cancer_type qtl_type tag_SNP LD SNP_id gene_id gene_symbol t-stat p-value FDR beta r Traits SNP_position Gene_position PAAD cis rs1577917 0.655 rs1059307 ENSG00000203875.9 SNHG5 18.89 9.92e-42 1.02e-34 1.06 0.84 Response to antipsychotic treatment; chr6:85678170 chr6:85660950~85678736:- PAAD cis rs1577917 0.655 rs9342045 ENSG00000203875.9 SNHG5 18.85 1.27e-41 1.05e-34 1.12 0.84 Response to antipsychotic treatment; chr6:85715430 chr6:85660950~85678736:- PAAD cis rs9322193 0.962 rs9688412 ENSG00000231760.4 RP11-350J20.5 -18.37 1.93e-40 4.65e-34 -1.07 -0.83 Lung cancer; chr6:149803147 chr6:149796151~149826294:- PAAD cis rs1577917 0.561 rs3087978 ENSG00000203875.9 SNHG5 18.22 4.66e-40 9.1e-34 1.07 0.83 Response to antipsychotic treatment; chr6:85678505 chr6:85660950~85678736:- PAAD cis rs9322193 0.962 rs3805748 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149772542 chr6:149796151~149826294:- PAAD cis rs9322193 0.736 rs10457851 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149775216 chr6:149796151~149826294:- PAAD cis rs9322193 0.886 rs10872652 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149775303 chr6:149796151~149826294:- PAAD cis rs9322193 0.886 rs12525871 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149775882 chr6:149796151~149826294:- PAAD cis rs9322193 0.886 rs17672976 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149776207 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs2184369 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149776681 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs2342861 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149777561 chr6:149796151~149826294:- PAAD cis rs9322193 0.926 rs2342860 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149777641 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs10872653 ENSG00000231760.4 RP11-350J20.5 17.86 3.74e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149778907 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs6899661 ENSG00000231760.4 RP11-350J20.5 17.81 4.88e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149818093 chr6:149796151~149826294:- PAAD cis rs9322193 0.926 rs9766562 ENSG00000231760.4 RP11-350J20.5 17.81 4.98e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149788709 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs12175575 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149763351 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs4869966 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149763714 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs1112730 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149766383 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs1112729 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149766491 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs10452626 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149767481 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs62441303 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149767547 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9765929 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149769680 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs11155683 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149779341 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9372044 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149780867 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs11155685 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149781649 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9322220 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149782897 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs10214845 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149783124 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9767122 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149783553 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs1413654 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149783956 chr6:149796151~149826294:- PAAD cis rs9322193 0.683 rs113281309 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149787289 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9688809 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149787920 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9689242 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149787970 chr6:149796151~149826294:- PAAD cis rs9322193 1 rs9767077 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149788479 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9688938 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149788941 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9688940 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149788977 chr6:149796151~149826294:- PAAD cis rs9322193 0.632 rs3828700 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149791033 chr6:149796151~149826294:- PAAD cis rs9322193 0.736 rs3828701 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149791063 chr6:149796151~149826294:- PAAD cis rs9322193 0.736 rs3805750 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149791065 chr6:149796151~149826294:- PAAD cis rs9322193 0.926 rs3805751 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149791193 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9689269 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149791861 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs62441335 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149792658 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs4816 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149793609 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs3805753 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149795662 chr6:149796151~149826294:- PAAD cis rs9322193 0.926 rs952166 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149798774 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs952165 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149798900 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs10872656 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149799444 chr6:149796151~149826294:- PAAD cis rs9322193 0.926 rs9285525 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149801253 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs2342858 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149805967 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs6914319 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149806304 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs2095375 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149807037 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs4869730 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149808187 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs11155689 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149808470 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs2151913 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149809506 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs933055 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149809701 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs4869731 ENSG00000231760.4 RP11-350J20.5 17.81 5.04e-39 1.74e-33 1.06 0.82 Lung cancer; chr6:149810072 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs2342857 ENSG00000231760.4 RP11-350J20.5 17.77 6.11e-39 2.02e-33 1.06 0.82 Lung cancer; chr6:149809537 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9479810 ENSG00000231760.4 RP11-350J20.5 17.75 6.97e-39 2.27e-33 1.05 0.82 Lung cancer; chr6:149751359 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs7818 ENSG00000231760.4 RP11-350J20.5 17.72 8.23e-39 2.64e-33 1.07 0.82 Lung cancer; chr6:149810956 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs7753812 ENSG00000231760.4 RP11-350J20.5 17.7 9.49e-39 2.88e-33 1.05 0.82 Lung cancer; chr6:149690150 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs12195866 ENSG00000231760.4 RP11-350J20.5 17.7 9.49e-39 2.88e-33 1.05 0.82 Lung cancer; chr6:149693334 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9285524 ENSG00000231760.4 RP11-350J20.5 17.7 9.49e-39 2.88e-33 1.05 0.82 Lung cancer; chr6:149694122 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10872645 ENSG00000231760.4 RP11-350J20.5 17.7 9.49e-39 2.88e-33 1.05 0.82 Lung cancer; chr6:149742840 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs12211511 ENSG00000231760.4 RP11-350J20.5 17.7 9.49e-39 2.88e-33 1.05 0.82 Lung cancer; chr6:149745206 chr6:149796151~149826294:- PAAD cis rs1577917 0.655 rs9450311 ENSG00000203875.9 SNHG5 17.67 1.12e-38 3.36e-33 1.07 0.82 Response to antipsychotic treatment; chr6:85666868 chr6:85660950~85678736:- PAAD cis rs9322193 0.962 rs2065664 ENSG00000231760.4 RP11-350J20.5 17.63 1.42e-38 4.11e-33 1.08 0.82 Lung cancer; chr6:149762485 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs4552 ENSG00000231760.4 RP11-350J20.5 17.63 1.44e-38 4.12e-33 1.07 0.82 Lung cancer; chr6:149811183 chr6:149796151~149826294:- PAAD cis rs1577917 0.559 rs1173418 ENSG00000203875.9 SNHG5 17.6 1.71e-38 4.86e-33 1.06 0.82 Response to antipsychotic treatment; chr6:85693198 chr6:85660950~85678736:- PAAD cis rs9322193 0.962 rs1413655 ENSG00000231760.4 RP11-350J20.5 17.48 3.29e-38 8.76e-33 1.06 0.82 Lung cancer; chr6:149821815 chr6:149796151~149826294:- PAAD cis rs9322193 0.926 rs9383546 ENSG00000231760.4 RP11-350J20.5 17.48 3.29e-38 8.76e-33 1.06 0.82 Lung cancer; chr6:149822743 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs2151912 ENSG00000231760.4 RP11-350J20.5 17.48 3.29e-38 8.76e-33 1.06 0.82 Lung cancer; chr6:149831772 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs4628176 ENSG00000230658.1 KLHL7-AS1 17.44 4.22e-38 1.1e-32 1.04 0.82 Cerebrospinal fluid biomarker levels; chr7:23102947 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs10488077 ENSG00000230658.1 KLHL7-AS1 17.44 4.22e-38 1.1e-32 1.04 0.82 Cerebrospinal fluid biomarker levels; chr7:23104563 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs14314 ENSG00000231760.4 RP11-350J20.5 17.44 4.34e-38 1.13e-32 1.05 0.82 Lung cancer; chr6:149820395 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs10235786 ENSG00000230658.1 KLHL7-AS1 17.43 4.4e-38 1.13e-32 1.03 0.82 Cerebrospinal fluid biomarker levels; chr7:23100321 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs10233039 ENSG00000230658.1 KLHL7-AS1 17.43 4.4e-38 1.13e-32 1.03 0.82 Cerebrospinal fluid biomarker levels; chr7:23103494 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs12174035 ENSG00000231760.4 RP11-350J20.5 17.41 4.97e-38 1.26e-32 1.05 0.82 Lung cancer; chr6:149763311 chr6:149796151~149826294:- PAAD cis rs1577917 0.56 rs12193777 ENSG00000203875.9 SNHG5 17.38 5.97e-38 1.42e-32 1.06 0.82 Response to antipsychotic treatment; chr6:85536991 chr6:85660950~85678736:- PAAD cis rs1577917 0.655 rs9444351 ENSG00000203875.9 SNHG5 17.38 5.97e-38 1.42e-32 1.06 0.82 Response to antipsychotic treatment; chr6:85538081 chr6:85660950~85678736:- PAAD cis rs1577917 0.655 rs7766485 ENSG00000203875.9 SNHG5 17.38 5.97e-38 1.42e-32 1.06 0.82 Response to antipsychotic treatment; chr6:85553837 chr6:85660950~85678736:- PAAD cis rs1577917 0.655 rs9444354 ENSG00000203875.9 SNHG5 17.38 5.97e-38 1.42e-32 1.06 0.82 Response to antipsychotic treatment; chr6:85582217 chr6:85660950~85678736:- PAAD cis rs858239 0.6 rs10266123 ENSG00000230658.1 KLHL7-AS1 17.37 6.45e-38 1.5e-32 1.04 0.82 Cerebrospinal fluid biomarker levels; chr7:23096868 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6461691 ENSG00000230658.1 KLHL7-AS1 17.37 6.45e-38 1.5e-32 1.04 0.82 Cerebrospinal fluid biomarker levels; chr7:23099726 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs10241208 ENSG00000230658.1 KLHL7-AS1 17.37 6.45e-38 1.5e-32 1.04 0.82 Cerebrospinal fluid biomarker levels; chr7:23105295 chr7:23101228~23105703:- PAAD cis rs9322193 0.962 rs3763162 ENSG00000231760.4 RP11-350J20.5 -17.36 6.73e-38 1.56e-32 -1.05 -0.82 Lung cancer; chr6:149819674 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9505974 ENSG00000231760.4 RP11-350J20.5 17.35 7.14e-38 1.65e-32 1.04 0.82 Lung cancer; chr6:149779294 chr6:149796151~149826294:- PAAD cis rs9322193 0.926 rs9689036 ENSG00000231760.4 RP11-350J20.5 17.27 1.13e-37 2.45e-32 1.04 0.81 Lung cancer; chr6:149780563 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9322218 ENSG00000231760.4 RP11-350J20.5 17.27 1.13e-37 2.45e-32 1.04 0.81 Lung cancer; chr6:149782183 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9322219 ENSG00000231760.4 RP11-350J20.5 17.27 1.13e-37 2.45e-32 1.04 0.81 Lung cancer; chr6:149782263 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs13215691 ENSG00000231760.4 RP11-350J20.5 17.27 1.13e-37 2.45e-32 1.04 0.81 Lung cancer; chr6:149792666 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9322223 ENSG00000231760.4 RP11-350J20.5 17.27 1.13e-37 2.45e-32 1.04 0.81 Lung cancer; chr6:149801509 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9397022 ENSG00000231760.4 RP11-350J20.5 17.23 1.4e-37 2.99e-32 1.04 0.81 Lung cancer; chr6:149812052 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9397357 ENSG00000231760.4 RP11-350J20.5 17.23 1.4e-37 2.99e-32 1.04 0.81 Lung cancer; chr6:149812465 chr6:149796151~149826294:- PAAD cis rs858239 0.511 rs10256996 ENSG00000230658.1 KLHL7-AS1 -17.23 1.41e-37 2.99e-32 -0.98 -0.81 Cerebrospinal fluid biomarker levels; chr7:23105676 chr7:23101228~23105703:- PAAD cis rs1577917 0.655 rs9444352 ENSG00000203875.9 SNHG5 17.23 1.48e-37 3.12e-32 1.08 0.81 Response to antipsychotic treatment; chr6:85547817 chr6:85660950~85678736:- PAAD cis rs9322193 0.962 rs9478848 ENSG00000231760.4 RP11-350J20.5 17.13 2.55e-37 5.25e-32 1.04 0.81 Lung cancer; chr6:149825080 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs17673294 ENSG00000231760.4 RP11-350J20.5 17.11 2.85e-37 5.78e-32 1.05 0.81 Lung cancer; chr6:149813857 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs7745915 ENSG00000231760.4 RP11-350J20.5 17.1 3.08e-37 6.23e-32 1.04 0.81 Lung cancer; chr6:149834111 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs1889473 ENSG00000231760.4 RP11-350J20.5 17.03 4.76e-37 9.24e-32 1.04 0.81 Lung cancer; chr6:149825485 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs1984111 ENSG00000231760.4 RP11-350J20.5 17.03 4.76e-37 9.24e-32 1.04 0.81 Lung cancer; chr6:149831720 chr6:149796151~149826294:- PAAD cis rs1577917 0.655 rs12203963 ENSG00000203875.9 SNHG5 16.95 7.63e-37 1.44e-31 1.07 0.81 Response to antipsychotic treatment; chr6:85513598 chr6:85660950~85678736:- PAAD cis rs1577917 0.655 rs6454472 ENSG00000203875.9 SNHG5 16.95 7.63e-37 1.44e-31 1.07 0.81 Response to antipsychotic treatment; chr6:85514335 chr6:85660950~85678736:- PAAD cis rs1577917 0.681 rs4707211 ENSG00000203875.9 SNHG5 16.95 7.63e-37 1.44e-31 1.07 0.81 Response to antipsychotic treatment; chr6:85522992 chr6:85660950~85678736:- PAAD cis rs1577917 0.655 rs2842600 ENSG00000203875.9 SNHG5 -16.85 1.31e-36 2.44e-31 -1.05 -0.81 Response to antipsychotic treatment; chr6:85615914 chr6:85660950~85678736:- PAAD cis rs9322193 0.962 rs9689447 ENSG00000231760.4 RP11-350J20.5 16.85 1.33e-36 2.47e-31 1.05 0.81 Lung cancer; chr6:149789350 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs12175504 ENSG00000231760.4 RP11-350J20.5 16.82 1.63e-36 2.95e-31 1.02 0.81 Lung cancer; chr6:149664079 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs35443312 ENSG00000231760.4 RP11-350J20.5 16.82 1.63e-36 2.95e-31 1.02 0.81 Lung cancer; chr6:149670625 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs62439843 ENSG00000231760.4 RP11-350J20.5 16.82 1.63e-36 2.95e-31 1.02 0.81 Lung cancer; chr6:149676521 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs35031906 ENSG00000231760.4 RP11-350J20.5 16.82 1.63e-36 2.95e-31 1.02 0.81 Lung cancer; chr6:149677438 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9322206 ENSG00000231760.4 RP11-350J20.5 16.8 1.82e-36 3.26e-31 1.01 0.81 Lung cancer; chr6:149641481 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9688750 ENSG00000231760.4 RP11-350J20.5 16.8 1.82e-36 3.26e-31 1.01 0.81 Lung cancer; chr6:149657633 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs2275046 ENSG00000231760.4 RP11-350J20.5 16.78 1.99e-36 3.55e-31 1.05 0.81 Lung cancer; chr6:149835865 chr6:149796151~149826294:- PAAD cis rs1577917 0.655 rs2842605 ENSG00000203875.9 SNHG5 -16.78 2.03e-36 3.56e-31 -1.06 -0.81 Response to antipsychotic treatment; chr6:85625432 chr6:85660950~85678736:- PAAD cis rs1577917 0.655 rs2758848 ENSG00000203875.9 SNHG5 -16.78 2.03e-36 3.56e-31 -1.06 -0.81 Response to antipsychotic treatment; chr6:85637887 chr6:85660950~85678736:- PAAD cis rs858239 0.6 rs9691762 ENSG00000230658.1 KLHL7-AS1 16.75 2.44e-36 4.25e-31 1.02 0.81 Cerebrospinal fluid biomarker levels; chr7:23086303 chr7:23101228~23105703:- PAAD cis rs9322193 0.961 rs9027 ENSG00000231760.4 RP11-350J20.5 16.75 2.45e-36 4.25e-31 1.02 0.81 Lung cancer; chr6:149594921 chr6:149796151~149826294:- PAAD cis rs9322193 1 rs9322193 ENSG00000231760.4 RP11-350J20.5 16.72 2.89e-36 4.91e-31 1.02 0.8 Lung cancer; chr6:149598007 chr6:149796151~149826294:- PAAD cis rs858239 0.601 rs10239760 ENSG00000230658.1 KLHL7-AS1 16.72 2.91e-36 4.91e-31 1.03 0.8 Cerebrospinal fluid biomarker levels; chr7:23110331 chr7:23101228~23105703:- PAAD cis rs1577917 0.727 rs9344539 ENSG00000203875.9 SNHG5 -16.71 3.1e-36 5.13e-31 -1.05 -0.8 Response to antipsychotic treatment; chr6:85643903 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs9362232 ENSG00000203875.9 SNHG5 -16.71 3.1e-36 5.13e-31 -1.05 -0.8 Response to antipsychotic treatment; chr6:85643904 chr6:85660950~85678736:- PAAD cis rs1577917 0.566 rs2842611 ENSG00000203875.9 SNHG5 -16.7 3.18e-36 5.21e-31 -1.04 -0.8 Response to antipsychotic treatment; chr6:85592316 chr6:85660950~85678736:- PAAD cis rs1577917 0.61 rs11752795 ENSG00000203875.9 SNHG5 16.7 3.18e-36 5.21e-31 1.04 0.8 Response to antipsychotic treatment; chr6:85577411 chr6:85660950~85678736:- PAAD cis rs9322193 0.962 rs3763163 ENSG00000231760.4 RP11-350J20.5 16.68 3.62e-36 5.89e-31 1.03 0.8 Lung cancer; chr6:149819770 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs4409314 ENSG00000230658.1 KLHL7-AS1 16.66 4.12e-36 6.65e-31 1.03 0.8 Cerebrospinal fluid biomarker levels; chr7:23088333 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs2014768 ENSG00000230658.1 KLHL7-AS1 16.65 4.4e-36 7.02e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23082821 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6978827 ENSG00000230658.1 KLHL7-AS1 16.65 4.4e-36 7.02e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23085925 chr7:23101228~23105703:- PAAD cis rs9322193 0.962 rs6903998 ENSG00000231760.4 RP11-350J20.5 16.64 4.54e-36 7.22e-31 1.05 0.8 Lung cancer; chr6:149831357 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs7785842 ENSG00000230658.1 KLHL7-AS1 16.61 5.69e-36 8.9e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23102087 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs7456915 ENSG00000230658.1 KLHL7-AS1 16.61 5.69e-36 8.9e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23103430 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs13438179 ENSG00000230658.1 KLHL7-AS1 16.61 5.69e-36 8.9e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23104232 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs9322197 ENSG00000231760.4 RP11-350J20.5 16.6 5.81e-36 9.02e-31 1.01 0.8 Lung cancer; chr6:149622577 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs9688858 ENSG00000231760.4 RP11-350J20.5 16.6 5.81e-36 9.02e-31 1.01 0.8 Lung cancer; chr6:149637911 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs7790157 ENSG00000230658.1 KLHL7-AS1 16.58 6.65e-36 9.96e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23087379 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6960001 ENSG00000230658.1 KLHL7-AS1 16.58 6.65e-36 9.96e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23091257 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs10237755 ENSG00000230658.1 KLHL7-AS1 16.58 6.65e-36 9.96e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23091945 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6961131 ENSG00000230658.1 KLHL7-AS1 16.58 6.65e-36 9.96e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23095171 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs1115941 ENSG00000230658.1 KLHL7-AS1 16.58 6.65e-36 9.96e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23097569 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs7787110 ENSG00000230658.1 KLHL7-AS1 16.58 6.65e-36 9.96e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23098855 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs28646184 ENSG00000230658.1 KLHL7-AS1 16.58 6.65e-36 9.96e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23099976 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs10256524 ENSG00000230658.1 KLHL7-AS1 16.58 6.65e-36 9.96e-31 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23105328 chr7:23101228~23105703:- PAAD cis rs1577917 0.655 rs2758849 ENSG00000203875.9 SNHG5 -16.58 6.74e-36 9.98e-31 -1.06 -0.8 Response to antipsychotic treatment; chr6:85634578 chr6:85660950~85678736:- PAAD cis rs916888 0.738 rs199515 ENSG00000262539.1 RP11-259G18.3 -16.4 1.92e-35 2.74e-30 -1.14 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46259551~46260606:- PAAD cis rs9322193 0.923 rs9688350 ENSG00000231760.4 RP11-350J20.5 16.39 2.09e-35 2.96e-30 1.02 0.8 Lung cancer; chr6:149730977 chr6:149796151~149826294:- PAAD cis rs858239 0.601 rs12539331 ENSG00000230658.1 KLHL7-AS1 16.37 2.25e-35 3.18e-30 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23111711 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs9767652 ENSG00000231760.4 RP11-350J20.5 16.33 2.97e-35 4.16e-30 1.02 0.8 Lung cancer; chr6:149734502 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10782314 ENSG00000231760.4 RP11-350J20.5 16.33 2.97e-35 4.16e-30 1.02 0.8 Lung cancer; chr6:149735527 chr6:149796151~149826294:- PAAD cis rs916888 0.697 rs199516 ENSG00000262539.1 RP11-259G18.3 -16.28 3.87e-35 5.18e-30 -1.16 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs199514 ENSG00000262539.1 RP11-259G18.3 -16.28 3.87e-35 5.18e-30 -1.16 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs199513 ENSG00000262539.1 RP11-259G18.3 -16.28 3.87e-35 5.18e-30 -1.16 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs199512 ENSG00000262539.1 RP11-259G18.3 -16.28 3.87e-35 5.18e-30 -1.16 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs199509 ENSG00000262539.1 RP11-259G18.3 -16.28 3.87e-35 5.18e-30 -1.16 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs199507 ENSG00000262539.1 RP11-259G18.3 -16.28 3.87e-35 5.18e-30 -1.16 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs199505 ENSG00000262539.1 RP11-259G18.3 -16.28 3.87e-35 5.18e-30 -1.16 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs70602 ENSG00000262539.1 RP11-259G18.3 -16.28 3.87e-35 5.18e-30 -1.16 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46259551~46260606:- PAAD cis rs9322193 0.962 rs4870048 ENSG00000231760.4 RP11-350J20.5 16.24 4.86e-35 6.47e-30 1.02 0.8 Lung cancer; chr6:149834324 chr6:149796151~149826294:- PAAD cis rs858239 0.632 rs7811903 ENSG00000230658.1 KLHL7-AS1 16.23 5.26e-35 6.98e-30 1.02 0.8 Cerebrospinal fluid biomarker levels; chr7:23079437 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs28483572 ENSG00000230658.1 KLHL7-AS1 16.12 1.03e-34 1.32e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23092166 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6961406 ENSG00000230658.1 KLHL7-AS1 16.12 1.03e-34 1.32e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23095272 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6461690 ENSG00000230658.1 KLHL7-AS1 16.12 1.03e-34 1.32e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23095915 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6967419 ENSG00000230658.1 KLHL7-AS1 16.12 1.03e-34 1.32e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23096691 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs1468592 ENSG00000230658.1 KLHL7-AS1 -16.12 1.03e-34 1.32e-29 -1.01 -0.79 Cerebrospinal fluid biomarker levels; chr7:23101028 chr7:23101228~23105703:- PAAD cis rs1577917 0.681 rs4348284 ENSG00000203875.9 SNHG5 -16.12 1.03e-34 1.32e-29 -1.04 -0.79 Response to antipsychotic treatment; chr6:85640676 chr6:85660950~85678736:- PAAD cis rs858239 0.6 rs7776649 ENSG00000230658.1 KLHL7-AS1 16.11 1.07e-34 1.36e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23079698 chr7:23101228~23105703:- PAAD cis rs9322193 0.884 rs9688699 ENSG00000231760.4 RP11-350J20.5 16.11 1.09e-34 1.38e-29 1.02 0.79 Lung cancer; chr6:149733680 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs2072368 ENSG00000230658.1 KLHL7-AS1 16.11 1.1e-34 1.39e-29 1.03 0.79 Cerebrospinal fluid biomarker levels; chr7:23106493 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs7805206 ENSG00000230658.1 KLHL7-AS1 16.11 1.11e-34 1.4e-29 0.98 0.79 Cerebrospinal fluid biomarker levels; chr7:23120591 chr7:23101228~23105703:- PAAD cis rs2739330 0.929 rs5751775 ENSG00000273295.1 AP000350.5 16.1 1.18e-34 1.48e-29 1.01 0.79 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23901432~23907068:- PAAD cis rs1577917 0.883 rs13212415 ENSG00000203875.9 SNHG5 -16.09 1.21e-34 1.5e-29 -1.04 -0.79 Response to antipsychotic treatment; chr6:85898365 chr6:85660950~85678736:- PAAD cis rs1577917 0.839 rs1447159 ENSG00000203875.9 SNHG5 -16.09 1.21e-34 1.5e-29 -1.04 -0.79 Response to antipsychotic treatment; chr6:85899531 chr6:85660950~85678736:- PAAD cis rs2739330 0.892 rs5751776 ENSG00000273295.1 AP000350.5 16.09 1.21e-34 1.5e-29 1.02 0.79 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23901432~23907068:- PAAD cis rs916888 0.821 rs199506 ENSG00000262539.1 RP11-259G18.3 -16.08 1.28e-34 1.57e-29 -1.16 -0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46259551~46260606:- PAAD cis rs858239 0.6 rs10256361 ENSG00000230658.1 KLHL7-AS1 16.07 1.41e-34 1.72e-29 1.02 0.79 Cerebrospinal fluid biomarker levels; chr7:23084266 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs12526675 ENSG00000231760.4 RP11-350J20.5 -16.05 1.57e-34 1.89e-29 -1.02 -0.79 Lung cancer; chr6:149729540 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs2072369 ENSG00000230658.1 KLHL7-AS1 15.99 2.28e-34 2.71e-29 1.02 0.79 Cerebrospinal fluid biomarker levels; chr7:23106570 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs1034963 ENSG00000230658.1 KLHL7-AS1 15.97 2.46e-34 2.86e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23108854 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs73272048 ENSG00000230658.1 KLHL7-AS1 15.97 2.46e-34 2.86e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23113034 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs15775 ENSG00000230658.1 KLHL7-AS1 15.97 2.46e-34 2.86e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23125082 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs4599714 ENSG00000230658.1 KLHL7-AS1 15.97 2.46e-34 2.86e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23129182 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs10278776 ENSG00000230658.1 KLHL7-AS1 15.97 2.46e-34 2.86e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23130140 chr7:23101228~23105703:- PAAD cis rs858239 0.632 rs13438452 ENSG00000230658.1 KLHL7-AS1 15.97 2.46e-34 2.86e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23134563 chr7:23101228~23105703:- PAAD cis rs1577917 0.839 rs6929514 ENSG00000203875.9 SNHG5 -15.97 2.48e-34 2.86e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85816050 chr6:85660950~85678736:- PAAD cis rs9322193 1 rs9377229 ENSG00000231760.4 RP11-350J20.5 15.96 2.62e-34 2.98e-29 0.99 0.79 Lung cancer; chr6:149607655 chr6:149796151~149826294:- PAAD cis rs858239 0.539 rs4559148 ENSG00000230658.1 KLHL7-AS1 15.95 2.86e-34 3.18e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23146348 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs4377861 ENSG00000230658.1 KLHL7-AS1 15.95 2.86e-34 3.18e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23146350 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6975852 ENSG00000230658.1 KLHL7-AS1 15.95 2.86e-34 3.18e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23147035 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs10247268 ENSG00000230658.1 KLHL7-AS1 15.95 2.86e-34 3.18e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23147560 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6461694 ENSG00000230658.1 KLHL7-AS1 15.95 2.86e-34 3.18e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23148160 chr7:23101228~23105703:- PAAD cis rs858239 0.508 rs7805071 ENSG00000230658.1 KLHL7-AS1 15.95 2.86e-34 3.18e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23150593 chr7:23101228~23105703:- PAAD cis rs858239 0.508 rs7805085 ENSG00000230658.1 KLHL7-AS1 15.95 2.86e-34 3.18e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23150624 chr7:23101228~23105703:- PAAD cis rs858239 0.508 rs2390754 ENSG00000230658.1 KLHL7-AS1 15.95 2.86e-34 3.18e-29 1.01 0.79 Cerebrospinal fluid biomarker levels; chr7:23150875 chr7:23101228~23105703:- PAAD cis rs1577917 0.883 rs2166664 ENSG00000203875.9 SNHG5 -15.91 3.5e-34 3.83e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85886904 chr6:85660950~85678736:- PAAD cis rs1577917 0.883 rs9450348 ENSG00000203875.9 SNHG5 -15.91 3.5e-34 3.83e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85888318 chr6:85660950~85678736:- PAAD cis rs9322193 0.884 rs62439837 ENSG00000231760.4 RP11-350J20.5 15.91 3.53e-34 3.84e-29 1.01 0.79 Lung cancer; chr6:149670380 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs59073109 ENSG00000230658.1 KLHL7-AS1 15.91 3.55e-34 3.84e-29 1.02 0.79 Cerebrospinal fluid biomarker levels; chr7:23093607 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs7788821 ENSG00000230658.1 KLHL7-AS1 15.91 3.55e-34 3.84e-29 1.02 0.79 Cerebrospinal fluid biomarker levels; chr7:23094026 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6956595 ENSG00000230658.1 KLHL7-AS1 15.91 3.55e-34 3.84e-29 1.02 0.79 Cerebrospinal fluid biomarker levels; chr7:23094637 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs4140959 ENSG00000230658.1 KLHL7-AS1 15.91 3.58e-34 3.87e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23131157 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs764534 ENSG00000230658.1 KLHL7-AS1 15.9 3.78e-34 4.04e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23114316 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs2068459 ENSG00000230658.1 KLHL7-AS1 15.9 3.78e-34 4.04e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23114694 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs73272053 ENSG00000230658.1 KLHL7-AS1 15.9 3.78e-34 4.04e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23115906 chr7:23101228~23105703:- PAAD cis rs2739330 0.929 rs5751775 ENSG00000218537.1 MIF-AS1 15.9 3.84e-34 4.09e-29 1.06 0.79 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23894426~23898930:- PAAD cis rs9322193 0.923 rs62439840 ENSG00000231760.4 RP11-350J20.5 15.9 3.88e-34 4.11e-29 1.01 0.79 Lung cancer; chr6:149674639 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs9393175 ENSG00000231760.4 RP11-350J20.5 15.9 3.88e-34 4.11e-29 1.01 0.79 Lung cancer; chr6:149677587 chr6:149796151~149826294:- PAAD cis rs1577917 0.959 rs2816822 ENSG00000203875.9 SNHG5 -15.88 4.32e-34 4.56e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85948574 chr6:85660950~85678736:- PAAD cis rs2739330 0.892 rs5751776 ENSG00000218537.1 MIF-AS1 15.88 4.37e-34 4.58e-29 1.06 0.79 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23894426~23898930:- PAAD cis rs858239 0.632 rs1985769 ENSG00000230658.1 KLHL7-AS1 15.87 4.44e-34 4.61e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23082887 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs28499396 ENSG00000230658.1 KLHL7-AS1 15.87 4.44e-34 4.61e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23084479 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs7789237 ENSG00000230658.1 KLHL7-AS1 15.87 4.44e-34 4.61e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23085094 chr7:23101228~23105703:- PAAD cis rs1577917 0.793 rs9362245 ENSG00000203875.9 SNHG5 -15.87 4.62e-34 4.77e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85786602 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs57938011 ENSG00000231760.4 RP11-350J20.5 15.86 4.73e-34 4.86e-29 1.01 0.79 Lung cancer; chr6:149642969 chr6:149796151~149826294:- PAAD cis rs858239 0.632 rs6952947 ENSG00000230658.1 KLHL7-AS1 -15.86 4.91e-34 5.03e-29 -1 -0.79 Cerebrospinal fluid biomarker levels; chr7:23081423 chr7:23101228~23105703:- PAAD cis rs916888 0.773 rs199447 ENSG00000262539.1 RP11-259G18.3 15.83 5.84e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46259551~46260606:- PAAD cis rs916888 0.773 rs199457 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46259551~46260606:- PAAD cis rs916888 0.687 rs199456 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46259551~46260606:- PAAD cis rs916888 0.773 rs199451 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46259551~46260606:- PAAD cis rs916888 0.773 rs199448 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46259551~46260606:- PAAD cis rs916888 0.773 rs199445 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46259551~46260606:- PAAD cis rs916888 0.773 rs199443 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46259551~46260606:- PAAD cis rs916888 0.773 rs199535 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46259551~46260606:- PAAD cis rs916888 0.779 rs199528 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs199525 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46259551~46260606:- PAAD cis rs916888 0.821 rs70600 ENSG00000262539.1 RP11-259G18.3 15.83 5.93e-34 5.88e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46259551~46260606:- PAAD cis rs858239 0.539 rs870476 ENSG00000230658.1 KLHL7-AS1 15.82 6.27e-34 6.2e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23153652 chr7:23101228~23105703:- PAAD cis rs1577917 0.796 rs12661231 ENSG00000203875.9 SNHG5 -15.8 6.87e-34 6.77e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85834753 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs66516768 ENSG00000231760.4 RP11-350J20.5 15.8 7.04e-34 6.92e-29 1 0.79 Lung cancer; chr6:149671999 chr6:149796151~149826294:- PAAD cis rs916888 0.821 rs199504 ENSG00000262539.1 RP11-259G18.3 -15.79 7.16e-34 7.02e-29 -1.15 -0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46259551~46260606:- PAAD cis rs9322193 0.923 rs12529698 ENSG00000231760.4 RP11-350J20.5 15.79 7.55e-34 7.34e-29 0.99 0.79 Lung cancer; chr6:149650951 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs2003555 ENSG00000230658.1 KLHL7-AS1 15.78 7.59e-34 7.34e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23083296 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs7784929 ENSG00000230658.1 KLHL7-AS1 15.78 7.59e-34 7.34e-29 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23084658 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs9800736 ENSG00000231760.4 RP11-350J20.5 15.77 8.28e-34 7.91e-29 0.99 0.79 Lung cancer; chr6:149661281 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs12660304 ENSG00000231760.4 RP11-350J20.5 15.77 8.28e-34 7.91e-29 0.99 0.79 Lung cancer; chr6:149739647 chr6:149796151~149826294:- PAAD cis rs916888 0.773 rs169201 ENSG00000262539.1 RP11-259G18.3 15.74 9.72e-34 9.16e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46259551~46260606:- PAAD cis rs916888 0.773 rs199439 ENSG00000262539.1 RP11-259G18.3 15.74 9.72e-34 9.16e-29 1.17 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46259551~46260606:- PAAD cis rs1577917 0.839 rs6454492 ENSG00000203875.9 SNHG5 -15.74 9.77e-34 9.19e-29 -1.02 -0.79 Response to antipsychotic treatment; chr6:85773496 chr6:85660950~85678736:- PAAD cis rs1577917 0.839 rs1596990 ENSG00000203875.9 SNHG5 -15.73 1.05e-33 9.62e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85840974 chr6:85660950~85678736:- PAAD cis rs1577917 0.916 rs12661611 ENSG00000203875.9 SNHG5 -15.73 1.05e-33 9.62e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85844117 chr6:85660950~85678736:- PAAD cis rs1577917 0.637 rs1838957 ENSG00000203875.9 SNHG5 -15.73 1.05e-33 9.62e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85855338 chr6:85660950~85678736:- PAAD cis rs1577917 0.839 rs1838956 ENSG00000203875.9 SNHG5 -15.73 1.05e-33 9.62e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85855545 chr6:85660950~85678736:- PAAD cis rs1577917 0.839 rs12216103 ENSG00000203875.9 SNHG5 -15.73 1.05e-33 9.62e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85861410 chr6:85660950~85678736:- PAAD cis rs1577917 0.839 rs12664634 ENSG00000203875.9 SNHG5 -15.73 1.05e-33 9.62e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85869696 chr6:85660950~85678736:- PAAD cis rs1577917 0.839 rs6454504 ENSG00000203875.9 SNHG5 -15.73 1.05e-33 9.62e-29 -1.03 -0.79 Response to antipsychotic treatment; chr6:85870612 chr6:85660950~85678736:- PAAD cis rs9322193 0.847 rs56103941 ENSG00000231760.4 RP11-350J20.5 15.73 1.05e-33 9.63e-29 1.03 0.79 Lung cancer; chr6:149816095 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs7341483 ENSG00000230658.1 KLHL7-AS1 -15.72 1.11e-33 1e-28 -1 -0.79 Cerebrospinal fluid biomarker levels; chr7:23088038 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs7799422 ENSG00000230658.1 KLHL7-AS1 15.72 1.11e-33 1e-28 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23088794 chr7:23101228~23105703:- PAAD cis rs916888 0.773 rs1378358 ENSG00000262539.1 RP11-259G18.3 15.72 1.12e-33 1.01e-28 1.16 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46259551~46260606:- PAAD cis rs858239 0.6 rs13438188 ENSG00000230658.1 KLHL7-AS1 -15.72 1.13e-33 1.02e-28 -1 -0.79 Cerebrospinal fluid biomarker levels; chr7:23104578 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs11155670 ENSG00000231760.4 RP11-350J20.5 15.72 1.15e-33 1.03e-28 0.99 0.79 Lung cancer; chr6:149644992 chr6:149796151~149826294:- PAAD cis rs1577917 0.883 rs6454505 ENSG00000203875.9 SNHG5 -15.69 1.37e-33 1.23e-28 -1.04 -0.79 Response to antipsychotic treatment; chr6:85882644 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs4870509 ENSG00000231760.4 RP11-350J20.5 15.68 1.43e-33 1.28e-28 1.02 0.79 Lung cancer; chr6:149702212 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs4321896 ENSG00000230658.1 KLHL7-AS1 15.68 1.44e-33 1.28e-28 1.02 0.79 Cerebrospinal fluid biomarker levels; chr7:23088437 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs61292332 ENSG00000230658.1 KLHL7-AS1 15.68 1.44e-33 1.28e-28 1.02 0.79 Cerebrospinal fluid biomarker levels; chr7:23092243 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs6461692 ENSG00000230658.1 KLHL7-AS1 15.68 1.44e-33 1.28e-28 1.02 0.79 Cerebrospinal fluid biomarker levels; chr7:23100076 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs9322214 ENSG00000231760.4 RP11-350J20.5 15.67 1.49e-33 1.31e-28 1.01 0.79 Lung cancer; chr6:149703986 chr6:149796151~149826294:- PAAD cis rs9322193 0.887 rs9767113 ENSG00000231760.4 RP11-350J20.5 15.67 1.49e-33 1.31e-28 1.01 0.79 Lung cancer; chr6:149718157 chr6:149796151~149826294:- PAAD cis rs9322193 0.81 rs62439811 ENSG00000231760.4 RP11-350J20.5 15.67 1.51e-33 1.33e-28 1 0.79 Lung cancer; chr6:149640416 chr6:149796151~149826294:- PAAD cis rs916888 0.773 rs538628 ENSG00000262539.1 RP11-259G18.3 15.66 1.6e-33 1.41e-28 1.16 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46259551~46260606:- PAAD cis rs916888 0.773 rs199534 ENSG00000262539.1 RP11-259G18.3 15.65 1.74e-33 1.53e-28 1.16 0.79 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46259551~46260606:- PAAD cis rs858239 0.57 rs10271613 ENSG00000230658.1 KLHL7-AS1 15.64 1.76e-33 1.53e-28 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23122967 chr7:23101228~23105703:- PAAD cis rs858239 0.57 rs10242166 ENSG00000230658.1 KLHL7-AS1 15.64 1.76e-33 1.53e-28 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23123180 chr7:23101228~23105703:- PAAD cis rs858239 0.57 rs6968242 ENSG00000230658.1 KLHL7-AS1 15.64 1.76e-33 1.53e-28 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23127792 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs1981665 ENSG00000230658.1 KLHL7-AS1 15.64 1.76e-33 1.53e-28 1 0.79 Cerebrospinal fluid biomarker levels; chr7:23128350 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs9383812 ENSG00000231760.4 RP11-350J20.5 15.64 1.82e-33 1.56e-28 1 0.79 Lung cancer; chr6:149712355 chr6:149796151~149826294:- PAAD cis rs9322193 0.847 rs9383844 ENSG00000231760.4 RP11-350J20.5 15.64 1.82e-33 1.56e-28 1 0.79 Lung cancer; chr6:149716268 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs56397000 ENSG00000231760.4 RP11-350J20.5 15.64 1.82e-33 1.56e-28 1 0.79 Lung cancer; chr6:149739347 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs9689702 ENSG00000231760.4 RP11-350J20.5 15.64 1.82e-33 1.56e-28 1 0.79 Lung cancer; chr6:149740720 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9800614 ENSG00000231760.4 RP11-350J20.5 15.62 2.05e-33 1.73e-28 0.99 0.78 Lung cancer; chr6:149644604 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9689716 ENSG00000231760.4 RP11-350J20.5 15.62 2.05e-33 1.73e-28 0.99 0.78 Lung cancer; chr6:149655662 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9322207 ENSG00000231760.4 RP11-350J20.5 15.62 2.05e-33 1.73e-28 0.99 0.78 Lung cancer; chr6:149657185 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9968911 ENSG00000231760.4 RP11-350J20.5 15.62 2.05e-33 1.73e-28 0.99 0.78 Lung cancer; chr6:149657419 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9322208 ENSG00000231760.4 RP11-350J20.5 15.62 2.05e-33 1.73e-28 0.99 0.78 Lung cancer; chr6:149658547 chr6:149796151~149826294:- PAAD cis rs858239 0.539 rs2390757 ENSG00000230658.1 KLHL7-AS1 15.62 2.09e-33 1.75e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23151873 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs35830138 ENSG00000231760.4 RP11-350J20.5 15.61 2.2e-33 1.84e-28 0.99 0.78 Lung cancer; chr6:149668635 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10782315 ENSG00000231760.4 RP11-350J20.5 15.6 2.36e-33 1.96e-28 1 0.78 Lung cancer; chr6:149743093 chr6:149796151~149826294:- PAAD cis rs858239 0.539 rs6945510 ENSG00000230658.1 KLHL7-AS1 15.59 2.39e-33 1.96e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23152621 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6965833 ENSG00000230658.1 KLHL7-AS1 15.59 2.39e-33 1.96e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23152747 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6949363 ENSG00000230658.1 KLHL7-AS1 15.59 2.39e-33 1.96e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23152775 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs987257 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23108221 chr7:23101228~23105703:- PAAD cis rs858239 0.57 rs10235467 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23109189 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs6980224 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23109518 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs1558313 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23116460 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs6962526 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23118614 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6971673 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23119904 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs10278700 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23120910 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs10263110 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23120932 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs11982002 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23123651 chr7:23101228~23105703:- PAAD cis rs858239 0.541 rs4624924 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23129224 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs6948469 ENSG00000230658.1 KLHL7-AS1 15.59 2.49e-33 2e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23135147 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs6461693 ENSG00000230658.1 KLHL7-AS1 -15.59 2.49e-33 2e-28 -1.01 -0.78 Cerebrospinal fluid biomarker levels; chr7:23120514 chr7:23101228~23105703:- PAAD cis rs9322193 0.884 rs7450246 ENSG00000231760.4 RP11-350J20.5 15.58 2.55e-33 2e-28 1.01 0.78 Lung cancer; chr6:149702517 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs35961297 ENSG00000231760.4 RP11-350J20.5 15.58 2.55e-33 2e-28 0.99 0.78 Lung cancer; chr6:149667929 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs35967444 ENSG00000231760.4 RP11-350J20.5 15.58 2.55e-33 2e-28 0.99 0.78 Lung cancer; chr6:149675588 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs62439842 ENSG00000231760.4 RP11-350J20.5 15.58 2.55e-33 2e-28 0.99 0.78 Lung cancer; chr6:149675847 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs3924871 ENSG00000231760.4 RP11-350J20.5 15.58 2.56e-33 2e-28 0.99 0.78 Lung cancer; chr6:149662080 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs11155674 ENSG00000231760.4 RP11-350J20.5 15.58 2.56e-33 2e-28 0.99 0.78 Lung cancer; chr6:149711111 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs2185352 ENSG00000231760.4 RP11-350J20.5 15.58 2.56e-33 2e-28 0.99 0.78 Lung cancer; chr6:149714640 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs12174349 ENSG00000231760.4 RP11-350J20.5 15.58 2.56e-33 2e-28 0.99 0.78 Lung cancer; chr6:149718012 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs2297932 ENSG00000231760.4 RP11-350J20.5 15.58 2.56e-33 2e-28 0.99 0.78 Lung cancer; chr6:149718225 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs2297930 ENSG00000231760.4 RP11-350J20.5 15.58 2.56e-33 2e-28 0.99 0.78 Lung cancer; chr6:149718360 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs2297928 ENSG00000231760.4 RP11-350J20.5 15.58 2.56e-33 2e-28 0.99 0.78 Lung cancer; chr6:149718584 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9479094 ENSG00000231760.4 RP11-350J20.5 15.58 2.56e-33 2e-28 0.99 0.78 Lung cancer; chr6:149725083 chr6:149796151~149826294:- PAAD cis rs858239 0.601 rs929507 ENSG00000230658.1 KLHL7-AS1 15.57 2.74e-33 2.14e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23127045 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs929508 ENSG00000230658.1 KLHL7-AS1 15.57 2.74e-33 2.14e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23127090 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs9478291 ENSG00000231760.4 RP11-350J20.5 15.53 3.58e-33 2.74e-28 0.99 0.78 Lung cancer; chr6:149729434 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9479494 ENSG00000231760.4 RP11-350J20.5 15.53 3.58e-33 2.74e-28 0.99 0.78 Lung cancer; chr6:149739108 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9800806 ENSG00000231760.4 RP11-350J20.5 15.53 3.58e-33 2.74e-28 0.99 0.78 Lung cancer; chr6:149740350 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9688517 ENSG00000231760.4 RP11-350J20.5 15.53 3.58e-33 2.74e-28 0.99 0.78 Lung cancer; chr6:149740655 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9322209 ENSG00000231760.4 RP11-350J20.5 15.52 3.66e-33 2.76e-28 1 0.78 Lung cancer; chr6:149691226 chr6:149796151~149826294:- PAAD cis rs1577917 0.883 rs1415749 ENSG00000203875.9 SNHG5 15.5 4.27e-33 3.18e-28 1.02 0.78 Response to antipsychotic treatment; chr6:86069366 chr6:85660950~85678736:- PAAD cis rs1577917 0.804 rs2786854 ENSG00000203875.9 SNHG5 -15.5 4.27e-33 3.18e-28 -1.02 -0.78 Response to antipsychotic treatment; chr6:85959022 chr6:85660950~85678736:- PAAD cis rs1577917 0.92 rs1337842 ENSG00000203875.9 SNHG5 -15.5 4.27e-33 3.18e-28 -1.02 -0.78 Response to antipsychotic treatment; chr6:85965379 chr6:85660950~85678736:- PAAD cis rs858239 0.539 rs2103281 ENSG00000230658.1 KLHL7-AS1 15.5 4.27e-33 3.18e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23154612 chr7:23101228~23105703:- PAAD cis rs1577917 0.883 rs9450375 ENSG00000203875.9 SNHG5 15.49 4.38e-33 3.23e-28 1.02 0.78 Response to antipsychotic treatment; chr6:86046911 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs10872650 ENSG00000231760.4 RP11-350J20.5 15.49 4.41e-33 3.25e-28 1 0.78 Lung cancer; chr6:149760959 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10872644 ENSG00000231760.4 RP11-350J20.5 15.49 4.56e-33 3.32e-28 0.99 0.78 Lung cancer; chr6:149741819 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs1572229 ENSG00000231760.4 RP11-350J20.5 15.49 4.56e-33 3.32e-28 0.99 0.78 Lung cancer; chr6:149743841 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs10872646 ENSG00000231760.4 RP11-350J20.5 15.49 4.56e-33 3.32e-28 0.99 0.78 Lung cancer; chr6:149746539 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs12528279 ENSG00000231760.4 RP11-350J20.5 15.49 4.56e-33 3.32e-28 0.99 0.78 Lung cancer; chr6:149750892 chr6:149796151~149826294:- PAAD cis rs9322193 0.809 rs9479808 ENSG00000231760.4 RP11-350J20.5 15.49 4.56e-33 3.32e-28 0.99 0.78 Lung cancer; chr6:149751328 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs62441284 ENSG00000231760.4 RP11-350J20.5 15.49 4.56e-33 3.32e-28 0.99 0.78 Lung cancer; chr6:149751542 chr6:149796151~149826294:- PAAD cis rs9322193 1 rs58189451 ENSG00000231760.4 RP11-350J20.5 15.46 5.27e-33 3.77e-28 0.99 0.78 Lung cancer; chr6:149600252 chr6:149796151~149826294:- PAAD cis rs1577917 0.839 rs9450333 ENSG00000203875.9 SNHG5 -15.46 5.37e-33 3.84e-28 -1.02 -0.78 Response to antipsychotic treatment; chr6:85810037 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs7767622 ENSG00000231760.4 RP11-350J20.5 15.46 5.52e-33 3.9e-28 1 0.78 Lung cancer; chr6:149681766 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs3798761 ENSG00000231760.4 RP11-350J20.5 15.46 5.52e-33 3.9e-28 1 0.78 Lung cancer; chr6:149683643 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs9322210 ENSG00000231760.4 RP11-350J20.5 15.46 5.52e-33 3.9e-28 1 0.78 Lung cancer; chr6:149695440 chr6:149796151~149826294:- PAAD cis rs858239 0.601 rs2141307 ENSG00000230658.1 KLHL7-AS1 15.43 6.32e-33 4.45e-28 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23151805 chr7:23101228~23105703:- PAAD cis rs9322193 0.962 rs7740784 ENSG00000231760.4 RP11-350J20.5 15.43 6.51e-33 4.57e-28 1.01 0.78 Lung cancer; chr6:149833364 chr6:149796151~149826294:- PAAD cis rs916888 0.773 rs199533 ENSG00000262539.1 RP11-259G18.3 15.43 6.55e-33 4.59e-28 1.15 0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46259551~46260606:- PAAD cis rs9322193 0.886 rs2065663 ENSG00000231760.4 RP11-350J20.5 15.41 7.16e-33 5e-28 1.02 0.78 Lung cancer; chr6:149760331 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs12205092 ENSG00000231760.4 RP11-350J20.5 15.41 7.16e-33 5e-28 1.02 0.78 Lung cancer; chr6:149761375 chr6:149796151~149826294:- PAAD cis rs916888 0.821 rs415430 ENSG00000262539.1 RP11-259G18.3 -15.41 7.32e-33 5.05e-28 -1.16 -0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:46259551~46260606:- PAAD cis rs916888 0.779 rs430685 ENSG00000262539.1 RP11-259G18.3 -15.41 7.32e-33 5.05e-28 -1.16 -0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:46259551~46260606:- PAAD cis rs1577917 0.883 rs2660575 ENSG00000203875.9 SNHG5 -15.41 7.36e-33 5.05e-28 -1.02 -0.78 Response to antipsychotic treatment; chr6:85975277 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs9800686 ENSG00000231760.4 RP11-350J20.5 15.41 7.36e-33 5.05e-28 0.99 0.78 Lung cancer; chr6:149634464 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs55849538 ENSG00000231760.4 RP11-350J20.5 15.41 7.36e-33 5.05e-28 0.99 0.78 Lung cancer; chr6:149635330 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10782318 ENSG00000231760.4 RP11-350J20.5 15.4 7.92e-33 5.43e-28 1 0.78 Lung cancer; chr6:149754137 chr6:149796151~149826294:- PAAD cis rs858239 0.601 rs764533 ENSG00000230658.1 KLHL7-AS1 15.37 9.1e-33 6.21e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23114256 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs6913486 ENSG00000231760.4 RP11-350J20.5 -15.37 9.44e-33 6.43e-28 -1.01 -0.78 Lung cancer; chr6:149705060 chr6:149796151~149826294:- PAAD cis rs858239 0.539 rs10280815 ENSG00000230658.1 KLHL7-AS1 15.36 9.56e-33 6.43e-28 0.99 0.78 Cerebrospinal fluid biomarker levels; chr7:23148751 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs10225608 ENSG00000230658.1 KLHL7-AS1 15.36 9.56e-33 6.43e-28 0.99 0.78 Cerebrospinal fluid biomarker levels; chr7:23149289 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs28624974 ENSG00000230658.1 KLHL7-AS1 15.36 9.56e-33 6.43e-28 0.99 0.78 Cerebrospinal fluid biomarker levels; chr7:23149317 chr7:23101228~23105703:- PAAD cis rs5850 0.557 rs10270788 ENSG00000230658.1 KLHL7-AS1 15.36 9.56e-33 6.43e-28 0.99 0.78 Blood protein levels; chr7:23149381 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs28716381 ENSG00000230658.1 KLHL7-AS1 15.36 9.56e-33 6.43e-28 0.99 0.78 Cerebrospinal fluid biomarker levels; chr7:23149396 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs1358442 ENSG00000230658.1 KLHL7-AS1 15.36 9.56e-33 6.43e-28 0.99 0.78 Cerebrospinal fluid biomarker levels; chr7:23150120 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs11984129 ENSG00000230658.1 KLHL7-AS1 15.35 1.02e-32 6.79e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23113058 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs6969733 ENSG00000230658.1 KLHL7-AS1 15.35 1.02e-32 6.79e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23128758 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs4440529 ENSG00000230658.1 KLHL7-AS1 15.35 1.02e-32 6.79e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23129132 chr7:23101228~23105703:- PAAD cis rs858239 0.571 rs6953020 ENSG00000230658.1 KLHL7-AS1 15.35 1.02e-32 6.79e-28 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23132513 chr7:23101228~23105703:- PAAD cis rs9322193 0.962 rs3805752 ENSG00000231760.4 RP11-350J20.5 15.35 1.06e-32 7.07e-28 1.01 0.78 Lung cancer; chr6:149795490 chr6:149796151~149826294:- PAAD cis rs9322193 0.847 rs12210605 ENSG00000231760.4 RP11-350J20.5 15.35 1.06e-32 7.07e-28 1.01 0.78 Lung cancer; chr6:149817267 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9371199 ENSG00000231760.4 RP11-350J20.5 15.35 1.06e-32 7.07e-28 1.01 0.78 Lung cancer; chr6:149817526 chr6:149796151~149826294:- PAAD cis rs858239 0.601 rs3735228 ENSG00000230658.1 KLHL7-AS1 15.34 1.09e-32 7.21e-28 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23130808 chr7:23101228~23105703:- PAAD cis rs858239 0.602 rs6953996 ENSG00000230658.1 KLHL7-AS1 15.32 1.25e-32 8.28e-28 0.99 0.78 Cerebrospinal fluid biomarker levels; chr7:23136327 chr7:23101228~23105703:- PAAD cis rs858239 0.601 rs10224327 ENSG00000230658.1 KLHL7-AS1 15.31 1.3e-32 8.59e-28 0.99 0.78 Cerebrospinal fluid biomarker levels; chr7:23122201 chr7:23101228~23105703:- PAAD cis rs9322193 0.962 rs2342764 ENSG00000231760.4 RP11-350J20.5 15.3 1.41e-32 9.31e-28 1.01 0.78 Lung cancer; chr6:149835068 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs12176034 ENSG00000231760.4 RP11-350J20.5 15.29 1.46e-32 9.59e-28 1.03 0.78 Lung cancer; chr6:149800557 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs12174716 ENSG00000231760.4 RP11-350J20.5 15.28 1.54e-32 1.01e-27 0.97 0.78 Lung cancer; chr6:149644487 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9800871 ENSG00000231760.4 RP11-350J20.5 15.28 1.54e-32 1.01e-27 0.97 0.78 Lung cancer; chr6:149644540 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9689723 ENSG00000231760.4 RP11-350J20.5 15.28 1.54e-32 1.01e-27 0.97 0.78 Lung cancer; chr6:149655935 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs4421206 ENSG00000231760.4 RP11-350J20.5 15.28 1.57e-32 1.02e-27 1 0.78 Lung cancer; chr6:149682891 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs62439836 ENSG00000231760.4 RP11-350J20.5 15.27 1.65e-32 1.07e-27 0.98 0.78 Lung cancer; chr6:149669173 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs4869812 ENSG00000231760.4 RP11-350J20.5 15.27 1.65e-32 1.07e-27 0.98 0.78 Lung cancer; chr6:149669447 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10782317 ENSG00000231760.4 RP11-350J20.5 -15.27 1.66e-32 1.07e-27 -0.99 -0.78 Lung cancer; chr6:149753911 chr6:149796151~149826294:- PAAD cis rs1577917 0.816 rs12664099 ENSG00000203875.9 SNHG5 -15.27 1.68e-32 1.08e-27 -1.01 -0.78 Response to antipsychotic treatment; chr6:85938854 chr6:85660950~85678736:- PAAD cis rs858239 0.601 rs10255228 ENSG00000230658.1 KLHL7-AS1 15.27 1.72e-32 1.11e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23119244 chr7:23101228~23105703:- PAAD cis rs858239 0.6 rs7776644 ENSG00000230658.1 KLHL7-AS1 15.25 1.86e-32 1.2e-27 0.99 0.78 Cerebrospinal fluid biomarker levels; chr7:23079688 chr7:23101228~23105703:- PAAD cis rs9322193 0.962 rs4380763 ENSG00000231760.4 RP11-350J20.5 15.25 1.89e-32 1.21e-27 0.98 0.78 Lung cancer; chr6:149678086 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9767123 ENSG00000231760.4 RP11-350J20.5 15.25 1.9e-32 1.21e-27 0.98 0.78 Lung cancer; chr6:149660323 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs4870267 ENSG00000231760.4 RP11-350J20.5 15.25 1.9e-32 1.21e-27 0.98 0.78 Lung cancer; chr6:149671572 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs4870529 ENSG00000231760.4 RP11-350J20.5 15.25 1.9e-32 1.21e-27 0.98 0.78 Lung cancer; chr6:149716436 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9767309 ENSG00000231760.4 RP11-350J20.5 15.25 1.9e-32 1.21e-27 0.98 0.78 Lung cancer; chr6:149716807 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs17745062 ENSG00000231760.4 RP11-350J20.5 15.25 1.9e-32 1.21e-27 0.98 0.78 Lung cancer; chr6:149721079 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs62441279 ENSG00000231760.4 RP11-350J20.5 15.25 1.9e-32 1.21e-27 0.98 0.78 Lung cancer; chr6:149721194 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs10256359 ENSG00000230658.1 KLHL7-AS1 15.24 2.05e-32 1.29e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23084258 chr7:23101228~23105703:- PAAD cis rs858239 0.509 rs57611130 ENSG00000230658.1 KLHL7-AS1 15.22 2.3e-32 1.44e-27 1.01 0.78 Cerebrospinal fluid biomarker levels; chr7:23144933 chr7:23101228~23105703:- PAAD cis rs1577917 0.816 rs1838952 ENSG00000203875.9 SNHG5 -15.22 2.33e-32 1.45e-27 -1.02 -0.78 Response to antipsychotic treatment; chr6:85891426 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs55993747 ENSG00000231760.4 RP11-350J20.5 15.21 2.36e-32 1.47e-27 0.98 0.78 Lung cancer; chr6:149622016 chr6:149796151~149826294:- PAAD cis rs9322193 0.847 rs12191643 ENSG00000231760.4 RP11-350J20.5 15.21 2.36e-32 1.47e-27 0.98 0.78 Lung cancer; chr6:149628912 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10782316 ENSG00000231760.4 RP11-350J20.5 15.2 2.56e-32 1.58e-27 0.98 0.78 Lung cancer; chr6:149752755 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs11155677 ENSG00000231760.4 RP11-350J20.5 15.2 2.56e-32 1.58e-27 0.98 0.78 Lung cancer; chr6:149756953 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10747276 ENSG00000231760.4 RP11-350J20.5 15.19 2.7e-32 1.66e-27 0.99 0.78 Lung cancer; chr6:149758739 chr6:149796151~149826294:- PAAD cis rs858239 0.6 rs6967475 ENSG00000230658.1 KLHL7-AS1 15.16 3.24e-32 1.99e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23089363 chr7:23101228~23105703:- PAAD cis rs1577917 0.883 rs1337854 ENSG00000203875.9 SNHG5 15.16 3.24e-32 1.99e-27 1.02 0.78 Response to antipsychotic treatment; chr6:86014297 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs4354168 ENSG00000231760.4 RP11-350J20.5 15.15 3.4e-32 2.04e-27 0.98 0.78 Lung cancer; chr6:149696642 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs4455682 ENSG00000231760.4 RP11-350J20.5 15.15 3.4e-32 2.04e-27 0.98 0.78 Lung cancer; chr6:149700161 chr6:149796151~149826294:- PAAD cis rs9322193 1 rs9377228 ENSG00000231760.4 RP11-350J20.5 15.14 3.71e-32 2.18e-27 0.98 0.78 Lung cancer; chr6:149600862 chr6:149796151~149826294:- PAAD cis rs9322193 0.961 rs2064520 ENSG00000231760.4 RP11-350J20.5 15.14 3.71e-32 2.18e-27 0.98 0.78 Lung cancer; chr6:149603650 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10872651 ENSG00000231760.4 RP11-350J20.5 15.14 3.71e-32 2.18e-27 1.01 0.78 Lung cancer; chr6:149768273 chr6:149796151~149826294:- PAAD cis rs9322193 0.962 rs3805749 ENSG00000231760.4 RP11-350J20.5 15.14 3.71e-32 2.18e-27 1.01 0.78 Lung cancer; chr6:149772546 chr6:149796151~149826294:- PAAD cis rs9322193 0.847 rs9505972 ENSG00000231760.4 RP11-350J20.5 15.14 3.71e-32 2.18e-27 1.01 0.78 Lung cancer; chr6:149775255 chr6:149796151~149826294:- PAAD cis rs858239 0.539 rs7791200 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23142502 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs57864591 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23144805 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs4294098 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23146376 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs4504540 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23146579 chr7:23101228~23105703:- PAAD cis rs858239 0.509 rs6975524 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23146833 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6955726 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23147072 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6955969 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23147080 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6976957 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23147714 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs6956828 ENSG00000230658.1 KLHL7-AS1 15.14 3.72e-32 2.18e-27 1 0.78 Cerebrospinal fluid biomarker levels; chr7:23147728 chr7:23101228~23105703:- PAAD cis rs9322193 0.884 rs9480009 ENSG00000231760.4 RP11-350J20.5 15.12 4.16e-32 2.42e-27 0.99 0.78 Lung cancer; chr6:149758502 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9480031 ENSG00000231760.4 RP11-350J20.5 15.12 4.16e-32 2.42e-27 0.99 0.78 Lung cancer; chr6:149758875 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10872649 ENSG00000231760.4 RP11-350J20.5 15.12 4.16e-32 2.42e-27 0.99 0.78 Lung cancer; chr6:149759454 chr6:149796151~149826294:- PAAD cis rs9322193 0.924 rs9498382 ENSG00000231760.4 RP11-350J20.5 15.12 4.19e-32 2.43e-27 0.97 0.78 Lung cancer; chr6:149610982 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs7740278 ENSG00000231760.4 RP11-350J20.5 15.12 4.19e-32 2.43e-27 0.97 0.78 Lung cancer; chr6:149640116 chr6:149796151~149826294:- PAAD cis rs9326248 1 rs9326248 ENSG00000254851.1 RP11-109L13.1 -15.11 4.33e-32 2.47e-27 -1.1 -0.77 Blood protein levels; chr11:117128509 chr11:117135528~117138582:+ PAAD cis rs9322193 1 rs9399693 ENSG00000231760.4 RP11-350J20.5 15.11 4.36e-32 2.47e-27 0.97 0.77 Lung cancer; chr6:149612718 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9404048 ENSG00000231760.4 RP11-350J20.5 15.11 4.36e-32 2.47e-27 0.97 0.77 Lung cancer; chr6:149616188 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9767554 ENSG00000231760.4 RP11-350J20.5 15.11 4.36e-32 2.47e-27 0.97 0.77 Lung cancer; chr6:149616860 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9505982 ENSG00000231760.4 RP11-350J20.5 15.11 4.36e-32 2.47e-27 0.97 0.77 Lung cancer; chr6:149618465 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9322196 ENSG00000231760.4 RP11-350J20.5 15.11 4.36e-32 2.47e-27 0.97 0.77 Lung cancer; chr6:149619645 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10747275 ENSG00000231760.4 RP11-350J20.5 15.11 4.36e-32 2.47e-27 0.97 0.77 Lung cancer; chr6:149622782 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs9688794 ENSG00000231760.4 RP11-350J20.5 15.11 4.36e-32 2.47e-27 0.97 0.77 Lung cancer; chr6:149632121 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9689084 ENSG00000231760.4 RP11-350J20.5 15.11 4.36e-32 2.47e-27 0.97 0.77 Lung cancer; chr6:149639648 chr6:149796151~149826294:- PAAD cis rs9326248 0.817 rs1242127 ENSG00000254851.1 RP11-109L13.1 15.09 4.99e-32 2.83e-27 1.08 0.77 Blood protein levels; chr11:117205848 chr11:117135528~117138582:+ PAAD cis rs858239 0.571 rs2390755 ENSG00000230658.1 KLHL7-AS1 15.09 5.05e-32 2.83e-27 0.99 0.77 Cerebrospinal fluid biomarker levels; chr7:23151097 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs4365988 ENSG00000230658.1 KLHL7-AS1 15.09 5.05e-32 2.83e-27 0.99 0.77 Cerebrospinal fluid biomarker levels; chr7:23151252 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs2178139 ENSG00000230658.1 KLHL7-AS1 15.09 5.05e-32 2.83e-27 0.99 0.77 Cerebrospinal fluid biomarker levels; chr7:23152017 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs2141306 ENSG00000230658.1 KLHL7-AS1 15.09 5.05e-32 2.83e-27 0.99 0.77 Cerebrospinal fluid biomarker levels; chr7:23152045 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs2141305 ENSG00000230658.1 KLHL7-AS1 15.09 5.05e-32 2.83e-27 0.99 0.77 Cerebrospinal fluid biomarker levels; chr7:23152280 chr7:23101228~23105703:- PAAD cis rs1577917 0.633 rs7770835 ENSG00000203875.9 SNHG5 -15.04 6.64e-32 3.72e-27 -1 -0.77 Response to antipsychotic treatment; chr6:85899189 chr6:85660950~85678736:- PAAD cis rs9322193 0.923 rs1934534 ENSG00000231760.4 RP11-350J20.5 15.03 7.05e-32 3.93e-27 0.96 0.77 Lung cancer; chr6:149711896 chr6:149796151~149826294:- PAAD cis rs9322193 0.961 rs9767713 ENSG00000231760.4 RP11-350J20.5 15.02 7.48e-32 4.17e-27 1.01 0.77 Lung cancer; chr6:149588241 chr6:149796151~149826294:- PAAD cis rs1577917 0.839 rs12055653 ENSG00000203875.9 SNHG5 -14.99 9.01e-32 4.99e-27 -1.01 -0.77 Response to antipsychotic treatment; chr6:85836945 chr6:85660950~85678736:- PAAD cis rs9322193 0.886 rs9767555 ENSG00000231760.4 RP11-350J20.5 14.99 9.37e-32 5.18e-27 0.98 0.77 Lung cancer; chr6:149647022 chr6:149796151~149826294:- PAAD cis rs1577917 0.629 rs6927475 ENSG00000203875.9 SNHG5 14.98 1.01e-31 5.57e-27 1 0.77 Response to antipsychotic treatment; chr6:85497055 chr6:85660950~85678736:- PAAD cis rs1577917 0.629 rs9450285 ENSG00000203875.9 SNHG5 14.97 1.01e-31 5.57e-27 1 0.77 Response to antipsychotic treatment; chr6:85498378 chr6:85660950~85678736:- PAAD cis rs858239 0.509 rs6962213 ENSG00000230658.1 KLHL7-AS1 14.92 1.38e-31 7.48e-27 1 0.77 Cerebrospinal fluid biomarker levels; chr7:23148490 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs2178140 ENSG00000230658.1 KLHL7-AS1 14.89 1.65e-31 8.99e-27 0.99 0.77 Cerebrospinal fluid biomarker levels; chr7:23152006 chr7:23101228~23105703:- PAAD cis rs9326248 0.906 rs171052 ENSG00000254851.1 RP11-109L13.1 14.88 1.77e-31 9.59e-27 1.08 0.77 Blood protein levels; chr11:117211047 chr11:117135528~117138582:+ PAAD cis rs9322193 0.923 rs9766004 ENSG00000231760.4 RP11-350J20.5 14.88 1.8e-31 9.76e-27 0.95 0.77 Lung cancer; chr6:149754363 chr6:149796151~149826294:- PAAD cis rs1577917 0.74 rs7752502 ENSG00000203875.9 SNHG5 14.88 1.82e-31 9.8e-27 1.03 0.77 Response to antipsychotic treatment; chr6:85700933 chr6:85660950~85678736:- PAAD cis rs1577917 0.74 rs2475792 ENSG00000203875.9 SNHG5 14.87 1.86e-31 1e-26 1.01 0.77 Response to antipsychotic treatment; chr6:85682384 chr6:85660950~85678736:- PAAD cis rs858239 0.539 rs4295546 ENSG00000230658.1 KLHL7-AS1 14.87 1.9e-31 1.02e-26 1 0.77 Cerebrospinal fluid biomarker levels; chr7:23151402 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs1080670 ENSG00000231760.4 RP11-350J20.5 14.87 1.92e-31 1.03e-26 0.96 0.77 Lung cancer; chr6:149620161 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9322204 ENSG00000231760.4 RP11-350J20.5 14.84 2.27e-31 1.21e-26 0.96 0.77 Lung cancer; chr6:149636047 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs11155671 ENSG00000231760.4 RP11-350J20.5 14.82 2.55e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149650996 chr6:149796151~149826294:- PAAD cis rs1577917 0.883 rs2782263 ENSG00000203875.9 SNHG5 -14.82 2.61e-31 1.33e-26 -1.01 -0.77 Response to antipsychotic treatment; chr6:86081589 chr6:85660950~85678736:- PAAD cis rs9322193 0.886 rs9485408 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149618888 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10782310 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149622458 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs10782311 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149622592 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs10782312 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149622669 chr6:149796151~149826294:- PAAD cis rs9322193 0.886 rs9322198 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149623772 chr6:149796151~149826294:- PAAD cis rs9322193 0.847 rs12234128 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149627553 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs57012784 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149627691 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9505823 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149628899 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9322200 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149630078 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9689599 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149631973 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9800580 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149632845 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs11155669 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149633501 chr6:149796151~149826294:- PAAD cis rs9322193 0.887 rs9505824 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149633663 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9505826 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149633912 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9766886 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149637048 chr6:149796151~149826294:- PAAD cis rs9322193 0.923 rs9688861 ENSG00000231760.4 RP11-350J20.5 14.82 2.62e-31 1.33e-26 0.96 0.77 Lung cancer; chr6:149637924 chr6:149796151~149826294:- PAAD cis rs2739330 0.892 rs4822455 ENSG00000273295.1 AP000350.5 14.78 3.23e-31 1.63e-26 0.95 0.77 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23901432~23907068:- PAAD cis rs9326248 0.911 rs11216284 ENSG00000254851.1 RP11-109L13.1 -14.78 3.25e-31 1.64e-26 -1.1 -0.77 Blood protein levels; chr11:117132344 chr11:117135528~117138582:+ PAAD cis rs858239 0.539 rs10254544 ENSG00000230658.1 KLHL7-AS1 14.78 3.39e-31 1.71e-26 1 0.77 Cerebrospinal fluid biomarker levels; chr7:23180616 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs9767105 ENSG00000231760.4 RP11-350J20.5 14.74 4.25e-31 2.13e-26 0.99 0.77 Lung cancer; chr6:149659591 chr6:149796151~149826294:- PAAD cis rs62445005 1 rs62445005 ENSG00000211697.3 TRGV5 14.74 4.27e-31 2.14e-26 1.08 0.77 Shingles; chr7:38346957 chr7:38343894~38350022:- PAAD cis rs9322193 0.923 rs9377230 ENSG00000231760.4 RP11-350J20.5 14.72 4.91e-31 2.45e-26 0.95 0.77 Lung cancer; chr6:149613607 chr6:149796151~149826294:- PAAD cis rs1577917 0.883 rs12214536 ENSG00000203875.9 SNHG5 -14.71 4.94e-31 2.46e-26 -1.01 -0.77 Response to antipsychotic treatment; chr6:86080592 chr6:85660950~85678736:- PAAD cis rs858239 0.539 rs6461695 ENSG00000230658.1 KLHL7-AS1 14.69 5.72e-31 2.85e-26 1 0.77 Cerebrospinal fluid biomarker levels; chr7:23158165 chr7:23101228~23105703:- PAAD cis rs2739330 0.929 rs5751777 ENSG00000273295.1 AP000350.5 14.67 6.36e-31 3.1e-26 0.98 0.77 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23901432~23907068:- PAAD cis rs9326248 1 rs585849 ENSG00000254851.1 RP11-109L13.1 -14.64 7.88e-31 3.61e-26 -1.07 -0.76 Blood protein levels; chr11:117198345 chr11:117135528~117138582:+ PAAD cis rs858239 0.601 rs6971002 ENSG00000230658.1 KLHL7-AS1 14.63 8.16e-31 3.73e-26 1.01 0.76 Cerebrospinal fluid biomarker levels; chr7:23132685 chr7:23101228~23105703:- PAAD cis rs2739330 0.892 rs4822455 ENSG00000218537.1 MIF-AS1 14.62 8.69e-31 3.92e-26 0.99 0.76 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23894426~23898930:- PAAD cis rs858239 0.508 rs10242104 ENSG00000230658.1 KLHL7-AS1 14.59 1.03e-30 4.64e-26 1.03 0.76 Cerebrospinal fluid biomarker levels; chr7:23180831 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs9766037 ENSG00000231760.4 RP11-350J20.5 14.55 1.36e-30 6.07e-26 1 0.76 Lung cancer; chr6:149616921 chr6:149796151~149826294:- PAAD cis rs9322193 0.924 rs9322189 ENSG00000231760.4 RP11-350J20.5 14.53 1.51e-30 6.72e-26 0.97 0.76 Lung cancer; chr6:149588797 chr6:149796151~149826294:- PAAD cis rs1577917 0.629 rs7761762 ENSG00000203875.9 SNHG5 14.52 1.61e-30 7.1e-26 0.97 0.76 Response to antipsychotic treatment; chr6:85496250 chr6:85660950~85678736:- PAAD cis rs9322193 0.886 rs9718079 ENSG00000231760.4 RP11-350J20.5 14.5 1.78e-30 7.81e-26 0.95 0.76 Lung cancer; chr6:149645947 chr6:149796151~149826294:- PAAD cis rs858239 0.512 rs55788996 ENSG00000230658.1 KLHL7-AS1 14.5 1.78e-30 7.83e-26 0.99 0.76 Cerebrospinal fluid biomarker levels; chr7:23153230 chr7:23101228~23105703:- PAAD cis rs9322193 0.651 rs9322188 ENSG00000231760.4 RP11-350J20.5 -14.5 1.87e-30 8.21e-26 -0.98 -0.76 Lung cancer; chr6:149588355 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs2064521 ENSG00000231760.4 RP11-350J20.5 -14.42 2.95e-30 1.29e-25 -0.94 -0.76 Lung cancer; chr6:149625336 chr6:149796151~149826294:- PAAD cis rs858239 0.699 rs858260 ENSG00000230658.1 KLHL7-AS1 14.4 3.33e-30 1.45e-25 0.99 0.76 Cerebrospinal fluid biomarker levels; chr7:23173315 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs10279194 ENSG00000230658.1 KLHL7-AS1 14.37 4.03e-30 1.75e-25 0.98 0.76 Cerebrospinal fluid biomarker levels; chr7:23151464 chr7:23101228~23105703:- PAAD cis rs858239 0.539 rs3950345 ENSG00000230658.1 KLHL7-AS1 14.37 4.03e-30 1.75e-25 0.98 0.76 Cerebrospinal fluid biomarker levels; chr7:23151495 chr7:23101228~23105703:- PAAD cis rs1577917 0.771 rs7762321 ENSG00000203875.9 SNHG5 14.35 4.7e-30 2.03e-25 1 0.76 Response to antipsychotic treatment; chr6:85702428 chr6:85660950~85678736:- PAAD cis rs8013143 1 rs11846575 ENSG00000279656.1 RP11-298I3.6 -14.31 5.69e-30 2.44e-25 -0.99 -0.76 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23022075 chr14:23023083~23024217:- PAAD cis rs8013143 1 rs8013143 ENSG00000279656.1 RP11-298I3.6 -14.31 5.69e-30 2.44e-25 -0.99 -0.76 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23025068 chr14:23023083~23024217:- PAAD cis rs8013143 1 rs941718 ENSG00000279656.1 RP11-298I3.6 -14.31 5.69e-30 2.44e-25 -0.99 -0.76 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23025839 chr14:23023083~23024217:- PAAD cis rs1577917 0.74 rs9344542 ENSG00000203875.9 SNHG5 14.28 6.83e-30 2.91e-25 0.99 0.76 Response to antipsychotic treatment; chr6:85684187 chr6:85660950~85678736:- PAAD cis rs858239 0.537 rs2286272 ENSG00000230658.1 KLHL7-AS1 14.27 7.51e-30 3.18e-25 0.99 0.76 Cerebrospinal fluid biomarker levels; chr7:23184748 chr7:23101228~23105703:- PAAD cis rs858239 0.537 rs6955115 ENSG00000230658.1 KLHL7-AS1 14.27 7.51e-30 3.18e-25 0.99 0.76 Cerebrospinal fluid biomarker levels; chr7:23187525 chr7:23101228~23105703:- PAAD cis rs858239 0.537 rs10279691 ENSG00000230658.1 KLHL7-AS1 14.27 7.51e-30 3.18e-25 0.99 0.76 Cerebrospinal fluid biomarker levels; chr7:23188768 chr7:23101228~23105703:- PAAD cis rs1577917 0.74 rs9353327 ENSG00000203875.9 SNHG5 -14.25 8.56e-30 3.61e-25 -1 -0.76 Response to antipsychotic treatment; chr6:85684348 chr6:85660950~85678736:- PAAD cis rs9322193 0.847 rs62439808 ENSG00000231760.4 RP11-350J20.5 14.24 8.71e-30 3.67e-25 0.96 0.76 Lung cancer; chr6:149629690 chr6:149796151~149826294:- PAAD cis rs858239 0.568 rs6970694 ENSG00000230658.1 KLHL7-AS1 14.23 9.26e-30 3.9e-25 1 0.76 Cerebrospinal fluid biomarker levels; chr7:23211209 chr7:23101228~23105703:- PAAD cis rs1577917 0.538 rs6454483 ENSG00000203875.9 SNHG5 14.21 1.06e-29 4.45e-25 1.02 0.76 Response to antipsychotic treatment; chr6:85708565 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs906695 ENSG00000253404.1 AC034243.1 14.2 1.11e-29 4.66e-25 0.96 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138803588 chr5:138744434~138753309:- PAAD cis rs8013143 0.961 rs7147308 ENSG00000279656.1 RP11-298I3.6 -14.2 1.15e-29 4.79e-25 -0.99 -0.76 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23028420 chr14:23023083~23024217:- PAAD cis rs9326248 0.954 rs4938349 ENSG00000254851.1 RP11-109L13.1 -14.18 1.29e-29 5.33e-25 -1.05 -0.75 Blood protein levels; chr11:117151207 chr11:117135528~117138582:+ PAAD cis rs9326248 1 rs3736120 ENSG00000254851.1 RP11-109L13.1 -14.18 1.29e-29 5.33e-25 -1.05 -0.75 Blood protein levels; chr11:117161409 chr11:117135528~117138582:+ PAAD cis rs1577917 0.518 rs2475787 ENSG00000203875.9 SNHG5 14.15 1.59e-29 6.56e-25 1 0.75 Response to antipsychotic treatment; chr6:85705518 chr6:85660950~85678736:- PAAD cis rs9326248 0.954 rs10790177 ENSG00000254851.1 RP11-109L13.1 -14.14 1.64e-29 6.73e-25 -1.04 -0.75 Blood protein levels; chr11:117177701 chr11:117135528~117138582:+ PAAD cis rs9326248 1 rs7946257 ENSG00000254851.1 RP11-109L13.1 -14.14 1.64e-29 6.73e-25 -1.04 -0.75 Blood protein levels; chr11:117182449 chr11:117135528~117138582:+ PAAD cis rs9326248 0.954 rs521171 ENSG00000254851.1 RP11-109L13.1 -14.14 1.64e-29 6.73e-25 -1.04 -0.75 Blood protein levels; chr11:117193977 chr11:117135528~117138582:+ PAAD cis rs9326248 0.954 rs8521 ENSG00000254851.1 RP11-109L13.1 -14.14 1.64e-29 6.73e-25 -1.04 -0.75 Blood protein levels; chr11:117196983 chr11:117135528~117138582:+ PAAD cis rs858239 0.665 rs6964665 ENSG00000230658.1 KLHL7-AS1 14.13 1.77e-29 7.26e-25 0.99 0.75 Cerebrospinal fluid biomarker levels; chr7:23171733 chr7:23101228~23105703:- PAAD cis rs2882667 0.654 rs288019 ENSG00000253404.1 AC034243.1 -14.11 1.95e-29 7.94e-25 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138855704 chr5:138744434~138753309:- PAAD cis rs916888 0.773 rs9896243 ENSG00000262539.1 RP11-259G18.3 14.11 1.98e-29 8.01e-25 1.12 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:46259551~46260606:- PAAD cis rs2882667 0.587 rs288015 ENSG00000253404.1 AC034243.1 -14.11 2.02e-29 8.01e-25 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138859528 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288013 ENSG00000253404.1 AC034243.1 -14.11 2.02e-29 8.01e-25 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138860128 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs176381 ENSG00000253404.1 AC034243.1 -14.11 2.02e-29 8.01e-25 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138861042 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288011 ENSG00000253404.1 AC034243.1 -14.11 2.02e-29 8.01e-25 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138864250 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288010 ENSG00000253404.1 AC034243.1 -14.11 2.02e-29 8.01e-25 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138864340 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs495638 ENSG00000253404.1 AC034243.1 -14.11 2.02e-29 8.01e-25 -0.97 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138865253 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288042 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138867345 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288041 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138868322 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288039 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138870511 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288038 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138871844 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288031 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138880377 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288030 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138880594 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288023 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138888359 chr5:138744434~138753309:- PAAD cis rs2882667 0.599 rs288008 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138893632 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288004 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138895956 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs2662543 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138898441 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs17207772 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138906131 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs13172507 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138907409 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6872423 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138911089 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs13177415 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138914251 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs13181762 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138914417 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs2351463 ENSG00000253404.1 AC034243.1 14.11 2.02e-29 8.01e-25 0.97 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138923113 chr5:138744434~138753309:- PAAD cis rs2739330 0.929 rs5751777 ENSG00000218537.1 MIF-AS1 14.1 2.08e-29 8.23e-25 1.02 0.75 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23894426~23898930:- PAAD cis rs858239 0.537 rs6942981 ENSG00000230658.1 KLHL7-AS1 14.1 2.18e-29 8.58e-25 1.02 0.75 Cerebrospinal fluid biomarker levels; chr7:23191929 chr7:23101228~23105703:- PAAD cis rs2486288 0.656 rs8039352 ENSG00000259520.4 CTD-2651B20.3 14.06 2.71e-29 1.06e-24 0.86 0.75 Glomerular filtration rate; chr15:45259592 chr15:45251580~45279251:- PAAD cis rs507080 0.883 rs12798453 ENSG00000255239.1 AP002954.6 14.05 2.91e-29 1.14e-24 0.98 0.75 Serum metabolite levels; chr11:118690701 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs625513 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118685010 chr11:118688039~118690600:- PAAD cis rs507080 0.845 rs613377 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118685375 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs546890 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118686489 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs555356 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118687369 chr11:118688039~118690600:- PAAD cis rs507080 0.883 rs693306 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118687624 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs561845 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118688118 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs638805 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118688180 chr11:118688039~118690600:- PAAD cis rs507080 0.845 rs510408 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118688192 chr11:118688039~118690600:- PAAD cis rs507080 0.845 rs509641 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118688243 chr11:118688039~118690600:- PAAD cis rs507080 0.883 rs563549 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118688244 chr11:118688039~118690600:- PAAD cis rs507080 0.885 rs533144 ENSG00000255239.1 AP002954.6 14.04 3.14e-29 1.2e-24 0.98 0.75 Serum metabolite levels; chr11:118688538 chr11:118688039~118690600:- PAAD cis rs9326248 1 rs4938344 ENSG00000254851.1 RP11-109L13.1 -14.01 3.6e-29 1.37e-24 -1.08 -0.75 Blood protein levels; chr11:117133033 chr11:117135528~117138582:+ PAAD cis rs9326248 1 rs664922 ENSG00000254851.1 RP11-109L13.1 -14.01 3.79e-29 1.44e-24 -1.05 -0.75 Blood protein levels; chr11:117200179 chr11:117135528~117138582:+ PAAD cis rs9326248 1 rs664082 ENSG00000254851.1 RP11-109L13.1 -14.01 3.79e-29 1.44e-24 -1.05 -0.75 Blood protein levels; chr11:117200354 chr11:117135528~117138582:+ PAAD cis rs9326248 0.953 rs488962 ENSG00000254851.1 RP11-109L13.1 14.01 3.79e-29 1.44e-24 1.05 0.75 Blood protein levels; chr11:117201809 chr11:117135528~117138582:+ PAAD cis rs9326248 0.953 rs634960 ENSG00000254851.1 RP11-109L13.1 14.01 3.79e-29 1.44e-24 1.05 0.75 Blood protein levels; chr11:117202247 chr11:117135528~117138582:+ PAAD cis rs507080 0.885 rs693037 ENSG00000255239.1 AP002954.6 13.99 4.29e-29 1.62e-24 0.96 0.75 Serum metabolite levels; chr11:118682617 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs514143 ENSG00000255239.1 AP002954.6 13.98 4.56e-29 1.72e-24 0.98 0.75 Serum metabolite levels; chr11:118687740 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs558907 ENSG00000255239.1 AP002954.6 13.98 4.56e-29 1.72e-24 0.98 0.75 Serum metabolite levels; chr11:118687746 chr11:118688039~118690600:- PAAD cis rs507080 0.885 rs7926959 ENSG00000255239.1 AP002954.6 13.98 4.56e-29 1.72e-24 0.98 0.75 Serum metabolite levels; chr11:118689157 chr11:118688039~118690600:- PAAD cis rs507080 0.663 rs7926970 ENSG00000255239.1 AP002954.6 13.98 4.56e-29 1.72e-24 0.98 0.75 Serum metabolite levels; chr11:118689172 chr11:118688039~118690600:- PAAD cis rs507080 0.885 rs4938530 ENSG00000255239.1 AP002954.6 13.98 4.56e-29 1.72e-24 0.98 0.75 Serum metabolite levels; chr11:118689861 chr11:118688039~118690600:- PAAD cis rs1577917 0.74 rs9344533 ENSG00000203875.9 SNHG5 13.97 4.86e-29 1.82e-24 0.99 0.75 Response to antipsychotic treatment; chr6:85526470 chr6:85660950~85678736:- PAAD cis rs1577917 0.74 rs7775864 ENSG00000203875.9 SNHG5 13.97 4.86e-29 1.82e-24 0.99 0.75 Response to antipsychotic treatment; chr6:85538041 chr6:85660950~85678736:- PAAD cis rs1577917 0.74 rs7771612 ENSG00000203875.9 SNHG5 13.97 4.86e-29 1.82e-24 0.99 0.75 Response to antipsychotic treatment; chr6:85554656 chr6:85660950~85678736:- PAAD cis rs858239 0.699 rs955187 ENSG00000230658.1 KLHL7-AS1 -13.94 5.75e-29 2.16e-24 -0.97 -0.75 Cerebrospinal fluid biomarker levels; chr7:23154986 chr7:23101228~23105703:- PAAD cis rs2882667 0.69 rs10038162 ENSG00000253404.1 AC034243.1 -13.92 6.25e-29 2.34e-24 -0.95 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138901066 chr5:138744434~138753309:- PAAD cis rs1577917 0.654 rs9450284 ENSG00000203875.9 SNHG5 13.92 6.51e-29 2.43e-24 0.94 0.75 Response to antipsychotic treatment; chr6:85489611 chr6:85660950~85678736:- PAAD cis rs858239 0.669 rs10950940 ENSG00000230658.1 KLHL7-AS1 -13.9 7.38e-29 2.75e-24 -0.98 -0.75 Cerebrospinal fluid biomarker levels; chr7:23157197 chr7:23101228~23105703:- PAAD cis rs507080 0.922 rs525485 ENSG00000255239.1 AP002954.6 13.89 7.84e-29 2.91e-24 0.98 0.75 Serum metabolite levels; chr11:118685045 chr11:118688039~118690600:- PAAD cis rs2486288 0.656 rs62026703 ENSG00000259520.4 CTD-2651B20.3 13.88 8.32e-29 3.08e-24 0.84 0.75 Glomerular filtration rate; chr15:45277731 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs7165039 ENSG00000259520.4 CTD-2651B20.3 13.88 8.32e-29 3.08e-24 0.84 0.75 Glomerular filtration rate; chr15:45278215 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs7166580 ENSG00000259520.4 CTD-2651B20.3 13.88 8.32e-29 3.08e-24 0.84 0.75 Glomerular filtration rate; chr15:45279011 chr15:45251580~45279251:- PAAD cis rs5850 0.602 rs1005786 ENSG00000230658.1 KLHL7-AS1 13.86 9.25e-29 3.4e-24 0.92 0.75 Blood protein levels; chr7:23106218 chr7:23101228~23105703:- PAAD cis rs9326248 0.798 rs10892079 ENSG00000254851.1 RP11-109L13.1 -13.85 1.01e-28 3.72e-24 -1.07 -0.75 Blood protein levels; chr11:117146108 chr11:117135528~117138582:+ PAAD cis rs1577917 0.74 rs9353320 ENSG00000203875.9 SNHG5 13.83 1.11e-28 4.06e-24 0.99 0.75 Response to antipsychotic treatment; chr6:85535130 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs160405 ENSG00000253404.1 AC034243.1 13.81 1.26e-28 4.6e-24 0.93 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138748387 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1627698 ENSG00000253404.1 AC034243.1 -13.81 1.26e-28 4.6e-24 -0.93 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138741777 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1725335 ENSG00000253404.1 AC034243.1 -13.81 1.26e-28 4.6e-24 -0.93 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138745541 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs160406 ENSG00000253404.1 AC034243.1 -13.81 1.26e-28 4.6e-24 -0.93 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138748032 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs700616 ENSG00000253404.1 AC034243.1 -13.81 1.26e-28 4.6e-24 -0.93 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138752184 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs700617 ENSG00000253404.1 AC034243.1 -13.81 1.26e-28 4.6e-24 -0.93 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138752290 chr5:138744434~138753309:- PAAD cis rs1577917 0.696 rs2842617 ENSG00000203875.9 SNHG5 -13.81 1.29e-28 4.7e-24 -0.99 -0.75 Response to antipsychotic treatment; chr6:85599980 chr6:85660950~85678736:- PAAD cis rs9326248 1 rs10790175 ENSG00000254851.1 RP11-109L13.1 -13.8 1.37e-28 4.96e-24 -1.03 -0.75 Blood protein levels; chr11:117164013 chr11:117135528~117138582:+ PAAD cis rs2486288 0.656 rs12911861 ENSG00000259520.4 CTD-2651B20.3 13.8 1.38e-28 4.97e-24 0.84 0.75 Glomerular filtration rate; chr15:45274520 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs12908818 ENSG00000259520.4 CTD-2651B20.3 13.8 1.38e-28 4.97e-24 0.84 0.75 Glomerular filtration rate; chr15:45279470 chr15:45251580~45279251:- PAAD cis rs2486288 0.586 rs12909625 ENSG00000259520.4 CTD-2651B20.3 13.8 1.38e-28 4.97e-24 0.84 0.75 Glomerular filtration rate; chr15:45279855 chr15:45251580~45279251:- PAAD cis rs2486288 0.586 rs12909883 ENSG00000259520.4 CTD-2651B20.3 13.8 1.38e-28 4.97e-24 0.84 0.75 Glomerular filtration rate; chr15:45279856 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs12910009 ENSG00000259520.4 CTD-2651B20.3 13.8 1.38e-28 4.97e-24 0.84 0.75 Glomerular filtration rate; chr15:45280210 chr15:45251580~45279251:- PAAD cis rs507080 0.922 rs4938524 ENSG00000255239.1 AP002954.6 13.79 1.44e-28 5.18e-24 0.96 0.75 Serum metabolite levels; chr11:118681365 chr11:118688039~118690600:- PAAD cis rs1577917 0.771 rs2484355 ENSG00000203875.9 SNHG5 -13.79 1.45e-28 5.23e-24 -0.98 -0.75 Response to antipsychotic treatment; chr6:85684685 chr6:85660950~85678736:- PAAD cis rs507080 0.961 rs34413584 ENSG00000255239.1 AP002954.6 13.78 1.54e-28 5.52e-24 0.96 0.75 Serum metabolite levels; chr11:118675072 chr11:118688039~118690600:- PAAD cis rs2882667 0.69 rs288016 ENSG00000253404.1 AC034243.1 -13.76 1.72e-28 6.14e-24 -0.95 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138859299 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs700624 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138763332 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs700625 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138763908 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs2940595 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138765348 chr5:138744434~138753309:- PAAD cis rs2882667 0.587 rs2174972 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138766229 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs851278 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138767577 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs2693963 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138770637 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1567313 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138775013 chr5:138744434~138753309:- PAAD cis rs2882667 0.589 rs825770 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138779530 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs825769 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138779666 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs700627 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138783711 chr5:138744434~138753309:- PAAD cis rs2882667 0.62 rs3789151 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138809771 chr5:138744434~138753309:- PAAD cis rs2882667 0.587 rs6596450 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138810831 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs884470 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138820236 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs4835705 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138827887 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1039789 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138835734 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1828187 ENSG00000253404.1 AC034243.1 13.75 1.84e-28 6.38e-24 0.94 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138836531 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6887841 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138840221 chr5:138744434~138753309:- PAAD cis rs2882667 0.72 rs56044552 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138841265 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs7710288 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138844049 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs10043478 ENSG00000253404.1 AC034243.1 13.75 1.84e-28 6.38e-24 0.94 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138853022 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs6863054 ENSG00000253404.1 AC034243.1 -13.75 1.84e-28 6.38e-24 -0.94 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138853166 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs176382 ENSG00000253404.1 AC034243.1 13.75 1.84e-28 6.38e-24 0.94 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138891078 chr5:138744434~138753309:- PAAD cis rs507080 0.922 rs582630 ENSG00000255239.1 AP002954.6 13.74 1.96e-28 6.78e-24 0.98 0.74 Serum metabolite levels; chr11:118692090 chr11:118688039~118690600:- PAAD cis rs507080 0.883 rs527475 ENSG00000255239.1 AP002954.6 13.74 1.96e-28 6.78e-24 0.98 0.74 Serum metabolite levels; chr11:118692530 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs585039 ENSG00000255239.1 AP002954.6 13.74 1.96e-28 6.78e-24 0.98 0.74 Serum metabolite levels; chr11:118692672 chr11:118688039~118690600:- PAAD cis rs2882667 0.69 rs891996 ENSG00000253404.1 AC034243.1 13.74 1.97e-28 6.83e-24 0.96 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138932127 chr5:138744434~138753309:- PAAD cis rs2486288 0.656 rs6493144 ENSG00000259520.4 CTD-2651B20.3 -13.74 1.98e-28 6.85e-24 -0.83 -0.74 Glomerular filtration rate; chr15:45281291 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs6493145 ENSG00000259520.4 CTD-2651B20.3 13.74 1.99e-28 6.88e-24 0.84 0.74 Glomerular filtration rate; chr15:45281664 chr15:45251580~45279251:- PAAD cis rs9326248 1 rs664971 ENSG00000254851.1 RP11-109L13.1 13.71 2.26e-28 7.8e-24 1.04 0.74 Blood protein levels; chr11:117200141 chr11:117135528~117138582:+ PAAD cis rs2486288 0.656 rs7171312 ENSG00000259520.4 CTD-2651B20.3 13.71 2.34e-28 8.03e-24 0.84 0.74 Glomerular filtration rate; chr15:45278027 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs6493143 ENSG00000259520.4 CTD-2651B20.3 13.71 2.34e-28 8.03e-24 0.84 0.74 Glomerular filtration rate; chr15:45278583 chr15:45251580~45279251:- PAAD cis rs1577917 0.682 rs6909767 ENSG00000203875.9 SNHG5 13.7 2.43e-28 8.33e-24 1 0.74 Response to antipsychotic treatment; chr6:85518391 chr6:85660950~85678736:- PAAD cis rs2486288 0.656 rs2413771 ENSG00000259520.4 CTD-2651B20.3 13.69 2.71e-28 9.29e-24 0.84 0.74 Glomerular filtration rate; chr15:45260942 chr15:45251580~45279251:- PAAD cis rs507080 0.922 rs478296 ENSG00000255239.1 AP002954.6 13.67 2.96e-28 1.01e-23 0.97 0.74 Serum metabolite levels; chr11:118696666 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs493834 ENSG00000255239.1 AP002954.6 13.67 2.96e-28 1.01e-23 0.97 0.74 Serum metabolite levels; chr11:118696735 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs644498 ENSG00000255239.1 AP002954.6 13.67 2.96e-28 1.01e-23 0.97 0.74 Serum metabolite levels; chr11:118696777 chr11:118688039~118690600:- PAAD cis rs1577917 0.682 rs1173417 ENSG00000203875.9 SNHG5 13.67 3.02e-28 1.02e-23 0.97 0.74 Response to antipsychotic treatment; chr6:85694223 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2842602 ENSG00000203875.9 SNHG5 -13.65 3.33e-28 1.12e-23 -0.99 -0.74 Response to antipsychotic treatment; chr6:85622169 chr6:85660950~85678736:- PAAD cis rs7847628 0.587 rs4837796 ENSG00000226752.6 PSMD5-AS1 13.64 3.49e-28 1.17e-23 0.82 0.74 Birth weight; chr9:120848010 chr9:120824828~120854385:+ PAAD cis rs916888 0.61 rs199529 ENSG00000262539.1 RP11-259G18.3 13.64 3.64e-28 1.22e-23 1.07 0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:46259551~46260606:- PAAD cis rs1577917 0.785 rs1885607 ENSG00000203875.9 SNHG5 13.63 3.84e-28 1.29e-23 0.97 0.74 Response to antipsychotic treatment; chr6:85685187 chr6:85660950~85678736:- PAAD cis rs1577917 0.655 rs7742691 ENSG00000203875.9 SNHG5 13.62 3.97e-28 1.32e-23 0.98 0.74 Response to antipsychotic treatment; chr6:85568973 chr6:85660950~85678736:- PAAD cis rs1577917 0.71 rs9342041 ENSG00000203875.9 SNHG5 13.62 3.97e-28 1.32e-23 0.98 0.74 Response to antipsychotic treatment; chr6:85571157 chr6:85660950~85678736:- PAAD cis rs1577917 0.682 rs6935918 ENSG00000203875.9 SNHG5 13.62 3.97e-28 1.32e-23 0.98 0.74 Response to antipsychotic treatment; chr6:85573857 chr6:85660950~85678736:- PAAD cis rs1577917 0.74 rs2758842 ENSG00000203875.9 SNHG5 -13.62 3.97e-28 1.32e-23 -0.98 -0.74 Response to antipsychotic treatment; chr6:85599013 chr6:85660950~85678736:- PAAD cis rs1577917 0.572 rs911927 ENSG00000203875.9 SNHG5 -13.62 3.97e-28 1.32e-23 -0.98 -0.74 Response to antipsychotic treatment; chr6:85618142 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs4441928 ENSG00000203875.9 SNHG5 13.62 4.1e-28 1.36e-23 0.98 0.74 Response to antipsychotic treatment; chr6:85532176 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs288025 ENSG00000253404.1 AC034243.1 13.62 4.11e-28 1.36e-23 0.95 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138887944 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs700618 ENSG00000253404.1 AC034243.1 -13.6 4.5e-28 1.49e-23 -0.93 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138752429 chr5:138744434~138753309:- PAAD cis rs7847628 0.587 rs1060817 ENSG00000226752.6 PSMD5-AS1 -13.6 4.65e-28 1.54e-23 -0.83 -0.74 Birth weight; chr9:120820914 chr9:120824828~120854385:+ PAAD cis rs7847628 0.587 rs10760117 ENSG00000226752.6 PSMD5-AS1 -13.6 4.65e-28 1.54e-23 -0.83 -0.74 Birth weight; chr9:120824459 chr9:120824828~120854385:+ PAAD cis rs858239 0.699 rs1881201 ENSG00000230658.1 KLHL7-AS1 -13.6 4.66e-28 1.54e-23 -0.96 -0.74 Cerebrospinal fluid biomarker levels; chr7:23154394 chr7:23101228~23105703:- PAAD cis rs507080 0.922 rs558781 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118693688 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs508640 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118693704 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs471227 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118693892 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs516153 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118694053 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs518028 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118694273 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs519982 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118694522 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs478371 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118694627 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs502601 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118694970 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs7114458 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118695466 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs7114216 ENSG00000255239.1 AP002954.6 13.59 4.79e-28 1.57e-23 0.97 0.74 Serum metabolite levels; chr11:118695525 chr11:118688039~118690600:- PAAD cis rs507080 0.883 rs692750 ENSG00000255239.1 AP002954.6 13.59 4.83e-28 1.58e-23 0.95 0.74 Serum metabolite levels; chr11:118667599 chr11:118688039~118690600:- PAAD cis rs2486288 0.656 rs8024620 ENSG00000259520.4 CTD-2651B20.3 13.59 4.97e-28 1.62e-23 0.84 0.74 Glomerular filtration rate; chr15:45282131 chr15:45251580~45279251:- PAAD cis rs1577917 0.518 rs6454482 ENSG00000203875.9 SNHG5 13.59 4.99e-28 1.63e-23 0.99 0.74 Response to antipsychotic treatment; chr6:85708470 chr6:85660950~85678736:- PAAD cis rs9326248 1 rs7107152 ENSG00000254851.1 RP11-109L13.1 13.58 5.14e-28 1.67e-23 1 0.74 Blood protein levels; chr11:117185364 chr11:117135528~117138582:+ PAAD cis rs1577917 0.74 rs2842614 ENSG00000203875.9 SNHG5 -13.58 5.32e-28 1.73e-23 -0.98 -0.74 Response to antipsychotic treatment; chr6:85596351 chr6:85660950~85678736:- PAAD cis rs1577917 0.74 rs2758843 ENSG00000203875.9 SNHG5 -13.58 5.32e-28 1.73e-23 -0.98 -0.74 Response to antipsychotic treatment; chr6:85618713 chr6:85660950~85678736:- PAAD cis rs507080 0.922 rs644867 ENSG00000255239.1 AP002954.6 13.57 5.4e-28 1.75e-23 0.97 0.74 Serum metabolite levels; chr11:118696836 chr11:118688039~118690600:- PAAD cis rs1577917 0.771 rs7742201 ENSG00000203875.9 SNHG5 -13.57 5.62e-28 1.82e-23 -0.97 -0.74 Response to antipsychotic treatment; chr6:85723212 chr6:85660950~85678736:- PAAD cis rs2882667 0.654 rs1703211 ENSG00000253404.1 AC034243.1 -13.57 5.68e-28 1.83e-23 -0.92 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138740587 chr5:138744434~138753309:- PAAD cis rs1577917 0.771 rs9450319 ENSG00000203875.9 SNHG5 13.57 5.7e-28 1.84e-23 0.99 0.74 Response to antipsychotic treatment; chr6:85717607 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs4383777 ENSG00000203875.9 SNHG5 13.57 5.7e-28 1.84e-23 0.99 0.74 Response to antipsychotic treatment; chr6:85726242 chr6:85660950~85678736:- PAAD cis rs9326248 0.911 rs474339 ENSG00000254851.1 RP11-109L13.1 -13.56 6.03e-28 1.94e-23 -1.01 -0.74 Blood protein levels; chr11:117188836 chr11:117135528~117138582:+ PAAD cis rs2882667 0.69 rs6421921 ENSG00000253404.1 AC034243.1 -13.55 6.42e-28 2.06e-23 -0.95 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138831581 chr5:138744434~138753309:- PAAD cis rs1577917 0.682 rs1173419 ENSG00000203875.9 SNHG5 -13.54 6.52e-28 2.09e-23 -0.96 -0.74 Response to antipsychotic treatment; chr6:85692445 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs160399 ENSG00000253404.1 AC034243.1 13.53 7.19e-28 2.3e-23 0.91 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138727552 chr5:138744434~138753309:- PAAD cis rs9322193 0.923 rs7769101 ENSG00000231760.4 RP11-350J20.5 13.52 7.64e-28 2.44e-23 0.97 0.74 Lung cancer; chr6:149848768 chr6:149796151~149826294:- PAAD cis rs858239 0.539 rs10270695 ENSG00000230658.1 KLHL7-AS1 -13.52 7.7e-28 2.45e-23 -0.99 -0.74 Cerebrospinal fluid biomarker levels; chr7:23149369 chr7:23101228~23105703:- PAAD cis rs2882667 0.69 rs9327827 ENSG00000253404.1 AC034243.1 13.51 7.82e-28 2.49e-23 0.93 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138846639 chr5:138744434~138753309:- PAAD cis rs2739330 0.753 rs4822452 ENSG00000273295.1 AP000350.5 13.5 8.51e-28 2.71e-23 0.94 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23901432~23907068:- PAAD cis rs1577917 0.727 rs9444361 ENSG00000203875.9 SNHG5 13.5 8.62e-28 2.74e-23 0.97 0.74 Response to antipsychotic treatment; chr6:85691182 chr6:85660950~85678736:- PAAD cis rs858239 0.601 rs28673077 ENSG00000230658.1 KLHL7-AS1 13.5 8.7e-28 2.76e-23 0.99 0.74 Cerebrospinal fluid biomarker levels; chr7:23211235 chr7:23101228~23105703:- PAAD cis rs507080 0.922 rs4589335 ENSG00000255239.1 AP002954.6 13.49 8.83e-28 2.8e-23 0.95 0.74 Serum metabolite levels; chr11:118668431 chr11:118688039~118690600:- PAAD cis rs7847628 0.55 rs12343516 ENSG00000226752.6 PSMD5-AS1 -13.48 9.87e-28 3.12e-23 -0.82 -0.74 Birth weight; chr9:120841191 chr9:120824828~120854385:+ PAAD cis rs507080 0.922 rs533646 ENSG00000255239.1 AP002954.6 13.48 9.89e-28 3.12e-23 0.98 0.74 Serum metabolite levels; chr11:118696037 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs642662 ENSG00000255239.1 AP002954.6 13.48 9.89e-28 3.12e-23 0.98 0.74 Serum metabolite levels; chr11:118696311 chr11:118688039~118690600:- PAAD cis rs507080 0.883 rs558593 ENSG00000255239.1 AP002954.6 13.47 1.03e-27 3.25e-23 0.97 0.74 Serum metabolite levels; chr11:118691811 chr11:118688039~118690600:- PAAD cis rs858239 0.67 rs6967526 ENSG00000230658.1 KLHL7-AS1 13.46 1.09e-27 3.43e-23 0.94 0.74 Cerebrospinal fluid biomarker levels; chr7:23119622 chr7:23101228~23105703:- PAAD cis rs9326248 1 rs4938354 ENSG00000254851.1 RP11-109L13.1 -13.46 1.1e-27 3.47e-23 -1.02 -0.74 Blood protein levels; chr11:117180449 chr11:117135528~117138582:+ PAAD cis rs1577917 0.71 rs1059306 ENSG00000203875.9 SNHG5 13.44 1.2e-27 3.76e-23 0.97 0.74 Response to antipsychotic treatment; chr6:85678391 chr6:85660950~85678736:- PAAD cis rs916888 0.779 rs199526 ENSG00000262539.1 RP11-259G18.3 -13.44 1.23e-27 3.87e-23 -1.02 -0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:46259551~46260606:- PAAD cis rs507080 0.961 rs642530 ENSG00000255239.1 AP002954.6 13.44 1.26e-27 3.93e-23 0.95 0.74 Serum metabolite levels; chr11:118680047 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs642497 ENSG00000255239.1 AP002954.6 13.44 1.26e-27 3.93e-23 0.95 0.74 Serum metabolite levels; chr11:118680075 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs592280 ENSG00000255239.1 AP002954.6 13.44 1.26e-27 3.93e-23 0.95 0.74 Serum metabolite levels; chr11:118682509 chr11:118688039~118690600:- PAAD cis rs916888 0.773 rs169201 ENSG00000214401.4 KANSL1-AS1 13.43 1.28e-27 3.96e-23 1.08 0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46193576~46196723:+ PAAD cis rs916888 0.773 rs199439 ENSG00000214401.4 KANSL1-AS1 13.43 1.28e-27 3.96e-23 1.08 0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46193576~46196723:+ PAAD cis rs507080 0.922 rs12788848 ENSG00000255239.1 AP002954.6 13.43 1.28e-27 3.96e-23 0.96 0.74 Serum metabolite levels; chr11:118683079 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs4474473 ENSG00000255239.1 AP002954.6 13.43 1.28e-27 3.96e-23 0.96 0.74 Serum metabolite levels; chr11:118683180 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs12796373 ENSG00000255239.1 AP002954.6 13.43 1.28e-27 3.96e-23 0.96 0.74 Serum metabolite levels; chr11:118684230 chr11:118688039~118690600:- PAAD cis rs2882667 0.591 rs56322405 ENSG00000253404.1 AC034243.1 -13.43 1.28e-27 3.96e-23 -0.93 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138837693 chr5:138744434~138753309:- PAAD cis rs1577917 0.771 rs2842608 ENSG00000203875.9 SNHG5 -13.43 1.29e-27 3.98e-23 -0.98 -0.74 Response to antipsychotic treatment; chr6:85586140 chr6:85660950~85678736:- PAAD cis rs2882667 0.628 rs3749663 ENSG00000253404.1 AC034243.1 13.4 1.6e-27 4.88e-23 0.95 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138935498 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs3749664 ENSG00000253404.1 AC034243.1 13.4 1.6e-27 4.88e-23 0.95 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138935732 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs10463975 ENSG00000253404.1 AC034243.1 13.39 1.64e-27 4.99e-23 0.95 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138927560 chr5:138744434~138753309:- PAAD cis rs1577917 0.771 rs9362237 ENSG00000203875.9 SNHG5 13.39 1.73e-27 5.21e-23 0.97 0.74 Response to antipsychotic treatment; chr6:85699346 chr6:85660950~85678736:- PAAD cis rs9322193 0.886 rs4870055 ENSG00000231760.4 RP11-350J20.5 13.38 1.75e-27 5.26e-23 0.95 0.74 Lung cancer; chr6:149848433 chr6:149796151~149826294:- PAAD cis rs2486288 0.656 rs7162022 ENSG00000259520.4 CTD-2651B20.3 13.38 1.75e-27 5.27e-23 0.84 0.74 Glomerular filtration rate; chr15:45273055 chr15:45251580~45279251:- PAAD cis rs1577917 0.56 rs9450288 ENSG00000203875.9 SNHG5 13.38 1.77e-27 5.3e-23 0.97 0.74 Response to antipsychotic treatment; chr6:85511868 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs10155636 ENSG00000253404.1 AC034243.1 13.38 1.79e-27 5.37e-23 0.94 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138926301 chr5:138744434~138753309:- PAAD cis rs2739330 0.828 rs5751770 ENSG00000273295.1 AP000350.5 13.37 1.86e-27 5.56e-23 0.94 0.74 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23901432~23907068:- PAAD cis rs1577917 0.538 rs7755996 ENSG00000203875.9 SNHG5 13.37 1.87e-27 5.59e-23 0.99 0.74 Response to antipsychotic treatment; chr6:85714002 chr6:85660950~85678736:- PAAD cis rs858239 0.636 rs28706766 ENSG00000230658.1 KLHL7-AS1 13.36 1.98e-27 5.9e-23 0.95 0.73 Cerebrospinal fluid biomarker levels; chr7:23130215 chr7:23101228~23105703:- PAAD cis rs858239 0.669 rs1006709 ENSG00000230658.1 KLHL7-AS1 13.36 1.99e-27 5.92e-23 0.94 0.73 Cerebrospinal fluid biomarker levels; chr7:23100480 chr7:23101228~23105703:- PAAD cis rs2486288 0.656 rs2413768 ENSG00000259520.4 CTD-2651B20.3 13.36 2.06e-27 6.14e-23 0.83 0.73 Glomerular filtration rate; chr15:45269786 chr15:45251580~45279251:- PAAD cis rs916888 0.773 rs199457 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46193576~46196723:+ PAAD cis rs916888 0.687 rs199456 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46193576~46196723:+ PAAD cis rs916888 0.773 rs199451 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46193576~46196723:+ PAAD cis rs916888 0.773 rs199448 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46193576~46196723:+ PAAD cis rs916888 0.773 rs199445 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46193576~46196723:+ PAAD cis rs916888 0.773 rs199443 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46193576~46196723:+ PAAD cis rs916888 0.773 rs199535 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46193576~46196723:+ PAAD cis rs916888 0.779 rs199528 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs199525 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs70600 ENSG00000214401.4 KANSL1-AS1 13.35 2.21e-27 6.52e-23 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46193576~46196723:+ PAAD cis rs7847628 0.587 rs12684934 ENSG00000226752.6 PSMD5-AS1 -13.34 2.34e-27 6.91e-23 -0.83 -0.73 Birth weight; chr9:120830881 chr9:120824828~120854385:+ PAAD cis rs858239 0.73 rs858279 ENSG00000230658.1 KLHL7-AS1 13.32 2.54e-27 7.47e-23 0.93 0.73 Cerebrospinal fluid biomarker levels; chr7:23211386 chr7:23101228~23105703:- PAAD cis rs507080 0.807 rs7926944 ENSG00000255239.1 AP002954.6 13.32 2.55e-27 7.5e-23 0.96 0.73 Serum metabolite levels; chr11:118689119 chr11:118688039~118690600:- PAAD cis rs2882667 0.69 rs1059110 ENSG00000253404.1 AC034243.1 13.32 2.63e-27 7.73e-23 0.94 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138930857 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs10068280 ENSG00000253404.1 AC034243.1 13.32 2.63e-27 7.73e-23 0.94 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138931394 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs13178601 ENSG00000253404.1 AC034243.1 13.32 2.63e-27 7.73e-23 0.94 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138931688 chr5:138744434~138753309:- PAAD cis rs2486288 0.656 rs7167146 ENSG00000259520.4 CTD-2651B20.3 -13.31 2.83e-27 8.31e-23 -0.84 -0.73 Glomerular filtration rate; chr15:45279188 chr15:45251580~45279251:- PAAD cis rs1577917 0.74 rs9450302 ENSG00000203875.9 SNHG5 13.3 3.02e-27 8.7e-23 0.96 0.73 Response to antipsychotic treatment; chr6:85579955 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs4351223 ENSG00000203875.9 SNHG5 13.29 3.03e-27 8.7e-23 0.97 0.73 Response to antipsychotic treatment; chr6:85528079 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs7452605 ENSG00000203875.9 SNHG5 13.29 3.03e-27 8.7e-23 0.97 0.73 Response to antipsychotic treatment; chr6:85531233 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs9294337 ENSG00000203875.9 SNHG5 13.29 3.03e-27 8.7e-23 0.97 0.73 Response to antipsychotic treatment; chr6:85538742 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2842613 ENSG00000203875.9 SNHG5 13.29 3.03e-27 8.7e-23 0.97 0.73 Response to antipsychotic treatment; chr6:85595984 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs12199873 ENSG00000203875.9 SNHG5 -13.29 3.03e-27 8.7e-23 -0.97 -0.73 Response to antipsychotic treatment; chr6:85585229 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2842609 ENSG00000203875.9 SNHG5 -13.29 3.03e-27 8.7e-23 -0.97 -0.73 Response to antipsychotic treatment; chr6:85587070 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2842612 ENSG00000203875.9 SNHG5 -13.29 3.03e-27 8.7e-23 -0.97 -0.73 Response to antipsychotic treatment; chr6:85593373 chr6:85660950~85678736:- PAAD cis rs1577917 0.727 rs2758840 ENSG00000203875.9 SNHG5 -13.29 3.03e-27 8.7e-23 -0.97 -0.73 Response to antipsychotic treatment; chr6:85594907 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs9362230 ENSG00000203875.9 SNHG5 -13.29 3.03e-27 8.7e-23 -0.97 -0.73 Response to antipsychotic treatment; chr6:85595295 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2842601 ENSG00000203875.9 SNHG5 -13.29 3.03e-27 8.7e-23 -0.97 -0.73 Response to antipsychotic treatment; chr6:85620415 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs12205013 ENSG00000203875.9 SNHG5 -13.29 3.03e-27 8.7e-23 -0.97 -0.73 Response to antipsychotic treatment; chr6:85623311 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs825758 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138791288 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs825754 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138796200 chr5:138744434~138753309:- PAAD cis rs2882667 0.722 rs825751 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138798180 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs825748 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138800378 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs825746 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138800930 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs825762 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138801981 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs825761 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138802318 chr5:138744434~138753309:- PAAD cis rs2882667 0.722 rs4835649 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138810534 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs12517514 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138814430 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs7714455 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138818281 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6873425 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138819556 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6860780 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138824367 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6884198 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138828618 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs4835706 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138829037 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1039788 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138835812 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1828188 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138836307 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs4835707 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138838831 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs12656942 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138840769 chr5:138744434~138753309:- PAAD cis rs2882667 0.686 rs62381196 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138841000 chr5:138744434~138753309:- PAAD cis rs2882667 0.621 rs55901834 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138844094 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1976568 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138844627 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6880786 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138845874 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs9327826 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138846318 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs1972072 ENSG00000253404.1 AC034243.1 -13.29 3.07e-27 8.7e-23 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138849604 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs10515504 ENSG00000253404.1 AC034243.1 -13.28 3.32e-27 9.4e-23 -0.93 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138887305 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs9327829 ENSG00000253404.1 AC034243.1 -13.28 3.32e-27 9.4e-23 -0.93 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138925982 chr5:138744434~138753309:- PAAD cis rs507080 0.922 rs519848 ENSG00000255239.1 AP002954.6 13.26 3.75e-27 1.06e-22 0.93 0.73 Serum metabolite levels; chr11:118682006 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs600969 ENSG00000255239.1 AP002954.6 13.23 4.44e-27 1.25e-22 0.94 0.73 Serum metabolite levels; chr11:118675087 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs12577485 ENSG00000255239.1 AP002954.6 13.23 4.44e-27 1.25e-22 0.94 0.73 Serum metabolite levels; chr11:118676793 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs673770 ENSG00000255239.1 AP002954.6 13.23 4.44e-27 1.25e-22 0.94 0.73 Serum metabolite levels; chr11:118679892 chr11:118688039~118690600:- PAAD cis rs858239 0.601 rs6461702 ENSG00000230658.1 KLHL7-AS1 13.23 4.54e-27 1.28e-22 0.98 0.73 Cerebrospinal fluid biomarker levels; chr7:23209654 chr7:23101228~23105703:- PAAD cis rs1577917 0.74 rs2758845 ENSG00000203875.9 SNHG5 -13.22 4.93e-27 1.38e-22 -0.97 -0.73 Response to antipsychotic treatment; chr6:85625130 chr6:85660950~85678736:- PAAD cis rs1577917 0.696 rs2842603 ENSG00000203875.9 SNHG5 -13.22 4.93e-27 1.38e-22 -0.97 -0.73 Response to antipsychotic treatment; chr6:85626619 chr6:85660950~85678736:- PAAD cis rs2739330 0.892 rs5751776 ENSG00000225282.1 AP000350.6 13.21 5.14e-27 1.43e-22 0.94 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23926900~23929574:+ PAAD cis rs916888 0.773 rs538628 ENSG00000214401.4 KANSL1-AS1 13.2 5.36e-27 1.5e-22 1.07 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46193576~46196723:+ PAAD cis rs9322193 0.923 rs9371486 ENSG00000231760.4 RP11-350J20.5 13.2 5.52e-27 1.54e-22 1.01 0.73 Lung cancer; chr6:149832090 chr6:149796151~149826294:- PAAD cis rs1577917 0.739 rs9344532 ENSG00000203875.9 SNHG5 13.2 5.54e-27 1.54e-22 0.97 0.73 Response to antipsychotic treatment; chr6:85524352 chr6:85660950~85678736:- PAAD cis rs2739330 0.929 rs5751775 ENSG00000225282.1 AP000350.6 13.19 5.77e-27 1.6e-22 0.94 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23926900~23929574:+ PAAD cis rs9322193 0.884 rs1125 ENSG00000231760.4 RP11-350J20.5 13.19 5.78e-27 1.61e-22 0.98 0.73 Lung cancer; chr6:149658280 chr6:149796151~149826294:- PAAD cis rs507080 0.961 rs520543 ENSG00000255239.1 AP002954.6 13.19 5.96e-27 1.65e-22 0.95 0.73 Serum metabolite levels; chr11:118667448 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs4457789 ENSG00000255239.1 AP002954.6 13.19 5.96e-27 1.65e-22 0.95 0.73 Serum metabolite levels; chr11:118668461 chr11:118688039~118690600:- PAAD cis rs2882667 0.69 rs288007 ENSG00000253404.1 AC034243.1 13.18 6.18e-27 1.71e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138894939 chr5:138744434~138753309:- PAAD cis rs2486288 0.656 rs1706768 ENSG00000259520.4 CTD-2651B20.3 13.18 6.22e-27 1.72e-22 0.82 0.73 Glomerular filtration rate; chr15:45277245 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs2461705 ENSG00000259520.4 CTD-2651B20.3 13.18 6.22e-27 1.72e-22 0.82 0.73 Glomerular filtration rate; chr15:45278043 chr15:45251580~45279251:- PAAD cis rs4853012 0.752 rs13413795 ENSG00000217702.2 RP11-287D1.4 13.18 6.33e-27 1.75e-22 1.15 0.73 Gestational age at birth (maternal effect); chr2:74122712 chr2:74130583~74135395:+ PAAD cis rs1577917 0.74 rs12212560 ENSG00000203875.9 SNHG5 -13.17 6.73e-27 1.85e-22 -0.97 -0.73 Response to antipsychotic treatment; chr6:85632961 chr6:85660950~85678736:- PAAD cis rs2486288 0.656 rs11637838 ENSG00000259520.4 CTD-2651B20.3 13.16 7.13e-27 1.96e-22 0.83 0.73 Glomerular filtration rate; chr15:45258459 chr15:45251580~45279251:- PAAD cis rs113525195 1 rs113525195 ENSG00000279656.1 RP11-298I3.6 -13.16 7.17e-27 1.97e-22 -0.98 -0.73 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin; chr14:23030112 chr14:23023083~23024217:- PAAD cis rs2739330 0.828 rs5760108 ENSG00000273295.1 AP000350.5 13.15 7.63e-27 2.09e-22 0.93 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23901432~23907068:- PAAD cis rs1577917 0.74 rs6926049 ENSG00000203875.9 SNHG5 13.14 8.06e-27 2.2e-22 0.97 0.73 Response to antipsychotic treatment; chr6:85556415 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2758844 ENSG00000203875.9 SNHG5 -13.14 8.06e-27 2.2e-22 -0.97 -0.73 Response to antipsychotic treatment; chr6:85620397 chr6:85660950~85678736:- PAAD cis rs507080 0.845 rs667982 ENSG00000255239.1 AP002954.6 13.14 8.08e-27 2.21e-22 0.96 0.73 Serum metabolite levels; chr11:118692058 chr11:118688039~118690600:- PAAD cis rs2739330 0.828 rs2877178 ENSG00000273295.1 AP000350.5 13.12 8.82e-27 2.4e-22 0.94 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23901432~23907068:- PAAD cis rs2739330 0.828 rs2154593 ENSG00000273295.1 AP000350.5 13.12 8.82e-27 2.4e-22 0.94 0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23901432~23907068:- PAAD cis rs916888 0.773 rs199534 ENSG00000214401.4 KANSL1-AS1 13.11 9.43e-27 2.56e-22 1.06 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46193576~46196723:+ PAAD cis rs2486288 0.656 rs2413774 ENSG00000259520.4 CTD-2651B20.3 13.11 9.55e-27 2.58e-22 0.83 0.73 Glomerular filtration rate; chr15:45257225 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs2413773 ENSG00000259520.4 CTD-2651B20.3 13.11 9.55e-27 2.58e-22 0.83 0.73 Glomerular filtration rate; chr15:45257244 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs2413772 ENSG00000259520.4 CTD-2651B20.3 13.11 9.55e-27 2.58e-22 0.83 0.73 Glomerular filtration rate; chr15:45257664 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11632724 ENSG00000259520.4 CTD-2651B20.3 13.11 9.55e-27 2.58e-22 0.83 0.73 Glomerular filtration rate; chr15:45258593 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11632651 ENSG00000259520.4 CTD-2651B20.3 13.11 9.55e-27 2.58e-22 0.83 0.73 Glomerular filtration rate; chr15:45258640 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs12440356 ENSG00000259520.4 CTD-2651B20.3 -13.11 9.62e-27 2.59e-22 -0.82 -0.73 Glomerular filtration rate; chr15:45275331 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11639349 ENSG00000259520.4 CTD-2651B20.3 13.11 9.62e-27 2.59e-22 0.82 0.73 Glomerular filtration rate; chr15:45276062 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs1719232 ENSG00000259520.4 CTD-2651B20.3 13.11 9.62e-27 2.59e-22 0.82 0.73 Glomerular filtration rate; chr15:45279874 chr15:45251580~45279251:- PAAD cis rs1577917 0.771 rs4419647 ENSG00000203875.9 SNHG5 13.1 9.88e-27 2.65e-22 0.96 0.73 Response to antipsychotic treatment; chr6:85516021 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs9353318 ENSG00000203875.9 SNHG5 13.1 9.88e-27 2.65e-22 0.96 0.73 Response to antipsychotic treatment; chr6:85522003 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs9450290 ENSG00000203875.9 SNHG5 13.1 9.88e-27 2.65e-22 0.96 0.73 Response to antipsychotic treatment; chr6:85523679 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2783171 ENSG00000203875.9 SNHG5 13.1 1.02e-26 2.74e-22 0.97 0.73 Response to antipsychotic treatment; chr6:85673047 chr6:85660950~85678736:- PAAD cis rs2486288 0.656 rs10519018 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45257067 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11637920 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45258707 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11632777 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45258847 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11632778 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45258858 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11632752 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45258942 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11632920 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45259066 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs12911186 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45259225 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs12915314 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45259293 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs8039138 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45259394 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs8039540 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45259644 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs8040185 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45259883 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs1060896 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45262069 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11632419 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45265258 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs2271438 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45265270 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11854365 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45265885 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11639420 ENSG00000259520.4 CTD-2651B20.3 13.07 1.19e-26 3.15e-22 0.83 0.73 Glomerular filtration rate; chr15:45267070 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs8039354 ENSG00000259520.4 CTD-2651B20.3 -13.07 1.19e-26 3.15e-22 -0.83 -0.73 Glomerular filtration rate; chr15:45259558 chr15:45251580~45279251:- PAAD cis rs9322193 0.884 rs9371201 ENSG00000231760.4 RP11-350J20.5 13.07 1.2e-26 3.15e-22 1 0.73 Lung cancer; chr6:149823865 chr6:149796151~149826294:- PAAD cis rs2882667 0.69 rs288014 ENSG00000253404.1 AC034243.1 -13.07 1.24e-26 3.24e-22 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138860104 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288012 ENSG00000253404.1 AC034243.1 -13.07 1.24e-26 3.24e-22 -0.92 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138860584 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288033 ENSG00000253404.1 AC034243.1 13.07 1.24e-26 3.24e-22 0.92 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138878405 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288022 ENSG00000253404.1 AC034243.1 13.07 1.24e-26 3.24e-22 0.92 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138888586 chr5:138744434~138753309:- PAAD cis rs2882667 0.598 rs288020 ENSG00000253404.1 AC034243.1 13.07 1.24e-26 3.24e-22 0.92 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138888609 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs7446631 ENSG00000253404.1 AC034243.1 13.07 1.24e-26 3.24e-22 0.92 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138891376 chr5:138744434~138753309:- PAAD cis rs2882667 0.659 rs12719515 ENSG00000253404.1 AC034243.1 13.07 1.24e-26 3.24e-22 0.92 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138905629 chr5:138744434~138753309:- PAAD cis rs2882667 0.659 rs10056014 ENSG00000253404.1 AC034243.1 13.07 1.24e-26 3.24e-22 0.92 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138920329 chr5:138744434~138753309:- PAAD cis rs2882667 0.598 rs10078179 ENSG00000253404.1 AC034243.1 13.07 1.24e-26 3.24e-22 0.92 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138920410 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs13158360 ENSG00000253404.1 AC034243.1 13.07 1.24e-26 3.24e-22 0.92 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138922488 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288028 ENSG00000253404.1 AC034243.1 13.05 1.39e-26 3.62e-22 0.91 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138886300 chr5:138744434~138753309:- PAAD cis rs2739330 0.76 rs1002286 ENSG00000273295.1 AP000350.5 -13.04 1.46e-26 3.8e-22 -0.89 -0.73 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23901432~23907068:- PAAD cis rs2882667 0.69 rs10078079 ENSG00000253404.1 AC034243.1 13.04 1.49e-26 3.86e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138920450 chr5:138744434~138753309:- PAAD cis rs916888 0.773 rs1378358 ENSG00000214401.4 KANSL1-AS1 13.03 1.52e-26 3.93e-22 1.05 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46193576~46196723:+ PAAD cis rs2486288 0.656 rs1706770 ENSG00000259520.4 CTD-2651B20.3 13.02 1.63e-26 4.2e-22 0.82 0.73 Glomerular filtration rate; chr15:45282864 chr15:45251580~45279251:- PAAD cis rs2882667 0.69 rs825672 ENSG00000253404.1 AC034243.1 -13.02 1.66e-26 4.23e-22 -0.93 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138759954 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288018 ENSG00000253404.1 AC034243.1 -13.02 1.66e-26 4.23e-22 -0.93 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138856727 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288017 ENSG00000253404.1 AC034243.1 -13.02 1.66e-26 4.23e-22 -0.93 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138857826 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs167009 ENSG00000253404.1 AC034243.1 -13.02 1.66e-26 4.23e-22 -0.93 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138864768 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288040 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138869205 chr5:138744434~138753309:- PAAD cis rs2882667 0.659 rs288037 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138872752 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288036 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138875206 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288035 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138876728 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288032 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138879639 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288026 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138886905 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288024 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138888103 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288021 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138888594 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288009 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138892973 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs185956 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138894574 chr5:138744434~138753309:- PAAD cis rs2882667 0.658 rs288003 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138896266 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288002 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138896398 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs10044401 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138901868 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs10067361 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138905185 chr5:138744434~138753309:- PAAD cis rs2882667 0.628 rs10076629 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138920272 chr5:138744434~138753309:- PAAD cis rs2882667 0.659 rs11750067 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138920589 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs10054682 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138923754 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs11953339 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138923853 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs9327828 ENSG00000253404.1 AC034243.1 13.02 1.66e-26 4.23e-22 0.93 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138925859 chr5:138744434~138753309:- PAAD cis rs858239 0.669 rs1990365 ENSG00000230658.1 KLHL7-AS1 13.01 1.73e-26 4.38e-22 0.91 0.73 Cerebrospinal fluid biomarker levels; chr7:23076347 chr7:23101228~23105703:- PAAD cis rs858239 0.899 rs2268747 ENSG00000230658.1 KLHL7-AS1 13.01 1.8e-26 4.54e-22 0.94 0.73 Cerebrospinal fluid biomarker levels; chr7:23273843 chr7:23101228~23105703:- PAAD cis rs9322193 0.884 rs10872648 ENSG00000231760.4 RP11-350J20.5 13.01 1.82e-26 4.58e-22 1 0.73 Lung cancer; chr6:149758699 chr6:149796151~149826294:- PAAD cis rs858239 0.536 rs6961109 ENSG00000230658.1 KLHL7-AS1 13 1.85e-26 4.65e-22 0.95 0.73 Cerebrospinal fluid biomarker levels; chr7:23212794 chr7:23101228~23105703:- PAAD cis rs858239 0.536 rs6956974 ENSG00000230658.1 KLHL7-AS1 -13 1.85e-26 4.65e-22 -0.95 -0.73 Cerebrospinal fluid biomarker levels; chr7:23212699 chr7:23101228~23105703:- PAAD cis rs2882667 0.69 rs825669 ENSG00000253404.1 AC034243.1 -13 1.89e-26 4.76e-22 -0.9 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138731258 chr5:138744434~138753309:- PAAD cis rs2882667 0.659 rs311595 ENSG00000253404.1 AC034243.1 12.99 1.98e-26 4.87e-22 0.9 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138736183 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1703212 ENSG00000253404.1 AC034243.1 -12.99 2.01e-26 4.88e-22 -0.9 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138742863 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1651032 ENSG00000253404.1 AC034243.1 -12.99 2.01e-26 4.88e-22 -0.9 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138743151 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs274119 ENSG00000253404.1 AC034243.1 12.99 2.01e-26 4.88e-22 0.9 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138728530 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs274118 ENSG00000253404.1 AC034243.1 12.99 2.01e-26 4.88e-22 0.9 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138729198 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs274117 ENSG00000253404.1 AC034243.1 12.99 2.01e-26 4.88e-22 0.9 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138729359 chr5:138744434~138753309:- PAAD cis rs858239 0.899 rs7794684 ENSG00000230658.1 KLHL7-AS1 12.98 2.11e-26 5.1e-22 0.94 0.73 Cerebrospinal fluid biomarker levels; chr7:23271186 chr7:23101228~23105703:- PAAD cis rs858239 0.636 rs7808488 ENSG00000230658.1 KLHL7-AS1 12.98 2.12e-26 5.12e-22 0.94 0.73 Cerebrospinal fluid biomarker levels; chr7:23182251 chr7:23101228~23105703:- PAAD cis rs9322193 0.923 rs2342765 ENSG00000231760.4 RP11-350J20.5 12.98 2.16e-26 5.21e-22 0.95 0.72 Lung cancer; chr6:149858873 chr6:149796151~149826294:- PAAD cis rs1577917 0.771 rs4145082 ENSG00000203875.9 SNHG5 -12.97 2.22e-26 5.33e-22 -0.96 -0.72 Response to antipsychotic treatment; chr6:85642298 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs9362233 ENSG00000203875.9 SNHG5 -12.97 2.22e-26 5.33e-22 -0.96 -0.72 Response to antipsychotic treatment; chr6:85648529 chr6:85660950~85678736:- PAAD cis rs1577917 0.727 rs9351065 ENSG00000203875.9 SNHG5 -12.97 2.22e-26 5.33e-22 -0.96 -0.72 Response to antipsychotic treatment; chr6:85650710 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2475791 ENSG00000203875.9 SNHG5 -12.97 2.22e-26 5.33e-22 -0.96 -0.72 Response to antipsychotic treatment; chr6:85658446 chr6:85660950~85678736:- PAAD cis rs9322193 0.884 rs11155675 ENSG00000231760.4 RP11-350J20.5 12.97 2.25e-26 5.4e-22 0.99 0.72 Lung cancer; chr6:149742883 chr6:149796151~149826294:- PAAD cis rs1577917 0.739 rs9450318 ENSG00000203875.9 SNHG5 12.97 2.25e-26 5.4e-22 0.97 0.72 Response to antipsychotic treatment; chr6:85717459 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs160398 ENSG00000253404.1 AC034243.1 12.96 2.41e-26 5.76e-22 0.9 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138727750 chr5:138744434~138753309:- PAAD cis rs2739330 0.791 rs4822458 ENSG00000273295.1 AP000350.5 12.95 2.58e-26 6.16e-22 0.94 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23901432~23907068:- PAAD cis rs2882667 0.69 rs423469 ENSG00000253404.1 AC034243.1 12.95 2.6e-26 6.21e-22 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138898427 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs13174008 ENSG00000253404.1 AC034243.1 12.95 2.6e-26 6.21e-22 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138922220 chr5:138744434~138753309:- PAAD cis rs916888 0.738 rs199515 ENSG00000214401.4 KANSL1-AS1 -12.94 2.68e-26 6.38e-22 -1.02 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46193576~46196723:+ PAAD cis rs916888 0.773 rs199447 ENSG00000214401.4 KANSL1-AS1 12.94 2.73e-26 6.49e-22 1.06 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46193576~46196723:+ PAAD cis rs858239 0.669 rs1618339 ENSG00000230658.1 KLHL7-AS1 12.94 2.76e-26 6.57e-22 0.95 0.72 Cerebrospinal fluid biomarker levels; chr7:23190155 chr7:23101228~23105703:- PAAD cis rs2486288 0.656 rs11629807 ENSG00000259520.4 CTD-2651B20.3 12.93 2.81e-26 6.65e-22 0.83 0.72 Glomerular filtration rate; chr15:45254839 chr15:45251580~45279251:- PAAD cis rs2486288 0.587 rs12899942 ENSG00000259520.4 CTD-2651B20.3 12.93 2.81e-26 6.65e-22 0.83 0.72 Glomerular filtration rate; chr15:45255082 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs12899058 ENSG00000259520.4 CTD-2651B20.3 12.93 2.81e-26 6.65e-22 0.83 0.72 Glomerular filtration rate; chr15:45255126 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs12904150 ENSG00000259520.4 CTD-2651B20.3 12.93 2.81e-26 6.65e-22 0.83 0.72 Glomerular filtration rate; chr15:45255407 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs9920290 ENSG00000259520.4 CTD-2651B20.3 12.93 2.81e-26 6.65e-22 0.83 0.72 Glomerular filtration rate; chr15:45255837 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11854325 ENSG00000259520.4 CTD-2651B20.3 12.93 2.81e-26 6.65e-22 0.83 0.72 Glomerular filtration rate; chr15:45256761 chr15:45251580~45279251:- PAAD cis rs1577917 0.771 rs2842607 ENSG00000203875.9 SNHG5 -12.93 2.85e-26 6.74e-22 -0.96 -0.72 Response to antipsychotic treatment; chr6:85635321 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs160401 ENSG00000253404.1 AC034243.1 -12.92 3.04e-26 7.18e-22 -0.88 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138725652 chr5:138744434~138753309:- PAAD cis rs9322193 0.847 rs868375 ENSG00000231760.4 RP11-350J20.5 12.92 3.17e-26 7.45e-22 0.92 0.72 Lung cancer; chr6:149844905 chr6:149796151~149826294:- PAAD cis rs858239 0.699 rs1881200 ENSG00000230658.1 KLHL7-AS1 -12.91 3.24e-26 7.63e-22 -0.94 -0.72 Cerebrospinal fluid biomarker levels; chr7:23162018 chr7:23101228~23105703:- PAAD cis rs2882667 0.69 rs311599 ENSG00000253404.1 AC034243.1 12.91 3.29e-26 7.72e-22 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138718994 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs311597 ENSG00000253404.1 AC034243.1 12.91 3.29e-26 7.72e-22 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138720212 chr5:138744434~138753309:- PAAD cis rs507080 0.883 rs656575 ENSG00000255239.1 AP002954.6 12.9 3.45e-26 8.06e-22 0.94 0.72 Serum metabolite levels; chr11:118679199 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs656505 ENSG00000255239.1 AP002954.6 12.9 3.45e-26 8.06e-22 0.94 0.72 Serum metabolite levels; chr11:118679245 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs660489 ENSG00000255239.1 AP002954.6 12.9 3.45e-26 8.06e-22 0.94 0.72 Serum metabolite levels; chr11:118679255 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs543327 ENSG00000255239.1 AP002954.6 12.9 3.45e-26 8.06e-22 0.94 0.72 Serum metabolite levels; chr11:118679276 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs543413 ENSG00000255239.1 AP002954.6 12.9 3.45e-26 8.06e-22 0.94 0.72 Serum metabolite levels; chr11:118679308 chr11:118688039~118690600:- PAAD cis rs916888 0.773 rs199533 ENSG00000214401.4 KANSL1-AS1 12.9 3.47e-26 8.12e-22 1.05 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46193576~46196723:+ PAAD cis rs2882667 0.69 rs160402 ENSG00000253404.1 AC034243.1 12.9 3.5e-26 8.18e-22 0.89 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138723599 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6890932 ENSG00000253404.1 AC034243.1 12.88 3.91e-26 9.08e-22 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138910639 chr5:138744434~138753309:- PAAD cis rs916888 0.697 rs199516 ENSG00000214401.4 KANSL1-AS1 -12.88 3.92e-26 9.08e-22 -1.04 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs199514 ENSG00000214401.4 KANSL1-AS1 -12.88 3.92e-26 9.08e-22 -1.04 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs199513 ENSG00000214401.4 KANSL1-AS1 -12.88 3.92e-26 9.08e-22 -1.04 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs199512 ENSG00000214401.4 KANSL1-AS1 -12.88 3.92e-26 9.08e-22 -1.04 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs199509 ENSG00000214401.4 KANSL1-AS1 -12.88 3.92e-26 9.08e-22 -1.04 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs199507 ENSG00000214401.4 KANSL1-AS1 -12.88 3.92e-26 9.08e-22 -1.04 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs199505 ENSG00000214401.4 KANSL1-AS1 -12.88 3.92e-26 9.08e-22 -1.04 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46193576~46196723:+ PAAD cis rs916888 0.821 rs70602 ENSG00000214401.4 KANSL1-AS1 -12.88 3.92e-26 9.08e-22 -1.04 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46193576~46196723:+ PAAD cis rs2739330 0.753 rs4822452 ENSG00000218537.1 MIF-AS1 12.87 4.07e-26 9.39e-22 0.97 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23894426~23898930:- PAAD cis rs2486288 0.656 rs9921025 ENSG00000259520.4 CTD-2651B20.3 12.87 4.12e-26 9.5e-22 0.83 0.72 Glomerular filtration rate; chr15:45254404 chr15:45251580~45279251:- PAAD cis rs2739330 0.627 rs9608219 ENSG00000273295.1 AP000350.5 12.87 4.13e-26 9.53e-22 0.95 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23901432~23907068:- PAAD cis rs1577917 0.74 rs2842604 ENSG00000203875.9 SNHG5 -12.87 4.16e-26 9.58e-22 -0.96 -0.72 Response to antipsychotic treatment; chr6:85626582 chr6:85660950~85678736:- PAAD cis rs2486288 0.656 rs11631021 ENSG00000259520.4 CTD-2651B20.3 12.87 4.19e-26 9.65e-22 0.81 0.72 Glomerular filtration rate; chr15:45264631 chr15:45251580~45279251:- PAAD cis rs507080 0.961 rs1784298 ENSG00000255239.1 AP002954.6 12.86 4.4e-26 1.01e-21 0.94 0.72 Serum metabolite levels; chr11:118677956 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs4938522 ENSG00000255239.1 AP002954.6 12.86 4.4e-26 1.01e-21 0.94 0.72 Serum metabolite levels; chr11:118677962 chr11:118688039~118690600:- PAAD cis rs507080 0.961 rs4938523 ENSG00000255239.1 AP002954.6 12.86 4.4e-26 1.01e-21 0.94 0.72 Serum metabolite levels; chr11:118678129 chr11:118688039~118690600:- PAAD cis rs507080 1 rs659969 ENSG00000255239.1 AP002954.6 12.86 4.4e-26 1.01e-21 0.94 0.72 Serum metabolite levels; chr11:118679094 chr11:118688039~118690600:- PAAD cis rs2486288 0.656 rs11637364 ENSG00000259520.4 CTD-2651B20.3 12.85 4.76e-26 1.08e-21 0.83 0.72 Glomerular filtration rate; chr15:45287040 chr15:45251580~45279251:- PAAD cis rs1577917 0.771 rs2758847 ENSG00000203875.9 SNHG5 -12.84 5.16e-26 1.17e-21 -0.96 -0.72 Response to antipsychotic treatment; chr6:85639385 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs12186373 ENSG00000253404.1 AC034243.1 12.83 5.42e-26 1.23e-21 0.92 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138912885 chr5:138744434~138753309:- PAAD cis rs2486288 0.656 rs8037583 ENSG00000259520.4 CTD-2651B20.3 12.83 5.47e-26 1.24e-21 0.83 0.72 Glomerular filtration rate; chr15:45254180 chr15:45251580~45279251:- PAAD cis rs1577917 0.771 rs10944133 ENSG00000203875.9 SNHG5 -12.82 5.7e-26 1.29e-21 -0.96 -0.72 Response to antipsychotic treatment; chr6:85649266 chr6:85660950~85678736:- PAAD cis rs1577917 0.771 rs2475790 ENSG00000203875.9 SNHG5 -12.82 5.7e-26 1.29e-21 -0.96 -0.72 Response to antipsychotic treatment; chr6:85658350 chr6:85660950~85678736:- PAAD cis rs2882667 0.654 rs700626 ENSG00000253404.1 AC034243.1 -12.81 6.18e-26 1.4e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138782249 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs311596 ENSG00000253404.1 AC034243.1 -12.8 6.67e-26 1.5e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138736393 chr5:138744434~138753309:- PAAD cis rs2882667 0.658 rs311592 ENSG00000253404.1 AC034243.1 12.8 6.67e-26 1.5e-21 0.89 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138734506 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs1095374 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138759517 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs700620 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138762247 chr5:138744434~138753309:- PAAD cis rs2882667 0.659 rs700621 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138762741 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs700623 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138762993 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs700629 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138788305 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6877187 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138823655 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs3804199 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138826440 chr5:138744434~138753309:- PAAD cis rs2882667 0.722 rs2011462 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138827083 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs4835708 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138844204 chr5:138744434~138753309:- PAAD cis rs2882667 0.587 rs1848506 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138846768 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1848505 ENSG00000253404.1 AC034243.1 -12.79 6.97e-26 1.55e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138846841 chr5:138744434~138753309:- PAAD cis rs1577917 0.696 rs10806334 ENSG00000203875.9 SNHG5 -12.79 6.99e-26 1.56e-21 -0.94 -0.72 Response to antipsychotic treatment; chr6:85729611 chr6:85660950~85678736:- PAAD cis rs2739330 0.828 rs2186366 ENSG00000273295.1 AP000350.5 -12.78 7.25e-26 1.6e-21 -0.91 -0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23901432~23907068:- PAAD cis rs4853012 0.838 rs4429500 ENSG00000217702.2 RP11-287D1.4 12.78 7.36e-26 1.62e-21 1.15 0.72 Gestational age at birth (maternal effect); chr2:74118209 chr2:74130583~74135395:+ PAAD cis rs2882667 0.69 rs1651358 ENSG00000253404.1 AC034243.1 -12.77 7.61e-26 1.68e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138745318 chr5:138744434~138753309:- PAAD cis rs2739330 0.828 rs4822451 ENSG00000273295.1 AP000350.5 12.77 7.79e-26 1.72e-21 0.93 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23901432~23907068:- PAAD cis rs2739330 0.828 rs5760099 ENSG00000273295.1 AP000350.5 12.77 7.79e-26 1.72e-21 0.93 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23901432~23907068:- PAAD cis rs2882667 0.69 rs11954103 ENSG00000253404.1 AC034243.1 12.77 7.93e-26 1.75e-21 0.93 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138933459 chr5:138744434~138753309:- PAAD cis rs9322193 0.884 rs10872647 ENSG00000231760.4 RP11-350J20.5 12.76 8.36e-26 1.84e-21 0.99 0.72 Lung cancer; chr6:149758687 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs11155679 ENSG00000231760.4 RP11-350J20.5 12.76 8.36e-26 1.84e-21 0.99 0.72 Lung cancer; chr6:149758881 chr6:149796151~149826294:- PAAD cis rs2739330 0.828 rs5751770 ENSG00000218537.1 MIF-AS1 12.75 8.71e-26 1.91e-21 0.96 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23894426~23898930:- PAAD cis rs2882667 0.587 rs825674 ENSG00000253404.1 AC034243.1 -12.74 9.12e-26 1.99e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138767031 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs288029 ENSG00000253404.1 AC034243.1 12.74 9.12e-26 1.99e-21 0.9 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138881616 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs17031 ENSG00000253404.1 AC034243.1 12.74 9.49e-26 2.07e-21 0.92 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138934853 chr5:138744434~138753309:- PAAD cis rs9326248 0.861 rs4938343 ENSG00000254851.1 RP11-109L13.1 -12.73 9.98e-26 2.18e-21 -1.07 -0.72 Blood protein levels; chr11:117132812 chr11:117135528~117138582:+ PAAD cis rs858239 0.669 rs6461687 ENSG00000230658.1 KLHL7-AS1 12.73 1.02e-25 2.23e-21 0.9 0.72 Cerebrospinal fluid biomarker levels; chr7:23076961 chr7:23101228~23105703:- PAAD cis rs2882667 0.69 rs160400 ENSG00000253404.1 AC034243.1 -12.72 1.04e-25 2.27e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138727330 chr5:138744434~138753309:- PAAD cis rs2739330 0.791 rs9612520 ENSG00000273295.1 AP000350.5 12.72 1.05e-25 2.27e-21 0.94 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23901432~23907068:- PAAD cis rs2882667 0.69 rs700619 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138753060 chr5:138744434~138753309:- PAAD cis rs2882667 0.652 rs700622 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138762862 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs7722965 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138764766 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs1976562 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138774905 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs825759 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138790250 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs825760 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138804285 chr5:138744434~138753309:- PAAD cis rs2882667 0.622 rs34645817 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138816944 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs7736925 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138818841 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs883333 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138819781 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6596455 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138831416 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs995177 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138833874 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs7710300 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138834793 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs2351247 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138849456 chr5:138744434~138753309:- PAAD cis rs2882667 0.619 rs6861556 ENSG00000253404.1 AC034243.1 -12.72 1.06e-25 2.27e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138852351 chr5:138744434~138753309:- PAAD cis rs507080 0.961 rs607527 ENSG00000255239.1 AP002954.6 -12.72 1.08e-25 2.31e-21 -0.94 -0.72 Serum metabolite levels; chr11:118667478 chr11:118688039~118690600:- PAAD cis rs2882667 0.628 rs311605 ENSG00000253404.1 AC034243.1 12.72 1.09e-25 2.34e-21 0.89 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138710150 chr5:138744434~138753309:- PAAD cis rs858239 0.669 rs6461688 ENSG00000230658.1 KLHL7-AS1 12.71 1.11e-25 2.38e-21 0.9 0.72 Cerebrospinal fluid biomarker levels; chr7:23076996 chr7:23101228~23105703:- PAAD cis rs2882667 0.69 rs311602 ENSG00000253404.1 AC034243.1 12.69 1.24e-25 2.64e-21 0.9 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138717370 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs930063 ENSG00000253404.1 AC034243.1 12.69 1.24e-25 2.64e-21 0.9 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138717929 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs930062 ENSG00000253404.1 AC034243.1 12.69 1.24e-25 2.64e-21 0.9 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138717934 chr5:138744434~138753309:- PAAD cis rs2882667 0.658 rs172664 ENSG00000253404.1 AC034243.1 12.69 1.24e-25 2.64e-21 0.9 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138720617 chr5:138744434~138753309:- PAAD cis rs507080 0.769 rs7389 ENSG00000255239.1 AP002954.6 -12.69 1.26e-25 2.67e-21 -0.96 -0.72 Serum metabolite levels; chr11:118657756 chr11:118688039~118690600:- PAAD cis rs1577917 0.771 rs6454486 ENSG00000203875.9 SNHG5 12.69 1.28e-25 2.72e-21 0.95 0.72 Response to antipsychotic treatment; chr6:85723869 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs2016720 ENSG00000253404.1 AC034243.1 12.69 1.28e-25 2.72e-21 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138928369 chr5:138744434~138753309:- PAAD cis rs507080 1 rs507080 ENSG00000255239.1 AP002954.6 12.68 1.32e-25 2.8e-21 0.92 0.72 Serum metabolite levels; chr11:118678873 chr11:118688039~118690600:- PAAD cis rs2739330 0.731 rs2000468 ENSG00000218537.1 MIF-AS1 12.68 1.32e-25 2.81e-21 0.92 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23894426~23898930:- PAAD cis rs2882667 0.69 rs825749 ENSG00000253404.1 AC034243.1 -12.68 1.37e-25 2.91e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138800232 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs884469 ENSG00000253404.1 AC034243.1 -12.68 1.37e-25 2.91e-21 -0.89 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138820270 chr5:138744434~138753309:- PAAD cis rs2739330 0.791 rs4822458 ENSG00000218537.1 MIF-AS1 12.68 1.4e-25 2.96e-21 0.98 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23894426~23898930:- PAAD cis rs2882667 0.69 rs311601 ENSG00000253404.1 AC034243.1 12.67 1.41e-25 2.98e-21 0.91 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138717697 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs160403 ENSG00000253404.1 AC034243.1 12.67 1.43e-25 3.02e-21 0.88 0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138722793 chr5:138744434~138753309:- PAAD cis rs2882667 0.628 rs13171173 ENSG00000253404.1 AC034243.1 -12.67 1.43e-25 3.02e-21 -0.9 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138706775 chr5:138744434~138753309:- PAAD cis rs4853012 0.838 rs72915068 ENSG00000217702.2 RP11-287D1.4 12.66 1.53e-25 3.23e-21 1.15 0.72 Gestational age at birth (maternal effect); chr2:74129058 chr2:74130583~74135395:+ PAAD cis rs507080 0.769 rs571001 ENSG00000255239.1 AP002954.6 12.66 1.56e-25 3.29e-21 0.95 0.72 Serum metabolite levels; chr11:118629457 chr11:118688039~118690600:- PAAD cis rs916888 0.821 rs199506 ENSG00000214401.4 KANSL1-AS1 -12.66 1.58e-25 3.34e-21 -1.03 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46193576~46196723:+ PAAD cis rs2739330 0.791 rs9612520 ENSG00000218537.1 MIF-AS1 12.64 1.78e-25 3.75e-21 0.99 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23894426~23898930:- PAAD cis rs9322193 0.923 rs4869750 ENSG00000231760.4 RP11-350J20.5 12.63 1.86e-25 3.9e-21 0.93 0.72 Lung cancer; chr6:149855996 chr6:149796151~149826294:- PAAD cis rs4853012 0.838 rs6715351 ENSG00000217702.2 RP11-287D1.4 12.63 1.87e-25 3.91e-21 1.14 0.72 Gestational age at birth (maternal effect); chr2:74118992 chr2:74130583~74135395:+ PAAD cis rs4853012 0.838 rs61521879 ENSG00000217702.2 RP11-287D1.4 12.63 1.87e-25 3.91e-21 1.14 0.72 Gestational age at birth (maternal effect); chr2:74119081 chr2:74130583~74135395:+ PAAD cis rs1577917 0.958 rs66807489 ENSG00000203875.9 SNHG5 -12.63 1.9e-25 3.96e-21 -0.92 -0.72 Response to antipsychotic treatment; chr6:85730984 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12213343 ENSG00000203875.9 SNHG5 -12.63 1.9e-25 3.96e-21 -0.92 -0.72 Response to antipsychotic treatment; chr6:85733301 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12215265 ENSG00000203875.9 SNHG5 -12.63 1.9e-25 3.96e-21 -0.92 -0.72 Response to antipsychotic treatment; chr6:85734251 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12197463 ENSG00000203875.9 SNHG5 -12.63 1.9e-25 3.96e-21 -0.92 -0.72 Response to antipsychotic treatment; chr6:85735524 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs13207173 ENSG00000203875.9 SNHG5 -12.63 1.9e-25 3.96e-21 -0.92 -0.72 Response to antipsychotic treatment; chr6:85747804 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs34795473 ENSG00000203875.9 SNHG5 -12.63 1.9e-25 3.96e-21 -0.92 -0.72 Response to antipsychotic treatment; chr6:85752081 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs4098044 ENSG00000203875.9 SNHG5 -12.63 1.9e-25 3.96e-21 -0.92 -0.72 Response to antipsychotic treatment; chr6:85752348 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12192033 ENSG00000203875.9 SNHG5 -12.63 1.9e-25 3.96e-21 -0.92 -0.72 Response to antipsychotic treatment; chr6:85762841 chr6:85660950~85678736:- PAAD cis rs2739330 0.828 rs5760108 ENSG00000218537.1 MIF-AS1 12.62 1.93e-25 4.02e-21 0.96 0.72 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23894426~23898930:- PAAD cis rs1577917 0.771 rs9362239 ENSG00000203875.9 SNHG5 12.62 2.02e-25 4.19e-21 0.96 0.72 Response to antipsychotic treatment; chr6:85719545 chr6:85660950~85678736:- PAAD cis rs916888 0.821 rs415430 ENSG00000214401.4 KANSL1-AS1 -12.61 2.06e-25 4.28e-21 -1.05 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:46193576~46196723:+ PAAD cis rs916888 0.779 rs430685 ENSG00000214401.4 KANSL1-AS1 -12.61 2.06e-25 4.28e-21 -1.05 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:46193576~46196723:+ PAAD cis rs507080 0.769 rs2077173 ENSG00000255239.1 AP002954.6 12.61 2.09e-25 4.33e-21 0.96 0.72 Serum metabolite levels; chr11:118621876 chr11:118688039~118690600:- PAAD cis rs2739330 0.731 rs2000468 ENSG00000273295.1 AP000350.5 12.6 2.17e-25 4.5e-21 0.87 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23901432~23907068:- PAAD cis rs2882667 0.69 rs825677 ENSG00000253404.1 AC034243.1 -12.59 2.32e-25 4.8e-21 -0.9 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138769081 chr5:138744434~138753309:- PAAD cis rs2486288 0.656 rs8039153 ENSG00000259520.4 CTD-2651B20.3 12.58 2.47e-25 5.09e-21 0.82 0.71 Glomerular filtration rate; chr15:45287615 chr15:45251580~45279251:- PAAD cis rs858239 0.899 rs2268745 ENSG00000230658.1 KLHL7-AS1 12.58 2.5e-25 5.14e-21 0.92 0.71 Cerebrospinal fluid biomarker levels; chr7:23277981 chr7:23101228~23105703:- PAAD cis rs2486288 0.656 rs9921035 ENSG00000259520.4 CTD-2651B20.3 12.57 2.67e-25 5.49e-21 0.81 0.71 Glomerular filtration rate; chr15:45254462 chr15:45251580~45279251:- PAAD cis rs2739330 0.828 rs2877178 ENSG00000218537.1 MIF-AS1 12.57 2.73e-25 5.59e-21 0.97 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23894426~23898930:- PAAD cis rs2739330 0.828 rs2154593 ENSG00000218537.1 MIF-AS1 12.57 2.73e-25 5.59e-21 0.97 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23894426~23898930:- PAAD cis rs1577917 0.958 rs10944136 ENSG00000203875.9 SNHG5 -12.57 2.76e-25 5.65e-21 -0.93 -0.71 Response to antipsychotic treatment; chr6:85738781 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12195776 ENSG00000203875.9 SNHG5 -12.56 2.82e-25 5.73e-21 -0.93 -0.71 Response to antipsychotic treatment; chr6:85778881 chr6:85660950~85678736:- PAAD cis rs1577917 0.916 rs12206726 ENSG00000203875.9 SNHG5 -12.56 2.82e-25 5.73e-21 -0.93 -0.71 Response to antipsychotic treatment; chr6:85789998 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs1414201 ENSG00000203875.9 SNHG5 -12.56 2.82e-25 5.73e-21 -0.93 -0.71 Response to antipsychotic treatment; chr6:85790598 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs7453105 ENSG00000203875.9 SNHG5 -12.56 2.82e-25 5.73e-21 -0.93 -0.71 Response to antipsychotic treatment; chr6:85791043 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12209259 ENSG00000203875.9 SNHG5 -12.56 2.82e-25 5.73e-21 -0.93 -0.71 Response to antipsychotic treatment; chr6:85792630 chr6:85660950~85678736:- PAAD cis rs916888 0.61 rs199454 ENSG00000262539.1 RP11-259G18.3 -12.56 2.93e-25 5.94e-21 -0.97 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46259551~46260606:- PAAD cis rs507080 0.769 rs11603616 ENSG00000255239.1 AP002954.6 12.55 3.05e-25 6.17e-21 0.94 0.71 Serum metabolite levels; chr11:118625350 chr11:118688039~118690600:- PAAD cis rs507080 0.769 rs570952 ENSG00000255239.1 AP002954.6 12.55 3.05e-25 6.17e-21 0.94 0.71 Serum metabolite levels; chr11:118629477 chr11:118688039~118690600:- PAAD cis rs507080 0.769 rs645637 ENSG00000255239.1 AP002954.6 12.55 3.05e-25 6.17e-21 0.94 0.71 Serum metabolite levels; chr11:118634373 chr11:118688039~118690600:- PAAD cis rs507080 0.769 rs483283 ENSG00000255239.1 AP002954.6 12.55 3.05e-25 6.17e-21 0.94 0.71 Serum metabolite levels; chr11:118635684 chr11:118688039~118690600:- PAAD cis rs507080 0.769 rs745663 ENSG00000255239.1 AP002954.6 12.55 3.05e-25 6.17e-21 0.94 0.71 Serum metabolite levels; chr11:118658886 chr11:118688039~118690600:- PAAD cis rs2739330 0.627 rs9608219 ENSG00000218537.1 MIF-AS1 12.54 3.22e-25 6.5e-21 0.99 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23894426~23898930:- PAAD cis rs916888 0.779 rs199526 ENSG00000214401.4 KANSL1-AS1 -12.54 3.29e-25 6.64e-21 -0.97 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:46193576~46196723:+ PAAD cis rs1577917 0.958 rs72907388 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85730489 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2225754 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85739980 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs11755642 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85740348 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12193904 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85742985 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs11754330 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85745352 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs34622605 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85746801 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs1335442 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85756974 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs13213899 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85763422 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs10806337 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85764531 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12205492 ENSG00000203875.9 SNHG5 -12.54 3.32e-25 6.65e-21 -0.91 -0.71 Response to antipsychotic treatment; chr6:85766258 chr6:85660950~85678736:- PAAD cis rs2882667 0.654 rs7709770 ENSG00000253404.1 AC034243.1 -12.52 3.58e-25 7.15e-21 -0.89 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138813650 chr5:138744434~138753309:- PAAD cis rs507080 0.769 rs570836 ENSG00000255239.1 AP002954.6 12.52 3.65e-25 7.28e-21 0.94 0.71 Serum metabolite levels; chr11:118641444 chr11:118688039~118690600:- PAAD cis rs2882667 0.69 rs4835703 ENSG00000253404.1 AC034243.1 -12.52 3.67e-25 7.33e-21 -0.9 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138815048 chr5:138744434~138753309:- PAAD cis rs2882667 0.654 rs4835704 ENSG00000253404.1 AC034243.1 -12.52 3.67e-25 7.33e-21 -0.9 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138815636 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs6596453 ENSG00000253404.1 AC034243.1 -12.52 3.67e-25 7.33e-21 -0.9 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138816202 chr5:138744434~138753309:- PAAD cis rs4853012 0.838 rs72911122 ENSG00000217702.2 RP11-287D1.4 12.52 3.69e-25 7.36e-21 1.15 0.71 Gestational age at birth (maternal effect); chr2:74116992 chr2:74130583~74135395:+ PAAD cis rs1577917 1 rs16876529 ENSG00000203875.9 SNHG5 -12.52 3.7e-25 7.36e-21 -0.93 -0.71 Response to antipsychotic treatment; chr6:85881484 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12204015 ENSG00000203875.9 SNHG5 -12.52 3.7e-25 7.36e-21 -0.93 -0.71 Response to antipsychotic treatment; chr6:85888616 chr6:85660950~85678736:- PAAD cis rs2739330 0.76 rs1002286 ENSG00000218537.1 MIF-AS1 -12.52 3.72e-25 7.39e-21 -0.92 -0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23894426~23898930:- PAAD cis rs2882667 0.69 rs311608 ENSG00000253404.1 AC034243.1 12.51 3.94e-25 7.81e-21 0.9 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138708000 chr5:138744434~138753309:- PAAD cis rs2882667 0.628 rs311606 ENSG00000253404.1 AC034243.1 12.51 3.97e-25 7.87e-21 0.89 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138709551 chr5:138744434~138753309:- PAAD cis rs4853012 0.838 rs59570457 ENSG00000217702.2 RP11-287D1.4 12.51 4.01e-25 7.94e-21 1.14 0.71 Gestational age at birth (maternal effect); chr2:74117155 chr2:74130583~74135395:+ PAAD cis rs9322193 0.772 rs7738696 ENSG00000231760.4 RP11-350J20.5 12.49 4.35e-25 8.6e-21 0.97 0.71 Lung cancer; chr6:149848985 chr6:149796151~149826294:- PAAD cis rs2882667 0.69 rs3763016 ENSG00000253404.1 AC034243.1 12.48 4.79e-25 9.45e-21 0.9 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138935043 chr5:138744434~138753309:- PAAD cis rs916888 0.61 rs199446 ENSG00000262539.1 RP11-259G18.3 -12.47 5.06e-25 9.95e-21 -0.97 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46259551~46260606:- PAAD cis rs916888 0.61 rs199536 ENSG00000262539.1 RP11-259G18.3 -12.47 5.06e-25 9.95e-21 -0.97 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46259551~46260606:- PAAD cis rs4853012 0.838 rs4452177 ENSG00000217702.2 RP11-287D1.4 12.46 5.26e-25 1.03e-20 1.13 0.71 Gestational age at birth (maternal effect); chr2:74118079 chr2:74130583~74135395:+ PAAD cis rs4853012 0.838 rs60705299 ENSG00000217702.2 RP11-287D1.4 12.46 5.26e-25 1.03e-20 1.13 0.71 Gestational age at birth (maternal effect); chr2:74118243 chr2:74130583~74135395:+ PAAD cis rs2739330 0.929 rs5751777 ENSG00000225282.1 AP000350.6 12.45 5.64e-25 1.11e-20 0.92 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23926900~23929574:+ PAAD cis rs1577917 0.958 rs1545376 ENSG00000203875.9 SNHG5 12.45 5.81e-25 1.13e-20 0.93 0.71 Response to antipsychotic treatment; chr6:85794864 chr6:85660950~85678736:- PAAD cis rs1577917 0.916 rs4142546 ENSG00000203875.9 SNHG5 -12.45 5.81e-25 1.13e-20 -0.93 -0.71 Response to antipsychotic treatment; chr6:85795593 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs6900436 ENSG00000203875.9 SNHG5 -12.45 5.81e-25 1.13e-20 -0.93 -0.71 Response to antipsychotic treatment; chr6:85796570 chr6:85660950~85678736:- PAAD cis rs1577917 0.687 rs1470531 ENSG00000203875.9 SNHG5 -12.45 5.81e-25 1.13e-20 -0.93 -0.71 Response to antipsychotic treatment; chr6:85797651 chr6:85660950~85678736:- PAAD cis rs1577917 0.876 rs4618490 ENSG00000203875.9 SNHG5 -12.45 5.81e-25 1.13e-20 -0.93 -0.71 Response to antipsychotic treatment; chr6:85808685 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12191340 ENSG00000203875.9 SNHG5 -12.45 5.81e-25 1.13e-20 -0.93 -0.71 Response to antipsychotic treatment; chr6:85811682 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs1414199 ENSG00000203875.9 SNHG5 -12.45 5.81e-25 1.13e-20 -0.93 -0.71 Response to antipsychotic treatment; chr6:85812652 chr6:85660950~85678736:- PAAD cis rs2739330 0.828 rs4822454 ENSG00000273295.1 AP000350.5 12.44 5.93e-25 1.16e-20 0.9 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23901432~23907068:- PAAD cis rs916888 0.821 rs199504 ENSG00000214401.4 KANSL1-AS1 -12.43 6.26e-25 1.22e-20 -1.02 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46193576~46196723:+ PAAD cis rs2882667 0.69 rs160404 ENSG00000253404.1 AC034243.1 12.43 6.3e-25 1.22e-20 0.9 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138748580 chr5:138744434~138753309:- PAAD cis rs1577917 0.958 rs4707223 ENSG00000203875.9 SNHG5 -12.42 7.04e-25 1.37e-20 -0.93 -0.71 Response to antipsychotic treatment; chr6:85800084 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs10944137 ENSG00000203875.9 SNHG5 -12.41 7.39e-25 1.43e-20 -0.91 -0.71 Response to antipsychotic treatment; chr6:85744596 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12212480 ENSG00000203875.9 SNHG5 -12.41 7.39e-25 1.43e-20 -0.91 -0.71 Response to antipsychotic treatment; chr6:85749059 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12664335 ENSG00000203875.9 SNHG5 12.39 8.07e-25 1.55e-20 0.92 0.71 Response to antipsychotic treatment; chr6:85888056 chr6:85660950~85678736:- PAAD cis rs2739330 0.703 rs5760112 ENSG00000273295.1 AP000350.5 12.39 8.07e-25 1.55e-20 0.89 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23901432~23907068:- PAAD cis rs1577917 0.958 rs12192546 ENSG00000203875.9 SNHG5 12.38 9e-25 1.73e-20 0.93 0.71 Response to antipsychotic treatment; chr6:85766766 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs10045605 ENSG00000253404.1 AC034243.1 12.37 9.22e-25 1.77e-20 0.91 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138936458 chr5:138744434~138753309:- PAAD cis rs1577917 0.958 rs10944144 ENSG00000203875.9 SNHG5 -12.37 9.58e-25 1.84e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85828037 chr6:85660950~85678736:- PAAD cis rs2882667 0.654 rs10044432 ENSG00000253404.1 AC034243.1 12.36 1.01e-24 1.94e-20 0.91 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138939207 chr5:138744434~138753309:- PAAD cis rs1577917 0.57 rs114854865 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85844518 chr6:85660950~85678736:- PAAD cis rs1577917 0.916 rs4706252 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85845462 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs1838959 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85847086 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs1579886 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85847473 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs1816937 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85847533 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2324840 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85847902 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs7382798 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85850116 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12202188 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85852982 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs36035797 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85853162 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs1838958 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85854250 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs2084293 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85856284 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12209668 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85856799 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs11752180 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85863447 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs12665464 ENSG00000203875.9 SNHG5 -12.35 1.06e-24 1.99e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85864415 chr6:85660950~85678736:- PAAD cis rs4853012 0.838 rs12619982 ENSG00000217702.2 RP11-287D1.4 12.35 1.08e-24 2.03e-20 1.13 0.71 Gestational age at birth (maternal effect); chr2:74128895 chr2:74130583~74135395:+ PAAD cis rs9322193 0.884 rs7743823 ENSG00000231760.4 RP11-350J20.5 12.34 1.15e-24 2.15e-20 0.95 0.71 Lung cancer; chr6:149849744 chr6:149796151~149826294:- PAAD cis rs2739330 0.828 rs4822451 ENSG00000218537.1 MIF-AS1 12.34 1.15e-24 2.15e-20 0.97 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23894426~23898930:- PAAD cis rs2739330 0.828 rs5760099 ENSG00000218537.1 MIF-AS1 12.34 1.15e-24 2.15e-20 0.97 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23894426~23898930:- PAAD cis rs9322193 0.884 rs7769115 ENSG00000231760.4 RP11-350J20.5 12.31 1.37e-24 2.54e-20 0.96 0.71 Lung cancer; chr6:149848796 chr6:149796151~149826294:- PAAD cis rs1577917 0.666 rs6454471 ENSG00000203875.9 SNHG5 12.29 1.53e-24 2.83e-20 0.93 0.71 Response to antipsychotic treatment; chr6:85504738 chr6:85660950~85678736:- PAAD cis rs1577917 0.665 rs4304137 ENSG00000203875.9 SNHG5 12.29 1.53e-24 2.83e-20 0.93 0.71 Response to antipsychotic treatment; chr6:85507730 chr6:85660950~85678736:- PAAD cis rs9322193 0.884 rs1108889 ENSG00000231760.4 RP11-350J20.5 12.29 1.53e-24 2.84e-20 0.94 0.71 Lung cancer; chr6:149845433 chr6:149796151~149826294:- PAAD cis rs858239 0.867 rs10250602 ENSG00000230658.1 KLHL7-AS1 12.29 1.55e-24 2.87e-20 0.91 0.71 Cerebrospinal fluid biomarker levels; chr7:23264082 chr7:23101228~23105703:- PAAD cis rs4853012 0.838 rs6707729 ENSG00000217702.2 RP11-287D1.4 12.27 1.69e-24 3.12e-20 1.12 0.71 Gestational age at birth (maternal effect); chr2:74117558 chr2:74130583~74135395:+ PAAD cis rs1577917 0.958 rs12216074 ENSG00000203875.9 SNHG5 -12.27 1.69e-24 3.13e-20 -0.93 -0.71 Response to antipsychotic treatment; chr6:85810284 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs10498958 ENSG00000203875.9 SNHG5 12.27 1.75e-24 3.21e-20 0.92 0.71 Response to antipsychotic treatment; chr6:85939987 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs34765423 ENSG00000203875.9 SNHG5 -12.27 1.75e-24 3.21e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85774730 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs2197651 ENSG00000203875.9 SNHG5 -12.27 1.75e-24 3.21e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85785724 chr6:85660950~85678736:- PAAD cis rs1577917 0.876 rs66986937 ENSG00000203875.9 SNHG5 -12.27 1.75e-24 3.21e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85822473 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs13219504 ENSG00000203875.9 SNHG5 -12.27 1.75e-24 3.21e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85847199 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs13196930 ENSG00000203875.9 SNHG5 -12.27 1.75e-24 3.21e-20 -0.92 -0.71 Response to antipsychotic treatment; chr6:85942527 chr6:85660950~85678736:- PAAD cis rs858239 1 rs156407 ENSG00000230658.1 KLHL7-AS1 12.26 1.85e-24 3.38e-20 0.89 0.71 Cerebrospinal fluid biomarker levels; chr7:23276020 chr7:23101228~23105703:- PAAD cis rs858239 0.899 rs5850 ENSG00000230658.1 KLHL7-AS1 12.26 1.86e-24 3.41e-20 0.91 0.71 Cerebrospinal fluid biomarker levels; chr7:23274928 chr7:23101228~23105703:- PAAD cis rs4853012 0.838 rs4563249 ENSG00000217702.2 RP11-287D1.4 12.25 2e-24 3.65e-20 1.12 0.7 Gestational age at birth (maternal effect); chr2:74126889 chr2:74130583~74135395:+ PAAD cis rs9322193 0.847 rs880246 ENSG00000231760.4 RP11-350J20.5 12.25 2e-24 3.66e-20 0.94 0.7 Lung cancer; chr6:149845972 chr6:149796151~149826294:- PAAD cis rs1577917 0.958 rs12190603 ENSG00000203875.9 SNHG5 -12.24 2.09e-24 3.82e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85766000 chr6:85660950~85678736:- PAAD cis rs858239 0.899 rs28635122 ENSG00000230658.1 KLHL7-AS1 12.23 2.21e-24 4.04e-20 0.91 0.7 Cerebrospinal fluid biomarker levels; chr7:23270562 chr7:23101228~23105703:- PAAD cis rs1577917 0.958 rs1591438 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85815496 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs1591437 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85815587 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12665542 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85834725 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs10944147 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85841068 chr6:85660950~85678736:- PAAD cis rs1577917 0.916 rs12198730 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85845420 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs13201730 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85846929 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12196377 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85857057 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2121594 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85867136 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2875456 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85892566 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12201571 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85900032 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12192992 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85900197 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs11759855 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85901123 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1857964 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85926276 chr6:85660950~85678736:- PAAD cis rs1577917 0.798 rs7772384 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85929962 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs35738006 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85936591 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs13194429 ENSG00000203875.9 SNHG5 -12.22 2.38e-24 4.28e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85936987 chr6:85660950~85678736:- PAAD cis rs2739330 0.703 rs5760112 ENSG00000218537.1 MIF-AS1 12.22 2.42e-24 4.36e-20 0.93 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23894426~23898930:- PAAD cis rs2739330 0.76 rs5751760 ENSG00000273295.1 AP000350.5 12.21 2.56e-24 4.59e-20 0.87 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23901432~23907068:- PAAD cis rs2739330 0.857 rs9608229 ENSG00000273295.1 AP000350.5 12.2 2.63e-24 4.73e-20 0.93 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:24002918 chr22:23901432~23907068:- PAAD cis rs1577917 0.655 rs9359658 ENSG00000203875.9 SNHG5 12.2 2.66e-24 4.77e-20 0.92 0.7 Response to antipsychotic treatment; chr6:85596051 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs11750163 ENSG00000253404.1 AC034243.1 12.19 2.82e-24 5.06e-20 0.87 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138705920 chr5:138744434~138753309:- PAAD cis rs2739330 0.796 rs2154594 ENSG00000273295.1 AP000350.5 -12.17 3.17e-24 5.66e-20 -0.9 -0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23901432~23907068:- PAAD cis rs858239 0.67 rs3807452 ENSG00000230658.1 KLHL7-AS1 -12.17 3.22e-24 5.74e-20 -0.88 -0.7 Cerebrospinal fluid biomarker levels; chr7:23122462 chr7:23101228~23105703:- PAAD cis rs1577917 0.739 rs6922 ENSG00000203875.9 SNHG5 12.17 3.23e-24 5.76e-20 0.93 0.7 Response to antipsychotic treatment; chr6:85495605 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12200330 ENSG00000203875.9 SNHG5 -12.17 3.25e-24 5.79e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85946935 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs825747 ENSG00000253404.1 AC034243.1 -12.17 3.28e-24 5.84e-20 -0.87 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138800896 chr5:138744434~138753309:- PAAD cis rs916888 0.61 rs199436 ENSG00000262539.1 RP11-259G18.3 -12.16 3.41e-24 6.05e-20 -0.95 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46259551~46260606:- PAAD cis rs916888 0.531 rs183211 ENSG00000262539.1 RP11-259G18.3 12.16 3.41e-24 6.05e-20 0.95 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46259551~46260606:- PAAD cis rs916888 0.61 rs199453 ENSG00000262539.1 RP11-259G18.3 12.16 3.41e-24 6.05e-20 0.95 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46259551~46260606:- PAAD cis rs916888 0.647 rs199449 ENSG00000262539.1 RP11-259G18.3 12.16 3.41e-24 6.05e-20 0.95 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46259551~46260606:- PAAD cis rs507080 0.769 rs527290 ENSG00000255239.1 AP002954.6 12.16 3.45e-24 6.1e-20 0.94 0.7 Serum metabolite levels; chr11:118644898 chr11:118688039~118690600:- PAAD cis rs858239 0.738 rs13225593 ENSG00000230658.1 KLHL7-AS1 12.16 3.48e-24 6.16e-20 0.91 0.7 Cerebrospinal fluid biomarker levels; chr7:23220688 chr7:23101228~23105703:- PAAD cis rs2882667 0.69 rs6596456 ENSG00000253404.1 AC034243.1 -12.15 3.64e-24 6.43e-20 -0.91 -0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138831808 chr5:138744434~138753309:- PAAD cis rs1577917 1 rs4706254 ENSG00000203875.9 SNHG5 -12.15 3.72e-24 6.56e-20 -0.92 -0.7 Response to antipsychotic treatment; chr6:85893095 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs13199006 ENSG00000203875.9 SNHG5 -12.15 3.72e-24 6.56e-20 -0.92 -0.7 Response to antipsychotic treatment; chr6:85898990 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs4707239 ENSG00000203875.9 SNHG5 -12.15 3.72e-24 6.56e-20 -0.92 -0.7 Response to antipsychotic treatment; chr6:85900999 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12198876 ENSG00000203875.9 SNHG5 -12.14 3.8e-24 6.68e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85815758 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs67024565 ENSG00000203875.9 SNHG5 -12.14 3.8e-24 6.68e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85844279 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs36053156 ENSG00000203875.9 SNHG5 -12.14 3.8e-24 6.68e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85865791 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs12202170 ENSG00000203875.9 SNHG5 -12.14 3.8e-24 6.68e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85880668 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs10455449 ENSG00000203875.9 SNHG5 -12.14 3.8e-24 6.68e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85882508 chr6:85660950~85678736:- PAAD cis rs1577917 0.959 rs16876540 ENSG00000203875.9 SNHG5 -12.14 3.8e-24 6.68e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85902801 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs35761942 ENSG00000203875.9 SNHG5 -12.14 3.8e-24 6.68e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85919786 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs955227 ENSG00000203875.9 SNHG5 -12.14 3.8e-24 6.68e-20 -0.91 -0.7 Response to antipsychotic treatment; chr6:85941314 chr6:85660950~85678736:- PAAD cis rs2882667 0.728 rs10037071 ENSG00000253404.1 AC034243.1 12.14 3.84e-24 6.74e-20 0.89 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138942158 chr5:138744434~138753309:- PAAD cis rs2882667 0.728 rs10068786 ENSG00000253404.1 AC034243.1 12.14 3.87e-24 6.78e-20 0.9 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138941255 chr5:138744434~138753309:- PAAD cis rs1577917 0.958 rs12213431 ENSG00000203875.9 SNHG5 -12.13 4.01e-24 7.02e-20 -0.92 -0.7 Response to antipsychotic treatment; chr6:85791238 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs11749163 ENSG00000253404.1 AC034243.1 12.13 4.07e-24 7.12e-20 0.86 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138926981 chr5:138744434~138753309:- PAAD cis rs916888 0.773 rs9896243 ENSG00000214401.4 KANSL1-AS1 12.13 4.18e-24 7.32e-20 1.02 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:46193576~46196723:+ PAAD cis rs4853012 0.793 rs6723185 ENSG00000217702.2 RP11-287D1.4 12.12 4.3e-24 7.51e-20 1.13 0.7 Gestational age at birth (maternal effect); chr2:74117757 chr2:74130583~74135395:+ PAAD cis rs2882667 0.69 rs9327830 ENSG00000253404.1 AC034243.1 12.12 4.34e-24 7.56e-20 0.88 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138936560 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs9942422 ENSG00000253404.1 AC034243.1 12.12 4.34e-24 7.56e-20 0.88 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138936847 chr5:138744434~138753309:- PAAD cis rs2882667 0.69 rs7709789 ENSG00000253404.1 AC034243.1 12.12 4.34e-24 7.56e-20 0.88 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138938762 chr5:138744434~138753309:- PAAD cis rs858239 0.698 rs858295 ENSG00000230658.1 KLHL7-AS1 12.12 4.48e-24 7.8e-20 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23205950 chr7:23101228~23105703:- PAAD cis rs2882667 0.658 rs10076442 ENSG00000253404.1 AC034243.1 12.11 4.75e-24 8.25e-20 0.89 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138941090 chr5:138744434~138753309:- PAAD cis rs507080 0.922 rs4936433 ENSG00000255239.1 AP002954.6 -12.11 4.77e-24 8.29e-20 -0.91 -0.7 Serum metabolite levels; chr11:118681711 chr11:118688039~118690600:- PAAD cis rs10256972 0.539 rs2949174 ENSG00000229043.2 AC091729.9 -12.1 5.07e-24 8.79e-20 -0.79 -0.7 Endometriosis;Longevity; chr7:1174287 chr7:1160374~1165267:+ PAAD cis rs2486288 0.554 rs1719235 ENSG00000259520.4 CTD-2651B20.3 12.1 5.12e-24 8.85e-20 0.8 0.7 Glomerular filtration rate; chr15:45283910 chr15:45251580~45279251:- PAAD cis rs10256972 0.567 rs2960850 ENSG00000229043.2 AC091729.9 -12.09 5.14e-24 8.89e-20 -0.78 -0.7 Endometriosis;Longevity; chr7:1172013 chr7:1160374~1165267:+ PAAD cis rs858239 0.806 rs10268610 ENSG00000230658.1 KLHL7-AS1 12.09 5.29e-24 9.14e-20 0.92 0.7 Cerebrospinal fluid biomarker levels; chr7:23235145 chr7:23101228~23105703:- PAAD cis rs507080 0.769 rs12290522 ENSG00000255239.1 AP002954.6 12.09 5.36e-24 9.26e-20 0.95 0.7 Serum metabolite levels; chr11:118615610 chr11:118688039~118690600:- PAAD cis rs1577917 1 rs1962716 ENSG00000203875.9 SNHG5 -12.09 5.39e-24 9.3e-20 -0.92 -0.7 Response to antipsychotic treatment; chr6:85938718 chr6:85660950~85678736:- PAAD cis rs916888 0.61 rs199438 ENSG00000262539.1 RP11-259G18.3 12.08 5.6e-24 9.66e-20 0.95 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46259551~46260606:- PAAD cis rs2882667 0.554 rs1368425 ENSG00000253404.1 AC034243.1 12.07 5.85e-24 1.01e-19 0.86 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138944528 chr5:138744434~138753309:- PAAD cis rs9326248 0.861 rs7120309 ENSG00000254851.1 RP11-109L13.1 -12.07 5.85e-24 1.01e-19 -1.01 -0.7 Blood protein levels; chr11:117172100 chr11:117135528~117138582:+ PAAD cis rs9326248 0.861 rs7120449 ENSG00000254851.1 RP11-109L13.1 -12.07 5.85e-24 1.01e-19 -1.01 -0.7 Blood protein levels; chr11:117172183 chr11:117135528~117138582:+ PAAD cis rs1577917 0.958 rs9647601 ENSG00000203875.9 SNHG5 -12.07 6.1e-24 1.04e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85740109 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs6454488 ENSG00000203875.9 SNHG5 -12.07 6.1e-24 1.04e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85741124 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2324817 ENSG00000203875.9 SNHG5 -12.07 6.1e-24 1.04e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85752936 chr6:85660950~85678736:- PAAD cis rs1577917 0.837 rs806529 ENSG00000203875.9 SNHG5 -12.07 6.1e-24 1.04e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85757403 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs6921315 ENSG00000203875.9 SNHG5 -12.07 6.1e-24 1.04e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85761950 chr6:85660950~85678736:- PAAD cis rs916888 0.61 rs199444 ENSG00000262539.1 RP11-259G18.3 12.06 6.18e-24 1.06e-19 0.95 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46259551~46260606:- PAAD cis rs916888 0.61 rs199442 ENSG00000262539.1 RP11-259G18.3 12.06 6.18e-24 1.06e-19 0.95 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46259551~46260606:- PAAD cis rs9326248 0.813 rs7115562 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117149754 chr11:117135528~117138582:+ PAAD cis rs9326248 0.727 rs4938347 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117151043 chr11:117135528~117138582:+ PAAD cis rs9326248 0.861 rs4938348 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117151161 chr11:117135528~117138582:+ PAAD cis rs9326248 0.813 rs4938350 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117151560 chr11:117135528~117138582:+ PAAD cis rs9326248 0.652 rs7128382 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117152771 chr11:117135528~117138582:+ PAAD cis rs9326248 0.768 rs4936366 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117156169 chr11:117135528~117138582:+ PAAD cis rs9326248 0.861 rs4938352 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117156765 chr11:117135528~117138582:+ PAAD cis rs9326248 0.861 rs7931335 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117166089 chr11:117135528~117138582:+ PAAD cis rs9326248 0.861 rs4938353 ENSG00000254851.1 RP11-109L13.1 -12.06 6.46e-24 1.1e-19 -1 -0.7 Blood protein levels; chr11:117175481 chr11:117135528~117138582:+ PAAD cis rs10256972 0.552 rs7805591 ENSG00000229043.2 AC091729.9 -12.06 6.47e-24 1.1e-19 -0.76 -0.7 Endometriosis;Longevity; chr7:1171109 chr7:1160374~1165267:+ PAAD cis rs4853012 0.941 rs60291089 ENSG00000217702.2 RP11-287D1.4 12.06 6.52e-24 1.1e-19 1.08 0.7 Gestational age at birth (maternal effect); chr2:74117763 chr2:74130583~74135395:+ PAAD cis rs4853012 0.838 rs58759652 ENSG00000217702.2 RP11-287D1.4 12.06 6.52e-24 1.1e-19 1.08 0.7 Gestational age at birth (maternal effect); chr2:74117775 chr2:74130583~74135395:+ PAAD cis rs2739330 0.731 rs4822450 ENSG00000273295.1 AP000350.5 12.05 6.72e-24 1.14e-19 0.86 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23901432~23907068:- PAAD cis rs9322193 0.884 rs880245 ENSG00000231760.4 RP11-350J20.5 -12.05 6.77e-24 1.14e-19 -0.92 -0.7 Lung cancer; chr6:149846262 chr6:149796151~149826294:- PAAD cis rs1577917 0.958 rs4707236 ENSG00000203875.9 SNHG5 -12.04 7.1e-24 1.2e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85874249 chr6:85660950~85678736:- PAAD cis rs9326248 0.813 rs474488 ENSG00000254851.1 RP11-109L13.1 -12.04 7.2e-24 1.21e-19 -1.02 -0.7 Blood protein levels; chr11:117198261 chr11:117135528~117138582:+ PAAD cis rs1577917 1 rs12190604 ENSG00000203875.9 SNHG5 -12.04 7.24e-24 1.22e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86006497 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1415753 ENSG00000203875.9 SNHG5 -12.04 7.36e-24 1.24e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:86043356 chr6:85660950~85678736:- PAAD cis rs858239 0.665 rs858306 ENSG00000230658.1 KLHL7-AS1 12.04 7.37e-24 1.24e-19 0.89 0.7 Cerebrospinal fluid biomarker levels; chr7:23203135 chr7:23101228~23105703:- PAAD cis rs801193 1 rs13239306 ENSG00000226824.5 RP4-756H11.3 12.03 7.63e-24 1.28e-19 0.8 0.7 Aortic root size; chr7:66671030 chr7:66654538~66669855:+ PAAD cis rs9322193 0.923 rs2880436 ENSG00000231760.4 RP11-350J20.5 12.03 7.64e-24 1.28e-19 0.95 0.7 Lung cancer; chr6:149859123 chr6:149796151~149826294:- PAAD cis rs2739330 0.685 rs4822453 ENSG00000273295.1 AP000350.5 12.03 7.71e-24 1.29e-19 0.9 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23901432~23907068:- PAAD cis rs1577917 1 rs10455455 ENSG00000203875.9 SNHG5 -12.03 7.9e-24 1.32e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85960496 chr6:85660950~85678736:- PAAD cis rs1577917 0.876 rs1582126 ENSG00000203875.9 SNHG5 -12.03 7.9e-24 1.32e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85987487 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12215037 ENSG00000203875.9 SNHG5 -12.03 7.9e-24 1.32e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:86017913 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs9327831 ENSG00000253404.1 AC034243.1 12.02 8.1e-24 1.35e-19 0.88 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138936597 chr5:138744434~138753309:- PAAD cis rs801193 1 rs2420824 ENSG00000226824.5 RP4-756H11.3 12.02 8.17e-24 1.36e-19 0.78 0.7 Aortic root size; chr7:66666129 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2659909 ENSG00000226824.5 RP4-756H11.3 -12.02 8.17e-24 1.36e-19 -0.78 -0.7 Aortic root size; chr7:66695292 chr7:66654538~66669855:+ PAAD cis rs9322193 0.884 rs9397036 ENSG00000231760.4 RP11-350J20.5 12.02 8.37e-24 1.39e-19 0.95 0.7 Lung cancer; chr6:149851787 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs9383864 ENSG00000231760.4 RP11-350J20.5 12.02 8.37e-24 1.39e-19 0.95 0.7 Lung cancer; chr6:149851969 chr6:149796151~149826294:- PAAD cis rs9322193 0.884 rs9383865 ENSG00000231760.4 RP11-350J20.5 12.02 8.37e-24 1.39e-19 0.95 0.7 Lung cancer; chr6:149852043 chr6:149796151~149826294:- PAAD cis rs1577917 1 rs12205548 ENSG00000203875.9 SNHG5 -12 8.97e-24 1.49e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86050052 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12665321 ENSG00000203875.9 SNHG5 -12 8.97e-24 1.49e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86059571 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12196175 ENSG00000203875.9 SNHG5 -12 8.97e-24 1.49e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86069652 chr6:85660950~85678736:- PAAD cis rs4853012 0.793 rs6707619 ENSG00000217702.2 RP11-287D1.4 11.99 9.58e-24 1.59e-19 1.09 0.7 Gestational age at birth (maternal effect); chr2:74117529 chr2:74130583~74135395:+ PAAD cis rs1577917 0.816 rs9353349 ENSG00000203875.9 SNHG5 11.98 1.02e-23 1.69e-19 0.92 0.7 Response to antipsychotic treatment; chr6:85998007 chr6:85660950~85678736:- PAAD cis rs1577917 0.739 rs2758846 ENSG00000203875.9 SNHG5 -11.98 1.04e-23 1.72e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85639852 chr6:85660950~85678736:- PAAD cis rs4853012 0.838 rs60964317 ENSG00000217702.2 RP11-287D1.4 11.98 1.05e-23 1.72e-19 1.12 0.7 Gestational age at birth (maternal effect); chr2:74116296 chr2:74130583~74135395:+ PAAD cis rs1577917 1 rs12208493 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85952549 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12213149 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85958926 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12216203 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85965583 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs11756615 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85970117 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs10944168 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85970438 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs35283633 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85981069 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs11756510 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85990076 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs34281561 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85992154 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs35419329 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85992573 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12216328 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85993700 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1999852 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85996020 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs34581302 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85996230 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs35797755 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85996836 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs68171315 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:85997682 chr6:85660950~85678736:- PAAD cis rs1577917 0.652 rs75593931 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86009821 chr6:85660950~85678736:- PAAD cis rs1577917 0.959 rs12201739 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86011021 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs35038582 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86011587 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs7760207 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86011982 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12205336 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86012649 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12207305 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86013784 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12209127 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86014709 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12212733 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86016295 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12199516 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86016503 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12199784 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86017090 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1337850 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86019385 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs955197 ENSG00000203875.9 SNHG5 -11.98 1.06e-23 1.72e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86019957 chr6:85660950~85678736:- PAAD cis rs10256972 0.577 rs2949179 ENSG00000229043.2 AC091729.9 -11.98 1.07e-23 1.75e-19 -0.72 -0.7 Endometriosis;Longevity; chr7:1170249 chr7:1160374~1165267:+ PAAD cis rs10256972 0.504 rs2949178 ENSG00000229043.2 AC091729.9 -11.98 1.07e-23 1.75e-19 -0.72 -0.7 Endometriosis;Longevity; chr7:1170289 chr7:1160374~1165267:+ PAAD cis rs9326248 0.773 rs1060211 ENSG00000254851.1 RP11-109L13.1 -11.97 1.12e-23 1.8e-19 -1.01 -0.7 Blood protein levels; chr11:117169081 chr11:117135528~117138582:+ PAAD cis rs10256972 0.552 rs6978842 ENSG00000229043.2 AC091729.9 -11.97 1.13e-23 1.8e-19 -0.72 -0.7 Endometriosis;Longevity; chr7:1164963 chr7:1160374~1165267:+ PAAD cis rs10256972 0.567 rs2949185 ENSG00000229043.2 AC091729.9 -11.96 1.15e-23 1.83e-19 -0.74 -0.7 Endometriosis;Longevity; chr7:1169377 chr7:1160374~1165267:+ PAAD cis rs1577917 1 rs1577919 ENSG00000203875.9 SNHG5 -11.96 1.17e-23 1.85e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86047578 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12203493 ENSG00000203875.9 SNHG5 -11.96 1.17e-23 1.85e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86048924 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12203924 ENSG00000203875.9 SNHG5 -11.96 1.17e-23 1.85e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86066694 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12215232 ENSG00000203875.9 SNHG5 -11.96 1.17e-23 1.85e-19 -0.9 -0.7 Response to antipsychotic treatment; chr6:86075712 chr6:85660950~85678736:- PAAD cis rs9326248 0.861 rs1871757 ENSG00000254851.1 RP11-109L13.1 -11.96 1.17e-23 1.85e-19 -0.99 -0.7 Blood protein levels; chr11:117159865 chr11:117135528~117138582:+ PAAD cis rs10256972 0.577 rs6962809 ENSG00000229043.2 AC091729.9 -11.96 1.18e-23 1.87e-19 -0.72 -0.7 Endometriosis;Longevity; chr7:1169253 chr7:1160374~1165267:+ PAAD cis rs875971 0.66 rs2013222 ENSG00000226824.5 RP4-756H11.3 11.96 1.21e-23 1.9e-19 0.78 0.7 Aortic root size; chr7:66570949 chr7:66654538~66669855:+ PAAD cis rs10256972 0.552 rs2949195 ENSG00000229043.2 AC091729.9 -11.95 1.25e-23 1.96e-19 -0.74 -0.7 Endometriosis;Longevity; chr7:1163069 chr7:1160374~1165267:+ PAAD cis rs10256972 0.567 rs2960835 ENSG00000229043.2 AC091729.9 -11.95 1.25e-23 1.96e-19 -0.74 -0.7 Endometriosis;Longevity; chr7:1163327 chr7:1160374~1165267:+ PAAD cis rs10256972 0.552 rs2949192 ENSG00000229043.2 AC091729.9 -11.95 1.25e-23 1.96e-19 -0.74 -0.7 Endometriosis;Longevity; chr7:1164205 chr7:1160374~1165267:+ PAAD cis rs10256972 0.552 rs2960830 ENSG00000229043.2 AC091729.9 -11.95 1.27e-23 1.99e-19 -0.72 -0.7 Endometriosis;Longevity; chr7:1161005 chr7:1160374~1165267:+ PAAD cis rs10256972 0.552 rs2960831 ENSG00000229043.2 AC091729.9 -11.95 1.27e-23 1.99e-19 -0.72 -0.7 Endometriosis;Longevity; chr7:1161556 chr7:1160374~1165267:+ PAAD cis rs1577917 0.874 rs11756621 ENSG00000203875.9 SNHG5 -11.95 1.29e-23 2.02e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:86030345 chr6:85660950~85678736:- PAAD cis rs858239 0.738 rs7807879 ENSG00000230658.1 KLHL7-AS1 11.95 1.29e-23 2.02e-19 0.9 0.7 Cerebrospinal fluid biomarker levels; chr7:23220969 chr7:23101228~23105703:- PAAD cis rs2739330 0.76 rs5751760 ENSG00000218537.1 MIF-AS1 11.94 1.34e-23 2.1e-19 0.91 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23894426~23898930:- PAAD cis rs1577917 1 rs2166663 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85884178 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs16876530 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85885923 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs7766645 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85912520 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1911552 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85928306 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs9647603 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85929623 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs7747824 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85937388 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs35385043 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85938828 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs35760725 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85939267 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2660576 ENSG00000203875.9 SNHG5 -11.94 1.35e-23 2.1e-19 -0.91 -0.7 Response to antipsychotic treatment; chr6:85941885 chr6:85660950~85678736:- PAAD cis rs2882667 0.728 rs7722413 ENSG00000253404.1 AC034243.1 11.94 1.36e-23 2.12e-19 0.88 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138942562 chr5:138744434~138753309:- PAAD cis rs9322193 0.923 rs9371207 ENSG00000231760.4 RP11-350J20.5 11.94 1.37e-23 2.13e-19 0.94 0.7 Lung cancer; chr6:149858087 chr6:149796151~149826294:- PAAD cis rs801193 0.935 rs2659916 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66686365 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs6958520 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66686466 chr7:66654538~66669855:+ PAAD cis rs801193 0.967 rs2707849 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66687725 chr7:66654538~66669855:+ PAAD cis rs801193 0.967 rs2707841 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66692033 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2659912 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66693012 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2707836 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66695448 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs4717310 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66696020 chr7:66654538~66669855:+ PAAD cis rs801193 0.844 rs7779971 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66696803 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2659906 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66700323 chr7:66654538~66669855:+ PAAD cis rs801193 0.935 rs2659899 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66721734 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs1553609 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66732152 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs1553610 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66732246 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2707845 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66733811 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2707850 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66738883 chr7:66654538~66669855:+ PAAD cis rs801193 0.967 rs1110414 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66740595 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs7783924 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66744070 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs7789184 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66745208 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2707856 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66746023 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2707854 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66747610 chr7:66654538~66669855:+ PAAD cis rs801193 0.967 rs2707853 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66749023 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2659889 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66752125 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs3800812 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66758474 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs4279493 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66761633 chr7:66654538~66669855:+ PAAD cis rs801193 0.761 rs2659888 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66765184 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs4717319 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66777606 chr7:66654538~66669855:+ PAAD cis rs801193 0.904 rs4718403 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66777742 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs3778909 ENSG00000226824.5 RP4-756H11.3 -11.92 1.48e-23 2.25e-19 -0.77 -0.7 Aortic root size; chr7:66790659 chr7:66654538~66669855:+ PAAD cis rs875971 0.638 rs7793569 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66651646 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs6975195 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66659787 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs3857688 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66662819 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2286684 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66664843 chr7:66654538~66669855:+ PAAD cis rs801193 0.935 rs2286683 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66664856 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs10274773 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66668591 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs7785213 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66673991 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs11773829 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66676087 chr7:66654538~66669855:+ PAAD cis rs801193 0.935 rs3800820 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66682191 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2003301 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66682669 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs7788576 ENSG00000226824.5 RP4-756H11.3 11.92 1.48e-23 2.25e-19 0.77 0.7 Aortic root size; chr7:66683315 chr7:66654538~66669855:+ PAAD cis rs2882667 0.654 rs6862845 ENSG00000253404.1 AC034243.1 11.92 1.52e-23 2.3e-19 0.87 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138937456 chr5:138744434~138753309:- PAAD cis rs1577917 1 rs10944163 ENSG00000203875.9 SNHG5 -11.91 1.63e-23 2.47e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85948975 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12661204 ENSG00000203875.9 SNHG5 -11.91 1.63e-23 2.47e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85968868 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1577917 ENSG00000203875.9 SNHG5 -11.91 1.63e-23 2.47e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85982222 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12196037 ENSG00000203875.9 SNHG5 -11.91 1.63e-23 2.47e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85984913 chr6:85660950~85678736:- PAAD cis rs858239 1 rs166663 ENSG00000230658.1 KLHL7-AS1 11.89 1.78e-23 2.69e-19 0.87 0.69 Cerebrospinal fluid biomarker levels; chr7:23277123 chr7:23101228~23105703:- PAAD cis rs875971 0.66 rs10215132 ENSG00000226824.5 RP4-756H11.3 11.89 1.87e-23 2.82e-19 0.77 0.69 Aortic root size; chr7:66589419 chr7:66654538~66669855:+ PAAD cis rs1577917 1 rs6914463 ENSG00000203875.9 SNHG5 -11.88 1.89e-23 2.85e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85943697 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs2816821 ENSG00000203875.9 SNHG5 -11.88 1.89e-23 2.85e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85947366 chr6:85660950~85678736:- PAAD cis rs801193 0.935 rs11772264 ENSG00000226824.5 RP4-756H11.3 -11.88 1.93e-23 2.91e-19 -0.77 -0.69 Aortic root size; chr7:66711400 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs7782320 ENSG00000226824.5 RP4-756H11.3 -11.88 1.93e-23 2.91e-19 -0.77 -0.69 Aortic root size; chr7:66712111 chr7:66654538~66669855:+ PAAD cis rs1577917 1 rs2324843 ENSG00000203875.9 SNHG5 -11.88 1.94e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85907783 chr6:85660950~85678736:- PAAD cis rs1577917 0.916 rs7759727 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85809160 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12196230 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85810242 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs34994386 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85814417 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs36042496 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85814496 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs1584273 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85814859 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12198971 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85815727 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs34230196 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85816304 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs4707226 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85818110 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs10455448 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85823893 chr6:85660950~85678736:- PAAD cis rs1577917 0.876 rs12212808 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85824254 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs13196576 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85824348 chr6:85660950~85678736:- PAAD cis rs1577917 0.917 rs13213603 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85825040 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs3857480 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85825431 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2324839 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85827224 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs3900313 ENSG00000203875.9 SNHG5 -11.88 1.95e-23 2.92e-19 -0.91 -0.69 Response to antipsychotic treatment; chr6:85827436 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12196411 ENSG00000203875.9 SNHG5 -11.88 1.96e-23 2.93e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:86070044 chr6:85660950~85678736:- PAAD cis rs875971 0.619 rs12533585 ENSG00000226824.5 RP4-756H11.3 -11.88 1.99e-23 2.93e-19 -0.77 -0.69 Aortic root size; chr7:66519618 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs12698534 ENSG00000226824.5 RP4-756H11.3 -11.88 1.99e-23 2.93e-19 -0.77 -0.69 Aortic root size; chr7:66521858 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs28698552 ENSG00000226824.5 RP4-756H11.3 -11.88 1.99e-23 2.93e-19 -0.77 -0.69 Aortic root size; chr7:66540031 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs62465434 ENSG00000226824.5 RP4-756H11.3 -11.88 1.99e-23 2.93e-19 -0.77 -0.69 Aortic root size; chr7:66540165 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs13224319 ENSG00000226824.5 RP4-756H11.3 -11.88 1.99e-23 2.93e-19 -0.77 -0.69 Aortic root size; chr7:66542376 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs801217 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66545590 chr7:66654538~66669855:+ PAAD cis rs875971 0.638 rs801216 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66546680 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs801211 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66550702 chr7:66654538~66669855:+ PAAD cis rs875971 0.638 rs801205 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66557157 chr7:66654538~66669855:+ PAAD cis rs875971 0.617 rs810400 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66557902 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs801193 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66565625 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs801192 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66566965 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs801190 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66568046 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs3857686 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66571204 chr7:66654538~66669855:+ PAAD cis rs875971 0.638 rs3898855 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66571411 chr7:66654538~66669855:+ PAAD cis rs875971 0.638 rs10278816 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66572000 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs10281080 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66577454 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs10950044 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66577989 chr7:66654538~66669855:+ PAAD cis rs875971 0.638 rs10249404 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66581737 chr7:66654538~66669855:+ PAAD cis rs875971 0.619 rs10278371 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66586553 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs1968127 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66591816 chr7:66654538~66669855:+ PAAD cis rs875971 0.638 rs6460305 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66595421 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs10272357 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66598087 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs79009421 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66603522 chr7:66654538~66669855:+ PAAD cis rs875971 0.638 rs6960778 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66606610 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs6460308 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66619753 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs7807930 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66622178 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs7807944 ENSG00000226824.5 RP4-756H11.3 11.88 1.99e-23 2.93e-19 0.77 0.69 Aortic root size; chr7:66622208 chr7:66654538~66669855:+ PAAD cis rs2739330 0.828 rs5760107 ENSG00000273295.1 AP000350.5 11.87 2.1e-23 3.08e-19 0.89 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23901432~23907068:- PAAD cis rs2739330 0.789 rs5760109 ENSG00000273295.1 AP000350.5 11.87 2.1e-23 3.08e-19 0.89 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23901432~23907068:- PAAD cis rs2739330 0.828 rs2330635 ENSG00000273295.1 AP000350.5 11.86 2.18e-23 3.19e-19 0.9 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23901432~23907068:- PAAD cis rs10256972 0.591 rs6968988 ENSG00000229043.2 AC091729.9 -11.86 2.23e-23 3.27e-19 -0.74 -0.69 Endometriosis;Longevity; chr7:1129983 chr7:1160374~1165267:+ PAAD cis rs801193 0.904 rs4718405 ENSG00000226824.5 RP4-756H11.3 -11.84 2.44e-23 3.57e-19 -0.78 -0.69 Aortic root size; chr7:66789659 chr7:66654538~66669855:+ PAAD cis rs2739330 0.796 rs5760097 ENSG00000273295.1 AP000350.5 11.84 2.48e-23 3.61e-19 0.91 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23901432~23907068:- PAAD cis rs2739330 0.828 rs5760098 ENSG00000273295.1 AP000350.5 11.84 2.48e-23 3.61e-19 0.91 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23901432~23907068:- PAAD cis rs1577917 1 rs12201741 ENSG00000203875.9 SNHG5 -11.84 2.48e-23 3.61e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85892901 chr6:85660950~85678736:- PAAD cis rs1577917 0.916 rs12203358 ENSG00000203875.9 SNHG5 -11.84 2.48e-23 3.61e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85893506 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs13213551 ENSG00000203875.9 SNHG5 -11.84 2.48e-23 3.61e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85898983 chr6:85660950~85678736:- PAAD cis rs1577917 0.876 rs12201992 ENSG00000203875.9 SNHG5 -11.84 2.48e-23 3.61e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85908501 chr6:85660950~85678736:- PAAD cis rs2739330 0.76 rs1007888 ENSG00000273295.1 AP000350.5 11.83 2.62e-23 3.79e-19 0.85 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23901432~23907068:- PAAD cis rs6952407 1 rs6952407 ENSG00000226824.5 RP4-756H11.3 11.83 2.66e-23 3.85e-19 0.77 0.69 Cotinine glucuronidation; chr7:66580525 chr7:66654538~66669855:+ PAAD cis rs1577917 1 rs6923148 ENSG00000203875.9 SNHG5 11.83 2.69e-23 3.89e-19 0.91 0.69 Response to antipsychotic treatment; chr6:86058068 chr6:85660950~85678736:- PAAD cis rs916888 0.647 rs199524 ENSG00000262539.1 RP11-259G18.3 -11.82 2.83e-23 4.09e-19 -0.94 -0.69 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46259551~46260606:- PAAD cis rs916888 0.647 rs199523 ENSG00000262539.1 RP11-259G18.3 -11.82 2.83e-23 4.09e-19 -0.94 -0.69 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46259551~46260606:- PAAD cis rs507080 0.845 rs481903 ENSG00000255239.1 AP002954.6 11.81 3.08e-23 4.44e-19 0.91 0.69 Serum metabolite levels; chr11:118697024 chr11:118688039~118690600:- PAAD cis rs1577917 0.958 rs6454487 ENSG00000203875.9 SNHG5 11.8 3.22e-23 4.64e-19 0.89 0.69 Response to antipsychotic treatment; chr6:85737150 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12213331 ENSG00000203875.9 SNHG5 -11.8 3.28e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85795079 chr6:85660950~85678736:- PAAD cis rs2739330 0.796 rs5760106 ENSG00000273295.1 AP000350.5 -11.8 3.28e-23 4.71e-19 -0.89 -0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23901432~23907068:- PAAD cis rs1577917 0.917 rs2218594 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85834048 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2197648 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85834169 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2100109 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85835208 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs1447160 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85836405 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs4707229 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85836519 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12198061 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85841267 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs1838955 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85855731 chr6:85660950~85678736:- PAAD cis rs1577917 0.874 rs1838954 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85855760 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs2084294 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85856225 chr6:85660950~85678736:- PAAD cis rs1577917 0.876 rs11752223 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85863676 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12660846 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85864091 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs7739241 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85866078 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12202712 ENSG00000203875.9 SNHG5 -11.79 3.31e-23 4.71e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85868823 chr6:85660950~85678736:- PAAD cis rs858239 1 rs199348 ENSG00000230658.1 KLHL7-AS1 11.79 3.44e-23 4.88e-19 0.88 0.69 Cerebrospinal fluid biomarker levels; chr7:23253479 chr7:23101228~23105703:- PAAD cis rs858239 0.932 rs199355 ENSG00000230658.1 KLHL7-AS1 11.79 3.44e-23 4.88e-19 0.88 0.69 Cerebrospinal fluid biomarker levels; chr7:23256914 chr7:23101228~23105703:- PAAD cis rs875971 0.642 rs35526611 ENSG00000226824.5 RP4-756H11.3 11.79 3.44e-23 4.89e-19 0.78 0.69 Aortic root size; chr7:66629021 chr7:66654538~66669855:+ PAAD cis rs9601248 0.529 rs2783125 ENSG00000227676.3 LINC01068 11.79 3.5e-23 4.96e-19 0.87 0.69 Major depressive disorder; chr13:79583755 chr13:79566727~79571436:+ PAAD cis rs9601248 0.529 rs2783126 ENSG00000227676.3 LINC01068 11.79 3.5e-23 4.96e-19 0.87 0.69 Major depressive disorder; chr13:79584566 chr13:79566727~79571436:+ PAAD cis rs9601248 0.529 rs9545142 ENSG00000227676.3 LINC01068 11.79 3.5e-23 4.96e-19 0.87 0.69 Major depressive disorder; chr13:79588420 chr13:79566727~79571436:+ PAAD cis rs801193 0.967 rs3800823 ENSG00000226824.5 RP4-756H11.3 11.78 3.61e-23 5.12e-19 0.78 0.69 Aortic root size; chr7:66682123 chr7:66654538~66669855:+ PAAD cis rs858239 0.799 rs10279941 ENSG00000230658.1 KLHL7-AS1 11.77 3.76e-23 5.31e-19 0.89 0.69 Cerebrospinal fluid biomarker levels; chr7:23330889 chr7:23101228~23105703:- PAAD cis rs875971 0.638 rs35986979 ENSG00000226824.5 RP4-756H11.3 11.77 3.79e-23 5.35e-19 0.78 0.69 Aortic root size; chr7:66624003 chr7:66654538~66669855:+ PAAD cis rs801193 0.967 rs2420827 ENSG00000226824.5 RP4-756H11.3 11.77 3.79e-23 5.36e-19 0.78 0.69 Aortic root size; chr7:66682114 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs2055682 ENSG00000226824.5 RP4-756H11.3 -11.77 3.79e-23 5.36e-19 -0.78 -0.69 Aortic root size; chr7:66795302 chr7:66654538~66669855:+ PAAD cis rs1577917 0.837 rs10944157 ENSG00000203875.9 SNHG5 -11.77 3.8e-23 5.37e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85867481 chr6:85660950~85678736:- PAAD cis rs858239 0.899 rs28458177 ENSG00000230658.1 KLHL7-AS1 11.77 3.83e-23 5.41e-19 0.91 0.69 Cerebrospinal fluid biomarker levels; chr7:23255253 chr7:23101228~23105703:- PAAD cis rs9322193 0.884 rs7744105 ENSG00000231760.4 RP11-350J20.5 11.76 4.11e-23 5.79e-19 0.93 0.69 Lung cancer; chr6:149849308 chr6:149796151~149826294:- PAAD cis rs2739330 0.731 rs4822450 ENSG00000218537.1 MIF-AS1 11.74 4.7e-23 6.59e-19 0.89 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23894426~23898930:- PAAD cis rs801193 0.967 rs34356500 ENSG00000226824.5 RP4-756H11.3 -11.74 4.77e-23 6.69e-19 -0.77 -0.69 Aortic root size; chr7:66771620 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs17566701 ENSG00000226824.5 RP4-756H11.3 -11.73 4.89e-23 6.85e-19 -0.78 -0.69 Aortic root size; chr7:66728196 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs10234018 ENSG00000226824.5 RP4-756H11.3 11.73 4.97e-23 6.96e-19 0.78 0.69 Aortic root size; chr7:66681297 chr7:66654538~66669855:+ PAAD cis rs9545047 0.901 rs7982263 ENSG00000227676.3 LINC01068 -11.72 5.26e-23 7.36e-19 -0.88 -0.69 Schizophrenia; chr13:79486939 chr13:79566727~79571436:+ PAAD cis rs10256972 0.552 rs2960837 ENSG00000229043.2 AC091729.9 -11.72 5.26e-23 7.36e-19 -0.73 -0.69 Endometriosis;Longevity; chr7:1164321 chr7:1160374~1165267:+ PAAD cis rs9545047 0.935 rs8002042 ENSG00000227676.3 LINC01068 -11.71 5.47e-23 7.65e-19 -0.88 -0.69 Schizophrenia; chr13:79486552 chr13:79566727~79571436:+ PAAD cis rs2739330 0.828 rs4820572 ENSG00000273295.1 AP000350.5 11.71 5.66e-23 7.9e-19 0.89 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23901432~23907068:- PAAD cis rs801193 1 rs2659915 ENSG00000226824.5 RP4-756H11.3 -11.71 5.66e-23 7.91e-19 -0.75 -0.69 Aortic root size; chr7:66688114 chr7:66654538~66669855:+ PAAD cis rs2882667 0.728 rs13181830 ENSG00000253404.1 AC034243.1 -11.7 6.07e-23 8.46e-19 -0.86 -0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138944727 chr5:138744434~138753309:- PAAD cis rs2739330 0.892 rs4822455 ENSG00000225282.1 AP000350.6 11.7 6.07e-23 8.47e-19 0.86 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23926900~23929574:+ PAAD cis rs858239 0.899 rs10262243 ENSG00000230658.1 KLHL7-AS1 11.7 6.12e-23 8.52e-19 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23251368 chr7:23101228~23105703:- PAAD cis rs858239 0.899 rs1881203 ENSG00000230658.1 KLHL7-AS1 11.7 6.12e-23 8.52e-19 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23253189 chr7:23101228~23105703:- PAAD cis rs507080 0.733 rs601318 ENSG00000255239.1 AP002954.6 11.69 6.14e-23 8.56e-19 0.92 0.69 Serum metabolite levels; chr11:118648845 chr11:118688039~118690600:- PAAD cis rs858239 0.932 rs858272 ENSG00000230658.1 KLHL7-AS1 11.69 6.21e-23 8.64e-19 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23237166 chr7:23101228~23105703:- PAAD cis rs801193 1 rs62466793 ENSG00000226824.5 RP4-756H11.3 -11.69 6.36e-23 8.84e-19 -0.77 -0.69 Aortic root size; chr7:66726530 chr7:66654538~66669855:+ PAAD cis rs801193 1 rs62466794 ENSG00000226824.5 RP4-756H11.3 -11.69 6.36e-23 8.84e-19 -0.77 -0.69 Aortic root size; chr7:66726592 chr7:66654538~66669855:+ PAAD cis rs1153858 0.621 rs2413769 ENSG00000259520.4 CTD-2651B20.3 -11.69 6.43e-23 8.92e-19 -0.88 -0.69 Homoarginine levels; chr15:45269670 chr15:45251580~45279251:- PAAD cis rs1153858 0.621 rs12913645 ENSG00000259520.4 CTD-2651B20.3 11.69 6.43e-23 8.92e-19 0.88 0.69 Homoarginine levels; chr15:45262868 chr15:45251580~45279251:- PAAD cis rs2882667 0.728 rs10068766 ENSG00000253404.1 AC034243.1 11.67 7.08e-23 9.8e-19 0.86 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138941095 chr5:138744434~138753309:- PAAD cis rs1577917 1 rs2812972 ENSG00000203875.9 SNHG5 -11.67 7.18e-23 9.92e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85960162 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs1337843 ENSG00000203875.9 SNHG5 -11.67 7.18e-23 9.92e-19 -0.9 -0.69 Response to antipsychotic treatment; chr6:85965827 chr6:85660950~85678736:- PAAD cis rs875971 0.628 rs6974355 ENSG00000226824.5 RP4-756H11.3 -11.66 7.51e-23 1.04e-18 -0.78 -0.69 Aortic root size; chr7:66376994 chr7:66654538~66669855:+ PAAD cis rs875971 0.706 rs1643374 ENSG00000226824.5 RP4-756H11.3 -11.66 7.51e-23 1.04e-18 -0.78 -0.69 Aortic root size; chr7:66407695 chr7:66654538~66669855:+ PAAD cis rs2739330 0.828 rs2186366 ENSG00000218537.1 MIF-AS1 -11.66 7.53e-23 1.04e-18 -0.91 -0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23894426~23898930:- PAAD cis rs1577917 1 rs1018184 ENSG00000203875.9 SNHG5 11.66 7.69e-23 1.06e-18 0.89 0.69 Response to antipsychotic treatment; chr6:85938757 chr6:85660950~85678736:- PAAD cis rs858239 1 rs199351 ENSG00000230658.1 KLHL7-AS1 11.65 7.92e-23 1.09e-18 0.9 0.69 Cerebrospinal fluid biomarker levels; chr7:23260430 chr7:23101228~23105703:- PAAD cis rs9326248 0.813 rs588534 ENSG00000254851.1 RP11-109L13.1 -11.64 8.58e-23 1.18e-18 -0.98 -0.69 Blood protein levels; chr11:117197788 chr11:117135528~117138582:+ PAAD cis rs10256972 0.527 rs28671326 ENSG00000229043.2 AC091729.9 -11.64 8.74e-23 1.19e-18 -0.74 -0.69 Endometriosis;Longevity; chr7:1135337 chr7:1160374~1165267:+ PAAD cis rs10256972 0.528 rs7784607 ENSG00000229043.2 AC091729.9 -11.64 8.74e-23 1.19e-18 -0.74 -0.69 Endometriosis;Longevity; chr7:1139058 chr7:1160374~1165267:+ PAAD cis rs2739330 0.76 rs5760095 ENSG00000273295.1 AP000350.5 11.64 8.76e-23 1.2e-18 0.88 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23901432~23907068:- PAAD cis rs1577917 1 rs13217384 ENSG00000203875.9 SNHG5 -11.64 8.82e-23 1.2e-18 -0.89 -0.69 Response to antipsychotic treatment; chr6:86010282 chr6:85660950~85678736:- PAAD cis rs916888 0.61 rs199452 ENSG00000262539.1 RP11-259G18.3 11.63 8.9e-23 1.22e-18 0.91 0.69 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46259551~46260606:- PAAD cis rs6597981 0.543 rs3901233 ENSG00000279672.1 CMB9-55F22.1 11.63 9.09e-23 1.24e-18 0.7 0.69 Breast cancer; chr11:749452 chr11:779617~780755:+ PAAD cis rs1577917 1 rs791856 ENSG00000203875.9 SNHG5 11.62 9.52e-23 1.3e-18 0.9 0.69 Response to antipsychotic treatment; chr6:85972123 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs2816815 ENSG00000203875.9 SNHG5 -11.62 9.52e-23 1.3e-18 -0.9 -0.69 Response to antipsychotic treatment; chr6:85981938 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs6454513 ENSG00000203875.9 SNHG5 11.62 9.52e-23 1.3e-18 0.9 0.69 Response to antipsychotic treatment; chr6:86010331 chr6:85660950~85678736:- PAAD cis rs9545047 0.901 rs1212082 ENSG00000227676.3 LINC01068 11.61 1.03e-22 1.4e-18 0.87 0.69 Schizophrenia; chr13:79552633 chr13:79566727~79571436:+ PAAD cis rs9601248 0.508 rs9601240 ENSG00000227676.3 LINC01068 11.61 1.03e-22 1.4e-18 0.87 0.69 Major depressive disorder; chr13:79558238 chr13:79566727~79571436:+ PAAD cis rs9545047 0.837 rs9601242 ENSG00000227676.3 LINC01068 11.61 1.03e-22 1.4e-18 0.87 0.69 Schizophrenia; chr13:79561543 chr13:79566727~79571436:+ PAAD cis rs9545047 0.901 rs73235963 ENSG00000227676.3 LINC01068 11.61 1.03e-22 1.4e-18 0.87 0.69 Schizophrenia; chr13:79562805 chr13:79566727~79571436:+ PAAD cis rs9545047 0.935 rs2484343 ENSG00000227676.3 LINC01068 11.61 1.03e-22 1.4e-18 0.87 0.69 Schizophrenia; chr13:79563587 chr13:79566727~79571436:+ PAAD cis rs9545047 0.868 rs2476173 ENSG00000227676.3 LINC01068 11.61 1.03e-22 1.4e-18 0.87 0.69 Schizophrenia; chr13:79565740 chr13:79566727~79571436:+ PAAD cis rs9545047 0.868 rs1208049 ENSG00000227676.3 LINC01068 11.61 1.03e-22 1.4e-18 0.87 0.69 Schizophrenia; chr13:79570220 chr13:79566727~79571436:+ PAAD cis rs2486288 0.656 rs8041702 ENSG00000259520.4 CTD-2651B20.3 11.61 1.04e-22 1.41e-18 0.8 0.69 Glomerular filtration rate; chr15:45254895 chr15:45251580~45279251:- PAAD cis rs1577917 1 rs12201880 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85917289 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs7756203 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85917989 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs10944161 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85920658 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1857965 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85921058 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs34622557 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85921134 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1911553 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85921174 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs7771342 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85922218 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1995688 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85922601 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12154056 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85924376 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs6940458 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85935274 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs7747897 ENSG00000203875.9 SNHG5 -11.61 1.05e-22 1.41e-18 -0.88 -0.69 Response to antipsychotic treatment; chr6:85937631 chr6:85660950~85678736:- PAAD cis rs2882667 0.69 rs10071381 ENSG00000253404.1 AC034243.1 11.61 1.05e-22 1.41e-18 0.85 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138937159 chr5:138744434~138753309:- PAAD cis rs2739330 0.76 rs5760095 ENSG00000218537.1 MIF-AS1 11.61 1.06e-22 1.42e-18 0.92 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23894426~23898930:- PAAD cis rs1577917 1 rs12201735 ENSG00000203875.9 SNHG5 -11.6 1.09e-22 1.47e-18 -0.89 -0.69 Response to antipsychotic treatment; chr6:85947221 chr6:85660950~85678736:- PAAD cis rs858239 0.899 rs10085838 ENSG00000230658.1 KLHL7-AS1 11.59 1.14e-22 1.54e-18 0.92 0.69 Cerebrospinal fluid biomarker levels; chr7:23258796 chr7:23101228~23105703:- PAAD cis rs801193 1 rs10252765 ENSG00000226824.5 RP4-756H11.3 -11.59 1.16e-22 1.56e-18 -0.77 -0.68 Aortic root size; chr7:66763745 chr7:66654538~66669855:+ PAAD cis rs507080 0.733 rs4486664 ENSG00000255239.1 AP002954.6 11.59 1.21e-22 1.62e-18 0.89 0.68 Serum metabolite levels; chr11:118698358 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs4393358 ENSG00000255239.1 AP002954.6 11.59 1.21e-22 1.62e-18 0.89 0.68 Serum metabolite levels; chr11:118698388 chr11:118688039~118690600:- PAAD cis rs9545047 0.905 rs9318644 ENSG00000227676.3 LINC01068 -11.58 1.26e-22 1.7e-18 -0.89 -0.68 Schizophrenia; chr13:79510042 chr13:79566727~79571436:+ PAAD cis rs9545047 0.935 rs7339303 ENSG00000227676.3 LINC01068 -11.58 1.26e-22 1.7e-18 -0.89 -0.68 Schizophrenia; chr13:79516730 chr13:79566727~79571436:+ PAAD cis rs9545047 0.905 rs7321953 ENSG00000227676.3 LINC01068 -11.58 1.26e-22 1.7e-18 -0.89 -0.68 Schizophrenia; chr13:79517404 chr13:79566727~79571436:+ PAAD cis rs1577917 0.559 rs7763210 ENSG00000203875.9 SNHG5 -11.57 1.31e-22 1.75e-18 -0.92 -0.68 Response to antipsychotic treatment; chr6:86098900 chr6:85660950~85678736:- PAAD cis rs1577917 0.559 rs2223788 ENSG00000203875.9 SNHG5 -11.57 1.31e-22 1.75e-18 -0.92 -0.68 Response to antipsychotic treatment; chr6:86102202 chr6:85660950~85678736:- PAAD cis rs1577917 0.523 rs1413724 ENSG00000203875.9 SNHG5 -11.57 1.31e-22 1.75e-18 -0.92 -0.68 Response to antipsychotic treatment; chr6:86104831 chr6:85660950~85678736:- PAAD cis rs507080 0.733 rs7108144 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118698985 chr11:118688039~118690600:- PAAD cis rs507080 0.663 rs523793 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118699988 chr11:118688039~118690600:- PAAD cis rs507080 0.736 rs659564 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118700205 chr11:118688039~118690600:- PAAD cis rs507080 0.736 rs642224 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118700210 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs541631 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118700314 chr11:118688039~118690600:- PAAD cis rs507080 0.736 rs658676 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118700414 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs488141 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118700459 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs657769 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118700607 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs544452 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118700648 chr11:118688039~118690600:- PAAD cis rs507080 0.697 rs656287 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118701081 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs570949 ENSG00000255239.1 AP002954.6 11.57 1.36e-22 1.81e-18 0.9 0.68 Serum metabolite levels; chr11:118701202 chr11:118688039~118690600:- PAAD cis rs1577917 1 rs12663690 ENSG00000203875.9 SNHG5 11.56 1.38e-22 1.83e-18 0.88 0.68 Response to antipsychotic treatment; chr6:85930444 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12199832 ENSG00000203875.9 SNHG5 -11.56 1.41e-22 1.87e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85943030 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12207374 ENSG00000203875.9 SNHG5 -11.56 1.41e-22 1.87e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85946927 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12213740 ENSG00000203875.9 SNHG5 -11.56 1.41e-22 1.87e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85947015 chr6:85660950~85678736:- PAAD cis rs9326248 0.817 rs6589598 ENSG00000254851.1 RP11-109L13.1 -11.56 1.45e-22 1.92e-18 -0.99 -0.68 Blood protein levels; chr11:117131687 chr11:117135528~117138582:+ PAAD cis rs2739330 0.753 rs4822452 ENSG00000225282.1 AP000350.6 11.54 1.61e-22 2.12e-18 0.88 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23926900~23929574:+ PAAD cis rs9545047 0.935 rs6563113 ENSG00000227676.3 LINC01068 -11.53 1.68e-22 2.22e-18 -0.88 -0.68 Schizophrenia; chr13:79490000 chr13:79566727~79571436:+ PAAD cis rs9545047 0.935 rs9530925 ENSG00000227676.3 LINC01068 -11.53 1.68e-22 2.22e-18 -0.88 -0.68 Schizophrenia; chr13:79492641 chr13:79566727~79571436:+ PAAD cis rs9545047 0.935 rs1577416 ENSG00000227676.3 LINC01068 -11.53 1.68e-22 2.22e-18 -0.88 -0.68 Schizophrenia; chr13:79500646 chr13:79566727~79571436:+ PAAD cis rs1577917 1 rs955196 ENSG00000203875.9 SNHG5 11.53 1.72e-22 2.27e-18 0.89 0.68 Response to antipsychotic treatment; chr6:86020233 chr6:85660950~85678736:- PAAD cis rs2739330 0.828 rs4822454 ENSG00000218537.1 MIF-AS1 11.52 1.77e-22 2.33e-18 0.91 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23894426~23898930:- PAAD cis rs1577917 0.958 rs11758508 ENSG00000203875.9 SNHG5 11.52 1.82e-22 2.4e-18 0.89 0.68 Response to antipsychotic treatment; chr6:85797160 chr6:85660950~85678736:- PAAD cis rs507080 0.697 rs653008 ENSG00000255239.1 AP002954.6 11.52 1.87e-22 2.45e-18 0.91 0.68 Serum metabolite levels; chr11:118649775 chr11:118688039~118690600:- PAAD cis rs9545047 0.935 rs2760102 ENSG00000227676.3 LINC01068 11.51 1.88e-22 2.47e-18 0.87 0.68 Schizophrenia; chr13:79555193 chr13:79566727~79571436:+ PAAD cis rs875971 0.66 rs10229345 ENSG00000226824.5 RP4-756H11.3 -11.51 1.9e-22 2.49e-18 -0.77 -0.68 Aortic root size; chr7:66517181 chr7:66654538~66669855:+ PAAD cis rs858239 0.932 rs1637190 ENSG00000230658.1 KLHL7-AS1 11.49 2.14e-22 2.81e-18 0.88 0.68 Cerebrospinal fluid biomarker levels; chr7:23229446 chr7:23101228~23105703:- PAAD cis rs9545047 0.935 rs9530922 ENSG00000227676.3 LINC01068 -11.49 2.18e-22 2.85e-18 -0.88 -0.68 Schizophrenia; chr13:79469002 chr13:79566727~79571436:+ PAAD cis rs9545047 0.935 rs4885633 ENSG00000227676.3 LINC01068 -11.49 2.18e-22 2.85e-18 -0.88 -0.68 Schizophrenia; chr13:79469720 chr13:79566727~79571436:+ PAAD cis rs9545047 0.935 rs7988601 ENSG00000227676.3 LINC01068 -11.49 2.18e-22 2.85e-18 -0.88 -0.68 Schizophrenia; chr13:79475648 chr13:79566727~79571436:+ PAAD cis rs9545047 0.935 rs6563110 ENSG00000227676.3 LINC01068 -11.49 2.18e-22 2.85e-18 -0.88 -0.68 Schizophrenia; chr13:79477137 chr13:79566727~79571436:+ PAAD cis rs9545047 0.901 rs7338530 ENSG00000227676.3 LINC01068 -11.49 2.18e-22 2.85e-18 -0.88 -0.68 Schizophrenia; chr13:79477715 chr13:79566727~79571436:+ PAAD cis rs9326248 0.689 rs236916 ENSG00000254851.1 RP11-109L13.1 11.49 2.2e-22 2.88e-18 1.06 0.68 Blood protein levels; chr11:117218912 chr11:117135528~117138582:+ PAAD cis rs2739330 0.76 rs1007888 ENSG00000218537.1 MIF-AS1 11.49 2.22e-22 2.9e-18 0.88 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23894426~23898930:- PAAD cis rs875971 0.666 rs13242072 ENSG00000226824.5 RP4-756H11.3 11.49 2.23e-22 2.91e-18 0.76 0.68 Aortic root size; chr7:66301001 chr7:66654538~66669855:+ PAAD cis rs507080 0.733 rs517445 ENSG00000255239.1 AP002954.6 11.48 2.29e-22 2.98e-18 0.9 0.68 Serum metabolite levels; chr11:118702826 chr11:118688039~118690600:- PAAD cis rs507080 0.771 rs687664 ENSG00000255239.1 AP002954.6 11.48 2.29e-22 2.98e-18 0.9 0.68 Serum metabolite levels; chr11:118703476 chr11:118688039~118690600:- PAAD cis rs507080 0.771 rs523715 ENSG00000255239.1 AP002954.6 11.48 2.29e-22 2.98e-18 0.9 0.68 Serum metabolite levels; chr11:118703479 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs611733 ENSG00000255239.1 AP002954.6 11.48 2.37e-22 3.08e-18 0.9 0.68 Serum metabolite levels; chr11:118702051 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs552079 ENSG00000255239.1 AP002954.6 11.48 2.37e-22 3.08e-18 0.9 0.68 Serum metabolite levels; chr11:118702313 chr11:118688039~118690600:- PAAD cis rs507080 0.733 rs673547 ENSG00000255239.1 AP002954.6 11.48 2.37e-22 3.08e-18 0.9 0.68 Serum metabolite levels; chr11:118702630 chr11:118688039~118690600:- PAAD cis rs1577917 1 rs11758849 ENSG00000203875.9 SNHG5 -11.47 2.5e-22 3.24e-18 -0.93 -0.68 Response to antipsychotic treatment; chr6:85998544 chr6:85660950~85678736:- PAAD cis rs2739330 0.796 rs2154594 ENSG00000218537.1 MIF-AS1 -11.47 2.52e-22 3.28e-18 -0.92 -0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23894426~23898930:- PAAD cis rs858239 0.896 rs1637193 ENSG00000230658.1 KLHL7-AS1 11.47 2.53e-22 3.29e-18 0.88 0.68 Cerebrospinal fluid biomarker levels; chr7:23220632 chr7:23101228~23105703:- PAAD cis rs2882667 0.628 rs13173618 ENSG00000253404.1 AC034243.1 11.44 3.03e-22 3.91e-18 0.9 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138804091 chr5:138744434~138753309:- PAAD cis rs1577917 1 rs884841 ENSG00000203875.9 SNHG5 -11.44 3.06e-22 3.96e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85970582 chr6:85660950~85678736:- PAAD cis rs2739330 0.828 rs5751770 ENSG00000225282.1 AP000350.6 11.42 3.32e-22 4.29e-18 0.87 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23926900~23929574:+ PAAD cis rs858239 0.863 rs274054 ENSG00000230658.1 KLHL7-AS1 11.42 3.38e-22 4.36e-18 0.86 0.68 Cerebrospinal fluid biomarker levels; chr7:23350848 chr7:23101228~23105703:- PAAD cis rs2739330 0.828 rs5760108 ENSG00000225282.1 AP000350.6 11.42 3.4e-22 4.38e-18 0.87 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23926900~23929574:+ PAAD cis rs10256972 0.591 rs11766651 ENSG00000229043.2 AC091729.9 -11.42 3.4e-22 4.38e-18 -0.73 -0.68 Endometriosis;Longevity; chr7:1122010 chr7:1160374~1165267:+ PAAD cis rs1577917 0.958 rs11755048 ENSG00000203875.9 SNHG5 -11.41 3.5e-22 4.5e-18 -0.9 -0.68 Response to antipsychotic treatment; chr6:85804616 chr6:85660950~85678736:- PAAD cis rs9545047 0.935 rs1475797 ENSG00000227676.3 LINC01068 -11.4 3.86e-22 4.95e-18 -0.86 -0.68 Schizophrenia; chr13:79519690 chr13:79566727~79571436:+ PAAD cis rs1153858 0.621 rs1706824 ENSG00000259520.4 CTD-2651B20.3 -11.39 3.99e-22 5.12e-18 -0.88 -0.68 Homoarginine levels; chr15:45287750 chr15:45251580~45279251:- PAAD cis rs1577917 1 rs10455456 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85960604 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs10455158 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85963107 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12215903 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85965310 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs34106666 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85966540 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs1337844 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85967555 chr6:85660950~85678736:- PAAD cis rs1577917 0.959 rs34258068 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85969731 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs884842 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85970679 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs10944169 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85973318 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs10944170 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85975751 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12207610 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85978298 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs12203457 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85979559 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs36096931 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85983416 chr6:85660950~85678736:- PAAD cis rs1577917 0.876 rs1582127 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85987486 chr6:85660950~85678736:- PAAD cis rs1577917 0.958 rs13207354 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85990545 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12204365 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85990814 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs12663651 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85991937 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs34852683 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85992612 chr6:85660950~85678736:- PAAD cis rs1577917 1 rs6936048 ENSG00000203875.9 SNHG5 -11.38 4.24e-22 5.37e-18 -0.88 -0.68 Response to antipsychotic treatment; chr6:85992890 chr6:85660950~85678736:- PAAD cis rs2486288 0.656 rs11629858 ENSG00000259520.4 CTD-2651B20.3 11.37 4.63e-22 5.86e-18 0.8 0.68 Glomerular filtration rate; chr15:45254916 chr15:45251580~45279251:- PAAD cis rs2486288 0.656 rs11629859 ENSG00000259520.4 CTD-2651B20.3 11.37 4.63e-22 5.86e-18 0.8 0.68 Glomerular filtration rate; chr15:45254923 chr15:45251580~45279251:- PAAD cis rs12439619 0.846 rs62011975 ENSG00000278603.1 RP13-608F4.5 11.36 4.94e-22 6.22e-18 1.09 0.68 Intelligence (multi-trait analysis); chr15:82159213 chr15:82472203~82472426:+ PAAD cis rs12439619 0.846 rs62012003 ENSG00000278603.1 RP13-608F4.5 11.36 4.94e-22 6.22e-18 1.09 0.68 Intelligence (multi-trait analysis); chr15:82183236 chr15:82472203~82472426:+ PAAD cis rs12439619 0.846 rs62012004 ENSG00000278603.1 RP13-608F4.5 11.36 4.94e-22 6.22e-18 1.09 0.68 Intelligence (multi-trait analysis); chr15:82183924 chr15:82472203~82472426:+ PAAD cis rs12439619 0.846 rs62013464 ENSG00000278603.1 RP13-608F4.5 11.36 4.94e-22 6.22e-18 1.09 0.68 Intelligence (multi-trait analysis); chr15:82288250 chr15:82472203~82472426:+ PAAD cis rs12439619 0.846 rs62010071 ENSG00000278603.1 RP13-608F4.5 11.36 4.94e-22 6.22e-18 1.09 0.68 Intelligence (multi-trait analysis); chr15:82289442 chr15:82472203~82472426:+ PAAD cis rs9545047 0.901 rs314688 ENSG00000227676.3 LINC01068 11.35 5.13e-22 6.45e-18 0.87 0.68 Schizophrenia; chr13:79449171 chr13:79566727~79571436:+ PAAD cis rs858239 1 rs156421 ENSG00000230658.1 KLHL7-AS1 11.35 5.19e-22 6.52e-18 0.83 0.68 Cerebrospinal fluid biomarker levels; chr7:23272868 chr7:23101228~23105703:- PAAD cis rs2486288 0.656 rs1719236 ENSG00000259520.4 CTD-2651B20.3 11.33 5.71e-22 7.16e-18 0.78 0.68 Glomerular filtration rate; chr15:45285585 chr15:45251580~45279251:- PAAD cis rs916888 0.61 rs199530 ENSG00000262539.1 RP11-259G18.3 -11.33 5.76e-22 7.23e-18 -0.9 -0.68 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46259551~46260606:- PAAD cis rs507080 0.733 rs489126 ENSG00000255239.1 AP002954.6 11.33 5.82e-22 7.3e-18 0.89 0.68 Serum metabolite levels; chr11:118702038 chr11:118688039~118690600:- PAAD cis rs12439619 0.846 rs7496227 ENSG00000278603.1 RP13-608F4.5 11.33 5.99e-22 7.51e-18 1.09 0.68 Intelligence (multi-trait analysis); chr15:82275241 chr15:82472203~82472426:+ PAAD cis rs1153858 0.621 rs1719237 ENSG00000259520.4 CTD-2651B20.3 -11.3 6.88e-22 8.62e-18 -0.87 -0.68 Homoarginine levels; chr15:45287624 chr15:45251580~45279251:- PAAD cis rs1153858 0.621 rs2687512 ENSG00000259520.4 CTD-2651B20.3 11.3 7e-22 8.76e-18 0.88 0.68 Homoarginine levels; chr15:45289297 chr15:45251580~45279251:- PAAD cis rs858239 1 rs156425 ENSG00000230658.1 KLHL7-AS1 -11.3 7.08e-22 8.85e-18 -0.82 -0.68 Cerebrospinal fluid biomarker levels; chr7:23269500 chr7:23101228~23105703:- PAAD cis rs2882667 0.628 rs13154573 ENSG00000253404.1 AC034243.1 11.29 7.32e-22 9.15e-18 0.9 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138812375 chr5:138744434~138753309:- PAAD cis rs858239 0.931 rs9690941 ENSG00000230658.1 KLHL7-AS1 11.28 8.2e-22 1.02e-17 0.9 0.67 Cerebrospinal fluid biomarker levels; chr7:23242134 chr7:23101228~23105703:- PAAD cis rs875971 0.619 rs2302918 ENSG00000226824.5 RP4-756H11.3 -11.27 8.32e-22 1.04e-17 -0.76 -0.67 Aortic root size; chr7:66535945 chr7:66654538~66669855:+ PAAD cis rs2739330 0.828 rs2877178 ENSG00000225282.1 AP000350.6 11.27 8.38e-22 1.04e-17 0.88 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23926900~23929574:+ PAAD cis rs2739330 0.828 rs2154593 ENSG00000225282.1 AP000350.6 11.27 8.38e-22 1.04e-17 0.88 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23926900~23929574:+ PAAD cis rs9326248 0.861 rs11216172 ENSG00000254851.1 RP11-109L13.1 -11.27 8.55e-22 1.07e-17 -0.97 -0.67 Blood protein levels; chr11:116879162 chr11:117135528~117138582:+ PAAD cis rs916888 0.61 rs142167 ENSG00000214401.4 KANSL1-AS1 -11.27 8.65e-22 1.08e-17 -0.91 -0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46193576~46196723:+ PAAD cis rs2739330 0.828 rs5760102 ENSG00000273295.1 AP000350.5 11.27 8.72e-22 1.09e-17 0.9 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23901432~23907068:- PAAD cis rs858239 1 rs199357 ENSG00000230658.1 KLHL7-AS1 -11.26 9.19e-22 1.14e-17 -0.87 -0.67 Cerebrospinal fluid biomarker levels; chr7:23248690 chr7:23101228~23105703:- PAAD cis rs875971 0.66 rs3764903 ENSG00000226824.5 RP4-756H11.3 11.25 9.87e-22 1.22e-17 0.75 0.67 Aortic root size; chr7:66633495 chr7:66654538~66669855:+ PAAD cis rs875971 0.66 rs1860470 ENSG00000226824.5 RP4-756H11.3 11.25 9.87e-22 1.22e-17 0.75 0.67 Aortic root size; chr7:66638707 chr7:66654538~66669855:+ PAAD cis rs9545047 0.935 rs2783119 ENSG00000227676.3 LINC01068 11.24 1.03e-21 1.27e-17 0.86 0.67 Schizophrenia; chr13:79524983 chr13:79566727~79571436:+ PAAD cis rs916888 0.531 rs183211 ENSG00000214401.4 KANSL1-AS1 11.24 1.04e-21 1.29e-17 0.9 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46193576~46196723:+ PAAD cis rs916888 0.61 rs199453 ENSG00000214401.4 KANSL1-AS1 11.24 1.04e-21 1.29e-17 0.9 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46193576~46196723:+ PAAD cis rs916888 0.647 rs199449 ENSG00000214401.4 KANSL1-AS1 11.24 1.04e-21 1.29e-17 0.9 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46193576~46196723:+ PAAD cis rs916888 0.61 rs199436 ENSG00000214401.4 KANSL1-AS1 -11.24 1.04e-21 1.29e-17 -0.9 -0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46193576~46196723:+ PAAD cis rs7617773 0.817 rs936427 ENSG00000229759.1 MRPS18AP1 -11.23 1.1e-21 1.36e-17 -0.72 -0.67 Coronary artery disease; chr3:48259584 chr3:48256350~48256938:- PAAD cis rs10256972 0.577 rs4999286 ENSG00000229043.2 AC091729.9 -11.23 1.1e-21 1.36e-17 -0.72 -0.67 Endometriosis;Longevity; chr7:1159870 chr7:1160374~1165267:+ PAAD cis rs858239 0.72 rs10227559 ENSG00000230658.1 KLHL7-AS1 11.22 1.14e-21 1.41e-17 0.92 0.67 Cerebrospinal fluid biomarker levels; chr7:23232525 chr7:23101228~23105703:- PAAD cis rs950027 0.549 rs9920634 ENSG00000259520.4 CTD-2651B20.3 11.21 1.2e-21 1.48e-17 0.78 0.67 Response to fenofibrate (adiponectin levels); chr15:45304348 chr15:45251580~45279251:- PAAD cis rs950027 0.549 rs11070452 ENSG00000259520.4 CTD-2651B20.3 11.21 1.21e-21 1.49e-17 0.78 0.67 Response to fenofibrate (adiponectin levels); chr15:45302638 chr15:45251580~45279251:- PAAD cis rs950027 0.549 rs2899375 ENSG00000259520.4 CTD-2651B20.3 11.21 1.21e-21 1.49e-17 0.78 0.67 Response to fenofibrate (adiponectin levels); chr15:45306137 chr15:45251580~45279251:- PAAD cis rs858239 0.633 rs858300 ENSG00000230658.1 KLHL7-AS1 11.21 1.25e-21 1.53e-17 0.88 0.67 Cerebrospinal fluid biomarker levels; chr7:23205012 chr7:23101228~23105703:- PAAD cis rs858239 0.73 rs858290 ENSG00000230658.1 KLHL7-AS1 11.21 1.25e-21 1.53e-17 0.88 0.67 Cerebrospinal fluid biomarker levels; chr7:23208417 chr7:23101228~23105703:- PAAD cis rs858239 0.73 rs858289 ENSG00000230658.1 KLHL7-AS1 11.21 1.25e-21 1.53e-17 0.88 0.67 Cerebrospinal fluid biomarker levels; chr7:23208539 chr7:23101228~23105703:- PAAD cis rs858239 0.829 rs2268744 ENSG00000230658.1 KLHL7-AS1 11.2 1.28e-21 1.53e-17 0.89 0.67 Cerebrospinal fluid biomarker levels; chr7:23292661 chr7:23101228~23105703:- PAAD cis rs7617773 0.851 rs7647817 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48195017 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs11707606 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48195597 chr3:48256350~48256938:- PAAD cis rs7617773 0.71 rs36064160 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48201611 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs17786132 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48207930 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs35456569 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48209409 chr3:48256350~48256938:- PAAD cis rs7617773 0.784 rs11715799 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48213730 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs34728236 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48217618 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs79310258 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48218177 chr3:48256350~48256938:- PAAD cis rs7617773 0.746 rs6796343 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48240531 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs13100815 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48245959 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs13059037 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48246389 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs35414021 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48252034 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs13068265 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48260124 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs3197223 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48294367 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs13067450 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48295716 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs4479622 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48296683 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs34946886 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48296997 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs13079728 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48297870 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs34589064 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48298059 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs2541 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48298128 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs13085251 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48298555 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs35297395 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48301392 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs36075665 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48301597 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs34630841 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48301771 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs35190747 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48301800 chr3:48256350~48256938:- PAAD cis rs7617773 0.743 rs7621785 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48302218 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs4511915 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48302368 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs13066758 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48302387 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs4392440 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48302430 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs13082859 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48303185 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs36121690 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48304021 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs35778847 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48305495 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs34749846 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48305678 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs7632297 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48306673 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs79089926 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48307074 chr3:48256350~48256938:- PAAD cis rs7617773 0.643 rs78159520 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48307533 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs77044321 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48307824 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs4511916 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48308876 chr3:48256350~48256938:- PAAD cis rs7617773 0.815 rs7624450 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48308885 chr3:48256350~48256938:- PAAD cis rs7617773 0.815 rs6793150 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48310070 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs6793239 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48310128 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs6782166 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48310193 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs4130522 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48310823 chr3:48256350~48256938:- PAAD cis rs7617773 0.746 rs4371540 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48312053 chr3:48256350~48256938:- PAAD cis rs7617773 0.674 rs13069029 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48313534 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs13081169 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48315307 chr3:48256350~48256938:- PAAD cis rs7617773 0.743 rs13081633 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48315791 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs35411187 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48318527 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs11714176 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48319372 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs11718350 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48319502 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs7653152 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48320607 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs7645425 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48320879 chr3:48256350~48256938:- PAAD cis rs7617773 0.743 rs11716371 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48321260 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs6793223 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48322611 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs4541431 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48323728 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs11714944 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48325481 chr3:48256350~48256938:- PAAD cis rs7617773 0.743 rs13071960 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48326047 chr3:48256350~48256938:- PAAD cis rs7617773 0.743 rs4632568 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48326329 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs11130164 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48327544 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs7653336 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48327974 chr3:48256350~48256938:- PAAD cis rs7617773 0.747 rs34076262 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48328926 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs13082158 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48330980 chr3:48256350~48256938:- PAAD cis rs7617773 0.676 rs13060020 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48331156 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs11710257 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48331724 chr3:48256350~48256938:- PAAD cis rs7617773 0.707 rs13061269 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48331853 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs71323395 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48332587 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs71323396 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48333244 chr3:48256350~48256938:- PAAD cis rs7617773 0.743 rs71323397 ENSG00000229759.1 MRPS18AP1 11.2 1.28e-21 1.53e-17 0.72 0.67 Coronary artery disease; chr3:48333384 chr3:48256350~48256938:- PAAD cis rs916888 0.61 rs199438 ENSG00000214401.4 KANSL1-AS1 11.2 1.34e-21 1.6e-17 0.9 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46193576~46196723:+ PAAD cis rs2882667 0.628 rs13162420 ENSG00000253404.1 AC034243.1 11.2 1.35e-21 1.61e-17 0.89 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138839070 chr5:138744434~138753309:- PAAD cis rs2882667 0.628 rs13167462 ENSG00000253404.1 AC034243.1 11.2 1.35e-21 1.61e-17 0.89 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138841572 chr5:138744434~138753309:- PAAD cis rs1577917 0.958 rs28442244 ENSG00000203875.9 SNHG5 11.19 1.39e-21 1.66e-17 0.88 0.67 Response to antipsychotic treatment; chr6:85991518 chr6:85660950~85678736:- PAAD cis rs2739330 0.857 rs9608229 ENSG00000218537.1 MIF-AS1 11.19 1.42e-21 1.69e-17 0.94 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:24002918 chr22:23894426~23898930:- PAAD cis rs2739330 0.796 rs5760097 ENSG00000218537.1 MIF-AS1 11.18 1.52e-21 1.8e-17 0.93 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23894426~23898930:- PAAD cis rs2739330 0.828 rs5760098 ENSG00000218537.1 MIF-AS1 11.18 1.52e-21 1.8e-17 0.93 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23894426~23898930:- PAAD cis rs7617773 0.817 rs3731555 ENSG00000229759.1 MRPS18AP1 11.17 1.55e-21 1.84e-17 0.72 0.67 Coronary artery disease; chr3:48164612 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs3731550 ENSG00000229759.1 MRPS18AP1 11.17 1.55e-21 1.84e-17 0.72 0.67 Coronary artery disease; chr3:48165093 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs3731534 ENSG00000229759.1 MRPS18AP1 11.17 1.55e-21 1.84e-17 0.72 0.67 Coronary artery disease; chr3:48170287 chr3:48256350~48256938:- PAAD cis rs858239 1 rs858239 ENSG00000230658.1 KLHL7-AS1 11.17 1.58e-21 1.87e-17 0.87 0.67 Cerebrospinal fluid biomarker levels; chr7:23246696 chr7:23101228~23105703:- PAAD cis rs858239 0.899 rs858271 ENSG00000230658.1 KLHL7-AS1 11.17 1.6e-21 1.89e-17 0.87 0.67 Cerebrospinal fluid biomarker levels; chr7:23238664 chr7:23101228~23105703:- PAAD cis rs2739330 0.828 rs5760107 ENSG00000218537.1 MIF-AS1 11.16 1.66e-21 1.96e-17 0.91 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23894426~23898930:- PAAD cis rs2739330 0.789 rs5760109 ENSG00000218537.1 MIF-AS1 11.16 1.66e-21 1.96e-17 0.91 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23894426~23898930:- PAAD cis rs858239 0.932 rs1624451 ENSG00000230658.1 KLHL7-AS1 -11.16 1.66e-21 1.97e-17 -0.86 -0.67 Cerebrospinal fluid biomarker levels; chr7:23222816 chr7:23101228~23105703:- PAAD cis rs10256972 0.616 rs4585652 ENSG00000229043.2 AC091729.9 -11.16 1.69e-21 2e-17 -0.72 -0.67 Endometriosis;Longevity; chr7:1105760 chr7:1160374~1165267:+ PAAD cis rs7617773 0.817 rs3731513 ENSG00000229759.1 MRPS18AP1 11.16 1.7e-21 2e-17 0.72 0.67 Coronary artery disease; chr3:48178047 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs3731497 ENSG00000229759.1 MRPS18AP1 11.16 1.7e-21 2e-17 0.72 0.67 Coronary artery disease; chr3:48185063 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs3731489 ENSG00000229759.1 MRPS18AP1 11.16 1.7e-21 2e-17 0.72 0.67 Coronary artery disease; chr3:48187416 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs3729577 ENSG00000229759.1 MRPS18AP1 11.16 1.7e-21 2e-17 0.72 0.67 Coronary artery disease; chr3:48187504 chr3:48256350~48256938:- PAAD cis rs7617773 0.779 rs3731487 ENSG00000229759.1 MRPS18AP1 11.16 1.7e-21 2e-17 0.72 0.67 Coronary artery disease; chr3:48188134 chr3:48256350~48256938:- PAAD cis rs10256972 0.553 rs4236381 ENSG00000229043.2 AC091729.9 -11.16 1.71e-21 2.02e-17 -0.72 -0.67 Endometriosis;Longevity; chr7:1126087 chr7:1160374~1165267:+ PAAD cis rs7301826 0.651 rs7971046 ENSG00000256250.1 RP11-989F5.1 -11.15 1.77e-21 2.09e-17 -0.78 -0.67 Plasma plasminogen activator levels; chr12:130802262 chr12:130810606~130812438:+ PAAD cis rs916888 0.61 rs199444 ENSG00000214401.4 KANSL1-AS1 11.14 1.87e-21 2.2e-17 0.9 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46193576~46196723:+ PAAD cis rs916888 0.61 rs199442 ENSG00000214401.4 KANSL1-AS1 11.14 1.87e-21 2.2e-17 0.9 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46193576~46196723:+ PAAD cis rs7617773 0.817 rs11720622 ENSG00000229759.1 MRPS18AP1 11.14 1.91e-21 2.24e-17 0.7 0.67 Coronary artery disease; chr3:48205189 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs11130162 ENSG00000229759.1 MRPS18AP1 11.14 1.91e-21 2.24e-17 0.7 0.67 Coronary artery disease; chr3:48256121 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs6787500 ENSG00000229759.1 MRPS18AP1 11.14 1.91e-21 2.24e-17 0.7 0.67 Coronary artery disease; chr3:48257949 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs6806112 ENSG00000229759.1 MRPS18AP1 11.13 2.03e-21 2.38e-17 0.7 0.67 Coronary artery disease; chr3:48234587 chr3:48256350~48256938:- PAAD cis rs2739330 0.828 rs2330635 ENSG00000218537.1 MIF-AS1 11.13 2.07e-21 2.42e-17 0.91 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23894426~23898930:- PAAD cis rs875971 0.577 rs34888281 ENSG00000226824.5 RP4-756H11.3 11.11 2.23e-21 2.61e-17 0.75 0.67 Aortic root size; chr7:66120784 chr7:66654538~66669855:+ PAAD cis rs7617773 0.78 rs11706277 ENSG00000229759.1 MRPS18AP1 11.11 2.24e-21 2.62e-17 0.75 0.67 Coronary artery disease; chr3:48318943 chr3:48256350~48256938:- PAAD cis rs4853012 0.887 rs77148265 ENSG00000217702.2 RP11-287D1.4 11.11 2.26e-21 2.64e-17 1.13 0.67 Gestational age at birth (maternal effect); chr2:74112392 chr2:74130583~74135395:+ PAAD cis rs4853012 0.887 rs6737314 ENSG00000217702.2 RP11-287D1.4 11.11 2.26e-21 2.64e-17 1.13 0.67 Gestational age at birth (maternal effect); chr2:74112459 chr2:74130583~74135395:+ PAAD cis rs875971 0.66 rs1860468 ENSG00000226824.5 RP4-756H11.3 11.1 2.38e-21 2.77e-17 0.75 0.67 Aortic root size; chr7:66642265 chr7:66654538~66669855:+ PAAD cis rs7617773 0.817 rs34225441 ENSG00000229759.1 MRPS18AP1 11.1 2.43e-21 2.83e-17 0.73 0.67 Coronary artery disease; chr3:48267401 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs11709691 ENSG00000229759.1 MRPS18AP1 11.1 2.5e-21 2.91e-17 0.72 0.67 Coronary artery disease; chr3:48262179 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs13072018 ENSG00000229759.1 MRPS18AP1 11.1 2.5e-21 2.91e-17 0.72 0.67 Coronary artery disease; chr3:48278842 chr3:48256350~48256938:- PAAD cis rs7617773 0.779 rs77957078 ENSG00000229759.1 MRPS18AP1 11.1 2.5e-21 2.91e-17 0.72 0.67 Coronary artery disease; chr3:48289796 chr3:48256350~48256938:- PAAD cis rs950027 0.572 rs12910764 ENSG00000259520.4 CTD-2651B20.3 11.1 2.51e-21 2.92e-17 0.77 0.67 Response to fenofibrate (adiponectin levels); chr15:45317162 chr15:45251580~45279251:- PAAD cis rs2739330 0.828 rs4822451 ENSG00000225282.1 AP000350.6 11.09 2.57e-21 2.99e-17 0.88 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23926900~23929574:+ PAAD cis rs2739330 0.828 rs5760099 ENSG00000225282.1 AP000350.6 11.09 2.57e-21 2.99e-17 0.88 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23926900~23929574:+ PAAD cis rs7617773 0.78 rs13084616 ENSG00000229759.1 MRPS18AP1 -11.09 2.61e-21 3.03e-17 -0.72 -0.67 Coronary artery disease; chr3:48298209 chr3:48256350~48256938:- PAAD cis rs916888 0.61 rs142167 ENSG00000262539.1 RP11-259G18.3 -11.09 2.62e-21 3.04e-17 -0.91 -0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46259551~46260606:- PAAD cis rs2739330 0.685 rs4822453 ENSG00000218537.1 MIF-AS1 11.08 2.67e-21 3.11e-17 0.9 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23894426~23898930:- PAAD cis rs858239 0.932 rs1728313 ENSG00000230658.1 KLHL7-AS1 11.08 2.76e-21 3.2e-17 0.85 0.67 Cerebrospinal fluid biomarker levels; chr7:23231412 chr7:23101228~23105703:- PAAD cis rs1577917 0.958 rs12208227 ENSG00000203875.9 SNHG5 -11.07 2.95e-21 3.42e-17 -0.85 -0.67 Response to antipsychotic treatment; chr6:85961226 chr6:85660950~85678736:- PAAD cis rs7617773 0.817 rs13094727 ENSG00000229759.1 MRPS18AP1 11.07 2.96e-21 3.43e-17 0.72 0.67 Coronary artery disease; chr3:48281999 chr3:48256350~48256938:- PAAD cis rs7301826 0.651 rs10848206 ENSG00000256250.1 RP11-989F5.1 -11.07 2.99e-21 3.46e-17 -0.78 -0.67 Plasma plasminogen activator levels; chr12:130796926 chr12:130810606~130812438:+ PAAD cis rs7617773 0.78 rs13090538 ENSG00000229759.1 MRPS18AP1 11.07 3.01e-21 3.49e-17 0.72 0.67 Coronary artery disease; chr3:48329279 chr3:48256350~48256938:- PAAD cis rs1577917 0.958 rs11755864 ENSG00000203875.9 SNHG5 -11.06 3.04e-21 3.52e-17 -0.84 -0.67 Response to antipsychotic treatment; chr6:85982073 chr6:85660950~85678736:- PAAD cis rs2739330 0.796 rs5760106 ENSG00000218537.1 MIF-AS1 -11.06 3.12e-21 3.61e-17 -0.91 -0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23894426~23898930:- PAAD cis rs17507216 1 rs17356118 ENSG00000278603.1 RP13-608F4.5 11.06 3.16e-21 3.65e-17 1.06 0.67 Excessive daytime sleepiness; chr15:82569149 chr15:82472203~82472426:+ PAAD cis rs17507216 0.958 rs72751643 ENSG00000278603.1 RP13-608F4.5 11.06 3.19e-21 3.68e-17 1.08 0.67 Excessive daytime sleepiness; chr15:82559444 chr15:82472203~82472426:+ PAAD cis rs875971 0.558 rs4433015 ENSG00000226824.5 RP4-756H11.3 11.06 3.21e-21 3.7e-17 0.77 0.67 Aortic root size; chr7:66174736 chr7:66654538~66669855:+ PAAD cis rs950027 0.549 rs12909409 ENSG00000259520.4 CTD-2651B20.3 11.05 3.34e-21 3.86e-17 0.76 0.67 Response to fenofibrate (adiponectin levels); chr15:45316384 chr15:45251580~45279251:- PAAD cis rs6597981 0.604 rs7945912 ENSG00000279672.1 CMB9-55F22.1 11.05 3.35e-21 3.86e-17 0.64 0.67 Breast cancer; chr11:750849 chr11:779617~780755:+ PAAD cis rs7301826 0.651 rs2037789 ENSG00000256250.1 RP11-989F5.1 11.05 3.39e-21 3.9e-17 0.79 0.67 Plasma plasminogen activator levels; chr12:130803747 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs7132657 ENSG00000256250.1 RP11-989F5.1 -11.04 3.5e-21 4.03e-17 -0.78 -0.67 Plasma plasminogen activator levels; chr12:130800642 chr12:130810606~130812438:+ PAAD cis rs12439619 0.768 rs28694364 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82208119 chr15:82472203~82472426:+ PAAD cis rs12439619 0.81 rs28876157 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82216708 chr15:82472203~82472426:+ PAAD cis rs12439619 0.739 rs62012046 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82236824 chr15:82472203~82472426:+ PAAD cis rs12439619 0.774 rs62012047 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82236852 chr15:82472203~82472426:+ PAAD cis rs12439619 0.81 rs62012049 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82237722 chr15:82472203~82472426:+ PAAD cis rs12439619 0.846 rs28470877 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82245797 chr15:82472203~82472426:+ PAAD cis rs12439619 0.846 rs62012056 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82247278 chr15:82472203~82472426:+ PAAD cis rs12439619 0.846 rs62012059 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82251669 chr15:82472203~82472426:+ PAAD cis rs12439619 0.774 rs2867649 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82262331 chr15:82472203~82472426:+ PAAD cis rs12439619 0.846 rs28697264 ENSG00000278603.1 RP13-608F4.5 11.04 3.54e-21 4.06e-17 1.08 0.67 Intelligence (multi-trait analysis); chr15:82265559 chr15:82472203~82472426:+ PAAD cis rs858239 0.831 rs7796541 ENSG00000230658.1 KLHL7-AS1 11.04 3.55e-21 4.07e-17 0.87 0.67 Cerebrospinal fluid biomarker levels; chr7:23349454 chr7:23101228~23105703:- PAAD cis rs7617773 0.78 rs13066044 ENSG00000229759.1 MRPS18AP1 11.02 3.94e-21 4.49e-17 0.72 0.67 Coronary artery disease; chr3:48335786 chr3:48256350~48256938:- PAAD cis rs7617773 0.778 rs11715776 ENSG00000229759.1 MRPS18AP1 11.02 3.94e-21 4.49e-17 0.72 0.67 Coronary artery disease; chr3:48336121 chr3:48256350~48256938:- PAAD cis rs7617773 0.778 rs11707997 ENSG00000229759.1 MRPS18AP1 11.02 3.94e-21 4.49e-17 0.72 0.67 Coronary artery disease; chr3:48336385 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs11720026 ENSG00000229759.1 MRPS18AP1 11.02 3.94e-21 4.49e-17 0.72 0.67 Coronary artery disease; chr3:48336431 chr3:48256350~48256938:- PAAD cis rs7617773 0.743 rs11715876 ENSG00000229759.1 MRPS18AP1 11.02 3.94e-21 4.49e-17 0.72 0.67 Coronary artery disease; chr3:48336432 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs35297486 ENSG00000229759.1 MRPS18AP1 11.02 3.94e-21 4.49e-17 0.72 0.67 Coronary artery disease; chr3:48336657 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs11716848 ENSG00000229759.1 MRPS18AP1 11.02 3.94e-21 4.49e-17 0.72 0.67 Coronary artery disease; chr3:48337010 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs6796490 ENSG00000229759.1 MRPS18AP1 11.02 3.95e-21 4.5e-17 0.7 0.67 Coronary artery disease; chr3:48195614 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs11130163 ENSG00000229759.1 MRPS18AP1 11.01 4.2e-21 4.77e-17 0.7 0.67 Coronary artery disease; chr3:48271168 chr3:48256350~48256938:- PAAD cis rs4853012 0.775 rs12465641 ENSG00000217702.2 RP11-287D1.4 -11.01 4.23e-21 4.8e-17 -1.16 -0.67 Gestational age at birth (maternal effect); chr2:74110588 chr2:74130583~74135395:+ PAAD cis rs7301826 0.651 rs4759517 ENSG00000256250.1 RP11-989F5.1 -11.01 4.29e-21 4.84e-17 -0.78 -0.67 Plasma plasminogen activator levels; chr12:130799153 chr12:130810606~130812438:+ PAAD cis rs17507216 0.958 rs28648832 ENSG00000278603.1 RP13-608F4.5 11.01 4.32e-21 4.84e-17 1.09 0.67 Excessive daytime sleepiness; chr15:82567642 chr15:82472203~82472426:+ PAAD cis rs2739330 0.828 rs4820572 ENSG00000218537.1 MIF-AS1 11 4.56e-21 5.09e-17 0.91 0.67 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23894426~23898930:- PAAD cis rs10256972 0.567 rs7782651 ENSG00000229043.2 AC091729.9 -11 4.63e-21 5.16e-17 -0.73 -0.67 Endometriosis;Longevity; chr7:1120259 chr7:1160374~1165267:+ PAAD cis rs858239 1 rs858240 ENSG00000230658.1 KLHL7-AS1 11 4.65e-21 5.18e-17 0.87 0.67 Cerebrospinal fluid biomarker levels; chr7:23244618 chr7:23101228~23105703:- PAAD cis rs916888 0.61 rs199454 ENSG00000214401.4 KANSL1-AS1 -11 4.66e-21 5.19e-17 -0.89 -0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46193576~46196723:+ PAAD cis rs9545047 0.935 rs4885634 ENSG00000227676.3 LINC01068 -10.99 4.74e-21 5.28e-17 -0.86 -0.67 Schizophrenia; chr13:79482772 chr13:79566727~79571436:+ PAAD cis rs916888 0.61 rs199529 ENSG00000214401.4 KANSL1-AS1 10.96 5.7e-21 6.33e-17 0.94 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:46193576~46196723:+ PAAD cis rs17507216 1 rs17507216 ENSG00000278603.1 RP13-608F4.5 -10.96 5.91e-21 6.55e-17 -1.06 -0.66 Excessive daytime sleepiness; chr15:82558175 chr15:82472203~82472426:+ PAAD cis rs4853012 0.941 rs2421752 ENSG00000217702.2 RP11-287D1.4 10.95 6.17e-21 6.84e-17 1.14 0.66 Gestational age at birth (maternal effect); chr2:74114488 chr2:74130583~74135395:+ PAAD cis rs4853012 0.941 rs7571083 ENSG00000217702.2 RP11-287D1.4 10.95 6.17e-21 6.84e-17 1.14 0.66 Gestational age at birth (maternal effect); chr2:74115133 chr2:74130583~74135395:+ PAAD cis rs7301826 0.61 rs7957899 ENSG00000256250.1 RP11-989F5.1 -10.94 6.42e-21 7.11e-17 -0.78 -0.66 Plasma plasminogen activator levels; chr12:130794531 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs1973834 ENSG00000256250.1 RP11-989F5.1 -10.94 6.42e-21 7.11e-17 -0.78 -0.66 Plasma plasminogen activator levels; chr12:130795612 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs10734979 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130804409 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs4759519 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130804963 chr12:130810606~130812438:+ PAAD cis rs7301826 0.627 rs10773823 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130809956 chr12:130810606~130812438:+ PAAD cis rs7301826 0.627 rs73162873 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130811468 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs12228957 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130811521 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs12228959 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130811523 chr12:130810606~130812438:+ PAAD cis rs7301826 0.571 rs4759788 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130811769 chr12:130810606~130812438:+ PAAD cis rs7301826 0.61 rs4759789 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130811835 chr12:130810606~130812438:+ PAAD cis rs7301826 0.61 rs4759791 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130811950 chr12:130810606~130812438:+ PAAD cis rs7301826 0.61 rs9668291 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130812363 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs4759521 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130812768 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs4759794 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130812803 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs10734981 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130813350 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs10744483 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130813661 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs10744484 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130813961 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs10744485 ENSG00000256250.1 RP11-989F5.1 -10.94 6.75e-21 7.43e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130814005 chr12:130810606~130812438:+ PAAD cis rs950027 0.549 rs1719250 ENSG00000259520.4 CTD-2651B20.3 -10.93 6.81e-21 7.5e-17 -0.76 -0.66 Response to fenofibrate (adiponectin levels); chr15:45317575 chr15:45251580~45279251:- PAAD cis rs7617773 0.746 rs7619865 ENSG00000229759.1 MRPS18AP1 10.93 6.99e-21 7.69e-17 0.69 0.66 Coronary artery disease; chr3:48329090 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs9846818 ENSG00000229759.1 MRPS18AP1 10.93 6.99e-21 7.69e-17 0.69 0.66 Coronary artery disease; chr3:48334195 chr3:48256350~48256938:- PAAD cis rs7617773 0.743 rs6804986 ENSG00000229759.1 MRPS18AP1 10.93 7.07e-21 7.78e-17 0.72 0.66 Coronary artery disease; chr3:48322105 chr3:48256350~48256938:- PAAD cis rs7617773 0.815 rs9825637 ENSG00000229759.1 MRPS18AP1 10.93 7.07e-21 7.78e-17 0.72 0.66 Coronary artery disease; chr3:48330792 chr3:48256350~48256938:- PAAD cis rs1153858 0.723 rs1719238 ENSG00000259520.4 CTD-2651B20.3 10.92 7.34e-21 8.04e-17 0.88 0.66 Homoarginine levels; chr15:45302568 chr15:45251580~45279251:- PAAD cis rs1153858 0.723 rs4580098 ENSG00000259520.4 CTD-2651B20.3 -10.92 7.34e-21 8.04e-17 -0.88 -0.66 Homoarginine levels; chr15:45304711 chr15:45251580~45279251:- PAAD cis rs2739330 0.828 rs2186366 ENSG00000225282.1 AP000350.6 -10.92 7.53e-21 8.25e-17 -0.84 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23926900~23929574:+ PAAD cis rs10256972 0.516 rs12702081 ENSG00000229043.2 AC091729.9 -10.92 7.54e-21 8.26e-17 -0.71 -0.66 Endometriosis;Longevity; chr7:1101892 chr7:1160374~1165267:+ PAAD cis rs916888 0.61 rs199446 ENSG00000214401.4 KANSL1-AS1 -10.91 7.86e-21 8.6e-17 -0.89 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46193576~46196723:+ PAAD cis rs916888 0.61 rs199536 ENSG00000214401.4 KANSL1-AS1 -10.91 7.86e-21 8.6e-17 -0.89 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46193576~46196723:+ PAAD cis rs2739330 0.828 rs5760102 ENSG00000218537.1 MIF-AS1 10.91 8.08e-21 8.83e-17 0.93 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23894426~23898930:- PAAD cis rs7301826 0.651 rs10773824 ENSG00000256250.1 RP11-989F5.1 -10.91 8.1e-21 8.83e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130814306 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs10773825 ENSG00000256250.1 RP11-989F5.1 -10.91 8.1e-21 8.83e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130814368 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs7295705 ENSG00000256250.1 RP11-989F5.1 -10.91 8.1e-21 8.83e-17 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130817340 chr12:130810606~130812438:+ PAAD cis rs10256972 0.568 rs1133043 ENSG00000229043.2 AC091729.9 -10.9 8.14e-21 8.86e-17 -0.71 -0.66 Endometriosis;Longevity; chr7:1093669 chr7:1160374~1165267:+ PAAD cis rs916888 0.61 rs199452 ENSG00000214401.4 KANSL1-AS1 10.9 8.15e-21 8.88e-17 0.87 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46193576~46196723:+ PAAD cis rs858239 1 rs199347 ENSG00000230658.1 KLHL7-AS1 10.9 8.58e-21 9.32e-17 0.87 0.66 Cerebrospinal fluid biomarker levels; chr7:23254127 chr7:23101228~23105703:- PAAD cis rs9326248 0.769 rs499910 ENSG00000254851.1 RP11-109L13.1 -10.89 8.74e-21 9.49e-17 -0.98 -0.66 Blood protein levels; chr11:116892318 chr11:117135528~117138582:+ PAAD cis rs7301826 0.651 rs1554807 ENSG00000256250.1 RP11-989F5.1 10.89 8.92e-21 9.68e-17 0.79 0.66 Plasma plasminogen activator levels; chr12:130795872 chr12:130810606~130812438:+ PAAD cis rs950027 0.62 rs872192 ENSG00000259520.4 CTD-2651B20.3 -10.88 9.77e-21 1.06e-16 -0.77 -0.66 Response to fenofibrate (adiponectin levels); chr15:45322304 chr15:45251580~45279251:- PAAD cis rs10256972 0.616 rs3802141 ENSG00000229043.2 AC091729.9 -10.87 9.83e-21 1.07e-16 -0.7 -0.66 Endometriosis;Longevity; chr7:1091720 chr7:1160374~1165267:+ PAAD cis rs5769707 0.967 rs5769698 ENSG00000188511.11 C22orf34 10.86 1.1e-20 1.19e-16 0.64 0.66 Monocyte percentage of white cells;Monocyte count; chr22:49604058 chr22:49414524~49657542:- PAAD cis rs1577917 1 rs12190598 ENSG00000203875.9 SNHG5 -10.84 1.18e-20 1.27e-16 -0.86 -0.66 Response to antipsychotic treatment; chr6:85976356 chr6:85660950~85678736:- PAAD cis rs875971 0.54 rs35510581 ENSG00000226824.5 RP4-756H11.3 10.84 1.19e-20 1.28e-16 0.74 0.66 Aortic root size; chr7:66113790 chr7:66654538~66669855:+ PAAD cis rs875971 0.577 rs35072105 ENSG00000226824.5 RP4-756H11.3 10.84 1.19e-20 1.28e-16 0.74 0.66 Aortic root size; chr7:66144830 chr7:66654538~66669855:+ PAAD cis rs7301826 0.651 rs10848210 ENSG00000256250.1 RP11-989F5.1 -10.84 1.24e-20 1.33e-16 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130827475 chr12:130810606~130812438:+ PAAD cis rs7301826 0.627 rs4325342 ENSG00000256250.1 RP11-989F5.1 -10.84 1.24e-20 1.33e-16 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130827937 chr12:130810606~130812438:+ PAAD cis rs7617773 0.746 rs4130995 ENSG00000229759.1 MRPS18AP1 10.83 1.32e-20 1.41e-16 0.69 0.66 Coronary artery disease; chr3:48316765 chr3:48256350~48256938:- PAAD cis rs7617773 0.709 rs4404473 ENSG00000229759.1 MRPS18AP1 10.83 1.32e-20 1.42e-16 0.72 0.66 Coronary artery disease; chr3:48312136 chr3:48256350~48256938:- PAAD cis rs10256972 0.63 rs13235747 ENSG00000229043.2 AC091729.9 -10.83 1.33e-20 1.42e-16 -0.7 -0.66 Endometriosis;Longevity; chr7:1089487 chr7:1160374~1165267:+ PAAD cis rs2739330 0.796 rs2154594 ENSG00000225282.1 AP000350.6 -10.82 1.34e-20 1.43e-16 -0.86 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23926900~23929574:+ PAAD cis rs10256972 0.591 rs6950319 ENSG00000229043.2 AC091729.9 -10.82 1.39e-20 1.48e-16 -0.72 -0.66 Endometriosis;Longevity; chr7:1121688 chr7:1160374~1165267:+ PAAD cis rs5769707 0.967 rs2187891 ENSG00000188511.11 C22orf34 10.82 1.41e-20 1.5e-16 0.64 0.66 Monocyte percentage of white cells;Monocyte count; chr22:49600446 chr22:49414524~49657542:- PAAD cis rs7301826 0.557 rs7953184 ENSG00000256250.1 RP11-989F5.1 10.81 1.46e-20 1.55e-16 0.77 0.66 Plasma plasminogen activator levels; chr12:130800307 chr12:130810606~130812438:+ PAAD cis rs2739330 0.76 rs5751761 ENSG00000273295.1 AP000350.5 -10.81 1.48e-20 1.57e-16 -0.85 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23901432~23907068:- PAAD cis rs858239 0.863 rs466225 ENSG00000230658.1 KLHL7-AS1 10.8 1.52e-20 1.62e-16 0.86 0.66 Cerebrospinal fluid biomarker levels; chr7:23292784 chr7:23101228~23105703:- PAAD cis rs1153858 0.668 rs63603561 ENSG00000259520.4 CTD-2651B20.3 10.8 1.55e-20 1.64e-16 0.88 0.66 Homoarginine levels; chr15:45301125 chr15:45251580~45279251:- PAAD cis rs7301826 0.651 rs7968675 ENSG00000256250.1 RP11-989F5.1 -10.8 1.59e-20 1.68e-16 -0.77 -0.66 Plasma plasminogen activator levels; chr12:130818832 chr12:130810606~130812438:+ PAAD cis rs858239 0.665 rs858305 ENSG00000230658.1 KLHL7-AS1 -10.78 1.71e-20 1.8e-16 -0.83 -0.66 Cerebrospinal fluid biomarker levels; chr7:23203211 chr7:23101228~23105703:- PAAD cis rs7617773 0.746 rs11713476 ENSG00000229759.1 MRPS18AP1 10.78 1.71e-20 1.8e-16 0.68 0.66 Coronary artery disease; chr3:48333944 chr3:48256350~48256938:- PAAD cis rs5769707 0.935 rs5770594 ENSG00000188511.11 C22orf34 10.75 2.09e-20 2.17e-16 0.59 0.66 Monocyte percentage of white cells;Monocyte count; chr22:49624849 chr22:49414524~49657542:- PAAD cis rs5769707 0.967 rs4524218 ENSG00000188511.11 C22orf34 10.75 2.09e-20 2.17e-16 0.59 0.66 Monocyte percentage of white cells;Monocyte count; chr22:49624991 chr22:49414524~49657542:- PAAD cis rs801193 0.901 rs4273746 ENSG00000226824.5 RP4-756H11.3 10.75 2.1e-20 2.18e-16 0.76 0.66 Aortic root size; chr7:66836124 chr7:66654538~66669855:+ PAAD cis rs9322193 0.847 rs4870054 ENSG00000231760.4 RP11-350J20.5 10.75 2.1e-20 2.19e-16 0.87 0.66 Lung cancer; chr6:149848402 chr6:149796151~149826294:- PAAD cis rs10256972 0.641 rs12702017 ENSG00000229043.2 AC091729.9 -10.75 2.12e-20 2.2e-16 -0.7 -0.66 Endometriosis;Longevity; chr7:1089777 chr7:1160374~1165267:+ PAAD cis rs858239 0.863 rs274058 ENSG00000230658.1 KLHL7-AS1 10.75 2.13e-20 2.22e-16 0.83 0.66 Cerebrospinal fluid biomarker levels; chr7:23351890 chr7:23101228~23105703:- PAAD cis rs10256972 0.591 rs10229680 ENSG00000229043.2 AC091729.9 -10.74 2.19e-20 2.28e-16 -0.72 -0.66 Endometriosis;Longevity; chr7:1118929 chr7:1160374~1165267:+ PAAD cis rs875971 0.66 rs10263935 ENSG00000226824.5 RP4-756H11.3 -10.74 2.2e-20 2.28e-16 -0.72 -0.66 Aortic root size; chr7:66631041 chr7:66654538~66669855:+ PAAD cis rs5769707 0.967 rs2051626 ENSG00000188511.11 C22orf34 10.74 2.29e-20 2.37e-16 0.63 0.66 Monocyte percentage of white cells;Monocyte count; chr22:49615325 chr22:49414524~49657542:- PAAD cis rs5769707 0.967 rs1018812 ENSG00000188511.11 C22orf34 10.74 2.29e-20 2.37e-16 0.63 0.66 Monocyte percentage of white cells;Monocyte count; chr22:49616425 chr22:49414524~49657542:- PAAD cis rs2739330 0.828 rs4822454 ENSG00000225282.1 AP000350.6 10.73 2.42e-20 2.5e-16 0.84 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23926900~23929574:+ PAAD cis rs2739330 0.627 rs9608219 ENSG00000225282.1 AP000350.6 10.72 2.52e-20 2.61e-16 0.87 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23926900~23929574:+ PAAD cis rs5769707 0.967 rs9616327 ENSG00000188511.11 C22orf34 10.71 2.67e-20 2.75e-16 0.63 0.66 Monocyte percentage of white cells;Monocyte count; chr22:49617243 chr22:49414524~49657542:- PAAD cis rs7617773 0.694 rs13099560 ENSG00000229759.1 MRPS18AP1 -10.71 2.74e-20 2.82e-16 -0.68 -0.66 Coronary artery disease; chr3:48163278 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs34523942 ENSG00000229759.1 MRPS18AP1 10.68 3.33e-20 3.42e-16 0.71 0.65 Coronary artery disease; chr3:48301179 chr3:48256350~48256938:- PAAD cis rs10256972 0.681 rs12702016 ENSG00000229043.2 AC091729.9 -10.67 3.39e-20 3.47e-16 -0.69 -0.65 Endometriosis;Longevity; chr7:1089756 chr7:1160374~1165267:+ PAAD cis rs7617773 0.817 rs17647717 ENSG00000229759.1 MRPS18AP1 10.66 3.59e-20 3.67e-16 0.71 0.65 Coronary artery disease; chr3:48263966 chr3:48256350~48256938:- PAAD cis rs5769707 0.967 rs5770585 ENSG00000188511.11 C22orf34 10.66 3.7e-20 3.77e-16 0.63 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49614226 chr22:49414524~49657542:- PAAD cis rs5769707 0.967 rs739248 ENSG00000188511.11 C22orf34 10.66 3.73e-20 3.8e-16 0.59 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49631557 chr22:49414524~49657542:- PAAD cis rs9545047 0.735 rs314690 ENSG00000227676.3 LINC01068 10.66 3.79e-20 3.86e-16 0.88 0.65 Schizophrenia; chr13:79434822 chr13:79566727~79571436:+ PAAD cis rs5769707 0.967 rs763127 ENSG00000188511.11 C22orf34 10.65 3.91e-20 3.99e-16 0.63 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49612430 chr22:49414524~49657542:- PAAD cis rs9326248 0.731 rs90192 ENSG00000254851.1 RP11-109L13.1 -10.64 4.1e-20 4.17e-16 -0.99 -0.65 Blood protein levels; chr11:117188631 chr11:117135528~117138582:+ PAAD cis rs5769707 0.967 rs9616701 ENSG00000188511.11 C22orf34 10.63 4.37e-20 4.44e-16 0.59 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49631898 chr22:49414524~49657542:- PAAD cis rs7309 0.935 rs6432674 ENSG00000227403.1 AC009299.3 -10.63 4.52e-20 4.58e-16 -0.83 -0.65 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161168811 chr2:161244739~161249050:+ PAAD cis rs7309 0.81 rs11684253 ENSG00000227403.1 AC009299.3 -10.63 4.52e-20 4.58e-16 -0.83 -0.65 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161178025 chr2:161244739~161249050:+ PAAD cis rs2739330 0.761 rs5760176 ENSG00000273295.1 AP000350.5 -10.63 4.55e-20 4.61e-16 -0.86 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23901432~23907068:- PAAD cis rs4853012 0.941 rs4852329 ENSG00000217702.2 RP11-287D1.4 10.62 4.66e-20 4.72e-16 1.12 0.65 Gestational age at birth (maternal effect); chr2:74127417 chr2:74130583~74135395:+ PAAD cis rs7617773 0.817 rs745116 ENSG00000229759.1 MRPS18AP1 10.62 4.76e-20 4.82e-16 0.71 0.65 Coronary artery disease; chr3:48231046 chr3:48256350~48256938:- PAAD cis rs2739330 0.731 rs5751792 ENSG00000273295.1 AP000350.5 10.62 4.78e-20 4.84e-16 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23901432~23907068:- PAAD cis rs2739330 0.732 rs5760175 ENSG00000273295.1 AP000350.5 10.61 4.88e-20 4.93e-16 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23901432~23907068:- PAAD cis rs7617773 0.817 rs9830016 ENSG00000229759.1 MRPS18AP1 10.61 5.05e-20 5.09e-16 0.7 0.65 Coronary artery disease; chr3:48241004 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs9847953 ENSG00000229759.1 MRPS18AP1 10.61 5.05e-20 5.09e-16 0.7 0.65 Coronary artery disease; chr3:48241205 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs11928691 ENSG00000229759.1 MRPS18AP1 10.61 5.05e-20 5.09e-16 0.7 0.65 Coronary artery disease; chr3:48245275 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs9311421 ENSG00000229759.1 MRPS18AP1 10.61 5.05e-20 5.09e-16 0.7 0.65 Coronary artery disease; chr3:48251588 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs11710861 ENSG00000229759.1 MRPS18AP1 10.61 5.05e-20 5.09e-16 0.7 0.65 Coronary artery disease; chr3:48256070 chr3:48256350~48256938:- PAAD cis rs7617773 0.784 rs9850672 ENSG00000229759.1 MRPS18AP1 10.61 5.05e-20 5.09e-16 0.7 0.65 Coronary artery disease; chr3:48259682 chr3:48256350~48256938:- PAAD cis rs4853012 0.941 rs78128123 ENSG00000217702.2 RP11-287D1.4 10.61 5.08e-20 5.11e-16 1.12 0.65 Gestational age at birth (maternal effect); chr2:74120398 chr2:74130583~74135395:+ PAAD cis rs507080 0.922 rs654792 ENSG00000255239.1 AP002954.6 -10.61 5.14e-20 5.16e-16 -0.81 -0.65 Serum metabolite levels; chr11:118682287 chr11:118688039~118690600:- PAAD cis rs2739330 0.76 rs5751761 ENSG00000218537.1 MIF-AS1 -10.61 5.15e-20 5.17e-16 -0.88 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23894426~23898930:- PAAD cis rs5769707 1 rs5769707 ENSG00000188511.11 C22orf34 10.6 5.24e-20 5.25e-16 0.6 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49619754 chr22:49414524~49657542:- PAAD cis rs950027 0.62 rs1617634 ENSG00000259520.4 CTD-2651B20.3 -10.59 5.76e-20 5.75e-16 -0.76 -0.65 Response to fenofibrate (adiponectin levels); chr15:45323380 chr15:45251580~45279251:- PAAD cis rs7301826 0.651 rs10848209 ENSG00000256250.1 RP11-989F5.1 -10.59 5.77e-20 5.76e-16 -0.76 -0.65 Plasma plasminogen activator levels; chr12:130826727 chr12:130810606~130812438:+ PAAD cis rs2739330 0.791 rs9612520 ENSG00000225282.1 AP000350.6 10.58 5.88e-20 5.86e-16 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23926900~23929574:+ PAAD cis rs5769707 0.874 rs9616714 ENSG00000188511.11 C22orf34 10.58 6.05e-20 6.04e-16 0.6 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49657211 chr22:49414524~49657542:- PAAD cis rs9326248 0.861 rs494356 ENSG00000254851.1 RP11-109L13.1 -10.57 6.42e-20 6.39e-16 -0.99 -0.65 Blood protein levels; chr11:117201254 chr11:117135528~117138582:+ PAAD cis rs7617773 0.817 rs6794644 ENSG00000229759.1 MRPS18AP1 10.56 6.74e-20 6.7e-16 0.7 0.65 Coronary artery disease; chr3:48288547 chr3:48256350~48256938:- PAAD cis rs2739330 0.732 rs5760175 ENSG00000250470.1 AP000351.3 10.55 7.29e-20 7.17e-16 0.94 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23976904~23977585:- PAAD cis rs2739330 0.731 rs5751792 ENSG00000250470.1 AP000351.3 10.54 7.56e-20 7.39e-16 0.94 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23976904~23977585:- PAAD cis rs2739330 0.796 rs5760097 ENSG00000225282.1 AP000350.6 10.54 7.65e-20 7.48e-16 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23926900~23929574:+ PAAD cis rs2739330 0.828 rs5760098 ENSG00000225282.1 AP000350.6 10.54 7.65e-20 7.48e-16 0.86 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23926900~23929574:+ PAAD cis rs2739330 0.761 rs5760176 ENSG00000250470.1 AP000351.3 -10.54 7.7e-20 7.52e-16 -0.94 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23976904~23977585:- PAAD cis rs950027 0.549 rs11636114 ENSG00000259520.4 CTD-2651B20.3 -10.52 8.73e-20 8.49e-16 -0.76 -0.65 Response to fenofibrate (adiponectin levels); chr15:45309214 chr15:45251580~45279251:- PAAD cis rs2739330 0.828 rs5760107 ENSG00000225282.1 AP000350.6 10.52 8.89e-20 8.63e-16 0.84 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23926900~23929574:+ PAAD cis rs2739330 0.789 rs5760109 ENSG00000225282.1 AP000350.6 10.52 8.89e-20 8.63e-16 0.84 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23926900~23929574:+ PAAD cis rs858239 0.862 rs1728292 ENSG00000230658.1 KLHL7-AS1 10.52 8.92e-20 8.66e-16 0.82 0.65 Cerebrospinal fluid biomarker levels; chr7:23223855 chr7:23101228~23105703:- PAAD cis rs858239 0.965 rs156429 ENSG00000230658.1 KLHL7-AS1 10.52 8.93e-20 8.67e-16 0.81 0.65 Cerebrospinal fluid biomarker levels; chr7:23266401 chr7:23101228~23105703:- PAAD cis rs5769707 0.967 rs2071904 ENSG00000188511.11 C22orf34 10.51 9.12e-20 8.85e-16 0.59 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49640829 chr22:49414524~49657542:- PAAD cis rs5769707 0.846 rs5770610 ENSG00000188511.11 C22orf34 10.51 9.12e-20 8.85e-16 0.59 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49643249 chr22:49414524~49657542:- PAAD cis rs5769707 0.935 rs9616332 ENSG00000188511.11 C22orf34 10.51 9.12e-20 8.85e-16 0.59 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49654030 chr22:49414524~49657542:- PAAD cis rs5769707 0.967 rs9616713 ENSG00000188511.11 C22orf34 10.51 9.12e-20 8.85e-16 0.59 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49655461 chr22:49414524~49657542:- PAAD cis rs9326248 0.689 rs4516002 ENSG00000254851.1 RP11-109L13.1 -10.51 9.27e-20 8.96e-16 -1.04 -0.65 Blood protein levels; chr11:117128343 chr11:117135528~117138582:+ PAAD cis rs7617773 0.779 rs11718329 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48268338 chr3:48256350~48256938:- PAAD cis rs7617773 0.78 rs6442111 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48270570 chr3:48256350~48256938:- PAAD cis rs7617773 0.851 rs6775179 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48271928 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs6800492 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48282400 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs9818937 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48283791 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs6801801 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48284943 chr3:48256350~48256938:- PAAD cis rs7617773 0.779 rs9833309 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48285960 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs9853804 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48286239 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs9834095 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48286261 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs4131361 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48287322 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs4131362 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48287546 chr3:48256350~48256938:- PAAD cis rs7617773 0.817 rs6791930 ENSG00000229759.1 MRPS18AP1 10.51 9.33e-20 8.96e-16 0.7 0.65 Coronary artery disease; chr3:48288410 chr3:48256350~48256938:- PAAD cis rs4853012 0.838 rs2177707 ENSG00000217702.2 RP11-287D1.4 10.49 1.05e-19 1e-15 1.11 0.65 Gestational age at birth (maternal effect); chr2:74129723 chr2:74130583~74135395:+ PAAD cis rs4853012 0.887 rs2280642 ENSG00000217702.2 RP11-287D1.4 10.49 1.05e-19 1e-15 1.11 0.65 Gestational age at birth (maternal effect); chr2:74131125 chr2:74130583~74135395:+ PAAD cis rs1153858 0.723 rs11855527 ENSG00000259520.4 CTD-2651B20.3 10.48 1.08e-19 1.03e-15 0.85 0.65 Homoarginine levels; chr15:45314487 chr15:45251580~45279251:- PAAD cis rs5769707 0.935 rs739239 ENSG00000188511.11 C22orf34 10.48 1.08e-19 1.03e-15 0.6 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49656820 chr22:49414524~49657542:- PAAD cis rs5769707 0.967 rs739241 ENSG00000188511.11 C22orf34 10.48 1.08e-19 1.03e-15 0.6 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49659273 chr22:49414524~49657542:- PAAD cis rs7617773 0.744 rs2125482 ENSG00000229759.1 MRPS18AP1 10.48 1.14e-19 1.09e-15 0.7 0.65 Coronary artery disease; chr3:48281643 chr3:48256350~48256938:- PAAD cis rs4853012 0.887 rs2122290 ENSG00000217702.2 RP11-287D1.4 10.47 1.18e-19 1.13e-15 1.11 0.65 Gestational age at birth (maternal effect); chr2:74131774 chr2:74130583~74135395:+ PAAD cis rs5769707 0.967 rs17182154 ENSG00000188511.11 C22orf34 10.47 1.18e-19 1.13e-15 0.61 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49596822 chr22:49414524~49657542:- PAAD cis rs5769707 0.837 rs5770599 ENSG00000188511.11 C22orf34 10.47 1.2e-19 1.14e-15 0.58 0.65 Monocyte percentage of white cells;Monocyte count; chr22:49626333 chr22:49414524~49657542:- PAAD cis rs9545047 0.904 rs2760105 ENSG00000227676.3 LINC01068 10.46 1.26e-19 1.19e-15 0.84 0.65 Schizophrenia; chr13:79535732 chr13:79566727~79571436:+ PAAD cis rs7301826 0.627 rs1077317 ENSG00000256250.1 RP11-989F5.1 -10.46 1.26e-19 1.2e-15 -0.75 -0.65 Plasma plasminogen activator levels; chr12:130830432 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs4759525 ENSG00000256250.1 RP11-989F5.1 -10.46 1.26e-19 1.2e-15 -0.75 -0.65 Plasma plasminogen activator levels; chr12:130831736 chr12:130810606~130812438:+ PAAD cis rs7617773 0.817 rs9819094 ENSG00000229759.1 MRPS18AP1 10.45 1.33e-19 1.26e-15 0.7 0.65 Coronary artery disease; chr3:48278068 chr3:48256350~48256938:- PAAD cis rs2739330 0.734 rs2000467 ENSG00000273295.1 AP000350.5 -10.45 1.37e-19 1.3e-15 -0.87 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23901432~23907068:- PAAD cis rs7301826 0.651 rs4514465 ENSG00000256250.1 RP11-989F5.1 -10.43 1.5e-19 1.42e-15 -0.75 -0.65 Plasma plasminogen activator levels; chr12:130829124 chr12:130810606~130812438:+ PAAD cis rs7617773 0.817 rs3937 ENSG00000229759.1 MRPS18AP1 10.42 1.61e-19 1.51e-15 0.71 0.65 Coronary artery disease; chr3:48270912 chr3:48256350~48256938:- PAAD cis rs801193 0.773 rs801207 ENSG00000226824.5 RP4-756H11.3 10.42 1.65e-19 1.55e-15 0.73 0.65 Aortic root size; chr7:66555603 chr7:66654538~66669855:+ PAAD cis rs7309 0.935 rs1921309 ENSG00000227403.1 AC009299.3 -10.41 1.73e-19 1.62e-15 -0.83 -0.65 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161192464 chr2:161244739~161249050:+ PAAD cis rs7309 0.935 rs11884495 ENSG00000227403.1 AC009299.3 -10.41 1.73e-19 1.62e-15 -0.83 -0.65 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161203458 chr2:161244739~161249050:+ PAAD cis rs7309 0.935 rs10930013 ENSG00000227403.1 AC009299.3 -10.41 1.73e-19 1.62e-15 -0.83 -0.65 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161213814 chr2:161244739~161249050:+ PAAD cis rs7617773 0.817 rs936426 ENSG00000229759.1 MRPS18AP1 10.4 1.79e-19 1.68e-15 0.69 0.64 Coronary artery disease; chr3:48173763 chr3:48256350~48256938:- PAAD cis rs2739330 0.828 rs2330635 ENSG00000225282.1 AP000350.6 10.4 1.8e-19 1.69e-15 0.84 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23926900~23929574:+ PAAD cis rs7617773 0.817 rs9837228 ENSG00000229759.1 MRPS18AP1 -10.4 1.84e-19 1.72e-15 -0.69 -0.64 Coronary artery disease; chr3:48282976 chr3:48256350~48256938:- PAAD cis rs801193 0.844 rs2244022 ENSG00000226824.5 RP4-756H11.3 -10.39 1.98e-19 1.84e-15 -0.72 -0.64 Aortic root size; chr7:66737443 chr7:66654538~66669855:+ PAAD cis rs1153858 1 rs4775895 ENSG00000259520.4 CTD-2651B20.3 -10.37 2.14e-19 1.99e-15 -0.86 -0.64 Homoarginine levels; chr15:45325759 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1980288 ENSG00000259520.4 CTD-2651B20.3 -10.37 2.14e-19 1.99e-15 -0.86 -0.64 Homoarginine levels; chr15:45328414 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12909158 ENSG00000259520.4 CTD-2651B20.3 -10.37 2.14e-19 1.99e-15 -0.86 -0.64 Homoarginine levels; chr15:45328976 chr15:45251580~45279251:- PAAD cis rs7617773 0.925 rs35942721 ENSG00000229759.1 MRPS18AP1 10.37 2.18e-19 2.03e-15 0.73 0.64 Coronary artery disease; chr3:48131579 chr3:48256350~48256938:- PAAD cis rs5769707 0.872 rs5770604 ENSG00000188511.11 C22orf34 10.37 2.19e-19 2.04e-15 0.58 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49637024 chr22:49414524~49657542:- PAAD cis rs7301826 0.651 rs2277336 ENSG00000256250.1 RP11-989F5.1 10.36 2.31e-19 2.13e-15 0.74 0.64 Plasma plasminogen activator levels; chr12:130801574 chr12:130810606~130812438:+ PAAD cis rs1577917 1 rs6933377 ENSG00000203875.9 SNHG5 10.36 2.37e-19 2.18e-15 0.76 0.64 Response to antipsychotic treatment; chr6:85995537 chr6:85660950~85678736:- PAAD cis rs9326248 0.53 rs11216171 ENSG00000254851.1 RP11-109L13.1 -10.35 2.4e-19 2.2e-15 -0.93 -0.64 Blood protein levels; chr11:116878397 chr11:117135528~117138582:+ PAAD cis rs858239 0.698 rs4265084 ENSG00000230658.1 KLHL7-AS1 10.35 2.42e-19 2.22e-15 0.82 0.64 Cerebrospinal fluid biomarker levels; chr7:23367621 chr7:23101228~23105703:- PAAD cis rs875971 0.543 rs801191 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66567968 chr7:66654538~66669855:+ PAAD cis rs875971 0.508 rs6947808 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66580095 chr7:66654538~66669855:+ PAAD cis rs875971 0.508 rs10242423 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66594188 chr7:66654538~66669855:+ PAAD cis rs875971 0.508 rs10253883 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66596151 chr7:66654538~66669855:+ PAAD cis rs875971 0.508 rs10258739 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66597948 chr7:66654538~66669855:+ PAAD cis rs875971 0.508 rs10950045 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66601386 chr7:66654538~66669855:+ PAAD cis rs801193 0.839 rs6968619 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66603880 chr7:66654538~66669855:+ PAAD cis rs801193 0.839 rs12534943 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66605533 chr7:66654538~66669855:+ PAAD cis rs801193 0.805 rs12532355 ENSG00000226824.5 RP4-756H11.3 10.35 2.45e-19 2.22e-15 0.72 0.64 Aortic root size; chr7:66605597 chr7:66654538~66669855:+ PAAD cis rs5769707 0.967 rs8141807 ENSG00000188511.11 C22orf34 10.35 2.45e-19 2.22e-15 0.59 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49650090 chr22:49414524~49657542:- PAAD cis rs875971 1 rs6956179 ENSG00000226824.5 RP4-756H11.3 10.35 2.51e-19 2.27e-15 0.74 0.64 Aortic root size; chr7:66341672 chr7:66654538~66669855:+ PAAD cis rs1153858 1 rs28679834 ENSG00000259520.4 CTD-2651B20.3 -10.35 2.53e-19 2.29e-15 -0.86 -0.64 Homoarginine levels; chr15:45324008 chr15:45251580~45279251:- PAAD cis rs7301826 0.627 rs4334059 ENSG00000256250.1 RP11-989F5.1 -10.34 2.58e-19 2.33e-15 -0.73 -0.64 Plasma plasminogen activator levels; chr12:130829669 chr12:130810606~130812438:+ PAAD cis rs5769707 0.837 rs5769709 ENSG00000188511.11 C22orf34 10.34 2.62e-19 2.36e-15 0.58 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49628109 chr22:49414524~49657542:- PAAD cis rs2739330 0.796 rs5760106 ENSG00000225282.1 AP000350.6 -10.32 2.97e-19 2.67e-15 -0.84 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23926900~23929574:+ PAAD cis rs7301826 0.585 rs6486600 ENSG00000256250.1 RP11-989F5.1 -10.32 3.04e-19 2.73e-15 -0.73 -0.64 Plasma plasminogen activator levels; chr12:130808432 chr12:130810606~130812438:+ PAAD cis rs1153858 1 rs2668747 ENSG00000259520.4 CTD-2651B20.3 -10.31 3.18e-19 2.85e-15 -0.86 -0.64 Homoarginine levels; chr15:45325018 chr15:45251580~45279251:- PAAD cis rs5769707 0.967 rs12485195 ENSG00000188511.11 C22orf34 10.3 3.36e-19 3e-15 0.6 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49660223 chr22:49414524~49657542:- PAAD cis rs5769707 0.777 rs739243 ENSG00000188511.11 C22orf34 10.3 3.36e-19 3.01e-15 0.6 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49663563 chr22:49414524~49657542:- PAAD cis rs858239 0.896 rs1637192 ENSG00000230658.1 KLHL7-AS1 10.29 3.63e-19 3.25e-15 0.84 0.64 Cerebrospinal fluid biomarker levels; chr7:23220895 chr7:23101228~23105703:- PAAD cis rs875971 0.965 rs7794930 ENSG00000226824.5 RP4-756H11.3 10.29 3.64e-19 3.25e-15 0.76 0.64 Aortic root size; chr7:66313559 chr7:66654538~66669855:+ PAAD cis rs7301826 0.61 rs36051740 ENSG00000256250.1 RP11-989F5.1 10.28 3.79e-19 3.38e-15 0.73 0.64 Plasma plasminogen activator levels; chr12:130808177 chr12:130810606~130812438:+ PAAD cis rs916888 0.647 rs199524 ENSG00000214401.4 KANSL1-AS1 -10.28 3.79e-19 3.38e-15 -0.86 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46193576~46196723:+ PAAD cis rs916888 0.647 rs199523 ENSG00000214401.4 KANSL1-AS1 -10.28 3.79e-19 3.38e-15 -0.86 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46193576~46196723:+ PAAD cis rs2739330 0.828 rs4820572 ENSG00000225282.1 AP000350.6 10.28 3.88e-19 3.46e-15 0.84 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23926900~23929574:+ PAAD cis rs12439619 0.705 rs4778665 ENSG00000278603.1 RP13-608F4.5 10.27 3.98e-19 3.54e-15 1.05 0.64 Intelligence (multi-trait analysis); chr15:82144163 chr15:82472203~82472426:+ PAAD cis rs858239 0.932 rs858275 ENSG00000230658.1 KLHL7-AS1 10.27 4.05e-19 3.59e-15 0.81 0.64 Cerebrospinal fluid biomarker levels; chr7:23254525 chr7:23101228~23105703:- PAAD cis rs875971 1 rs2420820 ENSG00000226824.5 RP4-756H11.3 10.26 4.35e-19 3.86e-15 0.78 0.64 Aortic root size; chr7:66626920 chr7:66654538~66669855:+ PAAD cis rs5769707 0.749 rs7286706 ENSG00000188511.11 C22orf34 10.25 4.41e-19 3.91e-15 0.59 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49664698 chr22:49414524~49657542:- PAAD cis rs5769707 0.837 rs1573726 ENSG00000188511.11 C22orf34 10.23 4.99e-19 4.41e-15 0.58 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49639224 chr22:49414524~49657542:- PAAD cis rs7617773 0.851 rs13068288 ENSG00000229759.1 MRPS18AP1 10.23 5.28e-19 4.66e-15 0.7 0.64 Coronary artery disease; chr3:48290261 chr3:48256350~48256938:- PAAD cis rs875971 1 rs709597 ENSG00000226824.5 RP4-756H11.3 10.22 5.32e-19 4.69e-15 0.73 0.64 Aortic root size; chr7:66360996 chr7:66654538~66669855:+ PAAD cis rs858239 0.796 rs433395 ENSG00000230658.1 KLHL7-AS1 10.22 5.43e-19 4.79e-15 0.8 0.64 Cerebrospinal fluid biomarker levels; chr7:23362336 chr7:23101228~23105703:- PAAD cis rs7617773 0.925 rs34513961 ENSG00000229759.1 MRPS18AP1 10.21 5.77e-19 5.08e-15 0.72 0.64 Coronary artery disease; chr3:48132163 chr3:48256350~48256938:- PAAD cis rs875971 0.964 rs60193905 ENSG00000226824.5 RP4-756H11.3 -10.2 6.16e-19 5.41e-15 -0.74 -0.64 Aortic root size; chr7:66506273 chr7:66654538~66669855:+ PAAD cis rs875971 0.965 rs10267430 ENSG00000226824.5 RP4-756H11.3 10.19 6.7e-19 5.77e-15 0.73 0.64 Aortic root size; chr7:66278036 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs10257427 ENSG00000226824.5 RP4-756H11.3 10.19 6.7e-19 5.77e-15 0.73 0.64 Aortic root size; chr7:66278221 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs10215948 ENSG00000226824.5 RP4-756H11.3 10.19 6.7e-19 5.77e-15 0.73 0.64 Aortic root size; chr7:66282799 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs55748098 ENSG00000226824.5 RP4-756H11.3 10.19 6.7e-19 5.77e-15 0.73 0.64 Aortic root size; chr7:66298631 chr7:66654538~66669855:+ PAAD cis rs875971 0.965 rs9969301 ENSG00000226824.5 RP4-756H11.3 10.19 6.7e-19 5.77e-15 0.73 0.64 Aortic root size; chr7:66316668 chr7:66654538~66669855:+ PAAD cis rs875971 0.867 rs1002053 ENSG00000226824.5 RP4-756H11.3 10.19 6.7e-19 5.77e-15 0.73 0.64 Aortic root size; chr7:66333558 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6460292 ENSG00000226824.5 RP4-756H11.3 10.19 6.7e-19 5.77e-15 0.73 0.64 Aortic root size; chr7:66345088 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs709595 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66352346 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs811880 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66353659 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs778726 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66363744 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs778723 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66364510 chr7:66654538~66669855:+ PAAD cis rs875971 0.767 rs1695815 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66366357 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs778685 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66371189 chr7:66654538~66669855:+ PAAD cis rs875971 0.929 rs778682 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66372947 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs11765965 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66377234 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs1643388 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66379575 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs778722 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66379841 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs778721 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66380410 chr7:66654538~66669855:+ PAAD cis rs875971 0.929 rs778712 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66384991 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs778710 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66389847 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs778708 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66391332 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs778706 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66395437 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs778700 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66401463 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs778699 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66403303 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs778696 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66405826 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs778694 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66406571 chr7:66654538~66669855:+ PAAD cis rs875971 0.929 rs778692 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66407462 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs4718343 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66409301 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs4718344 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66409394 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1968225 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66409786 chr7:66654538~66669855:+ PAAD cis rs875971 0.737 rs7803424 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66415618 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs7799834 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66415707 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6460295 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66417741 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs6978721 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66418217 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs3857684 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66473171 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs6978429 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66494889 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs4718357 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66495891 chr7:66654538~66669855:+ PAAD cis rs875971 0.929 rs12535036 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66499076 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs12533997 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66500390 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs12532998 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66502472 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs12698523 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66503126 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6970030 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66503692 chr7:66654538~66669855:+ PAAD cis rs875971 0.928 rs6970357 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66503891 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs3735148 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66506022 chr7:66654538~66669855:+ PAAD cis rs875971 0.929 rs10950041 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66508888 chr7:66654538~66669855:+ PAAD cis rs875971 0.929 rs6970860 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66511647 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6957199 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66513532 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6958271 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66514344 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6958277 ENSG00000226824.5 RP4-756H11.3 -10.19 6.7e-19 5.77e-15 -0.73 -0.64 Aortic root size; chr7:66514362 chr7:66654538~66669855:+ PAAD cis rs916888 0.779 rs199498 ENSG00000262539.1 RP11-259G18.3 10.19 6.76e-19 5.81e-15 0.92 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46259551~46260606:- PAAD cis rs2739330 0.731 rs2000468 ENSG00000225282.1 AP000350.6 10.18 6.81e-19 5.85e-15 0.78 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23926900~23929574:+ PAAD cis rs5769707 0.904 rs7288869 ENSG00000188511.11 C22orf34 10.18 7.03e-19 6.03e-15 0.58 0.64 Monocyte percentage of white cells;Monocyte count; chr22:49621679 chr22:49414524~49657542:- PAAD cis rs875971 1 rs7792762 ENSG00000226824.5 RP4-756H11.3 -10.18 7.09e-19 6.08e-15 -0.75 -0.64 Aortic root size; chr7:66539151 chr7:66654538~66669855:+ PAAD cis rs7301826 0.651 rs34749116 ENSG00000256250.1 RP11-989F5.1 10.18 7.12e-19 6.1e-15 0.72 0.64 Plasma plasminogen activator levels; chr12:130796207 chr12:130810606~130812438:+ PAAD cis rs875971 0.838 rs2173570 ENSG00000226824.5 RP4-756H11.3 10.18 7.13e-19 6.1e-15 0.75 0.64 Aortic root size; chr7:66297976 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs937495 ENSG00000226824.5 RP4-756H11.3 10.18 7.13e-19 6.1e-15 0.75 0.64 Aortic root size; chr7:66314811 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs2036264 ENSG00000226824.5 RP4-756H11.3 10.18 7.13e-19 6.1e-15 0.75 0.64 Aortic root size; chr7:66334917 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs7783613 ENSG00000226824.5 RP4-756H11.3 10.18 7.13e-19 6.1e-15 0.75 0.64 Aortic root size; chr7:66340274 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs778735 ENSG00000226824.5 RP4-756H11.3 -10.18 7.13e-19 6.1e-15 -0.75 -0.64 Aortic root size; chr7:66349822 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6979382 ENSG00000226824.5 RP4-756H11.3 -10.18 7.13e-19 6.1e-15 -0.75 -0.64 Aortic root size; chr7:66421388 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6961990 ENSG00000226824.5 RP4-756H11.3 -10.18 7.13e-19 6.1e-15 -0.75 -0.64 Aortic root size; chr7:66423583 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs4718358 ENSG00000226824.5 RP4-756H11.3 -10.18 7.13e-19 6.1e-15 -0.75 -0.64 Aortic root size; chr7:66508681 chr7:66654538~66669855:+ PAAD cis rs801193 0.66 rs2659914 ENSG00000226824.5 RP4-756H11.3 -10.18 7.13e-19 6.1e-15 -0.75 -0.64 Aortic root size; chr7:66691927 chr7:66654538~66669855:+ PAAD cis rs858239 0.73 rs10255155 ENSG00000230658.1 KLHL7-AS1 -10.16 7.74e-19 6.61e-15 -0.8 -0.64 Cerebrospinal fluid biomarker levels; chr7:23362528 chr7:23101228~23105703:- PAAD cis rs801193 0.66 rs10950049 ENSG00000226824.5 RP4-756H11.3 -10.14 8.68e-19 7.39e-15 -0.75 -0.64 Aortic root size; chr7:66765873 chr7:66654538~66669855:+ PAAD cis rs916888 0.61 rs199530 ENSG00000214401.4 KANSL1-AS1 -10.14 8.73e-19 7.4e-15 -0.83 -0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46193576~46196723:+ PAAD cis rs7301826 0.651 rs7299281 ENSG00000256250.1 RP11-989F5.1 10.14 8.92e-19 7.56e-15 0.72 0.64 Plasma plasminogen activator levels; chr12:130818587 chr12:130810606~130812438:+ PAAD cis rs875971 1 rs10244498 ENSG00000226824.5 RP4-756H11.3 -10.14 9.1e-19 7.68e-15 -0.75 -0.64 Aortic root size; chr7:66651069 chr7:66654538~66669855:+ PAAD cis rs801193 0.636 rs10233806 ENSG00000226824.5 RP4-756H11.3 10.14 9.1e-19 7.68e-15 0.75 0.64 Aortic root size; chr7:66653261 chr7:66654538~66669855:+ PAAD cis rs801193 0.613 rs2659900 ENSG00000226824.5 RP4-756H11.3 -10.14 9.1e-19 7.68e-15 -0.75 -0.64 Aortic root size; chr7:66719456 chr7:66654538~66669855:+ PAAD cis rs801193 0.66 rs2659897 ENSG00000226824.5 RP4-756H11.3 10.14 9.1e-19 7.68e-15 0.75 0.64 Aortic root size; chr7:66722728 chr7:66654538~66669855:+ PAAD cis rs801193 0.636 rs2659895 ENSG00000226824.5 RP4-756H11.3 -10.14 9.1e-19 7.68e-15 -0.75 -0.64 Aortic root size; chr7:66731484 chr7:66654538~66669855:+ PAAD cis rs801193 0.66 rs974239 ENSG00000226824.5 RP4-756H11.3 -10.14 9.1e-19 7.68e-15 -0.75 -0.64 Aortic root size; chr7:66748504 chr7:66654538~66669855:+ PAAD cis rs801193 0.66 rs1016265 ENSG00000226824.5 RP4-756H11.3 -10.14 9.1e-19 7.68e-15 -0.75 -0.64 Aortic root size; chr7:66749580 chr7:66654538~66669855:+ PAAD cis rs801193 0.66 rs4610622 ENSG00000226824.5 RP4-756H11.3 -10.14 9.1e-19 7.68e-15 -0.75 -0.64 Aortic root size; chr7:66759510 chr7:66654538~66669855:+ PAAD cis rs4853012 1 rs2280643 ENSG00000217702.2 RP11-287D1.4 10.13 9.54e-19 8.05e-15 1.08 0.63 Gestational age at birth (maternal effect); chr2:74131159 chr2:74130583~74135395:+ PAAD cis rs4853012 0.887 rs2280644 ENSG00000217702.2 RP11-287D1.4 10.13 9.54e-19 8.05e-15 1.08 0.63 Gestational age at birth (maternal effect); chr2:74131284 chr2:74130583~74135395:+ PAAD cis rs7301826 0.651 rs6486601 ENSG00000256250.1 RP11-989F5.1 10.11 1.05e-18 8.8e-15 0.71 0.63 Plasma plasminogen activator levels; chr12:130816692 chr12:130810606~130812438:+ PAAD cis rs2739330 0.76 rs1002286 ENSG00000225282.1 AP000350.6 -10.11 1.05e-18 8.8e-15 -0.78 -0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23926900~23929574:+ PAAD cis rs10256972 0.706 rs4285396 ENSG00000229043.2 AC091729.9 -10.11 1.06e-18 8.93e-15 -0.66 -0.63 Endometriosis;Longevity; chr7:1084102 chr7:1160374~1165267:+ PAAD cis rs875971 0.522 rs1880556 ENSG00000226824.5 RP4-756H11.3 -10.1 1.13e-18 9.43e-15 -0.73 -0.63 Aortic root size; chr7:65967557 chr7:66654538~66669855:+ PAAD cis rs7301826 0.61 rs7961690 ENSG00000256250.1 RP11-989F5.1 10.1 1.13e-18 9.47e-15 0.71 0.63 Plasma plasminogen activator levels; chr12:130812335 chr12:130810606~130812438:+ PAAD cis rs2739330 0.796 rs1006771 ENSG00000273295.1 AP000350.5 10.1 1.13e-18 9.48e-15 0.82 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23901432~23907068:- PAAD cis rs2739330 0.652 rs2000469 ENSG00000273295.1 AP000350.5 10.09 1.18e-18 9.7e-15 0.86 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23901432~23907068:- PAAD cis rs875971 0.522 rs781144 ENSG00000226824.5 RP4-756H11.3 -10.09 1.19e-18 9.76e-15 -0.73 -0.63 Aortic root size; chr7:65975357 chr7:66654538~66669855:+ PAAD cis rs1153858 1 rs1719247 ENSG00000259520.4 CTD-2651B20.3 -10.09 1.19e-18 9.81e-15 -0.85 -0.63 Homoarginine levels; chr15:45328787 chr15:45251580~45279251:- PAAD cis rs2739330 0.828 rs5760102 ENSG00000225282.1 AP000350.6 10.07 1.34e-18 1.09e-14 0.85 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23926900~23929574:+ PAAD cis rs875971 1 rs1544549 ENSG00000226824.5 RP4-756H11.3 10.07 1.35e-18 1.1e-14 0.77 0.63 Aortic root size; chr7:66625676 chr7:66654538~66669855:+ PAAD cis rs62388641 0.802 rs13202504 ENSG00000272279.1 RP11-157J24.2 10.07 1.37e-18 1.12e-14 0.95 0.63 Daytime sleep phenotypes; chr6:1537640 chr6:1528364~1528911:- PAAD cis rs7301826 0.627 rs61937256 ENSG00000256250.1 RP11-989F5.1 10.06 1.42e-18 1.16e-14 0.71 0.63 Plasma plasminogen activator levels; chr12:130818100 chr12:130810606~130812438:+ PAAD cis rs997154 0.579 rs12889177 ENSG00000279656.1 RP11-298I3.6 -10.06 1.45e-18 1.18e-14 -0.85 -0.63 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:23022120 chr14:23023083~23024217:- PAAD cis rs875971 0.505 rs1167386 ENSG00000226824.5 RP4-756H11.3 10.06 1.48e-18 1.19e-14 0.72 0.63 Aortic root size; chr7:66048109 chr7:66654538~66669855:+ PAAD cis rs12439619 0.693 rs4778989 ENSG00000278603.1 RP13-608F4.5 10.05 1.52e-18 1.23e-14 0.95 0.63 Intelligence (multi-trait analysis); chr15:82276963 chr15:82472203~82472426:+ PAAD cis rs7301826 0.627 rs7978987 ENSG00000256250.1 RP11-989F5.1 10.04 1.6e-18 1.29e-14 0.71 0.63 Plasma plasminogen activator levels; chr12:130796949 chr12:130810606~130812438:+ PAAD cis rs875971 0.505 rs1723275 ENSG00000226824.5 RP4-756H11.3 10.04 1.66e-18 1.33e-14 0.72 0.63 Aortic root size; chr7:66039646 chr7:66654538~66669855:+ PAAD cis rs875971 0.505 rs2462573 ENSG00000226824.5 RP4-756H11.3 10.04 1.66e-18 1.33e-14 0.72 0.63 Aortic root size; chr7:66042405 chr7:66654538~66669855:+ PAAD cis rs875971 0.505 rs1167385 ENSG00000226824.5 RP4-756H11.3 10.04 1.66e-18 1.33e-14 0.72 0.63 Aortic root size; chr7:66048321 chr7:66654538~66669855:+ PAAD cis rs5769707 0.935 rs1109320 ENSG00000188511.11 C22orf34 10.04 1.68e-18 1.35e-14 0.59 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49595458 chr22:49414524~49657542:- PAAD cis rs5769707 0.839 rs73176988 ENSG00000188511.11 C22orf34 10.04 1.68e-18 1.35e-14 0.59 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49596001 chr22:49414524~49657542:- PAAD cis rs875971 0.505 rs6955582 ENSG00000226824.5 RP4-756H11.3 -10.04 1.68e-18 1.35e-14 -0.72 -0.63 Aortic root size; chr7:65966699 chr7:66654538~66669855:+ PAAD cis rs875971 0.54 rs4717275 ENSG00000226824.5 RP4-756H11.3 10.03 1.73e-18 1.39e-14 0.72 0.63 Aortic root size; chr7:65800193 chr7:66654538~66669855:+ PAAD cis rs11763147 1 rs11763147 ENSG00000226824.5 RP4-756H11.3 10.03 1.73e-18 1.39e-14 0.72 0.63 Corneal structure; chr7:65861834 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs10807697 ENSG00000226824.5 RP4-756H11.3 -10.03 1.73e-18 1.39e-14 -0.72 -0.63 Aortic root size; chr7:65951183 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs2008188 ENSG00000226824.5 RP4-756H11.3 -10.03 1.73e-18 1.39e-14 -0.72 -0.63 Aortic root size; chr7:65964026 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs4718285 ENSG00000226824.5 RP4-756H11.3 -10.03 1.74e-18 1.39e-14 -0.72 -0.63 Aortic root size; chr7:65827018 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs4502988 ENSG00000226824.5 RP4-756H11.3 -10.03 1.74e-18 1.39e-14 -0.72 -0.63 Aortic root size; chr7:65832759 chr7:66654538~66669855:+ PAAD cis rs17711722 0.64 rs13237956 ENSG00000226824.5 RP4-756H11.3 -10.03 1.74e-18 1.39e-14 -0.72 -0.63 Calcium levels; chr7:65853042 chr7:66654538~66669855:+ PAAD cis rs17711722 0.727 rs1880555 ENSG00000226824.5 RP4-756H11.3 -10.03 1.75e-18 1.4e-14 -0.72 -0.63 Calcium levels; chr7:65967580 chr7:66654538~66669855:+ PAAD cis rs17711722 0.701 rs781143 ENSG00000226824.5 RP4-756H11.3 -10.03 1.75e-18 1.4e-14 -0.72 -0.63 Calcium levels; chr7:65974892 chr7:66654538~66669855:+ PAAD cis rs17711722 0.701 rs781145 ENSG00000226824.5 RP4-756H11.3 -10.03 1.75e-18 1.4e-14 -0.72 -0.63 Calcium levels; chr7:65975383 chr7:66654538~66669855:+ PAAD cis rs17711722 0.727 rs2658585 ENSG00000226824.5 RP4-756H11.3 -10.03 1.75e-18 1.4e-14 -0.72 -0.63 Calcium levels; chr7:65996954 chr7:66654538~66669855:+ PAAD cis rs12439619 0.693 rs7165536 ENSG00000278603.1 RP13-608F4.5 10.03 1.76e-18 1.4e-14 0.96 0.63 Intelligence (multi-trait analysis); chr15:82273743 chr15:82472203~82472426:+ PAAD cis rs801193 0.844 rs732465 ENSG00000226824.5 RP4-756H11.3 -10.02 1.87e-18 1.48e-14 -0.71 -0.63 Aortic root size; chr7:66533463 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs1917563 ENSG00000226824.5 RP4-756H11.3 10.02 1.87e-18 1.49e-14 0.71 0.63 Aortic root size; chr7:65950660 chr7:66654538~66669855:+ PAAD cis rs7301826 0.56 rs12829294 ENSG00000256250.1 RP11-989F5.1 10.01 1.94e-18 1.54e-14 0.71 0.63 Plasma plasminogen activator levels; chr12:130825427 chr12:130810606~130812438:+ PAAD cis rs5769707 0.933 rs2157444 ENSG00000188511.11 C22orf34 10 2.08e-18 1.63e-14 0.6 0.63 Monocyte percentage of white cells;Monocyte count; chr22:49600644 chr22:49414524~49657542:- PAAD cis rs2739330 0.685 rs4822453 ENSG00000225282.1 AP000350.6 9.99 2.24e-18 1.75e-14 0.81 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23926900~23929574:+ PAAD cis rs950027 0.62 rs1617984 ENSG00000259520.4 CTD-2651B20.3 -9.99 2.26e-18 1.77e-14 -0.74 -0.63 Response to fenofibrate (adiponectin levels); chr15:45330464 chr15:45251580~45279251:- PAAD cis rs67383717 0.777 rs591486 ENSG00000175611.10 LINC00476 -9.99 2.29e-18 1.79e-14 -0.57 -0.63 Parkinson's disease (pesticide exposure interaction); chr9:95887764 chr9:95759231~95875977:- PAAD cis rs875971 0.54 rs1723268 ENSG00000226824.5 RP4-756H11.3 -9.97 2.54e-18 1.97e-14 -0.72 -0.63 Aortic root size; chr7:66008093 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs1701760 ENSG00000226824.5 RP4-756H11.3 -9.97 2.54e-18 1.97e-14 -0.72 -0.63 Aortic root size; chr7:66008701 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs2949690 ENSG00000226824.5 RP4-756H11.3 9.97 2.54e-18 1.97e-14 0.72 0.63 Aortic root size; chr7:66018255 chr7:66654538~66669855:+ PAAD cis rs7617773 0.962 rs6797587 ENSG00000229759.1 MRPS18AP1 -9.97 2.57e-18 1.99e-14 -0.69 -0.63 Coronary artery disease; chr3:48156124 chr3:48256350~48256938:- PAAD cis rs875971 0.522 rs9530 ENSG00000226824.5 RP4-756H11.3 -9.96 2.67e-18 2.06e-14 -0.72 -0.63 Aortic root size; chr7:65960907 chr7:66654538~66669855:+ PAAD cis rs7301826 0.651 rs12820597 ENSG00000256250.1 RP11-989F5.1 9.96 2.67e-18 2.07e-14 0.71 0.63 Plasma plasminogen activator levels; chr12:130795640 chr12:130810606~130812438:+ PAAD cis rs875971 0.522 rs4718286 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Aortic root size; chr7:65827777 chr7:66654538~66669855:+ PAAD cis rs17711722 0.585 rs6942660 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Calcium levels; chr7:65837419 chr7:66654538~66669855:+ PAAD cis rs875971 0.516 rs6945322 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Aortic root size; chr7:65871069 chr7:66654538~66669855:+ PAAD cis rs17711722 0.701 rs55773927 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Calcium levels; chr7:65872915 chr7:66654538~66669855:+ PAAD cis rs17711722 0.727 rs35850374 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Calcium levels; chr7:65892789 chr7:66654538~66669855:+ PAAD cis rs17711722 0.701 rs4467826 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Calcium levels; chr7:65903721 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs7784623 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Aortic root size; chr7:65930047 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs34973832 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Aortic root size; chr7:65931217 chr7:66654538~66669855:+ PAAD cis rs17711722 0.74 rs7809991 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Calcium levels; chr7:65941231 chr7:66654538~66669855:+ PAAD cis rs875971 0.522 rs6960048 ENSG00000226824.5 RP4-756H11.3 -9.96 2.71e-18 2.09e-14 -0.72 -0.63 Aortic root size; chr7:65943052 chr7:66654538~66669855:+ PAAD cis rs4423214 1 rs4944957 ENSG00000254682.1 RP11-660L16.2 -9.95 2.86e-18 2.19e-14 -0.86 -0.63 Vitamin D levels; chr11:71456989 chr11:71448674~71452157:+ PAAD cis rs7301826 0.58 rs61938969 ENSG00000256250.1 RP11-989F5.1 9.95 2.9e-18 2.22e-14 0.71 0.63 Plasma plasminogen activator levels; chr12:130831525 chr12:130810606~130812438:+ PAAD cis rs875971 0.522 rs709604 ENSG00000226824.5 RP4-756H11.3 9.94 3.08e-18 2.36e-14 0.71 0.63 Aortic root size; chr7:66032447 chr7:66654538~66669855:+ PAAD cis rs2739330 0.796 rs1006771 ENSG00000218537.1 MIF-AS1 9.93 3.17e-18 2.43e-14 0.85 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23894426~23898930:- PAAD cis rs17711722 1 rs17711722 ENSG00000226824.5 RP4-756H11.3 9.92 3.46e-18 2.64e-14 0.72 0.63 Calcium levels; chr7:65806210 chr7:66654538~66669855:+ PAAD cis rs17711722 0.675 rs6947132 ENSG00000226824.5 RP4-756H11.3 9.92 3.46e-18 2.64e-14 0.72 0.63 Calcium levels; chr7:65808508 chr7:66654538~66669855:+ PAAD cis rs7301826 0.627 rs34103763 ENSG00000256250.1 RP11-989F5.1 9.92 3.47e-18 2.65e-14 0.7 0.63 Plasma plasminogen activator levels; chr12:130805604 chr12:130810606~130812438:+ PAAD cis rs2486288 0.656 rs1706767 ENSG00000259520.4 CTD-2651B20.3 9.92 3.51e-18 2.67e-14 0.72 0.63 Glomerular filtration rate; chr15:45276901 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1153862 ENSG00000259520.4 CTD-2651B20.3 -9.89 4.07e-18 3.08e-14 -0.74 -0.63 Response to fenofibrate (adiponectin levels); chr15:45339670 chr15:45251580~45279251:- PAAD cis rs12130219 0.5 rs1552991 ENSG00000237975.5 FLG-AS1 -9.88 4.41e-18 3.33e-14 -0.67 -0.63 Inflammatory skin disease; chr1:152193402 chr1:152168125~152445456:+ PAAD cis rs55879323 1 rs55879323 ENSG00000237975.5 FLG-AS1 -9.88 4.41e-18 3.33e-14 -0.67 -0.63 Inflammatory skin disease; chr1:152196264 chr1:152168125~152445456:+ PAAD cis rs875971 1 rs2420168 ENSG00000226824.5 RP4-756H11.3 9.87 4.5e-18 3.39e-14 0.72 0.63 Aortic root size; chr7:66165644 chr7:66654538~66669855:+ PAAD cis rs7847628 0.765 rs7026635 ENSG00000226752.6 PSMD5-AS1 9.87 4.6e-18 3.46e-14 0.8 0.62 Birth weight; chr9:120787749 chr9:120824828~120854385:+ PAAD cis rs1153858 1 rs12593370 ENSG00000259520.4 CTD-2651B20.3 -9.86 4.78e-18 3.59e-14 -0.85 -0.62 Homoarginine levels; chr15:45325219 chr15:45251580~45279251:- PAAD cis rs875971 1 rs6961717 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66122550 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs2087647 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66128201 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6958484 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66134459 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs4718307 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66146001 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs7801282 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66148700 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs875971 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66152608 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs55962648 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66160764 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs11974219 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66182423 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1565531 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66198126 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6963646 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66220780 chr7:66654538~66669855:+ PAAD cis rs875971 0.965 rs28682868 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66224822 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs9986696 ENSG00000226824.5 RP4-756H11.3 9.86 4.92e-18 3.67e-14 0.72 0.62 Aortic root size; chr7:66239589 chr7:66654538~66669855:+ PAAD cis rs801193 0.591 rs2707839 ENSG00000226824.5 RP4-756H11.3 -9.86 4.97e-18 3.71e-14 -0.75 -0.62 Aortic root size; chr7:66728097 chr7:66654538~66669855:+ PAAD cis rs1153858 0.895 rs12593402 ENSG00000259520.4 CTD-2651B20.3 -9.85 5.15e-18 3.84e-14 -0.85 -0.62 Homoarginine levels; chr15:45325194 chr15:45251580~45279251:- PAAD cis rs1577917 0.876 rs12190735 ENSG00000203875.9 SNHG5 -9.85 5.28e-18 3.92e-14 -0.79 -0.62 Response to antipsychotic treatment; chr6:85976749 chr6:85660950~85678736:- PAAD cis rs2739330 0.703 rs5760112 ENSG00000225282.1 AP000350.6 9.85 5.29e-18 3.93e-14 0.79 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23926900~23929574:+ PAAD cis rs875971 1 rs11971949 ENSG00000226824.5 RP4-756H11.3 9.84 5.43e-18 4.01e-14 0.73 0.62 Aortic root size; chr7:66161027 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs11974264 ENSG00000226824.5 RP4-756H11.3 9.84 5.43e-18 4.01e-14 0.73 0.62 Aortic root size; chr7:66182595 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1540651 ENSG00000226824.5 RP4-756H11.3 9.84 5.43e-18 4.01e-14 0.73 0.62 Aortic root size; chr7:66185134 chr7:66654538~66669855:+ PAAD cis rs875971 0.898 rs6977501 ENSG00000226824.5 RP4-756H11.3 9.84 5.43e-18 4.01e-14 0.73 0.62 Aortic root size; chr7:66228355 chr7:66654538~66669855:+ PAAD cis rs875971 0.965 rs6971509 ENSG00000226824.5 RP4-756H11.3 9.84 5.43e-18 4.01e-14 0.73 0.62 Aortic root size; chr7:66249983 chr7:66654538~66669855:+ PAAD cis rs950027 0.62 rs1145076 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.5e-18 4.06e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45392310 chr15:45251580~45279251:- PAAD cis rs5769707 0.967 rs763126 ENSG00000188511.11 C22orf34 -9.84 5.62e-18 4.15e-14 -0.58 -0.62 Monocyte percentage of white cells;Monocyte count; chr22:49594926 chr22:49414524~49657542:- PAAD cis rs950027 0.62 rs2467862 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45351645 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1145093 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45357615 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1145089 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45359856 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1049518 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45361169 chr15:45251580~45279251:- PAAD cis rs950027 0.584 rs1145086 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45362129 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1153857 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45366897 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1153855 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45368560 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs2486274 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45374030 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1145080 ENSG00000259520.4 CTD-2651B20.3 -9.84 5.69e-18 4.19e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45389140 chr15:45251580~45279251:- PAAD cis rs4423214 1 rs2852853 ENSG00000254682.1 RP11-660L16.2 9.83 5.8e-18 4.27e-14 0.87 0.62 Vitamin D levels; chr11:71439171 chr11:71448674~71452157:+ PAAD cis rs875971 0.522 rs1617484 ENSG00000226824.5 RP4-756H11.3 -9.82 6.14e-18 4.46e-14 -0.72 -0.62 Aortic root size; chr7:65998108 chr7:66654538~66669855:+ PAAD cis rs950027 0.62 rs1719245 ENSG00000259520.4 CTD-2651B20.3 -9.82 6.33e-18 4.59e-14 -0.74 -0.62 Response to fenofibrate (adiponectin levels); chr15:45331584 chr15:45251580~45279251:- PAAD cis rs7617773 0.925 rs6442105 ENSG00000229759.1 MRPS18AP1 -9.8 6.94e-18 5.01e-14 -0.66 -0.62 Coronary artery disease; chr3:48140836 chr3:48256350~48256938:- PAAD cis rs950027 0.62 rs1153860 ENSG00000259520.4 CTD-2651B20.3 9.78 7.79e-18 5.58e-14 0.73 0.62 Response to fenofibrate (adiponectin levels); chr15:45344386 chr15:45251580~45279251:- PAAD cis rs2739330 0.791 rs4822458 ENSG00000225282.1 AP000350.6 9.78 7.97e-18 5.7e-14 0.81 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23926900~23929574:+ PAAD cis rs10256972 0.681 rs6979076 ENSG00000229043.2 AC091729.9 9.77 8.21e-18 5.86e-14 0.65 0.62 Endometriosis;Longevity; chr7:1076611 chr7:1160374~1165267:+ PAAD cis rs950027 0.62 rs1719246 ENSG00000259520.4 CTD-2651B20.3 -9.77 8.44e-18 5.97e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45333281 chr15:45251580~45279251:- PAAD cis rs875971 0.929 rs34406470 ENSG00000226824.5 RP4-756H11.3 -9.76 8.76e-18 6.18e-14 -0.74 -0.62 Aortic root size; chr7:66464969 chr7:66654538~66669855:+ PAAD cis rs4853012 0.887 rs7570950 ENSG00000217702.2 RP11-287D1.4 9.76 9.04e-18 6.21e-14 1.06 0.62 Gestational age at birth (maternal effect); chr2:74111815 chr2:74130583~74135395:+ PAAD cis rs7617773 1 rs6442108 ENSG00000229759.1 MRPS18AP1 -9.75 9.56e-18 6.55e-14 -0.66 -0.62 Coronary artery disease; chr3:48151469 chr3:48256350~48256938:- PAAD cis rs7617773 1 rs6442109 ENSG00000229759.1 MRPS18AP1 -9.75 9.56e-18 6.55e-14 -0.66 -0.62 Coronary artery disease; chr3:48151491 chr3:48256350~48256938:- PAAD cis rs7617773 1 rs11711766 ENSG00000229759.1 MRPS18AP1 -9.75 9.56e-18 6.55e-14 -0.66 -0.62 Coronary artery disease; chr3:48151680 chr3:48256350~48256938:- PAAD cis rs7617773 1 rs7617773 ENSG00000229759.1 MRPS18AP1 -9.75 9.56e-18 6.55e-14 -0.66 -0.62 Coronary artery disease; chr3:48152025 chr3:48256350~48256938:- PAAD cis rs7617773 0.963 rs6771787 ENSG00000229759.1 MRPS18AP1 -9.75 9.56e-18 6.55e-14 -0.66 -0.62 Coronary artery disease; chr3:48152752 chr3:48256350~48256938:- PAAD cis rs7617773 1 rs6771889 ENSG00000229759.1 MRPS18AP1 -9.75 9.56e-18 6.55e-14 -0.66 -0.62 Coronary artery disease; chr3:48152836 chr3:48256350~48256938:- PAAD cis rs7617773 0.823 rs9839446 ENSG00000229759.1 MRPS18AP1 -9.75 9.56e-18 6.55e-14 -0.66 -0.62 Coronary artery disease; chr3:48153176 chr3:48256350~48256938:- PAAD cis rs7617773 0.823 rs9839447 ENSG00000229759.1 MRPS18AP1 -9.75 9.56e-18 6.55e-14 -0.66 -0.62 Coronary artery disease; chr3:48153177 chr3:48256350~48256938:- PAAD cis rs950027 0.62 rs1426932 ENSG00000259520.4 CTD-2651B20.3 -9.74 1.03e-17 7.04e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45395058 chr15:45251580~45279251:- PAAD cis rs950027 0.596 rs2467853 ENSG00000259520.4 CTD-2651B20.3 -9.74 1.03e-17 7.04e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45406595 chr15:45251580~45279251:- PAAD cis rs950027 0.595 rs2486288 ENSG00000259520.4 CTD-2651B20.3 -9.74 1.03e-17 7.04e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45420141 chr15:45251580~45279251:- PAAD cis rs2486288 0.539 rs2433601 ENSG00000259520.4 CTD-2651B20.3 -9.74 1.03e-17 7.04e-14 -0.73 -0.62 Glomerular filtration rate; chr15:45424227 chr15:45251580~45279251:- PAAD cis rs977987 0.735 rs11149831 ENSG00000261783.1 RP11-252K23.2 -9.74 1.04e-17 7.09e-14 -0.8 -0.62 Dupuytren's disease; chr16:75417563 chr16:75379818~75381260:- PAAD cis rs950027 0.62 rs35861938 ENSG00000259520.4 CTD-2651B20.3 -9.73 1.1e-17 7.5e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45345145 chr15:45251580~45279251:- PAAD cis rs950027 0.596 rs2467865 ENSG00000259520.4 CTD-2651B20.3 -9.73 1.1e-17 7.5e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45346109 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs2461700 ENSG00000259520.4 CTD-2651B20.3 -9.73 1.1e-17 7.5e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45348429 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs2453533 ENSG00000259520.4 CTD-2651B20.3 -9.73 1.1e-17 7.5e-14 -0.73 -0.62 Response to fenofibrate (adiponectin levels); chr15:45349027 chr15:45251580~45279251:- PAAD cis rs1153858 0.943 rs12439575 ENSG00000259520.4 CTD-2651B20.3 -9.72 1.17e-17 7.93e-14 -0.82 -0.62 Homoarginine levels; chr15:45392618 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs9783731 ENSG00000259520.4 CTD-2651B20.3 9.71 1.19e-17 8.05e-14 0.82 0.62 Homoarginine levels; chr15:45350686 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs16942000 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45340805 chr15:45251580~45279251:- PAAD cis rs1153858 0.945 rs7182300 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45342730 chr15:45251580~45279251:- PAAD cis rs1153858 0.887 rs7171163 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45344197 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12439274 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45344469 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs56669689 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45345531 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs56806728 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45345616 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4775906 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45346096 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs7179743 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45346133 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4775907 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45346449 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs7163720 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45347176 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs7167900 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45347273 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12591058 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45347974 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs7169587 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45348181 chr15:45251580~45279251:- PAAD cis rs1153858 0.943 rs28605551 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45349522 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4775909 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.05e-14 -0.82 -0.62 Homoarginine levels; chr15:45350844 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1145084 ENSG00000259520.4 CTD-2651B20.3 -9.71 1.19e-17 8.08e-14 -0.72 -0.62 Response to fenofibrate (adiponectin levels); chr15:45383242 chr15:45251580~45279251:- PAAD cis rs801193 0.742 rs9969300 ENSG00000226824.5 RP4-756H11.3 9.71 1.21e-17 8.15e-14 0.71 0.62 Aortic root size; chr7:66316659 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1167612 ENSG00000226824.5 RP4-756H11.3 9.7 1.28e-17 8.6e-14 0.72 0.62 Aortic root size; chr7:66102989 chr7:66654538~66669855:+ PAAD cis rs7617773 1 rs9832957 ENSG00000229759.1 MRPS18AP1 -9.7 1.28e-17 8.6e-14 -0.66 -0.62 Coronary artery disease; chr3:48143776 chr3:48256350~48256938:- PAAD cis rs875971 1 rs6945843 ENSG00000226824.5 RP4-756H11.3 9.69 1.37e-17 9.2e-14 0.71 0.62 Aortic root size; chr7:66269796 chr7:66654538~66669855:+ PAAD cis rs875971 0.54 rs736270 ENSG00000226824.5 RP4-756H11.3 -9.69 1.39e-17 9.35e-14 -0.72 -0.62 Aortic root size; chr7:65963835 chr7:66654538~66669855:+ PAAD cis rs7208859 0.673 rs79541516 ENSG00000263531.1 RP13-753N3.1 9.68 1.43e-17 9.63e-14 1.24 0.62 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913565 chr17:30863921~30864940:- PAAD cis rs9326248 0.581 rs10892076 ENSG00000254851.1 RP11-109L13.1 -9.68 1.46e-17 9.78e-14 -0.76 -0.62 Blood protein levels; chr11:117118220 chr11:117135528~117138582:+ PAAD cis rs1577917 0.687 rs34618171 ENSG00000203875.9 SNHG5 -9.67 1.52e-17 1.02e-13 -0.83 -0.62 Response to antipsychotic treatment; chr6:86101447 chr6:85660950~85678736:- PAAD cis rs61524473 1 rs61524473 ENSG00000259520.4 CTD-2651B20.3 -9.66 1.67e-17 1.12e-13 -0.82 -0.62 Metabolite levels (small molecules and protein measures); chr15:45354085 chr15:45251580~45279251:- PAAD cis rs2283792 0.718 rs239918 ENSG00000224086.5 LL22NC03-86G7.1 -9.65 1.73e-17 1.15e-13 -0.62 -0.62 Multiple sclerosis; chr22:21959457 chr22:21938293~21977632:+ PAAD cis rs11155671 0.53 rs2342770 ENSG00000216906.2 RP11-350J20.9 9.65 1.76e-17 1.17e-13 0.83 0.62 Testicular germ cell tumor; chr6:149895549 chr6:149904243~149906418:+ PAAD cis rs2739330 0.761 rs5760176 ENSG00000218537.1 MIF-AS1 -9.65 1.8e-17 1.2e-13 -0.85 -0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23894426~23898930:- PAAD cis rs4423214 1 rs12422045 ENSG00000254682.1 RP11-660L16.2 9.64 1.83e-17 1.22e-13 0.86 0.62 Vitamin D levels; chr11:71443774 chr11:71448674~71452157:+ PAAD cis rs7617773 0.963 rs6800730 ENSG00000229759.1 MRPS18AP1 9.64 1.86e-17 1.24e-13 0.65 0.62 Coronary artery disease; chr3:48132720 chr3:48256350~48256938:- PAAD cis rs2739330 0.731 rs5751792 ENSG00000218537.1 MIF-AS1 9.64 1.88e-17 1.25e-13 0.85 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23894426~23898930:- PAAD cis rs801193 0.548 rs2659904 ENSG00000226824.5 RP4-756H11.3 -9.63 1.93e-17 1.28e-13 -0.74 -0.62 Aortic root size; chr7:66713615 chr7:66654538~66669855:+ PAAD cis rs2739330 0.732 rs5760175 ENSG00000218537.1 MIF-AS1 9.63 1.97e-17 1.31e-13 0.85 0.62 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23894426~23898930:- PAAD cis rs4423214 1 rs909217 ENSG00000254682.1 RP11-660L16.2 9.62 2.05e-17 1.36e-13 0.86 0.62 Vitamin D levels; chr11:71435531 chr11:71448674~71452157:+ PAAD cis rs977987 0.735 rs166013 ENSG00000261783.1 RP11-252K23.2 9.6 2.32e-17 1.53e-13 0.78 0.61 Dupuytren's disease; chr16:75400248 chr16:75379818~75381260:- PAAD cis rs2739330 0.734 rs2000467 ENSG00000218537.1 MIF-AS1 -9.6 2.36e-17 1.56e-13 -0.87 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23894426~23898930:- PAAD cis rs950027 0.62 rs1346267 ENSG00000259520.4 CTD-2651B20.3 -9.6 2.4e-17 1.59e-13 -0.73 -0.61 Response to fenofibrate (adiponectin levels); chr15:45398791 chr15:45251580~45279251:- PAAD cis rs1577917 0.687 rs13197828 ENSG00000203875.9 SNHG5 -9.59 2.52e-17 1.66e-13 -0.83 -0.61 Response to antipsychotic treatment; chr6:86095912 chr6:85660950~85678736:- PAAD cis rs2739330 0.76 rs5751760 ENSG00000225282.1 AP000350.6 9.59 2.57e-17 1.7e-13 0.77 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23926900~23929574:+ PAAD cis rs875971 0.54 rs781152 ENSG00000226824.5 RP4-756H11.3 -9.58 2.6e-17 1.71e-13 -0.71 -0.61 Aortic root size; chr7:66014585 chr7:66654538~66669855:+ PAAD cis rs17711722 0.727 rs781151 ENSG00000226824.5 RP4-756H11.3 -9.58 2.6e-17 1.71e-13 -0.71 -0.61 Calcium levels; chr7:66014891 chr7:66654538~66669855:+ PAAD cis rs1153858 1 rs56850226 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45340920 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4774577 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45352487 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs11070453 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45352956 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4774578 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45353853 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12593230 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45354770 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs10444821 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45355038 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs72623915 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45355235 chr15:45251580~45279251:- PAAD cis rs1153858 0.725 rs74572151 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45355328 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs66714503 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45355840 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs67831559 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45357109 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs2066090 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45357820 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs61365925 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45358113 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs16952714 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45358160 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12101539 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45358468 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs8032904 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45359111 chr15:45251580~45279251:- PAAD cis rs1153858 0.943 rs8038342 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45359339 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4774579 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45359605 chr15:45251580~45279251:- PAAD cis rs1153858 0.943 rs4774580 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45359888 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4271549 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45360532 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4627277 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45360570 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1049503 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45361509 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12595087 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45363034 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs3759899 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45363705 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1890565 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45371101 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12594857 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45374980 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs7164602 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45379127 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12441971 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45379759 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1346268 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45380831 chr15:45251580~45279251:- PAAD cis rs1153858 0.943 rs67045941 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45384813 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs67744121 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45385039 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs16942568 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45385192 chr15:45251580~45279251:- PAAD cis rs1153858 0.943 rs11070454 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45388054 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs9788780 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45393289 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs7181167 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45394038 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs11070456 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45394637 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs11070457 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45394745 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs3809472 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45402120 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1820518 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45402381 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1365610 ENSG00000259520.4 CTD-2651B20.3 -9.58 2.61e-17 1.71e-13 -0.82 -0.61 Homoarginine levels; chr15:45402412 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1554521 ENSG00000259520.4 CTD-2651B20.3 9.58 2.61e-17 1.71e-13 0.82 0.61 Homoarginine levels; chr15:45371991 chr15:45251580~45279251:- PAAD cis rs2283792 0.687 rs381849 ENSG00000224086.5 LL22NC03-86G7.1 -9.57 2.79e-17 1.82e-13 -0.62 -0.61 Multiple sclerosis; chr22:21951341 chr22:21938293~21977632:+ PAAD cis rs1153858 1 rs66528868 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45376349 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs7494956 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45376367 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12437840 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45376857 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12437887 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45376896 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs2114501 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45378118 chr15:45251580~45279251:- PAAD cis rs1153858 0.887 rs7164139 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45378653 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs67461176 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45384621 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs66939267 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45384704 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4775937 ENSG00000259520.4 CTD-2651B20.3 -9.57 2.89e-17 1.88e-13 -0.82 -0.61 Homoarginine levels; chr15:45386416 chr15:45251580~45279251:- PAAD cis rs4423214 1 rs12797951 ENSG00000254682.1 RP11-660L16.2 -9.56 2.93e-17 1.9e-13 -0.84 -0.61 Vitamin D levels; chr11:71432220 chr11:71448674~71452157:+ PAAD cis rs2283792 0.812 rs94194 ENSG00000224086.5 LL22NC03-86G7.1 -9.56 2.98e-17 1.93e-13 -0.65 -0.61 Multiple sclerosis; chr22:21933937 chr22:21938293~21977632:+ PAAD cis rs2283792 0.812 rs5995269 ENSG00000224086.5 LL22NC03-86G7.1 -9.56 2.98e-17 1.93e-13 -0.65 -0.61 Multiple sclerosis; chr22:21935025 chr22:21938293~21977632:+ PAAD cis rs875971 1 rs3981131 ENSG00000226824.5 RP4-756H11.3 -9.56 3.06e-17 1.99e-13 -0.72 -0.61 Aortic root size; chr7:66486690 chr7:66654538~66669855:+ PAAD cis rs2455601 0.638 rs2742484 ENSG00000254860.4 TMEM9B-AS1 9.56 3.08e-17 2e-13 0.79 0.61 Schizophrenia; chr11:8966536 chr11:8964675~8977527:+ PAAD cis rs2455601 0.638 rs2248245 ENSG00000254860.4 TMEM9B-AS1 9.56 3.08e-17 2e-13 0.79 0.61 Schizophrenia; chr11:8966803 chr11:8964675~8977527:+ PAAD cis rs11673344 0.563 rs256744 ENSG00000226686.6 LINC01535 -9.56 3.09e-17 2e-13 -0.75 -0.61 Obesity-related traits; chr19:37364586 chr19:37251912~37265535:+ PAAD cis rs7208859 0.573 rs73267829 ENSG00000263531.1 RP13-753N3.1 9.55 3.11e-17 2.01e-13 1.15 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30676921 chr17:30863921~30864940:- PAAD cis rs7208859 0.562 rs11650923 ENSG00000263531.1 RP13-753N3.1 9.55 3.11e-17 2.01e-13 1.15 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30681149 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs56378576 ENSG00000263531.1 RP13-753N3.1 9.55 3.11e-17 2.01e-13 1.15 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30683102 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs35916850 ENSG00000263531.1 RP13-753N3.1 9.55 3.11e-17 2.01e-13 1.15 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30684155 chr17:30863921~30864940:- PAAD cis rs62388641 1 rs62388641 ENSG00000272279.1 RP11-157J24.2 9.55 3.12e-17 2.02e-13 0.9 0.61 Daytime sleep phenotypes; chr6:1539849 chr6:1528364~1528911:- PAAD cis rs2739330 0.857 rs9608229 ENSG00000225282.1 AP000350.6 9.55 3.12e-17 2.02e-13 0.82 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:24002918 chr22:23926900~23929574:+ PAAD cis rs1153858 1 rs59889118 ENSG00000259520.4 CTD-2651B20.3 -9.55 3.27e-17 2.11e-13 -0.84 -0.61 Homoarginine levels; chr15:45326532 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs2056493 ENSG00000259520.4 CTD-2651B20.3 -9.55 3.28e-17 2.12e-13 -0.82 -0.61 Homoarginine levels; chr15:45356074 chr15:45251580~45279251:- PAAD cis rs950027 0.62 rs1145077 ENSG00000259520.4 CTD-2651B20.3 9.54 3.37e-17 2.17e-13 0.73 0.61 Response to fenofibrate (adiponectin levels); chr15:45391597 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs2467864 ENSG00000259520.4 CTD-2651B20.3 9.54 3.4e-17 2.19e-13 0.82 0.61 Homoarginine levels; chr15:45348900 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs7169818 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45347993 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs2453541 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45353180 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs2461702 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45355229 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1145091 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45357798 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1049508 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45361394 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1145085 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45365606 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1288775 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45369480 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1145081 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45387469 chr15:45251580~45279251:- PAAD cis rs1153858 0.943 rs1145079 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45389563 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1346266 ENSG00000259520.4 CTD-2651B20.3 -9.54 3.4e-17 2.19e-13 -0.82 -0.61 Homoarginine levels; chr15:45402318 chr15:45251580~45279251:- PAAD cis rs9326248 0.648 rs11216257 ENSG00000254851.1 RP11-109L13.1 -9.54 3.4e-17 2.19e-13 -0.93 -0.61 Blood protein levels; chr11:117061845 chr11:117135528~117138582:+ PAAD cis rs2283792 0.812 rs240066 ENSG00000224086.5 LL22NC03-86G7.1 9.54 3.48e-17 2.22e-13 0.65 0.61 Multiple sclerosis; chr22:21938623 chr22:21938293~21977632:+ PAAD cis rs1153858 1 rs4775911 ENSG00000259520.4 CTD-2651B20.3 9.53 3.58e-17 2.29e-13 0.81 0.61 Homoarginine levels; chr15:45357589 chr15:45251580~45279251:- PAAD cis rs17507216 1 rs3850610 ENSG00000278603.1 RP13-608F4.5 -9.52 3.86e-17 2.46e-13 -0.93 -0.61 Excessive daytime sleepiness; chr15:82552642 chr15:82472203~82472426:+ PAAD cis rs7301826 0.603 rs7975825 ENSG00000256250.1 RP11-989F5.1 -9.52 3.91e-17 2.5e-13 -0.69 -0.61 Plasma plasminogen activator levels; chr12:130803899 chr12:130810606~130812438:+ PAAD cis rs12130219 0.5 rs4845743 ENSG00000237975.5 FLG-AS1 -9.51 3.99e-17 2.54e-13 -0.64 -0.61 Inflammatory skin disease; chr1:152211673 chr1:152168125~152445456:+ PAAD cis rs7208859 0.673 rs9895684 ENSG00000263531.1 RP13-753N3.1 9.51 4.18e-17 2.66e-13 1.23 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30915582 chr17:30863921~30864940:- PAAD cis rs6597981 0.592 rs10902218 ENSG00000279672.1 CMB9-55F22.1 -9.5 4.21e-17 2.67e-13 -0.59 -0.61 Breast cancer; chr11:743813 chr11:779617~780755:+ PAAD cis rs1153858 1 rs7402650 ENSG00000259520.4 CTD-2651B20.3 -9.5 4.31e-17 2.73e-13 -0.81 -0.61 Homoarginine levels; chr15:45409697 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs8042786 ENSG00000259520.4 CTD-2651B20.3 -9.5 4.31e-17 2.73e-13 -0.81 -0.61 Homoarginine levels; chr15:45411341 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs12440038 ENSG00000259520.4 CTD-2651B20.3 -9.5 4.31e-17 2.73e-13 -0.81 -0.61 Homoarginine levels; chr15:45414541 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs60476496 ENSG00000259520.4 CTD-2651B20.3 -9.5 4.31e-17 2.73e-13 -0.81 -0.61 Homoarginine levels; chr15:45421603 chr15:45251580~45279251:- PAAD cis rs9399135 0.967 rs1590975 ENSG00000232876.1 CTA-212D2.2 -9.5 4.42e-17 2.79e-13 -0.69 -0.61 Red blood cell count; chr6:135030950 chr6:135055033~135060550:+ PAAD cis rs1153858 0.832 rs1145078 ENSG00000259520.4 CTD-2651B20.3 -9.5 4.43e-17 2.8e-13 -0.82 -0.61 Homoarginine levels; chr15:45390079 chr15:45251580~45279251:- PAAD cis rs2455601 0.671 rs2568091 ENSG00000254860.4 TMEM9B-AS1 9.49 4.53e-17 2.86e-13 0.79 0.61 Schizophrenia; chr11:8964501 chr11:8964675~8977527:+ PAAD cis rs2739330 0.731 rs4822450 ENSG00000225282.1 AP000350.6 9.49 4.7e-17 2.96e-13 0.75 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23926900~23929574:+ PAAD cis rs1153858 1 rs4395020 ENSG00000259520.4 CTD-2651B20.3 -9.49 4.72e-17 2.98e-13 -0.81 -0.61 Homoarginine levels; chr15:45360691 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1153849 ENSG00000259520.4 CTD-2651B20.3 -9.48 4.9e-17 3.09e-13 -0.82 -0.61 Homoarginine levels; chr15:45403497 chr15:45251580~45279251:- PAAD cis rs1153858 0.945 rs2467854 ENSG00000259520.4 CTD-2651B20.3 -9.48 4.9e-17 3.09e-13 -0.82 -0.61 Homoarginine levels; chr15:45409399 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs2461701 ENSG00000259520.4 CTD-2651B20.3 -9.48 4.9e-17 3.09e-13 -0.82 -0.61 Homoarginine levels; chr15:45411193 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs2467858 ENSG00000259520.4 CTD-2651B20.3 -9.48 4.9e-17 3.09e-13 -0.82 -0.61 Homoarginine levels; chr15:45419294 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs10519022 ENSG00000259520.4 CTD-2651B20.3 9.47 5.05e-17 3.18e-13 0.81 0.61 Homoarginine levels; chr15:45371486 chr15:45251580~45279251:- PAAD cis rs7617773 0.963 rs12495221 ENSG00000229759.1 MRPS18AP1 -9.47 5.18e-17 3.26e-13 -0.65 -0.61 Coronary artery disease; chr3:48137688 chr3:48256350~48256938:- PAAD cis rs6597981 0.592 rs28625355 ENSG00000279672.1 CMB9-55F22.1 9.46 5.38e-17 3.38e-13 0.6 0.61 Breast cancer; chr11:736334 chr11:779617~780755:+ PAAD cis rs7208859 0.673 rs75142521 ENSG00000263531.1 RP13-753N3.1 9.46 5.67e-17 3.56e-13 1.2 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913519 chr17:30863921~30864940:- PAAD cis rs11673344 0.642 rs12462708 ENSG00000226686.6 LINC01535 -9.45 5.78e-17 3.62e-13 -0.73 -0.61 Obesity-related traits; chr19:37306676 chr19:37251912~37265535:+ PAAD cis rs11673344 0.642 rs12462487 ENSG00000226686.6 LINC01535 9.45 5.78e-17 3.62e-13 0.73 0.61 Obesity-related traits; chr19:37311211 chr19:37251912~37265535:+ PAAD cis rs1891275 0.513 rs1539041 ENSG00000228701.1 TNKS2-AS1 -9.45 5.85e-17 3.66e-13 -0.82 -0.61 Intelligence (multi-trait analysis); chr10:91817384 chr10:91782839~91798291:- PAAD cis rs1153858 1 rs2467863 ENSG00000259520.4 CTD-2651B20.3 -9.45 5.87e-17 3.67e-13 -0.82 -0.61 Homoarginine levels; chr15:45349682 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs1145074 ENSG00000259520.4 CTD-2651B20.3 -9.45 5.94e-17 3.71e-13 -0.81 -0.61 Homoarginine levels; chr15:45411626 chr15:45251580~45279251:- PAAD cis rs11118620 0.535 rs1389750 ENSG00000272823.1 RP11-295M18.6 9.44 6.21e-17 3.88e-13 0.73 0.61 Heart failure; chr1:220866829 chr1:220828676~220829211:- PAAD cis rs11155671 0.53 rs6557133 ENSG00000216906.2 RP11-350J20.9 9.43 6.49e-17 4.05e-13 0.82 0.61 Testicular germ cell tumor; chr6:149874248 chr6:149904243~149906418:+ PAAD cis rs1153858 1 rs1153858 ENSG00000259520.4 CTD-2651B20.3 9.43 6.5e-17 4.05e-13 0.81 0.61 Homoarginine levels; chr15:45360505 chr15:45251580~45279251:- PAAD cis rs875971 0.929 rs4122249 ENSG00000226824.5 RP4-756H11.3 -9.43 6.5e-17 4.05e-13 -0.72 -0.61 Aortic root size; chr7:66455949 chr7:66654538~66669855:+ PAAD cis rs11673344 0.642 rs73025481 ENSG00000226686.6 LINC01535 9.43 6.52e-17 4.07e-13 0.73 0.61 Obesity-related traits; chr19:37346437 chr19:37251912~37265535:+ PAAD cis rs2739330 0.652 rs2000469 ENSG00000218537.1 MIF-AS1 9.43 6.6e-17 4.11e-13 0.87 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23894426~23898930:- PAAD cis rs11673344 0.562 rs256740 ENSG00000226686.6 LINC01535 -9.43 6.62e-17 4.12e-13 -0.74 -0.61 Obesity-related traits; chr19:37365451 chr19:37251912~37265535:+ PAAD cis rs875971 0.964 rs12668936 ENSG00000226824.5 RP4-756H11.3 -9.43 6.65e-17 4.14e-13 -0.71 -0.61 Aortic root size; chr7:66449417 chr7:66654538~66669855:+ PAAD cis rs10256972 0.706 rs12701969 ENSG00000229043.2 AC091729.9 -9.43 6.69e-17 4.16e-13 -0.65 -0.61 Endometriosis;Longevity; chr7:1082213 chr7:1160374~1165267:+ PAAD cis rs1153858 1 rs1618874 ENSG00000259520.4 CTD-2651B20.3 -9.43 6.76e-17 4.2e-13 -0.83 -0.61 Homoarginine levels; chr15:45330588 chr15:45251580~45279251:- PAAD cis rs7301826 0.651 rs7956851 ENSG00000256250.1 RP11-989F5.1 -9.42 7.01e-17 4.35e-13 -0.69 -0.61 Plasma plasminogen activator levels; chr12:130834554 chr12:130810606~130812438:+ PAAD cis rs1153858 1 rs1613559 ENSG00000259520.4 CTD-2651B20.3 -9.42 7.17e-17 4.44e-13 -0.83 -0.61 Homoarginine levels; chr15:45329918 chr15:45251580~45279251:- PAAD cis rs875971 0.965 rs697968 ENSG00000226824.5 RP4-756H11.3 9.42 7.2e-17 4.46e-13 0.7 0.61 Aortic root size; chr7:66070046 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1167411 ENSG00000226824.5 RP4-756H11.3 9.42 7.2e-17 4.46e-13 0.7 0.61 Aortic root size; chr7:66074277 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1183245 ENSG00000226824.5 RP4-756H11.3 9.42 7.2e-17 4.46e-13 0.7 0.61 Aortic root size; chr7:66076198 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1144895 ENSG00000226824.5 RP4-756H11.3 9.42 7.2e-17 4.46e-13 0.7 0.61 Aortic root size; chr7:66076320 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1144894 ENSG00000226824.5 RP4-756H11.3 9.42 7.2e-17 4.46e-13 0.7 0.61 Aortic root size; chr7:66077907 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs4718349 ENSG00000226824.5 RP4-756H11.3 -9.41 7.23e-17 4.47e-13 -0.71 -0.61 Aortic root size; chr7:66444024 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6946143 ENSG00000226824.5 RP4-756H11.3 -9.41 7.53e-17 4.66e-13 -0.69 -0.61 Aortic root size; chr7:66114735 chr7:66654538~66669855:+ PAAD cis rs801193 0.66 rs1962050 ENSG00000226824.5 RP4-756H11.3 9.4 7.74e-17 4.78e-13 0.74 0.61 Aortic root size; chr7:66775021 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs2077593 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66427543 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6460296 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66430152 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs4717292 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66430611 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs2420591 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66447394 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs10755833 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66448930 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs1833495 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66456608 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs6945019 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66457471 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs6945032 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66457499 chr7:66654538~66669855:+ PAAD cis rs875971 0.929 rs12673810 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66458866 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs35149210 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66464938 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs2042133 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66466935 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs2161065 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66467918 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs6961155 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66468308 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs7789768 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66473993 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs12698521 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66474502 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1363055 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66478288 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs9691480 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66479319 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs7789554 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66481051 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs4717300 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66482393 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs1974769 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66485627 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs6460300 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66487937 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs7803416 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66489212 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs1981799 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66490572 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs2277911 ENSG00000226824.5 RP4-756H11.3 -9.4 7.87e-17 4.84e-13 -0.71 -0.61 Aortic root size; chr7:66493638 chr7:66654538~66669855:+ PAAD cis rs4423214 1 rs11233746 ENSG00000254682.1 RP11-660L16.2 9.4 7.91e-17 4.86e-13 0.84 0.61 Vitamin D levels; chr11:71460394 chr11:71448674~71452157:+ PAAD cis rs7396835 0.5 rs5092 ENSG00000254851.1 RP11-109L13.1 -9.39 8.32e-17 5.1e-13 -0.9 -0.61 Quantitative traits; chr11:116822748 chr11:117135528~117138582:+ PAAD cis rs7301826 0.58 rs12821464 ENSG00000256250.1 RP11-989F5.1 9.38 9.11e-17 5.57e-13 0.72 0.61 Plasma plasminogen activator levels; chr12:130838174 chr12:130810606~130812438:+ PAAD cis rs9399135 0.967 rs7741515 ENSG00000232876.1 CTA-212D2.2 9.38 9.13e-17 5.58e-13 0.67 0.61 Red blood cell count; chr6:135053230 chr6:135055033~135060550:+ PAAD cis rs7208859 0.673 rs12949860 ENSG00000263531.1 RP13-753N3.1 9.37 9.19e-17 5.61e-13 1.2 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896014 chr17:30863921~30864940:- PAAD cis rs7617773 0.963 rs6766754 ENSG00000229759.1 MRPS18AP1 -9.37 9.49e-17 5.77e-13 -0.64 -0.61 Coronary artery disease; chr3:48141099 chr3:48256350~48256938:- PAAD cis rs7617773 0.832 rs6775114 ENSG00000229759.1 MRPS18AP1 -9.37 9.49e-17 5.77e-13 -0.64 -0.61 Coronary artery disease; chr3:48141130 chr3:48256350~48256938:- PAAD cis rs1153858 1 rs7171577 ENSG00000259520.4 CTD-2651B20.3 -9.37 9.5e-17 5.78e-13 -0.8 -0.61 Homoarginine levels; chr15:45335781 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs10519021 ENSG00000259520.4 CTD-2651B20.3 -9.37 9.5e-17 5.78e-13 -0.8 -0.61 Homoarginine levels; chr15:45339597 chr15:45251580~45279251:- PAAD cis rs875971 0.895 rs7788984 ENSG00000226824.5 RP4-756H11.3 -9.37 9.54e-17 5.79e-13 -0.72 -0.61 Aortic root size; chr7:66450629 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1981798 ENSG00000226824.5 RP4-756H11.3 -9.37 9.54e-17 5.79e-13 -0.72 -0.61 Aortic root size; chr7:66489916 chr7:66654538~66669855:+ PAAD cis rs4423214 1 rs7928249 ENSG00000254682.1 RP11-660L16.2 9.36 9.76e-17 5.91e-13 0.85 0.6 Vitamin D levels; chr11:71450017 chr11:71448674~71452157:+ PAAD cis rs2455601 0.638 rs2742485 ENSG00000254860.4 TMEM9B-AS1 9.36 9.78e-17 5.92e-13 0.79 0.6 Schizophrenia; chr11:8965240 chr11:8964675~8977527:+ PAAD cis rs875971 0.895 rs4145009 ENSG00000226824.5 RP4-756H11.3 9.35 1.05e-16 6.32e-13 0.74 0.6 Aortic root size; chr7:66261628 chr7:66654538~66669855:+ PAAD cis rs7208859 0.673 rs9911989 ENSG00000263531.1 RP13-753N3.1 -9.35 1.06e-16 6.36e-13 -1.2 -0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910684 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs9905827 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Body mass index; chr17:30865150 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11652358 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30878462 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11656845 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879146 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9891179 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881142 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9891413 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881191 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73263776 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30884313 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11650271 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30886925 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73263785 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887790 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs55904046 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888373 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9889968 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30893110 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs61348930 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30894745 chr17:30863921~30864940:- PAAD cis rs7208859 0.614 rs28758251 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896294 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9899943 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896907 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11080138 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30897524 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73265612 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30898965 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs2433 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30899210 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11658435 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30901543 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73265624 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905048 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs2269915 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906326 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs2269916 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906745 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11649765 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906870 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs12103759 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908669 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs59029591 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908728 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73265633 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30909288 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9913782 ENSG00000263531.1 RP13-753N3.1 9.35 1.06e-16 6.36e-13 1.2 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910366 chr17:30863921~30864940:- PAAD cis rs10256972 0.706 rs12701970 ENSG00000229043.2 AC091729.9 -9.35 1.08e-16 6.45e-13 -0.64 -0.6 Endometriosis;Longevity; chr7:1082322 chr7:1160374~1165267:+ PAAD cis rs1153858 1 rs11852800 ENSG00000259520.4 CTD-2651B20.3 9.34 1.11e-16 6.61e-13 0.8 0.6 Homoarginine levels; chr15:45346933 chr15:45251580~45279251:- PAAD cis rs875971 1 rs2220626 ENSG00000226824.5 RP4-756H11.3 9.34 1.14e-16 6.79e-13 0.7 0.6 Aortic root size; chr7:66081075 chr7:66654538~66669855:+ PAAD cis rs875971 0.964 rs697969 ENSG00000226824.5 RP4-756H11.3 9.34 1.14e-16 6.79e-13 0.7 0.6 Aortic root size; chr7:66093491 chr7:66654538~66669855:+ PAAD cis rs875971 1 rs1182882 ENSG00000226824.5 RP4-756H11.3 9.34 1.14e-16 6.79e-13 0.7 0.6 Aortic root size; chr7:66097076 chr7:66654538~66669855:+ PAAD cis rs4423214 1 rs28364617 ENSG00000254682.1 RP11-660L16.2 9.34 1.15e-16 6.85e-13 0.85 0.6 Vitamin D levels; chr11:71448718 chr11:71448674~71452157:+ PAAD cis rs875971 1 rs697970 ENSG00000226824.5 RP4-756H11.3 9.33 1.2e-16 7.18e-13 0.71 0.6 Aortic root size; chr7:66095065 chr7:66654538~66669855:+ PAAD cis rs2739330 0.76 rs5760095 ENSG00000225282.1 AP000350.6 9.33 1.22e-16 7.26e-13 0.78 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23926900~23929574:+ PAAD cis rs1153858 1 rs4625670 ENSG00000259520.4 CTD-2651B20.3 -9.33 1.22e-16 7.3e-13 -0.81 -0.6 Homoarginine levels; chr15:45360728 chr15:45251580~45279251:- PAAD cis rs1153858 1 rs4534782 ENSG00000259520.4 CTD-2651B20.3 -9.33 1.22e-16 7.3e-13 -0.81 -0.6 Homoarginine levels; chr15:45360735 chr15:45251580~45279251:- PAAD cis rs1799949 1 rs2037075 ENSG00000198496.9 NBR2 -9.32 1.26e-16 7.46e-13 -0.58 -0.6 Menopause (age at onset); chr17:43153809 chr17:43125610~43153671:+ PAAD cis rs9326248 0.581 rs7120515 ENSG00000254851.1 RP11-109L13.1 -9.32 1.26e-16 7.46e-13 -0.73 -0.6 Blood protein levels; chr11:117121210 chr11:117135528~117138582:+ PAAD cis rs7396835 0.537 rs10892035 ENSG00000254851.1 RP11-109L13.1 -9.32 1.26e-16 7.5e-13 -0.89 -0.6 Quantitative traits; chr11:116824222 chr11:117135528~117138582:+ PAAD cis rs875971 0.862 rs12537823 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66255897 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778734 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66349862 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778724 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66364304 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778686 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66370923 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778684 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66371416 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778680 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66375427 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs11769079 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66377141 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs1695820 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66379576 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs778715 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66384222 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs809025 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66384832 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778702 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66399848 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs1643375 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66407690 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6962717 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66418748 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6460302 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66495270 chr7:66654538~66669855:+ PAAD cis rs875971 0.798 rs6460304 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66499741 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6945775 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66503987 chr7:66654538~66669855:+ PAAD cis rs875971 0.798 rs57739047 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66507579 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs6950137 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66511623 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs11763189 ENSG00000226824.5 RP4-756H11.3 -9.31 1.34e-16 7.89e-13 -0.73 -0.6 Aortic root size; chr7:66518542 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10282433 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66256452 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10276077 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66263424 chr7:66654538~66669855:+ PAAD cis rs875971 0.825 rs4587224 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66271195 chr7:66654538~66669855:+ PAAD cis rs875971 0.792 rs6971752 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66272999 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10950033 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66274686 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs11760844 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66274896 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs4149461 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66279745 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs4236208 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66284091 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10261398 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66285177 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10224872 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66294786 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs949930 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66301835 chr7:66654538~66669855:+ PAAD cis rs875971 0.825 rs1000464 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66312922 chr7:66654538~66669855:+ PAAD cis rs875971 0.928 rs2036263 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66335210 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10240949 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66339430 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs7782704 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66340379 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6460290 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66344119 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6959268 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66347979 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778720 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66381288 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs11773628 ENSG00000226824.5 RP4-756H11.3 9.31 1.34e-16 7.89e-13 0.73 0.6 Aortic root size; chr7:66517644 chr7:66654538~66669855:+ PAAD cis rs1153858 1 rs11858495 ENSG00000259520.4 CTD-2651B20.3 9.31 1.36e-16 7.98e-13 0.79 0.6 Homoarginine levels; chr15:45345464 chr15:45251580~45279251:- PAAD cis rs9545047 0.613 rs79774056 ENSG00000227676.3 LINC01068 9.31 1.38e-16 8.1e-13 0.79 0.6 Schizophrenia; chr13:79421486 chr13:79566727~79571436:+ PAAD cis rs875971 0.862 rs709596 ENSG00000226824.5 RP4-756H11.3 -9.31 1.39e-16 8.15e-13 -0.72 -0.6 Aortic root size; chr7:66360926 chr7:66654538~66669855:+ PAAD cis rs7208859 0.614 rs9914534 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30875646 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs4131618 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30877783 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11658344 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30880727 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9900144 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881371 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs11656121 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887025 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11650973 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887027 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73263788 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889472 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs56085216 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30890216 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11650305 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902343 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11654914 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902406 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9914271 ENSG00000263531.1 RP13-753N3.1 9.3 1.42e-16 8.27e-13 1.18 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905607 chr17:30863921~30864940:- PAAD cis rs2739330 0.734 rs2000467 ENSG00000225282.1 AP000350.6 -9.3 1.42e-16 8.27e-13 -0.82 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23926900~23929574:+ PAAD cis rs11673344 0.642 rs55926714 ENSG00000226686.6 LINC01535 9.3 1.48e-16 8.63e-13 0.73 0.6 Obesity-related traits; chr19:37307974 chr19:37251912~37265535:+ PAAD cis rs9326248 0.53 rs11216316 ENSG00000254851.1 RP11-109L13.1 9.29 1.5e-16 8.73e-13 1.01 0.6 Blood protein levels; chr11:117210784 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs236918 ENSG00000254851.1 RP11-109L13.1 9.29 1.5e-16 8.73e-13 1.01 0.6 Blood protein levels; chr11:117220893 chr11:117135528~117138582:+ PAAD cis rs7208859 0.623 rs383436 ENSG00000263531.1 RP13-753N3.1 9.29 1.51e-16 8.79e-13 1.12 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30632161 chr17:30863921~30864940:- PAAD cis rs17826219 0.714 rs11650821 ENSG00000263531.1 RP13-753N3.1 9.29 1.51e-16 8.79e-13 1.12 0.6 Body mass index; chr17:30641132 chr17:30863921~30864940:- PAAD cis rs12439619 0.705 rs17354185 ENSG00000278603.1 RP13-608F4.5 -9.29 1.51e-16 8.8e-13 -1 -0.6 Intelligence (multi-trait analysis); chr15:82133829 chr15:82472203~82472426:+ PAAD cis rs7617773 0.925 rs7374376 ENSG00000229759.1 MRPS18AP1 -9.29 1.54e-16 8.97e-13 -0.64 -0.6 Coronary artery disease; chr3:48131197 chr3:48256350~48256938:- PAAD cis rs9399135 0.967 rs12661423 ENSG00000232876.1 CTA-212D2.2 -9.29 1.54e-16 8.97e-13 -0.69 -0.6 Red blood cell count; chr6:135028432 chr6:135055033~135060550:+ PAAD cis rs2739330 0.76 rs1007888 ENSG00000225282.1 AP000350.6 9.29 1.56e-16 9.04e-13 0.74 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23926900~23929574:+ PAAD cis rs507080 0.501 rs625735 ENSG00000255239.1 AP002954.6 9.29 1.57e-16 9.13e-13 0.72 0.6 Serum metabolite levels; chr11:118704710 chr11:118688039~118690600:- PAAD cis rs11673344 0.642 rs11083420 ENSG00000226686.6 LINC01535 9.28 1.58e-16 9.15e-13 0.73 0.6 Obesity-related traits; chr19:37317901 chr19:37251912~37265535:+ PAAD cis rs9399135 0.967 rs9321481 ENSG00000232876.1 CTA-212D2.2 9.28 1.58e-16 9.15e-13 0.68 0.6 Red blood cell count; chr6:135031510 chr6:135055033~135060550:+ PAAD cis rs7617773 0.963 rs9822496 ENSG00000229759.1 MRPS18AP1 9.28 1.59e-16 9.19e-13 0.64 0.6 Coronary artery disease; chr3:48139843 chr3:48256350~48256938:- PAAD cis rs7617773 1 rs12496784 ENSG00000229759.1 MRPS18AP1 -9.28 1.59e-16 9.19e-13 -0.64 -0.6 Coronary artery disease; chr3:48144777 chr3:48256350~48256938:- PAAD cis rs9399135 1 rs1014021 ENSG00000232876.1 CTA-212D2.2 9.28 1.59e-16 9.21e-13 0.69 0.6 Red blood cell count; chr6:135013462 chr6:135055033~135060550:+ PAAD cis rs2283792 0.745 rs5756306 ENSG00000224086.5 LL22NC03-86G7.1 9.28 1.64e-16 9.47e-13 0.61 0.6 Multiple sclerosis; chr22:21978846 chr22:21938293~21977632:+ PAAD cis rs875971 0.83 rs12673450 ENSG00000226824.5 RP4-756H11.3 -9.27 1.68e-16 9.7e-13 -0.73 -0.6 Aortic root size; chr7:66544233 chr7:66654538~66669855:+ PAAD cis rs7115242 0.8 rs7131536 ENSG00000254851.1 RP11-109L13.1 -9.27 1.72e-16 9.9e-13 -1.03 -0.6 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117128730 chr11:117135528~117138582:+ PAAD cis rs11673344 0.555 rs502546 ENSG00000226686.6 LINC01535 -9.27 1.77e-16 1.02e-12 -0.73 -0.6 Obesity-related traits; chr19:37361788 chr19:37251912~37265535:+ PAAD cis rs11673344 0.642 rs55755939 ENSG00000226686.6 LINC01535 9.27 1.77e-16 1.02e-12 0.73 0.6 Obesity-related traits; chr19:37353723 chr19:37251912~37265535:+ PAAD cis rs875971 0.767 rs1643394 ENSG00000226824.5 RP4-756H11.3 -9.24 2.02e-16 1.15e-12 -0.73 -0.6 Aortic root size; chr7:66371107 chr7:66654538~66669855:+ PAAD cis rs4423214 1 rs4944946 ENSG00000254682.1 RP11-660L16.2 9.24 2.03e-16 1.16e-12 0.83 0.6 Vitamin D levels; chr11:71448383 chr11:71448674~71452157:+ PAAD cis rs9545047 1 rs9574422 ENSG00000227676.3 LINC01068 9.23 2.15e-16 1.22e-12 0.77 0.6 Schizophrenia; chr13:79415246 chr13:79566727~79571436:+ PAAD cis rs7208859 0.673 rs78799101 ENSG00000263531.1 RP13-753N3.1 9.23 2.24e-16 1.27e-12 1.19 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888142 chr17:30863921~30864940:- PAAD cis rs11155671 0.53 rs9397398 ENSG00000216906.2 RP11-350J20.9 9.23 2.25e-16 1.28e-12 0.8 0.6 Testicular germ cell tumor; chr6:149872467 chr6:149904243~149906418:+ PAAD cis rs4423214 1 rs12792306 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71455946 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12785878 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71456403 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs4944955 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71456631 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs4944956 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71456719 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs4944958 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71457027 chr11:71448674~71452157:+ PAAD cis rs4423214 0.959 rs12793224 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71457664 chr11:71448674~71452157:+ PAAD cis rs4423214 0.959 rs12794668 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71457669 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs2276360 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71458501 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs2276361 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71458602 chr11:71448674~71452157:+ PAAD cis rs4423214 0.819 rs7938885 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71458997 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12790010 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71459607 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12806844 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71459724 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12808368 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71459771 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12790558 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71459859 chr11:71448674~71452157:+ PAAD cis rs4423214 0.959 rs12800438 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71459957 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12807718 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71460124 chr11:71448674~71452157:+ PAAD cis rs4423214 0.959 rs11233747 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71460596 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs4423214 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71462208 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs11600569 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71462701 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs2276362 ENSG00000254682.1 RP11-660L16.2 9.22 2.26e-16 1.28e-12 0.84 0.6 Vitamin D levels; chr11:71463406 chr11:71448674~71452157:+ PAAD cis rs2739330 0.76 rs5751761 ENSG00000225282.1 AP000350.6 -9.22 2.27e-16 1.29e-12 -0.78 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23926900~23929574:+ PAAD cis rs858239 0.614 rs10229956 ENSG00000230658.1 KLHL7-AS1 -9.22 2.29e-16 1.29e-12 -0.73 -0.6 Cerebrospinal fluid biomarker levels; chr7:23363317 chr7:23101228~23105703:- PAAD cis rs9399135 0.967 rs6919862 ENSG00000232876.1 CTA-212D2.2 -9.22 2.32e-16 1.31e-12 -0.68 -0.6 Red blood cell count; chr6:135031305 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs10872427 ENSG00000232876.1 CTA-212D2.2 -9.22 2.32e-16 1.31e-12 -0.68 -0.6 Red blood cell count; chr6:135032314 chr6:135055033~135060550:+ PAAD cis rs2455601 0.638 rs2568092 ENSG00000254860.4 TMEM9B-AS1 -9.22 2.33e-16 1.32e-12 -0.74 -0.6 Schizophrenia; chr11:8965891 chr11:8964675~8977527:+ PAAD cis rs9399135 0.967 rs4451151 ENSG00000232876.1 CTA-212D2.2 -9.22 2.36e-16 1.34e-12 -0.69 -0.6 Red blood cell count; chr6:134989408 chr6:135055033~135060550:+ PAAD cis rs7617773 0.963 rs12493256 ENSG00000229759.1 MRPS18AP1 -9.22 2.37e-16 1.34e-12 -0.64 -0.6 Coronary artery disease; chr3:48135257 chr3:48256350~48256938:- PAAD cis rs7617773 0.963 rs12494304 ENSG00000229759.1 MRPS18AP1 -9.22 2.37e-16 1.34e-12 -0.64 -0.6 Coronary artery disease; chr3:48136539 chr3:48256350~48256938:- PAAD cis rs4423214 0.921 rs12807827 ENSG00000254682.1 RP11-660L16.2 9.21 2.5e-16 1.41e-12 0.83 0.6 Vitamin D levels; chr11:71492744 chr11:71448674~71452157:+ PAAD cis rs62388641 0.636 rs35412353 ENSG00000272279.1 RP11-157J24.2 9.21 2.52e-16 1.42e-12 0.89 0.6 Daytime sleep phenotypes; chr6:1529209 chr6:1528364~1528911:- PAAD cis rs62388641 0.636 rs62388638 ENSG00000272279.1 RP11-157J24.2 9.21 2.52e-16 1.42e-12 0.89 0.6 Daytime sleep phenotypes; chr6:1529224 chr6:1528364~1528911:- PAAD cis rs875971 0.861 rs801215 ENSG00000226824.5 RP4-756H11.3 9.21 2.52e-16 1.42e-12 0.73 0.6 Aortic root size; chr7:66546951 chr7:66654538~66669855:+ PAAD cis rs9326248 0.569 rs473172 ENSG00000254851.1 RP11-109L13.1 -9.2 2.6e-16 1.46e-12 -1.04 -0.6 Blood protein levels; chr11:116937254 chr11:117135528~117138582:+ PAAD cis rs9545047 1 rs2484345 ENSG00000227676.3 LINC01068 -9.2 2.61e-16 1.47e-12 -0.77 -0.6 Schizophrenia; chr13:79427913 chr13:79566727~79571436:+ PAAD cis rs7208859 0.614 rs73265646 ENSG00000263531.1 RP13-753N3.1 9.19 2.71e-16 1.52e-12 1.22 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917005 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs58908911 ENSG00000263531.1 RP13-753N3.1 9.19 2.71e-16 1.52e-12 1.22 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917540 chr17:30863921~30864940:- PAAD cis rs9399135 1 rs6569988 ENSG00000232876.1 CTA-212D2.2 -9.19 2.73e-16 1.53e-12 -0.69 -0.6 Red blood cell count; chr6:135031165 chr6:135055033~135060550:+ PAAD cis rs9322193 0.567 rs7742692 ENSG00000216906.2 RP11-350J20.9 9.19 2.74e-16 1.54e-12 0.79 0.6 Lung cancer; chr6:149892363 chr6:149904243~149906418:+ PAAD cis rs3091242 0.933 rs34933589 ENSG00000224183.1 SDHDP6 9.18 2.96e-16 1.64e-12 0.78 0.6 Erythrocyte sedimentation rate; chr1:25461707 chr1:25294164~25294643:- PAAD cis rs875971 0.825 rs6951503 ENSG00000226824.5 RP4-756H11.3 9.18 3.01e-16 1.67e-12 0.74 0.6 Aortic root size; chr7:66253949 chr7:66654538~66669855:+ PAAD cis rs2739330 0.652 rs2000469 ENSG00000225282.1 AP000350.6 9.17 3.15e-16 1.74e-12 0.81 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23926900~23929574:+ PAAD cis rs11155671 0.53 rs9371215 ENSG00000216906.2 RP11-350J20.9 9.17 3.15e-16 1.74e-12 0.8 0.6 Testicular germ cell tumor; chr6:149873162 chr6:149904243~149906418:+ PAAD cis rs1799949 0.931 rs34410138 ENSG00000198496.9 NBR2 -9.17 3.22e-16 1.77e-12 -0.58 -0.6 Menopause (age at onset); chr17:43127753 chr17:43125610~43153671:+ PAAD cis rs875971 0.964 rs160635 ENSG00000226824.5 RP4-756H11.3 -9.16 3.24e-16 1.79e-12 -0.69 -0.6 Aortic root size; chr7:66063931 chr7:66654538~66669855:+ PAAD cis rs9326248 0.581 rs7106437 ENSG00000254851.1 RP11-109L13.1 -9.16 3.28e-16 1.81e-12 -0.73 -0.6 Blood protein levels; chr11:117121360 chr11:117135528~117138582:+ PAAD cis rs507080 0.501 rs516503 ENSG00000255239.1 AP002954.6 9.16 3.28e-16 1.81e-12 0.72 0.6 Serum metabolite levels; chr11:118709639 chr11:118688039~118690600:- PAAD cis rs9545047 0.967 rs9574402 ENSG00000227676.3 LINC01068 9.16 3.28e-16 1.81e-12 0.76 0.6 Schizophrenia; chr13:79298392 chr13:79566727~79571436:+ PAAD cis rs875971 0.862 rs10256544 ENSG00000226824.5 RP4-756H11.3 -9.16 3.32e-16 1.83e-12 -0.73 -0.6 Aortic root size; chr7:66210141 chr7:66654538~66669855:+ PAAD cis rs875971 0.79 rs10257911 ENSG00000226824.5 RP4-756H11.3 9.16 3.41e-16 1.87e-12 0.73 0.6 Aortic root size; chr7:66278783 chr7:66654538~66669855:+ PAAD cis rs9399135 0.967 rs6902954 ENSG00000232876.1 CTA-212D2.2 -9.15 3.43e-16 1.88e-12 -0.69 -0.6 Red blood cell count; chr6:134992856 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs59329760 ENSG00000232876.1 CTA-212D2.2 -9.15 3.43e-16 1.89e-12 -0.69 -0.6 Red blood cell count; chr6:135021299 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs13218642 ENSG00000232876.1 CTA-212D2.2 -9.15 3.49e-16 1.92e-12 -0.69 -0.6 Red blood cell count; chr6:134988802 chr6:135055033~135060550:+ PAAD cis rs3091242 0.836 rs34997029 ENSG00000224183.1 SDHDP6 9.15 3.56e-16 1.95e-12 0.77 0.6 Erythrocyte sedimentation rate; chr1:25457332 chr1:25294164~25294643:- PAAD cis rs7208859 0.623 rs170051 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587135 chr17:30863921~30864940:- PAAD cis rs7208859 0.51 rs216402 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30590108 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs216434 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595317 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11651857 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30599344 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs216439 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30600866 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs216442 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604179 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs216445 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606558 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs216446 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606700 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs79607958 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607530 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs75136574 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607531 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs77544470 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607532 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs609063 ENSG00000263531.1 RP13-753N3.1 9.15 3.57e-16 1.96e-12 1.1 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624495 chr17:30863921~30864940:- PAAD cis rs9399135 0.967 rs4895436 ENSG00000232876.1 CTA-212D2.2 -9.14 3.69e-16 2.02e-12 -0.68 -0.6 Red blood cell count; chr6:134973863 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs4896122 ENSG00000232876.1 CTA-212D2.2 -9.14 3.69e-16 2.02e-12 -0.68 -0.6 Red blood cell count; chr6:134973943 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9376075 ENSG00000232876.1 CTA-212D2.2 -9.14 3.69e-16 2.02e-12 -0.68 -0.6 Red blood cell count; chr6:134975825 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs4273704 ENSG00000232876.1 CTA-212D2.2 -9.14 3.69e-16 2.02e-12 -0.68 -0.6 Red blood cell count; chr6:134976382 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs4637662 ENSG00000232876.1 CTA-212D2.2 -9.14 3.69e-16 2.02e-12 -0.68 -0.6 Red blood cell count; chr6:134977020 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs4376365 ENSG00000232876.1 CTA-212D2.2 -9.14 3.69e-16 2.02e-12 -0.68 -0.6 Red blood cell count; chr6:134986602 chr6:135055033~135060550:+ PAAD cis rs4423214 0.879 rs12803256 ENSG00000254682.1 RP11-660L16.2 9.14 3.77e-16 2.06e-12 0.83 0.6 Vitamin D levels; chr11:71421822 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs2002063 ENSG00000254682.1 RP11-660L16.2 9.14 3.81e-16 2.08e-12 0.84 0.6 Vitamin D levels; chr11:71452430 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs11600860 ENSG00000254682.1 RP11-660L16.2 9.14 3.81e-16 2.08e-12 0.84 0.6 Vitamin D levels; chr11:71452973 chr11:71448674~71452157:+ PAAD cis rs4423214 0.959 rs11606611 ENSG00000254682.1 RP11-660L16.2 9.14 3.81e-16 2.08e-12 0.84 0.6 Vitamin D levels; chr11:71453000 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs11606612 ENSG00000254682.1 RP11-660L16.2 9.14 3.81e-16 2.08e-12 0.84 0.6 Vitamin D levels; chr11:71453001 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs11606631 ENSG00000254682.1 RP11-660L16.2 9.14 3.81e-16 2.08e-12 0.84 0.6 Vitamin D levels; chr11:71453075 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12789751 ENSG00000254682.1 RP11-660L16.2 9.14 3.81e-16 2.08e-12 0.84 0.6 Vitamin D levels; chr11:71453425 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12791871 ENSG00000254682.1 RP11-660L16.2 9.14 3.81e-16 2.08e-12 0.84 0.6 Vitamin D levels; chr11:71453498 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs7944926 ENSG00000254682.1 RP11-660L16.2 9.14 3.81e-16 2.08e-12 0.84 0.6 Vitamin D levels; chr11:71454579 chr11:71448674~71452157:+ PAAD cis rs1153858 0.943 rs7402632 ENSG00000259520.4 CTD-2651B20.3 -9.13 3.96e-16 2.15e-12 -0.81 -0.6 Homoarginine levels; chr15:45409715 chr15:45251580~45279251:- PAAD cis rs12439619 0.693 rs17269819 ENSG00000278603.1 RP13-608F4.5 9.13 3.98e-16 2.16e-12 0.89 0.6 Intelligence (multi-trait analysis); chr15:82174660 chr15:82472203~82472426:+ PAAD cis rs12439619 0.693 rs8034801 ENSG00000278603.1 RP13-608F4.5 9.13 3.98e-16 2.16e-12 0.89 0.6 Intelligence (multi-trait analysis); chr15:82183996 chr15:82472203~82472426:+ PAAD cis rs9399135 0.967 rs3756799 ENSG00000232876.1 CTA-212D2.2 -9.13 3.99e-16 2.16e-12 -0.67 -0.6 Red blood cell count; chr6:135019873 chr6:135055033~135060550:+ PAAD cis rs9399135 0.838 rs4896126 ENSG00000232876.1 CTA-212D2.2 -9.13 3.99e-16 2.16e-12 -0.67 -0.6 Red blood cell count; chr6:135021648 chr6:135055033~135060550:+ PAAD cis rs9402673 0.517 rs978036 ENSG00000232876.1 CTA-212D2.2 -9.13 3.99e-16 2.16e-12 -0.67 -0.6 High light scatter reticulocyte count;Reticulocyte count; chr6:135021765 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs1023179 ENSG00000232876.1 CTA-212D2.2 -9.13 3.99e-16 2.16e-12 -0.67 -0.6 Red blood cell count; chr6:135022691 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9376082 ENSG00000232876.1 CTA-212D2.2 -9.13 3.99e-16 2.16e-12 -0.67 -0.6 Red blood cell count; chr6:135025251 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs952674 ENSG00000232876.1 CTA-212D2.2 -9.13 3.99e-16 2.16e-12 -0.67 -0.6 Red blood cell count; chr6:135028019 chr6:135055033~135060550:+ PAAD cis rs875971 0.862 rs1875057 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66266868 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6960446 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66268272 chr7:66654538~66669855:+ PAAD cis rs875971 0.789 rs10260426 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66271055 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs7796162 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66280771 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs2901152 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66300017 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10263690 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66301466 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10250544 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66301574 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs12531677 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66304099 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs7798630 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66306492 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs11984115 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66308872 chr7:66654538~66669855:+ PAAD cis rs875971 0.755 rs10228885 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66315542 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs3893216 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66325720 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6958294 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66329809 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs2088655 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66330724 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs10447522 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66331087 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs2088653 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66343621 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6460293 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66345205 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778736 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66348861 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs778711 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66386670 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs1083554 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66387354 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778707 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66392040 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778705 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66396128 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs778697 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66405439 chr7:66654538~66669855:+ PAAD cis rs875971 0.798 rs7789615 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66413674 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6978028 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66421313 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6947339 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66423483 chr7:66654538~66669855:+ PAAD cis rs875971 0.798 rs12698522 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66502354 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs28714531 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66503250 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs12698526 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66504118 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs13232191 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66521661 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs35378740 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66522725 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10950043 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66523623 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs17747530 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66529742 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs13226170 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66534311 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs2420611 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66534333 chr7:66654538~66669855:+ PAAD cis rs875971 0.767 rs61348003 ENSG00000226824.5 RP4-756H11.3 -9.13 4.02e-16 2.16e-12 -0.72 -0.6 Aortic root size; chr7:66540947 chr7:66654538~66669855:+ PAAD cis rs875971 0.756 rs2901210 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66552518 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs13536 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66554203 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs801209 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66554403 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs801206 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66556979 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs801204 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66557934 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs801203 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66558025 chr7:66654538~66669855:+ PAAD cis rs875971 0.825 rs801202 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66558942 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs801195 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66561128 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs801194 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66563508 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs2024192 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66576460 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6955837 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66578155 chr7:66654538~66669855:+ PAAD cis rs875971 0.825 rs10281499 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66583979 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs4718377 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66584691 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10278014 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66586277 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs1968126 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66592017 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6460306 ENSG00000226824.5 RP4-756H11.3 9.13 4.02e-16 2.16e-12 0.72 0.6 Aortic root size; chr7:66595806 chr7:66654538~66669855:+ PAAD cis rs2455601 0.574 rs2568094 ENSG00000254860.4 TMEM9B-AS1 9.13 4.02e-16 2.16e-12 0.78 0.6 Schizophrenia; chr11:8970671 chr11:8964675~8977527:+ PAAD cis rs9399135 0.967 rs6910530 ENSG00000232876.1 CTA-212D2.2 -9.13 4.05e-16 2.17e-12 -0.69 -0.6 Red blood cell count; chr6:135011632 chr6:135055033~135060550:+ PAAD cis rs916888 0.779 rs199498 ENSG00000214401.4 KANSL1-AS1 9.12 4.11e-16 2.21e-12 0.84 0.59 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46193576~46196723:+ PAAD cis rs9545047 0.967 rs9545097 ENSG00000227676.3 LINC01068 9.12 4.17e-16 2.24e-12 0.77 0.59 Schizophrenia; chr13:79387352 chr13:79566727~79571436:+ PAAD cis rs9545047 1 rs9574418 ENSG00000227676.3 LINC01068 9.12 4.17e-16 2.24e-12 0.77 0.59 Schizophrenia; chr13:79393874 chr13:79566727~79571436:+ PAAD cis rs9545047 0.967 rs9593396 ENSG00000227676.3 LINC01068 9.12 4.17e-16 2.24e-12 0.77 0.59 Schizophrenia; chr13:79396164 chr13:79566727~79571436:+ PAAD cis rs9545047 1 rs9545101 ENSG00000227676.3 LINC01068 9.12 4.17e-16 2.24e-12 0.77 0.59 Schizophrenia; chr13:79399806 chr13:79566727~79571436:+ PAAD cis rs875971 0.862 rs6971059 ENSG00000226824.5 RP4-756H11.3 9.12 4.33e-16 2.32e-12 0.73 0.59 Aortic root size; chr7:66602045 chr7:66654538~66669855:+ PAAD cis rs875971 0.755 rs76288834 ENSG00000226824.5 RP4-756H11.3 9.12 4.33e-16 2.32e-12 0.73 0.59 Aortic root size; chr7:66604815 chr7:66654538~66669855:+ PAAD cis rs875971 0.789 rs7808013 ENSG00000226824.5 RP4-756H11.3 9.12 4.33e-16 2.32e-12 0.73 0.59 Aortic root size; chr7:66606209 chr7:66654538~66669855:+ PAAD cis rs875971 0.825 rs7384021 ENSG00000226824.5 RP4-756H11.3 9.12 4.33e-16 2.32e-12 0.73 0.59 Aortic root size; chr7:66612917 chr7:66654538~66669855:+ PAAD cis rs875971 0.825 rs66981195 ENSG00000226824.5 RP4-756H11.3 9.12 4.33e-16 2.32e-12 0.73 0.59 Aortic root size; chr7:66614048 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs3926380 ENSG00000226824.5 RP4-756H11.3 9.12 4.33e-16 2.32e-12 0.73 0.59 Aortic root size; chr7:66615658 chr7:66654538~66669855:+ PAAD cis rs875971 0.825 rs1860472 ENSG00000226824.5 RP4-756H11.3 9.12 4.33e-16 2.32e-12 0.73 0.59 Aortic root size; chr7:66617736 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs427973 ENSG00000226824.5 RP4-756H11.3 -9.11 4.43e-16 2.37e-12 -0.68 -0.59 Aortic root size; chr7:66061661 chr7:66654538~66669855:+ PAAD cis rs875971 0.793 rs460678 ENSG00000226824.5 RP4-756H11.3 -9.11 4.43e-16 2.37e-12 -0.68 -0.59 Aortic root size; chr7:66062213 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs13226966 ENSG00000226824.5 RP4-756H11.3 -9.11 4.47e-16 2.39e-12 -0.72 -0.59 Aortic root size; chr7:66768636 chr7:66654538~66669855:+ PAAD cis rs7208859 0.673 rs28588622 ENSG00000263531.1 RP13-753N3.1 9.11 4.5e-16 2.41e-12 1.19 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30918681 chr17:30863921~30864940:- PAAD cis rs9399135 0.967 rs4388304 ENSG00000232876.1 CTA-212D2.2 -9.1 4.75e-16 2.54e-12 -0.69 -0.59 Red blood cell count; chr6:134988459 chr6:135055033~135060550:+ PAAD cis rs801193 0.569 rs2659908 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66695835 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs2659907 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66699045 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs7782587 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66701485 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs4717315 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66713338 chr7:66654538~66669855:+ PAAD cis rs801193 0.527 rs2707837 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66716086 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs2707824 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66724256 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs2659893 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66735006 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs2659892 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66735318 chr7:66654538~66669855:+ PAAD cis rs801193 0.548 rs2659891 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66736127 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs2707847 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66737884 chr7:66654538~66669855:+ PAAD cis rs801193 0.548 rs7805152 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66744266 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs11772819 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66752983 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs11761542 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66753209 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs7800620 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66758701 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs10950050 ENSG00000226824.5 RP4-756H11.3 -9.1 4.78e-16 2.54e-12 -0.72 -0.59 Aortic root size; chr7:66774601 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10274883 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66651104 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs881285 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66654433 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs3846973 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66655048 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs2013908 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66656082 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs13242290 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66656898 chr7:66654538~66669855:+ PAAD cis rs801193 0.548 rs2109297 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66657397 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs6978178 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66658097 chr7:66654538~66669855:+ PAAD cis rs801193 0.591 rs721717 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66665305 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs6951302 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66667525 chr7:66654538~66669855:+ PAAD cis rs801193 0.591 rs4506088 ENSG00000226824.5 RP4-756H11.3 9.1 4.78e-16 2.54e-12 0.72 0.59 Aortic root size; chr7:66670470 chr7:66654538~66669855:+ PAAD cis rs2739330 0.587 rs4820571 ENSG00000273295.1 AP000350.5 9.09 4.91e-16 2.61e-12 0.79 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23901432~23907068:- PAAD cis rs17507216 1 rs17158413 ENSG00000278603.1 RP13-608F4.5 9.09 5.12e-16 2.72e-12 0.96 0.59 Excessive daytime sleepiness; chr15:82566658 chr15:82472203~82472426:+ PAAD cis rs9399135 0.816 rs4134030 ENSG00000232876.1 CTA-212D2.2 -9.09 5.13e-16 2.72e-12 -0.67 -0.59 Red blood cell count; chr6:135032956 chr6:135055033~135060550:+ PAAD cis rs875971 0.895 rs12698520 ENSG00000226824.5 RP4-756H11.3 -9.08 5.37e-16 2.85e-12 -0.71 -0.59 Aortic root size; chr7:66453720 chr7:66654538~66669855:+ PAAD cis rs9545047 1 rs9545047 ENSG00000227676.3 LINC01068 9.07 5.58e-16 2.95e-12 0.77 0.59 Schizophrenia; chr13:79285321 chr13:79566727~79571436:+ PAAD cis rs9399135 0.967 rs4896121 ENSG00000232876.1 CTA-212D2.2 -9.07 5.58e-16 2.95e-12 -0.68 -0.59 Red blood cell count; chr6:134972507 chr6:135055033~135060550:+ PAAD cis rs1799949 1 rs8176318 ENSG00000198496.9 NBR2 -9.07 5.7e-16 3.01e-12 -0.57 -0.59 Menopause (age at onset); chr17:43045257 chr17:43125610~43153671:+ PAAD cis rs875971 0.862 rs1612452 ENSG00000226824.5 RP4-756H11.3 9.07 5.76e-16 3.04e-12 0.72 0.59 Aortic root size; chr7:66108909 chr7:66654538~66669855:+ PAAD cis rs9399135 0.967 rs4896125 ENSG00000232876.1 CTA-212D2.2 -9.07 5.78e-16 3.05e-12 -0.67 -0.59 Red blood cell count; chr6:135021431 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs949547 ENSG00000232876.1 CTA-212D2.2 -9.07 5.78e-16 3.05e-12 -0.67 -0.59 Red blood cell count; chr6:135022361 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs2150680 ENSG00000232876.1 CTA-212D2.2 -9.07 5.78e-16 3.05e-12 -0.67 -0.59 Red blood cell count; chr6:135025993 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs11756988 ENSG00000232876.1 CTA-212D2.2 -9.07 5.78e-16 3.05e-12 -0.67 -0.59 Red blood cell count; chr6:135026457 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs11754783 ENSG00000232876.1 CTA-212D2.2 -9.07 5.78e-16 3.05e-12 -0.67 -0.59 Red blood cell count; chr6:135026523 chr6:135055033~135060550:+ PAAD cis rs2739330 0.796 rs1006771 ENSG00000225282.1 AP000350.6 9.05 6.24e-16 3.28e-12 0.77 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23926900~23929574:+ PAAD cis rs9326248 0.53 rs579890 ENSG00000254851.1 RP11-109L13.1 -9.05 6.44e-16 3.38e-12 -1.09 -0.59 Blood protein levels; chr11:116928247 chr11:117135528~117138582:+ PAAD cis rs9399135 0.933 rs28384512 ENSG00000232876.1 CTA-212D2.2 -9.05 6.56e-16 3.44e-12 -0.68 -0.59 Red blood cell count; chr6:135055094 chr6:135055033~135060550:+ PAAD cis rs4423214 1 rs4944959 ENSG00000254682.1 RP11-660L16.2 -9.04 6.64e-16 3.48e-12 -0.82 -0.59 Vitamin D levels; chr11:71457188 chr11:71448674~71452157:+ PAAD cis rs9399135 0.967 rs4896120 ENSG00000232876.1 CTA-212D2.2 -9.04 6.83e-16 3.57e-12 -0.68 -0.59 Red blood cell count; chr6:134972374 chr6:135055033~135060550:+ PAAD cis rs9399135 1 rs4475342 ENSG00000232876.1 CTA-212D2.2 -9.04 6.9e-16 3.6e-12 -0.68 -0.59 Red blood cell count; chr6:134962210 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs13199205 ENSG00000232876.1 CTA-212D2.2 -9.04 6.9e-16 3.6e-12 -0.68 -0.59 Red blood cell count; chr6:134965367 chr6:135055033~135060550:+ PAAD cis rs9326248 0.603 rs7396061 ENSG00000254851.1 RP11-109L13.1 -9.04 6.91e-16 3.61e-12 -0.76 -0.59 Blood protein levels; chr11:116880158 chr11:117135528~117138582:+ PAAD cis rs9399135 0.967 rs12526055 ENSG00000232876.1 CTA-212D2.2 -9.03 7.02e-16 3.67e-12 -0.67 -0.59 Red blood cell count; chr6:135004780 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs7750300 ENSG00000232876.1 CTA-212D2.2 -9.03 7.03e-16 3.67e-12 -0.67 -0.59 Red blood cell count; chr6:135029812 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs6909975 ENSG00000232876.1 CTA-212D2.2 -9.03 7.08e-16 3.7e-12 -0.68 -0.59 Red blood cell count; chr6:134994432 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs7773126 ENSG00000232876.1 CTA-212D2.2 -9.03 7.08e-16 3.7e-12 -0.68 -0.59 Red blood cell count; chr6:134997252 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs4445070 ENSG00000232876.1 CTA-212D2.2 -9.03 7.15e-16 3.73e-12 -0.68 -0.59 Red blood cell count; chr6:134988074 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs6923827 ENSG00000232876.1 CTA-212D2.2 -9.03 7.15e-16 3.73e-12 -0.68 -0.59 Red blood cell count; chr6:135014244 chr6:135055033~135060550:+ PAAD cis rs9399135 1 rs35123050 ENSG00000232876.1 CTA-212D2.2 -9.03 7.25e-16 3.78e-12 -0.68 -0.59 Red blood cell count; chr6:134981602 chr6:135055033~135060550:+ PAAD cis rs9399135 0.933 rs41294852 ENSG00000232876.1 CTA-212D2.2 -9.02 7.5e-16 3.91e-12 -0.68 -0.59 Red blood cell count; chr6:135055241 chr6:135055033~135060550:+ PAAD cis rs4423214 1 rs7935125 ENSG00000254682.1 RP11-660L16.2 9.02 7.59e-16 3.95e-12 0.84 0.59 Vitamin D levels; chr11:71473144 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs4944062 ENSG00000254682.1 RP11-660L16.2 9.02 7.59e-16 3.95e-12 0.84 0.59 Vitamin D levels; chr11:71476248 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs3794060 ENSG00000254682.1 RP11-660L16.2 9.02 7.59e-16 3.95e-12 0.84 0.59 Vitamin D levels; chr11:71476633 chr11:71448674~71452157:+ PAAD cis rs9399135 0.967 rs9399129 ENSG00000232876.1 CTA-212D2.2 -9.02 7.67e-16 3.98e-12 -0.67 -0.59 Red blood cell count; chr6:134964010 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs4896119 ENSG00000232876.1 CTA-212D2.2 -9.02 7.75e-16 4.01e-12 -0.67 -0.59 Red blood cell count; chr6:134972253 chr6:135055033~135060550:+ PAAD cis rs875971 0.862 rs7783779 ENSG00000226824.5 RP4-756H11.3 9.02 7.75e-16 4.01e-12 0.72 0.59 Aortic root size; chr7:66331639 chr7:66654538~66669855:+ PAAD cis rs9399135 0.967 rs7766189 ENSG00000232876.1 CTA-212D2.2 -9.02 7.76e-16 4.02e-12 -0.67 -0.59 Red blood cell count; chr6:135032713 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9402676 ENSG00000232876.1 CTA-212D2.2 -9.02 7.76e-16 4.02e-12 -0.67 -0.59 Red blood cell count; chr6:135034369 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9376077 ENSG00000232876.1 CTA-212D2.2 -9.02 7.82e-16 4.05e-12 -0.67 -0.59 Red blood cell count; chr6:134978575 chr6:135055033~135060550:+ PAAD cis rs9399135 0.904 rs4895438 ENSG00000232876.1 CTA-212D2.2 -9.02 7.82e-16 4.05e-12 -0.67 -0.59 Red blood cell count; chr6:134996527 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9389256 ENSG00000232876.1 CTA-212D2.2 -9.02 7.82e-16 4.05e-12 -0.67 -0.59 Red blood cell count; chr6:135010116 chr6:135055033~135060550:+ PAAD cis rs3091242 0.933 rs35497030 ENSG00000224183.1 SDHDP6 9.01 7.89e-16 4.08e-12 0.76 0.59 Erythrocyte sedimentation rate; chr1:25456575 chr1:25294164~25294643:- PAAD cis rs3091242 0.902 rs36003018 ENSG00000224183.1 SDHDP6 9.01 7.89e-16 4.08e-12 0.76 0.59 Erythrocyte sedimentation rate; chr1:25457827 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs35403885 ENSG00000224183.1 SDHDP6 9.01 7.89e-16 4.08e-12 0.76 0.59 Erythrocyte sedimentation rate; chr1:25458060 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs35530120 ENSG00000224183.1 SDHDP6 9.01 7.89e-16 4.08e-12 0.76 0.59 Erythrocyte sedimentation rate; chr1:25458960 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs61775174 ENSG00000224183.1 SDHDP6 9.01 7.89e-16 4.08e-12 0.76 0.59 Erythrocyte sedimentation rate; chr1:25460822 chr1:25294164~25294643:- PAAD cis rs9399135 0.933 rs7755680 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:134973121 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs7741626 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:134993044 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs4895439 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:134997716 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs11754504 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135000371 chr6:135055033~135060550:+ PAAD cis rs9399135 0.869 rs9402675 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135004656 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9389253 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135008617 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9389254 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135009571 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs1014020 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135013288 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs1041481 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135013925 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs6902438 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135015449 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs6908681 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135016595 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs987690 ENSG00000232876.1 CTA-212D2.2 -9.01 7.91e-16 4.08e-12 -0.67 -0.59 Red blood cell count; chr6:135029241 chr6:135055033~135060550:+ PAAD cis rs2739330 0.857 rs9608229 ENSG00000250470.1 AP000351.3 9.01 8.21e-16 4.23e-12 0.86 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:24002918 chr22:23976904~23977585:- PAAD cis rs7208859 0.673 rs11657270 ENSG00000263531.1 RP13-753N3.1 9 8.38e-16 4.31e-12 1.13 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887369 chr17:30863921~30864940:- PAAD cis rs875971 0.862 rs1983372 ENSG00000226824.5 RP4-756H11.3 9 8.44e-16 4.34e-12 0.7 0.59 Aortic root size; chr7:66146364 chr7:66654538~66669855:+ PAAD cis rs11155671 0.53 rs9371544 ENSG00000216906.2 RP11-350J20.9 9 8.48e-16 4.36e-12 0.78 0.59 Testicular germ cell tumor; chr6:149896224 chr6:149904243~149906418:+ PAAD cis rs9322193 0.567 rs7747457 ENSG00000216906.2 RP11-350J20.9 9 8.5e-16 4.36e-12 0.79 0.59 Lung cancer; chr6:149892366 chr6:149904243~149906418:+ PAAD cis rs875971 0.893 rs62465470 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66136231 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs4368860 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66143495 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs908915 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66149664 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs7809814 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66150410 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs7786892 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66163889 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs2420174 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66180374 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs2420173 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66180412 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs4718319 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66187797 chr7:66654538~66669855:+ PAAD cis rs875971 0.723 rs28391294 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66189328 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs6967708 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66192326 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs7782806 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66192910 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs880166 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66205775 chr7:66654538~66669855:+ PAAD cis rs875971 0.756 rs4718328 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66228350 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs4718330 ENSG00000226824.5 RP4-756H11.3 9 8.51e-16 4.36e-12 0.72 0.59 Aortic root size; chr7:66250256 chr7:66654538~66669855:+ PAAD cis rs8062405 0.824 rs28698667 ENSG00000259982.1 CDC37P1 9 8.62e-16 4.41e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28521750 chr16:28700294~28701540:- PAAD cis rs8062405 0.754 rs62034323 ENSG00000259982.1 CDC37P1 9 8.62e-16 4.41e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525152 chr16:28700294~28701540:- PAAD cis rs8062405 0.824 rs62034324 ENSG00000259982.1 CDC37P1 9 8.62e-16 4.41e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525441 chr16:28700294~28701540:- PAAD cis rs8062405 0.824 rs62034326 ENSG00000259982.1 CDC37P1 9 8.62e-16 4.41e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28527972 chr16:28700294~28701540:- PAAD cis rs8062405 0.824 rs4788084 ENSG00000259982.1 CDC37P1 9 8.62e-16 4.41e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28528527 chr16:28700294~28701540:- PAAD cis rs8062405 0.792 rs12446550 ENSG00000259982.1 CDC37P1 9 8.62e-16 4.41e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28532060 chr16:28700294~28701540:- PAAD cis rs7617773 0.638 rs7644414 ENSG00000229759.1 MRPS18AP1 9 8.84e-16 4.51e-12 0.67 0.59 Coronary artery disease; chr3:48257589 chr3:48256350~48256938:- PAAD cis rs9399135 1 rs4896130 ENSG00000232876.1 CTA-212D2.2 -8.99 9.12e-16 4.64e-12 -0.68 -0.59 Red blood cell count; chr6:135033980 chr6:135055033~135060550:+ PAAD cis rs4423214 0.921 rs11603330 ENSG00000254682.1 RP11-660L16.2 8.99 9.22e-16 4.69e-12 0.83 0.59 Vitamin D levels; chr11:71442413 chr11:71448674~71452157:+ PAAD cis rs9399135 0.967 rs2150681 ENSG00000232876.1 CTA-212D2.2 8.98 9.79e-16 4.96e-12 0.69 0.59 Red blood cell count; chr6:135054094 chr6:135055033~135060550:+ PAAD cis rs1799949 1 rs16942 ENSG00000198496.9 NBR2 -8.97 1e-15 5.08e-12 -0.57 -0.59 Menopause (age at onset); chr17:43091983 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176145 ENSG00000198496.9 NBR2 -8.97 1e-15 5.08e-12 -0.57 -0.59 Menopause (age at onset); chr17:43097077 chr17:43125610~43153671:+ PAAD cis rs801193 0.548 rs6975044 ENSG00000226824.5 RP4-756H11.3 -8.97 1.03e-15 5.18e-12 -0.73 -0.59 Aortic root size; chr7:66762495 chr7:66654538~66669855:+ PAAD cis rs801193 0.569 rs35070132 ENSG00000226824.5 RP4-756H11.3 -8.97 1.03e-15 5.18e-12 -0.73 -0.59 Aortic root size; chr7:66773096 chr7:66654538~66669855:+ PAAD cis rs4423214 0.959 rs11606033 ENSG00000254682.1 RP11-660L16.2 8.97 1.03e-15 5.2e-12 0.83 0.59 Vitamin D levels; chr11:71443158 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs1044482 ENSG00000254682.1 RP11-660L16.2 8.97 1.03e-15 5.2e-12 0.83 0.59 Vitamin D levels; chr11:71444125 chr11:71448674~71452157:+ PAAD cis rs8062405 0.964 rs62036614 ENSG00000259982.1 CDC37P1 8.97 1.04e-15 5.21e-12 0.65 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28813364 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62036616 ENSG00000259982.1 CDC37P1 8.97 1.04e-15 5.21e-12 0.65 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814986 chr16:28700294~28701540:- PAAD cis rs11155671 0.53 rs9322228 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149888173 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs7774787 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149888296 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs2342767 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149888581 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs7764376 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149889208 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs6933882 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149889666 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs6939761 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149889858 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs3823021 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149889863 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs4869763 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149890548 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs4869764 ENSG00000216906.2 RP11-350J20.9 8.97 1.05e-15 5.29e-12 0.79 0.59 Testicular germ cell tumor; chr6:149890692 chr6:149904243~149906418:+ PAAD cis rs1799949 1 rs8176109 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43113759 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176103 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43115033 chr17:43125610~43153671:+ PAAD cis rs1799949 0.896 rs8176098 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43116189 chr17:43125610~43153671:+ PAAD cis rs1799949 0.896 rs8176086 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43122761 chr17:43125610~43153671:+ PAAD cis rs1799949 0.93 rs3765640 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43124230 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176077 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43124331 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11655505 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43126360 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs4793204 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43127281 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs12947782 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43127865 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs33945274 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43128056 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs33925201 ENSG00000198496.9 NBR2 -8.97 1.06e-15 5.31e-12 -0.58 -0.59 Menopause (age at onset); chr17:43128665 chr17:43125610~43153671:+ PAAD cis rs2487048 0.761 rs1800976 ENSG00000226334.1 RP11-217B7.2 -8.96 1.08e-15 5.42e-12 -0.7 -0.59 Intraocular pressure; chr9:104928428 chr9:104927553~104928892:+ PAAD cis rs8062405 0.789 rs240704 ENSG00000259982.1 CDC37P1 8.96 1.1e-15 5.47e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28518628 chr16:28700294~28701540:- PAAD cis rs8062405 0.824 rs240702 ENSG00000259982.1 CDC37P1 8.96 1.1e-15 5.47e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28520032 chr16:28700294~28701540:- PAAD cis rs8062405 0.824 rs62034319 ENSG00000259982.1 CDC37P1 8.96 1.1e-15 5.47e-12 0.64 0.59 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28520867 chr16:28700294~28701540:- PAAD cis rs1799949 1 rs4793229 ENSG00000198496.9 NBR2 8.96 1.1e-15 5.47e-12 0.57 0.59 Menopause (age at onset); chr17:43340966 chr17:43125610~43153671:+ PAAD cis rs1799949 0.501 rs2343819 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43332285 chr17:43125610~43153671:+ PAAD cis rs1799949 0.501 rs35399157 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43334234 chr17:43125610~43153671:+ PAAD cis rs1799949 0.602 rs4600503 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43336956 chr17:43125610~43153671:+ PAAD cis rs1799949 0.501 rs9675035 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43337648 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11649954 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43342667 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs1824889 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43344508 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs35956818 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43345617 chr17:43125610~43153671:+ PAAD cis rs1799949 0.93 rs4584865 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43347551 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11651341 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43350693 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs34572725 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43351298 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4534897 ENSG00000198496.9 NBR2 -8.96 1.1e-15 5.47e-12 -0.57 -0.59 Menopause (age at onset); chr17:43354440 chr17:43125610~43153671:+ PAAD cis rs1799949 0.894 rs8176160 ENSG00000198496.9 NBR2 -8.96 1.11e-15 5.53e-12 -0.57 -0.59 Menopause (age at onset); chr17:43089486 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs2070834 ENSG00000198496.9 NBR2 -8.96 1.11e-15 5.53e-12 -0.57 -0.59 Menopause (age at onset); chr17:43090268 chr17:43125610~43153671:+ PAAD cis rs7301826 0.651 rs1554807 ENSG00000256299.1 RP11-989F5.3 8.96 1.12e-15 5.57e-12 0.69 0.59 Plasma plasminogen activator levels; chr12:130795872 chr12:130810821~130812622:- PAAD cis rs2739330 0.791 rs4822458 ENSG00000250470.1 AP000351.3 8.96 1.12e-15 5.58e-12 0.83 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23976904~23977585:- PAAD cis rs875971 0.862 rs1167390 ENSG00000226824.5 RP4-756H11.3 8.95 1.13e-15 5.62e-12 0.71 0.59 Aortic root size; chr7:66110906 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs35034167 ENSG00000226824.5 RP4-756H11.3 8.95 1.13e-15 5.62e-12 0.71 0.59 Aortic root size; chr7:66115179 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs28470208 ENSG00000226824.5 RP4-756H11.3 8.95 1.13e-15 5.62e-12 0.71 0.59 Aortic root size; chr7:66119713 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs427575 ENSG00000226824.5 RP4-756H11.3 -8.95 1.14e-15 5.63e-12 -0.68 -0.59 Aortic root size; chr7:66054232 chr7:66654538~66669855:+ PAAD cis rs2739330 0.791 rs9612520 ENSG00000250470.1 AP000351.3 8.95 1.14e-15 5.66e-12 0.85 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23976904~23977585:- PAAD cis rs9322193 0.543 rs9371533 ENSG00000216906.2 RP11-350J20.9 8.95 1.14e-15 5.68e-12 0.76 0.59 Lung cancer; chr6:149889545 chr6:149904243~149906418:+ PAAD cis rs2455601 0.638 rs2742478 ENSG00000254860.4 TMEM9B-AS1 8.95 1.15e-15 5.7e-12 0.77 0.59 Schizophrenia; chr11:8974552 chr11:8964675~8977527:+ PAAD cis rs1799949 1 rs8176126 ENSG00000198496.9 NBR2 8.95 1.16e-15 5.75e-12 0.57 0.59 Menopause (age at onset); chr17:43107032 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs8176140 ENSG00000198496.9 NBR2 -8.95 1.16e-15 5.75e-12 -0.57 -0.59 Menopause (age at onset); chr17:43099629 chr17:43125610~43153671:+ PAAD cis rs1799949 0.896 rs35908185 ENSG00000198496.9 NBR2 -8.95 1.16e-15 5.75e-12 -0.57 -0.59 Menopause (age at onset); chr17:43103094 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs8176130 ENSG00000198496.9 NBR2 -8.95 1.16e-15 5.75e-12 -0.57 -0.59 Menopause (age at onset); chr17:43106026 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176120 ENSG00000198496.9 NBR2 -8.95 1.16e-15 5.75e-12 -0.57 -0.59 Menopause (age at onset); chr17:43109216 chr17:43125610~43153671:+ PAAD cis rs4423214 1 rs1981412 ENSG00000254682.1 RP11-660L16.2 8.95 1.16e-15 5.76e-12 0.84 0.59 Vitamin D levels; chr11:71427664 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12419279 ENSG00000254682.1 RP11-660L16.2 8.95 1.16e-15 5.76e-12 0.84 0.59 Vitamin D levels; chr11:71428015 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs12419334 ENSG00000254682.1 RP11-660L16.2 8.95 1.16e-15 5.76e-12 0.84 0.59 Vitamin D levels; chr11:71428426 chr11:71448674~71452157:+ PAAD cis rs9399135 0.967 rs6925424 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 Red blood cell count; chr6:134992810 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs17638970 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 Red blood cell count; chr6:134998925 chr6:135055033~135060550:+ PAAD cis rs9402673 0.558 rs9688342 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 High light scatter reticulocyte count;Reticulocyte count; chr6:135001888 chr6:135055033~135060550:+ PAAD cis rs9399135 0.933 rs4559100 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 Red blood cell count; chr6:135002947 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs12527707 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 Red blood cell count; chr6:135003373 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9389251 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 Red blood cell count; chr6:135004579 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs6929661 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 Red blood cell count; chr6:135007654 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs2327578 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 Red blood cell count; chr6:135008831 chr6:135055033~135060550:+ PAAD cis rs9389248 0.5 rs116273677 ENSG00000232876.1 CTA-212D2.2 -8.95 1.17e-15 5.77e-12 -0.67 -0.59 High light scatter reticulocyte percentage of red cells; chr6:135017997 chr6:135055033~135060550:+ PAAD cis rs875971 0.862 rs2909688 ENSG00000226824.5 RP4-756H11.3 -8.95 1.18e-15 5.83e-12 -0.72 -0.59 Aortic root size; chr7:66376625 chr7:66654538~66669855:+ PAAD cis rs9399135 0.967 rs45544135 ENSG00000232876.1 CTA-212D2.2 -8.95 1.19e-15 5.87e-12 -0.68 -0.59 Red blood cell count; chr6:135002913 chr6:135055033~135060550:+ PAAD cis rs875971 1 rs7781698 ENSG00000226824.5 RP4-756H11.3 -8.95 1.2e-15 5.9e-12 -0.69 -0.59 Aortic root size; chr7:66431325 chr7:66654538~66669855:+ PAAD cis rs875971 0.8 rs427557 ENSG00000226824.5 RP4-756H11.3 -8.94 1.2e-15 5.92e-12 -0.68 -0.59 Aortic root size; chr7:66054263 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs587360 ENSG00000226824.5 RP4-756H11.3 -8.94 1.2e-15 5.92e-12 -0.68 -0.59 Aortic root size; chr7:66057711 chr7:66654538~66669855:+ PAAD cis rs7208859 0.623 rs122898 ENSG00000263531.1 RP13-753N3.1 -8.94 1.24e-15 6.11e-12 -1.08 -0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30863921~30864940:- PAAD cis rs875971 0.564 rs313804 ENSG00000226824.5 RP4-756H11.3 -8.94 1.25e-15 6.16e-12 -0.68 -0.59 Aortic root size; chr7:66049635 chr7:66654538~66669855:+ PAAD cis rs875971 0.662 rs448725 ENSG00000226824.5 RP4-756H11.3 -8.94 1.25e-15 6.16e-12 -0.68 -0.59 Aortic root size; chr7:66049641 chr7:66654538~66669855:+ PAAD cis rs875971 0.658 rs432667 ENSG00000226824.5 RP4-756H11.3 -8.94 1.25e-15 6.16e-12 -0.68 -0.59 Aortic root size; chr7:66049646 chr7:66654538~66669855:+ PAAD cis rs9545047 0.967 rs3903388 ENSG00000227676.3 LINC01068 8.94 1.26e-15 6.19e-12 0.74 0.59 Schizophrenia; chr13:79330686 chr13:79566727~79571436:+ PAAD cis rs9545047 1 rs9545073 ENSG00000227676.3 LINC01068 8.94 1.26e-15 6.19e-12 0.74 0.59 Schizophrenia; chr13:79334872 chr13:79566727~79571436:+ PAAD cis rs9545047 1 rs9545078 ENSG00000227676.3 LINC01068 8.94 1.26e-15 6.19e-12 0.74 0.59 Schizophrenia; chr13:79339216 chr13:79566727~79571436:+ PAAD cis rs9545047 0.869 rs3742119 ENSG00000227676.3 LINC01068 8.94 1.26e-15 6.19e-12 0.74 0.59 Schizophrenia; chr13:79342859 chr13:79566727~79571436:+ PAAD cis rs9545047 1 rs9318626 ENSG00000227676.3 LINC01068 8.94 1.26e-15 6.19e-12 0.74 0.59 Schizophrenia; chr13:79351820 chr13:79566727~79571436:+ PAAD cis rs9399135 0.967 rs9389258 ENSG00000232876.1 CTA-212D2.2 -8.93 1.28e-15 6.28e-12 -0.67 -0.59 Red blood cell count; chr6:135040002 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs2327580 ENSG00000232876.1 CTA-212D2.2 -8.93 1.28e-15 6.28e-12 -0.67 -0.59 Red blood cell count; chr6:135043279 chr6:135055033~135060550:+ PAAD cis rs9399135 0.844 rs13209789 ENSG00000232876.1 CTA-212D2.2 -8.93 1.28e-15 6.28e-12 -0.67 -0.59 Red blood cell count; chr6:135046778 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs6915770 ENSG00000232876.1 CTA-212D2.2 -8.93 1.28e-15 6.28e-12 -0.67 -0.59 Red blood cell count; chr6:135048076 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs9376086 ENSG00000232876.1 CTA-212D2.2 -8.93 1.28e-15 6.28e-12 -0.67 -0.59 Red blood cell count; chr6:135050191 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs1041480 ENSG00000232876.1 CTA-212D2.2 -8.93 1.28e-15 6.28e-12 -0.67 -0.59 Red blood cell count; chr6:135051938 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs2297340 ENSG00000232876.1 CTA-212D2.2 -8.93 1.28e-15 6.28e-12 -0.67 -0.59 Red blood cell count; chr6:135054920 chr6:135055033~135060550:+ PAAD cis rs1799949 0.864 rs60309406 ENSG00000198496.9 NBR2 -8.93 1.31e-15 6.43e-12 -0.57 -0.59 Menopause (age at onset); chr17:43358297 chr17:43125610~43153671:+ PAAD cis rs494459 0.964 rs576283 ENSG00000255239.1 AP002954.6 8.93 1.32e-15 6.46e-12 0.71 0.59 Height; chr11:118703185 chr11:118688039~118690600:- PAAD cis rs494459 0.929 rs627391 ENSG00000255239.1 AP002954.6 8.93 1.32e-15 6.46e-12 0.71 0.59 Height; chr11:118703207 chr11:118688039~118690600:- PAAD cis rs507080 0.524 rs524409 ENSG00000255239.1 AP002954.6 8.93 1.32e-15 6.46e-12 0.71 0.59 Serum metabolite levels; chr11:118703602 chr11:118688039~118690600:- PAAD cis rs507080 0.501 rs494459 ENSG00000255239.1 AP002954.6 -8.93 1.32e-15 6.46e-12 -0.71 -0.59 Serum metabolite levels; chr11:118703966 chr11:118688039~118690600:- PAAD cis rs507080 0.501 rs626645 ENSG00000255239.1 AP002954.6 8.93 1.32e-15 6.46e-12 0.71 0.59 Serum metabolite levels; chr11:118704471 chr11:118688039~118690600:- PAAD cis rs507080 0.501 rs637563 ENSG00000255239.1 AP002954.6 8.93 1.32e-15 6.46e-12 0.71 0.59 Serum metabolite levels; chr11:118704770 chr11:118688039~118690600:- PAAD cis rs6452524 0.618 rs1478487 ENSG00000249664.1 CTD-2227C6.2 8.93 1.33e-15 6.53e-12 0.71 0.59 Hypertension (SNP x SNP interaction); chr5:83080900 chr5:83012285~83013109:- PAAD cis rs7208859 0.673 rs11655623 ENSG00000263531.1 RP13-753N3.1 8.93 1.33e-15 6.54e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30835155 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs73277960 ENSG00000263531.1 RP13-753N3.1 8.93 1.33e-15 6.54e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30850423 chr17:30863921~30864940:- PAAD cis rs6452524 0.618 rs4266384 ENSG00000249664.1 CTD-2227C6.2 8.92 1.38e-15 6.74e-12 0.71 0.59 Hypertension (SNP x SNP interaction); chr5:83080872 chr5:83012285~83013109:- PAAD cis rs7301826 0.585 rs6486600 ENSG00000256299.1 RP11-989F5.3 -8.92 1.4e-15 6.84e-12 -0.65 -0.59 Plasma plasminogen activator levels; chr12:130808432 chr12:130810821~130812622:- PAAD cis rs9399135 0.967 rs2297338 ENSG00000232876.1 CTA-212D2.2 -8.91 1.45e-15 7.09e-12 -0.68 -0.59 Red blood cell count; chr6:135054624 chr6:135055033~135060550:+ PAAD cis rs9399135 0.933 rs9389262 ENSG00000232876.1 CTA-212D2.2 -8.91 1.45e-15 7.09e-12 -0.68 -0.59 Red blood cell count; chr6:135055271 chr6:135055033~135060550:+ PAAD cis rs12439619 0.693 rs28689861 ENSG00000278603.1 RP13-608F4.5 8.91 1.46e-15 7.14e-12 0.88 0.59 Intelligence (multi-trait analysis); chr15:82206369 chr15:82472203~82472426:+ PAAD cis rs11155671 0.53 rs7756850 ENSG00000216906.2 RP11-350J20.9 8.91 1.47e-15 7.15e-12 0.78 0.59 Testicular germ cell tumor; chr6:149891460 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs9371542 ENSG00000216906.2 RP11-350J20.9 8.91 1.47e-15 7.15e-12 0.78 0.59 Testicular germ cell tumor; chr6:149891949 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs9371223 ENSG00000216906.2 RP11-350J20.9 8.91 1.47e-15 7.15e-12 0.78 0.59 Testicular germ cell tumor; chr6:149893670 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs9397420 ENSG00000216906.2 RP11-350J20.9 -8.91 1.51e-15 7.34e-12 -0.77 -0.59 Testicular germ cell tumor; chr6:149885645 chr6:149904243~149906418:+ PAAD cis rs7301826 0.651 rs10848206 ENSG00000256299.1 RP11-989F5.3 -8.9 1.53e-15 7.44e-12 -0.67 -0.59 Plasma plasminogen activator levels; chr12:130796926 chr12:130810821~130812622:- PAAD cis rs7208859 0.673 rs17826219 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834827 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs61223749 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30836729 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs3764420 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837136 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs3764421 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30840635 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11651858 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843700 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs36056619 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30845266 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9909497 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846210 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11080135 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30849463 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9894876 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855002 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73277967 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30857148 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs60020217 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30858036 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs73277974 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862851 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73277978 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864431 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11657391 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30867269 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs58089675 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869746 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73263755 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30871954 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9899349 ENSG00000263531.1 RP13-753N3.1 8.9 1.53e-15 7.44e-12 1.18 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30873104 chr17:30863921~30864940:- PAAD cis rs9545047 1 rs56911077 ENSG00000227676.3 LINC01068 8.9 1.57e-15 7.58e-12 0.74 0.59 Schizophrenia; chr13:79354126 chr13:79566727~79571436:+ PAAD cis rs9545047 1 rs9545086 ENSG00000227676.3 LINC01068 8.9 1.57e-15 7.58e-12 0.74 0.59 Schizophrenia; chr13:79364233 chr13:79566727~79571436:+ PAAD cis rs9545047 0.967 rs9545087 ENSG00000227676.3 LINC01068 8.9 1.57e-15 7.58e-12 0.74 0.59 Schizophrenia; chr13:79364440 chr13:79566727~79571436:+ PAAD cis rs2882667 0.893 rs7717375 ENSG00000253404.1 AC034243.1 8.9 1.59e-15 7.7e-12 0.72 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138955716 chr5:138744434~138753309:- PAAD cis rs2882667 0.893 rs10054796 ENSG00000253404.1 AC034243.1 8.9 1.59e-15 7.7e-12 0.72 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138958655 chr5:138744434~138753309:- PAAD cis rs2882667 0.893 rs10069961 ENSG00000253404.1 AC034243.1 8.9 1.59e-15 7.7e-12 0.72 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:138958879 chr5:138744434~138753309:- PAAD cis rs5769707 0.749 rs8137251 ENSG00000188511.11 C22orf34 8.89 1.62e-15 7.79e-12 0.58 0.59 Monocyte percentage of white cells;Monocyte count; chr22:49643021 chr22:49414524~49657542:- PAAD cis rs67383717 0.643 rs10759883 ENSG00000175611.10 LINC00476 -8.89 1.63e-15 7.83e-12 -0.49 -0.59 Parkinson's disease (pesticide exposure interaction); chr9:95790481 chr9:95759231~95875977:- PAAD cis rs7208859 0.623 rs216436 ENSG00000263531.1 RP13-753N3.1 8.89 1.63e-15 7.83e-12 1.09 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595882 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs216424 ENSG00000263531.1 RP13-753N3.1 8.89 1.65e-15 7.93e-12 1.03 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30616046 chr17:30863921~30864940:- PAAD cis rs1799949 0.965 rs8176087 ENSG00000198496.9 NBR2 -8.89 1.68e-15 8.04e-12 -0.58 -0.58 Menopause (age at onset); chr17:43118649 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs34942571 ENSG00000198496.9 NBR2 -8.89 1.68e-15 8.04e-12 -0.58 -0.58 Menopause (age at onset); chr17:43121362 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176083 ENSG00000198496.9 NBR2 -8.89 1.68e-15 8.04e-12 -0.58 -0.58 Menopause (age at onset); chr17:43123134 chr17:43125610~43153671:+ PAAD cis rs7301826 0.651 rs7971046 ENSG00000256299.1 RP11-989F5.3 -8.89 1.68e-15 8.05e-12 -0.67 -0.58 Plasma plasminogen activator levels; chr12:130802262 chr12:130810821~130812622:- PAAD cis rs11155671 0.53 rs2342769 ENSG00000216906.2 RP11-350J20.9 8.89 1.7e-15 8.13e-12 0.78 0.58 Testicular germ cell tumor; chr6:149895371 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs6935829 ENSG00000216906.2 RP11-350J20.9 8.89 1.7e-15 8.13e-12 0.78 0.58 Testicular germ cell tumor; chr6:149896675 chr6:149904243~149906418:+ PAAD cis rs9399135 0.967 rs6569990 ENSG00000232876.1 CTA-212D2.2 -8.88 1.71e-15 8.19e-12 -0.67 -0.58 Red blood cell count; chr6:135044680 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs13191501 ENSG00000232876.1 CTA-212D2.2 -8.88 1.71e-15 8.19e-12 -0.67 -0.58 Red blood cell count; chr6:135045742 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs6908512 ENSG00000232876.1 CTA-212D2.2 -8.88 1.71e-15 8.19e-12 -0.67 -0.58 Red blood cell count; chr6:135046619 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs11755229 ENSG00000232876.1 CTA-212D2.2 -8.88 1.71e-15 8.19e-12 -0.67 -0.58 Red blood cell count; chr6:135048775 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9376085 ENSG00000232876.1 CTA-212D2.2 -8.88 1.71e-15 8.19e-12 -0.67 -0.58 Red blood cell count; chr6:135050086 chr6:135055033~135060550:+ PAAD cis rs7301826 0.651 rs4759517 ENSG00000256299.1 RP11-989F5.3 -8.88 1.73e-15 8.29e-12 -0.67 -0.58 Plasma plasminogen activator levels; chr12:130799153 chr12:130810821~130812622:- PAAD cis rs9399135 0.967 rs1854865 ENSG00000232876.1 CTA-212D2.2 -8.88 1.73e-15 8.29e-12 -0.67 -0.58 Red blood cell count; chr6:135039162 chr6:135055033~135060550:+ PAAD cis rs2882667 0.964 rs2288824 ENSG00000253404.1 AC034243.1 8.88 1.74e-15 8.32e-12 0.71 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:138962707 chr5:138744434~138753309:- PAAD cis rs9399135 1 rs11754265 ENSG00000232876.1 CTA-212D2.2 -8.88 1.76e-15 8.42e-12 -0.67 -0.58 Red blood cell count; chr6:135035078 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs2183709 ENSG00000232876.1 CTA-212D2.2 -8.88 1.76e-15 8.43e-12 -0.68 -0.58 Red blood cell count; chr6:135055953 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs4142299 ENSG00000232876.1 CTA-212D2.2 -8.88 1.76e-15 8.43e-12 -0.68 -0.58 Red blood cell count; chr6:135056048 chr6:135055033~135060550:+ PAAD cis rs1799949 0.55 rs2343818 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43332406 chr17:43125610~43153671:+ PAAD cis rs1799949 0.526 rs4352088 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43337311 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs34633610 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43342017 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs11654051 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43342288 chr17:43125610~43153671:+ PAAD cis rs1799949 0.93 rs56729776 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43344763 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs9646417 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43346885 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs1545764 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43347197 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs9646412 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43348525 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4793231 ENSG00000198496.9 NBR2 -8.88 1.77e-15 8.43e-12 -0.57 -0.58 Menopause (age at onset); chr17:43350101 chr17:43125610~43153671:+ PAAD cis rs11155671 0.53 rs7757984 ENSG00000216906.2 RP11-350J20.9 8.88 1.78e-15 8.49e-12 0.79 0.58 Testicular germ cell tumor; chr6:149887515 chr6:149904243~149906418:+ PAAD cis rs9660180 0.62 rs3817856 ENSG00000268575.1 RP1-283E3.8 8.87 1.86e-15 8.87e-12 0.56 0.58 Body mass index; chr1:1732392 chr1:1702736~1737688:- PAAD cis rs321358 0.945 rs17537367 ENSG00000271584.1 RP11-89C3.4 8.87 1.87e-15 8.91e-12 0.79 0.58 Body mass index; chr11:111117008 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs17458885 ENSG00000271584.1 RP11-89C3.4 8.87 1.87e-15 8.91e-12 0.79 0.58 Body mass index; chr11:111117222 chr11:111091932~111097357:- PAAD cis rs1799949 1 rs4793197 ENSG00000198496.9 NBR2 -8.87 1.89e-15 9.01e-12 -0.57 -0.58 Menopause (age at onset); chr17:43079885 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs1060915 ENSG00000198496.9 NBR2 -8.87 1.89e-15 9.01e-12 -0.57 -0.58 Menopause (age at onset); chr17:43082453 chr17:43125610~43153671:+ PAAD cis rs2739330 0.627 rs9608219 ENSG00000250470.1 AP000351.3 8.87 1.9e-15 9.03e-12 0.84 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23976904~23977585:- PAAD cis rs929843 1 rs929843 ENSG00000226232.7 RP11-419C5.2 -8.87 1.91e-15 9.04e-12 -0.62 -0.58 Menarche (age at onset); chr16:70011845 chr16:69976388~69996188:- PAAD cis rs7301826 0.651 rs7132657 ENSG00000256299.1 RP11-989F5.3 -8.87 1.91e-15 9.07e-12 -0.67 -0.58 Plasma plasminogen activator levels; chr12:130800642 chr12:130810821~130812622:- PAAD cis rs9399135 0.967 rs9389261 ENSG00000232876.1 CTA-212D2.2 -8.86 1.93e-15 9.13e-12 -0.67 -0.58 Red blood cell count; chr6:135050010 chr6:135055033~135060550:+ PAAD cis rs7208859 0.673 rs11654331 ENSG00000263531.1 RP13-753N3.1 8.86 1.94e-15 9.2e-12 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837999 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73277964 ENSG00000263531.1 RP13-753N3.1 8.86 1.94e-15 9.2e-12 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30852183 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11652409 ENSG00000263531.1 RP13-753N3.1 8.86 1.94e-15 9.2e-12 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855689 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9896095 ENSG00000263531.1 RP13-753N3.1 8.86 1.94e-15 9.2e-12 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30860479 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs58920731 ENSG00000263531.1 RP13-753N3.1 8.86 1.94e-15 9.2e-12 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864728 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73277984 ENSG00000263531.1 RP13-753N3.1 8.86 1.94e-15 9.2e-12 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869115 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73277986 ENSG00000263531.1 RP13-753N3.1 8.86 1.94e-15 9.2e-12 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869179 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs12103588 ENSG00000263531.1 RP13-753N3.1 8.86 1.94e-15 9.2e-12 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30870442 chr17:30863921~30864940:- PAAD cis rs2487048 0.725 rs2422493 ENSG00000226334.1 RP11-217B7.2 -8.86 1.96e-15 9.28e-12 -0.69 -0.58 Intraocular pressure; chr9:104928714 chr9:104927553~104928892:+ PAAD cis rs2283792 0.812 rs240064 ENSG00000224086.5 LL22NC03-86G7.1 8.86 1.97e-15 9.33e-12 0.6 0.58 Multiple sclerosis; chr22:21927265 chr22:21938293~21977632:+ PAAD cis rs321358 0.836 rs17458597 ENSG00000271584.1 RP11-89C3.4 8.86 2.01e-15 9.48e-12 0.79 0.58 Body mass index; chr11:111113599 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs73017176 ENSG00000271584.1 RP11-89C3.4 8.86 2.01e-15 9.48e-12 0.79 0.58 Body mass index; chr11:111113879 chr11:111091932~111097357:- PAAD cis rs321358 0.887 rs80221187 ENSG00000271584.1 RP11-89C3.4 8.86 2.01e-15 9.48e-12 0.79 0.58 Body mass index; chr11:111113977 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs73017177 ENSG00000271584.1 RP11-89C3.4 8.86 2.01e-15 9.48e-12 0.79 0.58 Body mass index; chr11:111114034 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs73017179 ENSG00000271584.1 RP11-89C3.4 8.86 2.01e-15 9.48e-12 0.79 0.58 Body mass index; chr11:111114037 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs1356411 ENSG00000271584.1 RP11-89C3.4 8.86 2.01e-15 9.48e-12 0.79 0.58 Body mass index; chr11:111115371 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs12420595 ENSG00000271584.1 RP11-89C3.4 8.86 2.01e-15 9.48e-12 0.79 0.58 Body mass index; chr11:111115871 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs17537360 ENSG00000271584.1 RP11-89C3.4 8.86 2.01e-15 9.48e-12 0.79 0.58 Body mass index; chr11:111116921 chr11:111091932~111097357:- PAAD cis rs11673344 0.624 rs862234 ENSG00000226686.6 LINC01535 -8.86 2.02e-15 9.49e-12 -0.71 -0.58 Obesity-related traits; chr19:37237100 chr19:37251912~37265535:+ PAAD cis rs875971 0.862 rs6460307 ENSG00000226824.5 RP4-756H11.3 -8.85 2.04e-15 9.59e-12 -0.71 -0.58 Aortic root size; chr7:66595884 chr7:66654538~66669855:+ PAAD cis rs8062405 0.964 rs11860513 ENSG00000259982.1 CDC37P1 8.85 2.07e-15 9.7e-12 0.63 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814099 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs1987472 ENSG00000259982.1 CDC37P1 8.85 2.07e-15 9.7e-12 0.63 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814456 chr16:28700294~28701540:- PAAD cis rs8062405 0.895 rs56186137 ENSG00000259982.1 CDC37P1 8.85 2.07e-15 9.7e-12 0.63 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814632 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs2008514 ENSG00000259982.1 CDC37P1 -8.85 2.07e-15 9.7e-12 -0.63 -0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814284 chr16:28700294~28701540:- PAAD cis rs875971 0.862 rs6460282 ENSG00000226824.5 RP4-756H11.3 8.85 2.08e-15 9.77e-12 0.71 0.58 Aortic root size; chr7:66226259 chr7:66654538~66669855:+ PAAD cis rs11673344 0.58 rs320881 ENSG00000226686.6 LINC01535 8.85 2.08e-15 9.77e-12 0.71 0.58 Obesity-related traits; chr19:37246948 chr19:37251912~37265535:+ PAAD cis rs5769707 0.732 rs135865 ENSG00000188511.11 C22orf34 8.85 2.08e-15 9.77e-12 0.6 0.58 Monocyte percentage of white cells;Monocyte count; chr22:49611181 chr22:49414524~49657542:- PAAD cis rs9326248 0.53 rs7940310 ENSG00000254851.1 RP11-109L13.1 -8.85 2.09e-15 9.79e-12 -0.94 -0.58 Blood protein levels; chr11:117153765 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs7112513 ENSG00000254851.1 RP11-109L13.1 -8.85 2.09e-15 9.79e-12 -0.94 -0.58 Blood protein levels; chr11:117166645 chr11:117135528~117138582:+ PAAD cis rs9326248 0.569 rs10892082 ENSG00000254851.1 RP11-109L13.1 -8.85 2.09e-15 9.79e-12 -0.94 -0.58 Blood protein levels; chr11:117168609 chr11:117135528~117138582:+ PAAD cis rs3931020 0.72 rs927904 ENSG00000272864.1 RP11-17E13.2 -8.84 2.19e-15 1.03e-11 -0.71 -0.58 Resistin levels; chr1:74794644 chr1:74698769~74699333:- PAAD cis rs11155671 0.53 rs7758033 ENSG00000216906.2 RP11-350J20.9 8.84 2.24e-15 1.05e-11 0.76 0.58 Testicular germ cell tumor; chr6:149886999 chr6:149904243~149906418:+ PAAD cis rs9660180 0.967 rs12040325 ENSG00000268575.1 RP1-283E3.8 -8.84 2.25e-15 1.05e-11 -0.57 -0.58 Body mass index; chr1:1770997 chr1:1702736~1737688:- PAAD cis rs4423214 0.879 rs4945008 ENSG00000254682.1 RP11-660L16.2 8.84 2.25e-15 1.05e-11 0.81 0.58 Vitamin D levels; chr11:71510202 chr11:71448674~71452157:+ PAAD cis rs2945232 1 rs2945232 ENSG00000253893.2 FAM85B -8.84 2.26e-15 1.06e-11 -0.82 -0.58 Schizophrenia; chr8:8240516 chr8:8167819~8226614:- PAAD cis rs7208859 0.623 rs426434 ENSG00000263531.1 RP13-753N3.1 8.84 2.27e-15 1.06e-11 1.03 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30598335 chr17:30863921~30864940:- PAAD cis rs2882667 0.893 rs10044672 ENSG00000253404.1 AC034243.1 8.84 2.27e-15 1.06e-11 0.71 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:138954790 chr5:138744434~138753309:- PAAD cis rs2882667 0.893 rs13180851 ENSG00000253404.1 AC034243.1 8.84 2.27e-15 1.06e-11 0.71 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:138954918 chr5:138744434~138753309:- PAAD cis rs6452524 0.648 rs27364 ENSG00000249664.1 CTD-2227C6.2 8.84 2.29e-15 1.07e-11 0.7 0.58 Hypertension (SNP x SNP interaction); chr5:83052137 chr5:83012285~83013109:- PAAD cis rs8062405 0.824 rs153106 ENSG00000259982.1 CDC37P1 8.83 2.3e-15 1.07e-11 0.63 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28515576 chr16:28700294~28701540:- PAAD cis rs4423214 1 rs2040323 ENSG00000254682.1 RP11-660L16.2 8.83 2.34e-15 1.09e-11 0.81 0.58 Vitamin D levels; chr11:71461737 chr11:71448674~71452157:+ PAAD cis rs11155671 0.53 rs9383577 ENSG00000216906.2 RP11-350J20.9 8.83 2.42e-15 1.12e-11 0.76 0.58 Testicular germ cell tumor; chr6:149886059 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs9383914 ENSG00000216906.2 RP11-350J20.9 8.83 2.42e-15 1.12e-11 0.76 0.58 Testicular germ cell tumor; chr6:149886098 chr6:149904243~149906418:+ PAAD cis rs11155671 0.517 rs9397058 ENSG00000216906.2 RP11-350J20.9 8.83 2.42e-15 1.12e-11 0.76 0.58 Testicular germ cell tumor; chr6:149886113 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs7768626 ENSG00000216906.2 RP11-350J20.9 8.83 2.42e-15 1.12e-11 0.76 0.58 Testicular germ cell tumor; chr6:149886826 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs7768665 ENSG00000216906.2 RP11-350J20.9 8.83 2.42e-15 1.12e-11 0.76 0.58 Testicular germ cell tumor; chr6:149886888 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs7758020 ENSG00000216906.2 RP11-350J20.9 8.83 2.42e-15 1.12e-11 0.76 0.58 Testicular germ cell tumor; chr6:149886975 chr6:149904243~149906418:+ PAAD cis rs4718428 1 rs12534637 ENSG00000226824.5 RP4-756H11.3 -8.83 2.43e-15 1.13e-11 -0.72 -0.58 Corneal structure; chr7:66862667 chr7:66654538~66669855:+ PAAD cis rs875971 0.895 rs6460278 ENSG00000226824.5 RP4-756H11.3 8.82 2.44e-15 1.13e-11 0.71 0.58 Aortic root size; chr7:66197749 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6460279 ENSG00000226824.5 RP4-756H11.3 8.82 2.44e-15 1.13e-11 0.71 0.58 Aortic root size; chr7:66197774 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs28491091 ENSG00000226824.5 RP4-756H11.3 8.82 2.44e-15 1.13e-11 0.71 0.58 Aortic root size; chr7:66204077 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6952182 ENSG00000226824.5 RP4-756H11.3 8.82 2.44e-15 1.13e-11 0.71 0.58 Aortic root size; chr7:66218330 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs6964437 ENSG00000226824.5 RP4-756H11.3 8.82 2.44e-15 1.13e-11 0.71 0.58 Aortic root size; chr7:66221457 chr7:66654538~66669855:+ PAAD cis rs9399135 0.967 rs6923765 ENSG00000232876.1 CTA-212D2.2 8.82 2.5e-15 1.16e-11 0.68 0.58 Red blood cell count; chr6:135014038 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs7763836 ENSG00000232876.1 CTA-212D2.2 -8.82 2.52e-15 1.17e-11 -0.67 -0.58 Red blood cell count; chr6:135041240 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs34546690 ENSG00000232876.1 CTA-212D2.2 -8.82 2.52e-15 1.17e-11 -0.67 -0.58 Red blood cell count; chr6:135048571 chr6:135055033~135060550:+ PAAD cis rs9399135 0.967 rs9373122 ENSG00000232876.1 CTA-212D2.2 -8.82 2.52e-15 1.17e-11 -0.67 -0.58 Red blood cell count; chr6:135052396 chr6:135055033~135060550:+ PAAD cis rs6452524 0.618 rs1871203 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83059567 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs7722924 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83060223 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs10051445 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83060280 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs6867727 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83061333 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs7723639 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83062610 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs2306336 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83064964 chr5:83012285~83013109:- PAAD cis rs6452524 0.589 rs6882386 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83065555 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs6860752 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83065587 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs3899556 ENSG00000249664.1 CTD-2227C6.2 8.81 2.64e-15 1.22e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83067862 chr5:83012285~83013109:- PAAD cis rs5769707 0.681 rs4824068 ENSG00000188511.11 C22orf34 8.81 2.64e-15 1.22e-11 0.58 0.58 Monocyte percentage of white cells;Monocyte count; chr22:49631153 chr22:49414524~49657542:- PAAD cis rs1799949 1 rs16941 ENSG00000198496.9 NBR2 -8.81 2.64e-15 1.22e-11 -0.57 -0.58 Menopause (age at onset); chr17:43092418 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs16940 ENSG00000198496.9 NBR2 -8.81 2.64e-15 1.22e-11 -0.57 -0.58 Menopause (age at onset); chr17:43093220 chr17:43125610~43153671:+ PAAD cis rs1799949 0.93 rs66499067 ENSG00000198496.9 NBR2 -8.81 2.64e-15 1.22e-11 -0.57 -0.58 Menopause (age at onset); chr17:43096467 chr17:43125610~43153671:+ PAAD cis rs3091242 0.933 rs10903129 ENSG00000224183.1 SDHDP6 -8.81 2.65e-15 1.22e-11 -0.75 -0.58 Erythrocyte sedimentation rate; chr1:25442446 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs10903130 ENSG00000224183.1 SDHDP6 -8.81 2.65e-15 1.22e-11 -0.75 -0.58 Erythrocyte sedimentation rate; chr1:25442730 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs11249251 ENSG00000224183.1 SDHDP6 -8.81 2.65e-15 1.22e-11 -0.75 -0.58 Erythrocyte sedimentation rate; chr1:25443697 chr1:25294164~25294643:- PAAD cis rs3091242 0.9 rs4649086 ENSG00000224183.1 SDHDP6 -8.81 2.65e-15 1.22e-11 -0.75 -0.58 Erythrocyte sedimentation rate; chr1:25452476 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs34006994 ENSG00000224183.1 SDHDP6 8.81 2.65e-15 1.22e-11 0.75 0.58 Erythrocyte sedimentation rate; chr1:25454177 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs61775167 ENSG00000224183.1 SDHDP6 8.81 2.65e-15 1.22e-11 0.75 0.58 Erythrocyte sedimentation rate; chr1:25454402 chr1:25294164~25294643:- PAAD cis rs7301826 0.932 rs1007246 ENSG00000256250.1 RP11-989F5.1 -8.81 2.66e-15 1.22e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130795585 chr12:130810606~130812438:+ PAAD cis rs7301826 0.651 rs10848210 ENSG00000256299.1 RP11-989F5.3 -8.81 2.68e-15 1.23e-11 -0.67 -0.58 Plasma plasminogen activator levels; chr12:130827475 chr12:130810821~130812622:- PAAD cis rs7301826 0.627 rs4325342 ENSG00000256299.1 RP11-989F5.3 -8.81 2.68e-15 1.23e-11 -0.67 -0.58 Plasma plasminogen activator levels; chr12:130827937 chr12:130810821~130812622:- PAAD cis rs7829975 0.536 rs2980439 ENSG00000253893.2 FAM85B -8.81 2.68e-15 1.23e-11 -0.82 -0.58 Mood instability; chr8:8237348 chr8:8167819~8226614:- PAAD cis rs9399135 0.967 rs12527683 ENSG00000232876.1 CTA-212D2.2 -8.81 2.7e-15 1.24e-11 -0.66 -0.58 Red blood cell count; chr6:135003396 chr6:135055033~135060550:+ PAAD cis rs2487048 0.725 rs2246293 ENSG00000226334.1 RP11-217B7.2 8.81 2.7e-15 1.24e-11 0.69 0.58 Intraocular pressure; chr9:104928557 chr9:104927553~104928892:+ PAAD cis rs6452524 0.618 rs6452506 ENSG00000249664.1 CTD-2227C6.2 8.81 2.71e-15 1.25e-11 0.69 0.58 Hypertension (SNP x SNP interaction); chr5:83075844 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs1993948 ENSG00000249664.1 CTD-2227C6.2 8.81 2.71e-15 1.25e-11 0.69 0.58 Hypertension (SNP x SNP interaction); chr5:83076461 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs2075685 ENSG00000249664.1 CTD-2227C6.2 8.81 2.71e-15 1.25e-11 0.69 0.58 Hypertension (SNP x SNP interaction); chr5:83076846 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs10462394 ENSG00000249664.1 CTD-2227C6.2 8.81 2.74e-15 1.26e-11 0.69 0.58 Hypertension (SNP x SNP interaction); chr5:83058735 chr5:83012285~83013109:- PAAD cis rs6452524 0.56 rs6895174 ENSG00000249664.1 CTD-2227C6.2 8.81 2.74e-15 1.26e-11 0.69 0.58 Hypertension (SNP x SNP interaction); chr5:83071606 chr5:83012285~83013109:- PAAD cis rs858239 0.676 rs3807459 ENSG00000230658.1 KLHL7-AS1 8.8 2.74e-15 1.26e-11 0.71 0.58 Cerebrospinal fluid biomarker levels; chr7:23350132 chr7:23101228~23105703:- PAAD cis rs1799949 1 rs67060599 ENSG00000198496.9 NBR2 -8.8 2.75e-15 1.26e-11 -0.57 -0.58 Menopause (age at onset); chr17:43103085 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176133 ENSG00000198496.9 NBR2 -8.8 2.75e-15 1.26e-11 -0.57 -0.58 Menopause (age at onset); chr17:43105441 chr17:43125610~43153671:+ PAAD cis rs7301826 0.651 rs10773824 ENSG00000256299.1 RP11-989F5.3 -8.8 2.8e-15 1.28e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130814306 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs10773825 ENSG00000256299.1 RP11-989F5.3 -8.8 2.8e-15 1.28e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130814368 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs7295705 ENSG00000256299.1 RP11-989F5.3 -8.8 2.8e-15 1.28e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130817340 chr12:130810821~130812622:- PAAD cis rs4423214 1 rs732934 ENSG00000254682.1 RP11-660L16.2 8.8 2.8e-15 1.28e-11 0.82 0.58 Vitamin D levels; chr11:71475430 chr11:71448674~71452157:+ PAAD cis rs7301826 1 rs10773819 ENSG00000256250.1 RP11-989F5.1 -8.8 2.86e-15 1.31e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130794477 chr12:130810606~130812438:+ PAAD cis rs11155671 0.53 rs9968871 ENSG00000216906.2 RP11-350J20.9 8.8 2.86e-15 1.31e-11 0.77 0.58 Testicular germ cell tumor; chr6:149888060 chr6:149904243~149906418:+ PAAD cis rs11155671 0.53 rs9969044 ENSG00000216906.2 RP11-350J20.9 8.8 2.86e-15 1.31e-11 0.77 0.58 Testicular germ cell tumor; chr6:149888068 chr6:149904243~149906418:+ PAAD cis rs8040855 0.559 rs6496801 ENSG00000259295.5 CSPG4P12 -8.8 2.87e-15 1.31e-11 -0.64 -0.58 Bulimia nervosa; chr15:85185168 chr15:85191438~85213905:+ PAAD cis rs1799949 1 rs3950989 ENSG00000198496.9 NBR2 -8.8 2.89e-15 1.32e-11 -0.57 -0.58 Menopause (age at onset); chr17:43085936 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs8176161 ENSG00000198496.9 NBR2 -8.8 2.89e-15 1.32e-11 -0.57 -0.58 Menopause (age at onset); chr17:43089373 chr17:43125610~43153671:+ PAAD cis rs17826219 0.561 rs11655876 ENSG00000263531.1 RP13-753N3.1 8.79 2.97e-15 1.35e-11 1.03 0.58 Body mass index; chr17:30690132 chr17:30863921~30864940:- PAAD cis rs1799949 1 rs11653069 ENSG00000198496.9 NBR2 -8.78 3.08e-15 1.4e-11 -0.57 -0.58 Menopause (age at onset); chr17:43131360 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs33988650 ENSG00000198496.9 NBR2 -8.78 3.08e-15 1.4e-11 -0.57 -0.58 Menopause (age at onset); chr17:43135863 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11656097 ENSG00000198496.9 NBR2 -8.78 3.08e-15 1.4e-11 -0.57 -0.58 Menopause (age at onset); chr17:43138596 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs2292595 ENSG00000198496.9 NBR2 -8.78 3.08e-15 1.4e-11 -0.57 -0.58 Menopause (age at onset); chr17:43138657 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11658754 ENSG00000198496.9 NBR2 -8.78 3.08e-15 1.4e-11 -0.57 -0.58 Menopause (age at onset); chr17:43140722 chr17:43125610~43153671:+ PAAD cis rs1799949 0.93 rs33968979 ENSG00000198496.9 NBR2 -8.78 3.08e-15 1.4e-11 -0.57 -0.58 Menopause (age at onset); chr17:43145975 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs12952790 ENSG00000198496.9 NBR2 -8.78 3.08e-15 1.4e-11 -0.57 -0.58 Menopause (age at onset); chr17:43147590 chr17:43125610~43153671:+ PAAD cis rs7301826 0.651 rs10734979 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130804409 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs4759519 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130804963 chr12:130810821~130812622:- PAAD cis rs7301826 0.627 rs10773823 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130809956 chr12:130810821~130812622:- PAAD cis rs7301826 0.627 rs73162873 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130811468 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs12228957 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130811521 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs12228959 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130811523 chr12:130810821~130812622:- PAAD cis rs7301826 0.571 rs4759788 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130811769 chr12:130810821~130812622:- PAAD cis rs7301826 0.61 rs4759789 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130811835 chr12:130810821~130812622:- PAAD cis rs7301826 0.61 rs4759791 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130811950 chr12:130810821~130812622:- PAAD cis rs7301826 0.61 rs9668291 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130812363 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs4759521 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130812768 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs4759794 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130812803 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs10734981 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130813350 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs10744483 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130813661 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs10744484 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130813961 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs10744485 ENSG00000256299.1 RP11-989F5.3 -8.78 3.1e-15 1.41e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130814005 chr12:130810821~130812622:- PAAD cis rs801193 0.613 rs2016325 ENSG00000226824.5 RP4-756H11.3 8.78 3.1e-15 1.41e-11 0.7 0.58 Aortic root size; chr7:66858513 chr7:66654538~66669855:+ PAAD cis rs3091242 0.933 rs7541095 ENSG00000224183.1 SDHDP6 -8.78 3.15e-15 1.43e-11 -0.76 -0.58 Erythrocyte sedimentation rate; chr1:25434800 chr1:25294164~25294643:- PAAD cis rs9326248 0.53 rs473188 ENSG00000254851.1 RP11-109L13.1 -8.78 3.23e-15 1.46e-11 -1.03 -0.58 Blood protein levels; chr11:116941313 chr11:117135528~117138582:+ PAAD cis rs3091242 1 rs9689 ENSG00000224183.1 SDHDP6 -8.78 3.25e-15 1.48e-11 -0.73 -0.58 Erythrocyte sedimentation rate; chr1:25361785 chr1:25294164~25294643:- PAAD cis rs1799949 1 rs12950607 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43147911 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11079056 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43148782 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs12936816 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43149692 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs33926631 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43152446 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs1960605 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43153380 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs2037076 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43153866 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs12950779 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43154506 chr17:43125610~43153671:+ PAAD cis rs1799949 0.929 rs12937015 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43155456 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4340367 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43155755 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4792981 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43156257 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs35521261 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43161595 chr17:43125610~43153671:+ PAAD cis rs1799949 0.896 rs33933393 ENSG00000198496.9 NBR2 -8.77 3.29e-15 1.49e-11 -0.56 -0.58 Menopause (age at onset); chr17:43165415 chr17:43125610~43153671:+ PAAD cis rs5769707 0.681 rs9616329 ENSG00000188511.11 C22orf34 8.77 3.36e-15 1.52e-11 0.57 0.58 Monocyte percentage of white cells;Monocyte count; chr22:49632666 chr22:49414524~49657542:- PAAD cis rs9399135 0.935 rs11759999 ENSG00000232876.1 CTA-212D2.2 -8.76 3.53e-15 1.59e-11 -0.67 -0.58 Red blood cell count; chr6:135049357 chr6:135055033~135060550:+ PAAD cis rs9399135 0.935 rs11760000 ENSG00000232876.1 CTA-212D2.2 -8.76 3.53e-15 1.59e-11 -0.67 -0.58 Red blood cell count; chr6:135049358 chr6:135055033~135060550:+ PAAD cis rs3091242 0.806 rs35189848 ENSG00000224183.1 SDHDP6 8.76 3.55e-15 1.6e-11 0.76 0.58 Erythrocyte sedimentation rate; chr1:25461931 chr1:25294164~25294643:- PAAD cis rs3091242 0.836 rs35346083 ENSG00000224183.1 SDHDP6 8.76 3.55e-15 1.6e-11 0.76 0.58 Erythrocyte sedimentation rate; chr1:25461934 chr1:25294164~25294643:- PAAD cis rs858239 0.676 rs274032 ENSG00000230658.1 KLHL7-AS1 8.76 3.59e-15 1.61e-11 0.71 0.58 Cerebrospinal fluid biomarker levels; chr7:23334940 chr7:23101228~23105703:- PAAD cis rs1799949 1 rs35668327 ENSG00000198496.9 NBR2 -8.76 3.63e-15 1.63e-11 -0.57 -0.58 Menopause (age at onset); chr17:43121078 chr17:43125610~43153671:+ PAAD cis rs7301826 1 rs1106369 ENSG00000256250.1 RP11-989F5.1 -8.76 3.63e-15 1.63e-11 -0.65 -0.58 Plasma plasminogen activator levels; chr12:130815550 chr12:130810606~130812438:+ PAAD cis rs11155671 0.53 rs1334510 ENSG00000216906.2 RP11-350J20.9 8.76 3.66e-15 1.64e-11 0.77 0.58 Testicular germ cell tumor; chr6:149880043 chr6:149904243~149906418:+ PAAD cis rs977987 0.931 rs8057084 ENSG00000261783.1 RP11-252K23.2 8.76 3.66e-15 1.64e-11 0.71 0.58 Dupuytren's disease; chr16:75458808 chr16:75379818~75381260:- PAAD cis rs9326248 0.581 rs4938331 ENSG00000254851.1 RP11-109L13.1 -8.76 3.66e-15 1.64e-11 -0.71 -0.58 Blood protein levels; chr11:117059966 chr11:117135528~117138582:+ PAAD cis rs9326248 0.51 rs4938332 ENSG00000254851.1 RP11-109L13.1 -8.76 3.66e-15 1.64e-11 -0.71 -0.58 Blood protein levels; chr11:117060082 chr11:117135528~117138582:+ PAAD cis rs9326248 0.559 rs4938334 ENSG00000254851.1 RP11-109L13.1 -8.76 3.66e-15 1.64e-11 -0.71 -0.58 Blood protein levels; chr11:117060326 chr11:117135528~117138582:+ PAAD cis rs1799949 1 rs3092988 ENSG00000198496.9 NBR2 -8.75 3.68e-15 1.65e-11 -0.57 -0.58 Menopause (age at onset); chr17:43049685 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176273 ENSG00000198496.9 NBR2 -8.75 3.68e-15 1.65e-11 -0.57 -0.58 Menopause (age at onset); chr17:43059636 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176265 ENSG00000198496.9 NBR2 -8.75 3.68e-15 1.65e-11 -0.57 -0.58 Menopause (age at onset); chr17:43061979 chr17:43125610~43153671:+ PAAD cis rs3091242 0.933 rs932372 ENSG00000224183.1 SDHDP6 -8.75 3.69e-15 1.65e-11 -0.76 -0.58 Erythrocyte sedimentation rate; chr1:25428523 chr1:25294164~25294643:- PAAD cis rs55794721 0.509 rs909834 ENSG00000224183.1 SDHDP6 -8.75 3.69e-15 1.65e-11 -0.76 -0.58 Mean corpuscular volume;Plateletcrit; chr1:25431505 chr1:25294164~25294643:- PAAD cis rs7115242 0.8 rs6589597 ENSG00000254851.1 RP11-109L13.1 8.75 3.69e-15 1.65e-11 0.97 0.58 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117127082 chr11:117135528~117138582:+ PAAD cis rs7301826 0.61 rs7957899 ENSG00000256299.1 RP11-989F5.3 -8.75 3.75e-15 1.68e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130794531 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs1973834 ENSG00000256299.1 RP11-989F5.3 -8.75 3.75e-15 1.68e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130795612 chr12:130810821~130812622:- PAAD cis rs8062405 0.789 rs2106480 ENSG00000259982.1 CDC37P1 8.75 3.76e-15 1.68e-11 0.63 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28526650 chr16:28700294~28701540:- PAAD cis rs7208859 0.673 rs11651802 ENSG00000263531.1 RP13-753N3.1 8.75 3.86e-15 1.72e-11 1.17 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832642 chr17:30863921~30864940:- PAAD cis rs8062405 1 rs62036617 ENSG00000259982.1 CDC37P1 8.75 3.89e-15 1.74e-11 0.64 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28816177 chr16:28700294~28701540:- PAAD cis rs1799949 1 rs8176242 ENSG00000198496.9 NBR2 -8.74 3.9e-15 1.74e-11 -0.57 -0.58 Menopause (age at onset); chr17:43065857 chr17:43125610~43153671:+ PAAD cis rs9326248 0.53 rs1242229 ENSG00000254851.1 RP11-109L13.1 -8.74 3.92e-15 1.75e-11 -0.95 -0.58 Blood protein levels; chr11:117191654 chr11:117135528~117138582:+ PAAD cis rs1799949 1 rs33918839 ENSG00000198496.9 NBR2 -8.74 3.97e-15 1.77e-11 -0.56 -0.58 Menopause (age at onset); chr17:43177155 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs2175957 ENSG00000198496.9 NBR2 -8.74 3.98e-15 1.78e-11 -0.57 -0.58 Menopause (age at onset); chr17:43134805 chr17:43125610~43153671:+ PAAD cis rs6452524 0.618 rs6452502 ENSG00000249664.1 CTD-2227C6.2 8.74 3.99e-15 1.78e-11 0.69 0.58 Hypertension (SNP x SNP interaction); chr5:83074578 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs6452503 ENSG00000249664.1 CTD-2227C6.2 8.74 3.99e-15 1.78e-11 0.69 0.58 Hypertension (SNP x SNP interaction); chr5:83074596 chr5:83012285~83013109:- PAAD cis rs6452524 0.618 rs6452504 ENSG00000249664.1 CTD-2227C6.2 8.74 3.99e-15 1.78e-11 0.69 0.58 Hypertension (SNP x SNP interaction); chr5:83074625 chr5:83012285~83013109:- PAAD cis rs8062405 0.824 rs4788083 ENSG00000259982.1 CDC37P1 8.74 4e-15 1.78e-11 0.63 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534128 chr16:28700294~28701540:- PAAD cis rs1799949 1 rs33946455 ENSG00000198496.9 NBR2 -8.74 4.03e-15 1.8e-11 -0.56 -0.58 Menopause (age at onset); chr17:43169829 chr17:43125610~43153671:+ PAAD cis rs9545047 0.967 rs9318627 ENSG00000227676.3 LINC01068 8.74 4.03e-15 1.8e-11 0.72 0.58 Schizophrenia; chr13:79355944 chr13:79566727~79571436:+ PAAD cis rs11155671 0.53 rs9383940 ENSG00000216906.2 RP11-350J20.9 8.74 4.13e-15 1.84e-11 0.75 0.58 Testicular germ cell tumor; chr6:149904923 chr6:149904243~149906418:+ PAAD cis rs5760092 0.755 rs4585126 ENSG00000218537.1 MIF-AS1 -8.73 4.18e-15 1.86e-11 -0.86 -0.58 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23894426~23898930:- PAAD cis rs7301826 0.627 rs4334059 ENSG00000256299.1 RP11-989F5.3 -8.73 4.23e-15 1.88e-11 -0.65 -0.58 Plasma plasminogen activator levels; chr12:130829669 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs7968675 ENSG00000256299.1 RP11-989F5.3 -8.73 4.24e-15 1.88e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130818832 chr12:130810821~130812622:- PAAD cis rs6452524 0.532 rs26263 ENSG00000249664.1 CTD-2227C6.2 8.73 4.25e-15 1.88e-11 0.7 0.58 Hypertension (SNP x SNP interaction); chr5:83044465 chr5:83012285~83013109:- PAAD cis rs7301826 0.651 rs10848209 ENSG00000256299.1 RP11-989F5.3 -8.73 4.33e-15 1.92e-11 -0.66 -0.58 Plasma plasminogen activator levels; chr12:130826727 chr12:130810821~130812622:- PAAD cis rs977987 0.966 rs6564261 ENSG00000261783.1 RP11-252K23.2 -8.73 4.38e-15 1.94e-11 -0.71 -0.58 Dupuytren's disease; chr16:75458344 chr16:75379818~75381260:- PAAD cis rs2882667 0.964 rs67296915 ENSG00000253404.1 AC034243.1 8.72 4.42e-15 1.95e-11 0.7 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:138965910 chr5:138744434~138753309:- PAAD cis rs9326248 0.53 rs72645460 ENSG00000254851.1 RP11-109L13.1 8.72 4.44e-15 1.96e-11 1.09 0.58 Blood protein levels; chr11:116900659 chr11:117135528~117138582:+ PAAD cis rs55794721 0.509 rs12027135 ENSG00000224183.1 SDHDP6 -8.72 4.56e-15 2.01e-11 -0.74 -0.58 Mean corpuscular volume;Plateletcrit; chr1:25449242 chr1:25294164~25294643:- PAAD cis rs8040855 0.644 rs4635318 ENSG00000259295.5 CSPG4P12 -8.72 4.6e-15 2.03e-11 -0.63 -0.58 Bulimia nervosa; chr15:85183506 chr15:85191438~85213905:+ PAAD cis rs8062405 0.824 rs4788085 ENSG00000259982.1 CDC37P1 8.72 4.62e-15 2.04e-11 0.63 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523682 chr16:28700294~28701540:- PAAD cis rs8062405 0.824 rs28772958 ENSG00000259982.1 CDC37P1 8.72 4.62e-15 2.04e-11 0.63 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523984 chr16:28700294~28701540:- PAAD cis rs7301826 0.651 rs2037789 ENSG00000256299.1 RP11-989F5.3 8.72 4.64e-15 2.05e-11 0.67 0.58 Plasma plasminogen activator levels; chr12:130803747 chr12:130810821~130812622:- PAAD cis rs321358 0.945 rs10502129 ENSG00000271584.1 RP11-89C3.4 8.71 4.66e-15 2.05e-11 0.78 0.58 Body mass index; chr11:111107405 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs10502130 ENSG00000271584.1 RP11-89C3.4 8.71 4.66e-15 2.05e-11 0.78 0.58 Body mass index; chr11:111107437 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs73017109 ENSG00000271584.1 RP11-89C3.4 8.71 4.66e-15 2.05e-11 0.78 0.58 Body mass index; chr11:111108484 chr11:111091932~111097357:- PAAD cis rs321358 0.887 rs1470537 ENSG00000271584.1 RP11-89C3.4 8.71 4.66e-15 2.05e-11 0.78 0.58 Body mass index; chr11:111109328 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs12421769 ENSG00000271584.1 RP11-89C3.4 8.71 4.66e-15 2.05e-11 0.78 0.58 Body mass index; chr11:111109500 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs73017114 ENSG00000271584.1 RP11-89C3.4 8.71 4.66e-15 2.05e-11 0.78 0.58 Body mass index; chr11:111111582 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs17458493 ENSG00000271584.1 RP11-89C3.4 8.71 4.66e-15 2.05e-11 0.78 0.58 Body mass index; chr11:111112156 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs17458541 ENSG00000271584.1 RP11-89C3.4 8.71 4.66e-15 2.05e-11 0.78 0.58 Body mass index; chr11:111113182 chr11:111091932~111097357:- PAAD cis rs9326248 0.53 rs2155583 ENSG00000254851.1 RP11-109L13.1 -8.71 4.68e-15 2.06e-11 -1.02 -0.58 Blood protein levels; chr11:117044501 chr11:117135528~117138582:+ PAAD cis rs977987 0.902 rs34539062 ENSG00000261783.1 RP11-252K23.2 -8.71 4.68e-15 2.06e-11 -0.71 -0.58 Dupuytren's disease; chr16:75459381 chr16:75379818~75381260:- PAAD cis rs977987 0.866 rs17696831 ENSG00000261783.1 RP11-252K23.2 -8.71 4.68e-15 2.06e-11 -0.71 -0.58 Dupuytren's disease; chr16:75459400 chr16:75379818~75381260:- PAAD cis rs977987 0.898 rs12918797 ENSG00000261783.1 RP11-252K23.2 -8.71 4.68e-15 2.06e-11 -0.71 -0.58 Dupuytren's disease; chr16:75459912 chr16:75379818~75381260:- PAAD cis rs1799949 1 rs11653231 ENSG00000198496.9 NBR2 -8.71 4.69e-15 2.06e-11 -0.56 -0.58 Menopause (age at onset); chr17:43179443 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs1399323 ENSG00000198496.9 NBR2 -8.71 4.69e-15 2.06e-11 -0.56 -0.58 Menopause (age at onset); chr17:43180313 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs35954893 ENSG00000198496.9 NBR2 -8.71 4.69e-15 2.06e-11 -0.56 -0.58 Menopause (age at onset); chr17:43181769 chr17:43125610~43153671:+ PAAD cis rs1799949 0.93 rs4445938 ENSG00000198496.9 NBR2 -8.71 4.69e-15 2.06e-11 -0.56 -0.58 Menopause (age at onset); chr17:43185883 chr17:43125610~43153671:+ PAAD cis rs8062405 1 rs7498555 ENSG00000259982.1 CDC37P1 8.71 4.7e-15 2.06e-11 0.65 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28882250 chr16:28700294~28701540:- PAAD cis rs9326248 0.53 rs2000615 ENSG00000254851.1 RP11-109L13.1 -8.71 4.7e-15 2.07e-11 -1.02 -0.58 Blood protein levels; chr11:117045103 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs6589589 ENSG00000254851.1 RP11-109L13.1 -8.71 4.7e-15 2.07e-11 -1.02 -0.58 Blood protein levels; chr11:117061712 chr11:117135528~117138582:+ PAAD cis rs1062177 1 rs12654573 ENSG00000213433.5 RPLP1P6 -8.71 4.73e-15 2.08e-11 -0.65 -0.58 Preschool internalizing problems; chr5:151827912 chr5:151765859~151766378:- PAAD cis rs3091242 0.933 rs9438905 ENSG00000224183.1 SDHDP6 -8.71 4.8e-15 2.11e-11 -0.75 -0.58 Erythrocyte sedimentation rate; chr1:25437686 chr1:25294164~25294643:- PAAD cis rs7208859 0.673 rs1347360 ENSG00000263531.1 RP13-753N3.1 8.71 4.8e-15 2.11e-11 1.02 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587514 chr17:30863921~30864940:- PAAD cis rs3091242 0.935 rs4233043 ENSG00000224183.1 SDHDP6 -8.71 4.81e-15 2.11e-11 -0.75 -0.58 Erythrocyte sedimentation rate; chr1:25438992 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs11249250 ENSG00000224183.1 SDHDP6 -8.71 4.81e-15 2.11e-11 -0.75 -0.58 Erythrocyte sedimentation rate; chr1:25441118 chr1:25294164~25294643:- PAAD cis rs2882667 0.964 rs12055237 ENSG00000253404.1 AC034243.1 8.71 4.86e-15 2.13e-11 0.72 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:138971617 chr5:138744434~138753309:- PAAD cis rs7208859 0.623 rs8082537 ENSG00000263531.1 RP13-753N3.1 8.71 4.86e-15 2.13e-11 1.03 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30688914 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9907197 ENSG00000263531.1 RP13-753N3.1 8.71 4.86e-15 2.13e-11 1.03 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30691245 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9915963 ENSG00000263531.1 RP13-753N3.1 8.71 4.86e-15 2.13e-11 1.03 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30692625 chr17:30863921~30864940:- PAAD cis rs9326248 0.52 rs74830 ENSG00000254851.1 RP11-109L13.1 8.71 4.89e-15 2.14e-11 0.71 0.58 Blood protein levels; chr11:117219842 chr11:117135528~117138582:+ PAAD cis rs7208859 0.673 rs11656462 ENSG00000263531.1 RP13-753N3.1 8.71 4.92e-15 2.16e-11 1.15 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30833682 chr17:30863921~30864940:- PAAD cis rs1799949 0.965 rs33961729 ENSG00000198496.9 NBR2 -8.7 4.94e-15 2.16e-11 -0.57 -0.58 Menopause (age at onset); chr17:43135907 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11657835 ENSG00000198496.9 NBR2 -8.7 4.94e-15 2.16e-11 -0.57 -0.58 Menopause (age at onset); chr17:43139936 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs1135214 ENSG00000198496.9 NBR2 -8.7 4.94e-15 2.16e-11 -0.57 -0.58 Menopause (age at onset); chr17:43140306 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11652332 ENSG00000198496.9 NBR2 -8.7 4.94e-15 2.16e-11 -0.57 -0.58 Menopause (age at onset); chr17:43143472 chr17:43125610~43153671:+ PAAD cis rs9660180 0.78 rs12038111 ENSG00000268575.1 RP1-283E3.8 -8.7 4.98e-15 2.18e-11 -0.56 -0.58 Body mass index; chr1:1772410 chr1:1702736~1737688:- PAAD cis rs9660180 0.836 rs12038134 ENSG00000268575.1 RP1-283E3.8 -8.7 4.98e-15 2.18e-11 -0.56 -0.58 Body mass index; chr1:1772426 chr1:1702736~1737688:- PAAD cis rs9660180 0.836 rs72634845 ENSG00000268575.1 RP1-283E3.8 -8.7 4.98e-15 2.18e-11 -0.56 -0.58 Body mass index; chr1:1773460 chr1:1702736~1737688:- PAAD cis rs9660180 0.868 rs72634846 ENSG00000268575.1 RP1-283E3.8 -8.7 4.98e-15 2.18e-11 -0.56 -0.58 Body mass index; chr1:1773476 chr1:1702736~1737688:- PAAD cis rs67383717 0.689 rs1836404 ENSG00000175611.10 LINC00476 -8.7 5.12e-15 2.24e-11 -0.51 -0.58 Parkinson's disease (pesticide exposure interaction); chr9:95787982 chr9:95759231~95875977:- PAAD cis rs7104764 1 rs6598060 ENSG00000277290.1 RP11-326C3.16 -8.7 5.16e-15 2.26e-11 -0.54 -0.58 Menarche (age at onset); chr11:243987 chr11:243099~243483:- PAAD cis rs7208859 0.673 rs999797 ENSG00000263531.1 RP13-753N3.1 8.7 5.17e-15 2.26e-11 1.16 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832311 chr17:30863921~30864940:- PAAD cis rs875971 0.825 rs28480509 ENSG00000226824.5 RP4-756H11.3 8.7 5.19e-15 2.26e-11 0.71 0.58 Aortic root size; chr7:66634237 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs9791712 ENSG00000226824.5 RP4-756H11.3 8.7 5.19e-15 2.26e-11 0.71 0.58 Aortic root size; chr7:66640176 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs9791713 ENSG00000226824.5 RP4-756H11.3 8.7 5.19e-15 2.26e-11 0.71 0.58 Aortic root size; chr7:66640211 chr7:66654538~66669855:+ PAAD cis rs11155671 0.53 rs4870080 ENSG00000216906.2 RP11-350J20.9 8.69 5.33e-15 2.32e-11 0.77 0.58 Testicular germ cell tumor; chr6:149881508 chr6:149904243~149906418:+ PAAD cis rs6452524 0.618 rs255561 ENSG00000249664.1 CTD-2227C6.2 8.69 5.36e-15 2.34e-11 0.68 0.58 Hypertension (SNP x SNP interaction); chr5:83054991 chr5:83012285~83013109:- PAAD cis rs12439619 0.693 rs9944185 ENSG00000278603.1 RP13-608F4.5 8.69 5.39e-15 2.35e-11 0.83 0.58 Intelligence (multi-trait analysis); chr15:82157927 chr15:82472203~82472426:+ PAAD cis rs1799949 1 rs4793212 ENSG00000198496.9 NBR2 -8.69 5.41e-15 2.36e-11 -0.57 -0.58 Menopause (age at onset); chr17:43150733 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs34534709 ENSG00000198496.9 NBR2 -8.69 5.41e-15 2.36e-11 -0.57 -0.58 Menopause (age at onset); chr17:43150923 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs34059614 ENSG00000198496.9 NBR2 -8.69 5.41e-15 2.36e-11 -0.57 -0.58 Menopause (age at onset); chr17:43151054 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs1973646 ENSG00000198496.9 NBR2 -8.69 5.41e-15 2.36e-11 -0.57 -0.58 Menopause (age at onset); chr17:43158478 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4793215 ENSG00000198496.9 NBR2 -8.69 5.41e-15 2.36e-11 -0.57 -0.58 Menopause (age at onset); chr17:43166915 chr17:43125610~43153671:+ PAAD cis rs3814244 0.569 rs11177008 ENSG00000255733.4 IFNG-AS1 8.69 5.44e-15 2.37e-11 0.54 0.58 Itch intensity from mosquito bite adjusted by bite size; chr12:68021024 chr12:67989445~68234686:+ PAAD cis rs9326248 0.53 rs17120139 ENSG00000254851.1 RP11-109L13.1 8.69 5.47e-15 2.37e-11 1.08 0.58 Blood protein levels; chr11:116903485 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs7124741 ENSG00000254851.1 RP11-109L13.1 -8.69 5.5e-15 2.39e-11 -1.03 -0.58 Blood protein levels; chr11:116881503 chr11:117135528~117138582:+ PAAD cis rs977987 0.898 rs12918974 ENSG00000261783.1 RP11-252K23.2 -8.69 5.55e-15 2.41e-11 -0.72 -0.58 Dupuytren's disease; chr16:75460045 chr16:75379818~75381260:- PAAD cis rs977987 0.866 rs12932606 ENSG00000261783.1 RP11-252K23.2 -8.69 5.55e-15 2.41e-11 -0.72 -0.58 Dupuytren's disease; chr16:75460046 chr16:75379818~75381260:- PAAD cis rs5769707 0.609 rs2071890 ENSG00000188511.11 C22orf34 8.68 5.61e-15 2.43e-11 0.6 0.58 Monocyte percentage of white cells;Monocyte count; chr22:49607643 chr22:49414524~49657542:- PAAD cis rs8040855 0.621 rs6496796 ENSG00000259295.5 CSPG4P12 -8.68 5.64e-15 2.45e-11 -0.62 -0.58 Bulimia nervosa; chr15:85183617 chr15:85191438~85213905:+ PAAD cis rs9326248 0.53 rs2000614 ENSG00000254851.1 RP11-109L13.1 -8.68 5.71e-15 2.47e-11 -0.99 -0.58 Blood protein levels; chr11:117045026 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs2000616 ENSG00000254851.1 RP11-109L13.1 -8.68 5.71e-15 2.47e-11 -0.99 -0.58 Blood protein levels; chr11:117045813 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs10750100 ENSG00000254851.1 RP11-109L13.1 -8.68 5.71e-15 2.47e-11 -0.99 -0.58 Blood protein levels; chr11:117046528 chr11:117135528~117138582:+ PAAD cis rs1815787 1 rs1815787 ENSG00000254851.1 RP11-109L13.1 -8.68 5.71e-15 2.47e-11 -0.99 -0.58 Subjective well-being; chr11:117050681 chr11:117135528~117138582:+ PAAD cis rs7208859 0.573 rs216443 ENSG00000263531.1 RP13-753N3.1 8.68 5.74e-15 2.49e-11 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604853 chr17:30863921~30864940:- PAAD cis rs2455601 0.744 rs2163626 ENSG00000254860.4 TMEM9B-AS1 8.68 5.78e-15 2.5e-11 0.74 0.58 Schizophrenia; chr11:8962000 chr11:8964675~8977527:+ PAAD cis rs7208859 0.614 rs216412 ENSG00000263531.1 RP13-753N3.1 -8.68 5.82e-15 2.52e-11 -0.99 -0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576376 chr17:30863921~30864940:- PAAD cis rs9399135 0.967 rs4895434 ENSG00000232876.1 CTA-212D2.2 -8.68 5.86e-15 2.54e-11 -0.67 -0.58 Red blood cell count; chr6:134972227 chr6:135055033~135060550:+ PAAD cis rs9399135 1 rs4895435 ENSG00000232876.1 CTA-212D2.2 -8.68 5.86e-15 2.54e-11 -0.67 -0.58 Red blood cell count; chr6:134972325 chr6:135055033~135060550:+ PAAD cis rs8062405 1 rs4788095 ENSG00000259982.1 CDC37P1 8.67 5.92e-15 2.56e-11 0.64 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28820038 chr16:28700294~28701540:- PAAD cis rs8062405 0.964 rs72793809 ENSG00000259982.1 CDC37P1 8.67 5.92e-15 2.56e-11 0.64 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821061 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62036620 ENSG00000259982.1 CDC37P1 8.67 5.92e-15 2.56e-11 0.64 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821776 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62036621 ENSG00000259982.1 CDC37P1 8.67 5.92e-15 2.56e-11 0.64 0.58 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821978 chr16:28700294~28701540:- PAAD cis rs977987 0.732 rs999675 ENSG00000261783.1 RP11-252K23.2 -8.67 5.97e-15 2.58e-11 -0.76 -0.58 Dupuytren's disease; chr16:75272504 chr16:75379818~75381260:- PAAD cis rs1799949 1 rs8074136 ENSG00000198496.9 NBR2 -8.67 6e-15 2.59e-11 -0.57 -0.58 Menopause (age at onset); chr17:43190296 chr17:43125610~43153671:+ PAAD cis rs977987 0.931 rs11641430 ENSG00000261783.1 RP11-252K23.2 -8.67 6.13e-15 2.65e-11 -0.71 -0.58 Dupuytren's disease; chr16:75461378 chr16:75379818~75381260:- PAAD cis rs977987 0.931 rs7195161 ENSG00000261783.1 RP11-252K23.2 -8.67 6.13e-15 2.65e-11 -0.71 -0.58 Dupuytren's disease; chr16:75461674 chr16:75379818~75381260:- PAAD cis rs977987 0.931 rs1424013 ENSG00000261783.1 RP11-252K23.2 -8.67 6.13e-15 2.65e-11 -0.71 -0.58 Dupuytren's disease; chr16:75462088 chr16:75379818~75381260:- PAAD cis rs2455601 0.744 rs11042133 ENSG00000254860.4 TMEM9B-AS1 8.67 6.2e-15 2.68e-11 0.75 0.58 Schizophrenia; chr11:8944964 chr11:8964675~8977527:+ PAAD cis rs2455601 0.786 rs56680262 ENSG00000254860.4 TMEM9B-AS1 8.67 6.2e-15 2.68e-11 0.75 0.58 Schizophrenia; chr11:8950008 chr11:8964675~8977527:+ PAAD cis rs9399135 0.967 rs4896123 ENSG00000232876.1 CTA-212D2.2 -8.67 6.22e-15 2.69e-11 -0.67 -0.58 Red blood cell count; chr6:134974272 chr6:135055033~135060550:+ PAAD cis rs1799949 0.965 rs8176323 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43043694 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs8176322 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43043756 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs12516 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43044391 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4793190 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43048092 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176297 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43051308 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176296 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43051574 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4793191 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43052360 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4793192 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43052373 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176289 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43054039 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs35330014 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43060530 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs3092994 ENSG00000198496.9 NBR2 -8.66 6.25e-15 2.69e-11 -0.57 -0.58 Menopause (age at onset); chr17:43063808 chr17:43125610~43153671:+ PAAD cis rs1799949 0.93 rs8176194 ENSG00000198496.9 NBR2 -8.66 6.29e-15 2.71e-11 -0.57 -0.57 Menopause (age at onset); chr17:43079204 chr17:43125610~43153671:+ PAAD cis rs2882667 0.964 rs11958050 ENSG00000253404.1 AC034243.1 8.66 6.34e-15 2.73e-11 0.69 0.57 Age-related hearing impairment (SNP x SNP interaction); chr5:138966139 chr5:138744434~138753309:- PAAD cis rs8040855 0.644 rs7495437 ENSG00000259295.5 CSPG4P12 -8.66 6.34e-15 2.73e-11 -0.62 -0.57 Bulimia nervosa; chr15:85183059 chr15:85191438~85213905:+ PAAD cis rs9326248 0.581 rs10502222 ENSG00000254851.1 RP11-109L13.1 -8.66 6.39e-15 2.75e-11 -0.71 -0.57 Blood protein levels; chr11:116963014 chr11:117135528~117138582:+ PAAD cis rs9326248 0.559 rs10892052 ENSG00000254851.1 RP11-109L13.1 -8.66 6.39e-15 2.75e-11 -0.71 -0.57 Blood protein levels; chr11:116963597 chr11:117135528~117138582:+ PAAD cis rs1799949 1 rs4793194 ENSG00000198496.9 NBR2 -8.66 6.4e-15 2.75e-11 -0.57 -0.57 Menopause (age at onset); chr17:43066316 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176234 ENSG00000198496.9 NBR2 -8.66 6.4e-15 2.75e-11 -0.57 -0.57 Menopause (age at onset); chr17:43067763 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176233 ENSG00000198496.9 NBR2 -8.66 6.4e-15 2.75e-11 -0.57 -0.57 Menopause (age at onset); chr17:43067787 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs11651623 ENSG00000198496.9 NBR2 -8.66 6.41e-15 2.76e-11 -0.57 -0.57 Menopause (age at onset); chr17:43177830 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs11657883 ENSG00000198496.9 NBR2 -8.66 6.41e-15 2.76e-11 -0.57 -0.57 Menopause (age at onset); chr17:43178007 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs11656945 ENSG00000198496.9 NBR2 -8.66 6.41e-15 2.76e-11 -0.57 -0.57 Menopause (age at onset); chr17:43178248 chr17:43125610~43153671:+ PAAD cis rs4718428 1 rs1830070 ENSG00000226824.5 RP4-756H11.3 -8.66 6.5e-15 2.8e-11 -0.71 -0.57 Corneal structure; chr7:66884684 chr7:66654538~66669855:+ PAAD cis rs507080 0.733 rs4486664 ENSG00000255422.1 AP002954.4 -8.66 6.53e-15 2.8e-11 -0.69 -0.57 Serum metabolite levels; chr11:118698358 chr11:118704607~118750263:+ PAAD cis rs507080 0.733 rs4393358 ENSG00000255422.1 AP002954.4 -8.66 6.53e-15 2.8e-11 -0.69 -0.57 Serum metabolite levels; chr11:118698388 chr11:118704607~118750263:+ PAAD cis rs875971 0.862 rs1167408 ENSG00000226824.5 RP4-756H11.3 8.66 6.56e-15 2.82e-11 0.71 0.57 Aortic root size; chr7:66091121 chr7:66654538~66669855:+ PAAD cis rs875971 0.83 rs1167406 ENSG00000226824.5 RP4-756H11.3 8.66 6.56e-15 2.82e-11 0.71 0.57 Aortic root size; chr7:66091949 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs709609 ENSG00000226824.5 RP4-756H11.3 8.66 6.56e-15 2.82e-11 0.71 0.57 Aortic root size; chr7:66095574 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs1167399 ENSG00000226824.5 RP4-756H11.3 8.66 6.56e-15 2.82e-11 0.71 0.57 Aortic root size; chr7:66096890 chr7:66654538~66669855:+ PAAD cis rs321358 0.945 rs73015196 ENSG00000271584.1 RP11-89C3.4 8.66 6.57e-15 2.82e-11 0.78 0.57 Body mass index; chr11:111104608 chr11:111091932~111097357:- PAAD cis rs321358 0.945 rs73015199 ENSG00000271584.1 RP11-89C3.4 8.66 6.57e-15 2.82e-11 0.78 0.57 Body mass index; chr11:111104952 chr11:111091932~111097357:- PAAD cis rs55794721 0.509 rs6699113 ENSG00000224183.1 SDHDP6 -8.65 6.62e-15 2.84e-11 -0.74 -0.57 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25294164~25294643:- PAAD cis rs55794721 0.509 rs7554255 ENSG00000224183.1 SDHDP6 -8.65 6.62e-15 2.84e-11 -0.74 -0.57 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25294164~25294643:- PAAD cis rs55794721 0.509 rs4649085 ENSG00000224183.1 SDHDP6 -8.65 6.62e-15 2.84e-11 -0.74 -0.57 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25294164~25294643:- PAAD cis rs875971 0.862 rs57866200 ENSG00000226824.5 RP4-756H11.3 8.65 6.63e-15 2.85e-11 0.71 0.57 Aortic root size; chr7:66100405 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs1860469 ENSG00000226824.5 RP4-756H11.3 8.65 6.66e-15 2.86e-11 0.71 0.57 Aortic root size; chr7:66641888 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs4718383 ENSG00000226824.5 RP4-756H11.3 8.65 6.66e-15 2.86e-11 0.71 0.57 Aortic root size; chr7:66643422 chr7:66654538~66669855:+ PAAD cis rs7104764 1 rs2272563 ENSG00000277290.1 RP11-326C3.16 -8.65 6.67e-15 2.86e-11 -0.54 -0.57 Menarche (age at onset); chr11:236871 chr11:243099~243483:- PAAD cis rs7104764 0.917 rs1045288 ENSG00000277290.1 RP11-326C3.16 -8.65 6.67e-15 2.86e-11 -0.54 -0.57 Menarche (age at onset); chr11:237087 chr11:243099~243483:- PAAD cis rs7104764 0.957 rs3817629 ENSG00000277290.1 RP11-326C3.16 -8.65 6.67e-15 2.86e-11 -0.54 -0.57 Menarche (age at onset); chr11:237312 chr11:243099~243483:- PAAD cis rs7104764 1 rs10902110 ENSG00000277290.1 RP11-326C3.16 -8.65 6.67e-15 2.86e-11 -0.54 -0.57 Menarche (age at onset); chr11:237648 chr11:243099~243483:- PAAD cis rs7104764 1 rs7481993 ENSG00000277290.1 RP11-326C3.16 -8.65 6.67e-15 2.86e-11 -0.54 -0.57 Menarche (age at onset); chr11:237875 chr11:243099~243483:- PAAD cis rs7104764 1 rs6598069 ENSG00000277290.1 RP11-326C3.16 -8.65 6.67e-15 2.86e-11 -0.54 -0.57 Menarche (age at onset); chr11:240664 chr11:243099~243483:- PAAD cis rs67383717 0.643 rs72756397 ENSG00000175611.10 LINC00476 -8.65 6.9e-15 2.96e-11 -0.49 -0.57 Parkinson's disease (pesticide exposure interaction); chr9:95790861 chr9:95759231~95875977:- PAAD cis rs4423214 0.918 rs11233789 ENSG00000254682.1 RP11-660L16.2 8.64 7.05e-15 3.01e-11 0.8 0.57 Vitamin D levels; chr11:71470039 chr11:71448674~71452157:+ PAAD cis rs5769707 0.706 rs763128 ENSG00000188511.11 C22orf34 8.64 7.06e-15 3.02e-11 0.55 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49624397 chr22:49414524~49657542:- PAAD cis rs8040855 0.542 rs2342122 ENSG00000259295.5 CSPG4P12 -8.64 7.12e-15 3.04e-11 -0.62 -0.57 Bulimia nervosa; chr15:85185304 chr15:85191438~85213905:+ PAAD cis rs8040855 0.644 rs2342120 ENSG00000259295.5 CSPG4P12 -8.64 7.12e-15 3.04e-11 -0.62 -0.57 Bulimia nervosa; chr15:85185589 chr15:85191438~85213905:+ PAAD cis rs1799949 0.93 rs35292991 ENSG00000198496.9 NBR2 -8.64 7.19e-15 3.07e-11 -0.57 -0.57 Menopause (age at onset); chr17:43181999 chr17:43125610~43153671:+ PAAD cis rs8062405 0.625 rs8060365 ENSG00000259982.1 CDC37P1 -8.64 7.25e-15 3.09e-11 -0.68 -0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28899988 chr16:28700294~28701540:- PAAD cis rs8062405 0.698 rs8046545 ENSG00000259982.1 CDC37P1 -8.64 7.25e-15 3.09e-11 -0.68 -0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28903896 chr16:28700294~28701540:- PAAD cis rs8062405 0.698 rs10499 ENSG00000259982.1 CDC37P1 -8.64 7.25e-15 3.09e-11 -0.68 -0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28904206 chr16:28700294~28701540:- PAAD cis rs6452524 0.534 rs17284134 ENSG00000249664.1 CTD-2227C6.2 -8.64 7.28e-15 3.11e-11 -0.68 -0.57 Hypertension (SNP x SNP interaction); chr5:83068325 chr5:83012285~83013109:- PAAD cis rs3091242 0.904 rs6661533 ENSG00000224183.1 SDHDP6 -8.64 7.4e-15 3.15e-11 -0.74 -0.57 Erythrocyte sedimentation rate; chr1:25445224 chr1:25294164~25294643:- PAAD cis rs321358 0.945 rs7111445 ENSG00000271584.1 RP11-89C3.4 -8.64 7.42e-15 3.16e-11 -0.77 -0.57 Body mass index; chr11:111105787 chr11:111091932~111097357:- PAAD cis rs7104764 1 rs7395328 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:242624 chr11:243099~243483:- PAAD cis rs7104764 0.917 rs6598068 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:243092 chr11:243099~243483:- PAAD cis rs7104764 0.917 rs6598067 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:243093 chr11:243099~243483:- PAAD cis rs7104764 1 rs6598065 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:243211 chr11:243099~243483:- PAAD cis rs7104764 0.957 rs6598064 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:243557 chr11:243099~243483:- PAAD cis rs7104764 1 rs6598063 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:243672 chr11:243099~243483:- PAAD cis rs7104764 1 rs6598062 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:243712 chr11:243099~243483:- PAAD cis rs7104764 1 rs6598061 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:243853 chr11:243099~243483:- PAAD cis rs7104764 1 rs10902112 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:244106 chr11:243099~243483:- PAAD cis rs7104764 0.917 rs7107362 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:244108 chr11:243099~243483:- PAAD cis rs7104764 1 rs7128044 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:244115 chr11:243099~243483:- PAAD cis rs7104764 0.957 rs7116130 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:244129 chr11:243099~243483:- PAAD cis rs7104764 1 rs7128029 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:244141 chr11:243099~243483:- PAAD cis rs7104764 1 rs1128320 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:244167 chr11:243099~243483:- PAAD cis rs7104764 1 rs2272565 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:244414 chr11:243099~243483:- PAAD cis rs7104764 1 rs10902113 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:245523 chr11:243099~243483:- PAAD cis rs7104764 1 rs7482591 ENSG00000277290.1 RP11-326C3.16 -8.63 7.45e-15 3.17e-11 -0.54 -0.57 Menarche (age at onset); chr11:245861 chr11:243099~243483:- PAAD cis rs9326248 0.53 rs562179 ENSG00000254851.1 RP11-109L13.1 -8.63 7.54e-15 3.2e-11 -1.05 -0.57 Blood protein levels; chr11:116934488 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs2513095 ENSG00000254851.1 RP11-109L13.1 -8.63 7.54e-15 3.2e-11 -1.05 -0.57 Blood protein levels; chr11:116935553 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs2513093 ENSG00000254851.1 RP11-109L13.1 -8.63 7.54e-15 3.2e-11 -1.05 -0.57 Blood protein levels; chr11:116935971 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs510988 ENSG00000254851.1 RP11-109L13.1 -8.63 7.54e-15 3.2e-11 -1.05 -0.57 Blood protein levels; chr11:116943088 chr11:117135528~117138582:+ PAAD cis rs7115242 0.8 rs493134 ENSG00000254851.1 RP11-109L13.1 -8.63 7.54e-15 3.2e-11 -1.05 -0.57 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116962963 chr11:117135528~117138582:+ PAAD cis rs1799949 1 rs12944430 ENSG00000198496.9 NBR2 -8.63 7.6e-15 3.22e-11 -0.57 -0.57 Menopause (age at onset); chr17:43178803 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11653460 ENSG00000198496.9 NBR2 -8.63 7.6e-15 3.22e-11 -0.57 -0.57 Menopause (age at onset); chr17:43179289 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs11650913 ENSG00000198496.9 NBR2 -8.63 7.6e-15 3.22e-11 -0.57 -0.57 Menopause (age at onset); chr17:43179580 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs12936831 ENSG00000198496.9 NBR2 -8.63 7.6e-15 3.22e-11 -0.57 -0.57 Menopause (age at onset); chr17:43179799 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs11658499 ENSG00000198496.9 NBR2 -8.63 7.6e-15 3.22e-11 -0.57 -0.57 Menopause (age at onset); chr17:43182732 chr17:43125610~43153671:+ PAAD cis rs17507216 0.591 rs7163848 ENSG00000278603.1 RP13-608F4.5 8.63 7.63e-15 3.24e-11 0.98 0.57 Excessive daytime sleepiness; chr15:82729563 chr15:82472203~82472426:+ PAAD cis rs5760092 0.618 rs5996631 ENSG00000218537.1 MIF-AS1 -8.63 7.63e-15 3.24e-11 -0.82 -0.57 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23894426~23898930:- PAAD cis rs7115242 0.669 rs1241658 ENSG00000254851.1 RP11-109L13.1 -8.63 7.65e-15 3.24e-11 -1.06 -0.57 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116948901 chr11:117135528~117138582:+ PAAD cis rs9326248 0.501 rs4938351 ENSG00000254851.1 RP11-109L13.1 -8.63 7.66e-15 3.25e-11 -0.7 -0.57 Blood protein levels; chr11:117151636 chr11:117135528~117138582:+ PAAD cis rs9326248 0.52 rs6589602 ENSG00000254851.1 RP11-109L13.1 -8.63 7.66e-15 3.25e-11 -0.7 -0.57 Blood protein levels; chr11:117166349 chr11:117135528~117138582:+ PAAD cis rs9326248 0.539 rs7120565 ENSG00000254851.1 RP11-109L13.1 -8.63 7.66e-15 3.25e-11 -0.7 -0.57 Blood protein levels; chr11:117172233 chr11:117135528~117138582:+ PAAD cis rs7104764 0.957 rs519592 ENSG00000277290.1 RP11-326C3.16 -8.63 7.69e-15 3.26e-11 -0.54 -0.57 Menarche (age at onset); chr11:236811 chr11:243099~243483:- PAAD cis rs1799949 0.965 rs4793233 ENSG00000198496.9 NBR2 -8.63 7.69e-15 3.26e-11 -0.57 -0.57 Menopause (age at onset); chr17:43358069 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs4793234 ENSG00000198496.9 NBR2 -8.63 7.69e-15 3.26e-11 -0.57 -0.57 Menopause (age at onset); chr17:43358815 chr17:43125610~43153671:+ PAAD cis rs7104764 1 rs10902114 ENSG00000277290.1 RP11-326C3.16 -8.63 7.73e-15 3.27e-11 -0.54 -0.57 Menarche (age at onset); chr11:246234 chr11:243099~243483:- PAAD cis rs7115242 1 rs7115242 ENSG00000254851.1 RP11-109L13.1 8.63 7.73e-15 3.27e-11 1.09 0.57 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117037567 chr11:117135528~117138582:+ PAAD cis rs5769707 0.605 rs9616702 ENSG00000188511.11 C22orf34 8.62 7.91e-15 3.34e-11 0.58 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49632290 chr22:49414524~49657542:- PAAD cis rs2455601 0.638 rs11042148 ENSG00000254860.4 TMEM9B-AS1 8.62 8.01e-15 3.39e-11 0.74 0.57 Schizophrenia; chr11:8987127 chr11:8964675~8977527:+ PAAD cis rs5769707 0.706 rs2071903 ENSG00000188511.11 C22orf34 8.62 8.11e-15 3.43e-11 0.58 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49640869 chr22:49414524~49657542:- PAAD cis rs5769707 0.604 rs1018814 ENSG00000188511.11 C22orf34 8.62 8.11e-15 3.43e-11 0.58 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49643252 chr22:49414524~49657542:- PAAD cis rs5769707 0.681 rs739236 ENSG00000188511.11 C22orf34 8.62 8.11e-15 3.43e-11 0.58 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49647954 chr22:49414524~49657542:- PAAD cis rs9326248 0.581 rs10892048 ENSG00000254851.1 RP11-109L13.1 -8.62 8.12e-15 3.43e-11 -0.72 -0.57 Blood protein levels; chr11:116943880 chr11:117135528~117138582:+ PAAD cis rs2455601 0.573 rs2653573 ENSG00000254860.4 TMEM9B-AS1 8.62 8.24e-15 3.48e-11 0.69 0.57 Schizophrenia; chr11:8968327 chr11:8964675~8977527:+ PAAD cis rs321358 0.945 rs7931995 ENSG00000271584.1 RP11-89C3.4 8.62 8.28e-15 3.5e-11 0.77 0.57 Body mass index; chr11:111117691 chr11:111091932~111097357:- PAAD cis rs9326248 0.581 rs7120963 ENSG00000254851.1 RP11-109L13.1 8.61 8.44e-15 3.56e-11 0.7 0.57 Blood protein levels; chr11:116959545 chr11:117135528~117138582:+ PAAD cis rs881375 1 rs1953126 ENSG00000226752.6 PSMD5-AS1 -8.61 8.45e-15 3.57e-11 -0.63 -0.57 Rheumatoid arthritis; chr9:120878222 chr9:120824828~120854385:+ PAAD cis rs9326248 0.53 rs588918 ENSG00000254851.1 RP11-109L13.1 -8.61 8.66e-15 3.65e-11 -1.04 -0.57 Blood protein levels; chr11:116985926 chr11:117135528~117138582:+ PAAD cis rs67383717 0.689 rs62559007 ENSG00000175611.10 LINC00476 -8.61 8.71e-15 3.67e-11 -0.5 -0.57 Parkinson's disease (pesticide exposure interaction); chr9:95790981 chr9:95759231~95875977:- PAAD cis rs73086581 0.787 rs67633417 ENSG00000229539.1 RP11-119B16.2 8.61 8.75e-15 3.69e-11 0.9 0.57 Response to antidepressants in depression; chr20:3887610 chr20:3888239~3888868:- PAAD cis rs73086581 0.787 rs68127408 ENSG00000229539.1 RP11-119B16.2 8.61 8.75e-15 3.69e-11 0.9 0.57 Response to antidepressants in depression; chr20:3887800 chr20:3888239~3888868:- PAAD cis rs73086581 0.787 rs67724338 ENSG00000229539.1 RP11-119B16.2 8.61 8.75e-15 3.69e-11 0.9 0.57 Response to antidepressants in depression; chr20:3888410 chr20:3888239~3888868:- PAAD cis rs73086581 0.787 rs67202952 ENSG00000229539.1 RP11-119B16.2 8.61 8.75e-15 3.69e-11 0.9 0.57 Response to antidepressants in depression; chr20:3888452 chr20:3888239~3888868:- PAAD cis rs11155671 0.53 rs9383912 ENSG00000216906.2 RP11-350J20.9 8.6 8.88e-15 3.74e-11 0.75 0.57 Testicular germ cell tumor; chr6:149885479 chr6:149904243~149906418:+ PAAD cis rs3091242 0.933 rs1534954 ENSG00000224183.1 SDHDP6 -8.6 9.02e-15 3.8e-11 -0.74 -0.57 Erythrocyte sedimentation rate; chr1:25435433 chr1:25294164~25294643:- PAAD cis rs3091242 0.9 rs35345536 ENSG00000224183.1 SDHDP6 -8.6 9.02e-15 3.8e-11 -0.74 -0.57 Erythrocyte sedimentation rate; chr1:25439997 chr1:25294164~25294643:- PAAD cis rs17826219 0.706 rs609472 ENSG00000263531.1 RP13-753N3.1 8.6 9.12e-15 3.84e-11 1 0.57 Body mass index; chr17:30624409 chr17:30863921~30864940:- PAAD cis rs8062405 1 rs4451951 ENSG00000259982.1 CDC37P1 8.6 9.26e-15 3.89e-11 0.64 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28824884 chr16:28700294~28701540:- PAAD cis rs7301826 0.651 rs2277336 ENSG00000256299.1 RP11-989F5.3 8.6 9.29e-15 3.9e-11 0.64 0.57 Plasma plasminogen activator levels; chr12:130801574 chr12:130810821~130812622:- PAAD cis rs9322193 0.504 rs7771014 ENSG00000216906.2 RP11-350J20.9 8.6 9.39e-15 3.94e-11 0.76 0.57 Lung cancer; chr6:149884310 chr6:149904243~149906418:+ PAAD cis rs5769707 0.681 rs135879 ENSG00000188511.11 C22orf34 8.6 9.39e-15 3.94e-11 0.55 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49625003 chr22:49414524~49657542:- PAAD cis rs5769707 0.642 rs135880 ENSG00000188511.11 C22orf34 8.6 9.39e-15 3.94e-11 0.55 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49625006 chr22:49414524~49657542:- PAAD cis rs9326248 0.52 rs236919 ENSG00000254851.1 RP11-109L13.1 -8.6 9.41e-15 3.95e-11 -0.7 -0.57 Blood protein levels; chr11:117224645 chr11:117135528~117138582:+ PAAD cis rs2739330 0.76 rs1007888 ENSG00000250470.1 AP000351.3 8.59 9.47e-15 3.98e-11 0.77 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23976904~23977585:- PAAD cis rs6452524 0.561 rs4331874 ENSG00000249664.1 CTD-2227C6.2 8.59 9.83e-15 4.12e-11 0.68 0.57 Hypertension (SNP x SNP interaction); chr5:83068253 chr5:83012285~83013109:- PAAD cis rs3091242 0.933 rs12402120 ENSG00000224183.1 SDHDP6 -8.59 9.9e-15 4.15e-11 -0.74 -0.57 Erythrocyte sedimentation rate; chr1:25425141 chr1:25294164~25294643:- PAAD cis rs2739330 0.761 rs5760176 ENSG00000225282.1 AP000350.6 -8.58 9.99e-15 4.18e-11 -0.76 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23926900~23929574:+ PAAD cis rs3091242 0.933 rs909833 ENSG00000224183.1 SDHDP6 -8.58 1.01e-14 4.22e-11 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25427649 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs9438904 ENSG00000224183.1 SDHDP6 -8.58 1.01e-14 4.22e-11 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25430369 chr1:25294164~25294643:- PAAD cis rs1799949 1 rs915945 ENSG00000198496.9 NBR2 -8.58 1.01e-14 4.23e-11 -0.57 -0.57 Menopause (age at onset); chr17:43027847 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs12944597 ENSG00000198496.9 NBR2 -8.58 1.01e-14 4.23e-11 -0.57 -0.57 Menopause (age at onset); chr17:43035667 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs12942277 ENSG00000198496.9 NBR2 -8.58 1.01e-14 4.23e-11 -0.57 -0.57 Menopause (age at onset); chr17:43035957 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs34616041 ENSG00000198496.9 NBR2 -8.58 1.01e-14 4.23e-11 -0.57 -0.57 Menopause (age at onset); chr17:43036769 chr17:43125610~43153671:+ PAAD cis rs9399135 1 rs9399135 ENSG00000232876.1 CTA-212D2.2 -8.58 1.01e-14 4.23e-11 -0.67 -0.57 Red blood cell count; chr6:135047176 chr6:135055033~135060550:+ PAAD cis rs3091242 0.9 rs669063 ENSG00000224183.1 SDHDP6 -8.58 1.01e-14 4.24e-11 -0.74 -0.57 Erythrocyte sedimentation rate; chr1:25394663 chr1:25294164~25294643:- PAAD cis rs6452524 0.532 rs27363 ENSG00000249664.1 CTD-2227C6.2 8.58 1.02e-14 4.25e-11 0.68 0.57 Hypertension (SNP x SNP interaction); chr5:83040943 chr5:83012285~83013109:- PAAD cis rs1799949 0.965 rs8176193 ENSG00000198496.9 NBR2 -8.58 1.02e-14 4.25e-11 -0.57 -0.57 Menopause (age at onset); chr17:43079499 chr17:43125610~43153671:+ PAAD cis rs5769707 0.681 rs4622843 ENSG00000188511.11 C22orf34 8.58 1.02e-14 4.27e-11 0.56 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49643268 chr22:49414524~49657542:- PAAD cis rs3931020 0.53 rs12125889 ENSG00000272864.1 RP11-17E13.2 -8.58 1.05e-14 4.38e-11 -0.68 -0.57 Resistin levels; chr1:74776287 chr1:74698769~74699333:- PAAD cis rs11155671 0.53 rs7763849 ENSG00000216906.2 RP11-350J20.9 8.57 1.06e-14 4.42e-11 0.74 0.57 Testicular germ cell tumor; chr6:149885244 chr6:149904243~149906418:+ PAAD cis rs7115242 0.8 rs519794 ENSG00000254851.1 RP11-109L13.1 -8.57 1.06e-14 4.43e-11 -1.01 -0.57 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116988737 chr11:117135528~117138582:+ PAAD cis rs10256972 0.524 rs6945202 ENSG00000229043.2 AC091729.9 -8.57 1.07e-14 4.47e-11 -0.58 -0.57 Endometriosis;Longevity; chr7:1076922 chr7:1160374~1165267:+ PAAD cis rs9326248 0.581 rs7120706 ENSG00000254851.1 RP11-109L13.1 8.57 1.07e-14 4.47e-11 0.7 0.57 Blood protein levels; chr11:116959371 chr11:117135528~117138582:+ PAAD cis rs8062405 1 rs62036622 ENSG00000259982.1 CDC37P1 8.57 1.08e-14 4.48e-11 0.64 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28825882 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs72793812 ENSG00000259982.1 CDC37P1 8.57 1.08e-14 4.48e-11 0.64 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28829060 chr16:28700294~28701540:- PAAD cis rs2739330 0.731 rs5751792 ENSG00000225282.1 AP000350.6 8.57 1.08e-14 4.49e-11 0.75 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23926900~23929574:+ PAAD cis rs1799949 1 rs2271574 ENSG00000198496.9 NBR2 -8.57 1.08e-14 4.5e-11 -0.56 -0.57 Menopause (age at onset); chr17:43175631 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs33994002 ENSG00000198496.9 NBR2 -8.57 1.08e-14 4.5e-11 -0.56 -0.57 Menopause (age at onset); chr17:43176801 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs33920795 ENSG00000198496.9 NBR2 -8.57 1.08e-14 4.5e-11 -0.56 -0.57 Menopause (age at onset); chr17:43176993 chr17:43125610~43153671:+ PAAD cis rs7104764 1 rs10400248 ENSG00000277290.1 RP11-326C3.16 -8.57 1.09e-14 4.53e-11 -0.54 -0.57 Menarche (age at onset); chr11:247029 chr11:243099~243483:- PAAD cis rs5760092 0.618 rs4461358 ENSG00000218537.1 MIF-AS1 -8.57 1.1e-14 4.56e-11 -0.82 -0.57 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23894426~23898930:- PAAD cis rs9326248 0.581 rs6589582 ENSG00000254851.1 RP11-109L13.1 -8.57 1.11e-14 4.62e-11 -0.71 -0.57 Blood protein levels; chr11:116958484 chr11:117135528~117138582:+ PAAD cis rs2739330 0.732 rs5760175 ENSG00000225282.1 AP000350.6 8.57 1.11e-14 4.64e-11 0.75 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23926900~23929574:+ PAAD cis rs4423214 1 rs3750997 ENSG00000254682.1 RP11-660L16.2 8.57 1.12e-14 4.65e-11 0.79 0.57 Vitamin D levels; chr11:71447795 chr11:71448674~71452157:+ PAAD cis rs9601248 0.838 rs2783130 ENSG00000227676.3 LINC01068 -8.56 1.14e-14 4.74e-11 -0.74 -0.57 Major depressive disorder; chr13:79596025 chr13:79566727~79571436:+ PAAD cis rs62388641 0.774 rs13212794 ENSG00000272279.1 RP11-157J24.2 8.56 1.14e-14 4.74e-11 0.79 0.57 Daytime sleep phenotypes; chr6:1548349 chr6:1528364~1528911:- PAAD cis rs11155671 0.53 rs7742993 ENSG00000216906.2 RP11-350J20.9 8.56 1.17e-14 4.86e-11 0.75 0.57 Testicular germ cell tumor; chr6:149883959 chr6:149904243~149906418:+ PAAD cis rs1799949 0.93 rs3092987 ENSG00000198496.9 NBR2 -8.56 1.18e-14 4.88e-11 -0.56 -0.57 Menopause (age at onset); chr17:43070706 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8176202 ENSG00000198496.9 NBR2 -8.56 1.18e-14 4.88e-11 -0.56 -0.57 Menopause (age at onset); chr17:43078211 chr17:43125610~43153671:+ PAAD cis rs2739330 0.796 rs1006771 ENSG00000099984.9 GSTT2 -8.56 1.19e-14 4.91e-11 -0.74 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23980123~23983911:+ PAAD cis rs3814244 0.569 rs2051993 ENSG00000255733.4 IFNG-AS1 8.55 1.22e-14 5.06e-11 0.54 0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:68019898 chr12:67989445~68234686:+ PAAD cis rs2882667 0.964 rs12108892 ENSG00000253404.1 AC034243.1 8.55 1.24e-14 5.11e-11 0.69 0.57 Age-related hearing impairment (SNP x SNP interaction); chr5:138963941 chr5:138744434~138753309:- PAAD cis rs55794721 0.509 rs873308 ENSG00000224183.1 SDHDP6 8.55 1.24e-14 5.11e-11 0.73 0.57 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25294164~25294643:- PAAD cis rs6452524 0.534 rs10061690 ENSG00000249664.1 CTD-2227C6.2 8.55 1.25e-14 5.15e-11 0.68 0.57 Hypertension (SNP x SNP interaction); chr5:83063226 chr5:83012285~83013109:- PAAD cis rs3091242 0.866 rs11249249 ENSG00000224183.1 SDHDP6 -8.54 1.27e-14 5.22e-11 -0.74 -0.57 Erythrocyte sedimentation rate; chr1:25431643 chr1:25294164~25294643:- PAAD cis rs8062405 0.679 rs72793818 ENSG00000259982.1 CDC37P1 8.54 1.27e-14 5.22e-11 0.63 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28881816 chr16:28700294~28701540:- PAAD cis rs3091242 0.933 rs11802413 ENSG00000224183.1 SDHDP6 8.54 1.28e-14 5.27e-11 0.76 0.57 Erythrocyte sedimentation rate; chr1:25434429 chr1:25294164~25294643:- PAAD cis rs875971 0.862 rs6944374 ENSG00000226824.5 RP4-756H11.3 8.54 1.28e-14 5.29e-11 0.69 0.57 Aortic root size; chr7:66221942 chr7:66654538~66669855:+ PAAD cis rs7301826 0.61 rs36051740 ENSG00000256299.1 RP11-989F5.3 8.54 1.29e-14 5.33e-11 0.64 0.57 Plasma plasminogen activator levels; chr12:130808177 chr12:130810821~130812622:- PAAD cis rs1799949 1 rs4793236 ENSG00000198496.9 NBR2 -8.54 1.3e-14 5.35e-11 -0.57 -0.57 Menopause (age at onset); chr17:43359072 chr17:43125610~43153671:+ PAAD cis rs7301826 0.627 rs1077317 ENSG00000256299.1 RP11-989F5.3 -8.54 1.33e-14 5.47e-11 -0.65 -0.57 Plasma plasminogen activator levels; chr12:130830432 chr12:130810821~130812622:- PAAD cis rs7301826 0.651 rs4759525 ENSG00000256299.1 RP11-989F5.3 -8.54 1.33e-14 5.47e-11 -0.65 -0.57 Plasma plasminogen activator levels; chr12:130831736 chr12:130810821~130812622:- PAAD cis rs62388641 0.813 rs34114087 ENSG00000272279.1 RP11-157J24.2 8.54 1.33e-14 5.49e-11 0.78 0.57 Daytime sleep phenotypes; chr6:1553203 chr6:1528364~1528911:- PAAD cis rs881375 1 rs1609810 ENSG00000226752.6 PSMD5-AS1 -8.53 1.36e-14 5.61e-11 -0.62 -0.57 Rheumatoid arthritis; chr9:120880073 chr9:120824828~120854385:+ PAAD cis rs7104764 1 rs1128322 ENSG00000277290.1 RP11-326C3.16 8.53 1.37e-14 5.63e-11 0.53 0.57 Menarche (age at onset); chr11:244197 chr11:243099~243483:- PAAD cis rs1799949 0.965 rs4793230 ENSG00000198496.9 NBR2 -8.53 1.38e-14 5.67e-11 -0.56 -0.57 Menopause (age at onset); chr17:43350035 chr17:43125610~43153671:+ PAAD cis rs6452524 0.537 rs1583 ENSG00000249664.1 CTD-2227C6.2 8.53 1.38e-14 5.68e-11 0.69 0.57 Hypertension (SNP x SNP interaction); chr5:83052403 chr5:83012285~83013109:- PAAD cis rs4423214 1 rs12278461 ENSG00000254682.1 RP11-660L16.2 8.53 1.4e-14 5.74e-11 0.79 0.57 Vitamin D levels; chr11:71471139 chr11:71448674~71452157:+ PAAD cis rs11155671 0.53 rs4458704 ENSG00000216906.2 RP11-350J20.9 8.53 1.41e-14 5.76e-11 0.73 0.57 Testicular germ cell tumor; chr6:149911743 chr6:149904243~149906418:+ PAAD cis rs3091242 1 rs3091242 ENSG00000224183.1 SDHDP6 -8.53 1.41e-14 5.77e-11 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25348294 chr1:25294164~25294643:- PAAD cis rs8062405 0.728 rs9931989 ENSG00000259982.1 CDC37P1 -8.52 1.42e-14 5.83e-11 -0.66 -0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28894763 chr16:28700294~28701540:- PAAD cis rs8062405 0.656 rs7189927 ENSG00000259982.1 CDC37P1 -8.52 1.42e-14 5.83e-11 -0.66 -0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28902466 chr16:28700294~28701540:- PAAD cis rs8062405 0.698 rs7188071 ENSG00000259982.1 CDC37P1 -8.52 1.42e-14 5.83e-11 -0.66 -0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28906323 chr16:28700294~28701540:- PAAD cis rs3091242 0.935 rs3093632 ENSG00000224183.1 SDHDP6 -8.52 1.43e-14 5.86e-11 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25357521 chr1:25294164~25294643:- PAAD cis rs3091242 0.967 rs3091240 ENSG00000224183.1 SDHDP6 -8.52 1.45e-14 5.95e-11 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25350444 chr1:25294164~25294643:- PAAD cis rs55794721 0.509 rs6699896 ENSG00000224183.1 SDHDP6 -8.52 1.46e-14 5.97e-11 -0.74 -0.57 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs35148262 ENSG00000224183.1 SDHDP6 -8.52 1.46e-14 5.97e-11 -0.74 -0.57 Erythrocyte sedimentation rate; chr1:25440132 chr1:25294164~25294643:- PAAD cis rs5769707 0.521 rs5769719 ENSG00000188511.11 C22orf34 8.52 1.47e-14 6e-11 0.57 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49668453 chr22:49414524~49657542:- PAAD cis rs5769707 0.521 rs5769720 ENSG00000188511.11 C22orf34 8.52 1.47e-14 6e-11 0.57 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49668485 chr22:49414524~49657542:- PAAD cis rs5769707 0.521 rs5770633 ENSG00000188511.11 C22orf34 8.52 1.47e-14 6e-11 0.57 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49668779 chr22:49414524~49657542:- PAAD cis rs9326248 0.581 rs11216267 ENSG00000254851.1 RP11-109L13.1 -8.52 1.49e-14 6.11e-11 -0.69 -0.57 Blood protein levels; chr11:117081676 chr11:117135528~117138582:+ PAAD cis rs7208859 0.623 rs56325146 ENSG00000263531.1 RP13-753N3.1 8.51 1.51e-14 6.17e-11 1.07 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824006 chr17:30863921~30864940:- PAAD cis rs5769707 0.605 rs6009791 ENSG00000188511.11 C22orf34 8.51 1.52e-14 6.21e-11 0.57 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49631617 chr22:49414524~49657542:- PAAD cis rs5769707 0.667 rs4824069 ENSG00000188511.11 C22orf34 8.51 1.52e-14 6.21e-11 0.57 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49636677 chr22:49414524~49657542:- PAAD cis rs3091242 0.9 rs1883427 ENSG00000224183.1 SDHDP6 -8.51 1.54e-14 6.28e-11 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25417977 chr1:25294164~25294643:- PAAD cis rs1930961 0.85 rs5996945 ENSG00000272977.1 CTA-390C10.10 8.51 1.54e-14 6.3e-11 1.07 0.57 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25476218~25479971:+ PAAD cis rs7208859 0.623 rs216423 ENSG00000263531.1 RP13-753N3.1 8.51 1.54e-14 6.3e-11 0.99 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30615091 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs450585 ENSG00000263531.1 RP13-753N3.1 8.51 1.54e-14 6.3e-11 0.99 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624021 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs423151 ENSG00000263531.1 RP13-753N3.1 8.51 1.54e-14 6.3e-11 0.99 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30625268 chr17:30863921~30864940:- PAAD cis rs5769707 0.681 rs2071902 ENSG00000188511.11 C22orf34 8.51 1.55e-14 6.34e-11 0.57 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49640890 chr22:49414524~49657542:- PAAD cis rs5769707 0.681 rs8140095 ENSG00000188511.11 C22orf34 8.51 1.55e-14 6.34e-11 0.57 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49650147 chr22:49414524~49657542:- PAAD cis rs9326248 0.52 rs2735183 ENSG00000254851.1 RP11-109L13.1 -8.51 1.56e-14 6.38e-11 -0.71 -0.57 Blood protein levels; chr11:117144479 chr11:117135528~117138582:+ PAAD cis rs6452524 0.506 rs7891 ENSG00000249664.1 CTD-2227C6.2 8.51 1.57e-14 6.41e-11 0.69 0.57 Hypertension (SNP x SNP interaction); chr5:83053558 chr5:83012285~83013109:- PAAD cis rs6452524 0.534 rs7724935 ENSG00000249664.1 CTD-2227C6.2 8.51 1.57e-14 6.41e-11 0.69 0.57 Hypertension (SNP x SNP interaction); chr5:83057264 chr5:83012285~83013109:- PAAD cis rs6452524 0.506 rs7707143 ENSG00000249664.1 CTD-2227C6.2 8.51 1.57e-14 6.41e-11 0.69 0.57 Hypertension (SNP x SNP interaction); chr5:83057268 chr5:83012285~83013109:- PAAD cis rs6452524 0.563 rs10473863 ENSG00000249664.1 CTD-2227C6.2 8.51 1.57e-14 6.41e-11 0.69 0.57 Hypertension (SNP x SNP interaction); chr5:83057500 chr5:83012285~83013109:- PAAD cis rs6452524 0.534 rs72765386 ENSG00000249664.1 CTD-2227C6.2 8.51 1.57e-14 6.41e-11 0.69 0.57 Hypertension (SNP x SNP interaction); chr5:83061502 chr5:83012285~83013109:- PAAD cis rs6452524 0.534 rs9293328 ENSG00000249664.1 CTD-2227C6.2 8.51 1.57e-14 6.41e-11 0.69 0.57 Hypertension (SNP x SNP interaction); chr5:83066855 chr5:83012285~83013109:- PAAD cis rs6452524 0.534 rs11746747 ENSG00000249664.1 CTD-2227C6.2 8.51 1.57e-14 6.41e-11 0.69 0.57 Hypertension (SNP x SNP interaction); chr5:83067666 chr5:83012285~83013109:- PAAD cis rs4718428 1 rs4718428 ENSG00000226824.5 RP4-756H11.3 -8.51 1.58e-14 6.42e-11 -0.7 -0.57 Corneal structure; chr7:66956459 chr7:66654538~66669855:+ PAAD cis rs1799949 0.827 rs74252763 ENSG00000198496.9 NBR2 -8.5 1.59e-14 6.49e-11 -0.57 -0.57 Menopause (age at onset); chr17:43324652 chr17:43125610~43153671:+ PAAD cis rs5769707 0.568 rs2011097 ENSG00000188511.11 C22orf34 8.5 1.62e-14 6.59e-11 0.56 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49624421 chr22:49414524~49657542:- PAAD cis rs1799949 1 rs2298862 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43024671 chr17:43125610~43153671:+ PAAD cis rs1799949 0.93 rs2298861 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43024814 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs12944458 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43028755 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs36036395 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43029280 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs72829113 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43029818 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11653253 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43030645 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs12951869 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43035550 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11654452 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43037366 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs4793189 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43038698 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11657053 ENSG00000198496.9 NBR2 -8.5 1.62e-14 6.59e-11 -0.57 -0.57 Menopause (age at onset); chr17:43039112 chr17:43125610~43153671:+ PAAD cis rs3814244 0.528 rs10878723 ENSG00000255733.4 IFNG-AS1 8.5 1.62e-14 6.6e-11 0.54 0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:68005493 chr12:67989445~68234686:+ PAAD cis rs875971 0.83 rs6976714 ENSG00000226824.5 RP4-756H11.3 -8.5 1.63e-14 6.6e-11 -0.71 -0.57 Aortic root size; chr7:66426474 chr7:66654538~66669855:+ PAAD cis rs875971 0.651 rs2420596 ENSG00000226824.5 RP4-756H11.3 -8.5 1.63e-14 6.6e-11 -0.71 -0.57 Aortic root size; chr7:66450996 chr7:66654538~66669855:+ PAAD cis rs875971 0.52 rs2420597 ENSG00000226824.5 RP4-756H11.3 -8.5 1.63e-14 6.6e-11 -0.71 -0.57 Aortic root size; chr7:66450999 chr7:66654538~66669855:+ PAAD cis rs881375 1 rs10760121 ENSG00000226752.6 PSMD5-AS1 -8.5 1.66e-14 6.72e-11 -0.62 -0.57 Rheumatoid arthritis; chr9:120885637 chr9:120824828~120854385:+ PAAD cis rs8062405 0.728 rs8056890 ENSG00000259982.1 CDC37P1 8.5 1.66e-14 6.74e-11 0.66 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28886131 chr16:28700294~28701540:- PAAD cis rs2283792 0.622 rs239917 ENSG00000224086.5 LL22NC03-86G7.1 -8.5 1.69e-14 6.84e-11 -0.6 -0.57 Multiple sclerosis; chr22:21960091 chr22:21938293~21977632:+ PAAD cis rs1799949 1 rs8176269 ENSG00000198496.9 NBR2 -8.49 1.69e-14 6.85e-11 -0.57 -0.57 Menopause (age at onset); chr17:43061609 chr17:43125610~43153671:+ PAAD cis rs2739330 0.703 rs5760112 ENSG00000250470.1 AP000351.3 8.49 1.7e-14 6.89e-11 0.78 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23976904~23977585:- PAAD cis rs2739330 0.731 rs4822450 ENSG00000250470.1 AP000351.3 8.49 1.71e-14 6.93e-11 0.76 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23976904~23977585:- PAAD cis rs1799949 0.965 rs11650132 ENSG00000198496.9 NBR2 -8.49 1.76e-14 7.13e-11 -0.56 -0.57 Menopause (age at onset); chr17:43174070 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs11654731 ENSG00000198496.9 NBR2 -8.49 1.76e-14 7.13e-11 -0.56 -0.57 Menopause (age at onset); chr17:43174923 chr17:43125610~43153671:+ PAAD cis rs9326248 0.581 rs10892053 ENSG00000254851.1 RP11-109L13.1 -8.48 1.79e-14 7.24e-11 -0.7 -0.57 Blood protein levels; chr11:116986287 chr11:117135528~117138582:+ PAAD cis rs7208859 0.673 rs216409 ENSG00000263531.1 RP13-753N3.1 -8.48 1.81e-14 7.29e-11 -1 -0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30579251 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs73263982 ENSG00000263531.1 RP13-753N3.1 8.48 1.81e-14 7.29e-11 1 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593606 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs216433 ENSG00000263531.1 RP13-753N3.1 8.48 1.81e-14 7.29e-11 1 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30594842 chr17:30863921~30864940:- PAAD cis rs10256972 0.684 rs4724039 ENSG00000229043.2 AC091729.9 -8.48 1.82e-14 7.35e-11 -0.59 -0.57 Endometriosis;Longevity; chr7:1071997 chr7:1160374~1165267:+ PAAD cis rs62388641 0.813 rs34779492 ENSG00000272279.1 RP11-157J24.2 8.48 1.84e-14 7.42e-11 0.79 0.57 Daytime sleep phenotypes; chr6:1547737 chr6:1528364~1528911:- PAAD cis rs1799949 1 rs8176220 ENSG00000198496.9 NBR2 -8.48 1.85e-14 7.45e-11 -0.56 -0.57 Menopause (age at onset); chr17:43070445 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs1799966 ENSG00000198496.9 NBR2 -8.48 1.85e-14 7.45e-11 -0.56 -0.57 Menopause (age at onset); chr17:43071077 chr17:43125610~43153671:+ PAAD cis rs3814244 0.528 rs12582272 ENSG00000255733.4 IFNG-AS1 8.48 1.87e-14 7.53e-11 0.54 0.57 Itch intensity from mosquito bite adjusted by bite size; chr12:68006298 chr12:67989445~68234686:+ PAAD cis rs1799949 0.965 rs9897425 ENSG00000198496.9 NBR2 -8.47 1.97e-14 7.89e-11 -0.56 -0.57 Menopause (age at onset); chr17:43352811 chr17:43125610~43153671:+ PAAD cis rs7301826 0.651 rs4514465 ENSG00000256299.1 RP11-989F5.3 -8.47 1.99e-14 7.98e-11 -0.64 -0.57 Plasma plasminogen activator levels; chr12:130829124 chr12:130810821~130812622:- PAAD cis rs55794721 0.543 rs1293260 ENSG00000224183.1 SDHDP6 -8.47 1.99e-14 7.99e-11 -0.73 -0.57 Mean corpuscular volume;Plateletcrit; chr1:25382613 chr1:25294164~25294643:- PAAD cis rs1799949 0.965 rs4793237 ENSG00000198496.9 NBR2 -8.46 2.02e-14 8.11e-11 -0.56 -0.57 Menopause (age at onset); chr17:43359227 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs11080034 ENSG00000198496.9 NBR2 -8.46 2.03e-14 8.13e-11 -0.55 -0.57 Menopause (age at onset); chr17:43365646 chr17:43125610~43153671:+ PAAD cis rs9326248 0.581 rs6589590 ENSG00000254851.1 RP11-109L13.1 -8.46 2.04e-14 8.18e-11 -0.69 -0.57 Blood protein levels; chr11:117065365 chr11:117135528~117138582:+ PAAD cis rs7208859 0.614 rs216474 ENSG00000263531.1 RP13-753N3.1 -8.46 2.08e-14 8.34e-11 -0.98 -0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30538073 chr17:30863921~30864940:- PAAD cis rs881375 0.933 rs7859805 ENSG00000226752.6 PSMD5-AS1 -8.46 2.09e-14 8.37e-11 -0.62 -0.57 Rheumatoid arthritis; chr9:120901845 chr9:120824828~120854385:+ PAAD cis rs881375 0.933 rs10818485 ENSG00000226752.6 PSMD5-AS1 -8.46 2.09e-14 8.37e-11 -0.62 -0.57 Rheumatoid arthritis; chr9:120905538 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs10435843 ENSG00000226752.6 PSMD5-AS1 -8.46 2.09e-14 8.37e-11 -0.62 -0.57 Rheumatoid arthritis; chr9:120905755 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs10435844 ENSG00000226752.6 PSMD5-AS1 -8.46 2.09e-14 8.37e-11 -0.62 -0.57 Rheumatoid arthritis; chr9:120905921 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs7848332 ENSG00000226752.6 PSMD5-AS1 -8.46 2.09e-14 8.37e-11 -0.62 -0.57 Rheumatoid arthritis; chr9:120907218 chr9:120824828~120854385:+ PAAD cis rs881375 0.867 rs6478487 ENSG00000226752.6 PSMD5-AS1 -8.46 2.09e-14 8.37e-11 -0.62 -0.57 Rheumatoid arthritis; chr9:120910499 chr9:120824828~120854385:+ PAAD cis rs8062405 0.72 rs9926245 ENSG00000259982.1 CDC37P1 8.46 2.09e-14 8.37e-11 0.61 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544385 chr16:28700294~28701540:- PAAD cis rs8062405 0.823 rs7202948 ENSG00000259982.1 CDC37P1 8.46 2.09e-14 8.37e-11 0.61 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546968 chr16:28700294~28701540:- PAAD cis rs8062405 0.824 rs7191618 ENSG00000259982.1 CDC37P1 8.46 2.09e-14 8.37e-11 0.61 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554346 chr16:28700294~28701540:- PAAD cis rs8062405 0.754 rs3859172 ENSG00000259982.1 CDC37P1 8.46 2.09e-14 8.37e-11 0.61 0.57 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554837 chr16:28700294~28701540:- PAAD cis rs881375 0.967 rs3761849 ENSG00000226752.6 PSMD5-AS1 -8.46 2.11e-14 8.44e-11 -0.61 -0.57 Rheumatoid arthritis; chr9:120928679 chr9:120824828~120854385:+ PAAD cis rs2455601 0.638 rs3815991 ENSG00000254860.4 TMEM9B-AS1 -8.45 2.14e-14 8.53e-11 -0.75 -0.57 Schizophrenia; chr11:8986122 chr11:8964675~8977527:+ PAAD cis rs67383717 0.713 rs1369156 ENSG00000175611.10 LINC00476 -8.45 2.17e-14 8.64e-11 -0.5 -0.57 Parkinson's disease (pesticide exposure interaction); chr9:95794612 chr9:95759231~95875977:- PAAD cis rs9326248 0.581 rs10892072 ENSG00000254851.1 RP11-109L13.1 -8.45 2.18e-14 8.68e-11 -0.69 -0.57 Blood protein levels; chr11:117089597 chr11:117135528~117138582:+ PAAD cis rs2882667 0.964 rs12719517 ENSG00000253404.1 AC034243.1 8.45 2.18e-14 8.68e-11 0.7 0.57 Age-related hearing impairment (SNP x SNP interaction); chr5:138969813 chr5:138744434~138753309:- PAAD cis rs7208859 0.615 rs216462 ENSG00000263531.1 RP13-753N3.1 -8.45 2.19e-14 8.72e-11 -1.02 -0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30568879 chr17:30863921~30864940:- PAAD cis rs507080 0.733 rs7108144 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118698985 chr11:118704607~118750263:+ PAAD cis rs507080 0.663 rs523793 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118699988 chr11:118704607~118750263:+ PAAD cis rs507080 0.736 rs659564 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118700205 chr11:118704607~118750263:+ PAAD cis rs507080 0.736 rs642224 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118700210 chr11:118704607~118750263:+ PAAD cis rs507080 0.733 rs541631 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118700314 chr11:118704607~118750263:+ PAAD cis rs507080 0.736 rs658676 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118700414 chr11:118704607~118750263:+ PAAD cis rs507080 0.733 rs488141 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118700459 chr11:118704607~118750263:+ PAAD cis rs507080 0.733 rs657769 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118700607 chr11:118704607~118750263:+ PAAD cis rs507080 0.733 rs544452 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118700648 chr11:118704607~118750263:+ PAAD cis rs507080 0.697 rs656287 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118701081 chr11:118704607~118750263:+ PAAD cis rs507080 0.733 rs570949 ENSG00000255422.1 AP002954.4 -8.45 2.2e-14 8.74e-11 -0.68 -0.57 Serum metabolite levels; chr11:118701202 chr11:118704607~118750263:+ PAAD cis rs4423214 1 rs2282621 ENSG00000254682.1 RP11-660L16.2 8.45 2.23e-14 8.85e-11 0.79 0.57 Vitamin D levels; chr11:71472428 chr11:71448674~71452157:+ PAAD cis rs4423214 1 rs2282620 ENSG00000254682.1 RP11-660L16.2 8.45 2.23e-14 8.85e-11 0.79 0.57 Vitamin D levels; chr11:71472431 chr11:71448674~71452157:+ PAAD cis rs7208859 0.673 rs73263981 ENSG00000263531.1 RP13-753N3.1 8.45 2.24e-14 8.88e-11 1 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593484 chr17:30863921~30864940:- PAAD cis rs881375 0.933 rs2239657 ENSG00000226752.6 PSMD5-AS1 8.45 2.26e-14 8.95e-11 0.62 0.57 Rheumatoid arthritis; chr9:120909242 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs7046108 ENSG00000226752.6 PSMD5-AS1 8.45 2.26e-14 8.95e-11 0.61 0.57 Rheumatoid arthritis; chr9:120898061 chr9:120824828~120854385:+ PAAD cis rs5769707 0.632 rs6009782 ENSG00000188511.11 C22orf34 8.44 2.27e-14 8.96e-11 0.58 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49617164 chr22:49414524~49657542:- PAAD cis rs5769707 0.592 rs6009783 ENSG00000188511.11 C22orf34 8.44 2.27e-14 8.96e-11 0.58 0.57 Monocyte percentage of white cells;Monocyte count; chr22:49617353 chr22:49414524~49657542:- PAAD cis rs9326248 0.581 rs10892063 ENSG00000254851.1 RP11-109L13.1 -8.44 2.28e-14 9.01e-11 -0.71 -0.57 Blood protein levels; chr11:117025439 chr11:117135528~117138582:+ PAAD cis rs9326248 0.559 rs10892064 ENSG00000254851.1 RP11-109L13.1 -8.44 2.28e-14 9.01e-11 -0.71 -0.57 Blood protein levels; chr11:117025837 chr11:117135528~117138582:+ PAAD cis rs9326248 0.539 rs10892065 ENSG00000254851.1 RP11-109L13.1 -8.44 2.28e-14 9.01e-11 -0.71 -0.57 Blood protein levels; chr11:117026308 chr11:117135528~117138582:+ PAAD cis rs2739330 0.731 rs2000468 ENSG00000250470.1 AP000351.3 8.44 2.32e-14 9.16e-11 0.75 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23976904~23977585:- PAAD cis rs950027 0.787 rs1547487 ENSG00000259520.4 CTD-2651B20.3 -8.44 2.33e-14 9.19e-11 -0.69 -0.56 Response to fenofibrate (adiponectin levels); chr15:45431785 chr15:45251580~45279251:- PAAD cis rs7104764 0.957 rs1128321 ENSG00000277290.1 RP11-326C3.16 -8.44 2.35e-14 9.28e-11 -0.53 -0.56 Menarche (age at onset); chr11:244171 chr11:243099~243483:- PAAD cis rs881375 0.967 rs1860823 ENSG00000226752.6 PSMD5-AS1 -8.44 2.36e-14 9.32e-11 -0.62 -0.56 Rheumatoid arthritis; chr9:120897026 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs1860824 ENSG00000226752.6 PSMD5-AS1 -8.44 2.36e-14 9.32e-11 -0.62 -0.56 Rheumatoid arthritis; chr9:120897061 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs7875829 ENSG00000226752.6 PSMD5-AS1 -8.44 2.36e-14 9.32e-11 -0.62 -0.56 Rheumatoid arthritis; chr9:120898120 chr9:120824828~120854385:+ PAAD cis rs881375 0.867 rs10818484 ENSG00000226752.6 PSMD5-AS1 -8.44 2.36e-14 9.32e-11 -0.62 -0.56 Rheumatoid arthritis; chr9:120898916 chr9:120824828~120854385:+ PAAD cis rs9326248 0.581 rs7121898 ENSG00000254851.1 RP11-109L13.1 -8.43 2.41e-14 9.47e-11 -0.71 -0.56 Blood protein levels; chr11:116926130 chr11:117135528~117138582:+ PAAD cis rs9326248 0.52 rs1446105 ENSG00000254851.1 RP11-109L13.1 -8.43 2.41e-14 9.47e-11 -0.71 -0.56 Blood protein levels; chr11:116927828 chr11:117135528~117138582:+ PAAD cis rs9326248 0.581 rs10790167 ENSG00000254851.1 RP11-109L13.1 -8.43 2.41e-14 9.47e-11 -0.71 -0.56 Blood protein levels; chr11:116930227 chr11:117135528~117138582:+ PAAD cis rs321358 0.945 rs17458235 ENSG00000271584.1 RP11-89C3.4 -8.43 2.42e-14 9.52e-11 -0.72 -0.56 Body mass index; chr11:111106114 chr11:111091932~111097357:- PAAD cis rs881375 1 rs10818480 ENSG00000226752.6 PSMD5-AS1 -8.43 2.44e-14 9.56e-11 -0.62 -0.56 Rheumatoid arthritis; chr9:120880892 chr9:120824828~120854385:+ PAAD cis rs17826219 0.585 rs8064302 ENSG00000263531.1 RP13-753N3.1 -8.43 2.46e-14 9.65e-11 -0.98 -0.56 Body mass index; chr17:30397920 chr17:30863921~30864940:- PAAD cis rs9601248 0.845 rs1932197 ENSG00000227676.3 LINC01068 8.43 2.48e-14 9.69e-11 0.73 0.56 Major depressive disorder; chr13:79609218 chr13:79566727~79571436:+ PAAD cis rs9326248 0.53 rs2127905 ENSG00000254851.1 RP11-109L13.1 -8.43 2.51e-14 9.81e-11 -0.92 -0.56 Blood protein levels; chr11:117155658 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs7123517 ENSG00000254851.1 RP11-109L13.1 -8.43 2.51e-14 9.81e-11 -0.92 -0.56 Blood protein levels; chr11:117157039 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs7122944 ENSG00000254851.1 RP11-109L13.1 -8.43 2.51e-14 9.81e-11 -0.92 -0.56 Blood protein levels; chr11:117163903 chr11:117135528~117138582:+ PAAD cis rs7115242 0.514 rs4936367 ENSG00000254851.1 RP11-109L13.1 -8.43 2.51e-14 9.81e-11 -0.92 -0.56 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117171661 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs4604928 ENSG00000254851.1 RP11-109L13.1 -8.43 2.51e-14 9.81e-11 -0.92 -0.56 Blood protein levels; chr11:117173487 chr11:117135528~117138582:+ PAAD cis rs7208859 0.673 rs1347359 ENSG00000263531.1 RP13-753N3.1 8.43 2.52e-14 9.82e-11 1 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587511 chr17:30863921~30864940:- PAAD cis rs8062405 0.728 rs11642449 ENSG00000259982.1 CDC37P1 8.42 2.55e-14 9.97e-11 0.66 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28884694 chr16:28700294~28701540:- PAAD cis rs9326248 0.581 rs10892061 ENSG00000254851.1 RP11-109L13.1 -8.42 2.61e-14 1.02e-10 -0.7 -0.56 Blood protein levels; chr11:117015398 chr11:117135528~117138582:+ PAAD cis rs9326248 0.581 rs11216242 ENSG00000254851.1 RP11-109L13.1 -8.42 2.61e-14 1.02e-10 -0.7 -0.56 Blood protein levels; chr11:117030833 chr11:117135528~117138582:+ PAAD cis rs9326248 0.581 rs12804122 ENSG00000254851.1 RP11-109L13.1 -8.42 2.61e-14 1.02e-10 -0.7 -0.56 Blood protein levels; chr11:117031900 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs2471884 ENSG00000254851.1 RP11-109L13.1 -8.42 2.61e-14 1.02e-10 -0.98 -0.56 Blood protein levels; chr11:117139604 chr11:117135528~117138582:+ PAAD cis rs3091242 0.933 rs4649084 ENSG00000224183.1 SDHDP6 -8.42 2.61e-14 1.02e-10 -0.73 -0.56 Erythrocyte sedimentation rate; chr1:25426126 chr1:25294164~25294643:- PAAD cis rs55794721 0.509 rs11249248 ENSG00000224183.1 SDHDP6 -8.42 2.61e-14 1.02e-10 -0.73 -0.56 Mean corpuscular volume;Plateletcrit; chr1:25426560 chr1:25294164~25294643:- PAAD cis rs3814244 0.528 rs12228471 ENSG00000255733.4 IFNG-AS1 8.42 2.64e-14 1.03e-10 0.53 0.56 Itch intensity from mosquito bite adjusted by bite size; chr12:68027842 chr12:67989445~68234686:+ PAAD cis rs3814244 0.528 rs56393928 ENSG00000255733.4 IFNG-AS1 8.42 2.64e-14 1.03e-10 0.53 0.56 Itch intensity from mosquito bite adjusted by bite size; chr12:68029927 chr12:67989445~68234686:+ PAAD cis rs3814244 0.528 rs2870960 ENSG00000255733.4 IFNG-AS1 8.42 2.64e-14 1.03e-10 0.53 0.56 Itch intensity from mosquito bite adjusted by bite size; chr12:68032848 chr12:67989445~68234686:+ PAAD cis rs7208859 0.673 rs216420 ENSG00000263531.1 RP13-753N3.1 8.42 2.66e-14 1.03e-10 0.99 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30611490 chr17:30863921~30864940:- PAAD cis rs1799949 0.965 rs1842147 ENSG00000198496.9 NBR2 -8.41 2.75e-14 1.07e-10 -0.56 -0.56 Menopause (age at onset); chr17:43357824 chr17:43125610~43153671:+ PAAD cis rs7208859 0.623 rs3752019 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824687 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73271869 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825203 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73271872 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825210 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs55724095 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826040 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs56146117 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826307 chr17:30863921~30864940:- PAAD cis rs17826219 0.568 rs9903854 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Body mass index; chr17:30826980 chr17:30863921~30864940:- PAAD cis rs17826219 0.568 rs9907834 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Body mass index; chr17:30826995 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs80355557 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827403 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9911173 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827732 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs73271887 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827917 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9898858 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829193 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs55658077 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829501 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9899692 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829921 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9906957 ENSG00000263531.1 RP13-753N3.1 8.41 2.76e-14 1.07e-10 1.09 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30830737 chr17:30863921~30864940:- PAAD cis rs7301826 0.966 rs4759795 ENSG00000256250.1 RP11-989F5.1 -8.41 2.76e-14 1.07e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130816355 chr12:130810606~130812438:+ PAAD cis rs9326248 0.516 rs6589577 ENSG00000254851.1 RP11-109L13.1 -8.41 2.77e-14 1.07e-10 -1.02 -0.56 Blood protein levels; chr11:116879261 chr11:117135528~117138582:+ PAAD cis rs507080 0.733 rs517445 ENSG00000255422.1 AP002954.4 -8.41 2.78e-14 1.07e-10 -0.68 -0.56 Serum metabolite levels; chr11:118702826 chr11:118704607~118750263:+ PAAD cis rs507080 0.771 rs687664 ENSG00000255422.1 AP002954.4 -8.41 2.78e-14 1.07e-10 -0.68 -0.56 Serum metabolite levels; chr11:118703476 chr11:118704607~118750263:+ PAAD cis rs507080 0.771 rs523715 ENSG00000255422.1 AP002954.4 -8.41 2.78e-14 1.07e-10 -0.68 -0.56 Serum metabolite levels; chr11:118703479 chr11:118704607~118750263:+ PAAD cis rs2739330 0.76 rs5751760 ENSG00000250470.1 AP000351.3 8.41 2.78e-14 1.07e-10 0.77 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23976904~23977585:- PAAD cis rs7188445 0.556 rs7203910 ENSG00000261390.4 RP11-345M22.2 -8.41 2.8e-14 1.08e-10 -0.71 -0.56 Urate levels; chr16:79711722 chr16:79715232~79770563:- PAAD cis rs7188445 0.556 rs7194711 ENSG00000261390.4 RP11-345M22.2 -8.41 2.8e-14 1.08e-10 -0.71 -0.56 Urate levels; chr16:79715134 chr16:79715232~79770563:- PAAD cis rs507080 0.733 rs611733 ENSG00000255422.1 AP002954.4 -8.4 2.89e-14 1.11e-10 -0.68 -0.56 Serum metabolite levels; chr11:118702051 chr11:118704607~118750263:+ PAAD cis rs507080 0.733 rs552079 ENSG00000255422.1 AP002954.4 -8.4 2.89e-14 1.11e-10 -0.68 -0.56 Serum metabolite levels; chr11:118702313 chr11:118704607~118750263:+ PAAD cis rs507080 0.733 rs673547 ENSG00000255422.1 AP002954.4 -8.4 2.89e-14 1.11e-10 -0.68 -0.56 Serum metabolite levels; chr11:118702630 chr11:118704607~118750263:+ PAAD cis rs321358 0.895 rs6589210 ENSG00000271584.1 RP11-89C3.4 8.4 2.9e-14 1.12e-10 0.69 0.56 Body mass index; chr11:111088408 chr11:111091932~111097357:- PAAD cis rs7208859 0.673 rs3816780 ENSG00000263531.1 RP13-753N3.1 8.4 2.93e-14 1.13e-10 1.14 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834340 chr17:30863921~30864940:- PAAD cis rs3091242 0.934 rs666686 ENSG00000224183.1 SDHDP6 -8.4 3e-14 1.15e-10 -0.73 -0.56 Erythrocyte sedimentation rate; chr1:25393020 chr1:25294164~25294643:- PAAD cis rs977987 0.669 rs1001861 ENSG00000261783.1 RP11-252K23.2 -8.39 3.05e-14 1.17e-10 -0.72 -0.56 Dupuytren's disease; chr16:75272557 chr16:75379818~75381260:- PAAD cis rs7301826 1 rs10773822 ENSG00000256250.1 RP11-989F5.1 -8.39 3.09e-14 1.19e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130804562 chr12:130810606~130812438:+ PAAD cis rs7301826 1 rs4759787 ENSG00000256250.1 RP11-989F5.1 -8.39 3.09e-14 1.19e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130805635 chr12:130810606~130812438:+ PAAD cis rs7301826 1 rs7301826 ENSG00000256250.1 RP11-989F5.1 -8.39 3.09e-14 1.19e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130806556 chr12:130810606~130812438:+ PAAD cis rs7301826 0.966 rs10734980 ENSG00000256250.1 RP11-989F5.1 -8.39 3.09e-14 1.19e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130810081 chr12:130810606~130812438:+ PAAD cis rs7301826 0.967 rs4759790 ENSG00000256250.1 RP11-989F5.1 -8.39 3.09e-14 1.19e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130811845 chr12:130810606~130812438:+ PAAD cis rs7301826 1 rs4759793 ENSG00000256250.1 RP11-989F5.1 -8.39 3.09e-14 1.19e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130812693 chr12:130810606~130812438:+ PAAD cis rs5769707 0.542 rs739242 ENSG00000188511.11 C22orf34 8.39 3.11e-14 1.2e-10 0.58 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49663468 chr22:49414524~49657542:- PAAD cis rs1153858 0.945 rs1974981 ENSG00000259520.4 CTD-2651B20.3 8.39 3.12e-14 1.2e-10 0.78 0.56 Homoarginine levels; chr15:45436925 chr15:45251580~45279251:- PAAD cis rs7208859 0.673 rs216418 ENSG00000263531.1 RP13-753N3.1 8.39 3.13e-14 1.2e-10 0.99 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30609519 chr17:30863921~30864940:- PAAD cis rs881375 1 rs4323544 ENSG00000226752.6 PSMD5-AS1 -8.38 3.21e-14 1.23e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120885099 chr9:120824828~120854385:+ PAAD cis rs10760123 1 rs10760123 ENSG00000226752.6 PSMD5-AS1 -8.38 3.21e-14 1.23e-10 -0.61 -0.56 Allergic disease (asthma, hay fever or eczema); chr9:120888256 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs2270231 ENSG00000226752.6 PSMD5-AS1 -8.38 3.21e-14 1.23e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120888704 chr9:120824828~120854385:+ PAAD cis rs881375 1 rs881375 ENSG00000226752.6 PSMD5-AS1 -8.38 3.21e-14 1.23e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120890620 chr9:120824828~120854385:+ PAAD cis rs881375 1 rs10117059 ENSG00000226752.6 PSMD5-AS1 -8.38 3.21e-14 1.23e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120891199 chr9:120824828~120854385:+ PAAD cis rs977987 0.933 rs1834014 ENSG00000261783.1 RP11-252K23.2 -8.38 3.21e-14 1.23e-10 -0.69 -0.56 Dupuytren's disease; chr16:75467376 chr16:75379818~75381260:- PAAD cis rs9326248 0.53 rs1351452 ENSG00000254851.1 RP11-109L13.1 8.38 3.21e-14 1.23e-10 0.98 0.56 Blood protein levels; chr11:117072638 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs511676 ENSG00000254851.1 RP11-109L13.1 -8.38 3.23e-14 1.24e-10 -1.04 -0.56 Blood protein levels; chr11:116954168 chr11:117135528~117138582:+ PAAD cis rs55794721 0.509 rs2375313 ENSG00000224183.1 SDHDP6 -8.38 3.23e-14 1.24e-10 -0.72 -0.56 Mean corpuscular volume;Plateletcrit; chr1:25421744 chr1:25294164~25294643:- PAAD cis rs7188445 0.615 rs4340340 ENSG00000261390.4 RP11-345M22.2 -8.38 3.28e-14 1.26e-10 -0.7 -0.56 Urate levels; chr16:79716720 chr16:79715232~79770563:- PAAD cis rs9326248 0.53 rs10750101 ENSG00000254851.1 RP11-109L13.1 -8.38 3.3e-14 1.26e-10 -1 -0.56 Blood protein levels; chr11:117108973 chr11:117135528~117138582:+ PAAD cis rs1799949 1 rs11659028 ENSG00000198496.9 NBR2 -8.38 3.3e-14 1.27e-10 -0.56 -0.56 Menopause (age at onset); chr17:43043008 chr17:43125610~43153671:+ PAAD cis rs8062405 1 rs8062405 ENSG00000259982.1 CDC37P1 -8.38 3.31e-14 1.27e-10 -0.62 -0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826585 chr16:28700294~28701540:- PAAD cis rs7301826 1 rs10744482 ENSG00000256250.1 RP11-989F5.1 -8.38 3.32e-14 1.27e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130813650 chr12:130810606~130812438:+ PAAD cis rs9660180 0.839 rs12040826 ENSG00000268575.1 RP1-283E3.8 -8.38 3.35e-14 1.28e-10 -0.54 -0.56 Body mass index; chr1:1773848 chr1:1702736~1737688:- PAAD cis rs10256972 0.732 rs1574108 ENSG00000229043.2 AC091729.9 -8.38 3.36e-14 1.29e-10 -0.58 -0.56 Endometriosis;Longevity; chr7:1066169 chr7:1160374~1165267:+ PAAD cis rs10256972 0.732 rs12701856 ENSG00000229043.2 AC091729.9 -8.38 3.36e-14 1.29e-10 -0.58 -0.56 Endometriosis;Longevity; chr7:1068071 chr7:1160374~1165267:+ PAAD cis rs1799949 0.965 rs9646413 ENSG00000198496.9 NBR2 -8.37 3.43e-14 1.31e-10 -0.55 -0.56 Menopause (age at onset); chr17:43348789 chr17:43125610~43153671:+ PAAD cis rs2882667 0.964 rs11739351 ENSG00000253404.1 AC034243.1 8.37 3.43e-14 1.31e-10 0.69 0.56 Age-related hearing impairment (SNP x SNP interaction); chr5:138976053 chr5:138744434~138753309:- PAAD cis rs8062405 1 rs8061590 ENSG00000259982.1 CDC37P1 8.37 3.44e-14 1.32e-10 0.63 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28883809 chr16:28700294~28701540:- PAAD cis rs1153858 0.945 rs16943246 ENSG00000259520.4 CTD-2651B20.3 -8.37 3.45e-14 1.32e-10 -0.78 -0.56 Homoarginine levels; chr15:45428399 chr15:45251580~45279251:- PAAD cis rs1799949 0.931 rs9912203 ENSG00000198496.9 NBR2 8.37 3.45e-14 1.32e-10 0.55 0.56 Menopause (age at onset); chr17:43367777 chr17:43125610~43153671:+ PAAD cis rs1799949 0.536 rs4793227 ENSG00000198496.9 NBR2 -8.37 3.52e-14 1.34e-10 -0.56 -0.56 Menopause (age at onset); chr17:43334882 chr17:43125610~43153671:+ PAAD cis rs7301826 0.967 rs4759792 ENSG00000256250.1 RP11-989F5.1 -8.37 3.52e-14 1.34e-10 -0.63 -0.56 Plasma plasminogen activator levels; chr12:130812086 chr12:130810606~130812438:+ PAAD cis rs7208859 0.524 rs8069400 ENSG00000263531.1 RP13-753N3.1 8.37 3.52e-14 1.34e-10 1.07 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748949 chr17:30863921~30864940:- PAAD cis rs17711722 0.653 rs2460421 ENSG00000226824.5 RP4-756H11.3 8.37 3.52e-14 1.34e-10 0.64 0.56 Calcium levels; chr7:66026136 chr7:66654538~66669855:+ PAAD cis rs3091242 0.804 rs631133 ENSG00000224183.1 SDHDP6 -8.37 3.53e-14 1.35e-10 -0.72 -0.56 Erythrocyte sedimentation rate; chr1:25397655 chr1:25294164~25294643:- PAAD cis rs9601248 0.874 rs9545154 ENSG00000227676.3 LINC01068 8.37 3.54e-14 1.35e-10 0.73 0.56 Major depressive disorder; chr13:79617682 chr13:79566727~79571436:+ PAAD cis rs9601248 0.874 rs9545155 ENSG00000227676.3 LINC01068 8.37 3.54e-14 1.35e-10 0.73 0.56 Major depressive disorder; chr13:79617738 chr13:79566727~79571436:+ PAAD cis rs7104764 1 rs6598066 ENSG00000277290.1 RP11-326C3.16 -8.37 3.55e-14 1.36e-10 -0.53 -0.56 Menarche (age at onset); chr11:243185 chr11:243099~243483:- PAAD cis rs881375 0.933 rs4837799 ENSG00000226752.6 PSMD5-AS1 -8.37 3.59e-14 1.37e-10 -0.62 -0.56 Rheumatoid arthritis; chr9:120906048 chr9:120824828~120854385:+ PAAD cis rs3931020 0.548 rs969435 ENSG00000272864.1 RP11-17E13.2 8.37 3.6e-14 1.37e-10 0.7 0.56 Resistin levels; chr1:74808182 chr1:74698769~74699333:- PAAD cis rs881375 0.967 rs1930778 ENSG00000226752.6 PSMD5-AS1 -8.36 3.6e-14 1.37e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120879091 chr9:120824828~120854385:+ PAAD cis rs881375 1 rs10760118 ENSG00000226752.6 PSMD5-AS1 -8.36 3.6e-14 1.37e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120879338 chr9:120824828~120854385:+ PAAD cis rs977987 0.902 rs4888430 ENSG00000261783.1 RP11-252K23.2 -8.36 3.61e-14 1.38e-10 -0.68 -0.56 Dupuytren's disease; chr16:75460526 chr16:75379818~75381260:- PAAD cis rs1799949 0.859 rs11657004 ENSG00000198496.9 NBR2 -8.36 3.62e-14 1.38e-10 -0.56 -0.56 Menopause (age at onset); chr17:43365383 chr17:43125610~43153671:+ PAAD cis rs6452524 0.507 rs28592576 ENSG00000249664.1 CTD-2227C6.2 8.36 3.63e-14 1.38e-10 0.68 0.56 Hypertension (SNP x SNP interaction); chr5:83074772 chr5:83012285~83013109:- PAAD cis rs6452524 0.534 rs7727691 ENSG00000249664.1 CTD-2227C6.2 8.36 3.63e-14 1.38e-10 0.68 0.56 Hypertension (SNP x SNP interaction); chr5:83075876 chr5:83012285~83013109:- PAAD cis rs6452524 0.562 rs10474080 ENSG00000249664.1 CTD-2227C6.2 8.36 3.63e-14 1.38e-10 0.68 0.56 Hypertension (SNP x SNP interaction); chr5:83078300 chr5:83012285~83013109:- PAAD cis rs10256972 0.786 rs3735686 ENSG00000229043.2 AC091729.9 -8.36 3.66e-14 1.39e-10 -0.58 -0.56 Endometriosis;Longevity; chr7:1022891 chr7:1160374~1165267:+ PAAD cis rs12439619 0.921 rs4778672 ENSG00000278603.1 RP13-608F4.5 -8.36 3.67e-14 1.4e-10 -0.8 -0.56 Intelligence (multi-trait analysis); chr15:82245013 chr15:82472203~82472426:+ PAAD cis rs7208859 0.623 rs9895785 ENSG00000263531.1 RP13-753N3.1 -8.36 3.7e-14 1.41e-10 -1.05 -0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780690 chr17:30863921~30864940:- PAAD cis rs3091242 0.809 rs660129 ENSG00000224183.1 SDHDP6 -8.36 3.73e-14 1.42e-10 -0.72 -0.56 Erythrocyte sedimentation rate; chr1:25400947 chr1:25294164~25294643:- PAAD cis rs3091242 0.728 rs706845 ENSG00000224183.1 SDHDP6 -8.36 3.73e-14 1.42e-10 -0.72 -0.56 Erythrocyte sedimentation rate; chr1:25404222 chr1:25294164~25294643:- PAAD cis rs3091242 0.933 rs28633797 ENSG00000224183.1 SDHDP6 -8.36 3.73e-14 1.42e-10 -0.72 -0.56 Erythrocyte sedimentation rate; chr1:25415138 chr1:25294164~25294643:- PAAD cis rs55794721 0.509 rs2982358 ENSG00000224183.1 SDHDP6 -8.36 3.73e-14 1.42e-10 -0.72 -0.56 Mean corpuscular volume;Plateletcrit; chr1:25418713 chr1:25294164~25294643:- PAAD cis rs9601248 0.874 rs4141825 ENSG00000227676.3 LINC01068 8.36 3.74e-14 1.42e-10 0.74 0.56 Major depressive disorder; chr13:79616713 chr13:79566727~79571436:+ PAAD cis rs8062405 0.756 rs151182 ENSG00000259982.1 CDC37P1 8.36 3.75e-14 1.42e-10 0.64 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28484431 chr16:28700294~28701540:- PAAD cis rs8062405 0.756 rs151301 ENSG00000259982.1 CDC37P1 8.36 3.75e-14 1.42e-10 0.64 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28485738 chr16:28700294~28701540:- PAAD cis rs875971 0.825 rs1129531 ENSG00000226824.5 RP4-756H11.3 8.36 3.75e-14 1.42e-10 0.69 0.56 Aortic root size; chr7:66154117 chr7:66654538~66669855:+ PAAD cis rs9326248 0.559 rs12808524 ENSG00000254851.1 RP11-109L13.1 -8.36 3.76e-14 1.42e-10 -0.71 -0.56 Blood protein levels; chr11:117020277 chr11:117135528~117138582:+ PAAD cis rs62388641 0.813 rs55821127 ENSG00000272279.1 RP11-157J24.2 8.35 3.85e-14 1.45e-10 0.77 0.56 Daytime sleep phenotypes; chr6:1550635 chr6:1528364~1528911:- PAAD cis rs62388641 0.813 rs62390562 ENSG00000272279.1 RP11-157J24.2 8.35 3.85e-14 1.45e-10 0.77 0.56 Daytime sleep phenotypes; chr6:1551467 chr6:1528364~1528911:- PAAD cis rs6452524 0.534 rs10037377 ENSG00000249664.1 CTD-2227C6.2 8.35 3.89e-14 1.46e-10 0.68 0.56 Hypertension (SNP x SNP interaction); chr5:83071150 chr5:83012285~83013109:- PAAD cis rs3091242 0.867 rs602052 ENSG00000224183.1 SDHDP6 -8.35 3.91e-14 1.47e-10 -0.71 -0.56 Erythrocyte sedimentation rate; chr1:25395715 chr1:25294164~25294643:- PAAD cis rs8062405 0.965 rs8049439 ENSG00000259982.1 CDC37P1 8.35 3.91e-14 1.47e-10 0.61 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826194 chr16:28700294~28701540:- PAAD cis rs7115242 0.844 rs645258 ENSG00000254851.1 RP11-109L13.1 -8.35 4.04e-14 1.52e-10 -1.07 -0.56 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116930485 chr11:117135528~117138582:+ PAAD cis rs2739330 0.76 rs5760095 ENSG00000250470.1 AP000351.3 8.34 4.06e-14 1.52e-10 0.78 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23976904~23977585:- PAAD cis rs9326248 0.53 rs7114963 ENSG00000254851.1 RP11-109L13.1 -8.34 4.07e-14 1.53e-10 -1.03 -0.56 Blood protein levels; chr11:117005267 chr11:117135528~117138582:+ PAAD cis rs7115242 0.72 rs10790169 ENSG00000254851.1 RP11-109L13.1 -8.34 4.07e-14 1.53e-10 -1.03 -0.56 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117006443 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs7950364 ENSG00000254851.1 RP11-109L13.1 -8.34 4.07e-14 1.53e-10 -1.03 -0.56 Blood protein levels; chr11:117028170 chr11:117135528~117138582:+ PAAD cis rs11690935 1 rs11678984 ENSG00000228389.1 AC068039.4 -8.34 4.1e-14 1.54e-10 -0.7 -0.56 Schizophrenia; chr2:171679338 chr2:171773482~171775844:+ PAAD cis rs11690935 1 rs34542126 ENSG00000228389.1 AC068039.4 -8.34 4.1e-14 1.54e-10 -0.7 -0.56 Schizophrenia; chr2:171686195 chr2:171773482~171775844:+ PAAD cis rs7208859 0.673 rs216410 ENSG00000263531.1 RP13-753N3.1 -8.34 4.13e-14 1.55e-10 -0.96 -0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576813 chr17:30863921~30864940:- PAAD cis rs507080 0.733 rs489126 ENSG00000255422.1 AP002954.4 -8.34 4.14e-14 1.55e-10 -0.68 -0.56 Serum metabolite levels; chr11:118702038 chr11:118704607~118750263:+ PAAD cis rs8062405 1 rs72793811 ENSG00000259982.1 CDC37P1 8.34 4.16e-14 1.56e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828071 chr16:28700294~28701540:- PAAD cis rs9326248 0.53 rs10732856 ENSG00000254851.1 RP11-109L13.1 -8.34 4.21e-14 1.57e-10 -0.97 -0.56 Blood protein levels; chr11:117036397 chr11:117135528~117138582:+ PAAD cis rs881375 0.967 rs2239658 ENSG00000226752.6 PSMD5-AS1 -8.34 4.22e-14 1.58e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120909559 chr9:120824828~120854385:+ PAAD cis rs9601248 0.874 rs9545158 ENSG00000227676.3 LINC01068 8.34 4.24e-14 1.58e-10 0.73 0.56 Major depressive disorder; chr13:79618771 chr13:79566727~79571436:+ PAAD cis rs17507216 0.628 rs4627310 ENSG00000278603.1 RP13-608F4.5 8.34 4.28e-14 1.6e-10 0.93 0.56 Excessive daytime sleepiness; chr15:82708330 chr15:82472203~82472426:+ PAAD cis rs7208859 0.673 rs11653955 ENSG00000263531.1 RP13-753N3.1 8.33 4.32e-14 1.61e-10 1.08 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30706274 chr17:30863921~30864940:- PAAD cis rs3814244 0.528 rs7306466 ENSG00000255733.4 IFNG-AS1 8.33 4.34e-14 1.62e-10 0.54 0.56 Itch intensity from mosquito bite adjusted by bite size; chr12:68014942 chr12:67989445~68234686:+ PAAD cis rs875971 0.767 rs12668005 ENSG00000226824.5 RP4-756H11.3 -8.33 4.35e-14 1.62e-10 -0.7 -0.56 Aortic root size; chr7:66444034 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs11765791 ENSG00000226824.5 RP4-756H11.3 -8.33 4.35e-14 1.62e-10 -0.7 -0.56 Aortic root size; chr7:66471587 chr7:66654538~66669855:+ PAAD cis rs8062405 1 rs12443881 ENSG00000259982.1 CDC37P1 8.33 4.39e-14 1.64e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28830456 chr16:28700294~28701540:- PAAD cis rs55794721 0.509 rs12027110 ENSG00000224183.1 SDHDP6 -8.33 4.39e-14 1.64e-10 -0.73 -0.56 Mean corpuscular volume;Plateletcrit; chr1:25449191 chr1:25294164~25294643:- PAAD cis rs977987 0.931 rs1834013 ENSG00000261783.1 RP11-252K23.2 -8.33 4.4e-14 1.64e-10 -0.68 -0.56 Dupuytren's disease; chr16:75462265 chr16:75379818~75381260:- PAAD cis rs977987 0.645 rs34904236 ENSG00000261783.1 RP11-252K23.2 -8.33 4.4e-14 1.64e-10 -0.68 -0.56 Dupuytren's disease; chr16:75464355 chr16:75379818~75381260:- PAAD cis rs7301826 0.557 rs7953184 ENSG00000256299.1 RP11-989F5.3 8.33 4.42e-14 1.65e-10 0.64 0.56 Plasma plasminogen activator levels; chr12:130800307 chr12:130810821~130812622:- PAAD cis rs17826219 0.789 rs4794873 ENSG00000263531.1 RP13-753N3.1 8.33 4.49e-14 1.67e-10 0.96 0.56 Body mass index; chr17:30421334 chr17:30863921~30864940:- PAAD cis rs5769707 0.656 rs135875 ENSG00000188511.11 C22orf34 8.33 4.53e-14 1.69e-10 0.58 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49618771 chr22:49414524~49657542:- PAAD cis rs321358 0.945 rs7112932 ENSG00000271584.1 RP11-89C3.4 8.32 4.55e-14 1.7e-10 0.74 0.56 Body mass index; chr11:111101099 chr11:111091932~111097357:- PAAD cis rs881375 0.967 rs1008381 ENSG00000226752.6 PSMD5-AS1 -8.32 4.58e-14 1.71e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120918838 chr9:120824828~120854385:+ PAAD cis rs1799949 0.965 rs9646418 ENSG00000198496.9 NBR2 -8.32 4.64e-14 1.72e-10 -0.55 -0.56 Menopause (age at onset); chr17:43348533 chr17:43125610~43153671:+ PAAD cis rs7208859 0.562 rs216408 ENSG00000263531.1 RP13-753N3.1 -8.32 4.64e-14 1.72e-10 -0.96 -0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30580739 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs216440 ENSG00000263531.1 RP13-753N3.1 8.32 4.64e-14 1.72e-10 0.96 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30601291 chr17:30863921~30864940:- PAAD cis rs17826219 0.561 rs562840 ENSG00000263531.1 RP13-753N3.1 8.32 4.64e-14 1.72e-10 0.96 0.56 Body mass index; chr17:30622372 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs60890550 ENSG00000263531.1 RP13-753N3.1 8.32 4.66e-14 1.73e-10 1.07 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30703843 chr17:30863921~30864940:- PAAD cis rs5769707 0.521 rs6009810 ENSG00000188511.11 C22orf34 8.32 4.67e-14 1.73e-10 0.56 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49665892 chr22:49414524~49657542:- PAAD cis rs67383717 0.672 rs589458 ENSG00000175611.10 LINC00476 8.32 4.76e-14 1.77e-10 0.48 0.56 Parkinson's disease (pesticide exposure interaction); chr9:95878389 chr9:95759231~95875977:- PAAD cis rs881375 1 rs6478486 ENSG00000226752.6 PSMD5-AS1 -8.32 4.78e-14 1.77e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120893051 chr9:120824828~120854385:+ PAAD cis rs881375 1 rs7037140 ENSG00000226752.6 PSMD5-AS1 -8.32 4.78e-14 1.77e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120894049 chr9:120824828~120854385:+ PAAD cis rs7115242 0.8 rs7931770 ENSG00000254851.1 RP11-109L13.1 -8.31 4.83e-14 1.79e-10 -0.99 -0.56 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116995574 chr11:117135528~117138582:+ PAAD cis rs7115242 0.8 rs4245168 ENSG00000254851.1 RP11-109L13.1 -8.31 4.83e-14 1.79e-10 -0.99 -0.56 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117011922 chr11:117135528~117138582:+ PAAD cis rs1799949 0.628 rs4474733 ENSG00000198496.9 NBR2 -8.31 4.92e-14 1.82e-10 -0.59 -0.56 Menopause (age at onset); chr17:43356292 chr17:43125610~43153671:+ PAAD cis rs7188445 0.592 rs17767281 ENSG00000261390.4 RP11-345M22.2 -8.31 4.93e-14 1.83e-10 -0.7 -0.56 Urate levels; chr16:79708544 chr16:79715232~79770563:- PAAD cis rs881375 0.935 rs7034390 ENSG00000226752.6 PSMD5-AS1 -8.31 5.06e-14 1.87e-10 -0.6 -0.56 Rheumatoid arthritis; chr9:120884210 chr9:120824828~120854385:+ PAAD cis rs881375 1 rs6478484 ENSG00000226752.6 PSMD5-AS1 -8.3 5.19e-14 1.92e-10 -0.62 -0.56 Rheumatoid arthritis; chr9:120890102 chr9:120824828~120854385:+ PAAD cis rs858239 0.712 rs199650 ENSG00000230658.1 KLHL7-AS1 -8.3 5.24e-14 1.93e-10 -0.68 -0.56 Cerebrospinal fluid biomarker levels; chr7:23327570 chr7:23101228~23105703:- PAAD cis rs977987 0.705 rs4888377 ENSG00000261783.1 RP11-252K23.2 -8.3 5.29e-14 1.95e-10 -0.73 -0.56 Dupuytren's disease; chr16:75291788 chr16:75379818~75381260:- PAAD cis rs8062405 1 rs12325113 ENSG00000259982.1 CDC37P1 8.3 5.36e-14 1.97e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28837347 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs80275162 ENSG00000259982.1 CDC37P1 8.3 5.36e-14 1.97e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28852196 chr16:28700294~28701540:- PAAD cis rs56163509 1 rs56163509 ENSG00000259982.1 CDC37P1 8.3 5.36e-14 1.97e-10 0.62 0.56 Tonsillectomy;Mean corpuscular volume; chr16:28853150 chr16:28700294~28701540:- PAAD cis rs8062405 0.964 rs7187333 ENSG00000259982.1 CDC37P1 8.3 5.36e-14 1.97e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854595 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs12446589 ENSG00000259982.1 CDC37P1 8.3 5.36e-14 1.97e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859641 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62037369 ENSG00000259982.1 CDC37P1 8.3 5.36e-14 1.97e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28872520 chr16:28700294~28701540:- PAAD cis rs8062405 0.965 rs7359397 ENSG00000259982.1 CDC37P1 8.3 5.36e-14 1.97e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874338 chr16:28700294~28701540:- PAAD cis rs7829975 0.564 rs2921057 ENSG00000253893.2 FAM85B -8.29 5.47e-14 2.01e-10 -0.76 -0.56 Mood instability; chr8:8461157 chr8:8167819~8226614:- PAAD cis rs10256972 0.621 rs2363285 ENSG00000229043.2 AC091729.9 -8.29 5.49e-14 2.02e-10 -0.57 -0.56 Endometriosis;Longevity; chr7:1052008 chr7:1160374~1165267:+ PAAD cis rs7301826 0.651 rs34749116 ENSG00000256299.1 RP11-989F5.3 8.29 5.7e-14 2.09e-10 0.62 0.56 Plasma plasminogen activator levels; chr12:130796207 chr12:130810821~130812622:- PAAD cis rs858239 0.712 rs200717 ENSG00000230658.1 KLHL7-AS1 8.28 5.78e-14 2.12e-10 0.68 0.56 Cerebrospinal fluid biomarker levels; chr7:23352652 chr7:23101228~23105703:- PAAD cis rs11690935 1 rs6721680 ENSG00000228389.1 AC068039.4 -8.28 5.83e-14 2.14e-10 -0.7 -0.56 Schizophrenia; chr2:171687403 chr2:171773482~171775844:+ PAAD cis rs6907340 0.517 rs9465531 ENSG00000228412.5 RP4-625H18.2 8.28 5.86e-14 2.15e-10 0.7 0.56 Endometriosis; chr6:19798418 chr6:19802164~19804752:- PAAD cis rs1153858 0.887 rs28569043 ENSG00000259520.4 CTD-2651B20.3 -8.28 5.97e-14 2.19e-10 -0.78 -0.56 Homoarginine levels; chr15:45438728 chr15:45251580~45279251:- PAAD cis rs3091242 0.9 rs1811832 ENSG00000224183.1 SDHDP6 -8.28 6.02e-14 2.21e-10 -0.72 -0.56 Erythrocyte sedimentation rate; chr1:25427074 chr1:25294164~25294643:- PAAD cis rs62388641 0.547 rs2745610 ENSG00000272279.1 RP11-157J24.2 -8.27 6.13e-14 2.25e-10 -0.72 -0.56 Daytime sleep phenotypes; chr6:1553741 chr6:1528364~1528911:- PAAD cis rs6452524 0.534 rs10514246 ENSG00000249664.1 CTD-2227C6.2 8.27 6.24e-14 2.29e-10 0.67 0.56 Hypertension (SNP x SNP interaction); chr5:83069979 chr5:83012285~83013109:- PAAD cis rs881375 0.9 rs2241003 ENSG00000226752.6 PSMD5-AS1 -8.27 6.24e-14 2.29e-10 -0.6 -0.56 Rheumatoid arthritis; chr9:120904499 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs758959 ENSG00000226752.6 PSMD5-AS1 -8.27 6.26e-14 2.29e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120914421 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs876445 ENSG00000226752.6 PSMD5-AS1 -8.27 6.26e-14 2.29e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120914824 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs2109895 ENSG00000226752.6 PSMD5-AS1 -8.27 6.26e-14 2.29e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120915549 chr9:120824828~120854385:+ PAAD cis rs8062405 0.895 rs62036658 ENSG00000259982.1 CDC37P1 8.27 6.28e-14 2.3e-10 0.62 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28839050 chr16:28700294~28701540:- PAAD cis rs2283792 0.622 rs381523 ENSG00000224086.5 LL22NC03-86G7.1 -8.27 6.32e-14 2.31e-10 -0.59 -0.56 Multiple sclerosis; chr22:21951257 chr22:21938293~21977632:+ PAAD cis rs5769707 0.632 rs5770601 ENSG00000188511.11 C22orf34 8.27 6.33e-14 2.32e-10 0.58 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49628255 chr22:49414524~49657542:- PAAD cis rs7115242 0.702 rs672058 ENSG00000254851.1 RP11-109L13.1 -8.27 6.35e-14 2.32e-10 -1 -0.56 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116893305 chr11:117135528~117138582:+ PAAD cis rs7301826 1 rs10848205 ENSG00000256250.1 RP11-989F5.1 -8.27 6.35e-14 2.33e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130796169 chr12:130810606~130812438:+ PAAD cis rs17507216 0.588 rs28864981 ENSG00000278603.1 RP13-608F4.5 8.26 6.64e-14 2.43e-10 0.92 0.56 Excessive daytime sleepiness; chr15:82695420 chr15:82472203~82472426:+ PAAD cis rs17507216 0.628 rs8032321 ENSG00000278603.1 RP13-608F4.5 8.26 6.64e-14 2.43e-10 0.92 0.56 Excessive daytime sleepiness; chr15:82698956 chr15:82472203~82472426:+ PAAD cis rs17507216 0.628 rs8040488 ENSG00000278603.1 RP13-608F4.5 8.26 6.64e-14 2.43e-10 0.92 0.56 Excessive daytime sleepiness; chr15:82699081 chr15:82472203~82472426:+ PAAD cis rs17507216 0.628 rs4513065 ENSG00000278603.1 RP13-608F4.5 8.26 6.64e-14 2.43e-10 0.92 0.56 Excessive daytime sleepiness; chr15:82712096 chr15:82472203~82472426:+ PAAD cis rs17507216 0.628 rs28371837 ENSG00000278603.1 RP13-608F4.5 8.26 6.64e-14 2.43e-10 0.92 0.56 Excessive daytime sleepiness; chr15:82714435 chr15:82472203~82472426:+ PAAD cis rs11690935 1 rs312918 ENSG00000228389.1 AC068039.4 8.26 6.66e-14 2.43e-10 0.7 0.56 Schizophrenia; chr2:171713077 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs6705200 ENSG00000228389.1 AC068039.4 8.26 6.66e-14 2.43e-10 0.7 0.56 Schizophrenia; chr2:171781090 chr2:171773482~171775844:+ PAAD cis rs17507216 0.628 rs8028130 ENSG00000278603.1 RP13-608F4.5 8.26 6.68e-14 2.44e-10 0.93 0.56 Excessive daytime sleepiness; chr15:82734974 chr15:82472203~82472426:+ PAAD cis rs4718428 0.96 rs6460317 ENSG00000226824.5 RP4-756H11.3 -8.26 6.71e-14 2.45e-10 -0.69 -0.56 Corneal structure; chr7:66925268 chr7:66654538~66669855:+ PAAD cis rs10262624 0.504 rs59865844 ENSG00000234286.1 AC006026.13 8.26 6.72e-14 2.45e-10 0.62 0.56 Schizophrenia; chr7:23693421 chr7:23680195~23680786:- PAAD cis rs7208859 0.673 rs216435 ENSG00000263531.1 RP13-753N3.1 8.25 6.83e-14 2.49e-10 0.98 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595719 chr17:30863921~30864940:- PAAD cis rs9660180 1 rs3737628 ENSG00000268575.1 RP1-283E3.8 -8.25 6.85e-14 2.5e-10 -0.54 -0.56 Body mass index; chr1:1791493 chr1:1702736~1737688:- PAAD cis rs9326248 0.53 rs10790172 ENSG00000254851.1 RP11-109L13.1 -8.25 6.95e-14 2.54e-10 -0.98 -0.56 Blood protein levels; chr11:117057024 chr11:117135528~117138582:+ PAAD cis rs1799949 0.965 rs6503727 ENSG00000198496.9 NBR2 -8.25 7e-14 2.55e-10 -0.55 -0.56 Menopause (age at onset); chr17:43160842 chr17:43125610~43153671:+ PAAD cis rs881375 0.934 rs1468671 ENSG00000226752.6 PSMD5-AS1 -8.25 7.19e-14 2.62e-10 -0.59 -0.56 Rheumatoid arthritis; chr9:120895224 chr9:120824828~120854385:+ PAAD cis rs7301826 1 rs4619189 ENSG00000256250.1 RP11-989F5.1 -8.25 7.21e-14 2.63e-10 -0.64 -0.56 Plasma plasminogen activator levels; chr12:130829252 chr12:130810606~130812438:+ PAAD cis rs2739330 0.76 rs1002286 ENSG00000250470.1 AP000351.3 -8.24 7.34e-14 2.68e-10 -0.75 -0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23976904~23977585:- PAAD cis rs8062405 0.964 rs78613234 ENSG00000259982.1 CDC37P1 8.24 7.43e-14 2.7e-10 0.61 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828104 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62036624 ENSG00000259982.1 CDC37P1 8.24 7.43e-14 2.7e-10 0.61 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828609 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs55991577 ENSG00000259982.1 CDC37P1 8.24 7.43e-14 2.7e-10 0.61 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831704 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs56358680 ENSG00000259982.1 CDC37P1 8.24 7.43e-14 2.7e-10 0.61 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831797 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62036626 ENSG00000259982.1 CDC37P1 8.24 7.43e-14 2.7e-10 0.61 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28832963 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62036657 ENSG00000259982.1 CDC37P1 8.24 7.43e-14 2.7e-10 0.61 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833044 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs12444171 ENSG00000259982.1 CDC37P1 8.24 7.43e-14 2.7e-10 0.61 0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833930 chr16:28700294~28701540:- PAAD cis rs11673344 0.615 rs2921561 ENSG00000226686.6 LINC01535 8.24 7.43e-14 2.71e-10 0.65 0.56 Obesity-related traits; chr19:37348969 chr19:37251912~37265535:+ PAAD cis rs17507216 0.718 rs4779033 ENSG00000278603.1 RP13-608F4.5 -8.24 7.45e-14 2.71e-10 -0.92 -0.56 Excessive daytime sleepiness; chr15:82576634 chr15:82472203~82472426:+ PAAD cis rs881375 0.967 rs2416805 ENSG00000226752.6 PSMD5-AS1 -8.24 7.51e-14 2.73e-10 -0.61 -0.56 Rheumatoid arthritis; chr9:120914204 chr9:120824828~120854385:+ PAAD cis rs5769707 0.521 rs7285764 ENSG00000188511.11 C22orf34 8.24 7.53e-14 2.74e-10 0.56 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49664913 chr22:49414524~49657542:- PAAD cis rs5769707 0.521 rs9616715 ENSG00000188511.11 C22orf34 8.24 7.53e-14 2.74e-10 0.56 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49664934 chr22:49414524~49657542:- PAAD cis rs5769707 0.521 rs6009805 ENSG00000188511.11 C22orf34 8.24 7.53e-14 2.74e-10 0.56 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49665067 chr22:49414524~49657542:- PAAD cis rs5769707 0.521 rs6009807 ENSG00000188511.11 C22orf34 8.24 7.53e-14 2.74e-10 0.56 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49665274 chr22:49414524~49657542:- PAAD cis rs1799949 0.602 rs8176257 ENSG00000198496.9 NBR2 -8.23 7.67e-14 2.79e-10 -0.58 -0.56 Menopause (age at onset); chr17:43064188 chr17:43125610~43153671:+ PAAD cis rs10256972 0.758 rs2280724 ENSG00000229043.2 AC091729.9 -8.23 7.72e-14 2.8e-10 -0.56 -0.56 Endometriosis;Longevity; chr7:1025084 chr7:1160374~1165267:+ PAAD cis rs7829975 0.593 rs2921061 ENSG00000253893.2 FAM85B -8.23 7.76e-14 2.82e-10 -0.75 -0.56 Mood instability; chr8:8460105 chr8:8167819~8226614:- PAAD cis rs7115242 0.8 rs10736487 ENSG00000254851.1 RP11-109L13.1 -8.23 7.82e-14 2.84e-10 -0.99 -0.56 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117079516 chr11:117135528~117138582:+ PAAD cis rs8062405 0.655 rs7184597 ENSG00000259982.1 CDC37P1 -8.23 7.89e-14 2.86e-10 -0.65 -0.56 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910488 chr16:28700294~28701540:- PAAD cis rs3091242 0.934 rs686631 ENSG00000224183.1 SDHDP6 -8.23 7.96e-14 2.88e-10 -0.7 -0.56 Erythrocyte sedimentation rate; chr1:25393108 chr1:25294164~25294643:- PAAD cis rs1062177 1 rs62377945 ENSG00000213433.5 RPLP1P6 -8.23 8.01e-14 2.9e-10 -0.65 -0.56 Preschool internalizing problems; chr5:151828443 chr5:151765859~151766378:- PAAD cis rs5769707 0.632 rs135876 ENSG00000188511.11 C22orf34 8.23 8.03e-14 2.91e-10 0.57 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49619925 chr22:49414524~49657542:- PAAD cis rs5769707 0.616 rs6009786 ENSG00000188511.11 C22orf34 8.23 8.03e-14 2.91e-10 0.57 0.56 Monocyte percentage of white cells;Monocyte count; chr22:49621497 chr22:49414524~49657542:- PAAD cis rs5769707 0.554 rs10854876 ENSG00000188511.11 C22orf34 8.22 8.25e-14 2.99e-10 0.59 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49616922 chr22:49414524~49657542:- PAAD cis rs6907340 0.517 rs6939160 ENSG00000228412.5 RP4-625H18.2 8.22 8.26e-14 2.99e-10 0.67 0.55 Endometriosis; chr6:19802086 chr6:19802164~19804752:- PAAD cis rs760794 0.577 rs17483277 ENSG00000228412.5 RP4-625H18.2 8.22 8.29e-14 3e-10 0.65 0.55 Endometriosis; chr6:19790340 chr6:19802164~19804752:- PAAD cis rs3814244 0.528 rs11177002 ENSG00000255733.4 IFNG-AS1 8.22 8.36e-14 3.02e-10 0.53 0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:68003377 chr12:67989445~68234686:+ PAAD cis rs765787 0.53 rs1648285 ENSG00000259520.4 CTD-2651B20.3 8.21 8.64e-14 3.12e-10 0.67 0.55 Uric acid levels; chr15:45225307 chr15:45251580~45279251:- PAAD cis rs9326248 0.581 rs12225187 ENSG00000254851.1 RP11-109L13.1 -8.21 8.67e-14 3.13e-10 -0.71 -0.55 Blood protein levels; chr11:116922515 chr11:117135528~117138582:+ PAAD cis rs881375 0.967 rs1930780 ENSG00000226752.6 PSMD5-AS1 -8.21 8.73e-14 3.15e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120923941 chr9:120824828~120854385:+ PAAD cis rs17507216 0.718 rs17158403 ENSG00000278603.1 RP13-608F4.5 8.21 8.73e-14 3.15e-10 0.94 0.55 Excessive daytime sleepiness; chr15:82572478 chr15:82472203~82472426:+ PAAD cis rs5769707 0.632 rs135871 ENSG00000188511.11 C22orf34 8.21 8.79e-14 3.17e-10 0.58 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49615321 chr22:49414524~49657542:- PAAD cis rs1799949 0.602 rs8176235 ENSG00000198496.9 NBR2 -8.21 8.79e-14 3.17e-10 -0.59 -0.55 Menopause (age at onset); chr17:43067543 chr17:43125610~43153671:+ PAAD cis rs977987 0.654 rs8054194 ENSG00000261783.1 RP11-252K23.2 -8.21 8.87e-14 3.19e-10 -0.69 -0.55 Dupuytren's disease; chr16:75463262 chr16:75379818~75381260:- PAAD cis rs977987 0.581 rs8056141 ENSG00000261783.1 RP11-252K23.2 -8.21 8.87e-14 3.19e-10 -0.69 -0.55 Dupuytren's disease; chr16:75463264 chr16:75379818~75381260:- PAAD cis rs977987 0.832 rs37597 ENSG00000261783.1 RP11-252K23.2 8.21 8.87e-14 3.19e-10 0.69 0.55 Dupuytren's disease; chr16:75466377 chr16:75379818~75381260:- PAAD cis rs11690935 0.921 rs6710698 ENSG00000228389.1 AC068039.4 8.21 8.93e-14 3.21e-10 0.7 0.55 Schizophrenia; chr2:171739568 chr2:171773482~171775844:+ PAAD cis rs7208859 0.614 rs216477 ENSG00000263531.1 RP13-753N3.1 -8.2 9.41e-14 3.38e-10 -0.93 -0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30539726 chr17:30863921~30864940:- PAAD cis rs321358 0.697 rs522188 ENSG00000271584.1 RP11-89C3.4 -8.2 9.5e-14 3.4e-10 -0.65 -0.55 Body mass index; chr11:111169869 chr11:111091932~111097357:- PAAD cis rs8062405 1 rs3088215 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28842675 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs28403629 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28843448 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs61737565 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844201 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs4788099 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844406 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs9972693 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28848481 chr16:28700294~28701540:- PAAD cis rs8062405 0.964 rs9972768 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850413 chr16:28700294~28701540:- PAAD cis rs8062405 0.965 rs56040780 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850560 chr16:28700294~28701540:- PAAD cis rs8062405 0.965 rs62037363 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28853721 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs7205323 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854571 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs4788101 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28856483 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62037364 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857374 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62037365 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857641 chr16:28700294~28701540:- PAAD cis rs8062405 0.929 rs11150609 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859275 chr16:28700294~28701540:- PAAD cis rs8062405 0.737 rs11861132 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860539 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs11861174 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860668 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs4788102 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28862077 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62037367 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863226 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs7198606 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863801 chr16:28700294~28701540:- PAAD cis rs8062405 0.929 rs11864750 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863883 chr16:28700294~28701540:- PAAD cis rs8062405 0.964 rs7193733 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28864161 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs8055982 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28869881 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs7498665 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28871920 chr16:28700294~28701540:- PAAD cis rs8062405 0.964 rs11864107 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874610 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs62037371 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878810 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs8055138 ENSG00000259982.1 CDC37P1 8.2 9.5e-14 3.4e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28880144 chr16:28700294~28701540:- PAAD cis rs321358 0.731 rs73003518 ENSG00000271584.1 RP11-89C3.4 8.2 9.52e-14 3.41e-10 0.65 0.55 Body mass index; chr11:111163933 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs73003519 ENSG00000271584.1 RP11-89C3.4 8.2 9.52e-14 3.41e-10 0.65 0.55 Body mass index; chr11:111163943 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs547367 ENSG00000271584.1 RP11-89C3.4 -8.2 9.52e-14 3.41e-10 -0.65 -0.55 Body mass index; chr11:111165382 chr11:111091932~111097357:- PAAD cis rs9326248 0.539 rs660443 ENSG00000254851.1 RP11-109L13.1 -8.2 9.54e-14 3.41e-10 -0.7 -0.55 Blood protein levels; chr11:116889977 chr11:117135528~117138582:+ PAAD cis rs8062405 1 rs56404918 ENSG00000259982.1 CDC37P1 8.19 9.64e-14 3.45e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835519 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs55719896 ENSG00000259982.1 CDC37P1 8.19 9.64e-14 3.45e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835545 chr16:28700294~28701540:- PAAD cis rs8062405 1 rs55830740 ENSG00000259982.1 CDC37P1 8.19 9.64e-14 3.45e-10 0.61 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835828 chr16:28700294~28701540:- PAAD cis rs1577917 0.771 rs3812133 ENSG00000203875.9 SNHG5 -8.19 9.79e-14 3.5e-10 -0.79 -0.55 Response to antipsychotic treatment; chr6:85644693 chr6:85660950~85678736:- PAAD cis rs9601248 0.874 rs2093621 ENSG00000227676.3 LINC01068 8.19 9.89e-14 3.54e-10 0.72 0.55 Major depressive disorder; chr13:79613953 chr13:79566727~79571436:+ PAAD cis rs9601248 0.874 rs2093620 ENSG00000227676.3 LINC01068 8.19 9.89e-14 3.54e-10 0.72 0.55 Major depressive disorder; chr13:79613954 chr13:79566727~79571436:+ PAAD cis rs881375 0.9 rs1930786 ENSG00000226752.6 PSMD5-AS1 -8.19 9.98e-14 3.57e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120929191 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs7864019 ENSG00000226752.6 PSMD5-AS1 -8.19 9.98e-14 3.57e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120930590 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs10739579 ENSG00000226752.6 PSMD5-AS1 -8.19 9.98e-14 3.57e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120932510 chr9:120824828~120854385:+ PAAD cis rs17826219 0.706 rs57698184 ENSG00000263531.1 RP13-753N3.1 8.18 1.02e-13 3.65e-10 1.07 0.55 Body mass index; chr17:30737900 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs59923796 ENSG00000263531.1 RP13-753N3.1 8.18 1.02e-13 3.65e-10 1.07 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30863921~30864940:- PAAD cis rs3814244 0.528 rs61923060 ENSG00000255733.4 IFNG-AS1 8.18 1.03e-13 3.68e-10 0.53 0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:67997341 chr12:67989445~68234686:+ PAAD cis rs8062405 0.721 rs151181 ENSG00000259982.1 CDC37P1 8.18 1.04e-13 3.7e-10 0.62 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28479196 chr16:28700294~28701540:- PAAD cis rs7829975 0.633 rs2979181 ENSG00000253893.2 FAM85B -8.18 1.04e-13 3.7e-10 -0.76 -0.55 Mood instability; chr8:8465578 chr8:8167819~8226614:- PAAD cis rs881375 0.933 rs1548784 ENSG00000226752.6 PSMD5-AS1 -8.18 1.04e-13 3.71e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120923002 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs7034492 ENSG00000226752.6 PSMD5-AS1 -8.18 1.04e-13 3.71e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120924933 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs7034653 ENSG00000226752.6 PSMD5-AS1 -8.18 1.04e-13 3.71e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120925094 chr9:120824828~120854385:+ PAAD cis rs11690935 1 rs6433311 ENSG00000228389.1 AC068039.4 -8.18 1.07e-13 3.8e-10 -0.71 -0.55 Schizophrenia; chr2:171692738 chr2:171773482~171775844:+ PAAD cis rs11690935 1 rs6757773 ENSG00000228389.1 AC068039.4 -8.18 1.07e-13 3.8e-10 -0.71 -0.55 Schizophrenia; chr2:171693120 chr2:171773482~171775844:+ PAAD cis rs9326248 0.559 rs609177 ENSG00000254851.1 RP11-109L13.1 -8.18 1.08e-13 3.83e-10 -0.7 -0.55 Blood protein levels; chr11:116899801 chr11:117135528~117138582:+ PAAD cis rs7208859 0.614 rs7216394 ENSG00000263531.1 RP13-753N3.1 -8.17 1.09e-13 3.87e-10 -0.92 -0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30498738 chr17:30863921~30864940:- PAAD cis rs7208859 0.614 rs4794874 ENSG00000263531.1 RP13-753N3.1 -8.17 1.09e-13 3.87e-10 -0.92 -0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30514300 chr17:30863921~30864940:- PAAD cis rs8062405 0.721 rs151303 ENSG00000259982.1 CDC37P1 8.17 1.1e-13 3.9e-10 0.63 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28481189 chr16:28700294~28701540:- PAAD cis rs881375 0.9 rs1008383 ENSG00000226752.6 PSMD5-AS1 -8.17 1.1e-13 3.9e-10 -0.61 -0.55 Rheumatoid arthritis; chr9:120921301 chr9:120824828~120854385:+ PAAD cis rs881375 0.933 rs7031096 ENSG00000226752.6 PSMD5-AS1 -8.17 1.1e-13 3.91e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120932664 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs10739580 ENSG00000226752.6 PSMD5-AS1 -8.17 1.1e-13 3.91e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120933004 chr9:120824828~120854385:+ PAAD cis rs9399135 0.66 rs9376072 ENSG00000232876.1 CTA-212D2.2 -8.17 1.11e-13 3.95e-10 -0.65 -0.55 Red blood cell count; chr6:134959381 chr6:135055033~135060550:+ PAAD cis rs17507216 0.628 rs28607761 ENSG00000278603.1 RP13-608F4.5 8.17 1.12e-13 3.97e-10 0.92 0.55 Excessive daytime sleepiness; chr15:82715317 chr15:82472203~82472426:+ PAAD cis rs9322193 0.516 rs1999632 ENSG00000231760.4 RP11-350J20.5 8.17 1.12e-13 3.98e-10 0.81 0.55 Lung cancer; chr6:149866737 chr6:149796151~149826294:- PAAD cis rs9660180 1 rs9660180 ENSG00000268575.1 RP1-283E3.8 -8.16 1.14e-13 4.06e-10 -0.53 -0.55 Body mass index; chr1:1791592 chr1:1702736~1737688:- PAAD cis rs7208859 0.573 rs55661352 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs8075357 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Body mass index; chr17:30730179 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs59447372 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30730567 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs61643715 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Body mass index; chr17:30730744 chr17:30863921~30864940:- PAAD cis rs17826219 0.636 rs8080829 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Body mass index; chr17:30731712 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs8079891 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30731845 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73267858 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732719 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs56018041 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732967 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs56095789 ENSG00000263531.1 RP13-753N3.1 8.16 1.15e-13 4.07e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733152 chr17:30863921~30864940:- PAAD cis rs1972460 0.506 rs62012050 ENSG00000278603.1 RP13-608F4.5 8.16 1.15e-13 4.09e-10 0.79 0.55 Intelligence (multi-trait analysis); chr15:82239933 chr15:82472203~82472426:+ PAAD cis rs9660180 0.819 rs4648629 ENSG00000268575.1 RP1-283E3.8 8.16 1.18e-13 4.15e-10 0.52 0.55 Body mass index; chr1:1764023 chr1:1702736~1737688:- PAAD cis rs321358 0.731 rs536579 ENSG00000271584.1 RP11-89C3.4 8.16 1.19e-13 4.2e-10 0.63 0.55 Body mass index; chr11:111145748 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs576877 ENSG00000271584.1 RP11-89C3.4 8.16 1.19e-13 4.2e-10 0.63 0.55 Body mass index; chr11:111147472 chr11:111091932~111097357:- PAAD cis rs9326248 0.559 rs482371 ENSG00000254851.1 RP11-109L13.1 -8.16 1.2e-13 4.24e-10 -0.7 -0.55 Blood protein levels; chr11:116881447 chr11:117135528~117138582:+ PAAD cis rs9326248 0.559 rs1269329 ENSG00000254851.1 RP11-109L13.1 -8.16 1.2e-13 4.24e-10 -0.7 -0.55 Blood protein levels; chr11:116884325 chr11:117135528~117138582:+ PAAD cis rs8062405 1 rs7187776 ENSG00000259982.1 CDC37P1 8.16 1.2e-13 4.25e-10 0.6 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28846324 chr16:28700294~28701540:- PAAD cis rs6452524 0.618 rs6452501 ENSG00000249664.1 CTD-2227C6.2 8.16 1.21e-13 4.26e-10 0.64 0.55 Hypertension (SNP x SNP interaction); chr5:83068681 chr5:83012285~83013109:- PAAD cis rs3091242 0.933 rs926438 ENSG00000224183.1 SDHDP6 -8.15 1.21e-13 4.28e-10 -0.7 -0.55 Erythrocyte sedimentation rate; chr1:25427147 chr1:25294164~25294643:- PAAD cis rs2283792 0.622 rs5756323 ENSG00000224086.5 LL22NC03-86G7.1 8.15 1.22e-13 4.28e-10 0.59 0.55 Multiple sclerosis; chr22:21980398 chr22:21938293~21977632:+ PAAD cis rs765787 0.53 rs3759895 ENSG00000259520.4 CTD-2651B20.3 8.15 1.22e-13 4.28e-10 0.66 0.55 Uric acid levels; chr15:45251672 chr15:45251580~45279251:- PAAD cis rs881375 0.967 rs1930781 ENSG00000226752.6 PSMD5-AS1 -8.15 1.23e-13 4.33e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120925556 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs2416806 ENSG00000226752.6 PSMD5-AS1 -8.15 1.23e-13 4.33e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120928014 chr9:120824828~120854385:+ PAAD cis rs881375 0.933 rs7028641 ENSG00000226752.6 PSMD5-AS1 -8.15 1.23e-13 4.33e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120928863 chr9:120824828~120854385:+ PAAD cis rs2739330 0.587 rs4820571 ENSG00000218537.1 MIF-AS1 8.15 1.23e-13 4.33e-10 0.77 0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23894426~23898930:- PAAD cis rs7829975 0.564 rs2921060 ENSG00000253893.2 FAM85B 8.15 1.23e-13 4.33e-10 0.74 0.55 Mood instability; chr8:8460307 chr8:8167819~8226614:- PAAD cis rs977987 0.671 rs9922008 ENSG00000261783.1 RP11-252K23.2 -8.15 1.24e-13 4.36e-10 -0.69 -0.55 Dupuytren's disease; chr16:75301508 chr16:75379818~75381260:- PAAD cis rs11118620 0.535 rs1389750 ENSG00000238078.1 LINC01352 8.15 1.26e-13 4.42e-10 0.57 0.55 Heart failure; chr1:220866829 chr1:220829255~220832429:+ PAAD cis rs7208859 0.673 rs9915139 ENSG00000263531.1 RP13-753N3.1 8.15 1.26e-13 4.42e-10 1.03 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831497 chr17:30863921~30864940:- PAAD cis rs5760092 0.755 rs4585126 ENSG00000273295.1 AP000350.5 -8.15 1.26e-13 4.43e-10 -0.78 -0.55 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23901432~23907068:- PAAD cis rs7208859 0.623 rs11657662 ENSG00000263531.1 RP13-753N3.1 -8.15 1.27e-13 4.43e-10 -1.05 -0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749329 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11656844 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733579 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11652533 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733583 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11652631 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733748 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs79505916 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30735308 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs77498725 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs73267865 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30863921~30864940:- PAAD cis rs17826219 0.5 rs57005940 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Body mass index; chr17:30739311 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs73267872 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs9893922 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Body mass index; chr17:30741407 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs56812022 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs57670615 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30863921~30864940:- PAAD cis rs17826219 0.5 rs2874724 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Body mass index; chr17:30745415 chr17:30863921~30864940:- PAAD cis rs17826219 0.568 rs9898097 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Body mass index; chr17:30745654 chr17:30863921~30864940:- PAAD cis rs17826219 0.5 rs9891256 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Body mass index; chr17:30745674 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9911490 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7503542 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7503335 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs11656278 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs56031503 ENSG00000263531.1 RP13-753N3.1 8.15 1.27e-13 4.43e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30863921~30864940:- PAAD cis rs17507216 0.718 rs7165690 ENSG00000278603.1 RP13-608F4.5 8.15 1.27e-13 4.45e-10 0.91 0.55 Excessive daytime sleepiness; chr15:82654804 chr15:82472203~82472426:+ PAAD cis rs7301826 1 rs4759523 ENSG00000256250.1 RP11-989F5.1 -8.14 1.29e-13 4.51e-10 -0.63 -0.55 Plasma plasminogen activator levels; chr12:130830867 chr12:130810606~130812438:+ PAAD cis rs7301826 1 rs4759524 ENSG00000256250.1 RP11-989F5.1 -8.14 1.29e-13 4.51e-10 -0.63 -0.55 Plasma plasminogen activator levels; chr12:130831065 chr12:130810606~130812438:+ PAAD cis rs11690935 0.959 rs10184866 ENSG00000228389.1 AC068039.4 8.14 1.3e-13 4.55e-10 0.7 0.55 Schizophrenia; chr2:171752446 chr2:171773482~171775844:+ PAAD cis rs321358 0.731 rs7927998 ENSG00000271584.1 RP11-89C3.4 8.14 1.32e-13 4.62e-10 0.65 0.55 Body mass index; chr11:111153872 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs527397 ENSG00000271584.1 RP11-89C3.4 8.14 1.32e-13 4.62e-10 0.65 0.55 Body mass index; chr11:111159907 chr11:111091932~111097357:- PAAD cis rs17507216 0.609 rs1431716 ENSG00000278603.1 RP13-608F4.5 8.14 1.34e-13 4.66e-10 0.94 0.55 Excessive daytime sleepiness; chr15:82676180 chr15:82472203~82472426:+ PAAD cis rs17507216 0.718 rs28587782 ENSG00000278603.1 RP13-608F4.5 8.14 1.35e-13 4.72e-10 0.93 0.55 Excessive daytime sleepiness; chr15:82576881 chr15:82472203~82472426:+ PAAD cis rs10256972 0.758 rs7799391 ENSG00000229043.2 AC091729.9 -8.14 1.36e-13 4.72e-10 -0.57 -0.55 Endometriosis;Longevity; chr7:1042930 chr7:1160374~1165267:+ PAAD cis rs7188445 0.592 rs7196490 ENSG00000261390.4 RP11-345M22.2 -8.14 1.36e-13 4.72e-10 -0.69 -0.55 Urate levels; chr16:79718572 chr16:79715232~79770563:- PAAD cis rs2455601 0.529 rs2653569 ENSG00000254860.4 TMEM9B-AS1 8.13 1.39e-13 4.84e-10 0.67 0.55 Schizophrenia; chr11:8965431 chr11:8964675~8977527:+ PAAD cis rs9326248 0.53 rs900012 ENSG00000254851.1 RP11-109L13.1 -8.13 1.4e-13 4.89e-10 -0.98 -0.55 Blood protein levels; chr11:117095719 chr11:117135528~117138582:+ PAAD cis rs7115242 0.8 rs1320668 ENSG00000254851.1 RP11-109L13.1 -8.13 1.4e-13 4.89e-10 -0.98 -0.55 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117096950 chr11:117135528~117138582:+ PAAD cis rs7208859 0.528 rs3764416 ENSG00000263531.1 RP13-753N3.1 -8.13 1.4e-13 4.89e-10 -0.98 -0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30573690 chr17:30863921~30864940:- PAAD cis rs6907340 0.517 rs9465533 ENSG00000228412.5 RP4-625H18.2 8.13 1.43e-13 4.96e-10 0.69 0.55 Endometriosis; chr6:19801477 chr6:19802164~19804752:- PAAD cis rs8062405 0.691 rs11646653 ENSG00000259982.1 CDC37P1 -8.13 1.43e-13 4.98e-10 -0.63 -0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910828 chr16:28700294~28701540:- PAAD cis rs12439619 0.883 rs62012045 ENSG00000278603.1 RP13-608F4.5 8.13 1.44e-13 5e-10 0.79 0.55 Intelligence (multi-trait analysis); chr15:82229366 chr15:82472203~82472426:+ PAAD cis rs12439619 0.921 rs56042848 ENSG00000278603.1 RP13-608F4.5 8.13 1.44e-13 5e-10 0.79 0.55 Intelligence (multi-trait analysis); chr15:82235244 chr15:82472203~82472426:+ PAAD cis rs10256972 0.721 rs2030959 ENSG00000229043.2 AC091729.9 -8.12 1.45e-13 5.06e-10 -0.57 -0.55 Endometriosis;Longevity; chr7:1036270 chr7:1160374~1165267:+ PAAD cis rs881375 0.967 rs2109896 ENSG00000226752.6 PSMD5-AS1 -8.12 1.47e-13 5.12e-10 -0.6 -0.55 Rheumatoid arthritis; chr9:120920828 chr9:120824828~120854385:+ PAAD cis rs3814244 0.528 rs17104682 ENSG00000255733.4 IFNG-AS1 -8.12 1.49e-13 5.19e-10 -0.5 -0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:68033256 chr12:67989445~68234686:+ PAAD cis rs7208859 0.623 rs9914242 ENSG00000263531.1 RP13-753N3.1 8.12 1.5e-13 5.2e-10 1.08 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889227 chr17:30863921~30864940:- PAAD cis rs765787 0.53 rs11636410 ENSG00000259520.4 CTD-2651B20.3 -8.12 1.52e-13 5.27e-10 -0.66 -0.55 Uric acid levels; chr15:45243715 chr15:45251580~45279251:- PAAD cis rs2487048 0.761 rs2980083 ENSG00000226334.1 RP11-217B7.2 -8.12 1.52e-13 5.28e-10 -0.65 -0.55 Intraocular pressure; chr9:104929081 chr9:104927553~104928892:+ PAAD cis rs321358 0.895 rs73015171 ENSG00000271584.1 RP11-89C3.4 8.11 1.54e-13 5.35e-10 0.68 0.55 Body mass index; chr11:111087535 chr11:111091932~111097357:- PAAD cis rs17507216 0.671 rs4779035 ENSG00000278603.1 RP13-608F4.5 8.11 1.56e-13 5.4e-10 0.94 0.55 Excessive daytime sleepiness; chr15:82591686 chr15:82472203~82472426:+ PAAD cis rs17507216 0.718 rs72751662 ENSG00000278603.1 RP13-608F4.5 8.11 1.56e-13 5.4e-10 0.94 0.55 Excessive daytime sleepiness; chr15:82594705 chr15:82472203~82472426:+ PAAD cis rs17507216 0.718 rs72751675 ENSG00000278603.1 RP13-608F4.5 8.11 1.56e-13 5.4e-10 0.94 0.55 Excessive daytime sleepiness; chr15:82630452 chr15:82472203~82472426:+ PAAD cis rs1799949 0.965 rs799916 ENSG00000198496.9 NBR2 8.11 1.57e-13 5.42e-10 0.53 0.55 Menopause (age at onset); chr17:43091173 chr17:43125610~43153671:+ PAAD cis rs5769707 0.632 rs135877 ENSG00000188511.11 C22orf34 8.11 1.57e-13 5.43e-10 0.58 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49620354 chr22:49414524~49657542:- PAAD cis rs765787 0.53 rs28756676 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45248162 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs55771002 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45249368 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs55920042 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45249379 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4238376 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45249689 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4238377 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45249783 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775844 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45249850 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs3759893 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45250752 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs16941017 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45251083 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2413776 ENSG00000259520.4 CTD-2651B20.3 8.11 1.58e-13 5.47e-10 0.65 0.55 Uric acid levels; chr15:45251972 chr15:45251580~45279251:- PAAD cis rs950027 0.787 rs1153845 ENSG00000259520.4 CTD-2651B20.3 8.11 1.59e-13 5.48e-10 0.67 0.55 Response to fenofibrate (adiponectin levels); chr15:45432531 chr15:45251580~45279251:- PAAD cis rs2455601 0.882 rs11042115 ENSG00000254860.4 TMEM9B-AS1 8.11 1.6e-13 5.52e-10 0.7 0.55 Schizophrenia; chr11:8905132 chr11:8964675~8977527:+ PAAD cis rs2455601 0.882 rs11042116 ENSG00000254860.4 TMEM9B-AS1 8.11 1.6e-13 5.52e-10 0.7 0.55 Schizophrenia; chr11:8906925 chr11:8964675~8977527:+ PAAD cis rs2455601 0.882 rs11042118 ENSG00000254860.4 TMEM9B-AS1 8.11 1.6e-13 5.52e-10 0.7 0.55 Schizophrenia; chr11:8907244 chr11:8964675~8977527:+ PAAD cis rs17507216 0.718 rs7161977 ENSG00000278603.1 RP13-608F4.5 8.11 1.61e-13 5.56e-10 0.94 0.55 Excessive daytime sleepiness; chr15:82646782 chr15:82472203~82472426:+ PAAD cis rs17507216 0.681 rs28877110 ENSG00000278603.1 RP13-608F4.5 8.11 1.61e-13 5.56e-10 0.94 0.55 Excessive daytime sleepiness; chr15:82672111 chr15:82472203~82472426:+ PAAD cis rs7188445 0.592 rs4404082 ENSG00000261390.4 RP11-345M22.2 8.1 1.63e-13 5.63e-10 0.68 0.55 Urate levels; chr16:79716615 chr16:79715232~79770563:- PAAD cis rs9660180 0.935 rs9786942 ENSG00000268575.1 RP1-283E3.8 -8.1 1.67e-13 5.74e-10 -0.53 -0.55 Body mass index; chr1:1827774 chr1:1702736~1737688:- PAAD cis rs9660180 0.934 rs34849348 ENSG00000268575.1 RP1-283E3.8 -8.1 1.67e-13 5.74e-10 -0.53 -0.55 Body mass index; chr1:1831318 chr1:1702736~1737688:- PAAD cis rs9660180 0.967 rs10907191 ENSG00000268575.1 RP1-283E3.8 -8.1 1.67e-13 5.74e-10 -0.53 -0.55 Body mass index; chr1:1843381 chr1:1702736~1737688:- PAAD cis rs10256972 0.758 rs9801444 ENSG00000229043.2 AC091729.9 8.1 1.67e-13 5.77e-10 0.56 0.55 Endometriosis;Longevity; chr7:1040808 chr7:1160374~1165267:+ PAAD cis rs9322193 0.566 rs9397070 ENSG00000231760.4 RP11-350J20.5 -8.1 1.69e-13 5.8e-10 -0.78 -0.55 Lung cancer; chr6:149922073 chr6:149796151~149826294:- PAAD cis rs9660180 0.935 rs2180311 ENSG00000268575.1 RP1-283E3.8 -8.1 1.7e-13 5.81e-10 -0.53 -0.55 Body mass index; chr1:1817295 chr1:1702736~1737688:- PAAD cis rs9660180 0.967 rs6664664 ENSG00000268575.1 RP1-283E3.8 -8.1 1.7e-13 5.81e-10 -0.53 -0.55 Body mass index; chr1:1819825 chr1:1702736~1737688:- PAAD cis rs765787 0.53 rs2433229 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45223037 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4331289 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45223140 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2433228 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45223173 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11854690 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45223818 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs28733848 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45223849 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11854689 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45223854 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2433227 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45224921 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2668751 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45225095 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs1648286 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45225188 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs1706835 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45225686 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs1631533 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45226430 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2668737 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45230601 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs1706764 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45232058 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2413786 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45233196 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs28815867 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45234607 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775822 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45234929 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11854294 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45235798 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2899381 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45237432 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2413785 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45238183 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2413784 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45238318 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs7165889 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45239442 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11070451 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45241343 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs28897155 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45241776 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775831 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45242524 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775832 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45242630 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4442750 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45243130 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4444275 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45243149 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4270107 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45243152 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4544188 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45243195 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11636367 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45243664 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11636440 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45243784 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs28414644 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45244523 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs28396110 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45244711 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775834 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45245313 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775835 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45245355 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775836 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45245466 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775837 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45245486 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12917187 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45246099 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11639403 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45246152 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2413782 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45246292 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2413780 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45246668 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11636018 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45246939 chr15:45251580~45279251:- PAAD cis rs765787 0.556 rs2413778 ENSG00000259520.4 CTD-2651B20.3 8.1 1.7e-13 5.81e-10 0.65 0.55 Uric acid levels; chr15:45247199 chr15:45251580~45279251:- PAAD cis rs3931020 0.53 rs6668736 ENSG00000272864.1 RP11-17E13.2 -8.1 1.7e-13 5.83e-10 -0.67 -0.55 Resistin levels; chr1:74768866 chr1:74698769~74699333:- PAAD cis rs17826219 0.733 rs7221691 ENSG00000263531.1 RP13-753N3.1 -8.09 1.72e-13 5.88e-10 -0.95 -0.55 Body mass index; chr17:30396601 chr17:30863921~30864940:- PAAD cis rs17826219 0.562 rs719600 ENSG00000263531.1 RP13-753N3.1 -8.09 1.72e-13 5.88e-10 -0.95 -0.55 Body mass index; chr17:30404244 chr17:30863921~30864940:- PAAD cis rs3814244 0.528 rs7952790 ENSG00000255733.4 IFNG-AS1 8.09 1.73e-13 5.89e-10 0.52 0.55 Itch intensity from mosquito bite adjusted by bite size; chr12:68012672 chr12:67989445~68234686:+ PAAD cis rs7208859 0.623 rs6505207 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs7223803 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30863921~30864940:- PAAD cis rs17826219 0.568 rs2626985 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Body mass index; chr17:30750419 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs55814012 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30863921~30864940:- PAAD cis rs17826219 0.5 rs2449749 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Body mass index; chr17:30751280 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9894709 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9896603 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30863921~30864940:- PAAD cis rs17826219 0.636 rs4055314 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Body mass index; chr17:30752751 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7219712 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs8078656 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs8080882 ENSG00000263531.1 RP13-753N3.1 8.09 1.73e-13 5.9e-10 1.05 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30863921~30864940:- PAAD cis rs765787 0.53 rs4774550 ENSG00000259520.4 CTD-2651B20.3 8.09 1.76e-13 5.98e-10 0.65 0.55 Uric acid levels; chr15:45250114 chr15:45251580~45279251:- PAAD cis rs9399135 0.66 rs4472368 ENSG00000232876.1 CTA-212D2.2 -8.09 1.78e-13 6.03e-10 -0.66 -0.55 Red blood cell count; chr6:134953094 chr6:135055033~135060550:+ PAAD cis rs11673344 0.734 rs320887 ENSG00000226686.6 LINC01535 -8.09 1.8e-13 6.11e-10 -0.7 -0.55 Obesity-related traits; chr19:37202536 chr19:37251912~37265535:+ PAAD cis rs1150668 0.835 rs203869 ENSG00000216901.1 AL022393.7 8.09 1.81e-13 6.15e-10 0.68 0.55 Pubertal anthropometrics; chr6:28073041 chr6:28176188~28176674:+ PAAD cis rs172166 0.56 rs203878 ENSG00000216901.1 AL022393.7 8.09 1.81e-13 6.15e-10 0.68 0.55 Cardiac Troponin-T levels; chr6:28081218 chr6:28176188~28176674:+ PAAD cis rs9399135 0.66 rs9389248 ENSG00000232876.1 CTA-212D2.2 -8.08 1.82e-13 6.16e-10 -0.65 -0.55 Red blood cell count; chr6:134961518 chr6:135055033~135060550:+ PAAD cis rs7301826 0.627 rs7978987 ENSG00000256299.1 RP11-989F5.3 8.08 1.85e-13 6.26e-10 0.61 0.55 Plasma plasminogen activator levels; chr12:130796949 chr12:130810821~130812622:- PAAD cis rs10256972 0.758 rs4723649 ENSG00000229043.2 AC091729.9 -8.08 1.86e-13 6.31e-10 -0.57 -0.55 Endometriosis;Longevity; chr7:1032269 chr7:1160374~1165267:+ PAAD cis rs1799949 0.931 rs34474989 ENSG00000198496.9 NBR2 -8.08 1.86e-13 6.31e-10 -0.54 -0.55 Menopause (age at onset); chr17:43368042 chr17:43125610~43153671:+ PAAD cis rs2487048 0.804 rs2472496 ENSG00000226334.1 RP11-217B7.2 -8.08 1.87e-13 6.35e-10 -0.64 -0.55 Intraocular pressure; chr9:104933072 chr9:104927553~104928892:+ PAAD cis rs10256972 0.684 rs2363279 ENSG00000229043.2 AC091729.9 -8.08 1.88e-13 6.38e-10 -0.58 -0.55 Endometriosis;Longevity; chr7:1056507 chr7:1160374~1165267:+ PAAD cis rs7301826 0.651 rs7299281 ENSG00000256299.1 RP11-989F5.3 8.08 1.89e-13 6.39e-10 0.61 0.55 Plasma plasminogen activator levels; chr12:130818587 chr12:130810821~130812622:- PAAD cis rs1799949 1 rs2271573 ENSG00000198496.9 NBR2 -8.08 1.91e-13 6.46e-10 -0.55 -0.55 Menopause (age at onset); chr17:43175604 chr17:43125610~43153671:+ PAAD cis rs2487048 0.773 rs2472494 ENSG00000226334.1 RP11-217B7.2 -8.07 1.92e-13 6.5e-10 -0.63 -0.55 Intraocular pressure; chr9:104933258 chr9:104927553~104928892:+ PAAD cis rs2487048 0.773 rs2472493 ENSG00000226334.1 RP11-217B7.2 -8.07 1.92e-13 6.5e-10 -0.63 -0.55 Intraocular pressure; chr9:104933567 chr9:104927553~104928892:+ PAAD cis rs765787 0.53 rs2554454 ENSG00000259520.4 CTD-2651B20.3 8.07 1.95e-13 6.59e-10 0.65 0.55 Uric acid levels; chr15:45229338 chr15:45251580~45279251:- PAAD cis rs5769707 0.616 rs135869 ENSG00000188511.11 C22orf34 8.07 1.96e-13 6.61e-10 0.59 0.55 Monocyte percentage of white cells;Monocyte count; chr22:49614718 chr22:49414524~49657542:- PAAD cis rs9399135 0.66 rs4267967 ENSG00000232876.1 CTA-212D2.2 -8.07 1.99e-13 6.71e-10 -0.65 -0.55 Red blood cell count; chr6:134951339 chr6:135055033~135060550:+ PAAD cis rs10256972 0.758 rs11979275 ENSG00000229043.2 AC091729.9 -8.07 1.99e-13 6.73e-10 -0.56 -0.55 Endometriosis;Longevity; chr7:1029699 chr7:1160374~1165267:+ PAAD cis rs10256972 0.758 rs11980081 ENSG00000229043.2 AC091729.9 -8.07 1.99e-13 6.73e-10 -0.56 -0.55 Endometriosis;Longevity; chr7:1029736 chr7:1160374~1165267:+ PAAD cis rs10256972 0.721 rs4720249 ENSG00000229043.2 AC091729.9 -8.07 1.99e-13 6.73e-10 -0.56 -0.55 Endometriosis;Longevity; chr7:1032927 chr7:1160374~1165267:+ PAAD cis rs11690935 0.959 rs12692974 ENSG00000228389.1 AC068039.4 8.06 2.03e-13 6.87e-10 0.7 0.55 Schizophrenia; chr2:171806746 chr2:171773482~171775844:+ PAAD cis rs3091242 0.967 rs665372 ENSG00000224183.1 SDHDP6 -8.06 2.04e-13 6.89e-10 -0.69 -0.55 Erythrocyte sedimentation rate; chr1:25392744 chr1:25294164~25294643:- PAAD cis rs9660180 0.967 rs6603802 ENSG00000268575.1 RP1-283E3.8 -8.06 2.08e-13 7e-10 -0.52 -0.55 Body mass index; chr1:1881082 chr1:1702736~1737688:- PAAD cis rs7714584 1 rs59321715 ENSG00000197083.10 ZNF300P1 8.06 2.08e-13 7.01e-10 1.02 0.55 Crohn's disease; chr5:150933918 chr5:150930645~150946289:- PAAD cis rs765787 0.53 rs7167389 ENSG00000259520.4 CTD-2651B20.3 8.06 2.08e-13 7.02e-10 0.65 0.55 Uric acid levels; chr15:45243485 chr15:45251580~45279251:- PAAD cis rs321358 0.731 rs17460676 ENSG00000271584.1 RP11-89C3.4 8.06 2.1e-13 7.06e-10 0.65 0.55 Body mass index; chr11:111166625 chr11:111091932~111097357:- PAAD cis rs11690935 0.959 rs7597387 ENSG00000228389.1 AC068039.4 8.06 2.1e-13 7.07e-10 0.69 0.55 Schizophrenia; chr2:171720606 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs7562356 ENSG00000228389.1 AC068039.4 8.06 2.1e-13 7.07e-10 0.69 0.55 Schizophrenia; chr2:171770101 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs1113389 ENSG00000228389.1 AC068039.4 8.06 2.1e-13 7.07e-10 0.69 0.55 Schizophrenia; chr2:171778855 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs7355594 ENSG00000228389.1 AC068039.4 8.06 2.1e-13 7.07e-10 0.69 0.55 Schizophrenia; chr2:171782938 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10497374 ENSG00000228389.1 AC068039.4 8.06 2.1e-13 7.07e-10 0.69 0.55 Schizophrenia; chr2:171784113 chr2:171773482~171775844:+ PAAD cis rs6597981 0.675 rs4963120 ENSG00000279672.1 CMB9-55F22.1 -8.06 2.11e-13 7.09e-10 -0.52 -0.55 Breast cancer; chr11:825777 chr11:779617~780755:+ PAAD cis rs11690935 0.959 rs7608403 ENSG00000228389.1 AC068039.4 8.06 2.11e-13 7.12e-10 0.69 0.55 Schizophrenia; chr2:171790255 chr2:171773482~171775844:+ PAAD cis rs8062405 0.754 rs151179 ENSG00000259982.1 CDC37P1 8.06 2.12e-13 7.15e-10 0.62 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28475735 chr16:28700294~28701540:- PAAD cis rs17826219 0.636 rs7221463 ENSG00000263531.1 RP13-753N3.1 8.06 2.13e-13 7.17e-10 1.05 0.55 Body mass index; chr17:30753533 chr17:30863921~30864940:- PAAD cis rs11690935 0.851 rs9808259 ENSG00000228389.1 AC068039.4 8.06 2.15e-13 7.22e-10 0.7 0.55 Schizophrenia; chr2:171792464 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10167419 ENSG00000228389.1 AC068039.4 8.06 2.15e-13 7.22e-10 0.7 0.55 Schizophrenia; chr2:171793316 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs6433314 ENSG00000228389.1 AC068039.4 8.06 2.15e-13 7.22e-10 0.7 0.55 Schizophrenia; chr2:171804461 chr2:171773482~171775844:+ PAAD cis rs11690935 0.921 rs908670 ENSG00000228389.1 AC068039.4 8.05 2.16e-13 7.26e-10 0.69 0.55 Schizophrenia; chr2:171833670 chr2:171773482~171775844:+ PAAD cis rs11690935 0.879 rs908671 ENSG00000228389.1 AC068039.4 8.05 2.16e-13 7.26e-10 0.69 0.55 Schizophrenia; chr2:171833755 chr2:171773482~171775844:+ PAAD cis rs11690935 0.921 rs3770445 ENSG00000228389.1 AC068039.4 8.05 2.16e-13 7.26e-10 0.69 0.55 Schizophrenia; chr2:171852409 chr2:171773482~171775844:+ PAAD cis rs7115242 0.858 rs6589592 ENSG00000254851.1 RP11-109L13.1 -8.05 2.19e-13 7.37e-10 -1.02 -0.55 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117087191 chr11:117135528~117138582:+ PAAD cis rs765787 0.53 rs1706832 ENSG00000259520.4 CTD-2651B20.3 8.05 2.2e-13 7.4e-10 0.65 0.55 Uric acid levels; chr15:45224975 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs1706837 ENSG00000259520.4 CTD-2651B20.3 8.05 2.2e-13 7.4e-10 0.65 0.55 Uric acid levels; chr15:45226838 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4775819 ENSG00000259520.4 CTD-2651B20.3 8.05 2.2e-13 7.4e-10 0.65 0.55 Uric acid levels; chr15:45233768 chr15:45251580~45279251:- PAAD cis rs9322193 0.504 rs7771014 ENSG00000231760.4 RP11-350J20.5 8.05 2.21e-13 7.41e-10 0.72 0.55 Lung cancer; chr6:149884310 chr6:149796151~149826294:- PAAD cis rs2455601 0.786 rs3763914 ENSG00000254860.4 TMEM9B-AS1 8.05 2.22e-13 7.45e-10 0.71 0.55 Schizophrenia; chr11:8919156 chr11:8964675~8977527:+ PAAD cis rs2455601 0.935 rs12049908 ENSG00000254860.4 TMEM9B-AS1 8.05 2.23e-13 7.48e-10 0.7 0.55 Schizophrenia; chr11:8897762 chr11:8964675~8977527:+ PAAD cis rs950027 0.787 rs2433616 ENSG00000259520.4 CTD-2651B20.3 -8.05 2.24e-13 7.51e-10 -0.68 -0.55 Response to fenofibrate (adiponectin levels); chr15:45436401 chr15:45251580~45279251:- PAAD cis rs321358 0.895 rs73015151 ENSG00000271584.1 RP11-89C3.4 8.04 2.31e-13 7.72e-10 0.67 0.55 Body mass index; chr11:111084669 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs17535886 ENSG00000271584.1 RP11-89C3.4 8.04 2.31e-13 7.72e-10 0.67 0.55 Body mass index; chr11:111084852 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs17457375 ENSG00000271584.1 RP11-89C3.4 8.04 2.31e-13 7.72e-10 0.67 0.55 Body mass index; chr11:111085100 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs17535942 ENSG00000271584.1 RP11-89C3.4 8.04 2.31e-13 7.72e-10 0.67 0.55 Body mass index; chr11:111085233 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs17457430 ENSG00000271584.1 RP11-89C3.4 8.04 2.31e-13 7.72e-10 0.67 0.55 Body mass index; chr11:111085279 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs7101466 ENSG00000271584.1 RP11-89C3.4 8.04 2.31e-13 7.72e-10 0.67 0.55 Body mass index; chr11:111085729 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs7101576 ENSG00000271584.1 RP11-89C3.4 8.04 2.31e-13 7.72e-10 0.67 0.55 Body mass index; chr11:111085795 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs17457658 ENSG00000271584.1 RP11-89C3.4 8.04 2.31e-13 7.72e-10 0.67 0.55 Body mass index; chr11:111089448 chr11:111091932~111097357:- PAAD cis rs881375 0.933 rs4837804 ENSG00000226752.6 PSMD5-AS1 -8.04 2.31e-13 7.73e-10 -0.59 -0.55 Rheumatoid arthritis; chr9:120943026 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs7039505 ENSG00000226752.6 PSMD5-AS1 -8.04 2.31e-13 7.73e-10 -0.59 -0.55 Rheumatoid arthritis; chr9:120943667 chr9:120824828~120854385:+ PAAD cis rs881375 0.902 rs2900180 ENSG00000226752.6 PSMD5-AS1 -8.04 2.31e-13 7.73e-10 -0.59 -0.55 Rheumatoid arthritis; chr9:120944104 chr9:120824828~120854385:+ PAAD cis rs8062405 1 rs3888190 ENSG00000259982.1 CDC37P1 8.04 2.32e-13 7.76e-10 0.6 0.55 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878165 chr16:28700294~28701540:- PAAD cis rs380904 0.926 rs7842979 ENSG00000254859.1 RP11-661A12.5 -8.04 2.37e-13 7.92e-10 -0.79 -0.55 Venous thromboembolism (SNP x SNP interaction); chr8:143519726 chr8:143541973~143549729:- PAAD cis rs7301826 0.627 rs34103763 ENSG00000256299.1 RP11-989F5.3 8.03 2.45e-13 8.17e-10 0.6 0.55 Plasma plasminogen activator levels; chr12:130805604 chr12:130810821~130812622:- PAAD cis rs7208859 0.623 rs7219361 ENSG00000263531.1 RP13-753N3.1 8.03 2.45e-13 8.18e-10 1.02 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753375 chr17:30863921~30864940:- PAAD cis rs1799949 0.965 rs6503726 ENSG00000198496.9 NBR2 -8.03 2.45e-13 8.2e-10 -0.55 -0.55 Menopause (age at onset); chr17:43132725 chr17:43125610~43153671:+ PAAD cis rs9660180 0.967 rs6687065 ENSG00000268575.1 RP1-283E3.8 -8.03 2.51e-13 8.35e-10 -0.52 -0.55 Body mass index; chr1:1847030 chr1:1702736~1737688:- PAAD cis rs9399135 0.66 rs4646868 ENSG00000232876.1 CTA-212D2.2 -8.03 2.54e-13 8.44e-10 -0.65 -0.55 Red blood cell count; chr6:134950808 chr6:135055033~135060550:+ PAAD cis rs9660180 0.967 rs11260623 ENSG00000268575.1 RP1-283E3.8 -8.02 2.57e-13 8.54e-10 -0.52 -0.55 Body mass index; chr1:1850017 chr1:1702736~1737688:- PAAD cis rs9660180 0.837 rs915292 ENSG00000268575.1 RP1-283E3.8 -8.02 2.57e-13 8.54e-10 -0.52 -0.55 Body mass index; chr1:1860718 chr1:1702736~1737688:- PAAD cis rs9660180 0.967 rs9660106 ENSG00000268575.1 RP1-283E3.8 -8.02 2.57e-13 8.54e-10 -0.52 -0.55 Body mass index; chr1:1866508 chr1:1702736~1737688:- PAAD cis rs7301826 0.603 rs7975825 ENSG00000256299.1 RP11-989F5.3 -8.02 2.63e-13 8.73e-10 -0.61 -0.55 Plasma plasminogen activator levels; chr12:130803899 chr12:130810821~130812622:- PAAD cis rs9660180 0.967 rs6603803 ENSG00000268575.1 RP1-283E3.8 -8.02 2.66e-13 8.82e-10 -0.52 -0.55 Body mass index; chr1:1881249 chr1:1702736~1737688:- PAAD cis rs4718428 1 rs4718421 ENSG00000226824.5 RP4-756H11.3 -8.01 2.71e-13 9e-10 -0.69 -0.55 Corneal structure; chr7:66885313 chr7:66654538~66669855:+ PAAD cis rs1062177 1 rs2915878 ENSG00000213433.5 RPLP1P6 -8.01 2.75e-13 9.11e-10 -0.62 -0.54 Preschool internalizing problems; chr5:151770101 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs6890099 ENSG00000213433.5 RPLP1P6 -8.01 2.75e-13 9.11e-10 -0.62 -0.54 Preschool internalizing problems; chr5:151772401 chr5:151765859~151766378:- PAAD cis rs9326248 0.53 rs7121347 ENSG00000254851.1 RP11-109L13.1 -8.01 2.77e-13 9.16e-10 -1 -0.54 Blood protein levels; chr11:116996493 chr11:117135528~117138582:+ PAAD cis rs11690935 0.959 rs76324055 ENSG00000228389.1 AC068039.4 8.01 2.8e-13 9.26e-10 0.7 0.54 Schizophrenia; chr2:171763640 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs77280952 ENSG00000228389.1 AC068039.4 8.01 2.8e-13 9.26e-10 0.7 0.54 Schizophrenia; chr2:171763641 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs75922913 ENSG00000228389.1 AC068039.4 8.01 2.8e-13 9.26e-10 0.7 0.54 Schizophrenia; chr2:171763642 chr2:171773482~171775844:+ PAAD cis rs1799949 0.794 rs116409325 ENSG00000198496.9 NBR2 -8.01 2.8e-13 9.27e-10 -0.54 -0.54 Menopause (age at onset); chr17:43368092 chr17:43125610~43153671:+ PAAD cis rs2455601 0.786 rs11042127 ENSG00000254860.4 TMEM9B-AS1 8.01 2.82e-13 9.3e-10 0.72 0.54 Schizophrenia; chr11:8926039 chr11:8964675~8977527:+ PAAD cis rs765787 0.53 rs1706830 ENSG00000259520.4 CTD-2651B20.3 8.01 2.86e-13 9.43e-10 0.64 0.54 Uric acid levels; chr15:45224031 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs1706831 ENSG00000259520.4 CTD-2651B20.3 8.01 2.86e-13 9.43e-10 0.64 0.54 Uric acid levels; chr15:45224032 chr15:45251580~45279251:- PAAD cis rs8062405 0.688 rs3924376 ENSG00000259982.1 CDC37P1 -8 2.88e-13 9.5e-10 -0.65 -0.54 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28914657 chr16:28700294~28701540:- PAAD cis rs5769707 0.656 rs135878 ENSG00000188511.11 C22orf34 8 2.88e-13 9.51e-10 0.58 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49620721 chr22:49414524~49657542:- PAAD cis rs1799949 0.965 rs799912 ENSG00000198496.9 NBR2 -8 2.89e-13 9.54e-10 -0.54 -0.54 Menopause (age at onset); chr17:43105117 chr17:43125610~43153671:+ PAAD cis rs3091242 0.933 rs28530483 ENSG00000224183.1 SDHDP6 -8 2.9e-13 9.55e-10 -0.71 -0.54 Erythrocyte sedimentation rate; chr1:25414356 chr1:25294164~25294643:- PAAD cis rs3091242 1 rs646867 ENSG00000224183.1 SDHDP6 -8 2.9e-13 9.56e-10 -0.68 -0.54 Erythrocyte sedimentation rate; chr1:25382767 chr1:25294164~25294643:- PAAD cis rs2455601 0.882 rs10840139 ENSG00000254860.4 TMEM9B-AS1 8 2.91e-13 9.6e-10 0.71 0.54 Schizophrenia; chr11:8873291 chr11:8964675~8977527:+ PAAD cis rs2455601 0.882 rs11042106 ENSG00000254860.4 TMEM9B-AS1 -8 2.91e-13 9.6e-10 -0.71 -0.54 Schizophrenia; chr11:8874536 chr11:8964675~8977527:+ PAAD cis rs1799949 0.965 rs799917 ENSG00000198496.9 NBR2 -8 2.92e-13 9.6e-10 -0.54 -0.54 Menopause (age at onset); chr17:43092919 chr17:43125610~43153671:+ PAAD cis rs321358 0.731 rs7926634 ENSG00000271584.1 RP11-89C3.4 -8 2.93e-13 9.64e-10 -0.62 -0.54 Body mass index; chr11:111149618 chr11:111091932~111097357:- PAAD cis rs5769707 0.632 rs1476037 ENSG00000188511.11 C22orf34 8 2.96e-13 9.75e-10 0.58 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49597729 chr22:49414524~49657542:- PAAD cis rs321358 0.731 rs1517581 ENSG00000271584.1 RP11-89C3.4 8 3.01e-13 9.91e-10 0.64 0.54 Body mass index; chr11:111164533 chr11:111091932~111097357:- PAAD cis rs5769707 0.632 rs135872 ENSG00000188511.11 C22orf34 8 3.03e-13 9.97e-10 0.58 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49615652 chr22:49414524~49657542:- PAAD cis rs10262624 0.504 rs4722255 ENSG00000234286.1 AC006026.13 -7.99 3.03e-13 9.97e-10 -0.61 -0.54 Schizophrenia; chr7:23706453 chr7:23680195~23680786:- PAAD cis rs321358 0.731 rs534858 ENSG00000271584.1 RP11-89C3.4 7.99 3.05e-13 1e-09 0.61 0.54 Body mass index; chr11:111145583 chr11:111091932~111097357:- PAAD cis rs2455601 0.786 rs3763913 ENSG00000254860.4 TMEM9B-AS1 7.99 3.15e-13 1.03e-09 0.72 0.54 Schizophrenia; chr11:8929683 chr11:8964675~8977527:+ PAAD cis rs2455601 0.766 rs1109304 ENSG00000254860.4 TMEM9B-AS1 7.99 3.15e-13 1.03e-09 0.72 0.54 Schizophrenia; chr11:8933908 chr11:8964675~8977527:+ PAAD cis rs3091242 0.967 rs3093614 ENSG00000224183.1 SDHDP6 7.98 3.26e-13 1.07e-09 0.69 0.54 Erythrocyte sedimentation rate; chr1:25351353 chr1:25294164~25294643:- PAAD cis rs3091242 0.967 rs1053438 ENSG00000224183.1 SDHDP6 7.98 3.26e-13 1.07e-09 0.69 0.54 Erythrocyte sedimentation rate; chr1:25361410 chr1:25294164~25294643:- PAAD cis rs881375 0.934 rs2159778 ENSG00000226752.6 PSMD5-AS1 -7.98 3.34e-13 1.09e-09 -0.58 -0.54 Rheumatoid arthritis; chr9:120915851 chr9:120824828~120854385:+ PAAD cis rs62388641 0.547 rs9391923 ENSG00000272279.1 RP11-157J24.2 -7.98 3.34e-13 1.09e-09 -0.66 -0.54 Daytime sleep phenotypes; chr6:1554089 chr6:1528364~1528911:- PAAD cis rs5760092 0.618 rs5996631 ENSG00000273295.1 AP000350.5 -7.98 3.39e-13 1.11e-09 -0.74 -0.54 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23901432~23907068:- PAAD cis rs3091242 0.933 rs3093584 ENSG00000224183.1 SDHDP6 7.97 3.42e-13 1.12e-09 0.69 0.54 Erythrocyte sedimentation rate; chr1:25342223 chr1:25294164~25294643:- PAAD cis rs1062177 1 rs12515762 ENSG00000213433.5 RPLP1P6 -7.97 3.42e-13 1.12e-09 -0.64 -0.54 Preschool internalizing problems; chr5:151830361 chr5:151765859~151766378:- PAAD cis rs7429990 0.901 rs9825114 ENSG00000229759.1 MRPS18AP1 -7.97 3.42e-13 1.12e-09 -0.58 -0.54 Educational attainment (years of education); chr3:48096592 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs11720151 ENSG00000229759.1 MRPS18AP1 -7.97 3.42e-13 1.12e-09 -0.58 -0.54 Educational attainment (years of education); chr3:48099144 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs6766641 ENSG00000229759.1 MRPS18AP1 -7.97 3.42e-13 1.12e-09 -0.58 -0.54 Educational attainment (years of education); chr3:48103734 chr3:48256350~48256938:- PAAD cis rs8062405 0.754 rs149299 ENSG00000259982.1 CDC37P1 7.97 3.42e-13 1.12e-09 0.62 0.54 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28473820 chr16:28700294~28701540:- PAAD cis rs765787 0.53 rs4774542 ENSG00000259520.4 CTD-2651B20.3 -7.97 3.45e-13 1.13e-09 -0.64 -0.54 Uric acid levels; chr15:45233828 chr15:45251580~45279251:- PAAD cis rs9660180 0.967 rs12044597 ENSG00000268575.1 RP1-283E3.8 -7.97 3.47e-13 1.13e-09 -0.52 -0.54 Body mass index; chr1:1777362 chr1:1702736~1737688:- PAAD cis rs9660180 0.846 rs10907195 ENSG00000268575.1 RP1-283E3.8 7.97 3.53e-13 1.15e-09 0.5 0.54 Body mass index; chr1:1781909 chr1:1702736~1737688:- PAAD cis rs7208859 0.673 rs9889755 ENSG00000263531.1 RP13-753N3.1 -7.97 3.59e-13 1.17e-09 -1.01 -0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30907487 chr17:30863921~30864940:- PAAD cis rs7301826 0.651 rs12820597 ENSG00000256299.1 RP11-989F5.3 7.97 3.59e-13 1.17e-09 0.6 0.54 Plasma plasminogen activator levels; chr12:130795640 chr12:130810821~130812622:- PAAD cis rs321358 0.731 rs1517578 ENSG00000271584.1 RP11-89C3.4 7.96 3.61e-13 1.18e-09 0.65 0.54 Body mass index; chr11:111150750 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs1900556 ENSG00000271584.1 RP11-89C3.4 7.96 3.63e-13 1.18e-09 0.62 0.54 Body mass index; chr11:111148276 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs7940380 ENSG00000271584.1 RP11-89C3.4 7.96 3.63e-13 1.18e-09 0.62 0.54 Body mass index; chr11:111149974 chr11:111091932~111097357:- PAAD cis rs11690935 0.959 rs10803863 ENSG00000228389.1 AC068039.4 -7.96 3.64e-13 1.19e-09 -0.68 -0.54 Schizophrenia; chr2:171678827 chr2:171773482~171775844:+ PAAD cis rs11690935 1 rs12053003 ENSG00000228389.1 AC068039.4 -7.96 3.64e-13 1.19e-09 -0.68 -0.54 Schizophrenia; chr2:171680840 chr2:171773482~171775844:+ PAAD cis rs11690935 1 rs1554166 ENSG00000228389.1 AC068039.4 7.96 3.64e-13 1.19e-09 0.68 0.54 Schizophrenia; chr2:171685099 chr2:171773482~171775844:+ PAAD cis rs11155671 0.546 rs1999633 ENSG00000231760.4 RP11-350J20.5 7.96 3.67e-13 1.19e-09 0.76 0.54 Testicular germ cell tumor; chr6:149866576 chr6:149796151~149826294:- PAAD cis rs6700559 1 rs6656619 ENSG00000260088.1 RP11-92G12.3 7.96 3.76e-13 1.22e-09 0.71 0.54 Coronary artery disease; chr1:200671664 chr1:200669507~200694250:+ PAAD cis rs6700559 0.804 rs11588318 ENSG00000260088.1 RP11-92G12.3 -7.95 3.86e-13 1.25e-09 -0.72 -0.54 Coronary artery disease; chr1:200669534 chr1:200669507~200694250:+ PAAD cis rs6700559 0.903 rs6661240 ENSG00000260088.1 RP11-92G12.3 -7.95 3.86e-13 1.25e-09 -0.72 -0.54 Coronary artery disease; chr1:200669719 chr1:200669507~200694250:+ PAAD cis rs6700559 0.967 rs6688581 ENSG00000260088.1 RP11-92G12.3 -7.95 3.86e-13 1.25e-09 -0.72 -0.54 Coronary artery disease; chr1:200670028 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs3806358 ENSG00000260088.1 RP11-92G12.3 -7.95 3.86e-13 1.25e-09 -0.72 -0.54 Coronary artery disease; chr1:200670555 chr1:200669507~200694250:+ PAAD cis rs6700559 0.683 rs4915450 ENSG00000260088.1 RP11-92G12.3 -7.95 3.86e-13 1.25e-09 -0.72 -0.54 Coronary artery disease; chr1:200672461 chr1:200669507~200694250:+ PAAD cis rs10256972 0.721 rs6975972 ENSG00000229043.2 AC091729.9 -7.95 3.98e-13 1.29e-09 -0.56 -0.54 Endometriosis;Longevity; chr7:1030832 chr7:1160374~1165267:+ PAAD cis rs10793273 1 rs10793273 ENSG00000246174.6 KCTD21-AS1 -7.95 3.99e-13 1.29e-09 -0.7 -0.54 Pelvic organ prolapse; chr11:78031549 chr11:78139771~78175323:+ PAAD cis rs12439619 1 rs35152457 ENSG00000278603.1 RP13-608F4.5 7.95 4.02e-13 1.3e-09 0.77 0.54 Intelligence (multi-trait analysis); chr15:82254207 chr15:82472203~82472426:+ PAAD cis rs9326248 0.53 rs9919599 ENSG00000254851.1 RP11-109L13.1 -7.94 4.04e-13 1.31e-09 -0.98 -0.54 Blood protein levels; chr11:116874768 chr11:117135528~117138582:+ PAAD cis rs1799949 1 rs8070085 ENSG00000198496.9 NBR2 7.94 4.13e-13 1.33e-09 0.53 0.54 Menopause (age at onset); chr17:43189967 chr17:43125610~43153671:+ PAAD cis rs765787 0.53 rs28526629 ENSG00000259520.4 CTD-2651B20.3 7.94 4.13e-13 1.33e-09 0.65 0.54 Uric acid levels; chr15:45248264 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs28524974 ENSG00000259520.4 CTD-2651B20.3 7.94 4.13e-13 1.33e-09 0.65 0.54 Uric acid levels; chr15:45251330 chr15:45251580~45279251:- PAAD cis rs7301826 0.651 rs6486601 ENSG00000256299.1 RP11-989F5.3 7.94 4.16e-13 1.34e-09 0.59 0.54 Plasma plasminogen activator levels; chr12:130816692 chr12:130810821~130812622:- PAAD cis rs7208859 0.725 rs9897673 ENSG00000263531.1 RP13-753N3.1 7.94 4.18e-13 1.35e-09 0.96 0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916348 chr17:30863921~30864940:- PAAD cis rs2455601 0.786 rs3751064 ENSG00000254860.4 TMEM9B-AS1 7.94 4.22e-13 1.36e-09 0.7 0.54 Schizophrenia; chr11:8937356 chr11:8964675~8977527:+ PAAD cis rs321358 0.731 rs7939631 ENSG00000271584.1 RP11-89C3.4 7.94 4.25e-13 1.37e-09 0.65 0.54 Body mass index; chr11:111153506 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs73021576 ENSG00000271584.1 RP11-89C3.4 7.94 4.25e-13 1.37e-09 0.65 0.54 Body mass index; chr11:111155690 chr11:111091932~111097357:- PAAD cis rs321358 0.707 rs73021578 ENSG00000271584.1 RP11-89C3.4 7.94 4.25e-13 1.37e-09 0.65 0.54 Body mass index; chr11:111156211 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs73003515 ENSG00000271584.1 RP11-89C3.4 7.94 4.25e-13 1.37e-09 0.65 0.54 Body mass index; chr11:111160734 chr11:111091932~111097357:- PAAD cis rs2283792 0.622 rs2266979 ENSG00000224086.5 LL22NC03-86G7.1 -7.93 4.28e-13 1.38e-09 -0.58 -0.54 Multiple sclerosis; chr22:21977447 chr22:21938293~21977632:+ PAAD cis rs3091242 0.933 rs34933589 ENSG00000261349.1 RP3-465N24.5 7.93 4.29e-13 1.38e-09 0.67 0.54 Erythrocyte sedimentation rate; chr1:25461707 chr1:25266102~25267136:- PAAD cis rs172166 0.516 rs1225710 ENSG00000216901.1 AL022393.7 -7.93 4.29e-13 1.38e-09 -0.67 -0.54 Cardiac Troponin-T levels; chr6:28132862 chr6:28176188~28176674:+ PAAD cis rs765787 0.53 rs1648289 ENSG00000259520.4 CTD-2651B20.3 7.93 4.3e-13 1.38e-09 0.65 0.54 Uric acid levels; chr15:45224296 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs1648287 ENSG00000259520.4 CTD-2651B20.3 7.93 4.3e-13 1.38e-09 0.65 0.54 Uric acid levels; chr15:45224758 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs1706834 ENSG00000259520.4 CTD-2651B20.3 7.93 4.3e-13 1.38e-09 0.65 0.54 Uric acid levels; chr15:45225656 chr15:45251580~45279251:- PAAD cis rs765787 0.505 rs11630884 ENSG00000259520.4 CTD-2651B20.3 7.93 4.3e-13 1.38e-09 0.65 0.54 Uric acid levels; chr15:45240048 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs13329228 ENSG00000259520.4 CTD-2651B20.3 7.93 4.3e-13 1.38e-09 0.65 0.54 Uric acid levels; chr15:45240819 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11634794 ENSG00000259520.4 CTD-2651B20.3 7.93 4.3e-13 1.38e-09 0.65 0.54 Uric acid levels; chr15:45242294 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs4514617 ENSG00000259520.4 CTD-2651B20.3 7.93 4.3e-13 1.38e-09 0.65 0.54 Uric acid levels; chr15:45243241 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11636404 ENSG00000259520.4 CTD-2651B20.3 7.93 4.3e-13 1.38e-09 0.65 0.54 Uric acid levels; chr15:45243663 chr15:45251580~45279251:- PAAD cis rs11690935 0.921 rs7355523 ENSG00000228389.1 AC068039.4 7.93 4.37e-13 1.41e-09 0.69 0.54 Schizophrenia; chr2:171887911 chr2:171773482~171775844:+ PAAD cis rs9660180 0.967 rs61422524 ENSG00000268575.1 RP1-283E3.8 -7.93 4.38e-13 1.41e-09 -0.52 -0.54 Body mass index; chr1:1836126 chr1:1702736~1737688:- PAAD cis rs2487048 0.905 rs2437812 ENSG00000226334.1 RP11-217B7.2 -7.93 4.38e-13 1.41e-09 -0.66 -0.54 Intraocular pressure; chr9:104930920 chr9:104927553~104928892:+ PAAD cis rs17507216 0.718 rs72751657 ENSG00000278603.1 RP13-608F4.5 7.93 4.4e-13 1.41e-09 0.92 0.54 Excessive daytime sleepiness; chr15:82581259 chr15:82472203~82472426:+ PAAD cis rs765787 0.53 rs2413775 ENSG00000259520.4 CTD-2651B20.3 7.93 4.41e-13 1.42e-09 0.65 0.54 Uric acid levels; chr15:45252090 chr15:45251580~45279251:- PAAD cis rs11428934 1 rs11428934 ENSG00000232871.7 SEC1P 7.93 4.42e-13 1.42e-09 0.77 0.54 Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts; chr19:48640988 chr19:48638071~48682245:+ PAAD cis rs321358 0.895 rs7110930 ENSG00000271584.1 RP11-89C3.4 -7.93 4.44e-13 1.43e-09 -0.65 -0.54 Body mass index; chr11:111088556 chr11:111091932~111097357:- PAAD cis rs760794 0.577 rs7752808 ENSG00000228412.5 RP4-625H18.2 7.92 4.61e-13 1.48e-09 0.63 0.54 Endometriosis; chr6:19792665 chr6:19802164~19804752:- PAAD cis rs1799949 0.929 rs799905 ENSG00000198496.9 NBR2 -7.92 4.61e-13 1.48e-09 -0.55 -0.54 Menopause (age at onset); chr17:43125170 chr17:43125610~43153671:+ PAAD cis rs9326248 0.539 rs518181 ENSG00000254851.1 RP11-109L13.1 -7.92 4.75e-13 1.52e-09 -0.69 -0.54 Blood protein levels; chr11:116902071 chr11:117135528~117138582:+ PAAD cis rs7829975 0.593 rs2921051 ENSG00000253893.2 FAM85B -7.92 4.78e-13 1.53e-09 -0.73 -0.54 Mood instability; chr8:8462594 chr8:8167819~8226614:- PAAD cis rs11155671 0.53 rs7763849 ENSG00000231760.4 RP11-350J20.5 7.91 4.79e-13 1.53e-09 0.7 0.54 Testicular germ cell tumor; chr6:149885244 chr6:149796151~149826294:- PAAD cis rs1799949 0.965 rs799910 ENSG00000198496.9 NBR2 -7.91 4.8e-13 1.54e-09 -0.55 -0.54 Menopause (age at onset); chr17:43127544 chr17:43125610~43153671:+ PAAD cis rs765787 0.53 rs11636395 ENSG00000259520.4 CTD-2651B20.3 7.91 5.05e-13 1.61e-09 0.65 0.54 Uric acid levels; chr15:45243486 chr15:45251580~45279251:- PAAD cis rs321358 0.731 rs494921 ENSG00000271584.1 RP11-89C3.4 -7.91 5.05e-13 1.61e-09 -0.63 -0.54 Body mass index; chr11:111140385 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs17536059 ENSG00000271584.1 RP11-89C3.4 -7.91 5.06e-13 1.61e-09 -0.65 -0.54 Body mass index; chr11:111086611 chr11:111091932~111097357:- PAAD cis rs11690935 0.959 rs7586207 ENSG00000228389.1 AC068039.4 7.9 5.12e-13 1.63e-09 0.69 0.54 Schizophrenia; chr2:171814584 chr2:171773482~171775844:+ PAAD cis rs11690935 1 rs3795999 ENSG00000228389.1 AC068039.4 -7.9 5.16e-13 1.64e-09 -0.68 -0.54 Schizophrenia; chr2:171687973 chr2:171773482~171775844:+ PAAD cis rs977987 0.868 rs10871313 ENSG00000261783.1 RP11-252K23.2 -7.9 5.16e-13 1.64e-09 -0.68 -0.54 Dupuytren's disease; chr16:75473196 chr16:75379818~75381260:- PAAD cis rs172166 0.538 rs1150686 ENSG00000216901.1 AL022393.7 7.9 5.18e-13 1.65e-09 0.66 0.54 Cardiac Troponin-T levels; chr6:28193493 chr6:28176188~28176674:+ PAAD cis rs1150688 1 rs1150688 ENSG00000216901.1 AL022393.7 7.9 5.18e-13 1.65e-09 0.66 0.54 Autism spectrum disorder or schizophrenia; chr6:28195002 chr6:28176188~28176674:+ PAAD cis rs10256972 0.621 rs2280725 ENSG00000229043.2 AC091729.9 -7.9 5.2e-13 1.66e-09 -0.57 -0.54 Endometriosis;Longevity; chr7:1047790 chr7:1160374~1165267:+ PAAD cis rs10256972 0.621 rs10951594 ENSG00000229043.2 AC091729.9 -7.9 5.2e-13 1.66e-09 -0.57 -0.54 Endometriosis;Longevity; chr7:1048971 chr7:1160374~1165267:+ PAAD cis rs5760092 0.618 rs4461358 ENSG00000273295.1 AP000350.5 -7.89 5.37e-13 1.71e-09 -0.74 -0.54 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23901432~23907068:- PAAD cis rs2283792 0.633 rs240068 ENSG00000224086.5 LL22NC03-86G7.1 -7.89 5.42e-13 1.72e-09 -0.59 -0.54 Multiple sclerosis; chr22:21936031 chr22:21938293~21977632:+ PAAD cis rs321358 0.731 rs484021 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111136353 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs7112075 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111136407 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs559757 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111136885 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs560503 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111136911 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs514347 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111137333 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs565152 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111137443 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs539009 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111137694 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs516177 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111138173 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs580656 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111141436 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs536679 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111142497 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs502584 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111142620 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs511835 ENSG00000271584.1 RP11-89C3.4 7.89 5.43e-13 1.73e-09 0.62 0.54 Body mass index; chr11:111145338 chr11:111091932~111097357:- PAAD cis rs7714584 1 rs11743488 ENSG00000197083.10 ZNF300P1 7.89 5.44e-13 1.73e-09 0.98 0.54 Crohn's disease; chr5:150899656 chr5:150930645~150946289:- PAAD cis rs321358 0.79 rs4635115 ENSG00000271584.1 RP11-89C3.4 7.89 5.46e-13 1.73e-09 0.65 0.54 Body mass index; chr11:111076352 chr11:111091932~111097357:- PAAD cis rs3931020 0.772 rs1475396 ENSG00000272864.1 RP11-17E13.2 -7.89 5.57e-13 1.77e-09 -0.65 -0.54 Resistin levels; chr1:74776712 chr1:74698769~74699333:- PAAD cis rs977987 0.864 rs40446 ENSG00000261783.1 RP11-252K23.2 7.89 5.57e-13 1.77e-09 0.66 0.54 Dupuytren's disease; chr16:75462760 chr16:75379818~75381260:- PAAD cis rs977987 0.864 rs37592 ENSG00000261783.1 RP11-252K23.2 7.89 5.57e-13 1.77e-09 0.66 0.54 Dupuytren's disease; chr16:75462893 chr16:75379818~75381260:- PAAD cis rs977987 0.864 rs37593 ENSG00000261783.1 RP11-252K23.2 7.89 5.57e-13 1.77e-09 0.66 0.54 Dupuytren's disease; chr16:75463009 chr16:75379818~75381260:- PAAD cis rs9660180 0.783 rs1107910 ENSG00000268575.1 RP1-283E3.8 -7.89 5.64e-13 1.78e-09 -0.5 -0.54 Body mass index; chr1:1760882 chr1:1702736~1737688:- PAAD cis rs3931020 0.679 rs28671241 ENSG00000272864.1 RP11-17E13.2 -7.89 5.66e-13 1.79e-09 -0.65 -0.54 Resistin levels; chr1:74716197 chr1:74698769~74699333:- PAAD cis rs62388641 0.539 rs56016631 ENSG00000272279.1 RP11-157J24.2 7.89 5.67e-13 1.79e-09 0.63 0.54 Daytime sleep phenotypes; chr6:1542340 chr6:1528364~1528911:- PAAD cis rs62388641 0.539 rs56304710 ENSG00000272279.1 RP11-157J24.2 7.89 5.67e-13 1.79e-09 0.63 0.54 Daytime sleep phenotypes; chr6:1542341 chr6:1528364~1528911:- PAAD cis rs9660180 0.934 rs12729990 ENSG00000268575.1 RP1-283E3.8 -7.89 5.68e-13 1.8e-09 -0.52 -0.54 Body mass index; chr1:1880596 chr1:1702736~1737688:- PAAD cis rs1062177 1 rs2915882 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151765875 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2915880 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151767773 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs17741826 ENSG00000213433.5 RPLP1P6 7.88 5.74e-13 1.81e-09 0.61 0.54 Preschool internalizing problems; chr5:151769701 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2915877 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151771040 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2964576 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151771041 chr5:151765859~151766378:- PAAD cis rs1062177 0.906 rs2964573 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151780561 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2964571 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151791695 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2915869 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151791948 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2347596 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151799638 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs892006 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151801329 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs72802204 ENSG00000213433.5 RPLP1P6 -7.88 5.74e-13 1.81e-09 -0.61 -0.54 Preschool internalizing problems; chr5:151803622 chr5:151765859~151766378:- PAAD cis rs7301826 0.56 rs12829294 ENSG00000256299.1 RP11-989F5.3 7.88 5.84e-13 1.84e-09 0.6 0.54 Plasma plasminogen activator levels; chr12:130825427 chr12:130810821~130812622:- PAAD cis rs11690935 1 rs2138348 ENSG00000228389.1 AC068039.4 -7.88 5.91e-13 1.86e-09 -0.68 -0.54 Schizophrenia; chr2:171701662 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs12692973 ENSG00000228389.1 AC068039.4 -7.88 5.91e-13 1.86e-09 -0.68 -0.54 Schizophrenia; chr2:171785547 chr2:171773482~171775844:+ PAAD cis rs11690935 1 rs312925 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171707412 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs2674484 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171718102 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10206062 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171720766 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs973889 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171723444 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs11897196 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171729085 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10207085 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171729375 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs2292815 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171730141 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs7604918 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171731584 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10204501 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171732355 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10204502 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171732356 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10204622 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171732472 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs6709156 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171735434 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs6722757 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171735453 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs12692970 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171737687 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs4667694 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171748889 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10166005 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171750784 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs13419987 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171767404 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs10194102 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171769633 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs11904009 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171770833 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs7572215 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171777718 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs35391289 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171778473 chr2:171773482~171775844:+ PAAD cis rs11690935 0.918 rs11757 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171784535 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs6745143 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171793872 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs6758704 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171798587 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs1474074 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171803342 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs3770452 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171812172 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs3770451 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171812205 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs66835971 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171820949 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs6759575 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171832558 chr2:171773482~171775844:+ PAAD cis rs11690935 0.921 rs4668414 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171847781 chr2:171773482~171775844:+ PAAD cis rs11690935 0.959 rs6724337 ENSG00000228389.1 AC068039.4 7.88 5.91e-13 1.86e-09 0.68 0.54 Schizophrenia; chr2:171878819 chr2:171773482~171775844:+ PAAD cis rs5769707 0.609 rs2007024 ENSG00000188511.11 C22orf34 7.88 5.92e-13 1.86e-09 0.58 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49595167 chr22:49414524~49657542:- PAAD cis rs1799949 0.965 rs8176310 ENSG00000198496.9 NBR2 -7.88 5.95e-13 1.87e-09 -0.54 -0.54 Menopause (age at onset); chr17:43047896 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs8070179 ENSG00000198496.9 NBR2 -7.88 5.95e-13 1.87e-09 -0.54 -0.54 Menopause (age at onset); chr17:43050671 chr17:43125610~43153671:+ PAAD cis rs881375 0.967 rs1008382 ENSG00000226752.6 PSMD5-AS1 -7.87 6.04e-13 1.9e-09 -0.6 -0.54 Rheumatoid arthritis; chr9:120918977 chr9:120824828~120854385:+ PAAD cis rs7301826 0.627 rs61937256 ENSG00000256299.1 RP11-989F5.3 7.87 6.07e-13 1.91e-09 0.59 0.54 Plasma plasminogen activator levels; chr12:130818100 chr12:130810821~130812622:- PAAD cis rs7301826 0.61 rs7961690 ENSG00000256299.1 RP11-989F5.3 7.87 6.2e-13 1.95e-09 0.59 0.54 Plasma plasminogen activator levels; chr12:130812335 chr12:130810821~130812622:- PAAD cis rs7847628 0.566 rs10739575 ENSG00000226752.6 PSMD5-AS1 7.87 6.21e-13 1.95e-09 0.76 0.54 Birth weight; chr9:120843823 chr9:120824828~120854385:+ PAAD cis rs881375 0.967 rs10733648 ENSG00000226752.6 PSMD5-AS1 -7.87 6.23e-13 1.96e-09 -0.58 -0.54 Rheumatoid arthritis; chr9:120938501 chr9:120824828~120854385:+ PAAD cis rs9399135 0.66 rs4440481 ENSG00000232876.1 CTA-212D2.2 -7.87 6.26e-13 1.97e-09 -0.63 -0.54 Red blood cell count; chr6:134955558 chr6:135055033~135060550:+ PAAD cis rs7208859 0.673 rs216411 ENSG00000263531.1 RP13-753N3.1 -7.86 6.39e-13 2e-09 -0.95 -0.54 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576475 chr17:30863921~30864940:- PAAD cis rs172166 0.516 rs2622322 ENSG00000216901.1 AL022393.7 7.86 6.39e-13 2e-09 0.66 0.54 Cardiac Troponin-T levels; chr6:28149665 chr6:28176188~28176674:+ PAAD cis rs172166 0.516 rs1225618 ENSG00000216901.1 AL022393.7 7.86 6.39e-13 2e-09 0.66 0.54 Cardiac Troponin-T levels; chr6:28161935 chr6:28176188~28176674:+ PAAD cis rs172166 0.516 rs1150670 ENSG00000216901.1 AL022393.7 7.86 6.39e-13 2e-09 0.66 0.54 Cardiac Troponin-T levels; chr6:28162781 chr6:28176188~28176674:+ PAAD cis rs172166 0.516 rs2021826 ENSG00000216901.1 AL022393.7 7.86 6.39e-13 2e-09 0.66 0.54 Cardiac Troponin-T levels; chr6:28164978 chr6:28176188~28176674:+ PAAD cis rs1150668 0.835 rs1233696 ENSG00000216901.1 AL022393.7 7.86 6.39e-13 2e-09 0.66 0.54 Pubertal anthropometrics; chr6:28175232 chr6:28176188~28176674:+ PAAD cis rs9326248 0.559 rs484646 ENSG00000254851.1 RP11-109L13.1 -7.86 6.41e-13 2.01e-09 -0.69 -0.54 Blood protein levels; chr11:116862140 chr11:117135528~117138582:+ PAAD cis rs9326248 0.509 rs533556 ENSG00000254851.1 RP11-109L13.1 -7.86 6.41e-13 2.01e-09 -0.69 -0.54 Blood protein levels; chr11:116870856 chr11:117135528~117138582:+ PAAD cis rs11690935 0.838 rs10432423 ENSG00000228389.1 AC068039.4 7.86 6.46e-13 2.02e-09 0.66 0.54 Schizophrenia; chr2:171896785 chr2:171773482~171775844:+ PAAD cis rs7301826 0.58 rs61938969 ENSG00000256299.1 RP11-989F5.3 7.86 6.55e-13 2.05e-09 0.6 0.54 Plasma plasminogen activator levels; chr12:130831525 chr12:130810821~130812622:- PAAD cis rs73086581 0.947 rs73084523 ENSG00000229539.1 RP11-119B16.2 7.86 6.6e-13 2.06e-09 0.85 0.54 Response to antidepressants in depression; chr20:3894979 chr20:3888239~3888868:- PAAD cis rs7301826 1 rs2001483 ENSG00000256250.1 RP11-989F5.1 -7.85 6.84e-13 2.14e-09 -0.62 -0.54 Plasma plasminogen activator levels; chr12:130834100 chr12:130810606~130812438:+ PAAD cis rs321358 0.895 rs7950087 ENSG00000271584.1 RP11-89C3.4 -7.85 6.85e-13 2.14e-09 -0.69 -0.54 Body mass index; chr11:111082536 chr11:111091932~111097357:- PAAD cis rs6565180 0.507 rs4471699 ENSG00000183604.13 SMG1P5 -7.85 6.86e-13 2.14e-09 -0.56 -0.54 Tonsillectomy; chr16:30308986 chr16:30267553~30335374:- PAAD cis rs9326248 0.539 rs10892058 ENSG00000254851.1 RP11-109L13.1 -7.85 7.06e-13 2.2e-09 -0.69 -0.54 Blood protein levels; chr11:117005905 chr11:117135528~117138582:+ PAAD cis rs9326248 0.52 rs7127881 ENSG00000254851.1 RP11-109L13.1 -7.85 7.06e-13 2.2e-09 -0.69 -0.54 Blood protein levels; chr11:117010082 chr11:117135528~117138582:+ PAAD cis rs433852 0.718 rs386551 ENSG00000232871.7 SEC1P -7.84 7.14e-13 2.22e-09 -0.76 -0.54 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48635029 chr19:48638071~48682245:+ PAAD cis rs9326248 0.559 rs476399 ENSG00000254851.1 RP11-109L13.1 -7.84 7.19e-13 2.24e-09 -0.69 -0.54 Blood protein levels; chr11:116863012 chr11:117135528~117138582:+ PAAD cis rs1799949 0.965 rs7212284 ENSG00000198496.9 NBR2 -7.84 7.21e-13 2.24e-09 -0.54 -0.54 Menopause (age at onset); chr17:43053924 chr17:43125610~43153671:+ PAAD cis rs1799949 1 rs8077486 ENSG00000198496.9 NBR2 -7.84 7.21e-13 2.24e-09 -0.54 -0.54 Menopause (age at onset); chr17:43060788 chr17:43125610~43153671:+ PAAD cis rs5769707 0.609 rs739247 ENSG00000188511.11 C22orf34 7.84 7.24e-13 2.25e-09 0.57 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49603009 chr22:49414524~49657542:- PAAD cis rs5769707 0.609 rs135861 ENSG00000188511.11 C22orf34 7.84 7.24e-13 2.25e-09 0.57 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49604470 chr22:49414524~49657542:- PAAD cis rs977987 0.864 rs37594 ENSG00000261783.1 RP11-252K23.2 7.84 7.27e-13 2.26e-09 0.66 0.54 Dupuytren's disease; chr16:75463045 chr16:75379818~75381260:- PAAD cis rs977987 0.864 rs37595 ENSG00000261783.1 RP11-252K23.2 7.84 7.27e-13 2.26e-09 0.66 0.54 Dupuytren's disease; chr16:75463065 chr16:75379818~75381260:- PAAD cis rs321358 0.731 rs12421339 ENSG00000271584.1 RP11-89C3.4 7.84 7.49e-13 2.33e-09 0.62 0.54 Body mass index; chr11:111168744 chr11:111091932~111097357:- PAAD cis rs3091242 0.933 rs35497030 ENSG00000261349.1 RP3-465N24.5 7.83 7.6e-13 2.36e-09 0.66 0.54 Erythrocyte sedimentation rate; chr1:25456575 chr1:25266102~25267136:- PAAD cis rs3091242 0.902 rs36003018 ENSG00000261349.1 RP3-465N24.5 7.83 7.6e-13 2.36e-09 0.66 0.54 Erythrocyte sedimentation rate; chr1:25457827 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs35403885 ENSG00000261349.1 RP3-465N24.5 7.83 7.6e-13 2.36e-09 0.66 0.54 Erythrocyte sedimentation rate; chr1:25458060 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs35530120 ENSG00000261349.1 RP3-465N24.5 7.83 7.6e-13 2.36e-09 0.66 0.54 Erythrocyte sedimentation rate; chr1:25458960 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs61775174 ENSG00000261349.1 RP3-465N24.5 7.83 7.6e-13 2.36e-09 0.66 0.54 Erythrocyte sedimentation rate; chr1:25460822 chr1:25266102~25267136:- PAAD cis rs321358 0.731 rs17460781 ENSG00000271584.1 RP11-89C3.4 7.83 7.66e-13 2.37e-09 0.6 0.54 Body mass index; chr11:111169966 chr11:111091932~111097357:- PAAD cis rs7714584 1 rs11741861 ENSG00000197083.10 ZNF300P1 -7.83 7.8e-13 2.42e-09 -0.97 -0.54 Crohn's disease; chr5:150898347 chr5:150930645~150946289:- PAAD cis rs3096299 0.509 rs4785691 ENSG00000274627.1 RP11-104N10.2 7.83 7.85e-13 2.43e-09 0.47 0.54 Multiple myeloma (IgH translocation); chr16:89530813 chr16:89516797~89522217:+ PAAD cis rs11690935 0.921 rs10200608 ENSG00000228389.1 AC068039.4 7.83 7.89e-13 2.44e-09 0.68 0.54 Schizophrenia; chr2:171741419 chr2:171773482~171775844:+ PAAD cis rs11690935 0.798 rs13018768 ENSG00000228389.1 AC068039.4 7.83 7.89e-13 2.44e-09 0.68 0.54 Schizophrenia; chr2:171742082 chr2:171773482~171775844:+ PAAD cis rs11690935 1 rs312924 ENSG00000228389.1 AC068039.4 -7.83 7.94e-13 2.46e-09 -0.68 -0.54 Schizophrenia; chr2:171707511 chr2:171773482~171775844:+ PAAD cis rs1799949 0.929 rs799906 ENSG00000198496.9 NBR2 -7.83 7.94e-13 2.46e-09 -0.54 -0.54 Menopause (age at onset); chr17:43126099 chr17:43125610~43153671:+ PAAD cis rs1799949 0.965 rs799908 ENSG00000198496.9 NBR2 -7.83 7.94e-13 2.46e-09 -0.54 -0.54 Menopause (age at onset); chr17:43126899 chr17:43125610~43153671:+ PAAD cis rs2739330 0.587 rs4820571 ENSG00000225282.1 AP000350.6 7.83 7.97e-13 2.46e-09 0.72 0.54 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23926900~23929574:+ PAAD cis rs3091242 0.933 rs9645452 ENSG00000224183.1 SDHDP6 7.83 7.97e-13 2.47e-09 0.68 0.54 Erythrocyte sedimentation rate; chr1:25341835 chr1:25294164~25294643:- PAAD cis rs10262624 0.528 rs5029444 ENSG00000234286.1 AC006026.13 7.82 8e-13 2.47e-09 0.59 0.54 Schizophrenia; chr7:23698176 chr7:23680195~23680786:- PAAD cis rs9399135 0.636 rs4646871 ENSG00000232876.1 CTA-212D2.2 7.82 8.07e-13 2.49e-09 0.63 0.54 Red blood cell count; chr6:134944479 chr6:135055033~135060550:+ PAAD cis rs1799949 0.894 rs71367985 ENSG00000198496.9 NBR2 -7.82 8.09e-13 2.5e-09 -0.54 -0.54 Menopause (age at onset); chr17:43222443 chr17:43125610~43153671:+ PAAD cis rs433852 0.718 rs550455 ENSG00000232871.7 SEC1P -7.82 8.14e-13 2.52e-09 -0.75 -0.54 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48633258 chr19:48638071~48682245:+ PAAD cis rs5769707 0.681 rs2319346 ENSG00000188511.11 C22orf34 7.82 8.21e-13 2.54e-09 0.57 0.54 Monocyte percentage of white cells;Monocyte count; chr22:49635992 chr22:49414524~49657542:- PAAD cis rs10262624 0.528 rs722294 ENSG00000234286.1 AC006026.13 7.82 8.21e-13 2.54e-09 0.6 0.54 Schizophrenia; chr7:23706966 chr7:23680195~23680786:- PAAD cis rs3091242 0.867 rs602052 ENSG00000261349.1 RP3-465N24.5 -7.82 8.28e-13 2.56e-09 -0.65 -0.54 Erythrocyte sedimentation rate; chr1:25395715 chr1:25266102~25267136:- PAAD cis rs73086581 0.947 rs56123574 ENSG00000229539.1 RP11-119B16.2 7.82 8.33e-13 2.57e-09 0.84 0.54 Response to antidepressants in depression; chr20:3897434 chr20:3888239~3888868:- PAAD cis rs73086581 0.947 rs73084531 ENSG00000229539.1 RP11-119B16.2 7.82 8.33e-13 2.57e-09 0.84 0.54 Response to antidepressants in depression; chr20:3897782 chr20:3888239~3888868:- PAAD cis rs321358 0.731 rs516110 ENSG00000271584.1 RP11-89C3.4 7.82 8.36e-13 2.58e-09 0.61 0.54 Body mass index; chr11:111166525 chr11:111091932~111097357:- PAAD cis rs6700559 1 rs10494821 ENSG00000260088.1 RP11-92G12.3 -7.81 8.82e-13 2.71e-09 -0.71 -0.54 Coronary artery disease; chr1:200673357 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs6667172 ENSG00000260088.1 RP11-92G12.3 -7.81 8.82e-13 2.71e-09 -0.71 -0.54 Coronary artery disease; chr1:200674710 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs7527499 ENSG00000260088.1 RP11-92G12.3 -7.81 8.82e-13 2.71e-09 -0.71 -0.54 Coronary artery disease; chr1:200676217 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs6427838 ENSG00000260088.1 RP11-92G12.3 -7.81 8.82e-13 2.71e-09 -0.71 -0.54 Coronary artery disease; chr1:200676519 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs12061346 ENSG00000260088.1 RP11-92G12.3 -7.81 8.82e-13 2.71e-09 -0.71 -0.54 Coronary artery disease; chr1:200677648 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs7533971 ENSG00000260088.1 RP11-92G12.3 -7.81 8.82e-13 2.71e-09 -0.71 -0.54 Coronary artery disease; chr1:200678243 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs10919998 ENSG00000260088.1 RP11-92G12.3 -7.81 8.82e-13 2.71e-09 -0.71 -0.54 Coronary artery disease; chr1:200679182 chr1:200669507~200694250:+ PAAD cis rs6700559 0.967 rs4072552 ENSG00000260088.1 RP11-92G12.3 -7.81 8.82e-13 2.71e-09 -0.71 -0.54 Coronary artery disease; chr1:200680003 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs6700559 ENSG00000260088.1 RP11-92G12.3 7.81 8.82e-13 2.71e-09 0.71 0.54 Coronary artery disease; chr1:200676945 chr1:200669507~200694250:+ PAAD cis rs7208859 0.623 rs9898084 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs28556733 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30863921~30864940:- PAAD cis rs17826219 0.5 rs28452421 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30756962 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs28433704 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs28779471 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30863921~30864940:- PAAD cis rs17826219 0.5 rs61685770 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30758695 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs57486336 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs55764512 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30758740 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs73988172 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs12103440 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs12103508 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs11653605 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11657777 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73269913 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7217984 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73269916 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs60114476 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs8065744 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs8071236 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30772984 chr17:30863921~30864940:- PAAD cis rs17826219 0.636 rs2449770 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30774046 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs59913838 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs56163556 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs8067035 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs8067338 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs4055105 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30863921~30864940:- PAAD cis rs7208859 0.562 rs8078897 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs8075163 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs8075107 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30779631 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7223209 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7223404 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9916725 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9916727 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9914499 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73269945 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9897728 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs1054400 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs1054397 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9890558 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs12006 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs3752021 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs3752020 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9890855 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9893422 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9891166 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73269974 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs34756112 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs60724269 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs76633166 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs1061346 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs1061343 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs1061342 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs55938328 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73269988 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs55961983 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs7222803 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792879 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9899525 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30863921~30864940:- PAAD cis rs17826219 0.568 rs7213925 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30794616 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs11653098 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11658945 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11657990 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9911784 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9911997 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9890862 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs78071511 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11650982 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs2035494 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs3794796 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9915546 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9915566 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs28469200 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30806554 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs8064686 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs11657369 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs8075341 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73271842 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs9895815 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs7214313 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs8077116 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30863921~30864940:- PAAD cis rs7208859 0.524 rs28760584 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs73271850 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30815122 chr17:30863921~30864940:- PAAD cis rs17826219 0.636 rs79565452 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Body mass index; chr17:30815823 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7208088 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7212991 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7208441 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs28627615 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9912440 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30821754 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7220999 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs55638872 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs9899268 ENSG00000263531.1 RP13-753N3.1 7.8 8.96e-13 2.72e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30863921~30864940:- PAAD cis rs2455601 0.882 rs11042105 ENSG00000254860.4 TMEM9B-AS1 7.8 8.96e-13 2.72e-09 0.7 0.53 Schizophrenia; chr11:8872963 chr11:8964675~8977527:+ PAAD cis rs17507216 0.628 rs28737193 ENSG00000278603.1 RP13-608F4.5 7.8 9.02e-13 2.73e-09 0.88 0.53 Excessive daytime sleepiness; chr15:82701318 chr15:82472203~82472426:+ PAAD cis rs7208859 0.725 rs9891656 ENSG00000263531.1 RP13-753N3.1 7.8 9.21e-13 2.79e-09 0.93 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30863921~30864940:- PAAD cis rs17826219 0.636 rs12946563 ENSG00000263531.1 RP13-753N3.1 7.8 9.24e-13 2.79e-09 1.02 0.53 Body mass index; chr17:30776148 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs8081299 ENSG00000263531.1 RP13-753N3.1 7.8 9.24e-13 2.79e-09 1.02 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777278 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs8068645 ENSG00000263531.1 RP13-753N3.1 7.8 9.24e-13 2.79e-09 1.02 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs55811708 ENSG00000263531.1 RP13-753N3.1 7.8 9.24e-13 2.79e-09 1.02 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30863921~30864940:- PAAD cis rs17826219 0.706 rs2322197 ENSG00000263531.1 RP13-753N3.1 7.8 9.24e-13 2.79e-09 1.02 0.53 Body mass index; chr17:30778787 chr17:30863921~30864940:- PAAD cis rs10256972 0.521 rs7811577 ENSG00000229043.2 AC091729.9 -7.8 9.28e-13 2.81e-09 -0.53 -0.53 Endometriosis;Longevity; chr7:1063193 chr7:1160374~1165267:+ PAAD cis rs10256972 0.616 rs6957733 ENSG00000229043.2 AC091729.9 -7.8 9.28e-13 2.81e-09 -0.53 -0.53 Endometriosis;Longevity; chr7:1066691 chr7:1160374~1165267:+ PAAD cis rs11155671 0.53 rs7742993 ENSG00000231760.4 RP11-350J20.5 7.8 9.38e-13 2.84e-09 0.71 0.53 Testicular germ cell tumor; chr6:149883959 chr6:149796151~149826294:- PAAD cis rs3931020 0.548 rs17618340 ENSG00000272864.1 RP11-17E13.2 -7.8 9.43e-13 2.85e-09 -0.66 -0.53 Resistin levels; chr1:74781933 chr1:74698769~74699333:- PAAD cis rs11155671 0.53 rs9383912 ENSG00000231760.4 RP11-350J20.5 7.79 9.66e-13 2.92e-09 0.71 0.53 Testicular germ cell tumor; chr6:149885479 chr6:149796151~149826294:- PAAD cis rs67180937 0.921 rs35700460 ENSG00000272750.1 RP11-378J18.8 -7.79 9.81e-13 2.96e-09 -0.57 -0.53 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222638065 chr1:222658867~222661512:- PAAD cis rs7714584 1 rs4579248 ENSG00000197083.10 ZNF300P1 7.78 1.01e-12 3.06e-09 0.97 0.53 Crohn's disease; chr5:150888589 chr5:150930645~150946289:- PAAD cis rs8040855 0.557 rs9744503 ENSG00000259295.5 CSPG4P12 -7.78 1.02e-12 3.06e-09 -0.59 -0.53 Bulimia nervosa; chr15:85180986 chr15:85191438~85213905:+ PAAD cis rs11155671 0.53 rs9397398 ENSG00000231760.4 RP11-350J20.5 7.78 1.02e-12 3.07e-09 0.71 0.53 Testicular germ cell tumor; chr6:149872467 chr6:149796151~149826294:- PAAD cis rs1799949 0.587 rs1824890 ENSG00000198496.9 NBR2 -7.78 1.02e-12 3.09e-09 -0.58 -0.53 Menopause (age at onset); chr17:43344536 chr17:43125610~43153671:+ PAAD cis rs5769707 0.521 rs739244 ENSG00000188511.11 C22orf34 7.78 1.04e-12 3.12e-09 0.51 0.53 Monocyte percentage of white cells;Monocyte count; chr22:49666510 chr22:49414524~49657542:- PAAD cis rs10256972 0.521 rs10280960 ENSG00000229043.2 AC091729.9 -7.78 1.04e-12 3.13e-09 -0.53 -0.53 Endometriosis;Longevity; chr7:1064061 chr7:1160374~1165267:+ PAAD cis rs321358 1 rs73021573 ENSG00000271584.1 RP11-89C3.4 7.78 1.05e-12 3.15e-09 0.7 0.53 Body mass index; chr11:111155508 chr11:111091932~111097357:- PAAD cis rs321358 1 rs73003503 ENSG00000271584.1 RP11-89C3.4 7.78 1.05e-12 3.15e-09 0.7 0.53 Body mass index; chr11:111158360 chr11:111091932~111097357:- PAAD cis rs321358 1 rs73003511 ENSG00000271584.1 RP11-89C3.4 7.78 1.05e-12 3.15e-09 0.7 0.53 Body mass index; chr11:111160478 chr11:111091932~111097357:- PAAD cis rs321358 1 rs73003514 ENSG00000271584.1 RP11-89C3.4 7.78 1.05e-12 3.15e-09 0.7 0.53 Body mass index; chr11:111160605 chr11:111091932~111097357:- PAAD cis rs11690935 1 rs35549875 ENSG00000228389.1 AC068039.4 -7.78 1.05e-12 3.17e-09 -0.67 -0.53 Schizophrenia; chr2:171675882 chr2:171773482~171775844:+ PAAD cis rs7208859 0.623 rs11658022 ENSG00000263531.1 RP13-753N3.1 7.77 1.11e-12 3.34e-09 1.02 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758341 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs73269923 ENSG00000263531.1 RP13-753N3.1 7.77 1.11e-12 3.34e-09 1.02 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775553 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs11654035 ENSG00000263531.1 RP13-753N3.1 7.77 1.11e-12 3.34e-09 1.02 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809408 chr17:30863921~30864940:- PAAD cis rs7301826 0.58 rs12821464 ENSG00000256299.1 RP11-989F5.3 7.76 1.13e-12 3.38e-09 0.62 0.53 Plasma plasminogen activator levels; chr12:130838174 chr12:130810821~130812622:- PAAD cis rs7208859 0.623 rs9912283 ENSG00000263531.1 RP13-753N3.1 7.76 1.14e-12 3.43e-09 1.01 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30863921~30864940:- PAAD cis rs7208859 0.623 rs7220289 ENSG00000263531.1 RP13-753N3.1 7.76 1.16e-12 3.47e-09 1.02 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30776744 chr17:30863921~30864940:- PAAD cis rs11690935 0.959 rs12185567 ENSG00000228389.1 AC068039.4 -7.76 1.16e-12 3.48e-09 -0.68 -0.53 Schizophrenia; chr2:171704219 chr2:171773482~171775844:+ PAAD cis rs7104764 1 rs10794302 ENSG00000277290.1 RP11-326C3.16 -7.76 1.16e-12 3.48e-09 -0.5 -0.53 Menarche (age at onset); chr11:234102 chr11:243099~243483:- PAAD cis rs7104764 1 rs9795476 ENSG00000277290.1 RP11-326C3.16 -7.76 1.16e-12 3.48e-09 -0.5 -0.53 Menarche (age at onset); chr11:235894 chr11:243099~243483:- PAAD cis rs11118620 0.853 rs12037861 ENSG00000272823.1 RP11-295M18.6 7.76 1.18e-12 3.53e-09 0.65 0.53 Heart failure; chr1:220864835 chr1:220828676~220829211:- PAAD cis rs494459 0.838 rs567680 ENSG00000255239.1 AP002954.6 7.75 1.19e-12 3.56e-09 0.63 0.53 Height; chr11:118737823 chr11:118688039~118690600:- PAAD cis rs494459 0.838 rs566733 ENSG00000255239.1 AP002954.6 7.75 1.19e-12 3.56e-09 0.63 0.53 Height; chr11:118737916 chr11:118688039~118690600:- PAAD cis rs35160687 0.829 rs13017143 ENSG00000273080.1 RP11-301O19.1 -7.75 1.2e-12 3.58e-09 -0.63 -0.53 Night sleep phenotypes; chr2:86239426 chr2:86195590~86196049:+ PAAD cis rs977987 1 rs977985 ENSG00000261783.1 RP11-252K23.2 -7.75 1.2e-12 3.58e-09 -0.66 -0.53 Dupuytren's disease; chr16:75473049 chr16:75379818~75381260:- PAAD cis rs9660180 0.967 rs2272908 ENSG00000268575.1 RP1-283E3.8 7.75 1.2e-12 3.6e-09 0.5 0.53 Body mass index; chr1:1790040 chr1:1702736~1737688:- PAAD cis rs1799949 0.93 rs34210004 ENSG00000198496.9 NBR2 -7.75 1.22e-12 3.64e-09 -0.54 -0.53 Menopause (age at onset); chr17:43218318 chr17:43125610~43153671:+ PAAD cis rs11690935 0.694 rs312921 ENSG00000228389.1 AC068039.4 7.75 1.22e-12 3.65e-09 0.68 0.53 Schizophrenia; chr2:171710715 chr2:171773482~171775844:+ PAAD cis rs11118620 1 rs11118620 ENSG00000272823.1 RP11-295M18.6 7.75 1.23e-12 3.68e-09 0.66 0.53 Heart failure; chr1:220855166 chr1:220828676~220829211:- PAAD cis rs11118620 0.81 rs4587570 ENSG00000272823.1 RP11-295M18.6 7.75 1.23e-12 3.68e-09 0.66 0.53 Heart failure; chr1:220860693 chr1:220828676~220829211:- PAAD cis rs3091242 0.933 rs34006994 ENSG00000261349.1 RP3-465N24.5 7.75 1.24e-12 3.69e-09 0.66 0.53 Erythrocyte sedimentation rate; chr1:25454177 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs61775167 ENSG00000261349.1 RP3-465N24.5 7.75 1.24e-12 3.69e-09 0.66 0.53 Erythrocyte sedimentation rate; chr1:25454402 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs10903129 ENSG00000261349.1 RP3-465N24.5 -7.75 1.24e-12 3.69e-09 -0.66 -0.53 Erythrocyte sedimentation rate; chr1:25442446 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs10903130 ENSG00000261349.1 RP3-465N24.5 -7.75 1.24e-12 3.69e-09 -0.66 -0.53 Erythrocyte sedimentation rate; chr1:25442730 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs11249251 ENSG00000261349.1 RP3-465N24.5 -7.75 1.24e-12 3.69e-09 -0.66 -0.53 Erythrocyte sedimentation rate; chr1:25443697 chr1:25266102~25267136:- PAAD cis rs3091242 0.9 rs4649086 ENSG00000261349.1 RP3-465N24.5 -7.75 1.24e-12 3.69e-09 -0.66 -0.53 Erythrocyte sedimentation rate; chr1:25452476 chr1:25266102~25267136:- PAAD cis rs71335811 1 rs71335811 ENSG00000232871.7 SEC1P -7.75 1.24e-12 3.7e-09 -0.76 -0.53 Myeloid white cell count; chr19:48626814 chr19:48638071~48682245:+ PAAD cis rs73086581 0.891 rs11907503 ENSG00000229539.1 RP11-119B16.2 7.74 1.26e-12 3.76e-09 0.84 0.53 Response to antidepressants in depression; chr20:3906943 chr20:3888239~3888868:- PAAD cis rs67180937 0.885 rs2133187 ENSG00000272750.1 RP11-378J18.8 -7.74 1.26e-12 3.76e-09 -0.56 -0.53 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222640383 chr1:222658867~222661512:- PAAD cis rs3931020 0.745 rs1980851 ENSG00000272864.1 RP11-17E13.2 -7.74 1.28e-12 3.8e-09 -0.65 -0.53 Resistin levels; chr1:74803287 chr1:74698769~74699333:- PAAD cis rs11690935 0.959 rs4668412 ENSG00000228389.1 AC068039.4 7.74 1.28e-12 3.82e-09 0.68 0.53 Schizophrenia; chr2:171763260 chr2:171773482~171775844:+ PAAD cis rs881375 0.933 rs7021206 ENSG00000226752.6 PSMD5-AS1 7.74 1.31e-12 3.88e-09 0.57 0.53 Rheumatoid arthritis; chr9:120921879 chr9:120824828~120854385:+ PAAD cis rs3096299 0.685 rs4329923 ENSG00000274627.1 RP11-104N10.2 7.73 1.37e-12 4.05e-09 0.47 0.53 Multiple myeloma (IgH translocation); chr16:89493770 chr16:89516797~89522217:+ PAAD cis rs3931020 0.772 rs1409785 ENSG00000272864.1 RP11-17E13.2 -7.73 1.37e-12 4.06e-09 -0.65 -0.53 Resistin levels; chr1:74782438 chr1:74698769~74699333:- PAAD cis rs3814244 0.528 rs7962511 ENSG00000255733.4 IFNG-AS1 7.73 1.37e-12 4.07e-09 0.51 0.53 Itch intensity from mosquito bite adjusted by bite size; chr12:68002854 chr12:67989445~68234686:+ PAAD cis rs10256972 0.713 rs10435026 ENSG00000229043.2 AC091729.9 -7.73 1.38e-12 4.1e-09 -0.55 -0.53 Endometriosis;Longevity; chr7:1026312 chr7:1160374~1165267:+ PAAD cis rs8040855 0.579 rs28521166 ENSG00000259295.5 CSPG4P12 -7.73 1.4e-12 4.14e-09 -0.57 -0.53 Bulimia nervosa; chr15:85184801 chr15:85191438~85213905:+ PAAD cis rs2919917 1 rs2919917 ENSG00000254352.1 RP11-578O24.2 -7.72 1.41e-12 4.17e-09 -0.56 -0.53 Lymphocyte counts; chr8:78745028 chr8:78723796~78724136:- PAAD cis rs1062177 1 rs2915887 ENSG00000213433.5 RPLP1P6 -7.72 1.42e-12 4.2e-09 -0.62 -0.53 Preschool internalizing problems; chr5:151825943 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2964584 ENSG00000213433.5 RPLP1P6 -7.72 1.43e-12 4.23e-09 -0.6 -0.53 Preschool internalizing problems; chr5:151763317 chr5:151765859~151766378:- PAAD cis rs494459 0.838 rs1784543 ENSG00000255239.1 AP002954.6 7.72 1.44e-12 4.27e-09 0.63 0.53 Height; chr11:118760944 chr11:118688039~118690600:- PAAD cis rs67180937 0.961 rs2133189 ENSG00000272750.1 RP11-378J18.8 -7.72 1.45e-12 4.28e-09 -0.56 -0.53 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222641100 chr1:222658867~222661512:- PAAD cis rs11155671 0.53 rs7758033 ENSG00000231760.4 RP11-350J20.5 7.72 1.45e-12 4.28e-09 0.7 0.53 Testicular germ cell tumor; chr6:149886999 chr6:149796151~149826294:- PAAD cis rs7714584 1 rs4958426 ENSG00000197083.10 ZNF300P1 7.72 1.47e-12 4.35e-09 0.98 0.53 Crohn's disease; chr5:150898784 chr5:150930645~150946289:- PAAD cis rs7429990 0.932 rs936428 ENSG00000229759.1 MRPS18AP1 -7.72 1.47e-12 4.35e-09 -0.57 -0.53 Educational attainment (years of education); chr3:48125791 chr3:48256350~48256938:- PAAD cis rs7429990 0.901 rs7374482 ENSG00000229759.1 MRPS18AP1 -7.72 1.47e-12 4.35e-09 -0.57 -0.53 Educational attainment (years of education); chr3:48126900 chr3:48256350~48256938:- PAAD cis rs7195287 0.826 rs9925824 ENSG00000276791.1 CTD-2270P14.5 -7.71 1.49e-12 4.39e-09 -0.68 -0.53 Eosinophil counts; chr16:2777972 chr16:2777319~2780568:+ PAAD cis rs10256972 0.521 rs871019 ENSG00000229043.2 AC091729.9 -7.71 1.52e-12 4.47e-09 -0.52 -0.53 Endometriosis;Longevity; chr7:1065594 chr7:1160374~1165267:+ PAAD cis rs11155671 0.53 rs4870080 ENSG00000231760.4 RP11-350J20.5 7.7 1.57e-12 4.64e-09 0.71 0.53 Testicular germ cell tumor; chr6:149881508 chr6:149796151~149826294:- PAAD cis rs7188445 0.614 rs62043313 ENSG00000261390.4 RP11-345M22.2 -7.7 1.57e-12 4.64e-09 -0.67 -0.53 Urate levels; chr16:79710237 chr16:79715232~79770563:- PAAD cis rs73086581 0.947 rs67356712 ENSG00000229539.1 RP11-119B16.2 7.7 1.58e-12 4.64e-09 0.83 0.53 Response to antidepressants in depression; chr20:3912239 chr20:3888239~3888868:- PAAD cis rs11155671 0.53 rs9383577 ENSG00000231760.4 RP11-350J20.5 7.7 1.58e-12 4.64e-09 0.7 0.53 Testicular germ cell tumor; chr6:149886059 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs9383914 ENSG00000231760.4 RP11-350J20.5 7.7 1.58e-12 4.64e-09 0.7 0.53 Testicular germ cell tumor; chr6:149886098 chr6:149796151~149826294:- PAAD cis rs11155671 0.517 rs9397058 ENSG00000231760.4 RP11-350J20.5 7.7 1.58e-12 4.64e-09 0.7 0.53 Testicular germ cell tumor; chr6:149886113 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs7768626 ENSG00000231760.4 RP11-350J20.5 7.7 1.58e-12 4.64e-09 0.7 0.53 Testicular germ cell tumor; chr6:149886826 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs7768665 ENSG00000231760.4 RP11-350J20.5 7.7 1.58e-12 4.64e-09 0.7 0.53 Testicular germ cell tumor; chr6:149886888 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs7758020 ENSG00000231760.4 RP11-350J20.5 7.7 1.58e-12 4.64e-09 0.7 0.53 Testicular germ cell tumor; chr6:149886975 chr6:149796151~149826294:- PAAD cis rs11118620 0.81 rs1603047 ENSG00000272823.1 RP11-295M18.6 7.7 1.58e-12 4.65e-09 0.65 0.53 Heart failure; chr1:220849953 chr1:220828676~220829211:- PAAD cis rs321358 1 rs321356 ENSG00000271584.1 RP11-89C3.4 -7.7 1.61e-12 4.74e-09 -0.71 -0.53 Body mass index; chr11:111124957 chr11:111091932~111097357:- PAAD cis rs321358 0.731 rs17459717 ENSG00000271584.1 RP11-89C3.4 7.7 1.62e-12 4.75e-09 0.62 0.53 Body mass index; chr11:111139862 chr11:111091932~111097357:- PAAD cis rs73086581 0.947 rs11906612 ENSG00000229539.1 RP11-119B16.2 7.7 1.63e-12 4.77e-09 0.84 0.53 Response to antidepressants in depression; chr20:3922987 chr20:3888239~3888868:- PAAD cis rs494459 0.756 rs570806 ENSG00000255239.1 AP002954.6 7.7 1.65e-12 4.85e-09 0.63 0.53 Height; chr11:118786602 chr11:118688039~118690600:- PAAD cis rs494459 0.838 rs12796102 ENSG00000255239.1 AP002954.6 7.7 1.65e-12 4.85e-09 0.63 0.53 Height; chr11:118791319 chr11:118688039~118690600:- PAAD cis rs2739330 0.734 rs2000467 ENSG00000099984.9 GSTT2 7.7 1.66e-12 4.88e-09 0.72 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23980123~23983911:+ PAAD cis rs380904 1 rs12543128 ENSG00000254859.1 RP11-661A12.5 -7.69 1.67e-12 4.91e-09 -0.77 -0.53 Venous thromboembolism (SNP x SNP interaction); chr8:143512872 chr8:143541973~143549729:- PAAD cis rs9322193 0.607 rs10457852 ENSG00000231760.4 RP11-350J20.5 7.69 1.7e-12 4.98e-09 0.76 0.53 Lung cancer; chr6:149880584 chr6:149796151~149826294:- PAAD cis rs11690935 0.885 rs6727017 ENSG00000228389.1 AC068039.4 7.69 1.71e-12 5.01e-09 0.66 0.53 Schizophrenia; chr2:171910337 chr2:171773482~171775844:+ PAAD cis rs1799949 0.93 rs1554063 ENSG00000198496.9 NBR2 -7.69 1.73e-12 5.06e-09 -0.54 -0.53 Menopause (age at onset); chr17:43135128 chr17:43125610~43153671:+ PAAD cis rs881375 0.967 rs1014529 ENSG00000226752.6 PSMD5-AS1 -7.69 1.73e-12 5.08e-09 -0.57 -0.53 Rheumatoid arthritis; chr9:120922665 chr9:120824828~120854385:+ PAAD cis rs1799949 1 rs35070007 ENSG00000198496.9 NBR2 7.69 1.75e-12 5.11e-09 0.53 0.53 Menopause (age at onset); chr17:43164730 chr17:43125610~43153671:+ PAAD cis rs1799949 0.773 rs2137990 ENSG00000198496.9 NBR2 7.69 1.75e-12 5.11e-09 0.53 0.53 Menopause (age at onset); chr17:43165879 chr17:43125610~43153671:+ PAAD cis rs494459 0.657 rs614554 ENSG00000255239.1 AP002954.6 7.69 1.75e-12 5.12e-09 0.63 0.53 Height; chr11:118764443 chr11:118688039~118690600:- PAAD cis rs9601248 0.838 rs6563121 ENSG00000227676.3 LINC01068 -7.69 1.75e-12 5.13e-09 -0.67 -0.53 Major depressive disorder; chr13:79600865 chr13:79566727~79571436:+ PAAD cis rs8040855 0.599 rs6496791 ENSG00000259295.5 CSPG4P12 -7.68 1.76e-12 5.16e-09 -0.58 -0.53 Bulimia nervosa; chr15:85182428 chr15:85191438~85213905:+ PAAD cis rs1799949 0.965 rs2236762 ENSG00000198496.9 NBR2 -7.68 1.77e-12 5.18e-09 -0.53 -0.53 Menopause (age at onset); chr17:43074658 chr17:43125610~43153671:+ PAAD cis rs7714584 1 rs17727568 ENSG00000197083.10 ZNF300P1 7.68 1.78e-12 5.21e-09 0.98 0.53 Crohn's disease; chr5:150865126 chr5:150930645~150946289:- PAAD cis rs172166 0.516 rs2791333 ENSG00000216901.1 AL022393.7 7.68 1.79e-12 5.23e-09 0.64 0.53 Cardiac Troponin-T levels; chr6:28143336 chr6:28176188~28176674:+ PAAD cis rs977987 0.835 rs4888379 ENSG00000261783.1 RP11-252K23.2 -7.68 1.79e-12 5.23e-09 -0.66 -0.53 Dupuytren's disease; chr16:75306333 chr16:75379818~75381260:- PAAD cis rs8040855 0.599 rs6496792 ENSG00000259295.5 CSPG4P12 -7.68 1.81e-12 5.29e-09 -0.58 -0.53 Bulimia nervosa; chr15:85182514 chr15:85191438~85213905:+ PAAD cis rs8040855 0.599 rs6496793 ENSG00000259295.5 CSPG4P12 -7.68 1.81e-12 5.29e-09 -0.58 -0.53 Bulimia nervosa; chr15:85182515 chr15:85191438~85213905:+ PAAD cis rs8040855 0.599 rs6496795 ENSG00000259295.5 CSPG4P12 -7.68 1.81e-12 5.29e-09 -0.58 -0.53 Bulimia nervosa; chr15:85182622 chr15:85191438~85213905:+ PAAD cis rs7104764 1 rs7104764 ENSG00000277290.1 RP11-326C3.16 -7.68 1.84e-12 5.36e-09 -0.49 -0.53 Menarche (age at onset); chr11:229977 chr11:243099~243483:- PAAD cis rs7104764 0.957 rs3829998 ENSG00000277290.1 RP11-326C3.16 -7.68 1.84e-12 5.36e-09 -0.49 -0.53 Menarche (age at onset); chr11:230751 chr11:243099~243483:- PAAD cis rs7104764 1 rs7483951 ENSG00000277290.1 RP11-326C3.16 -7.68 1.84e-12 5.36e-09 -0.49 -0.53 Menarche (age at onset); chr11:231758 chr11:243099~243483:- PAAD cis rs9660180 0.967 rs12034740 ENSG00000268575.1 RP1-283E3.8 -7.68 1.84e-12 5.37e-09 -0.5 -0.53 Body mass index; chr1:1797530 chr1:1702736~1737688:- PAAD cis rs12439619 0.739 rs4778988 ENSG00000278603.1 RP13-608F4.5 7.68 1.84e-12 5.38e-09 0.75 0.53 Intelligence (multi-trait analysis); chr15:82247996 chr15:82472203~82472426:+ PAAD cis rs494459 0.688 rs1048040 ENSG00000255239.1 AP002954.6 7.68 1.84e-12 5.38e-09 0.63 0.53 Height; chr11:118747911 chr11:118688039~118690600:- PAAD cis rs977987 0.806 rs11862095 ENSG00000261783.1 RP11-252K23.2 -7.68 1.86e-12 5.42e-09 -0.65 -0.53 Dupuytren's disease; chr16:75351520 chr16:75379818~75381260:- PAAD cis rs321358 1 rs321355 ENSG00000271584.1 RP11-89C3.4 7.67 1.87e-12 5.46e-09 0.71 0.53 Body mass index; chr11:111124273 chr11:111091932~111097357:- PAAD cis rs321358 1 rs12419222 ENSG00000271584.1 RP11-89C3.4 7.67 1.87e-12 5.46e-09 0.71 0.53 Body mass index; chr11:111128439 chr11:111091932~111097357:- PAAD cis rs111321694 1 rs111321694 ENSG00000271584.1 RP11-89C3.4 7.67 1.88e-12 5.47e-09 0.68 0.53 Educational attainment (years of education); chr11:111079662 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs17457076 ENSG00000271584.1 RP11-89C3.4 7.67 1.88e-12 5.47e-09 0.68 0.53 Body mass index; chr11:111081030 chr11:111091932~111097357:- PAAD cis rs8040855 0.599 rs8037195 ENSG00000259295.5 CSPG4P12 -7.67 1.88e-12 5.48e-09 -0.58 -0.53 Bulimia nervosa; chr15:85181455 chr15:85191438~85213905:+ PAAD cis rs8040855 0.579 rs4843029 ENSG00000259295.5 CSPG4P12 -7.67 1.91e-12 5.57e-09 -0.58 -0.53 Bulimia nervosa; chr15:85182164 chr15:85191438~85213905:+ PAAD cis rs73086581 0.787 rs73084505 ENSG00000229539.1 RP11-119B16.2 7.67 1.92e-12 5.59e-09 0.86 0.53 Response to antidepressants in depression; chr20:3876227 chr20:3888239~3888868:- PAAD cis rs2739330 0.732 rs5760175 ENSG00000231271.1 AP000350.8 7.67 1.93e-12 5.63e-09 0.72 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23949918~23954042:+ PAAD cis rs3091242 0.933 rs926438 ENSG00000261349.1 RP3-465N24.5 -7.67 1.94e-12 5.64e-09 -0.64 -0.53 Erythrocyte sedimentation rate; chr1:25427147 chr1:25266102~25267136:- PAAD cis rs12439619 1 rs12439619 ENSG00000278603.1 RP13-608F4.5 7.67 1.96e-12 5.7e-09 0.75 0.53 Intelligence (multi-trait analysis); chr15:82254605 chr15:82472203~82472426:+ PAAD cis rs2739330 0.731 rs5751792 ENSG00000231271.1 AP000350.8 7.66 1.97e-12 5.73e-09 0.72 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23949918~23954042:+ PAAD cis rs977987 0.741 rs10514393 ENSG00000261783.1 RP11-252K23.2 -7.66 1.98e-12 5.74e-09 -0.66 -0.53 Dupuytren's disease; chr16:75310578 chr16:75379818~75381260:- PAAD cis rs765787 0.53 rs2554457 ENSG00000259520.4 CTD-2651B20.3 7.66 1.99e-12 5.78e-09 0.64 0.53 Uric acid levels; chr15:45228728 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2554456 ENSG00000259520.4 CTD-2651B20.3 7.66 1.99e-12 5.78e-09 0.64 0.53 Uric acid levels; chr15:45228940 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs10467979 ENSG00000259520.4 CTD-2651B20.3 7.66 1.99e-12 5.78e-09 0.64 0.53 Uric acid levels; chr15:45229072 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2554455 ENSG00000259520.4 CTD-2651B20.3 7.66 1.99e-12 5.78e-09 0.64 0.53 Uric acid levels; chr15:45229106 chr15:45251580~45279251:- PAAD cis rs3931020 0.772 rs11485555 ENSG00000272864.1 RP11-17E13.2 -7.66 1.99e-12 5.79e-09 -0.63 -0.53 Resistin levels; chr1:74720825 chr1:74698769~74699333:- PAAD cis rs11690935 0.885 rs6725388 ENSG00000228389.1 AC068039.4 7.66 1.99e-12 5.79e-09 0.66 0.53 Schizophrenia; chr2:171873505 chr2:171773482~171775844:+ PAAD cis rs2919917 0.955 rs1441850 ENSG00000254352.1 RP11-578O24.2 -7.66 2e-12 5.82e-09 -0.56 -0.53 Lymphocyte counts; chr8:78745431 chr8:78723796~78724136:- PAAD cis rs9326248 0.574 rs1263173 ENSG00000254851.1 RP11-109L13.1 -7.66 2e-12 5.82e-09 -0.76 -0.53 Blood protein levels; chr11:116810292 chr11:117135528~117138582:+ PAAD cis rs9326248 0.59 rs2542063 ENSG00000254851.1 RP11-109L13.1 -7.66 2e-12 5.82e-09 -0.76 -0.53 Blood protein levels; chr11:116814051 chr11:117135528~117138582:+ PAAD cis rs9399135 0.773 rs1331308 ENSG00000232876.1 CTA-212D2.2 7.66 2.01e-12 5.84e-09 0.61 0.53 Red blood cell count; chr6:135083984 chr6:135055033~135060550:+ PAAD cis rs2739330 0.761 rs5760176 ENSG00000231271.1 AP000350.8 -7.66 2.02e-12 5.87e-09 -0.72 -0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23949918~23954042:+ PAAD cis rs11690935 0.959 rs67204065 ENSG00000228389.1 AC068039.4 7.66 2.03e-12 5.88e-09 0.65 0.53 Schizophrenia; chr2:171816114 chr2:171773482~171775844:+ PAAD cis rs494459 0.838 rs488219 ENSG00000255239.1 AP002954.6 7.66 2.05e-12 5.93e-09 0.62 0.53 Height; chr11:118749988 chr11:118688039~118690600:- PAAD cis rs3091242 0.9 rs669063 ENSG00000261349.1 RP3-465N24.5 -7.66 2.06e-12 5.96e-09 -0.65 -0.53 Erythrocyte sedimentation rate; chr1:25394663 chr1:25266102~25267136:- PAAD cis rs321358 1 rs321357 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6e-09 0.71 0.53 Body mass index; chr11:111125002 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321358 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6e-09 0.71 0.53 Body mass index; chr11:111125247 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321359 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6e-09 0.71 0.53 Body mass index; chr11:111125257 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321360 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6e-09 0.71 0.53 Body mass index; chr11:111125346 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321361 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6e-09 0.71 0.53 Body mass index; chr11:111125495 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321362 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6e-09 0.71 0.53 Body mass index; chr11:111125754 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321363 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6e-09 0.71 0.53 Body mass index; chr11:111125929 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321365 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6e-09 0.71 0.53 Body mass index; chr11:111126676 chr11:111091932~111097357:- PAAD cis rs321358 0.848 rs78087740 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6.01e-09 0.67 0.53 Body mass index; chr11:111079016 chr11:111091932~111097357:- PAAD cis rs321358 0.848 rs73015146 ENSG00000271584.1 RP11-89C3.4 7.66 2.07e-12 6.01e-09 0.67 0.53 Body mass index; chr11:111079143 chr11:111091932~111097357:- PAAD cis rs494459 0.838 rs555649 ENSG00000255239.1 AP002954.6 7.66 2.08e-12 6.01e-09 0.63 0.53 Height; chr11:118781100 chr11:118688039~118690600:- PAAD cis rs977987 0.835 rs8046109 ENSG00000261783.1 RP11-252K23.2 -7.65 2.09e-12 6.04e-09 -0.66 -0.53 Dupuytren's disease; chr16:75326198 chr16:75379818~75381260:- PAAD cis rs9481169 1 rs9481169 ENSG00000255389.1 C6orf3 -7.65 2.11e-12 6.1e-09 -0.85 -0.53 Inflammatory skin disease; chr6:111608659 chr6:111599875~111602295:+ PAAD cis rs2455601 1 rs72632952 ENSG00000254860.4 TMEM9B-AS1 7.65 2.12e-12 6.12e-09 0.69 0.53 Schizophrenia; chr11:8896429 chr11:8964675~8977527:+ PAAD cis rs2455601 1 rs11042114 ENSG00000254860.4 TMEM9B-AS1 7.65 2.12e-12 6.12e-09 0.69 0.53 Schizophrenia; chr11:8898342 chr11:8964675~8977527:+ PAAD cis rs11690935 0.885 rs6750058 ENSG00000228389.1 AC068039.4 7.65 2.14e-12 6.19e-09 0.66 0.53 Schizophrenia; chr2:171930399 chr2:171773482~171775844:+ PAAD cis rs4718428 0.924 rs6971897 ENSG00000226824.5 RP4-756H11.3 -7.65 2.15e-12 6.2e-09 -0.67 -0.53 Corneal structure; chr7:66947787 chr7:66654538~66669855:+ PAAD cis rs10935480 0.904 rs13065271 ENSG00000239445.4 ST3GAL6-AS1 -7.64 2.2e-12 6.36e-09 -0.58 -0.53 Blood protein levels; chr3:98715649 chr3:98714330~98732651:- PAAD cis rs10256972 0.616 rs6463001 ENSG00000229043.2 AC091729.9 -7.64 2.21e-12 6.39e-09 -0.52 -0.53 Endometriosis;Longevity; chr7:1068636 chr7:1160374~1165267:+ PAAD cis rs8040855 0.579 rs6496797 ENSG00000259295.5 CSPG4P12 -7.64 2.22e-12 6.39e-09 -0.57 -0.53 Bulimia nervosa; chr15:85183624 chr15:85191438~85213905:+ PAAD cis rs3931020 0.72 rs1327090 ENSG00000272864.1 RP11-17E13.2 -7.64 2.22e-12 6.4e-09 -0.64 -0.53 Resistin levels; chr1:74800795 chr1:74698769~74699333:- PAAD cis rs1799949 0.965 rs9911630 ENSG00000198496.9 NBR2 -7.64 2.22e-12 6.4e-09 -0.53 -0.53 Menopause (age at onset); chr17:43036325 chr17:43125610~43153671:+ PAAD cis rs7684253 0.565 rs13108570 ENSG00000269949.1 RP11-738E22.3 -7.64 2.23e-12 6.43e-09 -0.68 -0.53 Migraine; chr4:56940917 chr4:56960927~56961373:- PAAD cis rs3091242 0.933 rs28530483 ENSG00000261349.1 RP3-465N24.5 -7.64 2.26e-12 6.51e-09 -0.65 -0.53 Erythrocyte sedimentation rate; chr1:25414356 chr1:25266102~25267136:- PAAD cis rs7429990 0.932 rs13085054 ENSG00000229759.1 MRPS18AP1 -7.64 2.26e-12 6.51e-09 -0.56 -0.53 Educational attainment (years of education); chr3:48092647 chr3:48256350~48256938:- PAAD cis rs7429990 0.87 rs13089844 ENSG00000229759.1 MRPS18AP1 -7.64 2.26e-12 6.51e-09 -0.56 -0.53 Educational attainment (years of education); chr3:48098741 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs11130155 ENSG00000229759.1 MRPS18AP1 -7.64 2.26e-12 6.51e-09 -0.56 -0.53 Educational attainment (years of education); chr3:48098938 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs12493348 ENSG00000229759.1 MRPS18AP1 -7.64 2.26e-12 6.51e-09 -0.56 -0.53 Educational attainment (years of education); chr3:48102048 chr3:48256350~48256938:- PAAD cis rs17826219 0.568 rs11658027 ENSG00000263531.1 RP13-753N3.1 -7.64 2.27e-12 6.54e-09 -1 -0.53 Body mass index; chr17:30767864 chr17:30863921~30864940:- PAAD cis rs494459 0.838 rs607125 ENSG00000255239.1 AP002954.6 7.64 2.28e-12 6.55e-09 0.63 0.53 Height; chr11:118746590 chr11:118688039~118690600:- PAAD cis rs321358 0.731 rs555063 ENSG00000271584.1 RP11-89C3.4 7.64 2.28e-12 6.55e-09 0.59 0.53 Body mass index; chr11:111168621 chr11:111091932~111097357:- PAAD cis rs11155671 0.53 rs9371215 ENSG00000231760.4 RP11-350J20.5 7.64 2.28e-12 6.56e-09 0.71 0.53 Testicular germ cell tumor; chr6:149873162 chr6:149796151~149826294:- PAAD cis rs321358 1 rs321368 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111129033 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321369 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111129797 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321370 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111129959 chr11:111091932~111097357:- PAAD cis rs321358 1 rs73019214 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111131680 chr11:111091932~111097357:- PAAD cis rs321358 1 rs419633 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111132187 chr11:111091932~111097357:- PAAD cis rs321358 1 rs429803 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111132263 chr11:111091932~111097357:- PAAD cis rs321358 0.943 rs402820 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111132480 chr11:111091932~111097357:- PAAD cis rs321358 0.943 rs17537987 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111134144 chr11:111091932~111097357:- PAAD cis rs321358 1 rs73019218 ENSG00000271584.1 RP11-89C3.4 7.64 2.29e-12 6.59e-09 0.71 0.53 Body mass index; chr11:111134521 chr11:111091932~111097357:- PAAD cis rs321358 1 rs321353 ENSG00000271584.1 RP11-89C3.4 -7.64 2.29e-12 6.59e-09 -0.71 -0.53 Body mass index; chr11:111123841 chr11:111091932~111097357:- PAAD cis rs3931020 0.745 rs1969111 ENSG00000272864.1 RP11-17E13.2 7.64 2.3e-12 6.6e-09 0.64 0.53 Resistin levels; chr1:74797801 chr1:74698769~74699333:- PAAD cis rs7104764 0.879 rs6598072 ENSG00000277290.1 RP11-326C3.16 -7.64 2.33e-12 6.68e-09 -0.49 -0.53 Menarche (age at onset); chr11:219793 chr11:243099~243483:- PAAD cis rs7104764 0.957 rs6598071 ENSG00000277290.1 RP11-326C3.16 -7.64 2.33e-12 6.68e-09 -0.49 -0.53 Menarche (age at onset); chr11:219800 chr11:243099~243483:- PAAD cis rs7104764 0.957 rs10794301 ENSG00000277290.1 RP11-326C3.16 -7.64 2.33e-12 6.68e-09 -0.49 -0.53 Menarche (age at onset); chr11:220401 chr11:243099~243483:- PAAD cis rs7104764 0.879 rs6421986 ENSG00000277290.1 RP11-326C3.16 -7.64 2.33e-12 6.68e-09 -0.49 -0.53 Menarche (age at onset); chr11:221659 chr11:243099~243483:- PAAD cis rs1577917 0.545 rs1335443 ENSG00000203875.9 SNHG5 -7.63 2.33e-12 6.68e-09 -0.69 -0.53 Response to antipsychotic treatment; chr6:85769019 chr6:85660950~85678736:- PAAD cis rs977987 0.933 rs4888431 ENSG00000261783.1 RP11-252K23.2 -7.63 2.34e-12 6.71e-09 -0.64 -0.53 Dupuytren's disease; chr16:75466801 chr16:75379818~75381260:- PAAD cis rs977987 1 rs62060550 ENSG00000261783.1 RP11-252K23.2 -7.63 2.34e-12 6.71e-09 -0.64 -0.53 Dupuytren's disease; chr16:75468354 chr16:75379818~75381260:- PAAD cis rs977987 0.966 rs62060551 ENSG00000261783.1 RP11-252K23.2 -7.63 2.34e-12 6.71e-09 -0.64 -0.53 Dupuytren's disease; chr16:75468414 chr16:75379818~75381260:- PAAD cis rs321358 1 rs321352 ENSG00000271584.1 RP11-89C3.4 7.63 2.36e-12 6.77e-09 0.71 0.53 Body mass index; chr11:111123001 chr11:111091932~111097357:- PAAD cis rs321358 1 rs167683 ENSG00000271584.1 RP11-89C3.4 7.63 2.36e-12 6.77e-09 0.71 0.53 Body mass index; chr11:111123131 chr11:111091932~111097357:- PAAD cis rs2919917 1 rs2953475 ENSG00000254352.1 RP11-578O24.2 -7.63 2.37e-12 6.79e-09 -0.55 -0.53 Lymphocyte counts; chr8:78725903 chr8:78723796~78724136:- PAAD cis rs977987 0.966 rs8055490 ENSG00000261783.1 RP11-252K23.2 -7.63 2.37e-12 6.8e-09 -0.64 -0.53 Dupuytren's disease; chr16:75463237 chr16:75379818~75381260:- PAAD cis rs977987 0.966 rs11643207 ENSG00000261783.1 RP11-252K23.2 -7.63 2.37e-12 6.8e-09 -0.64 -0.53 Dupuytren's disease; chr16:75464895 chr16:75379818~75381260:- PAAD cis rs321358 1 rs321366 ENSG00000271584.1 RP11-89C3.4 7.63 2.39e-12 6.84e-09 0.69 0.53 Body mass index; chr11:111128003 chr11:111091932~111097357:- PAAD cis rs1799949 0.965 rs8067269 ENSG00000198496.9 NBR2 -7.63 2.43e-12 6.96e-09 -0.52 -0.53 Menopause (age at onset); chr17:43083782 chr17:43125610~43153671:+ PAAD cis rs3091242 0.933 rs4649084 ENSG00000261349.1 RP3-465N24.5 -7.63 2.44e-12 6.99e-09 -0.65 -0.53 Erythrocyte sedimentation rate; chr1:25426126 chr1:25266102~25267136:- PAAD cis rs55794721 0.509 rs11249248 ENSG00000261349.1 RP3-465N24.5 -7.63 2.44e-12 6.99e-09 -0.65 -0.53 Mean corpuscular volume;Plateletcrit; chr1:25426560 chr1:25266102~25267136:- PAAD cis rs8040855 0.599 rs4577058 ENSG00000259295.5 CSPG4P12 -7.62 2.46e-12 7.04e-09 -0.57 -0.53 Bulimia nervosa; chr15:85183227 chr15:85191438~85213905:+ PAAD cis rs8040855 0.599 rs1964724 ENSG00000259295.5 CSPG4P12 -7.62 2.46e-12 7.04e-09 -0.57 -0.53 Bulimia nervosa; chr15:85183269 chr15:85191438~85213905:+ PAAD cis rs8040855 0.599 rs6496800 ENSG00000259295.5 CSPG4P12 -7.62 2.46e-12 7.04e-09 -0.57 -0.53 Bulimia nervosa; chr15:85185055 chr15:85191438~85213905:+ PAAD cis rs1799949 0.965 rs8071278 ENSG00000198496.9 NBR2 -7.62 2.5e-12 7.13e-09 -0.53 -0.53 Menopause (age at onset); chr17:43041893 chr17:43125610~43153671:+ PAAD cis rs11155671 0.53 rs9968871 ENSG00000231760.4 RP11-350J20.5 7.62 2.52e-12 7.2e-09 0.7 0.53 Testicular germ cell tumor; chr6:149888060 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs9969044 ENSG00000231760.4 RP11-350J20.5 7.62 2.52e-12 7.2e-09 0.7 0.53 Testicular germ cell tumor; chr6:149888068 chr6:149796151~149826294:- PAAD cis rs11118620 0.853 rs11118622 ENSG00000272823.1 RP11-295M18.6 7.62 2.53e-12 7.21e-09 0.64 0.53 Heart failure; chr1:220868833 chr1:220828676~220829211:- PAAD cis rs9322193 0.567 rs7742692 ENSG00000231760.4 RP11-350J20.5 7.62 2.54e-12 7.23e-09 0.69 0.53 Lung cancer; chr6:149892363 chr6:149796151~149826294:- PAAD cis rs11690935 0.851 rs7573003 ENSG00000228389.1 AC068039.4 7.62 2.55e-12 7.25e-09 0.65 0.53 Schizophrenia; chr2:171884905 chr2:171773482~171775844:+ PAAD cis rs11690935 0.885 rs10202823 ENSG00000228389.1 AC068039.4 7.62 2.55e-12 7.25e-09 0.65 0.53 Schizophrenia; chr2:171923622 chr2:171773482~171775844:+ PAAD cis rs2739330 0.652 rs2000469 ENSG00000099984.9 GSTT2 -7.62 2.59e-12 7.37e-09 -0.72 -0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23980123~23983911:+ PAAD cis rs977987 0.835 rs4888380 ENSG00000261783.1 RP11-252K23.2 -7.61 2.63e-12 7.47e-09 -0.66 -0.53 Dupuytren's disease; chr16:75313792 chr16:75379818~75381260:- PAAD cis rs977987 0.835 rs8057535 ENSG00000261783.1 RP11-252K23.2 -7.61 2.63e-12 7.47e-09 -0.66 -0.53 Dupuytren's disease; chr16:75314043 chr16:75379818~75381260:- PAAD cis rs977987 0.8 rs12922951 ENSG00000261783.1 RP11-252K23.2 -7.61 2.63e-12 7.47e-09 -0.66 -0.53 Dupuytren's disease; chr16:75321198 chr16:75379818~75381260:- PAAD cis rs7829975 0.627 rs876954 ENSG00000253893.2 FAM85B -7.61 2.68e-12 7.6e-09 -0.71 -0.53 Mood instability; chr8:8453413 chr8:8167819~8226614:- PAAD cis rs3931020 0.745 rs10874274 ENSG00000272864.1 RP11-17E13.2 -7.61 2.72e-12 7.72e-09 -0.63 -0.53 Resistin levels; chr1:74786450 chr1:74698769~74699333:- PAAD cis rs1799949 0.86 rs8176279 ENSG00000198496.9 NBR2 -7.61 2.72e-12 7.73e-09 -0.52 -0.53 Menopause (age at onset); chr17:43058379 chr17:43125610~43153671:+ PAAD cis rs494459 0.838 rs632124 ENSG00000255239.1 AP002954.6 7.61 2.73e-12 7.76e-09 0.62 0.53 Height; chr11:118742526 chr11:118688039~118690600:- PAAD cis rs11690935 0.921 rs7594711 ENSG00000228389.1 AC068039.4 7.61 2.75e-12 7.78e-09 0.65 0.53 Schizophrenia; chr2:172030734 chr2:171773482~171775844:+ PAAD cis rs3091242 0.809 rs660129 ENSG00000261349.1 RP3-465N24.5 -7.61 2.75e-12 7.78e-09 -0.64 -0.53 Erythrocyte sedimentation rate; chr1:25400947 chr1:25266102~25267136:- PAAD cis rs3091242 0.728 rs706845 ENSG00000261349.1 RP3-465N24.5 -7.61 2.75e-12 7.78e-09 -0.64 -0.53 Erythrocyte sedimentation rate; chr1:25404222 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs28633797 ENSG00000261349.1 RP3-465N24.5 -7.61 2.75e-12 7.78e-09 -0.64 -0.53 Erythrocyte sedimentation rate; chr1:25415138 chr1:25266102~25267136:- PAAD cis rs55794721 0.509 rs2982358 ENSG00000261349.1 RP3-465N24.5 -7.61 2.75e-12 7.78e-09 -0.64 -0.53 Mean corpuscular volume;Plateletcrit; chr1:25418713 chr1:25266102~25267136:- PAAD cis rs9399135 0.773 rs949895 ENSG00000232876.1 CTA-212D2.2 -7.6 2.79e-12 7.89e-09 -0.62 -0.52 Red blood cell count; chr6:135084221 chr6:135055033~135060550:+ PAAD cis rs494459 0.838 rs555639 ENSG00000255239.1 AP002954.6 -7.6 2.84e-12 8.05e-09 -0.62 -0.52 Height; chr11:118758322 chr11:118688039~118690600:- PAAD cis rs17507216 0.718 rs4779034 ENSG00000278603.1 RP13-608F4.5 7.6 2.88e-12 8.14e-09 0.87 0.52 Excessive daytime sleepiness; chr15:82576799 chr15:82472203~82472426:+ PAAD cis rs17507216 0.671 rs28582623 ENSG00000278603.1 RP13-608F4.5 7.6 2.88e-12 8.14e-09 0.87 0.52 Excessive daytime sleepiness; chr15:82577381 chr15:82472203~82472426:+ PAAD cis rs765787 0.505 rs1648302 ENSG00000259520.4 CTD-2651B20.3 7.59 2.92e-12 8.26e-09 0.64 0.52 Uric acid levels; chr15:45202040 chr15:45251580~45279251:- PAAD cis rs977987 0.806 rs4887818 ENSG00000261783.1 RP11-252K23.2 -7.59 2.94e-12 8.29e-09 -0.66 -0.52 Dupuytren's disease; chr16:75328097 chr16:75379818~75381260:- PAAD cis rs7714584 1 rs59531858 ENSG00000197083.10 ZNF300P1 7.59 2.94e-12 8.3e-09 0.94 0.52 Crohn's disease; chr5:150867501 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs12656538 ENSG00000197083.10 ZNF300P1 7.59 2.94e-12 8.3e-09 0.94 0.52 Crohn's disease; chr5:150871818 chr5:150930645~150946289:- PAAD cis rs172166 0.538 rs149956 ENSG00000216901.1 AL022393.7 7.59 2.96e-12 8.34e-09 0.66 0.52 Cardiac Troponin-T levels; chr6:28068473 chr6:28176188~28176674:+ PAAD cis rs7301826 0.651 rs7956851 ENSG00000256299.1 RP11-989F5.3 -7.59 2.96e-12 8.37e-09 -0.58 -0.52 Plasma plasminogen activator levels; chr12:130834554 chr12:130810821~130812622:- PAAD cis rs9326248 0.515 rs2727793 ENSG00000254851.1 RP11-109L13.1 -7.59 2.99e-12 8.43e-09 -0.75 -0.52 Blood protein levels; chr11:116812658 chr11:117135528~117138582:+ PAAD cis rs2919917 1 rs1441438 ENSG00000254352.1 RP11-578O24.2 -7.59 3.01e-12 8.49e-09 -0.55 -0.52 Lymphocyte counts; chr8:78729534 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs894221 ENSG00000254352.1 RP11-578O24.2 -7.59 3.01e-12 8.49e-09 -0.55 -0.52 Lymphocyte counts; chr8:78736822 chr8:78723796~78724136:- PAAD cis rs11155671 0.53 rs1334510 ENSG00000231760.4 RP11-350J20.5 7.59 3.01e-12 8.5e-09 0.69 0.52 Testicular germ cell tumor; chr6:149880043 chr6:149796151~149826294:- PAAD cis rs12220777 1 rs72644213 ENSG00000230091.5 TMEM254-AS1 7.59 3.03e-12 8.53e-09 0.9 0.52 Chronic obstructive pulmonary disease-related biomarkers; chr10:80023904 chr10:80046860~80078912:- PAAD cis rs17507216 0.718 rs72753931 ENSG00000278603.1 RP13-608F4.5 7.58 3.14e-12 8.84e-09 0.87 0.52 Excessive daytime sleepiness; chr15:82721485 chr15:82472203~82472426:+ PAAD cis rs3091242 0.935 rs3093632 ENSG00000261349.1 RP3-465N24.5 -7.58 3.16e-12 8.89e-09 -0.65 -0.52 Erythrocyte sedimentation rate; chr1:25357521 chr1:25266102~25267136:- PAAD cis rs9322193 0.566 rs5024811 ENSG00000231760.4 RP11-350J20.5 -7.58 3.16e-12 8.89e-09 -0.74 -0.52 Lung cancer; chr6:149924898 chr6:149796151~149826294:- PAAD cis rs1799949 0.894 rs36062488 ENSG00000198496.9 NBR2 7.58 3.16e-12 8.9e-09 0.53 0.52 Menopause (age at onset); chr17:43185455 chr17:43125610~43153671:+ PAAD cis rs172166 0.585 rs149963 ENSG00000216901.1 AL022393.7 7.58 3.16e-12 8.9e-09 0.66 0.52 Cardiac Troponin-T levels; chr6:28049354 chr6:28176188~28176674:+ PAAD cis rs3091242 0.967 rs3091240 ENSG00000261349.1 RP3-465N24.5 -7.58 3.17e-12 8.92e-09 -0.65 -0.52 Erythrocyte sedimentation rate; chr1:25350444 chr1:25266102~25267136:- PAAD cis rs7684253 0.565 rs7697176 ENSG00000269949.1 RP11-738E22.3 -7.58 3.18e-12 8.93e-09 -0.68 -0.52 Migraine; chr4:56956882 chr4:56960927~56961373:- PAAD cis rs7684253 0.565 rs7680140 ENSG00000269949.1 RP11-738E22.3 -7.58 3.18e-12 8.93e-09 -0.68 -0.52 Migraine; chr4:56957291 chr4:56960927~56961373:- PAAD cis rs7684253 0.565 rs6830774 ENSG00000269949.1 RP11-738E22.3 -7.58 3.18e-12 8.94e-09 -0.68 -0.52 Migraine; chr4:56950140 chr4:56960927~56961373:- PAAD cis rs7208859 0.573 rs8070182 ENSG00000263531.1 RP13-753N3.1 7.58 3.19e-12 8.95e-09 0.96 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30863921~30864940:- PAAD cis rs9399135 0.684 rs1135205 ENSG00000232876.1 CTA-212D2.2 -7.58 3.19e-12 8.98e-09 -0.64 -0.52 Red blood cell count; chr6:134960657 chr6:135055033~135060550:+ PAAD cis rs6597981 0.675 rs1138714 ENSG00000279672.1 CMB9-55F22.1 7.58 3.23e-12 9.07e-09 0.51 0.52 Breast cancer; chr11:825110 chr11:779617~780755:+ PAAD cis rs8062405 0.723 rs35175818 ENSG00000259982.1 CDC37P1 7.58 3.24e-12 9.09e-09 0.63 0.52 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597425 chr16:28700294~28701540:- PAAD cis rs3091242 1 rs3091242 ENSG00000261349.1 RP3-465N24.5 -7.58 3.25e-12 9.12e-09 -0.64 -0.52 Erythrocyte sedimentation rate; chr1:25348294 chr1:25266102~25267136:- PAAD cis rs1799949 0.965 rs7223952 ENSG00000198496.9 NBR2 -7.57 3.29e-12 9.22e-09 -0.53 -0.52 Menopause (age at onset); chr17:43042868 chr17:43125610~43153671:+ PAAD cis rs2919917 1 rs1026920 ENSG00000254352.1 RP11-578O24.2 7.57 3.32e-12 9.32e-09 0.55 0.52 Lymphocyte counts; chr8:78719775 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs2717538 ENSG00000254352.1 RP11-578O24.2 7.57 3.32e-12 9.32e-09 0.55 0.52 Lymphocyte counts; chr8:78720914 chr8:78723796~78724136:- PAAD cis rs2919917 0.915 rs2046339 ENSG00000254352.1 RP11-578O24.2 7.57 3.32e-12 9.32e-09 0.55 0.52 Lymphocyte counts; chr8:78724283 chr8:78723796~78724136:- PAAD cis rs2455601 0.786 rs2568068 ENSG00000254860.4 TMEM9B-AS1 7.57 3.32e-12 9.32e-09 0.65 0.52 Schizophrenia; chr11:8956283 chr11:8964675~8977527:+ PAAD cis rs3096299 0.559 rs9931073 ENSG00000274627.1 RP11-104N10.2 7.57 3.41e-12 9.55e-09 0.45 0.52 Multiple myeloma (IgH translocation); chr16:89502105 chr16:89516797~89522217:+ PAAD cis rs494459 0.838 rs581045 ENSG00000255239.1 AP002954.6 7.56 3.47e-12 9.7e-09 0.62 0.52 Height; chr11:118761813 chr11:118688039~118690600:- PAAD cis rs1799949 0.965 rs4239149 ENSG00000198496.9 NBR2 7.56 3.57e-12 9.97e-09 0.53 0.52 Menopause (age at onset); chr17:43176078 chr17:43125610~43153671:+ PAAD cis rs1062177 1 rs1062177 ENSG00000213433.5 RPLP1P6 -7.56 3.59e-12 1e-08 -0.61 -0.52 Preschool internalizing problems; chr5:151805140 chr5:151765859~151766378:- PAAD cis rs7104764 0.917 rs3825075 ENSG00000277290.1 RP11-326C3.16 7.56 3.6e-12 1e-08 0.46 0.52 Menarche (age at onset); chr11:217140 chr11:243099~243483:- PAAD cis rs1062177 1 rs2964585 ENSG00000213433.5 RPLP1P6 -7.55 3.7e-12 1.03e-08 -0.61 -0.52 Preschool internalizing problems; chr5:151762334 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2964578 ENSG00000213433.5 RPLP1P6 -7.55 3.7e-12 1.03e-08 -0.61 -0.52 Preschool internalizing problems; chr5:151767637 chr5:151765859~151766378:- PAAD cis rs1062177 0.951 rs2915876 ENSG00000213433.5 RPLP1P6 -7.55 3.7e-12 1.03e-08 -0.61 -0.52 Preschool internalizing problems; chr5:151771184 chr5:151765859~151766378:- PAAD cis rs1062177 0.95 rs892005 ENSG00000213433.5 RPLP1P6 -7.55 3.7e-12 1.03e-08 -0.61 -0.52 Preschool internalizing problems; chr5:151801060 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs973529 ENSG00000213433.5 RPLP1P6 -7.55 3.7e-12 1.03e-08 -0.61 -0.52 Preschool internalizing problems; chr5:151808597 chr5:151765859~151766378:- PAAD cis rs3096299 0.563 rs4600467 ENSG00000274627.1 RP11-104N10.2 7.55 3.76e-12 1.05e-08 0.45 0.52 Multiple myeloma (IgH translocation); chr16:89496108 chr16:89516797~89522217:+ PAAD cis rs3091242 0.933 rs11802413 ENSG00000261349.1 RP3-465N24.5 7.55 3.79e-12 1.06e-08 0.66 0.52 Erythrocyte sedimentation rate; chr1:25434429 chr1:25266102~25267136:- PAAD cis rs11673344 0.734 rs1234250 ENSG00000226686.6 LINC01535 -7.55 3.8e-12 1.06e-08 -0.68 -0.52 Obesity-related traits; chr19:37199518 chr19:37251912~37265535:+ PAAD cis rs9481169 0.85 rs35815577 ENSG00000255389.1 C6orf3 -7.55 3.8e-12 1.06e-08 -0.98 -0.52 Inflammatory skin disease; chr6:111603527 chr6:111599875~111602295:+ PAAD cis rs977987 0.843 rs11860231 ENSG00000261783.1 RP11-252K23.2 -7.55 3.81e-12 1.06e-08 -0.66 -0.52 Dupuytren's disease; chr16:75351261 chr16:75379818~75381260:- PAAD cis rs7208859 0.573 rs73267873 ENSG00000263531.1 RP13-753N3.1 7.55 3.82e-12 1.06e-08 0.95 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741439 chr17:30863921~30864940:- PAAD cis rs17826219 0.561 rs4085382 ENSG00000263531.1 RP13-753N3.1 7.55 3.82e-12 1.06e-08 0.95 0.52 Body mass index; chr17:30744184 chr17:30863921~30864940:- PAAD cis rs1062177 1 rs17804178 ENSG00000213433.5 RPLP1P6 -7.54 3.96e-12 1.1e-08 -0.61 -0.52 Preschool internalizing problems; chr5:151818168 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs2964612 ENSG00000213433.5 RPLP1P6 -7.54 3.96e-12 1.1e-08 -0.61 -0.52 Preschool internalizing problems; chr5:151819189 chr5:151765859~151766378:- PAAD cis rs9322193 0.543 rs9371533 ENSG00000231760.4 RP11-350J20.5 7.54 3.98e-12 1.1e-08 0.68 0.52 Lung cancer; chr6:149889545 chr6:149796151~149826294:- PAAD cis rs9322193 0.607 rs4869755 ENSG00000231760.4 RP11-350J20.5 7.54 4e-12 1.11e-08 0.77 0.52 Lung cancer; chr6:149886347 chr6:149796151~149826294:- PAAD cis rs9322193 0.639 rs4869756 ENSG00000231760.4 RP11-350J20.5 7.54 4e-12 1.11e-08 0.77 0.52 Lung cancer; chr6:149886360 chr6:149796151~149826294:- PAAD cis rs8040855 0.599 rs2342123 ENSG00000259295.5 CSPG4P12 7.54 4.02e-12 1.12e-08 0.57 0.52 Bulimia nervosa; chr15:85181918 chr15:85191438~85213905:+ PAAD cis rs11155671 0.53 rs6557133 ENSG00000231760.4 RP11-350J20.5 7.54 4.05e-12 1.12e-08 0.7 0.52 Testicular germ cell tumor; chr6:149874248 chr6:149796151~149826294:- PAAD cis rs67180937 0.844 rs35626308 ENSG00000272750.1 RP11-378J18.8 -7.54 4.05e-12 1.12e-08 -0.55 -0.52 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222643014 chr1:222658867~222661512:- PAAD cis rs3091242 0.933 rs7541095 ENSG00000261349.1 RP3-465N24.5 -7.54 4.05e-12 1.12e-08 -0.65 -0.52 Erythrocyte sedimentation rate; chr1:25434800 chr1:25266102~25267136:- PAAD cis rs11673344 0.526 rs8101610 ENSG00000226686.6 LINC01535 -7.53 4.09e-12 1.13e-08 -0.68 -0.52 Obesity-related traits; chr19:37566604 chr19:37251912~37265535:+ PAAD cis rs507080 0.922 rs654792 ENSG00000255422.1 AP002954.4 7.53 4.12e-12 1.14e-08 0.6 0.52 Serum metabolite levels; chr11:118682287 chr11:118704607~118750263:+ PAAD cis rs3091242 0.934 rs686631 ENSG00000261349.1 RP3-465N24.5 -7.53 4.19e-12 1.16e-08 -0.63 -0.52 Erythrocyte sedimentation rate; chr1:25393108 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs909833 ENSG00000261349.1 RP3-465N24.5 -7.53 4.21e-12 1.16e-08 -0.65 -0.52 Erythrocyte sedimentation rate; chr1:25427649 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs9438904 ENSG00000261349.1 RP3-465N24.5 -7.53 4.21e-12 1.16e-08 -0.65 -0.52 Erythrocyte sedimentation rate; chr1:25430369 chr1:25266102~25267136:- PAAD cis rs494459 0.838 rs2510897 ENSG00000255239.1 AP002954.6 7.53 4.28e-12 1.18e-08 0.62 0.52 Height; chr11:118773873 chr11:118688039~118690600:- PAAD cis rs11155671 0.53 rs9397420 ENSG00000231760.4 RP11-350J20.5 -7.53 4.3e-12 1.19e-08 -0.68 -0.52 Testicular germ cell tumor; chr6:149885645 chr6:149796151~149826294:- PAAD cis rs7829975 0.509 rs2945269 ENSG00000253893.2 FAM85B -7.52 4.32e-12 1.19e-08 -0.73 -0.52 Mood instability; chr8:8258056 chr8:8167819~8226614:- PAAD cis rs4423214 0.879 rs1790345 ENSG00000254682.1 RP11-660L16.2 -7.52 4.33e-12 1.19e-08 -0.74 -0.52 Vitamin D levels; chr11:71434895 chr11:71448674~71452157:+ PAAD cis rs4423214 0.879 rs1790330 ENSG00000254682.1 RP11-660L16.2 -7.52 4.33e-12 1.19e-08 -0.74 -0.52 Vitamin D levels; chr11:71436779 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1790328 ENSG00000254682.1 RP11-660L16.2 -7.52 4.33e-12 1.19e-08 -0.74 -0.52 Vitamin D levels; chr11:71436992 chr11:71448674~71452157:+ PAAD cis rs4423214 0.879 rs1792264 ENSG00000254682.1 RP11-660L16.2 -7.52 4.33e-12 1.19e-08 -0.74 -0.52 Vitamin D levels; chr11:71439201 chr11:71448674~71452157:+ PAAD cis rs4423214 0.879 rs1630498 ENSG00000254682.1 RP11-660L16.2 -7.52 4.33e-12 1.19e-08 -0.74 -0.52 Vitamin D levels; chr11:71439739 chr11:71448674~71452157:+ PAAD cis rs7208859 0.725 rs7210904 ENSG00000263531.1 RP13-753N3.1 7.52 4.4e-12 1.21e-08 0.94 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843187 chr17:30863921~30864940:- PAAD cis rs7208859 0.725 rs9915802 ENSG00000263531.1 RP13-753N3.1 7.52 4.4e-12 1.21e-08 0.94 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846040 chr17:30863921~30864940:- PAAD cis rs7208859 0.725 rs7342938 ENSG00000263531.1 RP13-753N3.1 7.52 4.4e-12 1.21e-08 0.94 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862812 chr17:30863921~30864940:- PAAD cis rs7208859 0.725 rs6505215 ENSG00000263531.1 RP13-753N3.1 7.52 4.4e-12 1.21e-08 0.94 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862885 chr17:30863921~30864940:- PAAD cis rs5850 0.55 rs76983703 ENSG00000230658.1 KLHL7-AS1 7.52 4.4e-12 1.21e-08 0.77 0.52 Blood protein levels; chr7:23337094 chr7:23101228~23105703:- PAAD cis rs2739330 0.892 rs5751776 ENSG00000250470.1 AP000351.3 7.52 4.41e-12 1.22e-08 0.73 0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23976904~23977585:- PAAD cis rs7429990 0.965 rs4858887 ENSG00000229759.1 MRPS18AP1 -7.52 4.46e-12 1.23e-08 -0.56 -0.52 Educational attainment (years of education); chr3:48050527 chr3:48256350~48256938:- PAAD cis rs9322193 0.607 rs12527391 ENSG00000231760.4 RP11-350J20.5 7.52 4.47e-12 1.23e-08 0.77 0.52 Lung cancer; chr6:149882156 chr6:149796151~149826294:- PAAD cis rs9326248 0.559 rs573549 ENSG00000254851.1 RP11-109L13.1 -7.52 4.51e-12 1.24e-08 -0.68 -0.52 Blood protein levels; chr11:116865963 chr11:117135528~117138582:+ PAAD cis rs1062177 0.826 rs2915879 ENSG00000213433.5 RPLP1P6 -7.52 4.51e-12 1.24e-08 -0.59 -0.52 Preschool internalizing problems; chr5:151767881 chr5:151765859~151766378:- PAAD cis rs2919917 1 rs2369440 ENSG00000254352.1 RP11-578O24.2 7.52 4.52e-12 1.24e-08 0.54 0.52 Lymphocyte counts; chr8:78709474 chr8:78723796~78724136:- PAAD cis rs7429990 0.864 rs6777081 ENSG00000229759.1 MRPS18AP1 -7.51 4.56e-12 1.25e-08 -0.56 -0.52 Educational attainment (years of education); chr3:48114079 chr3:48256350~48256938:- PAAD cis rs3091242 0.933 rs9438905 ENSG00000261349.1 RP3-465N24.5 -7.51 4.64e-12 1.28e-08 -0.65 -0.52 Erythrocyte sedimentation rate; chr1:25437686 chr1:25266102~25267136:- PAAD cis rs3091242 0.935 rs4233043 ENSG00000261349.1 RP3-465N24.5 -7.51 4.65e-12 1.28e-08 -0.65 -0.52 Erythrocyte sedimentation rate; chr1:25438992 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs11249250 ENSG00000261349.1 RP3-465N24.5 -7.51 4.65e-12 1.28e-08 -0.65 -0.52 Erythrocyte sedimentation rate; chr1:25441118 chr1:25266102~25267136:- PAAD cis rs5760092 0.842 rs5751763 ENSG00000218537.1 MIF-AS1 7.51 4.66e-12 1.28e-08 0.89 0.52 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23905606 chr22:23894426~23898930:- PAAD cis rs9399137 0.507 rs4896118 ENSG00000232876.1 CTA-212D2.2 7.51 4.71e-12 1.29e-08 0.63 0.52 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954927 chr6:135055033~135060550:+ PAAD cis rs7684253 0.565 rs12641030 ENSG00000269949.1 RP11-738E22.3 -7.51 4.74e-12 1.3e-08 -0.67 -0.52 Migraine; chr4:56937339 chr4:56960927~56961373:- PAAD cis rs977987 0.806 rs35683383 ENSG00000261783.1 RP11-252K23.2 -7.51 4.78e-12 1.31e-08 -0.64 -0.52 Dupuytren's disease; chr16:75445379 chr16:75379818~75381260:- PAAD cis rs9322193 0.607 rs7764677 ENSG00000231760.4 RP11-350J20.5 7.5 4.88e-12 1.34e-08 0.74 0.52 Lung cancer; chr6:149906197 chr6:149796151~149826294:- PAAD cis rs321358 0.895 rs7131434 ENSG00000271584.1 RP11-89C3.4 7.5 4.89e-12 1.34e-08 0.65 0.52 Body mass index; chr11:111085693 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs73015175 ENSG00000271584.1 RP11-89C3.4 7.5 4.89e-12 1.34e-08 0.65 0.52 Body mass index; chr11:111088593 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs17536143 ENSG00000271584.1 RP11-89C3.4 7.5 4.89e-12 1.34e-08 0.65 0.52 Body mass index; chr11:111088619 chr11:111091932~111097357:- PAAD cis rs321358 0.895 rs12419745 ENSG00000271584.1 RP11-89C3.4 7.5 4.89e-12 1.34e-08 0.65 0.52 Body mass index; chr11:111090741 chr11:111091932~111097357:- PAAD cis rs881375 0.967 rs1548783 ENSG00000226752.6 PSMD5-AS1 -7.5 4.9e-12 1.34e-08 -0.61 -0.52 Rheumatoid arthritis; chr9:120896361 chr9:120824828~120854385:+ PAAD cis rs6700559 1 rs4311922 ENSG00000260088.1 RP11-92G12.3 -7.5 4.97e-12 1.36e-08 -0.7 -0.52 Coronary artery disease; chr1:200674257 chr1:200669507~200694250:+ PAAD cis rs6700559 0.967 rs4447009 ENSG00000260088.1 RP11-92G12.3 -7.5 4.97e-12 1.36e-08 -0.7 -0.52 Coronary artery disease; chr1:200674278 chr1:200669507~200694250:+ PAAD cis rs6700559 1 rs4265457 ENSG00000260088.1 RP11-92G12.3 -7.5 4.97e-12 1.36e-08 -0.7 -0.52 Coronary artery disease; chr1:200674326 chr1:200669507~200694250:+ PAAD cis rs2882667 0.929 rs17207828 ENSG00000253404.1 AC034243.1 7.5 4.98e-12 1.36e-08 0.63 0.52 Age-related hearing impairment (SNP x SNP interaction); chr5:138964146 chr5:138744434~138753309:- PAAD cis rs67180937 0.921 rs17163360 ENSG00000272750.1 RP11-378J18.8 -7.5 5.06e-12 1.38e-08 -0.55 -0.52 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647448 chr1:222658867~222661512:- PAAD cis rs7301826 1 rs1609985 ENSG00000256250.1 RP11-989F5.1 -7.49 5.11e-12 1.4e-08 -0.6 -0.52 Plasma plasminogen activator levels; chr12:130835625 chr12:130810606~130812438:+ PAAD cis rs7826238 0.509 rs2948288 ENSG00000253893.2 FAM85B -7.49 5.12e-12 1.4e-08 -0.73 -0.52 Systolic blood pressure; chr8:8257782 chr8:8167819~8226614:- PAAD cis rs35160687 0.862 rs12476706 ENSG00000273080.1 RP11-301O19.1 7.49 5.15e-12 1.41e-08 0.62 0.52 Night sleep phenotypes; chr2:86301247 chr2:86195590~86196049:+ PAAD cis rs1062177 1 rs2016409 ENSG00000213433.5 RPLP1P6 7.49 5.21e-12 1.42e-08 0.6 0.52 Preschool internalizing problems; chr5:151746763 chr5:151765859~151766378:- PAAD cis rs2980439 0.807 rs2980438 ENSG00000253893.2 FAM85B -7.48 5.39e-12 1.47e-08 -0.73 -0.52 Neuroticism; chr8:8237303 chr8:8167819~8226614:- PAAD cis rs2739330 0.929 rs5751775 ENSG00000250470.1 AP000351.3 7.48 5.44e-12 1.48e-08 0.73 0.52 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23976904~23977585:- PAAD cis rs11690935 0.959 rs6738445 ENSG00000228389.1 AC068039.4 -7.48 5.52e-12 1.5e-08 -0.66 -0.52 Schizophrenia; chr2:171743105 chr2:171773482~171775844:+ PAAD cis rs7714584 1 rs58717741 ENSG00000197083.10 ZNF300P1 7.48 5.54e-12 1.51e-08 0.9 0.52 Crohn's disease; chr5:150905374 chr5:150930645~150946289:- PAAD cis rs7104764 0.833 rs12574034 ENSG00000277290.1 RP11-326C3.16 7.48 5.55e-12 1.51e-08 0.46 0.52 Menarche (age at onset); chr11:212262 chr11:243099~243483:- PAAD cis rs977987 0.843 rs28558946 ENSG00000261783.1 RP11-252K23.2 -7.48 5.63e-12 1.53e-08 -0.64 -0.52 Dupuytren's disease; chr16:75455424 chr16:75379818~75381260:- PAAD cis rs3091242 1 rs9689 ENSG00000261349.1 RP3-465N24.5 -7.48 5.63e-12 1.53e-08 -0.62 -0.52 Erythrocyte sedimentation rate; chr1:25361785 chr1:25266102~25267136:- PAAD cis rs55794721 0.543 rs1293260 ENSG00000261349.1 RP3-465N24.5 -7.48 5.65e-12 1.53e-08 -0.64 -0.52 Mean corpuscular volume;Plateletcrit; chr1:25382613 chr1:25266102~25267136:- PAAD cis rs9322193 0.607 rs9371228 ENSG00000231760.4 RP11-350J20.5 -7.47 5.73e-12 1.55e-08 -0.75 -0.52 Lung cancer; chr6:149921977 chr6:149796151~149826294:- PAAD cis rs9322193 0.566 rs4870118 ENSG00000231760.4 RP11-350J20.5 -7.47 5.73e-12 1.55e-08 -0.75 -0.52 Lung cancer; chr6:149923877 chr6:149796151~149826294:- PAAD cis rs9322193 0.566 rs4869767 ENSG00000231760.4 RP11-350J20.5 -7.47 5.73e-12 1.55e-08 -0.75 -0.52 Lung cancer; chr6:149923974 chr6:149796151~149826294:- PAAD cis rs9322193 0.566 rs4869768 ENSG00000231760.4 RP11-350J20.5 -7.47 5.73e-12 1.55e-08 -0.75 -0.52 Lung cancer; chr6:149924067 chr6:149796151~149826294:- PAAD cis rs7301826 0.934 rs10848212 ENSG00000256250.1 RP11-989F5.1 7.47 5.76e-12 1.56e-08 0.61 0.52 Plasma plasminogen activator levels; chr12:130837455 chr12:130810606~130812438:+ PAAD cis rs59482735 1 rs59482735 ENSG00000226752.6 PSMD5-AS1 -7.47 5.79e-12 1.57e-08 -0.59 -0.52 Prostate-specific antigen levels; chr9:120881148 chr9:120824828~120854385:+ PAAD cis rs7188445 0.592 rs7199794 ENSG00000261390.4 RP11-345M22.2 7.47 5.82e-12 1.57e-08 0.7 0.52 Urate levels; chr16:79708296 chr16:79715232~79770563:- PAAD cis rs977987 0.835 rs3851734 ENSG00000261783.1 RP11-252K23.2 -7.47 5.89e-12 1.59e-08 -0.65 -0.52 Dupuytren's disease; chr16:75338022 chr16:75379818~75381260:- PAAD cis rs11690935 0.851 rs7581072 ENSG00000228389.1 AC068039.4 7.47 5.96e-12 1.61e-08 0.65 0.52 Schizophrenia; chr2:171994938 chr2:171773482~171775844:+ PAAD cis rs10256972 0.521 rs7457418 ENSG00000229043.2 AC091729.9 -7.47 5.99e-12 1.62e-08 -0.52 -0.52 Endometriosis;Longevity; chr7:1070619 chr7:1160374~1165267:+ PAAD cis rs2919917 0.915 rs2953477 ENSG00000254352.1 RP11-578O24.2 7.46 6.26e-12 1.69e-08 0.55 0.52 Lymphocyte counts; chr8:78712370 chr8:78723796~78724136:- PAAD cis rs3091242 0.804 rs631133 ENSG00000261349.1 RP3-465N24.5 -7.45 6.38e-12 1.72e-08 -0.63 -0.52 Erythrocyte sedimentation rate; chr1:25397655 chr1:25266102~25267136:- PAAD cis rs55720021 1 rs55720021 ENSG00000232871.7 SEC1P 7.45 6.55e-12 1.76e-08 0.75 0.52 Neutrophil percentage of white cells;Lymphocyte percentage of white cells; chr19:48640984 chr19:48638071~48682245:+ PAAD cis rs507080 0.922 rs478296 ENSG00000255422.1 AP002954.4 -7.45 6.61e-12 1.78e-08 -0.62 -0.52 Serum metabolite levels; chr11:118696666 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs493834 ENSG00000255422.1 AP002954.4 -7.45 6.61e-12 1.78e-08 -0.62 -0.52 Serum metabolite levels; chr11:118696735 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs644498 ENSG00000255422.1 AP002954.4 -7.45 6.61e-12 1.78e-08 -0.62 -0.52 Serum metabolite levels; chr11:118696777 chr11:118704607~118750263:+ PAAD cis rs977987 0.806 rs2161684 ENSG00000261783.1 RP11-252K23.2 -7.45 6.62e-12 1.78e-08 -0.65 -0.52 Dupuytren's disease; chr16:75445255 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs34996006 ENSG00000261783.1 RP11-252K23.2 -7.45 6.62e-12 1.78e-08 -0.65 -0.52 Dupuytren's disease; chr16:75445536 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs12927562 ENSG00000261783.1 RP11-252K23.2 -7.45 6.62e-12 1.78e-08 -0.65 -0.52 Dupuytren's disease; chr16:75448962 chr16:75379818~75381260:- PAAD cis rs9399135 0.622 rs3817776 ENSG00000232876.1 CTA-212D2.2 7.45 6.62e-12 1.78e-08 0.6 0.52 Red blood cell count; chr6:134935618 chr6:135055033~135060550:+ PAAD cis rs7714584 1 rs57406211 ENSG00000197083.10 ZNF300P1 7.44 6.73e-12 1.81e-08 0.92 0.52 Crohn's disease; chr5:150791404 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs79442859 ENSG00000197083.10 ZNF300P1 7.44 6.73e-12 1.81e-08 0.92 0.52 Crohn's disease; chr5:150791648 chr5:150930645~150946289:- PAAD cis rs9322193 0.566 rs3922947 ENSG00000231760.4 RP11-350J20.5 -7.44 6.9e-12 1.85e-08 -0.74 -0.52 Lung cancer; chr6:149924856 chr6:149796151~149826294:- PAAD cis rs3091242 0.933 rs3093584 ENSG00000261349.1 RP3-465N24.5 7.44 7.03e-12 1.88e-08 0.62 0.52 Erythrocyte sedimentation rate; chr1:25342223 chr1:25266102~25267136:- PAAD cis rs3091242 0.967 rs3093614 ENSG00000261349.1 RP3-465N24.5 7.44 7.05e-12 1.89e-08 0.62 0.52 Erythrocyte sedimentation rate; chr1:25351353 chr1:25266102~25267136:- PAAD cis rs3091242 0.967 rs1053438 ENSG00000261349.1 RP3-465N24.5 7.44 7.05e-12 1.89e-08 0.62 0.52 Erythrocyte sedimentation rate; chr1:25361410 chr1:25266102~25267136:- PAAD cis rs11155671 0.53 rs9322228 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149888173 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs7774787 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149888296 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs2342767 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149888581 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs7764376 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149889208 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs6933882 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149889666 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs6939761 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149889858 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs3823021 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149889863 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs4869763 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149890548 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs4869764 ENSG00000231760.4 RP11-350J20.5 7.43 7.12e-12 1.9e-08 0.69 0.52 Testicular germ cell tumor; chr6:149890692 chr6:149796151~149826294:- PAAD cis rs977987 0.843 rs59155720 ENSG00000261783.1 RP11-252K23.2 -7.43 7.12e-12 1.9e-08 -0.65 -0.52 Dupuytren's disease; chr16:75449908 chr16:75379818~75381260:- PAAD cis rs2882667 1 rs2060222 ENSG00000253404.1 AC034243.1 7.43 7.15e-12 1.91e-08 0.64 0.52 Age-related hearing impairment (SNP x SNP interaction); chr5:138972777 chr5:138744434~138753309:- PAAD cis rs2882667 1 rs10064201 ENSG00000253404.1 AC034243.1 7.43 7.15e-12 1.91e-08 0.64 0.52 Age-related hearing impairment (SNP x SNP interaction); chr5:138973716 chr5:138744434~138753309:- PAAD cis rs977987 0.806 rs11644306 ENSG00000261783.1 RP11-252K23.2 -7.43 7.23e-12 1.93e-08 -0.63 -0.52 Dupuytren's disease; chr16:75456155 chr16:75379818~75381260:- PAAD cis rs3091242 0.967 rs665372 ENSG00000261349.1 RP3-465N24.5 -7.43 7.24e-12 1.93e-08 -0.62 -0.52 Erythrocyte sedimentation rate; chr1:25392744 chr1:25266102~25267136:- PAAD cis rs1799949 0.683 rs55737636 ENSG00000198496.9 NBR2 -7.43 7.28e-12 1.95e-08 -0.54 -0.52 Menopause (age at onset); chr17:43112722 chr17:43125610~43153671:+ PAAD cis rs9322193 0.567 rs7747457 ENSG00000231760.4 RP11-350J20.5 7.43 7.39e-12 1.97e-08 0.69 0.52 Lung cancer; chr6:149892366 chr6:149796151~149826294:- PAAD cis rs2455601 0.786 rs2568070 ENSG00000254860.4 TMEM9B-AS1 7.43 7.39e-12 1.97e-08 0.66 0.52 Schizophrenia; chr11:8955346 chr11:8964675~8977527:+ PAAD cis rs1062177 0.774 rs2964574 ENSG00000213433.5 RPLP1P6 -7.43 7.49e-12 2e-08 -0.59 -0.52 Preschool internalizing problems; chr5:151776150 chr5:151765859~151766378:- PAAD cis rs1062177 0.826 rs2053063 ENSG00000213433.5 RPLP1P6 -7.43 7.49e-12 2e-08 -0.59 -0.52 Preschool internalizing problems; chr5:151787203 chr5:151765859~151766378:- PAAD cis rs8062405 0.723 rs62031562 ENSG00000259982.1 CDC37P1 7.42 7.66e-12 2.04e-08 0.63 0.52 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28598008 chr16:28700294~28701540:- PAAD cis rs977987 0.742 rs34624768 ENSG00000261783.1 RP11-252K23.2 -7.42 7.75e-12 2.06e-08 -0.66 -0.52 Dupuytren's disease; chr16:75297674 chr16:75379818~75381260:- PAAD cis rs977987 0.8 rs4888378 ENSG00000261783.1 RP11-252K23.2 -7.42 7.75e-12 2.06e-08 -0.66 -0.52 Dupuytren's disease; chr16:75298143 chr16:75379818~75381260:- PAAD cis rs977987 0.8 rs12935787 ENSG00000261783.1 RP11-252K23.2 -7.42 7.75e-12 2.06e-08 -0.66 -0.52 Dupuytren's disease; chr16:75298437 chr16:75379818~75381260:- PAAD cis rs7714584 1 rs6874560 ENSG00000197083.10 ZNF300P1 7.42 7.75e-12 2.06e-08 0.91 0.52 Crohn's disease; chr5:150803151 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11748553 ENSG00000197083.10 ZNF300P1 7.42 7.75e-12 2.06e-08 0.91 0.52 Crohn's disease; chr5:150804991 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11746560 ENSG00000197083.10 ZNF300P1 7.42 7.75e-12 2.06e-08 0.91 0.52 Crohn's disease; chr5:150806363 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs4958422 ENSG00000197083.10 ZNF300P1 7.42 7.75e-12 2.06e-08 0.91 0.52 Crohn's disease; chr5:150807172 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs59715748 ENSG00000197083.10 ZNF300P1 7.42 7.75e-12 2.06e-08 0.91 0.52 Crohn's disease; chr5:150809725 chr5:150930645~150946289:- PAAD cis rs977987 0.843 rs10459859 ENSG00000261783.1 RP11-252K23.2 -7.42 7.9e-12 2.1e-08 -0.64 -0.52 Dupuytren's disease; chr16:75348052 chr16:75379818~75381260:- PAAD cis rs7115242 0.92 rs6589574 ENSG00000254851.1 RP11-109L13.1 -7.42 7.9e-12 2.1e-08 -0.98 -0.52 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116859922 chr11:117135528~117138582:+ PAAD cis rs35160687 0.64 rs13015186 ENSG00000273080.1 RP11-301O19.1 7.42 7.93e-12 2.11e-08 0.61 0.52 Night sleep phenotypes; chr2:86258455 chr2:86195590~86196049:+ PAAD cis rs7684253 0.565 rs13130605 ENSG00000269949.1 RP11-738E22.3 -7.41 7.95e-12 2.11e-08 -0.67 -0.52 Migraine; chr4:56943905 chr4:56960927~56961373:- PAAD cis rs35160687 0.862 rs17737955 ENSG00000273080.1 RP11-301O19.1 7.41 7.95e-12 2.11e-08 0.61 0.52 Night sleep phenotypes; chr2:86280891 chr2:86195590~86196049:+ PAAD cis rs35160687 0.862 rs13024964 ENSG00000273080.1 RP11-301O19.1 7.41 7.95e-12 2.11e-08 0.61 0.52 Night sleep phenotypes; chr2:86284745 chr2:86195590~86196049:+ PAAD cis rs9326248 0.569 rs11216161 ENSG00000254851.1 RP11-109L13.1 -7.41 8e-12 2.12e-08 -0.86 -0.52 Blood protein levels; chr11:116850485 chr11:117135528~117138582:+ PAAD cis rs2919917 1 rs13269243 ENSG00000254352.1 RP11-578O24.2 7.41 8.13e-12 2.16e-08 0.54 0.52 Lymphocyte counts; chr8:78669501 chr8:78723796~78724136:- PAAD cis rs977987 0.835 rs7200616 ENSG00000261783.1 RP11-252K23.2 -7.41 8.16e-12 2.17e-08 -0.64 -0.52 Dupuytren's disease; chr16:75332191 chr16:75379818~75381260:- PAAD cis rs35160687 0.862 rs13023154 ENSG00000273080.1 RP11-301O19.1 -7.41 8.21e-12 2.18e-08 -0.61 -0.52 Night sleep phenotypes; chr2:86289861 chr2:86195590~86196049:+ PAAD cis rs11118620 0.81 rs1603047 ENSG00000238078.1 LINC01352 7.41 8.23e-12 2.18e-08 0.55 0.52 Heart failure; chr1:220849953 chr1:220829255~220832429:+ PAAD cis rs7208859 0.623 rs7214570 ENSG00000263531.1 RP13-753N3.1 7.41 8.23e-12 2.18e-08 0.96 0.52 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30863921~30864940:- PAAD cis rs1577917 0.545 rs9294338 ENSG00000203875.9 SNHG5 7.41 8.31e-12 2.21e-08 0.65 0.51 Response to antipsychotic treatment; chr6:85764650 chr6:85660950~85678736:- PAAD cis rs7104764 1 rs6598074 ENSG00000277290.1 RP11-326C3.16 -7.41 8.35e-12 2.21e-08 -0.48 -0.51 Menarche (age at onset); chr11:219398 chr11:243099~243483:- PAAD cis rs7104764 0.879 rs6598070 ENSG00000277290.1 RP11-326C3.16 -7.41 8.35e-12 2.21e-08 -0.48 -0.51 Menarche (age at onset); chr11:225466 chr11:243099~243483:- PAAD cis rs7104764 1 rs2293167 ENSG00000277290.1 RP11-326C3.16 7.4 8.4e-12 2.23e-08 0.48 0.51 Menarche (age at onset); chr11:211644 chr11:243099~243483:- PAAD cis rs7104764 1 rs76552490 ENSG00000277290.1 RP11-326C3.16 7.4 8.4e-12 2.23e-08 0.48 0.51 Menarche (age at onset); chr11:212015 chr11:243099~243483:- PAAD cis rs7104764 1 rs1533825 ENSG00000277290.1 RP11-326C3.16 7.4 8.4e-12 2.23e-08 0.48 0.51 Menarche (age at onset); chr11:214163 chr11:243099~243483:- PAAD cis rs2455601 0.786 rs10279 ENSG00000254860.4 TMEM9B-AS1 7.4 8.41e-12 2.23e-08 0.66 0.51 Schizophrenia; chr11:8947762 chr11:8964675~8977527:+ PAAD cis rs7714584 0.826 rs12655654 ENSG00000197083.10 ZNF300P1 7.4 8.42e-12 2.23e-08 0.9 0.51 Crohn's disease; chr5:150794733 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs74955473 ENSG00000197083.10 ZNF300P1 7.4 8.42e-12 2.23e-08 0.9 0.51 Crohn's disease; chr5:150794996 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs79780973 ENSG00000197083.10 ZNF300P1 7.4 8.42e-12 2.23e-08 0.9 0.51 Crohn's disease; chr5:150795248 chr5:150930645~150946289:- PAAD cis rs2919917 1 rs11986947 ENSG00000254352.1 RP11-578O24.2 7.4 8.46e-12 2.24e-08 0.54 0.51 Lymphocyte counts; chr8:78708957 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs2717539 ENSG00000254352.1 RP11-578O24.2 7.4 8.46e-12 2.24e-08 0.54 0.51 Lymphocyte counts; chr8:78716804 chr8:78723796~78724136:- PAAD cis rs2919917 0.793 rs2625664 ENSG00000254352.1 RP11-578O24.2 7.4 8.46e-12 2.24e-08 0.54 0.51 Lymphocyte counts; chr8:78718373 chr8:78723796~78724136:- PAAD cis rs9322193 0.923 rs7769101 ENSG00000216906.2 RP11-350J20.9 7.4 8.58e-12 2.27e-08 0.67 0.51 Lung cancer; chr6:149848768 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs2342765 ENSG00000216906.2 RP11-350J20.9 7.4 8.59e-12 2.27e-08 0.67 0.51 Lung cancer; chr6:149858873 chr6:149904243~149906418:+ PAAD cis rs9322193 0.607 rs3798763 ENSG00000231760.4 RP11-350J20.5 7.4 8.62e-12 2.28e-08 0.76 0.51 Lung cancer; chr6:149889964 chr6:149796151~149826294:- PAAD cis rs2980439 0.818 rs2945249 ENSG00000253893.2 FAM85B -7.4 8.62e-12 2.28e-08 -0.74 -0.51 Neuroticism; chr8:8237204 chr8:8167819~8226614:- PAAD cis rs5760092 0.755 rs915589 ENSG00000218537.1 MIF-AS1 -7.4 8.69e-12 2.29e-08 -0.8 -0.51 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23894426~23898930:- PAAD cis rs11690935 0.851 rs6731562 ENSG00000228389.1 AC068039.4 7.4 8.78e-12 2.31e-08 0.61 0.51 Schizophrenia; chr2:171941742 chr2:171773482~171775844:+ PAAD cis rs11690935 0.851 rs10201430 ENSG00000228389.1 AC068039.4 7.4 8.78e-12 2.31e-08 0.61 0.51 Schizophrenia; chr2:171956715 chr2:171773482~171775844:+ PAAD cis rs11690935 0.851 rs6433319 ENSG00000228389.1 AC068039.4 7.4 8.78e-12 2.31e-08 0.61 0.51 Schizophrenia; chr2:171974442 chr2:171773482~171775844:+ PAAD cis rs11155671 0.53 rs9383940 ENSG00000231760.4 RP11-350J20.5 7.4 8.78e-12 2.31e-08 0.67 0.51 Testicular germ cell tumor; chr6:149904923 chr6:149796151~149826294:- PAAD cis rs1577917 0.545 rs7755958 ENSG00000203875.9 SNHG5 7.4 8.82e-12 2.32e-08 0.67 0.51 Response to antipsychotic treatment; chr6:85778793 chr6:85660950~85678736:- PAAD cis rs7714584 1 rs76872831 ENSG00000197083.10 ZNF300P1 7.39 8.9e-12 2.34e-08 0.9 0.51 Crohn's disease; chr5:150791997 chr5:150930645~150946289:- PAAD cis rs977987 0.8 rs3784935 ENSG00000261783.1 RP11-252K23.2 -7.39 8.95e-12 2.36e-08 -0.66 -0.51 Dupuytren's disease; chr16:75302532 chr16:75379818~75381260:- PAAD cis rs977987 0.8 rs11645329 ENSG00000261783.1 RP11-252K23.2 -7.39 8.95e-12 2.36e-08 -0.66 -0.51 Dupuytren's disease; chr16:75302781 chr16:75379818~75381260:- PAAD cis rs11690935 0.802 rs34636594 ENSG00000228389.1 AC068039.4 7.39 8.95e-12 2.36e-08 0.65 0.51 Schizophrenia; chr2:172046366 chr2:171773482~171775844:+ PAAD cis rs67383717 0.527 rs12004422 ENSG00000175611.10 LINC00476 7.39 8.99e-12 2.37e-08 0.48 0.51 Parkinson's disease (pesticide exposure interaction); chr9:95873393 chr9:95759231~95875977:- PAAD cis rs7615952 0.611 rs7632305 ENSG00000171084.14 FAM86JP 7.39 9.18e-12 2.41e-08 0.9 0.51 Blood pressure (smoking interaction); chr3:125915924 chr3:125916620~125930024:+ PAAD cis rs7615952 0.673 rs9841194 ENSG00000171084.14 FAM86JP 7.39 9.18e-12 2.41e-08 0.9 0.51 Blood pressure (smoking interaction); chr3:125916896 chr3:125916620~125930024:+ PAAD cis rs7615952 0.673 rs9289270 ENSG00000171084.14 FAM86JP 7.39 9.18e-12 2.41e-08 0.9 0.51 Blood pressure (smoking interaction); chr3:125918136 chr3:125916620~125930024:+ PAAD cis rs507080 0.922 rs644867 ENSG00000255422.1 AP002954.4 -7.39 9.25e-12 2.43e-08 -0.62 -0.51 Serum metabolite levels; chr11:118696836 chr11:118704607~118750263:+ PAAD cis rs11118620 1 rs11118620 ENSG00000238078.1 LINC01352 7.39 9.3e-12 2.44e-08 0.55 0.51 Heart failure; chr1:220855166 chr1:220829255~220832429:+ PAAD cis rs11118620 0.81 rs4587570 ENSG00000238078.1 LINC01352 7.39 9.3e-12 2.44e-08 0.55 0.51 Heart failure; chr1:220860693 chr1:220829255~220832429:+ PAAD cis rs997154 0.655 rs4981454 ENSG00000279656.1 RP11-298I3.6 7.39 9.35e-12 2.45e-08 0.69 0.51 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22952977 chr14:23023083~23024217:- PAAD cis rs977987 0.806 rs12933281 ENSG00000261783.1 RP11-252K23.2 -7.38 9.53e-12 2.5e-08 -0.64 -0.51 Dupuytren's disease; chr16:75449166 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs10871312 ENSG00000261783.1 RP11-252K23.2 -7.38 9.53e-12 2.5e-08 -0.64 -0.51 Dupuytren's disease; chr16:75452304 chr16:75379818~75381260:- PAAD cis rs1322639 1 rs1322639 ENSG00000261039.2 RP11-417E7.2 7.38 9.63e-12 2.52e-08 0.67 0.51 Pulse pressure; chr6:169187008 chr6:169175304~169182740:- PAAD cis rs7208859 0.725 rs9910051 ENSG00000263531.1 RP13-753N3.1 7.38 9.72e-12 2.55e-08 0.93 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834184 chr17:30863921~30864940:- PAAD cis rs8062405 0.755 rs4788076 ENSG00000259982.1 CDC37P1 7.38 9.77e-12 2.56e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558684 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs7193402 ENSG00000259982.1 CDC37P1 7.38 9.77e-12 2.56e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574806 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs62034358 ENSG00000259982.1 CDC37P1 7.38 9.77e-12 2.56e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576276 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs12445823 ENSG00000259982.1 CDC37P1 7.38 9.77e-12 2.56e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576728 chr16:28700294~28701540:- PAAD cis rs8062405 0.723 rs12445744 ENSG00000259982.1 CDC37P1 7.38 9.77e-12 2.56e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28577074 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs4787455 ENSG00000259982.1 CDC37P1 7.38 9.77e-12 2.56e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28578134 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs4788074 ENSG00000259982.1 CDC37P1 -7.38 9.77e-12 2.56e-08 -0.62 -0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582276 chr16:28700294~28701540:- PAAD cis rs3091242 0.9 rs1811832 ENSG00000261349.1 RP3-465N24.5 -7.37 9.96e-12 2.6e-08 -0.63 -0.51 Erythrocyte sedimentation rate; chr1:25427074 chr1:25266102~25267136:- PAAD cis rs11690935 0.885 rs7602037 ENSG00000228389.1 AC068039.4 7.37 9.99e-12 2.61e-08 0.63 0.51 Schizophrenia; chr2:171961268 chr2:171773482~171775844:+ PAAD cis rs11690935 0.885 rs6752812 ENSG00000228389.1 AC068039.4 7.37 9.99e-12 2.61e-08 0.63 0.51 Schizophrenia; chr2:171986588 chr2:171773482~171775844:+ PAAD cis rs11155671 0.53 rs7756850 ENSG00000231760.4 RP11-350J20.5 7.37 1.01e-11 2.64e-08 0.68 0.51 Testicular germ cell tumor; chr6:149891460 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs9371542 ENSG00000231760.4 RP11-350J20.5 7.37 1.01e-11 2.64e-08 0.68 0.51 Testicular germ cell tumor; chr6:149891949 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs9371223 ENSG00000231760.4 RP11-350J20.5 7.37 1.01e-11 2.64e-08 0.68 0.51 Testicular germ cell tumor; chr6:149893670 chr6:149796151~149826294:- PAAD cis rs8062405 0.723 rs762633 ENSG00000259982.1 CDC37P1 7.37 1.04e-11 2.72e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597020 chr16:28700294~28701540:- PAAD cis rs7301826 0.934 rs10773826 ENSG00000256250.1 RP11-989F5.1 -7.36 1.05e-11 2.73e-08 -0.6 -0.51 Plasma plasminogen activator levels; chr12:130836629 chr12:130810606~130812438:+ PAAD cis rs12220777 1 rs72644212 ENSG00000230091.5 TMEM254-AS1 7.36 1.05e-11 2.73e-08 0.89 0.51 Chronic obstructive pulmonary disease-related biomarkers; chr10:80022758 chr10:80046860~80078912:- PAAD cis rs11155671 0.53 rs2342769 ENSG00000231760.4 RP11-350J20.5 7.36 1.05e-11 2.73e-08 0.68 0.51 Testicular germ cell tumor; chr6:149895371 chr6:149796151~149826294:- PAAD cis rs11155671 0.53 rs6935829 ENSG00000231760.4 RP11-350J20.5 7.36 1.05e-11 2.73e-08 0.68 0.51 Testicular germ cell tumor; chr6:149896675 chr6:149796151~149826294:- PAAD cis rs8062405 0.69 rs7187604 ENSG00000259982.1 CDC37P1 7.36 1.06e-11 2.75e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554632 chr16:28700294~28701540:- PAAD cis rs11118620 0.853 rs12037861 ENSG00000238078.1 LINC01352 7.36 1.06e-11 2.76e-08 0.55 0.51 Heart failure; chr1:220864835 chr1:220829255~220832429:+ PAAD cis rs494459 0.691 rs607472 ENSG00000255239.1 AP002954.6 7.36 1.06e-11 2.77e-08 0.61 0.51 Height; chr11:118809363 chr11:118688039~118690600:- PAAD cis rs67180937 0.961 rs17163358 ENSG00000272750.1 RP11-378J18.8 -7.36 1.07e-11 2.77e-08 -0.54 -0.51 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222647297 chr1:222658867~222661512:- PAAD cis rs5760092 0.755 rs4585126 ENSG00000250470.1 AP000351.3 -7.36 1.07e-11 2.78e-08 -0.8 -0.51 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23976904~23977585:- PAAD cis rs73086581 0.786 rs6037705 ENSG00000229539.1 RP11-119B16.2 7.36 1.07e-11 2.79e-08 0.77 0.51 Response to antidepressants in depression; chr20:3972183 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs6037708 ENSG00000229539.1 RP11-119B16.2 7.36 1.07e-11 2.79e-08 0.77 0.51 Response to antidepressants in depression; chr20:3980606 chr20:3888239~3888868:- PAAD cis rs55794721 0.509 rs873308 ENSG00000261349.1 RP3-465N24.5 7.36 1.07e-11 2.79e-08 0.63 0.51 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25266102~25267136:- PAAD cis rs2739330 0.76 rs5751761 ENSG00000250470.1 AP000351.3 -7.36 1.08e-11 2.8e-08 -0.72 -0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23976904~23977585:- PAAD cis rs8062405 0.755 rs2077031 ENSG00000259982.1 CDC37P1 7.36 1.09e-11 2.82e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28591847 chr16:28700294~28701540:- PAAD cis rs8062405 0.69 rs762634 ENSG00000259982.1 CDC37P1 7.36 1.09e-11 2.82e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28592014 chr16:28700294~28701540:- PAAD cis rs62034325 0.697 rs710410 ENSG00000259982.1 CDC37P1 7.36 1.09e-11 2.82e-08 0.62 0.51 Body mass index; chr16:28592021 chr16:28700294~28701540:- PAAD cis rs977987 0.806 rs7202596 ENSG00000261783.1 RP11-252K23.2 -7.36 1.09e-11 2.82e-08 -0.64 -0.51 Dupuytren's disease; chr16:75457174 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs1030262 ENSG00000261783.1 RP11-252K23.2 -7.36 1.09e-11 2.82e-08 -0.64 -0.51 Dupuytren's disease; chr16:75457429 chr16:75379818~75381260:- PAAD cis rs1322639 0.806 rs1322640 ENSG00000261039.2 RP11-417E7.2 7.36 1.09e-11 2.82e-08 0.67 0.51 Pulse pressure; chr6:169186792 chr6:169175304~169182740:- PAAD cis rs507080 0.922 rs525485 ENSG00000255422.1 AP002954.4 -7.36 1.1e-11 2.85e-08 -0.62 -0.51 Serum metabolite levels; chr11:118685045 chr11:118704607~118750263:+ PAAD cis rs2919917 1 rs7010897 ENSG00000254352.1 RP11-578O24.2 7.35 1.12e-11 2.9e-08 0.54 0.51 Lymphocyte counts; chr8:78708119 chr8:78723796~78724136:- PAAD cis rs3091242 0.836 rs34997029 ENSG00000261349.1 RP3-465N24.5 7.35 1.14e-11 2.94e-08 0.63 0.51 Erythrocyte sedimentation rate; chr1:25457332 chr1:25266102~25267136:- PAAD cis rs12931792 0.748 rs11150585 ENSG00000183604.13 SMG1P5 7.35 1.15e-11 2.97e-08 0.53 0.51 Tonsillectomy; chr16:30172965 chr16:30267553~30335374:- PAAD cis rs2283792 0.566 rs1005579 ENSG00000224086.5 LL22NC03-86G7.1 -7.35 1.16e-11 2.99e-08 -0.55 -0.51 Multiple sclerosis; chr22:21946569 chr22:21938293~21977632:+ PAAD cis rs10256972 0.685 rs10263665 ENSG00000229043.2 AC091729.9 -7.35 1.16e-11 2.99e-08 -0.51 -0.51 Endometriosis;Longevity; chr7:1070992 chr7:1160374~1165267:+ PAAD cis rs494459 0.726 rs1784300 ENSG00000255239.1 AP002954.6 7.35 1.16e-11 3e-08 0.61 0.51 Height; chr11:118808920 chr11:118688039~118690600:- PAAD cis rs11155671 0.53 rs9371544 ENSG00000231760.4 RP11-350J20.5 7.35 1.16e-11 3e-08 0.68 0.51 Testicular germ cell tumor; chr6:149896224 chr6:149796151~149826294:- PAAD cis rs9322193 0.607 rs12204653 ENSG00000231760.4 RP11-350J20.5 7.35 1.16e-11 3e-08 0.76 0.51 Lung cancer; chr6:149891885 chr6:149796151~149826294:- PAAD cis rs2919917 1 rs2919936 ENSG00000254352.1 RP11-578O24.2 7.34 1.17e-11 3.02e-08 0.54 0.51 Lymphocyte counts; chr8:78721772 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs2046338 ENSG00000254352.1 RP11-578O24.2 7.34 1.17e-11 3.02e-08 0.54 0.51 Lymphocyte counts; chr8:78723734 chr8:78723796~78724136:- PAAD cis rs1150668 0.799 rs1150705 ENSG00000216901.1 AL022393.7 7.34 1.18e-11 3.04e-08 0.61 0.51 Pubertal anthropometrics; chr6:28226008 chr6:28176188~28176674:+ PAAD cis rs2919917 1 rs2717547 ENSG00000254352.1 RP11-578O24.2 -7.34 1.18e-11 3.04e-08 -0.54 -0.51 Lymphocyte counts; chr8:78744754 chr8:78723796~78724136:- PAAD cis rs9545047 0.704 rs9530904 ENSG00000227676.3 LINC01068 7.34 1.18e-11 3.04e-08 0.65 0.51 Schizophrenia; chr13:79370157 chr13:79566727~79571436:+ PAAD cis rs9545047 0.704 rs3742120 ENSG00000227676.3 LINC01068 7.34 1.18e-11 3.04e-08 0.65 0.51 Schizophrenia; chr13:79386700 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs3742122 ENSG00000227676.3 LINC01068 7.34 1.18e-11 3.04e-08 0.65 0.51 Schizophrenia; chr13:79387061 chr13:79566727~79571436:+ PAAD cis rs8062405 0.722 rs3785354 ENSG00000259982.1 CDC37P1 7.34 1.18e-11 3.04e-08 0.63 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28539346 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs4787457 ENSG00000259982.1 CDC37P1 7.34 1.18e-11 3.04e-08 0.63 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544079 chr16:28700294~28701540:- PAAD cis rs881375 0.678 rs7021049 ENSG00000226752.6 PSMD5-AS1 -7.34 1.18e-11 3.05e-08 -0.55 -0.51 Rheumatoid arthritis; chr9:120921704 chr9:120824828~120854385:+ PAAD cis rs9322193 0.607 rs9322229 ENSG00000231760.4 RP11-350J20.5 7.34 1.18e-11 3.05e-08 0.72 0.51 Lung cancer; chr6:149908949 chr6:149796151~149826294:- PAAD cis rs5760092 0.627 rs6519489 ENSG00000218537.1 MIF-AS1 -7.34 1.19e-11 3.05e-08 -0.8 -0.51 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23894426~23898930:- PAAD cis rs10935480 0.935 rs4857414 ENSG00000239445.4 ST3GAL6-AS1 -7.34 1.19e-11 3.05e-08 -0.57 -0.51 Blood protein levels; chr3:98713715 chr3:98714330~98732651:- PAAD cis rs7104764 0.957 rs1045454 ENSG00000277290.1 RP11-326C3.16 7.34 1.2e-11 3.08e-08 0.47 0.51 Menarche (age at onset); chr11:204228 chr11:243099~243483:- PAAD cis rs7104764 0.957 rs56357554 ENSG00000277290.1 RP11-326C3.16 7.34 1.2e-11 3.08e-08 0.47 0.51 Menarche (age at onset); chr11:204715 chr11:243099~243483:- PAAD cis rs3096299 0.685 rs4785571 ENSG00000274627.1 RP11-104N10.2 7.34 1.2e-11 3.1e-08 0.46 0.51 Multiple myeloma (IgH translocation); chr16:89498761 chr16:89516797~89522217:+ PAAD cis rs11690935 0.851 rs10174055 ENSG00000228389.1 AC068039.4 7.34 1.21e-11 3.1e-08 0.65 0.51 Schizophrenia; chr2:171993303 chr2:171773482~171775844:+ PAAD cis rs9545047 0.604 rs2876740 ENSG00000227676.3 LINC01068 -7.34 1.22e-11 3.14e-08 -0.62 -0.51 Schizophrenia; chr13:79409829 chr13:79566727~79571436:+ PAAD cis rs7714584 1 rs11739677 ENSG00000197083.10 ZNF300P1 7.34 1.23e-11 3.15e-08 0.89 0.51 Crohn's disease; chr5:150915321 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs76433514 ENSG00000197083.10 ZNF300P1 7.34 1.23e-11 3.15e-08 0.89 0.51 Crohn's disease; chr5:150926970 chr5:150930645~150946289:- PAAD cis rs9660180 0.875 rs4648727 ENSG00000268575.1 RP1-283E3.8 7.33 1.24e-11 3.19e-08 0.47 0.51 Body mass index; chr1:1844830 chr1:1702736~1737688:- PAAD cis rs944002 1 rs72706640 ENSG00000259444.1 RP11-736N17.8 7.33 1.27e-11 3.25e-08 0.62 0.51 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103103411 chr14:103094723~103098885:+ PAAD cis rs2455601 0.507 rs2568044 ENSG00000254860.4 TMEM9B-AS1 -7.33 1.27e-11 3.25e-08 -0.62 -0.51 Schizophrenia; chr11:8980930 chr11:8964675~8977527:+ PAAD cis rs321358 0.79 rs10502128 ENSG00000271584.1 RP11-89C3.4 7.33 1.29e-11 3.3e-08 0.63 0.51 Body mass index; chr11:111076827 chr11:111091932~111097357:- PAAD cis rs321358 0.848 rs57168185 ENSG00000271584.1 RP11-89C3.4 7.33 1.29e-11 3.3e-08 0.63 0.51 Body mass index; chr11:111078120 chr11:111091932~111097357:- PAAD cis rs997154 0.655 rs2008345 ENSG00000279656.1 RP11-298I3.6 7.33 1.29e-11 3.31e-08 0.69 0.51 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22932233 chr14:23023083~23024217:- PAAD cis rs997154 0.655 rs7147394 ENSG00000279656.1 RP11-298I3.6 7.33 1.3e-11 3.32e-08 0.69 0.51 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22941845 chr14:23023083~23024217:- PAAD cis rs507080 0.961 rs642530 ENSG00000255422.1 AP002954.4 -7.33 1.3e-11 3.32e-08 -0.6 -0.51 Serum metabolite levels; chr11:118680047 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs642497 ENSG00000255422.1 AP002954.4 -7.33 1.3e-11 3.32e-08 -0.6 -0.51 Serum metabolite levels; chr11:118680075 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs592280 ENSG00000255422.1 AP002954.4 -7.33 1.3e-11 3.32e-08 -0.6 -0.51 Serum metabolite levels; chr11:118682509 chr11:118704607~118750263:+ PAAD cis rs8062405 0.755 rs56209193 ENSG00000259982.1 CDC37P1 7.33 1.3e-11 3.32e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574315 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs7186573 ENSG00000259982.1 CDC37P1 7.33 1.3e-11 3.32e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576068 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs4788073 ENSG00000259982.1 CDC37P1 7.33 1.3e-11 3.32e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28583228 chr16:28700294~28701540:- PAAD cis rs2882667 1 rs10064130 ENSG00000253404.1 AC034243.1 7.32 1.31e-11 3.36e-08 0.63 0.51 Age-related hearing impairment (SNP x SNP interaction); chr5:138973618 chr5:138744434~138753309:- PAAD cis rs765787 0.53 rs12905246 ENSG00000259520.4 CTD-2651B20.3 -7.32 1.33e-11 3.41e-08 -0.61 -0.51 Uric acid levels; chr15:45208643 chr15:45251580~45279251:- PAAD cis rs977987 0.835 rs3851733 ENSG00000261783.1 RP11-252K23.2 -7.32 1.34e-11 3.42e-08 -0.63 -0.51 Dupuytren's disease; chr16:75336365 chr16:75379818~75381260:- PAAD cis rs977987 0.835 rs3863445 ENSG00000261783.1 RP11-252K23.2 -7.32 1.34e-11 3.42e-08 -0.63 -0.51 Dupuytren's disease; chr16:75337846 chr16:75379818~75381260:- PAAD cis rs7115242 0.699 rs17174502 ENSG00000254851.1 RP11-109L13.1 7.32 1.34e-11 3.42e-08 0.93 0.51 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116888939 chr11:117135528~117138582:+ PAAD cis rs507080 0.885 rs693037 ENSG00000255422.1 AP002954.4 -7.32 1.35e-11 3.43e-08 -0.6 -0.51 Serum metabolite levels; chr11:118682617 chr11:118704607~118750263:+ PAAD cis rs1062177 1 rs41494545 ENSG00000213433.5 RPLP1P6 7.32 1.35e-11 3.44e-08 0.6 0.51 Preschool internalizing problems; chr5:151855533 chr5:151765859~151766378:- PAAD cis rs11118620 0.853 rs11118622 ENSG00000238078.1 LINC01352 7.32 1.36e-11 3.48e-08 0.54 0.51 Heart failure; chr1:220868833 chr1:220829255~220832429:+ PAAD cis rs8062405 0.755 rs12447461 ENSG00000259982.1 CDC37P1 7.32 1.37e-11 3.49e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28571620 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs111693583 ENSG00000259982.1 CDC37P1 7.32 1.37e-11 3.49e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28572289 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs55792032 ENSG00000259982.1 CDC37P1 7.32 1.37e-11 3.49e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28588090 chr16:28700294~28701540:- PAAD cis rs8062405 0.691 rs743590 ENSG00000259982.1 CDC37P1 7.32 1.37e-11 3.5e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28596909 chr16:28700294~28701540:- PAAD cis rs9601248 0.711 rs9530937 ENSG00000227676.3 LINC01068 -7.32 1.38e-11 3.5e-08 -0.62 -0.51 Major depressive disorder; chr13:79603701 chr13:79566727~79571436:+ PAAD cis rs977987 0.806 rs35937717 ENSG00000261783.1 RP11-252K23.2 -7.32 1.38e-11 3.51e-08 -0.64 -0.51 Dupuytren's disease; chr16:75297669 chr16:75379818~75381260:- PAAD cis rs4423214 0.879 rs1792284 ENSG00000254682.1 RP11-660L16.2 7.31 1.38e-11 3.52e-08 0.72 0.51 Vitamin D levels; chr11:71423920 chr11:71448674~71452157:+ PAAD cis rs9545047 0.604 rs2765078 ENSG00000227676.3 LINC01068 7.31 1.38e-11 3.52e-08 0.64 0.51 Schizophrenia; chr13:79420604 chr13:79566727~79571436:+ PAAD cis rs7104764 0.957 rs3782120 ENSG00000277290.1 RP11-326C3.16 7.31 1.39e-11 3.54e-08 0.47 0.51 Menarche (age at onset); chr11:206089 chr11:243099~243483:- PAAD cis rs8062405 0.755 rs4149398 ENSG00000259982.1 CDC37P1 7.31 1.4e-11 3.55e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597617 chr16:28700294~28701540:- PAAD cis rs2739330 0.929 rs5751777 ENSG00000250470.1 AP000351.3 7.31 1.4e-11 3.57e-08 0.72 0.51 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23976904~23977585:- PAAD cis rs2919917 1 rs1545228 ENSG00000254352.1 RP11-578O24.2 -7.31 1.41e-11 3.58e-08 -0.55 -0.51 Lymphocyte counts; chr8:78732202 chr8:78723796~78724136:- PAAD cis rs9890032 0.581 rs62070592 ENSG00000266490.1 CTD-2349P21.9 7.31 1.41e-11 3.59e-08 0.47 0.51 Hip circumference adjusted for BMI; chr17:30695531 chr17:30792372~30792833:+ PAAD cis rs10935480 1 rs10935480 ENSG00000239445.4 ST3GAL6-AS1 -7.31 1.41e-11 3.59e-08 -0.57 -0.51 Blood protein levels; chr3:98713142 chr3:98714330~98732651:- PAAD cis rs67180937 0.582 rs71524942 ENSG00000272750.1 RP11-378J18.8 -7.31 1.41e-11 3.6e-08 -0.57 -0.51 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222689650 chr1:222658867~222661512:- PAAD cis rs2980439 0.818 rs2948294 ENSG00000253893.2 FAM85B -7.31 1.42e-11 3.61e-08 -0.74 -0.51 Neuroticism; chr8:8237439 chr8:8167819~8226614:- PAAD cis rs7208859 0.673 rs999796 ENSG00000263531.1 RP13-753N3.1 7.31 1.42e-11 3.61e-08 0.92 0.51 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832386 chr17:30863921~30864940:- PAAD cis rs8062405 0.723 rs113208333 ENSG00000259982.1 CDC37P1 7.31 1.42e-11 3.62e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28594839 chr16:28700294~28701540:- PAAD cis rs881375 0.715 rs11794516 ENSG00000226752.6 PSMD5-AS1 -7.31 1.43e-11 3.62e-08 -0.56 -0.51 Rheumatoid arthritis; chr9:120877952 chr9:120824828~120854385:+ PAAD cis rs73086581 0.898 rs11906452 ENSG00000229539.1 RP11-119B16.2 7.31 1.45e-11 3.69e-08 0.77 0.51 Response to antidepressants in depression; chr20:4000912 chr20:3888239~3888868:- PAAD cis rs4423214 0.84 rs1792224 ENSG00000254682.1 RP11-660L16.2 -7.3 1.48e-11 3.75e-08 -0.73 -0.51 Vitamin D levels; chr11:71465095 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1792226 ENSG00000254682.1 RP11-660L16.2 -7.3 1.48e-11 3.75e-08 -0.73 -0.51 Vitamin D levels; chr11:71465528 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1790344 ENSG00000254682.1 RP11-660L16.2 -7.3 1.48e-11 3.75e-08 -0.73 -0.51 Vitamin D levels; chr11:71465851 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1790343 ENSG00000254682.1 RP11-660L16.2 -7.3 1.48e-11 3.75e-08 -0.73 -0.51 Vitamin D levels; chr11:71466161 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1792227 ENSG00000254682.1 RP11-660L16.2 -7.3 1.48e-11 3.75e-08 -0.73 -0.51 Vitamin D levels; chr11:71466366 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1790341 ENSG00000254682.1 RP11-660L16.2 -7.3 1.48e-11 3.75e-08 -0.73 -0.51 Vitamin D levels; chr11:71466532 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1540127 ENSG00000254682.1 RP11-660L16.2 -7.3 1.48e-11 3.75e-08 -0.73 -0.51 Vitamin D levels; chr11:71467992 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1792229 ENSG00000254682.1 RP11-660L16.2 -7.3 1.48e-11 3.75e-08 -0.73 -0.51 Vitamin D levels; chr11:71468349 chr11:71448674~71452157:+ PAAD cis rs1167827 1 rs1167827 ENSG00000127957.15 PMS2P3 -7.3 1.49e-11 3.77e-08 -0.38 -0.51 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75533848 chr7:75502930~75528148:- PAAD cis rs9322193 0.923 rs4869750 ENSG00000216906.2 RP11-350J20.9 7.3 1.5e-11 3.81e-08 0.66 0.51 Lung cancer; chr6:149855996 chr6:149904243~149906418:+ PAAD cis rs55794721 0.509 rs2375313 ENSG00000261349.1 RP3-465N24.5 -7.3 1.51e-11 3.82e-08 -0.63 -0.51 Mean corpuscular volume;Plateletcrit; chr1:25421744 chr1:25266102~25267136:- PAAD cis rs1799949 0.602 rs8176199 ENSG00000198496.9 NBR2 -7.3 1.51e-11 3.83e-08 -0.55 -0.51 Menopause (age at onset); chr17:43078507 chr17:43125610~43153671:+ PAAD cis rs12931792 0.72 rs12102320 ENSG00000183604.13 SMG1P5 7.3 1.52e-11 3.86e-08 0.52 0.51 Tonsillectomy; chr16:30167195 chr16:30267553~30335374:- PAAD cis rs11690935 0.843 rs9784123 ENSG00000228389.1 AC068039.4 7.3 1.53e-11 3.86e-08 0.64 0.51 Schizophrenia; chr2:171928495 chr2:171773482~171775844:+ PAAD cis rs11690935 0.843 rs9784070 ENSG00000228389.1 AC068039.4 7.3 1.53e-11 3.86e-08 0.64 0.51 Schizophrenia; chr2:171928497 chr2:171773482~171775844:+ PAAD cis rs6452524 0.967 rs4616871 ENSG00000249664.1 CTD-2227C6.2 7.29 1.54e-11 3.9e-08 0.56 0.51 Hypertension (SNP x SNP interaction); chr5:83175271 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs11949474 ENSG00000249664.1 CTD-2227C6.2 7.29 1.54e-11 3.9e-08 0.56 0.51 Hypertension (SNP x SNP interaction); chr5:83179759 chr5:83012285~83013109:- PAAD cis rs507080 0.845 rs481903 ENSG00000255422.1 AP002954.4 -7.29 1.56e-11 3.93e-08 -0.62 -0.51 Serum metabolite levels; chr11:118697024 chr11:118704607~118750263:+ PAAD cis rs6452524 0.508 rs256795 ENSG00000249664.1 CTD-2227C6.2 -7.29 1.57e-11 3.95e-08 -0.58 -0.51 Hypertension (SNP x SNP interaction); chr5:83001543 chr5:83012285~83013109:- PAAD cis rs9545047 0.604 rs2265381 ENSG00000227676.3 LINC01068 -7.29 1.57e-11 3.98e-08 -0.63 -0.51 Schizophrenia; chr13:79425903 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2265382 ENSG00000227676.3 LINC01068 -7.29 1.57e-11 3.98e-08 -0.63 -0.51 Schizophrenia; chr13:79426196 chr13:79566727~79571436:+ PAAD cis rs7309 0.87 rs2358016 ENSG00000227403.1 AC009299.3 7.29 1.58e-11 3.99e-08 0.63 0.51 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161150919 chr2:161244739~161249050:+ PAAD cis rs6964833 1 rs17515241 ENSG00000123965.13 PMS2P5 -7.29 1.59e-11 4.01e-08 -0.83 -0.51 Menarche (age at onset); chr7:74717695 chr7:74894116~74897835:+ PAAD cis rs2980436 1 rs2980436 ENSG00000253893.2 FAM85B 7.29 1.6e-11 4.04e-08 0.74 0.51 Schizophrenia; chr8:8234503 chr8:8167819~8226614:- PAAD cis rs7714584 1 rs11747065 ENSG00000197083.10 ZNF300P1 7.29 1.61e-11 4.05e-08 0.87 0.51 Crohn's disease; chr5:150915924 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11740172 ENSG00000197083.10 ZNF300P1 7.29 1.61e-11 4.05e-08 0.87 0.51 Crohn's disease; chr5:150920716 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11746807 ENSG00000197083.10 ZNF300P1 7.29 1.61e-11 4.05e-08 0.87 0.51 Crohn's disease; chr5:150920857 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs12656600 ENSG00000197083.10 ZNF300P1 7.29 1.61e-11 4.05e-08 0.87 0.51 Crohn's disease; chr5:150932310 chr5:150930645~150946289:- PAAD cis rs3096299 0.685 rs4785568 ENSG00000274627.1 RP11-104N10.2 7.29 1.62e-11 4.08e-08 0.44 0.51 Multiple myeloma (IgH translocation); chr16:89487299 chr16:89516797~89522217:+ PAAD cis rs3091242 0.933 rs9645452 ENSG00000261349.1 RP3-465N24.5 7.29 1.62e-11 4.08e-08 0.61 0.51 Erythrocyte sedimentation rate; chr1:25341835 chr1:25266102~25267136:- PAAD cis rs7044106 0.791 rs10985009 ENSG00000226752.6 PSMD5-AS1 7.29 1.63e-11 4.1e-08 0.67 0.51 Hip circumference adjusted for BMI; chr9:120730761 chr9:120824828~120854385:+ PAAD cis rs7829975 0.623 rs7010753 ENSG00000253893.2 FAM85B -7.28 1.65e-11 4.17e-08 -0.66 -0.51 Mood instability; chr8:8516446 chr8:8167819~8226614:- PAAD cis rs977987 0.835 rs11641532 ENSG00000261783.1 RP11-252K23.2 -7.28 1.66e-11 4.18e-08 -0.64 -0.51 Dupuytren's disease; chr16:75295582 chr16:75379818~75381260:- PAAD cis rs7829975 0.623 rs10092965 ENSG00000253893.2 FAM85B -7.28 1.66e-11 4.18e-08 -0.66 -0.51 Mood instability; chr8:8515975 chr8:8167819~8226614:- PAAD cis rs9322193 0.607 rs12209310 ENSG00000231760.4 RP11-350J20.5 7.28 1.67e-11 4.21e-08 0.74 0.51 Lung cancer; chr6:149904882 chr6:149796151~149826294:- PAAD cis rs9322193 0.607 rs12210822 ENSG00000231760.4 RP11-350J20.5 7.28 1.67e-11 4.21e-08 0.74 0.51 Lung cancer; chr6:149905356 chr6:149796151~149826294:- PAAD cis rs10256972 0.616 rs7806746 ENSG00000229043.2 AC091729.9 -7.28 1.67e-11 4.21e-08 -0.52 -0.51 Endometriosis;Longevity; chr7:1035937 chr7:1160374~1165267:+ PAAD cis rs1976403 0.659 rs10799699 ENSG00000227001.3 NBPF2P 7.28 1.69e-11 4.26e-08 0.6 0.51 Liver enzyme levels (alkaline phosphatase); chr1:21494468 chr1:21424625~21427967:- PAAD cis rs1976403 0.659 rs10799700 ENSG00000227001.3 NBPF2P 7.28 1.69e-11 4.26e-08 0.6 0.51 Liver enzyme levels (alkaline phosphatase); chr1:21494475 chr1:21424625~21427967:- PAAD cis rs9326248 0.53 rs6589576 ENSG00000254851.1 RP11-109L13.1 7.28 1.7e-11 4.27e-08 0.89 0.51 Blood protein levels; chr11:116865072 chr11:117135528~117138582:+ PAAD cis rs992157 1 rs6736362 ENSG00000261338.2 RP11-378A13.1 7.28 1.71e-11 4.31e-08 0.58 0.51 Colorectal cancer; chr2:218250385 chr2:218255319~218257366:+ PAAD cis rs7829975 0.627 rs2979172 ENSG00000253893.2 FAM85B -7.28 1.72e-11 4.32e-08 -0.69 -0.51 Mood instability; chr8:8452998 chr8:8167819~8226614:- PAAD cis rs3091242 1 rs646867 ENSG00000261349.1 RP3-465N24.5 -7.27 1.72e-11 4.33e-08 -0.61 -0.51 Erythrocyte sedimentation rate; chr1:25382767 chr1:25266102~25267136:- PAAD cis rs8062405 0.755 rs4788080 ENSG00000259982.1 CDC37P1 7.27 1.72e-11 4.33e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546760 chr16:28700294~28701540:- PAAD cis rs8062405 0.723 rs4788079 ENSG00000259982.1 CDC37P1 7.27 1.72e-11 4.33e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548042 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs4787456 ENSG00000259982.1 CDC37P1 7.27 1.72e-11 4.33e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548252 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs4788078 ENSG00000259982.1 CDC37P1 7.27 1.72e-11 4.33e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28548660 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs62034350 ENSG00000259982.1 CDC37P1 7.27 1.72e-11 4.33e-08 0.62 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28550935 chr16:28700294~28701540:- PAAD cis rs11673344 0.526 rs17303902 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37551912 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs55754546 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37552860 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs17244713 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37559938 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs17244769 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37562031 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs8111790 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37565861 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs55909413 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37578663 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs55865869 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37578683 chr19:37251912~37265535:+ PAAD cis rs11673344 0.502 rs17304703 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37582646 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs73033122 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37586006 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs2306201 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37586573 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs2291001 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37594431 chr19:37251912~37265535:+ PAAD cis rs11673344 0.518 rs73033134 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37596046 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs17305193 ENSG00000226686.6 LINC01535 7.27 1.73e-11 4.34e-08 0.67 0.51 Obesity-related traits; chr19:37598764 chr19:37251912~37265535:+ PAAD cis rs881375 0.678 rs7037195 ENSG00000226752.6 PSMD5-AS1 -7.27 1.73e-11 4.35e-08 -0.54 -0.51 Rheumatoid arthritis; chr9:120921722 chr9:120824828~120854385:+ PAAD cis rs881375 0.678 rs1014530 ENSG00000226752.6 PSMD5-AS1 -7.27 1.73e-11 4.35e-08 -0.54 -0.51 Rheumatoid arthritis; chr9:120922814 chr9:120824828~120854385:+ PAAD cis rs3096299 0.658 rs4291902 ENSG00000274627.1 RP11-104N10.2 7.27 1.75e-11 4.39e-08 0.44 0.51 Multiple myeloma (IgH translocation); chr16:89493907 chr16:89516797~89522217:+ PAAD cis rs507080 0.922 rs519848 ENSG00000255422.1 AP002954.4 -7.27 1.76e-11 4.4e-08 -0.59 -0.51 Serum metabolite levels; chr11:118682006 chr11:118704607~118750263:+ PAAD cis rs1062177 1 rs62394155 ENSG00000213433.5 RPLP1P6 -7.27 1.77e-11 4.43e-08 -0.59 -0.51 Preschool internalizing problems; chr5:151868508 chr5:151765859~151766378:- PAAD cis rs1062177 1 rs12653926 ENSG00000213433.5 RPLP1P6 -7.27 1.77e-11 4.43e-08 -0.59 -0.51 Preschool internalizing problems; chr5:151870687 chr5:151765859~151766378:- PAAD cis rs5760092 0.627 rs6519489 ENSG00000273295.1 AP000350.5 -7.27 1.78e-11 4.44e-08 -0.76 -0.51 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23901432~23907068:- PAAD cis rs1322639 1 rs9689079 ENSG00000261039.2 RP11-417E7.2 7.27 1.78e-11 4.46e-08 0.66 0.51 Pulse pressure; chr6:169187053 chr6:169175304~169182740:- PAAD cis rs7945705 0.747 rs2653605 ENSG00000254860.4 TMEM9B-AS1 7.27 1.78e-11 4.46e-08 0.55 0.51 Hemoglobin concentration; chr11:8971762 chr11:8964675~8977527:+ PAAD cis rs9322193 0.566 rs12528243 ENSG00000231760.4 RP11-350J20.5 7.27 1.78e-11 4.46e-08 0.74 0.51 Lung cancer; chr6:149898491 chr6:149796151~149826294:- PAAD cis rs765787 0.53 rs12910270 ENSG00000259520.4 CTD-2651B20.3 -7.27 1.8e-11 4.51e-08 -0.61 -0.51 Uric acid levels; chr15:45219888 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12915804 ENSG00000259520.4 CTD-2651B20.3 -7.27 1.8e-11 4.51e-08 -0.61 -0.51 Uric acid levels; chr15:45220364 chr15:45251580~45279251:- PAAD cis rs765787 0.556 rs12915965 ENSG00000259520.4 CTD-2651B20.3 -7.27 1.8e-11 4.51e-08 -0.61 -0.51 Uric acid levels; chr15:45220449 chr15:45251580~45279251:- PAAD cis rs507080 0.922 rs4938524 ENSG00000255422.1 AP002954.4 -7.27 1.81e-11 4.52e-08 -0.6 -0.51 Serum metabolite levels; chr11:118681365 chr11:118704607~118750263:+ PAAD cis rs8062405 0.755 rs17640009 ENSG00000259982.1 CDC37P1 7.26 1.83e-11 4.56e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28584379 chr16:28700294~28701540:- PAAD cis rs1976403 0.659 rs10799701 ENSG00000227001.3 NBPF2P 7.26 1.83e-11 4.57e-08 0.6 0.51 Liver enzyme levels (alkaline phosphatase); chr1:21494497 chr1:21424625~21427967:- PAAD cis rs7829975 0.564 rs2976855 ENSG00000253893.2 FAM85B -7.26 1.84e-11 4.59e-08 -0.7 -0.51 Mood instability; chr8:8444284 chr8:8167819~8226614:- PAAD cis rs881375 0.678 rs10760128 ENSG00000226752.6 PSMD5-AS1 -7.26 1.84e-11 4.59e-08 -0.55 -0.51 Rheumatoid arthritis; chr9:120934047 chr9:120824828~120854385:+ PAAD cis rs55794721 0.509 rs6699113 ENSG00000261349.1 RP3-465N24.5 -7.26 1.84e-11 4.59e-08 -0.62 -0.51 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25266102~25267136:- PAAD cis rs55794721 0.509 rs7554255 ENSG00000261349.1 RP3-465N24.5 -7.26 1.84e-11 4.59e-08 -0.62 -0.51 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25266102~25267136:- PAAD cis rs55794721 0.509 rs4649085 ENSG00000261349.1 RP3-465N24.5 -7.26 1.84e-11 4.59e-08 -0.62 -0.51 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25266102~25267136:- PAAD cis rs4423214 0.879 rs1792283 ENSG00000254682.1 RP11-660L16.2 -7.26 1.85e-11 4.6e-08 -0.72 -0.51 Vitamin D levels; chr11:71424090 chr11:71448674~71452157:+ PAAD cis rs4423214 0.879 rs1792282 ENSG00000254682.1 RP11-660L16.2 -7.26 1.85e-11 4.6e-08 -0.72 -0.51 Vitamin D levels; chr11:71424120 chr11:71448674~71452157:+ PAAD cis rs881375 0.669 rs73541868 ENSG00000226752.6 PSMD5-AS1 -7.26 1.87e-11 4.65e-08 -0.55 -0.51 Rheumatoid arthritis; chr9:120876986 chr9:120824828~120854385:+ PAAD cis rs1062177 1 rs12518722 ENSG00000213433.5 RPLP1P6 -7.26 1.88e-11 4.68e-08 -0.59 -0.51 Preschool internalizing problems; chr5:151851899 chr5:151765859~151766378:- PAAD cis rs1062177 0.855 rs6892117 ENSG00000213433.5 RPLP1P6 7.26 1.89e-11 4.69e-08 0.58 0.51 Preschool internalizing problems; chr5:151885424 chr5:151765859~151766378:- PAAD cis rs8062405 0.755 rs17707300 ENSG00000259982.1 CDC37P1 7.26 1.89e-11 4.72e-08 0.59 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582026 chr16:28700294~28701540:- PAAD cis rs3091242 0.904 rs6661533 ENSG00000261349.1 RP3-465N24.5 -7.26 1.9e-11 4.72e-08 -0.62 -0.51 Erythrocyte sedimentation rate; chr1:25445224 chr1:25266102~25267136:- PAAD cis rs11690935 0.879 rs13017585 ENSG00000228389.1 AC068039.4 7.26 1.9e-11 4.73e-08 0.69 0.51 Schizophrenia; chr2:171865298 chr2:171773482~171775844:+ PAAD cis rs1062177 0.855 rs6884630 ENSG00000213433.5 RPLP1P6 -7.25 1.94e-11 4.83e-08 -0.57 -0.51 Preschool internalizing problems; chr5:151889436 chr5:151765859~151766378:- PAAD cis rs977987 0.806 rs4888390 ENSG00000261783.1 RP11-252K23.2 -7.25 1.99e-11 4.95e-08 -0.64 -0.51 Dupuytren's disease; chr16:75366422 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4888391 ENSG00000261783.1 RP11-252K23.2 -7.25 1.99e-11 4.95e-08 -0.64 -0.51 Dupuytren's disease; chr16:75366848 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs8054769 ENSG00000261783.1 RP11-252K23.2 -7.25 1.99e-11 4.95e-08 -0.64 -0.51 Dupuytren's disease; chr16:75367215 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs35415181 ENSG00000261783.1 RP11-252K23.2 -7.25 1.99e-11 4.95e-08 -0.64 -0.51 Dupuytren's disease; chr16:75369226 chr16:75379818~75381260:- PAAD cis rs2117029 0.553 rs731350 ENSG00000258017.1 RP11-386G11.10 -7.25 2e-11 4.96e-08 -0.66 -0.51 Intelligence (multi-trait analysis); chr12:49130804 chr12:49127782~49147869:+ PAAD cis rs4423214 0.765 rs2002064 ENSG00000254682.1 RP11-660L16.2 -7.25 2.01e-11 4.98e-08 -0.73 -0.51 Vitamin D levels; chr11:71452374 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1792315 ENSG00000254682.1 RP11-660L16.2 -7.25 2.01e-11 4.98e-08 -0.73 -0.51 Vitamin D levels; chr11:71454501 chr11:71448674~71452157:+ PAAD cis rs5760092 0.755 rs915589 ENSG00000273295.1 AP000350.5 -7.25 2.02e-11 4.99e-08 -0.75 -0.51 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23901432~23907068:- PAAD cis rs8062405 0.755 rs56272201 ENSG00000259982.1 CDC37P1 7.25 2.02e-11 5e-08 0.61 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569364 chr16:28700294~28701540:- PAAD cis rs8062405 0.755 rs62034355 ENSG00000259982.1 CDC37P1 7.25 2.02e-11 5e-08 0.61 0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569717 chr16:28700294~28701540:- PAAD cis rs4423214 0.879 rs1792281 ENSG00000254682.1 RP11-660L16.2 -7.25 2.03e-11 5e-08 -0.72 -0.51 Vitamin D levels; chr11:71424450 chr11:71448674~71452157:+ PAAD cis rs9322193 0.923 rs2880436 ENSG00000216906.2 RP11-350J20.9 7.25 2.03e-11 5e-08 0.69 0.51 Lung cancer; chr6:149859123 chr6:149904243~149906418:+ PAAD cis rs9545047 0.716 rs643778 ENSG00000227676.3 LINC01068 -7.24 2.05e-11 5.07e-08 -0.64 -0.51 Schizophrenia; chr13:79423937 chr13:79566727~79571436:+ PAAD cis rs7714584 1 rs12659118 ENSG00000197083.10 ZNF300P1 7.24 2.06e-11 5.08e-08 0.88 0.51 Crohn's disease; chr5:150945060 chr5:150930645~150946289:- PAAD cis rs494459 0.733 rs556437 ENSG00000255239.1 AP002954.6 7.24 2.08e-11 5.13e-08 0.6 0.51 Height; chr11:118835044 chr11:118688039~118690600:- PAAD cis rs507080 0.922 rs558781 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118693688 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs508640 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118693704 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs471227 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118693892 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs516153 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118694053 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs518028 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118694273 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs519982 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118694522 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs478371 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118694627 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs502601 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118694970 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs7114458 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118695466 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs7114216 ENSG00000255422.1 AP002954.4 -7.24 2.11e-11 5.19e-08 -0.61 -0.51 Serum metabolite levels; chr11:118695525 chr11:118704607~118750263:+ PAAD cis rs881375 0.678 rs1930782 ENSG00000226752.6 PSMD5-AS1 -7.24 2.13e-11 5.25e-08 -0.54 -0.51 Rheumatoid arthritis; chr9:120925627 chr9:120824828~120854385:+ PAAD cis rs2919917 1 rs1384804 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78659987 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs10093654 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78660360 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs10093797 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78660478 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs3808619 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78665491 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs7839152 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78677777 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs28429528 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78678782 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs9298316 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78680191 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs7842142 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78681501 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs11785966 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78681851 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs10092335 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78686218 chr8:78723796~78724136:- PAAD cis rs2919917 0.956 rs10112388 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78691512 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs6980663 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78691589 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs1054283 ENSG00000254352.1 RP11-578O24.2 7.24 2.14e-11 5.26e-08 0.53 0.51 Lymphocyte counts; chr8:78698475 chr8:78723796~78724136:- PAAD cis rs17826219 0.568 rs59858012 ENSG00000263531.1 RP13-753N3.1 7.23 2.14e-11 5.26e-08 1.01 0.51 Body mass index; chr17:30751564 chr17:30863921~30864940:- PAAD cis rs200367988 1 rs200367988 ENSG00000271670.1 RP11-95I16.4 -7.23 2.16e-11 5.29e-08 -0.52 -0.51 Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels; chr10:120915337 chr10:120879256~120880667:- PAAD cis rs1075265 0.584 rs1559037 ENSG00000233266.1 HMGB1P31 7.23 2.17e-11 5.31e-08 0.64 0.51 Chronotype;Morning vs. evening chronotype; chr2:54051448 chr2:54051334~54051760:+ PAAD cis rs1075265 0.584 rs7590846 ENSG00000233266.1 HMGB1P31 7.23 2.17e-11 5.31e-08 0.64 0.51 Chronotype;Morning vs. evening chronotype; chr2:54051530 chr2:54051334~54051760:+ PAAD cis rs1075265 0.584 rs1833497 ENSG00000233266.1 HMGB1P31 7.23 2.18e-11 5.33e-08 0.65 0.51 Chronotype;Morning vs. evening chronotype; chr2:54052186 chr2:54051334~54051760:+ PAAD cis rs1075265 0.584 rs1862122 ENSG00000233266.1 HMGB1P31 -7.23 2.18e-11 5.33e-08 -0.65 -0.51 Chronotype;Morning vs. evening chronotype; chr2:54052992 chr2:54051334~54051760:+ PAAD cis rs1075265 0.584 rs4671178 ENSG00000233266.1 HMGB1P31 -7.23 2.18e-11 5.33e-08 -0.65 -0.51 Chronotype;Morning vs. evening chronotype; chr2:54056356 chr2:54051334~54051760:+ PAAD cis rs73086581 0.945 rs6037715 ENSG00000229539.1 RP11-119B16.2 7.23 2.18e-11 5.34e-08 0.76 0.51 Response to antidepressants in depression; chr20:3991519 chr20:3888239~3888868:- PAAD cis rs172166 0.561 rs149976 ENSG00000216901.1 AL022393.7 -7.23 2.2e-11 5.4e-08 -0.63 -0.51 Cardiac Troponin-T levels; chr6:28019998 chr6:28176188~28176674:+ PAAD cis rs11155671 0.53 rs4458704 ENSG00000231760.4 RP11-350J20.5 7.23 2.21e-11 5.41e-08 0.65 0.51 Testicular germ cell tumor; chr6:149911743 chr6:149796151~149826294:- PAAD cis rs7714584 1 rs75294883 ENSG00000197083.10 ZNF300P1 7.23 2.22e-11 5.43e-08 0.96 0.51 Crohn's disease; chr5:150816941 chr5:150930645~150946289:- PAAD cis rs8062405 0.755 rs1074631 ENSG00000259982.1 CDC37P1 -7.23 2.24e-11 5.47e-08 -0.61 -0.51 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28542787 chr16:28700294~28701540:- PAAD cis rs507080 0.883 rs558593 ENSG00000255422.1 AP002954.4 -7.23 2.24e-11 5.49e-08 -0.61 -0.51 Serum metabolite levels; chr11:118691811 chr11:118704607~118750263:+ PAAD cis rs977987 0.806 rs4993969 ENSG00000261783.1 RP11-252K23.2 -7.22 2.27e-11 5.55e-08 -0.62 -0.51 Dupuytren's disease; chr16:75377623 chr16:75379818~75381260:- PAAD cis rs1075265 0.584 rs7558126 ENSG00000233266.1 HMGB1P31 7.22 2.29e-11 5.59e-08 0.65 0.51 Chronotype;Morning vs. evening chronotype; chr2:54053847 chr2:54051334~54051760:+ PAAD cis rs1075265 0.584 rs1862121 ENSG00000233266.1 HMGB1P31 7.22 2.29e-11 5.59e-08 0.65 0.51 Chronotype;Morning vs. evening chronotype; chr2:54058102 chr2:54051334~54051760:+ PAAD cis rs6452524 0.934 rs10473870 ENSG00000249664.1 CTD-2227C6.2 7.22 2.3e-11 5.62e-08 0.56 0.51 Hypertension (SNP x SNP interaction); chr5:83199768 chr5:83012285~83013109:- PAAD cis rs67180937 0.621 rs34885880 ENSG00000272750.1 RP11-378J18.8 -7.22 2.32e-11 5.65e-08 -0.54 -0.51 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222752593 chr1:222658867~222661512:- PAAD cis rs507080 0.922 rs514143 ENSG00000255422.1 AP002954.4 -7.22 2.32e-11 5.66e-08 -0.61 -0.51 Serum metabolite levels; chr11:118687740 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs558907 ENSG00000255422.1 AP002954.4 -7.22 2.32e-11 5.66e-08 -0.61 -0.51 Serum metabolite levels; chr11:118687746 chr11:118704607~118750263:+ PAAD cis rs507080 0.885 rs7926959 ENSG00000255422.1 AP002954.4 -7.22 2.32e-11 5.66e-08 -0.61 -0.51 Serum metabolite levels; chr11:118689157 chr11:118704607~118750263:+ PAAD cis rs507080 0.663 rs7926970 ENSG00000255422.1 AP002954.4 -7.22 2.32e-11 5.66e-08 -0.61 -0.51 Serum metabolite levels; chr11:118689172 chr11:118704607~118750263:+ PAAD cis rs507080 0.885 rs4938530 ENSG00000255422.1 AP002954.4 -7.22 2.32e-11 5.66e-08 -0.61 -0.51 Serum metabolite levels; chr11:118689861 chr11:118704607~118750263:+ PAAD cis rs9322193 0.607 rs915140 ENSG00000231760.4 RP11-350J20.5 7.22 2.32e-11 5.67e-08 0.74 0.51 Lung cancer; chr6:149899674 chr6:149796151~149826294:- PAAD cis rs977987 0.806 rs4888386 ENSG00000261783.1 RP11-252K23.2 -7.22 2.34e-11 5.7e-08 -0.62 -0.51 Dupuytren's disease; chr16:75355842 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4638613 ENSG00000261783.1 RP11-252K23.2 -7.22 2.34e-11 5.7e-08 -0.62 -0.51 Dupuytren's disease; chr16:75391655 chr16:75379818~75381260:- PAAD cis rs977987 0.75 rs4888407 ENSG00000261783.1 RP11-252K23.2 -7.22 2.34e-11 5.7e-08 -0.62 -0.51 Dupuytren's disease; chr16:75398492 chr16:75379818~75381260:- PAAD cis rs7615952 0.673 rs9821905 ENSG00000171084.14 FAM86JP -7.22 2.37e-11 5.77e-08 -0.9 -0.51 Blood pressure (smoking interaction); chr3:125902007 chr3:125916620~125930024:+ PAAD cis rs7429990 0.932 rs12486714 ENSG00000229759.1 MRPS18AP1 -7.22 2.37e-11 5.77e-08 -0.54 -0.51 Educational attainment (years of education); chr3:48107210 chr3:48256350~48256938:- PAAD cis rs7429990 0.901 rs6442102 ENSG00000229759.1 MRPS18AP1 -7.22 2.37e-11 5.77e-08 -0.54 -0.51 Educational attainment (years of education); chr3:48111072 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs2361684 ENSG00000229759.1 MRPS18AP1 -7.22 2.37e-11 5.77e-08 -0.54 -0.51 Educational attainment (years of education); chr3:48111128 chr3:48256350~48256938:- PAAD cis rs7429990 0.803 rs11714518 ENSG00000229759.1 MRPS18AP1 -7.22 2.37e-11 5.77e-08 -0.54 -0.51 Educational attainment (years of education); chr3:48115145 chr3:48256350~48256938:- PAAD cis rs7429990 0.896 rs7427648 ENSG00000229759.1 MRPS18AP1 -7.22 2.37e-11 5.77e-08 -0.54 -0.51 Educational attainment (years of education); chr3:48116749 chr3:48256350~48256938:- PAAD cis rs2882667 1 rs2882667 ENSG00000253404.1 AC034243.1 7.22 2.38e-11 5.79e-08 0.62 0.51 Age-related hearing impairment (SNP x SNP interaction); chr5:138978417 chr5:138744434~138753309:- PAAD cis rs3091242 0.866 rs11249249 ENSG00000261349.1 RP3-465N24.5 -7.21 2.4e-11 5.84e-08 -0.63 -0.51 Erythrocyte sedimentation rate; chr1:25431643 chr1:25266102~25267136:- PAAD cis rs9322193 0.886 rs4870055 ENSG00000216906.2 RP11-350J20.9 7.21 2.41e-11 5.85e-08 0.65 0.51 Lung cancer; chr6:149848433 chr6:149904243~149906418:+ PAAD cis rs4423214 0.798 rs12224205 ENSG00000254682.1 RP11-660L16.2 -7.21 2.41e-11 5.87e-08 -0.71 -0.5 Vitamin D levels; chr11:71469946 chr11:71448674~71452157:+ PAAD cis rs881375 0.678 rs10760130 ENSG00000226752.6 PSMD5-AS1 -7.21 2.45e-11 5.96e-08 -0.54 -0.5 Rheumatoid arthritis; chr9:120939712 chr9:120824828~120854385:+ PAAD cis rs73086581 0.68 rs11908158 ENSG00000229539.1 RP11-119B16.2 7.21 2.45e-11 5.96e-08 0.76 0.5 Response to antidepressants in depression; chr20:3956025 chr20:3888239~3888868:- PAAD cis rs507080 0.961 rs600969 ENSG00000255422.1 AP002954.4 -7.21 2.45e-11 5.96e-08 -0.6 -0.5 Serum metabolite levels; chr11:118675087 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs12577485 ENSG00000255422.1 AP002954.4 -7.21 2.45e-11 5.96e-08 -0.6 -0.5 Serum metabolite levels; chr11:118676793 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs673770 ENSG00000255422.1 AP002954.4 -7.21 2.45e-11 5.96e-08 -0.6 -0.5 Serum metabolite levels; chr11:118679892 chr11:118704607~118750263:+ PAAD cis rs9545047 0.519 rs8001281 ENSG00000227676.3 LINC01068 7.21 2.46e-11 5.98e-08 0.62 0.5 Schizophrenia; chr13:79410707 chr13:79566727~79571436:+ PAAD cis rs9545047 0.511 rs1624537 ENSG00000227676.3 LINC01068 7.21 2.46e-11 5.98e-08 0.62 0.5 Schizophrenia; chr13:79411686 chr13:79566727~79571436:+ PAAD cis rs977987 0.843 rs11644741 ENSG00000261783.1 RP11-252K23.2 -7.21 2.47e-11 6e-08 -0.62 -0.5 Dupuytren's disease; chr16:75432535 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs12917651 ENSG00000261783.1 RP11-252K23.2 -7.21 2.47e-11 6e-08 -0.62 -0.5 Dupuytren's disease; chr16:75432798 chr16:75379818~75381260:- PAAD cis rs7044106 0.791 rs10985008 ENSG00000226752.6 PSMD5-AS1 -7.21 2.48e-11 6.01e-08 -0.67 -0.5 Hip circumference adjusted for BMI; chr9:120730682 chr9:120824828~120854385:+ PAAD cis rs507080 0.961 rs34413584 ENSG00000255422.1 AP002954.4 -7.21 2.5e-11 6.05e-08 -0.6 -0.5 Serum metabolite levels; chr11:118675072 chr11:118704607~118750263:+ PAAD cis rs9545047 0.716 rs9565500 ENSG00000227676.3 LINC01068 -7.21 2.5e-11 6.05e-08 -0.63 -0.5 Schizophrenia; chr13:79433416 chr13:79566727~79571436:+ PAAD cis rs5760092 0.755 rs4585126 ENSG00000225282.1 AP000350.6 -7.21 2.5e-11 6.06e-08 -0.72 -0.5 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23926900~23929574:+ PAAD cis rs3096299 0.658 rs3934737 ENSG00000274627.1 RP11-104N10.2 7.21 2.51e-11 6.08e-08 0.44 0.5 Multiple myeloma (IgH translocation); chr16:89493801 chr16:89516797~89522217:+ PAAD cis rs9545047 0.625 rs9545109 ENSG00000227676.3 LINC01068 7.2 2.52e-11 6.11e-08 0.62 0.5 Schizophrenia; chr13:79413480 chr13:79566727~79571436:+ PAAD cis rs9545047 0.518 rs7328494 ENSG00000227676.3 LINC01068 7.2 2.52e-11 6.11e-08 0.62 0.5 Schizophrenia; chr13:79414673 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2147568 ENSG00000227676.3 LINC01068 7.2 2.52e-11 6.11e-08 0.62 0.5 Schizophrenia; chr13:79417091 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530917 ENSG00000227676.3 LINC01068 7.2 2.52e-11 6.11e-08 0.62 0.5 Schizophrenia; chr13:79417719 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7990321 ENSG00000227676.3 LINC01068 7.2 2.52e-11 6.11e-08 0.62 0.5 Schizophrenia; chr13:79418066 chr13:79566727~79571436:+ PAAD cis rs977987 0.843 rs4888415 ENSG00000261783.1 RP11-252K23.2 -7.2 2.53e-11 6.13e-08 -0.62 -0.5 Dupuytren's disease; chr16:75415023 chr16:75379818~75381260:- PAAD cis rs977987 0.872 rs2161648 ENSG00000261783.1 RP11-252K23.2 -7.2 2.57e-11 6.21e-08 -0.64 -0.5 Dupuytren's disease; chr16:75280731 chr16:75379818~75381260:- PAAD cis rs881375 0.692 rs2072438 ENSG00000226752.6 PSMD5-AS1 -7.2 2.58e-11 6.24e-08 -0.54 -0.5 Rheumatoid arthritis; chr9:120889023 chr9:120824828~120854385:+ PAAD cis rs881375 0.678 rs10739581 ENSG00000226752.6 PSMD5-AS1 -7.2 2.58e-11 6.25e-08 -0.54 -0.5 Rheumatoid arthritis; chr9:120934593 chr9:120824828~120854385:+ PAAD cis rs977987 0.843 rs12928036 ENSG00000261783.1 RP11-252K23.2 -7.2 2.59e-11 6.27e-08 -0.63 -0.5 Dupuytren's disease; chr16:75449234 chr16:75379818~75381260:- PAAD cis rs765787 0.53 rs7167731 ENSG00000259520.4 CTD-2651B20.3 -7.2 2.61e-11 6.3e-08 -0.61 -0.5 Uric acid levels; chr15:45218702 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12915027 ENSG00000259520.4 CTD-2651B20.3 -7.2 2.61e-11 6.3e-08 -0.61 -0.5 Uric acid levels; chr15:45220428 chr15:45251580~45279251:- PAAD cis rs11155671 0.53 rs2342770 ENSG00000231760.4 RP11-350J20.5 7.2 2.62e-11 6.33e-08 0.68 0.5 Testicular germ cell tumor; chr6:149895549 chr6:149796151~149826294:- PAAD cis rs12220777 1 rs72644211 ENSG00000230091.5 TMEM254-AS1 7.2 2.63e-11 6.35e-08 0.89 0.5 Chronic obstructive pulmonary disease-related biomarkers; chr10:80021939 chr10:80046860~80078912:- PAAD cis rs7615952 0.604 rs9837847 ENSG00000171084.14 FAM86JP 7.2 2.63e-11 6.36e-08 0.87 0.5 Blood pressure (smoking interaction); chr3:125905076 chr3:125916620~125930024:+ PAAD cis rs7615952 0.673 rs35955861 ENSG00000171084.14 FAM86JP 7.2 2.63e-11 6.36e-08 0.87 0.5 Blood pressure (smoking interaction); chr3:125907358 chr3:125916620~125930024:+ PAAD cis rs7615952 0.673 rs35001498 ENSG00000171084.14 FAM86JP 7.2 2.63e-11 6.36e-08 0.87 0.5 Blood pressure (smoking interaction); chr3:125909801 chr3:125916620~125930024:+ PAAD cis rs881375 0.526 rs1930785 ENSG00000226752.6 PSMD5-AS1 -7.2 2.63e-11 6.36e-08 -0.55 -0.5 Rheumatoid arthritis; chr9:120928959 chr9:120824828~120854385:+ PAAD cis rs2919917 0.915 rs3899796 ENSG00000254352.1 RP11-578O24.2 7.2 2.65e-11 6.39e-08 0.53 0.5 Lymphocyte counts; chr8:78655847 chr8:78723796~78724136:- PAAD cis rs977987 0.843 rs59465235 ENSG00000261783.1 RP11-252K23.2 -7.2 2.66e-11 6.42e-08 -0.63 -0.5 Dupuytren's disease; chr16:75449912 chr16:75379818~75381260:- PAAD cis rs7714584 1 rs61530785 ENSG00000197083.10 ZNF300P1 7.19 2.67e-11 6.45e-08 0.84 0.5 Crohn's disease; chr5:150881802 chr5:150930645~150946289:- PAAD cis rs977987 0.806 rs35787595 ENSG00000261783.1 RP11-252K23.2 -7.19 2.68e-11 6.47e-08 -0.62 -0.5 Dupuytren's disease; chr16:75432949 chr16:75379818~75381260:- PAAD cis rs1062177 0.855 rs6896664 ENSG00000213433.5 RPLP1P6 -7.19 2.69e-11 6.47e-08 -0.57 -0.5 Preschool internalizing problems; chr5:151885713 chr5:151765859~151766378:- PAAD cis rs6452524 0.967 rs11741420 ENSG00000249664.1 CTD-2227C6.2 7.19 2.69e-11 6.49e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83174913 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs4401555 ENSG00000249664.1 CTD-2227C6.2 7.19 2.69e-11 6.49e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83175267 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs62374400 ENSG00000249664.1 CTD-2227C6.2 7.19 2.69e-11 6.49e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83177053 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs10040363 ENSG00000249664.1 CTD-2227C6.2 7.19 2.69e-11 6.49e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83177826 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs10051542 ENSG00000249664.1 CTD-2227C6.2 7.19 2.69e-11 6.49e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83178268 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs10051557 ENSG00000249664.1 CTD-2227C6.2 7.19 2.69e-11 6.49e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83178307 chr5:83012285~83013109:- PAAD cis rs8062405 0.723 rs4788077 ENSG00000259982.1 CDC37P1 7.19 2.7e-11 6.51e-08 0.61 0.5 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558443 chr16:28700294~28701540:- PAAD cis rs73086581 1 rs17215529 ENSG00000229539.1 RP11-119B16.2 7.19 2.71e-11 6.53e-08 0.76 0.5 Response to antidepressants in depression; chr20:3994755 chr20:3888239~3888868:- PAAD cis rs6452524 0.967 rs2974443 ENSG00000249664.1 CTD-2227C6.2 7.19 2.72e-11 6.54e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83184595 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2974441 ENSG00000249664.1 CTD-2227C6.2 7.19 2.72e-11 6.54e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83193330 chr5:83012285~83013109:- PAAD cis rs3091242 0.806 rs35189848 ENSG00000261349.1 RP3-465N24.5 7.19 2.73e-11 6.58e-08 0.63 0.5 Erythrocyte sedimentation rate; chr1:25461931 chr1:25266102~25267136:- PAAD cis rs3091242 0.836 rs35346083 ENSG00000261349.1 RP3-465N24.5 7.19 2.73e-11 6.58e-08 0.63 0.5 Erythrocyte sedimentation rate; chr1:25461934 chr1:25266102~25267136:- PAAD cis rs4423214 0.84 rs1123007 ENSG00000254682.1 RP11-660L16.2 -7.19 2.74e-11 6.58e-08 -0.72 -0.5 Vitamin D levels; chr11:71474311 chr11:71448674~71452157:+ PAAD cis rs944002 1 rs2297067 ENSG00000259444.1 RP11-736N17.8 -7.19 2.74e-11 6.59e-08 -0.61 -0.5 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103100448 chr14:103094723~103098885:+ PAAD cis rs11690935 0.918 rs12692978 ENSG00000228389.1 AC068039.4 7.19 2.74e-11 6.59e-08 0.68 0.5 Schizophrenia; chr2:171869471 chr2:171773482~171775844:+ PAAD cis rs9545047 0.604 rs2477395 ENSG00000227676.3 LINC01068 -7.19 2.75e-11 6.62e-08 -0.62 -0.5 Schizophrenia; chr13:79427679 chr13:79566727~79571436:+ PAAD cis rs977987 0.843 rs4888427 ENSG00000261783.1 RP11-252K23.2 -7.19 2.75e-11 6.63e-08 -0.63 -0.5 Dupuytren's disease; chr16:75444549 chr16:75379818~75381260:- PAAD cis rs7829975 0.623 rs10087493 ENSG00000253893.2 FAM85B 7.19 2.81e-11 6.75e-08 0.66 0.5 Mood instability; chr8:8516047 chr8:8167819~8226614:- PAAD cis rs9545047 0.604 rs314695 ENSG00000227676.3 LINC01068 -7.19 2.81e-11 6.76e-08 -0.62 -0.5 Schizophrenia; chr13:79432206 chr13:79566727~79571436:+ PAAD cis rs3091242 0.933 rs12402120 ENSG00000261349.1 RP3-465N24.5 -7.19 2.81e-11 6.76e-08 -0.62 -0.5 Erythrocyte sedimentation rate; chr1:25425141 chr1:25266102~25267136:- PAAD cis rs7208859 0.673 rs999798 ENSG00000263531.1 RP13-753N3.1 7.19 2.81e-11 6.76e-08 0.88 0.5 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831822 chr17:30863921~30864940:- PAAD cis rs507080 0.883 rs12798453 ENSG00000255422.1 AP002954.4 -7.18 2.84e-11 6.82e-08 -0.6 -0.5 Serum metabolite levels; chr11:118690701 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs625513 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118685010 chr11:118704607~118750263:+ PAAD cis rs507080 0.845 rs613377 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118685375 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs546890 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118686489 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs555356 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118687369 chr11:118704607~118750263:+ PAAD cis rs507080 0.883 rs693306 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118687624 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs561845 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118688118 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs638805 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118688180 chr11:118704607~118750263:+ PAAD cis rs507080 0.845 rs510408 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118688192 chr11:118704607~118750263:+ PAAD cis rs507080 0.845 rs509641 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118688243 chr11:118704607~118750263:+ PAAD cis rs507080 0.883 rs563549 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118688244 chr11:118704607~118750263:+ PAAD cis rs507080 0.885 rs533144 ENSG00000255422.1 AP002954.4 -7.18 2.85e-11 6.85e-08 -0.6 -0.5 Serum metabolite levels; chr11:118688538 chr11:118704607~118750263:+ PAAD cis rs17507216 0.518 rs1877240 ENSG00000278603.1 RP13-608F4.5 7.18 2.86e-11 6.86e-08 0.82 0.5 Excessive daytime sleepiness; chr15:82770126 chr15:82472203~82472426:+ PAAD cis rs12220777 1 rs74372131 ENSG00000230091.5 TMEM254-AS1 7.18 2.88e-11 6.92e-08 0.85 0.5 Chronic obstructive pulmonary disease-related biomarkers; chr10:80027458 chr10:80046860~80078912:- PAAD cis rs7174755 0.772 rs80187654 ENSG00000260657.2 RP11-315D16.4 7.18 2.92e-11 6.99e-08 0.6 0.5 Major depressive disorder; chr15:68082833 chr15:68267792~68277994:- PAAD cis rs7586673 0.93 rs7591506 ENSG00000227403.1 AC009299.3 -7.18 2.93e-11 7.02e-08 -0.67 -0.5 Intelligence (multi-trait analysis); chr2:161104414 chr2:161244739~161249050:+ PAAD cis rs881375 0.678 rs3761846 ENSG00000226752.6 PSMD5-AS1 -7.18 2.93e-11 7.03e-08 -0.54 -0.5 Rheumatoid arthritis; chr9:120927319 chr9:120824828~120854385:+ PAAD cis rs1062177 0.855 rs62395861 ENSG00000213433.5 RPLP1P6 -7.18 2.94e-11 7.05e-08 -0.58 -0.5 Preschool internalizing problems; chr5:151889709 chr5:151765859~151766378:- PAAD cis rs1062177 0.95 rs59580263 ENSG00000213433.5 RPLP1P6 -7.18 2.94e-11 7.05e-08 -0.58 -0.5 Preschool internalizing problems; chr5:151890016 chr5:151765859~151766378:- PAAD cis rs507080 0.922 rs12788848 ENSG00000255422.1 AP002954.4 -7.18 2.95e-11 7.05e-08 -0.6 -0.5 Serum metabolite levels; chr11:118683079 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs4474473 ENSG00000255422.1 AP002954.4 -7.18 2.95e-11 7.05e-08 -0.6 -0.5 Serum metabolite levels; chr11:118683180 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs12796373 ENSG00000255422.1 AP002954.4 -7.18 2.95e-11 7.05e-08 -0.6 -0.5 Serum metabolite levels; chr11:118684230 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs582630 ENSG00000255422.1 AP002954.4 -7.18 2.96e-11 7.09e-08 -0.61 -0.5 Serum metabolite levels; chr11:118692090 chr11:118704607~118750263:+ PAAD cis rs507080 0.883 rs527475 ENSG00000255422.1 AP002954.4 -7.18 2.96e-11 7.09e-08 -0.61 -0.5 Serum metabolite levels; chr11:118692530 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs585039 ENSG00000255422.1 AP002954.4 -7.18 2.96e-11 7.09e-08 -0.61 -0.5 Serum metabolite levels; chr11:118692672 chr11:118704607~118750263:+ PAAD cis rs881375 0.702 rs3761847 ENSG00000226752.6 PSMD5-AS1 -7.18 2.96e-11 7.09e-08 -0.54 -0.5 Rheumatoid arthritis; chr9:120927961 chr9:120824828~120854385:+ PAAD cis rs9326248 0.569 rs10047459 ENSG00000254851.1 RP11-109L13.1 -7.17 2.98e-11 7.12e-08 -0.84 -0.5 Blood protein levels; chr11:116851110 chr11:117135528~117138582:+ PAAD cis rs67180937 0.849 rs4575092 ENSG00000272750.1 RP11-378J18.8 -7.17 2.98e-11 7.13e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222661161 chr1:222658867~222661512:- PAAD cis rs3096299 0.658 rs4785679 ENSG00000274627.1 RP11-104N10.2 7.17 3.01e-11 7.2e-08 0.44 0.5 Multiple myeloma (IgH translocation); chr16:89499705 chr16:89516797~89522217:+ PAAD cis rs977987 0.835 rs1010630 ENSG00000261783.1 RP11-252K23.2 -7.17 3.05e-11 7.28e-08 -0.63 -0.5 Dupuytren's disease; chr16:75294693 chr16:75379818~75381260:- PAAD cis rs507080 0.845 rs667982 ENSG00000255422.1 AP002954.4 -7.17 3.06e-11 7.31e-08 -0.61 -0.5 Serum metabolite levels; chr11:118692058 chr11:118704607~118750263:+ PAAD cis rs4423214 0.84 rs1792233 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71471133 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1792231 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71471635 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1790339 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71471715 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs4435028 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71472644 chr11:71448674~71452157:+ PAAD cis rs4423214 0.802 rs4616066 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71472800 chr11:71448674~71452157:+ PAAD cis rs4423214 0.802 rs4402322 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71472969 chr11:71448674~71452157:+ PAAD cis rs4423214 0.802 rs2276358 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71473452 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs3794057 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71475698 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs2017686 ENSG00000254682.1 RP11-660L16.2 -7.17 3.1e-11 7.39e-08 -0.72 -0.5 Vitamin D levels; chr11:71476015 chr11:71448674~71452157:+ PAAD cis rs67180937 0.961 rs17465637 ENSG00000272750.1 RP11-378J18.8 7.17 3.13e-11 7.46e-08 0.54 0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222650187 chr1:222658867~222661512:- PAAD cis rs67180937 1 rs67180937 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222650401 chr1:222658867~222661512:- PAAD cis rs67180937 0.961 rs17011681 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222651746 chr1:222658867~222661512:- PAAD cis rs67180937 0.922 rs10495198 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222652375 chr1:222658867~222661512:- PAAD cis rs67180937 0.884 rs2291832 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222653139 chr1:222658867~222661512:- PAAD cis rs67180937 0.961 rs17163363 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222655362 chr1:222658867~222661512:- PAAD cis rs35158675 1 rs35158675 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease; chr1:222656208 chr1:222658867~222661512:- PAAD cis rs67180937 0.921 rs2291834 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222658953 chr1:222658867~222661512:- PAAD cis rs67180937 0.922 rs1133220 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222661461 chr1:222658867~222661512:- PAAD cis rs67180937 0.961 rs17465940 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222663654 chr1:222658867~222661512:- PAAD cis rs67180937 0.922 rs17465982 ENSG00000272750.1 RP11-378J18.8 -7.17 3.13e-11 7.46e-08 -0.54 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222664597 chr1:222658867~222661512:- PAAD cis rs881375 0.631 rs2416808 ENSG00000226752.6 PSMD5-AS1 -7.16 3.15e-11 7.49e-08 -0.54 -0.5 Rheumatoid arthritis; chr9:120944005 chr9:120824828~120854385:+ PAAD cis rs9545047 0.716 rs9545108 ENSG00000227676.3 LINC01068 7.16 3.15e-11 7.5e-08 0.64 0.5 Schizophrenia; chr13:79411175 chr13:79566727~79571436:+ PAAD cis rs11673344 0.526 rs35153242 ENSG00000226686.6 LINC01535 -7.16 3.17e-11 7.54e-08 -0.66 -0.5 Obesity-related traits; chr19:37660841 chr19:37251912~37265535:+ PAAD cis rs7829975 0.593 rs2921077 ENSG00000253893.2 FAM85B -7.16 3.18e-11 7.57e-08 -0.67 -0.5 Mood instability; chr8:8446992 chr8:8167819~8226614:- PAAD cis rs9322193 0.607 rs6925151 ENSG00000231760.4 RP11-350J20.5 7.16 3.19e-11 7.58e-08 0.73 0.5 Lung cancer; chr6:149889587 chr6:149796151~149826294:- PAAD cis rs3091242 0.9 rs1883427 ENSG00000261349.1 RP3-465N24.5 -7.16 3.19e-11 7.6e-08 -0.62 -0.5 Erythrocyte sedimentation rate; chr1:25417977 chr1:25266102~25267136:- PAAD cis rs9322193 0.567 rs7747457 ENSG00000268592.3 RAET1E-AS1 7.16 3.21e-11 7.62e-08 0.61 0.5 Lung cancer; chr6:149892366 chr6:149863494~149919507:+ PAAD cis rs507080 0.922 rs533646 ENSG00000255422.1 AP002954.4 -7.16 3.21e-11 7.64e-08 -0.61 -0.5 Serum metabolite levels; chr11:118696037 chr11:118704607~118750263:+ PAAD cis rs507080 0.922 rs642662 ENSG00000255422.1 AP002954.4 -7.16 3.21e-11 7.64e-08 -0.61 -0.5 Serum metabolite levels; chr11:118696311 chr11:118704607~118750263:+ PAAD cis rs9399135 0.636 rs7749106 ENSG00000232876.1 CTA-212D2.2 -7.16 3.23e-11 7.68e-08 -0.62 -0.5 Red blood cell count; chr6:134947004 chr6:135055033~135060550:+ PAAD cis rs11155671 0.53 rs6557133 ENSG00000223701.3 RAET1E-AS1 7.16 3.27e-11 7.76e-08 0.6 0.5 Testicular germ cell tumor; chr6:149874248 chr6:149884431~149919508:+ PAAD cis rs977987 0.843 rs11649638 ENSG00000261783.1 RP11-252K23.2 -7.16 3.27e-11 7.76e-08 -0.62 -0.5 Dupuytren's disease; chr16:75454387 chr16:75379818~75381260:- PAAD cis rs977987 0.815 rs4887829 ENSG00000261783.1 RP11-252K23.2 -7.16 3.27e-11 7.76e-08 -0.62 -0.5 Dupuytren's disease; chr16:75455037 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs28655617 ENSG00000261783.1 RP11-252K23.2 -7.16 3.27e-11 7.76e-08 -0.62 -0.5 Dupuytren's disease; chr16:75455744 chr16:75379818~75381260:- PAAD cis rs2919917 1 rs7001074 ENSG00000254352.1 RP11-578O24.2 7.16 3.27e-11 7.77e-08 0.53 0.5 Lymphocyte counts; chr8:78691689 chr8:78723796~78724136:- PAAD cis rs9322193 0.567 rs7742692 ENSG00000268592.3 RAET1E-AS1 7.16 3.28e-11 7.79e-08 0.61 0.5 Lung cancer; chr6:149892363 chr6:149863494~149919507:+ PAAD cis rs2739330 0.828 rs4822451 ENSG00000099984.9 GSTT2 -7.16 3.28e-11 7.8e-08 -0.66 -0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23980123~23983911:+ PAAD cis rs2739330 0.828 rs5760099 ENSG00000099984.9 GSTT2 -7.16 3.28e-11 7.8e-08 -0.66 -0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23980123~23983911:+ PAAD cis rs9545047 0.716 rs586219 ENSG00000227676.3 LINC01068 -7.16 3.29e-11 7.81e-08 -0.64 -0.5 Schizophrenia; chr13:79425177 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs2265377 ENSG00000227676.3 LINC01068 -7.16 3.29e-11 7.81e-08 -0.64 -0.5 Schizophrenia; chr13:79425485 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs2265378 ENSG00000227676.3 LINC01068 -7.16 3.29e-11 7.81e-08 -0.64 -0.5 Schizophrenia; chr13:79425581 chr13:79566727~79571436:+ PAAD cis rs9545047 0.669 rs2095477 ENSG00000227676.3 LINC01068 -7.16 3.29e-11 7.81e-08 -0.64 -0.5 Schizophrenia; chr13:79427869 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs8001795 ENSG00000227676.3 LINC01068 7.16 3.29e-11 7.81e-08 0.64 0.5 Schizophrenia; chr13:79421402 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs8002838 ENSG00000227676.3 LINC01068 7.16 3.29e-11 7.81e-08 0.64 0.5 Schizophrenia; chr13:79421681 chr13:79566727~79571436:+ PAAD cis rs9545047 0.669 rs9545113 ENSG00000227676.3 LINC01068 7.16 3.29e-11 7.81e-08 0.64 0.5 Schizophrenia; chr13:79422017 chr13:79566727~79571436:+ PAAD cis rs9545047 0.68 rs9545114 ENSG00000227676.3 LINC01068 7.16 3.29e-11 7.81e-08 0.64 0.5 Schizophrenia; chr13:79423744 chr13:79566727~79571436:+ PAAD cis rs6452524 0.935 rs1017794 ENSG00000249664.1 CTD-2227C6.2 7.16 3.3e-11 7.82e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83086236 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs6880566 ENSG00000249664.1 CTD-2227C6.2 7.16 3.3e-11 7.82e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83086909 chr5:83012285~83013109:- PAAD cis rs6452524 0.905 rs6884981 ENSG00000249664.1 CTD-2227C6.2 7.16 3.3e-11 7.82e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83087339 chr5:83012285~83013109:- PAAD cis rs6452524 0.905 rs6896548 ENSG00000249664.1 CTD-2227C6.2 7.16 3.3e-11 7.82e-08 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83089247 chr5:83012285~83013109:- PAAD cis rs7714584 1 rs17800886 ENSG00000197083.10 ZNF300P1 7.16 3.3e-11 7.83e-08 0.82 0.5 Crohn's disease; chr5:150929977 chr5:150930645~150946289:- PAAD cis rs9322193 0.566 rs9397070 ENSG00000216906.2 RP11-350J20.9 -7.16 3.3e-11 7.83e-08 -0.71 -0.5 Lung cancer; chr6:149922073 chr6:149904243~149906418:+ PAAD cis rs9545047 0.716 rs9530920 ENSG00000227676.3 LINC01068 7.16 3.31e-11 7.84e-08 0.64 0.5 Schizophrenia; chr13:79423254 chr13:79566727~79571436:+ PAAD cis rs7586673 0.893 rs889925 ENSG00000227403.1 AC009299.3 -7.15 3.35e-11 7.92e-08 -0.67 -0.5 Intelligence (multi-trait analysis); chr2:161115086 chr2:161244739~161249050:+ PAAD cis rs7586673 0.93 rs2884364 ENSG00000227403.1 AC009299.3 -7.15 3.35e-11 7.92e-08 -0.67 -0.5 Intelligence (multi-trait analysis); chr2:161121136 chr2:161244739~161249050:+ PAAD cis rs7044106 0.5 rs56725168 ENSG00000226752.6 PSMD5-AS1 -7.15 3.36e-11 7.95e-08 -0.66 -0.5 Hip circumference adjusted for BMI; chr9:120730298 chr9:120824828~120854385:+ PAAD cis rs5760092 0.842 rs5751763 ENSG00000273295.1 AP000350.5 7.15 3.37e-11 7.97e-08 0.82 0.5 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23905606 chr22:23901432~23907068:- PAAD cis rs1062177 0.694 rs2915816 ENSG00000213433.5 RPLP1P6 7.15 3.4e-11 8.04e-08 0.54 0.5 Preschool internalizing problems; chr5:151736296 chr5:151765859~151766378:- PAAD cis rs3814244 0.868 rs10878726 ENSG00000255733.4 IFNG-AS1 7.15 3.41e-11 8.07e-08 0.44 0.5 Itch intensity from mosquito bite adjusted by bite size; chr12:68022865 chr12:67989445~68234686:+ PAAD cis rs1062177 0.855 rs919263 ENSG00000213433.5 RPLP1P6 -7.15 3.43e-11 8.11e-08 -0.56 -0.5 Preschool internalizing problems; chr5:151886292 chr5:151765859~151766378:- PAAD cis rs1062177 0.855 rs919262 ENSG00000213433.5 RPLP1P6 7.15 3.43e-11 8.11e-08 0.56 0.5 Preschool internalizing problems; chr5:151886523 chr5:151765859~151766378:- PAAD cis rs9660180 0.819 rs4648629 ENSG00000231050.1 RP1-140A9.1 -7.15 3.46e-11 8.17e-08 -0.58 -0.5 Body mass index; chr1:1764023 chr1:1891471~1892658:+ PAAD cis rs5760092 0.842 rs5760103 ENSG00000218537.1 MIF-AS1 7.15 3.47e-11 8.2e-08 0.88 0.5 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23906594 chr22:23894426~23898930:- PAAD cis rs7829975 0.593 rs2979241 ENSG00000253893.2 FAM85B -7.14 3.5e-11 8.27e-08 -0.7 -0.5 Mood instability; chr8:8445843 chr8:8167819~8226614:- PAAD cis rs977987 0.806 rs11865004 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75361879 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs1364077 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75363093 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs4887820 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75363389 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs34222958 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75364354 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs4887821 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75364676 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11640473 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75369391 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs8057203 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75371076 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs35552529 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75371981 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs56343285 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75375899 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs1544810 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75377265 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs11858992 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75377547 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4993970 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75377721 chr16:75379818~75381260:- PAAD cis rs977987 0.736 rs4888392 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75378364 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11860284 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75379009 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs2865530 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75380478 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs7203157 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75384022 chr16:75379818~75381260:- PAAD cis rs977987 0.771 rs8048527 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75388156 chr16:75379818~75381260:- PAAD cis rs977987 0.815 rs11149821 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75388919 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs4888400 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75391698 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4888404 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75394199 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs2285225 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75395354 chr16:75379818~75381260:- PAAD cis rs977987 0.527 rs62059844 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75395839 chr16:75379818~75381260:- PAAD cis rs977987 0.585 rs62059845 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75396815 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs62059846 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75396911 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11862582 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75397397 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs11862719 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75397810 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs11149824 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75397932 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs11641801 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75421550 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11648176 ENSG00000261783.1 RP11-252K23.2 -7.14 3.52e-11 8.29e-08 -0.62 -0.5 Dupuytren's disease; chr16:75422525 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4146809 ENSG00000261783.1 RP11-252K23.2 7.14 3.52e-11 8.29e-08 0.62 0.5 Dupuytren's disease; chr16:75381877 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs12444589 ENSG00000261783.1 RP11-252K23.2 7.14 3.52e-11 8.29e-08 0.62 0.5 Dupuytren's disease; chr16:75420506 chr16:75379818~75381260:- PAAD cis rs507080 0.961 rs1784298 ENSG00000255422.1 AP002954.4 -7.14 3.52e-11 8.29e-08 -0.6 -0.5 Serum metabolite levels; chr11:118677956 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs4938522 ENSG00000255422.1 AP002954.4 -7.14 3.52e-11 8.29e-08 -0.6 -0.5 Serum metabolite levels; chr11:118677962 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs4938523 ENSG00000255422.1 AP002954.4 -7.14 3.52e-11 8.29e-08 -0.6 -0.5 Serum metabolite levels; chr11:118678129 chr11:118704607~118750263:+ PAAD cis rs507080 1 rs659969 ENSG00000255422.1 AP002954.4 -7.14 3.52e-11 8.29e-08 -0.6 -0.5 Serum metabolite levels; chr11:118679094 chr11:118704607~118750263:+ PAAD cis rs11155671 0.53 rs6557133 ENSG00000268592.3 RAET1E-AS1 7.14 3.54e-11 8.33e-08 0.62 0.5 Testicular germ cell tumor; chr6:149874248 chr6:149863494~149919507:+ PAAD cis rs977987 0.645 rs10871311 ENSG00000261783.1 RP11-252K23.2 -7.14 3.54e-11 8.33e-08 -0.62 -0.5 Dupuytren's disease; chr16:75417014 chr16:75379818~75381260:- PAAD cis rs172166 0.561 rs149973 ENSG00000216901.1 AL022393.7 7.14 3.55e-11 8.35e-08 0.62 0.5 Cardiac Troponin-T levels; chr6:28015835 chr6:28176188~28176674:+ PAAD cis rs172166 0.561 rs149974 ENSG00000216901.1 AL022393.7 7.14 3.55e-11 8.35e-08 0.62 0.5 Cardiac Troponin-T levels; chr6:28017318 chr6:28176188~28176674:+ PAAD cis rs2283792 0.73 rs2329884 ENSG00000224086.5 LL22NC03-86G7.1 -7.14 3.55e-11 8.35e-08 -0.53 -0.5 Multiple sclerosis; chr22:21927890 chr22:21938293~21977632:+ PAAD cis rs6452524 1 rs10474093 ENSG00000249664.1 CTD-2227C6.2 7.14 3.57e-11 8.39e-08 0.57 0.5 Hypertension (SNP x SNP interaction); chr5:83141612 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs10473868 ENSG00000249664.1 CTD-2227C6.2 7.14 3.57e-11 8.39e-08 0.57 0.5 Hypertension (SNP x SNP interaction); chr5:83141628 chr5:83012285~83013109:- PAAD cis rs67180937 0.882 rs17163345 ENSG00000272750.1 RP11-378J18.8 -7.14 3.62e-11 8.51e-08 -0.53 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222632876 chr1:222658867~222661512:- PAAD cis rs977987 0.836 rs11646044 ENSG00000261783.1 RP11-252K23.2 -7.13 3.73e-11 8.74e-08 -0.63 -0.5 Dupuytren's disease; chr16:75278650 chr16:75379818~75381260:- PAAD cis rs9545047 0.692 rs314694 ENSG00000227676.3 LINC01068 -7.13 3.74e-11 8.76e-08 -0.63 -0.5 Schizophrenia; chr13:79432467 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs418150 ENSG00000227676.3 LINC01068 -7.13 3.74e-11 8.76e-08 -0.63 -0.5 Schizophrenia; chr13:79432675 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs416660 ENSG00000227676.3 LINC01068 -7.13 3.74e-11 8.76e-08 -0.63 -0.5 Schizophrenia; chr13:79432726 chr13:79566727~79571436:+ PAAD cis rs4423214 0.84 rs1792235 ENSG00000254682.1 RP11-660L16.2 -7.13 3.84e-11 8.98e-08 -0.72 -0.5 Vitamin D levels; chr11:71470427 chr11:71448674~71452157:+ PAAD cis rs4423214 0.84 rs1619577 ENSG00000254682.1 RP11-660L16.2 -7.13 3.84e-11 8.98e-08 -0.72 -0.5 Vitamin D levels; chr11:71470439 chr11:71448674~71452157:+ PAAD cis rs9326248 0.569 rs4938315 ENSG00000254851.1 RP11-109L13.1 -7.13 3.84e-11 8.98e-08 -0.87 -0.5 Blood protein levels; chr11:116860489 chr11:117135528~117138582:+ PAAD cis rs9545047 0.716 rs9545053 ENSG00000227676.3 LINC01068 7.13 3.85e-11 9e-08 0.63 0.5 Schizophrenia; chr13:79296079 chr13:79566727~79571436:+ PAAD cis rs944002 1 rs2297066 ENSG00000259444.1 RP11-736N17.8 7.13 3.86e-11 9.02e-08 0.61 0.5 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103100498 chr14:103094723~103098885:+ PAAD cis rs977987 0.806 rs4887823 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75399176 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs12051136 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75401833 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs4888409 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75402333 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs7206541 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75402815 chr16:75379818~75381260:- PAAD cis rs977987 0.788 rs7184525 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75403288 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs12051326 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75403989 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs12443834 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75404571 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs12924920 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75406235 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4887824 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75407715 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4888411 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75409285 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs4888412 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75409298 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs4888413 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75409325 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs8057849 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75409918 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs72787160 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75411264 chr16:75379818~75381260:- PAAD cis rs977987 0.75 rs4888414 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75413335 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs6564258 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75413465 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs6564259 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75413495 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs6564260 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75413528 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs8056236 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75414375 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs8051407 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75414761 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4888416 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75415278 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs7199132 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75416141 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs7188604 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75417272 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs12149063 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75417860 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11642572 ENSG00000261783.1 RP11-252K23.2 -7.13 3.89e-11 9.05e-08 -0.62 -0.5 Dupuytren's disease; chr16:75418884 chr16:75379818~75381260:- PAAD cis rs2283792 0.73 rs2083565 ENSG00000224086.5 LL22NC03-86G7.1 -7.13 3.89e-11 9.06e-08 -0.54 -0.5 Multiple sclerosis; chr22:21929985 chr22:21938293~21977632:+ PAAD cis rs853679 0.527 rs1997660 ENSG00000216901.1 AL022393.7 7.13 3.9e-11 9.07e-08 0.64 0.5 Depression; chr6:28301886 chr6:28176188~28176674:+ PAAD cis rs853679 0.527 rs9468333 ENSG00000216901.1 AL022393.7 7.13 3.9e-11 9.07e-08 0.64 0.5 Depression; chr6:28303421 chr6:28176188~28176674:+ PAAD cis rs6903823 0.527 rs4713158 ENSG00000216901.1 AL022393.7 7.13 3.9e-11 9.07e-08 0.64 0.5 Pulmonary function; chr6:28309994 chr6:28176188~28176674:+ PAAD cis rs9545047 0.567 rs7321186 ENSG00000227676.3 LINC01068 7.13 3.9e-11 9.08e-08 0.62 0.5 Schizophrenia; chr13:79383403 chr13:79566727~79571436:+ PAAD cis rs9322193 0.576 rs7452592 ENSG00000231760.4 RP11-350J20.5 7.12 3.91e-11 9.1e-08 0.8 0.5 Lung cancer; chr6:149875445 chr6:149796151~149826294:- PAAD cis rs507080 0.883 rs692750 ENSG00000255422.1 AP002954.4 -7.12 3.95e-11 9.19e-08 -0.59 -0.5 Serum metabolite levels; chr11:118667599 chr11:118704607~118750263:+ PAAD cis rs4423214 0.879 rs1790324 ENSG00000254682.1 RP11-660L16.2 -7.12 3.96e-11 9.21e-08 -0.69 -0.5 Vitamin D levels; chr11:71439474 chr11:71448674~71452157:+ PAAD cis rs11155671 0.53 rs7757984 ENSG00000231760.4 RP11-350J20.5 7.12 3.97e-11 9.22e-08 0.67 0.5 Testicular germ cell tumor; chr6:149887515 chr6:149796151~149826294:- PAAD cis rs977987 0.872 rs3743609 ENSG00000261783.1 RP11-252K23.2 -7.12 3.98e-11 9.25e-08 -0.61 -0.5 Dupuytren's disease; chr16:75433123 chr16:75379818~75381260:- PAAD cis rs73086581 1 rs73084575 ENSG00000229539.1 RP11-119B16.2 7.12 3.99e-11 9.26e-08 0.78 0.5 Response to antidepressants in depression; chr20:3926121 chr20:3888239~3888868:- PAAD cis rs11673344 0.566 rs256733 ENSG00000226686.6 LINC01535 7.12 4.01e-11 9.31e-08 0.59 0.5 Obesity-related traits; chr19:37384729 chr19:37251912~37265535:+ PAAD cis rs4423214 0.798 rs1894100 ENSG00000254682.1 RP11-660L16.2 -7.12 4.01e-11 9.31e-08 -0.7 -0.5 Vitamin D levels; chr11:71419297 chr11:71448674~71452157:+ PAAD cis rs6452524 0.508 rs40214 ENSG00000249664.1 CTD-2227C6.2 -7.12 4.05e-11 9.38e-08 -0.57 -0.5 Hypertension (SNP x SNP interaction); chr5:83000359 chr5:83012285~83013109:- PAAD cis rs9322193 0.607 rs9383941 ENSG00000231760.4 RP11-350J20.5 -7.12 4.06e-11 9.41e-08 -0.69 -0.5 Lung cancer; chr6:149912100 chr6:149796151~149826294:- PAAD cis rs11673344 0.526 rs73035160 ENSG00000226686.6 LINC01535 7.12 4.06e-11 9.41e-08 0.66 0.5 Obesity-related traits; chr19:37655135 chr19:37251912~37265535:+ PAAD cis rs11673344 0.526 rs1871196 ENSG00000226686.6 LINC01535 7.12 4.06e-11 9.41e-08 0.66 0.5 Obesity-related traits; chr19:37656022 chr19:37251912~37265535:+ PAAD cis rs73086581 0.945 rs6052222 ENSG00000229539.1 RP11-119B16.2 7.12 4.09e-11 9.47e-08 0.75 0.5 Response to antidepressants in depression; chr20:3992146 chr20:3888239~3888868:- PAAD cis rs9545047 0.604 rs1616547 ENSG00000227676.3 LINC01068 7.12 4.09e-11 9.48e-08 0.61 0.5 Schizophrenia; chr13:79411901 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs6563096 ENSG00000227676.3 LINC01068 -7.12 4.1e-11 9.49e-08 -0.62 -0.5 Schizophrenia; chr13:79284100 chr13:79566727~79571436:+ PAAD cis rs11155671 0.53 rs2342770 ENSG00000268592.3 RAET1E-AS1 7.11 4.13e-11 9.56e-08 0.62 0.5 Testicular germ cell tumor; chr6:149895549 chr6:149863494~149919507:+ PAAD cis rs977987 0.806 rs12599361 ENSG00000261783.1 RP11-252K23.2 -7.11 4.13e-11 9.57e-08 -0.62 -0.5 Dupuytren's disease; chr16:75401075 chr16:75379818~75381260:- PAAD cis rs12022452 0.506 rs6673386 ENSG00000238287.1 RP11-656D10.3 -7.11 4.14e-11 9.59e-08 -0.72 -0.5 Age-related hearing impairment (SNP x SNP interaction); chr1:40546207 chr1:40493157~40508661:- PAAD cis rs3814244 0.868 rs11177007 ENSG00000255733.4 IFNG-AS1 7.11 4.15e-11 9.61e-08 0.45 0.5 Itch intensity from mosquito bite adjusted by bite size; chr12:68020964 chr12:67989445~68234686:+ PAAD cis rs2739330 0.685 rs4822453 ENSG00000250470.1 AP000351.3 7.11 4.15e-11 9.62e-08 0.7 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23976904~23977585:- PAAD cis rs6452524 1 rs6452531 ENSG00000249664.1 CTD-2227C6.2 7.11 4.15e-11 9.62e-08 0.56 0.5 Hypertension (SNP x SNP interaction); chr5:83170355 chr5:83012285~83013109:- PAAD cis rs977987 0.778 rs1109341 ENSG00000261783.1 RP11-252K23.2 -7.11 4.18e-11 9.67e-08 -0.62 -0.5 Dupuytren's disease; chr16:75411707 chr16:75379818~75381260:- PAAD cis rs73086581 0.741 rs17212649 ENSG00000229539.1 RP11-119B16.2 7.11 4.22e-11 9.75e-08 0.79 0.5 Response to antidepressants in depression; chr20:3872446 chr20:3888239~3888868:- PAAD cis rs10515750 0.643 rs10063413 ENSG00000251405.2 CTB-109A12.1 -7.11 4.22e-11 9.77e-08 -0.85 -0.5 Lung function (FEV1/FVC); chr5:157384435 chr5:157362615~157460078:- PAAD cis rs10515750 0.643 rs10054755 ENSG00000251405.2 CTB-109A12.1 7.11 4.22e-11 9.77e-08 0.85 0.5 Lung function (FEV1/FVC); chr5:157384037 chr5:157362615~157460078:- PAAD cis rs10515750 0.643 rs10063539 ENSG00000251405.2 CTB-109A12.1 7.11 4.22e-11 9.77e-08 0.85 0.5 Lung function (FEV1/FVC); chr5:157384666 chr5:157362615~157460078:- PAAD cis rs977987 0.806 rs11643410 ENSG00000261783.1 RP11-252K23.2 -7.11 4.23e-11 9.78e-08 -0.62 -0.5 Dupuytren's disease; chr16:75394408 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11864102 ENSG00000261783.1 RP11-252K23.2 -7.11 4.27e-11 9.88e-08 -0.62 -0.5 Dupuytren's disease; chr16:75408462 chr16:75379818~75381260:- PAAD cis rs1062177 0.855 rs1346489 ENSG00000213433.5 RPLP1P6 -7.11 4.32e-11 9.97e-08 -0.56 -0.5 Preschool internalizing problems; chr5:151886973 chr5:151765859~151766378:- PAAD cis rs977987 0.806 rs4888418 ENSG00000261783.1 RP11-252K23.2 -7.11 4.32e-11 9.98e-08 -0.62 -0.5 Dupuytren's disease; chr16:75426408 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs17696749 ENSG00000261783.1 RP11-252K23.2 -7.11 4.35e-11 1e-07 -0.61 -0.5 Dupuytren's disease; chr16:75369164 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4888388 ENSG00000261783.1 RP11-252K23.2 -7.1 4.36e-11 1.01e-07 -0.62 -0.5 Dupuytren's disease; chr16:75360250 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs7185640 ENSG00000261783.1 RP11-252K23.2 -7.1 4.36e-11 1.01e-07 -0.62 -0.5 Dupuytren's disease; chr16:75360501 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11640674 ENSG00000261783.1 RP11-252K23.2 -7.1 4.36e-11 1.01e-07 -0.62 -0.5 Dupuytren's disease; chr16:75361046 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4888389 ENSG00000261783.1 RP11-252K23.2 -7.1 4.36e-11 1.01e-07 -0.62 -0.5 Dupuytren's disease; chr16:75361330 chr16:75379818~75381260:- PAAD cis rs2283792 0.73 rs738858 ENSG00000224086.5 LL22NC03-86G7.1 -7.1 4.37e-11 1.01e-07 -0.53 -0.5 Multiple sclerosis; chr22:21926544 chr22:21938293~21977632:+ PAAD cis rs1150668 0.799 rs9301 ENSG00000216901.1 AL022393.7 7.1 4.38e-11 1.01e-07 0.61 0.5 Pubertal anthropometrics; chr6:28324929 chr6:28176188~28176674:+ PAAD cis rs1150668 0.799 rs853684 ENSG00000216901.1 AL022393.7 7.1 4.38e-11 1.01e-07 0.61 0.5 Pubertal anthropometrics; chr6:28326773 chr6:28176188~28176674:+ PAAD cis rs1150668 0.799 rs1150707 ENSG00000216901.1 AL022393.7 7.1 4.44e-11 1.02e-07 0.58 0.5 Pubertal anthropometrics; chr6:28229827 chr6:28176188~28176674:+ PAAD cis rs1150668 0.768 rs1233713 ENSG00000216901.1 AL022393.7 7.1 4.44e-11 1.02e-07 0.58 0.5 Pubertal anthropometrics; chr6:28230503 chr6:28176188~28176674:+ PAAD cis rs12022452 0.506 rs11208363 ENSG00000238287.1 RP11-656D10.3 -7.1 4.46e-11 1.03e-07 -0.74 -0.5 Age-related hearing impairment (SNP x SNP interaction); chr1:40544782 chr1:40493157~40508661:- PAAD cis rs507080 0.922 rs4589335 ENSG00000255422.1 AP002954.4 -7.1 4.46e-11 1.03e-07 -0.59 -0.5 Serum metabolite levels; chr11:118668431 chr11:118704607~118750263:+ PAAD cis rs2283792 0.73 rs894095 ENSG00000224086.5 LL22NC03-86G7.1 -7.1 4.47e-11 1.03e-07 -0.53 -0.5 Multiple sclerosis; chr22:21928404 chr22:21938293~21977632:+ PAAD cis rs1062177 0.826 rs2915873 ENSG00000213433.5 RPLP1P6 -7.1 4.47e-11 1.03e-07 -0.58 -0.5 Preschool internalizing problems; chr5:151777097 chr5:151765859~151766378:- PAAD cis rs881375 0.678 rs10760129 ENSG00000226752.6 PSMD5-AS1 -7.1 4.51e-11 1.04e-07 -0.54 -0.5 Rheumatoid arthritis; chr9:120937905 chr9:120824828~120854385:+ PAAD cis rs673078 0.66 rs73205531 ENSG00000275759.1 RP11-131L12.3 -7.1 4.53e-11 1.04e-07 -0.77 -0.5 Glucose homeostasis traits; chr12:118282063 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61946067 ENSG00000275759.1 RP11-131L12.3 -7.1 4.53e-11 1.04e-07 -0.77 -0.5 Glucose homeostasis traits; chr12:118303152 chr12:118428281~118428870:+ PAAD cis rs9545047 0.716 rs314693 ENSG00000227676.3 LINC01068 -7.1 4.53e-11 1.04e-07 -0.63 -0.5 Schizophrenia; chr13:79432792 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs314692 ENSG00000227676.3 LINC01068 -7.1 4.53e-11 1.04e-07 -0.63 -0.5 Schizophrenia; chr13:79433091 chr13:79566727~79571436:+ PAAD cis rs977987 0.736 rs11865296 ENSG00000261783.1 RP11-252K23.2 -7.1 4.53e-11 1.04e-07 -0.61 -0.5 Dupuytren's disease; chr16:75439795 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs34021527 ENSG00000261783.1 RP11-252K23.2 -7.1 4.53e-11 1.04e-07 -0.61 -0.5 Dupuytren's disease; chr16:75440192 chr16:75379818~75381260:- PAAD cis rs977987 0.751 rs56004344 ENSG00000261783.1 RP11-252K23.2 -7.1 4.53e-11 1.04e-07 -0.61 -0.5 Dupuytren's disease; chr16:75440291 chr16:75379818~75381260:- PAAD cis rs8062405 0.69 rs62034351 ENSG00000259982.1 CDC37P1 7.1 4.56e-11 1.05e-07 0.61 0.5 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554168 chr16:28700294~28701540:- PAAD cis rs9399137 0.507 rs4520025 ENSG00000232876.1 CTA-212D2.2 -7.1 4.56e-11 1.05e-07 -0.6 -0.5 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134957481 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs4451150 ENSG00000232876.1 CTA-212D2.2 -7.1 4.56e-11 1.05e-07 -0.6 -0.5 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134957925 chr6:135055033~135060550:+ PAAD cis rs9399137 0.561 rs11753985 ENSG00000232876.1 CTA-212D2.2 -7.1 4.56e-11 1.05e-07 -0.6 -0.5 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134959300 chr6:135055033~135060550:+ PAAD cis rs7044106 0.791 rs735110 ENSG00000226752.6 PSMD5-AS1 -7.1 4.59e-11 1.05e-07 -0.65 -0.5 Hip circumference adjusted for BMI; chr9:120726662 chr9:120824828~120854385:+ PAAD cis rs507080 0.883 rs656575 ENSG00000255422.1 AP002954.4 -7.09 4.6e-11 1.05e-07 -0.6 -0.5 Serum metabolite levels; chr11:118679199 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs656505 ENSG00000255422.1 AP002954.4 -7.09 4.6e-11 1.05e-07 -0.6 -0.5 Serum metabolite levels; chr11:118679245 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs660489 ENSG00000255422.1 AP002954.4 -7.09 4.6e-11 1.05e-07 -0.6 -0.5 Serum metabolite levels; chr11:118679255 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs543327 ENSG00000255422.1 AP002954.4 -7.09 4.6e-11 1.05e-07 -0.6 -0.5 Serum metabolite levels; chr11:118679276 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs543413 ENSG00000255422.1 AP002954.4 -7.09 4.6e-11 1.05e-07 -0.6 -0.5 Serum metabolite levels; chr11:118679308 chr11:118704607~118750263:+ PAAD cis rs7429990 0.901 rs7431567 ENSG00000229759.1 MRPS18AP1 -7.09 4.6e-11 1.05e-07 -0.53 -0.5 Educational attainment (years of education); chr3:47986342 chr3:48256350~48256938:- PAAD cis rs7429990 0.901 rs6442091 ENSG00000229759.1 MRPS18AP1 -7.09 4.6e-11 1.05e-07 -0.53 -0.5 Educational attainment (years of education); chr3:48001568 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs4858810 ENSG00000229759.1 MRPS18AP1 -7.09 4.6e-11 1.05e-07 -0.53 -0.5 Educational attainment (years of education); chr3:48002247 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs4599334 ENSG00000229759.1 MRPS18AP1 -7.09 4.6e-11 1.05e-07 -0.53 -0.5 Educational attainment (years of education); chr3:48024910 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs4296617 ENSG00000229759.1 MRPS18AP1 -7.09 4.6e-11 1.05e-07 -0.53 -0.5 Educational attainment (years of education); chr3:48026818 chr3:48256350~48256938:- PAAD cis rs2739330 0.892 rs4822455 ENSG00000250470.1 AP000351.3 7.09 4.6e-11 1.06e-07 0.68 0.5 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23976904~23977585:- PAAD cis rs3096299 0.685 rs4785676 ENSG00000274627.1 RP11-104N10.2 7.09 4.61e-11 1.06e-07 0.43 0.5 Multiple myeloma (IgH translocation); chr16:89487216 chr16:89516797~89522217:+ PAAD cis rs3814244 0.528 rs1468487 ENSG00000255733.4 IFNG-AS1 -7.09 4.63e-11 1.06e-07 -0.47 -0.5 Itch intensity from mosquito bite adjusted by bite size; chr12:67996602 chr12:67989445~68234686:+ PAAD cis rs3814244 0.528 rs2860609 ENSG00000255733.4 IFNG-AS1 -7.09 4.63e-11 1.06e-07 -0.47 -0.5 Itch intensity from mosquito bite adjusted by bite size; chr12:67997215 chr12:67989445~68234686:+ PAAD cis rs11690935 0.959 rs6754817 ENSG00000228389.1 AC068039.4 7.09 4.64e-11 1.06e-07 0.64 0.5 Schizophrenia; chr2:171806884 chr2:171773482~171775844:+ PAAD cis rs3091242 0.933 rs932372 ENSG00000261349.1 RP3-465N24.5 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Erythrocyte sedimentation rate; chr1:25428523 chr1:25266102~25267136:- PAAD cis rs55794721 0.509 rs909834 ENSG00000261349.1 RP3-465N24.5 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Mean corpuscular volume;Plateletcrit; chr1:25431505 chr1:25266102~25267136:- PAAD cis rs977987 0.806 rs4888383 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75352451 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs8050769 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75354536 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs6564252 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75355042 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs2903033 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75355708 chr16:75379818~75381260:- PAAD cis rs977987 0.771 rs4888387 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75355857 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs2865531 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75356418 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs2113232 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75357287 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs35263058 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75358039 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs1895490 ENSG00000261783.1 RP11-252K23.2 -7.09 4.66e-11 1.07e-07 -0.62 -0.5 Dupuytren's disease; chr16:75358908 chr16:75379818~75381260:- PAAD cis rs3814244 0.832 rs11177006 ENSG00000255733.4 IFNG-AS1 7.09 4.74e-11 1.08e-07 0.45 0.5 Itch intensity from mosquito bite adjusted by bite size; chr12:68019317 chr12:67989445~68234686:+ PAAD cis rs977987 0.806 rs1549306 ENSG00000261783.1 RP11-252K23.2 -7.09 4.76e-11 1.09e-07 -0.62 -0.5 Dupuytren's disease; chr16:75381443 chr16:75379818~75381260:- PAAD cis rs977987 0.815 rs11861810 ENSG00000261783.1 RP11-252K23.2 -7.09 4.79e-11 1.09e-07 -0.62 -0.5 Dupuytren's disease; chr16:75427931 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11149832 ENSG00000261783.1 RP11-252K23.2 -7.09 4.79e-11 1.09e-07 -0.62 -0.5 Dupuytren's disease; chr16:75428815 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs12448947 ENSG00000261783.1 RP11-252K23.2 -7.09 4.79e-11 1.09e-07 -0.62 -0.5 Dupuytren's disease; chr16:75429056 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11149833 ENSG00000261783.1 RP11-252K23.2 -7.09 4.79e-11 1.09e-07 -0.62 -0.5 Dupuytren's disease; chr16:75430104 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs11641587 ENSG00000261783.1 RP11-252K23.2 -7.09 4.79e-11 1.09e-07 -0.62 -0.5 Dupuytren's disease; chr16:75430521 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs12930768 ENSG00000261783.1 RP11-252K23.2 -7.09 4.79e-11 1.09e-07 -0.62 -0.5 Dupuytren's disease; chr16:75430602 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs12445726 ENSG00000261783.1 RP11-252K23.2 -7.09 4.79e-11 1.09e-07 -0.62 -0.5 Dupuytren's disease; chr16:75431677 chr16:75379818~75381260:- PAAD cis rs507080 1 rs507080 ENSG00000255422.1 AP002954.4 -7.08 4.86e-11 1.11e-07 -0.59 -0.5 Serum metabolite levels; chr11:118678873 chr11:118704607~118750263:+ PAAD cis rs6452524 0.967 rs4541638 ENSG00000249664.1 CTD-2227C6.2 7.08 4.95e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83181325 chr5:83012285~83013109:- PAAD cis rs9322193 0.607 rs6557165 ENSG00000231760.4 RP11-350J20.5 -7.08 4.95e-11 1.13e-07 -0.69 -0.5 Lung cancer; chr6:149906883 chr6:149796151~149826294:- PAAD cis rs7429990 0.965 rs9854454 ENSG00000229759.1 MRPS18AP1 -7.08 4.96e-11 1.13e-07 -0.53 -0.5 Educational attainment (years of education); chr3:47971307 chr3:48256350~48256938:- PAAD cis rs1577917 0.545 rs9450325 ENSG00000203875.9 SNHG5 7.08 4.97e-11 1.13e-07 0.64 0.5 Response to antipsychotic treatment; chr6:85766096 chr6:85660950~85678736:- PAAD cis rs1577917 0.545 rs9344548 ENSG00000203875.9 SNHG5 7.08 4.97e-11 1.13e-07 0.64 0.5 Response to antipsychotic treatment; chr6:85777619 chr6:85660950~85678736:- PAAD cis rs881375 0.715 rs10818482 ENSG00000226752.6 PSMD5-AS1 7.08 4.97e-11 1.13e-07 0.54 0.5 Rheumatoid arthritis; chr9:120885807 chr9:120824828~120854385:+ PAAD cis rs67180937 0.774 rs3748626 ENSG00000272750.1 RP11-378J18.8 -7.08 4.98e-11 1.13e-07 -0.52 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222629461 chr1:222658867~222661512:- PAAD cis rs6452524 0.967 rs2974445 ENSG00000249664.1 CTD-2227C6.2 -7.08 4.99e-11 1.13e-07 -0.55 -0.5 Hypertension (SNP x SNP interaction); chr5:83185561 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs28360104 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83181525 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2974444 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83185174 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2940542 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83185734 chr5:83012285~83013109:- PAAD cis rs6452524 0.934 rs2940543 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83187297 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2974450 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83187323 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2974449 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83187465 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2662241 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83188774 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2731861 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83189445 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs2940544 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83189785 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2731865 ENSG00000249664.1 CTD-2227C6.2 7.08 4.99e-11 1.13e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83190570 chr5:83012285~83013109:- PAAD cis rs321358 0.732 rs17535419 ENSG00000271584.1 RP11-89C3.4 7.08 5e-11 1.13e-07 0.64 0.5 Body mass index; chr11:111075357 chr11:111091932~111097357:- PAAD cis rs321358 0.79 rs73015129 ENSG00000271584.1 RP11-89C3.4 7.08 5e-11 1.13e-07 0.64 0.5 Body mass index; chr11:111076157 chr11:111091932~111097357:- PAAD cis rs321358 0.79 rs73015134 ENSG00000271584.1 RP11-89C3.4 7.08 5e-11 1.13e-07 0.64 0.5 Body mass index; chr11:111076520 chr11:111091932~111097357:- PAAD cis rs321358 0.79 rs77820525 ENSG00000271584.1 RP11-89C3.4 7.08 5e-11 1.13e-07 0.64 0.5 Body mass index; chr11:111076697 chr11:111091932~111097357:- PAAD cis rs321358 0.848 rs73015141 ENSG00000271584.1 RP11-89C3.4 7.08 5e-11 1.13e-07 0.64 0.5 Body mass index; chr11:111077556 chr11:111091932~111097357:- PAAD cis rs321358 0.848 rs73015142 ENSG00000271584.1 RP11-89C3.4 7.08 5e-11 1.13e-07 0.64 0.5 Body mass index; chr11:111078647 chr11:111091932~111097357:- PAAD cis rs7044106 0.791 rs747819 ENSG00000226752.6 PSMD5-AS1 -7.08 5.01e-11 1.14e-07 -0.67 -0.5 Hip circumference adjusted for BMI; chr9:120726163 chr9:120824828~120854385:+ PAAD cis rs977987 0.778 rs12929908 ENSG00000261783.1 RP11-252K23.2 -7.08 5.01e-11 1.14e-07 -0.61 -0.5 Dupuytren's disease; chr16:75428173 chr16:75379818~75381260:- PAAD cis rs977987 0.742 rs12928898 ENSG00000261783.1 RP11-252K23.2 -7.08 5.01e-11 1.14e-07 -0.61 -0.5 Dupuytren's disease; chr16:75428183 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs17696696 ENSG00000261783.1 RP11-252K23.2 7.08 5.03e-11 1.14e-07 0.62 0.5 Dupuytren's disease; chr16:75359454 chr16:75379818~75381260:- PAAD cis rs9322193 0.923 rs9371207 ENSG00000216906.2 RP11-350J20.9 7.08 5.04e-11 1.14e-07 0.68 0.5 Lung cancer; chr6:149858087 chr6:149904243~149906418:+ PAAD cis rs55794721 0.509 rs12027135 ENSG00000261349.1 RP3-465N24.5 -7.08 5.04e-11 1.14e-07 -0.61 -0.5 Mean corpuscular volume;Plateletcrit; chr1:25449242 chr1:25266102~25267136:- PAAD cis rs977987 0.872 rs4887825 ENSG00000261783.1 RP11-252K23.2 -7.08 5.05e-11 1.14e-07 -0.61 -0.5 Dupuytren's disease; chr16:75438524 chr16:75379818~75381260:- PAAD cis rs7186831 1 rs7186831 ENSG00000261783.1 RP11-252K23.2 -7.08 5.05e-11 1.14e-07 -0.61 -0.5 Chronic obstructive pulmonary disease; chr16:75439257 chr16:75379818~75381260:- PAAD cis rs9399137 0.507 rs6923512 ENSG00000232876.1 CTA-212D2.2 7.08 5.07e-11 1.15e-07 0.6 0.5 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135014130 chr6:135055033~135060550:+ PAAD cis rs7945705 0.714 rs2653570 ENSG00000254860.4 TMEM9B-AS1 7.08 5.08e-11 1.15e-07 0.54 0.5 Hemoglobin concentration; chr11:8966276 chr11:8964675~8977527:+ PAAD cis rs7945705 0.747 rs2742480 ENSG00000254860.4 TMEM9B-AS1 7.08 5.08e-11 1.15e-07 0.54 0.5 Hemoglobin concentration; chr11:8971583 chr11:8964675~8977527:+ PAAD cis rs7945705 0.747 rs2568020 ENSG00000254860.4 TMEM9B-AS1 7.08 5.08e-11 1.15e-07 0.54 0.5 Hemoglobin concentration; chr11:8973168 chr11:8964675~8977527:+ PAAD cis rs7714584 1 rs4958842 ENSG00000197083.10 ZNF300P1 7.08 5.09e-11 1.15e-07 0.82 0.5 Crohn's disease; chr5:150845315 chr5:150930645~150946289:- PAAD cis rs881375 0.715 rs10985073 ENSG00000226752.6 PSMD5-AS1 -7.08 5.09e-11 1.15e-07 -0.54 -0.5 Rheumatoid arthritis; chr9:120881577 chr9:120824828~120854385:+ PAAD cis rs977987 0.771 rs12929673 ENSG00000261783.1 RP11-252K23.2 -7.08 5.1e-11 1.15e-07 -0.61 -0.5 Dupuytren's disease; chr16:75436397 chr16:75379818~75381260:- PAAD cis rs977987 0.836 rs35209155 ENSG00000261783.1 RP11-252K23.2 -7.08 5.1e-11 1.15e-07 -0.61 -0.5 Dupuytren's disease; chr16:75436598 chr16:75379818~75381260:- PAAD cis rs977987 0.836 rs8055974 ENSG00000261783.1 RP11-252K23.2 -7.08 5.1e-11 1.15e-07 -0.61 -0.5 Dupuytren's disease; chr16:75437088 chr16:75379818~75381260:- PAAD cis rs9389248 0.69 rs6569982 ENSG00000232876.1 CTA-212D2.2 -7.08 5.12e-11 1.16e-07 -0.58 -0.5 High light scatter reticulocyte percentage of red cells; chr6:134935357 chr6:135055033~135060550:+ PAAD cis rs4423214 0.84 rs1792234 ENSG00000254682.1 RP11-660L16.2 -7.07 5.12e-11 1.16e-07 -0.71 -0.5 Vitamin D levels; chr11:71470972 chr11:71448674~71452157:+ PAAD cis rs881375 0.715 rs7858209 ENSG00000226752.6 PSMD5-AS1 -7.07 5.14e-11 1.16e-07 -0.53 -0.5 Rheumatoid arthritis; chr9:120883482 chr9:120824828~120854385:+ PAAD cis rs881375 0.715 rs10760119 ENSG00000226752.6 PSMD5-AS1 -7.07 5.14e-11 1.16e-07 -0.53 -0.5 Rheumatoid arthritis; chr9:120883782 chr9:120824828~120854385:+ PAAD cis rs977987 0.806 rs11862684 ENSG00000261783.1 RP11-252K23.2 -7.07 5.17e-11 1.17e-07 -0.61 -0.5 Dupuytren's disease; chr16:75427848 chr16:75379818~75381260:- PAAD cis rs73086581 1 rs6107386 ENSG00000229539.1 RP11-119B16.2 7.07 5.18e-11 1.17e-07 0.76 0.5 Response to antidepressants in depression; chr20:3992109 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs73086581 ENSG00000229539.1 RP11-119B16.2 7.07 5.18e-11 1.17e-07 0.76 0.5 Response to antidepressants in depression; chr20:3996678 chr20:3888239~3888868:- PAAD cis rs2882667 1 rs10515505 ENSG00000253404.1 AC034243.1 7.07 5.18e-11 1.17e-07 0.61 0.5 Age-related hearing impairment (SNP x SNP interaction); chr5:138977457 chr5:138744434~138753309:- PAAD cis rs12022452 0.506 rs61779163 ENSG00000238287.1 RP11-656D10.3 -7.07 5.24e-11 1.18e-07 -0.72 -0.5 Age-related hearing impairment (SNP x SNP interaction); chr1:40549751 chr1:40493157~40508661:- PAAD cis rs7115242 0.748 rs1035237 ENSG00000254851.1 RP11-109L13.1 -7.07 5.26e-11 1.19e-07 -0.87 -0.5 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116857134 chr11:117135528~117138582:+ PAAD cis rs9545047 0.604 rs912639 ENSG00000227676.3 LINC01068 -7.07 5.27e-11 1.19e-07 -0.61 -0.5 Schizophrenia; chr13:79409788 chr13:79566727~79571436:+ PAAD cis rs55794721 0.509 rs12027110 ENSG00000261349.1 RP3-465N24.5 -7.07 5.28e-11 1.19e-07 -0.62 -0.5 Mean corpuscular volume;Plateletcrit; chr1:25449191 chr1:25266102~25267136:- PAAD cis rs7615952 0.673 rs34209763 ENSG00000171084.14 FAM86JP 7.07 5.3e-11 1.2e-07 0.88 0.5 Blood pressure (smoking interaction); chr3:125880752 chr3:125916620~125930024:+ PAAD cis rs7615952 0.611 rs35321002 ENSG00000171084.14 FAM86JP 7.07 5.3e-11 1.2e-07 0.88 0.5 Blood pressure (smoking interaction); chr3:125893222 chr3:125916620~125930024:+ PAAD cis rs7714584 1 rs76548544 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150843953 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs73282255 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150844085 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs80075680 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150844175 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs4958843 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150845362 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs4958424 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150845474 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs2004711 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150845506 chr5:150930645~150946289:- PAAD cis rs7714584 0.826 rs34005003 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150845637 chr5:150930645~150946289:- PAAD cis rs7714584 0.793 rs35707106 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150845815 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs61270113 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150846701 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11748151 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150846730 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11748158 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150846783 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10058821 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150846823 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10051804 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150846862 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10058943 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150847024 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10051924 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150847077 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs17111376 ENSG00000197083.10 ZNF300P1 7.07 5.34e-11 1.2e-07 0.75 0.5 Crohn's disease; chr5:150847337 chr5:150930645~150946289:- PAAD cis rs7615952 0.8 rs35390120 ENSG00000171084.14 FAM86JP 7.07 5.35e-11 1.2e-07 0.88 0.5 Blood pressure (smoking interaction); chr3:125880966 chr3:125916620~125930024:+ PAAD cis rs977987 0.778 rs12930452 ENSG00000261783.1 RP11-252K23.2 -7.06 5.41e-11 1.22e-07 -0.61 -0.5 Dupuytren's disease; chr16:75428157 chr16:75379818~75381260:- PAAD cis rs7174755 0.772 rs8025474 ENSG00000260657.2 RP11-315D16.4 7.06 5.45e-11 1.23e-07 0.6 0.5 Major depressive disorder; chr15:68094185 chr15:68267792~68277994:- PAAD cis rs977987 0.872 rs4888422 ENSG00000261783.1 RP11-252K23.2 -7.06 5.46e-11 1.23e-07 -0.6 -0.5 Dupuytren's disease; chr16:75436678 chr16:75379818~75381260:- PAAD cis rs765787 0.53 rs12440238 ENSG00000259520.4 CTD-2651B20.3 -7.06 5.48e-11 1.23e-07 -0.6 -0.5 Uric acid levels; chr15:45220707 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11070444 ENSG00000259520.4 CTD-2651B20.3 -7.06 5.48e-11 1.23e-07 -0.6 -0.5 Uric acid levels; chr15:45220923 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs11070445 ENSG00000259520.4 CTD-2651B20.3 -7.06 5.48e-11 1.23e-07 -0.6 -0.5 Uric acid levels; chr15:45220965 chr15:45251580~45279251:- PAAD cis rs765787 0.556 rs10851422 ENSG00000259520.4 CTD-2651B20.3 -7.06 5.48e-11 1.23e-07 -0.6 -0.5 Uric acid levels; chr15:45221540 chr15:45251580~45279251:- PAAD cis rs645901 1 rs645901 ENSG00000254851.1 RP11-109L13.1 -7.06 5.52e-11 1.24e-07 -0.77 -0.5 Plateletcrit; chr11:116831646 chr11:117135528~117138582:+ PAAD cis rs944002 1 rs944002 ENSG00000259444.1 RP11-736N17.8 7.06 5.55e-11 1.25e-07 0.61 0.5 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103106478 chr14:103094723~103098885:+ PAAD cis rs9481169 0.85 rs4947129 ENSG00000255389.1 C6orf3 -7.06 5.58e-11 1.25e-07 -0.91 -0.5 Inflammatory skin disease; chr6:111609703 chr6:111599875~111602295:+ PAAD cis rs73086581 1 rs73086535 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3963503 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs11906274 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3964889 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs6052196 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3965177 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs6116130 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3966379 chr20:3888239~3888868:- PAAD cis rs73086581 0.947 rs55794220 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3975755 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs6052209 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3981100 chr20:3888239~3888868:- PAAD cis rs73086581 0.891 rs55871214 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3985059 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs6052217 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3989564 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs6052218 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3989565 chr20:3888239~3888868:- PAAD cis rs73086581 0.945 rs6052219 ENSG00000229539.1 RP11-119B16.2 7.06 5.6e-11 1.26e-07 0.75 0.5 Response to antidepressants in depression; chr20:3989660 chr20:3888239~3888868:- PAAD cis rs9322193 0.504 rs7771014 ENSG00000268592.3 RAET1E-AS1 7.06 5.63e-11 1.26e-07 0.6 0.5 Lung cancer; chr6:149884310 chr6:149863494~149919507:+ PAAD cis rs73086581 1 rs14047 ENSG00000229539.1 RP11-119B16.2 7.06 5.63e-11 1.26e-07 0.78 0.5 Response to antidepressants in depression; chr20:3933568 chr20:3888239~3888868:- PAAD cis rs9545047 0.604 rs9318640 ENSG00000227676.3 LINC01068 -7.05 5.73e-11 1.28e-07 -0.61 -0.5 Schizophrenia; chr13:79426527 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9318641 ENSG00000227676.3 LINC01068 -7.05 5.73e-11 1.28e-07 -0.61 -0.5 Schizophrenia; chr13:79426545 chr13:79566727~79571436:+ PAAD cis rs1062177 0.756 rs2964588 ENSG00000213433.5 RPLP1P6 7.05 5.74e-11 1.29e-07 0.56 0.5 Preschool internalizing problems; chr5:151738825 chr5:151765859~151766378:- PAAD cis rs765787 0.505 rs12593605 ENSG00000259520.4 CTD-2651B20.3 -7.05 5.77e-11 1.29e-07 -0.6 -0.5 Uric acid levels; chr15:45205250 chr15:45251580~45279251:- PAAD cis rs1150668 0.799 rs7206 ENSG00000216901.1 AL022393.7 7.05 5.82e-11 1.3e-07 0.58 0.5 Pubertal anthropometrics; chr6:28233360 chr6:28176188~28176674:+ PAAD cis rs881375 0.678 rs10985102 ENSG00000226752.6 PSMD5-AS1 -7.05 5.84e-11 1.31e-07 -0.54 -0.5 Rheumatoid arthritis; chr9:120945219 chr9:120824828~120854385:+ PAAD cis rs507080 0.961 rs520543 ENSG00000255422.1 AP002954.4 -7.05 5.87e-11 1.32e-07 -0.59 -0.5 Serum metabolite levels; chr11:118667448 chr11:118704607~118750263:+ PAAD cis rs507080 0.961 rs4457789 ENSG00000255422.1 AP002954.4 -7.05 5.87e-11 1.32e-07 -0.59 -0.5 Serum metabolite levels; chr11:118668461 chr11:118704607~118750263:+ PAAD cis rs1150668 0.965 rs1654774 ENSG00000216901.1 AL022393.7 7.05 5.88e-11 1.32e-07 0.63 0.5 Pubertal anthropometrics; chr6:28128502 chr6:28176188~28176674:+ PAAD cis rs67180937 0.7 rs12043288 ENSG00000272750.1 RP11-378J18.8 -7.05 5.89e-11 1.32e-07 -0.52 -0.5 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222732952 chr1:222658867~222661512:- PAAD cis rs875971 0.545 rs73378304 ENSG00000237310.1 GS1-124K5.4 7.05 5.91e-11 1.32e-07 0.56 0.5 Aortic root size; chr7:66175760 chr7:66493706~66495474:+ PAAD cis rs6452524 0.901 rs1600362 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83091354 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1580311 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83091667 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1580310 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83091792 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1382376 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83095418 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs12109517 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83095947 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs12109514 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83095965 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1011979 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83097431 chr5:83012285~83013109:- PAAD cis rs6452524 0.901 rs17284211 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83098706 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1382374 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83101010 chr5:83012285~83013109:- PAAD cis rs6452524 0.868 rs10071617 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83103207 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs10076059 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83105698 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs11951257 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83107492 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs767771 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83108117 chr5:83012285~83013109:- PAAD cis rs6452524 0.905 rs1478482 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83111279 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs10045744 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83113688 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1542539 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83116033 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1543847 ENSG00000249664.1 CTD-2227C6.2 7.05 5.99e-11 1.34e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83116044 chr5:83012285~83013109:- PAAD cis rs977987 0.806 rs4888420 ENSG00000261783.1 RP11-252K23.2 -7.04 6.09e-11 1.36e-07 -0.61 -0.5 Dupuytren's disease; chr16:75429100 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs12449170 ENSG00000261783.1 RP11-252K23.2 -7.04 6.09e-11 1.36e-07 -0.61 -0.5 Dupuytren's disease; chr16:75429114 chr16:75379818~75381260:- PAAD cis rs12022452 0.591 rs6672398 ENSG00000238287.1 RP11-656D10.3 -7.04 6.12e-11 1.37e-07 -0.71 -0.5 Age-related hearing impairment (SNP x SNP interaction); chr1:40536505 chr1:40493157~40508661:- PAAD cis rs9322193 0.847 rs880246 ENSG00000216906.2 RP11-350J20.9 7.04 6.22e-11 1.39e-07 0.66 0.5 Lung cancer; chr6:149845972 chr6:149904243~149906418:+ PAAD cis rs6452524 0.901 rs10079680 ENSG00000249664.1 CTD-2227C6.2 7.04 6.26e-11 1.39e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83082746 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs11750799 ENSG00000249664.1 CTD-2227C6.2 7.04 6.26e-11 1.39e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83082983 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs7703318 ENSG00000249664.1 CTD-2227C6.2 7.04 6.26e-11 1.39e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83118234 chr5:83012285~83013109:- PAAD cis rs765787 0.53 rs12906537 ENSG00000259520.4 CTD-2651B20.3 -7.04 6.27e-11 1.4e-07 -0.6 -0.5 Uric acid levels; chr15:45227863 chr15:45251580~45279251:- PAAD cis rs977987 0.806 rs766521 ENSG00000261783.1 RP11-252K23.2 7.04 6.31e-11 1.4e-07 0.61 0.5 Dupuytren's disease; chr16:75390256 chr16:75379818~75381260:- PAAD cis rs12931792 0.782 rs6565176 ENSG00000183604.13 SMG1P5 7.04 6.34e-11 1.41e-07 0.5 0.5 Tonsillectomy; chr16:30163605 chr16:30267553~30335374:- PAAD cis rs997154 0.655 rs8015121 ENSG00000279656.1 RP11-298I3.6 7.03 6.37e-11 1.42e-07 0.66 0.5 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22906042 chr14:23023083~23024217:- PAAD cis rs997154 0.608 rs8007089 ENSG00000279656.1 RP11-298I3.6 7.03 6.37e-11 1.42e-07 0.66 0.5 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22922704 chr14:23023083~23024217:- PAAD cis rs6452524 0.935 rs7736783 ENSG00000249664.1 CTD-2227C6.2 7.03 6.37e-11 1.42e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83107050 chr5:83012285~83013109:- PAAD cis rs9545047 0.604 rs9530915 ENSG00000227676.3 LINC01068 7.03 6.4e-11 1.42e-07 0.6 0.5 Schizophrenia; chr13:79396512 chr13:79566727~79571436:+ PAAD cis rs73086581 1 rs56324992 ENSG00000229539.1 RP11-119B16.2 7.03 6.42e-11 1.43e-07 0.73 0.5 Response to antidepressants in depression; chr20:3997506 chr20:3888239~3888868:- PAAD cis rs7945705 0.869 rs7925728 ENSG00000254860.4 TMEM9B-AS1 7.03 6.43e-11 1.43e-07 0.55 0.5 Hemoglobin concentration; chr11:8991455 chr11:8964675~8977527:+ PAAD cis rs881375 0.678 rs10818488 ENSG00000226752.6 PSMD5-AS1 -7.03 6.44e-11 1.43e-07 -0.53 -0.5 Rheumatoid arthritis; chr9:120942809 chr9:120824828~120854385:+ PAAD cis rs6452524 0.935 rs6868416 ENSG00000249664.1 CTD-2227C6.2 7.03 6.44e-11 1.43e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83084320 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1478485 ENSG00000249664.1 CTD-2227C6.2 7.03 6.44e-11 1.43e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83084708 chr5:83012285~83013109:- PAAD cis rs6452524 0.836 rs1478484 ENSG00000249664.1 CTD-2227C6.2 7.03 6.44e-11 1.43e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83085055 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs7714710 ENSG00000249664.1 CTD-2227C6.2 7.03 6.44e-11 1.43e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83085750 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs1564211 ENSG00000249664.1 CTD-2227C6.2 7.03 6.51e-11 1.45e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83117014 chr5:83012285~83013109:- PAAD cis rs1062177 0.724 rs2915828 ENSG00000213433.5 RPLP1P6 7.03 6.55e-11 1.45e-07 0.55 0.5 Preschool internalizing problems; chr5:151738560 chr5:151765859~151766378:- PAAD cis rs2117029 0.556 rs1057725 ENSG00000258017.1 RP11-386G11.10 -7.03 6.56e-11 1.46e-07 -0.64 -0.5 Intelligence (multi-trait analysis); chr12:49128795 chr12:49127782~49147869:+ PAAD cis rs9545047 0.604 rs7327603 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79366676 chr13:79566727~79571436:+ PAAD cis rs9545047 0.589 rs9545090 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79367276 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530902 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79367748 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9545092 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79369809 chr13:79566727~79571436:+ PAAD cis rs9545047 0.611 rs9545093 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79371969 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530906 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79372401 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs8001392 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79374211 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs4146473 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79374548 chr13:79566727~79571436:+ PAAD cis rs9545047 0.584 rs1619669 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79378363 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs6563100 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79382978 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7322901 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79383505 chr13:79566727~79571436:+ PAAD cis rs9545047 0.588 rs9530913 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79384539 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7329331 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79384986 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7330479 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79385058 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs6563104 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79389718 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7981500 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79391461 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7986306 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79392530 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs57821487 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79392810 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7323246 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79392903 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7331766 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79394076 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9545104 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79404000 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9545106 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79404130 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2763810 ENSG00000227676.3 LINC01068 7.03 6.6e-11 1.46e-07 0.6 0.5 Schizophrenia; chr13:79405544 chr13:79566727~79571436:+ PAAD cis rs6452524 0.935 rs10942321 ENSG00000249664.1 CTD-2227C6.2 7.02 6.73e-11 1.49e-07 0.55 0.5 Hypertension (SNP x SNP interaction); chr5:83083200 chr5:83012285~83013109:- PAAD cis rs1799949 0.965 rs8176198 ENSG00000198496.9 NBR2 -7.02 6.73e-11 1.49e-07 -0.5 -0.5 Menopause (age at onset); chr17:43078520 chr17:43125610~43153671:+ PAAD cis rs11155671 0.53 rs9397398 ENSG00000268592.3 RAET1E-AS1 7.02 6.74e-11 1.49e-07 0.6 0.5 Testicular germ cell tumor; chr6:149872467 chr6:149863494~149919507:+ PAAD cis rs9545047 0.716 rs7140027 ENSG00000227676.3 LINC01068 7.02 6.74e-11 1.49e-07 0.62 0.5 Schizophrenia; chr13:79281162 chr13:79566727~79571436:+ PAAD cis rs2455601 0.744 rs7938995 ENSG00000254860.4 TMEM9B-AS1 7.02 6.76e-11 1.49e-07 0.63 0.5 Schizophrenia; chr11:8954128 chr11:8964675~8977527:+ PAAD cis rs4423214 0.84 rs1629220 ENSG00000254682.1 RP11-660L16.2 -7.02 6.78e-11 1.5e-07 -0.72 -0.49 Vitamin D levels; chr11:71463507 chr11:71448674~71452157:+ PAAD cis rs881375 0.678 rs2269060 ENSG00000226752.6 PSMD5-AS1 -7.02 6.81e-11 1.5e-07 -0.53 -0.49 Rheumatoid arthritis; chr9:120921291 chr9:120824828~120854385:+ PAAD cis rs6907340 0.513 rs6938418 ENSG00000228412.5 RP4-625H18.2 -7.02 6.86e-11 1.52e-07 -0.62 -0.49 Endometriosis; chr6:19808802 chr6:19802164~19804752:- PAAD cis rs3814244 0.528 rs2906854 ENSG00000255733.4 IFNG-AS1 -7.02 6.92e-11 1.53e-07 -0.47 -0.49 Itch intensity from mosquito bite adjusted by bite size; chr12:67993566 chr12:67989445~68234686:+ PAAD cis rs9545047 0.716 rs9545061 ENSG00000227676.3 LINC01068 7.02 6.93e-11 1.53e-07 0.61 0.49 Schizophrenia; chr13:79310695 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs9545067 ENSG00000227676.3 LINC01068 7.02 6.93e-11 1.53e-07 0.61 0.49 Schizophrenia; chr13:79323429 chr13:79566727~79571436:+ PAAD cis rs9545047 0.68 rs9574405 ENSG00000227676.3 LINC01068 7.02 6.93e-11 1.53e-07 0.61 0.49 Schizophrenia; chr13:79328943 chr13:79566727~79571436:+ PAAD cis rs9545047 0.74 rs9574409 ENSG00000227676.3 LINC01068 7.02 6.93e-11 1.53e-07 0.61 0.49 Schizophrenia; chr13:79341844 chr13:79566727~79571436:+ PAAD cis rs9545047 0.68 rs7987769 ENSG00000227676.3 LINC01068 7.02 6.93e-11 1.53e-07 0.61 0.49 Schizophrenia; chr13:79343965 chr13:79566727~79571436:+ PAAD cis rs9545047 0.716 rs7327386 ENSG00000227676.3 LINC01068 7.02 6.93e-11 1.53e-07 0.61 0.49 Schizophrenia; chr13:79347901 chr13:79566727~79571436:+ PAAD cis rs9545047 0.644 rs9318624 ENSG00000227676.3 LINC01068 7.02 6.93e-11 1.53e-07 0.61 0.49 Schizophrenia; chr13:79350915 chr13:79566727~79571436:+ PAAD cis rs1577917 0.545 rs1832070 ENSG00000203875.9 SNHG5 7.02 6.94e-11 1.53e-07 0.65 0.49 Response to antipsychotic treatment; chr6:85773454 chr6:85660950~85678736:- PAAD cis rs6452524 1 rs17284288 ENSG00000249664.1 CTD-2227C6.2 7.02 6.95e-11 1.53e-07 0.57 0.49 Hypertension (SNP x SNP interaction); chr5:83148997 chr5:83012285~83013109:- PAAD cis rs9322193 0.884 rs880245 ENSG00000216906.2 RP11-350J20.9 -7.02 7e-11 1.54e-07 -0.65 -0.49 Lung cancer; chr6:149846262 chr6:149904243~149906418:+ PAAD cis rs7429990 0.932 rs6442101 ENSG00000229759.1 MRPS18AP1 -7.02 7.02e-11 1.55e-07 -0.54 -0.49 Educational attainment (years of education); chr3:48089403 chr3:48256350~48256938:- PAAD cis rs977987 0.778 rs11149825 ENSG00000261783.1 RP11-252K23.2 -7.02 7.02e-11 1.55e-07 -0.62 -0.49 Dupuytren's disease; chr16:75400980 chr16:75379818~75381260:- PAAD cis rs12022452 0.591 rs12042242 ENSG00000238287.1 RP11-656D10.3 7.01 7.1e-11 1.56e-07 0.72 0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40528201 chr1:40493157~40508661:- PAAD cis rs73086581 1 rs17214949 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3960305 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs17215054 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3964132 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs17287486 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3965620 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs73086540 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3970203 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs73086544 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3970281 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs2326289 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3971653 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs73086549 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3974015 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs113812453 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3982546 chr20:3888239~3888868:- PAAD cis rs73086581 0.947 rs17287577 ENSG00000229539.1 RP11-119B16.2 7.01 7.14e-11 1.57e-07 0.75 0.49 Response to antidepressants in depression; chr20:3985607 chr20:3888239~3888868:- PAAD cis rs12022452 0.591 rs16827359 ENSG00000238287.1 RP11-656D10.3 7.01 7.21e-11 1.58e-07 0.72 0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40535766 chr1:40493157~40508661:- PAAD cis rs9322193 0.884 rs1108889 ENSG00000216906.2 RP11-350J20.9 7.01 7.22e-11 1.58e-07 0.66 0.49 Lung cancer; chr6:149845433 chr6:149904243~149906418:+ PAAD cis rs55794721 0.509 rs6699896 ENSG00000261349.1 RP3-465N24.5 -7.01 7.24e-11 1.59e-07 -0.61 -0.49 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25266102~25267136:- PAAD cis rs3091242 0.933 rs35148262 ENSG00000261349.1 RP3-465N24.5 -7.01 7.24e-11 1.59e-07 -0.61 -0.49 Erythrocyte sedimentation rate; chr1:25440132 chr1:25266102~25267136:- PAAD cis rs6452524 1 rs1382368 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83155256 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs1382366 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83156352 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs1382364 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83156677 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs1382363 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83156753 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs9293334 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83156984 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs11741897 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83157246 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs13358361 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83160237 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs2126990 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83161351 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10076000 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83161629 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6452528 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83162560 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6864479 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83166421 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs13436667 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83168948 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs7726564 ENSG00000249664.1 CTD-2227C6.2 7.01 7.25e-11 1.59e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83170274 chr5:83012285~83013109:- PAAD cis rs12931792 0.846 rs9924308 ENSG00000183604.13 SMG1P5 -7.01 7.34e-11 1.61e-07 -0.51 -0.49 Tonsillectomy; chr16:30143419 chr16:30267553~30335374:- PAAD cis rs7429990 0.965 rs34750113 ENSG00000229759.1 MRPS18AP1 7.01 7.34e-11 1.61e-07 0.53 0.49 Educational attainment (years of education); chr3:47944902 chr3:48256350~48256938:- PAAD cis rs944002 1 rs61418148 ENSG00000259444.1 RP11-736N17.8 7.01 7.38e-11 1.62e-07 0.61 0.49 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103100683 chr14:103094723~103098885:+ PAAD cis rs765787 0.53 rs3759892 ENSG00000259520.4 CTD-2651B20.3 -7.01 7.38e-11 1.62e-07 -0.6 -0.49 Uric acid levels; chr15:45250511 chr15:45251580~45279251:- PAAD cis rs3096299 0.632 rs8051537 ENSG00000274627.1 RP11-104N10.2 7.01 7.39e-11 1.62e-07 0.42 0.49 Multiple myeloma (IgH translocation); chr16:89477976 chr16:89516797~89522217:+ PAAD cis rs3096299 0.685 rs3803682 ENSG00000274627.1 RP11-104N10.2 7.01 7.39e-11 1.62e-07 0.42 0.49 Multiple myeloma (IgH translocation); chr16:89478228 chr16:89516797~89522217:+ PAAD cis rs3096299 0.685 rs3803681 ENSG00000274627.1 RP11-104N10.2 7.01 7.39e-11 1.62e-07 0.42 0.49 Multiple myeloma (IgH translocation); chr16:89478348 chr16:89516797~89522217:+ PAAD cis rs2919917 1 rs13280202 ENSG00000254352.1 RP11-578O24.2 -7.01 7.42e-11 1.62e-07 -0.52 -0.49 Lymphocyte counts; chr8:78700238 chr8:78723796~78724136:- PAAD cis rs977987 0.762 rs1364079 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75359233 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs2059256 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75361937 chr16:75379818~75381260:- PAAD cis rs977987 0.815 rs1364078 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75362983 chr16:75379818~75381260:- PAAD cis rs977987 0.815 rs11646677 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75375083 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs8056080 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75376900 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs4146810 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75381933 chr16:75379818~75381260:- PAAD cis rs977987 0.815 rs11149818 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75385475 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs11149820 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75388862 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs10514396 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75389005 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs7499872 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75392631 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs60730309 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75397871 chr16:75379818~75381260:- PAAD cis rs977987 0.75 rs4888406 ENSG00000261783.1 RP11-252K23.2 -7.01 7.42e-11 1.62e-07 -0.6 -0.49 Dupuytren's disease; chr16:75398436 chr16:75379818~75381260:- PAAD cis rs881375 0.678 rs10760125 ENSG00000226752.6 PSMD5-AS1 -7.01 7.44e-11 1.63e-07 -0.53 -0.49 Rheumatoid arthritis; chr9:120900312 chr9:120824828~120854385:+ PAAD cis rs881375 0.678 rs9886724 ENSG00000226752.6 PSMD5-AS1 -7.01 7.44e-11 1.63e-07 -0.53 -0.49 Rheumatoid arthritis; chr9:120902741 chr9:120824828~120854385:+ PAAD cis rs881375 0.631 rs10739577 ENSG00000226752.6 PSMD5-AS1 -7.01 7.44e-11 1.63e-07 -0.53 -0.49 Rheumatoid arthritis; chr9:120906576 chr9:120824828~120854385:+ PAAD cis rs2919917 1 rs1021156 ENSG00000254352.1 RP11-578O24.2 7.01 7.45e-11 1.63e-07 0.52 0.49 Lymphocyte counts; chr8:78663569 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs3736169 ENSG00000254352.1 RP11-578O24.2 7.01 7.45e-11 1.63e-07 0.52 0.49 Lymphocyte counts; chr8:78675620 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs10093127 ENSG00000254352.1 RP11-578O24.2 7.01 7.45e-11 1.63e-07 0.52 0.49 Lymphocyte counts; chr8:78686869 chr8:78723796~78724136:- PAAD cis rs2919917 1 rs1872072 ENSG00000254352.1 RP11-578O24.2 7.01 7.45e-11 1.63e-07 0.52 0.49 Lymphocyte counts; chr8:78689185 chr8:78723796~78724136:- PAAD cis rs1263173 0.91 rs1263170 ENSG00000254851.1 RP11-109L13.1 -7.01 7.47e-11 1.63e-07 -0.71 -0.49 HDL cholesterol; chr11:116807697 chr11:117135528~117138582:+ PAAD cis rs2739330 0.753 rs4822452 ENSG00000099984.9 GSTT2 -7 7.5e-11 1.64e-07 -0.63 -0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23980123~23983911:+ PAAD cis rs11155671 0.53 rs4870080 ENSG00000268592.3 RAET1E-AS1 7 7.51e-11 1.64e-07 0.61 0.49 Testicular germ cell tumor; chr6:149881508 chr6:149863494~149919507:+ PAAD cis rs765787 0.53 rs12439643 ENSG00000259520.4 CTD-2651B20.3 -7 7.65e-11 1.67e-07 -0.61 -0.49 Uric acid levels; chr15:45237569 chr15:45251580~45279251:- PAAD cis rs7429990 0.965 rs2882668 ENSG00000229759.1 MRPS18AP1 7 7.7e-11 1.68e-07 0.54 0.49 Educational attainment (years of education); chr3:47938816 chr3:48256350~48256938:- PAAD cis rs7684253 0.55 rs4566710 ENSG00000269949.1 RP11-738E22.3 -7 7.71e-11 1.68e-07 -0.66 -0.49 Migraine; chr4:56879297 chr4:56960927~56961373:- PAAD cis rs11155671 0.53 rs1334510 ENSG00000268592.3 RAET1E-AS1 7 7.77e-11 1.69e-07 0.6 0.49 Testicular germ cell tumor; chr6:149880043 chr6:149863494~149919507:+ PAAD cis rs977987 0.872 rs4887816 ENSG00000261783.1 RP11-252K23.2 -7 7.79e-11 1.7e-07 -0.62 -0.49 Dupuytren's disease; chr16:75285818 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs4243112 ENSG00000261783.1 RP11-252K23.2 -7 7.79e-11 1.7e-07 -0.62 -0.49 Dupuytren's disease; chr16:75287133 chr16:75379818~75381260:- PAAD cis rs977987 0.836 rs4888376 ENSG00000261783.1 RP11-252K23.2 -7 7.79e-11 1.7e-07 -0.62 -0.49 Dupuytren's disease; chr16:75288675 chr16:75379818~75381260:- PAAD cis rs977987 0.836 rs34673655 ENSG00000261783.1 RP11-252K23.2 -7 7.79e-11 1.7e-07 -0.62 -0.49 Dupuytren's disease; chr16:75289661 chr16:75379818~75381260:- PAAD cis rs977987 0.836 rs17685540 ENSG00000261783.1 RP11-252K23.2 -7 7.79e-11 1.7e-07 -0.62 -0.49 Dupuytren's disease; chr16:75289942 chr16:75379818~75381260:- PAAD cis rs1062177 0.826 rs1549920 ENSG00000213433.5 RPLP1P6 -7 7.8e-11 1.7e-07 -0.57 -0.49 Preschool internalizing problems; chr5:151761283 chr5:151765859~151766378:- PAAD cis rs1062177 0.826 rs2915822 ENSG00000213433.5 RPLP1P6 7 7.8e-11 1.7e-07 0.57 0.49 Preschool internalizing problems; chr5:151751340 chr5:151765859~151766378:- PAAD cis rs9545047 0.604 rs9601227 ENSG00000227676.3 LINC01068 -7 7.89e-11 1.71e-07 -0.62 -0.49 Schizophrenia; chr13:79420805 chr13:79566727~79571436:+ PAAD cis rs6452524 0.935 rs7718472 ENSG00000249664.1 CTD-2227C6.2 6.99 7.9e-11 1.71e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83082603 chr5:83012285~83013109:- PAAD cis rs765787 0.53 rs12592055 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45222279 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs10851423 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45223752 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12913123 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45224227 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12904331 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45226095 chr15:45251580~45279251:- PAAD cis rs765787 0.505 rs4439707 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45232018 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12904265 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45234515 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12440321 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45237187 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12442533 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45237433 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2899379 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45242601 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs2899378 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45245386 chr15:45251580~45279251:- PAAD cis rs765787 0.53 rs12903149 ENSG00000259520.4 CTD-2651B20.3 -6.99 7.92e-11 1.71e-07 -0.6 -0.49 Uric acid levels; chr15:45246878 chr15:45251580~45279251:- PAAD cis rs7714584 1 rs75774363 ENSG00000197083.10 ZNF300P1 6.99 7.93e-11 1.71e-07 0.78 0.49 Crohn's disease; chr5:150844160 chr5:150930645~150946289:- PAAD cis rs7811142 0.943 rs3900792 ENSG00000242294.5 STAG3L5P 6.99 7.97e-11 1.72e-07 0.37 0.49 Platelet count; chr7:100406954 chr7:100336079~100351900:+ PAAD cis rs7044106 0.791 rs12554440 ENSG00000226752.6 PSMD5-AS1 -6.99 7.97e-11 1.72e-07 -0.68 -0.49 Hip circumference adjusted for BMI; chr9:120723055 chr9:120824828~120854385:+ PAAD cis rs977987 0.806 rs7188231 ENSG00000261783.1 RP11-252K23.2 -6.99 7.98e-11 1.72e-07 -0.6 -0.49 Dupuytren's disease; chr16:75402663 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs12443904 ENSG00000261783.1 RP11-252K23.2 -6.99 7.98e-11 1.72e-07 -0.6 -0.49 Dupuytren's disease; chr16:75404872 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs35737321 ENSG00000261783.1 RP11-252K23.2 -6.99 7.98e-11 1.72e-07 -0.6 -0.49 Dupuytren's disease; chr16:75405287 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs62062564 ENSG00000261783.1 RP11-252K23.2 -6.99 7.98e-11 1.72e-07 -0.6 -0.49 Dupuytren's disease; chr16:75408724 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs62062568 ENSG00000261783.1 RP11-252K23.2 -6.99 7.98e-11 1.72e-07 -0.6 -0.49 Dupuytren's disease; chr16:75411426 chr16:75379818~75381260:- PAAD cis rs6452524 0.935 rs6896953 ENSG00000249664.1 CTD-2227C6.2 -6.99 7.99e-11 1.72e-07 -0.54 -0.49 Hypertension (SNP x SNP interaction); chr5:83089284 chr5:83012285~83013109:- PAAD cis rs9532669 0.926 rs4600337 ENSG00000176268.5 CYCSP34 6.99 8e-11 1.73e-07 0.48 0.49 Cervical cancer; chr13:40879564 chr13:40863599~40863902:- PAAD cis rs12022452 0.544 rs11208423 ENSG00000238287.1 RP11-656D10.3 -6.99 8.01e-11 1.73e-07 -0.71 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40563942 chr1:40493157~40508661:- PAAD cis rs977987 0.872 rs1559339 ENSG00000261783.1 RP11-252K23.2 -6.99 8.14e-11 1.76e-07 -0.6 -0.49 Dupuytren's disease; chr16:75284748 chr16:75379818~75381260:- PAAD cis rs3096299 0.685 rs8050512 ENSG00000274627.1 RP11-104N10.2 6.99 8.15e-11 1.76e-07 0.42 0.49 Multiple myeloma (IgH translocation); chr16:89485912 chr16:89516797~89522217:+ PAAD cis rs7208859 0.673 rs9912122 ENSG00000263531.1 RP13-753N3.1 6.99 8.19e-11 1.76e-07 0.86 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813698 chr17:30863921~30864940:- PAAD cis rs2980439 0.87 rs2945230 ENSG00000253893.2 FAM85B -6.99 8.29e-11 1.78e-07 -0.69 -0.49 Neuroticism; chr8:8252414 chr8:8167819~8226614:- PAAD cis rs7615952 0.611 rs9681518 ENSG00000171084.14 FAM86JP 6.99 8.29e-11 1.78e-07 0.88 0.49 Blood pressure (smoking interaction); chr3:125896287 chr3:125916620~125930024:+ PAAD cis rs9545047 0.716 rs9318638 ENSG00000227676.3 LINC01068 -6.98 8.48e-11 1.82e-07 -0.62 -0.49 Schizophrenia; chr13:79412018 chr13:79566727~79571436:+ PAAD cis rs977987 0.778 rs2865528 ENSG00000261783.1 RP11-252K23.2 -6.98 8.53e-11 1.83e-07 -0.6 -0.49 Dupuytren's disease; chr16:75422044 chr16:75379818~75381260:- PAAD cis rs977987 0.843 rs67409275 ENSG00000261783.1 RP11-252K23.2 -6.98 8.53e-11 1.83e-07 -0.6 -0.49 Dupuytren's disease; chr16:75423314 chr16:75379818~75381260:- PAAD cis rs7429990 1 rs1665982 ENSG00000229759.1 MRPS18AP1 -6.98 8.55e-11 1.84e-07 -0.57 -0.49 Educational attainment (years of education); chr3:47863589 chr3:48256350~48256938:- PAAD cis rs4722166 0.695 rs35779989 ENSG00000179428.2 AC073072.5 -6.98 8.6e-11 1.85e-07 -0.45 -0.49 Lung cancer; chr7:22760695 chr7:22725395~22727620:- PAAD cis rs7208859 0.673 rs2470251 ENSG00000263531.1 RP13-753N3.1 6.98 8.63e-11 1.85e-07 0.86 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs11652370 ENSG00000263531.1 RP13-753N3.1 6.98 8.63e-11 1.85e-07 0.86 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770205 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs56846352 ENSG00000263531.1 RP13-753N3.1 6.98 8.63e-11 1.85e-07 0.86 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792170 chr17:30863921~30864940:- PAAD cis rs7208859 0.673 rs7211776 ENSG00000263531.1 RP13-753N3.1 6.98 8.63e-11 1.85e-07 0.86 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793178 chr17:30863921~30864940:- PAAD cis rs7208859 0.573 rs8078182 ENSG00000263531.1 RP13-753N3.1 6.98 8.63e-11 1.85e-07 0.86 0.49 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822646 chr17:30863921~30864940:- PAAD cis rs7617773 0.539 rs13069884 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48339658 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs2017859 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48340771 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs2017858 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48340792 chr3:48256350~48256938:- PAAD cis rs7617773 0.501 rs12185901 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48341429 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs13082217 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48341774 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs11706939 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48342502 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs11130165 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48343231 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs1471217 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48343405 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs13094496 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48345560 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs17593974 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48345844 chr3:48256350~48256938:- PAAD cis rs7617773 0.514 rs11130166 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48346566 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs12486944 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48348526 chr3:48256350~48256938:- PAAD cis rs7617773 0.539 rs12486935 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48348674 chr3:48256350~48256938:- PAAD cis rs7617773 0.563 rs62263035 ENSG00000229759.1 MRPS18AP1 6.98 8.64e-11 1.85e-07 0.51 0.49 Coronary artery disease; chr3:48350079 chr3:48256350~48256938:- PAAD cis rs4722166 0.695 rs7808122 ENSG00000179428.2 AC073072.5 -6.98 8.7e-11 1.86e-07 -0.45 -0.49 Lung cancer; chr7:22758461 chr7:22725395~22727620:- PAAD cis rs4722166 0.695 rs4722177 ENSG00000179428.2 AC073072.5 -6.98 8.7e-11 1.86e-07 -0.45 -0.49 Lung cancer; chr7:22758912 chr7:22725395~22727620:- PAAD cis rs977987 0.843 rs10431974 ENSG00000261783.1 RP11-252K23.2 -6.98 8.74e-11 1.87e-07 -0.61 -0.49 Dupuytren's disease; chr16:75401563 chr16:75379818~75381260:- PAAD cis rs673078 0.66 rs17440433 ENSG00000275759.1 RP11-131L12.3 -6.98 8.75e-11 1.87e-07 -0.76 -0.49 Glucose homeostasis traits; chr12:118201507 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs17512219 ENSG00000275759.1 RP11-131L12.3 -6.98 8.75e-11 1.87e-07 -0.76 -0.49 Glucose homeostasis traits; chr12:118211468 chr12:118428281~118428870:+ PAAD cis rs62388641 0.547 rs4513844 ENSG00000272279.1 RP11-157J24.2 -6.97 8.79e-11 1.88e-07 -0.58 -0.49 Daytime sleep phenotypes; chr6:1551747 chr6:1528364~1528911:- PAAD cis rs977987 0.843 rs4888372 ENSG00000261783.1 RP11-252K23.2 -6.97 8.82e-11 1.89e-07 -0.61 -0.49 Dupuytren's disease; chr16:75279587 chr16:75379818~75381260:- PAAD cis rs7104764 0.957 rs6598075 ENSG00000277290.1 RP11-326C3.16 6.97 8.83e-11 1.89e-07 0.44 0.49 Menarche (age at onset); chr11:207275 chr11:243099~243483:- PAAD cis rs7104764 0.957 rs58692051 ENSG00000277290.1 RP11-326C3.16 6.97 8.83e-11 1.89e-07 0.44 0.49 Menarche (age at onset); chr11:207410 chr11:243099~243483:- PAAD cis rs73086581 1 rs73086505 ENSG00000229539.1 RP11-119B16.2 6.97 8.91e-11 1.91e-07 0.78 0.49 Response to antidepressants in depression; chr20:3940924 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs73086508 ENSG00000229539.1 RP11-119B16.2 6.97 8.91e-11 1.91e-07 0.78 0.49 Response to antidepressants in depression; chr20:3941068 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs73086510 ENSG00000229539.1 RP11-119B16.2 6.97 8.91e-11 1.91e-07 0.78 0.49 Response to antidepressants in depression; chr20:3941484 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs17286768 ENSG00000229539.1 RP11-119B16.2 6.97 8.91e-11 1.91e-07 0.78 0.49 Response to antidepressants in depression; chr20:3943922 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs17214621 ENSG00000229539.1 RP11-119B16.2 6.97 8.91e-11 1.91e-07 0.78 0.49 Response to antidepressants in depression; chr20:3945277 chr20:3888239~3888868:- PAAD cis rs1976403 0.633 rs1697422 ENSG00000227001.3 NBPF2P 6.97 8.92e-11 1.91e-07 0.58 0.49 Liver enzyme levels (alkaline phosphatase); chr1:21495404 chr1:21424625~21427967:- PAAD cis rs6452524 0.905 rs7736289 ENSG00000249664.1 CTD-2227C6.2 6.97 8.94e-11 1.91e-07 0.54 0.49 Hypertension (SNP x SNP interaction); chr5:83082401 chr5:83012285~83013109:- PAAD cis rs9545047 0.604 rs2147566 ENSG00000227676.3 LINC01068 6.97 8.97e-11 1.92e-07 0.59 0.49 Schizophrenia; chr13:79296580 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1028770 ENSG00000227676.3 LINC01068 -6.97 8.97e-11 1.92e-07 -0.59 -0.49 Schizophrenia; chr13:79297346 chr13:79566727~79571436:+ PAAD cis rs9545047 0.645 rs9635027 ENSG00000227676.3 LINC01068 6.97 9.1e-11 1.94e-07 0.62 0.49 Schizophrenia; chr13:79295538 chr13:79566727~79571436:+ PAAD cis rs172166 0.561 rs149971 ENSG00000216901.1 AL022393.7 6.97 9.12e-11 1.95e-07 0.62 0.49 Cardiac Troponin-T levels; chr6:28014374 chr6:28176188~28176674:+ PAAD cis rs73086581 1 rs73084594 ENSG00000229539.1 RP11-119B16.2 6.97 9.13e-11 1.95e-07 0.77 0.49 Response to antidepressants in depression; chr20:3935733 chr20:3888239~3888868:- PAAD cis rs11673344 0.566 rs256735 ENSG00000226686.6 LINC01535 -6.97 9.14e-11 1.95e-07 -0.59 -0.49 Obesity-related traits; chr19:37375141 chr19:37251912~37265535:+ PAAD cis rs11673344 0.566 rs185369 ENSG00000226686.6 LINC01535 -6.97 9.14e-11 1.95e-07 -0.59 -0.49 Obesity-related traits; chr19:37376137 chr19:37251912~37265535:+ PAAD cis rs11673344 0.566 rs185368 ENSG00000226686.6 LINC01535 -6.97 9.14e-11 1.95e-07 -0.59 -0.49 Obesity-related traits; chr19:37381827 chr19:37251912~37265535:+ PAAD cis rs9890032 0.509 rs11656986 ENSG00000266490.1 CTD-2349P21.9 6.97 9.15e-11 1.95e-07 0.47 0.49 Hip circumference adjusted for BMI; chr17:30694324 chr17:30792372~30792833:+ PAAD cis rs5760092 0.618 rs4461358 ENSG00000225282.1 AP000350.6 -6.97 9.25e-11 1.97e-07 -0.68 -0.49 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23926900~23929574:+ PAAD cis rs977987 0.836 rs7200053 ENSG00000261783.1 RP11-252K23.2 -6.97 9.28e-11 1.98e-07 -0.61 -0.49 Dupuytren's disease; chr16:75440720 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs7204984 ENSG00000261783.1 RP11-252K23.2 -6.97 9.28e-11 1.98e-07 -0.61 -0.49 Dupuytren's disease; chr16:75441622 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs35214308 ENSG00000261783.1 RP11-252K23.2 -6.97 9.28e-11 1.98e-07 -0.61 -0.49 Dupuytren's disease; chr16:75442190 chr16:75379818~75381260:- PAAD cis rs977987 0.806 rs4888425 ENSG00000261783.1 RP11-252K23.2 -6.97 9.28e-11 1.98e-07 -0.61 -0.49 Dupuytren's disease; chr16:75442465 chr16:75379818~75381260:- PAAD cis rs977987 0.778 rs4888426 ENSG00000261783.1 RP11-252K23.2 -6.97 9.28e-11 1.98e-07 -0.61 -0.49 Dupuytren's disease; chr16:75442553 chr16:75379818~75381260:- PAAD cis rs9660180 0.967 rs6603803 ENSG00000231050.1 RP1-140A9.1 6.96 9.29e-11 1.98e-07 0.58 0.49 Body mass index; chr1:1881249 chr1:1891471~1892658:+ PAAD cis rs9545047 0.604 rs7331867 ENSG00000227676.3 LINC01068 -6.96 9.29e-11 1.98e-07 -0.61 -0.49 Schizophrenia; chr13:79418791 chr13:79566727~79571436:+ PAAD cis rs765787 0.53 rs12909987 ENSG00000259520.4 CTD-2651B20.3 6.96 9.29e-11 1.98e-07 0.59 0.49 Uric acid levels; chr15:45220009 chr15:45251580~45279251:- PAAD cis rs9399137 0.507 rs4580893 ENSG00000232876.1 CTA-212D2.2 -6.96 9.37e-11 2e-07 -0.6 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134976524 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs10484496 ENSG00000232876.1 CTA-212D2.2 -6.96 9.37e-11 2e-07 -0.6 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134978544 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs13214669 ENSG00000232876.1 CTA-212D2.2 -6.96 9.37e-11 2e-07 -0.6 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134978821 chr6:135055033~135060550:+ PAAD cis rs9389248 0.737 rs56358308 ENSG00000232876.1 CTA-212D2.2 -6.96 9.37e-11 2e-07 -0.6 -0.49 High light scatter reticulocyte percentage of red cells; chr6:134985842 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs11754021 ENSG00000232876.1 CTA-212D2.2 -6.96 9.37e-11 2e-07 -0.6 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134987237 chr6:135055033~135060550:+ PAAD cis rs7714584 1 rs12652003 ENSG00000197083.10 ZNF300P1 6.96 9.38e-11 2e-07 0.81 0.49 Crohn's disease; chr5:150852383 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11167515 ENSG00000197083.10 ZNF300P1 6.96 9.38e-11 2e-07 0.81 0.49 Crohn's disease; chr5:150859909 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs1000113 ENSG00000197083.10 ZNF300P1 6.96 9.38e-11 2e-07 0.81 0.49 Crohn's disease; chr5:150860514 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11957134 ENSG00000197083.10 ZNF300P1 -6.96 9.38e-11 2e-07 -0.81 -0.49 Crohn's disease; chr5:150851388 chr5:150930645~150946289:- PAAD cis rs507080 0.961 rs607527 ENSG00000255422.1 AP002954.4 6.96 9.48e-11 2.02e-07 0.59 0.49 Serum metabolite levels; chr11:118667478 chr11:118704607~118750263:+ PAAD cis rs507080 0.807 rs7926944 ENSG00000255422.1 AP002954.4 -6.96 9.57e-11 2.04e-07 -0.59 -0.49 Serum metabolite levels; chr11:118689119 chr11:118704607~118750263:+ PAAD cis rs3096299 0.658 rs12443705 ENSG00000274627.1 RP11-104N10.2 6.96 9.64e-11 2.05e-07 0.42 0.49 Multiple myeloma (IgH translocation); chr16:89480646 chr16:89516797~89522217:+ PAAD cis rs9322193 0.772 rs7738696 ENSG00000216906.2 RP11-350J20.9 6.96 9.7e-11 2.06e-07 0.67 0.49 Lung cancer; chr6:149848985 chr6:149904243~149906418:+ PAAD cis rs9322193 0.607 rs6557165 ENSG00000216906.2 RP11-350J20.9 -6.96 9.74e-11 2.07e-07 -0.68 -0.49 Lung cancer; chr6:149906883 chr6:149904243~149906418:+ PAAD cis rs7945705 0.837 rs2742474 ENSG00000254860.4 TMEM9B-AS1 6.95 9.83e-11 2.09e-07 0.54 0.49 Hemoglobin concentration; chr11:8980542 chr11:8964675~8977527:+ PAAD cis rs7945705 0.869 rs2742471 ENSG00000254860.4 TMEM9B-AS1 6.95 9.83e-11 2.09e-07 0.54 0.49 Hemoglobin concentration; chr11:8982406 chr11:8964675~8977527:+ PAAD cis rs1150668 0.83 rs213240 ENSG00000216901.1 AL022393.7 6.95 9.88e-11 2.1e-07 0.59 0.49 Pubertal anthropometrics; chr6:28348098 chr6:28176188~28176674:+ PAAD cis rs6452524 0.967 rs6897075 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83122959 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs10065973 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83123181 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs12153441 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83125181 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs12152891 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83125217 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs6452507 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83125537 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs6452508 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83125546 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs7717964 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83126323 chr5:83012285~83013109:- PAAD cis rs6452524 0.934 rs1120477 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83127062 chr5:83012285~83013109:- PAAD cis rs6452524 0.934 rs1120478 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83127072 chr5:83012285~83013109:- PAAD cis rs6452524 0.934 rs6452512 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83127523 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs6452514 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83127627 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs6884543 ENSG00000249664.1 CTD-2227C6.2 6.95 1e-10 2.13e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83127939 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6452520 ENSG00000249664.1 CTD-2227C6.2 6.95 1.02e-10 2.15e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83133452 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6452521 ENSG00000249664.1 CTD-2227C6.2 6.95 1.02e-10 2.15e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83133453 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs6452522 ENSG00000249664.1 CTD-2227C6.2 6.95 1.02e-10 2.15e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83133471 chr5:83012285~83013109:- PAAD cis rs8040855 0.599 rs4643289 ENSG00000259295.5 CSPG4P12 -6.95 1.02e-10 2.15e-07 -0.53 -0.49 Bulimia nervosa; chr15:85183483 chr15:85191438~85213905:+ PAAD cis rs10885396 1 rs10885396 ENSG00000233547.1 RP11-57H14.2 -6.95 1.02e-10 2.17e-07 -0.46 -0.49 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112951996 chr10:112950646~112951875:- PAAD cis rs10885396 0.967 rs7094871 ENSG00000233547.1 RP11-57H14.2 -6.95 1.02e-10 2.17e-07 -0.46 -0.49 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112952395 chr10:112950646~112951875:- PAAD cis rs4718428 0.672 rs4718412 ENSG00000226824.5 RP4-756H11.3 6.95 1.03e-10 2.17e-07 0.65 0.49 Corneal structure; chr7:66821880 chr7:66654538~66669855:+ PAAD cis rs9322193 0.566 rs6912330 ENSG00000231760.4 RP11-350J20.5 -6.95 1.03e-10 2.17e-07 -0.7 -0.49 Lung cancer; chr6:149908811 chr6:149796151~149826294:- PAAD cis rs7617773 0.539 rs35460860 ENSG00000229759.1 MRPS18AP1 6.95 1.03e-10 2.17e-07 0.52 0.49 Coronary artery disease; chr3:48350595 chr3:48256350~48256938:- PAAD cis rs7617773 0.563 rs13082269 ENSG00000229759.1 MRPS18AP1 6.95 1.03e-10 2.17e-07 0.52 0.49 Coronary artery disease; chr3:48350784 chr3:48256350~48256938:- PAAD cis rs67180937 0.844 rs4846384 ENSG00000272750.1 RP11-378J18.8 -6.95 1.03e-10 2.17e-07 -0.51 -0.49 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222624272 chr1:222658867~222661512:- PAAD cis rs11155671 0.53 rs7742993 ENSG00000268592.3 RAET1E-AS1 6.95 1.03e-10 2.18e-07 0.59 0.49 Testicular germ cell tumor; chr6:149883959 chr6:149863494~149919507:+ PAAD cis rs9532669 0.89 rs9525417 ENSG00000176268.5 CYCSP34 6.94 1.04e-10 2.19e-07 0.47 0.49 Cervical cancer; chr13:40878431 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs9532638 ENSG00000176268.5 CYCSP34 6.94 1.04e-10 2.19e-07 0.47 0.49 Cervical cancer; chr13:40878471 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7997536 ENSG00000176268.5 CYCSP34 6.94 1.04e-10 2.19e-07 0.47 0.49 Cervical cancer; chr13:40878685 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7997560 ENSG00000176268.5 CYCSP34 6.94 1.04e-10 2.19e-07 0.47 0.49 Cervical cancer; chr13:40878723 chr13:40863599~40863902:- PAAD cis rs11155671 0.53 rs9371215 ENSG00000268592.3 RAET1E-AS1 6.94 1.04e-10 2.2e-07 0.6 0.49 Testicular germ cell tumor; chr6:149873162 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs9397036 ENSG00000216906.2 RP11-350J20.9 6.94 1.04e-10 2.2e-07 0.67 0.49 Lung cancer; chr6:149851787 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs9383864 ENSG00000216906.2 RP11-350J20.9 6.94 1.04e-10 2.2e-07 0.67 0.49 Lung cancer; chr6:149851969 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs9383865 ENSG00000216906.2 RP11-350J20.9 6.94 1.04e-10 2.2e-07 0.67 0.49 Lung cancer; chr6:149852043 chr6:149904243~149906418:+ PAAD cis rs673078 0.66 rs76621503 ENSG00000275759.1 RP11-131L12.3 -6.94 1.04e-10 2.2e-07 -0.76 -0.49 Glucose homeostasis traits; chr12:118179370 chr12:118428281~118428870:+ PAAD cis rs2919917 0.915 rs10957897 ENSG00000254352.1 RP11-578O24.2 6.94 1.05e-10 2.22e-07 0.52 0.49 Lymphocyte counts; chr8:78695658 chr8:78723796~78724136:- PAAD cis rs10170846 0.924 rs3768973 ENSG00000261428.2 RP11-16P6.1 6.94 1.05e-10 2.22e-07 0.64 0.49 Schizophrenia (inflammation and infection response interaction); chr2:222571683 chr2:222566899~222569719:- PAAD cis rs977987 0.8 rs1011121 ENSG00000261783.1 RP11-252K23.2 -6.94 1.06e-10 2.23e-07 -0.62 -0.49 Dupuytren's disease; chr16:75292035 chr16:75379818~75381260:- PAAD cis rs7829975 0.511 rs2948286 ENSG00000253893.2 FAM85B -6.94 1.06e-10 2.23e-07 -0.71 -0.49 Mood instability; chr8:8272638 chr8:8167819~8226614:- PAAD cis rs6452524 0.934 rs12153179 ENSG00000249664.1 CTD-2227C6.2 6.94 1.06e-10 2.24e-07 0.54 0.49 Hypertension (SNP x SNP interaction); chr5:83125109 chr5:83012285~83013109:- PAAD cis rs7714584 1 rs59980321 ENSG00000197083.10 ZNF300P1 6.94 1.07e-10 2.24e-07 0.78 0.49 Crohn's disease; chr5:150862251 chr5:150930645~150946289:- PAAD cis rs7429990 0.965 rs62260764 ENSG00000229759.1 MRPS18AP1 6.94 1.07e-10 2.26e-07 0.57 0.49 Educational attainment (years of education); chr3:47949010 chr3:48256350~48256938:- PAAD cis rs3096299 0.685 rs12935112 ENSG00000274627.1 RP11-104N10.2 -6.94 1.08e-10 2.27e-07 -0.41 -0.49 Multiple myeloma (IgH translocation); chr16:89476450 chr16:89516797~89522217:+ PAAD cis rs5760092 0.618 rs5996631 ENSG00000225282.1 AP000350.6 -6.94 1.08e-10 2.27e-07 -0.67 -0.49 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23926900~23929574:+ PAAD cis rs7829975 0.511 rs1543238 ENSG00000253893.2 FAM85B -6.94 1.08e-10 2.28e-07 -0.71 -0.49 Mood instability; chr8:8277287 chr8:8167819~8226614:- PAAD cis rs7829975 0.511 rs1401390 ENSG00000253893.2 FAM85B -6.94 1.08e-10 2.28e-07 -0.71 -0.49 Mood instability; chr8:8278888 chr8:8167819~8226614:- PAAD cis rs9532669 0.926 rs4254182 ENSG00000176268.5 CYCSP34 6.94 1.09e-10 2.29e-07 0.49 0.49 Cervical cancer; chr13:40879120 chr13:40863599~40863902:- PAAD cis rs9545047 0.716 rs943710 ENSG00000227676.3 LINC01068 6.94 1.09e-10 2.29e-07 0.62 0.49 Schizophrenia; chr13:79282987 chr13:79566727~79571436:+ PAAD cis rs944002 1 rs10131298 ENSG00000259444.1 RP11-736N17.8 6.93 1.1e-10 2.3e-07 0.6 0.49 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103102277 chr14:103094723~103098885:+ PAAD cis rs1322639 0.592 rs7743597 ENSG00000261039.2 RP11-417E7.2 -6.93 1.1e-10 2.31e-07 -0.57 -0.49 Pulse pressure; chr6:169191583 chr6:169175304~169182740:- PAAD cis rs944002 0.951 rs7150997 ENSG00000259444.1 RP11-736N17.8 6.93 1.1e-10 2.31e-07 0.6 0.49 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103105537 chr14:103094723~103098885:+ PAAD cis rs3096299 0.632 rs4399533 ENSG00000274627.1 RP11-104N10.2 6.93 1.1e-10 2.32e-07 0.41 0.49 Multiple myeloma (IgH translocation); chr16:89472974 chr16:89516797~89522217:+ PAAD cis rs3096299 0.685 rs4785675 ENSG00000274627.1 RP11-104N10.2 6.93 1.1e-10 2.32e-07 0.41 0.49 Multiple myeloma (IgH translocation); chr16:89473566 chr16:89516797~89522217:+ PAAD cis rs3096299 0.685 rs4238830 ENSG00000274627.1 RP11-104N10.2 6.93 1.1e-10 2.32e-07 0.41 0.49 Multiple myeloma (IgH translocation); chr16:89473833 chr16:89516797~89522217:+ PAAD cis rs9399137 0.507 rs4289677 ENSG00000232876.1 CTA-212D2.2 -6.93 1.11e-10 2.33e-07 -0.6 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954347 chr6:135055033~135060550:+ PAAD cis rs6452524 0.935 rs9293330 ENSG00000249664.1 CTD-2227C6.2 6.93 1.11e-10 2.34e-07 0.55 0.49 Hypertension (SNP x SNP interaction); chr5:83102299 chr5:83012285~83013109:- PAAD cis rs9481169 0.85 rs13210247 ENSG00000255389.1 C6orf3 -6.93 1.11e-10 2.34e-07 -0.86 -0.49 Inflammatory skin disease; chr6:111601517 chr6:111599875~111602295:+ PAAD cis rs6452524 0.935 rs7736296 ENSG00000249664.1 CTD-2227C6.2 -6.93 1.12e-10 2.35e-07 -0.54 -0.49 Hypertension (SNP x SNP interaction); chr5:83082421 chr5:83012285~83013109:- PAAD cis rs2117029 0.587 rs1865157 ENSG00000258017.1 RP11-386G11.10 -6.93 1.12e-10 2.35e-07 -0.64 -0.49 Intelligence (multi-trait analysis); chr12:49129003 chr12:49127782~49147869:+ PAAD cis rs2117029 0.653 rs1476137 ENSG00000258017.1 RP11-386G11.10 -6.93 1.12e-10 2.35e-07 -0.64 -0.49 Intelligence (multi-trait analysis); chr12:49129930 chr12:49127782~49147869:+ PAAD cis rs73086581 1 rs6052220 ENSG00000229539.1 RP11-119B16.2 6.93 1.12e-10 2.36e-07 0.74 0.49 Response to antidepressants in depression; chr20:3989947 chr20:3888239~3888868:- PAAD cis rs3096299 0.658 rs34590044 ENSG00000274627.1 RP11-104N10.2 6.93 1.13e-10 2.37e-07 0.41 0.49 Multiple myeloma (IgH translocation); chr16:89476749 chr16:89516797~89522217:+ PAAD cis rs58873874 0.522 rs6875379 ENSG00000251405.2 CTB-109A12.1 6.93 1.13e-10 2.38e-07 0.84 0.49 Bipolar disorder (body mass index interaction); chr5:157391295 chr5:157362615~157460078:- PAAD cis rs7714584 1 rs7709650 ENSG00000197083.10 ZNF300P1 6.93 1.14e-10 2.39e-07 0.78 0.49 Crohn's disease; chr5:150867123 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs12054923 ENSG00000197083.10 ZNF300P1 6.93 1.14e-10 2.39e-07 0.78 0.49 Crohn's disease; chr5:150869497 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs77698001 ENSG00000197083.10 ZNF300P1 6.93 1.14e-10 2.39e-07 0.78 0.49 Crohn's disease; chr5:150870805 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs2115069 ENSG00000197083.10 ZNF300P1 6.93 1.14e-10 2.39e-07 0.78 0.49 Crohn's disease; chr5:150872803 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10463307 ENSG00000197083.10 ZNF300P1 6.93 1.14e-10 2.39e-07 0.78 0.49 Crohn's disease; chr5:150875058 chr5:150930645~150946289:- PAAD cis rs7429990 0.965 rs184388 ENSG00000229759.1 MRPS18AP1 6.93 1.14e-10 2.39e-07 0.53 0.49 Educational attainment (years of education); chr3:47898136 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs319696 ENSG00000229759.1 MRPS18AP1 6.93 1.14e-10 2.39e-07 0.53 0.49 Educational attainment (years of education); chr3:47902371 chr3:48256350~48256938:- PAAD cis rs7429990 0.93 rs71323371 ENSG00000229759.1 MRPS18AP1 6.93 1.14e-10 2.39e-07 0.53 0.49 Educational attainment (years of education); chr3:47904327 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs35199727 ENSG00000229759.1 MRPS18AP1 6.93 1.14e-10 2.39e-07 0.53 0.49 Educational attainment (years of education); chr3:47905218 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs34025851 ENSG00000229759.1 MRPS18AP1 6.93 1.14e-10 2.39e-07 0.53 0.49 Educational attainment (years of education); chr3:47912243 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs11707679 ENSG00000229759.1 MRPS18AP1 6.93 1.14e-10 2.39e-07 0.53 0.49 Educational attainment (years of education); chr3:47915016 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs1060407 ENSG00000229759.1 MRPS18AP1 6.93 1.14e-10 2.39e-07 0.53 0.49 Educational attainment (years of education); chr3:47916547 chr3:48256350~48256938:- PAAD cis rs6452524 0.905 rs10040244 ENSG00000249664.1 CTD-2227C6.2 6.93 1.15e-10 2.4e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83089242 chr5:83012285~83013109:- PAAD cis rs2117029 0.586 rs10783307 ENSG00000258017.1 RP11-386G11.10 -6.92 1.15e-10 2.41e-07 -0.64 -0.49 Intelligence (multi-trait analysis); chr12:49135822 chr12:49127782~49147869:+ PAAD cis rs2117029 0.554 rs12306494 ENSG00000258017.1 RP11-386G11.10 -6.92 1.15e-10 2.41e-07 -0.64 -0.49 Intelligence (multi-trait analysis); chr12:49136998 chr12:49127782~49147869:+ PAAD cis rs2117029 0.586 rs11168884 ENSG00000258017.1 RP11-386G11.10 -6.92 1.15e-10 2.41e-07 -0.64 -0.49 Intelligence (multi-trait analysis); chr12:49146109 chr12:49127782~49147869:+ PAAD cis rs11168854 0.719 rs11168890 ENSG00000258017.1 RP11-386G11.10 -6.92 1.15e-10 2.41e-07 -0.64 -0.49 Body mass index; chr12:49150130 chr12:49127782~49147869:+ PAAD cis rs2117029 0.586 rs7954521 ENSG00000258017.1 RP11-386G11.10 -6.92 1.15e-10 2.41e-07 -0.64 -0.49 Intelligence (multi-trait analysis); chr12:49151857 chr12:49127782~49147869:+ PAAD cis rs73086581 1 rs3746665 ENSG00000229539.1 RP11-119B16.2 -6.92 1.16e-10 2.42e-07 -0.69 -0.49 Response to antidepressants in depression; chr20:3929759 chr20:3888239~3888868:- PAAD cis rs9399137 0.507 rs7768278 ENSG00000232876.1 CTA-212D2.2 -6.92 1.16e-10 2.43e-07 -0.6 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134953819 chr6:135055033~135060550:+ PAAD cis rs9545047 0.604 rs9574416 ENSG00000227676.3 LINC01068 -6.92 1.17e-10 2.44e-07 -0.59 -0.49 Schizophrenia; chr13:79388577 chr13:79566727~79571436:+ PAAD cis rs7786410 1 rs7786410 ENSG00000226278.1 PSPHP1 6.92 1.17e-10 2.44e-07 0.83 0.49 Age-related hearing impairment; chr7:55854630 chr7:55764797~55773288:+ PAAD cis rs2117029 0.586 rs6580701 ENSG00000258017.1 RP11-386G11.10 -6.92 1.17e-10 2.44e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49163482 chr12:49127782~49147869:+ PAAD cis rs7945705 0.902 rs7479407 ENSG00000254860.4 TMEM9B-AS1 -6.92 1.17e-10 2.45e-07 -0.54 -0.49 Hemoglobin concentration; chr11:9001874 chr11:8964675~8977527:+ PAAD cis rs6452524 0.967 rs2662243 ENSG00000249664.1 CTD-2227C6.2 6.92 1.17e-10 2.45e-07 0.54 0.49 Hypertension (SNP x SNP interaction); chr5:83192630 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs2731846 ENSG00000249664.1 CTD-2227C6.2 6.92 1.17e-10 2.45e-07 0.54 0.49 Hypertension (SNP x SNP interaction); chr5:83193781 chr5:83012285~83013109:- PAAD cis rs67180937 0.882 rs17163313 ENSG00000272750.1 RP11-378J18.8 -6.92 1.18e-10 2.46e-07 -0.51 -0.49 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222626283 chr1:222658867~222661512:- PAAD cis rs673078 0.66 rs61943362 ENSG00000275759.1 RP11-131L12.3 -6.92 1.19e-10 2.48e-07 -0.81 -0.49 Glucose homeostasis traits; chr12:118322042 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs7961312 ENSG00000275759.1 RP11-131L12.3 -6.92 1.19e-10 2.48e-07 -0.81 -0.49 Glucose homeostasis traits; chr12:118324431 chr12:118428281~118428870:+ PAAD cis rs7684253 0.587 rs2002154 ENSG00000269949.1 RP11-738E22.3 -6.92 1.2e-10 2.51e-07 -0.65 -0.49 Migraine; chr4:56879851 chr4:56960927~56961373:- PAAD cis rs7684253 0.587 rs7670313 ENSG00000269949.1 RP11-738E22.3 -6.92 1.2e-10 2.51e-07 -0.65 -0.49 Migraine; chr4:56880007 chr4:56960927~56961373:- PAAD cis rs7684253 0.587 rs2170074 ENSG00000269949.1 RP11-738E22.3 -6.92 1.2e-10 2.51e-07 -0.65 -0.49 Migraine; chr4:56880190 chr4:56960927~56961373:- PAAD cis rs7684253 0.587 rs2170073 ENSG00000269949.1 RP11-738E22.3 -6.92 1.2e-10 2.51e-07 -0.65 -0.49 Migraine; chr4:56880659 chr4:56960927~56961373:- PAAD cis rs3091242 0.934 rs666686 ENSG00000261349.1 RP3-465N24.5 -6.92 1.2e-10 2.51e-07 -0.61 -0.49 Erythrocyte sedimentation rate; chr1:25393020 chr1:25266102~25267136:- PAAD cis rs9399137 0.507 rs7748708 ENSG00000232876.1 CTA-212D2.2 -6.92 1.21e-10 2.52e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134954004 chr6:135055033~135060550:+ PAAD cis rs6452524 0.967 rs4290995 ENSG00000249664.1 CTD-2227C6.2 6.91 1.22e-10 2.53e-07 0.53 0.49 Hypertension (SNP x SNP interaction); chr5:83182177 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs965674 ENSG00000249664.1 CTD-2227C6.2 6.91 1.22e-10 2.53e-07 0.53 0.49 Hypertension (SNP x SNP interaction); chr5:83186765 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2662242 ENSG00000249664.1 CTD-2227C6.2 6.91 1.22e-10 2.53e-07 0.53 0.49 Hypertension (SNP x SNP interaction); chr5:83189066 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs2731844 ENSG00000249664.1 CTD-2227C6.2 6.91 1.22e-10 2.53e-07 0.53 0.49 Hypertension (SNP x SNP interaction); chr5:83192627 chr5:83012285~83013109:- PAAD cis rs6452524 0.901 rs2940540 ENSG00000249664.1 CTD-2227C6.2 6.91 1.22e-10 2.53e-07 0.53 0.49 Hypertension (SNP x SNP interaction); chr5:83193004 chr5:83012285~83013109:- PAAD cis rs9399137 0.507 rs4896128 ENSG00000232876.1 CTA-212D2.2 6.91 1.22e-10 2.53e-07 0.59 0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135028618 chr6:135055033~135060550:+ PAAD cis rs853679 0.527 rs853690 ENSG00000216901.1 AL022393.7 6.91 1.22e-10 2.54e-07 0.62 0.49 Depression; chr6:28317705 chr6:28176188~28176674:+ PAAD cis rs853679 0.527 rs707907 ENSG00000216901.1 AL022393.7 6.91 1.22e-10 2.54e-07 0.62 0.49 Depression; chr6:28323463 chr6:28176188~28176674:+ PAAD cis rs853679 0.527 rs853683 ENSG00000216901.1 AL022393.7 6.91 1.22e-10 2.54e-07 0.62 0.49 Depression; chr6:28327262 chr6:28176188~28176674:+ PAAD cis rs8046696 1 rs8046696 ENSG00000261783.1 RP11-252K23.2 -6.91 1.22e-10 2.54e-07 -0.61 -0.49 Coronary artery disease; chr16:75408245 chr16:75379818~75381260:- PAAD cis rs977987 0.737 rs8046697 ENSG00000261783.1 RP11-252K23.2 -6.91 1.22e-10 2.54e-07 -0.61 -0.49 Dupuytren's disease; chr16:75408246 chr16:75379818~75381260:- PAAD cis rs73086581 1 rs56069856 ENSG00000229539.1 RP11-119B16.2 6.91 1.23e-10 2.55e-07 0.74 0.49 Response to antidepressants in depression; chr20:3985062 chr20:3888239~3888868:- PAAD cis rs9532669 0.926 rs4941995 ENSG00000176268.5 CYCSP34 6.91 1.23e-10 2.55e-07 0.48 0.49 Cervical cancer; chr13:40850117 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9566582 ENSG00000176268.5 CYCSP34 6.91 1.23e-10 2.55e-07 0.48 0.49 Cervical cancer; chr13:40852121 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9315789 ENSG00000176268.5 CYCSP34 6.91 1.23e-10 2.55e-07 0.48 0.49 Cervical cancer; chr13:40852898 chr13:40863599~40863902:- PAAD cis rs9545047 0.604 rs2477397 ENSG00000227676.3 LINC01068 -6.91 1.23e-10 2.55e-07 -0.61 -0.49 Schizophrenia; chr13:79428211 chr13:79566727~79571436:+ PAAD cis rs11155671 0.53 rs9383912 ENSG00000268592.3 RAET1E-AS1 6.91 1.24e-10 2.58e-07 0.59 0.49 Testicular germ cell tumor; chr6:149885479 chr6:149863494~149919507:+ PAAD cis rs797680 0.576 rs55838267 ENSG00000223745.6 RP4-717I23.3 6.91 1.24e-10 2.58e-07 0.45 0.49 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93338159 chr1:93262186~93346025:- PAAD cis rs1062177 0.756 rs2915815 ENSG00000213433.5 RPLP1P6 6.91 1.26e-10 2.61e-07 0.54 0.49 Preschool internalizing problems; chr5:151736322 chr5:151765859~151766378:- PAAD cis rs7174755 0.772 rs75395345 ENSG00000260657.2 RP11-315D16.4 6.91 1.27e-10 2.63e-07 0.59 0.49 Major depressive disorder; chr15:68081380 chr15:68267792~68277994:- PAAD cis rs881375 0.678 rs10118357 ENSG00000226752.6 PSMD5-AS1 -6.9 1.28e-10 2.66e-07 -0.53 -0.49 Rheumatoid arthritis; chr9:120917790 chr9:120824828~120854385:+ PAAD cis rs9532669 0.926 rs9532640 ENSG00000176268.5 CYCSP34 6.9 1.29e-10 2.67e-07 0.48 0.49 Cervical cancer; chr13:40880628 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs9532641 ENSG00000176268.5 CYCSP34 6.9 1.29e-10 2.67e-07 0.48 0.49 Cervical cancer; chr13:40880648 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532643 ENSG00000176268.5 CYCSP34 6.9 1.29e-10 2.67e-07 0.48 0.49 Cervical cancer; chr13:40880800 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs9532644 ENSG00000176268.5 CYCSP34 6.9 1.29e-10 2.67e-07 0.48 0.49 Cervical cancer; chr13:40880860 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532645 ENSG00000176268.5 CYCSP34 6.9 1.29e-10 2.67e-07 0.48 0.49 Cervical cancer; chr13:40880898 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532646 ENSG00000176268.5 CYCSP34 6.9 1.29e-10 2.67e-07 0.48 0.49 Cervical cancer; chr13:40880989 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9525419 ENSG00000176268.5 CYCSP34 6.9 1.29e-10 2.67e-07 0.48 0.49 Cervical cancer; chr13:40881047 chr13:40863599~40863902:- PAAD cis rs11155671 0.53 rs9383940 ENSG00000268592.3 RAET1E-AS1 6.9 1.29e-10 2.68e-07 0.58 0.49 Testicular germ cell tumor; chr6:149904923 chr6:149863494~149919507:+ PAAD cis rs2739330 0.828 rs2877178 ENSG00000099984.9 GSTT2 -6.9 1.29e-10 2.68e-07 -0.63 -0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23980123~23983911:+ PAAD cis rs2739330 0.828 rs2154593 ENSG00000099984.9 GSTT2 -6.9 1.29e-10 2.68e-07 -0.63 -0.49 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23980123~23983911:+ PAAD cis rs7429990 1 rs319680 ENSG00000229759.1 MRPS18AP1 6.9 1.29e-10 2.68e-07 0.55 0.49 Educational attainment (years of education); chr3:47856817 chr3:48256350~48256938:- PAAD cis rs7429990 1 rs7429990 ENSG00000229759.1 MRPS18AP1 6.9 1.29e-10 2.68e-07 0.55 0.49 Educational attainment (years of education); chr3:47860313 chr3:48256350~48256938:- PAAD cis rs1061377 0.862 rs12508577 ENSG00000249207.1 RP11-360F5.1 -6.9 1.3e-10 2.69e-07 -0.54 -0.49 Uric acid levels; chr4:39107779 chr4:39112677~39126818:- PAAD cis rs977987 0.872 rs4243111 ENSG00000261783.1 RP11-252K23.2 -6.9 1.31e-10 2.71e-07 -0.6 -0.49 Dupuytren's disease; chr16:75286929 chr16:75379818~75381260:- PAAD cis rs2117029 0.554 rs2334931 ENSG00000258017.1 RP11-386G11.10 -6.9 1.33e-10 2.75e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49174130 chr12:49127782~49147869:+ PAAD cis rs2117029 0.586 rs10875929 ENSG00000258017.1 RP11-386G11.10 -6.9 1.33e-10 2.75e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49174605 chr12:49127782~49147869:+ PAAD cis rs2117029 0.554 rs2334930 ENSG00000258017.1 RP11-386G11.10 -6.9 1.33e-10 2.75e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49175528 chr12:49127782~49147869:+ PAAD cis rs2117029 0.586 rs11168904 ENSG00000258017.1 RP11-386G11.10 -6.9 1.33e-10 2.75e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49177234 chr12:49127782~49147869:+ PAAD cis rs2117029 0.586 rs10875931 ENSG00000258017.1 RP11-386G11.10 -6.9 1.33e-10 2.75e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49179513 chr12:49127782~49147869:+ PAAD cis rs2117029 0.554 rs7954530 ENSG00000258017.1 RP11-386G11.10 -6.9 1.33e-10 2.75e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49179742 chr12:49127782~49147869:+ PAAD cis rs2117029 0.586 rs7957998 ENSG00000258017.1 RP11-386G11.10 -6.9 1.33e-10 2.75e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49180240 chr12:49127782~49147869:+ PAAD cis rs2117029 0.553 rs11168909 ENSG00000258017.1 RP11-386G11.10 -6.9 1.33e-10 2.75e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49183092 chr12:49127782~49147869:+ PAAD cis rs7714584 1 rs1896707 ENSG00000197083.10 ZNF300P1 6.9 1.34e-10 2.77e-07 0.76 0.49 Crohn's disease; chr5:150865567 chr5:150930645~150946289:- PAAD cis rs3814244 0.528 rs2906859 ENSG00000255733.4 IFNG-AS1 6.9 1.34e-10 2.78e-07 0.45 0.49 Itch intensity from mosquito bite adjusted by bite size; chr12:68002355 chr12:67989445~68234686:+ PAAD cis rs2117029 0.587 rs57853986 ENSG00000258017.1 RP11-386G11.10 -6.89 1.35e-10 2.8e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49124612 chr12:49127782~49147869:+ PAAD cis rs977987 0.806 rs8050059 ENSG00000261783.1 RP11-252K23.2 -6.89 1.37e-10 2.82e-07 -0.61 -0.49 Dupuytren's disease; chr16:75354833 chr16:75379818~75381260:- PAAD cis rs67180937 0.733 rs17532708 ENSG00000272750.1 RP11-378J18.8 -6.89 1.37e-10 2.83e-07 -0.51 -0.49 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222726085 chr1:222658867~222661512:- PAAD cis rs35160687 0.798 rs6547674 ENSG00000273080.1 RP11-301O19.1 -6.89 1.39e-10 2.87e-07 -0.59 -0.49 Night sleep phenotypes; chr2:86325796 chr2:86195590~86196049:+ PAAD cis rs35160687 0.798 rs11127029 ENSG00000273080.1 RP11-301O19.1 -6.89 1.39e-10 2.87e-07 -0.59 -0.49 Night sleep phenotypes; chr2:86327502 chr2:86195590~86196049:+ PAAD cis rs881375 0.654 rs10760126 ENSG00000226752.6 PSMD5-AS1 -6.89 1.39e-10 2.87e-07 -0.53 -0.49 Rheumatoid arthritis; chr9:120900340 chr9:120824828~120854385:+ PAAD cis rs881375 0.678 rs4836834 ENSG00000226752.6 PSMD5-AS1 -6.89 1.39e-10 2.87e-07 -0.53 -0.49 Rheumatoid arthritis; chr9:120903623 chr9:120824828~120854385:+ PAAD cis rs944002 0.857 rs77071436 ENSG00000259444.1 RP11-736N17.8 6.89 1.39e-10 2.88e-07 0.6 0.49 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103102644 chr14:103094723~103098885:+ PAAD cis rs9322193 0.884 rs7769115 ENSG00000216906.2 RP11-350J20.9 6.89 1.4e-10 2.88e-07 0.66 0.49 Lung cancer; chr6:149848796 chr6:149904243~149906418:+ PAAD cis rs6452524 0.901 rs1842020 ENSG00000249664.1 CTD-2227C6.2 6.89 1.4e-10 2.89e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83125814 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs7718278 ENSG00000249664.1 CTD-2227C6.2 6.89 1.4e-10 2.89e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83126600 chr5:83012285~83013109:- PAAD cis rs6452524 0.934 rs1120476 ENSG00000249664.1 CTD-2227C6.2 6.89 1.4e-10 2.89e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83126824 chr5:83012285~83013109:- PAAD cis rs6452524 0.934 rs6452510 ENSG00000249664.1 CTD-2227C6.2 6.89 1.4e-10 2.89e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83127401 chr5:83012285~83013109:- PAAD cis rs1061377 1 rs10030904 ENSG00000249207.1 RP11-360F5.1 -6.89 1.41e-10 2.9e-07 -0.53 -0.49 Uric acid levels; chr4:39113603 chr4:39112677~39126818:- PAAD cis rs9532669 0.926 rs12871420 ENSG00000176268.5 CYCSP34 6.89 1.41e-10 2.91e-07 0.48 0.49 Cervical cancer; chr13:40880034 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs12871735 ENSG00000176268.5 CYCSP34 6.89 1.41e-10 2.91e-07 0.48 0.49 Cervical cancer; chr13:40880169 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs12871895 ENSG00000176268.5 CYCSP34 6.89 1.41e-10 2.91e-07 0.48 0.49 Cervical cancer; chr13:40880189 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs12872288 ENSG00000176268.5 CYCSP34 6.89 1.41e-10 2.91e-07 0.48 0.49 Cervical cancer; chr13:40880268 chr13:40863599~40863902:- PAAD cis rs8040855 0.825 rs4843021 ENSG00000259295.5 CSPG4P12 -6.89 1.42e-10 2.93e-07 -0.57 -0.49 Bulimia nervosa; chr15:85151317 chr15:85191438~85213905:+ PAAD cis rs992157 0.965 rs13419763 ENSG00000261338.2 RP11-378A13.1 6.88 1.43e-10 2.94e-07 0.57 0.49 Colorectal cancer; chr2:218270227 chr2:218255319~218257366:+ PAAD cis rs7429990 0.932 rs6803741 ENSG00000229759.1 MRPS18AP1 -6.88 1.43e-10 2.94e-07 -0.53 -0.49 Educational attainment (years of education); chr3:48082050 chr3:48256350~48256938:- PAAD cis rs1976403 0.633 rs1780324 ENSG00000227001.3 NBPF2P 6.88 1.44e-10 2.96e-07 0.59 0.49 Liver enzyme levels (alkaline phosphatase); chr1:21495264 chr1:21424625~21427967:- PAAD cis rs12220777 0.585 rs75995665 ENSG00000230091.5 TMEM254-AS1 6.88 1.44e-10 2.97e-07 0.8 0.49 Chronic obstructive pulmonary disease-related biomarkers; chr10:80017462 chr10:80046860~80078912:- PAAD cis rs2906856 0.848 rs3015001 ENSG00000255733.4 IFNG-AS1 -6.88 1.44e-10 2.97e-07 -0.46 -0.49 Mosquito bite size; chr12:68003593 chr12:67989445~68234686:+ PAAD cis rs2283792 1 rs5749986 ENSG00000224086.5 LL22NC03-86G7.1 6.88 1.45e-10 2.98e-07 0.5 0.49 Multiple sclerosis; chr22:21803372 chr22:21938293~21977632:+ PAAD cis rs9660180 0.934 rs12729990 ENSG00000231050.1 RP1-140A9.1 6.88 1.45e-10 2.99e-07 0.57 0.49 Body mass index; chr1:1880596 chr1:1891471~1892658:+ PAAD cis rs2882667 0.858 rs11744972 ENSG00000253404.1 AC034243.1 6.88 1.46e-10 2.99e-07 0.61 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:139093100 chr5:138744434~138753309:- PAAD cis rs11098499 0.954 rs2389802 ENSG00000245958.5 RP11-33B1.1 -6.88 1.46e-10 2.99e-07 -0.41 -0.49 Corneal astigmatism; chr4:119404577 chr4:119454791~119552025:+ PAAD cis rs12022452 0.591 rs11208356 ENSG00000238287.1 RP11-656D10.3 -6.88 1.46e-10 3e-07 -0.73 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40541259 chr1:40493157~40508661:- PAAD cis rs3096299 0.685 rs12446145 ENSG00000274627.1 RP11-104N10.2 6.88 1.46e-10 3e-07 0.41 0.49 Multiple myeloma (IgH translocation); chr16:89476287 chr16:89516797~89522217:+ PAAD cis rs9322193 0.884 rs7743823 ENSG00000216906.2 RP11-350J20.9 6.88 1.47e-10 3.02e-07 0.66 0.49 Lung cancer; chr6:149849744 chr6:149904243~149906418:+ PAAD cis rs1061377 0.861 rs35739603 ENSG00000249207.1 RP11-360F5.1 -6.88 1.47e-10 3.02e-07 -0.53 -0.49 Uric acid levels; chr4:39107938 chr4:39112677~39126818:- PAAD cis rs9532669 0.926 rs9525418 ENSG00000176268.5 CYCSP34 -6.88 1.48e-10 3.03e-07 -0.47 -0.49 Cervical cancer; chr13:40879081 chr13:40863599~40863902:- PAAD cis rs9399135 0.743 rs7745098 ENSG00000232876.1 CTA-212D2.2 -6.88 1.48e-10 3.04e-07 -0.58 -0.49 Red blood cell count; chr6:135093866 chr6:135055033~135060550:+ PAAD cis rs992157 1 rs736731 ENSG00000261338.2 RP11-378A13.1 6.88 1.48e-10 3.04e-07 0.57 0.49 Colorectal cancer; chr2:218255865 chr2:218255319~218257366:+ PAAD cis rs992157 1 rs10932766 ENSG00000261338.2 RP11-378A13.1 6.88 1.48e-10 3.04e-07 0.57 0.49 Colorectal cancer; chr2:218257367 chr2:218255319~218257366:+ PAAD cis rs10170846 0.8 rs10194743 ENSG00000261428.2 RP11-16P6.1 6.88 1.48e-10 3.05e-07 0.63 0.49 Schizophrenia (inflammation and infection response interaction); chr2:222653432 chr2:222566899~222569719:- PAAD cis rs7429990 0.965 rs7642590 ENSG00000229759.1 MRPS18AP1 -6.88 1.5e-10 3.07e-07 -0.53 -0.49 Educational attainment (years of education); chr3:48058260 chr3:48256350~48256938:- PAAD cis rs1062177 0.756 rs2964592 ENSG00000213433.5 RPLP1P6 6.88 1.5e-10 3.07e-07 0.53 0.49 Preschool internalizing problems; chr5:151736127 chr5:151765859~151766378:- PAAD cis rs7429990 0.965 rs1550914 ENSG00000229759.1 MRPS18AP1 6.88 1.5e-10 3.08e-07 0.52 0.49 Educational attainment (years of education); chr3:47953678 chr3:48256350~48256938:- PAAD cis rs1263173 0.566 rs4225 ENSG00000254851.1 RP11-109L13.1 -6.87 1.51e-10 3.09e-07 -0.65 -0.49 HDL cholesterol; chr11:116832955 chr11:117135528~117138582:+ PAAD cis rs6452524 0.934 rs12153440 ENSG00000249664.1 CTD-2227C6.2 6.87 1.52e-10 3.11e-07 0.56 0.49 Hypertension (SNP x SNP interaction); chr5:83125097 chr5:83012285~83013109:- PAAD cis rs11155671 0.53 rs7756850 ENSG00000268592.3 RAET1E-AS1 6.87 1.52e-10 3.12e-07 0.59 0.49 Testicular germ cell tumor; chr6:149891460 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs9371542 ENSG00000268592.3 RAET1E-AS1 6.87 1.52e-10 3.12e-07 0.59 0.49 Testicular germ cell tumor; chr6:149891949 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs9371223 ENSG00000268592.3 RAET1E-AS1 6.87 1.52e-10 3.12e-07 0.59 0.49 Testicular germ cell tumor; chr6:149893670 chr6:149863494~149919507:+ PAAD cis rs2117029 0.619 rs2753 ENSG00000258017.1 RP11-386G11.10 -6.87 1.53e-10 3.13e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49127889 chr12:49127782~49147869:+ PAAD cis rs1062177 0.756 rs2964591 ENSG00000213433.5 RPLP1P6 6.87 1.53e-10 3.13e-07 0.55 0.49 Preschool internalizing problems; chr5:151737836 chr5:151765859~151766378:- PAAD cis rs7714584 1 rs7734778 ENSG00000197083.10 ZNF300P1 6.87 1.54e-10 3.15e-07 0.76 0.49 Crohn's disease; chr5:150876994 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs1896708 ENSG00000197083.10 ZNF300P1 6.87 1.54e-10 3.15e-07 0.78 0.49 Crohn's disease; chr5:150865514 chr5:150930645~150946289:- PAAD cis rs7115242 0.925 rs7925256 ENSG00000254851.1 RP11-109L13.1 -6.87 1.55e-10 3.18e-07 -1.04 -0.49 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117174619 chr11:117135528~117138582:+ PAAD cis rs9532669 0.926 rs6560963 ENSG00000176268.5 CYCSP34 6.87 1.56e-10 3.2e-07 0.46 0.49 Cervical cancer; chr13:40871126 chr13:40863599~40863902:- PAAD cis rs9399137 0.507 rs61738647 ENSG00000232876.1 CTA-212D2.2 -6.87 1.57e-10 3.2e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134961597 chr6:135055033~135060550:+ PAAD cis rs7811142 0.72 rs112622797 ENSG00000242294.5 STAG3L5P 6.87 1.58e-10 3.22e-07 0.39 0.49 Platelet count; chr7:100319793 chr7:100336079~100351900:+ PAAD cis rs992157 1 rs4674280 ENSG00000261338.2 RP11-378A13.1 -6.87 1.58e-10 3.23e-07 -0.57 -0.49 Colorectal cancer; chr2:218276735 chr2:218255319~218257366:+ PAAD cis rs6452524 1 rs10042854 ENSG00000249664.1 CTD-2227C6.2 -6.87 1.59e-10 3.24e-07 -0.55 -0.49 Hypertension (SNP x SNP interaction); chr5:83143876 chr5:83012285~83013109:- PAAD cis rs9545047 0.716 rs9545063 ENSG00000227676.3 LINC01068 6.86 1.59e-10 3.25e-07 0.61 0.49 Schizophrenia; chr13:79316989 chr13:79566727~79571436:+ PAAD cis rs7945705 0.747 rs1980429 ENSG00000254860.4 TMEM9B-AS1 6.86 1.6e-10 3.26e-07 0.53 0.49 Hemoglobin concentration; chr11:8988927 chr11:8964675~8977527:+ PAAD cis rs9532669 0.89 rs9532593 ENSG00000176268.5 CYCSP34 6.86 1.61e-10 3.28e-07 0.48 0.49 Cervical cancer; chr13:40847717 chr13:40863599~40863902:- PAAD cis rs9532669 0.824 rs4941998 ENSG00000176268.5 CYCSP34 6.86 1.62e-10 3.3e-07 0.48 0.49 Cervical cancer; chr13:40859901 chr13:40863599~40863902:- PAAD cis rs6452524 0.901 rs1580309 ENSG00000249664.1 CTD-2227C6.2 6.86 1.62e-10 3.31e-07 0.54 0.49 Hypertension (SNP x SNP interaction); chr5:83091948 chr5:83012285~83013109:- PAAD cis rs12022452 0.591 rs12049435 ENSG00000238287.1 RP11-656D10.3 -6.86 1.64e-10 3.33e-07 -0.71 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40524888 chr1:40493157~40508661:- PAAD cis rs12022452 0.556 rs12037288 ENSG00000238287.1 RP11-656D10.3 -6.86 1.64e-10 3.33e-07 -0.71 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40530625 chr1:40493157~40508661:- PAAD cis rs12022452 0.591 rs1001400 ENSG00000238287.1 RP11-656D10.3 -6.86 1.64e-10 3.33e-07 -0.71 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr1:40533230 chr1:40493157~40508661:- PAAD cis rs977987 0.872 rs1542864 ENSG00000261783.1 RP11-252K23.2 -6.86 1.64e-10 3.34e-07 -0.59 -0.49 Dupuytren's disease; chr16:75437480 chr16:75379818~75381260:- PAAD cis rs9545047 0.604 rs9545085 ENSG00000227676.3 LINC01068 6.86 1.65e-10 3.36e-07 0.59 0.49 Schizophrenia; chr13:79363969 chr13:79566727~79571436:+ PAAD cis rs9532669 0.926 rs9532647 ENSG00000176268.5 CYCSP34 6.86 1.65e-10 3.36e-07 0.48 0.49 Cervical cancer; chr13:40881799 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs9525420 ENSG00000176268.5 CYCSP34 6.86 1.65e-10 3.36e-07 0.48 0.49 Cervical cancer; chr13:40882628 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7324383 ENSG00000176268.5 CYCSP34 6.86 1.65e-10 3.36e-07 0.48 0.49 Cervical cancer; chr13:40882754 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532648 ENSG00000176268.5 CYCSP34 6.86 1.65e-10 3.36e-07 0.48 0.49 Cervical cancer; chr13:40882795 chr13:40863599~40863902:- PAAD cis rs2882667 0.931 rs10074461 ENSG00000253404.1 AC034243.1 6.86 1.66e-10 3.37e-07 0.59 0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138984126 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs10044736 ENSG00000253404.1 AC034243.1 -6.86 1.66e-10 3.37e-07 -0.59 -0.49 Age-related hearing impairment (SNP x SNP interaction); chr5:138985120 chr5:138744434~138753309:- PAAD cis rs7945705 0.719 rs2012680 ENSG00000254860.4 TMEM9B-AS1 6.86 1.66e-10 3.38e-07 0.53 0.49 Hemoglobin concentration; chr11:8974512 chr11:8964675~8977527:+ PAAD cis rs7826238 0.539 rs2945891 ENSG00000253893.2 FAM85B -6.86 1.67e-10 3.39e-07 -0.68 -0.49 Systolic blood pressure; chr8:8297953 chr8:8167819~8226614:- PAAD cis rs992157 1 rs4791 ENSG00000261338.2 RP11-378A13.1 6.85 1.68e-10 3.42e-07 0.57 0.49 Colorectal cancer; chr2:218274217 chr2:218255319~218257366:+ PAAD cis rs2117029 0.619 rs9325145 ENSG00000258017.1 RP11-386G11.10 -6.85 1.68e-10 3.42e-07 -0.63 -0.49 Intelligence (multi-trait analysis); chr12:49132101 chr12:49127782~49147869:+ PAAD cis rs9532669 0.929 rs9532601 ENSG00000176268.5 CYCSP34 6.85 1.69e-10 3.43e-07 0.48 0.49 Cervical cancer; chr13:40861086 chr13:40863599~40863902:- PAAD cis rs977987 0.806 rs1109342 ENSG00000261783.1 RP11-252K23.2 6.85 1.69e-10 3.44e-07 0.6 0.49 Dupuytren's disease; chr16:75411777 chr16:75379818~75381260:- PAAD cis rs977987 0.836 rs7198873 ENSG00000261783.1 RP11-252K23.2 -6.85 1.7e-10 3.44e-07 -0.61 -0.49 Dupuytren's disease; chr16:75440856 chr16:75379818~75381260:- PAAD cis rs7811142 0.83 rs10085549 ENSG00000242294.5 STAG3L5P 6.85 1.7e-10 3.44e-07 0.38 0.49 Platelet count; chr7:100385512 chr7:100336079~100351900:+ PAAD cis rs9532669 0.926 rs2183144 ENSG00000176268.5 CYCSP34 -6.85 1.7e-10 3.46e-07 -0.47 -0.49 Cervical cancer; chr13:40862129 chr13:40863599~40863902:- PAAD cis rs9399137 0.507 rs13196486 ENSG00000232876.1 CTA-212D2.2 -6.85 1.72e-10 3.48e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134962736 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs6918512 ENSG00000232876.1 CTA-212D2.2 -6.85 1.72e-10 3.48e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134963701 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs13064 ENSG00000232876.1 CTA-212D2.2 -6.85 1.72e-10 3.48e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134966395 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs12664898 ENSG00000232876.1 CTA-212D2.2 -6.85 1.72e-10 3.48e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134967525 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs56164974 ENSG00000232876.1 CTA-212D2.2 -6.85 1.72e-10 3.48e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134967578 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs12663810 ENSG00000232876.1 CTA-212D2.2 -6.85 1.72e-10 3.48e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134968644 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs35571217 ENSG00000232876.1 CTA-212D2.2 -6.85 1.72e-10 3.48e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134969217 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs11757723 ENSG00000232876.1 CTA-212D2.2 -6.85 1.72e-10 3.48e-07 -0.59 -0.49 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134970155 chr6:135055033~135060550:+ PAAD cis rs7429990 0.965 rs319686 ENSG00000229759.1 MRPS18AP1 6.85 1.72e-10 3.48e-07 0.53 0.49 Educational attainment (years of education); chr3:47888930 chr3:48256350~48256938:- PAAD cis rs7714584 0.793 rs12653039 ENSG00000197083.10 ZNF300P1 6.85 1.73e-10 3.5e-07 0.84 0.49 Crohn's disease; chr5:150873069 chr5:150930645~150946289:- PAAD cis rs950169 0.881 rs72750843 ENSG00000259728.4 LINC00933 6.85 1.74e-10 3.52e-07 0.6 0.49 Schizophrenia; chr15:84592552 chr15:84570649~84580175:+ PAAD cis rs11155671 0.53 rs2342769 ENSG00000268592.3 RAET1E-AS1 6.85 1.74e-10 3.53e-07 0.59 0.49 Testicular germ cell tumor; chr6:149895371 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs6935829 ENSG00000268592.3 RAET1E-AS1 6.85 1.74e-10 3.53e-07 0.59 0.49 Testicular germ cell tumor; chr6:149896675 chr6:149863494~149919507:+ PAAD cis rs9660180 0.967 rs6603802 ENSG00000231050.1 RP1-140A9.1 6.85 1.75e-10 3.54e-07 0.57 0.49 Body mass index; chr1:1881082 chr1:1891471~1892658:+ PAAD cis rs9399135 0.527 rs61738492 ENSG00000232876.1 CTA-212D2.2 -6.85 1.76e-10 3.55e-07 -0.59 -0.49 Red blood cell count; chr6:134961633 chr6:135055033~135060550:+ PAAD cis rs3091242 0.933 rs1534954 ENSG00000261349.1 RP3-465N24.5 -6.84 1.79e-10 3.61e-07 -0.6 -0.49 Erythrocyte sedimentation rate; chr1:25435433 chr1:25266102~25267136:- PAAD cis rs3091242 0.9 rs35345536 ENSG00000261349.1 RP3-465N24.5 -6.84 1.79e-10 3.61e-07 -0.6 -0.49 Erythrocyte sedimentation rate; chr1:25439997 chr1:25266102~25267136:- PAAD cis rs7396835 1 rs7396835 ENSG00000254851.1 RP11-109L13.1 -6.84 1.79e-10 3.62e-07 -0.79 -0.49 Quantitative traits; chr11:116813312 chr11:117135528~117138582:+ PAAD cis rs4423214 0.879 rs10898144 ENSG00000254682.1 RP11-660L16.2 -6.84 1.8e-10 3.63e-07 -0.67 -0.49 Vitamin D levels; chr11:71440494 chr11:71448674~71452157:+ PAAD cis rs7811142 0.83 rs6955367 ENSG00000242294.5 STAG3L5P 6.84 1.8e-10 3.64e-07 0.37 0.49 Platelet count; chr7:100363571 chr7:100336079~100351900:+ PAAD cis rs950169 0.922 rs62029585 ENSG00000259728.4 LINC00933 6.84 1.82e-10 3.67e-07 0.61 0.49 Schizophrenia; chr15:84397176 chr15:84570649~84580175:+ PAAD cis rs7826238 0.566 rs2945886 ENSG00000253893.2 FAM85B -6.84 1.83e-10 3.69e-07 -0.68 -0.49 Systolic blood pressure; chr8:8290748 chr8:8167819~8226614:- PAAD cis rs4218 0.724 rs35168204 ENSG00000277144.1 RP11-59H7.4 -6.84 1.83e-10 3.7e-07 -0.64 -0.49 Social communication problems; chr15:59121354 chr15:59115547~59116089:- PAAD cis rs5760092 0.842 rs5751763 ENSG00000225282.1 AP000350.6 6.84 1.85e-10 3.73e-07 0.8 0.48 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23905606 chr22:23926900~23929574:+ PAAD cis rs9545047 0.567 rs2296287 ENSG00000227676.3 LINC01068 6.84 1.85e-10 3.74e-07 0.59 0.48 Schizophrenia; chr13:79407045 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1748761 ENSG00000227676.3 LINC01068 6.84 1.85e-10 3.74e-07 0.59 0.48 Schizophrenia; chr13:79407491 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2763809 ENSG00000227676.3 LINC01068 6.84 1.85e-10 3.74e-07 0.59 0.48 Schizophrenia; chr13:79407544 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1748762 ENSG00000227676.3 LINC01068 6.84 1.85e-10 3.74e-07 0.59 0.48 Schizophrenia; chr13:79407914 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1748763 ENSG00000227676.3 LINC01068 6.84 1.85e-10 3.74e-07 0.59 0.48 Schizophrenia; chr13:79407965 chr13:79566727~79571436:+ PAAD cis rs2739330 0.828 rs5760108 ENSG00000099984.9 GSTT2 -6.84 1.86e-10 3.74e-07 -0.62 -0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23980123~23983911:+ PAAD cis rs9545047 0.541 rs36152718 ENSG00000227676.3 LINC01068 6.84 1.86e-10 3.75e-07 0.6 0.48 Schizophrenia; chr13:79306069 chr13:79566727~79571436:+ PAAD cis rs9389248 0.69 rs1028314 ENSG00000232876.1 CTA-212D2.2 6.84 1.86e-10 3.75e-07 0.56 0.48 High light scatter reticulocyte percentage of red cells; chr6:134934572 chr6:135055033~135060550:+ PAAD cis rs2117029 0.586 rs10875928 ENSG00000258017.1 RP11-386G11.10 -6.83 1.87e-10 3.76e-07 -0.63 -0.48 Intelligence (multi-trait analysis); chr12:49162520 chr12:49127782~49147869:+ PAAD cis rs765787 0.53 rs12323957 ENSG00000259520.4 CTD-2651B20.3 -6.83 1.87e-10 3.76e-07 -0.58 -0.48 Uric acid levels; chr15:45198575 chr15:45251580~45279251:- PAAD cis rs950169 0.922 rs11638445 ENSG00000259728.4 LINC00933 6.83 1.87e-10 3.76e-07 0.59 0.48 Schizophrenia; chr15:84594463 chr15:84570649~84580175:+ PAAD cis rs9399137 0.507 rs7754722 ENSG00000232876.1 CTA-212D2.2 6.83 1.87e-10 3.77e-07 0.58 0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134939165 chr6:135055033~135060550:+ PAAD cis rs6452524 0.711 rs1478486 ENSG00000249664.1 CTD-2227C6.2 6.83 1.89e-10 3.81e-07 0.59 0.48 Hypertension (SNP x SNP interaction); chr5:83081185 chr5:83012285~83013109:- PAAD cis rs4218 0.813 rs8036907 ENSG00000277144.1 RP11-59H7.4 -6.83 1.89e-10 3.81e-07 -0.63 -0.48 Social communication problems; chr15:59121144 chr15:59115547~59116089:- PAAD cis rs6452524 0.967 rs2974448 ENSG00000249664.1 CTD-2227C6.2 6.83 1.9e-10 3.82e-07 0.55 0.48 Hypertension (SNP x SNP interaction); chr5:83190937 chr5:83012285~83013109:- PAAD cis rs9322193 0.847 rs868375 ENSG00000216906.2 RP11-350J20.9 6.83 1.91e-10 3.83e-07 0.62 0.48 Lung cancer; chr6:149844905 chr6:149904243~149906418:+ PAAD cis rs8040855 0.69 rs8041189 ENSG00000259295.5 CSPG4P12 -6.83 1.91e-10 3.84e-07 -0.58 -0.48 Bulimia nervosa; chr15:85143096 chr15:85191438~85213905:+ PAAD cis rs9326248 0.53 rs2075292 ENSG00000254851.1 RP11-109L13.1 -6.83 1.91e-10 3.84e-07 -0.85 -0.48 Blood protein levels; chr11:116861796 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs6589575 ENSG00000254851.1 RP11-109L13.1 -6.83 1.91e-10 3.84e-07 -0.85 -0.48 Blood protein levels; chr11:116862594 chr11:117135528~117138582:+ PAAD cis rs9326248 0.53 rs718847 ENSG00000254851.1 RP11-109L13.1 -6.83 1.91e-10 3.84e-07 -0.85 -0.48 Blood protein levels; chr11:116863430 chr11:117135528~117138582:+ PAAD cis rs67180937 0.733 rs61824331 ENSG00000272750.1 RP11-378J18.8 -6.83 1.93e-10 3.87e-07 -0.51 -0.48 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222708030 chr1:222658867~222661512:- PAAD cis rs12220777 1 rs12220777 ENSG00000230091.5 TMEM254-AS1 -6.83 1.95e-10 3.91e-07 -0.84 -0.48 Chronic obstructive pulmonary disease-related biomarkers; chr10:80028348 chr10:80046860~80078912:- PAAD cis rs4722166 0.597 rs1554606 ENSG00000179428.2 AC073072.5 -6.83 1.96e-10 3.93e-07 -0.46 -0.48 Lung cancer; chr7:22729088 chr7:22725395~22727620:- PAAD cis rs9322193 0.607 rs9322229 ENSG00000216906.2 RP11-350J20.9 6.82 1.97e-10 3.95e-07 0.68 0.48 Lung cancer; chr6:149908949 chr6:149904243~149906418:+ PAAD cis rs7811142 0.83 rs6945952 ENSG00000242294.5 STAG3L5P 6.82 1.99e-10 3.98e-07 0.38 0.48 Platelet count; chr7:100384152 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs73401450 ENSG00000242294.5 STAG3L5P 6.82 1.99e-10 3.98e-07 0.38 0.48 Platelet count; chr7:100384236 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs73401451 ENSG00000242294.5 STAG3L5P 6.82 1.99e-10 3.98e-07 0.38 0.48 Platelet count; chr7:100384272 chr7:100336079~100351900:+ PAAD cis rs11098499 0.865 rs11098513 ENSG00000245958.5 RP11-33B1.1 -6.82 2.01e-10 4e-07 -0.39 -0.48 Corneal astigmatism; chr4:119394920 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs28572238 ENSG00000245958.5 RP11-33B1.1 -6.82 2.01e-10 4e-07 -0.39 -0.48 Corneal astigmatism; chr4:119395531 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs28714195 ENSG00000245958.5 RP11-33B1.1 -6.82 2.01e-10 4e-07 -0.39 -0.48 Corneal astigmatism; chr4:119395795 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs12508173 ENSG00000245958.5 RP11-33B1.1 -6.82 2.01e-10 4e-07 -0.39 -0.48 Corneal astigmatism; chr4:119397371 chr4:119454791~119552025:+ PAAD cis rs11098499 0.908 rs12504149 ENSG00000245958.5 RP11-33B1.1 -6.82 2.01e-10 4e-07 -0.39 -0.48 Corneal astigmatism; chr4:119397422 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10008392 ENSG00000245958.5 RP11-33B1.1 -6.82 2.01e-10 4e-07 -0.39 -0.48 Corneal astigmatism; chr4:119397684 chr4:119454791~119552025:+ PAAD cis rs3096299 0.582 rs12935119 ENSG00000274627.1 RP11-104N10.2 6.82 2.01e-10 4.02e-07 0.41 0.48 Multiple myeloma (IgH translocation); chr16:89476466 chr16:89516797~89522217:+ PAAD cis rs7429990 0.932 rs7630685 ENSG00000229759.1 MRPS18AP1 -6.82 2.02e-10 4.03e-07 -0.54 -0.48 Educational attainment (years of education); chr3:48089680 chr3:48256350~48256938:- PAAD cis rs9399137 0.507 rs13209780 ENSG00000232876.1 CTA-212D2.2 -6.82 2.02e-10 4.03e-07 -0.6 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135023657 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs4896129 ENSG00000232876.1 CTA-212D2.2 -6.82 2.02e-10 4.03e-07 -0.6 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135028707 chr6:135055033~135060550:+ PAAD cis rs6452524 1 rs10474094 ENSG00000249664.1 CTD-2227C6.2 6.82 2.03e-10 4.05e-07 0.55 0.48 Hypertension (SNP x SNP interaction); chr5:83154678 chr5:83012285~83013109:- PAAD cis rs7811142 0.83 rs6948685 ENSG00000242294.5 STAG3L5P 6.82 2.05e-10 4.08e-07 0.38 0.48 Platelet count; chr7:100372565 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs7792525 ENSG00000242294.5 STAG3L5P 6.82 2.05e-10 4.09e-07 0.38 0.48 Platelet count; chr7:100374499 chr7:100336079~100351900:+ PAAD cis rs9322193 0.516 rs1999632 ENSG00000216906.2 RP11-350J20.9 6.82 2.06e-10 4.1e-07 0.71 0.48 Lung cancer; chr6:149866737 chr6:149904243~149906418:+ PAAD cis rs1062177 0.724 rs2964590 ENSG00000213433.5 RPLP1P6 6.82 2.06e-10 4.1e-07 0.54 0.48 Preschool internalizing problems; chr5:151738585 chr5:151765859~151766378:- PAAD cis rs1062177 0.756 rs2915827 ENSG00000213433.5 RPLP1P6 6.82 2.06e-10 4.1e-07 0.54 0.48 Preschool internalizing problems; chr5:151740144 chr5:151765859~151766378:- PAAD cis rs2117029 0.586 rs10783308 ENSG00000258017.1 RP11-386G11.10 -6.82 2.06e-10 4.1e-07 -0.63 -0.48 Intelligence (multi-trait analysis); chr12:49137675 chr12:49127782~49147869:+ PAAD cis rs2117029 0.586 rs2114846 ENSG00000258017.1 RP11-386G11.10 -6.82 2.06e-10 4.1e-07 -0.63 -0.48 Intelligence (multi-trait analysis); chr12:49154493 chr12:49127782~49147869:+ PAAD cis rs12022452 0.591 rs4660415 ENSG00000238287.1 RP11-656D10.3 -6.82 2.06e-10 4.1e-07 -0.7 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40512819 chr1:40493157~40508661:- PAAD cis rs12022452 0.556 rs11208298 ENSG00000238287.1 RP11-656D10.3 -6.82 2.06e-10 4.1e-07 -0.7 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40513206 chr1:40493157~40508661:- PAAD cis rs12022452 0.591 rs61781641 ENSG00000238287.1 RP11-656D10.3 -6.82 2.06e-10 4.1e-07 -0.7 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40517412 chr1:40493157~40508661:- PAAD cis rs12022452 0.591 rs11208315 ENSG00000238287.1 RP11-656D10.3 -6.82 2.06e-10 4.1e-07 -0.7 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40519730 chr1:40493157~40508661:- PAAD cis rs6452524 0.901 rs2662238 ENSG00000249664.1 CTD-2227C6.2 6.82 2.07e-10 4.11e-07 0.55 0.48 Hypertension (SNP x SNP interaction); chr5:83203488 chr5:83012285~83013109:- PAAD cis rs673078 0.607 rs17512483 ENSG00000275759.1 RP11-131L12.3 6.81 2.08e-10 4.13e-07 0.79 0.48 Glucose homeostasis traits; chr12:118312380 chr12:118428281~118428870:+ PAAD cis rs7945705 0.747 rs10840158 ENSG00000254860.4 TMEM9B-AS1 6.81 2.08e-10 4.14e-07 0.53 0.48 Hemoglobin concentration; chr11:8999350 chr11:8964675~8977527:+ PAAD cis rs2283792 1 rs3810610 ENSG00000224086.5 LL22NC03-86G7.1 -6.81 2.1e-10 4.17e-07 -0.49 -0.48 Multiple sclerosis; chr22:21761209 chr22:21938293~21977632:+ PAAD cis rs2283792 1 rs13943 ENSG00000224086.5 LL22NC03-86G7.1 -6.81 2.1e-10 4.17e-07 -0.49 -0.48 Multiple sclerosis; chr22:21761913 chr22:21938293~21977632:+ PAAD cis rs2283792 1 rs5999515 ENSG00000224086.5 LL22NC03-86G7.1 6.81 2.1e-10 4.17e-07 0.49 0.48 Multiple sclerosis; chr22:21790812 chr22:21938293~21977632:+ PAAD cis rs7617773 0.539 rs13087050 ENSG00000229759.1 MRPS18AP1 6.81 2.1e-10 4.17e-07 0.51 0.48 Coronary artery disease; chr3:48351310 chr3:48256350~48256938:- PAAD cis rs4218 0.689 rs11853828 ENSG00000277144.1 RP11-59H7.4 -6.81 2.12e-10 4.21e-07 -0.66 -0.48 Social communication problems; chr15:59136031 chr15:59115547~59116089:- PAAD cis rs507080 0.769 rs570836 ENSG00000255422.1 AP002954.4 -6.81 2.12e-10 4.21e-07 -0.59 -0.48 Serum metabolite levels; chr11:118641444 chr11:118704607~118750263:+ PAAD cis rs944002 1 rs62006947 ENSG00000259444.1 RP11-736N17.8 6.81 2.12e-10 4.21e-07 0.6 0.48 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103099033 chr14:103094723~103098885:+ PAAD cis rs7396835 0.8 rs6589572 ENSG00000254851.1 RP11-109L13.1 -6.81 2.12e-10 4.22e-07 -0.79 -0.48 Quantitative traits; chr11:116810847 chr11:117135528~117138582:+ PAAD cis rs7396835 0.866 rs7927820 ENSG00000254851.1 RP11-109L13.1 -6.81 2.12e-10 4.22e-07 -0.79 -0.48 Quantitative traits; chr11:116811440 chr11:117135528~117138582:+ PAAD cis rs5760092 0.618 rs4461358 ENSG00000250470.1 AP000351.3 -6.81 2.13e-10 4.22e-07 -0.73 -0.48 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23976904~23977585:- PAAD cis rs4722166 0.597 rs2069845 ENSG00000179428.2 AC073072.5 -6.81 2.13e-10 4.23e-07 -0.46 -0.48 Lung cancer; chr7:22730530 chr7:22725395~22727620:- PAAD cis rs7811142 0.83 rs11765869 ENSG00000242294.5 STAG3L5P 6.81 2.13e-10 4.23e-07 0.38 0.48 Platelet count; chr7:100367166 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs705866 ENSG00000242294.5 STAG3L5P 6.81 2.13e-10 4.23e-07 0.38 0.48 Platelet count; chr7:100367662 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs6965458 ENSG00000242294.5 STAG3L5P 6.81 2.13e-10 4.23e-07 0.38 0.48 Platelet count; chr7:100375779 chr7:100336079~100351900:+ PAAD cis rs7429990 0.932 rs9862913 ENSG00000229759.1 MRPS18AP1 6.81 2.14e-10 4.23e-07 0.52 0.48 Educational attainment (years of education); chr3:47974682 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs9814961 ENSG00000229759.1 MRPS18AP1 6.81 2.14e-10 4.23e-07 0.52 0.48 Educational attainment (years of education); chr3:47976127 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs6770467 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47977742 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs6770477 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47977768 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs28637561 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47979528 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7426976 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47981083 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7427418 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47981217 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs13075795 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47983139 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7431572 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47986361 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs13074973 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47986654 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs1013431 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47987628 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7430913 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47990867 chr3:48256350~48256938:- PAAD cis rs7429990 0.901 rs7433678 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47995588 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7430879 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:47997224 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs4293721 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:48003647 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs2166772 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:48006384 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs11130154 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:48027752 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs5012971 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:48033057 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs4392441 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:48036211 chr3:48256350~48256938:- PAAD cis rs7429990 0.813 rs7637622 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:48051561 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7627645 ENSG00000229759.1 MRPS18AP1 -6.81 2.14e-10 4.23e-07 -0.52 -0.48 Educational attainment (years of education); chr3:48051643 chr3:48256350~48256938:- PAAD cis rs9399137 0.507 rs6569986 ENSG00000232876.1 CTA-212D2.2 -6.81 2.14e-10 4.23e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134990503 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs13197750 ENSG00000232876.1 CTA-212D2.2 -6.81 2.14e-10 4.23e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134991242 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs7761964 ENSG00000232876.1 CTA-212D2.2 -6.81 2.14e-10 4.23e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134993127 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs11753673 ENSG00000232876.1 CTA-212D2.2 -6.81 2.14e-10 4.23e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134995338 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs12663447 ENSG00000232876.1 CTA-212D2.2 -6.81 2.14e-10 4.23e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134995888 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs4895437 ENSG00000232876.1 CTA-212D2.2 -6.81 2.14e-10 4.23e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134996216 chr6:135055033~135060550:+ PAAD cis rs6452524 0.901 rs1039786 ENSG00000249664.1 CTD-2227C6.2 6.81 2.14e-10 4.23e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83204222 chr5:83012285~83013109:- PAAD cis rs7811142 0.775 rs1636980 ENSG00000242294.5 STAG3L5P -6.81 2.14e-10 4.24e-07 -0.38 -0.48 Platelet count; chr7:100341241 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs77861211 ENSG00000242294.5 STAG3L5P 6.81 2.14e-10 4.24e-07 0.38 0.48 Platelet count; chr7:100364473 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs11769057 ENSG00000242294.5 STAG3L5P 6.81 2.14e-10 4.24e-07 0.38 0.48 Platelet count; chr7:100367038 chr7:100336079~100351900:+ PAAD cis rs9532669 0.857 rs7327018 ENSG00000176268.5 CYCSP34 6.81 2.15e-10 4.25e-07 0.48 0.48 Cervical cancer; chr13:40856376 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7327315 ENSG00000176268.5 CYCSP34 6.81 2.15e-10 4.25e-07 0.48 0.48 Cervical cancer; chr13:40856383 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7327059 ENSG00000176268.5 CYCSP34 6.81 2.15e-10 4.25e-07 0.48 0.48 Cervical cancer; chr13:40856458 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9594433 ENSG00000176268.5 CYCSP34 6.81 2.15e-10 4.25e-07 0.48 0.48 Cervical cancer; chr13:40856935 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9525403 ENSG00000176268.5 CYCSP34 6.81 2.15e-10 4.25e-07 0.48 0.48 Cervical cancer; chr13:40858292 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7318768 ENSG00000176268.5 CYCSP34 6.81 2.15e-10 4.25e-07 0.48 0.48 Cervical cancer; chr13:40859140 chr13:40863599~40863902:- PAAD cis rs9545047 0.604 rs7319212 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79365404 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7319252 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79365471 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9318633 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79369113 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9318634 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79369303 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs12872328 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79370489 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2182010 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79370618 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs35476664 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79375462 chr13:79566727~79571436:+ PAAD cis rs9545047 0.564 rs7336186 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79385497 chr13:79566727~79571436:+ PAAD cis rs9545047 0.547 rs1590465 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79393998 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2182009 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79397781 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs4605023 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79398700 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9565496 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79398751 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs12877507 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79401822 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9574419 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79402337 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9601226 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79403400 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs9574420 ENSG00000227676.3 LINC01068 -6.81 2.16e-10 4.27e-07 -0.58 -0.48 Schizophrenia; chr13:79404342 chr13:79566727~79571436:+ PAAD cis rs8062405 0.757 rs2411453 ENSG00000259982.1 CDC37P1 -6.81 2.17e-10 4.28e-07 -0.56 -0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620700 chr16:28700294~28701540:- PAAD cis rs11673344 0.526 rs17305823 ENSG00000226686.6 LINC01535 -6.81 2.17e-10 4.28e-07 -0.63 -0.48 Obesity-related traits; chr19:37644145 chr19:37251912~37265535:+ PAAD cis rs73086581 0.687 rs16989002 ENSG00000229539.1 RP11-119B16.2 6.81 2.18e-10 4.29e-07 0.77 0.48 Response to antidepressants in depression; chr20:3870056 chr20:3888239~3888868:- PAAD cis rs73086581 0.687 rs73082600 ENSG00000229539.1 RP11-119B16.2 6.8 2.2e-10 4.34e-07 0.77 0.48 Response to antidepressants in depression; chr20:3863718 chr20:3888239~3888868:- PAAD cis rs9545047 0.604 rs4573813 ENSG00000227676.3 LINC01068 6.8 2.2e-10 4.35e-07 0.58 0.48 Schizophrenia; chr13:79293357 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9545052 ENSG00000227676.3 LINC01068 6.8 2.2e-10 4.35e-07 0.58 0.48 Schizophrenia; chr13:79294875 chr13:79566727~79571436:+ PAAD cis rs67180937 0.621 rs2378607 ENSG00000272750.1 RP11-378J18.8 -6.8 2.22e-10 4.37e-07 -0.51 -0.48 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222746553 chr1:222658867~222661512:- PAAD cis rs9545047 0.604 rs9565497 ENSG00000227676.3 LINC01068 -6.8 2.22e-10 4.38e-07 -0.58 -0.48 Schizophrenia; chr13:79406330 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1853830 ENSG00000227676.3 LINC01068 -6.8 2.22e-10 4.38e-07 -0.58 -0.48 Schizophrenia; chr13:79406877 chr13:79566727~79571436:+ PAAD cis rs11690935 0.686 rs10165126 ENSG00000228389.1 AC068039.4 6.8 2.22e-10 4.38e-07 0.6 0.48 Schizophrenia; chr2:171963793 chr2:171773482~171775844:+ PAAD cis rs507080 0.922 rs4936433 ENSG00000255422.1 AP002954.4 6.8 2.23e-10 4.4e-07 0.58 0.48 Serum metabolite levels; chr11:118681711 chr11:118704607~118750263:+ PAAD cis rs10885396 0.967 rs7094463 ENSG00000233547.1 RP11-57H14.2 6.8 2.24e-10 4.41e-07 0.45 0.48 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112952224 chr10:112950646~112951875:- PAAD cis rs7714584 1 rs1428551 ENSG00000197083.10 ZNF300P1 6.8 2.24e-10 4.41e-07 0.75 0.48 Crohn's disease; chr5:150880270 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs1816256 ENSG00000197083.10 ZNF300P1 6.8 2.24e-10 4.41e-07 0.75 0.48 Crohn's disease; chr5:150893291 chr5:150930645~150946289:- PAAD cis rs9532669 0.926 rs4942000 ENSG00000176268.5 CYCSP34 6.8 2.24e-10 4.42e-07 0.48 0.48 Cervical cancer; chr13:40859979 chr13:40863599~40863902:- PAAD cis rs12022452 0.822 rs6600343 ENSG00000238287.1 RP11-656D10.3 -6.8 2.26e-10 4.45e-07 -0.71 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40562538 chr1:40493157~40508661:- PAAD cis rs7714584 1 rs1428555 ENSG00000197083.10 ZNF300P1 -6.8 2.27e-10 4.46e-07 -0.75 -0.48 Crohn's disease; chr5:150877829 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11747270 ENSG00000197083.10 ZNF300P1 -6.8 2.27e-10 4.46e-07 -0.75 -0.48 Crohn's disease; chr5:150879305 chr5:150930645~150946289:- PAAD cis rs12022452 0.63 rs3795346 ENSG00000238287.1 RP11-656D10.3 -6.8 2.3e-10 4.52e-07 -0.7 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40508753 chr1:40493157~40508661:- PAAD cis rs6452524 0.836 rs10041617 ENSG00000249664.1 CTD-2227C6.2 6.79 2.31e-10 4.54e-07 0.53 0.48 Hypertension (SNP x SNP interaction); chr5:83096535 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs3901654 ENSG00000249664.1 CTD-2227C6.2 6.79 2.31e-10 4.54e-07 0.53 0.48 Hypertension (SNP x SNP interaction); chr5:83110519 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs1478480 ENSG00000249664.1 CTD-2227C6.2 6.79 2.31e-10 4.54e-07 0.53 0.48 Hypertension (SNP x SNP interaction); chr5:83112117 chr5:83012285~83013109:- PAAD cis rs11155671 0.53 rs4458704 ENSG00000223701.3 RAET1E-AS1 6.79 2.32e-10 4.55e-07 0.55 0.48 Testicular germ cell tumor; chr6:149911743 chr6:149884431~149919508:+ PAAD cis rs2283792 0.967 rs3810609 ENSG00000224086.5 LL22NC03-86G7.1 -6.79 2.34e-10 4.59e-07 -0.49 -0.48 Multiple sclerosis; chr22:21758513 chr22:21938293~21977632:+ PAAD cis rs9545047 0.604 rs9545048 ENSG00000227676.3 LINC01068 6.79 2.34e-10 4.6e-07 0.58 0.48 Schizophrenia; chr13:79285593 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1626333 ENSG00000227676.3 LINC01068 6.79 2.34e-10 4.6e-07 0.58 0.48 Schizophrenia; chr13:79286932 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs1856996 ENSG00000227676.3 LINC01068 6.79 2.34e-10 4.6e-07 0.58 0.48 Schizophrenia; chr13:79287453 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs4885625 ENSG00000227676.3 LINC01068 6.79 2.34e-10 4.6e-07 0.58 0.48 Schizophrenia; chr13:79290355 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1324873 ENSG00000227676.3 LINC01068 6.79 2.34e-10 4.6e-07 0.58 0.48 Schizophrenia; chr13:79292246 chr13:79566727~79571436:+ PAAD cis rs7044106 0.734 rs12553070 ENSG00000226752.6 PSMD5-AS1 -6.79 2.35e-10 4.61e-07 -0.65 -0.48 Hip circumference adjusted for BMI; chr9:120722988 chr9:120824828~120854385:+ PAAD cis rs7714584 1 rs10078968 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150864711 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs1896709 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150865470 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs6862814 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150865697 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7709388 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150866977 chr5:150930645~150946289:- PAAD cis rs7714584 0.793 rs7709721 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150867296 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11950957 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150874352 chr5:150930645~150946289:- PAAD cis rs7714584 0.793 rs11958146 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150874596 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11951694 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150874776 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11955172 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150874816 chr5:150930645~150946289:- PAAD cis rs7714584 0.793 rs11955174 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150874829 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10061105 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150875623 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs6579803 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150875997 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs6579804 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150876369 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7734928 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150877051 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10463240 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150877291 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs9324660 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150877492 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs1428554 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150878054 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7715981 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150878545 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7736554 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150878746 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7736873 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150878920 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7716903 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150879012 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11167518 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150879358 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10041072 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150880080 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs1428552 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150880269 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10463310 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150881343 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs73284126 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150881745 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7732643 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150881874 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7732945 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150882039 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs1820682 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150882580 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs2344181 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150883012 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs4560537 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150883024 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11746108 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150885060 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11739619 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150885100 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11167519 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150885845 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11167520 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150886077 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs73284141 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150886524 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs3906527 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150886830 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs2345001 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150886956 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs3906528 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150887156 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs2344180 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150887795 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs2880791 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150887814 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs3857422 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150889047 chr5:150930645~150946289:- PAAD cis rs7714584 0.59 rs4352593 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150889770 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7709464 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150889879 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10053750 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150890489 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7714584 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150890858 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs6579806 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150891522 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs4958848 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150891560 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs1863998 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150892191 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11167521 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150892223 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10057988 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150892500 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs10052606 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150892655 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs57001853 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150892890 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs2217266 ENSG00000197083.10 ZNF300P1 6.79 2.36e-10 4.62e-07 0.75 0.48 Crohn's disease; chr5:150893059 chr5:150930645~150946289:- PAAD cis rs2882667 0.858 rs11741150 ENSG00000253404.1 AC034243.1 6.79 2.36e-10 4.62e-07 0.61 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139095768 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs13177503 ENSG00000253404.1 AC034243.1 6.79 2.36e-10 4.62e-07 0.61 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139097070 chr5:138744434~138753309:- PAAD cis rs2882667 0.754 rs11746434 ENSG00000253404.1 AC034243.1 6.79 2.36e-10 4.62e-07 0.61 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139099614 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs13170388 ENSG00000253404.1 AC034243.1 6.79 2.36e-10 4.62e-07 0.61 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139101176 chr5:138744434~138753309:- PAAD cis rs2117029 0.586 rs1874908 ENSG00000258017.1 RP11-386G11.10 -6.79 2.39e-10 4.67e-07 -0.62 -0.48 Intelligence (multi-trait analysis); chr12:49190247 chr12:49127782~49147869:+ PAAD cis rs7811142 0.83 rs11768967 ENSG00000242294.5 STAG3L5P 6.79 2.4e-10 4.69e-07 0.37 0.48 Platelet count; chr7:100370021 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs7792959 ENSG00000242294.5 STAG3L5P 6.79 2.4e-10 4.69e-07 0.37 0.48 Platelet count; chr7:100374780 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs6975660 ENSG00000242294.5 STAG3L5P 6.79 2.4e-10 4.69e-07 0.37 0.48 Platelet count; chr7:100377643 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs73401443 ENSG00000242294.5 STAG3L5P 6.79 2.4e-10 4.69e-07 0.37 0.48 Platelet count; chr7:100379959 chr7:100336079~100351900:+ PAAD cis rs9532669 0.926 rs4555012 ENSG00000176268.5 CYCSP34 6.79 2.4e-10 4.69e-07 0.48 0.48 Cervical cancer; chr13:40879997 chr13:40863599~40863902:- PAAD cis rs7826238 0.535 rs2979179 ENSG00000253893.2 FAM85B -6.79 2.41e-10 4.7e-07 -0.67 -0.48 Systolic blood pressure; chr8:8462519 chr8:8167819~8226614:- PAAD cis rs2283792 0.967 rs743409 ENSG00000224086.5 LL22NC03-86G7.1 -6.78 2.43e-10 4.74e-07 -0.49 -0.48 Multiple sclerosis; chr22:21774926 chr22:21938293~21977632:+ PAAD cis rs7714584 1 rs17800987 ENSG00000197083.10 ZNF300P1 6.78 2.44e-10 4.76e-07 0.75 0.48 Crohn's disease; chr5:150943866 chr5:150930645~150946289:- PAAD cis rs7811142 0.83 rs78256546 ENSG00000242294.5 STAG3L5P 6.78 2.44e-10 4.76e-07 0.37 0.48 Platelet count; chr7:100355347 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs41280971 ENSG00000242294.5 STAG3L5P 6.78 2.44e-10 4.76e-07 0.37 0.48 Platelet count; chr7:100356834 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs3087502 ENSG00000242294.5 STAG3L5P 6.78 2.44e-10 4.76e-07 0.37 0.48 Platelet count; chr7:100357741 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs61735533 ENSG00000242294.5 STAG3L5P 6.78 2.44e-10 4.76e-07 0.37 0.48 Platelet count; chr7:100358243 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs11761426 ENSG00000242294.5 STAG3L5P 6.78 2.44e-10 4.76e-07 0.37 0.48 Platelet count; chr7:100359270 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs76798830 ENSG00000242294.5 STAG3L5P 6.78 2.46e-10 4.79e-07 0.38 0.48 Platelet count; chr7:100355205 chr7:100336079~100351900:+ PAAD cis rs7811142 0.775 rs6946768 ENSG00000242294.5 STAG3L5P 6.78 2.46e-10 4.79e-07 0.38 0.48 Platelet count; chr7:100356770 chr7:100336079~100351900:+ PAAD cis rs7044106 0.791 rs10739572 ENSG00000226752.6 PSMD5-AS1 -6.78 2.46e-10 4.8e-07 -0.64 -0.48 Hip circumference adjusted for BMI; chr9:120727537 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs10760116 ENSG00000226752.6 PSMD5-AS1 -6.78 2.46e-10 4.8e-07 -0.63 -0.48 Hip circumference adjusted for BMI; chr9:120732403 chr9:120824828~120854385:+ PAAD cis rs9532669 0.926 rs4942005 ENSG00000176268.5 CYCSP34 6.78 2.48e-10 4.82e-07 0.46 0.48 Cervical cancer; chr13:40871636 chr13:40863599~40863902:- PAAD cis rs11098499 0.738 rs72918577 ENSG00000245958.5 RP11-33B1.1 -6.78 2.48e-10 4.82e-07 -0.4 -0.48 Corneal astigmatism; chr4:119405546 chr4:119454791~119552025:+ PAAD cis rs9532669 0.926 rs7331435 ENSG00000176268.5 CYCSP34 -6.78 2.5e-10 4.85e-07 -0.46 -0.48 Cervical cancer; chr13:40862396 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7328139 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40862295 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7328145 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40862307 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs7333274 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40862531 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs2324737 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40862808 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs35396630 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40863135 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4942001 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40863176 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4942003 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40863270 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs4942004 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40863598 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs9315791 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40863931 chr13:40863599~40863902:- PAAD cis rs9532669 0.824 rs9315792 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40863951 chr13:40863599~40863902:- PAAD cis rs9532669 0.684 rs7139788 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40864264 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7338617 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40870787 chr13:40863599~40863902:- PAAD cis rs9532669 0.857 rs6560961 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40870878 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs6560962 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40870948 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs1055588 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40871306 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs3610 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40871334 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4942006 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40871862 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4942008 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40871989 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs2039118 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40872260 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4356347 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40872516 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7982346 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40873273 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs12865032 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40873801 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs34123829 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40873808 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4488324 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40873864 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4288867 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40873880 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4415896 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40874001 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs4415897 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40874035 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4389021 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40874209 chr13:40863599~40863902:- PAAD cis rs9532669 0.824 rs4628828 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40874369 chr13:40863599~40863902:- PAAD cis rs9532669 0.737 rs34354179 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40874424 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9594445 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40874859 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9594446 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40874863 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4402423 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40875010 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs9532628 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40875172 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532629 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40875193 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7491149 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40875216 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532630 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40875472 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs4306385 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40875641 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4406939 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40876108 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4628824 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40876217 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532632 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40876309 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532633 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40876332 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532634 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40876369 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532635 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40876397 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs12428959 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40876638 chr13:40863599~40863902:- PAAD cis rs9532669 0.895 rs4942009 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40877243 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4334153 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40877737 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4309270 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40877827 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4270044 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40877923 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs11147824 ENSG00000176268.5 CYCSP34 6.78 2.5e-10 4.85e-07 0.46 0.48 Cervical cancer; chr13:40878183 chr13:40863599~40863902:- PAAD cis rs7714584 1 rs60134818 ENSG00000197083.10 ZNF300P1 6.78 2.5e-10 4.85e-07 0.73 0.48 Crohn's disease; chr5:150881481 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7714415 ENSG00000197083.10 ZNF300P1 6.78 2.5e-10 4.85e-07 0.73 0.48 Crohn's disease; chr5:150890730 chr5:150930645~150946289:- PAAD cis rs2404602 0.574 rs4886795 ENSG00000259422.1 RP11-593F23.1 -6.78 2.52e-10 4.89e-07 -0.62 -0.48 Blood metabolite levels; chr15:76349877 chr15:76174891~76181486:- PAAD cis rs4722166 0.508 rs1474347 ENSG00000179428.2 AC073072.5 6.78 2.53e-10 4.9e-07 0.45 0.48 Lung cancer; chr7:22728505 chr7:22725395~22727620:- PAAD cis rs8062405 0.755 rs62031607 ENSG00000259982.1 CDC37P1 6.77 2.56e-10 4.97e-07 0.58 0.48 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620209 chr16:28700294~28701540:- PAAD cis rs944002 1 rs59643720 ENSG00000259444.1 RP11-736N17.8 6.77 2.57e-10 4.98e-07 0.6 0.48 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103098470 chr14:103094723~103098885:+ PAAD cis rs944002 1 rs61462345 ENSG00000259444.1 RP11-736N17.8 6.77 2.57e-10 4.98e-07 0.6 0.48 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103098598 chr14:103094723~103098885:+ PAAD cis rs944002 1 rs56956502 ENSG00000259444.1 RP11-736N17.8 6.77 2.57e-10 4.98e-07 0.6 0.48 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103098707 chr14:103094723~103098885:+ PAAD cis rs6452524 1 rs6452519 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83133429 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs62374373 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83137389 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10043018 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83138498 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs10037501 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83138722 chr5:83012285~83013109:- PAAD cis rs6452524 0.904 rs6452525 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83138752 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs7716931 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83138856 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs7721416 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83139174 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6882220 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83139715 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6452526 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83140992 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6452527 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83141021 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10055844 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83141276 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10077862 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83141322 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6868817 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83142287 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs10042018 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83142490 chr5:83012285~83013109:- PAAD cis rs6452524 0.967 rs10036418 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83142493 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10055948 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83143437 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10037872 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83144101 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs62374374 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83144838 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs1382372 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83145237 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs1382371 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83145300 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs2126988 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83146496 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs2386240 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83147192 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs9986131 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83149037 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs11740478 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83150567 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs4591730 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83151983 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs1031902 ENSG00000249664.1 CTD-2227C6.2 6.77 2.58e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83152308 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6452524 ENSG00000249664.1 CTD-2227C6.2 -6.77 2.58e-10 5e-07 -0.54 -0.48 Hypertension (SNP x SNP interaction); chr5:83137962 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs11958314 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83132929 chr5:83012285~83013109:- PAAD cis rs6452524 0.686 rs6452517 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83133041 chr5:83012285~83013109:- PAAD cis rs6452524 0.686 rs6452518 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83133043 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10069402 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83133776 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10076271 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83133875 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10076274 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83133908 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10061521 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83133936 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs7733151 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83134655 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs7733330 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83134774 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs7733354 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83134859 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs4634330 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83134963 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs2386238 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83135266 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs2386239 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83135339 chr5:83012285~83013109:- PAAD cis rs6452524 0.934 rs7700253 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83135510 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs10067439 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83136274 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs7710900 ENSG00000249664.1 CTD-2227C6.2 6.77 2.59e-10 5e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83137201 chr5:83012285~83013109:- PAAD cis rs9322193 0.607 rs7764677 ENSG00000216906.2 RP11-350J20.9 6.77 2.59e-10 5e-07 0.69 0.48 Lung cancer; chr6:149906197 chr6:149904243~149906418:+ PAAD cis rs1322639 0.55 rs9505943 ENSG00000261039.2 RP11-417E7.2 -6.77 2.61e-10 5.05e-07 -0.57 -0.48 Pulse pressure; chr6:169192824 chr6:169175304~169182740:- PAAD cis rs508487 0.537 rs5072 ENSG00000254851.1 RP11-109L13.1 -6.77 2.63e-10 5.07e-07 -0.9 -0.48 Cardiovascular disease risk factors;Triglyceride levels; chr11:116836867 chr11:117135528~117138582:+ PAAD cis rs9890032 0.532 rs1808257 ENSG00000266490.1 CTD-2349P21.9 6.77 2.65e-10 5.12e-07 0.44 0.48 Hip circumference adjusted for BMI; chr17:30712948 chr17:30792372~30792833:+ PAAD cis rs9890032 0.52 rs2321926 ENSG00000266490.1 CTD-2349P21.9 6.77 2.65e-10 5.12e-07 0.44 0.48 Hip circumference adjusted for BMI; chr17:30714534 chr17:30792372~30792833:+ PAAD cis rs7945705 0.902 rs10769979 ENSG00000254860.4 TMEM9B-AS1 -6.77 2.65e-10 5.12e-07 -0.54 -0.48 Hemoglobin concentration; chr11:8989112 chr11:8964675~8977527:+ PAAD cis rs7945705 0.902 rs10769980 ENSG00000254860.4 TMEM9B-AS1 -6.77 2.65e-10 5.12e-07 -0.54 -0.48 Hemoglobin concentration; chr11:8992633 chr11:8964675~8977527:+ PAAD cis rs6452524 0.87 rs2174976 ENSG00000249664.1 CTD-2227C6.2 6.77 2.67e-10 5.15e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83197136 chr5:83012285~83013109:- PAAD cis rs2882667 0.858 rs11242447 ENSG00000253404.1 AC034243.1 6.77 2.68e-10 5.16e-07 0.61 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139090484 chr5:138744434~138753309:- PAAD cis rs7044106 0.791 rs10985004 ENSG00000226752.6 PSMD5-AS1 -6.77 2.69e-10 5.19e-07 -0.65 -0.48 Hip circumference adjusted for BMI; chr9:120722659 chr9:120824828~120854385:+ PAAD cis rs1061377 1 rs3796509 ENSG00000249207.1 RP11-360F5.1 -6.77 2.7e-10 5.2e-07 -0.52 -0.48 Uric acid levels; chr4:39108566 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs4974931 ENSG00000249207.1 RP11-360F5.1 -6.77 2.7e-10 5.2e-07 -0.52 -0.48 Uric acid levels; chr4:39108896 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs4974998 ENSG00000249207.1 RP11-360F5.1 -6.77 2.7e-10 5.2e-07 -0.52 -0.48 Uric acid levels; chr4:39109129 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7673299 ENSG00000249207.1 RP11-360F5.1 -6.77 2.7e-10 5.2e-07 -0.52 -0.48 Uric acid levels; chr4:39109138 chr4:39112677~39126818:- PAAD cis rs881375 0.678 rs7031752 ENSG00000226752.6 PSMD5-AS1 -6.77 2.7e-10 5.2e-07 -0.52 -0.48 Rheumatoid arthritis; chr9:120901204 chr9:120824828~120854385:+ PAAD cis rs6452524 1 rs1382369 ENSG00000249664.1 CTD-2227C6.2 6.77 2.7e-10 5.2e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83145610 chr5:83012285~83013109:- PAAD cis rs1061377 1 rs4974997 ENSG00000249207.1 RP11-360F5.1 -6.76 2.7e-10 5.21e-07 -0.52 -0.48 Uric acid levels; chr4:39109151 chr4:39112677~39126818:- PAAD cis rs9322193 0.607 rs4870078 ENSG00000231760.4 RP11-350J20.5 -6.76 2.71e-10 5.22e-07 -0.69 -0.48 Lung cancer; chr6:149880676 chr6:149796151~149826294:- PAAD cis rs507080 0.733 rs601318 ENSG00000255422.1 AP002954.4 -6.76 2.71e-10 5.22e-07 -0.59 -0.48 Serum metabolite levels; chr11:118648845 chr11:118704607~118750263:+ PAAD cis rs9532669 0.89 rs4941999 ENSG00000176268.5 CYCSP34 6.76 2.74e-10 5.28e-07 0.47 0.48 Cervical cancer; chr13:40859926 chr13:40863599~40863902:- PAAD cis rs7714584 1 rs10065172 ENSG00000197083.10 ZNF300P1 6.76 2.74e-10 5.28e-07 0.73 0.48 Crohn's disease; chr5:150848436 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs7705542 ENSG00000197083.10 ZNF300P1 6.76 2.74e-10 5.28e-07 0.73 0.48 Crohn's disease; chr5:150848756 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11749391 ENSG00000197083.10 ZNF300P1 6.76 2.74e-10 5.28e-07 0.73 0.48 Crohn's disease; chr5:150849504 chr5:150930645~150946289:- PAAD cis rs6723162 0.757 rs4852724 ENSG00000237751.2 LINC01143 -6.76 2.75e-10 5.29e-07 -0.57 -0.48 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70889967 chr2:70887871~70889959:+ PAAD cis rs2739330 0.857 rs9608229 ENSG00000231271.1 AP000350.8 6.76 2.77e-10 5.33e-07 0.66 0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:24002918 chr22:23949918~23954042:+ PAAD cis rs9660180 0.967 rs2272908 ENSG00000231050.1 RP1-140A9.1 -6.76 2.78e-10 5.34e-07 -0.56 -0.48 Body mass index; chr1:1790040 chr1:1891471~1892658:+ PAAD cis rs992157 1 rs992157 ENSG00000261338.2 RP11-378A13.1 -6.76 2.78e-10 5.35e-07 -0.54 -0.48 Colorectal cancer; chr2:218290058 chr2:218255319~218257366:+ PAAD cis rs858239 0.601 rs6966776 ENSG00000230658.1 KLHL7-AS1 6.76 2.81e-10 5.39e-07 0.52 0.48 Cerebrospinal fluid biomarker levels; chr7:23126389 chr7:23101228~23105703:- PAAD cis rs9322193 0.543 rs9371533 ENSG00000223701.3 RAET1E-AS1 6.76 2.81e-10 5.4e-07 0.55 0.48 Lung cancer; chr6:149889545 chr6:149884431~149919508:+ PAAD cis rs977987 0.836 rs7199062 ENSG00000261783.1 RP11-252K23.2 -6.76 2.82e-10 5.41e-07 -0.59 -0.48 Dupuytren's disease; chr16:75440929 chr16:75379818~75381260:- PAAD cis rs977987 0.872 rs7206665 ENSG00000261783.1 RP11-252K23.2 -6.76 2.82e-10 5.41e-07 -0.59 -0.48 Dupuytren's disease; chr16:75441389 chr16:75379818~75381260:- PAAD cis rs9399137 0.507 rs11758774 ENSG00000232876.1 CTA-212D2.2 -6.76 2.82e-10 5.41e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135062651 chr6:135055033~135060550:+ PAAD cis rs9389248 0.737 rs12664956 ENSG00000232876.1 CTA-212D2.2 -6.76 2.82e-10 5.41e-07 -0.59 -0.48 High light scatter reticulocyte percentage of red cells; chr6:135063050 chr6:135055033~135060550:+ PAAD cis rs9545047 0.604 rs2057573 ENSG00000227676.3 LINC01068 -6.76 2.83e-10 5.43e-07 -0.59 -0.48 Schizophrenia; chr13:79357736 chr13:79566727~79571436:+ PAAD cis rs11155671 0.53 rs9397398 ENSG00000223701.3 RAET1E-AS1 6.76 2.83e-10 5.43e-07 0.57 0.48 Testicular germ cell tumor; chr6:149872467 chr6:149884431~149919508:+ PAAD cis rs6452524 0.71 rs7708124 ENSG00000249664.1 CTD-2227C6.2 6.75 2.89e-10 5.53e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83132035 chr5:83012285~83013109:- PAAD cis rs7429990 0.965 rs9811277 ENSG00000229759.1 MRPS18AP1 6.75 2.92e-10 5.59e-07 0.51 0.48 Educational attainment (years of education); chr3:47970148 chr3:48256350~48256938:- PAAD cis rs4713118 0.505 rs156740 ENSG00000216901.1 AL022393.7 6.75 2.92e-10 5.59e-07 0.61 0.48 Parkinson's disease; chr6:27992657 chr6:28176188~28176674:+ PAAD cis rs9532669 0.7 rs9525406 ENSG00000176268.5 CYCSP34 6.75 2.92e-10 5.6e-07 0.47 0.48 Cervical cancer; chr13:40860812 chr13:40863599~40863902:- PAAD cis rs11098499 1 rs11098499 ENSG00000245958.5 RP11-33B1.1 -6.75 2.94e-10 5.62e-07 -0.39 -0.48 Corneal astigmatism; chr4:119266456 chr4:119454791~119552025:+ PAAD cis rs11098499 1 rs7659194 ENSG00000245958.5 RP11-33B1.1 -6.75 2.94e-10 5.62e-07 -0.39 -0.48 Corneal astigmatism; chr4:119285992 chr4:119454791~119552025:+ PAAD cis rs2929278 0.562 rs8033846 ENSG00000249839.1 AC011330.5 6.75 2.94e-10 5.62e-07 0.66 0.48 Schizophrenia; chr15:43743165 chr15:43663654~43684339:- PAAD cis rs2929278 0.589 rs7174732 ENSG00000249839.1 AC011330.5 6.75 2.94e-10 5.62e-07 0.66 0.48 Schizophrenia; chr15:43746265 chr15:43663654~43684339:- PAAD cis rs1062177 0.756 rs2915817 ENSG00000213433.5 RPLP1P6 6.75 2.94e-10 5.63e-07 0.53 0.48 Preschool internalizing problems; chr5:151735956 chr5:151765859~151766378:- PAAD cis rs2739330 0.828 rs5751770 ENSG00000099984.9 GSTT2 -6.75 2.94e-10 5.63e-07 -0.62 -0.48 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23980123~23983911:+ PAAD cis rs673078 0.615 rs61943528 ENSG00000275759.1 RP11-131L12.3 -6.75 2.95e-10 5.63e-07 -0.74 -0.48 Glucose homeostasis traits; chr12:118163134 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs61943535 ENSG00000275759.1 RP11-131L12.3 -6.75 2.95e-10 5.63e-07 -0.74 -0.48 Glucose homeostasis traits; chr12:118168307 chr12:118428281~118428870:+ PAAD cis rs2980439 0.846 rs2980437 ENSG00000253893.2 FAM85B 6.75 2.95e-10 5.63e-07 0.68 0.48 Neuroticism; chr8:8237241 chr8:8167819~8226614:- PAAD cis rs6452524 0.868 rs1011981 ENSG00000249664.1 CTD-2227C6.2 6.75 2.98e-10 5.69e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83097869 chr5:83012285~83013109:- PAAD cis rs6452524 0.868 rs17284218 ENSG00000249664.1 CTD-2227C6.2 6.75 2.98e-10 5.69e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83099530 chr5:83012285~83013109:- PAAD cis rs7811142 0.83 rs1063945 ENSG00000242294.5 STAG3L5P 6.75 2.98e-10 5.69e-07 0.37 0.48 Platelet count; chr7:100332824 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs11761253 ENSG00000242294.5 STAG3L5P 6.75 2.98e-10 5.69e-07 0.37 0.48 Platelet count; chr7:100341698 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs11771936 ENSG00000242294.5 STAG3L5P 6.75 2.98e-10 5.69e-07 0.37 0.48 Platelet count; chr7:100345660 chr7:100336079~100351900:+ PAAD cis rs7811142 0.779 rs77370288 ENSG00000242294.5 STAG3L5P 6.75 2.98e-10 5.69e-07 0.37 0.48 Platelet count; chr7:100350274 chr7:100336079~100351900:+ PAAD cis rs7811142 0.72 rs7795656 ENSG00000242294.5 STAG3L5P 6.75 2.98e-10 5.69e-07 0.37 0.48 Platelet count; chr7:100352674 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs7341507 ENSG00000242294.5 STAG3L5P 6.75 2.98e-10 5.69e-07 0.37 0.48 Platelet count; chr7:100353692 chr7:100336079~100351900:+ PAAD cis rs950169 0.922 rs11633075 ENSG00000259728.4 LINC00933 6.75 2.99e-10 5.71e-07 0.59 0.48 Schizophrenia; chr15:84570741 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs12912934 ENSG00000259728.4 LINC00933 6.75 2.99e-10 5.71e-07 0.59 0.48 Schizophrenia; chr15:84571216 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs11633534 ENSG00000259728.4 LINC00933 6.75 2.99e-10 5.71e-07 0.59 0.48 Schizophrenia; chr15:84581411 chr15:84570649~84580175:+ PAAD cis rs3931020 1 rs3931020 ENSG00000272864.1 RP11-17E13.2 -6.75 3e-10 5.73e-07 -0.62 -0.48 Resistin levels; chr1:74769633 chr1:74698769~74699333:- PAAD cis rs3931020 1 rs10874122 ENSG00000272864.1 RP11-17E13.2 -6.75 3e-10 5.73e-07 -0.62 -0.48 Resistin levels; chr1:74770182 chr1:74698769~74699333:- PAAD cis rs8040855 0.659 rs8037886 ENSG00000259295.5 CSPG4P12 -6.74 3.01e-10 5.74e-07 -0.57 -0.48 Bulimia nervosa; chr15:85143533 chr15:85191438~85213905:+ PAAD cis rs7811142 0.83 rs75636500 ENSG00000242294.5 STAG3L5P 6.74 3.01e-10 5.74e-07 0.38 0.48 Platelet count; chr7:100350034 chr7:100336079~100351900:+ PAAD cis rs6452524 0.967 rs62372752 ENSG00000249664.1 CTD-2227C6.2 6.74 3.01e-10 5.75e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83134239 chr5:83012285~83013109:- PAAD cis rs11155671 0.53 rs9968871 ENSG00000268592.3 RAET1E-AS1 6.74 3.01e-10 5.75e-07 0.59 0.48 Testicular germ cell tumor; chr6:149888060 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs9969044 ENSG00000268592.3 RAET1E-AS1 6.74 3.01e-10 5.75e-07 0.59 0.48 Testicular germ cell tumor; chr6:149888068 chr6:149863494~149919507:+ PAAD cis rs8040855 0.965 rs6496766 ENSG00000259295.5 CSPG4P12 -6.74 3.02e-10 5.75e-07 -0.54 -0.48 Bulimia nervosa; chr15:85159144 chr15:85191438~85213905:+ PAAD cis rs8040855 1 rs6496768 ENSG00000259295.5 CSPG4P12 -6.74 3.02e-10 5.75e-07 -0.54 -0.48 Bulimia nervosa; chr15:85159701 chr15:85191438~85213905:+ PAAD cis rs6452524 1 rs7716962 ENSG00000249664.1 CTD-2227C6.2 6.74 3.02e-10 5.76e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83138913 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6882179 ENSG00000249664.1 CTD-2227C6.2 6.74 3.02e-10 5.76e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83139582 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6863300 ENSG00000249664.1 CTD-2227C6.2 6.74 3.02e-10 5.76e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83139629 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs7732092 ENSG00000249664.1 CTD-2227C6.2 6.74 3.02e-10 5.76e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83141110 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs4590162 ENSG00000249664.1 CTD-2227C6.2 6.74 3.02e-10 5.76e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83145621 chr5:83012285~83013109:- PAAD cis rs9660180 0.967 rs12034740 ENSG00000231050.1 RP1-140A9.1 6.74 3.03e-10 5.78e-07 0.56 0.48 Body mass index; chr1:1797530 chr1:1891471~1892658:+ PAAD cis rs9545047 0.604 rs11620233 ENSG00000227676.3 LINC01068 -6.74 3.03e-10 5.78e-07 -0.58 -0.48 Schizophrenia; chr13:79373871 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7331872 ENSG00000227676.3 LINC01068 -6.74 3.03e-10 5.78e-07 -0.58 -0.48 Schizophrenia; chr13:79388717 chr13:79566727~79571436:+ PAAD cis rs7945705 0.902 rs11042152 ENSG00000254860.4 TMEM9B-AS1 -6.74 3.05e-10 5.8e-07 -0.54 -0.48 Hemoglobin concentration; chr11:8999440 chr11:8964675~8977527:+ PAAD cis rs1061377 1 rs9999327 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39110111 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs6833654 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39110701 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1036036 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39111104 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1036037 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39111272 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1036038 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39111383 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1560396 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39112092 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1560397 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39112265 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs2381285 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39112775 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs2163272 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39112790 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs2163273 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39112835 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs62310332 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39112939 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs3796510 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39113309 chr4:39112677~39126818:- PAAD cis rs1061377 0.932 rs6855118 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39114322 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs6829234 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39114586 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs6829450 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39114721 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs6812540 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39114803 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs10026775 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39115155 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs3733276 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39115291 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs3733277 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39115483 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs3733278 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39115615 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs3733279 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39115625 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs10018049 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39115781 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7685082 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39116472 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7664078 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39116583 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7685468 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39116649 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs9998481 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39117215 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs9998867 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39117542 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs2381284 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39117976 chr4:39112677~39126818:- PAAD cis rs1061377 0.803 rs6857761 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39118353 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs9997089 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39119263 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs28465556 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39119569 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs10027813 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39119818 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs9990755 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39119819 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7675782 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39120048 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7676008 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39120154 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs7677729 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39120370 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7655122 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39120396 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs3796511 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39120586 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs3733274 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39120957 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs13182 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39121293 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1061377 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39123130 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1982009 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39123253 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs1138494 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39123315 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs13109200 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39124396 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs2890659 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39125401 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs1046655 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39126127 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7694760 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39126481 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs34771104 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39127432 chr4:39112677~39126818:- PAAD cis rs1061377 0.932 rs35464499 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39127670 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs11728058 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39128224 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs13144374 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39128859 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs17508864 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39129025 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs9996285 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39130556 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1897136 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39131242 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs1897137 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39131387 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs35437629 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39131712 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7657926 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39132443 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs7681116 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39133015 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs11096982 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39133247 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs11727875 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39133699 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs10018622 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39133944 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs28607301 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39136460 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs36090629 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39137195 chr4:39112677~39126818:- PAAD cis rs1061377 0.87 rs73238544 ENSG00000249207.1 RP11-360F5.1 -6.74 3.05e-10 5.8e-07 -0.52 -0.48 Uric acid levels; chr4:39137343 chr4:39112677~39126818:- PAAD cis rs8040855 0.627 rs4842863 ENSG00000259295.5 CSPG4P12 6.74 3.07e-10 5.82e-07 0.55 0.48 Bulimia nervosa; chr15:85098974 chr15:85191438~85213905:+ PAAD cis rs1061377 0.965 rs3733275 ENSG00000249207.1 RP11-360F5.1 -6.74 3.07e-10 5.83e-07 -0.52 -0.48 Uric acid levels; chr4:39121077 chr4:39112677~39126818:- PAAD cis rs9389248 0.708 rs7750574 ENSG00000232876.1 CTA-212D2.2 -6.74 3.08e-10 5.84e-07 -0.59 -0.48 High light scatter reticulocyte percentage of red cells; chr6:135029794 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs7771310 ENSG00000232876.1 CTA-212D2.2 -6.74 3.09e-10 5.87e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134951397 chr6:135055033~135060550:+ PAAD cis rs9322193 0.607 rs4869755 ENSG00000216906.2 RP11-350J20.9 6.74 3.13e-10 5.93e-07 0.71 0.48 Lung cancer; chr6:149886347 chr6:149904243~149906418:+ PAAD cis rs9322193 0.639 rs4869756 ENSG00000216906.2 RP11-350J20.9 6.74 3.13e-10 5.93e-07 0.71 0.48 Lung cancer; chr6:149886360 chr6:149904243~149906418:+ PAAD cis rs10129255 0.5 rs10143242 ENSG00000223648.3 IGHV3-64 6.74 3.13e-10 5.93e-07 0.42 0.48 Kawasaki disease; chr14:106681814 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs2105991 ENSG00000223648.3 IGHV3-64 6.74 3.13e-10 5.93e-07 0.42 0.48 Kawasaki disease; chr14:106682022 chr14:106643132~106658258:- PAAD cis rs950169 0.887 rs220333 ENSG00000259728.4 LINC00933 6.74 3.13e-10 5.93e-07 0.59 0.48 Schizophrenia; chr15:84547902 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs11630507 ENSG00000259728.4 LINC00933 6.74 3.13e-10 5.93e-07 0.59 0.48 Schizophrenia; chr15:84552494 chr15:84570649~84580175:+ PAAD cis rs950169 0.881 rs34117475 ENSG00000259728.4 LINC00933 6.74 3.13e-10 5.93e-07 0.59 0.48 Schizophrenia; chr15:84565212 chr15:84570649~84580175:+ PAAD cis rs950169 0.686 rs12906474 ENSG00000259728.4 LINC00933 6.74 3.13e-10 5.93e-07 0.59 0.48 Schizophrenia; chr15:84566006 chr15:84570649~84580175:+ PAAD cis rs950169 0.81 rs2879976 ENSG00000259728.4 LINC00933 6.74 3.13e-10 5.93e-07 0.59 0.48 Schizophrenia; chr15:84566347 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs12915832 ENSG00000259728.4 LINC00933 6.74 3.13e-10 5.93e-07 0.59 0.48 Schizophrenia; chr15:84568226 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs11630760 ENSG00000259728.4 LINC00933 6.74 3.14e-10 5.94e-07 0.59 0.48 Schizophrenia; chr15:84570106 chr15:84570649~84580175:+ PAAD cis rs950169 0.887 rs71395453 ENSG00000259728.4 LINC00933 6.74 3.14e-10 5.94e-07 0.59 0.48 Schizophrenia; chr15:84570259 chr15:84570649~84580175:+ PAAD cis rs9399137 0.507 rs4594969 ENSG00000232876.1 CTA-212D2.2 -6.74 3.14e-10 5.95e-07 -0.58 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134964448 chr6:135055033~135060550:+ PAAD cis rs11155671 0.53 rs9322228 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149888173 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs7774787 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149888296 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs2342767 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149888581 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs7764376 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149889208 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs6933882 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149889666 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs6939761 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149889858 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs3823021 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149889863 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs4869763 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149890548 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs4869764 ENSG00000268592.3 RAET1E-AS1 6.74 3.17e-10 5.99e-07 0.59 0.48 Testicular germ cell tumor; chr6:149890692 chr6:149863494~149919507:+ PAAD cis rs9601248 0.51 rs9601250 ENSG00000227676.3 LINC01068 6.74 3.17e-10 5.99e-07 0.66 0.48 Major depressive disorder; chr13:79614567 chr13:79566727~79571436:+ PAAD cis rs507080 0.769 rs7389 ENSG00000255422.1 AP002954.4 6.73 3.17e-10 6.01e-07 0.59 0.48 Serum metabolite levels; chr11:118657756 chr11:118704607~118750263:+ PAAD cis rs6452524 0.967 rs62374401 ENSG00000249664.1 CTD-2227C6.2 6.73 3.19e-10 6.03e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83177159 chr5:83012285~83013109:- PAAD cis rs11098499 1 rs11726229 ENSG00000245958.5 RP11-33B1.1 -6.73 3.2e-10 6.05e-07 -0.39 -0.48 Corneal astigmatism; chr4:119290425 chr4:119454791~119552025:+ PAAD cis rs1061377 0.722 rs34803689 ENSG00000249207.1 RP11-360F5.1 -6.73 3.2e-10 6.05e-07 -0.52 -0.48 Uric acid levels; chr4:39116665 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs7669376 ENSG00000249207.1 RP11-360F5.1 -6.73 3.2e-10 6.05e-07 -0.52 -0.48 Uric acid levels; chr4:39116717 chr4:39112677~39126818:- PAAD cis rs4722166 0.695 rs56061963 ENSG00000179428.2 AC073072.5 -6.73 3.2e-10 6.06e-07 -0.44 -0.48 Lung cancer; chr7:22760778 chr7:22725395~22727620:- PAAD cis rs8040855 0.794 rs4843024 ENSG00000259295.5 CSPG4P12 -6.73 3.21e-10 6.06e-07 -0.56 -0.48 Bulimia nervosa; chr15:85162669 chr15:85191438~85213905:+ PAAD cis rs9399137 0.507 rs7745289 ENSG00000232876.1 CTA-212D2.2 -6.73 3.21e-10 6.07e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135059189 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs11759062 ENSG00000232876.1 CTA-212D2.2 -6.73 3.21e-10 6.07e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135060110 chr6:135055033~135060550:+ PAAD cis rs9399137 0.507 rs11759077 ENSG00000232876.1 CTA-212D2.2 -6.73 3.21e-10 6.07e-07 -0.59 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135060213 chr6:135055033~135060550:+ PAAD cis rs7174755 1 rs68069953 ENSG00000260657.2 RP11-315D16.4 6.73 3.23e-10 6.1e-07 0.58 0.48 Major depressive disorder; chr15:68304235 chr15:68267792~68277994:- PAAD cis rs9399137 0.507 rs6904897 ENSG00000232876.1 CTA-212D2.2 -6.73 3.29e-10 6.22e-07 -0.57 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135061842 chr6:135055033~135060550:+ PAAD cis rs6452524 0.935 rs10474081 ENSG00000249664.1 CTD-2227C6.2 6.73 3.29e-10 6.22e-07 0.55 0.48 Hypertension (SNP x SNP interaction); chr5:83095064 chr5:83012285~83013109:- PAAD cis rs62388641 0.547 rs2317966 ENSG00000272279.1 RP11-157J24.2 -6.73 3.3e-10 6.24e-07 -0.56 -0.48 Daytime sleep phenotypes; chr6:1550651 chr6:1528364~1528911:- PAAD cis rs5760092 0.755 rs915589 ENSG00000225282.1 AP000350.6 -6.73 3.31e-10 6.26e-07 -0.72 -0.48 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23926900~23929574:+ PAAD cis rs9532669 0.89 rs9532627 ENSG00000176268.5 CYCSP34 6.72 3.36e-10 6.34e-07 0.47 0.48 Cervical cancer; chr13:40874811 chr13:40863599~40863902:- PAAD cis rs9660180 0.967 rs11260623 ENSG00000231050.1 RP1-140A9.1 6.72 3.36e-10 6.35e-07 0.57 0.48 Body mass index; chr1:1850017 chr1:1891471~1892658:+ PAAD cis rs9660180 0.837 rs915292 ENSG00000231050.1 RP1-140A9.1 6.72 3.36e-10 6.35e-07 0.57 0.48 Body mass index; chr1:1860718 chr1:1891471~1892658:+ PAAD cis rs9660180 0.967 rs9660106 ENSG00000231050.1 RP1-140A9.1 6.72 3.36e-10 6.35e-07 0.57 0.48 Body mass index; chr1:1866508 chr1:1891471~1892658:+ PAAD cis rs1075265 0.633 rs3731967 ENSG00000233266.1 HMGB1P31 -6.72 3.38e-10 6.37e-07 -0.6 -0.48 Chronotype;Morning vs. evening chronotype; chr2:53975311 chr2:54051334~54051760:+ PAAD cis rs2283792 0.935 rs5750113 ENSG00000224086.5 LL22NC03-86G7.1 -6.72 3.38e-10 6.38e-07 -0.49 -0.48 Multiple sclerosis; chr22:21865784 chr22:21938293~21977632:+ PAAD cis rs507080 0.769 rs11603616 ENSG00000255422.1 AP002954.4 -6.72 3.43e-10 6.47e-07 -0.58 -0.48 Serum metabolite levels; chr11:118625350 chr11:118704607~118750263:+ PAAD cis rs507080 0.769 rs570952 ENSG00000255422.1 AP002954.4 -6.72 3.43e-10 6.47e-07 -0.58 -0.48 Serum metabolite levels; chr11:118629477 chr11:118704607~118750263:+ PAAD cis rs507080 0.769 rs645637 ENSG00000255422.1 AP002954.4 -6.72 3.43e-10 6.47e-07 -0.58 -0.48 Serum metabolite levels; chr11:118634373 chr11:118704607~118750263:+ PAAD cis rs507080 0.769 rs483283 ENSG00000255422.1 AP002954.4 -6.72 3.43e-10 6.47e-07 -0.58 -0.48 Serum metabolite levels; chr11:118635684 chr11:118704607~118750263:+ PAAD cis rs507080 0.769 rs745663 ENSG00000255422.1 AP002954.4 -6.72 3.43e-10 6.47e-07 -0.58 -0.48 Serum metabolite levels; chr11:118658886 chr11:118704607~118750263:+ PAAD cis rs7714584 1 rs34156253 ENSG00000197083.10 ZNF300P1 6.72 3.43e-10 6.47e-07 0.76 0.48 Crohn's disease; chr5:150846668 chr5:150930645~150946289:- PAAD cis rs7829975 0.501 rs2980769 ENSG00000253893.2 FAM85B -6.72 3.44e-10 6.48e-07 -0.67 -0.48 Mood instability; chr8:8462781 chr8:8167819~8226614:- PAAD cis rs2980439 0.557 rs2921056 ENSG00000253893.2 FAM85B -6.72 3.44e-10 6.49e-07 -0.67 -0.48 Neuroticism; chr8:8461672 chr8:8167819~8226614:- PAAD cis rs7826238 0.524 rs2921055 ENSG00000253893.2 FAM85B -6.72 3.44e-10 6.49e-07 -0.67 -0.48 Systolic blood pressure; chr8:8461832 chr8:8167819~8226614:- PAAD cis rs9545047 0.716 rs7333904 ENSG00000227676.3 LINC01068 6.72 3.45e-10 6.49e-07 0.6 0.48 Schizophrenia; chr13:79281413 chr13:79566727~79571436:+ PAAD cis rs9660180 0.967 rs6687065 ENSG00000231050.1 RP1-140A9.1 6.72 3.46e-10 6.52e-07 0.57 0.48 Body mass index; chr1:1847030 chr1:1891471~1892658:+ PAAD cis rs992157 0.932 rs56109829 ENSG00000261338.2 RP11-378A13.1 6.72 3.47e-10 6.54e-07 0.55 0.48 Colorectal cancer; chr2:218285017 chr2:218255319~218257366:+ PAAD cis rs12220777 0.786 rs2342607 ENSG00000230091.5 TMEM254-AS1 6.72 3.48e-10 6.54e-07 0.86 0.48 Chronic obstructive pulmonary disease-related biomarkers; chr10:80061733 chr10:80046860~80078912:- PAAD cis rs73086581 1 rs3746666 ENSG00000229539.1 RP11-119B16.2 6.72 3.48e-10 6.55e-07 0.74 0.48 Response to antidepressants in depression; chr20:3930214 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs17286349 ENSG00000229539.1 RP11-119B16.2 6.72 3.48e-10 6.55e-07 0.74 0.48 Response to antidepressants in depression; chr20:3933655 chr20:3888239~3888868:- PAAD cis rs6452524 1 rs9293332 ENSG00000249664.1 CTD-2227C6.2 6.72 3.51e-10 6.6e-07 0.54 0.48 Hypertension (SNP x SNP interaction); chr5:83141546 chr5:83012285~83013109:- PAAD cis rs2117029 0.521 rs1056875 ENSG00000258017.1 RP11-386G11.10 -6.72 3.52e-10 6.62e-07 -0.62 -0.48 Intelligence (multi-trait analysis); chr12:49186397 chr12:49127782~49147869:+ PAAD cis rs9545047 0.604 rs1324870 ENSG00000227676.3 LINC01068 -6.71 3.52e-10 6.63e-07 -0.58 -0.48 Schizophrenia; chr13:79297911 chr13:79566727~79571436:+ PAAD cis rs6452524 0.967 rs62374399 ENSG00000249664.1 CTD-2227C6.2 6.71 3.53e-10 6.64e-07 0.56 0.48 Hypertension (SNP x SNP interaction); chr5:83176051 chr5:83012285~83013109:- PAAD cis rs2283792 1 rs6518986 ENSG00000224086.5 LL22NC03-86G7.1 -6.71 3.53e-10 6.64e-07 -0.49 -0.48 Multiple sclerosis; chr22:21831058 chr22:21938293~21977632:+ PAAD cis rs2283792 1 rs1892846 ENSG00000224086.5 LL22NC03-86G7.1 -6.71 3.53e-10 6.64e-07 -0.49 -0.48 Multiple sclerosis; chr22:21832190 chr22:21938293~21977632:+ PAAD cis rs2283792 1 rs1892848 ENSG00000224086.5 LL22NC03-86G7.1 -6.71 3.53e-10 6.64e-07 -0.49 -0.48 Multiple sclerosis; chr22:21832273 chr22:21938293~21977632:+ PAAD cis rs1075265 0.554 rs10168293 ENSG00000233266.1 HMGB1P31 6.71 3.53e-10 6.64e-07 0.6 0.48 Chronotype;Morning vs. evening chronotype; chr2:53973793 chr2:54051334~54051760:+ PAAD cis rs1075265 0.567 rs66773232 ENSG00000233266.1 HMGB1P31 6.71 3.53e-10 6.64e-07 0.6 0.48 Chronotype;Morning vs. evening chronotype; chr2:53973970 chr2:54051334~54051760:+ PAAD cis rs8040855 0.965 rs1961276 ENSG00000259295.5 CSPG4P12 6.71 3.54e-10 6.65e-07 0.57 0.48 Bulimia nervosa; chr15:85170986 chr15:85191438~85213905:+ PAAD cis rs11098499 0.954 rs10034623 ENSG00000245958.5 RP11-33B1.1 -6.71 3.55e-10 6.67e-07 -0.4 -0.48 Corneal astigmatism; chr4:119476674 chr4:119454791~119552025:+ PAAD cis rs10129255 0.518 rs7143784 ENSG00000223648.3 IGHV3-64 6.71 3.56e-10 6.68e-07 0.42 0.48 Kawasaki disease; chr14:106687277 chr14:106643132~106658258:- PAAD cis rs4718428 0.705 rs68168107 ENSG00000226824.5 RP4-756H11.3 -6.71 3.58e-10 6.73e-07 -0.64 -0.48 Corneal structure; chr7:66790251 chr7:66654538~66669855:+ PAAD cis rs12439619 0.53 rs7162177 ENSG00000278603.1 RP13-608F4.5 6.71 3.59e-10 6.74e-07 0.62 0.48 Intelligence (multi-trait analysis); chr15:82181728 chr15:82472203~82472426:+ PAAD cis rs8040855 0.86 rs6496775 ENSG00000259295.5 CSPG4P12 -6.71 3.6e-10 6.76e-07 -0.56 -0.48 Bulimia nervosa; chr15:85164910 chr15:85191438~85213905:+ PAAD cis rs1075265 0.597 rs11694711 ENSG00000233266.1 HMGB1P31 6.71 3.6e-10 6.76e-07 0.6 0.48 Chronotype;Morning vs. evening chronotype; chr2:53971924 chr2:54051334~54051760:+ PAAD cis rs7396835 0.741 rs7396851 ENSG00000254851.1 RP11-109L13.1 6.71 3.61e-10 6.77e-07 0.8 0.48 Quantitative traits; chr11:116813448 chr11:117135528~117138582:+ PAAD cis rs12022452 0.506 rs12569328 ENSG00000238287.1 RP11-656D10.3 -6.71 3.61e-10 6.78e-07 -0.72 -0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40553549 chr1:40493157~40508661:- PAAD cis rs507080 0.769 rs527290 ENSG00000255422.1 AP002954.4 -6.71 3.63e-10 6.81e-07 -0.59 -0.48 Serum metabolite levels; chr11:118644898 chr11:118704607~118750263:+ PAAD cis rs7429990 0.965 rs7651237 ENSG00000229759.1 MRPS18AP1 -6.71 3.64e-10 6.83e-07 -0.55 -0.48 Educational attainment (years of education); chr3:48064038 chr3:48256350~48256938:- PAAD cis rs507080 0.769 rs571001 ENSG00000255422.1 AP002954.4 -6.71 3.67e-10 6.88e-07 -0.58 -0.48 Serum metabolite levels; chr11:118629457 chr11:118704607~118750263:+ PAAD cis rs11098499 1 rs11098500 ENSG00000245958.5 RP11-33B1.1 -6.71 3.7e-10 6.93e-07 -0.38 -0.48 Corneal astigmatism; chr4:119298084 chr4:119454791~119552025:+ PAAD cis rs2283792 1 rs2266967 ENSG00000224086.5 LL22NC03-86G7.1 -6.71 3.71e-10 6.95e-07 -0.49 -0.48 Multiple sclerosis; chr22:21802500 chr22:21938293~21977632:+ PAAD cis rs507080 0.697 rs653008 ENSG00000255422.1 AP002954.4 -6.7 3.72e-10 6.96e-07 -0.59 -0.48 Serum metabolite levels; chr11:118649775 chr11:118704607~118750263:+ PAAD cis rs6964833 1 rs34324835 ENSG00000123965.13 PMS2P5 6.7 3.75e-10 7.02e-07 0.79 0.48 Menarche (age at onset); chr7:74717986 chr7:74894116~74897835:+ PAAD cis rs7429990 0.965 rs9846062 ENSG00000229759.1 MRPS18AP1 6.7 3.76e-10 7.03e-07 0.51 0.48 Educational attainment (years of education); chr3:47957476 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7649981 ENSG00000229759.1 MRPS18AP1 6.7 3.76e-10 7.03e-07 0.51 0.48 Educational attainment (years of education); chr3:47957847 chr3:48256350~48256938:- PAAD cis rs7429990 0.93 rs7374516 ENSG00000229759.1 MRPS18AP1 6.7 3.76e-10 7.03e-07 0.51 0.48 Educational attainment (years of education); chr3:47961150 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs2166770 ENSG00000229759.1 MRPS18AP1 6.7 3.76e-10 7.03e-07 0.51 0.48 Educational attainment (years of education); chr3:47964183 chr3:48256350~48256938:- PAAD cis rs7826238 0.594 rs2948285 ENSG00000253893.2 FAM85B -6.7 3.76e-10 7.03e-07 -0.7 -0.48 Systolic blood pressure; chr8:8273016 chr8:8167819~8226614:- PAAD cis rs7829975 0.511 rs2955578 ENSG00000253893.2 FAM85B -6.7 3.76e-10 7.03e-07 -0.7 -0.48 Mood instability; chr8:8279561 chr8:8167819~8226614:- PAAD cis rs4718428 0.705 rs4718422 ENSG00000226824.5 RP4-756H11.3 -6.7 3.77e-10 7.06e-07 -0.64 -0.48 Corneal structure; chr7:66894282 chr7:66654538~66669855:+ PAAD cis rs4718428 0.705 rs13231140 ENSG00000226824.5 RP4-756H11.3 -6.7 3.77e-10 7.06e-07 -0.64 -0.48 Corneal structure; chr7:66896631 chr7:66654538~66669855:+ PAAD cis rs9660180 1 rs9660180 ENSG00000231050.1 RP1-140A9.1 6.7 3.78e-10 7.07e-07 0.56 0.48 Body mass index; chr1:1791592 chr1:1891471~1892658:+ PAAD cis rs4423214 0.879 rs736894 ENSG00000254682.1 RP11-660L16.2 6.7 3.8e-10 7.1e-07 0.67 0.48 Vitamin D levels; chr11:71441212 chr11:71448674~71452157:+ PAAD cis rs673078 0.66 rs61943524 ENSG00000275759.1 RP11-131L12.3 -6.7 3.81e-10 7.11e-07 -0.75 -0.48 Glucose homeostasis traits; chr12:118151530 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs17440315 ENSG00000275759.1 RP11-131L12.3 -6.7 3.81e-10 7.11e-07 -0.75 -0.48 Glucose homeostasis traits; chr12:118158819 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs73220119 ENSG00000275759.1 RP11-131L12.3 -6.7 3.81e-10 7.11e-07 -0.75 -0.48 Glucose homeostasis traits; chr12:118159864 chr12:118428281~118428870:+ PAAD cis rs9399137 0.529 rs7739722 ENSG00000232876.1 CTA-212D2.2 -6.7 3.81e-10 7.13e-07 -0.58 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134961087 chr6:135055033~135060550:+ PAAD cis rs2980439 0.557 rs2976876 ENSG00000253893.2 FAM85B -6.7 3.84e-10 7.17e-07 -0.67 -0.48 Neuroticism; chr8:8461340 chr8:8167819~8226614:- PAAD cis rs5760092 0.618 rs5996631 ENSG00000250470.1 AP000351.3 -6.7 3.85e-10 7.18e-07 -0.71 -0.48 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23976904~23977585:- PAAD cis rs67180937 0.733 rs35725247 ENSG00000272750.1 RP11-378J18.8 -6.7 3.85e-10 7.19e-07 -0.5 -0.48 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222706825 chr1:222658867~222661512:- PAAD cis rs9481169 0.85 rs60962769 ENSG00000255389.1 C6orf3 -6.7 3.85e-10 7.19e-07 -0.86 -0.48 Inflammatory skin disease; chr6:111598221 chr6:111599875~111602295:+ PAAD cis rs2108622 0.628 rs11086005 ENSG00000267453.5 AC004791.2 -6.7 3.87e-10 7.23e-07 -0.66 -0.48 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15864286 chr19:15851993~15864904:- PAAD cis rs2929278 0.617 rs12908467 ENSG00000249839.1 AC011330.5 6.7 3.89e-10 7.25e-07 0.66 0.48 Schizophrenia; chr15:43755232 chr15:43663654~43684339:- PAAD cis rs992157 1 rs2292553 ENSG00000261338.2 RP11-378A13.1 6.7 3.89e-10 7.26e-07 0.54 0.48 Colorectal cancer; chr2:218282080 chr2:218255319~218257366:+ PAAD cis rs12022452 0.822 rs7545012 ENSG00000238287.1 RP11-656D10.3 6.7 3.9e-10 7.28e-07 0.71 0.48 Age-related hearing impairment (SNP x SNP interaction); chr1:40562178 chr1:40493157~40508661:- PAAD cis rs7044106 0.791 rs4836829 ENSG00000226752.6 PSMD5-AS1 -6.7 3.92e-10 7.3e-07 -0.65 -0.48 Hip circumference adjusted for BMI; chr9:120720469 chr9:120824828~120854385:+ PAAD cis rs9660180 0.967 rs12044597 ENSG00000231050.1 RP1-140A9.1 6.69 3.93e-10 7.33e-07 0.56 0.48 Body mass index; chr1:1777362 chr1:1891471~1892658:+ PAAD cis rs2117029 0.554 rs35884657 ENSG00000258017.1 RP11-386G11.10 -6.69 3.95e-10 7.35e-07 -0.6 -0.48 Intelligence (multi-trait analysis); chr12:49137317 chr12:49127782~49147869:+ PAAD cis rs11168854 0.62 rs11168888 ENSG00000258017.1 RP11-386G11.10 -6.69 3.95e-10 7.35e-07 -0.6 -0.48 Body mass index; chr12:49149614 chr12:49127782~49147869:+ PAAD cis rs7044106 0.791 rs735109 ENSG00000226752.6 PSMD5-AS1 -6.69 3.95e-10 7.36e-07 -0.62 -0.48 Hip circumference adjusted for BMI; chr9:120726601 chr9:120824828~120854385:+ PAAD cis rs950169 0.922 rs11635505 ENSG00000259728.4 LINC00933 -6.69 3.96e-10 7.38e-07 -0.58 -0.48 Schizophrenia; chr15:84553803 chr15:84570649~84580175:+ PAAD cis rs9545047 0.604 rs943712 ENSG00000227676.3 LINC01068 6.69 3.97e-10 7.39e-07 0.58 0.48 Schizophrenia; chr13:79282671 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs943711 ENSG00000227676.3 LINC01068 6.69 3.97e-10 7.39e-07 0.58 0.48 Schizophrenia; chr13:79282886 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs943709 ENSG00000227676.3 LINC01068 6.69 3.97e-10 7.39e-07 0.58 0.48 Schizophrenia; chr13:79282990 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530891 ENSG00000227676.3 LINC01068 6.69 3.97e-10 7.39e-07 0.58 0.48 Schizophrenia; chr13:79284750 chr13:79566727~79571436:+ PAAD cis rs7429990 0.866 rs3732529 ENSG00000229759.1 MRPS18AP1 6.69 4.01e-10 7.46e-07 0.52 0.48 Educational attainment (years of education); chr3:47928619 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs60446735 ENSG00000229759.1 MRPS18AP1 6.69 4.01e-10 7.46e-07 0.52 0.48 Educational attainment (years of education); chr3:47929958 chr3:48256350~48256938:- PAAD cis rs875971 0.66 rs2191268 ENSG00000226824.5 RP4-756H11.3 -6.69 4.01e-10 7.47e-07 -0.53 -0.48 Aortic root size; chr7:66645237 chr7:66654538~66669855:+ PAAD cis rs992157 0.965 rs62182826 ENSG00000261338.2 RP11-378A13.1 6.69 4.01e-10 7.47e-07 0.54 0.48 Colorectal cancer; chr2:218284000 chr2:218255319~218257366:+ PAAD cis rs4718428 0.705 rs28648401 ENSG00000226824.5 RP4-756H11.3 -6.69 4.03e-10 7.5e-07 -0.64 -0.48 Corneal structure; chr7:66902145 chr7:66654538~66669855:+ PAAD cis rs4718428 0.607 rs66954441 ENSG00000226824.5 RP4-756H11.3 -6.69 4.03e-10 7.5e-07 -0.64 -0.48 Corneal structure; chr7:66904222 chr7:66654538~66669855:+ PAAD cis rs11098499 0.954 rs1546505 ENSG00000245958.5 RP11-33B1.1 -6.69 4.04e-10 7.51e-07 -0.39 -0.48 Corneal astigmatism; chr4:119320069 chr4:119454791~119552025:+ PAAD cis rs6723162 0.773 rs2900674 ENSG00000237751.2 LINC01143 -6.69 4.05e-10 7.52e-07 -0.56 -0.48 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70881930 chr2:70887871~70889959:+ PAAD cis rs6538678 0.824 rs4762631 ENSG00000258343.1 RP11-536G4.2 -6.69 4.06e-10 7.56e-07 -0.69 -0.48 Lupus nephritis in systemic lupus erythematosus; chr12:95855698 chr12:95795345~95858839:- PAAD cis rs6538678 0.824 rs2367583 ENSG00000258343.1 RP11-536G4.2 -6.69 4.06e-10 7.56e-07 -0.69 -0.48 Lupus nephritis in systemic lupus erythematosus; chr12:95856582 chr12:95795345~95858839:- PAAD cis rs4774565 0.762 rs11634585 ENSG00000244879.4 GABPB1-AS1 6.69 4.07e-10 7.58e-07 0.43 0.48 Breast cancer; chr15:50364252 chr15:50354959~50372202:+ PAAD cis rs2882667 0.858 rs11959851 ENSG00000253404.1 AC034243.1 6.69 4.08e-10 7.58e-07 0.59 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:139085716 chr5:138744434~138753309:- PAAD cis rs67383717 0.527 rs10760718 ENSG00000175611.10 LINC00476 6.69 4.09e-10 7.6e-07 0.39 0.48 Parkinson's disease (pesticide exposure interaction); chr9:96032397 chr9:95759231~95875977:- PAAD cis rs6452524 0.935 rs7718284 ENSG00000249664.1 CTD-2227C6.2 -6.69 4.11e-10 7.63e-07 -0.52 -0.48 Hypertension (SNP x SNP interaction); chr5:83082488 chr5:83012285~83013109:- PAAD cis rs7714584 0.793 rs2161363 ENSG00000197083.10 ZNF300P1 6.68 4.13e-10 7.67e-07 0.8 0.48 Crohn's disease; chr5:150802517 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs6875011 ENSG00000197083.10 ZNF300P1 6.68 4.13e-10 7.67e-07 0.8 0.48 Crohn's disease; chr5:150803148 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs73282234 ENSG00000197083.10 ZNF300P1 6.68 4.13e-10 7.67e-07 0.8 0.48 Crohn's disease; chr5:150816362 chr5:150930645~150946289:- PAAD cis rs1930961 1 rs6004658 ENSG00000272977.1 CTA-390C10.10 -6.68 4.17e-10 7.74e-07 -0.94 -0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25460264 chr22:25476218~25479971:+ PAAD cis rs11098499 0.954 rs878373 ENSG00000245958.5 RP11-33B1.1 -6.68 4.18e-10 7.75e-07 -0.39 -0.48 Corneal astigmatism; chr4:119316329 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs1546504 ENSG00000245958.5 RP11-33B1.1 -6.68 4.18e-10 7.75e-07 -0.39 -0.48 Corneal astigmatism; chr4:119320024 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10006877 ENSG00000245958.5 RP11-33B1.1 -6.68 4.18e-10 7.75e-07 -0.39 -0.48 Corneal astigmatism; chr4:119321638 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs11722183 ENSG00000245958.5 RP11-33B1.1 -6.68 4.18e-10 7.75e-07 -0.39 -0.48 Corneal astigmatism; chr4:119359442 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10017371 ENSG00000245958.5 RP11-33B1.1 -6.68 4.18e-10 7.75e-07 -0.39 -0.48 Corneal astigmatism; chr4:119372621 chr4:119454791~119552025:+ PAAD cis rs9399137 0.507 rs6940878 ENSG00000232876.1 CTA-212D2.2 -6.68 4.18e-10 7.75e-07 -0.58 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135045171 chr6:135055033~135060550:+ PAAD cis rs1062177 0.756 rs2915826 ENSG00000213433.5 RPLP1P6 6.68 4.18e-10 7.75e-07 0.54 0.48 Preschool internalizing problems; chr5:151740402 chr5:151765859~151766378:- PAAD cis rs1062177 0.756 rs2964587 ENSG00000213433.5 RPLP1P6 6.68 4.18e-10 7.75e-07 0.54 0.48 Preschool internalizing problems; chr5:151740411 chr5:151765859~151766378:- PAAD cis rs1891275 0.515 rs10881957 ENSG00000228701.1 TNKS2-AS1 -6.68 4.24e-10 7.85e-07 -0.58 -0.48 Intelligence (multi-trait analysis); chr10:91742119 chr10:91782839~91798291:- PAAD cis rs7945705 0.783 rs11042125 ENSG00000254860.4 TMEM9B-AS1 6.68 4.24e-10 7.85e-07 0.51 0.48 Hemoglobin concentration; chr11:8916502 chr11:8964675~8977527:+ PAAD cis rs950169 0.65 rs12902052 ENSG00000259728.4 LINC00933 6.68 4.25e-10 7.88e-07 0.59 0.48 Schizophrenia; chr15:84582607 chr15:84570649~84580175:+ PAAD cis rs2455601 0.744 rs2568085 ENSG00000254860.4 TMEM9B-AS1 -6.68 4.26e-10 7.89e-07 -0.62 -0.48 Schizophrenia; chr11:8954201 chr11:8964675~8977527:+ PAAD cis rs2882667 0.931 rs7720150 ENSG00000253404.1 AC034243.1 6.68 4.27e-10 7.91e-07 0.57 0.48 Age-related hearing impairment (SNP x SNP interaction); chr5:138998380 chr5:138744434~138753309:- PAAD cis rs950169 0.84 rs72748702 ENSG00000259728.4 LINC00933 6.68 4.27e-10 7.91e-07 0.6 0.48 Schizophrenia; chr15:84246494 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs4338765 ENSG00000259728.4 LINC00933 6.68 4.27e-10 7.91e-07 0.6 0.48 Schizophrenia; chr15:84248084 chr15:84570649~84580175:+ PAAD cis rs9532669 0.926 rs11147823 ENSG00000176268.5 CYCSP34 -6.68 4.28e-10 7.92e-07 -0.45 -0.48 Cervical cancer; chr13:40878138 chr13:40863599~40863902:- PAAD cis rs10129255 0.536 rs17113249 ENSG00000223648.3 IGHV3-64 6.68 4.28e-10 7.93e-07 0.43 0.48 Kawasaki disease; chr14:106678273 chr14:106643132~106658258:- PAAD cis rs1075265 0.568 rs7604357 ENSG00000233266.1 HMGB1P31 6.68 4.3e-10 7.96e-07 0.6 0.48 Chronotype;Morning vs. evening chronotype; chr2:54074026 chr2:54051334~54051760:+ PAAD cis rs12931792 0.875 rs58175255 ENSG00000183604.13 SMG1P5 6.68 4.3e-10 7.96e-07 0.5 0.48 Tonsillectomy; chr16:30143969 chr16:30267553~30335374:- PAAD cis rs12931792 0.774 rs7204270 ENSG00000183604.13 SMG1P5 6.68 4.3e-10 7.96e-07 0.5 0.48 Tonsillectomy; chr16:30145642 chr16:30267553~30335374:- PAAD cis rs12931792 0.875 rs7199462 ENSG00000183604.13 SMG1P5 6.68 4.3e-10 7.96e-07 0.5 0.48 Tonsillectomy; chr16:30147436 chr16:30267553~30335374:- PAAD cis rs17826219 0.5 rs117560728 ENSG00000263531.1 RP13-753N3.1 6.68 4.31e-10 7.98e-07 1.1 0.48 Body mass index; chr17:30743920 chr17:30863921~30864940:- PAAD cis rs4853012 0.539 rs9789534 ENSG00000217702.2 RP11-287D1.4 6.68 4.32e-10 7.98e-07 0.77 0.48 Gestational age at birth (maternal effect); chr2:74135863 chr2:74130583~74135395:+ PAAD cis rs2929278 0.617 rs4617832 ENSG00000249839.1 AC011330.5 6.68 4.32e-10 7.99e-07 0.66 0.48 Schizophrenia; chr15:43738381 chr15:43663654~43684339:- PAAD cis rs7714584 1 rs73282209 ENSG00000197083.10 ZNF300P1 6.68 4.33e-10 8.01e-07 0.79 0.48 Crohn's disease; chr5:150795397 chr5:150930645~150946289:- PAAD cis rs7429990 0.965 rs2053767 ENSG00000229759.1 MRPS18AP1 6.68 4.34e-10 8.02e-07 0.51 0.48 Educational attainment (years of education); chr3:47958184 chr3:48256350~48256938:- PAAD cis rs10716631 1 rs10716631 ENSG00000261338.2 RP11-378A13.1 6.67 4.36e-10 8.07e-07 0.56 0.48 Plateletcrit;High light scatter reticulocyte percentage of red cells; chr2:218273447 chr2:218255319~218257366:+ PAAD cis rs7617773 0.539 rs6779517 ENSG00000229759.1 MRPS18AP1 6.67 4.38e-10 8.1e-07 0.5 0.48 Coronary artery disease; chr3:48342898 chr3:48256350~48256938:- PAAD cis rs11155671 0.53 rs7758033 ENSG00000268592.3 RAET1E-AS1 6.67 4.4e-10 8.14e-07 0.57 0.48 Testicular germ cell tumor; chr6:149886999 chr6:149863494~149919507:+ PAAD cis rs1155848 0.892 rs1023293 ENSG00000227354.5 RBM26-AS1 6.67 4.42e-10 8.17e-07 0.94 0.48 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79480285 chr13:79406309~79424328:+ PAAD cis rs12439619 0.508 rs11856561 ENSG00000278603.1 RP13-608F4.5 6.67 4.42e-10 8.17e-07 0.63 0.48 Intelligence (multi-trait analysis); chr15:82161415 chr15:82472203~82472426:+ PAAD cis rs11098499 1 rs35643470 ENSG00000245958.5 RP11-33B1.1 -6.67 4.44e-10 8.19e-07 -0.38 -0.48 Corneal astigmatism; chr4:119263793 chr4:119454791~119552025:+ PAAD cis rs11098499 1 rs12506395 ENSG00000245958.5 RP11-33B1.1 -6.67 4.44e-10 8.19e-07 -0.38 -0.48 Corneal astigmatism; chr4:119263939 chr4:119454791~119552025:+ PAAD cis rs11098499 1 rs13116504 ENSG00000245958.5 RP11-33B1.1 -6.67 4.44e-10 8.19e-07 -0.38 -0.48 Corneal astigmatism; chr4:119288257 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs28555550 ENSG00000245958.5 RP11-33B1.1 -6.67 4.44e-10 8.19e-07 -0.38 -0.48 Corneal astigmatism; chr4:119289885 chr4:119454791~119552025:+ PAAD cis rs11098499 1 rs28419773 ENSG00000245958.5 RP11-33B1.1 -6.67 4.44e-10 8.19e-07 -0.38 -0.48 Corneal astigmatism; chr4:119289906 chr4:119454791~119552025:+ PAAD cis rs11168854 0.719 rs11168902 ENSG00000258017.1 RP11-386G11.10 -6.67 4.45e-10 8.21e-07 -0.59 -0.48 Body mass index; chr12:49174483 chr12:49127782~49147869:+ PAAD cis rs2117029 0.553 rs11168903 ENSG00000258017.1 RP11-386G11.10 -6.67 4.45e-10 8.21e-07 -0.59 -0.48 Intelligence (multi-trait analysis); chr12:49174883 chr12:49127782~49147869:+ PAAD cis rs2117029 0.521 rs1039225 ENSG00000258017.1 RP11-386G11.10 -6.67 4.45e-10 8.21e-07 -0.59 -0.48 Intelligence (multi-trait analysis); chr12:49188909 chr12:49127782~49147869:+ PAAD cis rs2117029 0.521 rs11168910 ENSG00000258017.1 RP11-386G11.10 -6.67 4.45e-10 8.21e-07 -0.59 -0.48 Intelligence (multi-trait analysis); chr12:49192707 chr12:49127782~49147869:+ PAAD cis rs9532669 0.926 rs9532657 ENSG00000176268.5 CYCSP34 -6.67 4.46e-10 8.24e-07 -0.45 -0.48 Cervical cancer; chr13:40918208 chr13:40863599~40863902:- PAAD cis rs11155671 0.53 rs9371215 ENSG00000223701.3 RAET1E-AS1 6.67 4.49e-10 8.28e-07 0.57 0.48 Testicular germ cell tumor; chr6:149873162 chr6:149884431~149919508:+ PAAD cis rs1155848 0.892 rs9565508 ENSG00000227354.5 RBM26-AS1 6.67 4.56e-10 8.4e-07 0.94 0.48 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79482451 chr13:79406309~79424328:+ PAAD cis rs4423214 0.625 rs78685409 ENSG00000254682.1 RP11-660L16.2 -6.67 4.56e-10 8.41e-07 -0.68 -0.48 Vitamin D levels; chr11:71426337 chr11:71448674~71452157:+ PAAD cis rs6452524 0.804 rs1478481 ENSG00000249664.1 CTD-2227C6.2 6.67 4.57e-10 8.42e-07 0.57 0.48 Hypertension (SNP x SNP interaction); chr5:83111286 chr5:83012285~83013109:- PAAD cis rs11098499 1 rs6849889 ENSG00000245958.5 RP11-33B1.1 -6.67 4.57e-10 8.43e-07 -0.4 -0.48 Corneal astigmatism; chr4:119265193 chr4:119454791~119552025:+ PAAD cis rs11098499 1 rs58601355 ENSG00000245958.5 RP11-33B1.1 -6.67 4.57e-10 8.43e-07 -0.4 -0.48 Corneal astigmatism; chr4:119265212 chr4:119454791~119552025:+ PAAD cis rs6538678 0.784 rs7297403 ENSG00000258343.1 RP11-536G4.2 -6.67 4.59e-10 8.45e-07 -0.69 -0.48 Lupus nephritis in systemic lupus erythematosus; chr12:95846683 chr12:95795345~95858839:- PAAD cis rs2980439 0.607 rs2980419 ENSG00000253893.2 FAM85B -6.66 4.59e-10 8.46e-07 -0.67 -0.48 Neuroticism; chr8:8256619 chr8:8167819~8226614:- PAAD cis rs950169 0.922 rs11631096 ENSG00000259728.4 LINC00933 6.66 4.6e-10 8.47e-07 0.59 0.48 Schizophrenia; chr15:84557698 chr15:84570649~84580175:+ PAAD cis rs950169 0.84 rs62019457 ENSG00000259728.4 LINC00933 6.66 4.6e-10 8.47e-07 0.59 0.48 Schizophrenia; chr15:84558911 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs67804993 ENSG00000259728.4 LINC00933 6.66 4.6e-10 8.47e-07 0.59 0.48 Schizophrenia; chr15:84560799 chr15:84570649~84580175:+ PAAD cis rs11673344 0.573 rs73039109 ENSG00000226686.6 LINC01535 6.66 4.6e-10 8.48e-07 0.68 0.48 Obesity-related traits; chr19:36891073 chr19:37251912~37265535:+ PAAD cis rs12931792 0.84 rs8050401 ENSG00000183604.13 SMG1P5 6.66 4.62e-10 8.5e-07 0.5 0.48 Tonsillectomy; chr16:30151836 chr16:30267553~30335374:- PAAD cis rs9545047 0.547 rs2876739 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79299057 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs7988331 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79299745 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1007569 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79306752 chr13:79566727~79571436:+ PAAD cis rs9545047 0.584 rs4885626 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79309765 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs4885627 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79309786 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs4885628 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79309830 chr13:79566727~79571436:+ PAAD cis rs9545047 0.554 rs4885629 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79309855 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1927506 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79311350 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1409019 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79312431 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7317343 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79312542 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs6563098 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79313102 chr13:79566727~79571436:+ PAAD cis rs9545047 0.532 rs1748768 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79313276 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1748767 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79313381 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs1409018 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79313403 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1410332 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79315171 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9545065 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79317034 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs3818563 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79318587 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs3187338 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79320601 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9545068 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79324101 chr13:79566727~79571436:+ PAAD cis rs9545047 0.625 rs9318621 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79325662 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7322167 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79325931 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9285309 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79326707 chr13:79566727~79571436:+ PAAD cis rs9545047 0.584 rs9545069 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79328065 chr13:79566727~79571436:+ PAAD cis rs9545047 0.647 rs7317416 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79328400 chr13:79566727~79571436:+ PAAD cis rs9545047 0.588 rs1408658 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79329294 chr13:79566727~79571436:+ PAAD cis rs9545047 0.625 rs1408657 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79329315 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1752649 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79331980 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1749983 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79332077 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs1752648 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79332124 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1752647 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79332741 chr13:79566727~79571436:+ PAAD cis rs9545047 0.532 rs1752646 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79332752 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1749988 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79333103 chr13:79566727~79571436:+ PAAD cis rs9545047 0.588 rs9530894 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79334020 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530895 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79334877 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs9530896 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79335507 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530897 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79336420 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7981067 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79341254 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7996652 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79341474 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9565488 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79341604 chr13:79566727~79571436:+ PAAD cis rs9545047 0.625 rs9565489 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79342106 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs3742117 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79342498 chr13:79566727~79571436:+ PAAD cis rs9545047 0.647 rs3742118 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79342838 chr13:79566727~79571436:+ PAAD cis rs9545047 0.625 rs7319320 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79343072 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs3752994 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79345076 chr13:79566727~79571436:+ PAAD cis rs9545047 0.532 rs9545079 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79346044 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs4884129 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79346448 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs1410336 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79347598 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9565492 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79348554 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9318625 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79351429 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530899 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79352461 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7338677 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79352580 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7322744 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79354070 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530900 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79355048 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9530901 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79355191 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs4328330 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79355503 chr13:79566727~79571436:+ PAAD cis rs9545047 0.567 rs4497554 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79355651 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2182873 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79356846 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2025913 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79357315 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9545082 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79358994 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7332913 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79359149 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9545083 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79360695 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7322756 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79361120 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7324006 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79361225 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7322673 ENSG00000227676.3 LINC01068 6.66 4.64e-10 8.51e-07 0.57 0.48 Schizophrenia; chr13:79361266 chr13:79566727~79571436:+ PAAD cis rs7429990 1 rs1684942 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47859213 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs800762 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47864080 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs2631721 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47881807 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs319692 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47882827 chr3:48256350~48256938:- PAAD cis rs319690 1 rs319690 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Diastolic blood pressure;Systolic blood pressure;Blood pressure; chr3:47885994 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs319685 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47890494 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs319684 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47890784 chr3:48256350~48256938:- PAAD cis rs7429990 0.932 rs810334 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47893813 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs796566 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47896864 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs34380889 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47905692 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs4858871 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47911915 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs6772396 ENSG00000229759.1 MRPS18AP1 6.66 4.64e-10 8.51e-07 0.52 0.48 Educational attainment (years of education); chr3:47918280 chr3:48256350~48256938:- PAAD cis rs10129255 0.5 rs1024350 ENSG00000223648.3 IGHV3-64 6.66 4.69e-10 8.53e-07 0.42 0.48 Kawasaki disease; chr14:106685105 chr14:106643132~106658258:- PAAD cis rs11098499 0.779 rs80242894 ENSG00000245958.5 RP11-33B1.1 -6.66 4.7e-10 8.53e-07 -0.4 -0.48 Corneal astigmatism; chr4:119454597 chr4:119454791~119552025:+ PAAD cis rs172166 0.543 rs1150691 ENSG00000216901.1 AL022393.7 6.66 4.7e-10 8.53e-07 0.61 0.48 Cardiac Troponin-T levels; chr6:28200255 chr6:28176188~28176674:+ PAAD cis rs8040855 0.93 rs6496767 ENSG00000259295.5 CSPG4P12 -6.66 4.7e-10 8.54e-07 -0.54 -0.48 Bulimia nervosa; chr15:85159522 chr15:85191438~85213905:+ PAAD cis rs11155671 0.53 rs9383577 ENSG00000268592.3 RAET1E-AS1 6.66 4.71e-10 8.56e-07 0.57 0.48 Testicular germ cell tumor; chr6:149886059 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs9383914 ENSG00000268592.3 RAET1E-AS1 6.66 4.71e-10 8.56e-07 0.57 0.48 Testicular germ cell tumor; chr6:149886098 chr6:149863494~149919507:+ PAAD cis rs11155671 0.517 rs9397058 ENSG00000268592.3 RAET1E-AS1 6.66 4.71e-10 8.56e-07 0.57 0.48 Testicular germ cell tumor; chr6:149886113 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs7768626 ENSG00000268592.3 RAET1E-AS1 6.66 4.71e-10 8.56e-07 0.57 0.48 Testicular germ cell tumor; chr6:149886826 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs7768665 ENSG00000268592.3 RAET1E-AS1 6.66 4.71e-10 8.56e-07 0.57 0.48 Testicular germ cell tumor; chr6:149886888 chr6:149863494~149919507:+ PAAD cis rs11155671 0.53 rs7758020 ENSG00000268592.3 RAET1E-AS1 6.66 4.71e-10 8.56e-07 0.57 0.48 Testicular germ cell tumor; chr6:149886975 chr6:149863494~149919507:+ PAAD cis rs6504622 0.721 rs8077021 ENSG00000262879.4 RP11-156P1.3 -6.66 4.72e-10 8.57e-07 -0.48 -0.48 Orofacial clefts; chr17:47061937 chr17:46984045~47100323:- PAAD cis rs6504622 0.755 rs34038545 ENSG00000262879.4 RP11-156P1.3 -6.66 4.72e-10 8.57e-07 -0.48 -0.48 Orofacial clefts; chr17:47067541 chr17:46984045~47100323:- PAAD cis rs1155848 0.892 rs953005 ENSG00000227354.5 RBM26-AS1 6.66 4.73e-10 8.58e-07 0.94 0.48 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79480544 chr13:79406309~79424328:+ PAAD cis rs9399137 0.507 rs11154791 ENSG00000232876.1 CTA-212D2.2 -6.66 4.73e-10 8.59e-07 -0.57 -0.48 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135058010 chr6:135055033~135060550:+ PAAD cis rs11673344 0.502 rs62108306 ENSG00000226686.6 LINC01535 6.66 4.75e-10 8.63e-07 0.62 0.48 Obesity-related traits; chr19:37691789 chr19:37251912~37265535:+ PAAD cis rs11673344 0.536 rs7259272 ENSG00000226686.6 LINC01535 6.66 4.75e-10 8.63e-07 0.62 0.48 Obesity-related traits; chr19:37692214 chr19:37251912~37265535:+ PAAD cis rs11098499 0.954 rs1022145 ENSG00000245958.5 RP11-33B1.1 -6.66 4.76e-10 8.64e-07 -0.39 -0.48 Corneal astigmatism; chr4:119309824 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs11722872 ENSG00000245958.5 RP11-33B1.1 -6.66 4.76e-10 8.64e-07 -0.39 -0.48 Corneal astigmatism; chr4:119311875 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs1546502 ENSG00000245958.5 RP11-33B1.1 -6.66 4.76e-10 8.64e-07 -0.39 -0.48 Corneal astigmatism; chr4:119314743 chr4:119454791~119552025:+ PAAD cis rs67180937 0.621 rs2068814 ENSG00000272750.1 RP11-378J18.8 -6.66 4.77e-10 8.65e-07 -0.5 -0.48 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222749659 chr1:222658867~222661512:- PAAD cis rs5760092 0.627 rs6519489 ENSG00000225282.1 AP000350.6 -6.66 4.79e-10 8.7e-07 -0.72 -0.48 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23926900~23929574:+ PAAD cis rs1930961 1 rs6004669 ENSG00000272977.1 CTA-390C10.10 -6.66 4.81e-10 8.72e-07 -0.92 -0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs5996946 ENSG00000272977.1 CTA-390C10.10 -6.66 4.81e-10 8.72e-07 -0.92 -0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs997873 ENSG00000272977.1 CTA-390C10.10 -6.66 4.81e-10 8.72e-07 -0.92 -0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs997872 ENSG00000272977.1 CTA-390C10.10 -6.66 4.81e-10 8.72e-07 -0.92 -0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs6004671 ENSG00000272977.1 CTA-390C10.10 -6.66 4.81e-10 8.72e-07 -0.92 -0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25483507 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs6004672 ENSG00000272977.1 CTA-390C10.10 -6.66 4.81e-10 8.72e-07 -0.92 -0.48 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25476218~25479971:+ PAAD cis rs2117029 0.553 rs2162644 ENSG00000258017.1 RP11-386G11.10 -6.66 4.82e-10 8.74e-07 -0.61 -0.48 Intelligence (multi-trait analysis); chr12:49154407 chr12:49127782~49147869:+ PAAD cis rs7829975 0.624 rs7823056 ENSG00000253893.2 FAM85B -6.66 4.83e-10 8.75e-07 -0.63 -0.48 Mood instability; chr8:8525195 chr8:8167819~8226614:- PAAD cis rs11690935 0.788 rs6715929 ENSG00000228389.1 AC068039.4 6.66 4.83e-10 8.75e-07 0.58 0.48 Schizophrenia; chr2:172012600 chr2:171773482~171775844:+ PAAD cis rs9322193 0.607 rs12204653 ENSG00000216906.2 RP11-350J20.9 6.65 4.84e-10 8.76e-07 0.7 0.48 Lung cancer; chr6:149891885 chr6:149904243~149906418:+ PAAD cis rs8040855 0.894 rs6496770 ENSG00000259295.5 CSPG4P12 -6.65 4.84e-10 8.77e-07 -0.54 -0.47 Bulimia nervosa; chr15:85161890 chr15:85191438~85213905:+ PAAD cis rs7044106 0.791 rs4837792 ENSG00000226752.6 PSMD5-AS1 -6.65 4.87e-10 8.83e-07 -0.63 -0.47 Hip circumference adjusted for BMI; chr9:120721281 chr9:120824828~120854385:+ PAAD cis rs2929278 0.561 rs2927071 ENSG00000249839.1 AC011330.5 -6.65 4.87e-10 8.83e-07 -0.67 -0.47 Schizophrenia; chr15:43626883 chr15:43663654~43684339:- PAAD cis rs8040855 0.657 rs6496733 ENSG00000259295.5 CSPG4P12 -6.65 4.92e-10 8.9e-07 -0.56 -0.47 Bulimia nervosa; chr15:85129945 chr15:85191438~85213905:+ PAAD cis rs7429990 0.932 rs7620736 ENSG00000229759.1 MRPS18AP1 -6.65 4.92e-10 8.9e-07 -0.51 -0.47 Educational attainment (years of education); chr3:48068479 chr3:48256350~48256938:- PAAD cis rs1150668 0.745 rs213238 ENSG00000216901.1 AL022393.7 6.65 4.93e-10 8.91e-07 0.57 0.47 Pubertal anthropometrics; chr6:28354216 chr6:28176188~28176674:+ PAAD cis rs7044106 0.791 rs4837793 ENSG00000226752.6 PSMD5-AS1 -6.65 4.93e-10 8.92e-07 -0.66 -0.47 Hip circumference adjusted for BMI; chr9:120721343 chr9:120824828~120854385:+ PAAD cis rs4718428 0.705 rs12536410 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66789303 chr7:66654538~66669855:+ PAAD cis rs4718428 0.705 rs3800817 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66798563 chr7:66654538~66669855:+ PAAD cis rs4718428 0.705 rs12698547 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66813271 chr7:66654538~66669855:+ PAAD cis rs4718428 0.705 rs62465692 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66830758 chr7:66654538~66669855:+ PAAD cis rs4718428 0.672 rs13241598 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66835665 chr7:66654538~66669855:+ PAAD cis rs4718428 0.662 rs34577323 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66845054 chr7:66654538~66669855:+ PAAD cis rs4718428 0.705 rs4717328 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66887678 chr7:66654538~66669855:+ PAAD cis rs4718428 0.705 rs4717331 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66913899 chr7:66654538~66669855:+ PAAD cis rs4718428 0.672 rs12530806 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66925737 chr7:66654538~66669855:+ PAAD cis rs4718428 0.705 rs10267335 ENSG00000226824.5 RP4-756H11.3 -6.65 4.94e-10 8.92e-07 -0.63 -0.47 Corneal structure; chr7:66938233 chr7:66654538~66669855:+ PAAD cis rs4718428 0.705 rs13220977 ENSG00000226824.5 RP4-756H11.3 6.65 4.94e-10 8.92e-07 0.63 0.47 Corneal structure; chr7:66872661 chr7:66654538~66669855:+ PAAD cis rs10875746 0.951 rs4760689 ENSG00000240399.1 RP1-228P16.1 -6.65 4.94e-10 8.92e-07 -0.54 -0.47 Longevity (90 years and older); chr12:48169861 chr12:48054813~48055591:- PAAD cis rs10875746 0.951 rs4760690 ENSG00000240399.1 RP1-228P16.1 -6.65 4.94e-10 8.92e-07 -0.54 -0.47 Longevity (90 years and older); chr12:48169870 chr12:48054813~48055591:- PAAD cis rs10875746 0.951 rs58865997 ENSG00000240399.1 RP1-228P16.1 -6.65 4.94e-10 8.92e-07 -0.54 -0.47 Longevity (90 years and older); chr12:48173090 chr12:48054813~48055591:- PAAD cis rs1155848 0.892 rs9565509 ENSG00000227354.5 RBM26-AS1 6.65 4.96e-10 8.96e-07 0.94 0.47 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79483696 chr13:79406309~79424328:+ PAAD cis rs1930961 1 rs6004654 ENSG00000272977.1 CTA-390C10.10 -6.65 4.97e-10 8.97e-07 -0.93 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25459237 chr22:25476218~25479971:+ PAAD cis rs9399137 0.507 rs7772031 ENSG00000232876.1 CTA-212D2.2 6.65 4.99e-10 9e-07 0.57 0.47 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:134938596 chr6:135055033~135060550:+ PAAD cis rs6452524 0.967 rs12186460 ENSG00000249664.1 CTD-2227C6.2 6.65 4.99e-10 9.01e-07 0.53 0.47 Hypertension (SNP x SNP interaction); chr5:83123950 chr5:83012285~83013109:- PAAD cis rs2283792 1 rs5999750 ENSG00000224086.5 LL22NC03-86G7.1 -6.65 5.02e-10 9.05e-07 -0.48 -0.47 Multiple sclerosis; chr22:21833720 chr22:21938293~21977632:+ PAAD cis rs950169 0.922 rs12910334 ENSG00000259728.4 LINC00933 6.65 5.05e-10 9.11e-07 0.6 0.47 Schizophrenia; chr15:84403620 chr15:84570649~84580175:+ PAAD cis rs7044106 0.791 rs7043969 ENSG00000226752.6 PSMD5-AS1 -6.65 5.06e-10 9.12e-07 -0.62 -0.47 Hip circumference adjusted for BMI; chr9:120731711 chr9:120824828~120854385:+ PAAD cis rs2882667 0.867 rs11749045 ENSG00000253404.1 AC034243.1 6.65 5.06e-10 9.13e-07 0.57 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139085271 chr5:138744434~138753309:- PAAD cis rs7829975 0.511 rs2980512 ENSG00000253893.2 FAM85B -6.65 5.09e-10 9.17e-07 -0.7 -0.47 Mood instability; chr8:8283379 chr8:8167819~8226614:- PAAD cis rs7829975 0.539 rs35571782 ENSG00000253893.2 FAM85B -6.65 5.09e-10 9.17e-07 -0.7 -0.47 Mood instability; chr8:8284301 chr8:8167819~8226614:- PAAD cis rs2980439 0.556 rs2921059 ENSG00000253893.2 FAM85B -6.64 5.11e-10 9.21e-07 -0.66 -0.47 Neuroticism; chr8:8460377 chr8:8167819~8226614:- PAAD cis rs11155671 0.53 rs9397420 ENSG00000268592.3 RAET1E-AS1 -6.64 5.12e-10 9.22e-07 -0.57 -0.47 Testicular germ cell tumor; chr6:149885645 chr6:149863494~149919507:+ PAAD cis rs9545047 0.604 rs7983344 ENSG00000227676.3 LINC01068 -6.64 5.13e-10 9.25e-07 -0.56 -0.47 Schizophrenia; chr13:79299295 chr13:79566727~79571436:+ PAAD cis rs2283792 0.935 rs8141851 ENSG00000224086.5 LL22NC03-86G7.1 -6.64 5.14e-10 9.27e-07 -0.48 -0.47 Multiple sclerosis; chr22:21812161 chr22:21938293~21977632:+ PAAD cis rs11673344 0.67 rs73039188 ENSG00000226686.6 LINC01535 6.64 5.15e-10 9.27e-07 0.66 0.47 Obesity-related traits; chr19:36922449 chr19:37251912~37265535:+ PAAD cis rs11098499 0.954 rs10518331 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119402440 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs13133522 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119403269 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs35091806 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119404374 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs35165976 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119404475 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs6846442 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119405168 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs4001305 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119438081 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs71614422 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119438185 chr4:119454791~119552025:+ PAAD cis rs11098499 0.738 rs34566984 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119440115 chr4:119454791~119552025:+ PAAD cis rs11098499 0.738 rs34965784 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119440431 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs17009122 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119441248 chr4:119454791~119552025:+ PAAD cis rs11098499 0.505 rs75122014 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119441271 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs9685777 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119444810 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs71614438 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119450097 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs66506550 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119450290 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs7659501 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119450397 chr4:119454791~119552025:+ PAAD cis rs11098499 0.697 rs28655325 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119451844 chr4:119454791~119552025:+ PAAD cis rs11098499 0.779 rs28495013 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119454676 chr4:119454791~119552025:+ PAAD cis rs11098499 0.738 rs28408407 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119454875 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs1809406 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119455967 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs2389809 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119456244 chr4:119454791~119552025:+ PAAD cis rs11098499 0.657 rs71614442 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119458191 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs2892848 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119460186 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs9994810 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119460435 chr4:119454791~119552025:+ PAAD cis rs11098499 0.697 rs10020027 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119460724 chr4:119454791~119552025:+ PAAD cis rs11098499 0.779 rs7356491 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119460819 chr4:119454791~119552025:+ PAAD cis rs11098499 0.697 rs11941899 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119461603 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs7681978 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119462620 chr4:119454791~119552025:+ PAAD cis rs11098499 0.821 rs28665282 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119463031 chr4:119454791~119552025:+ PAAD cis rs11098499 0.738 rs10026493 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119463039 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs7681214 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119464165 chr4:119454791~119552025:+ PAAD cis rs11098499 0.908 rs28559989 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119465472 chr4:119454791~119552025:+ PAAD cis rs11098499 0.908 rs28499576 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119465522 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs28632018 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119465575 chr4:119454791~119552025:+ PAAD cis rs11098499 0.908 rs71614449 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119465900 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs35063680 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119465947 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs34858317 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119465955 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs17046116 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119466104 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs17046118 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119466341 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs7654587 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119467251 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs11098525 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119468997 chr4:119454791~119552025:+ PAAD cis rs11098499 0.821 rs10032151 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119470473 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs10032158 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119470477 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs6838814 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119471288 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs13107475 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119471856 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs7436506 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119472614 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10008459 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119473076 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs2127821 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119473380 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10006525 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119487776 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs6849171 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119488394 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs12508504 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119489452 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs17005535 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119490407 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs3733520 ENSG00000245958.5 RP11-33B1.1 -6.64 5.19e-10 9.29e-07 -0.39 -0.47 Corneal astigmatism; chr4:119502325 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs9993199 ENSG00000245958.5 RP11-33B1.1 6.64 5.19e-10 9.29e-07 0.39 0.47 Corneal astigmatism; chr4:119471718 chr4:119454791~119552025:+ PAAD cis rs10129255 0.576 rs2157616 ENSG00000223648.3 IGHV3-64 6.64 5.2e-10 9.3e-07 0.42 0.47 Kawasaki disease; chr14:106767802 chr14:106643132~106658258:- PAAD cis rs7174755 0.961 rs11631030 ENSG00000260657.2 RP11-315D16.4 6.64 5.3e-10 9.45e-07 0.58 0.47 Major depressive disorder; chr15:68303463 chr15:68267792~68277994:- PAAD cis rs4718428 0.705 rs11028 ENSG00000226824.5 RP4-756H11.3 -6.64 5.3e-10 9.46e-07 -0.64 -0.47 Corneal structure; chr7:66811230 chr7:66654538~66669855:+ PAAD cis rs9545047 0.604 rs9545054 ENSG00000227676.3 LINC01068 6.64 5.3e-10 9.47e-07 0.58 0.47 Schizophrenia; chr13:79298833 chr13:79566727~79571436:+ PAAD cis rs2929278 0.561 rs62018952 ENSG00000249839.1 AC011330.5 6.64 5.33e-10 9.51e-07 0.67 0.47 Schizophrenia; chr15:43788539 chr15:43663654~43684339:- PAAD cis rs7945705 0.747 rs1123936 ENSG00000254860.4 TMEM9B-AS1 6.64 5.34e-10 9.52e-07 0.5 0.47 Hemoglobin concentration; chr11:8981759 chr11:8964675~8977527:+ PAAD cis rs2882667 0.898 rs3828600 ENSG00000253404.1 AC034243.1 6.64 5.34e-10 9.53e-07 0.57 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139051170 chr5:138744434~138753309:- PAAD cis rs6538678 0.824 rs7299632 ENSG00000258343.1 RP11-536G4.2 -6.64 5.35e-10 9.54e-07 -0.69 -0.47 Lupus nephritis in systemic lupus erythematosus; chr12:95838376 chr12:95795345~95858839:- PAAD cis rs6538678 0.746 rs1865736 ENSG00000258343.1 RP11-536G4.2 -6.64 5.35e-10 9.55e-07 -0.69 -0.47 Lupus nephritis in systemic lupus erythematosus; chr12:95854051 chr12:95795345~95858839:- PAAD cis rs6452524 0.78 rs10078661 ENSG00000249664.1 CTD-2227C6.2 6.64 5.37e-10 9.57e-07 0.57 0.47 Hypertension (SNP x SNP interaction); chr5:83182136 chr5:83012285~83013109:- PAAD cis rs4423214 0.879 rs1790353 ENSG00000254682.1 RP11-660L16.2 -6.64 5.37e-10 9.57e-07 -0.68 -0.47 Vitamin D levels; chr11:71425684 chr11:71448674~71452157:+ PAAD cis rs4423214 0.879 rs1792277 ENSG00000254682.1 RP11-660L16.2 -6.64 5.37e-10 9.57e-07 -0.68 -0.47 Vitamin D levels; chr11:71427872 chr11:71448674~71452157:+ PAAD cis rs8040855 0.627 rs12909971 ENSG00000259295.5 CSPG4P12 6.64 5.37e-10 9.57e-07 0.56 0.47 Bulimia nervosa; chr15:85045767 chr15:85191438~85213905:+ PAAD cis rs494459 0.536 rs10790267 ENSG00000255239.1 AP002954.6 6.63 5.37e-10 9.58e-07 0.56 0.47 Height; chr11:118856460 chr11:118688039~118690600:- PAAD cis rs494459 0.536 rs11217067 ENSG00000255239.1 AP002954.6 6.63 5.37e-10 9.58e-07 0.56 0.47 Height; chr11:118856623 chr11:118688039~118690600:- PAAD cis rs2510897 0.675 rs4936442 ENSG00000255239.1 AP002954.6 6.63 5.37e-10 9.58e-07 0.56 0.47 Height; chr11:118857611 chr11:118688039~118690600:- PAAD cis rs73086581 1 rs73086512 ENSG00000229539.1 RP11-119B16.2 6.63 5.38e-10 9.59e-07 0.73 0.47 Response to antidepressants in depression; chr20:3942125 chr20:3888239~3888868:- PAAD cis rs11673344 0.526 rs57654288 ENSG00000226686.6 LINC01535 6.63 5.38e-10 9.59e-07 0.62 0.47 Obesity-related traits; chr19:37587870 chr19:37251912~37265535:+ PAAD cis rs2929278 0.589 rs2411284 ENSG00000249839.1 AC011330.5 6.63 5.38e-10 9.59e-07 0.66 0.47 Schizophrenia; chr15:43746701 chr15:43663654~43684339:- PAAD cis rs7714584 1 rs13361189 ENSG00000197083.10 ZNF300P1 6.63 5.42e-10 9.64e-07 0.75 0.47 Crohn's disease; chr5:150843825 chr5:150930645~150946289:- PAAD cis rs7044106 0.762 rs10760107 ENSG00000226752.6 PSMD5-AS1 -6.63 5.43e-10 9.67e-07 -0.63 -0.47 Hip circumference adjusted for BMI; chr9:120621352 chr9:120824828~120854385:+ PAAD cis rs11098499 0.909 rs11723757 ENSG00000245958.5 RP11-33B1.1 -6.63 5.44e-10 9.67e-07 -0.39 -0.47 Corneal astigmatism; chr4:119378514 chr4:119454791~119552025:+ PAAD cis rs2283792 0.967 rs11704205 ENSG00000224086.5 LL22NC03-86G7.1 -6.63 5.47e-10 9.73e-07 -0.48 -0.47 Multiple sclerosis; chr22:21790964 chr22:21938293~21977632:+ PAAD cis rs11168854 0.651 rs12227770 ENSG00000258017.1 RP11-386G11.10 -6.63 5.48e-10 9.74e-07 -0.6 -0.47 Body mass index; chr12:49183065 chr12:49127782~49147869:+ PAAD cis rs8040855 0.627 rs12904238 ENSG00000259295.5 CSPG4P12 6.63 5.52e-10 9.81e-07 0.56 0.47 Bulimia nervosa; chr15:85096610 chr15:85191438~85213905:+ PAAD cis rs2739330 0.791 rs9612520 ENSG00000231271.1 AP000350.8 6.63 5.55e-10 9.86e-07 0.65 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23949918~23954042:+ PAAD cis rs9545047 0.553 rs7332004 ENSG00000227676.3 LINC01068 -6.63 5.57e-10 9.9e-07 -0.57 -0.47 Schizophrenia; chr13:79364128 chr13:79566727~79571436:+ PAAD cis rs172166 0.61 rs156737 ENSG00000216901.1 AL022393.7 6.63 5.57e-10 9.9e-07 0.6 0.47 Cardiac Troponin-T levels; chr6:27927435 chr6:28176188~28176674:+ PAAD cis rs172166 0.61 rs276369 ENSG00000216901.1 AL022393.7 6.63 5.57e-10 9.9e-07 0.6 0.47 Cardiac Troponin-T levels; chr6:27951465 chr6:28176188~28176674:+ PAAD cis rs9322193 0.884 rs7744105 ENSG00000216906.2 RP11-350J20.9 6.62 5.67e-10 1.01e-06 0.64 0.47 Lung cancer; chr6:149849308 chr6:149904243~149906418:+ PAAD cis rs9389248 0.69 rs6939543 ENSG00000232876.1 CTA-212D2.2 6.62 5.68e-10 1.01e-06 0.55 0.47 High light scatter reticulocyte percentage of red cells; chr6:134934005 chr6:135055033~135060550:+ PAAD cis rs11098499 0.954 rs4309825 ENSG00000245958.5 RP11-33B1.1 6.62 5.71e-10 1.01e-06 0.39 0.47 Corneal astigmatism; chr4:119393726 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs59394118 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119374396 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs9996417 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119374707 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs59866101 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119375436 chr4:119454791~119552025:+ PAAD cis rs11098499 0.618 rs6858383 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119375617 chr4:119454791~119552025:+ PAAD cis rs11098499 0.697 rs6832410 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119375645 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs1112817 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119376645 chr4:119454791~119552025:+ PAAD cis rs11098499 0.779 rs10016060 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119377257 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10005644 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119377322 chr4:119454791~119552025:+ PAAD cis rs11098499 0.697 rs10016448 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119377690 chr4:119454791~119552025:+ PAAD cis rs11098499 0.657 rs9996569 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119377849 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs11723839 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119378518 chr4:119454791~119552025:+ PAAD cis rs11098499 0.908 rs11729050 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119378911 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs28429722 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119378938 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10014845 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119379922 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs12506546 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119380463 chr4:119454791~119552025:+ PAAD cis rs11098499 0.779 rs7674500 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119382438 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs28884220 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119386056 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs28793658 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119386059 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs4507344 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119386330 chr4:119454791~119552025:+ PAAD cis rs11098499 0.697 rs4373140 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119386543 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs13113483 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119387884 chr4:119454791~119552025:+ PAAD cis rs11098499 0.542 rs10440343 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119388632 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs28668716 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119388720 chr4:119454791~119552025:+ PAAD cis rs11098499 0.779 rs10011097 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119389204 chr4:119454791~119552025:+ PAAD cis rs11098499 0.779 rs7699346 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119389387 chr4:119454791~119552025:+ PAAD cis rs11098499 0.542 rs7677836 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119389483 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs10002083 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119389997 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10024844 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119390373 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs7437420 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119391748 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs4345162 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119391804 chr4:119454791~119552025:+ PAAD cis rs11098499 0.657 rs4463052 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119392103 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs13151285 ENSG00000245958.5 RP11-33B1.1 -6.62 5.71e-10 1.01e-06 -0.39 -0.47 Corneal astigmatism; chr4:119393586 chr4:119454791~119552025:+ PAAD cis rs9532669 0.926 rs8002809 ENSG00000176268.5 CYCSP34 6.62 5.74e-10 1.01e-06 0.46 0.47 Cervical cancer; chr13:40872769 chr13:40863599~40863902:- PAAD cis rs9532669 0.929 rs7982421 ENSG00000176268.5 CYCSP34 6.62 5.74e-10 1.01e-06 0.46 0.47 Cervical cancer; chr13:40872776 chr13:40863599~40863902:- PAAD cis rs2283792 0.967 rs5999823 ENSG00000224086.5 LL22NC03-86G7.1 -6.62 5.75e-10 1.02e-06 -0.48 -0.47 Multiple sclerosis; chr22:21856587 chr22:21938293~21977632:+ PAAD cis rs875971 0.545 rs6460281 ENSG00000237310.1 GS1-124K5.4 6.62 5.77e-10 1.02e-06 0.54 0.47 Aortic root size; chr7:66216128 chr7:66493706~66495474:+ PAAD cis rs2739330 0.587 rs4820571 ENSG00000099984.9 GSTT2 -6.62 5.77e-10 1.02e-06 -0.64 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23980123~23983911:+ PAAD cis rs9399137 0.507 rs6940258 ENSG00000232876.1 CTA-212D2.2 -6.62 5.78e-10 1.02e-06 -0.57 -0.47 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135044994 chr6:135055033~135060550:+ PAAD cis rs6452524 0.901 rs4571449 ENSG00000249664.1 CTD-2227C6.2 6.62 5.8e-10 1.02e-06 0.57 0.47 Hypertension (SNP x SNP interaction); chr5:83175392 chr5:83012285~83013109:- PAAD cis rs950169 0.922 rs62021167 ENSG00000259728.4 LINC00933 6.62 5.8e-10 1.02e-06 0.59 0.47 Schizophrenia; chr15:84574820 chr15:84570649~84580175:+ PAAD cis rs6538678 0.746 rs4762630 ENSG00000258343.1 RP11-536G4.2 -6.62 5.81e-10 1.03e-06 -0.69 -0.47 Lupus nephritis in systemic lupus erythematosus; chr12:95850631 chr12:95795345~95858839:- PAAD cis rs11673344 0.544 rs6508721 ENSG00000226686.6 LINC01535 -6.62 5.84e-10 1.03e-06 -0.56 -0.47 Obesity-related traits; chr19:37419119 chr19:37251912~37265535:+ PAAD cis rs11673344 0.566 rs7254009 ENSG00000226686.6 LINC01535 -6.62 5.84e-10 1.03e-06 -0.56 -0.47 Obesity-related traits; chr19:37427707 chr19:37251912~37265535:+ PAAD cis rs11673344 0.566 rs2385180 ENSG00000226686.6 LINC01535 -6.62 5.84e-10 1.03e-06 -0.56 -0.47 Obesity-related traits; chr19:37431454 chr19:37251912~37265535:+ PAAD cis rs9660180 0.846 rs10907195 ENSG00000231050.1 RP1-140A9.1 -6.62 5.84e-10 1.03e-06 -0.54 -0.47 Body mass index; chr1:1781909 chr1:1891471~1892658:+ PAAD cis rs6723162 0.965 rs7594319 ENSG00000237751.2 LINC01143 -6.62 5.85e-10 1.03e-06 -0.57 -0.47 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70891627 chr2:70887871~70889959:+ PAAD cis rs11098499 1 rs1011054 ENSG00000245958.5 RP11-33B1.1 6.62 5.86e-10 1.03e-06 0.39 0.47 Corneal astigmatism; chr4:119281232 chr4:119454791~119552025:+ PAAD cis rs7714584 1 rs3900064 ENSG00000197083.10 ZNF300P1 -6.62 5.87e-10 1.03e-06 -0.72 -0.47 Crohn's disease; chr5:150884852 chr5:150930645~150946289:- PAAD cis rs673078 0.66 rs16948234 ENSG00000275759.1 RP11-131L12.3 6.62 5.87e-10 1.03e-06 0.68 0.47 Glucose homeostasis traits; chr12:118282464 chr12:118428281~118428870:+ PAAD cis rs11168854 0.656 rs7969967 ENSG00000258017.1 RP11-386G11.10 6.62 5.87e-10 1.03e-06 0.6 0.47 Body mass index; chr12:49118234 chr12:49127782~49147869:+ PAAD cis rs2929278 0.638 rs2016840 ENSG00000249839.1 AC011330.5 6.62 5.88e-10 1.04e-06 0.66 0.47 Schizophrenia; chr15:43919670 chr15:43663654~43684339:- PAAD cis rs6964833 0.935 rs13238996 ENSG00000123965.13 PMS2P5 6.62 5.88e-10 1.04e-06 0.79 0.47 Menarche (age at onset); chr7:74655318 chr7:74894116~74897835:+ PAAD cis rs6964833 1 rs36044436 ENSG00000123965.13 PMS2P5 6.62 5.88e-10 1.04e-06 0.79 0.47 Menarche (age at onset); chr7:74675495 chr7:74894116~74897835:+ PAAD cis rs7174755 0.961 rs12148843 ENSG00000260657.2 RP11-315D16.4 6.62 5.89e-10 1.04e-06 0.58 0.47 Major depressive disorder; chr15:68302184 chr15:68267792~68277994:- PAAD cis rs7174755 0.961 rs1122247 ENSG00000260657.2 RP11-315D16.4 6.62 5.89e-10 1.04e-06 0.58 0.47 Major depressive disorder; chr15:68302523 chr15:68267792~68277994:- PAAD cis rs2739330 0.828 rs5760102 ENSG00000099984.9 GSTT2 -6.62 5.9e-10 1.04e-06 -0.64 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23980123~23983911:+ PAAD cis rs9545047 0.604 rs7987193 ENSG00000227676.3 LINC01068 -6.62 5.93e-10 1.04e-06 -0.57 -0.47 Schizophrenia; chr13:79408449 chr13:79566727~79571436:+ PAAD cis rs2283792 0.967 rs5755099 ENSG00000224086.5 LL22NC03-86G7.1 -6.62 5.93e-10 1.04e-06 -0.49 -0.47 Multiple sclerosis; chr22:21770751 chr22:21938293~21977632:+ PAAD cis rs7174755 0.923 rs9672310 ENSG00000260657.2 RP11-315D16.4 6.62 5.95e-10 1.05e-06 0.58 0.47 Major depressive disorder; chr15:68306578 chr15:68267792~68277994:- PAAD cis rs6452524 0.904 rs10473867 ENSG00000249664.1 CTD-2227C6.2 6.62 5.95e-10 1.05e-06 0.59 0.47 Hypertension (SNP x SNP interaction); chr5:83141613 chr5:83012285~83013109:- PAAD cis rs673078 0.66 rs61945212 ENSG00000275759.1 RP11-131L12.3 -6.62 5.96e-10 1.05e-06 -0.73 -0.47 Glucose homeostasis traits; chr12:118252351 chr12:118428281~118428870:+ PAAD cis rs3931020 1 rs12410060 ENSG00000272864.1 RP11-17E13.2 -6.61 5.97e-10 1.05e-06 -0.61 -0.47 Resistin levels; chr1:74780164 chr1:74698769~74699333:- PAAD cis rs1075265 0.588 rs1477258 ENSG00000233266.1 HMGB1P31 6.61 6e-10 1.05e-06 0.61 0.47 Chronotype;Morning vs. evening chronotype; chr2:54000031 chr2:54051334~54051760:+ PAAD cis rs6538678 0.824 rs2887026 ENSG00000258343.1 RP11-536G4.2 -6.61 6.06e-10 1.06e-06 -0.69 -0.47 Lupus nephritis in systemic lupus erythematosus; chr12:95854713 chr12:95795345~95858839:- PAAD cis rs6538678 0.824 rs1436120 ENSG00000258343.1 RP11-536G4.2 6.61 6.06e-10 1.06e-06 0.67 0.47 Lupus nephritis in systemic lupus erythematosus; chr12:95826872 chr12:95795345~95858839:- PAAD cis rs9322193 0.543 rs9371533 ENSG00000268592.3 RAET1E-AS1 6.61 6.07e-10 1.07e-06 0.56 0.47 Lung cancer; chr6:149889545 chr6:149863494~149919507:+ PAAD cis rs6504622 0.702 rs11079747 ENSG00000262879.4 RP11-156P1.3 -6.61 6.09e-10 1.07e-06 -0.48 -0.47 Orofacial clefts; chr17:47001484 chr17:46984045~47100323:- PAAD cis rs17608059 0.504 rs11656981 ENSG00000141028.6 CDRT15P1 -6.61 6.1e-10 1.07e-06 -0.56 -0.47 Temperament; chr17:14075460 chr17:14024514~14025488:+ PAAD cis rs9532669 0.926 rs4942007 ENSG00000176268.5 CYCSP34 6.61 6.11e-10 1.07e-06 0.47 0.47 Cervical cancer; chr13:40871887 chr13:40863599~40863902:- PAAD cis rs950169 0.922 rs6603022 ENSG00000259728.4 LINC00933 -6.61 6.16e-10 1.08e-06 -0.59 -0.47 Schizophrenia; chr15:84161418 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs4842940 ENSG00000259728.4 LINC00933 -6.61 6.16e-10 1.08e-06 -0.59 -0.47 Schizophrenia; chr15:84162473 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs4842941 ENSG00000259728.4 LINC00933 -6.61 6.16e-10 1.08e-06 -0.59 -0.47 Schizophrenia; chr15:84162560 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs12911223 ENSG00000259728.4 LINC00933 -6.61 6.16e-10 1.08e-06 -0.59 -0.47 Schizophrenia; chr15:84162919 chr15:84570649~84580175:+ PAAD cis rs950169 0.84 rs12905223 ENSG00000259728.4 LINC00933 6.61 6.16e-10 1.08e-06 0.58 0.47 Schizophrenia; chr15:84571037 chr15:84570649~84580175:+ PAAD cis rs7684253 0.587 rs4339274 ENSG00000269949.1 RP11-738E22.3 6.61 6.17e-10 1.08e-06 0.61 0.47 Migraine; chr4:56881468 chr4:56960927~56961373:- PAAD cis rs1930961 1 rs6519611 ENSG00000272977.1 CTA-390C10.10 -6.61 6.21e-10 1.09e-06 -0.9 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25449888 chr22:25476218~25479971:+ PAAD cis rs1930961 0.867 rs6423498 ENSG00000272977.1 CTA-390C10.10 -6.61 6.21e-10 1.09e-06 -0.9 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25457401 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs6004659 ENSG00000272977.1 CTA-390C10.10 -6.61 6.21e-10 1.09e-06 -0.9 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25460444 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs6004662 ENSG00000272977.1 CTA-390C10.10 -6.61 6.21e-10 1.09e-06 -0.9 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25466157 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs760554 ENSG00000272977.1 CTA-390C10.10 -6.61 6.21e-10 1.09e-06 -0.9 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25476625 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs760555 ENSG00000272977.1 CTA-390C10.10 -6.61 6.21e-10 1.09e-06 -0.9 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25476870 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs7285549 ENSG00000272977.1 CTA-390C10.10 -6.61 6.21e-10 1.09e-06 -0.9 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25476218~25479971:+ PAAD cis rs11155671 0.53 rs7763849 ENSG00000268592.3 RAET1E-AS1 6.61 6.22e-10 1.09e-06 0.56 0.47 Testicular germ cell tumor; chr6:149885244 chr6:149863494~149919507:+ PAAD cis rs9545047 0.604 rs9545076 ENSG00000227676.3 LINC01068 -6.61 6.24e-10 1.09e-06 -0.57 -0.47 Schizophrenia; chr13:79335983 chr13:79566727~79571436:+ PAAD cis rs7811142 0.666 rs28401739 ENSG00000242294.5 STAG3L5P 6.61 6.24e-10 1.09e-06 0.37 0.47 Platelet count; chr7:100308061 chr7:100336079~100351900:+ PAAD cis rs977987 0.872 rs10781976 ENSG00000261783.1 RP11-252K23.2 -6.61 6.26e-10 1.1e-06 -0.59 -0.47 Dupuytren's disease; chr16:75280940 chr16:75379818~75381260:- PAAD cis rs881375 0.501 rs10156413 ENSG00000226752.6 PSMD5-AS1 -6.61 6.27e-10 1.1e-06 -0.62 -0.47 Rheumatoid arthritis; chr9:121105504 chr9:120824828~120854385:+ PAAD cis rs881375 0.502 rs4837811 ENSG00000226752.6 PSMD5-AS1 -6.61 6.27e-10 1.1e-06 -0.62 -0.47 Rheumatoid arthritis; chr9:121139316 chr9:120824828~120854385:+ PAAD cis rs2739330 0.828 rs5751770 ENSG00000250470.1 AP000351.3 6.61 6.28e-10 1.1e-06 0.66 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23976904~23977585:- PAAD cis rs4774565 0.762 rs34565064 ENSG00000244879.4 GABPB1-AS1 -6.6 6.3e-10 1.1e-06 -0.43 -0.47 Breast cancer; chr15:50371706 chr15:50354959~50372202:+ PAAD cis rs10129255 0.5 rs11627315 ENSG00000223648.3 IGHV3-64 6.6 6.32e-10 1.11e-06 0.42 0.47 Kawasaki disease; chr14:106802182 chr14:106643132~106658258:- PAAD cis rs3096299 0.503 rs9940093 ENSG00000274627.1 RP11-104N10.2 6.6 6.32e-10 1.11e-06 0.42 0.47 Multiple myeloma (IgH translocation); chr16:89492297 chr16:89516797~89522217:+ PAAD cis rs950169 0.922 rs2033284 ENSG00000259728.4 LINC00933 6.6 6.36e-10 1.11e-06 0.59 0.47 Schizophrenia; chr15:84391575 chr15:84570649~84580175:+ PAAD cis rs17301013 0.606 rs4650950 ENSG00000227373.4 RP11-160H22.5 6.6 6.37e-10 1.11e-06 0.68 0.47 Systemic lupus erythematosus; chr1:174134264 chr1:174115300~174160004:- PAAD cis rs7429990 0.965 rs319682 ENSG00000229759.1 MRPS18AP1 6.6 6.38e-10 1.12e-06 0.52 0.47 Educational attainment (years of education); chr3:47873628 chr3:48256350~48256938:- PAAD cis rs11673344 0.566 rs2385181 ENSG00000226686.6 LINC01535 -6.6 6.38e-10 1.12e-06 -0.56 -0.47 Obesity-related traits; chr19:37395428 chr19:37251912~37265535:+ PAAD cis rs950169 0.922 rs11639244 ENSG00000259728.4 LINC00933 6.6 6.39e-10 1.12e-06 0.59 0.47 Schizophrenia; chr15:84163898 chr15:84570649~84580175:+ PAAD cis rs950169 0.845 rs4106951 ENSG00000259728.4 LINC00933 6.6 6.39e-10 1.12e-06 0.59 0.47 Schizophrenia; chr15:84164642 chr15:84570649~84580175:+ PAAD cis rs10129255 0.518 rs10136903 ENSG00000223648.3 IGHV3-64 6.6 6.39e-10 1.12e-06 0.42 0.47 Kawasaki disease; chr14:106778866 chr14:106643132~106658258:- PAAD cis rs950169 0.8 rs34302901 ENSG00000259728.4 LINC00933 6.6 6.39e-10 1.12e-06 0.58 0.47 Schizophrenia; chr15:84567712 chr15:84570649~84580175:+ PAAD cis rs2283792 0.935 rs2283794 ENSG00000224086.5 LL22NC03-86G7.1 -6.6 6.42e-10 1.12e-06 -0.48 -0.47 Multiple sclerosis; chr22:21858180 chr22:21938293~21977632:+ PAAD cis rs992157 0.965 rs13427681 ENSG00000261338.2 RP11-378A13.1 6.6 6.44e-10 1.12e-06 0.54 0.47 Colorectal cancer; chr2:218302840 chr2:218255319~218257366:+ PAAD cis rs1891275 0.515 rs1361552 ENSG00000228701.1 TNKS2-AS1 -6.6 6.46e-10 1.13e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91774867 chr10:91782839~91798291:- PAAD cis rs9322193 0.607 rs3798763 ENSG00000216906.2 RP11-350J20.9 6.6 6.47e-10 1.13e-06 0.7 0.47 Lung cancer; chr6:149889964 chr6:149904243~149906418:+ PAAD cis rs7429990 0.965 rs6791834 ENSG00000229759.1 MRPS18AP1 -6.6 6.47e-10 1.13e-06 -0.51 -0.47 Educational attainment (years of education); chr3:48073598 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs35689209 ENSG00000229759.1 MRPS18AP1 -6.6 6.47e-10 1.13e-06 -0.51 -0.47 Educational attainment (years of education); chr3:48078273 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs4858881 ENSG00000229759.1 MRPS18AP1 -6.6 6.47e-10 1.13e-06 -0.51 -0.47 Educational attainment (years of education); chr3:48082306 chr3:48256350~48256938:- PAAD cis rs2739330 0.828 rs4822451 ENSG00000250470.1 AP000351.3 6.6 6.47e-10 1.13e-06 0.67 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23976904~23977585:- PAAD cis rs2739330 0.828 rs5760099 ENSG00000250470.1 AP000351.3 6.6 6.47e-10 1.13e-06 0.67 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23976904~23977585:- PAAD cis rs2799081 1 rs2799081 ENSG00000216901.1 AL022393.7 6.6 6.52e-10 1.14e-06 0.64 0.47 Myopia; chr6:28302807 chr6:28176188~28176674:+ PAAD cis rs6452524 1 rs10080123 ENSG00000249664.1 CTD-2227C6.2 -6.6 6.57e-10 1.15e-06 -0.56 -0.47 Hypertension (SNP x SNP interaction); chr5:83165447 chr5:83012285~83013109:- PAAD cis rs10129255 0.518 rs8010020 ENSG00000223648.3 IGHV3-64 6.6 6.6e-10 1.15e-06 0.42 0.47 Kawasaki disease; chr14:106778016 chr14:106643132~106658258:- PAAD cis rs67180937 0.645 rs2270707 ENSG00000272750.1 RP11-378J18.8 6.6 6.61e-10 1.15e-06 0.54 0.47 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222664252 chr1:222658867~222661512:- PAAD cis rs7826238 0.564 rs2921053 ENSG00000253893.2 FAM85B -6.59 6.63e-10 1.15e-06 -0.66 -0.47 Systolic blood pressure; chr8:8462453 chr8:8167819~8226614:- PAAD cis rs950169 0.763 rs35372971 ENSG00000259728.4 LINC00933 6.59 6.63e-10 1.16e-06 0.59 0.47 Schizophrenia; chr15:84387097 chr15:84570649~84580175:+ PAAD cis rs673078 0.66 rs61945224 ENSG00000275759.1 RP11-131L12.3 -6.59 6.66e-10 1.16e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118288623 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs61945225 ENSG00000275759.1 RP11-131L12.3 -6.59 6.66e-10 1.16e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118288960 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs17512407 ENSG00000275759.1 RP11-131L12.3 -6.59 6.66e-10 1.16e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118292705 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs61946064 ENSG00000275759.1 RP11-131L12.3 -6.59 6.66e-10 1.16e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118294495 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs2784 ENSG00000275759.1 RP11-131L12.3 -6.59 6.66e-10 1.16e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118311745 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7302387 ENSG00000275759.1 RP11-131L12.3 -6.59 6.66e-10 1.16e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118316546 chr12:118428281~118428870:+ PAAD cis rs9890032 0.618 rs55872374 ENSG00000266490.1 CTD-2349P21.9 6.59 6.69e-10 1.16e-06 0.45 0.47 Hip circumference adjusted for BMI; chr17:30822863 chr17:30792372~30792833:+ PAAD cis rs4722166 0.645 rs1404006 ENSG00000179428.2 AC073072.5 -6.59 6.75e-10 1.17e-06 -0.45 -0.47 Lung cancer; chr7:22755458 chr7:22725395~22727620:- PAAD cis rs7429990 0.965 rs4858880 ENSG00000229759.1 MRPS18AP1 -6.59 6.84e-10 1.19e-06 -0.51 -0.47 Educational attainment (years of education); chr3:48062959 chr3:48256350~48256938:- PAAD cis rs7811142 0.775 rs1059129 ENSG00000242294.5 STAG3L5P 6.59 6.85e-10 1.19e-06 0.36 0.47 Platelet count; chr7:100328899 chr7:100336079~100351900:+ PAAD cis rs7811142 0.562 rs7786844 ENSG00000242294.5 STAG3L5P 6.59 6.85e-10 1.19e-06 0.36 0.47 Platelet count; chr7:100336385 chr7:100336079~100351900:+ PAAD cis rs7811142 0.667 rs3873746 ENSG00000242294.5 STAG3L5P 6.59 6.85e-10 1.19e-06 0.36 0.47 Platelet count; chr7:100337474 chr7:100336079~100351900:+ PAAD cis rs7811142 0.83 rs6979910 ENSG00000242294.5 STAG3L5P 6.59 6.85e-10 1.19e-06 0.36 0.47 Platelet count; chr7:100343007 chr7:100336079~100351900:+ PAAD cis rs11098499 0.618 rs28491261 ENSG00000245958.5 RP11-33B1.1 -6.59 6.85e-10 1.19e-06 -0.39 -0.47 Corneal astigmatism; chr4:119373745 chr4:119454791~119552025:+ PAAD cis rs10129255 0.5 rs8022547 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106781985 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs8006888 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106782219 chr14:106643132~106658258:- PAAD cis rs2882667 0.931 rs1433009 ENSG00000253404.1 AC034243.1 6.59 6.86e-10 1.19e-06 0.56 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:138998095 chr5:138744434~138753309:- PAAD cis rs10129255 0.518 rs12590732 ENSG00000223648.3 IGHV3-64 -6.59 6.86e-10 1.19e-06 -0.42 -0.47 Kawasaki disease; chr14:106779612 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs4774189 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106768275 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs7161740 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106776119 chr14:106643132~106658258:- PAAD cis rs10129255 0.556 rs6576222 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106776442 chr14:106643132~106658258:- PAAD cis rs10129255 0.536 rs6576223 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106776448 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs988134 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106776698 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs988133 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106776724 chr14:106643132~106658258:- PAAD cis rs10129255 0.518 rs8009594 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106777494 chr14:106643132~106658258:- PAAD cis rs10129255 0.518 rs8009612 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106777510 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs6576225 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106778120 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs6576226 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106778135 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs6576230 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106778539 chr14:106643132~106658258:- PAAD cis rs10129255 0.518 rs11847766 ENSG00000223648.3 IGHV3-64 6.59 6.86e-10 1.19e-06 0.42 0.47 Kawasaki disease; chr14:106779186 chr14:106643132~106658258:- PAAD cis rs7044106 0.69 rs10739569 ENSG00000226752.6 PSMD5-AS1 -6.59 6.87e-10 1.19e-06 -0.59 -0.47 Hip circumference adjusted for BMI; chr9:120598749 chr9:120824828~120854385:+ PAAD cis rs977987 0.586 rs12920883 ENSG00000261783.1 RP11-252K23.2 -6.59 6.88e-10 1.19e-06 -0.6 -0.47 Dupuytren's disease; chr16:75398783 chr16:75379818~75381260:- PAAD cis rs977987 0.624 rs59867374 ENSG00000261783.1 RP11-252K23.2 -6.59 6.88e-10 1.19e-06 -0.6 -0.47 Dupuytren's disease; chr16:75398784 chr16:75379818~75381260:- PAAD cis rs11098499 0.908 rs2017057 ENSG00000245958.5 RP11-33B1.1 -6.59 6.9e-10 1.2e-06 -0.38 -0.47 Corneal astigmatism; chr4:119336556 chr4:119454791~119552025:+ PAAD cis rs7429990 0.965 rs35012836 ENSG00000229759.1 MRPS18AP1 6.59 6.9e-10 1.2e-06 0.56 0.47 Educational attainment (years of education); chr3:47670000 chr3:48256350~48256938:- PAAD cis rs9545047 0.584 rs12871015 ENSG00000227676.3 LINC01068 -6.59 6.9e-10 1.2e-06 -0.56 -0.47 Schizophrenia; chr13:79333564 chr13:79566727~79571436:+ PAAD cis rs9660180 0.875 rs4648727 ENSG00000231050.1 RP1-140A9.1 -6.59 6.95e-10 1.21e-06 -0.53 -0.47 Body mass index; chr1:1844830 chr1:1891471~1892658:+ PAAD cis rs858239 0.932 rs1728313 ENSG00000226816.2 AC005082.12 6.58 7.01e-10 1.21e-06 0.53 0.47 Cerebrospinal fluid biomarker levels; chr7:23231412 chr7:23206013~23208045:+ PAAD cis rs6504622 0.702 rs3851798 ENSG00000262879.4 RP11-156P1.3 6.58 7.03e-10 1.22e-06 0.48 0.47 Orofacial clefts; chr17:46988901 chr17:46984045~47100323:- PAAD cis rs6504622 0.702 rs2316758 ENSG00000262879.4 RP11-156P1.3 -6.58 7.03e-10 1.22e-06 -0.48 -0.47 Orofacial clefts; chr17:46988999 chr17:46984045~47100323:- PAAD cis rs6504622 0.702 rs3851799 ENSG00000262879.4 RP11-156P1.3 -6.58 7.03e-10 1.22e-06 -0.48 -0.47 Orofacial clefts; chr17:46989122 chr17:46984045~47100323:- PAAD cis rs6504622 0.667 rs11653589 ENSG00000262879.4 RP11-156P1.3 -6.58 7.03e-10 1.22e-06 -0.48 -0.47 Orofacial clefts; chr17:46990299 chr17:46984045~47100323:- PAAD cis rs6504622 0.634 rs8068715 ENSG00000262879.4 RP11-156P1.3 -6.58 7.03e-10 1.22e-06 -0.48 -0.47 Orofacial clefts; chr17:46991022 chr17:46984045~47100323:- PAAD cis rs6504622 0.514 rs60611133 ENSG00000262879.4 RP11-156P1.3 -6.58 7.03e-10 1.22e-06 -0.48 -0.47 Orofacial clefts; chr17:46993027 chr17:46984045~47100323:- PAAD cis rs1061377 1 rs12499266 ENSG00000249207.1 RP11-360F5.1 6.58 7.05e-10 1.22e-06 0.5 0.47 Uric acid levels; chr4:39118133 chr4:39112677~39126818:- PAAD cis rs1061377 1 rs35116118 ENSG00000249207.1 RP11-360F5.1 -6.58 7.05e-10 1.22e-06 -0.5 -0.47 Uric acid levels; chr4:39127293 chr4:39112677~39126818:- PAAD cis rs7044106 0.648 rs2031369 ENSG00000226752.6 PSMD5-AS1 -6.58 7.05e-10 1.22e-06 -0.59 -0.47 Hip circumference adjusted for BMI; chr9:120598016 chr9:120824828~120854385:+ PAAD cis rs9399135 0.682 rs9402684 ENSG00000232876.1 CTA-212D2.2 -6.58 7.11e-10 1.23e-06 -0.56 -0.47 Red blood cell count; chr6:135098167 chr6:135055033~135060550:+ PAAD cis rs9399135 0.715 rs7743042 ENSG00000232876.1 CTA-212D2.2 -6.58 7.11e-10 1.23e-06 -0.56 -0.47 Red blood cell count; chr6:135098696 chr6:135055033~135060550:+ PAAD cis rs673078 0.66 rs56708462 ENSG00000275759.1 RP11-131L12.3 -6.58 7.13e-10 1.23e-06 -0.7 -0.47 Glucose homeostasis traits; chr12:118284135 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs7962185 ENSG00000275759.1 RP11-131L12.3 -6.58 7.13e-10 1.23e-06 -0.7 -0.47 Glucose homeostasis traits; chr12:118287842 chr12:118428281~118428870:+ PAAD cis rs1891275 0.515 rs2153653 ENSG00000228701.1 TNKS2-AS1 -6.58 7.14e-10 1.24e-06 -0.58 -0.47 Intelligence (multi-trait analysis); chr10:91736169 chr10:91782839~91798291:- PAAD cis rs4774565 0.762 rs8041193 ENSG00000244879.4 GABPB1-AS1 -6.58 7.17e-10 1.24e-06 -0.42 -0.47 Breast cancer; chr15:50369960 chr15:50354959~50372202:+ PAAD cis rs6723162 0.965 rs11126307 ENSG00000237751.2 LINC01143 -6.58 7.17e-10 1.24e-06 -0.56 -0.47 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70884060 chr2:70887871~70889959:+ PAAD cis rs6723162 0.965 rs7564690 ENSG00000237751.2 LINC01143 -6.58 7.17e-10 1.24e-06 -0.56 -0.47 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70885113 chr2:70887871~70889959:+ PAAD cis rs6723162 0.868 rs2192403 ENSG00000237751.2 LINC01143 -6.58 7.17e-10 1.24e-06 -0.56 -0.47 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70886008 chr2:70887871~70889959:+ PAAD cis rs6723162 0.868 rs2215826 ENSG00000237751.2 LINC01143 -6.58 7.17e-10 1.24e-06 -0.56 -0.47 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70886266 chr2:70887871~70889959:+ PAAD cis rs6723162 0.965 rs11126308 ENSG00000237751.2 LINC01143 -6.58 7.17e-10 1.24e-06 -0.56 -0.47 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70887591 chr2:70887871~70889959:+ PAAD cis rs6723162 0.965 rs7567290 ENSG00000237751.2 LINC01143 -6.58 7.17e-10 1.24e-06 -0.56 -0.47 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70887870 chr2:70887871~70889959:+ PAAD cis rs6504622 0.702 rs3851796 ENSG00000262879.4 RP11-156P1.3 -6.58 7.22e-10 1.25e-06 -0.47 -0.47 Orofacial clefts; chr17:46983809 chr17:46984045~47100323:- PAAD cis rs4722166 0.63 rs6461667 ENSG00000179428.2 AC073072.5 -6.58 7.22e-10 1.25e-06 -0.44 -0.47 Lung cancer; chr7:22757124 chr7:22725395~22727620:- PAAD cis rs2470135 1 rs2470135 ENSG00000249839.1 AC011330.5 -6.58 7.23e-10 1.25e-06 -0.66 -0.47 Diastolic blood pressure; chr15:43703591 chr15:43663654~43684339:- PAAD cis rs1061377 1 rs9990742 ENSG00000249207.1 RP11-360F5.1 -6.58 7.25e-10 1.25e-06 -0.52 -0.47 Uric acid levels; chr4:39119794 chr4:39112677~39126818:- PAAD cis rs7044106 0.664 rs7861679 ENSG00000226752.6 PSMD5-AS1 6.58 7.33e-10 1.27e-06 0.59 0.47 Hip circumference adjusted for BMI; chr9:120613311 chr9:120824828~120854385:+ PAAD cis rs2882667 0.858 rs10900856 ENSG00000253404.1 AC034243.1 -6.58 7.34e-10 1.27e-06 -0.59 -0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139082057 chr5:138744434~138753309:- PAAD cis rs7044106 0.762 rs10739570 ENSG00000226752.6 PSMD5-AS1 -6.57 7.36e-10 1.27e-06 -0.62 -0.47 Hip circumference adjusted for BMI; chr9:120618944 chr9:120824828~120854385:+ PAAD cis rs7429990 0.965 rs1061003 ENSG00000229759.1 MRPS18AP1 6.57 7.37e-10 1.27e-06 0.51 0.47 Educational attainment (years of education); chr3:47851089 chr3:48256350~48256938:- PAAD cis rs6452524 1 rs7349753 ENSG00000249664.1 CTD-2227C6.2 6.57 7.38e-10 1.27e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83165632 chr5:83012285~83013109:- PAAD cis rs950169 0.8 rs4842847 ENSG00000259728.4 LINC00933 6.57 7.4e-10 1.28e-06 0.59 0.47 Schizophrenia; chr15:84262447 chr15:84570649~84580175:+ PAAD cis rs507080 0.769 rs2077173 ENSG00000255422.1 AP002954.4 -6.57 7.4e-10 1.28e-06 -0.58 -0.47 Serum metabolite levels; chr11:118621876 chr11:118704607~118750263:+ PAAD cis rs11155671 0.53 rs9383940 ENSG00000223701.3 RAET1E-AS1 6.57 7.49e-10 1.29e-06 0.54 0.47 Testicular germ cell tumor; chr6:149904923 chr6:149884431~149919508:+ PAAD cis rs11673344 0.864 rs1533736 ENSG00000226686.6 LINC01535 6.57 7.49e-10 1.29e-06 0.63 0.47 Obesity-related traits; chr19:37164074 chr19:37251912~37265535:+ PAAD cis rs1891275 0.515 rs7092745 ENSG00000228701.1 TNKS2-AS1 -6.57 7.51e-10 1.29e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91724063 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs1418161 ENSG00000228701.1 TNKS2-AS1 -6.57 7.51e-10 1.29e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91724898 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs7911755 ENSG00000228701.1 TNKS2-AS1 -6.57 7.51e-10 1.29e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91730060 chr10:91782839~91798291:- PAAD cis rs1891275 0.508 rs2096079 ENSG00000228701.1 TNKS2-AS1 -6.57 7.51e-10 1.29e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91736910 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs7475294 ENSG00000228701.1 TNKS2-AS1 -6.57 7.51e-10 1.29e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91748442 chr10:91782839~91798291:- PAAD cis rs10129255 0.518 rs2006284 ENSG00000223648.3 IGHV3-64 6.57 7.59e-10 1.31e-06 0.42 0.47 Kawasaki disease; chr14:106676185 chr14:106643132~106658258:- PAAD cis rs6452524 1 rs10068099 ENSG00000249664.1 CTD-2227C6.2 6.57 7.63e-10 1.31e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83161373 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs67683443 ENSG00000249664.1 CTD-2227C6.2 6.57 7.63e-10 1.31e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83167884 chr5:83012285~83013109:- PAAD cis rs11098499 0.697 rs4560394 ENSG00000245958.5 RP11-33B1.1 -6.57 7.64e-10 1.31e-06 -0.4 -0.47 Corneal astigmatism; chr4:119392280 chr4:119454791~119552025:+ PAAD cis rs10129255 0.5 rs2027902 ENSG00000223648.3 IGHV3-64 6.57 7.67e-10 1.32e-06 0.41 0.47 Kawasaki disease; chr14:106807157 chr14:106643132~106658258:- PAAD cis rs35160687 0.798 rs2367233 ENSG00000273080.1 RP11-301O19.1 -6.57 7.68e-10 1.32e-06 -0.58 -0.47 Night sleep phenotypes; chr2:86314543 chr2:86195590~86196049:+ PAAD cis rs992157 0.798 rs4996257 ENSG00000261338.2 RP11-378A13.1 6.57 7.68e-10 1.32e-06 0.55 0.47 Colorectal cancer; chr2:218298113 chr2:218255319~218257366:+ PAAD cis rs7945705 0.902 rs7930026 ENSG00000254860.4 TMEM9B-AS1 -6.57 7.74e-10 1.33e-06 -0.53 -0.47 Hemoglobin concentration; chr11:8992092 chr11:8964675~8977527:+ PAAD cis rs992157 1 rs2168704 ENSG00000261338.2 RP11-378A13.1 6.57 7.74e-10 1.33e-06 0.54 0.47 Colorectal cancer; chr2:218277769 chr2:218255319~218257366:+ PAAD cis rs992157 1 rs13429408 ENSG00000261338.2 RP11-378A13.1 6.57 7.74e-10 1.33e-06 0.54 0.47 Colorectal cancer; chr2:218278137 chr2:218255319~218257366:+ PAAD cis rs1075265 0.633 rs4671190 ENSG00000233266.1 HMGB1P31 6.56 7.76e-10 1.33e-06 0.59 0.47 Chronotype;Morning vs. evening chronotype; chr2:54085604 chr2:54051334~54051760:+ PAAD cis rs8040855 0.965 rs11073990 ENSG00000259295.5 CSPG4P12 6.56 7.78e-10 1.33e-06 0.52 0.47 Bulimia nervosa; chr15:85168070 chr15:85191438~85213905:+ PAAD cis rs10129255 0.536 rs10142951 ENSG00000223648.3 IGHV3-64 6.56 7.8e-10 1.34e-06 0.42 0.47 Kawasaki disease; chr14:106782337 chr14:106643132~106658258:- PAAD cis rs7615952 0.688 rs7624806 ENSG00000171084.14 FAM86JP 6.56 7.81e-10 1.34e-06 0.64 0.47 Blood pressure (smoking interaction); chr3:125880231 chr3:125916620~125930024:+ PAAD cis rs11098499 0.865 rs28634456 ENSG00000245958.5 RP11-33B1.1 -6.56 7.82e-10 1.34e-06 -0.39 -0.47 Corneal astigmatism; chr4:119454623 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs78332141 ENSG00000245958.5 RP11-33B1.1 -6.56 7.82e-10 1.34e-06 -0.39 -0.47 Corneal astigmatism; chr4:119454627 chr4:119454791~119552025:+ PAAD cis rs6452524 0.967 rs6452509 ENSG00000249664.1 CTD-2227C6.2 6.56 7.93e-10 1.36e-06 0.55 0.47 Hypertension (SNP x SNP interaction); chr5:83125564 chr5:83012285~83013109:- PAAD cis rs2882667 0.861 rs11242445 ENSG00000253404.1 AC034243.1 6.56 7.94e-10 1.36e-06 0.57 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139081365 chr5:138744434~138753309:- PAAD cis rs950169 0.922 rs17531523 ENSG00000259728.4 LINC00933 6.56 7.97e-10 1.37e-06 0.58 0.47 Schizophrenia; chr15:84589218 chr15:84570649~84580175:+ PAAD cis rs10129255 0.5 rs4774008 ENSG00000223648.3 IGHV3-64 6.56 7.97e-10 1.37e-06 0.42 0.47 Kawasaki disease; chr14:106681273 chr14:106643132~106658258:- PAAD cis rs9890032 0.57 rs8068504 ENSG00000266490.1 CTD-2349P21.9 6.56 8e-10 1.37e-06 0.45 0.47 Hip circumference adjusted for BMI; chr17:30785052 chr17:30792372~30792833:+ PAAD cis rs9890032 0.618 rs1979507 ENSG00000266490.1 CTD-2349P21.9 6.56 8e-10 1.37e-06 0.45 0.47 Hip circumference adjusted for BMI; chr17:30811002 chr17:30792372~30792833:+ PAAD cis rs9481169 0.85 rs4947128 ENSG00000255389.1 C6orf3 -6.56 8.03e-10 1.37e-06 -0.76 -0.47 Inflammatory skin disease; chr6:111597665 chr6:111599875~111602295:+ PAAD cis rs1891275 0.515 rs10786010 ENSG00000228701.1 TNKS2-AS1 -6.56 8.04e-10 1.38e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91684016 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs1986941 ENSG00000228701.1 TNKS2-AS1 -6.56 8.04e-10 1.38e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91684586 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs7098763 ENSG00000228701.1 TNKS2-AS1 -6.56 8.04e-10 1.38e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91685070 chr10:91782839~91798291:- PAAD cis rs1891275 0.508 rs7099557 ENSG00000228701.1 TNKS2-AS1 -6.56 8.04e-10 1.38e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91685607 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs4244930 ENSG00000228701.1 TNKS2-AS1 -6.56 8.04e-10 1.38e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91707092 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs11186666 ENSG00000228701.1 TNKS2-AS1 -6.56 8.04e-10 1.38e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91718162 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs1080496 ENSG00000228701.1 TNKS2-AS1 6.56 8.04e-10 1.38e-06 0.57 0.47 Intelligence (multi-trait analysis); chr10:91684505 chr10:91782839~91798291:- PAAD cis rs7829975 0.688 rs6995407 ENSG00000253893.2 FAM85B -6.56 8.05e-10 1.38e-06 -0.62 -0.47 Mood instability; chr8:8527137 chr8:8167819~8226614:- PAAD cis rs4423214 0.569 rs4944044 ENSG00000254682.1 RP11-660L16.2 6.56 8.08e-10 1.38e-06 0.61 0.47 Vitamin D levels; chr11:71409167 chr11:71448674~71452157:+ PAAD cis rs9532669 0.75 rs9532598 ENSG00000176268.5 CYCSP34 6.56 8.09e-10 1.38e-06 0.47 0.47 Cervical cancer; chr13:40860627 chr13:40863599~40863902:- PAAD cis rs9532669 0.611 rs9532599 ENSG00000176268.5 CYCSP34 6.56 8.09e-10 1.38e-06 0.47 0.47 Cervical cancer; chr13:40860633 chr13:40863599~40863902:- PAAD cis rs9532669 0.571 rs9525405 ENSG00000176268.5 CYCSP34 6.56 8.09e-10 1.38e-06 0.47 0.47 Cervical cancer; chr13:40860638 chr13:40863599~40863902:- PAAD cis rs950169 0.881 rs4842852 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84387263 chr15:84570649~84580175:+ PAAD cis rs950169 0.84 rs4842853 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84387606 chr15:84570649~84580175:+ PAAD cis rs950169 0.922 rs4842946 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84387633 chr15:84570649~84580175:+ PAAD cis rs950169 0.84 rs4842854 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84387641 chr15:84570649~84580175:+ PAAD cis rs950169 0.84 rs2896002 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84390423 chr15:84570649~84580175:+ PAAD cis rs950169 0.887 rs3860265 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84390487 chr15:84570649~84580175:+ PAAD cis rs950169 0.724 rs11632668 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84393989 chr15:84570649~84580175:+ PAAD cis rs950169 0.881 rs34591918 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84396135 chr15:84570649~84580175:+ PAAD cis rs950169 0.887 rs12903946 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84399732 chr15:84570649~84580175:+ PAAD cis rs950169 0.887 rs35986397 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84400409 chr15:84570649~84580175:+ PAAD cis rs950169 0.887 rs62029593 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84400482 chr15:84570649~84580175:+ PAAD cis rs950169 0.81 rs62029594 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84400554 chr15:84570649~84580175:+ PAAD cis rs950169 0.881 rs62029596 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84400736 chr15:84570649~84580175:+ PAAD cis rs950169 0.881 rs4081123 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84401537 chr15:84570649~84580175:+ PAAD cis rs950169 0.881 rs62029599 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84401867 chr15:84570649~84580175:+ PAAD cis rs950169 0.8 rs4099846 ENSG00000259728.4 LINC00933 6.56 8.11e-10 1.39e-06 0.59 0.47 Schizophrenia; chr15:84402196 chr15:84570649~84580175:+ PAAD cis rs72772090 0.539 rs114006288 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.14e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782300 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72773932 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.14e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782444 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11750934 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.14e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782783 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11738810 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.14e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96783351 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11748519 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.14e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96783624 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72773942 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.14e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96787663 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11743410 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.14e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96788750 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11135480 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.15e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774878 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs13601 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.15e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774892 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs56120748 ENSG00000248734.2 CTD-2260A17.1 -6.56 8.15e-10 1.39e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96774918 chr5:96784777~96785999:+ PAAD cis rs2283792 0.967 rs5999550 ENSG00000224086.5 LL22NC03-86G7.1 -6.55 8.2e-10 1.4e-06 -0.48 -0.47 Multiple sclerosis; chr22:21796997 chr22:21938293~21977632:+ PAAD cis rs8040855 0.756 rs12909477 ENSG00000259295.5 CSPG4P12 -6.55 8.21e-10 1.4e-06 -0.55 -0.47 Bulimia nervosa; chr15:85146644 chr15:85191438~85213905:+ PAAD cis rs7044106 0.762 rs1530370 ENSG00000226752.6 PSMD5-AS1 -6.55 8.22e-10 1.4e-06 -0.63 -0.47 Hip circumference adjusted for BMI; chr9:120662274 chr9:120824828~120854385:+ PAAD cis rs950169 0.84 rs62029595 ENSG00000259728.4 LINC00933 6.55 8.25e-10 1.41e-06 0.58 0.47 Schizophrenia; chr15:84400603 chr15:84570649~84580175:+ PAAD cis rs1075265 0.568 rs10865277 ENSG00000233266.1 HMGB1P31 6.55 8.28e-10 1.41e-06 0.58 0.47 Chronotype;Morning vs. evening chronotype; chr2:54074865 chr2:54051334~54051760:+ PAAD cis rs1075265 0.568 rs10865278 ENSG00000233266.1 HMGB1P31 6.55 8.28e-10 1.41e-06 0.58 0.47 Chronotype;Morning vs. evening chronotype; chr2:54074902 chr2:54051334~54051760:+ PAAD cis rs673078 0.66 rs61946068 ENSG00000275759.1 RP11-131L12.3 -6.55 8.29e-10 1.41e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118305861 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7307393 ENSG00000275759.1 RP11-131L12.3 -6.55 8.29e-10 1.41e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118308537 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17440669 ENSG00000275759.1 RP11-131L12.3 -6.55 8.29e-10 1.41e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118310397 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7309671 ENSG00000275759.1 RP11-131L12.3 -6.55 8.29e-10 1.41e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118313188 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17512525 ENSG00000275759.1 RP11-131L12.3 -6.55 8.29e-10 1.41e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118315467 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17440774 ENSG00000275759.1 RP11-131L12.3 -6.55 8.29e-10 1.41e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118316155 chr12:118428281~118428870:+ PAAD cis rs2882667 0.929 rs34846849 ENSG00000253404.1 AC034243.1 6.55 8.3e-10 1.41e-06 0.57 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139024889 chr5:138744434~138753309:- PAAD cis rs7829975 0.511 rs2980426 ENSG00000253893.2 FAM85B -6.55 8.31e-10 1.42e-06 -0.67 -0.47 Mood instability; chr8:8288087 chr8:8167819~8226614:- PAAD cis rs11155671 0.53 rs4458704 ENSG00000268592.3 RAET1E-AS1 6.55 8.31e-10 1.42e-06 0.55 0.47 Testicular germ cell tumor; chr6:149911743 chr6:149863494~149919507:+ PAAD cis rs12931792 0.84 rs8049778 ENSG00000183604.13 SMG1P5 6.55 8.35e-10 1.42e-06 0.49 0.47 Tonsillectomy; chr16:30151845 chr16:30267553~30335374:- PAAD cis rs11155671 0.546 rs1999633 ENSG00000216906.2 RP11-350J20.9 6.55 8.36e-10 1.42e-06 0.66 0.47 Testicular germ cell tumor; chr6:149866576 chr6:149904243~149906418:+ PAAD cis rs1891275 0.515 rs7093728 ENSG00000228701.1 TNKS2-AS1 -6.55 8.38e-10 1.43e-06 -0.57 -0.47 Intelligence (multi-trait analysis); chr10:91683860 chr10:91782839~91798291:- PAAD cis rs6452524 0.775 rs10071579 ENSG00000249664.1 CTD-2227C6.2 6.55 8.38e-10 1.43e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83113925 chr5:83012285~83013109:- PAAD cis rs6452524 0.868 rs10045104 ENSG00000249664.1 CTD-2227C6.2 6.55 8.38e-10 1.43e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83116543 chr5:83012285~83013109:- PAAD cis rs1891275 0.515 rs2421694 ENSG00000228701.1 TNKS2-AS1 -6.55 8.39e-10 1.43e-06 -0.58 -0.47 Intelligence (multi-trait analysis); chr10:91756347 chr10:91782839~91798291:- PAAD cis rs950169 0.922 rs62028133 ENSG00000259728.4 LINC00933 6.55 8.42e-10 1.43e-06 0.59 0.47 Schizophrenia; chr15:84250623 chr15:84570649~84580175:+ PAAD cis rs950169 0.723 rs17589320 ENSG00000259728.4 LINC00933 6.55 8.42e-10 1.43e-06 0.59 0.47 Schizophrenia; chr15:84251244 chr15:84570649~84580175:+ PAAD cis rs950169 0.845 rs4502182 ENSG00000259728.4 LINC00933 6.55 8.42e-10 1.43e-06 0.59 0.47 Schizophrenia; chr15:84254768 chr15:84570649~84580175:+ PAAD cis rs7615952 0.673 rs115942855 ENSG00000171084.14 FAM86JP 6.55 8.46e-10 1.44e-06 0.85 0.47 Blood pressure (smoking interaction); chr3:125883117 chr3:125916620~125930024:+ PAAD cis rs7429990 0.931 rs62262084 ENSG00000229759.1 MRPS18AP1 6.55 8.47e-10 1.44e-06 0.55 0.47 Educational attainment (years of education); chr3:47612332 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs17785248 ENSG00000229759.1 MRPS18AP1 6.55 8.47e-10 1.44e-06 0.55 0.47 Educational attainment (years of education); chr3:47631425 chr3:48256350~48256938:- PAAD cis rs9545047 0.604 rs1856997 ENSG00000227676.3 LINC01068 6.55 8.51e-10 1.45e-06 0.55 0.47 Schizophrenia; chr13:79287487 chr13:79566727~79571436:+ PAAD cis rs1891275 0.515 rs6583784 ENSG00000228701.1 TNKS2-AS1 6.55 8.53e-10 1.45e-06 0.57 0.47 Intelligence (multi-trait analysis); chr10:91731819 chr10:91782839~91798291:- PAAD cis rs2882667 0.931 rs7706391 ENSG00000253404.1 AC034243.1 6.55 8.54e-10 1.45e-06 0.56 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139013475 chr5:138744434~138753309:- PAAD cis rs72772090 0.539 rs72773922 ENSG00000248734.2 CTD-2260A17.1 -6.55 8.54e-10 1.45e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780956 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72773923 ENSG00000248734.2 CTD-2260A17.1 -6.55 8.54e-10 1.45e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96781875 chr5:96784777~96785999:+ PAAD cis rs6504622 0.755 rs7219544 ENSG00000262879.4 RP11-156P1.3 -6.55 8.57e-10 1.46e-06 -0.48 -0.47 Orofacial clefts; chr17:47089562 chr17:46984045~47100323:- PAAD cis rs11168854 0.656 rs7969963 ENSG00000258017.1 RP11-386G11.10 -6.54 8.64e-10 1.47e-06 -0.59 -0.47 Body mass index; chr12:49118222 chr12:49127782~49147869:+ PAAD cis rs2117029 0.555 rs9788140 ENSG00000258017.1 RP11-386G11.10 -6.54 8.64e-10 1.47e-06 -0.59 -0.47 Intelligence (multi-trait analysis); chr12:49126738 chr12:49127782~49147869:+ PAAD cis rs7429990 0.93 rs13075457 ENSG00000229759.1 MRPS18AP1 -6.54 8.64e-10 1.47e-06 -0.5 -0.47 Educational attainment (years of education); chr3:48013063 chr3:48256350~48256938:- PAAD cis rs7429990 0.93 rs11130152 ENSG00000229759.1 MRPS18AP1 -6.54 8.64e-10 1.47e-06 -0.5 -0.47 Educational attainment (years of education); chr3:48014919 chr3:48256350~48256938:- PAAD cis rs10129255 0.5 rs9324092 ENSG00000223648.3 IGHV3-64 -6.54 8.73e-10 1.48e-06 -0.42 -0.47 Kawasaki disease; chr14:106683806 chr14:106643132~106658258:- PAAD cis rs673078 0.571 rs61945220 ENSG00000275759.1 RP11-131L12.3 -6.54 8.74e-10 1.48e-06 -0.74 -0.47 Glucose homeostasis traits; chr12:118272924 chr12:118428281~118428870:+ PAAD cis rs673078 0.571 rs61945221 ENSG00000275759.1 RP11-131L12.3 -6.54 8.74e-10 1.48e-06 -0.74 -0.47 Glucose homeostasis traits; chr12:118272926 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943393 ENSG00000275759.1 RP11-131L12.3 -6.54 8.75e-10 1.48e-06 -0.72 -0.47 Glucose homeostasis traits; chr12:118383650 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs73205576 ENSG00000275759.1 RP11-131L12.3 -6.54 8.75e-10 1.48e-06 -0.72 -0.47 Glucose homeostasis traits; chr12:118384268 chr12:118428281~118428870:+ PAAD cis rs992157 0.798 rs1017698 ENSG00000261338.2 RP11-378A13.1 -6.54 8.82e-10 1.5e-06 -0.55 -0.47 Colorectal cancer; chr2:218305802 chr2:218255319~218257366:+ PAAD cis rs9660180 0.839 rs12040826 ENSG00000231050.1 RP1-140A9.1 6.54 8.86e-10 1.5e-06 0.55 0.47 Body mass index; chr1:1773848 chr1:1891471~1892658:+ PAAD cis rs9545047 0.604 rs9565483 ENSG00000227676.3 LINC01068 -6.54 8.93e-10 1.51e-06 -0.57 -0.47 Schizophrenia; chr13:79294001 chr13:79566727~79571436:+ PAAD cis rs977987 0.806 rs4888405 ENSG00000261783.1 RP11-252K23.2 -6.54 8.95e-10 1.52e-06 -0.58 -0.47 Dupuytren's disease; chr16:75394298 chr16:75379818~75381260:- PAAD cis rs72772090 0.539 rs116360011 ENSG00000248734.2 CTD-2260A17.1 -6.54 8.98e-10 1.52e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96782093 chr5:96784777~96785999:+ PAAD cis rs7044106 0.762 rs10984972 ENSG00000226752.6 PSMD5-AS1 -6.54 9.01e-10 1.53e-06 -0.64 -0.47 Hip circumference adjusted for BMI; chr9:120647586 chr9:120824828~120854385:+ PAAD cis rs875971 0.545 rs12670811 ENSG00000237310.1 GS1-124K5.4 6.54 9.02e-10 1.53e-06 0.54 0.47 Aortic root size; chr7:66358032 chr7:66493706~66495474:+ PAAD cis rs950169 0.881 rs150965 ENSG00000259728.4 LINC00933 6.54 9.03e-10 1.53e-06 0.59 0.47 Schizophrenia; chr15:84537296 chr15:84570649~84580175:+ PAAD cis rs3931020 0.962 rs2185695 ENSG00000272864.1 RP11-17E13.2 -6.53 9.09e-10 1.54e-06 -0.61 -0.47 Resistin levels; chr1:74792197 chr1:74698769~74699333:- PAAD cis rs72772090 0.539 rs11746534 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.09e-10 1.54e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789104 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs55773007 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.09e-10 1.54e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789215 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs111886458 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.09e-10 1.54e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789344 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs10515249 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.09e-10 1.54e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789556 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72773947 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.09e-10 1.54e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96789830 chr5:96784777~96785999:+ PAAD cis rs3096299 0.503 rs9925045 ENSG00000274627.1 RP11-104N10.2 6.53 9.09e-10 1.54e-06 0.42 0.47 Multiple myeloma (IgH translocation); chr16:89490068 chr16:89516797~89522217:+ PAAD cis rs2739330 0.828 rs5760108 ENSG00000250470.1 AP000351.3 6.53 9.13e-10 1.54e-06 0.66 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23976904~23977585:- PAAD cis rs2929278 0.617 rs11070410 ENSG00000249839.1 AC011330.5 6.53 9.14e-10 1.54e-06 0.65 0.47 Schizophrenia; chr15:43764847 chr15:43663654~43684339:- PAAD cis rs11098499 0.909 rs10020034 ENSG00000245958.5 RP11-33B1.1 -6.53 9.15e-10 1.55e-06 -0.39 -0.47 Corneal astigmatism; chr4:119373176 chr4:119454791~119552025:+ PAAD cis rs2117029 0.521 rs11168885 ENSG00000258017.1 RP11-386G11.10 -6.53 9.17e-10 1.55e-06 -0.59 -0.47 Intelligence (multi-trait analysis); chr12:49146204 chr12:49127782~49147869:+ PAAD cis rs11098499 0.866 rs72676074 ENSG00000245958.5 RP11-33B1.1 -6.53 9.19e-10 1.55e-06 -0.39 -0.47 Corneal astigmatism; chr4:119438686 chr4:119454791~119552025:+ PAAD cis rs2117029 0.521 rs58336603 ENSG00000258017.1 RP11-386G11.10 -6.53 9.26e-10 1.56e-06 -0.59 -0.47 Intelligence (multi-trait analysis); chr12:49163105 chr12:49127782~49147869:+ PAAD cis rs2117029 0.553 rs1991427 ENSG00000258017.1 RP11-386G11.10 -6.53 9.26e-10 1.56e-06 -0.59 -0.47 Intelligence (multi-trait analysis); chr12:49164175 chr12:49127782~49147869:+ PAAD cis rs2117029 0.521 rs6580702 ENSG00000258017.1 RP11-386G11.10 -6.53 9.26e-10 1.56e-06 -0.59 -0.47 Intelligence (multi-trait analysis); chr12:49169483 chr12:49127782~49147869:+ PAAD cis rs8040855 0.597 rs994989 ENSG00000259295.5 CSPG4P12 6.53 9.27e-10 1.57e-06 0.55 0.47 Bulimia nervosa; chr15:85117485 chr15:85191438~85213905:+ PAAD cis rs9545047 0.625 rs7338170 ENSG00000227676.3 LINC01068 -6.53 9.3e-10 1.57e-06 -0.57 -0.47 Schizophrenia; chr13:79286030 chr13:79566727~79571436:+ PAAD cis rs2929278 0.589 rs11638972 ENSG00000249839.1 AC011330.5 6.53 9.37e-10 1.58e-06 0.67 0.47 Schizophrenia; chr15:43782493 chr15:43663654~43684339:- PAAD cis rs7615952 0.8 rs11915699 ENSG00000171084.14 FAM86JP 6.53 9.38e-10 1.58e-06 0.63 0.47 Blood pressure (smoking interaction); chr3:125913841 chr3:125916620~125930024:+ PAAD cis rs7811142 0.779 rs111312383 ENSG00000242294.5 STAG3L5P 6.53 9.41e-10 1.58e-06 0.37 0.47 Platelet count; chr7:100307702 chr7:100336079~100351900:+ PAAD cis rs7811142 0.779 rs28680963 ENSG00000242294.5 STAG3L5P 6.53 9.41e-10 1.58e-06 0.37 0.47 Platelet count; chr7:100307852 chr7:100336079~100351900:+ PAAD cis rs2739330 0.828 rs2877178 ENSG00000250470.1 AP000351.3 6.53 9.42e-10 1.59e-06 0.66 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23976904~23977585:- PAAD cis rs2739330 0.828 rs2154593 ENSG00000250470.1 AP000351.3 6.53 9.42e-10 1.59e-06 0.66 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23976904~23977585:- PAAD cis rs1891275 0.515 rs7092884 ENSG00000228701.1 TNKS2-AS1 6.53 9.46e-10 1.59e-06 0.58 0.47 Intelligence (multi-trait analysis); chr10:91724115 chr10:91782839~91798291:- PAAD cis rs673078 0.66 rs117091919 ENSG00000275759.1 RP11-131L12.3 -6.53 9.49e-10 1.6e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118273228 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs7314987 ENSG00000275759.1 RP11-131L12.3 -6.53 9.49e-10 1.6e-06 -0.77 -0.47 Glucose homeostasis traits; chr12:118274072 chr12:118428281~118428870:+ PAAD cis rs73086581 1 rs73086588 ENSG00000229539.1 RP11-119B16.2 6.53 9.5e-10 1.6e-06 0.7 0.47 Response to antidepressants in depression; chr20:4001577 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs6107391 ENSG00000229539.1 RP11-119B16.2 6.53 9.5e-10 1.6e-06 0.7 0.47 Response to antidepressants in depression; chr20:4002436 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs73086595 ENSG00000229539.1 RP11-119B16.2 6.53 9.5e-10 1.6e-06 0.7 0.47 Response to antidepressants in depression; chr20:4002801 chr20:3888239~3888868:- PAAD cis rs73086581 1 rs73086597 ENSG00000229539.1 RP11-119B16.2 6.53 9.5e-10 1.6e-06 0.7 0.47 Response to antidepressants in depression; chr20:4002924 chr20:3888239~3888868:- PAAD cis rs10129255 0.5 rs59939897 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106783414 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs6576231 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106783693 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs12101190 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106784149 chr14:106643132~106658258:- PAAD cis rs10129255 0.518 rs8004895 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106785139 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs8004923 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106785926 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs6576232 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106787090 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs10131875 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106792798 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs11628999 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106800208 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs7157975 ENSG00000223648.3 IGHV3-64 6.53 9.51e-10 1.6e-06 0.41 0.47 Kawasaki disease; chr14:106804049 chr14:106643132~106658258:- PAAD cis rs72772090 0.539 rs72773969 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.51e-10 1.6e-06 -0.62 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96809493 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72773917 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96775598 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs10515248 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776301 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs56213813 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776580 chr5:96784777~96785999:+ PAAD cis rs72772090 0.52 rs56325109 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776591 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11747148 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777159 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11747179 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777265 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11741100 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777541 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs55996659 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778446 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs17481759 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778991 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs111237997 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779249 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs3333 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779407 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11749811 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780221 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs67140788 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96780582 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs17481856 ENSG00000248734.2 CTD-2260A17.1 -6.53 9.53e-10 1.6e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96781104 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11747896 ENSG00000248734.2 CTD-2260A17.1 6.53 9.53e-10 1.6e-06 0.63 0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777693 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11739020 ENSG00000248734.2 CTD-2260A17.1 6.53 9.53e-10 1.6e-06 0.63 0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96778134 chr5:96784777~96785999:+ PAAD cis rs875971 0.545 rs10950025 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66158946 chr7:66493706~66495474:+ PAAD cis rs875971 0.52 rs12666485 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66160135 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs67688847 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66161064 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs7787063 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66164012 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs12673308 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66166374 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs67397473 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66168318 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs10950027 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66169164 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs73376401 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66174841 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs6460276 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66182290 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs67775320 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66193792 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs17138149 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66228193 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs17138156 ENSG00000237310.1 GS1-124K5.4 6.53 9.55e-10 1.6e-06 0.53 0.47 Aortic root size; chr7:66249708 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs4441996 ENSG00000237310.1 GS1-124K5.4 -6.53 9.55e-10 1.6e-06 -0.53 -0.47 Aortic root size; chr7:66123233 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs316324 ENSG00000237310.1 GS1-124K5.4 -6.53 9.55e-10 1.6e-06 -0.53 -0.47 Aortic root size; chr7:66145627 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs316323 ENSG00000237310.1 GS1-124K5.4 -6.53 9.55e-10 1.6e-06 -0.53 -0.47 Aortic root size; chr7:66146002 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs316316 ENSG00000237310.1 GS1-124K5.4 -6.53 9.55e-10 1.6e-06 -0.53 -0.47 Aortic root size; chr7:66149270 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs316305 ENSG00000237310.1 GS1-124K5.4 -6.53 9.55e-10 1.6e-06 -0.53 -0.47 Aortic root size; chr7:66152984 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs316306 ENSG00000237310.1 GS1-124K5.4 -6.53 9.55e-10 1.6e-06 -0.53 -0.47 Aortic root size; chr7:66153687 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs2460427 ENSG00000237310.1 GS1-124K5.4 -6.53 9.55e-10 1.6e-06 -0.53 -0.47 Aortic root size; chr7:66154218 chr7:66493706~66495474:+ PAAD cis rs3814244 1 rs3814244 ENSG00000255733.4 IFNG-AS1 -6.52 9.59e-10 1.61e-06 -0.4 -0.47 Itch intensity from mosquito bite adjusted by bite size; chr12:68019691 chr12:67989445~68234686:+ PAAD cis rs6452524 0.868 rs11746977 ENSG00000249664.1 CTD-2227C6.2 6.52 9.62e-10 1.61e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83085581 chr5:83012285~83013109:- PAAD cis rs6452524 0.836 rs62372713 ENSG00000249664.1 CTD-2227C6.2 6.52 9.62e-10 1.61e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83090635 chr5:83012285~83013109:- PAAD cis rs6452524 0.868 rs62372714 ENSG00000249664.1 CTD-2227C6.2 6.52 9.62e-10 1.61e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83095449 chr5:83012285~83013109:- PAAD cis rs6452524 0.868 rs17205699 ENSG00000249664.1 CTD-2227C6.2 6.52 9.62e-10 1.61e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83098479 chr5:83012285~83013109:- PAAD cis rs6452524 0.868 rs10057303 ENSG00000249664.1 CTD-2227C6.2 6.52 9.62e-10 1.61e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83098564 chr5:83012285~83013109:- PAAD cis rs6452524 0.868 rs2386235 ENSG00000249664.1 CTD-2227C6.2 6.52 9.62e-10 1.61e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83101452 chr5:83012285~83013109:- PAAD cis rs6452524 0.78 rs2386237 ENSG00000249664.1 CTD-2227C6.2 6.52 9.62e-10 1.61e-06 0.56 0.47 Hypertension (SNP x SNP interaction); chr5:83101852 chr5:83012285~83013109:- PAAD cis rs2882667 0.931 rs10038799 ENSG00000253404.1 AC034243.1 6.52 9.63e-10 1.61e-06 0.56 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139026594 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs2351465 ENSG00000253404.1 AC034243.1 6.52 9.63e-10 1.61e-06 0.56 0.47 Age-related hearing impairment (SNP x SNP interaction); chr5:139028162 chr5:138744434~138753309:- PAAD cis rs1075265 0.584 rs34769118 ENSG00000233266.1 HMGB1P31 6.52 9.64e-10 1.61e-06 0.58 0.47 Chronotype;Morning vs. evening chronotype; chr2:54102173 chr2:54051334~54051760:+ PAAD cis rs11098499 0.58 rs12509234 ENSG00000245958.5 RP11-33B1.1 -6.52 9.65e-10 1.62e-06 -0.39 -0.47 Corneal astigmatism; chr4:119398279 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs10014719 ENSG00000245958.5 RP11-33B1.1 -6.52 9.65e-10 1.62e-06 -0.39 -0.47 Corneal astigmatism; chr4:119399560 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10017543 ENSG00000245958.5 RP11-33B1.1 -6.52 9.65e-10 1.62e-06 -0.39 -0.47 Corneal astigmatism; chr4:119400265 chr4:119454791~119552025:+ PAAD cis rs11098499 0.908 rs7695996 ENSG00000245958.5 RP11-33B1.1 -6.52 9.65e-10 1.62e-06 -0.39 -0.47 Corneal astigmatism; chr4:119400878 chr4:119454791~119552025:+ PAAD cis rs4423214 0.61 rs12793607 ENSG00000254682.1 RP11-660L16.2 -6.52 9.66e-10 1.62e-06 -0.61 -0.47 Vitamin D levels; chr11:71418270 chr11:71448674~71452157:+ PAAD cis rs7429990 0.965 rs777015 ENSG00000229759.1 MRPS18AP1 6.52 9.67e-10 1.62e-06 0.51 0.47 Educational attainment (years of education); chr3:47895582 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7619882 ENSG00000229759.1 MRPS18AP1 6.52 9.67e-10 1.62e-06 0.51 0.47 Educational attainment (years of education); chr3:47943334 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs7653368 ENSG00000229759.1 MRPS18AP1 6.52 9.67e-10 1.62e-06 0.51 0.47 Educational attainment (years of education); chr3:47943871 chr3:48256350~48256938:- PAAD cis rs1930961 1 rs6004657 ENSG00000272977.1 CTA-390C10.10 -6.52 9.67e-10 1.62e-06 -0.92 -0.47 Bipolar disorder with mood-incongruent psychosis; chr22:25459747 chr22:25476218~25479971:+ PAAD cis rs11690935 0.788 rs10201053 ENSG00000228389.1 AC068039.4 6.52 9.69e-10 1.62e-06 0.57 0.47 Schizophrenia; chr2:172024653 chr2:171773482~171775844:+ PAAD cis rs7811142 0.83 rs28495773 ENSG00000242294.5 STAG3L5P 6.52 9.78e-10 1.64e-06 0.37 0.47 Platelet count; chr7:100345960 chr7:100336079~100351900:+ PAAD cis rs875971 0.545 rs4718325 ENSG00000237310.1 GS1-124K5.4 6.52 9.81e-10 1.64e-06 0.54 0.47 Aortic root size; chr7:66215323 chr7:66493706~66495474:+ PAAD cis rs11098499 0.955 rs13129661 ENSG00000245958.5 RP11-33B1.1 -6.52 9.83e-10 1.64e-06 -0.38 -0.47 Corneal astigmatism; chr4:119231754 chr4:119454791~119552025:+ PAAD cis rs7429990 0.813 rs7627568 ENSG00000229759.1 MRPS18AP1 -6.52 9.85e-10 1.65e-06 -0.5 -0.47 Educational attainment (years of education); chr3:48051562 chr3:48256350~48256938:- PAAD cis rs7044106 0.718 rs10616 ENSG00000226752.6 PSMD5-AS1 -6.52 9.88e-10 1.65e-06 -0.59 -0.47 Hip circumference adjusted for BMI; chr9:120601255 chr9:120824828~120854385:+ PAAD cis rs8040855 0.627 rs12905036 ENSG00000259295.5 CSPG4P12 6.52 9.89e-10 1.65e-06 0.55 0.47 Bulimia nervosa; chr15:85094557 chr15:85191438~85213905:+ PAAD cis rs10935480 0.634 rs1585488 ENSG00000239445.4 ST3GAL6-AS1 -6.52 9.9e-10 1.65e-06 -0.52 -0.47 Blood protein levels; chr3:98640819 chr3:98714330~98732651:- PAAD cis rs4722166 0.508 rs1474348 ENSG00000179428.2 AC073072.5 -6.52 9.9e-10 1.65e-06 -0.44 -0.47 Lung cancer; chr7:22728289 chr7:22725395~22727620:- PAAD cis rs72772090 0.539 rs10515247 ENSG00000248734.2 CTD-2260A17.1 -6.52 9.97e-10 1.66e-06 -0.63 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96776022 chr5:96784777~96785999:+ PAAD cis rs9545047 0.604 rs7336581 ENSG00000227676.3 LINC01068 6.52 9.99e-10 1.67e-06 0.57 0.47 Schizophrenia; chr13:79385739 chr13:79566727~79571436:+ PAAD cis rs7044106 0.512 rs7873848 ENSG00000226752.6 PSMD5-AS1 -6.52 9.99e-10 1.67e-06 -0.58 -0.47 Hip circumference adjusted for BMI; chr9:120591944 chr9:120824828~120854385:+ PAAD cis rs1928295 0.786 rs7032255 ENSG00000233569.1 RP11-500B12.1 6.52 1e-09 1.67e-06 0.51 0.47 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117637809 chr9:117648606~117657027:+ PAAD cis rs875971 0.545 rs1547529 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66258859 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs2420456 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66280619 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs7783889 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66283366 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs1909508 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66301366 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs11767262 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66302237 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs66594357 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66327797 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs10950036 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66353241 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs75840613 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66376399 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs73148639 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66390342 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs6460298 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66442783 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs35459055 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66479399 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs75577046 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66493729 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs3735147 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66505541 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs6950988 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66511428 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs73152714 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66534641 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs4718364 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66536353 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs6961853 ENSG00000237310.1 GS1-124K5.4 6.51 1.01e-09 1.69e-06 0.53 0.47 Aortic root size; chr7:66537035 chr7:66493706~66495474:+ PAAD cis rs875971 0.528 rs801213 ENSG00000237310.1 GS1-124K5.4 -6.51 1.01e-09 1.69e-06 -0.53 -0.47 Aortic root size; chr7:66549931 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs801212 ENSG00000237310.1 GS1-124K5.4 -6.51 1.01e-09 1.69e-06 -0.53 -0.47 Aortic root size; chr7:66550643 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs801199 ENSG00000237310.1 GS1-124K5.4 -6.51 1.01e-09 1.69e-06 -0.53 -0.47 Aortic root size; chr7:66560286 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs1638724 ENSG00000237310.1 GS1-124K5.4 -6.51 1.01e-09 1.69e-06 -0.53 -0.47 Aortic root size; chr7:66575494 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs1267814 ENSG00000237310.1 GS1-124K5.4 -6.51 1.01e-09 1.69e-06 -0.53 -0.47 Aortic root size; chr7:66579422 chr7:66493706~66495474:+ PAAD cis rs10129255 0.518 rs10150460 ENSG00000223648.3 IGHV3-64 -6.51 1.01e-09 1.69e-06 -0.42 -0.47 Kawasaki disease; chr14:106677179 chr14:106643132~106658258:- PAAD cis rs7044106 0.762 rs1158553 ENSG00000226752.6 PSMD5-AS1 -6.51 1.02e-09 1.69e-06 -0.62 -0.47 Hip circumference adjusted for BMI; chr9:120638696 chr9:120824828~120854385:+ PAAD cis rs4722166 0.695 rs7793125 ENSG00000179428.2 AC073072.5 -6.51 1.02e-09 1.7e-06 -0.43 -0.47 Lung cancer; chr7:22769541 chr7:22725395~22727620:- PAAD cis rs4722166 0.695 rs6946509 ENSG00000179428.2 AC073072.5 -6.51 1.02e-09 1.7e-06 -0.43 -0.47 Lung cancer; chr7:22769871 chr7:22725395~22727620:- PAAD cis rs10129255 0.53 rs11624912 ENSG00000223648.3 IGHV3-64 6.51 1.02e-09 1.7e-06 0.42 0.47 Kawasaki disease; chr14:106673891 chr14:106643132~106658258:- PAAD cis rs881375 0.501 rs10739591 ENSG00000226752.6 PSMD5-AS1 -6.51 1.02e-09 1.7e-06 -0.61 -0.47 Rheumatoid arthritis; chr9:121123450 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs10760112 ENSG00000226752.6 PSMD5-AS1 -6.51 1.02e-09 1.7e-06 -0.62 -0.47 Hip circumference adjusted for BMI; chr9:120705292 chr9:120824828~120854385:+ PAAD cis rs6452524 0.868 rs1564379 ENSG00000249664.1 CTD-2227C6.2 6.51 1.02e-09 1.7e-06 0.54 0.47 Hypertension (SNP x SNP interaction); chr5:83082143 chr5:83012285~83013109:- PAAD cis rs7615952 0.932 rs13065725 ENSG00000171084.14 FAM86JP 6.51 1.02e-09 1.7e-06 0.63 0.47 Blood pressure (smoking interaction); chr3:125913446 chr3:125916620~125930024:+ PAAD cis rs7615952 0.551 rs6438945 ENSG00000171084.14 FAM86JP 6.51 1.02e-09 1.7e-06 0.63 0.47 Blood pressure (smoking interaction); chr3:125915630 chr3:125916620~125930024:+ PAAD cis rs7615952 0.673 rs7632557 ENSG00000171084.14 FAM86JP 6.51 1.02e-09 1.7e-06 0.63 0.47 Blood pressure (smoking interaction); chr3:125916038 chr3:125916620~125930024:+ PAAD cis rs7615952 0.932 rs9841157 ENSG00000171084.14 FAM86JP 6.51 1.02e-09 1.7e-06 0.63 0.47 Blood pressure (smoking interaction); chr3:125916812 chr3:125916620~125930024:+ PAAD cis rs7615952 0.551 rs12695470 ENSG00000171084.14 FAM86JP 6.51 1.02e-09 1.7e-06 0.63 0.47 Blood pressure (smoking interaction); chr3:125916875 chr3:125916620~125930024:+ PAAD cis rs748404 0.518 rs2927085 ENSG00000249839.1 AC011330.5 -6.51 1.03e-09 1.72e-06 -0.64 -0.47 Lung cancer; chr15:43697332 chr15:43663654~43684339:- PAAD cis rs10875746 0.669 rs10875772 ENSG00000240399.1 RP1-228P16.1 -6.51 1.04e-09 1.72e-06 -0.51 -0.47 Longevity (90 years and older); chr12:48215770 chr12:48054813~48055591:- PAAD cis rs2739330 0.796 rs5760097 ENSG00000099984.9 GSTT2 -6.51 1.04e-09 1.73e-06 -0.62 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23980123~23983911:+ PAAD cis rs2739330 0.828 rs5760098 ENSG00000099984.9 GSTT2 -6.51 1.04e-09 1.73e-06 -0.62 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23980123~23983911:+ PAAD cis rs9322193 0.567 rs7742692 ENSG00000223701.3 RAET1E-AS1 6.51 1.05e-09 1.75e-06 0.55 0.47 Lung cancer; chr6:149892363 chr6:149884431~149919508:+ PAAD cis rs7829975 0.51 rs2921073 ENSG00000253893.2 FAM85B -6.51 1.06e-09 1.75e-06 -0.65 -0.47 Mood instability; chr8:8450133 chr8:8167819~8226614:- PAAD cis rs7829975 0.51 rs2979160 ENSG00000253893.2 FAM85B -6.51 1.06e-09 1.75e-06 -0.65 -0.47 Mood instability; chr8:8450156 chr8:8167819~8226614:- PAAD cis rs7945705 0.902 rs2012696 ENSG00000254860.4 TMEM9B-AS1 -6.5 1.06e-09 1.76e-06 -0.52 -0.47 Hemoglobin concentration; chr11:8974271 chr11:8964675~8977527:+ PAAD cis rs7044106 0.708 rs10760113 ENSG00000226752.6 PSMD5-AS1 -6.5 1.06e-09 1.76e-06 -0.64 -0.47 Hip circumference adjusted for BMI; chr9:120711772 chr9:120824828~120854385:+ PAAD cis rs72772090 0.539 rs56319744 ENSG00000248734.2 CTD-2260A17.1 -6.5 1.06e-09 1.76e-06 -0.62 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96806235 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs10515250 ENSG00000248734.2 CTD-2260A17.1 -6.5 1.06e-09 1.76e-06 -0.62 -0.47 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96814490 chr5:96784777~96785999:+ PAAD cis rs2283792 1 rs2283792 ENSG00000224086.5 LL22NC03-86G7.1 -6.5 1.07e-09 1.77e-06 -0.47 -0.47 Multiple sclerosis; chr22:21776836 chr22:21938293~21977632:+ PAAD cis rs73086581 1 rs73088416 ENSG00000229539.1 RP11-119B16.2 6.5 1.07e-09 1.77e-06 0.74 0.47 Response to antidepressants in depression; chr20:4014629 chr20:3888239~3888868:- PAAD cis rs10129255 0.5 rs2105989 ENSG00000223648.3 IGHV3-64 6.5 1.07e-09 1.77e-06 0.42 0.47 Kawasaki disease; chr14:106682199 chr14:106643132~106658258:- PAAD cis rs2404602 0.552 rs11072613 ENSG00000259422.1 RP11-593F23.1 -6.5 1.07e-09 1.78e-06 -0.59 -0.47 Blood metabolite levels; chr15:76669185 chr15:76174891~76181486:- PAAD cis rs11098499 0.69 rs34818745 ENSG00000245958.5 RP11-33B1.1 -6.5 1.07e-09 1.78e-06 -0.39 -0.47 Corneal astigmatism; chr4:119335900 chr4:119454791~119552025:+ PAAD cis rs950169 0.881 rs150965 ENSG00000225151.9 GOLGA2P7 -6.5 1.07e-09 1.78e-06 -0.56 -0.47 Schizophrenia; chr15:84537296 chr15:84199311~84230136:- PAAD cis rs2919917 0.59 rs2919919 ENSG00000254352.1 RP11-578O24.2 -6.5 1.08e-09 1.8e-06 -0.51 -0.47 Lymphocyte counts; chr8:78745274 chr8:78723796~78724136:- PAAD cis rs12439619 0.508 rs8042665 ENSG00000278603.1 RP13-608F4.5 6.5 1.09e-09 1.8e-06 0.61 0.47 Intelligence (multi-trait analysis); chr15:82189008 chr15:82472203~82472426:+ PAAD cis rs7811142 0.83 rs118119933 ENSG00000242294.5 STAG3L5P 6.5 1.1e-09 1.81e-06 0.38 0.47 Platelet count; chr7:100341427 chr7:100336079~100351900:+ PAAD cis rs7429990 0.965 rs11709289 ENSG00000229759.1 MRPS18AP1 6.5 1.1e-09 1.82e-06 0.55 0.47 Educational attainment (years of education); chr3:47765159 chr3:48256350~48256938:- PAAD cis rs875971 0.571 rs160641 ENSG00000237310.1 GS1-124K5.4 -6.5 1.11e-09 1.83e-06 -0.53 -0.47 Aortic root size; chr7:66112359 chr7:66493706~66495474:+ PAAD cis rs9545047 0.584 rs1886494 ENSG00000227676.3 LINC01068 -6.5 1.11e-09 1.83e-06 -0.56 -0.47 Schizophrenia; chr13:79403005 chr13:79566727~79571436:+ PAAD cis rs7044106 0.708 rs959558 ENSG00000226752.6 PSMD5-AS1 -6.5 1.11e-09 1.84e-06 -0.61 -0.47 Hip circumference adjusted for BMI; chr9:120606633 chr9:120824828~120854385:+ PAAD cis rs6538678 0.857 rs4762626 ENSG00000258343.1 RP11-536G4.2 -6.49 1.12e-09 1.85e-06 -0.67 -0.47 Lupus nephritis in systemic lupus erythematosus; chr12:95811383 chr12:95795345~95858839:- PAAD cis rs9545047 0.604 rs7332367 ENSG00000227676.3 LINC01068 -6.49 1.13e-09 1.86e-06 -0.55 -0.47 Schizophrenia; chr13:79339816 chr13:79566727~79571436:+ PAAD cis rs9322193 0.566 rs5024811 ENSG00000216906.2 RP11-350J20.9 -6.49 1.13e-09 1.86e-06 -0.66 -0.47 Lung cancer; chr6:149924898 chr6:149904243~149906418:+ PAAD cis rs1075265 0.528 rs2018747 ENSG00000233266.1 HMGB1P31 6.49 1.13e-09 1.86e-06 0.58 0.47 Chronotype;Morning vs. evening chronotype; chr2:54082487 chr2:54051334~54051760:+ PAAD cis rs1075265 0.547 rs6741891 ENSG00000233266.1 HMGB1P31 6.49 1.13e-09 1.86e-06 0.58 0.47 Chronotype;Morning vs. evening chronotype; chr2:54088529 chr2:54051334~54051760:+ PAAD cis rs4423214 0.61 rs12789253 ENSG00000254682.1 RP11-660L16.2 6.49 1.13e-09 1.87e-06 0.6 0.47 Vitamin D levels; chr11:71414719 chr11:71448674~71452157:+ PAAD cis rs2919917 0.628 rs1036751 ENSG00000254352.1 RP11-578O24.2 -6.49 1.14e-09 1.87e-06 -0.51 -0.47 Lymphocyte counts; chr8:78729671 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs2583759 ENSG00000254352.1 RP11-578O24.2 -6.49 1.14e-09 1.87e-06 -0.51 -0.47 Lymphocyte counts; chr8:78732729 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs894222 ENSG00000254352.1 RP11-578O24.2 -6.49 1.14e-09 1.87e-06 -0.51 -0.47 Lymphocyte counts; chr8:78737034 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs2583778 ENSG00000254352.1 RP11-578O24.2 -6.49 1.14e-09 1.87e-06 -0.51 -0.47 Lymphocyte counts; chr8:78738906 chr8:78723796~78724136:- PAAD cis rs9494142 0.592 rs1547247 ENSG00000232876.1 CTA-212D2.2 -6.49 1.14e-09 1.88e-06 -0.62 -0.47 Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts; chr6:135069698 chr6:135055033~135060550:+ PAAD cis rs755249 0.701 rs1180342 ENSG00000237624.1 OXCT2P1 -6.49 1.14e-09 1.88e-06 -0.61 -0.47 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527206 chr1:39514956~39516490:+ PAAD cis rs950169 0.763 rs35372971 ENSG00000225151.9 GOLGA2P7 -6.49 1.14e-09 1.89e-06 -0.56 -0.47 Schizophrenia; chr15:84387097 chr15:84199311~84230136:- PAAD cis rs2919917 0.662 rs1483572 ENSG00000254352.1 RP11-578O24.2 6.49 1.15e-09 1.89e-06 0.47 0.47 Lymphocyte counts; chr8:78723008 chr8:78723796~78724136:- PAAD cis rs2412819 0.599 rs2470120 ENSG00000249839.1 AC011330.5 -6.49 1.16e-09 1.9e-06 -0.63 -0.47 Lung cancer; chr15:43636872 chr15:43663654~43684339:- PAAD cis rs6452524 0.967 rs1031901 ENSG00000249664.1 CTD-2227C6.2 6.49 1.16e-09 1.91e-06 0.53 0.47 Hypertension (SNP x SNP interaction); chr5:83147904 chr5:83012285~83013109:- PAAD cis rs6452524 0.839 rs28745307 ENSG00000249664.1 CTD-2227C6.2 6.49 1.17e-09 1.92e-06 0.57 0.47 Hypertension (SNP x SNP interaction); chr5:83122099 chr5:83012285~83013109:- PAAD cis rs11098499 0.954 rs3890049 ENSG00000245958.5 RP11-33B1.1 -6.49 1.17e-09 1.93e-06 -0.39 -0.47 Corneal astigmatism; chr4:119405128 chr4:119454791~119552025:+ PAAD cis rs11690935 0.851 rs10930502 ENSG00000228389.1 AC068039.4 6.49 1.18e-09 1.93e-06 0.56 0.47 Schizophrenia; chr2:172025679 chr2:171773482~171775844:+ PAAD cis rs2739330 0.753 rs4822452 ENSG00000250470.1 AP000351.3 6.49 1.18e-09 1.93e-06 0.65 0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23976904~23977585:- PAAD cis rs8040855 0.791 rs8042888 ENSG00000259295.5 CSPG4P12 -6.48 1.18e-09 1.94e-06 -0.55 -0.47 Bulimia nervosa; chr15:85152360 chr15:85191438~85213905:+ PAAD cis rs172166 0.516 rs1225715 ENSG00000216901.1 AL022393.7 -6.48 1.18e-09 1.94e-06 -0.57 -0.47 Cardiac Troponin-T levels; chr6:28145595 chr6:28176188~28176674:+ PAAD cis rs6700559 0.967 rs10919992 ENSG00000260088.1 RP11-92G12.3 -6.48 1.18e-09 1.94e-06 -0.6 -0.47 Coronary artery disease; chr1:200638338 chr1:200669507~200694250:+ PAAD cis rs950169 0.922 rs4586394 ENSG00000259728.4 LINC00933 -6.48 1.18e-09 1.94e-06 -0.58 -0.47 Schizophrenia; chr15:84153633 chr15:84570649~84580175:+ PAAD cis rs875971 0.597 rs11763224 ENSG00000237310.1 GS1-124K5.4 6.48 1.18e-09 1.95e-06 0.53 0.47 Aortic root size; chr7:66518628 chr7:66493706~66495474:+ PAAD cis rs6452524 0.901 rs72767146 ENSG00000249664.1 CTD-2227C6.2 6.48 1.19e-09 1.95e-06 0.55 0.47 Hypertension (SNP x SNP interaction); chr5:83126365 chr5:83012285~83013109:- PAAD cis rs9660180 0.935 rs9786942 ENSG00000231050.1 RP1-140A9.1 6.48 1.2e-09 1.97e-06 0.55 0.47 Body mass index; chr1:1827774 chr1:1891471~1892658:+ PAAD cis rs9660180 0.934 rs34849348 ENSG00000231050.1 RP1-140A9.1 6.48 1.2e-09 1.97e-06 0.55 0.47 Body mass index; chr1:1831318 chr1:1891471~1892658:+ PAAD cis rs9660180 0.967 rs10907191 ENSG00000231050.1 RP1-140A9.1 6.48 1.2e-09 1.97e-06 0.55 0.47 Body mass index; chr1:1843381 chr1:1891471~1892658:+ PAAD cis rs10875746 0.951 rs11168433 ENSG00000240399.1 RP1-228P16.1 -6.48 1.2e-09 1.98e-06 -0.51 -0.47 Longevity (90 years and older); chr12:48164281 chr12:48054813~48055591:- PAAD cis rs10129255 0.5 rs1974468 ENSG00000223648.3 IGHV3-64 6.48 1.21e-09 1.98e-06 0.42 0.47 Kawasaki disease; chr14:106686149 chr14:106643132~106658258:- PAAD cis rs67180937 0.645 rs1909197 ENSG00000272750.1 RP11-378J18.8 -6.48 1.21e-09 1.99e-06 -0.54 -0.47 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222645879 chr1:222658867~222661512:- PAAD cis rs8040855 0.965 rs4843027 ENSG00000259295.5 CSPG4P12 -6.48 1.22e-09 1.99e-06 -0.52 -0.47 Bulimia nervosa; chr15:85171892 chr15:85191438~85213905:+ PAAD cis rs11098499 0.954 rs2389803 ENSG00000245958.5 RP11-33B1.1 6.48 1.22e-09 1.99e-06 0.4 0.47 Corneal astigmatism; chr4:119472356 chr4:119454791~119552025:+ PAAD cis rs2739330 0.761 rs5760176 ENSG00000206090.4 AP000350.7 -6.48 1.22e-09 2e-06 -0.61 -0.47 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23939998~23942798:+ PAAD cis rs7044106 0.762 rs1470307 ENSG00000226752.6 PSMD5-AS1 -6.48 1.22e-09 2e-06 -0.63 -0.47 Hip circumference adjusted for BMI; chr9:120670761 chr9:120824828~120854385:+ PAAD cis rs9660180 0.935 rs2180311 ENSG00000231050.1 RP1-140A9.1 6.48 1.23e-09 2.01e-06 0.55 0.47 Body mass index; chr1:1817295 chr1:1891471~1892658:+ PAAD cis rs9660180 0.967 rs6664664 ENSG00000231050.1 RP1-140A9.1 6.48 1.23e-09 2.01e-06 0.55 0.47 Body mass index; chr1:1819825 chr1:1891471~1892658:+ PAAD cis rs9322193 0.607 rs6925151 ENSG00000216906.2 RP11-350J20.9 6.48 1.23e-09 2.02e-06 0.68 0.47 Lung cancer; chr6:149889587 chr6:149904243~149906418:+ PAAD cis rs2283792 1 rs5999521 ENSG00000224086.5 LL22NC03-86G7.1 -6.48 1.24e-09 2.03e-06 -0.47 -0.46 Multiple sclerosis; chr22:21792110 chr22:21938293~21977632:+ PAAD cis rs3096299 0.503 rs4785677 ENSG00000274627.1 RP11-104N10.2 6.48 1.24e-09 2.03e-06 0.4 0.46 Multiple myeloma (IgH translocation); chr16:89488693 chr16:89516797~89522217:+ PAAD cis rs7044106 0.791 rs4836830 ENSG00000226752.6 PSMD5-AS1 -6.48 1.24e-09 2.03e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120721390 chr9:120824828~120854385:+ PAAD cis rs2739330 0.732 rs5760175 ENSG00000206090.4 AP000350.7 6.47 1.24e-09 2.03e-06 0.61 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23939998~23942798:+ PAAD cis rs2739330 0.892 rs5751776 ENSG00000099984.9 GSTT2 -6.47 1.24e-09 2.03e-06 -0.6 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23980123~23983911:+ PAAD cis rs7945705 0.712 rs61876274 ENSG00000254860.4 TMEM9B-AS1 -6.47 1.25e-09 2.04e-06 -0.51 -0.46 Hemoglobin concentration; chr11:8997643 chr11:8964675~8977527:+ PAAD cis rs1891275 0.55 rs4933694 ENSG00000228701.1 TNKS2-AS1 -6.47 1.25e-09 2.05e-06 -0.58 -0.46 Intelligence (multi-trait analysis); chr10:91739456 chr10:91782839~91798291:- PAAD cis rs6452524 0.869 rs10051155 ENSG00000249664.1 CTD-2227C6.2 6.47 1.26e-09 2.06e-06 0.57 0.46 Hypertension (SNP x SNP interaction); chr5:83160851 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs72767160 ENSG00000249664.1 CTD-2227C6.2 6.47 1.26e-09 2.06e-06 0.57 0.46 Hypertension (SNP x SNP interaction); chr5:83161102 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs5000997 ENSG00000249664.1 CTD-2227C6.2 6.47 1.26e-09 2.06e-06 0.57 0.46 Hypertension (SNP x SNP interaction); chr5:83164248 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs10043698 ENSG00000249664.1 CTD-2227C6.2 6.47 1.26e-09 2.06e-06 0.57 0.46 Hypertension (SNP x SNP interaction); chr5:83169100 chr5:83012285~83013109:- PAAD cis rs6452524 0.935 rs6887915 ENSG00000249664.1 CTD-2227C6.2 6.47 1.26e-09 2.06e-06 0.57 0.46 Hypertension (SNP x SNP interaction); chr5:83170837 chr5:83012285~83013109:- PAAD cis rs12439619 0.508 rs8023960 ENSG00000278603.1 RP13-608F4.5 6.47 1.26e-09 2.07e-06 0.61 0.46 Intelligence (multi-trait analysis); chr15:82206704 chr15:82472203~82472426:+ PAAD cis rs8040855 1 rs8040855 ENSG00000259295.5 CSPG4P12 -6.47 1.27e-09 2.07e-06 -0.52 -0.46 Bulimia nervosa; chr15:85155976 chr15:85191438~85213905:+ PAAD cis rs2739330 0.731 rs5751792 ENSG00000206090.4 AP000350.7 6.47 1.27e-09 2.07e-06 0.61 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23939998~23942798:+ PAAD cis rs2117029 0.586 rs11168874 ENSG00000258017.1 RP11-386G11.10 -6.47 1.27e-09 2.07e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49133753 chr12:49127782~49147869:+ PAAD cis rs2882667 0.931 rs10075893 ENSG00000253404.1 AC034243.1 -6.47 1.27e-09 2.08e-06 -0.57 -0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139020182 chr5:138744434~138753309:- PAAD cis rs7945705 0.875 rs4929914 ENSG00000254860.4 TMEM9B-AS1 6.47 1.27e-09 2.08e-06 0.5 0.46 Hemoglobin concentration; chr11:8802841 chr11:8964675~8977527:+ PAAD cis rs6504622 0.755 rs12938690 ENSG00000262879.4 RP11-156P1.3 -6.47 1.27e-09 2.08e-06 -0.47 -0.46 Orofacial clefts; chr17:46997999 chr17:46984045~47100323:- PAAD cis rs4722166 0.508 rs2069832 ENSG00000179428.2 AC073072.5 -6.47 1.28e-09 2.08e-06 -0.44 -0.46 Lung cancer; chr7:22727814 chr7:22725395~22727620:- PAAD cis rs1800795 0.901 rs2069833 ENSG00000179428.2 AC073072.5 -6.47 1.28e-09 2.08e-06 -0.44 -0.46 Cerebrospinal fluid clusterin levels in APOEe4- carriers; chr7:22728045 chr7:22725395~22727620:- PAAD cis rs11098499 0.954 rs12505469 ENSG00000245958.5 RP11-33B1.1 -6.47 1.29e-09 2.1e-06 -0.38 -0.46 Corneal astigmatism; chr4:119328430 chr4:119454791~119552025:+ PAAD cis rs11155671 0.53 rs9371544 ENSG00000268592.3 RAET1E-AS1 6.47 1.29e-09 2.1e-06 0.56 0.46 Testicular germ cell tumor; chr6:149896224 chr6:149863494~149919507:+ PAAD cis rs9322193 0.607 rs12209310 ENSG00000216906.2 RP11-350J20.9 6.47 1.29e-09 2.11e-06 0.67 0.46 Lung cancer; chr6:149904882 chr6:149904243~149906418:+ PAAD cis rs9322193 0.607 rs12210822 ENSG00000216906.2 RP11-350J20.9 6.47 1.29e-09 2.11e-06 0.67 0.46 Lung cancer; chr6:149905356 chr6:149904243~149906418:+ PAAD cis rs2739330 0.929 rs5751775 ENSG00000099984.9 GSTT2 -6.47 1.29e-09 2.11e-06 -0.6 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23980123~23983911:+ PAAD cis rs2882667 0.931 rs3749665 ENSG00000253404.1 AC034243.1 6.47 1.29e-09 2.11e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139021522 chr5:138744434~138753309:- PAAD cis rs7586673 1 rs7586673 ENSG00000227403.1 AC009299.3 -6.47 1.29e-09 2.11e-06 -0.62 -0.46 Intelligence (multi-trait analysis); chr2:161067009 chr2:161244739~161249050:+ PAAD cis rs7586673 1 rs16845584 ENSG00000227403.1 AC009299.3 6.47 1.29e-09 2.11e-06 0.62 0.46 Intelligence (multi-trait analysis); chr2:161067319 chr2:161244739~161249050:+ PAAD cis rs4718428 0.672 rs36038499 ENSG00000226824.5 RP4-756H11.3 -6.47 1.29e-09 2.11e-06 -0.62 -0.46 Corneal structure; chr7:66824628 chr7:66654538~66669855:+ PAAD cis rs9532669 0.89 rs11619117 ENSG00000176268.5 CYCSP34 6.47 1.3e-09 2.12e-06 0.45 0.46 Cervical cancer; chr13:40880020 chr13:40863599~40863902:- PAAD cis rs2739330 0.828 rs2186366 ENSG00000099984.9 GSTT2 6.46 1.3e-09 2.13e-06 0.59 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23980123~23983911:+ PAAD cis rs8040855 0.756 rs2342118 ENSG00000259295.5 CSPG4P12 -6.46 1.31e-09 2.14e-06 -0.54 -0.46 Bulimia nervosa; chr15:85149785 chr15:85191438~85213905:+ PAAD cis rs10129255 0.5 rs8021941 ENSG00000223648.3 IGHV3-64 6.46 1.32e-09 2.15e-06 0.42 0.46 Kawasaki disease; chr14:106781490 chr14:106643132~106658258:- PAAD cis rs1150668 0.83 rs2023493 ENSG00000216901.1 AL022393.7 6.46 1.32e-09 2.15e-06 0.57 0.46 Pubertal anthropometrics; chr6:28432385 chr6:28176188~28176674:+ PAAD cis rs673078 0.66 rs17440364 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118186613 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs75752792 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118187005 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs75571641 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118187012 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs17512177 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118192335 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs17512198 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118194217 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs10507286 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118197101 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs61945180 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118216335 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs61945181 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118216651 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs61945183 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118221966 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs16948193 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118227115 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs61945187 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118228989 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs61945190 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118231345 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs7977403 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118233446 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs73205512 ENSG00000275759.1 RP11-131L12.3 -6.46 1.33e-09 2.17e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118235770 chr12:118428281~118428870:+ PAAD cis rs7115242 0.567 rs10047462 ENSG00000254851.1 RP11-109L13.1 -6.46 1.33e-09 2.17e-06 -0.84 -0.46 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116851325 chr11:117135528~117138582:+ PAAD cis rs9322193 0.607 rs9371228 ENSG00000216906.2 RP11-350J20.9 -6.46 1.33e-09 2.17e-06 -0.67 -0.46 Lung cancer; chr6:149921977 chr6:149904243~149906418:+ PAAD cis rs9322193 0.566 rs4870118 ENSG00000216906.2 RP11-350J20.9 -6.46 1.33e-09 2.17e-06 -0.67 -0.46 Lung cancer; chr6:149923877 chr6:149904243~149906418:+ PAAD cis rs9322193 0.566 rs4869767 ENSG00000216906.2 RP11-350J20.9 -6.46 1.33e-09 2.17e-06 -0.67 -0.46 Lung cancer; chr6:149923974 chr6:149904243~149906418:+ PAAD cis rs9322193 0.566 rs4869768 ENSG00000216906.2 RP11-350J20.9 -6.46 1.33e-09 2.17e-06 -0.67 -0.46 Lung cancer; chr6:149924067 chr6:149904243~149906418:+ PAAD cis rs6452524 0.868 rs10079372 ENSG00000249664.1 CTD-2227C6.2 6.46 1.34e-09 2.18e-06 0.55 0.46 Hypertension (SNP x SNP interaction); chr5:83117113 chr5:83012285~83013109:- PAAD cis rs7044106 0.762 rs1547268 ENSG00000226752.6 PSMD5-AS1 -6.46 1.35e-09 2.19e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120646410 chr9:120824828~120854385:+ PAAD cis rs2919917 0.628 rs2717540 ENSG00000254352.1 RP11-578O24.2 6.46 1.35e-09 2.2e-06 0.51 0.46 Lymphocyte counts; chr8:78710128 chr8:78723796~78724136:- PAAD cis rs73086581 1 rs17287822 ENSG00000229539.1 RP11-119B16.2 6.46 1.35e-09 2.2e-06 0.69 0.46 Response to antidepressants in depression; chr20:3997889 chr20:3888239~3888868:- PAAD cis rs7396835 0.866 rs6589571 ENSG00000254851.1 RP11-109L13.1 -6.46 1.36e-09 2.21e-06 -0.78 -0.46 Quantitative traits; chr11:116809702 chr11:117135528~117138582:+ PAAD cis rs9322193 0.566 rs3922947 ENSG00000216906.2 RP11-350J20.9 -6.46 1.36e-09 2.21e-06 -0.67 -0.46 Lung cancer; chr6:149924856 chr6:149904243~149906418:+ PAAD cis rs8040855 0.597 rs12902942 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85041573 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs12900012 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85046955 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs12909130 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85047270 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs11630697 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85063214 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs11634975 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85063247 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs4980357 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85064878 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs4980356 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85064901 chr15:85191438~85213905:+ PAAD cis rs8040855 0.658 rs11634877 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85068246 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs11632175 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85068449 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs62019482 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85071796 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs11631548 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85076017 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs1532776 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85081383 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs17540307 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85090614 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs12913859 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85095187 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs3816105 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85097680 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs2304418 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85097752 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs4843019 ENSG00000259295.5 CSPG4P12 -6.45 1.38e-09 2.24e-06 -0.54 -0.46 Bulimia nervosa; chr15:85101228 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs11637512 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85105528 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs17541051 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85106122 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs35668291 ENSG00000259295.5 CSPG4P12 6.45 1.38e-09 2.24e-06 0.54 0.46 Bulimia nervosa; chr15:85109582 chr15:85191438~85213905:+ PAAD cis rs7044106 0.762 rs1867254 ENSG00000226752.6 PSMD5-AS1 -6.45 1.38e-09 2.24e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120666800 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs12003646 ENSG00000226752.6 PSMD5-AS1 -6.45 1.38e-09 2.24e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120708343 chr9:120824828~120854385:+ PAAD cis rs2919917 0.628 rs2717544 ENSG00000254352.1 RP11-578O24.2 -6.45 1.38e-09 2.24e-06 -0.5 -0.46 Lymphocyte counts; chr8:78724307 chr8:78723796~78724136:- PAAD cis rs858239 0.932 rs1624451 ENSG00000226816.2 AC005082.12 -6.45 1.39e-09 2.25e-06 -0.52 -0.46 Cerebrospinal fluid biomarker levels; chr7:23222816 chr7:23206013~23208045:+ PAAD cis rs10129255 0.5 rs8011115 ENSG00000223648.3 IGHV3-64 6.45 1.39e-09 2.26e-06 0.41 0.46 Kawasaki disease; chr14:106786292 chr14:106643132~106658258:- PAAD cis rs2283792 0.871 rs8136867 ENSG00000224086.5 LL22NC03-86G7.1 -6.45 1.39e-09 2.26e-06 -0.48 -0.46 Multiple sclerosis; chr22:21850504 chr22:21938293~21977632:+ PAAD cis rs6452524 1 rs7738033 ENSG00000249664.1 CTD-2227C6.2 6.45 1.4e-09 2.26e-06 0.52 0.46 Hypertension (SNP x SNP interaction); chr5:83135470 chr5:83012285~83013109:- PAAD cis rs6452524 1 rs6860239 ENSG00000249664.1 CTD-2227C6.2 6.45 1.4e-09 2.26e-06 0.52 0.46 Hypertension (SNP x SNP interaction); chr5:83136022 chr5:83012285~83013109:- PAAD cis rs7945705 0.747 rs1980428 ENSG00000254860.4 TMEM9B-AS1 -6.45 1.4e-09 2.26e-06 -0.5 -0.46 Hemoglobin concentration; chr11:8988950 chr11:8964675~8977527:+ PAAD cis rs7945705 0.692 rs11042149 ENSG00000254860.4 TMEM9B-AS1 6.45 1.4e-09 2.26e-06 0.5 0.46 Hemoglobin concentration; chr11:8989190 chr11:8964675~8977527:+ PAAD cis rs7945705 0.747 rs11042150 ENSG00000254860.4 TMEM9B-AS1 6.45 1.4e-09 2.26e-06 0.5 0.46 Hemoglobin concentration; chr11:8989272 chr11:8964675~8977527:+ PAAD cis rs7044106 0.762 rs3903886 ENSG00000226752.6 PSMD5-AS1 6.45 1.4e-09 2.27e-06 0.6 0.46 Hip circumference adjusted for BMI; chr9:120621368 chr9:120824828~120854385:+ PAAD cis rs4423214 0.515 rs4944042 ENSG00000254682.1 RP11-660L16.2 6.45 1.41e-09 2.28e-06 0.59 0.46 Vitamin D levels; chr11:71407742 chr11:71448674~71452157:+ PAAD cis rs9532669 0.926 rs9532654 ENSG00000176268.5 CYCSP34 6.45 1.41e-09 2.28e-06 0.45 0.46 Cervical cancer; chr13:40909812 chr13:40863599~40863902:- PAAD cis rs875971 0.502 rs2465121 ENSG00000237310.1 GS1-124K5.4 -6.45 1.41e-09 2.28e-06 -0.53 -0.46 Aortic root size; chr7:66156017 chr7:66493706~66495474:+ PAAD cis rs1061377 0.76 rs7678457 ENSG00000249207.1 RP11-360F5.1 -6.45 1.42e-09 2.29e-06 -0.52 -0.46 Uric acid levels; chr4:39136041 chr4:39112677~39126818:- PAAD cis rs7044106 0.762 rs1158554 ENSG00000226752.6 PSMD5-AS1 -6.45 1.42e-09 2.3e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120638620 chr9:120824828~120854385:+ PAAD cis rs11098499 1 rs3749591 ENSG00000245958.5 RP11-33B1.1 -6.45 1.43e-09 2.31e-06 -0.38 -0.46 Corneal astigmatism; chr4:119292875 chr4:119454791~119552025:+ PAAD cis rs9545047 0.604 rs9601217 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79359797 chr13:79566727~79571436:+ PAAD cis rs9545047 0.584 rs9565485 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79307428 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs28579970 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79308726 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs1980883 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79310629 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9565486 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79317469 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs12875039 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79327449 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9285310 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79328340 chr13:79566727~79571436:+ PAAD cis rs9545047 0.625 rs9593391 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79329168 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs7988784 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79335337 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9574406 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79338982 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9574410 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79343091 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs2274555 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79344188 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9565491 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79346037 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9318623 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79346913 chr13:79566727~79571436:+ PAAD cis rs9545047 0.564 rs7998837 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79349190 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9574411 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79354342 chr13:79566727~79571436:+ PAAD cis rs9545047 0.584 rs7995243 ENSG00000227676.3 LINC01068 -6.45 1.43e-09 2.31e-06 -0.56 -0.46 Schizophrenia; chr13:79358645 chr13:79566727~79571436:+ PAAD cis rs2739330 0.76 rs1002286 ENSG00000231271.1 AP000350.8 -6.45 1.43e-09 2.31e-06 -0.59 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23949918~23954042:+ PAAD cis rs858239 1 rs156425 ENSG00000226816.2 AC005082.12 -6.45 1.43e-09 2.32e-06 -0.49 -0.46 Cerebrospinal fluid biomarker levels; chr7:23269500 chr7:23206013~23208045:+ PAAD cis rs7829975 0.688 rs7817376 ENSG00000253893.2 FAM85B 6.45 1.43e-09 2.32e-06 0.62 0.46 Mood instability; chr8:8523020 chr8:8167819~8226614:- PAAD cis rs6504622 0.755 rs12942936 ENSG00000262879.4 RP11-156P1.3 -6.45 1.44e-09 2.33e-06 -0.48 -0.46 Orofacial clefts; chr17:47075062 chr17:46984045~47100323:- PAAD cis rs9322193 0.566 rs12528243 ENSG00000216906.2 RP11-350J20.9 6.45 1.44e-09 2.33e-06 0.67 0.46 Lung cancer; chr6:149898491 chr6:149904243~149906418:+ PAAD cis rs5760092 0.842 rs5760103 ENSG00000273295.1 AP000350.5 6.45 1.45e-09 2.34e-06 0.77 0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23906594 chr22:23901432~23907068:- PAAD cis rs858239 1 rs166663 ENSG00000226816.2 AC005082.12 6.45 1.45e-09 2.34e-06 0.51 0.46 Cerebrospinal fluid biomarker levels; chr7:23277123 chr7:23206013~23208045:+ PAAD cis rs72772090 0.539 rs3335 ENSG00000248734.2 CTD-2260A17.1 -6.44 1.45e-09 2.34e-06 -0.62 -0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779366 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs3334 ENSG00000248734.2 CTD-2260A17.1 -6.44 1.45e-09 2.34e-06 -0.62 -0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96779381 chr5:96784777~96785999:+ PAAD cis rs2919917 0.628 rs2625663 ENSG00000254352.1 RP11-578O24.2 6.44 1.46e-09 2.35e-06 0.51 0.46 Lymphocyte counts; chr8:78718106 chr8:78723796~78724136:- PAAD cis rs11673344 0.536 rs62108291 ENSG00000226686.6 LINC01535 6.44 1.46e-09 2.35e-06 0.6 0.46 Obesity-related traits; chr19:37659457 chr19:37251912~37265535:+ PAAD cis rs9532669 0.889 rs6560964 ENSG00000176268.5 CYCSP34 6.44 1.46e-09 2.36e-06 0.44 0.46 Cervical cancer; chr13:40871132 chr13:40863599~40863902:- PAAD cis rs7714584 1 rs7724036 ENSG00000197083.10 ZNF300P1 -6.44 1.46e-09 2.36e-06 -0.65 -0.46 Crohn's disease; chr5:150905246 chr5:150930645~150946289:- PAAD cis rs11098499 0.954 rs67265404 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119438115 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs9759478 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119446843 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs71629403 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119451412 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs28571712 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119454825 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs9994730 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119460409 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs11098526 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119469204 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs12499324 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119472631 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs1480931 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119474654 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs9998585 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119475647 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs6842762 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119477081 chr4:119454791~119552025:+ PAAD cis rs11098499 0.908 rs11098527 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119478751 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10518328 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119480624 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs6848389 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119481467 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs6822679 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119481547 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs4577559 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119482888 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs7656252 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119483113 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs28845498 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119484031 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs28753180 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119484212 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs56270433 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119484875 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10006706 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119487997 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs7681544 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119490100 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs11940028 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119490752 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs11935596 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119491302 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs12507964 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119491906 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs11098530 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119491999 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs6834796 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119493538 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs11729521 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119495633 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs11734241 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119495717 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs17006190 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119497683 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs28685688 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119499179 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs7687843 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119500056 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs2306455 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119500814 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10031483 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119501481 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs10031665 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119501697 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs3733519 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119502293 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs3733523 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119502564 chr4:119454791~119552025:+ PAAD cis rs11098499 0.954 rs12510138 ENSG00000245958.5 RP11-33B1.1 -6.44 1.47e-09 2.37e-06 -0.39 -0.46 Corneal astigmatism; chr4:119502780 chr4:119454791~119552025:+ PAAD cis rs9640161 0.75 rs55974958 ENSG00000261305.1 RP4-584D14.7 6.44 1.48e-09 2.38e-06 0.71 0.46 Blood protein levels;Circulating chemerin levels; chr7:150340838 chr7:150341771~150342607:+ PAAD cis rs9640161 0.75 rs61421252 ENSG00000261305.1 RP4-584D14.7 6.44 1.48e-09 2.38e-06 0.71 0.46 Blood protein levels;Circulating chemerin levels; chr7:150340883 chr7:150341771~150342607:+ PAAD cis rs9640161 0.75 rs17173617 ENSG00000261305.1 RP4-584D14.7 6.44 1.48e-09 2.38e-06 0.71 0.46 Blood protein levels;Circulating chemerin levels; chr7:150340934 chr7:150341771~150342607:+ PAAD cis rs9898641 1 rs9898641 ENSG00000266992.1 DHX40P1 6.44 1.48e-09 2.39e-06 0.5 0.46 Interleukin-1-beta levels; chr17:59493672 chr17:59976009~60002384:- PAAD cis rs11098499 0.908 rs1002152 ENSG00000245958.5 RP11-33B1.1 -6.44 1.48e-09 2.39e-06 -0.38 -0.46 Corneal astigmatism; chr4:119352232 chr4:119454791~119552025:+ PAAD cis rs6452524 0.746 rs28745311 ENSG00000249664.1 CTD-2227C6.2 6.44 1.49e-09 2.39e-06 0.56 0.46 Hypertension (SNP x SNP interaction); chr5:83123030 chr5:83012285~83013109:- PAAD cis rs6452524 0.901 rs12188673 ENSG00000249664.1 CTD-2227C6.2 6.44 1.49e-09 2.39e-06 0.56 0.46 Hypertension (SNP x SNP interaction); chr5:83126268 chr5:83012285~83013109:- PAAD cis rs6452524 0.87 rs6452511 ENSG00000249664.1 CTD-2227C6.2 6.44 1.49e-09 2.39e-06 0.56 0.46 Hypertension (SNP x SNP interaction); chr5:83127403 chr5:83012285~83013109:- PAAD cis rs2404602 0.591 rs11635162 ENSG00000259422.1 RP11-593F23.1 -6.44 1.49e-09 2.39e-06 -0.58 -0.46 Blood metabolite levels; chr15:76658764 chr15:76174891~76181486:- PAAD cis rs2404602 0.575 rs11633309 ENSG00000259422.1 RP11-593F23.1 -6.44 1.49e-09 2.39e-06 -0.58 -0.46 Blood metabolite levels; chr15:76670008 chr15:76174891~76181486:- PAAD cis rs2404602 0.53 rs12915184 ENSG00000259422.1 RP11-593F23.1 -6.44 1.49e-09 2.39e-06 -0.58 -0.46 Blood metabolite levels; chr15:76673581 chr15:76174891~76181486:- PAAD cis rs2283792 0.622 rs239917 ENSG00000228050.1 TOP3BP1 6.44 1.5e-09 2.41e-06 0.52 0.46 Multiple sclerosis; chr22:21960091 chr22:22223187~22224566:- PAAD cis rs35160687 0.901 rs12620833 ENSG00000273080.1 RP11-301O19.1 6.44 1.5e-09 2.41e-06 0.53 0.46 Night sleep phenotypes; chr2:86245747 chr2:86195590~86196049:+ PAAD cis rs11673344 0.566 rs10419281 ENSG00000226686.6 LINC01535 -6.44 1.51e-09 2.42e-06 -0.55 -0.46 Obesity-related traits; chr19:37459351 chr19:37251912~37265535:+ PAAD cis rs7500321 1 rs7500321 ENSG00000259982.1 CDC37P1 -6.44 1.51e-09 2.43e-06 -0.56 -0.46 Intelligence (multi-trait analysis); chr16:28965699 chr16:28700294~28701540:- PAAD cis rs9660180 0.78 rs12038111 ENSG00000231050.1 RP1-140A9.1 6.44 1.51e-09 2.43e-06 0.55 0.46 Body mass index; chr1:1772410 chr1:1891471~1892658:+ PAAD cis rs9660180 0.836 rs12038134 ENSG00000231050.1 RP1-140A9.1 6.44 1.51e-09 2.43e-06 0.55 0.46 Body mass index; chr1:1772426 chr1:1891471~1892658:+ PAAD cis rs9660180 0.836 rs72634845 ENSG00000231050.1 RP1-140A9.1 6.44 1.51e-09 2.43e-06 0.55 0.46 Body mass index; chr1:1773460 chr1:1891471~1892658:+ PAAD cis rs9660180 0.868 rs72634846 ENSG00000231050.1 RP1-140A9.1 6.44 1.51e-09 2.43e-06 0.55 0.46 Body mass index; chr1:1773476 chr1:1891471~1892658:+ PAAD cis rs2882667 0.858 rs6596460 ENSG00000253404.1 AC034243.1 6.44 1.52e-09 2.44e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139078491 chr5:138744434~138753309:- PAAD cis rs1155848 0.892 rs28546558 ENSG00000227354.5 RBM26-AS1 6.44 1.52e-09 2.44e-06 0.91 0.46 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79516024 chr13:79406309~79424328:+ PAAD cis rs10129255 0.5 rs2027903 ENSG00000223648.3 IGHV3-64 6.43 1.52e-09 2.45e-06 0.41 0.46 Kawasaki disease; chr14:106807047 chr14:106643132~106658258:- PAAD cis rs2117029 0.555 rs9788139 ENSG00000258017.1 RP11-386G11.10 -6.43 1.54e-09 2.47e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49126886 chr12:49127782~49147869:+ PAAD cis rs8040855 0.931 rs11855471 ENSG00000259295.5 CSPG4P12 -6.43 1.54e-09 2.47e-06 -0.52 -0.46 Bulimia nervosa; chr15:85175976 chr15:85191438~85213905:+ PAAD cis rs7044106 0.762 rs1324473 ENSG00000226752.6 PSMD5-AS1 6.43 1.54e-09 2.47e-06 0.63 0.46 Hip circumference adjusted for BMI; chr9:120642332 chr9:120824828~120854385:+ PAAD cis rs72772090 0.539 rs11738115 ENSG00000248734.2 CTD-2260A17.1 6.43 1.55e-09 2.48e-06 0.6 0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777368 chr5:96784777~96785999:+ PAAD cis rs2739330 0.796 rs5760097 ENSG00000250470.1 AP000351.3 6.43 1.55e-09 2.48e-06 0.67 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23976904~23977585:- PAAD cis rs2739330 0.828 rs5760098 ENSG00000250470.1 AP000351.3 6.43 1.55e-09 2.48e-06 0.67 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23976904~23977585:- PAAD cis rs3931020 0.671 rs1327088 ENSG00000272864.1 RP11-17E13.2 -6.43 1.56e-09 2.5e-06 -0.58 -0.46 Resistin levels; chr1:74789807 chr1:74698769~74699333:- PAAD cis rs9601248 0.967 rs9545145 ENSG00000227676.3 LINC01068 -6.43 1.56e-09 2.5e-06 -0.59 -0.46 Major depressive disorder; chr13:79599625 chr13:79566727~79571436:+ PAAD cis rs950169 0.922 rs8037078 ENSG00000259728.4 LINC00933 -6.43 1.57e-09 2.51e-06 -0.57 -0.46 Schizophrenia; chr15:84150119 chr15:84570649~84580175:+ PAAD cis rs2882667 0.898 rs10079634 ENSG00000253404.1 AC034243.1 6.43 1.59e-09 2.54e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139077364 chr5:138744434~138753309:- PAAD cis rs10129255 0.5 rs10142931 ENSG00000223648.3 IGHV3-64 6.43 1.59e-09 2.54e-06 0.42 0.46 Kawasaki disease; chr14:106782288 chr14:106643132~106658258:- PAAD cis rs7829975 0.688 rs6601703 ENSG00000253893.2 FAM85B -6.43 1.6e-09 2.55e-06 -0.61 -0.46 Mood instability; chr8:8522714 chr8:8167819~8226614:- PAAD cis rs1155848 0.892 rs9574424 ENSG00000227354.5 RBM26-AS1 -6.43 1.6e-09 2.55e-06 -0.9 -0.46 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79448541 chr13:79406309~79424328:+ PAAD cis rs7945705 0.692 rs2742470 ENSG00000254860.4 TMEM9B-AS1 6.42 1.61e-09 2.57e-06 0.49 0.46 Hemoglobin concentration; chr11:8982455 chr11:8964675~8977527:+ PAAD cis rs7945705 0.747 rs2568045 ENSG00000254860.4 TMEM9B-AS1 6.42 1.61e-09 2.57e-06 0.49 0.46 Hemoglobin concentration; chr11:8982513 chr11:8964675~8977527:+ PAAD cis rs7044106 0.791 rs10985000 ENSG00000226752.6 PSMD5-AS1 -6.42 1.61e-09 2.57e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120721837 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs10985001 ENSG00000226752.6 PSMD5-AS1 -6.42 1.61e-09 2.57e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120721954 chr9:120824828~120854385:+ PAAD cis rs9322193 0.607 rs915140 ENSG00000216906.2 RP11-350J20.9 6.42 1.62e-09 2.58e-06 0.67 0.46 Lung cancer; chr6:149899674 chr6:149904243~149906418:+ PAAD cis rs2117029 0.523 rs12227296 ENSG00000258017.1 RP11-386G11.10 -6.42 1.63e-09 2.6e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49136712 chr12:49127782~49147869:+ PAAD cis rs2117029 0.521 rs10875925 ENSG00000258017.1 RP11-386G11.10 -6.42 1.63e-09 2.6e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49142575 chr12:49127782~49147869:+ PAAD cis rs2117029 0.586 rs11168882 ENSG00000258017.1 RP11-386G11.10 -6.42 1.63e-09 2.6e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49143560 chr12:49127782~49147869:+ PAAD cis rs2117029 0.521 rs12227610 ENSG00000258017.1 RP11-386G11.10 -6.42 1.63e-09 2.6e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49146153 chr12:49127782~49147869:+ PAAD cis rs673078 0.571 rs17440823 ENSG00000275759.1 RP11-131L12.3 -6.42 1.63e-09 2.61e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118353023 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs17512609 ENSG00000275759.1 RP11-131L12.3 -6.42 1.63e-09 2.61e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118354072 chr12:118428281~118428870:+ PAAD cis rs7044106 0.762 rs10984974 ENSG00000226752.6 PSMD5-AS1 -6.42 1.64e-09 2.61e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120659278 chr9:120824828~120854385:+ PAAD cis rs4938303 0.671 rs2008915 ENSG00000254851.1 RP11-109L13.1 -6.42 1.64e-09 2.62e-06 -0.72 -0.46 Triglycerides; chr11:116732418 chr11:117135528~117138582:+ PAAD cis rs10129255 0.5 rs988132 ENSG00000223648.3 IGHV3-64 6.42 1.64e-09 2.62e-06 0.42 0.46 Kawasaki disease; chr14:106776758 chr14:106643132~106658258:- PAAD cis rs7174755 1 rs7174755 ENSG00000260657.2 RP11-315D16.4 -6.42 1.65e-09 2.62e-06 -0.55 -0.46 Major depressive disorder; chr15:68304789 chr15:68267792~68277994:- PAAD cis rs1930961 1 rs6004667 ENSG00000272977.1 CTA-390C10.10 6.42 1.65e-09 2.63e-06 0.87 0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs6004668 ENSG00000272977.1 CTA-390C10.10 6.42 1.65e-09 2.63e-06 0.87 0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25476218~25479971:+ PAAD cis rs2117029 0.521 rs2114845 ENSG00000258017.1 RP11-386G11.10 -6.42 1.65e-09 2.63e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49164750 chr12:49127782~49147869:+ PAAD cis rs9532669 0.857 rs9525427 ENSG00000176268.5 CYCSP34 6.42 1.65e-09 2.63e-06 0.44 0.46 Cervical cancer; chr13:40918029 chr13:40863599~40863902:- PAAD cis rs4218 1 rs4218 ENSG00000277144.1 RP11-59H7.4 -6.42 1.65e-09 2.64e-06 -0.57 -0.46 Social communication problems; chr15:59136459 chr15:59115547~59116089:- PAAD cis rs950169 0.922 rs12906983 ENSG00000259728.4 LINC00933 6.42 1.66e-09 2.64e-06 0.58 0.46 Schizophrenia; chr15:84262270 chr15:84570649~84580175:+ PAAD cis rs6452524 1 rs6887846 ENSG00000249664.1 CTD-2227C6.2 -6.42 1.66e-09 2.65e-06 -0.52 -0.46 Hypertension (SNP x SNP interaction); chr5:83140542 chr5:83012285~83013109:- PAAD cis rs7044106 0.762 rs10760110 ENSG00000226752.6 PSMD5-AS1 6.42 1.66e-09 2.65e-06 0.6 0.46 Hip circumference adjusted for BMI; chr9:120650285 chr9:120824828~120854385:+ PAAD cis rs9399137 0.507 rs28384513 ENSG00000232876.1 CTA-212D2.2 -6.42 1.66e-09 2.65e-06 -0.57 -0.46 Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels; chr6:135055071 chr6:135055033~135060550:+ PAAD cis rs11098499 0.954 rs12502423 ENSG00000245958.5 RP11-33B1.1 -6.42 1.66e-09 2.65e-06 -0.39 -0.46 Corneal astigmatism; chr4:119503017 chr4:119454791~119552025:+ PAAD cis rs858239 0.698 rs858295 ENSG00000226816.2 AC005082.12 6.42 1.67e-09 2.65e-06 0.52 0.46 Cerebrospinal fluid biomarker levels; chr7:23205950 chr7:23206013~23208045:+ PAAD cis rs7044106 0.791 rs10984994 ENSG00000226752.6 PSMD5-AS1 6.42 1.67e-09 2.66e-06 0.63 0.46 Hip circumference adjusted for BMI; chr9:120716491 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs2416797 ENSG00000226752.6 PSMD5-AS1 -6.42 1.67e-09 2.66e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120718322 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs2416798 ENSG00000226752.6 PSMD5-AS1 -6.42 1.67e-09 2.66e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120718325 chr9:120824828~120854385:+ PAAD cis rs7044106 0.708 rs991121 ENSG00000226752.6 PSMD5-AS1 -6.42 1.68e-09 2.67e-06 -0.6 -0.46 Hip circumference adjusted for BMI; chr9:120608067 chr9:120824828~120854385:+ PAAD cis rs2882667 0.931 rs10070021 ENSG00000253404.1 AC034243.1 6.42 1.68e-09 2.67e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:138989017 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs11955952 ENSG00000253404.1 AC034243.1 6.42 1.68e-09 2.67e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:138993430 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs11749944 ENSG00000253404.1 AC034243.1 6.42 1.69e-09 2.68e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139077090 chr5:138744434~138753309:- PAAD cis rs11098499 1 rs10029750 ENSG00000245958.5 RP11-33B1.1 -6.42 1.69e-09 2.68e-06 -0.37 -0.46 Corneal astigmatism; chr4:119251388 chr4:119454791~119552025:+ PAAD cis rs11098499 1 rs6837898 ENSG00000245958.5 RP11-33B1.1 -6.42 1.69e-09 2.68e-06 -0.37 -0.46 Corneal astigmatism; chr4:119257999 chr4:119454791~119552025:+ PAAD cis rs11098499 1 rs28374891 ENSG00000245958.5 RP11-33B1.1 -6.42 1.69e-09 2.68e-06 -0.37 -0.46 Corneal astigmatism; chr4:119262395 chr4:119454791~119552025:+ PAAD cis rs6452524 0.87 rs12152892 ENSG00000249664.1 CTD-2227C6.2 6.41 1.7e-09 2.69e-06 0.56 0.46 Hypertension (SNP x SNP interaction); chr5:83125110 chr5:83012285~83013109:- PAAD cis rs10129255 0.5 rs34326748 ENSG00000223648.3 IGHV3-64 6.41 1.71e-09 2.71e-06 0.41 0.46 Kawasaki disease; chr14:106782523 chr14:106643132~106658258:- PAAD cis rs10129255 0.5 rs10143385 ENSG00000223648.3 IGHV3-64 6.41 1.71e-09 2.71e-06 0.41 0.46 Kawasaki disease; chr14:106782559 chr14:106643132~106658258:- PAAD cis rs2882667 0.894 rs1433008 ENSG00000253404.1 AC034243.1 6.41 1.71e-09 2.71e-06 0.55 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:138997975 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs13153618 ENSG00000253404.1 AC034243.1 6.41 1.71e-09 2.71e-06 0.55 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139017087 chr5:138744434~138753309:- PAAD cis rs2882667 0.894 rs10054478 ENSG00000253404.1 AC034243.1 6.41 1.71e-09 2.71e-06 0.55 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139018386 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs10077896 ENSG00000253404.1 AC034243.1 6.41 1.71e-09 2.71e-06 0.55 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139021067 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs11957633 ENSG00000253404.1 AC034243.1 6.41 1.72e-09 2.72e-06 0.57 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139028705 chr5:138744434~138753309:- PAAD cis rs2919917 0.554 rs2086755 ENSG00000254352.1 RP11-578O24.2 6.41 1.72e-09 2.73e-06 0.51 0.46 Lymphocyte counts; chr8:78701809 chr8:78723796~78724136:- PAAD cis rs1155848 0.892 rs3759438 ENSG00000227354.5 RBM26-AS1 6.41 1.72e-09 2.73e-06 0.91 0.46 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79566863 chr13:79406309~79424328:+ PAAD cis rs7044106 0.718 rs1981021 ENSG00000226752.6 PSMD5-AS1 -6.41 1.73e-09 2.73e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120626115 chr9:120824828~120854385:+ PAAD cis rs7044106 0.734 rs1981020 ENSG00000226752.6 PSMD5-AS1 -6.41 1.73e-09 2.73e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120626186 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs13291660 ENSG00000226752.6 PSMD5-AS1 -6.41 1.73e-09 2.73e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120630470 chr9:120824828~120854385:+ PAAD cis rs7429990 0.965 rs319689 ENSG00000229759.1 MRPS18AP1 6.41 1.73e-09 2.74e-06 0.5 0.46 Educational attainment (years of education); chr3:47886677 chr3:48256350~48256938:- PAAD cis rs1930961 1 rs9624834 ENSG00000272977.1 CTA-390C10.10 -6.41 1.73e-09 2.74e-06 -0.89 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25450048 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs9624835 ENSG00000272977.1 CTA-390C10.10 -6.41 1.73e-09 2.74e-06 -0.89 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25450054 chr22:25476218~25479971:+ PAAD cis rs1930961 1 rs9624836 ENSG00000272977.1 CTA-390C10.10 -6.41 1.73e-09 2.74e-06 -0.89 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25450120 chr22:25476218~25479971:+ PAAD cis rs875971 0.545 rs10950029 ENSG00000237310.1 GS1-124K5.4 6.41 1.73e-09 2.74e-06 0.53 0.46 Aortic root size; chr7:66169334 chr7:66493706~66495474:+ PAAD cis rs7301826 1 rs4619189 ENSG00000256299.1 RP11-989F5.3 -6.41 1.73e-09 2.74e-06 -0.52 -0.46 Plasma plasminogen activator levels; chr12:130829252 chr12:130810821~130812622:- PAAD cis rs673078 0.66 rs78690826 ENSG00000275759.1 RP11-131L12.3 -6.41 1.75e-09 2.76e-06 -0.75 -0.46 Glucose homeostasis traits; chr12:118176693 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17512644 ENSG00000275759.1 RP11-131L12.3 -6.41 1.75e-09 2.76e-06 -0.71 -0.46 Glucose homeostasis traits; chr12:118359963 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17512652 ENSG00000275759.1 RP11-131L12.3 -6.41 1.75e-09 2.76e-06 -0.71 -0.46 Glucose homeostasis traits; chr12:118361278 chr12:118428281~118428870:+ PAAD cis rs1061377 1 rs56119980 ENSG00000249207.1 RP11-360F5.1 -6.41 1.75e-09 2.76e-06 -0.51 -0.46 Uric acid levels; chr4:39139390 chr4:39112677~39126818:- PAAD cis rs858239 0.862 rs1728292 ENSG00000226816.2 AC005082.12 6.41 1.75e-09 2.76e-06 0.51 0.46 Cerebrospinal fluid biomarker levels; chr7:23223855 chr7:23206013~23208045:+ PAAD cis rs1891275 0.509 rs34190234 ENSG00000228701.1 TNKS2-AS1 -6.41 1.76e-09 2.78e-06 -0.56 -0.46 Intelligence (multi-trait analysis); chr10:91683317 chr10:91782839~91798291:- PAAD cis rs1891275 0.509 rs76313529 ENSG00000228701.1 TNKS2-AS1 -6.41 1.76e-09 2.78e-06 -0.56 -0.46 Intelligence (multi-trait analysis); chr10:91683319 chr10:91782839~91798291:- PAAD cis rs7188445 0.736 rs11642757 ENSG00000261390.4 RP11-345M22.2 -6.41 1.76e-09 2.78e-06 -0.6 -0.46 Urate levels; chr16:79719570 chr16:79715232~79770563:- PAAD cis rs17301013 0.606 rs1618408 ENSG00000227373.4 RP11-160H22.5 -6.41 1.77e-09 2.8e-06 -0.66 -0.46 Systemic lupus erythematosus; chr1:174777402 chr1:174115300~174160004:- PAAD cis rs7044106 0.791 rs10818473 ENSG00000226752.6 PSMD5-AS1 -6.41 1.78e-09 2.81e-06 -0.64 -0.46 Hip circumference adjusted for BMI; chr9:120721877 chr9:120824828~120854385:+ PAAD cis rs10875746 0.951 rs2269935 ENSG00000240399.1 RP1-228P16.1 -6.41 1.78e-09 2.81e-06 -0.52 -0.46 Longevity (90 years and older); chr12:48122681 chr12:48054813~48055591:- PAAD cis rs4722166 0.573 rs35436671 ENSG00000179428.2 AC073072.5 -6.4 1.79e-09 2.83e-06 -0.44 -0.46 Lung cancer; chr7:22735889 chr7:22725395~22727620:- PAAD cis rs10256972 0.933 rs35696159 ENSG00000229043.2 AC091729.9 -6.4 1.8e-09 2.84e-06 -0.5 -0.46 Endometriosis;Longevity; chr7:1007558 chr7:1160374~1165267:+ PAAD cis rs1075265 0.584 rs11896781 ENSG00000233266.1 HMGB1P31 6.4 1.8e-09 2.84e-06 0.57 0.46 Chronotype;Morning vs. evening chronotype; chr2:54096987 chr2:54051334~54051760:+ PAAD cis rs1075265 0.547 rs10865279 ENSG00000233266.1 HMGB1P31 6.4 1.8e-09 2.84e-06 0.57 0.46 Chronotype;Morning vs. evening chronotype; chr2:54097564 chr2:54051334~54051760:+ PAAD cis rs9322193 0.607 rs12527391 ENSG00000216906.2 RP11-350J20.9 6.4 1.8e-09 2.85e-06 0.68 0.46 Lung cancer; chr6:149882156 chr6:149904243~149906418:+ PAAD cis rs8040855 0.627 rs72757059 ENSG00000259295.5 CSPG4P12 6.4 1.8e-09 2.85e-06 0.54 0.46 Bulimia nervosa; chr15:85059918 chr15:85191438~85213905:+ PAAD cis rs4718428 0.705 rs4718424 ENSG00000226824.5 RP4-756H11.3 -6.4 1.8e-09 2.85e-06 -0.62 -0.46 Corneal structure; chr7:66911108 chr7:66654538~66669855:+ PAAD cis rs6452524 0.836 rs1015440 ENSG00000249664.1 CTD-2227C6.2 6.4 1.81e-09 2.85e-06 0.54 0.46 Hypertension (SNP x SNP interaction); chr5:83202986 chr5:83012285~83013109:- PAAD cis rs10875746 0.903 rs11168420 ENSG00000240399.1 RP1-228P16.1 -6.4 1.81e-09 2.86e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48122113 chr12:48054813~48055591:- PAAD cis rs7829975 0.688 rs7837587 ENSG00000253893.2 FAM85B -6.4 1.83e-09 2.88e-06 -0.61 -0.46 Mood instability; chr8:8521482 chr8:8167819~8226614:- PAAD cis rs7829975 0.688 rs7826654 ENSG00000253893.2 FAM85B -6.4 1.83e-09 2.88e-06 -0.61 -0.46 Mood instability; chr8:8521596 chr8:8167819~8226614:- PAAD cis rs7829975 0.688 rs7826660 ENSG00000253893.2 FAM85B -6.4 1.83e-09 2.88e-06 -0.61 -0.46 Mood instability; chr8:8521597 chr8:8167819~8226614:- PAAD cis rs11673344 0.9 rs11671112 ENSG00000226686.6 LINC01535 6.4 1.83e-09 2.88e-06 0.61 0.46 Obesity-related traits; chr19:37169384 chr19:37251912~37265535:+ PAAD cis rs7044106 0.791 rs7036196 ENSG00000226752.6 PSMD5-AS1 -6.4 1.83e-09 2.89e-06 -0.64 -0.46 Hip circumference adjusted for BMI; chr9:120717179 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs7036766 ENSG00000226752.6 PSMD5-AS1 -6.4 1.83e-09 2.89e-06 -0.64 -0.46 Hip circumference adjusted for BMI; chr9:120717343 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs3904196 ENSG00000226752.6 PSMD5-AS1 -6.4 1.83e-09 2.89e-06 -0.64 -0.46 Hip circumference adjusted for BMI; chr9:120718091 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs2416799 ENSG00000226752.6 PSMD5-AS1 -6.4 1.83e-09 2.89e-06 -0.64 -0.46 Hip circumference adjusted for BMI; chr9:120718588 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs10984998 ENSG00000226752.6 PSMD5-AS1 -6.4 1.83e-09 2.89e-06 -0.64 -0.46 Hip circumference adjusted for BMI; chr9:120719238 chr9:120824828~120854385:+ PAAD cis rs2882667 0.898 rs6890272 ENSG00000253404.1 AC034243.1 6.4 1.84e-09 2.9e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139035427 chr5:138744434~138753309:- PAAD cis rs72772090 0.634 rs12186366 ENSG00000248734.2 CTD-2260A17.1 -6.4 1.84e-09 2.9e-06 -0.59 -0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96753146 chr5:96784777~96785999:+ PAAD cis rs72772090 0.634 rs17401901 ENSG00000248734.2 CTD-2260A17.1 -6.4 1.84e-09 2.9e-06 -0.59 -0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96756221 chr5:96784777~96785999:+ PAAD cis rs72772090 0.634 rs72773906 ENSG00000248734.2 CTD-2260A17.1 -6.4 1.84e-09 2.9e-06 -0.59 -0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96756570 chr5:96784777~96785999:+ PAAD cis rs72772090 0.634 rs10515246 ENSG00000248734.2 CTD-2260A17.1 -6.4 1.84e-09 2.9e-06 -0.59 -0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96763561 chr5:96784777~96785999:+ PAAD cis rs72772090 0.634 rs17402639 ENSG00000248734.2 CTD-2260A17.1 -6.4 1.84e-09 2.9e-06 -0.59 -0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96771301 chr5:96784777~96785999:+ PAAD cis rs72772090 0.634 rs72773912 ENSG00000248734.2 CTD-2260A17.1 -6.4 1.84e-09 2.9e-06 -0.59 -0.46 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96772097 chr5:96784777~96785999:+ PAAD cis rs3096299 0.781 rs2965819 ENSG00000274627.1 RP11-104N10.2 -6.4 1.84e-09 2.91e-06 -0.4 -0.46 Multiple myeloma (IgH translocation); chr16:89434622 chr16:89516797~89522217:+ PAAD cis rs2919917 0.628 rs7010299 ENSG00000254352.1 RP11-578O24.2 6.4 1.85e-09 2.92e-06 0.51 0.46 Lymphocyte counts; chr8:78707786 chr8:78723796~78724136:- PAAD cis rs8062405 0.573 rs11645306 ENSG00000259982.1 CDC37P1 -6.4 1.86e-09 2.94e-06 -0.55 -0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28972615 chr16:28700294~28701540:- PAAD cis rs8062405 0.573 rs7187575 ENSG00000259982.1 CDC37P1 -6.4 1.86e-09 2.94e-06 -0.55 -0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28978780 chr16:28700294~28701540:- PAAD cis rs2117029 0.521 rs7953169 ENSG00000258017.1 RP11-386G11.10 -6.4 1.87e-09 2.95e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49184389 chr12:49127782~49147869:+ PAAD cis rs8062405 0.573 rs8045689 ENSG00000259982.1 CDC37P1 -6.39 1.87e-09 2.95e-06 -0.55 -0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28976948 chr16:28700294~28701540:- PAAD cis rs8062405 0.573 rs6565300 ENSG00000259982.1 CDC37P1 6.39 1.87e-09 2.95e-06 0.55 0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28981728 chr16:28700294~28701540:- PAAD cis rs8062405 0.573 rs7140 ENSG00000259982.1 CDC37P1 -6.39 1.87e-09 2.95e-06 -0.55 -0.46 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28984436 chr16:28700294~28701540:- PAAD cis rs12130219 1 rs12130219 ENSG00000237975.5 FLG-AS1 6.39 1.88e-09 2.95e-06 0.56 0.46 Inflammatory skin disease; chr1:152189630 chr1:152168125~152445456:+ PAAD cis rs950169 0.84 rs62029595 ENSG00000225151.9 GOLGA2P7 -6.39 1.88e-09 2.96e-06 -0.54 -0.46 Schizophrenia; chr15:84400603 chr15:84199311~84230136:- PAAD cis rs6504622 0.72 rs4968304 ENSG00000262879.4 RP11-156P1.3 -6.39 1.88e-09 2.96e-06 -0.47 -0.46 Orofacial clefts; chr17:47063235 chr17:46984045~47100323:- PAAD cis rs8040855 0.694 rs12908400 ENSG00000259295.5 CSPG4P12 6.39 1.88e-09 2.96e-06 0.53 0.46 Bulimia nervosa; chr15:85029945 chr15:85191438~85213905:+ PAAD cis rs8040855 0.627 rs11632899 ENSG00000259295.5 CSPG4P12 6.39 1.88e-09 2.96e-06 0.53 0.46 Bulimia nervosa; chr15:85057609 chr15:85191438~85213905:+ PAAD cis rs8040855 0.658 rs12909111 ENSG00000259295.5 CSPG4P12 6.39 1.88e-09 2.96e-06 0.53 0.46 Bulimia nervosa; chr15:85061095 chr15:85191438~85213905:+ PAAD cis rs8040855 0.658 rs4842864 ENSG00000259295.5 CSPG4P12 6.39 1.88e-09 2.96e-06 0.53 0.46 Bulimia nervosa; chr15:85101315 chr15:85191438~85213905:+ PAAD cis rs1075265 0.547 rs41385746 ENSG00000233266.1 HMGB1P31 -6.39 1.88e-09 2.96e-06 -0.57 -0.46 Chronotype;Morning vs. evening chronotype; chr2:54077893 chr2:54051334~54051760:+ PAAD cis rs1075265 0.568 rs959286 ENSG00000233266.1 HMGB1P31 6.39 1.88e-09 2.96e-06 0.57 0.46 Chronotype;Morning vs. evening chronotype; chr2:54078941 chr2:54051334~54051760:+ PAAD cis rs1075265 0.527 rs959285 ENSG00000233266.1 HMGB1P31 6.39 1.88e-09 2.96e-06 0.57 0.46 Chronotype;Morning vs. evening chronotype; chr2:54078964 chr2:54051334~54051760:+ PAAD cis rs7829975 0.688 rs13270194 ENSG00000253893.2 FAM85B -6.39 1.88e-09 2.96e-06 -0.61 -0.46 Mood instability; chr8:8520592 chr8:8167819~8226614:- PAAD cis rs6504622 0.755 rs4074249 ENSG00000262879.4 RP11-156P1.3 -6.39 1.89e-09 2.97e-06 -0.47 -0.46 Orofacial clefts; chr17:47072043 chr17:46984045~47100323:- PAAD cis rs6504622 0.755 rs11079750 ENSG00000262879.4 RP11-156P1.3 -6.39 1.89e-09 2.97e-06 -0.47 -0.46 Orofacial clefts; chr17:47072149 chr17:46984045~47100323:- PAAD cis rs2283792 1 rs6928 ENSG00000224086.5 LL22NC03-86G7.1 -6.39 1.89e-09 2.97e-06 -0.47 -0.46 Multiple sclerosis; chr22:21760715 chr22:21938293~21977632:+ PAAD cis rs673078 0.66 rs61945206 ENSG00000275759.1 RP11-131L12.3 -6.39 1.9e-09 2.98e-06 -0.68 -0.46 Glucose homeostasis traits; chr12:118238295 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs2055534 ENSG00000275759.1 RP11-131L12.3 -6.39 1.9e-09 2.98e-06 -0.71 -0.46 Glucose homeostasis traits; chr12:118386527 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs56157623 ENSG00000275759.1 RP11-131L12.3 -6.39 1.9e-09 2.98e-06 -0.71 -0.46 Glucose homeostasis traits; chr12:118388162 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs4767669 ENSG00000275759.1 RP11-131L12.3 -6.39 1.9e-09 2.98e-06 -0.71 -0.46 Glucose homeostasis traits; chr12:118390651 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs4767670 ENSG00000275759.1 RP11-131L12.3 -6.39 1.9e-09 2.98e-06 -0.71 -0.46 Glucose homeostasis traits; chr12:118390737 chr12:118428281~118428870:+ PAAD cis rs7044106 0.762 rs10491783 ENSG00000226752.6 PSMD5-AS1 -6.39 1.91e-09 3e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120687877 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs966397 ENSG00000226752.6 PSMD5-AS1 -6.39 1.91e-09 3e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120691034 chr9:120824828~120854385:+ PAAD cis rs7615952 0.8 rs11914298 ENSG00000171084.14 FAM86JP 6.39 1.92e-09 3.02e-06 0.66 0.46 Blood pressure (smoking interaction); chr3:125924929 chr3:125916620~125930024:+ PAAD cis rs2882667 0.867 rs6868085 ENSG00000253404.1 AC034243.1 6.39 1.92e-09 3.02e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139096757 chr5:138744434~138753309:- PAAD cis rs9660180 1 rs3737628 ENSG00000231050.1 RP1-140A9.1 6.39 1.92e-09 3.02e-06 0.55 0.46 Body mass index; chr1:1791493 chr1:1891471~1892658:+ PAAD cis rs11098499 0.955 rs6815725 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119237255 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs1551 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119237345 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs11931312 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119237868 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs1511018 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119240425 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs1397608 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119240589 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs7684942 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119241046 chr4:119454791~119552025:+ PAAD cis rs11098499 0.913 rs10010696 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119243148 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs1511019 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119244852 chr4:119454791~119552025:+ PAAD cis rs11098499 0.913 rs11098496 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119246311 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs35197422 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119248159 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs35434465 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119248223 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs1511015 ENSG00000245958.5 RP11-33B1.1 -6.39 1.93e-09 3.03e-06 -0.37 -0.46 Corneal astigmatism; chr4:119249318 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs11944880 ENSG00000245958.5 RP11-33B1.1 6.39 1.93e-09 3.03e-06 0.37 0.46 Corneal astigmatism; chr4:119238179 chr4:119454791~119552025:+ PAAD cis rs7301826 1 rs1106369 ENSG00000256299.1 RP11-989F5.3 -6.39 1.93e-09 3.03e-06 -0.51 -0.46 Plasma plasminogen activator levels; chr12:130815550 chr12:130810821~130812622:- PAAD cis rs1061377 1 rs12646251 ENSG00000249685.1 RP11-360F5.3 6.39 1.94e-09 3.04e-06 0.5 0.46 Uric acid levels; chr4:39132751 chr4:39133913~39135608:+ PAAD cis rs673078 0.66 rs61945217 ENSG00000275759.1 RP11-131L12.3 -6.39 1.94e-09 3.05e-06 -0.75 -0.46 Glucose homeostasis traits; chr12:118261194 chr12:118428281~118428870:+ PAAD cis rs6504622 0.755 rs34774205 ENSG00000262879.4 RP11-156P1.3 -6.39 1.97e-09 3.09e-06 -0.48 -0.46 Orofacial clefts; chr17:47083453 chr17:46984045~47100323:- PAAD cis rs11098499 0.909 rs10026736 ENSG00000245958.5 RP11-33B1.1 -6.38 1.98e-09 3.1e-06 -0.39 -0.46 Corneal astigmatism; chr4:119463167 chr4:119454791~119552025:+ PAAD cis rs12220777 1 rs11201660 ENSG00000230091.5 TMEM254-AS1 -6.38 1.99e-09 3.12e-06 -0.73 -0.46 Chronic obstructive pulmonary disease-related biomarkers; chr10:80094775 chr10:80046860~80078912:- PAAD cis rs5760092 0.842 rs5760103 ENSG00000225282.1 AP000350.6 6.38 1.99e-09 3.12e-06 0.77 0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23906594 chr22:23926900~23929574:+ PAAD cis rs950169 0.84 rs72748702 ENSG00000225151.9 GOLGA2P7 -6.38 2e-09 3.13e-06 -0.55 -0.46 Schizophrenia; chr15:84246494 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs4338765 ENSG00000225151.9 GOLGA2P7 -6.38 2e-09 3.13e-06 -0.55 -0.46 Schizophrenia; chr15:84248084 chr15:84199311~84230136:- PAAD cis rs9545047 0.604 rs12865187 ENSG00000227676.3 LINC01068 -6.38 2e-09 3.13e-06 -0.56 -0.46 Schizophrenia; chr13:79316469 chr13:79566727~79571436:+ PAAD cis rs9545047 0.604 rs9565487 ENSG00000227676.3 LINC01068 -6.38 2e-09 3.13e-06 -0.56 -0.46 Schizophrenia; chr13:79332742 chr13:79566727~79571436:+ PAAD cis rs2117029 0.554 rs12579015 ENSG00000258017.1 RP11-386G11.10 -6.38 2e-09 3.14e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49162648 chr12:49127782~49147869:+ PAAD cis rs1075265 0.633 rs28653587 ENSG00000233266.1 HMGB1P31 6.38 2.01e-09 3.14e-06 0.59 0.46 Chronotype;Morning vs. evening chronotype; chr2:53992435 chr2:54051334~54051760:+ PAAD cis rs1075265 0.633 rs7564912 ENSG00000233266.1 HMGB1P31 6.38 2.01e-09 3.14e-06 0.59 0.46 Chronotype;Morning vs. evening chronotype; chr2:53995048 chr2:54051334~54051760:+ PAAD cis rs1075265 0.61 rs6746965 ENSG00000233266.1 HMGB1P31 6.38 2.01e-09 3.14e-06 0.59 0.46 Chronotype;Morning vs. evening chronotype; chr2:53996388 chr2:54051334~54051760:+ PAAD cis rs875971 0.545 rs73142233 ENSG00000237310.1 GS1-124K5.4 6.38 2.02e-09 3.16e-06 0.53 0.46 Aortic root size; chr7:66221293 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs73142245 ENSG00000237310.1 GS1-124K5.4 6.38 2.02e-09 3.16e-06 0.53 0.46 Aortic root size; chr7:66226662 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs73142265 ENSG00000237310.1 GS1-124K5.4 6.38 2.02e-09 3.16e-06 0.53 0.46 Aortic root size; chr7:66234510 chr7:66493706~66495474:+ PAAD cis rs7044106 0.708 rs10984992 ENSG00000226752.6 PSMD5-AS1 -6.38 2.03e-09 3.17e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120711138 chr9:120824828~120854385:+ PAAD cis rs673078 0.607 rs61943367 ENSG00000275759.1 RP11-131L12.3 -6.38 2.03e-09 3.17e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118366316 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943368 ENSG00000275759.1 RP11-131L12.3 -6.38 2.03e-09 3.17e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118366568 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943385 ENSG00000275759.1 RP11-131L12.3 -6.38 2.03e-09 3.17e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118370339 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943388 ENSG00000275759.1 RP11-131L12.3 -6.38 2.03e-09 3.17e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118374590 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943389 ENSG00000275759.1 RP11-131L12.3 -6.38 2.03e-09 3.17e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118377467 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7299040 ENSG00000275759.1 RP11-131L12.3 -6.38 2.03e-09 3.17e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118380660 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7968011 ENSG00000275759.1 RP11-131L12.3 -6.38 2.03e-09 3.17e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118382001 chr12:118428281~118428870:+ PAAD cis rs875971 0.502 rs2946580 ENSG00000237310.1 GS1-124K5.4 -6.38 2.04e-09 3.18e-06 -0.54 -0.46 Aortic root size; chr7:66066855 chr7:66493706~66495474:+ PAAD cis rs42490 0.51 rs218890 ENSG00000251136.7 RP11-37B2.1 -6.38 2.04e-09 3.19e-06 -0.43 -0.46 Leprosy; chr8:89680848 chr8:89609409~89757727:- PAAD cis rs12022452 0.822 rs7514623 ENSG00000238287.1 RP11-656D10.3 -6.38 2.04e-09 3.19e-06 -0.69 -0.46 Age-related hearing impairment (SNP x SNP interaction); chr1:40559330 chr1:40493157~40508661:- PAAD cis rs2404602 0.552 rs11636612 ENSG00000259422.1 RP11-593F23.1 -6.38 2.06e-09 3.22e-06 -0.58 -0.46 Blood metabolite levels; chr15:76667189 chr15:76174891~76181486:- PAAD cis rs17264034 0.821 rs374218 ENSG00000250786.1 SNHG18 6.38 2.07e-09 3.22e-06 0.62 0.46 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9548331 chr5:9546200~9550609:+ PAAD cis rs17264034 0.861 rs431288 ENSG00000250786.1 SNHG18 6.38 2.07e-09 3.22e-06 0.62 0.46 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9549347 chr5:9546200~9550609:+ PAAD cis rs17264034 0.861 rs414396 ENSG00000250786.1 SNHG18 6.38 2.07e-09 3.22e-06 0.62 0.46 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9550596 chr5:9546200~9550609:+ PAAD cis rs6504622 0.677 rs12949446 ENSG00000262879.4 RP11-156P1.3 -6.38 2.07e-09 3.23e-06 -0.47 -0.46 Orofacial clefts; chr17:46994311 chr17:46984045~47100323:- PAAD cis rs6504622 0.693 rs12952596 ENSG00000262879.4 RP11-156P1.3 -6.38 2.07e-09 3.23e-06 -0.47 -0.46 Orofacial clefts; chr17:46994319 chr17:46984045~47100323:- PAAD cis rs7586673 0.857 rs16845580 ENSG00000227403.1 AC009299.3 -6.37 2.1e-09 3.26e-06 -0.6 -0.46 Intelligence (multi-trait analysis); chr2:161064373 chr2:161244739~161249050:+ PAAD cis rs7586673 0.93 rs6432667 ENSG00000227403.1 AC009299.3 -6.37 2.1e-09 3.28e-06 -0.6 -0.46 Intelligence (multi-trait analysis); chr2:161048490 chr2:161244739~161249050:+ PAAD cis rs6452524 0.806 rs10078084 ENSG00000249664.1 CTD-2227C6.2 6.37 2.11e-09 3.28e-06 0.54 0.46 Hypertension (SNP x SNP interaction); chr5:83106588 chr5:83012285~83013109:- PAAD cis rs6452524 0.868 rs11750836 ENSG00000249664.1 CTD-2227C6.2 6.37 2.11e-09 3.28e-06 0.54 0.46 Hypertension (SNP x SNP interaction); chr5:83107368 chr5:83012285~83013109:- PAAD cis rs4722166 0.695 rs7787893 ENSG00000179428.2 AC073072.5 -6.37 2.11e-09 3.29e-06 -0.43 -0.46 Lung cancer; chr7:22734818 chr7:22725395~22727620:- PAAD cis rs875971 0.502 rs11769702 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66255529 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs6970498 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66275908 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs73146609 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66302477 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs2173571 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66305392 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs11770063 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66318029 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs3936065 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66325577 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs4718335 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66339619 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs2279757 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66363676 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs6969224 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66370011 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs11766183 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66374173 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs1065265 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66376216 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs7811204 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66387213 chr7:66493706~66495474:+ PAAD cis rs875971 0.571 rs78668714 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66474464 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs73150604 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66480545 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs7810213 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66481592 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs2420612 ENSG00000237310.1 GS1-124K5.4 6.37 2.11e-09 3.29e-06 0.53 0.46 Aortic root size; chr7:66536825 chr7:66493706~66495474:+ PAAD cis rs4654748 0.741 rs1106357 ENSG00000227001.3 NBPF2P 6.37 2.12e-09 3.3e-06 0.56 0.46 Folate pathway vitamin levels; chr1:21490592 chr1:21424625~21427967:- PAAD cis rs7044106 0.762 rs10760115 ENSG00000226752.6 PSMD5-AS1 -6.37 2.13e-09 3.31e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120714674 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs10984995 ENSG00000226752.6 PSMD5-AS1 -6.37 2.13e-09 3.31e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120716932 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs3904197 ENSG00000226752.6 PSMD5-AS1 -6.37 2.13e-09 3.31e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120718100 chr9:120824828~120854385:+ PAAD cis rs7044106 0.791 rs4617229 ENSG00000226752.6 PSMD5-AS1 -6.37 2.13e-09 3.31e-06 -0.63 -0.46 Hip circumference adjusted for BMI; chr9:120718418 chr9:120824828~120854385:+ PAAD cis rs2455601 1 rs56336128 ENSG00000254860.4 TMEM9B-AS1 6.37 2.14e-09 3.32e-06 0.66 0.46 Schizophrenia; chr11:8886752 chr11:8964675~8977527:+ PAAD cis rs7044106 0.762 rs7357638 ENSG00000226752.6 PSMD5-AS1 -6.37 2.15e-09 3.34e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120626926 chr9:120824828~120854385:+ PAAD cis rs7044106 0.718 rs1960421 ENSG00000226752.6 PSMD5-AS1 -6.37 2.15e-09 3.34e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120632616 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs7024046 ENSG00000226752.6 PSMD5-AS1 -6.37 2.15e-09 3.34e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120656900 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs4837789 ENSG00000226752.6 PSMD5-AS1 -6.37 2.15e-09 3.34e-06 -0.61 -0.46 Hip circumference adjusted for BMI; chr9:120663978 chr9:120824828~120854385:+ PAAD cis rs9322193 0.607 rs10457852 ENSG00000216906.2 RP11-350J20.9 6.37 2.15e-09 3.34e-06 0.66 0.46 Lung cancer; chr6:149880584 chr6:149904243~149906418:+ PAAD cis rs858239 1 rs156421 ENSG00000226816.2 AC005082.12 6.37 2.16e-09 3.35e-06 0.49 0.46 Cerebrospinal fluid biomarker levels; chr7:23272868 chr7:23206013~23208045:+ PAAD cis rs9660180 0.967 rs12040325 ENSG00000231050.1 RP1-140A9.1 6.37 2.17e-09 3.37e-06 0.55 0.46 Body mass index; chr1:1770997 chr1:1891471~1892658:+ PAAD cis rs7301826 0.966 rs4759795 ENSG00000256299.1 RP11-989F5.3 -6.37 2.18e-09 3.39e-06 -0.51 -0.46 Plasma plasminogen activator levels; chr12:130816355 chr12:130810821~130812622:- PAAD cis rs7811142 0.943 rs111757992 ENSG00000242294.5 STAG3L5P 6.37 2.18e-09 3.39e-06 0.35 0.46 Platelet count; chr7:100418731 chr7:100336079~100351900:+ PAAD cis rs9532669 0.889 rs9549302 ENSG00000176268.5 CYCSP34 6.36 2.21e-09 3.42e-06 0.44 0.46 Cervical cancer; chr13:40843278 chr13:40863599~40863902:- PAAD cis rs2929278 0.561 rs3099045 ENSG00000249839.1 AC011330.5 -6.36 2.21e-09 3.42e-06 -0.62 -0.46 Schizophrenia; chr15:43631757 chr15:43663654~43684339:- PAAD cis rs7301826 0.932 rs1007246 ENSG00000256299.1 RP11-989F5.3 -6.36 2.21e-09 3.42e-06 -0.51 -0.46 Plasma plasminogen activator levels; chr12:130795585 chr12:130810821~130812622:- PAAD cis rs9389248 0.69 rs2064101 ENSG00000232876.1 CTA-212D2.2 6.36 2.23e-09 3.44e-06 0.55 0.46 High light scatter reticulocyte percentage of red cells; chr6:134929392 chr6:135055033~135060550:+ PAAD cis rs4423214 0.569 rs12806918 ENSG00000254682.1 RP11-660L16.2 6.36 2.23e-09 3.44e-06 0.6 0.46 Vitamin D levels; chr11:71407972 chr11:71448674~71452157:+ PAAD cis rs4423214 0.61 rs3763856 ENSG00000254682.1 RP11-660L16.2 6.36 2.23e-09 3.44e-06 0.6 0.46 Vitamin D levels; chr11:71414299 chr11:71448674~71452157:+ PAAD cis rs2882667 0.898 rs6863347 ENSG00000253404.1 AC034243.1 6.36 2.23e-09 3.45e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139025446 chr5:138744434~138753309:- PAAD cis rs875971 0.545 rs6979636 ENSG00000237310.1 GS1-124K5.4 6.36 2.23e-09 3.45e-06 0.52 0.46 Aortic root size; chr7:66276638 chr7:66493706~66495474:+ PAAD cis rs6700559 0.967 rs12041320 ENSG00000260088.1 RP11-92G12.3 -6.36 2.25e-09 3.47e-06 -0.6 -0.46 Coronary artery disease; chr1:200652107 chr1:200669507~200694250:+ PAAD cis rs7811142 1 rs7783550 ENSG00000242294.5 STAG3L5P -6.36 2.25e-09 3.47e-06 -0.34 -0.46 Platelet count; chr7:100390182 chr7:100336079~100351900:+ PAAD cis rs7615952 0.673 rs16834637 ENSG00000171084.14 FAM86JP 6.36 2.25e-09 3.48e-06 0.87 0.46 Blood pressure (smoking interaction); chr3:125886628 chr3:125916620~125930024:+ PAAD cis rs12439619 0.508 rs17354842 ENSG00000278603.1 RP13-608F4.5 -6.36 2.25e-09 3.48e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr15:82177259 chr15:82472203~82472426:+ PAAD cis rs9532669 0.926 rs12428966 ENSG00000176268.5 CYCSP34 6.36 2.26e-09 3.48e-06 0.44 0.46 Cervical cancer; chr13:40876552 chr13:40863599~40863902:- PAAD cis rs1930961 1 rs6004673 ENSG00000272977.1 CTA-390C10.10 -6.36 2.26e-09 3.49e-06 -0.92 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25476218~25479971:+ PAAD cis rs2739330 0.828 rs4820572 ENSG00000099984.9 GSTT2 -6.36 2.29e-09 3.53e-06 -0.6 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23980123~23983911:+ PAAD cis rs7811142 0.943 rs28578163 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100447131 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs67239991 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100448881 chr7:100336079~100351900:+ PAAD cis rs7811142 0.943 rs111493473 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100452119 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs4472444 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100473135 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs7809801 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100474408 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs11766752 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100475669 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs11559117 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100478991 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs4463351 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100480603 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs60844404 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100482851 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs113738841 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100483683 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs11763511 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100484321 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs60478351 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100491394 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs7787620 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100491611 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs11769700 ENSG00000242294.5 STAG3L5P 6.36 2.29e-09 3.53e-06 0.35 0.46 Platelet count; chr7:100492426 chr7:100336079~100351900:+ PAAD cis rs2739330 0.791 rs4822458 ENSG00000231271.1 AP000350.8 6.35 2.31e-09 3.57e-06 0.62 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23949918~23954042:+ PAAD cis rs9389248 0.69 rs2294321 ENSG00000232876.1 CTA-212D2.2 6.35 2.31e-09 3.57e-06 0.54 0.46 High light scatter reticulocyte percentage of red cells; chr6:134931910 chr6:135055033~135060550:+ PAAD cis rs9399135 0.507 rs2072825 ENSG00000232876.1 CTA-212D2.2 6.35 2.31e-09 3.57e-06 0.54 0.46 Red blood cell count; chr6:134932313 chr6:135055033~135060550:+ PAAD cis rs9389248 0.69 rs2072826 ENSG00000232876.1 CTA-212D2.2 6.35 2.31e-09 3.57e-06 0.54 0.46 High light scatter reticulocyte percentage of red cells; chr6:134932420 chr6:135055033~135060550:+ PAAD cis rs7044106 0.708 rs920745 ENSG00000226752.6 PSMD5-AS1 -6.35 2.32e-09 3.57e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120667665 chr9:120824828~120854385:+ PAAD cis rs7044106 0.734 rs10491784 ENSG00000226752.6 PSMD5-AS1 -6.35 2.32e-09 3.57e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120670011 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs1886337 ENSG00000226752.6 PSMD5-AS1 -6.35 2.32e-09 3.57e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120681498 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs1411158 ENSG00000226752.6 PSMD5-AS1 -6.35 2.32e-09 3.57e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120702526 chr9:120824828~120854385:+ PAAD cis rs4218 0.573 rs4775115 ENSG00000277144.1 RP11-59H7.4 -6.35 2.32e-09 3.58e-06 -0.6 -0.46 Social communication problems; chr15:59076311 chr15:59115547~59116089:- PAAD cis rs8037818 1 rs4643284 ENSG00000276724.1 RP11-1000B6.7 -6.35 2.32e-09 3.58e-06 -0.63 -0.46 Obesity-related traits; chr15:32639897 chr15:32583612~32584312:+ PAAD cis rs4722166 0.604 rs2390715 ENSG00000179428.2 AC073072.5 -6.35 2.33e-09 3.59e-06 -0.43 -0.46 Lung cancer; chr7:22744259 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs4722169 ENSG00000179428.2 AC073072.5 -6.35 2.33e-09 3.59e-06 -0.43 -0.46 Lung cancer; chr7:22745800 chr7:22725395~22727620:- PAAD cis rs4722166 0.598 rs4722171 ENSG00000179428.2 AC073072.5 -6.35 2.33e-09 3.59e-06 -0.43 -0.46 Lung cancer; chr7:22746098 chr7:22725395~22727620:- PAAD cis rs4722166 0.603 rs7801406 ENSG00000179428.2 AC073072.5 -6.35 2.33e-09 3.59e-06 -0.43 -0.46 Lung cancer; chr7:22748655 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs12537614 ENSG00000179428.2 AC073072.5 -6.35 2.33e-09 3.59e-06 -0.43 -0.46 Lung cancer; chr7:22749932 chr7:22725395~22727620:- PAAD cis rs2739330 0.685 rs4822453 ENSG00000231271.1 AP000350.8 6.35 2.34e-09 3.59e-06 0.61 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23949918~23954042:+ PAAD cis rs17301013 0.606 rs724889 ENSG00000227373.4 RP11-160H22.5 -6.35 2.34e-09 3.59e-06 -0.66 -0.46 Systemic lupus erythematosus; chr1:174180326 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4233169 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174118986 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs1853321 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174125295 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6694208 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174127631 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs727912 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174132729 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4650951 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174134368 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4652191 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174135473 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6676161 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174138555 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6670425 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174144204 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs6685499 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174144237 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4652193 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174144554 chr1:174115300~174160004:- PAAD cis rs17301013 0.632 rs12079214 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174149572 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12065785 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174151296 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs16846717 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174152180 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs16846718 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174152782 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912735 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174159002 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12354141 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174166078 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs3086 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174167236 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12082461 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174169876 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912737 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174172999 chr1:174115300~174160004:- PAAD cis rs17301013 0.531 rs12079687 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174175545 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12087808 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174178848 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912740 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174180224 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs724888 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174180403 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs7547766 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174180977 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs72711487 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174189002 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912746 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174210205 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6692437 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174213771 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs2103640 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174219147 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs56338048 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174220266 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs11802158 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174223973 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs12081445 ENSG00000227373.4 RP11-160H22.5 6.35 2.34e-09 3.59e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174226923 chr1:174115300~174160004:- PAAD cis rs9322193 0.567 rs7747457 ENSG00000223701.3 RAET1E-AS1 6.35 2.34e-09 3.6e-06 0.54 0.46 Lung cancer; chr6:149892366 chr6:149884431~149919508:+ PAAD cis rs12439619 0.508 rs8032033 ENSG00000278603.1 RP13-608F4.5 6.35 2.35e-09 3.61e-06 0.6 0.46 Intelligence (multi-trait analysis); chr15:82165555 chr15:82472203~82472426:+ PAAD cis rs12439619 0.53 rs28883606 ENSG00000278603.1 RP13-608F4.5 6.35 2.35e-09 3.61e-06 0.6 0.46 Intelligence (multi-trait analysis); chr15:82216713 chr15:82472203~82472426:+ PAAD cis rs12439619 0.693 rs28665836 ENSG00000278603.1 RP13-608F4.5 6.35 2.35e-09 3.61e-06 0.6 0.46 Intelligence (multi-trait analysis); chr15:82218955 chr15:82472203~82472426:+ PAAD cis rs12130219 1 rs34428306 ENSG00000237975.5 FLG-AS1 6.35 2.36e-09 3.62e-06 0.56 0.46 Inflammatory skin disease; chr1:152211840 chr1:152168125~152445456:+ PAAD cis rs2919917 0.578 rs11783804 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78652776 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs10111658 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78652834 chr8:78723796~78724136:- PAAD cis rs2919917 0.59 rs10098472 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78652955 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs13251931 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78653990 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs1351742 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78655823 chr8:78723796~78724136:- PAAD cis rs2919917 0.666 rs982032 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78655825 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs4739135 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78656057 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs13265305 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78656575 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs2887482 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78659633 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs1905364 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78660244 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs1021157 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78662938 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs979564 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78663924 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs9643739 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78679535 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs2170732 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78684261 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs10109359 ENSG00000254352.1 RP11-578O24.2 6.35 2.36e-09 3.62e-06 0.5 0.46 Lymphocyte counts; chr8:78694369 chr8:78723796~78724136:- PAAD cis rs8040855 0.894 rs4843023 ENSG00000259295.5 CSPG4P12 -6.35 2.36e-09 3.63e-06 -0.52 -0.46 Bulimia nervosa; chr15:85162641 chr15:85191438~85213905:+ PAAD cis rs2882667 0.861 rs11959727 ENSG00000253404.1 AC034243.1 6.35 2.36e-09 3.63e-06 0.55 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139061276 chr5:138744434~138753309:- PAAD cis rs10875746 0.951 rs2228500 ENSG00000240399.1 RP1-228P16.1 6.35 2.37e-09 3.63e-06 0.51 0.46 Longevity (90 years and older); chr12:48132929 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs725454 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48108317 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs17122666 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48108791 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs4760681 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48111447 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs11168414 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48118548 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs11168418 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48121971 chr12:48054813~48055591:- PAAD cis rs10875746 0.951 rs10875747 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48132078 chr12:48054813~48055591:- PAAD cis rs10875746 0.951 rs10875748 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48132577 chr12:48054813~48055591:- PAAD cis rs10875746 0.951 rs2286021 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48134437 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs11168427 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48145196 chr12:48054813~48055591:- PAAD cis rs10875746 0.951 rs61918826 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48150195 chr12:48054813~48055591:- PAAD cis rs10875746 0.904 rs10875750 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48151847 chr12:48054813~48055591:- PAAD cis rs10875746 0.951 rs7485355 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48154559 chr12:48054813~48055591:- PAAD cis rs10875746 0.951 rs10875756 ENSG00000240399.1 RP1-228P16.1 -6.35 2.37e-09 3.63e-06 -0.51 -0.46 Longevity (90 years and older); chr12:48168521 chr12:48054813~48055591:- PAAD cis rs2117029 0.555 rs3741621 ENSG00000258017.1 RP11-386G11.10 -6.35 2.37e-09 3.63e-06 -0.57 -0.46 Intelligence (multi-trait analysis); chr12:49100242 chr12:49127782~49147869:+ PAAD cis rs2117029 0.555 rs2047101 ENSG00000258017.1 RP11-386G11.10 -6.35 2.37e-09 3.63e-06 -0.57 -0.46 Intelligence (multi-trait analysis); chr12:49103860 chr12:49127782~49147869:+ PAAD cis rs9660180 0.967 rs61422524 ENSG00000231050.1 RP1-140A9.1 6.35 2.38e-09 3.65e-06 0.54 0.46 Body mass index; chr1:1836126 chr1:1891471~1892658:+ PAAD cis rs1062177 0.502 rs10463321 ENSG00000213433.5 RPLP1P6 -6.35 2.4e-09 3.67e-06 -0.58 -0.46 Preschool internalizing problems; chr5:151944344 chr5:151765859~151766378:- PAAD cis rs10129255 0.5 rs8014529 ENSG00000223648.3 IGHV3-64 6.35 2.4e-09 3.68e-06 0.4 0.46 Kawasaki disease; chr14:106784065 chr14:106643132~106658258:- PAAD cis rs6504622 0.755 rs7216950 ENSG00000262879.4 RP11-156P1.3 -6.35 2.4e-09 3.68e-06 -0.47 -0.46 Orofacial clefts; chr17:47011089 chr17:46984045~47100323:- PAAD cis rs7301826 1 rs10848205 ENSG00000256299.1 RP11-989F5.3 -6.34 2.43e-09 3.71e-06 -0.51 -0.46 Plasma plasminogen activator levels; chr12:130796169 chr12:130810821~130812622:- PAAD cis rs11673344 0.864 rs79407399 ENSG00000226686.6 LINC01535 6.34 2.44e-09 3.73e-06 0.62 0.46 Obesity-related traits; chr19:37000004 chr19:37251912~37265535:+ PAAD cis rs2739330 0.587 rs4820571 ENSG00000250470.1 AP000351.3 6.34 2.45e-09 3.74e-06 0.67 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23976904~23977585:- PAAD cis rs55665837 1 rs2305305 ENSG00000251991.1 RNU7-49P 6.34 2.45e-09 3.74e-06 0.55 0.46 Vitamin D levels; chr11:14519396 chr11:14478892~14478953:+ PAAD cis rs17301013 0.606 rs4652500 ENSG00000227373.4 RP11-160H22.5 6.34 2.46e-09 3.75e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174500656 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12071794 ENSG00000227373.4 RP11-160H22.5 6.34 2.46e-09 3.75e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174500767 chr1:174115300~174160004:- PAAD cis rs17301013 0.556 rs7535845 ENSG00000227373.4 RP11-160H22.5 6.34 2.46e-09 3.75e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174502672 chr1:174115300~174160004:- PAAD cis rs950169 0.881 rs4842852 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84387263 chr15:84199311~84230136:- PAAD cis rs950169 0.84 rs4842853 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84387606 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs4842946 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84387633 chr15:84199311~84230136:- PAAD cis rs950169 0.84 rs4842854 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84387641 chr15:84199311~84230136:- PAAD cis rs950169 0.84 rs2896002 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84390423 chr15:84199311~84230136:- PAAD cis rs950169 0.887 rs3860265 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84390487 chr15:84199311~84230136:- PAAD cis rs950169 0.724 rs11632668 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84393989 chr15:84199311~84230136:- PAAD cis rs950169 0.881 rs34591918 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84396135 chr15:84199311~84230136:- PAAD cis rs950169 0.887 rs12903946 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84399732 chr15:84199311~84230136:- PAAD cis rs950169 0.887 rs35986397 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84400409 chr15:84199311~84230136:- PAAD cis rs950169 0.887 rs62029593 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84400482 chr15:84199311~84230136:- PAAD cis rs950169 0.81 rs62029594 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84400554 chr15:84199311~84230136:- PAAD cis rs950169 0.881 rs62029596 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84400736 chr15:84199311~84230136:- PAAD cis rs950169 0.881 rs4081123 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84401537 chr15:84199311~84230136:- PAAD cis rs950169 0.881 rs62029599 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84401867 chr15:84199311~84230136:- PAAD cis rs950169 0.8 rs4099846 ENSG00000225151.9 GOLGA2P7 -6.34 2.46e-09 3.75e-06 -0.55 -0.46 Schizophrenia; chr15:84402196 chr15:84199311~84230136:- PAAD cis rs7945705 0.902 rs2016942 ENSG00000254860.4 TMEM9B-AS1 -6.34 2.46e-09 3.76e-06 -0.51 -0.46 Hemoglobin concentration; chr11:8917240 chr11:8964675~8977527:+ PAAD cis rs875971 0.545 rs1796226 ENSG00000237310.1 GS1-124K5.4 6.34 2.47e-09 3.77e-06 0.53 0.46 Aortic root size; chr7:66622723 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs1796217 ENSG00000237310.1 GS1-124K5.4 -6.34 2.47e-09 3.77e-06 -0.53 -0.46 Aortic root size; chr7:66620931 chr7:66493706~66495474:+ PAAD cis rs2882667 0.898 rs12719519 ENSG00000253404.1 AC034243.1 6.34 2.49e-09 3.8e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139039998 chr5:138744434~138753309:- PAAD cis rs4698412 0.56 rs4698119 ENSG00000214846.4 RP11-115L11.1 -6.34 2.49e-09 3.8e-06 -0.57 -0.46 Parkinson's disease; chr4:15737172 chr4:15730962~15731627:- PAAD cis rs7301826 1 rs10773819 ENSG00000256299.1 RP11-989F5.3 -6.34 2.52e-09 3.84e-06 -0.51 -0.46 Plasma plasminogen activator levels; chr12:130794477 chr12:130810821~130812622:- PAAD cis rs7429990 0.965 rs5016900 ENSG00000229759.1 MRPS18AP1 6.34 2.52e-09 3.84e-06 0.54 0.46 Educational attainment (years of education); chr3:47781387 chr3:48256350~48256938:- PAAD cis rs7429990 0.896 rs34448818 ENSG00000229759.1 MRPS18AP1 6.34 2.52e-09 3.84e-06 0.54 0.46 Educational attainment (years of education); chr3:47799822 chr3:48256350~48256938:- PAAD cis rs7429990 0.93 rs13072132 ENSG00000229759.1 MRPS18AP1 6.34 2.52e-09 3.84e-06 0.54 0.46 Educational attainment (years of education); chr3:47824671 chr3:48256350~48256938:- PAAD cis rs7429990 0.965 rs34507589 ENSG00000229759.1 MRPS18AP1 6.34 2.52e-09 3.84e-06 0.54 0.46 Educational attainment (years of education); chr3:47832552 chr3:48256350~48256938:- PAAD cis rs11123694 1 rs11123694 ENSG00000214184.3 AC012487.2 -6.34 2.53e-09 3.85e-06 -0.53 -0.46 Mean platelet volume; chr2:108448107 chr2:108507515~108534196:- PAAD cis rs11098499 0.754 rs9991959 ENSG00000245958.5 RP11-33B1.1 6.34 2.53e-09 3.86e-06 0.35 0.46 Corneal astigmatism; chr4:119332618 chr4:119454791~119552025:+ PAAD cis rs2882667 0.898 rs6862393 ENSG00000253404.1 AC034243.1 6.34 2.54e-09 3.86e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139029009 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs4643949 ENSG00000253404.1 AC034243.1 6.34 2.54e-09 3.86e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139036656 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs6867343 ENSG00000253404.1 AC034243.1 6.34 2.54e-09 3.86e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139038739 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs2882792 ENSG00000253404.1 AC034243.1 6.34 2.54e-09 3.86e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139044791 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs6882330 ENSG00000253404.1 AC034243.1 6.34 2.54e-09 3.86e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139046493 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs6882526 ENSG00000253404.1 AC034243.1 6.34 2.54e-09 3.86e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139046679 chr5:138744434~138753309:- PAAD cis rs11098499 0.955 rs7685268 ENSG00000245958.5 RP11-33B1.1 -6.34 2.54e-09 3.86e-06 -0.37 -0.46 Corneal astigmatism; chr4:119241033 chr4:119454791~119552025:+ PAAD cis rs11155671 0.53 rs2342770 ENSG00000223701.3 RAET1E-AS1 6.34 2.55e-09 3.88e-06 0.55 0.46 Testicular germ cell tumor; chr6:149895549 chr6:149884431~149919508:+ PAAD cis rs1061377 1 rs3796509 ENSG00000249685.1 RP11-360F5.3 6.33 2.56e-09 3.9e-06 0.49 0.46 Uric acid levels; chr4:39108566 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs4974931 ENSG00000249685.1 RP11-360F5.3 6.33 2.56e-09 3.9e-06 0.49 0.46 Uric acid levels; chr4:39108896 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs4974998 ENSG00000249685.1 RP11-360F5.3 6.33 2.56e-09 3.9e-06 0.49 0.46 Uric acid levels; chr4:39109129 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7673299 ENSG00000249685.1 RP11-360F5.3 6.33 2.56e-09 3.9e-06 0.49 0.46 Uric acid levels; chr4:39109138 chr4:39133913~39135608:+ PAAD cis rs1075265 0.633 rs10183655 ENSG00000233266.1 HMGB1P31 6.33 2.57e-09 3.91e-06 0.58 0.46 Chronotype;Morning vs. evening chronotype; chr2:53983644 chr2:54051334~54051760:+ PAAD cis rs10256972 1 rs10256972 ENSG00000229043.2 AC091729.9 6.33 2.57e-09 3.91e-06 0.49 0.46 Endometriosis;Longevity; chr7:999367 chr7:1160374~1165267:+ PAAD cis rs2919917 0.617 rs4641056 ENSG00000254352.1 RP11-578O24.2 6.33 2.58e-09 3.92e-06 0.5 0.46 Lymphocyte counts; chr8:78670261 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs7823970 ENSG00000254352.1 RP11-578O24.2 6.33 2.58e-09 3.92e-06 0.5 0.46 Lymphocyte counts; chr8:78681364 chr8:78723796~78724136:- PAAD cis rs2919917 0.616 rs7823723 ENSG00000254352.1 RP11-578O24.2 6.33 2.58e-09 3.92e-06 0.5 0.46 Lymphocyte counts; chr8:78681390 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs6997255 ENSG00000254352.1 RP11-578O24.2 6.33 2.58e-09 3.92e-06 0.5 0.46 Lymphocyte counts; chr8:78694850 chr8:78723796~78724136:- PAAD cis rs2919917 0.628 rs7017898 ENSG00000254352.1 RP11-578O24.2 6.33 2.58e-09 3.92e-06 0.5 0.46 Lymphocyte counts; chr8:78697147 chr8:78723796~78724136:- PAAD cis rs2404602 0.552 rs11634428 ENSG00000259422.1 RP11-593F23.1 -6.33 2.58e-09 3.92e-06 -0.57 -0.46 Blood metabolite levels; chr15:76792241 chr15:76174891~76181486:- PAAD cis rs4722166 0.63 rs13311155 ENSG00000179428.2 AC073072.5 -6.33 2.58e-09 3.93e-06 -0.43 -0.46 Lung cancer; chr7:22750170 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs13311199 ENSG00000179428.2 AC073072.5 -6.33 2.58e-09 3.93e-06 -0.43 -0.46 Lung cancer; chr7:22750174 chr7:22725395~22727620:- PAAD cis rs7586673 0.964 rs34444368 ENSG00000227403.1 AC009299.3 -6.33 2.58e-09 3.93e-06 -0.63 -0.46 Intelligence (multi-trait analysis); chr2:161097706 chr2:161244739~161249050:+ PAAD cis rs10875746 0.951 rs8804 ENSG00000240399.1 RP1-228P16.1 -6.33 2.59e-09 3.94e-06 -0.49 -0.46 Longevity (90 years and older); chr12:48147974 chr12:48054813~48055591:- PAAD cis rs4218 0.543 rs35658945 ENSG00000277144.1 RP11-59H7.4 -6.33 2.59e-09 3.94e-06 -0.55 -0.46 Social communication problems; chr15:59018053 chr15:59115547~59116089:- PAAD cis rs4722166 0.63 rs12700390 ENSG00000179428.2 AC073072.5 -6.33 2.6e-09 3.95e-06 -0.43 -0.46 Lung cancer; chr7:22737510 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs12700391 ENSG00000179428.2 AC073072.5 -6.33 2.6e-09 3.95e-06 -0.43 -0.46 Lung cancer; chr7:22737708 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs7781534 ENSG00000179428.2 AC073072.5 -6.33 2.6e-09 3.95e-06 -0.43 -0.46 Lung cancer; chr7:22738973 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs4722168 ENSG00000179428.2 AC073072.5 -6.33 2.6e-09 3.95e-06 -0.43 -0.46 Lung cancer; chr7:22739383 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs1581497 ENSG00000179428.2 AC073072.5 -6.33 2.6e-09 3.95e-06 -0.43 -0.46 Lung cancer; chr7:22739884 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs1829927 ENSG00000179428.2 AC073072.5 -6.33 2.6e-09 3.95e-06 -0.43 -0.46 Lung cancer; chr7:22740299 chr7:22725395~22727620:- PAAD cis rs4722166 0.63 rs6969258 ENSG00000179428.2 AC073072.5 -6.33 2.6e-09 3.95e-06 -0.43 -0.46 Lung cancer; chr7:22742909 chr7:22725395~22727620:- PAAD cis rs11098499 0.722 rs1814814 ENSG00000245958.5 RP11-33B1.1 -6.33 2.6e-09 3.96e-06 -0.32 -0.46 Corneal astigmatism; chr4:119336969 chr4:119454791~119552025:+ PAAD cis rs11155671 0.53 rs2342769 ENSG00000223701.3 RAET1E-AS1 6.33 2.61e-09 3.96e-06 0.54 0.46 Testicular germ cell tumor; chr6:149895371 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs6935829 ENSG00000223701.3 RAET1E-AS1 6.33 2.61e-09 3.96e-06 0.54 0.46 Testicular germ cell tumor; chr6:149896675 chr6:149884431~149919508:+ PAAD cis rs2739330 0.828 rs2330635 ENSG00000099984.9 GSTT2 -6.33 2.61e-09 3.96e-06 -0.6 -0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23980123~23983911:+ PAAD cis rs950169 0.922 rs8037078 ENSG00000225151.9 GOLGA2P7 6.33 2.63e-09 4e-06 0.54 0.46 Schizophrenia; chr15:84150119 chr15:84199311~84230136:- PAAD cis rs1928295 0.786 rs28693508 ENSG00000233569.1 RP11-500B12.1 6.33 2.64e-09 4e-06 0.5 0.46 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117599140 chr9:117648606~117657027:+ PAAD cis rs1928295 0.786 rs10759926 ENSG00000233569.1 RP11-500B12.1 6.33 2.64e-09 4e-06 0.5 0.46 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117603947 chr9:117648606~117657027:+ PAAD cis rs1928295 0.786 rs10983712 ENSG00000233569.1 RP11-500B12.1 6.33 2.64e-09 4e-06 0.5 0.46 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117606458 chr9:117648606~117657027:+ PAAD cis rs1928295 0.786 rs7038943 ENSG00000233569.1 RP11-500B12.1 6.33 2.64e-09 4e-06 0.5 0.46 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117614900 chr9:117648606~117657027:+ PAAD cis rs17301013 0.606 rs5015737 ENSG00000227373.4 RP11-160H22.5 6.33 2.64e-09 4e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174452857 chr1:174115300~174160004:- PAAD cis rs2882667 0.858 rs11242448 ENSG00000253404.1 AC034243.1 6.33 2.64e-09 4e-06 0.57 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139107465 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs13176497 ENSG00000253404.1 AC034243.1 6.33 2.64e-09 4e-06 0.57 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139110385 chr5:138744434~138753309:- PAAD cis rs4938303 0.718 rs3212282 ENSG00000254851.1 RP11-109L13.1 -6.33 2.64e-09 4.01e-06 -0.71 -0.46 Triglycerides; chr11:116731229 chr11:117135528~117138582:+ PAAD cis rs71327718 1 rs71327718 ENSG00000171084.14 FAM86JP 6.33 2.65e-09 4.02e-06 0.82 0.46 Metabolite levels (HVA/5-HIAA ratio); chr3:125874014 chr3:125916620~125930024:+ PAAD cis rs2117029 0.555 rs10783304 ENSG00000258017.1 RP11-386G11.10 -6.33 2.65e-09 4.02e-06 -0.57 -0.46 Intelligence (multi-trait analysis); chr12:49106615 chr12:49127782~49147869:+ PAAD cis rs11673344 0.566 rs11666708 ENSG00000226686.6 LINC01535 -6.33 2.65e-09 4.03e-06 -0.55 -0.46 Obesity-related traits; chr19:37396208 chr19:37251912~37265535:+ PAAD cis rs2739330 0.627 rs9608219 ENSG00000231271.1 AP000350.8 6.33 2.66e-09 4.03e-06 0.63 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23949918~23954042:+ PAAD cis rs4722166 0.541 rs1800795 ENSG00000179428.2 AC073072.5 -6.33 2.66e-09 4.03e-06 -0.43 -0.46 Lung cancer; chr7:22727026 chr7:22725395~22727620:- PAAD cis rs2739330 0.796 rs5760106 ENSG00000099984.9 GSTT2 6.33 2.67e-09 4.04e-06 0.6 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23980123~23983911:+ PAAD cis rs9389248 0.69 rs728030 ENSG00000232876.1 CTA-212D2.2 6.33 2.67e-09 4.04e-06 0.54 0.46 High light scatter reticulocyte percentage of red cells; chr6:134925156 chr6:135055033~135060550:+ PAAD cis rs11673344 0.77 rs34729406 ENSG00000226686.6 LINC01535 6.33 2.67e-09 4.06e-06 0.62 0.46 Obesity-related traits; chr19:37012764 chr19:37251912~37265535:+ PAAD cis rs11673344 0.75 rs78241494 ENSG00000226686.6 LINC01535 6.33 2.68e-09 4.06e-06 0.63 0.46 Obesity-related traits; chr19:37158846 chr19:37251912~37265535:+ PAAD cis rs11673344 0.838 rs111827672 ENSG00000226686.6 LINC01535 6.33 2.68e-09 4.06e-06 0.63 0.46 Obesity-related traits; chr19:37158964 chr19:37251912~37265535:+ PAAD cis rs2882667 0.858 rs7724108 ENSG00000253404.1 AC034243.1 -6.33 2.68e-09 4.07e-06 -0.56 -0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139075233 chr5:138744434~138753309:- PAAD cis rs11155671 0.53 rs9371544 ENSG00000223701.3 RAET1E-AS1 6.32 2.69e-09 4.08e-06 0.54 0.46 Testicular germ cell tumor; chr6:149896224 chr6:149884431~149919508:+ PAAD cis rs2739330 0.703 rs5760112 ENSG00000231271.1 AP000350.8 6.32 2.7e-09 4.1e-06 0.6 0.46 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23949918~23954042:+ PAAD cis rs11673344 0.566 rs1545755 ENSG00000226686.6 LINC01535 6.32 2.71e-09 4.1e-06 0.54 0.46 Obesity-related traits; chr19:37490607 chr19:37251912~37265535:+ PAAD cis rs10256972 0.967 rs1881122 ENSG00000229043.2 AC091729.9 -6.32 2.72e-09 4.12e-06 -0.49 -0.46 Endometriosis;Longevity; chr7:1001310 chr7:1160374~1165267:+ PAAD cis rs9640161 0.659 rs17837498 ENSG00000261305.1 RP4-584D14.7 6.32 2.73e-09 4.13e-06 0.67 0.46 Blood protein levels;Circulating chemerin levels; chr7:150312590 chr7:150341771~150342607:+ PAAD cis rs1928295 0.786 rs10983720 ENSG00000233569.1 RP11-500B12.1 6.32 2.74e-09 4.14e-06 0.5 0.46 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117625209 chr9:117648606~117657027:+ PAAD cis rs1928295 0.75 rs10818054 ENSG00000233569.1 RP11-500B12.1 6.32 2.74e-09 4.14e-06 0.5 0.46 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117625739 chr9:117648606~117657027:+ PAAD cis rs11098499 0.908 rs7696649 ENSG00000245958.5 RP11-33B1.1 -6.32 2.74e-09 4.15e-06 -0.39 -0.46 Corneal astigmatism; chr4:119401022 chr4:119454791~119552025:+ PAAD cis rs950169 0.922 rs2033284 ENSG00000225151.9 GOLGA2P7 -6.32 2.75e-09 4.17e-06 -0.55 -0.46 Schizophrenia; chr15:84391575 chr15:84199311~84230136:- PAAD cis rs17301013 0.54 rs72713601 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174482987 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs9729907 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174483607 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs2901818 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174486239 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6658315 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174489961 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12064743 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174496646 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs7536102 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174496801 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs7522253 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174496980 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912798 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174511420 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs10912799 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174511422 chr1:174115300~174160004:- PAAD cis rs17301013 0.556 rs10912800 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174513939 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs56213002 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174516512 chr1:174115300~174160004:- PAAD cis rs17301013 0.541 rs10798319 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174516983 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs9730220 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174519092 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12062170 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174528420 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12062483 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174529089 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6681970 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174532698 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12080535 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174569832 chr1:174115300~174160004:- PAAD cis rs17301013 0.54 rs61624206 ENSG00000227373.4 RP11-160H22.5 6.32 2.78e-09 4.19e-06 0.65 0.46 Systemic lupus erythematosus; chr1:174578374 chr1:174115300~174160004:- PAAD cis rs1061377 1 rs9999327 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39110111 chr4:39133913~39135608:+ PAAD cis rs1061377 0.965 rs6833654 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39110701 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1036036 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39111104 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1036037 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39111272 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1036038 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39111383 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1560396 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39112092 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1560397 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39112265 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs2381285 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39112775 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs2163272 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39112790 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs2163273 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39112835 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs62310332 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39112939 chr4:39133913~39135608:+ PAAD cis rs1061377 0.965 rs3796510 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39113309 chr4:39133913~39135608:+ PAAD cis rs1061377 0.932 rs6855118 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39114322 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs6829234 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39114586 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs6829450 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39114721 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs6812540 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39114803 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs10026775 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39115155 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs3733276 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39115291 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs3733277 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39115483 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs3733278 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39115615 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs3733279 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39115625 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs10018049 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39115781 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7685082 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39116472 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7664078 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39116583 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7685468 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39116649 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs9998481 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39117215 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs9998867 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39117542 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs2381284 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39117976 chr4:39133913~39135608:+ PAAD cis rs1061377 0.803 rs6857761 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39118353 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs9997089 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39119263 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs28465556 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39119569 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs10027813 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39119818 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs9990755 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39119819 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7675782 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39120048 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7676008 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39120154 chr4:39133913~39135608:+ PAAD cis rs1061377 0.965 rs7677729 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39120370 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7655122 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39120396 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs3796511 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39120586 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs3733274 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39120957 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs13182 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39121293 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1061377 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39123130 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1982009 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39123253 chr4:39133913~39135608:+ PAAD cis rs1061377 0.965 rs1138494 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39123315 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs13109200 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39124396 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs2890659 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39125401 chr4:39133913~39135608:+ PAAD cis rs1061377 0.965 rs1046655 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39126127 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7694760 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39126481 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs34771104 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39127432 chr4:39133913~39135608:+ PAAD cis rs1061377 0.932 rs35464499 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39127670 chr4:39133913~39135608:+ PAAD cis rs1061377 0.965 rs11728058 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39128224 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs13144374 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39128859 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs17508864 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39129025 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs9996285 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39130556 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1897136 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39131242 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs1897137 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39131387 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs35437629 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39131712 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7657926 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39132443 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs7681116 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39133015 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs11096982 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39133247 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs11727875 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39133699 chr4:39133913~39135608:+ PAAD cis rs1061377 0.965 rs10018622 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39133944 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs28607301 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39136460 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs36090629 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39137195 chr4:39133913~39135608:+ PAAD cis rs1061377 0.87 rs73238544 ENSG00000249685.1 RP11-360F5.3 6.32 2.78e-09 4.19e-06 0.49 0.46 Uric acid levels; chr4:39137343 chr4:39133913~39135608:+ PAAD cis rs11673344 0.566 rs8109103 ENSG00000226686.6 LINC01535 6.32 2.79e-09 4.2e-06 0.54 0.46 Obesity-related traits; chr19:37503209 chr19:37251912~37265535:+ PAAD cis rs7429990 0.895 rs35790549 ENSG00000229759.1 MRPS18AP1 6.32 2.81e-09 4.22e-06 0.51 0.46 Educational attainment (years of education); chr3:48029998 chr3:48256350~48256938:- PAAD cis rs11673344 0.832 rs112380313 ENSG00000226686.6 LINC01535 6.32 2.81e-09 4.23e-06 0.62 0.46 Obesity-related traits; chr19:37027979 chr19:37251912~37265535:+ PAAD cis rs11673344 0.832 rs76470527 ENSG00000226686.6 LINC01535 6.32 2.81e-09 4.23e-06 0.62 0.46 Obesity-related traits; chr19:37035981 chr19:37251912~37265535:+ PAAD cis rs11673344 0.74 rs113752815 ENSG00000226686.6 LINC01535 6.32 2.81e-09 4.23e-06 0.62 0.46 Obesity-related traits; chr19:37043829 chr19:37251912~37265535:+ PAAD cis rs6452524 0.836 rs4343818 ENSG00000249664.1 CTD-2227C6.2 6.31 2.83e-09 4.25e-06 0.53 0.46 Hypertension (SNP x SNP interaction); chr5:83205603 chr5:83012285~83013109:- PAAD cis rs7044106 0.762 rs10818471 ENSG00000226752.6 PSMD5-AS1 -6.31 2.83e-09 4.25e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120631767 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs1547267 ENSG00000226752.6 PSMD5-AS1 -6.31 2.83e-09 4.25e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120646458 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs4142158 ENSG00000226752.6 PSMD5-AS1 -6.31 2.83e-09 4.25e-06 -0.62 -0.46 Hip circumference adjusted for BMI; chr9:120648541 chr9:120824828~120854385:+ PAAD cis rs11673344 0.832 rs11540540 ENSG00000226686.6 LINC01535 6.31 2.85e-09 4.28e-06 0.62 0.46 Obesity-related traits; chr19:37129629 chr19:37251912~37265535:+ PAAD cis rs11673344 0.801 rs76806623 ENSG00000226686.6 LINC01535 6.31 2.85e-09 4.28e-06 0.62 0.46 Obesity-related traits; chr19:37132525 chr19:37251912~37265535:+ PAAD cis rs11673344 0.636 rs7255595 ENSG00000226686.6 LINC01535 6.31 2.85e-09 4.29e-06 0.64 0.46 Obesity-related traits; chr19:36896260 chr19:37251912~37265535:+ PAAD cis rs7301826 1 rs10744482 ENSG00000256299.1 RP11-989F5.3 -6.31 2.86e-09 4.29e-06 -0.51 -0.46 Plasma plasminogen activator levels; chr12:130813650 chr12:130810821~130812622:- PAAD cis rs6723162 1 rs6723162 ENSG00000237751.2 LINC01143 -6.31 2.86e-09 4.3e-06 -0.53 -0.46 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70875156 chr2:70887871~70889959:+ PAAD cis rs35160687 0.871 rs2278105 ENSG00000273080.1 RP11-301O19.1 6.31 2.86e-09 4.3e-06 0.51 0.46 Night sleep phenotypes; chr2:86239393 chr2:86195590~86196049:+ PAAD cis rs11673344 0.838 rs55856280 ENSG00000226686.6 LINC01535 6.31 2.88e-09 4.32e-06 0.63 0.46 Obesity-related traits; chr19:37150747 chr19:37251912~37265535:+ PAAD cis rs1061377 0.965 rs12504238 ENSG00000249685.1 RP11-360F5.3 6.31 2.88e-09 4.32e-06 0.49 0.46 Uric acid levels; chr4:39142824 chr4:39133913~39135608:+ PAAD cis rs1150668 0.796 rs1052215 ENSG00000216901.1 AL022393.7 -6.31 2.88e-09 4.33e-06 -0.56 -0.46 Pubertal anthropometrics; chr6:28380381 chr6:28176188~28176674:+ PAAD cis rs17264034 0.821 rs60322708 ENSG00000250786.1 SNHG18 6.31 2.89e-09 4.34e-06 0.6 0.46 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9555837 chr5:9546200~9550609:+ PAAD cis rs35160687 0.901 rs12622200 ENSG00000273080.1 RP11-301O19.1 -6.31 2.91e-09 4.36e-06 -0.51 -0.46 Night sleep phenotypes; chr2:86271472 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs10520415 ENSG00000273080.1 RP11-301O19.1 -6.31 2.91e-09 4.36e-06 -0.51 -0.46 Night sleep phenotypes; chr2:86271615 chr2:86195590~86196049:+ PAAD cis rs7811142 1 rs11771419 ENSG00000242294.5 STAG3L5P 6.31 2.91e-09 4.36e-06 0.35 0.46 Platelet count; chr7:100390780 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs76913697 ENSG00000242294.5 STAG3L5P 6.31 2.91e-09 4.36e-06 0.35 0.46 Platelet count; chr7:100405149 chr7:100336079~100351900:+ PAAD cis rs875971 0.545 rs10261710 ENSG00000237310.1 GS1-124K5.4 6.31 2.91e-09 4.37e-06 0.52 0.46 Aortic root size; chr7:66249202 chr7:66493706~66495474:+ PAAD cis rs2404602 0.552 rs11630185 ENSG00000259422.1 RP11-593F23.1 -6.31 2.91e-09 4.37e-06 -0.57 -0.46 Blood metabolite levels; chr15:76667442 chr15:76174891~76181486:- PAAD cis rs17301013 0.606 rs12079689 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174240514 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs7535987 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174240840 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs7551605 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174245718 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs12080977 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174247026 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs72713503 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174247553 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs16846816 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174251602 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912750 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174253637 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs12083540 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174254096 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12085311 ENSG00000227373.4 RP11-160H22.5 6.31 2.91e-09 4.37e-06 0.66 0.46 Systemic lupus erythematosus; chr1:174256097 chr1:174115300~174160004:- PAAD cis rs1061377 0.722 rs34803689 ENSG00000249685.1 RP11-360F5.3 6.31 2.92e-09 4.37e-06 0.49 0.46 Uric acid levels; chr4:39116665 chr4:39133913~39135608:+ PAAD cis rs1061377 0.965 rs7669376 ENSG00000249685.1 RP11-360F5.3 6.31 2.92e-09 4.37e-06 0.49 0.46 Uric acid levels; chr4:39116717 chr4:39133913~39135608:+ PAAD cis rs17301013 0.606 rs72711443 ENSG00000227373.4 RP11-160H22.5 6.31 2.93e-09 4.38e-06 0.67 0.46 Systemic lupus erythematosus; chr1:174090876 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912728 ENSG00000227373.4 RP11-160H22.5 6.31 2.93e-09 4.38e-06 0.67 0.46 Systemic lupus erythematosus; chr1:174093234 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4652168 ENSG00000227373.4 RP11-160H22.5 6.31 2.93e-09 4.38e-06 0.67 0.46 Systemic lupus erythematosus; chr1:174095077 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs28831202 ENSG00000227373.4 RP11-160H22.5 6.31 2.93e-09 4.38e-06 0.67 0.46 Systemic lupus erythematosus; chr1:174099231 chr1:174115300~174160004:- PAAD cis rs12022452 0.822 rs11811369 ENSG00000238287.1 RP11-656D10.3 -6.31 2.94e-09 4.4e-06 -0.68 -0.46 Age-related hearing impairment (SNP x SNP interaction); chr1:40560611 chr1:40493157~40508661:- PAAD cis rs55726902 0.506 rs1006476 ENSG00000276691.1 RP5-1057I20.5 6.31 2.94e-09 4.4e-06 0.56 0.46 Allergic disease (asthma, hay fever or eczema); chr12:47785564 chr12:47788426~47788971:+ PAAD cis rs3096299 0.504 rs4785574 ENSG00000274627.1 RP11-104N10.2 6.31 2.94e-09 4.41e-06 0.41 0.46 Multiple myeloma (IgH translocation); chr16:89502467 chr16:89516797~89522217:+ PAAD cis rs2117029 0.561 rs7957983 ENSG00000258017.1 RP11-386G11.10 -6.31 2.94e-09 4.41e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49115204 chr12:49127782~49147869:+ PAAD cis rs2117029 0.587 rs7958572 ENSG00000258017.1 RP11-386G11.10 -6.31 2.94e-09 4.41e-06 -0.59 -0.46 Intelligence (multi-trait analysis); chr12:49115658 chr12:49127782~49147869:+ PAAD cis rs2929278 0.736 rs2412823 ENSG00000249839.1 AC011330.5 6.31 2.96e-09 4.42e-06 0.62 0.46 Schizophrenia; chr15:43935072 chr15:43663654~43684339:- PAAD cis rs7811142 1 rs11771241 ENSG00000242294.5 STAG3L5P 6.31 2.96e-09 4.43e-06 0.35 0.46 Platelet count; chr7:100397162 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs67471932 ENSG00000242294.5 STAG3L5P 6.31 2.96e-09 4.43e-06 0.35 0.46 Platelet count; chr7:100412362 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs73161759 ENSG00000242294.5 STAG3L5P 6.31 2.96e-09 4.43e-06 0.35 0.46 Platelet count; chr7:100412371 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs67315960 ENSG00000242294.5 STAG3L5P 6.31 2.96e-09 4.43e-06 0.35 0.46 Platelet count; chr7:100417501 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs11763414 ENSG00000242294.5 STAG3L5P 6.31 2.96e-09 4.43e-06 0.35 0.46 Platelet count; chr7:100419221 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs66632384 ENSG00000242294.5 STAG3L5P 6.31 2.96e-09 4.43e-06 0.35 0.46 Platelet count; chr7:100421281 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs67163493 ENSG00000242294.5 STAG3L5P 6.31 2.96e-09 4.43e-06 0.35 0.46 Platelet count; chr7:100426215 chr7:100336079~100351900:+ PAAD cis rs7811142 0.943 rs73403312 ENSG00000242294.5 STAG3L5P 6.31 2.96e-09 4.43e-06 0.35 0.46 Platelet count; chr7:100426530 chr7:100336079~100351900:+ PAAD cis rs1061377 1 rs4974997 ENSG00000249685.1 RP11-360F5.3 6.31 2.96e-09 4.43e-06 0.49 0.46 Uric acid levels; chr4:39109151 chr4:39133913~39135608:+ PAAD cis rs12458462 0.787 rs56006341 ENSG00000274828.1 RP11-567M16.6 6.31 2.96e-09 4.43e-06 0.44 0.46 Monocyte count; chr18:79679844 chr18:79677287~79679358:- PAAD cis rs12458462 0.859 rs35493271 ENSG00000274828.1 RP11-567M16.6 6.31 2.96e-09 4.43e-06 0.44 0.46 Monocyte count; chr18:79688793 chr18:79677287~79679358:- PAAD cis rs853679 0.538 rs13199081 ENSG00000204709.4 LINC01556 6.31 2.97e-09 4.44e-06 0.68 0.46 Depression; chr6:28364057 chr6:28943877~28944537:+ PAAD cis rs1930961 1 rs1930961 ENSG00000272977.1 CTA-390C10.10 -6.31 2.97e-09 4.44e-06 -0.89 -0.46 Bipolar disorder with mood-incongruent psychosis; chr22:25479298 chr22:25476218~25479971:+ PAAD cis rs2882667 0.898 rs10058347 ENSG00000253404.1 AC034243.1 6.3 2.98e-09 4.45e-06 0.55 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139025669 chr5:138744434~138753309:- PAAD cis rs17264034 0.861 rs11749803 ENSG00000250786.1 SNHG18 6.3 2.99e-09 4.46e-06 0.6 0.46 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9553456 chr5:9546200~9550609:+ PAAD cis rs17264034 0.861 rs56344213 ENSG00000250786.1 SNHG18 6.3 2.99e-09 4.46e-06 0.6 0.46 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9553756 chr5:9546200~9550609:+ PAAD cis rs6452524 0.904 rs10474095 ENSG00000249664.1 CTD-2227C6.2 6.3 2.99e-09 4.47e-06 0.57 0.46 Hypertension (SNP x SNP interaction); chr5:83154887 chr5:83012285~83013109:- PAAD cis rs4218 0.543 rs2414618 ENSG00000277144.1 RP11-59H7.4 -6.3 2.99e-09 4.47e-06 -0.55 -0.46 Social communication problems; chr15:59019684 chr15:59115547~59116089:- PAAD cis rs4218 0.543 rs12050865 ENSG00000277144.1 RP11-59H7.4 -6.3 2.99e-09 4.47e-06 -0.55 -0.46 Social communication problems; chr15:59020689 chr15:59115547~59116089:- PAAD cis rs9322193 0.923 rs12526675 ENSG00000216906.2 RP11-350J20.9 -6.3 2.99e-09 4.47e-06 -0.58 -0.46 Lung cancer; chr6:149729540 chr6:149904243~149906418:+ PAAD cis rs6452524 0.836 rs62374402 ENSG00000249664.1 CTD-2227C6.2 6.3 3.01e-09 4.49e-06 0.55 0.46 Hypertension (SNP x SNP interaction); chr5:83207343 chr5:83012285~83013109:- PAAD cis rs673078 0.607 rs61943391 ENSG00000275759.1 RP11-131L12.3 -6.3 3.01e-09 4.49e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118382603 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943392 ENSG00000275759.1 RP11-131L12.3 -6.3 3.01e-09 4.49e-06 -0.7 -0.46 Glucose homeostasis traits; chr12:118382618 chr12:118428281~118428870:+ PAAD cis rs7301826 1 rs1609985 ENSG00000256299.1 RP11-989F5.3 -6.3 3.02e-09 4.51e-06 -0.51 -0.46 Plasma plasminogen activator levels; chr12:130835625 chr12:130810821~130812622:- PAAD cis rs5760092 0.572 rs738806 ENSG00000218537.1 MIF-AS1 6.3 3.03e-09 4.52e-06 0.66 0.46 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23894426~23898930:- PAAD cis rs2882667 0.858 rs35812969 ENSG00000253404.1 AC034243.1 6.3 3.04e-09 4.53e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139041861 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs11242442 ENSG00000253404.1 AC034243.1 6.3 3.04e-09 4.53e-06 0.56 0.46 Age-related hearing impairment (SNP x SNP interaction); chr5:139044800 chr5:138744434~138753309:- PAAD cis rs9601248 0.756 rs2146592 ENSG00000227676.3 LINC01068 -6.3 3.04e-09 4.53e-06 -0.57 -0.46 Major depressive disorder; chr13:79606146 chr13:79566727~79571436:+ PAAD cis rs6504622 0.755 rs11653838 ENSG00000262879.4 RP11-156P1.3 -6.3 3.04e-09 4.54e-06 -0.46 -0.46 Orofacial clefts; chr17:47006317 chr17:46984045~47100323:- PAAD cis rs2919917 0.628 rs1384803 ENSG00000254352.1 RP11-578O24.2 -6.3 3.05e-09 4.55e-06 -0.49 -0.46 Lymphocyte counts; chr8:78669393 chr8:78723796~78724136:- PAAD cis rs7811142 1 rs60257855 ENSG00000242294.5 STAG3L5P 6.3 3.05e-09 4.56e-06 0.35 0.46 Platelet count; chr7:100429157 chr7:100336079~100351900:+ PAAD cis rs12458462 0.851 rs3859317 ENSG00000274828.1 RP11-567M16.6 6.3 3.07e-09 4.57e-06 0.44 0.45 Monocyte count; chr18:79683093 chr18:79677287~79679358:- PAAD cis rs35160687 0.901 rs13020869 ENSG00000273080.1 RP11-301O19.1 6.3 3.07e-09 4.58e-06 0.51 0.45 Night sleep phenotypes; chr2:86296237 chr2:86195590~86196049:+ PAAD cis rs7811142 1 rs74460138 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100429716 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs6975729 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100430564 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs1073 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100433989 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs4989959 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100434665 chr7:100336079~100351900:+ PAAD cis rs7811142 0.887 rs4074838 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100435042 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs11764818 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100445432 chr7:100336079~100351900:+ PAAD cis rs7811142 0.945 rs6955362 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100458543 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs6975514 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100458597 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs7811142 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100467820 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs11773661 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100475446 chr7:100336079~100351900:+ PAAD cis rs7811142 0.943 rs66958101 ENSG00000242294.5 STAG3L5P 6.3 3.08e-09 4.58e-06 0.35 0.45 Platelet count; chr7:100476397 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs7794485 ENSG00000242294.5 STAG3L5P 6.3 3.1e-09 4.62e-06 0.35 0.45 Platelet count; chr7:100471313 chr7:100336079~100351900:+ PAAD cis rs9601248 0.756 rs928640 ENSG00000227676.3 LINC01068 -6.3 3.11e-09 4.62e-06 -0.57 -0.45 Major depressive disorder; chr13:79603348 chr13:79566727~79571436:+ PAAD cis rs6061231 0.837 rs6121558 ENSG00000273619.1 RP5-908M14.9 -6.3 3.11e-09 4.63e-06 -0.41 -0.45 Colorectal cancer; chr20:62386309 chr20:62386303~62386970:- PAAD cis rs2882667 0.861 rs10043676 ENSG00000253404.1 AC034243.1 6.3 3.12e-09 4.64e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139053872 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs10038121 ENSG00000253404.1 AC034243.1 6.3 3.12e-09 4.64e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139053913 chr5:138744434~138753309:- PAAD cis rs2882667 0.861 rs10075541 ENSG00000253404.1 AC034243.1 6.3 3.12e-09 4.64e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139054629 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs2116789 ENSG00000253404.1 AC034243.1 6.3 3.12e-09 4.64e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139058573 chr5:138744434~138753309:- PAAD cis rs9326248 1 rs664971 ENSG00000280143.1 AP000892.6 -6.29 3.13e-09 4.66e-06 -0.58 -0.45 Blood protein levels; chr11:117200141 chr11:117204967~117210292:+ PAAD cis rs17608059 0.518 rs4792436 ENSG00000141028.6 CDRT15P1 6.29 3.15e-09 4.68e-06 0.54 0.45 Temperament; chr17:14068990 chr17:14024514~14025488:+ PAAD cis rs2117029 0.619 rs10747562 ENSG00000258017.1 RP11-386G11.10 -6.29 3.15e-09 4.68e-06 -0.6 -0.45 Intelligence (multi-trait analysis); chr12:49111401 chr12:49127782~49147869:+ PAAD cis rs2117029 0.619 rs11168862 ENSG00000258017.1 RP11-386G11.10 -6.29 3.15e-09 4.68e-06 -0.6 -0.45 Intelligence (multi-trait analysis); chr12:49112175 chr12:49127782~49147869:+ PAAD cis rs11155671 0.53 rs7756850 ENSG00000223701.3 RAET1E-AS1 6.29 3.15e-09 4.68e-06 0.54 0.45 Testicular germ cell tumor; chr6:149891460 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs9371542 ENSG00000223701.3 RAET1E-AS1 6.29 3.15e-09 4.68e-06 0.54 0.45 Testicular germ cell tumor; chr6:149891949 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs9371223 ENSG00000223701.3 RAET1E-AS1 6.29 3.15e-09 4.68e-06 0.54 0.45 Testicular germ cell tumor; chr6:149893670 chr6:149884431~149919508:+ PAAD cis rs9399135 0.627 rs6930223 ENSG00000232876.1 CTA-212D2.2 -6.29 3.16e-09 4.7e-06 -0.51 -0.45 Red blood cell count; chr6:135103065 chr6:135055033~135060550:+ PAAD cis rs17301013 0.861 rs10912824 ENSG00000227373.4 RP11-160H22.5 6.29 3.17e-09 4.7e-06 0.6 0.45 Systemic lupus erythematosus; chr1:174625846 chr1:174115300~174160004:- PAAD cis rs7811142 1 rs7803454 ENSG00000242294.5 STAG3L5P 6.29 3.17e-09 4.71e-06 0.35 0.45 Platelet count; chr7:100393925 chr7:100336079~100351900:+ PAAD cis rs7811142 0.943 rs11769886 ENSG00000242294.5 STAG3L5P 6.29 3.17e-09 4.71e-06 0.35 0.45 Platelet count; chr7:100400984 chr7:100336079~100351900:+ PAAD cis rs875971 0.545 rs313830 ENSG00000237310.1 GS1-124K5.4 -6.29 3.18e-09 4.71e-06 -0.53 -0.45 Aortic root size; chr7:66086944 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs313828 ENSG00000237310.1 GS1-124K5.4 -6.29 3.18e-09 4.71e-06 -0.53 -0.45 Aortic root size; chr7:66087627 chr7:66493706~66495474:+ PAAD cis rs875971 0.571 rs160647 ENSG00000237310.1 GS1-124K5.4 -6.29 3.18e-09 4.71e-06 -0.53 -0.45 Aortic root size; chr7:66089365 chr7:66493706~66495474:+ PAAD cis rs875971 0.52 rs160645 ENSG00000237310.1 GS1-124K5.4 -6.29 3.18e-09 4.71e-06 -0.53 -0.45 Aortic root size; chr7:66091320 chr7:66493706~66495474:+ PAAD cis rs875971 0.789 rs28815324 ENSG00000237310.1 GS1-124K5.4 -6.29 3.18e-09 4.71e-06 -0.53 -0.45 Aortic root size; chr7:66100789 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs73136346 ENSG00000237310.1 GS1-124K5.4 -6.29 3.18e-09 4.71e-06 -0.53 -0.45 Aortic root size; chr7:66101095 chr7:66493706~66495474:+ PAAD cis rs875971 0.545 rs4718348 ENSG00000237310.1 GS1-124K5.4 6.29 3.18e-09 4.73e-06 0.53 0.45 Aortic root size; chr7:66441589 chr7:66493706~66495474:+ PAAD cis rs944002 0.951 rs7151779 ENSG00000259444.1 RP11-736N17.8 6.29 3.2e-09 4.75e-06 0.58 0.45 Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;Gamma gluatamyl transferase levels; chr14:103099825 chr14:103094723~103098885:+ PAAD cis rs11155671 0.53 rs9968871 ENSG00000223701.3 RAET1E-AS1 6.29 3.21e-09 4.76e-06 0.54 0.45 Testicular germ cell tumor; chr6:149888060 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs9969044 ENSG00000223701.3 RAET1E-AS1 6.29 3.21e-09 4.76e-06 0.54 0.45 Testicular germ cell tumor; chr6:149888068 chr6:149884431~149919508:+ PAAD cis rs950027 0.967 rs2486280 ENSG00000259520.4 CTD-2651B20.3 -6.29 3.21e-09 4.76e-06 -0.57 -0.45 Response to fenofibrate (adiponectin levels); chr15:45459691 chr15:45251580~45279251:- PAAD cis rs2404602 0.622 rs11632365 ENSG00000259422.1 RP11-593F23.1 -6.29 3.21e-09 4.76e-06 -0.57 -0.45 Blood metabolite levels; chr15:76846739 chr15:76174891~76181486:- PAAD cis rs673078 0.607 rs73207573 ENSG00000275759.1 RP11-131L12.3 -6.29 3.21e-09 4.76e-06 -0.7 -0.45 Glucose homeostasis traits; chr12:118444664 chr12:118428281~118428870:+ PAAD cis rs950027 0.967 rs3120975 ENSG00000259520.4 CTD-2651B20.3 -6.29 3.22e-09 4.76e-06 -0.57 -0.45 Response to fenofibrate (adiponectin levels); chr15:45452927 chr15:45251580~45279251:- PAAD cis rs42490 0.51 rs4961157 ENSG00000251136.7 RP11-37B2.1 -6.29 3.22e-09 4.77e-06 -0.42 -0.45 Leprosy; chr8:89684800 chr8:89609409~89757727:- PAAD cis rs160451 0.934 rs34036322 ENSG00000251136.7 RP11-37B2.1 6.29 3.22e-09 4.77e-06 0.42 0.45 Leprosy; chr8:89654670 chr8:89609409~89757727:- PAAD cis rs160451 0.966 rs1603289 ENSG00000251136.7 RP11-37B2.1 6.29 3.22e-09 4.77e-06 0.42 0.45 Leprosy; chr8:89655405 chr8:89609409~89757727:- PAAD cis rs160451 0.966 rs12216864 ENSG00000251136.7 RP11-37B2.1 6.29 3.22e-09 4.77e-06 0.42 0.45 Leprosy; chr8:89665895 chr8:89609409~89757727:- PAAD cis rs160451 0.966 rs28374917 ENSG00000251136.7 RP11-37B2.1 6.29 3.22e-09 4.77e-06 0.42 0.45 Leprosy; chr8:89666525 chr8:89609409~89757727:- PAAD cis rs42490 0.528 rs10956209 ENSG00000251136.7 RP11-37B2.1 6.29 3.22e-09 4.77e-06 0.42 0.45 Leprosy; chr8:89670923 chr8:89609409~89757727:- PAAD cis rs160451 0.899 rs218887 ENSG00000251136.7 RP11-37B2.1 6.29 3.22e-09 4.77e-06 0.42 0.45 Leprosy; chr8:89679295 chr8:89609409~89757727:- PAAD cis rs2882667 0.838 rs11958529 ENSG00000253404.1 AC034243.1 6.29 3.24e-09 4.8e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139059379 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs11952020 ENSG00000253404.1 AC034243.1 6.29 3.24e-09 4.8e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139059467 chr5:138744434~138753309:- PAAD cis rs10875746 0.859 rs11168371 ENSG00000240399.1 RP1-228P16.1 -6.29 3.26e-09 4.82e-06 -0.49 -0.45 Longevity (90 years and older); chr12:48043903 chr12:48054813~48055591:- PAAD cis rs2882667 0.898 rs2043272 ENSG00000253404.1 AC034243.1 6.29 3.26e-09 4.82e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139054942 chr5:138744434~138753309:- PAAD cis rs1061377 0.965 rs3733275 ENSG00000249685.1 RP11-360F5.3 6.29 3.27e-09 4.84e-06 0.49 0.45 Uric acid levels; chr4:39121077 chr4:39133913~39135608:+ PAAD cis rs9601248 0.756 rs9601251 ENSG00000227676.3 LINC01068 -6.29 3.28e-09 4.85e-06 -0.57 -0.45 Major depressive disorder; chr13:79615582 chr13:79566727~79571436:+ PAAD cis rs9601248 0.756 rs9601252 ENSG00000227676.3 LINC01068 -6.29 3.28e-09 4.85e-06 -0.57 -0.45 Major depressive disorder; chr13:79615607 chr13:79566727~79571436:+ PAAD cis rs11673344 0.583 rs10421436 ENSG00000226686.6 LINC01535 -6.28 3.31e-09 4.89e-06 -0.53 -0.45 Obesity-related traits; chr19:37394601 chr19:37251912~37265535:+ PAAD cis rs73086581 0.838 rs73088426 ENSG00000229539.1 RP11-119B16.2 6.28 3.31e-09 4.89e-06 0.74 0.45 Response to antidepressants in depression; chr20:4022636 chr20:3888239~3888868:- PAAD cis rs9601248 0.756 rs7997134 ENSG00000227676.3 LINC01068 -6.28 3.31e-09 4.89e-06 -0.57 -0.45 Major depressive disorder; chr13:79619594 chr13:79566727~79571436:+ PAAD cis rs7811142 0.887 rs35111986 ENSG00000242294.5 STAG3L5P 6.28 3.32e-09 4.91e-06 0.35 0.45 Platelet count; chr7:100402651 chr7:100336079~100351900:+ PAAD cis rs72772090 0.539 rs72773989 ENSG00000248734.2 CTD-2260A17.1 -6.28 3.33e-09 4.92e-06 -0.62 -0.45 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96827910 chr5:96784777~96785999:+ PAAD cis rs2919917 0.688 rs6993386 ENSG00000254352.1 RP11-578O24.2 -6.28 3.34e-09 4.93e-06 -0.46 -0.45 Lymphocyte counts; chr8:78741910 chr8:78723796~78724136:- PAAD cis rs9532669 0.963 rs1056835 ENSG00000176268.5 CYCSP34 6.28 3.34e-09 4.93e-06 0.42 0.45 Cervical cancer; chr13:40932585 chr13:40863599~40863902:- PAAD cis rs950169 0.922 rs62028133 ENSG00000225151.9 GOLGA2P7 -6.28 3.36e-09 4.96e-06 -0.55 -0.45 Schizophrenia; chr15:84250623 chr15:84199311~84230136:- PAAD cis rs950169 0.723 rs17589320 ENSG00000225151.9 GOLGA2P7 -6.28 3.36e-09 4.96e-06 -0.55 -0.45 Schizophrenia; chr15:84251244 chr15:84199311~84230136:- PAAD cis rs950169 0.845 rs4502182 ENSG00000225151.9 GOLGA2P7 -6.28 3.36e-09 4.96e-06 -0.55 -0.45 Schizophrenia; chr15:84254768 chr15:84199311~84230136:- PAAD cis rs7811142 1 rs1000215 ENSG00000242294.5 STAG3L5P 6.28 3.37e-09 4.97e-06 0.35 0.45 Platelet count; chr7:100406920 chr7:100336079~100351900:+ PAAD cis rs2117029 0.619 rs2241727 ENSG00000258017.1 RP11-386G11.10 -6.28 3.39e-09 4.99e-06 -0.58 -0.45 Intelligence (multi-trait analysis); chr12:49131225 chr12:49127782~49147869:+ PAAD cis rs11155671 0.53 rs9322228 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149888173 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs7774787 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149888296 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs2342767 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149888581 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs7764376 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149889208 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs6933882 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149889666 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs6939761 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149889858 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs3823021 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149889863 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs4869763 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149890548 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs4869764 ENSG00000223701.3 RAET1E-AS1 6.28 3.39e-09 5e-06 0.54 0.45 Testicular germ cell tumor; chr6:149890692 chr6:149884431~149919508:+ PAAD cis rs12458462 0.892 rs35928863 ENSG00000274828.1 RP11-567M16.6 6.28 3.4e-09 5.01e-06 0.44 0.45 Monocyte count; chr18:79678956 chr18:79677287~79679358:- PAAD cis rs11673344 0.801 rs56343212 ENSG00000226686.6 LINC01535 6.28 3.42e-09 5.04e-06 0.6 0.45 Obesity-related traits; chr19:37167684 chr19:37251912~37265535:+ PAAD cis rs9640161 0.789 rs3735172 ENSG00000261305.1 RP4-584D14.7 -6.28 3.43e-09 5.04e-06 -0.64 -0.45 Blood protein levels;Circulating chemerin levels; chr7:150331869 chr7:150341771~150342607:+ PAAD cis rs3096299 0.667 rs2965947 ENSG00000274627.1 RP11-104N10.2 6.28 3.43e-09 5.06e-06 0.38 0.45 Multiple myeloma (IgH translocation); chr16:89452262 chr16:89516797~89522217:+ PAAD cis rs200895692 1 rs200895692 ENSG00000227533.4 SLC2A1-AS1 6.28 3.46e-09 5.09e-06 0.71 0.45 Monocyte count; chr1:42956299 chr1:42959049~42983358:+ PAAD cis rs7044106 0.762 rs4837790 ENSG00000226752.6 PSMD5-AS1 -6.27 3.47e-09 5.11e-06 -0.61 -0.45 Hip circumference adjusted for BMI; chr9:120684047 chr9:120824828~120854385:+ PAAD cis rs673078 0.607 rs950288 ENSG00000275759.1 RP11-131L12.3 -6.27 3.47e-09 5.11e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118392201 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943399 ENSG00000275759.1 RP11-131L12.3 -6.27 3.47e-09 5.11e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118393628 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17440942 ENSG00000275759.1 RP11-131L12.3 6.27 3.47e-09 5.11e-06 0.68 0.45 Glucose homeostasis traits; chr12:118394030 chr12:118428281~118428870:+ PAAD cis rs7811142 1 rs11761725 ENSG00000242294.5 STAG3L5P 6.27 3.49e-09 5.13e-06 0.35 0.45 Platelet count; chr7:100442192 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs2406255 ENSG00000242294.5 STAG3L5P 6.27 3.49e-09 5.13e-06 0.35 0.45 Platelet count; chr7:100456067 chr7:100336079~100351900:+ PAAD cis rs8040855 0.575 rs12912860 ENSG00000259295.5 CSPG4P12 6.27 3.49e-09 5.14e-06 0.54 0.45 Bulimia nervosa; chr15:85030267 chr15:85191438~85213905:+ PAAD cis rs4218 0.62 rs17302191 ENSG00000277144.1 RP11-59H7.4 -6.27 3.49e-09 5.14e-06 -0.57 -0.45 Social communication problems; chr15:59116429 chr15:59115547~59116089:- PAAD cis rs1075265 0.633 rs7591431 ENSG00000233266.1 HMGB1P31 6.27 3.5e-09 5.15e-06 0.57 0.45 Chronotype;Morning vs. evening chronotype; chr2:53995028 chr2:54051334~54051760:+ PAAD cis rs6700559 1 rs10800720 ENSG00000260088.1 RP11-92G12.3 -6.27 3.52e-09 5.18e-06 -0.59 -0.45 Coronary artery disease; chr1:200679441 chr1:200669507~200694250:+ PAAD cis rs6700559 0.935 rs4072553 ENSG00000260088.1 RP11-92G12.3 -6.27 3.52e-09 5.18e-06 -0.59 -0.45 Coronary artery disease; chr1:200680036 chr1:200669507~200694250:+ PAAD cis rs7044106 0.791 rs10984997 ENSG00000226752.6 PSMD5-AS1 -6.27 3.52e-09 5.18e-06 -0.62 -0.45 Hip circumference adjusted for BMI; chr9:120718928 chr9:120824828~120854385:+ PAAD cis rs7811142 1 rs67040465 ENSG00000242294.5 STAG3L5P 6.27 3.52e-09 5.18e-06 0.35 0.45 Platelet count; chr7:100485455 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs6979335 ENSG00000242294.5 STAG3L5P 6.27 3.52e-09 5.18e-06 0.35 0.45 Platelet count; chr7:100492237 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs73405353 ENSG00000242294.5 STAG3L5P 6.27 3.52e-09 5.18e-06 0.35 0.45 Platelet count; chr7:100493592 chr7:100336079~100351900:+ PAAD cis rs987724 0.592 rs1430410 ENSG00000240875.4 LINC00886 -6.27 3.53e-09 5.19e-06 -0.56 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156807773 chr3:156747346~156817062:- PAAD cis rs987724 0.571 rs7641929 ENSG00000240875.4 LINC00886 -6.27 3.53e-09 5.19e-06 -0.56 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156811605 chr3:156747346~156817062:- PAAD cis rs987724 0.531 rs12492804 ENSG00000240875.4 LINC00886 -6.27 3.53e-09 5.19e-06 -0.56 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156814356 chr3:156747346~156817062:- PAAD cis rs987724 0.592 rs12497539 ENSG00000240875.4 LINC00886 -6.27 3.53e-09 5.19e-06 -0.56 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156816148 chr3:156747346~156817062:- PAAD cis rs987724 0.571 rs59717073 ENSG00000240875.4 LINC00886 -6.27 3.53e-09 5.19e-06 -0.56 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156816456 chr3:156747346~156817062:- PAAD cis rs7637701 0.818 rs11717133 ENSG00000240875.4 LINC00886 -6.27 3.53e-09 5.19e-06 -0.56 -0.45 Breast cancer; chr3:156816792 chr3:156747346~156817062:- PAAD cis rs987724 0.512 rs9842198 ENSG00000240875.4 LINC00886 -6.27 3.53e-09 5.19e-06 -0.56 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156821415 chr3:156747346~156817062:- PAAD cis rs10875746 0.859 rs12305511 ENSG00000240399.1 RP1-228P16.1 6.27 3.55e-09 5.21e-06 0.47 0.45 Longevity (90 years and older); chr12:48188933 chr12:48054813~48055591:- PAAD cis rs6504622 0.755 rs12939753 ENSG00000262879.4 RP11-156P1.3 -6.27 3.57e-09 5.24e-06 -0.47 -0.45 Orofacial clefts; chr17:47104133 chr17:46984045~47100323:- PAAD cis rs6504622 0.728 rs7222781 ENSG00000262879.4 RP11-156P1.3 -6.27 3.59e-09 5.27e-06 -0.47 -0.45 Orofacial clefts; chr17:47100059 chr17:46984045~47100323:- PAAD cis rs55665837 1 rs4412729 ENSG00000251991.1 RNU7-49P 6.27 3.59e-09 5.27e-06 0.55 0.45 Vitamin D levels; chr11:14417454 chr11:14478892~14478953:+ PAAD cis rs992157 0.775 rs1877714 ENSG00000261338.2 RP11-378A13.1 -6.27 3.59e-09 5.27e-06 -0.55 -0.45 Colorectal cancer; chr2:218270205 chr2:218255319~218257366:+ PAAD cis rs2919917 0.628 rs6990105 ENSG00000254352.1 RP11-578O24.2 6.27 3.6e-09 5.28e-06 0.5 0.45 Lymphocyte counts; chr8:78689652 chr8:78723796~78724136:- PAAD cis rs2739330 0.685 rs4822453 ENSG00000099984.9 GSTT2 -6.27 3.61e-09 5.29e-06 -0.59 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23980123~23983911:+ PAAD cis rs9322193 0.607 rs9383941 ENSG00000216906.2 RP11-350J20.9 -6.27 3.62e-09 5.3e-06 -0.63 -0.45 Lung cancer; chr6:149912100 chr6:149904243~149906418:+ PAAD cis rs2739330 0.828 rs5760107 ENSG00000099984.9 GSTT2 -6.27 3.65e-09 5.34e-06 -0.59 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23980123~23983911:+ PAAD cis rs2739330 0.789 rs5760109 ENSG00000099984.9 GSTT2 -6.27 3.65e-09 5.34e-06 -0.59 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23980123~23983911:+ PAAD cis rs4938303 0.718 rs10892023 ENSG00000254851.1 RP11-109L13.1 -6.26 3.65e-09 5.35e-06 -0.7 -0.45 Triglycerides; chr11:116727532 chr11:117135528~117138582:+ PAAD cis rs732716 0.785 rs11085073 ENSG00000267980.1 AC007292.6 6.26 3.66e-09 5.36e-06 0.6 0.45 Mean corpuscular volume; chr19:4375165 chr19:4363789~4364640:+ PAAD cis rs733592 0.929 rs4760678 ENSG00000240399.1 RP1-228P16.1 -6.26 3.67e-09 5.38e-06 -0.42 -0.45 Plateletcrit; chr12:48067798 chr12:48054813~48055591:- PAAD cis rs733592 0.965 rs1978161 ENSG00000240399.1 RP1-228P16.1 -6.26 3.67e-09 5.38e-06 -0.42 -0.45 Plateletcrit; chr12:48073938 chr12:48054813~48055591:- PAAD cis rs733592 0.894 rs886589 ENSG00000240399.1 RP1-228P16.1 -6.26 3.67e-09 5.38e-06 -0.42 -0.45 Plateletcrit; chr12:48083414 chr12:48054813~48055591:- PAAD cis rs160451 0.966 rs2101854 ENSG00000251136.7 RP11-37B2.1 6.26 3.69e-09 5.4e-06 0.42 0.45 Leprosy; chr8:89663517 chr8:89609409~89757727:- PAAD cis rs42490 0.528 rs1040327 ENSG00000251136.7 RP11-37B2.1 6.26 3.69e-09 5.4e-06 0.42 0.45 Leprosy; chr8:89669585 chr8:89609409~89757727:- PAAD cis rs42490 0.528 rs2840206 ENSG00000251136.7 RP11-37B2.1 6.26 3.69e-09 5.4e-06 0.42 0.45 Leprosy; chr8:89670184 chr8:89609409~89757727:- PAAD cis rs9640161 0.659 rs7806429 ENSG00000261305.1 RP4-584D14.7 6.26 3.7e-09 5.4e-06 0.65 0.45 Blood protein levels;Circulating chemerin levels; chr7:150316304 chr7:150341771~150342607:+ PAAD cis rs875971 0.545 rs1796222 ENSG00000237310.1 GS1-124K5.4 -6.26 3.7e-09 5.41e-06 -0.52 -0.45 Aortic root size; chr7:66592167 chr7:66493706~66495474:+ PAAD cis rs72772090 0.539 rs2042386 ENSG00000248734.2 CTD-2260A17.1 -6.26 3.71e-09 5.42e-06 -0.61 -0.45 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96821080 chr5:96784777~96785999:+ PAAD cis rs987724 0.592 rs1430411 ENSG00000240875.4 LINC00886 -6.26 3.73e-09 5.45e-06 -0.56 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156807607 chr3:156747346~156817062:- PAAD cis rs7188445 0.787 rs7189954 ENSG00000261390.4 RP11-345M22.2 6.26 3.73e-09 5.45e-06 0.61 0.45 Urate levels; chr16:79701150 chr16:79715232~79770563:- PAAD cis rs11673344 0.77 rs7257135 ENSG00000226686.6 LINC01535 6.26 3.73e-09 5.45e-06 0.62 0.45 Obesity-related traits; chr19:37088726 chr19:37251912~37265535:+ PAAD cis rs11673344 0.77 rs74770693 ENSG00000226686.6 LINC01535 6.26 3.73e-09 5.45e-06 0.62 0.45 Obesity-related traits; chr19:37135613 chr19:37251912~37265535:+ PAAD cis rs673078 0.607 rs73207564 ENSG00000275759.1 RP11-131L12.3 -6.26 3.73e-09 5.45e-06 -0.7 -0.45 Glucose homeostasis traits; chr12:118429566 chr12:118428281~118428870:+ PAAD cis rs11155671 0.53 rs7757984 ENSG00000223701.3 RAET1E-AS1 6.26 3.76e-09 5.49e-06 0.54 0.45 Testicular germ cell tumor; chr6:149887515 chr6:149884431~149919508:+ PAAD cis rs35160687 0.901 rs12478653 ENSG00000273080.1 RP11-301O19.1 -6.26 3.76e-09 5.5e-06 -0.5 -0.45 Night sleep phenotypes; chr2:86308271 chr2:86195590~86196049:+ PAAD cis rs11673344 0.838 rs112401881 ENSG00000226686.6 LINC01535 6.26 3.78e-09 5.52e-06 0.62 0.45 Obesity-related traits; chr19:37156092 chr19:37251912~37265535:+ PAAD cis rs17301013 0.861 rs7521870 ENSG00000227373.4 RP11-160H22.5 -6.26 3.79e-09 5.53e-06 -0.6 -0.45 Systemic lupus erythematosus; chr1:174497239 chr1:174115300~174160004:- PAAD cis rs7174755 0.961 rs58175526 ENSG00000260657.2 RP11-315D16.4 6.26 3.79e-09 5.53e-06 0.55 0.45 Major depressive disorder; chr15:68300789 chr15:68267792~68277994:- PAAD cis rs8040855 0.627 rs11632658 ENSG00000259295.5 CSPG4P12 -6.26 3.81e-09 5.56e-06 -0.54 -0.45 Bulimia nervosa; chr15:85062982 chr15:85191438~85213905:+ PAAD cis rs748404 0.518 rs2927085 ENSG00000205771.5 CATSPER2P1 -6.26 3.82e-09 5.57e-06 -0.59 -0.45 Lung cancer; chr15:43697332 chr15:43726918~43747094:- PAAD cis rs7044106 0.762 rs966396 ENSG00000226752.6 PSMD5-AS1 -6.26 3.82e-09 5.58e-06 -0.62 -0.45 Hip circumference adjusted for BMI; chr9:120691003 chr9:120824828~120854385:+ PAAD cis rs7811142 1 rs68116612 ENSG00000242294.5 STAG3L5P 6.25 3.84e-09 5.61e-06 0.35 0.45 Platelet count; chr7:100408870 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs28490152 ENSG00000242294.5 STAG3L5P 6.25 3.84e-09 5.61e-06 0.35 0.45 Platelet count; chr7:100423359 chr7:100336079~100351900:+ PAAD cis rs7811142 0.943 rs28660238 ENSG00000242294.5 STAG3L5P 6.25 3.84e-09 5.61e-06 0.35 0.45 Platelet count; chr7:100425685 chr7:100336079~100351900:+ PAAD cis rs17301013 0.606 rs11487399 ENSG00000227373.4 RP11-160H22.5 6.25 3.86e-09 5.62e-06 0.65 0.45 Systemic lupus erythematosus; chr1:174527129 chr1:174115300~174160004:- PAAD cis rs9322193 0.566 rs6912330 ENSG00000216906.2 RP11-350J20.9 -6.25 3.86e-09 5.62e-06 -0.65 -0.45 Lung cancer; chr6:149908811 chr6:149904243~149906418:+ PAAD cis rs6504622 0.755 rs4968253 ENSG00000262879.4 RP11-156P1.3 -6.25 3.86e-09 5.63e-06 -0.47 -0.45 Orofacial clefts; chr17:47093553 chr17:46984045~47100323:- PAAD cis rs6504622 0.693 rs12950276 ENSG00000262879.4 RP11-156P1.3 -6.25 3.86e-09 5.63e-06 -0.47 -0.45 Orofacial clefts; chr17:47095819 chr17:46984045~47100323:- PAAD cis rs6504622 0.755 rs12950699 ENSG00000262879.4 RP11-156P1.3 -6.25 3.86e-09 5.63e-06 -0.47 -0.45 Orofacial clefts; chr17:47096296 chr17:46984045~47100323:- PAAD cis rs6504622 0.748 rs7215573 ENSG00000262879.4 RP11-156P1.3 -6.25 3.86e-09 5.63e-06 -0.47 -0.45 Orofacial clefts; chr17:47096887 chr17:46984045~47100323:- PAAD cis rs6504622 0.721 rs7215903 ENSG00000262879.4 RP11-156P1.3 -6.25 3.86e-09 5.63e-06 -0.47 -0.45 Orofacial clefts; chr17:47097100 chr17:46984045~47100323:- PAAD cis rs17264034 1 rs414829 ENSG00000250786.1 SNHG18 6.25 3.86e-09 5.63e-06 0.6 0.45 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9552413 chr5:9546200~9550609:+ PAAD cis rs7396835 0.551 rs10750098 ENSG00000254851.1 RP11-109L13.1 -6.25 3.87e-09 5.64e-06 -0.82 -0.45 Quantitative traits; chr11:116834852 chr11:117135528~117138582:+ PAAD cis rs11155671 0.53 rs7757984 ENSG00000268592.3 RAET1E-AS1 6.25 3.88e-09 5.66e-06 0.56 0.45 Testicular germ cell tumor; chr6:149887515 chr6:149863494~149919507:+ PAAD cis rs10875746 0.859 rs11558768 ENSG00000240399.1 RP1-228P16.1 -6.25 3.89e-09 5.67e-06 -0.49 -0.45 Longevity (90 years and older); chr12:48184006 chr12:48054813~48055591:- PAAD cis rs10875746 0.859 rs12305647 ENSG00000240399.1 RP1-228P16.1 -6.25 3.89e-09 5.67e-06 -0.49 -0.45 Longevity (90 years and older); chr12:48189178 chr12:48054813~48055591:- PAAD cis rs465969 0.744 rs3851228 ENSG00000255389.1 C6orf3 6.25 3.89e-09 5.67e-06 0.73 0.45 Psoriasis; chr6:111526988 chr6:111599875~111602295:+ PAAD cis rs7811142 0.943 rs10241492 ENSG00000242294.5 STAG3L5P 6.25 3.89e-09 5.67e-06 0.35 0.45 Platelet count; chr7:100397190 chr7:100336079~100351900:+ PAAD cis rs3762637 1 rs16845530 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122423600 chr3:122416207~122443180:+ PAAD cis rs3762637 0.882 rs72958418 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122441526 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs7609972 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122480579 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs7653592 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122499524 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs72960431 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122509814 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs28434553 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122510668 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs9837149 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122511998 chr3:122416207~122443180:+ PAAD cis rs3762637 0.943 rs72960447 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122516258 chr3:122416207~122443180:+ PAAD cis rs3762637 0.943 rs6762156 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122517178 chr3:122416207~122443180:+ PAAD cis rs3762637 0.943 rs9872708 ENSG00000272758.4 RP11-299J3.8 -6.25 3.89e-09 5.67e-06 -0.67 -0.45 LDL cholesterol levels; chr3:122523960 chr3:122416207~122443180:+ PAAD cis rs7044106 0.615 rs10818470 ENSG00000226752.6 PSMD5-AS1 -6.25 3.92e-09 5.7e-06 -0.57 -0.45 Hip circumference adjusted for BMI; chr9:120596926 chr9:120824828~120854385:+ PAAD cis rs7044106 0.762 rs7849566 ENSG00000226752.6 PSMD5-AS1 -6.25 3.92e-09 5.71e-06 -0.62 -0.45 Hip circumference adjusted for BMI; chr9:120698491 chr9:120824828~120854385:+ PAAD cis rs2882667 0.858 rs11242444 ENSG00000253404.1 AC034243.1 6.25 3.92e-09 5.71e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139070690 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs11956159 ENSG00000253404.1 AC034243.1 6.25 3.92e-09 5.71e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139072879 chr5:138744434~138753309:- PAAD cis rs11673344 0.801 rs17707446 ENSG00000226686.6 LINC01535 -6.25 3.94e-09 5.74e-06 -0.62 -0.45 Obesity-related traits; chr19:37092140 chr19:37251912~37265535:+ PAAD cis rs9425766 0.566 rs12079820 ENSG00000227373.4 RP11-160H22.5 6.25 3.96e-09 5.76e-06 0.61 0.45 Life satisfaction; chr1:174240771 chr1:174115300~174160004:- PAAD cis rs9425766 0.541 rs4652274 ENSG00000227373.4 RP11-160H22.5 6.25 3.96e-09 5.76e-06 0.61 0.45 Life satisfaction; chr1:174249434 chr1:174115300~174160004:- PAAD cis rs1891275 0.516 rs10881935 ENSG00000228701.1 TNKS2-AS1 -6.25 3.96e-09 5.76e-06 -0.57 -0.45 Intelligence (multi-trait analysis); chr10:91637944 chr10:91782839~91798291:- PAAD cis rs17264034 0.861 rs1508798 ENSG00000250786.1 SNHG18 -6.25 3.96e-09 5.77e-06 -0.59 -0.45 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9556582 chr5:9546200~9550609:+ PAAD cis rs9322193 0.607 rs4870078 ENSG00000216906.2 RP11-350J20.9 -6.25 3.97e-09 5.78e-06 -0.65 -0.45 Lung cancer; chr6:149880676 chr6:149904243~149906418:+ PAAD cis rs11098499 0.909 rs10017335 ENSG00000245958.5 RP11-33B1.1 6.25 3.98e-09 5.78e-06 0.38 0.45 Corneal astigmatism; chr4:119460368 chr4:119454791~119552025:+ PAAD cis rs2929278 0.617 rs693919 ENSG00000205771.5 CATSPER2P1 6.25 4.01e-09 5.82e-06 0.57 0.45 Schizophrenia; chr15:43810130 chr15:43726918~43747094:- PAAD cis rs12594515 1 rs11070464 ENSG00000273972.1 CTD-2306A12.1 -6.25 4.02e-09 5.84e-06 -0.54 -0.45 Weight;Waist circumference; chr15:45692578 chr15:45702640~45703183:+ PAAD cis rs12594515 0.967 rs11070465 ENSG00000273972.1 CTD-2306A12.1 -6.25 4.02e-09 5.84e-06 -0.54 -0.45 Weight;Waist circumference; chr15:45692701 chr15:45702640~45703183:+ PAAD cis rs12594515 0.967 rs11070466 ENSG00000273972.1 CTD-2306A12.1 -6.25 4.02e-09 5.84e-06 -0.54 -0.45 Weight;Waist circumference; chr15:45692757 chr15:45702640~45703183:+ PAAD cis rs17301013 0.556 rs10912774 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174387706 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs16846938 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174400537 chr1:174115300~174160004:- PAAD cis rs17301013 0.632 rs10912782 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174418758 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12089182 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174463816 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12086693 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174527651 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6668096 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174537343 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6692173 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174544474 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12077529 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174549874 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs7530265 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174564603 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12083628 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174572097 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6691118 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174577798 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs12082139 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174589043 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12067463 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174625437 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912823 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174625602 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6677874 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174628410 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs333423 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174666557 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs333437 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174672224 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs332764 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174693056 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs332763 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174693482 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs332772 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174695740 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs333471 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174705062 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs332798 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174729096 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs459078 ENSG00000227373.4 RP11-160H22.5 6.25 4.03e-09 5.85e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174733772 chr1:174115300~174160004:- PAAD cis rs8059260 0.604 rs11863415 ENSG00000274038.1 RP11-66H6.4 -6.25 4.03e-09 5.85e-06 -0.72 -0.45 Alcohol consumption over the past year; chr16:11053237 chr16:11056556~11057034:+ PAAD cis rs9545047 0.604 rs1324868 ENSG00000227676.3 LINC01068 -6.25 4.03e-09 5.85e-06 -0.6 -0.45 Schizophrenia; chr13:79380040 chr13:79566727~79571436:+ PAAD cis rs7811142 0.943 rs67196635 ENSG00000242294.5 STAG3L5P 6.25 4.03e-09 5.85e-06 0.35 0.45 Platelet count; chr7:100427941 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs6962151 ENSG00000242294.5 STAG3L5P 6.25 4.03e-09 5.85e-06 0.35 0.45 Platelet count; chr7:100430861 chr7:100336079~100351900:+ PAAD cis rs7811142 0.943 rs67483801 ENSG00000242294.5 STAG3L5P 6.25 4.03e-09 5.85e-06 0.35 0.45 Platelet count; chr7:100434135 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs11761784 ENSG00000242294.5 STAG3L5P 6.25 4.03e-09 5.85e-06 0.35 0.45 Platelet count; chr7:100442347 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs112317829 ENSG00000242294.5 STAG3L5P 6.25 4.03e-09 5.85e-06 0.35 0.45 Platelet count; chr7:100445550 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs2406253 ENSG00000242294.5 STAG3L5P 6.25 4.03e-09 5.85e-06 0.35 0.45 Platelet count; chr7:100479650 chr7:100336079~100351900:+ PAAD cis rs7811142 1 rs2897358 ENSG00000242294.5 STAG3L5P 6.25 4.03e-09 5.85e-06 0.35 0.45 Platelet count; chr7:100491017 chr7:100336079~100351900:+ PAAD cis rs66486766 1 rs66486766 ENSG00000225151.9 GOLGA2P7 -6.25 4.04e-09 5.85e-06 -0.55 -0.45 Bipolar disorder lithium response (categorical) or schizophrenia; chr15:84137308 chr15:84199311~84230136:- PAAD cis rs7174755 0.608 rs10162905 ENSG00000260657.2 RP11-315D16.4 6.25 4.04e-09 5.86e-06 0.54 0.45 Major depressive disorder; chr15:68103709 chr15:68267792~68277994:- PAAD cis rs2739330 0.828 rs4822454 ENSG00000099984.9 GSTT2 -6.24 4.06e-09 5.88e-06 -0.58 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23980123~23983911:+ PAAD cis rs2882667 0.931 rs6596457 ENSG00000253404.1 AC034243.1 6.24 4.07e-09 5.9e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:138987690 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs10075039 ENSG00000253404.1 AC034243.1 6.24 4.07e-09 5.9e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139002165 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs10068237 ENSG00000253404.1 AC034243.1 6.24 4.07e-09 5.9e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139002271 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs12719518 ENSG00000253404.1 AC034243.1 6.24 4.07e-09 5.9e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139005287 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs10069528 ENSG00000253404.1 AC034243.1 6.24 4.07e-09 5.9e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139018338 chr5:138744434~138753309:- PAAD cis rs2882667 0.931 rs10075951 ENSG00000253404.1 AC034243.1 6.24 4.07e-09 5.9e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139020274 chr5:138744434~138753309:- PAAD cis rs1150668 0.764 rs9368565 ENSG00000216901.1 AL022393.7 -6.24 4.08e-09 5.91e-06 -0.55 -0.45 Pubertal anthropometrics; chr6:28377433 chr6:28176188~28176674:+ PAAD cis rs17301013 0.606 rs10912751 ENSG00000227373.4 RP11-160H22.5 6.24 4.1e-09 5.93e-06 0.65 0.45 Systemic lupus erythematosus; chr1:174262992 chr1:174115300~174160004:- PAAD cis rs4423214 0.55 rs4944885 ENSG00000254682.1 RP11-660L16.2 6.24 4.1e-09 5.94e-06 0.58 0.45 Vitamin D levels; chr11:71403029 chr11:71448674~71452157:+ PAAD cis rs950169 0.922 rs6603022 ENSG00000225151.9 GOLGA2P7 6.24 4.11e-09 5.95e-06 0.54 0.45 Schizophrenia; chr15:84161418 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs4842940 ENSG00000225151.9 GOLGA2P7 6.24 4.11e-09 5.95e-06 0.54 0.45 Schizophrenia; chr15:84162473 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs4842941 ENSG00000225151.9 GOLGA2P7 6.24 4.11e-09 5.95e-06 0.54 0.45 Schizophrenia; chr15:84162560 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs12911223 ENSG00000225151.9 GOLGA2P7 6.24 4.11e-09 5.95e-06 0.54 0.45 Schizophrenia; chr15:84162919 chr15:84199311~84230136:- PAAD cis rs1891275 0.515 rs1592051 ENSG00000228701.1 TNKS2-AS1 6.24 4.12e-09 5.96e-06 0.55 0.45 Intelligence (multi-trait analysis); chr10:91782429 chr10:91782839~91798291:- PAAD cis rs673078 0.607 rs16948230 ENSG00000275759.1 RP11-131L12.3 -6.24 4.12e-09 5.96e-06 -0.67 -0.45 Glucose homeostasis traits; chr12:118277086 chr12:118428281~118428870:+ PAAD cis rs858239 0.665 rs858306 ENSG00000226816.2 AC005082.12 6.24 4.14e-09 5.98e-06 0.51 0.45 Cerebrospinal fluid biomarker levels; chr7:23203135 chr7:23206013~23208045:+ PAAD cis rs875971 0.545 rs73376394 ENSG00000237310.1 GS1-124K5.4 6.24 4.14e-09 5.98e-06 0.52 0.45 Aortic root size; chr7:66172694 chr7:66493706~66495474:+ PAAD cis rs9640161 0.636 rs3735171 ENSG00000261305.1 RP4-584D14.7 6.24 4.14e-09 5.98e-06 0.68 0.45 Blood protein levels;Circulating chemerin levels; chr7:150336793 chr7:150341771~150342607:+ PAAD cis rs2882667 0.858 rs11949916 ENSG00000253404.1 AC034243.1 6.24 4.14e-09 5.98e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139060588 chr5:138744434~138753309:- PAAD cis rs2882667 0.822 rs11738376 ENSG00000253404.1 AC034243.1 6.24 4.14e-09 5.98e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139062483 chr5:138744434~138753309:- PAAD cis rs2882667 0.822 rs13187096 ENSG00000253404.1 AC034243.1 6.24 4.14e-09 5.98e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139068399 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs11957527 ENSG00000253404.1 AC034243.1 6.24 4.14e-09 5.98e-06 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139069206 chr5:138744434~138753309:- PAAD cis rs2117029 0.555 rs7978448 ENSG00000258017.1 RP11-386G11.10 -6.24 4.17e-09 6.03e-06 -0.57 -0.45 Intelligence (multi-trait analysis); chr12:49113157 chr12:49127782~49147869:+ PAAD cis rs950169 0.922 rs11635505 ENSG00000225151.9 GOLGA2P7 6.24 4.18e-09 6.04e-06 0.53 0.45 Schizophrenia; chr15:84553803 chr15:84199311~84230136:- PAAD cis rs55665837 1 rs12804549 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14416212 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10047429 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14417486 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10047457 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14417913 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs3923294 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14419856 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs12283797 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14420716 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10832256 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14421329 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10832257 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14421770 chr11:14478892~14478953:+ PAAD cis rs55665837 0.961 rs12795972 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14422229 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs12287715 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14423029 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs7121171 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14424874 chr11:14478892~14478953:+ PAAD cis rs55665837 0.922 rs12287212 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14428315 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs12295723 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14428655 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs12288873 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14428919 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs12295888 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14428985 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10832268 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14443522 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10832269 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14443523 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10832271 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14445373 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10832275 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14456678 chr11:14478892~14478953:+ PAAD cis rs55665837 0.961 rs12576926 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14458746 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs55665837 ENSG00000251991.1 RNU7-49P 6.24 4.18e-09 6.04e-06 0.54 0.45 Vitamin D levels; chr11:14473503 chr11:14478892~14478953:+ PAAD cis rs453301 0.592 rs4841084 ENSG00000253893.2 FAM85B -6.24 4.19e-09 6.05e-06 -0.6 -0.45 Joint mobility (Beighton score); chr8:9026395 chr8:8167819~8226614:- PAAD cis rs453301 0.653 rs2956244 ENSG00000253893.2 FAM85B -6.24 4.19e-09 6.05e-06 -0.6 -0.45 Joint mobility (Beighton score); chr8:9027656 chr8:8167819~8226614:- PAAD cis rs875971 0.545 rs1638735 ENSG00000237310.1 GS1-124K5.4 6.24 4.21e-09 6.07e-06 0.53 0.45 Aortic root size; chr7:66630751 chr7:66493706~66495474:+ PAAD cis rs8040855 0.547 rs17611171 ENSG00000259295.5 CSPG4P12 6.24 4.23e-09 6.09e-06 0.53 0.45 Bulimia nervosa; chr15:85029468 chr15:85191438~85213905:+ PAAD cis rs7615952 0.611 rs2971298 ENSG00000171084.14 FAM86JP 6.24 4.23e-09 6.1e-06 0.79 0.45 Blood pressure (smoking interaction); chr3:125883870 chr3:125916620~125930024:+ PAAD cis rs10256972 0.967 rs7799110 ENSG00000229043.2 AC091729.9 -6.24 4.24e-09 6.11e-06 -0.49 -0.45 Endometriosis;Longevity; chr7:999429 chr7:1160374~1165267:+ PAAD cis rs2404602 0.684 rs3910756 ENSG00000259422.1 RP11-593F23.1 -6.23 4.26e-09 6.14e-06 -0.56 -0.45 Blood metabolite levels; chr15:76653028 chr15:76174891~76181486:- PAAD cis rs2404602 0.552 rs4886823 ENSG00000259422.1 RP11-593F23.1 -6.23 4.26e-09 6.14e-06 -0.56 -0.45 Blood metabolite levels; chr15:76673061 chr15:76174891~76181486:- PAAD cis rs2404602 0.53 rs11072614 ENSG00000259422.1 RP11-593F23.1 -6.23 4.26e-09 6.14e-06 -0.56 -0.45 Blood metabolite levels; chr15:76674864 chr15:76174891~76181486:- PAAD cis rs17301013 0.606 rs1894198 ENSG00000227373.4 RP11-160H22.5 -6.23 4.27e-09 6.15e-06 -0.65 -0.45 Systemic lupus erythematosus; chr1:174835393 chr1:174115300~174160004:- PAAD cis rs17301013 0.659 rs1894199 ENSG00000227373.4 RP11-160H22.5 -6.23 4.27e-09 6.15e-06 -0.65 -0.45 Systemic lupus erythematosus; chr1:174835545 chr1:174115300~174160004:- PAAD cis rs9425766 0.566 rs56188862 ENSG00000227373.4 RP11-160H22.5 6.23 4.27e-09 6.15e-06 0.61 0.45 Life satisfaction; chr1:174220131 chr1:174115300~174160004:- PAAD cis rs763567 0.509 rs10919449 ENSG00000271811.1 RP1-79C4.4 6.23 4.28e-09 6.16e-06 0.42 0.45 Tonsillectomy; chr1:170669517 chr1:170667381~170669425:+ PAAD cis rs2919917 0.628 rs6981103 ENSG00000254352.1 RP11-578O24.2 6.23 4.29e-09 6.16e-06 0.5 0.45 Lymphocyte counts; chr8:78691702 chr8:78723796~78724136:- PAAD cis rs9322193 0.923 rs9688350 ENSG00000216906.2 RP11-350J20.9 6.23 4.29e-09 6.17e-06 0.57 0.45 Lung cancer; chr6:149730977 chr6:149904243~149906418:+ PAAD cis rs11098499 0.754 rs28643450 ENSG00000245958.5 RP11-33B1.1 -6.23 4.29e-09 6.17e-06 -0.35 -0.45 Corneal astigmatism; chr4:119324087 chr4:119454791~119552025:+ PAAD cis rs950169 0.8 rs4842847 ENSG00000225151.9 GOLGA2P7 -6.23 4.3e-09 6.18e-06 -0.54 -0.45 Schizophrenia; chr15:84262447 chr15:84199311~84230136:- PAAD cis rs35160687 0.901 rs6713456 ENSG00000273080.1 RP11-301O19.1 6.23 4.31e-09 6.2e-06 0.5 0.45 Night sleep phenotypes; chr2:86280530 chr2:86195590~86196049:+ PAAD cis rs7945705 0.837 rs10769981 ENSG00000254860.4 TMEM9B-AS1 -6.23 4.34e-09 6.23e-06 -0.51 -0.45 Hemoglobin concentration; chr11:9002913 chr11:8964675~8977527:+ PAAD cis rs1009647 0.961 rs1009648 ENSG00000258413.1 RP11-665C16.6 -6.23 4.35e-09 6.25e-06 -0.64 -0.45 Testicular germ cell tumor; chr14:55413451 chr14:55262767~55272075:- PAAD cis rs8037818 1 rs4544214 ENSG00000276724.1 RP11-1000B6.7 6.23 4.35e-09 6.25e-06 0.64 0.45 Obesity-related traits; chr15:32639703 chr15:32583612~32584312:+ PAAD cis rs17301013 0.606 rs162815 ENSG00000227373.4 RP11-160H22.5 6.23 4.37e-09 6.28e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174738792 chr1:174115300~174160004:- PAAD cis rs55665837 1 rs34382046 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14429772 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs7945167 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14430274 chr11:14478892~14478953:+ PAAD cis rs55665837 0.961 rs60622588 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14435452 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs11023223 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14435566 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs11023224 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14436193 chr11:14478892~14478953:+ PAAD cis rs55665837 0.961 rs11023226 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14437271 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs11023227 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14437541 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10832264 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14438436 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs11023229 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14439455 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs12276938 ENSG00000251991.1 RNU7-49P 6.23 4.38e-09 6.28e-06 0.54 0.45 Vitamin D levels; chr11:14441942 chr11:14478892~14478953:+ PAAD cis rs2882667 0.858 rs17207870 ENSG00000253404.1 AC034243.1 6.23 4.38e-09 6.28e-06 0.56 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139052048 chr5:138744434~138753309:- PAAD cis rs673078 0.66 rs7965350 ENSG00000275759.1 RP11-131L12.3 -6.23 4.39e-09 6.29e-06 -0.67 -0.45 Glucose homeostasis traits; chr12:118266710 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs17433217 ENSG00000275759.1 RP11-131L12.3 -6.23 4.39e-09 6.29e-06 -0.67 -0.45 Glucose homeostasis traits; chr12:118269076 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs73205526 ENSG00000275759.1 RP11-131L12.3 -6.23 4.39e-09 6.29e-06 -0.67 -0.45 Glucose homeostasis traits; chr12:118273172 chr12:118428281~118428870:+ PAAD cis rs673078 0.571 rs7954330 ENSG00000275759.1 RP11-131L12.3 -6.23 4.39e-09 6.29e-06 -0.67 -0.45 Glucose homeostasis traits; chr12:118275284 chr12:118428281~118428870:+ PAAD cis rs17301013 0.531 rs6678286 ENSG00000227373.4 RP11-160H22.5 6.23 4.4e-09 6.3e-06 0.65 0.45 Systemic lupus erythematosus; chr1:174200481 chr1:174115300~174160004:- PAAD cis rs7044106 0.762 rs7044226 ENSG00000226752.6 PSMD5-AS1 -6.23 4.41e-09 6.3e-06 -0.61 -0.45 Hip circumference adjusted for BMI; chr9:120704050 chr9:120824828~120854385:+ PAAD cis rs8062405 0.722 rs28729187 ENSG00000259982.1 CDC37P1 -6.23 4.41e-09 6.31e-06 -0.53 -0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28615645 chr16:28700294~28701540:- PAAD cis rs4718428 0.705 rs2901311 ENSG00000226824.5 RP4-756H11.3 -6.23 4.42e-09 6.32e-06 -0.64 -0.45 Corneal structure; chr7:66950082 chr7:66654538~66669855:+ PAAD cis rs11673344 0.583 rs7247090 ENSG00000226686.6 LINC01535 6.23 4.42e-09 6.32e-06 0.54 0.45 Obesity-related traits; chr19:37522509 chr19:37251912~37265535:+ PAAD cis rs9425766 0.566 rs4442420 ENSG00000227373.4 RP11-160H22.5 6.23 4.43e-09 6.33e-06 0.61 0.45 Life satisfaction; chr1:174199667 chr1:174115300~174160004:- PAAD cis rs9425766 0.566 rs4447042 ENSG00000227373.4 RP11-160H22.5 6.23 4.43e-09 6.33e-06 0.61 0.45 Life satisfaction; chr1:174212747 chr1:174115300~174160004:- PAAD cis rs11098499 1 rs13435802 ENSG00000245958.5 RP11-33B1.1 6.23 4.45e-09 6.36e-06 0.36 0.45 Corneal astigmatism; chr4:119256805 chr4:119454791~119552025:+ PAAD cis rs6452524 0.804 rs2048215 ENSG00000249664.1 CTD-2227C6.2 -6.23 4.45e-09 6.37e-06 -0.54 -0.45 Hypertension (SNP x SNP interaction); chr5:83208589 chr5:83012285~83013109:- PAAD cis rs6452524 0.836 rs11949301 ENSG00000249664.1 CTD-2227C6.2 -6.23 4.45e-09 6.37e-06 -0.54 -0.45 Hypertension (SNP x SNP interaction); chr5:83209334 chr5:83012285~83013109:- PAAD cis rs78579487 1 rs78579487 ENSG00000240875.4 LINC00886 -6.23 4.47e-09 6.38e-06 -0.56 -0.45 Breast cancer; chr3:156800879 chr3:156747346~156817062:- PAAD cis rs987724 0.551 rs1835372 ENSG00000240875.4 LINC00886 -6.23 4.47e-09 6.38e-06 -0.56 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156801238 chr3:156747346~156817062:- PAAD cis rs7811142 1 rs7783159 ENSG00000242294.5 STAG3L5P 6.23 4.47e-09 6.38e-06 0.35 0.45 Platelet count; chr7:100419831 chr7:100336079~100351900:+ PAAD cis rs73086581 1 rs34640283 ENSG00000229539.1 RP11-119B16.2 6.23 4.47e-09 6.38e-06 0.7 0.45 Response to antidepressants in depression; chr20:4008929 chr20:3888239~3888868:- PAAD cis rs638893 0.636 rs583213 ENSG00000278376.1 RP11-158I9.8 -6.23 4.47e-09 6.39e-06 -0.65 -0.45 Vitiligo; chr11:118798469 chr11:118791254~118793137:+ PAAD cis rs950169 0.922 rs12910334 ENSG00000225151.9 GOLGA2P7 -6.22 4.47e-09 6.39e-06 -0.54 -0.45 Schizophrenia; chr15:84403620 chr15:84199311~84230136:- PAAD cis rs17301013 0.606 rs913687 ENSG00000227373.4 RP11-160H22.5 6.22 4.52e-09 6.45e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174805993 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs1793315 ENSG00000227373.4 RP11-160H22.5 -6.22 4.52e-09 6.45e-06 -0.64 -0.45 Systemic lupus erythematosus; chr1:174808923 chr1:174115300~174160004:- PAAD cis rs853679 0.506 rs1150711 ENSG00000216901.1 AL022393.7 6.22 4.54e-09 6.48e-06 0.57 0.45 Depression; chr6:28240757 chr6:28176188~28176674:+ PAAD cis rs11168854 0.595 rs11168857 ENSG00000258017.1 RP11-386G11.10 -6.22 4.55e-09 6.49e-06 -0.57 -0.45 Body mass index; chr12:49096526 chr12:49127782~49147869:+ PAAD cis rs55665837 1 rs10766182 ENSG00000251991.1 RNU7-49P 6.22 4.55e-09 6.49e-06 0.54 0.45 Vitamin D levels; chr11:14477990 chr11:14478892~14478953:+ PAAD cis rs55665837 0.961 rs11023237 ENSG00000251991.1 RNU7-49P 6.22 4.55e-09 6.49e-06 0.54 0.45 Vitamin D levels; chr11:14478788 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs10466412 ENSG00000251991.1 RNU7-49P 6.22 4.55e-09 6.49e-06 0.54 0.45 Vitamin D levels; chr11:14483643 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs12364959 ENSG00000251991.1 RNU7-49P 6.22 4.55e-09 6.49e-06 0.54 0.45 Vitamin D levels; chr11:14485889 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs34980103 ENSG00000251991.1 RNU7-49P 6.22 4.55e-09 6.49e-06 0.54 0.45 Vitamin D levels; chr11:14491339 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs2305306 ENSG00000251991.1 RNU7-49P 6.22 4.55e-09 6.49e-06 0.54 0.45 Vitamin D levels; chr11:14513453 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs11023246 ENSG00000251991.1 RNU7-49P 6.22 4.55e-09 6.49e-06 0.54 0.45 Vitamin D levels; chr11:14515410 chr11:14478892~14478953:+ PAAD cis rs6700559 0.81 rs7529962 ENSG00000260088.1 RP11-92G12.3 -6.22 4.56e-09 6.51e-06 -0.57 -0.45 Coronary artery disease; chr1:200627849 chr1:200669507~200694250:+ PAAD cis rs4218 0.574 rs12907957 ENSG00000277144.1 RP11-59H7.4 -6.22 4.59e-09 6.55e-06 -0.57 -0.45 Social communication problems; chr15:59109486 chr15:59115547~59116089:- PAAD cis rs8018967 1 rs8018967 ENSG00000258695.2 RP3-414A15.2 -6.22 4.6e-09 6.56e-06 -0.55 -0.45 Blood metabolite ratios; chr14:73510230 chr14:73522878~73530610:+ PAAD cis rs2929278 0.617 rs575082 ENSG00000205771.5 CATSPER2P1 6.22 4.61e-09 6.57e-06 0.58 0.45 Schizophrenia; chr15:43817944 chr15:43726918~43747094:- PAAD cis rs2929278 0.617 rs2955969 ENSG00000205771.5 CATSPER2P1 6.22 4.61e-09 6.57e-06 0.58 0.45 Schizophrenia; chr15:43822329 chr15:43726918~43747094:- PAAD cis rs17301013 0.606 rs4650939 ENSG00000227373.4 RP11-160H22.5 6.22 4.63e-09 6.6e-06 0.66 0.45 Systemic lupus erythematosus; chr1:174096823 chr1:174115300~174160004:- PAAD cis rs35160687 1 rs35160687 ENSG00000273080.1 RP11-301O19.1 6.22 4.64e-09 6.61e-06 0.51 0.45 Night sleep phenotypes; chr2:86244991 chr2:86195590~86196049:+ PAAD cis rs732716 0.785 rs9973266 ENSG00000267980.1 AC007292.6 -6.22 4.68e-09 6.66e-06 -0.63 -0.45 Mean corpuscular volume; chr19:4392718 chr19:4363789~4364640:+ PAAD cis rs7429990 0.828 rs55823596 ENSG00000229759.1 MRPS18AP1 6.22 4.68e-09 6.66e-06 0.48 0.45 Educational attainment (years of education); chr3:47758541 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs4858853 ENSG00000229759.1 MRPS18AP1 6.22 4.68e-09 6.66e-06 0.48 0.45 Educational attainment (years of education); chr3:47760605 chr3:48256350~48256938:- PAAD cis rs638893 0.527 rs7933859 ENSG00000278376.1 RP11-158I9.8 -6.22 4.68e-09 6.67e-06 -0.65 -0.45 Vitiligo; chr11:118791336 chr11:118791254~118793137:+ PAAD cis rs638893 0.578 rs4508234 ENSG00000278376.1 RP11-158I9.8 -6.22 4.68e-09 6.67e-06 -0.65 -0.45 Vitiligo; chr11:118791494 chr11:118791254~118793137:+ PAAD cis rs638893 0.578 rs5006102 ENSG00000278376.1 RP11-158I9.8 -6.22 4.68e-09 6.67e-06 -0.65 -0.45 Vitiligo; chr11:118791631 chr11:118791254~118793137:+ PAAD cis rs8040855 0.825 rs3964197 ENSG00000259295.5 CSPG4P12 6.22 4.69e-09 6.67e-06 0.53 0.45 Bulimia nervosa; chr15:85178681 chr15:85191438~85213905:+ PAAD cis rs7945705 0.869 rs4909952 ENSG00000254860.4 TMEM9B-AS1 -6.21 4.72e-09 6.72e-06 -0.49 -0.45 Hemoglobin concentration; chr11:8942399 chr11:8964675~8977527:+ PAAD cis rs11098499 0.954 rs13145352 ENSG00000245958.5 RP11-33B1.1 6.21 4.75e-09 6.75e-06 0.39 0.45 Corneal astigmatism; chr4:119488808 chr4:119454791~119552025:+ PAAD cis rs1009647 0.961 rs946056 ENSG00000258413.1 RP11-665C16.6 -6.21 4.76e-09 6.77e-06 -0.64 -0.45 Testicular germ cell tumor; chr14:55414012 chr14:55262767~55272075:- PAAD cis rs1061377 1 rs10030904 ENSG00000249685.1 RP11-360F5.3 6.21 4.78e-09 6.79e-06 0.49 0.45 Uric acid levels; chr4:39113603 chr4:39133913~39135608:+ PAAD cis rs10256972 0.869 rs4720158 ENSG00000229043.2 AC091729.9 -6.21 4.81e-09 6.83e-06 -0.49 -0.45 Endometriosis;Longevity; chr7:1000689 chr7:1160374~1165267:+ PAAD cis rs858239 0.932 rs1637190 ENSG00000226816.2 AC005082.12 6.21 4.81e-09 6.83e-06 0.51 0.45 Cerebrospinal fluid biomarker levels; chr7:23229446 chr7:23206013~23208045:+ PAAD cis rs507080 0.769 rs12290522 ENSG00000255422.1 AP002954.4 -6.21 4.82e-09 6.83e-06 -0.56 -0.45 Serum metabolite levels; chr11:118615610 chr11:118704607~118750263:+ PAAD cis rs673078 0.607 rs7137055 ENSG00000275759.1 RP11-131L12.3 -6.21 4.84e-09 6.86e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118395030 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7137184 ENSG00000275759.1 RP11-131L12.3 -6.21 4.84e-09 6.86e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118395163 chr12:118428281~118428870:+ PAAD cis rs673078 0.562 rs4767672 ENSG00000275759.1 RP11-131L12.3 -6.21 4.84e-09 6.86e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118397048 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs73205594 ENSG00000275759.1 RP11-131L12.3 -6.21 4.84e-09 6.86e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118397168 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943400 ENSG00000275759.1 RP11-131L12.3 -6.21 4.84e-09 6.86e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118398236 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943401 ENSG00000275759.1 RP11-131L12.3 -6.21 4.84e-09 6.86e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118398527 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943402 ENSG00000275759.1 RP11-131L12.3 -6.21 4.84e-09 6.86e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118398808 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943404 ENSG00000275759.1 RP11-131L12.3 -6.21 4.84e-09 6.86e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118402062 chr12:118428281~118428870:+ PAAD cis rs7208859 0.778 rs6505219 ENSG00000263531.1 RP13-753N3.1 6.21 4.85e-09 6.88e-06 0.73 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30938603 chr17:30863921~30864940:- PAAD cis rs7188445 0.871 rs16950997 ENSG00000261390.4 RP11-345M22.2 -6.21 4.86e-09 6.88e-06 -0.61 -0.45 Urate levels; chr16:79673733 chr16:79715232~79770563:- PAAD cis rs7044106 0.708 rs2416760 ENSG00000226752.6 PSMD5-AS1 -6.21 4.87e-09 6.91e-06 -0.57 -0.45 Hip circumference adjusted for BMI; chr9:120612361 chr9:120824828~120854385:+ PAAD cis rs4972806 0.776 rs2072589 ENSG00000226363.3 HAGLROS -6.21 4.88e-09 6.92e-06 -0.54 -0.45 IgG glycosylation; chr2:176178143 chr2:176177717~176179008:+ PAAD cis rs950169 1 rs1818950 ENSG00000259728.4 LINC00933 6.21 4.89e-09 6.93e-06 0.56 0.45 Schizophrenia; chr15:84053769 chr15:84570649~84580175:+ PAAD cis rs72772090 0.539 rs11740375 ENSG00000248734.2 CTD-2260A17.1 -6.21 4.91e-09 6.96e-06 -0.59 -0.45 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777193 chr5:96784777~96785999:+ PAAD cis rs11098499 0.954 rs6849561 ENSG00000245958.5 RP11-33B1.1 6.21 4.91e-09 6.96e-06 0.38 0.45 Corneal astigmatism; chr4:119488539 chr4:119454791~119552025:+ PAAD cis rs2117029 0.521 rs12229524 ENSG00000258017.1 RP11-386G11.10 -6.21 4.93e-09 6.98e-06 -0.56 -0.45 Intelligence (multi-trait analysis); chr12:49191570 chr12:49127782~49147869:+ PAAD cis rs7301826 1 rs10773822 ENSG00000256299.1 RP11-989F5.3 -6.21 4.94e-09 6.99e-06 -0.5 -0.45 Plasma plasminogen activator levels; chr12:130804562 chr12:130810821~130812622:- PAAD cis rs7301826 1 rs4759787 ENSG00000256299.1 RP11-989F5.3 -6.21 4.94e-09 6.99e-06 -0.5 -0.45 Plasma plasminogen activator levels; chr12:130805635 chr12:130810821~130812622:- PAAD cis rs7301826 1 rs7301826 ENSG00000256299.1 RP11-989F5.3 -6.21 4.94e-09 6.99e-06 -0.5 -0.45 Plasma plasminogen activator levels; chr12:130806556 chr12:130810821~130812622:- PAAD cis rs7301826 0.966 rs10734980 ENSG00000256299.1 RP11-989F5.3 -6.21 4.94e-09 6.99e-06 -0.5 -0.45 Plasma plasminogen activator levels; chr12:130810081 chr12:130810821~130812622:- PAAD cis rs7301826 0.967 rs4759790 ENSG00000256299.1 RP11-989F5.3 -6.21 4.94e-09 6.99e-06 -0.5 -0.45 Plasma plasminogen activator levels; chr12:130811845 chr12:130810821~130812622:- PAAD cis rs7301826 1 rs4759793 ENSG00000256299.1 RP11-989F5.3 -6.21 4.94e-09 6.99e-06 -0.5 -0.45 Plasma plasminogen activator levels; chr12:130812693 chr12:130810821~130812622:- PAAD cis rs11673344 0.832 rs56080874 ENSG00000226686.6 LINC01535 6.2 4.96e-09 7.02e-06 0.62 0.45 Obesity-related traits; chr19:37085487 chr19:37251912~37265535:+ PAAD cis rs4218 0.513 rs17302142 ENSG00000277144.1 RP11-59H7.4 -6.2 4.97e-09 7.03e-06 -0.55 -0.45 Social communication problems; chr15:59053813 chr15:59115547~59116089:- PAAD cis rs9640161 0.659 rs77354576 ENSG00000261305.1 RP4-584D14.7 6.2 5e-09 7.08e-06 0.66 0.45 Blood protein levels;Circulating chemerin levels; chr7:150316211 chr7:150341771~150342607:+ PAAD cis rs875971 0.502 rs1796227 ENSG00000237310.1 GS1-124K5.4 -6.2 5.02e-09 7.1e-06 -0.52 -0.45 Aortic root size; chr7:66622032 chr7:66493706~66495474:+ PAAD cis rs10129255 0.5 rs7159033 ENSG00000223648.3 IGHV3-64 6.2 5.05e-09 7.14e-06 0.4 0.45 Kawasaki disease; chr14:106701709 chr14:106643132~106658258:- PAAD cis rs2929278 0.617 rs694461 ENSG00000249839.1 AC011330.5 6.2 5.05e-09 7.14e-06 0.61 0.45 Schizophrenia; chr15:43803865 chr15:43663654~43684339:- PAAD cis rs1061377 1 rs12499266 ENSG00000249685.1 RP11-360F5.3 -6.2 5.05e-09 7.14e-06 -0.48 -0.45 Uric acid levels; chr4:39118133 chr4:39133913~39135608:+ PAAD cis rs1061377 1 rs35116118 ENSG00000249685.1 RP11-360F5.3 6.2 5.05e-09 7.14e-06 0.48 0.45 Uric acid levels; chr4:39127293 chr4:39133913~39135608:+ PAAD cis rs950169 0.922 rs62021167 ENSG00000225151.9 GOLGA2P7 -6.2 5.06e-09 7.15e-06 -0.54 -0.45 Schizophrenia; chr15:84574820 chr15:84199311~84230136:- PAAD cis rs73086581 0.838 rs11907416 ENSG00000229539.1 RP11-119B16.2 6.2 5.06e-09 7.15e-06 0.73 0.45 Response to antidepressants in depression; chr20:4024972 chr20:3888239~3888868:- PAAD cis rs992157 0.804 rs6758540 ENSG00000261338.2 RP11-378A13.1 -6.2 5.06e-09 7.15e-06 -0.55 -0.45 Colorectal cancer; chr2:218273902 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs2292550 ENSG00000261338.2 RP11-378A13.1 -6.2 5.06e-09 7.15e-06 -0.55 -0.45 Colorectal cancer; chr2:218275565 chr2:218255319~218257366:+ PAAD cis rs659580 1 rs659580 ENSG00000271811.1 RP1-79C4.4 -6.2 5.07e-09 7.16e-06 -0.49 -0.45 Response to angiotensin II receptor blocker therapy;Lobe attachment (rater-scored or self-reported); chr1:170664755 chr1:170667381~170669425:+ PAAD cis rs494459 0.536 rs57719838 ENSG00000255239.1 AP002954.6 6.2 5.08e-09 7.17e-06 0.54 0.45 Height; chr11:118854014 chr11:118688039~118690600:- PAAD cis rs494459 0.536 rs11217063 ENSG00000255239.1 AP002954.6 6.2 5.08e-09 7.17e-06 0.54 0.45 Height; chr11:118855233 chr11:118688039~118690600:- PAAD cis rs494459 0.536 rs11217065 ENSG00000255239.1 AP002954.6 6.2 5.08e-09 7.17e-06 0.54 0.45 Height; chr11:118855938 chr11:118688039~118690600:- PAAD cis rs494459 0.504 rs7929520 ENSG00000255239.1 AP002954.6 6.2 5.08e-09 7.17e-06 0.54 0.45 Height; chr11:118859432 chr11:118688039~118690600:- PAAD cis rs494459 0.536 rs34561290 ENSG00000255239.1 AP002954.6 6.2 5.08e-09 7.17e-06 0.54 0.45 Height; chr11:118860890 chr11:118688039~118690600:- PAAD cis rs494459 0.536 rs11217072 ENSG00000255239.1 AP002954.6 6.2 5.08e-09 7.17e-06 0.54 0.45 Height; chr11:118861053 chr11:118688039~118690600:- PAAD cis rs200972 1 rs200972 ENSG00000216901.1 AL022393.7 6.2 5.08e-09 7.17e-06 0.61 0.45 Urinary tract infection frequency; chr6:27891059 chr6:28176188~28176674:+ PAAD cis rs950169 0.922 rs11639244 ENSG00000225151.9 GOLGA2P7 -6.2 5.09e-09 7.18e-06 -0.54 -0.45 Schizophrenia; chr15:84163898 chr15:84199311~84230136:- PAAD cis rs950169 0.845 rs4106951 ENSG00000225151.9 GOLGA2P7 -6.2 5.09e-09 7.18e-06 -0.54 -0.45 Schizophrenia; chr15:84164642 chr15:84199311~84230136:- PAAD cis rs35160687 0.901 rs13017338 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86274430 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs12472676 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86283692 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs35762338 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86286430 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs17738096 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86286770 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs12714179 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86287835 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs12714180 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86298200 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs35281683 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86299249 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs10200186 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86300300 chr2:86195590~86196049:+ PAAD cis rs35160687 0.842 rs10200526 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86300476 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs34048420 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86302625 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs34069316 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86302669 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs11127026 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86304625 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs12478575 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86308191 chr2:86195590~86196049:+ PAAD cis rs35160687 0.871 rs11127028 ENSG00000273080.1 RP11-301O19.1 6.2 5.09e-09 7.18e-06 0.5 0.45 Night sleep phenotypes; chr2:86310386 chr2:86195590~86196049:+ PAAD cis rs10875746 0.903 rs12313404 ENSG00000240399.1 RP1-228P16.1 -6.2 5.11e-09 7.21e-06 -0.5 -0.45 Longevity (90 years and older); chr12:48098265 chr12:48054813~48055591:- PAAD cis rs10875746 0.855 rs73102065 ENSG00000240399.1 RP1-228P16.1 -6.2 5.11e-09 7.21e-06 -0.5 -0.45 Longevity (90 years and older); chr12:48098824 chr12:48054813~48055591:- PAAD cis rs10875746 0.855 rs73102067 ENSG00000240399.1 RP1-228P16.1 -6.2 5.11e-09 7.21e-06 -0.5 -0.45 Longevity (90 years and older); chr12:48100643 chr12:48054813~48055591:- PAAD cis rs11098499 0.954 rs6847248 ENSG00000245958.5 RP11-33B1.1 -6.2 5.11e-09 7.21e-06 -0.38 -0.45 Corneal astigmatism; chr4:119304800 chr4:119454791~119552025:+ PAAD cis rs1061377 1 rs12646251 ENSG00000249207.1 RP11-360F5.1 -6.2 5.13e-09 7.23e-06 -0.49 -0.45 Uric acid levels; chr4:39132751 chr4:39112677~39126818:- PAAD cis rs992157 0.767 rs2014615 ENSG00000261338.2 RP11-378A13.1 6.2 5.13e-09 7.23e-06 0.53 0.45 Colorectal cancer; chr2:218306468 chr2:218255319~218257366:+ PAAD cis rs992157 0.767 rs2382822 ENSG00000261338.2 RP11-378A13.1 -6.2 5.13e-09 7.23e-06 -0.53 -0.45 Colorectal cancer; chr2:218308604 chr2:218255319~218257366:+ PAAD cis rs2739330 0.796 rs2154594 ENSG00000250470.1 AP000351.3 -6.2 5.17e-09 7.28e-06 -0.63 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23976904~23977585:- PAAD cis rs992157 0.731 rs1399132 ENSG00000261338.2 RP11-378A13.1 6.2 5.17e-09 7.29e-06 0.53 0.45 Colorectal cancer; chr2:218295047 chr2:218255319~218257366:+ PAAD cis rs992157 0.796 rs55680399 ENSG00000261338.2 RP11-378A13.1 6.2 5.17e-09 7.29e-06 0.53 0.45 Colorectal cancer; chr2:218295898 chr2:218255319~218257366:+ PAAD cis rs7301826 0.967 rs4759792 ENSG00000256299.1 RP11-989F5.3 -6.2 5.19e-09 7.3e-06 -0.5 -0.45 Plasma plasminogen activator levels; chr12:130812086 chr12:130810821~130812622:- PAAD cis rs1665050 0.571 rs1446238 ENSG00000277144.1 RP11-59H7.4 -6.2 5.2e-09 7.33e-06 -0.55 -0.45 Atopic dermatitis; chr15:59055558 chr15:59115547~59116089:- PAAD cis rs858239 0.932 rs858275 ENSG00000226816.2 AC005082.12 6.19 5.24e-09 7.37e-06 0.5 0.45 Cerebrospinal fluid biomarker levels; chr7:23254525 chr7:23206013~23208045:+ PAAD cis rs8062405 0.789 rs1968752 ENSG00000259982.1 CDC37P1 6.19 5.24e-09 7.38e-06 0.52 0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620264 chr16:28700294~28701540:- PAAD cis rs35160687 0.865 rs10189492 ENSG00000273080.1 RP11-301O19.1 6.19 5.25e-09 7.38e-06 0.51 0.45 Night sleep phenotypes; chr2:86251779 chr2:86195590~86196049:+ PAAD cis rs8040855 0.576 rs62022527 ENSG00000259295.5 CSPG4P12 6.19 5.25e-09 7.38e-06 0.56 0.45 Bulimia nervosa; chr15:84988022 chr15:85191438~85213905:+ PAAD cis rs35160687 0.901 rs6714362 ENSG00000273080.1 RP11-301O19.1 -6.19 5.28e-09 7.43e-06 -0.51 -0.45 Night sleep phenotypes; chr2:86249465 chr2:86195590~86196049:+ PAAD cis rs9601248 1 rs9601248 ENSG00000227676.3 LINC01068 -6.19 5.3e-09 7.46e-06 -0.56 -0.45 Major depressive disorder; chr13:79594869 chr13:79566727~79571436:+ PAAD cis rs11098499 0.754 rs1511017 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119329650 chr4:119454791~119552025:+ PAAD cis rs11098499 0.789 rs12498994 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119329663 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs12507565 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119329966 chr4:119454791~119552025:+ PAAD cis rs11098499 0.826 rs12511640 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119330093 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs1980026 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119330488 chr4:119454791~119552025:+ PAAD cis rs11098499 0.722 rs28713555 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119330840 chr4:119454791~119552025:+ PAAD cis rs11098499 0.743 rs11098501 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119330862 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs11098502 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119330908 chr4:119454791~119552025:+ PAAD cis rs11098499 0.708 rs11732686 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119331175 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs11724409 ENSG00000245958.5 RP11-33B1.1 -6.19 5.31e-09 7.46e-06 -0.35 -0.45 Corneal astigmatism; chr4:119331206 chr4:119454791~119552025:+ PAAD cis rs1075232 1 rs56396205 ENSG00000270055.1 CTD-3092A11.2 -6.19 5.33e-09 7.5e-06 -1.04 -0.45 Survival in colorectal cancer (non-distant metastatic); chr15:31386182 chr15:30487963~30490313:+ PAAD cis rs1075232 1 rs12438318 ENSG00000270055.1 CTD-3092A11.2 -6.19 5.33e-09 7.5e-06 -1.04 -0.45 Survival in colorectal cancer (non-distant metastatic); chr15:31388242 chr15:30487963~30490313:+ PAAD cis rs1075232 1 rs4450360 ENSG00000270055.1 CTD-3092A11.2 -6.19 5.33e-09 7.5e-06 -1.04 -0.45 Survival in colorectal cancer (non-distant metastatic); chr15:31389827 chr15:30487963~30490313:+ PAAD cis rs1075232 1 rs72722847 ENSG00000270055.1 CTD-3092A11.2 -6.19 5.33e-09 7.5e-06 -1.04 -0.45 Survival in colorectal cancer (non-distant metastatic); chr15:31390143 chr15:30487963~30490313:+ PAAD cis rs11098499 0.687 rs71610270 ENSG00000245958.5 RP11-33B1.1 -6.19 5.34e-09 7.5e-06 -0.33 -0.45 Corneal astigmatism; chr4:119366281 chr4:119454791~119552025:+ PAAD cis rs853679 0.567 rs7774981 ENSG00000204709.4 LINC01556 6.19 5.34e-09 7.51e-06 0.66 0.45 Depression; chr6:28379133 chr6:28943877~28944537:+ PAAD cis rs853679 0.567 rs7754960 ENSG00000204709.4 LINC01556 6.19 5.34e-09 7.51e-06 0.66 0.45 Depression; chr6:28379168 chr6:28943877~28944537:+ PAAD cis rs853679 0.567 rs3799499 ENSG00000204709.4 LINC01556 6.19 5.34e-09 7.51e-06 0.66 0.45 Depression; chr6:28386473 chr6:28943877~28944537:+ PAAD cis rs853679 0.567 rs2232427 ENSG00000204709.4 LINC01556 6.19 5.34e-09 7.51e-06 0.66 0.45 Depression; chr6:28391932 chr6:28943877~28944537:+ PAAD cis rs1061377 1 rs9990742 ENSG00000249685.1 RP11-360F5.3 6.19 5.38e-09 7.55e-06 0.49 0.45 Uric acid levels; chr4:39119794 chr4:39133913~39135608:+ PAAD cis rs7208859 0.573 rs73267829 ENSG00000266490.1 CTD-2349P21.9 6.19 5.39e-09 7.56e-06 0.57 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30676921 chr17:30792372~30792833:+ PAAD cis rs7208859 0.562 rs11650923 ENSG00000266490.1 CTD-2349P21.9 6.19 5.39e-09 7.56e-06 0.57 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30681149 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs56378576 ENSG00000266490.1 CTD-2349P21.9 6.19 5.39e-09 7.56e-06 0.57 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30683102 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs35916850 ENSG00000266490.1 CTD-2349P21.9 6.19 5.39e-09 7.56e-06 0.57 0.45 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30684155 chr17:30792372~30792833:+ PAAD cis rs9532669 0.926 rs2324742 ENSG00000176268.5 CYCSP34 6.19 5.39e-09 7.57e-06 0.43 0.45 Cervical cancer; chr13:40919059 chr13:40863599~40863902:- PAAD cis rs9532669 0.857 rs9594455 ENSG00000176268.5 CYCSP34 6.19 5.39e-09 7.57e-06 0.43 0.45 Cervical cancer; chr13:40919452 chr13:40863599~40863902:- PAAD cis rs7174755 0.608 rs62004789 ENSG00000260657.2 RP11-315D16.4 6.19 5.4e-09 7.58e-06 0.54 0.45 Major depressive disorder; chr15:68148268 chr15:68267792~68277994:- PAAD cis rs950169 0.8 rs34302901 ENSG00000225151.9 GOLGA2P7 -6.19 5.43e-09 7.62e-06 -0.53 -0.45 Schizophrenia; chr15:84567712 chr15:84199311~84230136:- PAAD cis rs7396835 0.866 rs6589570 ENSG00000254851.1 RP11-109L13.1 -6.19 5.44e-09 7.63e-06 -0.79 -0.45 Quantitative traits; chr11:116804578 chr11:117135528~117138582:+ PAAD cis rs3814244 0.515 rs2906862 ENSG00000255733.4 IFNG-AS1 -6.18 5.49e-09 7.69e-06 -0.43 -0.45 Itch intensity from mosquito bite adjusted by bite size; chr12:68005371 chr12:67989445~68234686:+ PAAD cis rs9640161 0.617 rs56019796 ENSG00000261305.1 RP4-584D14.7 6.18 5.51e-09 7.72e-06 0.66 0.45 Blood protein levels;Circulating chemerin levels; chr7:150312137 chr7:150341771~150342607:+ PAAD cis rs9640161 0.659 rs11974980 ENSG00000261305.1 RP4-584D14.7 6.18 5.51e-09 7.72e-06 0.66 0.45 Blood protein levels;Circulating chemerin levels; chr7:150312749 chr7:150341771~150342607:+ PAAD cis rs9640161 0.659 rs11975886 ENSG00000261305.1 RP4-584D14.7 6.18 5.51e-09 7.72e-06 0.66 0.45 Blood protein levels;Circulating chemerin levels; chr7:150313273 chr7:150341771~150342607:+ PAAD cis rs11098499 0.618 rs35265692 ENSG00000245958.5 RP11-33B1.1 -6.18 5.51e-09 7.72e-06 -0.38 -0.45 Corneal astigmatism; chr4:119403980 chr4:119454791~119552025:+ PAAD cis rs950169 0.92 rs2135551 ENSG00000259728.4 LINC00933 6.18 5.51e-09 7.72e-06 0.56 0.45 Schizophrenia; chr15:84039099 chr15:84570649~84580175:+ PAAD cis rs42490 0.528 rs1032516 ENSG00000251136.7 RP11-37B2.1 6.18 5.54e-09 7.75e-06 0.41 0.45 Leprosy; chr8:89670055 chr8:89609409~89757727:- PAAD cis rs11155671 0.53 rs1334510 ENSG00000223701.3 RAET1E-AS1 6.18 5.57e-09 7.79e-06 0.53 0.45 Testicular germ cell tumor; chr6:149880043 chr6:149884431~149919508:+ PAAD cis rs2919917 0.628 rs10113703 ENSG00000254352.1 RP11-578O24.2 6.18 5.62e-09 7.85e-06 0.5 0.45 Lymphocyte counts; chr8:78688404 chr8:78723796~78724136:- PAAD cis rs6964833 1 rs3846966 ENSG00000123965.13 PMS2P5 6.18 5.62e-09 7.86e-06 0.75 0.45 Menarche (age at onset); chr7:74698811 chr7:74894116~74897835:+ PAAD cis rs6964833 1 rs2301907 ENSG00000123965.13 PMS2P5 6.18 5.62e-09 7.86e-06 0.75 0.45 Menarche (age at onset); chr7:74700517 chr7:74894116~74897835:+ PAAD cis rs6964833 0.935 rs7795281 ENSG00000123965.13 PMS2P5 6.18 5.62e-09 7.86e-06 0.75 0.45 Menarche (age at onset); chr7:74708523 chr7:74894116~74897835:+ PAAD cis rs6964833 0.935 rs7795282 ENSG00000123965.13 PMS2P5 6.18 5.62e-09 7.86e-06 0.75 0.45 Menarche (age at onset); chr7:74708526 chr7:74894116~74897835:+ PAAD cis rs7829975 0.591 rs12677543 ENSG00000253893.2 FAM85B -6.18 5.63e-09 7.86e-06 -0.62 -0.45 Mood instability; chr8:8786764 chr8:8167819~8226614:- PAAD cis rs17301013 0.829 rs2006197 ENSG00000227373.4 RP11-160H22.5 6.18 5.66e-09 7.9e-06 0.59 0.45 Systemic lupus erythematosus; chr1:174432825 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs2038025 ENSG00000227373.4 RP11-160H22.5 6.18 5.66e-09 7.9e-06 0.59 0.45 Systemic lupus erythematosus; chr1:174574712 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs61826916 ENSG00000227373.4 RP11-160H22.5 6.18 5.66e-09 7.9e-06 0.59 0.45 Systemic lupus erythematosus; chr1:174616048 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs333418 ENSG00000227373.4 RP11-160H22.5 6.18 5.66e-09 7.9e-06 0.59 0.45 Systemic lupus erythematosus; chr1:174707294 chr1:174115300~174160004:- PAAD cis rs17301013 0.828 rs332783 ENSG00000227373.4 RP11-160H22.5 6.18 5.66e-09 7.9e-06 0.59 0.45 Systemic lupus erythematosus; chr1:174719260 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs170768 ENSG00000227373.4 RP11-160H22.5 6.18 5.66e-09 7.9e-06 0.59 0.45 Systemic lupus erythematosus; chr1:174720787 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs332796 ENSG00000227373.4 RP11-160H22.5 6.18 5.66e-09 7.9e-06 0.59 0.45 Systemic lupus erythematosus; chr1:174727142 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs332799 ENSG00000227373.4 RP11-160H22.5 6.18 5.66e-09 7.9e-06 0.59 0.45 Systemic lupus erythematosus; chr1:174731110 chr1:174115300~174160004:- PAAD cis rs950169 0.96 rs35159785 ENSG00000225151.9 GOLGA2P7 -6.18 5.66e-09 7.9e-06 -0.55 -0.45 Schizophrenia; chr15:84135262 chr15:84199311~84230136:- PAAD cis rs72772090 0.539 rs11748328 ENSG00000248734.2 CTD-2260A17.1 -6.18 5.67e-09 7.92e-06 -0.63 -0.45 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96834213 chr5:96784777~96785999:+ PAAD cis rs11155671 0.53 rs4870080 ENSG00000223701.3 RAET1E-AS1 6.18 5.67e-09 7.92e-06 0.53 0.45 Testicular germ cell tumor; chr6:149881508 chr6:149884431~149919508:+ PAAD cis rs7945705 0.967 rs10840141 ENSG00000254860.4 TMEM9B-AS1 -6.18 5.68e-09 7.93e-06 -0.5 -0.45 Hemoglobin concentration; chr11:8880671 chr11:8964675~8977527:+ PAAD cis rs17301013 0.606 rs7536987 ENSG00000227373.4 RP11-160H22.5 6.18 5.69e-09 7.94e-06 0.64 0.45 Systemic lupus erythematosus; chr1:174367978 chr1:174115300~174160004:- PAAD cis rs950169 0.922 rs62029585 ENSG00000225151.9 GOLGA2P7 -6.18 5.71e-09 7.98e-06 -0.54 -0.45 Schizophrenia; chr15:84397176 chr15:84199311~84230136:- PAAD cis rs10129255 0.536 rs3944157 ENSG00000223648.3 IGHV3-64 6.18 5.72e-09 7.98e-06 0.4 0.45 Kawasaki disease; chr14:106682286 chr14:106643132~106658258:- PAAD cis rs2919917 0.688 rs3780003 ENSG00000254352.1 RP11-578O24.2 6.18 5.72e-09 7.99e-06 0.45 0.45 Lymphocyte counts; chr8:78696019 chr8:78723796~78724136:- PAAD cis rs2882667 0.931 rs10077796 ENSG00000253404.1 AC034243.1 -6.18 5.72e-09 7.99e-06 -0.54 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139021086 chr5:138744434~138753309:- PAAD cis rs7829975 0.681 rs2271342 ENSG00000253893.2 FAM85B -6.17 5.77e-09 8.04e-06 -0.62 -0.45 Mood instability; chr8:8786428 chr8:8167819~8226614:- PAAD cis rs1075232 1 rs12439239 ENSG00000270055.1 CTD-3092A11.2 -6.17 5.77e-09 8.05e-06 -1.04 -0.45 Survival in colorectal cancer (non-distant metastatic); chr15:31359515 chr15:30487963~30490313:+ PAAD cis rs4718428 0.576 rs12698546 ENSG00000226824.5 RP4-756H11.3 -6.17 5.78e-09 8.06e-06 -0.63 -0.45 Corneal structure; chr7:66801919 chr7:66654538~66669855:+ PAAD cis rs42490 0.868 rs1605997 ENSG00000251136.7 RP11-37B2.1 6.17 5.78e-09 8.06e-06 0.42 0.45 Leprosy; chr8:89655885 chr8:89609409~89757727:- PAAD cis rs673078 0.607 rs73207578 ENSG00000275759.1 RP11-131L12.3 -6.17 5.85e-09 8.16e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118447080 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61944671 ENSG00000275759.1 RP11-131L12.3 -6.17 5.85e-09 8.16e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118450046 chr12:118428281~118428870:+ PAAD cis rs992157 0.732 rs10932771 ENSG00000261338.2 RP11-378A13.1 6.17 5.87e-09 8.17e-06 0.53 0.45 Colorectal cancer; chr2:218305513 chr2:218255319~218257366:+ PAAD cis rs7044106 1 rs7044106 ENSG00000226752.6 PSMD5-AS1 -6.17 5.93e-09 8.26e-06 -0.66 -0.45 Hip circumference adjusted for BMI; chr9:120731784 chr9:120824828~120854385:+ PAAD cis rs950169 0.922 rs4842939 ENSG00000225151.9 GOLGA2P7 6.17 5.98e-09 8.32e-06 0.53 0.45 Schizophrenia; chr15:84159214 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs4842939 ENSG00000259728.4 LINC00933 -6.17 5.98e-09 8.33e-06 -0.55 -0.45 Schizophrenia; chr15:84159214 chr15:84570649~84580175:+ PAAD cis rs950169 0.887 rs220333 ENSG00000225151.9 GOLGA2P7 -6.17 5.99e-09 8.34e-06 -0.53 -0.45 Schizophrenia; chr15:84547902 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs11630507 ENSG00000225151.9 GOLGA2P7 -6.17 5.99e-09 8.34e-06 -0.53 -0.45 Schizophrenia; chr15:84552494 chr15:84199311~84230136:- PAAD cis rs950169 0.881 rs34117475 ENSG00000225151.9 GOLGA2P7 -6.17 5.99e-09 8.34e-06 -0.53 -0.45 Schizophrenia; chr15:84565212 chr15:84199311~84230136:- PAAD cis rs950169 0.686 rs12906474 ENSG00000225151.9 GOLGA2P7 -6.17 5.99e-09 8.34e-06 -0.53 -0.45 Schizophrenia; chr15:84566006 chr15:84199311~84230136:- PAAD cis rs950169 0.81 rs2879976 ENSG00000225151.9 GOLGA2P7 -6.17 5.99e-09 8.34e-06 -0.53 -0.45 Schizophrenia; chr15:84566347 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs12915832 ENSG00000225151.9 GOLGA2P7 -6.17 5.99e-09 8.34e-06 -0.53 -0.45 Schizophrenia; chr15:84568226 chr15:84199311~84230136:- PAAD cis rs10875746 0.859 rs4760695 ENSG00000240399.1 RP1-228P16.1 -6.17 6e-09 8.35e-06 -0.48 -0.45 Longevity (90 years and older); chr12:48198065 chr12:48054813~48055591:- PAAD cis rs10875746 0.859 rs4760622 ENSG00000240399.1 RP1-228P16.1 -6.17 6e-09 8.35e-06 -0.48 -0.45 Longevity (90 years and older); chr12:48198177 chr12:48054813~48055591:- PAAD cis rs11098499 0.954 rs3733524 ENSG00000245958.5 RP11-33B1.1 -6.17 6.04e-09 8.4e-06 -0.38 -0.45 Corneal astigmatism; chr4:119502574 chr4:119454791~119552025:+ PAAD cis rs494459 0.536 rs7103067 ENSG00000255239.1 AP002954.6 6.17 6.06e-09 8.43e-06 0.54 0.45 Height; chr11:118852670 chr11:118688039~118690600:- PAAD cis rs1061377 0.76 rs7678457 ENSG00000249685.1 RP11-360F5.3 6.16 6.07e-09 8.44e-06 0.5 0.45 Uric acid levels; chr4:39136041 chr4:39133913~39135608:+ PAAD cis rs2115630 0.875 rs8039472 ENSG00000259728.4 LINC00933 -6.16 6.1e-09 8.48e-06 -0.54 -0.45 P wave terminal force; chr15:84818413 chr15:84570649~84580175:+ PAAD cis rs9322193 0.923 rs9800736 ENSG00000216906.2 RP11-350J20.9 6.16 6.1e-09 8.48e-06 0.56 0.45 Lung cancer; chr6:149661281 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs12660304 ENSG00000216906.2 RP11-350J20.9 6.16 6.1e-09 8.48e-06 0.56 0.45 Lung cancer; chr6:149739647 chr6:149904243~149906418:+ PAAD cis rs12458462 0.892 rs2242174 ENSG00000274828.1 RP11-567M16.6 6.16 6.11e-09 8.49e-06 0.44 0.45 Monocyte count; chr18:79698037 chr18:79677287~79679358:- PAAD cis rs2283792 0.567 rs2027789 ENSG00000224086.5 LL22NC03-86G7.1 -6.16 6.12e-09 8.51e-06 -0.5 -0.45 Multiple sclerosis; chr22:21933490 chr22:21938293~21977632:+ PAAD cis rs2929278 0.617 rs694461 ENSG00000205771.5 CATSPER2P1 6.16 6.13e-09 8.52e-06 0.58 0.45 Schizophrenia; chr15:43803865 chr15:43726918~43747094:- PAAD cis rs17264034 0.808 rs1706987 ENSG00000250786.1 SNHG18 6.16 6.15e-09 8.55e-06 0.61 0.45 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9547853 chr5:9546200~9550609:+ PAAD cis rs17264034 0.861 rs1398337 ENSG00000250786.1 SNHG18 6.16 6.15e-09 8.55e-06 0.61 0.45 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9547986 chr5:9546200~9550609:+ PAAD cis rs11098499 0.754 rs12510269 ENSG00000245958.5 RP11-33B1.1 -6.16 6.16e-09 8.56e-06 -0.35 -0.45 Corneal astigmatism; chr4:119320491 chr4:119454791~119552025:+ PAAD cis rs12594515 0.967 rs11854477 ENSG00000273972.1 CTD-2306A12.1 -6.16 6.18e-09 8.59e-06 -0.54 -0.45 Weight;Waist circumference; chr15:45706147 chr15:45702640~45703183:+ PAAD cis rs3096299 0.719 rs2353581 ENSG00000274627.1 RP11-104N10.2 6.16 6.2e-09 8.61e-06 0.38 0.45 Multiple myeloma (IgH translocation); chr16:89452500 chr16:89516797~89522217:+ PAAD cis rs10129255 0.536 rs6576201 ENSG00000223648.3 IGHV3-64 -6.16 6.21e-09 8.63e-06 -0.4 -0.45 Kawasaki disease; chr14:106683696 chr14:106643132~106658258:- PAAD cis rs673078 0.607 rs73207575 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118446711 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61944663 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118446886 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs73207577 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118447012 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs73207579 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118447123 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61944664 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118447145 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7969871 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118447331 chr12:118428281~118428870:+ PAAD cis rs673078 0.56 rs7970361 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118447723 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61944669 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118448530 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61944670 ENSG00000275759.1 RP11-131L12.3 -6.16 6.24e-09 8.66e-06 -0.69 -0.45 Glucose homeostasis traits; chr12:118448697 chr12:118428281~118428870:+ PAAD cis rs2929278 0.589 rs2411284 ENSG00000205771.5 CATSPER2P1 6.16 6.24e-09 8.66e-06 0.59 0.45 Schizophrenia; chr15:43746701 chr15:43726918~43747094:- PAAD cis rs3096299 0.719 rs12934708 ENSG00000274627.1 RP11-104N10.2 6.16 6.26e-09 8.68e-06 0.38 0.45 Multiple myeloma (IgH translocation); chr16:89457382 chr16:89516797~89522217:+ PAAD cis rs992157 0.798 rs10932772 ENSG00000261338.2 RP11-378A13.1 6.16 6.27e-09 8.7e-06 0.53 0.45 Colorectal cancer; chr2:218312425 chr2:218255319~218257366:+ PAAD cis rs10262624 0.935 rs8180700 ENSG00000234286.1 AC006026.13 -6.16 6.28e-09 8.72e-06 -0.5 -0.45 Schizophrenia; chr7:23870323 chr7:23680195~23680786:- PAAD cis rs8040855 0.52 rs67613323 ENSG00000259295.5 CSPG4P12 6.16 6.28e-09 8.72e-06 0.56 0.45 Bulimia nervosa; chr15:84986541 chr15:85191438~85213905:+ PAAD cis rs8040855 0.52 rs11629962 ENSG00000259295.5 CSPG4P12 6.16 6.28e-09 8.72e-06 0.56 0.45 Bulimia nervosa; chr15:84986797 chr15:85191438~85213905:+ PAAD cis rs12220777 0.892 rs72644219 ENSG00000230091.5 TMEM254-AS1 6.16 6.29e-09 8.72e-06 0.79 0.45 Chronic obstructive pulmonary disease-related biomarkers; chr10:80036457 chr10:80046860~80078912:- PAAD cis rs1153858 0.848 rs9806699 ENSG00000259520.4 CTD-2651B20.3 -6.16 6.29e-09 8.72e-06 -0.6 -0.45 Homoarginine levels; chr15:45448194 chr15:45251580~45279251:- PAAD cis rs433852 0.904 rs8102492 ENSG00000232871.7 SEC1P 6.16 6.31e-09 8.75e-06 0.68 0.45 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48637552 chr19:48638071~48682245:+ PAAD cis rs11098499 0.564 rs11098507 ENSG00000245958.5 RP11-33B1.1 -6.15 6.4e-09 8.87e-06 -0.33 -0.45 Corneal astigmatism; chr4:119367131 chr4:119454791~119552025:+ PAAD cis rs1075265 0.547 rs11125520 ENSG00000233266.1 HMGB1P31 6.15 6.41e-09 8.88e-06 0.56 0.45 Chronotype;Morning vs. evening chronotype; chr2:54076696 chr2:54051334~54051760:+ PAAD cis rs6504622 0.721 rs11079748 ENSG00000262879.4 RP11-156P1.3 -6.15 6.43e-09 8.9e-06 -0.47 -0.45 Orofacial clefts; chr17:47055097 chr17:46984045~47100323:- PAAD cis rs7044106 0.537 rs10818474 ENSG00000226752.6 PSMD5-AS1 -6.15 6.44e-09 8.92e-06 -0.59 -0.45 Hip circumference adjusted for BMI; chr9:120727686 chr9:120824828~120854385:+ PAAD cis rs453301 0.653 rs11784393 ENSG00000253893.2 FAM85B -6.15 6.55e-09 9.06e-06 -0.61 -0.45 Joint mobility (Beighton score); chr8:9045624 chr8:8167819~8226614:- PAAD cis rs453301 0.653 rs7005133 ENSG00000253893.2 FAM85B -6.15 6.56e-09 9.08e-06 -0.61 -0.45 Joint mobility (Beighton score); chr8:9043712 chr8:8167819~8226614:- PAAD cis rs2739330 0.76 rs5760095 ENSG00000231271.1 AP000350.8 6.15 6.59e-09 9.12e-06 0.59 0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23949918~23954042:+ PAAD cis rs11673344 0.668 rs7248693 ENSG00000226686.6 LINC01535 6.15 6.6e-09 9.13e-06 0.61 0.45 Obesity-related traits; chr19:36991864 chr19:37251912~37265535:+ PAAD cis rs858239 0.633 rs858300 ENSG00000226816.2 AC005082.12 6.15 6.62e-09 9.15e-06 0.51 0.45 Cerebrospinal fluid biomarker levels; chr7:23205012 chr7:23206013~23208045:+ PAAD cis rs858239 0.73 rs858290 ENSG00000226816.2 AC005082.12 6.15 6.62e-09 9.15e-06 0.51 0.45 Cerebrospinal fluid biomarker levels; chr7:23208417 chr7:23206013~23208045:+ PAAD cis rs858239 0.73 rs858289 ENSG00000226816.2 AC005082.12 6.15 6.62e-09 9.15e-06 0.51 0.45 Cerebrospinal fluid biomarker levels; chr7:23208539 chr7:23206013~23208045:+ PAAD cis rs11118620 0.622 rs11118618 ENSG00000238078.1 LINC01352 6.15 6.63e-09 9.17e-06 0.5 0.45 Heart failure; chr1:220838204 chr1:220829255~220832429:+ PAAD cis rs12594515 0.967 rs11857628 ENSG00000273972.1 CTD-2306A12.1 -6.15 6.64e-09 9.18e-06 -0.53 -0.45 Weight;Waist circumference; chr15:45706008 chr15:45702640~45703183:+ PAAD cis rs7429990 0.864 rs11712464 ENSG00000229759.1 MRPS18AP1 6.15 6.64e-09 9.18e-06 0.48 0.45 Educational attainment (years of education); chr3:47724057 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs56376646 ENSG00000229759.1 MRPS18AP1 6.15 6.64e-09 9.18e-06 0.48 0.45 Educational attainment (years of education); chr3:47732588 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs11927129 ENSG00000229759.1 MRPS18AP1 6.15 6.64e-09 9.18e-06 0.48 0.45 Educational attainment (years of education); chr3:47745413 chr3:48256350~48256938:- PAAD cis rs12022452 1 rs12048678 ENSG00000238287.1 RP11-656D10.3 -6.15 6.64e-09 9.18e-06 -0.71 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr1:40482096 chr1:40493157~40508661:- PAAD cis rs9326248 0.911 rs474339 ENSG00000280143.1 AP000892.6 6.15 6.65e-09 9.18e-06 0.55 0.45 Blood protein levels; chr11:117188836 chr11:117204967~117210292:+ PAAD cis rs673078 0.607 rs17441075 ENSG00000275759.1 RP11-131L12.3 -6.15 6.66e-09 9.2e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118410542 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs965524 ENSG00000275759.1 RP11-131L12.3 -6.15 6.66e-09 9.2e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118412361 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs74685643 ENSG00000275759.1 RP11-131L12.3 -6.15 6.66e-09 9.2e-06 -0.68 -0.45 Glucose homeostasis traits; chr12:118412761 chr12:118428281~118428870:+ PAAD cis rs7429990 0.864 rs319693 ENSG00000229759.1 MRPS18AP1 6.15 6.7e-09 9.25e-06 0.48 0.45 Educational attainment (years of education); chr3:47845090 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs4858863 ENSG00000229759.1 MRPS18AP1 -6.15 6.7e-09 9.25e-06 -0.48 -0.45 Educational attainment (years of education); chr3:47814143 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7629850 ENSG00000229759.1 MRPS18AP1 -6.15 6.7e-09 9.25e-06 -0.48 -0.45 Educational attainment (years of education); chr3:47815592 chr3:48256350~48256938:- PAAD cis rs1075232 1 rs72722861 ENSG00000270055.1 CTD-3092A11.2 -6.15 6.71e-09 9.26e-06 -1.03 -0.45 Survival in colorectal cancer (non-distant metastatic); chr15:31412085 chr15:30487963~30490313:+ PAAD cis rs1075232 0.826 rs12438813 ENSG00000270055.1 CTD-3092A11.2 -6.15 6.71e-09 9.26e-06 -1.03 -0.45 Survival in colorectal cancer (non-distant metastatic); chr15:31413710 chr15:30487963~30490313:+ PAAD cis rs9532669 0.89 rs2149570 ENSG00000176268.5 CYCSP34 6.14 6.72e-09 9.27e-06 0.44 0.45 Cervical cancer; chr13:40858533 chr13:40863599~40863902:- PAAD cis rs950169 0.922 rs11630760 ENSG00000225151.9 GOLGA2P7 -6.14 6.74e-09 9.31e-06 -0.53 -0.45 Schizophrenia; chr15:84570106 chr15:84199311~84230136:- PAAD cis rs950169 0.887 rs71395453 ENSG00000225151.9 GOLGA2P7 -6.14 6.74e-09 9.31e-06 -0.53 -0.45 Schizophrenia; chr15:84570259 chr15:84199311~84230136:- PAAD cis rs12022452 1 rs2184877 ENSG00000238287.1 RP11-656D10.3 -6.14 6.77e-09 9.33e-06 -0.72 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr1:40531260 chr1:40493157~40508661:- PAAD cis rs10129255 0.509 rs756583 ENSG00000223648.3 IGHV3-64 6.14 6.78e-09 9.36e-06 0.4 0.45 Kawasaki disease; chr14:106680002 chr14:106643132~106658258:- PAAD cis rs9640161 0.789 rs10952250 ENSG00000261305.1 RP4-584D14.7 6.14 6.79e-09 9.37e-06 0.64 0.45 Blood protein levels;Circulating chemerin levels; chr7:150328877 chr7:150341771~150342607:+ PAAD cis rs7811142 1 rs6972167 ENSG00000242294.5 STAG3L5P 6.14 6.8e-09 9.38e-06 0.34 0.45 Platelet count; chr7:100482390 chr7:100336079~100351900:+ PAAD cis rs73086581 0.838 rs41398349 ENSG00000229539.1 RP11-119B16.2 -6.14 6.83e-09 9.42e-06 -0.7 -0.45 Response to antidepressants in depression; chr20:4043792 chr20:3888239~3888868:- PAAD cis rs987724 0.592 rs9858861 ENSG00000240875.4 LINC00886 -6.14 6.86e-09 9.45e-06 -0.55 -0.45 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156824848 chr3:156747346~156817062:- PAAD cis rs10262624 1 rs4722286 ENSG00000234286.1 AC006026.13 6.14 6.89e-09 9.49e-06 0.49 0.45 Schizophrenia; chr7:23874005 chr7:23680195~23680786:- PAAD cis rs875971 0.545 rs13311962 ENSG00000237310.1 GS1-124K5.4 -6.14 6.89e-09 9.49e-06 -0.51 -0.45 Aortic root size; chr7:66603142 chr7:66493706~66495474:+ PAAD cis rs12022452 0.908 rs11811487 ENSG00000238287.1 RP11-656D10.3 -6.14 6.9e-09 9.51e-06 -0.7 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr1:40555398 chr1:40493157~40508661:- PAAD cis rs11098499 0.866 rs12501602 ENSG00000245958.5 RP11-33B1.1 -6.14 6.91e-09 9.52e-06 -0.33 -0.45 Corneal astigmatism; chr4:119366780 chr4:119454791~119552025:+ PAAD cis rs4963124 0.886 rs10902216 ENSG00000279672.1 CMB9-55F22.1 6.14 6.91e-09 9.52e-06 0.44 0.45 Proteinuria and chronic kidney disease; chr11:739392 chr11:779617~780755:+ PAAD cis rs7188445 0.932 rs17767419 ENSG00000261390.4 RP11-345M22.2 -6.14 6.94e-09 9.56e-06 -0.6 -0.45 Urate levels; chr16:79710651 chr16:79715232~79770563:- PAAD cis rs10262624 1 rs7792262 ENSG00000234286.1 AC006026.13 6.14 6.96e-09 9.58e-06 0.5 0.45 Schizophrenia; chr7:23876124 chr7:23680195~23680786:- PAAD cis rs507080 0.501 rs494459 ENSG00000255422.1 AP002954.4 6.14 6.97e-09 9.59e-06 0.5 0.45 Serum metabolite levels; chr11:118703966 chr11:118704607~118750263:+ PAAD cis rs494459 0.964 rs576283 ENSG00000255422.1 AP002954.4 -6.14 6.97e-09 9.59e-06 -0.5 -0.45 Height; chr11:118703185 chr11:118704607~118750263:+ PAAD cis rs494459 0.929 rs627391 ENSG00000255422.1 AP002954.4 -6.14 6.97e-09 9.59e-06 -0.5 -0.45 Height; chr11:118703207 chr11:118704607~118750263:+ PAAD cis rs507080 0.524 rs524409 ENSG00000255422.1 AP002954.4 -6.14 6.97e-09 9.59e-06 -0.5 -0.45 Serum metabolite levels; chr11:118703602 chr11:118704607~118750263:+ PAAD cis rs507080 0.501 rs626645 ENSG00000255422.1 AP002954.4 -6.14 6.97e-09 9.59e-06 -0.5 -0.45 Serum metabolite levels; chr11:118704471 chr11:118704607~118750263:+ PAAD cis rs507080 0.501 rs637563 ENSG00000255422.1 AP002954.4 -6.14 6.97e-09 9.59e-06 -0.5 -0.45 Serum metabolite levels; chr11:118704770 chr11:118704607~118750263:+ PAAD cis rs7945705 0.87 rs10840142 ENSG00000254860.4 TMEM9B-AS1 -6.14 6.98e-09 9.6e-06 -0.49 -0.45 Hemoglobin concentration; chr11:8884531 chr11:8964675~8977527:+ PAAD cis rs950169 1 rs12902672 ENSG00000259728.4 LINC00933 6.14 7e-09 9.63e-06 0.56 0.45 Schizophrenia; chr15:84048234 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs12903820 ENSG00000259728.4 LINC00933 6.14 7e-09 9.63e-06 0.56 0.45 Schizophrenia; chr15:84055068 chr15:84570649~84580175:+ PAAD cis rs3814244 0.515 rs2906856 ENSG00000255733.4 IFNG-AS1 -6.14 7.05e-09 9.69e-06 -0.43 -0.45 Itch intensity from mosquito bite adjusted by bite size; chr12:67996421 chr12:67989445~68234686:+ PAAD cis rs2929278 0.617 rs663214 ENSG00000205771.5 CATSPER2P1 6.14 7.05e-09 9.7e-06 0.57 0.45 Schizophrenia; chr15:43821584 chr15:43726918~43747094:- PAAD cis rs1930961 1 rs6004675 ENSG00000100058.11 CRYBB2P1 6.14 7.05e-09 9.7e-06 0.82 0.45 Bipolar disorder with mood-incongruent psychosis; chr22:25493418 chr22:25448105~25520854:+ PAAD cis rs2739330 0.892 rs4822455 ENSG00000099984.9 GSTT2 -6.13 7.06e-09 9.71e-06 -0.55 -0.45 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23980123~23983911:+ PAAD cis rs12022452 0.822 rs11208390 ENSG00000238287.1 RP11-656D10.3 -6.13 7.07e-09 9.71e-06 -0.66 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr1:40556342 chr1:40493157~40508661:- PAAD cis rs453301 0.653 rs1562211 ENSG00000253893.2 FAM85B 6.13 7.07e-09 9.72e-06 0.6 0.45 Joint mobility (Beighton score); chr8:9044914 chr8:8167819~8226614:- PAAD cis rs10256972 0.9 rs7812072 ENSG00000229043.2 AC091729.9 -6.13 7.09e-09 9.75e-06 -0.49 -0.45 Endometriosis;Longevity; chr7:1014226 chr7:1160374~1165267:+ PAAD cis rs55665837 1 rs10832254 ENSG00000251991.1 RNU7-49P 6.13 7.1e-09 9.75e-06 0.54 0.45 Vitamin D levels; chr11:14413152 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs11023214 ENSG00000251991.1 RNU7-49P 6.13 7.1e-09 9.75e-06 0.54 0.45 Vitamin D levels; chr11:14414713 chr11:14478892~14478953:+ PAAD cis rs55665837 1 rs11023216 ENSG00000251991.1 RNU7-49P 6.13 7.1e-09 9.75e-06 0.54 0.45 Vitamin D levels; chr11:14415607 chr11:14478892~14478953:+ PAAD cis rs4218 0.587 rs1446237 ENSG00000277144.1 RP11-59H7.4 -6.13 7.11e-09 9.77e-06 -0.55 -0.45 Social communication problems; chr15:59052603 chr15:59115547~59116089:- PAAD cis rs4218 0.528 rs57557135 ENSG00000277144.1 RP11-59H7.4 -6.13 7.11e-09 9.77e-06 -0.55 -0.45 Social communication problems; chr15:59054018 chr15:59115547~59116089:- PAAD cis rs1150668 0.699 rs2394049 ENSG00000216901.1 AL022393.7 6.13 7.11e-09 9.77e-06 0.52 0.45 Pubertal anthropometrics; chr6:28271903 chr6:28176188~28176674:+ PAAD cis rs6142102 0.58 rs761233 ENSG00000276073.1 RP5-1125A11.7 -6.13 7.13e-09 9.79e-06 -0.46 -0.45 Skin pigmentation; chr20:33981080 chr20:33985617~33988989:- PAAD cis rs35160687 0.901 rs12472390 ENSG00000273080.1 RP11-301O19.1 6.13 7.14e-09 9.8e-06 0.5 0.45 Night sleep phenotypes; chr2:86247960 chr2:86195590~86196049:+ PAAD cis rs7811142 0.887 rs111972532 ENSG00000242294.5 STAG3L5P 6.13 7.15e-09 9.82e-06 0.34 0.45 Platelet count; chr7:100471465 chr7:100336079~100351900:+ PAAD cis rs8062405 0.754 rs28410083 ENSG00000259982.1 CDC37P1 -6.13 7.2e-09 9.88e-06 -0.53 -0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620039 chr16:28700294~28701540:- PAAD cis rs8062405 0.789 rs1968751 ENSG00000259982.1 CDC37P1 -6.13 7.2e-09 9.88e-06 -0.53 -0.45 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620438 chr16:28700294~28701540:- PAAD cis rs11098499 0.754 rs938056 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119316298 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs878376 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119316547 chr4:119454791~119552025:+ PAAD cis rs11098499 0.789 rs9991166 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119316696 chr4:119454791~119552025:+ PAAD cis rs11098499 0.708 rs10005237 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119316742 chr4:119454791~119552025:+ PAAD cis rs11098499 0.575 rs907204 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119317499 chr4:119454791~119552025:+ PAAD cis rs11098499 0.575 rs907205 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119317509 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs878372 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119317625 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs10213267 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119317919 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs10212775 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119318089 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs2964 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119318976 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs1511025 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119319083 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs12711071 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119319779 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs1546503 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119320012 chr4:119454791~119552025:+ PAAD cis rs11098499 0.708 rs1546506 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119320085 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs12506610 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119320504 chr4:119454791~119552025:+ PAAD cis rs11098499 0.743 rs10003567 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119320519 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs10006259 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119320990 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs28652763 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119321157 chr4:119454791~119552025:+ PAAD cis rs10028773 0.7 rs7671797 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Educational attainment; chr4:119327002 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs7672372 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119327251 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs7672594 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119327388 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs7672778 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119327430 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs2036860 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119327779 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs2036857 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119328085 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs2036856 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119328133 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs4443261 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119328146 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs12513083 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119328457 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs12509621 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119328505 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs1980025 ENSG00000245958.5 RP11-33B1.1 6.13 7.22e-09 9.89e-06 0.35 0.45 Corneal astigmatism; chr4:119331651 chr4:119454791~119552025:+ PAAD cis rs11098499 0.789 rs1980024 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119331892 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs34425882 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119332022 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs4107728 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119332755 chr4:119454791~119552025:+ PAAD cis rs11098499 0.789 rs10212719 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119333282 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs17049949 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119334135 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs10213221 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119334771 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs7689729 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119335037 chr4:119454791~119552025:+ PAAD cis rs11098499 0.865 rs3956464 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119335609 chr4:119454791~119552025:+ PAAD cis rs11098499 0.619 rs28502463 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119335868 chr4:119454791~119552025:+ PAAD cis rs11098499 0.648 rs2002047 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119336073 chr4:119454791~119552025:+ PAAD cis rs11098499 0.775 rs2002049 ENSG00000245958.5 RP11-33B1.1 -6.13 7.22e-09 9.89e-06 -0.35 -0.45 Corneal astigmatism; chr4:119336262 chr4:119454791~119552025:+ PAAD cis rs9532669 0.889 rs7339089 ENSG00000176268.5 CYCSP34 6.13 7.25e-09 9.92e-06 0.45 0.45 Cervical cancer; chr13:40863790 chr13:40863599~40863902:- PAAD cis rs10129255 0.556 rs9324093 ENSG00000223648.3 IGHV3-64 6.13 7.26e-09 9.93e-06 0.4 0.45 Kawasaki disease; chr14:106683893 chr14:106643132~106658258:- PAAD cis rs17608059 1 rs17608059 ENSG00000141028.6 CDRT15P1 -6.13 7.28e-09 9.96e-06 -0.53 -0.45 Temperament; chr17:14007232 chr17:14024514~14025488:+ PAAD cis rs10129255 0.536 rs10139058 ENSG00000223648.3 IGHV3-64 6.13 7.28e-09 9.96e-06 0.4 0.45 Kawasaki disease; chr14:106685899 chr14:106643132~106658258:- PAAD cis rs10129255 0.536 rs8004835 ENSG00000223648.3 IGHV3-64 6.13 7.28e-09 9.96e-06 0.4 0.45 Kawasaki disease; chr14:106686361 chr14:106643132~106658258:- PAAD cis rs2882667 0.861 rs10037106 ENSG00000253404.1 AC034243.1 6.13 7.32e-09 1e-05 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139029801 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs3925110 ENSG00000253404.1 AC034243.1 6.13 7.32e-09 1e-05 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139035676 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs13163536 ENSG00000253404.1 AC034243.1 6.13 7.32e-09 1e-05 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139041530 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs6882583 ENSG00000253404.1 AC034243.1 6.13 7.32e-09 1e-05 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139050107 chr5:138744434~138753309:- PAAD cis rs2882667 0.898 rs13182437 ENSG00000253404.1 AC034243.1 6.13 7.32e-09 1e-05 0.55 0.45 Age-related hearing impairment (SNP x SNP interaction); chr5:139051460 chr5:138744434~138753309:- PAAD cis rs9322193 0.923 rs66516768 ENSG00000216906.2 RP11-350J20.9 6.13 7.34e-09 1e-05 0.56 0.45 Lung cancer; chr6:149671999 chr6:149904243~149906418:+ PAAD cis rs12022452 1 rs75936657 ENSG00000238287.1 RP11-656D10.3 -6.13 7.34e-09 1e-05 -0.72 -0.45 Age-related hearing impairment (SNP x SNP interaction); chr1:40536017 chr1:40493157~40508661:- PAAD cis rs10256972 0.967 rs4723338 ENSG00000229043.2 AC091729.9 -6.13 7.34e-09 1e-05 -0.47 -0.45 Endometriosis;Longevity; chr7:996605 chr7:1160374~1165267:+ PAAD cis rs6964833 1 rs4717907 ENSG00000123965.13 PMS2P5 6.13 7.36e-09 1.01e-05 0.71 0.45 Menarche (age at onset); chr7:74672169 chr7:74894116~74897835:+ PAAD cis rs2929278 0.617 rs663214 ENSG00000249839.1 AC011330.5 6.13 7.37e-09 1.01e-05 0.6 0.45 Schizophrenia; chr15:43821584 chr15:43663654~43684339:- PAAD cis rs3931020 0.508 rs2345436 ENSG00000272864.1 RP11-17E13.2 -6.13 7.39e-09 1.01e-05 -0.55 -0.44 Resistin levels; chr1:74733056 chr1:74698769~74699333:- PAAD cis rs3931020 0.508 rs28568334 ENSG00000272864.1 RP11-17E13.2 -6.13 7.39e-09 1.01e-05 -0.55 -0.44 Resistin levels; chr1:74733615 chr1:74698769~74699333:- PAAD cis rs673078 0.66 rs16948197 ENSG00000275759.1 RP11-131L12.3 6.12 7.44e-09 1.02e-05 0.66 0.44 Glucose homeostasis traits; chr12:118239135 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs7970481 ENSG00000275759.1 RP11-131L12.3 -6.12 7.44e-09 1.02e-05 -0.66 -0.44 Glucose homeostasis traits; chr12:118242112 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs7973455 ENSG00000275759.1 RP11-131L12.3 -6.12 7.44e-09 1.02e-05 -0.66 -0.44 Glucose homeostasis traits; chr12:118247490 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs58113338 ENSG00000275759.1 RP11-131L12.3 -6.12 7.44e-09 1.02e-05 -0.66 -0.44 Glucose homeostasis traits; chr12:118251335 chr12:118428281~118428870:+ PAAD cis rs673078 0.615 rs16948204 ENSG00000275759.1 RP11-131L12.3 -6.12 7.44e-09 1.02e-05 -0.66 -0.44 Glucose homeostasis traits; chr12:118258252 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs7303417 ENSG00000275759.1 RP11-131L12.3 -6.12 7.44e-09 1.02e-05 -0.66 -0.44 Glucose homeostasis traits; chr12:118258859 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7304342 ENSG00000275759.1 RP11-131L12.3 -6.12 7.47e-09 1.02e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118390166 chr12:118428281~118428870:+ PAAD cis rs673078 0.615 rs61943397 ENSG00000275759.1 RP11-131L12.3 -6.12 7.47e-09 1.02e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118390996 chr12:118428281~118428870:+ PAAD cis rs10129255 0.518 rs28378320 ENSG00000223648.3 IGHV3-64 6.12 7.48e-09 1.02e-05 0.4 0.44 Kawasaki disease; chr14:106808609 chr14:106643132~106658258:- PAAD cis rs673078 0.66 rs61943525 ENSG00000275759.1 RP11-131L12.3 -6.12 7.48e-09 1.02e-05 -0.73 -0.44 Glucose homeostasis traits; chr12:118152927 chr12:118428281~118428870:+ PAAD cis rs11098499 0.955 rs56386062 ENSG00000245958.5 RP11-33B1.1 -6.12 7.51e-09 1.02e-05 -0.36 -0.44 Corneal astigmatism; chr4:119233980 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs4145951 ENSG00000245958.5 RP11-33B1.1 -6.12 7.51e-09 1.02e-05 -0.36 -0.44 Corneal astigmatism; chr4:119234662 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs35916640 ENSG00000245958.5 RP11-33B1.1 -6.12 7.51e-09 1.02e-05 -0.36 -0.44 Corneal astigmatism; chr4:119234697 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs13113112 ENSG00000245958.5 RP11-33B1.1 -6.12 7.51e-09 1.02e-05 -0.36 -0.44 Corneal astigmatism; chr4:119234885 chr4:119454791~119552025:+ PAAD cis rs11098499 0.955 rs13114751 ENSG00000245958.5 RP11-33B1.1 -6.12 7.51e-09 1.02e-05 -0.36 -0.44 Corneal astigmatism; chr4:119235462 chr4:119454791~119552025:+ PAAD cis rs11098499 0.913 rs35271032 ENSG00000245958.5 RP11-33B1.1 -6.12 7.51e-09 1.02e-05 -0.36 -0.44 Corneal astigmatism; chr4:119235504 chr4:119454791~119552025:+ PAAD cis rs7301826 1 rs2001483 ENSG00000256299.1 RP11-989F5.3 -6.12 7.52e-09 1.03e-05 -0.5 -0.44 Plasma plasminogen activator levels; chr12:130834100 chr12:130810821~130812622:- PAAD cis rs17301013 0.606 rs1793307 ENSG00000227373.4 RP11-160H22.5 -6.12 7.57e-09 1.03e-05 -0.63 -0.44 Systemic lupus erythematosus; chr1:174758716 chr1:174115300~174160004:- PAAD cis rs17301013 0.62 rs1793310 ENSG00000227373.4 RP11-160H22.5 -6.12 7.57e-09 1.03e-05 -0.63 -0.44 Systemic lupus erythematosus; chr1:174770786 chr1:174115300~174160004:- PAAD cis rs9322193 0.962 rs2342764 ENSG00000216906.2 RP11-350J20.9 6.12 7.66e-09 1.04e-05 0.57 0.44 Lung cancer; chr6:149835068 chr6:149904243~149906418:+ PAAD cis rs7188445 0.898 rs11644758 ENSG00000261390.4 RP11-345M22.2 -6.12 7.69e-09 1.05e-05 -0.61 -0.44 Urate levels; chr16:79675094 chr16:79715232~79770563:- PAAD cis rs7188445 0.933 rs74637523 ENSG00000261390.4 RP11-345M22.2 -6.12 7.69e-09 1.05e-05 -0.61 -0.44 Urate levels; chr16:79677400 chr16:79715232~79770563:- PAAD cis rs8062405 0.789 rs28480369 ENSG00000259982.1 CDC37P1 -6.12 7.69e-09 1.05e-05 -0.53 -0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28615683 chr16:28700294~28701540:- PAAD cis rs8062405 0.789 rs28676837 ENSG00000259982.1 CDC37P1 -6.12 7.69e-09 1.05e-05 -0.53 -0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28615742 chr16:28700294~28701540:- PAAD cis rs8062405 0.69 rs6498089 ENSG00000259982.1 CDC37P1 -6.12 7.69e-09 1.05e-05 -0.53 -0.44 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28617979 chr16:28700294~28701540:- PAAD cis rs853679 0.567 rs1005126 ENSG00000204709.4 LINC01556 6.12 7.7e-09 1.05e-05 0.65 0.44 Depression; chr6:28399846 chr6:28943877~28944537:+ PAAD cis rs853679 0.567 rs13196606 ENSG00000204709.4 LINC01556 6.12 7.7e-09 1.05e-05 0.65 0.44 Depression; chr6:28402301 chr6:28943877~28944537:+ PAAD cis rs17301013 0.632 rs1653636 ENSG00000227373.4 RP11-160H22.5 -6.12 7.77e-09 1.06e-05 -0.61 -0.44 Systemic lupus erythematosus; chr1:174767739 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs1754360 ENSG00000227373.4 RP11-160H22.5 -6.12 7.77e-09 1.06e-05 -0.61 -0.44 Systemic lupus erythematosus; chr1:174775825 chr1:174115300~174160004:- PAAD cis rs11155671 0.53 rs7758033 ENSG00000223701.3 RAET1E-AS1 6.11 7.81e-09 1.06e-05 0.52 0.44 Testicular germ cell tumor; chr6:149886999 chr6:149884431~149919508:+ PAAD cis rs950169 1 rs950169 ENSG00000259728.4 LINC00933 6.11 7.85e-09 1.07e-05 0.56 0.44 Schizophrenia; chr15:84037709 chr15:84570649~84580175:+ PAAD cis rs875971 0.545 rs221986 ENSG00000237310.1 GS1-124K5.4 -6.11 7.86e-09 1.07e-05 -0.51 -0.44 Aortic root size; chr7:66105323 chr7:66493706~66495474:+ PAAD cis rs7174755 0.924 rs8035431 ENSG00000260657.2 RP11-315D16.4 6.11 7.86e-09 1.07e-05 0.55 0.44 Major depressive disorder; chr15:68305012 chr15:68267792~68277994:- PAAD cis rs17301013 0.531 rs4650958 ENSG00000227373.4 RP11-160H22.5 6.11 7.87e-09 1.07e-05 0.63 0.44 Systemic lupus erythematosus; chr1:174178378 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs2860907 ENSG00000227373.4 RP11-160H22.5 6.11 7.87e-09 1.07e-05 0.63 0.44 Systemic lupus erythematosus; chr1:174203246 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4607949 ENSG00000227373.4 RP11-160H22.5 6.11 7.87e-09 1.07e-05 0.63 0.44 Systemic lupus erythematosus; chr1:174212218 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs10912747 ENSG00000227373.4 RP11-160H22.5 -6.11 7.87e-09 1.07e-05 -0.63 -0.44 Systemic lupus erythematosus; chr1:174224564 chr1:174115300~174160004:- PAAD cis rs10262624 0.935 rs4722283 ENSG00000234286.1 AC006026.13 6.11 7.88e-09 1.07e-05 0.5 0.44 Schizophrenia; chr7:23866595 chr7:23680195~23680786:- PAAD cis rs73086581 1 rs6107393 ENSG00000229539.1 RP11-119B16.2 6.11 7.88e-09 1.07e-05 0.67 0.44 Response to antidepressants in depression; chr20:4007091 chr20:3888239~3888868:- PAAD cis rs465969 0.744 rs76257900 ENSG00000255389.1 C6orf3 -6.11 7.91e-09 1.07e-05 -0.73 -0.44 Psoriasis; chr6:111537286 chr6:111599875~111602295:+ PAAD cis rs11098499 0.738 rs28687057 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119359657 chr4:119454791~119552025:+ PAAD cis rs11098499 0.775 rs67281037 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119360002 chr4:119454791~119552025:+ PAAD cis rs10028773 0.506 rs12374346 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Educational attainment; chr4:119360550 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs12374244 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119360817 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs12374352 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119360822 chr4:119454791~119552025:+ PAAD cis rs11098499 0.775 rs10021601 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119361408 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs6857892 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119361541 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs28581362 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119362393 chr4:119454791~119552025:+ PAAD cis rs11098499 0.82 rs12503082 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119363162 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs12499602 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119363232 chr4:119454791~119552025:+ PAAD cis rs11098499 0.774 rs11098505 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119363472 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs11098506 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119363816 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs13105020 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119364533 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs6824111 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119364813 chr4:119454791~119552025:+ PAAD cis rs11098499 0.775 rs10029303 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119365600 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs9995136 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119365690 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs13125526 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119366864 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs12513310 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119366884 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs12510451 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119367988 chr4:119454791~119552025:+ PAAD cis rs11098499 0.774 rs73842616 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119369528 chr4:119454791~119552025:+ PAAD cis rs11098499 0.645 rs72676059 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119369673 chr4:119454791~119552025:+ PAAD cis rs11098499 0.569 rs55845118 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119369758 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs7677068 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119370549 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs9991221 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119370952 chr4:119454791~119552025:+ PAAD cis rs11098499 0.731 rs6846966 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119372053 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs6847778 ENSG00000245958.5 RP11-33B1.1 -6.11 7.91e-09 1.07e-05 -0.33 -0.44 Corneal astigmatism; chr4:119372427 chr4:119454791~119552025:+ PAAD cis rs11673344 0.566 rs1968251 ENSG00000226686.6 LINC01535 -6.11 7.94e-09 1.08e-05 -0.53 -0.44 Obesity-related traits; chr19:37457005 chr19:37251912~37265535:+ PAAD cis rs950169 0.84 rs12905223 ENSG00000225151.9 GOLGA2P7 -6.11 8.01e-09 1.09e-05 -0.53 -0.44 Schizophrenia; chr15:84571037 chr15:84199311~84230136:- PAAD cis rs10129255 0.5 rs4600373 ENSG00000223648.3 IGHV3-64 6.11 8.02e-09 1.09e-05 0.4 0.44 Kawasaki disease; chr14:106704809 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs4280141 ENSG00000274576.2 IGHV2-70 6.11 8.03e-09 1.09e-05 0.55 0.44 Alzheimer's disease (late onset); chr14:106780476 chr14:106770577~106771020:- PAAD cis rs17301013 0.794 rs1793293 ENSG00000227373.4 RP11-160H22.5 -6.11 8.07e-09 1.09e-05 -0.59 -0.44 Systemic lupus erythematosus; chr1:174774451 chr1:174115300~174160004:- PAAD cis rs673078 0.607 rs4766900 ENSG00000275759.1 RP11-131L12.3 -6.11 8.08e-09 1.09e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118375139 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs884844 ENSG00000275759.1 RP11-131L12.3 -6.11 8.08e-09 1.09e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118377033 chr12:118428281~118428870:+ PAAD cis rs9322193 0.923 rs9322209 ENSG00000216906.2 RP11-350J20.9 6.11 8.09e-09 1.1e-05 0.56 0.44 Lung cancer; chr6:149691226 chr6:149904243~149906418:+ PAAD cis rs42490 0.903 rs218902 ENSG00000251136.7 RP11-37B2.1 6.11 8.1e-09 1.1e-05 0.41 0.44 Leprosy; chr8:89719986 chr8:89609409~89757727:- PAAD cis rs8059260 0.604 rs741177 ENSG00000274038.1 RP11-66H6.4 -6.11 8.1e-09 1.1e-05 -0.72 -0.44 Alcohol consumption over the past year; chr16:11051791 chr16:11056556~11057034:+ PAAD cis rs1930961 1 rs6004673 ENSG00000100058.11 CRYBB2P1 6.11 8.11e-09 1.1e-05 0.83 0.44 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25448105~25520854:+ PAAD cis rs11155671 0.53 rs9383577 ENSG00000223701.3 RAET1E-AS1 6.11 8.13e-09 1.1e-05 0.52 0.44 Testicular germ cell tumor; chr6:149886059 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs9383914 ENSG00000223701.3 RAET1E-AS1 6.11 8.13e-09 1.1e-05 0.52 0.44 Testicular germ cell tumor; chr6:149886098 chr6:149884431~149919508:+ PAAD cis rs11155671 0.517 rs9397058 ENSG00000223701.3 RAET1E-AS1 6.11 8.13e-09 1.1e-05 0.52 0.44 Testicular germ cell tumor; chr6:149886113 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs7768626 ENSG00000223701.3 RAET1E-AS1 6.11 8.13e-09 1.1e-05 0.52 0.44 Testicular germ cell tumor; chr6:149886826 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs7768665 ENSG00000223701.3 RAET1E-AS1 6.11 8.13e-09 1.1e-05 0.52 0.44 Testicular germ cell tumor; chr6:149886888 chr6:149884431~149919508:+ PAAD cis rs11155671 0.53 rs7758020 ENSG00000223701.3 RAET1E-AS1 6.11 8.13e-09 1.1e-05 0.52 0.44 Testicular germ cell tumor; chr6:149886975 chr6:149884431~149919508:+ PAAD cis rs2739330 0.828 rs5760107 ENSG00000250470.1 AP000351.3 6.11 8.19e-09 1.11e-05 0.63 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23976904~23977585:- PAAD cis rs2739330 0.789 rs5760109 ENSG00000250470.1 AP000351.3 6.11 8.19e-09 1.11e-05 0.63 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23976904~23977585:- PAAD cis rs55665837 1 rs12792120 ENSG00000251991.1 RNU7-49P 6.1 8.22e-09 1.11e-05 0.53 0.44 Vitamin D levels; chr11:14447897 chr11:14478892~14478953:+ PAAD cis rs9322193 0.923 rs12529698 ENSG00000216906.2 RP11-350J20.9 6.1 8.22e-09 1.11e-05 0.56 0.44 Lung cancer; chr6:149650951 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs7767622 ENSG00000216906.2 RP11-350J20.9 6.1 8.23e-09 1.11e-05 0.56 0.44 Lung cancer; chr6:149681766 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs3798761 ENSG00000216906.2 RP11-350J20.9 6.1 8.23e-09 1.11e-05 0.56 0.44 Lung cancer; chr6:149683643 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs9322210 ENSG00000216906.2 RP11-350J20.9 6.1 8.23e-09 1.11e-05 0.56 0.44 Lung cancer; chr6:149695440 chr6:149904243~149906418:+ PAAD cis rs2739330 0.828 rs2330635 ENSG00000250470.1 AP000351.3 6.1 8.23e-09 1.11e-05 0.63 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23976904~23977585:- PAAD cis rs10129255 0.5 rs2078686 ENSG00000223648.3 IGHV3-64 6.1 8.24e-09 1.11e-05 0.4 0.44 Kawasaki disease; chr14:106703345 chr14:106643132~106658258:- PAAD cis rs35160687 0.901 rs12999029 ENSG00000273080.1 RP11-301O19.1 6.1 8.31e-09 1.12e-05 0.5 0.44 Night sleep phenotypes; chr2:86275790 chr2:86195590~86196049:+ PAAD cis rs35160687 0.901 rs67903513 ENSG00000273080.1 RP11-301O19.1 6.1 8.31e-09 1.12e-05 0.5 0.44 Night sleep phenotypes; chr2:86284976 chr2:86195590~86196049:+ PAAD cis rs11098499 0.909 rs73842633 ENSG00000245958.5 RP11-33B1.1 -6.1 8.31e-09 1.12e-05 -0.38 -0.44 Corneal astigmatism; chr4:119454309 chr4:119454791~119552025:+ PAAD cis rs2283792 1 rs2006893 ENSG00000224086.5 LL22NC03-86G7.1 -6.1 8.31e-09 1.12e-05 -0.46 -0.44 Multiple sclerosis; chr22:21774389 chr22:21938293~21977632:+ PAAD cis rs950169 0.922 rs4586394 ENSG00000225151.9 GOLGA2P7 6.1 8.33e-09 1.12e-05 0.53 0.44 Schizophrenia; chr15:84153633 chr15:84199311~84230136:- PAAD cis rs9640161 0.789 rs3735174 ENSG00000261305.1 RP4-584D14.7 6.1 8.34e-09 1.13e-05 0.63 0.44 Blood protein levels;Circulating chemerin levels; chr7:150323400 chr7:150341771~150342607:+ PAAD cis rs9640161 0.75 rs3735173 ENSG00000261305.1 RP4-584D14.7 6.1 8.34e-09 1.13e-05 0.63 0.44 Blood protein levels;Circulating chemerin levels; chr7:150323437 chr7:150341771~150342607:+ PAAD cis rs9640161 0.663 rs1916932 ENSG00000261305.1 RP4-584D14.7 6.1 8.34e-09 1.13e-05 0.63 0.44 Blood protein levels;Circulating chemerin levels; chr7:150324555 chr7:150341771~150342607:+ PAAD cis rs9640161 0.75 rs59211922 ENSG00000261305.1 RP4-584D14.7 6.1 8.34e-09 1.13e-05 0.63 0.44 Blood protein levels;Circulating chemerin levels; chr7:150326701 chr7:150341771~150342607:+ PAAD cis rs9640161 0.711 rs60268791 ENSG00000261305.1 RP4-584D14.7 6.1 8.34e-09 1.13e-05 0.63 0.44 Blood protein levels;Circulating chemerin levels; chr7:150326711 chr7:150341771~150342607:+ PAAD cis rs42490 0.528 rs7004089 ENSG00000251136.7 RP11-37B2.1 6.1 8.38e-09 1.13e-05 0.41 0.44 Leprosy; chr8:89688329 chr8:89609409~89757727:- PAAD cis rs7188445 0.933 rs12449161 ENSG00000261390.4 RP11-345M22.2 -6.1 8.43e-09 1.14e-05 -0.6 -0.44 Urate levels; chr16:79682409 chr16:79715232~79770563:- PAAD cis rs2283792 0.622 rs2266979 ENSG00000228050.1 TOP3BP1 6.1 8.44e-09 1.14e-05 0.5 0.44 Multiple sclerosis; chr22:21977447 chr22:22223187~22224566:- PAAD cis rs9640161 0.789 rs60283368 ENSG00000261305.1 RP4-584D14.7 6.1 8.46e-09 1.14e-05 0.63 0.44 Blood protein levels;Circulating chemerin levels; chr7:150326169 chr7:150341771~150342607:+ PAAD cis rs7301826 1 rs4759523 ENSG00000256299.1 RP11-989F5.3 -6.1 8.51e-09 1.15e-05 -0.49 -0.44 Plasma plasminogen activator levels; chr12:130830867 chr12:130810821~130812622:- PAAD cis rs7301826 1 rs4759524 ENSG00000256299.1 RP11-989F5.3 -6.1 8.51e-09 1.15e-05 -0.49 -0.44 Plasma plasminogen activator levels; chr12:130831065 chr12:130810821~130812622:- PAAD cis rs17301013 0.507 rs1793320 ENSG00000227373.4 RP11-160H22.5 6.1 8.55e-09 1.15e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174796308 chr1:174115300~174160004:- PAAD cis rs673078 0.66 rs17512142 ENSG00000275759.1 RP11-131L12.3 -6.1 8.57e-09 1.16e-05 -0.73 -0.44 Glucose homeostasis traits; chr12:118186186 chr12:118428281~118428870:+ PAAD cis rs2739330 0.828 rs2186366 ENSG00000250470.1 AP000351.3 -6.1 8.58e-09 1.16e-05 -0.61 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23976904~23977585:- PAAD cis rs2929278 0.638 rs2016840 ENSG00000205771.5 CATSPER2P1 6.1 8.6e-09 1.16e-05 0.58 0.44 Schizophrenia; chr15:43919670 chr15:43726918~43747094:- PAAD cis rs10262624 1 rs2106747 ENSG00000234286.1 AC006026.13 -6.1 8.6e-09 1.16e-05 -0.49 -0.44 Schizophrenia; chr7:23871880 chr7:23680195~23680786:- PAAD cis rs42490 0.903 rs393891 ENSG00000251136.7 RP11-37B2.1 -6.1 8.61e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89701556 chr8:89609409~89757727:- PAAD cis rs42490 0.844 rs444078 ENSG00000251136.7 RP11-37B2.1 -6.1 8.61e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89701558 chr8:89609409~89757727:- PAAD cis rs1061377 0.861 rs35739603 ENSG00000249685.1 RP11-360F5.3 6.1 8.62e-09 1.16e-05 0.48 0.44 Uric acid levels; chr4:39107938 chr4:39133913~39135608:+ PAAD cis rs11098499 0.691 rs9996644 ENSG00000245958.5 RP11-33B1.1 -6.09 8.63e-09 1.16e-05 -0.35 -0.44 Corneal astigmatism; chr4:119317722 chr4:119454791~119552025:+ PAAD cis rs11098499 0.691 rs9996494 ENSG00000245958.5 RP11-33B1.1 -6.09 8.63e-09 1.16e-05 -0.35 -0.44 Corneal astigmatism; chr4:119317725 chr4:119454791~119552025:+ PAAD cis rs42490 0.903 rs7824932 ENSG00000251136.7 RP11-37B2.1 6.09 8.64e-09 1.16e-05 0.41 0.44 Leprosy; chr8:89703848 chr8:89609409~89757727:- PAAD cis rs42490 0.903 rs218944 ENSG00000251136.7 RP11-37B2.1 -6.09 8.64e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89701839 chr8:89609409~89757727:- PAAD cis rs42490 0.903 rs184302 ENSG00000251136.7 RP11-37B2.1 -6.09 8.64e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89704396 chr8:89609409~89757727:- PAAD cis rs42490 0.934 rs218946 ENSG00000251136.7 RP11-37B2.1 -6.09 8.64e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89704478 chr8:89609409~89757727:- PAAD cis rs42490 0.903 rs218948 ENSG00000251136.7 RP11-37B2.1 -6.09 8.64e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89705617 chr8:89609409~89757727:- PAAD cis rs42490 0.873 rs218895 ENSG00000251136.7 RP11-37B2.1 -6.09 8.64e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89714320 chr8:89609409~89757727:- PAAD cis rs42490 0.903 rs218899 ENSG00000251136.7 RP11-37B2.1 -6.09 8.64e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89717279 chr8:89609409~89757727:- PAAD cis rs42490 0.903 rs218900 ENSG00000251136.7 RP11-37B2.1 -6.09 8.64e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89718678 chr8:89609409~89757727:- PAAD cis rs42490 0.903 rs218901 ENSG00000251136.7 RP11-37B2.1 -6.09 8.64e-09 1.16e-05 -0.41 -0.44 Leprosy; chr8:89719089 chr8:89609409~89757727:- PAAD cis rs1061377 0.748 rs11096977 ENSG00000249207.1 RP11-360F5.1 -6.09 8.65e-09 1.17e-05 -0.48 -0.44 Uric acid levels; chr4:39106186 chr4:39112677~39126818:- PAAD cis rs1061377 0.748 rs6810770 ENSG00000249207.1 RP11-360F5.1 -6.09 8.65e-09 1.17e-05 -0.48 -0.44 Uric acid levels; chr4:39106545 chr4:39112677~39126818:- PAAD cis rs1061377 0.748 rs6812316 ENSG00000249207.1 RP11-360F5.1 -6.09 8.65e-09 1.17e-05 -0.48 -0.44 Uric acid levels; chr4:39106617 chr4:39112677~39126818:- PAAD cis rs9322193 0.923 rs10872650 ENSG00000216906.2 RP11-350J20.9 6.09 8.66e-09 1.17e-05 0.57 0.44 Lung cancer; chr6:149760959 chr6:149904243~149906418:+ PAAD cis rs12022452 1 rs12034162 ENSG00000238287.1 RP11-656D10.3 -6.09 8.68e-09 1.17e-05 -0.71 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr1:40498933 chr1:40493157~40508661:- PAAD cis rs12022452 1 rs12031278 ENSG00000238287.1 RP11-656D10.3 -6.09 8.68e-09 1.17e-05 -0.71 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr1:40511246 chr1:40493157~40508661:- PAAD cis rs1150668 0.796 rs1005125 ENSG00000216901.1 AL022393.7 6.09 8.72e-09 1.17e-05 0.54 0.44 Pubertal anthropometrics; chr6:28399578 chr6:28176188~28176674:+ PAAD cis rs950169 0.922 rs11633075 ENSG00000225151.9 GOLGA2P7 -6.09 8.74e-09 1.18e-05 -0.53 -0.44 Schizophrenia; chr15:84570741 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs12912934 ENSG00000225151.9 GOLGA2P7 -6.09 8.74e-09 1.18e-05 -0.53 -0.44 Schizophrenia; chr15:84571216 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs11633534 ENSG00000225151.9 GOLGA2P7 -6.09 8.74e-09 1.18e-05 -0.53 -0.44 Schizophrenia; chr15:84581411 chr15:84199311~84230136:- PAAD cis rs3096299 0.642 rs12934829 ENSG00000274627.1 RP11-104N10.2 6.09 8.79e-09 1.18e-05 0.38 0.44 Multiple myeloma (IgH translocation); chr16:89456941 chr16:89516797~89522217:+ PAAD cis rs8059260 0.604 rs9940096 ENSG00000274038.1 RP11-66H6.4 -6.09 8.81e-09 1.18e-05 -0.77 -0.44 Alcohol consumption over the past year; chr16:11045737 chr16:11056556~11057034:+ PAAD cis rs2019137 0.56 rs7421852 ENSG00000189223.12 PAX8-AS1 -6.09 8.83e-09 1.19e-05 -0.54 -0.44 Lymphocyte counts; chr2:113232684 chr2:113211522~113276581:+ PAAD cis rs2019137 0.56 rs10206269 ENSG00000189223.12 PAX8-AS1 -6.09 8.83e-09 1.19e-05 -0.54 -0.44 Lymphocyte counts; chr2:113232816 chr2:113211522~113276581:+ PAAD cis rs10916248 0.559 rs56023673 ENSG00000232628.4 RP11-365O16.3 6.09 8.84e-09 1.19e-05 0.75 0.44 QT interval (drug interaction); chr1:224180821 chr1:224208747~224213279:- PAAD cis rs2882667 0.861 rs13176902 ENSG00000253404.1 AC034243.1 6.09 8.84e-09 1.19e-05 0.54 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139057640 chr5:138744434~138753309:- PAAD cis rs11098499 0.913 rs67073020 ENSG00000245958.5 RP11-33B1.1 -6.09 8.85e-09 1.19e-05 -0.37 -0.44 Corneal astigmatism; chr4:119231402 chr4:119454791~119552025:+ PAAD cis rs9425766 0.566 rs10912773 ENSG00000227373.4 RP11-160H22.5 6.09 8.86e-09 1.19e-05 0.59 0.44 Life satisfaction; chr1:174374567 chr1:174115300~174160004:- PAAD cis rs8040855 0.624 rs12903975 ENSG00000259295.5 CSPG4P12 6.09 8.89e-09 1.19e-05 0.49 0.44 Bulimia nervosa; chr15:85006004 chr15:85191438~85213905:+ PAAD cis rs950169 0.92 rs12915390 ENSG00000259728.4 LINC00933 6.09 8.89e-09 1.19e-05 0.56 0.44 Schizophrenia; chr15:84123317 chr15:84570649~84580175:+ PAAD cis rs7811142 1 rs6953107 ENSG00000242294.5 STAG3L5P 6.09 8.9e-09 1.19e-05 0.34 0.44 Platelet count; chr7:100498041 chr7:100336079~100351900:+ PAAD cis rs9828933 0.832 rs2292662 ENSG00000280620.1 SCAANT1 6.09 8.9e-09 1.19e-05 0.68 0.44 Type 2 diabetes; chr3:63911539 chr3:63911518~63911772:- PAAD cis rs2739330 0.828 rs4820572 ENSG00000250470.1 AP000351.3 6.09 8.9e-09 1.19e-05 0.63 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23976904~23977585:- PAAD cis rs17301013 0.606 rs10798307 ENSG00000227373.4 RP11-160H22.5 6.09 8.91e-09 1.2e-05 0.63 0.44 Systemic lupus erythematosus; chr1:174264172 chr1:174115300~174160004:- PAAD cis rs55665837 1 rs11023215 ENSG00000251991.1 RNU7-49P 6.09 8.91e-09 1.2e-05 0.53 0.44 Vitamin D levels; chr11:14415424 chr11:14478892~14478953:+ PAAD cis rs992157 0.835 rs7559416 ENSG00000261338.2 RP11-378A13.1 -6.09 8.92e-09 1.2e-05 -0.52 -0.44 Colorectal cancer; chr2:218285488 chr2:218255319~218257366:+ PAAD cis rs2019137 0.56 rs7578633 ENSG00000189223.12 PAX8-AS1 -6.09 8.93e-09 1.2e-05 -0.54 -0.44 Lymphocyte counts; chr2:113221073 chr2:113211522~113276581:+ PAAD cis rs2019137 0.539 rs11123170 ENSG00000189223.12 PAX8-AS1 -6.09 8.93e-09 1.2e-05 -0.54 -0.44 Lymphocyte counts; chr2:113221363 chr2:113211522~113276581:+ PAAD cis rs2019137 0.56 rs6707386 ENSG00000189223.12 PAX8-AS1 -6.09 8.93e-09 1.2e-05 -0.54 -0.44 Lymphocyte counts; chr2:113223445 chr2:113211522~113276581:+ PAAD cis rs6964833 0.935 rs34762099 ENSG00000123965.13 PMS2P5 6.09 8.94e-09 1.2e-05 0.73 0.44 Menarche (age at onset); chr7:74636378 chr7:74894116~74897835:+ PAAD cis rs6504622 0.755 rs36056466 ENSG00000262879.4 RP11-156P1.3 -6.09 8.95e-09 1.2e-05 -0.45 -0.44 Orofacial clefts; chr17:47006017 chr17:46984045~47100323:- PAAD cis rs10262624 1 rs10257777 ENSG00000234286.1 AC006026.13 -6.09 8.96e-09 1.2e-05 -0.49 -0.44 Schizophrenia; chr7:23871362 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs2106748 ENSG00000234286.1 AC006026.13 -6.09 8.96e-09 1.2e-05 -0.49 -0.44 Schizophrenia; chr7:23871694 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs2390847 ENSG00000234286.1 AC006026.13 -6.09 8.96e-09 1.2e-05 -0.49 -0.44 Schizophrenia; chr7:23872082 chr7:23680195~23680786:- PAAD cis rs10262624 0.967 rs2390848 ENSG00000234286.1 AC006026.13 -6.09 8.96e-09 1.2e-05 -0.49 -0.44 Schizophrenia; chr7:23872755 chr7:23680195~23680786:- PAAD cis rs10262624 0.967 rs7792734 ENSG00000234286.1 AC006026.13 -6.09 8.96e-09 1.2e-05 -0.49 -0.44 Schizophrenia; chr7:23876429 chr7:23680195~23680786:- PAAD cis rs2455601 0.679 rs2653559 ENSG00000254860.4 TMEM9B-AS1 6.09 8.98e-09 1.2e-05 0.55 0.44 Schizophrenia; chr11:8878847 chr11:8964675~8977527:+ PAAD cis rs755249 0.727 rs2242500 ENSG00000237624.1 OXCT2P1 6.09 8.99e-09 1.2e-05 0.57 0.44 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572230 chr1:39514956~39516490:+ PAAD cis rs755249 0.727 rs16826349 ENSG00000237624.1 OXCT2P1 6.09 8.99e-09 1.2e-05 0.57 0.44 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39573264 chr1:39514956~39516490:+ PAAD cis rs2882667 0.898 rs10045761 ENSG00000253404.1 AC034243.1 6.09 9e-09 1.21e-05 0.54 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139061600 chr5:138744434~138753309:- PAAD cis rs7188445 0.933 rs76390413 ENSG00000261390.4 RP11-345M22.2 -6.09 9.01e-09 1.21e-05 -0.6 -0.44 Urate levels; chr16:79680019 chr16:79715232~79770563:- PAAD cis rs42490 0.868 rs1605996 ENSG00000251136.7 RP11-37B2.1 6.09 9.01e-09 1.21e-05 0.41 0.44 Leprosy; chr8:89655674 chr8:89609409~89757727:- PAAD cis rs42490 0.868 rs4961155 ENSG00000251136.7 RP11-37B2.1 6.09 9.01e-09 1.21e-05 0.41 0.44 Leprosy; chr8:89666035 chr8:89609409~89757727:- PAAD cis rs2919917 0.628 rs9298314 ENSG00000254352.1 RP11-578O24.2 6.09 9.02e-09 1.21e-05 0.5 0.44 Lymphocyte counts; chr8:78660874 chr8:78723796~78724136:- PAAD cis rs465969 0.744 rs13212489 ENSG00000255389.1 C6orf3 -6.09 9.03e-09 1.21e-05 -0.73 -0.44 Psoriasis; chr6:111536863 chr6:111599875~111602295:+ PAAD cis rs2882667 0.858 rs11750382 ENSG00000253404.1 AC034243.1 -6.09 9.03e-09 1.21e-05 -0.55 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139121305 chr5:138744434~138753309:- PAAD cis rs1062177 0.756 rs2964589 ENSG00000213433.5 RPLP1P6 6.09 9.06e-09 1.21e-05 0.54 0.44 Preschool internalizing problems; chr5:151738628 chr5:151765859~151766378:- PAAD cis rs7429990 0.833 rs3755637 ENSG00000229759.1 MRPS18AP1 -6.09 9.06e-09 1.21e-05 -0.48 -0.44 Educational attainment (years of education); chr3:47580720 chr3:48256350~48256938:- PAAD cis rs2882667 0.898 rs11956089 ENSG00000253404.1 AC034243.1 -6.08 9.09e-09 1.22e-05 -0.54 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139058915 chr5:138744434~138753309:- PAAD cis rs7429990 0.803 rs13319205 ENSG00000229759.1 MRPS18AP1 6.08 9.12e-09 1.22e-05 0.5 0.44 Educational attainment (years of education); chr3:47758726 chr3:48256350~48256938:- PAAD cis rs673078 0.607 rs7136676 ENSG00000275759.1 RP11-131L12.3 -6.08 9.18e-09 1.23e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118403605 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17441033 ENSG00000275759.1 RP11-131L12.3 -6.08 9.18e-09 1.23e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118404101 chr12:118428281~118428870:+ PAAD cis rs673078 0.562 rs61943405 ENSG00000275759.1 RP11-131L12.3 -6.08 9.18e-09 1.23e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118405030 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943406 ENSG00000275759.1 RP11-131L12.3 -6.08 9.18e-09 1.23e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118405767 chr12:118428281~118428870:+ PAAD cis rs2739330 0.796 rs5760106 ENSG00000250470.1 AP000351.3 -6.08 9.18e-09 1.23e-05 -0.63 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23976904~23977585:- PAAD cis rs3762637 1 rs11932 ENSG00000272758.4 RP11-299J3.8 6.08 9.24e-09 1.23e-05 0.64 0.44 LDL cholesterol levels; chr3:122422288 chr3:122416207~122443180:+ PAAD cis rs9640161 0.711 rs3735170 ENSG00000261305.1 RP4-584D14.7 6.08 9.26e-09 1.24e-05 0.68 0.44 Blood protein levels;Circulating chemerin levels; chr7:150337095 chr7:150341771~150342607:+ PAAD cis rs9640161 0.75 rs3735169 ENSG00000261305.1 RP4-584D14.7 6.08 9.26e-09 1.24e-05 0.68 0.44 Blood protein levels;Circulating chemerin levels; chr7:150337289 chr7:150341771~150342607:+ PAAD cis rs7772486 0.558 rs702322 ENSG00000235652.6 RP11-545I5.3 -6.08 9.31e-09 1.24e-05 -0.38 -0.44 Lobe attachment (rater-scored or self-reported); chr6:145686030 chr6:145799409~145886585:+ PAAD cis rs7772486 0.558 rs2142978 ENSG00000235652.6 RP11-545I5.3 -6.08 9.31e-09 1.24e-05 -0.38 -0.44 Lobe attachment (rater-scored or self-reported); chr6:145690925 chr6:145799409~145886585:+ PAAD cis rs7615952 0.932 rs13325495 ENSG00000171084.14 FAM86JP 6.08 9.33e-09 1.25e-05 0.61 0.44 Blood pressure (smoking interaction); chr3:125918573 chr3:125916620~125930024:+ PAAD cis rs9322193 0.923 rs9383812 ENSG00000216906.2 RP11-350J20.9 6.08 9.36e-09 1.25e-05 0.56 0.44 Lung cancer; chr6:149712355 chr6:149904243~149906418:+ PAAD cis rs9322193 0.847 rs9383844 ENSG00000216906.2 RP11-350J20.9 6.08 9.36e-09 1.25e-05 0.56 0.44 Lung cancer; chr6:149716268 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs56397000 ENSG00000216906.2 RP11-350J20.9 6.08 9.36e-09 1.25e-05 0.56 0.44 Lung cancer; chr6:149739347 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs9689702 ENSG00000216906.2 RP11-350J20.9 6.08 9.36e-09 1.25e-05 0.56 0.44 Lung cancer; chr6:149740720 chr6:149904243~149906418:+ PAAD cis rs673078 0.607 rs61943443 ENSG00000275759.1 RP11-131L12.3 -6.08 9.37e-09 1.25e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118416602 chr12:118428281~118428870:+ PAAD cis rs56080343 0.808 rs1045552 ENSG00000275759.1 RP11-131L12.3 -6.08 9.37e-09 1.25e-05 -0.67 -0.44 Neuroticism; chr12:118417678 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7305647 ENSG00000275759.1 RP11-131L12.3 -6.08 9.37e-09 1.25e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118417761 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7132753 ENSG00000275759.1 RP11-131L12.3 -6.08 9.37e-09 1.25e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118420383 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943444 ENSG00000275759.1 RP11-131L12.3 -6.08 9.37e-09 1.25e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118421641 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs73207504 ENSG00000275759.1 RP11-131L12.3 -6.08 9.37e-09 1.25e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118427914 chr12:118428281~118428870:+ PAAD cis rs950169 0.65 rs12902052 ENSG00000225151.9 GOLGA2P7 -6.08 9.37e-09 1.25e-05 -0.53 -0.44 Schizophrenia; chr15:84582607 chr15:84199311~84230136:- PAAD cis rs4713118 0.505 rs276371 ENSG00000216901.1 AL022393.7 6.08 9.42e-09 1.26e-05 0.55 0.44 Parkinson's disease; chr6:27942930 chr6:28176188~28176674:+ PAAD cis rs7188445 0.932 rs7203756 ENSG00000261390.4 RP11-345M22.2 6.08 9.45e-09 1.26e-05 0.6 0.44 Urate levels; chr16:79711709 chr16:79715232~79770563:- PAAD cis rs11098499 0.691 rs10028773 ENSG00000245958.5 RP11-33B1.1 6.08 9.47e-09 1.26e-05 0.31 0.44 Corneal astigmatism; chr4:119344104 chr4:119454791~119552025:+ PAAD cis rs9532669 0.963 rs9562238 ENSG00000176268.5 CYCSP34 6.08 9.51e-09 1.27e-05 0.42 0.44 Cervical cancer; chr13:40924785 chr13:40863599~40863902:- PAAD cis rs2929278 0.617 rs533143 ENSG00000249839.1 AC011330.5 -6.08 9.52e-09 1.27e-05 -0.58 -0.44 Schizophrenia; chr15:43896656 chr15:43663654~43684339:- PAAD cis rs62229266 0.682 rs2835224 ENSG00000231106.2 LINC01436 6.08 9.52e-09 1.27e-05 0.65 0.44 Mitral valve prolapse; chr21:35997732 chr21:36005338~36007838:+ PAAD cis rs673078 0.562 rs56347775 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118438002 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943451 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118438929 chr12:118428281~118428870:+ PAAD cis rs673078 0.518 rs61943452 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118438990 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943454 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118439140 chr12:118428281~118428870:+ PAAD cis rs673078 0.517 rs61943455 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118439414 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs73207566 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118439471 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs2393416 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118439968 chr12:118428281~118428870:+ PAAD cis rs673078 0.56 rs4406856 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118440094 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs4457791 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118440144 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943456 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118440326 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17513006 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118440383 chr12:118428281~118428870:+ PAAD cis rs673078 0.56 rs61943457 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118440487 chr12:118428281~118428870:+ PAAD cis rs673078 0.562 rs55883417 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118440801 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs55842338 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118441259 chr12:118428281~118428870:+ PAAD cis rs673078 0.518 rs17441251 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118441361 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17513013 ENSG00000275759.1 RP11-131L12.3 -6.08 9.53e-09 1.27e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118442070 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs17440336 ENSG00000275759.1 RP11-131L12.3 6.08 9.54e-09 1.27e-05 0.66 0.44 Glucose homeostasis traits; chr12:118163305 chr12:118428281~118428870:+ PAAD cis rs9322193 0.923 rs3924871 ENSG00000216906.2 RP11-350J20.9 6.07 9.56e-09 1.27e-05 0.56 0.44 Lung cancer; chr6:149662080 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs11155674 ENSG00000216906.2 RP11-350J20.9 6.07 9.56e-09 1.27e-05 0.56 0.44 Lung cancer; chr6:149711111 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs2185352 ENSG00000216906.2 RP11-350J20.9 6.07 9.56e-09 1.27e-05 0.56 0.44 Lung cancer; chr6:149714640 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs12174349 ENSG00000216906.2 RP11-350J20.9 6.07 9.56e-09 1.27e-05 0.56 0.44 Lung cancer; chr6:149718012 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs2297932 ENSG00000216906.2 RP11-350J20.9 6.07 9.56e-09 1.27e-05 0.56 0.44 Lung cancer; chr6:149718225 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs2297930 ENSG00000216906.2 RP11-350J20.9 6.07 9.56e-09 1.27e-05 0.56 0.44 Lung cancer; chr6:149718360 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs2297928 ENSG00000216906.2 RP11-350J20.9 6.07 9.56e-09 1.27e-05 0.56 0.44 Lung cancer; chr6:149718584 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9479094 ENSG00000216906.2 RP11-350J20.9 6.07 9.56e-09 1.27e-05 0.56 0.44 Lung cancer; chr6:149725083 chr6:149904243~149906418:+ PAAD cis rs11098499 0.954 rs6857105 ENSG00000245958.5 RP11-33B1.1 -6.07 9.6e-09 1.27e-05 -0.36 -0.44 Corneal astigmatism; chr4:119301143 chr4:119454791~119552025:+ PAAD cis rs1075265 0.87 rs6749817 ENSG00000233266.1 HMGB1P31 6.07 9.6e-09 1.27e-05 0.57 0.44 Chronotype;Morning vs. evening chronotype; chr2:54032396 chr2:54051334~54051760:+ PAAD cis rs6538678 0.824 rs4762633 ENSG00000258343.1 RP11-536G4.2 -6.07 9.61e-09 1.27e-05 -0.59 -0.44 Lupus nephritis in systemic lupus erythematosus; chr12:95860295 chr12:95795345~95858839:- PAAD cis rs10028773 0.7 rs7690338 ENSG00000245958.5 RP11-33B1.1 -6.07 9.61e-09 1.27e-05 -0.35 -0.44 Educational attainment; chr4:119335313 chr4:119454791~119552025:+ PAAD cis rs2882667 0.898 rs11950819 ENSG00000253404.1 AC034243.1 6.07 9.66e-09 1.28e-05 0.53 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139061411 chr5:138744434~138753309:- PAAD cis rs7188445 0.932 rs3813582 ENSG00000261390.4 RP11-345M22.2 -6.07 9.69e-09 1.28e-05 -0.58 -0.44 Urate levels; chr16:79715456 chr16:79715232~79770563:- PAAD cis rs42490 1 rs218905 ENSG00000251136.7 RP11-37B2.1 -6.07 9.69e-09 1.28e-05 -0.4 -0.44 Leprosy; chr8:89723661 chr8:89609409~89757727:- PAAD cis rs10875746 0.855 rs10875730 ENSG00000240399.1 RP1-228P16.1 -6.07 9.69e-09 1.28e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48034092 chr12:48054813~48055591:- PAAD cis rs10875746 0.855 rs11168369 ENSG00000240399.1 RP1-228P16.1 -6.07 9.69e-09 1.28e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48037385 chr12:48054813~48055591:- PAAD cis rs10875746 0.855 rs10875731 ENSG00000240399.1 RP1-228P16.1 -6.07 9.69e-09 1.28e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48038960 chr12:48054813~48055591:- PAAD cis rs9532669 0.926 rs2875421 ENSG00000176268.5 CYCSP34 6.07 9.72e-09 1.29e-05 0.41 0.44 Cervical cancer; chr13:40936536 chr13:40863599~40863902:- PAAD cis rs875971 0.545 rs316328 ENSG00000237310.1 GS1-124K5.4 -6.07 9.78e-09 1.3e-05 -0.48 -0.44 Aortic root size; chr7:66143851 chr7:66493706~66495474:+ PAAD cis rs7429990 0.833 rs2293226 ENSG00000229759.1 MRPS18AP1 6.07 9.79e-09 1.3e-05 0.47 0.44 Educational attainment (years of education); chr3:47585292 chr3:48256350~48256938:- PAAD cis rs10256972 0.869 rs1007766 ENSG00000229043.2 AC091729.9 -6.07 9.79e-09 1.3e-05 -0.46 -0.44 Endometriosis;Longevity; chr7:995267 chr7:1160374~1165267:+ PAAD cis rs875971 0.545 rs2707851 ENSG00000237310.1 GS1-124K5.4 -6.07 9.82e-09 1.3e-05 -0.53 -0.44 Aortic root size; chr7:66624178 chr7:66493706~66495474:+ PAAD cis rs7945705 0.967 rs10769968 ENSG00000254860.4 TMEM9B-AS1 -6.07 9.87e-09 1.31e-05 -0.49 -0.44 Hemoglobin concentration; chr11:8886036 chr11:8964675~8977527:+ PAAD cis rs6700559 0.654 rs66717951 ENSG00000260088.1 RP11-92G12.3 6.07 9.88e-09 1.31e-05 0.57 0.44 Coronary artery disease; chr1:200626437 chr1:200669507~200694250:+ PAAD cis rs6700559 0.654 rs2809346 ENSG00000260088.1 RP11-92G12.3 6.07 9.88e-09 1.31e-05 0.57 0.44 Coronary artery disease; chr1:200627089 chr1:200669507~200694250:+ PAAD cis rs11098499 0.754 rs10212714 ENSG00000245958.5 RP11-33B1.1 -6.07 9.88e-09 1.31e-05 -0.34 -0.44 Corneal astigmatism; chr4:119333147 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs1849457 ENSG00000245958.5 RP11-33B1.1 -6.07 9.88e-09 1.31e-05 -0.34 -0.44 Corneal astigmatism; chr4:119333200 chr4:119454791~119552025:+ PAAD cis rs11098499 0.663 rs9996501 ENSG00000245958.5 RP11-33B1.1 -6.07 9.95e-09 1.32e-05 -0.35 -0.44 Corneal astigmatism; chr4:119317763 chr4:119454791~119552025:+ PAAD cis rs11098499 0.697 rs28458294 ENSG00000245958.5 RP11-33B1.1 -6.07 9.95e-09 1.32e-05 -0.35 -0.44 Corneal astigmatism; chr4:119317769 chr4:119454791~119552025:+ PAAD cis rs11098499 0.663 rs28369503 ENSG00000245958.5 RP11-33B1.1 -6.07 9.95e-09 1.32e-05 -0.35 -0.44 Corneal astigmatism; chr4:119317770 chr4:119454791~119552025:+ PAAD cis rs7945705 0.935 rs10769971 ENSG00000254860.4 TMEM9B-AS1 -6.07 9.96e-09 1.32e-05 -0.49 -0.44 Hemoglobin concentration; chr11:8903729 chr11:8964675~8977527:+ PAAD cis rs7945705 0.967 rs10769973 ENSG00000254860.4 TMEM9B-AS1 -6.07 9.96e-09 1.32e-05 -0.49 -0.44 Hemoglobin concentration; chr11:8907068 chr11:8964675~8977527:+ PAAD cis rs12022452 1 rs12022452 ENSG00000238287.1 RP11-656D10.3 -6.07 9.96e-09 1.32e-05 -0.71 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr1:40487628 chr1:40493157~40508661:- PAAD cis rs17301013 0.606 rs332784 ENSG00000227373.4 RP11-160H22.5 6.07 9.97e-09 1.32e-05 0.62 0.44 Systemic lupus erythematosus; chr1:174719927 chr1:174115300~174160004:- PAAD cis rs9322193 0.962 rs17673294 ENSG00000216906.2 RP11-350J20.9 6.07 9.98e-09 1.32e-05 0.57 0.44 Lung cancer; chr6:149813857 chr6:149904243~149906418:+ PAAD cis rs507080 0.501 rs516503 ENSG00000255422.1 AP002954.4 -6.07 1e-08 1.32e-05 -0.49 -0.44 Serum metabolite levels; chr11:118709639 chr11:118704607~118750263:+ PAAD cis rs9322193 0.923 rs10782315 ENSG00000216906.2 RP11-350J20.9 6.06 1e-08 1.33e-05 0.56 0.44 Lung cancer; chr6:149743093 chr6:149904243~149906418:+ PAAD cis rs7104764 0.507 rs7111364 ENSG00000277290.1 RP11-326C3.16 -6.06 1.01e-08 1.33e-05 -0.43 -0.44 Menarche (age at onset); chr11:258542 chr11:243099~243483:- PAAD cis rs673078 0.607 rs7967900 ENSG00000275759.1 RP11-131L12.3 6.06 1.01e-08 1.33e-05 0.67 0.44 Glucose homeostasis traits; chr12:118381902 chr12:118428281~118428870:+ PAAD cis rs7772486 0.597 rs1970306 ENSG00000235652.6 RP11-545I5.3 6.06 1.01e-08 1.34e-05 0.37 0.44 Lobe attachment (rater-scored or self-reported); chr6:145833407 chr6:145799409~145886585:+ PAAD cis rs7772486 0.597 rs9386136 ENSG00000235652.6 RP11-545I5.3 6.06 1.01e-08 1.34e-05 0.37 0.44 Lobe attachment (rater-scored or self-reported); chr6:145837164 chr6:145799409~145886585:+ PAAD cis rs1075265 0.527 rs10167891 ENSG00000233266.1 HMGB1P31 6.06 1.01e-08 1.34e-05 0.57 0.44 Chronotype;Morning vs. evening chronotype; chr2:54003658 chr2:54051334~54051760:+ PAAD cis rs465969 1 rs13208890 ENSG00000255389.1 C6orf3 -6.06 1.02e-08 1.34e-05 -0.73 -0.44 Psoriasis; chr6:111500620 chr6:111599875~111602295:+ PAAD cis rs465969 0.744 rs36007392 ENSG00000255389.1 C6orf3 -6.06 1.02e-08 1.34e-05 -0.73 -0.44 Psoriasis; chr6:111509287 chr6:111599875~111602295:+ PAAD cis rs465969 0.546 rs77990243 ENSG00000255389.1 C6orf3 -6.06 1.02e-08 1.34e-05 -0.73 -0.44 Psoriasis; chr6:111513183 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs4509157 ENSG00000255389.1 C6orf3 -6.06 1.02e-08 1.34e-05 -0.73 -0.44 Psoriasis; chr6:111513875 chr6:111599875~111602295:+ PAAD cis rs465969 0.744 rs71562296 ENSG00000255389.1 C6orf3 -6.06 1.02e-08 1.34e-05 -0.73 -0.44 Psoriasis; chr6:111521444 chr6:111599875~111602295:+ PAAD cis rs465969 0.744 rs6939657 ENSG00000255389.1 C6orf3 -6.06 1.02e-08 1.34e-05 -0.73 -0.44 Psoriasis; chr6:111521822 chr6:111599875~111602295:+ PAAD cis rs56205728 0.606 rs2898991 ENSG00000273855.1 RP11-133K1.12 6.06 1.02e-08 1.34e-05 0.51 0.44 Schizophrenia; chr15:40304367 chr15:40285468~40285909:- PAAD cis rs56205728 0.606 rs3784398 ENSG00000273855.1 RP11-133K1.12 6.06 1.02e-08 1.34e-05 0.51 0.44 Schizophrenia; chr15:40304665 chr15:40285468~40285909:- PAAD cis rs950169 1 rs11638297 ENSG00000259728.4 LINC00933 6.06 1.02e-08 1.34e-05 0.56 0.44 Schizophrenia; chr15:84113665 chr15:84570649~84580175:+ PAAD cis rs9532669 0.963 rs2324739 ENSG00000176268.5 CYCSP34 6.06 1.02e-08 1.35e-05 0.41 0.44 Cervical cancer; chr13:40925479 chr13:40863599~40863902:- PAAD cis rs17301013 0.606 rs1417186 ENSG00000227373.4 RP11-160H22.5 -6.06 1.02e-08 1.35e-05 -0.64 -0.44 Systemic lupus erythematosus; chr1:174171090 chr1:174115300~174160004:- PAAD cis rs42490 1 rs2735870 ENSG00000251136.7 RP11-37B2.1 6.06 1.03e-08 1.35e-05 0.4 0.44 Leprosy; chr8:89730456 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs2735871 ENSG00000251136.7 RP11-37B2.1 6.06 1.03e-08 1.35e-05 0.4 0.44 Leprosy; chr8:89731154 chr8:89609409~89757727:- PAAD cis rs42490 1 rs2735873 ENSG00000251136.7 RP11-37B2.1 6.06 1.03e-08 1.35e-05 0.4 0.44 Leprosy; chr8:89737748 chr8:89609409~89757727:- PAAD cis rs42490 1 rs218907 ENSG00000251136.7 RP11-37B2.1 -6.06 1.03e-08 1.35e-05 -0.4 -0.44 Leprosy; chr8:89728164 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs218908 ENSG00000251136.7 RP11-37B2.1 -6.06 1.03e-08 1.35e-05 -0.4 -0.44 Leprosy; chr8:89728886 chr8:89609409~89757727:- PAAD cis rs42490 1 rs218913 ENSG00000251136.7 RP11-37B2.1 -6.06 1.03e-08 1.35e-05 -0.4 -0.44 Leprosy; chr8:89732206 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs218914 ENSG00000251136.7 RP11-37B2.1 -6.06 1.03e-08 1.35e-05 -0.4 -0.44 Leprosy; chr8:89733130 chr8:89609409~89757727:- PAAD cis rs2929278 0.617 rs524908 ENSG00000249839.1 AC011330.5 6.06 1.03e-08 1.35e-05 0.59 0.44 Schizophrenia; chr15:43895793 chr15:43663654~43684339:- PAAD cis rs9425766 0.541 rs12691474 ENSG00000227373.4 RP11-160H22.5 6.06 1.03e-08 1.35e-05 0.6 0.44 Life satisfaction; chr1:174200867 chr1:174115300~174160004:- PAAD cis rs9322193 0.923 rs4421206 ENSG00000216906.2 RP11-350J20.9 6.06 1.03e-08 1.35e-05 0.56 0.44 Lung cancer; chr6:149682891 chr6:149904243~149906418:+ PAAD cis rs17301013 0.507 rs1613634 ENSG00000227373.4 RP11-160H22.5 -6.06 1.03e-08 1.36e-05 -0.63 -0.44 Systemic lupus erythematosus; chr1:174803184 chr1:174115300~174160004:- PAAD cis rs732716 0.785 rs62129354 ENSG00000267980.1 AC007292.6 -6.06 1.04e-08 1.36e-05 -0.61 -0.44 Mean corpuscular volume; chr19:4396508 chr19:4363789~4364640:+ PAAD cis rs7945705 0.87 rs1109305 ENSG00000254860.4 TMEM9B-AS1 -6.06 1.04e-08 1.36e-05 -0.5 -0.44 Hemoglobin concentration; chr11:8933725 chr11:8964675~8977527:+ PAAD cis rs9425766 0.591 rs2049991 ENSG00000227373.4 RP11-160H22.5 6.06 1.04e-08 1.36e-05 0.58 0.44 Life satisfaction; chr1:174356428 chr1:174115300~174160004:- PAAD cis rs7301826 0.934 rs10848212 ENSG00000256299.1 RP11-989F5.3 6.06 1.04e-08 1.37e-05 0.51 0.44 Plasma plasminogen activator levels; chr12:130837455 chr12:130810821~130812622:- PAAD cis rs42490 1 rs1003843 ENSG00000251136.7 RP11-37B2.1 -6.06 1.04e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89727252 chr8:89609409~89757727:- PAAD cis rs673078 0.607 rs7958551 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118442585 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7958652 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118442630 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs111607725 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118442957 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs76809232 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118444979 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61944660 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118445326 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61944661 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118445514 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61944662 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118445520 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs4254101 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118445877 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs4622305 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118445912 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs2393418 ENSG00000275759.1 RP11-131L12.3 -6.06 1.04e-08 1.37e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118445995 chr12:118428281~118428870:+ PAAD cis rs3096299 0.746 rs9931120 ENSG00000274627.1 RP11-104N10.2 6.06 1.05e-08 1.37e-05 0.38 0.44 Multiple myeloma (IgH translocation); chr16:89434949 chr16:89516797~89522217:+ PAAD cis rs73086581 1 rs73088421 ENSG00000229539.1 RP11-119B16.2 6.06 1.05e-08 1.37e-05 0.72 0.44 Response to antidepressants in depression; chr20:4017224 chr20:3888239~3888868:- PAAD cis rs42490 0.966 rs2644033 ENSG00000251136.7 RP11-37B2.1 6.06 1.05e-08 1.37e-05 0.4 0.44 Leprosy; chr8:89739196 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs218932 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89740725 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs2735878 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89742720 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs218936 ENSG00000251136.7 RP11-37B2.1 6.06 1.05e-08 1.37e-05 0.4 0.44 Leprosy; chr8:89743186 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs6992985 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89746330 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs6993133 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89746396 chr8:89609409~89757727:- PAAD cis rs42490 1 rs13252917 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89747202 chr8:89609409~89757727:- PAAD cis rs42490 1 rs6470366 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89747760 chr8:89609409~89757727:- PAAD cis rs42490 1 rs10112852 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89749257 chr8:89609409~89757727:- PAAD cis rs42490 0.934 rs10095743 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89749445 chr8:89609409~89757727:- PAAD cis rs42490 1 rs67143546 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89753950 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs385524 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89754242 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs419754 ENSG00000251136.7 RP11-37B2.1 -6.06 1.05e-08 1.37e-05 -0.4 -0.44 Leprosy; chr8:89755452 chr8:89609409~89757727:- PAAD cis rs2919917 0.628 rs12680932 ENSG00000254352.1 RP11-578O24.2 -6.06 1.05e-08 1.38e-05 -0.53 -0.44 Lymphocyte counts; chr8:78685516 chr8:78723796~78724136:- PAAD cis rs4218 0.716 rs12900331 ENSG00000277144.1 RP11-59H7.4 -6.06 1.05e-08 1.38e-05 -0.6 -0.44 Social communication problems; chr15:59139563 chr15:59115547~59116089:- PAAD cis rs7945705 0.967 rs1569408 ENSG00000254860.4 TMEM9B-AS1 -6.06 1.05e-08 1.38e-05 -0.48 -0.44 Hemoglobin concentration; chr11:8888185 chr11:8964675~8977527:+ PAAD cis rs7945705 0.967 rs10769970 ENSG00000254860.4 TMEM9B-AS1 -6.06 1.05e-08 1.38e-05 -0.48 -0.44 Hemoglobin concentration; chr11:8896390 chr11:8964675~8977527:+ PAAD cis rs7945705 0.967 rs10840148 ENSG00000254860.4 TMEM9B-AS1 -6.06 1.05e-08 1.38e-05 -0.48 -0.44 Hemoglobin concentration; chr11:8901981 chr11:8964675~8977527:+ PAAD cis rs73086581 1 rs56141565 ENSG00000229539.1 RP11-119B16.2 6.05 1.06e-08 1.38e-05 0.73 0.44 Response to antidepressants in depression; chr20:4017956 chr20:3888239~3888868:- PAAD cis rs7772486 0.754 rs4896838 ENSG00000235652.6 RP11-545I5.3 -6.05 1.06e-08 1.38e-05 -0.38 -0.44 Lobe attachment (rater-scored or self-reported); chr6:145694315 chr6:145799409~145886585:+ PAAD cis rs2117029 0.555 rs7958241 ENSG00000258017.1 RP11-386G11.10 6.05 1.06e-08 1.38e-05 0.57 0.44 Intelligence (multi-trait analysis); chr12:49115479 chr12:49127782~49147869:+ PAAD cis rs2906856 0.921 rs1019076 ENSG00000255733.4 IFNG-AS1 -6.05 1.06e-08 1.38e-05 -0.42 -0.44 Mosquito bite size; chr12:68004338 chr12:67989445~68234686:+ PAAD cis rs992157 0.835 rs11677953 ENSG00000261338.2 RP11-378A13.1 -6.05 1.06e-08 1.38e-05 -0.53 -0.44 Colorectal cancer; chr2:218256940 chr2:218255319~218257366:+ PAAD cis rs9322193 0.923 rs11155670 ENSG00000216906.2 RP11-350J20.9 6.05 1.06e-08 1.39e-05 0.56 0.44 Lung cancer; chr6:149644992 chr6:149904243~149906418:+ PAAD cis rs673078 0.607 rs17441172 ENSG00000275759.1 RP11-131L12.3 6.05 1.06e-08 1.39e-05 0.68 0.44 Glucose homeostasis traits; chr12:118430456 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17440893 ENSG00000275759.1 RP11-131L12.3 -6.05 1.06e-08 1.39e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118362532 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943447 ENSG00000275759.1 RP11-131L12.3 -6.05 1.06e-08 1.39e-05 -0.68 -0.44 Glucose homeostasis traits; chr12:118430598 chr12:118428281~118428870:+ PAAD cis rs992157 0.798 rs2382817 ENSG00000261338.2 RP11-378A13.1 6.05 1.06e-08 1.39e-05 0.52 0.44 Colorectal cancer; chr2:218286495 chr2:218255319~218257366:+ PAAD cis rs1150668 0.796 rs1124132 ENSG00000216901.1 AL022393.7 6.05 1.07e-08 1.4e-05 0.54 0.44 Pubertal anthropometrics; chr6:28412544 chr6:28176188~28176674:+ PAAD cis rs1150668 0.796 rs2531832 ENSG00000216901.1 AL022393.7 6.05 1.07e-08 1.4e-05 0.54 0.44 Pubertal anthropometrics; chr6:28421445 chr6:28176188~28176674:+ PAAD cis rs10875746 0.855 rs12296244 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48047696 chr12:48054813~48055591:- PAAD cis rs10875746 0.855 rs12310999 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48053875 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs61918774 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48054351 chr12:48054813~48055591:- PAAD cis rs10875746 0.807 rs12297004 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48060037 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs58952582 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48064665 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs10875735 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48070023 chr12:48054813~48055591:- PAAD cis rs10875746 0.855 rs17122620 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48070692 chr12:48054813~48055591:- PAAD cis rs10875746 0.859 rs4760680 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48072914 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs11168386 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48074194 chr12:48054813~48055591:- PAAD cis rs10875746 0.807 rs12313300 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48076934 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs12315625 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48078670 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs10875738 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48079956 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs12301339 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48081450 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs886588 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48083639 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs11168401 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48087736 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs12304476 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48088370 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs3782911 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48089709 chr12:48054813~48055591:- PAAD cis rs10875746 0.859 rs3782910 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48089724 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs61918806 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48090650 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs11168403 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48091175 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs10875740 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48095334 chr12:48054813~48055591:- PAAD cis rs10875746 0.903 rs2158516 ENSG00000240399.1 RP1-228P16.1 -6.05 1.07e-08 1.4e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48097051 chr12:48054813~48055591:- PAAD cis rs465969 1 rs13197107 ENSG00000255389.1 C6orf3 -6.05 1.08e-08 1.4e-05 -0.73 -0.44 Psoriasis; chr6:111512031 chr6:111599875~111602295:+ PAAD cis rs17301013 0.507 rs333452 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174654718 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs411665 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174656563 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs333438 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174672782 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2771401 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174678302 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs464540 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174679250 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs467437 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174679861 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs398350 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174706168 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs3117843 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174711581 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs332786 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174713584 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs332779 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174716623 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs332781 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174718483 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs193082 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174725439 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs460878 ENSG00000227373.4 RP11-160H22.5 6.05 1.08e-08 1.41e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174732645 chr1:174115300~174160004:- PAAD cis rs11651753 0.561 rs60580012 ENSG00000264920.1 RP11-6N17.4 -6.05 1.08e-08 1.41e-05 -0.5 -0.44 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47892442 chr17:47891255~47895812:- PAAD cis rs11651753 0.561 rs61422354 ENSG00000264920.1 RP11-6N17.4 -6.05 1.08e-08 1.41e-05 -0.5 -0.44 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47892443 chr17:47891255~47895812:- PAAD cis rs55665837 1 rs10832276 ENSG00000251991.1 RNU7-49P 6.05 1.09e-08 1.42e-05 0.53 0.44 Vitamin D levels; chr11:14461728 chr11:14478892~14478953:+ PAAD cis rs6061231 0.793 rs2427320 ENSG00000273619.1 RP5-908M14.9 -6.05 1.09e-08 1.42e-05 -0.41 -0.44 Colorectal cancer; chr20:62401667 chr20:62386303~62386970:- PAAD cis rs6061231 0.793 rs6061512 ENSG00000273619.1 RP5-908M14.9 -6.05 1.09e-08 1.42e-05 -0.41 -0.44 Colorectal cancer; chr20:62401873 chr20:62386303~62386970:- PAAD cis rs6061231 0.837 rs6061235 ENSG00000273619.1 RP5-908M14.9 -6.05 1.09e-08 1.42e-05 -0.41 -0.44 Colorectal cancer; chr20:62403468 chr20:62386303~62386970:- PAAD cis rs3096299 0.692 rs4785565 ENSG00000274627.1 RP11-104N10.2 6.05 1.09e-08 1.42e-05 0.38 0.44 Multiple myeloma (IgH translocation); chr16:89449351 chr16:89516797~89522217:+ PAAD cis rs992157 0.866 rs2292554 ENSG00000261338.2 RP11-378A13.1 -6.05 1.1e-08 1.43e-05 -0.52 -0.44 Colorectal cancer; chr2:218282145 chr2:218255319~218257366:+ PAAD cis rs992157 0.932 rs4672884 ENSG00000261338.2 RP11-378A13.1 -6.05 1.1e-08 1.43e-05 -0.51 -0.44 Colorectal cancer; chr2:218317758 chr2:218255319~218257366:+ PAAD cis rs950169 1 rs79318564 ENSG00000259728.4 LINC00933 6.05 1.1e-08 1.43e-05 0.56 0.44 Schizophrenia; chr15:84117398 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs1911155 ENSG00000259728.4 LINC00933 6.05 1.1e-08 1.43e-05 0.56 0.44 Schizophrenia; chr15:84118883 chr15:84570649~84580175:+ PAAD cis rs36229146 1 rs36229146 ENSG00000179428.2 AC073072.5 -6.05 1.1e-08 1.43e-05 -0.43 -0.44 Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells; chr7:22744893 chr7:22725395~22727620:- PAAD cis rs1891275 0.551 rs7908678 ENSG00000228701.1 TNKS2-AS1 6.05 1.1e-08 1.44e-05 0.55 0.44 Intelligence (multi-trait analysis); chr10:91659253 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs7358148 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91658775 chr10:91782839~91798291:- PAAD cis rs1891275 0.601 rs7358034 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91659007 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs7908547 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91659230 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs7908980 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91659545 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs4933690 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91659810 chr10:91782839~91798291:- PAAD cis rs1891275 0.576 rs4933216 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91659825 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs4933691 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91660200 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2421626 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91661177 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2421627 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91662226 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2421628 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91662412 chr10:91782839~91798291:- PAAD cis rs1891275 0.515 rs10881945 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91663826 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2421629 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91664018 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs4933692 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91664876 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs7900863 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91665737 chr10:91782839~91798291:- PAAD cis rs1891275 0.588 rs6583782 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91666022 chr10:91782839~91798291:- PAAD cis rs1891275 0.576 rs1891272 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91666306 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs1891271 ENSG00000228701.1 TNKS2-AS1 -6.05 1.1e-08 1.44e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91666566 chr10:91782839~91798291:- PAAD cis rs12220777 1 rs11201312 ENSG00000230091.5 TMEM254-AS1 6.04 1.11e-08 1.44e-05 0.79 0.44 Chronic obstructive pulmonary disease-related biomarkers; chr10:80036022 chr10:80046860~80078912:- PAAD cis rs7945705 0.902 rs10743095 ENSG00000254860.4 TMEM9B-AS1 -6.04 1.11e-08 1.44e-05 -0.49 -0.44 Hemoglobin concentration; chr11:8915437 chr11:8964675~8977527:+ PAAD cis rs673078 0.607 rs17441061 ENSG00000275759.1 RP11-131L12.3 -6.04 1.11e-08 1.44e-05 -0.67 -0.44 Glucose homeostasis traits; chr12:118409847 chr12:118428281~118428870:+ PAAD cis rs7044106 0.537 rs4434680 ENSG00000226752.6 PSMD5-AS1 -6.04 1.11e-08 1.44e-05 -0.59 -0.44 Hip circumference adjusted for BMI; chr9:120727410 chr9:120824828~120854385:+ PAAD cis rs7044106 0.537 rs10739573 ENSG00000226752.6 PSMD5-AS1 -6.04 1.11e-08 1.44e-05 -0.59 -0.44 Hip circumference adjusted for BMI; chr9:120727540 chr9:120824828~120854385:+ PAAD cis rs4218 0.543 rs4775110 ENSG00000277144.1 RP11-59H7.4 -6.04 1.12e-08 1.45e-05 -0.51 -0.44 Social communication problems; chr15:59023685 chr15:59115547~59116089:- PAAD cis rs7188445 0.871 rs7202770 ENSG00000261390.4 RP11-345M22.2 -6.04 1.12e-08 1.45e-05 -0.6 -0.44 Urate levels; chr16:79672643 chr16:79715232~79770563:- PAAD cis rs7188445 0.835 rs1424231 ENSG00000261390.4 RP11-345M22.2 -6.04 1.12e-08 1.45e-05 -0.6 -0.44 Urate levels; chr16:79672854 chr16:79715232~79770563:- PAAD cis rs2019137 0.56 rs11123172 ENSG00000189223.12 PAX8-AS1 6.04 1.12e-08 1.45e-05 0.53 0.44 Lymphocyte counts; chr2:113226726 chr2:113211522~113276581:+ PAAD cis rs2019137 0.539 rs6755040 ENSG00000189223.12 PAX8-AS1 -6.04 1.12e-08 1.45e-05 -0.53 -0.44 Lymphocyte counts; chr2:113223560 chr2:113211522~113276581:+ PAAD cis rs2019137 0.539 rs4849177 ENSG00000189223.12 PAX8-AS1 -6.04 1.12e-08 1.45e-05 -0.53 -0.44 Lymphocyte counts; chr2:113225007 chr2:113211522~113276581:+ PAAD cis rs2019137 0.56 rs4849179 ENSG00000189223.12 PAX8-AS1 -6.04 1.12e-08 1.45e-05 -0.53 -0.44 Lymphocyte counts; chr2:113227593 chr2:113211522~113276581:+ PAAD cis rs2019137 0.56 rs10175462 ENSG00000189223.12 PAX8-AS1 -6.04 1.12e-08 1.45e-05 -0.53 -0.44 Lymphocyte counts; chr2:113230915 chr2:113211522~113276581:+ PAAD cis rs11722779 0.844 rs7694724 ENSG00000246560.2 RP11-10L12.4 6.04 1.12e-08 1.46e-05 0.5 0.44 Schizophrenia; chr4:103041375 chr4:102828055~102844075:+ PAAD cis rs9322193 0.923 rs10782317 ENSG00000216906.2 RP11-350J20.9 -6.04 1.13e-08 1.46e-05 -0.56 -0.44 Lung cancer; chr6:149753911 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs35830138 ENSG00000216906.2 RP11-350J20.9 6.04 1.13e-08 1.47e-05 0.56 0.44 Lung cancer; chr6:149668635 chr6:149904243~149906418:+ PAAD cis rs950169 0.922 rs12906983 ENSG00000225151.9 GOLGA2P7 -6.04 1.13e-08 1.47e-05 -0.53 -0.44 Schizophrenia; chr15:84262270 chr15:84199311~84230136:- PAAD cis rs62229266 0.682 rs11700546 ENSG00000231106.2 LINC01436 6.04 1.13e-08 1.47e-05 0.65 0.44 Mitral valve prolapse; chr21:35998841 chr21:36005338~36007838:+ PAAD cis rs6142102 0.58 rs4911139 ENSG00000276073.1 RP5-1125A11.7 -6.04 1.13e-08 1.47e-05 -0.46 -0.44 Skin pigmentation; chr20:33963729 chr20:33985617~33988989:- PAAD cis rs1930961 1 rs6004675 ENSG00000272977.1 CTA-390C10.10 -6.04 1.14e-08 1.48e-05 -0.86 -0.44 Bipolar disorder with mood-incongruent psychosis; chr22:25493418 chr22:25476218~25479971:+ PAAD cis rs42490 0.837 rs218916 ENSG00000251136.7 RP11-37B2.1 -6.04 1.14e-08 1.48e-05 -0.41 -0.44 Leprosy; chr8:89688709 chr8:89609409~89757727:- PAAD cis rs42490 0.8 rs56291556 ENSG00000251136.7 RP11-37B2.1 6.04 1.14e-08 1.48e-05 0.41 0.44 Leprosy; chr8:89662546 chr8:89609409~89757727:- PAAD cis rs42490 0.868 rs12675281 ENSG00000251136.7 RP11-37B2.1 6.04 1.14e-08 1.48e-05 0.41 0.44 Leprosy; chr8:89681561 chr8:89609409~89757727:- PAAD cis rs42490 0.868 rs4961158 ENSG00000251136.7 RP11-37B2.1 6.04 1.14e-08 1.48e-05 0.41 0.44 Leprosy; chr8:89685607 chr8:89609409~89757727:- PAAD cis rs6700559 0.654 rs2809345 ENSG00000260088.1 RP11-92G12.3 6.04 1.14e-08 1.48e-05 0.56 0.44 Coronary artery disease; chr1:200627135 chr1:200669507~200694250:+ PAAD cis rs1150668 0.796 rs213236 ENSG00000204709.4 LINC01556 6.04 1.14e-08 1.48e-05 0.56 0.44 Pubertal anthropometrics; chr6:28356620 chr6:28943877~28944537:+ PAAD cis rs10129255 0.556 rs8010005 ENSG00000223648.3 IGHV3-64 6.04 1.14e-08 1.48e-05 0.39 0.44 Kawasaki disease; chr14:106777987 chr14:106643132~106658258:- PAAD cis rs10129255 0.556 rs6576224 ENSG00000223648.3 IGHV3-64 6.04 1.14e-08 1.48e-05 0.39 0.44 Kawasaki disease; chr14:106777997 chr14:106643132~106658258:- PAAD cis rs8059260 0.604 rs9302458 ENSG00000274038.1 RP11-66H6.4 -6.04 1.15e-08 1.49e-05 -0.73 -0.44 Alcohol consumption over the past year; chr16:11050352 chr16:11056556~11057034:+ PAAD cis rs763567 0.585 rs577827 ENSG00000271811.1 RP1-79C4.4 6.04 1.15e-08 1.49e-05 0.42 0.44 Tonsillectomy; chr1:170593942 chr1:170667381~170669425:+ PAAD cis rs1061377 0.965 rs7690465 ENSG00000249685.1 RP11-360F5.3 6.04 1.15e-08 1.49e-05 0.47 0.44 Uric acid levels; chr4:39147015 chr4:39133913~39135608:+ PAAD cis rs17301013 0.861 rs12568655 ENSG00000227373.4 RP11-160H22.5 6.04 1.15e-08 1.49e-05 0.59 0.44 Systemic lupus erythematosus; chr1:174465194 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2568098 ENSG00000227373.4 RP11-160H22.5 6.04 1.16e-08 1.5e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174732183 chr1:174115300~174160004:- PAAD cis rs72772090 0.539 rs72773991 ENSG00000248734.2 CTD-2260A17.1 -6.04 1.16e-08 1.5e-05 -0.6 -0.44 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96828072 chr5:96784777~96785999:+ PAAD cis rs2882667 0.861 rs7703288 ENSG00000253404.1 AC034243.1 6.04 1.16e-08 1.5e-05 0.53 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139030850 chr5:138744434~138753309:- PAAD cis rs5760092 0.842 rs5751763 ENSG00000250470.1 AP000351.3 6.04 1.16e-08 1.5e-05 0.79 0.44 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23905606 chr22:23976904~23977585:- PAAD cis rs9322193 0.651 rs9322188 ENSG00000216906.2 RP11-350J20.9 -6.03 1.17e-08 1.51e-05 -0.56 -0.44 Lung cancer; chr6:149588355 chr6:149904243~149906418:+ PAAD cis rs42490 0.966 rs39505 ENSG00000251136.7 RP11-37B2.1 -6.03 1.17e-08 1.51e-05 -0.39 -0.44 Leprosy; chr8:89779838 chr8:89609409~89757727:- PAAD cis rs42490 1 rs39506 ENSG00000251136.7 RP11-37B2.1 -6.03 1.17e-08 1.51e-05 -0.39 -0.44 Leprosy; chr8:89779899 chr8:89609409~89757727:- PAAD cis rs113835537 0.529 rs80100524 ENSG00000255517.5 CTD-3074O7.5 -6.03 1.18e-08 1.52e-05 -0.57 -0.44 Airway imaging phenotypes; chr11:66478465 chr11:66473490~66480233:- PAAD cis rs12022452 0.818 rs11810978 ENSG00000238287.1 RP11-656D10.3 -6.03 1.18e-08 1.52e-05 -0.71 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr1:40554175 chr1:40493157~40508661:- PAAD cis rs7429990 0.833 rs3755638 ENSG00000229759.1 MRPS18AP1 -6.03 1.18e-08 1.52e-05 -0.48 -0.44 Educational attainment (years of education); chr3:47580841 chr3:48256350~48256938:- PAAD cis rs12594515 1 rs12594515 ENSG00000273972.1 CTD-2306A12.1 6.03 1.18e-08 1.52e-05 0.52 0.44 Weight;Waist circumference; chr15:45692873 chr15:45702640~45703183:+ PAAD cis rs7829975 0.688 rs7827182 ENSG00000253893.2 FAM85B -6.03 1.18e-08 1.52e-05 -0.58 -0.44 Mood instability; chr8:8522961 chr8:8167819~8226614:- PAAD cis rs7772486 0.875 rs10872583 ENSG00000235652.6 RP11-545I5.3 -6.03 1.18e-08 1.52e-05 -0.36 -0.44 Lobe attachment (rater-scored or self-reported); chr6:146075563 chr6:145799409~145886585:+ PAAD cis rs17301013 0.507 rs913688 ENSG00000227373.4 RP11-160H22.5 -6.03 1.18e-08 1.52e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174805080 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2860725 ENSG00000227373.4 RP11-160H22.5 -6.03 1.18e-08 1.52e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174815447 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1754354 ENSG00000227373.4 RP11-160H22.5 -6.03 1.18e-08 1.52e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174817196 chr1:174115300~174160004:- PAAD cis rs17301013 0.556 rs1754353 ENSG00000227373.4 RP11-160H22.5 -6.03 1.18e-08 1.52e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174822229 chr1:174115300~174160004:- PAAD cis rs17301013 0.531 rs1793318 ENSG00000227373.4 RP11-160H22.5 -6.03 1.18e-08 1.52e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174824678 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1793316 ENSG00000227373.4 RP11-160H22.5 6.03 1.18e-08 1.52e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174825006 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1754352 ENSG00000227373.4 RP11-160H22.5 6.03 1.18e-08 1.52e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174835984 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2987872 ENSG00000227373.4 RP11-160H22.5 -6.03 1.18e-08 1.52e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174840935 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1793305 ENSG00000227373.4 RP11-160H22.5 -6.03 1.18e-08 1.52e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174841124 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1894201 ENSG00000227373.4 RP11-160H22.5 -6.03 1.18e-08 1.52e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174841452 chr1:174115300~174160004:- PAAD cis rs12220777 0.585 rs11201146 ENSG00000230091.5 TMEM254-AS1 -6.03 1.19e-08 1.54e-05 -0.7 -0.44 Chronic obstructive pulmonary disease-related biomarkers; chr10:80007581 chr10:80046860~80078912:- PAAD cis rs17301013 0.507 rs3117838 ENSG00000227373.4 RP11-160H22.5 6.03 1.19e-08 1.54e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174749205 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1923818 ENSG00000227373.4 RP11-160H22.5 6.03 1.19e-08 1.54e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174749737 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs332801 ENSG00000227373.4 RP11-160H22.5 6.03 1.19e-08 1.54e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174753192 chr1:174115300~174160004:- PAAD cis rs12220777 1 rs11201298 ENSG00000230091.5 TMEM254-AS1 6.03 1.2e-08 1.54e-05 0.77 0.44 Chronic obstructive pulmonary disease-related biomarkers; chr10:80033995 chr10:80046860~80078912:- PAAD cis rs2929278 0.617 rs11070410 ENSG00000205771.5 CATSPER2P1 6.03 1.2e-08 1.54e-05 0.58 0.44 Schizophrenia; chr15:43764847 chr15:43726918~43747094:- PAAD cis rs9601248 0.627 rs2146593 ENSG00000227676.3 LINC01068 6.03 1.2e-08 1.54e-05 0.59 0.44 Major depressive disorder; chr13:79605977 chr13:79566727~79571436:+ PAAD cis rs9640161 0.659 rs7788316 ENSG00000261305.1 RP4-584D14.7 6.03 1.2e-08 1.55e-05 0.65 0.44 Blood protein levels;Circulating chemerin levels; chr7:150316906 chr7:150341771~150342607:+ PAAD cis rs2882667 0.898 rs4380651 ENSG00000253404.1 AC034243.1 6.03 1.2e-08 1.55e-05 0.53 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139055383 chr5:138744434~138753309:- PAAD cis rs673078 0.66 rs61945176 ENSG00000275759.1 RP11-131L12.3 -6.03 1.21e-08 1.55e-05 -0.58 -0.44 Glucose homeostasis traits; chr12:118204735 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs2280711 ENSG00000275759.1 RP11-131L12.3 -6.03 1.21e-08 1.55e-05 -0.58 -0.44 Glucose homeostasis traits; chr12:118212149 chr12:118428281~118428870:+ PAAD cis rs673078 0.615 rs73222058 ENSG00000275759.1 RP11-131L12.3 -6.03 1.21e-08 1.55e-05 -0.58 -0.44 Glucose homeostasis traits; chr12:118221066 chr12:118428281~118428870:+ PAAD cis rs42490 0.934 rs218925 ENSG00000251136.7 RP11-37B2.1 -6.03 1.21e-08 1.56e-05 -0.4 -0.44 Leprosy; chr8:89737352 chr8:89609409~89757727:- PAAD cis rs673078 0.607 rs61943398 ENSG00000275759.1 RP11-131L12.3 -6.03 1.21e-08 1.56e-05 -0.65 -0.44 Glucose homeostasis traits; chr12:118393280 chr12:118428281~118428870:+ PAAD cis rs17301013 0.507 rs2568096 ENSG00000227373.4 RP11-160H22.5 6.03 1.22e-08 1.56e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174735463 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs333436 ENSG00000227373.4 RP11-160H22.5 6.03 1.22e-08 1.56e-05 0.65 0.44 Systemic lupus erythematosus; chr1:174739069 chr1:174115300~174160004:- PAAD cis rs7429990 0.864 rs13085978 ENSG00000229759.1 MRPS18AP1 6.03 1.22e-08 1.56e-05 0.47 0.44 Educational attainment (years of education); chr3:47608585 chr3:48256350~48256938:- PAAD cis rs7429990 0.727 rs61675361 ENSG00000229759.1 MRPS18AP1 6.03 1.22e-08 1.56e-05 0.47 0.44 Educational attainment (years of education); chr3:47610630 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs883662 ENSG00000229759.1 MRPS18AP1 6.03 1.22e-08 1.56e-05 0.47 0.44 Educational attainment (years of education); chr3:47619342 chr3:48256350~48256938:- PAAD cis rs7429990 0.828 rs11712152 ENSG00000229759.1 MRPS18AP1 6.03 1.22e-08 1.56e-05 0.47 0.44 Educational attainment (years of education); chr3:47655314 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs12635438 ENSG00000229759.1 MRPS18AP1 6.03 1.22e-08 1.56e-05 0.47 0.44 Educational attainment (years of education); chr3:47693210 chr3:48256350~48256938:- PAAD cis rs7174755 0.884 rs11634026 ENSG00000260657.2 RP11-315D16.4 6.03 1.22e-08 1.57e-05 0.55 0.44 Major depressive disorder; chr15:68305668 chr15:68267792~68277994:- PAAD cis rs7772486 0.79 rs2243665 ENSG00000235652.6 RP11-545I5.3 6.02 1.23e-08 1.58e-05 0.36 0.44 Lobe attachment (rater-scored or self-reported); chr6:145886984 chr6:145799409~145886585:+ PAAD cis rs7429990 0.803 rs6776963 ENSG00000229759.1 MRPS18AP1 -6.02 1.23e-08 1.58e-05 -0.47 -0.44 Educational attainment (years of education); chr3:47789251 chr3:48256350~48256938:- PAAD cis rs8059260 0.551 rs8061043 ENSG00000274038.1 RP11-66H6.4 -6.02 1.23e-08 1.58e-05 -0.77 -0.44 Alcohol consumption over the past year; chr16:11067072 chr16:11056556~11057034:+ PAAD cis rs7174755 0.558 rs11071975 ENSG00000260657.2 RP11-315D16.4 -6.02 1.23e-08 1.58e-05 -0.53 -0.44 Major depressive disorder; chr15:68037106 chr15:68267792~68277994:- PAAD cis rs7945705 0.869 rs11042154 ENSG00000254860.4 TMEM9B-AS1 6.02 1.24e-08 1.59e-05 0.49 0.44 Hemoglobin concentration; chr11:9008153 chr11:8964675~8977527:+ PAAD cis rs6570726 0.599 rs4398765 ENSG00000235652.6 RP11-545I5.3 6.02 1.24e-08 1.59e-05 0.37 0.44 Lobe attachment (rater-scored or self-reported); chr6:145613870 chr6:145799409~145886585:+ PAAD cis rs9322193 0.923 rs10747276 ENSG00000216906.2 RP11-350J20.9 6.02 1.25e-08 1.6e-05 0.56 0.44 Lung cancer; chr6:149758739 chr6:149904243~149906418:+ PAAD cis rs6452524 0.904 rs10076056 ENSG00000249664.1 CTD-2227C6.2 -6.02 1.25e-08 1.6e-05 -0.52 -0.44 Hypertension (SNP x SNP interaction); chr5:83161702 chr5:83012285~83013109:- PAAD cis rs9322193 0.923 rs9800614 ENSG00000216906.2 RP11-350J20.9 6.02 1.25e-08 1.61e-05 0.55 0.44 Lung cancer; chr6:149644604 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9689716 ENSG00000216906.2 RP11-350J20.9 6.02 1.25e-08 1.61e-05 0.55 0.44 Lung cancer; chr6:149655662 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9322207 ENSG00000216906.2 RP11-350J20.9 6.02 1.25e-08 1.61e-05 0.55 0.44 Lung cancer; chr6:149657185 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9968911 ENSG00000216906.2 RP11-350J20.9 6.02 1.25e-08 1.61e-05 0.55 0.44 Lung cancer; chr6:149657419 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9322208 ENSG00000216906.2 RP11-350J20.9 6.02 1.25e-08 1.61e-05 0.55 0.44 Lung cancer; chr6:149658547 chr6:149904243~149906418:+ PAAD cis rs7429990 0.864 rs13091913 ENSG00000229759.1 MRPS18AP1 -6.02 1.26e-08 1.61e-05 -0.48 -0.44 Educational attainment (years of education); chr3:47762307 chr3:48256350~48256938:- PAAD cis rs950169 1 rs11638394 ENSG00000259728.4 LINC00933 6.02 1.26e-08 1.61e-05 0.56 0.44 Schizophrenia; chr15:84110176 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs35658069 ENSG00000259728.4 LINC00933 6.02 1.26e-08 1.61e-05 0.56 0.44 Schizophrenia; chr15:84111394 chr15:84570649~84580175:+ PAAD cis rs17301013 0.507 rs333422 ENSG00000227373.4 RP11-160H22.5 -6.02 1.26e-08 1.62e-05 -0.65 -0.44 Systemic lupus erythematosus; chr1:174664167 chr1:174115300~174160004:- PAAD cis rs9322193 0.923 rs35961297 ENSG00000216906.2 RP11-350J20.9 6.02 1.26e-08 1.62e-05 0.55 0.44 Lung cancer; chr6:149667929 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs35967444 ENSG00000216906.2 RP11-350J20.9 6.02 1.26e-08 1.62e-05 0.55 0.44 Lung cancer; chr6:149675588 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs62439842 ENSG00000216906.2 RP11-350J20.9 6.02 1.26e-08 1.62e-05 0.55 0.44 Lung cancer; chr6:149675847 chr6:149904243~149906418:+ PAAD cis rs11098499 0.73 rs78971550 ENSG00000245958.5 RP11-33B1.1 -6.02 1.26e-08 1.62e-05 -0.32 -0.44 Corneal astigmatism; chr4:119359886 chr4:119454791~119552025:+ PAAD cis rs11098499 0.645 rs78422072 ENSG00000245958.5 RP11-33B1.1 -6.02 1.26e-08 1.62e-05 -0.32 -0.44 Corneal astigmatism; chr4:119359887 chr4:119454791~119552025:+ PAAD cis rs4774565 0.762 rs7182201 ENSG00000244879.4 GABPB1-AS1 -6.02 1.26e-08 1.62e-05 -0.41 -0.44 Breast cancer; chr15:50364377 chr15:50354959~50372202:+ PAAD cis rs4774565 0.724 rs2555486 ENSG00000244879.4 GABPB1-AS1 6.02 1.26e-08 1.62e-05 0.41 0.44 Breast cancer; chr15:50363924 chr15:50354959~50372202:+ PAAD cis rs17301013 0.507 rs3118990 ENSG00000227373.4 RP11-160H22.5 -6.02 1.27e-08 1.62e-05 -0.63 -0.44 Systemic lupus erythematosus; chr1:174818586 chr1:174115300~174160004:- PAAD cis rs9322193 0.962 rs9688412 ENSG00000216906.2 RP11-350J20.9 -6.02 1.27e-08 1.62e-05 -0.56 -0.44 Lung cancer; chr6:149803147 chr6:149904243~149906418:+ PAAD cis rs42490 0.934 rs218947 ENSG00000251136.7 RP11-37B2.1 6.02 1.27e-08 1.62e-05 0.41 0.44 Leprosy; chr8:89705148 chr8:89609409~89757727:- PAAD cis rs2882667 0.858 rs66839813 ENSG00000253404.1 AC034243.1 6.02 1.28e-08 1.64e-05 0.55 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139106633 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs13174479 ENSG00000253404.1 AC034243.1 6.02 1.28e-08 1.64e-05 0.55 0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139108481 chr5:138744434~138753309:- PAAD cis rs42490 1 rs405734 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89756211 chr8:89609409~89757727:- PAAD cis rs42490 1 rs402886 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89760272 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs39500 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89760437 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs39761 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89760692 chr8:89609409~89757727:- PAAD cis rs42490 0.934 rs43225 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89760776 chr8:89609409~89757727:- PAAD cis rs42490 1 rs40452 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89765931 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs39503 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89767579 chr8:89609409~89757727:- PAAD cis rs42490 1 rs447618 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89773457 chr8:89609409~89757727:- PAAD cis rs42490 1 rs40545 ENSG00000251136.7 RP11-37B2.1 -6.02 1.29e-08 1.64e-05 -0.39 -0.44 Leprosy; chr8:89777483 chr8:89609409~89757727:- PAAD cis rs6570726 0.599 rs9376951 ENSG00000235652.6 RP11-545I5.3 6.01 1.29e-08 1.64e-05 0.37 0.44 Lobe attachment (rater-scored or self-reported); chr6:145577775 chr6:145799409~145886585:+ PAAD cis rs6570726 0.62 rs12201226 ENSG00000235652.6 RP11-545I5.3 6.01 1.29e-08 1.64e-05 0.37 0.44 Lobe attachment (rater-scored or self-reported); chr6:145592283 chr6:145799409~145886585:+ PAAD cis rs7104764 0.507 rs7121085 ENSG00000277290.1 RP11-326C3.16 -6.01 1.29e-08 1.64e-05 -0.43 -0.44 Menarche (age at onset); chr11:258523 chr11:243099~243483:- PAAD cis rs11673344 0.832 rs56210764 ENSG00000226686.6 LINC01535 6.01 1.29e-08 1.64e-05 0.62 0.44 Obesity-related traits; chr19:37125970 chr19:37251912~37265535:+ PAAD cis rs9322193 0.923 rs9767652 ENSG00000216906.2 RP11-350J20.9 6.01 1.29e-08 1.64e-05 0.56 0.44 Lung cancer; chr6:149734502 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs10782314 ENSG00000216906.2 RP11-350J20.9 6.01 1.29e-08 1.64e-05 0.56 0.44 Lung cancer; chr6:149735527 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9478291 ENSG00000216906.2 RP11-350J20.9 6.01 1.3e-08 1.66e-05 0.55 0.44 Lung cancer; chr6:149729434 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9479494 ENSG00000216906.2 RP11-350J20.9 6.01 1.3e-08 1.66e-05 0.55 0.44 Lung cancer; chr6:149739108 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9800806 ENSG00000216906.2 RP11-350J20.9 6.01 1.3e-08 1.66e-05 0.55 0.44 Lung cancer; chr6:149740350 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9688517 ENSG00000216906.2 RP11-350J20.9 6.01 1.3e-08 1.66e-05 0.55 0.44 Lung cancer; chr6:149740655 chr6:149904243~149906418:+ PAAD cis rs4722166 0.63 rs10950916 ENSG00000179428.2 AC073072.5 -6.01 1.31e-08 1.66e-05 -0.41 -0.44 Lung cancer; chr7:22760048 chr7:22725395~22727620:- PAAD cis rs56205728 0.606 rs3784397 ENSG00000273855.1 RP11-133K1.12 6.01 1.31e-08 1.67e-05 0.5 0.44 Schizophrenia; chr15:40304643 chr15:40285468~40285909:- PAAD cis rs6570726 0.846 rs7773939 ENSG00000235652.6 RP11-545I5.3 -6.01 1.32e-08 1.68e-05 -0.37 -0.44 Lobe attachment (rater-scored or self-reported); chr6:145606248 chr6:145799409~145886585:+ PAAD cis rs2739330 0.828 rs4822454 ENSG00000250470.1 AP000351.3 6.01 1.32e-08 1.68e-05 0.61 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23976904~23977585:- PAAD cis rs3762637 0.765 rs28718697 ENSG00000272758.4 RP11-299J3.8 -6.01 1.33e-08 1.69e-05 -0.73 -0.44 LDL cholesterol levels; chr3:122430650 chr3:122416207~122443180:+ PAAD cis rs11673344 0.665 rs74435359 ENSG00000226686.6 LINC01535 6.01 1.34e-08 1.69e-05 0.6 0.44 Obesity-related traits; chr19:36955252 chr19:37251912~37265535:+ PAAD cis rs748404 0.56 rs529611 ENSG00000249839.1 AC011330.5 -6.01 1.34e-08 1.7e-05 -0.66 -0.44 Lung cancer; chr15:43513790 chr15:43663654~43684339:- PAAD cis rs7772486 0.534 rs34541797 ENSG00000235652.6 RP11-545I5.3 6.01 1.34e-08 1.7e-05 0.36 0.44 Lobe attachment (rater-scored or self-reported); chr6:145884168 chr6:145799409~145886585:+ PAAD cis rs7772486 0.597 rs6570732 ENSG00000235652.6 RP11-545I5.3 -6.01 1.34e-08 1.7e-05 -0.36 -0.44 Lobe attachment (rater-scored or self-reported); chr6:145924015 chr6:145799409~145886585:+ PAAD cis rs7772486 0.597 rs6912351 ENSG00000235652.6 RP11-545I5.3 -6.01 1.34e-08 1.7e-05 -0.36 -0.44 Lobe attachment (rater-scored or self-reported); chr6:145942935 chr6:145799409~145886585:+ PAAD cis rs11155671 0.53 rs9397420 ENSG00000223701.3 RAET1E-AS1 -6.01 1.35e-08 1.71e-05 -0.51 -0.44 Testicular germ cell tumor; chr6:149885645 chr6:149884431~149919508:+ PAAD cis rs4972806 0.814 rs6710370 ENSG00000226363.3 HAGLROS -6 1.35e-08 1.71e-05 -0.53 -0.44 IgG glycosylation; chr2:176181241 chr2:176177717~176179008:+ PAAD cis rs4972806 0.814 rs4246626 ENSG00000226363.3 HAGLROS -6 1.35e-08 1.71e-05 -0.53 -0.44 IgG glycosylation; chr2:176181702 chr2:176177717~176179008:+ PAAD cis rs7772486 0.875 rs1331639 ENSG00000235652.6 RP11-545I5.3 -6 1.36e-08 1.72e-05 -0.36 -0.44 Lobe attachment (rater-scored or self-reported); chr6:146110733 chr6:145799409~145886585:+ PAAD cis rs1150668 0.768 rs1150709 ENSG00000216901.1 AL022393.7 -6 1.36e-08 1.72e-05 -0.49 -0.44 Pubertal anthropometrics; chr6:28239585 chr6:28176188~28176674:+ PAAD cis rs950169 0.579 rs881983 ENSG00000225151.9 GOLGA2P7 -6 1.37e-08 1.73e-05 -0.55 -0.44 Schizophrenia; chr15:83978556 chr15:84199311~84230136:- PAAD cis rs1075265 0.87 rs1421617 ENSG00000233266.1 HMGB1P31 6 1.37e-08 1.74e-05 0.56 0.44 Chronotype;Morning vs. evening chronotype; chr2:54032995 chr2:54051334~54051760:+ PAAD cis rs11098499 0.754 rs1814813 ENSG00000245958.5 RP11-33B1.1 6 1.37e-08 1.74e-05 0.3 0.44 Corneal astigmatism; chr4:119337052 chr4:119454791~119552025:+ PAAD cis rs1061377 0.71 rs12503506 ENSG00000249207.1 RP11-360F5.1 -6 1.37e-08 1.74e-05 -0.46 -0.44 Uric acid levels; chr4:39082553 chr4:39112677~39126818:- PAAD cis rs2117029 0.555 rs2279596 ENSG00000258017.1 RP11-386G11.10 -6 1.38e-08 1.74e-05 -0.54 -0.44 Intelligence (multi-trait analysis); chr12:49104968 chr12:49127782~49147869:+ PAAD cis rs1075232 1 rs12437749 ENSG00000270055.1 CTD-3092A11.2 -6 1.38e-08 1.74e-05 -0.98 -0.44 Survival in colorectal cancer (non-distant metastatic); chr15:31357685 chr15:30487963~30490313:+ PAAD cis rs7811142 0.945 rs34989573 ENSG00000242294.5 STAG3L5P 6 1.39e-08 1.75e-05 0.34 0.44 Platelet count; chr7:100500272 chr7:100336079~100351900:+ PAAD cis rs7811142 0.945 rs6974282 ENSG00000242294.5 STAG3L5P 6 1.39e-08 1.75e-05 0.34 0.44 Platelet count; chr7:100500672 chr7:100336079~100351900:+ PAAD cis rs9322193 0.923 rs10872644 ENSG00000216906.2 RP11-350J20.9 6 1.39e-08 1.76e-05 0.55 0.44 Lung cancer; chr6:149741819 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs1572229 ENSG00000216906.2 RP11-350J20.9 6 1.39e-08 1.76e-05 0.55 0.44 Lung cancer; chr6:149743841 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs10872646 ENSG00000216906.2 RP11-350J20.9 6 1.39e-08 1.76e-05 0.55 0.44 Lung cancer; chr6:149746539 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs12528279 ENSG00000216906.2 RP11-350J20.9 6 1.39e-08 1.76e-05 0.55 0.44 Lung cancer; chr6:149750892 chr6:149904243~149906418:+ PAAD cis rs9322193 0.809 rs9479808 ENSG00000216906.2 RP11-350J20.9 6 1.39e-08 1.76e-05 0.55 0.44 Lung cancer; chr6:149751328 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs62441284 ENSG00000216906.2 RP11-350J20.9 6 1.39e-08 1.76e-05 0.55 0.44 Lung cancer; chr6:149751542 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9767105 ENSG00000216906.2 RP11-350J20.9 6 1.39e-08 1.76e-05 0.56 0.44 Lung cancer; chr6:149659591 chr6:149904243~149906418:+ PAAD cis rs992157 0.835 rs6729058 ENSG00000261338.2 RP11-378A13.1 -6 1.39e-08 1.76e-05 -0.52 -0.44 Colorectal cancer; chr2:218283646 chr2:218255319~218257366:+ PAAD cis rs992157 0.775 rs7559428 ENSG00000261338.2 RP11-378A13.1 -6 1.39e-08 1.76e-05 -0.52 -0.44 Colorectal cancer; chr2:218285515 chr2:218255319~218257366:+ PAAD cis rs992157 0.804 rs7559525 ENSG00000261338.2 RP11-378A13.1 -6 1.39e-08 1.76e-05 -0.52 -0.44 Colorectal cancer; chr2:218285584 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs13005100 ENSG00000261338.2 RP11-378A13.1 -6 1.39e-08 1.76e-05 -0.52 -0.44 Colorectal cancer; chr2:218287044 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs13031757 ENSG00000261338.2 RP11-378A13.1 -6 1.39e-08 1.76e-05 -0.52 -0.44 Colorectal cancer; chr2:218287203 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs34353396 ENSG00000261338.2 RP11-378A13.1 -6 1.39e-08 1.76e-05 -0.52 -0.44 Colorectal cancer; chr2:218289259 chr2:218255319~218257366:+ PAAD cis rs5760092 0.755 rs915589 ENSG00000250470.1 AP000351.3 -6 1.4e-08 1.76e-05 -0.71 -0.44 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23976904~23977585:- PAAD cis rs4722166 0.598 rs7804146 ENSG00000179428.2 AC073072.5 -6 1.4e-08 1.77e-05 -0.38 -0.44 Lung cancer; chr7:22761310 chr7:22725395~22727620:- PAAD cis rs2115630 0.846 rs8024538 ENSG00000259728.4 LINC00933 -6 1.4e-08 1.77e-05 -0.54 -0.44 P wave terminal force; chr15:84825188 chr15:84570649~84580175:+ PAAD cis rs72772090 0.539 rs72773981 ENSG00000248734.2 CTD-2260A17.1 -6 1.41e-08 1.77e-05 -0.59 -0.44 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96820356 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72773986 ENSG00000248734.2 CTD-2260A17.1 -6 1.41e-08 1.77e-05 -0.59 -0.44 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96824014 chr5:96784777~96785999:+ PAAD cis rs7615952 0.932 rs11922218 ENSG00000171084.14 FAM86JP 6 1.41e-08 1.77e-05 0.59 0.44 Blood pressure (smoking interaction); chr3:125912446 chr3:125916620~125930024:+ PAAD cis rs7615952 0.866 rs11922276 ENSG00000171084.14 FAM86JP 6 1.41e-08 1.77e-05 0.59 0.44 Blood pressure (smoking interaction); chr3:125912483 chr3:125916620~125930024:+ PAAD cis rs9322193 0.923 rs4354168 ENSG00000216906.2 RP11-350J20.9 6 1.41e-08 1.78e-05 0.55 0.44 Lung cancer; chr6:149696642 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs4455682 ENSG00000216906.2 RP11-350J20.9 6 1.41e-08 1.78e-05 0.55 0.44 Lung cancer; chr6:149700161 chr6:149904243~149906418:+ PAAD cis rs17301013 0.861 rs1793319 ENSG00000227373.4 RP11-160H22.5 6 1.41e-08 1.78e-05 0.59 0.44 Systemic lupus erythematosus; chr1:174795470 chr1:174115300~174160004:- PAAD cis rs732716 0.74 rs62129356 ENSG00000267980.1 AC007292.6 -6 1.41e-08 1.78e-05 -0.61 -0.44 Mean corpuscular volume; chr19:4400317 chr19:4363789~4364640:+ PAAD cis rs1061377 1 rs56119980 ENSG00000249685.1 RP11-360F5.3 6 1.42e-08 1.79e-05 0.48 0.44 Uric acid levels; chr4:39139390 chr4:39133913~39135608:+ PAAD cis rs6504950 0.79 rs8076984 ENSG00000275710.1 RP11-257O5.4 6 1.42e-08 1.79e-05 0.57 0.44 Breast cancer; chr17:54958067 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs17745231 ENSG00000275710.1 RP11-257O5.4 6 1.42e-08 1.79e-05 0.57 0.44 Breast cancer; chr17:54959168 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs12938118 ENSG00000275710.1 RP11-257O5.4 6 1.42e-08 1.79e-05 0.57 0.44 Breast cancer; chr17:54959998 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs1802212 ENSG00000275710.1 RP11-257O5.4 6 1.42e-08 1.79e-05 0.57 0.44 Breast cancer; chr17:54961293 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs17817901 ENSG00000275710.1 RP11-257O5.4 6 1.42e-08 1.79e-05 0.57 0.44 Breast cancer; chr17:54961384 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs12150038 ENSG00000275710.1 RP11-257O5.4 6 1.42e-08 1.79e-05 0.57 0.44 Breast cancer; chr17:54964159 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs12951542 ENSG00000275710.1 RP11-257O5.4 6 1.42e-08 1.79e-05 0.57 0.44 Breast cancer; chr17:54964604 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs72831295 ENSG00000275710.1 RP11-257O5.4 6 1.42e-08 1.79e-05 0.57 0.44 Breast cancer; chr17:54966443 chr17:54964474~54964679:+ PAAD cis rs1075265 0.87 rs1363062 ENSG00000233266.1 HMGB1P31 5.99 1.43e-08 1.8e-05 0.58 0.44 Chronotype;Morning vs. evening chronotype; chr2:54054625 chr2:54051334~54051760:+ PAAD cis rs1891275 0.551 rs2421621 ENSG00000228701.1 TNKS2-AS1 -5.99 1.44e-08 1.81e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91640344 chr10:91782839~91798291:- PAAD cis rs2929278 0.617 rs3087657 ENSG00000249839.1 AC011330.5 -5.99 1.44e-08 1.81e-05 -0.61 -0.44 Schizophrenia; chr15:43771661 chr15:43663654~43684339:- PAAD cis rs10262624 0.935 rs6966641 ENSG00000234286.1 AC006026.13 -5.99 1.44e-08 1.81e-05 -0.5 -0.44 Schizophrenia; chr7:23866979 chr7:23680195~23680786:- PAAD cis rs10262624 0.901 rs6966655 ENSG00000234286.1 AC006026.13 -5.99 1.44e-08 1.81e-05 -0.5 -0.44 Schizophrenia; chr7:23867010 chr7:23680195~23680786:- PAAD cis rs858239 0.896 rs1637192 ENSG00000226816.2 AC005082.12 5.99 1.45e-08 1.82e-05 0.51 0.44 Cerebrospinal fluid biomarker levels; chr7:23220895 chr7:23206013~23208045:+ PAAD cis rs9322193 0.884 rs2064521 ENSG00000216906.2 RP11-350J20.9 -5.99 1.45e-08 1.83e-05 -0.54 -0.44 Lung cancer; chr6:149625336 chr6:149904243~149906418:+ PAAD cis rs6683071 0.54 rs1391558 ENSG00000272750.1 RP11-378J18.8 5.99 1.45e-08 1.83e-05 0.55 0.44 Cognitive performance; chr1:222674687 chr1:222658867~222661512:- PAAD cis rs992157 0.835 rs10932768 ENSG00000261338.2 RP11-378A13.1 -5.99 1.45e-08 1.83e-05 -0.52 -0.44 Colorectal cancer; chr2:218281476 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs7585702 ENSG00000261338.2 RP11-378A13.1 -5.99 1.45e-08 1.83e-05 -0.52 -0.44 Colorectal cancer; chr2:218281884 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs2292555 ENSG00000261338.2 RP11-378A13.1 -5.99 1.45e-08 1.83e-05 -0.52 -0.44 Colorectal cancer; chr2:218282159 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs10932769 ENSG00000261338.2 RP11-378A13.1 -5.99 1.45e-08 1.83e-05 -0.52 -0.44 Colorectal cancer; chr2:218282522 chr2:218255319~218257366:+ PAAD cis rs1075232 0.826 rs12437800 ENSG00000270055.1 CTD-3092A11.2 -5.99 1.46e-08 1.83e-05 -0.98 -0.44 Survival in colorectal cancer (non-distant metastatic); chr15:31379229 chr15:30487963~30490313:+ PAAD cis rs875971 0.895 rs4145009 ENSG00000237310.1 GS1-124K5.4 -5.99 1.46e-08 1.83e-05 -0.44 -0.44 Aortic root size; chr7:66261628 chr7:66493706~66495474:+ PAAD cis rs11155671 0.53 rs9383912 ENSG00000223701.3 RAET1E-AS1 5.99 1.46e-08 1.84e-05 0.51 0.44 Testicular germ cell tumor; chr6:149885479 chr6:149884431~149919508:+ PAAD cis rs9322193 0.923 rs1934534 ENSG00000216906.2 RP11-350J20.9 5.99 1.48e-08 1.85e-05 0.54 0.44 Lung cancer; chr6:149711896 chr6:149904243~149906418:+ PAAD cis rs2739330 0.857 rs9608229 ENSG00000206090.4 AP000350.7 5.99 1.48e-08 1.85e-05 0.57 0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:24002918 chr22:23939998~23942798:+ PAAD cis rs1799810 0.899 rs4662726 ENSG00000236682.1 AC068282.3 5.99 1.48e-08 1.85e-05 0.58 0.44 Self-rated health; chr2:127413086 chr2:127389130~127400580:+ PAAD cis rs11098499 0.779 rs10857066 ENSG00000245958.5 RP11-33B1.1 -5.99 1.48e-08 1.85e-05 -0.32 -0.44 Corneal astigmatism; chr4:119365441 chr4:119454791~119552025:+ PAAD cis rs1891275 0.527 rs35812291 ENSG00000228701.1 TNKS2-AS1 -5.99 1.48e-08 1.85e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91642584 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs4933681 ENSG00000228701.1 TNKS2-AS1 -5.99 1.48e-08 1.85e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91643365 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs7071844 ENSG00000228701.1 TNKS2-AS1 -5.99 1.48e-08 1.85e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91644092 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs4933684 ENSG00000228701.1 TNKS2-AS1 -5.99 1.48e-08 1.85e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91647805 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs4933687 ENSG00000228701.1 TNKS2-AS1 -5.99 1.48e-08 1.85e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91650642 chr10:91782839~91798291:- PAAD cis rs6700559 0.935 rs10920001 ENSG00000260088.1 RP11-92G12.3 -5.99 1.48e-08 1.86e-05 -0.58 -0.44 Coronary artery disease; chr1:200682420 chr1:200669507~200694250:+ PAAD cis rs8040855 0.576 rs62022528 ENSG00000259295.5 CSPG4P12 5.99 1.49e-08 1.86e-05 0.54 0.44 Bulimia nervosa; chr15:84992030 chr15:85191438~85213905:+ PAAD cis rs1061377 0.748 rs12649085 ENSG00000249207.1 RP11-360F5.1 -5.99 1.49e-08 1.86e-05 -0.47 -0.44 Uric acid levels; chr4:39106459 chr4:39112677~39126818:- PAAD cis rs11651753 0.561 rs4794261 ENSG00000264920.1 RP11-6N17.4 -5.99 1.49e-08 1.86e-05 -0.5 -0.44 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47904980 chr17:47891255~47895812:- PAAD cis rs11651753 0.561 rs1108833 ENSG00000264920.1 RP11-6N17.4 -5.99 1.49e-08 1.86e-05 -0.5 -0.44 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47905431 chr17:47891255~47895812:- PAAD cis rs11651753 0.561 rs7211859 ENSG00000264920.1 RP11-6N17.4 -5.99 1.49e-08 1.86e-05 -0.5 -0.44 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47908916 chr17:47891255~47895812:- PAAD cis rs2739330 0.627 rs9608219 ENSG00000099984.9 GSTT2 -5.99 1.49e-08 1.86e-05 -0.58 -0.44 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23980123~23983911:+ PAAD cis rs73086581 0.838 rs73088424 ENSG00000229539.1 RP11-119B16.2 5.99 1.49e-08 1.87e-05 0.69 0.44 Response to antidepressants in depression; chr20:4020359 chr20:3888239~3888868:- PAAD cis rs35160687 0.901 rs7571424 ENSG00000273080.1 RP11-301O19.1 5.98 1.5e-08 1.87e-05 0.49 0.44 Night sleep phenotypes; chr2:86312037 chr2:86195590~86196049:+ PAAD cis rs11651753 0.561 rs11654010 ENSG00000264920.1 RP11-6N17.4 5.98 1.5e-08 1.87e-05 0.5 0.44 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47883499 chr17:47891255~47895812:- PAAD cis rs17826219 0.561 rs11655876 ENSG00000266490.1 CTD-2349P21.9 5.98 1.5e-08 1.87e-05 0.53 0.44 Body mass index; chr17:30690132 chr17:30792372~30792833:+ PAAD cis rs10262624 0.967 rs13235406 ENSG00000234286.1 AC006026.13 -5.98 1.5e-08 1.87e-05 -0.49 -0.44 Schizophrenia; chr7:23879212 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs11767124 ENSG00000234286.1 AC006026.13 -5.98 1.5e-08 1.87e-05 -0.49 -0.44 Schizophrenia; chr7:23879461 chr7:23680195~23680786:- PAAD cis rs17301013 0.606 rs1407127 ENSG00000227373.4 RP11-160H22.5 -5.98 1.51e-08 1.88e-05 -0.64 -0.44 Systemic lupus erythematosus; chr1:174119548 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs56152378 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174106480 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4652179 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174107185 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs17353198 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174107439 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs17350991 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174114330 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs57407575 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174115504 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6656491 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174127524 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs72711457 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174135385 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs6668008 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174138752 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs4652204 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174150682 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs56158362 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174166437 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs77379897 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174169373 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs56375942 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174176206 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs56404641 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174176323 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs56239105 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174179346 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs17300775 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174191901 chr1:174115300~174160004:- PAAD cis rs17301013 0.566 rs72711492 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174195464 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4650968 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174223322 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs4650969 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174229622 chr1:174115300~174160004:- PAAD cis rs17301013 0.581 rs72711501 ENSG00000227373.4 RP11-160H22.5 5.98 1.51e-08 1.88e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174233081 chr1:174115300~174160004:- PAAD cis rs453301 0.653 rs1045529 ENSG00000253893.2 FAM85B 5.98 1.51e-08 1.88e-05 0.58 0.44 Joint mobility (Beighton score); chr8:9032588 chr8:8167819~8226614:- PAAD cis rs8059260 0.604 rs76969865 ENSG00000274038.1 RP11-66H6.4 -5.98 1.51e-08 1.88e-05 -0.76 -0.44 Alcohol consumption over the past year; chr16:11050092 chr16:11056556~11057034:+ PAAD cis rs8059260 0.604 rs16957984 ENSG00000274038.1 RP11-66H6.4 -5.98 1.51e-08 1.88e-05 -0.76 -0.44 Alcohol consumption over the past year; chr16:11051105 chr16:11056556~11057034:+ PAAD cis rs8059260 0.604 rs78753859 ENSG00000274038.1 RP11-66H6.4 -5.98 1.51e-08 1.88e-05 -0.76 -0.44 Alcohol consumption over the past year; chr16:11052774 chr16:11056556~11057034:+ PAAD cis rs42490 1 rs43134 ENSG00000251136.7 RP11-37B2.1 5.98 1.51e-08 1.89e-05 0.39 0.44 Leprosy; chr8:89775732 chr8:89609409~89757727:- PAAD cis rs7429990 0.864 rs13098128 ENSG00000229759.1 MRPS18AP1 -5.98 1.51e-08 1.89e-05 -0.47 -0.44 Educational attainment (years of education); chr3:47756066 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7637950 ENSG00000229759.1 MRPS18AP1 -5.98 1.51e-08 1.89e-05 -0.47 -0.44 Educational attainment (years of education); chr3:47758204 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6442085 ENSG00000229759.1 MRPS18AP1 -5.98 1.51e-08 1.89e-05 -0.47 -0.44 Educational attainment (years of education); chr3:47760080 chr3:48256350~48256938:- PAAD cis rs10170846 0.861 rs6740452 ENSG00000261428.2 RP11-16P6.1 5.98 1.52e-08 1.89e-05 0.58 0.44 Schizophrenia (inflammation and infection response interaction); chr2:222653733 chr2:222566899~222569719:- PAAD cis rs10170846 0.789 rs972650 ENSG00000261428.2 RP11-16P6.1 5.98 1.52e-08 1.89e-05 0.58 0.44 Schizophrenia (inflammation and infection response interaction); chr2:222655568 chr2:222566899~222569719:- PAAD cis rs10170846 0.861 rs12694582 ENSG00000261428.2 RP11-16P6.1 5.98 1.52e-08 1.89e-05 0.58 0.44 Schizophrenia (inflammation and infection response interaction); chr2:222657236 chr2:222566899~222569719:- PAAD cis rs10170846 0.731 rs10180632 ENSG00000261428.2 RP11-16P6.1 5.98 1.52e-08 1.89e-05 0.58 0.44 Schizophrenia (inflammation and infection response interaction); chr2:222661665 chr2:222566899~222569719:- PAAD cis rs10170846 0.8 rs10180462 ENSG00000261428.2 RP11-16P6.1 5.98 1.52e-08 1.89e-05 0.58 0.44 Schizophrenia (inflammation and infection response interaction); chr2:222661666 chr2:222566899~222569719:- PAAD cis rs17301013 0.606 rs6425277 ENSG00000227373.4 RP11-160H22.5 5.98 1.52e-08 1.9e-05 0.62 0.44 Systemic lupus erythematosus; chr1:174296153 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs12074276 ENSG00000227373.4 RP11-160H22.5 5.98 1.52e-08 1.9e-05 0.62 0.44 Systemic lupus erythematosus; chr1:174302167 chr1:174115300~174160004:- PAAD cis rs17301013 0.659 rs59649440 ENSG00000227373.4 RP11-160H22.5 5.98 1.52e-08 1.9e-05 0.62 0.44 Systemic lupus erythematosus; chr1:174332024 chr1:174115300~174160004:- PAAD cis rs11098499 0.874 rs13139045 ENSG00000245958.5 RP11-33B1.1 -5.98 1.53e-08 1.9e-05 -0.32 -0.44 Corneal astigmatism; chr4:119247433 chr4:119454791~119552025:+ PAAD cis rs10875746 0.855 rs2269936 ENSG00000240399.1 RP1-228P16.1 -5.98 1.53e-08 1.9e-05 -0.49 -0.44 Longevity (90 years and older); chr12:48031452 chr12:48054813~48055591:- PAAD cis rs9532669 0.889 rs7333447 ENSG00000176268.5 CYCSP34 5.98 1.53e-08 1.9e-05 0.41 0.44 Cervical cancer; chr13:40917586 chr13:40863599~40863902:- PAAD cis rs4972806 0.668 rs2072588 ENSG00000226363.3 HAGLROS -5.98 1.53e-08 1.91e-05 -0.52 -0.44 IgG glycosylation; chr2:176178202 chr2:176177717~176179008:+ PAAD cis rs10262624 0.967 rs35988560 ENSG00000234286.1 AC006026.13 -5.98 1.53e-08 1.91e-05 -0.49 -0.44 Schizophrenia; chr7:23878561 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs17347692 ENSG00000234286.1 AC006026.13 -5.98 1.53e-08 1.91e-05 -0.49 -0.44 Schizophrenia; chr7:23878748 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs17347733 ENSG00000234286.1 AC006026.13 -5.98 1.53e-08 1.91e-05 -0.49 -0.44 Schizophrenia; chr7:23878891 chr7:23680195~23680786:- PAAD cis rs10262624 0.967 rs2188845 ENSG00000234286.1 AC006026.13 -5.98 1.53e-08 1.91e-05 -0.5 -0.44 Schizophrenia; chr7:23882391 chr7:23680195~23680786:- PAAD cis rs7188445 0.932 rs17689159 ENSG00000261390.4 RP11-345M22.2 -5.98 1.54e-08 1.91e-05 -0.59 -0.44 Urate levels; chr16:79708493 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs73575076 ENSG00000261390.4 RP11-345M22.2 -5.98 1.54e-08 1.91e-05 -0.59 -0.44 Urate levels; chr16:79710251 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs17767383 ENSG00000261390.4 RP11-345M22.2 -5.98 1.54e-08 1.91e-05 -0.59 -0.44 Urate levels; chr16:79710504 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs17689455 ENSG00000261390.4 RP11-345M22.2 -5.98 1.54e-08 1.91e-05 -0.59 -0.44 Urate levels; chr16:79712438 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs73575083 ENSG00000261390.4 RP11-345M22.2 -5.98 1.54e-08 1.91e-05 -0.59 -0.44 Urate levels; chr16:79713958 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs73575085 ENSG00000261390.4 RP11-345M22.2 -5.98 1.54e-08 1.91e-05 -0.59 -0.44 Urate levels; chr16:79714179 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs73575086 ENSG00000261390.4 RP11-345M22.2 -5.98 1.54e-08 1.91e-05 -0.59 -0.44 Urate levels; chr16:79714588 chr16:79715232~79770563:- PAAD cis rs1062177 0.901 rs1549622 ENSG00000213433.5 RPLP1P6 -5.98 1.54e-08 1.92e-05 -0.51 -0.44 Preschool internalizing problems; chr5:151886488 chr5:151765859~151766378:- PAAD cis rs3931020 0.508 rs11485298 ENSG00000272864.1 RP11-17E13.2 -5.98 1.54e-08 1.92e-05 -0.54 -0.44 Resistin levels; chr1:74752068 chr1:74698769~74699333:- PAAD cis rs3931020 0.508 rs4145871 ENSG00000272864.1 RP11-17E13.2 -5.98 1.54e-08 1.92e-05 -0.54 -0.44 Resistin levels; chr1:74753020 chr1:74698769~74699333:- PAAD cis rs7174755 0.637 rs113002386 ENSG00000260657.2 RP11-315D16.4 5.98 1.55e-08 1.93e-05 0.53 0.44 Major depressive disorder; chr15:68172375 chr15:68267792~68277994:- PAAD cis rs2337406 0.5 rs57619050 ENSG00000274576.2 IGHV2-70 -5.98 1.55e-08 1.93e-05 -0.59 -0.44 Alzheimer's disease (late onset); chr14:106820074 chr14:106770577~106771020:- PAAD cis rs1075232 1 rs9672214 ENSG00000270055.1 CTD-3092A11.2 -5.98 1.57e-08 1.95e-05 -1.04 -0.44 Survival in colorectal cancer (non-distant metastatic); chr15:31385572 chr15:30487963~30490313:+ PAAD cis rs17301013 0.606 rs6666588 ENSG00000227373.4 RP11-160H22.5 5.98 1.57e-08 1.95e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174248972 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs72713504 ENSG00000227373.4 RP11-160H22.5 5.98 1.57e-08 1.95e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174251916 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs72713505 ENSG00000227373.4 RP11-160H22.5 5.98 1.57e-08 1.95e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174255911 chr1:174115300~174160004:- PAAD cis rs1075265 0.87 rs17268179 ENSG00000233266.1 HMGB1P31 5.97 1.58e-08 1.96e-05 0.56 0.44 Chronotype;Morning vs. evening chronotype; chr2:54036876 chr2:54051334~54051760:+ PAAD cis rs1075265 0.818 rs12713253 ENSG00000233266.1 HMGB1P31 5.97 1.58e-08 1.96e-05 0.56 0.44 Chronotype;Morning vs. evening chronotype; chr2:54037323 chr2:54051334~54051760:+ PAAD cis rs2455601 1 rs12418190 ENSG00000254860.4 TMEM9B-AS1 5.97 1.58e-08 1.96e-05 0.65 0.44 Schizophrenia; chr11:8878271 chr11:8964675~8977527:+ PAAD cis rs2455601 1 rs12223690 ENSG00000254860.4 TMEM9B-AS1 5.97 1.58e-08 1.96e-05 0.65 0.44 Schizophrenia; chr11:8880277 chr11:8964675~8977527:+ PAAD cis rs2455601 1 rs7104661 ENSG00000254860.4 TMEM9B-AS1 5.97 1.58e-08 1.96e-05 0.65 0.44 Schizophrenia; chr11:8880954 chr11:8964675~8977527:+ PAAD cis rs7772486 0.597 rs7746618 ENSG00000235652.6 RP11-545I5.3 -5.97 1.59e-08 1.97e-05 -0.36 -0.44 Lobe attachment (rater-scored or self-reported); chr6:145960231 chr6:145799409~145886585:+ PAAD cis rs12458462 0.892 rs58675823 ENSG00000274828.1 RP11-567M16.6 5.97 1.59e-08 1.97e-05 0.43 0.44 Monocyte count; chr18:79703672 chr18:79677287~79679358:- PAAD cis rs9640161 0.83 rs3757425 ENSG00000261305.1 RP4-584D14.7 5.97 1.59e-08 1.98e-05 0.6 0.44 Blood protein levels;Circulating chemerin levels; chr7:150370551 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs3757424 ENSG00000261305.1 RP4-584D14.7 5.97 1.59e-08 1.98e-05 0.6 0.44 Blood protein levels;Circulating chemerin levels; chr7:150370590 chr7:150341771~150342607:+ PAAD cis rs9322193 0.884 rs9688699 ENSG00000216906.2 RP11-350J20.9 5.97 1.59e-08 1.98e-05 0.56 0.44 Lung cancer; chr6:149733680 chr6:149904243~149906418:+ PAAD cis rs853679 0.567 rs13209596 ENSG00000204709.4 LINC01556 5.97 1.6e-08 1.99e-05 0.64 0.44 Depression; chr6:28428413 chr6:28943877~28944537:+ PAAD cis rs853679 0.567 rs9969098 ENSG00000204709.4 LINC01556 5.97 1.6e-08 1.99e-05 0.64 0.44 Depression; chr6:28430971 chr6:28943877~28944537:+ PAAD cis rs853679 0.567 rs7740429 ENSG00000204709.4 LINC01556 5.97 1.6e-08 1.99e-05 0.64 0.44 Depression; chr6:28431469 chr6:28943877~28944537:+ PAAD cis rs853679 0.567 rs16894106 ENSG00000204709.4 LINC01556 5.97 1.6e-08 1.99e-05 0.64 0.44 Depression; chr6:28432562 chr6:28943877~28944537:+ PAAD cis rs7188445 0.933 rs11644082 ENSG00000261390.4 RP11-345M22.2 -5.97 1.6e-08 1.99e-05 -0.59 -0.44 Urate levels; chr16:79680519 chr16:79715232~79770563:- PAAD cis rs7188445 0.933 rs12449109 ENSG00000261390.4 RP11-345M22.2 -5.97 1.6e-08 1.99e-05 -0.59 -0.44 Urate levels; chr16:79682146 chr16:79715232~79770563:- PAAD cis rs27434 0.51 rs27038 ENSG00000272109.1 CTD-2260A17.3 -5.97 1.6e-08 1.99e-05 -0.7 -0.44 Ankylosing spondylitis; chr5:96777250 chr5:96804353~96806105:+ PAAD cis rs17301013 0.507 rs2760057 ENSG00000227373.4 RP11-160H22.5 5.97 1.61e-08 1.99e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174743384 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs392307 ENSG00000227373.4 RP11-160H22.5 5.97 1.61e-08 1.99e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174744243 chr1:174115300~174160004:- PAAD cis rs10262624 1 rs10238070 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23870172 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs2023787 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23875521 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs2023786 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23875534 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs17347505 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23875664 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs12671624 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23875794 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs12671584 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23875803 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs10262624 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23876057 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs9769098 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23877113 chr7:23680195~23680786:- PAAD cis rs10262624 0.967 rs12333669 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23877267 chr7:23680195~23680786:- PAAD cis rs10262624 0.935 rs10487596 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23877458 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs10950973 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23877658 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs10950974 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23877661 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs10950975 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23877861 chr7:23680195~23680786:- PAAD cis rs10262624 0.967 rs13244145 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23878123 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs13244265 ENSG00000234286.1 AC006026.13 -5.97 1.61e-08 2e-05 -0.49 -0.44 Schizophrenia; chr7:23878284 chr7:23680195~23680786:- PAAD cis rs453301 0.653 rs7016139 ENSG00000253893.2 FAM85B 5.97 1.62e-08 2e-05 0.57 0.44 Joint mobility (Beighton score); chr8:9037960 chr8:8167819~8226614:- PAAD cis rs6061231 0.798 rs2427308 ENSG00000273619.1 RP5-908M14.9 -5.97 1.62e-08 2.01e-05 -0.4 -0.44 Colorectal cancer; chr20:62394395 chr20:62386303~62386970:- PAAD cis rs3814244 0.966 rs10784666 ENSG00000255733.4 IFNG-AS1 -5.97 1.62e-08 2.01e-05 -0.38 -0.44 Itch intensity from mosquito bite adjusted by bite size; chr12:68021923 chr12:67989445~68234686:+ PAAD cis rs3814244 0.966 rs10784667 ENSG00000255733.4 IFNG-AS1 -5.97 1.62e-08 2.01e-05 -0.38 -0.44 Itch intensity from mosquito bite adjusted by bite size; chr12:68021996 chr12:67989445~68234686:+ PAAD cis rs11089937 0.929 rs5757155 ENSG00000211639.2 IGLV4-60 5.97 1.62e-08 2.01e-05 0.41 0.44 Periodontitis (PAL4Q3); chr22:22165378 chr22:22162199~22162681:+ PAAD cis rs227275 0.525 rs7660298 ENSG00000246560.2 RP11-10L12.4 5.97 1.62e-08 2.01e-05 0.49 0.44 Allergic disease (asthma, hay fever or eczema); chr4:103039611 chr4:102828055~102844075:+ PAAD cis rs2882667 0.858 rs6882112 ENSG00000253404.1 AC034243.1 -5.97 1.64e-08 2.03e-05 -0.54 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr5:139078046 chr5:138744434~138753309:- PAAD cis rs7188445 0.871 rs8048928 ENSG00000261390.4 RP11-345M22.2 -5.97 1.64e-08 2.03e-05 -0.59 -0.44 Urate levels; chr16:79671039 chr16:79715232~79770563:- PAAD cis rs17301013 0.606 rs55698100 ENSG00000227373.4 RP11-160H22.5 5.97 1.64e-08 2.03e-05 0.64 0.44 Systemic lupus erythematosus; chr1:174258295 chr1:174115300~174160004:- PAAD cis rs733592 1 rs1859440 ENSG00000240399.1 RP1-228P16.1 -5.97 1.64e-08 2.03e-05 -0.41 -0.44 Plateletcrit; chr12:48033546 chr12:48054813~48055591:- PAAD cis rs733592 1 rs733592 ENSG00000240399.1 RP1-228P16.1 -5.97 1.64e-08 2.03e-05 -0.41 -0.44 Plateletcrit; chr12:48035993 chr12:48054813~48055591:- PAAD cis rs733592 0.931 rs765260 ENSG00000240399.1 RP1-228P16.1 -5.97 1.64e-08 2.03e-05 -0.41 -0.44 Plateletcrit; chr12:48038153 chr12:48054813~48055591:- PAAD cis rs11098499 0.754 rs11732087 ENSG00000245958.5 RP11-33B1.1 -5.97 1.64e-08 2.03e-05 -0.34 -0.44 Corneal astigmatism; chr4:119318676 chr4:119454791~119552025:+ PAAD cis rs2455601 1 rs11042108 ENSG00000254860.4 TMEM9B-AS1 5.97 1.65e-08 2.04e-05 0.65 0.44 Schizophrenia; chr11:8884474 chr11:8964675~8977527:+ PAAD cis rs7945705 0.818 rs2742537 ENSG00000254860.4 TMEM9B-AS1 5.96 1.65e-08 2.05e-05 0.45 0.44 Hemoglobin concentration; chr11:8886842 chr11:8964675~8977527:+ PAAD cis rs67180937 0.553 rs2133188 ENSG00000272750.1 RP11-378J18.8 5.96 1.66e-08 2.05e-05 0.51 0.44 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222640411 chr1:222658867~222661512:- PAAD cis rs67180937 0.553 rs1498382 ENSG00000272750.1 RP11-378J18.8 5.96 1.66e-08 2.05e-05 0.51 0.44 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222641495 chr1:222658867~222661512:- PAAD cis rs7044106 0.708 rs1324472 ENSG00000226752.6 PSMD5-AS1 -5.96 1.66e-08 2.05e-05 -0.56 -0.44 Hip circumference adjusted for BMI; chr9:120612832 chr9:120824828~120854385:+ PAAD cis rs1150668 0.796 rs213236 ENSG00000216901.1 AL022393.7 5.96 1.66e-08 2.06e-05 0.5 0.44 Pubertal anthropometrics; chr6:28356620 chr6:28176188~28176674:+ PAAD cis rs11155671 0.53 rs7742993 ENSG00000223701.3 RAET1E-AS1 5.96 1.66e-08 2.06e-05 0.51 0.44 Testicular germ cell tumor; chr6:149883959 chr6:149884431~149919508:+ PAAD cis rs11098499 0.78 rs10013652 ENSG00000245958.5 RP11-33B1.1 -5.96 1.66e-08 2.06e-05 -0.32 -0.44 Corneal astigmatism; chr4:119371101 chr4:119454791~119552025:+ PAAD cis rs9322193 0.962 rs7745915 ENSG00000216906.2 RP11-350J20.9 5.96 1.67e-08 2.06e-05 0.56 0.44 Lung cancer; chr6:149834111 chr6:149904243~149906418:+ PAAD cis rs12022452 1 rs3738471 ENSG00000238287.1 RP11-656D10.3 -5.96 1.67e-08 2.06e-05 -0.71 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr1:40540873 chr1:40493157~40508661:- PAAD cis rs12022452 0.73 rs2297755 ENSG00000238287.1 RP11-656D10.3 -5.96 1.67e-08 2.06e-05 -0.71 -0.44 Age-related hearing impairment (SNP x SNP interaction); chr1:40547343 chr1:40493157~40508661:- PAAD cis rs9322193 0.923 rs9767123 ENSG00000216906.2 RP11-350J20.9 5.96 1.67e-08 2.06e-05 0.55 0.44 Lung cancer; chr6:149660323 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs4870267 ENSG00000216906.2 RP11-350J20.9 5.96 1.67e-08 2.06e-05 0.55 0.44 Lung cancer; chr6:149671572 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs4870529 ENSG00000216906.2 RP11-350J20.9 5.96 1.67e-08 2.06e-05 0.55 0.44 Lung cancer; chr6:149716436 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9767309 ENSG00000216906.2 RP11-350J20.9 5.96 1.67e-08 2.06e-05 0.55 0.44 Lung cancer; chr6:149716807 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs17745062 ENSG00000216906.2 RP11-350J20.9 5.96 1.67e-08 2.06e-05 0.55 0.44 Lung cancer; chr6:149721079 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs62441279 ENSG00000216906.2 RP11-350J20.9 5.96 1.67e-08 2.06e-05 0.55 0.44 Lung cancer; chr6:149721194 chr6:149904243~149906418:+ PAAD cis rs8037818 1 rs8037102 ENSG00000276724.1 RP11-1000B6.7 -5.96 1.67e-08 2.07e-05 -0.64 -0.44 Obesity-related traits; chr15:32640449 chr15:32583612~32584312:+ PAAD cis rs9322193 0.884 rs9480009 ENSG00000216906.2 RP11-350J20.9 5.96 1.68e-08 2.08e-05 0.55 0.44 Lung cancer; chr6:149758502 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9480031 ENSG00000216906.2 RP11-350J20.9 5.96 1.68e-08 2.08e-05 0.55 0.44 Lung cancer; chr6:149758875 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs10872649 ENSG00000216906.2 RP11-350J20.9 5.96 1.68e-08 2.08e-05 0.55 0.44 Lung cancer; chr6:149759454 chr6:149904243~149906418:+ PAAD cis rs4218 0.588 rs9788719 ENSG00000277144.1 RP11-59H7.4 -5.96 1.69e-08 2.08e-05 -0.53 -0.44 Social communication problems; chr15:59028920 chr15:59115547~59116089:- PAAD cis rs9322193 0.962 rs2275046 ENSG00000216906.2 RP11-350J20.9 5.96 1.69e-08 2.09e-05 0.56 0.44 Lung cancer; chr6:149835865 chr6:149904243~149906418:+ PAAD cis rs4774565 0.801 rs12911017 ENSG00000244879.4 GABPB1-AS1 -5.96 1.7e-08 2.1e-05 -0.41 -0.44 Breast cancer; chr15:50375802 chr15:50354959~50372202:+ PAAD cis rs1891275 0.601 rs1970506 ENSG00000228701.1 TNKS2-AS1 -5.96 1.7e-08 2.1e-05 -0.55 -0.44 Intelligence (multi-trait analysis); chr10:91668529 chr10:91782839~91798291:- PAAD cis rs1150668 0.83 rs2531831 ENSG00000204709.4 LINC01556 5.96 1.71e-08 2.11e-05 0.56 0.44 Pubertal anthropometrics; chr6:28420988 chr6:28943877~28944537:+ PAAD cis rs7772486 0.754 rs702318 ENSG00000235652.6 RP11-545I5.3 -5.96 1.71e-08 2.11e-05 -0.38 -0.44 Lobe attachment (rater-scored or self-reported); chr6:145684737 chr6:145799409~145886585:+ PAAD cis rs673078 0.607 rs61943403 ENSG00000275759.1 RP11-131L12.3 -5.96 1.72e-08 2.12e-05 -0.65 -0.44 Glucose homeostasis traits; chr12:118399887 chr12:118428281~118428870:+ PAAD cis rs2929278 0.562 rs8033846 ENSG00000205771.5 CATSPER2P1 5.96 1.72e-08 2.12e-05 0.57 0.44 Schizophrenia; chr15:43743165 chr15:43726918~43747094:- PAAD cis rs2929278 0.589 rs7174732 ENSG00000205771.5 CATSPER2P1 5.96 1.72e-08 2.12e-05 0.57 0.44 Schizophrenia; chr15:43746265 chr15:43726918~43747094:- PAAD cis rs7188445 0.866 rs11644799 ENSG00000261390.4 RP11-345M22.2 -5.96 1.72e-08 2.12e-05 -0.59 -0.44 Urate levels; chr16:79675212 chr16:79715232~79770563:- PAAD cis rs7188445 0.933 rs7187128 ENSG00000261390.4 RP11-345M22.2 -5.96 1.72e-08 2.12e-05 -0.59 -0.44 Urate levels; chr16:79675606 chr16:79715232~79770563:- PAAD cis rs7188445 0.898 rs74037508 ENSG00000261390.4 RP11-345M22.2 -5.96 1.72e-08 2.12e-05 -0.59 -0.44 Urate levels; chr16:79677439 chr16:79715232~79770563:- PAAD cis rs7188445 0.933 rs28773265 ENSG00000261390.4 RP11-345M22.2 -5.96 1.72e-08 2.12e-05 -0.59 -0.44 Urate levels; chr16:79678864 chr16:79715232~79770563:- PAAD cis rs7188445 0.933 rs74037509 ENSG00000261390.4 RP11-345M22.2 -5.96 1.72e-08 2.12e-05 -0.59 -0.44 Urate levels; chr16:79679107 chr16:79715232~79770563:- PAAD cis rs7188445 0.898 rs74247468 ENSG00000261390.4 RP11-345M22.2 -5.96 1.72e-08 2.12e-05 -0.59 -0.44 Urate levels; chr16:79679188 chr16:79715232~79770563:- PAAD cis rs2412819 0.599 rs2470120 ENSG00000205771.5 CATSPER2P1 -5.96 1.72e-08 2.12e-05 -0.56 -0.44 Lung cancer; chr15:43636872 chr15:43726918~43747094:- PAAD cis rs673078 0.607 rs7309484 ENSG00000275759.1 RP11-131L12.3 -5.96 1.73e-08 2.13e-05 -0.66 -0.43 Glucose homeostasis traits; chr12:118400833 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs17512763 ENSG00000275759.1 RP11-131L12.3 -5.96 1.73e-08 2.13e-05 -0.66 -0.43 Glucose homeostasis traits; chr12:118400974 chr12:118428281~118428870:+ PAAD cis rs2739330 0.828 rs4822451 ENSG00000231271.1 AP000350.8 5.96 1.73e-08 2.13e-05 0.59 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23949918~23954042:+ PAAD cis rs2739330 0.828 rs5760099 ENSG00000231271.1 AP000350.8 5.96 1.73e-08 2.13e-05 0.59 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23949918~23954042:+ PAAD cis rs17301013 0.861 rs10218528 ENSG00000227373.4 RP11-160H22.5 5.96 1.73e-08 2.13e-05 0.58 0.43 Systemic lupus erythematosus; chr1:174478450 chr1:174115300~174160004:- PAAD cis rs10875746 0.669 rs17122812 ENSG00000240399.1 RP1-228P16.1 -5.96 1.73e-08 2.14e-05 -0.49 -0.43 Longevity (90 years and older); chr12:48203270 chr12:48054813~48055591:- PAAD cis rs10875746 0.669 rs11168487 ENSG00000240399.1 RP1-228P16.1 -5.96 1.73e-08 2.14e-05 -0.49 -0.43 Longevity (90 years and older); chr12:48246926 chr12:48054813~48055591:- PAAD cis rs10875746 0.624 rs11168498 ENSG00000240399.1 RP1-228P16.1 -5.96 1.73e-08 2.14e-05 -0.49 -0.43 Longevity (90 years and older); chr12:48261305 chr12:48054813~48055591:- PAAD cis rs10875746 0.537 rs4760625 ENSG00000240399.1 RP1-228P16.1 -5.96 1.73e-08 2.14e-05 -0.49 -0.43 Longevity (90 years and older); chr12:48279960 chr12:48054813~48055591:- PAAD cis rs9660180 0.783 rs1107910 ENSG00000231050.1 RP1-140A9.1 5.95 1.74e-08 2.14e-05 0.49 0.43 Body mass index; chr1:1760882 chr1:1891471~1892658:+ PAAD cis rs6700559 0.742 rs10399790 ENSG00000260088.1 RP11-92G12.3 -5.95 1.74e-08 2.14e-05 -0.57 -0.43 Coronary artery disease; chr1:200626241 chr1:200669507~200694250:+ PAAD cis rs6700559 0.81 rs10919991 ENSG00000260088.1 RP11-92G12.3 -5.95 1.74e-08 2.14e-05 -0.57 -0.43 Coronary artery disease; chr1:200627217 chr1:200669507~200694250:+ PAAD cis rs11089937 0.857 rs5750580 ENSG00000211639.2 IGLV4-60 5.95 1.75e-08 2.15e-05 0.39 0.43 Periodontitis (PAL4Q3); chr22:22137471 chr22:22162199~22162681:+ PAAD cis rs10875746 0.81 rs10875732 ENSG00000240399.1 RP1-228P16.1 -5.95 1.75e-08 2.15e-05 -0.48 -0.43 Longevity (90 years and older); chr12:48048322 chr12:48054813~48055591:- PAAD cis rs2404602 0.622 rs2003344 ENSG00000259422.1 RP11-593F23.1 -5.95 1.75e-08 2.15e-05 -0.57 -0.43 Blood metabolite levels; chr15:76339960 chr15:76174891~76181486:- PAAD cis rs2117029 0.555 rs10747561 ENSG00000258017.1 RP11-386G11.10 -5.95 1.75e-08 2.15e-05 -0.54 -0.43 Intelligence (multi-trait analysis); chr12:49106726 chr12:49127782~49147869:+ PAAD cis rs2882667 0.824 rs13189485 ENSG00000253404.1 AC034243.1 5.95 1.76e-08 2.16e-05 0.54 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139139712 chr5:138744434~138753309:- PAAD cis rs2882667 0.756 rs11957953 ENSG00000253404.1 AC034243.1 5.95 1.76e-08 2.16e-05 0.54 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139143688 chr5:138744434~138753309:- PAAD cis rs2882667 0.788 rs11959691 ENSG00000253404.1 AC034243.1 5.95 1.76e-08 2.16e-05 0.54 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139145399 chr5:138744434~138753309:- PAAD cis rs2283792 0.967 rs5749998 ENSG00000224086.5 LL22NC03-86G7.1 -5.95 1.77e-08 2.18e-05 -0.44 -0.43 Multiple sclerosis; chr22:21808085 chr22:21938293~21977632:+ PAAD cis rs2283792 1 rs9607287 ENSG00000224086.5 LL22NC03-86G7.1 -5.95 1.77e-08 2.18e-05 -0.44 -0.43 Multiple sclerosis; chr22:21809136 chr22:21938293~21977632:+ PAAD cis rs2337406 0.789 rs60000589 ENSG00000274576.2 IGHV2-70 -5.95 1.77e-08 2.18e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106782459 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs111881598 ENSG00000274576.2 IGHV2-70 -5.95 1.77e-08 2.18e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106783113 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs61164979 ENSG00000274576.2 IGHV2-70 -5.95 1.77e-08 2.18e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106783133 chr14:106770577~106771020:- PAAD cis rs6142102 0.602 rs4911395 ENSG00000276073.1 RP5-1125A11.7 -5.95 1.78e-08 2.18e-05 -0.45 -0.43 Skin pigmentation; chr20:33992095 chr20:33985617~33988989:- PAAD cis rs6142102 0.602 rs4911396 ENSG00000276073.1 RP5-1125A11.7 -5.95 1.78e-08 2.18e-05 -0.45 -0.43 Skin pigmentation; chr20:33992139 chr20:33985617~33988989:- PAAD cis rs6142102 0.602 rs2268079 ENSG00000276073.1 RP5-1125A11.7 -5.95 1.78e-08 2.18e-05 -0.45 -0.43 Skin pigmentation; chr20:34008944 chr20:33985617~33988989:- PAAD cis rs950169 0.881 rs72750843 ENSG00000225151.9 GOLGA2P7 -5.95 1.78e-08 2.19e-05 -0.51 -0.43 Schizophrenia; chr15:84592552 chr15:84199311~84230136:- PAAD cis rs7829975 0.711 rs12682352 ENSG00000253893.2 FAM85B -5.95 1.78e-08 2.19e-05 -0.6 -0.43 Mood instability; chr8:8788736 chr8:8167819~8226614:- PAAD cis rs1891275 0.551 rs7088831 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91652695 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2000177 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91653237 chr10:91782839~91798291:- PAAD cis rs1891275 0.576 rs2000178 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91653287 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2027486 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91654229 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2421623 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91654700 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs10881941 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91655154 chr10:91782839~91798291:- PAAD cis rs1891275 0.576 rs10881942 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91655263 chr10:91782839~91798291:- PAAD cis rs1891275 0.516 rs10881943 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91655373 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs7087959 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91656160 chr10:91782839~91798291:- PAAD cis rs1891275 0.54 rs10732773 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91656468 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2421624 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91656659 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs2421625 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91656744 chr10:91782839~91798291:- PAAD cis rs1891275 0.576 rs7900117 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91657530 chr10:91782839~91798291:- PAAD cis rs1891275 0.551 rs4933213 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91657947 chr10:91782839~91798291:- PAAD cis rs1891275 0.506 rs4933214 ENSG00000228701.1 TNKS2-AS1 -5.95 1.79e-08 2.19e-05 -0.55 -0.43 Intelligence (multi-trait analysis); chr10:91658004 chr10:91782839~91798291:- PAAD cis rs12022452 0.908 rs4660423 ENSG00000238287.1 RP11-656D10.3 -5.95 1.8e-08 2.2e-05 -0.71 -0.43 Age-related hearing impairment (SNP x SNP interaction); chr1:40554632 chr1:40493157~40508661:- PAAD cis rs67180937 0.553 rs3002148 ENSG00000272750.1 RP11-378J18.8 5.95 1.8e-08 2.2e-05 0.52 0.43 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222637575 chr1:222658867~222661512:- PAAD cis rs10875746 0.669 rs61941003 ENSG00000240399.1 RP1-228P16.1 -5.95 1.8e-08 2.2e-05 -0.48 -0.43 Longevity (90 years and older); chr12:48225842 chr12:48054813~48055591:- PAAD cis rs10875746 0.579 rs10875778 ENSG00000240399.1 RP1-228P16.1 -5.95 1.8e-08 2.2e-05 -0.48 -0.43 Longevity (90 years and older); chr12:48230872 chr12:48054813~48055591:- PAAD cis rs10875746 0.669 rs10875779 ENSG00000240399.1 RP1-228P16.1 -5.95 1.8e-08 2.2e-05 -0.48 -0.43 Longevity (90 years and older); chr12:48236086 chr12:48054813~48055591:- PAAD cis rs10875746 0.669 rs11168499 ENSG00000240399.1 RP1-228P16.1 -5.95 1.8e-08 2.2e-05 -0.48 -0.43 Longevity (90 years and older); chr12:48268887 chr12:48054813~48055591:- PAAD cis rs638893 0.636 rs493720 ENSG00000278376.1 RP11-158I9.8 -5.95 1.8e-08 2.21e-05 -0.62 -0.43 Vitiligo; chr11:118733969 chr11:118791254~118793137:+ PAAD cis rs673078 0.66 rs11068917 ENSG00000275759.1 RP11-131L12.3 -5.95 1.8e-08 2.21e-05 -0.56 -0.43 Glucose homeostasis traits; chr12:118353315 chr12:118428281~118428870:+ PAAD cis rs9640161 0.789 rs4554381 ENSG00000261305.1 RP4-584D14.7 5.95 1.8e-08 2.21e-05 0.63 0.43 Blood protein levels;Circulating chemerin levels; chr7:150328478 chr7:150341771~150342607:+ PAAD cis rs9640161 0.702 rs11765692 ENSG00000261305.1 RP4-584D14.7 5.95 1.8e-08 2.21e-05 0.63 0.43 Blood protein levels;Circulating chemerin levels; chr7:150329478 chr7:150341771~150342607:+ PAAD cis rs72843506 0.722 rs74658636 ENSG00000189423.10 USP32P3 5.95 1.8e-08 2.21e-05 0.68 0.43 Schizophrenia; chr17:20294669 chr17:20415547~20431008:+ PAAD cis rs17301013 0.507 rs332800 ENSG00000227373.4 RP11-160H22.5 5.95 1.81e-08 2.21e-05 0.65 0.43 Systemic lupus erythematosus; chr1:174753467 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs464635 ENSG00000227373.4 RP11-160H22.5 5.95 1.81e-08 2.21e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174732730 chr1:174115300~174160004:- PAAD cis rs9309711 0.621 rs12993215 ENSG00000225234.1 TRAPPC12-AS1 -5.95 1.82e-08 2.22e-05 -0.44 -0.43 Neurofibrillary tangles; chr2:3469956 chr2:3481242~3482409:- PAAD cis rs1075265 0.744 rs2909460 ENSG00000233266.1 HMGB1P31 5.95 1.82e-08 2.22e-05 0.55 0.43 Chronotype;Morning vs. evening chronotype; chr2:53967611 chr2:54051334~54051760:+ PAAD cis rs1075265 0.811 rs805308 ENSG00000233266.1 HMGB1P31 5.95 1.82e-08 2.22e-05 0.55 0.43 Chronotype;Morning vs. evening chronotype; chr2:53967797 chr2:54051334~54051760:+ PAAD cis rs950169 0.922 rs11631096 ENSG00000225151.9 GOLGA2P7 -5.94 1.82e-08 2.23e-05 -0.52 -0.43 Schizophrenia; chr15:84557698 chr15:84199311~84230136:- PAAD cis rs950169 0.84 rs62019457 ENSG00000225151.9 GOLGA2P7 -5.94 1.82e-08 2.23e-05 -0.52 -0.43 Schizophrenia; chr15:84558911 chr15:84199311~84230136:- PAAD cis rs950169 0.922 rs67804993 ENSG00000225151.9 GOLGA2P7 -5.94 1.82e-08 2.23e-05 -0.52 -0.43 Schizophrenia; chr15:84560799 chr15:84199311~84230136:- PAAD cis rs4774565 0.762 rs1056682 ENSG00000244879.4 GABPB1-AS1 -5.94 1.83e-08 2.23e-05 -0.4 -0.43 Breast cancer; chr15:50368004 chr15:50354959~50372202:+ PAAD cis rs4774565 0.762 rs17431150 ENSG00000244879.4 GABPB1-AS1 -5.94 1.83e-08 2.23e-05 -0.4 -0.43 Breast cancer; chr15:50371385 chr15:50354959~50372202:+ PAAD cis rs4774565 0.762 rs17431171 ENSG00000244879.4 GABPB1-AS1 -5.94 1.83e-08 2.23e-05 -0.4 -0.43 Breast cancer; chr15:50371424 chr15:50354959~50372202:+ PAAD cis rs4774565 0.762 rs720599 ENSG00000244879.4 GABPB1-AS1 -5.94 1.83e-08 2.23e-05 -0.4 -0.43 Breast cancer; chr15:50372318 chr15:50354959~50372202:+ PAAD cis rs113835537 0.529 rs11821155 ENSG00000255517.5 CTD-3074O7.5 5.94 1.83e-08 2.24e-05 0.55 0.43 Airway imaging phenotypes; chr11:66478866 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs4930378 ENSG00000255517.5 CTD-3074O7.5 -5.94 1.83e-08 2.24e-05 -0.55 -0.43 Airway imaging phenotypes; chr11:66488044 chr11:66473490~66480233:- PAAD cis rs2882667 0.755 rs55650316 ENSG00000253404.1 AC034243.1 5.94 1.83e-08 2.24e-05 0.54 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139131603 chr5:138744434~138753309:- PAAD cis rs6964833 0.786 rs35633336 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74643961 chr7:74894116~74897835:+ PAAD cis rs6964833 0.935 rs34630792 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74646869 chr7:74894116~74897835:+ PAAD cis rs6964833 0.935 rs35735900 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74651887 chr7:74894116~74897835:+ PAAD cis rs6964833 0.872 rs4717903 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74653827 chr7:74894116~74897835:+ PAAD cis rs6964833 1 rs4717906 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74671923 chr7:74894116~74897835:+ PAAD cis rs6964833 1 rs13227433 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74680386 chr7:74894116~74897835:+ PAAD cis rs6964833 1 rs6967152 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74684983 chr7:74894116~74897835:+ PAAD cis rs6964833 1 rs6964833 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74687575 chr7:74894116~74897835:+ PAAD cis rs6964833 1 rs35203738 ENSG00000123965.13 PMS2P5 5.94 1.83e-08 2.24e-05 0.72 0.43 Menarche (age at onset); chr7:74690864 chr7:74894116~74897835:+ PAAD cis rs2882667 0.858 rs11959803 ENSG00000253404.1 AC034243.1 5.94 1.84e-08 2.24e-05 0.54 0.43 Age-related hearing impairment (SNP x SNP interaction); chr5:139115626 chr5:138744434~138753309:- PAAD cis rs9322193 0.923 rs55993747 ENSG00000216906.2 RP11-350J20.9 5.94 1.84e-08 2.25e-05 0.55 0.43 Lung cancer; chr6:149622016 chr6:149904243~149906418:+ PAAD cis rs9322193 0.847 rs12191643 ENSG00000216906.2 RP11-350J20.9 5.94 1.84e-08 2.25e-05 0.55 0.43 Lung cancer; chr6:149628912 chr6:149904243~149906418:+ PAAD cis rs853679 0.567 rs16894091 ENSG00000204709.4 LINC01556 -5.94 1.85e-08 2.26e-05 -0.63 -0.43 Depression; chr6:28422360 chr6:28943877~28944537:+ PAAD cis rs7811142 0.945 rs6978739 ENSG00000242294.5 STAG3L5P 5.94 1.86e-08 2.27e-05 0.34 0.43 Platelet count; chr7:100501057 chr7:100336079~100351900:+ PAAD cis rs11651753 0.561 rs35336840 ENSG00000264920.1 RP11-6N17.4 -5.94 1.86e-08 2.27e-05 -0.5 -0.43 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47888742 chr17:47891255~47895812:- PAAD cis rs673078 0.607 rs11068926 ENSG00000275759.1 RP11-131L12.3 -5.94 1.86e-08 2.27e-05 -0.59 -0.43 Glucose homeostasis traits; chr12:118367320 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs4442583 ENSG00000275759.1 RP11-131L12.3 -5.94 1.86e-08 2.27e-05 -0.59 -0.43 Glucose homeostasis traits; chr12:118367914 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943370 ENSG00000275759.1 RP11-131L12.3 -5.94 1.86e-08 2.27e-05 -0.59 -0.43 Glucose homeostasis traits; chr12:118369469 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943371 ENSG00000275759.1 RP11-131L12.3 -5.94 1.86e-08 2.27e-05 -0.59 -0.43 Glucose homeostasis traits; chr12:118369600 chr12:118428281~118428870:+ PAAD cis rs6142102 0.602 rs6142069 ENSG00000276073.1 RP5-1125A11.7 -5.94 1.86e-08 2.27e-05 -0.45 -0.43 Skin pigmentation; chr20:33972736 chr20:33985617~33988989:- PAAD cis rs113835537 0.529 rs2279864 ENSG00000255517.5 CTD-3074O7.5 -5.94 1.87e-08 2.28e-05 -0.56 -0.43 Airway imaging phenotypes; chr11:66480373 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs78999944 ENSG00000255517.5 CTD-3074O7.5 -5.94 1.87e-08 2.28e-05 -0.56 -0.43 Airway imaging phenotypes; chr11:66483757 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11550299 ENSG00000255517.5 CTD-3074O7.5 -5.94 1.87e-08 2.28e-05 -0.56 -0.43 Airway imaging phenotypes; chr11:66486614 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs4930379 ENSG00000255517.5 CTD-3074O7.5 -5.94 1.87e-08 2.28e-05 -0.56 -0.43 Airway imaging phenotypes; chr11:66488203 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs4930183 ENSG00000255517.5 CTD-3074O7.5 -5.94 1.87e-08 2.28e-05 -0.56 -0.43 Airway imaging phenotypes; chr11:66488261 chr11:66473490~66480233:- PAAD cis rs950169 0.919 rs12915589 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84065712 chr15:84570649~84580175:+ PAAD cis rs950169 0.959 rs66801143 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84067905 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs35648189 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84071996 chr15:84570649~84580175:+ PAAD cis rs950169 0.92 rs17300048 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84080725 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs1848093 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84086775 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs12915234 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84089549 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs34751999 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84089667 chr15:84570649~84580175:+ PAAD cis rs950169 0.919 rs17300292 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84093816 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs12916348 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84096775 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs35297609 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84104144 chr15:84570649~84580175:+ PAAD cis rs950169 1 rs62026530 ENSG00000259728.4 LINC00933 5.94 1.87e-08 2.28e-05 0.55 0.43 Schizophrenia; chr15:84107088 chr15:84570649~84580175:+ PAAD cis rs992157 0.798 rs7557709 ENSG00000261338.2 RP11-378A13.1 5.94 1.87e-08 2.28e-05 0.52 0.43 Colorectal cancer; chr2:218302806 chr2:218255319~218257366:+ PAAD cis rs853679 0.538 rs13199081 ENSG00000216901.1 AL022393.7 5.94 1.87e-08 2.28e-05 0.59 0.43 Depression; chr6:28364057 chr6:28176188~28176674:+ PAAD cis rs10875746 0.903 rs11168370 ENSG00000240399.1 RP1-228P16.1 -5.94 1.89e-08 2.3e-05 -0.45 -0.43 Longevity (90 years and older); chr12:48041497 chr12:48054813~48055591:- PAAD cis rs638893 0.578 rs582200 ENSG00000278376.1 RP11-158I9.8 5.94 1.89e-08 2.3e-05 0.62 0.43 Vitiligo; chr11:118798199 chr11:118791254~118793137:+ PAAD cis rs7188445 0.899 rs58722186 ENSG00000261390.4 RP11-345M22.2 -5.94 1.89e-08 2.31e-05 -0.57 -0.43 Urate levels; chr16:79717694 chr16:79715232~79770563:- PAAD cis rs17301013 0.507 rs1793298 ENSG00000227373.4 RP11-160H22.5 -5.94 1.89e-08 2.31e-05 -0.63 -0.43 Systemic lupus erythematosus; chr1:174784601 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1653630 ENSG00000227373.4 RP11-160H22.5 -5.94 1.89e-08 2.31e-05 -0.63 -0.43 Systemic lupus erythematosus; chr1:174791810 chr1:174115300~174160004:- PAAD cis rs6142102 0.602 rs1054534 ENSG00000276073.1 RP5-1125A11.7 -5.94 1.89e-08 2.31e-05 -0.44 -0.43 Skin pigmentation; chr20:34017521 chr20:33985617~33988989:- PAAD cis rs6142102 0.602 rs4911145 ENSG00000276073.1 RP5-1125A11.7 5.94 1.89e-08 2.31e-05 0.44 0.43 Skin pigmentation; chr20:34027417 chr20:33985617~33988989:- PAAD cis rs5760092 0.627 rs6519489 ENSG00000250470.1 AP000351.3 -5.94 1.9e-08 2.31e-05 -0.71 -0.43 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23976904~23977585:- PAAD cis rs1061377 0.862 rs12508577 ENSG00000249685.1 RP11-360F5.3 5.94 1.91e-08 2.33e-05 0.48 0.43 Uric acid levels; chr4:39107779 chr4:39133913~39135608:+ PAAD cis rs7772486 0.875 rs9403765 ENSG00000235652.6 RP11-545I5.3 -5.93 1.92e-08 2.33e-05 -0.35 -0.43 Lobe attachment (rater-scored or self-reported); chr6:146046905 chr6:145799409~145886585:+ PAAD cis rs17301013 0.861 rs7538650 ENSG00000227373.4 RP11-160H22.5 -5.93 1.92e-08 2.34e-05 -0.57 -0.43 Systemic lupus erythematosus; chr1:174788821 chr1:174115300~174160004:- PAAD cis rs12594515 1 rs8038058 ENSG00000273972.1 CTD-2306A12.1 -5.93 1.92e-08 2.34e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45698074 chr15:45702640~45703183:+ PAAD cis rs72772090 0.539 rs72775810 ENSG00000248734.2 CTD-2260A17.1 -5.93 1.92e-08 2.34e-05 -0.57 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96849604 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11750671 ENSG00000248734.2 CTD-2260A17.1 -5.93 1.92e-08 2.34e-05 -0.57 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96852779 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72775817 ENSG00000248734.2 CTD-2260A17.1 -5.93 1.92e-08 2.34e-05 -0.57 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96855006 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72775818 ENSG00000248734.2 CTD-2260A17.1 -5.93 1.92e-08 2.34e-05 -0.57 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96857512 chr5:96784777~96785999:+ PAAD cis rs227275 0.554 rs223467 ENSG00000246560.2 RP11-10L12.4 5.93 1.92e-08 2.34e-05 0.47 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102779721 chr4:102828055~102844075:+ PAAD cis rs7945705 0.935 rs11042103 ENSG00000254860.4 TMEM9B-AS1 -5.93 1.92e-08 2.34e-05 -0.48 -0.43 Hemoglobin concentration; chr11:8867153 chr11:8964675~8977527:+ PAAD cis rs2281636 0.798 rs3184991 ENSG00000233690.1 EBAG9P1 -5.93 1.92e-08 2.34e-05 -0.52 -0.43 Obesity-related traits; chr10:99755559 chr10:99697407~99697949:- PAAD cis rs17301013 0.507 rs1793292 ENSG00000227373.4 RP11-160H22.5 -5.93 1.92e-08 2.34e-05 -0.63 -0.43 Systemic lupus erythematosus; chr1:174778185 chr1:174115300~174160004:- PAAD cis rs11098499 0.908 rs9995234 ENSG00000245958.5 RP11-33B1.1 -5.93 1.92e-08 2.34e-05 -0.37 -0.43 Corneal astigmatism; chr4:119400672 chr4:119454791~119552025:+ PAAD cis rs12458462 0.892 rs12456692 ENSG00000274828.1 RP11-567M16.6 5.93 1.92e-08 2.34e-05 0.42 0.43 Monocyte count; chr18:79722189 chr18:79677287~79679358:- PAAD cis rs11098499 0.863 rs1010739 ENSG00000245958.5 RP11-33B1.1 -5.93 1.93e-08 2.35e-05 -0.37 -0.43 Corneal astigmatism; chr4:119542316 chr4:119454791~119552025:+ PAAD cis rs11673344 0.931 rs7256746 ENSG00000226686.6 LINC01535 5.93 1.93e-08 2.35e-05 0.57 0.43 Obesity-related traits; chr19:37175073 chr19:37251912~37265535:+ PAAD cis rs748404 0.56 rs1869258 ENSG00000249839.1 AC011330.5 -5.93 1.93e-08 2.35e-05 -0.65 -0.43 Lung cancer; chr15:43511423 chr15:43663654~43684339:- PAAD cis rs6860806 0.507 rs272878 ENSG00000233006.5 AC034220.3 -5.93 1.94e-08 2.36e-05 -0.37 -0.43 Breast cancer; chr5:132336076 chr5:132311285~132369916:- PAAD cis rs673078 0.66 rs12229607 ENSG00000275759.1 RP11-131L12.3 -5.93 1.95e-08 2.37e-05 -0.61 -0.43 Glucose homeostasis traits; chr12:118338333 chr12:118428281~118428870:+ PAAD cis rs17301013 0.581 rs11801385 ENSG00000227373.4 RP11-160H22.5 5.93 1.95e-08 2.37e-05 0.65 0.43 Systemic lupus erythematosus; chr1:174089454 chr1:174115300~174160004:- PAAD cis rs17301013 0.606 rs17350956 ENSG00000227373.4 RP11-160H22.5 5.93 1.95e-08 2.37e-05 0.65 0.43 Systemic lupus erythematosus; chr1:174093863 chr1:174115300~174160004:- PAAD cis rs17301013 0.502 rs6703836 ENSG00000227373.4 RP11-160H22.5 5.93 1.95e-08 2.37e-05 0.65 0.43 Systemic lupus erythematosus; chr1:174099675 chr1:174115300~174160004:- PAAD cis rs7772486 0.536 rs9373467 ENSG00000235652.6 RP11-545I5.3 5.93 1.95e-08 2.37e-05 0.37 0.43 Lobe attachment (rater-scored or self-reported); chr6:145634469 chr6:145799409~145886585:+ PAAD cis rs58873874 0.737 rs10515750 ENSG00000251405.2 CTB-109A12.1 5.93 1.95e-08 2.37e-05 0.87 0.43 Bipolar disorder (body mass index interaction); chr5:157383064 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs10061544 ENSG00000251405.2 CTB-109A12.1 5.93 1.95e-08 2.37e-05 0.87 0.43 Bipolar disorder (body mass index interaction); chr5:157383871 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs10078836 ENSG00000251405.2 CTB-109A12.1 5.93 1.95e-08 2.37e-05 0.87 0.43 Bipolar disorder (body mass index interaction); chr5:157384604 chr5:157362615~157460078:- PAAD cis rs7208859 0.623 rs9895785 ENSG00000266490.1 CTD-2349P21.9 -5.93 1.95e-08 2.37e-05 -0.55 -0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780690 chr17:30792372~30792833:+ PAAD cis rs9322193 0.884 rs62439836 ENSG00000216906.2 RP11-350J20.9 5.93 1.96e-08 2.37e-05 0.54 0.43 Lung cancer; chr6:149669173 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs4869812 ENSG00000216906.2 RP11-350J20.9 5.93 1.96e-08 2.37e-05 0.54 0.43 Lung cancer; chr6:149669447 chr6:149904243~149906418:+ PAAD cis rs2929278 0.617 rs4617832 ENSG00000205771.5 CATSPER2P1 5.93 1.96e-08 2.37e-05 0.57 0.43 Schizophrenia; chr15:43738381 chr15:43726918~43747094:- PAAD cis rs733592 0.723 rs10875766 ENSG00000240399.1 RP1-228P16.1 5.93 1.97e-08 2.38e-05 0.4 0.43 Plateletcrit; chr12:48199797 chr12:48054813~48055591:- PAAD cis rs10463554 0.655 rs152138 ENSG00000175749.11 EIF3KP1 5.93 1.97e-08 2.39e-05 0.58 0.43 Parkinson's disease; chr5:103223727 chr5:103032376~103033031:+ PAAD cis rs9322193 0.847 rs62439808 ENSG00000216906.2 RP11-350J20.9 5.93 1.97e-08 2.39e-05 0.55 0.43 Lung cancer; chr6:149629690 chr6:149904243~149906418:+ PAAD cis rs10875746 0.669 rs11168510 ENSG00000240399.1 RP1-228P16.1 -5.93 1.97e-08 2.39e-05 -0.49 -0.43 Longevity (90 years and older); chr12:48291772 chr12:48054813~48055591:- PAAD cis rs2919917 0.614 rs10102877 ENSG00000254352.1 RP11-578O24.2 5.93 1.97e-08 2.39e-05 0.44 0.43 Lymphocyte counts; chr8:78686127 chr8:78723796~78724136:- PAAD cis rs7429990 0.864 rs35698005 ENSG00000229759.1 MRPS18AP1 -5.93 1.97e-08 2.39e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47800558 chr3:48256350~48256938:- PAAD cis rs950169 0.959 rs12911210 ENSG00000259728.4 LINC00933 5.93 1.97e-08 2.39e-05 0.54 0.43 Schizophrenia; chr15:84123331 chr15:84570649~84580175:+ PAAD cis rs950169 0.959 rs12902070 ENSG00000259728.4 LINC00933 5.93 1.97e-08 2.39e-05 0.54 0.43 Schizophrenia; chr15:84124806 chr15:84570649~84580175:+ PAAD cis rs1155848 0.571 rs7983556 ENSG00000227354.5 RBM26-AS1 5.93 1.99e-08 2.4e-05 0.78 0.43 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79608777 chr13:79406309~79424328:+ PAAD cis rs17301013 0.507 rs10494492 ENSG00000227373.4 RP11-160H22.5 -5.93 1.99e-08 2.4e-05 -0.65 -0.43 Systemic lupus erythematosus; chr1:174723499 chr1:174115300~174160004:- PAAD cis rs7945705 0.52 rs1984791 ENSG00000254860.4 TMEM9B-AS1 -5.93 1.99e-08 2.4e-05 -0.52 -0.43 Hemoglobin concentration; chr11:9013480 chr11:8964675~8977527:+ PAAD cis rs7429990 0.828 rs6792350 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47797451 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs3888 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47816085 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs4858860 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47817344 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs3772399 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47826237 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs3915654 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47827132 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs35582375 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47829639 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs13077230 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47832232 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs11130150 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47832449 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs11710199 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47836588 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs17290490 ENSG00000229759.1 MRPS18AP1 -5.93 1.99e-08 2.41e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47841237 chr3:48256350~48256938:- PAAD cis rs7615952 0.736 rs13063122 ENSG00000171084.14 FAM86JP 5.93 2e-08 2.41e-05 0.58 0.43 Blood pressure (smoking interaction); chr3:125925017 chr3:125916620~125930024:+ PAAD cis rs75422866 0.764 rs73104177 ENSG00000257433.4 RP1-197B17.3 5.93 2e-08 2.41e-05 0.93 0.43 Pneumonia; chr12:47713550 chr12:47706085~47742294:+ PAAD cis rs75422866 0.764 rs73104184 ENSG00000257433.4 RP1-197B17.3 5.93 2e-08 2.41e-05 0.93 0.43 Pneumonia; chr12:47715623 chr12:47706085~47742294:+ PAAD cis rs75422866 0.764 rs73104188 ENSG00000257433.4 RP1-197B17.3 5.93 2e-08 2.41e-05 0.93 0.43 Pneumonia; chr12:47715885 chr12:47706085~47742294:+ PAAD cis rs17301013 0.531 rs1653634 ENSG00000227373.4 RP11-160H22.5 -5.93 2e-08 2.41e-05 -0.62 -0.43 Systemic lupus erythematosus; chr1:174783348 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10798324 ENSG00000227373.4 RP11-160H22.5 -5.93 2e-08 2.41e-05 -0.62 -0.43 Systemic lupus erythematosus; chr1:174787485 chr1:174115300~174160004:- PAAD cis rs1150668 0.796 rs213237 ENSG00000204709.4 LINC01556 5.93 2.01e-08 2.42e-05 0.55 0.43 Pubertal anthropometrics; chr6:28356161 chr6:28943877~28944537:+ PAAD cis rs9322193 0.923 rs10782316 ENSG00000216906.2 RP11-350J20.9 5.92 2.02e-08 2.44e-05 0.55 0.43 Lung cancer; chr6:149752755 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs11155677 ENSG00000216906.2 RP11-350J20.9 5.92 2.02e-08 2.44e-05 0.55 0.43 Lung cancer; chr6:149756953 chr6:149904243~149906418:+ PAAD cis rs11673344 0.698 rs56161518 ENSG00000226686.6 LINC01535 5.92 2.02e-08 2.44e-05 0.61 0.43 Obesity-related traits; chr19:36978555 chr19:37251912~37265535:+ PAAD cis rs7188445 0.583 rs80170002 ENSG00000261390.4 RP11-345M22.2 -5.92 2.02e-08 2.44e-05 -0.59 -0.43 Urate levels; chr16:79677817 chr16:79715232~79770563:- PAAD cis rs72772090 0.539 rs11742261 ENSG00000248734.2 CTD-2260A17.1 -5.92 2.03e-08 2.45e-05 -0.6 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96831905 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs11748795 ENSG00000248734.2 CTD-2260A17.1 -5.92 2.03e-08 2.45e-05 -0.6 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96832353 chr5:96784777~96785999:+ PAAD cis rs11098499 0.754 rs10213554 ENSG00000245958.5 RP11-33B1.1 5.92 2.04e-08 2.45e-05 0.34 0.43 Corneal astigmatism; chr4:119339630 chr4:119454791~119552025:+ PAAD cis rs7208859 0.623 rs8082537 ENSG00000266490.1 CTD-2349P21.9 5.92 2.04e-08 2.46e-05 0.52 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30688914 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9907197 ENSG00000266490.1 CTD-2349P21.9 5.92 2.04e-08 2.46e-05 0.52 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30691245 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9915963 ENSG00000266490.1 CTD-2349P21.9 5.92 2.04e-08 2.46e-05 0.52 0.43 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30692625 chr17:30792372~30792833:+ PAAD cis rs2739330 0.791 rs9612520 ENSG00000099984.9 GSTT2 -5.92 2.05e-08 2.46e-05 -0.57 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23980123~23983911:+ PAAD cis rs17301013 0.507 rs1622802 ENSG00000227373.4 RP11-160H22.5 -5.92 2.05e-08 2.47e-05 -0.62 -0.43 Systemic lupus erythematosus; chr1:174766066 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1329281 ENSG00000227373.4 RP11-160H22.5 -5.92 2.05e-08 2.47e-05 -0.62 -0.43 Systemic lupus erythematosus; chr1:174766432 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6696465 ENSG00000227373.4 RP11-160H22.5 -5.92 2.05e-08 2.47e-05 -0.62 -0.43 Systemic lupus erythematosus; chr1:174769700 chr1:174115300~174160004:- PAAD cis rs7923609 0.578 rs10761789 ENSG00000232075.1 MRPL35P2 -5.92 2.05e-08 2.47e-05 -0.57 -0.43 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63636804 chr10:63634317~63634827:- PAAD cis rs7923609 0.578 rs3858121 ENSG00000232075.1 MRPL35P2 -5.92 2.05e-08 2.47e-05 -0.57 -0.43 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63640237 chr10:63634317~63634827:- PAAD cis rs732716 0.785 rs62130979 ENSG00000267980.1 AC007292.6 -5.92 2.05e-08 2.47e-05 -0.6 -0.43 Mean corpuscular volume; chr19:4432447 chr19:4363789~4364640:+ PAAD cis rs9532669 0.926 rs9532659 ENSG00000176268.5 CYCSP34 5.92 2.05e-08 2.47e-05 0.41 0.43 Cervical cancer; chr13:40920380 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs9594457 ENSG00000176268.5 CYCSP34 5.92 2.05e-08 2.47e-05 0.41 0.43 Cervical cancer; chr13:40920439 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9594458 ENSG00000176268.5 CYCSP34 5.92 2.05e-08 2.47e-05 0.41 0.43 Cervical cancer; chr13:40920448 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9590562 ENSG00000176268.5 CYCSP34 5.92 2.05e-08 2.47e-05 0.41 0.43 Cervical cancer; chr13:40920503 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs12857052 ENSG00000176268.5 CYCSP34 5.92 2.05e-08 2.47e-05 0.41 0.43 Cervical cancer; chr13:40920831 chr13:40863599~40863902:- PAAD cis rs12594515 1 rs12906442 ENSG00000273972.1 CTD-2306A12.1 -5.92 2.05e-08 2.47e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45693056 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs12911309 ENSG00000273972.1 CTD-2306A12.1 -5.92 2.05e-08 2.47e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45693521 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs12595137 ENSG00000273972.1 CTD-2306A12.1 -5.92 2.05e-08 2.47e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45693907 chr15:45702640~45703183:+ PAAD cis rs12594515 0.967 rs12595138 ENSG00000273972.1 CTD-2306A12.1 -5.92 2.05e-08 2.47e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45693910 chr15:45702640~45703183:+ PAAD cis rs2283792 0.622 rs5756323 ENSG00000228050.1 TOP3BP1 -5.92 2.06e-08 2.48e-05 -0.48 -0.43 Multiple sclerosis; chr22:21980398 chr22:22223187~22224566:- PAAD cis rs12594515 0.6 rs12903858 ENSG00000273972.1 CTD-2306A12.1 -5.92 2.06e-08 2.48e-05 -0.5 -0.43 Weight;Waist circumference; chr15:45679968 chr15:45702640~45703183:+ PAAD cis rs17301013 0.507 rs969472 ENSG00000227373.4 RP11-160H22.5 5.92 2.07e-08 2.48e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174458562 chr1:174115300~174160004:- PAAD cis rs11098499 0.826 rs4472123 ENSG00000245958.5 RP11-33B1.1 -5.92 2.07e-08 2.49e-05 -0.34 -0.43 Corneal astigmatism; chr4:119315475 chr4:119454791~119552025:+ PAAD cis rs858239 0.636 rs7808488 ENSG00000226816.2 AC005082.12 5.92 2.07e-08 2.49e-05 0.49 0.43 Cerebrospinal fluid biomarker levels; chr7:23182251 chr7:23206013~23208045:+ PAAD cis rs9322193 0.884 rs7450246 ENSG00000216906.2 RP11-350J20.9 5.92 2.08e-08 2.5e-05 0.56 0.43 Lung cancer; chr6:149702517 chr6:149904243~149906418:+ PAAD cis rs7188445 0.932 rs17767904 ENSG00000261390.4 RP11-345M22.2 -5.92 2.08e-08 2.5e-05 -0.57 -0.43 Urate levels; chr16:79716078 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs73575095 ENSG00000261390.4 RP11-345M22.2 -5.92 2.08e-08 2.5e-05 -0.57 -0.43 Urate levels; chr16:79716435 chr16:79715232~79770563:- PAAD cis rs7188445 0.899 rs57652769 ENSG00000261390.4 RP11-345M22.2 -5.92 2.08e-08 2.5e-05 -0.57 -0.43 Urate levels; chr16:79720079 chr16:79715232~79770563:- PAAD cis rs2739330 0.731 rs2000468 ENSG00000231271.1 AP000350.8 5.92 2.08e-08 2.5e-05 0.55 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23949918~23954042:+ PAAD cis rs9532669 0.89 rs2324738 ENSG00000176268.5 CYCSP34 5.92 2.08e-08 2.5e-05 0.4 0.43 Cervical cancer; chr13:40925242 chr13:40863599~40863902:- PAAD cis rs17301013 0.507 rs332767 ENSG00000227373.4 RP11-160H22.5 5.92 2.09e-08 2.5e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174686386 chr1:174115300~174160004:- PAAD cis rs734999 0.967 rs6667605 ENSG00000225931.3 RP3-395M20.7 5.92 2.09e-08 2.51e-05 0.42 0.43 Ulcerative colitis; chr1:2571341 chr1:2566410~2569888:+ PAAD cis rs734999 0.967 rs6672381 ENSG00000225931.3 RP3-395M20.7 5.92 2.09e-08 2.51e-05 0.42 0.43 Ulcerative colitis; chr1:2571395 chr1:2566410~2569888:+ PAAD cis rs734999 0.869 rs1555791 ENSG00000225931.3 RP3-395M20.7 5.92 2.09e-08 2.51e-05 0.42 0.43 Ulcerative colitis; chr1:2567423 chr1:2566410~2569888:+ PAAD cis rs7429990 0.833 rs869508 ENSG00000229759.1 MRPS18AP1 5.92 2.09e-08 2.51e-05 0.47 0.43 Educational attainment (years of education); chr3:47571812 chr3:48256350~48256938:- PAAD cis rs3814244 0.933 rs10878725 ENSG00000255733.4 IFNG-AS1 -5.92 2.09e-08 2.51e-05 -0.38 -0.43 Itch intensity from mosquito bite adjusted by bite size; chr12:68020930 chr12:67989445~68234686:+ PAAD cis rs734999 0.967 rs10797433 ENSG00000225931.3 RP3-395M20.7 5.92 2.1e-08 2.52e-05 0.42 0.43 Ulcerative colitis; chr1:2570571 chr1:2566410~2569888:+ PAAD cis rs7829975 0.572 rs28446104 ENSG00000253893.2 FAM85B 5.92 2.1e-08 2.52e-05 0.57 0.43 Mood instability; chr8:8938391 chr8:8167819~8226614:- PAAD cis rs9322193 1 rs9399693 ENSG00000216906.2 RP11-350J20.9 5.92 2.1e-08 2.52e-05 0.54 0.43 Lung cancer; chr6:149612718 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9404048 ENSG00000216906.2 RP11-350J20.9 5.92 2.1e-08 2.52e-05 0.54 0.43 Lung cancer; chr6:149616188 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9767554 ENSG00000216906.2 RP11-350J20.9 5.92 2.1e-08 2.52e-05 0.54 0.43 Lung cancer; chr6:149616860 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9505982 ENSG00000216906.2 RP11-350J20.9 5.92 2.1e-08 2.52e-05 0.54 0.43 Lung cancer; chr6:149618465 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9322196 ENSG00000216906.2 RP11-350J20.9 5.92 2.1e-08 2.52e-05 0.54 0.43 Lung cancer; chr6:149619645 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs10747275 ENSG00000216906.2 RP11-350J20.9 5.92 2.1e-08 2.52e-05 0.54 0.43 Lung cancer; chr6:149622782 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs9688794 ENSG00000216906.2 RP11-350J20.9 5.92 2.1e-08 2.52e-05 0.54 0.43 Lung cancer; chr6:149632121 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9689084 ENSG00000216906.2 RP11-350J20.9 5.92 2.1e-08 2.52e-05 0.54 0.43 Lung cancer; chr6:149639648 chr6:149904243~149906418:+ PAAD cis rs9601248 0.627 rs9545151 ENSG00000227676.3 LINC01068 -5.92 2.11e-08 2.53e-05 -0.57 -0.43 Major depressive disorder; chr13:79608400 chr13:79566727~79571436:+ PAAD cis rs9601248 0.627 rs2876741 ENSG00000227676.3 LINC01068 -5.92 2.11e-08 2.53e-05 -0.57 -0.43 Major depressive disorder; chr13:79612577 chr13:79566727~79571436:+ PAAD cis rs2739330 0.731 rs4822450 ENSG00000231271.1 AP000350.8 5.92 2.11e-08 2.53e-05 0.55 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23949918~23954042:+ PAAD cis rs3814244 0.933 rs12423194 ENSG00000255733.4 IFNG-AS1 5.91 2.12e-08 2.54e-05 0.37 0.43 Itch intensity from mosquito bite adjusted by bite size; chr12:68020387 chr12:67989445~68234686:+ PAAD cis rs2929278 0.617 rs575082 ENSG00000249839.1 AC011330.5 5.91 2.13e-08 2.55e-05 0.58 0.43 Schizophrenia; chr15:43817944 chr15:43663654~43684339:- PAAD cis rs2929278 0.617 rs2955969 ENSG00000249839.1 AC011330.5 5.91 2.13e-08 2.55e-05 0.58 0.43 Schizophrenia; chr15:43822329 chr15:43663654~43684339:- PAAD cis rs2470135 1 rs2470135 ENSG00000205771.5 CATSPER2P1 -5.91 2.13e-08 2.55e-05 -0.57 -0.43 Diastolic blood pressure; chr15:43703591 chr15:43726918~43747094:- PAAD cis rs1061377 0.965 rs12504238 ENSG00000249207.1 RP11-360F5.1 -5.91 2.13e-08 2.55e-05 -0.47 -0.43 Uric acid levels; chr4:39142824 chr4:39112677~39126818:- PAAD cis rs1061377 0.965 rs7690465 ENSG00000249207.1 RP11-360F5.1 -5.91 2.14e-08 2.55e-05 -0.47 -0.43 Uric acid levels; chr4:39147015 chr4:39112677~39126818:- PAAD cis rs4774565 0.762 rs17431095 ENSG00000244879.4 GABPB1-AS1 -5.91 2.14e-08 2.55e-05 -0.4 -0.43 Breast cancer; chr15:50369252 chr15:50354959~50372202:+ PAAD cis rs10463554 0.889 rs246912 ENSG00000175749.11 EIF3KP1 5.91 2.14e-08 2.56e-05 0.58 0.43 Parkinson's disease; chr5:103225140 chr5:103032376~103033031:+ PAAD cis rs17301013 0.897 rs1793291 ENSG00000227373.4 RP11-160H22.5 -5.91 2.14e-08 2.56e-05 -0.57 -0.43 Systemic lupus erythematosus; chr1:174822675 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs1894200 ENSG00000227373.4 RP11-160H22.5 -5.91 2.14e-08 2.56e-05 -0.57 -0.43 Systemic lupus erythematosus; chr1:174842039 chr1:174115300~174160004:- PAAD cis rs2404602 0.598 rs11855999 ENSG00000259422.1 RP11-593F23.1 -5.91 2.14e-08 2.56e-05 -0.56 -0.43 Blood metabolite levels; chr15:76334992 chr15:76174891~76181486:- PAAD cis rs4774565 0.724 rs606118 ENSG00000244879.4 GABPB1-AS1 -5.91 2.14e-08 2.56e-05 -0.41 -0.43 Breast cancer; chr15:50362974 chr15:50354959~50372202:+ PAAD cis rs7429990 0.864 rs6806860 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47708218 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6768699 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47711258 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6785669 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47715771 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6786001 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47718500 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs12495204 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47720540 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7618758 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47720993 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs6442079 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47721044 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs13094264 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47722723 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs4858851 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47724165 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs34777284 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47726585 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs7649393 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47727501 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7638103 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47727585 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6442081 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47728890 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs11130148 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47729797 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7612219 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47739676 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs35148469 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47739873 chr3:48256350~48256938:- PAAD cis rs7429990 0.694 rs7645846 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47740829 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs17079785 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47743160 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6442082 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47743991 chr3:48256350~48256938:- PAAD cis rs7429990 0.747 rs6442083 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47744305 chr3:48256350~48256938:- PAAD cis rs7429990 0.786 rs13064183 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47745405 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs6777632 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47748775 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7637372 ENSG00000229759.1 MRPS18AP1 -5.91 2.15e-08 2.56e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47750385 chr3:48256350~48256938:- PAAD cis rs734999 0.967 rs10797434 ENSG00000225931.3 RP3-395M20.7 5.91 2.15e-08 2.57e-05 0.41 0.43 Ulcerative colitis; chr1:2579841 chr1:2566410~2569888:+ PAAD cis rs7923609 0.578 rs10740138 ENSG00000232075.1 MRPL35P2 -5.91 2.15e-08 2.57e-05 -0.57 -0.43 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63635373 chr10:63634317~63634827:- PAAD cis rs17301013 0.507 rs12065527 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174627066 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12064403 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174627067 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12065825 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174627902 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6667107 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174628667 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912828 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174635701 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912829 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174635894 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6689153 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174639550 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs395109 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174641233 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2760058 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174641320 chr1:174115300~174160004:- PAAD cis rs17301013 0.531 rs332806 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174653645 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs333454 ENSG00000227373.4 RP11-160H22.5 5.91 2.16e-08 2.58e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174653939 chr1:174115300~174160004:- PAAD cis rs638893 0.636 rs6421569 ENSG00000278376.1 RP11-158I9.8 -5.91 2.17e-08 2.59e-05 -0.62 -0.43 Vitiligo; chr11:118785066 chr11:118791254~118793137:+ PAAD cis rs638893 0.578 rs1790188 ENSG00000278376.1 RP11-158I9.8 -5.91 2.17e-08 2.59e-05 -0.62 -0.43 Vitiligo; chr11:118790346 chr11:118791254~118793137:+ PAAD cis rs950169 0.922 rs17531523 ENSG00000225151.9 GOLGA2P7 -5.91 2.17e-08 2.59e-05 -0.51 -0.43 Schizophrenia; chr15:84589218 chr15:84199311~84230136:- PAAD cis rs113835537 0.627 rs4630309 ENSG00000255517.5 CTD-3074O7.5 5.91 2.17e-08 2.59e-05 0.57 0.43 Airway imaging phenotypes; chr11:66565601 chr11:66473490~66480233:- PAAD cis rs9322193 0.962 rs4380763 ENSG00000216906.2 RP11-350J20.9 5.91 2.17e-08 2.59e-05 0.54 0.43 Lung cancer; chr6:149678086 chr6:149904243~149906418:+ PAAD cis rs8059260 0.611 rs34143079 ENSG00000274038.1 RP11-66H6.4 -5.91 2.17e-08 2.59e-05 -0.78 -0.43 Alcohol consumption over the past year; chr16:11069069 chr16:11056556~11057034:+ PAAD cis rs8059260 0.541 rs7195452 ENSG00000274038.1 RP11-66H6.4 -5.91 2.17e-08 2.59e-05 -0.78 -0.43 Alcohol consumption over the past year; chr16:11069469 chr16:11056556~11057034:+ PAAD cis rs9322193 0.923 rs12174716 ENSG00000216906.2 RP11-350J20.9 5.91 2.17e-08 2.59e-05 0.54 0.43 Lung cancer; chr6:149644487 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9800871 ENSG00000216906.2 RP11-350J20.9 5.91 2.17e-08 2.59e-05 0.54 0.43 Lung cancer; chr6:149644540 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9689723 ENSG00000216906.2 RP11-350J20.9 5.91 2.17e-08 2.59e-05 0.54 0.43 Lung cancer; chr6:149655935 chr6:149904243~149906418:+ PAAD cis rs4910157 1 rs4910157 ENSG00000254860.4 TMEM9B-AS1 -5.91 2.17e-08 2.59e-05 -0.47 -0.43 Tonsillectomy; chr11:8919668 chr11:8964675~8977527:+ PAAD cis rs11098499 0.913 rs12186259 ENSG00000245958.5 RP11-33B1.1 -5.91 2.18e-08 2.6e-05 -0.37 -0.43 Corneal astigmatism; chr4:119230884 chr4:119454791~119552025:+ PAAD cis rs72772090 0.539 rs35898772 ENSG00000248734.2 CTD-2260A17.1 -5.91 2.18e-08 2.6e-05 -0.57 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96843982 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs17405676 ENSG00000248734.2 CTD-2260A17.1 -5.91 2.18e-08 2.6e-05 -0.57 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96846912 chr5:96784777~96785999:+ PAAD cis rs72772090 0.539 rs72775809 ENSG00000248734.2 CTD-2260A17.1 -5.91 2.18e-08 2.6e-05 -0.57 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96847853 chr5:96784777~96785999:+ PAAD cis rs12931792 0.712 rs4787495 ENSG00000183604.13 SMG1P5 -5.91 2.19e-08 2.61e-05 -0.46 -0.43 Tonsillectomy; chr16:30154404 chr16:30267553~30335374:- PAAD cis rs8059260 0.604 rs2160042 ENSG00000274038.1 RP11-66H6.4 -5.91 2.2e-08 2.62e-05 -0.76 -0.43 Alcohol consumption over the past year; chr16:11064375 chr16:11056556~11057034:+ PAAD cis rs6061231 0.724 rs1570027 ENSG00000273619.1 RP5-908M14.9 -5.91 2.2e-08 2.62e-05 -0.4 -0.43 Colorectal cancer; chr20:62393540 chr20:62386303~62386970:- PAAD cis rs7429990 0.864 rs12495520 ENSG00000229759.1 MRPS18AP1 -5.91 2.2e-08 2.62e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47766269 chr3:48256350~48256938:- PAAD cis rs9322193 0.847 rs4870054 ENSG00000216906.2 RP11-350J20.9 5.91 2.21e-08 2.63e-05 0.57 0.43 Lung cancer; chr6:149848402 chr6:149904243~149906418:+ PAAD cis rs6700559 0.81 rs10399615 ENSG00000260088.1 RP11-92G12.3 5.91 2.21e-08 2.64e-05 0.56 0.43 Coronary artery disease; chr1:200626145 chr1:200669507~200694250:+ PAAD cis rs6700559 0.81 rs10919990 ENSG00000260088.1 RP11-92G12.3 -5.91 2.21e-08 2.64e-05 -0.56 -0.43 Coronary artery disease; chr1:200627076 chr1:200669507~200694250:+ PAAD cis rs6700559 0.81 rs2809344 ENSG00000260088.1 RP11-92G12.3 5.91 2.21e-08 2.64e-05 0.56 0.43 Coronary artery disease; chr1:200627478 chr1:200669507~200694250:+ PAAD cis rs17711722 0.522 rs4642526 ENSG00000234585.5 CCT6P3 5.9 2.23e-08 2.65e-05 0.35 0.43 Calcium levels; chr7:65751755 chr7:65038354~65074713:+ PAAD cis rs12594515 1 rs11070467 ENSG00000273972.1 CTD-2306A12.1 5.9 2.23e-08 2.65e-05 0.51 0.43 Weight;Waist circumference; chr15:45692803 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8039622 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45694233 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8039974 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45694467 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs6493167 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45694611 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs6493168 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45694613 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs6493169 ENSG00000273972.1 CTD-2306A12.1 5.9 2.23e-08 2.65e-05 0.51 0.43 Weight;Waist circumference; chr15:45694796 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs6493170 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45694821 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs6493172 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45695015 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8025258 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45695356 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8027000 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45695597 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8026221 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45695712 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8031128 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45696330 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8032361 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45696355 chr15:45702640~45703183:+ PAAD cis rs12594515 0.967 rs71405295 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45696723 chr15:45702640~45703183:+ PAAD cis rs12594515 0.506 rs74199860 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45696992 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs6493175 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45697700 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs6493176 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45697828 chr15:45702640~45703183:+ PAAD cis rs12594515 0.967 rs8039088 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45697980 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8038320 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45698069 chr15:45702640~45703183:+ PAAD cis rs12594515 0.967 rs67854274 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45698320 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs58368732 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45698333 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs7172161 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45698582 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs7173144 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45698998 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs7162201 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45700460 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8029209 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45701291 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs12592190 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45701830 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs11854554 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45702348 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs12185095 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45702437 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs35182335 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45702986 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs11855509 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45703276 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs11855562 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45703461 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8043291 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45704049 chr15:45702640~45703183:+ PAAD cis rs12594515 0.935 rs8042519 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45704143 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs56412446 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45704226 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs56220882 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45704877 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8032835 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45705699 chr15:45702640~45703183:+ PAAD cis rs12594515 1 rs8033148 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45705731 chr15:45702640~45703183:+ PAAD cis rs12594515 0.904 rs8032875 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45705812 chr15:45702640~45703183:+ PAAD cis rs12594515 0.874 rs8032878 ENSG00000273972.1 CTD-2306A12.1 -5.9 2.23e-08 2.65e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45705817 chr15:45702640~45703183:+ PAAD cis rs12931792 0.712 rs56399904 ENSG00000183604.13 SMG1P5 5.9 2.23e-08 2.66e-05 0.46 0.43 Tonsillectomy; chr16:30154862 chr16:30267553~30335374:- PAAD cis rs7772486 0.603 rs2223411 ENSG00000235652.6 RP11-545I5.3 -5.9 2.24e-08 2.66e-05 -0.37 -0.43 Lobe attachment (rater-scored or self-reported); chr6:145707631 chr6:145799409~145886585:+ PAAD cis rs7772486 0.558 rs9497403 ENSG00000235652.6 RP11-545I5.3 -5.9 2.24e-08 2.66e-05 -0.37 -0.43 Lobe attachment (rater-scored or self-reported); chr6:145733559 chr6:145799409~145886585:+ PAAD cis rs7772486 0.727 rs2235481 ENSG00000235652.6 RP11-545I5.3 -5.9 2.24e-08 2.66e-05 -0.37 -0.43 Lobe attachment (rater-scored or self-reported); chr6:145735712 chr6:145799409~145886585:+ PAAD cis rs6700559 1 rs12076877 ENSG00000260088.1 RP11-92G12.3 -5.9 2.26e-08 2.68e-05 -0.57 -0.43 Coronary artery disease; chr1:200674277 chr1:200669507~200694250:+ PAAD cis rs10875746 0.903 rs12306451 ENSG00000240399.1 RP1-228P16.1 -5.9 2.26e-08 2.69e-05 -0.48 -0.43 Longevity (90 years and older); chr12:48089458 chr12:48054813~48055591:- PAAD cis rs3762637 0.943 rs28403550 ENSG00000272758.4 RP11-299J3.8 -5.9 2.26e-08 2.69e-05 -0.63 -0.43 LDL cholesterol levels; chr3:122532991 chr3:122416207~122443180:+ PAAD cis rs2337406 0.866 rs4583128 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106780669 chr14:106770577~106771020:- PAAD cis rs2337406 0.929 rs12050200 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106780983 chr14:106770577~106771020:- PAAD cis rs2337406 0.852 rs12050239 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781132 chr14:106770577~106771020:- PAAD cis rs2337406 0.929 rs59263250 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781183 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs58083017 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781256 chr14:106770577~106771020:- PAAD cis rs2337406 0.789 rs60390024 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781327 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74092532 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781363 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74092534 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781364 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74092535 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781722 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74092537 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781883 chr14:106770577~106771020:- PAAD cis rs2337406 0.81 rs74092538 ENSG00000274576.2 IGHV2-70 -5.9 2.27e-08 2.7e-05 -0.54 -0.43 Alzheimer's disease (late onset); chr14:106781942 chr14:106770577~106771020:- PAAD cis rs8059260 0.604 rs8052325 ENSG00000274038.1 RP11-66H6.4 -5.9 2.27e-08 2.7e-05 -0.72 -0.43 Alcohol consumption over the past year; chr16:11044121 chr16:11056556~11057034:+ PAAD cis rs992157 0.835 rs6707559 ENSG00000261338.2 RP11-378A13.1 5.9 2.27e-08 2.7e-05 0.51 0.43 Colorectal cancer; chr2:218278050 chr2:218255319~218257366:+ PAAD cis rs9640161 0.871 rs56156367 ENSG00000261305.1 RP4-584D14.7 5.9 2.28e-08 2.7e-05 0.65 0.43 Blood protein levels;Circulating chemerin levels; chr7:150350112 chr7:150341771~150342607:+ PAAD cis rs1150668 0.796 rs213237 ENSG00000216901.1 AL022393.7 5.9 2.28e-08 2.7e-05 0.5 0.43 Pubertal anthropometrics; chr6:28356161 chr6:28176188~28176674:+ PAAD cis rs755249 0.727 rs12028034 ENSG00000237624.1 OXCT2P1 -5.9 2.29e-08 2.72e-05 -0.56 -0.43 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39574035 chr1:39514956~39516490:+ PAAD cis rs992157 0.717 rs11692780 ENSG00000261338.2 RP11-378A13.1 -5.9 2.29e-08 2.72e-05 -0.51 -0.43 Colorectal cancer; chr2:218284440 chr2:218255319~218257366:+ PAAD cis rs10170846 1 rs10170846 ENSG00000261428.2 RP11-16P6.1 -5.9 2.3e-08 2.73e-05 -0.57 -0.43 Schizophrenia (inflammation and infection response interaction); chr2:222652986 chr2:222566899~222569719:- PAAD cis rs2243480 0.666 rs1880311 ENSG00000226824.5 RP4-756H11.3 5.9 2.3e-08 2.73e-05 0.81 0.43 Diabetic kidney disease; chr7:65811765 chr7:66654538~66669855:+ PAAD cis rs2115630 0.645 rs2292463 ENSG00000275120.1 RP11-182J1.17 -5.9 2.3e-08 2.73e-05 -0.43 -0.43 P wave terminal force; chr15:84632519 chr15:84599434~84606463:- PAAD cis rs7714584 1 rs7724558 ENSG00000197083.10 ZNF300P1 5.9 2.3e-08 2.73e-05 0.72 0.43 Crohn's disease; chr5:150949304 chr5:150930645~150946289:- PAAD cis rs9640161 0.83 rs3757423 ENSG00000261305.1 RP4-584D14.7 -5.9 2.3e-08 2.73e-05 -0.58 -0.43 Blood protein levels;Circulating chemerin levels; chr7:150370625 chr7:150341771~150342607:+ PAAD cis rs7201929 1 rs7201929 ENSG00000259982.1 CDC37P1 5.9 2.31e-08 2.74e-05 0.54 0.43 QT interval; chr16:28860645 chr16:28700294~28701540:- PAAD cis rs7772486 0.597 rs2246132 ENSG00000235652.6 RP11-545I5.3 5.9 2.32e-08 2.75e-05 0.36 0.43 Lobe attachment (rater-scored or self-reported); chr6:145861379 chr6:145799409~145886585:+ PAAD cis rs9640161 0.789 rs28432021 ENSG00000261305.1 RP4-584D14.7 5.9 2.32e-08 2.75e-05 0.65 0.43 Blood protein levels;Circulating chemerin levels; chr7:150349146 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs28439010 ENSG00000261305.1 RP4-584D14.7 5.9 2.32e-08 2.75e-05 0.65 0.43 Blood protein levels;Circulating chemerin levels; chr7:150349187 chr7:150341771~150342607:+ PAAD cis rs7188445 0.933 rs56892402 ENSG00000261390.4 RP11-345M22.2 -5.9 2.32e-08 2.75e-05 -0.59 -0.43 Urate levels; chr16:79682728 chr16:79715232~79770563:- PAAD cis rs673078 0.66 rs11068908 ENSG00000275759.1 RP11-131L12.3 -5.9 2.33e-08 2.76e-05 -0.61 -0.43 Glucose homeostasis traits; chr12:118327265 chr12:118428281~118428870:+ PAAD cis rs7429990 0.727 rs319695 ENSG00000229759.1 MRPS18AP1 -5.9 2.33e-08 2.76e-05 -0.48 -0.43 Educational attainment (years of education); chr3:47842749 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs12497826 ENSG00000229759.1 MRPS18AP1 -5.89 2.34e-08 2.78e-05 -0.47 -0.43 Educational attainment (years of education); chr3:47628059 chr3:48256350~48256938:- PAAD cis rs853679 0.567 rs6905380 ENSG00000204709.4 LINC01556 5.89 2.36e-08 2.79e-05 0.64 0.43 Depression; chr6:28407125 chr6:28943877~28944537:+ PAAD cis rs6538678 0.895 rs7137751 ENSG00000258343.1 RP11-536G4.2 -5.89 2.36e-08 2.79e-05 -0.57 -0.43 Lupus nephritis in systemic lupus erythematosus; chr12:95861806 chr12:95795345~95858839:- PAAD cis rs10463554 0.963 rs13340364 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103003406 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs13340345 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103003518 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs3776860 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103014266 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs62362546 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103015615 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs17154959 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103020587 chr5:103032376~103033031:+ PAAD cis rs10463554 0.926 rs3776858 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103021790 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs3776857 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103022456 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs7717343 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103026279 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs7721530 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103026488 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs6596530 ENSG00000175749.11 EIF3KP1 5.89 2.36e-08 2.79e-05 0.55 0.43 Parkinson's disease; chr5:103035736 chr5:103032376~103033031:+ PAAD cis rs7945705 0.967 rs34842234 ENSG00000254860.4 TMEM9B-AS1 -5.89 2.36e-08 2.79e-05 -0.48 -0.43 Hemoglobin concentration; chr11:8870347 chr11:8964675~8977527:+ PAAD cis rs7945705 0.967 rs7123861 ENSG00000254860.4 TMEM9B-AS1 -5.89 2.36e-08 2.79e-05 -0.48 -0.43 Hemoglobin concentration; chr11:8870776 chr11:8964675~8977527:+ PAAD cis rs62229266 0.654 rs62230787 ENSG00000231106.2 LINC01436 5.89 2.37e-08 2.8e-05 0.63 0.43 Mitral valve prolapse; chr21:36004182 chr21:36005338~36007838:+ PAAD cis rs17301013 0.507 rs11806996 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174654784 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2060158 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174667379 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs3862941 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174689418 chr1:174115300~174160004:- PAAD cis rs17301013 0.531 rs55688014 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174693321 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs55667039 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174698699 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72715281 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174711533 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2861005 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174711832 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs17842156 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174715050 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2146564 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174716214 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs17842157 ENSG00000227373.4 RP11-160H22.5 5.89 2.38e-08 2.81e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174719442 chr1:174115300~174160004:- PAAD cis rs8059260 0.604 rs741176 ENSG00000274038.1 RP11-66H6.4 5.89 2.38e-08 2.82e-05 0.72 0.43 Alcohol consumption over the past year; chr16:11051953 chr16:11056556~11057034:+ PAAD cis rs9322193 0.504 rs7771014 ENSG00000223701.3 RAET1E-AS1 5.89 2.38e-08 2.82e-05 0.51 0.43 Lung cancer; chr6:149884310 chr6:149884431~149919508:+ PAAD cis rs858239 1 rs156407 ENSG00000226816.2 AC005082.12 5.89 2.38e-08 2.82e-05 0.48 0.43 Cerebrospinal fluid biomarker levels; chr7:23276020 chr7:23206013~23208045:+ PAAD cis rs8059260 0.604 rs16957966 ENSG00000274038.1 RP11-66H6.4 -5.89 2.38e-08 2.82e-05 -0.71 -0.43 Alcohol consumption over the past year; chr16:11046280 chr16:11056556~11057034:+ PAAD cis rs1930961 1 rs6004667 ENSG00000100058.11 CRYBB2P1 -5.89 2.39e-08 2.82e-05 -0.76 -0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs6004668 ENSG00000100058.11 CRYBB2P1 -5.89 2.39e-08 2.82e-05 -0.76 -0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25448105~25520854:+ PAAD cis rs6142102 0.602 rs10485503 ENSG00000276073.1 RP5-1125A11.7 -5.89 2.4e-08 2.83e-05 -0.44 -0.43 Skin pigmentation; chr20:33970036 chr20:33985617~33988989:- PAAD cis rs7615952 0.515 rs7637246 ENSG00000171084.14 FAM86JP 5.89 2.4e-08 2.84e-05 0.68 0.43 Blood pressure (smoking interaction); chr3:125959863 chr3:125916620~125930024:+ PAAD cis rs6683071 0.688 rs2936049 ENSG00000272750.1 RP11-378J18.8 5.89 2.41e-08 2.85e-05 0.54 0.43 Cognitive performance; chr1:222684825 chr1:222658867~222661512:- PAAD cis rs6683071 0.643 rs35507977 ENSG00000272750.1 RP11-378J18.8 -5.89 2.41e-08 2.85e-05 -0.54 -0.43 Cognitive performance; chr1:222700776 chr1:222658867~222661512:- PAAD cis rs67180937 0.553 rs11485123 ENSG00000272750.1 RP11-378J18.8 -5.89 2.41e-08 2.85e-05 -0.54 -0.43 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222704833 chr1:222658867~222661512:- PAAD cis rs6683071 0.643 rs34433664 ENSG00000272750.1 RP11-378J18.8 -5.89 2.41e-08 2.85e-05 -0.54 -0.43 Cognitive performance; chr1:222709607 chr1:222658867~222661512:- PAAD cis rs6683071 0.688 rs3811465 ENSG00000272750.1 RP11-378J18.8 -5.89 2.41e-08 2.85e-05 -0.54 -0.43 Cognitive performance; chr1:222712777 chr1:222658867~222661512:- PAAD cis rs12594515 0.967 rs11856523 ENSG00000273972.1 CTD-2306A12.1 -5.89 2.41e-08 2.85e-05 -0.51 -0.43 Weight;Waist circumference; chr15:45697297 chr15:45702640~45703183:+ PAAD cis rs7772486 0.558 rs9376965 ENSG00000235652.6 RP11-545I5.3 5.89 2.42e-08 2.86e-05 0.36 0.43 Lobe attachment (rater-scored or self-reported); chr6:145808919 chr6:145799409~145886585:+ PAAD cis rs7772486 0.597 rs2485631 ENSG00000235652.6 RP11-545I5.3 5.89 2.42e-08 2.86e-05 0.36 0.43 Lobe attachment (rater-scored or self-reported); chr6:145868941 chr6:145799409~145886585:+ PAAD cis rs7772486 0.641 rs2253757 ENSG00000235652.6 RP11-545I5.3 5.89 2.42e-08 2.86e-05 0.36 0.43 Lobe attachment (rater-scored or self-reported); chr6:145878550 chr6:145799409~145886585:+ PAAD cis rs7772486 0.558 rs7753273 ENSG00000235652.6 RP11-545I5.3 -5.89 2.42e-08 2.86e-05 -0.36 -0.43 Lobe attachment (rater-scored or self-reported); chr6:145744903 chr6:145799409~145886585:+ PAAD cis rs7772486 0.59 rs1890170 ENSG00000235652.6 RP11-545I5.3 -5.89 2.42e-08 2.86e-05 -0.36 -0.43 Lobe attachment (rater-scored or self-reported); chr6:145750703 chr6:145799409~145886585:+ PAAD cis rs9326248 0.911 rs11216284 ENSG00000280143.1 AP000892.6 5.89 2.43e-08 2.87e-05 0.56 0.43 Blood protein levels; chr11:117132344 chr11:117204967~117210292:+ PAAD cis rs113835537 0.597 rs7939759 ENSG00000255517.5 CTD-3074O7.5 -5.89 2.44e-08 2.88e-05 -0.55 -0.43 Airway imaging phenotypes; chr11:66570493 chr11:66473490~66480233:- PAAD cis rs113835537 0.597 rs10896129 ENSG00000255517.5 CTD-3074O7.5 -5.89 2.44e-08 2.88e-05 -0.55 -0.43 Airway imaging phenotypes; chr11:66570829 chr11:66473490~66480233:- PAAD cis rs113835537 0.559 rs57045447 ENSG00000255517.5 CTD-3074O7.5 -5.89 2.44e-08 2.88e-05 -0.55 -0.43 Airway imaging phenotypes; chr11:66572212 chr11:66473490~66480233:- PAAD cis rs1930961 1 rs6004669 ENSG00000100058.11 CRYBB2P1 5.89 2.45e-08 2.89e-05 0.78 0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs5996946 ENSG00000100058.11 CRYBB2P1 5.89 2.45e-08 2.89e-05 0.78 0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs997873 ENSG00000100058.11 CRYBB2P1 5.89 2.45e-08 2.89e-05 0.78 0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs997872 ENSG00000100058.11 CRYBB2P1 5.89 2.45e-08 2.89e-05 0.78 0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs6004671 ENSG00000100058.11 CRYBB2P1 5.89 2.45e-08 2.89e-05 0.78 0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25483507 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs6004672 ENSG00000100058.11 CRYBB2P1 5.89 2.45e-08 2.89e-05 0.78 0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25448105~25520854:+ PAAD cis rs9640161 0.789 rs6964110 ENSG00000261305.1 RP4-584D14.7 5.89 2.45e-08 2.89e-05 0.65 0.43 Blood protein levels;Circulating chemerin levels; chr7:150344747 chr7:150341771~150342607:+ PAAD cis rs7188445 0.836 rs3813580 ENSG00000261390.4 RP11-345M22.2 -5.88 2.46e-08 2.9e-05 -0.58 -0.43 Urate levels; chr16:79715383 chr16:79715232~79770563:- PAAD cis rs11098499 0.754 rs17595608 ENSG00000245958.5 RP11-33B1.1 -5.88 2.47e-08 2.91e-05 -0.34 -0.43 Corneal astigmatism; chr4:119329351 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs1980027 ENSG00000245958.5 RP11-33B1.1 -5.88 2.47e-08 2.91e-05 -0.34 -0.43 Corneal astigmatism; chr4:119330422 chr4:119454791~119552025:+ PAAD cis rs2739330 0.828 rs2186366 ENSG00000231271.1 AP000350.8 -5.88 2.47e-08 2.91e-05 -0.57 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23949918~23954042:+ PAAD cis rs858239 1 rs199351 ENSG00000226816.2 AC005082.12 5.88 2.47e-08 2.91e-05 0.49 0.43 Cerebrospinal fluid biomarker levels; chr7:23260430 chr7:23206013~23208045:+ PAAD cis rs6683071 0.688 rs2378604 ENSG00000272750.1 RP11-378J18.8 -5.88 2.47e-08 2.92e-05 -0.54 -0.43 Cognitive performance; chr1:222730968 chr1:222658867~222661512:- PAAD cis rs17301013 0.507 rs10912775 ENSG00000227373.4 RP11-160H22.5 5.88 2.48e-08 2.92e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174388034 chr1:174115300~174160004:- PAAD cis rs2404602 0.598 rs71405204 ENSG00000259422.1 RP11-593F23.1 -5.88 2.49e-08 2.93e-05 -0.56 -0.43 Blood metabolite levels; chr15:76342964 chr15:76174891~76181486:- PAAD cis rs9640161 0.789 rs10282458 ENSG00000261305.1 RP4-584D14.7 5.88 2.51e-08 2.95e-05 0.65 0.43 Blood protein levels;Circulating chemerin levels; chr7:150348213 chr7:150341771~150342607:+ PAAD cis rs5769707 0.521 rs74351010 ENSG00000188511.11 C22orf34 -5.88 2.52e-08 2.96e-05 -0.53 -0.43 Monocyte percentage of white cells;Monocyte count; chr22:49643172 chr22:49414524~49657542:- PAAD cis rs8059260 0.604 rs12102345 ENSG00000274038.1 RP11-66H6.4 -5.88 2.52e-08 2.97e-05 -0.71 -0.43 Alcohol consumption over the past year; chr16:11053863 chr16:11056556~11057034:+ PAAD cis rs3096299 0.719 rs2911262 ENSG00000274627.1 RP11-104N10.2 5.88 2.52e-08 2.97e-05 0.37 0.43 Multiple myeloma (IgH translocation); chr16:89448633 chr16:89516797~89522217:+ PAAD cis rs9322193 0.962 rs3805748 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149772542 chr6:149904243~149906418:+ PAAD cis rs9322193 0.736 rs10457851 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149775216 chr6:149904243~149906418:+ PAAD cis rs9322193 0.886 rs10872652 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149775303 chr6:149904243~149906418:+ PAAD cis rs9322193 0.886 rs12525871 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149775882 chr6:149904243~149906418:+ PAAD cis rs9322193 0.886 rs17672976 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149776207 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs2184369 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149776681 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs2342861 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149777561 chr6:149904243~149906418:+ PAAD cis rs9322193 0.926 rs2342860 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149777641 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs10872653 ENSG00000216906.2 RP11-350J20.9 5.88 2.53e-08 2.98e-05 0.56 0.43 Lung cancer; chr6:149778907 chr6:149904243~149906418:+ PAAD cis rs10510102 0.808 rs11200296 ENSG00000276742.1 RP11-500G22.4 5.88 2.54e-08 2.98e-05 0.65 0.43 Breast cancer; chr10:121971956 chr10:121956782~121957098:+ PAAD cis rs950169 0.919 rs12915589 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84065712 chr15:84199311~84230136:- PAAD cis rs950169 0.959 rs66801143 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84067905 chr15:84199311~84230136:- PAAD cis rs950169 1 rs35648189 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84071996 chr15:84199311~84230136:- PAAD cis rs950169 0.92 rs17300048 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84080725 chr15:84199311~84230136:- PAAD cis rs950169 1 rs1848093 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84086775 chr15:84199311~84230136:- PAAD cis rs950169 1 rs12915234 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84089549 chr15:84199311~84230136:- PAAD cis rs950169 1 rs34751999 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84089667 chr15:84199311~84230136:- PAAD cis rs950169 0.919 rs17300292 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84093816 chr15:84199311~84230136:- PAAD cis rs950169 1 rs12916348 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84096775 chr15:84199311~84230136:- PAAD cis rs950169 1 rs35297609 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84104144 chr15:84199311~84230136:- PAAD cis rs950169 1 rs62026530 ENSG00000225151.9 GOLGA2P7 -5.88 2.54e-08 2.99e-05 -0.52 -0.43 Schizophrenia; chr15:84107088 chr15:84199311~84230136:- PAAD cis rs3814244 0.902 rs2870961 ENSG00000255733.4 IFNG-AS1 -5.88 2.54e-08 2.99e-05 -0.38 -0.43 Itch intensity from mosquito bite adjusted by bite size; chr12:68024262 chr12:67989445~68234686:+ PAAD cis rs3814244 0.933 rs10748093 ENSG00000255733.4 IFNG-AS1 -5.88 2.54e-08 2.99e-05 -0.38 -0.43 Itch intensity from mosquito bite adjusted by bite size; chr12:68024469 chr12:67989445~68234686:+ PAAD cis rs875971 0.83 rs6976714 ENSG00000237310.1 GS1-124K5.4 5.88 2.54e-08 2.99e-05 0.44 0.43 Aortic root size; chr7:66426474 chr7:66493706~66495474:+ PAAD cis rs875971 0.651 rs2420596 ENSG00000237310.1 GS1-124K5.4 5.88 2.54e-08 2.99e-05 0.44 0.43 Aortic root size; chr7:66450996 chr7:66493706~66495474:+ PAAD cis rs875971 0.52 rs2420597 ENSG00000237310.1 GS1-124K5.4 5.88 2.54e-08 2.99e-05 0.44 0.43 Aortic root size; chr7:66450999 chr7:66493706~66495474:+ PAAD cis rs2115630 0.691 rs8040066 ENSG00000275120.1 RP11-182J1.17 -5.88 2.55e-08 2.99e-05 -0.44 -0.43 P wave terminal force; chr15:84633234 chr15:84599434~84606463:- PAAD cis rs950169 0.526 rs698620 ENSG00000275120.1 RP11-182J1.17 -5.88 2.55e-08 2.99e-05 -0.44 -0.43 Schizophrenia; chr15:84633977 chr15:84599434~84606463:- PAAD cis rs9601248 0.841 rs9545146 ENSG00000227676.3 LINC01068 -5.88 2.55e-08 3e-05 -0.56 -0.43 Major depressive disorder; chr13:79601471 chr13:79566727~79571436:+ PAAD cis rs992157 0.798 rs7587220 ENSG00000261338.2 RP11-378A13.1 -5.88 2.56e-08 3e-05 -0.51 -0.43 Colorectal cancer; chr2:218296141 chr2:218255319~218257366:+ PAAD cis rs992157 0.798 rs4674284 ENSG00000261338.2 RP11-378A13.1 -5.88 2.56e-08 3e-05 -0.51 -0.43 Colorectal cancer; chr2:218296518 chr2:218255319~218257366:+ PAAD cis rs992157 0.798 rs12053514 ENSG00000261338.2 RP11-378A13.1 -5.88 2.56e-08 3e-05 -0.51 -0.43 Colorectal cancer; chr2:218303242 chr2:218255319~218257366:+ PAAD cis rs992157 0.798 rs10193383 ENSG00000261338.2 RP11-378A13.1 5.88 2.56e-08 3e-05 0.51 0.43 Colorectal cancer; chr2:218292969 chr2:218255319~218257366:+ PAAD cis rs992157 0.798 rs10206064 ENSG00000261338.2 RP11-378A13.1 5.88 2.56e-08 3e-05 0.51 0.43 Colorectal cancer; chr2:218293236 chr2:218255319~218257366:+ PAAD cis rs992157 0.7 rs10165153 ENSG00000261338.2 RP11-378A13.1 5.88 2.56e-08 3e-05 0.51 0.43 Colorectal cancer; chr2:218294906 chr2:218255319~218257366:+ PAAD cis rs17301013 0.507 rs2860955 ENSG00000227373.4 RP11-160H22.5 -5.88 2.56e-08 3e-05 -0.62 -0.43 Systemic lupus erythematosus; chr1:174391380 chr1:174115300~174160004:- PAAD cis rs1075232 0.655 rs28451043 ENSG00000270055.1 CTD-3092A11.2 -5.88 2.56e-08 3e-05 -1.02 -0.43 Survival in colorectal cancer (non-distant metastatic); chr15:31295359 chr15:30487963~30490313:+ PAAD cis rs1075232 0.655 rs77987193 ENSG00000270055.1 CTD-3092A11.2 -5.88 2.56e-08 3e-05 -1.02 -0.43 Survival in colorectal cancer (non-distant metastatic); chr15:31296055 chr15:30487963~30490313:+ PAAD cis rs3096299 0.719 rs2965945 ENSG00000274627.1 RP11-104N10.2 5.88 2.56e-08 3e-05 0.36 0.43 Multiple myeloma (IgH translocation); chr16:89447609 chr16:89516797~89522217:+ PAAD cis rs4972806 0.814 rs966801 ENSG00000226363.3 HAGLROS -5.88 2.57e-08 3.01e-05 -0.52 -0.43 IgG glycosylation; chr2:176173099 chr2:176177717~176179008:+ PAAD cis rs453301 0.682 rs2929308 ENSG00000253893.2 FAM85B 5.87 2.58e-08 3.02e-05 0.6 0.43 Joint mobility (Beighton score); chr8:9226611 chr8:8167819~8226614:- PAAD cis rs1150668 0.796 rs728122 ENSG00000216901.1 AL022393.7 5.87 2.58e-08 3.02e-05 0.51 0.43 Pubertal anthropometrics; chr6:28431347 chr6:28176188~28176674:+ PAAD cis rs2739330 0.828 rs2877178 ENSG00000231271.1 AP000350.8 5.87 2.59e-08 3.03e-05 0.58 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23949918~23954042:+ PAAD cis rs2739330 0.828 rs2154593 ENSG00000231271.1 AP000350.8 5.87 2.59e-08 3.03e-05 0.58 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23949918~23954042:+ PAAD cis rs673078 0.607 rs8467 ENSG00000275759.1 RP11-131L12.3 -5.87 2.59e-08 3.04e-05 -0.65 -0.43 Glucose homeostasis traits; chr12:118417479 chr12:118428281~118428870:+ PAAD cis rs7829975 0.606 rs6601274 ENSG00000253893.2 FAM85B 5.87 2.59e-08 3.04e-05 0.58 0.43 Mood instability; chr8:8941549 chr8:8167819~8226614:- PAAD cis rs17301013 0.507 rs72715294 ENSG00000227373.4 RP11-160H22.5 5.87 2.6e-08 3.04e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174754922 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1813136 ENSG00000227373.4 RP11-160H22.5 5.87 2.6e-08 3.04e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174756656 chr1:174115300~174160004:- PAAD cis rs7188445 0.932 rs73575079 ENSG00000261390.4 RP11-345M22.2 -5.87 2.6e-08 3.04e-05 -0.58 -0.43 Urate levels; chr16:79711344 chr16:79715232~79770563:- PAAD cis rs465969 0.744 rs574056 ENSG00000255389.1 C6orf3 -5.87 2.61e-08 3.05e-05 -0.82 -0.43 Psoriasis; chr6:111305787 chr6:111599875~111602295:+ PAAD cis rs11651753 0.598 rs4794286 ENSG00000264920.1 RP11-6N17.4 -5.87 2.61e-08 3.05e-05 -0.49 -0.43 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47913231 chr17:47891255~47895812:- PAAD cis rs755249 0.701 rs4660823 ENSG00000237624.1 OXCT2P1 5.87 2.61e-08 3.06e-05 0.55 0.43 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39532851 chr1:39514956~39516490:+ PAAD cis rs3096299 0.719 rs2965817 ENSG00000274627.1 RP11-104N10.2 5.87 2.61e-08 3.06e-05 0.37 0.43 Multiple myeloma (IgH translocation); chr16:89446826 chr16:89516797~89522217:+ PAAD cis rs10262624 0.901 rs6977550 ENSG00000234286.1 AC006026.13 -5.87 2.61e-08 3.06e-05 -0.5 -0.43 Schizophrenia; chr7:23865825 chr7:23680195~23680786:- PAAD cis rs7188445 0.871 rs8047723 ENSG00000261390.4 RP11-345M22.2 5.87 2.63e-08 3.07e-05 0.58 0.43 Urate levels; chr16:79671018 chr16:79715232~79770563:- PAAD cis rs4218 0.648 rs877269 ENSG00000277144.1 RP11-59H7.4 -5.87 2.63e-08 3.08e-05 -0.6 -0.43 Social communication problems; chr15:59081595 chr15:59115547~59116089:- PAAD cis rs11089937 0.864 rs5757041 ENSG00000211639.2 IGLV4-60 5.87 2.63e-08 3.08e-05 0.4 0.43 Periodontitis (PAL4Q3); chr22:22140538 chr22:22162199~22162681:+ PAAD cis rs10771431 1 rs10771431 ENSG00000111788.10 RP11-22B23.1 5.87 2.63e-08 3.08e-05 0.39 0.43 Breast size; chr12:9228263 chr12:9277235~9313241:+ PAAD cis rs9322193 0.923 rs9766037 ENSG00000216906.2 RP11-350J20.9 5.87 2.63e-08 3.08e-05 0.56 0.43 Lung cancer; chr6:149616921 chr6:149904243~149906418:+ PAAD cis rs17301013 0.507 rs7521109 ENSG00000227373.4 RP11-160H22.5 5.87 2.64e-08 3.09e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174802629 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72717616 ENSG00000227373.4 RP11-160H22.5 5.87 2.64e-08 3.09e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174812711 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2183202 ENSG00000227373.4 RP11-160H22.5 5.87 2.64e-08 3.09e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174824553 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6687616 ENSG00000227373.4 RP11-160H22.5 5.87 2.64e-08 3.09e-05 0.66 0.43 Systemic lupus erythematosus; chr1:174840322 chr1:174115300~174160004:- PAAD cis rs673078 0.607 rs1060964 ENSG00000275759.1 RP11-131L12.3 -5.87 2.65e-08 3.09e-05 -0.64 -0.43 Glucose homeostasis traits; chr12:118414906 chr12:118428281~118428870:+ PAAD cis rs950169 0.96 rs35159785 ENSG00000259728.4 LINC00933 5.87 2.65e-08 3.1e-05 0.55 0.43 Schizophrenia; chr15:84135262 chr15:84570649~84580175:+ PAAD cis rs2283792 1 rs3788332 ENSG00000224086.5 LL22NC03-86G7.1 -5.87 2.65e-08 3.1e-05 -0.44 -0.43 Multiple sclerosis; chr22:21817278 chr22:21938293~21977632:+ PAAD cis rs2739330 0.828 rs5760102 ENSG00000250470.1 AP000351.3 5.87 2.65e-08 3.1e-05 0.63 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23976904~23977585:- PAAD cis rs72772090 0.539 rs56395748 ENSG00000248734.2 CTD-2260A17.1 -5.87 2.65e-08 3.1e-05 -0.59 -0.43 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96841190 chr5:96784777~96785999:+ PAAD cis rs1928295 0.786 rs957512 ENSG00000233569.1 RP11-500B12.1 5.87 2.66e-08 3.11e-05 0.49 0.43 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117643427 chr9:117648606~117657027:+ PAAD cis rs7188445 0.932 rs17767491 ENSG00000261390.4 RP11-345M22.2 -5.87 2.66e-08 3.11e-05 -0.59 -0.43 Urate levels; chr16:79711590 chr16:79715232~79770563:- PAAD cis rs9322193 0.962 rs12175575 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149763351 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs4869966 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149763714 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs1112730 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149766383 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs1112729 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149766491 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs10452626 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149767481 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs62441303 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149767547 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9765929 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149769680 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs11155683 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149779341 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9372044 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149780867 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs11155685 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149781649 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9322220 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149782897 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs10214845 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149783124 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9767122 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149783553 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs1413654 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149783956 chr6:149904243~149906418:+ PAAD cis rs9322193 0.683 rs113281309 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149787289 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9688809 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149787920 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9689242 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149787970 chr6:149904243~149906418:+ PAAD cis rs9322193 1 rs9767077 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149788479 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9688938 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149788941 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9688940 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149788977 chr6:149904243~149906418:+ PAAD cis rs9322193 0.632 rs3828700 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149791033 chr6:149904243~149906418:+ PAAD cis rs9322193 0.736 rs3828701 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149791063 chr6:149904243~149906418:+ PAAD cis rs9322193 0.736 rs3805750 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149791065 chr6:149904243~149906418:+ PAAD cis rs9322193 0.926 rs3805751 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149791193 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9689269 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149791861 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs62441335 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149792658 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs4816 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149793609 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs3805753 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149795662 chr6:149904243~149906418:+ PAAD cis rs9322193 0.926 rs952166 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149798774 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs952165 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149798900 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs10872656 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149799444 chr6:149904243~149906418:+ PAAD cis rs9322193 0.926 rs9285525 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149801253 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs2342858 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149805967 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs6914319 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149806304 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs2095375 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149807037 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs4869730 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149808187 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs11155689 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149808470 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs2151913 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149809506 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs933055 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149809701 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs4869731 ENSG00000216906.2 RP11-350J20.9 5.87 2.67e-08 3.11e-05 0.55 0.43 Lung cancer; chr6:149810072 chr6:149904243~149906418:+ PAAD cis rs113835537 0.597 rs2075792 ENSG00000255517.5 CTD-3074O7.5 -5.87 2.67e-08 3.12e-05 -0.55 -0.43 Airway imaging phenotypes; chr11:66567085 chr11:66473490~66480233:- PAAD cis rs6538678 0.833 rs10859966 ENSG00000258343.1 RP11-536G4.2 5.87 2.68e-08 3.13e-05 0.53 0.43 Lupus nephritis in systemic lupus erythematosus; chr12:95859597 chr12:95795345~95858839:- PAAD cis rs11123170 0.543 rs4849178 ENSG00000189223.12 PAX8-AS1 -5.87 2.68e-08 3.13e-05 -0.61 -0.43 Renal function-related traits (BUN); chr2:113225031 chr2:113211522~113276581:+ PAAD cis rs6504622 0.687 rs11871364 ENSG00000262879.4 RP11-156P1.3 -5.87 2.69e-08 3.14e-05 -0.43 -0.43 Orofacial clefts; chr17:47105786 chr17:46984045~47100323:- PAAD cis rs9532669 0.963 rs4942012 ENSG00000176268.5 CYCSP34 5.87 2.69e-08 3.14e-05 0.4 0.43 Cervical cancer; chr13:40939112 chr13:40863599~40863902:- PAAD cis rs10875746 0.903 rs989144 ENSG00000240399.1 RP1-228P16.1 -5.87 2.69e-08 3.14e-05 -0.48 -0.43 Longevity (90 years and older); chr12:48090190 chr12:48054813~48055591:- PAAD cis rs2115630 0.645 rs3825877 ENSG00000275120.1 RP11-182J1.17 -5.87 2.69e-08 3.14e-05 -0.43 -0.43 P wave terminal force; chr15:84631400 chr15:84599434~84606463:- PAAD cis rs2115630 0.645 rs3825878 ENSG00000275120.1 RP11-182J1.17 -5.87 2.69e-08 3.14e-05 -0.43 -0.43 P wave terminal force; chr15:84631524 chr15:84599434~84606463:- PAAD cis rs73086581 0.838 rs56401022 ENSG00000229539.1 RP11-119B16.2 5.87 2.7e-08 3.15e-05 0.68 0.43 Response to antidepressants in depression; chr20:4043634 chr20:3888239~3888868:- PAAD cis rs73086581 0.735 rs6037730 ENSG00000229539.1 RP11-119B16.2 5.87 2.7e-08 3.15e-05 0.68 0.43 Response to antidepressants in depression; chr20:4046171 chr20:3888239~3888868:- PAAD cis rs73086581 0.838 rs6052265 ENSG00000229539.1 RP11-119B16.2 5.87 2.7e-08 3.15e-05 0.68 0.43 Response to antidepressants in depression; chr20:4046188 chr20:3888239~3888868:- PAAD cis rs73086581 0.838 rs11906481 ENSG00000229539.1 RP11-119B16.2 5.87 2.7e-08 3.15e-05 0.68 0.43 Response to antidepressants in depression; chr20:4048059 chr20:3888239~3888868:- PAAD cis rs7429990 0.864 rs7631950 ENSG00000229759.1 MRPS18AP1 -5.86 2.71e-08 3.15e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47591865 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs11716582 ENSG00000229759.1 MRPS18AP1 -5.86 2.71e-08 3.15e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47592269 chr3:48256350~48256938:- PAAD cis rs7429990 0.52 rs78838427 ENSG00000229759.1 MRPS18AP1 -5.86 2.71e-08 3.15e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47595561 chr3:48256350~48256938:- PAAD cis rs507080 0.501 rs625735 ENSG00000255422.1 AP002954.4 -5.86 2.71e-08 3.16e-05 -0.47 -0.43 Serum metabolite levels; chr11:118704710 chr11:118704607~118750263:+ PAAD cis rs2115630 0.645 rs6496284 ENSG00000275120.1 RP11-182J1.17 -5.86 2.71e-08 3.16e-05 -0.43 -0.43 P wave terminal force; chr15:84635039 chr15:84599434~84606463:- PAAD cis rs9322193 0.962 rs9505974 ENSG00000216906.2 RP11-350J20.9 5.86 2.71e-08 3.16e-05 0.55 0.43 Lung cancer; chr6:149779294 chr6:149904243~149906418:+ PAAD cis rs17301013 0.93 rs6425279 ENSG00000227373.4 RP11-160H22.5 -5.86 2.71e-08 3.16e-05 -0.56 -0.43 Systemic lupus erythematosus; chr1:174418717 chr1:174115300~174160004:- PAAD cis rs2243480 0.706 rs34466769 ENSG00000226824.5 RP4-756H11.3 -5.86 2.71e-08 3.16e-05 -0.69 -0.43 Diabetic kidney disease; chr7:65988305 chr7:66654538~66669855:+ PAAD cis rs67180937 0.504 rs3008625 ENSG00000272750.1 RP11-378J18.8 5.86 2.72e-08 3.16e-05 0.51 0.43 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222646680 chr1:222658867~222661512:- PAAD cis rs67180937 0.553 rs2936020 ENSG00000272750.1 RP11-378J18.8 5.86 2.72e-08 3.16e-05 0.51 0.43 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222655754 chr1:222658867~222661512:- PAAD cis rs67180937 0.553 rs2936023 ENSG00000272750.1 RP11-378J18.8 5.86 2.72e-08 3.16e-05 0.51 0.43 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222656989 chr1:222658867~222661512:- PAAD cis rs797680 0.586 rs2281525 ENSG00000223745.6 RP4-717I23.3 5.86 2.73e-08 3.18e-05 0.34 0.43 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93129749 chr1:93262186~93346025:- PAAD cis rs1075265 0.704 rs10084374 ENSG00000233266.1 HMGB1P31 5.86 2.73e-08 3.18e-05 0.55 0.43 Chronotype;Morning vs. evening chronotype; chr2:54022175 chr2:54051334~54051760:+ PAAD cis rs7945705 0.935 rs11042102 ENSG00000254860.4 TMEM9B-AS1 -5.86 2.74e-08 3.19e-05 -0.48 -0.43 Hemoglobin concentration; chr11:8860617 chr11:8964675~8977527:+ PAAD cis rs2929278 0.617 rs12908467 ENSG00000205771.5 CATSPER2P1 5.86 2.74e-08 3.19e-05 0.57 0.43 Schizophrenia; chr15:43755232 chr15:43726918~43747094:- PAAD cis rs9828933 0.516 rs704371 ENSG00000280620.1 SCAANT1 -5.86 2.74e-08 3.19e-05 -0.63 -0.43 Type 2 diabetes; chr3:63881852 chr3:63911518~63911772:- PAAD cis rs875971 0.862 rs10282433 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66256452 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10276077 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66263424 chr7:66493706~66495474:+ PAAD cis rs875971 0.825 rs4587224 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66271195 chr7:66493706~66495474:+ PAAD cis rs875971 0.792 rs6971752 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66272999 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10950033 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66274686 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs11760844 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66274896 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs4149461 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66279745 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs4236208 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66284091 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10261398 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66285177 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10224872 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66294786 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs949930 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66301835 chr7:66493706~66495474:+ PAAD cis rs875971 0.825 rs1000464 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66312922 chr7:66493706~66495474:+ PAAD cis rs875971 0.928 rs2036263 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66335210 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10240949 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66339430 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs7782704 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66340379 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6460290 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66344119 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6959268 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66347979 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778720 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66381288 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs11773628 ENSG00000237310.1 GS1-124K5.4 -5.86 2.74e-08 3.19e-05 -0.43 -0.43 Aortic root size; chr7:66517644 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs12537823 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66255897 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778734 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66349862 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778724 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66364304 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778686 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66370923 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778684 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66371416 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778680 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66375427 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs11769079 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66377141 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs1695820 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66379576 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs778715 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66384222 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs809025 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66384832 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778702 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66399848 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs1643375 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66407690 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6962717 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66418748 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6460302 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66495270 chr7:66493706~66495474:+ PAAD cis rs875971 0.798 rs6460304 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66499741 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6945775 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66503987 chr7:66493706~66495474:+ PAAD cis rs875971 0.798 rs57739047 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66507579 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs6950137 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66511623 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs11763189 ENSG00000237310.1 GS1-124K5.4 5.86 2.74e-08 3.19e-05 0.43 0.43 Aortic root size; chr7:66518542 chr7:66493706~66495474:+ PAAD cis rs453301 0.653 rs7853 ENSG00000253893.2 FAM85B -5.86 2.74e-08 3.19e-05 -0.57 -0.43 Joint mobility (Beighton score); chr8:9033304 chr8:8167819~8226614:- PAAD cis rs9322193 0.923 rs9479810 ENSG00000216906.2 RP11-350J20.9 5.86 2.75e-08 3.19e-05 0.55 0.43 Lung cancer; chr6:149751359 chr6:149904243~149906418:+ PAAD cis rs12220777 1 rs11201297 ENSG00000230091.5 TMEM254-AS1 5.86 2.75e-08 3.2e-05 0.75 0.43 Chronic obstructive pulmonary disease-related biomarkers; chr10:80033993 chr10:80046860~80078912:- PAAD cis rs17608059 0.901 rs11078215 ENSG00000141028.6 CDRT15P1 -5.86 2.76e-08 3.2e-05 -0.5 -0.43 Temperament; chr17:14003617 chr17:14024514~14025488:+ PAAD cis rs6683071 0.688 rs3008637 ENSG00000272750.1 RP11-378J18.8 5.86 2.76e-08 3.21e-05 0.54 0.43 Cognitive performance; chr1:222684427 chr1:222658867~222661512:- PAAD cis rs6683071 0.738 rs2030076 ENSG00000272750.1 RP11-378J18.8 -5.86 2.76e-08 3.21e-05 -0.54 -0.43 Cognitive performance; chr1:222701624 chr1:222658867~222661512:- PAAD cis rs7044106 0.887 rs1359328 ENSG00000226752.6 PSMD5-AS1 -5.86 2.76e-08 3.21e-05 -0.64 -0.43 Hip circumference adjusted for BMI; chr9:120608544 chr9:120824828~120854385:+ PAAD cis rs10170846 0.861 rs7571732 ENSG00000261428.2 RP11-16P6.1 -5.86 2.76e-08 3.21e-05 -0.57 -0.43 Schizophrenia (inflammation and infection response interaction); chr2:222673597 chr2:222566899~222569719:- PAAD cis rs10170846 0.861 rs4674677 ENSG00000261428.2 RP11-16P6.1 5.86 2.76e-08 3.21e-05 0.57 0.43 Schizophrenia (inflammation and infection response interaction); chr2:222664939 chr2:222566899~222569719:- PAAD cis rs10463554 0.963 rs3776859 ENSG00000175749.11 EIF3KP1 5.86 2.77e-08 3.21e-05 0.55 0.43 Parkinson's disease; chr5:103016330 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs17154953 ENSG00000175749.11 EIF3KP1 5.86 2.77e-08 3.21e-05 0.55 0.43 Parkinson's disease; chr5:103019557 chr5:103032376~103033031:+ PAAD cis rs9640161 0.83 rs3735165 ENSG00000261305.1 RP4-584D14.7 5.86 2.8e-08 3.25e-05 0.59 0.43 Blood protein levels;Circulating chemerin levels; chr7:150371282 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs6722 ENSG00000261305.1 RP4-584D14.7 5.86 2.8e-08 3.25e-05 0.59 0.43 Blood protein levels;Circulating chemerin levels; chr7:150371844 chr7:150341771~150342607:+ PAAD cis rs673078 0.66 rs17586342 ENSG00000275759.1 RP11-131L12.3 -5.86 2.8e-08 3.25e-05 -0.57 -0.43 Glucose homeostasis traits; chr12:118162399 chr12:118428281~118428870:+ PAAD cis rs6903823 0.508 rs1778484 ENSG00000216901.1 AL022393.7 5.86 2.81e-08 3.25e-05 0.51 0.43 Pulmonary function; chr6:28273021 chr6:28176188~28176674:+ PAAD cis rs2919917 0.628 rs13267679 ENSG00000254352.1 RP11-578O24.2 -5.86 2.81e-08 3.26e-05 -0.53 -0.43 Lymphocyte counts; chr8:78711603 chr8:78723796~78724136:- PAAD cis rs2115630 0.653 rs61394864 ENSG00000275120.1 RP11-182J1.17 -5.86 2.83e-08 3.27e-05 -0.44 -0.43 P wave terminal force; chr15:84626943 chr15:84599434~84606463:- PAAD cis rs6142102 0.625 rs4911381 ENSG00000276073.1 RP5-1125A11.7 5.86 2.83e-08 3.27e-05 0.45 0.43 Skin pigmentation; chr20:33962539 chr20:33985617~33988989:- PAAD cis rs6142102 0.602 rs6141435 ENSG00000276073.1 RP5-1125A11.7 -5.86 2.83e-08 3.27e-05 -0.45 -0.43 Skin pigmentation; chr20:33963473 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs1883707 ENSG00000276073.1 RP5-1125A11.7 5.86 2.83e-08 3.27e-05 0.45 0.43 Skin pigmentation; chr20:33964781 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs1883706 ENSG00000276073.1 RP5-1125A11.7 -5.86 2.83e-08 3.27e-05 -0.45 -0.43 Skin pigmentation; chr20:33965071 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs1883705 ENSG00000276073.1 RP5-1125A11.7 -5.86 2.83e-08 3.27e-05 -0.45 -0.43 Skin pigmentation; chr20:33965072 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs4012234 ENSG00000276073.1 RP5-1125A11.7 -5.86 2.83e-08 3.27e-05 -0.45 -0.43 Skin pigmentation; chr20:33965241 chr20:33985617~33988989:- PAAD cis rs6142102 0.649 rs4911382 ENSG00000276073.1 RP5-1125A11.7 -5.86 2.83e-08 3.27e-05 -0.45 -0.43 Skin pigmentation; chr20:33965289 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs6141436 ENSG00000276073.1 RP5-1125A11.7 -5.86 2.83e-08 3.27e-05 -0.45 -0.43 Skin pigmentation; chr20:33966765 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs4911384 ENSG00000276073.1 RP5-1125A11.7 -5.86 2.83e-08 3.27e-05 -0.45 -0.43 Skin pigmentation; chr20:33968001 chr20:33985617~33988989:- PAAD cis rs2404602 0.735 rs4886798 ENSG00000259422.1 RP11-593F23.1 5.86 2.83e-08 3.27e-05 0.53 0.43 Blood metabolite levels; chr15:76380885 chr15:76174891~76181486:- PAAD cis rs17301013 0.606 rs10912754 ENSG00000227373.4 RP11-160H22.5 5.86 2.83e-08 3.28e-05 0.61 0.43 Systemic lupus erythematosus; chr1:174273667 chr1:174115300~174160004:- PAAD cis rs12701220 0.52 rs7803208 ENSG00000229043.2 AC091729.9 -5.86 2.84e-08 3.29e-05 -0.52 -0.43 Bronchopulmonary dysplasia; chr7:1122448 chr7:1160374~1165267:+ PAAD cis rs9322193 0.962 rs6899661 ENSG00000216906.2 RP11-350J20.9 5.85 2.84e-08 3.3e-05 0.55 0.43 Lung cancer; chr6:149818093 chr6:149904243~149906418:+ PAAD cis rs17301013 0.507 rs72717617 ENSG00000227373.4 RP11-160H22.5 5.85 2.85e-08 3.3e-05 0.64 0.43 Systemic lupus erythematosus; chr1:174815514 chr1:174115300~174160004:- PAAD cis rs2739330 0.796 rs2154594 ENSG00000099984.9 GSTT2 5.85 2.85e-08 3.3e-05 0.56 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23980123~23983911:+ PAAD cis rs2337406 0.866 rs8016203 ENSG00000274576.2 IGHV2-70 -5.85 2.85e-08 3.3e-05 -0.55 -0.43 Alzheimer's disease (late onset); chr14:106780575 chr14:106770577~106771020:- PAAD cis rs7772486 0.754 rs702319 ENSG00000235652.6 RP11-545I5.3 -5.85 2.86e-08 3.31e-05 -0.37 -0.43 Lobe attachment (rater-scored or self-reported); chr6:145684981 chr6:145799409~145886585:+ PAAD cis rs2946504 0.501 rs2946509 ENSG00000251468.2 RP11-369K16.1 -5.85 2.86e-08 3.31e-05 -0.49 -0.43 Type 2 diabetes; chr8:12950782 chr8:12958387~12962200:+ PAAD cis rs9322193 0.962 rs3763162 ENSG00000216906.2 RP11-350J20.9 -5.85 2.86e-08 3.31e-05 -0.55 -0.43 Lung cancer; chr6:149819674 chr6:149904243~149906418:+ PAAD cis rs2115630 0.645 rs6496284 ENSG00000259728.4 LINC00933 -5.85 2.86e-08 3.31e-05 -0.51 -0.43 P wave terminal force; chr15:84635039 chr15:84570649~84580175:+ PAAD cis rs17301013 0.507 rs7537823 ENSG00000227373.4 RP11-160H22.5 5.85 2.88e-08 3.33e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174502222 chr1:174115300~174160004:- PAAD cis rs9322193 0.923 rs7753812 ENSG00000216906.2 RP11-350J20.9 5.85 2.9e-08 3.35e-05 0.55 0.43 Lung cancer; chr6:149690150 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs12195866 ENSG00000216906.2 RP11-350J20.9 5.85 2.9e-08 3.35e-05 0.55 0.43 Lung cancer; chr6:149693334 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9285524 ENSG00000216906.2 RP11-350J20.9 5.85 2.9e-08 3.35e-05 0.55 0.43 Lung cancer; chr6:149694122 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs10872645 ENSG00000216906.2 RP11-350J20.9 5.85 2.9e-08 3.35e-05 0.55 0.43 Lung cancer; chr6:149742840 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs12211511 ENSG00000216906.2 RP11-350J20.9 5.85 2.9e-08 3.35e-05 0.55 0.43 Lung cancer; chr6:149745206 chr6:149904243~149906418:+ PAAD cis rs9326248 0.906 rs171052 ENSG00000280143.1 AP000892.6 -5.85 2.9e-08 3.36e-05 -0.54 -0.43 Blood protein levels; chr11:117211047 chr11:117204967~117210292:+ PAAD cis rs9322193 0.926 rs9689036 ENSG00000216906.2 RP11-350J20.9 5.85 2.92e-08 3.37e-05 0.55 0.43 Lung cancer; chr6:149780563 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9322218 ENSG00000216906.2 RP11-350J20.9 5.85 2.92e-08 3.37e-05 0.55 0.43 Lung cancer; chr6:149782183 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9322219 ENSG00000216906.2 RP11-350J20.9 5.85 2.92e-08 3.37e-05 0.55 0.43 Lung cancer; chr6:149782263 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs13215691 ENSG00000216906.2 RP11-350J20.9 5.85 2.92e-08 3.37e-05 0.55 0.43 Lung cancer; chr6:149792666 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9322223 ENSG00000216906.2 RP11-350J20.9 5.85 2.92e-08 3.37e-05 0.55 0.43 Lung cancer; chr6:149801509 chr6:149904243~149906418:+ PAAD cis rs7104764 0.507 rs6598054 ENSG00000277290.1 RP11-326C3.16 5.85 2.92e-08 3.37e-05 0.41 0.43 Menarche (age at onset); chr11:254010 chr11:243099~243483:- PAAD cis rs3814244 0.933 rs11610126 ENSG00000255733.4 IFNG-AS1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Itch intensity from mosquito bite adjusted by bite size; chr12:68026493 chr12:67989445~68234686:+ PAAD cis rs11098499 0.863 rs13134665 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119505275 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3775843 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119506689 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3775844 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119506878 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3822190 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119506943 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3822191 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119506946 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs7664986 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119508797 chr4:119454791~119552025:+ PAAD cis rs11098499 0.818 rs10008791 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119510314 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs11736416 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119510506 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3775845 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119511292 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs1383533 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119513421 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs2291185 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119513678 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs10030660 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119515549 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs13149407 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119516670 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs34868248 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119521275 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3733525 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119525893 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3775847 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119526487 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3775848 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119526569 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs10013305 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119529269 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3775849 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119529753 chr4:119454791~119552025:+ PAAD cis rs11098499 0.818 rs7688802 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119530513 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs7695620 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119531621 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs12502389 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119533036 chr4:119454791~119552025:+ PAAD cis rs11098499 0.821 rs3775852 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119533401 chr4:119454791~119552025:+ PAAD cis rs11098499 0.82 rs6534140 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119534156 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs7657849 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119534339 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs10034450 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119534494 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs1480939 ENSG00000245958.5 RP11-33B1.1 -5.85 2.93e-08 3.38e-05 -0.37 -0.43 Corneal astigmatism; chr4:119535772 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs7699064 ENSG00000245958.5 RP11-33B1.1 5.85 2.93e-08 3.38e-05 0.37 0.43 Corneal astigmatism; chr4:119507154 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs1383532 ENSG00000245958.5 RP11-33B1.1 5.85 2.93e-08 3.38e-05 0.37 0.43 Corneal astigmatism; chr4:119513249 chr4:119454791~119552025:+ PAAD cis rs2281636 0.723 rs1128642 ENSG00000233690.1 EBAG9P1 5.85 2.93e-08 3.39e-05 0.5 0.43 Obesity-related traits; chr10:99711938 chr10:99697407~99697949:- PAAD cis rs17301013 0.507 rs10912753 ENSG00000227373.4 RP11-160H22.5 5.85 2.94e-08 3.39e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174265226 chr1:174115300~174160004:- PAAD cis rs11098499 0.697 rs35280960 ENSG00000245958.5 RP11-33B1.1 -5.85 2.94e-08 3.39e-05 -0.34 -0.43 Corneal astigmatism; chr4:119335904 chr4:119454791~119552025:+ PAAD cis rs17301013 0.606 rs12076453 ENSG00000227373.4 RP11-160H22.5 5.85 2.95e-08 3.4e-05 0.6 0.43 Systemic lupus erythematosus; chr1:174230438 chr1:174115300~174160004:- PAAD cis rs9926296 0.533 rs9938865 ENSG00000260259.1 RP11-368I7.4 -5.85 2.95e-08 3.4e-05 -0.53 -0.43 Vitiligo; chr16:89801389 chr16:89682620~89686569:- PAAD cis rs2108622 0.727 rs12609900 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871604 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs62107763 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871788 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs62107764 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871848 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs76984410 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871890 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs77780918 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871897 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs8104311 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871950 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs8101038 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872054 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs9305069 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872576 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs7254940 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15873698 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs62107770 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15874615 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs2158511 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15875837 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs3093216 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15876927 chr19:15851993~15864904:- PAAD cis rs2108622 0.701 rs3093209 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15877610 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs3093207 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15877848 chr19:15851993~15864904:- PAAD cis rs2108622 0.785 rs3093199 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15879061 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs3093193 ENSG00000267453.5 AC004791.2 -5.85 2.96e-08 3.41e-05 -0.63 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15881104 chr19:15851993~15864904:- PAAD cis rs10463554 1 rs3776864 ENSG00000175749.11 EIF3KP1 5.85 2.96e-08 3.41e-05 0.55 0.43 Parkinson's disease; chr5:102992164 chr5:103032376~103033031:+ PAAD cis rs2739330 0.929 rs5751777 ENSG00000099984.9 GSTT2 -5.85 2.96e-08 3.41e-05 -0.56 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23980123~23983911:+ PAAD cis rs17264034 0.821 rs605126 ENSG00000250786.1 SNHG18 5.85 2.98e-08 3.43e-05 0.59 0.43 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9541754 chr5:9546200~9550609:+ PAAD cis rs1930961 1 rs6004654 ENSG00000100058.11 CRYBB2P1 5.85 2.98e-08 3.43e-05 0.78 0.43 Bipolar disorder with mood-incongruent psychosis; chr22:25459237 chr22:25448105~25520854:+ PAAD cis rs2455601 0.608 rs11042104 ENSG00000254860.4 TMEM9B-AS1 -5.84 2.99e-08 3.44e-05 -0.5 -0.43 Schizophrenia; chr11:8869377 chr11:8964675~8977527:+ PAAD cis rs2455601 0.608 rs16906256 ENSG00000254860.4 TMEM9B-AS1 5.84 2.99e-08 3.44e-05 0.5 0.43 Schizophrenia; chr11:8865550 chr11:8964675~8977527:+ PAAD cis rs2455601 0.608 rs10840137 ENSG00000254860.4 TMEM9B-AS1 5.84 2.99e-08 3.44e-05 0.5 0.43 Schizophrenia; chr11:8868532 chr11:8964675~8977527:+ PAAD cis rs875971 0.502 rs6460311 ENSG00000237310.1 GS1-124K5.4 -5.84 2.99e-08 3.44e-05 -0.51 -0.43 Aortic root size; chr7:66646886 chr7:66493706~66495474:+ PAAD cis rs950169 0.959 rs12911210 ENSG00000225151.9 GOLGA2P7 -5.84 2.99e-08 3.45e-05 -0.52 -0.43 Schizophrenia; chr15:84123331 chr15:84199311~84230136:- PAAD cis rs950169 0.959 rs12902070 ENSG00000225151.9 GOLGA2P7 -5.84 2.99e-08 3.45e-05 -0.52 -0.43 Schizophrenia; chr15:84124806 chr15:84199311~84230136:- PAAD cis rs9322193 1 rs9377228 ENSG00000216906.2 RP11-350J20.9 5.84 3e-08 3.45e-05 0.54 0.43 Lung cancer; chr6:149600862 chr6:149904243~149906418:+ PAAD cis rs9322193 0.961 rs2064520 ENSG00000216906.2 RP11-350J20.9 5.84 3e-08 3.45e-05 0.54 0.43 Lung cancer; chr6:149603650 chr6:149904243~149906418:+ PAAD cis rs8091660 0.893 rs1567656 ENSG00000278983.1 RP11-426J5.3 -5.84 3.01e-08 3.46e-05 -0.52 -0.43 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48568420 chr18:48564795~48568342:+ PAAD cis rs950169 0.614 rs765524 ENSG00000225151.9 GOLGA2P7 -5.84 3.02e-08 3.47e-05 -0.52 -0.43 Schizophrenia; chr15:84013030 chr15:84199311~84230136:- PAAD cis rs992157 0.835 rs2271543 ENSG00000261338.2 RP11-378A13.1 -5.84 3.02e-08 3.47e-05 -0.5 -0.43 Colorectal cancer; chr2:218277768 chr2:218255319~218257366:+ PAAD cis rs992157 0.717 rs3817266 ENSG00000261338.2 RP11-378A13.1 -5.84 3.02e-08 3.47e-05 -0.5 -0.43 Colorectal cancer; chr2:218277871 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs2292551 ENSG00000261338.2 RP11-378A13.1 -5.84 3.02e-08 3.47e-05 -0.5 -0.43 Colorectal cancer; chr2:218278506 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs12987180 ENSG00000261338.2 RP11-378A13.1 -5.84 3.02e-08 3.47e-05 -0.5 -0.43 Colorectal cancer; chr2:218279366 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs12987219 ENSG00000261338.2 RP11-378A13.1 -5.84 3.02e-08 3.47e-05 -0.5 -0.43 Colorectal cancer; chr2:218279426 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs4674282 ENSG00000261338.2 RP11-378A13.1 -5.84 3.02e-08 3.47e-05 -0.5 -0.43 Colorectal cancer; chr2:218279507 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs4674283 ENSG00000261338.2 RP11-378A13.1 -5.84 3.02e-08 3.47e-05 -0.5 -0.43 Colorectal cancer; chr2:218279531 chr2:218255319~218257366:+ PAAD cis rs992157 0.835 rs2045434 ENSG00000261338.2 RP11-378A13.1 -5.84 3.02e-08 3.47e-05 -0.5 -0.43 Colorectal cancer; chr2:218279775 chr2:218255319~218257366:+ PAAD cis rs2404602 0.575 rs11072611 ENSG00000259422.1 RP11-593F23.1 5.84 3.02e-08 3.47e-05 0.54 0.43 Blood metabolite levels; chr15:76655642 chr15:76174891~76181486:- PAAD cis rs7586673 0.866 rs747003 ENSG00000227403.1 AC009299.3 5.84 3.03e-08 3.48e-05 0.56 0.43 Intelligence (multi-trait analysis); chr2:161059898 chr2:161244739~161249050:+ PAAD cis rs9326248 0.817 rs1242127 ENSG00000280143.1 AP000892.6 -5.84 3.03e-08 3.49e-05 -0.54 -0.43 Blood protein levels; chr11:117205848 chr11:117204967~117210292:+ PAAD cis rs66486766 1 rs66486766 ENSG00000259728.4 LINC00933 5.84 3.05e-08 3.5e-05 0.55 0.43 Bipolar disorder lithium response (categorical) or schizophrenia; chr15:84137308 chr15:84570649~84580175:+ PAAD cis rs17301013 0.507 rs7515116 ENSG00000227373.4 RP11-160H22.5 -5.84 3.05e-08 3.5e-05 -0.64 -0.43 Systemic lupus erythematosus; chr1:174474516 chr1:174115300~174160004:- PAAD cis rs7429990 0.833 rs883661 ENSG00000229759.1 MRPS18AP1 -5.84 3.05e-08 3.5e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47618611 chr3:48256350~48256938:- PAAD cis rs17301013 0.507 rs4652460 ENSG00000227373.4 RP11-160H22.5 5.84 3.05e-08 3.5e-05 0.61 0.43 Systemic lupus erythematosus; chr1:174459499 chr1:174115300~174160004:- PAAD cis rs9532669 0.926 rs2039119 ENSG00000176268.5 CYCSP34 -5.84 3.05e-08 3.51e-05 -0.41 -0.43 Cervical cancer; chr13:40872432 chr13:40863599~40863902:- PAAD cis rs11098499 0.863 rs3775841 ENSG00000245958.5 RP11-33B1.1 -5.84 3.05e-08 3.51e-05 -0.37 -0.43 Corneal astigmatism; chr4:119504622 chr4:119454791~119552025:+ PAAD cis rs17608059 0.524 rs9897978 ENSG00000141028.6 CDRT15P1 5.84 3.06e-08 3.52e-05 0.52 0.43 Temperament; chr17:13996939 chr17:14024514~14025488:+ PAAD cis rs9322193 0.962 rs9397022 ENSG00000216906.2 RP11-350J20.9 5.84 3.07e-08 3.52e-05 0.55 0.43 Lung cancer; chr6:149812052 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9397357 ENSG00000216906.2 RP11-350J20.9 5.84 3.07e-08 3.52e-05 0.55 0.43 Lung cancer; chr6:149812465 chr6:149904243~149906418:+ PAAD cis rs17301013 0.965 rs7548540 ENSG00000227373.4 RP11-160H22.5 5.84 3.08e-08 3.53e-05 0.55 0.43 Systemic lupus erythematosus; chr1:174411672 chr1:174115300~174160004:- PAAD cis rs17301013 0.965 rs2179214 ENSG00000227373.4 RP11-160H22.5 5.84 3.08e-08 3.53e-05 0.55 0.43 Systemic lupus erythematosus; chr1:174413954 chr1:174115300~174160004:- PAAD cis rs17301013 0.93 rs7523263 ENSG00000227373.4 RP11-160H22.5 5.84 3.08e-08 3.53e-05 0.55 0.43 Systemic lupus erythematosus; chr1:174414542 chr1:174115300~174160004:- PAAD cis rs7772486 0.686 rs1292334 ENSG00000235652.6 RP11-545I5.3 5.84 3.08e-08 3.53e-05 0.35 0.43 Lobe attachment (rater-scored or self-reported); chr6:145647152 chr6:145799409~145886585:+ PAAD cis rs734999 0.933 rs4648648 ENSG00000225931.3 RP3-395M20.7 5.84 3.08e-08 3.53e-05 0.4 0.43 Ulcerative colitis; chr1:2581013 chr1:2566410~2569888:+ PAAD cis rs10262624 0.967 rs10229233 ENSG00000234286.1 AC006026.13 -5.84 3.08e-08 3.53e-05 -0.48 -0.43 Schizophrenia; chr7:23867900 chr7:23680195~23680786:- PAAD cis rs10262624 1 rs10245161 ENSG00000234286.1 AC006026.13 -5.84 3.08e-08 3.53e-05 -0.48 -0.43 Schizophrenia; chr7:23868073 chr7:23680195~23680786:- PAAD cis rs6964833 0.873 rs4717905 ENSG00000123965.13 PMS2P5 5.84 3.09e-08 3.54e-05 0.73 0.43 Menarche (age at onset); chr7:74668903 chr7:74894116~74897835:+ PAAD cis rs858239 0.932 rs858272 ENSG00000226816.2 AC005082.12 5.84 3.1e-08 3.56e-05 0.49 0.43 Cerebrospinal fluid biomarker levels; chr7:23237166 chr7:23206013~23208045:+ PAAD cis rs16828019 0.777 rs35044078 ENSG00000235358.1 RP11-399E6.1 5.84 3.11e-08 3.57e-05 0.86 0.43 Intelligence (multi-trait analysis); chr1:41008728 chr1:41242373~41284861:+ PAAD cis rs16828019 0.704 rs4996176 ENSG00000235358.1 RP11-399E6.1 5.84 3.11e-08 3.57e-05 0.86 0.43 Intelligence (multi-trait analysis); chr1:41022496 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs35496942 ENSG00000235358.1 RP11-399E6.1 5.84 3.11e-08 3.57e-05 0.86 0.43 Intelligence (multi-trait analysis); chr1:41023232 chr1:41242373~41284861:+ PAAD cis rs465969 0.744 rs34659678 ENSG00000255389.1 C6orf3 -5.84 3.11e-08 3.57e-05 -0.86 -0.43 Psoriasis; chr6:111567337 chr6:111599875~111602295:+ PAAD cis rs17711722 0.565 rs73372653 ENSG00000234585.5 CCT6P3 5.84 3.12e-08 3.57e-05 0.35 0.43 Calcium levels; chr7:65977808 chr7:65038354~65074713:+ PAAD cis rs748404 0.588 rs2255410 ENSG00000249839.1 AC011330.5 -5.84 3.13e-08 3.58e-05 -0.63 -0.43 Lung cancer; chr15:43538899 chr15:43663654~43684339:- PAAD cis rs9640161 0.789 rs68107602 ENSG00000261305.1 RP4-584D14.7 5.83 3.15e-08 3.61e-05 0.62 0.43 Blood protein levels;Circulating chemerin levels; chr7:150357057 chr7:150341771~150342607:+ PAAD cis rs75422866 0.867 rs73104163 ENSG00000257433.4 RP1-197B17.3 5.83 3.16e-08 3.62e-05 0.88 0.43 Pneumonia; chr12:47706187 chr12:47706085~47742294:+ PAAD cis rs75422866 1 rs12423045 ENSG00000257433.4 RP1-197B17.3 5.83 3.16e-08 3.62e-05 0.88 0.43 Pneumonia; chr12:47706275 chr12:47706085~47742294:+ PAAD cis rs4218 0.619 rs10851643 ENSG00000277144.1 RP11-59H7.4 -5.83 3.17e-08 3.63e-05 -0.52 -0.43 Social communication problems; chr15:59102985 chr15:59115547~59116089:- PAAD cis rs17301013 0.932 rs6664764 ENSG00000227373.4 RP11-160H22.5 5.83 3.18e-08 3.63e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174443402 chr1:174115300~174160004:- PAAD cis rs7615952 0.736 rs11921945 ENSG00000171084.14 FAM86JP 5.83 3.18e-08 3.63e-05 0.57 0.43 Blood pressure (smoking interaction); chr3:125924876 chr3:125916620~125930024:+ PAAD cis rs67180937 0.553 rs3008629 ENSG00000272750.1 RP11-378J18.8 5.83 3.18e-08 3.64e-05 0.52 0.43 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222662588 chr1:222658867~222661512:- PAAD cis rs7104764 0.507 rs6598056 ENSG00000277290.1 RP11-326C3.16 5.83 3.2e-08 3.64e-05 0.41 0.43 Menarche (age at onset); chr11:252283 chr11:243099~243483:- PAAD cis rs9640161 0.742 rs11767726 ENSG00000261305.1 RP4-584D14.7 -5.83 3.2e-08 3.65e-05 -0.62 -0.43 Blood protein levels;Circulating chemerin levels; chr7:150321007 chr7:150341771~150342607:+ PAAD cis rs17301013 0.507 rs12097931 ENSG00000227373.4 RP11-160H22.5 5.83 3.21e-08 3.65e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174454841 chr1:174115300~174160004:- PAAD cis rs113835537 0.597 rs4576 ENSG00000255517.5 CTD-3074O7.5 -5.83 3.22e-08 3.66e-05 -0.56 -0.43 Airway imaging phenotypes; chr11:66563529 chr11:66473490~66480233:- PAAD cis rs950027 0.967 rs2643718 ENSG00000259520.4 CTD-2651B20.3 -5.83 3.23e-08 3.67e-05 -0.52 -0.43 Response to fenofibrate (adiponectin levels); chr15:45502464 chr15:45251580~45279251:- PAAD cis rs992157 0.698 rs6746089 ENSG00000261338.2 RP11-378A13.1 5.83 3.23e-08 3.68e-05 0.51 0.43 Colorectal cancer; chr2:218305654 chr2:218255319~218257366:+ PAAD cis rs113835537 0.627 rs11227534 ENSG00000255517.5 CTD-3074O7.5 -5.83 3.23e-08 3.68e-05 -0.55 -0.43 Airway imaging phenotypes; chr11:66568700 chr11:66473490~66480233:- PAAD cis rs10875746 0.904 rs11168422 ENSG00000240399.1 RP1-228P16.1 -5.83 3.23e-08 3.68e-05 -0.48 -0.43 Longevity (90 years and older); chr12:48125722 chr12:48054813~48055591:- PAAD cis rs673078 0.607 rs882927 ENSG00000275759.1 RP11-131L12.3 -5.83 3.23e-08 3.68e-05 -0.64 -0.43 Glucose homeostasis traits; chr12:118406737 chr12:118428281~118428870:+ PAAD cis rs9640161 0.83 rs12703061 ENSG00000261305.1 RP4-584D14.7 5.83 3.25e-08 3.69e-05 0.6 0.43 Blood protein levels;Circulating chemerin levels; chr7:150365456 chr7:150341771~150342607:+ PAAD cis rs875971 0.893 rs62465470 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66136231 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs4368860 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66143495 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs908915 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66149664 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs7809814 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66150410 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs7786892 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66163889 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs2420174 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66180374 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs2420173 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66180412 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs4718319 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66187797 chr7:66493706~66495474:+ PAAD cis rs875971 0.723 rs28391294 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66189328 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs6967708 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66192326 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs7782806 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66192910 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs880166 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66205775 chr7:66493706~66495474:+ PAAD cis rs875971 0.756 rs4718328 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66228350 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs4718330 ENSG00000237310.1 GS1-124K5.4 -5.83 3.25e-08 3.69e-05 -0.43 -0.43 Aortic root size; chr7:66250256 chr7:66493706~66495474:+ PAAD cis rs7811142 1 rs73161762 ENSG00000242294.5 STAG3L5P 5.83 3.26e-08 3.7e-05 0.34 0.43 Platelet count; chr7:100417223 chr7:100336079~100351900:+ PAAD cis rs673078 0.66 rs17512574 ENSG00000275759.1 RP11-131L12.3 -5.83 3.26e-08 3.7e-05 -0.64 -0.43 Glucose homeostasis traits; chr12:118350198 chr12:118428281~118428870:+ PAAD cis rs12701220 0.696 rs12112029 ENSG00000229043.2 AC091729.9 -5.83 3.27e-08 3.71e-05 -0.57 -0.43 Bronchopulmonary dysplasia; chr7:1098253 chr7:1160374~1165267:+ PAAD cis rs9322193 0.926 rs9766562 ENSG00000216906.2 RP11-350J20.9 5.83 3.29e-08 3.73e-05 0.55 0.43 Lung cancer; chr6:149788709 chr6:149904243~149906418:+ PAAD cis rs950169 0.579 rs11633088 ENSG00000225151.9 GOLGA2P7 5.82 3.3e-08 3.75e-05 0.52 0.43 Schizophrenia; chr15:84003429 chr15:84199311~84230136:- PAAD cis rs113835537 0.529 rs57634456 ENSG00000255517.5 CTD-3074O7.5 -5.82 3.3e-08 3.75e-05 -0.55 -0.43 Airway imaging phenotypes; chr11:66483367 chr11:66473490~66480233:- PAAD cis rs227275 0.554 rs223454 ENSG00000246560.2 RP11-10L12.4 5.82 3.3e-08 3.75e-05 0.46 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102789773 chr4:102828055~102844075:+ PAAD cis rs9322193 0.923 rs2342857 ENSG00000216906.2 RP11-350J20.9 5.82 3.31e-08 3.76e-05 0.55 0.43 Lung cancer; chr6:149809537 chr6:149904243~149906418:+ PAAD cis rs2739330 0.857 rs9608229 ENSG00000099984.9 GSTT2 -5.82 3.33e-08 3.77e-05 -0.57 -0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:24002918 chr22:23980123~23983911:+ PAAD cis rs17301013 0.507 rs10912777 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174393764 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912778 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174393827 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2205937 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174394440 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12084291 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174395721 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2901815 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174397404 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1883262 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174401104 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2860959 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174403704 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912779 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174404311 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12090860 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174405166 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12064126 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174405312 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10798310 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174408581 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs11799704 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174413640 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2901817 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174414479 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6701534 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174418612 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10798312 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174419089 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4652422 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174419501 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4233181 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174419697 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10489258 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174420447 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10798313 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174420995 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912786 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174427609 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12069134 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174434287 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6677262 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174434539 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs60409344 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174438724 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72713584 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174439129 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12077381 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174439566 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs74126805 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174440226 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12078960 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174440891 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12079011 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174441055 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12080407 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174441964 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10798314 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174458958 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912789 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174465616 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6684141 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174467305 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12058377 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174470971 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6656925 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174474161 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912791 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174479298 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12079334 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174480815 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4652494 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174495861 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2281011 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174509890 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2072759 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174510189 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4652511 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174515500 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4652513 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174515794 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6665535 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174522480 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12084948 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174525776 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs11809482 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174530269 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs909533 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174531428 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12093966 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174535120 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs7550472 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174536442 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs11484645 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174542993 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12063545 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174552863 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs3920486 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174567714 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12079118 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174568885 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs7414200 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174569820 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12079879 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174571877 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2092084 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174581547 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10489264 ENSG00000227373.4 RP11-160H22.5 5.82 3.33e-08 3.77e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174584310 chr1:174115300~174160004:- PAAD cis rs55665837 1 rs10832278 ENSG00000251991.1 RNU7-49P 5.82 3.33e-08 3.77e-05 0.51 0.43 Vitamin D levels; chr11:14475073 chr11:14478892~14478953:+ PAAD cis rs9926296 0.568 rs1230 ENSG00000260259.1 RP11-368I7.4 5.82 3.33e-08 3.77e-05 0.52 0.43 Vitiligo; chr16:89738447 chr16:89682620~89686569:- PAAD cis rs2739330 0.796 rs5760097 ENSG00000231271.1 AP000350.8 5.82 3.34e-08 3.78e-05 0.58 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23949918~23954042:+ PAAD cis rs2739330 0.828 rs5760098 ENSG00000231271.1 AP000350.8 5.82 3.34e-08 3.78e-05 0.58 0.43 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23949918~23954042:+ PAAD cis rs9425766 0.679 rs12079062 ENSG00000227373.4 RP11-160H22.5 5.82 3.34e-08 3.78e-05 0.55 0.43 Life satisfaction; chr1:174110446 chr1:174115300~174160004:- PAAD cis rs11089937 0.929 rs2236727 ENSG00000211639.2 IGLV4-60 5.82 3.35e-08 3.79e-05 0.4 0.43 Periodontitis (PAL4Q3); chr22:22156654 chr22:22162199~22162681:+ PAAD cis rs9928842 0.882 rs8048956 ENSG00000280152.1 RP11-331F4.5 -5.82 3.35e-08 3.79e-05 -0.52 -0.43 Alcoholic chronic pancreatitis; chr16:75221068 chr16:75245994~75250077:- PAAD cis rs7188445 0.932 rs17689625 ENSG00000261390.4 RP11-345M22.2 -5.82 3.35e-08 3.79e-05 -0.57 -0.43 Urate levels; chr16:79715065 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs17767742 ENSG00000261390.4 RP11-345M22.2 -5.82 3.35e-08 3.79e-05 -0.57 -0.43 Urate levels; chr16:79715108 chr16:79715232~79770563:- PAAD cis rs2658782 0.547 rs4344448 ENSG00000279684.1 RP11-755E23.2 -5.82 3.36e-08 3.79e-05 -0.62 -0.43 Pulmonary function decline; chr11:93313881 chr11:93286629~93288903:- PAAD cis rs2658782 0.547 rs10765602 ENSG00000279684.1 RP11-755E23.2 -5.82 3.36e-08 3.79e-05 -0.62 -0.43 Pulmonary function decline; chr11:93314999 chr11:93286629~93288903:- PAAD cis rs7188445 0.932 rs4575545 ENSG00000261390.4 RP11-345M22.2 -5.82 3.36e-08 3.8e-05 -0.57 -0.43 Urate levels; chr16:79721549 chr16:79715232~79770563:- PAAD cis rs67180937 0.553 rs1391557 ENSG00000272750.1 RP11-378J18.8 5.82 3.36e-08 3.8e-05 0.51 0.43 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222636274 chr1:222658867~222661512:- PAAD cis rs6570726 0.599 rs426371 ENSG00000235652.6 RP11-545I5.3 -5.82 3.36e-08 3.8e-05 -0.36 -0.43 Lobe attachment (rater-scored or self-reported); chr6:145565333 chr6:145799409~145886585:+ PAAD cis rs9308062 1 rs9308062 ENSG00000273449.1 RP11-218F10.3 -5.82 3.37e-08 3.81e-05 -0.32 -0.43 Small cell lung carcinoma; chr4:163517048 chr4:163529771~163530697:+ PAAD cis rs853679 0.567 rs13209596 ENSG00000216901.1 AL022393.7 5.82 3.38e-08 3.82e-05 0.57 0.43 Depression; chr6:28428413 chr6:28176188~28176674:+ PAAD cis rs853679 0.567 rs9969098 ENSG00000216901.1 AL022393.7 5.82 3.38e-08 3.82e-05 0.57 0.43 Depression; chr6:28430971 chr6:28176188~28176674:+ PAAD cis rs853679 0.567 rs7740429 ENSG00000216901.1 AL022393.7 5.82 3.38e-08 3.82e-05 0.57 0.43 Depression; chr6:28431469 chr6:28176188~28176674:+ PAAD cis rs853679 0.567 rs16894106 ENSG00000216901.1 AL022393.7 5.82 3.38e-08 3.82e-05 0.57 0.43 Depression; chr6:28432562 chr6:28176188~28176674:+ PAAD cis rs7201929 0.801 rs9933198 ENSG00000259982.1 CDC37P1 -5.82 3.39e-08 3.83e-05 -0.54 -0.43 QT interval; chr16:28877088 chr16:28700294~28701540:- PAAD cis rs17301013 0.507 rs6701911 ENSG00000227373.4 RP11-160H22.5 5.82 3.4e-08 3.84e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174364755 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs61218633 ENSG00000227373.4 RP11-160H22.5 5.82 3.4e-08 3.84e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174375955 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs56148594 ENSG00000227373.4 RP11-160H22.5 5.82 3.4e-08 3.84e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174383932 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12091056 ENSG00000227373.4 RP11-160H22.5 5.82 3.4e-08 3.84e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174384470 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs57953555 ENSG00000227373.4 RP11-160H22.5 5.82 3.4e-08 3.84e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174384958 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4651019 ENSG00000227373.4 RP11-160H22.5 5.82 3.4e-08 3.84e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174385079 chr1:174115300~174160004:- PAAD cis rs7923609 0.578 rs3858122 ENSG00000232075.1 MRPL35P2 -5.82 3.41e-08 3.84e-05 -0.56 -0.43 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63640320 chr10:63634317~63634827:- PAAD cis rs9322193 0.923 rs9322204 ENSG00000216906.2 RP11-350J20.9 5.82 3.42e-08 3.86e-05 0.53 0.43 Lung cancer; chr6:149636047 chr6:149904243~149906418:+ PAAD cis rs17301013 0.932 rs11804941 ENSG00000227373.4 RP11-160H22.5 -5.82 3.42e-08 3.86e-05 -0.54 -0.43 Systemic lupus erythematosus; chr1:174624074 chr1:174115300~174160004:- PAAD cis rs2337406 0.714 rs7152055 ENSG00000274576.2 IGHV2-70 -5.82 3.43e-08 3.87e-05 -0.57 -0.43 Alzheimer's disease (late onset); chr14:106818996 chr14:106770577~106771020:- PAAD cis rs875971 0.862 rs1167390 ENSG00000237310.1 GS1-124K5.4 -5.82 3.43e-08 3.87e-05 -0.43 -0.43 Aortic root size; chr7:66110906 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs35034167 ENSG00000237310.1 GS1-124K5.4 -5.82 3.43e-08 3.87e-05 -0.43 -0.43 Aortic root size; chr7:66115179 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs28470208 ENSG00000237310.1 GS1-124K5.4 -5.82 3.43e-08 3.87e-05 -0.43 -0.43 Aortic root size; chr7:66119713 chr7:66493706~66495474:+ PAAD cis rs9322193 0.923 rs9766004 ENSG00000216906.2 RP11-350J20.9 5.82 3.44e-08 3.88e-05 0.52 0.43 Lung cancer; chr6:149754363 chr6:149904243~149906418:+ PAAD cis rs11098499 0.754 rs9999724 ENSG00000245958.5 RP11-33B1.1 -5.82 3.44e-08 3.88e-05 -0.34 -0.43 Corneal astigmatism; chr4:119318789 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs714899 ENSG00000245958.5 RP11-33B1.1 -5.82 3.44e-08 3.88e-05 -0.34 -0.43 Corneal astigmatism; chr4:119321880 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs66900435 ENSG00000245958.5 RP11-33B1.1 -5.82 3.44e-08 3.88e-05 -0.34 -0.43 Corneal astigmatism; chr4:119328270 chr4:119454791~119552025:+ PAAD cis rs9322193 0.884 rs62439837 ENSG00000216906.2 RP11-350J20.9 5.81 3.46e-08 3.9e-05 0.55 0.43 Lung cancer; chr6:149670380 chr6:149904243~149906418:+ PAAD cis rs732716 0.785 rs56272533 ENSG00000267980.1 AC007292.6 -5.81 3.47e-08 3.91e-05 -0.58 -0.43 Mean corpuscular volume; chr19:4420045 chr19:4363789~4364640:+ PAAD cis rs17301013 0.507 rs6689327 ENSG00000227373.4 RP11-160H22.5 5.81 3.47e-08 3.91e-05 0.61 0.43 Systemic lupus erythematosus; chr1:174464274 chr1:174115300~174160004:- PAAD cis rs673078 0.66 rs11068891 ENSG00000275759.1 RP11-131L12.3 5.81 3.47e-08 3.91e-05 0.56 0.43 Glucose homeostasis traits; chr12:118259814 chr12:118428281~118428870:+ PAAD cis rs9640161 0.83 rs1051760 ENSG00000261305.1 RP4-584D14.7 5.81 3.47e-08 3.91e-05 0.59 0.43 Blood protein levels;Circulating chemerin levels; chr7:150373541 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs1051764 ENSG00000261305.1 RP4-584D14.7 5.81 3.47e-08 3.91e-05 0.59 0.43 Blood protein levels;Circulating chemerin levels; chr7:150373574 chr7:150341771~150342607:+ PAAD cis rs9322193 0.923 rs14314 ENSG00000216906.2 RP11-350J20.9 5.81 3.48e-08 3.92e-05 0.55 0.43 Lung cancer; chr6:149820395 chr6:149904243~149906418:+ PAAD cis rs9322193 0.924 rs9498382 ENSG00000216906.2 RP11-350J20.9 5.81 3.48e-08 3.92e-05 0.53 0.43 Lung cancer; chr6:149610982 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs7740278 ENSG00000216906.2 RP11-350J20.9 5.81 3.48e-08 3.92e-05 0.53 0.43 Lung cancer; chr6:149640116 chr6:149904243~149906418:+ PAAD cis rs2243480 0.706 rs6460257 ENSG00000226824.5 RP4-756H11.3 -5.81 3.48e-08 3.92e-05 -0.69 -0.43 Diabetic kidney disease; chr7:65731813 chr7:66654538~66669855:+ PAAD cis rs16828019 0.777 rs3738369 ENSG00000235358.1 RP11-399E6.1 5.81 3.48e-08 3.92e-05 0.86 0.43 Intelligence (multi-trait analysis); chr1:41020736 chr1:41242373~41284861:+ PAAD cis rs9425766 0.679 rs6681390 ENSG00000227373.4 RP11-160H22.5 5.81 3.5e-08 3.94e-05 0.55 0.43 Life satisfaction; chr1:174261331 chr1:174115300~174160004:- PAAD cis rs4722166 0.598 rs4722178 ENSG00000179428.2 AC073072.5 -5.81 3.5e-08 3.94e-05 -0.37 -0.43 Lung cancer; chr7:22759031 chr7:22725395~22727620:- PAAD cis rs9928842 0.823 rs11149811 ENSG00000280152.1 RP11-331F4.5 5.81 3.5e-08 3.94e-05 0.55 0.43 Alcoholic chronic pancreatitis; chr16:75266810 chr16:75245994~75250077:- PAAD cis rs7188445 1 rs11646791 ENSG00000261390.4 RP11-345M22.2 -5.81 3.53e-08 3.97e-05 -0.55 -0.43 Urate levels; chr16:79667641 chr16:79715232~79770563:- PAAD cis rs9532669 0.963 rs1056824 ENSG00000176268.5 CYCSP34 5.81 3.53e-08 3.97e-05 0.39 0.43 Cervical cancer; chr13:40932748 chr13:40863599~40863902:- PAAD cis rs2108622 0.683 rs6512067 ENSG00000267453.5 AC004791.2 -5.81 3.53e-08 3.97e-05 -0.62 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872141 chr19:15851993~15864904:- PAAD cis rs9322193 0.886 rs9485408 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149618888 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs10782310 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149622458 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs10782311 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149622592 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs10782312 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149622669 chr6:149904243~149906418:+ PAAD cis rs9322193 0.886 rs9322198 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149623772 chr6:149904243~149906418:+ PAAD cis rs9322193 0.847 rs12234128 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149627553 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs57012784 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149627691 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9505823 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149628899 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9322200 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149630078 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9689599 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149631973 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9800580 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149632845 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs11155669 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149633501 chr6:149904243~149906418:+ PAAD cis rs9322193 0.887 rs9505824 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149633663 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9505826 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149633912 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9766886 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149637048 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9688861 ENSG00000216906.2 RP11-350J20.9 5.81 3.54e-08 3.97e-05 0.53 0.43 Lung cancer; chr6:149637924 chr6:149904243~149906418:+ PAAD cis rs6860806 0.507 rs272872 ENSG00000233006.5 AC034220.3 -5.81 3.54e-08 3.98e-05 -0.37 -0.43 Breast cancer; chr5:132340171 chr5:132311285~132369916:- PAAD cis rs2929278 0.617 rs533143 ENSG00000205771.5 CATSPER2P1 -5.81 3.55e-08 3.99e-05 -0.54 -0.43 Schizophrenia; chr15:43896656 chr15:43726918~43747094:- PAAD cis rs9322193 0.923 rs4870509 ENSG00000216906.2 RP11-350J20.9 5.81 3.56e-08 4e-05 0.55 0.43 Lung cancer; chr6:149702212 chr6:149904243~149906418:+ PAAD cis rs11098499 0.954 rs6820115 ENSG00000245958.5 RP11-33B1.1 -5.81 3.56e-08 4e-05 -0.32 -0.43 Corneal astigmatism; chr4:119477027 chr4:119454791~119552025:+ PAAD cis rs9640161 0.75 rs11764936 ENSG00000261305.1 RP4-584D14.7 5.81 3.56e-08 4e-05 0.65 0.43 Blood protein levels;Circulating chemerin levels; chr7:150328826 chr7:150341771~150342607:+ PAAD cis rs9640161 0.711 rs3800781 ENSG00000261305.1 RP4-584D14.7 5.81 3.56e-08 4e-05 0.65 0.43 Blood protein levels;Circulating chemerin levels; chr7:150330235 chr7:150341771~150342607:+ PAAD cis rs9425766 0.631 rs10158289 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174081529 chr1:174115300~174160004:- PAAD cis rs9425766 0.523 rs6668959 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174088488 chr1:174115300~174160004:- PAAD cis rs9425766 0.64 rs6685314 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174089905 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs12563301 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174090924 chr1:174115300~174160004:- PAAD cis rs9425766 0.665 rs7553788 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174093773 chr1:174115300~174160004:- PAAD cis rs9425766 0.655 rs4652169 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174095343 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs6682017 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174097809 chr1:174115300~174160004:- PAAD cis rs9425766 0.655 rs2145376 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174098911 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs6663794 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174099791 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs6691711 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174100283 chr1:174115300~174160004:- PAAD cis rs9425766 0.64 rs6658769 ENSG00000227373.4 RP11-160H22.5 5.81 3.57e-08 4.01e-05 0.55 0.43 Life satisfaction; chr1:174100843 chr1:174115300~174160004:- PAAD cis rs1062177 0.547 rs2915818 ENSG00000213433.5 RPLP1P6 5.81 3.57e-08 4.01e-05 0.47 0.43 Preschool internalizing problems; chr5:151735729 chr5:151765859~151766378:- PAAD cis rs7429990 0.864 rs1464614 ENSG00000229759.1 MRPS18AP1 5.81 3.58e-08 4.02e-05 0.46 0.43 Educational attainment (years of education); chr3:47612885 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs61620099 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47600755 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs11130143 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47614943 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6774170 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47615977 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs1403578 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47617997 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs870622 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47618683 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs868255 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47619074 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs883663 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47619306 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs4858842 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47619574 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs11130144 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47626444 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs12492915 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47636545 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs12636863 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47638629 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7613934 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47640681 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs6442072 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47642960 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7621236 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47646677 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7624474 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47647786 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs2882611 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47651532 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs4858846 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47654591 chr3:48256350~48256938:- PAAD cis rs7429990 0.803 rs13081356 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47660067 chr3:48256350~48256938:- PAAD cis rs7429990 0.803 rs11130145 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47661780 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs2140335 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47663625 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs11130146 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47666322 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs12633604 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47673308 chr3:48256350~48256938:- PAAD cis rs7429990 0.803 rs6773732 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47677772 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs2049301 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47681369 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6772301 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47682366 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs13063042 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47683825 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs7429162 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47683845 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs2133601 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47692525 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs6792497 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47693684 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs4410463 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47693907 chr3:48256350~48256938:- PAAD cis rs7429990 0.833 rs2030596 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47701712 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs2047559 ENSG00000229759.1 MRPS18AP1 -5.81 3.58e-08 4.02e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47704695 chr3:48256350~48256938:- PAAD cis rs2281636 0.723 rs11190255 ENSG00000233690.1 EBAG9P1 5.81 3.58e-08 4.02e-05 0.5 0.43 Obesity-related traits; chr10:99714742 chr10:99697407~99697949:- PAAD cis rs7829975 1 rs7829975 ENSG00000253893.2 FAM85B 5.81 3.59e-08 4.03e-05 0.61 0.43 Mood instability; chr8:8690607 chr8:8167819~8226614:- PAAD cis rs950169 0.579 rs62027818 ENSG00000225151.9 GOLGA2P7 -5.81 3.6e-08 4.04e-05 -0.53 -0.43 Schizophrenia; chr15:83992393 chr15:84199311~84230136:- PAAD cis rs950169 0.579 rs12913054 ENSG00000225151.9 GOLGA2P7 -5.81 3.6e-08 4.04e-05 -0.53 -0.43 Schizophrenia; chr15:83995704 chr15:84199311~84230136:- PAAD cis rs7615952 0.611 rs2947646 ENSG00000171084.14 FAM86JP -5.81 3.6e-08 4.04e-05 -0.74 -0.43 Blood pressure (smoking interaction); chr3:125874759 chr3:125916620~125930024:+ PAAD cis rs12458462 0.892 rs2242175 ENSG00000274828.1 RP11-567M16.6 5.81 3.61e-08 4.04e-05 0.41 0.43 Monocyte count; chr18:79704406 chr18:79677287~79679358:- PAAD cis rs2929278 0.561 rs62018952 ENSG00000205771.5 CATSPER2P1 5.81 3.62e-08 4.06e-05 0.58 0.43 Schizophrenia; chr15:43788539 chr15:43726918~43747094:- PAAD cis rs9640161 0.75 rs11538922 ENSG00000261305.1 RP4-584D14.7 5.8 3.63e-08 4.07e-05 0.66 0.43 Blood protein levels;Circulating chemerin levels; chr7:150338094 chr7:150341771~150342607:+ PAAD cis rs11098499 0.657 rs10434028 ENSG00000245958.5 RP11-33B1.1 -5.8 3.63e-08 4.07e-05 -0.32 -0.43 Corneal astigmatism; chr4:119373309 chr4:119454791~119552025:+ PAAD cis rs5760092 0.842 rs5760103 ENSG00000250470.1 AP000351.3 5.8 3.65e-08 4.09e-05 0.78 0.43 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23906594 chr22:23976904~23977585:- PAAD cis rs9640161 0.789 rs2098053 ENSG00000261305.1 RP4-584D14.7 5.8 3.66e-08 4.1e-05 0.66 0.43 Blood protein levels;Circulating chemerin levels; chr7:150346116 chr7:150341771~150342607:+ PAAD cis rs9640161 0.673 rs34489187 ENSG00000261305.1 RP4-584D14.7 5.8 3.66e-08 4.1e-05 0.66 0.43 Blood protein levels;Circulating chemerin levels; chr7:150347290 chr7:150341771~150342607:+ PAAD cis rs2283792 0.745 rs5756306 ENSG00000228050.1 TOP3BP1 -5.8 3.67e-08 4.11e-05 -0.45 -0.43 Multiple sclerosis; chr22:21978846 chr22:22223187~22224566:- PAAD cis rs17301013 0.507 rs12065454 ENSG00000227373.4 RP11-160H22.5 5.8 3.68e-08 4.11e-05 0.62 0.43 Systemic lupus erythematosus; chr1:174492226 chr1:174115300~174160004:- PAAD cis rs1075232 1 rs72722829 ENSG00000270055.1 CTD-3092A11.2 -5.8 3.68e-08 4.12e-05 -0.95 -0.43 Survival in colorectal cancer (non-distant metastatic); chr15:31346911 chr15:30487963~30490313:+ PAAD cis rs1075232 1 rs16956707 ENSG00000270055.1 CTD-3092A11.2 -5.8 3.68e-08 4.12e-05 -0.95 -0.43 Survival in colorectal cancer (non-distant metastatic); chr15:31349430 chr15:30487963~30490313:+ PAAD cis rs9640161 0.742 rs2159236 ENSG00000261305.1 RP4-584D14.7 5.8 3.68e-08 4.12e-05 0.63 0.43 Blood protein levels;Circulating chemerin levels; chr7:150320125 chr7:150341771~150342607:+ PAAD cis rs875971 0.545 rs1796219 ENSG00000237310.1 GS1-124K5.4 -5.8 3.69e-08 4.12e-05 -0.51 -0.43 Aortic root size; chr7:66645977 chr7:66493706~66495474:+ PAAD cis rs9425766 0.679 rs6667267 ENSG00000227373.4 RP11-160H22.5 5.8 3.69e-08 4.13e-05 0.55 0.43 Life satisfaction; chr1:174243623 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs2064149 ENSG00000227373.4 RP11-160H22.5 5.8 3.69e-08 4.13e-05 0.55 0.43 Life satisfaction; chr1:174255856 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs2901785 ENSG00000227373.4 RP11-160H22.5 5.8 3.7e-08 4.13e-05 0.54 0.43 Life satisfaction; chr1:174135605 chr1:174115300~174160004:- PAAD cis rs2919917 0.628 rs12544041 ENSG00000254352.1 RP11-578O24.2 -5.8 3.71e-08 4.15e-05 -0.5 -0.43 Lymphocyte counts; chr8:78731404 chr8:78723796~78724136:- PAAD cis rs9425766 0.679 rs9787001 ENSG00000227373.4 RP11-160H22.5 5.8 3.72e-08 4.16e-05 0.55 0.43 Life satisfaction; chr1:174222556 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs972361 ENSG00000227373.4 RP11-160H22.5 5.8 3.72e-08 4.16e-05 0.55 0.43 Life satisfaction; chr1:174228270 chr1:174115300~174160004:- PAAD cis rs1800795 0.652 rs7802307 ENSG00000179428.2 AC073072.5 -5.8 3.73e-08 4.17e-05 -0.4 -0.43 Cerebrospinal fluid clusterin levels in APOEe4- carriers; chr7:22726814 chr7:22725395~22727620:- PAAD cis rs1075232 0.579 rs58156651 ENSG00000270055.1 CTD-3092A11.2 -5.8 3.74e-08 4.18e-05 -0.95 -0.43 Survival in colorectal cancer (non-distant metastatic); chr15:31456864 chr15:30487963~30490313:+ PAAD cis rs9425766 0.679 rs4652234 ENSG00000227373.4 RP11-160H22.5 5.8 3.74e-08 4.18e-05 0.55 0.43 Life satisfaction; chr1:174181712 chr1:174115300~174160004:- PAAD cis rs9425766 0.732 rs6658543 ENSG00000227373.4 RP11-160H22.5 5.8 3.74e-08 4.18e-05 0.55 0.43 Life satisfaction; chr1:174183338 chr1:174115300~174160004:- PAAD cis rs7567389 0.511 rs61185143 ENSG00000236682.1 AC068282.3 5.8 3.76e-08 4.2e-05 0.57 0.43 Self-rated health; chr2:127407902 chr2:127389130~127400580:+ PAAD cis rs1075265 0.589 rs2253760 ENSG00000233266.1 HMGB1P31 5.8 3.76e-08 4.2e-05 0.53 0.43 Chronotype;Morning vs. evening chronotype; chr2:53806851 chr2:54051334~54051760:+ PAAD cis rs2455601 0.744 rs11042107 ENSG00000254860.4 TMEM9B-AS1 5.8 3.77e-08 4.21e-05 0.56 0.43 Schizophrenia; chr11:8884324 chr11:8964675~8977527:+ PAAD cis rs11123170 0.543 rs12472361 ENSG00000189223.12 PAX8-AS1 -5.8 3.77e-08 4.21e-05 -0.6 -0.43 Renal function-related traits (BUN); chr2:113223068 chr2:113211522~113276581:+ PAAD cis rs11123170 0.543 rs4849180 ENSG00000189223.12 PAX8-AS1 -5.8 3.77e-08 4.21e-05 -0.6 -0.43 Renal function-related traits (BUN); chr2:113227609 chr2:113211522~113276581:+ PAAD cis rs11123170 0.543 rs35222158 ENSG00000189223.12 PAX8-AS1 -5.8 3.77e-08 4.21e-05 -0.6 -0.43 Renal function-related traits (BUN); chr2:113229052 chr2:113211522~113276581:+ PAAD cis rs11123170 0.543 rs2863242 ENSG00000189223.12 PAX8-AS1 -5.8 3.77e-08 4.21e-05 -0.6 -0.43 Renal function-related traits (BUN); chr2:113231659 chr2:113211522~113276581:+ PAAD cis rs7429990 0.833 rs1486915 ENSG00000229759.1 MRPS18AP1 -5.8 3.78e-08 4.22e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47781053 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs13086149 ENSG00000229759.1 MRPS18AP1 -5.8 3.78e-08 4.22e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47784158 chr3:48256350~48256938:- PAAD cis rs35160687 0.814 rs7563887 ENSG00000273080.1 RP11-301O19.1 5.8 3.78e-08 4.22e-05 0.48 0.43 Night sleep phenotypes; chr2:86288998 chr2:86195590~86196049:+ PAAD cis rs35160687 0.814 rs6547673 ENSG00000273080.1 RP11-301O19.1 5.8 3.78e-08 4.22e-05 0.48 0.43 Night sleep phenotypes; chr2:86301815 chr2:86195590~86196049:+ PAAD cis rs875971 0.767 rs1643394 ENSG00000237310.1 GS1-124K5.4 5.8 3.78e-08 4.22e-05 0.43 0.43 Aortic root size; chr7:66371107 chr7:66493706~66495474:+ PAAD cis rs1075232 0.826 rs16956738 ENSG00000270055.1 CTD-3092A11.2 5.8 3.78e-08 4.22e-05 1 0.43 Survival in colorectal cancer (non-distant metastatic); chr15:31444028 chr15:30487963~30490313:+ PAAD cis rs2108622 0.545 rs59140933 ENSG00000267453.5 AC004791.2 -5.8 3.79e-08 4.23e-05 -0.6 -0.43 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15864498 chr19:15851993~15864904:- PAAD cis rs9322193 0.962 rs1413655 ENSG00000216906.2 RP11-350J20.9 5.8 3.8e-08 4.24e-05 0.55 0.43 Lung cancer; chr6:149821815 chr6:149904243~149906418:+ PAAD cis rs9322193 0.926 rs9383546 ENSG00000216906.2 RP11-350J20.9 5.8 3.8e-08 4.24e-05 0.55 0.43 Lung cancer; chr6:149822743 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs2151912 ENSG00000216906.2 RP11-350J20.9 5.8 3.8e-08 4.24e-05 0.55 0.43 Lung cancer; chr6:149831772 chr6:149904243~149906418:+ PAAD cis rs11098499 0.82 rs13122709 ENSG00000245958.5 RP11-33B1.1 -5.8 3.81e-08 4.25e-05 -0.36 -0.43 Corneal astigmatism; chr4:119634201 chr4:119454791~119552025:+ PAAD cis rs9322193 0.962 rs9478848 ENSG00000216906.2 RP11-350J20.9 5.8 3.81e-08 4.25e-05 0.54 0.43 Lung cancer; chr6:149825080 chr6:149904243~149906418:+ PAAD cis rs9928842 0.882 rs11641896 ENSG00000280152.1 RP11-331F4.5 5.79 3.82e-08 4.26e-05 0.55 0.43 Alcoholic chronic pancreatitis; chr16:75266281 chr16:75245994~75250077:- PAAD cis rs17301013 0.794 rs6425283 ENSG00000227373.4 RP11-160H22.5 5.79 3.82e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174499853 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs6425282 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174493387 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs727279 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174496026 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs2072760 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174510186 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs10912797 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174511225 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs6668053 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174515139 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs10912807 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174547228 chr1:174115300~174160004:- PAAD cis rs17301013 0.9 rs56347239 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174564476 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs7542389 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174565104 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs12074753 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174565768 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs1016466 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174570652 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs10753086 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174580802 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs7555533 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174589983 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs6671824 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174603721 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs6672148 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174604016 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs10912813 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174607342 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs67967476 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174616119 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs6683602 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174617615 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs6696197 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174617860 chr1:174115300~174160004:- PAAD cis rs17301013 0.73 rs12060177 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174618545 chr1:174115300~174160004:- PAAD cis rs17301013 0.612 rs56199565 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174640992 chr1:174115300~174160004:- PAAD cis rs17301013 0.761 rs332805 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174652487 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs34819375 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174654958 chr1:174115300~174160004:- PAAD cis rs17301013 0.896 rs332773 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174695711 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs444678 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174706080 chr1:174115300~174160004:- PAAD cis rs17301013 0.896 rs332791 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174709784 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs332795 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174726785 chr1:174115300~174160004:- PAAD cis rs17301013 0.896 rs13375788 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174524207 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs332770 ENSG00000227373.4 RP11-160H22.5 5.79 3.83e-08 4.27e-05 0.54 0.43 Systemic lupus erythematosus; chr1:174681511 chr1:174115300~174160004:- PAAD cis rs4218 0.543 rs11852461 ENSG00000277144.1 RP11-59H7.4 -5.79 3.84e-08 4.27e-05 -0.5 -0.43 Social communication problems; chr15:59021728 chr15:59115547~59116089:- PAAD cis rs4218 0.543 rs8027536 ENSG00000277144.1 RP11-59H7.4 -5.79 3.84e-08 4.27e-05 -0.5 -0.43 Social communication problems; chr15:59022364 chr15:59115547~59116089:- PAAD cis rs11673344 0.583 rs10425719 ENSG00000226686.6 LINC01535 -5.79 3.85e-08 4.29e-05 -0.5 -0.43 Obesity-related traits; chr19:37459896 chr19:37251912~37265535:+ PAAD cis rs2115630 0.645 rs2292463 ENSG00000259728.4 LINC00933 -5.79 3.85e-08 4.29e-05 -0.51 -0.43 P wave terminal force; chr15:84632519 chr15:84570649~84580175:+ PAAD cis rs227275 0.554 rs223363 ENSG00000246560.2 RP11-10L12.4 5.79 3.86e-08 4.29e-05 0.47 0.43 Allergic disease (asthma, hay fever or eczema); chr4:102846182 chr4:102828055~102844075:+ PAAD cis rs10771431 1 rs11611670 ENSG00000111788.10 RP11-22B23.1 5.79 3.86e-08 4.29e-05 0.38 0.43 Breast size; chr12:9232939 chr12:9277235~9313241:+ PAAD cis rs1061377 0.674 rs34506243 ENSG00000249685.1 RP11-360F5.3 5.79 3.87e-08 4.3e-05 0.43 0.43 Uric acid levels; chr4:39082702 chr4:39133913~39135608:+ PAAD cis rs9322193 0.923 rs57938011 ENSG00000216906.2 RP11-350J20.9 5.79 3.87e-08 4.31e-05 0.54 0.43 Lung cancer; chr6:149642969 chr6:149904243~149906418:+ PAAD cis rs6683071 0.894 rs12073392 ENSG00000272750.1 RP11-378J18.8 -5.79 3.88e-08 4.31e-05 -0.55 -0.43 Cognitive performance; chr1:222753336 chr1:222658867~222661512:- PAAD cis rs9322193 0.923 rs62439840 ENSG00000216906.2 RP11-350J20.9 5.79 3.88e-08 4.31e-05 0.54 0.43 Lung cancer; chr6:149674639 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9393175 ENSG00000216906.2 RP11-350J20.9 5.79 3.88e-08 4.31e-05 0.54 0.43 Lung cancer; chr6:149677587 chr6:149904243~149906418:+ PAAD cis rs858239 0.669 rs6461687 ENSG00000226816.2 AC005082.12 5.79 3.88e-08 4.32e-05 0.47 0.43 Cerebrospinal fluid biomarker levels; chr7:23076961 chr7:23206013~23208045:+ PAAD cis rs7829975 0.617 rs4841072 ENSG00000253893.2 FAM85B 5.79 3.9e-08 4.33e-05 0.55 0.43 Mood instability; chr8:8933743 chr8:8167819~8226614:- PAAD cis rs17301013 0.507 rs926349 ENSG00000227373.4 RP11-160H22.5 5.79 3.9e-08 4.34e-05 0.63 0.43 Systemic lupus erythematosus; chr1:174368408 chr1:174115300~174160004:- PAAD cis rs673078 0.66 rs17619932 ENSG00000275759.1 RP11-131L12.3 -5.79 3.92e-08 4.36e-05 -0.56 -0.43 Glucose homeostasis traits; chr12:118352228 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs11068919 ENSG00000275759.1 RP11-131L12.3 -5.79 3.92e-08 4.36e-05 -0.56 -0.43 Glucose homeostasis traits; chr12:118354925 chr12:118428281~118428870:+ PAAD cis rs10515750 0.643 rs10063413 ENSG00000248544.2 CTB-47B11.3 -5.79 3.93e-08 4.36e-05 -0.75 -0.43 Lung function (FEV1/FVC); chr5:157384435 chr5:157375741~157384950:- PAAD cis rs10515750 0.643 rs10054755 ENSG00000248544.2 CTB-47B11.3 5.79 3.93e-08 4.36e-05 0.75 0.43 Lung function (FEV1/FVC); chr5:157384037 chr5:157375741~157384950:- PAAD cis rs10515750 0.643 rs10063539 ENSG00000248544.2 CTB-47B11.3 5.79 3.93e-08 4.36e-05 0.75 0.43 Lung function (FEV1/FVC); chr5:157384666 chr5:157375741~157384950:- PAAD cis rs7429990 0.833 rs4858801 ENSG00000229759.1 MRPS18AP1 -5.79 3.93e-08 4.37e-05 -0.46 -0.43 Educational attainment (years of education); chr3:47599432 chr3:48256350~48256938:- PAAD cis rs7772486 0.875 rs2814863 ENSG00000235652.6 RP11-545I5.3 -5.79 3.93e-08 4.37e-05 -0.35 -0.43 Lobe attachment (rater-scored or self-reported); chr6:146026163 chr6:145799409~145886585:+ PAAD cis rs9322193 0.962 rs7740784 ENSG00000216906.2 RP11-350J20.9 5.79 3.93e-08 4.37e-05 0.55 0.42 Lung cancer; chr6:149833364 chr6:149904243~149906418:+ PAAD cis rs17301013 0.507 rs12076548 ENSG00000227373.4 RP11-160H22.5 -5.79 3.94e-08 4.38e-05 -0.63 -0.42 Systemic lupus erythematosus; chr1:174479005 chr1:174115300~174160004:- PAAD cis rs755249 0.642 rs28788506 ENSG00000237624.1 OXCT2P1 5.79 3.95e-08 4.39e-05 0.56 0.42 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39611108 chr1:39514956~39516490:+ PAAD cis rs755249 0.669 rs4660311 ENSG00000237624.1 OXCT2P1 5.79 3.95e-08 4.39e-05 0.56 0.42 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39613442 chr1:39514956~39516490:+ PAAD cis rs1185460 0.546 rs592190 ENSG00000271751.1 RP11-110I1.14 5.79 3.96e-08 4.39e-05 0.57 0.42 Coronary artery disease; chr11:119084604 chr11:119065263~119065677:- PAAD cis rs1185460 0.546 rs589925 ENSG00000271751.1 RP11-110I1.14 5.79 3.96e-08 4.39e-05 0.57 0.42 Coronary artery disease; chr11:119084969 chr11:119065263~119065677:- PAAD cis rs11722779 0.81 rs223417 ENSG00000246560.2 RP11-10L12.4 5.79 3.96e-08 4.39e-05 0.46 0.42 Schizophrenia; chr4:102810568 chr4:102828055~102844075:+ PAAD cis rs11722779 0.805 rs223416 ENSG00000246560.2 RP11-10L12.4 5.79 3.96e-08 4.39e-05 0.46 0.42 Schizophrenia; chr4:102810580 chr4:102828055~102844075:+ PAAD cis rs7829975 0.777 rs486781 ENSG00000253893.2 FAM85B 5.79 3.97e-08 4.41e-05 0.61 0.42 Mood instability; chr8:8782230 chr8:8167819~8226614:- PAAD cis rs6584283 0.713 rs1332100 ENSG00000257582.4 LINC01475 5.79 3.98e-08 4.41e-05 0.47 0.42 Ulcerative colitis; chr10:99541589 chr10:99526350~99531177:- PAAD cis rs4774565 0.84 rs55948407 ENSG00000244879.4 GABPB1-AS1 -5.79 3.98e-08 4.42e-05 -0.4 -0.42 Breast cancer; chr15:50376704 chr15:50354959~50372202:+ PAAD cis rs17301013 0.507 rs4652797 ENSG00000227373.4 RP11-160H22.5 5.79 3.99e-08 4.43e-05 0.64 0.42 Systemic lupus erythematosus; chr1:174791236 chr1:174115300~174160004:- PAAD cis rs9926296 0.533 rs10852623 ENSG00000260259.1 RP11-368I7.4 -5.79 4e-08 4.43e-05 -0.52 -0.42 Vitiligo; chr16:89798834 chr16:89682620~89686569:- PAAD cis rs6700559 0.81 rs2808248 ENSG00000260088.1 RP11-92G12.3 5.79 4e-08 4.43e-05 0.55 0.42 Coronary artery disease; chr1:200623147 chr1:200669507~200694250:+ PAAD cis rs6700559 0.81 rs7521550 ENSG00000260088.1 RP11-92G12.3 -5.79 4e-08 4.43e-05 -0.55 -0.42 Coronary artery disease; chr1:200623235 chr1:200669507~200694250:+ PAAD cis rs6700559 0.81 rs2808250 ENSG00000260088.1 RP11-92G12.3 -5.79 4e-08 4.43e-05 -0.55 -0.42 Coronary artery disease; chr1:200623419 chr1:200669507~200694250:+ PAAD cis rs987724 0.778 rs2321295 ENSG00000240875.4 LINC00886 -5.78 4e-08 4.44e-05 -0.51 -0.42 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156944556 chr3:156747346~156817062:- PAAD cis rs6452524 0.935 rs2386241 ENSG00000249664.1 CTD-2227C6.2 -5.78 4.01e-08 4.44e-05 -0.52 -0.42 Hypertension (SNP x SNP interaction); chr5:83149872 chr5:83012285~83013109:- PAAD cis rs2019137 0.868 rs6755639 ENSG00000189223.12 PAX8-AS1 -5.78 4.01e-08 4.45e-05 -0.52 -0.42 Lymphocyte counts; chr2:113224233 chr2:113211522~113276581:+ PAAD cis rs7772486 0.754 rs697055 ENSG00000235652.6 RP11-545I5.3 5.78 4.02e-08 4.45e-05 0.36 0.42 Lobe attachment (rater-scored or self-reported); chr6:145682654 chr6:145799409~145886585:+ PAAD cis rs1150668 0.796 rs1005125 ENSG00000204709.4 LINC01556 5.78 4.03e-08 4.46e-05 0.56 0.42 Pubertal anthropometrics; chr6:28399578 chr6:28943877~28944537:+ PAAD cis rs10875746 0.669 rs10875792 ENSG00000240399.1 RP1-228P16.1 -5.78 4.03e-08 4.46e-05 -0.47 -0.42 Longevity (90 years and older); chr12:48303640 chr12:48054813~48055591:- PAAD cis rs10875746 0.623 rs10875793 ENSG00000240399.1 RP1-228P16.1 -5.78 4.03e-08 4.46e-05 -0.47 -0.42 Longevity (90 years and older); chr12:48303647 chr12:48054813~48055591:- PAAD cis rs526231 0.511 rs3756582 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103003848 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs45518833 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103007286 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs1826673 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103010212 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs62362545 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103011748 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs3910557 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103014767 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs2288389 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103018104 chr5:103032376~103033031:+ PAAD cis rs26232 0.521 rs3776856 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Rheumatoid arthritis; chr5:103023102 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs17154965 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103023862 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs55896090 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103026300 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs55810112 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103026645 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs1011453 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103032323 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs62362558 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103032789 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs4421079 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103033372 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs4386712 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103033530 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs56235607 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103036902 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs55741939 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103036984 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs17155009 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Primary biliary cholangitis; chr5:103038440 chr5:103032376~103033031:+ PAAD cis rs26232 0.521 rs67019105 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Rheumatoid arthritis; chr5:103038459 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs72785733 ENSG00000175749.11 EIF3KP1 5.78 4.04e-08 4.47e-05 0.55 0.42 Parkinson's disease; chr5:103038488 chr5:103032376~103033031:+ PAAD cis rs2115630 0.645 rs4842978 ENSG00000275120.1 RP11-182J1.17 -5.78 4.04e-08 4.47e-05 -0.43 -0.42 P wave terminal force; chr15:84654022 chr15:84599434~84606463:- PAAD cis rs17301013 0.507 rs72717618 ENSG00000227373.4 RP11-160H22.5 5.78 4.04e-08 4.47e-05 0.65 0.42 Systemic lupus erythematosus; chr1:174816839 chr1:174115300~174160004:- PAAD cis rs1322639 0.542 rs9689153 ENSG00000261039.2 RP11-417E7.2 5.78 4.06e-08 4.49e-05 0.6 0.42 Pulse pressure; chr6:169186730 chr6:169175304~169182740:- PAAD cis rs12594515 1 rs57299255 ENSG00000273972.1 CTD-2306A12.1 -5.78 4.08e-08 4.51e-05 -0.51 -0.42 Weight;Waist circumference; chr15:45704334 chr15:45702640~45703183:+ PAAD cis rs11155671 0.53 rs7763849 ENSG00000223701.3 RAET1E-AS1 5.78 4.08e-08 4.51e-05 0.49 0.42 Testicular germ cell tumor; chr6:149885244 chr6:149884431~149919508:+ PAAD cis rs2115630 0.645 rs1107179 ENSG00000275120.1 RP11-182J1.17 5.78 4.09e-08 4.52e-05 0.43 0.42 P wave terminal force; chr15:84655131 chr15:84599434~84606463:- PAAD cis rs763567 0.585 rs476810 ENSG00000271811.1 RP1-79C4.4 -5.78 4.09e-08 4.52e-05 -0.4 -0.42 Tonsillectomy; chr1:170604673 chr1:170667381~170669425:+ PAAD cis rs763567 0.585 rs1234233 ENSG00000271811.1 RP1-79C4.4 -5.78 4.09e-08 4.52e-05 -0.4 -0.42 Tonsillectomy; chr1:170605787 chr1:170667381~170669425:+ PAAD cis rs763567 0.546 rs566850 ENSG00000271811.1 RP1-79C4.4 -5.78 4.09e-08 4.52e-05 -0.4 -0.42 Tonsillectomy; chr1:170607597 chr1:170667381~170669425:+ PAAD cis rs763567 0.565 rs546258 ENSG00000271811.1 RP1-79C4.4 -5.78 4.09e-08 4.52e-05 -0.4 -0.42 Tonsillectomy; chr1:170610453 chr1:170667381~170669425:+ PAAD cis rs763567 0.605 rs619456 ENSG00000271811.1 RP1-79C4.4 -5.78 4.09e-08 4.52e-05 -0.4 -0.42 Tonsillectomy; chr1:170616691 chr1:170667381~170669425:+ PAAD cis rs9326248 1 rs664922 ENSG00000280143.1 AP000892.6 5.78 4.09e-08 4.52e-05 0.54 0.42 Blood protein levels; chr11:117200179 chr11:117204967~117210292:+ PAAD cis rs9326248 1 rs664082 ENSG00000280143.1 AP000892.6 5.78 4.09e-08 4.52e-05 0.54 0.42 Blood protein levels; chr11:117200354 chr11:117204967~117210292:+ PAAD cis rs9326248 0.953 rs488962 ENSG00000280143.1 AP000892.6 -5.78 4.09e-08 4.52e-05 -0.54 -0.42 Blood protein levels; chr11:117201809 chr11:117204967~117210292:+ PAAD cis rs9326248 0.953 rs634960 ENSG00000280143.1 AP000892.6 -5.78 4.09e-08 4.52e-05 -0.54 -0.42 Blood protein levels; chr11:117202247 chr11:117204967~117210292:+ PAAD cis rs9322193 0.923 rs1080670 ENSG00000216906.2 RP11-350J20.9 5.78 4.12e-08 4.54e-05 0.53 0.42 Lung cancer; chr6:149620161 chr6:149904243~149906418:+ PAAD cis rs3096299 0.719 rs2911265 ENSG00000274627.1 RP11-104N10.2 5.78 4.12e-08 4.55e-05 0.36 0.42 Multiple myeloma (IgH translocation); chr16:89444920 chr16:89516797~89522217:+ PAAD cis rs2280018 0.538 rs7404526 ENSG00000260735.1 RP11-72I8.1 -5.78 4.12e-08 4.55e-05 -0.57 -0.42 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15035305 chr16:15094411~15109197:+ PAAD cis rs2281636 0.723 rs3740078 ENSG00000233690.1 EBAG9P1 5.78 4.14e-08 4.57e-05 0.49 0.42 Obesity-related traits; chr10:99685834 chr10:99697407~99697949:- PAAD cis rs227275 0.554 rs223334 ENSG00000246560.2 RP11-10L12.4 -5.78 4.15e-08 4.58e-05 -0.46 -0.42 Allergic disease (asthma, hay fever or eczema); chr4:102867054 chr4:102828055~102844075:+ PAAD cis rs17301013 0.507 rs10912757 ENSG00000227373.4 RP11-160H22.5 5.78 4.15e-08 4.58e-05 0.63 0.42 Systemic lupus erythematosus; chr1:174299064 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6693198 ENSG00000227373.4 RP11-160H22.5 5.78 4.15e-08 4.58e-05 0.63 0.42 Systemic lupus erythematosus; chr1:174304301 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912762 ENSG00000227373.4 RP11-160H22.5 5.78 4.15e-08 4.58e-05 0.63 0.42 Systemic lupus erythematosus; chr1:174312477 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12097252 ENSG00000227373.4 RP11-160H22.5 5.78 4.15e-08 4.58e-05 0.63 0.42 Systemic lupus erythematosus; chr1:174318374 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4651008 ENSG00000227373.4 RP11-160H22.5 5.78 4.15e-08 4.58e-05 0.63 0.42 Systemic lupus erythematosus; chr1:174342681 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs12077622 ENSG00000227373.4 RP11-160H22.5 5.78 4.16e-08 4.59e-05 0.54 0.42 Systemic lupus erythematosus; chr1:174442507 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs6664864 ENSG00000227373.4 RP11-160H22.5 5.78 4.16e-08 4.59e-05 0.54 0.42 Systemic lupus erythematosus; chr1:174622912 chr1:174115300~174160004:- PAAD cis rs3814244 0.54 rs2159064 ENSG00000255733.4 IFNG-AS1 -5.78 4.16e-08 4.59e-05 -0.39 -0.42 Itch intensity from mosquito bite adjusted by bite size; chr12:68017126 chr12:67989445~68234686:+ PAAD cis rs4879677 0.736 rs12379575 ENSG00000260390.1 RP11-575I8.1 -5.78 4.16e-08 4.59e-05 -0.52 -0.42 Gut microbiome composition (summer and winter); chr9:27639812 chr9:27829276~27844481:+ PAAD cis rs734999 0.967 rs4486391 ENSG00000225931.3 RP3-395M20.7 5.78 4.16e-08 4.59e-05 0.4 0.42 Ulcerative colitis; chr1:2581616 chr1:2566410~2569888:+ PAAD cis rs875971 0.825 rs1129531 ENSG00000237310.1 GS1-124K5.4 -5.78 4.17e-08 4.6e-05 -0.43 -0.42 Aortic root size; chr7:66154117 chr7:66493706~66495474:+ PAAD cis rs638893 0.636 rs6589687 ENSG00000278376.1 RP11-158I9.8 -5.78 4.18e-08 4.6e-05 -0.6 -0.42 Vitiligo; chr11:118744951 chr11:118791254~118793137:+ PAAD cis rs638893 0.53 rs1961138 ENSG00000278376.1 RP11-158I9.8 -5.78 4.18e-08 4.6e-05 -0.6 -0.42 Vitiligo; chr11:118748714 chr11:118791254~118793137:+ PAAD cis rs638893 0.578 rs485901 ENSG00000278376.1 RP11-158I9.8 -5.78 4.18e-08 4.6e-05 -0.6 -0.42 Vitiligo; chr11:118751536 chr11:118791254~118793137:+ PAAD cis rs638893 0.578 rs580079 ENSG00000278376.1 RP11-158I9.8 -5.78 4.18e-08 4.6e-05 -0.6 -0.42 Vitiligo; chr11:118754900 chr11:118791254~118793137:+ PAAD cis rs638893 0.588 rs529717 ENSG00000278376.1 RP11-158I9.8 -5.78 4.18e-08 4.6e-05 -0.6 -0.42 Vitiligo; chr11:118769372 chr11:118791254~118793137:+ PAAD cis rs638893 0.588 rs2508929 ENSG00000278376.1 RP11-158I9.8 -5.78 4.18e-08 4.6e-05 -0.6 -0.42 Vitiligo; chr11:118770742 chr11:118791254~118793137:+ PAAD cis rs638893 0.636 rs548167 ENSG00000278376.1 RP11-158I9.8 -5.78 4.18e-08 4.6e-05 -0.6 -0.42 Vitiligo; chr11:118777687 chr11:118791254~118793137:+ PAAD cis rs638893 0.685 rs486651 ENSG00000278376.1 RP11-158I9.8 -5.78 4.18e-08 4.6e-05 -0.6 -0.42 Vitiligo; chr11:118779150 chr11:118791254~118793137:+ PAAD cis rs12458462 1 rs12458462 ENSG00000274828.1 RP11-567M16.6 5.78 4.18e-08 4.6e-05 0.41 0.42 Monocyte count; chr18:79712436 chr18:79677287~79679358:- PAAD cis rs950169 1 rs11638394 ENSG00000225151.9 GOLGA2P7 -5.78 4.18e-08 4.6e-05 -0.52 -0.42 Schizophrenia; chr15:84110176 chr15:84199311~84230136:- PAAD cis rs950169 1 rs35658069 ENSG00000225151.9 GOLGA2P7 -5.78 4.18e-08 4.6e-05 -0.52 -0.42 Schizophrenia; chr15:84111394 chr15:84199311~84230136:- PAAD cis rs9322193 0.923 rs9377230 ENSG00000216906.2 RP11-350J20.9 5.78 4.18e-08 4.6e-05 0.53 0.42 Lung cancer; chr6:149613607 chr6:149904243~149906418:+ PAAD cis rs11098499 0.863 rs1552092 ENSG00000245958.5 RP11-33B1.1 -5.78 4.18e-08 4.61e-05 -0.37 -0.42 Corneal astigmatism; chr4:119567341 chr4:119454791~119552025:+ PAAD cis rs734999 0.967 rs10910089 ENSG00000225931.3 RP3-395M20.7 5.78 4.19e-08 4.62e-05 0.41 0.42 Ulcerative colitis; chr1:2567179 chr1:2566410~2569888:+ PAAD cis rs3096299 0.728 rs1011749 ENSG00000274627.1 RP11-104N10.2 5.78 4.19e-08 4.62e-05 0.37 0.42 Multiple myeloma (IgH translocation); chr16:89444461 chr16:89516797~89522217:+ PAAD cis rs228614 0.51 rs150893 ENSG00000246560.2 RP11-10L12.4 -5.78 4.2e-08 4.62e-05 -0.46 -0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102817075 chr4:102828055~102844075:+ PAAD cis rs858239 0.669 rs6461688 ENSG00000226816.2 AC005082.12 5.77 4.2e-08 4.63e-05 0.46 0.42 Cerebrospinal fluid biomarker levels; chr7:23076996 chr7:23206013~23208045:+ PAAD cis rs858239 0.699 rs1881201 ENSG00000226816.2 AC005082.12 -5.77 4.21e-08 4.63e-05 -0.48 -0.42 Cerebrospinal fluid biomarker levels; chr7:23154394 chr7:23206013~23208045:+ PAAD cis rs950169 1 rs11638297 ENSG00000225151.9 GOLGA2P7 -5.77 4.22e-08 4.65e-05 -0.51 -0.42 Schizophrenia; chr15:84113665 chr15:84199311~84230136:- PAAD cis rs9532669 0.963 rs9315794 ENSG00000176268.5 CYCSP34 5.77 4.23e-08 4.65e-05 0.39 0.42 Cervical cancer; chr13:40939489 chr13:40863599~40863902:- PAAD cis rs17301013 0.507 rs72715300 ENSG00000227373.4 RP11-160H22.5 5.77 4.24e-08 4.67e-05 0.63 0.42 Systemic lupus erythematosus; chr1:174768405 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs55844798 ENSG00000227373.4 RP11-160H22.5 5.77 4.24e-08 4.67e-05 0.63 0.42 Systemic lupus erythematosus; chr1:174768973 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12074416 ENSG00000227373.4 RP11-160H22.5 5.77 4.24e-08 4.67e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174430109 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72717608 ENSG00000227373.4 RP11-160H22.5 5.77 4.24e-08 4.67e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174788316 chr1:174115300~174160004:- PAAD cis rs7208859 0.623 rs383436 ENSG00000266490.1 CTD-2349P21.9 5.77 4.25e-08 4.67e-05 0.53 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30632161 chr17:30792372~30792833:+ PAAD cis rs17826219 0.714 rs11650821 ENSG00000266490.1 CTD-2349P21.9 5.77 4.25e-08 4.67e-05 0.53 0.42 Body mass index; chr17:30641132 chr17:30792372~30792833:+ PAAD cis rs11098499 0.662 rs13108589 ENSG00000245958.5 RP11-33B1.1 -5.77 4.25e-08 4.68e-05 -0.34 -0.42 Corneal astigmatism; chr4:119346947 chr4:119454791~119552025:+ PAAD cis rs12220777 1 rs118110670 ENSG00000230091.5 TMEM254-AS1 5.77 4.25e-08 4.68e-05 0.78 0.42 Chronic obstructive pulmonary disease-related biomarkers; chr10:80032486 chr10:80046860~80078912:- PAAD cis rs9309711 0.623 rs4641971 ENSG00000225234.1 TRAPPC12-AS1 5.77 4.25e-08 4.68e-05 0.43 0.42 Neurofibrillary tangles; chr2:3478086 chr2:3481242~3482409:- PAAD cis rs638893 0.636 rs526850 ENSG00000278376.1 RP11-158I9.8 -5.77 4.27e-08 4.7e-05 -0.61 -0.42 Vitiligo; chr11:118734418 chr11:118791254~118793137:+ PAAD cis rs7429990 0.864 rs13061412 ENSG00000229759.1 MRPS18AP1 -5.77 4.28e-08 4.71e-05 -0.46 -0.42 Educational attainment (years of education); chr3:47660092 chr3:48256350~48256938:- PAAD cis rs55665837 0.778 rs11023212 ENSG00000251991.1 RNU7-49P 5.77 4.28e-08 4.71e-05 0.51 0.42 Vitamin D levels; chr11:14410163 chr11:14478892~14478953:+ PAAD cis rs17301013 0.507 rs12074107 ENSG00000227373.4 RP11-160H22.5 -5.77 4.29e-08 4.72e-05 -0.63 -0.42 Systemic lupus erythematosus; chr1:174307926 chr1:174115300~174160004:- PAAD cis rs10463554 1 rs12656131 ENSG00000175749.11 EIF3KP1 -5.77 4.29e-08 4.72e-05 -0.54 -0.42 Parkinson's disease; chr5:102990174 chr5:103032376~103033031:+ PAAD cis rs17301013 0.507 rs16828481 ENSG00000227373.4 RP11-160H22.5 5.77 4.3e-08 4.73e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174415979 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12065326 ENSG00000227373.4 RP11-160H22.5 5.77 4.3e-08 4.73e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174426892 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72715224 ENSG00000227373.4 RP11-160H22.5 5.77 4.3e-08 4.73e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174534256 chr1:174115300~174160004:- PAAD cis rs2108622 0.649 rs113055956 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866502 chr19:15851993~15864904:- PAAD cis rs2108622 0.711 rs113059233 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866558 chr19:15851993~15864904:- PAAD cis rs2108622 0.683 rs111388185 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866604 chr19:15851993~15864904:- PAAD cis rs2108622 0.683 rs112571591 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866635 chr19:15851993~15864904:- PAAD cis rs2108622 0.647 rs111427692 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866669 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs12609468 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867004 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs12610967 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867119 chr19:15851993~15864904:- PAAD cis rs2108622 0.711 rs12609820 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867247 chr19:15851993~15864904:- PAAD cis rs2108622 0.668 rs62106153 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867697 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs12611242 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867754 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs12611308 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867776 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs12610189 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15867831 chr19:15851993~15864904:- PAAD cis rs2108622 0.711 rs113343664 ENSG00000267453.5 AC004791.2 -5.77 4.31e-08 4.73e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15868183 chr19:15851993~15864904:- PAAD cis rs17264034 0.861 rs1614229 ENSG00000250786.1 SNHG18 5.77 4.31e-08 4.74e-05 0.59 0.42 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9546883 chr5:9546200~9550609:+ PAAD cis rs2882667 0.824 rs1560656 ENSG00000253404.1 AC034243.1 -5.77 4.31e-08 4.74e-05 -0.52 -0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139135100 chr5:138744434~138753309:- PAAD cis rs9322193 0.923 rs11155671 ENSG00000216906.2 RP11-350J20.9 5.77 4.33e-08 4.75e-05 0.53 0.42 Lung cancer; chr6:149650996 chr6:149904243~149906418:+ PAAD cis rs6142102 0.581 rs4911148 ENSG00000276073.1 RP5-1125A11.7 -5.77 4.33e-08 4.75e-05 -0.44 -0.42 Skin pigmentation; chr20:34080438 chr20:33985617~33988989:- PAAD cis rs7829975 0.582 rs6982832 ENSG00000253893.2 FAM85B 5.77 4.33e-08 4.75e-05 0.56 0.42 Mood instability; chr8:8934707 chr8:8167819~8226614:- PAAD cis rs7829975 0.582 rs6983150 ENSG00000253893.2 FAM85B 5.77 4.33e-08 4.75e-05 0.56 0.42 Mood instability; chr8:8934916 chr8:8167819~8226614:- PAAD cis rs2337406 0.929 rs12050233 ENSG00000274576.2 IGHV2-70 -5.77 4.33e-08 4.75e-05 -0.53 -0.42 Alzheimer's disease (late onset); chr14:106781123 chr14:106770577~106771020:- PAAD cis rs2337406 0.852 rs12050466 ENSG00000274576.2 IGHV2-70 -5.77 4.33e-08 4.75e-05 -0.53 -0.42 Alzheimer's disease (late onset); chr14:106781131 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs61419485 ENSG00000274576.2 IGHV2-70 -5.77 4.33e-08 4.75e-05 -0.53 -0.42 Alzheimer's disease (late onset); chr14:106783374 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs8015361 ENSG00000274576.2 IGHV2-70 -5.77 4.33e-08 4.75e-05 -0.53 -0.42 Alzheimer's disease (late onset); chr14:106783991 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74090151 ENSG00000274576.2 IGHV2-70 -5.77 4.33e-08 4.75e-05 -0.53 -0.42 Alzheimer's disease (late onset); chr14:106785377 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs11488879 ENSG00000274576.2 IGHV2-70 -5.77 4.33e-08 4.75e-05 -0.53 -0.42 Alzheimer's disease (late onset); chr14:106786097 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs8012619 ENSG00000274576.2 IGHV2-70 -5.77 4.33e-08 4.75e-05 -0.53 -0.42 Alzheimer's disease (late onset); chr14:106793907 chr14:106770577~106771020:- PAAD cis rs10463554 0.963 rs62364874 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103056475 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs62364876 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103058454 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs158254 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103059179 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34381 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103060852 chr5:103032376~103033031:+ PAAD cis rs10463554 0.857 rs34376 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103065409 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34375 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103065419 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs40061 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103067412 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34373 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103068590 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs158253 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103069502 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs158252 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103070546 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs154369 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103071140 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs158246 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103073145 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs158245 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103073801 chr5:103032376~103033031:+ PAAD cis rs10463554 0.857 rs158397 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103076497 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs158399 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103077564 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs158403 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103080064 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs158404 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103080206 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs257305 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103081533 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257306 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103081770 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs257307 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103081805 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257308 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103082557 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257311 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103083394 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257314 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103085391 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257316 ENSG00000175749.11 EIF3KP1 -5.77 4.34e-08 4.75e-05 -0.56 -0.42 Parkinson's disease; chr5:103086739 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs468844 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103087872 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs469094 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103087875 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34795 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103088716 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34796 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103088725 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34799 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103090498 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34800 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103090799 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34802 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103091301 chr5:103032376~103033031:+ PAAD cis rs526231 0.508 rs34805 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Primary biliary cholangitis; chr5:103092608 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34821 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103101913 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34824 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103103227 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34825 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103103614 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34826 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103106044 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs34830 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103108349 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34831 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103108385 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs257319 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103110123 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs39666 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103111423 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34769 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103111523 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs464591 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103111600 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34772 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103114808 chr5:103032376~103033031:+ PAAD cis rs10463554 0.889 rs34775 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103115572 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34776 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103116090 chr5:103032376~103033031:+ PAAD cis rs10463554 0.667 rs34782 ENSG00000175749.11 EIF3KP1 5.77 4.34e-08 4.75e-05 0.56 0.42 Parkinson's disease; chr5:103118766 chr5:103032376~103033031:+ PAAD cis rs2281636 0.66 rs11190184 ENSG00000233690.1 EBAG9P1 5.77 4.34e-08 4.76e-05 0.51 0.42 Obesity-related traits; chr10:99608442 chr10:99697407~99697949:- PAAD cis rs2455601 0.671 rs10840135 ENSG00000254860.4 TMEM9B-AS1 5.77 4.35e-08 4.77e-05 0.49 0.42 Schizophrenia; chr11:8858247 chr11:8964675~8977527:+ PAAD cis rs950169 0.58 rs11636189 ENSG00000225151.9 GOLGA2P7 -5.77 4.36e-08 4.77e-05 -0.51 -0.42 Schizophrenia; chr15:84650323 chr15:84199311~84230136:- PAAD cis rs950169 0.58 rs35516100 ENSG00000225151.9 GOLGA2P7 -5.77 4.36e-08 4.77e-05 -0.51 -0.42 Schizophrenia; chr15:84652199 chr15:84199311~84230136:- PAAD cis rs950169 0.58 rs62021208 ENSG00000225151.9 GOLGA2P7 -5.77 4.36e-08 4.77e-05 -0.51 -0.42 Schizophrenia; chr15:84653013 chr15:84199311~84230136:- PAAD cis rs3814244 0.515 rs3015002 ENSG00000255733.4 IFNG-AS1 -5.77 4.36e-08 4.78e-05 -0.41 -0.42 Itch intensity from mosquito bite adjusted by bite size; chr12:68010853 chr12:67989445~68234686:+ PAAD cis rs853679 0.567 rs6905380 ENSG00000216901.1 AL022393.7 5.77 4.37e-08 4.79e-05 0.57 0.42 Depression; chr6:28407125 chr6:28176188~28176674:+ PAAD cis rs12458462 0.859 rs2242177 ENSG00000274828.1 RP11-567M16.6 5.77 4.37e-08 4.79e-05 0.41 0.42 Monocyte count; chr18:79717379 chr18:79677287~79679358:- PAAD cis rs2980439 0.525 rs2945238 ENSG00000253893.2 FAM85B -5.77 4.38e-08 4.79e-05 -0.57 -0.42 Neuroticism; chr8:8312614 chr8:8167819~8226614:- PAAD cis rs7301826 0.934 rs10773826 ENSG00000256299.1 RP11-989F5.3 -5.77 4.38e-08 4.79e-05 -0.48 -0.42 Plasma plasminogen activator levels; chr12:130836629 chr12:130810821~130812622:- PAAD cis rs17301013 0.932 rs10912804 ENSG00000227373.4 RP11-160H22.5 5.77 4.39e-08 4.8e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174527412 chr1:174115300~174160004:- PAAD cis rs17301013 0.9 rs12088073 ENSG00000227373.4 RP11-160H22.5 5.77 4.39e-08 4.8e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174528504 chr1:174115300~174160004:- PAAD cis rs12458462 0.892 rs3786228 ENSG00000274828.1 RP11-567M16.6 -5.77 4.41e-08 4.82e-05 -0.41 -0.42 Monocyte count; chr18:79704170 chr18:79677287~79679358:- PAAD cis rs2739330 0.791 rs9612520 ENSG00000206090.4 AP000350.7 5.77 4.41e-08 4.83e-05 0.55 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23927272 chr22:23939998~23942798:+ PAAD cis rs9640161 0.75 rs4395803 ENSG00000261305.1 RP4-584D14.7 5.76 4.41e-08 4.83e-05 0.65 0.42 Blood protein levels;Circulating chemerin levels; chr7:150328278 chr7:150341771~150342607:+ PAAD cis rs4218 0.573 rs16940998 ENSG00000277144.1 RP11-59H7.4 5.76 4.42e-08 4.83e-05 0.52 0.42 Social communication problems; chr15:59086095 chr15:59115547~59116089:- PAAD cis rs875971 0.862 rs709596 ENSG00000237310.1 GS1-124K5.4 5.76 4.42e-08 4.84e-05 0.42 0.42 Aortic root size; chr7:66360926 chr7:66493706~66495474:+ PAAD cis rs58873874 0.522 rs6875379 ENSG00000248544.2 CTB-47B11.3 5.76 4.42e-08 4.84e-05 0.75 0.42 Bipolar disorder (body mass index interaction); chr5:157391295 chr5:157375741~157384950:- PAAD cis rs6538678 0.746 rs12820313 ENSG00000258343.1 RP11-536G4.2 -5.76 4.46e-08 4.88e-05 -0.55 -0.42 Lupus nephritis in systemic lupus erythematosus; chr12:95861926 chr12:95795345~95858839:- PAAD cis rs7586673 0.866 rs7579662 ENSG00000227403.1 AC009299.3 -5.76 4.46e-08 4.88e-05 -0.56 -0.42 Intelligence (multi-trait analysis); chr2:161059299 chr2:161244739~161249050:+ PAAD cis rs526231 0.543 rs152137 ENSG00000175749.11 EIF3KP1 5.76 4.46e-08 4.88e-05 0.57 0.42 Primary biliary cholangitis; chr5:103224362 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs246913 ENSG00000175749.11 EIF3KP1 5.76 4.46e-08 4.88e-05 0.57 0.42 Primary biliary cholangitis; chr5:103224669 chr5:103032376~103033031:+ PAAD cis rs9425766 0.64 rs6693423 ENSG00000227373.4 RP11-160H22.5 5.76 4.47e-08 4.89e-05 0.54 0.42 Life satisfaction; chr1:174364680 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs60363188 ENSG00000227373.4 RP11-160H22.5 5.76 4.47e-08 4.89e-05 0.54 0.42 Life satisfaction; chr1:174375959 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs12084119 ENSG00000227373.4 RP11-160H22.5 5.76 4.47e-08 4.89e-05 0.54 0.42 Life satisfaction; chr1:174377138 chr1:174115300~174160004:- PAAD cis rs72843506 0.722 rs117096120 ENSG00000189423.10 USP32P3 5.76 4.48e-08 4.9e-05 0.68 0.42 Schizophrenia; chr17:20264380 chr17:20415547~20431008:+ PAAD cis rs6538678 0.746 rs703693 ENSG00000258343.1 RP11-536G4.2 -5.76 4.5e-08 4.92e-05 -0.56 -0.42 Lupus nephritis in systemic lupus erythematosus; chr12:95866214 chr12:95795345~95858839:- PAAD cis rs9425766 0.679 rs4650989 ENSG00000227373.4 RP11-160H22.5 5.76 4.52e-08 4.94e-05 0.54 0.42 Life satisfaction; chr1:174289739 chr1:174115300~174160004:- PAAD cis rs2739330 0.892 rs5751776 ENSG00000231271.1 AP000350.8 5.76 4.52e-08 4.94e-05 0.56 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23949918~23954042:+ PAAD cis rs732716 0.785 rs55660045 ENSG00000267980.1 AC007292.6 -5.76 4.52e-08 4.94e-05 -0.58 -0.42 Mean corpuscular volume; chr19:4425308 chr19:4363789~4364640:+ PAAD cis rs732716 0.785 rs62130978 ENSG00000267980.1 AC007292.6 -5.76 4.52e-08 4.94e-05 -0.58 -0.42 Mean corpuscular volume; chr19:4429010 chr19:4363789~4364640:+ PAAD cis rs732716 0.819 rs12459919 ENSG00000267980.1 AC007292.6 -5.76 4.52e-08 4.94e-05 -0.58 -0.42 Mean corpuscular volume; chr19:4434506 chr19:4363789~4364640:+ PAAD cis rs11098499 0.821 rs56155624 ENSG00000245958.5 RP11-33B1.1 -5.76 4.52e-08 4.94e-05 -0.32 -0.42 Corneal astigmatism; chr4:119369871 chr4:119454791~119552025:+ PAAD cis rs17301013 0.507 rs6684688 ENSG00000227373.4 RP11-160H22.5 5.76 4.52e-08 4.94e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174357180 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs28628056 ENSG00000227373.4 RP11-160H22.5 5.76 4.52e-08 4.94e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174369545 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912772 ENSG00000227373.4 RP11-160H22.5 5.76 4.52e-08 4.94e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174370832 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12073751 ENSG00000227373.4 RP11-160H22.5 5.76 4.52e-08 4.94e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174373177 chr1:174115300~174160004:- PAAD cis rs4774565 0.8 rs34174311 ENSG00000244879.4 GABPB1-AS1 -5.76 4.53e-08 4.95e-05 -0.39 -0.42 Breast cancer; chr15:50381084 chr15:50354959~50372202:+ PAAD cis rs1823913 0.927 rs34765012 ENSG00000280083.1 RP11-317J9.1 -5.76 4.54e-08 4.96e-05 -0.56 -0.42 Obesity-related traits; chr2:191247926 chr2:191154118~191156070:- PAAD cis rs9322193 0.962 rs3805752 ENSG00000216906.2 RP11-350J20.9 5.76 4.55e-08 4.97e-05 0.55 0.42 Lung cancer; chr6:149795490 chr6:149904243~149906418:+ PAAD cis rs9322193 0.847 rs12210605 ENSG00000216906.2 RP11-350J20.9 5.76 4.55e-08 4.97e-05 0.55 0.42 Lung cancer; chr6:149817267 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs9371199 ENSG00000216906.2 RP11-350J20.9 5.76 4.55e-08 4.97e-05 0.55 0.42 Lung cancer; chr6:149817526 chr6:149904243~149906418:+ PAAD cis rs10875746 0.624 rs7297298 ENSG00000240399.1 RP1-228P16.1 -5.76 4.56e-08 4.98e-05 -0.48 -0.42 Longevity (90 years and older); chr12:48278523 chr12:48054813~48055591:- PAAD cis rs9322193 0.923 rs9322214 ENSG00000216906.2 RP11-350J20.9 5.76 4.58e-08 5e-05 0.54 0.42 Lung cancer; chr6:149703986 chr6:149904243~149906418:+ PAAD cis rs9322193 0.887 rs9767113 ENSG00000216906.2 RP11-350J20.9 5.76 4.58e-08 5e-05 0.54 0.42 Lung cancer; chr6:149718157 chr6:149904243~149906418:+ PAAD cis rs113835537 0.529 rs7943327 ENSG00000255517.5 CTD-3074O7.5 -5.76 4.58e-08 5e-05 -0.54 -0.42 Airway imaging phenotypes; chr11:66489110 chr11:66473490~66480233:- PAAD cis rs2739330 0.791 rs4822458 ENSG00000206090.4 AP000350.7 5.76 4.59e-08 5.01e-05 0.54 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23939998~23942798:+ PAAD cis rs4218 0.648 rs35769647 ENSG00000277144.1 RP11-59H7.4 -5.76 4.6e-08 5.02e-05 -0.59 -0.42 Social communication problems; chr15:59081670 chr15:59115547~59116089:- PAAD cis rs6570726 0.577 rs403345 ENSG00000235652.6 RP11-545I5.3 5.76 4.6e-08 5.02e-05 0.36 0.42 Lobe attachment (rater-scored or self-reported); chr6:145524035 chr6:145799409~145886585:+ PAAD cis rs7104764 0.673 rs3782118 ENSG00000277290.1 RP11-326C3.16 -5.76 4.61e-08 5.03e-05 -0.37 -0.42 Menarche (age at onset); chr11:222620 chr11:243099~243483:- PAAD cis rs7188445 1 rs11150190 ENSG00000261390.4 RP11-345M22.2 -5.76 4.62e-08 5.04e-05 -0.57 -0.42 Urate levels; chr16:79700352 chr16:79715232~79770563:- PAAD cis rs1155848 0.571 rs6563125 ENSG00000227354.5 RBM26-AS1 5.76 4.63e-08 5.05e-05 0.73 0.42 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79630618 chr13:79406309~79424328:+ PAAD cis rs1155848 0.571 rs58739959 ENSG00000227354.5 RBM26-AS1 5.76 4.63e-08 5.05e-05 0.73 0.42 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79633468 chr13:79406309~79424328:+ PAAD cis rs1155848 0.571 rs6563127 ENSG00000227354.5 RBM26-AS1 5.76 4.63e-08 5.05e-05 0.73 0.42 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79642012 chr13:79406309~79424328:+ PAAD cis rs12908161 0.959 rs11637728 ENSG00000225151.9 GOLGA2P7 -5.75 4.64e-08 5.06e-05 -0.51 -0.42 Schizophrenia; chr15:84660161 chr15:84199311~84230136:- PAAD cis rs9322193 0.962 rs4552 ENSG00000216906.2 RP11-350J20.9 5.75 4.65e-08 5.08e-05 0.55 0.42 Lung cancer; chr6:149811183 chr6:149904243~149906418:+ PAAD cis rs17301013 0.507 rs16847337 ENSG00000227373.4 RP11-160H22.5 -5.75 4.66e-08 5.08e-05 -0.66 -0.42 Systemic lupus erythematosus; chr1:174683121 chr1:174115300~174160004:- PAAD cis rs748404 0.56 rs1060939 ENSG00000249839.1 AC011330.5 -5.75 4.66e-08 5.08e-05 -0.62 -0.42 Lung cancer; chr15:43524719 chr15:43663654~43684339:- PAAD cis rs113835537 0.529 rs11227499 ENSG00000255517.5 CTD-3074O7.5 -5.75 4.68e-08 5.1e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66505353 chr11:66473490~66480233:- PAAD cis rs7615952 0.8 rs2062773 ENSG00000171084.14 FAM86JP 5.75 4.68e-08 5.1e-05 0.56 0.42 Blood pressure (smoking interaction); chr3:125920805 chr3:125916620~125930024:+ PAAD cis rs7615952 0.799 rs13315434 ENSG00000171084.14 FAM86JP 5.75 4.68e-08 5.1e-05 0.56 0.42 Blood pressure (smoking interaction); chr3:125922551 chr3:125916620~125930024:+ PAAD cis rs7615952 0.866 rs13063119 ENSG00000171084.14 FAM86JP 5.75 4.68e-08 5.1e-05 0.56 0.42 Blood pressure (smoking interaction); chr3:125925004 chr3:125916620~125930024:+ PAAD cis rs2739330 0.76 rs5751760 ENSG00000231271.1 AP000350.8 5.75 4.69e-08 5.11e-05 0.55 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23949918~23954042:+ PAAD cis rs10463554 0.963 rs11955683 ENSG00000175749.11 EIF3KP1 5.75 4.71e-08 5.13e-05 0.54 0.42 Parkinson's disease; chr5:102990992 chr5:103032376~103033031:+ PAAD cis rs10463554 1 rs11949145 ENSG00000175749.11 EIF3KP1 5.75 4.71e-08 5.13e-05 0.54 0.42 Parkinson's disease; chr5:102994552 chr5:103032376~103033031:+ PAAD cis rs10463554 1 rs3776862 ENSG00000175749.11 EIF3KP1 5.75 4.71e-08 5.13e-05 0.54 0.42 Parkinson's disease; chr5:102996017 chr5:103032376~103033031:+ PAAD cis rs10463554 1 rs1593842 ENSG00000175749.11 EIF3KP1 5.75 4.71e-08 5.13e-05 0.54 0.42 Parkinson's disease; chr5:102999018 chr5:103032376~103033031:+ PAAD cis rs10463554 1 rs12659870 ENSG00000175749.11 EIF3KP1 5.75 4.71e-08 5.13e-05 0.54 0.42 Parkinson's disease; chr5:103000867 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs1552916 ENSG00000175749.11 EIF3KP1 5.75 4.71e-08 5.13e-05 0.54 0.42 Parkinson's disease; chr5:103002036 chr5:103032376~103033031:+ PAAD cis rs950027 1 rs950027 ENSG00000259520.4 CTD-2651B20.3 5.75 4.72e-08 5.14e-05 0.52 0.42 Response to fenofibrate (adiponectin levels); chr15:45508837 chr15:45251580~45279251:- PAAD cis rs858239 0.699 rs1881200 ENSG00000226816.2 AC005082.12 -5.75 4.73e-08 5.15e-05 -0.48 -0.42 Cerebrospinal fluid biomarker levels; chr7:23162018 chr7:23206013~23208045:+ PAAD cis rs7201929 1 rs12920514 ENSG00000259982.1 CDC37P1 -5.75 4.74e-08 5.16e-05 -0.55 -0.42 QT interval; chr16:28824579 chr16:28700294~28701540:- PAAD cis rs858239 0.863 rs274054 ENSG00000226816.2 AC005082.12 5.75 4.74e-08 5.16e-05 0.47 0.42 Cerebrospinal fluid biomarker levels; chr7:23350848 chr7:23206013~23208045:+ PAAD cis rs17264034 0.821 rs422309 ENSG00000250786.1 SNHG18 5.75 4.75e-08 5.17e-05 0.58 0.42 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9544284 chr5:9546200~9550609:+ PAAD cis rs11123170 0.543 rs2166421 ENSG00000189223.12 PAX8-AS1 -5.75 4.77e-08 5.19e-05 -0.6 -0.42 Renal function-related traits (BUN); chr2:113232665 chr2:113211522~113276581:+ PAAD cis rs763567 0.585 rs553905 ENSG00000271811.1 RP1-79C4.4 -5.75 4.77e-08 5.19e-05 -0.4 -0.42 Tonsillectomy; chr1:170611336 chr1:170667381~170669425:+ PAAD cis rs2739330 0.753 rs4822452 ENSG00000231271.1 AP000350.8 5.75 4.79e-08 5.21e-05 0.56 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23949918~23954042:+ PAAD cis rs7945705 0.875 rs2568065 ENSG00000254860.4 TMEM9B-AS1 5.75 4.8e-08 5.23e-05 0.44 0.42 Hemoglobin concentration; chr11:8868101 chr11:8964675~8977527:+ PAAD cis rs6570726 0.577 rs441982 ENSG00000235652.6 RP11-545I5.3 5.75 4.81e-08 5.23e-05 0.36 0.42 Lobe attachment (rater-scored or self-reported); chr6:145521712 chr6:145799409~145886585:+ PAAD cis rs10463554 0.889 rs34822 ENSG00000175749.11 EIF3KP1 5.75 4.81e-08 5.23e-05 0.56 0.42 Parkinson's disease; chr5:103102007 chr5:103032376~103033031:+ PAAD cis rs11651753 0.561 rs17616603 ENSG00000264920.1 RP11-6N17.4 -5.75 4.81e-08 5.24e-05 -0.48 -0.42 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47882254 chr17:47891255~47895812:- PAAD cis rs7104764 0.701 rs3782115 ENSG00000277290.1 RP11-326C3.16 -5.75 4.82e-08 5.24e-05 -0.37 -0.42 Menarche (age at onset); chr11:223272 chr11:243099~243483:- PAAD cis rs17301013 0.9 rs1754351 ENSG00000227373.4 RP11-160H22.5 -5.75 4.82e-08 5.24e-05 -0.53 -0.42 Systemic lupus erythematosus; chr1:174762458 chr1:174115300~174160004:- PAAD cis rs17301013 0.9 rs1793300 ENSG00000227373.4 RP11-160H22.5 -5.75 4.82e-08 5.24e-05 -0.53 -0.42 Systemic lupus erythematosus; chr1:174768559 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs7517516 ENSG00000227373.4 RP11-160H22.5 5.75 4.85e-08 5.28e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174346187 chr1:174115300~174160004:- PAAD cis rs9322193 0.576 rs7452592 ENSG00000223701.3 RAET1E-AS1 5.75 4.86e-08 5.28e-05 0.6 0.42 Lung cancer; chr6:149875445 chr6:149884431~149919508:+ PAAD cis rs2281636 0.625 rs7075305 ENSG00000233690.1 EBAG9P1 -5.74 4.86e-08 5.29e-05 -0.5 -0.42 Obesity-related traits; chr10:99604767 chr10:99697407~99697949:- PAAD cis rs7208859 0.673 rs9903862 ENSG00000263531.1 RP13-753N3.1 5.74 4.87e-08 5.29e-05 1.12 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879415 chr17:30863921~30864940:- PAAD cis rs11123170 0.569 rs1049137 ENSG00000189223.12 PAX8-AS1 -5.74 4.87e-08 5.29e-05 -0.58 -0.42 Renal function-related traits (BUN); chr2:113217533 chr2:113211522~113276581:+ PAAD cis rs11168854 0.93 rs10783302 ENSG00000258017.1 RP11-386G11.10 5.74 4.87e-08 5.3e-05 0.54 0.42 Body mass index; chr12:49104347 chr12:49127782~49147869:+ PAAD cis rs858239 0.796 rs433395 ENSG00000226816.2 AC005082.12 5.74 4.89e-08 5.31e-05 0.46 0.42 Cerebrospinal fluid biomarker levels; chr7:23362336 chr7:23206013~23208045:+ PAAD cis rs4218 0.871 rs2414621 ENSG00000277144.1 RP11-59H7.4 -5.74 4.89e-08 5.32e-05 -0.56 -0.42 Social communication problems; chr15:59142129 chr15:59115547~59116089:- PAAD cis rs4660456 0.913 rs6667368 ENSG00000237899.1 RP4-739H11.3 5.74 4.9e-08 5.32e-05 0.58 0.42 Platelet count; chr1:40694887 chr1:40669089~40687588:- PAAD cis rs113835537 0.529 rs17147644 ENSG00000255517.5 CTD-3074O7.5 -5.74 4.9e-08 5.32e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66489189 chr11:66473490~66480233:- PAAD cis rs8018967 0.622 rs2041073 ENSG00000258695.2 RP3-414A15.2 5.74 4.9e-08 5.32e-05 0.51 0.42 Blood metabolite ratios; chr14:73505831 chr14:73522878~73530610:+ PAAD cis rs11098499 0.863 rs3736115 ENSG00000245958.5 RP11-33B1.1 5.74 4.9e-08 5.32e-05 0.36 0.42 Corneal astigmatism; chr4:119567548 chr4:119454791~119552025:+ PAAD cis rs6782228 0.606 rs6775270 ENSG00000242551.2 POU5F1P6 -5.74 4.91e-08 5.33e-05 -0.49 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128684655 chr3:128674735~128677005:- PAAD cis rs7772486 0.558 rs62435775 ENSG00000235652.6 RP11-545I5.3 5.74 4.92e-08 5.35e-05 0.35 0.42 Lobe attachment (rater-scored or self-reported); chr6:145815279 chr6:145799409~145886585:+ PAAD cis rs3814244 0.897 rs4141135 ENSG00000255733.4 IFNG-AS1 5.74 4.93e-08 5.35e-05 0.36 0.42 Itch intensity from mosquito bite adjusted by bite size; chr12:68025050 chr12:67989445~68234686:+ PAAD cis rs17301013 0.507 rs16847335 ENSG00000227373.4 RP11-160H22.5 5.74 4.93e-08 5.36e-05 0.65 0.42 Systemic lupus erythematosus; chr1:174682746 chr1:174115300~174160004:- PAAD cis rs10463554 0.963 rs26817 ENSG00000175749.11 EIF3KP1 -5.74 4.93e-08 5.36e-05 -0.54 -0.42 Parkinson's disease; chr5:103204665 chr5:103032376~103033031:+ PAAD cis rs17264034 0.861 rs1651285 ENSG00000250786.1 SNHG18 5.74 4.94e-08 5.37e-05 0.59 0.42 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9547829 chr5:9546200~9550609:+ PAAD cis rs17301013 0.896 rs6425287 ENSG00000227373.4 RP11-160H22.5 5.74 4.96e-08 5.38e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174566264 chr1:174115300~174160004:- PAAD cis rs17301013 0.896 rs6425292 ENSG00000227373.4 RP11-160H22.5 5.74 4.96e-08 5.38e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174618364 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs6689170 ENSG00000227373.4 RP11-160H22.5 5.74 4.96e-08 5.38e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174639596 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs332771 ENSG00000227373.4 RP11-160H22.5 5.74 4.96e-08 5.38e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174704141 chr1:174115300~174160004:- PAAD cis rs17301013 0.861 rs332789 ENSG00000227373.4 RP11-160H22.5 5.74 4.96e-08 5.38e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174735754 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs461910 ENSG00000227373.4 RP11-160H22.5 5.74 4.96e-08 5.38e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174736351 chr1:174115300~174160004:- PAAD cis rs227275 0.525 rs2086499 ENSG00000246560.2 RP11-10L12.4 5.74 4.97e-08 5.39e-05 0.47 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103008672 chr4:102828055~102844075:+ PAAD cis rs12701220 0.553 rs9639882 ENSG00000229043.2 AC091729.9 -5.74 4.99e-08 5.42e-05 -0.57 -0.42 Bronchopulmonary dysplasia; chr7:1094095 chr7:1160374~1165267:+ PAAD cis rs12701220 0.655 rs10215292 ENSG00000229043.2 AC091729.9 -5.74 4.99e-08 5.42e-05 -0.57 -0.42 Bronchopulmonary dysplasia; chr7:1095627 chr7:1160374~1165267:+ PAAD cis rs12701220 0.604 rs34904312 ENSG00000229043.2 AC091729.9 -5.74 4.99e-08 5.42e-05 -0.57 -0.42 Bronchopulmonary dysplasia; chr7:1096247 chr7:1160374~1165267:+ PAAD cis rs1061377 0.748 rs12642261 ENSG00000249207.1 RP11-360F5.1 -5.74 4.99e-08 5.42e-05 -0.45 -0.42 Uric acid levels; chr4:39096278 chr4:39112677~39126818:- PAAD cis rs5760092 0.572 rs738806 ENSG00000273295.1 AP000350.5 5.74 5.03e-08 5.45e-05 0.58 0.42 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23901432~23907068:- PAAD cis rs9425766 0.679 rs2860846 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174106786 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs2860847 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174106787 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs6672986 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174107726 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs7533430 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174109279 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs7526024 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174109722 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs12079063 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174110447 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs12094341 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174110562 chr1:174115300~174160004:- PAAD cis rs9425766 0.64 rs10912734 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174141977 chr1:174115300~174160004:- PAAD cis rs9425766 0.628 rs6425274 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174144270 chr1:174115300~174160004:- PAAD cis rs9425766 0.566 rs6696076 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174149900 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs57919173 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174159856 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs12087441 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174188696 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs4652237 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174189718 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs2143114 ENSG00000227373.4 RP11-160H22.5 5.74 5.06e-08 5.47e-05 0.54 0.42 Life satisfaction; chr1:174192292 chr1:174115300~174160004:- PAAD cis rs6570726 0.577 rs406868 ENSG00000235652.6 RP11-545I5.3 5.74 5.06e-08 5.48e-05 0.36 0.42 Lobe attachment (rater-scored or self-reported); chr6:145488847 chr6:145799409~145886585:+ PAAD cis rs6570726 0.62 rs367693 ENSG00000235652.6 RP11-545I5.3 5.74 5.06e-08 5.48e-05 0.36 0.42 Lobe attachment (rater-scored or self-reported); chr6:145494813 chr6:145799409~145886585:+ PAAD cis rs6570726 0.557 rs403956 ENSG00000235652.6 RP11-545I5.3 5.74 5.06e-08 5.48e-05 0.36 0.42 Lobe attachment (rater-scored or self-reported); chr6:145508820 chr6:145799409~145886585:+ PAAD cis rs2115630 0.645 rs3825877 ENSG00000259728.4 LINC00933 -5.74 5.07e-08 5.48e-05 -0.51 -0.42 P wave terminal force; chr15:84631400 chr15:84570649~84580175:+ PAAD cis rs2115630 0.645 rs3825878 ENSG00000259728.4 LINC00933 -5.74 5.07e-08 5.48e-05 -0.51 -0.42 P wave terminal force; chr15:84631524 chr15:84570649~84580175:+ PAAD cis rs2243480 1 rs464895 ENSG00000226824.5 RP4-756H11.3 -5.74 5.08e-08 5.49e-05 -0.77 -0.42 Diabetic kidney disease; chr7:66062119 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs160633 ENSG00000226824.5 RP4-756H11.3 -5.74 5.08e-08 5.49e-05 -0.77 -0.42 Diabetic kidney disease; chr7:66063241 chr7:66654538~66669855:+ PAAD cis rs4423214 0.535 rs1540129 ENSG00000254682.1 RP11-660L16.2 5.74 5.08e-08 5.49e-05 0.59 0.42 Vitamin D levels; chr11:71418477 chr11:71448674~71452157:+ PAAD cis rs4972806 0.849 rs2113561 ENSG00000226363.3 HAGLROS -5.74 5.09e-08 5.5e-05 -0.51 -0.42 IgG glycosylation; chr2:176166197 chr2:176177717~176179008:+ PAAD cis rs6683071 0.501 rs3002146 ENSG00000272750.1 RP11-378J18.8 5.74 5.09e-08 5.51e-05 0.5 0.42 Cognitive performance; chr1:222636066 chr1:222658867~222661512:- PAAD cis rs9322193 0.886 rs9718079 ENSG00000216906.2 RP11-350J20.9 5.73 5.1e-08 5.52e-05 0.52 0.42 Lung cancer; chr6:149645947 chr6:149904243~149906418:+ PAAD cis rs1150668 0.699 rs13408 ENSG00000216901.1 AL022393.7 5.73 5.1e-08 5.52e-05 0.48 0.42 Pubertal anthropometrics; chr6:28244970 chr6:28176188~28176674:+ PAAD cis rs2108622 0.727 rs8102532 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869250 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs62106155 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869550 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs62106156 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869614 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs62106157 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869638 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs62106158 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869682 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs7256877 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15869873 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs7253873 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870090 chr19:15851993~15864904:- PAAD cis rs2108622 0.559 rs7252638 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870215 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs7253684 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870316 chr19:15851993~15864904:- PAAD cis rs2108622 0.727 rs55954696 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15870995 chr19:15851993~15864904:- PAAD cis rs2108622 0.683 rs56228205 ENSG00000267453.5 AC004791.2 -5.73 5.14e-08 5.56e-05 -0.62 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871163 chr19:15851993~15864904:- PAAD cis rs9322193 0.886 rs2065663 ENSG00000216906.2 RP11-350J20.9 5.73 5.15e-08 5.56e-05 0.55 0.42 Lung cancer; chr6:149760331 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs12205092 ENSG00000216906.2 RP11-350J20.9 5.73 5.15e-08 5.56e-05 0.55 0.42 Lung cancer; chr6:149761375 chr6:149904243~149906418:+ PAAD cis rs875971 0.862 rs1983372 ENSG00000237310.1 GS1-124K5.4 -5.73 5.17e-08 5.58e-05 -0.41 -0.42 Aortic root size; chr7:66146364 chr7:66493706~66495474:+ PAAD cis rs1150668 0.796 rs2531825 ENSG00000216901.1 AL022393.7 5.73 5.19e-08 5.58e-05 0.5 0.42 Pubertal anthropometrics; chr6:28381487 chr6:28176188~28176674:+ PAAD cis rs950169 0.614 rs12911536 ENSG00000225151.9 GOLGA2P7 -5.73 5.19e-08 5.58e-05 -0.52 -0.42 Schizophrenia; chr15:84004278 chr15:84199311~84230136:- PAAD cis rs12701220 0.655 rs34696066 ENSG00000229043.2 AC091729.9 -5.73 5.2e-08 5.58e-05 -0.57 -0.42 Bronchopulmonary dysplasia; chr7:1101283 chr7:1160374~1165267:+ PAAD cis rs17301013 0.507 rs12082012 ENSG00000227373.4 RP11-160H22.5 5.73 5.22e-08 5.6e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174588729 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12085652 ENSG00000227373.4 RP11-160H22.5 5.73 5.22e-08 5.6e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174588864 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs11802092 ENSG00000227373.4 RP11-160H22.5 5.73 5.22e-08 5.6e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174601773 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4451598 ENSG00000227373.4 RP11-160H22.5 5.73 5.22e-08 5.6e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174606576 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912822 ENSG00000227373.4 RP11-160H22.5 5.73 5.22e-08 5.6e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174624490 chr1:174115300~174160004:- PAAD cis rs9640161 0.673 rs11773351 ENSG00000261305.1 RP4-584D14.7 5.73 5.22e-08 5.61e-05 0.66 0.42 Blood protein levels;Circulating chemerin levels; chr7:150333874 chr7:150341771~150342607:+ PAAD cis rs9640161 0.75 rs3735167 ENSG00000261305.1 RP4-584D14.7 5.73 5.22e-08 5.61e-05 0.66 0.42 Blood protein levels;Circulating chemerin levels; chr7:150342466 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs36069544 ENSG00000261305.1 RP4-584D14.7 5.73 5.23e-08 5.61e-05 0.59 0.42 Blood protein levels;Circulating chemerin levels; chr7:150364449 chr7:150341771~150342607:+ PAAD cis rs9640161 0.783 rs35435439 ENSG00000261305.1 RP4-584D14.7 5.73 5.23e-08 5.61e-05 0.59 0.42 Blood protein levels;Circulating chemerin levels; chr7:150366445 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs11768108 ENSG00000261305.1 RP4-584D14.7 5.73 5.23e-08 5.61e-05 0.59 0.42 Blood protein levels;Circulating chemerin levels; chr7:150367061 chr7:150341771~150342607:+ PAAD cis rs10463554 0.927 rs34810 ENSG00000175749.11 EIF3KP1 5.73 5.23e-08 5.61e-05 0.56 0.42 Parkinson's disease; chr5:103095045 chr5:103032376~103033031:+ PAAD cis rs10463554 0.824 rs427430 ENSG00000175749.11 EIF3KP1 5.73 5.23e-08 5.61e-05 0.56 0.42 Parkinson's disease; chr5:103096320 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs34816 ENSG00000175749.11 EIF3KP1 5.73 5.23e-08 5.61e-05 0.56 0.42 Parkinson's disease; chr5:103098941 chr5:103032376~103033031:+ PAAD cis rs2658782 0.507 rs4457713 ENSG00000279684.1 RP11-755E23.2 -5.73 5.24e-08 5.62e-05 -0.62 -0.42 Pulmonary function decline; chr11:93304264 chr11:93286629~93288903:- PAAD cis rs2658782 0.547 rs4753453 ENSG00000279684.1 RP11-755E23.2 -5.73 5.24e-08 5.62e-05 -0.62 -0.42 Pulmonary function decline; chr11:93308008 chr11:93286629~93288903:- PAAD cis rs7945705 0.967 rs10840147 ENSG00000254860.4 TMEM9B-AS1 -5.73 5.25e-08 5.63e-05 -0.47 -0.42 Hemoglobin concentration; chr11:8899157 chr11:8964675~8977527:+ PAAD cis rs26232 0.526 rs61654927 ENSG00000175749.11 EIF3KP1 5.73 5.25e-08 5.63e-05 0.55 0.42 Rheumatoid arthritis; chr5:103047021 chr5:103032376~103033031:+ PAAD cis rs10463554 0.667 rs57714862 ENSG00000175749.11 EIF3KP1 5.73 5.25e-08 5.63e-05 0.55 0.42 Parkinson's disease; chr5:103047025 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs59292735 ENSG00000175749.11 EIF3KP1 5.73 5.25e-08 5.63e-05 0.55 0.42 Parkinson's disease; chr5:103047047 chr5:103032376~103033031:+ PAAD cis rs2108622 0.701 rs118144071 ENSG00000267453.5 AC004791.2 -5.73 5.25e-08 5.63e-05 -0.63 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15868384 chr19:15851993~15864904:- PAAD cis rs1075265 0.704 rs10181999 ENSG00000233266.1 HMGB1P31 5.73 5.27e-08 5.64e-05 0.55 0.42 Chronotype;Morning vs. evening chronotype; chr2:54025360 chr2:54051334~54051760:+ PAAD cis rs2946504 0.52 rs2272624 ENSG00000251468.2 RP11-369K16.1 -5.73 5.27e-08 5.65e-05 -0.48 -0.42 Type 2 diabetes; chr8:12952158 chr8:12958387~12962200:+ PAAD cis rs9322193 0.962 rs1889473 ENSG00000216906.2 RP11-350J20.9 5.73 5.3e-08 5.68e-05 0.54 0.42 Lung cancer; chr6:149825485 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs1984111 ENSG00000216906.2 RP11-350J20.9 5.73 5.3e-08 5.68e-05 0.54 0.42 Lung cancer; chr6:149831720 chr6:149904243~149906418:+ PAAD cis rs2283792 0.776 rs9610458 ENSG00000224086.5 LL22NC03-86G7.1 -5.73 5.3e-08 5.68e-05 -0.43 -0.42 Multiple sclerosis; chr22:21851064 chr22:21938293~21977632:+ PAAD cis rs9481169 0.717 rs13191781 ENSG00000255389.1 C6orf3 -5.73 5.3e-08 5.68e-05 -0.72 -0.42 Inflammatory skin disease; chr6:111620083 chr6:111599875~111602295:+ PAAD cis rs10463554 0.963 rs257115 ENSG00000175749.11 EIF3KP1 5.73 5.31e-08 5.68e-05 0.54 0.42 Parkinson's disease; chr5:103196107 chr5:103032376~103033031:+ PAAD cis rs673078 0.607 rs2036314 ENSG00000275759.1 RP11-131L12.3 -5.73 5.31e-08 5.69e-05 -0.56 -0.42 Glucose homeostasis traits; chr12:118367132 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs61943369 ENSG00000275759.1 RP11-131L12.3 -5.73 5.31e-08 5.69e-05 -0.56 -0.42 Glucose homeostasis traits; chr12:118368145 chr12:118428281~118428870:+ PAAD cis rs1075265 0.704 rs805402 ENSG00000233266.1 HMGB1P31 5.73 5.34e-08 5.71e-05 0.54 0.42 Chronotype;Morning vs. evening chronotype; chr2:53889212 chr2:54051334~54051760:+ PAAD cis rs2929278 0.617 rs3087657 ENSG00000205771.5 CATSPER2P1 -5.73 5.34e-08 5.71e-05 -0.55 -0.42 Schizophrenia; chr15:43771661 chr15:43726918~43747094:- PAAD cis rs2739330 0.929 rs5751775 ENSG00000231271.1 AP000350.8 5.73 5.34e-08 5.72e-05 0.56 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23949918~23954042:+ PAAD cis rs227275 0.556 rs7676765 ENSG00000246560.2 RP11-10L12.4 -5.73 5.35e-08 5.72e-05 -0.46 -0.42 Allergic disease (asthma, hay fever or eczema); chr4:103016776 chr4:102828055~102844075:+ PAAD cis rs6570726 0.577 rs9497315 ENSG00000235652.6 RP11-545I5.3 -5.73 5.35e-08 5.72e-05 -0.36 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145470831 chr6:145799409~145886585:+ PAAD cis rs6570726 0.577 rs399502 ENSG00000235652.6 RP11-545I5.3 5.73 5.35e-08 5.72e-05 0.36 0.42 Lobe attachment (rater-scored or self-reported); chr6:145484738 chr6:145799409~145886585:+ PAAD cis rs10875746 0.729 rs11168357 ENSG00000240399.1 RP1-228P16.1 -5.72 5.36e-08 5.73e-05 -0.46 -0.42 Longevity (90 years and older); chr12:48018355 chr12:48054813~48055591:- PAAD cis rs7829975 0.567 rs6601273 ENSG00000253893.2 FAM85B 5.72 5.36e-08 5.74e-05 0.56 0.42 Mood instability; chr8:8939009 chr8:8167819~8226614:- PAAD cis rs7829975 0.606 rs7819827 ENSG00000253893.2 FAM85B 5.72 5.36e-08 5.74e-05 0.56 0.42 Mood instability; chr8:8939545 chr8:8167819~8226614:- PAAD cis rs7829975 0.509 rs7838674 ENSG00000253893.2 FAM85B 5.72 5.36e-08 5.74e-05 0.56 0.42 Mood instability; chr8:8939563 chr8:8167819~8226614:- PAAD cis rs7829975 0.573 rs7842359 ENSG00000253893.2 FAM85B 5.72 5.36e-08 5.74e-05 0.56 0.42 Mood instability; chr8:8939568 chr8:8167819~8226614:- PAAD cis rs7714584 1 rs59043558 ENSG00000197083.10 ZNF300P1 5.72 5.39e-08 5.76e-05 0.65 0.42 Crohn's disease; chr5:150955100 chr5:150930645~150946289:- PAAD cis rs10875746 0.768 rs4760609 ENSG00000240399.1 RP1-228P16.1 5.72 5.4e-08 5.78e-05 0.46 0.42 Longevity (90 years and older); chr12:48021974 chr12:48054813~48055591:- PAAD cis rs67180937 0.553 rs2088514 ENSG00000272750.1 RP11-378J18.8 -5.72 5.41e-08 5.79e-05 -0.5 -0.42 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222658030 chr1:222658867~222661512:- PAAD cis rs950169 0.614 rs12903883 ENSG00000225151.9 GOLGA2P7 -5.72 5.43e-08 5.8e-05 -0.51 -0.42 Schizophrenia; chr15:84011801 chr15:84199311~84230136:- PAAD cis rs10875746 0.669 rs2279464 ENSG00000240399.1 RP1-228P16.1 -5.72 5.43e-08 5.8e-05 -0.48 -0.42 Longevity (90 years and older); chr12:48296626 chr12:48054813~48055591:- PAAD cis rs7615952 0.932 rs13321217 ENSG00000171084.14 FAM86JP 5.72 5.44e-08 5.81e-05 0.56 0.42 Blood pressure (smoking interaction); chr3:125912928 chr3:125916620~125930024:+ PAAD cis rs17264034 0.821 rs460234 ENSG00000250786.1 SNHG18 5.72 5.45e-08 5.82e-05 0.58 0.42 Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease; chr5:9543022 chr5:9546200~9550609:+ PAAD cis rs10510102 0.872 rs11200277 ENSG00000276742.1 RP11-500G22.4 5.72 5.45e-08 5.82e-05 0.6 0.42 Breast cancer; chr10:121944295 chr10:121956782~121957098:+ PAAD cis rs453301 0.624 rs2915251 ENSG00000253893.2 FAM85B -5.72 5.46e-08 5.83e-05 -0.56 -0.42 Joint mobility (Beighton score); chr8:9009901 chr8:8167819~8226614:- PAAD cis rs8040855 0.603 rs10520585 ENSG00000259295.5 CSPG4P12 -5.72 5.47e-08 5.84e-05 -0.51 -0.42 Bulimia nervosa; chr15:85118275 chr15:85191438~85213905:+ PAAD cis rs3096299 0.719 rs2965818 ENSG00000274627.1 RP11-104N10.2 5.72 5.47e-08 5.84e-05 0.36 0.42 Multiple myeloma (IgH translocation); chr16:89444086 chr16:89516797~89522217:+ PAAD cis rs2658782 0.547 rs3020052 ENSG00000279684.1 RP11-755E23.2 -5.72 5.47e-08 5.84e-05 -0.61 -0.42 Pulmonary function decline; chr11:93322018 chr11:93286629~93288903:- PAAD cis rs2658782 0.547 rs3133454 ENSG00000279684.1 RP11-755E23.2 -5.72 5.47e-08 5.84e-05 -0.61 -0.42 Pulmonary function decline; chr11:93325853 chr11:93286629~93288903:- PAAD cis rs2658782 0.547 rs3020065 ENSG00000279684.1 RP11-755E23.2 -5.72 5.47e-08 5.84e-05 -0.61 -0.42 Pulmonary function decline; chr11:93326733 chr11:93286629~93288903:- PAAD cis rs7829975 0.572 rs28730413 ENSG00000253893.2 FAM85B 5.72 5.47e-08 5.85e-05 0.56 0.42 Mood instability; chr8:8937937 chr8:8167819~8226614:- PAAD cis rs9322193 0.924 rs9322189 ENSG00000216906.2 RP11-350J20.9 5.72 5.48e-08 5.85e-05 0.54 0.42 Lung cancer; chr6:149588797 chr6:149904243~149906418:+ PAAD cis rs17711722 0.528 rs73138179 ENSG00000234585.5 CCT6P3 5.72 5.48e-08 5.85e-05 0.35 0.42 Calcium levels; chr7:65829495 chr7:65038354~65074713:+ PAAD cis rs6504622 0.905 rs197926 ENSG00000262879.4 RP11-156P1.3 5.72 5.49e-08 5.86e-05 0.43 0.42 Orofacial clefts; chr17:46934721 chr17:46984045~47100323:- PAAD cis rs9326248 0.954 rs4938349 ENSG00000280143.1 AP000892.6 5.72 5.5e-08 5.87e-05 0.53 0.42 Blood protein levels; chr11:117151207 chr11:117204967~117210292:+ PAAD cis rs9326248 1 rs3736120 ENSG00000280143.1 AP000892.6 5.72 5.5e-08 5.87e-05 0.53 0.42 Blood protein levels; chr11:117161409 chr11:117204967~117210292:+ PAAD cis rs10463554 0.963 rs28301 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103105778 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34828 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103107209 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs257318 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103109766 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs40322 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103111253 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34771 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103114713 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34773 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103114872 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34774 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103115116 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34777 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103116554 chr5:103032376~103033031:+ PAAD cis rs10463554 0.926 rs34778 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103116852 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs26524 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103120600 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs32842 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103142298 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs32840 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103143446 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs27970 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103151019 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs154355 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103163177 chr5:103032376~103033031:+ PAAD cis rs26232 0.517 rs154356 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Rheumatoid arthritis; chr5:103163440 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs187427 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103177102 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs26821 ENSG00000175749.11 EIF3KP1 5.72 5.52e-08 5.89e-05 0.55 0.42 Parkinson's disease; chr5:103184699 chr5:103032376~103033031:+ PAAD cis rs17301013 0.932 rs6425281 ENSG00000227373.4 RP11-160H22.5 5.72 5.53e-08 5.89e-05 0.54 0.42 Systemic lupus erythematosus; chr1:174449784 chr1:174115300~174160004:- PAAD cis rs6142102 0.625 rs7263727 ENSG00000276073.1 RP5-1125A11.7 -5.72 5.53e-08 5.9e-05 -0.44 -0.42 Skin pigmentation; chr20:33953133 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs6142056 ENSG00000276073.1 RP5-1125A11.7 -5.72 5.53e-08 5.9e-05 -0.44 -0.42 Skin pigmentation; chr20:33953349 chr20:33985617~33988989:- PAAD cis rs1061377 0.674 rs34506243 ENSG00000249207.1 RP11-360F5.1 -5.72 5.53e-08 5.9e-05 -0.43 -0.42 Uric acid levels; chr4:39082702 chr4:39112677~39126818:- PAAD cis rs950169 0.96 rs12905475 ENSG00000225151.9 GOLGA2P7 -5.72 5.53e-08 5.9e-05 -0.52 -0.42 Schizophrenia; chr15:84131743 chr15:84199311~84230136:- PAAD cis rs274567 0.602 rs272853 ENSG00000233006.5 AC034220.3 5.72 5.53e-08 5.9e-05 0.37 0.42 Blood metabolite levels; chr5:132352868 chr5:132311285~132369916:- PAAD cis rs950169 0.656 rs748455 ENSG00000225151.9 GOLGA2P7 -5.72 5.54e-08 5.91e-05 -0.51 -0.42 Schizophrenia; chr15:84606344 chr15:84199311~84230136:- PAAD cis rs228614 0.509 rs223480 ENSG00000246560.2 RP11-10L12.4 5.72 5.54e-08 5.91e-05 0.47 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766881 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223378 ENSG00000246560.2 RP11-10L12.4 5.72 5.55e-08 5.91e-05 0.47 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102833488 chr4:102828055~102844075:+ PAAD cis rs17301013 0.507 rs10912817 ENSG00000227373.4 RP11-160H22.5 5.72 5.56e-08 5.93e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174615581 chr1:174115300~174160004:- PAAD cis rs3096299 0.73 rs3114895 ENSG00000274627.1 RP11-104N10.2 5.72 5.57e-08 5.93e-05 0.38 0.42 Multiple myeloma (IgH translocation); chr16:89328402 chr16:89516797~89522217:+ PAAD cis rs748404 0.518 rs480108 ENSG00000249839.1 AC011330.5 -5.72 5.57e-08 5.94e-05 -0.61 -0.42 Lung cancer; chr15:43525208 chr15:43663654~43684339:- PAAD cis rs748404 0.56 rs572837 ENSG00000249839.1 AC011330.5 -5.72 5.57e-08 5.94e-05 -0.61 -0.42 Lung cancer; chr15:43531615 chr15:43663654~43684339:- PAAD cis rs748404 0.56 rs570933 ENSG00000249839.1 AC011330.5 -5.72 5.57e-08 5.94e-05 -0.61 -0.42 Lung cancer; chr15:43531832 chr15:43663654~43684339:- PAAD cis rs748404 0.56 rs689797 ENSG00000249839.1 AC011330.5 -5.72 5.57e-08 5.94e-05 -0.61 -0.42 Lung cancer; chr15:43534359 chr15:43663654~43684339:- PAAD cis rs11098499 0.863 rs1480940 ENSG00000245958.5 RP11-33B1.1 -5.72 5.58e-08 5.94e-05 -0.36 -0.42 Corneal astigmatism; chr4:119536527 chr4:119454791~119552025:+ PAAD cis rs4984778 0.75 rs7198064 ENSG00000260182.1 RP11-616M22.5 5.72 5.58e-08 5.94e-05 0.55 0.42 Blood protein levels; chr16:1222472 chr16:1257339~1258074:+ PAAD cis rs7580658 0.676 rs4150407 ENSG00000236682.1 AC068282.3 5.72 5.59e-08 5.95e-05 0.53 0.42 Protein C levels; chr2:127292055 chr2:127389130~127400580:+ PAAD cis rs11123170 0.65 rs2289897 ENSG00000189223.12 PAX8-AS1 -5.72 5.59e-08 5.95e-05 -0.58 -0.42 Renal function-related traits (BUN); chr2:113219877 chr2:113211522~113276581:+ PAAD cis rs67180937 0.631 rs1909195 ENSG00000272750.1 RP11-378J18.8 -5.72 5.59e-08 5.96e-05 -0.48 -0.42 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222623985 chr1:222658867~222661512:- PAAD cis rs67180937 0.677 rs17011666 ENSG00000272750.1 RP11-378J18.8 -5.72 5.59e-08 5.96e-05 -0.48 -0.42 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222625623 chr1:222658867~222661512:- PAAD cis rs7829975 0.517 rs12542733 ENSG00000253893.2 FAM85B 5.72 5.6e-08 5.96e-05 0.54 0.42 Mood instability; chr8:8967348 chr8:8167819~8226614:- PAAD cis rs453301 0.598 rs1025395 ENSG00000253893.2 FAM85B -5.72 5.6e-08 5.96e-05 -0.54 -0.42 Joint mobility (Beighton score); chr8:8979093 chr8:8167819~8226614:- PAAD cis rs2404602 0.598 rs11634019 ENSG00000259422.1 RP11-593F23.1 -5.72 5.62e-08 5.97e-05 -0.55 -0.42 Blood metabolite levels; chr15:76342339 chr15:76174891~76181486:- PAAD cis rs950169 1 rs79318564 ENSG00000225151.9 GOLGA2P7 -5.71 5.62e-08 5.98e-05 -0.51 -0.42 Schizophrenia; chr15:84117398 chr15:84199311~84230136:- PAAD cis rs950169 1 rs1911155 ENSG00000225151.9 GOLGA2P7 -5.71 5.62e-08 5.98e-05 -0.51 -0.42 Schizophrenia; chr15:84118883 chr15:84199311~84230136:- PAAD cis rs2739330 0.703 rs5760112 ENSG00000206090.4 AP000350.7 5.71 5.63e-08 5.99e-05 0.52 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23939998~23942798:+ PAAD cis rs11098499 0.698 rs4422403 ENSG00000245958.5 RP11-33B1.1 -5.71 5.64e-08 5.99e-05 -0.3 -0.42 Corneal astigmatism; chr4:119337039 chr4:119454791~119552025:+ PAAD cis rs11098499 0.569 rs10023641 ENSG00000245958.5 RP11-33B1.1 -5.71 5.64e-08 5.99e-05 -0.3 -0.42 Corneal astigmatism; chr4:119337255 chr4:119454791~119552025:+ PAAD cis rs11098499 0.644 rs3986377 ENSG00000245958.5 RP11-33B1.1 -5.71 5.64e-08 5.99e-05 -0.3 -0.42 Corneal astigmatism; chr4:119339115 chr4:119454791~119552025:+ PAAD cis rs10028773 0.556 rs4473640 ENSG00000245958.5 RP11-33B1.1 -5.71 5.64e-08 5.99e-05 -0.3 -0.42 Educational attainment; chr4:119339282 chr4:119454791~119552025:+ PAAD cis rs853679 0.567 rs7774981 ENSG00000216901.1 AL022393.7 5.71 5.64e-08 6e-05 0.57 0.42 Depression; chr6:28379133 chr6:28176188~28176674:+ PAAD cis rs853679 0.567 rs7754960 ENSG00000216901.1 AL022393.7 5.71 5.64e-08 6e-05 0.57 0.42 Depression; chr6:28379168 chr6:28176188~28176674:+ PAAD cis rs853679 0.567 rs3799499 ENSG00000216901.1 AL022393.7 5.71 5.64e-08 6e-05 0.57 0.42 Depression; chr6:28386473 chr6:28176188~28176674:+ PAAD cis rs853679 0.567 rs2232427 ENSG00000216901.1 AL022393.7 5.71 5.64e-08 6e-05 0.57 0.42 Depression; chr6:28391932 chr6:28176188~28176674:+ PAAD cis rs17301013 0.896 rs3118980 ENSG00000227373.4 RP11-160H22.5 -5.71 5.66e-08 6.01e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174793701 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs2987874 ENSG00000227373.4 RP11-160H22.5 -5.71 5.66e-08 6.01e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174801053 chr1:174115300~174160004:- PAAD cis rs17301013 0.869 rs3133270 ENSG00000227373.4 RP11-160H22.5 -5.71 5.66e-08 6.01e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174819547 chr1:174115300~174160004:- PAAD cis rs11118620 0.535 rs1389750 ENSG00000257551.1 HLX-AS1 5.71 5.66e-08 6.02e-05 0.46 0.42 Heart failure; chr1:220866829 chr1:220832763~220880140:- PAAD cis rs17711722 0.51 rs11767457 ENSG00000234585.5 CCT6P3 5.71 5.67e-08 6.02e-05 0.35 0.42 Calcium levels; chr7:65825628 chr7:65038354~65074713:+ PAAD cis rs2337406 0.866 rs7153964 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106790480 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs2301536 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106790636 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs2301535 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106790663 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs7144369 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106793065 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs78525520 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106795643 chr14:106770577~106771020:- PAAD cis rs10129255 0.646 rs55995061 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Kawasaki disease; chr14:106799309 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs76871148 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106799722 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs61521632 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106801091 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs4774019 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106805386 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs58850145 ENSG00000274576.2 IGHV2-70 -5.71 5.67e-08 6.02e-05 -0.55 -0.42 Alzheimer's disease (late onset); chr14:106806185 chr14:106770577~106771020:- PAAD cis rs950169 0.92 rs12915390 ENSG00000225151.9 GOLGA2P7 -5.71 5.67e-08 6.03e-05 -0.51 -0.42 Schizophrenia; chr15:84123317 chr15:84199311~84230136:- PAAD cis rs6700559 0.708 rs17450217 ENSG00000260088.1 RP11-92G12.3 -5.71 5.7e-08 6.05e-05 -0.55 -0.42 Coronary artery disease; chr1:200621724 chr1:200669507~200694250:+ PAAD cis rs113835537 0.597 rs11227527 ENSG00000255517.5 CTD-3074O7.5 -5.71 5.72e-08 6.07e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66545555 chr11:66473490~66480233:- PAAD cis rs172166 0.516 rs2791333 ENSG00000204709.4 LINC01556 5.71 5.73e-08 6.08e-05 0.56 0.42 Cardiac Troponin-T levels; chr6:28143336 chr6:28943877~28944537:+ PAAD cis rs10463554 0.963 rs257294 ENSG00000175749.11 EIF3KP1 5.71 5.74e-08 6.09e-05 0.55 0.42 Parkinson's disease; chr5:103131563 chr5:103032376~103033031:+ PAAD cis rs113835537 0.529 rs2277302 ENSG00000255517.5 CTD-3074O7.5 -5.71 5.74e-08 6.09e-05 -0.53 -0.42 Airway imaging phenotypes; chr11:66473411 chr11:66473490~66480233:- PAAD cis rs526231 0.543 rs171558 ENSG00000175749.11 EIF3KP1 5.71 5.75e-08 6.1e-05 0.55 0.42 Primary biliary cholangitis; chr5:103242193 chr5:103032376~103033031:+ PAAD cis rs853679 0.567 rs1005126 ENSG00000216901.1 AL022393.7 5.71 5.76e-08 6.11e-05 0.57 0.42 Depression; chr6:28399846 chr6:28176188~28176674:+ PAAD cis rs853679 0.567 rs13196606 ENSG00000216901.1 AL022393.7 5.71 5.76e-08 6.11e-05 0.57 0.42 Depression; chr6:28402301 chr6:28176188~28176674:+ PAAD cis rs10463554 0.824 rs34818 ENSG00000175749.11 EIF3KP1 5.71 5.77e-08 6.12e-05 0.55 0.42 Parkinson's disease; chr5:103100407 chr5:103032376~103033031:+ PAAD cis rs42490 1 rs218929 ENSG00000251136.7 RP11-37B2.1 -5.71 5.79e-08 6.13e-05 -0.38 -0.42 Leprosy; chr8:89739091 chr8:89609409~89757727:- PAAD cis rs9640161 0.75 rs73170185 ENSG00000261305.1 RP4-584D14.7 5.71 5.79e-08 6.13e-05 0.64 0.42 Blood protein levels;Circulating chemerin levels; chr7:150333102 chr7:150341771~150342607:+ PAAD cis rs9640161 0.75 rs3800780 ENSG00000261305.1 RP4-584D14.7 5.71 5.81e-08 6.15e-05 0.64 0.42 Blood protein levels;Circulating chemerin levels; chr7:150330195 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs7800196 ENSG00000261305.1 RP4-584D14.7 5.71 5.82e-08 6.16e-05 0.59 0.42 Blood protein levels;Circulating chemerin levels; chr7:150364445 chr7:150341771~150342607:+ PAAD cis rs2739330 0.828 rs5751770 ENSG00000231271.1 AP000350.8 5.71 5.83e-08 6.17e-05 0.56 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23949918~23954042:+ PAAD cis rs11089937 0.926 rs5750601 ENSG00000211639.2 IGLV4-60 5.71 5.83e-08 6.17e-05 0.38 0.42 Periodontitis (PAL4Q3); chr22:22144396 chr22:22162199~22162681:+ PAAD cis rs9322193 0.923 rs10872651 ENSG00000216906.2 RP11-350J20.9 5.71 5.86e-08 6.2e-05 0.55 0.42 Lung cancer; chr6:149768273 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs3805749 ENSG00000216906.2 RP11-350J20.9 5.71 5.86e-08 6.2e-05 0.55 0.42 Lung cancer; chr6:149772546 chr6:149904243~149906418:+ PAAD cis rs9322193 0.847 rs9505972 ENSG00000216906.2 RP11-350J20.9 5.71 5.86e-08 6.2e-05 0.55 0.42 Lung cancer; chr6:149775255 chr6:149904243~149906418:+ PAAD cis rs17301013 0.932 rs1653627 ENSG00000227373.4 RP11-160H22.5 -5.71 5.87e-08 6.21e-05 -0.53 -0.42 Systemic lupus erythematosus; chr1:174771879 chr1:174115300~174160004:- PAAD cis rs17608059 0.611 rs62052300 ENSG00000141028.6 CDRT15P1 -5.71 5.88e-08 6.22e-05 -0.5 -0.42 Temperament; chr17:14013482 chr17:14024514~14025488:+ PAAD cis rs11098499 0.691 rs10010355 ENSG00000245958.5 RP11-33B1.1 -5.71 5.9e-08 6.23e-05 -0.3 -0.42 Corneal astigmatism; chr4:119339888 chr4:119454791~119552025:+ PAAD cis rs11098499 0.691 rs9307471 ENSG00000245958.5 RP11-33B1.1 -5.71 5.9e-08 6.23e-05 -0.3 -0.42 Corneal astigmatism; chr4:119340107 chr4:119454791~119552025:+ PAAD cis rs7772486 0.754 rs2328709 ENSG00000235652.6 RP11-545I5.3 -5.7 5.9e-08 6.24e-05 -0.35 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145785683 chr6:145799409~145886585:+ PAAD cis rs1075265 0.589 rs2542571 ENSG00000233266.1 HMGB1P31 5.7 5.9e-08 6.24e-05 0.53 0.42 Chronotype;Morning vs. evening chronotype; chr2:53814846 chr2:54051334~54051760:+ PAAD cis rs9425766 0.679 rs2049992 ENSG00000227373.4 RP11-160H22.5 5.7 5.9e-08 6.24e-05 0.53 0.42 Life satisfaction; chr1:174356554 chr1:174115300~174160004:- PAAD cis rs673078 0.66 rs61943365 ENSG00000275759.1 RP11-131L12.3 -5.7 5.91e-08 6.24e-05 -0.57 -0.42 Glucose homeostasis traits; chr12:118339166 chr12:118428281~118428870:+ PAAD cis rs6683071 1 rs2378606 ENSG00000272750.1 RP11-378J18.8 5.7 5.91e-08 6.24e-05 0.51 0.42 Cognitive performance; chr1:222746406 chr1:222658867~222661512:- PAAD cis rs9532669 0.926 rs9532671 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40927761 chr13:40863599~40863902:- PAAD cis rs9532669 0.833 rs9532672 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40928285 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs7324625 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40928606 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4454835 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40928978 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs1571116 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40929765 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs9532673 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40930412 chr13:40863599~40863902:- PAAD cis rs9532669 0.89 rs9532676 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40935626 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs4941391 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40939787 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs4343141 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40940497 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs3887418 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40940560 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs1056820 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40941150 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532678 ENSG00000176268.5 CYCSP34 5.7 5.91e-08 6.25e-05 0.39 0.42 Cervical cancer; chr13:40941862 chr13:40863599~40863902:- PAAD cis rs2929278 0.588 rs688009 ENSG00000249839.1 AC011330.5 -5.7 5.92e-08 6.25e-05 -0.57 -0.42 Schizophrenia; chr15:43864104 chr15:43663654~43684339:- PAAD cis rs7188445 0.871 rs11150187 ENSG00000261390.4 RP11-345M22.2 5.7 5.92e-08 6.25e-05 0.56 0.42 Urate levels; chr16:79670515 chr16:79715232~79770563:- PAAD cis rs638893 0.636 rs2186781 ENSG00000278376.1 RP11-158I9.8 -5.7 5.92e-08 6.25e-05 -0.6 -0.42 Vitiligo; chr11:118734738 chr11:118791254~118793137:+ PAAD cis rs638893 0.636 rs7119702 ENSG00000278376.1 RP11-158I9.8 -5.7 5.92e-08 6.25e-05 -0.6 -0.42 Vitiligo; chr11:118736985 chr11:118791254~118793137:+ PAAD cis rs7772486 0.875 rs863820 ENSG00000235652.6 RP11-545I5.3 -5.7 5.93e-08 6.26e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:146026266 chr6:145799409~145886585:+ PAAD cis rs17301013 0.507 rs72713537 ENSG00000227373.4 RP11-160H22.5 5.7 5.93e-08 6.26e-05 0.61 0.42 Systemic lupus erythematosus; chr1:174354189 chr1:174115300~174160004:- PAAD cis rs9595066 0.564 rs12869383 ENSG00000227258.4 SMIM2-AS1 -5.7 5.93e-08 6.26e-05 -0.53 -0.42 Schizophrenia; chr13:44131305 chr13:44110451~44240517:+ PAAD cis rs9425766 0.655 rs6666767 ENSG00000227373.4 RP11-160H22.5 5.7 5.95e-08 6.28e-05 0.53 0.42 Life satisfaction; chr1:174357564 chr1:174115300~174160004:- PAAD cis rs7188445 0.899 rs17689024 ENSG00000261390.4 RP11-345M22.2 -5.7 5.97e-08 6.3e-05 -0.56 -0.42 Urate levels; chr16:79706081 chr16:79715232~79770563:- PAAD cis rs7188445 0.932 rs56738967 ENSG00000261390.4 RP11-345M22.2 -5.7 5.97e-08 6.3e-05 -0.56 -0.42 Urate levels; chr16:79706644 chr16:79715232~79770563:- PAAD cis rs9322193 0.923 rs9800686 ENSG00000216906.2 RP11-350J20.9 5.7 5.97e-08 6.3e-05 0.53 0.42 Lung cancer; chr6:149634464 chr6:149904243~149906418:+ PAAD cis rs9322193 0.923 rs55849538 ENSG00000216906.2 RP11-350J20.9 5.7 5.97e-08 6.3e-05 0.53 0.42 Lung cancer; chr6:149635330 chr6:149904243~149906418:+ PAAD cis rs228614 0.509 rs223481 ENSG00000246560.2 RP11-10L12.4 5.7 6e-08 6.33e-05 0.46 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766860 chr4:102828055~102844075:+ PAAD cis rs4972806 0.775 rs2857534 ENSG00000226363.3 HAGLROS -5.7 6.02e-08 6.35e-05 -0.51 -0.42 IgG glycosylation; chr2:176170948 chr2:176177717~176179008:+ PAAD cis rs875971 0.862 rs10256544 ENSG00000237310.1 GS1-124K5.4 5.7 6.05e-08 6.37e-05 0.42 0.42 Aortic root size; chr7:66210141 chr7:66493706~66495474:+ PAAD cis rs732716 0.785 rs34080966 ENSG00000267980.1 AC007292.6 5.7 6.08e-08 6.41e-05 0.58 0.42 Mean corpuscular volume; chr19:4417848 chr19:4363789~4364640:+ PAAD cis rs11673344 0.548 rs2058852 ENSG00000226686.6 LINC01535 5.7 6.08e-08 6.41e-05 0.52 0.42 Obesity-related traits; chr19:37673701 chr19:37251912~37265535:+ PAAD cis rs72843506 0.722 rs74255387 ENSG00000189423.10 USP32P3 5.7 6.09e-08 6.41e-05 0.68 0.42 Schizophrenia; chr17:20198070 chr17:20415547~20431008:+ PAAD cis rs2337406 0.789 rs9324095 ENSG00000274576.2 IGHV2-70 -5.7 6.09e-08 6.42e-05 -0.52 -0.42 Alzheimer's disease (late onset); chr14:106795885 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs58154560 ENSG00000274576.2 IGHV2-70 -5.7 6.09e-08 6.42e-05 -0.52 -0.42 Alzheimer's disease (late onset); chr14:106799601 chr14:106770577~106771020:- PAAD cis rs526231 0.511 rs3776861 ENSG00000175749.11 EIF3KP1 5.7 6.1e-08 6.42e-05 0.54 0.42 Primary biliary cholangitis; chr5:103013958 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs11951374 ENSG00000175749.11 EIF3KP1 5.7 6.1e-08 6.42e-05 0.54 0.42 Primary biliary cholangitis; chr5:103020094 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs7731395 ENSG00000175749.11 EIF3KP1 5.7 6.1e-08 6.42e-05 0.54 0.42 Primary biliary cholangitis; chr5:103026057 chr5:103032376~103033031:+ PAAD cis rs26232 0.521 rs11958562 ENSG00000175749.11 EIF3KP1 5.7 6.1e-08 6.42e-05 0.54 0.42 Rheumatoid arthritis; chr5:103027357 chr5:103032376~103033031:+ PAAD cis rs8091660 0.929 rs11082685 ENSG00000278983.1 RP11-426J5.3 5.7 6.1e-08 6.42e-05 0.51 0.42 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48566806 chr18:48564795~48568342:+ PAAD cis rs11098499 0.82 rs28394116 ENSG00000245958.5 RP11-33B1.1 -5.7 6.1e-08 6.43e-05 -0.36 -0.42 Corneal astigmatism; chr4:119603128 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs3756156 ENSG00000245958.5 RP11-33B1.1 -5.7 6.1e-08 6.43e-05 -0.36 -0.42 Corneal astigmatism; chr4:119603686 chr4:119454791~119552025:+ PAAD cis rs17301013 0.932 rs3737651 ENSG00000227373.4 RP11-160H22.5 -5.7 6.1e-08 6.43e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174475414 chr1:174115300~174160004:- PAAD cis rs1075265 0.84 rs805309 ENSG00000233266.1 HMGB1P31 5.7 6.12e-08 6.44e-05 0.54 0.42 Chronotype;Morning vs. evening chronotype; chr2:53968877 chr2:54051334~54051760:+ PAAD cis rs6142102 0.625 rs6142067 ENSG00000276073.1 RP5-1125A11.7 -5.7 6.13e-08 6.45e-05 -0.45 -0.42 Skin pigmentation; chr20:33968766 chr20:33985617~33988989:- PAAD cis rs9322193 0.81 rs62439811 ENSG00000216906.2 RP11-350J20.9 5.7 6.13e-08 6.46e-05 0.53 0.42 Lung cancer; chr6:149640416 chr6:149904243~149906418:+ PAAD cis rs72843506 0.722 rs78041331 ENSG00000189423.10 USP32P3 5.7 6.14e-08 6.46e-05 0.67 0.42 Schizophrenia; chr17:20305533 chr17:20415547~20431008:+ PAAD cis rs7772486 0.79 rs9497431 ENSG00000235652.6 RP11-545I5.3 -5.7 6.14e-08 6.46e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145927041 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs7753092 ENSG00000235652.6 RP11-545I5.3 -5.7 6.14e-08 6.46e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145927727 chr6:145799409~145886585:+ PAAD cis rs7772486 0.764 rs2265468 ENSG00000235652.6 RP11-545I5.3 5.7 6.14e-08 6.46e-05 0.34 0.42 Lobe attachment (rater-scored or self-reported); chr6:145897210 chr6:145799409~145886585:+ PAAD cis rs6504950 0.83 rs17817877 ENSG00000275710.1 RP11-257O5.4 5.7 6.14e-08 6.47e-05 0.55 0.42 Breast cancer; chr17:54957267 chr17:54964474~54964679:+ PAAD cis rs17301013 0.932 rs1653626 ENSG00000227373.4 RP11-160H22.5 -5.7 6.15e-08 6.47e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174770348 chr1:174115300~174160004:- PAAD cis rs9640161 0.83 rs35840727 ENSG00000261305.1 RP4-584D14.7 5.7 6.15e-08 6.47e-05 0.59 0.42 Blood protein levels;Circulating chemerin levels; chr7:150366115 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs35635199 ENSG00000261305.1 RP4-584D14.7 5.7 6.15e-08 6.47e-05 0.59 0.42 Blood protein levels;Circulating chemerin levels; chr7:150366253 chr7:150341771~150342607:+ PAAD cis rs72772090 0.539 rs72775807 ENSG00000248734.2 CTD-2260A17.1 -5.7 6.15e-08 6.47e-05 -0.55 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96844058 chr5:96784777~96785999:+ PAAD cis rs2243480 1 rs3885839 ENSG00000226824.5 RP4-756H11.3 -5.7 6.16e-08 6.48e-05 -0.76 -0.42 Diabetic kidney disease; chr7:65825416 chr7:66654538~66669855:+ PAAD cis rs7772486 0.875 rs2748483 ENSG00000235652.6 RP11-545I5.3 -5.7 6.16e-08 6.48e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:146014424 chr6:145799409~145886585:+ PAAD cis rs7188445 1 rs16950982 ENSG00000261390.4 RP11-345M22.2 -5.7 6.17e-08 6.49e-05 -0.53 -0.42 Urate levels; chr16:79668474 chr16:79715232~79770563:- PAAD cis rs11098499 0.722 rs17595727 ENSG00000245958.5 RP11-33B1.1 5.7 6.19e-08 6.5e-05 0.3 0.42 Corneal astigmatism; chr4:119340919 chr4:119454791~119552025:+ PAAD cis rs11098499 0.644 rs17517414 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119340946 chr4:119454791~119552025:+ PAAD cis rs11098499 0.722 rs10006192 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119341867 chr4:119454791~119552025:+ PAAD cis rs11098499 0.615 rs28551750 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119343746 chr4:119454791~119552025:+ PAAD cis rs11098499 0.691 rs9995716 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119343841 chr4:119454791~119552025:+ PAAD cis rs10028773 0.6 rs4001390 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Educational attainment; chr4:119344628 chr4:119454791~119552025:+ PAAD cis rs11098499 0.691 rs2136911 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119344704 chr4:119454791~119552025:+ PAAD cis rs11098499 0.554 rs2175381 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119344812 chr4:119454791~119552025:+ PAAD cis rs11098499 0.599 rs3864142 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119345036 chr4:119454791~119552025:+ PAAD cis rs11098499 0.605 rs6833140 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119345667 chr4:119454791~119552025:+ PAAD cis rs11098499 0.779 rs6815934 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Corneal astigmatism; chr4:119346155 chr4:119454791~119552025:+ PAAD cis rs10028773 0.568 rs6838457 ENSG00000245958.5 RP11-33B1.1 -5.7 6.19e-08 6.5e-05 -0.3 -0.42 Educational attainment; chr4:119346212 chr4:119454791~119552025:+ PAAD cis rs1061377 0.748 rs12642261 ENSG00000249685.1 RP11-360F5.3 5.69 6.24e-08 6.55e-05 0.44 0.42 Uric acid levels; chr4:39096278 chr4:39133913~39135608:+ PAAD cis rs2658782 0.526 rs3020062 ENSG00000279684.1 RP11-755E23.2 -5.69 6.24e-08 6.56e-05 -0.61 -0.42 Pulmonary function decline; chr11:93327993 chr11:93286629~93288903:- PAAD cis rs12908161 0.92 rs12904605 ENSG00000225151.9 GOLGA2P7 -5.69 6.24e-08 6.56e-05 -0.5 -0.42 Schizophrenia; chr15:84658188 chr15:84199311~84230136:- PAAD cis rs950169 0.512 rs4374136 ENSG00000259728.4 LINC00933 5.69 6.25e-08 6.56e-05 0.55 0.42 Schizophrenia; chr15:83976255 chr15:84570649~84580175:+ PAAD cis rs17301013 0.507 rs6697959 ENSG00000227373.4 RP11-160H22.5 5.69 6.25e-08 6.56e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174285450 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12066504 ENSG00000227373.4 RP11-160H22.5 5.69 6.25e-08 6.56e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174288695 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912758 ENSG00000227373.4 RP11-160H22.5 5.69 6.25e-08 6.56e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174300822 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs1121537 ENSG00000227373.4 RP11-160H22.5 5.69 6.25e-08 6.56e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174307568 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912763 ENSG00000227373.4 RP11-160H22.5 5.69 6.25e-08 6.56e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174316083 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912764 ENSG00000227373.4 RP11-160H22.5 5.69 6.25e-08 6.56e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174316085 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912765 ENSG00000227373.4 RP11-160H22.5 5.69 6.25e-08 6.56e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174322812 chr1:174115300~174160004:- PAAD cis rs3096299 0.754 rs2965816 ENSG00000274627.1 RP11-104N10.2 -5.69 6.26e-08 6.57e-05 -0.35 -0.42 Multiple myeloma (IgH translocation); chr16:89447775 chr16:89516797~89522217:+ PAAD cis rs228614 0.51 rs223438 ENSG00000246560.2 RP11-10L12.4 -5.69 6.28e-08 6.59e-05 -0.45 -0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798584 chr4:102828055~102844075:+ PAAD cis rs9640161 0.659 rs59572505 ENSG00000261305.1 RP4-584D14.7 5.69 6.31e-08 6.62e-05 0.63 0.42 Blood protein levels;Circulating chemerin levels; chr7:150317897 chr7:150341771~150342607:+ PAAD cis rs6570726 0.599 rs9403725 ENSG00000235652.6 RP11-545I5.3 -5.69 6.31e-08 6.62e-05 -0.36 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145576486 chr6:145799409~145886585:+ PAAD cis rs228614 0.51 rs170565 ENSG00000246560.2 RP11-10L12.4 5.69 6.31e-08 6.62e-05 0.47 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798277 chr4:102828055~102844075:+ PAAD cis rs9425766 0.679 rs10912761 ENSG00000227373.4 RP11-160H22.5 5.69 6.32e-08 6.62e-05 0.54 0.42 Life satisfaction; chr1:174312466 chr1:174115300~174160004:- PAAD cis rs1150668 0.796 rs2531825 ENSG00000204709.4 LINC01556 5.69 6.33e-08 6.63e-05 0.54 0.42 Pubertal anthropometrics; chr6:28381487 chr6:28943877~28944537:+ PAAD cis rs9322193 0.576 rs7452592 ENSG00000216906.2 RP11-350J20.9 5.69 6.35e-08 6.66e-05 0.67 0.42 Lung cancer; chr6:149875445 chr6:149904243~149906418:+ PAAD cis rs12701220 0.655 rs9638973 ENSG00000229043.2 AC091729.9 -5.69 6.37e-08 6.68e-05 -0.56 -0.42 Bronchopulmonary dysplasia; chr7:1094042 chr7:1160374~1165267:+ PAAD cis rs12701220 0.655 rs7799656 ENSG00000229043.2 AC091729.9 -5.69 6.37e-08 6.68e-05 -0.56 -0.42 Bronchopulmonary dysplasia; chr7:1100879 chr7:1160374~1165267:+ PAAD cis rs1799810 0.899 rs7599210 ENSG00000236682.1 AC068282.3 -5.69 6.38e-08 6.69e-05 -0.56 -0.42 Self-rated health; chr2:127406601 chr2:127389130~127400580:+ PAAD cis rs673078 0.607 rs11068906 ENSG00000275759.1 RP11-131L12.3 -5.69 6.38e-08 6.69e-05 -0.59 -0.42 Glucose homeostasis traits; chr12:118315098 chr12:118428281~118428870:+ PAAD cis rs12220777 1 rs75913297 ENSG00000230091.5 TMEM254-AS1 5.69 6.39e-08 6.7e-05 0.76 0.42 Chronic obstructive pulmonary disease-related biomarkers; chr10:80030089 chr10:80046860~80078912:- PAAD cis rs10875746 0.68 rs4760610 ENSG00000240399.1 RP1-228P16.1 -5.69 6.4e-08 6.71e-05 -0.46 -0.42 Longevity (90 years and older); chr12:48024442 chr12:48054813~48055591:- PAAD cis rs9425766 0.679 rs6670617 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174277574 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs4650990 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174289943 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs7555067 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174297504 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs6695636 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174303087 chr1:174115300~174160004:- PAAD cis rs9425766 0.64 rs7512930 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174319464 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs7523460 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174319664 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs7552830 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174321643 chr1:174115300~174160004:- PAAD cis rs9425766 0.679 rs7523938 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174327373 chr1:174115300~174160004:- PAAD cis rs9425766 0.64 rs6681780 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174328980 chr1:174115300~174160004:- PAAD cis rs9425766 0.55 rs57366619 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174334929 chr1:174115300~174160004:- PAAD cis rs9425766 0.64 rs17301013 ENSG00000227373.4 RP11-160H22.5 5.69 6.4e-08 6.71e-05 0.54 0.42 Life satisfaction; chr1:174343675 chr1:174115300~174160004:- PAAD cis rs6142102 0.602 rs2268086 ENSG00000276073.1 RP5-1125A11.7 5.69 6.41e-08 6.71e-05 0.43 0.42 Skin pigmentation; chr20:34060932 chr20:33985617~33988989:- PAAD cis rs7829975 0.777 rs560544 ENSG00000253893.2 FAM85B 5.69 6.41e-08 6.71e-05 0.6 0.42 Mood instability; chr8:8779919 chr8:8167819~8226614:- PAAD cis rs6565180 0.962 rs35480350 ENSG00000183604.13 SMG1P5 -5.69 6.41e-08 6.72e-05 -0.48 -0.42 Tonsillectomy; chr16:30354718 chr16:30267553~30335374:- PAAD cis rs6565180 0.962 rs11642676 ENSG00000183604.13 SMG1P5 -5.69 6.41e-08 6.72e-05 -0.48 -0.42 Tonsillectomy; chr16:30360334 chr16:30267553~30335374:- PAAD cis rs6565180 0.962 rs6565182 ENSG00000183604.13 SMG1P5 -5.69 6.41e-08 6.72e-05 -0.48 -0.42 Tonsillectomy; chr16:30363060 chr16:30267553~30335374:- PAAD cis rs9322193 0.962 rs7818 ENSG00000216906.2 RP11-350J20.9 5.69 6.43e-08 6.73e-05 0.54 0.42 Lung cancer; chr6:149810956 chr6:149904243~149906418:+ PAAD cis rs6142102 0.602 rs4911402 ENSG00000276073.1 RP5-1125A11.7 -5.69 6.43e-08 6.74e-05 -0.43 -0.42 Skin pigmentation; chr20:34079839 chr20:33985617~33988989:- PAAD cis rs7188445 0.966 rs11150188 ENSG00000261390.4 RP11-345M22.2 -5.69 6.44e-08 6.74e-05 -0.57 -0.42 Urate levels; chr16:79673401 chr16:79715232~79770563:- PAAD cis rs9322193 0.962 rs9689447 ENSG00000216906.2 RP11-350J20.9 5.69 6.44e-08 6.74e-05 0.54 0.42 Lung cancer; chr6:149789350 chr6:149904243~149906418:+ PAAD cis rs72772090 0.71 rs17400685 ENSG00000248734.2 CTD-2260A17.1 5.69 6.46e-08 6.76e-05 0.54 0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96730662 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs17479052 ENSG00000248734.2 CTD-2260A17.1 -5.69 6.46e-08 6.76e-05 -0.54 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96729932 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs17400741 ENSG00000248734.2 CTD-2260A17.1 -5.69 6.46e-08 6.76e-05 -0.54 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96730872 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs11750400 ENSG00000248734.2 CTD-2260A17.1 -5.69 6.46e-08 6.76e-05 -0.54 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96742264 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs10515244 ENSG00000248734.2 CTD-2260A17.1 -5.69 6.46e-08 6.76e-05 -0.54 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96742633 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs1559085 ENSG00000248734.2 CTD-2260A17.1 -5.69 6.46e-08 6.76e-05 -0.54 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96742998 chr5:96784777~96785999:+ PAAD cis rs9425766 0.54 rs2294492 ENSG00000227373.4 RP11-160H22.5 5.69 6.48e-08 6.78e-05 0.52 0.42 Life satisfaction; chr1:174157884 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs60811893 ENSG00000227373.4 RP11-160H22.5 5.69 6.49e-08 6.79e-05 0.62 0.42 Systemic lupus erythematosus; chr1:174765968 chr1:174115300~174160004:- PAAD cis rs1061377 0.748 rs13117988 ENSG00000249207.1 RP11-360F5.1 -5.69 6.49e-08 6.79e-05 -0.44 -0.42 Uric acid levels; chr4:39092219 chr4:39112677~39126818:- PAAD cis rs6782228 0.565 rs11719239 ENSG00000242551.2 POU5F1P6 -5.69 6.5e-08 6.79e-05 -0.49 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128700211 chr3:128674735~128677005:- PAAD cis rs6142102 0.625 rs6142051 ENSG00000276073.1 RP5-1125A11.7 -5.68 6.51e-08 6.81e-05 -0.44 -0.42 Skin pigmentation; chr20:33945212 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs4911137 ENSG00000276073.1 RP5-1125A11.7 -5.68 6.51e-08 6.81e-05 -0.44 -0.42 Skin pigmentation; chr20:33947657 chr20:33985617~33988989:- PAAD cis rs2115630 0.645 rs1107179 ENSG00000259728.4 LINC00933 5.68 6.51e-08 6.81e-05 0.51 0.42 P wave terminal force; chr15:84655131 chr15:84570649~84580175:+ PAAD cis rs10463554 0.926 rs5855 ENSG00000175749.11 EIF3KP1 -5.68 6.53e-08 6.82e-05 -0.53 -0.42 Parkinson's disease; chr5:103029482 chr5:103032376~103033031:+ PAAD cis rs26232 0.52 rs26432 ENSG00000175749.11 EIF3KP1 -5.68 6.53e-08 6.82e-05 -0.53 -0.42 Rheumatoid arthritis; chr5:103030006 chr5:103032376~103033031:+ PAAD cis rs26232 0.583 rs26430 ENSG00000175749.11 EIF3KP1 -5.68 6.53e-08 6.82e-05 -0.53 -0.42 Rheumatoid arthritis; chr5:103030228 chr5:103032376~103033031:+ PAAD cis rs10463554 0.926 rs26429 ENSG00000175749.11 EIF3KP1 -5.68 6.53e-08 6.82e-05 -0.53 -0.42 Parkinson's disease; chr5:103030349 chr5:103032376~103033031:+ PAAD cis rs10463554 0.89 rs26428 ENSG00000175749.11 EIF3KP1 -5.68 6.53e-08 6.82e-05 -0.53 -0.42 Parkinson's disease; chr5:103030780 chr5:103032376~103033031:+ PAAD cis rs11098499 0.866 rs10518329 ENSG00000245958.5 RP11-33B1.1 -5.68 6.55e-08 6.84e-05 -0.31 -0.42 Corneal astigmatism; chr4:119480680 chr4:119454791~119552025:+ PAAD cis rs11098499 0.866 rs7665125 ENSG00000245958.5 RP11-33B1.1 -5.68 6.55e-08 6.84e-05 -0.31 -0.42 Corneal astigmatism; chr4:119480924 chr4:119454791~119552025:+ PAAD cis rs75422866 0.867 rs73102195 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47666309 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102201 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47669269 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104103 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47669604 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104104 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47671986 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104111 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47673994 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104115 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47684843 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104116 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47685023 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104138 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47692302 chr12:47706085~47742294:+ PAAD cis rs75422866 0.717 rs73104143 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47693449 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104144 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47694390 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104148 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47696732 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104152 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47699091 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73104155 ENSG00000257433.4 RP1-197B17.3 5.68 6.56e-08 6.84e-05 0.85 0.42 Pneumonia; chr12:47700790 chr12:47706085~47742294:+ PAAD cis rs2280018 0.581 rs7404524 ENSG00000260735.1 RP11-72I8.1 -5.68 6.56e-08 6.85e-05 -0.55 -0.42 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15035301 chr16:15094411~15109197:+ PAAD cis rs42490 0.51 rs218885 ENSG00000251136.7 RP11-37B2.1 5.68 6.57e-08 6.86e-05 0.38 0.42 Leprosy; chr8:89678313 chr8:89609409~89757727:- PAAD cis rs7945705 0.902 rs1560569 ENSG00000254860.4 TMEM9B-AS1 5.68 6.58e-08 6.87e-05 0.46 0.42 Hemoglobin concentration; chr11:8918340 chr11:8964675~8977527:+ PAAD cis rs9326248 1 rs10790175 ENSG00000280143.1 AP000892.6 5.68 6.58e-08 6.87e-05 0.52 0.42 Blood protein levels; chr11:117164013 chr11:117204967~117210292:+ PAAD cis rs2929278 0.617 rs693919 ENSG00000249839.1 AC011330.5 5.68 6.59e-08 6.88e-05 0.56 0.42 Schizophrenia; chr15:43810130 chr15:43663654~43684339:- PAAD cis rs6538678 0.929 rs10745733 ENSG00000258343.1 RP11-536G4.2 -5.68 6.6e-08 6.88e-05 -0.55 -0.42 Lupus nephritis in systemic lupus erythematosus; chr12:95868728 chr12:95795345~95858839:- PAAD cis rs6538678 0.926 rs10745734 ENSG00000258343.1 RP11-536G4.2 -5.68 6.6e-08 6.88e-05 -0.55 -0.42 Lupus nephritis in systemic lupus erythematosus; chr12:95868936 chr12:95795345~95858839:- PAAD cis rs858239 0.896 rs1637193 ENSG00000226816.2 AC005082.12 5.68 6.6e-08 6.88e-05 0.47 0.42 Cerebrospinal fluid biomarker levels; chr7:23220632 chr7:23206013~23208045:+ PAAD cis rs6142102 0.538 rs6142058 ENSG00000276073.1 RP5-1125A11.7 -5.68 6.63e-08 6.91e-05 -0.44 -0.42 Skin pigmentation; chr20:33954995 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs2050208 ENSG00000276073.1 RP5-1125A11.7 -5.68 6.63e-08 6.91e-05 -0.44 -0.42 Skin pigmentation; chr20:33955767 chr20:33985617~33988989:- PAAD cis rs6142102 0.602 rs4911380 ENSG00000276073.1 RP5-1125A11.7 -5.68 6.63e-08 6.91e-05 -0.44 -0.42 Skin pigmentation; chr20:33958418 chr20:33985617~33988989:- PAAD cis rs2919917 0.666 rs10957898 ENSG00000254352.1 RP11-578O24.2 -5.68 6.63e-08 6.91e-05 -0.52 -0.42 Lymphocyte counts; chr8:78705078 chr8:78723796~78724136:- PAAD cis rs7772486 0.754 rs1415747 ENSG00000235652.6 RP11-545I5.3 5.68 6.66e-08 6.94e-05 0.35 0.42 Lobe attachment (rater-scored or self-reported); chr6:145756113 chr6:145799409~145886585:+ PAAD cis rs1075265 0.584 rs2357954 ENSG00000233266.1 HMGB1P31 5.68 6.66e-08 6.94e-05 0.54 0.42 Chronotype;Morning vs. evening chronotype; chr2:54135300 chr2:54051334~54051760:+ PAAD cis rs2882667 0.515 rs13161286 ENSG00000253404.1 AC034243.1 5.68 6.67e-08 6.95e-05 0.52 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139148416 chr5:138744434~138753309:- PAAD cis rs7945705 0.902 rs2568059 ENSG00000254860.4 TMEM9B-AS1 5.68 6.67e-08 6.95e-05 0.44 0.42 Hemoglobin concentration; chr11:8862614 chr11:8964675~8977527:+ PAAD cis rs7945705 0.875 rs2653616 ENSG00000254860.4 TMEM9B-AS1 5.68 6.67e-08 6.95e-05 0.44 0.42 Hemoglobin concentration; chr11:8864345 chr11:8964675~8977527:+ PAAD cis rs7945705 0.935 rs2568061 ENSG00000254860.4 TMEM9B-AS1 5.68 6.67e-08 6.95e-05 0.44 0.42 Hemoglobin concentration; chr11:8864713 chr11:8964675~8977527:+ PAAD cis rs8059260 0.545 rs2286972 ENSG00000274038.1 RP11-66H6.4 -5.68 6.67e-08 6.95e-05 -0.72 -0.42 Alcohol consumption over the past year; chr16:11061141 chr16:11056556~11057034:+ PAAD cis rs75422866 0.764 rs67408202 ENSG00000257433.4 RP1-197B17.3 5.68 6.69e-08 6.96e-05 0.88 0.42 Pneumonia; chr12:47713564 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs57848393 ENSG00000257433.4 RP1-197B17.3 5.68 6.69e-08 6.96e-05 0.88 0.42 Pneumonia; chr12:47714734 chr12:47706085~47742294:+ PAAD cis rs75422866 0.764 rs67201012 ENSG00000257433.4 RP1-197B17.3 5.68 6.69e-08 6.96e-05 0.88 0.42 Pneumonia; chr12:47715881 chr12:47706085~47742294:+ PAAD cis rs3762637 1 rs6777596 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122414474 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9836309 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122416348 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs9873842 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122416484 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs12633461 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122417050 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9879508 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122417633 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9858558 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122420895 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs7626861 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122436349 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9842736 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122442254 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs13321097 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122443160 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs112768052 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122450537 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs77599736 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122460662 chr3:122416207~122443180:+ PAAD cis rs3762637 0.943 rs10439995 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122470313 chr3:122416207~122443180:+ PAAD cis rs3762637 0.882 rs7630833 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122471577 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs7644540 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122491205 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs78381804 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122503415 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs28497203 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122512972 chr3:122416207~122443180:+ PAAD cis rs3762637 0.943 rs9822345 ENSG00000272758.4 RP11-299J3.8 -5.68 6.69e-08 6.96e-05 -0.63 -0.42 LDL cholesterol levels; chr3:122526751 chr3:122416207~122443180:+ PAAD cis rs2739330 0.791 rs4822458 ENSG00000099984.9 GSTT2 -5.68 6.71e-08 6.98e-05 -0.55 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23923472 chr22:23980123~23983911:+ PAAD cis rs10028773 0.632 rs34481394 ENSG00000245958.5 RP11-33B1.1 -5.68 6.72e-08 6.99e-05 -0.33 -0.42 Educational attainment; chr4:119327219 chr4:119454791~119552025:+ PAAD cis rs10028773 0.666 rs35231872 ENSG00000245958.5 RP11-33B1.1 -5.68 6.72e-08 6.99e-05 -0.33 -0.42 Educational attainment; chr4:119327221 chr4:119454791~119552025:+ PAAD cis rs10028773 0.7 rs35653026 ENSG00000245958.5 RP11-33B1.1 -5.68 6.72e-08 6.99e-05 -0.33 -0.42 Educational attainment; chr4:119327223 chr4:119454791~119552025:+ PAAD cis rs11118620 0.622 rs11118618 ENSG00000272823.1 RP11-295M18.6 5.68 6.72e-08 7e-05 0.54 0.42 Heart failure; chr1:220838204 chr1:220828676~220829211:- PAAD cis rs2739330 0.828 rs5760108 ENSG00000231271.1 AP000350.8 5.68 6.73e-08 7e-05 0.56 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23949918~23954042:+ PAAD cis rs9322193 0.923 rs6913486 ENSG00000216906.2 RP11-350J20.9 -5.68 6.73e-08 7e-05 -0.54 -0.42 Lung cancer; chr6:149705060 chr6:149904243~149906418:+ PAAD cis rs1009647 1 rs1009647 ENSG00000258413.1 RP11-665C16.6 -5.68 6.76e-08 7.03e-05 -0.58 -0.42 Testicular germ cell tumor; chr14:55413329 chr14:55262767~55272075:- PAAD cis rs755249 0.546 rs7533743 ENSG00000237624.1 OXCT2P1 -5.68 6.77e-08 7.04e-05 -0.53 -0.42 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39491497 chr1:39514956~39516490:+ PAAD cis rs755249 0.565 rs7555699 ENSG00000237624.1 OXCT2P1 -5.68 6.77e-08 7.04e-05 -0.53 -0.42 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39491629 chr1:39514956~39516490:+ PAAD cis rs755249 0.565 rs1809697 ENSG00000237624.1 OXCT2P1 -5.68 6.77e-08 7.04e-05 -0.53 -0.42 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39493413 chr1:39514956~39516490:+ PAAD cis rs7580658 0.724 rs7568261 ENSG00000236682.1 AC068282.3 -5.68 6.77e-08 7.04e-05 -0.53 -0.42 Protein C levels; chr2:127359748 chr2:127389130~127400580:+ PAAD cis rs9926296 0.744 rs352939 ENSG00000260259.1 RP11-368I7.4 5.68 6.77e-08 7.04e-05 0.52 0.42 Vitiligo; chr16:89643970 chr16:89682620~89686569:- PAAD cis rs1862618 0.573 rs832532 ENSG00000271828.1 CTD-2310F14.1 5.68 6.78e-08 7.05e-05 0.64 0.42 Initial pursuit acceleration; chr5:56926111 chr5:56927874~56929573:+ PAAD cis rs2882667 0.824 rs11748097 ENSG00000253404.1 AC034243.1 5.68 6.79e-08 7.06e-05 0.52 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139144198 chr5:138744434~138753309:- PAAD cis rs2882667 0.824 rs12173085 ENSG00000253404.1 AC034243.1 5.68 6.79e-08 7.06e-05 0.52 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139144336 chr5:138744434~138753309:- PAAD cis rs10262624 0.564 rs58051142 ENSG00000234286.1 AC006026.13 -5.68 6.79e-08 7.06e-05 -0.48 -0.42 Schizophrenia; chr7:23866047 chr7:23680195~23680786:- PAAD cis rs9425766 0.679 rs7537517 ENSG00000227373.4 RP11-160H22.5 5.68 6.82e-08 7.08e-05 0.55 0.42 Life satisfaction; chr1:174207225 chr1:174115300~174160004:- PAAD cis rs7429990 0.774 rs3772402 ENSG00000229759.1 MRPS18AP1 -5.67 6.83e-08 7.1e-05 -0.46 -0.42 Educational attainment (years of education); chr3:47574661 chr3:48256350~48256938:- PAAD cis rs2929278 0.588 rs1975364 ENSG00000249839.1 AC011330.5 -5.67 6.83e-08 7.1e-05 -0.57 -0.42 Schizophrenia; chr15:43857991 chr15:43663654~43684339:- PAAD cis rs11123170 0.529 rs35606997 ENSG00000189223.12 PAX8-AS1 -5.67 6.84e-08 7.1e-05 -0.59 -0.42 Renal function-related traits (BUN); chr2:113215773 chr2:113211522~113276581:+ PAAD cis rs9532669 0.853 rs9315795 ENSG00000176268.5 CYCSP34 5.67 6.86e-08 7.13e-05 0.39 0.42 Cervical cancer; chr13:40943382 chr13:40863599~40863902:- PAAD cis rs9532669 0.963 rs3764056 ENSG00000176268.5 CYCSP34 5.67 6.86e-08 7.13e-05 0.39 0.42 Cervical cancer; chr13:40943849 chr13:40863599~40863902:- PAAD cis rs9928842 0.823 rs6564243 ENSG00000280152.1 RP11-331F4.5 5.67 6.87e-08 7.13e-05 0.54 0.42 Alcoholic chronic pancreatitis; chr16:75262103 chr16:75245994~75250077:- PAAD cis rs113835537 0.597 rs2305534 ENSG00000255517.5 CTD-3074O7.5 -5.67 6.87e-08 7.14e-05 -0.57 -0.42 Airway imaging phenotypes; chr11:66545732 chr11:66473490~66480233:- PAAD cis rs453301 0.624 rs2288671 ENSG00000253893.2 FAM85B -5.67 6.9e-08 7.17e-05 -0.56 -0.42 Joint mobility (Beighton score); chr8:9003384 chr8:8167819~8226614:- PAAD cis rs7945705 0.967 rs56316046 ENSG00000254860.4 TMEM9B-AS1 -5.67 6.91e-08 7.17e-05 -0.47 -0.42 Hemoglobin concentration; chr11:8855051 chr11:8964675~8977527:+ PAAD cis rs6782228 0.606 rs2001950 ENSG00000242551.2 POU5F1P6 -5.67 6.92e-08 7.18e-05 -0.49 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128700913 chr3:128674735~128677005:- PAAD cis rs1061377 0.748 rs13117988 ENSG00000249685.1 RP11-360F5.3 5.67 6.93e-08 7.2e-05 0.43 0.42 Uric acid levels; chr4:39092219 chr4:39133913~39135608:+ PAAD cis rs17301013 0.932 rs1754349 ENSG00000227373.4 RP11-160H22.5 -5.67 6.94e-08 7.21e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174837663 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs1793297 ENSG00000227373.4 RP11-160H22.5 -5.67 6.95e-08 7.22e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174784411 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs4233195 ENSG00000227373.4 RP11-160H22.5 -5.67 6.95e-08 7.22e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174806736 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs1754355 ENSG00000227373.4 RP11-160H22.5 -5.67 6.95e-08 7.22e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174807407 chr1:174115300~174160004:- PAAD cis rs17301013 0.932 rs2987869 ENSG00000227373.4 RP11-160H22.5 -5.67 6.95e-08 7.22e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174820269 chr1:174115300~174160004:- PAAD cis rs17301013 0.827 rs1793309 ENSG00000227373.4 RP11-160H22.5 -5.67 6.95e-08 7.22e-05 -0.52 -0.42 Systemic lupus erythematosus; chr1:174826199 chr1:174115300~174160004:- PAAD cis rs858239 0.73 rs858279 ENSG00000226816.2 AC005082.12 5.67 6.99e-08 7.25e-05 0.46 0.42 Cerebrospinal fluid biomarker levels; chr7:23211386 chr7:23206013~23208045:+ PAAD cis rs9640161 0.83 rs13307276 ENSG00000261305.1 RP4-584D14.7 5.67 7e-08 7.26e-05 0.59 0.42 Blood protein levels;Circulating chemerin levels; chr7:150364436 chr7:150341771~150342607:+ PAAD cis rs9322193 0.962 rs2065664 ENSG00000216906.2 RP11-350J20.9 5.67 7.02e-08 7.28e-05 0.55 0.42 Lung cancer; chr6:149762485 chr6:149904243~149906418:+ PAAD cis rs950169 0.509 rs71395455 ENSG00000225151.9 GOLGA2P7 -5.67 7.02e-08 7.28e-05 -0.51 -0.42 Schizophrenia; chr15:84610573 chr15:84199311~84230136:- PAAD cis rs2929278 0.546 rs686666 ENSG00000249839.1 AC011330.5 -5.67 7.02e-08 7.28e-05 -0.57 -0.42 Schizophrenia; chr15:43869352 chr15:43663654~43684339:- PAAD cis rs11098499 0.691 rs12502524 ENSG00000245958.5 RP11-33B1.1 -5.67 7.03e-08 7.29e-05 -0.3 -0.42 Corneal astigmatism; chr4:119350259 chr4:119454791~119552025:+ PAAD cis rs11098499 0.691 rs28396837 ENSG00000245958.5 RP11-33B1.1 -5.67 7.03e-08 7.29e-05 -0.3 -0.42 Corneal astigmatism; chr4:119350386 chr4:119454791~119552025:+ PAAD cis rs11098499 0.629 rs28369518 ENSG00000245958.5 RP11-33B1.1 -5.67 7.03e-08 7.29e-05 -0.3 -0.42 Corneal astigmatism; chr4:119350475 chr4:119454791~119552025:+ PAAD cis rs11098499 0.722 rs10025925 ENSG00000245958.5 RP11-33B1.1 -5.67 7.03e-08 7.29e-05 -0.3 -0.42 Corneal astigmatism; chr4:119350589 chr4:119454791~119552025:+ PAAD cis rs11098499 0.731 rs10015579 ENSG00000245958.5 RP11-33B1.1 -5.67 7.03e-08 7.29e-05 -0.3 -0.42 Corneal astigmatism; chr4:119350647 chr4:119454791~119552025:+ PAAD cis rs7188445 1 rs76819459 ENSG00000261390.4 RP11-345M22.2 -5.67 7.03e-08 7.29e-05 -0.56 -0.42 Urate levels; chr16:79685020 chr16:79715232~79770563:- PAAD cis rs10028773 0.666 rs12498657 ENSG00000245958.5 RP11-33B1.1 -5.67 7.04e-08 7.3e-05 -0.3 -0.42 Educational attainment; chr4:119341711 chr4:119454791~119552025:+ PAAD cis rs1075265 0.84 rs10084355 ENSG00000233266.1 HMGB1P31 5.67 7.06e-08 7.32e-05 0.54 0.42 Chronotype;Morning vs. evening chronotype; chr2:54021711 chr2:54051334~54051760:+ PAAD cis rs950169 0.922 rs11638445 ENSG00000225151.9 GOLGA2P7 -5.67 7.06e-08 7.32e-05 -0.49 -0.42 Schizophrenia; chr15:84594463 chr15:84199311~84230136:- PAAD cis rs9640161 0.789 rs10248490 ENSG00000261305.1 RP4-584D14.7 5.67 7.06e-08 7.32e-05 0.61 0.42 Blood protein levels;Circulating chemerin levels; chr7:150354329 chr7:150341771~150342607:+ PAAD cis rs10463554 0.963 rs1595553 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103043164 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs12655592 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103043715 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs61418746 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103043914 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs12055075 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103044553 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs12054848 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103044736 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs11242484 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103046172 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs10434791 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103053768 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs62364875 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103056486 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34382 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103060521 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs34380 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103061245 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs158250 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103071075 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs464702 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103071180 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs464720 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103071183 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs158396 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103076015 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs158401 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103079764 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257304 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103081114 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257312 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103083923 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs185387 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103084315 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs257313 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103084943 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257315 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103085725 chr5:103032376~103033031:+ PAAD cis rs526231 0.578 rs42860 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Primary biliary cholangitis; chr5:103092414 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34806 ENSG00000175749.11 EIF3KP1 5.67 7.07e-08 7.32e-05 0.54 0.42 Parkinson's disease; chr5:103092733 chr5:103032376~103033031:+ PAAD cis rs1061377 0.71 rs12503506 ENSG00000249685.1 RP11-360F5.3 5.67 7.09e-08 7.34e-05 0.43 0.42 Uric acid levels; chr4:39082553 chr4:39133913~39135608:+ PAAD cis rs1075265 0.836 rs1363063 ENSG00000233266.1 HMGB1P31 5.67 7.09e-08 7.34e-05 0.54 0.42 Chronotype;Morning vs. evening chronotype; chr2:54047433 chr2:54051334~54051760:+ PAAD cis rs151227923 1 rs151227923 ENSG00000273117.1 AC144652.1 5.67 7.14e-08 7.39e-05 0.49 0.42 Stem cell growth factor beta levels; chr7:155314854 chr7:155295918~155297541:- PAAD cis rs140365914 1 rs140365914 ENSG00000273117.1 AC144652.1 5.67 7.14e-08 7.39e-05 0.49 0.42 Coronary artery calcified atherosclerotic plaque score in type 2 diabetes; chr7:155314860 chr7:155295918~155297541:- PAAD cis rs10463554 0.963 rs67068617 ENSG00000175749.11 EIF3KP1 5.66 7.17e-08 7.42e-05 0.55 0.42 Parkinson's disease; chr5:103039977 chr5:103032376~103033031:+ PAAD cis rs4218 0.648 rs12910987 ENSG00000277144.1 RP11-59H7.4 -5.66 7.18e-08 7.43e-05 -0.58 -0.42 Social communication problems; chr15:59092782 chr15:59115547~59116089:- PAAD cis rs11098499 0.691 rs17009144 ENSG00000245958.5 RP11-33B1.1 5.66 7.19e-08 7.43e-05 0.3 0.42 Corneal astigmatism; chr4:119349640 chr4:119454791~119552025:+ PAAD cis rs72772090 0.71 rs56122780 ENSG00000248734.2 CTD-2260A17.1 -5.66 7.19e-08 7.44e-05 -0.55 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96724191 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs113710451 ENSG00000248734.2 CTD-2260A17.1 -5.66 7.19e-08 7.44e-05 -0.55 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96724602 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs112178674 ENSG00000248734.2 CTD-2260A17.1 -5.66 7.19e-08 7.44e-05 -0.55 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96724651 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs11745122 ENSG00000248734.2 CTD-2260A17.1 -5.66 7.19e-08 7.44e-05 -0.55 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96725034 chr5:96784777~96785999:+ PAAD cis rs72772090 0.71 rs11750399 ENSG00000248734.2 CTD-2260A17.1 -5.66 7.19e-08 7.44e-05 -0.54 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96742236 chr5:96784777~96785999:+ PAAD cis rs10463554 0.927 rs56361326 ENSG00000175749.11 EIF3KP1 5.66 7.23e-08 7.48e-05 0.54 0.42 Parkinson's disease; chr5:103054184 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs158408 ENSG00000175749.11 EIF3KP1 5.66 7.23e-08 7.48e-05 0.54 0.42 Parkinson's disease; chr5:103071670 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs257317 ENSG00000175749.11 EIF3KP1 5.66 7.23e-08 7.48e-05 0.54 0.42 Parkinson's disease; chr5:103086881 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs34820 ENSG00000175749.11 EIF3KP1 5.66 7.23e-08 7.48e-05 0.54 0.42 Parkinson's disease; chr5:103101164 chr5:103032376~103033031:+ PAAD cis rs2739330 0.796 rs2154594 ENSG00000231271.1 AP000350.8 -5.66 7.24e-08 7.48e-05 -0.56 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23949918~23954042:+ PAAD cis rs6538678 1 rs6538678 ENSG00000258343.1 RP11-536G4.2 -5.66 7.26e-08 7.5e-05 -0.54 -0.42 Lupus nephritis in systemic lupus erythematosus; chr12:95867790 chr12:95795345~95858839:- PAAD cis rs227275 0.554 rs223359 ENSG00000246560.2 RP11-10L12.4 5.66 7.27e-08 7.52e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102849422 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223357 ENSG00000246560.2 RP11-10L12.4 5.66 7.27e-08 7.52e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102851095 chr4:102828055~102844075:+ PAAD cis rs4972806 0.814 rs1446575 ENSG00000226363.3 HAGLROS -5.66 7.28e-08 7.53e-05 -0.51 -0.42 IgG glycosylation; chr2:176183073 chr2:176177717~176179008:+ PAAD cis rs732716 0.719 rs56088814 ENSG00000267980.1 AC007292.6 -5.66 7.29e-08 7.53e-05 -0.56 -0.42 Mean corpuscular volume; chr19:4422181 chr19:4363789~4364640:+ PAAD cis rs12701220 0.655 rs11489405 ENSG00000229043.2 AC091729.9 -5.66 7.3e-08 7.55e-05 -0.57 -0.42 Bronchopulmonary dysplasia; chr7:1100256 chr7:1160374~1165267:+ PAAD cis rs227275 0.554 rs149576 ENSG00000246560.2 RP11-10L12.4 5.66 7.31e-08 7.55e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102811411 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223377 ENSG00000246560.2 RP11-10L12.4 5.66 7.31e-08 7.55e-05 0.46 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102834919 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223367 ENSG00000246560.2 RP11-10L12.4 5.66 7.32e-08 7.56e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102843836 chr4:102828055~102844075:+ PAAD cis rs2281636 0.66 rs7072263 ENSG00000233690.1 EBAG9P1 5.66 7.32e-08 7.56e-05 0.5 0.42 Obesity-related traits; chr10:99607888 chr10:99697407~99697949:- PAAD cis rs453301 0.624 rs2979256 ENSG00000253893.2 FAM85B -5.66 7.33e-08 7.57e-05 -0.55 -0.42 Joint mobility (Beighton score); chr8:9014200 chr8:8167819~8226614:- PAAD cis rs227275 0.554 rs223424 ENSG00000246560.2 RP11-10L12.4 5.66 7.33e-08 7.57e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102804177 chr4:102828055~102844075:+ PAAD cis rs149313 0.901 rs697976 ENSG00000248734.2 CTD-2260A17.1 5.66 7.34e-08 7.58e-05 0.37 0.42 Blood protein levels; chr5:96733063 chr5:96784777~96785999:+ PAAD cis rs113835537 0.529 rs3892818 ENSG00000255517.5 CTD-3074O7.5 -5.66 7.34e-08 7.58e-05 -0.52 -0.42 Airway imaging phenotypes; chr11:66472720 chr11:66473490~66480233:- PAAD cis rs9326248 1 rs585849 ENSG00000280143.1 AP000892.6 5.66 7.34e-08 7.58e-05 0.53 0.42 Blood protein levels; chr11:117198345 chr11:117204967~117210292:+ PAAD cis rs10463554 0.553 rs72785712 ENSG00000175749.11 EIF3KP1 5.66 7.35e-08 7.58e-05 0.53 0.42 Parkinson's disease; chr5:102988693 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs3776863 ENSG00000175749.11 EIF3KP1 5.66 7.35e-08 7.58e-05 0.53 0.42 Primary biliary cholangitis; chr5:102992165 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs17154913 ENSG00000175749.11 EIF3KP1 5.66 7.35e-08 7.58e-05 0.53 0.42 Primary biliary cholangitis; chr5:102992786 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs7714539 ENSG00000175749.11 EIF3KP1 5.66 7.35e-08 7.58e-05 0.53 0.42 Primary biliary cholangitis; chr5:102993174 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs60633061 ENSG00000175749.11 EIF3KP1 5.66 7.35e-08 7.58e-05 0.53 0.42 Primary biliary cholangitis; chr5:102994345 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs62362544 ENSG00000175749.11 EIF3KP1 5.66 7.35e-08 7.58e-05 0.53 0.42 Primary biliary cholangitis; chr5:102998543 chr5:103032376~103033031:+ PAAD cis rs526231 0.575 rs55652053 ENSG00000175749.11 EIF3KP1 5.66 7.35e-08 7.58e-05 0.53 0.42 Primary biliary cholangitis; chr5:103001466 chr5:103032376~103033031:+ PAAD cis rs2882667 0.858 rs11948429 ENSG00000253404.1 AC034243.1 5.66 7.37e-08 7.6e-05 0.51 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139122895 chr5:138744434~138753309:- PAAD cis rs2882667 0.858 rs2043271 ENSG00000253404.1 AC034243.1 5.66 7.37e-08 7.6e-05 0.51 0.42 Age-related hearing impairment (SNP x SNP interaction); chr5:139123419 chr5:138744434~138753309:- PAAD cis rs227275 0.554 rs223457 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102788506 chr4:102828055~102844075:+ PAAD cis rs227275 0.524 rs150894 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102811541 chr4:102828055~102844075:+ PAAD cis rs11722779 0.692 rs223414 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Schizophrenia; chr4:102811688 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223409 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102815023 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223404 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102816951 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223399 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102820800 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223395 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102823801 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223388 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102828287 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223386 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102829111 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223385 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102829159 chr4:102828055~102844075:+ PAAD cis rs11722779 0.873 rs223384 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Schizophrenia; chr4:102829976 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223383 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102830094 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223382 ENSG00000246560.2 RP11-10L12.4 5.66 7.37e-08 7.6e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102831145 chr4:102828055~102844075:+ PAAD cis rs1061377 0.748 rs10856841 ENSG00000249207.1 RP11-360F5.1 -5.66 7.37e-08 7.6e-05 -0.44 -0.42 Uric acid levels; chr4:39095240 chr4:39112677~39126818:- PAAD cis rs950169 0.58 rs11630887 ENSG00000225151.9 GOLGA2P7 -5.66 7.38e-08 7.61e-05 -0.5 -0.42 Schizophrenia; chr15:84649784 chr15:84199311~84230136:- PAAD cis rs10463554 0.856 rs26427 ENSG00000175749.11 EIF3KP1 -5.66 7.38e-08 7.62e-05 -0.53 -0.42 Parkinson's disease; chr5:103031079 chr5:103032376~103033031:+ PAAD cis rs10463554 0.926 rs26433 ENSG00000175749.11 EIF3KP1 5.66 7.38e-08 7.62e-05 0.53 0.42 Parkinson's disease; chr5:103028154 chr5:103032376~103033031:+ PAAD cis rs465969 0.744 rs7758483 ENSG00000255389.1 C6orf3 -5.66 7.39e-08 7.63e-05 -0.69 -0.42 Psoriasis; chr6:111467945 chr6:111599875~111602295:+ PAAD cis rs227275 0.554 rs150895 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102791432 chr4:102828055~102844075:+ PAAD cis rs227275 0.586 rs223448 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102792189 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223442 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102793960 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223441 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102794228 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223439 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102798377 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223436 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102798749 chr4:102828055~102844075:+ PAAD cis rs227275 0.524 rs223423 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102804737 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223422 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102805616 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223421 ENSG00000246560.2 RP11-10L12.4 5.66 7.41e-08 7.64e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102805861 chr4:102828055~102844075:+ PAAD cis rs2455601 0.608 rs59025804 ENSG00000254860.4 TMEM9B-AS1 5.65 7.54e-08 7.77e-05 0.49 0.42 Schizophrenia; chr11:8848754 chr11:8964675~8977527:+ PAAD cis rs6683071 1 rs6683071 ENSG00000272750.1 RP11-378J18.8 -5.65 7.57e-08 7.79e-05 -0.51 -0.42 Cognitive performance; chr1:222750009 chr1:222658867~222661512:- PAAD cis rs2564921 0.765 rs35333155 ENSG00000242142.1 SERBP1P3 5.65 7.59e-08 7.81e-05 0.48 0.42 Height; chr3:53073764 chr3:53064283~53065091:- PAAD cis rs2564921 0.765 rs2581799 ENSG00000242142.1 SERBP1P3 -5.65 7.59e-08 7.81e-05 -0.48 -0.42 Height; chr3:53074760 chr3:53064283~53065091:- PAAD cis rs7174755 0.923 rs4777033 ENSG00000260657.2 RP11-315D16.4 -5.65 7.61e-08 7.83e-05 -0.52 -0.42 Major depressive disorder; chr15:68308010 chr15:68267792~68277994:- PAAD cis rs7174755 0.962 rs4777034 ENSG00000260657.2 RP11-315D16.4 -5.65 7.61e-08 7.83e-05 -0.52 -0.42 Major depressive disorder; chr15:68309546 chr15:68267792~68277994:- PAAD cis rs7174755 0.962 rs1020842 ENSG00000260657.2 RP11-315D16.4 -5.65 7.61e-08 7.83e-05 -0.52 -0.42 Major depressive disorder; chr15:68309840 chr15:68267792~68277994:- PAAD cis rs7174755 0.923 rs898590 ENSG00000260657.2 RP11-315D16.4 -5.65 7.61e-08 7.83e-05 -0.52 -0.42 Major depressive disorder; chr15:68311837 chr15:68267792~68277994:- PAAD cis rs1075265 0.73 rs11893270 ENSG00000233266.1 HMGB1P31 5.65 7.62e-08 7.84e-05 0.53 0.42 Chronotype;Morning vs. evening chronotype; chr2:54019828 chr2:54051334~54051760:+ PAAD cis rs3762637 1 rs9843165 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122412264 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs12630576 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122420670 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs55853677 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122421769 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs3762637 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122426477 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9833415 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122440993 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9882100 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122451061 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9968189 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122456289 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs60222267 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122460785 chr3:122416207~122443180:+ PAAD cis rs3762637 0.882 rs56074178 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122461164 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs72958458 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122466702 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs7642869 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122471939 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs7617042 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122472138 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs6790051 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122473999 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9878699 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122475384 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs12638866 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122475535 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs10049131 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122483255 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs9867429 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122513821 chr3:122416207~122443180:+ PAAD cis rs3762637 0.823 rs59569049 ENSG00000272758.4 RP11-299J3.8 -5.65 7.63e-08 7.84e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122519941 chr3:122416207~122443180:+ PAAD cis rs2337406 0.866 rs7140974 ENSG00000274576.2 IGHV2-70 -5.65 7.63e-08 7.84e-05 -0.54 -0.42 Alzheimer's disease (late onset); chr14:106795976 chr14:106770577~106771020:- PAAD cis rs4218 0.608 rs34859729 ENSG00000277144.1 RP11-59H7.4 -5.65 7.64e-08 7.85e-05 -0.58 -0.42 Social communication problems; chr15:59070117 chr15:59115547~59116089:- PAAD cis rs227275 0.554 rs223466 ENSG00000246560.2 RP11-10L12.4 5.65 7.64e-08 7.85e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102780039 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs223461 ENSG00000246560.2 RP11-10L12.4 5.65 7.64e-08 7.85e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102782372 chr4:102828055~102844075:+ PAAD cis rs2337406 0.866 rs112089985 ENSG00000274576.2 IGHV2-70 -5.65 7.65e-08 7.86e-05 -0.51 -0.42 Alzheimer's disease (late onset); chr14:106780074 chr14:106770577~106771020:- PAAD cis rs113835537 0.529 rs11227495 ENSG00000255517.5 CTD-3074O7.5 -5.65 7.65e-08 7.86e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66495772 chr11:66473490~66480233:- PAAD cis rs113835537 0.559 rs11227498 ENSG00000255517.5 CTD-3074O7.5 -5.65 7.65e-08 7.86e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66502243 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227509 ENSG00000255517.5 CTD-3074O7.5 -5.65 7.65e-08 7.86e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66513723 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227510 ENSG00000255517.5 CTD-3074O7.5 -5.65 7.65e-08 7.86e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66513749 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227512 ENSG00000255517.5 CTD-3074O7.5 -5.65 7.65e-08 7.86e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66513820 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs2298806 ENSG00000255517.5 CTD-3074O7.5 -5.65 7.65e-08 7.86e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66514624 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs2276406 ENSG00000255517.5 CTD-3074O7.5 -5.65 7.65e-08 7.86e-05 -0.55 -0.42 Airway imaging phenotypes; chr11:66515786 chr11:66473490~66480233:- PAAD cis rs9322193 0.923 rs12174035 ENSG00000216906.2 RP11-350J20.9 5.65 7.66e-08 7.86e-05 0.53 0.42 Lung cancer; chr6:149763311 chr6:149904243~149906418:+ PAAD cis rs17301013 0.507 rs3118988 ENSG00000227373.4 RP11-160H22.5 -5.65 7.66e-08 7.86e-05 -0.61 -0.42 Systemic lupus erythematosus; chr1:174819245 chr1:174115300~174160004:- PAAD cis rs6142102 0.502 rs58393429 ENSG00000276073.1 RP5-1125A11.7 -5.65 7.66e-08 7.87e-05 -0.44 -0.42 Skin pigmentation; chr20:33957996 chr20:33985617~33988989:- PAAD cis rs7580658 0.676 rs2174270 ENSG00000236682.1 AC068282.3 -5.65 7.66e-08 7.87e-05 -0.53 -0.42 Protein C levels; chr2:127248502 chr2:127389130~127400580:+ PAAD cis rs17301013 0.932 rs6425280 ENSG00000227373.4 RP11-160H22.5 5.65 7.68e-08 7.89e-05 0.53 0.42 Systemic lupus erythematosus; chr1:174422186 chr1:174115300~174160004:- PAAD cis rs1075265 0.749 rs805375 ENSG00000233266.1 HMGB1P31 5.65 7.69e-08 7.9e-05 0.54 0.42 Chronotype;Morning vs. evening chronotype; chr2:53863268 chr2:54051334~54051760:+ PAAD cis rs1075265 0.749 rs805380 ENSG00000233266.1 HMGB1P31 5.65 7.69e-08 7.9e-05 0.54 0.42 Chronotype;Morning vs. evening chronotype; chr2:53867284 chr2:54051334~54051760:+ PAAD cis rs7429990 0.864 rs4274776 ENSG00000229759.1 MRPS18AP1 5.65 7.7e-08 7.9e-05 0.45 0.42 Educational attainment (years of education); chr3:47605868 chr3:48256350~48256938:- PAAD cis rs7208859 0.623 rs426434 ENSG00000266490.1 CTD-2349P21.9 5.65 7.7e-08 7.9e-05 0.5 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30598335 chr17:30792372~30792833:+ PAAD cis rs6570726 0.577 rs867056 ENSG00000235652.6 RP11-545I5.3 -5.65 7.71e-08 7.91e-05 -0.35 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145463669 chr6:145799409~145886585:+ PAAD cis rs10875746 0.729 rs11168355 ENSG00000240399.1 RP1-228P16.1 5.65 7.72e-08 7.92e-05 0.45 0.42 Longevity (90 years and older); chr12:48017195 chr12:48054813~48055591:- PAAD cis rs9640161 0.75 rs11769348 ENSG00000261305.1 RP4-584D14.7 -5.65 7.73e-08 7.93e-05 -0.64 -0.42 Blood protein levels;Circulating chemerin levels; chr7:150329664 chr7:150341771~150342607:+ PAAD cis rs1150668 0.796 rs9468372 ENSG00000204709.4 LINC01556 5.65 7.75e-08 7.94e-05 0.54 0.42 Pubertal anthropometrics; chr6:28411584 chr6:28943877~28944537:+ PAAD cis rs453301 0.624 rs4841083 ENSG00000253893.2 FAM85B -5.65 7.75e-08 7.94e-05 -0.55 -0.42 Joint mobility (Beighton score); chr8:9012918 chr8:8167819~8226614:- PAAD cis rs11098499 0.909 rs79026312 ENSG00000245958.5 RP11-33B1.1 -5.65 7.75e-08 7.95e-05 -0.36 -0.42 Corneal astigmatism; chr4:119519522 chr4:119454791~119552025:+ PAAD cis rs11098499 0.909 rs35111518 ENSG00000245958.5 RP11-33B1.1 -5.65 7.75e-08 7.95e-05 -0.36 -0.42 Corneal astigmatism; chr4:119519527 chr4:119454791~119552025:+ PAAD cis rs12908161 0.959 rs1051168 ENSG00000225151.9 GOLGA2P7 -5.65 7.78e-08 7.97e-05 -0.5 -0.42 Schizophrenia; chr15:84657289 chr15:84199311~84230136:- PAAD cis rs228614 0.51 rs223405 ENSG00000246560.2 RP11-10L12.4 5.65 7.78e-08 7.97e-05 0.46 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102815894 chr4:102828055~102844075:+ PAAD cis rs2281636 0.723 rs11190246 ENSG00000233690.1 EBAG9P1 5.65 7.82e-08 8.01e-05 0.49 0.42 Obesity-related traits; chr10:99691854 chr10:99697407~99697949:- PAAD cis rs453301 0.624 rs2979265 ENSG00000253893.2 FAM85B -5.65 7.84e-08 8.03e-05 -0.55 -0.42 Joint mobility (Beighton score); chr8:9001207 chr8:8167819~8226614:- PAAD cis rs11722779 0.933 rs7695096 ENSG00000246560.2 RP11-10L12.4 5.65 7.85e-08 8.03e-05 0.46 0.42 Schizophrenia; chr4:103011399 chr4:102828055~102844075:+ PAAD cis rs7829975 0.511 rs2921028 ENSG00000253893.2 FAM85B -5.65 7.86e-08 8.05e-05 -0.57 -0.42 Mood instability; chr8:8482967 chr8:8167819~8226614:- PAAD cis rs7201929 1 rs7499878 ENSG00000259982.1 CDC37P1 -5.65 7.86e-08 8.05e-05 -0.53 -0.42 QT interval; chr16:28857143 chr16:28700294~28701540:- PAAD cis rs17711722 0.522 rs62469933 ENSG00000234585.5 CCT6P3 5.65 7.87e-08 8.05e-05 0.34 0.42 Calcium levels; chr7:65800652 chr7:65038354~65074713:+ PAAD cis rs3761847 0.651 rs1323472 ENSG00000226752.6 PSMD5-AS1 -5.65 7.87e-08 8.05e-05 -0.46 -0.42 Rheumatoid arthritis; chr9:121064057 chr9:120824828~120854385:+ PAAD cis rs875971 0.862 rs1612452 ENSG00000237310.1 GS1-124K5.4 -5.65 7.87e-08 8.06e-05 -0.42 -0.42 Aortic root size; chr7:66108909 chr7:66493706~66495474:+ PAAD cis rs7104764 0.778 rs7930823 ENSG00000277290.1 RP11-326C3.16 5.64 7.88e-08 8.06e-05 0.35 0.42 Menarche (age at onset); chr11:206767 chr11:243099~243483:- PAAD cis rs8091660 0.929 rs4939780 ENSG00000278983.1 RP11-426J5.3 5.64 7.89e-08 8.07e-05 0.5 0.42 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48568873 chr18:48564795~48568342:+ PAAD cis rs992157 0.932 rs1870125 ENSG00000261338.2 RP11-378A13.1 5.64 7.89e-08 8.07e-05 0.47 0.42 Colorectal cancer; chr2:218323178 chr2:218255319~218257366:+ PAAD cis rs4722166 0.63 rs2091115 ENSG00000179428.2 AC073072.5 -5.64 7.89e-08 8.08e-05 -0.38 -0.42 Lung cancer; chr7:22770547 chr7:22725395~22727620:- PAAD cis rs6142102 0.625 rs4911138 ENSG00000276073.1 RP5-1125A11.7 -5.64 7.9e-08 8.08e-05 -0.44 -0.42 Skin pigmentation; chr20:33959893 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs4243974 ENSG00000276073.1 RP5-1125A11.7 -5.64 7.9e-08 8.08e-05 -0.44 -0.42 Skin pigmentation; chr20:33960062 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs6142061 ENSG00000276073.1 RP5-1125A11.7 -5.64 7.9e-08 8.08e-05 -0.44 -0.42 Skin pigmentation; chr20:33960529 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs6142062 ENSG00000276073.1 RP5-1125A11.7 -5.64 7.9e-08 8.08e-05 -0.44 -0.42 Skin pigmentation; chr20:33960706 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs6141432 ENSG00000276073.1 RP5-1125A11.7 -5.64 7.9e-08 8.08e-05 -0.44 -0.42 Skin pigmentation; chr20:33960791 chr20:33985617~33988989:- PAAD cis rs6142102 0.602 rs6141433 ENSG00000276073.1 RP5-1125A11.7 -5.64 7.9e-08 8.08e-05 -0.44 -0.42 Skin pigmentation; chr20:33961056 chr20:33985617~33988989:- PAAD cis rs4218 0.551 rs12906212 ENSG00000277144.1 RP11-59H7.4 -5.64 7.96e-08 8.14e-05 -0.58 -0.42 Social communication problems; chr15:59070556 chr15:59115547~59116089:- PAAD cis rs4218 0.648 rs34407560 ENSG00000277144.1 RP11-59H7.4 -5.64 7.96e-08 8.14e-05 -0.58 -0.42 Social communication problems; chr15:59073397 chr15:59115547~59116089:- PAAD cis rs4218 0.648 rs12442134 ENSG00000277144.1 RP11-59H7.4 -5.64 7.96e-08 8.14e-05 -0.58 -0.42 Social communication problems; chr15:59074478 chr15:59115547~59116089:- PAAD cis rs3762637 1 rs10934602 ENSG00000272758.4 RP11-299J3.8 5.64 7.96e-08 8.14e-05 0.62 0.42 LDL cholesterol levels; chr3:122504335 chr3:122416207~122443180:+ PAAD cis rs9926296 0.548 rs6500439 ENSG00000260259.1 RP11-368I7.4 -5.64 7.97e-08 8.14e-05 -0.51 -0.42 Vitiligo; chr16:89741867 chr16:89682620~89686569:- PAAD cis rs755249 0.753 rs72663529 ENSG00000237624.1 OXCT2P1 5.64 7.99e-08 8.16e-05 0.54 0.42 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557684 chr1:39514956~39516490:+ PAAD cis rs3762637 1 rs7645862 ENSG00000272758.4 RP11-299J3.8 -5.64 8.02e-08 8.19e-05 -0.62 -0.42 LDL cholesterol levels; chr3:122502292 chr3:122416207~122443180:+ PAAD cis rs2658782 0.547 rs3020064 ENSG00000279684.1 RP11-755E23.2 -5.64 8.02e-08 8.2e-05 -0.61 -0.42 Pulmonary function decline; chr11:93327685 chr11:93286629~93288903:- PAAD cis rs733592 0.524 rs10875741 ENSG00000240399.1 RP1-228P16.1 -5.64 8.06e-08 8.21e-05 -0.39 -0.42 Plateletcrit; chr12:48099139 chr12:48054813~48055591:- PAAD cis rs733592 0.507 rs7304428 ENSG00000240399.1 RP1-228P16.1 -5.64 8.06e-08 8.21e-05 -0.39 -0.42 Plateletcrit; chr12:48100492 chr12:48054813~48055591:- PAAD cis rs733592 0.524 rs10875744 ENSG00000240399.1 RP1-228P16.1 5.64 8.06e-08 8.21e-05 0.39 0.42 Plateletcrit; chr12:48104657 chr12:48054813~48055591:- PAAD cis rs11722779 0.873 rs6533041 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Schizophrenia; chr4:102951615 chr4:102828055~102844075:+ PAAD cis rs11722779 0.935 rs3857199 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Schizophrenia; chr4:102957991 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs5028609 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102959294 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs6815540 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102959922 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs4698867 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102961049 chr4:102828055~102844075:+ PAAD cis rs11722779 0.658 rs6533044 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Schizophrenia; chr4:102965261 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs7663876 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102966174 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs6533050 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102979044 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs10032234 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102980538 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs28845922 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102981959 chr4:102828055~102844075:+ PAAD cis rs228614 0.517 rs3886722 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102983084 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs11737544 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102983877 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs7672319 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102990002 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs6533051 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102990065 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs6533052 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102990624 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs3974485 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102993283 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs7688940 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102994153 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs11097796 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103002401 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs11097797 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103002507 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs13117110 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103003981 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs13144033 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103004032 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs10029073 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103006991 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs724446 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103010206 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs28445579 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103016438 chr4:102828055~102844075:+ PAAD cis rs11722779 0.935 rs7676736 ENSG00000246560.2 RP11-10L12.4 5.64 8.06e-08 8.21e-05 0.46 0.42 Schizophrenia; chr4:103016729 chr4:102828055~102844075:+ PAAD cis rs2243480 1 rs34703416 ENSG00000226824.5 RP4-756H11.3 -5.64 8.06e-08 8.22e-05 -0.76 -0.42 Diabetic kidney disease; chr7:65835655 chr7:66654538~66669855:+ PAAD cis rs2739330 0.627 rs9608219 ENSG00000206090.4 AP000350.7 5.64 8.07e-08 8.22e-05 0.54 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23931932 chr22:23939998~23942798:+ PAAD cis rs7945705 0.934 rs1988709 ENSG00000254860.4 TMEM9B-AS1 -5.64 8.07e-08 8.23e-05 -0.46 -0.42 Hemoglobin concentration; chr11:8861343 chr11:8964675~8977527:+ PAAD cis rs72772090 0.614 rs10447215 ENSG00000248734.2 CTD-2260A17.1 -5.64 8.09e-08 8.24e-05 -0.54 -0.42 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96720669 chr5:96784777~96785999:+ PAAD cis rs2108622 0.727 rs7251296 ENSG00000267453.5 AC004791.2 -5.64 8.09e-08 8.24e-05 -0.6 -0.42 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15872926 chr19:15851993~15864904:- PAAD cis rs9425766 0.679 rs6656188 ENSG00000227373.4 RP11-160H22.5 5.64 8.1e-08 8.25e-05 0.54 0.42 Life satisfaction; chr1:174183550 chr1:174115300~174160004:- PAAD cis rs11098499 0.82 rs28578366 ENSG00000245958.5 RP11-33B1.1 5.64 8.11e-08 8.26e-05 0.35 0.42 Corneal astigmatism; chr4:119615750 chr4:119454791~119552025:+ PAAD cis rs734999 1 rs10797432 ENSG00000225931.3 RP3-395M20.7 5.64 8.11e-08 8.26e-05 0.4 0.42 Ulcerative colitis; chr1:2569899 chr1:2566410~2569888:+ PAAD cis rs35160687 0.842 rs1863052 ENSG00000273080.1 RP11-301O19.1 5.64 8.14e-08 8.29e-05 0.48 0.42 Night sleep phenotypes; chr2:86332235 chr2:86195590~86196049:+ PAAD cis rs35160687 0.736 rs6746198 ENSG00000273080.1 RP11-301O19.1 -5.64 8.14e-08 8.29e-05 -0.48 -0.42 Night sleep phenotypes; chr2:86314990 chr2:86195590~86196049:+ PAAD cis rs35160687 0.842 rs10200619 ENSG00000273080.1 RP11-301O19.1 -5.64 8.14e-08 8.29e-05 -0.48 -0.42 Night sleep phenotypes; chr2:86321725 chr2:86195590~86196049:+ PAAD cis rs35160687 0.842 rs7593440 ENSG00000273080.1 RP11-301O19.1 -5.64 8.14e-08 8.29e-05 -0.48 -0.42 Night sleep phenotypes; chr2:86323534 chr2:86195590~86196049:+ PAAD cis rs35160687 0.814 rs4392258 ENSG00000273080.1 RP11-301O19.1 -5.64 8.14e-08 8.29e-05 -0.48 -0.42 Night sleep phenotypes; chr2:86325454 chr2:86195590~86196049:+ PAAD cis rs35160687 0.842 rs11685863 ENSG00000273080.1 RP11-301O19.1 -5.64 8.14e-08 8.29e-05 -0.48 -0.42 Night sleep phenotypes; chr2:86327361 chr2:86195590~86196049:+ PAAD cis rs7429990 0.76 rs319694 ENSG00000229759.1 MRPS18AP1 5.64 8.15e-08 8.29e-05 0.46 0.42 Educational attainment (years of education); chr3:47843463 chr3:48256350~48256938:- PAAD cis rs7772486 0.79 rs9390365 ENSG00000235652.6 RP11-545I5.3 -5.64 8.16e-08 8.3e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145914490 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs6917482 ENSG00000235652.6 RP11-545I5.3 -5.64 8.16e-08 8.3e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145922445 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs4566902 ENSG00000235652.6 RP11-545I5.3 -5.64 8.16e-08 8.3e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145922992 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs6923545 ENSG00000235652.6 RP11-545I5.3 -5.64 8.16e-08 8.3e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145923607 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs6922507 ENSG00000235652.6 RP11-545I5.3 -5.64 8.16e-08 8.3e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145929019 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs4075694 ENSG00000235652.6 RP11-545I5.3 -5.64 8.16e-08 8.3e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145929972 chr6:145799409~145886585:+ PAAD cis rs11098499 0.818 rs55825515 ENSG00000245958.5 RP11-33B1.1 -5.64 8.16e-08 8.3e-05 -0.36 -0.42 Corneal astigmatism; chr4:119565247 chr4:119454791~119552025:+ PAAD cis rs10463554 0.963 rs32850 ENSG00000175749.11 EIF3KP1 5.64 8.16e-08 8.3e-05 0.54 0.42 Parkinson's disease; chr5:103134325 chr5:103032376~103033031:+ PAAD cis rs7772486 0.875 rs9322043 ENSG00000235652.6 RP11-545I5.3 5.64 8.17e-08 8.32e-05 0.34 0.42 Lobe attachment (rater-scored or self-reported); chr6:146031554 chr6:145799409~145886585:+ PAAD cis rs227275 0.525 rs4698874 ENSG00000246560.2 RP11-10L12.4 5.64 8.18e-08 8.32e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103009354 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs4699046 ENSG00000246560.2 RP11-10L12.4 5.64 8.19e-08 8.34e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103004514 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs4699047 ENSG00000246560.2 RP11-10L12.4 5.64 8.19e-08 8.34e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103005385 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs28778380 ENSG00000246560.2 RP11-10L12.4 5.64 8.19e-08 8.34e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103006416 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs13150426 ENSG00000246560.2 RP11-10L12.4 5.64 8.19e-08 8.34e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103013743 chr4:102828055~102844075:+ PAAD cis rs9322193 0.962 rs4870048 ENSG00000216906.2 RP11-350J20.9 5.64 8.21e-08 8.35e-05 0.53 0.42 Lung cancer; chr6:149834324 chr6:149904243~149906418:+ PAAD cis rs227275 0.525 rs4699037 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102957010 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs3857198 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102957720 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs4699039 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102958354 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs6821173 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102966404 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs3886723 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102983013 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs7685399 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102991926 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs2866417 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102993481 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs1383733 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:102995297 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs4623004 ENSG00000246560.2 RP11-10L12.4 5.64 8.21e-08 8.35e-05 0.46 0.42 Allergic disease (asthma, hay fever or eczema); chr4:103000141 chr4:102828055~102844075:+ PAAD cis rs7772486 0.905 rs9373486 ENSG00000235652.6 RP11-545I5.3 -5.64 8.22e-08 8.36e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:146124888 chr6:145799409~145886585:+ PAAD cis rs1009647 1 rs35502084 ENSG00000258413.1 RP11-665C16.6 -5.64 8.22e-08 8.36e-05 -0.59 -0.42 Testicular germ cell tumor; chr14:55409545 chr14:55262767~55272075:- PAAD cis rs1061377 0.748 rs35904472 ENSG00000249207.1 RP11-360F5.1 -5.64 8.24e-08 8.37e-05 -0.44 -0.42 Uric acid levels; chr4:39094901 chr4:39112677~39126818:- PAAD cis rs2739330 0.828 rs4820572 ENSG00000231271.1 AP000350.8 5.63 8.26e-08 8.4e-05 0.56 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23949918~23954042:+ PAAD cis rs2739330 0.796 rs5760106 ENSG00000231271.1 AP000350.8 -5.63 8.28e-08 8.41e-05 -0.56 -0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23949918~23954042:+ PAAD cis rs673078 0.607 rs7295288 ENSG00000275759.1 RP11-131L12.3 -5.63 8.28e-08 8.41e-05 -0.6 -0.42 Glucose homeostasis traits; chr12:118418008 chr12:118428281~118428870:+ PAAD cis rs17711722 0.522 rs6957759 ENSG00000234585.5 CCT6P3 5.63 8.29e-08 8.42e-05 0.34 0.42 Calcium levels; chr7:65806798 chr7:65038354~65074713:+ PAAD cis rs11098499 0.78 rs12504773 ENSG00000245958.5 RP11-33B1.1 -5.63 8.31e-08 8.44e-05 -0.35 -0.42 Corneal astigmatism; chr4:119640994 chr4:119454791~119552025:+ PAAD cis rs11098499 0.78 rs7680914 ENSG00000245958.5 RP11-33B1.1 -5.63 8.31e-08 8.44e-05 -0.35 -0.42 Corneal astigmatism; chr4:119641898 chr4:119454791~119552025:+ PAAD cis rs2281636 0.66 rs61871318 ENSG00000233690.1 EBAG9P1 5.63 8.35e-08 8.48e-05 0.5 0.42 Obesity-related traits; chr10:99606784 chr10:99697407~99697949:- PAAD cis rs9640161 0.83 rs17173681 ENSG00000261305.1 RP4-584D14.7 -5.63 8.35e-08 8.48e-05 -0.58 -0.42 Blood protein levels;Circulating chemerin levels; chr7:150362325 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs34311995 ENSG00000261305.1 RP4-584D14.7 5.63 8.35e-08 8.48e-05 0.58 0.42 Blood protein levels;Circulating chemerin levels; chr7:150362166 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs76741564 ENSG00000261305.1 RP4-584D14.7 5.63 8.35e-08 8.48e-05 0.58 0.42 Blood protein levels;Circulating chemerin levels; chr7:150362440 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs17173682 ENSG00000261305.1 RP4-584D14.7 5.63 8.35e-08 8.48e-05 0.58 0.42 Blood protein levels;Circulating chemerin levels; chr7:150362513 chr7:150341771~150342607:+ PAAD cis rs9640161 0.783 rs1132261 ENSG00000261305.1 RP4-584D14.7 5.63 8.35e-08 8.48e-05 0.58 0.42 Blood protein levels;Circulating chemerin levels; chr7:150362898 chr7:150341771~150342607:+ PAAD cis rs6570726 0.791 rs383841 ENSG00000235652.6 RP11-545I5.3 -5.63 8.35e-08 8.48e-05 -0.34 -0.42 Lobe attachment (rater-scored or self-reported); chr6:145567193 chr6:145799409~145886585:+ PAAD cis rs2019137 0.868 rs3748916 ENSG00000189223.12 PAX8-AS1 5.63 8.36e-08 8.49e-05 0.5 0.42 Lymphocyte counts; chr2:113226456 chr2:113211522~113276581:+ PAAD cis rs6565180 0.963 rs4787642 ENSG00000183604.13 SMG1P5 -5.63 8.38e-08 8.51e-05 -0.47 -0.42 Tonsillectomy; chr16:30348087 chr16:30267553~30335374:- PAAD cis rs1263173 0.696 rs1263172 ENSG00000254851.1 RP11-109L13.1 -5.63 8.39e-08 8.51e-05 -0.65 -0.42 HDL cholesterol; chr11:116810202 chr11:117135528~117138582:+ PAAD cis rs10463554 0.927 rs34811 ENSG00000175749.11 EIF3KP1 5.63 8.45e-08 8.57e-05 0.54 0.42 Parkinson's disease; chr5:103096117 chr5:103032376~103033031:+ PAAD cis rs4218 0.517 rs71480503 ENSG00000277144.1 RP11-59H7.4 -5.63 8.46e-08 8.58e-05 -0.59 -0.42 Social communication problems; chr15:59098246 chr15:59115547~59116089:- PAAD cis rs6142102 0.625 rs6141431 ENSG00000276073.1 RP5-1125A11.7 -5.63 8.47e-08 8.59e-05 -0.43 -0.42 Skin pigmentation; chr20:33952508 chr20:33985617~33988989:- PAAD cis rs6142102 0.625 rs9753690 ENSG00000276073.1 RP5-1125A11.7 -5.63 8.47e-08 8.59e-05 -0.43 -0.42 Skin pigmentation; chr20:33952995 chr20:33985617~33988989:- PAAD cis rs6142102 0.58 rs9753679 ENSG00000276073.1 RP5-1125A11.7 -5.63 8.47e-08 8.59e-05 -0.43 -0.42 Skin pigmentation; chr20:33953054 chr20:33985617~33988989:- PAAD cis rs1075265 0.548 rs805448 ENSG00000233266.1 HMGB1P31 5.63 8.47e-08 8.59e-05 0.54 0.42 Chronotype;Morning vs. evening chronotype; chr2:53950055 chr2:54051334~54051760:+ PAAD cis rs7188445 1 rs11644836 ENSG00000261390.4 RP11-345M22.2 -5.63 8.49e-08 8.6e-05 -0.56 -0.42 Urate levels; chr16:79678758 chr16:79715232~79770563:- PAAD cis rs1075232 0.677 rs72714666 ENSG00000270055.1 CTD-3092A11.2 -5.63 8.5e-08 8.61e-05 -0.95 -0.42 Survival in colorectal cancer (non-distant metastatic); chr15:31200023 chr15:30487963~30490313:+ PAAD cis rs9425766 0.692 rs4652294 ENSG00000227373.4 RP11-160H22.5 5.63 8.5e-08 8.62e-05 0.53 0.42 Life satisfaction; chr1:174272027 chr1:174115300~174160004:- PAAD cis rs733592 0.56 rs2158515 ENSG00000240399.1 RP1-228P16.1 -5.63 8.52e-08 8.64e-05 -0.39 -0.42 Plateletcrit; chr12:48113885 chr12:48054813~48055591:- PAAD cis rs673078 0.571 rs7963464 ENSG00000275759.1 RP11-131L12.3 -5.63 8.53e-08 8.65e-05 -0.54 -0.42 Glucose homeostasis traits; chr12:118264924 chr12:118428281~118428870:+ PAAD cis rs7772486 0.764 rs7762562 ENSG00000235652.6 RP11-545I5.3 5.63 8.55e-08 8.67e-05 0.34 0.42 Lobe attachment (rater-scored or self-reported); chr6:145837858 chr6:145799409~145886585:+ PAAD cis rs9640161 0.789 rs34728606 ENSG00000261305.1 RP4-584D14.7 5.63 8.56e-08 8.67e-05 0.61 0.42 Blood protein levels;Circulating chemerin levels; chr7:150357605 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs34495356 ENSG00000261305.1 RP4-584D14.7 5.63 8.56e-08 8.67e-05 0.61 0.42 Blood protein levels;Circulating chemerin levels; chr7:150360702 chr7:150341771~150342607:+ PAAD cis rs9322193 0.847 rs56103941 ENSG00000216906.2 RP11-350J20.9 5.63 8.56e-08 8.68e-05 0.54 0.42 Lung cancer; chr6:149816095 chr6:149904243~149906418:+ PAAD cis rs58873874 0.737 rs78738433 ENSG00000251405.2 CTB-109A12.1 5.63 8.58e-08 8.69e-05 0.87 0.42 Bipolar disorder (body mass index interaction); chr5:157386503 chr5:157362615~157460078:- PAAD cis rs6782228 0.606 rs10048945 ENSG00000242551.2 POU5F1P6 -5.63 8.58e-08 8.69e-05 -0.49 -0.42 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128690837 chr3:128674735~128677005:- PAAD cis rs858239 0.863 rs466225 ENSG00000226816.2 AC005082.12 5.63 8.59e-08 8.7e-05 0.47 0.42 Cerebrospinal fluid biomarker levels; chr7:23292784 chr7:23206013~23208045:+ PAAD cis rs17826219 0.568 rs59858012 ENSG00000266490.1 CTD-2349P21.9 5.63 8.59e-08 8.7e-05 0.56 0.42 Body mass index; chr17:30751564 chr17:30792372~30792833:+ PAAD cis rs172166 0.543 rs1150691 ENSG00000204709.4 LINC01556 5.63 8.6e-08 8.71e-05 0.58 0.42 Cardiac Troponin-T levels; chr6:28200255 chr6:28943877~28944537:+ PAAD cis rs2739330 0.76 rs1007888 ENSG00000231271.1 AP000350.8 5.63 8.65e-08 8.76e-05 0.53 0.42 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23949918~23954042:+ PAAD cis rs12701220 0.655 rs10241018 ENSG00000229043.2 AC091729.9 -5.63 8.66e-08 8.77e-05 -0.54 -0.42 Bronchopulmonary dysplasia; chr7:1105138 chr7:1160374~1165267:+ PAAD cis rs7772486 0.764 rs2265471 ENSG00000235652.6 RP11-545I5.3 5.62 8.67e-08 8.78e-05 0.34 0.42 Lobe attachment (rater-scored or self-reported); chr6:145899114 chr6:145799409~145886585:+ PAAD cis rs7208859 0.623 rs170051 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587135 chr17:30792372~30792833:+ PAAD cis rs7208859 0.51 rs216402 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30590108 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs216434 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595317 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11651857 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30599344 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs216439 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30600866 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs216442 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604179 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs216445 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606558 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs216446 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30606700 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs79607958 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607530 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs75136574 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607531 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs77544470 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30607532 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs609063 ENSG00000266490.1 CTD-2349P21.9 5.62 8.67e-08 8.78e-05 0.52 0.42 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624495 chr17:30792372~30792833:+ PAAD cis rs9322193 0.923 rs10782318 ENSG00000216906.2 RP11-350J20.9 5.62 8.69e-08 8.79e-05 0.53 0.42 Lung cancer; chr6:149754137 chr6:149904243~149906418:+ PAAD cis rs3761847 0.593 rs10985140 ENSG00000226752.6 PSMD5-AS1 -5.62 8.7e-08 8.8e-05 -0.46 -0.42 Rheumatoid arthritis; chr9:121060559 chr9:120824828~120854385:+ PAAD cis rs2243480 1 rs160655 ENSG00000226824.5 RP4-756H11.3 -5.62 8.72e-08 8.82e-05 -0.72 -0.42 Diabetic kidney disease; chr7:66068227 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs160649 ENSG00000226824.5 RP4-756H11.3 -5.62 8.72e-08 8.82e-05 -0.72 -0.42 Diabetic kidney disease; chr7:66078212 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs160648 ENSG00000226824.5 RP4-756H11.3 -5.62 8.72e-08 8.82e-05 -0.72 -0.42 Diabetic kidney disease; chr7:66078397 chr7:66654538~66669855:+ PAAD cis rs2658782 0.547 rs3020054 ENSG00000279684.1 RP11-755E23.2 -5.62 8.72e-08 8.82e-05 -0.59 -0.42 Pulmonary function decline; chr11:93322390 chr11:93286629~93288903:- PAAD cis rs11098499 0.82 rs28535956 ENSG00000245958.5 RP11-33B1.1 5.62 8.73e-08 8.83e-05 0.36 0.41 Corneal astigmatism; chr4:119615703 chr4:119454791~119552025:+ PAAD cis rs11098499 0.73 rs12505735 ENSG00000245958.5 RP11-33B1.1 -5.62 8.73e-08 8.83e-05 -0.36 -0.41 Corneal astigmatism; chr4:119611801 chr4:119454791~119552025:+ PAAD cis rs72772090 0.539 rs11750464 ENSG00000248734.2 CTD-2260A17.1 5.62 8.74e-08 8.84e-05 0.55 0.41 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96777327 chr5:96784777~96785999:+ PAAD cis rs6504950 1 rs12940106 ENSG00000275710.1 RP11-257O5.4 5.62 8.75e-08 8.85e-05 0.56 0.41 Breast cancer; chr17:54990322 chr17:54964474~54964679:+ PAAD cis rs7188445 1 rs12444166 ENSG00000261390.4 RP11-345M22.2 -5.62 8.79e-08 8.88e-05 -0.56 -0.41 Urate levels; chr16:79676053 chr16:79715232~79770563:- PAAD cis rs2243480 0.901 rs73142137 ENSG00000226824.5 RP4-756H11.3 -5.62 8.8e-08 8.89e-05 -0.75 -0.41 Diabetic kidney disease; chr7:65878455 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35735127 ENSG00000226824.5 RP4-756H11.3 -5.62 8.8e-08 8.9e-05 -0.75 -0.41 Diabetic kidney disease; chr7:65835436 chr7:66654538~66669855:+ PAAD cis rs1061377 0.748 rs10856841 ENSG00000249685.1 RP11-360F5.3 5.62 8.84e-08 8.93e-05 0.43 0.41 Uric acid levels; chr4:39095240 chr4:39133913~39135608:+ PAAD cis rs2243480 1 rs160652 ENSG00000226824.5 RP4-756H11.3 -5.62 8.84e-08 8.93e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66073444 chr7:66654538~66669855:+ PAAD cis rs10463554 0.963 rs34829 ENSG00000175749.11 EIF3KP1 5.62 8.85e-08 8.94e-05 0.52 0.41 Parkinson's disease; chr5:103108260 chr5:103032376~103033031:+ PAAD cis rs10771431 0.967 rs7137443 ENSG00000111788.10 RP11-22B23.1 5.62 8.86e-08 8.94e-05 0.38 0.41 Breast size; chr12:9219433 chr12:9277235~9313241:+ PAAD cis rs10771431 0.935 rs1117735 ENSG00000111788.10 RP11-22B23.1 5.62 8.86e-08 8.94e-05 0.38 0.41 Breast size; chr12:9220132 chr12:9277235~9313241:+ PAAD cis rs1061377 0.748 rs35904472 ENSG00000249685.1 RP11-360F5.3 5.62 8.87e-08 8.95e-05 0.43 0.41 Uric acid levels; chr4:39094901 chr4:39133913~39135608:+ PAAD cis rs4218 0.689 rs60262196 ENSG00000277144.1 RP11-59H7.4 -5.62 8.88e-08 8.96e-05 -0.58 -0.41 Social communication problems; chr15:59088853 chr15:59115547~59116089:- PAAD cis rs11673344 0.704 rs1667384 ENSG00000226686.6 LINC01535 5.62 8.89e-08 8.98e-05 0.57 0.41 Obesity-related traits; chr19:36925852 chr19:37251912~37265535:+ PAAD cis rs10510102 0.872 rs7907815 ENSG00000276742.1 RP11-500G22.4 5.62 8.91e-08 9e-05 0.61 0.41 Breast cancer; chr10:121965951 chr10:121956782~121957098:+ PAAD cis rs17301013 0.932 rs1653632 ENSG00000227373.4 RP11-160H22.5 -5.62 8.92e-08 9.01e-05 -0.51 -0.41 Systemic lupus erythematosus; chr1:174786459 chr1:174115300~174160004:- PAAD cis rs2929278 0.589 rs11638972 ENSG00000205771.5 CATSPER2P1 5.62 8.94e-08 9.03e-05 0.56 0.41 Schizophrenia; chr15:43782493 chr15:43726918~43747094:- PAAD cis rs7772486 0.79 rs2254257 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145882588 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2254283 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145883153 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs11760 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145884837 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs1062068 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145886329 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs1062067 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145886427 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2256998 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145886521 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2814880 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145887801 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2247429 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145896633 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2265469 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145897913 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2265918 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145898028 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2247666 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145899273 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2265472 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145899622 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2265919 ENSG00000235652.6 RP11-545I5.3 5.62 8.96e-08 9.03e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145900617 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs3923579 ENSG00000235652.6 RP11-545I5.3 -5.62 8.96e-08 9.03e-05 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145909096 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9403755 ENSG00000235652.6 RP11-545I5.3 -5.62 8.96e-08 9.03e-05 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145910334 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs4435956 ENSG00000235652.6 RP11-545I5.3 -5.62 8.96e-08 9.03e-05 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145911267 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs6926076 ENSG00000235652.6 RP11-545I5.3 -5.62 8.96e-08 9.03e-05 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145911668 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs3924498 ENSG00000235652.6 RP11-545I5.3 -5.62 8.96e-08 9.03e-05 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145912202 chr6:145799409~145886585:+ PAAD cis rs6538678 0.929 rs10777744 ENSG00000258343.1 RP11-536G4.2 -5.62 8.98e-08 9.06e-05 -0.54 -0.41 Lupus nephritis in systemic lupus erythematosus; chr12:95864561 chr12:95795345~95858839:- PAAD cis rs11098499 0.863 rs10004484 ENSG00000245958.5 RP11-33B1.1 -5.62 8.99e-08 9.07e-05 -0.36 -0.41 Corneal astigmatism; chr4:119521273 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs1155576 ENSG00000245958.5 RP11-33B1.1 -5.62 8.99e-08 9.07e-05 -0.36 -0.41 Corneal astigmatism; chr4:119529004 chr4:119454791~119552025:+ PAAD cis rs7772486 0.79 rs3924499 ENSG00000235652.6 RP11-545I5.3 -5.62 9.03e-08 9.1e-05 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145911842 chr6:145799409~145886585:+ PAAD cis rs10463554 0.963 rs40093 ENSG00000175749.11 EIF3KP1 5.62 9.04e-08 9.11e-05 0.55 0.41 Parkinson's disease; chr5:103104121 chr5:103032376~103033031:+ PAAD cis rs9926296 0.512 rs11076626 ENSG00000260259.1 RP11-368I7.4 -5.62 9.04e-08 9.11e-05 -0.5 -0.41 Vitiligo; chr16:89798695 chr16:89682620~89686569:- PAAD cis rs9926296 0.533 rs7190823 ENSG00000260259.1 RP11-368I7.4 -5.62 9.04e-08 9.11e-05 -0.5 -0.41 Vitiligo; chr16:89799635 chr16:89682620~89686569:- PAAD cis rs2281636 0.723 rs2150916 ENSG00000233690.1 EBAG9P1 5.62 9.04e-08 9.11e-05 0.49 0.41 Obesity-related traits; chr10:99692737 chr10:99697407~99697949:- PAAD cis rs7201929 1 rs11644151 ENSG00000259982.1 CDC37P1 -5.62 9.05e-08 9.12e-05 -0.53 -0.41 QT interval; chr16:28884339 chr16:28700294~28701540:- PAAD cis rs7208859 0.623 rs7219361 ENSG00000266490.1 CTD-2349P21.9 5.62 9.05e-08 9.12e-05 0.53 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753375 chr17:30792372~30792833:+ PAAD cis rs6142102 0.517 rs6059577 ENSG00000276073.1 RP5-1125A11.7 -5.62 9.06e-08 9.13e-05 -0.43 -0.41 Skin pigmentation; chr20:33939880 chr20:33985617~33988989:- PAAD cis rs673078 0.607 rs6490177 ENSG00000275759.1 RP11-131L12.3 -5.62 9.08e-08 9.15e-05 -0.54 -0.41 Glucose homeostasis traits; chr12:118358280 chr12:118428281~118428870:+ PAAD cis rs748404 0.69 rs2467737 ENSG00000249839.1 AC011330.5 -5.61 9.12e-08 9.19e-05 -0.6 -0.41 Lung cancer; chr15:43444990 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs2439846 ENSG00000249839.1 AC011330.5 -5.61 9.12e-08 9.19e-05 -0.6 -0.41 Lung cancer; chr15:43448772 chr15:43663654~43684339:- PAAD cis rs6142102 0.517 rs8119076 ENSG00000276073.1 RP5-1125A11.7 -5.61 9.14e-08 9.2e-05 -0.44 -0.41 Skin pigmentation; chr20:33937909 chr20:33985617~33988989:- PAAD cis rs9640161 0.742 rs2108852 ENSG00000261305.1 RP4-584D14.7 5.61 9.14e-08 9.2e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150322539 chr7:150341771~150342607:+ PAAD cis rs9640161 0.742 rs2108851 ENSG00000261305.1 RP4-584D14.7 5.61 9.14e-08 9.2e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150322545 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs2159234 ENSG00000261305.1 RP4-584D14.7 5.61 9.14e-08 9.2e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150323333 chr7:150341771~150342607:+ PAAD cis rs9640161 0.702 rs3735175 ENSG00000261305.1 RP4-584D14.7 5.61 9.14e-08 9.2e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150323368 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs1464751 ENSG00000261305.1 RP4-584D14.7 5.61 9.14e-08 9.2e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150324193 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs1464752 ENSG00000261305.1 RP4-584D14.7 5.61 9.14e-08 9.2e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150324195 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs1464753 ENSG00000261305.1 RP4-584D14.7 5.61 9.14e-08 9.2e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150324261 chr7:150341771~150342607:+ PAAD cis rs9640161 0.75 rs1983440 ENSG00000261305.1 RP4-584D14.7 5.61 9.14e-08 9.2e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150326852 chr7:150341771~150342607:+ PAAD cis rs1400745 0.729 rs1741196 ENSG00000258738.1 RP11-73E17.2 5.61 9.16e-08 9.22e-05 0.47 0.41 Monocyte count; chr14:34877814 chr14:34874343~34876459:+ PAAD cis rs694739 1 rs1783521 ENSG00000236935.1 AP003774.1 5.61 9.16e-08 9.22e-05 0.44 0.41 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338819 chr11:64325050~64329504:- PAAD cis rs9926296 0.533 rs12102297 ENSG00000260259.1 RP11-368I7.4 -5.61 9.17e-08 9.23e-05 -0.5 -0.41 Vitiligo; chr16:89746354 chr16:89682620~89686569:- PAAD cis rs6142102 0.602 rs4911399 ENSG00000276073.1 RP5-1125A11.7 -5.61 9.18e-08 9.24e-05 -0.43 -0.41 Skin pigmentation; chr20:34035612 chr20:33985617~33988989:- PAAD cis rs6142102 0.602 rs2300209 ENSG00000276073.1 RP5-1125A11.7 -5.61 9.18e-08 9.24e-05 -0.43 -0.41 Skin pigmentation; chr20:34055294 chr20:33985617~33988989:- PAAD cis rs6142102 0.602 rs932388 ENSG00000276073.1 RP5-1125A11.7 -5.61 9.18e-08 9.24e-05 -0.43 -0.41 Skin pigmentation; chr20:34069572 chr20:33985617~33988989:- PAAD cis rs2524005 1 rs2524005 ENSG00000228078.1 HLA-U -5.61 9.19e-08 9.25e-05 -0.68 -0.41 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29934101~29934286:+ PAAD cis rs3761847 0.622 rs10435888 ENSG00000226752.6 PSMD5-AS1 -5.61 9.22e-08 9.27e-05 -0.46 -0.41 Rheumatoid arthritis; chr9:121057325 chr9:120824828~120854385:+ PAAD cis rs3761847 0.622 rs1323471 ENSG00000226752.6 PSMD5-AS1 -5.61 9.22e-08 9.27e-05 -0.46 -0.41 Rheumatoid arthritis; chr9:121064037 chr9:120824828~120854385:+ PAAD cis rs6504622 0.702 rs3851792 ENSG00000262879.4 RP11-156P1.3 5.61 9.22e-08 9.27e-05 0.41 0.41 Orofacial clefts; chr17:46982458 chr17:46984045~47100323:- PAAD cis rs9928842 0.823 rs2870472 ENSG00000280152.1 RP11-331F4.5 5.61 9.25e-08 9.3e-05 0.53 0.41 Alcoholic chronic pancreatitis; chr16:75244943 chr16:75245994~75250077:- PAAD cis rs992157 0.932 rs10203039 ENSG00000261338.2 RP11-378A13.1 5.61 9.28e-08 9.32e-05 0.47 0.41 Colorectal cancer; chr2:218322644 chr2:218255319~218257366:+ PAAD cis rs1150668 0.83 rs2531831 ENSG00000216901.1 AL022393.7 5.61 9.28e-08 9.32e-05 0.48 0.41 Pubertal anthropometrics; chr6:28420988 chr6:28176188~28176674:+ PAAD cis rs7829975 0.617 rs4841071 ENSG00000253893.2 FAM85B -5.61 9.29e-08 9.33e-05 -0.54 -0.41 Mood instability; chr8:8933634 chr8:8167819~8226614:- PAAD cis rs2243480 0.901 rs3813708 ENSG00000226824.5 RP4-756H11.3 -5.61 9.32e-08 9.36e-05 -0.75 -0.41 Diabetic kidney disease; chr7:65840645 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs73142122 ENSG00000226824.5 RP4-756H11.3 -5.61 9.32e-08 9.36e-05 -0.75 -0.41 Diabetic kidney disease; chr7:65846311 chr7:66654538~66669855:+ PAAD cis rs2337406 0.866 rs2027901 ENSG00000274576.2 IGHV2-70 -5.61 9.34e-08 9.38e-05 -0.54 -0.41 Alzheimer's disease (late onset); chr14:106807164 chr14:106770577~106771020:- PAAD cis rs2739330 0.929 rs5751777 ENSG00000231271.1 AP000350.8 5.61 9.34e-08 9.38e-05 0.55 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23949918~23954042:+ PAAD cis rs10463554 0.963 rs26262 ENSG00000175749.11 EIF3KP1 5.61 9.37e-08 9.4e-05 0.55 0.41 Parkinson's disease; chr5:103209462 chr5:103032376~103033031:+ PAAD cis rs227275 0.556 rs28367331 ENSG00000246560.2 RP11-10L12.4 5.61 9.38e-08 9.41e-05 0.46 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102900734 chr4:102828055~102844075:+ PAAD cis rs10463554 0.963 rs11242483 ENSG00000175749.11 EIF3KP1 5.61 9.38e-08 9.41e-05 0.53 0.41 Parkinson's disease; chr5:102988062 chr5:103032376~103033031:+ PAAD cis rs75422866 0.867 rs73102166 ENSG00000257433.4 RP1-197B17.3 5.61 9.39e-08 9.41e-05 0.84 0.41 Pneumonia; chr12:47653769 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102168 ENSG00000257433.4 RP1-197B17.3 5.61 9.39e-08 9.41e-05 0.84 0.41 Pneumonia; chr12:47654010 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102171 ENSG00000257433.4 RP1-197B17.3 5.61 9.39e-08 9.41e-05 0.84 0.41 Pneumonia; chr12:47656077 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs76100981 ENSG00000257433.4 RP1-197B17.3 5.61 9.39e-08 9.41e-05 0.84 0.41 Pneumonia; chr12:47660092 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102188 ENSG00000257433.4 RP1-197B17.3 5.61 9.39e-08 9.41e-05 0.84 0.41 Pneumonia; chr12:47662993 chr12:47706085~47742294:+ PAAD cis rs9322193 0.886 rs9767555 ENSG00000216906.2 RP11-350J20.9 5.61 9.4e-08 9.43e-05 0.53 0.41 Lung cancer; chr6:149647022 chr6:149904243~149906418:+ PAAD cis rs638893 0.636 rs1784295 ENSG00000278376.1 RP11-158I9.8 -5.61 9.4e-08 9.43e-05 -0.62 -0.41 Vitiligo; chr11:118790223 chr11:118791254~118793137:+ PAAD cis rs7772486 0.875 rs854146 ENSG00000235652.6 RP11-545I5.3 5.61 9.41e-08 9.43e-05 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146019897 chr6:145799409~145886585:+ PAAD cis rs1009647 0.656 rs10147254 ENSG00000258413.1 RP11-665C16.6 -5.61 9.44e-08 9.46e-05 -0.56 -0.41 Testicular germ cell tumor; chr14:55383597 chr14:55262767~55272075:- PAAD cis rs2108622 0.64 rs58858790 ENSG00000267453.5 AC004791.2 -5.61 9.46e-08 9.48e-05 -0.61 -0.41 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15863463 chr19:15851993~15864904:- PAAD cis rs9640161 0.789 rs36035506 ENSG00000261305.1 RP4-584D14.7 5.61 9.49e-08 9.51e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150360754 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs11767409 ENSG00000261305.1 RP4-584D14.7 5.61 9.49e-08 9.51e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150360954 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs13223702 ENSG00000261305.1 RP4-584D14.7 5.61 9.49e-08 9.51e-05 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150361879 chr7:150341771~150342607:+ PAAD cis rs4218 0.648 rs2289895 ENSG00000277144.1 RP11-59H7.4 -5.61 9.5e-08 9.52e-05 -0.58 -0.41 Social communication problems; chr15:59089570 chr15:59115547~59116089:- PAAD cis rs2019137 0.901 rs4849176 ENSG00000189223.12 PAX8-AS1 5.61 9.51e-08 9.53e-05 0.5 0.41 Lymphocyte counts; chr2:113220359 chr2:113211522~113276581:+ PAAD cis rs17301013 0.507 rs6677243 ENSG00000227373.4 RP11-160H22.5 5.61 9.51e-08 9.53e-05 0.61 0.41 Systemic lupus erythematosus; chr1:174339471 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912766 ENSG00000227373.4 RP11-160H22.5 5.61 9.51e-08 9.53e-05 0.61 0.41 Systemic lupus erythematosus; chr1:174341129 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12059307 ENSG00000227373.4 RP11-160H22.5 5.61 9.51e-08 9.53e-05 0.61 0.41 Systemic lupus erythematosus; chr1:174342105 chr1:174115300~174160004:- PAAD cis rs2243480 1 rs313814 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66038306 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs402418 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66044482 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs423187 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66044512 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs431318 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66046610 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313803 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66049744 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313802 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66051386 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs403089 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66052736 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs458291 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66055492 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs466983 ENSG00000226824.5 RP4-756H11.3 -5.61 9.52e-08 9.53e-05 -0.75 -0.41 Diabetic kidney disease; chr7:66055509 chr7:66654538~66669855:+ PAAD cis rs4218 0.648 rs1074702 ENSG00000277144.1 RP11-59H7.4 -5.61 9.53e-08 9.54e-05 -0.58 -0.41 Social communication problems; chr15:59073900 chr15:59115547~59116089:- PAAD cis rs12908161 0.959 rs2175567 ENSG00000225151.9 GOLGA2P7 -5.6 9.55e-08 9.56e-05 -0.5 -0.41 Schizophrenia; chr15:84657715 chr15:84199311~84230136:- PAAD cis rs11098499 0.863 rs13136462 ENSG00000245958.5 RP11-33B1.1 -5.6 9.56e-08 9.57e-05 -0.35 -0.41 Corneal astigmatism; chr4:119622018 chr4:119454791~119552025:+ PAAD cis rs113835537 0.559 rs11227497 ENSG00000255517.5 CTD-3074O7.5 -5.6 9.56e-08 9.57e-05 -0.53 -0.41 Airway imaging phenotypes; chr11:66501993 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227500 ENSG00000255517.5 CTD-3074O7.5 -5.6 9.56e-08 9.57e-05 -0.53 -0.41 Airway imaging phenotypes; chr11:66505762 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227502 ENSG00000255517.5 CTD-3074O7.5 -5.6 9.56e-08 9.57e-05 -0.53 -0.41 Airway imaging phenotypes; chr11:66506677 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227503 ENSG00000255517.5 CTD-3074O7.5 -5.6 9.56e-08 9.57e-05 -0.53 -0.41 Airway imaging phenotypes; chr11:66507771 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs4542420 ENSG00000255517.5 CTD-3074O7.5 -5.6 9.56e-08 9.57e-05 -0.53 -0.41 Airway imaging phenotypes; chr11:66510139 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227511 ENSG00000255517.5 CTD-3074O7.5 -5.6 9.56e-08 9.57e-05 -0.53 -0.41 Airway imaging phenotypes; chr11:66513773 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs10896125 ENSG00000255517.5 CTD-3074O7.5 -5.6 9.56e-08 9.57e-05 -0.53 -0.41 Airway imaging phenotypes; chr11:66521262 chr11:66473490~66480233:- PAAD cis rs1862618 0.573 rs1550821 ENSG00000271828.1 CTD-2310F14.1 -5.6 9.58e-08 9.59e-05 -0.63 -0.41 Initial pursuit acceleration; chr5:56946496 chr5:56927874~56929573:+ PAAD cis rs1862618 0.573 rs2034245 ENSG00000271828.1 CTD-2310F14.1 -5.6 9.58e-08 9.59e-05 -0.63 -0.41 Initial pursuit acceleration; chr5:56947858 chr5:56927874~56929573:+ PAAD cis rs10510102 0.748 rs11200297 ENSG00000276742.1 RP11-500G22.4 5.6 9.61e-08 9.61e-05 0.62 0.41 Breast cancer; chr10:121972916 chr10:121956782~121957098:+ PAAD cis rs9900062 1 rs11871616 ENSG00000270714.1 MINOS1P2 -5.6 9.66e-08 9.66e-05 -0.61 -0.41 QT interval; chr17:64741484 chr17:64747264~64747492:- PAAD cis rs7945705 0.935 rs1883098 ENSG00000254860.4 TMEM9B-AS1 5.6 9.69e-08 9.69e-05 0.44 0.41 Hemoglobin concentration; chr11:8869047 chr11:8964675~8977527:+ PAAD cis rs2019137 0.539 rs4849181 ENSG00000189223.12 PAX8-AS1 -5.6 9.71e-08 9.7e-05 -0.51 -0.41 Lymphocyte counts; chr2:113234393 chr2:113211522~113276581:+ PAAD cis rs2739330 0.828 rs2330635 ENSG00000231271.1 AP000350.8 5.6 9.75e-08 9.74e-05 0.56 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23949918~23954042:+ PAAD cis rs4218 0.607 rs2414619 ENSG00000277144.1 RP11-59H7.4 -5.6 9.79e-08 9.77e-05 -0.49 -0.41 Social communication problems; chr15:59113060 chr15:59115547~59116089:- PAAD cis rs732716 0.74 rs78869060 ENSG00000267980.1 AC007292.6 -5.6 9.84e-08 9.82e-05 -0.53 -0.41 Mean corpuscular volume; chr19:4444745 chr19:4363789~4364640:+ PAAD cis rs732716 0.785 rs11085073 ENSG00000267769.1 CTB-50L17.9 5.6 9.89e-08 9.86e-05 0.56 0.41 Mean corpuscular volume; chr19:4375165 chr19:4454014~4455286:+ PAAD cis rs4218 0.689 rs34338282 ENSG00000277144.1 RP11-59H7.4 -5.6 9.91e-08 9.88e-05 -0.56 -0.41 Social communication problems; chr15:59096897 chr15:59115547~59116089:- PAAD cis rs4218 0.681 rs34977427 ENSG00000277144.1 RP11-59H7.4 -5.6 9.91e-08 9.88e-05 -0.56 -0.41 Social communication problems; chr15:59098172 chr15:59115547~59116089:- PAAD cis rs732716 0.785 rs55660045 ENSG00000267769.1 CTB-50L17.9 -5.6 9.94e-08 9.92e-05 -0.58 -0.41 Mean corpuscular volume; chr19:4425308 chr19:4454014~4455286:+ PAAD cis rs732716 0.785 rs62130978 ENSG00000267769.1 CTB-50L17.9 -5.6 9.94e-08 9.92e-05 -0.58 -0.41 Mean corpuscular volume; chr19:4429010 chr19:4454014~4455286:+ PAAD cis rs732716 0.819 rs12459919 ENSG00000267769.1 CTB-50L17.9 -5.6 9.94e-08 9.92e-05 -0.58 -0.41 Mean corpuscular volume; chr19:4434506 chr19:4454014~4455286:+ PAAD cis rs1150668 0.83 rs2859365 ENSG00000204709.4 LINC01556 -5.6 9.94e-08 9.92e-05 -0.53 -0.41 Pubertal anthropometrics; chr6:28423688 chr6:28943877~28944537:+ PAAD cis rs1150668 0.796 rs2247002 ENSG00000204709.4 LINC01556 5.6 9.94e-08 9.92e-05 0.53 0.41 Pubertal anthropometrics; chr6:28430174 chr6:28943877~28944537:+ PAAD cis rs732716 0.74 rs62129356 ENSG00000267769.1 CTB-50L17.9 -5.6 9.94e-08 9.92e-05 -0.58 -0.41 Mean corpuscular volume; chr19:4400317 chr19:4454014~4455286:+ PAAD cis rs1150668 0.83 rs2859365 ENSG00000216901.1 AL022393.7 -5.6 9.98e-08 9.95e-05 -0.48 -0.41 Pubertal anthropometrics; chr6:28423688 chr6:28176188~28176674:+ PAAD cis rs1150668 0.796 rs2247002 ENSG00000216901.1 AL022393.7 5.6 9.98e-08 9.95e-05 0.48 0.41 Pubertal anthropometrics; chr6:28430174 chr6:28176188~28176674:+ PAAD cis rs9322193 0.923 rs12175504 ENSG00000216906.2 RP11-350J20.9 5.6 1e-07 9.98e-05 0.52 0.41 Lung cancer; chr6:149664079 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs35443312 ENSG00000216906.2 RP11-350J20.9 5.6 1e-07 9.98e-05 0.52 0.41 Lung cancer; chr6:149670625 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs62439843 ENSG00000216906.2 RP11-350J20.9 5.6 1e-07 9.98e-05 0.52 0.41 Lung cancer; chr6:149676521 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs35031906 ENSG00000216906.2 RP11-350J20.9 5.6 1e-07 9.98e-05 0.52 0.41 Lung cancer; chr6:149677438 chr6:149904243~149906418:+ PAAD cis rs7772486 0.754 rs4896839 ENSG00000235652.6 RP11-545I5.3 -5.59 1e-07 9.98e-05 -0.35 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145698553 chr6:145799409~145886585:+ PAAD cis rs2243480 1 rs34815098 ENSG00000226824.5 RP4-756H11.3 -5.59 1e-07 9.99e-05 -0.75 -0.41 Diabetic kidney disease; chr7:65827267 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs7456042 ENSG00000226824.5 RP4-756H11.3 -5.59 1e-07 9.99e-05 -0.75 -0.41 Diabetic kidney disease; chr7:65834791 chr7:66654538~66669855:+ PAAD cis rs950169 0.544 rs2036949 ENSG00000225151.9 GOLGA2P7 -5.59 1e-07 1e-04 -0.5 -0.41 Schizophrenia; chr15:84620374 chr15:84199311~84230136:- PAAD cis rs10510102 0.872 rs11814703 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121964774 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12259144 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121965433 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12246728 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121966618 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12261371 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121966686 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11200292 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121967383 chr10:121956782~121957098:+ PAAD cis rs10510102 0.808 rs17102804 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121968365 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12265369 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121968455 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12265542 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121968740 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11200293 ENSG00000276742.1 RP11-500G22.4 5.59 1e-07 1e-04 0.6 0.41 Breast cancer; chr10:121969195 chr10:121956782~121957098:+ PAAD cis rs10875746 0.551 rs12322347 ENSG00000240399.1 RP1-228P16.1 -5.59 1.01e-07 1e-04 -0.44 -0.41 Longevity (90 years and older); chr12:48313915 chr12:48054813~48055591:- PAAD cis rs10875746 0.551 rs12322348 ENSG00000240399.1 RP1-228P16.1 -5.59 1.01e-07 1e-04 -0.44 -0.41 Longevity (90 years and older); chr12:48313916 chr12:48054813~48055591:- PAAD cis rs7945705 0.905 rs2568054 ENSG00000254860.4 TMEM9B-AS1 5.59 1.01e-07 1e-04 0.44 0.41 Hemoglobin concentration; chr11:8854482 chr11:8964675~8977527:+ PAAD cis rs950169 0.58 rs11635597 ENSG00000225151.9 GOLGA2P7 -5.59 1.01e-07 1e-04 -0.5 -0.41 Schizophrenia; chr15:84622468 chr15:84199311~84230136:- PAAD cis rs2337406 0.714 rs7150993 ENSG00000274576.2 IGHV2-70 -5.59 1.01e-07 0.000101 -0.55 -0.41 Alzheimer's disease (late onset); chr14:106818515 chr14:106770577~106771020:- PAAD cis rs7945705 0.935 rs2568062 ENSG00000254860.4 TMEM9B-AS1 5.59 1.01e-07 0.000101 0.44 0.41 Hemoglobin concentration; chr11:8866398 chr11:8964675~8977527:+ PAAD cis rs7945705 0.935 rs2653567 ENSG00000254860.4 TMEM9B-AS1 5.59 1.01e-07 0.000101 0.44 0.41 Hemoglobin concentration; chr11:8868083 chr11:8964675~8977527:+ PAAD cis rs748404 0.587 rs690276 ENSG00000249839.1 AC011330.5 -5.59 1.01e-07 0.000101 -0.59 -0.41 Lung cancer; chr15:43412360 chr15:43663654~43684339:- PAAD cis rs26232 0.583 rs154258 ENSG00000175749.11 EIF3KP1 -5.59 1.02e-07 0.000101 -0.53 -0.41 Rheumatoid arthritis; chr5:103027919 chr5:103032376~103033031:+ PAAD cis rs26232 0.551 rs26431 ENSG00000175749.11 EIF3KP1 -5.59 1.02e-07 0.000101 -0.53 -0.41 Rheumatoid arthritis; chr5:103030090 chr5:103032376~103033031:+ PAAD cis rs2739330 0.76 rs1002286 ENSG00000099984.9 GSTT2 5.59 1.02e-07 0.000101 0.51 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23980123~23983911:+ PAAD cis rs453301 0.598 rs10104303 ENSG00000253893.2 FAM85B -5.59 1.02e-07 0.000101 -0.52 -0.41 Joint mobility (Beighton score); chr8:8977018 chr8:8167819~8226614:- PAAD cis rs2274273 0.774 rs17128440 ENSG00000258413.1 RP11-665C16.6 -5.59 1.02e-07 0.000102 -0.51 -0.41 Protein biomarker; chr14:55395194 chr14:55262767~55272075:- PAAD cis rs453301 0.624 rs6987558 ENSG00000253893.2 FAM85B -5.59 1.02e-07 0.000102 -0.55 -0.41 Joint mobility (Beighton score); chr8:9005011 chr8:8167819~8226614:- PAAD cis rs694739 1 rs11231757 ENSG00000236935.1 AP003774.1 5.59 1.02e-07 0.000102 0.44 0.41 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338845 chr11:64325050~64329504:- PAAD cis rs694739 1 rs499425 ENSG00000236935.1 AP003774.1 -5.59 1.02e-07 0.000102 -0.44 -0.41 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64338457 chr11:64325050~64329504:- PAAD cis rs17301013 0.507 rs34409674 ENSG00000227373.4 RP11-160H22.5 -5.59 1.02e-07 0.000102 -0.62 -0.41 Systemic lupus erythematosus; chr1:174560246 chr1:174115300~174160004:- PAAD cis rs12701220 0.503 rs2949177 ENSG00000229043.2 AC091729.9 -5.59 1.02e-07 0.000102 -0.52 -0.41 Bronchopulmonary dysplasia; chr7:1171882 chr7:1160374~1165267:+ PAAD cis rs62229266 0.771 rs7280136 ENSG00000231106.2 LINC01436 -5.59 1.03e-07 0.000102 -0.59 -0.41 Mitral valve prolapse; chr21:36060612 chr21:36005338~36007838:+ PAAD cis rs1150668 0.796 rs728122 ENSG00000204709.4 LINC01556 5.59 1.03e-07 0.000102 0.53 0.41 Pubertal anthropometrics; chr6:28431347 chr6:28943877~28944537:+ PAAD cis rs4713118 0.516 rs6931858 ENSG00000226314.6 ZNF192P1 -5.59 1.03e-07 0.000102 -0.7 -0.41 Parkinson's disease; chr6:28110633 chr6:28161781~28169594:+ PAAD cis rs858239 1 rs199348 ENSG00000226816.2 AC005082.12 5.59 1.03e-07 0.000102 0.46 0.41 Cerebrospinal fluid biomarker levels; chr7:23253479 chr7:23206013~23208045:+ PAAD cis rs858239 0.932 rs199355 ENSG00000226816.2 AC005082.12 5.59 1.03e-07 0.000102 0.46 0.41 Cerebrospinal fluid biomarker levels; chr7:23256914 chr7:23206013~23208045:+ PAAD cis rs526231 0.543 rs246909 ENSG00000175749.11 EIF3KP1 5.59 1.03e-07 0.000103 0.55 0.41 Primary biliary cholangitis; chr5:103227976 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs246906 ENSG00000175749.11 EIF3KP1 5.59 1.03e-07 0.000103 0.55 0.41 Primary biliary cholangitis; chr5:103230770 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs62362884 ENSG00000175749.11 EIF3KP1 5.59 1.03e-07 0.000103 0.55 0.41 Primary biliary cholangitis; chr5:103231754 chr5:103032376~103033031:+ PAAD cis rs2929278 0.561 rs3099045 ENSG00000205771.5 CATSPER2P1 -5.59 1.03e-07 0.000103 -0.53 -0.41 Schizophrenia; chr15:43631757 chr15:43726918~43747094:- PAAD cis rs11098499 0.874 rs12509054 ENSG00000245958.5 RP11-33B1.1 -5.59 1.04e-07 0.000103 -0.33 -0.41 Corneal astigmatism; chr4:119193920 chr4:119454791~119552025:+ PAAD cis rs11098499 0.874 rs10022508 ENSG00000245958.5 RP11-33B1.1 -5.59 1.04e-07 0.000103 -0.33 -0.41 Corneal astigmatism; chr4:119194073 chr4:119454791~119552025:+ PAAD cis rs11098499 0.874 rs12502503 ENSG00000245958.5 RP11-33B1.1 -5.59 1.04e-07 0.000103 -0.33 -0.41 Corneal astigmatism; chr4:119195100 chr4:119454791~119552025:+ PAAD cis rs11098499 0.874 rs6851169 ENSG00000245958.5 RP11-33B1.1 -5.59 1.04e-07 0.000103 -0.33 -0.41 Corneal astigmatism; chr4:119196355 chr4:119454791~119552025:+ PAAD cis rs34375054 0.738 rs10846834 ENSG00000279233.1 RP11-158L12.4 5.59 1.04e-07 0.000103 0.37 0.41 Post bronchodilator FEV1/FVC ratio; chr12:125141024 chr12:125138245~125141711:+ PAAD cis rs673078 0.66 rs7136216 ENSG00000275759.1 RP11-131L12.3 -5.59 1.04e-07 0.000103 -0.54 -0.41 Glucose homeostasis traits; chr12:118170475 chr12:118428281~118428870:+ PAAD cis rs7615952 0.736 rs9862893 ENSG00000171084.14 FAM86JP 5.59 1.04e-07 0.000103 0.71 0.41 Blood pressure (smoking interaction); chr3:125968131 chr3:125916620~125930024:+ PAAD cis rs11673344 1 rs11673344 ENSG00000226686.6 LINC01535 5.59 1.04e-07 0.000103 0.55 0.41 Obesity-related traits; chr19:37194064 chr19:37251912~37265535:+ PAAD cis rs17301013 0.507 rs6678209 ENSG00000227373.4 RP11-160H22.5 -5.59 1.04e-07 0.000103 -0.59 -0.41 Systemic lupus erythematosus; chr1:174325607 chr1:174115300~174160004:- PAAD cis rs7714584 1 rs4958852 ENSG00000197083.10 ZNF300P1 5.59 1.04e-07 0.000103 0.74 0.41 Crohn's disease; chr5:150951069 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs11167526 ENSG00000197083.10 ZNF300P1 5.59 1.04e-07 0.000103 0.74 0.41 Crohn's disease; chr5:150952919 chr5:150930645~150946289:- PAAD cis rs7714584 1 rs931058 ENSG00000197083.10 ZNF300P1 5.59 1.04e-07 0.000103 0.74 0.41 Crohn's disease; chr5:150954136 chr5:150930645~150946289:- PAAD cis rs12468226 1 rs74766638 ENSG00000273456.1 RP11-686O6.2 5.59 1.05e-07 0.000104 0.62 0.41 Urate levels; chr2:202445168 chr2:202374932~202375604:- PAAD cis rs1075265 0.84 rs2884254 ENSG00000233266.1 HMGB1P31 5.59 1.05e-07 0.000104 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:53979326 chr2:54051334~54051760:+ PAAD cis rs6504950 0.83 rs35097996 ENSG00000275710.1 RP11-257O5.4 5.59 1.05e-07 0.000104 0.53 0.41 Breast cancer; chr17:54944562 chr17:54964474~54964679:+ PAAD cis rs6504950 0.79 rs8066833 ENSG00000275710.1 RP11-257O5.4 5.59 1.05e-07 0.000104 0.53 0.41 Breast cancer; chr17:54948114 chr17:54964474~54964679:+ PAAD cis rs6504950 0.821 rs8066588 ENSG00000275710.1 RP11-257O5.4 5.59 1.05e-07 0.000104 0.53 0.41 Breast cancer; chr17:54948328 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs3087650 ENSG00000275710.1 RP11-257O5.4 5.59 1.05e-07 0.000104 0.53 0.41 Breast cancer; chr17:54951967 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs12937006 ENSG00000275710.1 RP11-257O5.4 5.59 1.05e-07 0.000104 0.53 0.41 Breast cancer; chr17:54953100 chr17:54964474~54964679:+ PAAD cis rs4218 0.689 rs35555888 ENSG00000277144.1 RP11-59H7.4 -5.58 1.05e-07 0.000104 -0.56 -0.41 Social communication problems; chr15:59093935 chr15:59115547~59116089:- PAAD cis rs7615952 0.8 rs12489350 ENSG00000171084.14 FAM86JP 5.58 1.05e-07 0.000104 0.55 0.41 Blood pressure (smoking interaction); chr3:125925273 chr3:125916620~125930024:+ PAAD cis rs763567 0.933 rs588837 ENSG00000271811.1 RP1-79C4.4 5.58 1.06e-07 0.000105 0.39 0.41 Tonsillectomy; chr1:170653968 chr1:170667381~170669425:+ PAAD cis rs10463554 0.892 rs17154860 ENSG00000175749.11 EIF3KP1 5.58 1.06e-07 0.000105 0.52 0.41 Parkinson's disease; chr5:102955441 chr5:103032376~103033031:+ PAAD cis rs10463554 0.857 rs3776871 ENSG00000175749.11 EIF3KP1 5.58 1.06e-07 0.000105 0.52 0.41 Parkinson's disease; chr5:102956507 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs2195272 ENSG00000175749.11 EIF3KP1 5.58 1.06e-07 0.000105 0.52 0.41 Parkinson's disease; chr5:102959800 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs17154859 ENSG00000175749.11 EIF3KP1 -5.58 1.06e-07 0.000105 -0.52 -0.41 Parkinson's disease; chr5:102955208 chr5:103032376~103033031:+ PAAD cis rs17301013 0.803 rs2187562 ENSG00000227373.4 RP11-160H22.5 5.58 1.06e-07 0.000105 0.5 0.41 Systemic lupus erythematosus; chr1:174842513 chr1:174115300~174160004:- PAAD cis rs11673344 0.966 rs111927298 ENSG00000226686.6 LINC01535 5.58 1.06e-07 0.000105 0.55 0.41 Obesity-related traits; chr19:37193034 chr19:37251912~37265535:+ PAAD cis rs734999 0.967 rs10752745 ENSG00000225931.3 RP3-395M20.7 5.58 1.06e-07 0.000105 0.4 0.41 Ulcerative colitis; chr1:2576499 chr1:2566410~2569888:+ PAAD cis rs10910092 1 rs10910092 ENSG00000225931.3 RP3-395M20.7 5.58 1.06e-07 0.000105 0.4 0.41 Ulcerative colitis; chr1:2570077 chr1:2566410~2569888:+ PAAD cis rs858239 0.676 rs274032 ENSG00000226816.2 AC005082.12 5.58 1.06e-07 0.000105 0.44 0.41 Cerebrospinal fluid biomarker levels; chr7:23334940 chr7:23206013~23208045:+ PAAD cis rs7174755 0.637 rs10152713 ENSG00000260657.2 RP11-315D16.4 -5.58 1.06e-07 0.000105 -0.5 -0.41 Major depressive disorder; chr15:68179553 chr15:68267792~68277994:- PAAD cis rs453301 0.598 rs2921383 ENSG00000253893.2 FAM85B -5.58 1.07e-07 0.000106 -0.54 -0.41 Joint mobility (Beighton score); chr8:9034711 chr8:8167819~8226614:- PAAD cis rs6142102 0.602 rs11696338 ENSG00000276073.1 RP5-1125A11.7 -5.58 1.07e-07 0.000106 -0.43 -0.41 Skin pigmentation; chr20:34099805 chr20:33985617~33988989:- PAAD cis rs11098499 0.863 rs6534139 ENSG00000245958.5 RP11-33B1.1 5.58 1.07e-07 0.000106 0.36 0.41 Corneal astigmatism; chr4:119528301 chr4:119454791~119552025:+ PAAD cis rs11098499 0.82 rs13128602 ENSG00000245958.5 RP11-33B1.1 5.58 1.07e-07 0.000106 0.36 0.41 Corneal astigmatism; chr4:119538211 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs1010740 ENSG00000245958.5 RP11-33B1.1 5.58 1.07e-07 0.000106 0.36 0.41 Corneal astigmatism; chr4:119542254 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs58452170 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119538519 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs1552095 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119539151 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs7678400 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119540802 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs1480936 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119541706 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs11098531 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119543846 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs28718422 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119545149 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs12498539 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119547215 chr4:119454791~119552025:+ PAAD cis rs11098499 0.818 rs12498599 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119547348 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs10009626 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119548850 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3822194 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119550493 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3822195 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119550505 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3775854 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119550816 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs2306456 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119551267 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs11947234 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119553704 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs6853998 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119554705 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs6858777 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119554811 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs11933966 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119555560 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs36040693 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119556461 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs11731756 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119557541 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs34308924 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119560276 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs2170276 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119564669 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs59732491 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119568433 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs9884402 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119568827 chr4:119454791~119552025:+ PAAD cis rs11098499 0.731 rs9995026 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119569344 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs11723090 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119569437 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs11098532 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119569571 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs13140391 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119582282 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs13140409 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119582305 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs6833334 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119583072 chr4:119454791~119552025:+ PAAD cis rs11098499 0.82 rs6829903 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119585729 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs7669520 ENSG00000245958.5 RP11-33B1.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Corneal astigmatism; chr4:119594123 chr4:119454791~119552025:+ PAAD cis rs149313 1 rs149313 ENSG00000248734.2 CTD-2260A17.1 -5.58 1.07e-07 0.000106 -0.36 -0.41 Blood protein levels; chr5:96734501 chr5:96784777~96785999:+ PAAD cis rs12701220 0.655 rs12702117 ENSG00000229043.2 AC091729.9 -5.58 1.07e-07 0.000106 -0.54 -0.41 Bronchopulmonary dysplasia; chr7:1109066 chr7:1160374~1165267:+ PAAD cis rs12701220 0.604 rs12702122 ENSG00000229043.2 AC091729.9 -5.58 1.07e-07 0.000106 -0.54 -0.41 Bronchopulmonary dysplasia; chr7:1109858 chr7:1160374~1165267:+ PAAD cis rs1185460 0.546 rs474201 ENSG00000271751.1 RP11-110I1.14 -5.58 1.07e-07 0.000106 -0.55 -0.41 Coronary artery disease; chr11:119087519 chr11:119065263~119065677:- PAAD cis rs2274273 0.84 rs66486619 ENSG00000258413.1 RP11-665C16.6 -5.58 1.07e-07 0.000106 -0.51 -0.41 Protein biomarker; chr14:55402837 chr14:55262767~55272075:- PAAD cis rs1823913 0.927 rs13025919 ENSG00000280083.1 RP11-317J9.1 -5.58 1.07e-07 0.000106 -0.53 -0.41 Obesity-related traits; chr2:191260175 chr2:191154118~191156070:- PAAD cis rs4308124 0.708 rs6747657 ENSG00000227992.1 AC108463.2 -5.58 1.07e-07 0.000106 -0.47 -0.41 Vitiligo; chr2:111245586 chr2:111203964~111206215:- PAAD cis rs10463554 0.963 rs26816 ENSG00000175749.11 EIF3KP1 5.58 1.07e-07 0.000106 0.54 0.41 Parkinson's disease; chr5:103204821 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs26261 ENSG00000175749.11 EIF3KP1 5.58 1.07e-07 0.000106 0.54 0.41 Parkinson's disease; chr5:103209992 chr5:103032376~103033031:+ PAAD cis rs7772486 0.701 rs2244308 ENSG00000235652.6 RP11-545I5.3 5.58 1.08e-07 0.000106 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145892570 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2180192 ENSG00000235652.6 RP11-545I5.3 5.58 1.08e-07 0.000106 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146001148 chr6:145799409~145886585:+ PAAD cis rs7945705 0.818 rs1988708 ENSG00000254860.4 TMEM9B-AS1 5.58 1.08e-07 0.000106 0.44 0.41 Hemoglobin concentration; chr11:8861346 chr11:8964675~8977527:+ PAAD cis rs11089937 0.963 rs5757098 ENSG00000211639.2 IGLV4-60 -5.58 1.08e-07 0.000106 -0.39 -0.41 Periodontitis (PAL4Q3); chr22:22154322 chr22:22162199~22162681:+ PAAD cis rs11089937 0.857 rs5750578 ENSG00000211639.2 IGLV4-60 5.58 1.08e-07 0.000107 0.37 0.41 Periodontitis (PAL4Q3); chr22:22136444 chr22:22162199~22162681:+ PAAD cis rs4218 0.648 rs12915899 ENSG00000277144.1 RP11-59H7.4 -5.58 1.08e-07 0.000107 -0.58 -0.41 Social communication problems; chr15:59084332 chr15:59115547~59116089:- PAAD cis rs6903823 0.508 rs1150726 ENSG00000216901.1 AL022393.7 5.58 1.09e-07 0.000107 0.49 0.41 Pulmonary function; chr6:28275265 chr6:28176188~28176674:+ PAAD cis rs2739330 0.892 rs4822455 ENSG00000231271.1 AP000350.8 5.58 1.09e-07 0.000108 0.53 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23949918~23954042:+ PAAD cis rs10463554 0.892 rs72783889 ENSG00000175749.11 EIF3KP1 5.58 1.09e-07 0.000108 0.53 0.41 Parkinson's disease; chr5:102938835 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs72783890 ENSG00000175749.11 EIF3KP1 5.58 1.09e-07 0.000108 0.53 0.41 Parkinson's disease; chr5:102938836 chr5:103032376~103033031:+ PAAD cis rs9322193 0.962 rs9322206 ENSG00000216906.2 RP11-350J20.9 5.58 1.09e-07 0.000108 0.52 0.41 Lung cancer; chr6:149641481 chr6:149904243~149906418:+ PAAD cis rs9322193 0.962 rs9688750 ENSG00000216906.2 RP11-350J20.9 5.58 1.09e-07 0.000108 0.52 0.41 Lung cancer; chr6:149657633 chr6:149904243~149906418:+ PAAD cis rs2274273 0.624 rs8015211 ENSG00000258413.1 RP11-665C16.6 -5.58 1.1e-07 0.000108 -0.56 -0.41 Protein biomarker; chr14:55374729 chr14:55262767~55272075:- PAAD cis rs2929278 0.617 rs524908 ENSG00000205771.5 CATSPER2P1 5.58 1.1e-07 0.000108 0.52 0.41 Schizophrenia; chr15:43895793 chr15:43726918~43747094:- PAAD cis rs673078 0.607 rs56080343 ENSG00000275759.1 RP11-131L12.3 -5.57 1.1e-07 0.000109 -0.55 -0.41 Glucose homeostasis traits; chr12:118439113 chr12:118428281~118428870:+ PAAD cis rs9640161 0.658 rs74348353 ENSG00000261305.1 RP4-584D14.7 5.57 1.1e-07 0.000109 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150356566 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs66688634 ENSG00000261305.1 RP4-584D14.7 5.57 1.1e-07 0.000109 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150356717 chr7:150341771~150342607:+ PAAD cis rs11098499 0.863 rs10019674 ENSG00000245958.5 RP11-33B1.1 5.57 1.11e-07 0.000109 0.36 0.41 Corneal astigmatism; chr4:119522334 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3822192 ENSG00000245958.5 RP11-33B1.1 -5.57 1.11e-07 0.000109 -0.36 -0.41 Corneal astigmatism; chr4:119524565 chr4:119454791~119552025:+ PAAD cis rs526231 0.511 rs73179850 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103012873 chr5:103032376~103033031:+ PAAD cis rs26232 0.521 rs3776855 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Rheumatoid arthritis; chr5:103023111 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs10434792 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103053898 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs10434793 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103054111 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs12109860 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103057408 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34377 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103064852 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs158395 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103075685 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs158400 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103077628 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs257302 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103080426 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs257303 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103081023 chr5:103032376~103033031:+ PAAD cis rs526231 0.578 rs34794 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103087664 chr5:103032376~103033031:+ PAAD cis rs526231 0.512 rs34797 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103090023 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34801 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103090809 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34807 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103092818 chr5:103032376~103033031:+ PAAD cis rs10463554 0.526 rs114525197 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Parkinson's disease; chr5:103107341 chr5:103032376~103033031:+ PAAD cis rs26232 0.521 rs40508 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Rheumatoid arthritis; chr5:103108234 chr5:103032376~103033031:+ PAAD cis rs10463554 0.759 rs461609 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Parkinson's disease; chr5:103111601 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34779 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103117064 chr5:103032376~103033031:+ PAAD cis rs526231 0.547 rs34780 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103117853 chr5:103032376~103033031:+ PAAD cis rs10463554 0.759 rs34781 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Parkinson's disease; chr5:103118735 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34784 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103121626 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34785 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103122399 chr5:103032376~103033031:+ PAAD cis rs526231 0.578 rs34786 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103122409 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34787 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103123199 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34789 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103125035 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34791 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103126400 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs26525 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103129219 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs75913944 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103143799 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs27896 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103152867 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34767 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103153807 chr5:103032376~103033031:+ PAAD cis rs10463554 0.727 rs34768 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Parkinson's disease; chr5:103155798 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34765 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103171160 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs183752 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103172108 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34766 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103175219 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs26820 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103192391 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs26819 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103193700 chr5:103032376~103033031:+ PAAD cis rs526231 0.615 rs26818 ENSG00000175749.11 EIF3KP1 5.57 1.11e-07 0.000109 0.54 0.41 Primary biliary cholangitis; chr5:103194018 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs17154942 ENSG00000175749.11 EIF3KP1 -5.57 1.11e-07 0.000109 -0.54 -0.41 Primary biliary cholangitis; chr5:103017014 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34379 ENSG00000175749.11 EIF3KP1 -5.57 1.11e-07 0.000109 -0.54 -0.41 Primary biliary cholangitis; chr5:103062994 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs42431 ENSG00000175749.11 EIF3KP1 -5.57 1.11e-07 0.000109 -0.54 -0.41 Primary biliary cholangitis; chr5:103064359 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs27698 ENSG00000175749.11 EIF3KP1 -5.57 1.11e-07 0.000109 -0.54 -0.41 Primary biliary cholangitis; chr5:103190474 chr5:103032376~103033031:+ PAAD cis rs4218 0.597 rs62002544 ENSG00000277144.1 RP11-59H7.4 -5.57 1.11e-07 0.000109 -0.57 -0.41 Social communication problems; chr15:59066663 chr15:59115547~59116089:- PAAD cis rs9425766 0.679 rs6681618 ENSG00000227373.4 RP11-160H22.5 -5.57 1.11e-07 0.00011 -0.52 -0.41 Life satisfaction; chr1:174201203 chr1:174115300~174160004:- PAAD cis rs2929278 0.736 rs2412823 ENSG00000205771.5 CATSPER2P1 5.57 1.11e-07 0.00011 0.54 0.41 Schizophrenia; chr15:43935072 chr15:43726918~43747094:- PAAD cis rs4218 0.681 rs35204615 ENSG00000277144.1 RP11-59H7.4 -5.57 1.11e-07 0.00011 -0.56 -0.41 Social communication problems; chr15:59099637 chr15:59115547~59116089:- PAAD cis rs4218 0.689 rs12907187 ENSG00000277144.1 RP11-59H7.4 -5.57 1.11e-07 0.00011 -0.56 -0.41 Social communication problems; chr15:59100607 chr15:59115547~59116089:- PAAD cis rs6782228 0.509 rs6780447 ENSG00000242551.2 POU5F1P6 -5.57 1.12e-07 0.00011 -0.49 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694965 chr3:128674735~128677005:- PAAD cis rs7615952 1 rs9289275 ENSG00000171084.14 FAM86JP 5.57 1.12e-07 0.00011 0.56 0.41 Blood pressure (smoking interaction); chr3:125929816 chr3:125916620~125930024:+ PAAD cis rs17301013 0.507 rs16846949 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174402071 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs7413513 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174403163 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs74128393 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174407961 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs11799535 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174415790 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72713586 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174441265 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72713591 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174442956 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72715204 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174492787 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2901820 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174505201 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2281010 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174509917 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4652512 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174515519 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs57512497 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174518346 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs11807229 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174519456 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72715218 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174529056 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs55748748 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174546252 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs41266050 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174547861 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72715237 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174550527 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72715240 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174560838 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs11805578 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174573174 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4652652 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174596582 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4651103 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174596750 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72715259 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174604590 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72715262 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174607088 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4615901 ENSG00000227373.4 RP11-160H22.5 5.57 1.12e-07 0.000111 0.63 0.41 Systemic lupus erythematosus; chr1:174609432 chr1:174115300~174160004:- PAAD cis rs227275 0.525 rs3974608 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102925641 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs10028116 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102931421 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs9307281 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102934971 chr4:102828055~102844075:+ PAAD cis rs11722779 0.903 rs6533037 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Schizophrenia; chr4:102935865 chr4:102828055~102844075:+ PAAD cis rs11722779 0.903 rs4530634 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Schizophrenia; chr4:102937924 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs7676943 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102938135 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs6419160 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102938648 chr4:102828055~102844075:+ PAAD cis rs11722779 0.838 rs3974494 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Schizophrenia; chr4:102945323 chr4:102828055~102844075:+ PAAD cis rs228614 0.514 rs59550147 ENSG00000246560.2 RP11-10L12.4 5.57 1.13e-07 0.000111 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102914239 chr4:102828055~102844075:+ PAAD cis rs17301013 0.507 rs2142864 ENSG00000227373.4 RP11-160H22.5 5.57 1.13e-07 0.000111 0.6 0.41 Systemic lupus erythematosus; chr1:174304924 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2860909 ENSG00000227373.4 RP11-160H22.5 5.57 1.13e-07 0.000111 0.6 0.41 Systemic lupus erythematosus; chr1:174305211 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6700482 ENSG00000227373.4 RP11-160H22.5 5.57 1.13e-07 0.000111 0.6 0.41 Systemic lupus erythematosus; chr1:174306699 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs7553317 ENSG00000227373.4 RP11-160H22.5 5.57 1.13e-07 0.000111 0.6 0.41 Systemic lupus erythematosus; chr1:174307182 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs10912759 ENSG00000227373.4 RP11-160H22.5 5.57 1.13e-07 0.000111 0.6 0.41 Systemic lupus erythematosus; chr1:174312178 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs6425278 ENSG00000227373.4 RP11-160H22.5 5.57 1.13e-07 0.000111 0.6 0.41 Systemic lupus erythematosus; chr1:174313148 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12083548 ENSG00000227373.4 RP11-160H22.5 5.57 1.13e-07 0.000111 0.6 0.41 Systemic lupus erythematosus; chr1:174319134 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12083814 ENSG00000227373.4 RP11-160H22.5 5.57 1.13e-07 0.000111 0.6 0.41 Systemic lupus erythematosus; chr1:174319917 chr1:174115300~174160004:- PAAD cis rs113835537 0.529 rs116867234 ENSG00000255517.5 CTD-3074O7.5 -5.57 1.13e-07 0.000111 -0.56 -0.41 Airway imaging phenotypes; chr11:66441553 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs60358007 ENSG00000255517.5 CTD-3074O7.5 -5.57 1.13e-07 0.000111 -0.56 -0.41 Airway imaging phenotypes; chr11:66454882 chr11:66473490~66480233:- PAAD cis rs7772486 0.79 rs4280983 ENSG00000235652.6 RP11-545I5.3 -5.57 1.13e-07 0.000111 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145959654 chr6:145799409~145886585:+ PAAD cis rs9926296 0.744 rs460879 ENSG00000260259.1 RP11-368I7.4 5.57 1.13e-07 0.000111 0.51 0.41 Vitiligo; chr16:89646481 chr16:89682620~89686569:- PAAD cis rs6538678 0.929 rs7962359 ENSG00000258343.1 RP11-536G4.2 -5.57 1.13e-07 0.000111 -0.54 -0.41 Lupus nephritis in systemic lupus erythematosus; chr12:95862566 chr12:95795345~95858839:- PAAD cis rs2745572 0.557 rs2745569 ENSG00000272279.1 RP11-157J24.2 -5.57 1.13e-07 0.000111 -0.47 -0.41 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1547396 chr6:1528364~1528911:- PAAD cis rs10463554 0.889 rs246911 ENSG00000175749.11 EIF3KP1 5.57 1.13e-07 0.000111 0.54 0.41 Parkinson's disease; chr5:103227502 chr5:103032376~103033031:+ PAAD cis rs10463554 0.889 rs246908 ENSG00000175749.11 EIF3KP1 5.57 1.13e-07 0.000111 0.54 0.41 Parkinson's disease; chr5:103228476 chr5:103032376~103033031:+ PAAD cis rs10463554 0.853 rs246907 ENSG00000175749.11 EIF3KP1 5.57 1.13e-07 0.000111 0.54 0.41 Parkinson's disease; chr5:103230577 chr5:103032376~103033031:+ PAAD cis rs4865169 0.791 rs11731868 ENSG00000269949.1 RP11-738E22.3 -5.57 1.13e-07 0.000111 -0.51 -0.41 Breast cancer; chr4:57029048 chr4:56960927~56961373:- PAAD cis rs673078 0.66 rs7974718 ENSG00000275759.1 RP11-131L12.3 -5.57 1.14e-07 0.000111 -0.53 -0.41 Glucose homeostasis traits; chr12:118243258 chr12:118428281~118428870:+ PAAD cis rs12220777 0.892 rs7083787 ENSG00000230091.5 TMEM254-AS1 5.57 1.14e-07 0.000112 0.75 0.41 Chronic obstructive pulmonary disease-related biomarkers; chr10:80029185 chr10:80046860~80078912:- PAAD cis rs4972806 0.849 rs2071581 ENSG00000226363.3 HAGLROS -5.57 1.14e-07 0.000112 -0.5 -0.41 IgG glycosylation; chr2:176161420 chr2:176177717~176179008:+ PAAD cis rs7615952 0.932 rs13314869 ENSG00000171084.14 FAM86JP 5.57 1.14e-07 0.000112 0.55 0.41 Blood pressure (smoking interaction); chr3:125925826 chr3:125916620~125930024:+ PAAD cis rs7615952 0.741 rs13314845 ENSG00000171084.14 FAM86JP 5.57 1.14e-07 0.000112 0.55 0.41 Blood pressure (smoking interaction); chr3:125925939 chr3:125916620~125930024:+ PAAD cis rs7615952 0.733 rs13314847 ENSG00000171084.14 FAM86JP 5.57 1.14e-07 0.000112 0.55 0.41 Blood pressure (smoking interaction); chr3:125925945 chr3:125916620~125930024:+ PAAD cis rs7615952 0.932 rs13086087 ENSG00000171084.14 FAM86JP 5.57 1.14e-07 0.000112 0.55 0.41 Blood pressure (smoking interaction); chr3:125927438 chr3:125916620~125930024:+ PAAD cis rs7615952 0.8 rs13086460 ENSG00000171084.14 FAM86JP 5.57 1.14e-07 0.000112 0.55 0.41 Blood pressure (smoking interaction); chr3:125927574 chr3:125916620~125930024:+ PAAD cis rs7615952 0.866 rs1976459 ENSG00000171084.14 FAM86JP 5.57 1.14e-07 0.000112 0.55 0.41 Blood pressure (smoking interaction); chr3:125928643 chr3:125916620~125930024:+ PAAD cis rs748404 0.56 rs2255663 ENSG00000249839.1 AC011330.5 5.57 1.14e-07 0.000112 0.59 0.41 Lung cancer; chr15:43536810 chr15:43663654~43684339:- PAAD cis rs4218 0.689 rs12902628 ENSG00000277144.1 RP11-59H7.4 -5.57 1.14e-07 0.000112 -0.56 -0.41 Social communication problems; chr15:59100193 chr15:59115547~59116089:- PAAD cis rs1862618 0.529 rs978406 ENSG00000271828.1 CTD-2310F14.1 -5.57 1.14e-07 0.000112 -0.61 -0.41 Initial pursuit acceleration; chr5:56963981 chr5:56927874~56929573:+ PAAD cis rs12931792 0.712 rs2887799 ENSG00000183604.13 SMG1P5 5.57 1.14e-07 0.000112 0.43 0.41 Tonsillectomy; chr16:30152512 chr16:30267553~30335374:- PAAD cis rs11722779 0.844 rs3974602 ENSG00000246560.2 RP11-10L12.4 5.57 1.14e-07 0.000112 0.45 0.41 Schizophrenia; chr4:102928840 chr4:102828055~102844075:+ PAAD cis rs9425766 0.679 rs12085290 ENSG00000227373.4 RP11-160H22.5 -5.57 1.14e-07 0.000112 -0.52 -0.41 Life satisfaction; chr1:174124699 chr1:174115300~174160004:- PAAD cis rs528808 1 rs528808 ENSG00000219755.1 RP1-199J3.5 5.57 1.14e-07 0.000112 0.62 0.41 Age-related hearing impairment; chr6:99656413 chr6:99575712~99576456:+ PAAD cis rs2281636 0.723 rs11190195 ENSG00000233690.1 EBAG9P1 -5.57 1.14e-07 0.000112 -0.47 -0.41 Obesity-related traits; chr10:99626710 chr10:99697407~99697949:- PAAD cis rs17711722 0.565 rs4275112 ENSG00000234585.5 CCT6P3 -5.57 1.14e-07 0.000112 -0.34 -0.41 Calcium levels; chr7:65733651 chr7:65038354~65074713:+ PAAD cis rs7772486 0.79 rs9403756 ENSG00000235652.6 RP11-545I5.3 -5.57 1.14e-07 0.000112 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145936625 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9376970 ENSG00000235652.6 RP11-545I5.3 -5.57 1.14e-07 0.000112 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145920336 chr6:145799409~145886585:+ PAAD cis rs2946504 0.501 rs2977092 ENSG00000251468.2 RP11-369K16.1 -5.57 1.14e-07 0.000112 -0.46 -0.41 Type 2 diabetes; chr8:12949867 chr8:12958387~12962200:+ PAAD cis rs2111504 0.559 rs12460112 ENSG00000267213.4 AC007773.2 5.57 1.15e-07 0.000112 0.52 0.41 Bipolar disorder; chr19:32363928 chr19:32390050~32405560:- PAAD cis rs2111504 0.583 rs2868082 ENSG00000267213.4 AC007773.2 5.57 1.15e-07 0.000112 0.52 0.41 Bipolar disorder; chr19:32368475 chr19:32390050~32405560:- PAAD cis rs2111504 0.583 rs8104714 ENSG00000267213.4 AC007773.2 5.57 1.15e-07 0.000112 0.52 0.41 Bipolar disorder; chr19:32381203 chr19:32390050~32405560:- PAAD cis rs72772090 0.71 rs11739280 ENSG00000248734.2 CTD-2260A17.1 5.57 1.15e-07 0.000112 0.5 0.41 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96738443 chr5:96784777~96785999:+ PAAD cis rs227275 0.554 rs223319 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000112 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102881157 chr4:102828055~102844075:+ PAAD cis rs228614 0.509 rs223318 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000112 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102881422 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223315 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000112 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102884286 chr4:102828055~102844075:+ PAAD cis rs11722779 0.838 rs4533776 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000112 0.45 0.41 Schizophrenia; chr4:102912732 chr4:102828055~102844075:+ PAAD cis rs11722779 0.838 rs6821247 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000112 0.45 0.41 Schizophrenia; chr4:102913483 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs9917919 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000112 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102918497 chr4:102828055~102844075:+ PAAD cis rs11722779 0.901 rs28674656 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000112 0.45 0.41 Schizophrenia; chr4:102944396 chr4:102828055~102844075:+ PAAD cis rs11098499 0.874 rs6832670 ENSG00000245958.5 RP11-33B1.1 -5.57 1.15e-07 0.000113 -0.34 -0.41 Corneal astigmatism; chr4:119197637 chr4:119454791~119552025:+ PAAD cis rs11098499 0.874 rs6822498 ENSG00000245958.5 RP11-33B1.1 -5.57 1.15e-07 0.000113 -0.34 -0.41 Corneal astigmatism; chr4:119199028 chr4:119454791~119552025:+ PAAD cis rs227275 0.525 rs1080081 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000113 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:103029268 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs4699049 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000113 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:103030467 chr4:102828055~102844075:+ PAAD cis rs11722779 0.903 rs13130741 ENSG00000246560.2 RP11-10L12.4 5.57 1.15e-07 0.000113 0.45 0.41 Schizophrenia; chr4:103035799 chr4:102828055~102844075:+ PAAD cis rs10463554 0.963 rs6883113 ENSG00000175749.11 EIF3KP1 5.56 1.16e-07 0.000113 0.54 0.41 Parkinson's disease; chr5:103042185 chr5:103032376~103033031:+ PAAD cis rs853679 0.517 rs6932109 ENSG00000226314.6 ZNF192P1 5.56 1.16e-07 0.000113 0.68 0.41 Depression; chr6:28110525 chr6:28161781~28169594:+ PAAD cis rs17608059 0.71 rs8080167 ENSG00000141028.6 CDRT15P1 -5.56 1.16e-07 0.000113 -0.5 -0.41 Temperament; chr17:14046511 chr17:14024514~14025488:+ PAAD cis rs17608059 0.679 rs9898056 ENSG00000141028.6 CDRT15P1 -5.56 1.16e-07 0.000113 -0.5 -0.41 Temperament; chr17:14048649 chr17:14024514~14025488:+ PAAD cis rs526231 0.543 rs32851 ENSG00000175749.11 EIF3KP1 5.56 1.16e-07 0.000113 0.54 0.41 Primary biliary cholangitis; chr5:103132967 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs32849 ENSG00000175749.11 EIF3KP1 5.56 1.16e-07 0.000113 0.54 0.41 Primary biliary cholangitis; chr5:103134339 chr5:103032376~103033031:+ PAAD cis rs7772486 0.754 rs702323 ENSG00000235652.6 RP11-545I5.3 -5.56 1.16e-07 0.000113 -0.35 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145687138 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs1337839 ENSG00000235652.6 RP11-545I5.3 -5.56 1.16e-07 0.000113 -0.35 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145689103 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9497395 ENSG00000235652.6 RP11-545I5.3 -5.56 1.16e-07 0.000113 -0.35 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145692456 chr6:145799409~145886585:+ PAAD cis rs1891275 0.551 rs11186640 ENSG00000228701.1 TNKS2-AS1 -5.56 1.17e-07 0.000113 -0.52 -0.41 Intelligence (multi-trait analysis); chr10:91640674 chr10:91782839~91798291:- PAAD cis rs2929278 0.588 rs1975364 ENSG00000205771.5 CATSPER2P1 -5.56 1.17e-07 0.000114 -0.53 -0.41 Schizophrenia; chr15:43857991 chr15:43726918~43747094:- PAAD cis rs227275 0.525 rs17215211 ENSG00000246560.2 RP11-10L12.4 5.56 1.17e-07 0.000114 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:103025961 chr4:102828055~102844075:+ PAAD cis rs2281636 0.723 rs11190245 ENSG00000233690.1 EBAG9P1 5.56 1.17e-07 0.000114 0.49 0.41 Obesity-related traits; chr10:99691502 chr10:99697407~99697949:- PAAD cis rs2243480 0.901 rs778732 ENSG00000226824.5 RP4-756H11.3 -5.56 1.17e-07 0.000114 -0.73 -0.41 Diabetic kidney disease; chr7:66357373 chr7:66654538~66669855:+ PAAD cis rs1075265 0.87 rs7569370 ENSG00000233266.1 HMGB1P31 5.56 1.17e-07 0.000114 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:53989212 chr2:54051334~54051760:+ PAAD cis rs7772486 0.686 rs9403739 ENSG00000235652.6 RP11-545I5.3 -5.56 1.18e-07 0.000114 -0.35 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145694221 chr6:145799409~145886585:+ PAAD cis rs227275 0.525 rs4596243 ENSG00000246560.2 RP11-10L12.4 5.56 1.18e-07 0.000115 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102964411 chr4:102828055~102844075:+ PAAD cis rs9928842 0.722 rs1035540 ENSG00000280152.1 RP11-331F4.5 5.56 1.18e-07 0.000115 0.52 0.41 Alcoholic chronic pancreatitis; chr16:75244897 chr16:75245994~75250077:- PAAD cis rs9928842 0.77 rs4888364 ENSG00000280152.1 RP11-331F4.5 5.56 1.18e-07 0.000115 0.52 0.41 Alcoholic chronic pancreatitis; chr16:75245612 chr16:75245994~75250077:- PAAD cis rs6782228 0.606 rs6807019 ENSG00000242551.2 POU5F1P6 -5.56 1.18e-07 0.000115 -0.48 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128687091 chr3:128674735~128677005:- PAAD cis rs9322193 0.607 rs4870078 ENSG00000268592.3 RAET1E-AS1 -5.56 1.18e-07 0.000115 -0.54 -0.41 Lung cancer; chr6:149880676 chr6:149863494~149919507:+ PAAD cis rs80285556 1 rs80285556 ENSG00000161643.11 SIGLEC16 5.56 1.19e-07 0.000115 0.96 0.41 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50036913 chr19:49969673~49975814:+ PAAD cis rs4722166 0.598 rs35658589 ENSG00000179428.2 AC073072.5 -5.56 1.19e-07 0.000115 -0.37 -0.41 Lung cancer; chr7:22760816 chr7:22725395~22727620:- PAAD cis rs227275 0.527 rs223308 ENSG00000246560.2 RP11-10L12.4 5.56 1.19e-07 0.000115 0.46 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102891342 chr4:102828055~102844075:+ PAAD cis rs113835537 0.529 rs57724777 ENSG00000255517.5 CTD-3074O7.5 -5.56 1.19e-07 0.000116 -0.56 -0.41 Airway imaging phenotypes; chr11:66468960 chr11:66473490~66480233:- PAAD cis rs6142102 0.625 rs6142068 ENSG00000276073.1 RP5-1125A11.7 5.56 1.19e-07 0.000116 0.44 0.41 Skin pigmentation; chr20:33969366 chr20:33985617~33988989:- PAAD cis rs950169 0.544 rs12913702 ENSG00000225151.9 GOLGA2P7 -5.56 1.19e-07 0.000116 -0.5 -0.41 Schizophrenia; chr15:84609953 chr15:84199311~84230136:- PAAD cis rs2274273 0.87 rs7160523 ENSG00000258413.1 RP11-665C16.6 -5.56 1.19e-07 0.000116 -0.51 -0.41 Protein biomarker; chr14:55127842 chr14:55262767~55272075:- PAAD cis rs2274273 0.935 rs8004787 ENSG00000258413.1 RP11-665C16.6 -5.56 1.19e-07 0.000116 -0.51 -0.41 Protein biomarker; chr14:55140648 chr14:55262767~55272075:- PAAD cis rs2274273 0.905 rs2075601 ENSG00000258413.1 RP11-665C16.6 -5.56 1.19e-07 0.000116 -0.51 -0.41 Protein biomarker; chr14:55142516 chr14:55262767~55272075:- PAAD cis rs2274273 0.875 rs2075602 ENSG00000258413.1 RP11-665C16.6 -5.56 1.19e-07 0.000116 -0.51 -0.41 Protein biomarker; chr14:55143056 chr14:55262767~55272075:- PAAD cis rs801193 0.591 rs9986881 ENSG00000226824.5 RP4-756H11.3 -5.56 1.2e-07 0.000116 -0.48 -0.41 Aortic root size; chr7:66708053 chr7:66654538~66669855:+ PAAD cis rs9926296 0.533 rs12102290 ENSG00000260259.1 RP11-368I7.4 -5.56 1.2e-07 0.000116 -0.5 -0.41 Vitiligo; chr16:89746209 chr16:89682620~89686569:- PAAD cis rs2283792 0.765 rs34550586 ENSG00000224086.5 LL22NC03-86G7.1 -5.56 1.2e-07 0.000116 -0.42 -0.41 Multiple sclerosis; chr22:21791345 chr22:21938293~21977632:+ PAAD cis rs113835537 0.529 rs7950407 ENSG00000255517.5 CTD-3074O7.5 -5.56 1.2e-07 0.000116 -0.51 -0.41 Airway imaging phenotypes; chr11:66490535 chr11:66473490~66480233:- PAAD cis rs6504950 0.745 rs35079296 ENSG00000275710.1 RP11-257O5.4 5.56 1.2e-07 0.000117 0.53 0.41 Breast cancer; chr17:54916849 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs17745344 ENSG00000275710.1 RP11-257O5.4 5.55 1.21e-07 0.000118 0.55 0.41 Breast cancer; chr17:54970958 chr17:54964474~54964679:+ PAAD cis rs748404 0.66 rs548704 ENSG00000249839.1 AC011330.5 -5.55 1.21e-07 0.000118 -0.61 -0.41 Lung cancer; chr15:43499508 chr15:43663654~43684339:- PAAD cis rs526231 0.511 rs158402 ENSG00000175749.11 EIF3KP1 5.55 1.22e-07 0.000118 0.54 0.41 Primary biliary cholangitis; chr5:103079821 chr5:103032376~103033031:+ PAAD cis rs228614 0.51 rs223362 ENSG00000246560.2 RP11-10L12.4 5.55 1.22e-07 0.000118 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102848077 chr4:102828055~102844075:+ PAAD cis rs7580658 0.676 rs12465955 ENSG00000236682.1 AC068282.3 -5.55 1.22e-07 0.000118 -0.52 -0.41 Protein C levels; chr2:127249498 chr2:127389130~127400580:+ PAAD cis rs113835537 0.529 rs79798028 ENSG00000255517.5 CTD-3074O7.5 -5.55 1.22e-07 0.000118 -0.51 -0.41 Airway imaging phenotypes; chr11:66431891 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs2279865 ENSG00000255517.5 CTD-3074O7.5 -5.55 1.22e-07 0.000118 -0.51 -0.41 Airway imaging phenotypes; chr11:66435554 chr11:66473490~66480233:- PAAD cis rs113835537 0.502 rs7104378 ENSG00000255517.5 CTD-3074O7.5 -5.55 1.22e-07 0.000118 -0.51 -0.41 Airway imaging phenotypes; chr11:66449204 chr11:66473490~66480233:- PAAD cis rs11123170 0.529 rs112692022 ENSG00000189223.12 PAX8-AS1 -5.55 1.22e-07 0.000119 -0.58 -0.41 Renal function-related traits (BUN); chr2:113212605 chr2:113211522~113276581:+ PAAD cis rs6570726 0.791 rs1509213 ENSG00000235652.6 RP11-545I5.3 -5.55 1.22e-07 0.000119 -0.35 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145462224 chr6:145799409~145886585:+ PAAD cis rs7916697 0.891 rs4746748 ENSG00000233590.1 RP11-153K11.3 5.55 1.22e-07 0.000119 0.56 0.41 Optic disc area; chr10:68249631 chr10:68233251~68242379:- PAAD cis rs7916697 0.842 rs4746749 ENSG00000233590.1 RP11-153K11.3 5.55 1.22e-07 0.000119 0.56 0.41 Optic disc area; chr10:68249632 chr10:68233251~68242379:- PAAD cis rs2115630 0.645 rs4842978 ENSG00000259728.4 LINC00933 -5.55 1.23e-07 0.000119 -0.5 -0.41 P wave terminal force; chr15:84654022 chr15:84570649~84580175:+ PAAD cis rs10463554 0.784 rs187424 ENSG00000175749.11 EIF3KP1 5.55 1.23e-07 0.000119 0.54 0.41 Parkinson's disease; chr5:103251882 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs1011454 ENSG00000175749.11 EIF3KP1 5.55 1.23e-07 0.000119 0.52 0.41 Parkinson's disease; chr5:103032551 chr5:103032376~103033031:+ PAAD cis rs732716 0.785 rs56272533 ENSG00000267769.1 CTB-50L17.9 -5.55 1.23e-07 0.000119 -0.57 -0.41 Mean corpuscular volume; chr19:4420045 chr19:4454014~4455286:+ PAAD cis rs992157 0.735 rs13392177 ENSG00000261338.2 RP11-378A13.1 -5.55 1.23e-07 0.000119 -0.46 -0.41 Colorectal cancer; chr2:218248233 chr2:218255319~218257366:+ PAAD cis rs4218 0.597 rs12438962 ENSG00000277144.1 RP11-59H7.4 -5.55 1.23e-07 0.000119 -0.57 -0.41 Social communication problems; chr15:59065694 chr15:59115547~59116089:- PAAD cis rs4218 0.597 rs10431762 ENSG00000277144.1 RP11-59H7.4 -5.55 1.23e-07 0.000119 -0.57 -0.41 Social communication problems; chr15:59066330 chr15:59115547~59116089:- PAAD cis rs42490 0.873 rs218903 ENSG00000251136.7 RP11-37B2.1 -5.55 1.23e-07 0.000119 -0.38 -0.41 Leprosy; chr8:89721458 chr8:89609409~89757727:- PAAD cis rs732716 0.889 rs62129355 ENSG00000267980.1 AC007292.6 -5.55 1.23e-07 0.000119 -0.53 -0.41 Mean corpuscular volume; chr19:4397037 chr19:4363789~4364640:+ PAAD cis rs2243480 1 rs4548056 ENSG00000226824.5 RP4-756H11.3 -5.55 1.23e-07 0.000119 -0.75 -0.41 Diabetic kidney disease; chr7:65833886 chr7:66654538~66669855:+ PAAD cis rs227275 0.554 rs223371 ENSG00000246560.2 RP11-10L12.4 5.55 1.23e-07 0.000119 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102838032 chr4:102828055~102844075:+ PAAD cis rs35160687 0.712 rs7560886 ENSG00000273080.1 RP11-301O19.1 -5.55 1.24e-07 0.00012 -0.48 -0.41 Night sleep phenotypes; chr2:86265907 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs11674249 ENSG00000273080.1 RP11-301O19.1 -5.55 1.24e-07 0.00012 -0.48 -0.41 Night sleep phenotypes; chr2:86270283 chr2:86195590~86196049:+ PAAD cis rs11722779 0.815 rs223347 ENSG00000246560.2 RP11-10L12.4 5.55 1.24e-07 0.00012 0.46 0.41 Schizophrenia; chr4:102858815 chr4:102828055~102844075:+ PAAD cis rs11722779 0.873 rs223346 ENSG00000246560.2 RP11-10L12.4 5.55 1.24e-07 0.00012 0.46 0.41 Schizophrenia; chr4:102859339 chr4:102828055~102844075:+ PAAD cis rs6570726 0.791 rs9403729 ENSG00000235652.6 RP11-545I5.3 5.55 1.24e-07 0.00012 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145585871 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs10457788 ENSG00000235652.6 RP11-545I5.3 5.55 1.24e-07 0.00012 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145600000 chr6:145799409~145886585:+ PAAD cis rs9926296 0.568 rs7203907 ENSG00000260259.1 RP11-368I7.4 -5.55 1.24e-07 0.00012 -0.49 -0.41 Vitiligo; chr16:89767366 chr16:89682620~89686569:- PAAD cis rs7580658 0.676 rs58475809 ENSG00000236682.1 AC068282.3 -5.55 1.24e-07 0.00012 -0.52 -0.41 Protein C levels; chr2:127245074 chr2:127389130~127400580:+ PAAD cis rs11690935 0.688 rs7600835 ENSG00000228389.1 AC068039.4 5.55 1.25e-07 0.000121 0.47 0.41 Schizophrenia; chr2:171665317 chr2:171773482~171775844:+ PAAD cis rs7772486 0.754 rs1415746 ENSG00000235652.6 RP11-545I5.3 -5.55 1.25e-07 0.000121 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145755971 chr6:145799409~145886585:+ PAAD cis rs228614 0.51 rs223453 ENSG00000246560.2 RP11-10L12.4 5.55 1.25e-07 0.000121 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789895 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs65671 ENSG00000246560.2 RP11-10L12.4 5.55 1.25e-07 0.000121 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102801081 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223412 ENSG00000246560.2 RP11-10L12.4 5.55 1.25e-07 0.000121 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102812443 chr4:102828055~102844075:+ PAAD cis rs228614 0.534 rs223387 ENSG00000246560.2 RP11-10L12.4 5.55 1.25e-07 0.000121 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102828359 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223381 ENSG00000246560.2 RP11-10L12.4 5.55 1.25e-07 0.000121 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102832578 chr4:102828055~102844075:+ PAAD cis rs1075265 0.87 rs7569214 ENSG00000233266.1 HMGB1P31 5.55 1.25e-07 0.000121 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:53989049 chr2:54051334~54051760:+ PAAD cis rs1075265 0.729 rs10201364 ENSG00000233266.1 HMGB1P31 5.55 1.25e-07 0.000121 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:53990220 chr2:54051334~54051760:+ PAAD cis rs6860806 0.507 rs270608 ENSG00000233006.5 AC034220.3 5.55 1.25e-07 0.000121 0.36 0.41 Breast cancer; chr5:132312713 chr5:132311285~132369916:- PAAD cis rs228614 0.51 rs223358 ENSG00000246560.2 RP11-10L12.4 5.55 1.26e-07 0.000122 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102849637 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223356 ENSG00000246560.2 RP11-10L12.4 5.55 1.26e-07 0.000122 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102852344 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223353 ENSG00000246560.2 RP11-10L12.4 5.55 1.26e-07 0.000122 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102854547 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223352 ENSG00000246560.2 RP11-10L12.4 5.55 1.26e-07 0.000122 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102855710 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223349 ENSG00000246560.2 RP11-10L12.4 5.55 1.26e-07 0.000122 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102857277 chr4:102828055~102844075:+ PAAD cis rs17301013 0.507 rs72713532 ENSG00000227373.4 RP11-160H22.5 5.55 1.26e-07 0.000122 0.6 0.41 Systemic lupus erythematosus; chr1:174337826 chr1:174115300~174160004:- PAAD cis rs10510102 0.872 rs12240306 ENSG00000276742.1 RP11-500G22.4 5.55 1.26e-07 0.000122 0.59 0.41 Breast cancer; chr10:121963391 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12240308 ENSG00000276742.1 RP11-500G22.4 5.55 1.26e-07 0.000122 0.59 0.41 Breast cancer; chr10:121963407 chr10:121956782~121957098:+ PAAD cis rs11098499 0.913 rs10006304 ENSG00000245958.5 RP11-33B1.1 -5.55 1.26e-07 0.000122 -0.33 -0.41 Corneal astigmatism; chr4:119203150 chr4:119454791~119552025:+ PAAD cis rs11098499 0.913 rs56122576 ENSG00000245958.5 RP11-33B1.1 -5.55 1.26e-07 0.000122 -0.33 -0.41 Corneal astigmatism; chr4:119208181 chr4:119454791~119552025:+ PAAD cis rs11098499 0.913 rs68128210 ENSG00000245958.5 RP11-33B1.1 -5.55 1.26e-07 0.000122 -0.33 -0.41 Corneal astigmatism; chr4:119216664 chr4:119454791~119552025:+ PAAD cis rs11098499 0.913 rs13126596 ENSG00000245958.5 RP11-33B1.1 -5.55 1.26e-07 0.000122 -0.33 -0.41 Corneal astigmatism; chr4:119219574 chr4:119454791~119552025:+ PAAD cis rs453301 0.624 rs2288673 ENSG00000253893.2 FAM85B -5.55 1.26e-07 0.000122 -0.55 -0.41 Joint mobility (Beighton score); chr8:9002766 chr8:8167819~8226614:- PAAD cis rs2980436 1 rs2980436 ENSG00000173295.6 FAM86B3P -5.55 1.26e-07 0.000122 -0.45 -0.41 Schizophrenia; chr8:8234503 chr8:8228595~8244865:+ PAAD cis rs11098499 0.661 rs10015965 ENSG00000245958.5 RP11-33B1.1 -5.55 1.26e-07 0.000122 -0.29 -0.41 Corneal astigmatism; chr4:119347082 chr4:119454791~119552025:+ PAAD cis rs11098499 0.535 rs10005542 ENSG00000245958.5 RP11-33B1.1 -5.55 1.26e-07 0.000122 -0.29 -0.41 Corneal astigmatism; chr4:119347147 chr4:119454791~119552025:+ PAAD cis rs748404 0.66 rs693510 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43422427 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs509306 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43422973 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs690512 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43425480 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs542898 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43427194 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs690012 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43427557 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs2249952 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43428335 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs689767 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43429879 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs2439845 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43430412 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs2467745 ENSG00000249839.1 AC011330.5 -5.55 1.26e-07 0.000122 -0.6 -0.41 Lung cancer; chr15:43430544 chr15:43663654~43684339:- PAAD cis rs16828019 0.64 rs1140227 ENSG00000235358.1 RP11-399E6.1 5.55 1.26e-07 0.000122 0.79 0.41 Intelligence (multi-trait analysis); chr1:41028139 chr1:41242373~41284861:+ PAAD cis rs875971 0.862 rs6944374 ENSG00000237310.1 GS1-124K5.4 -5.55 1.27e-07 0.000122 -0.41 -0.41 Aortic root size; chr7:66221942 chr7:66493706~66495474:+ PAAD cis rs7580658 0.724 rs71414745 ENSG00000236682.1 AC068282.3 -5.55 1.27e-07 0.000122 -0.52 -0.41 Protein C levels; chr2:127235012 chr2:127389130~127400580:+ PAAD cis rs9926296 0.565 rs8055825 ENSG00000260259.1 RP11-368I7.4 -5.55 1.27e-07 0.000122 -0.49 -0.41 Vitiligo; chr16:89766440 chr16:89682620~89686569:- PAAD cis rs9322193 0.962 rs6903998 ENSG00000216906.2 RP11-350J20.9 5.54 1.27e-07 0.000123 0.53 0.41 Lung cancer; chr6:149831357 chr6:149904243~149906418:+ PAAD cis rs10463554 0.853 rs458598 ENSG00000175749.11 EIF3KP1 5.54 1.27e-07 0.000123 0.54 0.41 Parkinson's disease; chr5:103233677 chr5:103032376~103033031:+ PAAD cis rs8135665 0.6 rs8139025 ENSG00000233739.1 RP5-1039K5.13 5.54 1.28e-07 0.000123 0.51 0.41 Advanced age-related macular degeneration;Age-related macular degeneration; chr22:38054874 chr22:38057180~38073940:- PAAD cis rs11673344 0.932 rs76350084 ENSG00000226686.6 LINC01535 5.54 1.28e-07 0.000123 0.55 0.41 Obesity-related traits; chr19:37187917 chr19:37251912~37265535:+ PAAD cis rs113835537 0.529 rs17580784 ENSG00000255517.5 CTD-3074O7.5 -5.54 1.28e-07 0.000123 -0.56 -0.41 Airway imaging phenotypes; chr11:66447388 chr11:66473490~66480233:- PAAD cis rs9322193 0.961 rs9767713 ENSG00000216906.2 RP11-350J20.9 5.54 1.28e-07 0.000123 0.54 0.41 Lung cancer; chr6:149588241 chr6:149904243~149906418:+ PAAD cis rs17301013 0.507 rs116545832 ENSG00000227373.4 RP11-160H22.5 5.54 1.28e-07 0.000124 0.6 0.41 Systemic lupus erythematosus; chr1:174438725 chr1:174115300~174160004:- PAAD cis rs9532669 0.927 rs9532670 ENSG00000176268.5 CYCSP34 -5.54 1.29e-07 0.000124 -0.38 -0.41 Cervical cancer; chr13:40927691 chr13:40863599~40863902:- PAAD cis rs2929278 0.588 rs688009 ENSG00000205771.5 CATSPER2P1 -5.54 1.29e-07 0.000124 -0.53 -0.41 Schizophrenia; chr15:43864104 chr15:43726918~43747094:- PAAD cis rs11098499 0.863 rs6835635 ENSG00000245958.5 RP11-33B1.1 -5.54 1.29e-07 0.000124 -0.35 -0.41 Corneal astigmatism; chr4:119537712 chr4:119454791~119552025:+ PAAD cis rs12701220 0.655 rs34344742 ENSG00000229043.2 AC091729.9 -5.54 1.29e-07 0.000124 -0.53 -0.41 Bronchopulmonary dysplasia; chr7:1109652 chr7:1160374~1165267:+ PAAD cis rs9640161 0.742 rs2108854 ENSG00000261305.1 RP4-584D14.7 -5.54 1.29e-07 0.000124 -0.59 -0.41 Blood protein levels;Circulating chemerin levels; chr7:150320319 chr7:150341771~150342607:+ PAAD cis rs9640161 0.742 rs2108853 ENSG00000261305.1 RP4-584D14.7 5.54 1.29e-07 0.000124 0.59 0.41 Blood protein levels;Circulating chemerin levels; chr7:150320500 chr7:150341771~150342607:+ PAAD cis rs2274273 0.588 rs7155054 ENSG00000258413.1 RP11-665C16.6 -5.54 1.29e-07 0.000125 -0.54 -0.41 Protein biomarker; chr14:55283944 chr14:55262767~55272075:- PAAD cis rs7829975 0.606 rs6422352 ENSG00000253893.2 FAM85B 5.54 1.29e-07 0.000125 0.54 0.41 Mood instability; chr8:8936683 chr8:8167819~8226614:- PAAD cis rs7829975 0.606 rs891570 ENSG00000253893.2 FAM85B 5.54 1.29e-07 0.000125 0.54 0.41 Mood instability; chr8:8936944 chr8:8167819~8226614:- PAAD cis rs950169 0.58 rs11634320 ENSG00000225151.9 GOLGA2P7 5.54 1.3e-07 0.000125 0.49 0.41 Schizophrenia; chr15:84628952 chr15:84199311~84230136:- PAAD cis rs17507216 0.628 rs17158396 ENSG00000278603.1 RP13-608F4.5 5.54 1.3e-07 0.000125 0.62 0.41 Excessive daytime sleepiness; chr15:82615688 chr15:82472203~82472426:+ PAAD cis rs1862618 0.573 rs185220 ENSG00000271828.1 CTD-2310F14.1 5.54 1.3e-07 0.000125 0.63 0.41 Initial pursuit acceleration; chr5:56909530 chr5:56927874~56929573:+ PAAD cis rs9309711 0.621 rs7586472 ENSG00000225234.1 TRAPPC12-AS1 -5.54 1.3e-07 0.000125 -0.41 -0.41 Neurofibrillary tangles; chr2:3469899 chr2:3481242~3482409:- PAAD cis rs9640161 0.742 rs2159235 ENSG00000261305.1 RP4-584D14.7 5.54 1.3e-07 0.000125 0.59 0.41 Blood protein levels;Circulating chemerin levels; chr7:150320139 chr7:150341771~150342607:+ PAAD cis rs9640161 0.711 rs55881542 ENSG00000261305.1 RP4-584D14.7 5.54 1.3e-07 0.000125 0.63 0.41 Blood protein levels;Circulating chemerin levels; chr7:150328645 chr7:150341771~150342607:+ PAAD cis rs228614 0.51 rs223472 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102774327 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223470 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102778004 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223468 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102779265 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223465 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780174 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223464 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780603 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223463 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102780620 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs223462 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102780661 chr4:102828055~102844075:+ PAAD cis rs227275 0.531 rs223460 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102782903 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223459 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102788229 chr4:102828055~102844075:+ PAAD cis rs227275 0.588 rs223458 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102788414 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223455 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102789026 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223447 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102792202 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223446 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793025 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223445 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793337 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223443 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102793629 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223437 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102798736 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs3774987 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799709 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223435 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799826 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223434 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102799902 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs223426 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102801330 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223425 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102802836 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223420 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102806853 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223419 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102808586 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223418 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102809336 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223415 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102811016 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223410 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102813568 chr4:102828055~102844075:+ PAAD cis rs227275 0.555 rs223403 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102817086 chr4:102828055~102844075:+ PAAD cis rs227275 0.555 rs223402 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102817198 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223400 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102820439 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs223398 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102821256 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223397 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102821494 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223392 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102824599 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223390 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102827640 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs50034 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102832214 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs223380 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102833343 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs223379 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102833434 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223375 ENSG00000246560.2 RP11-10L12.4 5.54 1.3e-07 0.000125 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102836484 chr4:102828055~102844075:+ PAAD cis rs734999 1 rs734999 ENSG00000225931.3 RP3-395M20.7 5.54 1.3e-07 0.000125 0.39 0.41 Ulcerative colitis; chr1:2581777 chr1:2566410~2569888:+ PAAD cis rs734999 1 rs2016366 ENSG00000225931.3 RP3-395M20.7 5.54 1.3e-07 0.000125 0.39 0.41 Ulcerative colitis; chr1:2582239 chr1:2566410~2569888:+ PAAD cis rs1075265 0.729 rs7571086 ENSG00000233266.1 HMGB1P31 5.54 1.31e-07 0.000126 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:54007899 chr2:54051334~54051760:+ PAAD cis rs72843506 0.722 rs16964352 ENSG00000189423.10 USP32P3 5.54 1.31e-07 0.000126 0.61 0.41 Schizophrenia; chr17:20245095 chr17:20415547~20431008:+ PAAD cis rs1185460 0.546 rs17075 ENSG00000271751.1 RP11-110I1.14 5.54 1.31e-07 0.000126 0.55 0.41 Coronary artery disease; chr11:119088621 chr11:119065263~119065677:- PAAD cis rs11089937 0.825 rs5757012 ENSG00000211639.2 IGLV4-60 5.54 1.32e-07 0.000126 0.38 0.41 Periodontitis (PAL4Q3); chr22:22135515 chr22:22162199~22162681:+ PAAD cis rs4218 0.56 rs8039514 ENSG00000277144.1 RP11-59H7.4 -5.54 1.32e-07 0.000126 -0.5 -0.41 Social communication problems; chr15:59114382 chr15:59115547~59116089:- PAAD cis rs113835537 0.529 rs75003264 ENSG00000255517.5 CTD-3074O7.5 -5.54 1.32e-07 0.000127 -0.56 -0.41 Airway imaging phenotypes; chr11:66488628 chr11:66473490~66480233:- PAAD cis rs4218 0.541 rs8030246 ENSG00000277144.1 RP11-59H7.4 -5.54 1.32e-07 0.000127 -0.53 -0.41 Social communication problems; chr15:59049447 chr15:59115547~59116089:- PAAD cis rs75422866 0.85 rs73111220 ENSG00000257433.4 RP1-197B17.3 5.54 1.32e-07 0.000127 1.11 0.41 Pneumonia; chr12:47578764 chr12:47706085~47742294:+ PAAD cis rs7829975 0.606 rs11776838 ENSG00000253893.2 FAM85B 5.54 1.32e-07 0.000127 0.54 0.41 Mood instability; chr8:8937291 chr8:8167819~8226614:- PAAD cis rs7684253 0.587 rs9685436 ENSG00000269949.1 RP11-738E22.3 -5.54 1.33e-07 0.000127 -0.58 -0.41 Migraine; chr4:56881195 chr4:56960927~56961373:- PAAD cis rs7945705 0.782 rs2742545 ENSG00000254860.4 TMEM9B-AS1 5.54 1.33e-07 0.000127 0.43 0.41 Hemoglobin concentration; chr11:8862761 chr11:8964675~8977527:+ PAAD cis rs7945705 0.84 rs10840136 ENSG00000254860.4 TMEM9B-AS1 5.54 1.33e-07 0.000127 0.43 0.41 Hemoglobin concentration; chr11:8863477 chr11:8964675~8977527:+ PAAD cis rs12701220 0.553 rs13245507 ENSG00000229043.2 AC091729.9 -5.54 1.33e-07 0.000127 -0.51 -0.41 Bronchopulmonary dysplasia; chr7:1124058 chr7:1160374~1165267:+ PAAD cis rs4218 0.689 rs73418863 ENSG00000277144.1 RP11-59H7.4 -5.54 1.33e-07 0.000127 -0.56 -0.41 Social communication problems; chr15:59098923 chr15:59115547~59116089:- PAAD cis rs4218 0.689 rs12900369 ENSG00000277144.1 RP11-59H7.4 -5.54 1.33e-07 0.000127 -0.56 -0.41 Social communication problems; chr15:59099254 chr15:59115547~59116089:- PAAD cis rs4218 0.689 rs28514475 ENSG00000277144.1 RP11-59H7.4 -5.54 1.33e-07 0.000127 -0.56 -0.41 Social communication problems; chr15:59099896 chr15:59115547~59116089:- PAAD cis rs4218 0.689 rs28610479 ENSG00000277144.1 RP11-59H7.4 -5.54 1.33e-07 0.000127 -0.56 -0.41 Social communication problems; chr15:59099906 chr15:59115547~59116089:- PAAD cis rs4218 0.689 rs28391430 ENSG00000277144.1 RP11-59H7.4 -5.54 1.33e-07 0.000127 -0.56 -0.41 Social communication problems; chr15:59100318 chr15:59115547~59116089:- PAAD cis rs10463554 0.759 rs34815 ENSG00000175749.11 EIF3KP1 5.54 1.33e-07 0.000128 0.54 0.41 Parkinson's disease; chr5:103098561 chr5:103032376~103033031:+ PAAD cis rs113835537 0.597 rs57288351 ENSG00000255517.5 CTD-3074O7.5 -5.53 1.33e-07 0.000128 -0.56 -0.41 Airway imaging phenotypes; chr11:66540018 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227525 ENSG00000255517.5 CTD-3074O7.5 -5.53 1.33e-07 0.000128 -0.56 -0.41 Airway imaging phenotypes; chr11:66540594 chr11:66473490~66480233:- PAAD cis rs11673344 0.931 rs1234251 ENSG00000226686.6 LINC01535 5.53 1.34e-07 0.000128 0.53 0.41 Obesity-related traits; chr19:37180354 chr19:37251912~37265535:+ PAAD cis rs10463554 0.963 rs6889592 ENSG00000175749.11 EIF3KP1 5.53 1.34e-07 0.000128 0.52 0.41 Parkinson's disease; chr5:102978235 chr5:103032376~103033031:+ PAAD cis rs10463554 1 rs17154893 ENSG00000175749.11 EIF3KP1 5.53 1.34e-07 0.000128 0.52 0.41 Parkinson's disease; chr5:102980902 chr5:103032376~103033031:+ PAAD cis rs10463554 1 rs6596529 ENSG00000175749.11 EIF3KP1 5.53 1.34e-07 0.000128 0.52 0.41 Parkinson's disease; chr5:102981338 chr5:103032376~103033031:+ PAAD cis rs367615 0.512 rs246104 ENSG00000249476.1 CTD-2587M2.1 -5.53 1.34e-07 0.000128 -0.47 -0.41 Colorectal cancer (SNP x SNP interaction); chr5:109365281 chr5:109237120~109326369:- PAAD cis rs7772486 0.875 rs932522 ENSG00000235652.6 RP11-545I5.3 -5.53 1.34e-07 0.000129 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:146052890 chr6:145799409~145886585:+ PAAD cis rs9322193 0.962 rs3763163 ENSG00000216906.2 RP11-350J20.9 5.53 1.34e-07 0.000129 0.52 0.41 Lung cancer; chr6:149819770 chr6:149904243~149906418:+ PAAD cis rs8091660 0.929 rs2175564 ENSG00000278983.1 RP11-426J5.3 5.53 1.35e-07 0.000129 0.5 0.41 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48570838 chr18:48564795~48568342:+ PAAD cis rs453301 0.571 rs2929456 ENSG00000253893.2 FAM85B 5.53 1.35e-07 0.000129 0.56 0.41 Joint mobility (Beighton score); chr8:9225906 chr8:8167819~8226614:- PAAD cis rs73219805 0.597 rs3824232 ENSG00000228451.3 SDAD1P1 -5.53 1.35e-07 0.00013 -0.69 -0.41 Schizophrenia; chr8:26370083 chr8:26379259~26382953:- PAAD cis rs10875746 0.729 rs1990028 ENSG00000240399.1 RP1-228P16.1 -5.53 1.35e-07 0.00013 -0.42 -0.41 Longevity (90 years and older); chr12:48014230 chr12:48054813~48055591:- PAAD cis rs1930961 1 rs6519611 ENSG00000100058.11 CRYBB2P1 5.53 1.36e-07 0.00013 0.73 0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25449888 chr22:25448105~25520854:+ PAAD cis rs1930961 0.867 rs6423498 ENSG00000100058.11 CRYBB2P1 5.53 1.36e-07 0.00013 0.73 0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25457401 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs6004659 ENSG00000100058.11 CRYBB2P1 5.53 1.36e-07 0.00013 0.73 0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25460444 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs6004662 ENSG00000100058.11 CRYBB2P1 5.53 1.36e-07 0.00013 0.73 0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25466157 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs760554 ENSG00000100058.11 CRYBB2P1 5.53 1.36e-07 0.00013 0.73 0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25476625 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs760555 ENSG00000100058.11 CRYBB2P1 5.53 1.36e-07 0.00013 0.73 0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25476870 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs7285549 ENSG00000100058.11 CRYBB2P1 5.53 1.36e-07 0.00013 0.73 0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25448105~25520854:+ PAAD cis rs2280018 0.609 rs2941253 ENSG00000260735.1 RP11-72I8.1 -5.53 1.36e-07 0.00013 -0.53 -0.41 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15079889 chr16:15094411~15109197:+ PAAD cis rs950169 0.545 rs4842841 ENSG00000259728.4 LINC00933 5.53 1.36e-07 0.00013 0.53 0.41 Schizophrenia; chr15:83972373 chr15:84570649~84580175:+ PAAD cis rs2581828 0.656 rs34530577 ENSG00000242142.1 SERBP1P3 5.53 1.36e-07 0.00013 0.48 0.41 Crohn's disease; chr3:53069780 chr3:53064283~53065091:- PAAD cis rs10754283 0.756 rs17441836 ENSG00000231613.1 RP5-943J3.1 5.53 1.36e-07 0.00013 0.46 0.41 Amyotrophic lateral sclerosis (sporadic); chr1:89669874 chr1:89788914~89790492:+ PAAD cis rs9322193 0.961 rs9027 ENSG00000216906.2 RP11-350J20.9 5.53 1.36e-07 0.00013 0.52 0.41 Lung cancer; chr6:149594921 chr6:149904243~149906418:+ PAAD cis rs526231 0.543 rs7709726 ENSG00000175749.11 EIF3KP1 -5.53 1.36e-07 0.000131 -0.51 -0.41 Primary biliary cholangitis; chr5:102991759 chr5:103032376~103033031:+ PAAD cis rs17711722 0.565 rs4717276 ENSG00000234585.5 CCT6P3 5.53 1.37e-07 0.000131 0.33 0.41 Calcium levels; chr7:65829754 chr7:65038354~65074713:+ PAAD cis rs8062405 0.964 rs62036614 ENSG00000251417.2 RP11-1348G14.4 -5.53 1.37e-07 0.000131 -0.36 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28813364 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62036616 ENSG00000251417.2 RP11-1348G14.4 -5.53 1.37e-07 0.000131 -0.36 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814986 chr16:28802743~28817828:+ PAAD cis rs1009647 1 rs1890256 ENSG00000258413.1 RP11-665C16.6 -5.53 1.37e-07 0.000131 -0.57 -0.41 Testicular germ cell tumor; chr14:55414558 chr14:55262767~55272075:- PAAD cis rs6504622 0.902 rs1052586 ENSG00000262879.4 RP11-156P1.3 -5.53 1.37e-07 0.000131 -0.43 -0.41 Orofacial clefts; chr17:46941097 chr17:46984045~47100323:- PAAD cis rs7829975 0.606 rs10112585 ENSG00000253893.2 FAM85B 5.53 1.37e-07 0.000131 0.54 0.41 Mood instability; chr8:8937520 chr8:8167819~8226614:- PAAD cis rs17495987 0.63 rs17496524 ENSG00000219545.8 UMAD1 5.53 1.37e-07 0.000131 0.54 0.41 Tonsillectomy; chr7:7868543 chr7:7640711~8004059:+ PAAD cis rs17495987 0.63 rs17562406 ENSG00000219545.8 UMAD1 5.53 1.37e-07 0.000131 0.54 0.41 Tonsillectomy; chr7:7868699 chr7:7640711~8004059:+ PAAD cis rs7916697 1 rs7916697 ENSG00000233590.1 RP11-153K11.3 5.53 1.38e-07 0.000131 0.56 0.41 Optic disc area; chr10:68232096 chr10:68233251~68242379:- PAAD cis rs748404 0.578 rs2012467 ENSG00000249839.1 AC011330.5 -5.53 1.38e-07 0.000132 -0.58 -0.41 Lung cancer; chr15:43398367 chr15:43663654~43684339:- PAAD cis rs7829975 0.572 rs7005000 ENSG00000253893.2 FAM85B 5.53 1.38e-07 0.000132 0.54 0.41 Mood instability; chr8:8939092 chr8:8167819~8226614:- PAAD cis rs172166 0.61 rs276369 ENSG00000204709.4 LINC01556 5.53 1.38e-07 0.000132 0.56 0.41 Cardiac Troponin-T levels; chr6:27951465 chr6:28943877~28944537:+ PAAD cis rs2243480 1 rs313813 ENSG00000226824.5 RP4-756H11.3 -5.53 1.38e-07 0.000132 -0.74 -0.41 Diabetic kidney disease; chr7:66038513 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs427044 ENSG00000226824.5 RP4-756H11.3 -5.53 1.38e-07 0.000132 -0.74 -0.41 Diabetic kidney disease; chr7:66043558 chr7:66654538~66669855:+ PAAD cis rs7916697 0.947 rs1900004 ENSG00000233590.1 RP11-153K11.3 -5.53 1.38e-07 0.000132 -0.55 -0.41 Optic disc area; chr10:68241124 chr10:68233251~68242379:- PAAD cis rs17608059 0.545 rs9915045 ENSG00000141028.6 CDRT15P1 -5.53 1.38e-07 0.000132 -0.49 -0.41 Temperament; chr17:13999319 chr17:14024514~14025488:+ PAAD cis rs638893 0.842 rs480791 ENSG00000278376.1 RP11-158I9.8 -5.53 1.38e-07 0.000132 -0.56 -0.41 Vitiligo; chr11:118833546 chr11:118791254~118793137:+ PAAD cis rs17608059 0.545 rs9944522 ENSG00000141028.6 CDRT15P1 -5.53 1.38e-07 0.000132 -0.5 -0.41 Temperament; chr17:14015466 chr17:14024514~14025488:+ PAAD cis rs9640161 0.658 rs60467296 ENSG00000261305.1 RP4-584D14.7 5.53 1.38e-07 0.000132 0.61 0.41 Blood protein levels;Circulating chemerin levels; chr7:150318382 chr7:150341771~150342607:+ PAAD cis rs72843506 0.722 rs9908032 ENSG00000189423.10 USP32P3 5.53 1.39e-07 0.000132 0.62 0.41 Schizophrenia; chr17:20204871 chr17:20415547~20431008:+ PAAD cis rs72843506 0.591 rs75925580 ENSG00000189423.10 USP32P3 5.53 1.39e-07 0.000132 0.62 0.41 Schizophrenia; chr17:20211700 chr17:20415547~20431008:+ PAAD cis rs72843506 0.722 rs12051550 ENSG00000189423.10 USP32P3 5.53 1.39e-07 0.000132 0.62 0.41 Schizophrenia; chr17:20226233 chr17:20415547~20431008:+ PAAD cis rs72843506 0.722 rs9901484 ENSG00000189423.10 USP32P3 5.53 1.39e-07 0.000132 0.62 0.41 Schizophrenia; chr17:20229581 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs16959946 ENSG00000189423.10 USP32P3 5.53 1.39e-07 0.000132 0.62 0.41 Schizophrenia; chr17:20269134 chr17:20415547~20431008:+ PAAD cis rs72843506 0.722 rs5025290 ENSG00000189423.10 USP32P3 5.53 1.39e-07 0.000132 0.62 0.41 Schizophrenia; chr17:20302504 chr17:20415547~20431008:+ PAAD cis rs72843506 0.722 rs9895177 ENSG00000189423.10 USP32P3 5.53 1.39e-07 0.000132 0.62 0.41 Schizophrenia; chr17:20304281 chr17:20415547~20431008:+ PAAD cis rs1150668 0.699 rs12214383 ENSG00000216901.1 AL022393.7 -5.53 1.39e-07 0.000132 -0.46 -0.41 Pubertal anthropometrics; chr6:28255953 chr6:28176188~28176674:+ PAAD cis rs1150668 0.699 rs1736895 ENSG00000216901.1 AL022393.7 5.53 1.39e-07 0.000132 0.46 0.41 Pubertal anthropometrics; chr6:28252048 chr6:28176188~28176674:+ PAAD cis rs732716 0.889 rs55637375 ENSG00000267980.1 AC007292.6 -5.53 1.39e-07 0.000133 -0.53 -0.41 Mean corpuscular volume; chr19:4386848 chr19:4363789~4364640:+ PAAD cis rs7580658 0.676 rs4662717 ENSG00000236682.1 AC068282.3 -5.53 1.39e-07 0.000133 -0.51 -0.41 Protein C levels; chr2:127255928 chr2:127389130~127400580:+ PAAD cis rs853679 0.527 rs853693 ENSG00000216901.1 AL022393.7 5.53 1.39e-07 0.000133 0.51 0.41 Depression; chr6:28314871 chr6:28176188~28176674:+ PAAD cis rs932287 0.54 rs4910442 ENSG00000254860.4 TMEM9B-AS1 -5.53 1.39e-07 0.000133 -0.45 -0.41 Colonoscopy-negative controls vs population controls; chr11:9022790 chr11:8964675~8977527:+ PAAD cis rs4660456 0.913 rs2744808 ENSG00000237899.1 RP4-739H11.3 -5.52 1.4e-07 0.000133 -0.55 -0.41 Platelet count; chr1:40712271 chr1:40669089~40687588:- PAAD cis rs227275 0.556 rs6842179 ENSG00000246560.2 RP11-10L12.4 5.52 1.4e-07 0.000134 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:103018363 chr4:102828055~102844075:+ PAAD cis rs160451 0.966 rs160447 ENSG00000251136.7 RP11-37B2.1 5.52 1.4e-07 0.000134 0.38 0.41 Leprosy; chr8:89647432 chr8:89609409~89757727:- PAAD cis rs160451 0.966 rs183363 ENSG00000251136.7 RP11-37B2.1 5.52 1.4e-07 0.000134 0.38 0.41 Leprosy; chr8:89665951 chr8:89609409~89757727:- PAAD cis rs160451 0.933 rs2088198 ENSG00000251136.7 RP11-37B2.1 5.52 1.4e-07 0.000134 0.38 0.41 Leprosy; chr8:89678693 chr8:89609409~89757727:- PAAD cis rs732716 0.785 rs62130979 ENSG00000267769.1 CTB-50L17.9 -5.52 1.4e-07 0.000134 -0.58 -0.41 Mean corpuscular volume; chr19:4432447 chr19:4454014~4455286:+ PAAD cis rs2243480 1 rs437889 ENSG00000226824.5 RP4-756H11.3 -5.52 1.41e-07 0.000134 -0.74 -0.41 Diabetic kidney disease; chr7:66044247 chr7:66654538~66669855:+ PAAD cis rs9828933 1 rs9828933 ENSG00000280620.1 SCAANT1 5.52 1.41e-07 0.000134 0.67 0.41 Type 2 diabetes; chr3:64017221 chr3:63911518~63911772:- PAAD cis rs9828933 0.938 rs7617036 ENSG00000280620.1 SCAANT1 5.52 1.41e-07 0.000134 0.67 0.41 Type 2 diabetes; chr3:64017319 chr3:63911518~63911772:- PAAD cis rs453301 0.571 rs2929454 ENSG00000253893.2 FAM85B 5.52 1.41e-07 0.000135 0.56 0.41 Joint mobility (Beighton score); chr8:9226344 chr8:8167819~8226614:- PAAD cis rs10463554 0.963 rs11242485 ENSG00000175749.11 EIF3KP1 5.52 1.41e-07 0.000135 0.53 0.41 Parkinson's disease; chr5:103046330 chr5:103032376~103033031:+ PAAD cis rs189798 0.738 rs330911 ENSG00000254340.1 RP11-10A14.3 5.52 1.42e-07 0.000135 0.55 0.41 Myopia (pathological); chr8:9138763 chr8:9141424~9145435:+ PAAD cis rs858239 0.665 rs858305 ENSG00000226816.2 AC005082.12 -5.52 1.42e-07 0.000135 -0.45 -0.41 Cerebrospinal fluid biomarker levels; chr7:23203211 chr7:23206013~23208045:+ PAAD cis rs4218 0.648 rs60285686 ENSG00000277144.1 RP11-59H7.4 -5.52 1.42e-07 0.000135 -0.58 -0.41 Social communication problems; chr15:59079829 chr15:59115547~59116089:- PAAD cis rs4218 0.648 rs60741546 ENSG00000277144.1 RP11-59H7.4 -5.52 1.42e-07 0.000135 -0.58 -0.41 Social communication problems; chr15:59079831 chr15:59115547~59116089:- PAAD cis rs72843506 0.722 rs79590067 ENSG00000189423.10 USP32P3 5.52 1.42e-07 0.000135 0.62 0.41 Schizophrenia; chr17:20204101 chr17:20415547~20431008:+ PAAD cis rs72843506 0.722 rs75226250 ENSG00000189423.10 USP32P3 5.52 1.42e-07 0.000135 0.62 0.41 Schizophrenia; chr17:20229004 chr17:20415547~20431008:+ PAAD cis rs72843506 0.722 rs78477504 ENSG00000189423.10 USP32P3 5.52 1.42e-07 0.000135 0.62 0.41 Schizophrenia; chr17:20235034 chr17:20415547~20431008:+ PAAD cis rs72843506 0.722 rs76309839 ENSG00000189423.10 USP32P3 5.52 1.42e-07 0.000135 0.62 0.41 Schizophrenia; chr17:20272147 chr17:20415547~20431008:+ PAAD cis rs1155848 0.892 rs1977354 ENSG00000227354.5 RBM26-AS1 5.52 1.42e-07 0.000136 0.82 0.41 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79383273 chr13:79406309~79424328:+ PAAD cis rs1155848 0.892 rs3742121 ENSG00000227354.5 RBM26-AS1 5.52 1.42e-07 0.000136 0.82 0.41 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79387009 chr13:79406309~79424328:+ PAAD cis rs80285556 0.85 rs55975323 ENSG00000161643.11 SIGLEC16 5.52 1.42e-07 0.000136 0.94 0.41 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50071686 chr19:49969673~49975814:+ PAAD cis rs6142102 0.58 rs6142101 ENSG00000276073.1 RP5-1125A11.7 -5.52 1.43e-07 0.000136 -0.42 -0.41 Skin pigmentation; chr20:34110039 chr20:33985617~33988989:- PAAD cis rs2274273 0.84 rs11547116 ENSG00000258413.1 RP11-665C16.6 -5.52 1.43e-07 0.000136 -0.51 -0.41 Protein biomarker; chr14:55271447 chr14:55262767~55272075:- PAAD cis rs4308124 0.708 rs6716091 ENSG00000227992.1 AC108463.2 -5.52 1.43e-07 0.000136 -0.47 -0.41 Vitiligo; chr2:111233556 chr2:111203964~111206215:- PAAD cis rs4308124 0.708 rs6749633 ENSG00000227992.1 AC108463.2 5.52 1.43e-07 0.000136 0.47 0.41 Vitiligo; chr2:111230439 chr2:111203964~111206215:- PAAD cis rs9828933 0.577 rs832193 ENSG00000280620.1 SCAANT1 -5.52 1.43e-07 0.000136 -0.68 -0.41 Type 2 diabetes; chr3:63868769 chr3:63911518~63911772:- PAAD cis rs4218 0.597 rs12442301 ENSG00000277144.1 RP11-59H7.4 -5.52 1.43e-07 0.000136 -0.57 -0.41 Social communication problems; chr15:59065968 chr15:59115547~59116089:- PAAD cis rs950169 0.545 rs4354897 ENSG00000259728.4 LINC00933 5.52 1.43e-07 0.000136 0.52 0.41 Schizophrenia; chr15:83976219 chr15:84570649~84580175:+ PAAD cis rs2739330 0.731 rs2000468 ENSG00000206090.4 AP000350.7 5.52 1.44e-07 0.000137 0.49 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23939998~23942798:+ PAAD cis rs2274273 0.638 rs3825614 ENSG00000258413.1 RP11-665C16.6 -5.52 1.44e-07 0.000137 -0.56 -0.41 Protein biomarker; chr14:55262669 chr14:55262767~55272075:- PAAD cis rs12701220 0.655 rs7784403 ENSG00000229043.2 AC091729.9 -5.52 1.44e-07 0.000137 -0.53 -0.41 Bronchopulmonary dysplasia; chr7:1113441 chr7:1160374~1165267:+ PAAD cis rs12701220 0.553 rs7782024 ENSG00000229043.2 AC091729.9 -5.52 1.44e-07 0.000137 -0.53 -0.41 Bronchopulmonary dysplasia; chr7:1117866 chr7:1160374~1165267:+ PAAD cis rs227275 0.525 rs7698608 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:103016817 chr4:102828055~102844075:+ PAAD cis rs7772486 0.846 rs866473 ENSG00000235652.6 RP11-545I5.3 5.52 1.45e-07 0.000137 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146032278 chr6:145799409~145886585:+ PAAD cis rs11722779 0.844 rs10003326 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Schizophrenia; chr4:102948193 chr4:102828055~102844075:+ PAAD cis rs11722779 0.787 rs6533040 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Schizophrenia; chr4:102951421 chr4:102828055~102844075:+ PAAD cis rs11722779 0.903 rs6830193 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Schizophrenia; chr4:102955457 chr4:102828055~102844075:+ PAAD cis rs11722779 0.935 rs6533046 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Schizophrenia; chr4:102965917 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs4455413 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102971925 chr4:102828055~102844075:+ PAAD cis rs11722779 0.935 rs7681629 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Schizophrenia; chr4:102974407 chr4:102828055~102844075:+ PAAD cis rs11722779 0.844 rs17033381 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Schizophrenia; chr4:102974952 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs4699044 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102976939 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs4699045 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102977009 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs12508069 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102983598 chr4:102828055~102844075:+ PAAD cis rs227275 0.527 rs12500379 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102983665 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs10015289 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102984956 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs6852141 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102986439 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs9999303 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102986881 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs6810668 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102987574 chr4:102828055~102844075:+ PAAD cis rs228614 0.509 rs4455415 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102993663 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs6853193 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102994888 chr4:102828055~102844075:+ PAAD cis rs11722779 0.935 rs3857200 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Schizophrenia; chr4:103001864 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs724447 ENSG00000246560.2 RP11-10L12.4 -5.52 1.45e-07 0.000137 -0.45 -0.41 Allergic disease (asthma, hay fever or eczema); chr4:103010149 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs11731885 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:103010913 chr4:102828055~102844075:+ PAAD cis rs11722779 0.935 rs11938650 ENSG00000246560.2 RP11-10L12.4 5.52 1.45e-07 0.000137 0.45 0.41 Schizophrenia; chr4:103021639 chr4:102828055~102844075:+ PAAD cis rs2274273 0.905 rs4652 ENSG00000258413.1 RP11-665C16.6 -5.52 1.45e-07 0.000137 -0.51 -0.41 Protein biomarker; chr14:55138318 chr14:55262767~55272075:- PAAD cis rs9322193 1 rs9322193 ENSG00000216906.2 RP11-350J20.9 5.52 1.45e-07 0.000137 0.52 0.41 Lung cancer; chr6:149598007 chr6:149904243~149906418:+ PAAD cis rs4218 0.541 rs8030323 ENSG00000277144.1 RP11-59H7.4 -5.52 1.45e-07 0.000138 -0.52 -0.41 Social communication problems; chr15:59048048 chr15:59115547~59116089:- PAAD cis rs1400745 0.756 rs10136352 ENSG00000258738.1 RP11-73E17.2 5.52 1.45e-07 0.000138 0.47 0.41 Monocyte count; chr14:34865349 chr14:34874343~34876459:+ PAAD cis rs17301013 0.507 rs10489256 ENSG00000227373.4 RP11-160H22.5 5.52 1.45e-07 0.000138 0.62 0.41 Systemic lupus erythematosus; chr1:174359663 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs4651016 ENSG00000227373.4 RP11-160H22.5 5.52 1.45e-07 0.000138 0.62 0.41 Systemic lupus erythematosus; chr1:174375146 chr1:174115300~174160004:- PAAD cis rs858239 1 rs199347 ENSG00000226816.2 AC005082.12 5.52 1.46e-07 0.000139 0.47 0.41 Cerebrospinal fluid biomarker levels; chr7:23254127 chr7:23206013~23208045:+ PAAD cis rs7772486 0.875 rs854145 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146028514 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9376975 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146034445 chr6:145799409~145886585:+ PAAD cis rs7772486 0.846 rs9376976 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146034469 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs7761033 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146034970 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9403763 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146036519 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9403764 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146039446 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9399572 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146041809 chr6:145799409~145886585:+ PAAD cis rs7772486 0.846 rs9373482 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146041987 chr6:145799409~145886585:+ PAAD cis rs7772486 0.817 rs9386145 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146042383 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9390372 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146042502 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9373483 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146043058 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs7766463 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146043317 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs7766595 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146043371 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs13198450 ENSG00000235652.6 RP11-545I5.3 5.51 1.47e-07 0.000139 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146049388 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs6932863 ENSG00000235652.6 RP11-545I5.3 -5.51 1.47e-07 0.000139 -0.35 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145700119 chr6:145799409~145886585:+ PAAD cis rs8062405 1 rs8062405 ENSG00000251417.2 RP11-1348G14.4 5.51 1.47e-07 0.000139 0.36 0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826585 chr16:28802743~28817828:+ PAAD cis rs1400745 0.812 rs72678789 ENSG00000258738.1 RP11-73E17.2 -5.51 1.48e-07 0.00014 -0.47 -0.41 Monocyte count; chr14:34878995 chr14:34874343~34876459:+ PAAD cis rs6860806 0.531 rs270607 ENSG00000233006.5 AC034220.3 5.51 1.48e-07 0.000141 0.36 0.41 Breast cancer; chr5:132313493 chr5:132311285~132369916:- PAAD cis rs7945705 0.846 rs4929911 ENSG00000254860.4 TMEM9B-AS1 -5.51 1.49e-07 0.000141 -0.44 -0.41 Hemoglobin concentration; chr11:8794948 chr11:8964675~8977527:+ PAAD cis rs2115630 0.653 rs61394864 ENSG00000259728.4 LINC00933 -5.51 1.49e-07 0.000141 -0.49 -0.41 P wave terminal force; chr15:84626943 chr15:84570649~84580175:+ PAAD cis rs3761847 0.622 rs4837807 ENSG00000226752.6 PSMD5-AS1 -5.51 1.49e-07 0.000142 -0.46 -0.41 Rheumatoid arthritis; chr9:121029727 chr9:120824828~120854385:+ PAAD cis rs11722779 0.935 rs3974481 ENSG00000246560.2 RP11-10L12.4 5.51 1.5e-07 0.000142 0.45 0.41 Schizophrenia; chr4:102956834 chr4:102828055~102844075:+ PAAD cis rs4218 0.636 rs4775116 ENSG00000277144.1 RP11-59H7.4 5.51 1.5e-07 0.000142 0.53 0.41 Social communication problems; chr15:59135608 chr15:59115547~59116089:- PAAD cis rs12701220 0.655 rs6955290 ENSG00000229043.2 AC091729.9 5.51 1.51e-07 0.000143 0.53 0.41 Bronchopulmonary dysplasia; chr7:1111430 chr7:1160374~1165267:+ PAAD cis rs2274273 0.84 rs943590 ENSG00000258413.1 RP11-665C16.6 -5.51 1.51e-07 0.000143 -0.5 -0.41 Protein biomarker; chr14:55271878 chr14:55262767~55272075:- PAAD cis rs6504622 0.967 rs11869840 ENSG00000262879.4 RP11-156P1.3 -5.51 1.51e-07 0.000143 -0.42 -0.41 Orofacial clefts; chr17:46918734 chr17:46984045~47100323:- PAAD cis rs34375054 0.672 rs2291247 ENSG00000279233.1 RP11-158L12.4 5.51 1.51e-07 0.000143 0.34 0.41 Post bronchodilator FEV1/FVC ratio; chr12:125134407 chr12:125138245~125141711:+ PAAD cis rs7916697 0.891 rs7897809 ENSG00000233590.1 RP11-153K11.3 -5.51 1.51e-07 0.000143 -0.55 -0.41 Optic disc area; chr10:68240536 chr10:68233251~68242379:- PAAD cis rs7916697 0.947 rs9783176 ENSG00000233590.1 RP11-153K11.3 -5.51 1.51e-07 0.000143 -0.55 -0.41 Optic disc area; chr10:68242636 chr10:68233251~68242379:- PAAD cis rs10463554 0.889 rs246899 ENSG00000175749.11 EIF3KP1 5.51 1.51e-07 0.000143 0.53 0.41 Parkinson's disease; chr5:103241438 chr5:103032376~103033031:+ PAAD cis rs2337406 0.714 rs117798641 ENSG00000274576.2 IGHV2-70 -5.51 1.51e-07 0.000143 -0.5 -0.41 Alzheimer's disease (late onset); chr14:106777984 chr14:106770577~106771020:- PAAD cis rs17608059 0.566 rs17676459 ENSG00000141028.6 CDRT15P1 -5.51 1.52e-07 0.000144 -0.49 -0.41 Temperament; chr17:14007198 chr17:14024514~14025488:+ PAAD cis rs17608059 0.566 rs5005684 ENSG00000141028.6 CDRT15P1 -5.51 1.52e-07 0.000144 -0.49 -0.41 Temperament; chr17:14007316 chr17:14024514~14025488:+ PAAD cis rs73219805 0.554 rs3808566 ENSG00000228451.3 SDAD1P1 5.51 1.52e-07 0.000144 0.69 0.41 Schizophrenia; chr8:26365942 chr8:26379259~26382953:- PAAD cis rs6782228 0.606 rs4857861 ENSG00000242551.2 POU5F1P6 -5.51 1.52e-07 0.000144 -0.48 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128687924 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs4857919 ENSG00000242551.2 POU5F1P6 -5.51 1.52e-07 0.000144 -0.48 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128688652 chr3:128674735~128677005:- PAAD cis rs1823913 0.927 rs35339956 ENSG00000280083.1 RP11-317J9.1 -5.51 1.52e-07 0.000144 -0.53 -0.41 Obesity-related traits; chr2:191261668 chr2:191154118~191156070:- PAAD cis rs1823913 0.927 rs56209234 ENSG00000280083.1 RP11-317J9.1 -5.51 1.52e-07 0.000144 -0.53 -0.41 Obesity-related traits; chr2:191261748 chr2:191154118~191156070:- PAAD cis rs526231 0.543 rs152134 ENSG00000175749.11 EIF3KP1 5.51 1.53e-07 0.000144 0.52 0.41 Primary biliary cholangitis; chr5:103176745 chr5:103032376~103033031:+ PAAD cis rs7772486 0.72 rs702320 ENSG00000235652.6 RP11-545I5.3 -5.5 1.54e-07 0.000145 -0.34 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145685518 chr6:145799409~145886585:+ PAAD cis rs6723162 0.51 rs11126309 ENSG00000237751.2 LINC01143 5.5 1.54e-07 0.000145 0.54 0.41 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70922163 chr2:70887871~70889959:+ PAAD cis rs526231 0.511 rs6881612 ENSG00000175749.11 EIF3KP1 5.5 1.54e-07 0.000145 0.54 0.41 Primary biliary cholangitis; chr5:103041309 chr5:103032376~103033031:+ PAAD cis rs2243480 1 rs73142121 ENSG00000226824.5 RP4-756H11.3 -5.5 1.54e-07 0.000145 -0.73 -0.41 Diabetic kidney disease; chr7:65846219 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs34004500 ENSG00000226824.5 RP4-756H11.3 -5.5 1.54e-07 0.000145 -0.73 -0.41 Diabetic kidney disease; chr7:65847191 chr7:66654538~66669855:+ PAAD cis rs734999 0.87 rs2147905 ENSG00000225931.3 RP3-395M20.7 -5.5 1.54e-07 0.000145 -0.4 -0.41 Ulcerative colitis; chr1:2551482 chr1:2566410~2569888:+ PAAD cis rs1075265 0.722 rs805374 ENSG00000233266.1 HMGB1P31 5.5 1.55e-07 0.000146 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:53862720 chr2:54051334~54051760:+ PAAD cis rs6570726 0.791 rs12208019 ENSG00000235652.6 RP11-545I5.3 5.5 1.56e-07 0.000147 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145614436 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs11155435 ENSG00000235652.6 RP11-545I5.3 5.5 1.56e-07 0.000147 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145617409 chr6:145799409~145886585:+ PAAD cis rs2726040 0.902 rs33957528 ENSG00000259982.1 CDC37P1 -5.5 1.56e-07 0.000147 -0.45 -0.41 Hip circumference; chr16:28296619 chr16:28700294~28701540:- PAAD cis rs2281636 0.6 rs56901709 ENSG00000233690.1 EBAG9P1 5.5 1.56e-07 0.000147 0.46 0.41 Obesity-related traits; chr10:99639205 chr10:99697407~99697949:- PAAD cis rs2745572 0.538 rs4587210 ENSG00000272279.1 RP11-157J24.2 5.5 1.56e-07 0.000147 0.46 0.41 Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure); chr6:1542956 chr6:1528364~1528911:- PAAD cis rs6570726 0.791 rs6912079 ENSG00000235652.6 RP11-545I5.3 5.5 1.56e-07 0.000147 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145573813 chr6:145799409~145886585:+ PAAD cis rs2115630 0.691 rs8040066 ENSG00000259728.4 LINC00933 -5.5 1.56e-07 0.000147 -0.49 -0.41 P wave terminal force; chr15:84633234 chr15:84570649~84580175:+ PAAD cis rs950169 0.526 rs698620 ENSG00000259728.4 LINC00933 -5.5 1.56e-07 0.000147 -0.49 -0.41 Schizophrenia; chr15:84633977 chr15:84570649~84580175:+ PAAD cis rs3761847 0.508 rs4837813 ENSG00000226752.6 PSMD5-AS1 -5.5 1.56e-07 0.000147 -0.48 -0.41 Rheumatoid arthritis; chr9:121172185 chr9:120824828~120854385:+ PAAD cis rs9532669 1 rs9532669 ENSG00000176268.5 CYCSP34 5.5 1.56e-07 0.000147 0.37 0.41 Cervical cancer; chr13:40927414 chr13:40863599~40863902:- PAAD cis rs1075265 0.73 rs7597188 ENSG00000233266.1 HMGB1P31 5.5 1.56e-07 0.000147 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:54014732 chr2:54051334~54051760:+ PAAD cis rs1075265 0.73 rs7597189 ENSG00000233266.1 HMGB1P31 5.5 1.56e-07 0.000147 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:54014733 chr2:54051334~54051760:+ PAAD cis rs227275 0.554 rs223339 ENSG00000246560.2 RP11-10L12.4 5.5 1.57e-07 0.000148 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102864700 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223333 ENSG00000246560.2 RP11-10L12.4 5.5 1.57e-07 0.000148 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102868653 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223328 ENSG00000246560.2 RP11-10L12.4 5.5 1.57e-07 0.000148 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873379 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223325 ENSG00000246560.2 RP11-10L12.4 5.5 1.57e-07 0.000148 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102875751 chr4:102828055~102844075:+ PAAD cis rs7945705 0.87 rs4929922 ENSG00000254860.4 TMEM9B-AS1 5.5 1.57e-07 0.000148 0.47 0.41 Hemoglobin concentration; chr11:8954229 chr11:8964675~8977527:+ PAAD cis rs673078 0.66 rs61945219 ENSG00000275759.1 RP11-131L12.3 -5.5 1.57e-07 0.000148 -0.54 -0.41 Glucose homeostasis traits; chr12:118272916 chr12:118428281~118428870:+ PAAD cis rs8135665 0.625 rs8142185 ENSG00000233739.1 RP5-1039K5.13 5.5 1.57e-07 0.000148 0.5 0.41 Advanced age-related macular degeneration;Age-related macular degeneration; chr22:38055073 chr22:38057180~38073940:- PAAD cis rs10875746 0.855 rs10875729 ENSG00000240399.1 RP1-228P16.1 -5.5 1.58e-07 0.000148 -0.45 -0.41 Longevity (90 years and older); chr12:48032943 chr12:48054813~48055591:- PAAD cis rs4660456 0.913 rs545218 ENSG00000237899.1 RP4-739H11.3 5.5 1.58e-07 0.000148 0.6 0.41 Platelet count; chr1:40675313 chr1:40669089~40687588:- PAAD cis rs2739330 0.652 rs2000469 ENSG00000250470.1 AP000351.3 5.5 1.58e-07 0.000149 0.6 0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23976904~23977585:- PAAD cis rs2086824 0.538 rs4785673 ENSG00000274627.1 RP11-104N10.2 5.5 1.58e-07 0.000149 0.35 0.41 Multiple myeloma (IgH translocation); chr16:89470137 chr16:89516797~89522217:+ PAAD cis rs6504950 1 rs7221223 ENSG00000275710.1 RP11-257O5.4 5.5 1.59e-07 0.000149 0.55 0.41 Breast cancer; chr17:54981646 chr17:54964474~54964679:+ PAAD cis rs7829975 0.659 rs4382480 ENSG00000253893.2 FAM85B -5.5 1.59e-07 0.000149 -0.56 -0.41 Mood instability; chr8:8863963 chr8:8167819~8226614:- PAAD cis rs950169 1 rs12902672 ENSG00000225151.9 GOLGA2P7 -5.5 1.6e-07 0.00015 -0.49 -0.41 Schizophrenia; chr15:84048234 chr15:84199311~84230136:- PAAD cis rs950169 1 rs12903820 ENSG00000225151.9 GOLGA2P7 -5.5 1.6e-07 0.00015 -0.49 -0.41 Schizophrenia; chr15:84055068 chr15:84199311~84230136:- PAAD cis rs228614 0.536 rs223484 ENSG00000246560.2 RP11-10L12.4 5.5 1.6e-07 0.00015 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102764314 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223477 ENSG00000246560.2 RP11-10L12.4 5.5 1.6e-07 0.00015 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769099 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs150897 ENSG00000246560.2 RP11-10L12.4 5.5 1.6e-07 0.00015 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769309 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223475 ENSG00000246560.2 RP11-10L12.4 5.5 1.6e-07 0.00015 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771986 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223474 ENSG00000246560.2 RP11-10L12.4 5.5 1.6e-07 0.00015 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102772007 chr4:102828055~102844075:+ PAAD cis rs1122900 1 rs1122900 ENSG00000250155.1 CTD-2353F22.1 5.5 1.6e-07 0.00015 0.41 0.41 Aggressive periodontitis; chr5:36689079 chr5:36666214~36725195:- PAAD cis rs9928842 0.941 rs8057145 ENSG00000280152.1 RP11-331F4.5 5.5 1.6e-07 0.000151 0.52 0.41 Alcoholic chronic pancreatitis; chr16:75222353 chr16:75245994~75250077:- PAAD cis rs12458462 0.812 rs34583578 ENSG00000274828.1 RP11-567M16.6 5.5 1.61e-07 0.000151 0.41 0.41 Monocyte count; chr18:79731070 chr18:79677287~79679358:- PAAD cis rs1930961 1 rs1930961 ENSG00000100058.11 CRYBB2P1 5.5 1.61e-07 0.000151 0.74 0.41 Bipolar disorder with mood-incongruent psychosis; chr22:25479298 chr22:25448105~25520854:+ PAAD cis rs1185460 0.546 rs2508948 ENSG00000271751.1 RP11-110I1.14 5.5 1.61e-07 0.000151 0.54 0.41 Coronary artery disease; chr11:119080932 chr11:119065263~119065677:- PAAD cis rs2980439 0.525 rs1850511 ENSG00000253893.2 FAM85B -5.5 1.61e-07 0.000151 -0.54 -0.41 Neuroticism; chr8:8312807 chr8:8167819~8226614:- PAAD cis rs11992186 0.505 rs7845203 ENSG00000173295.6 FAM86B3P 5.49 1.61e-07 0.000152 0.43 0.41 Neuroticism; chr8:8287918 chr8:8228595~8244865:+ PAAD cis rs4660456 0.827 rs617413 ENSG00000237899.1 RP4-739H11.3 5.49 1.61e-07 0.000152 0.56 0.41 Platelet count; chr1:40669846 chr1:40669089~40687588:- PAAD cis rs4660456 0.869 rs616954 ENSG00000237899.1 RP4-739H11.3 5.49 1.61e-07 0.000152 0.56 0.41 Platelet count; chr1:40669947 chr1:40669089~40687588:- PAAD cis rs1075265 0.704 rs9631059 ENSG00000233266.1 HMGB1P31 5.49 1.62e-07 0.000152 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:54015160 chr2:54051334~54051760:+ PAAD cis rs4218 0.597 rs62002543 ENSG00000277144.1 RP11-59H7.4 -5.49 1.62e-07 0.000152 -0.57 -0.41 Social communication problems; chr15:59066646 chr15:59115547~59116089:- PAAD cis rs2280018 0.526 rs2966129 ENSG00000260735.1 RP11-72I8.1 5.49 1.62e-07 0.000152 0.54 0.41 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059070 chr16:15094411~15109197:+ PAAD cis rs7829975 0.514 rs2920983 ENSG00000253893.2 FAM85B -5.49 1.62e-07 0.000152 -0.56 -0.41 Mood instability; chr8:8410553 chr8:8167819~8226614:- PAAD cis rs1167827 0.68 rs1167800 ENSG00000127957.15 PMS2P3 -5.49 1.63e-07 0.000152 -0.31 -0.41 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75546898 chr7:75502930~75528148:- PAAD cis rs7772486 0.79 rs2250387 ENSG00000235652.6 RP11-545I5.3 5.49 1.63e-07 0.000153 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145884097 chr6:145799409~145886585:+ PAAD cis rs227275 0.524 rs223337 ENSG00000246560.2 RP11-10L12.4 5.49 1.63e-07 0.000153 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102865214 chr4:102828055~102844075:+ PAAD cis rs4423214 0.65 rs2186777 ENSG00000254682.1 RP11-660L16.2 5.49 1.63e-07 0.000153 0.61 0.41 Vitamin D levels; chr11:71508757 chr11:71448674~71452157:+ PAAD cis rs10875746 0.669 rs61940962 ENSG00000240399.1 RP1-228P16.1 -5.49 1.63e-07 0.000153 -0.45 -0.41 Longevity (90 years and older); chr12:48201694 chr12:48054813~48055591:- PAAD cis rs4660456 0.913 rs12743517 ENSG00000237899.1 RP4-739H11.3 5.49 1.63e-07 0.000153 0.59 0.41 Platelet count; chr1:40759682 chr1:40669089~40687588:- PAAD cis rs1823913 0.927 rs35092718 ENSG00000280083.1 RP11-317J9.1 -5.49 1.63e-07 0.000153 -0.52 -0.41 Obesity-related traits; chr2:191243882 chr2:191154118~191156070:- PAAD cis rs2274273 0.662 rs2147970 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55193499 chr14:55262767~55272075:- PAAD cis rs2274273 0.662 rs66476033 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55194145 chr14:55262767~55272075:- PAAD cis rs2274273 0.662 rs2094436 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55194777 chr14:55262767~55272075:- PAAD cis rs2274273 0.662 rs67588230 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55200312 chr14:55262767~55272075:- PAAD cis rs2274273 0.662 rs67958555 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55204148 chr14:55262767~55272075:- PAAD cis rs2274273 0.662 rs67092614 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55205337 chr14:55262767~55272075:- PAAD cis rs2274273 0.615 rs17672058 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55206676 chr14:55262767~55272075:- PAAD cis rs2274273 0.662 rs67215571 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55207005 chr14:55262767~55272075:- PAAD cis rs2274273 0.662 rs4040064 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55211370 chr14:55262767~55272075:- PAAD cis rs2274273 0.638 rs58269011 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55217670 chr14:55262767~55272075:- PAAD cis rs2274273 0.638 rs9919921 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55228787 chr14:55262767~55272075:- PAAD cis rs2274273 0.638 rs67416413 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55235545 chr14:55262767~55272075:- PAAD cis rs2274273 0.615 rs67008693 ENSG00000258413.1 RP11-665C16.6 -5.49 1.63e-07 0.000153 -0.55 -0.41 Protein biomarker; chr14:55235975 chr14:55262767~55272075:- PAAD cis rs6570726 0.643 rs9403735 ENSG00000235652.6 RP11-545I5.3 5.49 1.64e-07 0.000154 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145615455 chr6:145799409~145886585:+ PAAD cis rs6782228 0.527 rs6767383 ENSG00000242551.2 POU5F1P6 -5.49 1.64e-07 0.000154 -0.48 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694744 chr3:128674735~128677005:- PAAD cis rs113835537 0.529 rs3179961 ENSG00000255517.5 CTD-3074O7.5 -5.49 1.64e-07 0.000154 -0.52 -0.41 Airway imaging phenotypes; chr11:66476983 chr11:66473490~66480233:- PAAD cis rs7772486 0.817 rs9322047 ENSG00000235652.6 RP11-545I5.3 5.49 1.64e-07 0.000154 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:146079258 chr6:145799409~145886585:+ PAAD cis rs6782228 0.527 rs7426806 ENSG00000242551.2 POU5F1P6 -5.49 1.64e-07 0.000154 -0.48 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128694087 chr3:128674735~128677005:- PAAD cis rs3761847 0.622 rs10818498 ENSG00000226752.6 PSMD5-AS1 -5.49 1.65e-07 0.000155 -0.45 -0.41 Rheumatoid arthritis; chr9:121025288 chr9:120824828~120854385:+ PAAD cis rs11098499 0.722 rs7673476 ENSG00000245958.5 RP11-33B1.1 -5.49 1.65e-07 0.000155 -0.31 -0.41 Corneal astigmatism; chr4:119327528 chr4:119454791~119552025:+ PAAD cis rs160451 0.899 rs218918 ENSG00000251136.7 RP11-37B2.1 -5.49 1.65e-07 0.000155 -0.39 -0.41 Leprosy; chr8:89690153 chr8:89609409~89757727:- PAAD cis rs1075265 0.783 rs6545376 ENSG00000233266.1 HMGB1P31 5.49 1.66e-07 0.000155 0.52 0.41 Chronotype;Morning vs. evening chronotype; chr2:53987685 chr2:54051334~54051760:+ PAAD cis rs1075265 0.749 rs805430 ENSG00000233266.1 HMGB1P31 5.49 1.66e-07 0.000155 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:53848279 chr2:54051334~54051760:+ PAAD cis rs3858145 0.588 rs736535 ENSG00000233590.1 RP11-153K11.3 -5.49 1.66e-07 0.000155 -0.58 -0.41 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68284159 chr10:68233251~68242379:- PAAD cis rs3858145 0.588 rs4142048 ENSG00000233590.1 RP11-153K11.3 -5.49 1.66e-07 0.000155 -0.58 -0.41 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68284274 chr10:68233251~68242379:- PAAD cis rs3858145 0.588 rs4142049 ENSG00000233590.1 RP11-153K11.3 -5.49 1.66e-07 0.000155 -0.58 -0.41 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68284695 chr10:68233251~68242379:- PAAD cis rs3858145 0.588 rs7081284 ENSG00000233590.1 RP11-153K11.3 -5.49 1.66e-07 0.000155 -0.58 -0.41 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68285035 chr10:68233251~68242379:- PAAD cis rs4218 0.648 rs17236453 ENSG00000277144.1 RP11-59H7.4 -5.49 1.66e-07 0.000156 -0.57 -0.41 Social communication problems; chr15:59092156 chr15:59115547~59116089:- PAAD cis rs7208859 0.623 rs9912283 ENSG00000266490.1 CTD-2349P21.9 5.49 1.66e-07 0.000156 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783355 chr17:30792372~30792833:+ PAAD cis rs6903823 0.508 rs1150724 ENSG00000216901.1 AL022393.7 5.49 1.67e-07 0.000156 0.49 0.41 Pulmonary function; chr6:28282459 chr6:28176188~28176674:+ PAAD cis rs853679 0.527 rs213228 ENSG00000216901.1 AL022393.7 5.49 1.67e-07 0.000156 0.53 0.41 Depression; chr6:28363475 chr6:28176188~28176674:+ PAAD cis rs1823913 1 rs68014803 ENSG00000280083.1 RP11-317J9.1 -5.49 1.67e-07 0.000156 -0.53 -0.41 Obesity-related traits; chr2:191241877 chr2:191154118~191156070:- PAAD cis rs2115630 0.691 rs2292462 ENSG00000275120.1 RP11-182J1.17 -5.49 1.67e-07 0.000156 -0.42 -0.41 P wave terminal force; chr15:84657523 chr15:84599434~84606463:- PAAD cis rs2111504 0.583 rs2111503 ENSG00000267213.4 AC007773.2 5.49 1.67e-07 0.000156 0.51 0.41 Bipolar disorder; chr19:32383819 chr19:32390050~32405560:- PAAD cis rs9640161 0.742 rs11983355 ENSG00000261305.1 RP4-584D14.7 5.49 1.67e-07 0.000157 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150319608 chr7:150341771~150342607:+ PAAD cis rs8062405 1 rs72793811 ENSG00000251417.2 RP11-1348G14.4 -5.49 1.68e-07 0.000157 -0.36 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828071 chr16:28802743~28817828:+ PAAD cis rs9928842 0.77 rs8048371 ENSG00000280152.1 RP11-331F4.5 5.49 1.68e-07 0.000157 0.52 0.41 Alcoholic chronic pancreatitis; chr16:75241649 chr16:75245994~75250077:- PAAD cis rs3781264 0.557 rs7092226 ENSG00000273450.1 RP11-76P2.4 5.49 1.68e-07 0.000157 0.54 0.41 Esophageal cancer and gastric cancer; chr10:94352476 chr10:94314907~94315327:- PAAD cis rs4218 0.648 rs57361749 ENSG00000277144.1 RP11-59H7.4 -5.49 1.68e-07 0.000157 -0.57 -0.41 Social communication problems; chr15:59091352 chr15:59115547~59116089:- PAAD cis rs4218 0.608 rs16941014 ENSG00000277144.1 RP11-59H7.4 -5.49 1.68e-07 0.000157 -0.57 -0.41 Social communication problems; chr15:59091503 chr15:59115547~59116089:- PAAD cis rs113835537 0.529 rs11824771 ENSG00000255517.5 CTD-3074O7.5 -5.49 1.69e-07 0.000158 -0.52 -0.41 Airway imaging phenotypes; chr11:66495079 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227501 ENSG00000255517.5 CTD-3074O7.5 -5.49 1.69e-07 0.000158 -0.52 -0.41 Airway imaging phenotypes; chr11:66506601 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs61561111 ENSG00000255517.5 CTD-3074O7.5 -5.49 1.69e-07 0.000158 -0.52 -0.41 Airway imaging phenotypes; chr11:66508452 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227514 ENSG00000255517.5 CTD-3074O7.5 -5.49 1.69e-07 0.000158 -0.52 -0.41 Airway imaging phenotypes; chr11:66519156 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs11227515 ENSG00000255517.5 CTD-3074O7.5 -5.49 1.69e-07 0.000158 -0.52 -0.41 Airway imaging phenotypes; chr11:66519912 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs17495838 ENSG00000255517.5 CTD-3074O7.5 -5.48 1.69e-07 0.000158 -0.55 -0.41 Airway imaging phenotypes; chr11:66428794 chr11:66473490~66480233:- PAAD cis rs9532669 0.926 rs4356344 ENSG00000176268.5 CYCSP34 5.48 1.69e-07 0.000158 0.42 0.41 Cervical cancer; chr13:40874086 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9594450 ENSG00000176268.5 CYCSP34 5.48 1.69e-07 0.000158 0.42 0.41 Cervical cancer; chr13:40880067 chr13:40863599~40863902:- PAAD cis rs6504950 0.751 rs12937760 ENSG00000275710.1 RP11-257O5.4 5.48 1.69e-07 0.000158 0.53 0.41 Breast cancer; chr17:54938769 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs56175787 ENSG00000275710.1 RP11-257O5.4 5.48 1.69e-07 0.000158 0.53 0.41 Breast cancer; chr17:54940386 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs17817847 ENSG00000275710.1 RP11-257O5.4 5.48 1.69e-07 0.000158 0.53 0.41 Breast cancer; chr17:54940920 chr17:54964474~54964679:+ PAAD cis rs494459 0.756 rs570806 ENSG00000255422.1 AP002954.4 -5.48 1.69e-07 0.000158 -0.44 -0.41 Height; chr11:118786602 chr11:118704607~118750263:+ PAAD cis rs494459 0.838 rs12796102 ENSG00000255422.1 AP002954.4 -5.48 1.69e-07 0.000158 -0.44 -0.41 Height; chr11:118791319 chr11:118704607~118750263:+ PAAD cis rs950169 0.96 rs12905475 ENSG00000259728.4 LINC00933 5.48 1.69e-07 0.000158 0.53 0.41 Schizophrenia; chr15:84131743 chr15:84570649~84580175:+ PAAD cis rs2281636 0.63 rs12355655 ENSG00000233690.1 EBAG9P1 5.48 1.69e-07 0.000158 0.48 0.41 Obesity-related traits; chr10:99616982 chr10:99697407~99697949:- PAAD cis rs9926296 0.712 rs258332 ENSG00000260259.1 RP11-368I7.4 5.48 1.69e-07 0.000158 0.51 0.41 Vitiligo; chr16:89661275 chr16:89682620~89686569:- PAAD cis rs2115630 1 rs11854291 ENSG00000259728.4 LINC00933 -5.48 1.69e-07 0.000158 -0.5 -0.41 P wave terminal force; chr15:84820477 chr15:84570649~84580175:+ PAAD cis rs172166 0.516 rs2622322 ENSG00000204709.4 LINC01556 5.48 1.7e-07 0.000159 0.54 0.41 Cardiac Troponin-T levels; chr6:28149665 chr6:28943877~28944537:+ PAAD cis rs172166 0.516 rs1225618 ENSG00000204709.4 LINC01556 5.48 1.7e-07 0.000159 0.54 0.41 Cardiac Troponin-T levels; chr6:28161935 chr6:28943877~28944537:+ PAAD cis rs172166 0.516 rs1150670 ENSG00000204709.4 LINC01556 5.48 1.7e-07 0.000159 0.54 0.41 Cardiac Troponin-T levels; chr6:28162781 chr6:28943877~28944537:+ PAAD cis rs172166 0.516 rs2021826 ENSG00000204709.4 LINC01556 5.48 1.7e-07 0.000159 0.54 0.41 Cardiac Troponin-T levels; chr6:28164978 chr6:28943877~28944537:+ PAAD cis rs1150668 0.835 rs1233696 ENSG00000204709.4 LINC01556 5.48 1.7e-07 0.000159 0.54 0.41 Pubertal anthropometrics; chr6:28175232 chr6:28943877~28944537:+ PAAD cis rs9926296 0.548 rs12447465 ENSG00000260259.1 RP11-368I7.4 -5.48 1.7e-07 0.000159 -0.49 -0.41 Vitiligo; chr16:89763487 chr16:89682620~89686569:- PAAD cis rs7208859 0.573 rs8070182 ENSG00000266490.1 CTD-2349P21.9 5.48 1.7e-07 0.000159 0.51 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30792372~30792833:+ PAAD cis rs6903823 0.508 rs1150718 ENSG00000216901.1 AL022393.7 5.48 1.7e-07 0.000159 0.49 0.41 Pulmonary function; chr6:28289170 chr6:28176188~28176674:+ PAAD cis rs6903823 0.508 rs1233660 ENSG00000216901.1 AL022393.7 5.48 1.7e-07 0.000159 0.49 0.41 Pulmonary function; chr6:28292472 chr6:28176188~28176674:+ PAAD cis rs11098499 0.754 rs10518300 ENSG00000245958.5 RP11-33B1.1 5.48 1.7e-07 0.000159 0.32 0.41 Corneal astigmatism; chr4:119328344 chr4:119454791~119552025:+ PAAD cis rs2283792 0.622 rs381523 ENSG00000228050.1 TOP3BP1 5.48 1.71e-07 0.000159 0.45 0.41 Multiple sclerosis; chr22:21951257 chr22:22223187~22224566:- PAAD cis rs6782228 0.675 rs56141228 ENSG00000242551.2 POU5F1P6 -5.48 1.71e-07 0.000159 -0.49 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128667199 chr3:128674735~128677005:- PAAD cis rs6782228 0.651 rs9852825 ENSG00000242551.2 POU5F1P6 -5.48 1.71e-07 0.000159 -0.49 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128668514 chr3:128674735~128677005:- PAAD cis rs6782228 0.651 rs9289332 ENSG00000242551.2 POU5F1P6 -5.48 1.71e-07 0.000159 -0.49 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128669041 chr3:128674735~128677005:- PAAD cis rs732716 0.853 rs1127888 ENSG00000267980.1 AC007292.6 -5.48 1.71e-07 0.000159 -0.56 -0.41 Mean corpuscular volume; chr19:4454086 chr19:4363789~4364640:+ PAAD cis rs732716 0.853 rs72990643 ENSG00000267980.1 AC007292.6 -5.48 1.71e-07 0.000159 -0.56 -0.41 Mean corpuscular volume; chr19:4454739 chr19:4363789~4364640:+ PAAD cis rs732716 0.853 rs12459922 ENSG00000267980.1 AC007292.6 -5.48 1.71e-07 0.000159 -0.56 -0.41 Mean corpuscular volume; chr19:4455865 chr19:4363789~4364640:+ PAAD cis rs1167827 0.68 rs1167796 ENSG00000127957.15 PMS2P3 5.48 1.71e-07 0.00016 0.31 0.41 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75543861 chr7:75502930~75528148:- PAAD cis rs7772486 0.875 rs2748482 ENSG00000235652.6 RP11-545I5.3 5.48 1.72e-07 0.00016 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146015396 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs1331637 ENSG00000235652.6 RP11-545I5.3 5.48 1.72e-07 0.00016 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146015951 chr6:145799409~145886585:+ PAAD cis rs7772486 0.846 rs1331636 ENSG00000235652.6 RP11-545I5.3 5.48 1.72e-07 0.00016 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146017690 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs1929523 ENSG00000235652.6 RP11-545I5.3 5.48 1.72e-07 0.00016 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146018853 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2224121 ENSG00000235652.6 RP11-545I5.3 5.48 1.72e-07 0.00016 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146022078 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2224120 ENSG00000235652.6 RP11-545I5.3 5.48 1.72e-07 0.00016 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146022144 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2777476 ENSG00000235652.6 RP11-545I5.3 5.48 1.72e-07 0.00016 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146023888 chr6:145799409~145886585:+ PAAD cis rs9481169 0.557 rs13190932 ENSG00000255389.1 C6orf3 -5.48 1.72e-07 0.00016 -0.75 -0.41 Inflammatory skin disease; chr6:111591867 chr6:111599875~111602295:+ PAAD cis rs526231 0.511 rs26255 ENSG00000175749.11 EIF3KP1 5.48 1.72e-07 0.00016 0.54 0.41 Primary biliary cholangitis; chr5:103218399 chr5:103032376~103033031:+ PAAD cis rs9926296 0.605 rs7205053 ENSG00000260259.1 RP11-368I7.4 -5.48 1.72e-07 0.00016 -0.49 -0.41 Vitiligo; chr16:89790355 chr16:89682620~89686569:- PAAD cis rs638893 0.636 rs61901411 ENSG00000278376.1 RP11-158I9.8 5.48 1.72e-07 0.00016 0.63 0.41 Vitiligo; chr11:118794615 chr11:118791254~118793137:+ PAAD cis rs35160687 0.787 rs10186289 ENSG00000273080.1 RP11-301O19.1 5.48 1.72e-07 0.00016 0.46 0.41 Night sleep phenotypes; chr2:86285865 chr2:86195590~86196049:+ PAAD cis rs8062405 1 rs12443881 ENSG00000251417.2 RP11-1348G14.4 -5.48 1.72e-07 0.000161 -0.36 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28830456 chr16:28802743~28817828:+ PAAD cis rs9322193 0.923 rs9322197 ENSG00000216906.2 RP11-350J20.9 5.48 1.72e-07 0.000161 0.51 0.41 Lung cancer; chr6:149622577 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs9688858 ENSG00000216906.2 RP11-350J20.9 5.48 1.72e-07 0.000161 0.51 0.41 Lung cancer; chr6:149637911 chr6:149904243~149906418:+ PAAD cis rs7772486 0.875 rs2073287 ENSG00000235652.6 RP11-545I5.3 5.48 1.73e-07 0.000161 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:146029128 chr6:145799409~145886585:+ PAAD cis rs3931020 0.657 rs10890142 ENSG00000272864.1 RP11-17E13.2 -5.48 1.73e-07 0.000161 -0.57 -0.41 Resistin levels; chr1:74713445 chr1:74698769~74699333:- PAAD cis rs6570726 0.599 rs455001 ENSG00000235652.6 RP11-545I5.3 5.48 1.73e-07 0.000161 0.35 0.41 Lobe attachment (rater-scored or self-reported); chr6:145533314 chr6:145799409~145886585:+ PAAD cis rs10463554 0.892 rs1898673 ENSG00000175749.11 EIF3KP1 5.48 1.73e-07 0.000161 0.51 0.41 Parkinson's disease; chr5:102957676 chr5:103032376~103033031:+ PAAD cis rs227275 0.554 rs223485 ENSG00000246560.2 RP11-10L12.4 5.48 1.73e-07 0.000161 0.45 0.41 Allergic disease (asthma, hay fever or eczema); chr4:102764018 chr4:102828055~102844075:+ PAAD cis rs228614 0.509 rs223482 ENSG00000246560.2 RP11-10L12.4 5.48 1.73e-07 0.000161 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102766051 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223478 ENSG00000246560.2 RP11-10L12.4 5.48 1.73e-07 0.000161 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102768648 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs150898 ENSG00000246560.2 RP11-10L12.4 5.48 1.73e-07 0.000161 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102769234 chr4:102828055~102844075:+ PAAD cis rs228614 0.509 rs223476 ENSG00000246560.2 RP11-10L12.4 5.48 1.73e-07 0.000161 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771000 chr4:102828055~102844075:+ PAAD cis rs228614 0.509 rs150896 ENSG00000246560.2 RP11-10L12.4 5.48 1.73e-07 0.000161 0.45 0.41 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102771186 chr4:102828055~102844075:+ PAAD cis rs732716 0.889 rs11666856 ENSG00000267980.1 AC007292.6 -5.48 1.73e-07 0.000162 -0.52 -0.41 Mean corpuscular volume; chr19:4437453 chr19:4363789~4364640:+ PAAD cis rs950027 0.787 rs1547487 ENSG00000259433.2 CTD-2651B20.4 -5.48 1.73e-07 0.000162 -0.48 -0.41 Response to fenofibrate (adiponectin levels); chr15:45431785 chr15:45330209~45332634:- PAAD cis rs9926296 0.546 rs6500442 ENSG00000260259.1 RP11-368I7.4 -5.48 1.74e-07 0.000162 -0.49 -0.41 Vitiligo; chr16:89762454 chr16:89682620~89686569:- PAAD cis rs2115630 0.645 rs4842978 ENSG00000225151.9 GOLGA2P7 5.48 1.74e-07 0.000162 0.47 0.41 P wave terminal force; chr15:84654022 chr15:84199311~84230136:- PAAD cis rs9640161 0.711 rs10259796 ENSG00000261305.1 RP4-584D14.7 5.48 1.74e-07 0.000162 0.6 0.41 Blood protein levels;Circulating chemerin levels; chr7:150353338 chr7:150341771~150342607:+ PAAD cis rs10463554 0.963 rs26254 ENSG00000175749.11 EIF3KP1 5.48 1.74e-07 0.000162 0.54 0.41 Parkinson's disease; chr5:103221158 chr5:103032376~103033031:+ PAAD cis rs7772486 0.754 rs13214277 ENSG00000235652.6 RP11-545I5.3 5.48 1.74e-07 0.000162 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:145814989 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs9386132 ENSG00000235652.6 RP11-545I5.3 5.48 1.74e-07 0.000162 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:145819615 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs9386134 ENSG00000235652.6 RP11-545I5.3 5.48 1.74e-07 0.000162 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:145824372 chr6:145799409~145886585:+ PAAD cis rs2243480 0.901 rs35256305 ENSG00000226824.5 RP4-756H11.3 -5.48 1.74e-07 0.000162 -0.73 -0.41 Diabetic kidney disease; chr7:65841418 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35825738 ENSG00000226824.5 RP4-756H11.3 -5.48 1.74e-07 0.000162 -0.73 -0.41 Diabetic kidney disease; chr7:65853040 chr7:66654538~66669855:+ PAAD cis rs1862618 0.526 rs2591963 ENSG00000271828.1 CTD-2310F14.1 -5.48 1.75e-07 0.000163 -0.62 -0.41 Initial pursuit acceleration; chr5:56941308 chr5:56927874~56929573:+ PAAD cis rs1862618 0.573 rs2591962 ENSG00000271828.1 CTD-2310F14.1 -5.48 1.75e-07 0.000163 -0.62 -0.41 Initial pursuit acceleration; chr5:56941328 chr5:56927874~56929573:+ PAAD cis rs9828933 1 rs1060897 ENSG00000280620.1 SCAANT1 -5.48 1.75e-07 0.000163 -0.61 -0.41 Type 2 diabetes; chr3:64012196 chr3:63911518~63911772:- PAAD cis rs6782228 0.675 rs9841987 ENSG00000242551.2 POU5F1P6 -5.48 1.75e-07 0.000163 -0.49 -0.41 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128666299 chr3:128674735~128677005:- PAAD cis rs172166 0.516 rs1225715 ENSG00000204709.4 LINC01556 -5.48 1.75e-07 0.000163 -0.55 -0.41 Cardiac Troponin-T levels; chr6:28145595 chr6:28943877~28944537:+ PAAD cis rs858239 1 rs858240 ENSG00000226816.2 AC005082.12 5.48 1.76e-07 0.000163 0.46 0.41 Cerebrospinal fluid biomarker levels; chr7:23244618 chr7:23206013~23208045:+ PAAD cis rs2739330 0.76 rs5760095 ENSG00000099984.9 GSTT2 -5.48 1.76e-07 0.000163 -0.52 -0.41 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23980123~23983911:+ PAAD cis rs1075265 0.749 rs805436 ENSG00000233266.1 HMGB1P31 5.48 1.76e-07 0.000163 0.52 0.41 Chronotype;Morning vs. evening chronotype; chr2:53837843 chr2:54051334~54051760:+ PAAD cis rs7208859 0.623 rs60890550 ENSG00000266490.1 CTD-2349P21.9 5.48 1.76e-07 0.000163 0.53 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30703843 chr17:30792372~30792833:+ PAAD cis rs113835537 0.559 rs74933537 ENSG00000255517.5 CTD-3074O7.5 -5.48 1.77e-07 0.000164 -0.53 -0.41 Airway imaging phenotypes; chr11:66507487 chr11:66473490~66480233:- PAAD cis rs6504950 0.83 rs8073158 ENSG00000275710.1 RP11-257O5.4 5.47 1.77e-07 0.000165 0.53 0.41 Breast cancer; chr17:54951254 chr17:54964474~54964679:+ PAAD cis rs6570726 0.764 rs9403733 ENSG00000235652.6 RP11-545I5.3 5.47 1.77e-07 0.000165 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145591175 chr6:145799409~145886585:+ PAAD cis rs6570726 0.738 rs6917199 ENSG00000235652.6 RP11-545I5.3 5.47 1.77e-07 0.000165 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:145597184 chr6:145799409~145886585:+ PAAD cis rs11123170 0.64 rs2863240 ENSG00000189223.12 PAX8-AS1 5.47 1.78e-07 0.000165 0.53 0.41 Renal function-related traits (BUN); chr2:113212539 chr2:113211522~113276581:+ PAAD cis rs7772486 0.875 rs1331644 ENSG00000235652.6 RP11-545I5.3 5.47 1.78e-07 0.000165 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:146077524 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs11755334 ENSG00000235652.6 RP11-545I5.3 5.47 1.78e-07 0.000165 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:146078161 chr6:145799409~145886585:+ PAAD cis rs2115630 1 rs6496441 ENSG00000259728.4 LINC00933 -5.47 1.78e-07 0.000165 -0.5 -0.41 P wave terminal force; chr15:84820117 chr15:84570649~84580175:+ PAAD cis rs2274273 0.686 rs57033289 ENSG00000258413.1 RP11-665C16.6 -5.47 1.78e-07 0.000166 -0.56 -0.41 Protein biomarker; chr14:55156599 chr14:55262767~55272075:- PAAD cis rs2274273 0.686 rs11624679 ENSG00000258413.1 RP11-665C16.6 -5.47 1.78e-07 0.000166 -0.56 -0.41 Protein biomarker; chr14:55157526 chr14:55262767~55272075:- PAAD cis rs2274273 0.686 rs2296489 ENSG00000258413.1 RP11-665C16.6 -5.47 1.78e-07 0.000166 -0.56 -0.41 Protein biomarker; chr14:55158259 chr14:55262767~55272075:- PAAD cis rs4218 0.734 rs12912071 ENSG00000277144.1 RP11-59H7.4 -5.47 1.79e-07 0.000166 -0.47 -0.41 Social communication problems; chr15:59150951 chr15:59115547~59116089:- PAAD cis rs1862618 0.627 rs744023 ENSG00000271828.1 CTD-2310F14.1 5.47 1.79e-07 0.000166 0.64 0.41 Initial pursuit acceleration; chr5:56901251 chr5:56927874~56929573:+ PAAD cis rs7772486 0.79 rs6926657 ENSG00000235652.6 RP11-545I5.3 -5.47 1.79e-07 0.000166 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145934658 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9376971 ENSG00000235652.6 RP11-545I5.3 -5.47 1.79e-07 0.000166 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145938369 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs4314514 ENSG00000235652.6 RP11-545I5.3 -5.47 1.79e-07 0.000166 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145938874 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs9497434 ENSG00000235652.6 RP11-545I5.3 -5.47 1.79e-07 0.000166 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145939617 chr6:145799409~145886585:+ PAAD cis rs7772486 0.72 rs9403757 ENSG00000235652.6 RP11-545I5.3 -5.47 1.79e-07 0.000166 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145940135 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs6924159 ENSG00000235652.6 RP11-545I5.3 -5.47 1.79e-07 0.000166 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145946737 chr6:145799409~145886585:+ PAAD cis rs2274273 0.638 rs17672364 ENSG00000258413.1 RP11-665C16.6 -5.47 1.8e-07 0.000167 -0.55 -0.41 Protein biomarker; chr14:55239186 chr14:55262767~55272075:- PAAD cis rs7916697 0.947 rs7916410 ENSG00000233590.1 RP11-153K11.3 5.47 1.8e-07 0.000167 0.56 0.41 Optic disc area; chr10:68235910 chr10:68233251~68242379:- PAAD cis rs7772486 0.875 rs9322044 ENSG00000235652.6 RP11-545I5.3 5.47 1.8e-07 0.000167 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:146048472 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2474356 ENSG00000235652.6 RP11-545I5.3 5.47 1.8e-07 0.000167 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:145975662 chr6:145799409~145886585:+ PAAD cis rs748404 0.66 rs690446 ENSG00000249839.1 AC011330.5 -5.47 1.8e-07 0.000167 -0.6 -0.41 Lung cancer; chr15:43469066 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs518288 ENSG00000249839.1 AC011330.5 -5.47 1.8e-07 0.000167 -0.6 -0.41 Lung cancer; chr15:43471801 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs690472 ENSG00000249839.1 AC011330.5 -5.47 1.8e-07 0.000167 -0.6 -0.41 Lung cancer; chr15:43472170 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs560191 ENSG00000249839.1 AC011330.5 -5.47 1.8e-07 0.000167 -0.6 -0.41 Lung cancer; chr15:43475576 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs2444251 ENSG00000249839.1 AC011330.5 -5.47 1.8e-07 0.000167 -0.6 -0.41 Lung cancer; chr15:43496397 chr15:43663654~43684339:- PAAD cis rs4218 0.648 rs35460138 ENSG00000277144.1 RP11-59H7.4 -5.47 1.81e-07 0.000167 -0.55 -0.41 Social communication problems; chr15:59093200 chr15:59115547~59116089:- PAAD cis rs3858145 0.588 rs2305083 ENSG00000233590.1 RP11-153K11.3 -5.47 1.81e-07 0.000167 -0.58 -0.41 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68285180 chr10:68233251~68242379:- PAAD cis rs992157 0.764 rs2015863 ENSG00000261338.2 RP11-378A13.1 -5.47 1.81e-07 0.000167 -0.48 -0.41 Colorectal cancer; chr2:218320438 chr2:218255319~218257366:+ PAAD cis rs992157 0.644 rs6741757 ENSG00000261338.2 RP11-378A13.1 5.47 1.81e-07 0.000167 0.48 0.41 Colorectal cancer; chr2:218318025 chr2:218255319~218257366:+ PAAD cis rs10463554 0.963 rs26253 ENSG00000175749.11 EIF3KP1 5.47 1.81e-07 0.000168 0.54 0.41 Parkinson's disease; chr5:103221266 chr5:103032376~103033031:+ PAAD cis rs1075265 0.744 rs10203576 ENSG00000233266.1 HMGB1P31 5.47 1.82e-07 0.000168 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:54060939 chr2:54051334~54051760:+ PAAD cis rs113835537 0.597 rs7116921 ENSG00000255517.5 CTD-3074O7.5 -5.47 1.82e-07 0.000168 -0.53 -0.41 Airway imaging phenotypes; chr11:66536383 chr11:66473490~66480233:- PAAD cis rs113835537 0.597 rs11227523 ENSG00000255517.5 CTD-3074O7.5 -5.47 1.82e-07 0.000168 -0.53 -0.41 Airway imaging phenotypes; chr11:66538467 chr11:66473490~66480233:- PAAD cis rs113835537 0.597 rs3825065 ENSG00000255517.5 CTD-3074O7.5 -5.47 1.82e-07 0.000168 -0.53 -0.41 Airway imaging phenotypes; chr11:66543540 chr11:66473490~66480233:- PAAD cis rs7208859 0.623 rs9898084 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs28556733 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30792372~30792833:+ PAAD cis rs17826219 0.5 rs28452421 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30756962 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs28433704 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs28779471 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30792372~30792833:+ PAAD cis rs17826219 0.5 rs61685770 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30758695 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs57486336 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs55764512 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30758740 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs73988172 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs12103440 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs12103508 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs11653605 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11657777 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73269913 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7217984 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73269916 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs60114476 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs8065744 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs8071236 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30772984 chr17:30792372~30792833:+ PAAD cis rs17826219 0.636 rs2449770 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30774046 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs59913838 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs56163556 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs8067035 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs8067338 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs4055105 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30792372~30792833:+ PAAD cis rs7208859 0.562 rs8078897 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs8075163 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs8075107 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30779631 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7223209 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7223404 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9916725 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9916727 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9914499 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73269945 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9897728 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs1054400 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs1054397 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9890558 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs12006 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs3752021 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs3752020 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9890855 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9893422 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9891166 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73269974 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs34756112 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs60724269 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs76633166 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs1061346 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs1061343 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs1061342 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs55938328 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73269988 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs55961983 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs7222803 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792879 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9899525 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30792372~30792833:+ PAAD cis rs17826219 0.568 rs7213925 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30794616 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs11653098 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11658945 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11657990 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9911784 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9911997 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9890862 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs78071511 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11650982 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs2035494 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs3794796 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9915546 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9915566 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs28469200 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30806554 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs8064686 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11657369 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs8075341 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73271842 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9895815 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs7214313 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs8077116 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs28760584 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs73271850 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30815122 chr17:30792372~30792833:+ PAAD cis rs17826219 0.636 rs79565452 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Body mass index; chr17:30815823 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7208088 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7212991 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7208441 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs28627615 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9912440 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30821754 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7220999 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs55638872 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9899268 ENSG00000266490.1 CTD-2349P21.9 5.47 1.82e-07 0.000168 0.52 0.41 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30792372~30792833:+ PAAD cis rs755249 0.614 rs10888798 ENSG00000237624.1 OXCT2P1 -5.47 1.82e-07 0.000168 -0.51 -0.41 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39492408 chr1:39514956~39516490:+ PAAD cis rs732716 0.785 rs62129354 ENSG00000267769.1 CTB-50L17.9 -5.47 1.83e-07 0.000168 -0.57 -0.41 Mean corpuscular volume; chr19:4396508 chr19:4454014~4455286:+ PAAD cis rs7772486 0.846 rs9403767 ENSG00000235652.6 RP11-545I5.3 5.47 1.83e-07 0.000169 0.34 0.41 Lobe attachment (rater-scored or self-reported); chr6:146081250 chr6:145799409~145886585:+ PAAD cis rs10875746 0.855 rs10875728 ENSG00000240399.1 RP1-228P16.1 -5.47 1.83e-07 0.000169 -0.45 -0.41 Longevity (90 years and older); chr12:48032609 chr12:48054813~48055591:- PAAD cis rs12922040 1 rs2075516 ENSG00000263335.1 AF001548.5 5.47 1.83e-07 0.000169 0.48 0.41 Serum uric acid levels in response to allopurinol in gout; chr16:15775668 chr16:15726674~15732993:+ PAAD cis rs4713118 0.505 rs156740 ENSG00000204709.4 LINC01556 5.47 1.84e-07 0.000169 0.56 0.41 Parkinson's disease; chr6:27992657 chr6:28943877~28944537:+ PAAD cis rs6504622 0.905 rs736603 ENSG00000262879.4 RP11-156P1.3 5.47 1.84e-07 0.000169 0.42 0.41 Orofacial clefts; chr17:46947379 chr17:46984045~47100323:- PAAD cis rs6504622 0.905 rs736604 ENSG00000262879.4 RP11-156P1.3 5.47 1.84e-07 0.000169 0.42 0.41 Orofacial clefts; chr17:46947443 chr17:46984045~47100323:- PAAD cis rs7772486 0.79 rs2254288 ENSG00000235652.6 RP11-545I5.3 5.47 1.84e-07 0.00017 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:145883334 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2247206 ENSG00000235652.6 RP11-545I5.3 5.47 1.84e-07 0.00017 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:145895048 chr6:145799409~145886585:+ PAAD cis rs7772486 0.764 rs2247211 ENSG00000235652.6 RP11-545I5.3 5.47 1.84e-07 0.00017 0.33 0.41 Lobe attachment (rater-scored or self-reported); chr6:145895243 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9497424 ENSG00000235652.6 RP11-545I5.3 -5.47 1.84e-07 0.00017 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145904135 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9497425 ENSG00000235652.6 RP11-545I5.3 -5.47 1.84e-07 0.00017 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145913061 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9497427 ENSG00000235652.6 RP11-545I5.3 -5.47 1.84e-07 0.00017 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145917166 chr6:145799409~145886585:+ PAAD cis rs7772486 0.764 rs9399569 ENSG00000235652.6 RP11-545I5.3 -5.47 1.84e-07 0.00017 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145921806 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs4360151 ENSG00000235652.6 RP11-545I5.3 -5.47 1.84e-07 0.00017 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145933943 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9497435 ENSG00000235652.6 RP11-545I5.3 -5.47 1.84e-07 0.00017 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145944204 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9791313 ENSG00000235652.6 RP11-545I5.3 -5.47 1.84e-07 0.00017 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145945036 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9386141 ENSG00000235652.6 RP11-545I5.3 -5.47 1.84e-07 0.00017 -0.33 -0.41 Lobe attachment (rater-scored or self-reported); chr6:145947487 chr6:145799409~145886585:+ PAAD cis rs526231 0.511 rs58344084 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103042508 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs158244 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103075062 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs257310 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103083149 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs40092 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103088509 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34808 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103093484 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34832 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103108891 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34770 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103111942 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs26523 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103120550 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs34783 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103121337 chr5:103032376~103033031:+ PAAD cis rs526231 0.512 rs28022 ENSG00000175749.11 EIF3KP1 5.47 1.84e-07 0.00017 0.53 0.41 Primary biliary cholangitis; chr5:103128663 chr5:103032376~103033031:+ PAAD cis rs35160687 0.712 rs6738585 ENSG00000273080.1 RP11-301O19.1 -5.47 1.84e-07 0.00017 -0.47 -0.41 Night sleep phenotypes; chr2:86283161 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs6725234 ENSG00000273080.1 RP11-301O19.1 -5.47 1.84e-07 0.00017 -0.47 -0.41 Night sleep phenotypes; chr2:86283165 chr2:86195590~86196049:+ PAAD cis rs12701220 0.503 rs12531999 ENSG00000229043.2 AC091729.9 -5.47 1.85e-07 0.00017 -0.51 -0.41 Bronchopulmonary dysplasia; chr7:1141965 chr7:1160374~1165267:+ PAAD cis rs465969 1 rs9400478 ENSG00000255389.1 C6orf3 5.47 1.85e-07 0.00017 0.69 0.41 Psoriasis; chr6:111478441 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs7750803 ENSG00000255389.1 C6orf3 5.47 1.85e-07 0.00017 0.69 0.41 Psoriasis; chr6:111478910 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs1407644 ENSG00000255389.1 C6orf3 5.47 1.85e-07 0.00017 0.69 0.41 Psoriasis; chr6:111480895 chr6:111599875~111602295:+ PAAD cis rs8062405 1 rs62036622 ENSG00000251417.2 RP11-1348G14.4 -5.47 1.85e-07 0.000171 -0.36 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28825882 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs72793812 ENSG00000251417.2 RP11-1348G14.4 -5.47 1.85e-07 0.000171 -0.36 -0.41 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28829060 chr16:28802743~28817828:+ PAAD cis rs950169 0.579 rs12912716 ENSG00000259728.4 LINC00933 5.46 1.86e-07 0.000171 0.52 0.41 Schizophrenia; chr15:83995511 chr15:84570649~84580175:+ PAAD cis rs6565180 1 rs11646130 ENSG00000183604.13 SMG1P5 -5.46 1.86e-07 0.000171 -0.46 -0.41 Tonsillectomy; chr16:30365638 chr16:30267553~30335374:- PAAD cis rs853679 0.567 rs16894091 ENSG00000216901.1 AL022393.7 -5.46 1.86e-07 0.000171 -0.54 -0.41 Depression; chr6:28422360 chr6:28176188~28176674:+ PAAD cis rs10262624 0.935 rs6955884 ENSG00000234286.1 AC006026.13 -5.46 1.86e-07 0.000171 -0.47 -0.41 Schizophrenia; chr7:23865654 chr7:23680195~23680786:- PAAD cis rs734999 0.967 rs6671426 ENSG00000225931.3 RP3-395M20.7 5.46 1.86e-07 0.000171 0.39 0.41 Ulcerative colitis; chr1:2572795 chr1:2566410~2569888:+ PAAD cis rs113835537 0.529 rs75685325 ENSG00000255517.5 CTD-3074O7.5 -5.46 1.87e-07 0.000172 -0.55 -0.41 Airway imaging phenotypes; chr11:66467771 chr11:66473490~66480233:- PAAD cis rs4774565 0.762 rs7164848 ENSG00000244879.4 GABPB1-AS1 5.46 1.88e-07 0.000173 0.37 0.41 Breast cancer; chr15:50370833 chr15:50354959~50372202:+ PAAD cis rs35160687 0.712 rs11675942 ENSG00000273080.1 RP11-301O19.1 -5.46 1.88e-07 0.000173 -0.47 -0.41 Night sleep phenotypes; chr2:86280565 chr2:86195590~86196049:+ PAAD cis rs35160687 0.688 rs4832033 ENSG00000273080.1 RP11-301O19.1 -5.46 1.88e-07 0.000173 -0.47 -0.41 Night sleep phenotypes; chr2:86281640 chr2:86195590~86196049:+ PAAD cis rs7826238 0.72 rs12546760 ENSG00000253893.2 FAM85B 5.46 1.88e-07 0.000173 0.54 0.41 Systolic blood pressure; chr8:8517326 chr8:8167819~8226614:- PAAD cis rs6860806 0.507 rs270606 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132315174 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs156322 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132318232 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs270601 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132321304 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs273917 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132323925 chr5:132311285~132369916:- PAAD cis rs270601 0.913 rs273916 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Acylcarnitine levels; chr5:132324137 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs273915 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132324426 chr5:132311285~132369916:- PAAD cis rs270601 0.955 rs273911 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Acylcarnitine levels; chr5:132325833 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs272892 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132328656 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs272891 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132328701 chr5:132311285~132369916:- PAAD cis rs6860806 0.531 rs272888 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132329730 chr5:132311285~132369916:- PAAD cis rs6860806 0.531 rs272887 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132330020 chr5:132311285~132369916:- PAAD cis rs274567 0.55 rs272885 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Blood metabolite levels; chr5:132332043 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs272883 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132333005 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs272882 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132333468 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs272880 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132334485 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs272868 ENSG00000233006.5 AC034220.3 5.46 1.88e-07 0.000173 0.36 0.41 Breast cancer; chr5:132345058 chr5:132311285~132369916:- PAAD cis rs113835537 0.529 rs57207756 ENSG00000255517.5 CTD-3074O7.5 -5.46 1.89e-07 0.000173 -0.54 -0.41 Airway imaging phenotypes; chr11:66502889 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs17496250 ENSG00000255517.5 CTD-3074O7.5 -5.46 1.89e-07 0.000173 -0.54 -0.41 Airway imaging phenotypes; chr11:66503303 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs75683511 ENSG00000255517.5 CTD-3074O7.5 -5.46 1.89e-07 0.000173 -0.54 -0.41 Airway imaging phenotypes; chr11:66507555 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs17065 ENSG00000255517.5 CTD-3074O7.5 -5.46 1.89e-07 0.000173 -0.54 -0.41 Airway imaging phenotypes; chr11:66509564 chr11:66473490~66480233:- PAAD cis rs2274273 0.638 rs11622636 ENSG00000258413.1 RP11-665C16.6 -5.46 1.89e-07 0.000173 -0.55 -0.41 Protein biomarker; chr14:55181122 chr14:55262767~55272075:- PAAD cis rs2274273 0.638 rs3759667 ENSG00000258413.1 RP11-665C16.6 -5.46 1.89e-07 0.000173 -0.55 -0.41 Protein biomarker; chr14:55191703 chr14:55262767~55272075:- PAAD cis rs1075265 0.68 rs6715488 ENSG00000233266.1 HMGB1P31 5.46 1.89e-07 0.000173 0.53 0.41 Chronotype;Morning vs. evening chronotype; chr2:54004130 chr2:54051334~54051760:+ PAAD cis rs7772486 0.875 rs7767660 ENSG00000235652.6 RP11-545I5.3 5.46 1.89e-07 0.000173 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146115414 chr6:145799409~145886585:+ PAAD cis rs992157 0.672 rs2382829 ENSG00000261338.2 RP11-378A13.1 5.46 1.89e-07 0.000174 0.48 0.4 Colorectal cancer; chr2:218319894 chr2:218255319~218257366:+ PAAD cis rs992157 0.764 rs2891079 ENSG00000261338.2 RP11-378A13.1 5.46 1.89e-07 0.000174 0.48 0.4 Colorectal cancer; chr2:218319968 chr2:218255319~218257366:+ PAAD cis rs992157 0.764 rs4552182 ENSG00000261338.2 RP11-378A13.1 5.46 1.89e-07 0.000174 0.48 0.4 Colorectal cancer; chr2:218320149 chr2:218255319~218257366:+ PAAD cis rs992157 0.764 rs4423579 ENSG00000261338.2 RP11-378A13.1 5.46 1.89e-07 0.000174 0.48 0.4 Colorectal cancer; chr2:218320310 chr2:218255319~218257366:+ PAAD cis rs160451 0.934 rs160453 ENSG00000251136.7 RP11-37B2.1 5.46 1.9e-07 0.000174 0.37 0.4 Leprosy; chr8:89652326 chr8:89609409~89757727:- PAAD cis rs42490 0.51 rs13278061 ENSG00000251136.7 RP11-37B2.1 -5.46 1.9e-07 0.000174 -0.37 -0.4 Leprosy; chr8:89686032 chr8:89609409~89757727:- PAAD cis rs9926296 0.585 rs6500441 ENSG00000260259.1 RP11-368I7.4 -5.46 1.9e-07 0.000174 -0.48 -0.4 Vitiligo; chr16:89762261 chr16:89682620~89686569:- PAAD cis rs72843506 0.652 rs28550747 ENSG00000189423.10 USP32P3 5.46 1.9e-07 0.000175 0.61 0.4 Schizophrenia; chr17:20274999 chr17:20415547~20431008:+ PAAD cis rs7945705 0.818 rs2742552 ENSG00000254860.4 TMEM9B-AS1 5.46 1.91e-07 0.000175 0.42 0.4 Hemoglobin concentration; chr11:8855305 chr11:8964675~8977527:+ PAAD cis rs9640161 0.636 rs56190213 ENSG00000261305.1 RP4-584D14.7 5.46 1.91e-07 0.000176 0.62 0.4 Blood protein levels;Circulating chemerin levels; chr7:150328631 chr7:150341771~150342607:+ PAAD cis rs80285556 1 rs17661933 ENSG00000161643.11 SIGLEC16 -5.46 1.92e-07 0.000176 -0.86 -0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50031263 chr19:49969673~49975814:+ PAAD cis rs7772486 0.79 rs2265474 ENSG00000235652.6 RP11-545I5.3 5.46 1.92e-07 0.000176 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145860956 chr6:145799409~145886585:+ PAAD cis rs7772486 0.641 rs2748489 ENSG00000235652.6 RP11-545I5.3 5.46 1.92e-07 0.000176 0.34 0.4 Lobe attachment (rater-scored or self-reported); chr6:146010151 chr6:145799409~145886585:+ PAAD cis rs1075265 0.783 rs805453 ENSG00000233266.1 HMGB1P31 5.46 1.92e-07 0.000176 0.52 0.4 Chronotype;Morning vs. evening chronotype; chr2:53955761 chr2:54051334~54051760:+ PAAD cis rs1075265 0.73 rs2111868 ENSG00000233266.1 HMGB1P31 5.46 1.92e-07 0.000176 0.52 0.4 Chronotype;Morning vs. evening chronotype; chr2:53958916 chr2:54051334~54051760:+ PAAD cis rs4218 0.689 rs2121237 ENSG00000277144.1 RP11-59H7.4 -5.46 1.92e-07 0.000176 -0.55 -0.4 Social communication problems; chr15:59091888 chr15:59115547~59116089:- PAAD cis rs7772486 0.641 rs9390374 ENSG00000235652.6 RP11-545I5.3 5.46 1.92e-07 0.000176 0.34 0.4 Lobe attachment (rater-scored or self-reported); chr6:146047039 chr6:145799409~145886585:+ PAAD cis rs748404 0.646 rs2253268 ENSG00000249839.1 AC011330.5 -5.46 1.93e-07 0.000176 -0.61 -0.4 Lung cancer; chr15:43508770 chr15:43663654~43684339:- PAAD cis rs7772486 0.641 rs9390370 ENSG00000235652.6 RP11-545I5.3 5.46 1.93e-07 0.000177 0.34 0.4 Lobe attachment (rater-scored or self-reported); chr6:146036433 chr6:145799409~145886585:+ PAAD cis rs7772486 0.641 rs960385 ENSG00000235652.6 RP11-545I5.3 5.46 1.93e-07 0.000177 0.34 0.4 Lobe attachment (rater-scored or self-reported); chr6:146049938 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9373485 ENSG00000235652.6 RP11-545I5.3 5.46 1.93e-07 0.000177 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146080293 chr6:145799409~145886585:+ PAAD cis rs12458462 0.665 rs2035085 ENSG00000274828.1 RP11-567M16.6 5.46 1.93e-07 0.000177 0.41 0.4 Monocyte count; chr18:79725280 chr18:79677287~79679358:- PAAD cis rs12458462 0.851 rs62097746 ENSG00000274828.1 RP11-567M16.6 5.46 1.93e-07 0.000177 0.41 0.4 Monocyte count; chr18:79727508 chr18:79677287~79679358:- PAAD cis rs12458462 0.812 rs36073957 ENSG00000274828.1 RP11-567M16.6 5.46 1.93e-07 0.000177 0.41 0.4 Monocyte count; chr18:79728441 chr18:79677287~79679358:- PAAD cis rs12458462 0.851 rs2169249 ENSG00000274828.1 RP11-567M16.6 5.46 1.93e-07 0.000177 0.41 0.4 Monocyte count; chr18:79729649 chr18:79677287~79679358:- PAAD cis rs526231 0.543 rs27361 ENSG00000175749.11 EIF3KP1 5.46 1.94e-07 0.000178 0.53 0.4 Primary biliary cholangitis; chr5:103213266 chr5:103032376~103033031:+ PAAD cis rs10463554 0.75 rs26257 ENSG00000175749.11 EIF3KP1 5.46 1.94e-07 0.000178 0.53 0.4 Parkinson's disease; chr5:103214830 chr5:103032376~103033031:+ PAAD cis rs858239 0.931 rs9690941 ENSG00000226816.2 AC005082.12 5.46 1.94e-07 0.000178 0.47 0.4 Cerebrospinal fluid biomarker levels; chr7:23242134 chr7:23206013~23208045:+ PAAD cis rs1075265 0.875 rs12616212 ENSG00000233266.1 HMGB1P31 5.45 1.94e-07 0.000178 0.53 0.4 Chronotype;Morning vs. evening chronotype; chr2:54039109 chr2:54051334~54051760:+ PAAD cis rs11123170 0.503 rs28679654 ENSG00000189223.12 PAX8-AS1 -5.45 1.95e-07 0.000178 -0.57 -0.4 Renal function-related traits (BUN); chr2:113210040 chr2:113211522~113276581:+ PAAD cis rs9928842 0.882 rs9319481 ENSG00000280152.1 RP11-331F4.5 5.45 1.95e-07 0.000179 0.52 0.4 Alcoholic chronic pancreatitis; chr16:75225580 chr16:75245994~75250077:- PAAD cis rs9928842 0.882 rs1107593 ENSG00000280152.1 RP11-331F4.5 5.45 1.95e-07 0.000179 0.52 0.4 Alcoholic chronic pancreatitis; chr16:75227431 chr16:75245994~75250077:- PAAD cis rs9928842 0.824 rs12924999 ENSG00000280152.1 RP11-331F4.5 5.45 1.95e-07 0.000179 0.52 0.4 Alcoholic chronic pancreatitis; chr16:75228527 chr16:75245994~75250077:- PAAD cis rs1150668 0.83 rs213240 ENSG00000204709.4 LINC01556 5.45 1.96e-07 0.000179 0.53 0.4 Pubertal anthropometrics; chr6:28348098 chr6:28943877~28944537:+ PAAD cis rs7772486 0.875 rs1331640 ENSG00000235652.6 RP11-545I5.3 5.45 1.97e-07 0.00018 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146106114 chr6:145799409~145886585:+ PAAD cis rs227275 0.525 rs13113923 ENSG00000246560.2 RP11-10L12.4 5.45 1.97e-07 0.00018 0.44 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102918936 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs3974604 ENSG00000246560.2 RP11-10L12.4 5.45 1.97e-07 0.00018 0.44 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102928601 chr4:102828055~102844075:+ PAAD cis rs2739330 0.828 rs4822454 ENSG00000231271.1 AP000350.8 5.45 1.98e-07 0.000181 0.54 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23949918~23954042:+ PAAD cis rs10506328 0.689 rs4759348 ENSG00000248265.1 FLJ12825 5.45 1.98e-07 0.000181 0.44 0.4 Mean platelet volume; chr12:54236733 chr12:54058254~54122234:+ PAAD cis rs7772486 0.875 rs6913797 ENSG00000235652.6 RP11-545I5.3 5.45 1.98e-07 0.000181 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146092622 chr6:145799409~145886585:+ PAAD cis rs1322639 0.614 rs6925201 ENSG00000261039.2 RP11-417E7.2 5.45 1.98e-07 0.000181 0.66 0.4 Pulse pressure; chr6:169163262 chr6:169175304~169182740:- PAAD cis rs35160687 0.712 rs11691726 ENSG00000273080.1 RP11-301O19.1 -5.45 1.98e-07 0.000181 -0.48 -0.4 Night sleep phenotypes; chr2:86267147 chr2:86195590~86196049:+ PAAD cis rs8135665 0.625 rs34385006 ENSG00000233739.1 RP5-1039K5.13 5.45 1.98e-07 0.000181 0.5 0.4 Advanced age-related macular degeneration;Age-related macular degeneration; chr22:38054284 chr22:38057180~38073940:- PAAD cis rs4218 0.648 rs12442086 ENSG00000277144.1 RP11-59H7.4 -5.45 1.99e-07 0.000182 -0.57 -0.4 Social communication problems; chr15:59074364 chr15:59115547~59116089:- PAAD cis rs4218 0.648 rs10851642 ENSG00000277144.1 RP11-59H7.4 -5.45 1.99e-07 0.000182 -0.57 -0.4 Social communication problems; chr15:59077909 chr15:59115547~59116089:- PAAD cis rs7772486 0.875 rs7739371 ENSG00000235652.6 RP11-545I5.3 5.45 2e-07 0.000183 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146103217 chr6:145799409~145886585:+ PAAD cis rs992157 0.932 rs10194082 ENSG00000261338.2 RP11-378A13.1 5.45 2e-07 0.000183 0.46 0.4 Colorectal cancer; chr2:218323854 chr2:218255319~218257366:+ PAAD cis rs11722779 0.869 rs223323 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Schizophrenia; chr4:102878412 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223316 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102881949 chr4:102828055~102844075:+ PAAD cis rs227275 0.554 rs223314 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102884642 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223313 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102886563 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs7254 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888488 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223311 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102888757 chr4:102828055~102844075:+ PAAD cis rs11722779 0.566 rs6822658 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Schizophrenia; chr4:102891964 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs6823625 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892437 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs6846762 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892577 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs4699032 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102892724 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs6830407 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102895366 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs4235407 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102897427 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs4699033 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102897577 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs6815526 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102899729 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs6824070 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102901676 chr4:102828055~102844075:+ PAAD cis rs11722779 0.935 rs6856176 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Schizophrenia; chr4:102902574 chr4:102828055~102844075:+ PAAD cis rs227275 0.556 rs11722779 ENSG00000246560.2 RP11-10L12.4 5.45 2e-07 0.000183 0.45 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102906331 chr4:102828055~102844075:+ PAAD cis rs11123170 0.529 rs1015755 ENSG00000189223.12 PAX8-AS1 -5.45 2.01e-07 0.000183 -0.57 -0.4 Renal function-related traits (BUN); chr2:113210730 chr2:113211522~113276581:+ PAAD cis rs9532669 0.889 rs9525397 ENSG00000176268.5 CYCSP34 5.45 2.01e-07 0.000183 0.42 0.4 Cervical cancer; chr13:40851575 chr13:40863599~40863902:- PAAD cis rs2108622 0.527 rs67617968 ENSG00000267453.5 AC004791.2 -5.45 2.01e-07 0.000183 -0.56 -0.4 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15866755 chr19:15851993~15864904:- PAAD cis rs7615952 0.673 rs3811677 ENSG00000171084.14 FAM86JP 5.45 2.01e-07 0.000184 0.53 0.4 Blood pressure (smoking interaction); chr3:125929237 chr3:125916620~125930024:+ PAAD cis rs7615952 0.932 rs3811679 ENSG00000171084.14 FAM86JP 5.45 2.01e-07 0.000184 0.53 0.4 Blood pressure (smoking interaction); chr3:125929440 chr3:125916620~125930024:+ PAAD cis rs2283792 0.633 rs240068 ENSG00000228050.1 TOP3BP1 5.45 2.01e-07 0.000184 0.46 0.4 Multiple sclerosis; chr22:21936031 chr22:22223187~22224566:- PAAD cis rs4722166 0.598 rs4722179 ENSG00000179428.2 AC073072.5 -5.45 2.02e-07 0.000184 -0.35 -0.4 Lung cancer; chr7:22764242 chr7:22725395~22727620:- PAAD cis rs4266144 0.821 rs4325879 ENSG00000244515.1 KRT18P34 -5.45 2.02e-07 0.000184 -0.56 -0.4 Coronary artery disease; chr3:157134195 chr3:157162663~157163932:- PAAD cis rs2283792 0.905 rs5755694 ENSG00000224086.5 LL22NC03-86G7.1 -5.45 2.02e-07 0.000184 -0.41 -0.4 Multiple sclerosis; chr22:21846241 chr22:21938293~21977632:+ PAAD cis rs992157 0.73 rs4280446 ENSG00000261338.2 RP11-378A13.1 5.45 2.02e-07 0.000184 0.48 0.4 Colorectal cancer; chr2:218319998 chr2:218255319~218257366:+ PAAD cis rs9326248 0.954 rs10790177 ENSG00000280143.1 AP000892.6 5.45 2.02e-07 0.000184 0.51 0.4 Blood protein levels; chr11:117177701 chr11:117204967~117210292:+ PAAD cis rs9326248 1 rs7946257 ENSG00000280143.1 AP000892.6 5.45 2.02e-07 0.000184 0.51 0.4 Blood protein levels; chr11:117182449 chr11:117204967~117210292:+ PAAD cis rs9326248 0.954 rs521171 ENSG00000280143.1 AP000892.6 5.45 2.02e-07 0.000184 0.51 0.4 Blood protein levels; chr11:117193977 chr11:117204967~117210292:+ PAAD cis rs9326248 0.954 rs8521 ENSG00000280143.1 AP000892.6 5.45 2.02e-07 0.000184 0.51 0.4 Blood protein levels; chr11:117196983 chr11:117204967~117210292:+ PAAD cis rs9322193 0.566 rs9397070 ENSG00000223701.3 RAET1E-AS1 -5.45 2.03e-07 0.000185 -0.51 -0.4 Lung cancer; chr6:149922073 chr6:149884431~149919508:+ PAAD cis rs7829975 0.742 rs7832968 ENSG00000253893.2 FAM85B -5.45 2.04e-07 0.000185 -0.57 -0.4 Mood instability; chr8:8795379 chr8:8167819~8226614:- PAAD cis rs10463554 1 rs6879788 ENSG00000175749.11 EIF3KP1 5.44 2.04e-07 0.000186 0.52 0.4 Parkinson's disease; chr5:102978353 chr5:103032376~103033031:+ PAAD cis rs10463554 1 rs10463554 ENSG00000175749.11 EIF3KP1 5.44 2.04e-07 0.000186 0.52 0.4 Parkinson's disease; chr5:102983270 chr5:103032376~103033031:+ PAAD cis rs10463554 0.963 rs10463555 ENSG00000175749.11 EIF3KP1 5.44 2.04e-07 0.000186 0.52 0.4 Parkinson's disease; chr5:102983333 chr5:103032376~103033031:+ PAAD cis rs10463554 1 rs56372231 ENSG00000175749.11 EIF3KP1 5.44 2.04e-07 0.000186 0.52 0.4 Parkinson's disease; chr5:102986201 chr5:103032376~103033031:+ PAAD cis rs7208859 0.573 rs216443 ENSG00000266490.1 CTD-2349P21.9 5.44 2.05e-07 0.000186 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604853 chr17:30792372~30792833:+ PAAD cis rs1400745 0.756 rs3783316 ENSG00000258738.1 RP11-73E17.2 5.44 2.05e-07 0.000186 0.46 0.4 Monocyte count; chr14:34867986 chr14:34874343~34876459:+ PAAD cis rs875971 0.862 rs57866200 ENSG00000237310.1 GS1-124K5.4 -5.44 2.05e-07 0.000186 -0.41 -0.4 Aortic root size; chr7:66100405 chr7:66493706~66495474:+ PAAD cis rs10463554 0.895 rs3756583 ENSG00000175749.11 EIF3KP1 5.44 2.05e-07 0.000187 0.5 0.4 Parkinson's disease; chr5:102998340 chr5:103032376~103033031:+ PAAD cis rs964184 0.63 rs6589566 ENSG00000254851.1 RP11-109L13.1 -5.44 2.06e-07 0.000187 -0.92 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116781707 chr11:117135528~117138582:+ PAAD cis rs992157 0.735 rs10932765 ENSG00000261338.2 RP11-378A13.1 5.44 2.06e-07 0.000188 0.45 0.4 Colorectal cancer; chr2:218234761 chr2:218255319~218257366:+ PAAD cis rs2153535 0.563 rs1796687 ENSG00000230939.1 RP11-314C16.1 -5.44 2.07e-07 0.000188 -0.44 -0.4 Motion sickness; chr6:8535885 chr6:8784178~8785445:+ PAAD cis rs7772486 0.754 rs9373476 ENSG00000235652.6 RP11-545I5.3 5.44 2.07e-07 0.000188 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145818605 chr6:145799409~145886585:+ PAAD cis rs7772486 0.727 rs11155442 ENSG00000235652.6 RP11-545I5.3 5.44 2.07e-07 0.000188 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145819589 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs9390358 ENSG00000235652.6 RP11-545I5.3 5.44 2.07e-07 0.000188 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145824542 chr6:145799409~145886585:+ PAAD cis rs8062405 1 rs56404918 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.07e-07 0.000188 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835519 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs55719896 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.07e-07 0.000188 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835545 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs55830740 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.07e-07 0.000188 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28835828 chr16:28802743~28817828:+ PAAD cis rs7772486 0.84 rs2474355 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145991404 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2474353 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146002747 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs1854900 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146010246 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2777484 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146013026 chr6:145799409~145886585:+ PAAD cis rs7772486 0.817 rs2144477 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146085112 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9403768 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146085322 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs6934467 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146089393 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs6938972 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146089472 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs12194437 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146090304 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs10457793 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146094267 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs10457794 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146094472 chr6:145799409~145886585:+ PAAD cis rs7772486 0.84 rs11155451 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146101388 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9403770 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146102198 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs11155452 ENSG00000235652.6 RP11-545I5.3 5.44 2.08e-07 0.000189 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146103495 chr6:145799409~145886585:+ PAAD cis rs2019137 0.936 rs902696 ENSG00000189223.12 PAX8-AS1 -5.44 2.08e-07 0.000189 -0.49 -0.4 Lymphocyte counts; chr2:113197302 chr2:113211522~113276581:+ PAAD cis rs8062405 1 rs12325113 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.08e-07 0.000189 -0.36 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28837347 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs80275162 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.08e-07 0.000189 -0.36 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28852196 chr16:28802743~28817828:+ PAAD cis rs56163509 1 rs56163509 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.08e-07 0.000189 -0.36 -0.4 Tonsillectomy;Mean corpuscular volume; chr16:28853150 chr16:28802743~28817828:+ PAAD cis rs8062405 0.964 rs7187333 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.08e-07 0.000189 -0.36 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854595 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs12446589 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.08e-07 0.000189 -0.36 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859641 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62037369 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.08e-07 0.000189 -0.36 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28872520 chr16:28802743~28817828:+ PAAD cis rs8062405 0.965 rs7359397 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.08e-07 0.000189 -0.36 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874338 chr16:28802743~28817828:+ PAAD cis rs853679 0.517 rs16893666 ENSG00000226314.6 ZNF192P1 5.44 2.08e-07 0.000189 0.66 0.4 Depression; chr6:28086929 chr6:28161781~28169594:+ PAAD cis rs2882667 0.652 rs6596463 ENSG00000253404.1 AC034243.1 5.44 2.08e-07 0.000189 0.47 0.4 Age-related hearing impairment (SNP x SNP interaction); chr5:139109237 chr5:138744434~138753309:- PAAD cis rs2739330 0.76 rs5751760 ENSG00000099984.9 GSTT2 -5.44 2.09e-07 0.00019 -0.5 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23980123~23983911:+ PAAD cis rs11098499 0.535 rs7671759 ENSG00000245958.5 RP11-33B1.1 -5.44 2.1e-07 0.00019 -0.33 -0.4 Corneal astigmatism; chr4:119326939 chr4:119454791~119552025:+ PAAD cis rs9322193 0.923 rs7769101 ENSG00000223701.3 RAET1E-AS1 5.44 2.1e-07 0.00019 0.47 0.4 Lung cancer; chr6:149848768 chr6:149884431~149919508:+ PAAD cis rs6584283 1 rs6584283 ENSG00000257582.4 LINC01475 -5.44 2.1e-07 0.000191 -0.44 -0.4 Ulcerative colitis; chr10:99530544 chr10:99526350~99531177:- PAAD cis rs875971 0.862 rs1167408 ENSG00000237310.1 GS1-124K5.4 -5.44 2.1e-07 0.000191 -0.41 -0.4 Aortic root size; chr7:66091121 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs1167406 ENSG00000237310.1 GS1-124K5.4 -5.44 2.1e-07 0.000191 -0.41 -0.4 Aortic root size; chr7:66091949 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs709609 ENSG00000237310.1 GS1-124K5.4 -5.44 2.1e-07 0.000191 -0.41 -0.4 Aortic root size; chr7:66095574 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs1167399 ENSG00000237310.1 GS1-124K5.4 -5.44 2.1e-07 0.000191 -0.41 -0.4 Aortic root size; chr7:66096890 chr7:66493706~66495474:+ PAAD cis rs10510102 0.872 rs10887032 ENSG00000276742.1 RP11-500G22.4 -5.44 2.1e-07 0.000191 -0.58 -0.4 Breast cancer; chr10:121955887 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12246693 ENSG00000276742.1 RP11-500G22.4 5.44 2.1e-07 0.000191 0.58 0.4 Breast cancer; chr10:121957373 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12248806 ENSG00000276742.1 RP11-500G22.4 5.44 2.1e-07 0.000191 0.58 0.4 Breast cancer; chr10:121958638 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12255832 ENSG00000276742.1 RP11-500G22.4 5.44 2.1e-07 0.000191 0.58 0.4 Breast cancer; chr10:121958762 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12247367 ENSG00000276742.1 RP11-500G22.4 5.44 2.1e-07 0.000191 0.58 0.4 Breast cancer; chr10:121961556 chr10:121956782~121957098:+ PAAD cis rs950169 0.92 rs11637666 ENSG00000259728.4 LINC00933 5.44 2.11e-07 0.000192 0.52 0.4 Schizophrenia; chr15:84035122 chr15:84570649~84580175:+ PAAD cis rs7078219 0.576 rs989979 ENSG00000257582.4 LINC01475 -5.44 2.11e-07 0.000192 -0.44 -0.4 Dental caries; chr10:99562666 chr10:99526350~99531177:- PAAD cis rs113835537 0.529 rs7950790 ENSG00000255517.5 CTD-3074O7.5 -5.44 2.12e-07 0.000192 -0.51 -0.4 Airway imaging phenotypes; chr11:66490582 chr11:66473490~66480233:- PAAD cis rs8062405 1 rs4451951 ENSG00000251417.2 RP11-1348G14.4 -5.44 2.12e-07 0.000192 -0.36 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28824884 chr16:28802743~28817828:+ PAAD cis rs10463554 0.892 rs6596528 ENSG00000175749.11 EIF3KP1 5.44 2.13e-07 0.000193 0.52 0.4 Parkinson's disease; chr5:102969924 chr5:103032376~103033031:+ PAAD cis rs11168351 0.517 rs10875754 ENSG00000240399.1 RP1-228P16.1 5.44 2.13e-07 0.000193 0.38 0.4 Bipolar disorder and schizophrenia; chr12:48164139 chr12:48054813~48055591:- PAAD cis rs6504950 1 rs56348638 ENSG00000275710.1 RP11-257O5.4 5.44 2.13e-07 0.000193 0.53 0.4 Breast cancer; chr17:54987189 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs7219874 ENSG00000275710.1 RP11-257O5.4 5.44 2.13e-07 0.000193 0.53 0.4 Breast cancer; chr17:54988446 chr17:54964474~54964679:+ PAAD cis rs950169 1 rs1818950 ENSG00000225151.9 GOLGA2P7 -5.44 2.13e-07 0.000193 -0.48 -0.4 Schizophrenia; chr15:84053769 chr15:84199311~84230136:- PAAD cis rs113835537 0.529 rs2305532 ENSG00000255517.5 CTD-3074O7.5 -5.44 2.13e-07 0.000193 -0.55 -0.4 Airway imaging phenotypes; chr11:66531123 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs2305533 ENSG00000255517.5 CTD-3074O7.5 -5.44 2.13e-07 0.000193 -0.55 -0.4 Airway imaging phenotypes; chr11:66531152 chr11:66473490~66480233:- PAAD cis rs9926296 0.568 rs886950 ENSG00000260259.1 RP11-368I7.4 -5.43 2.15e-07 0.000194 -0.49 -0.4 Vitiligo; chr16:89770464 chr16:89682620~89686569:- PAAD cis rs9481169 0.557 rs33980500 ENSG00000255389.1 C6orf3 -5.43 2.15e-07 0.000194 -0.68 -0.4 Inflammatory skin disease; chr6:111592059 chr6:111599875~111602295:+ PAAD cis rs4218 0.541 rs1374155 ENSG00000277144.1 RP11-59H7.4 -5.43 2.15e-07 0.000195 -0.5 -0.4 Social communication problems; chr15:59030630 chr15:59115547~59116089:- PAAD cis rs638893 0.947 rs1170396 ENSG00000278376.1 RP11-158I9.8 -5.43 2.15e-07 0.000195 -0.57 -0.4 Vitiligo; chr11:118833108 chr11:118791254~118793137:+ PAAD cis rs638893 1 rs649338 ENSG00000278376.1 RP11-158I9.8 -5.43 2.15e-07 0.000195 -0.57 -0.4 Vitiligo; chr11:118834945 chr11:118791254~118793137:+ PAAD cis rs9926296 0.712 rs2437957 ENSG00000260259.1 RP11-368I7.4 5.43 2.15e-07 0.000195 0.51 0.4 Vitiligo; chr16:89649240 chr16:89682620~89686569:- PAAD cis rs526231 0.543 rs246900 ENSG00000175749.11 EIF3KP1 5.43 2.15e-07 0.000195 0.53 0.4 Primary biliary cholangitis; chr5:103198928 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs28025 ENSG00000175749.11 EIF3KP1 5.43 2.15e-07 0.000195 0.53 0.4 Primary biliary cholangitis; chr5:103201678 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs8488 ENSG00000175749.11 EIF3KP1 5.43 2.15e-07 0.000195 0.53 0.4 Primary biliary cholangitis; chr5:103203051 chr5:103032376~103033031:+ PAAD cis rs526231 0.511 rs34823 ENSG00000175749.11 EIF3KP1 -5.43 2.15e-07 0.000195 -0.53 -0.4 Primary biliary cholangitis; chr5:103102587 chr5:103032376~103033031:+ PAAD cis rs9926296 0.568 rs4420527 ENSG00000260259.1 RP11-368I7.4 5.43 2.16e-07 0.000195 0.49 0.4 Vitiligo; chr16:89747780 chr16:89682620~89686569:- PAAD cis rs4218 0.648 rs12441973 ENSG00000277144.1 RP11-59H7.4 -5.43 2.16e-07 0.000195 -0.56 -0.4 Social communication problems; chr15:59057016 chr15:59115547~59116089:- PAAD cis rs9322193 0.607 rs9322229 ENSG00000223701.3 RAET1E-AS1 5.43 2.16e-07 0.000195 0.5 0.4 Lung cancer; chr6:149908949 chr6:149884431~149919508:+ PAAD cis rs801193 0.773 rs801207 ENSG00000237310.1 GS1-124K5.4 -5.43 2.16e-07 0.000195 -0.37 -0.4 Aortic root size; chr7:66555603 chr7:66493706~66495474:+ PAAD cis rs7615952 1 rs7616044 ENSG00000171084.14 FAM86JP 5.43 2.16e-07 0.000195 0.53 0.4 Blood pressure (smoking interaction); chr3:125930511 chr3:125916620~125930024:+ PAAD cis rs7615952 1 rs7615952 ENSG00000171084.14 FAM86JP -5.43 2.16e-07 0.000195 -0.53 -0.4 Blood pressure (smoking interaction); chr3:125930560 chr3:125916620~125930024:+ PAAD cis rs7615952 0.932 rs7629977 ENSG00000171084.14 FAM86JP 5.43 2.16e-07 0.000195 0.53 0.4 Blood pressure (smoking interaction); chr3:125930730 chr3:125916620~125930024:+ PAAD cis rs7615952 0.932 rs6438948 ENSG00000171084.14 FAM86JP -5.43 2.16e-07 0.000195 -0.53 -0.4 Blood pressure (smoking interaction); chr3:125931202 chr3:125916620~125930024:+ PAAD cis rs2337406 0.714 rs115401799 ENSG00000274576.2 IGHV2-70 -5.43 2.16e-07 0.000195 -0.54 -0.4 Alzheimer's disease (late onset); chr14:106813739 chr14:106770577~106771020:- PAAD cis rs7772486 0.875 rs56181683 ENSG00000235652.6 RP11-545I5.3 -5.43 2.16e-07 0.000195 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145965484 chr6:145799409~145886585:+ PAAD cis rs8062405 0.964 rs11860513 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.16e-07 0.000195 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814099 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs1987472 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.16e-07 0.000195 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814456 chr16:28802743~28817828:+ PAAD cis rs8062405 0.895 rs56186137 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.16e-07 0.000195 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814632 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs2008514 ENSG00000251417.2 RP11-1348G14.4 5.43 2.16e-07 0.000195 0.35 0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28814284 chr16:28802743~28817828:+ PAAD cis rs9640161 0.75 rs11765644 ENSG00000261305.1 RP4-584D14.7 5.43 2.16e-07 0.000195 0.62 0.4 Blood protein levels;Circulating chemerin levels; chr7:150329250 chr7:150341771~150342607:+ PAAD cis rs1400745 0.756 rs799683 ENSG00000258738.1 RP11-73E17.2 5.43 2.16e-07 0.000195 0.46 0.4 Monocyte count; chr14:34880030 chr14:34874343~34876459:+ PAAD cis rs1400745 0.756 rs799682 ENSG00000258738.1 RP11-73E17.2 5.43 2.16e-07 0.000195 0.46 0.4 Monocyte count; chr14:34880778 chr14:34874343~34876459:+ PAAD cis rs1400745 0.718 rs799681 ENSG00000258738.1 RP11-73E17.2 5.43 2.16e-07 0.000195 0.46 0.4 Monocyte count; chr14:34881373 chr14:34874343~34876459:+ PAAD cis rs6142102 0.517 rs6142050 ENSG00000276073.1 RP5-1125A11.7 -5.43 2.16e-07 0.000196 -0.42 -0.4 Skin pigmentation; chr20:33939322 chr20:33985617~33988989:- PAAD cis rs875971 0.862 rs2909688 ENSG00000237310.1 GS1-124K5.4 5.43 2.17e-07 0.000196 0.41 0.4 Aortic root size; chr7:66376625 chr7:66493706~66495474:+ PAAD cis rs6903823 0.508 rs1150721 ENSG00000216901.1 AL022393.7 5.43 2.17e-07 0.000196 0.48 0.4 Pulmonary function; chr6:28287263 chr6:28176188~28176674:+ PAAD cis rs7772486 0.875 rs13204280 ENSG00000235652.6 RP11-545I5.3 5.43 2.17e-07 0.000196 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146094232 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs2096201 ENSG00000235652.6 RP11-545I5.3 5.43 2.17e-07 0.000196 0.34 0.4 Lobe attachment (rater-scored or self-reported); chr6:145613137 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2814877 ENSG00000235652.6 RP11-545I5.3 5.43 2.17e-07 0.000196 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145978627 chr6:145799409~145886585:+ PAAD cis rs2581828 0.656 rs4687701 ENSG00000242142.1 SERBP1P3 -5.43 2.18e-07 0.000197 -0.47 -0.4 Crohn's disease; chr3:53087260 chr3:53064283~53065091:- PAAD cis rs858239 1 rs858239 ENSG00000226816.2 AC005082.12 5.43 2.18e-07 0.000197 0.46 0.4 Cerebrospinal fluid biomarker levels; chr7:23246696 chr7:23206013~23208045:+ PAAD cis rs633715 0.918 rs543874 ENSG00000254154.7 RP4-798P15.3 5.43 2.18e-07 0.000197 0.35 0.4 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177920345 chr1:177928788~178038007:- PAAD cis rs633715 0.959 rs539515 ENSG00000254154.7 RP4-798P15.3 -5.43 2.18e-07 0.000197 -0.35 -0.4 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177919890 chr1:177928788~178038007:- PAAD cis rs633715 0.918 rs506589 ENSG00000254154.7 RP4-798P15.3 -5.43 2.18e-07 0.000197 -0.35 -0.4 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177925152 chr1:177928788~178038007:- PAAD cis rs113835537 0.529 rs57691879 ENSG00000255517.5 CTD-3074O7.5 -5.43 2.18e-07 0.000197 -0.51 -0.4 Airway imaging phenotypes; chr11:66469133 chr11:66473490~66480233:- PAAD cis rs748404 0.69 rs1079309 ENSG00000249839.1 AC011330.5 -5.43 2.18e-07 0.000197 -0.61 -0.4 Lung cancer; chr15:43490966 chr15:43663654~43684339:- PAAD cis rs748404 0.69 rs2924369 ENSG00000249839.1 AC011330.5 5.43 2.18e-07 0.000197 0.61 0.4 Lung cancer; chr15:43485787 chr15:43663654~43684339:- PAAD cis rs10463554 0.892 rs3776874 ENSG00000175749.11 EIF3KP1 5.43 2.19e-07 0.000197 0.52 0.4 Parkinson's disease; chr5:102946613 chr5:103032376~103033031:+ PAAD cis rs10463554 0.857 rs3776873 ENSG00000175749.11 EIF3KP1 5.43 2.19e-07 0.000197 0.52 0.4 Parkinson's disease; chr5:102946768 chr5:103032376~103033031:+ PAAD cis rs633715 0.918 rs509325 ENSG00000254154.7 RP4-798P15.3 -5.43 2.19e-07 0.000198 -0.35 -0.4 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177925456 chr1:177928788~178038007:- PAAD cis rs964184 0.564 rs2266788 ENSG00000254851.1 RP11-109L13.1 -5.43 2.19e-07 0.000198 -0.91 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116789970 chr11:117135528~117138582:+ PAAD cis rs9326246 0.643 rs2072560 ENSG00000254851.1 RP11-109L13.1 -5.43 2.19e-07 0.000198 -0.91 -0.4 Coronary artery disease; chr11:116791110 chr11:117135528~117138582:+ PAAD cis rs12220777 0.681 rs117394476 ENSG00000230091.5 TMEM254-AS1 5.43 2.19e-07 0.000198 0.66 0.4 Chronic obstructive pulmonary disease-related biomarkers; chr10:80103000 chr10:80046860~80078912:- PAAD cis rs2739330 0.76 rs1007888 ENSG00000099984.9 GSTT2 -5.43 2.19e-07 0.000198 -0.5 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23980123~23983911:+ PAAD cis rs6782228 0.606 rs7613073 ENSG00000242551.2 POU5F1P6 -5.43 2.2e-07 0.000198 -0.48 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128669660 chr3:128674735~128677005:- PAAD cis rs6782228 0.628 rs7641584 ENSG00000242551.2 POU5F1P6 -5.43 2.2e-07 0.000198 -0.48 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128673787 chr3:128674735~128677005:- PAAD cis rs2581828 0.656 rs2564940 ENSG00000242142.1 SERBP1P3 5.43 2.2e-07 0.000198 0.47 0.4 Crohn's disease; chr3:53073553 chr3:53064283~53065091:- PAAD cis rs7208859 0.673 rs216420 ENSG00000266490.1 CTD-2349P21.9 5.43 2.21e-07 0.000199 0.48 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30611490 chr17:30792372~30792833:+ PAAD cis rs6570726 0.791 rs1280276 ENSG00000235652.6 RP11-545I5.3 5.43 2.21e-07 0.000199 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145571214 chr6:145799409~145886585:+ PAAD cis rs950169 1 rs950169 ENSG00000225151.9 GOLGA2P7 -5.43 2.21e-07 0.000199 -0.49 -0.4 Schizophrenia; chr15:84037709 chr15:84199311~84230136:- PAAD cis rs189798 0.807 rs330912 ENSG00000254340.1 RP11-10A14.3 5.43 2.21e-07 0.000199 0.57 0.4 Myopia (pathological); chr8:9138784 chr8:9141424~9145435:+ PAAD cis rs7772486 0.72 rs991507 ENSG00000235652.6 RP11-545I5.3 -5.43 2.21e-07 0.000199 -0.34 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145702473 chr6:145799409~145886585:+ PAAD cis rs4879677 1 rs2150022 ENSG00000260390.1 RP11-575I8.1 -5.43 2.21e-07 0.000199 -0.51 -0.4 Gut microbiome composition (summer and winter); chr9:27688031 chr9:27829276~27844481:+ PAAD cis rs72843506 0.722 rs16942325 ENSG00000189423.10 USP32P3 5.43 2.21e-07 0.000199 0.66 0.4 Schizophrenia; chr17:20123750 chr17:20415547~20431008:+ PAAD cis rs8062405 0.964 rs78613234 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.21e-07 0.000199 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828104 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62036624 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.21e-07 0.000199 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28828609 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs55991577 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.21e-07 0.000199 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831704 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs56358680 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.21e-07 0.000199 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28831797 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62036626 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.21e-07 0.000199 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28832963 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62036657 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.21e-07 0.000199 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833044 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs12444171 ENSG00000251417.2 RP11-1348G14.4 -5.43 2.21e-07 0.000199 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28833930 chr16:28802743~28817828:+ PAAD cis rs4266144 0.821 rs56237906 ENSG00000244515.1 KRT18P34 -5.43 2.21e-07 2e-04 -0.54 -0.4 Coronary artery disease; chr3:157134684 chr3:157162663~157163932:- PAAD cis rs35160687 0.712 rs4832261 ENSG00000273080.1 RP11-301O19.1 5.43 2.21e-07 2e-04 0.46 0.4 Night sleep phenotypes; chr2:86257375 chr2:86195590~86196049:+ PAAD cis rs72843506 0.591 rs75334890 ENSG00000189423.10 USP32P3 5.43 2.22e-07 2e-04 0.61 0.4 Schizophrenia; chr17:20318087 chr17:20415547~20431008:+ PAAD cis rs526231 0.543 rs34809 ENSG00000175749.11 EIF3KP1 5.43 2.22e-07 2e-04 0.53 0.4 Primary biliary cholangitis; chr5:103094413 chr5:103032376~103033031:+ PAAD cis rs10875746 0.768 rs10875724 ENSG00000240399.1 RP1-228P16.1 -5.43 2.23e-07 0.000201 -0.44 -0.4 Longevity (90 years and older); chr12:48026470 chr12:48054813~48055591:- PAAD cis rs10875746 0.768 rs12305182 ENSG00000240399.1 RP1-228P16.1 -5.43 2.23e-07 0.000201 -0.44 -0.4 Longevity (90 years and older); chr12:48027624 chr12:48054813~48055591:- PAAD cis rs10875746 0.768 rs4760676 ENSG00000240399.1 RP1-228P16.1 -5.43 2.23e-07 0.000201 -0.44 -0.4 Longevity (90 years and older); chr12:48027880 chr12:48054813~48055591:- PAAD cis rs17826219 0.568 rs11658027 ENSG00000266490.1 CTD-2349P21.9 -5.43 2.23e-07 0.000201 -0.52 -0.4 Body mass index; chr17:30767864 chr17:30792372~30792833:+ PAAD cis rs7772486 0.754 rs9399561 ENSG00000235652.6 RP11-545I5.3 5.43 2.23e-07 0.000201 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145634551 chr6:145799409~145886585:+ PAAD cis rs992157 0.764 rs4672886 ENSG00000261338.2 RP11-378A13.1 -5.43 2.23e-07 0.000201 -0.47 -0.4 Colorectal cancer; chr2:218320822 chr2:218255319~218257366:+ PAAD cis rs35160687 0.712 rs2303358 ENSG00000273080.1 RP11-301O19.1 -5.43 2.24e-07 0.000201 -0.47 -0.4 Night sleep phenotypes; chr2:86251541 chr2:86195590~86196049:+ PAAD cis rs4218 0.648 rs8042896 ENSG00000277144.1 RP11-59H7.4 -5.42 2.24e-07 0.000202 -0.54 -0.4 Social communication problems; chr15:59067727 chr15:59115547~59116089:- PAAD cis rs2337406 0.789 rs112027230 ENSG00000274576.2 IGHV2-70 -5.42 2.24e-07 0.000202 -0.52 -0.4 Alzheimer's disease (late onset); chr14:106810329 chr14:106770577~106771020:- PAAD cis rs160451 0.966 rs160423 ENSG00000251136.7 RP11-37B2.1 5.42 2.24e-07 0.000202 0.37 0.4 Leprosy; chr8:89658395 chr8:89609409~89757727:- PAAD cis rs858239 0.899 rs858271 ENSG00000226816.2 AC005082.12 5.42 2.24e-07 0.000202 0.46 0.4 Cerebrospinal fluid biomarker levels; chr7:23238664 chr7:23206013~23208045:+ PAAD cis rs6700559 0.873 rs7542210 ENSG00000260088.1 RP11-92G12.3 -5.42 2.25e-07 0.000203 -0.53 -0.4 Coronary artery disease; chr1:200693087 chr1:200669507~200694250:+ PAAD cis rs2274273 0.529 rs10131562 ENSG00000258413.1 RP11-665C16.6 -5.42 2.25e-07 0.000203 -0.54 -0.4 Protein biomarker; chr14:55380297 chr14:55262767~55272075:- PAAD cis rs7772486 0.846 rs6908063 ENSG00000235652.6 RP11-545I5.3 5.42 2.25e-07 0.000203 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146082482 chr6:145799409~145886585:+ PAAD cis rs4218 0.638 rs8042516 ENSG00000277144.1 RP11-59H7.4 -5.42 2.26e-07 0.000203 -0.54 -0.4 Social communication problems; chr15:59067525 chr15:59115547~59116089:- PAAD cis rs748404 0.66 rs690367 ENSG00000249839.1 AC011330.5 5.42 2.26e-07 0.000203 0.59 0.4 Lung cancer; chr15:43456106 chr15:43663654~43684339:- PAAD cis rs1061377 0.585 rs3733271 ENSG00000249685.1 RP11-360F5.3 5.42 2.26e-07 0.000203 0.42 0.4 Uric acid levels; chr4:39047948 chr4:39133913~39135608:+ PAAD cis rs1061377 0.621 rs11096974 ENSG00000249685.1 RP11-360F5.3 5.42 2.26e-07 0.000203 0.42 0.4 Uric acid levels; chr4:39062039 chr4:39133913~39135608:+ PAAD cis rs1061377 0.585 rs12648581 ENSG00000249685.1 RP11-360F5.3 5.42 2.27e-07 0.000204 0.42 0.4 Uric acid levels; chr4:39054024 chr4:39133913~39135608:+ PAAD cis rs7208859 0.528 rs3764416 ENSG00000266490.1 CTD-2349P21.9 -5.42 2.27e-07 0.000204 -0.49 -0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30573690 chr17:30792372~30792833:+ PAAD cis rs17301013 0.507 rs61528155 ENSG00000227373.4 RP11-160H22.5 5.42 2.27e-07 0.000204 0.61 0.4 Systemic lupus erythematosus; chr1:174276140 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12066700 ENSG00000227373.4 RP11-160H22.5 5.42 2.27e-07 0.000204 0.61 0.4 Systemic lupus erythematosus; chr1:174282054 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12060460 ENSG00000227373.4 RP11-160H22.5 5.42 2.27e-07 0.000204 0.61 0.4 Systemic lupus erythematosus; chr1:174284513 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs72713528 ENSG00000227373.4 RP11-160H22.5 5.42 2.27e-07 0.000204 0.61 0.4 Systemic lupus erythematosus; chr1:174319862 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs12091076 ENSG00000227373.4 RP11-160H22.5 5.42 2.27e-07 0.000204 0.61 0.4 Systemic lupus erythematosus; chr1:174321545 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs16846861 ENSG00000227373.4 RP11-160H22.5 5.42 2.27e-07 0.000204 0.61 0.4 Systemic lupus erythematosus; chr1:174338731 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs2860954 ENSG00000227373.4 RP11-160H22.5 5.42 2.27e-07 0.000204 0.61 0.4 Systemic lupus erythematosus; chr1:174344313 chr1:174115300~174160004:- PAAD cis rs17301013 0.507 rs60864659 ENSG00000227373.4 RP11-160H22.5 5.42 2.27e-07 0.000204 0.61 0.4 Systemic lupus erythematosus; chr1:174344641 chr1:174115300~174160004:- PAAD cis rs4972806 0.849 rs2857541 ENSG00000226363.3 HAGLROS -5.42 2.28e-07 0.000205 -0.49 -0.4 IgG glycosylation; chr2:176164358 chr2:176177717~176179008:+ PAAD cis rs2337406 0.636 rs74090069 ENSG00000274576.2 IGHV2-70 -5.42 2.28e-07 0.000205 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106777532 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74090071 ENSG00000274576.2 IGHV2-70 -5.42 2.28e-07 0.000205 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106777533 chr14:106770577~106771020:- PAAD cis rs853679 0.527 rs853690 ENSG00000204709.4 LINC01556 5.42 2.28e-07 0.000205 0.56 0.4 Depression; chr6:28317705 chr6:28943877~28944537:+ PAAD cis rs853679 0.527 rs707907 ENSG00000204709.4 LINC01556 5.42 2.28e-07 0.000205 0.56 0.4 Depression; chr6:28323463 chr6:28943877~28944537:+ PAAD cis rs853679 0.527 rs853683 ENSG00000204709.4 LINC01556 5.42 2.28e-07 0.000205 0.56 0.4 Depression; chr6:28327262 chr6:28943877~28944537:+ PAAD cis rs2581828 0.656 rs11242 ENSG00000242142.1 SERBP1P3 -5.42 2.28e-07 0.000205 -0.46 -0.4 Crohn's disease; chr3:53091906 chr3:53064283~53065091:- PAAD cis rs80285556 1 rs17605685 ENSG00000161643.11 SIGLEC16 5.42 2.28e-07 0.000205 0.98 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49983484 chr19:49969673~49975814:+ PAAD cis rs80285556 1 rs79633979 ENSG00000161643.11 SIGLEC16 5.42 2.28e-07 0.000205 0.98 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49985355 chr19:49969673~49975814:+ PAAD cis rs7772486 0.754 rs2064185 ENSG00000235652.6 RP11-545I5.3 -5.42 2.28e-07 0.000205 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145745678 chr6:145799409~145886585:+ PAAD cis rs7772486 0.719 rs2206141 ENSG00000235652.6 RP11-545I5.3 -5.42 2.28e-07 0.000205 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145765056 chr6:145799409~145886585:+ PAAD cis rs7772486 0.654 rs6906402 ENSG00000235652.6 RP11-545I5.3 -5.42 2.28e-07 0.000205 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145768171 chr6:145799409~145886585:+ PAAD cis rs11123170 0.529 rs1015753 ENSG00000189223.12 PAX8-AS1 -5.42 2.29e-07 0.000206 -0.57 -0.4 Renal function-related traits (BUN); chr2:113211226 chr2:113211522~113276581:+ PAAD cis rs992157 0.697 rs13384682 ENSG00000261338.2 RP11-378A13.1 5.42 2.3e-07 0.000206 0.45 0.4 Colorectal cancer; chr2:218204414 chr2:218255319~218257366:+ PAAD cis rs992157 0.71 rs7569907 ENSG00000261338.2 RP11-378A13.1 5.42 2.3e-07 0.000206 0.45 0.4 Colorectal cancer; chr2:218205828 chr2:218255319~218257366:+ PAAD cis rs748404 0.66 rs2467741 ENSG00000249839.1 AC011330.5 -5.42 2.31e-07 0.000207 -0.59 -0.4 Lung cancer; chr15:43450428 chr15:43663654~43684339:- PAAD cis rs992157 0.735 rs13393821 ENSG00000261338.2 RP11-378A13.1 5.42 2.31e-07 0.000207 0.45 0.4 Colorectal cancer; chr2:218212019 chr2:218255319~218257366:+ PAAD cis rs8059260 0.604 rs16958021 ENSG00000274038.1 RP11-66H6.4 -5.42 2.31e-07 0.000207 -0.64 -0.4 Alcohol consumption over the past year; chr16:11076190 chr16:11056556~11057034:+ PAAD cis rs4660456 0.913 rs6661855 ENSG00000237899.1 RP4-739H11.3 5.42 2.32e-07 0.000208 0.55 0.4 Platelet count; chr1:40703245 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs2744799 ENSG00000237899.1 RP4-739H11.3 5.42 2.32e-07 0.000208 0.55 0.4 Platelet count; chr1:40719862 chr1:40669089~40687588:- PAAD cis rs2283792 0.819 rs2266965 ENSG00000224086.5 LL22NC03-86G7.1 -5.42 2.32e-07 0.000208 -0.41 -0.4 Multiple sclerosis; chr22:21766866 chr22:21938293~21977632:+ PAAD cis rs7772486 0.875 rs10872582 ENSG00000235652.6 RP11-545I5.3 5.42 2.32e-07 0.000208 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146051925 chr6:145799409~145886585:+ PAAD cis rs881375 0.678 rs2416804 ENSG00000226752.6 PSMD5-AS1 5.42 2.32e-07 0.000208 0.44 0.4 Rheumatoid arthritis; chr9:120914118 chr9:120824828~120854385:+ PAAD cis rs801193 0.844 rs732465 ENSG00000237310.1 GS1-124K5.4 5.42 2.33e-07 0.000209 0.37 0.4 Aortic root size; chr7:66533463 chr7:66493706~66495474:+ PAAD cis rs7772486 0.72 rs4896837 ENSG00000235652.6 RP11-545I5.3 -5.42 2.33e-07 0.000209 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145693032 chr6:145799409~145886585:+ PAAD cis rs11722779 0.844 rs223345 ENSG00000246560.2 RP11-10L12.4 5.42 2.33e-07 0.000209 0.44 0.4 Schizophrenia; chr4:102859366 chr4:102828055~102844075:+ PAAD cis rs11722779 0.873 rs223344 ENSG00000246560.2 RP11-10L12.4 5.42 2.33e-07 0.000209 0.44 0.4 Schizophrenia; chr4:102859765 chr4:102828055~102844075:+ PAAD cis rs11722779 0.775 rs223341 ENSG00000246560.2 RP11-10L12.4 5.42 2.33e-07 0.000209 0.44 0.4 Schizophrenia; chr4:102862343 chr4:102828055~102844075:+ PAAD cis rs875971 0.767 rs12668005 ENSG00000237310.1 GS1-124K5.4 5.42 2.34e-07 0.00021 0.41 0.4 Aortic root size; chr7:66444034 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs11765791 ENSG00000237310.1 GS1-124K5.4 5.42 2.34e-07 0.00021 0.41 0.4 Aortic root size; chr7:66471587 chr7:66493706~66495474:+ PAAD cis rs2283792 0.718 rs239918 ENSG00000228050.1 TOP3BP1 5.42 2.34e-07 0.00021 0.43 0.4 Multiple sclerosis; chr22:21959457 chr22:22223187~22224566:- PAAD cis rs1400745 0.756 rs3783314 ENSG00000258738.1 RP11-73E17.2 5.42 2.34e-07 0.00021 0.46 0.4 Monocyte count; chr14:34868178 chr14:34874343~34876459:+ PAAD cis rs3761847 0.622 rs10818500 ENSG00000226752.6 PSMD5-AS1 5.42 2.34e-07 0.00021 0.45 0.4 Rheumatoid arthritis; chr9:121048605 chr9:120824828~120854385:+ PAAD cis rs2337406 0.866 rs8003852 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106776648 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs988131 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106776833 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs8005518 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106777009 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs988130 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106777154 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs57684263 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106777263 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs7152038 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106778230 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs7152809 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106778385 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs7152832 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106778427 chr14:106770577~106771020:- PAAD cis rs2337406 0.5 rs7152934 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106778702 chr14:106770577~106771020:- PAAD cis rs2337406 0.789 rs12050392 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106779073 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74092505 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106779163 chr14:106770577~106771020:- PAAD cis rs2337406 0.789 rs74092507 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106779174 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74092511 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106779234 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74092512 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106779306 chr14:106770577~106771020:- PAAD cis rs2337406 0.789 rs74092514 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106779385 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs74092520 ENSG00000274576.2 IGHV2-70 -5.41 2.35e-07 0.00021 -0.5 -0.4 Alzheimer's disease (late onset); chr14:106779632 chr14:106770577~106771020:- PAAD cis rs875971 0.543 rs801191 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66567968 chr7:66493706~66495474:+ PAAD cis rs875971 0.508 rs6947808 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66580095 chr7:66493706~66495474:+ PAAD cis rs875971 0.508 rs10242423 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66594188 chr7:66493706~66495474:+ PAAD cis rs875971 0.508 rs10253883 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66596151 chr7:66493706~66495474:+ PAAD cis rs875971 0.508 rs10258739 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66597948 chr7:66493706~66495474:+ PAAD cis rs875971 0.508 rs10950045 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66601386 chr7:66493706~66495474:+ PAAD cis rs801193 0.839 rs6968619 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66603880 chr7:66493706~66495474:+ PAAD cis rs801193 0.839 rs12534943 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66605533 chr7:66493706~66495474:+ PAAD cis rs801193 0.805 rs12532355 ENSG00000237310.1 GS1-124K5.4 -5.41 2.35e-07 0.00021 -0.37 -0.4 Aortic root size; chr7:66605597 chr7:66493706~66495474:+ PAAD cis rs748404 0.66 rs493377 ENSG00000249839.1 AC011330.5 -5.41 2.35e-07 0.00021 -0.6 -0.4 Lung cancer; chr15:43481269 chr15:43663654~43684339:- PAAD cis rs950169 0.58 rs1061737 ENSG00000225151.9 GOLGA2P7 -5.41 2.36e-07 0.000211 -0.48 -0.4 Schizophrenia; chr15:84640559 chr15:84199311~84230136:- PAAD cis rs9640161 0.702 rs1962004 ENSG00000261305.1 RP4-584D14.7 5.41 2.36e-07 0.000211 0.62 0.4 Blood protein levels;Circulating chemerin levels; chr7:150323292 chr7:150341771~150342607:+ PAAD cis rs9640161 0.789 rs2373751 ENSG00000261305.1 RP4-584D14.7 5.41 2.36e-07 0.000211 0.62 0.4 Blood protein levels;Circulating chemerin levels; chr7:150324510 chr7:150341771~150342607:+ PAAD cis rs992157 0.735 rs2271541 ENSG00000261338.2 RP11-378A13.1 5.41 2.36e-07 0.000211 0.45 0.4 Colorectal cancer; chr2:218217396 chr2:218255319~218257366:+ PAAD cis rs992157 0.71 rs12694432 ENSG00000261338.2 RP11-378A13.1 5.41 2.36e-07 0.000211 0.45 0.4 Colorectal cancer; chr2:218217607 chr2:218255319~218257366:+ PAAD cis rs992157 0.735 rs12990082 ENSG00000261338.2 RP11-378A13.1 5.41 2.36e-07 0.000211 0.45 0.4 Colorectal cancer; chr2:218237609 chr2:218255319~218257366:+ PAAD cis rs992157 0.71 rs12996912 ENSG00000261338.2 RP11-378A13.1 5.41 2.36e-07 0.000211 0.45 0.4 Colorectal cancer; chr2:218245832 chr2:218255319~218257366:+ PAAD cis rs992157 0.687 rs35271699 ENSG00000261338.2 RP11-378A13.1 5.41 2.36e-07 0.000211 0.45 0.4 Colorectal cancer; chr2:218252759 chr2:218255319~218257366:+ PAAD cis rs992157 0.71 rs10169718 ENSG00000261338.2 RP11-378A13.1 -5.41 2.36e-07 0.000211 -0.45 -0.4 Colorectal cancer; chr2:218238857 chr2:218255319~218257366:+ PAAD cis rs1075265 0.836 rs1421622 ENSG00000233266.1 HMGB1P31 -5.41 2.36e-07 0.000211 -0.52 -0.4 Chronotype;Morning vs. evening chronotype; chr2:54062644 chr2:54051334~54051760:+ PAAD cis rs6504950 1 rs8082471 ENSG00000275710.1 RP11-257O5.4 5.41 2.37e-07 0.000212 0.53 0.4 Breast cancer; chr17:54990632 chr17:54964474~54964679:+ PAAD cis rs4664293 0.605 rs890095 ENSG00000226266.5 AC009961.3 5.41 2.37e-07 0.000212 0.52 0.4 Monocyte percentage of white cells; chr2:159604708 chr2:159670708~159712435:- PAAD cis rs4664293 0.585 rs35081473 ENSG00000226266.5 AC009961.3 5.41 2.37e-07 0.000212 0.52 0.4 Monocyte percentage of white cells; chr2:159679970 chr2:159670708~159712435:- PAAD cis rs4664293 0.605 rs7556888 ENSG00000226266.5 AC009961.3 5.41 2.37e-07 0.000212 0.52 0.4 Monocyte percentage of white cells; chr2:159683750 chr2:159670708~159712435:- PAAD cis rs2739330 0.76 rs5751760 ENSG00000206090.4 AP000350.7 5.41 2.37e-07 0.000212 0.49 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23939998~23942798:+ PAAD cis rs7772486 0.754 rs4895682 ENSG00000235652.6 RP11-545I5.3 -5.41 2.38e-07 0.000212 -0.34 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145741725 chr6:145799409~145886585:+ PAAD cis rs7916697 0.52 rs12246624 ENSG00000233590.1 RP11-153K11.3 -5.41 2.38e-07 0.000213 -0.53 -0.4 Optic disc area; chr10:68276805 chr10:68233251~68242379:- PAAD cis rs7916697 0.52 rs12265247 ENSG00000233590.1 RP11-153K11.3 -5.41 2.38e-07 0.000213 -0.53 -0.4 Optic disc area; chr10:68278641 chr10:68233251~68242379:- PAAD cis rs7772486 0.79 rs2265917 ENSG00000235652.6 RP11-545I5.3 5.41 2.38e-07 0.000213 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145891149 chr6:145799409~145886585:+ PAAD cis rs950169 0.544 rs62021193 ENSG00000225151.9 GOLGA2P7 -5.41 2.38e-07 0.000213 -0.48 -0.4 Schizophrenia; chr15:84627352 chr15:84199311~84230136:- PAAD cis rs950169 0.58 rs17598114 ENSG00000225151.9 GOLGA2P7 -5.41 2.38e-07 0.000213 -0.48 -0.4 Schizophrenia; chr15:84628086 chr15:84199311~84230136:- PAAD cis rs950169 0.58 rs17532346 ENSG00000225151.9 GOLGA2P7 -5.41 2.38e-07 0.000213 -0.48 -0.4 Schizophrenia; chr15:84628264 chr15:84199311~84230136:- PAAD cis rs950169 0.58 rs11634322 ENSG00000225151.9 GOLGA2P7 -5.41 2.38e-07 0.000213 -0.48 -0.4 Schizophrenia; chr15:84628978 chr15:84199311~84230136:- PAAD cis rs950169 0.58 rs4603535 ENSG00000225151.9 GOLGA2P7 -5.41 2.38e-07 0.000213 -0.48 -0.4 Schizophrenia; chr15:84630641 chr15:84199311~84230136:- PAAD cis rs950169 0.541 rs10795 ENSG00000225151.9 GOLGA2P7 -5.41 2.38e-07 0.000213 -0.48 -0.4 Schizophrenia; chr15:84634066 chr15:84199311~84230136:- PAAD cis rs950169 0.58 rs36126054 ENSG00000225151.9 GOLGA2P7 -5.41 2.38e-07 0.000213 -0.48 -0.4 Schizophrenia; chr15:84634492 chr15:84199311~84230136:- PAAD cis rs950169 0.58 rs11633762 ENSG00000225151.9 GOLGA2P7 -5.41 2.38e-07 0.000213 -0.48 -0.4 Schizophrenia; chr15:84643921 chr15:84199311~84230136:- PAAD cis rs2739330 0.828 rs5760107 ENSG00000231271.1 AP000350.8 5.41 2.38e-07 0.000213 0.54 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23949918~23954042:+ PAAD cis rs2739330 0.789 rs5760109 ENSG00000231271.1 AP000350.8 5.41 2.38e-07 0.000213 0.54 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23949918~23954042:+ PAAD cis rs11098499 0.863 rs2306457 ENSG00000245958.5 RP11-33B1.1 -5.41 2.39e-07 0.000213 -0.35 -0.4 Corneal astigmatism; chr4:119551684 chr4:119454791~119552025:+ PAAD cis rs7916697 0.947 rs4745950 ENSG00000233590.1 RP11-153K11.3 5.41 2.39e-07 0.000213 0.56 0.4 Optic disc area; chr10:68236698 chr10:68233251~68242379:- PAAD cis rs2404602 0.735 rs1607015 ENSG00000259422.1 RP11-593F23.1 -5.41 2.39e-07 0.000214 -0.5 -0.4 Blood metabolite levels; chr15:76410088 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs12906143 ENSG00000259422.1 RP11-593F23.1 -5.41 2.39e-07 0.000214 -0.5 -0.4 Blood metabolite levels; chr15:76417182 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs11632222 ENSG00000259422.1 RP11-593F23.1 -5.41 2.39e-07 0.000214 -0.5 -0.4 Blood metabolite levels; chr15:76420586 chr15:76174891~76181486:- PAAD cis rs56205728 0.582 rs1869901 ENSG00000273855.1 RP11-133K1.12 5.41 2.39e-07 0.000214 0.46 0.4 Schizophrenia; chr15:40303426 chr15:40285468~40285909:- PAAD cis rs8059260 0.542 rs7196077 ENSG00000274038.1 RP11-66H6.4 -5.41 2.39e-07 0.000214 -0.63 -0.4 Alcohol consumption over the past year; chr16:11033198 chr16:11056556~11057034:+ PAAD cis rs9322193 0.886 rs4870055 ENSG00000223701.3 RAET1E-AS1 5.41 2.4e-07 0.000214 0.46 0.4 Lung cancer; chr6:149848433 chr6:149884431~149919508:+ PAAD cis rs6570726 0.791 rs11155433 ENSG00000235652.6 RP11-545I5.3 -5.41 2.41e-07 0.000215 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145586695 chr6:145799409~145886585:+ PAAD cis rs11123170 0.542 rs28522253 ENSG00000189223.12 PAX8-AS1 -5.41 2.41e-07 0.000215 -0.57 -0.4 Renal function-related traits (BUN); chr2:113209810 chr2:113211522~113276581:+ PAAD cis rs9900062 1 rs2521879 ENSG00000270714.1 MINOS1P2 -5.41 2.42e-07 0.000216 -0.58 -0.4 QT interval; chr17:64746560 chr17:64747264~64747492:- PAAD cis rs7772486 0.719 rs702317 ENSG00000235652.6 RP11-545I5.3 -5.41 2.42e-07 0.000216 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145683874 chr6:145799409~145886585:+ PAAD cis rs172166 0.585 rs149963 ENSG00000204709.4 LINC01556 5.41 2.42e-07 0.000216 0.55 0.4 Cardiac Troponin-T levels; chr6:28049354 chr6:28943877~28944537:+ PAAD cis rs9926296 0.529 rs7195906 ENSG00000260259.1 RP11-368I7.4 -5.41 2.42e-07 0.000216 -0.49 -0.4 Vitiligo; chr16:89739939 chr16:89682620~89686569:- PAAD cis rs7772486 0.875 rs1412081 ENSG00000235652.6 RP11-545I5.3 5.41 2.42e-07 0.000216 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146088597 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs10457792 ENSG00000235652.6 RP11-545I5.3 5.41 2.42e-07 0.000216 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146091279 chr6:145799409~145886585:+ PAAD cis rs7772486 0.846 rs1854901 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146004549 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs1960885 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146004794 chr6:145799409~145886585:+ PAAD cis rs7772486 0.817 rs2748491 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146006623 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2777483 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146008099 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2748485 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146011285 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2207785 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146011648 chr6:145799409~145886585:+ PAAD cis rs7772486 0.748 rs2748484 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146012517 chr6:145799409~145886585:+ PAAD cis rs987724 0.727 rs6776157 ENSG00000240875.4 LINC00886 -5.41 2.43e-07 0.000217 -0.49 -0.4 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156825693 chr3:156747346~156817062:- PAAD cis rs7772486 0.79 rs6570723 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145830094 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs6570724 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145830147 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs6917135 ENSG00000235652.6 RP11-545I5.3 5.41 2.43e-07 0.000217 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145831290 chr6:145799409~145886585:+ PAAD cis rs2115630 0.691 rs2292462 ENSG00000259728.4 LINC00933 -5.41 2.43e-07 0.000217 -0.49 -0.4 P wave terminal force; chr15:84657523 chr15:84570649~84580175:+ PAAD cis rs35160687 0.712 rs4832031 ENSG00000273080.1 RP11-301O19.1 5.41 2.43e-07 0.000217 0.47 0.4 Night sleep phenotypes; chr2:86251857 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs4832030 ENSG00000273080.1 RP11-301O19.1 -5.41 2.43e-07 0.000217 -0.47 -0.4 Night sleep phenotypes; chr2:86251746 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs12988844 ENSG00000273080.1 RP11-301O19.1 -5.41 2.43e-07 0.000217 -0.47 -0.4 Night sleep phenotypes; chr2:86251912 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs17438687 ENSG00000273080.1 RP11-301O19.1 -5.41 2.43e-07 0.000217 -0.47 -0.4 Night sleep phenotypes; chr2:86252164 chr2:86195590~86196049:+ PAAD cis rs7208859 0.614 rs9914534 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30875646 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs4131618 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30877783 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11658344 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30880727 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9900144 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881371 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs11656121 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887025 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11650973 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887027 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73263788 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889472 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs56085216 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30890216 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11650305 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902343 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11654914 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902406 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9914271 ENSG00000266490.1 CTD-2349P21.9 5.41 2.43e-07 0.000217 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905607 chr17:30792372~30792833:+ PAAD cis rs35160687 0.712 rs2303359 ENSG00000273080.1 RP11-301O19.1 -5.41 2.44e-07 0.000217 -0.46 -0.4 Night sleep phenotypes; chr2:86251547 chr2:86195590~86196049:+ PAAD cis rs732716 0.853 rs62129349 ENSG00000267980.1 AC007292.6 -5.41 2.44e-07 0.000217 -0.52 -0.4 Mean corpuscular volume; chr19:4385662 chr19:4363789~4364640:+ PAAD cis rs732716 0.889 rs11085074 ENSG00000267980.1 AC007292.6 -5.41 2.44e-07 0.000217 -0.52 -0.4 Mean corpuscular volume; chr19:4386355 chr19:4363789~4364640:+ PAAD cis rs7615952 0.932 rs7630077 ENSG00000171084.14 FAM86JP 5.41 2.44e-07 0.000218 0.53 0.4 Blood pressure (smoking interaction); chr3:125930833 chr3:125916620~125930024:+ PAAD cis rs7772486 0.782 rs7747576 ENSG00000235652.6 RP11-545I5.3 -5.41 2.44e-07 0.000218 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145956691 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs7753696 ENSG00000235652.6 RP11-545I5.3 -5.41 2.44e-07 0.000218 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145957962 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs9399571 ENSG00000235652.6 RP11-545I5.3 -5.41 2.44e-07 0.000218 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145960925 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs4896852 ENSG00000235652.6 RP11-545I5.3 -5.41 2.44e-07 0.000218 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145963485 chr6:145799409~145886585:+ PAAD cis rs465969 1 rs463543 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111346349 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs459048 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111368429 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs479343 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111369701 chr6:111599875~111602295:+ PAAD cis rs465969 0.744 rs458017 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111374888 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs13213522 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111384138 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs17510761 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111387380 chr6:111599875~111602295:+ PAAD cis rs465969 0.655 rs13203984 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111388538 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs17510733 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111389715 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs78945802 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111407143 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs17072683 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111410007 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs34382476 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111423551 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs17090837 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111430650 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs35208445 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111434944 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs35248830 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111435547 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs35151650 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111436524 chr6:111599875~111602295:+ PAAD cis rs465969 0.744 rs34089926 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111439043 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs4580915 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111439561 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs35856111 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111452265 chr6:111599875~111602295:+ PAAD cis rs465969 0.744 rs13220692 ENSG00000255389.1 C6orf3 -5.41 2.45e-07 0.000218 -0.68 -0.4 Psoriasis; chr6:111455836 chr6:111599875~111602295:+ PAAD cis rs465969 1 rs459888 ENSG00000255389.1 C6orf3 5.41 2.45e-07 0.000218 0.68 0.4 Psoriasis; chr6:111329953 chr6:111599875~111602295:+ PAAD cis rs465969 0.793 rs7752225 ENSG00000255389.1 C6orf3 5.41 2.45e-07 0.000218 0.68 0.4 Psoriasis; chr6:111459412 chr6:111599875~111602295:+ PAAD cis rs465969 0.744 rs9400477 ENSG00000255389.1 C6orf3 5.41 2.45e-07 0.000218 0.68 0.4 Psoriasis; chr6:111469440 chr6:111599875~111602295:+ PAAD cis rs465969 0.546 rs7772141 ENSG00000255389.1 C6orf3 5.41 2.45e-07 0.000218 0.68 0.4 Psoriasis; chr6:111472358 chr6:111599875~111602295:+ PAAD cis rs465969 0.793 rs7776047 ENSG00000255389.1 C6orf3 5.41 2.45e-07 0.000218 0.68 0.4 Psoriasis; chr6:111472391 chr6:111599875~111602295:+ PAAD cis rs6991838 0.584 rs14213 ENSG00000200714.1 Y_RNA 5.41 2.45e-07 0.000218 0.47 0.4 Intelligence (multi-trait analysis); chr8:65602719 chr8:65592731~65592820:+ PAAD cis rs526231 0.578 rs1898672 ENSG00000175749.11 EIF3KP1 -5.41 2.45e-07 0.000218 -0.51 -0.4 Primary biliary cholangitis; chr5:102958149 chr5:103032376~103033031:+ PAAD cis rs11098499 0.691 rs12510133 ENSG00000245958.5 RP11-33B1.1 -5.41 2.45e-07 0.000218 -0.29 -0.4 Corneal astigmatism; chr4:119350189 chr4:119454791~119552025:+ PAAD cis rs11098499 0.754 rs12506487 ENSG00000245958.5 RP11-33B1.1 -5.41 2.45e-07 0.000218 -0.29 -0.4 Corneal astigmatism; chr4:119350206 chr4:119454791~119552025:+ PAAD cis rs56205728 0.601 rs3784399 ENSG00000273855.1 RP11-133K1.12 -5.41 2.45e-07 0.000218 -0.49 -0.4 Schizophrenia; chr15:40306093 chr15:40285468~40285909:- PAAD cis rs875971 0.862 rs1875057 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66266868 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6960446 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66268272 chr7:66493706~66495474:+ PAAD cis rs875971 0.789 rs10260426 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66271055 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs7796162 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66280771 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs2901152 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66300017 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10263690 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66301466 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10250544 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66301574 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs12531677 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66304099 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs7798630 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66306492 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs11984115 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66308872 chr7:66493706~66495474:+ PAAD cis rs875971 0.755 rs10228885 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66315542 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs3893216 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66325720 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6958294 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66329809 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs2088655 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66330724 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs10447522 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66331087 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs2088653 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66343621 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6460293 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66345205 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778736 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66348861 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs778711 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66386670 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs1083554 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66387354 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778707 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66392040 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778705 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66396128 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs778697 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66405439 chr7:66493706~66495474:+ PAAD cis rs875971 0.798 rs7789615 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66413674 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6978028 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66421313 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6947339 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66423483 chr7:66493706~66495474:+ PAAD cis rs875971 0.798 rs12698522 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66502354 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs28714531 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66503250 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs12698526 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66504118 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs13232191 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66521661 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs35378740 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66522725 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10950043 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66523623 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs17747530 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66529742 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs13226170 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66534311 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs2420611 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66534333 chr7:66493706~66495474:+ PAAD cis rs875971 0.767 rs61348003 ENSG00000237310.1 GS1-124K5.4 5.41 2.45e-07 0.000218 0.4 0.4 Aortic root size; chr7:66540947 chr7:66493706~66495474:+ PAAD cis rs875971 0.756 rs2901210 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66552518 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs13536 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66554203 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs801209 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66554403 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs801206 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66556979 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs801204 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66557934 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs801203 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66558025 chr7:66493706~66495474:+ PAAD cis rs875971 0.825 rs801202 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66558942 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs801195 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66561128 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs801194 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66563508 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs2024192 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66576460 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6955837 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66578155 chr7:66493706~66495474:+ PAAD cis rs875971 0.825 rs10281499 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66583979 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs4718377 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66584691 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs10278014 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66586277 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs1968126 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66592017 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6460306 ENSG00000237310.1 GS1-124K5.4 -5.41 2.45e-07 0.000218 -0.4 -0.4 Aortic root size; chr7:66595806 chr7:66493706~66495474:+ PAAD cis rs7772486 0.846 rs7755440 ENSG00000235652.6 RP11-545I5.3 5.41 2.45e-07 0.000218 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146054770 chr6:145799409~145886585:+ PAAD cis rs7772486 0.817 rs12198065 ENSG00000235652.6 RP11-545I5.3 5.41 2.45e-07 0.000218 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146064150 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9390377 ENSG00000235652.6 RP11-545I5.3 5.41 2.45e-07 0.000218 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146065796 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs6570736 ENSG00000235652.6 RP11-545I5.3 5.41 2.45e-07 0.000218 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146067184 chr6:145799409~145886585:+ PAAD cis rs7916697 0.578 rs4745951 ENSG00000233590.1 RP11-153K11.3 5.41 2.45e-07 0.000218 0.59 0.4 Optic disc area; chr10:68236867 chr10:68233251~68242379:- PAAD cis rs1823913 0.963 rs4146105 ENSG00000280083.1 RP11-317J9.1 -5.41 2.45e-07 0.000218 -0.52 -0.4 Obesity-related traits; chr2:191245240 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs13019004 ENSG00000280083.1 RP11-317J9.1 -5.41 2.45e-07 0.000218 -0.52 -0.4 Obesity-related traits; chr2:191245493 chr2:191154118~191156070:- PAAD cis rs172166 0.538 rs1150686 ENSG00000204709.4 LINC01556 5.41 2.46e-07 0.000218 0.54 0.4 Cardiac Troponin-T levels; chr6:28193493 chr6:28943877~28944537:+ PAAD cis rs1150688 1 rs1150688 ENSG00000204709.4 LINC01556 5.41 2.46e-07 0.000218 0.54 0.4 Autism spectrum disorder or schizophrenia; chr6:28195002 chr6:28943877~28944537:+ PAAD cis rs3858145 0.588 rs731063 ENSG00000233590.1 RP11-153K11.3 5.41 2.46e-07 0.000218 0.57 0.4 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68283433 chr10:68233251~68242379:- PAAD cis rs17301013 0.507 rs41472847 ENSG00000227373.4 RP11-160H22.5 -5.4 2.46e-07 0.000219 -0.62 -0.4 Systemic lupus erythematosus; chr1:174475342 chr1:174115300~174160004:- PAAD cis rs12908161 1 rs11638290 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84684405 chr15:84199311~84230136:- PAAD cis rs12908161 0.959 rs34028043 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84688354 chr15:84199311~84230136:- PAAD cis rs12908161 0.959 rs34784022 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84688675 chr15:84199311~84230136:- PAAD cis rs12908161 0.959 rs12908699 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84697172 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs35316992 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84704902 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs4643294 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84707022 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs62021219 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84712928 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs34900908 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84714368 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs35524990 ENSG00000225151.9 GOLGA2P7 -5.4 2.46e-07 0.000219 -0.49 -0.4 Schizophrenia; chr15:84714972 chr15:84199311~84230136:- PAAD cis rs4218 0.597 rs4775114 ENSG00000277144.1 RP11-59H7.4 -5.4 2.46e-07 0.000219 -0.56 -0.4 Social communication problems; chr15:59059635 chr15:59115547~59116089:- PAAD cis rs58873874 0.737 rs80320835 ENSG00000251405.2 CTB-109A12.1 5.4 2.48e-07 0.00022 0.84 0.4 Bipolar disorder (body mass index interaction); chr5:157389887 chr5:157362615~157460078:- PAAD cis rs7208859 0.623 rs122898 ENSG00000266490.1 CTD-2349P21.9 -5.4 2.48e-07 0.00022 -0.5 -0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30578236 chr17:30792372~30792833:+ PAAD cis rs4218 0.608 rs59282449 ENSG00000277144.1 RP11-59H7.4 -5.4 2.48e-07 0.00022 -0.57 -0.4 Social communication problems; chr15:59078881 chr15:59115547~59116089:- PAAD cis rs950169 0.579 rs12912716 ENSG00000225151.9 GOLGA2P7 -5.4 2.48e-07 0.00022 -0.49 -0.4 Schizophrenia; chr15:83995511 chr15:84199311~84230136:- PAAD cis rs526231 0.511 rs10515341 ENSG00000175749.11 EIF3KP1 5.4 2.49e-07 0.000221 0.52 0.4 Primary biliary cholangitis; chr5:102981413 chr5:103032376~103033031:+ PAAD cis rs526231 0.575 rs10463990 ENSG00000175749.11 EIF3KP1 5.4 2.49e-07 0.000221 0.52 0.4 Primary biliary cholangitis; chr5:102981714 chr5:103032376~103033031:+ PAAD cis rs964184 0.507 rs6589565 ENSG00000254851.1 RP11-109L13.1 -5.4 2.49e-07 0.000221 -0.91 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116769521 chr11:117135528~117138582:+ PAAD cis rs673078 0.607 rs55929628 ENSG00000275759.1 RP11-131L12.3 -5.4 2.5e-07 0.000221 -0.67 -0.4 Glucose homeostasis traits; chr12:118371332 chr12:118428281~118428870:+ PAAD cis rs673078 0.517 rs73205578 ENSG00000275759.1 RP11-131L12.3 -5.4 2.5e-07 0.000221 -0.67 -0.4 Glucose homeostasis traits; chr12:118385113 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs73205579 ENSG00000275759.1 RP11-131L12.3 -5.4 2.5e-07 0.000221 -0.67 -0.4 Glucose homeostasis traits; chr12:118385125 chr12:118428281~118428870:+ PAAD cis rs7916697 0.898 rs1900005 ENSG00000233590.1 RP11-153K11.3 5.4 2.5e-07 0.000222 0.54 0.4 Optic disc area; chr10:68238298 chr10:68233251~68242379:- PAAD cis rs7772486 0.754 rs697053 ENSG00000235652.6 RP11-545I5.3 -5.4 2.5e-07 0.000222 -0.34 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145668671 chr6:145799409~145886585:+ PAAD cis rs4664293 0.51 rs1968343 ENSG00000226266.5 AC009961.3 5.4 2.5e-07 0.000222 0.52 0.4 Monocyte percentage of white cells; chr2:159712247 chr2:159670708~159712435:- PAAD cis rs10262624 0.935 rs6955725 ENSG00000234286.1 AC006026.13 -5.4 2.5e-07 0.000222 -0.46 -0.4 Schizophrenia; chr7:23865523 chr7:23680195~23680786:- PAAD cis rs2274273 0.588 rs2880103 ENSG00000258413.1 RP11-665C16.6 -5.4 2.51e-07 0.000222 -0.54 -0.4 Protein biomarker; chr14:55271114 chr14:55262767~55272075:- PAAD cis rs2274273 0.553 rs56166765 ENSG00000258413.1 RP11-665C16.6 -5.4 2.51e-07 0.000222 -0.54 -0.4 Protein biomarker; chr14:55271300 chr14:55262767~55272075:- PAAD cis rs2274273 0.563 rs79163357 ENSG00000258413.1 RP11-665C16.6 -5.4 2.51e-07 0.000222 -0.54 -0.4 Protein biomarker; chr14:55271731 chr14:55262767~55272075:- PAAD cis rs6921919 0.789 rs17301128 ENSG00000204709.4 LINC01556 5.4 2.51e-07 0.000222 0.67 0.4 Autism spectrum disorder or schizophrenia; chr6:28340257 chr6:28943877~28944537:+ PAAD cis rs17301013 0.507 rs2142863 ENSG00000227373.4 RP11-160H22.5 5.4 2.51e-07 0.000223 0.61 0.4 Systemic lupus erythematosus; chr1:174301582 chr1:174115300~174160004:- PAAD cis rs1275468 0.798 rs1275474 ENSG00000257497.2 RP11-585P4.5 -5.4 2.52e-07 0.000223 -0.56 -0.4 Polycystic ovary syndrome; chr12:75525870 chr12:75483454~75489820:- PAAD cis rs35160687 0.712 rs12052607 ENSG00000273080.1 RP11-301O19.1 -5.4 2.52e-07 0.000223 -0.46 -0.4 Night sleep phenotypes; chr2:86279394 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs1863059 ENSG00000273080.1 RP11-301O19.1 -5.4 2.52e-07 0.000223 -0.46 -0.4 Night sleep phenotypes; chr2:86282265 chr2:86195590~86196049:+ PAAD cis rs2274273 0.837 rs6573010 ENSG00000258413.1 RP11-665C16.6 -5.4 2.53e-07 0.000224 -0.5 -0.4 Protein biomarker; chr14:55254874 chr14:55262767~55272075:- PAAD cis rs7772486 0.79 rs9403749 ENSG00000235652.6 RP11-545I5.3 5.4 2.53e-07 0.000224 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145841103 chr6:145799409~145886585:+ PAAD cis rs1075265 0.73 rs805391 ENSG00000233266.1 HMGB1P31 -5.4 2.53e-07 0.000224 -0.54 -0.4 Chronotype;Morning vs. evening chronotype; chr2:53877181 chr2:54051334~54051760:+ PAAD cis rs9928842 0.679 rs4888361 ENSG00000280152.1 RP11-331F4.5 5.4 2.53e-07 0.000224 0.52 0.4 Alcoholic chronic pancreatitis; chr16:75233778 chr16:75245994~75250077:- PAAD cis rs2581828 0.656 rs2581782 ENSG00000242142.1 SERBP1P3 5.4 2.53e-07 0.000224 0.47 0.4 Crohn's disease; chr3:53088241 chr3:53064283~53065091:- PAAD cis rs2581828 0.656 rs2581783 ENSG00000242142.1 SERBP1P3 5.4 2.53e-07 0.000224 0.47 0.4 Crohn's disease; chr3:53088242 chr3:53064283~53065091:- PAAD cis rs2581828 0.607 rs2581784 ENSG00000242142.1 SERBP1P3 5.4 2.53e-07 0.000224 0.47 0.4 Crohn's disease; chr3:53088354 chr3:53064283~53065091:- PAAD cis rs2581828 0.656 rs891368 ENSG00000242142.1 SERBP1P3 5.4 2.53e-07 0.000224 0.47 0.4 Crohn's disease; chr3:53089257 chr3:53064283~53065091:- PAAD cis rs2581828 0.656 rs1078968 ENSG00000242142.1 SERBP1P3 5.4 2.53e-07 0.000224 0.47 0.4 Crohn's disease; chr3:53089470 chr3:53064283~53065091:- PAAD cis rs7301826 0.504 rs11061164 ENSG00000256250.1 RP11-989F5.1 -5.4 2.53e-07 0.000225 -0.45 -0.4 Plasma plasminogen activator levels; chr12:130839724 chr12:130810606~130812438:+ PAAD cis rs9928842 0.722 rs4888362 ENSG00000280152.1 RP11-331F4.5 5.4 2.54e-07 0.000225 0.52 0.4 Alcoholic chronic pancreatitis; chr16:75234347 chr16:75245994~75250077:- PAAD cis rs748404 0.631 rs1133395 ENSG00000249839.1 AC011330.5 -5.4 2.54e-07 0.000225 -0.58 -0.4 Lung cancer; chr15:43358186 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs3809482 ENSG00000249839.1 AC011330.5 -5.4 2.54e-07 0.000225 -0.58 -0.4 Lung cancer; chr15:43369604 chr15:43663654~43684339:- PAAD cis rs6570726 0.791 rs370112 ENSG00000235652.6 RP11-545I5.3 5.4 2.54e-07 0.000225 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145538717 chr6:145799409~145886585:+ PAAD cis rs17826219 0.636 rs7221463 ENSG00000266490.1 CTD-2349P21.9 5.4 2.54e-07 0.000225 0.52 0.4 Body mass index; chr17:30753533 chr17:30792372~30792833:+ PAAD cis rs7772486 0.727 rs6941429 ENSG00000235652.6 RP11-545I5.3 5.4 2.54e-07 0.000225 0.34 0.4 Lobe attachment (rater-scored or self-reported); chr6:145631147 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs857881 ENSG00000235652.6 RP11-545I5.3 -5.4 2.54e-07 0.000225 -0.34 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145649657 chr6:145799409~145886585:+ PAAD cis rs7772486 0.84 rs2814867 ENSG00000235652.6 RP11-545I5.3 5.4 2.54e-07 0.000225 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146012894 chr6:145799409~145886585:+ PAAD cis rs16828019 0.704 rs12031277 ENSG00000235358.1 RP11-399E6.1 5.4 2.54e-07 0.000225 0.8 0.4 Intelligence (multi-trait analysis); chr1:41026129 chr1:41242373~41284861:+ PAAD cis rs9640161 0.83 rs17173702 ENSG00000261305.1 RP4-584D14.7 5.4 2.54e-07 0.000225 0.56 0.4 Blood protein levels;Circulating chemerin levels; chr7:150371516 chr7:150341771~150342607:+ PAAD cis rs9640161 0.83 rs17173703 ENSG00000261305.1 RP4-584D14.7 5.4 2.54e-07 0.000225 0.56 0.4 Blood protein levels;Circulating chemerin levels; chr7:150371531 chr7:150341771~150342607:+ PAAD cis rs6570726 0.791 rs1509214 ENSG00000235652.6 RP11-545I5.3 -5.4 2.54e-07 0.000225 -0.34 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145463470 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs427128 ENSG00000235652.6 RP11-545I5.3 5.4 2.55e-07 0.000226 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145544781 chr6:145799409~145886585:+ PAAD cis rs6570726 0.818 rs437147 ENSG00000235652.6 RP11-545I5.3 5.4 2.55e-07 0.000226 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145554287 chr6:145799409~145886585:+ PAAD cis rs4218 0.597 rs12438208 ENSG00000277144.1 RP11-59H7.4 -5.4 2.55e-07 0.000226 -0.55 -0.4 Social communication problems; chr15:59057715 chr15:59115547~59116089:- PAAD cis rs7044106 0.655 rs1359329 ENSG00000226752.6 PSMD5-AS1 -5.4 2.55e-07 0.000226 -0.65 -0.4 Hip circumference adjusted for BMI; chr9:120608707 chr9:120824828~120854385:+ PAAD cis rs35160687 0.814 rs1863063 ENSG00000273080.1 RP11-301O19.1 5.4 2.55e-07 0.000226 0.46 0.4 Night sleep phenotypes; chr2:86291126 chr2:86195590~86196049:+ PAAD cis rs2111504 0.583 rs1015839 ENSG00000267213.4 AC007773.2 5.4 2.55e-07 0.000226 0.51 0.4 Bipolar disorder; chr19:32390365 chr19:32390050~32405560:- PAAD cis rs10875746 0.669 rs11168516 ENSG00000240399.1 RP1-228P16.1 -5.4 2.56e-07 0.000226 -0.43 -0.4 Longevity (90 years and older); chr12:48308282 chr12:48054813~48055591:- PAAD cis rs2115630 0.846 rs8024538 ENSG00000225151.9 GOLGA2P7 5.4 2.56e-07 0.000226 0.47 0.4 P wave terminal force; chr15:84825188 chr15:84199311~84230136:- PAAD cis rs2581828 0.656 rs2253209 ENSG00000242142.1 SERBP1P3 5.4 2.56e-07 0.000226 0.46 0.4 Crohn's disease; chr3:53081144 chr3:53064283~53065091:- PAAD cis rs2581828 0.694 rs2336725 ENSG00000242142.1 SERBP1P3 5.4 2.56e-07 0.000226 0.46 0.4 Crohn's disease; chr3:53084723 chr3:53064283~53065091:- PAAD cis rs2581828 0.656 rs2253656 ENSG00000242142.1 SERBP1P3 5.4 2.56e-07 0.000226 0.46 0.4 Crohn's disease; chr3:53085083 chr3:53064283~53065091:- PAAD cis rs2581828 0.656 rs2253685 ENSG00000242142.1 SERBP1P3 5.4 2.56e-07 0.000226 0.46 0.4 Crohn's disease; chr3:53085687 chr3:53064283~53065091:- PAAD cis rs2581828 0.656 rs2253796 ENSG00000242142.1 SERBP1P3 5.4 2.56e-07 0.000226 0.46 0.4 Crohn's disease; chr3:53086082 chr3:53064283~53065091:- PAAD cis rs2581828 0.656 rs11130338 ENSG00000242142.1 SERBP1P3 5.4 2.56e-07 0.000226 0.46 0.4 Crohn's disease; chr3:53086908 chr3:53064283~53065091:- PAAD cis rs7712401 0.715 rs13163098 ENSG00000263432.2 RN7SL689P -5.4 2.56e-07 0.000226 -0.52 -0.4 Mean platelet volume; chr5:123010841 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs13164161 ENSG00000263432.2 RN7SL689P -5.4 2.56e-07 0.000226 -0.52 -0.4 Mean platelet volume; chr5:123011202 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs401226 ENSG00000263432.2 RN7SL689P -5.4 2.56e-07 0.000226 -0.52 -0.4 Mean platelet volume; chr5:123012031 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs395981 ENSG00000263432.2 RN7SL689P -5.4 2.56e-07 0.000226 -0.52 -0.4 Mean platelet volume; chr5:123012216 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs424247 ENSG00000263432.2 RN7SL689P -5.4 2.56e-07 0.000226 -0.52 -0.4 Mean platelet volume; chr5:123012298 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs424262 ENSG00000263432.2 RN7SL689P -5.4 2.56e-07 0.000226 -0.52 -0.4 Mean platelet volume; chr5:123012317 chr5:123022487~123022783:- PAAD cis rs9926296 0.744 rs460984 ENSG00000260259.1 RP11-368I7.4 5.4 2.56e-07 0.000227 0.52 0.4 Vitiligo; chr16:89646766 chr16:89682620~89686569:- PAAD cis rs10463554 0.892 rs62362519 ENSG00000175749.11 EIF3KP1 5.4 2.56e-07 0.000227 0.51 0.4 Parkinson's disease; chr5:102965759 chr5:103032376~103033031:+ PAAD cis rs10463554 0.853 rs2241565 ENSG00000175749.11 EIF3KP1 5.4 2.56e-07 0.000227 0.51 0.4 Parkinson's disease; chr5:102966233 chr5:103032376~103033031:+ PAAD cis rs10463554 0.818 rs2241564 ENSG00000175749.11 EIF3KP1 5.4 2.56e-07 0.000227 0.51 0.4 Parkinson's disease; chr5:102966547 chr5:103032376~103033031:+ PAAD cis rs9309711 0.643 rs4535074 ENSG00000225234.1 TRAPPC12-AS1 -5.4 2.56e-07 0.000227 -0.41 -0.4 Neurofibrillary tangles; chr2:3477866 chr2:3481242~3482409:- PAAD cis rs964184 0.63 rs2160669 ENSG00000254851.1 RP11-109L13.1 -5.4 2.57e-07 0.000227 -0.9 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116776891 chr11:117135528~117138582:+ PAAD cis rs964184 0.63 rs2075290 ENSG00000254851.1 RP11-109L13.1 -5.4 2.57e-07 0.000227 -0.9 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116782580 chr11:117135528~117138582:+ PAAD cis rs964184 0.63 rs10750096 ENSG00000254851.1 RP11-109L13.1 -5.4 2.57e-07 0.000227 -0.9 -0.4 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116786072 chr11:117135528~117138582:+ PAAD cis rs8062405 0.895 rs62036658 ENSG00000251417.2 RP11-1348G14.4 -5.4 2.57e-07 0.000227 -0.36 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28839050 chr16:28802743~28817828:+ PAAD cis rs638893 0.636 rs61901410 ENSG00000278376.1 RP11-158I9.8 5.4 2.57e-07 0.000227 0.62 0.4 Vitiligo; chr11:118790488 chr11:118791254~118793137:+ PAAD cis rs7772486 0.875 rs2492855 ENSG00000235652.6 RP11-545I5.3 5.4 2.57e-07 0.000227 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145975790 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs7739418 ENSG00000235652.6 RP11-545I5.3 5.4 2.57e-07 0.000227 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146038052 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9390371 ENSG00000235652.6 RP11-545I5.3 5.4 2.57e-07 0.000227 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146042044 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs6909827 ENSG00000235652.6 RP11-545I5.3 5.4 2.57e-07 0.000227 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146044602 chr6:145799409~145886585:+ PAAD cis rs1075232 0.737 rs4779876 ENSG00000270055.1 CTD-3092A11.2 -5.4 2.57e-07 0.000227 -0.82 -0.4 Survival in colorectal cancer (non-distant metastatic); chr15:31442233 chr15:30487963~30490313:+ PAAD cis rs2946504 0.628 rs2946510 ENSG00000251468.2 RP11-369K16.1 -5.4 2.57e-07 0.000227 -0.44 -0.4 Type 2 diabetes; chr8:12950371 chr8:12958387~12962200:+ PAAD cis rs11673344 0.966 rs56330606 ENSG00000226686.6 LINC01535 5.4 2.58e-07 0.000228 0.53 0.4 Obesity-related traits; chr19:37183051 chr19:37251912~37265535:+ PAAD cis rs7772486 0.754 rs9399567 ENSG00000235652.6 RP11-545I5.3 5.39 2.58e-07 0.000228 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145826159 chr6:145799409~145886585:+ PAAD cis rs6504950 0.615 rs66898273 ENSG00000275710.1 RP11-257O5.4 5.39 2.58e-07 0.000228 0.52 0.4 Breast cancer; chr17:54916595 chr17:54964474~54964679:+ PAAD cis rs6504950 0.745 rs1962045 ENSG00000275710.1 RP11-257O5.4 5.39 2.58e-07 0.000228 0.52 0.4 Breast cancer; chr17:54918789 chr17:54964474~54964679:+ PAAD cis rs6504950 0.72 rs9914596 ENSG00000275710.1 RP11-257O5.4 5.39 2.58e-07 0.000228 0.52 0.4 Breast cancer; chr17:54919190 chr17:54964474~54964679:+ PAAD cis rs72772090 0.908 rs76539796 ENSG00000248734.2 CTD-2260A17.1 -5.39 2.58e-07 0.000228 -0.49 -0.4 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96702971 chr5:96784777~96785999:+ PAAD cis rs2115630 1 rs4633690 ENSG00000259728.4 LINC00933 -5.39 2.58e-07 0.000228 -0.49 -0.4 P wave terminal force; chr15:84818729 chr15:84570649~84580175:+ PAAD cis rs7772486 0.641 rs2777485 ENSG00000235652.6 RP11-545I5.3 5.39 2.59e-07 0.000229 0.34 0.4 Lobe attachment (rater-scored or self-reported); chr6:146013241 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs6570718 ENSG00000235652.6 RP11-545I5.3 -5.39 2.6e-07 0.000229 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145767307 chr6:145799409~145886585:+ PAAD cis rs9322193 0.847 rs880246 ENSG00000223701.3 RAET1E-AS1 5.39 2.6e-07 0.00023 0.48 0.4 Lung cancer; chr6:149845972 chr6:149884431~149919508:+ PAAD cis rs755249 0.565 rs12138051 ENSG00000237624.1 OXCT2P1 -5.39 2.6e-07 0.00023 -0.5 -0.4 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39482552 chr1:39514956~39516490:+ PAAD cis rs755249 0.564 rs6691194 ENSG00000237624.1 OXCT2P1 -5.39 2.6e-07 0.00023 -0.5 -0.4 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39483069 chr1:39514956~39516490:+ PAAD cis rs6782228 0.585 rs6774515 ENSG00000242551.2 POU5F1P6 -5.39 2.6e-07 0.00023 -0.47 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128697035 chr3:128674735~128677005:- PAAD cis rs11098499 0.874 rs28452522 ENSG00000245958.5 RP11-33B1.1 -5.39 2.6e-07 0.00023 -0.32 -0.4 Corneal astigmatism; chr4:119189629 chr4:119454791~119552025:+ PAAD cis rs1930961 1 rs9624834 ENSG00000100058.11 CRYBB2P1 5.39 2.6e-07 0.00023 0.72 0.4 Bipolar disorder with mood-incongruent psychosis; chr22:25450048 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs9624835 ENSG00000100058.11 CRYBB2P1 5.39 2.6e-07 0.00023 0.72 0.4 Bipolar disorder with mood-incongruent psychosis; chr22:25450054 chr22:25448105~25520854:+ PAAD cis rs1930961 1 rs9624836 ENSG00000100058.11 CRYBB2P1 5.39 2.6e-07 0.00023 0.72 0.4 Bipolar disorder with mood-incongruent psychosis; chr22:25450120 chr22:25448105~25520854:+ PAAD cis rs2929278 0.546 rs686666 ENSG00000205771.5 CATSPER2P1 -5.39 2.6e-07 0.00023 -0.52 -0.4 Schizophrenia; chr15:43869352 chr15:43726918~43747094:- PAAD cis rs6782228 0.675 rs9813845 ENSG00000242551.2 POU5F1P6 -5.39 2.61e-07 0.00023 -0.48 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128680780 chr3:128674735~128677005:- PAAD cis rs4698412 0.531 rs6852450 ENSG00000214846.4 RP11-115L11.1 -5.39 2.61e-07 0.00023 -0.47 -0.4 Parkinson's disease; chr4:15741363 chr4:15730962~15731627:- PAAD cis rs755249 0.588 rs2275767 ENSG00000237624.1 OXCT2P1 -5.39 2.61e-07 0.00023 -0.5 -0.4 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39479625 chr1:39514956~39516490:+ PAAD cis rs12922040 1 rs12922040 ENSG00000263335.1 AF001548.5 -5.39 2.62e-07 0.000231 -0.46 -0.4 Serum uric acid levels in response to allopurinol in gout; chr16:15775609 chr16:15726674~15732993:+ PAAD cis rs6504950 1 rs17818028 ENSG00000275710.1 RP11-257O5.4 -5.39 2.62e-07 0.000231 -0.53 -0.4 Breast cancer; chr17:54985394 chr17:54964474~54964679:+ PAAD cis rs56205728 0.573 rs2305645 ENSG00000273855.1 RP11-133K1.12 -5.39 2.63e-07 0.000232 -0.48 -0.4 Schizophrenia; chr15:40303364 chr15:40285468~40285909:- PAAD cis rs12908161 0.959 rs17598603 ENSG00000225151.9 GOLGA2P7 5.39 2.64e-07 0.000233 0.48 0.4 Schizophrenia; chr15:84656980 chr15:84199311~84230136:- PAAD cis rs2274273 0.624 rs7147247 ENSG00000258413.1 RP11-665C16.6 -5.39 2.66e-07 0.000234 -0.53 -0.4 Protein biomarker; chr14:55310995 chr14:55262767~55272075:- PAAD cis rs494459 0.726 rs1784300 ENSG00000255422.1 AP002954.4 -5.39 2.66e-07 0.000234 -0.44 -0.4 Height; chr11:118808920 chr11:118704607~118750263:+ PAAD cis rs2404602 0.735 rs1607017 ENSG00000259422.1 RP11-593F23.1 -5.39 2.67e-07 0.000235 -0.5 -0.4 Blood metabolite levels; chr15:76434124 chr15:76174891~76181486:- PAAD cis rs875971 0.861 rs801215 ENSG00000237310.1 GS1-124K5.4 -5.39 2.67e-07 0.000235 -0.4 -0.4 Aortic root size; chr7:66546951 chr7:66493706~66495474:+ PAAD cis rs7174755 0.923 rs4777036 ENSG00000260657.2 RP11-315D16.4 -5.39 2.67e-07 0.000235 -0.49 -0.4 Major depressive disorder; chr15:68313230 chr15:68267792~68277994:- PAAD cis rs11089937 0.597 rs4821772 ENSG00000211639.2 IGLV4-60 -5.39 2.67e-07 0.000235 -0.42 -0.4 Periodontitis (PAL4Q3); chr22:22131383 chr22:22162199~22162681:+ PAAD cis rs11089937 0.929 rs5750624 ENSG00000211639.2 IGLV4-60 5.39 2.68e-07 0.000235 0.36 0.4 Periodontitis (PAL4Q3); chr22:22165354 chr22:22162199~22162681:+ PAAD cis rs875971 0.79 rs10257911 ENSG00000237310.1 GS1-124K5.4 -5.39 2.68e-07 0.000236 -0.4 -0.4 Aortic root size; chr7:66278783 chr7:66493706~66495474:+ PAAD cis rs992157 0.764 rs13020391 ENSG00000261338.2 RP11-378A13.1 -5.39 2.68e-07 0.000236 -0.48 -0.4 Colorectal cancer; chr2:218319713 chr2:218255319~218257366:+ PAAD cis rs7826238 0.539 rs2945891 ENSG00000173295.6 FAM86B3P 5.39 2.69e-07 0.000236 0.43 0.4 Systolic blood pressure; chr8:8297953 chr8:8228595~8244865:+ PAAD cis rs227275 0.527 rs223338 ENSG00000246560.2 RP11-10L12.4 5.39 2.69e-07 0.000236 0.44 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102864959 chr4:102828055~102844075:+ PAAD cis rs227275 0.525 rs223332 ENSG00000246560.2 RP11-10L12.4 5.39 2.69e-07 0.000236 0.44 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102869029 chr4:102828055~102844075:+ PAAD cis rs228614 0.543 rs223330 ENSG00000246560.2 RP11-10L12.4 5.39 2.69e-07 0.000236 0.44 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102872502 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223329 ENSG00000246560.2 RP11-10L12.4 5.39 2.69e-07 0.000236 0.44 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873031 chr4:102828055~102844075:+ PAAD cis rs228614 0.536 rs223327 ENSG00000246560.2 RP11-10L12.4 5.39 2.69e-07 0.000236 0.44 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873560 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223326 ENSG00000246560.2 RP11-10L12.4 5.39 2.69e-07 0.000236 0.44 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102873770 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223324 ENSG00000246560.2 RP11-10L12.4 5.39 2.69e-07 0.000236 0.44 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102876177 chr4:102828055~102844075:+ PAAD cis rs6921919 0.789 rs6912584 ENSG00000204709.4 LINC01556 5.39 2.7e-07 0.000237 0.66 0.4 Autism spectrum disorder or schizophrenia; chr6:28341813 chr6:28943877~28944537:+ PAAD cis rs2739330 0.731 rs4822450 ENSG00000099984.9 GSTT2 -5.39 2.7e-07 0.000237 -0.5 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23980123~23983911:+ PAAD cis rs2115630 0.645 rs1107179 ENSG00000225151.9 GOLGA2P7 -5.38 2.7e-07 0.000237 -0.47 -0.4 P wave terminal force; chr15:84655131 chr15:84199311~84230136:- PAAD cis rs4308124 0.708 rs28766030 ENSG00000227992.1 AC108463.2 -5.38 2.71e-07 0.000238 -0.45 -0.4 Vitiligo; chr2:111204852 chr2:111203964~111206215:- PAAD cis rs4308124 0.708 rs28871990 ENSG00000227992.1 AC108463.2 -5.38 2.71e-07 0.000238 -0.45 -0.4 Vitiligo; chr2:111204864 chr2:111203964~111206215:- PAAD cis rs4308124 0.708 rs67816163 ENSG00000227992.1 AC108463.2 -5.38 2.71e-07 0.000238 -0.45 -0.4 Vitiligo; chr2:111205733 chr2:111203964~111206215:- PAAD cis rs4308124 0.679 rs7600458 ENSG00000227992.1 AC108463.2 -5.38 2.71e-07 0.000238 -0.45 -0.4 Vitiligo; chr2:111206013 chr2:111203964~111206215:- PAAD cis rs73219805 0.554 rs13266943 ENSG00000228451.3 SDAD1P1 -5.38 2.71e-07 0.000238 -0.7 -0.4 Schizophrenia; chr8:26336629 chr8:26379259~26382953:- PAAD cis rs7829975 0.846 rs1879957 ENSG00000253893.2 FAM85B 5.38 2.71e-07 0.000238 0.58 0.4 Mood instability; chr8:8687298 chr8:8167819~8226614:- PAAD cis rs17301013 0.507 rs2064150 ENSG00000227373.4 RP11-160H22.5 -5.38 2.72e-07 0.000238 -0.6 -0.4 Systemic lupus erythematosus; chr1:174339289 chr1:174115300~174160004:- PAAD cis rs2337406 0.866 rs79901786 ENSG00000274576.2 IGHV2-70 -5.38 2.72e-07 0.000238 -0.49 -0.4 Alzheimer's disease (late onset); chr14:106777623 chr14:106770577~106771020:- PAAD cis rs1075265 0.783 rs805450 ENSG00000233266.1 HMGB1P31 5.38 2.72e-07 0.000239 0.51 0.4 Chronotype;Morning vs. evening chronotype; chr2:53951772 chr2:54051334~54051760:+ PAAD cis rs8062405 1 rs3088215 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28842675 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs28403629 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28843448 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs61737565 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844201 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs4788099 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28844406 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs9972693 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28848481 chr16:28802743~28817828:+ PAAD cis rs8062405 0.964 rs9972768 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850413 chr16:28802743~28817828:+ PAAD cis rs8062405 0.965 rs56040780 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28850560 chr16:28802743~28817828:+ PAAD cis rs8062405 0.965 rs62037363 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28853721 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs7205323 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28854571 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs4788101 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28856483 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62037364 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857374 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62037365 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28857641 chr16:28802743~28817828:+ PAAD cis rs8062405 0.929 rs11150609 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28859275 chr16:28802743~28817828:+ PAAD cis rs8062405 0.737 rs11861132 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860539 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs11861174 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28860668 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs4788102 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28862077 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62037367 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863226 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs7198606 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863801 chr16:28802743~28817828:+ PAAD cis rs8062405 0.929 rs11864750 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28863883 chr16:28802743~28817828:+ PAAD cis rs8062405 0.964 rs7193733 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28864161 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs8055982 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28869881 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs7498665 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28871920 chr16:28802743~28817828:+ PAAD cis rs8062405 0.964 rs11864107 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28874610 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62037371 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878810 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs8055138 ENSG00000251417.2 RP11-1348G14.4 -5.38 2.73e-07 0.000239 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28880144 chr16:28802743~28817828:+ PAAD cis rs1322639 0.614 rs7751131 ENSG00000261039.2 RP11-417E7.2 -5.38 2.73e-07 0.000239 -0.67 -0.4 Pulse pressure; chr6:169178615 chr6:169175304~169182740:- PAAD cis rs1322639 0.574 rs9364360 ENSG00000261039.2 RP11-417E7.2 -5.38 2.73e-07 0.000239 -0.67 -0.4 Pulse pressure; chr6:169180079 chr6:169175304~169182740:- PAAD cis rs465969 1 rs9387010 ENSG00000255389.1 C6orf3 5.38 2.73e-07 0.000239 0.71 0.4 Psoriasis; chr6:111384741 chr6:111599875~111602295:+ PAAD cis rs6504950 0.76 rs7214573 ENSG00000275710.1 RP11-257O5.4 5.38 2.73e-07 0.00024 0.52 0.4 Breast cancer; chr17:54929293 chr17:54964474~54964679:+ PAAD cis rs6504950 0.83 rs12949538 ENSG00000275710.1 RP11-257O5.4 -5.38 2.73e-07 0.00024 -0.52 -0.4 Breast cancer; chr17:54933309 chr17:54964474~54964679:+ PAAD cis rs6504950 0.76 rs17745189 ENSG00000275710.1 RP11-257O5.4 5.38 2.73e-07 0.00024 0.52 0.4 Breast cancer; chr17:54936619 chr17:54964474~54964679:+ PAAD cis rs7772486 0.79 rs10223507 ENSG00000235652.6 RP11-545I5.3 -5.38 2.74e-07 0.00024 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145964068 chr6:145799409~145886585:+ PAAD cis rs7772486 0.727 rs10223508 ENSG00000235652.6 RP11-545I5.3 -5.38 2.74e-07 0.00024 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145964069 chr6:145799409~145886585:+ PAAD cis rs10771431 0.935 rs1988852 ENSG00000111788.10 RP11-22B23.1 5.38 2.74e-07 0.00024 0.37 0.4 Breast size; chr12:9220266 chr12:9277235~9313241:+ PAAD cis rs6921919 0.697 rs12180820 ENSG00000216901.1 AL022393.7 -5.38 2.74e-07 0.00024 -0.54 -0.4 Autism spectrum disorder or schizophrenia; chr6:28348701 chr6:28176188~28176674:+ PAAD cis rs1275468 0.798 rs2366987 ENSG00000257497.2 RP11-585P4.5 -5.38 2.74e-07 0.00024 -0.55 -0.4 Polycystic ovary syndrome; chr12:75536346 chr12:75483454~75489820:- PAAD cis rs9926296 0.712 rs258330 ENSG00000260259.1 RP11-368I7.4 5.38 2.74e-07 0.00024 0.5 0.4 Vitiligo; chr16:89663166 chr16:89682620~89686569:- PAAD cis rs13178541 0.81 rs2304075 ENSG00000250378.1 RP11-119J18.1 -5.38 2.76e-07 0.000241 -0.59 -0.4 IgG glycosylation; chr5:135842435 chr5:135812667~135826582:+ PAAD cis rs7772486 0.875 rs10457795 ENSG00000235652.6 RP11-545I5.3 5.38 2.76e-07 0.000241 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146094529 chr6:145799409~145886585:+ PAAD cis rs4664293 0.605 rs12991516 ENSG00000226266.5 AC009961.3 -5.38 2.76e-07 0.000241 -0.52 -0.4 Monocyte percentage of white cells; chr2:159585554 chr2:159670708~159712435:- PAAD cis rs9322193 0.923 rs12176034 ENSG00000216906.2 RP11-350J20.9 5.38 2.77e-07 0.000242 0.53 0.4 Lung cancer; chr6:149800557 chr6:149904243~149906418:+ PAAD cis rs9309711 0.666 rs4321399 ENSG00000225234.1 TRAPPC12-AS1 -5.38 2.77e-07 0.000242 -0.41 -0.4 Neurofibrillary tangles; chr2:3477888 chr2:3481242~3482409:- PAAD cis rs1823913 0.892 rs35596292 ENSG00000280083.1 RP11-317J9.1 -5.38 2.77e-07 0.000242 -0.52 -0.4 Obesity-related traits; chr2:191246890 chr2:191154118~191156070:- PAAD cis rs1823913 0.927 rs35530564 ENSG00000280083.1 RP11-317J9.1 -5.38 2.77e-07 0.000242 -0.52 -0.4 Obesity-related traits; chr2:191247324 chr2:191154118~191156070:- PAAD cis rs2412819 0.571 rs56226333 ENSG00000205771.5 CATSPER2P1 -5.38 2.77e-07 0.000242 -0.62 -0.4 Lung cancer; chr15:43632410 chr15:43726918~43747094:- PAAD cis rs6061231 0.834 rs2427307 ENSG00000273619.1 RP5-908M14.9 -5.38 2.77e-07 0.000242 -0.32 -0.4 Colorectal cancer; chr20:62391630 chr20:62386303~62386970:- PAAD cis rs465969 0.744 rs79052344 ENSG00000255389.1 C6orf3 -5.38 2.77e-07 0.000242 -0.71 -0.4 Psoriasis; chr6:111550755 chr6:111599875~111602295:+ PAAD cis rs2921073 0.51 rs2976944 ENSG00000253893.2 FAM85B -5.38 2.77e-07 0.000242 -0.57 -0.4 Parkinson's disease; chr8:8413404 chr8:8167819~8226614:- PAAD cis rs35160687 0.712 rs6745235 ENSG00000273080.1 RP11-301O19.1 -5.38 2.79e-07 0.000243 -0.47 -0.4 Night sleep phenotypes; chr2:86259960 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs7568971 ENSG00000273080.1 RP11-301O19.1 -5.38 2.79e-07 0.000243 -0.47 -0.4 Night sleep phenotypes; chr2:86260917 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs12476826 ENSG00000273080.1 RP11-301O19.1 -5.38 2.79e-07 0.000243 -0.47 -0.4 Night sleep phenotypes; chr2:86262397 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs4832270 ENSG00000273080.1 RP11-301O19.1 -5.38 2.79e-07 0.000243 -0.47 -0.4 Night sleep phenotypes; chr2:86263065 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs6547668 ENSG00000273080.1 RP11-301O19.1 -5.38 2.79e-07 0.000243 -0.47 -0.4 Night sleep phenotypes; chr2:86263538 chr2:86195590~86196049:+ PAAD cis rs72843506 0.591 rs74319100 ENSG00000189423.10 USP32P3 5.38 2.79e-07 0.000244 0.6 0.4 Schizophrenia; chr17:20318079 chr17:20415547~20431008:+ PAAD cis rs72772090 1 rs72772090 ENSG00000248734.2 CTD-2260A17.1 -5.38 2.8e-07 0.000244 -0.49 -0.4 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96700607 chr5:96784777~96785999:+ PAAD cis rs7712401 0.765 rs4349713 ENSG00000263432.2 RN7SL689P 5.38 2.8e-07 0.000244 0.5 0.4 Mean platelet volume; chr5:123055931 chr5:123022487~123022783:- PAAD cis rs2739330 0.731 rs2000468 ENSG00000099984.9 GSTT2 -5.38 2.8e-07 0.000244 -0.49 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23980123~23983911:+ PAAD cis rs2739330 0.734 rs2000467 ENSG00000250470.1 AP000351.3 -5.38 2.8e-07 0.000245 -0.59 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23976904~23977585:- PAAD cis rs6860806 0.507 rs200837 ENSG00000233006.5 AC034220.3 5.38 2.81e-07 0.000245 0.35 0.4 Breast cancer; chr5:132364266 chr5:132311285~132369916:- PAAD cis rs270601 0.909 rs2569265 ENSG00000233006.5 AC034220.3 -5.38 2.81e-07 0.000245 -0.35 -0.4 Acylcarnitine levels; chr5:132368827 chr5:132311285~132369916:- PAAD cis rs67180937 0.583 rs61827168 ENSG00000272750.1 RP11-378J18.8 5.38 2.81e-07 0.000245 0.47 0.4 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222634138 chr1:222658867~222661512:- PAAD cis rs10463554 0.856 rs26522 ENSG00000175749.11 EIF3KP1 -5.38 2.81e-07 0.000245 -0.5 -0.4 Parkinson's disease; chr5:103148695 chr5:103032376~103033031:+ PAAD cis rs10463554 0.856 rs257292 ENSG00000175749.11 EIF3KP1 5.38 2.81e-07 0.000245 0.5 0.4 Parkinson's disease; chr5:103159047 chr5:103032376~103033031:+ PAAD cis rs10463554 0.856 rs257293 ENSG00000175749.11 EIF3KP1 5.38 2.81e-07 0.000245 0.5 0.4 Parkinson's disease; chr5:103159824 chr5:103032376~103033031:+ PAAD cis rs10463554 0.856 rs2432169 ENSG00000175749.11 EIF3KP1 5.38 2.81e-07 0.000245 0.5 0.4 Parkinson's disease; chr5:103179056 chr5:103032376~103033031:+ PAAD cis rs2281636 0.691 rs11190218 ENSG00000233690.1 EBAG9P1 5.38 2.81e-07 0.000245 0.46 0.4 Obesity-related traits; chr10:99650305 chr10:99697407~99697949:- PAAD cis rs113835537 0.529 rs3819247 ENSG00000255517.5 CTD-3074O7.5 -5.38 2.81e-07 0.000245 -0.53 -0.4 Airway imaging phenotypes; chr11:66526308 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs74869459 ENSG00000255517.5 CTD-3074O7.5 -5.38 2.81e-07 0.000245 -0.53 -0.4 Airway imaging phenotypes; chr11:66529098 chr11:66473490~66480233:- PAAD cis rs1075265 0.716 rs7573991 ENSG00000233266.1 HMGB1P31 5.38 2.81e-07 0.000245 0.5 0.4 Chronotype;Morning vs. evening chronotype; chr2:53726830 chr2:54051334~54051760:+ PAAD cis rs1185460 0.546 rs549893 ENSG00000271751.1 RP11-110I1.14 5.38 2.82e-07 0.000246 0.53 0.4 Coronary artery disease; chr11:119089022 chr11:119065263~119065677:- PAAD cis rs1075265 0.783 rs805439 ENSG00000233266.1 HMGB1P31 5.38 2.83e-07 0.000246 0.51 0.4 Chronotype;Morning vs. evening chronotype; chr2:53829437 chr2:54051334~54051760:+ PAAD cis rs172166 0.516 rs1225710 ENSG00000204709.4 LINC01556 -5.37 2.83e-07 0.000247 -0.54 -0.4 Cardiac Troponin-T levels; chr6:28132862 chr6:28943877~28944537:+ PAAD cis rs6860806 0.507 rs270614 ENSG00000233006.5 AC034220.3 5.37 2.83e-07 0.000247 0.36 0.4 Breast cancer; chr5:132305120 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs270615 ENSG00000233006.5 AC034220.3 5.37 2.83e-07 0.000247 0.36 0.4 Breast cancer; chr5:132305880 chr5:132311285~132369916:- PAAD cis rs9828933 0.577 rs704374 ENSG00000280620.1 SCAANT1 -5.37 2.84e-07 0.000247 -0.65 -0.4 Type 2 diabetes; chr3:63880271 chr3:63911518~63911772:- PAAD cis rs12458462 0.892 rs2007483 ENSG00000274828.1 RP11-567M16.6 5.37 2.84e-07 0.000247 0.38 0.4 Monocyte count; chr18:79716131 chr18:79677287~79679358:- PAAD cis rs992157 0.764 rs2891077 ENSG00000261338.2 RP11-378A13.1 5.37 2.84e-07 0.000247 0.48 0.4 Colorectal cancer; chr2:218319707 chr2:218255319~218257366:+ PAAD cis rs992157 0.73 rs2891078 ENSG00000261338.2 RP11-378A13.1 5.37 2.84e-07 0.000247 0.48 0.4 Colorectal cancer; chr2:218319709 chr2:218255319~218257366:+ PAAD cis rs638893 0.578 rs500254 ENSG00000278376.1 RP11-158I9.8 5.37 2.84e-07 0.000247 0.57 0.4 Vitiligo; chr11:118808071 chr11:118791254~118793137:+ PAAD cis rs748404 0.66 rs2467742 ENSG00000249839.1 AC011330.5 -5.37 2.84e-07 0.000247 -0.59 -0.4 Lung cancer; chr15:43458039 chr15:43663654~43684339:- PAAD cis rs748404 0.69 rs2244981 ENSG00000249839.1 AC011330.5 -5.37 2.84e-07 0.000247 -0.59 -0.4 Lung cancer; chr15:43460553 chr15:43663654~43684339:- PAAD cis rs748404 0.66 rs694725 ENSG00000249839.1 AC011330.5 -5.37 2.84e-07 0.000247 -0.59 -0.4 Lung cancer; chr15:43464012 chr15:43663654~43684339:- PAAD cis rs7829975 0.511 rs2976902 ENSG00000253893.2 FAM85B -5.37 2.84e-07 0.000247 -0.54 -0.4 Mood instability; chr8:8483595 chr8:8167819~8226614:- PAAD cis rs7829975 0.582 rs448231 ENSG00000253893.2 FAM85B 5.37 2.84e-07 0.000248 0.52 0.4 Mood instability; chr8:8932549 chr8:8167819~8226614:- PAAD cis rs11673344 0.704 rs1644710 ENSG00000226686.6 LINC01535 5.37 2.85e-07 0.000248 0.56 0.4 Obesity-related traits; chr19:36926160 chr19:37251912~37265535:+ PAAD cis rs17507216 0.667 rs72753916 ENSG00000278603.1 RP13-608F4.5 5.37 2.85e-07 0.000248 0.61 0.4 Excessive daytime sleepiness; chr15:82684001 chr15:82472203~82472426:+ PAAD cis rs6782228 0.675 rs6806687 ENSG00000242551.2 POU5F1P6 5.37 2.85e-07 0.000248 0.47 0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128672946 chr3:128674735~128677005:- PAAD cis rs10875746 0.669 rs11168459 ENSG00000240399.1 RP1-228P16.1 -5.37 2.85e-07 0.000248 -0.44 -0.4 Longevity (90 years and older); chr12:48202458 chr12:48054813~48055591:- PAAD cis rs875971 0.895 rs6460278 ENSG00000237310.1 GS1-124K5.4 -5.37 2.85e-07 0.000248 -0.4 -0.4 Aortic root size; chr7:66197749 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6460279 ENSG00000237310.1 GS1-124K5.4 -5.37 2.85e-07 0.000248 -0.4 -0.4 Aortic root size; chr7:66197774 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs28491091 ENSG00000237310.1 GS1-124K5.4 -5.37 2.85e-07 0.000248 -0.4 -0.4 Aortic root size; chr7:66204077 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6952182 ENSG00000237310.1 GS1-124K5.4 -5.37 2.85e-07 0.000248 -0.4 -0.4 Aortic root size; chr7:66218330 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs6964437 ENSG00000237310.1 GS1-124K5.4 -5.37 2.85e-07 0.000248 -0.4 -0.4 Aortic root size; chr7:66221457 chr7:66493706~66495474:+ PAAD cis rs526231 0.543 rs246915 ENSG00000175749.11 EIF3KP1 5.37 2.86e-07 0.000249 0.54 0.4 Primary biliary cholangitis; chr5:103222343 chr5:103032376~103033031:+ PAAD cis rs9926296 0.605 rs886951 ENSG00000260259.1 RP11-368I7.4 -5.37 2.86e-07 0.000249 -0.48 -0.4 Vitiligo; chr16:89770457 chr16:89682620~89686569:- PAAD cis rs9828933 0.938 rs2578011 ENSG00000280620.1 SCAANT1 5.37 2.86e-07 0.000249 0.66 0.4 Type 2 diabetes; chr3:64019143 chr3:63911518~63911772:- PAAD cis rs1075265 0.73 rs6711105 ENSG00000233266.1 HMGB1P31 5.37 2.86e-07 0.000249 0.52 0.4 Chronotype;Morning vs. evening chronotype; chr2:54017775 chr2:54051334~54051760:+ PAAD cis rs1075265 0.704 rs6711217 ENSG00000233266.1 HMGB1P31 5.37 2.86e-07 0.000249 0.52 0.4 Chronotype;Morning vs. evening chronotype; chr2:54017892 chr2:54051334~54051760:+ PAAD cis rs2115630 1 rs2879828 ENSG00000259728.4 LINC00933 -5.37 2.86e-07 0.000249 -0.49 -0.4 P wave terminal force; chr15:84818746 chr15:84570649~84580175:+ PAAD cis rs2280018 0.526 rs2966128 ENSG00000260735.1 RP11-72I8.1 -5.37 2.86e-07 0.000249 -0.53 -0.4 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059532 chr16:15094411~15109197:+ PAAD cis rs8062405 1 rs4788095 ENSG00000251417.2 RP11-1348G14.4 -5.37 2.87e-07 0.00025 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28820038 chr16:28802743~28817828:+ PAAD cis rs8062405 0.964 rs72793809 ENSG00000251417.2 RP11-1348G14.4 -5.37 2.87e-07 0.00025 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821061 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62036620 ENSG00000251417.2 RP11-1348G14.4 -5.37 2.87e-07 0.00025 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821776 chr16:28802743~28817828:+ PAAD cis rs8062405 1 rs62036621 ENSG00000251417.2 RP11-1348G14.4 -5.37 2.87e-07 0.00025 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28821978 chr16:28802743~28817828:+ PAAD cis rs7712401 0.715 rs6880480 ENSG00000263432.2 RN7SL689P -5.37 2.87e-07 0.00025 -0.51 -0.4 Mean platelet volume; chr5:123019031 chr5:123022487~123022783:- PAAD cis rs2274273 0.624 rs7150763 ENSG00000258413.1 RP11-665C16.6 -5.37 2.87e-07 0.00025 -0.55 -0.4 Protein biomarker; chr14:55373083 chr14:55262767~55272075:- PAAD cis rs8091660 0.929 rs12606093 ENSG00000278983.1 RP11-426J5.3 5.37 2.88e-07 0.00025 0.47 0.4 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550924 chr18:48564795~48568342:+ PAAD cis rs748404 0.588 rs506120 ENSG00000249839.1 AC011330.5 -5.37 2.88e-07 0.000251 -0.6 -0.4 Lung cancer; chr15:43509826 chr15:43663654~43684339:- PAAD cis rs4879677 0.92 rs3861018 ENSG00000260390.1 RP11-575I8.1 -5.37 2.89e-07 0.000252 -0.52 -0.4 Gut microbiome composition (summer and winter); chr9:27654018 chr9:27829276~27844481:+ PAAD cis rs6782228 0.565 rs12695509 ENSG00000242551.2 POU5F1P6 -5.37 2.9e-07 0.000252 -0.47 -0.4 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128698201 chr3:128674735~128677005:- PAAD cis rs6142102 0.517 rs6142046 ENSG00000276073.1 RP5-1125A11.7 -5.37 2.9e-07 0.000252 -0.42 -0.4 Skin pigmentation; chr20:33926255 chr20:33985617~33988989:- PAAD cis rs4879677 0.92 rs1826742 ENSG00000260390.1 RP11-575I8.1 -5.37 2.91e-07 0.000253 -0.52 -0.4 Gut microbiome composition (summer and winter); chr9:27654052 chr9:27829276~27844481:+ PAAD cis rs6565180 1 rs12930787 ENSG00000183604.13 SMG1P5 -5.37 2.91e-07 0.000253 -0.45 -0.4 Tonsillectomy; chr16:30369982 chr16:30267553~30335374:- PAAD cis rs7208859 0.623 rs6505207 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749553 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs7223803 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750175 chr17:30792372~30792833:+ PAAD cis rs17826219 0.568 rs2626985 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Body mass index; chr17:30750419 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs55814012 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30750679 chr17:30792372~30792833:+ PAAD cis rs17826219 0.5 rs2449749 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Body mass index; chr17:30751280 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9894709 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751436 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9896603 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30751494 chr17:30792372~30792833:+ PAAD cis rs17826219 0.636 rs4055314 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Body mass index; chr17:30752751 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7219712 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753552 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs8078656 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30753953 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs8080882 ENSG00000266490.1 CTD-2349P21.9 5.37 2.91e-07 0.000253 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30754128 chr17:30792372~30792833:+ PAAD cis rs858239 0.863 rs274058 ENSG00000226816.2 AC005082.12 5.37 2.92e-07 0.000253 0.44 0.4 Cerebrospinal fluid biomarker levels; chr7:23351890 chr7:23206013~23208045:+ PAAD cis rs2274273 0.805 rs7159808 ENSG00000258413.1 RP11-665C16.6 -5.37 2.92e-07 0.000254 -0.5 -0.4 Protein biomarker; chr14:55157609 chr14:55262767~55272075:- PAAD cis rs2274273 0.868 rs6573007 ENSG00000258413.1 RP11-665C16.6 -5.37 2.92e-07 0.000254 -0.5 -0.4 Protein biomarker; chr14:55159220 chr14:55262767~55272075:- PAAD cis rs2274273 0.905 rs10134800 ENSG00000258413.1 RP11-665C16.6 -5.37 2.92e-07 0.000254 -0.5 -0.4 Protein biomarker; chr14:55168491 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs8018110 ENSG00000258413.1 RP11-665C16.6 -5.37 2.92e-07 0.000254 -0.5 -0.4 Protein biomarker; chr14:55174996 chr14:55262767~55272075:- PAAD cis rs7772486 0.754 rs697054 ENSG00000235652.6 RP11-545I5.3 5.37 2.93e-07 0.000254 0.34 0.4 Lobe attachment (rater-scored or self-reported); chr6:145682634 chr6:145799409~145886585:+ PAAD cis rs80285556 0.51 rs75463146 ENSG00000161643.11 SIGLEC16 5.37 2.93e-07 0.000254 0.98 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49989087 chr19:49969673~49975814:+ PAAD cis rs80285556 1 rs80202648 ENSG00000161643.11 SIGLEC16 5.37 2.93e-07 0.000254 0.98 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49991129 chr19:49969673~49975814:+ PAAD cis rs80285556 1 rs77187281 ENSG00000161643.11 SIGLEC16 5.37 2.93e-07 0.000254 0.98 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50004410 chr19:49969673~49975814:+ PAAD cis rs80285556 1 rs10500303 ENSG00000161643.11 SIGLEC16 5.37 2.93e-07 0.000254 0.98 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50008776 chr19:49969673~49975814:+ PAAD cis rs80285556 0.655 rs17311832 ENSG00000161643.11 SIGLEC16 5.37 2.93e-07 0.000254 0.98 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022059 chr19:49969673~49975814:+ PAAD cis rs80285556 1 rs80314222 ENSG00000161643.11 SIGLEC16 5.37 2.93e-07 0.000254 0.98 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022257 chr19:49969673~49975814:+ PAAD cis rs950169 0.92 rs2135551 ENSG00000225151.9 GOLGA2P7 -5.37 2.94e-07 0.000255 -0.48 -0.4 Schizophrenia; chr15:84039099 chr15:84199311~84230136:- PAAD cis rs6061231 0.834 rs2427311 ENSG00000273619.1 RP5-908M14.9 -5.37 2.94e-07 0.000255 -0.32 -0.4 Colorectal cancer; chr20:62395067 chr20:62386303~62386970:- PAAD cis rs6570726 0.791 rs9497357 ENSG00000235652.6 RP11-545I5.3 5.37 2.95e-07 0.000255 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145591752 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs4263604 ENSG00000235652.6 RP11-545I5.3 5.37 2.95e-07 0.000255 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145595561 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs11759979 ENSG00000235652.6 RP11-545I5.3 5.37 2.95e-07 0.000255 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145597745 chr6:145799409~145886585:+ PAAD cis rs12220777 0.748 rs11201633 ENSG00000230091.5 TMEM254-AS1 5.37 2.95e-07 0.000255 0.63 0.4 Chronic obstructive pulmonary disease-related biomarkers; chr10:80090068 chr10:80046860~80078912:- PAAD cis rs228614 0.51 rs223452 ENSG00000246560.2 RP11-10L12.4 5.37 2.95e-07 0.000255 0.43 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102790277 chr4:102828055~102844075:+ PAAD cis rs7772486 0.754 rs10872580 ENSG00000235652.6 RP11-545I5.3 -5.37 2.95e-07 0.000255 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145819145 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9322045 ENSG00000235652.6 RP11-545I5.3 5.37 2.95e-07 0.000256 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146063814 chr6:145799409~145886585:+ PAAD cis rs10463554 0.853 rs2432177 ENSG00000175749.11 EIF3KP1 5.36 2.97e-07 0.000258 0.52 0.4 Parkinson's disease; chr5:103236172 chr5:103032376~103033031:+ PAAD cis rs6570726 0.738 rs7746330 ENSG00000235652.6 RP11-545I5.3 5.36 2.98e-07 0.000258 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145578121 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs12208812 ENSG00000235652.6 RP11-545I5.3 5.36 2.98e-07 0.000258 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145579788 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs4335004 ENSG00000235652.6 RP11-545I5.3 5.36 2.98e-07 0.000258 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145583628 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9399558 ENSG00000235652.6 RP11-545I5.3 5.36 2.98e-07 0.000258 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145590594 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9376953 ENSG00000235652.6 RP11-545I5.3 5.36 2.98e-07 0.000258 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145591090 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs13202312 ENSG00000235652.6 RP11-545I5.3 5.36 2.98e-07 0.000258 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145591957 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs7765675 ENSG00000235652.6 RP11-545I5.3 5.36 2.98e-07 0.000258 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145593941 chr6:145799409~145886585:+ PAAD cis rs6570726 0.738 rs4495284 ENSG00000235652.6 RP11-545I5.3 5.36 2.98e-07 0.000258 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145595481 chr6:145799409~145886585:+ PAAD cis rs6504622 1 rs4968285 ENSG00000262879.4 RP11-156P1.3 -5.36 2.98e-07 0.000258 -0.4 -0.4 Orofacial clefts; chr17:46938266 chr17:46984045~47100323:- PAAD cis rs992157 0.764 rs2382827 ENSG00000261338.2 RP11-378A13.1 5.36 2.99e-07 0.000259 0.48 0.4 Colorectal cancer; chr2:218319664 chr2:218255319~218257366:+ PAAD cis rs992157 0.764 rs2891076 ENSG00000261338.2 RP11-378A13.1 5.36 2.99e-07 0.000259 0.48 0.4 Colorectal cancer; chr2:218319675 chr2:218255319~218257366:+ PAAD cis rs992157 0.73 rs2382828 ENSG00000261338.2 RP11-378A13.1 5.36 2.99e-07 0.000259 0.48 0.4 Colorectal cancer; chr2:218319769 chr2:218255319~218257366:+ PAAD cis rs7916697 0.52 rs4745957 ENSG00000233590.1 RP11-153K11.3 5.36 2.99e-07 0.000259 0.53 0.4 Optic disc area; chr10:68284945 chr10:68233251~68242379:- PAAD cis rs12908161 1 rs58416181 ENSG00000225151.9 GOLGA2P7 -5.36 3e-07 0.000259 -0.49 -0.4 Schizophrenia; chr15:84721230 chr15:84199311~84230136:- PAAD cis rs6061231 1 rs11908473 ENSG00000273619.1 RP5-908M14.9 -5.36 3e-07 0.00026 -0.32 -0.4 Colorectal cancer; chr20:62382714 chr20:62386303~62386970:- PAAD cis rs6061231 1 rs67941642 ENSG00000273619.1 RP5-908M14.9 -5.36 3e-07 0.00026 -0.32 -0.4 Colorectal cancer; chr20:62383052 chr20:62386303~62386970:- PAAD cis rs6061231 1 rs13043313 ENSG00000273619.1 RP5-908M14.9 -5.36 3e-07 0.00026 -0.32 -0.4 Colorectal cancer; chr20:62383213 chr20:62386303~62386970:- PAAD cis rs7772486 0.875 rs2814866 ENSG00000235652.6 RP11-545I5.3 5.36 3e-07 0.00026 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146018278 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2328712 ENSG00000235652.6 RP11-545I5.3 5.36 3e-07 0.00026 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146023427 chr6:145799409~145886585:+ PAAD cis rs75422866 0.51 rs73105803 ENSG00000257433.4 RP1-197B17.3 5.36 3e-07 0.00026 0.75 0.4 Pneumonia; chr12:47722135 chr12:47706085~47742294:+ PAAD cis rs75422866 0.51 rs73105812 ENSG00000257433.4 RP1-197B17.3 5.36 3e-07 0.00026 0.75 0.4 Pneumonia; chr12:47724404 chr12:47706085~47742294:+ PAAD cis rs75422866 0.51 rs74733564 ENSG00000257433.4 RP1-197B17.3 5.36 3e-07 0.00026 0.75 0.4 Pneumonia; chr12:47724644 chr12:47706085~47742294:+ PAAD cis rs75422866 0.51 rs73105814 ENSG00000257433.4 RP1-197B17.3 5.36 3e-07 0.00026 0.75 0.4 Pneumonia; chr12:47725817 chr12:47706085~47742294:+ PAAD cis rs2255336 1 rs2255336 ENSG00000245648.1 RP11-277P12.20 5.36 3e-07 0.00026 0.59 0.4 Blood protein levels; chr12:10379727 chr12:10363769~10398506:+ PAAD cis rs172166 0.561 rs149976 ENSG00000204709.4 LINC01556 -5.36 3.01e-07 0.00026 -0.54 -0.4 Cardiac Troponin-T levels; chr6:28019998 chr6:28943877~28944537:+ PAAD cis rs733592 0.507 rs7138917 ENSG00000240399.1 RP1-228P16.1 -5.36 3.01e-07 0.000261 -0.37 -0.4 Plateletcrit; chr12:48061472 chr12:48054813~48055591:- PAAD cis rs733592 0.507 rs3825403 ENSG00000240399.1 RP1-228P16.1 -5.36 3.01e-07 0.000261 -0.37 -0.4 Plateletcrit; chr12:48063376 chr12:48054813~48055591:- PAAD cis rs733592 0.507 rs10747529 ENSG00000240399.1 RP1-228P16.1 -5.36 3.01e-07 0.000261 -0.37 -0.4 Plateletcrit; chr12:48079586 chr12:48054813~48055591:- PAAD cis rs733592 0.507 rs56129148 ENSG00000240399.1 RP1-228P16.1 -5.36 3.01e-07 0.000261 -0.37 -0.4 Plateletcrit; chr12:48091747 chr12:48054813~48055591:- PAAD cis rs733592 0.507 rs7299704 ENSG00000240399.1 RP1-228P16.1 5.36 3.01e-07 0.000261 0.37 0.4 Plateletcrit; chr12:48050705 chr12:48054813~48055591:- PAAD cis rs6570726 0.791 rs443628 ENSG00000235652.6 RP11-545I5.3 5.36 3.02e-07 0.000261 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145562348 chr6:145799409~145886585:+ PAAD cis rs4218 0.648 rs58087223 ENSG00000277144.1 RP11-59H7.4 -5.36 3.02e-07 0.000261 -0.58 -0.4 Social communication problems; chr15:59075132 chr15:59115547~59116089:- PAAD cis rs7772486 0.641 rs67882056 ENSG00000235652.6 RP11-545I5.3 5.36 3.02e-07 0.000261 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146095165 chr6:145799409~145886585:+ PAAD cis rs10463554 0.892 rs66505956 ENSG00000175749.11 EIF3KP1 5.36 3.02e-07 0.000261 0.5 0.4 Parkinson's disease; chr5:102943853 chr5:103032376~103033031:+ PAAD cis rs6570726 0.791 rs11155426 ENSG00000235652.6 RP11-545I5.3 5.36 3.02e-07 0.000261 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145495994 chr6:145799409~145886585:+ PAAD cis rs2281636 0.595 rs11190169 ENSG00000233690.1 EBAG9P1 5.36 3.03e-07 0.000262 0.5 0.4 Obesity-related traits; chr10:99597878 chr10:99697407~99697949:- PAAD cis rs950027 0.787 rs2433616 ENSG00000259433.2 CTD-2651B20.4 -5.36 3.03e-07 0.000262 -0.48 -0.4 Response to fenofibrate (adiponectin levels); chr15:45436401 chr15:45330209~45332634:- PAAD cis rs755249 0.565 rs722357 ENSG00000237624.1 OXCT2P1 -5.36 3.04e-07 0.000262 -0.5 -0.4 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39479096 chr1:39514956~39516490:+ PAAD cis rs72772090 1 rs56116814 ENSG00000248734.2 CTD-2260A17.1 -5.36 3.04e-07 0.000262 -0.49 -0.4 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96713010 chr5:96784777~96785999:+ PAAD cis rs7772486 0.688 rs1884364 ENSG00000235652.6 RP11-545I5.3 5.36 3.04e-07 0.000263 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146016681 chr6:145799409~145886585:+ PAAD cis rs2404602 0.735 rs4886493 ENSG00000259422.1 RP11-593F23.1 -5.36 3.05e-07 0.000263 -0.49 -0.4 Blood metabolite levels; chr15:76386685 chr15:76174891~76181486:- PAAD cis rs11673344 0.864 rs8106386 ENSG00000226686.6 LINC01535 -5.36 3.05e-07 0.000263 -0.54 -0.4 Obesity-related traits; chr19:37012997 chr19:37251912~37265535:+ PAAD cis rs2111504 0.583 rs10853921 ENSG00000267213.4 AC007773.2 -5.36 3.05e-07 0.000263 -0.5 -0.4 Bipolar disorder; chr19:32370899 chr19:32390050~32405560:- PAAD cis rs2274273 0.87 rs6573009 ENSG00000258413.1 RP11-665C16.6 -5.36 3.05e-07 0.000264 -0.49 -0.4 Protein biomarker; chr14:55215606 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs6573013 ENSG00000258413.1 RP11-665C16.6 -5.36 3.05e-07 0.000264 -0.49 -0.4 Protein biomarker; chr14:55269155 chr14:55262767~55272075:- PAAD cis rs858239 0.699 rs955187 ENSG00000226816.2 AC005082.12 -5.36 3.06e-07 0.000264 -0.45 -0.4 Cerebrospinal fluid biomarker levels; chr7:23154986 chr7:23206013~23208045:+ PAAD cis rs75422866 0.558 rs73104190 ENSG00000257433.4 RP1-197B17.3 5.36 3.06e-07 0.000264 0.76 0.4 Pneumonia; chr12:47716040 chr12:47706085~47742294:+ PAAD cis rs9322193 0.884 rs1108889 ENSG00000223701.3 RAET1E-AS1 5.36 3.06e-07 0.000264 0.47 0.4 Lung cancer; chr6:149845433 chr6:149884431~149919508:+ PAAD cis rs7772486 0.719 rs4391282 ENSG00000235652.6 RP11-545I5.3 -5.36 3.06e-07 0.000264 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145955644 chr6:145799409~145886585:+ PAAD cis rs7208859 0.573 rs55661352 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30718610 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs8075357 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Body mass index; chr17:30730179 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs59447372 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30730567 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs61643715 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Body mass index; chr17:30730744 chr17:30792372~30792833:+ PAAD cis rs17826219 0.636 rs8080829 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Body mass index; chr17:30731712 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs8079891 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30731845 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73267858 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732719 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs56018041 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30732967 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs56095789 ENSG00000266490.1 CTD-2349P21.9 5.36 3.06e-07 0.000264 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733152 chr17:30792372~30792833:+ PAAD cis rs992157 0.735 rs13430006 ENSG00000261338.2 RP11-378A13.1 -5.36 3.06e-07 0.000264 -0.45 -0.4 Colorectal cancer; chr2:218248366 chr2:218255319~218257366:+ PAAD cis rs9926296 0.605 rs6500449 ENSG00000260259.1 RP11-368I7.4 -5.36 3.08e-07 0.000265 -0.49 -0.4 Vitiligo; chr16:89789985 chr16:89682620~89686569:- PAAD cis rs9926296 0.585 rs8045232 ENSG00000260259.1 RP11-368I7.4 -5.36 3.08e-07 0.000265 -0.49 -0.4 Vitiligo; chr16:89791140 chr16:89682620~89686569:- PAAD cis rs4308124 0.708 rs6727313 ENSG00000227992.1 AC108463.2 -5.36 3.08e-07 0.000265 -0.45 -0.4 Vitiligo; chr2:111213963 chr2:111203964~111206215:- PAAD cis rs2739330 0.76 rs1002286 ENSG00000206090.4 AP000350.7 -5.36 3.08e-07 0.000265 -0.49 -0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23939998~23942798:+ PAAD cis rs7044106 0.578 rs4837788 ENSG00000226752.6 PSMD5-AS1 -5.36 3.08e-07 0.000265 -0.67 -0.4 Hip circumference adjusted for BMI; chr9:120634523 chr9:120824828~120854385:+ PAAD cis rs2404602 0.735 rs11857015 ENSG00000259422.1 RP11-593F23.1 -5.36 3.08e-07 0.000266 -0.49 -0.4 Blood metabolite levels; chr15:76357049 chr15:76174891~76181486:- PAAD cis rs9322193 0.772 rs7738696 ENSG00000223701.3 RAET1E-AS1 5.36 3.08e-07 0.000266 0.48 0.4 Lung cancer; chr6:149848985 chr6:149884431~149919508:+ PAAD cis rs950169 0.649 rs12901010 ENSG00000225151.9 GOLGA2P7 -5.36 3.09e-07 0.000266 -0.51 -0.4 Schizophrenia; chr15:84030282 chr15:84199311~84230136:- PAAD cis rs950169 0.69 rs12901166 ENSG00000225151.9 GOLGA2P7 -5.36 3.09e-07 0.000266 -0.51 -0.4 Schizophrenia; chr15:84030361 chr15:84199311~84230136:- PAAD cis rs42490 1 rs13252013 ENSG00000251136.7 RP11-37B2.1 -5.36 3.09e-07 0.000267 -0.35 -0.4 Leprosy; chr8:89746881 chr8:89609409~89757727:- PAAD cis rs42490 1 rs13279023 ENSG00000251136.7 RP11-37B2.1 -5.36 3.09e-07 0.000267 -0.35 -0.4 Leprosy; chr8:89748816 chr8:89609409~89757727:- PAAD cis rs42490 1 rs454441 ENSG00000251136.7 RP11-37B2.1 -5.36 3.09e-07 0.000267 -0.35 -0.4 Leprosy; chr8:89750842 chr8:89609409~89757727:- PAAD cis rs42490 1 rs40246 ENSG00000251136.7 RP11-37B2.1 -5.36 3.09e-07 0.000267 -0.35 -0.4 Leprosy; chr8:89752944 chr8:89609409~89757727:- PAAD cis rs853679 0.527 rs1997660 ENSG00000204709.4 LINC01556 5.36 3.09e-07 0.000267 0.55 0.4 Depression; chr6:28301886 chr6:28943877~28944537:+ PAAD cis rs853679 0.527 rs9468333 ENSG00000204709.4 LINC01556 5.36 3.09e-07 0.000267 0.55 0.4 Depression; chr6:28303421 chr6:28943877~28944537:+ PAAD cis rs6903823 0.527 rs4713158 ENSG00000204709.4 LINC01556 5.36 3.09e-07 0.000267 0.55 0.4 Pulmonary function; chr6:28309994 chr6:28943877~28944537:+ PAAD cis rs16828019 0.852 rs12045171 ENSG00000235358.1 RP11-399E6.1 5.36 3.1e-07 0.000267 0.75 0.4 Intelligence (multi-trait analysis); chr1:41063133 chr1:41242373~41284861:+ PAAD cis rs875971 0.862 rs6460282 ENSG00000237310.1 GS1-124K5.4 -5.36 3.1e-07 0.000267 -0.4 -0.4 Aortic root size; chr7:66226259 chr7:66493706~66495474:+ PAAD cis rs1322639 0.697 rs12661910 ENSG00000261039.2 RP11-417E7.2 -5.35 3.11e-07 0.000268 -0.66 -0.4 Pulse pressure; chr6:169184293 chr6:169175304~169182740:- PAAD cis rs526231 0.543 rs246916 ENSG00000175749.11 EIF3KP1 5.35 3.11e-07 0.000268 0.53 0.4 Primary biliary cholangitis; chr5:103221814 chr5:103032376~103033031:+ PAAD cis rs2111504 0.583 rs1008425 ENSG00000267213.4 AC007773.2 5.35 3.12e-07 0.000268 0.5 0.4 Bipolar disorder; chr19:32361239 chr19:32390050~32405560:- PAAD cis rs7772486 0.754 rs2328707 ENSG00000235652.6 RP11-545I5.3 -5.35 3.12e-07 0.000268 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145732362 chr6:145799409~145886585:+ PAAD cis rs6538678 0.824 rs7307510 ENSG00000258343.1 RP11-536G4.2 -5.35 3.12e-07 0.000269 -0.57 -0.4 Lupus nephritis in systemic lupus erythematosus; chr12:95843792 chr12:95795345~95858839:- PAAD cis rs113835537 0.529 rs12099041 ENSG00000255517.5 CTD-3074O7.5 -5.35 3.12e-07 0.000269 -0.5 -0.4 Airway imaging phenotypes; chr11:66465302 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs7928882 ENSG00000255517.5 CTD-3074O7.5 -5.35 3.12e-07 0.000269 -0.5 -0.4 Airway imaging phenotypes; chr11:66467294 chr11:66473490~66480233:- PAAD cis rs2337406 0.641 rs10133227 ENSG00000274576.2 IGHV2-70 5.35 3.12e-07 0.000269 0.52 0.4 Alzheimer's disease (late onset); chr14:106814260 chr14:106770577~106771020:- PAAD cis rs2337406 0.714 rs8022729 ENSG00000274576.2 IGHV2-70 5.35 3.12e-07 0.000269 0.52 0.4 Alzheimer's disease (late onset); chr14:106816928 chr14:106770577~106771020:- PAAD cis rs3762637 0.943 rs78429050 ENSG00000272758.4 RP11-299J3.8 -5.35 3.12e-07 0.000269 -0.59 -0.4 LDL cholesterol levels; chr3:122533581 chr3:122416207~122443180:+ PAAD cis rs8062405 1 rs62036617 ENSG00000251417.2 RP11-1348G14.4 -5.35 3.13e-07 0.000269 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28816177 chr16:28802743~28817828:+ PAAD cis rs12439619 1 rs12439619 ENSG00000255769.6 GOLGA2P10 -5.35 3.13e-07 0.000269 -0.46 -0.4 Intelligence (multi-trait analysis); chr15:82254605 chr15:82472993~82513950:- PAAD cis rs113835537 0.597 rs3737525 ENSG00000255517.5 CTD-3074O7.5 -5.35 3.13e-07 0.000269 -0.55 -0.4 Airway imaging phenotypes; chr11:66538884 chr11:66473490~66480233:- PAAD cis rs13178541 0.748 rs13158124 ENSG00000250378.1 RP11-119J18.1 -5.35 3.13e-07 0.00027 -0.62 -0.4 IgG glycosylation; chr5:135730290 chr5:135812667~135826582:+ PAAD cis rs35160687 0.712 rs11691807 ENSG00000273080.1 RP11-301O19.1 -5.35 3.14e-07 0.00027 -0.46 -0.4 Night sleep phenotypes; chr2:86255898 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs11681689 ENSG00000273080.1 RP11-301O19.1 -5.35 3.14e-07 0.00027 -0.46 -0.4 Night sleep phenotypes; chr2:86256039 chr2:86195590~86196049:+ PAAD cis rs35160687 0.688 rs12466728 ENSG00000273080.1 RP11-301O19.1 -5.35 3.14e-07 0.00027 -0.46 -0.4 Night sleep phenotypes; chr2:86256976 chr2:86195590~86196049:+ PAAD cis rs35160687 0.666 rs36104799 ENSG00000273080.1 RP11-301O19.1 -5.35 3.14e-07 0.00027 -0.46 -0.4 Night sleep phenotypes; chr2:86257000 chr2:86195590~86196049:+ PAAD cis rs35160687 0.666 rs7583074 ENSG00000273080.1 RP11-301O19.1 -5.35 3.14e-07 0.00027 -0.46 -0.4 Night sleep phenotypes; chr2:86257069 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs6705366 ENSG00000273080.1 RP11-301O19.1 -5.35 3.14e-07 0.00027 -0.46 -0.4 Night sleep phenotypes; chr2:86257659 chr2:86195590~86196049:+ PAAD cis rs35160687 0.712 rs4832262 ENSG00000273080.1 RP11-301O19.1 -5.35 3.14e-07 0.00027 -0.46 -0.4 Night sleep phenotypes; chr2:86258011 chr2:86195590~86196049:+ PAAD cis rs2243480 1 rs10807702 ENSG00000226824.5 RP4-756H11.3 -5.35 3.14e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:66302856 chr7:66654538~66669855:+ PAAD cis rs11098499 0.863 rs6858592 ENSG00000245958.5 RP11-33B1.1 -5.35 3.14e-07 0.00027 -0.34 -0.4 Corneal astigmatism; chr4:119537537 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs9997631 ENSG00000245958.5 RP11-33B1.1 -5.35 3.14e-07 0.00027 -0.34 -0.4 Corneal astigmatism; chr4:119548840 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs10018280 ENSG00000245958.5 RP11-33B1.1 -5.35 3.14e-07 0.00027 -0.34 -0.4 Corneal astigmatism; chr4:119556984 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs6534141 ENSG00000245958.5 RP11-33B1.1 -5.35 3.14e-07 0.00027 -0.34 -0.4 Corneal astigmatism; chr4:119564068 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs2127823 ENSG00000245958.5 RP11-33B1.1 -5.35 3.14e-07 0.00027 -0.34 -0.4 Corneal astigmatism; chr4:119564515 chr4:119454791~119552025:+ PAAD cis rs11098499 0.863 rs3775858 ENSG00000245958.5 RP11-33B1.1 -5.35 3.14e-07 0.00027 -0.34 -0.4 Corneal astigmatism; chr4:119564873 chr4:119454791~119552025:+ PAAD cis rs2243480 1 rs4718269 ENSG00000226824.5 RP4-756H11.3 5.35 3.15e-07 0.00027 0.72 0.4 Diabetic kidney disease; chr7:65735810 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6460260 ENSG00000226824.5 RP4-756H11.3 5.35 3.15e-07 0.00027 0.72 0.4 Diabetic kidney disease; chr7:65750468 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6460261 ENSG00000226824.5 RP4-756H11.3 5.35 3.15e-07 0.00027 0.72 0.4 Diabetic kidney disease; chr7:65750593 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs4718270 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65737415 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs2900904 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65739282 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs13247184 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65893941 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35283677 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65894246 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35421653 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65898442 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs73142162 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65909309 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs73142166 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65910845 chr7:66654538~66669855:+ PAAD cis rs2243480 0.908 rs55876148 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65914813 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs56016656 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65918494 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs56291018 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65925352 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs36033484 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65925571 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34193460 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65928123 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34560516 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65939105 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs57057549 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65940751 chr7:66654538~66669855:+ PAAD cis rs2243480 0.808 rs12698508 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65946971 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2961102 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65959671 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34970380 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65966506 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs73148097 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65966800 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs906134 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65979301 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs73150014 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:65985932 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1723270 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:66004843 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1723269 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:66007799 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs781150 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:66015986 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313798 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:66028044 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35396113 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:66030474 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313809 ENSG00000226824.5 RP4-756H11.3 -5.35 3.15e-07 0.00027 -0.72 -0.4 Diabetic kidney disease; chr7:66034996 chr7:66654538~66669855:+ PAAD cis rs2581828 0.656 rs2564921 ENSG00000242142.1 SERBP1P3 -5.35 3.15e-07 0.00027 -0.46 -0.4 Crohn's disease; chr3:53091569 chr3:53064283~53065091:- PAAD cis rs2581828 0.656 rs2581786 ENSG00000242142.1 SERBP1P3 5.35 3.15e-07 0.00027 0.46 0.4 Crohn's disease; chr3:53092127 chr3:53064283~53065091:- PAAD cis rs75422866 0.51 rs73104197 ENSG00000257433.4 RP1-197B17.3 5.35 3.15e-07 0.00027 0.75 0.4 Pneumonia; chr12:47717273 chr12:47706085~47742294:+ PAAD cis rs8059260 0.542 rs80000109 ENSG00000274038.1 RP11-66H6.4 -5.35 3.15e-07 0.000271 -0.62 -0.4 Alcohol consumption over the past year; chr16:11031457 chr16:11056556~11057034:+ PAAD cis rs1075265 0.568 rs805416 ENSG00000233266.1 HMGB1P31 -5.35 3.15e-07 0.000271 -0.5 -0.4 Chronotype;Morning vs. evening chronotype; chr2:53898121 chr2:54051334~54051760:+ PAAD cis rs7829975 0.711 rs4481596 ENSG00000253893.2 FAM85B -5.35 3.17e-07 0.000272 -0.56 -0.4 Mood instability; chr8:8846820 chr8:8167819~8226614:- PAAD cis rs7772486 0.72 rs1890171 ENSG00000235652.6 RP11-545I5.3 -5.35 3.17e-07 0.000272 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145750978 chr6:145799409~145886585:+ PAAD cis rs7772486 0.72 rs4896844 ENSG00000235652.6 RP11-545I5.3 -5.35 3.17e-07 0.000272 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145754088 chr6:145799409~145886585:+ PAAD cis rs7772486 0.558 rs702316 ENSG00000235652.6 RP11-545I5.3 -5.35 3.17e-07 0.000272 -0.37 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145683541 chr6:145799409~145886585:+ PAAD cis rs10463554 0.856 rs26260 ENSG00000175749.11 EIF3KP1 5.35 3.18e-07 0.000272 0.5 0.4 Parkinson's disease; chr5:103211493 chr5:103032376~103033031:+ PAAD cis rs11123170 0.64 rs931472 ENSG00000189223.12 PAX8-AS1 5.35 3.18e-07 0.000273 0.51 0.4 Renal function-related traits (BUN); chr2:113212371 chr2:113211522~113276581:+ PAAD cis rs7945705 0.806 rs12224436 ENSG00000254860.4 TMEM9B-AS1 -5.35 3.18e-07 0.000273 -0.43 -0.4 Hemoglobin concentration; chr11:8794278 chr11:8964675~8977527:+ PAAD cis rs732716 0.785 rs34080966 ENSG00000267769.1 CTB-50L17.9 5.35 3.21e-07 0.000275 0.56 0.4 Mean corpuscular volume; chr19:4417848 chr19:4454014~4455286:+ PAAD cis rs7772486 0.875 rs969694 ENSG00000235652.6 RP11-545I5.3 5.35 3.21e-07 0.000275 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146073519 chr6:145799409~145886585:+ PAAD cis rs992157 0.735 rs13388024 ENSG00000261338.2 RP11-378A13.1 5.35 3.22e-07 0.000276 0.45 0.4 Colorectal cancer; chr2:218233050 chr2:218255319~218257366:+ PAAD cis rs992157 0.661 rs17653757 ENSG00000261338.2 RP11-378A13.1 5.35 3.22e-07 0.000276 0.45 0.4 Colorectal cancer; chr2:218244641 chr2:218255319~218257366:+ PAAD cis rs875971 0.651 rs313829 ENSG00000237310.1 GS1-124K5.4 -5.35 3.22e-07 0.000276 -0.43 -0.4 Aortic root size; chr7:66087510 chr7:66493706~66495474:+ PAAD cis rs763567 0.817 rs598993 ENSG00000271811.1 RP1-79C4.4 5.35 3.24e-07 0.000278 0.38 0.4 Tonsillectomy; chr1:170634981 chr1:170667381~170669425:+ PAAD cis rs763567 0.935 rs541557 ENSG00000271811.1 RP1-79C4.4 5.35 3.24e-07 0.000278 0.38 0.4 Tonsillectomy; chr1:170635797 chr1:170667381~170669425:+ PAAD cis rs2929278 0.561 rs2927071 ENSG00000205771.5 CATSPER2P1 -5.35 3.25e-07 0.000278 -0.53 -0.4 Schizophrenia; chr15:43626883 chr15:43726918~43747094:- PAAD cis rs17301013 0.507 rs1474575 ENSG00000227373.4 RP11-160H22.5 -5.35 3.25e-07 0.000278 -0.59 -0.4 Systemic lupus erythematosus; chr1:174569563 chr1:174115300~174160004:- PAAD cis rs7916697 0.593 rs7912895 ENSG00000233590.1 RP11-153K11.3 -5.34 3.25e-07 0.000278 -0.52 -0.4 Optic disc area; chr10:68261741 chr10:68233251~68242379:- PAAD cis rs7916697 0.54 rs4551651 ENSG00000233590.1 RP11-153K11.3 -5.34 3.25e-07 0.000278 -0.52 -0.4 Optic disc area; chr10:68264772 chr10:68233251~68242379:- PAAD cis rs7772486 0.846 rs2748499 ENSG00000235652.6 RP11-545I5.3 5.34 3.26e-07 0.000279 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145993866 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2814869 ENSG00000235652.6 RP11-545I5.3 5.34 3.26e-07 0.000279 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145994373 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2748498 ENSG00000235652.6 RP11-545I5.3 5.34 3.26e-07 0.000279 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145998030 chr6:145799409~145886585:+ PAAD cis rs6993244 1 rs6993244 ENSG00000253893.2 FAM85B -5.34 3.27e-07 0.000279 -0.53 -0.4 Mean corpuscular hemoglobin; chr8:9005549 chr8:8167819~8226614:- PAAD cis rs6504622 1 rs1047779 ENSG00000262879.4 RP11-156P1.3 -5.34 3.27e-07 0.00028 -0.41 -0.4 Orofacial clefts; chr17:46941877 chr17:46984045~47100323:- PAAD cis rs6504622 1 rs2003539 ENSG00000262879.4 RP11-156P1.3 -5.34 3.27e-07 0.00028 -0.41 -0.4 Orofacial clefts; chr17:46947953 chr17:46984045~47100323:- PAAD cis rs17826219 0.636 rs12946563 ENSG00000266490.1 CTD-2349P21.9 5.34 3.27e-07 0.00028 0.52 0.4 Body mass index; chr17:30776148 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs8081299 ENSG00000266490.1 CTD-2349P21.9 5.34 3.27e-07 0.00028 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777278 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs8068645 ENSG00000266490.1 CTD-2349P21.9 5.34 3.27e-07 0.00028 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777324 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs55811708 ENSG00000266490.1 CTD-2349P21.9 5.34 3.27e-07 0.00028 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30777713 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs2322197 ENSG00000266490.1 CTD-2349P21.9 5.34 3.27e-07 0.00028 0.52 0.4 Body mass index; chr17:30778787 chr17:30792372~30792833:+ PAAD cis rs7772486 0.754 rs12199362 ENSG00000235652.6 RP11-545I5.3 5.34 3.27e-07 0.00028 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145797089 chr6:145799409~145886585:+ PAAD cis rs732716 0.785 rs11667543 ENSG00000267769.1 CTB-50L17.9 -5.34 3.27e-07 0.00028 -0.55 -0.4 Mean corpuscular volume; chr19:4374853 chr19:4454014~4455286:+ PAAD cis rs801193 0.591 rs9986881 ENSG00000237310.1 GS1-124K5.4 5.34 3.28e-07 0.00028 0.38 0.4 Aortic root size; chr7:66708053 chr7:66493706~66495474:+ PAAD cis rs9926296 0.605 rs1800287 ENSG00000260259.1 RP11-368I7.4 -5.34 3.28e-07 0.000281 -0.49 -0.4 Vitiligo; chr16:89792117 chr16:89682620~89686569:- PAAD cis rs9926296 0.605 rs6500453 ENSG00000260259.1 RP11-368I7.4 -5.34 3.28e-07 0.000281 -0.49 -0.4 Vitiligo; chr16:89792249 chr16:89682620~89686569:- PAAD cis rs732716 0.785 rs56033249 ENSG00000267980.1 AC007292.6 -5.34 3.28e-07 0.000281 -0.55 -0.4 Mean corpuscular volume; chr19:4369450 chr19:4363789~4364640:+ PAAD cis rs2274273 0.686 rs66842809 ENSG00000258413.1 RP11-665C16.6 -5.34 3.29e-07 0.000281 -0.54 -0.4 Protein biomarker; chr14:55163853 chr14:55262767~55272075:- PAAD cis rs1185460 0.565 rs584115 ENSG00000271751.1 RP11-110I1.14 5.34 3.29e-07 0.000281 0.53 0.4 Coronary artery disease; chr11:119068169 chr11:119065263~119065677:- PAAD cis rs62229266 0.804 rs2835231 ENSG00000231106.2 LINC01436 5.34 3.3e-07 0.000282 0.59 0.4 Mitral valve prolapse; chr21:36018300 chr21:36005338~36007838:+ PAAD cis rs1167827 0.71 rs1167836 ENSG00000127957.15 PMS2P3 -5.34 3.31e-07 0.000283 -0.3 -0.4 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75539580 chr7:75502930~75528148:- PAAD cis rs932287 0.666 rs10840161 ENSG00000254860.4 TMEM9B-AS1 -5.34 3.32e-07 0.000284 -0.42 -0.4 Colonoscopy-negative controls vs population controls; chr11:9032277 chr11:8964675~8977527:+ PAAD cis rs7945705 0.935 rs2653593 ENSG00000254860.4 TMEM9B-AS1 5.34 3.32e-07 0.000284 0.42 0.4 Hemoglobin concentration; chr11:8855770 chr11:8964675~8977527:+ PAAD cis rs12908161 0.92 rs35738019 ENSG00000225151.9 GOLGA2P7 -5.34 3.33e-07 0.000284 -0.48 -0.4 Schizophrenia; chr15:84736979 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs34570071 ENSG00000225151.9 GOLGA2P7 -5.34 3.33e-07 0.000284 -0.48 -0.4 Schizophrenia; chr15:84736981 chr15:84199311~84230136:- PAAD cis rs526231 0.511 rs28062 ENSG00000175749.11 EIF3KP1 5.34 3.33e-07 0.000284 0.52 0.4 Primary biliary cholangitis; chr5:103204500 chr5:103032376~103033031:+ PAAD cis rs9326248 1 rs4938354 ENSG00000280143.1 AP000892.6 5.34 3.34e-07 0.000285 0.5 0.4 Blood protein levels; chr11:117180449 chr11:117204967~117210292:+ PAAD cis rs2337406 0.714 rs7145254 ENSG00000274576.2 IGHV2-70 -5.34 3.34e-07 0.000285 -0.51 -0.4 Alzheimer's disease (late onset); chr14:106817783 chr14:106770577~106771020:- PAAD cis rs2337406 0.81 rs7161739 ENSG00000274576.2 IGHV2-70 -5.34 3.34e-07 0.000285 -0.51 -0.4 Alzheimer's disease (late onset); chr14:106776118 chr14:106770577~106771020:- PAAD cis rs2337406 0.866 rs78462736 ENSG00000274576.2 IGHV2-70 -5.34 3.34e-07 0.000285 -0.51 -0.4 Alzheimer's disease (late onset); chr14:106779942 chr14:106770577~106771020:- PAAD cis rs1322639 0.614 rs9364361 ENSG00000261039.2 RP11-417E7.2 -5.34 3.34e-07 0.000285 -0.63 -0.4 Pulse pressure; chr6:169180404 chr6:169175304~169182740:- PAAD cis rs494459 0.838 rs488219 ENSG00000255422.1 AP002954.4 -5.34 3.34e-07 0.000285 -0.43 -0.4 Height; chr11:118749988 chr11:118704607~118750263:+ PAAD cis rs6504622 0.818 rs28451958 ENSG00000262879.4 RP11-156P1.3 5.34 3.34e-07 0.000285 0.41 0.4 Orofacial clefts; chr17:46968528 chr17:46984045~47100323:- PAAD cis rs42490 0.966 rs39499 ENSG00000251136.7 RP11-37B2.1 -5.34 3.35e-07 0.000286 -0.35 -0.4 Leprosy; chr8:89758381 chr8:89609409~89757727:- PAAD cis rs42490 1 rs431264 ENSG00000251136.7 RP11-37B2.1 -5.34 3.35e-07 0.000286 -0.35 -0.4 Leprosy; chr8:89765282 chr8:89609409~89757727:- PAAD cis rs42490 1 rs42490 ENSG00000251136.7 RP11-37B2.1 -5.34 3.35e-07 0.000286 -0.35 -0.4 Leprosy; chr8:89766285 chr8:89609409~89757727:- PAAD cis rs42490 1 rs40544 ENSG00000251136.7 RP11-37B2.1 -5.34 3.35e-07 0.000286 -0.35 -0.4 Leprosy; chr8:89768867 chr8:89609409~89757727:- PAAD cis rs42490 0.966 rs40377 ENSG00000251136.7 RP11-37B2.1 -5.34 3.35e-07 0.000286 -0.35 -0.4 Leprosy; chr8:89769725 chr8:89609409~89757727:- PAAD cis rs950169 0.545 rs4354897 ENSG00000225151.9 GOLGA2P7 -5.34 3.36e-07 0.000287 -0.49 -0.4 Schizophrenia; chr15:83976219 chr15:84199311~84230136:- PAAD cis rs526231 0.578 rs6860588 ENSG00000175749.11 EIF3KP1 -5.34 3.37e-07 0.000288 -0.51 -0.4 Primary biliary cholangitis; chr5:102944598 chr5:103032376~103033031:+ PAAD cis rs3762637 0.823 rs9849013 ENSG00000272758.4 RP11-299J3.8 -5.34 3.37e-07 0.000288 -0.58 -0.4 LDL cholesterol levels; chr3:122531758 chr3:122416207~122443180:+ PAAD cis rs228614 0.51 rs223451 ENSG00000246560.2 RP11-10L12.4 5.34 3.38e-07 0.000288 0.44 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791032 chr4:102828055~102844075:+ PAAD cis rs228614 0.51 rs223450 ENSG00000246560.2 RP11-10L12.4 5.34 3.38e-07 0.000288 0.44 0.4 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102791052 chr4:102828055~102844075:+ PAAD cis rs2115630 0.875 rs8039472 ENSG00000275120.1 RP11-182J1.17 -5.34 3.38e-07 0.000288 -0.4 -0.4 P wave terminal force; chr15:84818413 chr15:84599434~84606463:- PAAD cis rs7772486 0.875 rs865913 ENSG00000235652.6 RP11-545I5.3 5.34 3.39e-07 0.000288 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145987738 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2814873 ENSG00000235652.6 RP11-545I5.3 5.34 3.39e-07 0.000288 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145987796 chr6:145799409~145886585:+ PAAD cis rs7772486 0.84 rs2777478 ENSG00000235652.6 RP11-545I5.3 5.34 3.39e-07 0.000288 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145987981 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs854148 ENSG00000235652.6 RP11-545I5.3 5.34 3.39e-07 0.000288 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145989843 chr6:145799409~145886585:+ PAAD cis rs6991838 0.53 rs6472217 ENSG00000200714.1 Y_RNA 5.34 3.39e-07 0.000289 0.47 0.4 Intelligence (multi-trait analysis); chr8:65635496 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs6472218 ENSG00000200714.1 Y_RNA 5.34 3.39e-07 0.000289 0.47 0.4 Intelligence (multi-trait analysis); chr8:65635502 chr8:65592731~65592820:+ PAAD cis rs858239 0.669 rs1618339 ENSG00000226816.2 AC005082.12 5.34 3.39e-07 0.000289 0.46 0.4 Cerebrospinal fluid biomarker levels; chr7:23190155 chr7:23206013~23208045:+ PAAD cis rs7188445 0.932 rs11150191 ENSG00000261390.4 RP11-345M22.2 -5.34 3.39e-07 0.000289 -0.54 -0.4 Urate levels; chr16:79700390 chr16:79715232~79770563:- PAAD cis rs6538678 0.963 rs11108310 ENSG00000258343.1 RP11-536G4.2 -5.34 3.39e-07 0.000289 -0.51 -0.4 Lupus nephritis in systemic lupus erythematosus; chr12:95864164 chr12:95795345~95858839:- PAAD cis rs8177376 0.906 rs8177380 ENSG00000254905.1 RP11-712L6.7 -5.34 3.4e-07 0.000289 -0.51 -0.4 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126295671 chr11:126292922~126294254:- PAAD cis rs8177376 0.861 rs4937119 ENSG00000254905.1 RP11-712L6.7 5.34 3.4e-07 0.000289 0.51 0.4 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126297825 chr11:126292922~126294254:- PAAD cis rs1665050 0.545 rs59540276 ENSG00000277144.1 RP11-59H7.4 -5.33 3.41e-07 0.00029 -0.51 -0.4 Atopic dermatitis; chr15:59037559 chr15:59115547~59116089:- PAAD cis rs6504950 0.8 rs35647022 ENSG00000275710.1 RP11-257O5.4 5.33 3.41e-07 0.00029 0.52 0.4 Breast cancer; chr17:54930710 chr17:54964474~54964679:+ PAAD cis rs7772486 0.875 rs9399573 ENSG00000235652.6 RP11-545I5.3 5.33 3.42e-07 0.000291 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:146082119 chr6:145799409~145886585:+ PAAD cis rs227275 0.556 rs223449 ENSG00000246560.2 RP11-10L12.4 5.33 3.42e-07 0.000291 0.44 0.4 Allergic disease (asthma, hay fever or eczema); chr4:102791180 chr4:102828055~102844075:+ PAAD cis rs1275468 1 rs1148004 ENSG00000257497.2 RP11-585P4.5 -5.33 3.42e-07 0.000291 -0.58 -0.4 Polycystic ovary syndrome; chr12:75584897 chr12:75483454~75489820:- PAAD cis rs2274273 0.686 rs66531545 ENSG00000258413.1 RP11-665C16.6 -5.33 3.43e-07 0.000292 -0.54 -0.4 Protein biomarker; chr14:55120742 chr14:55262767~55272075:- PAAD cis rs2274273 0.686 rs2182207 ENSG00000258413.1 RP11-665C16.6 -5.33 3.43e-07 0.000292 -0.54 -0.4 Protein biomarker; chr14:55123085 chr14:55262767~55272075:- PAAD cis rs2274273 0.71 rs67395212 ENSG00000258413.1 RP11-665C16.6 -5.33 3.43e-07 0.000292 -0.54 -0.4 Protein biomarker; chr14:55125221 chr14:55262767~55272075:- PAAD cis rs11098499 0.82 rs11737395 ENSG00000245958.5 RP11-33B1.1 -5.33 3.45e-07 0.000293 -0.35 -0.4 Corneal astigmatism; chr4:119599549 chr4:119454791~119552025:+ PAAD cis rs1075265 0.749 rs805434 ENSG00000233266.1 HMGB1P31 5.33 3.45e-07 0.000293 0.51 0.4 Chronotype;Morning vs. evening chronotype; chr2:53836196 chr2:54051334~54051760:+ PAAD cis rs494459 0.657 rs614554 ENSG00000255422.1 AP002954.4 -5.33 3.45e-07 0.000294 -0.43 -0.4 Height; chr11:118764443 chr11:118704607~118750263:+ PAAD cis rs10510102 0.688 rs76573813 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121928955 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11200268 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121932661 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11200269 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121934021 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11498944 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121938748 chr10:121956782~121957098:+ PAAD cis rs10510102 0.81 rs12267347 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121939110 chr10:121956782~121957098:+ PAAD cis rs10510102 0.808 rs12253007 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121939360 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs79865971 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121941208 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs74318512 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121941465 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12257207 ENSG00000276742.1 RP11-500G22.4 5.33 3.46e-07 0.000294 0.58 0.4 Breast cancer; chr10:121941737 chr10:121956782~121957098:+ PAAD cis rs6570726 0.791 rs9403734 ENSG00000235652.6 RP11-545I5.3 5.33 3.46e-07 0.000294 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145610323 chr6:145799409~145886585:+ PAAD cis rs274567 0.501 rs272856 ENSG00000233006.5 AC034220.3 5.33 3.47e-07 0.000295 0.35 0.4 Blood metabolite levels; chr5:132351388 chr5:132311285~132369916:- PAAD cis rs274567 0.501 rs272855 ENSG00000233006.5 AC034220.3 5.33 3.47e-07 0.000295 0.35 0.4 Blood metabolite levels; chr5:132351482 chr5:132311285~132369916:- PAAD cis rs494459 0.733 rs556437 ENSG00000255422.1 AP002954.4 -5.33 3.47e-07 0.000295 -0.44 -0.4 Height; chr11:118835044 chr11:118704607~118750263:+ PAAD cis rs4722166 0.63 rs7808457 ENSG00000179428.2 AC073072.5 5.33 3.49e-07 0.000296 0.38 0.4 Lung cancer; chr7:22758646 chr7:22725395~22727620:- PAAD cis rs12908161 1 rs12911736 ENSG00000225151.9 GOLGA2P7 -5.33 3.51e-07 0.000298 -0.48 -0.4 Schizophrenia; chr15:84696777 chr15:84199311~84230136:- PAAD cis rs6504622 0.791 rs758392 ENSG00000262879.4 RP11-156P1.3 -5.33 3.51e-07 0.000298 -0.44 -0.4 Orofacial clefts; chr17:46940493 chr17:46984045~47100323:- PAAD cis rs763567 0.933 rs531007 ENSG00000271811.1 RP1-79C4.4 5.33 3.53e-07 0.000299 0.37 0.4 Tonsillectomy; chr1:170649241 chr1:170667381~170669425:+ PAAD cis rs7772486 0.701 rs7772717 ENSG00000235652.6 RP11-545I5.3 5.33 3.53e-07 0.000299 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145633718 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs440477 ENSG00000235652.6 RP11-545I5.3 5.33 3.53e-07 0.000299 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145533052 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs385729 ENSG00000235652.6 RP11-545I5.3 5.33 3.53e-07 0.000299 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145534329 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs7755253 ENSG00000235652.6 RP11-545I5.3 5.33 3.53e-07 0.000299 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145537757 chr6:145799409~145886585:+ PAAD cis rs494459 0.688 rs1048040 ENSG00000255422.1 AP002954.4 -5.33 3.53e-07 0.000299 -0.43 -0.4 Height; chr11:118747911 chr11:118704607~118750263:+ PAAD cis rs7772486 0.754 rs6921073 ENSG00000235652.6 RP11-545I5.3 5.33 3.53e-07 0.000299 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145823241 chr6:145799409~145886585:+ PAAD cis rs494459 0.838 rs1784543 ENSG00000255422.1 AP002954.4 -5.33 3.53e-07 0.000299 -0.43 -0.4 Height; chr11:118760944 chr11:118704607~118750263:+ PAAD cis rs7580658 0.637 rs3902960 ENSG00000236682.1 AC068282.3 -5.33 3.53e-07 0.000299 -0.52 -0.4 Protein C levels; chr2:127230666 chr2:127389130~127400580:+ PAAD cis rs2283792 0.812 rs94194 ENSG00000228050.1 TOP3BP1 5.33 3.54e-07 3e-04 0.44 0.4 Multiple sclerosis; chr22:21933937 chr22:22223187~22224566:- PAAD cis rs2283792 0.812 rs5995269 ENSG00000228050.1 TOP3BP1 5.33 3.54e-07 3e-04 0.44 0.4 Multiple sclerosis; chr22:21935025 chr22:22223187~22224566:- PAAD cis rs7688014 1 rs7688014 ENSG00000246560.2 RP11-10L12.4 5.33 3.54e-07 3e-04 0.44 0.4 Schizophrenia; chr4:103053903 chr4:102828055~102844075:+ PAAD cis rs9309711 0.643 rs4264589 ENSG00000225234.1 TRAPPC12-AS1 -5.33 3.54e-07 3e-04 -0.41 -0.4 Neurofibrillary tangles; chr2:3477327 chr2:3481242~3482409:- PAAD cis rs6570726 0.764 rs376257 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145541813 chr6:145799409~145886585:+ PAAD cis rs6570726 0.693 rs450921 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145543124 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs365747 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145545648 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs448258 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145548009 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs9399553 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145552528 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs408443 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145553507 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs436156 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145553737 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs436498 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145555211 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs446362 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145557580 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs370654 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145557869 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs400329 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145558306 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs414600 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145558470 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs435671 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145560079 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs367065 ENSG00000235652.6 RP11-545I5.3 5.33 3.54e-07 3e-04 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145561173 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs392612 ENSG00000235652.6 RP11-545I5.3 -5.33 3.54e-07 3e-04 -0.32 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145560450 chr6:145799409~145886585:+ PAAD cis rs7615952 0.515 rs4441610 ENSG00000171084.14 FAM86JP 5.33 3.54e-07 3e-04 0.59 0.4 Blood pressure (smoking interaction); chr3:125962464 chr3:125916620~125930024:+ PAAD cis rs8062405 1 rs3888190 ENSG00000251417.2 RP11-1348G14.4 -5.33 3.55e-07 3e-04 -0.35 -0.4 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28878165 chr16:28802743~28817828:+ PAAD cis rs35160687 0.712 rs11127020 ENSG00000273080.1 RP11-301O19.1 -5.33 3.55e-07 3e-04 -0.46 -0.4 Night sleep phenotypes; chr2:86247421 chr2:86195590~86196049:+ PAAD cis rs7772486 0.738 rs2246334 ENSG00000235652.6 RP11-545I5.3 5.33 3.56e-07 0.000301 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145862499 chr6:145799409~145886585:+ PAAD cis rs6504950 1 rs9915183 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54969776 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9895808 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54971081 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9897447 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54971108 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9896044 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54971181 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9902687 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54971563 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs8080491 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54972508 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs6504948 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54972626 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs6504949 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54972772 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9914732 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54977006 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9916642 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54977136 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9915832 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54977336 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9893306 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54977388 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9894529 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54977885 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs6504950 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54979110 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs6504951 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54979614 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9903146 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54980386 chr17:54964474~54964679:+ PAAD cis rs6504950 0.962 rs9902950 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54980403 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9903220 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54980504 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9903444 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54980532 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9903825 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54980553 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs28558726 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54981315 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs16955471 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54981446 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9891865 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54982672 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9892173 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54982853 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs9892976 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54982968 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs1990674 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54983714 chr17:54964474~54964679:+ PAAD cis rs6504950 1 rs10468513 ENSG00000275710.1 RP11-257O5.4 5.33 3.56e-07 0.000301 0.52 0.4 Breast cancer; chr17:54985542 chr17:54964474~54964679:+ PAAD cis rs7772486 0.558 rs2142980 ENSG00000235652.6 RP11-545I5.3 -5.33 3.56e-07 0.000301 -0.37 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145759543 chr6:145799409~145886585:+ PAAD cis rs6991838 0.584 rs7836349 ENSG00000200714.1 Y_RNA -5.32 3.57e-07 0.000302 -0.47 -0.4 Intelligence (multi-trait analysis); chr8:65591328 chr8:65592731~65592820:+ PAAD cis rs9928842 0.882 rs9927264 ENSG00000280152.1 RP11-331F4.5 5.32 3.57e-07 0.000302 0.51 0.4 Alcoholic chronic pancreatitis; chr16:75226343 chr16:75245994~75250077:- PAAD cis rs7712401 0.765 rs10079941 ENSG00000263432.2 RN7SL689P 5.32 3.58e-07 0.000302 0.5 0.4 Mean platelet volume; chr5:123045668 chr5:123022487~123022783:- PAAD cis rs7208859 0.623 rs11657662 ENSG00000266490.1 CTD-2349P21.9 -5.32 3.58e-07 0.000302 -0.51 -0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30749329 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11656844 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733579 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11652533 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733583 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11652631 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30733748 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs79505916 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30735308 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs77498725 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30736968 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs73267865 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737186 chr17:30792372~30792833:+ PAAD cis rs17826219 0.5 rs57005940 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Body mass index; chr17:30739311 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs73267872 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30740189 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs9893922 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Body mass index; chr17:30741407 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs56812022 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741715 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs57670615 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30742480 chr17:30792372~30792833:+ PAAD cis rs17826219 0.5 rs2874724 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Body mass index; chr17:30745415 chr17:30792372~30792833:+ PAAD cis rs17826219 0.568 rs9898097 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Body mass index; chr17:30745654 chr17:30792372~30792833:+ PAAD cis rs17826219 0.5 rs9891256 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Body mass index; chr17:30745674 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9911490 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30745995 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7503542 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746812 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs7503335 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30746944 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs11656278 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748170 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs56031503 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000302 0.51 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748647 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs1347359 ENSG00000266490.1 CTD-2349P21.9 5.32 3.58e-07 0.000303 0.48 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587511 chr17:30792372~30792833:+ PAAD cis rs7772486 0.72 rs6901888 ENSG00000235652.6 RP11-545I5.3 -5.32 3.59e-07 0.000303 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145702008 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs4896841 ENSG00000235652.6 RP11-545I5.3 -5.32 3.59e-07 0.000303 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145720386 chr6:145799409~145886585:+ PAAD cis rs526231 0.543 rs152123 ENSG00000175749.11 EIF3KP1 -5.32 3.59e-07 0.000303 -0.53 -0.4 Primary biliary cholangitis; chr5:103196218 chr5:103032376~103033031:+ PAAD cis rs7772486 0.846 rs2492856 ENSG00000235652.6 RP11-545I5.3 5.32 3.6e-07 0.000304 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146002792 chr6:145799409~145886585:+ PAAD cis rs763567 0.626 rs1234230 ENSG00000271811.1 RP1-79C4.4 -5.32 3.6e-07 0.000304 -0.35 -0.4 Tonsillectomy; chr1:170602702 chr1:170667381~170669425:+ PAAD cis rs763567 0.605 rs647438 ENSG00000271811.1 RP1-79C4.4 -5.32 3.6e-07 0.000304 -0.35 -0.4 Tonsillectomy; chr1:170608094 chr1:170667381~170669425:+ PAAD cis rs7712401 0.715 rs6859163 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123019225 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs385996 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123019533 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs436160 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123020258 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs434789 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123021615 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs1139334 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123022724 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs1062350 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123022811 chr5:123022487~123022783:- PAAD cis rs7712401 0.678 rs401535 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123022990 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs15577 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123023495 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs451195 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123023945 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs6862366 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123024463 chr5:123022487~123022783:- PAAD cis rs7712401 0.715 rs407392 ENSG00000263432.2 RN7SL689P -5.32 3.6e-07 0.000304 -0.51 -0.4 Mean platelet volume; chr5:123025299 chr5:123022487~123022783:- PAAD cis rs274567 0.711 rs404771 ENSG00000233006.5 AC034220.3 5.32 3.6e-07 0.000304 0.36 0.4 Blood metabolite levels; chr5:132299399 chr5:132311285~132369916:- PAAD cis rs6860806 0.531 rs270612 ENSG00000233006.5 AC034220.3 5.32 3.6e-07 0.000304 0.36 0.4 Breast cancer; chr5:132301645 chr5:132311285~132369916:- PAAD cis rs7772486 0.701 rs697056 ENSG00000235652.6 RP11-545I5.3 -5.32 3.6e-07 0.000304 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145682761 chr6:145799409~145886585:+ PAAD cis rs17301013 0.507 rs72715260 ENSG00000227373.4 RP11-160H22.5 5.32 3.61e-07 0.000305 0.61 0.4 Systemic lupus erythematosus; chr1:174604995 chr1:174115300~174160004:- PAAD cis rs6570726 0.791 rs6915094 ENSG00000235652.6 RP11-545I5.3 5.32 3.63e-07 0.000306 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145562404 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs365869 ENSG00000235652.6 RP11-545I5.3 5.32 3.63e-07 0.000306 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:145563615 chr6:145799409~145886585:+ PAAD cis rs10875746 1 rs10875746 ENSG00000240399.1 RP1-228P16.1 -5.32 3.63e-07 0.000306 -0.44 -0.4 Longevity (90 years and older); chr12:48124481 chr12:48054813~48055591:- PAAD cis rs1928295 1 rs7047007 ENSG00000233569.1 RP11-500B12.1 5.32 3.64e-07 0.000307 0.44 0.4 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117609256 chr9:117648606~117657027:+ PAAD cis rs72772090 0.908 rs72772091 ENSG00000248734.2 CTD-2260A17.1 -5.32 3.64e-07 0.000307 -0.48 -0.4 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96704418 chr5:96784777~96785999:+ PAAD cis rs4722166 0.598 rs4722180 ENSG00000179428.2 AC073072.5 -5.32 3.64e-07 0.000307 -0.35 -0.4 Lung cancer; chr7:22765453 chr7:22725395~22727620:- PAAD cis rs7208859 0.673 rs11653955 ENSG00000266490.1 CTD-2349P21.9 5.32 3.64e-07 0.000307 0.52 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30706274 chr17:30792372~30792833:+ PAAD cis rs858239 0.669 rs1990365 ENSG00000226816.2 AC005082.12 5.32 3.65e-07 0.000308 0.44 0.4 Cerebrospinal fluid biomarker levels; chr7:23076347 chr7:23206013~23208045:+ PAAD cis rs2739330 0.796 rs1006771 ENSG00000250470.1 AP000351.3 5.32 3.66e-07 0.000309 0.56 0.4 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23976904~23977585:- PAAD cis rs1150668 0.796 rs9468372 ENSG00000216901.1 AL022393.7 5.32 3.66e-07 0.000309 0.47 0.4 Pubertal anthropometrics; chr6:28411584 chr6:28176188~28176674:+ PAAD cis rs1075265 0.749 rs2692518 ENSG00000233266.1 HMGB1P31 5.32 3.66e-07 0.000309 0.5 0.4 Chronotype;Morning vs. evening chronotype; chr2:53804746 chr2:54051334~54051760:+ PAAD cis rs3858145 0.546 rs7912806 ENSG00000233590.1 RP11-153K11.3 5.32 3.67e-07 0.000309 0.53 0.4 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68296578 chr10:68233251~68242379:- PAAD cis rs853679 0.517 rs1340004 ENSG00000226314.6 ZNF192P1 -5.32 3.67e-07 0.000309 -0.66 -0.4 Depression; chr6:28135913 chr6:28161781~28169594:+ PAAD cis rs12908161 1 rs60957376 ENSG00000225151.9 GOLGA2P7 -5.32 3.68e-07 0.00031 -0.48 -0.4 Schizophrenia; chr15:84737561 chr15:84199311~84230136:- PAAD cis rs494459 0.838 rs555639 ENSG00000255422.1 AP002954.4 5.32 3.68e-07 0.00031 0.43 0.4 Height; chr11:118758322 chr11:118704607~118750263:+ PAAD cis rs853679 0.517 rs17711344 ENSG00000226314.6 ZNF192P1 5.32 3.69e-07 0.00031 0.67 0.4 Depression; chr6:28109824 chr6:28161781~28169594:+ PAAD cis rs12908161 1 rs12905057 ENSG00000225151.9 GOLGA2P7 -5.32 3.69e-07 0.000311 -0.48 -0.4 Schizophrenia; chr15:84667534 chr15:84199311~84230136:- PAAD cis rs12701220 0.655 rs7778968 ENSG00000229043.2 AC091729.9 -5.32 3.7e-07 0.000312 -0.52 -0.4 Bronchopulmonary dysplasia; chr7:1104986 chr7:1160374~1165267:+ PAAD cis rs380904 0.519 rs12541790 ENSG00000254859.1 RP11-661A12.5 -5.32 3.7e-07 0.000312 -0.75 -0.4 Venous thromboembolism (SNP x SNP interaction); chr8:143561151 chr8:143541973~143549729:- PAAD cis rs7772486 0.875 rs2748502 ENSG00000235652.6 RP11-545I5.3 5.32 3.71e-07 0.000312 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145977103 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs864390 ENSG00000235652.6 RP11-545I5.3 5.32 3.71e-07 0.000312 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145993899 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2748490 ENSG00000235652.6 RP11-545I5.3 5.32 3.71e-07 0.000312 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146008545 chr6:145799409~145886585:+ PAAD cis rs4698412 0.646 rs4698120 ENSG00000214846.4 RP11-115L11.1 -5.32 3.71e-07 0.000312 -0.46 -0.4 Parkinson's disease; chr4:15741709 chr4:15730962~15731627:- PAAD cis rs7772486 0.79 rs2249386 ENSG00000235652.6 RP11-545I5.3 5.32 3.71e-07 0.000312 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145865475 chr6:145799409~145886585:+ PAAD cis rs10463554 0.927 rs55641526 ENSG00000175749.11 EIF3KP1 5.32 3.73e-07 0.000313 0.51 0.4 Parkinson's disease; chr5:102915301 chr5:103032376~103033031:+ PAAD cis rs7945705 0.776 rs2316865 ENSG00000254860.4 TMEM9B-AS1 -5.32 3.74e-07 0.000314 -0.44 -0.4 Hemoglobin concentration; chr11:8793923 chr11:8964675~8977527:+ PAAD cis rs172166 0.561 rs149973 ENSG00000204709.4 LINC01556 5.31 3.74e-07 0.000314 0.54 0.4 Cardiac Troponin-T levels; chr6:28015835 chr6:28943877~28944537:+ PAAD cis rs172166 0.561 rs149974 ENSG00000204709.4 LINC01556 5.31 3.74e-07 0.000314 0.54 0.4 Cardiac Troponin-T levels; chr6:28017318 chr6:28943877~28944537:+ PAAD cis rs748404 0.66 rs2467738 ENSG00000249839.1 AC011330.5 -5.31 3.74e-07 0.000314 -0.58 -0.4 Lung cancer; chr15:43447738 chr15:43663654~43684339:- PAAD cis rs7772486 0.846 rs2748496 ENSG00000235652.6 RP11-545I5.3 5.31 3.74e-07 0.000314 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:146000693 chr6:145799409~145886585:+ PAAD cis rs7208859 0.673 rs73263981 ENSG00000266490.1 CTD-2349P21.9 5.31 3.74e-07 0.000314 0.48 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593484 chr17:30792372~30792833:+ PAAD cis rs7772486 0.686 rs857880 ENSG00000235652.6 RP11-545I5.3 -5.31 3.75e-07 0.000315 -0.32 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145649979 chr6:145799409~145886585:+ PAAD cis rs9309711 0.689 rs4535075 ENSG00000225234.1 TRAPPC12-AS1 -5.31 3.75e-07 0.000315 -0.41 -0.4 Neurofibrillary tangles; chr2:3477945 chr2:3481242~3482409:- PAAD cis rs9309711 0.666 rs6767 ENSG00000225234.1 TRAPPC12-AS1 -5.31 3.75e-07 0.000315 -0.41 -0.4 Neurofibrillary tangles; chr2:3479434 chr2:3481242~3482409:- PAAD cis rs9309711 0.623 rs7569694 ENSG00000225234.1 TRAPPC12-AS1 -5.31 3.75e-07 0.000315 -0.41 -0.4 Neurofibrillary tangles; chr2:3479619 chr2:3481242~3482409:- PAAD cis rs9309711 0.666 rs6723101 ENSG00000225234.1 TRAPPC12-AS1 -5.31 3.75e-07 0.000315 -0.41 -0.4 Neurofibrillary tangles; chr2:3480672 chr2:3481242~3482409:- PAAD cis rs9309711 0.666 rs6723126 ENSG00000225234.1 TRAPPC12-AS1 -5.31 3.75e-07 0.000315 -0.41 -0.4 Neurofibrillary tangles; chr2:3480729 chr2:3481242~3482409:- PAAD cis rs7772486 0.875 rs9322048 ENSG00000235652.6 RP11-545I5.3 5.31 3.75e-07 0.000315 0.32 0.4 Lobe attachment (rater-scored or self-reported); chr6:146079303 chr6:145799409~145886585:+ PAAD cis rs35160687 0.712 rs9677502 ENSG00000273080.1 RP11-301O19.1 -5.31 3.76e-07 0.000316 -0.46 -0.4 Night sleep phenotypes; chr2:86253815 chr2:86195590~86196049:+ PAAD cis rs1075265 0.756 rs2542576 ENSG00000233266.1 HMGB1P31 5.31 3.76e-07 0.000316 0.5 0.4 Chronotype;Morning vs. evening chronotype; chr2:53821659 chr2:54051334~54051760:+ PAAD cis rs7208859 0.623 rs7214570 ENSG00000266490.1 CTD-2349P21.9 5.31 3.76e-07 0.000316 0.5 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30820146 chr17:30792372~30792833:+ PAAD cis rs526231 0.543 rs62362521 ENSG00000175749.11 EIF3KP1 5.31 3.77e-07 0.000316 0.51 0.4 Primary biliary cholangitis; chr5:102970357 chr5:103032376~103033031:+ PAAD cis rs526231 0.575 rs12652973 ENSG00000175749.11 EIF3KP1 5.31 3.77e-07 0.000316 0.51 0.4 Primary biliary cholangitis; chr5:102970618 chr5:103032376~103033031:+ PAAD cis rs526231 0.575 rs66730942 ENSG00000175749.11 EIF3KP1 5.31 3.77e-07 0.000316 0.51 0.4 Primary biliary cholangitis; chr5:102971075 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs6880911 ENSG00000175749.11 EIF3KP1 5.31 3.77e-07 0.000316 0.51 0.4 Primary biliary cholangitis; chr5:102971767 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs6881225 ENSG00000175749.11 EIF3KP1 5.31 3.77e-07 0.000316 0.51 0.4 Primary biliary cholangitis; chr5:102971888 chr5:103032376~103033031:+ PAAD cis rs526231 0.575 rs62362523 ENSG00000175749.11 EIF3KP1 5.31 3.77e-07 0.000316 0.51 0.4 Primary biliary cholangitis; chr5:102977979 chr5:103032376~103033031:+ PAAD cis rs526231 0.575 rs62362524 ENSG00000175749.11 EIF3KP1 5.31 3.77e-07 0.000316 0.51 0.4 Primary biliary cholangitis; chr5:102978523 chr5:103032376~103033031:+ PAAD cis rs526231 0.543 rs62362541 ENSG00000175749.11 EIF3KP1 5.31 3.77e-07 0.000316 0.51 0.4 Primary biliary cholangitis; chr5:102986744 chr5:103032376~103033031:+ PAAD cis rs9890032 1 rs28539246 ENSG00000266490.1 CTD-2349P21.9 5.31 3.77e-07 0.000316 0.36 0.4 Hip circumference adjusted for BMI; chr17:30899612 chr17:30792372~30792833:+ PAAD cis rs9890032 0.967 rs9897628 ENSG00000266490.1 CTD-2349P21.9 5.31 3.77e-07 0.000316 0.36 0.4 Hip circumference adjusted for BMI; chr17:30899634 chr17:30792372~30792833:+ PAAD cis rs6061231 1 rs6061231 ENSG00000273619.1 RP5-908M14.9 -5.31 3.77e-07 0.000316 -0.32 -0.4 Colorectal cancer; chr20:62381861 chr20:62386303~62386970:- PAAD cis rs2283792 0.764 rs2298432 ENSG00000224086.5 LL22NC03-86G7.1 -5.31 3.77e-07 0.000317 -0.42 -0.4 Multiple sclerosis; chr22:21768900 chr22:21938293~21977632:+ PAAD cis rs367615 0.537 rs17161729 ENSG00000249476.1 CTD-2587M2.1 -5.31 3.78e-07 0.000317 -0.43 -0.4 Colorectal cancer (SNP x SNP interaction); chr5:109324827 chr5:109237120~109326369:- PAAD cis rs748404 0.586 rs2584700 ENSG00000249839.1 AC011330.5 -5.31 3.79e-07 0.000318 -0.58 -0.4 Lung cancer; chr15:43393134 chr15:43663654~43684339:- PAAD cis rs1150668 0.745 rs213238 ENSG00000204709.4 LINC01556 5.31 3.79e-07 0.000318 0.52 0.4 Pubertal anthropometrics; chr6:28354216 chr6:28943877~28944537:+ PAAD cis rs113835537 0.66 rs7116940 ENSG00000255517.5 CTD-3074O7.5 -5.31 3.8e-07 0.000319 -0.52 -0.4 Airway imaging phenotypes; chr11:66536424 chr11:66473490~66480233:- PAAD cis rs4660456 0.913 rs569159 ENSG00000237899.1 RP4-739H11.3 -5.31 3.8e-07 0.000319 -0.52 -0.4 Platelet count; chr1:40701862 chr1:40669089~40687588:- PAAD cis rs4972806 0.849 rs1542180 ENSG00000226363.3 HAGLROS -5.31 3.81e-07 0.000319 -0.48 -0.4 IgG glycosylation; chr2:176164039 chr2:176177717~176179008:+ PAAD cis rs4879677 1 rs10125353 ENSG00000260390.1 RP11-575I8.1 5.31 3.82e-07 0.00032 0.49 0.4 Gut microbiome composition (summer and winter); chr9:27677546 chr9:27829276~27844481:+ PAAD cis rs9926296 0.744 rs6860 ENSG00000260259.1 RP11-368I7.4 5.31 3.82e-07 0.00032 0.5 0.4 Vitiligo; chr16:89644712 chr16:89682620~89686569:- PAAD cis rs7945705 0.782 rs3763918 ENSG00000254860.4 TMEM9B-AS1 -5.31 3.83e-07 0.000321 -0.43 -0.4 Hemoglobin concentration; chr11:8798136 chr11:8964675~8977527:+ PAAD cis rs1275468 1 rs1148005 ENSG00000257497.2 RP11-585P4.5 -5.31 3.83e-07 0.000321 -0.58 -0.4 Polycystic ovary syndrome; chr12:75584733 chr12:75483454~75489820:- PAAD cis rs7208859 0.623 rs216436 ENSG00000266490.1 CTD-2349P21.9 5.31 3.83e-07 0.000321 0.5 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595882 chr17:30792372~30792833:+ PAAD cis rs1075265 0.783 rs805438 ENSG00000233266.1 HMGB1P31 5.31 3.85e-07 0.000322 0.51 0.4 Chronotype;Morning vs. evening chronotype; chr2:53829051 chr2:54051334~54051760:+ PAAD cis rs6504622 1 rs4968286 ENSG00000262879.4 RP11-156P1.3 -5.31 3.85e-07 0.000322 -0.4 -0.4 Orofacial clefts; chr17:46940279 chr17:46984045~47100323:- PAAD cis rs7772486 0.738 rs75288066 ENSG00000235652.6 RP11-545I5.3 5.31 3.87e-07 0.000324 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145998250 chr6:145799409~145886585:+ PAAD cis rs7772486 0.713 rs79248977 ENSG00000235652.6 RP11-545I5.3 5.31 3.87e-07 0.000324 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145998252 chr6:145799409~145886585:+ PAAD cis rs9549328 0.731 rs7983602 ENSG00000267868.1 RP11-120K24.3 5.31 3.88e-07 0.000325 0.44 0.4 Systolic blood pressure; chr13:112966168 chr13:112964835~112966131:- PAAD cis rs1400745 0.718 rs1200414 ENSG00000258738.1 RP11-73E17.2 5.31 3.88e-07 0.000325 0.46 0.4 Monocyte count; chr14:34861687 chr14:34874343~34876459:+ PAAD cis rs465969 1 rs465969 ENSG00000255389.1 C6orf3 -5.31 3.89e-07 0.000326 -0.52 -0.4 Psoriasis; chr6:111334327 chr6:111599875~111602295:+ PAAD cis rs801193 0.844 rs2244022 ENSG00000237310.1 GS1-124K5.4 5.31 3.89e-07 0.000326 0.37 0.4 Aortic root size; chr7:66737443 chr7:66493706~66495474:+ PAAD cis rs2274273 0.87 rs61210954 ENSG00000258413.1 RP11-665C16.6 -5.31 3.9e-07 0.000327 -0.5 -0.4 Protein biomarker; chr14:55298684 chr14:55262767~55272075:- PAAD cis rs10875746 0.669 rs11168508 ENSG00000240399.1 RP1-228P16.1 -5.31 3.9e-07 0.000327 -0.44 -0.4 Longevity (90 years and older); chr12:48289728 chr12:48054813~48055591:- PAAD cis rs4660456 0.913 rs3767951 ENSG00000237899.1 RP4-739H11.3 -5.31 3.9e-07 0.000327 -0.54 -0.4 Platelet count; chr1:40767359 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs3767950 ENSG00000237899.1 RP4-739H11.3 -5.31 3.9e-07 0.000327 -0.54 -0.4 Platelet count; chr1:40767541 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs3754179 ENSG00000237899.1 RP4-739H11.3 -5.31 3.9e-07 0.000327 -0.54 -0.4 Platelet count; chr1:40768464 chr1:40669089~40687588:- PAAD cis rs9322193 0.884 rs7743823 ENSG00000223701.3 RAET1E-AS1 5.31 3.9e-07 0.000327 0.47 0.4 Lung cancer; chr6:149849744 chr6:149884431~149919508:+ PAAD cis rs6700559 0.873 rs7526367 ENSG00000260088.1 RP11-92G12.3 -5.31 3.9e-07 0.000327 -0.52 -0.4 Coronary artery disease; chr1:200688025 chr1:200669507~200694250:+ PAAD cis rs1275468 0.798 rs10879928 ENSG00000257497.2 RP11-585P4.5 5.31 3.91e-07 0.000327 0.56 0.4 Polycystic ovary syndrome; chr12:75531996 chr12:75483454~75489820:- PAAD cis rs2524005 1 rs2524005 ENSG00000176998.4 HCG4 -5.3 3.92e-07 0.000328 -0.57 -0.4 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29791753~29792750:- PAAD cis rs4722166 0.564 rs1800797 ENSG00000179428.2 AC073072.5 -5.3 3.92e-07 0.000328 -0.4 -0.4 Lung cancer; chr7:22726602 chr7:22725395~22727620:- PAAD cis rs80285556 1 rs111902838 ENSG00000161643.11 SIGLEC16 5.3 3.92e-07 0.000328 0.97 0.4 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:49993357 chr19:49969673~49975814:+ PAAD cis rs3858145 0.588 rs61854837 ENSG00000233590.1 RP11-153K11.3 -5.3 3.92e-07 0.000328 -0.56 -0.4 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68282613 chr10:68233251~68242379:- PAAD cis rs2243480 0.803 rs55700941 ENSG00000226824.5 RP4-756H11.3 -5.3 3.93e-07 0.000328 -0.72 -0.4 Diabetic kidney disease; chr7:65924813 chr7:66654538~66669855:+ PAAD cis rs7188445 0.899 rs7195321 ENSG00000261390.4 RP11-345M22.2 -5.3 3.93e-07 0.000329 -0.53 -0.4 Urate levels; chr16:79701065 chr16:79715232~79770563:- PAAD cis rs7208859 0.673 rs75142521 ENSG00000266490.1 CTD-2349P21.9 5.3 3.93e-07 0.000329 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913519 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs12949860 ENSG00000266490.1 CTD-2349P21.9 5.3 3.93e-07 0.000329 0.53 0.4 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896014 chr17:30792372~30792833:+ PAAD cis rs7250849 1 rs7250849 ENSG00000273837.1 LLNLR-470E3.1 5.3 3.93e-07 0.000329 0.53 0.4 Blood protein levels; chr19:51655063 chr19:51639478~51639931:- PAAD cis rs853679 0.527 rs213228 ENSG00000204709.4 LINC01556 5.3 3.94e-07 0.000329 0.56 0.4 Depression; chr6:28363475 chr6:28943877~28944537:+ PAAD cis rs2799081 1 rs2799081 ENSG00000204709.4 LINC01556 5.3 3.94e-07 0.00033 0.58 0.4 Myopia; chr6:28302807 chr6:28943877~28944537:+ PAAD cis rs10463554 0.892 rs1561404 ENSG00000175749.11 EIF3KP1 5.3 3.94e-07 0.00033 0.5 0.4 Parkinson's disease; chr5:102963647 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs1560040 ENSG00000175749.11 EIF3KP1 5.3 3.94e-07 0.00033 0.5 0.4 Parkinson's disease; chr5:102964363 chr5:103032376~103033031:+ PAAD cis rs7772486 0.658 rs9403737 ENSG00000235652.6 RP11-545I5.3 5.3 3.95e-07 0.00033 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145641057 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs4896832 ENSG00000235652.6 RP11-545I5.3 5.3 3.95e-07 0.00033 0.33 0.4 Lobe attachment (rater-scored or self-reported); chr6:145643015 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs857883 ENSG00000235652.6 RP11-545I5.3 -5.3 3.95e-07 0.00033 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145648078 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs857882 ENSG00000235652.6 RP11-545I5.3 -5.3 3.95e-07 0.00033 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145648580 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs857877 ENSG00000235652.6 RP11-545I5.3 -5.3 3.95e-07 0.00033 -0.33 -0.4 Lobe attachment (rater-scored or self-reported); chr6:145655094 chr6:145799409~145886585:+ PAAD cis rs189798 0.738 rs330908 ENSG00000254340.1 RP11-10A14.3 5.3 3.95e-07 0.00033 0.51 0.4 Myopia (pathological); chr8:9137656 chr8:9141424~9145435:+ PAAD cis rs673078 0.66 rs6490175 ENSG00000275759.1 RP11-131L12.3 -5.3 3.95e-07 0.00033 -0.49 -0.4 Glucose homeostasis traits; chr12:118293559 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs9943819 ENSG00000275759.1 RP11-131L12.3 -5.3 3.95e-07 0.00033 -0.49 -0.4 Glucose homeostasis traits; chr12:118298917 chr12:118428281~118428870:+ PAAD cis rs111580313 0.685 rs76570728 ENSG00000270020.1 RP11-463O9.9 5.3 3.96e-07 0.000331 1.06 0.4 Systemic juvenile idiopathic arthritis; chr16:86561849 chr16:86520383~86523897:- PAAD cis rs67180937 0.583 rs2936052 ENSG00000272750.1 RP11-378J18.8 5.3 3.98e-07 0.000332 0.46 0.4 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222629034 chr1:222658867~222661512:- PAAD cis rs853679 0.517 rs9380052 ENSG00000226314.6 ZNF192P1 -5.3 3.99e-07 0.000333 -0.66 -0.4 Depression; chr6:28096845 chr6:28161781~28169594:+ PAAD cis rs228614 0.509 rs223486 ENSG00000246560.2 RP11-10L12.4 5.3 3.99e-07 0.000333 0.43 0.39 Primary sclerosing cholangitis;Multiple sclerosis; chr4:102763796 chr4:102828055~102844075:+ PAAD cis rs2115630 1 rs6496452 ENSG00000259728.4 LINC00933 -5.3 4e-07 0.000334 -0.49 -0.39 P wave terminal force; chr15:84829414 chr15:84570649~84580175:+ PAAD cis rs7829975 0.902 rs777707 ENSG00000253893.2 FAM85B -5.3 4e-07 0.000334 -0.56 -0.39 Mood instability; chr8:8726834 chr8:8167819~8226614:- PAAD cis rs3931020 0.626 rs277402 ENSG00000272864.1 RP11-17E13.2 5.3 4.01e-07 0.000334 0.57 0.39 Resistin levels; chr1:74722637 chr1:74698769~74699333:- PAAD cis rs2581828 0.931 rs2336722 ENSG00000242142.1 SERBP1P3 5.3 4.01e-07 0.000335 0.46 0.39 Crohn's disease; chr3:53105961 chr3:53064283~53065091:- PAAD cis rs2274273 0.6 rs10131730 ENSG00000258413.1 RP11-665C16.6 -5.3 4.01e-07 0.000335 -0.54 -0.39 Protein biomarker; chr14:55373374 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs12050123 ENSG00000258413.1 RP11-665C16.6 -5.3 4.01e-07 0.000335 -0.54 -0.39 Protein biomarker; chr14:55373668 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs10132453 ENSG00000258413.1 RP11-665C16.6 -5.3 4.01e-07 0.000335 -0.54 -0.39 Protein biomarker; chr14:55374133 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs8014540 ENSG00000258413.1 RP11-665C16.6 -5.3 4.01e-07 0.000335 -0.54 -0.39 Protein biomarker; chr14:55374970 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs67412516 ENSG00000258413.1 RP11-665C16.6 -5.3 4.01e-07 0.000335 -0.54 -0.39 Protein biomarker; chr14:55386519 chr14:55262767~55272075:- PAAD cis rs12468226 1 rs3731696 ENSG00000273456.1 RP11-686O6.2 5.3 4.02e-07 0.000335 0.62 0.39 Urate levels; chr2:202567081 chr2:202374932~202375604:- PAAD cis rs12468226 0.81 rs115255999 ENSG00000273456.1 RP11-686O6.2 5.3 4.02e-07 0.000335 0.62 0.39 Urate levels; chr2:202572326 chr2:202374932~202375604:- PAAD cis rs6921919 0.789 rs11970439 ENSG00000204709.4 LINC01556 5.3 4.02e-07 0.000335 0.65 0.39 Autism spectrum disorder or schizophrenia; chr6:28335687 chr6:28943877~28944537:+ PAAD cis rs2111504 0.559 rs7250813 ENSG00000267213.4 AC007773.2 5.3 4.03e-07 0.000336 0.5 0.39 Bipolar disorder; chr19:32358815 chr19:32390050~32405560:- PAAD cis rs3762637 1 rs76599189 ENSG00000272758.4 RP11-299J3.8 -5.3 4.03e-07 0.000336 -0.59 -0.39 LDL cholesterol levels; chr3:122405229 chr3:122416207~122443180:+ PAAD cis rs3762637 1 rs7615673 ENSG00000272758.4 RP11-299J3.8 -5.3 4.03e-07 0.000336 -0.59 -0.39 LDL cholesterol levels; chr3:122406697 chr3:122416207~122443180:+ PAAD cis rs950169 0.922 rs17531523 ENSG00000259295.5 CSPG4P12 5.3 4.04e-07 0.000336 0.43 0.39 Schizophrenia; chr15:84589218 chr15:85191438~85213905:+ PAAD cis rs9532669 0.963 rs4600338 ENSG00000176268.5 CYCSP34 5.3 4.04e-07 0.000337 0.37 0.39 Cervical cancer; chr13:40925175 chr13:40863599~40863902:- PAAD cis rs1185460 0.565 rs540261 ENSG00000271751.1 RP11-110I1.14 5.3 4.06e-07 0.000338 0.53 0.39 Coronary artery disease; chr11:119076924 chr11:119065263~119065677:- PAAD cis rs7829975 0.811 rs7011229 ENSG00000253893.2 FAM85B 5.3 4.07e-07 0.000339 0.58 0.39 Mood instability; chr8:8685814 chr8:8167819~8226614:- PAAD cis rs1275468 1 rs3847669 ENSG00000257497.2 RP11-585P4.5 -5.3 4.07e-07 0.000339 -0.57 -0.39 Polycystic ovary syndrome; chr12:75555378 chr12:75483454~75489820:- PAAD cis rs2404602 0.735 rs2957614 ENSG00000259422.1 RP11-593F23.1 5.3 4.07e-07 0.000339 0.49 0.39 Blood metabolite levels; chr15:76404294 chr15:76174891~76181486:- PAAD cis rs2243480 0.908 rs4718273 ENSG00000226824.5 RP4-756H11.3 5.3 4.08e-07 0.000339 0.71 0.39 Diabetic kidney disease; chr7:65751112 chr7:66654538~66669855:+ PAAD cis rs6538678 0.929 rs10735336 ENSG00000258343.1 RP11-536G4.2 -5.3 4.08e-07 0.000339 -0.51 -0.39 Lupus nephritis in systemic lupus erythematosus; chr12:95869661 chr12:95795345~95858839:- PAAD cis rs2283792 0.765 rs9340 ENSG00000224086.5 LL22NC03-86G7.1 -5.3 4.08e-07 0.00034 -0.4 -0.39 Multiple sclerosis; chr22:21761064 chr22:21938293~21977632:+ PAAD cis rs2283792 0.765 rs1063311 ENSG00000224086.5 LL22NC03-86G7.1 -5.3 4.08e-07 0.00034 -0.4 -0.39 Multiple sclerosis; chr22:21762178 chr22:21938293~21977632:+ PAAD cis rs2283792 0.765 rs2266966 ENSG00000224086.5 LL22NC03-86G7.1 -5.3 4.08e-07 0.00034 -0.4 -0.39 Multiple sclerosis; chr22:21767265 chr22:21938293~21977632:+ PAAD cis rs17507216 0.667 rs13379724 ENSG00000278603.1 RP13-608F4.5 5.3 4.08e-07 0.00034 0.59 0.39 Excessive daytime sleepiness; chr15:82619892 chr15:82472203~82472426:+ PAAD cis rs9926296 0.715 rs2115401 ENSG00000260259.1 RP11-368I7.4 -5.3 4.09e-07 0.000341 -0.47 -0.39 Vitiligo; chr16:89674201 chr16:89682620~89686569:- PAAD cis rs2243480 1 rs1723267 ENSG00000226824.5 RP4-756H11.3 -5.29 4.1e-07 0.000342 -0.71 -0.39 Diabetic kidney disease; chr7:66008327 chr7:66654538~66669855:+ PAAD cis rs9926296 0.605 rs12448860 ENSG00000260259.1 RP11-368I7.4 -5.29 4.11e-07 0.000342 -0.48 -0.39 Vitiligo; chr16:89783221 chr16:89682620~89686569:- PAAD cis rs9926296 0.605 rs12709094 ENSG00000260259.1 RP11-368I7.4 -5.29 4.11e-07 0.000342 -0.48 -0.39 Vitiligo; chr16:89786609 chr16:89682620~89686569:- PAAD cis rs9926296 0.605 rs8047486 ENSG00000260259.1 RP11-368I7.4 -5.29 4.11e-07 0.000342 -0.48 -0.39 Vitiligo; chr16:89787617 chr16:89682620~89686569:- PAAD cis rs1075265 0.783 rs805424 ENSG00000233266.1 HMGB1P31 5.29 4.11e-07 0.000342 0.52 0.39 Chronotype;Morning vs. evening chronotype; chr2:53901098 chr2:54051334~54051760:+ PAAD cis rs9322193 0.884 rs7769115 ENSG00000223701.3 RAET1E-AS1 5.29 4.11e-07 0.000342 0.47 0.39 Lung cancer; chr6:149848796 chr6:149884431~149919508:+ PAAD cis rs10463554 0.892 rs10463988 ENSG00000175749.11 EIF3KP1 5.29 4.11e-07 0.000342 0.51 0.39 Parkinson's disease; chr5:102913595 chr5:103032376~103033031:+ PAAD cis rs10875746 0.624 rs10875777 ENSG00000240399.1 RP1-228P16.1 -5.29 4.11e-07 0.000342 -0.43 -0.39 Longevity (90 years and older); chr12:48228288 chr12:48054813~48055591:- PAAD cis rs10875746 0.669 rs61941006 ENSG00000240399.1 RP1-228P16.1 -5.29 4.11e-07 0.000342 -0.43 -0.39 Longevity (90 years and older); chr12:48237350 chr12:48054813~48055591:- PAAD cis rs12439619 0.768 rs28694364 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82208119 chr15:82472993~82513950:- PAAD cis rs12439619 0.81 rs28876157 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82216708 chr15:82472993~82513950:- PAAD cis rs12439619 0.739 rs62012046 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82236824 chr15:82472993~82513950:- PAAD cis rs12439619 0.774 rs62012047 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82236852 chr15:82472993~82513950:- PAAD cis rs12439619 0.81 rs62012049 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82237722 chr15:82472993~82513950:- PAAD cis rs12439619 0.846 rs28470877 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82245797 chr15:82472993~82513950:- PAAD cis rs12439619 0.846 rs62012056 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82247278 chr15:82472993~82513950:- PAAD cis rs12439619 0.846 rs62012059 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82251669 chr15:82472993~82513950:- PAAD cis rs12439619 0.774 rs2867649 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82262331 chr15:82472993~82513950:- PAAD cis rs12439619 0.846 rs28697264 ENSG00000255769.6 GOLGA2P10 -5.29 4.11e-07 0.000342 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82265559 chr15:82472993~82513950:- PAAD cis rs9322193 1 rs9377229 ENSG00000216906.2 RP11-350J20.9 5.29 4.11e-07 0.000342 0.49 0.39 Lung cancer; chr6:149607655 chr6:149904243~149906418:+ PAAD cis rs6860806 0.507 rs274570 ENSG00000233006.5 AC034220.3 -5.29 4.11e-07 0.000342 -0.35 -0.39 Breast cancer; chr5:132377534 chr5:132311285~132369916:- PAAD cis rs4879677 1 rs10812637 ENSG00000260390.1 RP11-575I8.1 -5.29 4.11e-07 0.000342 -0.51 -0.39 Gut microbiome composition (summer and winter); chr9:27664832 chr9:27829276~27844481:+ PAAD cis rs6860806 0.507 rs2631364 ENSG00000233006.5 AC034220.3 -5.29 4.12e-07 0.000342 -0.35 -0.39 Breast cancer; chr5:132371222 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs2631362 ENSG00000233006.5 AC034220.3 -5.29 4.12e-07 0.000342 -0.35 -0.39 Breast cancer; chr5:132371601 chr5:132311285~132369916:- PAAD cis rs6860806 0.531 rs2631359 ENSG00000233006.5 AC034220.3 -5.29 4.12e-07 0.000342 -0.35 -0.39 Breast cancer; chr5:132372200 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs582490 ENSG00000233006.5 AC034220.3 -5.29 4.12e-07 0.000342 -0.35 -0.39 Breast cancer; chr5:132374403 chr5:132311285~132369916:- PAAD cis rs274567 0.501 rs581968 ENSG00000233006.5 AC034220.3 -5.29 4.12e-07 0.000342 -0.35 -0.39 Blood metabolite levels; chr5:132374510 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs274572 ENSG00000233006.5 AC034220.3 -5.29 4.12e-07 0.000342 -0.35 -0.39 Breast cancer; chr5:132375225 chr5:132311285~132369916:- PAAD cis rs274567 0.501 rs274571 ENSG00000233006.5 AC034220.3 -5.29 4.12e-07 0.000342 -0.35 -0.39 Blood metabolite levels; chr5:132376433 chr5:132311285~132369916:- PAAD cis rs6782228 0.585 rs2712392 ENSG00000242551.2 POU5F1P6 -5.29 4.13e-07 0.000343 -0.47 -0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128705414 chr3:128674735~128677005:- PAAD cis rs694739 0.93 rs574087 ENSG00000236935.1 AP003774.1 5.29 4.13e-07 0.000343 0.42 0.39 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64335476 chr11:64325050~64329504:- PAAD cis rs11673344 0.868 rs1047333 ENSG00000226686.6 LINC01535 5.29 4.14e-07 0.000345 0.54 0.39 Obesity-related traits; chr19:37151263 chr19:37251912~37265535:+ PAAD cis rs7772486 0.875 rs2777479 ENSG00000235652.6 RP11-545I5.3 5.29 4.16e-07 0.000346 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145988042 chr6:145799409~145886585:+ PAAD cis rs10875746 0.587 rs9788082 ENSG00000240399.1 RP1-228P16.1 -5.29 4.17e-07 0.000346 -0.43 -0.39 Longevity (90 years and older); chr12:48358273 chr12:48054813~48055591:- PAAD cis rs9549328 0.7 rs2185001 ENSG00000267868.1 RP11-120K24.3 5.29 4.17e-07 0.000347 0.44 0.39 Systolic blood pressure; chr13:112962055 chr13:112964835~112966131:- PAAD cis rs7772486 0.727 rs10447449 ENSG00000235652.6 RP11-545I5.3 5.29 4.18e-07 0.000347 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145817571 chr6:145799409~145886585:+ PAAD cis rs8135665 0.6 rs6519096 ENSG00000233739.1 RP5-1039K5.13 5.29 4.18e-07 0.000348 0.5 0.39 Advanced age-related macular degeneration;Age-related macular degeneration; chr22:38055382 chr22:38057180~38073940:- PAAD cis rs8135665 0.6 rs6519097 ENSG00000233739.1 RP5-1039K5.13 5.29 4.18e-07 0.000348 0.5 0.39 Advanced age-related macular degeneration;Age-related macular degeneration; chr22:38055458 chr22:38057180~38073940:- PAAD cis rs34375054 0.738 rs10773145 ENSG00000279233.1 RP11-158L12.4 -5.29 4.18e-07 0.000348 -0.34 -0.39 Post bronchodilator FEV1/FVC ratio; chr12:125141057 chr12:125138245~125141711:+ PAAD cis rs6570726 0.764 rs366673 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145493492 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs447992 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145496048 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs425999 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145498234 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs387376 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145501429 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs1912023 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145503142 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9376945 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145506944 chr6:145799409~145886585:+ PAAD cis rs6570726 0.755 rs451699 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145509458 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs401331 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145510272 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs401561 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145514781 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs405206 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145515737 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs374478 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145518886 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs407887 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145522623 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs451108 ENSG00000235652.6 RP11-545I5.3 5.29 4.19e-07 0.000348 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145523173 chr6:145799409~145886585:+ PAAD cis rs638893 0.947 rs515707 ENSG00000278376.1 RP11-158I9.8 -5.29 4.19e-07 0.000348 -0.53 -0.39 Vitiligo; chr11:118814772 chr11:118791254~118793137:+ PAAD cis rs7208859 0.623 rs11658022 ENSG00000266490.1 CTD-2349P21.9 5.29 4.2e-07 0.000348 0.51 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758341 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73269923 ENSG00000266490.1 CTD-2349P21.9 5.29 4.2e-07 0.000348 0.51 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775553 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs11654035 ENSG00000266490.1 CTD-2349P21.9 5.29 4.2e-07 0.000348 0.51 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809408 chr17:30792372~30792833:+ PAAD cis rs2404602 0.735 rs3765115 ENSG00000259422.1 RP11-593F23.1 -5.29 4.21e-07 0.000349 -0.49 -0.39 Blood metabolite levels; chr15:76381375 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs56246286 ENSG00000259422.1 RP11-593F23.1 -5.29 4.21e-07 0.000349 -0.49 -0.39 Blood metabolite levels; chr15:76398390 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs12903874 ENSG00000259422.1 RP11-593F23.1 -5.29 4.21e-07 0.000349 -0.49 -0.39 Blood metabolite levels; chr15:76400977 chr15:76174891~76181486:- PAAD cis rs2274273 1 rs8011834 ENSG00000258413.1 RP11-665C16.6 -5.29 4.21e-07 0.000349 -0.5 -0.39 Protein biomarker; chr14:55159259 chr14:55262767~55272075:- PAAD cis rs6860806 0.507 rs273912 ENSG00000233006.5 AC034220.3 -5.29 4.21e-07 0.00035 -0.35 -0.39 Breast cancer; chr5:132325656 chr5:132311285~132369916:- PAAD cis rs950027 0.787 rs1153845 ENSG00000259433.2 CTD-2651B20.4 5.29 4.21e-07 0.00035 0.46 0.39 Response to fenofibrate (adiponectin levels); chr15:45432531 chr15:45330209~45332634:- PAAD cis rs9928842 0.771 rs8059190 ENSG00000280152.1 RP11-331F4.5 5.29 4.22e-07 0.00035 0.5 0.39 Alcoholic chronic pancreatitis; chr16:75226899 chr16:75245994~75250077:- PAAD cis rs2858942 0.78 rs2858014 ENSG00000268836.1 LA16c-OS12.2 5.29 4.23e-07 0.00035 0.39 0.39 Mean corpuscular hemoglobin; chr16:198358 chr16:185748~186294:- PAAD cis rs2858942 0.818 rs2685123 ENSG00000268836.1 LA16c-OS12.2 5.29 4.23e-07 0.00035 0.39 0.39 Mean corpuscular hemoglobin; chr16:198419 chr16:185748~186294:- PAAD cis rs7772486 0.79 rs2253768 ENSG00000235652.6 RP11-545I5.3 5.29 4.23e-07 0.000351 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145878786 chr6:145799409~145886585:+ PAAD cis rs2243480 1 rs35820085 ENSG00000226824.5 RP4-756H11.3 -5.29 4.23e-07 0.000351 -0.71 -0.39 Diabetic kidney disease; chr7:65977771 chr7:66654538~66669855:+ PAAD cis rs9926296 0.712 rs447735 ENSG00000260259.1 RP11-368I7.4 5.29 4.23e-07 0.000351 0.49 0.39 Vitiligo; chr16:89667941 chr16:89682620~89686569:- PAAD cis rs6570726 0.537 rs1280279 ENSG00000235652.6 RP11-545I5.3 5.29 4.23e-07 0.000351 0.37 0.39 Lobe attachment (rater-scored or self-reported); chr6:145562912 chr6:145799409~145886585:+ PAAD cis rs11098499 0.954 rs11098524 ENSG00000245958.5 RP11-33B1.1 -5.29 4.23e-07 0.000351 -0.32 -0.39 Corneal astigmatism; chr4:119468877 chr4:119454791~119552025:+ PAAD cis rs9926296 0.605 rs8046243 ENSG00000260259.1 RP11-368I7.4 -5.29 4.25e-07 0.000352 -0.48 -0.39 Vitiligo; chr16:89785725 chr16:89682620~89686569:- PAAD cis rs17023223 0.537 rs10923759 ENSG00000231365.4 RP11-418J17.1 5.29 4.25e-07 0.000353 0.43 0.39 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119149571 chr1:119140396~119275973:+ PAAD cis rs73219805 0.597 rs71517887 ENSG00000228451.3 SDAD1P1 -5.29 4.26e-07 0.000353 -0.69 -0.39 Schizophrenia; chr8:26374081 chr8:26379259~26382953:- PAAD cis rs7826238 0.502 rs10503377 ENSG00000253893.2 FAM85B -5.29 4.26e-07 0.000353 -0.54 -0.39 Systolic blood pressure; chr8:8520912 chr8:8167819~8226614:- PAAD cis rs7916697 0.52 rs10762201 ENSG00000233590.1 RP11-153K11.3 5.29 4.26e-07 0.000353 0.52 0.39 Optic disc area; chr10:68280354 chr10:68233251~68242379:- PAAD cis rs1150668 0.699 rs1531681 ENSG00000216901.1 AL022393.7 5.29 4.27e-07 0.000354 0.43 0.39 Pubertal anthropometrics; chr6:28259100 chr6:28176188~28176674:+ PAAD cis rs2274273 0.624 rs10146637 ENSG00000258413.1 RP11-665C16.6 -5.29 4.28e-07 0.000354 -0.53 -0.39 Protein biomarker; chr14:55278092 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs7155954 ENSG00000258413.1 RP11-665C16.6 -5.29 4.28e-07 0.000354 -0.53 -0.39 Protein biomarker; chr14:55284225 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs7154796 ENSG00000258413.1 RP11-665C16.6 -5.29 4.28e-07 0.000354 -0.53 -0.39 Protein biomarker; chr14:55304740 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs10129505 ENSG00000258413.1 RP11-665C16.6 -5.29 4.28e-07 0.000354 -0.53 -0.39 Protein biomarker; chr14:55309657 chr14:55262767~55272075:- PAAD cis rs2274273 0.6 rs35112084 ENSG00000258413.1 RP11-665C16.6 -5.29 4.28e-07 0.000354 -0.53 -0.39 Protein biomarker; chr14:55314382 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs1972221 ENSG00000258413.1 RP11-665C16.6 -5.29 4.28e-07 0.000354 -0.53 -0.39 Protein biomarker; chr14:55318663 chr14:55262767~55272075:- PAAD cis rs9322193 0.884 rs880245 ENSG00000223701.3 RAET1E-AS1 -5.28 4.29e-07 0.000356 -0.46 -0.39 Lung cancer; chr6:149846262 chr6:149884431~149919508:+ PAAD cis rs9549328 0.67 rs2873372 ENSG00000267868.1 RP11-120K24.3 5.28 4.3e-07 0.000356 0.44 0.39 Systolic blood pressure; chr13:112959069 chr13:112964835~112966131:- PAAD cis rs11673344 0.864 rs7247589 ENSG00000226686.6 LINC01535 5.28 4.3e-07 0.000356 0.54 0.39 Obesity-related traits; chr19:37019879 chr19:37251912~37265535:+ PAAD cis rs2115630 1 rs2115630 ENSG00000259728.4 LINC00933 -5.28 4.31e-07 0.000357 -0.49 -0.39 P wave terminal force; chr15:84821285 chr15:84570649~84580175:+ PAAD cis rs2283792 0.812 rs240064 ENSG00000228050.1 TOP3BP1 -5.28 4.31e-07 0.000357 -0.42 -0.39 Multiple sclerosis; chr22:21927265 chr22:22223187~22224566:- PAAD cis rs2599510 0.703 rs58852184 ENSG00000276334.1 AL133243.1 5.28 4.32e-07 0.000357 0.48 0.39 Interleukin-18 levels; chr2:32504696 chr2:32521927~32523547:+ PAAD cis rs9828933 0.678 rs704366 ENSG00000280620.1 SCAANT1 -5.28 4.32e-07 0.000358 -0.61 -0.39 Type 2 diabetes; chr3:63885972 chr3:63911518~63911772:- PAAD cis rs6844153 0.941 rs75656258 ENSG00000240005.4 RP11-293A21.1 -5.28 4.32e-07 0.000358 -0.65 -0.39 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26843577 chr4:26859806~26860599:- PAAD cis rs7772486 0.875 rs10457796 ENSG00000235652.6 RP11-545I5.3 5.28 4.33e-07 0.000358 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:146094951 chr6:145799409~145886585:+ PAAD cis rs11089937 0.963 rs5757078 ENSG00000211639.2 IGLV4-60 5.28 4.33e-07 0.000358 0.36 0.39 Periodontitis (PAL4Q3); chr22:22145526 chr22:22162199~22162681:+ PAAD cis rs7772486 0.738 rs9485039 ENSG00000235652.6 RP11-545I5.3 5.28 4.33e-07 0.000358 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145998251 chr6:145799409~145886585:+ PAAD cis rs2115630 0.875 rs8039472 ENSG00000225151.9 GOLGA2P7 5.28 4.33e-07 0.000359 0.46 0.39 P wave terminal force; chr15:84818413 chr15:84199311~84230136:- PAAD cis rs9322193 1 rs58189451 ENSG00000216906.2 RP11-350J20.9 5.28 4.34e-07 0.000359 0.5 0.39 Lung cancer; chr6:149600252 chr6:149904243~149906418:+ PAAD cis rs380904 0.519 rs1377663 ENSG00000254859.1 RP11-661A12.5 -5.28 4.37e-07 0.000361 -0.73 -0.39 Venous thromboembolism (SNP x SNP interaction); chr8:143562617 chr8:143541973~143549729:- PAAD cis rs12908161 1 rs12908161 ENSG00000225151.9 GOLGA2P7 -5.28 4.38e-07 0.000362 -0.47 -0.39 Schizophrenia; chr15:84664594 chr15:84199311~84230136:- PAAD cis rs7772486 0.79 rs2485632 ENSG00000235652.6 RP11-545I5.3 5.28 4.38e-07 0.000362 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145872092 chr6:145799409~145886585:+ PAAD cis rs7772486 0.692 rs2265915 ENSG00000235652.6 RP11-545I5.3 5.28 4.38e-07 0.000362 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145873196 chr6:145799409~145886585:+ PAAD cis rs7772486 0.713 rs1986729 ENSG00000235652.6 RP11-545I5.3 5.28 4.38e-07 0.000362 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145873695 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2253307 ENSG00000235652.6 RP11-545I5.3 5.28 4.38e-07 0.000362 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145875045 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2253654 ENSG00000235652.6 RP11-545I5.3 5.28 4.38e-07 0.000362 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145878309 chr6:145799409~145886585:+ PAAD cis rs75422866 0.867 rs7304743 ENSG00000257433.4 RP1-197B17.3 -5.28 4.39e-07 0.000362 -0.78 -0.39 Pneumonia; chr12:47683658 chr12:47706085~47742294:+ PAAD cis rs732716 0.813 rs760369 ENSG00000267980.1 AC007292.6 5.28 4.39e-07 0.000362 0.5 0.39 Mean corpuscular volume; chr19:4449290 chr19:4363789~4364640:+ PAAD cis rs4664293 0.801 rs7590595 ENSG00000226266.5 AC009961.3 -5.28 4.39e-07 0.000362 -0.48 -0.39 Monocyte percentage of white cells; chr2:159715198 chr2:159670708~159712435:- PAAD cis rs4664293 0.801 rs6432552 ENSG00000226266.5 AC009961.3 -5.28 4.39e-07 0.000362 -0.48 -0.39 Monocyte percentage of white cells; chr2:159717613 chr2:159670708~159712435:- PAAD cis rs4664293 0.801 rs7589771 ENSG00000226266.5 AC009961.3 -5.28 4.39e-07 0.000362 -0.48 -0.39 Monocyte percentage of white cells; chr2:159727621 chr2:159670708~159712435:- PAAD cis rs4664293 0.801 rs7607143 ENSG00000226266.5 AC009961.3 -5.28 4.39e-07 0.000362 -0.48 -0.39 Monocyte percentage of white cells; chr2:159728250 chr2:159670708~159712435:- PAAD cis rs4664293 0.833 rs10170336 ENSG00000226266.5 AC009961.3 -5.28 4.39e-07 0.000362 -0.48 -0.39 Monocyte percentage of white cells; chr2:159732832 chr2:159670708~159712435:- PAAD cis rs8059260 0.542 rs11860777 ENSG00000274038.1 RP11-66H6.4 -5.28 4.39e-07 0.000362 -0.64 -0.39 Alcohol consumption over the past year; chr16:11033718 chr16:11056556~11057034:+ PAAD cis rs8059260 0.542 rs16957948 ENSG00000274038.1 RP11-66H6.4 -5.28 4.39e-07 0.000362 -0.64 -0.39 Alcohol consumption over the past year; chr16:11034208 chr16:11056556~11057034:+ PAAD cis rs950169 0.58 rs2271431 ENSG00000225151.9 GOLGA2P7 -5.28 4.39e-07 0.000362 -0.47 -0.39 Schizophrenia; chr15:84646233 chr15:84199311~84230136:- PAAD cis rs7945705 0.776 rs11042069 ENSG00000254860.4 TMEM9B-AS1 -5.28 4.39e-07 0.000363 -0.43 -0.39 Hemoglobin concentration; chr11:8795768 chr11:8964675~8977527:+ PAAD cis rs10875746 0.669 rs10467101 ENSG00000240399.1 RP1-228P16.1 -5.28 4.39e-07 0.000363 -0.44 -0.39 Longevity (90 years and older); chr12:48213954 chr12:48054813~48055591:- PAAD cis rs10875746 0.625 rs2898065 ENSG00000240399.1 RP1-228P16.1 -5.28 4.39e-07 0.000363 -0.44 -0.39 Longevity (90 years and older); chr12:48250836 chr12:48054813~48055591:- PAAD cis rs10875746 0.669 rs11168496 ENSG00000240399.1 RP1-228P16.1 -5.28 4.39e-07 0.000363 -0.44 -0.39 Longevity (90 years and older); chr12:48257072 chr12:48054813~48055591:- PAAD cis rs10875746 0.669 rs10783244 ENSG00000240399.1 RP1-228P16.1 -5.28 4.39e-07 0.000363 -0.44 -0.39 Longevity (90 years and older); chr12:48271206 chr12:48054813~48055591:- PAAD cis rs4879677 1 rs7858681 ENSG00000260390.1 RP11-575I8.1 -5.28 4.39e-07 0.000363 -0.51 -0.39 Gut microbiome composition (summer and winter); chr9:27659161 chr9:27829276~27844481:+ PAAD cis rs875971 0.862 rs7783779 ENSG00000237310.1 GS1-124K5.4 -5.28 4.4e-07 0.000363 -0.4 -0.39 Aortic root size; chr7:66331639 chr7:66493706~66495474:+ PAAD cis rs2243480 1 rs2462569 ENSG00000226824.5 RP4-756H11.3 5.28 4.4e-07 0.000363 0.7 0.39 Diabetic kidney disease; chr7:66009859 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1039664 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:65984729 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1964692 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:65989196 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs2456483 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:65996588 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1701750 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66002158 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1701758 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66005214 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs1701759 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66005945 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs781157 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66013324 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs781156 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66014154 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs781149 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66016297 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs451396 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66019087 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs58207111 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66021736 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1167613 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66022452 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1715235 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66023407 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313799 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66029343 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313807 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66034494 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs313808 ENSG00000226824.5 RP4-756H11.3 -5.28 4.4e-07 0.000363 -0.7 -0.39 Diabetic kidney disease; chr7:66034886 chr7:66654538~66669855:+ PAAD cis rs1075265 0.722 rs7596349 ENSG00000233266.1 HMGB1P31 5.28 4.41e-07 0.000363 0.5 0.39 Chronotype;Morning vs. evening chronotype; chr2:53709123 chr2:54051334~54051760:+ PAAD cis rs1275468 1 rs3858534 ENSG00000257497.2 RP11-585P4.5 -5.28 4.41e-07 0.000364 -0.56 -0.39 Polycystic ovary syndrome; chr12:75553304 chr12:75483454~75489820:- PAAD cis rs2739330 0.731 rs4822450 ENSG00000206090.4 AP000350.7 5.28 4.42e-07 0.000364 0.48 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23939998~23942798:+ PAAD cis rs1075265 0.783 rs6708095 ENSG00000233266.1 HMGB1P31 5.28 4.42e-07 0.000364 0.5 0.39 Chronotype;Morning vs. evening chronotype; chr2:53710365 chr2:54051334~54051760:+ PAAD cis rs4879677 1 rs4879677 ENSG00000260390.1 RP11-575I8.1 5.28 4.42e-07 0.000364 0.51 0.39 Gut microbiome composition (summer and winter); chr9:27664434 chr9:27829276~27844481:+ PAAD cis rs763567 0.935 rs639652 ENSG00000271811.1 RP1-79C4.4 5.28 4.43e-07 0.000365 0.38 0.39 Tonsillectomy; chr1:170643732 chr1:170667381~170669425:+ PAAD cis rs1075265 0.756 rs805423 ENSG00000233266.1 HMGB1P31 5.28 4.43e-07 0.000365 0.51 0.39 Chronotype;Morning vs. evening chronotype; chr2:53899904 chr2:54051334~54051760:+ PAAD cis rs3858145 0.588 rs78041174 ENSG00000233590.1 RP11-153K11.3 -5.28 4.43e-07 0.000365 -0.56 -0.39 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68279014 chr10:68233251~68242379:- PAAD cis rs17301013 0.507 rs12072050 ENSG00000227373.4 RP11-160H22.5 5.28 4.44e-07 0.000366 0.6 0.39 Systemic lupus erythematosus; chr1:174269648 chr1:174115300~174160004:- PAAD cis rs2581828 0.656 rs1864367 ENSG00000242142.1 SERBP1P3 5.28 4.44e-07 0.000366 0.46 0.39 Crohn's disease; chr3:53077688 chr3:53064283~53065091:- PAAD cis rs113835537 0.529 rs2305535 ENSG00000255517.5 CTD-3074O7.5 5.28 4.45e-07 0.000366 0.52 0.39 Airway imaging phenotypes; chr11:66504766 chr11:66473490~66480233:- PAAD cis rs3858145 0.588 rs76854765 ENSG00000233590.1 RP11-153K11.3 -5.28 4.46e-07 0.000367 -0.56 -0.39 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68277699 chr10:68233251~68242379:- PAAD cis rs9926296 0.744 rs164748 ENSG00000260259.1 RP11-368I7.4 5.28 4.46e-07 0.000368 0.49 0.39 Vitiligo; chr16:89641884 chr16:89682620~89686569:- PAAD cis rs1862618 0.525 rs832403 ENSG00000271828.1 CTD-2310F14.1 -5.28 4.47e-07 0.000368 -0.59 -0.39 Initial pursuit acceleration; chr5:56970165 chr5:56927874~56929573:+ PAAD cis rs6570726 0.818 rs412350 ENSG00000235652.6 RP11-545I5.3 5.28 4.49e-07 0.000369 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145531273 chr6:145799409~145886585:+ PAAD cis rs4938303 0.718 rs10892020 ENSG00000254851.1 RP11-109L13.1 -5.27 4.5e-07 0.00037 -0.57 -0.39 Triglycerides; chr11:116718936 chr11:117135528~117138582:+ PAAD cis rs4423214 0.57 rs7118246 ENSG00000254682.1 RP11-660L16.2 5.27 4.5e-07 0.000371 0.59 0.39 Vitamin D levels; chr11:71520078 chr11:71448674~71452157:+ PAAD cis rs7174755 0.743 rs4777035 ENSG00000260657.2 RP11-315D16.4 -5.27 4.51e-07 0.000371 -0.45 -0.39 Major depressive disorder; chr15:68312831 chr15:68267792~68277994:- PAAD cis rs2581828 0.656 rs2581787 ENSG00000242142.1 SERBP1P3 5.27 4.51e-07 0.000371 0.46 0.39 Crohn's disease; chr3:53093661 chr3:53064283~53065091:- PAAD cis rs10262624 0.967 rs7804966 ENSG00000234286.1 AC006026.13 -5.27 4.51e-07 0.000371 -0.45 -0.39 Schizophrenia; chr7:23865141 chr7:23680195~23680786:- PAAD cis rs7772486 0.764 rs7745696 ENSG00000235652.6 RP11-545I5.3 5.27 4.51e-07 0.000371 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145841693 chr6:145799409~145886585:+ PAAD cis rs2274273 0.967 rs1009978 ENSG00000258413.1 RP11-665C16.6 -5.27 4.53e-07 0.000372 -0.49 -0.39 Protein biomarker; chr14:55136343 chr14:55262767~55272075:- PAAD cis rs10463554 0.895 rs12656561 ENSG00000175749.11 EIF3KP1 5.27 4.53e-07 0.000372 0.49 0.39 Parkinson's disease; chr5:102989988 chr5:103032376~103033031:+ PAAD cis rs9532669 0.963 rs7989303 ENSG00000176268.5 CYCSP34 5.27 4.54e-07 0.000373 0.36 0.39 Cervical cancer; chr13:40950087 chr13:40863599~40863902:- PAAD cis rs732716 0.785 rs11666453 ENSG00000267980.1 AC007292.6 -5.27 4.54e-07 0.000373 -0.55 -0.39 Mean corpuscular volume; chr19:4368800 chr19:4363789~4364640:+ PAAD cis rs7826238 0.623 rs2976893 ENSG00000253893.2 FAM85B 5.27 4.56e-07 0.000374 0.53 0.39 Systolic blood pressure; chr8:8480709 chr8:8167819~8226614:- PAAD cis rs6504622 0.818 rs758391 ENSG00000262879.4 RP11-156P1.3 5.27 4.56e-07 0.000374 0.44 0.39 Orofacial clefts; chr17:46939875 chr17:46984045~47100323:- PAAD cis rs7829975 0.806 rs2428 ENSG00000253893.2 FAM85B -5.27 4.56e-07 0.000375 -0.55 -0.39 Mood instability; chr8:8783635 chr8:8167819~8226614:- PAAD cis rs2274273 0.837 rs7146748 ENSG00000258413.1 RP11-665C16.6 -5.27 4.56e-07 0.000375 -0.49 -0.39 Protein biomarker; chr14:55280368 chr14:55262767~55272075:- PAAD cis rs1275468 0.954 rs6582292 ENSG00000257497.2 RP11-585P4.5 5.27 4.56e-07 0.000375 0.55 0.39 Polycystic ovary syndrome; chr12:75539175 chr12:75483454~75489820:- PAAD cis rs7208859 0.524 rs8069400 ENSG00000266490.1 CTD-2349P21.9 5.27 4.57e-07 0.000375 0.51 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30748949 chr17:30792372~30792833:+ PAAD cis rs2019137 1 rs2019137 ENSG00000189223.12 PAX8-AS1 5.27 4.58e-07 0.000376 0.48 0.39 Lymphocyte counts; chr2:113216055 chr2:113211522~113276581:+ PAAD cis rs2019137 0.967 rs895412 ENSG00000189223.12 PAX8-AS1 5.27 4.58e-07 0.000376 0.48 0.39 Lymphocyte counts; chr2:113216387 chr2:113211522~113276581:+ PAAD cis rs6504622 0.818 rs11079742 ENSG00000262879.4 RP11-156P1.3 -5.27 4.58e-07 0.000376 -0.44 -0.39 Orofacial clefts; chr17:46942762 chr17:46984045~47100323:- PAAD cis rs4308124 0.708 rs10179596 ENSG00000227992.1 AC108463.2 -5.27 4.58e-07 0.000376 -0.45 -0.39 Vitiligo; chr2:111212803 chr2:111203964~111206215:- PAAD cis rs11722779 0.869 rs223350 ENSG00000246560.2 RP11-10L12.4 5.27 4.58e-07 0.000376 0.45 0.39 Schizophrenia; chr4:102856899 chr4:102828055~102844075:+ PAAD cis rs950169 0.92 rs34672825 ENSG00000259728.4 LINC00933 5.27 4.58e-07 0.000376 0.5 0.39 Schizophrenia; chr15:84034718 chr15:84570649~84580175:+ PAAD cis rs113835537 0.569 rs17496586 ENSG00000255517.5 CTD-3074O7.5 -5.27 4.59e-07 0.000377 -0.54 -0.39 Airway imaging phenotypes; chr11:66548041 chr11:66473490~66480233:- PAAD cis rs7772486 0.79 rs9403750 ENSG00000235652.6 RP11-545I5.3 5.27 4.59e-07 0.000377 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145846626 chr6:145799409~145886585:+ PAAD cis rs12908161 1 rs17601029 ENSG00000225151.9 GOLGA2P7 -5.27 4.6e-07 0.000377 -0.49 -0.39 Schizophrenia; chr15:84804478 chr15:84199311~84230136:- PAAD cis rs7829975 0.711 rs4841051 ENSG00000253893.2 FAM85B 5.27 4.6e-07 0.000378 0.54 0.39 Mood instability; chr8:8828136 chr8:8167819~8226614:- PAAD cis rs858239 0.73 rs10255155 ENSG00000226816.2 AC005082.12 -5.27 4.61e-07 0.000378 -0.43 -0.39 Cerebrospinal fluid biomarker levels; chr7:23362528 chr7:23206013~23208045:+ PAAD cis rs7772486 0.597 rs9285508 ENSG00000235652.6 RP11-545I5.3 -5.27 4.61e-07 0.000378 -0.36 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145941561 chr6:145799409~145886585:+ PAAD cis rs7208859 0.673 rs1347360 ENSG00000266490.1 CTD-2349P21.9 5.27 4.61e-07 0.000379 0.47 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30587514 chr17:30792372~30792833:+ PAAD cis rs950169 0.579 rs62027818 ENSG00000259728.4 LINC00933 5.27 4.62e-07 0.000379 0.51 0.39 Schizophrenia; chr15:83992393 chr15:84570649~84580175:+ PAAD cis rs950169 0.579 rs12913054 ENSG00000259728.4 LINC00933 5.27 4.62e-07 0.000379 0.51 0.39 Schizophrenia; chr15:83995704 chr15:84570649~84580175:+ PAAD cis rs732716 0.785 rs56033249 ENSG00000267769.1 CTB-50L17.9 -5.27 4.63e-07 0.00038 -0.56 -0.39 Mean corpuscular volume; chr19:4369450 chr19:4454014~4455286:+ PAAD cis rs9928842 0.882 rs6564241 ENSG00000280152.1 RP11-331F4.5 5.27 4.63e-07 0.00038 0.51 0.39 Alcoholic chronic pancreatitis; chr16:75230076 chr16:75245994~75250077:- PAAD cis rs10510102 0.872 rs7916008 ENSG00000276742.1 RP11-500G22.4 5.27 4.63e-07 0.00038 0.58 0.39 Breast cancer; chr10:121943578 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs7916380 ENSG00000276742.1 RP11-500G22.4 5.27 4.63e-07 0.00038 0.58 0.39 Breast cancer; chr10:121943773 chr10:121956782~121957098:+ PAAD cis rs10510102 0.808 rs7920024 ENSG00000276742.1 RP11-500G22.4 5.27 4.63e-07 0.00038 0.58 0.39 Breast cancer; chr10:121944063 chr10:121956782~121957098:+ PAAD cis rs10510102 0.688 rs74570569 ENSG00000276742.1 RP11-500G22.4 5.27 4.63e-07 0.00038 0.58 0.39 Breast cancer; chr10:121945347 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs7076727 ENSG00000276742.1 RP11-500G22.4 5.27 4.63e-07 0.00038 0.58 0.39 Breast cancer; chr10:121947000 chr10:121956782~121957098:+ PAAD cis rs10510102 0.745 rs7076882 ENSG00000276742.1 RP11-500G22.4 5.27 4.63e-07 0.00038 0.58 0.39 Breast cancer; chr10:121947039 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs7077035 ENSG00000276742.1 RP11-500G22.4 5.27 4.63e-07 0.00038 0.58 0.39 Breast cancer; chr10:121947130 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs7906271 ENSG00000276742.1 RP11-500G22.4 -5.27 4.63e-07 0.00038 -0.58 -0.39 Breast cancer; chr10:121948207 chr10:121956782~121957098:+ PAAD cis rs6504950 0.72 rs28564882 ENSG00000275710.1 RP11-257O5.4 5.27 4.63e-07 0.00038 0.51 0.39 Breast cancer; chr17:54912237 chr17:54964474~54964679:+ PAAD cis rs6504950 0.745 rs9915913 ENSG00000275710.1 RP11-257O5.4 5.27 4.63e-07 0.00038 0.51 0.39 Breast cancer; chr17:54920807 chr17:54964474~54964679:+ PAAD cis rs694739 0.734 rs663743 ENSG00000236935.1 AP003774.1 5.27 4.64e-07 0.00038 0.4 0.39 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64340263 chr11:64325050~64329504:- PAAD cis rs4227 0.565 rs858526 ENSG00000233223.2 AC113189.5 -5.27 4.65e-07 0.000381 -0.42 -0.39 IgA nephropathy; chr17:7596064 chr17:7581964~7584072:- PAAD cis rs10463554 0.892 rs1837256 ENSG00000175749.11 EIF3KP1 5.27 4.65e-07 0.000381 0.5 0.39 Parkinson's disease; chr5:102968852 chr5:103032376~103033031:+ PAAD cis rs638893 1 rs638893 ENSG00000278376.1 RP11-158I9.8 -5.27 4.66e-07 0.000382 -0.53 -0.39 Vitiligo; chr11:118827828 chr11:118791254~118793137:+ PAAD cis rs638893 1 rs28827279 ENSG00000278376.1 RP11-158I9.8 -5.27 4.66e-07 0.000382 -0.53 -0.39 Vitiligo; chr11:118830054 chr11:118791254~118793137:+ PAAD cis rs3858145 0.588 rs61854831 ENSG00000233590.1 RP11-153K11.3 -5.27 4.67e-07 0.000383 -0.56 -0.39 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68276080 chr10:68233251~68242379:- PAAD cis rs3858145 0.588 rs55888445 ENSG00000233590.1 RP11-153K11.3 -5.27 4.67e-07 0.000383 -0.56 -0.39 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68276699 chr10:68233251~68242379:- PAAD cis rs3858145 0.588 rs61854833 ENSG00000233590.1 RP11-153K11.3 -5.27 4.67e-07 0.000383 -0.56 -0.39 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68277570 chr10:68233251~68242379:- PAAD cis rs7772486 0.846 rs2144478 ENSG00000235652.6 RP11-545I5.3 5.27 4.67e-07 0.000383 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:146060309 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs6930975 ENSG00000235652.6 RP11-545I5.3 5.27 4.67e-07 0.000383 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:146065975 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs9322046 ENSG00000235652.6 RP11-545I5.3 5.27 4.67e-07 0.000383 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:146072489 chr6:145799409~145886585:+ PAAD cis rs494459 0.838 rs567680 ENSG00000255422.1 AP002954.4 -5.27 4.68e-07 0.000383 -0.43 -0.39 Height; chr11:118737823 chr11:118704607~118750263:+ PAAD cis rs494459 0.838 rs566733 ENSG00000255422.1 AP002954.4 -5.27 4.68e-07 0.000383 -0.43 -0.39 Height; chr11:118737916 chr11:118704607~118750263:+ PAAD cis rs6700559 0.873 rs7526031 ENSG00000260088.1 RP11-92G12.3 -5.27 4.68e-07 0.000383 -0.52 -0.39 Coronary artery disease; chr1:200695174 chr1:200669507~200694250:+ PAAD cis rs732716 0.785 rs11666453 ENSG00000267769.1 CTB-50L17.9 -5.27 4.68e-07 0.000383 -0.55 -0.39 Mean corpuscular volume; chr19:4368800 chr19:4454014~4455286:+ PAAD cis rs2739330 0.76 rs5760095 ENSG00000206090.4 AP000350.7 5.27 4.68e-07 0.000383 0.5 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905106 chr22:23939998~23942798:+ PAAD cis rs2243480 1 rs313832 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66085904 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313831 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66086239 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs160646 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66091293 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs465359 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66093177 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs462853 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66093180 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs160644 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66093199 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs160642 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66093386 chr7:66654538~66669855:+ PAAD cis rs2243480 0.614 rs34032527 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66100154 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs36127118 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66100518 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316307 ENSG00000226824.5 RP4-756H11.3 -5.27 4.68e-07 0.000383 -0.7 -0.39 Diabetic kidney disease; chr7:66105184 chr7:66654538~66669855:+ PAAD cis rs11089937 0.963 rs2226943 ENSG00000211639.2 IGLV4-60 5.27 4.69e-07 0.000384 0.36 0.39 Periodontitis (PAL4Q3); chr22:22143100 chr22:22162199~22162681:+ PAAD cis rs7829975 0.514 rs2979139 ENSG00000253893.2 FAM85B -5.27 4.69e-07 0.000384 -0.54 -0.39 Mood instability; chr8:8410803 chr8:8167819~8226614:- PAAD cis rs7208859 0.623 rs7220289 ENSG00000266490.1 CTD-2349P21.9 5.27 4.7e-07 0.000385 0.51 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30776744 chr17:30792372~30792833:+ PAAD cis rs6700559 0.873 rs6427840 ENSG00000260088.1 RP11-92G12.3 -5.27 4.7e-07 0.000385 -0.52 -0.39 Coronary artery disease; chr1:200685659 chr1:200669507~200694250:+ PAAD cis rs35160687 0.842 rs1863051 ENSG00000273080.1 RP11-301O19.1 5.26 4.71e-07 0.000385 0.44 0.39 Night sleep phenotypes; chr2:86332025 chr2:86195590~86196049:+ PAAD cis rs7188445 1 rs7188445 ENSG00000261390.4 RP11-345M22.2 -5.26 4.71e-07 0.000385 -0.53 -0.39 Urate levels; chr16:79701090 chr16:79715232~79770563:- PAAD cis rs6921919 0.848 rs56131013 ENSG00000204709.4 LINC01556 5.26 4.71e-07 0.000385 0.65 0.39 Autism spectrum disorder or schizophrenia; chr6:28352900 chr6:28943877~28944537:+ PAAD cis rs6921919 0.848 rs6903652 ENSG00000204709.4 LINC01556 5.26 4.71e-07 0.000385 0.65 0.39 Autism spectrum disorder or schizophrenia; chr6:28354343 chr6:28943877~28944537:+ PAAD cis rs6921919 0.848 rs6903823 ENSG00000204709.4 LINC01556 5.26 4.71e-07 0.000385 0.65 0.39 Autism spectrum disorder or schizophrenia; chr6:28354519 chr6:28943877~28944537:+ PAAD cis rs72843506 0.722 rs9897161 ENSG00000189423.10 USP32P3 5.26 4.72e-07 0.000386 0.6 0.39 Schizophrenia; chr17:20130957 chr17:20415547~20431008:+ PAAD cis rs72843506 0.722 rs9897168 ENSG00000189423.10 USP32P3 5.26 4.72e-07 0.000386 0.6 0.39 Schizophrenia; chr17:20130961 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs9913018 ENSG00000189423.10 USP32P3 5.26 4.72e-07 0.000386 0.6 0.39 Schizophrenia; chr17:20160759 chr17:20415547~20431008:+ PAAD cis rs367615 0.552 rs7720036 ENSG00000249476.1 CTD-2587M2.1 -5.26 4.72e-07 0.000386 -0.43 -0.39 Colorectal cancer (SNP x SNP interaction); chr5:109374998 chr5:109237120~109326369:- PAAD cis rs9928842 0.823 rs4888365 ENSG00000280152.1 RP11-331F4.5 5.26 4.73e-07 0.000387 0.5 0.39 Alcoholic chronic pancreatitis; chr16:75248349 chr16:75245994~75250077:- PAAD cis rs10875746 0.669 rs4760701 ENSG00000240399.1 RP1-228P16.1 -5.26 4.73e-07 0.000387 -0.42 -0.39 Longevity (90 years and older); chr12:48304735 chr12:48054813~48055591:- PAAD cis rs2739330 0.828 rs5760102 ENSG00000231271.1 AP000350.8 5.26 4.74e-07 0.000387 0.55 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906574 chr22:23949918~23954042:+ PAAD cis rs2412819 0.571 rs7174260 ENSG00000249839.1 AC011330.5 -5.26 4.74e-07 0.000388 -0.65 -0.39 Lung cancer; chr15:43751988 chr15:43663654~43684339:- PAAD cis rs8059260 0.604 rs71381192 ENSG00000274038.1 RP11-66H6.4 -5.26 4.74e-07 0.000388 -0.66 -0.39 Alcohol consumption over the past year; chr16:11075528 chr16:11056556~11057034:+ PAAD cis rs2581828 0.646 rs2564923 ENSG00000242142.1 SERBP1P3 5.26 4.74e-07 0.000388 0.45 0.39 Crohn's disease; chr3:53069246 chr3:53064283~53065091:- PAAD cis rs673078 0.66 rs61946063 ENSG00000275759.1 RP11-131L12.3 -5.26 4.74e-07 0.000388 -0.49 -0.39 Glucose homeostasis traits; chr12:118294448 chr12:118428281~118428870:+ PAAD cis rs638893 1 rs636736 ENSG00000278376.1 RP11-158I9.8 -5.26 4.75e-07 0.000388 -0.56 -0.39 Vitiligo; chr11:118834436 chr11:118791254~118793137:+ PAAD cis rs875971 0.825 rs6951503 ENSG00000237310.1 GS1-124K5.4 -5.26 4.75e-07 0.000388 -0.4 -0.39 Aortic root size; chr7:66253949 chr7:66493706~66495474:+ PAAD cis rs270601 0.837 rs367805 ENSG00000233006.5 AC034220.3 5.26 4.75e-07 0.000388 0.35 0.39 Acylcarnitine levels; chr5:132365587 chr5:132311285~132369916:- PAAD cis rs875971 0.83 rs12673450 ENSG00000237310.1 GS1-124K5.4 5.26 4.76e-07 0.000389 0.4 0.39 Aortic root size; chr7:66544233 chr7:66493706~66495474:+ PAAD cis rs858239 0.712 rs199650 ENSG00000226816.2 AC005082.12 -5.26 4.77e-07 0.000389 -0.42 -0.39 Cerebrospinal fluid biomarker levels; chr7:23327570 chr7:23206013~23208045:+ PAAD cis rs1185460 0.565 rs1182922 ENSG00000271751.1 RP11-110I1.14 5.26 4.77e-07 0.000389 0.52 0.39 Coronary artery disease; chr11:119062148 chr11:119065263~119065677:- PAAD cis rs3096299 0.967 rs2911257 ENSG00000274627.1 RP11-104N10.2 5.26 4.77e-07 0.00039 0.35 0.39 Multiple myeloma (IgH translocation); chr16:89417726 chr16:89516797~89522217:+ PAAD cis rs2412819 0.571 rs62018900 ENSG00000249839.1 AC011330.5 -5.26 4.78e-07 0.00039 -0.65 -0.39 Lung cancer; chr15:43633252 chr15:43663654~43684339:- PAAD cis rs2412819 0.545 rs35333173 ENSG00000249839.1 AC011330.5 -5.26 4.78e-07 0.00039 -0.65 -0.39 Lung cancer; chr15:43640818 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs112667279 ENSG00000249839.1 AC011330.5 -5.26 4.78e-07 0.00039 -0.65 -0.39 Lung cancer; chr15:43649258 chr15:43663654~43684339:- PAAD cis rs2412819 0.545 rs17795279 ENSG00000249839.1 AC011330.5 5.26 4.78e-07 0.00039 0.65 0.39 Lung cancer; chr15:43637180 chr15:43663654~43684339:- PAAD cis rs7188445 1 rs11864901 ENSG00000261390.4 RP11-345M22.2 -5.26 4.78e-07 0.000391 -0.55 -0.39 Urate levels; chr16:79697908 chr16:79715232~79770563:- PAAD cis rs2581828 0.656 rs2336723 ENSG00000242142.1 SERBP1P3 5.26 4.79e-07 0.000391 0.46 0.39 Crohn's disease; chr3:53072031 chr3:53064283~53065091:- PAAD cis rs730566 0.64 rs6442112 ENSG00000229759.1 MRPS18AP1 5.26 4.81e-07 0.000393 0.46 0.39 Prion diseases; chr3:48274544 chr3:48256350~48256938:- PAAD cis rs6921919 0.638 rs1416920 ENSG00000216901.1 AL022393.7 5.26 4.82e-07 0.000393 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28335007 chr6:28176188~28176674:+ PAAD cis rs6921919 0.525 rs1361386 ENSG00000216901.1 AL022393.7 5.26 4.82e-07 0.000393 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28337827 chr6:28176188~28176674:+ PAAD cis rs6921919 0.638 rs6456815 ENSG00000216901.1 AL022393.7 5.26 4.82e-07 0.000393 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28338360 chr6:28176188~28176674:+ PAAD cis rs6921919 0.638 rs2108926 ENSG00000216901.1 AL022393.7 5.26 4.82e-07 0.000393 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28340970 chr6:28176188~28176674:+ PAAD cis rs1075265 0.783 rs698858 ENSG00000233266.1 HMGB1P31 5.26 4.84e-07 0.000394 0.5 0.39 Chronotype;Morning vs. evening chronotype; chr2:53943333 chr2:54051334~54051760:+ PAAD cis rs1075265 0.756 rs805367 ENSG00000233266.1 HMGB1P31 5.26 4.84e-07 0.000394 0.5 0.39 Chronotype;Morning vs. evening chronotype; chr2:53943956 chr2:54051334~54051760:+ PAAD cis rs1075265 0.783 rs718872 ENSG00000233266.1 HMGB1P31 5.26 4.84e-07 0.000394 0.5 0.39 Chronotype;Morning vs. evening chronotype; chr2:53946569 chr2:54051334~54051760:+ PAAD cis rs26232 0.583 rs26434 ENSG00000175749.11 EIF3KP1 -5.26 4.84e-07 0.000394 -0.52 -0.39 Rheumatoid arthritis; chr5:103027698 chr5:103032376~103033031:+ PAAD cis rs6991838 0.584 rs6993876 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65601240 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs4737748 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65613630 chr8:65592731~65592820:+ PAAD cis rs6991838 0.55 rs12335006 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65619394 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs10957361 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65619626 chr8:65592731~65592820:+ PAAD cis rs6991838 0.612 rs12335276 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65619668 chr8:65592731~65592820:+ PAAD cis rs6991838 0.612 rs7832407 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65621071 chr8:65592731~65592820:+ PAAD cis rs6991838 0.551 rs7007505 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65621719 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs7012856 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65622740 chr8:65592731~65592820:+ PAAD cis rs6991838 0.55 rs7817112 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65624885 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs2048650 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65625664 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs4737749 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65627672 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs10092109 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65627683 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs6997959 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65628247 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs7814841 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65629328 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs11985628 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65630504 chr8:65592731~65592820:+ PAAD cis rs6991838 0.557 rs13266834 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65631303 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs13268343 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65631742 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs7835313 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65633891 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs3812412 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65634857 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs1533285 ENSG00000200714.1 Y_RNA 5.26 4.84e-07 0.000394 0.46 0.39 Intelligence (multi-trait analysis); chr8:65637129 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs34226237 ENSG00000200714.1 Y_RNA -5.26 4.84e-07 0.000394 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65600930 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs6994213 ENSG00000200714.1 Y_RNA -5.26 4.84e-07 0.000394 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65601497 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs3765205 ENSG00000200714.1 Y_RNA -5.26 4.84e-07 0.000394 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65605251 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs7841652 ENSG00000200714.1 Y_RNA -5.26 4.84e-07 0.000394 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65606392 chr8:65592731~65592820:+ PAAD cis rs6991838 0.53 rs35038843 ENSG00000200714.1 Y_RNA -5.26 4.84e-07 0.000394 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65610263 chr8:65592731~65592820:+ PAAD cis rs12908161 0.959 rs61074241 ENSG00000225151.9 GOLGA2P7 -5.26 4.84e-07 0.000394 -0.54 -0.39 Schizophrenia; chr15:84790165 chr15:84199311~84230136:- PAAD cis rs2243480 1 rs34702770 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65879836 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs35480979 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65892097 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34637256 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65895144 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35391607 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65895842 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs13220979 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65898217 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34974928 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65899019 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs67728539 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65913137 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34136756 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65916269 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs78803505 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65917585 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34933526 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65918212 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34577383 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65920739 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6949812 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65922114 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs55895244 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65922691 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6970243 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65923503 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs7794661 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65924743 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs7795242 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65925107 chr7:66654538~66669855:+ PAAD cis rs2243480 0.708 rs35310401 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65925372 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35058610 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65925938 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2177703 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65926730 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35432774 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65928032 chr7:66654538~66669855:+ PAAD cis rs2243480 0.831 rs7806717 ENSG00000226824.5 RP4-756H11.3 5.26 4.84e-07 0.000394 0.71 0.39 Diabetic kidney disease; chr7:65928187 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs56985706 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65929575 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs60683927 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65929781 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs58062456 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65929865 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34529418 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65938222 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs35087093 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65940221 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35046236 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65943626 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs36068983 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65944004 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs68189316 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65944182 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs34804747 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65947955 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs59794892 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65950886 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs36004293 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65951525 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs35268390 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65951549 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs12698509 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65953889 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs11538349 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65956884 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs937108 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65963465 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs35542501 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65966228 chr7:66654538~66669855:+ PAAD cis rs2243480 0.711 rs1626926 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65970805 chr7:66654538~66669855:+ PAAD cis rs2243480 0.708 rs781141 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65973566 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs781142 ENSG00000226824.5 RP4-756H11.3 -5.26 4.84e-07 0.000394 -0.71 -0.39 Diabetic kidney disease; chr7:65973791 chr7:66654538~66669855:+ PAAD cis rs367615 0.552 rs2963010 ENSG00000249476.1 CTD-2587M2.1 -5.26 4.86e-07 0.000396 -0.43 -0.39 Colorectal cancer (SNP x SNP interaction); chr5:109401342 chr5:109237120~109326369:- PAAD cis rs2019137 0.836 rs4848318 ENSG00000189223.12 PAX8-AS1 5.26 4.86e-07 0.000396 0.47 0.39 Lymphocyte counts; chr2:113196375 chr2:113211522~113276581:+ PAAD cis rs6504950 1 rs9902718 ENSG00000275710.1 RP11-257O5.4 5.26 4.86e-07 0.000396 0.51 0.39 Breast cancer; chr17:54984261 chr17:54964474~54964679:+ PAAD cis rs7208859 0.673 rs9911989 ENSG00000266490.1 CTD-2349P21.9 -5.26 4.86e-07 0.000396 -0.53 -0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910684 chr17:30792372~30792833:+ PAAD cis rs17826219 0.706 rs9905827 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Body mass index; chr17:30865150 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11652358 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30878462 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11656845 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879146 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9891179 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881142 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9891413 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881191 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73263776 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30884313 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11650271 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30886925 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73263785 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887790 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs55904046 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888373 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9889968 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30893110 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs61348930 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30894745 chr17:30792372~30792833:+ PAAD cis rs7208859 0.614 rs28758251 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896294 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9899943 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896907 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11080138 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30897524 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73265612 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30898965 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs2433 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30899210 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11658435 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30901543 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73265624 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905048 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs2269915 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906326 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs2269916 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906745 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11649765 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906870 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs12103759 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908669 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs59029591 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908728 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73265633 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30909288 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9913782 ENSG00000266490.1 CTD-2349P21.9 5.26 4.86e-07 0.000396 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910366 chr17:30792372~30792833:+ PAAD cis rs17711722 0.565 rs4717276 ENSG00000226824.5 RP4-756H11.3 -5.26 4.87e-07 0.000396 -0.46 -0.39 Calcium levels; chr7:65829754 chr7:66654538~66669855:+ PAAD cis rs8091660 0.929 rs12456253 ENSG00000278983.1 RP11-426J5.3 -5.26 4.88e-07 0.000397 -0.46 -0.39 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550603 chr18:48564795~48568342:+ PAAD cis rs1075265 0.783 rs805359 ENSG00000233266.1 HMGB1P31 5.26 4.89e-07 0.000397 0.5 0.39 Chronotype;Morning vs. evening chronotype; chr2:53935317 chr2:54051334~54051760:+ PAAD cis rs3858145 0.588 rs10998059 ENSG00000233590.1 RP11-153K11.3 5.26 4.89e-07 0.000397 0.53 0.39 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68302750 chr10:68233251~68242379:- PAAD cis rs2153535 0.58 rs6914276 ENSG00000230939.1 RP11-314C16.1 5.26 4.9e-07 0.000398 0.42 0.39 Motion sickness; chr6:8450202 chr6:8784178~8785445:+ PAAD cis rs6991838 0.584 rs61083799 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65574868 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs4449837 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65575917 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs57042777 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65576855 chr8:65592731~65592820:+ PAAD cis rs6991838 0.557 rs67046768 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65577486 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs4388482 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65583968 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs4637885 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65584849 chr8:65592731~65592820:+ PAAD cis rs6991838 0.556 rs7846527 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65586522 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs4320587 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65586991 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs35941313 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65587498 chr8:65592731~65592820:+ PAAD cis rs6991838 0.557 rs4737222 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65587878 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs4275254 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65589129 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs35790435 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65590288 chr8:65592731~65592820:+ PAAD cis rs6991838 0.557 rs7012578 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65592592 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs7812446 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65593753 chr8:65592731~65592820:+ PAAD cis rs6991838 0.557 rs7812390 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65593982 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs16932245 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65597810 chr8:65592731~65592820:+ PAAD cis rs6991838 0.557 rs57419568 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65598633 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs16932250 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65598779 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs34494846 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65602397 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs1053088 ENSG00000200714.1 Y_RNA 5.26 4.9e-07 0.000398 0.46 0.39 Intelligence (multi-trait analysis); chr8:65603548 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs1053087 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65603630 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs1053085 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65603753 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs7823840 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65606766 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs4737747 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65607024 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs73236948 ENSG00000200714.1 Y_RNA -5.26 4.9e-07 0.000398 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65609176 chr8:65592731~65592820:+ PAAD cis rs9890032 1 rs9890032 ENSG00000266490.1 CTD-2349P21.9 -5.26 4.91e-07 0.000399 -0.36 -0.39 Hip circumference adjusted for BMI; chr17:30838916 chr17:30792372~30792833:+ PAAD cis rs9890032 0.967 rs7342976 ENSG00000266490.1 CTD-2349P21.9 5.26 4.91e-07 0.000399 0.36 0.39 Hip circumference adjusted for BMI; chr17:30863001 chr17:30792372~30792833:+ PAAD cis rs748404 0.631 rs2412781 ENSG00000249839.1 AC011330.5 5.26 4.91e-07 0.000399 0.56 0.39 Lung cancer; chr15:43375702 chr15:43663654~43684339:- PAAD cis rs9326248 1 rs4938344 ENSG00000280143.1 AP000892.6 5.26 4.92e-07 0.000399 0.51 0.39 Blood protein levels; chr11:117133033 chr11:117204967~117210292:+ PAAD cis rs2274273 0.773 rs8006525 ENSG00000258413.1 RP11-665C16.6 -5.26 4.92e-07 0.000399 -0.5 -0.39 Protein biomarker; chr14:55346676 chr14:55262767~55272075:- PAAD cis rs964611 0.882 rs11857977 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48353478 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4775750 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48360567 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4775751 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48360910 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs11631831 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48361563 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs11629805 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48363267 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs11070636 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48364720 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs11070637 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48364881 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs12439526 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48366050 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs12148383 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48368235 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs12148465 ENSG00000259488.2 RP11-154J22.1 5.25 4.94e-07 4e-04 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48368261 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4775747 ENSG00000259488.2 RP11-154J22.1 -5.25 4.94e-07 4e-04 -0.43 -0.39 Metabolite levels (Pyroglutamine); chr15:48346146 chr15:48312353~48331856:- PAAD cis rs62229266 0.771 rs62230790 ENSG00000231106.2 LINC01436 5.25 4.94e-07 4e-04 0.57 0.39 Mitral valve prolapse; chr21:36016613 chr21:36005338~36007838:+ PAAD cis rs1823913 0.927 rs1454761 ENSG00000280083.1 RP11-317J9.1 -5.25 4.94e-07 0.000401 -0.52 -0.39 Obesity-related traits; chr2:191237092 chr2:191154118~191156070:- PAAD cis rs2739330 0.703 rs5760112 ENSG00000099984.9 GSTT2 -5.25 4.95e-07 0.000401 -0.5 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:23917585 chr22:23980123~23983911:+ PAAD cis rs2274273 0.624 rs66464079 ENSG00000258413.1 RP11-665C16.6 -5.25 4.95e-07 0.000402 -0.53 -0.39 Protein biomarker; chr14:55299446 chr14:55262767~55272075:- PAAD cis rs7772486 0.875 rs1125461 ENSG00000235652.6 RP11-545I5.3 5.25 4.95e-07 0.000402 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:146096517 chr6:145799409~145886585:+ PAAD cis rs9473147 0.543 rs4711878 ENSG00000270761.1 RP11-385F7.1 -5.25 4.97e-07 0.000403 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47488382 chr6:47477243~47477572:- PAAD cis rs2274273 0.837 rs6573017 ENSG00000258413.1 RP11-665C16.6 -5.25 4.97e-07 0.000403 -0.49 -0.39 Protein biomarker; chr14:55335525 chr14:55262767~55272075:- PAAD cis rs2274273 0.714 rs7154889 ENSG00000258413.1 RP11-665C16.6 -5.25 4.97e-07 0.000403 -0.49 -0.39 Protein biomarker; chr14:55340167 chr14:55262767~55272075:- PAAD cis rs4879677 1 rs620232 ENSG00000260390.1 RP11-575I8.1 5.25 4.98e-07 0.000403 0.5 0.39 Gut microbiome composition (summer and winter); chr9:27656448 chr9:27829276~27844481:+ PAAD cis rs7772486 0.846 rs1474871 ENSG00000235652.6 RP11-545I5.3 5.25 4.98e-07 0.000404 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:146085158 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs6570738 ENSG00000235652.6 RP11-545I5.3 5.25 4.98e-07 0.000404 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:146091559 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs1412080 ENSG00000235652.6 RP11-545I5.3 5.25 4.98e-07 0.000404 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:146096168 chr6:145799409~145886585:+ PAAD cis rs8135665 0.6 rs8142379 ENSG00000233739.1 RP5-1039K5.13 5.25 4.99e-07 0.000404 0.49 0.39 Advanced age-related macular degeneration;Age-related macular degeneration; chr22:38054964 chr22:38057180~38073940:- PAAD cis rs858239 0.712 rs200717 ENSG00000226816.2 AC005082.12 5.25 4.99e-07 0.000404 0.42 0.39 Cerebrospinal fluid biomarker levels; chr7:23352652 chr7:23206013~23208045:+ PAAD cis rs7772486 0.875 rs2814871 ENSG00000235652.6 RP11-545I5.3 5.25 4.99e-07 0.000405 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145991138 chr6:145799409~145886585:+ PAAD cis rs10875746 0.669 rs9634261 ENSG00000240399.1 RP1-228P16.1 -5.25 5.01e-07 0.000406 -0.43 -0.39 Longevity (90 years and older); chr12:48293088 chr12:48054813~48055591:- PAAD cis rs7945705 0.967 rs11042082 ENSG00000254860.4 TMEM9B-AS1 -5.25 5.01e-07 0.000406 -0.46 -0.39 Hemoglobin concentration; chr11:8817682 chr11:8964675~8977527:+ PAAD cis rs7945705 0.902 rs11042088 ENSG00000254860.4 TMEM9B-AS1 -5.25 5.01e-07 0.000406 -0.46 -0.39 Hemoglobin concentration; chr11:8821968 chr11:8964675~8977527:+ PAAD cis rs801193 0.548 rs6975044 ENSG00000237310.1 GS1-124K5.4 5.25 5.02e-07 0.000406 0.4 0.39 Aortic root size; chr7:66762495 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs35070132 ENSG00000237310.1 GS1-124K5.4 5.25 5.02e-07 0.000406 0.4 0.39 Aortic root size; chr7:66773096 chr7:66493706~66495474:+ PAAD cis rs72772090 0.908 rs6864233 ENSG00000248734.2 CTD-2260A17.1 5.25 5.02e-07 0.000407 0.47 0.39 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96708977 chr5:96784777~96785999:+ PAAD cis rs9473147 0.516 rs7740963 ENSG00000270761.1 RP11-385F7.1 -5.25 5.03e-07 0.000407 -0.4 -0.39 Platelet distribution width;Mean platelet volume; chr6:47459875 chr6:47477243~47477572:- PAAD cis rs13178541 0.81 rs4466158 ENSG00000250378.1 RP11-119J18.1 -5.25 5.03e-07 0.000407 -0.61 -0.39 IgG glycosylation; chr5:135829468 chr5:135812667~135826582:+ PAAD cis rs5760092 0.842 rs5760103 ENSG00000099984.9 GSTT2 -5.25 5.04e-07 0.000408 -0.66 -0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23906594 chr22:23980123~23983911:+ PAAD cis rs113835537 0.529 rs3741360 ENSG00000255517.5 CTD-3074O7.5 -5.25 5.04e-07 0.000408 -0.52 -0.39 Airway imaging phenotypes; chr11:66532877 chr11:66473490~66480233:- PAAD cis rs17711722 0.503 rs453835 ENSG00000237310.1 GS1-124K5.4 -5.25 5.04e-07 0.000409 -0.38 -0.39 Calcium levels; chr7:66046172 chr7:66493706~66495474:+ PAAD cis rs710913 0.816 rs1180341 ENSG00000237624.1 OXCT2P1 -5.25 5.05e-07 0.000409 -0.48 -0.39 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527136 chr1:39514956~39516490:+ PAAD cis rs62229266 0.74 rs4817759 ENSG00000231106.2 LINC01436 5.25 5.06e-07 0.000409 0.58 0.39 Mitral valve prolapse; chr21:36017261 chr21:36005338~36007838:+ PAAD cis rs62229266 0.771 rs2835232 ENSG00000231106.2 LINC01436 5.25 5.06e-07 0.000409 0.58 0.39 Mitral valve prolapse; chr21:36021129 chr21:36005338~36007838:+ PAAD cis rs62229266 0.74 rs2835233 ENSG00000231106.2 LINC01436 5.25 5.06e-07 0.000409 0.58 0.39 Mitral valve prolapse; chr21:36021284 chr21:36005338~36007838:+ PAAD cis rs113835537 0.529 rs117112180 ENSG00000255517.5 CTD-3074O7.5 -5.25 5.06e-07 0.00041 -0.54 -0.39 Airway imaging phenotypes; chr11:66525802 chr11:66473490~66480233:- PAAD cis rs113835537 0.529 rs3816492 ENSG00000255517.5 CTD-3074O7.5 -5.25 5.06e-07 0.00041 -0.54 -0.39 Airway imaging phenotypes; chr11:66529892 chr11:66473490~66480233:- PAAD cis rs6570726 0.791 rs952406 ENSG00000235652.6 RP11-545I5.3 5.25 5.06e-07 0.00041 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145604480 chr6:145799409~145886585:+ PAAD cis rs2153535 0.542 rs9393012 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8439576 chr6:8784178~8785445:+ PAAD cis rs2153535 0.542 rs6912740 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8439726 chr6:8784178~8785445:+ PAAD cis rs2153535 0.542 rs6905925 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8439797 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs6905934 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8439810 chr6:8784178~8785445:+ PAAD cis rs2153535 0.542 rs915354 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8440124 chr6:8784178~8785445:+ PAAD cis rs2153535 0.542 rs915353 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8440137 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327050 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8440397 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4404802 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8441819 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs5001130 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8442065 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1932275 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8442100 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1932276 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8442360 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs915352 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8442533 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs915351 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8442560 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs945304 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8442659 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327056 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8443072 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327057 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8443086 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs3938660 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8443102 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1889715 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8443242 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1577466 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8443959 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1577467 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8444008 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1577468 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8444033 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs1855765 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8444092 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406143 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8444350 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6941670 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446113 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6921964 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446162 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs4637688 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446268 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4639392 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446314 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1832100 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446723 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327058 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446785 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs2327059 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446838 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327060 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446878 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327061 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8446998 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7453115 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8447028 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2184582 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8447560 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2184583 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8447575 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6929206 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8447728 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6910742 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8448095 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9505446 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8448458 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1335633 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8448567 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1115079 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8449382 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1115078 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8449405 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597322 ENSG00000230939.1 RP11-314C16.1 -5.25 5.07e-07 0.00041 -0.41 -0.39 Motion sickness; chr6:8449719 chr6:8784178~8785445:+ PAAD cis rs7772486 0.754 rs9497401 ENSG00000235652.6 RP11-545I5.3 -5.25 5.07e-07 0.00041 -0.33 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145730135 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs1055212 ENSG00000235652.6 RP11-545I5.3 -5.25 5.07e-07 0.00041 -0.33 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145737179 chr6:145799409~145886585:+ PAAD cis rs763567 0.935 rs580487 ENSG00000271811.1 RP1-79C4.4 5.25 5.08e-07 0.00041 0.38 0.39 Tonsillectomy; chr1:170640484 chr1:170667381~170669425:+ PAAD cis rs7772486 0.79 rs1133832 ENSG00000235652.6 RP11-545I5.3 -5.25 5.09e-07 0.00041 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145884468 chr6:145799409~145886585:+ PAAD cis rs9549328 0.731 rs2873371 ENSG00000267868.1 RP11-120K24.3 5.25 5.11e-07 0.000411 0.44 0.39 Systolic blood pressure; chr13:112961928 chr13:112964835~112966131:- PAAD cis rs694739 0.857 rs574835 ENSG00000236935.1 AP003774.1 5.25 5.11e-07 0.000412 0.42 0.39 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64343196 chr11:64325050~64329504:- PAAD cis rs113835537 0.529 rs10501397 ENSG00000255517.5 CTD-3074O7.5 -5.25 5.12e-07 0.000412 -0.5 -0.39 Airway imaging phenotypes; chr11:66505505 chr11:66473490~66480233:- PAAD cis rs75422866 0.867 rs73111258 ENSG00000257433.4 RP1-197B17.3 5.25 5.14e-07 0.000413 0.82 0.39 Pneumonia; chr12:47597313 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs117388682 ENSG00000257433.4 RP1-197B17.3 5.25 5.14e-07 0.000413 0.82 0.39 Pneumonia; chr12:47599713 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs79113930 ENSG00000257433.4 RP1-197B17.3 5.25 5.14e-07 0.000413 0.82 0.39 Pneumonia; chr12:47600628 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs35044089 ENSG00000257433.4 RP1-197B17.3 5.25 5.14e-07 0.000413 0.82 0.39 Pneumonia; chr12:47610881 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs78912815 ENSG00000257433.4 RP1-197B17.3 5.25 5.14e-07 0.000413 0.82 0.39 Pneumonia; chr12:47612065 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73113117 ENSG00000257433.4 RP1-197B17.3 5.25 5.14e-07 0.000413 0.82 0.39 Pneumonia; chr12:47617299 chr12:47706085~47742294:+ PAAD cis rs11168351 0.591 rs4258439 ENSG00000240399.1 RP1-228P16.1 -5.25 5.14e-07 0.000413 -0.37 -0.39 Bipolar disorder and schizophrenia; chr12:48074869 chr12:48054813~48055591:- PAAD cis rs13178541 0.81 rs7705245 ENSG00000250378.1 RP11-119J18.1 -5.25 5.15e-07 0.000414 -0.58 -0.39 IgG glycosylation; chr5:135849056 chr5:135812667~135826582:+ PAAD cis rs2243480 0.901 rs2949697 ENSG00000226824.5 RP4-756H11.3 -5.25 5.15e-07 0.000414 -0.7 -0.39 Diabetic kidney disease; chr7:65999249 chr7:66654538~66669855:+ PAAD cis rs10463554 0.892 rs66759661 ENSG00000175749.11 EIF3KP1 5.25 5.15e-07 0.000414 0.51 0.39 Parkinson's disease; chr5:102925894 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs6872442 ENSG00000175749.11 EIF3KP1 5.25 5.15e-07 0.000414 0.51 0.39 Parkinson's disease; chr5:102930818 chr5:103032376~103033031:+ PAAD cis rs4660456 0.913 rs4660449 ENSG00000237899.1 RP4-739H11.3 5.25 5.15e-07 0.000414 0.52 0.39 Platelet count; chr1:40739780 chr1:40669089~40687588:- PAAD cis rs858239 0.669 rs1006709 ENSG00000226816.2 AC005082.12 5.25 5.15e-07 0.000414 0.44 0.39 Cerebrospinal fluid biomarker levels; chr7:23100480 chr7:23206013~23208045:+ PAAD cis rs7772486 0.686 rs702314 ENSG00000235652.6 RP11-545I5.3 -5.24 5.16e-07 0.000415 -0.33 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145682374 chr6:145799409~145886585:+ PAAD cis rs9425766 0.679 rs4650945 ENSG00000227373.4 RP11-160H22.5 -5.24 5.16e-07 0.000415 -0.5 -0.39 Life satisfaction; chr1:174114966 chr1:174115300~174160004:- PAAD cis rs2274273 0.87 rs10134339 ENSG00000258413.1 RP11-665C16.6 -5.24 5.17e-07 0.000416 -0.49 -0.39 Protein biomarker; chr14:55347662 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs28716725 ENSG00000258413.1 RP11-665C16.6 -5.24 5.17e-07 0.000416 -0.49 -0.39 Protein biomarker; chr14:55349892 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs7153110 ENSG00000258413.1 RP11-665C16.6 -5.24 5.17e-07 0.000416 -0.49 -0.39 Protein biomarker; chr14:55353910 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs7159144 ENSG00000258413.1 RP11-665C16.6 -5.24 5.17e-07 0.000416 -0.49 -0.39 Protein biomarker; chr14:55354606 chr14:55262767~55272075:- PAAD cis rs2274273 0.744 rs8011808 ENSG00000258413.1 RP11-665C16.6 -5.24 5.17e-07 0.000416 -0.49 -0.39 Protein biomarker; chr14:55356626 chr14:55262767~55272075:- PAAD cis rs11089937 0.609 rs2213158 ENSG00000211639.2 IGLV4-60 5.24 5.19e-07 0.000417 0.42 0.39 Periodontitis (PAL4Q3); chr22:22138099 chr22:22162199~22162681:+ PAAD cis rs11089937 0.637 rs2213159 ENSG00000211639.2 IGLV4-60 5.24 5.19e-07 0.000417 0.42 0.39 Periodontitis (PAL4Q3); chr22:22138100 chr22:22162199~22162681:+ PAAD cis rs2274273 0.87 rs10149420 ENSG00000258413.1 RP11-665C16.6 -5.24 5.21e-07 0.000418 -0.49 -0.39 Protein biomarker; chr14:55387539 chr14:55262767~55272075:- PAAD cis rs2412819 0.571 rs12900924 ENSG00000249839.1 AC011330.5 -5.24 5.21e-07 0.000419 -0.66 -0.39 Lung cancer; chr15:43737329 chr15:43663654~43684339:- PAAD cis rs950169 0.545 rs4842841 ENSG00000225151.9 GOLGA2P7 -5.24 5.22e-07 0.000419 -0.48 -0.39 Schizophrenia; chr15:83972373 chr15:84199311~84230136:- PAAD cis rs6570726 0.846 rs6570698 ENSG00000235652.6 RP11-545I5.3 5.24 5.22e-07 0.000419 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145597499 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs6914304 ENSG00000235652.6 RP11-545I5.3 5.24 5.22e-07 0.000419 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145599881 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs7762536 ENSG00000235652.6 RP11-545I5.3 5.24 5.22e-07 0.000419 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145602009 chr6:145799409~145886585:+ PAAD cis rs6570726 0.818 rs952405 ENSG00000235652.6 RP11-545I5.3 5.24 5.22e-07 0.000419 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145604816 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs4896824 ENSG00000235652.6 RP11-545I5.3 5.24 5.22e-07 0.000419 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145605912 chr6:145799409~145886585:+ PAAD cis rs638893 0.541 rs498912 ENSG00000278376.1 RP11-158I9.8 -5.24 5.24e-07 0.00042 -0.63 -0.39 Vitiligo; chr11:118706288 chr11:118791254~118793137:+ PAAD cis rs10463554 0.927 rs11952361 ENSG00000175749.11 EIF3KP1 5.24 5.24e-07 0.000421 0.5 0.39 Parkinson's disease; chr5:102952216 chr5:103032376~103033031:+ PAAD cis rs17301013 0.507 rs10489255 ENSG00000227373.4 RP11-160H22.5 5.24 5.24e-07 0.000421 0.57 0.39 Systemic lupus erythematosus; chr1:174341985 chr1:174115300~174160004:- PAAD cis rs9926296 0.508 rs1558184 ENSG00000260259.1 RP11-368I7.4 -5.24 5.24e-07 0.000421 -0.47 -0.39 Vitiligo; chr16:89775966 chr16:89682620~89686569:- PAAD cis rs964611 0.816 rs1426722 ENSG00000259488.2 RP11-154J22.1 -5.24 5.24e-07 0.000421 -0.39 -0.39 Metabolite levels (Pyroglutamine); chr15:48277212 chr15:48312353~48331856:- PAAD cis rs4660456 0.913 rs2780952 ENSG00000237899.1 RP4-739H11.3 5.24 5.24e-07 0.000421 0.53 0.39 Platelet count; chr1:40689711 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs656230 ENSG00000237899.1 RP4-739H11.3 5.24 5.24e-07 0.000421 0.53 0.39 Platelet count; chr1:40692701 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs2780953 ENSG00000237899.1 RP4-739H11.3 5.24 5.24e-07 0.000421 0.53 0.39 Platelet count; chr1:40694105 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs7551747 ENSG00000237899.1 RP4-739H11.3 5.24 5.24e-07 0.000421 0.53 0.39 Platelet count; chr1:40699407 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs7542019 ENSG00000237899.1 RP4-739H11.3 5.24 5.24e-07 0.000421 0.53 0.39 Platelet count; chr1:40704039 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs1494 ENSG00000237899.1 RP4-739H11.3 5.24 5.24e-07 0.000421 0.53 0.39 Platelet count; chr1:40706176 chr1:40669089~40687588:- PAAD cis rs4660456 0.869 rs7518344 ENSG00000237899.1 RP4-739H11.3 5.24 5.24e-07 0.000421 0.53 0.39 Platelet count; chr1:40708327 chr1:40669089~40687588:- PAAD cis rs4660456 0.827 rs10736404 ENSG00000237899.1 RP4-739H11.3 5.24 5.24e-07 0.000421 0.53 0.39 Platelet count; chr1:40710331 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs12727412 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40723243 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs4660448 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40724682 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs7532802 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40725528 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs2361648 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40726825 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs6675886 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40727955 chr1:40669089~40687588:- PAAD cis rs4660456 0.83 rs12742219 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40728665 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs6668453 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40733299 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs35881320 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40733893 chr1:40669089~40687588:- PAAD cis rs4660456 0.871 rs34512220 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40733912 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs6664044 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40735089 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs6702983 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40735585 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs12566733 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40736067 chr1:40669089~40687588:- PAAD cis rs4660456 0.83 rs12566786 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40742709 chr1:40669089~40687588:- PAAD cis rs4660456 0.871 rs2274957 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40747290 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs4660173 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40747876 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs4660452 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40748519 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs12567925 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40751428 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs12728776 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40751718 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs12567755 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40751813 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs16827532 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40755064 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs12729696 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40755099 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs16827552 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40758336 chr1:40669089~40687588:- PAAD cis rs4660456 0.871 rs7549789 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40759362 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs16827569 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40761655 chr1:40669089~40687588:- PAAD cis rs4660456 0.564 rs34320811 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40763288 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs2361650 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40764678 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs954654 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40764979 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs34212676 ENSG00000237899.1 RP4-739H11.3 -5.24 5.24e-07 0.000421 -0.53 -0.39 Platelet count; chr1:40766522 chr1:40669089~40687588:- PAAD cis rs7772486 0.875 rs1331645 ENSG00000235652.6 RP11-545I5.3 5.24 5.25e-07 0.000421 0.31 0.39 Lobe attachment (rater-scored or self-reported); chr6:146077271 chr6:145799409~145886585:+ PAAD cis rs8059260 0.604 rs34573672 ENSG00000274038.1 RP11-66H6.4 -5.24 5.25e-07 0.000421 -0.59 -0.39 Alcohol consumption over the past year; chr16:11111882 chr16:11056556~11057034:+ PAAD cis rs6570726 0.791 rs6902404 ENSG00000235652.6 RP11-545I5.3 5.24 5.26e-07 0.000422 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145584118 chr6:145799409~145886585:+ PAAD cis rs2581828 0.656 rs2163167 ENSG00000242142.1 SERBP1P3 5.24 5.27e-07 0.000422 0.45 0.39 Crohn's disease; chr3:53097756 chr3:53064283~53065091:- PAAD cis rs2581828 0.541 rs2115781 ENSG00000242142.1 SERBP1P3 5.24 5.27e-07 0.000422 0.45 0.39 Crohn's disease; chr3:53097813 chr3:53064283~53065091:- PAAD cis rs6061231 1 rs11696991 ENSG00000273619.1 RP5-908M14.9 -5.24 5.27e-07 0.000423 -0.32 -0.39 Colorectal cancer; chr20:62384638 chr20:62386303~62386970:- PAAD cis rs6991838 0.584 rs4737221 ENSG00000200714.1 Y_RNA -5.24 5.28e-07 0.000423 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65569075 chr8:65592731~65592820:+ PAAD cis rs964611 0.882 rs1872304 ENSG00000259488.2 RP11-154J22.1 5.24 5.29e-07 0.000423 0.45 0.39 Metabolite levels (Pyroglutamine); chr15:48366591 chr15:48312353~48331856:- PAAD cis rs7772486 0.754 rs864148 ENSG00000235652.6 RP11-545I5.3 -5.24 5.29e-07 0.000424 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145655539 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs702304 ENSG00000235652.6 RP11-545I5.3 -5.24 5.29e-07 0.000424 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145669661 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs702306 ENSG00000235652.6 RP11-545I5.3 -5.24 5.29e-07 0.000424 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145669893 chr6:145799409~145886585:+ PAAD cis rs4879677 1 rs10757676 ENSG00000260390.1 RP11-575I8.1 -5.24 5.31e-07 0.000425 -0.5 -0.39 Gut microbiome composition (summer and winter); chr9:27680309 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs4879706 ENSG00000260390.1 RP11-575I8.1 -5.24 5.31e-07 0.000425 -0.5 -0.39 Gut microbiome composition (summer and winter); chr9:27685777 chr9:27829276~27844481:+ PAAD cis rs6700559 0.873 rs7542840 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200686558 chr1:200669507~200694250:+ PAAD cis rs6700559 0.873 rs7524025 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200687859 chr1:200669507~200694250:+ PAAD cis rs6700559 0.815 rs7526365 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200688020 chr1:200669507~200694250:+ PAAD cis rs6700559 0.873 rs7526482 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200688310 chr1:200669507~200694250:+ PAAD cis rs6700559 0.873 rs7526853 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200688529 chr1:200669507~200694250:+ PAAD cis rs6700559 0.844 rs61825137 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200689267 chr1:200669507~200694250:+ PAAD cis rs6700559 0.873 rs7545177 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200690727 chr1:200669507~200694250:+ PAAD cis rs6700559 0.873 rs7539646 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200692534 chr1:200669507~200694250:+ PAAD cis rs6700559 0.873 rs7519383 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200692968 chr1:200669507~200694250:+ PAAD cis rs6700559 0.815 rs12141497 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200693389 chr1:200669507~200694250:+ PAAD cis rs6700559 0.873 rs12126708 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200693397 chr1:200669507~200694250:+ PAAD cis rs6700559 0.873 rs10920008 ENSG00000260088.1 RP11-92G12.3 -5.24 5.31e-07 0.000425 -0.52 -0.39 Coronary artery disease; chr1:200694546 chr1:200669507~200694250:+ PAAD cis rs9926296 0.585 rs6500450 ENSG00000260259.1 RP11-368I7.4 -5.24 5.31e-07 0.000425 -0.48 -0.39 Vitiligo; chr16:89791616 chr16:89682620~89686569:- PAAD cis rs638893 0.541 rs553188 ENSG00000278376.1 RP11-158I9.8 -5.24 5.35e-07 0.000428 -0.63 -0.39 Vitiligo; chr11:118706053 chr11:118791254~118793137:+ PAAD cis rs2019137 0.936 rs4849169 ENSG00000189223.12 PAX8-AS1 5.24 5.35e-07 0.000428 0.47 0.39 Lymphocyte counts; chr2:113196080 chr2:113211522~113276581:+ PAAD cis rs4308124 0.708 rs56693625 ENSG00000227992.1 AC108463.2 -5.24 5.35e-07 0.000428 -0.44 -0.39 Vitiligo; chr2:111207578 chr2:111203964~111206215:- PAAD cis rs4308124 0.708 rs61358692 ENSG00000227992.1 AC108463.2 -5.24 5.35e-07 0.000428 -0.44 -0.39 Vitiligo; chr2:111207582 chr2:111203964~111206215:- PAAD cis rs6991838 0.584 rs7463649 ENSG00000200714.1 Y_RNA -5.24 5.35e-07 0.000428 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65573760 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs66467166 ENSG00000200714.1 Y_RNA -5.24 5.35e-07 0.000428 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65574165 chr8:65592731~65592820:+ PAAD cis rs6991838 0.557 rs67685675 ENSG00000200714.1 Y_RNA -5.24 5.35e-07 0.000428 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65574371 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs66486920 ENSG00000200714.1 Y_RNA -5.24 5.35e-07 0.000428 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65574458 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs60023200 ENSG00000200714.1 Y_RNA -5.24 5.35e-07 0.000428 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65574547 chr8:65592731~65592820:+ PAAD cis rs7772486 0.719 rs7753770 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145745025 chr6:145799409~145886585:+ PAAD cis rs7772486 0.692 rs1577916 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145748653 chr6:145799409~145886585:+ PAAD cis rs7772486 0.655 rs2142981 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145750559 chr6:145799409~145886585:+ PAAD cis rs7772486 0.72 rs7752286 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145751526 chr6:145799409~145886585:+ PAAD cis rs7772486 0.72 rs6570713 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145753949 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs6906258 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145768220 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs6915718 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145779540 chr6:145799409~145886585:+ PAAD cis rs7772486 0.72 rs6931553 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145791212 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs6937661 ENSG00000235652.6 RP11-545I5.3 -5.24 5.36e-07 0.000429 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145792163 chr6:145799409~145886585:+ PAAD cis rs13178541 0.748 rs4976308 ENSG00000250378.1 RP11-119J18.1 -5.24 5.37e-07 0.000429 -0.6 -0.39 IgG glycosylation; chr5:135729915 chr5:135812667~135826582:+ PAAD cis rs7208859 0.673 rs78799101 ENSG00000266490.1 CTD-2349P21.9 5.24 5.37e-07 0.000429 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888142 chr17:30792372~30792833:+ PAAD cis rs992157 0.687 rs10206984 ENSG00000261338.2 RP11-378A13.1 5.24 5.37e-07 0.000429 0.44 0.39 Colorectal cancer; chr2:218202257 chr2:218255319~218257366:+ PAAD cis rs9926296 0.715 rs467035 ENSG00000260259.1 RP11-368I7.4 -5.24 5.4e-07 0.000432 -0.47 -0.39 Vitiligo; chr16:89673877 chr16:89682620~89686569:- PAAD cis rs7078219 0.505 rs1548964 ENSG00000257582.4 LINC01475 5.24 5.4e-07 0.000432 0.43 0.39 Dental caries; chr10:99529896 chr10:99526350~99531177:- PAAD cis rs2658782 0.789 rs56091149 ENSG00000279684.1 RP11-755E23.2 5.23 5.41e-07 0.000432 0.64 0.39 Pulmonary function decline; chr11:93340474 chr11:93286629~93288903:- PAAD cis rs3096299 0.9 rs3114867 ENSG00000274627.1 RP11-104N10.2 5.23 5.42e-07 0.000432 0.35 0.39 Multiple myeloma (IgH translocation); chr16:89362559 chr16:89516797~89522217:+ PAAD cis rs2243480 1 rs316331 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66139635 chr7:66654538~66669855:+ PAAD cis rs2243480 0.908 rs2460431 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66157859 chr7:66654538~66669855:+ PAAD cis rs2243480 0.711 rs2460426 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66158142 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs4718309 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66162777 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6460274 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66163497 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs7787230 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66164112 chr7:66654538~66669855:+ PAAD cis rs2243480 0.711 rs2420172 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66170354 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2420171 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66172773 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6974723 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66172952 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs9769882 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66177938 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6966322 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66181767 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs4145008 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66182524 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs4718315 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66183554 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs4718316 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66183744 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1873494 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66184912 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6959002 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66185509 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1546059 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66189722 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2420170 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66191066 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6958289 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66192124 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs7804223 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66199572 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs12530490 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66226660 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs7778911 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66229519 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1979823 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66239626 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6964245 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66253730 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs10807701 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66259699 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1499613 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66265873 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1553174 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66266207 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs10950032 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66273604 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs6958420 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66286184 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1392104 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66294120 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs4718333 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66307771 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs7792391 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66308442 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs10247526 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66315709 chr7:66654538~66669855:+ PAAD cis rs2243480 0.908 rs1532573 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Diabetic kidney disease; chr7:66333815 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs1882655 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Gout; chr7:66682070 chr7:66654538~66669855:+ PAAD cis rs1499614 0.831 rs3800822 ENSG00000226824.5 RP4-756H11.3 5.23 5.42e-07 0.000432 0.7 0.39 Gout; chr7:66682162 chr7:66654538~66669855:+ PAAD cis rs2243480 0.908 rs313822 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66108952 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313820 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66109479 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs160639 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66115000 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs313824 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66116220 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs186378 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66117071 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs160637 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66119331 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs422164 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66121618 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316313 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66128561 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316312 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66131504 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs419603 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66132354 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs387676 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66133233 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs13310597 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66133553 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs431076 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66135333 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2257790 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66135463 chr7:66654538~66669855:+ PAAD cis rs2243480 0.764 rs2460423 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66136229 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2460422 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66136518 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316334 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66137139 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316332 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66139312 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316329 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66143429 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316326 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66144466 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316325 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66144531 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316322 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66146246 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316321 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66146626 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316318 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66147917 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316317 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66148650 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs316304 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66151907 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2465120 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66155987 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1499614 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66265811 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs778729 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66359432 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs4149468 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66360703 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs778687 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66370832 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs778679 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66375924 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs778704 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66398480 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs778693 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66407358 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs778691 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66408105 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs13235972 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66418618 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs34192067 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66422670 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs34807232 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66500146 chr7:66654538~66669855:+ PAAD cis rs2243480 0.901 rs35823062 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66500834 chr7:66654538~66669855:+ PAAD cis rs2243480 0.708 rs35825036 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66521515 chr7:66654538~66669855:+ PAAD cis rs2243480 0.803 rs13224048 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66528779 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs13237037 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66532895 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1796228 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66568097 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1267820 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66585308 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2533288 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66591724 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2707844 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66594522 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs1796220 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66597113 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs2707831 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Diabetic kidney disease; chr7:66597524 chr7:66654538~66669855:+ PAAD cis rs1499614 0.803 rs1796229 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66654674 chr7:66654538~66669855:+ PAAD cis rs1499614 0.901 rs3936 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66661502 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2707832 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66671562 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs1638731 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66679692 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2659913 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66692349 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2707840 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66693028 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2659911 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66693433 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2707838 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66694214 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs60326618 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66701371 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2707830 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66702658 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2707828 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66706390 chr7:66654538~66669855:+ PAAD cis rs1499614 0.803 rs1922723 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66710076 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2659903 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66715944 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs2141924 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66721259 chr7:66654538~66669855:+ PAAD cis rs1499614 0.901 rs2178742 ENSG00000226824.5 RP4-756H11.3 -5.23 5.42e-07 0.000432 -0.7 -0.39 Gout; chr7:66732812 chr7:66654538~66669855:+ PAAD cis rs9322193 0.884 rs7744105 ENSG00000223701.3 RAET1E-AS1 5.23 5.43e-07 0.000432 0.47 0.39 Lung cancer; chr6:149849308 chr6:149884431~149919508:+ PAAD cis rs2153535 0.58 rs915350 ENSG00000230939.1 RP11-314C16.1 -5.23 5.44e-07 0.000433 -0.41 -0.39 Motion sickness; chr6:8443253 chr6:8784178~8785445:+ PAAD cis rs1275468 1 rs1795379 ENSG00000257497.2 RP11-585P4.5 -5.23 5.44e-07 0.000433 -0.58 -0.39 Polycystic ovary syndrome; chr12:75547262 chr12:75483454~75489820:- PAAD cis rs694739 0.796 rs479777 ENSG00000236935.1 AP003774.1 5.23 5.44e-07 0.000433 0.4 0.39 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64340005 chr11:64325050~64329504:- PAAD cis rs2274273 0.686 rs28631821 ENSG00000258413.1 RP11-665C16.6 -5.23 5.45e-07 0.000433 -0.49 -0.39 Protein biomarker; chr14:55379269 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs946059 ENSG00000258413.1 RP11-665C16.6 -5.23 5.45e-07 0.000433 -0.49 -0.39 Protein biomarker; chr14:55380748 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs10144345 ENSG00000258413.1 RP11-665C16.6 -5.23 5.45e-07 0.000433 -0.49 -0.39 Protein biomarker; chr14:55381019 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs3783650 ENSG00000258413.1 RP11-665C16.6 -5.23 5.45e-07 0.000433 -0.49 -0.39 Protein biomarker; chr14:55382254 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs4597235 ENSG00000258413.1 RP11-665C16.6 -5.23 5.45e-07 0.000433 -0.49 -0.39 Protein biomarker; chr14:55385269 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs3825616 ENSG00000258413.1 RP11-665C16.6 -5.23 5.45e-07 0.000433 -0.49 -0.39 Protein biomarker; chr14:55386570 chr14:55262767~55272075:- PAAD cis rs7772486 0.701 rs11155438 ENSG00000235652.6 RP11-545I5.3 5.23 5.45e-07 0.000434 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145628976 chr6:145799409~145886585:+ PAAD cis rs9532669 0.819 rs9532652 ENSG00000176268.5 CYCSP34 5.23 5.45e-07 0.000434 0.4 0.39 Cervical cancer; chr13:40903300 chr13:40863599~40863902:- PAAD cis rs6584283 0.766 rs7911680 ENSG00000257582.4 LINC01475 -5.23 5.45e-07 0.000434 -0.43 -0.39 Ulcerative colitis; chr10:99533711 chr10:99526350~99531177:- PAAD cis rs17711722 0.565 rs4275112 ENSG00000226824.5 RP4-756H11.3 5.23 5.46e-07 0.000434 0.46 0.39 Calcium levels; chr7:65733651 chr7:66654538~66669855:+ PAAD cis rs3096299 0.933 rs889576 ENSG00000274627.1 RP11-104N10.2 -5.23 5.46e-07 0.000434 -0.34 -0.39 Multiple myeloma (IgH translocation); chr16:89363245 chr16:89516797~89522217:+ PAAD cis rs4227 0.565 rs10438740 ENSG00000233223.2 AC113189.5 -5.23 5.46e-07 0.000434 -0.43 -0.39 IgA nephropathy; chr17:7569566 chr17:7581964~7584072:- PAAD cis rs2274273 0.588 rs17675223 ENSG00000258413.1 RP11-665C16.6 -5.23 5.48e-07 0.000436 -0.52 -0.39 Protein biomarker; chr14:55395518 chr14:55262767~55272075:- PAAD cis rs2404602 0.709 rs11072591 ENSG00000259422.1 RP11-593F23.1 5.23 5.48e-07 0.000436 0.48 0.39 Blood metabolite levels; chr15:76357221 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs2280306 ENSG00000259422.1 RP11-593F23.1 -5.23 5.48e-07 0.000436 -0.48 -0.39 Blood metabolite levels; chr15:76359917 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs11638767 ENSG00000259422.1 RP11-593F23.1 -5.23 5.48e-07 0.000436 -0.48 -0.39 Blood metabolite levels; chr15:76363597 chr15:76174891~76181486:- PAAD cis rs3762637 0.943 rs9289196 ENSG00000272758.4 RP11-299J3.8 -5.23 5.49e-07 0.000436 -0.52 -0.39 LDL cholesterol levels; chr3:122549659 chr3:122416207~122443180:+ PAAD cis rs4814920 0.818 rs4813376 ENSG00000275142.1 RP5-999L4.2 5.23 5.5e-07 0.000437 0.7 0.39 Bipolar disorder (body mass index interaction); chr20:19870811 chr20:19871891~19872284:+ PAAD cis rs2274273 0.624 rs10143136 ENSG00000258413.1 RP11-665C16.6 -5.23 5.5e-07 0.000437 -0.52 -0.39 Protein biomarker; chr14:55276810 chr14:55262767~55272075:- PAAD cis rs9473147 0.516 rs6931478 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47494177 chr6:47477243~47477572:- PAAD cis rs9369695 0.881 rs9349409 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Reticulocyte count; chr6:47495390 chr6:47477243~47477572:- PAAD cis rs9369695 0.842 rs9395262 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Reticulocyte count; chr6:47497531 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs7738044 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47501537 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs9473122 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47507226 chr6:47477243~47477572:- PAAD cis rs9473147 0.503 rs9473123 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47507603 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs13211285 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47511882 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs1872505 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47513239 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs7749271 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47517266 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9296561 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47521202 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs7749167 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47526204 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9296564 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47527023 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs7754282 ENSG00000270761.1 RP11-385F7.1 5.23 5.51e-07 0.000437 0.39 0.39 Platelet distribution width;Mean platelet volume; chr6:47534288 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs6904764 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47535761 chr6:47477243~47477572:- PAAD cis rs9369695 0.883 rs9473128 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Reticulocyte count; chr6:47537274 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs2151974 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47547894 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs2151975 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47547927 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9367284 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47548633 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9381575 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47561028 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9395279 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47575128 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9357546 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47581759 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9395283 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47583708 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9349415 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47584125 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9349416 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47584202 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs1485780 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47588894 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs9381578 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47588898 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9381579 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47588944 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs10456570 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47591715 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs6903331 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47595179 chr6:47477243~47477572:- PAAD cis rs9369695 0.842 rs2396825 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Reticulocyte count; chr6:47600960 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9395286 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47607596 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs13212790 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47608631 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs9349417 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47612921 chr6:47477243~47477572:- PAAD cis rs9369695 0.883 rs9381581 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Reticulocyte count; chr6:47612959 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9463342 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47617370 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs10948367 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47617879 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs7754971 ENSG00000270761.1 RP11-385F7.1 -5.23 5.51e-07 0.000437 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47622740 chr6:47477243~47477572:- PAAD cis rs2274273 0.87 rs10147434 ENSG00000258413.1 RP11-665C16.6 -5.23 5.51e-07 0.000437 -0.49 -0.39 Protein biomarker; chr14:55208129 chr14:55262767~55272075:- PAAD cis rs2274273 0.837 rs7142857 ENSG00000258413.1 RP11-665C16.6 -5.23 5.51e-07 0.000437 -0.49 -0.39 Protein biomarker; chr14:55237410 chr14:55262767~55272075:- PAAD cis rs2274273 0.805 rs10131926 ENSG00000258413.1 RP11-665C16.6 -5.23 5.51e-07 0.000437 -0.49 -0.39 Protein biomarker; chr14:55246528 chr14:55262767~55272075:- PAAD cis rs2274273 0.934 rs8021940 ENSG00000258413.1 RP11-665C16.6 -5.23 5.51e-07 0.000437 -0.49 -0.39 Protein biomarker; chr14:55252997 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs10467798 ENSG00000258413.1 RP11-665C16.6 -5.23 5.51e-07 0.000437 -0.49 -0.39 Protein biomarker; chr14:55258209 chr14:55262767~55272075:- PAAD cis rs2274273 0.934 rs2341621 ENSG00000258413.1 RP11-665C16.6 -5.23 5.51e-07 0.000437 -0.49 -0.39 Protein biomarker; chr14:55259707 chr14:55262767~55272075:- PAAD cis rs2274273 0.773 rs8012380 ENSG00000258413.1 RP11-665C16.6 -5.23 5.51e-07 0.000437 -0.49 -0.39 Protein biomarker; chr14:55268292 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs2341622 ENSG00000258413.1 RP11-665C16.6 -5.23 5.51e-07 0.000437 -0.49 -0.39 Protein biomarker; chr14:55270525 chr14:55262767~55272075:- PAAD cis rs12449000 1 rs12449000 ENSG00000260259.1 RP11-368I7.4 -5.23 5.51e-07 0.000437 -0.49 -0.39 Schizophrenia; chr16:89806562 chr16:89682620~89686569:- PAAD cis rs633715 0.877 rs545608 ENSG00000254154.7 RP4-798P15.3 -5.23 5.51e-07 0.000438 -0.34 -0.39 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177929986 chr1:177928788~178038007:- PAAD cis rs2274273 0.624 rs7159824 ENSG00000258413.1 RP11-665C16.6 -5.23 5.52e-07 0.000438 -0.52 -0.39 Protein biomarker; chr14:55305818 chr14:55262767~55272075:- PAAD cis rs7772486 0.754 rs9497419 ENSG00000235652.6 RP11-545I5.3 5.23 5.52e-07 0.000439 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145821473 chr6:145799409~145886585:+ PAAD cis rs7772486 0.727 rs12190966 ENSG00000235652.6 RP11-545I5.3 5.23 5.52e-07 0.000439 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145825684 chr6:145799409~145886585:+ PAAD cis rs75422866 0.867 rs7303895 ENSG00000257433.4 RP1-197B17.3 5.23 5.53e-07 0.000439 0.78 0.39 Pneumonia; chr12:47683290 chr12:47706085~47742294:+ PAAD cis rs2581828 0.965 rs2581829 ENSG00000242142.1 SERBP1P3 -5.23 5.54e-07 0.000439 -0.44 -0.39 Crohn's disease; chr3:53099510 chr3:53064283~53065091:- PAAD cis rs67180937 0.583 rs3008622 ENSG00000272750.1 RP11-378J18.8 5.23 5.54e-07 0.00044 0.47 0.39 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222632356 chr1:222658867~222661512:- PAAD cis rs7615952 0.515 rs7630575 ENSG00000171084.14 FAM86JP 5.23 5.55e-07 0.000441 0.59 0.39 Blood pressure (smoking interaction); chr3:125963487 chr3:125916620~125930024:+ PAAD cis rs6570726 0.791 rs378937 ENSG00000235652.6 RP11-545I5.3 5.23 5.57e-07 0.000441 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145513609 chr6:145799409~145886585:+ PAAD cis rs748404 0.66 rs693510 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43422427 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs509306 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43422973 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs690512 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43425480 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs542898 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43427194 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs690012 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43427557 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs2249952 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43428335 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs689767 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43429879 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs2439845 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43430412 chr15:43726918~43747094:- PAAD cis rs748404 0.631 rs2467745 ENSG00000205771.5 CATSPER2P1 -5.23 5.57e-07 0.000442 -0.54 -0.39 Lung cancer; chr15:43430544 chr15:43726918~43747094:- PAAD cis rs7916697 0.593 rs3740587 ENSG00000233590.1 RP11-153K11.3 5.23 5.58e-07 0.000442 0.51 0.39 Optic disc area; chr10:68261045 chr10:68233251~68242379:- PAAD cis rs7916697 0.593 rs10762198 ENSG00000233590.1 RP11-153K11.3 5.23 5.58e-07 0.000442 0.51 0.39 Optic disc area; chr10:68263296 chr10:68233251~68242379:- PAAD cis rs7684253 0.526 rs34112167 ENSG00000269949.1 RP11-738E22.3 -5.23 5.6e-07 0.000444 -0.54 -0.39 Migraine; chr4:56853383 chr4:56960927~56961373:- PAAD cis rs10875746 0.669 rs1021313 ENSG00000240399.1 RP1-228P16.1 -5.23 5.6e-07 0.000444 -0.43 -0.39 Longevity (90 years and older); chr12:48244258 chr12:48054813~48055591:- PAAD cis rs3096299 0.967 rs2965935 ENSG00000274627.1 RP11-104N10.2 -5.23 5.6e-07 0.000444 -0.35 -0.39 Multiple myeloma (IgH translocation); chr16:89414866 chr16:89516797~89522217:+ PAAD cis rs2980436 1 rs2980436 ENSG00000253981.4 ALG1L13P -5.23 5.61e-07 0.000444 -0.49 -0.39 Schizophrenia; chr8:8234503 chr8:8236003~8244667:- PAAD cis rs638893 0.717 rs622690 ENSG00000278376.1 RP11-158I9.8 -5.23 5.61e-07 0.000444 -0.55 -0.39 Vitiligo; chr11:118833556 chr11:118791254~118793137:+ PAAD cis rs7078219 0.505 rs4129132 ENSG00000257582.4 LINC01475 -5.23 5.61e-07 0.000444 -0.43 -0.39 Dental caries; chr10:99524880 chr10:99526350~99531177:- PAAD cis rs3762637 0.943 rs10222564 ENSG00000272758.4 RP11-299J3.8 -5.23 5.63e-07 0.000445 -0.58 -0.39 LDL cholesterol levels; chr3:122547489 chr3:122416207~122443180:+ PAAD cis rs3762637 0.943 rs9289198 ENSG00000272758.4 RP11-299J3.8 -5.23 5.63e-07 0.000445 -0.58 -0.39 LDL cholesterol levels; chr3:122558313 chr3:122416207~122443180:+ PAAD cis rs3762637 0.943 rs9289199 ENSG00000272758.4 RP11-299J3.8 -5.23 5.63e-07 0.000445 -0.58 -0.39 LDL cholesterol levels; chr3:122558325 chr3:122416207~122443180:+ PAAD cis rs3762637 0.943 rs9841897 ENSG00000272758.4 RP11-299J3.8 -5.23 5.63e-07 0.000445 -0.58 -0.39 LDL cholesterol levels; chr3:122563722 chr3:122416207~122443180:+ PAAD cis rs72772090 1 rs11738135 ENSG00000248734.2 CTD-2260A17.1 -5.23 5.64e-07 0.000446 -0.47 -0.39 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96712632 chr5:96784777~96785999:+ PAAD cis rs638893 0.898 rs587816 ENSG00000278376.1 RP11-158I9.8 -5.23 5.64e-07 0.000446 -0.52 -0.39 Vitiligo; chr11:118819162 chr11:118791254~118793137:+ PAAD cis rs638893 0.898 rs577121 ENSG00000278376.1 RP11-158I9.8 -5.23 5.64e-07 0.000446 -0.52 -0.39 Vitiligo; chr11:118819841 chr11:118791254~118793137:+ PAAD cis rs4950322 0.57 rs17360443 ENSG00000278811.3 LINC00624 5.23 5.65e-07 0.000447 0.41 0.39 Protein quantitative trait loci; chr1:147279737 chr1:147258885~147517875:- PAAD cis rs2153535 0.58 rs962590 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8450666 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs5001324 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8451371 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs5001322 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8451375 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs969422 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8451547 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs969421 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8451716 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs969420 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8451733 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7741456 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8452191 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7742689 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8452200 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7767756 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8453195 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7767780 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8453229 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7767926 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8453324 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7748455 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8453392 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327062 ENSG00000230939.1 RP11-314C16.1 -5.23 5.65e-07 0.000447 -0.41 -0.39 Motion sickness; chr6:8453625 chr6:8784178~8785445:+ PAAD cis rs7916697 0.626 rs61854803 ENSG00000233590.1 RP11-153K11.3 -5.23 5.65e-07 0.000447 -0.51 -0.39 Optic disc area; chr10:68254881 chr10:68233251~68242379:- PAAD cis rs7772486 0.521 rs9485017 ENSG00000235652.6 RP11-545I5.3 5.22 5.66e-07 0.000447 0.33 0.39 Lobe attachment (rater-scored or self-reported); chr6:145702190 chr6:145799409~145886585:+ PAAD cis rs3931020 0.657 rs7522428 ENSG00000272864.1 RP11-17E13.2 -5.22 5.66e-07 0.000448 -0.55 -0.39 Resistin levels; chr1:74712676 chr1:74698769~74699333:- PAAD cis rs1400745 0.729 rs28472856 ENSG00000258738.1 RP11-73E17.2 5.22 5.66e-07 0.000448 0.45 0.39 Monocyte count; chr14:34862951 chr14:34874343~34876459:+ PAAD cis rs950169 0.649 rs12911612 ENSG00000259728.4 LINC00933 5.22 5.67e-07 0.000448 0.51 0.39 Schizophrenia; chr15:84022262 chr15:84570649~84580175:+ PAAD cis rs950169 0.649 rs12905952 ENSG00000259728.4 LINC00933 5.22 5.67e-07 0.000448 0.51 0.39 Schizophrenia; chr15:84022509 chr15:84570649~84580175:+ PAAD cis rs950169 0.61 rs34529571 ENSG00000259728.4 LINC00933 5.22 5.67e-07 0.000448 0.51 0.39 Schizophrenia; chr15:84023055 chr15:84570649~84580175:+ PAAD cis rs2019137 0.936 rs3811059 ENSG00000189223.12 PAX8-AS1 5.22 5.67e-07 0.000448 0.48 0.39 Lymphocyte counts; chr2:113204494 chr2:113211522~113276581:+ PAAD cis rs2019137 0.936 rs12620738 ENSG00000189223.12 PAX8-AS1 5.22 5.67e-07 0.000448 0.48 0.39 Lymphocyte counts; chr2:113206162 chr2:113211522~113276581:+ PAAD cis rs4660456 0.913 rs552147 ENSG00000237899.1 RP4-739H11.3 -5.22 5.67e-07 0.000448 -0.52 -0.39 Platelet count; chr1:40689141 chr1:40669089~40687588:- PAAD cis rs172166 0.538 rs149956 ENSG00000204709.4 LINC01556 5.22 5.67e-07 0.000448 0.54 0.39 Cardiac Troponin-T levels; chr6:28068473 chr6:28943877~28944537:+ PAAD cis rs4774565 0.84 rs4775880 ENSG00000244879.4 GABPB1-AS1 5.22 5.67e-07 0.000448 0.36 0.39 Breast cancer; chr15:50383621 chr15:50354959~50372202:+ PAAD cis rs7772486 0.719 rs702307 ENSG00000235652.6 RP11-545I5.3 -5.22 5.68e-07 0.000449 -0.33 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145672318 chr6:145799409~145886585:+ PAAD cis rs4879677 1 rs10968061 ENSG00000260390.1 RP11-575I8.1 5.22 5.68e-07 0.000449 0.5 0.39 Gut microbiome composition (summer and winter); chr9:27688780 chr9:27829276~27844481:+ PAAD cis rs4879677 0.959 rs10812643 ENSG00000260390.1 RP11-575I8.1 -5.22 5.68e-07 0.000449 -0.5 -0.39 Gut microbiome composition (summer and winter); chr9:27690092 chr9:27829276~27844481:+ PAAD cis rs4927850 0.829 rs6768483 ENSG00000231464.1 AC024937.4 5.22 5.69e-07 0.000449 0.49 0.39 Pancreatic cancer; chr3:196019092 chr3:195996738~195998233:+ PAAD cis rs7188445 1 rs61221126 ENSG00000261390.4 RP11-345M22.2 -5.22 5.69e-07 0.00045 -0.55 -0.39 Urate levels; chr16:79699377 chr16:79715232~79770563:- PAAD cis rs6782228 0.675 rs4443194 ENSG00000242551.2 POU5F1P6 -5.22 5.69e-07 0.00045 -0.47 -0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128664603 chr3:128674735~128677005:- PAAD cis rs6782228 0.675 rs4857918 ENSG00000242551.2 POU5F1P6 -5.22 5.69e-07 0.00045 -0.47 -0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128665117 chr3:128674735~128677005:- PAAD cis rs4879677 1 rs10812633 ENSG00000260390.1 RP11-575I8.1 -5.22 5.69e-07 0.00045 -0.51 -0.39 Gut microbiome composition (summer and winter); chr9:27656975 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs7859172 ENSG00000260390.1 RP11-575I8.1 -5.22 5.69e-07 0.00045 -0.51 -0.39 Gut microbiome composition (summer and winter); chr9:27659388 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs12237360 ENSG00000260390.1 RP11-575I8.1 -5.22 5.69e-07 0.00045 -0.51 -0.39 Gut microbiome composition (summer and winter); chr9:27660200 chr9:27829276~27844481:+ PAAD cis rs11673344 0.704 rs510757 ENSG00000226686.6 LINC01535 -5.22 5.7e-07 0.00045 -0.53 -0.39 Obesity-related traits; chr19:36931900 chr19:37251912~37265535:+ PAAD cis rs7772486 0.79 rs9376968 ENSG00000235652.6 RP11-545I5.3 5.22 5.7e-07 0.00045 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145859228 chr6:145799409~145886585:+ PAAD cis rs11673344 0.832 rs11084871 ENSG00000226686.6 LINC01535 5.22 5.71e-07 0.000451 0.53 0.39 Obesity-related traits; chr19:37042023 chr19:37251912~37265535:+ PAAD cis rs11673344 0.832 rs77772684 ENSG00000226686.6 LINC01535 5.22 5.71e-07 0.000451 0.53 0.39 Obesity-related traits; chr19:37055838 chr19:37251912~37265535:+ PAAD cis rs12922040 0.701 rs12149912 ENSG00000263335.1 AF001548.5 -5.22 5.71e-07 0.000451 -0.45 -0.39 Serum uric acid levels in response to allopurinol in gout; chr16:15774798 chr16:15726674~15732993:+ PAAD cis rs7916697 0.626 rs3858144 ENSG00000233590.1 RP11-153K11.3 -5.22 5.71e-07 0.000451 -0.51 -0.39 Optic disc area; chr10:68251597 chr10:68233251~68242379:- PAAD cis rs7829975 0.846 rs7005216 ENSG00000253893.2 FAM85B 5.22 5.72e-07 0.000452 0.56 0.39 Mood instability; chr8:8689600 chr8:8167819~8226614:- PAAD cis rs12468226 1 rs2350809 ENSG00000273456.1 RP11-686O6.2 5.22 5.73e-07 0.000452 0.55 0.39 Urate levels; chr2:202464210 chr2:202374932~202375604:- PAAD cis rs7188445 0.966 rs8053589 ENSG00000261390.4 RP11-345M22.2 -5.22 5.73e-07 0.000453 -0.54 -0.39 Urate levels; chr16:79693093 chr16:79715232~79770563:- PAAD cis rs4308124 0.708 rs7585313 ENSG00000227992.1 AC108463.2 -5.22 5.74e-07 0.000453 -0.45 -0.39 Vitiligo; chr2:111217626 chr2:111203964~111206215:- PAAD cis rs2115630 0.645 rs2292463 ENSG00000225151.9 GOLGA2P7 5.22 5.74e-07 0.000453 0.45 0.39 P wave terminal force; chr15:84632519 chr15:84199311~84230136:- PAAD cis rs780094 0.585 rs3739095 ENSG00000234072.1 AC074117.10 -5.22 5.74e-07 0.000453 -0.3 -0.39 Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels; chr2:27333854 chr2:27356246~27367622:+ PAAD cis rs6991838 0.584 rs7459944 ENSG00000200714.1 Y_RNA -5.22 5.75e-07 0.000453 -0.46 -0.39 Intelligence (multi-trait analysis); chr8:65566040 chr8:65592731~65592820:+ PAAD cis rs1150668 0.799 rs9301 ENSG00000204709.4 LINC01556 5.22 5.75e-07 0.000454 0.52 0.39 Pubertal anthropometrics; chr6:28324929 chr6:28943877~28944537:+ PAAD cis rs1150668 0.799 rs853684 ENSG00000204709.4 LINC01556 5.22 5.75e-07 0.000454 0.52 0.39 Pubertal anthropometrics; chr6:28326773 chr6:28943877~28944537:+ PAAD cis rs2412819 0.571 rs62018900 ENSG00000205771.5 CATSPER2P1 -5.22 5.75e-07 0.000454 -0.62 -0.39 Lung cancer; chr15:43633252 chr15:43726918~43747094:- PAAD cis rs2412819 0.545 rs35333173 ENSG00000205771.5 CATSPER2P1 -5.22 5.75e-07 0.000454 -0.62 -0.39 Lung cancer; chr15:43640818 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs112667279 ENSG00000205771.5 CATSPER2P1 -5.22 5.75e-07 0.000454 -0.62 -0.39 Lung cancer; chr15:43649258 chr15:43726918~43747094:- PAAD cis rs2412819 0.545 rs17795279 ENSG00000205771.5 CATSPER2P1 5.22 5.75e-07 0.000454 0.62 0.39 Lung cancer; chr15:43637180 chr15:43726918~43747094:- PAAD cis rs6570726 0.72 rs412623 ENSG00000235652.6 RP11-545I5.3 5.22 5.76e-07 0.000454 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145562121 chr6:145799409~145886585:+ PAAD cis rs11098499 0.71 rs4145952 ENSG00000245958.5 RP11-33B1.1 -5.22 5.77e-07 0.000455 -0.28 -0.39 Corneal astigmatism; chr4:119234651 chr4:119454791~119552025:+ PAAD cis rs4683346 0.581 rs339684 ENSG00000173811.9 CCDC13-AS1 -5.22 5.77e-07 0.000455 -0.41 -0.39 Granulocyte percentage of myeloid white cells; chr3:42742143 chr3:42732575~42746768:+ PAAD cis rs6723162 0.51 rs887885 ENSG00000237751.2 LINC01143 -5.22 5.77e-07 0.000455 -0.52 -0.39 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70921556 chr2:70887871~70889959:+ PAAD cis rs9309711 0.666 rs11127429 ENSG00000225234.1 TRAPPC12-AS1 -5.22 5.78e-07 0.000455 -0.4 -0.39 Neurofibrillary tangles; chr2:3481453 chr2:3481242~3482409:- PAAD cis rs9309711 0.666 rs11127430 ENSG00000225234.1 TRAPPC12-AS1 -5.22 5.78e-07 0.000455 -0.4 -0.39 Neurofibrillary tangles; chr2:3481471 chr2:3481242~3482409:- PAAD cis rs2274273 0.806 rs7146752 ENSG00000258413.1 RP11-665C16.6 -5.22 5.78e-07 0.000455 -0.49 -0.39 Protein biomarker; chr14:55272189 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs13379169 ENSG00000258413.1 RP11-665C16.6 -5.22 5.78e-07 0.000455 -0.49 -0.39 Protein biomarker; chr14:55274569 chr14:55262767~55272075:- PAAD cis rs6921919 0.515 rs1558205 ENSG00000204709.4 LINC01556 -5.22 5.78e-07 0.000455 -0.53 -0.39 Autism spectrum disorder or schizophrenia; chr6:28414485 chr6:28943877~28944537:+ PAAD cis rs2243480 1 rs6964530 ENSG00000226824.5 RP4-756H11.3 5.22 5.78e-07 0.000456 0.7 0.39 Diabetic kidney disease; chr7:66253864 chr7:66654538~66669855:+ PAAD cis rs4660456 0.913 rs556875 ENSG00000237899.1 RP4-739H11.3 -5.22 5.79e-07 0.000456 -0.51 -0.39 Platelet count; chr1:40688571 chr1:40669089~40687588:- PAAD cis rs6782228 0.848 rs6439140 ENSG00000242551.2 POU5F1P6 5.22 5.8e-07 0.000457 0.5 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128699917 chr3:128674735~128677005:- PAAD cis rs2019137 0.936 rs2241978 ENSG00000189223.12 PAX8-AS1 5.22 5.8e-07 0.000457 0.47 0.39 Lymphocyte counts; chr2:113196429 chr2:113211522~113276581:+ PAAD cis rs2019137 0.936 rs3828188 ENSG00000189223.12 PAX8-AS1 5.22 5.8e-07 0.000457 0.47 0.39 Lymphocyte counts; chr2:113196670 chr2:113211522~113276581:+ PAAD cis rs2019137 0.936 rs3828189 ENSG00000189223.12 PAX8-AS1 5.22 5.8e-07 0.000457 0.47 0.39 Lymphocyte counts; chr2:113196919 chr2:113211522~113276581:+ PAAD cis rs2404602 0.647 rs7181506 ENSG00000259422.1 RP11-593F23.1 5.22 5.81e-07 0.000458 0.48 0.39 Blood metabolite levels; chr15:76643336 chr15:76174891~76181486:- PAAD cis rs2019137 0.967 rs902695 ENSG00000189223.12 PAX8-AS1 5.22 5.81e-07 0.000458 0.47 0.39 Lymphocyte counts; chr2:113197497 chr2:113211522~113276581:+ PAAD cis rs2019137 0.905 rs2276561 ENSG00000189223.12 PAX8-AS1 5.22 5.81e-07 0.000458 0.47 0.39 Lymphocyte counts; chr2:113198794 chr2:113211522~113276581:+ PAAD cis rs2019137 0.936 rs2305133 ENSG00000189223.12 PAX8-AS1 5.22 5.81e-07 0.000458 0.47 0.39 Lymphocyte counts; chr2:113199244 chr2:113211522~113276581:+ PAAD cis rs2019137 0.936 rs12612729 ENSG00000189223.12 PAX8-AS1 5.22 5.81e-07 0.000458 0.47 0.39 Lymphocyte counts; chr2:113199471 chr2:113211522~113276581:+ PAAD cis rs2019137 0.936 rs731834 ENSG00000189223.12 PAX8-AS1 5.22 5.81e-07 0.000458 0.47 0.39 Lymphocyte counts; chr2:113199621 chr2:113211522~113276581:+ PAAD cis rs12554020 0.892 rs12555047 ENSG00000227603.1 RP11-165J3.6 5.22 5.81e-07 0.000458 0.6 0.39 Schizophrenia; chr9:93424208 chr9:93435332~93437121:- PAAD cis rs17826219 0.706 rs57698184 ENSG00000266490.1 CTD-2349P21.9 5.22 5.81e-07 0.000458 0.51 0.39 Body mass index; chr17:30737900 chr17:30792372~30792833:+ PAAD cis rs7208859 0.524 rs59923796 ENSG00000266490.1 CTD-2349P21.9 5.22 5.81e-07 0.000458 0.51 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30737901 chr17:30792372~30792833:+ PAAD cis rs72772090 0.908 rs11750510 ENSG00000248734.2 CTD-2260A17.1 -5.22 5.84e-07 0.00046 -0.47 -0.39 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96706391 chr5:96784777~96785999:+ PAAD cis rs72772090 1 rs72772092 ENSG00000248734.2 CTD-2260A17.1 -5.22 5.84e-07 0.00046 -0.47 -0.39 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96711208 chr5:96784777~96785999:+ PAAD cis rs7772486 0.79 rs1832362 ENSG00000235652.6 RP11-545I5.3 5.22 5.85e-07 0.00046 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145858819 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2249147 ENSG00000235652.6 RP11-545I5.3 5.22 5.85e-07 0.00046 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145863863 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2253764 ENSG00000235652.6 RP11-545I5.3 5.22 5.85e-07 0.00046 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145878745 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2253880 ENSG00000235652.6 RP11-545I5.3 5.22 5.85e-07 0.00046 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145879638 chr6:145799409~145886585:+ PAAD cis rs7772486 0.79 rs2814879 ENSG00000235652.6 RP11-545I5.3 5.22 5.85e-07 0.00046 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145880607 chr6:145799409~145886585:+ PAAD cis rs9473147 0.503 rs2171086 ENSG00000270761.1 RP11-385F7.1 -5.22 5.85e-07 0.000461 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47622368 chr6:47477243~47477572:- PAAD cis rs7078219 0.505 rs10883365 ENSG00000257582.4 LINC01475 -5.22 5.89e-07 0.000464 -0.42 -0.39 Dental caries; chr10:99528007 chr10:99526350~99531177:- PAAD cis rs964611 0.882 rs10152424 ENSG00000259488.2 RP11-154J22.1 -5.22 5.89e-07 0.000464 -0.43 -0.39 Metabolite levels (Pyroglutamine); chr15:48299790 chr15:48312353~48331856:- PAAD cis rs964611 0.58 rs75570984 ENSG00000259488.2 RP11-154J22.1 5.22 5.9e-07 0.000464 0.43 0.39 Metabolite levels (Pyroglutamine); chr15:48361246 chr15:48312353~48331856:- PAAD cis rs2581828 1 rs2581828 ENSG00000242142.1 SERBP1P3 5.22 5.9e-07 0.000464 0.44 0.39 Crohn's disease; chr3:53099133 chr3:53064283~53065091:- PAAD cis rs6504622 0.905 rs9898981 ENSG00000262879.4 RP11-156P1.3 5.22 5.9e-07 0.000464 0.4 0.39 Orofacial clefts; chr17:46949349 chr17:46984045~47100323:- PAAD cis rs6504622 0.905 rs2317997 ENSG00000262879.4 RP11-156P1.3 5.22 5.9e-07 0.000464 0.4 0.39 Orofacial clefts; chr17:46950282 chr17:46984045~47100323:- PAAD cis rs6504622 0.935 rs740617 ENSG00000262879.4 RP11-156P1.3 5.22 5.9e-07 0.000464 0.4 0.39 Orofacial clefts; chr17:46950635 chr17:46984045~47100323:- PAAD cis rs6504622 0.905 rs3809854 ENSG00000262879.4 RP11-156P1.3 5.22 5.9e-07 0.000464 0.4 0.39 Orofacial clefts; chr17:46951928 chr17:46984045~47100323:- PAAD cis rs4308124 0.708 rs10178095 ENSG00000227992.1 AC108463.2 -5.22 5.9e-07 0.000464 -0.45 -0.39 Vitiligo; chr2:111214939 chr2:111203964~111206215:- PAAD cis rs2274273 1 rs7142704 ENSG00000258413.1 RP11-665C16.6 -5.22 5.91e-07 0.000465 -0.5 -0.39 Protein biomarker; chr14:55163885 chr14:55262767~55272075:- PAAD cis rs2412819 0.571 rs56226333 ENSG00000249839.1 AC011330.5 -5.21 5.93e-07 0.000467 -0.63 -0.39 Lung cancer; chr15:43632410 chr15:43663654~43684339:- PAAD cis rs2404602 0.735 rs2436996 ENSG00000259422.1 RP11-593F23.1 -5.21 5.94e-07 0.000467 -0.48 -0.39 Blood metabolite levels; chr15:76525079 chr15:76174891~76181486:- PAAD cis rs2274273 1 rs7160110 ENSG00000258413.1 RP11-665C16.6 -5.21 5.96e-07 0.000468 -0.49 -0.39 Protein biomarker; chr14:55127917 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs1009977 ENSG00000258413.1 RP11-665C16.6 -5.21 5.96e-07 0.000468 -0.49 -0.39 Protein biomarker; chr14:55136284 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs6573006 ENSG00000258413.1 RP11-665C16.6 -5.21 5.96e-07 0.000468 -0.49 -0.39 Protein biomarker; chr14:55143714 chr14:55262767~55272075:- PAAD cis rs7429990 0.864 rs34616865 ENSG00000229759.1 MRPS18AP1 -5.21 5.96e-07 0.000468 -0.42 -0.39 Educational attainment (years of education); chr3:47608508 chr3:48256350~48256938:- PAAD cis rs7429990 0.864 rs1014228 ENSG00000229759.1 MRPS18AP1 -5.21 5.96e-07 0.000468 -0.42 -0.39 Educational attainment (years of education); chr3:47611149 chr3:48256350~48256938:- PAAD cis rs12468226 1 rs11899836 ENSG00000273456.1 RP11-686O6.2 5.21 5.97e-07 0.000469 0.57 0.39 Urate levels; chr2:202371316 chr2:202374932~202375604:- PAAD cis rs7945705 0.818 rs2653613 ENSG00000254860.4 TMEM9B-AS1 5.21 5.98e-07 0.00047 0.41 0.39 Hemoglobin concentration; chr11:8857558 chr11:8964675~8977527:+ PAAD cis rs75422866 0.867 rs73104112 ENSG00000257433.4 RP1-197B17.3 5.21 5.98e-07 0.00047 0.77 0.39 Pneumonia; chr12:47680969 chr12:47706085~47742294:+ PAAD cis rs858239 0.899 rs2268745 ENSG00000226816.2 AC005082.12 5.21 5.98e-07 0.00047 0.44 0.39 Cerebrospinal fluid biomarker levels; chr7:23277981 chr7:23206013~23208045:+ PAAD cis rs950169 0.922 rs11630760 ENSG00000259295.5 CSPG4P12 5.21 5.99e-07 0.00047 0.43 0.39 Schizophrenia; chr15:84570106 chr15:85191438~85213905:+ PAAD cis rs950169 0.887 rs71395453 ENSG00000259295.5 CSPG4P12 5.21 5.99e-07 0.00047 0.43 0.39 Schizophrenia; chr15:84570259 chr15:85191438~85213905:+ PAAD cis rs6860806 0.507 rs2631371 ENSG00000233006.5 AC034220.3 -5.21 6e-07 0.000471 -0.35 -0.39 Breast cancer; chr5:132367999 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs2631369 ENSG00000233006.5 AC034220.3 -5.21 6e-07 0.000471 -0.35 -0.39 Breast cancer; chr5:132369574 chr5:132311285~132369916:- PAAD cis rs274567 0.501 rs2631368 ENSG00000233006.5 AC034220.3 -5.21 6e-07 0.000471 -0.35 -0.39 Blood metabolite levels; chr5:132369605 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs272854 ENSG00000233006.5 AC034220.3 5.21 6e-07 0.000471 0.35 0.39 Breast cancer; chr5:132352324 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs273901 ENSG00000233006.5 AC034220.3 5.21 6e-07 0.000471 0.35 0.39 Breast cancer; chr5:132358667 chr5:132311285~132369916:- PAAD cis rs270601 0.913 rs273899 ENSG00000233006.5 AC034220.3 5.21 6e-07 0.000471 0.35 0.39 Acylcarnitine levels; chr5:132359485 chr5:132311285~132369916:- PAAD cis rs11123170 0.64 rs1015754 ENSG00000189223.12 PAX8-AS1 5.21 6e-07 0.000471 0.5 0.39 Renal function-related traits (BUN); chr2:113210413 chr2:113211522~113276581:+ PAAD cis rs8091660 0.929 rs3744827 ENSG00000278983.1 RP11-426J5.3 -5.21 6.01e-07 0.000471 -0.47 -0.39 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48569572 chr18:48564795~48568342:+ PAAD cis rs2337406 0.714 rs2337463 ENSG00000274576.2 IGHV2-70 -5.21 6.01e-07 0.000471 -0.51 -0.39 Alzheimer's disease (late onset); chr14:106816066 chr14:106770577~106771020:- PAAD cis rs12908161 1 rs11632465 ENSG00000225151.9 GOLGA2P7 -5.21 6.01e-07 0.000472 -0.47 -0.39 Schizophrenia; chr15:84738814 chr15:84199311~84230136:- PAAD cis rs9926296 0.744 rs154657 ENSG00000260259.1 RP11-368I7.4 -5.21 6.02e-07 0.000472 -0.49 -0.39 Vitiligo; chr16:89641688 chr16:89682620~89686569:- PAAD cis rs9926296 0.744 rs154656 ENSG00000260259.1 RP11-368I7.4 5.21 6.02e-07 0.000472 0.49 0.39 Vitiligo; chr16:89641595 chr16:89682620~89686569:- PAAD cis rs9926296 0.744 rs164747 ENSG00000260259.1 RP11-368I7.4 5.21 6.02e-07 0.000472 0.49 0.39 Vitiligo; chr16:89642272 chr16:89682620~89686569:- PAAD cis rs4879677 1 rs642259 ENSG00000260390.1 RP11-575I8.1 -5.21 6.02e-07 0.000473 -0.49 -0.39 Gut microbiome composition (summer and winter); chr9:27661755 chr9:27829276~27844481:+ PAAD cis rs9660180 0.62 rs3817856 ENSG00000231050.1 RP1-140A9.1 -5.21 6.03e-07 0.000473 -0.46 -0.39 Body mass index; chr1:1732392 chr1:1891471~1892658:+ PAAD cis rs494459 0.838 rs555649 ENSG00000255422.1 AP002954.4 -5.21 6.04e-07 0.000474 -0.43 -0.39 Height; chr11:118781100 chr11:118704607~118750263:+ PAAD cis rs7772486 0.727 rs4896843 ENSG00000235652.6 RP11-545I5.3 -5.21 6.04e-07 0.000474 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145742315 chr6:145799409~145886585:+ PAAD cis rs1928295 1 rs10759928 ENSG00000233569.1 RP11-500B12.1 5.21 6.05e-07 0.000474 0.44 0.39 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117636125 chr9:117648606~117657027:+ PAAD cis rs3762637 0.943 rs3817040 ENSG00000272758.4 RP11-299J3.8 -5.21 6.05e-07 0.000475 -0.57 -0.39 LDL cholesterol levels; chr3:122535922 chr3:122416207~122443180:+ PAAD cis rs3096299 0.586 rs4572400 ENSG00000274627.1 RP11-104N10.2 5.21 6.05e-07 0.000475 0.33 0.39 Multiple myeloma (IgH translocation); chr16:89467108 chr16:89516797~89522217:+ PAAD cis rs6921919 0.697 rs6942030 ENSG00000216901.1 AL022393.7 5.21 6.06e-07 0.000475 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28348181 chr6:28176188~28176674:+ PAAD cis rs12439619 0.846 rs62011975 ENSG00000255769.6 GOLGA2P10 -5.21 6.07e-07 0.000476 -0.5 -0.39 Intelligence (multi-trait analysis); chr15:82159213 chr15:82472993~82513950:- PAAD cis rs12439619 0.846 rs62012003 ENSG00000255769.6 GOLGA2P10 -5.21 6.07e-07 0.000476 -0.5 -0.39 Intelligence (multi-trait analysis); chr15:82183236 chr15:82472993~82513950:- PAAD cis rs12439619 0.846 rs62012004 ENSG00000255769.6 GOLGA2P10 -5.21 6.07e-07 0.000476 -0.5 -0.39 Intelligence (multi-trait analysis); chr15:82183924 chr15:82472993~82513950:- PAAD cis rs12439619 0.846 rs62013464 ENSG00000255769.6 GOLGA2P10 -5.21 6.07e-07 0.000476 -0.5 -0.39 Intelligence (multi-trait analysis); chr15:82288250 chr15:82472993~82513950:- PAAD cis rs12439619 0.846 rs62010071 ENSG00000255769.6 GOLGA2P10 -5.21 6.07e-07 0.000476 -0.5 -0.39 Intelligence (multi-trait analysis); chr15:82289442 chr15:82472993~82513950:- PAAD cis rs2243480 1 rs316330 ENSG00000226824.5 RP4-756H11.3 -5.21 6.09e-07 0.000477 -0.69 -0.39 Diabetic kidney disease; chr7:66140385 chr7:66654538~66669855:+ PAAD cis rs1075265 0.87 rs6724389 ENSG00000233266.1 HMGB1P31 5.21 6.09e-07 0.000477 0.5 0.39 Chronotype;Morning vs. evening chronotype; chr2:53985698 chr2:54051334~54051760:+ PAAD cis rs11098499 0.874 rs13123591 ENSG00000245958.5 RP11-33B1.1 -5.21 6.1e-07 0.000478 -0.31 -0.39 Corneal astigmatism; chr4:119184835 chr4:119454791~119552025:+ PAAD cis rs11098499 0.874 rs9995277 ENSG00000245958.5 RP11-33B1.1 -5.21 6.1e-07 0.000478 -0.31 -0.39 Corneal astigmatism; chr4:119187448 chr4:119454791~119552025:+ PAAD cis rs11098499 0.874 rs17839089 ENSG00000245958.5 RP11-33B1.1 -5.21 6.1e-07 0.000478 -0.31 -0.39 Corneal astigmatism; chr4:119189914 chr4:119454791~119552025:+ PAAD cis rs11098499 0.874 rs6826823 ENSG00000245958.5 RP11-33B1.1 -5.21 6.1e-07 0.000478 -0.31 -0.39 Corneal astigmatism; chr4:119190943 chr4:119454791~119552025:+ PAAD cis rs7916697 0.626 rs3858145 ENSG00000233590.1 RP11-153K11.3 -5.21 6.12e-07 0.000479 -0.51 -0.39 Optic disc area; chr10:68252081 chr10:68233251~68242379:- PAAD cis rs8062405 0.754 rs149299 ENSG00000251417.2 RP11-1348G14.4 -5.21 6.12e-07 0.000479 -0.35 -0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28473820 chr16:28802743~28817828:+ PAAD cis rs2274273 0.686 rs66782529 ENSG00000258413.1 RP11-665C16.6 -5.21 6.13e-07 0.00048 -0.53 -0.39 Protein biomarker; chr14:55121149 chr14:55262767~55272075:- PAAD cis rs6570726 0.764 rs4896821 ENSG00000235652.6 RP11-545I5.3 5.21 6.15e-07 0.000482 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145575045 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs7765687 ENSG00000235652.6 RP11-545I5.3 5.21 6.16e-07 0.000482 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145593964 chr6:145799409~145886585:+ PAAD cis rs2455601 0.507 rs7948452 ENSG00000254860.4 TMEM9B-AS1 5.21 6.16e-07 0.000482 0.43 0.39 Schizophrenia; chr11:8856157 chr11:8964675~8977527:+ PAAD cis rs8059260 0.544 rs35347079 ENSG00000274038.1 RP11-66H6.4 -5.21 6.16e-07 0.000482 -0.6 -0.39 Alcohol consumption over the past year; chr16:11099696 chr16:11056556~11057034:+ PAAD cis rs12439619 0.846 rs7496227 ENSG00000255769.6 GOLGA2P10 -5.21 6.17e-07 0.000483 -0.5 -0.39 Intelligence (multi-trait analysis); chr15:82275241 chr15:82472993~82513950:- PAAD cis rs9828933 0.766 rs704372 ENSG00000280620.1 SCAANT1 -5.21 6.17e-07 0.000483 -0.59 -0.39 Type 2 diabetes; chr3:63881777 chr3:63911518~63911772:- PAAD cis rs2243480 0.901 rs57126451 ENSG00000226824.5 RP4-756H11.3 -5.21 6.18e-07 0.000484 -0.7 -0.39 Diabetic kidney disease; chr7:65951319 chr7:66654538~66669855:+ PAAD cis rs1075265 0.73 rs805392 ENSG00000233266.1 HMGB1P31 5.21 6.18e-07 0.000484 0.5 0.39 Chronotype;Morning vs. evening chronotype; chr2:53877594 chr2:54051334~54051760:+ PAAD cis rs13178541 0.81 rs878068 ENSG00000250378.1 RP11-119J18.1 5.21 6.18e-07 0.000484 0.6 0.39 IgG glycosylation; chr5:135826667 chr5:135812667~135826582:+ PAAD cis rs9322193 0.884 rs1125 ENSG00000216906.2 RP11-350J20.9 5.2 6.2e-07 0.000485 0.52 0.39 Lung cancer; chr6:149658280 chr6:149904243~149906418:+ PAAD cis rs2243480 0.831 rs57294491 ENSG00000226824.5 RP4-756H11.3 5.2 6.2e-07 0.000485 0.7 0.39 Diabetic kidney disease; chr7:66219914 chr7:66654538~66669855:+ PAAD cis rs2882667 0.638 rs2351905 ENSG00000253404.1 AC034243.1 5.2 6.23e-07 0.000488 0.46 0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139135641 chr5:138744434~138753309:- PAAD cis rs6570726 0.791 rs621382 ENSG00000235652.6 RP11-545I5.3 5.2 6.24e-07 0.000488 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145478008 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs422099 ENSG00000235652.6 RP11-545I5.3 5.2 6.24e-07 0.000488 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145485800 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6914203 ENSG00000235652.6 RP11-545I5.3 5.2 6.24e-07 0.000488 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145578839 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs9403726 ENSG00000235652.6 RP11-545I5.3 5.2 6.24e-07 0.000488 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145580550 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs1935612 ENSG00000235652.6 RP11-545I5.3 5.2 6.24e-07 0.000488 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145584954 chr6:145799409~145886585:+ PAAD cis rs34375054 0.672 rs2291248 ENSG00000279233.1 RP11-158L12.4 5.2 6.24e-07 0.000488 0.33 0.39 Post bronchodilator FEV1/FVC ratio; chr12:125134762 chr12:125138245~125141711:+ PAAD cis rs8091660 0.862 rs12607412 ENSG00000278983.1 RP11-426J5.3 5.2 6.24e-07 0.000488 0.48 0.39 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48545949 chr18:48564795~48568342:+ PAAD cis rs1823913 1 rs10445783 ENSG00000280083.1 RP11-317J9.1 5.2 6.25e-07 0.000489 0.5 0.39 Obesity-related traits; chr2:191236772 chr2:191154118~191156070:- PAAD cis rs7916697 0.626 rs3858146 ENSG00000233590.1 RP11-153K11.3 -5.2 6.25e-07 0.000489 -0.52 -0.39 Optic disc area; chr10:68253493 chr10:68233251~68242379:- PAAD cis rs9322193 0.607 rs9383941 ENSG00000223701.3 RAET1E-AS1 -5.2 6.28e-07 0.000491 -0.48 -0.39 Lung cancer; chr6:149912100 chr6:149884431~149919508:+ PAAD cis rs7078219 0.505 rs4409764 ENSG00000257582.4 LINC01475 -5.2 6.28e-07 0.000491 -0.43 -0.39 Dental caries; chr10:99524480 chr10:99526350~99531177:- PAAD cis rs7078219 0.523 rs4129134 ENSG00000257582.4 LINC01475 -5.2 6.28e-07 0.000491 -0.43 -0.39 Dental caries; chr10:99524588 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs4129133 ENSG00000257582.4 LINC01475 -5.2 6.28e-07 0.000491 -0.43 -0.39 Dental caries; chr10:99524813 chr10:99526350~99531177:- PAAD cis rs1150668 0.835 rs203869 ENSG00000204709.4 LINC01556 5.2 6.28e-07 0.000491 0.53 0.39 Pubertal anthropometrics; chr6:28073041 chr6:28943877~28944537:+ PAAD cis rs172166 0.56 rs203878 ENSG00000204709.4 LINC01556 5.2 6.28e-07 0.000491 0.53 0.39 Cardiac Troponin-T levels; chr6:28081218 chr6:28943877~28944537:+ PAAD cis rs72772090 1 rs72772095 ENSG00000248734.2 CTD-2260A17.1 -5.2 6.29e-07 0.000491 -0.48 -0.39 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96718149 chr5:96784777~96785999:+ PAAD cis rs2274273 0.837 rs10141552 ENSG00000258413.1 RP11-665C16.6 5.2 6.29e-07 0.000491 0.49 0.39 Protein biomarker; chr14:55279373 chr14:55262767~55272075:- PAAD cis rs17711722 0.522 rs6957759 ENSG00000226824.5 RP4-756H11.3 -5.2 6.29e-07 0.000492 -0.46 -0.39 Calcium levels; chr7:65806798 chr7:66654538~66669855:+ PAAD cis rs6570726 0.791 rs4896820 ENSG00000235652.6 RP11-545I5.3 5.2 6.3e-07 0.000492 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145573821 chr6:145799409~145886585:+ PAAD cis rs3814244 0.788 rs3741649 ENSG00000255733.4 IFNG-AS1 -5.2 6.3e-07 0.000493 -0.33 -0.39 Itch intensity from mosquito bite adjusted by bite size; chr12:68028351 chr12:67989445~68234686:+ PAAD cis rs3814244 0.788 rs11177014 ENSG00000255733.4 IFNG-AS1 -5.2 6.3e-07 0.000493 -0.33 -0.39 Itch intensity from mosquito bite adjusted by bite size; chr12:68031871 chr12:67989445~68234686:+ PAAD cis rs9900062 1 rs9900062 ENSG00000270714.1 MINOS1P2 -5.2 6.34e-07 0.000495 -0.56 -0.39 QT interval; chr17:64743456 chr17:64747264~64747492:- PAAD cis rs7188445 1 rs7190187 ENSG00000261390.4 RP11-345M22.2 -5.2 6.34e-07 0.000496 -0.52 -0.39 Urate levels; chr16:79701281 chr16:79715232~79770563:- PAAD cis rs2404602 0.698 rs12909656 ENSG00000259422.1 RP11-593F23.1 -5.2 6.38e-07 0.000498 -0.48 -0.39 Blood metabolite levels; chr15:76372037 chr15:76174891~76181486:- PAAD cis rs950169 0.579 rs881983 ENSG00000259728.4 LINC00933 5.2 6.38e-07 0.000498 0.51 0.39 Schizophrenia; chr15:83978556 chr15:84570649~84580175:+ PAAD cis rs2153535 0.541 rs9379207 ENSG00000230939.1 RP11-314C16.1 -5.2 6.38e-07 0.000498 -0.41 -0.39 Motion sickness; chr6:8457953 chr6:8784178~8785445:+ PAAD cis rs13178541 0.748 rs9327727 ENSG00000250378.1 RP11-119J18.1 -5.2 6.39e-07 0.000499 -0.6 -0.39 IgG glycosylation; chr5:135725997 chr5:135812667~135826582:+ PAAD cis rs7772486 0.686 rs9376961 ENSG00000235652.6 RP11-545I5.3 5.2 6.4e-07 0.000499 0.31 0.39 Lobe attachment (rater-scored or self-reported); chr6:145727601 chr6:145799409~145886585:+ PAAD cis rs2658782 0.826 rs1975820 ENSG00000279684.1 RP11-755E23.2 -5.2 6.4e-07 0.000499 -0.64 -0.39 Pulmonary function decline; chr11:93348649 chr11:93286629~93288903:- PAAD cis rs11673344 0.633 rs519606 ENSG00000226686.6 LINC01535 5.2 6.41e-07 5e-04 0.54 0.39 Obesity-related traits; chr19:36942327 chr19:37251912~37265535:+ PAAD cis rs7772486 0.79 rs9485024 ENSG00000235652.6 RP11-545I5.3 -5.2 6.42e-07 0.000501 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145821351 chr6:145799409~145886585:+ PAAD cis rs4660456 0.871 rs669072 ENSG00000237899.1 RP4-739H11.3 5.2 6.43e-07 0.000502 0.53 0.39 Platelet count; chr1:40679946 chr1:40669089~40687588:- PAAD cis rs4660456 0.912 rs658806 ENSG00000237899.1 RP4-739H11.3 5.2 6.43e-07 0.000502 0.53 0.39 Platelet count; chr1:40683312 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs489222 ENSG00000237899.1 RP4-739H11.3 5.2 6.43e-07 0.000502 0.53 0.39 Platelet count; chr1:40683422 chr1:40669089~40687588:- PAAD cis rs4660456 0.871 rs671704 ENSG00000237899.1 RP4-739H11.3 5.2 6.43e-07 0.000502 0.53 0.39 Platelet count; chr1:40683974 chr1:40669089~40687588:- PAAD cis rs4660456 0.826 rs507914 ENSG00000237899.1 RP4-739H11.3 5.2 6.43e-07 0.000502 0.53 0.39 Platelet count; chr1:40686529 chr1:40669089~40687588:- PAAD cis rs4660456 0.913 rs2780950 ENSG00000237899.1 RP4-739H11.3 5.2 6.43e-07 0.000502 0.53 0.39 Platelet count; chr1:40686937 chr1:40669089~40687588:- PAAD cis rs4660456 0.826 rs2744802 ENSG00000237899.1 RP4-739H11.3 5.2 6.43e-07 0.000502 0.53 0.39 Platelet count; chr1:40687577 chr1:40669089~40687588:- PAAD cis rs526231 0.578 rs3776870 ENSG00000175749.11 EIF3KP1 5.2 6.43e-07 0.000502 0.5 0.39 Primary biliary cholangitis; chr5:102959366 chr5:103032376~103033031:+ PAAD cis rs7829975 0.846 rs6601724 ENSG00000253893.2 FAM85B 5.2 6.44e-07 0.000502 0.57 0.39 Mood instability; chr8:8687362 chr8:8167819~8226614:- PAAD cis rs2115630 1 rs55646601 ENSG00000259728.4 LINC00933 -5.2 6.45e-07 0.000503 -0.48 -0.39 P wave terminal force; chr15:84780337 chr15:84570649~84580175:+ PAAD cis rs72772090 0.708 rs17082200 ENSG00000248734.2 CTD-2260A17.1 -5.2 6.45e-07 0.000503 -0.47 -0.39 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96712900 chr5:96784777~96785999:+ PAAD cis rs3814244 0.788 rs3741647 ENSG00000255733.4 IFNG-AS1 -5.2 6.46e-07 0.000504 -0.33 -0.39 Itch intensity from mosquito bite adjusted by bite size; chr12:68028249 chr12:67989445~68234686:+ PAAD cis rs1800795 0.553 rs1524099 ENSG00000179428.2 AC073072.5 -5.2 6.47e-07 0.000504 -0.36 -0.39 Cerebrospinal fluid clusterin levels in APOEe4- carriers; chr7:22742038 chr7:22725395~22727620:- PAAD cis rs7829975 0.508 rs4841006 ENSG00000253893.2 FAM85B 5.2 6.48e-07 0.000505 0.54 0.39 Mood instability; chr8:8643964 chr8:8167819~8226614:- PAAD cis rs494459 0.691 rs607472 ENSG00000255422.1 AP002954.4 -5.2 6.48e-07 0.000505 -0.42 -0.39 Height; chr11:118809363 chr11:118704607~118750263:+ PAAD cis rs2284378 0.515 rs6059579 ENSG00000276073.1 RP5-1125A11.7 -5.19 6.49e-07 0.000505 -0.42 -0.39 Breast cancer; chr20:33940059 chr20:33985617~33988989:- PAAD cis rs944722 0.512 rs4795911 ENSG00000266786.1 LGALS9DP -5.19 6.49e-07 0.000506 -0.42 -0.39 Fractional exhaled nitric oxide (childhood); chr17:27690219 chr17:27746132~27754954:+ PAAD cis rs11079159 0.5 rs7223165 ENSG00000263096.1 RP11-515O17.2 5.19 6.5e-07 0.000506 0.5 0.39 QRS duration; chr17:55286477 chr17:55271504~55273653:- PAAD cis rs367615 0.537 rs10463600 ENSG00000249476.1 CTD-2587M2.1 5.19 6.5e-07 0.000506 0.42 0.39 Colorectal cancer (SNP x SNP interaction); chr5:109327935 chr5:109237120~109326369:- PAAD cis rs1155848 0.803 rs61966637 ENSG00000227354.5 RBM26-AS1 5.19 6.52e-07 0.000508 0.8 0.39 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79327074 chr13:79406309~79424328:+ PAAD cis rs1155848 0.892 rs9574421 ENSG00000227354.5 RBM26-AS1 5.19 6.52e-07 0.000508 0.8 0.39 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79406205 chr13:79406309~79424328:+ PAAD cis rs1075232 0.579 rs58156651 ENSG00000215302.7 CTD-3092A11.1 -5.19 6.53e-07 0.000508 -0.92 -0.39 Survival in colorectal cancer (non-distant metastatic); chr15:31456864 chr15:30470779~30507623:+ PAAD cis rs875971 0.545 rs1796222 ENSG00000226824.5 RP4-756H11.3 5.19 6.54e-07 0.000509 0.54 0.39 Aortic root size; chr7:66592167 chr7:66654538~66669855:+ PAAD cis rs3762637 0.943 rs7629285 ENSG00000272758.4 RP11-299J3.8 5.19 6.54e-07 0.000509 0.57 0.39 LDL cholesterol levels; chr3:122546892 chr3:122416207~122443180:+ PAAD cis rs9322193 0.923 rs2342765 ENSG00000223701.3 RAET1E-AS1 5.19 6.54e-07 0.000509 0.45 0.39 Lung cancer; chr6:149858873 chr6:149884431~149919508:+ PAAD cis rs62229266 0.773 rs878606 ENSG00000231106.2 LINC01436 5.19 6.55e-07 0.00051 0.57 0.39 Mitral valve prolapse; chr21:36034394 chr21:36005338~36007838:+ PAAD cis rs858239 0.676 rs3807459 ENSG00000226816.2 AC005082.12 5.19 6.55e-07 0.00051 0.42 0.39 Cerebrospinal fluid biomarker levels; chr7:23350132 chr7:23206013~23208045:+ PAAD cis rs2882667 0.627 rs1549203 ENSG00000253404.1 AC034243.1 -5.19 6.55e-07 0.00051 -0.45 -0.39 Age-related hearing impairment (SNP x SNP interaction); chr5:139132655 chr5:138744434~138753309:- PAAD cis rs6782228 0.848 rs3935016 ENSG00000242551.2 POU5F1P6 5.19 6.57e-07 0.000511 0.5 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701591 chr3:128674735~128677005:- PAAD cis rs6782228 0.848 rs6439141 ENSG00000242551.2 POU5F1P6 5.19 6.57e-07 0.000511 0.5 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701691 chr3:128674735~128677005:- PAAD cis rs6782228 0.883 rs6439142 ENSG00000242551.2 POU5F1P6 5.19 6.57e-07 0.000511 0.5 0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128701714 chr3:128674735~128677005:- PAAD cis rs950169 0.649 rs12901010 ENSG00000259728.4 LINC00933 5.19 6.58e-07 0.000512 0.52 0.39 Schizophrenia; chr15:84030282 chr15:84570649~84580175:+ PAAD cis rs950169 0.69 rs12901166 ENSG00000259728.4 LINC00933 5.19 6.58e-07 0.000512 0.52 0.39 Schizophrenia; chr15:84030361 chr15:84570649~84580175:+ PAAD cis rs2015599 0.601 rs17715086 ENSG00000257176.2 RP11-996F15.2 -5.19 6.58e-07 0.000512 -0.39 -0.39 Platelet count;Mean platelet volume; chr12:29329073 chr12:29280418~29317848:- PAAD cis rs763567 0.933 rs623752 ENSG00000271811.1 RP1-79C4.4 5.19 6.58e-07 0.000512 0.37 0.39 Tonsillectomy; chr1:170649150 chr1:170667381~170669425:+ PAAD cis rs11098499 0.78 rs7692994 ENSG00000245958.5 RP11-33B1.1 -5.19 6.59e-07 0.000513 -0.3 -0.39 Corneal astigmatism; chr4:119506334 chr4:119454791~119552025:+ PAAD cis rs12701220 0.504 rs12702092 ENSG00000229043.2 AC091729.9 -5.19 6.61e-07 0.000513 -0.56 -0.39 Bronchopulmonary dysplasia; chr7:1106232 chr7:1160374~1165267:+ PAAD cis rs2274273 0.84 rs6573014 ENSG00000258413.1 RP11-665C16.6 5.19 6.62e-07 0.000515 0.48 0.39 Protein biomarker; chr14:55269174 chr14:55262767~55272075:- PAAD cis rs6921919 0.697 rs758398 ENSG00000216901.1 AL022393.7 5.19 6.63e-07 0.000515 0.52 0.39 Autism spectrum disorder or schizophrenia; chr6:28352897 chr6:28176188~28176674:+ PAAD cis rs7772486 0.846 rs2892453 ENSG00000235652.6 RP11-545I5.3 5.19 6.67e-07 0.000518 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:146056581 chr6:145799409~145886585:+ PAAD cis rs858239 0.965 rs156429 ENSG00000226816.2 AC005082.12 5.19 6.67e-07 0.000518 0.43 0.39 Cerebrospinal fluid biomarker levels; chr7:23266401 chr7:23206013~23208045:+ PAAD cis rs964611 0.808 rs35405890 ENSG00000259488.2 RP11-154J22.1 -5.19 6.69e-07 0.00052 -0.41 -0.39 Metabolite levels (Pyroglutamine); chr15:48299070 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs16960737 ENSG00000259488.2 RP11-154J22.1 -5.19 6.69e-07 0.00052 -0.41 -0.39 Metabolite levels (Pyroglutamine); chr15:48299863 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs66823218 ENSG00000259488.2 RP11-154J22.1 -5.19 6.69e-07 0.00052 -0.41 -0.39 Metabolite levels (Pyroglutamine); chr15:48299886 chr15:48312353~48331856:- PAAD cis rs7078219 0.543 rs10786557 ENSG00000257582.4 LINC01475 -5.19 6.71e-07 0.000521 -0.43 -0.39 Dental caries; chr10:99523571 chr10:99526350~99531177:- PAAD cis rs7945705 0.875 rs10769957 ENSG00000254860.4 TMEM9B-AS1 5.19 6.72e-07 0.000521 0.43 0.39 Hemoglobin concentration; chr11:8787469 chr11:8964675~8977527:+ PAAD cis rs6782228 0.606 rs6787559 ENSG00000242551.2 POU5F1P6 -5.19 6.73e-07 0.000522 -0.47 -0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128662243 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs2001703 ENSG00000242551.2 POU5F1P6 -5.19 6.73e-07 0.000522 -0.47 -0.39 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128664254 chr3:128674735~128677005:- PAAD cis rs6921919 0.832 rs17312661 ENSG00000216901.1 AL022393.7 5.19 6.73e-07 0.000522 0.62 0.39 Autism spectrum disorder or schizophrenia; chr6:28332559 chr6:28176188~28176674:+ PAAD cis rs673078 0.66 rs73205551 ENSG00000275759.1 RP11-131L12.3 -5.19 6.74e-07 0.000522 -0.51 -0.39 Glucose homeostasis traits; chr12:118330808 chr12:118428281~118428870:+ PAAD cis rs673078 0.66 rs11068910 ENSG00000275759.1 RP11-131L12.3 -5.19 6.74e-07 0.000522 -0.51 -0.39 Glucose homeostasis traits; chr12:118336076 chr12:118428281~118428870:+ PAAD cis rs9926296 0.712 rs2434872 ENSG00000260259.1 RP11-368I7.4 5.19 6.74e-07 0.000523 0.49 0.39 Vitiligo; chr16:89650507 chr16:89682620~89686569:- PAAD cis rs9926296 0.682 rs467357 ENSG00000260259.1 RP11-368I7.4 5.19 6.74e-07 0.000523 0.49 0.39 Vitiligo; chr16:89650989 chr16:89682620~89686569:- PAAD cis rs8059260 0.604 rs12929596 ENSG00000274038.1 RP11-66H6.4 -5.19 6.75e-07 0.000523 -0.59 -0.39 Alcohol consumption over the past year; chr16:11105495 chr16:11056556~11057034:+ PAAD cis rs73086581 0.645 rs2103659 ENSG00000229539.1 RP11-119B16.2 -5.19 6.75e-07 0.000523 -0.48 -0.39 Response to antidepressants in depression; chr20:4001925 chr20:3888239~3888868:- PAAD cis rs2153535 0.58 rs4587214 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8453886 chr6:8784178~8785445:+ PAAD cis rs2153535 0.623 rs2152346 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8454419 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6921036 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8455167 chr6:8784178~8785445:+ PAAD cis rs2153535 0.562 rs6901765 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8455203 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9502715 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8455476 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6926759 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8455943 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6912193 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8456073 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6912374 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8456190 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs6908504 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8456545 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6913100 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8456622 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7755284 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8457246 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7769020 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8457491 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9392220 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8457713 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9379206 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8457788 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs9405386 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8457834 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9393016 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8458340 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4960421 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8459059 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4960422 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8459076 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7761937 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8459201 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7742794 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8459490 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9505448 ENSG00000230939.1 RP11-314C16.1 -5.19 6.75e-07 0.000523 -0.41 -0.39 Motion sickness; chr6:8459571 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6927589 ENSG00000230939.1 RP11-314C16.1 5.19 6.75e-07 0.000523 0.41 0.39 Motion sickness; chr6:8456399 chr6:8784178~8785445:+ PAAD cis rs8059260 0.544 rs34846673 ENSG00000274038.1 RP11-66H6.4 -5.19 6.76e-07 0.000523 -0.59 -0.39 Alcohol consumption over the past year; chr16:11102829 chr16:11056556~11057034:+ PAAD cis rs8059260 0.542 rs7184915 ENSG00000274038.1 RP11-66H6.4 -5.19 6.76e-07 0.000524 -0.63 -0.39 Alcohol consumption over the past year; chr16:11034509 chr16:11056556~11057034:+ PAAD cis rs12468226 1 rs6739198 ENSG00000273456.1 RP11-686O6.2 5.19 6.76e-07 0.000524 0.55 0.39 Urate levels; chr2:202492273 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs7565875 ENSG00000273456.1 RP11-686O6.2 5.19 6.76e-07 0.000524 0.55 0.39 Urate levels; chr2:202516412 chr2:202374932~202375604:- PAAD cis rs2274273 0.588 rs9323285 ENSG00000258413.1 RP11-665C16.6 5.19 6.76e-07 0.000524 0.52 0.39 Protein biomarker; chr14:55397111 chr14:55262767~55272075:- PAAD cis rs10463554 0.824 rs3776868 ENSG00000175749.11 EIF3KP1 5.19 6.76e-07 0.000524 0.49 0.39 Parkinson's disease; chr5:102963012 chr5:103032376~103033031:+ PAAD cis rs12701220 0.655 rs6463317 ENSG00000229043.2 AC091729.9 -5.19 6.77e-07 0.000525 -0.5 -0.39 Bronchopulmonary dysplasia; chr7:1119607 chr7:1160374~1165267:+ PAAD cis rs2015599 0.623 rs2288128 ENSG00000257176.2 RP11-996F15.2 5.19 6.78e-07 0.000525 0.39 0.39 Platelet count;Mean platelet volume; chr12:29316054 chr12:29280418~29317848:- PAAD cis rs2015599 0.584 rs2288129 ENSG00000257176.2 RP11-996F15.2 5.19 6.78e-07 0.000525 0.39 0.39 Platelet count;Mean platelet volume; chr12:29316355 chr12:29280418~29317848:- PAAD cis rs2015599 0.623 rs10843385 ENSG00000257176.2 RP11-996F15.2 -5.19 6.78e-07 0.000525 -0.39 -0.39 Platelet count;Mean platelet volume; chr12:29323100 chr12:29280418~29317848:- PAAD cis rs950169 0.922 rs11633075 ENSG00000259295.5 CSPG4P12 5.18 6.8e-07 0.000526 0.43 0.39 Schizophrenia; chr15:84570741 chr15:85191438~85213905:+ PAAD cis rs950169 0.922 rs12912934 ENSG00000259295.5 CSPG4P12 5.18 6.8e-07 0.000526 0.43 0.39 Schizophrenia; chr15:84571216 chr15:85191438~85213905:+ PAAD cis rs950169 0.922 rs11633534 ENSG00000259295.5 CSPG4P12 5.18 6.8e-07 0.000526 0.43 0.39 Schizophrenia; chr15:84581411 chr15:85191438~85213905:+ PAAD cis rs7712401 0.584 rs28373879 ENSG00000263432.2 RN7SL689P 5.18 6.8e-07 0.000527 0.49 0.39 Mean platelet volume; chr5:123036707 chr5:123022487~123022783:- PAAD cis rs7712401 0.584 rs4836382 ENSG00000263432.2 RN7SL689P 5.18 6.8e-07 0.000527 0.49 0.39 Mean platelet volume; chr5:123040946 chr5:123022487~123022783:- PAAD cis rs875971 0.545 rs6979636 ENSG00000226824.5 RP4-756H11.3 -5.18 6.81e-07 0.000527 -0.53 -0.39 Aortic root size; chr7:66276638 chr7:66654538~66669855:+ PAAD cis rs763567 0.9 rs525489 ENSG00000271811.1 RP1-79C4.4 5.18 6.81e-07 0.000527 0.37 0.39 Tonsillectomy; chr1:170665861 chr1:170667381~170669425:+ PAAD cis rs763567 0.835 rs503706 ENSG00000271811.1 RP1-79C4.4 5.18 6.81e-07 0.000527 0.37 0.39 Tonsillectomy; chr1:170665943 chr1:170667381~170669425:+ PAAD cis rs763567 0.9 rs473133 ENSG00000271811.1 RP1-79C4.4 5.18 6.81e-07 0.000527 0.37 0.39 Tonsillectomy; chr1:170666938 chr1:170667381~170669425:+ PAAD cis rs11650106 0.529 rs35391268 ENSG00000266992.1 DHX40P1 -5.18 6.81e-07 0.000527 -0.41 -0.39 Lipoprotein-associated phospholipase A2 activity and mass; chr17:59692637 chr17:59976009~60002384:- PAAD cis rs964611 0.882 rs11070635 ENSG00000259488.2 RP11-154J22.1 5.18 6.81e-07 0.000527 0.44 0.39 Metabolite levels (Pyroglutamine); chr15:48361928 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4257154 ENSG00000259488.2 RP11-154J22.1 5.18 6.81e-07 0.000527 0.44 0.39 Metabolite levels (Pyroglutamine); chr15:48362879 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs12438457 ENSG00000259488.2 RP11-154J22.1 5.18 6.81e-07 0.000527 0.44 0.39 Metabolite levels (Pyroglutamine); chr15:48364246 chr15:48312353~48331856:- PAAD cis rs10510102 0.872 rs12248004 ENSG00000276742.1 RP11-500G22.4 5.18 6.82e-07 0.000528 0.63 0.39 Breast cancer; chr10:121972215 chr10:121956782~121957098:+ PAAD cis rs2274273 1 rs61508494 ENSG00000258413.1 RP11-665C16.6 -5.18 6.82e-07 0.000528 -0.49 -0.39 Protein biomarker; chr14:55120579 chr14:55262767~55272075:- PAAD cis rs2274273 0.967 rs2094102 ENSG00000258413.1 RP11-665C16.6 -5.18 6.82e-07 0.000528 -0.49 -0.39 Protein biomarker; chr14:55124380 chr14:55262767~55272075:- PAAD cis rs367615 0.537 rs431669 ENSG00000249476.1 CTD-2587M2.1 5.18 6.83e-07 0.000528 0.42 0.39 Colorectal cancer (SNP x SNP interaction); chr5:109327414 chr5:109237120~109326369:- PAAD cis rs2243480 1 rs2243480 ENSG00000226824.5 RP4-756H11.3 -5.18 6.83e-07 0.000528 -0.69 -0.39 Diabetic kidney disease; chr7:66134209 chr7:66654538~66669855:+ PAAD cis rs2115630 1 rs11854313 ENSG00000259728.4 LINC00933 -5.18 6.83e-07 0.000529 -0.48 -0.39 P wave terminal force; chr15:84760817 chr15:84570649~84580175:+ PAAD cis rs2153535 0.58 rs2327064 ENSG00000230939.1 RP11-314C16.1 -5.18 6.85e-07 0.00053 -0.41 -0.39 Motion sickness; chr6:8453819 chr6:8784178~8785445:+ PAAD cis rs1322639 0.574 rs9689193 ENSG00000261039.2 RP11-417E7.2 -5.18 6.85e-07 0.00053 -0.65 -0.39 Pulse pressure; chr6:169187979 chr6:169175304~169182740:- PAAD cis rs1322639 0.618 rs9505942 ENSG00000261039.2 RP11-417E7.2 -5.18 6.85e-07 0.00053 -0.65 -0.39 Pulse pressure; chr6:169191698 chr6:169175304~169182740:- PAAD cis rs673078 0.66 rs6490173 ENSG00000275759.1 RP11-131L12.3 -5.18 6.85e-07 0.00053 -0.48 -0.39 Glucose homeostasis traits; chr12:118278637 chr12:118428281~118428870:+ PAAD cis rs12908161 0.65 rs182517 ENSG00000275120.1 RP11-182J1.17 5.18 6.86e-07 0.00053 0.43 0.39 Schizophrenia; chr15:84846400 chr15:84599434~84606463:- PAAD cis rs6991838 0.584 rs7463740 ENSG00000200714.1 Y_RNA -5.18 6.86e-07 0.000531 -0.45 -0.39 Intelligence (multi-trait analysis); chr8:65573950 chr8:65592731~65592820:+ PAAD cis rs2019137 0.56 rs7421852 ENSG00000274877.1 RP11-65I12.1 -5.18 6.87e-07 0.000531 -0.44 -0.39 Lymphocyte counts; chr2:113232684 chr2:113237595~113240825:+ PAAD cis rs2019137 0.56 rs10206269 ENSG00000274877.1 RP11-65I12.1 -5.18 6.87e-07 0.000531 -0.44 -0.39 Lymphocyte counts; chr2:113232816 chr2:113237595~113240825:+ PAAD cis rs7772486 0.875 rs2748501 ENSG00000235652.6 RP11-545I5.3 5.18 6.89e-07 0.000533 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145991122 chr6:145799409~145886585:+ PAAD cis rs4879677 1 rs10812642 ENSG00000260390.1 RP11-575I8.1 -5.18 6.9e-07 0.000533 -0.49 -0.39 Gut microbiome composition (summer and winter); chr9:27684906 chr9:27829276~27844481:+ PAAD cis rs4879677 0.881 rs10968058 ENSG00000260390.1 RP11-575I8.1 -5.18 6.9e-07 0.000533 -0.49 -0.39 Gut microbiome composition (summer and winter); chr9:27685336 chr9:27829276~27844481:+ PAAD cis rs11673344 0.864 rs1879497 ENSG00000226686.6 LINC01535 5.18 6.91e-07 0.000534 0.53 0.39 Obesity-related traits; chr19:37141975 chr19:37251912~37265535:+ PAAD cis rs4218 0.517 rs2899640 ENSG00000277144.1 RP11-59H7.4 -5.18 6.93e-07 0.000535 -0.53 -0.39 Social communication problems; chr15:59060281 chr15:59115547~59116089:- PAAD cis rs4984778 0.717 rs2738892 ENSG00000260182.1 RP11-616M22.5 5.18 6.93e-07 0.000535 0.5 0.39 Blood protein levels; chr16:1218758 chr16:1257339~1258074:+ PAAD cis rs2581828 0.931 rs2564942 ENSG00000242142.1 SERBP1P3 5.18 6.93e-07 0.000536 0.44 0.39 Crohn's disease; chr3:53105490 chr3:53064283~53065091:- PAAD cis rs2581828 0.931 rs2581774 ENSG00000242142.1 SERBP1P3 5.18 6.93e-07 0.000536 0.44 0.39 Crohn's disease; chr3:53105491 chr3:53064283~53065091:- PAAD cis rs6504622 0.905 rs9889741 ENSG00000262879.4 RP11-156P1.3 5.18 6.94e-07 0.000536 0.4 0.39 Orofacial clefts; chr17:46948967 chr17:46984045~47100323:- PAAD cis rs1185460 1 rs7938944 ENSG00000271751.1 RP11-110I1.14 -5.18 6.94e-07 0.000536 -0.49 -0.39 Coronary artery disease; chr11:119083356 chr11:119065263~119065677:- PAAD cis rs7772486 0.79 rs7753833 ENSG00000235652.6 RP11-545I5.3 5.18 6.94e-07 0.000536 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145840296 chr6:145799409~145886585:+ PAAD cis rs72772090 0.539 rs17484359 ENSG00000248734.2 CTD-2260A17.1 -5.18 6.95e-07 0.000537 -0.55 -0.39 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96861310 chr5:96784777~96785999:+ PAAD cis rs6051080 1 rs6051080 ENSG00000125804.12 FAM182A 5.18 6.96e-07 0.000537 0.52 0.39 Colorectal or endometrial cancer; chr20:25995038 chr20:26054655~26086917:+ PAAD cis rs2243480 0.808 rs11769505 ENSG00000226824.5 RP4-756H11.3 5.18 6.97e-07 0.000538 0.71 0.39 Diabetic kidney disease; chr7:65778268 chr7:66654538~66669855:+ PAAD cis rs7078219 0.505 rs10883371 ENSG00000257582.4 LINC01475 -5.18 6.97e-07 0.000538 -0.42 -0.39 Dental caries; chr10:99532698 chr10:99526350~99531177:- PAAD cis rs11673344 0.704 rs484001 ENSG00000226686.6 LINC01535 5.18 6.98e-07 0.000539 0.54 0.39 Obesity-related traits; chr19:36931320 chr19:37251912~37265535:+ PAAD cis rs12908161 0.96 rs34452033 ENSG00000225151.9 GOLGA2P7 -5.18 7e-07 0.00054 -0.47 -0.39 Schizophrenia; chr15:84678762 chr15:84199311~84230136:- PAAD cis rs7772486 0.686 rs1011596 ENSG00000235652.6 RP11-545I5.3 5.18 7.01e-07 0.000541 0.31 0.39 Lobe attachment (rater-scored or self-reported); chr6:145755297 chr6:145799409~145886585:+ PAAD cis rs7188445 1 rs11150189 ENSG00000261390.4 RP11-345M22.2 -5.18 7.01e-07 0.000541 -0.52 -0.39 Urate levels; chr16:79700330 chr16:79715232~79770563:- PAAD cis rs10875746 0.551 rs11168536 ENSG00000240399.1 RP1-228P16.1 -5.18 7.01e-07 0.000541 -0.41 -0.39 Longevity (90 years and older); chr12:48351268 chr12:48054813~48055591:- PAAD cis rs16828019 0.852 rs34386859 ENSG00000235358.1 RP11-399E6.1 5.18 7.02e-07 0.000541 0.7 0.39 Intelligence (multi-trait analysis); chr1:41098352 chr1:41242373~41284861:+ PAAD cis rs2243480 1 rs1404147 ENSG00000226824.5 RP4-756H11.3 -5.18 7.02e-07 0.000541 -0.68 -0.39 Diabetic kidney disease; chr7:65799537 chr7:66654538~66669855:+ PAAD cis rs7772486 0.654 rs702321 ENSG00000235652.6 RP11-545I5.3 -5.18 7.02e-07 0.000542 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145685559 chr6:145799409~145886585:+ PAAD cis rs7772486 0.659 rs9376957 ENSG00000235652.6 RP11-545I5.3 -5.18 7.02e-07 0.000542 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145689928 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9497396 ENSG00000235652.6 RP11-545I5.3 -5.18 7.02e-07 0.000542 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145693827 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9390357 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145808211 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9390336 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145575687 chr6:145799409~145886585:+ PAAD cis rs6570726 0.738 rs6925594 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145577318 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs11155432 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145577625 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6913727 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145578690 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs10872577 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145579424 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6570692 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145583265 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6902410 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145584125 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9322029 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145585547 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9373464 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145586031 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9403730 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145586097 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs9403731 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145586801 chr6:145799409~145886585:+ PAAD cis rs6570726 0.818 rs9390338 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145587129 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6570693 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145589705 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6570694 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145590068 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6570695 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145590150 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs9386125 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145590541 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9373466 ENSG00000235652.6 RP11-545I5.3 5.18 7.04e-07 0.000543 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145590880 chr6:145799409~145886585:+ PAAD cis rs4879677 0.959 rs4878536 ENSG00000260390.1 RP11-575I8.1 -5.18 7.05e-07 0.000543 -0.5 -0.39 Gut microbiome composition (summer and winter); chr9:27682259 chr9:27829276~27844481:+ PAAD cis rs12468226 1 rs79919139 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202382786 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs12472408 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202413973 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs115170232 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202416790 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs76284304 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202427116 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs16839149 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202427621 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs76528043 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202466116 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs12468226 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202472278 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs75040639 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202486973 chr2:202374932~202375604:- PAAD cis rs12468226 0.872 rs115187557 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202495351 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs76021735 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202511476 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs57080353 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202511824 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs74508472 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202517290 chr2:202374932~202375604:- PAAD cis rs12468226 0.81 rs3736578 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202519989 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs116439150 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202523814 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs12467409 ENSG00000273456.1 RP11-686O6.2 5.18 7.05e-07 0.000543 0.57 0.39 Urate levels; chr2:202529625 chr2:202374932~202375604:- PAAD cis rs80285556 1 rs17311679 ENSG00000161643.11 SIGLEC16 -5.18 7.05e-07 0.000543 -0.88 -0.39 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50018074 chr19:49969673~49975814:+ PAAD cis rs6504950 1 rs8078550 ENSG00000275710.1 RP11-257O5.4 5.18 7.06e-07 0.000544 0.51 0.39 Breast cancer; chr17:54976018 chr17:54964474~54964679:+ PAAD cis rs17711722 0.503 rs453835 ENSG00000164669.11 INTS4P1 5.18 7.06e-07 0.000544 0.47 0.39 Calcium levels; chr7:66046172 chr7:65141225~65234216:+ PAAD cis rs11673344 0.704 rs1726724 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36925890 chr19:37251912~37265535:+ PAAD cis rs11673344 0.704 rs1644711 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36926420 chr19:37251912~37265535:+ PAAD cis rs11673344 0.704 rs826262 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36928540 chr19:37251912~37265535:+ PAAD cis rs11673344 0.704 rs485034 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36931455 chr19:37251912~37265535:+ PAAD cis rs11673344 0.704 rs517110 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36931492 chr19:37251912~37265535:+ PAAD cis rs11673344 0.734 rs2551047 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36935174 chr19:37251912~37265535:+ PAAD cis rs11673344 0.704 rs551717 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36936977 chr19:37251912~37265535:+ PAAD cis rs11673344 0.704 rs826290 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36937543 chr19:37251912~37265535:+ PAAD cis rs11673344 0.67 rs505717 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36939414 chr19:37251912~37265535:+ PAAD cis rs11673344 0.704 rs544543 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36939921 chr19:37251912~37265535:+ PAAD cis rs11673344 0.67 rs568654 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36940285 chr19:37251912~37265535:+ PAAD cis rs11673344 0.67 rs35011739 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36943328 chr19:37251912~37265535:+ PAAD cis rs11673344 0.704 rs540451 ENSG00000226686.6 LINC01535 5.18 7.08e-07 0.000545 0.54 0.39 Obesity-related traits; chr19:36944619 chr19:37251912~37265535:+ PAAD cis rs694739 1 rs646153 ENSG00000236935.1 AP003774.1 5.18 7.08e-07 0.000545 0.42 0.39 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64322116 chr11:64325050~64329504:- PAAD cis rs526231 0.543 rs246901 ENSG00000175749.11 EIF3KP1 5.18 7.08e-07 0.000545 0.53 0.39 Primary biliary cholangitis; chr5:103248477 chr5:103032376~103033031:+ PAAD cis rs732716 0.785 rs9973266 ENSG00000267769.1 CTB-50L17.9 -5.18 7.08e-07 0.000545 -0.55 -0.39 Mean corpuscular volume; chr19:4392718 chr19:4454014~4455286:+ PAAD cis rs1799810 0.739 rs13030284 ENSG00000236682.1 AC068282.3 5.18 7.09e-07 0.000546 0.53 0.39 Self-rated health; chr2:127401143 chr2:127389130~127400580:+ PAAD cis rs858239 0.669 rs10950940 ENSG00000226816.2 AC005082.12 -5.18 7.1e-07 0.000546 -0.44 -0.39 Cerebrospinal fluid biomarker levels; chr7:23157197 chr7:23206013~23208045:+ PAAD cis rs7712401 0.58 rs10066632 ENSG00000263432.2 RN7SL689P 5.18 7.1e-07 0.000547 0.51 0.39 Mean platelet volume; chr5:123028988 chr5:123022487~123022783:- PAAD cis rs7712401 0.58 rs10076327 ENSG00000263432.2 RN7SL689P 5.18 7.1e-07 0.000547 0.51 0.39 Mean platelet volume; chr5:123031652 chr5:123022487~123022783:- PAAD cis rs858239 0.636 rs28706766 ENSG00000226816.2 AC005082.12 5.17 7.11e-07 0.000547 0.44 0.39 Cerebrospinal fluid biomarker levels; chr7:23130215 chr7:23206013~23208045:+ PAAD cis rs75422866 0.867 rs73113139 ENSG00000257433.4 RP1-197B17.3 5.17 7.12e-07 0.000548 0.82 0.39 Pneumonia; chr12:47622826 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73113143 ENSG00000257433.4 RP1-197B17.3 5.17 7.12e-07 0.000548 0.82 0.39 Pneumonia; chr12:47623060 chr12:47706085~47742294:+ PAAD cis rs964611 0.938 rs12050648 ENSG00000259488.2 RP11-154J22.1 -5.17 7.12e-07 0.000548 -0.41 -0.39 Metabolite levels (Pyroglutamine); chr15:48297544 chr15:48312353~48331856:- PAAD cis rs7945705 0.846 rs4929912 ENSG00000254860.4 TMEM9B-AS1 5.17 7.13e-07 0.000549 0.42 0.39 Hemoglobin concentration; chr11:8795148 chr11:8964675~8977527:+ PAAD cis rs1155848 0.892 rs2296286 ENSG00000227354.5 RBM26-AS1 5.17 7.18e-07 0.000552 0.8 0.39 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79406474 chr13:79406309~79424328:+ PAAD cis rs2274273 0.87 rs3783652 ENSG00000258413.1 RP11-665C16.6 -5.17 7.18e-07 0.000552 -0.51 -0.39 Protein biomarker; chr14:55387490 chr14:55262767~55272075:- PAAD cis rs4814920 0.756 rs6075586 ENSG00000275142.1 RP5-999L4.2 -5.17 7.21e-07 0.000554 -0.68 -0.39 Bipolar disorder (body mass index interaction); chr20:19874650 chr20:19871891~19872284:+ PAAD cis rs964611 0.751 rs8032420 ENSG00000259488.2 RP11-154J22.1 -5.17 7.21e-07 0.000554 -0.41 -0.39 Metabolite levels (Pyroglutamine); chr15:48253184 chr15:48312353~48331856:- PAAD cis rs9926296 0.509 rs2159113 ENSG00000260259.1 RP11-368I7.4 -5.17 7.22e-07 0.000555 -0.47 -0.39 Vitiligo; chr16:89765675 chr16:89682620~89686569:- PAAD cis rs10510102 0.748 rs4589226 ENSG00000276742.1 RP11-500G22.4 5.17 7.23e-07 0.000555 0.57 0.39 Breast cancer; chr10:121951073 chr10:121956782~121957098:+ PAAD cis rs17301013 0.507 rs72713512 ENSG00000227373.4 RP11-160H22.5 5.17 7.23e-07 0.000555 0.52 0.39 Systemic lupus erythematosus; chr1:174283505 chr1:174115300~174160004:- PAAD cis rs1150668 0.796 rs1052215 ENSG00000204709.4 LINC01556 -5.17 7.24e-07 0.000556 -0.52 -0.39 Pubertal anthropometrics; chr6:28380381 chr6:28943877~28944537:+ PAAD cis rs526231 0.578 rs10515337 ENSG00000175749.11 EIF3KP1 -5.17 7.24e-07 0.000556 -0.5 -0.39 Primary biliary cholangitis; chr5:102965664 chr5:103032376~103033031:+ PAAD cis rs8059260 0.668 rs79389789 ENSG00000274038.1 RP11-66H6.4 -5.17 7.25e-07 0.000557 -0.62 -0.39 Alcohol consumption over the past year; chr16:11015168 chr16:11056556~11057034:+ PAAD cis rs3762637 1 rs7615930 ENSG00000272758.4 RP11-299J3.8 -5.17 7.25e-07 0.000557 -0.54 -0.39 LDL cholesterol levels; chr3:122406903 chr3:122416207~122443180:+ PAAD cis rs748404 0.66 rs2602141 ENSG00000249839.1 AC011330.5 -5.17 7.25e-07 0.000557 -0.56 -0.39 Lung cancer; chr15:43432448 chr15:43663654~43684339:- PAAD cis rs62229266 0.771 rs11701590 ENSG00000231106.2 LINC01436 5.17 7.27e-07 0.000558 0.56 0.39 Mitral valve prolapse; chr21:36012432 chr21:36005338~36007838:+ PAAD cis rs1322639 0.657 rs9355135 ENSG00000261039.2 RP11-417E7.2 -5.17 7.28e-07 0.000559 -0.63 -0.39 Pulse pressure; chr6:169172911 chr6:169175304~169182740:- PAAD cis rs2115630 0.645 rs3825877 ENSG00000225151.9 GOLGA2P7 5.17 7.3e-07 0.00056 0.44 0.39 P wave terminal force; chr15:84631400 chr15:84199311~84230136:- PAAD cis rs2115630 0.645 rs3825878 ENSG00000225151.9 GOLGA2P7 5.17 7.3e-07 0.00056 0.44 0.39 P wave terminal force; chr15:84631524 chr15:84199311~84230136:- PAAD cis rs2115630 0.905 rs6496401 ENSG00000259728.4 LINC00933 -5.17 7.32e-07 0.000561 -0.47 -0.39 P wave terminal force; chr15:84754562 chr15:84570649~84580175:+ PAAD cis rs2115630 0.967 rs11073702 ENSG00000259728.4 LINC00933 -5.17 7.32e-07 0.000561 -0.47 -0.39 P wave terminal force; chr15:84766840 chr15:84570649~84580175:+ PAAD cis rs172166 0.561 rs149971 ENSG00000204709.4 LINC01556 5.17 7.32e-07 0.000562 0.53 0.39 Cardiac Troponin-T levels; chr6:28014374 chr6:28943877~28944537:+ PAAD cis rs7208859 0.673 rs216424 ENSG00000266490.1 CTD-2349P21.9 5.17 7.34e-07 0.000563 0.46 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30616046 chr17:30792372~30792833:+ PAAD cis rs9322193 0.923 rs2880436 ENSG00000223701.3 RAET1E-AS1 5.17 7.34e-07 0.000563 0.47 0.39 Lung cancer; chr6:149859123 chr6:149884431~149919508:+ PAAD cis rs9532669 0.963 rs9532681 ENSG00000176268.5 CYCSP34 5.17 7.35e-07 0.000564 0.37 0.39 Cervical cancer; chr13:40951633 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs4516083 ENSG00000176268.5 CYCSP34 5.17 7.35e-07 0.000564 0.37 0.39 Cervical cancer; chr13:40951783 chr13:40863599~40863902:- PAAD cis rs8059260 0.604 rs12928945 ENSG00000274038.1 RP11-66H6.4 -5.17 7.35e-07 0.000564 -0.6 -0.39 Alcohol consumption over the past year; chr16:11106309 chr16:11056556~11057034:+ PAAD cis rs950169 0.887 rs220333 ENSG00000259295.5 CSPG4P12 5.17 7.36e-07 0.000564 0.42 0.39 Schizophrenia; chr15:84547902 chr15:85191438~85213905:+ PAAD cis rs950169 0.922 rs11630507 ENSG00000259295.5 CSPG4P12 5.17 7.36e-07 0.000564 0.42 0.39 Schizophrenia; chr15:84552494 chr15:85191438~85213905:+ PAAD cis rs950169 0.881 rs34117475 ENSG00000259295.5 CSPG4P12 5.17 7.36e-07 0.000564 0.42 0.39 Schizophrenia; chr15:84565212 chr15:85191438~85213905:+ PAAD cis rs950169 0.686 rs12906474 ENSG00000259295.5 CSPG4P12 5.17 7.36e-07 0.000564 0.42 0.39 Schizophrenia; chr15:84566006 chr15:85191438~85213905:+ PAAD cis rs950169 0.81 rs2879976 ENSG00000259295.5 CSPG4P12 5.17 7.36e-07 0.000564 0.42 0.39 Schizophrenia; chr15:84566347 chr15:85191438~85213905:+ PAAD cis rs950169 0.922 rs12915832 ENSG00000259295.5 CSPG4P12 5.17 7.36e-07 0.000564 0.42 0.39 Schizophrenia; chr15:84568226 chr15:85191438~85213905:+ PAAD cis rs7916697 0.578 rs61854799 ENSG00000233590.1 RP11-153K11.3 -5.17 7.36e-07 0.000564 -0.57 -0.39 Optic disc area; chr10:68246902 chr10:68233251~68242379:- PAAD cis rs6570726 0.846 rs6570700 ENSG00000235652.6 RP11-545I5.3 5.17 7.38e-07 0.000566 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145610416 chr6:145799409~145886585:+ PAAD cis rs67180937 0.583 rs2936054 ENSG00000272750.1 RP11-378J18.8 5.17 7.38e-07 0.000566 0.45 0.39 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222627290 chr1:222658867~222661512:- PAAD cis rs8396 1 rs9918016 ENSG00000271817.2 U3 5.17 7.38e-07 0.000566 0.43 0.39 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158700845 chr4:158700691~158700909:+ PAAD cis rs7772486 0.754 rs9390356 ENSG00000235652.6 RP11-545I5.3 -5.17 7.39e-07 0.000566 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145797847 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs9373475 ENSG00000235652.6 RP11-545I5.3 5.17 7.39e-07 0.000566 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145805283 chr6:145799409~145886585:+ PAAD cis rs367615 0.512 rs814153 ENSG00000249476.1 CTD-2587M2.1 5.17 7.39e-07 0.000566 0.42 0.39 Colorectal cancer (SNP x SNP interaction); chr5:109332128 chr5:109237120~109326369:- PAAD cis rs367615 0.512 rs414724 ENSG00000249476.1 CTD-2587M2.1 5.17 7.39e-07 0.000566 0.42 0.39 Colorectal cancer (SNP x SNP interaction); chr5:109334720 chr5:109237120~109326369:- PAAD cis rs2115630 0.936 rs11073663 ENSG00000259728.4 LINC00933 -5.17 7.39e-07 0.000567 -0.47 -0.39 P wave terminal force; chr15:84717037 chr15:84570649~84580175:+ PAAD cis rs2333194 0.869 rs177368 ENSG00000258695.2 RP3-414A15.2 -5.17 7.4e-07 0.000567 -0.42 -0.39 Bipolar disorder with mood-incongruent psychosis; chr14:73294539 chr14:73522878~73530610:+ PAAD cis rs10461617 0.531 rs2662033 ENSG00000271828.1 CTD-2310F14.1 5.17 7.4e-07 0.000567 0.6 0.39 Type 2 diabetes; chr5:56917583 chr5:56927874~56929573:+ PAAD cis rs2283792 0.967 rs5999823 ENSG00000228050.1 TOP3BP1 5.17 7.4e-07 0.000567 0.41 0.39 Multiple sclerosis; chr22:21856587 chr22:22223187~22224566:- PAAD cis rs4835473 0.897 rs1450249 ENSG00000251600.4 RP11-673E1.1 5.17 7.41e-07 0.000568 0.43 0.39 Immature fraction of reticulocytes; chr4:143724425 chr4:143912331~143982454:+ PAAD cis rs2404602 0.569 rs2469249 ENSG00000259422.1 RP11-593F23.1 -5.17 7.41e-07 0.000568 -0.49 -0.39 Blood metabolite levels; chr15:76479721 chr15:76174891~76181486:- PAAD cis rs2658782 0.756 rs3019223 ENSG00000279684.1 RP11-755E23.2 -5.17 7.43e-07 0.000569 -0.64 -0.39 Pulmonary function decline; chr11:93351016 chr11:93286629~93288903:- PAAD cis rs2658782 0.826 rs2925355 ENSG00000279684.1 RP11-755E23.2 -5.17 7.43e-07 0.000569 -0.64 -0.39 Pulmonary function decline; chr11:93357721 chr11:93286629~93288903:- PAAD cis rs2019137 0.56 rs7578633 ENSG00000274877.1 RP11-65I12.1 -5.17 7.43e-07 0.000569 -0.44 -0.39 Lymphocyte counts; chr2:113221073 chr2:113237595~113240825:+ PAAD cis rs2019137 0.539 rs11123170 ENSG00000274877.1 RP11-65I12.1 -5.17 7.43e-07 0.000569 -0.44 -0.39 Lymphocyte counts; chr2:113221363 chr2:113237595~113240825:+ PAAD cis rs2019137 0.56 rs6707386 ENSG00000274877.1 RP11-65I12.1 -5.17 7.43e-07 0.000569 -0.44 -0.39 Lymphocyte counts; chr2:113223445 chr2:113237595~113240825:+ PAAD cis rs12439619 0.705 rs4778665 ENSG00000255769.6 GOLGA2P10 -5.17 7.43e-07 0.000569 -0.51 -0.39 Intelligence (multi-trait analysis); chr15:82144163 chr15:82472993~82513950:- PAAD cis rs732716 0.785 rs7769 ENSG00000267980.1 AC007292.6 -5.16 7.44e-07 0.00057 -0.54 -0.39 Mean corpuscular volume; chr19:4360546 chr19:4363789~4364640:+ PAAD cis rs8059260 0.541 rs35126143 ENSG00000274038.1 RP11-66H6.4 -5.16 7.45e-07 0.000571 -0.68 -0.39 Alcohol consumption over the past year; chr16:11070455 chr16:11056556~11057034:+ PAAD cis rs9926296 0.546 rs7187436 ENSG00000260259.1 RP11-368I7.4 -5.16 7.46e-07 0.000571 -0.46 -0.39 Vitiligo; chr16:89778702 chr16:89682620~89686569:- PAAD cis rs9926296 0.585 rs1800337 ENSG00000260259.1 RP11-368I7.4 -5.16 7.46e-07 0.000571 -0.46 -0.39 Vitiligo; chr16:89778786 chr16:89682620~89686569:- PAAD cis rs9926296 0.605 rs3743859 ENSG00000260259.1 RP11-368I7.4 5.16 7.46e-07 0.000571 0.46 0.39 Vitiligo; chr16:89779642 chr16:89682620~89686569:- PAAD cis rs9926296 0.527 rs1800335 ENSG00000260259.1 RP11-368I7.4 -5.16 7.46e-07 0.000571 -0.46 -0.39 Vitiligo; chr16:89779787 chr16:89682620~89686569:- PAAD cis rs10875746 0.669 rs10875770 ENSG00000240399.1 RP1-228P16.1 -5.16 7.47e-07 0.000572 -0.41 -0.39 Longevity (90 years and older); chr12:48206737 chr12:48054813~48055591:- PAAD cis rs2283792 0.935 rs2283794 ENSG00000228050.1 TOP3BP1 5.16 7.48e-07 0.000572 0.41 0.39 Multiple sclerosis; chr22:21858180 chr22:22223187~22224566:- PAAD cis rs4218 0.569 rs73418864 ENSG00000277144.1 RP11-59H7.4 -5.16 7.49e-07 0.000573 -0.52 -0.39 Social communication problems; chr15:59098996 chr15:59115547~59116089:- PAAD cis rs7829975 0.846 rs11779061 ENSG00000253893.2 FAM85B 5.16 7.53e-07 0.000576 0.55 0.39 Mood instability; chr8:8691922 chr8:8167819~8226614:- PAAD cis rs72843506 0.722 rs74255392 ENSG00000189423.10 USP32P3 5.16 7.56e-07 0.000578 0.61 0.39 Schizophrenia; chr17:20425739 chr17:20415547~20431008:+ PAAD cis rs964611 0.882 rs2291342 ENSG00000259488.2 RP11-154J22.1 -5.16 7.57e-07 0.000579 -0.42 -0.39 Metabolite levels (Pyroglutamine); chr15:48291886 chr15:48312353~48331856:- PAAD cis rs964611 0.938 rs7174051 ENSG00000259488.2 RP11-154J22.1 -5.16 7.57e-07 0.000579 -0.42 -0.39 Metabolite levels (Pyroglutamine); chr15:48292131 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs68004907 ENSG00000259488.2 RP11-154J22.1 -5.16 7.57e-07 0.000579 -0.42 -0.39 Metabolite levels (Pyroglutamine); chr15:48293162 chr15:48312353~48331856:- PAAD cis rs875971 0.862 rs6971059 ENSG00000237310.1 GS1-124K5.4 -5.16 7.6e-07 0.000581 -0.39 -0.39 Aortic root size; chr7:66602045 chr7:66493706~66495474:+ PAAD cis rs875971 0.755 rs76288834 ENSG00000237310.1 GS1-124K5.4 -5.16 7.6e-07 0.000581 -0.39 -0.39 Aortic root size; chr7:66604815 chr7:66493706~66495474:+ PAAD cis rs875971 0.789 rs7808013 ENSG00000237310.1 GS1-124K5.4 -5.16 7.6e-07 0.000581 -0.39 -0.39 Aortic root size; chr7:66606209 chr7:66493706~66495474:+ PAAD cis rs875971 0.825 rs7384021 ENSG00000237310.1 GS1-124K5.4 -5.16 7.6e-07 0.000581 -0.39 -0.39 Aortic root size; chr7:66612917 chr7:66493706~66495474:+ PAAD cis rs875971 0.825 rs66981195 ENSG00000237310.1 GS1-124K5.4 -5.16 7.6e-07 0.000581 -0.39 -0.39 Aortic root size; chr7:66614048 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs3926380 ENSG00000237310.1 GS1-124K5.4 -5.16 7.6e-07 0.000581 -0.39 -0.39 Aortic root size; chr7:66615658 chr7:66493706~66495474:+ PAAD cis rs875971 0.825 rs1860472 ENSG00000237310.1 GS1-124K5.4 -5.16 7.6e-07 0.000581 -0.39 -0.39 Aortic root size; chr7:66617736 chr7:66493706~66495474:+ PAAD cis rs9595908 0.865 rs2761365 ENSG00000212293.1 SNORA16 -5.16 7.62e-07 0.000582 -0.46 -0.39 Body mass index; chr13:32437687 chr13:32420390~32420516:- PAAD cis rs9595908 0.827 rs2761366 ENSG00000212293.1 SNORA16 -5.16 7.62e-07 0.000582 -0.46 -0.39 Body mass index; chr13:32437735 chr13:32420390~32420516:- PAAD cis rs6570726 0.846 rs870491 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145612254 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs4332001 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145613705 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs1935616 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145622376 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs9376954 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145622601 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs9399559 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145624642 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs1045820 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145625944 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9376956 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145628708 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs4896827 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145632202 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs4896828 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145632203 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs6570701 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145632954 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9497380 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145634169 chr6:145799409~145886585:+ PAAD cis rs7772486 0.754 rs6570703 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145635916 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs6570705 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145640065 chr6:145799409~145886585:+ PAAD cis rs7772486 0.658 rs6570706 ENSG00000235652.6 RP11-545I5.3 5.16 7.62e-07 0.000582 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145641786 chr6:145799409~145886585:+ PAAD cis rs7772486 0.651 rs1292338 ENSG00000235652.6 RP11-545I5.3 -5.16 7.62e-07 0.000582 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145646335 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs1292337 ENSG00000235652.6 RP11-545I5.3 -5.16 7.62e-07 0.000582 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145646671 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs702305 ENSG00000235652.6 RP11-545I5.3 -5.16 7.62e-07 0.000582 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145652704 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs857879 ENSG00000235652.6 RP11-545I5.3 -5.16 7.62e-07 0.000582 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145652907 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs857875 ENSG00000235652.6 RP11-545I5.3 -5.16 7.62e-07 0.000582 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145658897 chr6:145799409~145886585:+ PAAD cis rs7208859 0.673 rs79541516 ENSG00000266490.1 CTD-2349P21.9 5.16 7.63e-07 0.000583 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913565 chr17:30792372~30792833:+ PAAD cis rs62229266 0.804 rs2835241 ENSG00000231106.2 LINC01436 -5.16 7.63e-07 0.000583 -0.57 -0.39 Mitral valve prolapse; chr21:36039082 chr21:36005338~36007838:+ PAAD cis rs11089937 0.559 rs2330014 ENSG00000211639.2 IGLV4-60 5.16 7.66e-07 0.000585 0.41 0.39 Periodontitis (PAL4Q3); chr22:22166155 chr22:22162199~22162681:+ PAAD cis rs9549328 0.577 rs4907477 ENSG00000267868.1 RP11-120K24.3 5.16 7.67e-07 0.000586 0.43 0.39 Systolic blood pressure; chr13:112964170 chr13:112964835~112966131:- PAAD cis rs9549328 0.577 rs4907478 ENSG00000267868.1 RP11-120K24.3 5.16 7.67e-07 0.000586 0.43 0.39 Systolic blood pressure; chr13:112964173 chr13:112964835~112966131:- PAAD cis rs9549328 0.577 rs4907571 ENSG00000267868.1 RP11-120K24.3 5.16 7.67e-07 0.000586 0.43 0.39 Systolic blood pressure; chr13:112964182 chr13:112964835~112966131:- PAAD cis rs2283792 0.687 rs381849 ENSG00000228050.1 TOP3BP1 5.16 7.69e-07 0.000587 0.41 0.39 Multiple sclerosis; chr22:21951341 chr22:22223187~22224566:- PAAD cis rs6921919 1 rs6922111 ENSG00000204709.4 LINC01556 5.16 7.69e-07 0.000587 0.65 0.39 Autism spectrum disorder or schizophrenia; chr6:28357531 chr6:28943877~28944537:+ PAAD cis rs17301013 0.507 rs12067852 ENSG00000227373.4 RP11-160H22.5 -5.16 7.69e-07 0.000587 -0.58 -0.39 Systemic lupus erythematosus; chr1:174302481 chr1:174115300~174160004:- PAAD cis rs9322193 0.847 rs868375 ENSG00000223701.3 RAET1E-AS1 5.16 7.69e-07 0.000587 0.44 0.39 Lung cancer; chr6:149844905 chr6:149884431~149919508:+ PAAD cis rs2274273 0.87 rs10139000 ENSG00000258413.1 RP11-665C16.6 -5.16 7.72e-07 0.000589 -0.51 -0.39 Protein biomarker; chr14:55383158 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs8013713 ENSG00000258413.1 RP11-665C16.6 5.16 7.72e-07 0.000589 0.51 0.39 Protein biomarker; chr14:55374534 chr14:55262767~55272075:- PAAD cis rs1862618 0.525 rs2662016 ENSG00000271828.1 CTD-2310F14.1 -5.16 7.73e-07 0.000589 -0.58 -0.39 Initial pursuit acceleration; chr5:56973220 chr5:56927874~56929573:+ PAAD cis rs4927850 0.794 rs2019472 ENSG00000231464.1 AC024937.4 5.16 7.73e-07 0.000589 0.48 0.39 Pancreatic cancer; chr3:196008500 chr3:195996738~195998233:+ PAAD cis rs9309711 0.621 rs11127428 ENSG00000225234.1 TRAPPC12-AS1 -5.16 7.73e-07 0.00059 -0.39 -0.39 Neurofibrillary tangles; chr2:3467375 chr2:3481242~3482409:- PAAD cis rs7945705 0.818 rs10769948 ENSG00000254860.4 TMEM9B-AS1 5.16 7.73e-07 0.00059 0.43 0.39 Hemoglobin concentration; chr11:8740235 chr11:8964675~8977527:+ PAAD cis rs5760092 0.755 rs4585126 ENSG00000231271.1 AP000350.8 -5.16 7.74e-07 0.00059 -0.57 -0.39 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23949918~23954042:+ PAAD cis rs8030379 0.811 rs7162542 ENSG00000230373.7 GOLGA6L5P -5.16 7.74e-07 0.00059 -0.32 -0.39 Waist circumference;Waist circumference adjusted for body mass index; chr15:83845538 chr15:84507885~84516814:- PAAD cis rs7772486 0.686 rs4896833 ENSG00000235652.6 RP11-545I5.3 5.16 7.77e-07 0.000592 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145644537 chr6:145799409~145886585:+ PAAD cis rs7580658 0.637 rs4580338 ENSG00000236682.1 AC068282.3 -5.16 7.78e-07 0.000593 -0.5 -0.39 Protein C levels; chr2:127217361 chr2:127389130~127400580:+ PAAD cis rs7208859 0.673 rs9895684 ENSG00000266490.1 CTD-2349P21.9 5.15 7.79e-07 0.000594 0.53 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30915582 chr17:30792372~30792833:+ PAAD cis rs34375054 0.738 rs3751181 ENSG00000279233.1 RP11-158L12.4 5.15 7.8e-07 0.000595 0.34 0.39 Post bronchodilator FEV1/FVC ratio; chr12:125141989 chr12:125138245~125141711:+ PAAD cis rs6921919 0.609 rs9461455 ENSG00000216901.1 AL022393.7 5.15 7.82e-07 0.000595 0.51 0.39 Autism spectrum disorder or schizophrenia; chr6:28361954 chr6:28176188~28176674:+ PAAD cis rs6921919 0.551 rs13201753 ENSG00000216901.1 AL022393.7 5.15 7.82e-07 0.000595 0.51 0.39 Autism spectrum disorder or schizophrenia; chr6:28363351 chr6:28176188~28176674:+ PAAD cis rs2274273 0.87 rs7158768 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55296894 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs10142547 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55297245 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs8023197 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55300677 chr14:55262767~55272075:- PAAD cis rs2274273 0.837 rs7148171 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55304026 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs1109170 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55319070 chr14:55262767~55272075:- PAAD cis rs2274273 0.837 rs10141483 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55320153 chr14:55262767~55272075:- PAAD cis rs2274273 0.837 rs10131913 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55320702 chr14:55262767~55272075:- PAAD cis rs2274273 0.901 rs112870553 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55323344 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs28568813 ENSG00000258413.1 RP11-665C16.6 -5.15 7.82e-07 0.000596 -0.48 -0.39 Protein biomarker; chr14:55327396 chr14:55262767~55272075:- PAAD cis rs7208859 0.673 rs2470251 ENSG00000266490.1 CTD-2349P21.9 5.15 7.82e-07 0.000596 0.46 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11652370 ENSG00000266490.1 CTD-2349P21.9 5.15 7.82e-07 0.000596 0.46 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770205 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs56846352 ENSG00000266490.1 CTD-2349P21.9 5.15 7.82e-07 0.000596 0.46 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792170 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs7211776 ENSG00000266490.1 CTD-2349P21.9 5.15 7.82e-07 0.000596 0.46 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793178 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs8078182 ENSG00000266490.1 CTD-2349P21.9 5.15 7.82e-07 0.000596 0.46 0.39 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822646 chr17:30792372~30792833:+ PAAD cis rs2880765 0.566 rs12911430 ENSG00000259295.5 CSPG4P12 5.15 7.83e-07 0.000596 0.43 0.39 Coronary artery disease; chr15:85468033 chr15:85191438~85213905:+ PAAD cis rs2880765 0.566 rs11630381 ENSG00000259295.5 CSPG4P12 5.15 7.83e-07 0.000596 0.43 0.39 Coronary artery disease; chr15:85469272 chr15:85191438~85213905:+ PAAD cis rs2880765 0.545 rs11631739 ENSG00000259295.5 CSPG4P12 5.15 7.83e-07 0.000596 0.43 0.39 Coronary artery disease; chr15:85469347 chr15:85191438~85213905:+ PAAD cis rs9473147 0.516 rs9381562 ENSG00000270761.1 RP11-385F7.1 -5.15 7.85e-07 0.000597 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47462031 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9473117 ENSG00000270761.1 RP11-385F7.1 -5.15 7.85e-07 0.000597 -0.39 -0.39 Platelet distribution width;Mean platelet volume; chr6:47463548 chr6:47477243~47477572:- PAAD cis rs6570726 0.818 rs9399555 ENSG00000235652.6 RP11-545I5.3 5.15 7.85e-07 0.000597 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145556418 chr6:145799409~145886585:+ PAAD cis rs7580658 0.637 rs4560059 ENSG00000236682.1 AC068282.3 -5.15 7.85e-07 0.000597 -0.5 -0.39 Protein C levels; chr2:127214652 chr2:127389130~127400580:+ PAAD cis rs12908161 1 rs35630683 ENSG00000225151.9 GOLGA2P7 -5.15 7.86e-07 0.000598 -0.48 -0.39 Schizophrenia; chr15:84806000 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs56864281 ENSG00000225151.9 GOLGA2P7 -5.15 7.86e-07 0.000598 -0.48 -0.39 Schizophrenia; chr15:84814418 chr15:84199311~84230136:- PAAD cis rs9322193 0.607 rs7764677 ENSG00000223701.3 RAET1E-AS1 5.15 7.87e-07 0.000599 0.49 0.39 Lung cancer; chr6:149906197 chr6:149884431~149919508:+ PAAD cis rs2948294 0.524 rs13270062 ENSG00000173295.6 FAM86B3P 5.15 7.88e-07 0.000599 0.41 0.39 Red cell distribution width; chr8:8255128 chr8:8228595~8244865:+ PAAD cis rs79040073 0.53 rs17476940 ENSG00000259531.2 RP11-295H24.3 -5.15 7.88e-07 0.000599 -0.58 -0.39 Lung cancer in ever smokers; chr15:49332587 chr15:49365124~49366685:- PAAD cis rs7615952 0.932 rs1976458 ENSG00000171084.14 FAM86JP 5.15 7.88e-07 6e-04 0.53 0.39 Blood pressure (smoking interaction); chr3:125928669 chr3:125916620~125930024:+ PAAD cis rs2880765 0.566 rs55899824 ENSG00000259295.5 CSPG4P12 5.15 7.88e-07 6e-04 0.43 0.39 Coronary artery disease; chr15:85460860 chr15:85191438~85213905:+ PAAD cis rs2880765 0.631 rs55767890 ENSG00000259295.5 CSPG4P12 5.15 7.88e-07 6e-04 0.43 0.39 Coronary artery disease; chr15:85460911 chr15:85191438~85213905:+ PAAD cis rs7772486 0.875 rs2748497 ENSG00000235652.6 RP11-545I5.3 5.15 7.88e-07 6e-04 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145998281 chr6:145799409~145886585:+ PAAD cis rs12468226 1 rs7597469 ENSG00000273456.1 RP11-686O6.2 5.15 7.89e-07 6e-04 0.58 0.39 Urate levels; chr2:202329547 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs113877751 ENSG00000273456.1 RP11-686O6.2 5.15 7.89e-07 6e-04 0.58 0.39 Urate levels; chr2:202329998 chr2:202374932~202375604:- PAAD cis rs17711722 0.565 rs73372653 ENSG00000164669.11 INTS4P1 -5.15 7.89e-07 6e-04 -0.47 -0.39 Calcium levels; chr7:65977808 chr7:65141225~65234216:+ PAAD cis rs4814920 0.818 rs4813377 ENSG00000275142.1 RP5-999L4.2 -5.15 7.91e-07 0.000601 -0.59 -0.39 Bipolar disorder (body mass index interaction); chr20:19870822 chr20:19871891~19872284:+ PAAD cis rs7916697 0.947 rs56238729 ENSG00000233590.1 RP11-153K11.3 -5.15 7.94e-07 0.000604 -0.53 -0.39 Optic disc area; chr10:68241883 chr10:68233251~68242379:- PAAD cis rs7829975 0.774 rs13259216 ENSG00000253893.2 FAM85B -5.15 7.94e-07 0.000604 -0.53 -0.39 Mood instability; chr8:8816091 chr8:8167819~8226614:- PAAD cis rs748404 0.631 rs7167882 ENSG00000249839.1 AC011330.5 -5.15 7.94e-07 0.000604 -0.55 -0.39 Lung cancer; chr15:43386465 chr15:43663654~43684339:- PAAD cis rs1075265 0.692 rs805358 ENSG00000233266.1 HMGB1P31 5.15 7.95e-07 0.000604 0.48 0.39 Chronotype;Morning vs. evening chronotype; chr2:53934885 chr2:54051334~54051760:+ PAAD cis rs6570726 0.791 rs441290 ENSG00000235652.6 RP11-545I5.3 5.15 7.96e-07 0.000605 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145562047 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs6919684 ENSG00000235652.6 RP11-545I5.3 5.15 7.96e-07 0.000605 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145562665 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs6899900 ENSG00000235652.6 RP11-545I5.3 5.15 7.96e-07 0.000605 0.32 0.39 Lobe attachment (rater-scored or self-reported); chr6:145562737 chr6:145799409~145886585:+ PAAD cis rs58873874 0.737 rs10515750 ENSG00000248544.2 CTB-47B11.3 5.15 7.97e-07 0.000606 0.79 0.39 Bipolar disorder (body mass index interaction); chr5:157383064 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs10061544 ENSG00000248544.2 CTB-47B11.3 5.15 7.97e-07 0.000606 0.79 0.39 Bipolar disorder (body mass index interaction); chr5:157383871 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs10078836 ENSG00000248544.2 CTB-47B11.3 5.15 7.97e-07 0.000606 0.79 0.39 Bipolar disorder (body mass index interaction); chr5:157384604 chr5:157375741~157384950:- PAAD cis rs12908161 0.96 rs17599989 ENSG00000225151.9 GOLGA2P7 -5.15 7.97e-07 0.000606 -0.48 -0.39 Schizophrenia; chr15:84742305 chr15:84199311~84230136:- PAAD cis rs13178541 0.81 rs4976496 ENSG00000250378.1 RP11-119J18.1 -5.15 7.98e-07 0.000606 -0.56 -0.39 IgG glycosylation; chr5:135850086 chr5:135812667~135826582:+ PAAD cis rs8062405 0.688 rs3924376 ENSG00000251417.2 RP11-1348G14.4 5.15 8e-07 0.000607 0.36 0.39 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28914657 chr16:28802743~28817828:+ PAAD cis rs2739330 0.731 rs5751792 ENSG00000099984.9 GSTT2 -5.15 8.01e-07 0.000608 -0.51 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23980123~23983911:+ PAAD cis rs4423214 0.65 rs4245442 ENSG00000254682.1 RP11-660L16.2 5.15 8.01e-07 0.000608 0.57 0.39 Vitamin D levels; chr11:71509863 chr11:71448674~71452157:+ PAAD cis rs62229266 0.835 rs998384 ENSG00000231106.2 LINC01436 5.15 8.02e-07 0.000609 0.57 0.39 Mitral valve prolapse; chr21:36073228 chr21:36005338~36007838:+ PAAD cis rs17301013 0.729 rs12094143 ENSG00000227373.4 RP11-160H22.5 5.15 8.03e-07 0.000609 0.48 0.39 Systemic lupus erythematosus; chr1:174511986 chr1:174115300~174160004:- PAAD cis rs3931020 0.688 rs1051122 ENSG00000272864.1 RP11-17E13.2 -5.15 8.05e-07 0.00061 -0.54 -0.39 Resistin levels; chr1:74724768 chr1:74698769~74699333:- PAAD cis rs3931020 0.688 rs455032 ENSG00000272864.1 RP11-17E13.2 5.15 8.05e-07 0.00061 0.54 0.39 Resistin levels; chr1:74730804 chr1:74698769~74699333:- PAAD cis rs2739330 0.761 rs5760176 ENSG00000099984.9 GSTT2 5.15 8.06e-07 0.000612 0.51 0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23980123~23983911:+ PAAD cis rs6921919 0.832 rs17312661 ENSG00000204709.4 LINC01556 5.15 8.07e-07 0.000612 0.67 0.39 Autism spectrum disorder or schizophrenia; chr6:28332559 chr6:28943877~28944537:+ PAAD cis rs964611 0.872 rs2279366 ENSG00000259488.2 RP11-154J22.1 -5.15 8.07e-07 0.000612 -0.44 -0.39 Metabolite levels (Pyroglutamine); chr15:48249830 chr15:48312353~48331856:- PAAD cis rs9322193 0.566 rs3922947 ENSG00000223701.3 RAET1E-AS1 -5.15 8.08e-07 0.000613 -0.49 -0.39 Lung cancer; chr6:149924856 chr6:149884431~149919508:+ PAAD cis rs2658782 0.526 rs7127240 ENSG00000279684.1 RP11-755E23.2 -5.15 8.09e-07 0.000613 -0.56 -0.39 Pulmonary function decline; chr11:93451726 chr11:93286629~93288903:- PAAD cis rs2658782 0.526 rs7131487 ENSG00000279684.1 RP11-755E23.2 -5.15 8.09e-07 0.000613 -0.56 -0.39 Pulmonary function decline; chr11:93452786 chr11:93286629~93288903:- PAAD cis rs2115630 1 rs56074163 ENSG00000259728.4 LINC00933 -5.15 8.14e-07 0.000617 -0.47 -0.39 P wave terminal force; chr15:84808101 chr15:84570649~84580175:+ PAAD cis rs875971 0.651 rs313829 ENSG00000226824.5 RP4-756H11.3 5.15 8.14e-07 0.000617 0.5 0.39 Aortic root size; chr7:66087510 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs4718334 ENSG00000226824.5 RP4-756H11.3 5.15 8.14e-07 0.000617 0.69 0.39 Diabetic kidney disease; chr7:66324467 chr7:66654538~66669855:+ PAAD cis rs2739330 0.732 rs5760175 ENSG00000099984.9 GSTT2 -5.14 8.15e-07 0.000618 -0.51 -0.39 Liver enzyme levels (gamma-glutamyl transferase); chr22:24003209 chr22:23980123~23983911:+ PAAD cis rs3931020 0.688 rs277374 ENSG00000272864.1 RP11-17E13.2 5.14 8.15e-07 0.000618 0.54 0.39 Resistin levels; chr1:74734802 chr1:74698769~74699333:- PAAD cis rs694739 1 rs694739 ENSG00000236935.1 AP003774.1 5.14 8.16e-07 0.000618 0.41 0.39 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64329761 chr11:64325050~64329504:- PAAD cis rs7712401 0.58 rs4288111 ENSG00000263432.2 RN7SL689P -5.14 8.16e-07 0.000618 -0.49 -0.39 Mean platelet volume; chr5:123052487 chr5:123022487~123022783:- PAAD cis rs9322193 0.923 rs9371486 ENSG00000216906.2 RP11-350J20.9 5.14 8.17e-07 0.000619 0.53 0.39 Lung cancer; chr6:149832090 chr6:149904243~149906418:+ PAAD cis rs75422866 0.717 rs73113159 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47631318 chr12:47706085~47742294:+ PAAD cis rs75422866 0.717 rs73113161 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47632361 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs117022227 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47633282 chr12:47706085~47742294:+ PAAD cis rs75422866 1 rs73102120 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47637280 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102125 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47637869 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs12426849 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47638975 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs117950951 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47639794 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs7954764 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47641136 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs12422974 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47644559 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102127 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47645341 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102140 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47647497 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102148 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47648013 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs73102151 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47648023 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs75568526 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47649718 chr12:47706085~47742294:+ PAAD cis rs75422866 0.867 rs116302411 ENSG00000257433.4 RP1-197B17.3 5.14 8.17e-07 0.000619 0.77 0.39 Pneumonia; chr12:47649788 chr12:47706085~47742294:+ PAAD cis rs8135665 0.6 rs3026682 ENSG00000233739.1 RP5-1039K5.13 5.14 8.19e-07 0.00062 0.49 0.39 Advanced age-related macular degeneration;Age-related macular degeneration; chr22:38056475 chr22:38057180~38073940:- PAAD cis rs7772486 0.624 rs6930154 ENSG00000235652.6 RP11-545I5.3 -5.14 8.2e-07 0.00062 -0.32 -0.39 Lobe attachment (rater-scored or self-reported); chr6:145704526 chr6:145799409~145886585:+ PAAD cis rs2243480 1 rs383402 ENSG00000226824.5 RP4-756H11.3 5.14 8.21e-07 0.000621 0.71 0.39 Diabetic kidney disease; chr7:66121666 chr7:66654538~66669855:+ PAAD cis rs1150668 0.764 rs9368565 ENSG00000204709.4 LINC01556 -5.14 8.21e-07 0.000621 -0.52 -0.39 Pubertal anthropometrics; chr6:28377433 chr6:28943877~28944537:+ PAAD cis rs7772486 0.681 rs9390343 ENSG00000235652.6 RP11-545I5.3 -5.14 8.23e-07 0.000622 -0.33 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145689391 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs418701 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145568856 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs1280275 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145571266 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6900040 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145571998 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs6923074 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145572196 chr6:145799409~145886585:+ PAAD cis rs6570726 0.755 rs2092296 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145572548 chr6:145799409~145886585:+ PAAD cis rs6570726 0.755 rs2092297 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145572629 chr6:145799409~145886585:+ PAAD cis rs6570726 0.755 rs2103633 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145572885 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs9373463 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145573626 chr6:145799409~145886585:+ PAAD cis rs6570726 0.764 rs9322028 ENSG00000235652.6 RP11-545I5.3 5.14 8.24e-07 0.000623 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145574661 chr6:145799409~145886585:+ PAAD cis rs4835473 0.897 rs7678190 ENSG00000251600.4 RP11-673E1.1 5.14 8.25e-07 0.000624 0.43 0.38 Immature fraction of reticulocytes; chr4:143722421 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs12505617 ENSG00000251600.4 RP11-673E1.1 5.14 8.25e-07 0.000624 0.43 0.38 Immature fraction of reticulocytes; chr4:143723522 chr4:143912331~143982454:+ PAAD cis rs4698412 0.874 rs3213710 ENSG00000214846.4 RP11-115L11.1 -5.14 8.25e-07 0.000624 -0.42 -0.38 Parkinson's disease; chr4:15715698 chr4:15730962~15731627:- PAAD cis rs2153535 0.504 rs5001323 ENSG00000230939.1 RP11-314C16.1 -5.14 8.26e-07 0.000624 -0.41 -0.38 Motion sickness; chr6:8451372 chr6:8784178~8785445:+ PAAD cis rs16828019 0.789 rs36084778 ENSG00000235358.1 RP11-399E6.1 5.14 8.26e-07 0.000624 0.74 0.38 Intelligence (multi-trait analysis); chr1:41013866 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs11209363 ENSG00000235358.1 RP11-399E6.1 5.14 8.26e-07 0.000624 0.74 0.38 Intelligence (multi-trait analysis); chr1:41019405 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs16911 ENSG00000235358.1 RP11-399E6.1 5.14 8.26e-07 0.000624 0.74 0.38 Intelligence (multi-trait analysis); chr1:41032349 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs2300658 ENSG00000235358.1 RP11-399E6.1 5.14 8.26e-07 0.000624 0.74 0.38 Intelligence (multi-trait analysis); chr1:41039350 chr1:41242373~41284861:+ PAAD cis rs73186030 0.546 rs73188388 ENSG00000272758.4 RP11-299J3.8 5.14 8.27e-07 0.000625 0.53 0.38 Serum parathyroid hormone levels; chr3:122399229 chr3:122416207~122443180:+ PAAD cis rs7945705 0.846 rs2742540 ENSG00000254860.4 TMEM9B-AS1 -5.14 8.28e-07 0.000626 -0.41 -0.38 Hemoglobin concentration; chr11:8877981 chr11:8964675~8977527:+ PAAD cis rs12468226 1 rs7597156 ENSG00000273456.1 RP11-686O6.2 5.14 8.28e-07 0.000626 0.58 0.38 Urate levels; chr2:202329339 chr2:202374932~202375604:- PAAD cis rs8059260 0.604 rs35715760 ENSG00000274038.1 RP11-66H6.4 -5.14 8.29e-07 0.000626 -0.6 -0.38 Alcohol consumption over the past year; chr16:11102091 chr16:11056556~11057034:+ PAAD cis rs964611 0.938 rs11631385 ENSG00000259488.2 RP11-154J22.1 5.14 8.29e-07 0.000626 0.43 0.38 Metabolite levels (Pyroglutamine); chr15:48315886 chr15:48312353~48331856:- PAAD cis rs2880765 0.545 rs17553734 ENSG00000259295.5 CSPG4P12 -5.14 8.29e-07 0.000627 -0.43 -0.38 Coronary artery disease; chr15:85469828 chr15:85191438~85213905:+ PAAD cis rs2880765 0.566 rs17553790 ENSG00000259295.5 CSPG4P12 -5.14 8.29e-07 0.000627 -0.43 -0.38 Coronary artery disease; chr15:85470434 chr15:85191438~85213905:+ PAAD cis rs2412819 0.571 rs8038068 ENSG00000249839.1 AC011330.5 -5.14 8.31e-07 0.000628 -0.67 -0.38 Lung cancer; chr15:43622175 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs8030536 ENSG00000249839.1 AC011330.5 -5.14 8.31e-07 0.000628 -0.67 -0.38 Lung cancer; chr15:43627365 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs56246169 ENSG00000249839.1 AC011330.5 -5.14 8.31e-07 0.000628 -0.67 -0.38 Lung cancer; chr15:43628358 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs6493084 ENSG00000249839.1 AC011330.5 -5.14 8.31e-07 0.000628 -0.55 -0.38 Lung cancer; chr15:43355429 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs12905772 ENSG00000249839.1 AC011330.5 -5.14 8.31e-07 0.000628 -0.55 -0.38 Lung cancer; chr15:43356246 chr15:43663654~43684339:- PAAD cis rs748404 0.676 rs4401024 ENSG00000249839.1 AC011330.5 -5.14 8.31e-07 0.000628 -0.55 -0.38 Lung cancer; chr15:43358137 chr15:43663654~43684339:- PAAD cis rs7772486 0.622 rs1292333 ENSG00000235652.6 RP11-545I5.3 -5.14 8.32e-07 0.000628 -0.32 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145661208 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs2179323 ENSG00000235652.6 RP11-545I5.3 -5.14 8.32e-07 0.000628 -0.32 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145661650 chr6:145799409~145886585:+ PAAD cis rs494459 0.838 rs581045 ENSG00000255422.1 AP002954.4 -5.14 8.32e-07 0.000629 -0.42 -0.38 Height; chr11:118761813 chr11:118704607~118750263:+ PAAD cis rs4879677 1 rs10757677 ENSG00000260390.1 RP11-575I8.1 -5.14 8.33e-07 0.000629 -0.49 -0.38 Gut microbiome composition (summer and winter); chr9:27684534 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs10116400 ENSG00000260390.1 RP11-575I8.1 -5.14 8.33e-07 0.000629 -0.49 -0.38 Gut microbiome composition (summer and winter); chr9:27686882 chr9:27829276~27844481:+ PAAD cis rs7208859 0.673 rs9912122 ENSG00000266490.1 CTD-2349P21.9 5.14 8.33e-07 0.000629 0.45 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813698 chr17:30792372~30792833:+ PAAD cis rs2274273 0.624 rs8003279 ENSG00000258413.1 RP11-665C16.6 -5.14 8.33e-07 0.00063 -0.53 -0.38 Protein biomarker; chr14:55397412 chr14:55262767~55272075:- PAAD cis rs748404 0.516 rs523156 ENSG00000249839.1 AC011330.5 5.14 8.34e-07 0.00063 0.58 0.38 Lung cancer; chr15:43519645 chr15:43663654~43684339:- PAAD cis rs2880765 0.566 rs17553249 ENSG00000259295.5 CSPG4P12 5.14 8.34e-07 0.00063 0.43 0.38 Coronary artery disease; chr15:85463463 chr15:85191438~85213905:+ PAAD cis rs17711722 0.523 rs313812 ENSG00000226824.5 RP4-756H11.3 5.14 8.36e-07 0.000631 0.45 0.38 Calcium levels; chr7:66040056 chr7:66654538~66669855:+ PAAD cis rs17711722 0.523 rs365896 ENSG00000226824.5 RP4-756H11.3 5.14 8.36e-07 0.000631 0.45 0.38 Calcium levels; chr7:66045710 chr7:66654538~66669855:+ PAAD cis rs6570726 0.791 rs12205752 ENSG00000235652.6 RP11-545I5.3 5.14 8.37e-07 0.000632 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145574982 chr6:145799409~145886585:+ PAAD cis rs12468226 1 rs116635509 ENSG00000273456.1 RP11-686O6.2 5.14 8.37e-07 0.000632 0.57 0.38 Urate levels; chr2:202460027 chr2:202374932~202375604:- PAAD cis rs12468226 0.746 rs75987655 ENSG00000273456.1 RP11-686O6.2 5.14 8.4e-07 0.000634 0.61 0.38 Urate levels; chr2:202581913 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs116601501 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202274567 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs80282360 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202275121 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs76658848 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202275548 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs57571703 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202281997 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs78928733 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202283787 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs77062060 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202285639 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs3731700 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202291213 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs12464254 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202301641 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs16841867 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202303512 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs79117531 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202307690 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs16839065 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202308774 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs12471060 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202309597 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs115418918 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202315145 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs114922024 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202315958 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs77261109 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202316233 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs12466003 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202317317 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs76501067 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202318042 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs80315897 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202318044 chr2:202374932~202375604:- PAAD cis rs12468226 0.935 rs113021930 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202330448 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs113491584 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202331724 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs112306637 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202334195 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs111252524 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202334465 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs112753638 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202334496 chr2:202374932~202375604:- PAAD cis rs12468226 0.935 rs113188021 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202336237 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs6731027 ENSG00000273456.1 RP11-686O6.2 5.14 8.41e-07 0.000634 0.58 0.38 Urate levels; chr2:202337443 chr2:202374932~202375604:- PAAD cis rs2333194 0.875 rs28716532 ENSG00000258695.2 RP3-414A15.2 -5.14 8.41e-07 0.000634 -0.42 -0.38 Bipolar disorder with mood-incongruent psychosis; chr14:73302547 chr14:73522878~73530610:+ PAAD cis rs10935480 0.771 rs7634817 ENSG00000239445.4 ST3GAL6-AS1 5.14 8.44e-07 0.000636 0.42 0.38 Blood protein levels; chr3:98743681 chr3:98714330~98732651:- PAAD cis rs17023223 0.537 rs61319010 ENSG00000231365.4 RP11-418J17.1 -5.14 8.44e-07 0.000637 -0.43 -0.38 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119200388 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs12083510 ENSG00000231365.4 RP11-418J17.1 -5.14 8.44e-07 0.000637 -0.43 -0.38 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119203997 chr1:119140396~119275973:+ PAAD cis rs8031584 0.918 rs3817498 ENSG00000260382.1 RP11-540B6.2 5.14 8.45e-07 0.000637 0.49 0.38 Huntington's disease progression; chr15:30976578 chr15:30882267~30883231:- PAAD cis rs12908161 1 rs12903134 ENSG00000225151.9 GOLGA2P7 -5.14 8.45e-07 0.000637 -0.48 -0.38 Schizophrenia; chr15:84794468 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs35726233 ENSG00000225151.9 GOLGA2P7 -5.14 8.45e-07 0.000637 -0.48 -0.38 Schizophrenia; chr15:84794569 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs35960805 ENSG00000225151.9 GOLGA2P7 -5.14 8.45e-07 0.000637 -0.48 -0.38 Schizophrenia; chr15:84800749 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs12912388 ENSG00000225151.9 GOLGA2P7 -5.14 8.45e-07 0.000637 -0.48 -0.38 Schizophrenia; chr15:84801319 chr15:84199311~84230136:- PAAD cis rs62229266 0.804 rs998383 ENSG00000231106.2 LINC01436 5.14 8.46e-07 0.000638 0.57 0.38 Mitral valve prolapse; chr21:36073441 chr21:36005338~36007838:+ PAAD cis rs6570726 0.689 rs411785 ENSG00000235652.6 RP11-545I5.3 5.14 8.48e-07 0.000639 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145567262 chr6:145799409~145886585:+ PAAD cis rs2283792 0.715 rs55891647 ENSG00000224086.5 LL22NC03-86G7.1 -5.14 8.49e-07 0.00064 -0.39 -0.38 Multiple sclerosis; chr22:21824198 chr22:21938293~21977632:+ PAAD cis rs977987 0.528 rs9926933 ENSG00000261783.1 RP11-252K23.2 5.14 8.49e-07 0.00064 0.59 0.38 Dupuytren's disease; chr16:75467669 chr16:75379818~75381260:- PAAD cis rs13178541 0.683 rs7378856 ENSG00000250378.1 RP11-119J18.1 -5.14 8.51e-07 0.000641 -0.6 -0.38 IgG glycosylation; chr5:135751404 chr5:135812667~135826582:+ PAAD cis rs13178541 0.683 rs4036630 ENSG00000250378.1 RP11-119J18.1 -5.14 8.51e-07 0.000641 -0.6 -0.38 IgG glycosylation; chr5:135752980 chr5:135812667~135826582:+ PAAD cis rs13178541 0.748 rs7379672 ENSG00000250378.1 RP11-119J18.1 -5.14 8.51e-07 0.000641 -0.6 -0.38 IgG glycosylation; chr5:135754136 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs11950793 ENSG00000250378.1 RP11-119J18.1 -5.14 8.51e-07 0.000641 -0.6 -0.38 IgG glycosylation; chr5:135754394 chr5:135812667~135826582:+ PAAD cis rs2243480 1 rs958550 ENSG00000226824.5 RP4-756H11.3 5.14 8.51e-07 0.000641 0.7 0.38 Diabetic kidney disease; chr7:66170692 chr7:66654538~66669855:+ PAAD cis rs858239 0.6 rs4409314 ENSG00000226816.2 AC005082.12 5.14 8.52e-07 0.000642 0.43 0.38 Cerebrospinal fluid biomarker levels; chr7:23088333 chr7:23206013~23208045:+ PAAD cis rs2274273 0.624 rs7151754 ENSG00000258413.1 RP11-665C16.6 -5.13 8.52e-07 0.000642 -0.51 -0.38 Protein biomarker; chr14:55321783 chr14:55262767~55272075:- PAAD cis rs2333194 0.707 rs10134224 ENSG00000258695.2 RP3-414A15.2 -5.13 8.53e-07 0.000642 -0.42 -0.38 Bipolar disorder with mood-incongruent psychosis; chr14:73315235 chr14:73522878~73530610:+ PAAD cis rs763567 1 rs12755237 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170599573 chr1:170667381~170669425:+ PAAD cis rs763567 1 rs12742164 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170599755 chr1:170667381~170669425:+ PAAD cis rs763567 1 rs3903239 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170600176 chr1:170667381~170669425:+ PAAD cis rs763567 0.967 rs7412231 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170601358 chr1:170667381~170669425:+ PAAD cis rs763567 1 rs10919437 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170603805 chr1:170667381~170669425:+ PAAD cis rs763567 1 rs61217505 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170604117 chr1:170667381~170669425:+ PAAD cis rs763567 1 rs2206062 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170606966 chr1:170667381~170669425:+ PAAD cis rs763567 0.967 rs10919444 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170612493 chr1:170667381~170669425:+ PAAD cis rs763567 0.967 rs1952675 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170613434 chr1:170667381~170669425:+ PAAD cis rs763567 1 rs6677540 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170614370 chr1:170667381~170669425:+ PAAD cis rs763567 0.967 rs6690642 ENSG00000271811.1 RP1-79C4.4 -5.13 8.53e-07 0.000643 -0.37 -0.38 Tonsillectomy; chr1:170614803 chr1:170667381~170669425:+ PAAD cis rs1150668 0.796 rs1124132 ENSG00000204709.4 LINC01556 5.13 8.55e-07 0.000644 0.51 0.38 Pubertal anthropometrics; chr6:28412544 chr6:28943877~28944537:+ PAAD cis rs1150668 0.796 rs2531832 ENSG00000204709.4 LINC01556 5.13 8.55e-07 0.000644 0.51 0.38 Pubertal anthropometrics; chr6:28421445 chr6:28943877~28944537:+ PAAD cis rs7829975 0.511 rs2976906 ENSG00000253893.2 FAM85B -5.13 8.56e-07 0.000644 -0.52 -0.38 Mood instability; chr8:8484905 chr8:8167819~8226614:- PAAD cis rs10463554 0.892 rs1438687 ENSG00000175749.11 EIF3KP1 5.13 8.57e-07 0.000645 0.48 0.38 Parkinson's disease; chr5:102968792 chr5:103032376~103033031:+ PAAD cis rs4218 0.681 rs58335303 ENSG00000277144.1 RP11-59H7.4 -5.13 8.57e-07 0.000645 -0.51 -0.38 Social communication problems; chr15:59073206 chr15:59115547~59116089:- PAAD cis rs9926296 0.744 rs164749 ENSG00000260259.1 RP11-368I7.4 5.13 8.58e-07 0.000646 0.47 0.38 Vitiligo; chr16:89641816 chr16:89682620~89686569:- PAAD cis rs7772486 0.754 rs6570708 ENSG00000235652.6 RP11-545I5.3 -5.13 8.6e-07 0.000647 -0.32 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145668292 chr6:145799409~145886585:+ PAAD cis rs2115630 0.936 rs8033459 ENSG00000259728.4 LINC00933 -5.13 8.62e-07 0.000648 -0.47 -0.38 P wave terminal force; chr15:84710027 chr15:84570649~84580175:+ PAAD cis rs10483853 0.525 rs10138789 ENSG00000258695.2 RP3-414A15.2 -5.13 8.63e-07 0.000649 -0.6 -0.38 Coronary artery calcification; chr14:73497574 chr14:73522878~73530610:+ PAAD cis rs7916410 0.512 rs1900003 ENSG00000233590.1 RP11-153K11.3 -5.13 8.63e-07 0.000649 -0.52 -0.38 Optic disc area; chr10:68244794 chr10:68233251~68242379:- PAAD cis rs7916697 0.578 rs1900002 ENSG00000233590.1 RP11-153K11.3 -5.13 8.63e-07 0.000649 -0.52 -0.38 Optic disc area; chr10:68244795 chr10:68233251~68242379:- PAAD cis rs4308124 1 rs62160391 ENSG00000227992.1 AC108463.2 -5.13 8.66e-07 0.000651 -0.38 -0.38 Vitiligo; chr2:111251258 chr2:111203964~111206215:- PAAD cis rs11098499 0.874 rs7661020 ENSG00000245958.5 RP11-33B1.1 -5.13 8.66e-07 0.000651 -0.31 -0.38 Corneal astigmatism; chr4:119185827 chr4:119454791~119552025:+ PAAD cis rs6921919 0.609 rs9461455 ENSG00000204709.4 LINC01556 5.13 8.66e-07 0.000651 0.55 0.38 Autism spectrum disorder or schizophrenia; chr6:28361954 chr6:28943877~28944537:+ PAAD cis rs6921919 0.551 rs13201753 ENSG00000204709.4 LINC01556 5.13 8.66e-07 0.000651 0.55 0.38 Autism spectrum disorder or schizophrenia; chr6:28363351 chr6:28943877~28944537:+ PAAD cis rs526231 0.578 rs17154821 ENSG00000175749.11 EIF3KP1 5.13 8.68e-07 0.000652 0.5 0.38 Primary biliary cholangitis; chr5:102905637 chr5:103032376~103033031:+ PAAD cis rs526231 0.578 rs6876278 ENSG00000175749.11 EIF3KP1 5.13 8.68e-07 0.000652 0.5 0.38 Primary biliary cholangitis; chr5:102913842 chr5:103032376~103033031:+ PAAD cis rs12468226 0.873 rs79071680 ENSG00000273456.1 RP11-686O6.2 5.13 8.69e-07 0.000653 0.59 0.38 Urate levels; chr2:202191520 chr2:202374932~202375604:- PAAD cis rs12468226 0.873 rs79860867 ENSG00000273456.1 RP11-686O6.2 5.13 8.69e-07 0.000653 0.59 0.38 Urate levels; chr2:202192397 chr2:202374932~202375604:- PAAD cis rs12468226 0.873 rs78798541 ENSG00000273456.1 RP11-686O6.2 5.13 8.69e-07 0.000653 0.59 0.38 Urate levels; chr2:202194708 chr2:202374932~202375604:- PAAD cis rs2404602 0.735 rs11072598 ENSG00000259422.1 RP11-593F23.1 -5.13 8.69e-07 0.000653 -0.47 -0.38 Blood metabolite levels; chr15:76472447 chr15:76174891~76181486:- PAAD cis rs2115630 0.645 rs6496284 ENSG00000225151.9 GOLGA2P7 5.13 8.69e-07 0.000654 0.44 0.38 P wave terminal force; chr15:84635039 chr15:84199311~84230136:- PAAD cis rs35160687 0.644 rs56394965 ENSG00000273080.1 RP11-301O19.1 -5.13 8.71e-07 0.000654 -0.46 -0.38 Night sleep phenotypes; chr2:86271226 chr2:86195590~86196049:+ PAAD cis rs1928295 1 rs9299254 ENSG00000233569.1 RP11-500B12.1 5.13 8.71e-07 0.000655 0.43 0.38 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117612117 chr9:117648606~117657027:+ PAAD cis rs1928295 1 rs1013985 ENSG00000233569.1 RP11-500B12.1 5.13 8.71e-07 0.000655 0.43 0.38 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117612630 chr9:117648606~117657027:+ PAAD cis rs1928295 0.867 rs9299255 ENSG00000233569.1 RP11-500B12.1 5.13 8.71e-07 0.000655 0.43 0.38 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117618208 chr9:117648606~117657027:+ PAAD cis rs1928295 0.967 rs9409189 ENSG00000233569.1 RP11-500B12.1 5.13 8.71e-07 0.000655 0.43 0.38 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117620649 chr9:117648606~117657027:+ PAAD cis rs2274273 0.84 rs2009291 ENSG00000258413.1 RP11-665C16.6 5.13 8.72e-07 0.000655 0.49 0.38 Protein biomarker; chr14:55371512 chr14:55262767~55272075:- PAAD cis rs858239 0.799 rs10279941 ENSG00000226816.2 AC005082.12 5.13 8.75e-07 0.000657 0.43 0.38 Cerebrospinal fluid biomarker levels; chr7:23330889 chr7:23206013~23208045:+ PAAD cis rs1075265 0.811 rs805322 ENSG00000233266.1 HMGB1P31 -5.13 8.77e-07 0.000659 -0.5 -0.38 Chronotype;Morning vs. evening chronotype; chr2:53912758 chr2:54051334~54051760:+ PAAD cis rs964611 0.765 rs6493311 ENSG00000259488.2 RP11-154J22.1 -5.13 8.78e-07 0.000659 -0.43 -0.38 Metabolite levels (Pyroglutamine); chr15:48247390 chr15:48312353~48331856:- PAAD cis rs2333194 0.875 rs7140876 ENSG00000258695.2 RP3-414A15.2 -5.13 8.79e-07 0.00066 -0.42 -0.38 Bipolar disorder with mood-incongruent psychosis; chr14:73326230 chr14:73522878~73530610:+ PAAD cis rs7580658 0.637 rs4662710 ENSG00000236682.1 AC068282.3 -5.13 8.8e-07 0.00066 -0.5 -0.38 Protein C levels; chr2:127219241 chr2:127389130~127400580:+ PAAD cis rs7580658 0.637 rs9636235 ENSG00000236682.1 AC068282.3 -5.13 8.8e-07 0.00066 -0.5 -0.38 Protein C levels; chr2:127223975 chr2:127389130~127400580:+ PAAD cis rs7580658 0.637 rs9636236 ENSG00000236682.1 AC068282.3 -5.13 8.8e-07 0.00066 -0.5 -0.38 Protein C levels; chr2:127225365 chr2:127389130~127400580:+ PAAD cis rs7580658 0.711 rs12469035 ENSG00000236682.1 AC068282.3 -5.13 8.8e-07 0.00066 -0.5 -0.38 Protein C levels; chr2:127227341 chr2:127389130~127400580:+ PAAD cis rs12468226 0.81 rs77090459 ENSG00000273456.1 RP11-686O6.2 5.13 8.8e-07 0.00066 0.57 0.38 Urate levels; chr2:202542132 chr2:202374932~202375604:- PAAD cis rs6921919 0.638 rs9468344 ENSG00000216901.1 AL022393.7 5.13 8.81e-07 0.000661 0.51 0.38 Autism spectrum disorder or schizophrenia; chr6:28341792 chr6:28176188~28176674:+ PAAD cis rs9926296 0.605 rs12599180 ENSG00000260259.1 RP11-368I7.4 5.13 8.81e-07 0.000661 0.46 0.38 Vitiligo; chr16:89772898 chr16:89682620~89686569:- PAAD cis rs2274273 0.588 rs7145727 ENSG00000258413.1 RP11-665C16.6 -5.13 8.81e-07 0.000661 -0.48 -0.38 Protein biomarker; chr14:55380855 chr14:55262767~55272075:- PAAD cis rs4218 0.701 rs7174277 ENSG00000277144.1 RP11-59H7.4 -5.13 8.82e-07 0.000661 -0.45 -0.38 Social communication problems; chr15:59150390 chr15:59115547~59116089:- PAAD cis rs11673344 0.864 rs55921822 ENSG00000226686.6 LINC01535 5.13 8.82e-07 0.000661 0.52 0.38 Obesity-related traits; chr19:37005910 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs55792845 ENSG00000226686.6 LINC01535 5.13 8.82e-07 0.000661 0.52 0.38 Obesity-related traits; chr19:37007783 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs56208574 ENSG00000226686.6 LINC01535 5.13 8.82e-07 0.000661 0.52 0.38 Obesity-related traits; chr19:37007843 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs8107192 ENSG00000226686.6 LINC01535 5.13 8.82e-07 0.000661 0.52 0.38 Obesity-related traits; chr19:37008725 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs79927931 ENSG00000226686.6 LINC01535 5.13 8.82e-07 0.000661 0.52 0.38 Obesity-related traits; chr19:37012241 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs11670216 ENSG00000226686.6 LINC01535 5.13 8.82e-07 0.000661 0.52 0.38 Obesity-related traits; chr19:37012526 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs8104919 ENSG00000226686.6 LINC01535 5.13 8.82e-07 0.000661 0.52 0.38 Obesity-related traits; chr19:37012881 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs7256213 ENSG00000226686.6 LINC01535 5.13 8.82e-07 0.000661 0.52 0.38 Obesity-related traits; chr19:37020589 chr19:37251912~37265535:+ PAAD cis rs11673344 0.8 rs8108214 ENSG00000226686.6 LINC01535 -5.13 8.82e-07 0.000661 -0.52 -0.38 Obesity-related traits; chr19:37025184 chr19:37251912~37265535:+ PAAD cis rs7916697 0.588 rs10823165 ENSG00000233590.1 RP11-153K11.3 5.13 8.82e-07 0.000661 0.57 0.38 Optic disc area; chr10:68248269 chr10:68233251~68242379:- PAAD cis rs1185460 1 rs15818 ENSG00000271751.1 RP11-110I1.14 -5.13 8.82e-07 0.000662 -0.49 -0.38 Coronary artery disease; chr11:119081463 chr11:119065263~119065677:- PAAD cis rs875971 0.825 rs28480509 ENSG00000237310.1 GS1-124K5.4 -5.13 8.82e-07 0.000662 -0.39 -0.38 Aortic root size; chr7:66634237 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs9791712 ENSG00000237310.1 GS1-124K5.4 -5.13 8.82e-07 0.000662 -0.39 -0.38 Aortic root size; chr7:66640176 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs9791713 ENSG00000237310.1 GS1-124K5.4 -5.13 8.82e-07 0.000662 -0.39 -0.38 Aortic root size; chr7:66640211 chr7:66493706~66495474:+ PAAD cis rs17711722 0.51 rs11767457 ENSG00000237310.1 GS1-124K5.4 5.13 8.83e-07 0.000662 0.38 0.38 Calcium levels; chr7:65825628 chr7:66493706~66495474:+ PAAD cis rs2948294 0.588 rs12544596 ENSG00000173295.6 FAM86B3P 5.13 8.86e-07 0.000664 0.41 0.38 Red cell distribution width; chr8:8258824 chr8:8228595~8244865:+ PAAD cis rs6921919 0.583 rs16894060 ENSG00000216901.1 AL022393.7 5.13 8.86e-07 0.000664 0.52 0.38 Autism spectrum disorder or schizophrenia; chr6:28394694 chr6:28176188~28176674:+ PAAD cis rs7829975 0.514 rs2976926 ENSG00000253893.2 FAM85B -5.13 8.86e-07 0.000664 -0.52 -0.38 Mood instability; chr8:8404114 chr8:8167819~8226614:- PAAD cis rs16828019 0.632 rs12749196 ENSG00000235358.1 RP11-399E6.1 5.13 8.87e-07 0.000665 0.86 0.38 Intelligence (multi-trait analysis); chr1:40995111 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs12047657 ENSG00000235358.1 RP11-399E6.1 5.13 8.87e-07 0.000665 0.86 0.38 Intelligence (multi-trait analysis); chr1:40995841 chr1:41242373~41284861:+ PAAD cis rs16828019 0.85 rs12027691 ENSG00000235358.1 RP11-399E6.1 5.13 8.87e-07 0.000665 0.86 0.38 Intelligence (multi-trait analysis); chr1:40996360 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs12047078 ENSG00000235358.1 RP11-399E6.1 5.13 8.87e-07 0.000665 0.86 0.38 Intelligence (multi-trait analysis); chr1:40997314 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs12739052 ENSG00000235358.1 RP11-399E6.1 5.13 8.87e-07 0.000665 0.86 0.38 Intelligence (multi-trait analysis); chr1:40998783 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs12748235 ENSG00000235358.1 RP11-399E6.1 5.13 8.87e-07 0.000665 0.86 0.38 Intelligence (multi-trait analysis); chr1:41000549 chr1:41242373~41284861:+ PAAD cis rs4879677 0.959 rs2150021 ENSG00000260390.1 RP11-575I8.1 5.13 8.87e-07 0.000665 0.49 0.38 Gut microbiome composition (summer and winter); chr9:27688292 chr9:27829276~27844481:+ PAAD cis rs9926296 0.682 rs645019 ENSG00000260259.1 RP11-368I7.4 5.13 8.89e-07 0.000666 0.48 0.38 Vitiligo; chr16:89650475 chr16:89682620~89686569:- PAAD cis rs763567 0.967 rs736791 ENSG00000271811.1 RP1-79C4.4 -5.13 8.9e-07 0.000667 -0.37 -0.38 Tonsillectomy; chr1:170617174 chr1:170667381~170669425:+ PAAD cis rs62103177 0.608 rs4799115 ENSG00000261126.6 RP11-795F19.1 -5.13 8.91e-07 0.000668 -0.57 -0.38 Opioid sensitivity; chr18:79976365 chr18:80046900~80095482:+ PAAD cis rs10463554 0.927 rs62362489 ENSG00000175749.11 EIF3KP1 5.12 8.92e-07 0.000668 0.49 0.38 Parkinson's disease; chr5:102909841 chr5:103032376~103033031:+ PAAD cis rs10463554 0.927 rs6862616 ENSG00000175749.11 EIF3KP1 5.12 8.92e-07 0.000668 0.49 0.38 Parkinson's disease; chr5:102910334 chr5:103032376~103033031:+ PAAD cis rs73186030 0.546 rs67818421 ENSG00000272758.4 RP11-299J3.8 5.12 8.96e-07 0.000671 0.51 0.38 Serum parathyroid hormone levels; chr3:122389871 chr3:122416207~122443180:+ PAAD cis rs73186030 0.546 rs9857972 ENSG00000272758.4 RP11-299J3.8 5.12 8.96e-07 0.000671 0.51 0.38 Serum parathyroid hormone levels; chr3:122390602 chr3:122416207~122443180:+ PAAD cis rs950169 0.614 rs12911536 ENSG00000259728.4 LINC00933 5.12 8.97e-07 0.000672 0.5 0.38 Schizophrenia; chr15:84004278 chr15:84570649~84580175:+ PAAD cis rs34375054 0.735 rs34961756 ENSG00000279233.1 RP11-158L12.4 5.12 8.98e-07 0.000672 0.34 0.38 Post bronchodilator FEV1/FVC ratio; chr12:125144052 chr12:125138245~125141711:+ PAAD cis rs7829975 0.902 rs485107 ENSG00000253893.2 FAM85B 5.12 9.01e-07 0.000674 0.57 0.38 Mood instability; chr8:8723898 chr8:8167819~8226614:- PAAD cis rs12468226 0.873 rs76552560 ENSG00000273456.1 RP11-686O6.2 5.12 9.02e-07 0.000675 0.58 0.38 Urate levels; chr2:202173123 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs12463937 ENSG00000273456.1 RP11-686O6.2 5.12 9.02e-07 0.000675 0.58 0.38 Urate levels; chr2:202246543 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs16839077 ENSG00000273456.1 RP11-686O6.2 5.12 9.02e-07 0.000675 0.58 0.38 Urate levels; chr2:202343970 chr2:202374932~202375604:- PAAD cis rs1928295 0.967 rs1252008 ENSG00000233569.1 RP11-500B12.1 5.12 9.02e-07 0.000675 0.43 0.38 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117600560 chr9:117648606~117657027:+ PAAD cis rs1928295 1 rs9408901 ENSG00000233569.1 RP11-500B12.1 5.12 9.02e-07 0.000675 0.43 0.38 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117602573 chr9:117648606~117657027:+ PAAD cis rs1928295 0.967 rs4443733 ENSG00000233569.1 RP11-500B12.1 5.12 9.02e-07 0.000675 0.43 0.38 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117626774 chr9:117648606~117657027:+ PAAD cis rs11295209 1 rs11295209 ENSG00000248280.1 RP11-33B1.2 -5.12 9.03e-07 0.000676 -0.35 -0.38 Plateletcrit; chr4:119559079 chr4:119440561~119450157:- PAAD cis rs9481169 0.557 rs2179070 ENSG00000255389.1 C6orf3 -5.12 9.04e-07 0.000676 -0.75 -0.38 Inflammatory skin disease; chr6:111564549 chr6:111599875~111602295:+ PAAD cis rs9481169 0.557 rs34896684 ENSG00000255389.1 C6orf3 -5.12 9.04e-07 0.000676 -0.75 -0.38 Inflammatory skin disease; chr6:111572034 chr6:111599875~111602295:+ PAAD cis rs9481169 0.557 rs13194006 ENSG00000255389.1 C6orf3 -5.12 9.04e-07 0.000676 -0.75 -0.38 Inflammatory skin disease; chr6:111575051 chr6:111599875~111602295:+ PAAD cis rs2072438 0.503 rs2146838 ENSG00000226752.6 PSMD5-AS1 5.12 9.06e-07 0.000678 0.43 0.38 Rheumatoid arthritis; chr9:121114027 chr9:120824828~120854385:+ PAAD cis rs748404 0.578 rs2244746 ENSG00000249839.1 AC011330.5 -5.12 9.07e-07 0.000678 -0.54 -0.38 Lung cancer; chr15:43402885 chr15:43663654~43684339:- PAAD cis rs62229266 0.804 rs62230822 ENSG00000231106.2 LINC01436 5.12 9.07e-07 0.000678 0.56 0.38 Mitral valve prolapse; chr21:36057647 chr21:36005338~36007838:+ PAAD cis rs6921919 0.583 rs7764722 ENSG00000204709.4 LINC01556 5.12 9.09e-07 0.000679 0.54 0.38 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28943877~28944537:+ PAAD cis rs2348418 0.715 rs1581076 ENSG00000247934.4 RP11-967K21.1 5.12 9.09e-07 0.000679 0.38 0.38 Lung function (FEV1);Lung function (FVC); chr12:28570724 chr12:28163298~28190738:- PAAD cis rs950169 0.65 rs12902052 ENSG00000259295.5 CSPG4P12 5.12 9.09e-07 0.00068 0.42 0.38 Schizophrenia; chr15:84582607 chr15:85191438~85213905:+ PAAD cis rs1823913 0.562 rs17347499 ENSG00000280083.1 RP11-317J9.1 -5.12 9.09e-07 0.00068 -0.47 -0.38 Obesity-related traits; chr2:191301116 chr2:191154118~191156070:- PAAD cis rs732716 0.785 rs7769 ENSG00000267769.1 CTB-50L17.9 -5.12 9.1e-07 0.00068 -0.55 -0.38 Mean corpuscular volume; chr19:4360546 chr19:4454014~4455286:+ PAAD cis rs7580658 0.637 rs12463909 ENSG00000236682.1 AC068282.3 5.12 9.11e-07 0.000681 0.49 0.38 Protein C levels; chr2:127214162 chr2:127389130~127400580:+ PAAD cis rs919433 0.963 rs1896857 ENSG00000231621.1 AC013264.2 5.12 9.13e-07 0.000682 0.37 0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197299806 chr2:197197991~197199273:+ PAAD cis rs7208859 0.615 rs216462 ENSG00000266490.1 CTD-2349P21.9 -5.12 9.13e-07 0.000683 -0.47 -0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30568879 chr17:30792372~30792833:+ PAAD cis rs1061377 0.585 rs3733271 ENSG00000249207.1 RP11-360F5.1 -5.12 9.13e-07 0.000683 -0.4 -0.38 Uric acid levels; chr4:39047948 chr4:39112677~39126818:- PAAD cis rs1061377 0.621 rs11096974 ENSG00000249207.1 RP11-360F5.1 -5.12 9.13e-07 0.000683 -0.4 -0.38 Uric acid levels; chr4:39062039 chr4:39112677~39126818:- PAAD cis rs964611 0.882 rs10851463 ENSG00000259488.2 RP11-154J22.1 5.12 9.14e-07 0.000683 0.42 0.38 Metabolite levels (Pyroglutamine); chr15:48283229 chr15:48312353~48331856:- PAAD cis rs748404 0.587 rs9920879 ENSG00000249839.1 AC011330.5 -5.12 9.15e-07 0.000683 -0.54 -0.38 Lung cancer; chr15:43347572 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs7166812 ENSG00000249839.1 AC011330.5 -5.12 9.15e-07 0.000683 -0.54 -0.38 Lung cancer; chr15:43352562 chr15:43663654~43684339:- PAAD cis rs1075265 0.749 rs2357693 ENSG00000233266.1 HMGB1P31 5.12 9.16e-07 0.000684 0.48 0.38 Chronotype;Morning vs. evening chronotype; chr2:53735699 chr2:54051334~54051760:+ PAAD cis rs1061377 0.585 rs12648581 ENSG00000249207.1 RP11-360F5.1 -5.12 9.16e-07 0.000684 -0.4 -0.38 Uric acid levels; chr4:39054024 chr4:39112677~39126818:- PAAD cis rs964611 0.882 rs12594698 ENSG00000259488.2 RP11-154J22.1 -5.12 9.18e-07 0.000686 -0.39 -0.38 Metabolite levels (Pyroglutamine); chr15:48282759 chr15:48312353~48331856:- PAAD cis rs7772486 0.754 rs9386133 ENSG00000235652.6 RP11-545I5.3 5.12 9.18e-07 0.000686 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145820077 chr6:145799409~145886585:+ PAAD cis rs9322193 0.884 rs9397036 ENSG00000223701.3 RAET1E-AS1 5.12 9.2e-07 0.000687 0.46 0.38 Lung cancer; chr6:149851787 chr6:149884431~149919508:+ PAAD cis rs9322193 0.884 rs9383864 ENSG00000223701.3 RAET1E-AS1 5.12 9.2e-07 0.000687 0.46 0.38 Lung cancer; chr6:149851969 chr6:149884431~149919508:+ PAAD cis rs9322193 0.884 rs9383865 ENSG00000223701.3 RAET1E-AS1 5.12 9.2e-07 0.000687 0.46 0.38 Lung cancer; chr6:149852043 chr6:149884431~149919508:+ PAAD cis rs7188445 0.966 rs79193369 ENSG00000261390.4 RP11-345M22.2 -5.12 9.22e-07 0.000689 -0.54 -0.38 Urate levels; chr16:79691119 chr16:79715232~79770563:- PAAD cis rs2274273 0.662 rs4525413 ENSG00000258413.1 RP11-665C16.6 -5.12 9.22e-07 0.000689 -0.52 -0.38 Protein biomarker; chr14:55194420 chr14:55262767~55272075:- PAAD cis rs5760092 0.572 rs738806 ENSG00000225282.1 AP000350.6 5.12 9.23e-07 0.000689 0.53 0.38 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23926900~23929574:+ PAAD cis rs7945705 0.875 rs11042059 ENSG00000254860.4 TMEM9B-AS1 -5.12 9.23e-07 0.000689 -0.42 -0.38 Hemoglobin concentration; chr11:8773533 chr11:8964675~8977527:+ PAAD cis rs2274273 0.624 rs7152390 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55344983 chr14:55262767~55272075:- PAAD cis rs2274273 0.588 rs9919923 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55347181 chr14:55262767~55272075:- PAAD cis rs2274273 0.588 rs9919932 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55347362 chr14:55262767~55272075:- PAAD cis rs2274273 0.588 rs7154831 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55357247 chr14:55262767~55272075:- PAAD cis rs2274273 0.588 rs58296156 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55361609 chr14:55262767~55272075:- PAAD cis rs2274273 0.588 rs7158791 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55361889 chr14:55262767~55272075:- PAAD cis rs2274273 0.588 rs11158037 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55365434 chr14:55262767~55272075:- PAAD cis rs2274273 0.564 rs3783649 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55367692 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs3783651 ENSG00000258413.1 RP11-665C16.6 -5.12 9.23e-07 0.000689 -0.51 -0.38 Protein biomarker; chr14:55384255 chr14:55262767~55272075:- PAAD cis rs9326248 0.581 rs7106437 ENSG00000280143.1 AP000892.6 5.12 9.23e-07 0.000689 0.42 0.38 Blood protein levels; chr11:117121360 chr11:117204967~117210292:+ PAAD cis rs1075265 0.901 rs1058320 ENSG00000233266.1 HMGB1P31 5.12 9.23e-07 0.000689 0.5 0.38 Chronotype;Morning vs. evening chronotype; chr2:54085016 chr2:54051334~54051760:+ PAAD cis rs1075265 0.933 rs7560947 ENSG00000233266.1 HMGB1P31 5.12 9.23e-07 0.000689 0.5 0.38 Chronotype;Morning vs. evening chronotype; chr2:54087473 chr2:54051334~54051760:+ PAAD cis rs34375054 0.553 rs12580221 ENSG00000279233.1 RP11-158L12.4 5.12 9.24e-07 0.00069 0.33 0.38 Post bronchodilator FEV1/FVC ratio; chr12:125136520 chr12:125138245~125141711:+ PAAD cis rs6570726 0.846 rs453834 ENSG00000235652.6 RP11-545I5.3 5.12 9.24e-07 0.00069 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145565125 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs409553 ENSG00000235652.6 RP11-545I5.3 5.12 9.24e-07 0.00069 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145565827 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs371186 ENSG00000235652.6 RP11-545I5.3 5.12 9.24e-07 0.00069 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145565835 chr6:145799409~145886585:+ PAAD cis rs10875746 0.669 rs10431526 ENSG00000240399.1 RP1-228P16.1 -5.12 9.25e-07 0.00069 -0.43 -0.38 Longevity (90 years and older); chr12:48296360 chr12:48054813~48055591:- PAAD cis rs3858145 0.505 rs12765827 ENSG00000233590.1 RP11-153K11.3 5.12 9.26e-07 0.000691 0.56 0.38 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68286821 chr10:68233251~68242379:- PAAD cis rs11673344 0.667 rs504549 ENSG00000226686.6 LINC01535 5.12 9.27e-07 0.000691 0.53 0.38 Obesity-related traits; chr19:36946299 chr19:37251912~37265535:+ PAAD cis rs9322193 0.847 rs4870054 ENSG00000223701.3 RAET1E-AS1 5.12 9.27e-07 0.000691 0.45 0.38 Lung cancer; chr6:149848402 chr6:149884431~149919508:+ PAAD cis rs10985070 0.504 rs2296077 ENSG00000226752.6 PSMD5-AS1 -5.12 9.27e-07 0.000692 -0.43 -0.38 Rheumatoid arthritis; chr9:121182665 chr9:120824828~120854385:+ PAAD cis rs11079159 0.837 rs4794559 ENSG00000263096.1 RP11-515O17.2 5.12 9.28e-07 0.000692 0.52 0.38 QRS duration; chr17:55286939 chr17:55271504~55273653:- PAAD cis rs858239 1 rs199357 ENSG00000226816.2 AC005082.12 -5.12 9.29e-07 0.000693 -0.44 -0.38 Cerebrospinal fluid biomarker levels; chr7:23248690 chr7:23206013~23208045:+ PAAD cis rs3931020 0.688 rs452242 ENSG00000272864.1 RP11-17E13.2 5.12 9.3e-07 0.000694 0.54 0.38 Resistin levels; chr1:74759941 chr1:74698769~74699333:- PAAD cis rs3931020 0.657 rs277368 ENSG00000272864.1 RP11-17E13.2 5.11 9.33e-07 0.000695 0.54 0.38 Resistin levels; chr1:74764922 chr1:74698769~74699333:- PAAD cis rs3931020 0.657 rs277369 ENSG00000272864.1 RP11-17E13.2 5.11 9.33e-07 0.000695 0.54 0.38 Resistin levels; chr1:74768977 chr1:74698769~74699333:- PAAD cis rs17711722 0.522 rs62469933 ENSG00000226824.5 RP4-756H11.3 -5.11 9.33e-07 0.000696 -0.45 -0.38 Calcium levels; chr7:65800652 chr7:66654538~66669855:+ PAAD cis rs7829975 0.774 rs1039915 ENSG00000253893.2 FAM85B -5.11 9.34e-07 0.000696 -0.53 -0.38 Mood instability; chr8:8822104 chr8:8167819~8226614:- PAAD cis rs7829975 0.774 rs57312668 ENSG00000253893.2 FAM85B -5.11 9.34e-07 0.000696 -0.53 -0.38 Mood instability; chr8:8822967 chr8:8167819~8226614:- PAAD cis rs7829975 0.744 rs2409092 ENSG00000253893.2 FAM85B -5.11 9.34e-07 0.000696 -0.53 -0.38 Mood instability; chr8:8824682 chr8:8167819~8226614:- PAAD cis rs11089937 0.524 rs2877021 ENSG00000211639.2 IGLV4-60 5.11 9.35e-07 0.000697 0.41 0.38 Periodontitis (PAL4Q3); chr22:22165909 chr22:22162199~22162681:+ PAAD cis rs7772486 0.686 rs1415744 ENSG00000235652.6 RP11-545I5.3 5.11 9.35e-07 0.000697 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145701395 chr6:145799409~145886585:+ PAAD cis rs7772486 0.624 rs9485018 ENSG00000235652.6 RP11-545I5.3 -5.11 9.35e-07 0.000697 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145704595 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs2092263 ENSG00000235652.6 RP11-545I5.3 -5.11 9.35e-07 0.000697 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145708551 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9403741 ENSG00000235652.6 RP11-545I5.3 -5.11 9.35e-07 0.000697 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145709412 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs1004752 ENSG00000235652.6 RP11-545I5.3 -5.11 9.35e-07 0.000697 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145716686 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9390347 ENSG00000235652.6 RP11-545I5.3 -5.11 9.35e-07 0.000697 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145723611 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9390348 ENSG00000235652.6 RP11-545I5.3 -5.11 9.35e-07 0.000697 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145723612 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9485019 ENSG00000235652.6 RP11-545I5.3 -5.11 9.35e-07 0.000697 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145725245 chr6:145799409~145886585:+ PAAD cis rs7772486 0.632 rs9386128 ENSG00000235652.6 RP11-545I5.3 -5.11 9.35e-07 0.000697 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145727917 chr6:145799409~145886585:+ PAAD cis rs9828933 0.938 rs9809432 ENSG00000280620.1 SCAANT1 5.11 9.37e-07 0.000698 0.63 0.38 Type 2 diabetes; chr3:64017277 chr3:63911518~63911772:- PAAD cis rs2274273 0.624 rs72717738 ENSG00000258413.1 RP11-665C16.6 -5.11 9.37e-07 0.000699 -0.51 -0.38 Protein biomarker; chr14:55376043 chr14:55262767~55272075:- PAAD cis rs10510102 0.872 rs116521083 ENSG00000276742.1 RP11-500G22.4 5.11 9.38e-07 0.000699 0.56 0.38 Breast cancer; chr10:121950611 chr10:121956782~121957098:+ PAAD cis rs10510102 0.81 rs34738294 ENSG00000276742.1 RP11-500G22.4 5.11 9.38e-07 0.000699 0.56 0.38 Breast cancer; chr10:121951357 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12258234 ENSG00000276742.1 RP11-500G22.4 5.11 9.38e-07 0.000699 0.56 0.38 Breast cancer; chr10:121952828 chr10:121956782~121957098:+ PAAD cis rs10510102 0.515 rs11200285 ENSG00000276742.1 RP11-500G22.4 5.11 9.38e-07 0.000699 0.56 0.38 Breast cancer; chr10:121953931 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs75831447 ENSG00000276742.1 RP11-500G22.4 5.11 9.38e-07 0.000699 0.56 0.38 Breast cancer; chr10:121953963 chr10:121956782~121957098:+ PAAD cis rs10510102 0.63 rs79960726 ENSG00000276742.1 RP11-500G22.4 5.11 9.38e-07 0.000699 0.56 0.38 Breast cancer; chr10:121954358 chr10:121956782~121957098:+ PAAD cis rs3931020 0.688 rs405445 ENSG00000272864.1 RP11-17E13.2 5.11 9.41e-07 0.000701 0.53 0.38 Resistin levels; chr1:74755466 chr1:74698769~74699333:- PAAD cis rs3931020 0.688 rs277375 ENSG00000272864.1 RP11-17E13.2 -5.11 9.41e-07 0.000701 -0.53 -0.38 Resistin levels; chr1:74738459 chr1:74698769~74699333:- PAAD cis rs3858145 0.5 rs4633337 ENSG00000233590.1 RP11-153K11.3 5.11 9.42e-07 0.000701 0.56 0.38 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68285970 chr10:68233251~68242379:- PAAD cis rs34375054 0.553 rs12581512 ENSG00000279233.1 RP11-158L12.4 5.11 9.44e-07 0.000703 0.34 0.38 Post bronchodilator FEV1/FVC ratio; chr12:125137716 chr12:125138245~125141711:+ PAAD cis rs494459 0.838 rs632124 ENSG00000255422.1 AP002954.4 -5.11 9.44e-07 0.000703 -0.42 -0.38 Height; chr11:118742526 chr11:118704607~118750263:+ PAAD cis rs1075265 0.749 rs805379 ENSG00000233266.1 HMGB1P31 5.11 9.45e-07 0.000703 0.49 0.38 Chronotype;Morning vs. evening chronotype; chr2:53865847 chr2:54051334~54051760:+ PAAD cis rs11673344 0.931 rs73622783 ENSG00000226686.6 LINC01535 5.11 9.47e-07 0.000705 0.5 0.38 Obesity-related traits; chr19:37165155 chr19:37251912~37265535:+ PAAD cis rs4927850 0.958 rs2044599 ENSG00000231464.1 AC024937.4 5.11 9.48e-07 0.000706 0.45 0.38 Pancreatic cancer; chr3:196009869 chr3:195996738~195998233:+ PAAD cis rs3931020 0.688 rs968358 ENSG00000272864.1 RP11-17E13.2 -5.11 9.51e-07 0.000707 -0.53 -0.38 Resistin levels; chr1:74728305 chr1:74698769~74699333:- PAAD cis rs6921919 0.525 rs11760133 ENSG00000216901.1 AL022393.7 5.11 9.52e-07 0.000708 0.5 0.38 Autism spectrum disorder or schizophrenia; chr6:28418962 chr6:28176188~28176674:+ PAAD cis rs6504622 0.935 rs62075889 ENSG00000262879.4 RP11-156P1.3 -5.11 9.52e-07 0.000708 -0.39 -0.38 Orofacial clefts; chr17:46950671 chr17:46984045~47100323:- PAAD cis rs6504622 1 rs12940071 ENSG00000262879.4 RP11-156P1.3 -5.11 9.52e-07 0.000708 -0.39 -0.38 Orofacial clefts; chr17:46950686 chr17:46984045~47100323:- PAAD cis rs6504622 0.935 rs17608961 ENSG00000262879.4 RP11-156P1.3 -5.11 9.52e-07 0.000708 -0.39 -0.38 Orofacial clefts; chr17:46952302 chr17:46984045~47100323:- PAAD cis rs13178541 0.745 rs6596262 ENSG00000250378.1 RP11-119J18.1 -5.11 9.52e-07 0.000708 -0.57 -0.38 IgG glycosylation; chr5:135723983 chr5:135812667~135826582:+ PAAD cis rs4853525 0.59 rs2355570 ENSG00000235852.1 AC005540.3 5.11 9.53e-07 0.000709 0.56 0.38 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190916443 chr2:190880797~190882059:- PAAD cis rs732716 0.853 rs1127888 ENSG00000267769.1 CTB-50L17.9 -5.11 9.56e-07 0.00071 -0.54 -0.38 Mean corpuscular volume; chr19:4454086 chr19:4454014~4455286:+ PAAD cis rs732716 0.853 rs72990643 ENSG00000267769.1 CTB-50L17.9 -5.11 9.56e-07 0.00071 -0.54 -0.38 Mean corpuscular volume; chr19:4454739 chr19:4454014~4455286:+ PAAD cis rs732716 0.853 rs12459922 ENSG00000267769.1 CTB-50L17.9 -5.11 9.56e-07 0.00071 -0.54 -0.38 Mean corpuscular volume; chr19:4455865 chr19:4454014~4455286:+ PAAD cis rs9399135 0.507 rs7766963 ENSG00000232876.1 CTA-212D2.2 5.11 9.57e-07 0.00071 0.44 0.38 Red blood cell count; chr6:135111745 chr6:135055033~135060550:+ PAAD cis rs1075265 1 rs1075265 ENSG00000233266.1 HMGB1P31 5.11 9.58e-07 0.00071 0.51 0.38 Chronotype;Morning vs. evening chronotype; chr2:54127790 chr2:54051334~54051760:+ PAAD cis rs2115630 0.967 rs11073731 ENSG00000259728.4 LINC00933 -5.11 9.58e-07 0.00071 -0.47 -0.38 P wave terminal force; chr15:84811882 chr15:84570649~84580175:+ PAAD cis rs2115630 1 rs8037423 ENSG00000259728.4 LINC00933 -5.11 9.58e-07 0.00071 -0.47 -0.38 P wave terminal force; chr15:84812263 chr15:84570649~84580175:+ PAAD cis rs763567 1 rs12760630 ENSG00000271811.1 RP1-79C4.4 -5.11 9.6e-07 0.000711 -0.37 -0.38 Tonsillectomy; chr1:170600548 chr1:170667381~170669425:+ PAAD cis rs734999 0.611 rs10797431 ENSG00000225931.3 RP3-395M20.7 5.11 9.62e-07 0.000712 0.36 0.38 Ulcerative colitis; chr1:2569783 chr1:2566410~2569888:+ PAAD cis rs7208859 0.562 rs216408 ENSG00000266490.1 CTD-2349P21.9 -5.11 9.62e-07 0.000712 -0.44 -0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30580739 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs216440 ENSG00000266490.1 CTD-2349P21.9 5.11 9.62e-07 0.000712 0.44 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30601291 chr17:30792372~30792833:+ PAAD cis rs17826219 0.561 rs562840 ENSG00000266490.1 CTD-2349P21.9 5.11 9.62e-07 0.000712 0.44 0.38 Body mass index; chr17:30622372 chr17:30792372~30792833:+ PAAD cis rs526231 0.578 rs17154825 ENSG00000175749.11 EIF3KP1 5.11 9.64e-07 0.000713 0.5 0.38 Primary biliary cholangitis; chr5:102910365 chr5:103032376~103033031:+ PAAD cis rs526231 0.578 rs35100629 ENSG00000175749.11 EIF3KP1 5.11 9.64e-07 0.000713 0.5 0.38 Primary biliary cholangitis; chr5:102910381 chr5:103032376~103033031:+ PAAD cis rs526231 0.578 rs10463553 ENSG00000175749.11 EIF3KP1 5.11 9.64e-07 0.000713 0.5 0.38 Primary biliary cholangitis; chr5:102913503 chr5:103032376~103033031:+ PAAD cis rs494459 0.838 rs607125 ENSG00000255422.1 AP002954.4 -5.11 9.64e-07 0.000713 -0.42 -0.38 Height; chr11:118746590 chr11:118704607~118750263:+ PAAD cis rs875971 0.862 rs1860469 ENSG00000237310.1 GS1-124K5.4 -5.11 9.7e-07 0.000717 -0.39 -0.38 Aortic root size; chr7:66641888 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs4718383 ENSG00000237310.1 GS1-124K5.4 -5.11 9.7e-07 0.000717 -0.39 -0.38 Aortic root size; chr7:66643422 chr7:66493706~66495474:+ PAAD cis rs9322193 0.923 rs9371207 ENSG00000223701.3 RAET1E-AS1 5.11 9.71e-07 0.000718 0.46 0.38 Lung cancer; chr6:149858087 chr6:149884431~149919508:+ PAAD cis rs12468226 0.873 rs60722019 ENSG00000273456.1 RP11-686O6.2 5.11 9.72e-07 0.000718 0.58 0.38 Urate levels; chr2:202282060 chr2:202374932~202375604:- PAAD cis rs17023223 0.537 rs4590715 ENSG00000231365.4 RP11-418J17.1 -5.11 9.74e-07 0.00072 -0.42 -0.38 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119207578 chr1:119140396~119275973:+ PAAD cis rs2274273 0.624 rs7151581 ENSG00000258413.1 RP11-665C16.6 5.11 9.74e-07 0.00072 0.5 0.38 Protein biomarker; chr14:55321727 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs11158034 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55286842 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs11848456 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55288674 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs11848575 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55289070 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs67386901 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55290646 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs7140628 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55293963 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs68138420 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55311249 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs4580079 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55313648 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs7157308 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55315325 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs66551709 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55324304 chr14:55262767~55272075:- PAAD cis rs2274273 0.6 rs10134317 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55326730 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs67795323 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55331115 chr14:55262767~55272075:- PAAD cis rs2274273 0.624 rs8005450 ENSG00000258413.1 RP11-665C16.6 -5.11 9.74e-07 0.00072 -0.5 -0.38 Protein biomarker; chr14:55332447 chr14:55262767~55272075:- PAAD cis rs4218 0.597 rs12438111 ENSG00000277144.1 RP11-59H7.4 -5.11 9.75e-07 0.00072 -0.51 -0.38 Social communication problems; chr15:59057540 chr15:59115547~59116089:- PAAD cis rs7829975 0.742 rs12547493 ENSG00000253893.2 FAM85B 5.1 9.78e-07 0.000722 0.54 0.38 Mood instability; chr8:8804024 chr8:8167819~8226614:- PAAD cis rs7665090 0.728 rs228630 ENSG00000246560.2 RP11-10L12.4 -5.1 9.79e-07 0.000723 -0.43 -0.38 Primary biliary cholangitis; chr4:102652592 chr4:102828055~102844075:+ PAAD cis rs7665090 0.728 rs179195 ENSG00000246560.2 RP11-10L12.4 -5.1 9.79e-07 0.000723 -0.43 -0.38 Primary biliary cholangitis; chr4:102653910 chr4:102828055~102844075:+ PAAD cis rs4660456 1 rs4660456 ENSG00000237899.1 RP4-739H11.3 -5.1 9.79e-07 0.000723 -0.51 -0.38 Platelet count; chr1:40773839 chr1:40669089~40687588:- PAAD cis rs10463554 0.853 rs257309 ENSG00000175749.11 EIF3KP1 5.1 9.8e-07 0.000724 0.49 0.38 Parkinson's disease; chr5:103082900 chr5:103032376~103033031:+ PAAD cis rs4664293 0.967 rs2357526 ENSG00000226266.5 AC009961.3 5.1 9.83e-07 0.000725 0.47 0.38 Monocyte percentage of white cells; chr2:159668085 chr2:159670708~159712435:- PAAD cis rs7772486 0.79 rs7742333 ENSG00000235652.6 RP11-545I5.3 -5.1 9.83e-07 0.000725 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145837893 chr6:145799409~145886585:+ PAAD cis rs4660456 0.826 rs3767952 ENSG00000237899.1 RP4-739H11.3 -5.1 9.84e-07 0.000726 -0.53 -0.38 Platelet count; chr1:40765360 chr1:40669089~40687588:- PAAD cis rs2948294 0.588 rs7011221 ENSG00000173295.6 FAM86B3P 5.1 9.85e-07 0.000726 0.41 0.38 Red cell distribution width; chr8:8256724 chr8:8228595~8244865:+ PAAD cis rs2948294 0.545 rs11776397 ENSG00000173295.6 FAM86B3P 5.1 9.85e-07 0.000726 0.41 0.38 Red cell distribution width; chr8:8257639 chr8:8228595~8244865:+ PAAD cis rs62103177 0.565 rs473119 ENSG00000261126.6 RP11-795F19.1 -5.1 9.87e-07 0.000728 -0.53 -0.38 Opioid sensitivity; chr18:80091557 chr18:80046900~80095482:+ PAAD cis rs875971 0.502 rs1796227 ENSG00000226824.5 RP4-756H11.3 5.1 9.88e-07 0.000729 0.54 0.38 Aortic root size; chr7:66622032 chr7:66654538~66669855:+ PAAD cis rs7772486 0.743 rs9403742 ENSG00000235652.6 RP11-545I5.3 5.1 9.89e-07 0.000729 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145739057 chr6:145799409~145886585:+ PAAD cis rs2274273 0.624 rs8014477 ENSG00000258413.1 RP11-665C16.6 5.1 9.89e-07 0.000729 0.52 0.38 Protein biomarker; chr14:55374759 chr14:55262767~55272075:- PAAD cis rs35160687 0.644 rs10204589 ENSG00000273080.1 RP11-301O19.1 5.1 9.9e-07 0.00073 0.45 0.38 Night sleep phenotypes; chr2:86266100 chr2:86195590~86196049:+ PAAD cis rs6504950 0.85 rs2541242 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55012326 chr17:54964474~54964679:+ PAAD cis rs6504950 0.889 rs2541245 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55023839 chr17:54964474~54964679:+ PAAD cis rs6504950 0.889 rs2787505 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55030071 chr17:54964474~54964679:+ PAAD cis rs6504950 0.85 rs2628309 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55038058 chr17:54964474~54964679:+ PAAD cis rs6504950 0.85 rs2787507 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55050563 chr17:54964474~54964679:+ PAAD cis rs6504950 0.813 rs9889687 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55055050 chr17:54964474~54964679:+ PAAD cis rs6504950 0.85 rs17745534 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55060145 chr17:54964474~54964679:+ PAAD cis rs6504950 0.889 rs9303363 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55060613 chr17:54964474~54964679:+ PAAD cis rs6504950 0.889 rs2541237 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55086676 chr17:54964474~54964679:+ PAAD cis rs6504950 0.889 rs1484769 ENSG00000275710.1 RP11-257O5.4 -5.1 9.9e-07 0.00073 -0.51 -0.38 Breast cancer; chr17:55089290 chr17:54964474~54964679:+ PAAD cis rs62229266 0.804 rs2255858 ENSG00000231106.2 LINC01436 5.1 9.91e-07 0.000731 0.56 0.38 Mitral valve prolapse; chr21:36040454 chr21:36005338~36007838:+ PAAD cis rs62229266 0.804 rs12483151 ENSG00000231106.2 LINC01436 5.1 9.91e-07 0.000731 0.56 0.38 Mitral valve prolapse; chr21:36047280 chr21:36005338~36007838:+ PAAD cis rs62229266 0.804 rs880221 ENSG00000231106.2 LINC01436 5.1 9.91e-07 0.000731 0.56 0.38 Mitral valve prolapse; chr21:36048487 chr21:36005338~36007838:+ PAAD cis rs62229266 0.804 rs11088331 ENSG00000231106.2 LINC01436 5.1 9.91e-07 0.000731 0.56 0.38 Mitral valve prolapse; chr21:36049574 chr21:36005338~36007838:+ PAAD cis rs62229266 0.804 rs56279140 ENSG00000231106.2 LINC01436 5.1 9.91e-07 0.000731 0.56 0.38 Mitral valve prolapse; chr21:36052063 chr21:36005338~36007838:+ PAAD cis rs62229266 0.804 rs62230821 ENSG00000231106.2 LINC01436 5.1 9.91e-07 0.000731 0.56 0.38 Mitral valve prolapse; chr21:36052818 chr21:36005338~36007838:+ PAAD cis rs62229266 0.804 rs2835259 ENSG00000231106.2 LINC01436 5.1 9.91e-07 0.000731 0.56 0.38 Mitral valve prolapse; chr21:36053004 chr21:36005338~36007838:+ PAAD cis rs7772486 0.686 rs1292336 ENSG00000235652.6 RP11-545I5.3 -5.1 9.94e-07 0.000733 -0.32 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145646682 chr6:145799409~145886585:+ PAAD cis rs12439619 1 rs35152457 ENSG00000255769.6 GOLGA2P10 -5.1 9.96e-07 0.000734 -0.44 -0.38 Intelligence (multi-trait analysis); chr15:82254207 chr15:82472993~82513950:- PAAD cis rs2404602 0.735 rs2454450 ENSG00000259422.1 RP11-593F23.1 -5.1 9.97e-07 0.000734 -0.46 -0.38 Blood metabolite levels; chr15:76538895 chr15:76174891~76181486:- PAAD cis rs58873874 0.737 rs75326191 ENSG00000251405.2 CTB-109A12.1 5.1 9.97e-07 0.000734 0.79 0.38 Bipolar disorder (body mass index interaction); chr5:157445797 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs75022277 ENSG00000251405.2 CTB-109A12.1 5.1 9.97e-07 0.000734 0.79 0.38 Bipolar disorder (body mass index interaction); chr5:157454954 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs78565801 ENSG00000251405.2 CTB-109A12.1 5.1 9.97e-07 0.000734 0.79 0.38 Bipolar disorder (body mass index interaction); chr5:157459326 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs79951742 ENSG00000251405.2 CTB-109A12.1 5.1 9.97e-07 0.000734 0.79 0.38 Bipolar disorder (body mass index interaction); chr5:157459705 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs76634949 ENSG00000251405.2 CTB-109A12.1 5.1 9.97e-07 0.000734 0.79 0.38 Bipolar disorder (body mass index interaction); chr5:157463391 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs79339674 ENSG00000251405.2 CTB-109A12.1 5.1 9.97e-07 0.000734 0.79 0.38 Bipolar disorder (body mass index interaction); chr5:157464318 chr5:157362615~157460078:- PAAD cis rs2921073 0.51 rs2976945 ENSG00000253893.2 FAM85B -5.1 9.99e-07 0.000735 -0.54 -0.38 Parkinson's disease; chr8:8413361 chr8:8167819~8226614:- PAAD cis rs950169 0.544 rs12913702 ENSG00000259728.4 LINC00933 5.1 1e-06 0.000736 0.49 0.38 Schizophrenia; chr15:84609953 chr15:84570649~84580175:+ PAAD cis rs6504622 0.934 rs3760377 ENSG00000262879.4 RP11-156P1.3 -5.1 1e-06 0.000737 -0.39 -0.38 Orofacial clefts; chr17:46964713 chr17:46984045~47100323:- PAAD cis rs6504622 1 rs11079745 ENSG00000262879.4 RP11-156P1.3 -5.1 1e-06 0.000737 -0.39 -0.38 Orofacial clefts; chr17:46966781 chr17:46984045~47100323:- PAAD cis rs62103177 0.608 rs34383580 ENSG00000261126.6 RP11-795F19.1 -5.1 1.01e-06 0.000741 -0.52 -0.38 Opioid sensitivity; chr18:80074960 chr18:80046900~80095482:+ PAAD cis rs62103177 0.608 rs551643 ENSG00000261126.6 RP11-795F19.1 -5.1 1.01e-06 0.000741 -0.52 -0.38 Opioid sensitivity; chr18:80081068 chr18:80046900~80095482:+ PAAD cis rs62103177 0.608 rs613847 ENSG00000261126.6 RP11-795F19.1 -5.1 1.01e-06 0.000741 -0.52 -0.38 Opioid sensitivity; chr18:80087736 chr18:80046900~80095482:+ PAAD cis rs62103177 0.525 rs612913 ENSG00000261126.6 RP11-795F19.1 -5.1 1.01e-06 0.000741 -0.52 -0.38 Opioid sensitivity; chr18:80087974 chr18:80046900~80095482:+ PAAD cis rs1075265 0.935 rs6545384 ENSG00000233266.1 HMGB1P31 5.1 1.01e-06 0.000741 0.5 0.38 Chronotype;Morning vs. evening chronotype; chr2:54073927 chr2:54051334~54051760:+ PAAD cis rs1075265 0.791 rs1833498 ENSG00000233266.1 HMGB1P31 5.1 1.01e-06 0.000741 0.5 0.38 Chronotype;Morning vs. evening chronotype; chr2:54080801 chr2:54051334~54051760:+ PAAD cis rs964611 0.882 rs7179535 ENSG00000259488.2 RP11-154J22.1 -5.1 1.01e-06 0.000741 -0.41 -0.38 Metabolite levels (Pyroglutamine); chr15:48287507 chr15:48312353~48331856:- PAAD cis rs6921919 0.583 rs16894060 ENSG00000204709.4 LINC01556 5.1 1.01e-06 0.000741 0.56 0.38 Autism spectrum disorder or schizophrenia; chr6:28394694 chr6:28943877~28944537:+ PAAD cis rs2946504 0.705 rs1879487 ENSG00000251468.2 RP11-369K16.1 -5.1 1.01e-06 0.000742 -0.45 -0.38 Type 2 diabetes; chr8:12947413 chr8:12958387~12962200:+ PAAD cis rs11673344 0.864 rs11667146 ENSG00000226686.6 LINC01535 5.1 1.01e-06 0.000742 0.52 0.38 Obesity-related traits; chr19:37004493 chr19:37251912~37265535:+ PAAD cis rs4879677 1 rs10812638 ENSG00000260390.1 RP11-575I8.1 -5.1 1.01e-06 0.000743 -0.49 -0.38 Gut microbiome composition (summer and winter); chr9:27668808 chr9:27829276~27844481:+ PAAD cis rs10800713 0.607 rs6682828 ENSG00000260088.1 RP11-92G12.3 -5.1 1.01e-06 0.000744 -0.48 -0.38 Tandem gait; chr1:200537968 chr1:200669507~200694250:+ PAAD cis rs9322193 0.607 rs6557165 ENSG00000223701.3 RAET1E-AS1 -5.1 1.02e-06 0.000746 -0.47 -0.38 Lung cancer; chr6:149906883 chr6:149884431~149919508:+ PAAD cis rs6504622 1 rs6504622 ENSG00000262879.4 RP11-156P1.3 5.1 1.02e-06 0.000747 0.39 0.38 Orofacial clefts; chr17:46942365 chr17:46984045~47100323:- PAAD cis rs2404602 0.735 rs11635463 ENSG00000259422.1 RP11-593F23.1 -5.1 1.02e-06 0.000748 -0.47 -0.38 Blood metabolite levels; chr15:76470645 chr15:76174891~76181486:- PAAD cis rs2404602 0.709 rs11072597 ENSG00000259422.1 RP11-593F23.1 -5.1 1.02e-06 0.000748 -0.47 -0.38 Blood metabolite levels; chr15:76471173 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs11857327 ENSG00000259422.1 RP11-593F23.1 -5.1 1.02e-06 0.000748 -0.47 -0.38 Blood metabolite levels; chr15:76471922 chr15:76174891~76181486:- PAAD cis rs964611 0.882 rs60899194 ENSG00000259488.2 RP11-154J22.1 -5.1 1.02e-06 0.000748 -0.41 -0.38 Metabolite levels (Pyroglutamine); chr15:48290763 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs67904691 ENSG00000259488.2 RP11-154J22.1 -5.1 1.02e-06 0.000748 -0.41 -0.38 Metabolite levels (Pyroglutamine); chr15:48295386 chr15:48312353~48331856:- PAAD cis rs11098499 0.644 rs28787668 ENSG00000245958.5 RP11-33B1.1 -5.1 1.02e-06 0.000749 -0.31 -0.38 Corneal astigmatism; chr4:119633532 chr4:119454791~119552025:+ PAAD cis rs11098499 0.644 rs7676296 ENSG00000245958.5 RP11-33B1.1 -5.1 1.02e-06 0.000749 -0.31 -0.38 Corneal astigmatism; chr4:119634532 chr4:119454791~119552025:+ PAAD cis rs2072438 0.505 rs7034074 ENSG00000226752.6 PSMD5-AS1 -5.09 1.02e-06 0.00075 -0.43 -0.38 Rheumatoid arthritis; chr9:121160751 chr9:120824828~120854385:+ PAAD cis rs1075265 0.836 rs10208233 ENSG00000233266.1 HMGB1P31 5.09 1.02e-06 0.00075 0.5 0.38 Chronotype;Morning vs. evening chronotype; chr2:54066433 chr2:54051334~54051760:+ PAAD cis rs11673344 0.704 rs571340 ENSG00000226686.6 LINC01535 5.09 1.02e-06 0.000751 0.53 0.38 Obesity-related traits; chr19:36933981 chr19:37251912~37265535:+ PAAD cis rs4664293 0.546 rs12469866 ENSG00000226266.5 AC009961.3 5.09 1.02e-06 0.000751 0.5 0.38 Monocyte percentage of white cells; chr2:159766119 chr2:159670708~159712435:- PAAD cis rs210138 0.882 rs407710 ENSG00000197251.3 LINC00336 5.09 1.03e-06 0.000754 0.54 0.38 Testicular germ cell tumor; chr6:33586480 chr6:33586106~33593338:- PAAD cis rs2015599 0.563 rs11050168 ENSG00000257176.2 RP11-996F15.2 5.09 1.03e-06 0.000754 0.39 0.38 Platelet count;Mean platelet volume; chr12:29273760 chr12:29280418~29317848:- PAAD cis rs9928842 0.771 rs4888363 ENSG00000280152.1 RP11-331F4.5 5.09 1.03e-06 0.000756 0.47 0.38 Alcoholic chronic pancreatitis; chr16:75243446 chr16:75245994~75250077:- PAAD cis rs4835473 0.897 rs6835827 ENSG00000251600.4 RP11-673E1.1 5.09 1.03e-06 0.000758 0.42 0.38 Immature fraction of reticulocytes; chr4:143712803 chr4:143912331~143982454:+ PAAD cis rs2115630 0.905 rs1975277 ENSG00000259728.4 LINC00933 -5.09 1.03e-06 0.000759 -0.45 -0.38 P wave terminal force; chr15:84786327 chr15:84570649~84580175:+ PAAD cis rs12468226 0.935 rs75597391 ENSG00000273456.1 RP11-686O6.2 5.09 1.04e-06 0.000762 0.57 0.38 Urate levels; chr2:202398850 chr2:202374932~202375604:- PAAD cis rs2115630 1 rs10220733 ENSG00000259728.4 LINC00933 -5.09 1.04e-06 0.000762 -0.46 -0.38 P wave terminal force; chr15:84737633 chr15:84570649~84580175:+ PAAD cis rs2115630 1 rs1030863 ENSG00000259728.4 LINC00933 -5.09 1.04e-06 0.000762 -0.46 -0.38 P wave terminal force; chr15:84739404 chr15:84570649~84580175:+ PAAD cis rs950027 0.62 rs35861938 ENSG00000259433.2 CTD-2651B20.4 -5.09 1.04e-06 0.000762 -0.43 -0.38 Response to fenofibrate (adiponectin levels); chr15:45345145 chr15:45330209~45332634:- PAAD cis rs950027 0.596 rs2467865 ENSG00000259433.2 CTD-2651B20.4 -5.09 1.04e-06 0.000762 -0.43 -0.38 Response to fenofibrate (adiponectin levels); chr15:45346109 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs2461700 ENSG00000259433.2 CTD-2651B20.4 -5.09 1.04e-06 0.000762 -0.43 -0.38 Response to fenofibrate (adiponectin levels); chr15:45348429 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs2453533 ENSG00000259433.2 CTD-2651B20.4 -5.09 1.04e-06 0.000762 -0.43 -0.38 Response to fenofibrate (adiponectin levels); chr15:45349027 chr15:45330209~45332634:- PAAD cis rs2412819 0.571 rs17727853 ENSG00000249839.1 AC011330.5 -5.09 1.04e-06 0.000763 -0.64 -0.38 Lung cancer; chr15:43630299 chr15:43663654~43684339:- PAAD cis rs10985070 0.507 rs12551347 ENSG00000226752.6 PSMD5-AS1 -5.09 1.04e-06 0.000764 -0.44 -0.38 Rheumatoid arthritis; chr9:121174316 chr9:120824828~120854385:+ PAAD cis rs964184 0.564 rs3825041 ENSG00000254851.1 RP11-109L13.1 -5.09 1.04e-06 0.000764 -0.86 -0.38 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116760991 chr11:117135528~117138582:+ PAAD cis rs950027 0.62 rs872192 ENSG00000259433.2 CTD-2651B20.4 -5.09 1.04e-06 0.000765 -0.43 -0.38 Response to fenofibrate (adiponectin levels); chr15:45322304 chr15:45330209~45332634:- PAAD cis rs2243480 0.901 rs778730 ENSG00000226824.5 RP4-756H11.3 -5.09 1.04e-06 0.000765 -0.68 -0.38 Diabetic kidney disease; chr7:66358338 chr7:66654538~66669855:+ PAAD cis rs9326248 0.581 rs7120515 ENSG00000280143.1 AP000892.6 5.09 1.05e-06 0.000766 0.42 0.38 Blood protein levels; chr11:117121210 chr11:117204967~117210292:+ PAAD cis rs10754283 0.871 rs72712569 ENSG00000231613.1 RP5-943J3.1 -5.09 1.05e-06 0.000767 -0.41 -0.38 Amyotrophic lateral sclerosis (sporadic); chr1:89660098 chr1:89788914~89790492:+ PAAD cis rs6570726 0.791 rs398408 ENSG00000235652.6 RP11-545I5.3 5.09 1.05e-06 0.000767 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145479884 chr6:145799409~145886585:+ PAAD cis rs11673344 0.704 rs1726719 ENSG00000226686.6 LINC01535 5.09 1.05e-06 0.000768 0.53 0.38 Obesity-related traits; chr19:36927130 chr19:37251912~37265535:+ PAAD cis rs17711722 0.565 rs73372653 ENSG00000226824.5 RP4-756H11.3 -5.09 1.05e-06 0.000768 -0.45 -0.38 Calcium levels; chr7:65977808 chr7:66654538~66669855:+ PAAD cis rs7826238 0.601 rs2979206 ENSG00000253893.2 FAM85B -5.09 1.05e-06 0.000768 -0.5 -0.38 Systolic blood pressure; chr8:8488071 chr8:8167819~8226614:- PAAD cis rs6538678 0.895 rs4762637 ENSG00000258343.1 RP11-536G4.2 -5.09 1.05e-06 0.00077 -0.48 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95888877 chr12:95795345~95858839:- PAAD cis rs992157 0.764 rs62183964 ENSG00000261338.2 RP11-378A13.1 5.09 1.05e-06 0.000771 0.45 0.38 Colorectal cancer; chr2:218321869 chr2:218255319~218257366:+ PAAD cis rs11673344 0.711 rs112857724 ENSG00000226686.6 LINC01535 5.09 1.05e-06 0.000771 0.52 0.38 Obesity-related traits; chr19:37030176 chr19:37251912~37265535:+ PAAD cis rs11673344 0.832 rs76781063 ENSG00000226686.6 LINC01535 5.09 1.05e-06 0.000771 0.52 0.38 Obesity-related traits; chr19:37036040 chr19:37251912~37265535:+ PAAD cis rs11673344 0.618 rs4420645 ENSG00000226686.6 LINC01535 5.09 1.05e-06 0.000771 0.52 0.38 Obesity-related traits; chr19:37054086 chr19:37251912~37265535:+ PAAD cis rs11673344 0.832 rs2011475 ENSG00000226686.6 LINC01535 5.09 1.05e-06 0.000771 0.52 0.38 Obesity-related traits; chr19:37054712 chr19:37251912~37265535:+ PAAD cis rs13178541 0.745 rs9986164 ENSG00000250378.1 RP11-119J18.1 -5.09 1.05e-06 0.000772 -0.59 -0.38 IgG glycosylation; chr5:135827074 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs9986268 ENSG00000250378.1 RP11-119J18.1 -5.09 1.05e-06 0.000772 -0.59 -0.38 IgG glycosylation; chr5:135827124 chr5:135812667~135826582:+ PAAD cis rs308403 0.509 rs309376 ENSG00000224786.1 CETN4P 5.09 1.05e-06 0.000772 0.46 0.38 Blood protein levels; chr4:122759036 chr4:122730548~122732193:- PAAD cis rs7615952 0.866 rs6438949 ENSG00000171084.14 FAM86JP 5.09 1.06e-06 0.000773 0.5 0.38 Blood pressure (smoking interaction); chr3:125931221 chr3:125916620~125930024:+ PAAD cis rs13178541 0.81 rs9327731 ENSG00000250378.1 RP11-119J18.1 -5.09 1.06e-06 0.000773 -0.54 -0.38 IgG glycosylation; chr5:135861438 chr5:135812667~135826582:+ PAAD cis rs160451 0.966 rs160427 ENSG00000251136.7 RP11-37B2.1 5.09 1.06e-06 0.000774 0.35 0.38 Leprosy; chr8:89659156 chr8:89609409~89757727:- PAAD cis rs308403 0.509 rs309372 ENSG00000224786.1 CETN4P 5.09 1.06e-06 0.000775 0.46 0.38 Blood protein levels; chr4:122761484 chr4:122730548~122732193:- PAAD cis rs496547 1 rs496547 ENSG00000255239.1 AP002954.6 5.09 1.06e-06 0.000775 0.46 0.38 Hip minimal joint space width; chr11:118705754 chr11:118688039~118690600:- PAAD cis rs2115630 1 rs58581703 ENSG00000259728.4 LINC00933 -5.09 1.06e-06 0.000778 -0.47 -0.38 P wave terminal force; chr15:84733704 chr15:84570649~84580175:+ PAAD cis rs2115630 0.967 rs8028490 ENSG00000259728.4 LINC00933 -5.09 1.06e-06 0.000778 -0.47 -0.38 P wave terminal force; chr15:84734657 chr15:84570649~84580175:+ PAAD cis rs7580658 0.637 rs1566822 ENSG00000236682.1 AC068282.3 -5.09 1.06e-06 0.000778 -0.5 -0.38 Protein C levels; chr2:127229815 chr2:127389130~127400580:+ PAAD cis rs72843506 0.722 rs9908418 ENSG00000189423.10 USP32P3 5.09 1.07e-06 0.000779 0.56 0.38 Schizophrenia; chr17:20311252 chr17:20415547~20431008:+ PAAD cis rs2337406 1 rs2157618 ENSG00000274576.2 IGHV2-70 -5.08 1.07e-06 0.000781 -0.52 -0.38 Alzheimer's disease (late onset); chr14:106711313 chr14:106770577~106771020:- PAAD cis rs12468226 0.938 rs6435139 ENSG00000273456.1 RP11-686O6.2 -5.08 1.07e-06 0.000781 -0.57 -0.38 Urate levels; chr2:202255145 chr2:202374932~202375604:- PAAD cis rs1275468 1 rs1679381 ENSG00000257497.2 RP11-585P4.5 -5.08 1.07e-06 0.000781 -0.55 -0.38 Polycystic ovary syndrome; chr12:75552344 chr12:75483454~75489820:- PAAD cis rs7712401 0.541 rs6867714 ENSG00000263432.2 RN7SL689P 5.08 1.07e-06 0.000782 0.5 0.38 Mean platelet volume; chr5:123046364 chr5:123022487~123022783:- PAAD cis rs72772090 0.71 rs17478897 ENSG00000248734.2 CTD-2260A17.1 -5.08 1.07e-06 0.000782 -0.56 -0.38 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96726913 chr5:96784777~96785999:+ PAAD cis rs673078 0.607 rs2036489 ENSG00000275759.1 RP11-131L12.3 -5.08 1.07e-06 0.000783 -0.47 -0.38 Glucose homeostasis traits; chr12:118364643 chr12:118428281~118428870:+ PAAD cis rs2404602 0.569 rs283793 ENSG00000259422.1 RP11-593F23.1 5.08 1.07e-06 0.000783 0.48 0.38 Blood metabolite levels; chr15:76482411 chr15:76174891~76181486:- PAAD cis rs763567 0.935 rs2988392 ENSG00000271811.1 RP1-79C4.4 5.08 1.07e-06 0.000783 0.37 0.38 Tonsillectomy; chr1:170647214 chr1:170667381~170669425:+ PAAD cis rs72843506 0.722 rs9902683 ENSG00000189423.10 USP32P3 5.08 1.07e-06 0.000783 0.59 0.38 Schizophrenia; chr17:20112115 chr17:20415547~20431008:+ PAAD cis rs453301 0.538 rs7830804 ENSG00000253893.2 FAM85B 5.08 1.07e-06 0.000785 0.52 0.38 Joint mobility (Beighton score); chr8:9113252 chr8:8167819~8226614:- PAAD cis rs6921919 1 rs35875412 ENSG00000204709.4 LINC01556 5.08 1.08e-06 0.000786 0.66 0.38 Autism spectrum disorder or schizophrenia; chr6:28364041 chr6:28943877~28944537:+ PAAD cis rs6584283 0.875 rs1548962 ENSG00000257582.4 LINC01475 5.08 1.08e-06 0.000786 0.42 0.38 Ulcerative colitis; chr10:99529978 chr10:99526350~99531177:- PAAD cis rs7078219 0.523 rs10883366 ENSG00000257582.4 LINC01475 -5.08 1.08e-06 0.000786 -0.42 -0.38 Dental caries; chr10:99528028 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs10883367 ENSG00000257582.4 LINC01475 -5.08 1.08e-06 0.000786 -0.42 -0.38 Dental caries; chr10:99528233 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs7085798 ENSG00000257582.4 LINC01475 -5.08 1.08e-06 0.000786 -0.42 -0.38 Dental caries; chr10:99528590 chr10:99526350~99531177:- PAAD cis rs7078219 0.524 rs1548963 ENSG00000257582.4 LINC01475 -5.08 1.08e-06 0.000786 -0.42 -0.38 Dental caries; chr10:99529946 chr10:99526350~99531177:- PAAD cis rs3814244 0.751 rs12832728 ENSG00000255733.4 IFNG-AS1 -5.08 1.08e-06 0.000789 -0.32 -0.38 Itch intensity from mosquito bite adjusted by bite size; chr12:68026623 chr12:67989445~68234686:+ PAAD cis rs4218 0.689 rs12440692 ENSG00000277144.1 RP11-59H7.4 -5.08 1.08e-06 0.000789 -0.51 -0.38 Social communication problems; chr15:59090671 chr15:59115547~59116089:- PAAD cis rs694739 0.894 rs887314 ENSG00000236935.1 AP003774.1 5.08 1.08e-06 0.000789 0.41 0.38 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64285685 chr11:64325050~64329504:- PAAD cis rs12468226 0.872 rs1061157 ENSG00000273456.1 RP11-686O6.2 5.08 1.08e-06 0.000789 0.57 0.38 Urate levels; chr2:202556476 chr2:202374932~202375604:- PAAD cis rs875971 0.502 rs11769702 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66255529 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs6970498 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66275908 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs73146609 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66302477 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs2173571 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66305392 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs11770063 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66318029 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs3936065 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66325577 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs4718335 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66339619 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs2279757 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66363676 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs6969224 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66370011 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs11766183 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66374173 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs1065265 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66376216 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs7811204 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66387213 chr7:66654538~66669855:+ PAAD cis rs875971 0.571 rs78668714 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66474464 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs73150604 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66480545 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs7810213 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66481592 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs2420612 ENSG00000226824.5 RP4-756H11.3 -5.08 1.08e-06 0.000789 -0.53 -0.38 Aortic root size; chr7:66536825 chr7:66654538~66669855:+ PAAD cis rs6570726 0.846 rs372904 ENSG00000235652.6 RP11-545I5.3 5.08 1.08e-06 0.000791 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145566289 chr6:145799409~145886585:+ PAAD cis rs6570726 0.791 rs414297 ENSG00000235652.6 RP11-545I5.3 5.08 1.08e-06 0.000791 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145566420 chr6:145799409~145886585:+ PAAD cis rs944722 0.621 rs9904749 ENSG00000266786.1 LGALS9DP 5.08 1.08e-06 0.000791 0.42 0.38 Fractional exhaled nitric oxide (childhood); chr17:27707236 chr17:27746132~27754954:+ PAAD cis rs4927850 0.666 rs4927853 ENSG00000231464.1 AC024937.4 5.08 1.09e-06 0.000793 0.48 0.38 Pancreatic cancer; chr3:196025182 chr3:195996738~195998233:+ PAAD cis rs7665090 0.728 rs228628 ENSG00000246560.2 RP11-10L12.4 -5.08 1.09e-06 0.000793 -0.43 -0.38 Primary biliary cholangitis; chr4:102652166 chr4:102828055~102844075:+ PAAD cis rs7665090 0.692 rs228629 ENSG00000246560.2 RP11-10L12.4 -5.08 1.09e-06 0.000793 -0.43 -0.38 Primary biliary cholangitis; chr4:102652220 chr4:102828055~102844075:+ PAAD cis rs73186030 0.546 rs55780469 ENSG00000272758.4 RP11-299J3.8 5.08 1.09e-06 0.000793 0.52 0.38 Serum parathyroid hormone levels; chr3:122388590 chr3:122416207~122443180:+ PAAD cis rs73186030 0.546 rs55857899 ENSG00000272758.4 RP11-299J3.8 5.08 1.09e-06 0.000793 0.52 0.38 Serum parathyroid hormone levels; chr3:122390705 chr3:122416207~122443180:+ PAAD cis rs73186030 0.546 rs73188320 ENSG00000272758.4 RP11-299J3.8 5.08 1.09e-06 0.000793 0.52 0.38 Serum parathyroid hormone levels; chr3:122391694 chr3:122416207~122443180:+ PAAD cis rs34375054 0.525 rs1080910 ENSG00000279233.1 RP11-158L12.4 5.08 1.09e-06 0.000794 0.33 0.38 Post bronchodilator FEV1/FVC ratio; chr12:125123946 chr12:125138245~125141711:+ PAAD cis rs6584283 0.744 rs1332099 ENSG00000257582.4 LINC01475 -5.08 1.09e-06 0.000794 -0.42 -0.38 Ulcerative colitis; chr10:99538694 chr10:99526350~99531177:- PAAD cis rs2274273 0.967 rs2340931 ENSG00000258413.1 RP11-665C16.6 -5.08 1.09e-06 0.000794 -0.48 -0.38 Protein biomarker; chr14:55150219 chr14:55262767~55272075:- PAAD cis rs8396 0.96 rs6839534 ENSG00000271817.2 U3 5.08 1.09e-06 0.000795 0.43 0.38 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158716843 chr4:158700691~158700909:+ PAAD cis rs8396 0.96 rs17843902 ENSG00000271817.2 U3 5.08 1.09e-06 0.000795 0.43 0.38 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158719996 chr4:158700691~158700909:+ PAAD cis rs2404602 0.735 rs4886805 ENSG00000259422.1 RP11-593F23.1 5.08 1.09e-06 0.000795 0.47 0.38 Blood metabolite levels; chr15:76447043 chr15:76174891~76181486:- PAAD cis rs2019137 0.56 rs11123172 ENSG00000274877.1 RP11-65I12.1 5.08 1.09e-06 0.000795 0.43 0.38 Lymphocyte counts; chr2:113226726 chr2:113237595~113240825:+ PAAD cis rs2019137 0.539 rs6755040 ENSG00000274877.1 RP11-65I12.1 -5.08 1.09e-06 0.000795 -0.43 -0.38 Lymphocyte counts; chr2:113223560 chr2:113237595~113240825:+ PAAD cis rs2019137 0.539 rs4849177 ENSG00000274877.1 RP11-65I12.1 -5.08 1.09e-06 0.000795 -0.43 -0.38 Lymphocyte counts; chr2:113225007 chr2:113237595~113240825:+ PAAD cis rs2019137 0.56 rs4849179 ENSG00000274877.1 RP11-65I12.1 -5.08 1.09e-06 0.000795 -0.43 -0.38 Lymphocyte counts; chr2:113227593 chr2:113237595~113240825:+ PAAD cis rs2019137 0.56 rs10175462 ENSG00000274877.1 RP11-65I12.1 -5.08 1.09e-06 0.000795 -0.43 -0.38 Lymphocyte counts; chr2:113230915 chr2:113237595~113240825:+ PAAD cis rs9322193 0.566 rs5024811 ENSG00000223701.3 RAET1E-AS1 -5.08 1.09e-06 0.000795 -0.48 -0.38 Lung cancer; chr6:149924898 chr6:149884431~149919508:+ PAAD cis rs801193 0.569 rs13226966 ENSG00000237310.1 GS1-124K5.4 5.08 1.09e-06 0.000797 0.38 0.38 Aortic root size; chr7:66768636 chr7:66493706~66495474:+ PAAD cis rs6504622 0.875 rs2316330 ENSG00000262879.4 RP11-156P1.3 5.08 1.09e-06 0.000797 0.39 0.38 Orofacial clefts; chr17:46962666 chr17:46984045~47100323:- PAAD cis rs6504622 0.905 rs3851785 ENSG00000262879.4 RP11-156P1.3 5.08 1.09e-06 0.000797 0.39 0.38 Orofacial clefts; chr17:46962781 chr17:46984045~47100323:- PAAD cis rs6504622 0.875 rs11652318 ENSG00000262879.4 RP11-156P1.3 5.08 1.09e-06 0.000797 0.39 0.38 Orofacial clefts; chr17:46963728 chr17:46984045~47100323:- PAAD cis rs4927850 0.794 rs13070153 ENSG00000231464.1 AC024937.4 5.08 1.09e-06 0.000798 0.48 0.38 Pancreatic cancer; chr3:196014314 chr3:195996738~195998233:+ PAAD cis rs73186030 0.546 rs73188327 ENSG00000272758.4 RP11-299J3.8 5.08 1.09e-06 0.000798 0.52 0.38 Serum parathyroid hormone levels; chr3:122394819 chr3:122416207~122443180:+ PAAD cis rs17711722 0.522 rs6957759 ENSG00000164669.11 INTS4P1 -5.08 1.1e-06 0.000798 -0.46 -0.38 Calcium levels; chr7:65806798 chr7:65141225~65234216:+ PAAD cis rs732716 0.752 rs11085072 ENSG00000267980.1 AC007292.6 -5.08 1.1e-06 0.000799 -0.54 -0.38 Mean corpuscular volume; chr19:4368145 chr19:4363789~4364640:+ PAAD cis rs1075265 0.749 rs6738369 ENSG00000233266.1 HMGB1P31 5.08 1.1e-06 0.000799 0.48 0.38 Chronotype;Morning vs. evening chronotype; chr2:53756547 chr2:54051334~54051760:+ PAAD cis rs9322193 0.884 rs9371201 ENSG00000216906.2 RP11-350J20.9 5.08 1.1e-06 0.000802 0.52 0.38 Lung cancer; chr6:149823865 chr6:149904243~149906418:+ PAAD cis rs1075265 0.901 rs7591194 ENSG00000233266.1 HMGB1P31 -5.08 1.1e-06 0.000803 -0.5 -0.38 Chronotype;Morning vs. evening chronotype; chr2:54086699 chr2:54051334~54051760:+ PAAD cis rs62229266 0.804 rs2835263 ENSG00000231106.2 LINC01436 -5.08 1.1e-06 0.000803 -0.56 -0.38 Mitral valve prolapse; chr21:36057947 chr21:36005338~36007838:+ PAAD cis rs733592 0.524 rs10875726 ENSG00000240399.1 RP1-228P16.1 -5.08 1.1e-06 0.000803 -0.35 -0.38 Plateletcrit; chr12:48032209 chr12:48054813~48055591:- PAAD cis rs733592 0.524 rs10875727 ENSG00000240399.1 RP1-228P16.1 -5.08 1.1e-06 0.000803 -0.35 -0.38 Plateletcrit; chr12:48032360 chr12:48054813~48055591:- PAAD cis rs12468226 0.873 rs59293950 ENSG00000273456.1 RP11-686O6.2 5.08 1.1e-06 0.000803 0.58 0.38 Urate levels; chr2:202214069 chr2:202374932~202375604:- PAAD cis rs2239557 0.529 rs2041185 ENSG00000259065.1 RP5-1021I20.1 5.08 1.11e-06 0.000805 0.51 0.38 Common traits (Other); chr14:73815387 chr14:73787360~73803270:+ PAAD cis rs17711722 0.51 rs11767457 ENSG00000164669.11 INTS4P1 -5.08 1.11e-06 0.000805 -0.47 -0.38 Calcium levels; chr7:65825628 chr7:65141225~65234216:+ PAAD cis rs4664293 0.769 rs1365798 ENSG00000226266.5 AC009961.3 5.08 1.11e-06 0.000806 0.47 0.38 Monocyte percentage of white cells; chr2:159795853 chr2:159670708~159712435:- PAAD cis rs4308124 0.708 rs2137168 ENSG00000227992.1 AC108463.2 -5.08 1.11e-06 0.000807 -0.44 -0.38 Vitiligo; chr2:111228932 chr2:111203964~111206215:- PAAD cis rs6921919 1 rs6921919 ENSG00000204709.4 LINC01556 5.08 1.11e-06 0.000808 0.64 0.38 Autism spectrum disorder or schizophrenia; chr6:28357424 chr6:28943877~28944537:+ PAAD cis rs4728142 0.604 rs12155080 ENSG00000275106.1 RP11-309L24.10 -5.08 1.11e-06 0.000808 -0.51 -0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129018685 chr7:128952527~128953316:- PAAD cis rs9532669 0.963 rs9532662 ENSG00000176268.5 CYCSP34 5.08 1.11e-06 0.000808 0.35 0.38 Cervical cancer; chr13:40926215 chr13:40863599~40863902:- PAAD cis rs367615 0.512 rs246105 ENSG00000249476.1 CTD-2587M2.1 5.08 1.11e-06 0.000809 0.41 0.38 Colorectal cancer (SNP x SNP interaction); chr5:109337245 chr5:109237120~109326369:- PAAD cis rs763567 0.967 rs473832 ENSG00000271811.1 RP1-79C4.4 5.08 1.11e-06 0.00081 0.36 0.38 Tonsillectomy; chr1:170640049 chr1:170667381~170669425:+ PAAD cis rs8059260 0.668 rs75811377 ENSG00000274038.1 RP11-66H6.4 -5.08 1.11e-06 0.00081 -0.64 -0.38 Alcohol consumption over the past year; chr16:11023451 chr16:11056556~11057034:+ PAAD cis rs17711722 0.503 rs453835 ENSG00000236529.1 RP13-254B10.1 -5.08 1.12e-06 0.000812 -0.43 -0.38 Calcium levels; chr7:66046172 chr7:65840212~65840596:+ PAAD cis rs6921919 0.515 rs1339898 ENSG00000216901.1 AL022393.7 5.08 1.12e-06 0.000812 0.48 0.38 Autism spectrum disorder or schizophrenia; chr6:28427729 chr6:28176188~28176674:+ PAAD cis rs12701220 0.503 rs13222294 ENSG00000229043.2 AC091729.9 -5.07 1.12e-06 0.000812 -0.48 -0.38 Bronchopulmonary dysplasia; chr7:1133333 chr7:1160374~1165267:+ PAAD cis rs2581828 0.965 rs2581830 ENSG00000242142.1 SERBP1P3 5.07 1.12e-06 0.000812 0.43 0.38 Crohn's disease; chr3:53100082 chr3:53064283~53065091:- PAAD cis rs2581828 0.965 rs35783750 ENSG00000242142.1 SERBP1P3 5.07 1.12e-06 0.000812 0.43 0.38 Crohn's disease; chr3:53100847 chr3:53064283~53065091:- PAAD cis rs2581828 0.965 rs34454739 ENSG00000242142.1 SERBP1P3 5.07 1.12e-06 0.000812 0.43 0.38 Crohn's disease; chr3:53100955 chr3:53064283~53065091:- PAAD cis rs2581828 0.965 rs2564961 ENSG00000242142.1 SERBP1P3 5.07 1.12e-06 0.000812 0.43 0.38 Crohn's disease; chr3:53102445 chr3:53064283~53065091:- PAAD cis rs2581828 0.965 rs4337632 ENSG00000242142.1 SERBP1P3 5.07 1.12e-06 0.000812 0.43 0.38 Crohn's disease; chr3:53103295 chr3:53064283~53065091:- PAAD cis rs3931020 0.688 rs525487 ENSG00000272864.1 RP11-17E13.2 5.07 1.12e-06 0.000812 0.53 0.38 Resistin levels; chr1:74751736 chr1:74698769~74699333:- PAAD cis rs2072438 0.503 rs1323474 ENSG00000226752.6 PSMD5-AS1 -5.07 1.12e-06 0.000813 -0.43 -0.38 Rheumatoid arthritis; chr9:121090581 chr9:120824828~120854385:+ PAAD cis rs2072438 0.503 rs10739590 ENSG00000226752.6 PSMD5-AS1 -5.07 1.12e-06 0.000813 -0.43 -0.38 Rheumatoid arthritis; chr9:121109203 chr9:120824828~120854385:+ PAAD cis rs2072438 0.503 rs4837810 ENSG00000226752.6 PSMD5-AS1 -5.07 1.12e-06 0.000813 -0.43 -0.38 Rheumatoid arthritis; chr9:121118921 chr9:120824828~120854385:+ PAAD cis rs9322193 0.923 rs4869750 ENSG00000223701.3 RAET1E-AS1 5.07 1.12e-06 0.000813 0.44 0.38 Lung cancer; chr6:149855996 chr6:149884431~149919508:+ PAAD cis rs453301 0.522 rs1964356 ENSG00000253893.2 FAM85B -5.07 1.12e-06 0.000813 -0.51 -0.38 Joint mobility (Beighton score); chr8:8995760 chr8:8167819~8226614:- PAAD cis rs1823913 0.599 rs2124095 ENSG00000280083.1 RP11-317J9.1 -5.07 1.12e-06 0.000813 -0.46 -0.38 Obesity-related traits; chr2:191301728 chr2:191154118~191156070:- PAAD cis rs4268898 0.722 rs11691212 ENSG00000242628.4 AC009228.1 -5.07 1.12e-06 0.000814 -0.44 -0.38 Asthma; chr2:24181864 chr2:24214381~24221516:+ PAAD cis rs4268898 0.722 rs10445893 ENSG00000242628.4 AC009228.1 -5.07 1.12e-06 0.000814 -0.44 -0.38 Asthma; chr2:24184259 chr2:24214381~24221516:+ PAAD cis rs9926296 0.682 rs258328 ENSG00000260259.1 RP11-368I7.4 5.07 1.12e-06 0.000814 0.48 0.38 Vitiligo; chr16:89663906 chr16:89682620~89686569:- PAAD cis rs9926296 0.712 rs459920 ENSG00000260259.1 RP11-368I7.4 5.07 1.12e-06 0.000814 0.48 0.38 Vitiligo; chr16:89664419 chr16:89682620~89686569:- PAAD cis rs9926296 0.712 rs258319 ENSG00000260259.1 RP11-368I7.4 5.07 1.12e-06 0.000814 0.48 0.38 Vitiligo; chr16:89665616 chr16:89682620~89686569:- PAAD cis rs9926296 0.687 rs258317 ENSG00000260259.1 RP11-368I7.4 5.07 1.12e-06 0.000814 0.48 0.38 Vitiligo; chr16:89665830 chr16:89682620~89686569:- PAAD cis rs1150668 0.83 rs2023493 ENSG00000204709.4 LINC01556 5.07 1.12e-06 0.000815 0.51 0.38 Pubertal anthropometrics; chr6:28432385 chr6:28943877~28944537:+ PAAD cis rs3931020 0.688 rs277396 ENSG00000272864.1 RP11-17E13.2 5.07 1.13e-06 0.000818 0.53 0.38 Resistin levels; chr1:74747964 chr1:74698769~74699333:- PAAD cis rs6860806 0.507 rs635620 ENSG00000233006.5 AC034220.3 -5.07 1.13e-06 0.000819 -0.34 -0.38 Breast cancer; chr5:132384571 chr5:132311285~132369916:- PAAD cis rs6860806 0.507 rs635619 ENSG00000233006.5 AC034220.3 -5.07 1.13e-06 0.000819 -0.34 -0.38 Breast cancer; chr5:132384573 chr5:132311285~132369916:- PAAD cis rs4950322 0.57 rs7554833 ENSG00000278811.3 LINC00624 -5.07 1.13e-06 0.000819 -0.4 -0.38 Protein quantitative trait loci; chr1:147289362 chr1:147258885~147517875:- PAAD cis rs7078219 0.505 rs10883372 ENSG00000257582.4 LINC01475 -5.07 1.13e-06 0.000819 -0.42 -0.38 Dental caries; chr10:99532726 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs10883373 ENSG00000257582.4 LINC01475 -5.07 1.13e-06 0.000819 -0.42 -0.38 Dental caries; chr10:99532727 chr10:99526350~99531177:- PAAD cis rs12468226 0.817 rs6722588 ENSG00000273456.1 RP11-686O6.2 -5.07 1.13e-06 0.00082 -0.57 -0.38 Urate levels; chr2:202187163 chr2:202374932~202375604:- PAAD cis rs2562456 0.755 rs2914646 ENSG00000213976.4 CTD-2561J22.2 5.07 1.13e-06 0.00082 0.42 0.38 Pain; chr19:21454359 chr19:21382865~21387177:+ PAAD cis rs9473147 0.516 rs9349413 ENSG00000270761.1 RP11-385F7.1 -5.07 1.13e-06 0.000822 -0.4 -0.38 Platelet distribution width;Mean platelet volume; chr6:47543755 chr6:47477243~47477572:- PAAD cis rs6584283 0.875 rs10748783 ENSG00000257582.4 LINC01475 -5.07 1.13e-06 0.000822 -0.42 -0.38 Ulcerative colitis; chr10:99526115 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs6584282 ENSG00000257582.4 LINC01475 -5.07 1.13e-06 0.000822 -0.42 -0.38 Dental caries; chr10:99526738 chr10:99526350~99531177:- PAAD cis rs6584283 0.846 rs11190135 ENSG00000257582.4 LINC01475 -5.07 1.13e-06 0.000822 -0.42 -0.38 Ulcerative colitis; chr10:99527091 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs10883362 ENSG00000257582.4 LINC01475 -5.07 1.13e-06 0.000822 -0.42 -0.38 Dental caries; chr10:99527227 chr10:99526350~99531177:- PAAD cis rs2412819 0.571 rs12900924 ENSG00000205771.5 CATSPER2P1 -5.07 1.13e-06 0.000822 -0.61 -0.38 Lung cancer; chr15:43737329 chr15:43726918~43747094:- PAAD cis rs4728142 0.604 rs2272347 ENSG00000275106.1 RP11-309L24.10 5.07 1.14e-06 0.000824 0.52 0.38 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128979361 chr7:128952527~128953316:- PAAD cis rs1823913 0.637 rs1378162 ENSG00000280083.1 RP11-317J9.1 -5.07 1.14e-06 0.000824 -0.46 -0.38 Obesity-related traits; chr2:191298523 chr2:191154118~191156070:- PAAD cis rs12701220 0.553 rs34062359 ENSG00000229043.2 AC091729.9 -5.07 1.14e-06 0.000824 -0.51 -0.38 Bronchopulmonary dysplasia; chr7:1099440 chr7:1160374~1165267:+ PAAD cis rs7829975 0.514 rs2945873 ENSG00000253893.2 FAM85B -5.07 1.14e-06 0.000824 -0.52 -0.38 Mood instability; chr8:8402935 chr8:8167819~8226614:- PAAD cis rs2221433 1 rs2354423 ENSG00000260310.1 RP11-27M24.2 5.07 1.14e-06 0.000824 0.44 0.38 Eating disorders; chr16:10578271 chr16:10576499~10578183:- PAAD cis rs1075265 0.87 rs10207537 ENSG00000233266.1 HMGB1P31 5.07 1.14e-06 0.000827 0.5 0.38 Chronotype;Morning vs. evening chronotype; chr2:54101700 chr2:54051334~54051760:+ PAAD cis rs2243480 0.901 rs13237344 ENSG00000226824.5 RP4-756H11.3 -5.07 1.14e-06 0.000827 -0.68 -0.38 Diabetic kidney disease; chr7:66557269 chr7:66654538~66669855:+ PAAD cis rs875971 0.862 rs10274883 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66651104 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs881285 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66654433 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs3846973 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66655048 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs2013908 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66656082 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs13242290 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66656898 chr7:66493706~66495474:+ PAAD cis rs801193 0.548 rs2109297 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66657397 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs6978178 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66658097 chr7:66493706~66495474:+ PAAD cis rs801193 0.591 rs721717 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66665305 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs6951302 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66667525 chr7:66493706~66495474:+ PAAD cis rs801193 0.591 rs4506088 ENSG00000237310.1 GS1-124K5.4 -5.07 1.14e-06 0.000827 -0.38 -0.38 Aortic root size; chr7:66670470 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs2659908 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66695835 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs2659907 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66699045 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs7782587 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66701485 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs4717315 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66713338 chr7:66493706~66495474:+ PAAD cis rs801193 0.527 rs2707837 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66716086 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs2707824 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66724256 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs2659893 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66735006 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs2659892 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66735318 chr7:66493706~66495474:+ PAAD cis rs801193 0.548 rs2659891 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66736127 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs2707847 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66737884 chr7:66493706~66495474:+ PAAD cis rs801193 0.548 rs7805152 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66744266 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs11772819 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66752983 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs11761542 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66753209 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs7800620 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66758701 chr7:66493706~66495474:+ PAAD cis rs801193 0.569 rs10950050 ENSG00000237310.1 GS1-124K5.4 5.07 1.14e-06 0.000827 0.38 0.38 Aortic root size; chr7:66774601 chr7:66493706~66495474:+ PAAD cis rs2280018 0.526 rs2941257 ENSG00000260735.1 RP11-72I8.1 -5.07 1.15e-06 0.000828 -0.49 -0.38 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072588 chr16:15094411~15109197:+ PAAD cis rs2280018 0.526 rs1510148 ENSG00000260735.1 RP11-72I8.1 -5.07 1.15e-06 0.000828 -0.49 -0.38 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15073522 chr16:15094411~15109197:+ PAAD cis rs8062405 0.756 rs151182 ENSG00000251417.2 RP11-1348G14.4 -5.07 1.15e-06 0.000829 -0.35 -0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28484431 chr16:28802743~28817828:+ PAAD cis rs8062405 0.756 rs151301 ENSG00000251417.2 RP11-1348G14.4 -5.07 1.15e-06 0.000829 -0.35 -0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28485738 chr16:28802743~28817828:+ PAAD cis rs7772486 0.714 rs1883365 ENSG00000235652.6 RP11-545I5.3 -5.07 1.15e-06 0.000829 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145755613 chr6:145799409~145886585:+ PAAD cis rs74233809 0.901 rs17115100 ENSG00000213277.3 MARCKSL1P1 5.07 1.15e-06 0.00083 0.6 0.38 Birth weight; chr10:102831636 chr10:103175554~103176094:+ PAAD cis rs34375054 0.525 rs7398636 ENSG00000279233.1 RP11-158L12.4 5.07 1.15e-06 0.000832 0.34 0.38 Post bronchodilator FEV1/FVC ratio; chr12:125114058 chr12:125138245~125141711:+ PAAD cis rs12468226 0.938 rs10931993 ENSG00000273456.1 RP11-686O6.2 5.07 1.15e-06 0.000832 0.57 0.38 Urate levels; chr2:202243017 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs10166594 ENSG00000273456.1 RP11-686O6.2 5.07 1.15e-06 0.000832 0.57 0.38 Urate levels; chr2:202250262 chr2:202374932~202375604:- PAAD cis rs12468226 0.873 rs6761131 ENSG00000273456.1 RP11-686O6.2 -5.07 1.15e-06 0.000832 -0.57 -0.38 Urate levels; chr2:202237675 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs4675274 ENSG00000273456.1 RP11-686O6.2 -5.07 1.15e-06 0.000832 -0.57 -0.38 Urate levels; chr2:202243145 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs3843338 ENSG00000273456.1 RP11-686O6.2 -5.07 1.15e-06 0.000832 -0.57 -0.38 Urate levels; chr2:202246102 chr2:202374932~202375604:- PAAD cis rs10510102 0.872 rs28586586 ENSG00000276742.1 RP11-500G22.4 5.07 1.15e-06 0.000832 0.56 0.38 Breast cancer; chr10:121950228 chr10:121956782~121957098:+ PAAD cis rs8031584 0.958 rs35256769 ENSG00000260382.1 RP11-540B6.2 5.07 1.15e-06 0.000834 0.48 0.38 Huntington's disease progression; chr15:30945573 chr15:30882267~30883231:- PAAD cis rs8031584 0.958 rs11629793 ENSG00000260382.1 RP11-540B6.2 5.07 1.15e-06 0.000834 0.48 0.38 Huntington's disease progression; chr15:30946220 chr15:30882267~30883231:- PAAD cis rs13178541 0.683 rs9800300 ENSG00000250378.1 RP11-119J18.1 -5.07 1.16e-06 0.000835 -0.59 -0.38 IgG glycosylation; chr5:135760622 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs11242264 ENSG00000250378.1 RP11-119J18.1 -5.07 1.16e-06 0.000835 -0.59 -0.38 IgG glycosylation; chr5:135762546 chr5:135812667~135826582:+ PAAD cis rs13178541 0.626 rs4510575 ENSG00000250378.1 RP11-119J18.1 -5.07 1.16e-06 0.000835 -0.59 -0.38 IgG glycosylation; chr5:135770111 chr5:135812667~135826582:+ PAAD cis rs4268898 0.76 rs11676939 ENSG00000242628.4 AC009228.1 -5.07 1.16e-06 0.000836 -0.45 -0.38 Asthma; chr2:24256188 chr2:24214381~24221516:+ PAAD cis rs12468226 0.873 rs12472035 ENSG00000273456.1 RP11-686O6.2 5.07 1.16e-06 0.000837 0.58 0.38 Urate levels; chr2:202221970 chr2:202374932~202375604:- PAAD cis rs12468226 0.873 rs12470401 ENSG00000273456.1 RP11-686O6.2 5.07 1.16e-06 0.000837 0.58 0.38 Urate levels; chr2:202236436 chr2:202374932~202375604:- PAAD cis rs1075265 0.73 rs7559380 ENSG00000233266.1 HMGB1P31 5.07 1.16e-06 0.000838 0.48 0.38 Chronotype;Morning vs. evening chronotype; chr2:54129660 chr2:54051334~54051760:+ PAAD cis rs950169 0.84 rs12905223 ENSG00000259295.5 CSPG4P12 5.07 1.16e-06 0.00084 0.42 0.38 Schizophrenia; chr15:84571037 chr15:85191438~85213905:+ PAAD cis rs7945705 0.967 rs2568090 ENSG00000254860.4 TMEM9B-AS1 -5.06 1.17e-06 0.000844 -0.44 -0.38 Hemoglobin concentration; chr11:8827948 chr11:8964675~8977527:+ PAAD cis rs2337406 0.866 rs8016203 ENSG00000211974.3 IGHV2-70 -5.06 1.17e-06 0.000846 -0.52 -0.38 Alzheimer's disease (late onset); chr14:106780575 chr14:106723574~106724093:- PAAD cis rs7208859 0.673 rs11654331 ENSG00000266490.1 CTD-2349P21.9 5.06 1.17e-06 0.000846 0.51 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837999 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73277964 ENSG00000266490.1 CTD-2349P21.9 5.06 1.17e-06 0.000846 0.51 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30852183 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11652409 ENSG00000266490.1 CTD-2349P21.9 5.06 1.17e-06 0.000846 0.51 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855689 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9896095 ENSG00000266490.1 CTD-2349P21.9 5.06 1.17e-06 0.000846 0.51 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30860479 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs58920731 ENSG00000266490.1 CTD-2349P21.9 5.06 1.17e-06 0.000846 0.51 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864728 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73277984 ENSG00000266490.1 CTD-2349P21.9 5.06 1.17e-06 0.000846 0.51 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869115 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73277986 ENSG00000266490.1 CTD-2349P21.9 5.06 1.17e-06 0.000846 0.51 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869179 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs12103588 ENSG00000266490.1 CTD-2349P21.9 5.06 1.17e-06 0.000846 0.51 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30870442 chr17:30792372~30792833:+ PAAD cis rs2380205 0.5 rs688388 ENSG00000232807.2 RP11-536K7.3 -5.06 1.17e-06 0.000847 -0.43 -0.38 Breast cancer; chr10:5918667 chr10:5934270~5945900:- PAAD cis rs8062405 0.754 rs151179 ENSG00000251417.2 RP11-1348G14.4 -5.06 1.17e-06 0.000847 -0.34 -0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28475735 chr16:28802743~28817828:+ PAAD cis rs42490 0.834 rs10102245 ENSG00000251136.7 RP11-37B2.1 5.06 1.18e-06 0.000849 0.36 0.38 Leprosy; chr8:89638317 chr8:89609409~89757727:- PAAD cis rs1545257 0.505 rs894466 ENSG00000242628.4 AC009228.1 5.06 1.18e-06 0.00085 0.44 0.38 Sjögren's syndrome; chr2:24410902 chr2:24214381~24221516:+ PAAD cis rs902774 0.554 rs4919749 ENSG00000278185.1 RP11-153F5.7 5.06 1.18e-06 0.000851 0.48 0.38 Prostate cancer; chr12:52964250 chr12:52946614~52947125:- PAAD cis rs2404602 0.735 rs62028423 ENSG00000259422.1 RP11-593F23.1 -5.06 1.18e-06 0.000852 -0.46 -0.38 Blood metabolite levels; chr15:76462173 chr15:76174891~76181486:- PAAD cis rs4268898 0.722 rs7564420 ENSG00000242628.4 AC009228.1 5.06 1.18e-06 0.000852 0.44 0.38 Asthma; chr2:24191133 chr2:24214381~24221516:+ PAAD cis rs240993 0.809 rs11153277 ENSG00000230177.1 RP5-1112D6.4 -5.06 1.18e-06 0.000853 -0.32 -0.38 Inflammatory skin disease;Psoriasis; chr6:111259358 chr6:111277932~111278742:+ PAAD cis rs2455601 1 rs2455601 ENSG00000254860.4 TMEM9B-AS1 5.06 1.19e-06 0.000855 0.53 0.38 Schizophrenia; chr11:8877853 chr11:8964675~8977527:+ PAAD cis rs2274273 0.624 rs10141396 ENSG00000258413.1 RP11-665C16.6 -5.06 1.19e-06 0.000856 -0.51 -0.38 Protein biomarker; chr14:55350207 chr14:55262767~55272075:- PAAD cis rs9928842 0.823 rs8061356 ENSG00000280152.1 RP11-331F4.5 5.06 1.19e-06 0.000857 0.47 0.38 Alcoholic chronic pancreatitis; chr16:75260334 chr16:75245994~75250077:- PAAD cis rs8059260 0.668 rs7198089 ENSG00000274038.1 RP11-66H6.4 -5.06 1.19e-06 0.000858 -0.63 -0.38 Alcohol consumption over the past year; chr16:11027199 chr16:11056556~11057034:+ PAAD cis rs7208859 0.673 rs999798 ENSG00000266490.1 CTD-2349P21.9 5.06 1.19e-06 0.000859 0.45 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831822 chr17:30792372~30792833:+ PAAD cis rs964611 0.882 rs7170447 ENSG00000259488.2 RP11-154J22.1 5.06 1.19e-06 0.000859 0.41 0.38 Metabolite levels (Pyroglutamine); chr15:48361245 chr15:48312353~48331856:- PAAD cis rs858239 0.67 rs3807452 ENSG00000226816.2 AC005082.12 -5.06 1.19e-06 0.00086 -0.42 -0.38 Cerebrospinal fluid biomarker levels; chr7:23122462 chr7:23206013~23208045:+ PAAD cis rs6504950 0.72 rs9914836 ENSG00000275710.1 RP11-257O5.4 5.06 1.19e-06 0.00086 0.5 0.38 Breast cancer; chr17:54920514 chr17:54964474~54964679:+ PAAD cis rs10463554 0.892 rs11952337 ENSG00000175749.11 EIF3KP1 5.06 1.2e-06 0.000861 0.49 0.38 Parkinson's disease; chr5:102928043 chr5:103032376~103033031:+ PAAD cis rs10463554 0.892 rs6871715 ENSG00000175749.11 EIF3KP1 5.06 1.2e-06 0.000861 0.49 0.38 Parkinson's disease; chr5:102930398 chr5:103032376~103033031:+ PAAD cis rs7208859 0.623 rs3752019 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824687 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73271869 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825203 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs73271872 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825210 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs55724095 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826040 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs56146117 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826307 chr17:30792372~30792833:+ PAAD cis rs17826219 0.568 rs9903854 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Body mass index; chr17:30826980 chr17:30792372~30792833:+ PAAD cis rs17826219 0.568 rs9907834 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Body mass index; chr17:30826995 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs80355557 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827403 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9911173 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827732 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73271887 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827917 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9898858 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829193 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs55658077 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829501 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9899692 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829921 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs9906957 ENSG00000266490.1 CTD-2349P21.9 5.06 1.2e-06 0.000861 0.5 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30830737 chr17:30792372~30792833:+ PAAD cis rs2274273 0.837 rs8011329 ENSG00000258413.1 RP11-665C16.6 -5.06 1.2e-06 0.000863 -0.47 -0.38 Protein biomarker; chr14:55210537 chr14:55262767~55272075:- PAAD cis rs763567 0.845 rs539045 ENSG00000271811.1 RP1-79C4.4 5.06 1.2e-06 0.000865 0.36 0.38 Tonsillectomy; chr1:170638940 chr1:170667381~170669425:+ PAAD cis rs7772486 0.806 rs2265477 ENSG00000235652.6 RP11-545I5.3 5.06 1.2e-06 0.000866 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145891202 chr6:145799409~145886585:+ PAAD cis rs7772486 0.806 rs2247317 ENSG00000235652.6 RP11-545I5.3 5.06 1.2e-06 0.000866 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145896434 chr6:145799409~145886585:+ PAAD cis rs7772486 0.776 rs2265467 ENSG00000235652.6 RP11-545I5.3 5.06 1.2e-06 0.000866 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145897203 chr6:145799409~145886585:+ PAAD cis rs7772486 0.776 rs4316025 ENSG00000235652.6 RP11-545I5.3 -5.06 1.2e-06 0.000866 -0.32 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145916896 chr6:145799409~145886585:+ PAAD cis rs7772486 0.806 rs4075696 ENSG00000235652.6 RP11-545I5.3 -5.06 1.2e-06 0.000866 -0.32 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145929811 chr6:145799409~145886585:+ PAAD cis rs7772486 0.806 rs4075695 ENSG00000235652.6 RP11-545I5.3 -5.06 1.2e-06 0.000866 -0.32 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145929823 chr6:145799409~145886585:+ PAAD cis rs7665090 0.728 rs228632 ENSG00000246560.2 RP11-10L12.4 -5.06 1.2e-06 0.000866 -0.43 -0.38 Primary biliary cholangitis; chr4:102652747 chr4:102828055~102844075:+ PAAD cis rs67180937 0.583 rs3008616 ENSG00000272750.1 RP11-378J18.8 5.06 1.2e-06 0.000867 0.44 0.38 Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr1:222623831 chr1:222658867~222661512:- PAAD cis rs989978 0.958 rs1332102 ENSG00000257582.4 LINC01475 -5.06 1.21e-06 0.000867 -0.46 -0.38 Red blood cell count; chr10:99564679 chr10:99526350~99531177:- PAAD cis rs10853057 0.541 rs62065481 ENSG00000214174.7 AMZ2P1 5.06 1.21e-06 0.000868 0.65 0.38 White matter microstructure (global fractional anisotropy); chr17:65008273 chr17:64966550~64975576:- PAAD cis rs526231 0.578 rs59323174 ENSG00000175749.11 EIF3KP1 5.06 1.21e-06 0.00087 0.49 0.38 Primary biliary cholangitis; chr5:102932165 chr5:103032376~103033031:+ PAAD cis rs2658782 0.547 rs2085334 ENSG00000279684.1 RP11-755E23.2 -5.06 1.21e-06 0.00087 -0.55 -0.38 Pulmonary function decline; chr11:93447884 chr11:93286629~93288903:- PAAD cis rs1322639 0.614 rs6900964 ENSG00000261039.2 RP11-417E7.2 -5.06 1.21e-06 0.000871 -0.62 -0.38 Pulse pressure; chr6:169166668 chr6:169175304~169182740:- PAAD cis rs7826238 0.601 rs2976907 ENSG00000253893.2 FAM85B -5.06 1.21e-06 0.000871 -0.51 -0.38 Systolic blood pressure; chr8:8487658 chr8:8167819~8226614:- PAAD cis rs2115630 1 rs7183401 ENSG00000259728.4 LINC00933 -5.06 1.21e-06 0.000872 -0.47 -0.38 P wave terminal force; chr15:84828713 chr15:84570649~84580175:+ PAAD cis rs694739 0.964 rs2510066 ENSG00000236935.1 AP003774.1 5.06 1.21e-06 0.000873 0.41 0.38 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64284975 chr11:64325050~64329504:- PAAD cis rs8396 0.96 rs17843919 ENSG00000271817.2 U3 5.06 1.22e-06 0.000873 0.43 0.38 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158717814 chr4:158700691~158700909:+ PAAD cis rs2562456 0.833 rs2968076 ENSG00000213976.4 CTD-2561J22.2 5.06 1.22e-06 0.000875 0.41 0.38 Pain; chr19:21454299 chr19:21382865~21387177:+ PAAD cis rs2562456 0.793 rs2650819 ENSG00000213976.4 CTD-2561J22.2 5.06 1.22e-06 0.000875 0.41 0.38 Pain; chr19:21456071 chr19:21382865~21387177:+ PAAD cis rs1545257 0.505 rs12988810 ENSG00000242628.4 AC009228.1 5.06 1.22e-06 0.000876 0.44 0.38 Sjögren's syndrome; chr2:24412224 chr2:24214381~24221516:+ PAAD cis rs4268898 0.686 rs2042468 ENSG00000242628.4 AC009228.1 -5.06 1.22e-06 0.000876 -0.44 -0.38 Asthma; chr2:24175577 chr2:24214381~24221516:+ PAAD cis rs2115630 1 rs11073730 ENSG00000259728.4 LINC00933 -5.06 1.22e-06 0.000877 -0.47 -0.38 P wave terminal force; chr15:84811365 chr15:84570649~84580175:+ PAAD cis rs7208859 0.623 rs216423 ENSG00000266490.1 CTD-2349P21.9 5.05 1.22e-06 0.000878 0.45 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30615091 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs450585 ENSG00000266490.1 CTD-2349P21.9 5.05 1.22e-06 0.000878 0.45 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30624021 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs423151 ENSG00000266490.1 CTD-2349P21.9 5.05 1.22e-06 0.000878 0.45 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30625268 chr17:30792372~30792833:+ PAAD cis rs4664293 0.867 rs2059698 ENSG00000226266.5 AC009961.3 5.05 1.22e-06 0.000879 0.47 0.38 Monocyte percentage of white cells; chr2:159785905 chr2:159670708~159712435:- PAAD cis rs2658782 0.901 rs11604909 ENSG00000279684.1 RP11-755E23.2 -5.05 1.22e-06 0.000879 -0.64 -0.38 Pulmonary function decline; chr11:93485189 chr11:93286629~93288903:- PAAD cis rs9595908 0.865 rs497255 ENSG00000212293.1 SNORA16 -5.05 1.23e-06 0.00088 -0.44 -0.38 Body mass index; chr13:32424754 chr13:32420390~32420516:- PAAD cis rs6782228 0.606 rs4634140 ENSG00000242551.2 POU5F1P6 5.05 1.23e-06 0.000881 0.45 0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128705613 chr3:128674735~128677005:- PAAD cis rs1322639 0.614 rs9364356 ENSG00000261039.2 RP11-417E7.2 -5.05 1.23e-06 0.000881 -0.62 -0.38 Pulse pressure; chr6:169167013 chr6:169175304~169182740:- PAAD cis rs10875746 0.669 rs10875767 ENSG00000240399.1 RP1-228P16.1 -5.05 1.23e-06 0.000882 -0.42 -0.38 Longevity (90 years and older); chr12:48205474 chr12:48054813~48055591:- PAAD cis rs7829975 0.626 rs907183 ENSG00000253893.2 FAM85B 5.05 1.23e-06 0.000883 0.53 0.38 Mood instability; chr8:8872251 chr8:8167819~8226614:- PAAD cis rs6764388 0.696 rs6809565 ENSG00000270059.1 RP11-88H12.2 -5.05 1.23e-06 0.000883 -0.52 -0.38 Corneal astigmatism; chr3:65319305 chr3:65359268~65359717:- PAAD cis rs950027 0.549 rs11636114 ENSG00000259433.2 CTD-2651B20.4 -5.05 1.23e-06 0.000883 -0.43 -0.38 Response to fenofibrate (adiponectin levels); chr15:45309214 chr15:45330209~45332634:- PAAD cis rs2404602 0.735 rs11629888 ENSG00000259422.1 RP11-593F23.1 -5.05 1.23e-06 0.000884 -0.48 -0.38 Blood metabolite levels; chr15:76427539 chr15:76174891~76181486:- PAAD cis rs12922040 0.651 rs35288467 ENSG00000263335.1 AF001548.5 -5.05 1.23e-06 0.000885 -0.44 -0.38 Serum uric acid levels in response to allopurinol in gout; chr16:15773097 chr16:15726674~15732993:+ PAAD cis rs8062405 0.679 rs72793818 ENSG00000251417.2 RP11-1348G14.4 -5.05 1.24e-06 0.000886 -0.34 -0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28881816 chr16:28802743~28817828:+ PAAD cis rs66887589 0.967 rs2892869 ENSG00000248280.1 RP11-33B1.2 -5.05 1.24e-06 0.000887 -0.34 -0.38 Diastolic blood pressure; chr4:119600142 chr4:119440561~119450157:- PAAD cis rs7208859 0.623 rs56325146 ENSG00000266490.1 CTD-2349P21.9 5.05 1.24e-06 0.000887 0.49 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824006 chr17:30792372~30792833:+ PAAD cis rs3779195 0.591 rs77968419 ENSG00000272950.1 RP11-307C18.1 -5.05 1.24e-06 0.000889 -0.67 -0.38 Sex hormone-binding globulin levels; chr7:98237168 chr7:98322853~98323430:+ PAAD cis rs7208859 0.573 rs73267873 ENSG00000266490.1 CTD-2349P21.9 5.05 1.24e-06 0.000889 0.47 0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30741439 chr17:30792372~30792833:+ PAAD cis rs17826219 0.561 rs4085382 ENSG00000266490.1 CTD-2349P21.9 5.05 1.24e-06 0.000889 0.47 0.38 Body mass index; chr17:30744184 chr17:30792372~30792833:+ PAAD cis rs1075265 0.749 rs10203095 ENSG00000233266.1 HMGB1P31 5.05 1.24e-06 0.00089 0.48 0.38 Chronotype;Morning vs. evening chronotype; chr2:53737150 chr2:54051334~54051760:+ PAAD cis rs9322193 0.923 rs7769101 ENSG00000268592.3 RAET1E-AS1 5.05 1.25e-06 0.000893 0.45 0.38 Lung cancer; chr6:149848768 chr6:149863494~149919507:+ PAAD cis rs61142792 0.59 rs747861 ENSG00000249109.1 RP11-1026M7.2 -5.05 1.25e-06 0.000896 -0.89 -0.38 Alzheimer disease and age of onset; chr5:177610396 chr5:177782197~177794396:+ PAAD cis rs950169 0.8 rs34302901 ENSG00000259295.5 CSPG4P12 5.05 1.25e-06 0.000896 0.42 0.38 Schizophrenia; chr15:84567712 chr15:85191438~85213905:+ PAAD cis rs79040073 0.53 rs2078024 ENSG00000259531.2 RP11-295H24.3 5.05 1.25e-06 0.000896 0.57 0.38 Lung cancer in ever smokers; chr15:49329413 chr15:49365124~49366685:- PAAD cis rs6565180 1 rs11862806 ENSG00000183604.13 SMG1P5 -5.05 1.25e-06 0.000897 -0.42 -0.38 Tonsillectomy; chr16:30352750 chr16:30267553~30335374:- PAAD cis rs2581828 0.656 rs2581800 ENSG00000242142.1 SERBP1P3 5.05 1.26e-06 0.000899 0.44 0.38 Crohn's disease; chr3:53075336 chr3:53064283~53065091:- PAAD cis rs9473147 0.543 rs9296559 ENSG00000270761.1 RP11-385F7.1 -5.05 1.26e-06 0.000901 -0.38 -0.38 Platelet distribution width;Mean platelet volume; chr6:47484534 chr6:47477243~47477572:- PAAD cis rs6921919 0.583 rs7759191 ENSG00000204709.4 LINC01556 5.05 1.26e-06 0.000902 0.54 0.38 Autism spectrum disorder or schizophrenia; chr6:28385657 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs7764737 ENSG00000204709.4 LINC01556 5.05 1.26e-06 0.000902 0.54 0.38 Autism spectrum disorder or schizophrenia; chr6:28386838 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs9461458 ENSG00000204709.4 LINC01556 5.05 1.26e-06 0.000902 0.54 0.38 Autism spectrum disorder or schizophrenia; chr6:28388098 chr6:28943877~28944537:+ PAAD cis rs6921919 0.609 rs9468365 ENSG00000204709.4 LINC01556 5.05 1.26e-06 0.000902 0.54 0.38 Autism spectrum disorder or schizophrenia; chr6:28390189 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs1361385 ENSG00000204709.4 LINC01556 5.05 1.26e-06 0.000902 0.54 0.38 Autism spectrum disorder or schizophrenia; chr6:28390543 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs1416918 ENSG00000204709.4 LINC01556 5.05 1.26e-06 0.000902 0.54 0.38 Autism spectrum disorder or schizophrenia; chr6:28390558 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs9468367 ENSG00000204709.4 LINC01556 5.05 1.26e-06 0.000902 0.54 0.38 Autism spectrum disorder or schizophrenia; chr6:28392469 chr6:28943877~28944537:+ PAAD cis rs6504950 1 rs7222197 ENSG00000275710.1 RP11-257O5.4 -5.05 1.26e-06 0.000902 -0.48 -0.38 Breast cancer; chr17:54970138 chr17:54964474~54964679:+ PAAD cis rs4218 0.635 rs10431792 ENSG00000277144.1 RP11-59H7.4 -5.05 1.26e-06 0.000902 -0.5 -0.38 Social communication problems; chr15:59066181 chr15:59115547~59116089:- PAAD cis rs10129255 0.517 rs11625572 ENSG00000223648.3 IGHV3-64 5.05 1.26e-06 0.000903 0.42 0.38 Kawasaki disease; chr14:106656426 chr14:106643132~106658258:- PAAD cis rs9532669 0.963 rs3736953 ENSG00000176268.5 CYCSP34 5.05 1.26e-06 0.000904 0.35 0.38 Cervical cancer; chr13:40951450 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7322399 ENSG00000176268.5 CYCSP34 5.05 1.26e-06 0.000904 0.35 0.38 Cervical cancer; chr13:40952511 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs7322097 ENSG00000176268.5 CYCSP34 5.05 1.26e-06 0.000904 0.35 0.38 Cervical cancer; chr13:40952513 chr13:40863599~40863902:- PAAD cis rs733592 0.507 rs10875739 ENSG00000240399.1 RP1-228P16.1 5.05 1.26e-06 0.000904 0.36 0.38 Plateletcrit; chr12:48087136 chr12:48054813~48055591:- PAAD cis rs6921919 0.583 rs2041230 ENSG00000204709.4 LINC01556 5.05 1.26e-06 0.000905 0.53 0.38 Autism spectrum disorder or schizophrenia; chr6:28397738 chr6:28943877~28944537:+ PAAD cis rs7772486 0.686 rs9386131 ENSG00000235652.6 RP11-545I5.3 5.05 1.27e-06 0.000906 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145800472 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs7739735 ENSG00000235652.6 RP11-545I5.3 5.05 1.27e-06 0.000906 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145802400 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs7744014 ENSG00000235652.6 RP11-545I5.3 5.05 1.27e-06 0.000906 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145802682 chr6:145799409~145886585:+ PAAD cis rs7772486 0.623 rs9485021 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145747661 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs1569540 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145747976 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs2142983 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145748565 chr6:145799409~145886585:+ PAAD cis rs7772486 0.654 rs6928007 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145753805 chr6:145799409~145886585:+ PAAD cis rs7772486 0.654 rs1011597 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145754536 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9399564 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145757771 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs6933161 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145760233 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9399565 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145760770 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs2328708 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145774603 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9403746 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145782632 chr6:145799409~145886585:+ PAAD cis rs7772486 0.625 rs9390355 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145791806 chr6:145799409~145886585:+ PAAD cis rs7772486 0.658 rs4895683 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145792518 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs4895684 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145792887 chr6:145799409~145886585:+ PAAD cis rs7772486 0.625 rs2050027 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000906 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145794977 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2814876 ENSG00000235652.6 RP11-545I5.3 5.05 1.27e-06 0.000906 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145982894 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2814875 ENSG00000235652.6 RP11-545I5.3 5.05 1.27e-06 0.000906 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145984674 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs2814874 ENSG00000235652.6 RP11-545I5.3 5.05 1.27e-06 0.000906 0.32 0.38 Lobe attachment (rater-scored or self-reported); chr6:145984759 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs9390349 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000908 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145733294 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs2072911 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000908 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145735665 chr6:145799409~145886585:+ PAAD cis rs7772486 0.686 rs1337841 ENSG00000235652.6 RP11-545I5.3 -5.05 1.27e-06 0.000908 -0.31 -0.38 Lobe attachment (rater-scored or self-reported); chr6:145738351 chr6:145799409~145886585:+ PAAD cis rs7829975 0.626 rs332040 ENSG00000253893.2 FAM85B -5.05 1.27e-06 0.000908 -0.53 -0.38 Mood instability; chr8:8872978 chr8:8167819~8226614:- PAAD cis rs4835473 0.897 rs4835095 ENSG00000251600.4 RP11-673E1.1 5.05 1.27e-06 0.000908 0.44 0.38 Immature fraction of reticulocytes; chr4:143960431 chr4:143912331~143982454:+ PAAD cis rs4835473 0.831 rs2667353 ENSG00000251600.4 RP11-673E1.1 5.05 1.27e-06 0.000908 0.44 0.38 Immature fraction of reticulocytes; chr4:143960462 chr4:143912331~143982454:+ PAAD cis rs2739330 0.76 rs1007888 ENSG00000206090.4 AP000350.7 5.05 1.27e-06 0.000909 0.46 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23939998~23942798:+ PAAD cis rs9473147 0.543 rs9369693 ENSG00000270761.1 RP11-385F7.1 -5.05 1.27e-06 0.000909 -0.38 -0.38 Platelet distribution width;Mean platelet volume; chr6:47466015 chr6:47477243~47477572:- PAAD cis rs189798 0.807 rs12785 ENSG00000254340.1 RP11-10A14.3 5.05 1.27e-06 0.000909 0.51 0.38 Myopia (pathological); chr8:9137426 chr8:9141424~9145435:+ PAAD cis rs189798 0.807 rs330909 ENSG00000254340.1 RP11-10A14.3 5.05 1.27e-06 0.000909 0.51 0.38 Myopia (pathological); chr8:9137877 chr8:9141424~9145435:+ PAAD cis rs2283792 1 rs6928 ENSG00000228050.1 TOP3BP1 5.05 1.28e-06 0.000911 0.4 0.38 Multiple sclerosis; chr22:21760715 chr22:22223187~22224566:- PAAD cis rs9287719 0.753 rs1990613 ENSG00000234818.1 AC092687.5 -5.05 1.28e-06 0.000911 -0.41 -0.38 Prostate cancer; chr2:10641849 chr2:10589166~10604830:+ PAAD cis rs160451 1 rs160441 ENSG00000251136.7 RP11-37B2.1 5.05 1.28e-06 0.000911 0.35 0.38 Leprosy; chr8:89644760 chr8:89609409~89757727:- PAAD cis rs160451 1 rs160448 ENSG00000251136.7 RP11-37B2.1 5.05 1.28e-06 0.000911 0.35 0.38 Leprosy; chr8:89647622 chr8:89609409~89757727:- PAAD cis rs160451 0.966 rs160450 ENSG00000251136.7 RP11-37B2.1 5.05 1.28e-06 0.000911 0.35 0.38 Leprosy; chr8:89650354 chr8:89609409~89757727:- PAAD cis rs160451 1 rs160451 ENSG00000251136.7 RP11-37B2.1 5.05 1.28e-06 0.000911 0.35 0.38 Leprosy; chr8:89650713 chr8:89609409~89757727:- PAAD cis rs160451 0.966 rs218886 ENSG00000251136.7 RP11-37B2.1 -5.05 1.28e-06 0.000911 -0.35 -0.38 Leprosy; chr8:89678365 chr8:89609409~89757727:- PAAD cis rs160451 0.933 rs218888 ENSG00000251136.7 RP11-37B2.1 -5.05 1.28e-06 0.000911 -0.35 -0.38 Leprosy; chr8:89679693 chr8:89609409~89757727:- PAAD cis rs160451 0.933 rs218889 ENSG00000251136.7 RP11-37B2.1 -5.05 1.28e-06 0.000911 -0.35 -0.38 Leprosy; chr8:89679935 chr8:89609409~89757727:- PAAD cis rs17772222 0.696 rs28666030 ENSG00000258983.2 RP11-507K2.2 5.05 1.28e-06 0.000911 0.5 0.38 Coronary artery calcification; chr14:88511463 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs28493481 ENSG00000258983.2 RP11-507K2.2 5.05 1.28e-06 0.000911 0.5 0.38 Coronary artery calcification; chr14:88511491 chr14:88499334~88515502:+ PAAD cis rs2015599 0.623 rs3782505 ENSG00000257176.2 RP11-996F15.2 5.05 1.28e-06 0.000912 0.38 0.38 Platelet count;Mean platelet volume; chr12:29292236 chr12:29280418~29317848:- PAAD cis rs2015599 0.549 rs7134796 ENSG00000257176.2 RP11-996F15.2 5.05 1.28e-06 0.000912 0.38 0.38 Platelet count;Mean platelet volume; chr12:29294361 chr12:29280418~29317848:- PAAD cis rs72772090 0.908 rs17086588 ENSG00000248734.2 CTD-2260A17.1 5.05 1.28e-06 0.000912 0.45 0.38 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr5:96709210 chr5:96784777~96785999:+ PAAD cis rs11673344 0.764 rs10424584 ENSG00000226686.6 LINC01535 5.04 1.28e-06 0.000913 0.51 0.38 Obesity-related traits; chr19:36975986 chr19:37251912~37265535:+ PAAD cis rs1823913 0.599 rs13020656 ENSG00000280083.1 RP11-317J9.1 -5.04 1.28e-06 0.000913 -0.46 -0.38 Obesity-related traits; chr2:191314197 chr2:191154118~191156070:- PAAD cis rs6142102 0.517 rs6059580 ENSG00000276073.1 RP5-1125A11.7 -5.04 1.28e-06 0.000913 -0.41 -0.38 Skin pigmentation; chr20:33940067 chr20:33985617~33988989:- PAAD cis rs1823913 0.599 rs67781530 ENSG00000280083.1 RP11-317J9.1 -5.04 1.28e-06 0.000914 -0.45 -0.38 Obesity-related traits; chr2:191295608 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs67342262 ENSG00000280083.1 RP11-317J9.1 -5.04 1.28e-06 0.000914 -0.45 -0.38 Obesity-related traits; chr2:191295612 chr2:191154118~191156070:- PAAD cis rs2302464 1 rs6835705 ENSG00000214846.4 RP11-115L11.1 -5.04 1.28e-06 0.000914 -0.97 -0.38 Cerebrospinal fluid biomarker levels; chr4:15736747 chr4:15730962~15731627:- PAAD cis rs4813802 0.764 rs990929 ENSG00000278192.1 RP5-1056H1.2 -5.04 1.28e-06 0.000915 -0.4 -0.38 Colorectal cancer; chr20:6712943 chr20:6065966~6067897:- PAAD cis rs6570726 0.846 rs426874 ENSG00000235652.6 RP11-545I5.3 5.04 1.28e-06 0.000917 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145559494 chr6:145799409~145886585:+ PAAD cis rs1075265 0.692 rs805361 ENSG00000233266.1 HMGB1P31 5.04 1.29e-06 0.000917 0.47 0.38 Chronotype;Morning vs. evening chronotype; chr2:53938709 chr2:54051334~54051760:+ PAAD cis rs17711722 0.528 rs73138179 ENSG00000236529.1 RP13-254B10.1 5.04 1.29e-06 0.000918 0.43 0.38 Calcium levels; chr7:65829495 chr7:65840212~65840596:+ PAAD cis rs2712381 0.797 rs62270806 ENSG00000242551.2 POU5F1P6 -5.04 1.29e-06 0.000919 -0.46 -0.38 Monocyte count; chr3:128657426 chr3:128674735~128677005:- PAAD cis rs6504622 0.875 rs28553405 ENSG00000262879.4 RP11-156P1.3 5.04 1.29e-06 0.000919 0.39 0.38 Orofacial clefts; chr17:46968529 chr17:46984045~47100323:- PAAD cis rs8040855 0.52 rs11629963 ENSG00000259295.5 CSPG4P12 -5.04 1.29e-06 0.000921 -0.49 -0.38 Bulimia nervosa; chr15:84986808 chr15:85191438~85213905:+ PAAD cis rs12468226 0.938 rs114177656 ENSG00000273456.1 RP11-686O6.2 5.04 1.29e-06 0.000922 0.57 0.38 Urate levels; chr2:202291596 chr2:202374932~202375604:- PAAD cis rs8031584 0.958 rs7168641 ENSG00000260382.1 RP11-540B6.2 5.04 1.29e-06 0.000922 0.48 0.38 Huntington's disease progression; chr15:30943249 chr15:30882267~30883231:- PAAD cis rs12908161 0.92 rs35758837 ENSG00000225151.9 GOLGA2P7 -5.04 1.29e-06 0.000922 -0.47 -0.38 Schizophrenia; chr15:84768151 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs36033486 ENSG00000225151.9 GOLGA2P7 -5.04 1.29e-06 0.000922 -0.47 -0.38 Schizophrenia; chr15:84776461 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs12908549 ENSG00000225151.9 GOLGA2P7 -5.04 1.29e-06 0.000922 -0.47 -0.38 Schizophrenia; chr15:84779120 chr15:84199311~84230136:- PAAD cis rs17507216 1 rs17158413 ENSG00000255769.6 GOLGA2P10 -5.04 1.29e-06 0.000922 -0.49 -0.38 Excessive daytime sleepiness; chr15:82566658 chr15:82472993~82513950:- PAAD cis rs10875746 0.551 rs1471998 ENSG00000240399.1 RP1-228P16.1 -5.04 1.3e-06 0.000924 -0.4 -0.38 Longevity (90 years and older); chr12:48318219 chr12:48054813~48055591:- PAAD cis rs10875746 0.551 rs2054904 ENSG00000240399.1 RP1-228P16.1 -5.04 1.3e-06 0.000924 -0.4 -0.38 Longevity (90 years and older); chr12:48330571 chr12:48054813~48055591:- PAAD cis rs10875746 0.551 rs2054903 ENSG00000240399.1 RP1-228P16.1 -5.04 1.3e-06 0.000924 -0.4 -0.38 Longevity (90 years and older); chr12:48330710 chr12:48054813~48055591:- PAAD cis rs10853057 0.541 rs77675516 ENSG00000214174.7 AMZ2P1 5.04 1.3e-06 0.000924 0.61 0.38 White matter microstructure (global fractional anisotropy); chr17:65050690 chr17:64966550~64975576:- PAAD cis rs160451 1 rs160449 ENSG00000251136.7 RP11-37B2.1 5.04 1.3e-06 0.000924 0.35 0.38 Leprosy; chr8:89648287 chr8:89609409~89757727:- PAAD cis rs160451 1 rs160446 ENSG00000251136.7 RP11-37B2.1 5.04 1.3e-06 0.000925 0.35 0.38 Leprosy; chr8:89647035 chr8:89609409~89757727:- PAAD cis rs1075265 0.584 rs10164409 ENSG00000233266.1 HMGB1P31 5.04 1.3e-06 0.000925 0.48 0.38 Chronotype;Morning vs. evening chronotype; chr2:53940867 chr2:54051334~54051760:+ PAAD cis rs11673344 0.832 rs8104296 ENSG00000226686.6 LINC01535 5.04 1.3e-06 0.000926 0.52 0.38 Obesity-related traits; chr19:37025634 chr19:37251912~37265535:+ PAAD cis rs9473147 0.516 rs1931833 ENSG00000270761.1 RP11-385F7.1 -5.04 1.3e-06 0.000926 -0.38 -0.38 Platelet distribution width;Mean platelet volume; chr6:47459545 chr6:47477243~47477572:- PAAD cis rs875971 0.545 rs10261710 ENSG00000226824.5 RP4-756H11.3 -5.04 1.3e-06 0.000926 -0.53 -0.38 Aortic root size; chr7:66249202 chr7:66654538~66669855:+ PAAD cis rs9532669 0.926 rs9562254 ENSG00000176268.5 CYCSP34 -5.04 1.3e-06 0.000926 -0.36 -0.38 Cervical cancer; chr13:40960902 chr13:40863599~40863902:- PAAD cis rs17711722 0.565 rs4717276 ENSG00000164669.11 INTS4P1 -5.04 1.3e-06 0.000927 -0.46 -0.38 Calcium levels; chr7:65829754 chr7:65141225~65234216:+ PAAD cis rs72843506 0.722 rs3764436 ENSG00000189423.10 USP32P3 5.04 1.3e-06 0.000928 0.6 0.38 Schizophrenia; chr17:20110489 chr17:20415547~20431008:+ PAAD cis rs748404 0.578 rs1058298 ENSG00000249839.1 AC011330.5 -5.04 1.31e-06 0.000934 -0.53 -0.38 Lung cancer; chr15:43408732 chr15:43663654~43684339:- PAAD cis rs73219805 0.759 rs3758098 ENSG00000228451.3 SDAD1P1 -5.04 1.31e-06 0.000934 -0.67 -0.38 Schizophrenia; chr8:26381867 chr8:26379259~26382953:- PAAD cis rs6921919 0.638 rs7772827 ENSG00000216901.1 AL022393.7 5.04 1.31e-06 0.000936 0.51 0.38 Autism spectrum disorder or schizophrenia; chr6:28333366 chr6:28176188~28176674:+ PAAD cis rs9828933 0.882 rs3816156 ENSG00000280620.1 SCAANT1 5.04 1.32e-06 0.000936 0.58 0.38 Type 2 diabetes; chr3:64014036 chr3:63911518~63911772:- PAAD cis rs11098499 0.644 rs34835603 ENSG00000245958.5 RP11-33B1.1 -5.04 1.32e-06 0.000936 -0.31 -0.38 Corneal astigmatism; chr4:119632273 chr4:119454791~119552025:+ PAAD cis rs11098499 0.615 rs28850368 ENSG00000245958.5 RP11-33B1.1 -5.04 1.32e-06 0.000936 -0.31 -0.38 Corneal astigmatism; chr4:119633158 chr4:119454791~119552025:+ PAAD cis rs8062405 0.558 rs231976 ENSG00000259982.1 CDC37P1 5.04 1.32e-06 0.000936 0.4 0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534266 chr16:28700294~28701540:- PAAD cis rs9309711 0.643 rs10188449 ENSG00000225234.1 TRAPPC12-AS1 -5.04 1.32e-06 0.000937 -0.39 -0.38 Neurofibrillary tangles; chr2:3476595 chr2:3481242~3482409:- PAAD cis rs964611 0.816 rs3784615 ENSG00000259488.2 RP11-154J22.1 -5.04 1.32e-06 0.000939 -0.42 -0.38 Metabolite levels (Pyroglutamine); chr15:48248002 chr15:48312353~48331856:- PAAD cis rs964611 0.816 rs8030205 ENSG00000259488.2 RP11-154J22.1 -5.04 1.32e-06 0.000939 -0.42 -0.38 Metabolite levels (Pyroglutamine); chr15:48248739 chr15:48312353~48331856:- PAAD cis rs964611 0.816 rs12438598 ENSG00000259488.2 RP11-154J22.1 -5.04 1.32e-06 0.000939 -0.42 -0.38 Metabolite levels (Pyroglutamine); chr15:48248812 chr15:48312353~48331856:- PAAD cis rs964611 0.816 rs8034192 ENSG00000259488.2 RP11-154J22.1 -5.04 1.32e-06 0.000939 -0.42 -0.38 Metabolite levels (Pyroglutamine); chr15:48249197 chr15:48312353~48331856:- PAAD cis rs3931020 0.657 rs277376 ENSG00000272864.1 RP11-17E13.2 5.04 1.32e-06 0.000939 0.53 0.38 Resistin levels; chr1:74776562 chr1:74698769~74699333:- PAAD cis rs2739330 0.892 rs5751776 ENSG00000206090.4 AP000350.7 5.04 1.32e-06 0.00094 0.48 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924767 chr22:23939998~23942798:+ PAAD cis rs2153535 0.58 rs7747306 ENSG00000230939.1 RP11-314C16.1 5.04 1.32e-06 0.00094 0.4 0.38 Motion sickness; chr6:8453430 chr6:8784178~8785445:+ PAAD cis rs17711722 0.565 rs4275112 ENSG00000164669.11 INTS4P1 5.04 1.32e-06 0.000942 0.46 0.38 Calcium levels; chr7:65733651 chr7:65141225~65234216:+ PAAD cis rs8059260 0.668 rs76212701 ENSG00000274038.1 RP11-66H6.4 -5.04 1.33e-06 0.000943 -0.62 -0.38 Alcohol consumption over the past year; chr16:11023634 chr16:11056556~11057034:+ PAAD cis rs2739330 0.929 rs5751775 ENSG00000206090.4 AP000350.7 5.04 1.33e-06 0.000944 0.48 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924539 chr22:23939998~23942798:+ PAAD cis rs4268898 0.722 rs2288072 ENSG00000242628.4 AC009228.1 -5.04 1.33e-06 0.000944 -0.43 -0.38 Asthma; chr2:24167648 chr2:24214381~24221516:+ PAAD cis rs4268898 0.722 rs6723257 ENSG00000242628.4 AC009228.1 -5.04 1.33e-06 0.000944 -0.43 -0.38 Asthma; chr2:24168260 chr2:24214381~24221516:+ PAAD cis rs2117029 0.767 rs11614738 ENSG00000258017.1 RP11-386G11.10 -5.04 1.33e-06 0.000944 -0.5 -0.38 Intelligence (multi-trait analysis); chr12:49030833 chr12:49127782~49147869:+ PAAD cis rs494459 0.838 rs2510897 ENSG00000255422.1 AP002954.4 -5.04 1.33e-06 0.000944 -0.42 -0.38 Height; chr11:118773873 chr11:118704607~118750263:+ PAAD cis rs2564921 0.73 rs60579898 ENSG00000242142.1 SERBP1P3 -5.04 1.33e-06 0.000944 -0.47 -0.38 Height; chr3:53069965 chr3:53064283~53065091:- PAAD cis rs2115630 0.967 rs10438428 ENSG00000259728.4 LINC00933 -5.04 1.33e-06 0.000946 -0.45 -0.38 P wave terminal force; chr15:84787514 chr15:84570649~84580175:+ PAAD cis rs12682352 0.652 rs1567398 ENSG00000253893.2 FAM85B 5.04 1.33e-06 0.000947 0.49 0.38 Neuroticism; chr8:8869294 chr8:8167819~8226614:- PAAD cis rs10853057 0.541 rs8076716 ENSG00000214174.7 AMZ2P1 5.04 1.33e-06 0.000947 0.61 0.38 White matter microstructure (global fractional anisotropy); chr17:65051891 chr17:64966550~64975576:- PAAD cis rs763567 1 rs1928715 ENSG00000271811.1 RP1-79C4.4 -5.04 1.33e-06 0.000947 -0.36 -0.38 Tonsillectomy; chr1:170598296 chr1:170667381~170669425:+ PAAD cis rs2412819 0.571 rs4923964 ENSG00000205771.5 CATSPER2P1 5.03 1.34e-06 0.00095 0.59 0.38 Lung cancer; chr15:43722882 chr15:43726918~43747094:- PAAD cis rs950169 0.512 rs4374136 ENSG00000225151.9 GOLGA2P7 -5.03 1.34e-06 0.000953 -0.48 -0.38 Schizophrenia; chr15:83976255 chr15:84199311~84230136:- PAAD cis rs13178541 0.81 rs4976465 ENSG00000250378.1 RP11-119J18.1 -5.03 1.34e-06 0.000954 -0.58 -0.38 IgG glycosylation; chr5:135815226 chr5:135812667~135826582:+ PAAD cis rs7829975 0.66 rs10093926 ENSG00000253893.2 FAM85B 5.03 1.34e-06 0.000955 0.54 0.38 Mood instability; chr8:8691510 chr8:8167819~8226614:- PAAD cis rs4423214 0.65 rs7940244 ENSG00000254682.1 RP11-660L16.2 -5.03 1.34e-06 0.000955 -0.56 -0.38 Vitamin D levels; chr11:71510528 chr11:71448674~71452157:+ PAAD cis rs10483853 0.525 rs2302041 ENSG00000258695.2 RP3-414A15.2 -5.03 1.35e-06 0.000957 -0.58 -0.38 Coronary artery calcification; chr14:73494166 chr14:73522878~73530610:+ PAAD cis rs1075265 0.722 rs2111623 ENSG00000233266.1 HMGB1P31 -5.03 1.35e-06 0.000958 -0.48 -0.38 Chronotype;Morning vs. evening chronotype; chr2:53757820 chr2:54051334~54051760:+ PAAD cis rs73086581 0.524 rs2253977 ENSG00000229539.1 RP11-119B16.2 -5.03 1.35e-06 0.000959 -0.47 -0.38 Response to antidepressants in depression; chr20:3958493 chr20:3888239~3888868:- PAAD cis rs7208859 0.673 rs216410 ENSG00000266490.1 CTD-2349P21.9 -5.03 1.35e-06 0.00096 -0.44 -0.38 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576813 chr17:30792372~30792833:+ PAAD cis rs1930961 1 rs6004657 ENSG00000100058.11 CRYBB2P1 5.03 1.35e-06 0.000961 0.69 0.38 Bipolar disorder with mood-incongruent psychosis; chr22:25459747 chr22:25448105~25520854:+ PAAD cis rs73086581 0.568 rs6084541 ENSG00000229539.1 RP11-119B16.2 -5.03 1.35e-06 0.000961 -0.48 -0.38 Response to antidepressants in depression; chr20:3982084 chr20:3888239~3888868:- PAAD cis rs2404602 0.735 rs437131 ENSG00000259422.1 RP11-593F23.1 5.03 1.35e-06 0.000961 0.46 0.38 Blood metabolite levels; chr15:76488710 chr15:76174891~76181486:- PAAD cis rs633715 0.588 rs8030 ENSG00000254154.7 RP4-798P15.3 -5.03 1.35e-06 0.000962 -0.29 -0.38 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177928840 chr1:177928788~178038007:- PAAD cis rs3931020 0.616 rs277381 ENSG00000272864.1 RP11-17E13.2 5.03 1.36e-06 0.000962 0.53 0.38 Resistin levels; chr1:74801131 chr1:74698769~74699333:- PAAD cis rs8031584 0.958 rs1043742 ENSG00000260382.1 RP11-540B6.2 5.03 1.36e-06 0.000963 0.48 0.38 Huntington's disease progression; chr15:30940378 chr15:30882267~30883231:- PAAD cis rs8031584 0.958 rs11293 ENSG00000260382.1 RP11-540B6.2 5.03 1.36e-06 0.000963 0.48 0.38 Huntington's disease progression; chr15:30942778 chr15:30882267~30883231:- PAAD cis rs8031584 0.958 rs3512 ENSG00000260382.1 RP11-540B6.2 5.03 1.36e-06 0.000963 0.48 0.38 Huntington's disease progression; chr15:30942802 chr15:30882267~30883231:- PAAD cis rs763567 0.845 rs492804 ENSG00000271811.1 RP1-79C4.4 5.03 1.36e-06 0.000965 0.36 0.38 Tonsillectomy; chr1:170643121 chr1:170667381~170669425:+ PAAD cis rs763567 0.967 rs654461 ENSG00000271811.1 RP1-79C4.4 5.03 1.36e-06 0.000965 0.36 0.38 Tonsillectomy; chr1:170644709 chr1:170667381~170669425:+ PAAD cis rs763567 0.933 rs567328 ENSG00000271811.1 RP1-79C4.4 5.03 1.36e-06 0.000965 0.36 0.38 Tonsillectomy; chr1:170644728 chr1:170667381~170669425:+ PAAD cis rs763567 0.904 rs544478 ENSG00000271811.1 RP1-79C4.4 5.03 1.36e-06 0.000965 0.36 0.38 Tonsillectomy; chr1:170644901 chr1:170667381~170669425:+ PAAD cis rs763567 0.967 rs593560 ENSG00000271811.1 RP1-79C4.4 5.03 1.36e-06 0.000965 0.36 0.38 Tonsillectomy; chr1:170646776 chr1:170667381~170669425:+ PAAD cis rs853679 1 rs1679709 ENSG00000226314.6 ZNF192P1 5.03 1.36e-06 0.000966 0.68 0.38 Depression; chr6:28260564 chr6:28161781~28169594:+ PAAD cis rs853679 1 rs1778511 ENSG00000226314.6 ZNF192P1 5.03 1.36e-06 0.000966 0.68 0.38 Depression; chr6:28261633 chr6:28161781~28169594:+ PAAD cis rs9595908 0.865 rs499966 ENSG00000212293.1 SNORA16 -5.03 1.36e-06 0.000968 -0.43 -0.38 Body mass index; chr13:32424473 chr13:32420390~32420516:- PAAD cis rs4664293 0.867 rs13432 ENSG00000226266.5 AC009961.3 -5.03 1.37e-06 0.000969 -0.46 -0.38 Monocyte percentage of white cells; chr2:159769216 chr2:159670708~159712435:- PAAD cis rs11673344 0.864 rs8108727 ENSG00000226686.6 LINC01535 5.03 1.37e-06 0.000971 0.52 0.38 Obesity-related traits; chr19:37090622 chr19:37251912~37265535:+ PAAD cis rs8062405 1 rs7187776 ENSG00000251417.2 RP11-1348G14.4 -5.03 1.37e-06 0.000972 -0.33 -0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28846324 chr16:28802743~28817828:+ PAAD cis rs6504622 0.818 rs9910899 ENSG00000262879.4 RP11-156P1.3 5.03 1.37e-06 0.000973 0.42 0.38 Orofacial clefts; chr17:46956976 chr17:46984045~47100323:- PAAD cis rs6504622 0.818 rs9912794 ENSG00000262879.4 RP11-156P1.3 5.03 1.37e-06 0.000973 0.42 0.38 Orofacial clefts; chr17:46957075 chr17:46984045~47100323:- PAAD cis rs6504622 0.818 rs9898527 ENSG00000262879.4 RP11-156P1.3 5.03 1.37e-06 0.000973 0.42 0.38 Orofacial clefts; chr17:46958844 chr17:46984045~47100323:- PAAD cis rs6504622 0.791 rs61671555 ENSG00000262879.4 RP11-156P1.3 5.03 1.37e-06 0.000973 0.42 0.38 Orofacial clefts; chr17:46960491 chr17:46984045~47100323:- PAAD cis rs6504622 0.818 rs9303532 ENSG00000262879.4 RP11-156P1.3 -5.03 1.37e-06 0.000973 -0.42 -0.38 Orofacial clefts; chr17:46956636 chr17:46984045~47100323:- PAAD cis rs3858145 0.588 rs116428218 ENSG00000233590.1 RP11-153K11.3 -5.03 1.37e-06 0.000974 -0.56 -0.38 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68282614 chr10:68233251~68242379:- PAAD cis rs2404602 0.735 rs283789 ENSG00000259422.1 RP11-593F23.1 5.03 1.38e-06 0.000975 0.46 0.38 Blood metabolite levels; chr15:76485236 chr15:76174891~76181486:- PAAD cis rs1185460 1 rs4614 ENSG00000271751.1 RP11-110I1.14 -5.03 1.38e-06 0.000975 -0.48 -0.38 Coronary artery disease; chr11:119081661 chr11:119065263~119065677:- PAAD cis rs4927850 1 rs4927704 ENSG00000231464.1 AC024937.4 5.03 1.38e-06 0.000976 0.44 0.38 Pancreatic cancer; chr3:196011357 chr3:195996738~195998233:+ PAAD cis rs4927850 1 rs4927848 ENSG00000231464.1 AC024937.4 5.03 1.38e-06 0.000976 0.44 0.38 Pancreatic cancer; chr3:196011535 chr3:195996738~195998233:+ PAAD cis rs1322639 0.657 rs12203887 ENSG00000261039.2 RP11-417E7.2 -5.03 1.38e-06 0.000976 -0.61 -0.38 Pulse pressure; chr6:169172157 chr6:169175304~169182740:- PAAD cis rs9928842 0.823 rs889514 ENSG00000280152.1 RP11-331F4.5 5.03 1.38e-06 0.000977 0.47 0.38 Alcoholic chronic pancreatitis; chr16:75238614 chr16:75245994~75250077:- PAAD cis rs6504622 0.875 rs3851786 ENSG00000262879.4 RP11-156P1.3 5.03 1.38e-06 0.000977 0.39 0.38 Orofacial clefts; chr17:46969566 chr17:46984045~47100323:- PAAD cis rs6504622 0.905 rs3851787 ENSG00000262879.4 RP11-156P1.3 5.03 1.38e-06 0.000977 0.39 0.38 Orofacial clefts; chr17:46969616 chr17:46984045~47100323:- PAAD cis rs7945705 0.967 rs7943377 ENSG00000254860.4 TMEM9B-AS1 -5.03 1.38e-06 0.000977 -0.43 -0.38 Hemoglobin concentration; chr11:8827153 chr11:8964675~8977527:+ PAAD cis rs9637599 0.967 rs7656367 ENSG00000246375.2 RP11-10L7.1 5.03 1.38e-06 0.000977 0.45 0.38 Metabolite levels (small molecules and protein measures); chr4:88275669 chr4:88284942~88331421:+ PAAD cis rs1545257 0.537 rs11125582 ENSG00000242628.4 AC009228.1 5.03 1.38e-06 0.000979 0.44 0.38 Sjögren's syndrome; chr2:24423344 chr2:24214381~24221516:+ PAAD cis rs1545257 0.537 rs11125583 ENSG00000242628.4 AC009228.1 5.03 1.38e-06 0.000979 0.44 0.38 Sjögren's syndrome; chr2:24423409 chr2:24214381~24221516:+ PAAD cis rs6496932 0.563 rs2344083 ENSG00000259295.5 CSPG4P12 -5.03 1.38e-06 0.000979 -0.4 -0.38 Central corneal thickness;Corneal structure; chr15:85354201 chr15:85191438~85213905:+ PAAD cis rs308403 0.509 rs309357 ENSG00000224786.1 CETN4P 5.03 1.38e-06 0.00098 0.46 0.38 Blood protein levels; chr4:122732421 chr4:122730548~122732193:- PAAD cis rs308403 0.509 rs309379 ENSG00000224786.1 CETN4P 5.03 1.38e-06 0.00098 0.46 0.38 Blood protein levels; chr4:122750301 chr4:122730548~122732193:- PAAD cis rs308403 0.533 rs309377 ENSG00000224786.1 CETN4P 5.03 1.38e-06 0.00098 0.46 0.38 Blood protein levels; chr4:122755198 chr4:122730548~122732193:- PAAD cis rs12817211 0.502 rs1554844 ENSG00000272368.2 RP4-605O3.4 -5.03 1.38e-06 0.00098 -0.36 -0.38 Colorectal or endometrial cancer; chr12:50120582 chr12:50112197~50165618:+ PAAD cis rs4879677 1 rs10435785 ENSG00000260390.1 RP11-575I8.1 -5.03 1.38e-06 0.00098 -0.46 -0.38 Gut microbiome composition (summer and winter); chr9:27683815 chr9:27829276~27844481:+ PAAD cis rs2153535 0.58 rs6597318 ENSG00000230939.1 RP11-314C16.1 -5.03 1.39e-06 0.000981 -0.4 -0.38 Motion sickness; chr6:8437056 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6920779 ENSG00000230939.1 RP11-314C16.1 -5.03 1.39e-06 0.000981 -0.4 -0.38 Motion sickness; chr6:8437391 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7743418 ENSG00000230939.1 RP11-314C16.1 -5.03 1.39e-06 0.000981 -0.4 -0.38 Motion sickness; chr6:8437895 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4960411 ENSG00000230939.1 RP11-314C16.1 -5.03 1.39e-06 0.000981 -0.4 -0.38 Motion sickness; chr6:8437998 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4960412 ENSG00000230939.1 RP11-314C16.1 -5.03 1.39e-06 0.000981 -0.4 -0.38 Motion sickness; chr6:8438028 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4960413 ENSG00000230939.1 RP11-314C16.1 -5.03 1.39e-06 0.000981 -0.4 -0.38 Motion sickness; chr6:8438233 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs4960414 ENSG00000230939.1 RP11-314C16.1 -5.03 1.39e-06 0.000981 -0.4 -0.38 Motion sickness; chr6:8438308 chr6:8784178~8785445:+ PAAD cis rs2337406 0.866 rs4773949 ENSG00000274576.2 IGHV2-70 5.03 1.39e-06 0.000981 0.46 0.38 Alzheimer's disease (late onset); chr14:106808070 chr14:106770577~106771020:- PAAD cis rs1185460 0.934 rs1006195 ENSG00000271751.1 RP11-110I1.14 5.03 1.39e-06 0.000982 0.49 0.38 Coronary artery disease; chr11:119088159 chr11:119065263~119065677:- PAAD cis rs35160687 0.644 rs4832271 ENSG00000273080.1 RP11-301O19.1 -5.03 1.39e-06 0.000982 -0.45 -0.38 Night sleep phenotypes; chr2:86278204 chr2:86195590~86196049:+ PAAD cis rs9322193 0.607 rs9371228 ENSG00000223701.3 RAET1E-AS1 -5.03 1.39e-06 0.000982 -0.48 -0.38 Lung cancer; chr6:149921977 chr6:149884431~149919508:+ PAAD cis rs9322193 0.566 rs4870118 ENSG00000223701.3 RAET1E-AS1 -5.03 1.39e-06 0.000982 -0.48 -0.38 Lung cancer; chr6:149923877 chr6:149884431~149919508:+ PAAD cis rs9322193 0.566 rs4869767 ENSG00000223701.3 RAET1E-AS1 -5.03 1.39e-06 0.000982 -0.48 -0.38 Lung cancer; chr6:149923974 chr6:149884431~149919508:+ PAAD cis rs9322193 0.566 rs4869768 ENSG00000223701.3 RAET1E-AS1 -5.03 1.39e-06 0.000982 -0.48 -0.38 Lung cancer; chr6:149924067 chr6:149884431~149919508:+ PAAD cis rs4266144 0.926 rs4368453 ENSG00000244515.1 KRT18P34 -5.03 1.39e-06 0.000985 -0.49 -0.38 Coronary artery disease; chr3:157134352 chr3:157162663~157163932:- PAAD cis rs4266144 1 rs12487629 ENSG00000244515.1 KRT18P34 -5.03 1.39e-06 0.000985 -0.49 -0.38 Coronary artery disease; chr3:157134416 chr3:157162663~157163932:- PAAD cis rs2280018 1 rs2280017 ENSG00000260735.1 RP11-72I8.1 5.03 1.39e-06 0.000985 0.47 0.38 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15057504 chr16:15094411~15109197:+ PAAD cis rs17123764 0.71 rs933738 ENSG00000257464.1 RP11-161H23.8 -5.03 1.39e-06 0.000986 -0.53 -0.38 Intelligence (multi-trait analysis); chr12:49549339 chr12:49442424~49442652:- PAAD cis rs4853525 0.561 rs12693589 ENSG00000235852.1 AC005540.3 5.02 1.4e-06 0.000988 0.56 0.38 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190967936 chr2:190880797~190882059:- PAAD cis rs4853525 0.62 rs6718902 ENSG00000235852.1 AC005540.3 -5.02 1.4e-06 0.000988 -0.56 -0.38 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190973478 chr2:190880797~190882059:- PAAD cis rs8091660 1 rs8091660 ENSG00000278983.1 RP11-426J5.3 5.02 1.4e-06 0.000991 0.45 0.38 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48561565 chr18:48564795~48568342:+ PAAD cis rs9987353 0.522 rs2929466 ENSG00000253893.2 FAM85B 5.02 1.4e-06 0.000992 0.51 0.38 Recombination measurement; chr8:9206389 chr8:8167819~8226614:- PAAD cis rs2274273 0.588 rs2297816 ENSG00000258413.1 RP11-665C16.6 -5.02 1.4e-06 0.000992 -0.51 -0.38 Protein biomarker; chr14:55366320 chr14:55262767~55272075:- PAAD cis rs1823913 0.599 rs13035132 ENSG00000280083.1 RP11-317J9.1 -5.02 1.41e-06 0.000995 -0.44 -0.38 Obesity-related traits; chr2:191265275 chr2:191154118~191156070:- PAAD cis rs2153535 0.58 rs1832101 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8459944 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1119690 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8460427 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1119689 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8460521 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1119688 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8460617 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597325 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8460820 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6918391 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8460945 chr6:8784178~8785445:+ PAAD cis rs2153535 0.521 rs6939827 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8461127 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs6923558 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8461234 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9379210 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8461695 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9393019 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8461858 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1577470 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8462193 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1414342 ENSG00000230939.1 RP11-314C16.1 -5.02 1.41e-06 0.000997 -0.4 -0.38 Motion sickness; chr6:8462319 chr6:8784178~8785445:+ PAAD cis rs308403 0.532 rs309386 ENSG00000224786.1 CETN4P 5.02 1.41e-06 0.000997 0.46 0.38 Blood protein levels; chr4:122744836 chr4:122730548~122732193:- PAAD cis rs308403 0.509 rs309382 ENSG00000224786.1 CETN4P 5.02 1.41e-06 0.000997 0.46 0.38 Blood protein levels; chr4:122748617 chr4:122730548~122732193:- PAAD cis rs2274273 0.87 rs1952087 ENSG00000258413.1 RP11-665C16.6 -5.02 1.41e-06 0.000999 -0.47 -0.38 Protein biomarker; chr14:55216493 chr14:55262767~55272075:- PAAD cis rs35160687 0.644 rs28488524 ENSG00000273080.1 RP11-301O19.1 -5.02 1.42e-06 0.001 -0.45 -0.38 Night sleep phenotypes; chr2:86284021 chr2:86195590~86196049:+ PAAD cis rs17711722 0.522 rs4642526 ENSG00000164669.11 INTS4P1 -5.02 1.42e-06 0.001 -0.46 -0.38 Calcium levels; chr7:65751755 chr7:65141225~65234216:+ PAAD cis rs2255336 0.938 rs2255364 ENSG00000245648.1 RP11-277P12.20 5.02 1.42e-06 0.001 0.57 0.38 Blood protein levels; chr12:10379297 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs2255353 ENSG00000245648.1 RP11-277P12.20 5.02 1.42e-06 0.001 0.57 0.38 Blood protein levels; chr12:10379512 chr12:10363769~10398506:+ PAAD cis rs75422866 0.85 rs73111226 ENSG00000257433.4 RP1-197B17.3 5.02 1.42e-06 0.001 0.87 0.38 Pneumonia; chr12:47582204 chr12:47706085~47742294:+ PAAD cis rs75422866 0.702 rs12426387 ENSG00000257433.4 RP1-197B17.3 5.02 1.42e-06 0.001 0.87 0.38 Pneumonia; chr12:47582915 chr12:47706085~47742294:+ PAAD cis rs75422866 0.85 rs12423789 ENSG00000257433.4 RP1-197B17.3 5.02 1.42e-06 0.001 0.87 0.38 Pneumonia; chr12:47583112 chr12:47706085~47742294:+ PAAD cis rs75422866 0.702 rs73111229 ENSG00000257433.4 RP1-197B17.3 5.02 1.42e-06 0.001 0.87 0.38 Pneumonia; chr12:47583333 chr12:47706085~47742294:+ PAAD cis rs75422866 0.85 rs73111231 ENSG00000257433.4 RP1-197B17.3 5.02 1.42e-06 0.001 0.87 0.38 Pneumonia; chr12:47584539 chr12:47706085~47742294:+ PAAD cis rs2274273 0.901 rs8011288 ENSG00000258413.1 RP11-665C16.6 -5.02 1.42e-06 0.001 -0.46 -0.38 Protein biomarker; chr14:55268394 chr14:55262767~55272075:- PAAD cis rs2255336 0.938 rs1478310 ENSG00000245648.1 RP11-277P12.20 5.02 1.42e-06 0.001 0.57 0.38 Blood protein levels; chr12:10382279 chr12:10363769~10398506:+ PAAD cis rs755249 0.588 rs6665948 ENSG00000237624.1 OXCT2P1 -5.02 1.43e-06 0.00101 -0.47 -0.38 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39478508 chr1:39514956~39516490:+ PAAD cis rs2283792 0.765 rs8139376 ENSG00000224086.5 LL22NC03-86G7.1 -5.02 1.43e-06 0.00101 -0.39 -0.38 Multiple sclerosis; chr22:21755307 chr22:21938293~21977632:+ PAAD cis rs4268898 0.735 rs12469585 ENSG00000242628.4 AC009228.1 -5.02 1.43e-06 0.00101 -0.45 -0.38 Asthma; chr2:24266185 chr2:24214381~24221516:+ PAAD cis rs4268898 0.76 rs11125535 ENSG00000242628.4 AC009228.1 -5.02 1.43e-06 0.00101 -0.45 -0.38 Asthma; chr2:24305245 chr2:24214381~24221516:+ PAAD cis rs11690935 0.571 rs1008151 ENSG00000228389.1 AC068039.4 -5.02 1.43e-06 0.00101 -0.43 -0.38 Schizophrenia; chr2:172047370 chr2:171773482~171775844:+ PAAD cis rs7829975 0.782 rs6990746 ENSG00000253893.2 FAM85B 5.02 1.43e-06 0.00101 0.54 0.38 Mood instability; chr8:8690301 chr8:8167819~8226614:- PAAD cis rs710913 0.717 rs11206377 ENSG00000237624.1 OXCT2P1 5.02 1.43e-06 0.00101 0.46 0.38 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39583432 chr1:39514956~39516490:+ PAAD cis rs10888838 0.567 rs3766453 ENSG00000198711.5 SSBP3-AS1 5.02 1.43e-06 0.00101 0.39 0.38 Mitochondrial DNA levels; chr1:54237196 chr1:54236440~54239063:+ PAAD cis rs35828350 1 rs35828350 ENSG00000225151.9 GOLGA2P7 -5.02 1.43e-06 0.00101 -0.47 -0.38 Autism spectrum disorder or schizophrenia; chr15:84812610 chr15:84199311~84230136:- PAAD cis rs10875746 0.551 rs3751273 ENSG00000240399.1 RP1-228P16.1 -5.02 1.43e-06 0.00101 -0.4 -0.38 Longevity (90 years and older); chr12:48345655 chr12:48054813~48055591:- PAAD cis rs7078219 0.505 rs7916751 ENSG00000257582.4 LINC01475 -5.02 1.44e-06 0.00101 -0.41 -0.38 Dental caries; chr10:99525893 chr10:99526350~99531177:- PAAD cis rs6584283 0.846 rs7917446 ENSG00000257582.4 LINC01475 -5.02 1.44e-06 0.00101 -0.41 -0.38 Ulcerative colitis; chr10:99526450 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs6584281 ENSG00000257582.4 LINC01475 -5.02 1.44e-06 0.00101 -0.41 -0.38 Dental caries; chr10:99526723 chr10:99526350~99531177:- PAAD cis rs6538678 0.818 rs7976294 ENSG00000258343.1 RP11-536G4.2 -5.02 1.44e-06 0.00101 -0.49 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95876868 chr12:95795345~95858839:- PAAD cis rs6538678 0.818 rs1036429 ENSG00000258343.1 RP11-536G4.2 -5.02 1.44e-06 0.00101 -0.49 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95877650 chr12:95795345~95858839:- PAAD cis rs989978 0.958 rs10458728 ENSG00000257582.4 LINC01475 -5.02 1.44e-06 0.00101 -0.46 -0.38 Red blood cell count; chr10:99564219 chr10:99526350~99531177:- PAAD cis rs2274273 0.624 rs7150234 ENSG00000258413.1 RP11-665C16.6 -5.02 1.44e-06 0.00101 -0.5 -0.38 Protein biomarker; chr14:55335463 chr14:55262767~55272075:- PAAD cis rs694739 0.892 rs647152 ENSG00000236935.1 AP003774.1 5.02 1.44e-06 0.00102 0.41 0.38 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64341646 chr11:64325050~64329504:- PAAD cis rs919433 0.963 rs4850787 ENSG00000231621.1 AC013264.2 5.02 1.45e-06 0.00102 0.36 0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197317026 chr2:197197991~197199273:+ PAAD cis rs3779195 0.929 rs10953259 ENSG00000272950.1 RP11-307C18.1 -5.02 1.45e-06 0.00102 -0.6 -0.38 Sex hormone-binding globulin levels; chr7:98383795 chr7:98322853~98323430:+ PAAD cis rs12468226 0.873 rs3181153 ENSG00000273456.1 RP11-686O6.2 -5.02 1.45e-06 0.00102 -0.57 -0.38 Urate levels; chr2:202205155 chr2:202374932~202375604:- PAAD cis rs12468226 0.679 rs6435133 ENSG00000273456.1 RP11-686O6.2 -5.02 1.45e-06 0.00102 -0.57 -0.38 Urate levels; chr2:202209237 chr2:202374932~202375604:- PAAD cis rs12468226 0.817 rs12693965 ENSG00000273456.1 RP11-686O6.2 -5.02 1.45e-06 0.00102 -0.57 -0.38 Urate levels; chr2:202210188 chr2:202374932~202375604:- PAAD cis rs12468226 0.873 rs3769817 ENSG00000273456.1 RP11-686O6.2 -5.02 1.45e-06 0.00102 -0.57 -0.38 Urate levels; chr2:202214584 chr2:202374932~202375604:- PAAD cis rs12468226 0.873 rs6435134 ENSG00000273456.1 RP11-686O6.2 -5.02 1.45e-06 0.00102 -0.57 -0.38 Urate levels; chr2:202214857 chr2:202374932~202375604:- PAAD cis rs12468226 0.817 rs6435135 ENSG00000273456.1 RP11-686O6.2 -5.02 1.45e-06 0.00102 -0.57 -0.38 Urate levels; chr2:202217469 chr2:202374932~202375604:- PAAD cis rs9828933 0.938 rs3816157 ENSG00000280620.1 SCAANT1 5.02 1.45e-06 0.00102 0.62 0.38 Type 2 diabetes; chr3:64013646 chr3:63911518~63911772:- PAAD cis rs2739330 0.892 rs4822455 ENSG00000206090.4 AP000350.7 5.02 1.45e-06 0.00102 0.46 0.38 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23939998~23942798:+ PAAD cis rs4813802 1 rs6085662 ENSG00000278192.1 RP5-1056H1.2 -5.02 1.45e-06 0.00102 -0.4 -0.38 Colorectal cancer; chr20:6717725 chr20:6065966~6067897:- PAAD cis rs919433 0.963 rs12693815 ENSG00000231621.1 AC013264.2 5.02 1.46e-06 0.00102 0.36 0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197303679 chr2:197197991~197199273:+ PAAD cis rs919433 0.963 rs4850428 ENSG00000231621.1 AC013264.2 5.02 1.46e-06 0.00102 0.36 0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197305048 chr2:197197991~197199273:+ PAAD cis rs919433 0.963 rs7582736 ENSG00000231621.1 AC013264.2 5.02 1.46e-06 0.00102 0.36 0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197305618 chr2:197197991~197199273:+ PAAD cis rs919433 0.927 rs7592748 ENSG00000231621.1 AC013264.2 5.02 1.46e-06 0.00102 0.36 0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197305964 chr2:197197991~197199273:+ PAAD cis rs919433 0.963 rs12618612 ENSG00000231621.1 AC013264.2 5.02 1.46e-06 0.00102 0.36 0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197306334 chr2:197197991~197199273:+ PAAD cis rs919433 0.963 rs13033821 ENSG00000231621.1 AC013264.2 5.02 1.46e-06 0.00102 0.36 0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197308812 chr2:197197991~197199273:+ PAAD cis rs858239 0.829 rs2268744 ENSG00000226816.2 AC005082.12 5.02 1.46e-06 0.00103 0.43 0.38 Cerebrospinal fluid biomarker levels; chr7:23292661 chr7:23206013~23208045:+ PAAD cis rs8059260 0.541 rs16958028 ENSG00000274038.1 RP11-66H6.4 -5.02 1.46e-06 0.00103 -0.62 -0.38 Alcohol consumption over the past year; chr16:11082811 chr16:11056556~11057034:+ PAAD cis rs270601 0.817 rs460089 ENSG00000233006.5 AC034220.3 5.01 1.46e-06 0.00103 0.34 0.38 Acylcarnitine levels; chr5:132294079 chr5:132311285~132369916:- PAAD cis rs270601 0.866 rs460271 ENSG00000233006.5 AC034220.3 5.01 1.46e-06 0.00103 0.34 0.38 Acylcarnitine levels; chr5:132294369 chr5:132311285~132369916:- PAAD cis rs8177376 1 rs7932766 ENSG00000254905.1 RP11-712L6.7 5.01 1.46e-06 0.00103 0.49 0.38 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126292967 chr11:126292922~126294254:- PAAD cis rs9652601 0.959 rs12919083 ENSG00000274038.1 RP11-66H6.4 5.01 1.47e-06 0.00103 0.42 0.38 Systemic lupus erythematosus; chr16:11095073 chr16:11056556~11057034:+ PAAD cis rs11673344 0.864 rs7256876 ENSG00000226686.6 LINC01535 5.01 1.47e-06 0.00103 0.52 0.38 Obesity-related traits; chr19:37088570 chr19:37251912~37265535:+ PAAD cis rs6504950 0.889 rs1484776 ENSG00000275710.1 RP11-257O5.4 -5.01 1.47e-06 0.00103 -0.5 -0.38 Breast cancer; chr17:55034022 chr17:54964474~54964679:+ PAAD cis rs6504950 0.889 rs2628305 ENSG00000275710.1 RP11-257O5.4 5.01 1.47e-06 0.00103 0.5 0.38 Breast cancer; chr17:55063066 chr17:54964474~54964679:+ PAAD cis rs4268898 0.697 rs6714652 ENSG00000242628.4 AC009228.1 -5.01 1.47e-06 0.00103 -0.43 -0.38 Asthma; chr2:24160189 chr2:24214381~24221516:+ PAAD cis rs2946504 0.553 rs2977078 ENSG00000251468.2 RP11-369K16.1 -5.01 1.48e-06 0.00104 -0.45 -0.38 Type 2 diabetes; chr8:12959997 chr8:12958387~12962200:+ PAAD cis rs2946504 0.506 rs9644017 ENSG00000251468.2 RP11-369K16.1 -5.01 1.48e-06 0.00104 -0.45 -0.38 Type 2 diabetes; chr8:12961375 chr8:12958387~12962200:+ PAAD cis rs950169 0.519 rs7237 ENSG00000225151.9 GOLGA2P7 -5.01 1.48e-06 0.00104 -0.47 -0.38 Schizophrenia; chr15:84643346 chr15:84199311~84230136:- PAAD cis rs732716 0.719 rs56088814 ENSG00000267769.1 CTB-50L17.9 -5.01 1.48e-06 0.00104 -0.51 -0.38 Mean corpuscular volume; chr19:4422181 chr19:4454014~4455286:+ PAAD cis rs7829975 0.871 rs7829826 ENSG00000253893.2 FAM85B 5.01 1.48e-06 0.00104 0.55 0.38 Mood instability; chr8:8720610 chr8:8167819~8226614:- PAAD cis rs7684253 0.548 rs13108002 ENSG00000269949.1 RP11-738E22.3 -5.01 1.49e-06 0.00104 -0.5 -0.38 Migraine; chr4:56852087 chr4:56960927~56961373:- PAAD cis rs6921919 0.583 rs1054372 ENSG00000216901.1 AL022393.7 5.01 1.49e-06 0.00105 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28368965 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs9468354 ENSG00000216901.1 AL022393.7 5.01 1.49e-06 0.00105 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28370024 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs7773051 ENSG00000216901.1 AL022393.7 5.01 1.49e-06 0.00105 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28372539 chr6:28176188~28176674:+ PAAD cis rs6061231 0.583 rs2427313 ENSG00000273619.1 RP5-908M14.9 -5.01 1.49e-06 0.00105 -0.34 -0.38 Colorectal cancer; chr20:62395619 chr20:62386303~62386970:- PAAD cis rs950169 0.614 rs765524 ENSG00000259728.4 LINC00933 5.01 1.49e-06 0.00105 0.47 0.38 Schizophrenia; chr15:84013030 chr15:84570649~84580175:+ PAAD cis rs12468226 0.817 rs2350360 ENSG00000273456.1 RP11-686O6.2 -5.01 1.49e-06 0.00105 -0.56 -0.38 Urate levels; chr2:202222980 chr2:202374932~202375604:- PAAD cis rs12468226 0.873 rs6435138 ENSG00000273456.1 RP11-686O6.2 -5.01 1.49e-06 0.00105 -0.56 -0.38 Urate levels; chr2:202234310 chr2:202374932~202375604:- PAAD cis rs3779195 0.86 rs12704986 ENSG00000272950.1 RP11-307C18.1 5.01 1.49e-06 0.00105 0.59 0.38 Sex hormone-binding globulin levels; chr7:98357118 chr7:98322853~98323430:+ PAAD cis rs3779195 0.858 rs3779196 ENSG00000272950.1 RP11-307C18.1 5.01 1.49e-06 0.00105 0.59 0.38 Sex hormone-binding globulin levels; chr7:98360794 chr7:98322853~98323430:+ PAAD cis rs3779195 0.789 rs6965424 ENSG00000272950.1 RP11-307C18.1 5.01 1.49e-06 0.00105 0.59 0.38 Sex hormone-binding globulin levels; chr7:98361813 chr7:98322853~98323430:+ PAAD cis rs1075232 0.826 rs12437800 ENSG00000215302.7 CTD-3092A11.1 -5.01 1.49e-06 0.00105 -0.9 -0.38 Survival in colorectal cancer (non-distant metastatic); chr15:31379229 chr15:30470779~30507623:+ PAAD cis rs6538678 0.712 rs10777748 ENSG00000258343.1 RP11-536G4.2 -5.01 1.49e-06 0.00105 -0.49 -0.38 Lupus nephritis in systemic lupus erythematosus; chr12:95880227 chr12:95795345~95858839:- PAAD cis rs6504950 0.889 rs1156287 ENSG00000275710.1 RP11-257O5.4 -5.01 1.5e-06 0.00105 -0.51 -0.38 Breast cancer; chr17:54999438 chr17:54964474~54964679:+ PAAD cis rs1823913 1 rs11691372 ENSG00000280083.1 RP11-317J9.1 5.01 1.5e-06 0.00105 0.48 0.38 Obesity-related traits; chr2:191249952 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs6749232 ENSG00000280083.1 RP11-317J9.1 5.01 1.5e-06 0.00105 0.48 0.38 Obesity-related traits; chr2:191250326 chr2:191154118~191156070:- PAAD cis rs1400745 0.756 rs761924 ENSG00000258738.1 RP11-73E17.2 -5.01 1.5e-06 0.00105 -0.47 -0.38 Monocyte count; chr14:34864077 chr14:34874343~34876459:+ PAAD cis rs42490 0.506 rs160429 ENSG00000251136.7 RP11-37B2.1 5.01 1.5e-06 0.00105 0.35 0.38 Leprosy; chr8:89661255 chr8:89609409~89757727:- PAAD cis rs42490 0.546 rs160437 ENSG00000251136.7 RP11-37B2.1 5.01 1.5e-06 0.00105 0.35 0.38 Leprosy; chr8:89669656 chr8:89609409~89757727:- PAAD cis rs950169 0.922 rs12910334 ENSG00000259295.5 CSPG4P12 5.01 1.5e-06 0.00106 0.42 0.38 Schizophrenia; chr15:84403620 chr15:85191438~85213905:+ PAAD cis rs11673344 0.764 rs519551 ENSG00000226686.6 LINC01535 5.01 1.51e-06 0.00106 0.5 0.38 Obesity-related traits; chr19:36965046 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs12151313 ENSG00000226686.6 LINC01535 5.01 1.51e-06 0.00106 0.52 0.38 Obesity-related traits; chr19:37072309 chr19:37251912~37265535:+ PAAD cis rs1155848 0.892 rs61966633 ENSG00000227354.5 RBM26-AS1 5.01 1.51e-06 0.00106 0.8 0.38 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79300406 chr13:79406309~79424328:+ PAAD cis rs1155848 1 rs1155848 ENSG00000227354.5 RBM26-AS1 5.01 1.51e-06 0.00106 0.8 0.38 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79314341 chr13:79406309~79424328:+ PAAD cis rs1155848 0.892 rs17185717 ENSG00000227354.5 RBM26-AS1 5.01 1.51e-06 0.00106 0.8 0.38 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79338764 chr13:79406309~79424328:+ PAAD cis rs748404 0.578 rs576557 ENSG00000249839.1 AC011330.5 -5.01 1.51e-06 0.00106 -0.57 -0.38 Lung cancer; chr15:43305539 chr15:43663654~43684339:- PAAD cis rs748404 0.578 rs510108 ENSG00000249839.1 AC011330.5 -5.01 1.51e-06 0.00106 -0.57 -0.38 Lung cancer; chr15:43313241 chr15:43663654~43684339:- PAAD cis rs2333194 0.772 rs12589739 ENSG00000258695.2 RP3-414A15.2 -5.01 1.51e-06 0.00106 -0.42 -0.38 Bipolar disorder with mood-incongruent psychosis; chr14:73436348 chr14:73522878~73530610:+ PAAD cis rs8396 1 rs9410 ENSG00000271817.2 U3 5.01 1.51e-06 0.00106 0.42 0.38 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158710839 chr4:158700691~158700909:+ PAAD cis rs2278034 0.516 rs9829709 ENSG00000271662.1 RP11-141C7.3 -5.01 1.51e-06 0.00106 -0.43 -0.38 Bronchopulmonary dysplasia; chr3:195889802 chr3:195650146~195651472:- PAAD cis rs2283792 1 rs5749986 ENSG00000228050.1 TOP3BP1 -5.01 1.51e-06 0.00106 -0.4 -0.38 Multiple sclerosis; chr22:21803372 chr22:22223187~22224566:- PAAD cis rs6570726 0.846 rs439035 ENSG00000235652.6 RP11-545I5.3 5.01 1.52e-06 0.00106 0.31 0.38 Lobe attachment (rater-scored or self-reported); chr6:145566854 chr6:145799409~145886585:+ PAAD cis rs964611 0.816 rs8033965 ENSG00000259488.2 RP11-154J22.1 -5.01 1.52e-06 0.00106 -0.42 -0.38 Metabolite levels (Pyroglutamine); chr15:48249316 chr15:48312353~48331856:- PAAD cis rs964611 0.816 rs2279367 ENSG00000259488.2 RP11-154J22.1 -5.01 1.52e-06 0.00106 -0.42 -0.38 Metabolite levels (Pyroglutamine); chr15:48249907 chr15:48312353~48331856:- PAAD cis rs9322193 0.884 rs11155675 ENSG00000216906.2 RP11-350J20.9 5.01 1.52e-06 0.00107 0.51 0.38 Lung cancer; chr6:149742883 chr6:149904243~149906418:+ PAAD cis rs4835473 0.897 rs2219912 ENSG00000251600.4 RP11-673E1.1 5.01 1.52e-06 0.00107 0.42 0.38 Immature fraction of reticulocytes; chr4:143707909 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs1597446 ENSG00000251600.4 RP11-673E1.1 5.01 1.52e-06 0.00107 0.42 0.38 Immature fraction of reticulocytes; chr4:143708338 chr4:143912331~143982454:+ PAAD cis rs950169 0.922 rs11635505 ENSG00000259295.5 CSPG4P12 -5.01 1.52e-06 0.00107 -0.41 -0.38 Schizophrenia; chr15:84553803 chr15:85191438~85213905:+ PAAD cis rs17826219 0.706 rs609472 ENSG00000266490.1 CTD-2349P21.9 5.01 1.52e-06 0.00107 0.45 0.38 Body mass index; chr17:30624409 chr17:30792372~30792833:+ PAAD cis rs79040073 0.53 rs1055254 ENSG00000259531.2 RP11-295H24.3 5.01 1.52e-06 0.00107 0.57 0.38 Lung cancer in ever smokers; chr15:49328003 chr15:49365124~49366685:- PAAD cis rs2882667 0.537 rs10057545 ENSG00000253404.1 AC034243.1 5.01 1.52e-06 0.00107 0.41 0.38 Age-related hearing impairment (SNP x SNP interaction); chr5:139095319 chr5:138744434~138753309:- PAAD cis rs2243480 1 rs316327 ENSG00000226824.5 RP4-756H11.3 5.01 1.53e-06 0.00107 0.67 0.38 Diabetic kidney disease; chr7:66144214 chr7:66654538~66669855:+ PAAD cis rs8396 1 rs8396 ENSG00000271817.2 U3 -5.01 1.53e-06 0.00107 -0.42 -0.38 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158709665 chr4:158700691~158700909:+ PAAD cis rs7829975 0.536 rs2980439 ENSG00000173295.6 FAM86B3P 5.01 1.53e-06 0.00107 0.41 0.38 Mood instability; chr8:8237348 chr8:8228595~8244865:+ PAAD cis rs2153535 0.58 rs1932280 ENSG00000230939.1 RP11-314C16.1 -5.01 1.53e-06 0.00107 -0.4 -0.38 Motion sickness; chr6:8473421 chr6:8784178~8785445:+ PAAD cis rs4879677 1 rs10968050 ENSG00000260390.1 RP11-575I8.1 -5 1.53e-06 0.00107 -0.48 -0.38 Gut microbiome composition (summer and winter); chr9:27677633 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs10968051 ENSG00000260390.1 RP11-575I8.1 -5 1.53e-06 0.00107 -0.48 -0.38 Gut microbiome composition (summer and winter); chr9:27677646 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs10757674 ENSG00000260390.1 RP11-575I8.1 5 1.53e-06 0.00107 0.48 0.38 Gut microbiome composition (summer and winter); chr9:27671312 chr9:27829276~27844481:+ PAAD cis rs6504622 0.875 rs4968250 ENSG00000262879.4 RP11-156P1.3 5 1.53e-06 0.00107 0.39 0.38 Orofacial clefts; chr17:46967985 chr17:46984045~47100323:- PAAD cis rs2274273 0.905 rs8007614 ENSG00000258413.1 RP11-665C16.6 -5 1.54e-06 0.00108 -0.48 -0.38 Protein biomarker; chr14:55119857 chr14:55262767~55272075:- PAAD cis rs1545257 0.537 rs3108793 ENSG00000242628.4 AC009228.1 5 1.54e-06 0.00108 0.44 0.38 Sjögren's syndrome; chr2:24425269 chr2:24214381~24221516:+ PAAD cis rs11673344 0.764 rs10403679 ENSG00000226686.6 LINC01535 5 1.54e-06 0.00108 0.51 0.38 Obesity-related traits; chr19:36980810 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs13345491 ENSG00000226686.6 LINC01535 5 1.54e-06 0.00108 0.51 0.38 Obesity-related traits; chr19:36982197 chr19:37251912~37265535:+ PAAD cis rs2921036 0.529 rs2979192 ENSG00000253893.2 FAM85B -5 1.54e-06 0.00108 -0.54 -0.38 Neuroticism; chr8:8480637 chr8:8167819~8226614:- PAAD cis rs6921919 0.583 rs2027361 ENSG00000216901.1 AL022393.7 5 1.54e-06 0.00108 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28420531 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs4642462 ENSG00000216901.1 AL022393.7 5 1.54e-06 0.00108 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28421474 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs3800328 ENSG00000216901.1 AL022393.7 5 1.54e-06 0.00108 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28423066 chr6:28176188~28176674:+ PAAD cis rs6921919 0.609 rs67211468 ENSG00000216901.1 AL022393.7 5 1.54e-06 0.00108 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28424210 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs35560946 ENSG00000216901.1 AL022393.7 5 1.54e-06 0.00108 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28427660 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs740621 ENSG00000216901.1 AL022393.7 5 1.54e-06 0.00108 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28430010 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs740622 ENSG00000216901.1 AL022393.7 5 1.54e-06 0.00108 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28430514 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs16894108 ENSG00000216901.1 AL022393.7 5 1.54e-06 0.00108 0.49 0.38 Autism spectrum disorder or schizophrenia; chr6:28434013 chr6:28176188~28176674:+ PAAD cis rs34375054 0.525 rs10846829 ENSG00000279233.1 RP11-158L12.4 5 1.54e-06 0.00108 0.33 0.38 Post bronchodilator FEV1/FVC ratio; chr12:125110512 chr12:125138245~125141711:+ PAAD cis rs34375054 0.525 rs7136220 ENSG00000279233.1 RP11-158L12.4 5 1.54e-06 0.00108 0.33 0.38 Post bronchodilator FEV1/FVC ratio; chr12:125118138 chr12:125138245~125141711:+ PAAD cis rs1075265 0.722 rs1877907 ENSG00000233266.1 HMGB1P31 5 1.55e-06 0.00108 0.47 0.38 Chronotype;Morning vs. evening chronotype; chr2:54137118 chr2:54051334~54051760:+ PAAD cis rs8396 1 rs6536365 ENSG00000271817.2 U3 5 1.55e-06 0.00108 0.42 0.38 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158711141 chr4:158700691~158700909:+ PAAD cis rs10916248 0.511 rs1060386 ENSG00000232628.4 RP11-365O16.3 5 1.55e-06 0.00108 0.57 0.38 QT interval (drug interaction); chr1:224192776 chr1:224208747~224213279:- PAAD cis rs2153535 0.601 rs330105 ENSG00000230939.1 RP11-314C16.1 -5 1.56e-06 0.00109 -0.4 -0.38 Motion sickness; chr6:8543748 chr6:8784178~8785445:+ PAAD cis rs710913 0.738 rs1180347 ENSG00000237624.1 OXCT2P1 -5 1.56e-06 0.00109 -0.48 -0.38 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39531044 chr1:39514956~39516490:+ PAAD cis rs12701220 0.503 rs12702024 ENSG00000229043.2 AC091729.9 -5 1.56e-06 0.00109 -0.5 -0.38 Bronchopulmonary dysplasia; chr7:1090184 chr7:1160374~1165267:+ PAAD cis rs2274273 0.87 rs11851169 ENSG00000258413.1 RP11-665C16.6 -5 1.56e-06 0.00109 -0.49 -0.38 Protein biomarker; chr14:55349214 chr14:55262767~55272075:- PAAD cis rs2274273 0.805 rs28612464 ENSG00000258413.1 RP11-665C16.6 -5 1.56e-06 0.00109 -0.49 -0.38 Protein biomarker; chr14:55349693 chr14:55262767~55272075:- PAAD cis rs2274273 0.773 rs28430823 ENSG00000258413.1 RP11-665C16.6 -5 1.56e-06 0.00109 -0.49 -0.38 Protein biomarker; chr14:55349842 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs17741831 ENSG00000258413.1 RP11-665C16.6 -5 1.56e-06 0.00109 -0.49 -0.38 Protein biomarker; chr14:55349997 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs10136596 ENSG00000258413.1 RP11-665C16.6 -5 1.56e-06 0.00109 -0.49 -0.38 Protein biomarker; chr14:55370055 chr14:55262767~55272075:- PAAD cis rs2274273 0.804 rs28428911 ENSG00000258413.1 RP11-665C16.6 -5 1.56e-06 0.00109 -0.49 -0.38 Protein biomarker; chr14:55376878 chr14:55262767~55272075:- PAAD cis rs2274273 0.805 rs28660594 ENSG00000258413.1 RP11-665C16.6 -5 1.56e-06 0.00109 -0.49 -0.38 Protein biomarker; chr14:55379456 chr14:55262767~55272075:- PAAD cis rs9481169 0.557 rs73534579 ENSG00000255389.1 C6orf3 -5 1.56e-06 0.00109 -0.67 -0.38 Inflammatory skin disease; chr6:111589486 chr6:111599875~111602295:+ PAAD cis rs160451 1 rs160424 ENSG00000251136.7 RP11-37B2.1 5 1.57e-06 0.00109 0.35 0.38 Leprosy; chr8:89658452 chr8:89609409~89757727:- PAAD cis rs453301 0.606 rs7462373 ENSG00000253893.2 FAM85B 5 1.57e-06 0.00109 0.52 0.38 Joint mobility (Beighton score); chr8:9041808 chr8:8167819~8226614:- PAAD cis rs2581828 0.896 rs12637287 ENSG00000242142.1 SERBP1P3 5 1.57e-06 0.00109 0.43 0.38 Crohn's disease; chr3:53105425 chr3:53064283~53065091:- PAAD cis rs2412819 0.571 rs66903736 ENSG00000249839.1 AC011330.5 -5 1.57e-06 0.00109 -0.66 -0.38 Lung cancer; chr15:43619435 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs66749753 ENSG00000249839.1 AC011330.5 -5 1.57e-06 0.00109 -0.66 -0.38 Lung cancer; chr15:43619601 chr15:43663654~43684339:- PAAD cis rs7829975 0.514 rs2976929 ENSG00000253893.2 FAM85B -5 1.57e-06 0.00109 -0.51 -0.38 Mood instability; chr8:8401202 chr8:8167819~8226614:- PAAD cis rs4835473 0.897 rs1553070 ENSG00000251600.4 RP11-673E1.1 5 1.57e-06 0.00109 0.42 0.38 Immature fraction of reticulocytes; chr4:143715981 chr4:143912331~143982454:+ PAAD cis rs4879677 1 rs72712238 ENSG00000260390.1 RP11-575I8.1 -5 1.57e-06 0.0011 -0.48 -0.38 Gut microbiome composition (summer and winter); chr9:27675371 chr9:27829276~27844481:+ PAAD cis rs4879677 0.959 rs10968049 ENSG00000260390.1 RP11-575I8.1 -5 1.57e-06 0.0011 -0.48 -0.38 Gut microbiome composition (summer and winter); chr9:27676933 chr9:27829276~27844481:+ PAAD cis rs8062405 0.721 rs151303 ENSG00000251417.2 RP11-1348G14.4 -5 1.57e-06 0.0011 -0.34 -0.38 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28481189 chr16:28802743~28817828:+ PAAD cis rs16828019 0.852 rs12742379 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41060709 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs16827876 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41073864 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs34979067 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41077412 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs35190461 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41077463 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12022978 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41088416 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs2300649 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41103531 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs11209531 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41105349 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs3904243 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41109180 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs11209545 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41110685 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs11209576 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41120357 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs3766324 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41122981 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12759023 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41138306 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs34286980 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41142717 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs71648534 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41148075 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs71648535 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41148078 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12048187 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41150511 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs71648536 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41166336 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12742803 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41182459 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12408956 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41186280 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs35992757 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41187190 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12044539 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41196060 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12759050 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41198532 chr1:41242373~41284861:+ PAAD cis rs16828019 0.789 rs34216154 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41205235 chr1:41242373~41284861:+ PAAD cis rs16828019 0.929 rs12029321 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41216858 chr1:41242373~41284861:+ PAAD cis rs16828019 0.929 rs11209734 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41232402 chr1:41242373~41284861:+ PAAD cis rs16828019 0.929 rs12037037 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41232584 chr1:41242373~41284861:+ PAAD cis rs16828019 0.929 rs8179465 ENSG00000235358.1 RP11-399E6.1 5 1.57e-06 0.0011 0.71 0.38 Intelligence (multi-trait analysis); chr1:41236075 chr1:41242373~41284861:+ PAAD cis rs673078 0.607 rs17440956 ENSG00000275759.1 RP11-131L12.3 5 1.58e-06 0.0011 0.64 0.38 Glucose homeostasis traits; chr12:118394639 chr12:118428281~118428870:+ PAAD cis rs17711722 0.565 rs73372653 ENSG00000236529.1 RP13-254B10.1 5 1.58e-06 0.0011 0.42 0.38 Calcium levels; chr7:65977808 chr7:65840212~65840596:+ PAAD cis rs8059260 0.604 rs34215426 ENSG00000274038.1 RP11-66H6.4 -5 1.58e-06 0.0011 -0.57 -0.38 Alcohol consumption over the past year; chr16:11113614 chr16:11056556~11057034:+ PAAD cis rs4853525 0.59 rs13414554 ENSG00000235852.1 AC005540.3 5 1.58e-06 0.0011 0.55 0.38 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190929215 chr2:190880797~190882059:- PAAD cis rs4853525 0.561 rs13414648 ENSG00000235852.1 AC005540.3 5 1.58e-06 0.0011 0.55 0.38 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190929310 chr2:190880797~190882059:- PAAD cis rs4853525 0.59 rs3771308 ENSG00000235852.1 AC005540.3 5 1.58e-06 0.0011 0.55 0.38 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190936179 chr2:190880797~190882059:- PAAD cis rs4853525 0.561 rs10931476 ENSG00000235852.1 AC005540.3 5 1.58e-06 0.0011 0.55 0.38 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190938082 chr2:190880797~190882059:- PAAD cis rs4853525 0.504 rs2883582 ENSG00000235852.1 AC005540.3 5 1.58e-06 0.0011 0.55 0.38 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190939306 chr2:190880797~190882059:- PAAD cis rs10483853 0.525 rs7158272 ENSG00000258695.2 RP3-414A15.2 5 1.58e-06 0.0011 0.56 0.38 Coronary artery calcification; chr14:73476486 chr14:73522878~73530610:+ PAAD cis rs9928842 0.771 rs2870471 ENSG00000280152.1 RP11-331F4.5 -5 1.58e-06 0.0011 -0.47 -0.38 Alcoholic chronic pancreatitis; chr16:75240384 chr16:75245994~75250077:- PAAD cis rs1075265 0.692 rs805318 ENSG00000233266.1 HMGB1P31 5 1.58e-06 0.0011 0.47 0.38 Chronotype;Morning vs. evening chronotype; chr2:53907915 chr2:54051334~54051760:+ PAAD cis rs2274273 0.87 rs11625001 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55291442 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs67514154 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55300664 chr14:55262767~55272075:- PAAD cis rs2274273 0.805 rs11628437 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55308750 chr14:55262767~55272075:- PAAD cis rs2274273 0.837 rs59871474 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55312645 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs7153612 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55322044 chr14:55262767~55272075:- PAAD cis rs2274273 0.837 rs56949365 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55323360 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs4496026 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55323794 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs4366639 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55323798 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs11625423 ENSG00000258413.1 RP11-665C16.6 -5 1.58e-06 0.0011 -0.48 -0.38 Protein biomarker; chr14:55329195 chr14:55262767~55272075:- PAAD cis rs4814920 0.818 rs6046387 ENSG00000275142.1 RP5-999L4.2 -5 1.59e-06 0.0011 -0.68 -0.38 Bipolar disorder (body mass index interaction); chr20:19869186 chr20:19871891~19872284:+ PAAD cis rs2948294 0.588 rs4840913 ENSG00000173295.6 FAM86B3P 5 1.59e-06 0.0011 0.4 0.38 Red cell distribution width; chr8:8259384 chr8:8228595~8244865:+ PAAD cis rs11098499 0.82 rs2389885 ENSG00000245958.5 RP11-33B1.1 -5 1.59e-06 0.00111 -0.33 -0.38 Corneal astigmatism; chr4:119612776 chr4:119454791~119552025:+ PAAD cis rs9473147 0.543 rs9296558 ENSG00000270761.1 RP11-385F7.1 -5 1.59e-06 0.00111 -0.38 -0.38 Platelet distribution width;Mean platelet volume; chr6:47484147 chr6:47477243~47477572:- PAAD cis rs2243480 1 rs160634 ENSG00000226824.5 RP4-756H11.3 5 1.59e-06 0.00111 0.68 0.38 Diabetic kidney disease; chr7:66063677 chr7:66654538~66669855:+ PAAD cis rs16828019 0.852 rs12729448 ENSG00000235358.1 RP11-399E6.1 5 1.59e-06 0.00111 0.71 0.38 Intelligence (multi-trait analysis); chr1:41044162 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs2268678 ENSG00000235358.1 RP11-399E6.1 5 1.59e-06 0.00111 0.71 0.38 Intelligence (multi-trait analysis); chr1:41045381 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs10489520 ENSG00000235358.1 RP11-399E6.1 5 1.59e-06 0.00111 0.71 0.38 Intelligence (multi-trait analysis); chr1:41046083 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12406620 ENSG00000235358.1 RP11-399E6.1 5 1.59e-06 0.00111 0.71 0.38 Intelligence (multi-trait analysis); chr1:41046992 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs12729586 ENSG00000235358.1 RP11-399E6.1 5 1.59e-06 0.00111 0.71 0.38 Intelligence (multi-trait analysis); chr1:41056705 chr1:41242373~41284861:+ PAAD cis rs16828019 0.704 rs34486565 ENSG00000235358.1 RP11-399E6.1 5 1.59e-06 0.00111 0.71 0.38 Intelligence (multi-trait analysis); chr1:41056838 chr1:41242373~41284861:+ PAAD cis rs4835473 0.932 rs17018238 ENSG00000251600.4 RP11-673E1.1 -5 1.6e-06 0.00111 -0.41 -0.38 Immature fraction of reticulocytes; chr4:143782737 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13152209 ENSG00000251600.4 RP11-673E1.1 5 1.6e-06 0.00111 0.41 0.38 Immature fraction of reticulocytes; chr4:143776088 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs10016223 ENSG00000251600.4 RP11-673E1.1 5 1.6e-06 0.00111 0.41 0.38 Immature fraction of reticulocytes; chr4:143777429 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13129702 ENSG00000251600.4 RP11-673E1.1 5 1.6e-06 0.00111 0.41 0.38 Immature fraction of reticulocytes; chr4:143785132 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4383567 ENSG00000251600.4 RP11-673E1.1 5 1.6e-06 0.00111 0.41 0.38 Immature fraction of reticulocytes; chr4:143788873 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs11100812 ENSG00000251600.4 RP11-673E1.1 5 1.6e-06 0.00111 0.41 0.38 Immature fraction of reticulocytes; chr4:143790400 chr4:143912331~143982454:+ PAAD cis rs4835473 0.545 rs10022856 ENSG00000251600.4 RP11-673E1.1 5 1.6e-06 0.00111 0.41 0.38 Immature fraction of reticulocytes; chr4:143793157 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1842484 ENSG00000251600.4 RP11-673E1.1 5 1.6e-06 0.00111 0.41 0.38 Immature fraction of reticulocytes; chr4:143793829 chr4:143912331~143982454:+ PAAD cis rs7684253 0.548 rs13106200 ENSG00000269949.1 RP11-738E22.3 -4.99 1.6e-06 0.00111 -0.5 -0.38 Migraine; chr4:56852029 chr4:56960927~56961373:- PAAD cis rs2015599 0.584 rs7299283 ENSG00000257176.2 RP11-996F15.2 4.99 1.6e-06 0.00111 0.38 0.38 Platelet count;Mean platelet volume; chr12:29277442 chr12:29280418~29317848:- PAAD cis rs189798 0.592 rs10111263 ENSG00000253893.2 FAM85B 4.99 1.6e-06 0.00111 0.51 0.38 Myopia (pathological); chr8:9111923 chr8:8167819~8226614:- PAAD cis rs919433 0.963 rs4850429 ENSG00000231621.1 AC013264.2 -4.99 1.6e-06 0.00111 -0.36 -0.38 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197313685 chr2:197197991~197199273:+ PAAD cis rs2115630 0.967 rs28595395 ENSG00000259728.4 LINC00933 -4.99 1.61e-06 0.00112 -0.46 -0.38 P wave terminal force; chr15:84791721 chr15:84570649~84580175:+ PAAD cis rs2283792 0.74 rs8138075 ENSG00000224086.5 LL22NC03-86G7.1 -4.99 1.61e-06 0.00112 -0.39 -0.38 Multiple sclerosis; chr22:21755092 chr22:21938293~21977632:+ PAAD cis rs12554020 0.786 rs7035657 ENSG00000227603.1 RP11-165J3.6 -4.99 1.61e-06 0.00112 -0.58 -0.38 Schizophrenia; chr9:93434769 chr9:93435332~93437121:- PAAD cis rs12554020 0.786 rs6479482 ENSG00000227603.1 RP11-165J3.6 4.99 1.61e-06 0.00112 0.58 0.38 Schizophrenia; chr9:93435814 chr9:93435332~93437121:- PAAD cis rs13178541 0.745 rs4976326 ENSG00000250378.1 RP11-119J18.1 4.99 1.61e-06 0.00112 0.59 0.38 IgG glycosylation; chr5:135728800 chr5:135812667~135826582:+ PAAD cis rs6991838 0.55 rs4737750 ENSG00000200714.1 Y_RNA 4.99 1.61e-06 0.00112 0.44 0.38 Intelligence (multi-trait analysis); chr8:65638724 chr8:65592731~65592820:+ PAAD cis rs2946504 0.822 rs2977097 ENSG00000251468.2 RP11-369K16.1 4.99 1.61e-06 0.00112 0.44 0.38 Type 2 diabetes; chr8:12946592 chr8:12958387~12962200:+ PAAD cis rs875971 0.545 rs316328 ENSG00000226824.5 RP4-756H11.3 4.99 1.62e-06 0.00112 0.49 0.38 Aortic root size; chr7:66143851 chr7:66654538~66669855:+ PAAD cis rs2921073 0.509 rs2976931 ENSG00000253893.2 FAM85B -4.99 1.62e-06 0.00112 -0.51 -0.38 Parkinson's disease; chr8:8399807 chr8:8167819~8226614:- PAAD cis rs2015599 0.56 rs11050147 ENSG00000257176.2 RP11-996F15.2 -4.99 1.62e-06 0.00112 -0.38 -0.38 Platelet count;Mean platelet volume; chr12:29242746 chr12:29280418~29317848:- PAAD cis rs13178541 0.553 rs4976374 ENSG00000250378.1 RP11-119J18.1 -4.99 1.62e-06 0.00112 -0.55 -0.38 IgG glycosylation; chr5:135853131 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs6879905 ENSG00000250378.1 RP11-119J18.1 -4.99 1.62e-06 0.00112 -0.55 -0.38 IgG glycosylation; chr5:135854608 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs2304074 ENSG00000250378.1 RP11-119J18.1 4.99 1.62e-06 0.00112 0.58 0.38 IgG glycosylation; chr5:135824368 chr5:135812667~135826582:+ PAAD cis rs2243480 1 rs1638734 ENSG00000226824.5 RP4-756H11.3 -4.99 1.62e-06 0.00112 -0.67 -0.38 Diabetic kidney disease; chr7:66632552 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs1267818 ENSG00000226824.5 RP4-756H11.3 -4.99 1.62e-06 0.00112 -0.67 -0.38 Gout; chr7:66642037 chr7:66654538~66669855:+ PAAD cis rs1499614 1 rs1267817 ENSG00000226824.5 RP4-756H11.3 -4.99 1.62e-06 0.00112 -0.67 -0.38 Gout; chr7:66645053 chr7:66654538~66669855:+ PAAD cis rs80285556 1 rs79602855 ENSG00000161643.11 SIGLEC16 4.99 1.62e-06 0.00113 0.89 0.38 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022468 chr19:49969673~49975814:+ PAAD cis rs80285556 1 rs55914901 ENSG00000161643.11 SIGLEC16 4.99 1.62e-06 0.00113 0.89 0.38 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50025089 chr19:49969673~49975814:+ PAAD cis rs1928295 1 rs1928295 ENSG00000233569.1 RP11-500B12.1 4.99 1.62e-06 0.00113 0.42 0.38 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117616205 chr9:117648606~117657027:+ PAAD cis rs6782228 0.509 rs4481172 ENSG00000242551.2 POU5F1P6 -4.99 1.62e-06 0.00113 -0.45 -0.38 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128653814 chr3:128674735~128677005:- PAAD cis rs7829975 0.871 rs572307 ENSG00000253893.2 FAM85B 4.99 1.63e-06 0.00113 0.56 0.38 Mood instability; chr8:8721301 chr8:8167819~8226614:- PAAD cis rs9473147 0.543 rs9349407 ENSG00000270761.1 RP11-385F7.1 -4.99 1.63e-06 0.00113 -0.38 -0.38 Platelet distribution width;Mean platelet volume; chr6:47485642 chr6:47477243~47477572:- PAAD cis rs4723738 1 rs2159501 ENSG00000227191.5 TRGC2 -4.99 1.63e-06 0.00113 -0.33 -0.38 Treatment response for severe sepsis; chr7:38199675 chr7:38239580~38368091:- PAAD cis rs4723738 0.934 rs1860522 ENSG00000227191.5 TRGC2 -4.99 1.63e-06 0.00113 -0.33 -0.38 Treatment response for severe sepsis; chr7:38200439 chr7:38239580~38368091:- PAAD cis rs4723738 0.967 rs10480164 ENSG00000227191.5 TRGC2 -4.99 1.63e-06 0.00113 -0.33 -0.38 Treatment response for severe sepsis; chr7:38206281 chr7:38239580~38368091:- PAAD cis rs4723738 1 rs6462817 ENSG00000227191.5 TRGC2 -4.99 1.63e-06 0.00113 -0.33 -0.38 Treatment response for severe sepsis; chr7:38211264 chr7:38239580~38368091:- PAAD cis rs1510272 0.515 rs2089735 ENSG00000243926.1 TIPARP-AS1 -4.99 1.63e-06 0.00113 -0.57 -0.38 Testicular germ cell tumor; chr3:156624763 chr3:156671862~156674378:- PAAD cis rs1510272 0.515 rs6762762 ENSG00000243926.1 TIPARP-AS1 -4.99 1.63e-06 0.00113 -0.57 -0.38 Testicular germ cell tumor; chr3:156625194 chr3:156671862~156674378:- PAAD cis rs10754283 0.967 rs10801764 ENSG00000231613.1 RP5-943J3.1 4.99 1.63e-06 0.00113 0.41 0.38 Amyotrophic lateral sclerosis (sporadic); chr1:89656192 chr1:89788914~89790492:+ PAAD cis rs2948294 0.566 rs13274039 ENSG00000173295.6 FAM86B3P 4.99 1.63e-06 0.00113 0.4 0.38 Red cell distribution width; chr8:8254137 chr8:8228595~8244865:+ PAAD cis rs2948294 0.566 rs13261997 ENSG00000173295.6 FAM86B3P 4.99 1.63e-06 0.00113 0.4 0.38 Red cell distribution width; chr8:8254773 chr8:8228595~8244865:+ PAAD cis rs2153535 0.563 rs3117071 ENSG00000230939.1 RP11-314C16.1 -4.99 1.63e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8537675 chr6:8784178~8785445:+ PAAD cis rs2153535 0.526 rs9406179 ENSG00000230939.1 RP11-314C16.1 -4.99 1.63e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8537991 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9379224 ENSG00000230939.1 RP11-314C16.1 -4.99 1.63e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8538180 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9505472 ENSG00000230939.1 RP11-314C16.1 -4.99 1.63e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8538532 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9505473 ENSG00000230939.1 RP11-314C16.1 -4.99 1.63e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8538544 chr6:8784178~8785445:+ PAAD cis rs2153535 0.546 rs9378559 ENSG00000230939.1 RP11-314C16.1 -4.99 1.63e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8538825 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs1737581 ENSG00000230939.1 RP11-314C16.1 -4.99 1.63e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8538905 chr6:8784178~8785445:+ PAAD cis rs2658782 0.639 rs2100552 ENSG00000279684.1 RP11-755E23.2 -4.99 1.63e-06 0.00113 -0.55 -0.38 Pulmonary function decline; chr11:93449083 chr11:93286629~93288903:- PAAD cis rs11089937 0.568 rs5756989 ENSG00000211639.2 IGLV4-60 4.99 1.63e-06 0.00113 0.39 0.38 Periodontitis (PAL4Q3); chr22:22132415 chr22:22162199~22162681:+ PAAD cis rs453301 0.658 rs12114954 ENSG00000253893.2 FAM85B 4.99 1.64e-06 0.00113 0.52 0.38 Joint mobility (Beighton score); chr8:9047352 chr8:8167819~8226614:- PAAD cis rs17711722 0.522 rs62469933 ENSG00000164669.11 INTS4P1 -4.99 1.64e-06 0.00113 -0.45 -0.38 Calcium levels; chr7:65800652 chr7:65141225~65234216:+ PAAD cis rs2153535 0.505 rs9405395 ENSG00000230939.1 RP11-314C16.1 -4.99 1.64e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8468389 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9392223 ENSG00000230939.1 RP11-314C16.1 -4.99 1.64e-06 0.00113 -0.4 -0.38 Motion sickness; chr6:8468417 chr6:8784178~8785445:+ PAAD cis rs4813802 0.764 rs2010978 ENSG00000278192.1 RP5-1056H1.2 -4.99 1.64e-06 0.00114 -0.39 -0.38 Colorectal cancer; chr20:6712875 chr20:6065966~6067897:- PAAD cis rs950027 0.62 rs1617634 ENSG00000259433.2 CTD-2651B20.4 -4.99 1.64e-06 0.00114 -0.42 -0.38 Response to fenofibrate (adiponectin levels); chr15:45323380 chr15:45330209~45332634:- PAAD cis rs2581828 0.606 rs1004807 ENSG00000242142.1 SERBP1P3 4.99 1.64e-06 0.00114 0.49 0.38 Crohn's disease; chr3:53106587 chr3:53064283~53065091:- PAAD cis rs17711722 0.528 rs73138179 ENSG00000164669.11 INTS4P1 -4.99 1.64e-06 0.00114 -0.46 -0.38 Calcium levels; chr7:65829495 chr7:65141225~65234216:+ PAAD cis rs950169 0.614 rs12903883 ENSG00000259728.4 LINC00933 4.99 1.65e-06 0.00114 0.47 0.38 Schizophrenia; chr15:84011801 chr15:84570649~84580175:+ PAAD cis rs62103177 0.608 rs8088089 ENSG00000261126.6 RP11-795F19.1 -4.99 1.65e-06 0.00114 -0.53 -0.38 Opioid sensitivity; chr18:80073851 chr18:80046900~80095482:+ PAAD cis rs2153535 0.58 rs1932283 ENSG00000230939.1 RP11-314C16.1 -4.99 1.65e-06 0.00114 -0.4 -0.38 Motion sickness; chr6:8477428 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1932284 ENSG00000230939.1 RP11-314C16.1 -4.99 1.65e-06 0.00114 -0.4 -0.38 Motion sickness; chr6:8477461 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1932285 ENSG00000230939.1 RP11-314C16.1 -4.99 1.65e-06 0.00114 -0.4 -0.38 Motion sickness; chr6:8477486 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7775909 ENSG00000230939.1 RP11-314C16.1 -4.99 1.65e-06 0.00114 -0.4 -0.38 Motion sickness; chr6:8477545 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7743995 ENSG00000230939.1 RP11-314C16.1 -4.99 1.65e-06 0.00114 -0.4 -0.38 Motion sickness; chr6:8495979 chr6:8784178~8785445:+ PAAD cis rs633715 1 rs633715 ENSG00000254154.7 RP4-798P15.3 -4.99 1.65e-06 0.00114 -0.35 -0.38 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177883445 chr1:177928788~178038007:- PAAD cis rs633715 1 rs516636 ENSG00000254154.7 RP4-798P15.3 -4.99 1.65e-06 0.00114 -0.35 -0.38 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177886382 chr1:177928788~178038007:- PAAD cis rs633715 1 rs571567 ENSG00000254154.7 RP4-798P15.3 -4.99 1.65e-06 0.00114 -0.35 -0.38 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177903770 chr1:177928788~178038007:- PAAD cis rs633715 0.918 rs574367 ENSG00000254154.7 RP4-798P15.3 -4.99 1.65e-06 0.00114 -0.35 -0.38 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177904075 chr1:177928788~178038007:- PAAD cis rs633715 1 rs490689 ENSG00000254154.7 RP4-798P15.3 -4.99 1.65e-06 0.00114 -0.35 -0.38 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177904706 chr1:177928788~178038007:- PAAD cis rs633715 1 rs589500 ENSG00000254154.7 RP4-798P15.3 -4.99 1.65e-06 0.00114 -0.35 -0.38 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177907811 chr1:177928788~178038007:- PAAD cis rs633715 1 rs633754 ENSG00000254154.7 RP4-798P15.3 -4.99 1.65e-06 0.00114 -0.35 -0.38 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177910800 chr1:177928788~178038007:- PAAD cis rs950027 0.62 rs1153862 ENSG00000259433.2 CTD-2651B20.4 -4.99 1.65e-06 0.00114 -0.43 -0.38 Response to fenofibrate (adiponectin levels); chr15:45339670 chr15:45330209~45332634:- PAAD cis rs1545257 0.537 rs2249387 ENSG00000242628.4 AC009228.1 -4.99 1.65e-06 0.00114 -0.43 -0.37 Sjögren's syndrome; chr2:24426932 chr2:24214381~24221516:+ PAAD cis rs2274273 0.84 rs7144737 ENSG00000258413.1 RP11-665C16.6 -4.99 1.66e-06 0.00115 -0.49 -0.37 Protein biomarker; chr14:55356228 chr14:55262767~55272075:- PAAD cis rs748404 0.578 rs2278856 ENSG00000249839.1 AC011330.5 -4.99 1.66e-06 0.00115 -0.55 -0.37 Lung cancer; chr15:43339158 chr15:43663654~43684339:- PAAD cis rs875971 0.545 rs4441996 ENSG00000164669.11 INTS4P1 4.99 1.66e-06 0.00115 0.54 0.37 Aortic root size; chr7:66123233 chr7:65141225~65234216:+ PAAD cis rs4835473 0.897 rs6832749 ENSG00000251600.4 RP11-673E1.1 4.99 1.66e-06 0.00115 0.42 0.37 Immature fraction of reticulocytes; chr4:143709473 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs6831477 ENSG00000251600.4 RP11-673E1.1 4.99 1.66e-06 0.00115 0.42 0.37 Immature fraction of reticulocytes; chr4:143709487 chr4:143912331~143982454:+ PAAD cis rs9322193 0.884 rs10872647 ENSG00000216906.2 RP11-350J20.9 4.99 1.66e-06 0.00115 0.52 0.37 Lung cancer; chr6:149758687 chr6:149904243~149906418:+ PAAD cis rs9322193 0.884 rs11155679 ENSG00000216906.2 RP11-350J20.9 4.99 1.66e-06 0.00115 0.52 0.37 Lung cancer; chr6:149758881 chr6:149904243~149906418:+ PAAD cis rs1510272 0.515 rs6807235 ENSG00000243926.1 TIPARP-AS1 -4.99 1.67e-06 0.00115 -0.57 -0.37 Testicular germ cell tumor; chr3:156623812 chr3:156671862~156674378:- PAAD cis rs56080343 0.688 rs10083190 ENSG00000275759.1 RP11-131L12.3 -4.99 1.67e-06 0.00115 -0.46 -0.37 Neuroticism; chr12:118365385 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs10082823 ENSG00000275759.1 RP11-131L12.3 -4.99 1.67e-06 0.00115 -0.46 -0.37 Glucose homeostasis traits; chr12:118365386 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs2062519 ENSG00000275759.1 RP11-131L12.3 -4.99 1.67e-06 0.00115 -0.46 -0.37 Glucose homeostasis traits; chr12:118367577 chr12:118428281~118428870:+ PAAD cis rs2153535 0.58 rs9378551 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8463511 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9378552 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8463515 chr6:8784178~8785445:+ PAAD cis rs2153535 0.562 rs9379211 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8463694 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406158 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8463919 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1319169 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8464223 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs965706 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8464475 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6938071 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8464612 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406159 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8464626 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9406160 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8464674 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1335636 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8464814 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1335637 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8464868 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs986060 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8465195 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9393021 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8465890 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406161 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8465911 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406162 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8465963 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9405390 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8465976 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9405391 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8466315 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9393022 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8466355 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406163 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8466409 chr6:8784178~8785445:+ PAAD cis rs2153535 0.504 rs9405393 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8467199 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs9392222 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8467416 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs6932434 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8467446 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1034273 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8467912 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2184584 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8468174 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs9328471 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8468609 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs7774752 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8468745 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1034272 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8469102 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9505450 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8469669 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9505451 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8469717 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9393023 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8469761 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406164 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8469815 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7341201 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8470037 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7341206 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8470256 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7341381 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8470304 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7341382 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8470316 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7341383 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8470401 chr6:8784178~8785445:+ PAAD cis rs2153535 0.504 rs9328472 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8470615 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1414344 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8471132 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1414345 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8471304 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1414346 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8471341 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6905237 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8471557 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6905242 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8471566 chr6:8784178~8785445:+ PAAD cis rs2153535 0.542 rs4440510 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8471585 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs1414347 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8471598 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1414348 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8471707 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1414349 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8472057 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1414350 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8472098 chr6:8784178~8785445:+ PAAD cis rs2153535 0.526 rs7748404 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8472267 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9392224 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8472381 chr6:8784178~8785445:+ PAAD cis rs2153535 0.542 rs9378553 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8472399 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs1855768 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8472736 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1855769 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8472862 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1932279 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8473420 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1932281 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8473532 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6900007 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8473802 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2184585 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8473935 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2152347 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8474048 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2152348 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8474068 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9379213 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8474712 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6902001 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8476822 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4960423 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8476977 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1932282 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8477097 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9505454 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8478299 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9505455 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8478389 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs9505456 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8478768 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9505457 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8478909 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9505458 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8478982 chr6:8784178~8785445:+ PAAD cis rs2153535 0.56 rs9379214 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8480637 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9379215 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8480992 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9379216 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8481002 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7450817 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8481188 chr6:8784178~8785445:+ PAAD cis rs2153535 0.56 rs2210798 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8481289 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2225765 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8481552 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2225766 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8481600 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597326 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8481786 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597327 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8481924 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7753192 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8482404 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7763190 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8483964 chr6:8784178~8785445:+ PAAD cis rs2153535 0.546 rs1335640 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8485092 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs1414352 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8485314 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs1414353 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8485409 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1577471 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8485672 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1577472 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8485982 chr6:8784178~8785445:+ PAAD cis rs2153535 0.542 rs1120393 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8486657 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1120392 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8486820 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1335641 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8487627 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1335643 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8487788 chr6:8784178~8785445:+ PAAD cis rs2153535 0.525 rs1335644 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8487808 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9378554 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8488235 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406165 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8488604 chr6:8784178~8785445:+ PAAD cis rs2153535 0.563 rs4428546 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8490143 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9393025 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8490385 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1414340 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8490906 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1335628 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8491509 chr6:8784178~8785445:+ PAAD cis rs2153535 0.505 rs1335629 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8491630 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597330 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8491843 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs763376 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8492543 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6941771 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8494219 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6937186 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8494260 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9505467 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8519986 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1360054 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8520144 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9328483 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8521062 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9393033 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8521213 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs6938688 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8521396 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9328484 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8524610 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1410766 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8525127 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7743686 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8525878 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1328862 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8526448 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs718502 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8527167 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs718503 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8527230 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs718504 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8527279 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597335 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8527481 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9328486 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8527775 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2183112 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8527979 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9328487 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8529145 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9328488 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8529178 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs1928183 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8529785 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs2143353 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8529878 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs2143352 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8530015 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs7775274 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8530070 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs7741024 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8530080 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6421948 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8530787 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597337 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8531419 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6421949 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8531536 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs1928184 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8531875 chr6:8784178~8785445:+ PAAD cis rs1167827 1 rs1167827 ENSG00000278416.1 PMS2L2 4.99 1.67e-06 0.00115 0.43 0.37 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75533848 chr7:75344015~75359550:- PAAD cis rs16828019 0.929 rs1032728 ENSG00000235358.1 RP11-399E6.1 4.99 1.67e-06 0.00115 0.71 0.37 Intelligence (multi-trait analysis); chr1:41213894 chr1:41242373~41284861:+ PAAD cis rs16828019 0.929 rs35286837 ENSG00000235358.1 RP11-399E6.1 4.99 1.67e-06 0.00115 0.71 0.37 Intelligence (multi-trait analysis); chr1:41217326 chr1:41242373~41284861:+ PAAD cis rs2153535 0.58 rs2184586 ENSG00000230939.1 RP11-314C16.1 -4.99 1.67e-06 0.00115 -0.4 -0.37 Motion sickness; chr6:8473949 chr6:8784178~8785445:+ PAAD cis rs875971 0.502 rs6460311 ENSG00000226824.5 RP4-756H11.3 4.99 1.67e-06 0.00115 0.54 0.37 Aortic root size; chr7:66646886 chr7:66654538~66669855:+ PAAD cis rs2333194 0.739 rs61987083 ENSG00000258695.2 RP3-414A15.2 -4.98 1.67e-06 0.00115 -0.41 -0.37 Bipolar disorder with mood-incongruent psychosis; chr14:73449154 chr14:73522878~73530610:+ PAAD cis rs2337406 0.81 rs7161739 ENSG00000211974.3 IGHV2-70 -4.98 1.67e-06 0.00115 -0.51 -0.37 Alzheimer's disease (late onset); chr14:106776118 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs78462736 ENSG00000211974.3 IGHV2-70 -4.98 1.67e-06 0.00115 -0.51 -0.37 Alzheimer's disease (late onset); chr14:106779942 chr14:106723574~106724093:- PAAD cis rs6921919 0.583 rs2041230 ENSG00000216901.1 AL022393.7 4.98 1.67e-06 0.00115 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28397738 chr6:28176188~28176674:+ PAAD cis rs11673344 0.764 rs16971873 ENSG00000226686.6 LINC01535 4.98 1.68e-06 0.00115 0.51 0.37 Obesity-related traits; chr19:36978521 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs7260386 ENSG00000226686.6 LINC01535 4.98 1.68e-06 0.00116 0.5 0.37 Obesity-related traits; chr19:37158656 chr19:37251912~37265535:+ PAAD cis rs11673344 0.801 rs112263309 ENSG00000226686.6 LINC01535 4.98 1.68e-06 0.00116 0.5 0.37 Obesity-related traits; chr19:37160333 chr19:37251912~37265535:+ PAAD cis rs2283792 0.765 rs9607241 ENSG00000224086.5 LL22NC03-86G7.1 -4.98 1.68e-06 0.00116 -0.39 -0.37 Multiple sclerosis; chr22:21750584 chr22:21938293~21977632:+ PAAD cis rs4713118 0.587 rs61471148 ENSG00000226314.6 ZNF192P1 -4.98 1.68e-06 0.00116 -0.64 -0.37 Parkinson's disease; chr6:28069254 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393884 ENSG00000226314.6 ZNF192P1 -4.98 1.68e-06 0.00116 -0.64 -0.37 Depression; chr6:28079011 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393887 ENSG00000226314.6 ZNF192P1 -4.98 1.68e-06 0.00116 -0.64 -0.37 Depression; chr6:28091242 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs6922063 ENSG00000226314.6 ZNF192P1 -4.98 1.68e-06 0.00116 -0.64 -0.37 Depression; chr6:28126588 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs2275508 ENSG00000226314.6 ZNF192P1 -4.98 1.68e-06 0.00116 -0.64 -0.37 Depression; chr6:28126953 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs1904841 ENSG00000226314.6 ZNF192P1 -4.98 1.68e-06 0.00116 -0.64 -0.37 Depression; chr6:28140307 chr6:28161781~28169594:+ PAAD cis rs2274273 0.84 rs6573020 ENSG00000258413.1 RP11-665C16.6 -4.98 1.68e-06 0.00116 -0.46 -0.37 Protein biomarker; chr14:55404734 chr14:55262767~55272075:- PAAD cis rs2562456 0.516 rs56072098 ENSG00000213976.4 CTD-2561J22.2 4.98 1.68e-06 0.00116 0.42 0.37 Pain; chr19:21469158 chr19:21382865~21387177:+ PAAD cis rs4728142 0.584 rs7796963 ENSG00000275106.1 RP11-309L24.10 -4.98 1.68e-06 0.00116 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128988947 chr7:128952527~128953316:- PAAD cis rs4728142 0.604 rs7807018 ENSG00000275106.1 RP11-309L24.10 -4.98 1.68e-06 0.00116 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129000134 chr7:128952527~128953316:- PAAD cis rs4728142 0.564 rs11767711 ENSG00000275106.1 RP11-309L24.10 -4.98 1.68e-06 0.00116 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129011778 chr7:128952527~128953316:- PAAD cis rs4728142 0.584 rs6965542 ENSG00000275106.1 RP11-309L24.10 -4.98 1.68e-06 0.00116 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129015864 chr7:128952527~128953316:- PAAD cis rs6570726 0.791 rs379040 ENSG00000235652.6 RP11-545I5.3 4.98 1.69e-06 0.00116 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145567899 chr6:145799409~145886585:+ PAAD cis rs950169 0.579 rs11633088 ENSG00000259728.4 LINC00933 -4.98 1.69e-06 0.00116 -0.48 -0.37 Schizophrenia; chr15:84003429 chr15:84570649~84580175:+ PAAD cis rs4723738 1 rs7795499 ENSG00000227191.5 TRGC2 -4.98 1.69e-06 0.00116 -0.33 -0.37 Treatment response for severe sepsis; chr7:38228794 chr7:38239580~38368091:- PAAD cis rs2255336 0.938 rs2617152 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10380507 chr12:10363769~10398506:+ PAAD cis rs2255336 0.882 rs2733847 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10380608 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs2417734 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10380807 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs1382265 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10381206 chr12:10363769~10398506:+ PAAD cis rs2255336 0.882 rs2733853 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10381483 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs1600127 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10383648 chr12:10363769~10398506:+ PAAD cis rs2255336 0.882 rs2617156 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10384280 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs2617157 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10384299 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs2927561 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10384974 chr12:10363769~10398506:+ PAAD cis rs2255336 0.882 rs2126889 ENSG00000245648.1 RP11-277P12.20 4.98 1.69e-06 0.00116 0.56 0.37 Blood protein levels; chr12:10385280 chr12:10363769~10398506:+ PAAD cis rs1545257 0.514 rs2584940 ENSG00000242628.4 AC009228.1 4.98 1.69e-06 0.00116 0.44 0.37 Sjögren's syndrome; chr2:24418770 chr2:24214381~24221516:+ PAAD cis rs9322193 0.923 rs2342765 ENSG00000268592.3 RAET1E-AS1 4.98 1.69e-06 0.00117 0.45 0.37 Lung cancer; chr6:149858873 chr6:149863494~149919507:+ PAAD cis rs3779195 0.697 rs1688606 ENSG00000272950.1 RP11-307C18.1 4.98 1.69e-06 0.00117 0.59 0.37 Sex hormone-binding globulin levels; chr7:98345539 chr7:98322853~98323430:+ PAAD cis rs2243480 1 rs4718317 ENSG00000226824.5 RP4-756H11.3 4.98 1.7e-06 0.00117 0.67 0.37 Diabetic kidney disease; chr7:66183914 chr7:66654538~66669855:+ PAAD cis rs10510102 1 rs10886994 ENSG00000276742.1 RP11-500G22.4 4.98 1.7e-06 0.00117 0.55 0.37 Breast cancer; chr10:121841075 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200187 ENSG00000276742.1 RP11-500G22.4 4.98 1.7e-06 0.00117 0.55 0.37 Breast cancer; chr10:121843050 chr10:121956782~121957098:+ PAAD cis rs710913 0.816 rs1727098 ENSG00000237624.1 OXCT2P1 -4.98 1.7e-06 0.00117 -0.47 -0.37 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39523655 chr1:39514956~39516490:+ PAAD cis rs2904804 0.688 rs6601881 ENSG00000224251.5 RP11-499O7.7 4.98 1.7e-06 0.00117 0.42 0.37 Economic and political preferences (immigration/crime); chr10:4977409 chr10:4995488~4997380:+ PAAD cis rs710913 0.738 rs755247 ENSG00000237624.1 OXCT2P1 -4.98 1.7e-06 0.00117 -0.47 -0.37 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39528873 chr1:39514956~39516490:+ PAAD cis rs1075265 0.669 rs805317 ENSG00000233266.1 HMGB1P31 4.98 1.7e-06 0.00117 0.47 0.37 Chronotype;Morning vs. evening chronotype; chr2:53907867 chr2:54051334~54051760:+ PAAD cis rs8031584 0.958 rs34294266 ENSG00000260382.1 RP11-540B6.2 4.98 1.71e-06 0.00117 0.47 0.37 Huntington's disease progression; chr15:30954637 chr15:30882267~30883231:- PAAD cis rs11098499 0.675 rs11098534 ENSG00000245958.5 RP11-33B1.1 -4.98 1.71e-06 0.00117 -0.3 -0.37 Corneal astigmatism; chr4:119635617 chr4:119454791~119552025:+ PAAD cis rs2283792 0.566 rs1005579 ENSG00000228050.1 TOP3BP1 4.98 1.71e-06 0.00117 0.43 0.37 Multiple sclerosis; chr22:21946569 chr22:22223187~22224566:- PAAD cis rs7829975 0.871 rs777709 ENSG00000253893.2 FAM85B 4.98 1.71e-06 0.00117 0.55 0.37 Mood instability; chr8:8726362 chr8:8167819~8226614:- PAAD cis rs964611 0.882 rs16960809 ENSG00000259488.2 RP11-154J22.1 4.98 1.71e-06 0.00118 0.4 0.37 Metabolite levels (Pyroglutamine); chr15:48354318 chr15:48312353~48331856:- PAAD cis rs13178541 0.81 rs2304078 ENSG00000250378.1 RP11-119J18.1 -4.98 1.72e-06 0.00118 -0.54 -0.37 IgG glycosylation; chr5:135852525 chr5:135812667~135826582:+ PAAD cis rs748404 0.578 rs507178 ENSG00000249839.1 AC011330.5 -4.98 1.72e-06 0.00118 -0.56 -0.37 Lung cancer; chr15:43317937 chr15:43663654~43684339:- PAAD cis rs748404 0.578 rs478028 ENSG00000249839.1 AC011330.5 -4.98 1.72e-06 0.00118 -0.56 -0.37 Lung cancer; chr15:43318574 chr15:43663654~43684339:- PAAD cis rs748404 0.578 rs552701 ENSG00000249839.1 AC011330.5 -4.98 1.72e-06 0.00118 -0.56 -0.37 Lung cancer; chr15:43321612 chr15:43663654~43684339:- PAAD cis rs748404 0.578 rs573615 ENSG00000249839.1 AC011330.5 -4.98 1.72e-06 0.00118 -0.56 -0.37 Lung cancer; chr15:43322083 chr15:43663654~43684339:- PAAD cis rs17711722 0.528 rs73138179 ENSG00000237310.1 GS1-124K5.4 4.98 1.72e-06 0.00118 0.37 0.37 Calcium levels; chr7:65829495 chr7:66493706~66495474:+ PAAD cis rs1061377 0.748 rs12649085 ENSG00000249685.1 RP11-360F5.3 4.98 1.72e-06 0.00118 0.4 0.37 Uric acid levels; chr4:39106459 chr4:39133913~39135608:+ PAAD cis rs34375054 0.526 rs883315 ENSG00000279233.1 RP11-158L12.4 4.98 1.72e-06 0.00118 0.32 0.37 Post bronchodilator FEV1/FVC ratio; chr12:125192343 chr12:125138245~125141711:+ PAAD cis rs34375054 0.526 rs2343638 ENSG00000279233.1 RP11-158L12.4 4.98 1.72e-06 0.00118 0.32 0.37 Post bronchodilator FEV1/FVC ratio; chr12:125192576 chr12:125138245~125141711:+ PAAD cis rs9287719 0.967 rs6432121 ENSG00000234818.1 AC092687.5 4.98 1.73e-06 0.00119 0.42 0.37 Prostate cancer; chr2:10613678 chr2:10589166~10604830:+ PAAD cis rs1150668 0.768 rs1150709 ENSG00000204709.4 LINC01556 -4.98 1.73e-06 0.00119 -0.46 -0.37 Pubertal anthropometrics; chr6:28239585 chr6:28943877~28944537:+ PAAD cis rs375092 0.543 rs449271 ENSG00000230658.1 KLHL7-AS1 4.98 1.74e-06 0.00119 0.63 0.37 Personality dimensions; chr7:23376798 chr7:23101228~23105703:- PAAD cis rs7772486 0.875 rs6914813 ENSG00000235652.6 RP11-545I5.3 4.98 1.74e-06 0.00119 0.3 0.37 Lobe attachment (rater-scored or self-reported); chr6:146076662 chr6:145799409~145886585:+ PAAD cis rs2243480 1 rs316315 ENSG00000226824.5 RP4-756H11.3 4.98 1.74e-06 0.00119 0.58 0.37 Diabetic kidney disease; chr7:66126218 chr7:66654538~66669855:+ PAAD cis rs1075265 0.548 rs2542575 ENSG00000233266.1 HMGB1P31 4.98 1.74e-06 0.00119 0.47 0.37 Chronotype;Morning vs. evening chronotype; chr2:53821221 chr2:54051334~54051760:+ PAAD cis rs1075265 0.568 rs2542577 ENSG00000233266.1 HMGB1P31 4.98 1.74e-06 0.00119 0.47 0.37 Chronotype;Morning vs. evening chronotype; chr2:53822111 chr2:54051334~54051760:+ PAAD cis rs1075265 0.568 rs3095756 ENSG00000233266.1 HMGB1P31 4.98 1.74e-06 0.00119 0.47 0.37 Chronotype;Morning vs. evening chronotype; chr2:53822332 chr2:54051334~54051760:+ PAAD cis rs2404602 0.735 rs11637490 ENSG00000259422.1 RP11-593F23.1 -4.98 1.74e-06 0.00119 -0.45 -0.37 Blood metabolite levels; chr15:76467224 chr15:76174891~76181486:- PAAD cis rs453301 0.658 rs6983877 ENSG00000253893.2 FAM85B 4.98 1.74e-06 0.00119 0.52 0.37 Joint mobility (Beighton score); chr8:9047129 chr8:8167819~8226614:- PAAD cis rs9326248 0.52 rs74830 ENSG00000280143.1 AP000892.6 -4.98 1.74e-06 0.00119 -0.41 -0.37 Blood protein levels; chr11:117219842 chr11:117204967~117210292:+ PAAD cis rs763567 1 rs763567 ENSG00000271811.1 RP1-79C4.4 -4.98 1.74e-06 0.00119 -0.36 -0.37 Tonsillectomy; chr1:170596864 chr1:170667381~170669425:+ PAAD cis rs1075265 0.868 rs1877906 ENSG00000233266.1 HMGB1P31 4.98 1.74e-06 0.0012 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:54136700 chr2:54051334~54051760:+ PAAD cis rs6921919 0.583 rs12697938 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28373322 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs13437294 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28373758 chr6:28943877~28944537:+ PAAD cis rs6921919 0.609 rs9468357 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28374276 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs34513104 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28375566 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs9461456 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28376039 chr6:28943877~28944537:+ PAAD cis rs6921919 0.525 rs9468360 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28376661 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs16894021 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28377249 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs11751693 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28377306 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs7749736 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28378254 chr6:28943877~28944537:+ PAAD cis rs6921919 0.525 rs9468361 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28378541 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs7775132 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28379236 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs3734563 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28381948 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs1591913 ENSG00000204709.4 LINC01556 4.97 1.75e-06 0.0012 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28383951 chr6:28943877~28944537:+ PAAD cis rs7945705 0.875 rs10769955 ENSG00000254860.4 TMEM9B-AS1 -4.97 1.75e-06 0.0012 -0.42 -0.37 Hemoglobin concentration; chr11:8763100 chr11:8964675~8977527:+ PAAD cis rs2280018 0.963 rs12928424 ENSG00000260735.1 RP11-72I8.1 -4.97 1.75e-06 0.0012 -0.46 -0.37 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15056916 chr16:15094411~15109197:+ PAAD cis rs2280018 1 rs2280018 ENSG00000260735.1 RP11-72I8.1 -4.97 1.75e-06 0.0012 -0.46 -0.37 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15056976 chr16:15094411~15109197:+ PAAD cis rs807029 0.577 rs3740489 ENSG00000272572.1 RP11-179B2.2 -4.97 1.75e-06 0.0012 -0.46 -0.37 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100994481 chr10:100911103~100912739:- PAAD cis rs2904804 0.58 rs10128163 ENSG00000224251.5 RP11-499O7.7 4.97 1.75e-06 0.0012 0.42 0.37 Economic and political preferences (immigration/crime); chr10:4976520 chr10:4995488~4997380:+ PAAD cis rs34375054 0.525 rs7133614 ENSG00000279233.1 RP11-158L12.4 4.97 1.76e-06 0.0012 0.32 0.37 Post bronchodilator FEV1/FVC ratio; chr12:125121411 chr12:125138245~125141711:+ PAAD cis rs34375054 0.525 rs7133006 ENSG00000279233.1 RP11-158L12.4 4.97 1.76e-06 0.0012 0.32 0.37 Post bronchodilator FEV1/FVC ratio; chr12:125121577 chr12:125138245~125141711:+ PAAD cis rs34375054 0.525 rs7133864 ENSG00000279233.1 RP11-158L12.4 4.97 1.76e-06 0.0012 0.32 0.37 Post bronchodilator FEV1/FVC ratio; chr12:125121634 chr12:125138245~125141711:+ PAAD cis rs12908161 0.96 rs62019463 ENSG00000225151.9 GOLGA2P7 -4.97 1.76e-06 0.00121 -0.46 -0.37 Schizophrenia; chr15:84744856 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs62019464 ENSG00000225151.9 GOLGA2P7 -4.97 1.76e-06 0.00121 -0.46 -0.37 Schizophrenia; chr15:84751238 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs12910012 ENSG00000225151.9 GOLGA2P7 -4.97 1.76e-06 0.00121 -0.46 -0.37 Schizophrenia; chr15:84755431 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs12899981 ENSG00000225151.9 GOLGA2P7 -4.97 1.76e-06 0.00121 -0.46 -0.37 Schizophrenia; chr15:84759142 chr15:84199311~84230136:- PAAD cis rs4853525 0.59 rs2203715 ENSG00000235852.1 AC005540.3 4.97 1.76e-06 0.00121 0.55 0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190944157 chr2:190880797~190882059:- PAAD cis rs4698412 0.617 rs35519415 ENSG00000214846.4 RP11-115L11.1 4.97 1.76e-06 0.00121 0.4 0.37 Parkinson's disease; chr4:15708707 chr4:15730962~15731627:- PAAD cis rs1075265 0.756 rs809280 ENSG00000233266.1 HMGB1P31 4.97 1.76e-06 0.00121 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:53921270 chr2:54051334~54051760:+ PAAD cis rs763567 1 rs2022372 ENSG00000271811.1 RP1-79C4.4 -4.97 1.77e-06 0.00121 -0.36 -0.37 Tonsillectomy; chr1:170620769 chr1:170667381~170669425:+ PAAD cis rs763567 0.967 rs1234274 ENSG00000271811.1 RP1-79C4.4 4.97 1.77e-06 0.00121 0.36 0.37 Tonsillectomy; chr1:170627232 chr1:170667381~170669425:+ PAAD cis rs763567 0.81 rs638704 ENSG00000271811.1 RP1-79C4.4 4.97 1.77e-06 0.00121 0.36 0.37 Tonsillectomy; chr1:170629046 chr1:170667381~170669425:+ PAAD cis rs6921919 0.583 rs7740351 ENSG00000204709.4 LINC01556 4.97 1.77e-06 0.00121 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28431635 chr6:28943877~28944537:+ PAAD cis rs4927850 0.709 rs6783079 ENSG00000231464.1 AC024937.4 4.97 1.77e-06 0.00121 0.46 0.37 Pancreatic cancer; chr3:195925837 chr3:195996738~195998233:+ PAAD cis rs4927850 0.709 rs6765762 ENSG00000231464.1 AC024937.4 4.97 1.77e-06 0.00121 0.46 0.37 Pancreatic cancer; chr3:195925980 chr3:195996738~195998233:+ PAAD cis rs919433 0.963 rs10153881 ENSG00000231621.1 AC013264.2 4.97 1.77e-06 0.00121 0.36 0.37 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197306374 chr2:197197991~197199273:+ PAAD cis rs2739330 0.929 rs5751777 ENSG00000206090.4 AP000350.7 4.97 1.77e-06 0.00121 0.48 0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23924860 chr22:23939998~23942798:+ PAAD cis rs1823913 1 rs4853561 ENSG00000280083.1 RP11-317J9.1 4.97 1.77e-06 0.00121 0.48 0.37 Obesity-related traits; chr2:191242980 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs6704784 ENSG00000280083.1 RP11-317J9.1 4.97 1.77e-06 0.00121 0.48 0.37 Obesity-related traits; chr2:191244832 chr2:191154118~191156070:- PAAD cis rs7712401 0.601 rs246285 ENSG00000263432.2 RN7SL689P -4.97 1.78e-06 0.00121 -0.48 -0.37 Mean platelet volume; chr5:122909273 chr5:123022487~123022783:- PAAD cis rs2115630 0.691 rs2292462 ENSG00000225151.9 GOLGA2P7 4.97 1.78e-06 0.00122 0.44 0.37 P wave terminal force; chr15:84657523 chr15:84199311~84230136:- PAAD cis rs11079757 0.681 rs34811916 ENSG00000262879.4 RP11-156P1.3 4.97 1.78e-06 0.00122 0.48 0.37 Erythema nodosum in inflammatory bowel disease; chr17:47111431 chr17:46984045~47100323:- PAAD cis rs9322193 0.886 rs4870055 ENSG00000268592.3 RAET1E-AS1 4.97 1.78e-06 0.00122 0.44 0.37 Lung cancer; chr6:149848433 chr6:149863494~149919507:+ PAAD cis rs66887589 0.934 rs2715016 ENSG00000248280.1 RP11-33B1.2 -4.97 1.78e-06 0.00122 -0.34 -0.37 Diastolic blood pressure; chr4:119531201 chr4:119440561~119450157:- PAAD cis rs4853525 0.62 rs2066804 ENSG00000235852.1 AC005540.3 4.97 1.79e-06 0.00122 0.55 0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190977033 chr2:190880797~190882059:- PAAD cis rs1075265 0.704 rs805405 ENSG00000233266.1 HMGB1P31 4.97 1.79e-06 0.00122 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:53891014 chr2:54051334~54051760:+ PAAD cis rs2243480 1 rs709607 ENSG00000226824.5 RP4-756H11.3 4.97 1.79e-06 0.00122 0.66 0.37 Diabetic kidney disease; chr7:65984554 chr7:66654538~66669855:+ PAAD cis rs2274273 0.901 rs10140801 ENSG00000258413.1 RP11-665C16.6 -4.97 1.79e-06 0.00122 -0.48 -0.37 Protein biomarker; chr14:55263686 chr14:55262767~55272075:- PAAD cis rs4423214 0.559 rs10898201 ENSG00000254682.1 RP11-660L16.2 -4.97 1.79e-06 0.00123 -0.61 -0.37 Vitamin D levels; chr11:71490481 chr11:71448674~71452157:+ PAAD cis rs710913 0.745 rs67563067 ENSG00000237624.1 OXCT2P1 -4.97 1.8e-06 0.00123 -0.46 -0.37 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39581323 chr1:39514956~39516490:+ PAAD cis rs4835473 0.932 rs7356157 ENSG00000251600.4 RP11-673E1.1 4.97 1.8e-06 0.00123 0.41 0.37 Immature fraction of reticulocytes; chr4:143739233 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2127788 ENSG00000251600.4 RP11-673E1.1 4.97 1.8e-06 0.00123 0.41 0.37 Immature fraction of reticulocytes; chr4:143741996 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6851999 ENSG00000251600.4 RP11-673E1.1 4.97 1.8e-06 0.00123 0.41 0.37 Immature fraction of reticulocytes; chr4:143742567 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6852195 ENSG00000251600.4 RP11-673E1.1 4.97 1.8e-06 0.00123 0.41 0.37 Immature fraction of reticulocytes; chr4:143742584 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1839448 ENSG00000251600.4 RP11-673E1.1 4.97 1.8e-06 0.00123 0.41 0.37 Immature fraction of reticulocytes; chr4:143752113 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs10021860 ENSG00000251600.4 RP11-673E1.1 4.97 1.8e-06 0.00123 0.41 0.37 Immature fraction of reticulocytes; chr4:143754593 chr4:143912331~143982454:+ PAAD cis rs2274273 0.87 rs8021583 ENSG00000258413.1 RP11-665C16.6 -4.97 1.8e-06 0.00123 -0.48 -0.37 Protein biomarker; chr14:55282889 chr14:55262767~55272075:- PAAD cis rs10510102 0.935 rs11200260 ENSG00000276742.1 RP11-500G22.4 4.97 1.8e-06 0.00123 0.56 0.37 Breast cancer; chr10:121920169 chr10:121956782~121957098:+ PAAD cis rs11673344 0.864 rs7259513 ENSG00000226686.6 LINC01535 4.97 1.8e-06 0.00123 0.51 0.37 Obesity-related traits; chr19:37085802 chr19:37251912~37265535:+ PAAD cis rs66887589 1 rs66887589 ENSG00000248280.1 RP11-33B1.2 -4.97 1.8e-06 0.00123 -0.33 -0.37 Diastolic blood pressure; chr4:119588124 chr4:119440561~119450157:- PAAD cis rs2153535 0.58 rs4451187 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8473677 chr6:8784178~8785445:+ PAAD cis rs2153535 0.504 rs4493781 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8473708 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs5026687 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8473724 chr6:8784178~8785445:+ PAAD cis rs10875746 0.551 rs3185921 ENSG00000240399.1 RP1-228P16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Longevity (90 years and older); chr12:48340948 chr12:48054813~48055591:- PAAD cis rs950169 0.656 rs748455 ENSG00000259728.4 LINC00933 4.97 1.81e-06 0.00123 0.47 0.37 Schizophrenia; chr15:84606344 chr15:84570649~84580175:+ PAAD cis rs2153535 0.563 rs1737586 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8535664 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs2015281 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8539440 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9505474 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8539561 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs2327091 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8540136 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9502719 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8540799 chr6:8784178~8785445:+ PAAD cis rs2153535 0.547 rs9502720 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8541129 chr6:8784178~8785445:+ PAAD cis rs2153535 0.584 rs9502721 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8541146 chr6:8784178~8785445:+ PAAD cis rs2153535 0.607 rs9502722 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8541250 chr6:8784178~8785445:+ PAAD cis rs2153535 0.584 rs9502723 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8541271 chr6:8784178~8785445:+ PAAD cis rs2153535 0.547 rs9505475 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8542657 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs6906170 ENSG00000230939.1 RP11-314C16.1 -4.97 1.81e-06 0.00123 -0.4 -0.37 Motion sickness; chr6:8542895 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7741403 ENSG00000230939.1 RP11-314C16.1 4.97 1.81e-06 0.00123 0.39 0.37 Motion sickness; chr6:8530345 chr6:8784178~8785445:+ PAAD cis rs17711722 0.653 rs2460421 ENSG00000237310.1 GS1-124K5.4 -4.97 1.81e-06 0.00123 -0.35 -0.37 Calcium levels; chr7:66026136 chr7:66493706~66495474:+ PAAD cis rs964611 0.882 rs7162774 ENSG00000259488.2 RP11-154J22.1 4.97 1.81e-06 0.00123 0.43 0.37 Metabolite levels (Pyroglutamine); chr15:48367336 chr15:48312353~48331856:- PAAD cis rs633715 0.766 rs35215534 ENSG00000254154.7 RP4-798P15.3 -4.97 1.81e-06 0.00123 -0.36 -0.37 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177861491 chr1:177928788~178038007:- PAAD cis rs633715 0.766 rs4142027 ENSG00000254154.7 RP4-798P15.3 -4.97 1.81e-06 0.00123 -0.36 -0.37 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177864441 chr1:177928788~178038007:- PAAD cis rs633715 0.766 rs34472009 ENSG00000254154.7 RP4-798P15.3 -4.97 1.81e-06 0.00123 -0.36 -0.37 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177866503 chr1:177928788~178038007:- PAAD cis rs2882667 0.638 rs6895690 ENSG00000253404.1 AC034243.1 4.97 1.81e-06 0.00124 0.43 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139130162 chr5:138744434~138753309:- PAAD cis rs919433 0.963 rs12469546 ENSG00000231621.1 AC013264.2 4.97 1.81e-06 0.00124 0.36 0.37 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197314102 chr2:197197991~197199273:+ PAAD cis rs919433 0.963 rs6738836 ENSG00000231621.1 AC013264.2 4.97 1.81e-06 0.00124 0.36 0.37 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197317708 chr2:197197991~197199273:+ PAAD cis rs919433 0.963 rs4850430 ENSG00000231621.1 AC013264.2 4.97 1.81e-06 0.00124 0.36 0.37 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197318072 chr2:197197991~197199273:+ PAAD cis rs919433 0.963 rs10166569 ENSG00000231621.1 AC013264.2 4.97 1.81e-06 0.00124 0.36 0.37 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197318715 chr2:197197991~197199273:+ PAAD cis rs2658782 0.694 rs3019221 ENSG00000279684.1 RP11-755E23.2 -4.97 1.81e-06 0.00124 -0.59 -0.37 Pulmonary function decline; chr11:93346534 chr11:93286629~93288903:- PAAD cis rs964611 0.882 rs11629707 ENSG00000259488.2 RP11-154J22.1 4.97 1.81e-06 0.00124 0.4 0.37 Metabolite levels (Pyroglutamine); chr15:48348148 chr15:48312353~48331856:- PAAD cis rs2882667 0.66 rs3088052 ENSG00000253404.1 AC034243.1 4.97 1.81e-06 0.00124 0.43 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139121126 chr5:138744434~138753309:- PAAD cis rs11089937 0.597 rs9619794 ENSG00000211639.2 IGLV4-60 4.97 1.81e-06 0.00124 0.39 0.37 Periodontitis (PAL4Q3); chr22:22132999 chr22:22162199~22162681:+ PAAD cis rs73219805 0.554 rs3808569 ENSG00000228451.3 SDAD1P1 -4.97 1.81e-06 0.00124 -0.66 -0.37 Schizophrenia; chr8:26356252 chr8:26379259~26382953:- PAAD cis rs12908161 1 rs17600551 ENSG00000225151.9 GOLGA2P7 -4.97 1.82e-06 0.00124 -0.46 -0.37 Schizophrenia; chr15:84776027 chr15:84199311~84230136:- PAAD cis rs12908161 1 rs62019469 ENSG00000225151.9 GOLGA2P7 -4.97 1.82e-06 0.00124 -0.46 -0.37 Schizophrenia; chr15:84777989 chr15:84199311~84230136:- PAAD cis rs964611 0.882 rs75094472 ENSG00000259488.2 RP11-154J22.1 -4.97 1.82e-06 0.00124 -0.41 -0.37 Metabolite levels (Pyroglutamine); chr15:48351917 chr15:48312353~48331856:- PAAD cis rs11089937 0.54 rs9622920 ENSG00000211639.2 IGLV4-60 -4.97 1.82e-06 0.00124 -0.39 -0.37 Periodontitis (PAL4Q3); chr22:22133024 chr22:22162199~22162681:+ PAAD cis rs9595908 0.931 rs9591001 ENSG00000212293.1 SNORA16 -4.97 1.82e-06 0.00124 -0.43 -0.37 Body mass index; chr13:32468733 chr13:32420390~32420516:- PAAD cis rs4660456 0.913 rs2361651 ENSG00000237899.1 RP4-739H11.3 4.97 1.82e-06 0.00124 0.52 0.37 Platelet count; chr1:40764542 chr1:40669089~40687588:- PAAD cis rs8031584 0.958 rs61997079 ENSG00000260382.1 RP11-540B6.2 4.97 1.82e-06 0.00124 0.47 0.37 Huntington's disease progression; chr15:30946068 chr15:30882267~30883231:- PAAD cis rs8031584 0.958 rs11637469 ENSG00000260382.1 RP11-540B6.2 4.97 1.82e-06 0.00124 0.47 0.37 Huntington's disease progression; chr15:30946580 chr15:30882267~30883231:- PAAD cis rs8031584 0.958 rs8034856 ENSG00000260382.1 RP11-540B6.2 4.97 1.82e-06 0.00124 0.47 0.37 Huntington's disease progression; chr15:30948754 chr15:30882267~30883231:- PAAD cis rs8031584 0.872 rs11634761 ENSG00000260382.1 RP11-540B6.2 4.97 1.82e-06 0.00124 0.47 0.37 Huntington's disease progression; chr15:30950970 chr15:30882267~30883231:- PAAD cis rs75422866 0.85 rs73111210 ENSG00000257433.4 RP1-197B17.3 4.97 1.82e-06 0.00124 0.95 0.37 Pneumonia; chr12:47576949 chr12:47706085~47742294:+ PAAD cis rs3762637 0.943 rs28372690 ENSG00000272758.4 RP11-299J3.8 -4.96 1.83e-06 0.00125 -0.56 -0.37 LDL cholesterol levels; chr3:122564248 chr3:122416207~122443180:+ PAAD cis rs673078 0.66 rs76842574 ENSG00000275759.1 RP11-131L12.3 -4.96 1.83e-06 0.00125 -0.46 -0.37 Glucose homeostasis traits; chr12:118371789 chr12:118428281~118428870:+ PAAD cis rs673078 0.615 rs56324376 ENSG00000275759.1 RP11-131L12.3 -4.96 1.83e-06 0.00125 -0.46 -0.37 Glucose homeostasis traits; chr12:118372134 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs59594854 ENSG00000275759.1 RP11-131L12.3 -4.96 1.83e-06 0.00125 -0.46 -0.37 Glucose homeostasis traits; chr12:118374000 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs4766899 ENSG00000275759.1 RP11-131L12.3 -4.96 1.83e-06 0.00125 -0.46 -0.37 Glucose homeostasis traits; chr12:118374888 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs10850967 ENSG00000275759.1 RP11-131L12.3 -4.96 1.83e-06 0.00125 -0.46 -0.37 Glucose homeostasis traits; chr12:118380072 chr12:118428281~118428870:+ PAAD cis rs2274273 0.84 rs11626751 ENSG00000258413.1 RP11-665C16.6 -4.96 1.83e-06 0.00125 -0.48 -0.37 Protein biomarker; chr14:55368509 chr14:55262767~55272075:- PAAD cis rs2348418 0.715 rs1912782 ENSG00000247934.4 RP11-967K21.1 4.96 1.83e-06 0.00125 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28568774 chr12:28163298~28190738:- PAAD cis rs6860806 0.507 rs183898 ENSG00000233006.5 AC034220.3 -4.96 1.83e-06 0.00125 -0.34 -0.37 Breast cancer; chr5:132381210 chr5:132311285~132369916:- PAAD cis rs6921919 0.583 rs2071965 ENSG00000216901.1 AL022393.7 4.96 1.83e-06 0.00125 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28435448 chr6:28176188~28176674:+ PAAD cis rs8177376 1 rs598169 ENSG00000254905.1 RP11-712L6.7 4.96 1.83e-06 0.00125 0.5 0.37 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126219158 chr11:126292922~126294254:- PAAD cis rs8177376 1 rs655540 ENSG00000254905.1 RP11-712L6.7 4.96 1.83e-06 0.00125 0.5 0.37 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126281347 chr11:126292922~126294254:- PAAD cis rs9473147 0.543 rs4711880 ENSG00000270761.1 RP11-385F7.1 -4.96 1.83e-06 0.00125 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47512940 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs9473126 ENSG00000270761.1 RP11-385F7.1 -4.96 1.83e-06 0.00125 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47514097 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs4715025 ENSG00000270761.1 RP11-385F7.1 -4.96 1.83e-06 0.00125 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47515917 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs7767350 ENSG00000270761.1 RP11-385F7.1 -4.96 1.83e-06 0.00125 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47517390 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs10948363 ENSG00000270761.1 RP11-385F7.1 -4.96 1.83e-06 0.00125 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47520026 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs2171089 ENSG00000270761.1 RP11-385F7.1 -4.96 1.83e-06 0.00125 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47548075 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs9369716 ENSG00000270761.1 RP11-385F7.1 -4.96 1.83e-06 0.00125 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47584444 chr6:47477243~47477572:- PAAD cis rs16828019 0.929 rs2363805 ENSG00000235358.1 RP11-399E6.1 4.96 1.84e-06 0.00125 0.7 0.37 Intelligence (multi-trait analysis); chr1:41253762 chr1:41242373~41284861:+ PAAD cis rs16828019 0.852 rs71648540 ENSG00000235358.1 RP11-399E6.1 4.96 1.84e-06 0.00125 0.7 0.37 Intelligence (multi-trait analysis); chr1:41256623 chr1:41242373~41284861:+ PAAD cis rs6565180 1 rs68051857 ENSG00000183604.13 SMG1P5 -4.96 1.84e-06 0.00125 -0.42 -0.37 Tonsillectomy; chr16:30348690 chr16:30267553~30335374:- PAAD cis rs11098499 0.863 rs17050695 ENSG00000245958.5 RP11-33B1.1 -4.96 1.84e-06 0.00125 -0.31 -0.37 Corneal astigmatism; chr4:119568372 chr4:119454791~119552025:+ PAAD cis rs2333194 0.875 rs10220356 ENSG00000258695.2 RP3-414A15.2 4.96 1.84e-06 0.00125 0.41 0.37 Bipolar disorder with mood-incongruent psychosis; chr14:73342768 chr14:73522878~73530610:+ PAAD cis rs4835473 0.932 rs1813908 ENSG00000251600.4 RP11-673E1.1 4.96 1.84e-06 0.00125 0.43 0.37 Immature fraction of reticulocytes; chr4:143728174 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs4835454 ENSG00000251600.4 RP11-673E1.1 4.96 1.84e-06 0.00125 0.43 0.37 Immature fraction of reticulocytes; chr4:143730081 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1450250 ENSG00000251600.4 RP11-673E1.1 4.96 1.84e-06 0.00125 0.43 0.37 Immature fraction of reticulocytes; chr4:143731873 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7664248 ENSG00000251600.4 RP11-673E1.1 4.96 1.84e-06 0.00125 0.43 0.37 Immature fraction of reticulocytes; chr4:143732554 chr4:143912331~143982454:+ PAAD cis rs2179367 0.959 rs2262617 ENSG00000231760.4 RP11-350J20.5 4.96 1.84e-06 0.00125 0.48 0.37 Dupuytren's disease; chr6:149438590 chr6:149796151~149826294:- PAAD cis rs7727544 0.735 rs272875 ENSG00000233006.5 AC034220.3 4.96 1.84e-06 0.00125 0.3 0.37 Blood metabolite levels; chr5:132339195 chr5:132311285~132369916:- PAAD cis rs875971 0.545 rs1796226 ENSG00000226824.5 RP4-756H11.3 -4.96 1.85e-06 0.00126 -0.52 -0.37 Aortic root size; chr7:66622723 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs1796217 ENSG00000226824.5 RP4-756H11.3 4.96 1.85e-06 0.00126 0.52 0.37 Aortic root size; chr7:66620931 chr7:66654538~66669855:+ PAAD cis rs1075232 0.737 rs4779876 ENSG00000215302.7 CTD-3092A11.1 -4.96 1.85e-06 0.00126 -0.81 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31442233 chr15:30470779~30507623:+ PAAD cis rs10463554 0.927 rs34798 ENSG00000175749.11 EIF3KP1 4.96 1.85e-06 0.00126 0.6 0.37 Parkinson's disease; chr5:103090047 chr5:103032376~103033031:+ PAAD cis rs992157 0.764 rs1870123 ENSG00000261338.2 RP11-378A13.1 4.96 1.85e-06 0.00126 0.44 0.37 Colorectal cancer; chr2:218322975 chr2:218255319~218257366:+ PAAD cis rs8062405 0.54 rs193628 ENSG00000259982.1 CDC37P1 -4.96 1.86e-06 0.00126 -0.39 -0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28570821 chr16:28700294~28701540:- PAAD cis rs11673344 0.864 rs703530 ENSG00000226686.6 LINC01535 4.96 1.86e-06 0.00126 0.5 0.37 Obesity-related traits; chr19:37010016 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs826322 ENSG00000226686.6 LINC01535 4.96 1.86e-06 0.00126 0.5 0.37 Obesity-related traits; chr19:37013694 chr19:37251912~37265535:+ PAAD cis rs11673344 0.8 rs826323 ENSG00000226686.6 LINC01535 4.96 1.86e-06 0.00126 0.5 0.37 Obesity-related traits; chr19:37014051 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs703535 ENSG00000226686.6 LINC01535 4.96 1.86e-06 0.00126 0.5 0.37 Obesity-related traits; chr19:37014838 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs703537 ENSG00000226686.6 LINC01535 4.96 1.86e-06 0.00126 0.5 0.37 Obesity-related traits; chr19:37016827 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs2562587 ENSG00000226686.6 LINC01535 4.96 1.86e-06 0.00126 0.5 0.37 Obesity-related traits; chr19:37019357 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs2562595 ENSG00000226686.6 LINC01535 4.96 1.86e-06 0.00126 0.5 0.37 Obesity-related traits; chr19:37023964 chr19:37251912~37265535:+ PAAD cis rs11673344 0.832 rs8101407 ENSG00000226686.6 LINC01535 4.96 1.86e-06 0.00126 0.5 0.37 Obesity-related traits; chr19:37024444 chr19:37251912~37265535:+ PAAD cis rs1185460 0.967 rs1784459 ENSG00000271751.1 RP11-110I1.14 -4.96 1.86e-06 0.00126 -0.48 -0.37 Coronary artery disease; chr11:119067677 chr11:119065263~119065677:- PAAD cis rs1185460 0.967 rs1786684 ENSG00000271751.1 RP11-110I1.14 -4.96 1.86e-06 0.00126 -0.48 -0.37 Coronary artery disease; chr11:119067724 chr11:119065263~119065677:- PAAD cis rs7250849 0.79 rs73052830 ENSG00000273837.1 LLNLR-470E3.1 -4.96 1.86e-06 0.00126 -0.53 -0.37 Blood protein levels; chr19:51657512 chr19:51639478~51639931:- PAAD cis rs1185460 0.967 rs1786685 ENSG00000271751.1 RP11-110I1.14 -4.96 1.87e-06 0.00127 -0.48 -0.37 Coronary artery disease; chr11:119068246 chr11:119065263~119065677:- PAAD cis rs1185460 0.967 rs1784302 ENSG00000271751.1 RP11-110I1.14 -4.96 1.87e-06 0.00127 -0.48 -0.37 Coronary artery disease; chr11:119070247 chr11:119065263~119065677:- PAAD cis rs9926296 0.528 rs4785721 ENSG00000260259.1 RP11-368I7.4 -4.96 1.87e-06 0.00127 -0.46 -0.37 Vitiligo; chr16:89773589 chr16:89682620~89686569:- PAAD cis rs6921919 0.583 rs4254981 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28403625 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs6928771 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28407432 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs6928773 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28407433 chr6:28176188~28176674:+ PAAD cis rs6921919 0.525 rs6929825 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28411182 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs35599905 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28411886 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs1124131 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28412471 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs6899389 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28413363 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs6922374 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28413495 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs6899603 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28413528 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs6922429 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28413568 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs6922169 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28415155 chr6:28176188~28176674:+ PAAD cis rs6921919 0.559 rs13210866 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28416065 chr6:28176188~28176674:+ PAAD cis rs6921919 0.609 rs36018474 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28417752 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs13201726 ENSG00000216901.1 AL022393.7 4.96 1.87e-06 0.00127 0.49 0.37 Autism spectrum disorder or schizophrenia; chr6:28417774 chr6:28176188~28176674:+ PAAD cis rs964611 0.938 rs7163887 ENSG00000259488.2 RP11-154J22.1 4.96 1.87e-06 0.00127 0.43 0.37 Metabolite levels (Pyroglutamine); chr15:48367357 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4630496 ENSG00000259488.2 RP11-154J22.1 -4.96 1.87e-06 0.00127 -0.43 -0.37 Metabolite levels (Pyroglutamine); chr15:48366466 chr15:48312353~48331856:- PAAD cis rs694739 0.894 rs11601860 ENSG00000236935.1 AP003774.1 4.96 1.87e-06 0.00127 0.41 0.37 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64342950 chr11:64325050~64329504:- PAAD cis rs7772486 0.806 rs4243478 ENSG00000235652.6 RP11-545I5.3 -4.96 1.87e-06 0.00127 -0.32 -0.37 Lobe attachment (rater-scored or self-reported); chr6:145963424 chr6:145799409~145886585:+ PAAD cis rs7078219 0.576 rs989979 ENSG00000228778.1 RP11-129J12.1 -4.96 1.87e-06 0.00127 -0.4 -0.37 Dental caries; chr10:99562666 chr10:99527081~99528261:+ PAAD cis rs4660456 0.956 rs4660457 ENSG00000237899.1 RP4-739H11.3 -4.96 1.88e-06 0.00127 -0.5 -0.37 Platelet count; chr1:40774121 chr1:40669089~40687588:- PAAD cis rs7945705 0.936 rs978636 ENSG00000254860.4 TMEM9B-AS1 -4.96 1.88e-06 0.00127 -0.43 -0.37 Hemoglobin concentration; chr11:8815049 chr11:8964675~8977527:+ PAAD cis rs2115630 0.967 rs12595786 ENSG00000259728.4 LINC00933 -4.96 1.88e-06 0.00127 -0.46 -0.37 P wave terminal force; chr15:84793439 chr15:84570649~84580175:+ PAAD cis rs13178541 0.748 rs4317317 ENSG00000250378.1 RP11-119J18.1 -4.96 1.88e-06 0.00127 -0.58 -0.37 IgG glycosylation; chr5:135740765 chr5:135812667~135826582:+ PAAD cis rs9601248 0.711 rs9530937 ENSG00000227354.5 RBM26-AS1 -4.96 1.88e-06 0.00127 -0.36 -0.37 Major depressive disorder; chr13:79603701 chr13:79406309~79424328:+ PAAD cis rs6844153 0.68 rs6833053 ENSG00000240005.4 RP11-293A21.1 -4.96 1.88e-06 0.00128 -0.54 -0.37 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26870838 chr4:26859806~26860599:- PAAD cis rs2948294 0.588 rs4840913 ENSG00000253893.2 FAM85B -4.96 1.89e-06 0.00128 -0.52 -0.37 Red cell distribution width; chr8:8259384 chr8:8167819~8226614:- PAAD cis rs950169 0.509 rs71395455 ENSG00000259728.4 LINC00933 4.96 1.89e-06 0.00128 0.47 0.37 Schizophrenia; chr15:84610573 chr15:84570649~84580175:+ PAAD cis rs4268898 0.76 rs4665675 ENSG00000242628.4 AC009228.1 4.96 1.89e-06 0.00128 0.45 0.37 Asthma; chr2:24245263 chr2:24214381~24221516:+ PAAD cis rs6860806 0.531 rs274556 ENSG00000233006.5 AC034220.3 -4.96 1.89e-06 0.00128 -0.34 -0.37 Breast cancer; chr5:132386383 chr5:132311285~132369916:- PAAD cis rs875971 0.862 rs6460307 ENSG00000237310.1 GS1-124K5.4 4.96 1.89e-06 0.00128 0.38 0.37 Aortic root size; chr7:66595884 chr7:66493706~66495474:+ PAAD cis rs1322639 0.614 rs6925188 ENSG00000261039.2 RP11-417E7.2 -4.96 1.89e-06 0.00128 -0.61 -0.37 Pulse pressure; chr6:169163242 chr6:169175304~169182740:- PAAD cis rs2281636 0.691 rs6584306 ENSG00000233690.1 EBAG9P1 4.96 1.9e-06 0.00128 0.43 0.37 Obesity-related traits; chr10:99662739 chr10:99697407~99697949:- PAAD cis rs950169 0.922 rs11631096 ENSG00000259295.5 CSPG4P12 4.96 1.9e-06 0.00128 0.41 0.37 Schizophrenia; chr15:84557698 chr15:85191438~85213905:+ PAAD cis rs950169 0.84 rs62019457 ENSG00000259295.5 CSPG4P12 4.96 1.9e-06 0.00128 0.41 0.37 Schizophrenia; chr15:84558911 chr15:85191438~85213905:+ PAAD cis rs950169 0.922 rs67804993 ENSG00000259295.5 CSPG4P12 4.96 1.9e-06 0.00128 0.41 0.37 Schizophrenia; chr15:84560799 chr15:85191438~85213905:+ PAAD cis rs4664293 0.836 rs13016015 ENSG00000226266.5 AC009961.3 -4.96 1.9e-06 0.00128 -0.45 -0.37 Monocyte percentage of white cells; chr2:159790018 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs2114626 ENSG00000226266.5 AC009961.3 4.96 1.9e-06 0.00128 0.45 0.37 Monocyte percentage of white cells; chr2:159783459 chr2:159670708~159712435:- PAAD cis rs7208859 0.673 rs11655623 ENSG00000266490.1 CTD-2349P21.9 4.96 1.9e-06 0.00129 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30835155 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs73277960 ENSG00000266490.1 CTD-2349P21.9 4.96 1.9e-06 0.00129 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30850423 chr17:30792372~30792833:+ PAAD cis rs950027 0.549 rs9920634 ENSG00000259433.2 CTD-2651B20.4 4.96 1.9e-06 0.00129 0.42 0.37 Response to fenofibrate (adiponectin levels); chr15:45304348 chr15:45330209~45332634:- PAAD cis rs964611 0.882 rs1905612 ENSG00000259488.2 RP11-154J22.1 4.96 1.9e-06 0.00129 0.41 0.37 Metabolite levels (Pyroglutamine); chr15:48363720 chr15:48312353~48331856:- PAAD cis rs2348418 0.864 rs11049716 ENSG00000247934.4 RP11-967K21.1 4.95 1.91e-06 0.00129 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28564713 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7136843 ENSG00000247934.4 RP11-967K21.1 4.95 1.91e-06 0.00129 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28564875 chr12:28163298~28190738:- PAAD cis rs2348418 0.831 rs7137119 ENSG00000247934.4 RP11-967K21.1 4.95 1.91e-06 0.00129 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28565058 chr12:28163298~28190738:- PAAD cis rs2348418 0.831 rs7296538 ENSG00000247934.4 RP11-967K21.1 -4.95 1.91e-06 0.00129 -0.36 -0.37 Lung function (FEV1);Lung function (FVC); chr12:28558850 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7957495 ENSG00000247934.4 RP11-967K21.1 -4.95 1.91e-06 0.00129 -0.36 -0.37 Lung function (FEV1);Lung function (FVC); chr12:28564522 chr12:28163298~28190738:- PAAD cis rs7727544 0.735 rs272842 ENSG00000233006.5 AC034220.3 4.95 1.91e-06 0.00129 0.3 0.37 Blood metabolite levels; chr5:132320824 chr5:132311285~132369916:- PAAD cis rs10170846 0.893 rs1447108 ENSG00000261428.2 RP11-16P6.1 4.95 1.91e-06 0.00129 0.5 0.37 Schizophrenia (inflammation and infection response interaction); chr2:222677512 chr2:222566899~222569719:- PAAD cis rs10170846 0.893 rs12614976 ENSG00000261428.2 RP11-16P6.1 4.95 1.91e-06 0.00129 0.5 0.37 Schizophrenia (inflammation and infection response interaction); chr2:222678177 chr2:222566899~222569719:- PAAD cis rs11079159 0.958 rs11656277 ENSG00000263096.1 RP11-515O17.2 4.95 1.91e-06 0.00129 0.49 0.37 QRS duration; chr17:55293686 chr17:55271504~55273653:- PAAD cis rs7208859 0.673 rs11656462 ENSG00000266490.1 CTD-2349P21.9 4.95 1.91e-06 0.0013 0.5 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30833682 chr17:30792372~30792833:+ PAAD cis rs6844153 0.752 rs11737218 ENSG00000240005.4 RP11-293A21.1 4.95 1.92e-06 0.0013 0.54 0.37 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26884151 chr4:26859806~26860599:- PAAD cis rs2111504 0.887 rs68013007 ENSG00000267213.4 AC007773.2 -4.95 1.92e-06 0.0013 -0.59 -0.37 Bipolar disorder; chr19:32447775 chr19:32390050~32405560:- PAAD cis rs12468226 0.938 rs55681656 ENSG00000273456.1 RP11-686O6.2 4.95 1.92e-06 0.0013 0.53 0.37 Urate levels; chr2:202319041 chr2:202374932~202375604:- PAAD cis rs633715 1 rs527248 ENSG00000254154.7 RP4-798P15.3 -4.95 1.92e-06 0.0013 -0.35 -0.37 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177906379 chr1:177928788~178038007:- PAAD cis rs4853525 0.651 rs1921908 ENSG00000235852.1 AC005540.3 4.95 1.93e-06 0.0013 0.55 0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190870481 chr2:190880797~190882059:- PAAD cis rs7615952 0.515 rs4267608 ENSG00000171084.14 FAM86JP 4.95 1.93e-06 0.00131 0.56 0.37 Blood pressure (smoking interaction); chr3:125961657 chr3:125916620~125930024:+ PAAD cis rs62103177 0.564 rs1715230 ENSG00000261126.6 RP11-795F19.1 4.95 1.93e-06 0.00131 0.5 0.37 Opioid sensitivity; chr18:80090098 chr18:80046900~80095482:+ PAAD cis rs7772486 0.875 rs2814872 ENSG00000235652.6 RP11-545I5.3 4.95 1.94e-06 0.00131 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145989098 chr6:145799409~145886585:+ PAAD cis rs2115630 0.641 rs11073613 ENSG00000259728.4 LINC00933 -4.95 1.95e-06 0.00131 -0.45 -0.37 P wave terminal force; chr15:84642662 chr15:84570649~84580175:+ PAAD cis rs8059260 0.604 rs9652600 ENSG00000274038.1 RP11-66H6.4 -4.95 1.95e-06 0.00131 -0.58 -0.37 Alcohol consumption over the past year; chr16:11080157 chr16:11056556~11057034:+ PAAD cis rs1075232 1 rs56396205 ENSG00000215302.7 CTD-3092A11.1 -4.95 1.95e-06 0.00132 -0.92 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31386182 chr15:30470779~30507623:+ PAAD cis rs1075232 1 rs12438318 ENSG00000215302.7 CTD-3092A11.1 -4.95 1.95e-06 0.00132 -0.92 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31388242 chr15:30470779~30507623:+ PAAD cis rs1075232 1 rs4450360 ENSG00000215302.7 CTD-3092A11.1 -4.95 1.95e-06 0.00132 -0.92 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31389827 chr15:30470779~30507623:+ PAAD cis rs1075232 1 rs72722847 ENSG00000215302.7 CTD-3092A11.1 -4.95 1.95e-06 0.00132 -0.92 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31390143 chr15:30470779~30507623:+ PAAD cis rs1322639 0.575 rs9294966 ENSG00000261039.2 RP11-417E7.2 -4.95 1.95e-06 0.00132 -0.61 -0.37 Pulse pressure; chr6:169165223 chr6:169175304~169182740:- PAAD cis rs1322639 0.614 rs7768154 ENSG00000261039.2 RP11-417E7.2 -4.95 1.95e-06 0.00132 -0.61 -0.37 Pulse pressure; chr6:169165375 chr6:169175304~169182740:- PAAD cis rs1322639 0.614 rs6900200 ENSG00000261039.2 RP11-417E7.2 -4.95 1.95e-06 0.00132 -0.61 -0.37 Pulse pressure; chr6:169166078 chr6:169175304~169182740:- PAAD cis rs7772486 0.686 rs10872579 ENSG00000235652.6 RP11-545I5.3 4.95 1.95e-06 0.00132 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145644876 chr6:145799409~145886585:+ PAAD cis rs748404 0.578 rs4547312 ENSG00000249839.1 AC011330.5 -4.95 1.95e-06 0.00132 -0.55 -0.37 Lung cancer; chr15:43339940 chr15:43663654~43684339:- PAAD cis rs4879677 1 rs10968045 ENSG00000260390.1 RP11-575I8.1 -4.95 1.95e-06 0.00132 -0.47 -0.37 Gut microbiome composition (summer and winter); chr9:27674262 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs10968046 ENSG00000260390.1 RP11-575I8.1 -4.95 1.95e-06 0.00132 -0.47 -0.37 Gut microbiome composition (summer and winter); chr9:27674369 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs12237023 ENSG00000260390.1 RP11-575I8.1 -4.95 1.95e-06 0.00132 -0.47 -0.37 Gut microbiome composition (summer and winter); chr9:27674972 chr9:27829276~27844481:+ PAAD cis rs4950322 0.748 rs17360812 ENSG00000278811.3 LINC00624 -4.95 1.96e-06 0.00132 -0.39 -0.37 Protein quantitative trait loci; chr1:147355010 chr1:147258885~147517875:- PAAD cis rs4728142 0.604 rs6969930 ENSG00000275106.1 RP11-309L24.10 -4.95 1.96e-06 0.00132 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128990259 chr7:128952527~128953316:- PAAD cis rs4728142 0.604 rs4731536 ENSG00000275106.1 RP11-309L24.10 -4.95 1.96e-06 0.00132 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129000239 chr7:128952527~128953316:- PAAD cis rs4728142 0.604 rs10954215 ENSG00000275106.1 RP11-309L24.10 -4.95 1.96e-06 0.00132 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129005459 chr7:128952527~128953316:- PAAD cis rs4728142 0.604 rs10239340 ENSG00000275106.1 RP11-309L24.10 -4.95 1.96e-06 0.00132 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129028456 chr7:128952527~128953316:- PAAD cis rs4728142 0.604 rs6467222 ENSG00000275106.1 RP11-309L24.10 -4.95 1.96e-06 0.00132 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129034365 chr7:128952527~128953316:- PAAD cis rs16828019 0.929 rs10524 ENSG00000235358.1 RP11-399E6.1 4.95 1.96e-06 0.00132 0.7 0.37 Intelligence (multi-trait analysis); chr1:41260801 chr1:41242373~41284861:+ PAAD cis rs13178541 0.748 rs4360035 ENSG00000250378.1 RP11-119J18.1 -4.95 1.96e-06 0.00132 -0.58 -0.37 IgG glycosylation; chr5:135760843 chr5:135812667~135826582:+ PAAD cis rs853679 0.657 rs1778483 ENSG00000216901.1 AL022393.7 4.95 1.96e-06 0.00132 0.46 0.37 Depression; chr6:28273214 chr6:28176188~28176674:+ PAAD cis rs853679 0.657 rs1778482 ENSG00000216901.1 AL022393.7 4.95 1.96e-06 0.00132 0.46 0.37 Depression; chr6:28273215 chr6:28176188~28176674:+ PAAD cis rs1930961 1 rs6004658 ENSG00000100058.11 CRYBB2P1 4.95 1.97e-06 0.00133 0.69 0.37 Bipolar disorder with mood-incongruent psychosis; chr22:25460264 chr22:25448105~25520854:+ PAAD cis rs858239 0.899 rs2268747 ENSG00000226816.2 AC005082.12 4.95 1.97e-06 0.00133 0.42 0.37 Cerebrospinal fluid biomarker levels; chr7:23273843 chr7:23206013~23208045:+ PAAD cis rs1185460 1 rs7127212 ENSG00000271751.1 RP11-110I1.14 4.95 1.97e-06 0.00133 0.48 0.37 Coronary artery disease; chr11:119082492 chr11:119065263~119065677:- PAAD cis rs875971 0.545 rs1547529 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66258859 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs2420456 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66280619 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs7783889 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66283366 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs1909508 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66301366 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs11767262 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66302237 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs66594357 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66327797 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs10950036 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66353241 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs75840613 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66376399 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs73148639 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66390342 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs6460298 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66442783 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs35459055 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66479399 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs75577046 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66493729 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs3735147 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66505541 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs6950988 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66511428 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs73152714 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66534641 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs4718364 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66536353 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs6961853 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.51 -0.37 Aortic root size; chr7:66537035 chr7:66654538~66669855:+ PAAD cis rs875971 0.528 rs801213 ENSG00000226824.5 RP4-756H11.3 4.95 1.97e-06 0.00133 0.51 0.37 Aortic root size; chr7:66549931 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs801212 ENSG00000226824.5 RP4-756H11.3 4.95 1.97e-06 0.00133 0.51 0.37 Aortic root size; chr7:66550643 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs801199 ENSG00000226824.5 RP4-756H11.3 4.95 1.97e-06 0.00133 0.51 0.37 Aortic root size; chr7:66560286 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs1638724 ENSG00000226824.5 RP4-756H11.3 4.95 1.97e-06 0.00133 0.51 0.37 Aortic root size; chr7:66575494 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs1267814 ENSG00000226824.5 RP4-756H11.3 4.95 1.97e-06 0.00133 0.51 0.37 Aortic root size; chr7:66579422 chr7:66654538~66669855:+ PAAD cis rs9987353 0.544 rs2929469 ENSG00000253893.2 FAM85B -4.95 1.97e-06 0.00133 -0.5 -0.37 Recombination measurement; chr8:9205146 chr8:8167819~8226614:- PAAD cis rs17711722 0.522 rs4642526 ENSG00000226824.5 RP4-756H11.3 -4.95 1.97e-06 0.00133 -0.43 -0.37 Calcium levels; chr7:65751755 chr7:66654538~66669855:+ PAAD cis rs9900062 0.844 rs9908143 ENSG00000270714.1 MINOS1P2 -4.95 1.97e-06 0.00133 -0.56 -0.37 QT interval; chr17:64758468 chr17:64747264~64747492:- PAAD cis rs9987353 0.544 rs2929470 ENSG00000253893.2 FAM85B 4.95 1.97e-06 0.00133 0.49 0.37 Recombination measurement; chr8:9204980 chr8:8167819~8226614:- PAAD cis rs1185460 0.967 rs4454730 ENSG00000271751.1 RP11-110I1.14 -4.95 1.98e-06 0.00133 -0.47 -0.37 Coronary artery disease; chr11:119066733 chr11:119065263~119065677:- PAAD cis rs1185460 0.967 rs4545564 ENSG00000271751.1 RP11-110I1.14 -4.95 1.98e-06 0.00133 -0.47 -0.37 Coronary artery disease; chr11:119066807 chr11:119065263~119065677:- PAAD cis rs1185460 0.967 rs1784461 ENSG00000271751.1 RP11-110I1.14 -4.95 1.98e-06 0.00133 -0.47 -0.37 Coronary artery disease; chr11:119067274 chr11:119065263~119065677:- PAAD cis rs2255336 0.938 rs2126888 ENSG00000245648.1 RP11-277P12.20 4.95 1.98e-06 0.00133 0.57 0.37 Blood protein levels; chr12:10393789 chr12:10363769~10398506:+ PAAD cis rs9326248 0.861 rs11216172 ENSG00000280143.1 AP000892.6 4.95 1.98e-06 0.00133 0.49 0.37 Blood protein levels; chr11:116879162 chr11:117204967~117210292:+ PAAD cis rs17711722 0.51 rs11767457 ENSG00000236529.1 RP13-254B10.1 4.95 1.98e-06 0.00134 0.42 0.37 Calcium levels; chr7:65825628 chr7:65840212~65840596:+ PAAD cis rs4723738 0.967 rs12531618 ENSG00000227191.5 TRGC2 -4.95 1.98e-06 0.00134 -0.33 -0.37 Treatment response for severe sepsis; chr7:38213263 chr7:38239580~38368091:- PAAD cis rs4713118 0.516 rs7739216 ENSG00000226314.6 ZNF192P1 -4.95 1.99e-06 0.00134 -0.63 -0.37 Parkinson's disease; chr6:28112168 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs35512245 ENSG00000226314.6 ZNF192P1 -4.95 1.99e-06 0.00134 -0.63 -0.37 Depression; chr6:28112175 chr6:28161781~28169594:+ PAAD cis rs6921919 0.515 rs1339898 ENSG00000204709.4 LINC01556 4.95 1.99e-06 0.00134 0.51 0.37 Autism spectrum disorder or schizophrenia; chr6:28427729 chr6:28943877~28944537:+ PAAD cis rs2015599 0.623 rs7358667 ENSG00000257176.2 RP11-996F15.2 4.95 1.99e-06 0.00134 0.37 0.37 Platelet count;Mean platelet volume; chr12:29290236 chr12:29280418~29317848:- PAAD cis rs2564921 0.73 rs2564922 ENSG00000242142.1 SERBP1P3 4.95 1.99e-06 0.00134 0.46 0.37 Height; chr3:53091453 chr3:53064283~53065091:- PAAD cis rs10754283 0.934 rs6661282 ENSG00000231613.1 RP5-943J3.1 4.94 2e-06 0.00134 0.4 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89654433 chr1:89788914~89790492:+ PAAD cis rs4927850 0.794 rs4927849 ENSG00000231464.1 AC024937.4 4.94 2e-06 0.00135 0.48 0.37 Pancreatic cancer; chr3:196011611 chr3:195996738~195998233:+ PAAD cis rs2348418 0.715 rs12307612 ENSG00000247934.4 RP11-967K21.1 4.94 2e-06 0.00135 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28566713 chr12:28163298~28190738:- PAAD cis rs2348418 0.715 rs12307709 ENSG00000247934.4 RP11-967K21.1 4.94 2e-06 0.00135 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28566767 chr12:28163298~28190738:- PAAD cis rs2348418 0.715 rs11049719 ENSG00000247934.4 RP11-967K21.1 4.94 2e-06 0.00135 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28567446 chr12:28163298~28190738:- PAAD cis rs2348418 0.715 rs11049720 ENSG00000247934.4 RP11-967K21.1 4.94 2e-06 0.00135 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28567477 chr12:28163298~28190738:- PAAD cis rs2348418 0.647 rs938081 ENSG00000247934.4 RP11-967K21.1 4.94 2e-06 0.00135 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28567680 chr12:28163298~28190738:- PAAD cis rs2348418 0.715 rs1355471 ENSG00000247934.4 RP11-967K21.1 -4.94 2e-06 0.00135 -0.36 -0.37 Lung function (FEV1);Lung function (FVC); chr12:28568792 chr12:28163298~28190738:- PAAD cis rs2348418 0.715 rs4931083 ENSG00000247934.4 RP11-967K21.1 -4.94 2e-06 0.00135 -0.36 -0.37 Lung function (FEV1);Lung function (FVC); chr12:28568952 chr12:28163298~28190738:- PAAD cis rs2348418 0.715 rs10843206 ENSG00000247934.4 RP11-967K21.1 4.94 2e-06 0.00135 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28569823 chr12:28163298~28190738:- PAAD cis rs2348418 0.681 rs10843207 ENSG00000247934.4 RP11-967K21.1 4.94 2e-06 0.00135 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28569929 chr12:28163298~28190738:- PAAD cis rs2348418 0.715 rs7971717 ENSG00000247934.4 RP11-967K21.1 4.94 2e-06 0.00135 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28570087 chr12:28163298~28190738:- PAAD cis rs7772486 0.875 rs2777477 ENSG00000235652.6 RP11-545I5.3 4.94 2e-06 0.00135 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145984355 chr6:145799409~145886585:+ PAAD cis rs7772486 0.875 rs1330939 ENSG00000235652.6 RP11-545I5.3 4.94 2e-06 0.00135 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145987382 chr6:145799409~145886585:+ PAAD cis rs11651753 0.636 rs12602494 ENSG00000264920.1 RP11-6N17.4 -4.94 2e-06 0.00135 -0.45 -0.37 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47960241 chr17:47891255~47895812:- PAAD cis rs11651753 0.636 rs4794332 ENSG00000264920.1 RP11-6N17.4 -4.94 2e-06 0.00135 -0.45 -0.37 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47963201 chr17:47891255~47895812:- PAAD cis rs11651753 0.636 rs4793737 ENSG00000264920.1 RP11-6N17.4 -4.94 2e-06 0.00135 -0.45 -0.37 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47964891 chr17:47891255~47895812:- PAAD cis rs1075232 1 rs12439239 ENSG00000215302.7 CTD-3092A11.1 -4.94 2e-06 0.00135 -0.91 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31359515 chr15:30470779~30507623:+ PAAD cis rs4972806 0.739 rs10834 ENSG00000226363.3 HAGLROS -4.94 2.01e-06 0.00135 -0.46 -0.37 IgG glycosylation; chr2:176177359 chr2:176177717~176179008:+ PAAD cis rs919433 0.857 rs36071109 ENSG00000231621.1 AC013264.2 4.94 2.01e-06 0.00135 0.36 0.37 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197318467 chr2:197197991~197199273:+ PAAD cis rs8059260 0.544 rs16958051 ENSG00000274038.1 RP11-66H6.4 4.94 2.01e-06 0.00135 0.56 0.37 Alcohol consumption over the past year; chr16:11097362 chr16:11056556~11057034:+ PAAD cis rs1862618 0.525 rs2662021 ENSG00000271828.1 CTD-2310F14.1 -4.94 2.01e-06 0.00135 -0.56 -0.37 Initial pursuit acceleration; chr5:56965864 chr5:56927874~56929573:+ PAAD cis rs748404 0.578 rs2584701 ENSG00000249839.1 AC011330.5 -4.94 2.01e-06 0.00135 -0.52 -0.37 Lung cancer; chr15:43392741 chr15:43663654~43684339:- PAAD cis rs453301 0.605 rs7843024 ENSG00000253893.2 FAM85B 4.94 2.01e-06 0.00135 0.51 0.37 Joint mobility (Beighton score); chr8:8942466 chr8:8167819~8226614:- PAAD cis rs453301 0.631 rs7843789 ENSG00000253893.2 FAM85B 4.94 2.01e-06 0.00135 0.51 0.37 Joint mobility (Beighton score); chr8:8943051 chr8:8167819~8226614:- PAAD cis rs453301 0.631 rs4840376 ENSG00000253893.2 FAM85B 4.94 2.01e-06 0.00135 0.51 0.37 Joint mobility (Beighton score); chr8:8944591 chr8:8167819~8226614:- PAAD cis rs9309711 0.544 rs9752130 ENSG00000225234.1 TRAPPC12-AS1 -4.94 2.02e-06 0.00136 -0.39 -0.37 Neurofibrillary tangles; chr2:3484731 chr2:3481242~3482409:- PAAD cis rs4266144 1 rs4266144 ENSG00000244515.1 KRT18P34 -4.94 2.02e-06 0.00136 -0.48 -0.37 Coronary artery disease; chr3:157134803 chr3:157162663~157163932:- PAAD cis rs3779195 0.585 rs58699591 ENSG00000272950.1 RP11-307C18.1 -4.94 2.02e-06 0.00136 -0.65 -0.37 Sex hormone-binding globulin levels; chr7:98247392 chr7:98322853~98323430:+ PAAD cis rs3779195 0.524 rs80195155 ENSG00000272950.1 RP11-307C18.1 -4.94 2.02e-06 0.00136 -0.65 -0.37 Sex hormone-binding globulin levels; chr7:98248841 chr7:98322853~98323430:+ PAAD cis rs950027 0.62 rs2467862 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45351645 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs1145093 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45357615 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs1145089 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45359856 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs1049518 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45361169 chr15:45330209~45332634:- PAAD cis rs950027 0.584 rs1145086 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45362129 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs1153857 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45366897 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs1153855 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45368560 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs2486274 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45374030 chr15:45330209~45332634:- PAAD cis rs950027 0.62 rs1145080 ENSG00000259433.2 CTD-2651B20.4 -4.94 2.02e-06 0.00136 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45389140 chr15:45330209~45332634:- PAAD cis rs1275468 1 rs1148003 ENSG00000257497.2 RP11-585P4.5 -4.94 2.03e-06 0.00136 -0.54 -0.37 Polycystic ovary syndrome; chr12:75585216 chr12:75483454~75489820:- PAAD cis rs1823913 0.599 rs58106487 ENSG00000280083.1 RP11-317J9.1 -4.94 2.03e-06 0.00136 -0.44 -0.37 Obesity-related traits; chr2:191292404 chr2:191154118~191156070:- PAAD cis rs6921919 0.789 rs1119211 ENSG00000216901.1 AL022393.7 -4.94 2.03e-06 0.00136 -0.55 -0.37 Autism spectrum disorder or schizophrenia; chr6:28341359 chr6:28176188~28176674:+ PAAD cis rs9928842 0.54 rs8051363 ENSG00000280152.1 RP11-331F4.5 4.94 2.03e-06 0.00136 0.4 0.37 Alcoholic chronic pancreatitis; chr16:75221319 chr16:75245994~75250077:- PAAD cis rs17684571 0.687 rs17752213 ENSG00000231441.1 RP11-472M19.2 4.94 2.03e-06 0.00136 0.71 0.37 Schizophrenia; chr6:56864627 chr6:56844002~56864078:+ PAAD cis rs853679 0.55 rs9295762 ENSG00000226314.6 ZNF192P1 4.94 2.03e-06 0.00136 0.62 0.37 Depression; chr6:28187640 chr6:28161781~28169594:+ PAAD cis rs2153535 0.563 rs1796688 ENSG00000230939.1 RP11-314C16.1 -4.94 2.03e-06 0.00137 -0.4 -0.37 Motion sickness; chr6:8536190 chr6:8784178~8785445:+ PAAD cis rs2153535 0.526 rs1796689 ENSG00000230939.1 RP11-314C16.1 -4.94 2.03e-06 0.00137 -0.4 -0.37 Motion sickness; chr6:8536200 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327053 ENSG00000230939.1 RP11-314C16.1 -4.94 2.03e-06 0.00137 -0.4 -0.37 Motion sickness; chr6:8442894 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs2327054 ENSG00000230939.1 RP11-314C16.1 -4.94 2.03e-06 0.00137 -0.4 -0.37 Motion sickness; chr6:8442897 chr6:8784178~8785445:+ PAAD cis rs2153535 0.623 rs2327055 ENSG00000230939.1 RP11-314C16.1 -4.94 2.03e-06 0.00137 -0.4 -0.37 Motion sickness; chr6:8442912 chr6:8784178~8785445:+ PAAD cis rs4218 0.532 rs17236369 ENSG00000277144.1 RP11-59H7.4 -4.94 2.03e-06 0.00137 -0.43 -0.37 Social communication problems; chr15:59021656 chr15:59115547~59116089:- PAAD cis rs638893 1 rs583905 ENSG00000278376.1 RP11-158I9.8 -4.94 2.04e-06 0.00137 -0.52 -0.37 Vitiligo; chr11:118825199 chr11:118791254~118793137:+ PAAD cis rs1075265 0.518 rs13414393 ENSG00000233266.1 HMGB1P31 4.94 2.04e-06 0.00137 0.5 0.37 Chronotype;Morning vs. evening chronotype; chr2:54048025 chr2:54051334~54051760:+ PAAD cis rs6565180 0.888 rs8060853 ENSG00000183604.13 SMG1P5 4.94 2.04e-06 0.00137 0.42 0.37 Tonsillectomy; chr16:30392537 chr16:30267553~30335374:- PAAD cis rs3096299 0.967 rs2965830 ENSG00000274627.1 RP11-104N10.2 4.94 2.04e-06 0.00137 0.34 0.37 Multiple myeloma (IgH translocation); chr16:89393882 chr16:89516797~89522217:+ PAAD cis rs10510102 0.935 rs10466217 ENSG00000276742.1 RP11-500G22.4 4.94 2.04e-06 0.00137 0.56 0.37 Breast cancer; chr10:121860362 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs10887003 ENSG00000276742.1 RP11-500G22.4 4.94 2.04e-06 0.00137 0.56 0.37 Breast cancer; chr10:121864660 chr10:121956782~121957098:+ PAAD cis rs4664293 0.867 rs1427329 ENSG00000226266.5 AC009961.3 -4.94 2.04e-06 0.00137 -0.45 -0.37 Monocyte percentage of white cells; chr2:159748301 chr2:159670708~159712435:- PAAD cis rs1150668 0.965 rs1654774 ENSG00000204709.4 LINC01556 4.94 2.05e-06 0.00137 0.52 0.37 Pubertal anthropometrics; chr6:28128502 chr6:28943877~28944537:+ PAAD cis rs9287719 0.967 rs10206225 ENSG00000234818.1 AC092687.5 4.94 2.05e-06 0.00138 0.42 0.37 Prostate cancer; chr2:10618531 chr2:10589166~10604830:+ PAAD cis rs4664293 0.833 rs3764969 ENSG00000226266.5 AC009961.3 -4.94 2.05e-06 0.00138 -0.45 -0.37 Monocyte percentage of white cells; chr2:159764337 chr2:159670708~159712435:- PAAD cis rs2337406 1 rs78631692 ENSG00000274576.2 IGHV2-70 -4.94 2.06e-06 0.00138 -0.52 -0.37 Alzheimer's disease (late onset); chr14:106709371 chr14:106770577~106771020:- PAAD cis rs2404602 0.735 rs4886800 ENSG00000259422.1 RP11-593F23.1 -4.94 2.06e-06 0.00138 -0.47 -0.37 Blood metabolite levels; chr15:76386351 chr15:76174891~76181486:- PAAD cis rs189798 0.807 rs9949 ENSG00000254340.1 RP11-10A14.3 4.94 2.06e-06 0.00138 0.53 0.37 Myopia (pathological); chr8:9137002 chr8:9141424~9145435:+ PAAD cis rs9322193 0.607 rs12209310 ENSG00000223701.3 RAET1E-AS1 4.94 2.06e-06 0.00139 0.48 0.37 Lung cancer; chr6:149904882 chr6:149884431~149919508:+ PAAD cis rs9322193 0.607 rs12210822 ENSG00000223701.3 RAET1E-AS1 4.94 2.06e-06 0.00139 0.48 0.37 Lung cancer; chr6:149905356 chr6:149884431~149919508:+ PAAD cis rs10463554 0.895 rs3733939 ENSG00000175749.11 EIF3KP1 4.94 2.06e-06 0.00139 0.46 0.37 Parkinson's disease; chr5:102974462 chr5:103032376~103033031:+ PAAD cis rs944722 0.651 rs4293436 ENSG00000266786.1 LGALS9DP 4.94 2.07e-06 0.00139 0.4 0.37 Fractional exhaled nitric oxide (childhood); chr17:27737916 chr17:27746132~27754954:+ PAAD cis rs12468226 0.938 rs116109808 ENSG00000273456.1 RP11-686O6.2 4.94 2.07e-06 0.00139 0.57 0.37 Urate levels; chr2:202287356 chr2:202374932~202375604:- PAAD cis rs12468226 0.873 rs78175596 ENSG00000273456.1 RP11-686O6.2 4.94 2.07e-06 0.00139 0.57 0.37 Urate levels; chr2:202287993 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs74454549 ENSG00000273456.1 RP11-686O6.2 4.94 2.07e-06 0.00139 0.57 0.37 Urate levels; chr2:202288044 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs56684065 ENSG00000273456.1 RP11-686O6.2 4.94 2.07e-06 0.00139 0.57 0.37 Urate levels; chr2:202289528 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs1474001 ENSG00000273456.1 RP11-686O6.2 4.94 2.07e-06 0.00139 0.57 0.37 Urate levels; chr2:202290230 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs76664732 ENSG00000273456.1 RP11-686O6.2 4.94 2.07e-06 0.00139 0.57 0.37 Urate levels; chr2:202296298 chr2:202374932~202375604:- PAAD cis rs12682352 0.605 rs60707155 ENSG00000253893.2 FAM85B -4.94 2.07e-06 0.00139 -0.51 -0.37 Neuroticism; chr8:8866905 chr8:8167819~8226614:- PAAD cis rs7208859 0.725 rs7210904 ENSG00000266490.1 CTD-2349P21.9 4.94 2.07e-06 0.00139 0.46 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843187 chr17:30792372~30792833:+ PAAD cis rs7208859 0.725 rs9915802 ENSG00000266490.1 CTD-2349P21.9 4.94 2.07e-06 0.00139 0.46 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846040 chr17:30792372~30792833:+ PAAD cis rs7208859 0.725 rs7342938 ENSG00000266490.1 CTD-2349P21.9 4.94 2.07e-06 0.00139 0.46 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862812 chr17:30792372~30792833:+ PAAD cis rs7208859 0.725 rs6505215 ENSG00000266490.1 CTD-2349P21.9 4.94 2.07e-06 0.00139 0.46 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862885 chr17:30792372~30792833:+ PAAD cis rs4664293 0.867 rs6720304 ENSG00000226266.5 AC009961.3 -4.94 2.07e-06 0.00139 -0.45 -0.37 Monocyte percentage of white cells; chr2:159787321 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs3764968 ENSG00000226266.5 AC009961.3 -4.94 2.07e-06 0.00139 -0.45 -0.37 Monocyte percentage of white cells; chr2:159790579 chr2:159670708~159712435:- PAAD cis rs9549328 0.8 rs9549616 ENSG00000267868.1 RP11-120K24.3 4.94 2.07e-06 0.00139 0.43 0.37 Systolic blood pressure; chr13:112973448 chr13:112964835~112966131:- PAAD cis rs9549328 0.8 rs9549617 ENSG00000267868.1 RP11-120K24.3 4.94 2.07e-06 0.00139 0.43 0.37 Systolic blood pressure; chr13:112973756 chr13:112964835~112966131:- PAAD cis rs9549328 0.837 rs9549618 ENSG00000267868.1 RP11-120K24.3 4.94 2.07e-06 0.00139 0.43 0.37 Systolic blood pressure; chr13:112974334 chr13:112964835~112966131:- PAAD cis rs9549328 0.8 rs9549326 ENSG00000267868.1 RP11-120K24.3 4.94 2.07e-06 0.00139 0.43 0.37 Systolic blood pressure; chr13:112976139 chr13:112964835~112966131:- PAAD cis rs6565180 1 rs6565180 ENSG00000183604.13 SMG1P5 -4.94 2.07e-06 0.00139 -0.42 -0.37 Tonsillectomy; chr16:30350020 chr16:30267553~30335374:- PAAD cis rs7772486 0.623 rs735535 ENSG00000235652.6 RP11-545I5.3 -4.94 2.08e-06 0.00139 -0.31 -0.37 Lobe attachment (rater-scored or self-reported); chr6:145715693 chr6:145799409~145886585:+ PAAD cis rs7772486 0.566 rs735536 ENSG00000235652.6 RP11-545I5.3 -4.94 2.08e-06 0.00139 -0.31 -0.37 Lobe attachment (rater-scored or self-reported); chr6:145715696 chr6:145799409~145886585:+ PAAD cis rs4664293 0.802 rs7563417 ENSG00000226266.5 AC009961.3 -4.94 2.08e-06 0.00139 -0.46 -0.37 Monocyte percentage of white cells; chr2:159727762 chr2:159670708~159712435:- PAAD cis rs7208859 0.524 rs73263982 ENSG00000266490.1 CTD-2349P21.9 4.94 2.08e-06 0.00139 0.44 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30593606 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs216433 ENSG00000266490.1 CTD-2349P21.9 4.94 2.08e-06 0.00139 0.44 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30594842 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs216409 ENSG00000266490.1 CTD-2349P21.9 -4.94 2.08e-06 0.00139 -0.44 -0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30579251 chr17:30792372~30792833:+ PAAD cis rs380904 0.517 rs11775744 ENSG00000254859.1 RP11-661A12.5 -4.93 2.09e-06 0.0014 -0.67 -0.37 Venous thromboembolism (SNP x SNP interaction); chr8:143567022 chr8:143541973~143549729:- PAAD cis rs9926296 0.605 rs886952 ENSG00000260259.1 RP11-368I7.4 -4.93 2.09e-06 0.0014 -0.45 -0.37 Vitiligo; chr16:89770373 chr16:89682620~89686569:- PAAD cis rs10754283 0.967 rs6428559 ENSG00000231613.1 RP5-943J3.1 4.93 2.09e-06 0.0014 0.4 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89633477 chr1:89788914~89790492:+ PAAD cis rs4227 0.565 rs1641550 ENSG00000233223.2 AC113189.5 4.93 2.1e-06 0.0014 0.41 0.37 IgA nephropathy; chr17:7600470 chr17:7581964~7584072:- PAAD cis rs4664293 0.805 rs7593273 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159749349 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs34392518 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159749367 chr2:159670708~159712435:- PAAD cis rs4664293 0.805 rs6432559 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159750649 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs6432560 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159750758 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs3863924 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159758247 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs11681565 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159760362 chr2:159670708~159712435:- PAAD cis rs4664293 0.836 rs11687502 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159760464 chr2:159670708~159712435:- PAAD cis rs4664293 0.836 rs13401087 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159760957 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs12692564 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159761326 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs1427328 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159762064 chr2:159670708~159712435:- PAAD cis rs4664293 0.613 rs9784044 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159765854 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs4664301 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159766855 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs12617546 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159767079 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs1126842 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159770806 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs3771721 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159771644 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs11681245 ENSG00000226266.5 AC009961.3 -4.93 2.1e-06 0.0014 -0.45 -0.37 Monocyte percentage of white cells; chr2:159772882 chr2:159670708~159712435:- PAAD cis rs79040073 0.53 rs73394357 ENSG00000259531.2 RP11-295H24.3 4.93 2.1e-06 0.0014 0.55 0.37 Lung cancer in ever smokers; chr15:49300314 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs3784630 ENSG00000259531.2 RP11-295H24.3 4.93 2.1e-06 0.0014 0.55 0.37 Lung cancer in ever smokers; chr15:49322952 chr15:49365124~49366685:- PAAD cis rs7169304 0.531 rs59356430 ENSG00000259531.2 RP11-295H24.3 4.93 2.1e-06 0.0014 0.55 0.37 Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma; chr15:49324835 chr15:49365124~49366685:- PAAD cis rs2274273 0.624 rs78205412 ENSG00000258413.1 RP11-665C16.6 -4.93 2.1e-06 0.00141 -0.49 -0.37 Protein biomarker; chr14:55314532 chr14:55262767~55272075:- PAAD cis rs227275 0.53 rs3960788 ENSG00000246560.2 RP11-10L12.4 4.93 2.1e-06 0.00141 0.39 0.37 Allergic disease (asthma, hay fever or eczema); chr4:102994461 chr4:102828055~102844075:+ PAAD cis rs1075265 0.933 rs11888384 ENSG00000233266.1 HMGB1P31 4.93 2.1e-06 0.00141 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:54110984 chr2:54051334~54051760:+ PAAD cis rs9890032 0.934 rs7225461 ENSG00000266490.1 CTD-2349P21.9 4.93 2.11e-06 0.00141 0.34 0.37 Hip circumference adjusted for BMI; chr17:30932881 chr17:30792372~30792833:+ PAAD cis rs9322193 0.923 rs4869750 ENSG00000268592.3 RAET1E-AS1 4.93 2.11e-06 0.00141 0.44 0.37 Lung cancer; chr6:149855996 chr6:149863494~149919507:+ PAAD cis rs3096299 0.967 rs2911255 ENSG00000274627.1 RP11-104N10.2 4.93 2.11e-06 0.00141 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89420729 chr16:89516797~89522217:+ PAAD cis rs11079159 0.606 rs1114603 ENSG00000263096.1 RP11-515O17.2 4.93 2.11e-06 0.00141 0.45 0.37 QRS duration; chr17:55291706 chr17:55271504~55273653:- PAAD cis rs453301 0.686 rs11787026 ENSG00000253893.2 FAM85B -4.93 2.11e-06 0.00141 -0.52 -0.37 Joint mobility (Beighton score); chr8:9044861 chr8:8167819~8226614:- PAAD cis rs4889009 0.533 rs12596569 ENSG00000261390.4 RP11-345M22.2 4.93 2.11e-06 0.00141 0.49 0.37 Thyroid peroxidase antibody positivity; chr16:79701354 chr16:79715232~79770563:- PAAD cis rs964184 0.63 rs7930786 ENSG00000254851.1 RP11-109L13.1 -4.93 2.12e-06 0.00142 -0.83 -0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116754011 chr11:117135528~117138582:+ PAAD cis rs2980439 0.517 rs793753 ENSG00000253893.2 FAM85B 4.93 2.12e-06 0.00142 0.52 0.37 Neuroticism; chr8:8247837 chr8:8167819~8226614:- PAAD cis rs950027 0.549 rs11070452 ENSG00000259433.2 CTD-2651B20.4 4.93 2.13e-06 0.00142 0.41 0.37 Response to fenofibrate (adiponectin levels); chr15:45302638 chr15:45330209~45332634:- PAAD cis rs950027 0.549 rs2899375 ENSG00000259433.2 CTD-2651B20.4 4.93 2.13e-06 0.00142 0.41 0.37 Response to fenofibrate (adiponectin levels); chr15:45306137 chr15:45330209~45332634:- PAAD cis rs16828019 0.704 rs12024115 ENSG00000235358.1 RP11-399E6.1 4.93 2.13e-06 0.00142 0.72 0.37 Intelligence (multi-trait analysis); chr1:41068685 chr1:41242373~41284861:+ PAAD cis rs8062405 0.558 rs3743963 ENSG00000259982.1 CDC37P1 4.93 2.13e-06 0.00142 0.39 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28593365 chr16:28700294~28701540:- PAAD cis rs2274273 0.84 rs1045002 ENSG00000258413.1 RP11-665C16.6 -4.93 2.13e-06 0.00142 -0.48 -0.37 Protein biomarker; chr14:55351799 chr14:55262767~55272075:- PAAD cis rs2274273 0.773 rs10147765 ENSG00000258413.1 RP11-665C16.6 -4.93 2.13e-06 0.00142 -0.48 -0.37 Protein biomarker; chr14:55361108 chr14:55262767~55272075:- PAAD cis rs4950322 0.57 rs72691032 ENSG00000278811.3 LINC00624 4.93 2.13e-06 0.00142 0.39 0.37 Protein quantitative trait loci; chr1:147261120 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691033 ENSG00000278811.3 LINC00624 4.93 2.13e-06 0.00142 0.39 0.37 Protein quantitative trait loci; chr1:147261267 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs111370771 ENSG00000278811.3 LINC00624 4.93 2.13e-06 0.00142 0.39 0.37 Protein quantitative trait loci; chr1:147261420 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4301678 ENSG00000278811.3 LINC00624 4.93 2.13e-06 0.00142 0.39 0.37 Protein quantitative trait loci; chr1:147261907 chr1:147258885~147517875:- PAAD cis rs2412819 0.571 rs7174260 ENSG00000205771.5 CATSPER2P1 -4.93 2.13e-06 0.00143 -0.59 -0.37 Lung cancer; chr15:43751988 chr15:43726918~43747094:- PAAD cis rs58873874 0.737 rs11134766 ENSG00000251405.2 CTB-109A12.1 4.93 2.14e-06 0.00143 0.78 0.37 Bipolar disorder (body mass index interaction); chr5:157481309 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs11134767 ENSG00000251405.2 CTB-109A12.1 4.93 2.14e-06 0.00143 0.78 0.37 Bipolar disorder (body mass index interaction); chr5:157481645 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs11466807 ENSG00000251405.2 CTB-109A12.1 4.93 2.14e-06 0.00143 0.78 0.37 Bipolar disorder (body mass index interaction); chr5:157487920 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs77273565 ENSG00000251405.2 CTB-109A12.1 4.93 2.14e-06 0.00143 0.78 0.37 Bipolar disorder (body mass index interaction); chr5:157489547 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs111759027 ENSG00000251405.2 CTB-109A12.1 4.93 2.14e-06 0.00143 0.78 0.37 Bipolar disorder (body mass index interaction); chr5:157489628 chr5:157362615~157460078:- PAAD cis rs992157 0.71 rs12612347 ENSG00000261338.2 RP11-378A13.1 -4.93 2.14e-06 0.00143 -0.42 -0.37 Colorectal cancer; chr2:218192615 chr2:218255319~218257366:+ PAAD cis rs1061377 0.748 rs11096977 ENSG00000249685.1 RP11-360F5.3 4.93 2.14e-06 0.00143 0.4 0.37 Uric acid levels; chr4:39106186 chr4:39133913~39135608:+ PAAD cis rs1061377 0.748 rs6810770 ENSG00000249685.1 RP11-360F5.3 4.93 2.14e-06 0.00143 0.4 0.37 Uric acid levels; chr4:39106545 chr4:39133913~39135608:+ PAAD cis rs1061377 0.748 rs6812316 ENSG00000249685.1 RP11-360F5.3 4.93 2.14e-06 0.00143 0.4 0.37 Uric acid levels; chr4:39106617 chr4:39133913~39135608:+ PAAD cis rs875971 0.545 rs1796219 ENSG00000226824.5 RP4-756H11.3 4.93 2.15e-06 0.00143 0.53 0.37 Aortic root size; chr7:66645977 chr7:66654538~66669855:+ PAAD cis rs1545257 0.505 rs2584950 ENSG00000242628.4 AC009228.1 4.93 2.15e-06 0.00143 0.43 0.37 Sjögren's syndrome; chr2:24409893 chr2:24214381~24221516:+ PAAD cis rs1545257 0.538 rs729921 ENSG00000242628.4 AC009228.1 4.93 2.15e-06 0.00143 0.43 0.37 Sjögren's syndrome; chr2:24410255 chr2:24214381~24221516:+ PAAD cis rs1545257 0.505 rs7583687 ENSG00000242628.4 AC009228.1 4.93 2.15e-06 0.00143 0.43 0.37 Sjögren's syndrome; chr2:24411134 chr2:24214381~24221516:+ PAAD cis rs1545257 0.505 rs958352 ENSG00000242628.4 AC009228.1 4.93 2.15e-06 0.00143 0.43 0.37 Sjögren's syndrome; chr2:24411371 chr2:24214381~24221516:+ PAAD cis rs1545257 0.505 rs13016195 ENSG00000242628.4 AC009228.1 4.93 2.15e-06 0.00143 0.43 0.37 Sjögren's syndrome; chr2:24412073 chr2:24214381~24221516:+ PAAD cis rs638893 0.528 rs521910 ENSG00000278376.1 RP11-158I9.8 4.93 2.15e-06 0.00144 0.49 0.37 Vitiligo; chr11:118739920 chr11:118791254~118793137:+ PAAD cis rs4814920 0.756 rs6046400 ENSG00000275142.1 RP5-999L4.2 -4.93 2.15e-06 0.00144 -0.68 -0.37 Bipolar disorder (body mass index interaction); chr20:19878482 chr20:19871891~19872284:+ PAAD cis rs4814920 0.818 rs6035467 ENSG00000275142.1 RP5-999L4.2 -4.93 2.15e-06 0.00144 -0.68 -0.37 Bipolar disorder (body mass index interaction); chr20:19879602 chr20:19871891~19872284:+ PAAD cis rs8059260 0.542 rs11860851 ENSG00000274038.1 RP11-66H6.4 -4.93 2.15e-06 0.00144 -0.61 -0.37 Alcohol consumption over the past year; chr16:11033893 chr16:11056556~11057034:+ PAAD cis rs2274273 0.84 rs72715769 ENSG00000258413.1 RP11-665C16.6 -4.93 2.15e-06 0.00144 -0.47 -0.37 Protein biomarker; chr14:55295711 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs66696758 ENSG00000258413.1 RP11-665C16.6 -4.93 2.15e-06 0.00144 -0.47 -0.37 Protein biomarker; chr14:55299791 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs7153645 ENSG00000258413.1 RP11-665C16.6 -4.93 2.15e-06 0.00144 -0.47 -0.37 Protein biomarker; chr14:55304800 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs10139083 ENSG00000258413.1 RP11-665C16.6 -4.93 2.15e-06 0.00144 -0.47 -0.37 Protein biomarker; chr14:55316017 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs10145203 ENSG00000258413.1 RP11-665C16.6 -4.93 2.15e-06 0.00144 -0.47 -0.37 Protein biomarker; chr14:55317740 chr14:55262767~55272075:- PAAD cis rs2153535 0.601 rs4140584 ENSG00000230939.1 RP11-314C16.1 4.93 2.16e-06 0.00144 0.4 0.37 Motion sickness; chr6:8540381 chr6:8784178~8785445:+ PAAD cis rs989978 1 rs989978 ENSG00000257582.4 LINC01475 4.93 2.16e-06 0.00144 0.45 0.37 Red blood cell count; chr10:99562798 chr10:99526350~99531177:- PAAD cis rs897984 0.572 rs112906665 ENSG00000260911.2 RP11-196G11.2 4.93 2.16e-06 0.00144 0.33 0.37 Dementia with Lewy bodies; chr16:31028818 chr16:31043150~31049868:+ PAAD cis rs897984 0.645 rs58726213 ENSG00000260911.2 RP11-196G11.2 4.93 2.16e-06 0.00144 0.33 0.37 Dementia with Lewy bodies; chr16:31033362 chr16:31043150~31049868:+ PAAD cis rs897984 0.609 rs12445650 ENSG00000260911.2 RP11-196G11.2 4.93 2.16e-06 0.00144 0.33 0.37 Dementia with Lewy bodies; chr16:31033576 chr16:31043150~31049868:+ PAAD cis rs897984 0.609 rs35468353 ENSG00000260911.2 RP11-196G11.2 4.93 2.16e-06 0.00144 0.33 0.37 Dementia with Lewy bodies; chr16:31045112 chr16:31043150~31049868:+ PAAD cis rs897984 0.609 rs11862744 ENSG00000260911.2 RP11-196G11.2 4.93 2.16e-06 0.00144 0.33 0.37 Dementia with Lewy bodies; chr16:31046479 chr16:31043150~31049868:+ PAAD cis rs7727544 0.735 rs270605 ENSG00000233006.5 AC034220.3 4.93 2.16e-06 0.00144 0.3 0.37 Blood metabolite levels; chr5:132316118 chr5:132311285~132369916:- PAAD cis rs964611 0.882 rs9635331 ENSG00000259488.2 RP11-154J22.1 -4.93 2.16e-06 0.00144 -0.41 -0.37 Metabolite levels (Pyroglutamine); chr15:48277940 chr15:48312353~48331856:- PAAD cis rs6504950 0.85 rs2628308 ENSG00000275710.1 RP11-257O5.4 -4.93 2.17e-06 0.00144 -0.48 -0.37 Breast cancer; chr17:55046212 chr17:54964474~54964679:+ PAAD cis rs6504950 0.785 rs2628304 ENSG00000275710.1 RP11-257O5.4 -4.93 2.17e-06 0.00144 -0.48 -0.37 Breast cancer; chr17:55079828 chr17:54964474~54964679:+ PAAD cis rs6504950 0.889 rs2628296 ENSG00000275710.1 RP11-257O5.4 -4.93 2.17e-06 0.00144 -0.48 -0.37 Breast cancer; chr17:55089134 chr17:54964474~54964679:+ PAAD cis rs964184 0.688 rs1558860 ENSG00000254851.1 RP11-109L13.1 -4.93 2.17e-06 0.00145 -0.83 -0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116736652 chr11:117135528~117138582:+ PAAD cis rs964184 0.63 rs1558861 ENSG00000254851.1 RP11-109L13.1 -4.93 2.17e-06 0.00145 -0.83 -0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116736721 chr11:117135528~117138582:+ PAAD cis rs964184 0.63 rs9326246 ENSG00000254851.1 RP11-109L13.1 -4.93 2.17e-06 0.00145 -0.83 -0.37 Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total; chr11:116741017 chr11:117135528~117138582:+ PAAD cis rs1275468 1 rs1148006 ENSG00000257497.2 RP11-585P4.5 -4.93 2.17e-06 0.00145 -0.53 -0.37 Polycystic ovary syndrome; chr12:75584578 chr12:75483454~75489820:- PAAD cis rs12817211 0.549 rs7972465 ENSG00000272368.2 RP4-605O3.4 4.93 2.17e-06 0.00145 0.36 0.37 Colorectal or endometrial cancer; chr12:50152342 chr12:50112197~50165618:+ PAAD cis rs11673344 0.864 rs2562606 ENSG00000226686.6 LINC01535 4.93 2.17e-06 0.00145 0.5 0.37 Obesity-related traits; chr19:37029628 chr19:37251912~37265535:+ PAAD cis rs11673344 0.864 rs2263167 ENSG00000226686.6 LINC01535 4.93 2.17e-06 0.00145 0.5 0.37 Obesity-related traits; chr19:37030025 chr19:37251912~37265535:+ PAAD cis rs11673344 0.796 rs9676450 ENSG00000226686.6 LINC01535 4.93 2.18e-06 0.00145 0.51 0.37 Obesity-related traits; chr19:36998505 chr19:37251912~37265535:+ PAAD cis rs2562456 0.833 rs2562487 ENSG00000213976.4 CTD-2561J22.2 -4.92 2.18e-06 0.00145 -0.42 -0.37 Pain; chr19:21468580 chr19:21382865~21387177:+ PAAD cis rs1972460 0.506 rs62012050 ENSG00000255769.6 GOLGA2P10 -4.92 2.18e-06 0.00145 -0.42 -0.37 Intelligence (multi-trait analysis); chr15:82239933 chr15:82472993~82513950:- PAAD cis rs9828933 0.766 rs3774725 ENSG00000280620.1 SCAANT1 4.92 2.18e-06 0.00145 0.6 0.37 Type 2 diabetes; chr3:63988582 chr3:63911518~63911772:- PAAD cis rs6921919 0.583 rs7759191 ENSG00000216901.1 AL022393.7 4.92 2.18e-06 0.00145 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28385657 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs7764737 ENSG00000216901.1 AL022393.7 4.92 2.18e-06 0.00145 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28386838 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs9461458 ENSG00000216901.1 AL022393.7 4.92 2.18e-06 0.00145 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28388098 chr6:28176188~28176674:+ PAAD cis rs6921919 0.609 rs9468365 ENSG00000216901.1 AL022393.7 4.92 2.18e-06 0.00145 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28390189 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs1361385 ENSG00000216901.1 AL022393.7 4.92 2.18e-06 0.00145 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28390543 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs1416918 ENSG00000216901.1 AL022393.7 4.92 2.18e-06 0.00145 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28390558 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs9468367 ENSG00000216901.1 AL022393.7 4.92 2.18e-06 0.00145 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28392469 chr6:28176188~28176674:+ PAAD cis rs526231 0.578 rs6867392 ENSG00000175749.11 EIF3KP1 4.92 2.19e-06 0.00146 0.48 0.37 Primary biliary cholangitis; chr5:102946183 chr5:103032376~103033031:+ PAAD cis rs2882667 0.66 rs11951084 ENSG00000253404.1 AC034243.1 4.92 2.19e-06 0.00146 0.43 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139125858 chr5:138744434~138753309:- PAAD cis rs6584283 0.846 rs10883370 ENSG00000257582.4 LINC01475 -4.92 2.19e-06 0.00146 -0.41 -0.37 Ulcerative colitis; chr10:99531715 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs11190140 ENSG00000257582.4 LINC01475 -4.92 2.19e-06 0.00146 -0.41 -0.37 Dental caries; chr10:99531836 chr10:99526350~99531177:- PAAD cis rs11089937 0.597 rs5756991 ENSG00000211639.2 IGLV4-60 4.92 2.19e-06 0.00146 0.39 0.37 Periodontitis (PAL4Q3); chr22:22132541 chr22:22162199~22162681:+ PAAD cis rs11089937 0.54 rs5756992 ENSG00000211639.2 IGLV4-60 4.92 2.19e-06 0.00146 0.39 0.37 Periodontitis (PAL4Q3); chr22:22132636 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs9622919 ENSG00000211639.2 IGLV4-60 4.92 2.19e-06 0.00146 0.39 0.37 Periodontitis (PAL4Q3); chr22:22132863 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs9619793 ENSG00000211639.2 IGLV4-60 4.92 2.19e-06 0.00146 0.39 0.37 Periodontitis (PAL4Q3); chr22:22132952 chr22:22162199~22162681:+ PAAD cis rs7829975 0.508 rs1594437 ENSG00000253893.2 FAM85B -4.92 2.19e-06 0.00146 -0.51 -0.37 Mood instability; chr8:8968365 chr8:8167819~8226614:- PAAD cis rs7306456 0.623 rs10902513 ENSG00000256576.2 RP13-977J11.2 4.92 2.2e-06 0.00146 0.44 0.37 Anti-saccade response; chr12:132208942 chr12:132186735~132189695:- PAAD cis rs964611 0.938 rs12592330 ENSG00000259488.2 RP11-154J22.1 4.92 2.2e-06 0.00146 0.41 0.37 Metabolite levels (Pyroglutamine); chr15:48353083 chr15:48312353~48331856:- PAAD cis rs7945705 0.875 rs10769947 ENSG00000254860.4 TMEM9B-AS1 -4.92 2.2e-06 0.00146 -0.41 -0.37 Hemoglobin concentration; chr11:8736567 chr11:8964675~8977527:+ PAAD cis rs7665090 0.728 rs2978641 ENSG00000246560.2 RP11-10L12.4 -4.92 2.2e-06 0.00147 -0.42 -0.37 Primary biliary cholangitis; chr4:102654123 chr4:102828055~102844075:+ PAAD cis rs7665090 0.728 rs228612 ENSG00000246560.2 RP11-10L12.4 -4.92 2.2e-06 0.00147 -0.42 -0.37 Primary biliary cholangitis; chr4:102654228 chr4:102828055~102844075:+ PAAD cis rs10050311 0.698 rs10516778 ENSG00000251411.1 RP11-397E7.4 -4.92 2.21e-06 0.00147 -0.44 -0.37 Insulin-related traits; chr4:86714898 chr4:86913266~86914817:- PAAD cis rs10050311 0.698 rs17454154 ENSG00000251411.1 RP11-397E7.4 -4.92 2.21e-06 0.00147 -0.44 -0.37 Insulin-related traits; chr4:86715007 chr4:86913266~86914817:- PAAD cis rs10050311 0.698 rs78818211 ENSG00000251411.1 RP11-397E7.4 -4.92 2.21e-06 0.00147 -0.44 -0.37 Insulin-related traits; chr4:86715235 chr4:86913266~86914817:- PAAD cis rs964611 0.882 rs11636311 ENSG00000259488.2 RP11-154J22.1 4.92 2.21e-06 0.00147 0.42 0.37 Metabolite levels (Pyroglutamine); chr15:48365226 chr15:48312353~48331856:- PAAD cis rs13178541 0.748 rs4976306 ENSG00000250378.1 RP11-119J18.1 4.92 2.21e-06 0.00147 0.57 0.37 IgG glycosylation; chr5:135728489 chr5:135812667~135826582:+ PAAD cis rs853679 0.628 rs9368560 ENSG00000204709.4 LINC01556 4.92 2.21e-06 0.00147 0.64 0.37 Depression; chr6:28192182 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs9461459 ENSG00000204709.4 LINC01556 4.92 2.21e-06 0.00147 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28394139 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs28360638 ENSG00000204709.4 LINC01556 4.92 2.21e-06 0.00147 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28394552 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs9468368 ENSG00000204709.4 LINC01556 4.92 2.21e-06 0.00147 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28397172 chr6:28943877~28944537:+ PAAD cis rs6921919 0.609 rs1005127 ENSG00000204709.4 LINC01556 4.92 2.21e-06 0.00147 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28399881 chr6:28943877~28944537:+ PAAD cis rs853679 0.515 rs4580862 ENSG00000204709.4 LINC01556 4.92 2.21e-06 0.00147 0.53 0.37 Depression; chr6:28399886 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs4357130 ENSG00000204709.4 LINC01556 4.92 2.21e-06 0.00147 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28399906 chr6:28943877~28944537:+ PAAD cis rs1823913 0.526 rs36028476 ENSG00000280083.1 RP11-317J9.1 -4.92 2.21e-06 0.00147 -0.45 -0.37 Obesity-related traits; chr2:191300595 chr2:191154118~191156070:- PAAD cis rs4683346 0.616 rs2372110 ENSG00000173811.9 CCDC13-AS1 -4.92 2.21e-06 0.00147 -0.41 -0.37 Granulocyte percentage of myeloid white cells; chr3:42778365 chr3:42732575~42746768:+ PAAD cis rs8059260 0.541 rs12917947 ENSG00000274038.1 RP11-66H6.4 -4.92 2.21e-06 0.00147 -0.57 -0.37 Alcohol consumption over the past year; chr16:11116386 chr16:11056556~11057034:+ PAAD cis rs11214589 0.747 rs10891537 ENSG00000270179.1 RP11-159N11.4 -4.92 2.22e-06 0.00147 -0.41 -0.37 Neuroticism; chr11:113340648 chr11:113368478~113369117:+ PAAD cis rs2115630 0.846 rs8024538 ENSG00000275120.1 RP11-182J1.17 -4.92 2.22e-06 0.00148 -0.38 -0.37 P wave terminal force; chr15:84825188 chr15:84599434~84606463:- PAAD cis rs75422866 0.85 rs73111212 ENSG00000257433.4 RP1-197B17.3 4.92 2.22e-06 0.00148 0.85 0.37 Pneumonia; chr12:47577638 chr12:47706085~47742294:+ PAAD cis rs75422866 0.85 rs73111216 ENSG00000257433.4 RP1-197B17.3 4.92 2.22e-06 0.00148 0.85 0.37 Pneumonia; chr12:47577671 chr12:47706085~47742294:+ PAAD cis rs75422866 0.85 rs73111217 ENSG00000257433.4 RP1-197B17.3 4.92 2.22e-06 0.00148 0.85 0.37 Pneumonia; chr12:47577693 chr12:47706085~47742294:+ PAAD cis rs858239 0.67 rs6967526 ENSG00000226816.2 AC005082.12 4.92 2.22e-06 0.00148 0.42 0.37 Cerebrospinal fluid biomarker levels; chr7:23119622 chr7:23206013~23208045:+ PAAD cis rs3096299 0.967 rs7205785 ENSG00000274627.1 RP11-104N10.2 4.92 2.22e-06 0.00148 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89392576 chr16:89516797~89522217:+ PAAD cis rs4664293 0.836 rs2556102 ENSG00000226266.5 AC009961.3 -4.92 2.22e-06 0.00148 -0.45 -0.37 Monocyte percentage of white cells; chr2:159798611 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs6740910 ENSG00000226266.5 AC009961.3 -4.92 2.22e-06 0.00148 -0.45 -0.37 Monocyte percentage of white cells; chr2:159792709 chr2:159670708~159712435:- PAAD cis rs4218 0.531 rs10431791 ENSG00000277144.1 RP11-59H7.4 -4.92 2.23e-06 0.00148 -0.44 -0.37 Social communication problems; chr15:59055159 chr15:59115547~59116089:- PAAD cis rs1823913 0.599 rs1454754 ENSG00000280083.1 RP11-317J9.1 -4.92 2.23e-06 0.00148 -0.45 -0.37 Obesity-related traits; chr2:191303562 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs13010441 ENSG00000280083.1 RP11-317J9.1 -4.92 2.23e-06 0.00148 -0.45 -0.37 Obesity-related traits; chr2:191303903 chr2:191154118~191156070:- PAAD cis rs453301 0.658 rs3855900 ENSG00000253893.2 FAM85B 4.92 2.23e-06 0.00148 0.51 0.37 Joint mobility (Beighton score); chr8:9044411 chr8:8167819~8226614:- PAAD cis rs10754283 0.967 rs10737707 ENSG00000231613.1 RP5-943J3.1 4.92 2.23e-06 0.00148 0.4 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89653745 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs10737708 ENSG00000231613.1 RP5-943J3.1 4.92 2.23e-06 0.00148 0.4 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89654245 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs10801763 ENSG00000231613.1 RP5-943J3.1 4.92 2.23e-06 0.00148 0.4 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89655263 chr1:89788914~89790492:+ PAAD cis rs17711722 0.583 rs10085415 ENSG00000234585.5 CCT6P3 -4.92 2.23e-06 0.00148 -0.3 -0.37 Calcium levels; chr7:65628655 chr7:65038354~65074713:+ PAAD cis rs9322193 0.607 rs915140 ENSG00000223701.3 RAET1E-AS1 4.92 2.23e-06 0.00148 0.48 0.37 Lung cancer; chr6:149899674 chr6:149884431~149919508:+ PAAD cis rs13178541 0.81 rs11951836 ENSG00000250378.1 RP11-119J18.1 -4.92 2.23e-06 0.00148 -0.57 -0.37 IgG glycosylation; chr5:135816068 chr5:135812667~135826582:+ PAAD cis rs6782228 0.675 rs2253151 ENSG00000242551.2 POU5F1P6 -4.92 2.23e-06 0.00148 -0.43 -0.37 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611294 chr3:128674735~128677005:- PAAD cis rs10510102 0.872 rs11200267 ENSG00000276742.1 RP11-500G22.4 4.92 2.24e-06 0.00149 0.56 0.37 Breast cancer; chr10:121929851 chr10:121956782~121957098:+ PAAD cis rs11675119 0.517 rs12619851 ENSG00000225234.1 TRAPPC12-AS1 -4.92 2.24e-06 0.00149 -0.38 -0.37 Neurofibrillary tangles; chr2:3488976 chr2:3481242~3482409:- PAAD cis rs2115630 0.691 rs8040066 ENSG00000225151.9 GOLGA2P7 4.92 2.24e-06 0.00149 0.43 0.37 P wave terminal force; chr15:84633234 chr15:84199311~84230136:- PAAD cis rs950169 0.526 rs698620 ENSG00000225151.9 GOLGA2P7 4.92 2.24e-06 0.00149 0.43 0.37 Schizophrenia; chr15:84633977 chr15:84199311~84230136:- PAAD cis rs4268898 1 rs10165445 ENSG00000242628.4 AC009228.1 -4.92 2.24e-06 0.00149 -0.45 -0.37 Asthma; chr2:24218829 chr2:24214381~24221516:+ PAAD cis rs4268898 1 rs6707781 ENSG00000242628.4 AC009228.1 -4.92 2.24e-06 0.00149 -0.45 -0.37 Asthma; chr2:24219014 chr2:24214381~24221516:+ PAAD cis rs4268898 1 rs1203 ENSG00000242628.4 AC009228.1 -4.92 2.24e-06 0.00149 -0.45 -0.37 Asthma; chr2:24220461 chr2:24214381~24221516:+ PAAD cis rs7712401 0.691 rs62377436 ENSG00000263432.2 RN7SL689P -4.92 2.24e-06 0.00149 -0.48 -0.37 Mean platelet volume; chr5:123018007 chr5:123022487~123022783:- PAAD cis rs6700559 0.683 rs7548530 ENSG00000260088.1 RP11-92G12.3 -4.92 2.25e-06 0.00149 -0.5 -0.37 Coronary artery disease; chr1:200687904 chr1:200669507~200694250:+ PAAD cis rs6700559 0.683 rs7526136 ENSG00000260088.1 RP11-92G12.3 -4.92 2.25e-06 0.00149 -0.5 -0.37 Coronary artery disease; chr1:200687911 chr1:200669507~200694250:+ PAAD cis rs6700559 0.733 rs7526265 ENSG00000260088.1 RP11-92G12.3 -4.92 2.25e-06 0.00149 -0.5 -0.37 Coronary artery disease; chr1:200687916 chr1:200669507~200694250:+ PAAD cis rs17711722 0.523 rs313812 ENSG00000164669.11 INTS4P1 4.92 2.25e-06 0.00149 0.45 0.37 Calcium levels; chr7:66040056 chr7:65141225~65234216:+ PAAD cis rs17711722 0.523 rs365896 ENSG00000164669.11 INTS4P1 4.92 2.25e-06 0.00149 0.45 0.37 Calcium levels; chr7:66045710 chr7:65141225~65234216:+ PAAD cis rs2348418 0.864 rs2137071 ENSG00000247934.4 RP11-967K21.1 4.92 2.25e-06 0.00149 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28563797 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7968563 ENSG00000247934.4 RP11-967K21.1 4.92 2.25e-06 0.00149 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28563844 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs2137072 ENSG00000247934.4 RP11-967K21.1 4.92 2.25e-06 0.00149 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28563872 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs2175464 ENSG00000247934.4 RP11-967K21.1 -4.92 2.25e-06 0.00149 -0.36 -0.37 Lung function (FEV1);Lung function (FVC); chr12:28564178 chr12:28163298~28190738:- PAAD cis rs7829975 0.807 rs519019 ENSG00000253893.2 FAM85B 4.92 2.25e-06 0.0015 0.54 0.37 Mood instability; chr8:8737594 chr8:8167819~8226614:- PAAD cis rs6504950 0.925 rs244317 ENSG00000275710.1 RP11-257O5.4 -4.92 2.25e-06 0.0015 -0.54 -0.37 Breast cancer; chr17:55139624 chr17:54964474~54964679:+ PAAD cis rs8059260 0.544 rs12925161 ENSG00000274038.1 RP11-66H6.4 -4.92 2.25e-06 0.0015 -0.54 -0.37 Alcohol consumption over the past year; chr16:11112719 chr16:11056556~11057034:+ PAAD cis rs55665837 0.701 rs10766188 ENSG00000251991.1 RNU7-49P 4.92 2.25e-06 0.0015 0.43 0.37 Vitamin D levels; chr11:14639280 chr11:14478892~14478953:+ PAAD cis rs55665837 0.701 rs2007361 ENSG00000251991.1 RNU7-49P 4.92 2.25e-06 0.0015 0.43 0.37 Vitamin D levels; chr11:14641176 chr11:14478892~14478953:+ PAAD cis rs113835537 1 rs113835537 ENSG00000255517.5 CTD-3074O7.5 -4.92 2.26e-06 0.0015 -0.61 -0.37 Airway imaging phenotypes; chr11:66572168 chr11:66473490~66480233:- PAAD cis rs8062405 1 rs7498555 ENSG00000251417.2 RP11-1348G14.4 -4.92 2.26e-06 0.0015 -0.33 -0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28882250 chr16:28802743~28817828:+ PAAD cis rs807029 0.577 rs701834 ENSG00000272572.1 RP11-179B2.2 -4.92 2.26e-06 0.0015 -0.46 -0.37 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:101002044 chr10:100911103~100912739:- PAAD cis rs4660456 0.711 rs12409109 ENSG00000237899.1 RP4-739H11.3 -4.92 2.27e-06 0.0015 -0.5 -0.37 Platelet count; chr1:40727216 chr1:40669089~40687588:- PAAD cis rs58873874 0.737 rs11739062 ENSG00000251405.2 CTB-109A12.1 4.92 2.27e-06 0.0015 0.78 0.37 Bipolar disorder (body mass index interaction); chr5:157474693 chr5:157362615~157460078:- PAAD cis rs3096299 0.9 rs744327 ENSG00000274627.1 RP11-104N10.2 4.92 2.27e-06 0.0015 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89372862 chr16:89516797~89522217:+ PAAD cis rs4664293 0.867 rs3771718 ENSG00000226266.5 AC009961.3 -4.92 2.27e-06 0.00151 -0.45 -0.37 Monocyte percentage of white cells; chr2:159780397 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs2303550 ENSG00000226266.5 AC009961.3 -4.92 2.27e-06 0.00151 -0.45 -0.37 Monocyte percentage of white cells; chr2:159781110 chr2:159670708~159712435:- PAAD cis rs10510102 0.688 rs11812208 ENSG00000276742.1 RP11-500G22.4 4.92 2.27e-06 0.00151 0.56 0.37 Breast cancer; chr10:121924831 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs77447688 ENSG00000276742.1 RP11-500G22.4 4.92 2.27e-06 0.00151 0.56 0.37 Breast cancer; chr10:121925721 chr10:121956782~121957098:+ PAAD cis rs17507216 1 rs17356118 ENSG00000255769.6 GOLGA2P10 -4.92 2.28e-06 0.00151 -0.47 -0.37 Excessive daytime sleepiness; chr15:82569149 chr15:82472993~82513950:- PAAD cis rs858239 0.899 rs7794684 ENSG00000226816.2 AC005082.12 4.91 2.28e-06 0.00151 0.42 0.37 Cerebrospinal fluid biomarker levels; chr7:23271186 chr7:23206013~23208045:+ PAAD cis rs7829975 0.84 rs555617 ENSG00000253893.2 FAM85B 4.91 2.28e-06 0.00151 0.54 0.37 Mood instability; chr8:8735335 chr8:8167819~8226614:- PAAD cis rs10510102 0.935 rs12255859 ENSG00000276742.1 RP11-500G22.4 4.91 2.28e-06 0.00151 0.54 0.37 Breast cancer; chr10:121831661 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs7923634 ENSG00000276742.1 RP11-500G22.4 4.91 2.28e-06 0.00151 0.54 0.37 Breast cancer; chr10:121832800 chr10:121956782~121957098:+ PAAD cis rs8031584 1 rs1474380 ENSG00000260382.1 RP11-540B6.2 4.91 2.28e-06 0.00151 0.46 0.37 Huntington's disease progression; chr15:30977032 chr15:30882267~30883231:- PAAD cis rs8031584 0.918 rs34095794 ENSG00000260382.1 RP11-540B6.2 4.91 2.28e-06 0.00151 0.46 0.37 Huntington's disease progression; chr15:30977488 chr15:30882267~30883231:- PAAD cis rs8031584 0.918 rs61997139 ENSG00000260382.1 RP11-540B6.2 4.91 2.28e-06 0.00151 0.46 0.37 Huntington's disease progression; chr15:30981399 chr15:30882267~30883231:- PAAD cis rs11098499 0.644 rs10050092 ENSG00000245958.5 RP11-33B1.1 -4.91 2.28e-06 0.00151 -0.3 -0.37 Corneal astigmatism; chr4:119610930 chr4:119454791~119552025:+ PAAD cis rs12468226 0.938 rs58834901 ENSG00000273456.1 RP11-686O6.2 4.91 2.28e-06 0.00151 0.53 0.37 Urate levels; chr2:202288169 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs6753044 ENSG00000273456.1 RP11-686O6.2 4.91 2.28e-06 0.00151 0.53 0.37 Urate levels; chr2:202300710 chr2:202374932~202375604:- PAAD cis rs4664293 0.867 rs13022404 ENSG00000226266.5 AC009961.3 -4.91 2.29e-06 0.00151 -0.46 -0.37 Monocyte percentage of white cells; chr2:159732981 chr2:159670708~159712435:- PAAD cis rs9322193 0.516 rs1999632 ENSG00000223701.3 RAET1E-AS1 4.91 2.29e-06 0.00151 0.49 0.37 Lung cancer; chr6:149866737 chr6:149884431~149919508:+ PAAD cis rs964611 0.882 rs10163162 ENSG00000259488.2 RP11-154J22.1 -4.91 2.29e-06 0.00152 -0.4 -0.37 Metabolite levels (Pyroglutamine); chr15:48266334 chr15:48312353~48331856:- PAAD cis rs2404602 0.684 rs10851888 ENSG00000259422.1 RP11-593F23.1 -4.91 2.29e-06 0.00152 -0.45 -0.37 Blood metabolite levels; chr15:76610165 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs34103231 ENSG00000259422.1 RP11-593F23.1 -4.91 2.29e-06 0.00152 -0.45 -0.37 Blood metabolite levels; chr15:76620349 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs12591622 ENSG00000259422.1 RP11-593F23.1 -4.91 2.29e-06 0.00152 -0.45 -0.37 Blood metabolite levels; chr15:76638314 chr15:76174891~76181486:- PAAD cis rs2404602 0.611 rs2404734 ENSG00000259422.1 RP11-593F23.1 -4.91 2.29e-06 0.00152 -0.45 -0.37 Blood metabolite levels; chr15:76643824 chr15:76174891~76181486:- PAAD cis rs2280018 0.963 rs11075255 ENSG00000260735.1 RP11-72I8.1 -4.91 2.3e-06 0.00152 -0.46 -0.37 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15072375 chr16:15094411~15109197:+ PAAD cis rs919433 0.927 rs1429418 ENSG00000231621.1 AC013264.2 4.91 2.3e-06 0.00152 0.36 0.37 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197293427 chr2:197197991~197199273:+ PAAD cis rs66887589 0.967 rs56173225 ENSG00000248280.1 RP11-33B1.2 -4.91 2.3e-06 0.00152 -0.33 -0.37 Diastolic blood pressure; chr4:119588817 chr4:119440561~119450157:- PAAD cis rs66887589 0.967 rs7678973 ENSG00000248280.1 RP11-33B1.2 -4.91 2.3e-06 0.00152 -0.33 -0.37 Diastolic blood pressure; chr4:119590662 chr4:119440561~119450157:- PAAD cis rs7829975 0.711 rs1039916 ENSG00000253893.2 FAM85B -4.91 2.3e-06 0.00152 -0.51 -0.37 Mood instability; chr8:8828344 chr8:8167819~8226614:- PAAD cis rs1185460 0.967 rs1784460 ENSG00000271751.1 RP11-110I1.14 4.91 2.3e-06 0.00152 0.47 0.37 Coronary artery disease; chr11:119067660 chr11:119065263~119065677:- PAAD cis rs12817211 0.502 rs12819883 ENSG00000272368.2 RP4-605O3.4 -4.91 2.31e-06 0.00153 -0.36 -0.37 Colorectal or endometrial cancer; chr12:50140005 chr12:50112197~50165618:+ PAAD cis rs1185460 0.967 rs1786690 ENSG00000271751.1 RP11-110I1.14 -4.91 2.31e-06 0.00153 -0.47 -0.37 Coronary artery disease; chr11:119071357 chr11:119065263~119065677:- PAAD cis rs8062405 0.965 rs8049439 ENSG00000251417.2 RP11-1348G14.4 -4.91 2.31e-06 0.00153 -0.32 -0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28826194 chr16:28802743~28817828:+ PAAD cis rs4835473 0.835 rs1450247 ENSG00000251600.4 RP11-673E1.1 4.91 2.31e-06 0.00153 0.41 0.37 Immature fraction of reticulocytes; chr4:143708529 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs6537171 ENSG00000251600.4 RP11-673E1.1 4.91 2.31e-06 0.00153 0.41 0.37 Immature fraction of reticulocytes; chr4:143709222 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs6832722 ENSG00000251600.4 RP11-673E1.1 4.91 2.31e-06 0.00153 0.41 0.37 Immature fraction of reticulocytes; chr4:143709430 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs6537172 ENSG00000251600.4 RP11-673E1.1 4.91 2.31e-06 0.00153 0.41 0.37 Immature fraction of reticulocytes; chr4:143710612 chr4:143912331~143982454:+ PAAD cis rs4835473 0.714 rs10013005 ENSG00000251600.4 RP11-673E1.1 4.91 2.31e-06 0.00153 0.41 0.37 Immature fraction of reticulocytes; chr4:143711351 chr4:143912331~143982454:+ PAAD cis rs950169 0.92 rs34672825 ENSG00000225151.9 GOLGA2P7 -4.91 2.31e-06 0.00153 -0.45 -0.37 Schizophrenia; chr15:84034718 chr15:84199311~84230136:- PAAD cis rs7727544 0.788 rs270613 ENSG00000233006.5 AC034220.3 4.91 2.31e-06 0.00153 0.3 0.37 Blood metabolite levels; chr5:132304890 chr5:132311285~132369916:- PAAD cis rs9987353 0.519 rs13276350 ENSG00000253893.2 FAM85B 4.91 2.31e-06 0.00153 0.5 0.37 Recombination measurement; chr8:9205647 chr8:8167819~8226614:- PAAD cis rs34375054 0.525 rs12316499 ENSG00000279233.1 RP11-158L12.4 4.91 2.31e-06 0.00153 0.33 0.37 Post bronchodilator FEV1/FVC ratio; chr12:125108772 chr12:125138245~125141711:+ PAAD cis rs7772486 0.875 rs2777481 ENSG00000235652.6 RP11-545I5.3 4.91 2.31e-06 0.00153 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145988900 chr6:145799409~145886585:+ PAAD cis rs42490 0.664 rs372981 ENSG00000251136.7 RP11-37B2.1 -4.91 2.32e-06 0.00153 -0.33 -0.37 Leprosy; chr8:89784740 chr8:89609409~89757727:- PAAD cis rs8059260 0.736 rs80207136 ENSG00000274038.1 RP11-66H6.4 -4.91 2.32e-06 0.00153 -0.62 -0.37 Alcohol consumption over the past year; chr16:11015480 chr16:11056556~11057034:+ PAAD cis rs8059260 0.668 rs78573173 ENSG00000274038.1 RP11-66H6.4 -4.91 2.32e-06 0.00153 -0.62 -0.37 Alcohol consumption over the past year; chr16:11017642 chr16:11056556~11057034:+ PAAD cis rs8059260 0.542 rs6498148 ENSG00000274038.1 RP11-66H6.4 -4.91 2.32e-06 0.00153 -0.62 -0.37 Alcohol consumption over the past year; chr16:11018374 chr16:11056556~11057034:+ PAAD cis rs875971 0.571 rs160641 ENSG00000164669.11 INTS4P1 4.91 2.32e-06 0.00153 0.53 0.37 Aortic root size; chr7:66112359 chr7:65141225~65234216:+ PAAD cis rs2108622 1 rs62107762 ENSG00000267453.5 AC004791.2 -4.91 2.32e-06 0.00153 -0.55 -0.37 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871728 chr19:15851993~15864904:- PAAD cis rs7208859 0.673 rs17826219 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834827 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs61223749 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30836729 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs3764420 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837136 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs3764421 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30840635 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11651858 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843700 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs36056619 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30845266 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9909497 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846210 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs11080135 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30849463 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9894876 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855002 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73277967 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30857148 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs60020217 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30858036 chr17:30792372~30792833:+ PAAD cis rs7208859 0.573 rs73277974 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862851 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73277978 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864431 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs11657391 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30867269 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs58089675 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869746 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs73263755 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30871954 chr17:30792372~30792833:+ PAAD cis rs7208859 0.673 rs9899349 ENSG00000266490.1 CTD-2349P21.9 4.91 2.32e-06 0.00153 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30873104 chr17:30792372~30792833:+ PAAD cis rs9322193 0.566 rs6912330 ENSG00000223701.3 RAET1E-AS1 -4.91 2.32e-06 0.00153 -0.47 -0.37 Lung cancer; chr6:149908811 chr6:149884431~149919508:+ PAAD cis rs9287719 0.81 rs7601748 ENSG00000234818.1 AC092687.5 4.91 2.32e-06 0.00153 0.41 0.37 Prostate cancer; chr2:10645320 chr2:10589166~10604830:+ PAAD cis rs964611 0.938 rs8026751 ENSG00000259488.2 RP11-154J22.1 -4.91 2.32e-06 0.00154 -0.4 -0.37 Metabolite levels (Pyroglutamine); chr15:48290648 chr15:48312353~48331856:- PAAD cis rs964611 0.872 rs72623972 ENSG00000259488.2 RP11-154J22.1 -4.91 2.32e-06 0.00154 -0.4 -0.37 Metabolite levels (Pyroglutamine); chr15:48294797 chr15:48312353~48331856:- PAAD cis rs3096299 0.933 rs2965938 ENSG00000274627.1 RP11-104N10.2 4.91 2.33e-06 0.00154 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89424928 chr16:89516797~89522217:+ PAAD cis rs2153535 0.623 rs6597338 ENSG00000230939.1 RP11-314C16.1 -4.91 2.33e-06 0.00154 -0.4 -0.37 Motion sickness; chr6:8533275 chr6:8784178~8785445:+ PAAD cis rs950027 0.62 rs1145076 ENSG00000259433.2 CTD-2651B20.4 -4.91 2.33e-06 0.00154 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45392310 chr15:45330209~45332634:- PAAD cis rs1075232 1 rs72722861 ENSG00000215302.7 CTD-3092A11.1 -4.91 2.33e-06 0.00154 -0.91 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31412085 chr15:30470779~30507623:+ PAAD cis rs1075232 0.826 rs12438813 ENSG00000215302.7 CTD-3092A11.1 -4.91 2.33e-06 0.00154 -0.91 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31413710 chr15:30470779~30507623:+ PAAD cis rs633715 0.588 rs575908 ENSG00000254154.7 RP4-798P15.3 -4.91 2.33e-06 0.00154 -0.28 -0.37 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177930963 chr1:177928788~178038007:- PAAD cis rs638893 1 rs73005500 ENSG00000278376.1 RP11-158I9.8 4.91 2.33e-06 0.00154 0.54 0.37 Vitiligo; chr11:118826666 chr11:118791254~118793137:+ PAAD cis rs638893 1 rs113641235 ENSG00000278376.1 RP11-158I9.8 4.91 2.33e-06 0.00154 0.54 0.37 Vitiligo; chr11:118829555 chr11:118791254~118793137:+ PAAD cis rs950169 0.881 rs72750843 ENSG00000259295.5 CSPG4P12 4.91 2.33e-06 0.00154 0.4 0.37 Schizophrenia; chr15:84592552 chr15:85191438~85213905:+ PAAD cis rs12220777 1 rs11201799 ENSG00000230091.5 TMEM254-AS1 -4.91 2.34e-06 0.00154 -0.61 -0.37 Chronic obstructive pulmonary disease-related biomarkers; chr10:80122198 chr10:80046860~80078912:- PAAD cis rs1823913 0.599 rs17414109 ENSG00000280083.1 RP11-317J9.1 -4.91 2.34e-06 0.00154 -0.45 -0.37 Obesity-related traits; chr2:191310675 chr2:191154118~191156070:- PAAD cis rs13178541 0.81 rs4457070 ENSG00000250378.1 RP11-119J18.1 4.91 2.34e-06 0.00154 0.57 0.37 IgG glycosylation; chr5:135814396 chr5:135812667~135826582:+ PAAD cis rs7727544 0.74 rs419291 ENSG00000233006.5 AC034220.3 4.91 2.34e-06 0.00154 0.3 0.37 Blood metabolite levels; chr5:132297662 chr5:132311285~132369916:- PAAD cis rs17711722 0.522 rs4642526 ENSG00000236529.1 RP13-254B10.1 4.91 2.34e-06 0.00154 0.41 0.37 Calcium levels; chr7:65751755 chr7:65840212~65840596:+ PAAD cis rs853679 0.517 rs868987 ENSG00000226314.6 ZNF192P1 4.91 2.34e-06 0.00154 0.63 0.37 Depression; chr6:28142370 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9283884 ENSG00000226314.6 ZNF192P1 4.91 2.34e-06 0.00154 0.63 0.37 Depression; chr6:28167882 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380047 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28070115 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs7755442 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28071237 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713135 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28071808 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs12174753 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28074687 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs55747925 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28076559 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs56310871 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28076704 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs34716816 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28078391 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380049 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28080757 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380050 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28080760 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393885 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28082231 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393886 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28082261 chr6:28161781~28169594:+ PAAD cis rs4713118 0.515 rs9368549 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Parkinson's disease; chr6:28082269 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs56364346 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28082984 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9357061 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28083994 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368550 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28084025 chr6:28161781~28169594:+ PAAD cis rs853679 0.542 rs2295594 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28085319 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs2273564 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28089816 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs1853097 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28090857 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393888 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28091439 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs3734573 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28091659 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9357063 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28092227 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs3823180 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28093966 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368551 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28094014 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393890 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28096077 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9366715 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28096855 chr6:28161781~28169594:+ PAAD cis rs853679 0.598 rs9380054 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28099759 chr6:28161781~28169594:+ PAAD cis rs4713118 0.547 rs2116981 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Parkinson's disease; chr6:28100173 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368552 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28100648 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs2281588 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28104824 chr6:28161781~28169594:+ PAAD cis rs853679 0.542 rs34131763 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28107222 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs35193936 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28108492 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs36078605 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28110254 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393891 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28111382 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9468286 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28111650 chr6:28161781~28169594:+ PAAD cis rs853679 0.542 rs9393892 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28113616 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380055 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28113851 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368553 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28114487 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368554 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28114933 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713137 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28115743 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9348793 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28116411 chr6:28161781~28169594:+ PAAD cis rs4713118 0.586 rs6905516 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Parkinson's disease; chr6:28118700 chr6:28161781~28169594:+ PAAD cis rs4713118 0.586 rs6905522 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Parkinson's disease; chr6:28118701 chr6:28161781~28169594:+ PAAD cis rs853679 0.542 rs6934769 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28123153 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs17711801 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28124529 chr6:28161781~28169594:+ PAAD cis rs4713118 0.527 rs9461433 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Parkinson's disease; chr6:28127394 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9468292 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28127577 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs1947863 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28131566 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713141 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28133900 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380056 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28136698 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380057 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28136856 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs1947862 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28137418 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs6941992 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28138363 chr6:28161781~28169594:+ PAAD cis rs4713118 0.516 rs4713142 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Parkinson's disease; chr6:28138569 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713143 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28138981 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713144 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28139012 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713145 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28139049 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs3757187 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28139876 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs3757185 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28139998 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs1904840 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28140454 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368555 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28141189 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393893 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28141484 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713146 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28143758 chr6:28161781~28169594:+ PAAD cis rs853679 0.513 rs9468296 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28145952 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4711164 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28147378 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4711165 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28147406 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713148 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28148143 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9348794 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28149979 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9468297 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28151096 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9295758 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28152885 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs17774663 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28153120 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9468298 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28154567 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9295759 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28156691 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9348796 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28158424 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs11552219 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28159056 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393895 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28159843 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9357065 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28161802 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9357066 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28162053 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368556 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28163375 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368557 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28163759 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380059 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28164580 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380060 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28164825 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs35227624 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28164948 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380061 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28165025 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9368558 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28165528 chr6:28161781~28169594:+ PAAD cis rs4713118 0.587 rs9393899 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Parkinson's disease; chr6:28165750 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713150 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28168434 chr6:28161781~28169594:+ PAAD cis rs4713118 0.527 rs4713151 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Parkinson's disease; chr6:28168578 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393901 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28169019 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs3173443 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28169249 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs4713152 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28169676 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9348797 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28169755 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380062 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28169791 chr6:28161781~28169594:+ PAAD cis rs853679 0.542 rs9380063 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28170075 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs12332979 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28173770 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs67878650 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28174809 chr6:28161781~28169594:+ PAAD cis rs853679 0.569 rs9348798 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28175233 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9380065 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28176973 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9295761 ENSG00000226314.6 ZNF192P1 -4.91 2.34e-06 0.00154 -0.63 -0.37 Depression; chr6:28180209 chr6:28161781~28169594:+ PAAD cis rs11673344 0.764 rs569371 ENSG00000226686.6 LINC01535 4.91 2.35e-06 0.00155 0.49 0.37 Obesity-related traits; chr19:36963095 chr19:37251912~37265535:+ PAAD cis rs964611 0.882 rs7182177 ENSG00000259488.2 RP11-154J22.1 -4.91 2.35e-06 0.00155 -0.4 -0.37 Metabolite levels (Pyroglutamine); chr15:48354357 chr15:48312353~48331856:- PAAD cis rs12701220 0.5 rs6463224 ENSG00000229043.2 AC091729.9 -4.91 2.35e-06 0.00155 -0.48 -0.37 Bronchopulmonary dysplasia; chr7:1100782 chr7:1160374~1165267:+ PAAD cis rs34375054 0.526 rs34764657 ENSG00000279233.1 RP11-158L12.4 4.91 2.35e-06 0.00155 0.31 0.37 Post bronchodilator FEV1/FVC ratio; chr12:125195093 chr12:125138245~125141711:+ PAAD cis rs3864261 0.515 rs12186995 ENSG00000272081.1 CTD-2376I4.2 4.91 2.35e-06 0.00155 0.44 0.37 Discordance in emotional problems in monozygotic twins; chr5:73039500 chr5:72955206~72955699:- PAAD cis rs10888838 0.756 rs59455983 ENSG00000198711.5 SSBP3-AS1 4.91 2.36e-06 0.00155 0.47 0.37 Mitochondrial DNA levels; chr1:54229275 chr1:54236440~54239063:+ PAAD cis rs6921919 0.583 rs7740351 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28431635 chr6:28176188~28176674:+ PAAD cis rs633715 0.879 rs10913469 ENSG00000254154.7 RP4-798P15.3 -4.91 2.36e-06 0.00155 -0.33 -0.37 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177944384 chr1:177928788~178038007:- PAAD cis rs3762637 0.941 rs6788746 ENSG00000272758.4 RP11-299J3.8 -4.91 2.36e-06 0.00155 -0.55 -0.37 LDL cholesterol levels; chr3:122387896 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs79493664 ENSG00000272758.4 RP11-299J3.8 -4.91 2.36e-06 0.00155 -0.55 -0.37 LDL cholesterol levels; chr3:122390699 chr3:122416207~122443180:+ PAAD cis rs6921919 0.583 rs12697938 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28373322 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs13437294 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28373758 chr6:28176188~28176674:+ PAAD cis rs6921919 0.609 rs9468357 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28374276 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs34513104 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28375566 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs9461456 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28376039 chr6:28176188~28176674:+ PAAD cis rs6921919 0.525 rs9468360 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28376661 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs16894021 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28377249 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs11751693 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28377306 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs7749736 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28378254 chr6:28176188~28176674:+ PAAD cis rs6921919 0.525 rs9468361 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28378541 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs7775132 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28379236 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs3734563 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28381948 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs1591913 ENSG00000216901.1 AL022393.7 4.91 2.36e-06 0.00155 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28383951 chr6:28176188~28176674:+ PAAD cis rs2348418 0.864 rs7977817 ENSG00000247934.4 RP11-967K21.1 4.91 2.37e-06 0.00156 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28562549 chr12:28163298~28190738:- PAAD cis rs2348418 0.831 rs7977525 ENSG00000247934.4 RP11-967K21.1 4.91 2.37e-06 0.00156 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28562584 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7977850 ENSG00000247934.4 RP11-967K21.1 4.91 2.37e-06 0.00156 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28562715 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7978086 ENSG00000247934.4 RP11-967K21.1 4.91 2.37e-06 0.00156 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28562761 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs11609924 ENSG00000247934.4 RP11-967K21.1 4.91 2.37e-06 0.00156 0.36 0.37 Lung function (FEV1);Lung function (FVC); chr12:28563197 chr12:28163298~28190738:- PAAD cis rs4879677 0.959 rs10968039 ENSG00000260390.1 RP11-575I8.1 -4.91 2.37e-06 0.00156 -0.47 -0.37 Gut microbiome composition (summer and winter); chr9:27670118 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs10968041 ENSG00000260390.1 RP11-575I8.1 -4.91 2.37e-06 0.00156 -0.47 -0.37 Gut microbiome composition (summer and winter); chr9:27670205 chr9:27829276~27844481:+ PAAD cis rs4879677 1 rs10757673 ENSG00000260390.1 RP11-575I8.1 -4.91 2.37e-06 0.00156 -0.47 -0.37 Gut microbiome composition (summer and winter); chr9:27670815 chr9:27829276~27844481:+ PAAD cis rs992157 0.71 rs56364928 ENSG00000261338.2 RP11-378A13.1 4.91 2.37e-06 0.00156 0.41 0.37 Colorectal cancer; chr2:218194335 chr2:218255319~218257366:+ PAAD cis rs7727544 0.735 rs272894 ENSG00000233006.5 AC034220.3 4.91 2.37e-06 0.00156 0.3 0.37 Blood metabolite levels; chr5:132326767 chr5:132311285~132369916:- PAAD cis rs7727544 0.66 rs272886 ENSG00000233006.5 AC034220.3 4.91 2.37e-06 0.00156 0.3 0.37 Blood metabolite levels; chr5:132330147 chr5:132311285~132369916:- PAAD cis rs7727544 0.735 rs272884 ENSG00000233006.5 AC034220.3 4.91 2.37e-06 0.00156 0.3 0.37 Blood metabolite levels; chr5:132332961 chr5:132311285~132369916:- PAAD cis rs7727544 0.735 rs272881 ENSG00000233006.5 AC034220.3 4.91 2.37e-06 0.00156 0.3 0.37 Blood metabolite levels; chr5:132333571 chr5:132311285~132369916:- PAAD cis rs7727544 0.735 rs272879 ENSG00000233006.5 AC034220.3 4.91 2.37e-06 0.00156 0.3 0.37 Blood metabolite levels; chr5:132334853 chr5:132311285~132369916:- PAAD cis rs7727544 0.735 rs4705933 ENSG00000233006.5 AC034220.3 4.91 2.37e-06 0.00156 0.3 0.37 Blood metabolite levels; chr5:132342719 chr5:132311285~132369916:- PAAD cis rs7727544 0.735 rs272867 ENSG00000233006.5 AC034220.3 4.91 2.37e-06 0.00156 0.3 0.37 Blood metabolite levels; chr5:132345364 chr5:132311285~132369916:- PAAD cis rs2739330 0.76 rs5751761 ENSG00000231271.1 AP000350.8 -4.91 2.37e-06 0.00156 -0.5 -0.37 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23949918~23954042:+ PAAD cis rs6921919 0.583 rs2071965 ENSG00000204709.4 LINC01556 4.91 2.38e-06 0.00156 0.53 0.37 Autism spectrum disorder or schizophrenia; chr6:28435448 chr6:28943877~28944537:+ PAAD cis rs897984 0.609 rs17839567 ENSG00000260911.2 RP11-196G11.2 4.91 2.38e-06 0.00156 0.32 0.37 Dementia with Lewy bodies; chr16:31046624 chr16:31043150~31049868:+ PAAD cis rs10754283 0.967 rs10737706 ENSG00000231613.1 RP5-943J3.1 4.9 2.38e-06 0.00156 0.4 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89647020 chr1:89788914~89790492:+ PAAD cis rs2980439 0.525 rs2980508 ENSG00000253893.2 FAM85B -4.9 2.38e-06 0.00156 -0.5 -0.37 Neuroticism; chr8:8314210 chr8:8167819~8226614:- PAAD cis rs4879677 1 rs12235880 ENSG00000260390.1 RP11-575I8.1 -4.9 2.38e-06 0.00156 -0.47 -0.37 Gut microbiome composition (summer and winter); chr9:27674779 chr9:27829276~27844481:+ PAAD cis rs7829975 0.742 rs882462 ENSG00000253893.2 FAM85B -4.9 2.38e-06 0.00157 -0.5 -0.37 Mood instability; chr8:8821020 chr8:8167819~8226614:- PAAD cis rs7829975 0.774 rs11775523 ENSG00000253893.2 FAM85B -4.9 2.38e-06 0.00157 -0.5 -0.37 Mood instability; chr8:8821666 chr8:8167819~8226614:- PAAD cis rs3096299 0.967 rs2911256 ENSG00000274627.1 RP11-104N10.2 4.9 2.39e-06 0.00157 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89418688 chr16:89516797~89522217:+ PAAD cis rs4723738 1 rs4723738 ENSG00000227191.5 TRGC2 -4.9 2.39e-06 0.00157 -0.32 -0.37 Treatment response for severe sepsis; chr7:38201307 chr7:38239580~38368091:- PAAD cis rs6570726 0.967 rs6903252 ENSG00000235652.6 RP11-545I5.3 4.9 2.39e-06 0.00157 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145601641 chr6:145799409~145886585:+ PAAD cis rs3096299 0.933 rs2965934 ENSG00000274627.1 RP11-104N10.2 4.9 2.39e-06 0.00157 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89414821 chr16:89516797~89522217:+ PAAD cis rs902774 0.515 rs2363635 ENSG00000278185.1 RP11-153F5.7 4.9 2.39e-06 0.00157 0.47 0.37 Prostate cancer; chr12:52960838 chr12:52946614~52947125:- PAAD cis rs4950322 0.57 rs4950400 ENSG00000278811.3 LINC00624 -4.9 2.4e-06 0.00157 -0.39 -0.37 Protein quantitative trait loci; chr1:147319383 chr1:147258885~147517875:- PAAD cis rs7945705 0.818 rs4929916 ENSG00000254860.4 TMEM9B-AS1 -4.9 2.4e-06 0.00157 -0.4 -0.37 Hemoglobin concentration; chr11:8803449 chr11:8964675~8977527:+ PAAD cis rs6921919 0.583 rs9461459 ENSG00000216901.1 AL022393.7 4.9 2.4e-06 0.00157 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28394139 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs28360638 ENSG00000216901.1 AL022393.7 4.9 2.4e-06 0.00157 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28394552 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs9468368 ENSG00000216901.1 AL022393.7 4.9 2.4e-06 0.00157 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28397172 chr6:28176188~28176674:+ PAAD cis rs6921919 0.609 rs1005127 ENSG00000216901.1 AL022393.7 4.9 2.4e-06 0.00157 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28399881 chr6:28176188~28176674:+ PAAD cis rs853679 0.515 rs4580862 ENSG00000216901.1 AL022393.7 4.9 2.4e-06 0.00157 0.48 0.37 Depression; chr6:28399886 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs4357130 ENSG00000216901.1 AL022393.7 4.9 2.4e-06 0.00157 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28399906 chr6:28176188~28176674:+ PAAD cis rs10754283 0.967 rs10801757 ENSG00000231613.1 RP5-943J3.1 4.9 2.4e-06 0.00157 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89637521 chr1:89788914~89790492:+ PAAD cis rs7712401 0.642 rs17388251 ENSG00000263432.2 RN7SL689P 4.9 2.4e-06 0.00158 0.44 0.37 Mean platelet volume; chr5:123024708 chr5:123022487~123022783:- PAAD cis rs3931020 0.616 rs277380 ENSG00000272864.1 RP11-17E13.2 4.9 2.41e-06 0.00158 0.52 0.37 Resistin levels; chr1:74797404 chr1:74698769~74699333:- PAAD cis rs875971 0.545 rs73142233 ENSG00000226824.5 RP4-756H11.3 -4.9 2.41e-06 0.00158 -0.51 -0.37 Aortic root size; chr7:66221293 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs73142245 ENSG00000226824.5 RP4-756H11.3 -4.9 2.41e-06 0.00158 -0.51 -0.37 Aortic root size; chr7:66226662 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs73142265 ENSG00000226824.5 RP4-756H11.3 -4.9 2.41e-06 0.00158 -0.51 -0.37 Aortic root size; chr7:66234510 chr7:66654538~66669855:+ PAAD cis rs4853525 0.651 rs12623559 ENSG00000235852.1 AC005540.3 4.9 2.41e-06 0.00158 0.55 0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190868617 chr2:190880797~190882059:- PAAD cis rs950027 0.62 rs1346267 ENSG00000259433.2 CTD-2651B20.4 -4.9 2.41e-06 0.00158 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45398791 chr15:45330209~45332634:- PAAD cis rs4835473 0.864 rs57137521 ENSG00000251600.4 RP11-673E1.1 -4.9 2.41e-06 0.00158 -0.41 -0.37 Immature fraction of reticulocytes; chr4:143704045 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs55945293 ENSG00000251600.4 RP11-673E1.1 -4.9 2.41e-06 0.00158 -0.41 -0.37 Immature fraction of reticulocytes; chr4:143704766 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs7695328 ENSG00000251600.4 RP11-673E1.1 4.9 2.41e-06 0.00158 0.41 0.37 Immature fraction of reticulocytes; chr4:143703768 chr4:143912331~143982454:+ PAAD cis rs748404 0.66 rs2467738 ENSG00000205771.5 CATSPER2P1 -4.9 2.41e-06 0.00158 -0.51 -0.37 Lung cancer; chr15:43447738 chr15:43726918~43747094:- PAAD cis rs13178541 0.81 rs7379100 ENSG00000250378.1 RP11-119J18.1 -4.9 2.41e-06 0.00158 -0.57 -0.37 IgG glycosylation; chr5:135773790 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs11959707 ENSG00000250378.1 RP11-119J18.1 -4.9 2.41e-06 0.00158 -0.57 -0.37 IgG glycosylation; chr5:135775123 chr5:135812667~135826582:+ PAAD cis rs13178541 0.745 rs11950987 ENSG00000250378.1 RP11-119J18.1 -4.9 2.41e-06 0.00158 -0.57 -0.37 IgG glycosylation; chr5:135776266 chr5:135812667~135826582:+ PAAD cis rs13178541 0.745 rs4513690 ENSG00000250378.1 RP11-119J18.1 -4.9 2.41e-06 0.00158 -0.57 -0.37 IgG glycosylation; chr5:135776703 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs11242275 ENSG00000250378.1 RP11-119J18.1 -4.9 2.41e-06 0.00158 -0.57 -0.37 IgG glycosylation; chr5:135777234 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs11242278 ENSG00000250378.1 RP11-119J18.1 -4.9 2.41e-06 0.00158 -0.57 -0.37 IgG glycosylation; chr5:135778043 chr5:135812667~135826582:+ PAAD cis rs10800713 0.954 rs4623737 ENSG00000260088.1 RP11-92G12.3 -4.9 2.42e-06 0.00158 -0.48 -0.37 Tandem gait; chr1:200594578 chr1:200669507~200694250:+ PAAD cis rs875971 0.502 rs2465121 ENSG00000226824.5 RP4-756H11.3 4.9 2.42e-06 0.00159 0.51 0.37 Aortic root size; chr7:66156017 chr7:66654538~66669855:+ PAAD cis rs75422866 0.51 rs73105818 ENSG00000257433.4 RP1-197B17.3 4.9 2.42e-06 0.00159 0.73 0.37 Pneumonia; chr12:47726538 chr12:47706085~47742294:+ PAAD cis rs75422866 0.51 rs73105819 ENSG00000257433.4 RP1-197B17.3 4.9 2.42e-06 0.00159 0.73 0.37 Pneumonia; chr12:47727190 chr12:47706085~47742294:+ PAAD cis rs4227 0.565 rs1642772 ENSG00000233223.2 AC113189.5 4.9 2.42e-06 0.00159 0.4 0.37 IgA nephropathy; chr17:7600841 chr17:7581964~7584072:- PAAD cis rs7208859 0.614 rs73265646 ENSG00000266490.1 CTD-2349P21.9 4.9 2.42e-06 0.00159 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917005 chr17:30792372~30792833:+ PAAD cis rs7208859 0.623 rs58908911 ENSG00000266490.1 CTD-2349P21.9 4.9 2.42e-06 0.00159 0.51 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917540 chr17:30792372~30792833:+ PAAD cis rs11098499 0.644 rs3806808 ENSG00000245958.5 RP11-33B1.1 -4.9 2.43e-06 0.00159 -0.29 -0.37 Corneal astigmatism; chr4:119629930 chr4:119454791~119552025:+ PAAD cis rs10510102 0.935 rs11200263 ENSG00000276742.1 RP11-500G22.4 4.9 2.43e-06 0.00159 0.56 0.37 Breast cancer; chr10:121922836 chr10:121956782~121957098:+ PAAD cis rs35160687 0.644 rs10165626 ENSG00000273080.1 RP11-301O19.1 -4.9 2.43e-06 0.00159 -0.44 -0.37 Night sleep phenotypes; chr2:86309584 chr2:86195590~86196049:+ PAAD cis rs2108622 0.958 rs79400241 ENSG00000267453.5 AC004791.2 -4.9 2.43e-06 0.00159 -0.56 -0.37 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15873592 chr19:15851993~15864904:- PAAD cis rs950169 0.649 rs12911612 ENSG00000225151.9 GOLGA2P7 -4.9 2.43e-06 0.00159 -0.46 -0.37 Schizophrenia; chr15:84022262 chr15:84199311~84230136:- PAAD cis rs950169 0.649 rs12905952 ENSG00000225151.9 GOLGA2P7 -4.9 2.43e-06 0.00159 -0.46 -0.37 Schizophrenia; chr15:84022509 chr15:84199311~84230136:- PAAD cis rs950169 0.61 rs34529571 ENSG00000225151.9 GOLGA2P7 -4.9 2.43e-06 0.00159 -0.46 -0.37 Schizophrenia; chr15:84023055 chr15:84199311~84230136:- PAAD cis rs9287719 0.934 rs6727884 ENSG00000234818.1 AC092687.5 -4.9 2.43e-06 0.00159 -0.41 -0.37 Prostate cancer; chr2:10617431 chr2:10589166~10604830:+ PAAD cis rs7829975 0.755 rs3789849 ENSG00000253893.2 FAM85B -4.9 2.43e-06 0.00159 -0.5 -0.37 Mood instability; chr8:8829544 chr8:8167819~8226614:- PAAD cis rs7646881 0.951 rs6441222 ENSG00000240207.5 RP11-379F4.4 -4.9 2.43e-06 0.00159 -0.54 -0.37 Tetralogy of Fallot; chr3:158731978 chr3:158732263~158784070:+ PAAD cis rs7646881 1 rs73015652 ENSG00000240207.5 RP11-379F4.4 -4.9 2.43e-06 0.00159 -0.54 -0.37 Tetralogy of Fallot; chr3:158733594 chr3:158732263~158784070:+ PAAD cis rs7646881 1 rs73015655 ENSG00000240207.5 RP11-379F4.4 -4.9 2.43e-06 0.00159 -0.54 -0.37 Tetralogy of Fallot; chr3:158734093 chr3:158732263~158784070:+ PAAD cis rs7646881 1 rs61558956 ENSG00000240207.5 RP11-379F4.4 -4.9 2.43e-06 0.00159 -0.54 -0.37 Tetralogy of Fallot; chr3:158734866 chr3:158732263~158784070:+ PAAD cis rs7646881 1 rs59918529 ENSG00000240207.5 RP11-379F4.4 -4.9 2.43e-06 0.00159 -0.54 -0.37 Tetralogy of Fallot; chr3:158734916 chr3:158732263~158784070:+ PAAD cis rs4950322 0.748 rs56392137 ENSG00000278811.3 LINC00624 4.9 2.44e-06 0.0016 0.39 0.37 Protein quantitative trait loci; chr1:147352450 chr1:147258885~147517875:- PAAD cis rs748404 0.706 rs35975365 ENSG00000205771.5 CATSPER2P1 -4.9 2.44e-06 0.0016 -0.6 -0.37 Lung cancer; chr15:43379347 chr15:43726918~43747094:- PAAD cis rs12908161 0.959 rs34342559 ENSG00000225151.9 GOLGA2P7 -4.9 2.44e-06 0.0016 -0.45 -0.37 Schizophrenia; chr15:84788040 chr15:84199311~84230136:- PAAD cis rs12908161 0.959 rs62019472 ENSG00000225151.9 GOLGA2P7 -4.9 2.44e-06 0.0016 -0.45 -0.37 Schizophrenia; chr15:84788262 chr15:84199311~84230136:- PAAD cis rs12908161 0.959 rs35557864 ENSG00000225151.9 GOLGA2P7 -4.9 2.44e-06 0.0016 -0.45 -0.37 Schizophrenia; chr15:84788398 chr15:84199311~84230136:- PAAD cis rs8059260 0.736 rs80079627 ENSG00000274038.1 RP11-66H6.4 -4.9 2.44e-06 0.0016 -0.63 -0.37 Alcohol consumption over the past year; chr16:10948741 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs77920180 ENSG00000274038.1 RP11-66H6.4 -4.9 2.44e-06 0.0016 -0.63 -0.37 Alcohol consumption over the past year; chr16:10949041 chr16:11056556~11057034:+ PAAD cis rs858239 0.6 rs4321896 ENSG00000226816.2 AC005082.12 4.9 2.44e-06 0.0016 0.42 0.37 Cerebrospinal fluid biomarker levels; chr7:23088437 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs61292332 ENSG00000226816.2 AC005082.12 4.9 2.44e-06 0.0016 0.42 0.37 Cerebrospinal fluid biomarker levels; chr7:23092243 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6461692 ENSG00000226816.2 AC005082.12 4.9 2.44e-06 0.0016 0.42 0.37 Cerebrospinal fluid biomarker levels; chr7:23100076 chr7:23206013~23208045:+ PAAD cis rs964611 0.751 rs2291340 ENSG00000259488.2 RP11-154J22.1 -4.9 2.44e-06 0.0016 -0.4 -0.37 Metabolite levels (Pyroglutamine); chr15:48255779 chr15:48312353~48331856:- PAAD cis rs12908161 1 rs11637142 ENSG00000225151.9 GOLGA2P7 -4.9 2.45e-06 0.00161 -0.45 -0.37 Schizophrenia; chr15:84752696 chr15:84199311~84230136:- PAAD cis rs10754283 0.967 rs4658302 ENSG00000231613.1 RP5-943J3.1 4.9 2.46e-06 0.00161 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89637777 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs7513928 ENSG00000231613.1 RP5-943J3.1 4.9 2.46e-06 0.00161 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89639275 chr1:89788914~89790492:+ PAAD cis rs10754283 0.901 rs10922683 ENSG00000231613.1 RP5-943J3.1 4.9 2.46e-06 0.00161 0.4 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89650509 chr1:89788914~89790492:+ PAAD cis rs1823913 0.538 rs35311234 ENSG00000280083.1 RP11-317J9.1 -4.9 2.46e-06 0.00161 -0.45 -0.37 Obesity-related traits; chr2:191316952 chr2:191154118~191156070:- PAAD cis rs875971 0.545 rs4718325 ENSG00000226824.5 RP4-756H11.3 -4.9 2.46e-06 0.00161 -0.51 -0.37 Aortic root size; chr7:66215323 chr7:66654538~66669855:+ PAAD cis rs748404 0.66 rs2602141 ENSG00000205771.5 CATSPER2P1 -4.9 2.46e-06 0.00161 -0.5 -0.37 Lung cancer; chr15:43432448 chr15:43726918~43747094:- PAAD cis rs12594515 0.548 rs12912226 ENSG00000273972.1 CTD-2306A12.1 -4.9 2.46e-06 0.00161 -0.46 -0.37 Weight;Waist circumference; chr15:45693510 chr15:45702640~45703183:+ PAAD cis rs12594515 0.591 rs35554150 ENSG00000273972.1 CTD-2306A12.1 -4.9 2.46e-06 0.00161 -0.46 -0.37 Weight;Waist circumference; chr15:45698100 chr15:45702640~45703183:+ PAAD cis rs2115630 0.653 rs61394864 ENSG00000225151.9 GOLGA2P7 4.9 2.47e-06 0.00162 0.43 0.37 P wave terminal force; chr15:84626943 chr15:84199311~84230136:- PAAD cis rs10486158 0.521 rs11526212 ENSG00000155070.8 UNC93B2 -4.9 2.48e-06 0.00162 -0.43 -0.37 Bipolar disorder and schizophrenia; chr7:7387904 chr7:6855485~6859830:- PAAD cis rs4853525 0.59 rs6740086 ENSG00000235852.1 AC005540.3 4.9 2.48e-06 0.00162 0.56 0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190871204 chr2:190880797~190882059:- PAAD cis rs9473147 0.571 rs9463335 ENSG00000270761.1 RP11-385F7.1 -4.9 2.48e-06 0.00162 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47511400 chr6:47477243~47477572:- PAAD cis rs9473147 0.602 rs9296567 ENSG00000270761.1 RP11-385F7.1 -4.9 2.48e-06 0.00162 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47585666 chr6:47477243~47477572:- PAAD cis rs9473147 0.571 rs9395285 ENSG00000270761.1 RP11-385F7.1 -4.9 2.48e-06 0.00162 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47586441 chr6:47477243~47477572:- PAAD cis rs9473147 0.571 rs9369717 ENSG00000270761.1 RP11-385F7.1 -4.9 2.48e-06 0.00162 -0.38 -0.37 Platelet distribution width;Mean platelet volume; chr6:47586732 chr6:47477243~47477572:- PAAD cis rs2404602 0.662 rs908817 ENSG00000259422.1 RP11-593F23.1 -4.9 2.48e-06 0.00162 -0.46 -0.37 Blood metabolite levels; chr15:76346850 chr15:76174891~76181486:- PAAD cis rs11673344 0.796 rs16971886 ENSG00000226686.6 LINC01535 4.9 2.48e-06 0.00162 0.5 0.37 Obesity-related traits; chr19:36997073 chr19:37251912~37265535:+ PAAD cis rs11673344 0.83 rs3745770 ENSG00000226686.6 LINC01535 4.9 2.48e-06 0.00162 0.5 0.37 Obesity-related traits; chr19:36997663 chr19:37251912~37265535:+ PAAD cis rs11673344 0.797 rs3745768 ENSG00000226686.6 LINC01535 4.9 2.48e-06 0.00162 0.5 0.37 Obesity-related traits; chr19:36997907 chr19:37251912~37265535:+ PAAD cis rs992157 0.764 rs1870124 ENSG00000261338.2 RP11-378A13.1 4.89 2.49e-06 0.00163 0.43 0.37 Colorectal cancer; chr2:218323017 chr2:218255319~218257366:+ PAAD cis rs2153535 0.58 rs2143357 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8496963 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406167 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8502619 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs4140586 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8502959 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs4140585 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8503065 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597332 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8504515 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs6597334 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8504546 chr6:8784178~8785445:+ PAAD cis rs2153535 0.542 rs9505465 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8510613 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs7745043 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8513274 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406170 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8513920 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9378556 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8514462 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9379222 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8514555 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406171 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8515129 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406172 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8515231 chr6:8784178~8785445:+ PAAD cis rs2153535 0.601 rs9393030 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8516256 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9406174 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8516531 chr6:8784178~8785445:+ PAAD cis rs2153535 0.54 rs9378557 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8517148 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2143356 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8517442 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2143355 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8517623 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2143354 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8517674 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs2327067 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8518249 chr6:8784178~8785445:+ PAAD cis rs2153535 0.541 rs9328477 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8518876 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9328478 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8518950 chr6:8784178~8785445:+ PAAD cis rs2153535 0.58 rs9328479 ENSG00000230939.1 RP11-314C16.1 -4.89 2.49e-06 0.00163 -0.39 -0.37 Motion sickness; chr6:8519413 chr6:8784178~8785445:+ PAAD cis rs858239 0.698 rs4265084 ENSG00000226816.2 AC005082.12 4.89 2.49e-06 0.00163 0.41 0.37 Cerebrospinal fluid biomarker levels; chr7:23367621 chr7:23206013~23208045:+ PAAD cis rs8091660 0.624 rs907546 ENSG00000278983.1 RP11-426J5.3 4.89 2.49e-06 0.00163 0.46 0.37 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48549919 chr18:48564795~48568342:+ PAAD cis rs453301 0.606 rs6601279 ENSG00000253893.2 FAM85B 4.89 2.5e-06 0.00163 0.53 0.37 Joint mobility (Beighton score); chr8:9050721 chr8:8167819~8226614:- PAAD cis rs453301 0.606 rs6981060 ENSG00000253893.2 FAM85B 4.89 2.5e-06 0.00163 0.53 0.37 Joint mobility (Beighton score); chr8:9050725 chr8:8167819~8226614:- PAAD cis rs73219805 0.759 rs3808578 ENSG00000228451.3 SDAD1P1 -4.89 2.5e-06 0.00163 -0.65 -0.37 Schizophrenia; chr8:26393906 chr8:26379259~26382953:- PAAD cis rs73219805 0.759 rs17055186 ENSG00000228451.3 SDAD1P1 -4.89 2.5e-06 0.00163 -0.65 -0.37 Schizophrenia; chr8:26403394 chr8:26379259~26382953:- PAAD cis rs7727544 0.735 rs273914 ENSG00000233006.5 AC034220.3 4.89 2.5e-06 0.00163 0.3 0.37 Blood metabolite levels; chr5:132324738 chr5:132311285~132369916:- PAAD cis rs7201929 1 rs8061877 ENSG00000259982.1 CDC37P1 -4.89 2.51e-06 0.00164 -0.48 -0.37 QT interval; chr16:28845498 chr16:28700294~28701540:- PAAD cis rs10754283 0.967 rs4658308 ENSG00000231613.1 RP5-943J3.1 4.89 2.52e-06 0.00164 0.4 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89657372 chr1:89788914~89790492:+ PAAD cis rs4664293 0.836 rs13032500 ENSG00000226266.5 AC009961.3 -4.89 2.52e-06 0.00164 -0.45 -0.37 Monocyte percentage of white cells; chr2:159749740 chr2:159670708~159712435:- PAAD cis rs2255336 0.938 rs4548707 ENSG00000245648.1 RP11-277P12.20 -4.89 2.53e-06 0.00165 -0.57 -0.37 Blood protein levels; chr12:10467634 chr12:10363769~10398506:+ PAAD cis rs5758659 0.652 rs4822084 ENSG00000273366.1 CTA-989H11.1 4.89 2.53e-06 0.00165 0.45 0.37 Cognitive function; chr22:42039864 chr22:42278188~42278846:+ PAAD cis rs6584283 0.713 rs1332100 ENSG00000228778.1 RP11-129J12.1 4.89 2.54e-06 0.00165 0.41 0.37 Ulcerative colitis; chr10:99541589 chr10:99527081~99528261:+ PAAD cis rs875971 0.545 rs13311962 ENSG00000226824.5 RP4-756H11.3 4.89 2.54e-06 0.00165 0.52 0.37 Aortic root size; chr7:66603142 chr7:66654538~66669855:+ PAAD cis rs4268898 0.697 rs10445892 ENSG00000242628.4 AC009228.1 -4.89 2.54e-06 0.00166 -0.42 -0.37 Asthma; chr2:24184089 chr2:24214381~24221516:+ PAAD cis rs1990950 0.605 rs4704863 ENSG00000251405.2 CTB-109A12.1 -4.89 2.54e-06 0.00166 -0.43 -0.37 Lung function (FEV1/FVC); chr5:157452719 chr5:157362615~157460078:- PAAD cis rs1990950 0.605 rs7715241 ENSG00000251405.2 CTB-109A12.1 -4.89 2.54e-06 0.00166 -0.43 -0.37 Lung function (FEV1/FVC); chr5:157453762 chr5:157362615~157460078:- PAAD cis rs4723738 1 rs10282407 ENSG00000227191.5 TRGC2 -4.89 2.54e-06 0.00166 -0.32 -0.37 Treatment response for severe sepsis; chr7:38193791 chr7:38239580~38368091:- PAAD cis rs4853525 0.59 rs3771310 ENSG00000235852.1 AC005540.3 4.89 2.54e-06 0.00166 0.54 0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190908462 chr2:190880797~190882059:- PAAD cis rs12468226 0.938 rs7568159 ENSG00000273456.1 RP11-686O6.2 4.89 2.54e-06 0.00166 0.52 0.37 Urate levels; chr2:202286226 chr2:202374932~202375604:- PAAD cis rs1075265 0.756 rs1075264 ENSG00000233266.1 HMGB1P31 4.89 2.54e-06 0.00166 0.47 0.37 Chronotype;Morning vs. evening chronotype; chr2:54127916 chr2:54051334~54051760:+ PAAD cis rs4835473 0.932 rs4835013 ENSG00000251600.4 RP11-673E1.1 4.89 2.54e-06 0.00166 0.43 0.37 Immature fraction of reticulocytes; chr4:143748485 chr4:143912331~143982454:+ PAAD cis rs875971 1 rs6945843 ENSG00000237310.1 GS1-124K5.4 -4.89 2.55e-06 0.00166 -0.35 -0.37 Aortic root size; chr7:66269796 chr7:66493706~66495474:+ PAAD cis rs10754283 0.967 rs1934045 ENSG00000231613.1 RP5-943J3.1 -4.89 2.55e-06 0.00166 -0.39 -0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89642240 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs1317864 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89639889 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs2390763 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89640129 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs2002883 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89640279 chr1:89788914~89790492:+ PAAD cis rs10754283 0.934 rs1934043 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89641086 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs2185195 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89641138 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs6657988 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89641186 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs6698273 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89641232 chr1:89788914~89790492:+ PAAD cis rs10754283 0.905 rs7519969 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89643162 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs7519971 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89643184 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs7546410 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89644256 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs7515375 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89644295 chr1:89788914~89790492:+ PAAD cis rs10754283 0.901 rs6663526 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89645303 chr1:89788914~89790492:+ PAAD cis rs10754283 0.934 rs6428563 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89646024 chr1:89788914~89790492:+ PAAD cis rs10754283 0.934 rs7529653 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89646292 chr1:89788914~89790492:+ PAAD cis rs10754283 0.87 rs2390764 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89647268 chr1:89788914~89790492:+ PAAD cis rs10754283 0.901 rs4520403 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89647281 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs4658130 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89647888 chr1:89788914~89790492:+ PAAD cis rs10754283 0.934 rs10754284 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89648143 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs10801759 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89648186 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs10801760 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89648265 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs7528433 ENSG00000231613.1 RP5-943J3.1 4.89 2.55e-06 0.00166 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89648512 chr1:89788914~89790492:+ PAAD cis rs11089937 0.626 rs5757011 ENSG00000211639.2 IGLV4-60 4.89 2.55e-06 0.00166 0.39 0.37 Periodontitis (PAL4Q3); chr22:22135336 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs5757013 ENSG00000211639.2 IGLV4-60 4.89 2.55e-06 0.00166 0.39 0.37 Periodontitis (PAL4Q3); chr22:22135544 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs5757014 ENSG00000211639.2 IGLV4-60 4.89 2.55e-06 0.00166 0.39 0.37 Periodontitis (PAL4Q3); chr22:22135612 chr22:22162199~22162681:+ PAAD cis rs74233809 1 rs3781285 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103065908 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs943037 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103076162 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12217501 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103092132 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12412038 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103096405 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191555 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103097766 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191557 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103104857 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191558 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103104921 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191560 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103109281 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12413046 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103111447 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs10883832 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103111522 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs79082900 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103117545 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12220375 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103141734 chr10:103175554~103176094:+ PAAD cis rs74233809 0.901 rs12416331 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103169157 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs34747231 ENSG00000213277.3 MARCKSL1P1 4.89 2.55e-06 0.00166 0.63 0.37 Birth weight; chr10:103182487 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191580 ENSG00000213277.3 MARCKSL1P1 -4.89 2.55e-06 0.00166 -0.63 -0.37 Birth weight; chr10:103146454 chr10:103175554~103176094:+ PAAD cis rs748404 0.578 rs512628 ENSG00000249839.1 AC011330.5 -4.89 2.55e-06 0.00166 -0.55 -0.37 Lung cancer; chr15:43326536 chr15:43663654~43684339:- PAAD cis rs4683346 0.616 rs3846063 ENSG00000173811.9 CCDC13-AS1 4.89 2.57e-06 0.00167 0.41 0.37 Granulocyte percentage of myeloid white cells; chr3:42762336 chr3:42732575~42746768:+ PAAD cis rs2283792 0.765 rs5999749 ENSG00000224086.5 LL22NC03-86G7.1 4.89 2.57e-06 0.00167 0.37 0.37 Multiple sclerosis; chr22:21833371 chr22:21938293~21977632:+ PAAD cis rs11098499 0.644 rs7693919 ENSG00000245958.5 RP11-33B1.1 -4.89 2.57e-06 0.00167 -0.3 -0.37 Corneal astigmatism; chr4:119619416 chr4:119454791~119552025:+ PAAD cis rs11098499 0.57 rs6832740 ENSG00000245958.5 RP11-33B1.1 -4.89 2.57e-06 0.00167 -0.3 -0.37 Corneal astigmatism; chr4:119624981 chr4:119454791~119552025:+ PAAD cis rs11098499 0.644 rs6855918 ENSG00000245958.5 RP11-33B1.1 -4.89 2.57e-06 0.00167 -0.3 -0.37 Corneal astigmatism; chr4:119625144 chr4:119454791~119552025:+ PAAD cis rs2717559 0.522 rs2585160 ENSG00000253741.1 CTD-2292P10.4 -4.89 2.57e-06 0.00167 -0.49 -0.37 Urinary tract infection frequency; chr8:142793788 chr8:142702252~142726973:- PAAD cis rs1075265 0.933 rs7573491 ENSG00000233266.1 HMGB1P31 4.89 2.57e-06 0.00167 0.49 0.37 Chronotype;Morning vs. evening chronotype; chr2:54115875 chr2:54051334~54051760:+ PAAD cis rs1075265 0.933 rs2042143 ENSG00000233266.1 HMGB1P31 4.89 2.57e-06 0.00167 0.49 0.37 Chronotype;Morning vs. evening chronotype; chr2:54116377 chr2:54051334~54051760:+ PAAD cis rs710913 0.717 rs2068473 ENSG00000237624.1 OXCT2P1 -4.89 2.57e-06 0.00167 -0.46 -0.37 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572925 chr1:39514956~39516490:+ PAAD cis rs919433 1 rs919433 ENSG00000231621.1 AC013264.2 4.89 2.57e-06 0.00167 0.35 0.37 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197301841 chr2:197197991~197199273:+ PAAD cis rs9326248 0.501 rs4938351 ENSG00000280143.1 AP000892.6 4.89 2.58e-06 0.00167 0.41 0.37 Blood protein levels; chr11:117151636 chr11:117204967~117210292:+ PAAD cis rs9326248 0.52 rs6589602 ENSG00000280143.1 AP000892.6 4.89 2.58e-06 0.00167 0.41 0.37 Blood protein levels; chr11:117166349 chr11:117204967~117210292:+ PAAD cis rs9326248 0.539 rs7120565 ENSG00000280143.1 AP000892.6 4.89 2.58e-06 0.00167 0.41 0.37 Blood protein levels; chr11:117172233 chr11:117204967~117210292:+ PAAD cis rs4664293 0.867 rs13415025 ENSG00000226266.5 AC009961.3 -4.89 2.58e-06 0.00168 -0.45 -0.37 Monocyte percentage of white cells; chr2:159729799 chr2:159670708~159712435:- PAAD cis rs11673344 0.764 rs826303 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36951549 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs826304 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36952681 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs529468 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36955298 chr19:37251912~37265535:+ PAAD cis rs11673344 0.582 rs114437741 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36955379 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs524802 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36956045 chr19:37251912~37265535:+ PAAD cis rs11673344 0.73 rs826314 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36959533 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs474017 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36963217 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs565721 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36964929 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs472226 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36967811 chr19:37251912~37265535:+ PAAD cis rs11673344 0.73 rs475026 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36968115 chr19:37251912~37265535:+ PAAD cis rs11673344 0.734 rs1644638 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36970513 chr19:37251912~37265535:+ PAAD cis rs11673344 0.734 rs1667343 ENSG00000226686.6 LINC01535 4.89 2.58e-06 0.00168 0.49 0.37 Obesity-related traits; chr19:36978196 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs547483 ENSG00000226686.6 LINC01535 -4.89 2.58e-06 0.00168 -0.49 -0.37 Obesity-related traits; chr19:36950463 chr19:37251912~37265535:+ PAAD cis rs375092 0.543 rs6461708 ENSG00000230658.1 KLHL7-AS1 -4.89 2.58e-06 0.00168 -0.63 -0.37 Personality dimensions; chr7:23375698 chr7:23101228~23105703:- PAAD cis rs526231 0.578 rs2112886 ENSG00000175749.11 EIF3KP1 -4.89 2.59e-06 0.00168 -0.48 -0.37 Primary biliary cholangitis; chr5:102915678 chr5:103032376~103033031:+ PAAD cis rs62103177 0.564 rs7228971 ENSG00000261126.6 RP11-795F19.1 -4.89 2.59e-06 0.00168 -0.54 -0.37 Opioid sensitivity; chr18:79978025 chr18:80046900~80095482:+ PAAD cis rs2562456 0.793 rs627522 ENSG00000213976.4 CTD-2561J22.2 -4.89 2.59e-06 0.00168 -0.4 -0.37 Pain; chr19:21313002 chr19:21382865~21387177:+ PAAD cis rs2562456 0.833 rs516519 ENSG00000213976.4 CTD-2561J22.2 4.89 2.59e-06 0.00168 0.4 0.37 Pain; chr19:21298730 chr19:21382865~21387177:+ PAAD cis rs2562456 0.833 rs552800 ENSG00000213976.4 CTD-2561J22.2 4.89 2.59e-06 0.00168 0.4 0.37 Pain; chr19:21301840 chr19:21382865~21387177:+ PAAD cis rs2015599 0.645 rs12578931 ENSG00000257176.2 RP11-996F15.2 -4.89 2.59e-06 0.00168 -0.37 -0.37 Platelet count;Mean platelet volume; chr12:29358608 chr12:29280418~29317848:- PAAD cis rs2015599 0.623 rs4931174 ENSG00000257176.2 RP11-996F15.2 -4.89 2.59e-06 0.00168 -0.37 -0.37 Platelet count;Mean platelet volume; chr12:29360545 chr12:29280418~29317848:- PAAD cis rs4835473 0.932 rs7356305 ENSG00000251600.4 RP11-673E1.1 4.89 2.59e-06 0.00168 0.41 0.37 Immature fraction of reticulocytes; chr4:143737850 chr4:143912331~143982454:+ PAAD cis rs2015599 0.514 rs10843376 ENSG00000257176.2 RP11-996F15.2 4.89 2.59e-06 0.00168 0.36 0.37 Platelet count;Mean platelet volume; chr12:29283651 chr12:29280418~29317848:- PAAD cis rs10754283 0.84 rs6428560 ENSG00000231613.1 RP5-943J3.1 4.88 2.61e-06 0.00169 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89636903 chr1:89788914~89790492:+ PAAD cis rs11690935 0.571 rs13020884 ENSG00000228389.1 AC068039.4 -4.88 2.61e-06 0.00169 -0.42 -0.37 Schizophrenia; chr2:172036795 chr2:171773482~171775844:+ PAAD cis rs11690935 0.549 rs62183819 ENSG00000228389.1 AC068039.4 -4.88 2.61e-06 0.00169 -0.42 -0.37 Schizophrenia; chr2:172039610 chr2:171773482~171775844:+ PAAD cis rs17772222 0.74 rs10138002 ENSG00000258983.2 RP11-507K2.2 -4.88 2.61e-06 0.0017 -0.47 -0.37 Coronary artery calcification; chr14:88510071 chr14:88499334~88515502:+ PAAD cis rs17772222 0.653 rs1346996 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88507174 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs7160471 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88507241 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs9323830 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88507260 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs7160647 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88507340 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs7143642 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88507616 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs10143744 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88508073 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs1999177 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88508298 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs1999176 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88508371 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs1864746 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88508455 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs1864747 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88508523 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs7151164 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88509329 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs12433026 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88509495 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs10138139 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88510027 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs10150311 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88510128 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs10138309 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88510352 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs3783885 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88510714 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs11159857 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88510796 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs4390529 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88510853 chr14:88499334~88515502:+ PAAD cis rs17772222 0.771 rs4516145 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88510953 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs4594187 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88511071 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs4514599 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88511083 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs61975276 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88511193 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs61975277 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88511202 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs61975278 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88511223 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs73317739 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88511400 chr14:88499334~88515502:+ PAAD cis rs17772222 0.74 rs10150986 ENSG00000258983.2 RP11-507K2.2 4.88 2.61e-06 0.0017 0.47 0.37 Coronary artery calcification; chr14:88517326 chr14:88499334~88515502:+ PAAD cis rs4950322 0.57 rs17356492 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147296089 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691093 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147297977 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs76236344 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147297989 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691095 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147298305 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691097 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147299711 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691098 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147300142 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691102 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147301189 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692904 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147301437 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692905 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147301560 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692907 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147301921 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692914 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147302946 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692917 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147304389 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692920 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147308501 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs66580541 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147308828 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs945742 ENSG00000278811.3 LINC00624 4.88 2.62e-06 0.0017 0.38 0.37 Protein quantitative trait loci; chr1:147313437 chr1:147258885~147517875:- PAAD cis rs6504950 0.85 rs11658717 ENSG00000275710.1 RP11-257O5.4 -4.88 2.62e-06 0.0017 -0.48 -0.37 Breast cancer; chr17:54999625 chr17:54964474~54964679:+ PAAD cis rs7829975 0.774 rs35039922 ENSG00000253893.2 FAM85B -4.88 2.62e-06 0.0017 -0.5 -0.37 Mood instability; chr8:8817815 chr8:8167819~8226614:- PAAD cis rs13178541 0.872 rs4447978 ENSG00000250378.1 RP11-119J18.1 4.88 2.62e-06 0.0017 0.55 0.37 IgG glycosylation; chr5:135839129 chr5:135812667~135826582:+ PAAD cis rs9322193 0.607 rs3798763 ENSG00000223701.3 RAET1E-AS1 4.88 2.62e-06 0.0017 0.48 0.37 Lung cancer; chr6:149889964 chr6:149884431~149919508:+ PAAD cis rs4268898 0.722 rs35520052 ENSG00000242628.4 AC009228.1 -4.88 2.63e-06 0.0017 -0.43 -0.37 Asthma; chr2:24192408 chr2:24214381~24221516:+ PAAD cis rs9326248 0.798 rs10892079 ENSG00000280143.1 AP000892.6 4.88 2.63e-06 0.00171 0.48 0.37 Blood protein levels; chr11:117146108 chr11:117204967~117210292:+ PAAD cis rs3779195 0.585 rs7777991 ENSG00000272950.1 RP11-307C18.1 -4.88 2.63e-06 0.00171 -0.66 -0.37 Sex hormone-binding globulin levels; chr7:98236445 chr7:98322853~98323430:+ PAAD cis rs950169 0.922 rs62028133 ENSG00000259295.5 CSPG4P12 4.88 2.64e-06 0.00171 0.41 0.37 Schizophrenia; chr15:84250623 chr15:85191438~85213905:+ PAAD cis rs950169 0.723 rs17589320 ENSG00000259295.5 CSPG4P12 4.88 2.64e-06 0.00171 0.41 0.37 Schizophrenia; chr15:84251244 chr15:85191438~85213905:+ PAAD cis rs950169 0.845 rs4502182 ENSG00000259295.5 CSPG4P12 4.88 2.64e-06 0.00171 0.41 0.37 Schizophrenia; chr15:84254768 chr15:85191438~85213905:+ PAAD cis rs2337406 0.866 rs4280141 ENSG00000211974.3 IGHV2-70 4.88 2.64e-06 0.00171 0.48 0.37 Alzheimer's disease (late onset); chr14:106780476 chr14:106723574~106724093:- PAAD cis rs853679 1 rs7740487 ENSG00000226314.6 ZNF192P1 -4.88 2.64e-06 0.00171 -0.66 -0.37 Depression; chr6:28248708 chr6:28161781~28169594:+ PAAD cis rs853679 1 rs68141011 ENSG00000226314.6 ZNF192P1 -4.88 2.64e-06 0.00171 -0.66 -0.37 Depression; chr6:28250019 chr6:28161781~28169594:+ PAAD cis rs853679 1 rs13200462 ENSG00000226314.6 ZNF192P1 -4.88 2.64e-06 0.00171 -0.66 -0.37 Depression; chr6:28250421 chr6:28161781~28169594:+ PAAD cis rs853679 1 rs9986596 ENSG00000226314.6 ZNF192P1 -4.88 2.64e-06 0.00171 -0.66 -0.37 Depression; chr6:28251883 chr6:28161781~28169594:+ PAAD cis rs853679 1 rs1679732 ENSG00000226314.6 ZNF192P1 4.88 2.64e-06 0.00171 0.66 0.37 Depression; chr6:28253486 chr6:28161781~28169594:+ PAAD cis rs748404 0.626 rs57938858 ENSG00000249839.1 AC011330.5 -4.88 2.64e-06 0.00171 -0.65 -0.37 Lung cancer; chr15:43520259 chr15:43663654~43684339:- PAAD cis rs748404 0.589 rs62020612 ENSG00000249839.1 AC011330.5 -4.88 2.64e-06 0.00171 -0.65 -0.37 Lung cancer; chr15:43525881 chr15:43663654~43684339:- PAAD cis rs911555 0.655 rs10141157 ENSG00000259775.1 RP11-45P15.4 -4.88 2.64e-06 0.00171 -0.37 -0.37 Intelligence (multi-trait analysis); chr14:103551768 chr14:103331674~103332367:- PAAD cis rs734999 0.549 rs867436 ENSG00000225931.3 RP3-395M20.7 4.88 2.65e-06 0.00171 0.35 0.37 Ulcerative colitis; chr1:2592284 chr1:2566410~2569888:+ PAAD cis rs1823913 0.637 rs13382985 ENSG00000280083.1 RP11-317J9.1 4.88 2.65e-06 0.00171 0.44 0.37 Obesity-related traits; chr2:191306335 chr2:191154118~191156070:- PAAD cis rs74233809 1 rs11191515 ENSG00000213277.3 MARCKSL1P1 4.88 2.65e-06 0.00171 0.63 0.37 Birth weight; chr10:103016770 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs75970938 ENSG00000213277.3 MARCKSL1P1 4.88 2.65e-06 0.00171 0.63 0.37 Birth weight; chr10:103033891 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs79668541 ENSG00000213277.3 MARCKSL1P1 4.88 2.65e-06 0.00171 0.63 0.37 Birth weight; chr10:103034147 chr10:103175554~103176094:+ PAAD cis rs6009824 0.545 rs5770659 ENSG00000188511.11 C22orf34 4.88 2.65e-06 0.00172 0.41 0.37 Natriuretic peptide levels; chr22:49690204 chr22:49414524~49657542:- PAAD cis rs11168351 0.926 rs10875719 ENSG00000240399.1 RP1-228P16.1 4.88 2.65e-06 0.00172 0.37 0.37 Bipolar disorder and schizophrenia; chr12:48017375 chr12:48054813~48055591:- PAAD cis rs4950322 0.634 rs7542951 ENSG00000278811.3 LINC00624 4.88 2.65e-06 0.00172 0.39 0.37 Protein quantitative trait loci; chr1:147340308 chr1:147258885~147517875:- PAAD cis rs4728142 0.625 rs4731533 ENSG00000275106.1 RP11-309L24.10 -4.88 2.66e-06 0.00172 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128962088 chr7:128952527~128953316:- PAAD cis rs4660456 0.913 rs2223486 ENSG00000237899.1 RP4-739H11.3 -4.88 2.66e-06 0.00172 -0.5 -0.37 Platelet count; chr1:40693557 chr1:40669089~40687588:- PAAD cis rs61270009 0.955 rs13172095 ENSG00000247828.6 TMEM161B-AS1 -4.88 2.66e-06 0.00172 -0.3 -0.37 Depressive symptoms; chr5:88295130 chr5:88268895~88436685:+ PAAD cis rs4835473 0.932 rs1597445 ENSG00000251600.4 RP11-673E1.1 -4.88 2.67e-06 0.00173 -0.41 -0.37 Immature fraction of reticulocytes; chr4:143768543 chr4:143912331~143982454:+ PAAD cis rs858239 0.614 rs10229956 ENSG00000226816.2 AC005082.12 -4.88 2.68e-06 0.00173 -0.39 -0.37 Cerebrospinal fluid biomarker levels; chr7:23363317 chr7:23206013~23208045:+ PAAD cis rs11673344 0.73 rs1644641 ENSG00000226686.6 LINC01535 4.88 2.68e-06 0.00173 0.49 0.37 Obesity-related traits; chr19:36971237 chr19:37251912~37265535:+ PAAD cis rs2015599 0.623 rs1006410 ENSG00000257176.2 RP11-996F15.2 4.88 2.68e-06 0.00173 0.37 0.37 Platelet count;Mean platelet volume; chr12:29282682 chr12:29280418~29317848:- PAAD cis rs42490 0.51 rs218917 ENSG00000251136.7 RP11-37B2.1 -4.88 2.68e-06 0.00173 -0.34 -0.37 Leprosy; chr8:89688902 chr8:89609409~89757727:- PAAD cis rs42490 0.51 rs7003919 ENSG00000251136.7 RP11-37B2.1 4.88 2.68e-06 0.00173 0.34 0.37 Leprosy; chr8:89688185 chr8:89609409~89757727:- PAAD cis rs6782228 0.883 rs11712115 ENSG00000242551.2 POU5F1P6 4.88 2.68e-06 0.00173 0.46 0.37 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128685426 chr3:128674735~128677005:- PAAD cis rs11123170 0.65 rs2289897 ENSG00000274877.1 RP11-65I12.1 -4.88 2.68e-06 0.00173 -0.48 -0.37 Renal function-related traits (BUN); chr2:113219877 chr2:113237595~113240825:+ PAAD cis rs7078219 0.543 rs7095491 ENSG00000257582.4 LINC01475 -4.88 2.68e-06 0.00173 -0.4 -0.37 Dental caries; chr10:99514301 chr10:99526350~99531177:- PAAD cis rs7078219 0.543 rs10786556 ENSG00000257582.4 LINC01475 -4.88 2.68e-06 0.00173 -0.4 -0.37 Dental caries; chr10:99518567 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs7077040 ENSG00000257582.4 LINC01475 -4.88 2.68e-06 0.00173 -0.4 -0.37 Dental caries; chr10:99521257 chr10:99526350~99531177:- PAAD cis rs964611 0.816 rs8029997 ENSG00000259488.2 RP11-154J22.1 -4.88 2.68e-06 0.00173 -0.4 -0.37 Metabolite levels (Pyroglutamine); chr15:48248596 chr15:48312353~48331856:- PAAD cis rs3096299 0.933 rs2930219 ENSG00000274627.1 RP11-104N10.2 4.88 2.69e-06 0.00173 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89425641 chr16:89516797~89522217:+ PAAD cis rs3096299 0.933 rs2965939 ENSG00000274627.1 RP11-104N10.2 4.88 2.69e-06 0.00173 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89426635 chr16:89516797~89522217:+ PAAD cis rs6921919 0.515 rs1558205 ENSG00000216901.1 AL022393.7 -4.88 2.69e-06 0.00174 -0.46 -0.37 Autism spectrum disorder or schizophrenia; chr6:28414485 chr6:28176188~28176674:+ PAAD cis rs6504950 0.83 rs12936860 ENSG00000275710.1 RP11-257O5.4 4.88 2.69e-06 0.00174 0.47 0.37 Breast cancer; chr17:54952865 chr17:54964474~54964679:+ PAAD cis rs7923609 0.776 rs10761785 ENSG00000232075.1 MRPL35P2 -4.88 2.69e-06 0.00174 -0.44 -0.37 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63559006 chr10:63634317~63634827:- PAAD cis rs34375054 0.526 rs4412800 ENSG00000279233.1 RP11-158L12.4 -4.88 2.69e-06 0.00174 -0.31 -0.37 Post bronchodilator FEV1/FVC ratio; chr12:125190196 chr12:125138245~125141711:+ PAAD cis rs1185460 0.565 rs538478 ENSG00000271751.1 RP11-110I1.14 4.88 2.69e-06 0.00174 0.49 0.37 Coronary artery disease; chr11:119054629 chr11:119065263~119065677:- PAAD cis rs964611 0.882 rs4775749 ENSG00000259488.2 RP11-154J22.1 4.88 2.69e-06 0.00174 0.4 0.37 Metabolite levels (Pyroglutamine); chr15:48350064 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs56308793 ENSG00000259488.2 RP11-154J22.1 -4.88 2.69e-06 0.00174 -0.4 -0.37 Metabolite levels (Pyroglutamine); chr15:48350611 chr15:48312353~48331856:- PAAD cis rs9828933 0.752 rs13434089 ENSG00000280620.1 SCAANT1 -4.88 2.7e-06 0.00174 -0.61 -0.37 Type 2 diabetes; chr3:63962890 chr3:63911518~63911772:- PAAD cis rs9549328 0.8 rs1317507 ENSG00000267868.1 RP11-120K24.3 4.88 2.7e-06 0.00174 0.41 0.37 Systolic blood pressure; chr13:112977466 chr13:112964835~112966131:- PAAD cis rs1075265 0.901 rs2048749 ENSG00000233266.1 HMGB1P31 4.88 2.7e-06 0.00174 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:54130483 chr2:54051334~54051760:+ PAAD cis rs633715 1 rs670323 ENSG00000254154.7 RP4-798P15.3 -4.88 2.7e-06 0.00174 -0.34 -0.37 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177899855 chr1:177928788~178038007:- PAAD cis rs633715 0.959 rs693232 ENSG00000254154.7 RP4-798P15.3 -4.88 2.7e-06 0.00174 -0.34 -0.37 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177912516 chr1:177928788~178038007:- PAAD cis rs858239 0.601 rs10224327 ENSG00000226816.2 AC005082.12 4.88 2.7e-06 0.00174 0.41 0.37 Cerebrospinal fluid biomarker levels; chr7:23122201 chr7:23206013~23208045:+ PAAD cis rs748404 0.631 rs8042688 ENSG00000249839.1 AC011330.5 -4.88 2.7e-06 0.00174 -0.52 -0.37 Lung cancer; chr15:43346327 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs4296223 ENSG00000249839.1 AC011330.5 -4.88 2.7e-06 0.00174 -0.52 -0.37 Lung cancer; chr15:43353048 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs11070399 ENSG00000249839.1 AC011330.5 -4.88 2.7e-06 0.00174 -0.52 -0.37 Lung cancer; chr15:43354149 chr15:43663654~43684339:- PAAD cis rs748404 0.631 rs6493086 ENSG00000249839.1 AC011330.5 -4.88 2.7e-06 0.00174 -0.52 -0.37 Lung cancer; chr15:43363196 chr15:43663654~43684339:- PAAD cis rs1185460 0.967 rs1184902 ENSG00000271751.1 RP11-110I1.14 -4.88 2.7e-06 0.00175 -0.47 -0.37 Coronary artery disease; chr11:119074627 chr11:119065263~119065677:- PAAD cis rs1823913 0.637 rs2067610 ENSG00000280083.1 RP11-317J9.1 -4.88 2.71e-06 0.00175 -0.45 -0.37 Obesity-related traits; chr2:191299251 chr2:191154118~191156070:- PAAD cis rs2337406 0.85 rs11161008 ENSG00000274576.2 IGHV2-70 -4.87 2.72e-06 0.00175 -0.5 -0.37 Alzheimer's disease (late onset); chr14:106705261 chr14:106770577~106771020:- PAAD cis rs10510102 0.935 rs12245528 ENSG00000276742.1 RP11-500G22.4 -4.87 2.73e-06 0.00176 -0.54 -0.37 Breast cancer; chr10:121881006 chr10:121956782~121957098:+ PAAD cis rs6991838 0.584 rs2175810 ENSG00000200714.1 Y_RNA -4.87 2.73e-06 0.00176 -0.43 -0.37 Intelligence (multi-trait analysis); chr8:65643583 chr8:65592731~65592820:+ PAAD cis rs9987353 0.566 rs34491841 ENSG00000253893.2 FAM85B 4.87 2.73e-06 0.00176 0.51 0.37 Recombination measurement; chr8:9208000 chr8:8167819~8226614:- PAAD cis rs35160687 0.722 rs6728029 ENSG00000273080.1 RP11-301O19.1 -4.87 2.73e-06 0.00176 -0.42 -0.37 Night sleep phenotypes; chr2:86328258 chr2:86195590~86196049:+ PAAD cis rs6921919 0.638 rs7772827 ENSG00000204709.4 LINC01556 4.87 2.73e-06 0.00176 0.54 0.37 Autism spectrum disorder or schizophrenia; chr6:28333366 chr6:28943877~28944537:+ PAAD cis rs875971 0.597 rs11763224 ENSG00000226824.5 RP4-756H11.3 -4.87 2.74e-06 0.00176 -0.51 -0.37 Aortic root size; chr7:66518628 chr7:66654538~66669855:+ PAAD cis rs748404 0.631 rs7163288 ENSG00000249839.1 AC011330.5 -4.87 2.74e-06 0.00176 -0.53 -0.37 Lung cancer; chr15:43379157 chr15:43663654~43684339:- PAAD cis rs66887589 0.934 rs12648182 ENSG00000248280.1 RP11-33B1.2 -4.87 2.74e-06 0.00177 -0.33 -0.37 Diastolic blood pressure; chr4:119582736 chr4:119440561~119450157:- PAAD cis rs4853525 0.59 rs12619017 ENSG00000235852.1 AC005540.3 4.87 2.74e-06 0.00177 0.55 0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190865167 chr2:190880797~190882059:- PAAD cis rs4853525 0.59 rs12619138 ENSG00000235852.1 AC005540.3 4.87 2.74e-06 0.00177 0.55 0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190865474 chr2:190880797~190882059:- PAAD cis rs2564921 0.73 rs2253675 ENSG00000242142.1 SERBP1P3 -4.87 2.74e-06 0.00177 -0.46 -0.37 Height; chr3:53085518 chr3:53064283~53065091:- PAAD cis rs9326248 1 rs7107152 ENSG00000280143.1 AP000892.6 -4.87 2.74e-06 0.00177 -0.45 -0.37 Blood protein levels; chr11:117185364 chr11:117204967~117210292:+ PAAD cis rs453301 0.686 rs4840389 ENSG00000253893.2 FAM85B 4.87 2.75e-06 0.00177 0.5 0.37 Joint mobility (Beighton score); chr8:9026993 chr8:8167819~8226614:- PAAD cis rs453301 0.658 rs13271797 ENSG00000253893.2 FAM85B 4.87 2.75e-06 0.00177 0.5 0.37 Joint mobility (Beighton score); chr8:9028444 chr8:8167819~8226614:- PAAD cis rs10510102 0.935 rs11200201 ENSG00000276742.1 RP11-500G22.4 4.87 2.75e-06 0.00177 0.55 0.37 Breast cancer; chr10:121864790 chr10:121956782~121957098:+ PAAD cis rs11118620 1 rs11118620 ENSG00000257551.1 HLX-AS1 4.87 2.75e-06 0.00177 0.41 0.37 Heart failure; chr1:220855166 chr1:220832763~220880140:- PAAD cis rs11118620 0.81 rs4587570 ENSG00000257551.1 HLX-AS1 4.87 2.75e-06 0.00177 0.41 0.37 Heart failure; chr1:220860693 chr1:220832763~220880140:- PAAD cis rs2412819 0.571 rs2930529 ENSG00000205771.5 CATSPER2P1 4.87 2.75e-06 0.00177 0.53 0.37 Lung cancer; chr15:43819467 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs2930530 ENSG00000205771.5 CATSPER2P1 4.87 2.75e-06 0.00177 0.53 0.37 Lung cancer; chr15:43823268 chr15:43726918~43747094:- PAAD cis rs27432 0.608 rs2927619 ENSG00000248734.2 CTD-2260A17.1 4.87 2.76e-06 0.00178 0.34 0.37 Psoriasis vulgaris; chr5:96847014 chr5:96784777~96785999:+ PAAD cis rs1075265 0.933 rs2287642 ENSG00000233266.1 HMGB1P31 4.87 2.76e-06 0.00178 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:54108447 chr2:54051334~54051760:+ PAAD cis rs12554020 0.892 rs6479483 ENSG00000227603.1 RP11-165J3.6 4.87 2.76e-06 0.00178 0.57 0.37 Schizophrenia; chr9:93441746 chr9:93435332~93437121:- PAAD cis rs7580658 0.864 rs3088374 ENSG00000236682.1 AC068282.3 -4.87 2.77e-06 0.00178 -0.47 -0.37 Protein C levels; chr2:127304472 chr2:127389130~127400580:+ PAAD cis rs79040073 0.53 rs73396206 ENSG00000259531.2 RP11-295H24.3 4.87 2.77e-06 0.00178 0.54 0.37 Lung cancer in ever smokers; chr15:49323632 chr15:49365124~49366685:- PAAD cis rs7615952 0.546 rs2979306 ENSG00000171084.14 FAM86JP 4.87 2.77e-06 0.00178 0.54 0.37 Blood pressure (smoking interaction); chr3:125593286 chr3:125916620~125930024:+ PAAD cis rs7829975 0.51 rs332037 ENSG00000253893.2 FAM85B -4.87 2.78e-06 0.00179 -0.49 -0.37 Mood instability; chr8:8865165 chr8:8167819~8226614:- PAAD cis rs74233809 0.901 rs11191425 ENSG00000213277.3 MARCKSL1P1 4.87 2.78e-06 0.00179 0.63 0.37 Birth weight; chr10:102866213 chr10:103175554~103176094:+ PAAD cis rs875971 0.545 rs73378304 ENSG00000226824.5 RP4-756H11.3 -4.87 2.8e-06 0.0018 -0.5 -0.37 Aortic root size; chr7:66175760 chr7:66654538~66669855:+ PAAD cis rs2337406 0.866 rs4583128 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106780669 chr14:106723574~106724093:- PAAD cis rs2337406 0.929 rs12050200 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106780983 chr14:106723574~106724093:- PAAD cis rs2337406 0.852 rs12050239 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781132 chr14:106723574~106724093:- PAAD cis rs2337406 0.929 rs59263250 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781183 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs58083017 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781256 chr14:106723574~106724093:- PAAD cis rs2337406 0.789 rs60390024 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781327 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74092532 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781363 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74092534 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781364 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74092535 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781722 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74092537 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781883 chr14:106723574~106724093:- PAAD cis rs2337406 0.81 rs74092538 ENSG00000211974.3 IGHV2-70 -4.87 2.8e-06 0.0018 -0.48 -0.37 Alzheimer's disease (late onset); chr14:106781942 chr14:106723574~106724093:- PAAD cis rs62229266 0.804 rs62230788 ENSG00000231106.2 LINC01436 4.87 2.8e-06 0.0018 0.54 0.37 Mitral valve prolapse; chr21:36008039 chr21:36005338~36007838:+ PAAD cis rs7829975 0.522 rs6601689 ENSG00000173295.6 FAM86B3P 4.87 2.8e-06 0.0018 0.38 0.37 Mood instability; chr8:8314761 chr8:8228595~8244865:+ PAAD cis rs9322193 0.884 rs10872648 ENSG00000216906.2 RP11-350J20.9 4.87 2.8e-06 0.0018 0.51 0.37 Lung cancer; chr6:149758699 chr6:149904243~149906418:+ PAAD cis rs10754283 0.967 rs10922679 ENSG00000231613.1 RP5-943J3.1 4.87 2.81e-06 0.0018 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89635366 chr1:89788914~89790492:+ PAAD cis rs10754283 0.935 rs10801756 ENSG00000231613.1 RP5-943J3.1 4.87 2.81e-06 0.0018 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89636273 chr1:89788914~89790492:+ PAAD cis rs10754283 0.934 rs6684676 ENSG00000231613.1 RP5-943J3.1 4.87 2.81e-06 0.0018 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89636614 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs6428561 ENSG00000231613.1 RP5-943J3.1 4.87 2.81e-06 0.0018 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89637060 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs6428562 ENSG00000231613.1 RP5-943J3.1 4.87 2.81e-06 0.0018 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89637106 chr1:89788914~89790492:+ PAAD cis rs853679 1 rs853676 ENSG00000204709.4 LINC01556 4.87 2.81e-06 0.0018 0.66 0.37 Depression; chr6:28331910 chr6:28943877~28944537:+ PAAD cis rs10050311 0.79 rs17012132 ENSG00000251411.1 RP11-397E7.4 -4.87 2.81e-06 0.00181 -0.46 -0.37 Insulin-related traits; chr4:86860135 chr4:86913266~86914817:- PAAD cis rs4664293 0.867 rs10194483 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159739883 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs2357531 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159740907 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs16844269 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159742569 chr2:159670708~159712435:- PAAD cis rs4664293 0.836 rs4664300 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159743927 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs16822556 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159744392 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs16822558 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159744496 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs1834761 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159745278 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs6432558 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159745397 chr2:159670708~159712435:- PAAD cis rs4664293 0.836 rs7567818 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159746186 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs12692563 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159746300 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs12620924 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159746452 chr2:159670708~159712435:- PAAD cis rs4664293 0.836 rs13397597 ENSG00000226266.5 AC009961.3 -4.87 2.81e-06 0.00181 -0.45 -0.37 Monocyte percentage of white cells; chr2:159747084 chr2:159670708~159712435:- PAAD cis rs66887589 0.967 rs59516282 ENSG00000248280.1 RP11-33B1.2 -4.87 2.82e-06 0.00181 -0.33 -0.37 Diastolic blood pressure; chr4:119580861 chr4:119440561~119450157:- PAAD cis rs4728142 0.525 rs4731534 ENSG00000275106.1 RP11-309L24.10 -4.87 2.82e-06 0.00181 -0.5 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128965540 chr7:128952527~128953316:- PAAD cis rs1275468 1 rs1275468 ENSG00000257497.2 RP11-585P4.5 -4.87 2.82e-06 0.00181 -0.54 -0.37 Polycystic ovary syndrome; chr12:75541377 chr12:75483454~75489820:- PAAD cis rs4835473 0.897 rs7681914 ENSG00000251600.4 RP11-673E1.1 4.87 2.82e-06 0.00181 0.41 0.37 Immature fraction of reticulocytes; chr4:143708838 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs7682096 ENSG00000251600.4 RP11-673E1.1 4.87 2.82e-06 0.00181 0.41 0.37 Immature fraction of reticulocytes; chr4:143708892 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs7682128 ENSG00000251600.4 RP11-673E1.1 4.87 2.82e-06 0.00181 0.41 0.37 Immature fraction of reticulocytes; chr4:143708950 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs7687317 ENSG00000251600.4 RP11-673E1.1 4.87 2.82e-06 0.00181 0.41 0.37 Immature fraction of reticulocytes; chr4:143709010 chr4:143912331~143982454:+ PAAD cis rs4713118 0.621 rs9295755 ENSG00000226314.6 ZNF192P1 4.87 2.82e-06 0.00181 0.62 0.37 Parkinson's disease; chr6:28065396 chr6:28161781~28169594:+ PAAD cis rs4713118 0.621 rs10484403 ENSG00000226314.6 ZNF192P1 -4.87 2.82e-06 0.00181 -0.62 -0.37 Parkinson's disease; chr6:28065745 chr6:28161781~28169594:+ PAAD cis rs4713118 0.621 rs4713132 ENSG00000226314.6 ZNF192P1 -4.87 2.82e-06 0.00181 -0.62 -0.37 Parkinson's disease; chr6:28066257 chr6:28161781~28169594:+ PAAD cis rs4713118 0.621 rs4713133 ENSG00000226314.6 ZNF192P1 -4.87 2.82e-06 0.00181 -0.62 -0.37 Parkinson's disease; chr6:28066263 chr6:28161781~28169594:+ PAAD cis rs4713118 0.621 rs4713134 ENSG00000226314.6 ZNF192P1 -4.87 2.82e-06 0.00181 -0.62 -0.37 Parkinson's disease; chr6:28066343 chr6:28161781~28169594:+ PAAD cis rs73173548 0.502 rs4144466 ENSG00000247828.6 TMEM161B-AS1 4.87 2.82e-06 0.00181 0.3 0.37 Macular telangiectasia type 2; chr5:88412379 chr5:88268895~88436685:+ PAAD cis rs1823913 0.599 rs12988037 ENSG00000280083.1 RP11-317J9.1 -4.87 2.82e-06 0.00181 -0.44 -0.37 Obesity-related traits; chr2:191306419 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs13015653 ENSG00000280083.1 RP11-317J9.1 -4.87 2.82e-06 0.00181 -0.44 -0.37 Obesity-related traits; chr2:191306813 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs12994212 ENSG00000280083.1 RP11-317J9.1 -4.87 2.82e-06 0.00181 -0.44 -0.37 Obesity-related traits; chr2:191306910 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs12994236 ENSG00000280083.1 RP11-317J9.1 -4.87 2.82e-06 0.00181 -0.44 -0.37 Obesity-related traits; chr2:191306991 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs35495506 ENSG00000280083.1 RP11-317J9.1 -4.87 2.82e-06 0.00181 -0.44 -0.37 Obesity-related traits; chr2:191307551 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs34691559 ENSG00000280083.1 RP11-317J9.1 -4.87 2.82e-06 0.00181 -0.44 -0.37 Obesity-related traits; chr2:191307688 chr2:191154118~191156070:- PAAD cis rs1823913 0.561 rs55790432 ENSG00000280083.1 RP11-317J9.1 -4.87 2.82e-06 0.00181 -0.44 -0.37 Obesity-related traits; chr2:191307722 chr2:191154118~191156070:- PAAD cis rs4660214 0.724 rs3931300 ENSG00000237624.1 OXCT2P1 -4.87 2.83e-06 0.00181 -0.49 -0.37 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39195175 chr1:39514956~39516490:+ PAAD cis rs6504950 0.705 rs9899545 ENSG00000275710.1 RP11-257O5.4 4.87 2.83e-06 0.00181 0.48 0.37 Breast cancer; chr17:54909484 chr17:54964474~54964679:+ PAAD cis rs964611 0.882 rs6493315 ENSG00000259488.2 RP11-154J22.1 -4.87 2.83e-06 0.00182 -0.4 -0.37 Metabolite levels (Pyroglutamine); chr15:48274817 chr15:48312353~48331856:- PAAD cis rs6496932 0.563 rs2344083 ENSG00000259295.5 CSPG4P12 4.86 2.83e-06 0.00182 0.43 0.37 Central corneal thickness;Corneal structure; chr15:85354201 chr15:85191438~85213905:+ PAAD cis rs12817211 0.502 rs12369049 ENSG00000272368.2 RP4-605O3.4 -4.86 2.84e-06 0.00182 -0.36 -0.37 Colorectal or endometrial cancer; chr12:50116679 chr12:50112197~50165618:+ PAAD cis rs7580658 0.75 rs4497825 ENSG00000236682.1 AC068282.3 -4.86 2.84e-06 0.00182 -0.46 -0.37 Protein C levels; chr2:127303477 chr2:127389130~127400580:+ PAAD cis rs9322193 0.607 rs4869755 ENSG00000223701.3 RAET1E-AS1 4.86 2.84e-06 0.00182 0.48 0.37 Lung cancer; chr6:149886347 chr6:149884431~149919508:+ PAAD cis rs9322193 0.639 rs4869756 ENSG00000223701.3 RAET1E-AS1 4.86 2.84e-06 0.00182 0.48 0.37 Lung cancer; chr6:149886360 chr6:149884431~149919508:+ PAAD cis rs801193 0.591 rs9986881 ENSG00000236529.1 RP13-254B10.1 4.86 2.85e-06 0.00182 0.41 0.37 Aortic root size; chr7:66708053 chr7:65840212~65840596:+ PAAD cis rs1707322 0.686 rs2991977 ENSG00000280836.1 AL355480.1 4.86 2.85e-06 0.00183 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45588011 chr1:45581219~45581321:- PAAD cis rs1707322 0.656 rs2991981 ENSG00000280836.1 AL355480.1 4.86 2.85e-06 0.00183 0.44 0.37 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45591472 chr1:45581219~45581321:- PAAD cis rs2946504 0.607 rs2977080 ENSG00000251468.2 RP11-369K16.1 -4.86 2.86e-06 0.00183 -0.44 -0.37 Type 2 diabetes; chr8:12959492 chr8:12958387~12962200:+ PAAD cis rs2946504 0.553 rs2977079 ENSG00000251468.2 RP11-369K16.1 -4.86 2.86e-06 0.00183 -0.44 -0.37 Type 2 diabetes; chr8:12959500 chr8:12958387~12962200:+ PAAD cis rs8100891 0.537 rs113427979 ENSG00000267213.4 AC007773.2 -4.86 2.86e-06 0.00183 -0.59 -0.37 Neuroticism; chr19:32364502 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs4805758 ENSG00000267213.4 AC007773.2 -4.86 2.86e-06 0.00183 -0.59 -0.37 Neuroticism; chr19:32375518 chr19:32390050~32405560:- PAAD cis rs13217239 0.574 rs9366680 ENSG00000241549.7 GUSBP2 4.86 2.86e-06 0.00183 0.38 0.37 Schizophrenia; chr6:27038344 chr6:26871484~26956554:- PAAD cis rs7829975 0.714 rs4840362 ENSG00000253893.2 FAM85B 4.86 2.86e-06 0.00183 0.51 0.37 Mood instability; chr8:8812572 chr8:8167819~8226614:- PAAD cis rs7188445 0.736 rs7500666 ENSG00000261390.4 RP11-345M22.2 4.86 2.87e-06 0.00184 0.48 0.37 Urate levels; chr16:79672509 chr16:79715232~79770563:- PAAD cis rs13178541 0.81 rs6891354 ENSG00000250378.1 RP11-119J18.1 -4.86 2.87e-06 0.00184 -0.58 -0.37 IgG glycosylation; chr5:135798986 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs4976389 ENSG00000250378.1 RP11-119J18.1 -4.86 2.87e-06 0.00184 -0.58 -0.37 IgG glycosylation; chr5:135799469 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs10076529 ENSG00000250378.1 RP11-119J18.1 -4.86 2.87e-06 0.00184 -0.58 -0.37 IgG glycosylation; chr5:135800916 chr5:135812667~135826582:+ PAAD cis rs13178541 0.639 rs6596264 ENSG00000250378.1 RP11-119J18.1 -4.86 2.87e-06 0.00184 -0.58 -0.37 IgG glycosylation; chr5:135801128 chr5:135812667~135826582:+ PAAD cis rs964611 0.938 rs1820494 ENSG00000259488.2 RP11-154J22.1 4.86 2.88e-06 0.00184 0.41 0.37 Metabolite levels (Pyroglutamine); chr15:48310977 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs1820491 ENSG00000259488.2 RP11-154J22.1 4.86 2.88e-06 0.00184 0.41 0.37 Metabolite levels (Pyroglutamine); chr15:48311245 chr15:48312353~48331856:- PAAD cis rs1075232 0.655 rs28451043 ENSG00000215302.7 CTD-3092A11.1 -4.86 2.88e-06 0.00184 -0.92 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31295359 chr15:30470779~30507623:+ PAAD cis rs1075232 0.655 rs77987193 ENSG00000215302.7 CTD-3092A11.1 -4.86 2.88e-06 0.00184 -0.92 -0.37 Survival in colorectal cancer (non-distant metastatic); chr15:31296055 chr15:30470779~30507623:+ PAAD cis rs17711722 0.522 rs6957759 ENSG00000237310.1 GS1-124K5.4 4.86 2.89e-06 0.00185 0.36 0.37 Calcium levels; chr7:65806798 chr7:66493706~66495474:+ PAAD cis rs55665837 0.701 rs11023278 ENSG00000251991.1 RNU7-49P 4.86 2.89e-06 0.00185 0.43 0.37 Vitamin D levels; chr11:14619638 chr11:14478892~14478953:+ PAAD cis rs6921919 0.583 rs11755942 ENSG00000204709.4 LINC01556 4.86 2.89e-06 0.00185 0.52 0.37 Autism spectrum disorder or schizophrenia; chr6:28401760 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs6908137 ENSG00000204709.4 LINC01556 4.86 2.89e-06 0.00185 0.52 0.37 Autism spectrum disorder or schizophrenia; chr6:28402616 chr6:28943877~28944537:+ PAAD cis rs4723738 1 rs6975531 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38179748 chr7:38239580~38368091:- PAAD cis rs4723738 0.935 rs10233340 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38183679 chr7:38239580~38368091:- PAAD cis rs4723738 1 rs35997004 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38186081 chr7:38239580~38368091:- PAAD cis rs4723738 1 rs7788819 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38187056 chr7:38239580~38368091:- PAAD cis rs4723738 1 rs11766312 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38187990 chr7:38239580~38368091:- PAAD cis rs4723738 1 rs17171307 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38188976 chr7:38239580~38368091:- PAAD cis rs4723738 1 rs2159499 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38189300 chr7:38239580~38368091:- PAAD cis rs4723738 1 rs10951552 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38190180 chr7:38239580~38368091:- PAAD cis rs4723738 1 rs4723733 ENSG00000227191.5 TRGC2 4.86 2.89e-06 0.00185 0.32 0.37 Treatment response for severe sepsis; chr7:38184011 chr7:38239580~38368091:- PAAD cis rs6921919 0.583 rs11755942 ENSG00000216901.1 AL022393.7 4.86 2.89e-06 0.00185 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28401760 chr6:28176188~28176674:+ PAAD cis rs6921919 0.583 rs6908137 ENSG00000216901.1 AL022393.7 4.86 2.89e-06 0.00185 0.48 0.37 Autism spectrum disorder or schizophrenia; chr6:28402616 chr6:28176188~28176674:+ PAAD cis rs964611 0.882 rs59324936 ENSG00000259488.2 RP11-154J22.1 -4.86 2.89e-06 0.00185 -0.41 -0.37 Metabolite levels (Pyroglutamine); chr15:48354061 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs73406442 ENSG00000259488.2 RP11-154J22.1 -4.86 2.89e-06 0.00185 -0.41 -0.37 Metabolite levels (Pyroglutamine); chr15:48354146 chr15:48312353~48331856:- PAAD cis rs4723738 1 rs1019180 ENSG00000227191.5 TRGC2 -4.86 2.89e-06 0.00185 -0.32 -0.37 Treatment response for severe sepsis; chr7:38179410 chr7:38239580~38368091:- PAAD cis rs1928295 1 rs9408902 ENSG00000233569.1 RP11-500B12.1 4.86 2.89e-06 0.00185 0.42 0.37 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117616686 chr9:117648606~117657027:+ PAAD cis rs4268898 0.722 rs12185638 ENSG00000242628.4 AC009228.1 -4.86 2.89e-06 0.00185 -0.41 -0.37 Asthma; chr2:24159160 chr2:24214381~24221516:+ PAAD cis rs4268898 0.722 rs4665253 ENSG00000242628.4 AC009228.1 -4.86 2.89e-06 0.00185 -0.41 -0.37 Asthma; chr2:24159676 chr2:24214381~24221516:+ PAAD cis rs858239 0.6 rs59073109 ENSG00000226816.2 AC005082.12 4.86 2.9e-06 0.00185 0.41 0.37 Cerebrospinal fluid biomarker levels; chr7:23093607 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs7788821 ENSG00000226816.2 AC005082.12 4.86 2.9e-06 0.00185 0.41 0.37 Cerebrospinal fluid biomarker levels; chr7:23094026 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6956595 ENSG00000226816.2 AC005082.12 4.86 2.9e-06 0.00185 0.41 0.37 Cerebrospinal fluid biomarker levels; chr7:23094637 chr7:23206013~23208045:+ PAAD cis rs4950322 0.543 rs4950318 ENSG00000278811.3 LINC00624 4.86 2.9e-06 0.00186 0.38 0.37 Protein quantitative trait loci; chr1:147316240 chr1:147258885~147517875:- PAAD cis rs4950322 0.543 rs4950319 ENSG00000278811.3 LINC00624 4.86 2.9e-06 0.00186 0.38 0.37 Protein quantitative trait loci; chr1:147316250 chr1:147258885~147517875:- PAAD cis rs4950322 0.543 rs4453096 ENSG00000278811.3 LINC00624 4.86 2.9e-06 0.00186 0.38 0.37 Protein quantitative trait loci; chr1:147316574 chr1:147258885~147517875:- PAAD cis rs4950322 0.571 rs4373796 ENSG00000278811.3 LINC00624 4.86 2.9e-06 0.00186 0.38 0.37 Protein quantitative trait loci; chr1:147316747 chr1:147258885~147517875:- PAAD cis rs4950322 0.543 rs4568882 ENSG00000278811.3 LINC00624 4.86 2.9e-06 0.00186 0.38 0.37 Protein quantitative trait loci; chr1:147316885 chr1:147258885~147517875:- PAAD cis rs4950322 0.543 rs2883323 ENSG00000278811.3 LINC00624 4.86 2.9e-06 0.00186 0.38 0.37 Protein quantitative trait loci; chr1:147316995 chr1:147258885~147517875:- PAAD cis rs4950322 0.543 rs2883324 ENSG00000278811.3 LINC00624 4.86 2.9e-06 0.00186 0.38 0.37 Protein quantitative trait loci; chr1:147317157 chr1:147258885~147517875:- PAAD cis rs2274273 1 rs2274273 ENSG00000258413.1 RP11-665C16.6 4.86 2.9e-06 0.00186 0.48 0.37 Protein biomarker; chr14:55147918 chr14:55262767~55272075:- PAAD cis rs11118620 0.853 rs12037861 ENSG00000257551.1 HLX-AS1 4.86 2.9e-06 0.00186 0.41 0.37 Heart failure; chr1:220864835 chr1:220832763~220880140:- PAAD cis rs8062405 0.54 rs480400 ENSG00000259982.1 CDC37P1 4.86 2.91e-06 0.00186 0.38 0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28563294 chr16:28700294~28701540:- PAAD cis rs1075265 0.933 rs7562055 ENSG00000233266.1 HMGB1P31 4.86 2.91e-06 0.00186 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:54112694 chr2:54051334~54051760:+ PAAD cis rs11089937 0.626 rs5757017 ENSG00000211639.2 IGLV4-60 4.86 2.91e-06 0.00186 0.38 0.37 Periodontitis (PAL4Q3); chr22:22135947 chr22:22162199~22162681:+ PAAD cis rs11089937 0.568 rs59356111 ENSG00000211639.2 IGLV4-60 4.86 2.91e-06 0.00186 0.38 0.37 Periodontitis (PAL4Q3); chr22:22136175 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs5757019 ENSG00000211639.2 IGLV4-60 4.86 2.91e-06 0.00186 0.38 0.37 Periodontitis (PAL4Q3); chr22:22136286 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs5750579 ENSG00000211639.2 IGLV4-60 4.86 2.91e-06 0.00186 0.38 0.37 Periodontitis (PAL4Q3); chr22:22136581 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs5750582 ENSG00000211639.2 IGLV4-60 4.86 2.91e-06 0.00186 0.38 0.37 Periodontitis (PAL4Q3); chr22:22137690 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs5757028 ENSG00000211639.2 IGLV4-60 4.86 2.91e-06 0.00186 0.38 0.37 Periodontitis (PAL4Q3); chr22:22137699 chr22:22162199~22162681:+ PAAD cis rs964611 0.816 rs2279365 ENSG00000259488.2 RP11-154J22.1 4.86 2.91e-06 0.00186 0.41 0.37 Metabolite levels (Pyroglutamine); chr15:48249503 chr15:48312353~48331856:- PAAD cis rs1823913 0.576 rs13011608 ENSG00000280083.1 RP11-317J9.1 -4.86 2.91e-06 0.00186 -0.43 -0.37 Obesity-related traits; chr2:191267097 chr2:191154118~191156070:- PAAD cis rs8062405 1 rs8061590 ENSG00000251417.2 RP11-1348G14.4 -4.86 2.91e-06 0.00186 -0.32 -0.37 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28883809 chr16:28802743~28817828:+ PAAD cis rs12817211 0.502 rs7961065 ENSG00000272368.2 RP4-605O3.4 -4.86 2.92e-06 0.00186 -0.35 -0.37 Colorectal or endometrial cancer; chr12:50119904 chr12:50112197~50165618:+ PAAD cis rs1075265 0.933 rs7607066 ENSG00000233266.1 HMGB1P31 4.86 2.93e-06 0.00187 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:54110054 chr2:54051334~54051760:+ PAAD cis rs1075265 0.933 rs929734 ENSG00000233266.1 HMGB1P31 4.86 2.93e-06 0.00187 0.48 0.37 Chronotype;Morning vs. evening chronotype; chr2:54111158 chr2:54051334~54051760:+ PAAD cis rs4835473 0.932 rs1839449 ENSG00000251600.4 RP11-673E1.1 4.86 2.93e-06 0.00187 0.42 0.37 Immature fraction of reticulocytes; chr4:143730222 chr4:143912331~143982454:+ PAAD cis rs1075265 0.605 rs805418 ENSG00000233266.1 HMGB1P31 4.86 2.93e-06 0.00187 0.47 0.37 Chronotype;Morning vs. evening chronotype; chr2:53898634 chr2:54051334~54051760:+ PAAD cis rs858239 0.6 rs6967475 ENSG00000226816.2 AC005082.12 4.86 2.93e-06 0.00187 0.41 0.37 Cerebrospinal fluid biomarker levels; chr7:23089363 chr7:23206013~23208045:+ PAAD cis rs7772486 0.902 rs1331643 ENSG00000235652.6 RP11-545I5.3 4.86 2.93e-06 0.00187 0.3 0.37 Lobe attachment (rater-scored or self-reported); chr6:146077737 chr6:145799409~145886585:+ PAAD cis rs9322193 0.566 rs12528243 ENSG00000223701.3 RAET1E-AS1 4.86 2.94e-06 0.00187 0.48 0.37 Lung cancer; chr6:149898491 chr6:149884431~149919508:+ PAAD cis rs7646881 1 rs73015649 ENSG00000240207.5 RP11-379F4.4 -4.86 2.94e-06 0.00187 -0.54 -0.37 Tetralogy of Fallot; chr3:158732509 chr3:158732263~158784070:+ PAAD cis rs7646881 1 rs73015654 ENSG00000240207.5 RP11-379F4.4 -4.86 2.94e-06 0.00187 -0.54 -0.37 Tetralogy of Fallot; chr3:158733865 chr3:158732263~158784070:+ PAAD cis rs7646881 0.953 rs73015657 ENSG00000240207.5 RP11-379F4.4 -4.86 2.94e-06 0.00187 -0.54 -0.37 Tetralogy of Fallot; chr3:158734143 chr3:158732263~158784070:+ PAAD cis rs7646881 1 rs59313096 ENSG00000240207.5 RP11-379F4.4 -4.86 2.94e-06 0.00187 -0.54 -0.37 Tetralogy of Fallot; chr3:158734453 chr3:158732263~158784070:+ PAAD cis rs7646881 1 rs59217052 ENSG00000240207.5 RP11-379F4.4 -4.86 2.94e-06 0.00187 -0.54 -0.37 Tetralogy of Fallot; chr3:158734667 chr3:158732263~158784070:+ PAAD cis rs7646881 1 rs7646881 ENSG00000240207.5 RP11-379F4.4 -4.86 2.94e-06 0.00187 -0.54 -0.37 Tetralogy of Fallot; chr3:158735490 chr3:158732263~158784070:+ PAAD cis rs4853525 0.62 rs1914408 ENSG00000235852.1 AC005540.3 -4.86 2.94e-06 0.00188 -0.53 -0.37 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190975250 chr2:190880797~190882059:- PAAD cis rs8177376 1 rs534804 ENSG00000254905.1 RP11-712L6.7 4.86 2.94e-06 0.00188 0.48 0.37 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126205873 chr11:126292922~126294254:- PAAD cis rs2283792 0.871 rs8136867 ENSG00000228050.1 TOP3BP1 4.86 2.95e-06 0.00188 0.39 0.37 Multiple sclerosis; chr22:21850504 chr22:22223187~22224566:- PAAD cis rs6844153 0.752 rs6815719 ENSG00000240005.4 RP11-293A21.1 -4.86 2.95e-06 0.00188 -0.53 -0.37 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26880232 chr4:26859806~26860599:- PAAD cis rs227275 0.526 rs223497 ENSG00000246560.2 RP11-10L12.4 4.86 2.95e-06 0.00188 0.41 0.37 Allergic disease (asthma, hay fever or eczema); chr4:102732819 chr4:102828055~102844075:+ PAAD cis rs9288520 1 rs9288520 ENSG00000230838.1 AC093850.2 -4.86 2.95e-06 0.00188 -0.43 -0.37 Esophageal cancer (alcohol interaction); chr2:216616548 chr2:215718043~215719424:+ PAAD cis rs879620 1 rs879620 ENSG00000262888.1 RP11-462G12.2 4.86 2.95e-06 0.00188 0.48 0.37 Hip circumference;Body mass index; chr16:3965728 chr16:3931217~3946305:- PAAD cis rs2015599 0.54 rs12301475 ENSG00000257176.2 RP11-996F15.2 4.86 2.95e-06 0.00188 0.37 0.37 Platelet count;Mean platelet volume; chr12:29253144 chr12:29280418~29317848:- PAAD cis rs911555 0.706 rs10129426 ENSG00000259775.1 RP11-45P15.4 -4.86 2.95e-06 0.00188 -0.37 -0.37 Intelligence (multi-trait analysis); chr14:103552118 chr14:103331674~103332367:- PAAD cis rs1075265 0.756 rs6751105 ENSG00000233266.1 HMGB1P31 4.86 2.95e-06 0.00188 0.47 0.37 Chronotype;Morning vs. evening chronotype; chr2:54129214 chr2:54051334~54051760:+ PAAD cis rs4713118 0.586 rs9468290 ENSG00000226314.6 ZNF192P1 -4.86 2.96e-06 0.00189 -0.62 -0.37 Parkinson's disease; chr6:28119896 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393894 ENSG00000226314.6 ZNF192P1 -4.86 2.96e-06 0.00189 -0.62 -0.37 Depression; chr6:28144784 chr6:28161781~28169594:+ PAAD cis rs3813579 0.568 rs4506909 ENSG00000261390.4 RP11-345M22.2 -4.85 2.97e-06 0.00189 -0.49 -0.37 Thyroid volume; chr16:79719622 chr16:79715232~79770563:- PAAD cis rs732716 0.785 rs11667543 ENSG00000267980.1 AC007292.6 -4.85 2.97e-06 0.00189 -0.5 -0.37 Mean corpuscular volume; chr19:4374853 chr19:4363789~4364640:+ PAAD cis rs7580658 0.724 rs12623948 ENSG00000236682.1 AC068282.3 -4.85 2.97e-06 0.00189 -0.46 -0.37 Protein C levels; chr2:127243766 chr2:127389130~127400580:+ PAAD cis rs5760092 0.572 rs738806 ENSG00000250470.1 AP000351.3 4.85 2.97e-06 0.00189 0.55 0.37 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23976904~23977585:- PAAD cis rs6504622 0.967 rs9889762 ENSG00000262879.4 RP11-156P1.3 4.85 2.97e-06 0.00189 0.37 0.37 Orofacial clefts; chr17:46949000 chr17:46984045~47100323:- PAAD cis rs11089937 0.864 rs4820338 ENSG00000211639.2 IGLV4-60 4.85 2.97e-06 0.00189 0.35 0.37 Periodontitis (PAL4Q3); chr22:22166665 chr22:22162199~22162681:+ PAAD cis rs11673344 0.808 rs57916401 ENSG00000226686.6 LINC01535 4.85 2.98e-06 0.0019 0.49 0.37 Obesity-related traits; chr19:37153149 chr19:37251912~37265535:+ PAAD cis rs4268898 1 rs4268898 ENSG00000242628.4 AC009228.1 -4.85 2.98e-06 0.0019 -0.45 -0.37 Asthma; chr2:24267544 chr2:24214381~24221516:+ PAAD cis rs4664293 0.585 rs10460301 ENSG00000226266.5 AC009961.3 4.85 2.98e-06 0.0019 0.47 0.37 Monocyte percentage of white cells; chr2:159778566 chr2:159670708~159712435:- PAAD cis rs4950322 0.57 rs17356184 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147262943 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs80270233 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147263320 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4950392 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147264889 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs17356219 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147265684 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691041 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147267084 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs17356233 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147268843 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs17356240 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147269877 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs1999820 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147270329 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs3737855 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147271257 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4950316 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147273712 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs2354428 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147277512 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691054 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147277942 chr1:147258885~147517875:- PAAD cis rs4950322 0.517 rs114823926 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147281805 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs6703892 ENSG00000278811.3 LINC00624 4.85 2.98e-06 0.0019 0.38 0.37 Protein quantitative trait loci; chr1:147287627 chr1:147258885~147517875:- PAAD cis rs12908161 0.96 rs11633450 ENSG00000225151.9 GOLGA2P7 -4.85 2.99e-06 0.0019 -0.45 -0.37 Schizophrenia; chr15:84764056 chr15:84199311~84230136:- PAAD cis rs9890032 1 rs3764419 ENSG00000266490.1 CTD-2349P21.9 4.85 2.99e-06 0.00191 0.34 0.37 Hip circumference adjusted for BMI; chr17:30837005 chr17:30792372~30792833:+ PAAD cis rs4835473 0.897 rs924234 ENSG00000251600.4 RP11-673E1.1 4.85 3.01e-06 0.00191 0.41 0.37 Immature fraction of reticulocytes; chr4:143706799 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs28825455 ENSG00000251600.4 RP11-673E1.1 4.85 3.01e-06 0.00191 0.41 0.37 Immature fraction of reticulocytes; chr4:143707593 chr4:143912331~143982454:+ PAAD cis rs66887589 0.934 rs56843000 ENSG00000248280.1 RP11-33B1.2 -4.85 3.01e-06 0.00191 -0.33 -0.37 Diastolic blood pressure; chr4:119595442 chr4:119440561~119450157:- PAAD cis rs2015599 0.623 rs12581107 ENSG00000257176.2 RP11-996F15.2 -4.85 3.01e-06 0.00191 -0.37 -0.37 Platelet count;Mean platelet volume; chr12:29352358 chr12:29280418~29317848:- PAAD cis rs3762637 0.769 rs13317855 ENSG00000272758.4 RP11-299J3.8 -4.85 3.01e-06 0.00192 -0.6 -0.37 LDL cholesterol levels; chr3:122385387 chr3:122416207~122443180:+ PAAD cis rs2015599 0.56 rs3948497 ENSG00000257176.2 RP11-996F15.2 -4.85 3.01e-06 0.00192 -0.37 -0.37 Platelet count;Mean platelet volume; chr12:29247552 chr12:29280418~29317848:- PAAD cis rs8091660 0.624 rs9948328 ENSG00000278983.1 RP11-426J5.3 4.85 3.02e-06 0.00192 0.45 0.37 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48569613 chr18:48564795~48568342:+ PAAD cis rs875971 0.545 rs1638735 ENSG00000226824.5 RP4-756H11.3 -4.85 3.02e-06 0.00192 -0.52 -0.37 Aortic root size; chr7:66630751 chr7:66654538~66669855:+ PAAD cis rs10754283 0.967 rs6663363 ENSG00000231613.1 RP5-943J3.1 4.85 3.02e-06 0.00192 0.39 0.37 Amyotrophic lateral sclerosis (sporadic); chr1:89651295 chr1:89788914~89790492:+ PAAD cis rs1823913 1 rs12623832 ENSG00000280083.1 RP11-317J9.1 4.85 3.02e-06 0.00192 0.46 0.37 Obesity-related traits; chr2:191260918 chr2:191154118~191156070:- PAAD cis rs2980439 0.818 rs2948294 ENSG00000173295.6 FAM86B3P 4.85 3.02e-06 0.00192 0.41 0.37 Neuroticism; chr8:8237439 chr8:8228595~8244865:+ PAAD cis rs9531006 0.636 rs6563146 ENSG00000227676.3 LINC01068 4.85 3.03e-06 0.00193 0.55 0.37 Sleep duration; chr13:79883400 chr13:79566727~79571436:+ PAAD cis rs9531006 0.636 rs7333212 ENSG00000227676.3 LINC01068 4.85 3.03e-06 0.00193 0.55 0.37 Sleep duration; chr13:79883619 chr13:79566727~79571436:+ PAAD cis rs210138 1 rs210138 ENSG00000197251.3 LINC00336 -4.85 3.03e-06 0.00193 -0.56 -0.37 Testicular germ cell tumor; chr6:33574761 chr6:33586106~33593338:- PAAD cis rs210138 1 rs210137 ENSG00000197251.3 LINC00336 4.85 3.03e-06 0.00193 0.56 0.37 Testicular germ cell tumor; chr6:33574701 chr6:33586106~33593338:- PAAD cis rs7772486 0.754 rs702324 ENSG00000235652.6 RP11-545I5.3 -4.85 3.04e-06 0.00193 -0.32 -0.37 Lobe attachment (rater-scored or self-reported); chr6:145687657 chr6:145799409~145886585:+ PAAD cis rs6921919 0.525 rs11760133 ENSG00000204709.4 LINC01556 4.85 3.04e-06 0.00193 0.52 0.37 Autism spectrum disorder or schizophrenia; chr6:28418962 chr6:28943877~28944537:+ PAAD cis rs4683346 0.616 rs12639142 ENSG00000173811.9 CCDC13-AS1 -4.85 3.04e-06 0.00193 -0.4 -0.37 Granulocyte percentage of myeloid white cells; chr3:42790040 chr3:42732575~42746768:+ PAAD cis rs4683346 0.616 rs34868846 ENSG00000173811.9 CCDC13-AS1 -4.85 3.04e-06 0.00193 -0.4 -0.37 Granulocyte percentage of myeloid white cells; chr3:42791723 chr3:42732575~42746768:+ PAAD cis rs875971 0.545 rs6460281 ENSG00000226824.5 RP4-756H11.3 -4.85 3.05e-06 0.00193 -0.51 -0.37 Aortic root size; chr7:66216128 chr7:66654538~66669855:+ PAAD cis rs1964356 0.967 rs2953802 ENSG00000253893.2 FAM85B -4.85 3.05e-06 0.00194 -0.49 -0.37 Mean corpuscular volume; chr8:8994371 chr8:8167819~8226614:- PAAD cis rs950169 0.922 rs12906983 ENSG00000259295.5 CSPG4P12 4.85 3.05e-06 0.00194 0.41 0.37 Schizophrenia; chr15:84262270 chr15:85191438~85213905:+ PAAD cis rs8031584 0.678 rs3122 ENSG00000260382.1 RP11-540B6.2 -4.85 3.05e-06 0.00194 -0.49 -0.37 Huntington's disease progression; chr15:30878087 chr15:30882267~30883231:- PAAD cis rs17711722 0.522 rs4642526 ENSG00000237310.1 GS1-124K5.4 4.85 3.05e-06 0.00194 0.35 0.37 Calcium levels; chr7:65751755 chr7:66493706~66495474:+ PAAD cis rs1823913 0.599 rs55685315 ENSG00000280083.1 RP11-317J9.1 -4.85 3.06e-06 0.00194 -0.44 -0.37 Obesity-related traits; chr2:191306451 chr2:191154118~191156070:- PAAD cis rs1545257 0.505 rs7595372 ENSG00000242628.4 AC009228.1 4.85 3.06e-06 0.00194 0.42 0.37 Sjögren's syndrome; chr2:24409253 chr2:24214381~24221516:+ PAAD cis rs10998036 0.591 rs10823171 ENSG00000233590.1 RP11-153K11.3 4.85 3.06e-06 0.00194 0.52 0.37 Optic cup area; chr10:68292171 chr10:68233251~68242379:- PAAD cis rs4938303 0.718 rs4938300 ENSG00000254851.1 RP11-109L13.1 4.85 3.06e-06 0.00194 0.62 0.37 Triglycerides; chr11:116696903 chr11:117135528~117138582:+ PAAD cis rs950027 0.62 rs1617984 ENSG00000259433.2 CTD-2651B20.4 -4.85 3.06e-06 0.00194 -0.42 -0.37 Response to fenofibrate (adiponectin levels); chr15:45330464 chr15:45330209~45332634:- PAAD cis rs4728142 0.604 rs10229001 ENSG00000275106.1 RP11-309L24.10 -4.85 3.06e-06 0.00194 -0.49 -0.37 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128959343 chr7:128952527~128953316:- PAAD cis rs11651753 0.636 rs4793731 ENSG00000264920.1 RP11-6N17.4 -4.85 3.06e-06 0.00194 -0.44 -0.37 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47956327 chr17:47891255~47895812:- PAAD cis rs11651753 0.636 rs4793733 ENSG00000264920.1 RP11-6N17.4 -4.85 3.06e-06 0.00194 -0.44 -0.37 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47956616 chr17:47891255~47895812:- PAAD cis rs11651753 0.636 rs35280206 ENSG00000264920.1 RP11-6N17.4 -4.85 3.06e-06 0.00194 -0.44 -0.37 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47957645 chr17:47891255~47895812:- PAAD cis rs992157 0.71 rs6719789 ENSG00000261338.2 RP11-378A13.1 -4.85 3.07e-06 0.00195 -0.4 -0.37 Colorectal cancer; chr2:218193087 chr2:218255319~218257366:+ PAAD cis rs1823913 1 rs4853562 ENSG00000280083.1 RP11-317J9.1 4.85 3.07e-06 0.00195 0.46 0.37 Obesity-related traits; chr2:191253696 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs4853461 ENSG00000280083.1 RP11-317J9.1 4.85 3.07e-06 0.00195 0.46 0.37 Obesity-related traits; chr2:191254572 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs4853563 ENSG00000280083.1 RP11-317J9.1 4.85 3.07e-06 0.00195 0.46 0.37 Obesity-related traits; chr2:191254808 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs1840377 ENSG00000280083.1 RP11-317J9.1 4.85 3.07e-06 0.00195 0.46 0.37 Obesity-related traits; chr2:191257992 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs4853564 ENSG00000280083.1 RP11-317J9.1 4.85 3.07e-06 0.00195 0.46 0.37 Obesity-related traits; chr2:191258939 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs4853565 ENSG00000280083.1 RP11-317J9.1 4.85 3.07e-06 0.00195 0.46 0.37 Obesity-related traits; chr2:191259020 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs4853462 ENSG00000280083.1 RP11-317J9.1 4.85 3.07e-06 0.00195 0.46 0.37 Obesity-related traits; chr2:191259078 chr2:191154118~191156070:- PAAD cis rs4664293 0.769 rs2729726 ENSG00000226266.5 AC009961.3 -4.85 3.07e-06 0.00195 -0.46 -0.37 Monocyte percentage of white cells; chr2:159811597 chr2:159670708~159712435:- PAAD cis rs4664293 0.738 rs1549580 ENSG00000226266.5 AC009961.3 -4.85 3.07e-06 0.00195 -0.46 -0.37 Monocyte percentage of white cells; chr2:159812177 chr2:159670708~159712435:- PAAD cis rs1545257 0.514 rs7581577 ENSG00000242628.4 AC009228.1 4.85 3.07e-06 0.00195 0.42 0.37 Sjögren's syndrome; chr2:24415238 chr2:24214381~24221516:+ PAAD cis rs1545257 0.537 rs4581852 ENSG00000242628.4 AC009228.1 4.85 3.07e-06 0.00195 0.42 0.37 Sjögren's syndrome; chr2:24415387 chr2:24214381~24221516:+ PAAD cis rs1823913 0.622 rs55787447 ENSG00000280083.1 RP11-317J9.1 -4.85 3.08e-06 0.00195 -0.43 -0.37 Obesity-related traits; chr2:191288596 chr2:191154118~191156070:- PAAD cis rs7665090 0.755 rs228619 ENSG00000246560.2 RP11-10L12.4 -4.85 3.08e-06 0.00195 -0.41 -0.37 Primary biliary cholangitis; chr4:102648126 chr4:102828055~102844075:+ PAAD cis rs4927850 1 rs10881563 ENSG00000231464.1 AC024937.4 4.85 3.08e-06 0.00195 0.43 0.37 Pancreatic cancer; chr3:196023354 chr3:195996738~195998233:+ PAAD cis rs9531006 0.636 rs4052505 ENSG00000227676.3 LINC01068 4.85 3.08e-06 0.00195 0.58 0.37 Sleep duration; chr13:79938352 chr13:79566727~79571436:+ PAAD cis rs7772486 0.869 rs2777473 ENSG00000235652.6 RP11-545I5.3 4.85 3.08e-06 0.00195 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145980358 chr6:145799409~145886585:+ PAAD cis rs7772486 0.902 rs2748500 ENSG00000235652.6 RP11-545I5.3 4.85 3.08e-06 0.00195 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145993716 chr6:145799409~145886585:+ PAAD cis rs2274273 1 rs7493394 ENSG00000258413.1 RP11-665C16.6 -4.85 3.08e-06 0.00195 -0.48 -0.37 Protein biomarker; chr14:55151037 chr14:55262767~55272075:- PAAD cis rs2274273 0.967 rs11622740 ENSG00000258413.1 RP11-665C16.6 -4.85 3.08e-06 0.00195 -0.48 -0.37 Protein biomarker; chr14:55151126 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs15870 ENSG00000258413.1 RP11-665C16.6 -4.85 3.08e-06 0.00195 -0.48 -0.37 Protein biomarker; chr14:55152593 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs10149435 ENSG00000258413.1 RP11-665C16.6 -4.85 3.08e-06 0.00195 -0.48 -0.37 Protein biomarker; chr14:55160771 chr14:55262767~55272075:- PAAD cis rs7772486 0.902 rs2144476 ENSG00000235652.6 RP11-545I5.3 4.85 3.08e-06 0.00195 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:146001348 chr6:145799409~145886585:+ PAAD cis rs7772486 0.837 rs2474354 ENSG00000235652.6 RP11-545I5.3 4.85 3.08e-06 0.00195 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:146002659 chr6:145799409~145886585:+ PAAD cis rs858239 0.6 rs13438188 ENSG00000226816.2 AC005082.12 -4.85 3.09e-06 0.00196 -0.41 -0.37 Cerebrospinal fluid biomarker levels; chr7:23104578 chr7:23206013~23208045:+ PAAD cis rs1545257 0.537 rs12988283 ENSG00000242628.4 AC009228.1 4.84 3.09e-06 0.00196 0.42 0.37 Sjögren's syndrome; chr2:24419217 chr2:24214381~24221516:+ PAAD cis rs1545257 0.537 rs2702088 ENSG00000242628.4 AC009228.1 4.84 3.09e-06 0.00196 0.42 0.37 Sjögren's syndrome; chr2:24419666 chr2:24214381~24221516:+ PAAD cis rs2283792 0.812 rs240066 ENSG00000228050.1 TOP3BP1 -4.84 3.09e-06 0.00196 -0.41 -0.37 Multiple sclerosis; chr22:21938623 chr22:22223187~22224566:- PAAD cis rs17507216 1 rs3850610 ENSG00000255769.6 GOLGA2P10 4.84 3.1e-06 0.00196 0.45 0.37 Excessive daytime sleepiness; chr15:82552642 chr15:82472993~82513950:- PAAD cis rs1075265 0.695 rs1877908 ENSG00000233266.1 HMGB1P31 4.84 3.1e-06 0.00196 0.46 0.37 Chronotype;Morning vs. evening chronotype; chr2:54140877 chr2:54051334~54051760:+ PAAD cis rs1075265 0.662 rs6706363 ENSG00000233266.1 HMGB1P31 4.84 3.1e-06 0.00196 0.46 0.37 Chronotype;Morning vs. evening chronotype; chr2:54141569 chr2:54051334~54051760:+ PAAD cis rs11214589 0.747 rs10891536 ENSG00000270179.1 RP11-159N11.4 -4.84 3.1e-06 0.00196 -0.39 -0.37 Neuroticism; chr11:113338706 chr11:113368478~113369117:+ PAAD cis rs950169 0.8 rs4842847 ENSG00000259295.5 CSPG4P12 4.84 3.11e-06 0.00197 0.41 0.37 Schizophrenia; chr15:84262447 chr15:85191438~85213905:+ PAAD cis rs11089937 0.553 rs35336247 ENSG00000211639.2 IGLV4-60 4.84 3.11e-06 0.00197 0.38 0.37 Periodontitis (PAL4Q3); chr22:22131593 chr22:22162199~22162681:+ PAAD cis rs11089937 0.553 rs34088081 ENSG00000211639.2 IGLV4-60 4.84 3.11e-06 0.00197 0.38 0.37 Periodontitis (PAL4Q3); chr22:22131601 chr22:22162199~22162681:+ PAAD cis rs4554975 0.689 rs11183630 ENSG00000274723.1 RP11-618L22.1 -4.84 3.12e-06 0.00197 -0.41 -0.37 Metabolite levels (small molecules and protein measures); chr12:46843286 chr12:46970504~46972155:+ PAAD cis rs216345 0.635 rs12342186 ENSG00000230074.1 RP11-195F19.9 4.84 3.12e-06 0.00197 0.49 0.37 Bipolar disorder; chr9:34048794 chr9:34665665~34681298:+ PAAD cis rs7772486 0.654 rs4896829 ENSG00000235652.6 RP11-545I5.3 4.84 3.12e-06 0.00197 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145632539 chr6:145799409~145886585:+ PAAD cis rs11098499 0.644 rs10009566 ENSG00000245958.5 RP11-33B1.1 -4.84 3.12e-06 0.00197 -0.29 -0.37 Corneal astigmatism; chr4:119637453 chr4:119454791~119552025:+ PAAD cis rs11098499 0.644 rs10012252 ENSG00000245958.5 RP11-33B1.1 -4.84 3.12e-06 0.00197 -0.29 -0.37 Corneal astigmatism; chr4:119637984 chr4:119454791~119552025:+ PAAD cis rs2255336 0.938 rs12578507 ENSG00000245648.1 RP11-277P12.20 -4.84 3.12e-06 0.00197 -0.59 -0.37 Blood protein levels; chr12:10470396 chr12:10363769~10398506:+ PAAD cis rs7945705 0.791 rs6484484 ENSG00000254860.4 TMEM9B-AS1 -4.84 3.12e-06 0.00197 -0.4 -0.37 Hemoglobin concentration; chr11:8795659 chr11:8964675~8977527:+ PAAD cis rs10888838 0.818 rs61776465 ENSG00000198711.5 SSBP3-AS1 4.84 3.12e-06 0.00198 0.48 0.37 Mitochondrial DNA levels; chr1:54229077 chr1:54236440~54239063:+ PAAD cis rs4865169 0.595 rs9998008 ENSG00000269949.1 RP11-738E22.3 4.84 3.12e-06 0.00198 0.47 0.37 Breast cancer; chr4:56899886 chr4:56960927~56961373:- PAAD cis rs3096299 0.935 rs3102387 ENSG00000274627.1 RP11-104N10.2 4.84 3.12e-06 0.00198 0.32 0.37 Multiple myeloma (IgH translocation); chr16:89365868 chr16:89516797~89522217:+ PAAD cis rs1823913 0.599 rs1378155 ENSG00000280083.1 RP11-317J9.1 -4.84 3.13e-06 0.00198 -0.43 -0.37 Obesity-related traits; chr2:191266610 chr2:191154118~191156070:- PAAD cis rs7615952 0.546 rs11718647 ENSG00000171084.14 FAM86JP 4.84 3.13e-06 0.00198 0.54 0.37 Blood pressure (smoking interaction); chr3:125633178 chr3:125916620~125930024:+ PAAD cis rs9987353 0.519 rs2929465 ENSG00000253893.2 FAM85B 4.84 3.13e-06 0.00198 0.49 0.37 Recombination measurement; chr8:9206492 chr8:8167819~8226614:- PAAD cis rs2404602 0.647 rs11072610 ENSG00000259422.1 RP11-593F23.1 -4.84 3.13e-06 0.00198 -0.45 -0.37 Blood metabolite levels; chr15:76638464 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11637096 ENSG00000259422.1 RP11-593F23.1 -4.84 3.13e-06 0.00198 -0.45 -0.37 Blood metabolite levels; chr15:76638761 chr15:76174891~76181486:- PAAD cis rs4723738 1 rs10240479 ENSG00000227191.5 TRGC2 -4.84 3.13e-06 0.00198 -0.32 -0.37 Treatment response for severe sepsis; chr7:38181654 chr7:38239580~38368091:- PAAD cis rs453301 0.652 rs2043129 ENSG00000253893.2 FAM85B -4.84 3.13e-06 0.00198 -0.51 -0.37 Joint mobility (Beighton score); chr8:8967994 chr8:8167819~8226614:- PAAD cis rs75422866 0.51 rs35784744 ENSG00000257433.4 RP1-197B17.3 4.84 3.14e-06 0.00199 0.71 0.37 Pneumonia; chr12:47729646 chr12:47706085~47742294:+ PAAD cis rs11089937 0.512 rs34963809 ENSG00000211639.2 IGLV4-60 4.84 3.14e-06 0.00199 0.37 0.37 Periodontitis (PAL4Q3); chr22:22130737 chr22:22162199~22162681:+ PAAD cis rs11089937 0.568 rs35626600 ENSG00000211639.2 IGLV4-60 4.84 3.14e-06 0.00199 0.37 0.37 Periodontitis (PAL4Q3); chr22:22130811 chr22:22162199~22162681:+ PAAD cis rs11089937 0.539 rs34228957 ENSG00000211639.2 IGLV4-60 4.84 3.14e-06 0.00199 0.37 0.37 Periodontitis (PAL4Q3); chr22:22130838 chr22:22162199~22162681:+ PAAD cis rs11089937 0.512 rs13054756 ENSG00000211639.2 IGLV4-60 4.84 3.14e-06 0.00199 0.37 0.37 Periodontitis (PAL4Q3); chr22:22130948 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs4821768 ENSG00000211639.2 IGLV4-60 4.84 3.14e-06 0.00199 0.37 0.37 Periodontitis (PAL4Q3); chr22:22131047 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs4821770 ENSG00000211639.2 IGLV4-60 4.84 3.14e-06 0.00199 0.37 0.37 Periodontitis (PAL4Q3); chr22:22131281 chr22:22162199~22162681:+ PAAD cis rs11089937 0.568 rs4821771 ENSG00000211639.2 IGLV4-60 4.84 3.14e-06 0.00199 0.37 0.37 Periodontitis (PAL4Q3); chr22:22131287 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs4821773 ENSG00000211639.2 IGLV4-60 4.84 3.14e-06 0.00199 0.37 0.37 Periodontitis (PAL4Q3); chr22:22131434 chr22:22162199~22162681:+ PAAD cis rs7615952 0.611 rs114419739 ENSG00000171084.14 FAM86JP 4.84 3.14e-06 0.00199 0.77 0.37 Blood pressure (smoking interaction); chr3:126003647 chr3:125916620~125930024:+ PAAD cis rs2283792 0.967 rs3810609 ENSG00000228050.1 TOP3BP1 4.84 3.15e-06 0.00199 0.39 0.37 Multiple sclerosis; chr22:21758513 chr22:22223187~22224566:- PAAD cis rs16828019 0.777 rs67460888 ENSG00000235358.1 RP11-399E6.1 4.84 3.15e-06 0.00199 0.78 0.37 Intelligence (multi-trait analysis); chr1:41003665 chr1:41242373~41284861:+ PAAD cis rs9309711 0.544 rs9309712 ENSG00000225234.1 TRAPPC12-AS1 -4.84 3.15e-06 0.00199 -0.38 -0.37 Neurofibrillary tangles; chr2:3487556 chr2:3481242~3482409:- PAAD cis rs9890032 0.934 rs3760318 ENSG00000266490.1 CTD-2349P21.9 4.84 3.15e-06 0.00199 0.35 0.37 Hip circumference adjusted for BMI; chr17:30920697 chr17:30792372~30792833:+ PAAD cis rs34375054 0.526 rs7302475 ENSG00000279233.1 RP11-158L12.4 4.84 3.15e-06 0.00199 0.31 0.37 Post bronchodilator FEV1/FVC ratio; chr12:125193340 chr12:125138245~125141711:+ PAAD cis rs1545257 0.505 rs67786999 ENSG00000242628.4 AC009228.1 4.84 3.16e-06 0.002 0.42 0.37 Sjögren's syndrome; chr2:24414291 chr2:24214381~24221516:+ PAAD cis rs4663866 0.505 rs3739064 ENSG00000186235.9 AC016757.3 4.84 3.16e-06 0.002 0.52 0.37 Irritable bowel syndrome; chr2:238267745 chr2:238224552~238231677:- PAAD cis rs6504950 0.705 rs17745123 ENSG00000275710.1 RP11-257O5.4 4.84 3.16e-06 0.002 0.5 0.37 Breast cancer; chr17:54910871 chr17:54964474~54964679:+ PAAD cis rs8059260 0.736 rs7195509 ENSG00000274038.1 RP11-66H6.4 -4.84 3.17e-06 0.002 -0.61 -0.37 Alcohol consumption over the past year; chr16:10951572 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs8059156 ENSG00000274038.1 RP11-66H6.4 -4.84 3.17e-06 0.002 -0.61 -0.37 Alcohol consumption over the past year; chr16:10952135 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs8044180 ENSG00000274038.1 RP11-66H6.4 -4.84 3.17e-06 0.002 -0.61 -0.37 Alcohol consumption over the past year; chr16:10952531 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs7192171 ENSG00000274038.1 RP11-66H6.4 -4.84 3.17e-06 0.002 -0.61 -0.37 Alcohol consumption over the past year; chr16:10955262 chr16:11056556~11057034:+ PAAD cis rs11118620 0.853 rs11118622 ENSG00000257551.1 HLX-AS1 4.84 3.17e-06 0.002 0.41 0.37 Heart failure; chr1:220868833 chr1:220832763~220880140:- PAAD cis rs16828019 0.777 rs34502739 ENSG00000235358.1 RP11-399E6.1 4.84 3.17e-06 0.002 0.78 0.37 Intelligence (multi-trait analysis); chr1:40993474 chr1:41242373~41284861:+ PAAD cis rs733592 0.56 rs61918773 ENSG00000240399.1 RP1-228P16.1 -4.84 3.17e-06 0.002 -0.34 -0.37 Plateletcrit; chr12:48027991 chr12:48054813~48055591:- PAAD cis rs2882667 0.537 rs13181793 ENSG00000253404.1 AC034243.1 4.84 3.17e-06 0.002 0.41 0.37 Age-related hearing impairment (SNP x SNP interaction); chr5:139073267 chr5:138744434~138753309:- PAAD cis rs131777 0.577 rs131748 ENSG00000205559.3 CHKB-AS1 4.84 3.18e-06 0.00201 0.41 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586408 chr22:50583026~50583877:+ PAAD cis rs189798 0.807 rs330905 ENSG00000254340.1 RP11-10A14.3 4.84 3.18e-06 0.00201 0.46 0.37 Myopia (pathological); chr8:9136041 chr8:9141424~9145435:+ PAAD cis rs4713118 0.5 rs9461434 ENSG00000204709.4 LINC01556 4.84 3.18e-06 0.00201 0.66 0.37 Parkinson's disease; chr6:28134687 chr6:28943877~28944537:+ PAAD cis rs3096299 0.809 rs2911264 ENSG00000274627.1 RP11-104N10.2 4.84 3.18e-06 0.00201 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89432864 chr16:89516797~89522217:+ PAAD cis rs2153535 0.58 rs9406169 ENSG00000230939.1 RP11-314C16.1 -4.84 3.19e-06 0.00201 -0.39 -0.37 Motion sickness; chr6:8509237 chr6:8784178~8785445:+ PAAD cis rs13178541 0.81 rs13170007 ENSG00000250378.1 RP11-119J18.1 -4.84 3.19e-06 0.00201 -0.56 -0.37 IgG glycosylation; chr5:135740893 chr5:135812667~135826582:+ PAAD cis rs16828019 0.777 rs67450703 ENSG00000235358.1 RP11-399E6.1 4.84 3.19e-06 0.00201 0.78 0.37 Intelligence (multi-trait analysis); chr1:40994457 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs13376450 ENSG00000235358.1 RP11-399E6.1 4.84 3.19e-06 0.00201 0.78 0.37 Intelligence (multi-trait analysis); chr1:41003371 chr1:41242373~41284861:+ PAAD cis rs16828019 0.777 rs12023079 ENSG00000235358.1 RP11-399E6.1 4.84 3.19e-06 0.00201 0.78 0.37 Intelligence (multi-trait analysis); chr1:41004439 chr1:41242373~41284861:+ PAAD cis rs2948294 0.588 rs12544596 ENSG00000253893.2 FAM85B -4.84 3.19e-06 0.00201 -0.51 -0.37 Red cell distribution width; chr8:8258824 chr8:8167819~8226614:- PAAD cis rs5758511 0.689 rs17478227 ENSG00000205702.9 CYP2D7 -4.84 3.19e-06 0.00201 -0.37 -0.37 Birth weight; chr22:42258321 chr22:42140203~42144577:- PAAD cis rs4664293 0.647 rs1425042 ENSG00000226266.5 AC009961.3 -4.84 3.19e-06 0.00201 -0.46 -0.37 Monocyte percentage of white cells; chr2:159584004 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs7576644 ENSG00000226266.5 AC009961.3 -4.84 3.19e-06 0.00201 -0.46 -0.37 Monocyte percentage of white cells; chr2:159584947 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs7562850 ENSG00000226266.5 AC009961.3 -4.84 3.19e-06 0.00201 -0.46 -0.37 Monocyte percentage of white cells; chr2:159585023 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs7580539 ENSG00000226266.5 AC009961.3 -4.84 3.19e-06 0.00201 -0.46 -0.37 Monocyte percentage of white cells; chr2:159589238 chr2:159670708~159712435:- PAAD cis rs4664293 0.539 rs7580661 ENSG00000226266.5 AC009961.3 -4.84 3.19e-06 0.00201 -0.46 -0.37 Monocyte percentage of white cells; chr2:159589326 chr2:159670708~159712435:- PAAD cis rs7208859 0.673 rs3816780 ENSG00000266490.1 CTD-2349P21.9 4.84 3.19e-06 0.00201 0.5 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834340 chr17:30792372~30792833:+ PAAD cis rs11214589 0.747 rs11214582 ENSG00000270179.1 RP11-159N11.4 -4.84 3.2e-06 0.00202 -0.39 -0.37 Neuroticism; chr11:113347328 chr11:113368478~113369117:+ PAAD cis rs1665050 0.895 rs8028752 ENSG00000277144.1 RP11-59H7.4 -4.84 3.2e-06 0.00202 -0.46 -0.37 Atopic dermatitis; chr15:59003803 chr15:59115547~59116089:- PAAD cis rs2980439 0.517 rs17594065 ENSG00000253893.2 FAM85B 4.84 3.21e-06 0.00202 0.52 0.37 Neuroticism; chr8:8247883 chr8:8167819~8226614:- PAAD cis rs7208859 0.673 rs11657270 ENSG00000266490.1 CTD-2349P21.9 4.84 3.21e-06 0.00202 0.47 0.37 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887369 chr17:30792372~30792833:+ PAAD cis rs7772486 0.743 rs9376955 ENSG00000235652.6 RP11-545I5.3 4.84 3.21e-06 0.00202 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145628268 chr6:145799409~145886585:+ PAAD cis rs7772486 0.805 rs4896831 ENSG00000235652.6 RP11-545I5.3 4.84 3.21e-06 0.00202 0.31 0.37 Lobe attachment (rater-scored or self-reported); chr6:145638345 chr6:145799409~145886585:+ PAAD cis rs2283792 1 rs3810610 ENSG00000228050.1 TOP3BP1 4.84 3.21e-06 0.00202 0.39 0.37 Multiple sclerosis; chr22:21761209 chr22:22223187~22224566:- PAAD cis rs2283792 1 rs13943 ENSG00000228050.1 TOP3BP1 4.84 3.21e-06 0.00202 0.39 0.37 Multiple sclerosis; chr22:21761913 chr22:22223187~22224566:- PAAD cis rs2283792 1 rs5999515 ENSG00000228050.1 TOP3BP1 -4.84 3.21e-06 0.00202 -0.39 -0.37 Multiple sclerosis; chr22:21790812 chr22:22223187~22224566:- PAAD cis rs9926296 0.585 rs4785595 ENSG00000260259.1 RP11-368I7.4 4.84 3.21e-06 0.00203 0.43 0.37 Vitiligo; chr16:89769113 chr16:89682620~89686569:- PAAD cis rs2153535 0.601 rs7738877 ENSG00000230939.1 RP11-314C16.1 -4.84 3.21e-06 0.00203 -0.38 -0.37 Motion sickness; chr6:8541997 chr6:8784178~8785445:+ PAAD cis rs9987353 0.519 rs11779181 ENSG00000253893.2 FAM85B -4.84 3.21e-06 0.00203 -0.47 -0.37 Recombination measurement; chr8:9205517 chr8:8167819~8226614:- PAAD cis rs3762637 0.941 rs74467988 ENSG00000272758.4 RP11-299J3.8 -4.84 3.21e-06 0.00203 -0.55 -0.37 LDL cholesterol levels; chr3:122364293 chr3:122416207~122443180:+ PAAD cis rs3762637 0.882 rs9818537 ENSG00000272758.4 RP11-299J3.8 -4.84 3.21e-06 0.00203 -0.55 -0.37 LDL cholesterol levels; chr3:122367610 chr3:122416207~122443180:+ PAAD cis rs3762637 0.882 rs9856011 ENSG00000272758.4 RP11-299J3.8 -4.84 3.21e-06 0.00203 -0.55 -0.37 LDL cholesterol levels; chr3:122374723 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs9863712 ENSG00000272758.4 RP11-299J3.8 -4.84 3.21e-06 0.00203 -0.55 -0.37 LDL cholesterol levels; chr3:122381059 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs28679619 ENSG00000272758.4 RP11-299J3.8 -4.84 3.21e-06 0.00203 -0.55 -0.37 LDL cholesterol levels; chr3:122381502 chr3:122416207~122443180:+ PAAD cis rs7078219 0.543 rs7096296 ENSG00000257582.4 LINC01475 4.84 3.22e-06 0.00203 0.4 0.37 Dental caries; chr10:99518059 chr10:99526350~99531177:- PAAD cis rs2274273 0.84 rs3742569 ENSG00000258413.1 RP11-665C16.6 -4.84 3.22e-06 0.00203 -0.47 -0.37 Protein biomarker; chr14:55351988 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs10150760 ENSG00000258413.1 RP11-665C16.6 4.84 3.22e-06 0.00203 0.47 0.37 Protein biomarker; chr14:55354830 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs28493647 ENSG00000258413.1 RP11-665C16.6 -4.84 3.22e-06 0.00203 -0.47 -0.37 Protein biomarker; chr14:55357745 chr14:55262767~55272075:- PAAD cis rs2274273 0.84 rs17674463 ENSG00000258413.1 RP11-665C16.6 -4.84 3.22e-06 0.00203 -0.47 -0.37 Protein biomarker; chr14:55358145 chr14:55262767~55272075:- PAAD cis rs2274273 0.837 rs8008119 ENSG00000258413.1 RP11-665C16.6 -4.84 3.22e-06 0.00203 -0.47 -0.37 Protein biomarker; chr14:55364510 chr14:55262767~55272075:- PAAD cis rs2274273 0.87 rs2016931 ENSG00000258413.1 RP11-665C16.6 -4.84 3.22e-06 0.00203 -0.47 -0.37 Protein biomarker; chr14:55375614 chr14:55262767~55272075:- PAAD cis rs12554020 0.892 rs7025805 ENSG00000227603.1 RP11-165J3.6 -4.84 3.22e-06 0.00203 -0.57 -0.37 Schizophrenia; chr9:93481463 chr9:93435332~93437121:- PAAD cis rs2280018 0.963 rs4985147 ENSG00000260735.1 RP11-72I8.1 -4.84 3.22e-06 0.00203 -0.45 -0.37 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15074903 chr16:15094411~15109197:+ PAAD cis rs911555 0.655 rs10149470 ENSG00000259775.1 RP11-45P15.4 -4.84 3.22e-06 0.00203 -0.37 -0.37 Intelligence (multi-trait analysis); chr14:103551616 chr14:103331674~103332367:- PAAD cis rs3096299 0.967 rs2911253 ENSG00000274627.1 RP11-104N10.2 4.84 3.23e-06 0.00203 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89422179 chr16:89516797~89522217:+ PAAD cis rs17772222 0.74 rs11845147 ENSG00000258983.2 RP11-507K2.2 4.84 3.23e-06 0.00203 0.47 0.37 Coronary artery calcification; chr14:88502804 chr14:88499334~88515502:+ PAAD cis rs2564921 0.73 rs930122 ENSG00000242142.1 SERBP1P3 4.84 3.23e-06 0.00204 0.45 0.37 Height; chr3:53085313 chr3:53064283~53065091:- PAAD cis rs3096299 0.9 rs2911258 ENSG00000274627.1 RP11-104N10.2 4.84 3.23e-06 0.00204 0.33 0.37 Multiple myeloma (IgH translocation); chr16:89414352 chr16:89516797~89522217:+ PAAD cis rs10129255 0.613 rs916546 ENSG00000223648.3 IGHV3-64 4.84 3.23e-06 0.00204 0.4 0.37 Kawasaki disease; chr14:106654441 chr14:106643132~106658258:- PAAD cis rs9322193 0.607 rs12204653 ENSG00000223701.3 RAET1E-AS1 4.84 3.23e-06 0.00204 0.48 0.37 Lung cancer; chr6:149891885 chr6:149884431~149919508:+ PAAD cis rs10129255 0.544 rs61997583 ENSG00000223648.3 IGHV3-64 4.84 3.23e-06 0.00204 0.4 0.37 Kawasaki disease; chr14:106654351 chr14:106643132~106658258:- PAAD cis rs4664293 0.647 rs6711049 ENSG00000226266.5 AC009961.3 -4.83 3.23e-06 0.00204 -0.46 -0.37 Monocyte percentage of white cells; chr2:159584634 chr2:159670708~159712435:- PAAD cis rs734999 0.549 rs6667564 ENSG00000225931.3 RP3-395M20.7 4.83 3.23e-06 0.00204 0.34 0.37 Ulcerative colitis; chr1:2588863 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs6701238 ENSG00000225931.3 RP3-395M20.7 4.83 3.23e-06 0.00204 0.34 0.37 Ulcerative colitis; chr1:2589061 chr1:2566410~2569888:+ PAAD cis rs734999 0.549 rs6670198 ENSG00000225931.3 RP3-395M20.7 4.83 3.23e-06 0.00204 0.34 0.37 Ulcerative colitis; chr1:2589088 chr1:2566410~2569888:+ PAAD cis rs9532669 0.926 rs9532689 ENSG00000176268.5 CYCSP34 4.83 3.24e-06 0.00204 0.34 0.37 Cervical cancer; chr13:40957990 chr13:40863599~40863902:- PAAD cis rs9532669 0.926 rs9532690 ENSG00000176268.5 CYCSP34 4.83 3.24e-06 0.00204 0.34 0.37 Cervical cancer; chr13:40968654 chr13:40863599~40863902:- PAAD cis rs1823913 0.599 rs55786000 ENSG00000280083.1 RP11-317J9.1 -4.83 3.24e-06 0.00204 -0.43 -0.37 Obesity-related traits; chr2:191284500 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs17346412 ENSG00000280083.1 RP11-317J9.1 -4.83 3.24e-06 0.00204 -0.43 -0.37 Obesity-related traits; chr2:191285902 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs17412239 ENSG00000280083.1 RP11-317J9.1 -4.83 3.24e-06 0.00204 -0.43 -0.37 Obesity-related traits; chr2:191285937 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs35098152 ENSG00000280083.1 RP11-317J9.1 -4.83 3.24e-06 0.00204 -0.43 -0.37 Obesity-related traits; chr2:191286658 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs35150635 ENSG00000280083.1 RP11-317J9.1 -4.83 3.24e-06 0.00204 -0.43 -0.37 Obesity-related traits; chr2:191287303 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs2168166 ENSG00000280083.1 RP11-317J9.1 -4.83 3.24e-06 0.00204 -0.43 -0.37 Obesity-related traits; chr2:191288063 chr2:191154118~191156070:- PAAD cis rs10510102 0.872 rs7906462 ENSG00000276742.1 RP11-500G22.4 4.83 3.24e-06 0.00204 0.53 0.37 Breast cancer; chr10:121948098 chr10:121956782~121957098:+ PAAD cis rs7078219 0.543 rs4919342 ENSG00000257582.4 LINC01475 -4.83 3.24e-06 0.00204 -0.4 -0.37 Dental caries; chr10:99522796 chr10:99526350~99531177:- PAAD cis rs4664293 0.625 rs4665102 ENSG00000226266.5 AC009961.3 4.83 3.24e-06 0.00204 0.46 0.37 Monocyte percentage of white cells; chr2:159666076 chr2:159670708~159712435:- PAAD cis rs989978 0.958 rs7901824 ENSG00000257582.4 LINC01475 -4.83 3.24e-06 0.00204 -0.44 -0.37 Red blood cell count; chr10:99565066 chr10:99526350~99531177:- PAAD cis rs8059260 0.668 rs4781029 ENSG00000274038.1 RP11-66H6.4 -4.83 3.25e-06 0.00205 -0.59 -0.36 Alcohol consumption over the past year; chr16:10983717 chr16:11056556~11057034:+ PAAD cis rs4927850 1 rs6799572 ENSG00000231464.1 AC024937.4 4.83 3.26e-06 0.00205 0.43 0.36 Pancreatic cancer; chr3:196013537 chr3:195996738~195998233:+ PAAD cis rs7829975 0.535 rs4841005 ENSG00000253893.2 FAM85B 4.83 3.26e-06 0.00205 0.51 0.36 Mood instability; chr8:8643720 chr8:8167819~8226614:- PAAD cis rs2153535 0.58 rs7766852 ENSG00000230939.1 RP11-314C16.1 -4.83 3.26e-06 0.00205 -0.39 -0.36 Motion sickness; chr6:8472184 chr6:8784178~8785445:+ PAAD cis rs10754283 0.967 rs10801761 ENSG00000231613.1 RP5-943J3.1 4.83 3.26e-06 0.00205 0.39 0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89649710 chr1:89788914~89790492:+ PAAD cis rs17495987 1 rs17495987 ENSG00000219545.8 UMAD1 4.83 3.26e-06 0.00205 0.5 0.36 Tonsillectomy; chr7:7860334 chr7:7640711~8004059:+ PAAD cis rs2658782 0.724 rs1563445 ENSG00000279684.1 RP11-755E23.2 -4.83 3.27e-06 0.00206 -0.6 -0.36 Pulmonary function decline; chr11:93512876 chr11:93286629~93288903:- PAAD cis rs7580658 0.724 rs6712213 ENSG00000236682.1 AC068282.3 -4.83 3.27e-06 0.00206 -0.46 -0.36 Protein C levels; chr2:127240654 chr2:127389130~127400580:+ PAAD cis rs7580658 0.724 rs6712446 ENSG00000236682.1 AC068282.3 -4.83 3.27e-06 0.00206 -0.46 -0.36 Protein C levels; chr2:127240823 chr2:127389130~127400580:+ PAAD cis rs7580658 0.724 rs6712551 ENSG00000236682.1 AC068282.3 -4.83 3.27e-06 0.00206 -0.46 -0.36 Protein C levels; chr2:127240909 chr2:127389130~127400580:+ PAAD cis rs6504950 0.85 rs11079143 ENSG00000275710.1 RP11-257O5.4 -4.83 3.27e-06 0.00206 -0.48 -0.36 Breast cancer; chr17:55005761 chr17:54964474~54964679:+ PAAD cis rs9494145 0.68 rs9389269 ENSG00000232876.1 CTA-212D2.2 -4.83 3.27e-06 0.00206 -0.45 -0.36 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135106021 chr6:135055033~135060550:+ PAAD cis rs9494145 0.68 rs9402686 ENSG00000232876.1 CTA-212D2.2 -4.83 3.27e-06 0.00206 -0.45 -0.36 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135106679 chr6:135055033~135060550:+ PAAD cis rs2179367 0.959 rs4895789 ENSG00000231760.4 RP11-350J20.5 4.83 3.27e-06 0.00206 0.47 0.36 Dupuytren's disease; chr6:149443518 chr6:149796151~149826294:- PAAD cis rs9847710 0.524 rs11712910 ENSG00000242142.1 SERBP1P3 4.83 3.28e-06 0.00206 0.48 0.36 Ulcerative colitis; chr3:53060178 chr3:53064283~53065091:- PAAD cis rs17023223 0.581 rs11811859 ENSG00000231365.4 RP11-418J17.1 -4.83 3.28e-06 0.00206 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119165057 chr1:119140396~119275973:+ PAAD cis rs2255336 0.938 rs2733840 ENSG00000245648.1 RP11-277P12.20 4.83 3.28e-06 0.00206 0.54 0.36 Blood protein levels; chr12:10393326 chr12:10363769~10398506:+ PAAD cis rs6921919 0.789 rs6456814 ENSG00000216901.1 AL022393.7 4.83 3.29e-06 0.00207 0.53 0.36 Autism spectrum disorder or schizophrenia; chr6:28338035 chr6:28176188~28176674:+ PAAD cis rs6921919 0.789 rs13210258 ENSG00000216901.1 AL022393.7 4.83 3.29e-06 0.00207 0.53 0.36 Autism spectrum disorder or schizophrenia; chr6:28340894 chr6:28176188~28176674:+ PAAD cis rs2108622 0.958 rs56340170 ENSG00000267453.5 AC004791.2 -4.83 3.29e-06 0.00207 -0.55 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871067 chr19:15851993~15864904:- PAAD cis rs11690935 0.595 rs788166 ENSG00000228389.1 AC068039.4 -4.83 3.29e-06 0.00207 -0.42 -0.36 Schizophrenia; chr2:172050761 chr2:171773482~171775844:+ PAAD cis rs17826219 0.561 rs4794869 ENSG00000263531.1 RP13-753N3.1 4.83 3.29e-06 0.00207 0.91 0.36 Body mass index; chr17:30364082 chr17:30863921~30864940:- PAAD cis rs1823913 1 rs4853568 ENSG00000280083.1 RP11-317J9.1 4.83 3.29e-06 0.00207 0.46 0.36 Obesity-related traits; chr2:191261464 chr2:191154118~191156070:- PAAD cis rs9326248 0.52 rs2735183 ENSG00000280143.1 AP000892.6 4.83 3.3e-06 0.00207 0.41 0.36 Blood protein levels; chr11:117144479 chr11:117204967~117210292:+ PAAD cis rs10875746 0.551 rs10875799 ENSG00000240399.1 RP1-228P16.1 -4.83 3.3e-06 0.00207 -0.39 -0.36 Longevity (90 years and older); chr12:48347096 chr12:48054813~48055591:- PAAD cis rs11673344 0.764 rs1644643 ENSG00000226686.6 LINC01535 4.83 3.3e-06 0.00208 0.49 0.36 Obesity-related traits; chr19:36972269 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs1644645 ENSG00000226686.6 LINC01535 4.83 3.3e-06 0.00208 0.49 0.36 Obesity-related traits; chr19:36972528 chr19:37251912~37265535:+ PAAD cis rs964611 0.882 rs4775746 ENSG00000259488.2 RP11-154J22.1 4.83 3.3e-06 0.00208 0.4 0.36 Metabolite levels (Pyroglutamine); chr15:48346050 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4775748 ENSG00000259488.2 RP11-154J22.1 4.83 3.3e-06 0.00208 0.4 0.36 Metabolite levels (Pyroglutamine); chr15:48346598 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs11630744 ENSG00000259488.2 RP11-154J22.1 4.83 3.3e-06 0.00208 0.4 0.36 Metabolite levels (Pyroglutamine); chr15:48355310 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs971952 ENSG00000259488.2 RP11-154J22.1 4.83 3.3e-06 0.00208 0.4 0.36 Metabolite levels (Pyroglutamine); chr15:48363743 chr15:48312353~48331856:- PAAD cis rs12468226 1 rs13426118 ENSG00000273456.1 RP11-686O6.2 4.83 3.31e-06 0.00208 0.52 0.36 Urate levels; chr2:202390762 chr2:202374932~202375604:- PAAD cis rs2564921 0.73 rs62255897 ENSG00000242142.1 SERBP1P3 -4.83 3.31e-06 0.00208 -0.46 -0.36 Height; chr3:53029854 chr3:53064283~53065091:- PAAD cis rs6565180 0.888 rs12447833 ENSG00000183604.13 SMG1P5 4.83 3.31e-06 0.00208 0.4 0.36 Tonsillectomy; chr16:30378993 chr16:30267553~30335374:- PAAD cis rs3096299 0.967 rs16965692 ENSG00000274627.1 RP11-104N10.2 4.83 3.32e-06 0.00208 0.33 0.36 Multiple myeloma (IgH translocation); chr16:89405074 chr16:89516797~89522217:+ PAAD cis rs3096299 0.967 rs28644774 ENSG00000274627.1 RP11-104N10.2 4.83 3.32e-06 0.00208 0.33 0.36 Multiple myeloma (IgH translocation); chr16:89405773 chr16:89516797~89522217:+ PAAD cis rs3096299 0.933 rs747485 ENSG00000274627.1 RP11-104N10.2 4.83 3.32e-06 0.00208 0.33 0.36 Multiple myeloma (IgH translocation); chr16:89407686 chr16:89516797~89522217:+ PAAD cis rs11651753 0.613 rs4793732 ENSG00000264920.1 RP11-6N17.4 -4.83 3.32e-06 0.00208 -0.45 -0.36 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47956488 chr17:47891255~47895812:- PAAD cis rs807029 0.577 rs3740490 ENSG00000272572.1 RP11-179B2.2 -4.83 3.32e-06 0.00208 -0.45 -0.36 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100996986 chr10:100911103~100912739:- PAAD cis rs807029 0.577 rs11190786 ENSG00000272572.1 RP11-179B2.2 -4.83 3.32e-06 0.00208 -0.45 -0.36 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100997685 chr10:100911103~100912739:- PAAD cis rs807029 0.577 rs7902510 ENSG00000272572.1 RP11-179B2.2 -4.83 3.32e-06 0.00208 -0.45 -0.36 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100998177 chr10:100911103~100912739:- PAAD cis rs807029 0.577 rs7903239 ENSG00000272572.1 RP11-179B2.2 -4.83 3.32e-06 0.00208 -0.45 -0.36 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100998580 chr10:100911103~100912739:- PAAD cis rs807029 0.544 rs55646950 ENSG00000272572.1 RP11-179B2.2 -4.83 3.32e-06 0.00208 -0.45 -0.36 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:101001239 chr10:100911103~100912739:- PAAD cis rs807029 0.577 rs750866 ENSG00000272572.1 RP11-179B2.2 -4.83 3.32e-06 0.00208 -0.45 -0.36 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:101001701 chr10:100911103~100912739:- PAAD cis rs807029 0.577 rs701835 ENSG00000272572.1 RP11-179B2.2 -4.83 3.32e-06 0.00208 -0.45 -0.36 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:101002370 chr10:100911103~100912739:- PAAD cis rs992157 0.71 rs13026485 ENSG00000261338.2 RP11-378A13.1 -4.83 3.32e-06 0.00208 -0.41 -0.36 Colorectal cancer; chr2:218193261 chr2:218255319~218257366:+ PAAD cis rs1155848 0.571 rs17511364 ENSG00000227354.5 RBM26-AS1 4.83 3.32e-06 0.00209 0.68 0.36 Response to anti-TNF alpha therapy in inflammatory bowel disease; chr13:79678460 chr13:79406309~79424328:+ PAAD cis rs73219805 0.793 rs3808573 ENSG00000228451.3 SDAD1P1 -4.83 3.32e-06 0.00209 -0.55 -0.36 Schizophrenia; chr8:26339117 chr8:26379259~26382953:- PAAD cis rs12908161 0.959 rs12906348 ENSG00000225151.9 GOLGA2P7 -4.83 3.33e-06 0.00209 -0.45 -0.36 Schizophrenia; chr15:84786190 chr15:84199311~84230136:- PAAD cis rs4950322 0.515 rs72691016 ENSG00000278811.3 LINC00624 4.83 3.34e-06 0.00209 0.37 0.36 Protein quantitative trait loci; chr1:147245375 chr1:147258885~147517875:- PAAD cis rs964611 0.882 rs79379792 ENSG00000259488.2 RP11-154J22.1 -4.83 3.34e-06 0.00209 -0.41 -0.36 Metabolite levels (Pyroglutamine); chr15:48351980 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs13380180 ENSG00000259488.2 RP11-154J22.1 -4.83 3.34e-06 0.00209 -0.41 -0.36 Metabolite levels (Pyroglutamine); chr15:48352572 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs13379705 ENSG00000259488.2 RP11-154J22.1 -4.83 3.34e-06 0.00209 -0.41 -0.36 Metabolite levels (Pyroglutamine); chr15:48352611 chr15:48312353~48331856:- PAAD cis rs35160687 0.623 rs4832263 ENSG00000273080.1 RP11-301O19.1 -4.83 3.34e-06 0.00209 -0.42 -0.36 Night sleep phenotypes; chr2:86258034 chr2:86195590~86196049:+ PAAD cis rs710913 0.557 rs1180320 ENSG00000237624.1 OXCT2P1 4.83 3.35e-06 0.0021 0.45 0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39616330 chr1:39514956~39516490:+ PAAD cis rs2274273 0.87 rs17741542 ENSG00000258413.1 RP11-665C16.6 4.83 3.35e-06 0.0021 0.46 0.36 Protein biomarker; chr14:55339143 chr14:55262767~55272075:- PAAD cis rs6480314 0.522 rs10762212 ENSG00000233590.1 RP11-153K11.3 4.83 3.35e-06 0.0021 0.58 0.36 Optic nerve measurement (disc area); chr10:68295190 chr10:68233251~68242379:- PAAD cis rs6844153 1 rs74895929 ENSG00000240005.4 RP11-293A21.1 -4.83 3.36e-06 0.00211 -0.62 -0.36 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26846035 chr4:26859806~26860599:- PAAD cis rs9532669 0.926 rs9525438 ENSG00000176268.5 CYCSP34 4.83 3.36e-06 0.00211 0.34 0.36 Cervical cancer; chr13:40964123 chr13:40863599~40863902:- PAAD cis rs2179367 0.919 rs4897124 ENSG00000231760.4 RP11-350J20.5 4.83 3.37e-06 0.00211 0.47 0.36 Dupuytren's disease; chr6:149442073 chr6:149796151~149826294:- PAAD cis rs7615952 0.546 rs2979333 ENSG00000171084.14 FAM86JP 4.82 3.38e-06 0.00212 0.54 0.36 Blood pressure (smoking interaction); chr3:125641499 chr3:125916620~125930024:+ PAAD cis rs7615952 0.546 rs111812401 ENSG00000171084.14 FAM86JP 4.82 3.38e-06 0.00212 0.54 0.36 Blood pressure (smoking interaction); chr3:125642651 chr3:125916620~125930024:+ PAAD cis rs7615952 0.546 rs2979350 ENSG00000171084.14 FAM86JP 4.82 3.38e-06 0.00212 0.54 0.36 Blood pressure (smoking interaction); chr3:125643371 chr3:125916620~125930024:+ PAAD cis rs1322639 0.614 rs6940913 ENSG00000261039.2 RP11-417E7.2 -4.82 3.38e-06 0.00212 -0.6 -0.36 Pulse pressure; chr6:169163571 chr6:169175304~169182740:- PAAD cis rs1322639 0.614 rs6903921 ENSG00000261039.2 RP11-417E7.2 -4.82 3.38e-06 0.00212 -0.6 -0.36 Pulse pressure; chr6:169163862 chr6:169175304~169182740:- PAAD cis rs1322639 0.614 rs6925950 ENSG00000261039.2 RP11-417E7.2 -4.82 3.38e-06 0.00212 -0.6 -0.36 Pulse pressure; chr6:169163863 chr6:169175304~169182740:- PAAD cis rs17711722 0.523 rs313812 ENSG00000237310.1 GS1-124K5.4 -4.82 3.4e-06 0.00213 -0.35 -0.36 Calcium levels; chr7:66040056 chr7:66493706~66495474:+ PAAD cis rs17711722 0.523 rs365896 ENSG00000237310.1 GS1-124K5.4 -4.82 3.4e-06 0.00213 -0.35 -0.36 Calcium levels; chr7:66045710 chr7:66493706~66495474:+ PAAD cis rs12134133 1 rs6673333 ENSG00000274245.1 RP11-357P18.2 4.82 3.4e-06 0.00213 0.6 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207285802 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs61822697 ENSG00000274245.1 RP11-357P18.2 4.82 3.4e-06 0.00213 0.6 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207311819 chr1:207372559~207373252:+ PAAD cis rs10483853 0.579 rs10134243 ENSG00000258695.2 RP3-414A15.2 -4.82 3.41e-06 0.00214 -0.54 -0.36 Coronary artery calcification; chr14:73478444 chr14:73522878~73530610:+ PAAD cis rs7208859 0.725 rs9910051 ENSG00000266490.1 CTD-2349P21.9 4.82 3.41e-06 0.00214 0.45 0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834184 chr17:30792372~30792833:+ PAAD cis rs734999 0.588 rs745367 ENSG00000225931.3 RP3-395M20.7 4.82 3.42e-06 0.00214 0.34 0.36 Ulcerative colitis; chr1:2593018 chr1:2566410~2569888:+ PAAD cis rs734999 0.549 rs3828154 ENSG00000225931.3 RP3-395M20.7 4.82 3.42e-06 0.00214 0.34 0.36 Ulcerative colitis; chr1:2593504 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs3748817 ENSG00000225931.3 RP3-395M20.7 4.82 3.42e-06 0.00214 0.34 0.36 Ulcerative colitis; chr1:2594226 chr1:2566410~2569888:+ PAAD cis rs4664293 0.867 rs7579206 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159715992 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs7565297 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159716008 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs7594329 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159716207 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs7582124 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159716326 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs7606046 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159719647 chr2:159670708~159712435:- PAAD cis rs4664293 0.802 rs13025347 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159721056 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs6432554 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159722573 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs6760485 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159723179 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs6761145 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159725673 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs6732987 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159725918 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs7589941 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159727589 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs7566584 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159728284 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs3732289 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159728887 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs3821299 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159729229 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs13415100 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159729716 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs13389662 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159729926 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs7562060 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159730618 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs4665110 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159731014 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs34893664 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159732266 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs34795915 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159732420 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs10204867 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159732674 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs35196716 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159733266 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs6432557 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159735699 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs7603274 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159736179 chr2:159670708~159712435:- PAAD cis rs4664293 0.836 rs13403371 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159736603 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs13428679 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159736687 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs12623283 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159736959 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs2098976 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159737264 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs2081723 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159737649 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs2081722 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159737697 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs10166694 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159738380 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs2357529 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159738922 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs12692562 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159739199 chr2:159670708~159712435:- PAAD cis rs4664293 0.867 rs12998291 ENSG00000226266.5 AC009961.3 -4.82 3.42e-06 0.00214 -0.44 -0.36 Monocyte percentage of white cells; chr2:159739392 chr2:159670708~159712435:- PAAD cis rs1823913 1 rs10445782 ENSG00000280083.1 RP11-317J9.1 4.82 3.43e-06 0.00214 0.47 0.36 Obesity-related traits; chr2:191236639 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs1454749 ENSG00000280083.1 RP11-317J9.1 -4.82 3.43e-06 0.00214 -0.47 -0.36 Obesity-related traits; chr2:191240909 chr2:191154118~191156070:- PAAD cis rs2337406 0.714 rs117798641 ENSG00000211974.3 IGHV2-70 -4.82 3.43e-06 0.00214 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106777984 chr14:106723574~106724093:- PAAD cis rs4794202 0.618 rs4794224 ENSG00000264920.1 RP11-6N17.4 -4.82 3.43e-06 0.00215 -0.52 -0.36 Alzheimer's disease (cognitive decline); chr17:47880097 chr17:47891255~47895812:- PAAD cis rs4813802 0.764 rs990999 ENSG00000278192.1 RP5-1056H1.2 -4.82 3.43e-06 0.00215 -0.38 -0.36 Colorectal cancer; chr20:6711882 chr20:6065966~6067897:- PAAD cis rs73173548 0.502 rs12187348 ENSG00000247828.6 TMEM161B-AS1 4.82 3.44e-06 0.00215 0.3 0.36 Macular telangiectasia type 2; chr5:88424724 chr5:88268895~88436685:+ PAAD cis rs2283792 0.935 rs9610375 ENSG00000224086.5 LL22NC03-86G7.1 -4.82 3.44e-06 0.00215 -0.36 -0.36 Multiple sclerosis; chr22:21832804 chr22:21938293~21977632:+ PAAD cis rs4835473 0.932 rs10030428 ENSG00000251600.4 RP11-673E1.1 4.82 3.44e-06 0.00215 0.39 0.36 Immature fraction of reticulocytes; chr4:143762699 chr4:143912331~143982454:+ PAAD cis rs7580658 0.724 rs4662711 ENSG00000236682.1 AC068282.3 -4.82 3.44e-06 0.00215 -0.46 -0.36 Protein C levels; chr2:127233264 chr2:127389130~127400580:+ PAAD cis rs964611 0.882 rs3784621 ENSG00000259488.2 RP11-154J22.1 4.82 3.44e-06 0.00215 0.41 0.36 Metabolite levels (Pyroglutamine); chr15:48340895 chr15:48312353~48331856:- PAAD cis rs10754283 0.967 rs1320563 ENSG00000231613.1 RP5-943J3.1 4.82 3.45e-06 0.00215 0.39 0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89655473 chr1:89788914~89790492:+ PAAD cis rs4664293 0.967 rs13397722 ENSG00000226266.5 AC009961.3 -4.82 3.45e-06 0.00216 -0.45 -0.36 Monocyte percentage of white cells; chr2:159659140 chr2:159670708~159712435:- PAAD cis rs4664293 0.899 rs7588710 ENSG00000226266.5 AC009961.3 -4.82 3.45e-06 0.00216 -0.45 -0.36 Monocyte percentage of white cells; chr2:159673011 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs4665103 ENSG00000226266.5 AC009961.3 -4.82 3.45e-06 0.00216 -0.45 -0.36 Monocyte percentage of white cells; chr2:159675801 chr2:159670708~159712435:- PAAD cis rs4664293 0.903 rs10185155 ENSG00000226266.5 AC009961.3 -4.82 3.45e-06 0.00216 -0.45 -0.36 Monocyte percentage of white cells; chr2:159696717 chr2:159670708~159712435:- PAAD cis rs4664293 0.934 rs1365800 ENSG00000226266.5 AC009961.3 -4.82 3.45e-06 0.00216 -0.45 -0.36 Monocyte percentage of white cells; chr2:159699112 chr2:159670708~159712435:- PAAD cis rs7945705 0.791 rs7944560 ENSG00000254860.4 TMEM9B-AS1 -4.82 3.45e-06 0.00216 -0.39 -0.36 Hemoglobin concentration; chr11:8795729 chr11:8964675~8977527:+ PAAD cis rs2980439 0.517 rs712253 ENSG00000253893.2 FAM85B 4.82 3.45e-06 0.00216 0.52 0.36 Neuroticism; chr8:8246260 chr8:8167819~8226614:- PAAD cis rs950169 0.84 rs72748702 ENSG00000259295.5 CSPG4P12 4.82 3.45e-06 0.00216 0.4 0.36 Schizophrenia; chr15:84246494 chr15:85191438~85213905:+ PAAD cis rs950169 0.922 rs4338765 ENSG00000259295.5 CSPG4P12 4.82 3.45e-06 0.00216 0.4 0.36 Schizophrenia; chr15:84248084 chr15:85191438~85213905:+ PAAD cis rs11118620 0.81 rs1603047 ENSG00000257551.1 HLX-AS1 4.82 3.45e-06 0.00216 0.41 0.36 Heart failure; chr1:220849953 chr1:220832763~220880140:- PAAD cis rs734999 0.572 rs4310388 ENSG00000225931.3 RP3-395M20.7 4.82 3.45e-06 0.00216 0.35 0.36 Ulcerative colitis; chr1:2575976 chr1:2566410~2569888:+ PAAD cis rs1153858 0.623 rs17618637 ENSG00000259520.4 CTD-2651B20.3 -4.82 3.46e-06 0.00216 -0.77 -0.36 Homoarginine levels; chr15:45361196 chr15:45251580~45279251:- PAAD cis rs4853525 0.561 rs7597768 ENSG00000235852.1 AC005540.3 4.82 3.46e-06 0.00216 0.53 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190977153 chr2:190880797~190882059:- PAAD cis rs780094 0.606 rs6729709 ENSG00000234072.1 AC074117.10 -4.82 3.46e-06 0.00216 -0.29 -0.36 Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels; chr2:27360289 chr2:27356246~27367622:+ PAAD cis rs2274273 0.967 rs17832359 ENSG00000258413.1 RP11-665C16.6 -4.82 3.46e-06 0.00216 -0.48 -0.36 Protein biomarker; chr14:55149223 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs11621351 ENSG00000258413.1 RP11-665C16.6 -4.82 3.46e-06 0.00216 -0.48 -0.36 Protein biomarker; chr14:55150022 chr14:55262767~55272075:- PAAD cis rs992157 0.56 rs6436048 ENSG00000261338.2 RP11-378A13.1 4.82 3.46e-06 0.00216 0.42 0.36 Colorectal cancer; chr2:218244310 chr2:218255319~218257366:+ PAAD cis rs2882667 0.683 rs13188935 ENSG00000253404.1 AC034243.1 4.82 3.46e-06 0.00216 0.41 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139116536 chr5:138744434~138753309:- PAAD cis rs2337406 0.866 rs7140974 ENSG00000211974.3 IGHV2-70 -4.82 3.46e-06 0.00216 -0.5 -0.36 Alzheimer's disease (late onset); chr14:106795976 chr14:106723574~106724093:- PAAD cis rs4266144 1 rs4561781 ENSG00000244515.1 KRT18P34 4.82 3.46e-06 0.00216 0.47 0.36 Coronary artery disease; chr3:157135154 chr3:157162663~157163932:- PAAD cis rs2153535 0.58 rs4365970 ENSG00000230939.1 RP11-314C16.1 4.82 3.47e-06 0.00216 0.38 0.36 Motion sickness; chr6:8453580 chr6:8784178~8785445:+ PAAD cis rs748404 0.604 rs2278857 ENSG00000249839.1 AC011330.5 -4.82 3.47e-06 0.00217 -0.53 -0.36 Lung cancer; chr15:43340351 chr15:43663654~43684339:- PAAD cis rs2658782 0.951 rs117384439 ENSG00000279684.1 RP11-755E23.2 4.82 3.47e-06 0.00217 0.6 0.36 Pulmonary function decline; chr11:93378312 chr11:93286629~93288903:- PAAD cis rs10463554 0.824 rs60588319 ENSG00000175749.11 EIF3KP1 4.82 3.48e-06 0.00217 0.48 0.36 Parkinson's disease; chr5:102988656 chr5:103032376~103033031:+ PAAD cis rs1545257 0.56 rs7561752 ENSG00000242628.4 AC009228.1 -4.82 3.48e-06 0.00217 -0.42 -0.36 Sjögren's syndrome; chr2:24420965 chr2:24214381~24221516:+ PAAD cis rs2153535 0.58 rs4960433 ENSG00000230939.1 RP11-314C16.1 -4.82 3.48e-06 0.00217 -0.38 -0.36 Motion sickness; chr6:8523464 chr6:8784178~8785445:+ PAAD cis rs2946504 0.553 rs2946498 ENSG00000251468.2 RP11-369K16.1 -4.82 3.48e-06 0.00217 -0.43 -0.36 Type 2 diabetes; chr8:12960578 chr8:12958387~12962200:+ PAAD cis rs10754283 0.967 rs4658307 ENSG00000231613.1 RP5-943J3.1 4.82 3.49e-06 0.00218 0.39 0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89652027 chr1:89788914~89790492:+ PAAD cis rs6782228 0.606 rs2811488 ENSG00000242551.2 POU5F1P6 -4.82 3.49e-06 0.00218 -0.43 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128617674 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs58977394 ENSG00000242551.2 POU5F1P6 -4.82 3.49e-06 0.00218 -0.43 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619074 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs2712381 ENSG00000242551.2 POU5F1P6 -4.82 3.49e-06 0.00218 -0.43 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619757 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs1127030 ENSG00000242551.2 POU5F1P6 -4.82 3.49e-06 0.00218 -0.43 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128620110 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs2712419 ENSG00000242551.2 POU5F1P6 -4.82 3.49e-06 0.00218 -0.43 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128622053 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs2811489 ENSG00000242551.2 POU5F1P6 4.82 3.49e-06 0.00218 0.43 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128618528 chr3:128674735~128677005:- PAAD cis rs12819124 0.502 rs10875718 ENSG00000240399.1 RP1-228P16.1 4.82 3.49e-06 0.00218 0.37 0.36 Glycated hemoglobin levels; chr12:48017319 chr12:48054813~48055591:- PAAD cis rs10483853 0.579 rs58546337 ENSG00000258695.2 RP3-414A15.2 -4.82 3.49e-06 0.00218 -0.53 -0.36 Coronary artery calcification; chr14:73483753 chr14:73522878~73530610:+ PAAD cis rs964611 1 rs1820492 ENSG00000259488.2 RP11-154J22.1 4.82 3.49e-06 0.00218 0.4 0.36 Metabolite levels (Pyroglutamine); chr15:48311230 chr15:48312353~48331856:- PAAD cis rs11089937 0.54 rs2329931 ENSG00000211639.2 IGLV4-60 4.82 3.49e-06 0.00218 0.39 0.36 Periodontitis (PAL4Q3); chr22:22131994 chr22:22162199~22162681:+ PAAD cis rs10486158 0.521 rs11525818 ENSG00000155070.8 UNC93B2 4.82 3.5e-06 0.00218 0.44 0.36 Bipolar disorder and schizophrenia; chr7:7387813 chr7:6855485~6859830:- PAAD cis rs8062405 0.655 rs7184597 ENSG00000251417.2 RP11-1348G14.4 4.82 3.5e-06 0.00218 0.34 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910488 chr16:28802743~28817828:+ PAAD cis rs11089937 0.568 rs2876996 ENSG00000211639.2 IGLV4-60 4.82 3.5e-06 0.00218 0.39 0.36 Periodontitis (PAL4Q3); chr22:22132006 chr22:22162199~22162681:+ PAAD cis rs35160687 0.623 rs11127019 ENSG00000273080.1 RP11-301O19.1 -4.82 3.5e-06 0.00218 -0.43 -0.36 Night sleep phenotypes; chr2:86240495 chr2:86195590~86196049:+ PAAD cis rs73173548 0.502 rs4451795 ENSG00000247828.6 TMEM161B-AS1 4.82 3.5e-06 0.00218 0.29 0.36 Macular telangiectasia type 2; chr5:88422879 chr5:88268895~88436685:+ PAAD cis rs710913 0.587 rs6690413 ENSG00000237624.1 OXCT2P1 4.82 3.5e-06 0.00218 0.44 0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39620620 chr1:39514956~39516490:+ PAAD cis rs4268898 0.735 rs34125395 ENSG00000242628.4 AC009228.1 -4.82 3.5e-06 0.00218 -0.43 -0.36 Asthma; chr2:24335373 chr2:24214381~24221516:+ PAAD cis rs7615952 0.611 rs12488771 ENSG00000171084.14 FAM86JP 4.82 3.51e-06 0.00219 0.77 0.36 Blood pressure (smoking interaction); chr3:125981683 chr3:125916620~125930024:+ PAAD cis rs7615952 0.611 rs79405914 ENSG00000171084.14 FAM86JP 4.82 3.51e-06 0.00219 0.77 0.36 Blood pressure (smoking interaction); chr3:126004780 chr3:125916620~125930024:+ PAAD cis rs2658782 0.724 rs2605629 ENSG00000279684.1 RP11-755E23.2 4.82 3.51e-06 0.00219 0.57 0.36 Pulmonary function decline; chr11:93530871 chr11:93286629~93288903:- PAAD cis rs4950322 0.518 rs55697094 ENSG00000278811.3 LINC00624 4.82 3.51e-06 0.00219 0.37 0.36 Protein quantitative trait loci; chr1:147121205 chr1:147258885~147517875:- PAAD cis rs13178541 0.81 rs10070559 ENSG00000250378.1 RP11-119J18.1 -4.82 3.52e-06 0.00219 -0.56 -0.36 IgG glycosylation; chr5:135822430 chr5:135812667~135826582:+ PAAD cis rs4834770 0.746 rs2389747 ENSG00000245958.5 RP11-33B1.1 -4.82 3.52e-06 0.00219 -0.29 -0.36 Blood protein levels; chr4:119314947 chr4:119454791~119552025:+ PAAD cis rs4834770 0.717 rs1022146 ENSG00000245958.5 RP11-33B1.1 -4.82 3.52e-06 0.00219 -0.29 -0.36 Blood protein levels; chr4:119314948 chr4:119454791~119552025:+ PAAD cis rs2412819 0.571 rs17727853 ENSG00000205771.5 CATSPER2P1 -4.82 3.52e-06 0.00219 -0.58 -0.36 Lung cancer; chr15:43630299 chr15:43726918~43747094:- PAAD cis rs11214589 0.747 rs1893695 ENSG00000270179.1 RP11-159N11.4 -4.82 3.52e-06 0.00219 -0.4 -0.36 Neuroticism; chr11:113335363 chr11:113368478~113369117:+ PAAD cis rs11214589 0.747 rs2155462 ENSG00000270179.1 RP11-159N11.4 -4.82 3.52e-06 0.00219 -0.4 -0.36 Neuroticism; chr11:113336077 chr11:113368478~113369117:+ PAAD cis rs992157 0.764 rs3731861 ENSG00000261338.2 RP11-378A13.1 -4.82 3.52e-06 0.00219 -0.43 -0.36 Colorectal cancer; chr2:218326533 chr2:218255319~218257366:+ PAAD cis rs3096299 0.679 rs3096322 ENSG00000274627.1 RP11-104N10.2 -4.81 3.53e-06 0.0022 -0.32 -0.36 Multiple myeloma (IgH translocation); chr16:89374715 chr16:89516797~89522217:+ PAAD cis rs11976180 1 rs2961117 ENSG00000273234.1 OR2A13P -4.81 3.54e-06 0.0022 -0.46 -0.36 Obesity-related traits; chr7:144058160 chr7:144142009~144142938:+ PAAD cis rs6061231 0.561 rs67072353 ENSG00000273619.1 RP5-908M14.9 -4.81 3.54e-06 0.0022 -0.35 -0.36 Colorectal cancer; chr20:62365646 chr20:62386303~62386970:- PAAD cis rs8059260 0.736 rs2302558 ENSG00000274038.1 RP11-66H6.4 -4.81 3.54e-06 0.0022 -0.59 -0.36 Alcohol consumption over the past year; chr16:10969154 chr16:11056556~11057034:+ PAAD cis rs6723162 0.51 rs959053 ENSG00000237751.2 LINC01143 -4.81 3.55e-06 0.00221 -0.49 -0.36 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70928442 chr2:70887871~70889959:+ PAAD cis rs871012 0.547 rs4305634 ENSG00000248544.2 CTB-47B11.3 -4.81 3.55e-06 0.00221 -0.46 -0.36 IgG glycosylation; chr5:157384662 chr5:157375741~157384950:- PAAD cis rs7829975 0.714 rs11777085 ENSG00000253893.2 FAM85B -4.81 3.55e-06 0.00221 -0.51 -0.36 Mood instability; chr8:8814919 chr8:8167819~8226614:- PAAD cis rs9487094 0.645 rs34292461 ENSG00000260273.1 RP11-425D10.10 4.81 3.56e-06 0.00221 0.52 0.36 Height; chr6:109352277 chr6:109382795~109383666:+ PAAD cis rs9326248 0.581 rs10892076 ENSG00000280143.1 AP000892.6 4.81 3.56e-06 0.00221 0.41 0.36 Blood protein levels; chr11:117118220 chr11:117204967~117210292:+ PAAD cis rs2599510 0.783 rs13385788 ENSG00000276334.1 AL133243.1 4.81 3.56e-06 0.00221 0.43 0.36 Interleukin-18 levels; chr2:32494625 chr2:32521927~32523547:+ PAAD cis rs950027 0.62 rs1719246 ENSG00000259433.2 CTD-2651B20.4 -4.81 3.56e-06 0.00221 -0.41 -0.36 Response to fenofibrate (adiponectin levels); chr15:45333281 chr15:45330209~45332634:- PAAD cis rs2333194 0.846 rs7159794 ENSG00000258695.2 RP3-414A15.2 -4.81 3.56e-06 0.00221 -0.4 -0.36 Bipolar disorder with mood-incongruent psychosis; chr14:73337735 chr14:73522878~73530610:+ PAAD cis rs66887589 0.967 rs3775842 ENSG00000248280.1 RP11-33B1.2 4.81 3.57e-06 0.00222 0.33 0.36 Diastolic blood pressure; chr4:119506577 chr4:119440561~119450157:- PAAD cis rs66887589 0.967 rs6844263 ENSG00000248280.1 RP11-33B1.2 4.81 3.57e-06 0.00222 0.33 0.36 Diastolic blood pressure; chr4:119512652 chr4:119440561~119450157:- PAAD cis rs4950322 0.748 rs17356680 ENSG00000278811.3 LINC00624 4.81 3.57e-06 0.00222 0.38 0.36 Protein quantitative trait loci; chr1:147354934 chr1:147258885~147517875:- PAAD cis rs2333194 0.846 rs6574118 ENSG00000258695.2 RP3-414A15.2 -4.81 3.57e-06 0.00222 -0.4 -0.36 Bipolar disorder with mood-incongruent psychosis; chr14:73345284 chr14:73522878~73530610:+ PAAD cis rs4950322 0.57 rs17160051 ENSG00000278811.3 LINC00624 4.81 3.57e-06 0.00222 0.38 0.36 Protein quantitative trait loci; chr1:147255733 chr1:147258885~147517875:- PAAD cis rs7615952 0.605 rs11708269 ENSG00000171084.14 FAM86JP 4.81 3.57e-06 0.00222 0.59 0.36 Blood pressure (smoking interaction); chr3:125613306 chr3:125916620~125930024:+ PAAD cis rs4853525 0.59 rs11893307 ENSG00000235852.1 AC005540.3 -4.81 3.58e-06 0.00222 -0.55 -0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190863318 chr2:190880797~190882059:- PAAD cis rs4853525 0.59 rs10198852 ENSG00000235852.1 AC005540.3 4.81 3.58e-06 0.00222 0.55 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190863606 chr2:190880797~190882059:- PAAD cis rs1075265 0.901 rs9808326 ENSG00000233266.1 HMGB1P31 4.81 3.58e-06 0.00222 0.48 0.36 Chronotype;Morning vs. evening chronotype; chr2:54115971 chr2:54051334~54051760:+ PAAD cis rs2302464 1 rs16892289 ENSG00000214846.4 RP11-115L11.1 -4.81 3.58e-06 0.00223 -0.96 -0.36 Cerebrospinal fluid biomarker levels; chr4:15730680 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs12651052 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15726813 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs56381553 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15726824 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs12645513 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15727155 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs58335439 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15727183 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs73123625 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15727550 chr4:15730962~15731627:- PAAD cis rs7657257 1 rs12643722 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Blood protein levels; chr4:15728480 chr4:15730962~15731627:- PAAD cis rs7657257 1 rs12640554 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Blood protein levels; chr4:15728484 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs111541714 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15728782 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs73125993 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15728890 chr4:15730962~15731627:- PAAD cis rs7657257 1 rs16892283 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Blood protein levels; chr4:15729911 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs16892287 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15730570 chr4:15730962~15731627:- PAAD cis rs7657257 1 rs4321629 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Blood protein levels; chr4:15730757 chr4:15730962~15731627:- PAAD cis rs7657257 1 rs10516290 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Blood protein levels; chr4:15730833 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs10516291 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15731168 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs4342183 ENSG00000214846.4 RP11-115L11.1 4.81 3.58e-06 0.00223 0.96 0.36 Cerebrospinal fluid biomarker levels; chr4:15733817 chr4:15730962~15731627:- PAAD cis rs2486288 0.656 rs8039153 ENSG00000259433.2 CTD-2651B20.4 4.81 3.58e-06 0.00223 0.4 0.36 Glomerular filtration rate; chr15:45287615 chr15:45330209~45332634:- PAAD cis rs860554 0.515 rs12038867 ENSG00000249007.1 RP11-510N19.5 4.81 3.58e-06 0.00223 0.29 0.36 Panic disorder; chr1:201273249 chr1:202011370~202015657:+ PAAD cis rs8031584 0.918 rs34331396 ENSG00000260382.1 RP11-540B6.2 4.81 3.58e-06 0.00223 0.46 0.36 Huntington's disease progression; chr15:30956533 chr15:30882267~30883231:- PAAD cis rs8031584 0.918 rs34693097 ENSG00000260382.1 RP11-540B6.2 4.81 3.58e-06 0.00223 0.46 0.36 Huntington's disease progression; chr15:30961781 chr15:30882267~30883231:- PAAD cis rs8031584 0.918 rs35784593 ENSG00000260382.1 RP11-540B6.2 4.81 3.58e-06 0.00223 0.46 0.36 Huntington's disease progression; chr15:30962385 chr15:30882267~30883231:- PAAD cis rs8031584 0.918 rs61997138 ENSG00000260382.1 RP11-540B6.2 4.81 3.58e-06 0.00223 0.46 0.36 Huntington's disease progression; chr15:30978573 chr15:30882267~30883231:- PAAD cis rs8031584 0.918 rs61997140 ENSG00000260382.1 RP11-540B6.2 4.81 3.58e-06 0.00223 0.46 0.36 Huntington's disease progression; chr15:30985109 chr15:30882267~30883231:- PAAD cis rs10510102 0.935 rs11200258 ENSG00000276742.1 RP11-500G22.4 4.81 3.59e-06 0.00223 0.54 0.36 Breast cancer; chr10:121918392 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12264495 ENSG00000276742.1 RP11-500G22.4 4.81 3.59e-06 0.00223 0.54 0.36 Breast cancer; chr10:121919967 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11200261 ENSG00000276742.1 RP11-500G22.4 4.81 3.59e-06 0.00223 0.54 0.36 Breast cancer; chr10:121921133 chr10:121956782~121957098:+ PAAD cis rs3761847 0.593 rs1468673 ENSG00000226752.6 PSMD5-AS1 -4.81 3.59e-06 0.00223 -0.41 -0.36 Rheumatoid arthritis; chr9:121047612 chr9:120824828~120854385:+ PAAD cis rs36051354 0.554 rs4687662 ENSG00000242142.1 SERBP1P3 4.81 3.59e-06 0.00223 0.5 0.36 Intelligence (multi-trait analysis); chr3:52836308 chr3:53064283~53065091:- PAAD cis rs35160687 0.623 rs35408390 ENSG00000273080.1 RP11-301O19.1 -4.81 3.59e-06 0.00223 -0.43 -0.36 Night sleep phenotypes; chr2:86244659 chr2:86195590~86196049:+ PAAD cis rs7829975 0.714 rs4841040 ENSG00000253893.2 FAM85B -4.81 3.59e-06 0.00223 -0.5 -0.36 Mood instability; chr8:8797017 chr8:8167819~8226614:- PAAD cis rs62229266 0.659 rs2026259 ENSG00000231106.2 LINC01436 4.81 3.59e-06 0.00223 0.52 0.36 Mitral valve prolapse; chr21:36058329 chr21:36005338~36007838:+ PAAD cis rs9532669 0.926 rs7799 ENSG00000176268.5 CYCSP34 4.81 3.59e-06 0.00223 0.34 0.36 Cervical cancer; chr13:40958916 chr13:40863599~40863902:- PAAD cis rs75422866 0.51 rs73105829 ENSG00000257433.4 RP1-197B17.3 4.81 3.59e-06 0.00223 0.7 0.36 Pneumonia; chr12:47734162 chr12:47706085~47742294:+ PAAD cis rs75422866 0.51 rs75424057 ENSG00000257433.4 RP1-197B17.3 4.81 3.59e-06 0.00223 0.7 0.36 Pneumonia; chr12:47737294 chr12:47706085~47742294:+ PAAD cis rs75422866 0.51 rs73105845 ENSG00000257433.4 RP1-197B17.3 4.81 3.59e-06 0.00223 0.7 0.36 Pneumonia; chr12:47741824 chr12:47706085~47742294:+ PAAD cis rs875971 0.545 rs12670811 ENSG00000226824.5 RP4-756H11.3 -4.81 3.6e-06 0.00223 -0.5 -0.36 Aortic root size; chr7:66358032 chr7:66654538~66669855:+ PAAD cis rs875971 0.502 rs2946580 ENSG00000164669.11 INTS4P1 4.81 3.6e-06 0.00223 0.53 0.36 Aortic root size; chr7:66066855 chr7:65141225~65234216:+ PAAD cis rs1185460 1 rs1185460 ENSG00000271751.1 RP11-110I1.14 4.81 3.6e-06 0.00224 0.48 0.36 Coronary artery disease; chr11:119072723 chr11:119065263~119065677:- PAAD cis rs950169 0.92 rs11637666 ENSG00000225151.9 GOLGA2P7 -4.81 3.61e-06 0.00224 -0.45 -0.36 Schizophrenia; chr15:84035122 chr15:84199311~84230136:- PAAD cis rs4794202 0.618 rs11079799 ENSG00000264920.1 RP11-6N17.4 4.81 3.61e-06 0.00224 0.53 0.36 Alzheimer's disease (cognitive decline); chr17:47878707 chr17:47891255~47895812:- PAAD cis rs10510102 0.872 rs12244199 ENSG00000276742.1 RP11-500G22.4 4.81 3.61e-06 0.00224 0.56 0.36 Breast cancer; chr10:121965117 chr10:121956782~121957098:+ PAAD cis rs1275468 1 rs17115231 ENSG00000257497.2 RP11-585P4.5 -4.81 3.62e-06 0.00224 -0.52 -0.36 Polycystic ovary syndrome; chr12:75539895 chr12:75483454~75489820:- PAAD cis rs1275468 1 rs1275469 ENSG00000257497.2 RP11-585P4.5 -4.81 3.62e-06 0.00224 -0.52 -0.36 Polycystic ovary syndrome; chr12:75541450 chr12:75483454~75489820:- PAAD cis rs66887589 0.967 rs13104219 ENSG00000248280.1 RP11-33B1.2 4.81 3.62e-06 0.00224 0.32 0.36 Diastolic blood pressure; chr4:119517019 chr4:119440561~119450157:- PAAD cis rs9326248 0.769 rs499910 ENSG00000280143.1 AP000892.6 4.81 3.62e-06 0.00224 0.48 0.36 Blood protein levels; chr11:116892318 chr11:117204967~117210292:+ PAAD cis rs12134133 1 rs6660254 ENSG00000274245.1 RP11-357P18.2 4.81 3.62e-06 0.00225 0.6 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207272746 chr1:207372559~207373252:+ PAAD cis rs897984 0.571 rs7184567 ENSG00000260911.2 RP11-196G11.2 4.81 3.62e-06 0.00225 0.32 0.36 Dementia with Lewy bodies; chr16:31009757 chr16:31043150~31049868:+ PAAD cis rs897984 0.609 rs4889609 ENSG00000260911.2 RP11-196G11.2 4.81 3.62e-06 0.00225 0.32 0.36 Dementia with Lewy bodies; chr16:31015106 chr16:31043150~31049868:+ PAAD cis rs897984 0.572 rs4889526 ENSG00000260911.2 RP11-196G11.2 4.81 3.62e-06 0.00225 0.32 0.36 Dementia with Lewy bodies; chr16:31019023 chr16:31043150~31049868:+ PAAD cis rs897984 0.609 rs57576577 ENSG00000260911.2 RP11-196G11.2 4.81 3.62e-06 0.00225 0.32 0.36 Dementia with Lewy bodies; chr16:31025046 chr16:31043150~31049868:+ PAAD cis rs10754283 0.967 rs1934044 ENSG00000231613.1 RP5-943J3.1 -4.81 3.62e-06 0.00225 -0.38 -0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89641942 chr1:89788914~89790492:+ PAAD cis rs17772222 0.74 rs61984675 ENSG00000258983.2 RP11-507K2.2 4.81 3.63e-06 0.00225 0.47 0.36 Coronary artery calcification; chr14:88511236 chr14:88499334~88515502:+ PAAD cis rs11089937 1 rs11089937 ENSG00000211639.2 IGLV4-60 4.81 3.63e-06 0.00225 0.34 0.36 Periodontitis (PAL4Q3); chr22:22152176 chr22:22162199~22162681:+ PAAD cis rs7829975 0.714 rs7823757 ENSG00000253893.2 FAM85B -4.81 3.63e-06 0.00225 -0.5 -0.36 Mood instability; chr8:8812667 chr8:8167819~8226614:- PAAD cis rs3823536 0.583 rs1072767 ENSG00000275106.1 RP11-309L24.10 -4.81 3.63e-06 0.00225 -0.49 -0.36 Sjögren's syndrome; chr7:129033151 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs6973975 ENSG00000275106.1 RP11-309L24.10 -4.81 3.63e-06 0.00225 -0.49 -0.36 Sjögren's syndrome; chr7:129035495 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs921403 ENSG00000275106.1 RP11-309L24.10 -4.81 3.63e-06 0.00225 -0.49 -0.36 Sjögren's syndrome; chr7:129036670 chr7:128952527~128953316:- PAAD cis rs6921919 0.583 rs9468370 ENSG00000204709.4 LINC01556 4.81 3.64e-06 0.00225 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28401163 chr6:28943877~28944537:+ PAAD cis rs9531006 0.636 rs996823 ENSG00000227676.3 LINC01068 4.81 3.64e-06 0.00226 0.53 0.36 Sleep duration; chr13:79884544 chr13:79566727~79571436:+ PAAD cis rs9531006 0.636 rs9601281 ENSG00000227676.3 LINC01068 4.81 3.64e-06 0.00226 0.53 0.36 Sleep duration; chr13:79886160 chr13:79566727~79571436:+ PAAD cis rs9531006 0.538 rs7329042 ENSG00000227676.3 LINC01068 4.81 3.64e-06 0.00226 0.53 0.36 Sleep duration; chr13:79886522 chr13:79566727~79571436:+ PAAD cis rs9531006 0.603 rs7329614 ENSG00000227676.3 LINC01068 4.81 3.64e-06 0.00226 0.53 0.36 Sleep duration; chr13:79886616 chr13:79566727~79571436:+ PAAD cis rs9531006 0.603 rs2007276 ENSG00000227676.3 LINC01068 4.81 3.64e-06 0.00226 0.53 0.36 Sleep duration; chr13:79887063 chr13:79566727~79571436:+ PAAD cis rs9531006 0.603 rs9593417 ENSG00000227676.3 LINC01068 4.81 3.64e-06 0.00226 0.53 0.36 Sleep duration; chr13:79887281 chr13:79566727~79571436:+ PAAD cis rs9531006 0.604 rs4884141 ENSG00000227676.3 LINC01068 4.81 3.64e-06 0.00226 0.53 0.36 Sleep duration; chr13:79888178 chr13:79566727~79571436:+ PAAD cis rs2274273 0.967 rs10137409 ENSG00000258413.1 RP11-665C16.6 -4.81 3.64e-06 0.00226 -0.47 -0.36 Protein biomarker; chr14:55144723 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs7140872 ENSG00000258413.1 RP11-665C16.6 -4.81 3.64e-06 0.00226 -0.47 -0.36 Protein biomarker; chr14:55146026 chr14:55262767~55272075:- PAAD cis rs4664293 0.585 rs13019325 ENSG00000226266.5 AC009961.3 4.81 3.64e-06 0.00226 0.47 0.36 Monocyte percentage of white cells; chr2:159772479 chr2:159670708~159712435:- PAAD cis rs367615 0.537 rs1965670 ENSG00000249476.1 CTD-2587M2.1 -4.81 3.65e-06 0.00226 -0.39 -0.36 Colorectal cancer (SNP x SNP interaction); chr5:109314097 chr5:109237120~109326369:- PAAD cis rs4938303 0.633 rs12800436 ENSG00000254851.1 RP11-109L13.1 4.81 3.65e-06 0.00226 0.64 0.36 Triglycerides; chr11:116688086 chr11:117135528~117138582:+ PAAD cis rs6921919 0.945 rs61289879 ENSG00000204709.4 LINC01556 4.81 3.65e-06 0.00226 0.63 0.36 Autism spectrum disorder or schizophrenia; chr6:28451385 chr6:28943877~28944537:+ PAAD cis rs6921919 0.848 rs9468350 ENSG00000216901.1 AL022393.7 4.81 3.65e-06 0.00226 0.53 0.36 Autism spectrum disorder or schizophrenia; chr6:28351330 chr6:28176188~28176674:+ PAAD cis rs6921919 0.525 rs16894095 ENSG00000216901.1 AL022393.7 4.81 3.66e-06 0.00227 0.47 0.36 Autism spectrum disorder or schizophrenia; chr6:28422453 chr6:28176188~28176674:+ PAAD cis rs7829975 0.5 rs7841082 ENSG00000253893.2 FAM85B 4.81 3.66e-06 0.00227 0.5 0.36 Mood instability; chr8:8311465 chr8:8167819~8226614:- PAAD cis rs7712401 0.623 rs7723798 ENSG00000263432.2 RN7SL689P 4.81 3.66e-06 0.00227 0.44 0.36 Mean platelet volume; chr5:123034022 chr5:123022487~123022783:- PAAD cis rs7615952 0.546 rs4428131 ENSG00000171084.14 FAM86JP 4.81 3.66e-06 0.00227 0.53 0.36 Blood pressure (smoking interaction); chr3:125627635 chr3:125916620~125930024:+ PAAD cis rs9287719 0.967 rs10929688 ENSG00000234818.1 AC092687.5 4.81 3.66e-06 0.00227 0.4 0.36 Prostate cancer; chr2:10616524 chr2:10589166~10604830:+ PAAD cis rs6844153 0.752 rs28497454 ENSG00000240005.4 RP11-293A21.1 -4.81 3.66e-06 0.00227 -0.51 -0.36 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26906230 chr4:26859806~26860599:- PAAD cis rs748404 0.56 rs2255663 ENSG00000205771.5 CATSPER2P1 4.81 3.67e-06 0.00227 0.5 0.36 Lung cancer; chr15:43536810 chr15:43726918~43747094:- PAAD cis rs453301 0.653 rs7853 ENSG00000254340.1 RP11-10A14.3 4.81 3.67e-06 0.00227 0.43 0.36 Joint mobility (Beighton score); chr8:9033304 chr8:9141424~9145435:+ PAAD cis rs1185460 1 rs1784305 ENSG00000271751.1 RP11-110I1.14 -4.81 3.68e-06 0.00228 -0.46 -0.36 Coronary artery disease; chr11:119071338 chr11:119065263~119065677:- PAAD cis rs11214589 0.747 rs7939992 ENSG00000270179.1 RP11-159N11.4 -4.8 3.68e-06 0.00228 -0.39 -0.36 Neuroticism; chr11:113358943 chr11:113368478~113369117:+ PAAD cis rs9322193 0.772 rs7738696 ENSG00000268592.3 RAET1E-AS1 4.8 3.69e-06 0.00228 0.45 0.36 Lung cancer; chr6:149848985 chr6:149863494~149919507:+ PAAD cis rs9532669 0.926 rs7329302 ENSG00000176268.5 CYCSP34 -4.8 3.69e-06 0.00228 -0.34 -0.36 Cervical cancer; chr13:40962396 chr13:40863599~40863902:- PAAD cis rs6565180 0.791 rs4247355 ENSG00000183604.13 SMG1P5 4.8 3.7e-06 0.00229 0.4 0.36 Tonsillectomy; chr16:30380778 chr16:30267553~30335374:- PAAD cis rs6565180 0.926 rs4787643 ENSG00000183604.13 SMG1P5 4.8 3.7e-06 0.00229 0.4 0.36 Tonsillectomy; chr16:30382339 chr16:30267553~30335374:- PAAD cis rs6565180 0.926 rs4788409 ENSG00000183604.13 SMG1P5 4.8 3.7e-06 0.00229 0.4 0.36 Tonsillectomy; chr16:30382450 chr16:30267553~30335374:- PAAD cis rs8059260 0.736 rs16957836 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10959229 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs3871209 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10962907 chr16:11056556~11057034:+ PAAD cis rs8059260 0.673 rs74985998 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10967208 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs8049278 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10968766 chr16:11056556~11057034:+ PAAD cis rs8059260 0.668 rs16957855 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10977116 chr16:11056556~11057034:+ PAAD cis rs8059260 0.668 rs75637865 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10982439 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs78121798 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10984224 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs7202408 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10984758 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs113120936 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10989474 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs12149904 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10991789 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs16957883 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10994788 chr16:11056556~11057034:+ PAAD cis rs8059260 0.668 rs16957894 ENSG00000274038.1 RP11-66H6.4 -4.8 3.7e-06 0.00229 -0.61 -0.36 Alcohol consumption over the past year; chr16:10996501 chr16:11056556~11057034:+ PAAD cis rs4664293 0.647 rs7587700 ENSG00000226266.5 AC009961.3 -4.8 3.7e-06 0.00229 -0.45 -0.36 Monocyte percentage of white cells; chr2:159587809 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs7595044 ENSG00000226266.5 AC009961.3 -4.8 3.7e-06 0.00229 -0.45 -0.36 Monocyte percentage of white cells; chr2:159589694 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs12623149 ENSG00000226266.5 AC009961.3 -4.8 3.7e-06 0.00229 -0.45 -0.36 Monocyte percentage of white cells; chr2:159590835 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs6432539 ENSG00000226266.5 AC009961.3 -4.8 3.7e-06 0.00229 -0.45 -0.36 Monocyte percentage of white cells; chr2:159592209 chr2:159670708~159712435:- PAAD cis rs4664293 0.631 rs6714899 ENSG00000226266.5 AC009961.3 -4.8 3.7e-06 0.00229 -0.45 -0.36 Monocyte percentage of white cells; chr2:159592895 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs6714917 ENSG00000226266.5 AC009961.3 -4.8 3.7e-06 0.00229 -0.45 -0.36 Monocyte percentage of white cells; chr2:159592942 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs4665090 ENSG00000226266.5 AC009961.3 -4.8 3.7e-06 0.00229 -0.45 -0.36 Monocyte percentage of white cells; chr2:159597396 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs4635484 ENSG00000226266.5 AC009961.3 -4.8 3.7e-06 0.00229 -0.45 -0.36 Monocyte percentage of white cells; chr2:159597619 chr2:159670708~159712435:- PAAD cis rs7208859 0.673 rs11651802 ENSG00000266490.1 CTD-2349P21.9 4.8 3.7e-06 0.00229 0.5 0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832642 chr17:30792372~30792833:+ PAAD cis rs9287719 0.837 rs4233882 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.41 0.36 Prostate cancer; chr2:10615438 chr2:10589166~10604830:+ PAAD cis rs9287719 0.837 rs4331474 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.41 0.36 Prostate cancer; chr2:10615457 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs715247 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10596165 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs715246 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10596229 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs2010073 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10596352 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs2010080 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10596426 chr2:10589166~10604830:+ PAAD cis rs9287719 0.901 rs6432109 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10596695 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7592691 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10597300 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs6432110 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10597892 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7605461 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10598008 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7593496 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10598050 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7608498 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10598302 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7582775 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10598323 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6750891 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10598437 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6733416 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10598558 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6751398 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10598846 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4519489 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10598961 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4453662 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599002 chr2:10589166~10604830:+ PAAD cis rs9287719 0.901 rs13034017 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599466 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs13034061 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599525 chr2:10589166~10604830:+ PAAD cis rs9287719 0.935 rs7600495 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599674 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7600587 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599725 chr2:10589166~10604830:+ PAAD cis rs9287719 0.839 rs7600695 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599819 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7587114 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599837 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7600728 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599873 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7600820 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599918 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7587231 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10599967 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4668691 ENSG00000234818.1 AC092687.5 4.8 3.7e-06 0.00229 0.4 0.36 Prostate cancer; chr2:10600368 chr2:10589166~10604830:+ PAAD cis rs2255336 0.938 rs12315123 ENSG00000245648.1 RP11-277P12.20 -4.8 3.71e-06 0.00229 -0.58 -0.36 Blood protein levels; chr12:10481540 chr12:10363769~10398506:+ PAAD cis rs6504950 0.889 rs2628301 ENSG00000275710.1 RP11-257O5.4 -4.8 3.71e-06 0.00229 -0.49 -0.36 Breast cancer; chr17:55081912 chr17:54964474~54964679:+ PAAD cis rs11089937 0.626 rs5757051 ENSG00000211639.2 IGLV4-60 -4.8 3.71e-06 0.00229 -0.38 -0.36 Periodontitis (PAL4Q3); chr22:22141753 chr22:22162199~22162681:+ PAAD cis rs17023223 0.537 rs12092807 ENSG00000231365.4 RP11-418J17.1 4.8 3.71e-06 0.00229 0.43 0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119208021 chr1:119140396~119275973:+ PAAD cis rs9549328 0.8 rs9549619 ENSG00000267868.1 RP11-120K24.3 4.8 3.72e-06 0.00229 0.4 0.36 Systolic blood pressure; chr13:112978306 chr13:112964835~112966131:- PAAD cis rs2348418 0.647 rs10843210 ENSG00000247934.4 RP11-967K21.1 4.8 3.72e-06 0.00229 0.35 0.36 Lung function (FEV1);Lung function (FVC); chr12:28575800 chr12:28163298~28190738:- PAAD cis rs17772222 0.74 rs11847417 ENSG00000258983.2 RP11-507K2.2 -4.8 3.72e-06 0.0023 -0.47 -0.36 Coronary artery calcification; chr14:88510606 chr14:88499334~88515502:+ PAAD cis rs944722 0.623 rs9913854 ENSG00000266786.1 LGALS9DP 4.8 3.72e-06 0.0023 0.39 0.36 Fractional exhaled nitric oxide (childhood); chr17:27735336 chr17:27746132~27754954:+ PAAD cis rs2015599 0.623 rs7313552 ENSG00000257176.2 RP11-996F15.2 4.8 3.73e-06 0.0023 0.37 0.36 Platelet count;Mean platelet volume; chr12:29277302 chr12:29280418~29317848:- PAAD cis rs7772486 0.806 rs2253648 ENSG00000235652.6 RP11-545I5.3 4.8 3.73e-06 0.0023 0.3 0.36 Lobe attachment (rater-scored or self-reported); chr6:145878160 chr6:145799409~145886585:+ PAAD cis rs2277027 0.518 rs73309982 ENSG00000251405.2 CTB-109A12.1 4.8 3.74e-06 0.00231 0.46 0.36 Pulmonary function;Pulmonary function (smoking interaction); chr5:157505140 chr5:157362615~157460078:- PAAD cis rs1962636 1 rs1962636 ENSG00000260306.1 RP11-645C24.5 -4.8 3.74e-06 0.00231 -0.34 -0.36 Schizophrenia; chr16:22053074 chr16:21794095~21795759:- PAAD cis rs10486158 0.521 rs7803541 ENSG00000155070.8 UNC93B2 -4.8 3.74e-06 0.00231 -0.43 -0.36 Bipolar disorder and schizophrenia; chr7:7388011 chr7:6855485~6859830:- PAAD cis rs12554020 0.786 rs7036984 ENSG00000227603.1 RP11-165J3.6 4.8 3.74e-06 0.00231 0.56 0.36 Schizophrenia; chr9:93438258 chr9:93435332~93437121:- PAAD cis rs12554020 0.892 rs7028729 ENSG00000227603.1 RP11-165J3.6 4.8 3.74e-06 0.00231 0.56 0.36 Schizophrenia; chr9:93443206 chr9:93435332~93437121:- PAAD cis rs2188561 0.638 rs3735609 ENSG00000241764.3 AC002467.7 4.8 3.74e-06 0.00231 0.47 0.36 Alcohol consumption; chr7:107743299 chr7:107742817~107744581:- PAAD cis rs2188561 0.697 rs3735607 ENSG00000241764.3 AC002467.7 4.8 3.74e-06 0.00231 0.47 0.36 Alcohol consumption; chr7:107743833 chr7:107742817~107744581:- PAAD cis rs919433 1 rs7422899 ENSG00000231621.1 AC013264.2 4.8 3.75e-06 0.00231 0.35 0.36 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197298803 chr2:197197991~197199273:+ PAAD cis rs2274273 0.905 rs8007620 ENSG00000258413.1 RP11-665C16.6 -4.8 3.75e-06 0.00231 -0.47 -0.36 Protein biomarker; chr14:55119869 chr14:55262767~55272075:- PAAD cis rs7829975 0.536 rs2980439 ENSG00000253981.4 ALG1L13P 4.8 3.75e-06 0.00232 0.44 0.36 Mood instability; chr8:8237348 chr8:8236003~8244667:- PAAD cis rs9828933 0.882 rs3733127 ENSG00000280620.1 SCAANT1 4.8 3.75e-06 0.00232 0.64 0.36 Type 2 diabetes; chr3:64002498 chr3:63911518~63911772:- PAAD cis rs4664293 0.737 rs1549579 ENSG00000226266.5 AC009961.3 -4.8 3.75e-06 0.00232 -0.44 -0.36 Monocyte percentage of white cells; chr2:159812150 chr2:159670708~159712435:- PAAD cis rs2882667 0.66 rs6894907 ENSG00000253404.1 AC034243.1 4.8 3.76e-06 0.00232 0.42 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139106815 chr5:138744434~138753309:- PAAD cis rs2333194 0.772 rs8009466 ENSG00000258695.2 RP3-414A15.2 -4.8 3.77e-06 0.00232 -0.4 -0.36 Bipolar disorder with mood-incongruent psychosis; chr14:73365605 chr14:73522878~73530610:+ PAAD cis rs2153535 0.563 rs1737584 ENSG00000230939.1 RP11-314C16.1 -4.8 3.77e-06 0.00232 -0.38 -0.36 Motion sickness; chr6:8536509 chr6:8784178~8785445:+ PAAD cis rs2153535 0.505 rs1737583 ENSG00000230939.1 RP11-314C16.1 -4.8 3.77e-06 0.00232 -0.38 -0.36 Motion sickness; chr6:8536579 chr6:8784178~8785445:+ PAAD cis rs7773456 0.711 rs9358277 ENSG00000228412.5 RP4-625H18.2 -4.8 3.77e-06 0.00233 -0.51 -0.36 Lupus nephritis in systemic lupus erythematosus; chr6:19816398 chr6:19802164~19804752:- PAAD cis rs2404602 0.684 rs57682236 ENSG00000259422.1 RP11-593F23.1 -4.8 3.77e-06 0.00233 -0.45 -0.36 Blood metabolite levels; chr15:76576137 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs12898810 ENSG00000259422.1 RP11-593F23.1 -4.8 3.77e-06 0.00233 -0.45 -0.36 Blood metabolite levels; chr15:76612397 chr15:76174891~76181486:- PAAD cis rs3779195 0.929 rs2906184 ENSG00000272950.1 RP11-307C18.1 -4.8 3.77e-06 0.00233 -0.6 -0.36 Sex hormone-binding globulin levels; chr7:98310675 chr7:98322853~98323430:+ PAAD cis rs2404602 0.647 rs36114653 ENSG00000259422.1 RP11-593F23.1 -4.8 3.78e-06 0.00233 -0.44 -0.36 Blood metabolite levels; chr15:76733052 chr15:76174891~76181486:- PAAD cis rs6921919 0.583 rs1054372 ENSG00000204709.4 LINC01556 4.8 3.78e-06 0.00233 0.52 0.36 Autism spectrum disorder or schizophrenia; chr6:28368965 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs9468354 ENSG00000204709.4 LINC01556 4.8 3.78e-06 0.00233 0.52 0.36 Autism spectrum disorder or schizophrenia; chr6:28370024 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs7773051 ENSG00000204709.4 LINC01556 4.8 3.78e-06 0.00233 0.52 0.36 Autism spectrum disorder or schizophrenia; chr6:28372539 chr6:28943877~28944537:+ PAAD cis rs950027 0.62 rs1153860 ENSG00000259433.2 CTD-2651B20.4 4.8 3.8e-06 0.00234 0.41 0.36 Response to fenofibrate (adiponectin levels); chr15:45344386 chr15:45330209~45332634:- PAAD cis rs4853525 0.59 rs13399044 ENSG00000235852.1 AC005540.3 4.8 3.81e-06 0.00235 0.54 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190944844 chr2:190880797~190882059:- PAAD cis rs9531006 0.571 rs12583025 ENSG00000227676.3 LINC01068 4.8 3.81e-06 0.00235 0.57 0.36 Sleep duration; chr13:79930017 chr13:79566727~79571436:+ PAAD cis rs2337406 0.866 rs8003852 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106776648 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs988131 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106776833 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs8005518 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106777009 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs988130 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106777154 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs57684263 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106777263 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs7152038 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106778230 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs7152809 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106778385 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs7152832 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106778427 chr14:106723574~106724093:- PAAD cis rs2337406 0.5 rs7152934 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106778702 chr14:106723574~106724093:- PAAD cis rs2337406 0.789 rs12050392 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106779073 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74092505 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106779163 chr14:106723574~106724093:- PAAD cis rs2337406 0.789 rs74092507 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106779174 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74092511 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106779234 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74092512 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106779306 chr14:106723574~106724093:- PAAD cis rs2337406 0.789 rs74092514 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106779385 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74092520 ENSG00000211974.3 IGHV2-70 -4.8 3.82e-06 0.00235 -0.47 -0.36 Alzheimer's disease (late onset); chr14:106779632 chr14:106723574~106724093:- PAAD cis rs7615952 0.546 rs2922194 ENSG00000171084.14 FAM86JP 4.8 3.82e-06 0.00235 0.54 0.36 Blood pressure (smoking interaction); chr3:125613419 chr3:125916620~125930024:+ PAAD cis rs17023223 0.537 rs12097967 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119160290 chr1:119140396~119275973:+ PAAD cis rs17023223 0.553 rs56234947 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119165121 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs6677107 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119166142 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs12064033 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119166935 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs12064137 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119167126 chr1:119140396~119275973:+ PAAD cis rs17023223 0.509 rs61806978 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119170592 chr1:119140396~119275973:+ PAAD cis rs17023223 0.509 rs56195272 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119171374 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs12065809 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119181912 chr1:119140396~119275973:+ PAAD cis rs17023223 0.553 rs11484962 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182563 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs55836852 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182778 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs66715579 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119182809 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs11487668 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119184173 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs10923766 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119184309 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs61806983 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119188901 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs12087987 ENSG00000231365.4 RP11-418J17.1 -4.8 3.82e-06 0.00235 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119192198 chr1:119140396~119275973:+ PAAD cis rs732716 0.752 rs11085072 ENSG00000267769.1 CTB-50L17.9 -4.8 3.82e-06 0.00235 -0.52 -0.36 Mean corpuscular volume; chr19:4368145 chr19:4454014~4455286:+ PAAD cis rs6921919 0.583 rs2027361 ENSG00000204709.4 LINC01556 4.8 3.82e-06 0.00235 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28420531 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs4642462 ENSG00000204709.4 LINC01556 4.8 3.82e-06 0.00235 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28421474 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs3800328 ENSG00000204709.4 LINC01556 4.8 3.82e-06 0.00235 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28423066 chr6:28943877~28944537:+ PAAD cis rs6921919 0.609 rs67211468 ENSG00000204709.4 LINC01556 4.8 3.82e-06 0.00235 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28424210 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs35560946 ENSG00000204709.4 LINC01556 4.8 3.82e-06 0.00235 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28427660 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs740621 ENSG00000204709.4 LINC01556 4.8 3.82e-06 0.00235 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28430010 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs740622 ENSG00000204709.4 LINC01556 4.8 3.82e-06 0.00235 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28430514 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs16894108 ENSG00000204709.4 LINC01556 4.8 3.82e-06 0.00235 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28434013 chr6:28943877~28944537:+ PAAD cis rs7829975 0.514 rs2920991 ENSG00000253893.2 FAM85B -4.8 3.83e-06 0.00236 -0.49 -0.36 Mood instability; chr8:8401607 chr8:8167819~8226614:- PAAD cis rs13178541 0.81 rs7379060 ENSG00000250378.1 RP11-119J18.1 -4.8 3.83e-06 0.00236 -0.58 -0.36 IgG glycosylation; chr5:135745789 chr5:135812667~135826582:+ PAAD cis rs4664293 0.609 rs10209829 ENSG00000226266.5 AC009961.3 -4.8 3.84e-06 0.00236 -0.45 -0.36 Monocyte percentage of white cells; chr2:159591113 chr2:159670708~159712435:- PAAD cis rs13178541 0.81 rs11743994 ENSG00000250378.1 RP11-119J18.1 -4.8 3.84e-06 0.00236 -0.57 -0.36 IgG glycosylation; chr5:135741104 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs7379050 ENSG00000250378.1 RP11-119J18.1 -4.8 3.84e-06 0.00236 -0.57 -0.36 IgG glycosylation; chr5:135745702 chr5:135812667~135826582:+ PAAD cis rs4950322 0.542 rs72692942 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147318467 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs113498894 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147318880 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4950399 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147319302 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4950401 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147319571 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4950402 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147319684 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4950403 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147319723 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4950404 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147319834 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692946 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147319966 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692948 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147320298 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692951 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147320551 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs77118461 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147320718 chr1:147258885~147517875:- PAAD cis rs4950322 0.517 rs116479391 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147320940 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs78681047 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147321013 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692953 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147321416 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs80070044 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147330238 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692963 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147331090 chr1:147258885~147517875:- PAAD cis rs4950322 0.518 rs72692965 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147332085 chr1:147258885~147517875:- PAAD cis rs4950322 0.518 rs72692968 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147332884 chr1:147258885~147517875:- PAAD cis rs4950322 0.518 rs72692970 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147332887 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692971 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147333088 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692973 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147333281 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692975 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147333506 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4950409 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147335879 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692979 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147336094 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72692980 ENSG00000278811.3 LINC00624 4.79 3.84e-06 0.00236 0.38 0.36 Protein quantitative trait loci; chr1:147337830 chr1:147258885~147517875:- PAAD cis rs34375054 0.558 rs12578774 ENSG00000279233.1 RP11-158L12.4 -4.79 3.84e-06 0.00236 -0.3 -0.36 Post bronchodilator FEV1/FVC ratio; chr12:125197215 chr12:125138245~125141711:+ PAAD cis rs1823913 1 rs1823913 ENSG00000280083.1 RP11-317J9.1 -4.79 3.85e-06 0.00236 -0.46 -0.36 Obesity-related traits; chr2:191253321 chr2:191154118~191156070:- PAAD cis rs748404 0.723 rs11853991 ENSG00000249839.1 AC011330.5 -4.79 3.85e-06 0.00236 -0.51 -0.36 Lung cancer; chr15:43265351 chr15:43663654~43684339:- PAAD cis rs12468226 1 rs111542497 ENSG00000273456.1 RP11-686O6.2 4.79 3.85e-06 0.00236 0.52 0.36 Urate levels; chr2:202330369 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs77435512 ENSG00000273456.1 RP11-686O6.2 4.79 3.85e-06 0.00236 0.52 0.36 Urate levels; chr2:202334165 chr2:202374932~202375604:- PAAD cis rs4835473 0.897 rs62337587 ENSG00000251600.4 RP11-673E1.1 -4.79 3.85e-06 0.00237 -0.41 -0.36 Immature fraction of reticulocytes; chr4:143725839 chr4:143912331~143982454:+ PAAD cis rs964611 0.882 rs6493317 ENSG00000259488.2 RP11-154J22.1 -4.79 3.86e-06 0.00237 -0.4 -0.36 Metabolite levels (Pyroglutamine); chr15:48275959 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs6493318 ENSG00000259488.2 RP11-154J22.1 -4.79 3.86e-06 0.00237 -0.4 -0.36 Metabolite levels (Pyroglutamine); chr15:48276062 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs6493319 ENSG00000259488.2 RP11-154J22.1 -4.79 3.86e-06 0.00237 -0.4 -0.36 Metabolite levels (Pyroglutamine); chr15:48276071 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4325499 ENSG00000259488.2 RP11-154J22.1 -4.79 3.86e-06 0.00237 -0.4 -0.36 Metabolite levels (Pyroglutamine); chr15:48289551 chr15:48312353~48331856:- PAAD cis rs964611 0.872 rs6493320 ENSG00000259488.2 RP11-154J22.1 -4.79 3.86e-06 0.00237 -0.4 -0.36 Metabolite levels (Pyroglutamine); chr15:48290070 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs6493321 ENSG00000259488.2 RP11-154J22.1 -4.79 3.86e-06 0.00237 -0.4 -0.36 Metabolite levels (Pyroglutamine); chr15:48290117 chr15:48312353~48331856:- PAAD cis rs875971 0.545 rs2707851 ENSG00000226824.5 RP4-756H11.3 4.79 3.86e-06 0.00237 0.52 0.36 Aortic root size; chr7:66624178 chr7:66654538~66669855:+ PAAD cis rs9531006 0.636 rs3861143 ENSG00000227676.3 LINC01068 4.79 3.87e-06 0.00237 0.54 0.36 Sleep duration; chr13:79916467 chr13:79566727~79571436:+ PAAD cis rs3020264 0.638 rs2980655 ENSG00000271743.1 CTD-2541M15.3 -4.79 3.87e-06 0.00238 -0.52 -0.36 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6634870 chr8:6615604~6617198:- PAAD cis rs3020264 0.638 rs3020266 ENSG00000271743.1 CTD-2541M15.3 -4.79 3.87e-06 0.00238 -0.52 -0.36 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6634977 chr8:6615604~6617198:- PAAD cis rs10754283 0.901 rs10922684 ENSG00000231613.1 RP5-943J3.1 4.79 3.87e-06 0.00238 0.39 0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89652375 chr1:89788914~89790492:+ PAAD cis rs1322639 0.614 rs6937001 ENSG00000261039.2 RP11-417E7.2 4.79 3.88e-06 0.00238 0.59 0.36 Pulse pressure; chr6:169164991 chr6:169175304~169182740:- PAAD cis rs7772486 0.902 rs1125462 ENSG00000235652.6 RP11-545I5.3 4.79 3.88e-06 0.00238 0.3 0.36 Lobe attachment (rater-scored or self-reported); chr6:146096696 chr6:145799409~145886585:+ PAAD cis rs7829975 0.774 rs35431455 ENSG00000253893.2 FAM85B -4.79 3.88e-06 0.00238 -0.5 -0.36 Mood instability; chr8:8816226 chr8:8167819~8226614:- PAAD cis rs992157 0.643 rs10191283 ENSG00000261338.2 RP11-378A13.1 4.79 3.88e-06 0.00238 0.41 0.36 Colorectal cancer; chr2:218192032 chr2:218255319~218257366:+ PAAD cis rs9287719 0.967 rs6748036 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10577363 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4284804 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10581998 chr2:10589166~10604830:+ PAAD cis rs9287719 0.935 rs10803723 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10582751 chr2:10589166~10604830:+ PAAD cis rs9287719 0.935 rs6751075 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10583420 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs12622765 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10588205 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs759402 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10589428 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs759403 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10589771 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs11674433 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10590713 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs2024431 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10591201 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs10929682 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10592063 chr2:10589166~10604830:+ PAAD cis rs9287719 0.901 rs10210859 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10593803 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs10181806 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10601015 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs11687023 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10601286 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs10454738 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10601923 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6706542 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10602365 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs2287061 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10603027 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs2287062 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10603065 chr2:10589166~10604830:+ PAAD cis rs9287719 0.935 rs1309 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10603420 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs3815521 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10603528 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs10929686 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10603579 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4470306 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10603872 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4613248 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10603925 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs10191883 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10604010 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs4629131 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10604033 chr2:10589166~10604830:+ PAAD cis rs9287719 0.901 rs4555317 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10604121 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4555318 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10604169 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs4622695 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10604201 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs6432111 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10604494 chr2:10589166~10604830:+ PAAD cis rs9287719 0.87 rs728135 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10605006 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs963831 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10605058 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs728134 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10605061 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs2884233 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10605177 chr2:10589166~10604830:+ PAAD cis rs9287719 0.839 rs12692415 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10605348 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs12692416 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10605501 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs12692417 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10605592 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs12692418 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10605744 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6755548 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10606000 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6761678 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10606215 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6759100 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10606584 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6759714 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10607081 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6744854 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10607120 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6759740 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10607145 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6709466 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10608131 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6719701 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10608157 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs6432115 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10608217 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6432116 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10608489 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs2110776 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10608684 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs2110778 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10608844 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6432117 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10609233 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6432118 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10609315 chr2:10589166~10604830:+ PAAD cis rs9287719 0.935 rs728283 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10609964 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs728282 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10610177 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs728281 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10610229 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs6721510 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10610920 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6721514 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10610936 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs6706763 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10611281 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs10203664 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10612251 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs10201077 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10612300 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs10203785 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10612382 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs9287720 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10612538 chr2:10589166~10604830:+ PAAD cis rs9287719 0.87 rs10167676 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10613014 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs12995159 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10613197 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs12995602 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10613416 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6432119 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10613561 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6432120 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10613645 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6432122 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10613718 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6712304 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10614249 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6712406 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10614294 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs10195802 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10614406 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7566875 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10614666 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs4371336 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10615597 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4405729 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10615653 chr2:10589166~10604830:+ PAAD cis rs9287719 0.839 rs11683335 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10616539 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6432126 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10616975 chr2:10589166~10604830:+ PAAD cis rs9287719 0.904 rs55738250 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10617006 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6727768 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10617353 chr2:10589166~10604830:+ PAAD cis rs9287719 0.934 rs6710033 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10617551 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4669598 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10617712 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs4669599 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10617903 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs10167129 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10618449 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs12467642 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10621358 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs12464908 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10621370 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7563816 ENSG00000234818.1 AC092687.5 4.79 3.88e-06 0.00238 0.4 0.36 Prostate cancer; chr2:10623274 chr2:10589166~10604830:+ PAAD cis rs7208859 0.673 rs999796 ENSG00000266490.1 CTD-2349P21.9 4.79 3.88e-06 0.00238 0.44 0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832386 chr17:30792372~30792833:+ PAAD cis rs2243480 1 rs410128 ENSG00000226824.5 RP4-756H11.3 -4.79 3.89e-06 0.00238 -0.68 -0.36 Diabetic kidney disease; chr7:66138186 chr7:66654538~66669855:+ PAAD cis rs8055167 1 rs8055167 ENSG00000280152.1 RP11-331F4.5 4.79 3.89e-06 0.00239 0.37 0.36 Alcoholic chronic pancreatitis; chr16:75220991 chr16:75245994~75250077:- PAAD cis rs919433 0.926 rs12618567 ENSG00000231621.1 AC013264.2 4.79 3.9e-06 0.00239 0.35 0.36 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197283467 chr2:197197991~197199273:+ PAAD cis rs17265703 0.524 rs12107092 ENSG00000272758.4 RP11-299J3.8 4.79 3.91e-06 0.00239 0.49 0.36 Phosphorus levels; chr3:122405001 chr3:122416207~122443180:+ PAAD cis rs5760092 0.842 rs5751763 ENSG00000099984.9 GSTT2 -4.79 3.91e-06 0.00239 -0.6 -0.36 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23905606 chr22:23980123~23983911:+ PAAD cis rs4835473 0.8 rs1849134 ENSG00000251600.4 RP11-673E1.1 4.79 3.91e-06 0.00239 0.42 0.36 Immature fraction of reticulocytes; chr4:143958260 chr4:143912331~143982454:+ PAAD cis rs4835473 0.8 rs1849133 ENSG00000251600.4 RP11-673E1.1 4.79 3.91e-06 0.00239 0.42 0.36 Immature fraction of reticulocytes; chr4:143958262 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs1849132 ENSG00000251600.4 RP11-673E1.1 4.79 3.91e-06 0.00239 0.42 0.36 Immature fraction of reticulocytes; chr4:143958309 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13123407 ENSG00000251600.4 RP11-673E1.1 4.79 3.91e-06 0.00239 0.42 0.36 Immature fraction of reticulocytes; chr4:143958713 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs61611095 ENSG00000251600.4 RP11-673E1.1 4.79 3.91e-06 0.00239 0.42 0.36 Immature fraction of reticulocytes; chr4:143958802 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs4835449 ENSG00000251600.4 RP11-673E1.1 4.79 3.91e-06 0.00239 0.42 0.36 Immature fraction of reticulocytes; chr4:143958830 chr4:143912331~143982454:+ PAAD cis rs4835473 0.771 rs4835097 ENSG00000251600.4 RP11-673E1.1 4.79 3.91e-06 0.00239 0.42 0.36 Immature fraction of reticulocytes; chr4:143960687 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1838516 ENSG00000251600.4 RP11-673E1.1 4.79 3.91e-06 0.00239 0.42 0.36 Immature fraction of reticulocytes; chr4:143962082 chr4:143912331~143982454:+ PAAD cis rs6921919 0.583 rs9468355 ENSG00000204709.4 LINC01556 4.79 3.91e-06 0.0024 0.53 0.36 Autism spectrum disorder or schizophrenia; chr6:28374100 chr6:28943877~28944537:+ PAAD cis rs875971 0.522 rs4718286 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Aortic root size; chr7:65827777 chr7:65038354~65074713:+ PAAD cis rs17711722 0.585 rs6942660 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Calcium levels; chr7:65837419 chr7:65038354~65074713:+ PAAD cis rs875971 0.516 rs6945322 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Aortic root size; chr7:65871069 chr7:65038354~65074713:+ PAAD cis rs17711722 0.701 rs55773927 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Calcium levels; chr7:65872915 chr7:65038354~65074713:+ PAAD cis rs17711722 0.727 rs35850374 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Calcium levels; chr7:65892789 chr7:65038354~65074713:+ PAAD cis rs17711722 0.701 rs4467826 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Calcium levels; chr7:65903721 chr7:65038354~65074713:+ PAAD cis rs875971 0.522 rs7784623 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Aortic root size; chr7:65930047 chr7:65038354~65074713:+ PAAD cis rs875971 0.522 rs34973832 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Aortic root size; chr7:65931217 chr7:65038354~65074713:+ PAAD cis rs17711722 0.74 rs7809991 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Calcium levels; chr7:65941231 chr7:65038354~65074713:+ PAAD cis rs875971 0.522 rs6960048 ENSG00000234585.5 CCT6P3 4.79 3.92e-06 0.0024 0.29 0.36 Aortic root size; chr7:65943052 chr7:65038354~65074713:+ PAAD cis rs734999 0.549 rs2764845 ENSG00000225931.3 RP3-395M20.7 -4.79 3.93e-06 0.0024 -0.34 -0.36 Ulcerative colitis; chr1:2597560 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs2843403 ENSG00000225931.3 RP3-395M20.7 -4.79 3.93e-06 0.0024 -0.34 -0.36 Ulcerative colitis; chr1:2597658 chr1:2566410~2569888:+ PAAD cis rs734999 0.549 rs2764840 ENSG00000225931.3 RP3-395M20.7 -4.79 3.93e-06 0.0024 -0.34 -0.36 Ulcerative colitis; chr1:2597998 chr1:2566410~2569888:+ PAAD cis rs2153535 0.58 rs2327051 ENSG00000230939.1 RP11-314C16.1 4.79 3.93e-06 0.0024 0.39 0.36 Motion sickness; chr6:8440917 chr6:8784178~8785445:+ PAAD cis rs7078219 0.505 rs41290504 ENSG00000257582.4 LINC01475 -4.79 3.93e-06 0.0024 -0.4 -0.36 Dental caries; chr10:99533278 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs7908704 ENSG00000257582.4 LINC01475 -4.79 3.93e-06 0.0024 -0.4 -0.36 Dental caries; chr10:99533561 chr10:99526350~99531177:- PAAD cis rs7078219 0.505 rs7893840 ENSG00000257582.4 LINC01475 -4.79 3.93e-06 0.0024 -0.4 -0.36 Dental caries; chr10:99533584 chr10:99526350~99531177:- PAAD cis rs2274273 0.87 rs59629906 ENSG00000258413.1 RP11-665C16.6 -4.79 3.93e-06 0.0024 -0.46 -0.36 Protein biomarker; chr14:55314471 chr14:55262767~55272075:- PAAD cis rs7684253 0.548 rs922570 ENSG00000269949.1 RP11-738E22.3 -4.79 3.93e-06 0.00241 -0.48 -0.36 Migraine; chr4:56851192 chr4:56960927~56961373:- PAAD cis rs10463554 0.853 rs246903 ENSG00000175749.11 EIF3KP1 4.79 3.94e-06 0.00241 0.47 0.36 Parkinson's disease; chr5:103253753 chr5:103032376~103033031:+ PAAD cis rs2283792 0.935 rs5750113 ENSG00000228050.1 TOP3BP1 4.79 3.94e-06 0.00241 0.39 0.36 Multiple sclerosis; chr22:21865784 chr22:22223187~22224566:- PAAD cis rs2599510 0.811 rs176413 ENSG00000276334.1 AL133243.1 -4.79 3.94e-06 0.00241 -0.42 -0.36 Interleukin-18 levels; chr2:32421779 chr2:32521927~32523547:+ PAAD cis rs1823913 0.637 rs12992372 ENSG00000280083.1 RP11-317J9.1 -4.79 3.94e-06 0.00241 -0.45 -0.36 Obesity-related traits; chr2:191289251 chr2:191154118~191156070:- PAAD cis rs11089937 0.568 rs11089919 ENSG00000211639.2 IGLV4-60 4.79 3.95e-06 0.00241 0.38 0.36 Periodontitis (PAL4Q3); chr22:22131648 chr22:22162199~22162681:+ PAAD cis rs2108622 1 rs55744319 ENSG00000267453.5 AC004791.2 -4.79 3.95e-06 0.00241 -0.54 -0.36 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15871011 chr19:15851993~15864904:- PAAD cis rs4853525 0.62 rs6751868 ENSG00000235852.1 AC005540.3 4.79 3.95e-06 0.00242 0.53 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190877222 chr2:190880797~190882059:- PAAD cis rs763567 0.933 rs608930 ENSG00000271811.1 RP1-79C4.4 4.79 3.95e-06 0.00242 0.35 0.36 Tonsillectomy; chr1:170648165 chr1:170667381~170669425:+ PAAD cis rs710913 0.717 rs1180349 ENSG00000237624.1 OXCT2P1 -4.79 3.96e-06 0.00242 -0.45 -0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39540380 chr1:39514956~39516490:+ PAAD cis rs710913 0.691 rs1180351 ENSG00000237624.1 OXCT2P1 -4.79 3.96e-06 0.00242 -0.45 -0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39541605 chr1:39514956~39516490:+ PAAD cis rs710913 0.717 rs1180352 ENSG00000237624.1 OXCT2P1 -4.79 3.96e-06 0.00242 -0.45 -0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39542157 chr1:39514956~39516490:+ PAAD cis rs710913 0.745 rs1180334 ENSG00000237624.1 OXCT2P1 -4.79 3.96e-06 0.00242 -0.45 -0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39555972 chr1:39514956~39516490:+ PAAD cis rs7712401 0.56 rs13168225 ENSG00000263432.2 RN7SL689P -4.79 3.97e-06 0.00242 -0.47 -0.36 Mean platelet volume; chr5:123011569 chr5:123022487~123022783:- PAAD cis rs4835473 0.9 rs935732 ENSG00000251600.4 RP11-673E1.1 -4.79 3.97e-06 0.00242 -0.41 -0.36 Immature fraction of reticulocytes; chr4:143759164 chr4:143912331~143982454:+ PAAD cis rs4218 0.593 rs8040456 ENSG00000277144.1 RP11-59H7.4 -4.79 3.97e-06 0.00243 -0.48 -0.36 Social communication problems; chr15:59063904 chr15:59115547~59116089:- PAAD cis rs2274273 0.934 rs10139337 ENSG00000258413.1 RP11-665C16.6 -4.79 3.97e-06 0.00243 -0.46 -0.36 Protein biomarker; chr14:55275395 chr14:55262767~55272075:- PAAD cis rs10510102 0.935 rs12240893 ENSG00000276742.1 RP11-500G22.4 4.79 3.98e-06 0.00243 0.54 0.36 Breast cancer; chr10:121870572 chr10:121956782~121957098:+ PAAD cis rs2658782 0.756 rs3019222 ENSG00000279684.1 RP11-755E23.2 -4.79 3.98e-06 0.00243 -0.59 -0.36 Pulmonary function decline; chr11:93346552 chr11:93286629~93288903:- PAAD cis rs3779195 1 rs3779195 ENSG00000272950.1 RP11-307C18.1 -4.79 3.98e-06 0.00243 -0.58 -0.36 Sex hormone-binding globulin levels; chr7:98364050 chr7:98322853~98323430:+ PAAD cis rs17495987 0.913 rs73059192 ENSG00000219545.8 UMAD1 4.79 3.98e-06 0.00243 0.5 0.36 Tonsillectomy; chr7:7860495 chr7:7640711~8004059:+ PAAD cis rs10129255 0.642 rs11624918 ENSG00000223648.3 IGHV3-64 4.79 3.98e-06 0.00243 0.39 0.36 Kawasaki disease; chr14:106664672 chr14:106643132~106658258:- PAAD cis rs9287719 0.967 rs7563894 ENSG00000234818.1 AC092687.5 4.79 3.99e-06 0.00243 0.4 0.36 Prostate cancer; chr2:10614523 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs7566767 ENSG00000234818.1 AC092687.5 4.79 3.99e-06 0.00243 0.4 0.36 Prostate cancer; chr2:10614537 chr2:10589166~10604830:+ PAAD cis rs2283792 0.935 rs8141851 ENSG00000228050.1 TOP3BP1 4.79 3.99e-06 0.00244 0.38 0.36 Multiple sclerosis; chr22:21812161 chr22:22223187~22224566:- PAAD cis rs9287719 0.781 rs6714413 ENSG00000234818.1 AC092687.5 4.79 4e-06 0.00244 0.4 0.36 Prostate cancer; chr2:10618733 chr2:10589166~10604830:+ PAAD cis rs9287719 0.746 rs6742448 ENSG00000234818.1 AC092687.5 4.79 4e-06 0.00244 0.4 0.36 Prostate cancer; chr2:10619000 chr2:10589166~10604830:+ PAAD cis rs9287719 0.781 rs6714795 ENSG00000234818.1 AC092687.5 4.79 4e-06 0.00244 0.4 0.36 Prostate cancer; chr2:10619008 chr2:10589166~10604830:+ PAAD cis rs9287719 0.781 rs6732671 ENSG00000234818.1 AC092687.5 4.79 4e-06 0.00244 0.4 0.36 Prostate cancer; chr2:10619023 chr2:10589166~10604830:+ PAAD cis rs9287719 0.753 rs2018512 ENSG00000234818.1 AC092687.5 4.79 4e-06 0.00244 0.4 0.36 Prostate cancer; chr2:10619153 chr2:10589166~10604830:+ PAAD cis rs9287719 0.781 rs12472807 ENSG00000234818.1 AC092687.5 4.79 4e-06 0.00244 0.4 0.36 Prostate cancer; chr2:10641479 chr2:10589166~10604830:+ PAAD cis rs9287719 0.81 rs1990612 ENSG00000234818.1 AC092687.5 4.79 4e-06 0.00244 0.4 0.36 Prostate cancer; chr2:10641818 chr2:10589166~10604830:+ PAAD cis rs6921919 0.583 rs6907950 ENSG00000216901.1 AL022393.7 4.79 4e-06 0.00244 0.47 0.36 Autism spectrum disorder or schizophrenia; chr6:28402469 chr6:28176188~28176674:+ PAAD cis rs858239 0.632 rs1985769 ENSG00000226816.2 AC005082.12 4.79 4e-06 0.00244 0.4 0.36 Cerebrospinal fluid biomarker levels; chr7:23082887 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs28499396 ENSG00000226816.2 AC005082.12 4.79 4e-06 0.00244 0.4 0.36 Cerebrospinal fluid biomarker levels; chr7:23084479 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs7789237 ENSG00000226816.2 AC005082.12 4.79 4e-06 0.00244 0.4 0.36 Cerebrospinal fluid biomarker levels; chr7:23085094 chr7:23206013~23208045:+ PAAD cis rs7829975 0.742 rs1533058 ENSG00000253893.2 FAM85B -4.79 4e-06 0.00244 -0.48 -0.36 Mood instability; chr8:8827680 chr8:8167819~8226614:- PAAD cis rs2562456 0.833 rs2928211 ENSG00000213976.4 CTD-2561J22.2 4.79 4e-06 0.00244 0.4 0.36 Pain; chr19:21358495 chr19:21382865~21387177:+ PAAD cis rs595244 1 rs7170686 ENSG00000259705.1 RP11-227D13.1 4.79 4e-06 0.00244 0.58 0.36 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48529153 chr15:48645951~48652016:+ PAAD cis rs9322193 0.847 rs868375 ENSG00000268592.3 RAET1E-AS1 4.79 4e-06 0.00244 0.42 0.36 Lung cancer; chr6:149844905 chr6:149863494~149919507:+ PAAD cis rs2283792 1 rs5999750 ENSG00000228050.1 TOP3BP1 4.79 4e-06 0.00244 0.38 0.36 Multiple sclerosis; chr22:21833720 chr22:22223187~22224566:- PAAD cis rs797680 0.856 rs7526112 ENSG00000223745.6 RP4-717I23.3 -4.79 4e-06 0.00244 -0.29 -0.36 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93282126 chr1:93262186~93346025:- PAAD cis rs4660456 0.913 rs657149 ENSG00000237899.1 RP4-739H11.3 4.79 4e-06 0.00244 0.5 0.36 Platelet count; chr1:40692486 chr1:40669089~40687588:- PAAD cis rs950027 0.62 rs1426932 ENSG00000259433.2 CTD-2651B20.4 -4.79 4e-06 0.00244 -0.41 -0.36 Response to fenofibrate (adiponectin levels); chr15:45395058 chr15:45330209~45332634:- PAAD cis rs950027 0.596 rs2467853 ENSG00000259433.2 CTD-2651B20.4 -4.79 4e-06 0.00244 -0.41 -0.36 Response to fenofibrate (adiponectin levels); chr15:45406595 chr15:45330209~45332634:- PAAD cis rs950027 0.595 rs2486288 ENSG00000259433.2 CTD-2651B20.4 -4.79 4e-06 0.00244 -0.41 -0.36 Response to fenofibrate (adiponectin levels); chr15:45420141 chr15:45330209~45332634:- PAAD cis rs2486288 0.539 rs2433601 ENSG00000259433.2 CTD-2651B20.4 -4.79 4e-06 0.00244 -0.41 -0.36 Glomerular filtration rate; chr15:45424227 chr15:45330209~45332634:- PAAD cis rs35160687 0.644 rs11676515 ENSG00000273080.1 RP11-301O19.1 -4.79 4.01e-06 0.00244 -0.43 -0.36 Night sleep phenotypes; chr2:86268934 chr2:86195590~86196049:+ PAAD cis rs12908161 1 rs3803405 ENSG00000225151.9 GOLGA2P7 -4.79 4.01e-06 0.00244 -0.46 -0.36 Schizophrenia; chr15:84840409 chr15:84199311~84230136:- PAAD cis rs710913 0.618 rs11206437 ENSG00000237624.1 OXCT2P1 4.79 4.01e-06 0.00244 0.45 0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39613039 chr1:39514956~39516490:+ PAAD cis rs13178541 0.81 rs4566785 ENSG00000250378.1 RP11-119J18.1 -4.79 4.01e-06 0.00244 -0.57 -0.36 IgG glycosylation; chr5:135774028 chr5:135812667~135826582:+ PAAD cis rs9287719 0.967 rs4669596 ENSG00000234818.1 AC092687.5 4.78 4.02e-06 0.00245 0.4 0.36 Prostate cancer; chr2:10580446 chr2:10589166~10604830:+ PAAD cis rs3096299 0.967 rs2965932 ENSG00000274627.1 RP11-104N10.2 -4.78 4.03e-06 0.00246 -0.33 -0.36 Multiple myeloma (IgH translocation); chr16:89410643 chr16:89516797~89522217:+ PAAD cis rs12817211 0.502 rs12369104 ENSG00000272368.2 RP4-605O3.4 -4.78 4.03e-06 0.00246 -0.35 -0.36 Colorectal or endometrial cancer; chr12:50141207 chr12:50112197~50165618:+ PAAD cis rs7772486 0.743 rs9390344 ENSG00000235652.6 RP11-545I5.3 -4.78 4.04e-06 0.00246 -0.3 -0.36 Lobe attachment (rater-scored or self-reported); chr6:145691619 chr6:145799409~145886585:+ PAAD cis rs4950322 0.57 rs72691090 ENSG00000278811.3 LINC00624 4.78 4.04e-06 0.00246 0.38 0.36 Protein quantitative trait loci; chr1:147297884 chr1:147258885~147517875:- PAAD cis rs11079159 0.628 rs884303 ENSG00000263096.1 RP11-515O17.2 4.78 4.04e-06 0.00246 0.45 0.36 QRS duration; chr17:55289939 chr17:55271504~55273653:- PAAD cis rs11079159 0.628 rs884301 ENSG00000263096.1 RP11-515O17.2 4.78 4.04e-06 0.00246 0.45 0.36 QRS duration; chr17:55290103 chr17:55271504~55273653:- PAAD cis rs780094 0.585 rs7586601 ENSG00000234072.1 AC074117.10 -4.78 4.04e-06 0.00246 -0.29 -0.36 Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels; chr2:27361799 chr2:27356246~27367622:+ PAAD cis rs2658782 0.901 rs7116173 ENSG00000279684.1 RP11-755E23.2 4.78 4.04e-06 0.00246 0.62 0.36 Pulmonary function decline; chr11:93489145 chr11:93286629~93288903:- PAAD cis rs1322639 0.668 rs9766666 ENSG00000261039.2 RP11-417E7.2 -4.78 4.05e-06 0.00247 -0.45 -0.36 Pulse pressure; chr6:169213446 chr6:169175304~169182740:- PAAD cis rs9828933 0.752 rs832192 ENSG00000280620.1 SCAANT1 -4.78 4.05e-06 0.00247 -0.62 -0.36 Type 2 diabetes; chr3:63867747 chr3:63911518~63911772:- PAAD cis rs2562456 0.833 rs2650801 ENSG00000213976.4 CTD-2561J22.2 -4.78 4.05e-06 0.00247 -0.37 -0.36 Pain; chr19:21452553 chr19:21382865~21387177:+ PAAD cis rs858239 0.831 rs7796541 ENSG00000226816.2 AC005082.12 4.78 4.06e-06 0.00247 0.41 0.36 Cerebrospinal fluid biomarker levels; chr7:23349454 chr7:23206013~23208045:+ PAAD cis rs62229266 0.563 rs6517325 ENSG00000231106.2 LINC01436 4.78 4.06e-06 0.00247 0.51 0.36 Mitral valve prolapse; chr21:36062680 chr21:36005338~36007838:+ PAAD cis rs2367970 0.57 rs7123583 ENSG00000254851.1 RP11-109L13.1 4.78 4.06e-06 0.00247 0.52 0.36 HDL cholesterol; chr11:116729305 chr11:117135528~117138582:+ PAAD cis rs9287719 0.967 rs6432114 ENSG00000234818.1 AC092687.5 4.78 4.06e-06 0.00247 0.4 0.36 Prostate cancer; chr2:10604804 chr2:10589166~10604830:+ PAAD cis rs12468226 1 rs13389798 ENSG00000273456.1 RP11-686O6.2 4.78 4.07e-06 0.00248 0.53 0.36 Urate levels; chr2:202348370 chr2:202374932~202375604:- PAAD cis rs950169 0.922 rs11638445 ENSG00000259295.5 CSPG4P12 4.78 4.07e-06 0.00248 0.39 0.36 Schizophrenia; chr15:84594463 chr15:85191438~85213905:+ PAAD cis rs4664293 0.867 rs7566802 ENSG00000226266.5 AC009961.3 -4.78 4.07e-06 0.00248 -0.44 -0.36 Monocyte percentage of white cells; chr2:159728480 chr2:159670708~159712435:- PAAD cis rs11089937 0.597 rs4821774 ENSG00000211639.2 IGLV4-60 4.78 4.08e-06 0.00248 0.38 0.36 Periodontitis (PAL4Q3); chr22:22131536 chr22:22162199~22162681:+ PAAD cis rs12908161 0.959 rs61074241 ENSG00000259728.4 LINC00933 4.78 4.08e-06 0.00248 0.52 0.36 Schizophrenia; chr15:84790165 chr15:84570649~84580175:+ PAAD cis rs12908161 0.959 rs3748376 ENSG00000225151.9 GOLGA2P7 -4.78 4.08e-06 0.00248 -0.44 -0.36 Schizophrenia; chr15:84785121 chr15:84199311~84230136:- PAAD cis rs2404602 0.647 rs62026889 ENSG00000259422.1 RP11-593F23.1 -4.78 4.08e-06 0.00248 -0.44 -0.36 Blood metabolite levels; chr15:76625544 chr15:76174891~76181486:- PAAD cis rs8062405 0.721 rs151181 ENSG00000251417.2 RP11-1348G14.4 -4.78 4.09e-06 0.00248 -0.32 -0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28479196 chr16:28802743~28817828:+ PAAD cis rs7829975 0.54 rs2976909 ENSG00000253893.2 FAM85B 4.78 4.09e-06 0.00249 0.48 0.36 Mood instability; chr8:8489180 chr8:8167819~8226614:- PAAD cis rs3779195 0.52 rs17169479 ENSG00000272950.1 RP11-307C18.1 4.78 4.09e-06 0.00249 0.64 0.36 Sex hormone-binding globulin levels; chr7:98238721 chr7:98322853~98323430:+ PAAD cis rs61270009 0.955 rs35300532 ENSG00000247828.6 TMEM161B-AS1 4.78 4.09e-06 0.00249 0.29 0.36 Depressive symptoms; chr5:88293219 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs12659252 ENSG00000247828.6 TMEM161B-AS1 4.78 4.09e-06 0.00249 0.29 0.36 Depressive symptoms; chr5:88297472 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs6872223 ENSG00000247828.6 TMEM161B-AS1 4.78 4.09e-06 0.00249 0.29 0.36 Depressive symptoms; chr5:88306555 chr5:88268895~88436685:+ PAAD cis rs61270009 0.818 rs4916718 ENSG00000247828.6 TMEM161B-AS1 4.78 4.09e-06 0.00249 0.29 0.36 Depressive symptoms; chr5:88316825 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs78909929 ENSG00000247828.6 TMEM161B-AS1 4.78 4.09e-06 0.00249 0.29 0.36 Depressive symptoms; chr5:88344154 chr5:88268895~88436685:+ PAAD cis rs11089937 0.589 rs4239891 ENSG00000211639.2 IGLV4-60 4.78 4.1e-06 0.00249 0.38 0.36 Periodontitis (PAL4Q3); chr22:22165674 chr22:22162199~22162681:+ PAAD cis rs9531006 0.636 rs996824 ENSG00000227676.3 LINC01068 4.78 4.1e-06 0.00249 0.53 0.36 Sleep duration; chr13:79884515 chr13:79566727~79571436:+ PAAD cis rs7727544 0.66 rs2631361 ENSG00000233006.5 AC034220.3 -4.78 4.1e-06 0.0025 -0.29 -0.36 Blood metabolite levels; chr5:132371688 chr5:132311285~132369916:- PAAD cis rs12908161 1 rs35808647 ENSG00000225151.9 GOLGA2P7 -4.78 4.11e-06 0.0025 -0.45 -0.36 Schizophrenia; chr15:84834210 chr15:84199311~84230136:- PAAD cis rs111580313 0.685 rs76341367 ENSG00000270020.1 RP11-463O9.9 4.78 4.11e-06 0.0025 0.91 0.36 Systemic juvenile idiopathic arthritis; chr16:86563669 chr16:86520383~86523897:- PAAD cis rs74233809 0.901 rs11191416 ENSG00000213277.3 MARCKSL1P1 -4.78 4.11e-06 0.0025 -0.59 -0.36 Birth weight; chr10:102845159 chr10:103175554~103176094:+ PAAD cis rs964611 0.882 rs11854679 ENSG00000259488.2 RP11-154J22.1 -4.78 4.11e-06 0.0025 -0.38 -0.36 Metabolite levels (Pyroglutamine); chr15:48265376 chr15:48312353~48331856:- PAAD cis rs7712401 0.601 rs404442 ENSG00000263432.2 RN7SL689P -4.78 4.11e-06 0.0025 -0.47 -0.36 Mean platelet volume; chr5:123009236 chr5:123022487~123022783:- PAAD cis rs9595908 0.931 rs9595595 ENSG00000212293.1 SNORA16 4.78 4.12e-06 0.0025 0.42 0.36 Body mass index; chr13:32473678 chr13:32420390~32420516:- PAAD cis rs9595908 0.931 rs11839309 ENSG00000212293.1 SNORA16 4.78 4.12e-06 0.0025 0.42 0.36 Body mass index; chr13:32473853 chr13:32420390~32420516:- PAAD cis rs5760092 0.618 rs4461358 ENSG00000206090.4 AP000350.7 -4.78 4.12e-06 0.0025 -0.49 -0.36 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23939998~23942798:+ PAAD cis rs2486288 0.656 rs62026703 ENSG00000259433.2 CTD-2651B20.4 4.78 4.12e-06 0.00251 0.39 0.36 Glomerular filtration rate; chr15:45277731 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs7165039 ENSG00000259433.2 CTD-2651B20.4 4.78 4.12e-06 0.00251 0.39 0.36 Glomerular filtration rate; chr15:45278215 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs7166580 ENSG00000259433.2 CTD-2651B20.4 4.78 4.12e-06 0.00251 0.39 0.36 Glomerular filtration rate; chr15:45279011 chr15:45330209~45332634:- PAAD cis rs3762637 0.941 rs75344200 ENSG00000272758.4 RP11-299J3.8 -4.78 4.13e-06 0.00251 -0.54 -0.36 LDL cholesterol levels; chr3:122354574 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs9810996 ENSG00000272758.4 RP11-299J3.8 -4.78 4.13e-06 0.00251 -0.54 -0.36 LDL cholesterol levels; chr3:122355540 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs9810999 ENSG00000272758.4 RP11-299J3.8 -4.78 4.13e-06 0.00251 -0.54 -0.36 LDL cholesterol levels; chr3:122355544 chr3:122416207~122443180:+ PAAD cis rs3762637 0.941 rs9289192 ENSG00000272758.4 RP11-299J3.8 -4.78 4.13e-06 0.00251 -0.54 -0.36 LDL cholesterol levels; chr3:122357268 chr3:122416207~122443180:+ PAAD cis rs10754283 0.934 rs10493829 ENSG00000231613.1 RP5-943J3.1 4.78 4.13e-06 0.00251 0.39 0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89652274 chr1:89788914~89790492:+ PAAD cis rs964611 0.882 rs10851465 ENSG00000259488.2 RP11-154J22.1 4.78 4.13e-06 0.00251 0.41 0.36 Metabolite levels (Pyroglutamine); chr15:48337687 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs873661 ENSG00000259488.2 RP11-154J22.1 4.78 4.13e-06 0.00251 0.41 0.36 Metabolite levels (Pyroglutamine); chr15:48368914 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4775753 ENSG00000259488.2 RP11-154J22.1 4.78 4.13e-06 0.00251 0.41 0.36 Metabolite levels (Pyroglutamine); chr15:48369022 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs4775754 ENSG00000259488.2 RP11-154J22.1 4.78 4.13e-06 0.00251 0.41 0.36 Metabolite levels (Pyroglutamine); chr15:48369146 chr15:48312353~48331856:- PAAD cis rs3096299 0.935 rs3114890 ENSG00000274627.1 RP11-104N10.2 4.78 4.13e-06 0.00251 0.32 0.36 Multiple myeloma (IgH translocation); chr16:89383138 chr16:89516797~89522217:+ PAAD cis rs12908161 1 rs3803403 ENSG00000225151.9 GOLGA2P7 -4.78 4.14e-06 0.00251 -0.46 -0.36 Schizophrenia; chr15:84839914 chr15:84199311~84230136:- PAAD cis rs1075265 0.669 rs805330 ENSG00000233266.1 HMGB1P31 4.78 4.14e-06 0.00251 0.45 0.36 Chronotype;Morning vs. evening chronotype; chr2:53921194 chr2:54051334~54051760:+ PAAD cis rs9287719 0.967 rs7570118 ENSG00000234818.1 AC092687.5 4.78 4.14e-06 0.00252 0.4 0.36 Prostate cancer; chr2:10577881 chr2:10589166~10604830:+ PAAD cis rs1823913 0.599 rs17412635 ENSG00000280083.1 RP11-317J9.1 4.78 4.14e-06 0.00252 0.43 0.36 Obesity-related traits; chr2:191294834 chr2:191154118~191156070:- PAAD cis rs2179367 0.959 rs4897125 ENSG00000231760.4 RP11-350J20.5 4.78 4.14e-06 0.00252 0.46 0.36 Dupuytren's disease; chr6:149445072 chr6:149796151~149826294:- PAAD cis rs2790457 0.874 rs2790446 ENSG00000254635.4 WAC-AS1 -4.78 4.15e-06 0.00252 -0.36 -0.36 Multiple myeloma; chr10:28512101 chr10:28522652~28532743:- PAAD cis rs8031584 0.679 rs34017474 ENSG00000260382.1 RP11-540B6.2 4.78 4.15e-06 0.00252 0.46 0.36 Huntington's disease progression; chr15:30938408 chr15:30882267~30883231:- PAAD cis rs11662586 1 rs7243921 ENSG00000267270.4 PARD6G-AS1 -4.78 4.15e-06 0.00252 -0.5 -0.36 Exploratory eye movement dysfunction in schizophrenia (responsive search score); chr18:79935237 chr18:80147924~80178432:+ PAAD cis rs2980439 0.818 rs2945249 ENSG00000173295.6 FAM86B3P 4.78 4.15e-06 0.00252 0.4 0.36 Neuroticism; chr8:8237204 chr8:8228595~8244865:+ PAAD cis rs950169 0.922 rs62021167 ENSG00000259295.5 CSPG4P12 4.78 4.16e-06 0.00252 0.4 0.36 Schizophrenia; chr15:84574820 chr15:85191438~85213905:+ PAAD cis rs4268898 0.76 rs55863105 ENSG00000242628.4 AC009228.1 -4.78 4.16e-06 0.00252 -0.43 -0.36 Asthma; chr2:24347826 chr2:24214381~24221516:+ PAAD cis rs3096299 0.738 rs9929606 ENSG00000274627.1 RP11-104N10.2 4.78 4.16e-06 0.00253 0.32 0.36 Multiple myeloma (IgH translocation); chr16:89461129 chr16:89516797~89522217:+ PAAD cis rs3096299 0.967 rs11648663 ENSG00000274627.1 RP11-104N10.2 4.78 4.18e-06 0.00254 0.33 0.36 Multiple myeloma (IgH translocation); chr16:89399899 chr16:89516797~89522217:+ PAAD cis rs1545257 0.505 rs11125570 ENSG00000242628.4 AC009228.1 4.78 4.19e-06 0.00254 0.42 0.36 Sjögren's syndrome; chr2:24406708 chr2:24214381~24221516:+ PAAD cis rs2283792 0.967 rs5755099 ENSG00000228050.1 TOP3BP1 4.78 4.19e-06 0.00254 0.39 0.36 Multiple sclerosis; chr22:21770751 chr22:22223187~22224566:- PAAD cis rs932287 0.505 rs2742536 ENSG00000254860.4 TMEM9B-AS1 4.77 4.2e-06 0.00254 0.37 0.36 Colonoscopy-negative controls vs population controls; chr11:8888269 chr11:8964675~8977527:+ PAAD cis rs6504950 0.72 rs9910653 ENSG00000275710.1 RP11-257O5.4 4.77 4.2e-06 0.00255 0.44 0.36 Breast cancer; chr17:54914907 chr17:54964474~54964679:+ PAAD cis rs6504950 0.72 rs12602751 ENSG00000275710.1 RP11-257O5.4 4.77 4.2e-06 0.00255 0.44 0.36 Breast cancer; chr17:54916813 chr17:54964474~54964679:+ PAAD cis rs453301 0.631 rs28572014 ENSG00000253893.2 FAM85B 4.77 4.2e-06 0.00255 0.48 0.36 Joint mobility (Beighton score); chr8:8936097 chr8:8167819~8226614:- PAAD cis rs3096299 0.967 rs28575874 ENSG00000274627.1 RP11-104N10.2 4.77 4.2e-06 0.00255 0.33 0.36 Multiple myeloma (IgH translocation); chr16:89403482 chr16:89516797~89522217:+ PAAD cis rs950169 0.881 rs4842852 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84387263 chr15:85191438~85213905:+ PAAD cis rs950169 0.84 rs4842853 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84387606 chr15:85191438~85213905:+ PAAD cis rs950169 0.922 rs4842946 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84387633 chr15:85191438~85213905:+ PAAD cis rs950169 0.84 rs4842854 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84387641 chr15:85191438~85213905:+ PAAD cis rs950169 0.84 rs2896002 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84390423 chr15:85191438~85213905:+ PAAD cis rs950169 0.887 rs3860265 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84390487 chr15:85191438~85213905:+ PAAD cis rs950169 0.724 rs11632668 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84393989 chr15:85191438~85213905:+ PAAD cis rs950169 0.881 rs34591918 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84396135 chr15:85191438~85213905:+ PAAD cis rs950169 0.887 rs12903946 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84399732 chr15:85191438~85213905:+ PAAD cis rs950169 0.887 rs35986397 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84400409 chr15:85191438~85213905:+ PAAD cis rs950169 0.887 rs62029593 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84400482 chr15:85191438~85213905:+ PAAD cis rs950169 0.81 rs62029594 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84400554 chr15:85191438~85213905:+ PAAD cis rs950169 0.881 rs62029596 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84400736 chr15:85191438~85213905:+ PAAD cis rs950169 0.881 rs4081123 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84401537 chr15:85191438~85213905:+ PAAD cis rs950169 0.881 rs62029599 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84401867 chr15:85191438~85213905:+ PAAD cis rs950169 0.8 rs4099846 ENSG00000259295.5 CSPG4P12 4.77 4.2e-06 0.00255 0.4 0.36 Schizophrenia; chr15:84402196 chr15:85191438~85213905:+ PAAD cis rs9322193 0.607 rs12527391 ENSG00000223701.3 RAET1E-AS1 4.77 4.2e-06 0.00255 0.48 0.36 Lung cancer; chr6:149882156 chr6:149884431~149919508:+ PAAD cis rs2117029 0.767 rs3741622 ENSG00000258017.1 RP11-386G11.10 -4.77 4.2e-06 0.00255 -0.47 -0.36 Intelligence (multi-trait analysis); chr12:49032195 chr12:49127782~49147869:+ PAAD cis rs1862618 0.525 rs2662019 ENSG00000271828.1 CTD-2310F14.1 -4.77 4.21e-06 0.00255 -0.54 -0.36 Initial pursuit acceleration; chr5:56967277 chr5:56927874~56929573:+ PAAD cis rs12682352 0.652 rs3789843 ENSG00000253893.2 FAM85B -4.77 4.21e-06 0.00255 -0.47 -0.36 Neuroticism; chr8:8866747 chr8:8167819~8226614:- PAAD cis rs12682352 0.652 rs3827806 ENSG00000253893.2 FAM85B -4.77 4.21e-06 0.00255 -0.47 -0.36 Neuroticism; chr8:8866766 chr8:8167819~8226614:- PAAD cis rs3020264 0.59 rs2515561 ENSG00000271743.1 CTD-2541M15.3 -4.77 4.22e-06 0.00256 -0.51 -0.36 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6633454 chr8:6615604~6617198:- PAAD cis rs4713118 0.621 rs9368548 ENSG00000226314.6 ZNF192P1 -4.77 4.23e-06 0.00256 -0.61 -0.36 Parkinson's disease; chr6:28066959 chr6:28161781~28169594:+ PAAD cis rs12817211 0.502 rs34167640 ENSG00000272368.2 RP4-605O3.4 -4.77 4.23e-06 0.00256 -0.35 -0.36 Colorectal or endometrial cancer; chr12:50123208 chr12:50112197~50165618:+ PAAD cis rs12817211 0.524 rs1554845 ENSG00000272368.2 RP4-605O3.4 -4.77 4.23e-06 0.00256 -0.35 -0.36 Colorectal or endometrial cancer; chr12:50129721 chr12:50112197~50165618:+ PAAD cis rs12817211 0.502 rs3741562 ENSG00000272368.2 RP4-605O3.4 -4.77 4.23e-06 0.00256 -0.35 -0.36 Colorectal or endometrial cancer; chr12:50135953 chr12:50112197~50165618:+ PAAD cis rs875971 0.545 rs4441996 ENSG00000226824.5 RP4-756H11.3 4.77 4.23e-06 0.00256 0.5 0.36 Aortic root size; chr7:66123233 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs316324 ENSG00000226824.5 RP4-756H11.3 4.77 4.23e-06 0.00256 0.5 0.36 Aortic root size; chr7:66145627 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs316323 ENSG00000226824.5 RP4-756H11.3 4.77 4.23e-06 0.00256 0.5 0.36 Aortic root size; chr7:66146002 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs316316 ENSG00000226824.5 RP4-756H11.3 4.77 4.23e-06 0.00256 0.5 0.36 Aortic root size; chr7:66149270 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs316305 ENSG00000226824.5 RP4-756H11.3 4.77 4.23e-06 0.00256 0.5 0.36 Aortic root size; chr7:66152984 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs316306 ENSG00000226824.5 RP4-756H11.3 4.77 4.23e-06 0.00256 0.5 0.36 Aortic root size; chr7:66153687 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs2460427 ENSG00000226824.5 RP4-756H11.3 4.77 4.23e-06 0.00256 0.5 0.36 Aortic root size; chr7:66154218 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs10950025 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66158946 chr7:66654538~66669855:+ PAAD cis rs875971 0.52 rs12666485 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66160135 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs67688847 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66161064 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs7787063 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66164012 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs12673308 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66166374 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs67397473 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66168318 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs10950027 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66169164 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs73376401 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66174841 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs6460276 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66182290 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs67775320 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66193792 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs17138149 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66228193 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs17138156 ENSG00000226824.5 RP4-756H11.3 -4.77 4.23e-06 0.00256 -0.5 -0.36 Aortic root size; chr7:66249708 chr7:66654538~66669855:+ PAAD cis rs12817211 0.524 rs7967979 ENSG00000272368.2 RP4-605O3.4 -4.77 4.23e-06 0.00256 -0.35 -0.36 Colorectal or endometrial cancer; chr12:50126893 chr12:50112197~50165618:+ PAAD cis rs12817211 0.548 rs2204684 ENSG00000272368.2 RP4-605O3.4 -4.77 4.23e-06 0.00256 -0.35 -0.36 Colorectal or endometrial cancer; chr12:50128689 chr12:50112197~50165618:+ PAAD cis rs62229266 0.693 rs2835264 ENSG00000231106.2 LINC01436 4.77 4.23e-06 0.00256 0.51 0.36 Mitral valve prolapse; chr21:36063667 chr21:36005338~36007838:+ PAAD cis rs7772486 0.806 rs7740785 ENSG00000235652.6 RP11-545I5.3 4.77 4.23e-06 0.00256 0.3 0.36 Lobe attachment (rater-scored or self-reported); chr6:145850163 chr6:145799409~145886585:+ PAAD cis rs42490 0.664 rs389848 ENSG00000251136.7 RP11-37B2.1 -4.77 4.23e-06 0.00256 -0.32 -0.36 Leprosy; chr8:89784739 chr8:89609409~89757727:- PAAD cis rs12468226 0.938 rs13392645 ENSG00000273456.1 RP11-686O6.2 4.77 4.24e-06 0.00256 0.51 0.36 Urate levels; chr2:202270116 chr2:202374932~202375604:- PAAD cis rs2832077 0.689 rs2832055 ENSG00000176054.6 RPL23P2 4.77 4.24e-06 0.00256 0.38 0.36 Cognitive test performance; chr21:28760060 chr21:28997613~28998033:- PAAD cis rs1075232 1 rs9672214 ENSG00000215302.7 CTD-3092A11.1 -4.77 4.25e-06 0.00257 -0.91 -0.36 Survival in colorectal cancer (non-distant metastatic); chr15:31385572 chr15:30470779~30507623:+ PAAD cis rs2404602 0.647 rs12905181 ENSG00000259422.1 RP11-593F23.1 -4.77 4.25e-06 0.00257 -0.44 -0.36 Blood metabolite levels; chr15:76806090 chr15:76174891~76181486:- PAAD cis rs2948294 0.588 rs7011221 ENSG00000253893.2 FAM85B -4.77 4.25e-06 0.00257 -0.5 -0.36 Red cell distribution width; chr8:8256724 chr8:8167819~8226614:- PAAD cis rs2948294 0.545 rs11776397 ENSG00000253893.2 FAM85B -4.77 4.25e-06 0.00257 -0.5 -0.36 Red cell distribution width; chr8:8257639 chr8:8167819~8226614:- PAAD cis rs72843506 0.656 rs74333705 ENSG00000189423.10 USP32P3 4.77 4.25e-06 0.00257 0.54 0.36 Schizophrenia; chr17:20097448 chr17:20415547~20431008:+ PAAD cis rs9287719 0.901 rs55861579 ENSG00000234818.1 AC092687.5 4.77 4.25e-06 0.00257 0.4 0.36 Prostate cancer; chr2:10623214 chr2:10589166~10604830:+ PAAD cis rs2404602 0.647 rs11072625 ENSG00000259422.1 RP11-593F23.1 4.77 4.27e-06 0.00258 0.44 0.36 Blood metabolite levels; chr15:76792643 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs12914196 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76649020 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs2404604 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76698764 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs1011084 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76715139 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11629727 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76716697 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11072618 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76727001 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs1443115 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76749488 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs12898416 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76749951 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs12904149 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76751311 chr15:76174891~76181486:- PAAD cis rs2404602 0.672 rs35374222 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76779053 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11852395 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76795444 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs12439141 ENSG00000259422.1 RP11-593F23.1 -4.77 4.27e-06 0.00258 -0.44 -0.36 Blood metabolite levels; chr15:76803082 chr15:76174891~76181486:- PAAD cis rs74233809 0.901 rs3824754 ENSG00000213277.3 MARCKSL1P1 4.77 4.27e-06 0.00258 0.6 0.36 Birth weight; chr10:102854593 chr10:103175554~103176094:+ PAAD cis rs11673344 0.765 rs826296 ENSG00000226686.6 LINC01535 4.77 4.27e-06 0.00258 0.49 0.36 Obesity-related traits; chr19:36947384 chr19:37251912~37265535:+ PAAD cis rs11673344 0.764 rs513406 ENSG00000226686.6 LINC01535 4.77 4.27e-06 0.00258 0.49 0.36 Obesity-related traits; chr19:36948245 chr19:37251912~37265535:+ PAAD cis rs11673344 0.734 rs496872 ENSG00000226686.6 LINC01535 4.77 4.27e-06 0.00258 0.49 0.36 Obesity-related traits; chr19:36948579 chr19:37251912~37265535:+ PAAD cis rs7826238 0.517 rs35144760 ENSG00000253893.2 FAM85B 4.77 4.28e-06 0.00258 0.57 0.36 Systolic blood pressure; chr8:8504213 chr8:8167819~8226614:- PAAD cis rs2921036 0.505 rs35190619 ENSG00000253893.2 FAM85B 4.77 4.28e-06 0.00258 0.57 0.36 Neuroticism; chr8:8504313 chr8:8167819~8226614:- PAAD cis rs74233809 1 rs11191543 ENSG00000213277.3 MARCKSL1P1 4.77 4.28e-06 0.00259 0.61 0.36 Birth weight; chr10:103064630 chr10:103175554~103176094:+ PAAD cis rs7829975 0.714 rs12544992 ENSG00000253893.2 FAM85B -4.77 4.29e-06 0.00259 -0.48 -0.36 Mood instability; chr8:8804171 chr8:8167819~8226614:- PAAD cis rs4835473 0.897 rs11723113 ENSG00000251600.4 RP11-673E1.1 4.77 4.29e-06 0.00259 0.4 0.36 Immature fraction of reticulocytes; chr4:143707283 chr4:143912331~143982454:+ PAAD cis rs9322193 0.847 rs880246 ENSG00000268592.3 RAET1E-AS1 4.77 4.29e-06 0.00259 0.44 0.36 Lung cancer; chr6:149845972 chr6:149863494~149919507:+ PAAD cis rs7945705 0.846 rs11042055 ENSG00000254860.4 TMEM9B-AS1 -4.77 4.29e-06 0.00259 -0.41 -0.36 Hemoglobin concentration; chr11:8735309 chr11:8964675~8977527:+ PAAD cis rs964611 0.786 rs10519169 ENSG00000259488.2 RP11-154J22.1 -4.77 4.3e-06 0.0026 -0.4 -0.36 Metabolite levels (Pyroglutamine); chr15:48372829 chr15:48312353~48331856:- PAAD cis rs1322639 0.531 rs11751421 ENSG00000261039.2 RP11-417E7.2 4.77 4.3e-06 0.0026 0.41 0.36 Pulse pressure; chr6:169174898 chr6:169175304~169182740:- PAAD cis rs11098499 0.644 rs2389880 ENSG00000245958.5 RP11-33B1.1 -4.77 4.31e-06 0.0026 -0.29 -0.36 Corneal astigmatism; chr4:119638715 chr4:119454791~119552025:+ PAAD cis rs12571093 0.572 rs10762216 ENSG00000233590.1 RP11-153K11.3 4.77 4.31e-06 0.0026 0.57 0.36 Optic nerve measurement (disc area); chr10:68308820 chr10:68233251~68242379:- PAAD cis rs2348418 0.864 rs7295120 ENSG00000247934.4 RP11-967K21.1 4.77 4.31e-06 0.0026 0.35 0.36 Lung function (FEV1);Lung function (FVC); chr12:28565175 chr12:28163298~28190738:- PAAD cis rs992157 0.71 rs6752254 ENSG00000261338.2 RP11-378A13.1 4.77 4.32e-06 0.00261 0.4 0.36 Colorectal cancer; chr2:218194020 chr2:218255319~218257366:+ PAAD cis rs7829975 0.84 rs572366 ENSG00000253893.2 FAM85B -4.77 4.32e-06 0.00261 -0.54 -0.36 Mood instability; chr8:8721284 chr8:8167819~8226614:- PAAD cis rs4664293 0.625 rs35241460 ENSG00000226266.5 AC009961.3 4.77 4.33e-06 0.00261 0.45 0.36 Monocyte percentage of white cells; chr2:159651689 chr2:159670708~159712435:- PAAD cis rs12468226 1 rs7587234 ENSG00000273456.1 RP11-686O6.2 4.77 4.33e-06 0.00261 0.53 0.36 Urate levels; chr2:202351699 chr2:202374932~202375604:- PAAD cis rs35160687 0.644 rs4832264 ENSG00000273080.1 RP11-301O19.1 -4.77 4.34e-06 0.00262 -0.42 -0.36 Night sleep phenotypes; chr2:86259711 chr2:86195590~86196049:+ PAAD cis rs35160687 0.623 rs13005014 ENSG00000273080.1 RP11-301O19.1 -4.77 4.34e-06 0.00262 -0.42 -0.36 Night sleep phenotypes; chr2:86260093 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs4832265 ENSG00000273080.1 RP11-301O19.1 -4.77 4.34e-06 0.00262 -0.42 -0.36 Night sleep phenotypes; chr2:86261142 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs1863056 ENSG00000273080.1 RP11-301O19.1 -4.77 4.34e-06 0.00262 -0.42 -0.36 Night sleep phenotypes; chr2:86264122 chr2:86195590~86196049:+ PAAD cis rs950027 0.62 rs1145084 ENSG00000259433.2 CTD-2651B20.4 -4.77 4.34e-06 0.00262 -0.41 -0.36 Response to fenofibrate (adiponectin levels); chr15:45383242 chr15:45330209~45332634:- PAAD cis rs2790457 0.793 rs2153302 ENSG00000254635.4 WAC-AS1 -4.77 4.35e-06 0.00262 -0.36 -0.36 Multiple myeloma; chr10:28529607 chr10:28522652~28532743:- PAAD cis rs6921919 0.945 rs61289879 ENSG00000216901.1 AL022393.7 4.77 4.35e-06 0.00262 0.57 0.36 Autism spectrum disorder or schizophrenia; chr6:28451385 chr6:28176188~28176674:+ PAAD cis rs498872 1 rs498872 ENSG00000255239.1 AP002954.6 4.77 4.35e-06 0.00263 0.46 0.36 Glioma; chr11:118606652 chr11:118688039~118690600:- PAAD cis rs60733400 0.667 rs4385650 ENSG00000225931.3 RP3-395M20.7 4.77 4.36e-06 0.00263 0.35 0.36 Multiple sclerosis; chr1:2568459 chr1:2566410~2569888:+ PAAD cis rs2153535 0.584 rs55945625 ENSG00000230939.1 RP11-314C16.1 4.77 4.37e-06 0.00263 0.39 0.36 Motion sickness; chr6:8371134 chr6:8784178~8785445:+ PAAD cis rs2153535 0.584 rs62395677 ENSG00000230939.1 RP11-314C16.1 4.77 4.37e-06 0.00263 0.39 0.36 Motion sickness; chr6:8371356 chr6:8784178~8785445:+ PAAD cis rs2153535 0.584 rs62395678 ENSG00000230939.1 RP11-314C16.1 4.77 4.37e-06 0.00263 0.39 0.36 Motion sickness; chr6:8371456 chr6:8784178~8785445:+ PAAD cis rs8062405 0.691 rs11646653 ENSG00000251417.2 RP11-1348G14.4 4.77 4.37e-06 0.00264 0.33 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28910828 chr16:28802743~28817828:+ PAAD cis rs6142102 0.602 rs68051854 ENSG00000276073.1 RP5-1125A11.7 -4.77 4.37e-06 0.00264 -0.37 -0.36 Skin pigmentation; chr20:34114150 chr20:33985617~33988989:- PAAD cis rs9987353 0.566 rs6998368 ENSG00000253893.2 FAM85B 4.77 4.37e-06 0.00264 0.49 0.36 Recombination measurement; chr8:9212778 chr8:8167819~8226614:- PAAD cis rs2658782 0.724 rs2658770 ENSG00000279684.1 RP11-755E23.2 -4.77 4.38e-06 0.00264 -0.59 -0.36 Pulmonary function decline; chr11:93528720 chr11:93286629~93288903:- PAAD cis rs2658782 0.666 rs2925361 ENSG00000279684.1 RP11-755E23.2 -4.77 4.38e-06 0.00264 -0.59 -0.36 Pulmonary function decline; chr11:93365657 chr11:93286629~93288903:- PAAD cis rs2658782 0.789 rs3020073 ENSG00000279684.1 RP11-755E23.2 -4.77 4.38e-06 0.00264 -0.59 -0.36 Pulmonary function decline; chr11:93370664 chr11:93286629~93288903:- PAAD cis rs17023223 0.537 rs12081198 ENSG00000231365.4 RP11-418J17.1 -4.76 4.38e-06 0.00264 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119143481 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs12081327 ENSG00000231365.4 RP11-418J17.1 -4.76 4.38e-06 0.00264 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119143735 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs12086686 ENSG00000231365.4 RP11-418J17.1 -4.76 4.38e-06 0.00264 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119146461 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs12085616 ENSG00000231365.4 RP11-418J17.1 -4.76 4.38e-06 0.00264 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119146525 chr1:119140396~119275973:+ PAAD cis rs61270009 0.955 rs1367233 ENSG00000247828.6 TMEM161B-AS1 4.76 4.38e-06 0.00264 0.3 0.36 Depressive symptoms; chr5:88301195 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs11740776 ENSG00000247828.6 TMEM161B-AS1 4.76 4.38e-06 0.00264 0.3 0.36 Depressive symptoms; chr5:88303489 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs4916717 ENSG00000247828.6 TMEM161B-AS1 4.76 4.38e-06 0.00264 0.3 0.36 Depressive symptoms; chr5:88305802 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs4916719 ENSG00000247828.6 TMEM161B-AS1 4.76 4.38e-06 0.00264 0.3 0.36 Depressive symptoms; chr5:88327844 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs12653830 ENSG00000247828.6 TMEM161B-AS1 4.76 4.38e-06 0.00264 0.3 0.36 Depressive symptoms; chr5:88353712 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs2305104 ENSG00000247828.6 TMEM161B-AS1 -4.76 4.38e-06 0.00264 -0.3 -0.36 Depressive symptoms; chr5:88324853 chr5:88268895~88436685:+ PAAD cis rs7727544 0.684 rs274567 ENSG00000233006.5 AC034220.3 -4.76 4.39e-06 0.00265 -0.29 -0.36 Blood metabolite levels; chr5:132378717 chr5:132311285~132369916:- PAAD cis rs7727544 0.684 rs270602 ENSG00000233006.5 AC034220.3 4.76 4.39e-06 0.00265 0.29 0.36 Blood metabolite levels; chr5:132321007 chr5:132311285~132369916:- PAAD cis rs7727544 0.684 rs272893 ENSG00000233006.5 AC034220.3 4.76 4.39e-06 0.00265 0.29 0.36 Blood metabolite levels; chr5:132327369 chr5:132311285~132369916:- PAAD cis rs7727544 0.684 rs272869 ENSG00000233006.5 AC034220.3 4.76 4.39e-06 0.00265 0.29 0.36 Blood metabolite levels; chr5:132342304 chr5:132311285~132369916:- PAAD cis rs2658782 0.789 rs3019206 ENSG00000279684.1 RP11-755E23.2 -4.76 4.39e-06 0.00265 -0.59 -0.36 Pulmonary function decline; chr11:93377907 chr11:93286629~93288903:- PAAD cis rs7665090 0.728 rs228617 ENSG00000246560.2 RP11-10L12.4 -4.76 4.4e-06 0.00265 -0.4 -0.36 Primary biliary cholangitis; chr4:102659631 chr4:102828055~102844075:+ PAAD cis rs9549328 0.8 rs9549620 ENSG00000267868.1 RP11-120K24.3 4.76 4.4e-06 0.00265 0.4 0.36 Systolic blood pressure; chr13:112979107 chr13:112964835~112966131:- PAAD cis rs9549328 0.8 rs9549621 ENSG00000267868.1 RP11-120K24.3 4.76 4.4e-06 0.00265 0.4 0.36 Systolic blood pressure; chr13:112979265 chr13:112964835~112966131:- PAAD cis rs9549328 0.842 rs6577024 ENSG00000267868.1 RP11-120K24.3 4.76 4.4e-06 0.00265 0.4 0.36 Systolic blood pressure; chr13:112979777 chr13:112964835~112966131:- PAAD cis rs9549328 0.718 rs7139939 ENSG00000267868.1 RP11-120K24.3 4.76 4.4e-06 0.00265 0.4 0.36 Systolic blood pressure; chr13:112980095 chr13:112964835~112966131:- PAAD cis rs10751647 0.804 rs3809112 ENSG00000251661.3 RP11-326C3.11 -4.76 4.4e-06 0.00265 -0.36 -0.36 Monocyte count; chr11:307036 chr11:318640~325631:+ PAAD cis rs42490 0.653 rs40247 ENSG00000251136.7 RP11-37B2.1 -4.76 4.4e-06 0.00265 -0.32 -0.36 Leprosy; chr8:89789744 chr8:89609409~89757727:- PAAD cis rs42490 0.653 rs40453 ENSG00000251136.7 RP11-37B2.1 -4.76 4.4e-06 0.00265 -0.32 -0.36 Leprosy; chr8:89789817 chr8:89609409~89757727:- PAAD cis rs42490 0.752 rs400411 ENSG00000251136.7 RP11-37B2.1 -4.76 4.4e-06 0.00265 -0.32 -0.36 Leprosy; chr8:89789871 chr8:89609409~89757727:- PAAD cis rs42490 0.738 rs39509 ENSG00000251136.7 RP11-37B2.1 -4.76 4.4e-06 0.00265 -0.32 -0.36 Leprosy; chr8:89791937 chr8:89609409~89757727:- PAAD cis rs42490 0.752 rs411279 ENSG00000251136.7 RP11-37B2.1 -4.76 4.4e-06 0.00265 -0.32 -0.36 Leprosy; chr8:89795929 chr8:89609409~89757727:- PAAD cis rs6061231 0.631 rs2427310 ENSG00000273619.1 RP5-908M14.9 -4.76 4.4e-06 0.00265 -0.3 -0.36 Colorectal cancer; chr20:62394873 chr20:62386303~62386970:- PAAD cis rs10170846 0.893 rs10932967 ENSG00000261428.2 RP11-16P6.1 4.76 4.41e-06 0.00265 0.49 0.36 Schizophrenia (inflammation and infection response interaction); chr2:222679392 chr2:222566899~222569719:- PAAD cis rs6921919 0.583 rs6907950 ENSG00000204709.4 LINC01556 4.76 4.41e-06 0.00265 0.52 0.36 Autism spectrum disorder or schizophrenia; chr6:28402469 chr6:28943877~28944537:+ PAAD cis rs3779195 0.627 rs6950023 ENSG00000272950.1 RP11-307C18.1 4.76 4.41e-06 0.00265 0.6 0.36 Sex hormone-binding globulin levels; chr7:98286323 chr7:98322853~98323430:+ PAAD cis rs3779195 0.627 rs6967728 ENSG00000272950.1 RP11-307C18.1 4.76 4.41e-06 0.00265 0.6 0.36 Sex hormone-binding globulin levels; chr7:98286325 chr7:98322853~98323430:+ PAAD cis rs4713118 0.621 rs9295756 ENSG00000226314.6 ZNF192P1 -4.76 4.42e-06 0.00266 -0.61 -0.36 Parkinson's disease; chr6:28065618 chr6:28161781~28169594:+ PAAD cis rs8396 1 rs4690909 ENSG00000271817.2 U3 -4.76 4.43e-06 0.00267 -0.39 -0.36 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158707999 chr4:158700691~158700909:+ PAAD cis rs7119038 0.509 rs10892260 ENSG00000255239.1 AP002954.6 -4.76 4.43e-06 0.00267 -0.47 -0.36 Sjögren's syndrome; chr11:118712816 chr11:118688039~118690600:- PAAD cis rs734999 0.572 rs3748816 ENSG00000225931.3 RP3-395M20.7 4.76 4.44e-06 0.00267 0.34 0.36 Ulcerative colitis; chr1:2595307 chr1:2566410~2569888:+ PAAD cis rs2404602 0.647 rs11633869 ENSG00000259422.1 RP11-593F23.1 4.76 4.44e-06 0.00267 0.44 0.36 Blood metabolite levels; chr15:76840981 chr15:76174891~76181486:- PAAD cis rs6782228 1 rs11711038 ENSG00000242551.2 POU5F1P6 4.76 4.44e-06 0.00267 0.47 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128675467 chr3:128674735~128677005:- PAAD cis rs9549328 0.731 rs55804996 ENSG00000267868.1 RP11-120K24.3 4.76 4.45e-06 0.00268 0.41 0.36 Systolic blood pressure; chr13:112971053 chr13:112964835~112966131:- PAAD cis rs7684253 0.548 rs62308071 ENSG00000269949.1 RP11-738E22.3 -4.76 4.45e-06 0.00268 -0.48 -0.36 Migraine; chr4:56850720 chr4:56960927~56961373:- PAAD cis rs673078 0.607 rs7294498 ENSG00000275759.1 RP11-131L12.3 -4.76 4.45e-06 0.00268 -0.49 -0.36 Glucose homeostasis traits; chr12:118321680 chr12:118428281~118428870:+ PAAD cis rs4664293 0.625 rs6432543 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159638820 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs4665099 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159639027 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs6724151 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159642788 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs34573069 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159643561 chr2:159670708~159712435:- PAAD cis rs4664293 0.567 rs6711125 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159645040 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs4144512 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159651008 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs13006088 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159652915 chr2:159670708~159712435:- PAAD cis rs4664293 0.605 rs2042774 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159653496 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs2042775 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159653581 chr2:159670708~159712435:- PAAD cis rs4664293 0.585 rs34385495 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159656372 chr2:159670708~159712435:- PAAD cis rs4664293 0.605 rs12474082 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159657403 chr2:159670708~159712435:- PAAD cis rs4664293 0.585 rs1991372 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159659556 chr2:159670708~159712435:- PAAD cis rs4664293 0.546 rs1991373 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159659714 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs6707985 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159659877 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs62171641 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159659994 chr2:159670708~159712435:- PAAD cis rs4664293 0.585 rs35293435 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159662396 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs62171646 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159662563 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs4664295 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159663807 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs6722715 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159668515 chr2:159670708~159712435:- PAAD cis rs4664293 0.669 rs2042778 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159672119 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs62171654 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159675107 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs11903816 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159675347 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs6738523 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159681203 chr2:159670708~159712435:- PAAD cis rs4664293 0.585 rs11893106 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159684294 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs11899419 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159688858 chr2:159670708~159712435:- PAAD cis rs4664293 0.605 rs6745815 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159693558 chr2:159670708~159712435:- PAAD cis rs4664293 0.551 rs11898293 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159696082 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs6756502 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159698072 chr2:159670708~159712435:- PAAD cis rs4664293 0.605 rs6741498 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159698111 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs6760931 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159702600 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs6713600 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159706559 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs7607394 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159707286 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs3821300 ENSG00000226266.5 AC009961.3 4.76 4.45e-06 0.00268 0.45 0.36 Monocyte percentage of white cells; chr2:159710719 chr2:159670708~159712435:- PAAD cis rs4664293 0.609 rs10167143 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159606885 chr2:159670708~159712435:- PAAD cis rs4664293 0.669 rs13389096 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159611246 chr2:159670708~159712435:- PAAD cis rs4664293 0.609 rs12470879 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159612116 chr2:159670708~159712435:- PAAD cis rs4664293 0.55 rs13388082 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159616439 chr2:159670708~159712435:- PAAD cis rs4664293 0.582 rs1046496 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159616888 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs7580816 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159619370 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs1966530 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159620897 chr2:159670708~159712435:- PAAD cis rs4664293 0.669 rs357021 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159632572 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs357028 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159635331 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs357030 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159636515 chr2:159670708~159712435:- PAAD cis rs4664293 0.609 rs357033 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159637962 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs1863686 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159647538 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs2114625 ENSG00000226266.5 AC009961.3 -4.76 4.45e-06 0.00268 -0.45 -0.36 Monocyte percentage of white cells; chr2:159687297 chr2:159670708~159712435:- PAAD cis rs6908034 0.66 rs7746588 ENSG00000228412.5 RP4-625H18.2 4.76 4.45e-06 0.00268 0.66 0.36 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19804409 chr6:19802164~19804752:- PAAD cis rs6908034 0.556 rs7750703 ENSG00000228412.5 RP4-625H18.2 4.76 4.45e-06 0.00268 0.66 0.36 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19804583 chr6:19802164~19804752:- PAAD cis rs6908034 0.66 rs7750716 ENSG00000228412.5 RP4-625H18.2 4.76 4.45e-06 0.00268 0.66 0.36 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19804608 chr6:19802164~19804752:- PAAD cis rs9649213 0.593 rs7812180 ENSG00000272950.1 RP11-307C18.1 -4.76 4.46e-06 0.00268 -0.42 -0.36 Prostate cancer (SNP x SNP interaction); chr7:98339828 chr7:98322853~98323430:+ PAAD cis rs4268898 0.76 rs7597919 ENSG00000242628.4 AC009228.1 -4.76 4.46e-06 0.00268 -0.43 -0.36 Asthma; chr2:24340777 chr2:24214381~24221516:+ PAAD cis rs1185460 1 rs1614264 ENSG00000271751.1 RP11-110I1.14 -4.76 4.46e-06 0.00268 -0.46 -0.36 Coronary artery disease; chr11:119071928 chr11:119065263~119065677:- PAAD cis rs61270009 0.955 rs12515274 ENSG00000247828.6 TMEM161B-AS1 4.76 4.46e-06 0.00268 0.3 0.36 Depressive symptoms; chr5:88359845 chr5:88268895~88436685:+ PAAD cis rs7923609 0.871 rs12245149 ENSG00000232075.1 MRPL35P2 4.76 4.47e-06 0.00268 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63561387 chr10:63634317~63634827:- PAAD cis rs26528 0.584 rs153103 ENSG00000259982.1 CDC37P1 -4.76 4.47e-06 0.00268 -0.41 -0.36 Ulcerative colitis;Crohn's disease;Inflammatory bowel disease; chr16:28517302 chr16:28700294~28701540:- PAAD cis rs4853525 0.59 rs7587672 ENSG00000235852.1 AC005540.3 4.76 4.47e-06 0.00269 0.54 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190858549 chr2:190880797~190882059:- PAAD cis rs4853525 0.59 rs1921910 ENSG00000235852.1 AC005540.3 4.76 4.47e-06 0.00269 0.54 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190859206 chr2:190880797~190882059:- PAAD cis rs4853525 0.59 rs1860168 ENSG00000235852.1 AC005540.3 4.76 4.47e-06 0.00269 0.54 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190859774 chr2:190880797~190882059:- PAAD cis rs4853525 0.59 rs9973507 ENSG00000235852.1 AC005540.3 4.76 4.47e-06 0.00269 0.54 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190860922 chr2:190880797~190882059:- PAAD cis rs453301 0.686 rs7814328 ENSG00000253893.2 FAM85B 4.76 4.48e-06 0.00269 0.49 0.36 Joint mobility (Beighton score); chr8:9018719 chr8:8167819~8226614:- PAAD cis rs12134133 1 rs11580387 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207245063 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs7518565 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207246998 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs61822669 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207247869 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs7532664 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207253598 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs55638602 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207255597 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs4844588 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207256323 chr1:207372559~207373252:+ PAAD cis rs12134133 0.927 rs4844589 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207259285 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs6540893 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207262382 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs1583090 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207262438 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs61822674 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207263378 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs10442696 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207264783 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs7535532 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207264991 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs7543117 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265351 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs6684804 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265670 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs11582249 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207268263 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs11584921 ENSG00000274245.1 RP11-357P18.2 4.76 4.48e-06 0.00269 0.59 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207268630 chr1:207372559~207373252:+ PAAD cis rs4713118 0.715 rs200480 ENSG00000216901.1 AL022393.7 4.76 4.48e-06 0.00269 0.44 0.36 Parkinson's disease; chr6:27805886 chr6:28176188~28176674:+ PAAD cis rs4664293 0.647 rs10198053 ENSG00000226266.5 AC009961.3 -4.76 4.48e-06 0.00269 -0.45 -0.36 Monocyte percentage of white cells; chr2:159605169 chr2:159670708~159712435:- PAAD cis rs4664293 0.669 rs10174515 ENSG00000226266.5 AC009961.3 -4.76 4.48e-06 0.00269 -0.45 -0.36 Monocyte percentage of white cells; chr2:159605524 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs357022 ENSG00000226266.5 AC009961.3 -4.76 4.48e-06 0.00269 -0.45 -0.36 Monocyte percentage of white cells; chr2:159632933 chr2:159670708~159712435:- PAAD cis rs2337406 0.866 rs7153964 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106790480 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs2301536 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106790636 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs2301535 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106790663 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs7144369 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106793065 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs78525520 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106795643 chr14:106723574~106724093:- PAAD cis rs10129255 0.646 rs55995061 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Kawasaki disease; chr14:106799309 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs76871148 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106799722 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs61521632 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106801091 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs4774019 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106805386 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs58850145 ENSG00000211974.3 IGHV2-70 -4.76 4.49e-06 0.00269 -0.49 -0.36 Alzheimer's disease (late onset); chr14:106806185 chr14:106723574~106724093:- PAAD cis rs17711722 0.522 rs62469933 ENSG00000236529.1 RP13-254B10.1 4.76 4.49e-06 0.0027 0.4 0.36 Calcium levels; chr7:65800652 chr7:65840212~65840596:+ PAAD cis rs2562456 0.755 rs2562421 ENSG00000213976.4 CTD-2561J22.2 4.76 4.5e-06 0.0027 0.4 0.36 Pain; chr19:21448502 chr19:21382865~21387177:+ PAAD cis rs2562456 0.793 rs2562420 ENSG00000213976.4 CTD-2561J22.2 4.76 4.5e-06 0.0027 0.4 0.36 Pain; chr19:21448503 chr19:21382865~21387177:+ PAAD cis rs2902193 0.667 rs7241820 ENSG00000267325.1 LINC01415 4.76 4.5e-06 0.0027 0.35 0.36 Cancer; chr18:55989970 chr18:55776727~55781721:- PAAD cis rs4835473 0.808 rs13134564 ENSG00000251600.4 RP11-673E1.1 -4.76 4.5e-06 0.0027 -0.4 -0.36 Immature fraction of reticulocytes; chr4:143738763 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs13134571 ENSG00000251600.4 RP11-673E1.1 -4.76 4.5e-06 0.0027 -0.4 -0.36 Immature fraction of reticulocytes; chr4:143738771 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13139738 ENSG00000251600.4 RP11-673E1.1 -4.76 4.5e-06 0.0027 -0.4 -0.36 Immature fraction of reticulocytes; chr4:143738828 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs17018165 ENSG00000251600.4 RP11-673E1.1 -4.76 4.5e-06 0.0027 -0.4 -0.36 Immature fraction of reticulocytes; chr4:143738849 chr4:143912331~143982454:+ PAAD cis rs1185460 1 rs1799993 ENSG00000271751.1 RP11-110I1.14 4.76 4.5e-06 0.0027 0.45 0.36 Coronary artery disease; chr11:119087417 chr11:119065263~119065677:- PAAD cis rs1150668 0.799 rs1150705 ENSG00000204709.4 LINC01556 4.76 4.51e-06 0.0027 0.47 0.36 Pubertal anthropometrics; chr6:28226008 chr6:28943877~28944537:+ PAAD cis rs74233809 1 rs11191454 ENSG00000213277.3 MARCKSL1P1 4.76 4.51e-06 0.0027 0.61 0.36 Birth weight; chr10:102900247 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12411886 ENSG00000213277.3 MARCKSL1P1 4.76 4.51e-06 0.0027 0.61 0.36 Birth weight; chr10:102925542 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191472 ENSG00000213277.3 MARCKSL1P1 4.76 4.51e-06 0.0027 0.61 0.36 Birth weight; chr10:102947259 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191505 ENSG00000213277.3 MARCKSL1P1 4.76 4.51e-06 0.0027 0.61 0.36 Birth weight; chr10:103007134 chr10:103175554~103176094:+ PAAD cis rs11662586 1 rs12605316 ENSG00000267270.4 PARD6G-AS1 -4.76 4.51e-06 0.0027 -0.5 -0.36 Exploratory eye movement dysfunction in schizophrenia (responsive search score); chr18:79933600 chr18:80147924~80178432:+ PAAD cis rs1823913 0.599 rs13027086 ENSG00000280083.1 RP11-317J9.1 -4.76 4.51e-06 0.00271 -0.43 -0.36 Obesity-related traits; chr2:191294058 chr2:191154118~191156070:- PAAD cis rs6061231 0.556 rs6121571 ENSG00000273619.1 RP5-908M14.9 -4.76 4.51e-06 0.00271 -0.32 -0.36 Colorectal cancer; chr20:62402267 chr20:62386303~62386970:- PAAD cis rs7773456 0.576 rs12206194 ENSG00000228412.5 RP4-625H18.2 4.76 4.52e-06 0.00271 0.5 0.36 Lupus nephritis in systemic lupus erythematosus; chr6:19819677 chr6:19802164~19804752:- PAAD cis rs2255336 0.873 rs11053806 ENSG00000245648.1 RP11-277P12.20 -4.76 4.52e-06 0.00271 -0.58 -0.36 Blood protein levels; chr12:10455822 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs10161486 ENSG00000245648.1 RP11-277P12.20 -4.76 4.52e-06 0.00271 -0.58 -0.36 Blood protein levels; chr12:10457167 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs73070924 ENSG00000245648.1 RP11-277P12.20 -4.76 4.52e-06 0.00271 -0.58 -0.36 Blood protein levels; chr12:10457386 chr12:10363769~10398506:+ PAAD cis rs113835537 0.866 rs59566349 ENSG00000255517.5 CTD-3074O7.5 -4.76 4.52e-06 0.00271 -0.61 -0.36 Airway imaging phenotypes; chr11:66598523 chr11:66473490~66480233:- PAAD cis rs113835537 0.866 rs59320108 ENSG00000255517.5 CTD-3074O7.5 -4.76 4.52e-06 0.00271 -0.61 -0.36 Airway imaging phenotypes; chr11:66598525 chr11:66473490~66480233:- PAAD cis rs8100891 0.537 rs73036023 ENSG00000267213.4 AC007773.2 -4.76 4.53e-06 0.00271 -0.59 -0.36 Neuroticism; chr19:32457414 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs11880569 ENSG00000267213.4 AC007773.2 -4.76 4.53e-06 0.00271 -0.59 -0.36 Neuroticism; chr19:32478348 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs16967141 ENSG00000267213.4 AC007773.2 -4.76 4.53e-06 0.00271 -0.59 -0.36 Neuroticism; chr19:32480317 chr19:32390050~32405560:- PAAD cis rs7615952 0.546 rs16836896 ENSG00000171084.14 FAM86JP 4.76 4.53e-06 0.00272 0.53 0.36 Blood pressure (smoking interaction); chr3:125592418 chr3:125916620~125930024:+ PAAD cis rs1976403 0.51 rs1697421 ENSG00000227001.3 NBPF2P 4.76 4.54e-06 0.00272 0.42 0.36 Liver enzyme levels (alkaline phosphatase); chr1:21496799 chr1:21424625~21427967:- PAAD cis rs2302464 1 rs57326588 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15723813 chr4:15730962~15731627:- PAAD cis rs7657257 1 rs11931532 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Blood protein levels; chr4:15724143 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs11944132 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15724291 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs73123607 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15725058 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs6844968 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15725641 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs58978163 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15726385 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs16892272 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15726456 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs73123615 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15726553 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs16892276 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15726614 chr4:15730962~15731627:- PAAD cis rs2302464 1 rs60913985 ENSG00000214846.4 RP11-115L11.1 4.76 4.54e-06 0.00272 0.92 0.36 Cerebrospinal fluid biomarker levels; chr4:15726671 chr4:15730962~15731627:- PAAD cis rs871012 0.547 rs4305634 ENSG00000251405.2 CTB-109A12.1 -4.76 4.55e-06 0.00272 -0.44 -0.36 IgG glycosylation; chr5:157384662 chr5:157362615~157460078:- PAAD cis rs42490 0.899 rs1397308 ENSG00000251136.7 RP11-37B2.1 4.76 4.55e-06 0.00272 0.34 0.36 Leprosy; chr8:89628493 chr8:89609409~89757727:- PAAD cis rs9326248 1 rs9326248 ENSG00000280143.1 AP000892.6 4.76 4.55e-06 0.00273 0.46 0.36 Blood protein levels; chr11:117128509 chr11:117204967~117210292:+ PAAD cis rs875971 0.929 rs34406470 ENSG00000237310.1 GS1-124K5.4 4.76 4.55e-06 0.00273 0.35 0.36 Aortic root size; chr7:66464969 chr7:66493706~66495474:+ PAAD cis rs7923609 0.841 rs2163188 ENSG00000232075.1 MRPL35P2 4.76 4.55e-06 0.00273 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63554951 chr10:63634317~63634827:- PAAD cis rs7923609 0.871 rs2393984 ENSG00000232075.1 MRPL35P2 4.76 4.55e-06 0.00273 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63555211 chr10:63634317~63634827:- PAAD cis rs7923609 0.871 rs6479905 ENSG00000232075.1 MRPL35P2 4.76 4.55e-06 0.00273 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63555471 chr10:63634317~63634827:- PAAD cis rs7923609 0.811 rs7919685 ENSG00000232075.1 MRPL35P2 4.76 4.55e-06 0.00273 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63556040 chr10:63634317~63634827:- PAAD cis rs7923609 0.749 rs12247907 ENSG00000232075.1 MRPL35P2 4.76 4.55e-06 0.00273 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63557285 chr10:63634317~63634827:- PAAD cis rs7923609 0.746 rs7070761 ENSG00000232075.1 MRPL35P2 4.76 4.55e-06 0.00273 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63557296 chr10:63634317~63634827:- PAAD cis rs7923609 0.871 rs7898861 ENSG00000232075.1 MRPL35P2 4.76 4.55e-06 0.00273 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63559918 chr10:63634317~63634827:- PAAD cis rs10754283 0.967 rs7552896 ENSG00000231613.1 RP5-943J3.1 4.76 4.56e-06 0.00273 0.38 0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89637635 chr1:89788914~89790492:+ PAAD cis rs989978 0.643 rs1360522 ENSG00000257582.4 LINC01475 4.76 4.57e-06 0.00273 0.43 0.36 Red blood cell count; chr10:99566040 chr10:99526350~99531177:- PAAD cis rs9322193 0.607 rs12527391 ENSG00000268592.3 RAET1E-AS1 4.76 4.57e-06 0.00273 0.49 0.36 Lung cancer; chr6:149882156 chr6:149863494~149919507:+ PAAD cis rs12134133 1 rs2564973 ENSG00000274245.1 RP11-357P18.2 4.75 4.57e-06 0.00274 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207306759 chr1:207372559~207373252:+ PAAD cis rs73173548 0.528 rs16903178 ENSG00000247828.6 TMEM161B-AS1 4.75 4.58e-06 0.00274 0.29 0.36 Macular telangiectasia type 2; chr5:88480913 chr5:88268895~88436685:+ PAAD cis rs11976180 0.517 rs6949375 ENSG00000170356.8 OR2A20P -4.75 4.58e-06 0.00274 -0.54 -0.36 Obesity-related traits; chr7:144076758 chr7:144250045~144252957:- PAAD cis rs1275468 0.954 rs1148002 ENSG00000257497.2 RP11-585P4.5 4.75 4.58e-06 0.00274 0.51 0.36 Polycystic ovary syndrome; chr12:75539244 chr12:75483454~75489820:- PAAD cis rs2153535 0.563 rs1737585 ENSG00000230939.1 RP11-314C16.1 4.75 4.58e-06 0.00274 0.38 0.36 Motion sickness; chr6:8536361 chr6:8784178~8785445:+ PAAD cis rs61270009 0.955 rs4916899 ENSG00000247828.6 TMEM161B-AS1 4.75 4.59e-06 0.00274 0.29 0.36 Depressive symptoms; chr5:88292209 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs4916898 ENSG00000247828.6 TMEM161B-AS1 4.75 4.59e-06 0.00274 0.29 0.36 Depressive symptoms; chr5:88290245 chr5:88268895~88436685:+ PAAD cis rs7615952 0.546 rs11711150 ENSG00000171084.14 FAM86JP 4.75 4.59e-06 0.00275 0.53 0.36 Blood pressure (smoking interaction); chr3:125596819 chr3:125916620~125930024:+ PAAD cis rs7615952 0.546 rs11717632 ENSG00000171084.14 FAM86JP 4.75 4.59e-06 0.00275 0.53 0.36 Blood pressure (smoking interaction); chr3:125602286 chr3:125916620~125930024:+ PAAD cis rs7615952 0.546 rs2922197 ENSG00000171084.14 FAM86JP 4.75 4.59e-06 0.00275 0.53 0.36 Blood pressure (smoking interaction); chr3:125603188 chr3:125916620~125930024:+ PAAD cis rs7727544 0.684 rs274561 ENSG00000233006.5 AC034220.3 4.75 4.6e-06 0.00275 0.29 0.36 Blood metabolite levels; chr5:132383536 chr5:132311285~132369916:- PAAD cis rs2179367 1 rs2179367 ENSG00000231760.4 RP11-350J20.5 4.75 4.6e-06 0.00275 0.47 0.36 Dupuytren's disease; chr6:149441401 chr6:149796151~149826294:- PAAD cis rs4218 0.531 rs6494065 ENSG00000277144.1 RP11-59H7.4 4.75 4.61e-06 0.00275 0.42 0.36 Social communication problems; chr15:59053249 chr15:59115547~59116089:- PAAD cis rs2348418 0.733 rs10771414 ENSG00000247934.4 RP11-967K21.1 4.75 4.61e-06 0.00276 0.36 0.36 Lung function (FEV1);Lung function (FVC); chr12:28241369 chr12:28163298~28190738:- PAAD cis rs2041895 0.565 rs10861679 ENSG00000260329.1 RP11-412D9.4 -4.75 4.61e-06 0.00276 -0.34 -0.36 Glaucoma (low intraocular pressure); chr12:106929137 chr12:106954029~106955497:- PAAD cis rs12594515 0.694 rs2068295 ENSG00000273972.1 CTD-2306A12.1 -4.75 4.61e-06 0.00276 -0.42 -0.36 Weight;Waist circumference; chr15:45693348 chr15:45702640~45703183:+ PAAD cis rs7208859 0.614 rs216474 ENSG00000266490.1 CTD-2349P21.9 -4.75 4.62e-06 0.00276 -0.42 -0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30538073 chr17:30792372~30792833:+ PAAD cis rs12571093 0.572 rs7100599 ENSG00000233590.1 RP11-153K11.3 -4.75 4.62e-06 0.00276 -0.6 -0.36 Optic nerve measurement (disc area); chr10:68309476 chr10:68233251~68242379:- PAAD cis rs12908161 0.65 rs182517 ENSG00000259728.4 LINC00933 4.75 4.62e-06 0.00276 0.48 0.36 Schizophrenia; chr15:84846400 chr15:84570649~84580175:+ PAAD cis rs74233809 0.901 rs1004467 ENSG00000213277.3 MARCKSL1P1 4.75 4.63e-06 0.00277 0.57 0.36 Birth weight; chr10:102834750 chr10:103175554~103176094:+ PAAD cis rs61270009 0.955 rs4916907 ENSG00000247828.6 TMEM161B-AS1 4.75 4.63e-06 0.00277 0.29 0.36 Depressive symptoms; chr5:88364163 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs12657776 ENSG00000247828.6 TMEM161B-AS1 4.75 4.63e-06 0.00277 0.29 0.36 Depressive symptoms; chr5:88365776 chr5:88268895~88436685:+ PAAD cis rs72843506 0.656 rs9901357 ENSG00000189423.10 USP32P3 4.75 4.64e-06 0.00277 0.53 0.36 Schizophrenia; chr17:20105729 chr17:20415547~20431008:+ PAAD cis rs964611 0.882 rs8027003 ENSG00000259488.2 RP11-154J22.1 -4.75 4.64e-06 0.00277 -0.42 -0.36 Metabolite levels (Pyroglutamine); chr15:48355229 chr15:48312353~48331856:- PAAD cis rs4268898 0.965 rs13033241 ENSG00000242628.4 AC009228.1 -4.75 4.64e-06 0.00277 -0.44 -0.36 Asthma; chr2:24253249 chr2:24214381~24221516:+ PAAD cis rs7772486 0.743 rs1292339 ENSG00000235652.6 RP11-545I5.3 -4.75 4.64e-06 0.00277 -0.3 -0.36 Lobe attachment (rater-scored or self-reported); chr6:145645950 chr6:145799409~145886585:+ PAAD cis rs748404 0.578 rs538238 ENSG00000249839.1 AC011330.5 -4.75 4.68e-06 0.00279 -0.54 -0.36 Lung cancer; chr15:43293322 chr15:43663654~43684339:- PAAD cis rs8059260 0.736 rs16957835 ENSG00000274038.1 RP11-66H6.4 -4.75 4.69e-06 0.0028 -0.58 -0.36 Alcohol consumption over the past year; chr16:10958198 chr16:11056556~11057034:+ PAAD cis rs8059260 0.551 rs7187539 ENSG00000274038.1 RP11-66H6.4 -4.75 4.69e-06 0.0028 -0.58 -0.36 Alcohol consumption over the past year; chr16:10964900 chr16:11056556~11057034:+ PAAD cis rs748404 0.587 rs690276 ENSG00000205771.5 CATSPER2P1 -4.75 4.69e-06 0.0028 -0.49 -0.36 Lung cancer; chr15:43412360 chr15:43726918~43747094:- PAAD cis rs6570726 0.846 rs973856 ENSG00000235652.6 RP11-545I5.3 -4.75 4.69e-06 0.0028 -0.29 -0.36 Lobe attachment (rater-scored or self-reported); chr6:145460780 chr6:145799409~145886585:+ PAAD cis rs2283792 1 rs2283792 ENSG00000228050.1 TOP3BP1 4.75 4.71e-06 0.00281 0.38 0.36 Multiple sclerosis; chr22:21776836 chr22:22223187~22224566:- PAAD cis rs1707322 0.656 rs3014210 ENSG00000280836.1 AL355480.1 4.75 4.72e-06 0.00281 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45600936 chr1:45581219~45581321:- PAAD cis rs7727544 0.684 rs2631363 ENSG00000233006.5 AC034220.3 -4.75 4.72e-06 0.00282 -0.29 -0.36 Blood metabolite levels; chr5:132371403 chr5:132311285~132369916:- PAAD cis rs7727544 0.684 rs611084 ENSG00000233006.5 AC034220.3 -4.75 4.72e-06 0.00282 -0.29 -0.36 Blood metabolite levels; chr5:132374047 chr5:132311285~132369916:- PAAD cis rs7727544 0.636 rs2631365 ENSG00000233006.5 AC034220.3 -4.75 4.73e-06 0.00282 -0.29 -0.36 Blood metabolite levels; chr5:132370257 chr5:132311285~132369916:- PAAD cis rs7727544 0.735 rs2569266 ENSG00000233006.5 AC034220.3 -4.75 4.73e-06 0.00282 -0.29 -0.36 Blood metabolite levels; chr5:132371099 chr5:132311285~132369916:- PAAD cis rs7727544 0.735 rs274568 ENSG00000233006.5 AC034220.3 -4.75 4.73e-06 0.00282 -0.29 -0.36 Blood metabolite levels; chr5:132377886 chr5:132311285~132369916:- PAAD cis rs2283792 0.715 rs56227348 ENSG00000224086.5 LL22NC03-86G7.1 -4.75 4.73e-06 0.00282 -0.37 -0.36 Multiple sclerosis; chr22:21791443 chr22:21938293~21977632:+ PAAD cis rs9473147 0.543 rs1004173 ENSG00000270761.1 RP11-385F7.1 -4.75 4.73e-06 0.00282 -0.36 -0.36 Platelet distribution width;Mean platelet volume; chr6:47477281 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs4715019 ENSG00000270761.1 RP11-385F7.1 -4.75 4.73e-06 0.00282 -0.36 -0.36 Platelet distribution width;Mean platelet volume; chr6:47479305 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs9367279 ENSG00000270761.1 RP11-385F7.1 -4.75 4.73e-06 0.00282 -0.36 -0.36 Platelet distribution width;Mean platelet volume; chr6:47480600 chr6:47477243~47477572:- PAAD cis rs9473147 0.543 rs9473119 ENSG00000270761.1 RP11-385F7.1 -4.75 4.73e-06 0.00282 -0.36 -0.36 Platelet distribution width;Mean platelet volume; chr6:47482882 chr6:47477243~47477572:- PAAD cis rs10754283 0.967 rs7523046 ENSG00000231613.1 RP5-943J3.1 4.75 4.74e-06 0.00282 0.38 0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89643940 chr1:89788914~89790492:+ PAAD cis rs10754283 0.967 rs7523518 ENSG00000231613.1 RP5-943J3.1 4.75 4.74e-06 0.00282 0.38 0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89644451 chr1:89788914~89790492:+ PAAD cis rs66887589 0.777 rs4643791 ENSG00000248280.1 RP11-33B1.2 -4.75 4.74e-06 0.00283 -0.32 -0.36 Diastolic blood pressure; chr4:119344464 chr4:119440561~119450157:- PAAD cis rs61270009 0.955 rs11743103 ENSG00000247828.6 TMEM161B-AS1 -4.75 4.74e-06 0.00283 -0.29 -0.36 Depressive symptoms; chr5:88380145 chr5:88268895~88436685:+ PAAD cis rs2486288 0.656 rs1706767 ENSG00000259433.2 CTD-2651B20.4 4.75 4.74e-06 0.00283 0.4 0.36 Glomerular filtration rate; chr15:45276901 chr15:45330209~45332634:- PAAD cis rs8177376 1 rs674218 ENSG00000254905.1 RP11-712L6.7 4.75 4.74e-06 0.00283 0.47 0.36 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126239165 chr11:126292922~126294254:- PAAD cis rs8177376 0.861 rs4340064 ENSG00000254905.1 RP11-712L6.7 4.75 4.74e-06 0.00283 0.47 0.36 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126242165 chr11:126292922~126294254:- PAAD cis rs8177376 1 rs73017350 ENSG00000254905.1 RP11-712L6.7 4.75 4.74e-06 0.00283 0.47 0.36 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126246064 chr11:126292922~126294254:- PAAD cis rs8177376 0.813 rs667627 ENSG00000254905.1 RP11-712L6.7 4.75 4.74e-06 0.00283 0.47 0.36 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126277802 chr11:126292922~126294254:- PAAD cis rs8177376 1 rs671492 ENSG00000254905.1 RP11-712L6.7 4.75 4.74e-06 0.00283 0.47 0.36 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126280025 chr11:126292922~126294254:- PAAD cis rs12429206 0.52 rs1870839 ENSG00000233672.5 RNASEH2B-AS1 -4.75 4.75e-06 0.00283 -0.46 -0.36 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50899732 chr13:50862172~50910764:- PAAD cis rs9287719 0.837 rs4233883 ENSG00000234818.1 AC092687.5 4.75 4.76e-06 0.00283 0.4 0.36 Prostate cancer; chr2:10615470 chr2:10589166~10604830:+ PAAD cis rs4218 0.543 rs8025246 ENSG00000277144.1 RP11-59H7.4 -4.75 4.76e-06 0.00284 -0.42 -0.36 Social communication problems; chr15:59025814 chr15:59115547~59116089:- PAAD cis rs7208859 0.673 rs216411 ENSG00000266490.1 CTD-2349P21.9 -4.75 4.76e-06 0.00284 -0.43 -0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576475 chr17:30792372~30792833:+ PAAD cis rs2404602 0.684 rs8029283 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76544799 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs12437981 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76550060 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs1603860 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76557250 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs8037847 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76564210 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs28895952 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76564435 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs11072600 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76575574 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs2047504 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76591175 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs4886819 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76609357 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11072607 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76616188 chr15:76174891~76181486:- PAAD cis rs2404602 0.66 rs11852777 ENSG00000259422.1 RP11-593F23.1 -4.74 4.77e-06 0.00284 -0.44 -0.36 Blood metabolite levels; chr15:76637451 chr15:76174891~76181486:- PAAD cis rs4273100 1 rs868698 ENSG00000228157.4 AC007952.5 4.74 4.78e-06 0.00285 0.58 0.36 Schizophrenia; chr17:19281898 chr17:19092974~19096837:+ PAAD cis rs4273100 1 rs16960499 ENSG00000228157.4 AC007952.5 4.74 4.78e-06 0.00285 0.58 0.36 Schizophrenia; chr17:19299719 chr17:19092974~19096837:+ PAAD cis rs73173548 0.502 rs6865693 ENSG00000247828.6 TMEM161B-AS1 4.74 4.78e-06 0.00285 0.29 0.36 Macular telangiectasia type 2; chr5:88419422 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs6452789 ENSG00000247828.6 TMEM161B-AS1 4.74 4.78e-06 0.00285 0.29 0.36 Macular telangiectasia type 2; chr5:88429498 chr5:88268895~88436685:+ PAAD cis rs17711722 0.523 rs313812 ENSG00000236529.1 RP13-254B10.1 -4.74 4.78e-06 0.00285 -0.4 -0.36 Calcium levels; chr7:66040056 chr7:65840212~65840596:+ PAAD cis rs17711722 0.523 rs365896 ENSG00000236529.1 RP13-254B10.1 -4.74 4.78e-06 0.00285 -0.4 -0.36 Calcium levels; chr7:66045710 chr7:65840212~65840596:+ PAAD cis rs77372450 0.748 rs11134819 ENSG00000251405.2 CTB-109A12.1 4.74 4.79e-06 0.00285 0.6 0.36 Bipolar disorder (body mass index interaction); chr5:157564500 chr5:157362615~157460078:- PAAD cis rs4853525 0.651 rs62182473 ENSG00000235852.1 AC005540.3 4.74 4.79e-06 0.00285 0.51 0.36 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190876270 chr2:190880797~190882059:- PAAD cis rs2274273 0.686 rs17253695 ENSG00000258413.1 RP11-665C16.6 4.74 4.8e-06 0.00285 0.48 0.36 Protein biomarker; chr14:55107892 chr14:55262767~55272075:- PAAD cis rs11651753 0.805 rs55822955 ENSG00000264920.1 RP11-6N17.4 -4.74 4.8e-06 0.00286 -0.39 -0.36 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47884447 chr17:47891255~47895812:- PAAD cis rs2274273 1 rs66871576 ENSG00000258413.1 RP11-665C16.6 -4.74 4.81e-06 0.00286 -0.47 -0.36 Protein biomarker; chr14:55162332 chr14:55262767~55272075:- PAAD cis rs10932679 0.708 rs741382 ENSG00000229352.1 AC007563.3 4.74 4.82e-06 0.00287 0.46 0.36 Pulse pressure; chr2:216817524 chr2:216799608~216805335:+ PAAD cis rs1075265 0.626 rs805412 ENSG00000233266.1 HMGB1P31 4.74 4.82e-06 0.00287 0.45 0.36 Chronotype;Morning vs. evening chronotype; chr2:53893683 chr2:54051334~54051760:+ PAAD cis rs710913 0.717 rs2243761 ENSG00000237624.1 OXCT2P1 -4.74 4.82e-06 0.00287 -0.44 -0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39585944 chr1:39514956~39516490:+ PAAD cis rs867529 0.722 rs67110763 ENSG00000230006.6 ANKRD36BP2 -4.74 4.82e-06 0.00287 -0.3 -0.36 Height; chr2:88651398 chr2:88765807~88806612:+ PAAD cis rs13178541 0.872 rs11242285 ENSG00000250378.1 RP11-119J18.1 -4.74 4.82e-06 0.00287 -0.56 -0.36 IgG glycosylation; chr5:135788267 chr5:135812667~135826582:+ PAAD cis rs8031584 0.958 rs7176569 ENSG00000260382.1 RP11-540B6.2 -4.74 4.82e-06 0.00287 -0.46 -0.36 Huntington's disease progression; chr15:30952292 chr15:30882267~30883231:- PAAD cis rs720064 0.586 rs891282 ENSG00000264745.1 TTC39C-AS1 4.74 4.83e-06 0.00287 0.45 0.36 Strep throat; chr18:23959096 chr18:23994213~24015339:- PAAD cis rs8100891 0.537 rs2302773 ENSG00000267213.4 AC007773.2 -4.74 4.84e-06 0.00288 -0.59 -0.36 Neuroticism; chr19:32436405 chr19:32390050~32405560:- PAAD cis rs9322193 0.607 rs4870078 ENSG00000223701.3 RAET1E-AS1 -4.74 4.84e-06 0.00288 -0.46 -0.36 Lung cancer; chr6:149880676 chr6:149884431~149919508:+ PAAD cis rs4794202 0.629 rs2010952 ENSG00000264920.1 RP11-6N17.4 4.74 4.84e-06 0.00288 0.74 0.36 Alzheimer's disease (cognitive decline); chr17:47815493 chr17:47891255~47895812:- PAAD cis rs4268898 1 rs2303294 ENSG00000242628.4 AC009228.1 -4.74 4.84e-06 0.00288 -0.44 -0.36 Asthma; chr2:24209751 chr2:24214381~24221516:+ PAAD cis rs2281636 0.823 rs4917877 ENSG00000233690.1 EBAG9P1 4.74 4.84e-06 0.00288 0.38 0.36 Obesity-related traits; chr10:99670281 chr10:99697407~99697949:- PAAD cis rs992157 0.56 rs7578940 ENSG00000261338.2 RP11-378A13.1 -4.74 4.84e-06 0.00288 -0.41 -0.36 Colorectal cancer; chr2:218218595 chr2:218255319~218257366:+ PAAD cis rs10510102 0.566 rs885543 ENSG00000276742.1 RP11-500G22.4 4.74 4.84e-06 0.00288 0.53 0.36 Breast cancer; chr10:121973536 chr10:121956782~121957098:+ PAAD cis rs11976180 1 rs6464574 ENSG00000273234.1 OR2A13P -4.74 4.85e-06 0.00288 -0.45 -0.36 Obesity-related traits; chr7:144051164 chr7:144142009~144142938:+ PAAD cis rs160451 0.782 rs160408 ENSG00000251136.7 RP11-37B2.1 4.74 4.85e-06 0.00288 0.35 0.36 Leprosy; chr8:89634730 chr8:89609409~89757727:- PAAD cis rs4218 0.681 rs12913177 ENSG00000277144.1 RP11-59H7.4 4.74 4.86e-06 0.00288 0.48 0.36 Social communication problems; chr15:59066273 chr15:59115547~59116089:- PAAD cis rs2717559 0.522 rs2572918 ENSG00000253741.1 CTD-2292P10.4 -4.74 4.86e-06 0.00289 -0.48 -0.36 Urinary tract infection frequency; chr8:142794305 chr8:142702252~142726973:- PAAD cis rs2717559 0.522 rs2585159 ENSG00000253741.1 CTD-2292P10.4 -4.74 4.86e-06 0.00289 -0.48 -0.36 Urinary tract infection frequency; chr8:142794401 chr8:142702252~142726973:- PAAD cis rs2717559 0.522 rs2585158 ENSG00000253741.1 CTD-2292P10.4 -4.74 4.86e-06 0.00289 -0.48 -0.36 Urinary tract infection frequency; chr8:142794416 chr8:142702252~142726973:- PAAD cis rs61270009 0.955 rs11741675 ENSG00000247828.6 TMEM161B-AS1 4.74 4.86e-06 0.00289 0.3 0.36 Depressive symptoms; chr5:88332984 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs4916904 ENSG00000247828.6 TMEM161B-AS1 4.74 4.86e-06 0.00289 0.3 0.36 Depressive symptoms; chr5:88338780 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs11748768 ENSG00000247828.6 TMEM161B-AS1 4.74 4.86e-06 0.00289 0.3 0.36 Depressive symptoms; chr5:88354818 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs11750391 ENSG00000247828.6 TMEM161B-AS1 4.74 4.86e-06 0.00289 0.3 0.36 Depressive symptoms; chr5:88356255 chr5:88268895~88436685:+ PAAD cis rs9287719 0.967 rs6735074 ENSG00000234818.1 AC092687.5 -4.74 4.86e-06 0.00289 -0.4 -0.36 Prostate cancer; chr2:10594640 chr2:10589166~10604830:+ PAAD cis rs55757919 1 rs55757919 ENSG00000231742.4 LINC01273 4.74 4.86e-06 0.00289 0.52 0.36 Monocyte percentage of white cells; chr20:50132011 chr20:50172550~50176671:+ PAAD cis rs2283792 0.967 rs743409 ENSG00000228050.1 TOP3BP1 4.74 4.86e-06 0.00289 0.38 0.36 Multiple sclerosis; chr22:21774926 chr22:22223187~22224566:- PAAD cis rs1545257 0.537 rs2702089 ENSG00000242628.4 AC009228.1 -4.74 4.87e-06 0.00289 -0.41 -0.36 Sjögren's syndrome; chr2:24420422 chr2:24214381~24221516:+ PAAD cis rs61270009 0.863 rs6452782 ENSG00000247828.6 TMEM161B-AS1 4.74 4.87e-06 0.00289 0.29 0.36 Depressive symptoms; chr5:88376887 chr5:88268895~88436685:+ PAAD cis rs6061231 0.654 rs2427322 ENSG00000273619.1 RP5-908M14.9 -4.74 4.88e-06 0.00289 -0.29 -0.36 Colorectal cancer; chr20:62404314 chr20:62386303~62386970:- PAAD cis rs10463554 0.746 rs6876072 ENSG00000175749.11 EIF3KP1 4.74 4.88e-06 0.00289 0.46 0.36 Parkinson's disease; chr5:103251872 chr5:103032376~103033031:+ PAAD cis rs58873874 0.737 rs11749762 ENSG00000251405.2 CTB-109A12.1 4.74 4.88e-06 0.0029 0.7 0.36 Bipolar disorder (body mass index interaction); chr5:157474607 chr5:157362615~157460078:- PAAD cis rs11651753 0.613 rs3096 ENSG00000264920.1 RP11-6N17.4 -4.74 4.88e-06 0.0029 -0.43 -0.36 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47952066 chr17:47891255~47895812:- PAAD cis rs2179367 0.959 rs585022 ENSG00000231760.4 RP11-350J20.5 4.74 4.88e-06 0.0029 0.46 0.36 Dupuytren's disease; chr6:149432168 chr6:149796151~149826294:- PAAD cis rs13178541 1 rs13178541 ENSG00000250378.1 RP11-119J18.1 -4.74 4.88e-06 0.0029 -0.53 -0.36 IgG glycosylation; chr5:135828929 chr5:135812667~135826582:+ PAAD cis rs8100891 0.537 rs10415145 ENSG00000267213.4 AC007773.2 4.74 4.88e-06 0.0029 0.56 0.36 Neuroticism; chr19:32350147 chr19:32390050~32405560:- PAAD cis rs2281636 0.898 rs7903514 ENSG00000233690.1 EBAG9P1 4.74 4.88e-06 0.0029 0.38 0.36 Obesity-related traits; chr10:99705951 chr10:99697407~99697949:- PAAD cis rs12468226 0.938 rs1474002 ENSG00000273456.1 RP11-686O6.2 4.74 4.89e-06 0.0029 0.51 0.36 Urate levels; chr2:202290195 chr2:202374932~202375604:- PAAD cis rs1275468 1 rs1148000 ENSG00000257497.2 RP11-585P4.5 -4.74 4.89e-06 0.0029 -0.51 -0.36 Polycystic ovary syndrome; chr12:75542521 chr12:75483454~75489820:- PAAD cis rs13178541 0.689 rs12521005 ENSG00000250378.1 RP11-119J18.1 -4.74 4.9e-06 0.00291 -0.56 -0.36 IgG glycosylation; chr5:135823313 chr5:135812667~135826582:+ PAAD cis rs1707322 0.627 rs3014213 ENSG00000280836.1 AL355480.1 4.74 4.91e-06 0.00291 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45579850 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs2152078 ENSG00000280836.1 AL355480.1 4.74 4.91e-06 0.00291 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45589928 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs2991979 ENSG00000280836.1 AL355480.1 4.74 4.91e-06 0.00291 0.43 0.36 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45590186 chr1:45581219~45581321:- PAAD cis rs879620 1 rs2531995 ENSG00000262888.1 RP11-462G12.2 -4.74 4.91e-06 0.00291 -0.47 -0.36 Hip circumference;Body mass index; chr16:3963466 chr16:3931217~3946305:- PAAD cis rs8396 1 rs11737481 ENSG00000271817.2 U3 -4.74 4.91e-06 0.00292 -0.39 -0.36 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158700098 chr4:158700691~158700909:+ PAAD cis rs2255336 0.817 rs4764430 ENSG00000245648.1 RP11-277P12.20 4.74 4.92e-06 0.00292 0.63 0.36 Blood protein levels; chr12:10365209 chr12:10363769~10398506:+ PAAD cis rs4660214 0.666 rs4617393 ENSG00000237624.1 OXCT2P1 -4.74 4.92e-06 0.00292 -0.47 -0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39474551 chr1:39514956~39516490:+ PAAD cis rs7429990 0.895 rs35790549 ENSG00000228638.1 FCF1P2 -4.74 4.92e-06 0.00292 -0.42 -0.36 Educational attainment (years of education); chr3:48029998 chr3:48290793~48291375:- PAAD cis rs17507216 0.958 rs72751643 ENSG00000255769.6 GOLGA2P10 -4.74 4.93e-06 0.00292 -0.46 -0.36 Excessive daytime sleepiness; chr15:82559444 chr15:82472993~82513950:- PAAD cis rs2404602 0.684 rs157759 ENSG00000259422.1 RP11-593F23.1 4.74 4.93e-06 0.00292 0.43 0.36 Blood metabolite levels; chr15:76554649 chr15:76174891~76181486:- PAAD cis rs8091660 0.624 rs6507852 ENSG00000278983.1 RP11-426J5.3 -4.74 4.94e-06 0.00293 -0.44 -0.36 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48548678 chr18:48564795~48568342:+ PAAD cis rs4664293 0.867 rs2357532 ENSG00000226266.5 AC009961.3 -4.74 4.94e-06 0.00293 -0.44 -0.36 Monocyte percentage of white cells; chr2:159740916 chr2:159670708~159712435:- PAAD cis rs2562456 0.833 rs2968078 ENSG00000213976.4 CTD-2561J22.2 4.74 4.94e-06 0.00293 0.4 0.36 Pain; chr19:21458942 chr19:21382865~21387177:+ PAAD cis rs2562456 0.755 rs2650773 ENSG00000213976.4 CTD-2561J22.2 4.74 4.94e-06 0.00293 0.4 0.36 Pain; chr19:21461286 chr19:21382865~21387177:+ PAAD cis rs9326248 0.53 rs11216171 ENSG00000280143.1 AP000892.6 4.74 4.95e-06 0.00293 0.47 0.36 Blood protein levels; chr11:116878397 chr11:117204967~117210292:+ PAAD cis rs73086581 0.592 rs6037702 ENSG00000229539.1 RP11-119B16.2 -4.74 4.95e-06 0.00293 -0.44 -0.36 Response to antidepressants in depression; chr20:3955745 chr20:3888239~3888868:- PAAD cis rs992157 0.56 rs1514132 ENSG00000261338.2 RP11-378A13.1 -4.74 4.95e-06 0.00294 -0.41 -0.36 Colorectal cancer; chr2:218219359 chr2:218255319~218257366:+ PAAD cis rs992157 0.56 rs10932763 ENSG00000261338.2 RP11-378A13.1 -4.74 4.95e-06 0.00294 -0.41 -0.36 Colorectal cancer; chr2:218221140 chr2:218255319~218257366:+ PAAD cis rs992157 0.56 rs12992937 ENSG00000261338.2 RP11-378A13.1 -4.74 4.95e-06 0.00294 -0.41 -0.36 Colorectal cancer; chr2:218222349 chr2:218255319~218257366:+ PAAD cis rs992157 0.56 rs4674274 ENSG00000261338.2 RP11-378A13.1 -4.74 4.95e-06 0.00294 -0.41 -0.36 Colorectal cancer; chr2:218224408 chr2:218255319~218257366:+ PAAD cis rs2382817 0.58 rs6756265 ENSG00000261338.2 RP11-378A13.1 -4.74 4.95e-06 0.00294 -0.41 -0.36 Crohn's disease;Ulcerative colitis;Inflammatory bowel disease; chr2:218230831 chr2:218255319~218257366:+ PAAD cis rs496547 0.756 rs562059 ENSG00000255239.1 AP002954.6 4.74 4.96e-06 0.00294 0.42 0.36 Hip minimal joint space width; chr11:118731349 chr11:118688039~118690600:- PAAD cis rs9322193 0.923 rs2880436 ENSG00000268592.3 RAET1E-AS1 4.74 4.97e-06 0.00294 0.44 0.36 Lung cancer; chr6:149859123 chr6:149863494~149919507:+ PAAD cis rs2283792 0.74 rs8140258 ENSG00000224086.5 LL22NC03-86G7.1 -4.74 4.97e-06 0.00294 -0.38 -0.36 Multiple sclerosis; chr22:21755545 chr22:21938293~21977632:+ PAAD cis rs10129255 0.585 rs2008440 ENSG00000223648.3 IGHV3-64 4.74 4.97e-06 0.00294 0.39 0.36 Kawasaki disease; chr14:106654988 chr14:106643132~106658258:- PAAD cis rs6504950 0.72 rs7216138 ENSG00000275710.1 RP11-257O5.4 4.74 4.98e-06 0.00295 0.44 0.36 Breast cancer; chr17:54918303 chr17:54964474~54964679:+ PAAD cis rs12594515 0.548 rs55932467 ENSG00000273972.1 CTD-2306A12.1 -4.74 4.98e-06 0.00295 -0.45 -0.36 Weight;Waist circumference; chr15:45704926 chr15:45702640~45703183:+ PAAD cis rs11123170 0.543 rs4849178 ENSG00000274877.1 RP11-65I12.1 -4.74 4.98e-06 0.00295 -0.48 -0.36 Renal function-related traits (BUN); chr2:113225031 chr2:113237595~113240825:+ PAAD cis rs858239 0.601 rs764534 ENSG00000226816.2 AC005082.12 4.73 4.98e-06 0.00295 0.4 0.36 Cerebrospinal fluid biomarker levels; chr7:23114316 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs2068459 ENSG00000226816.2 AC005082.12 4.73 4.98e-06 0.00295 0.4 0.36 Cerebrospinal fluid biomarker levels; chr7:23114694 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs73272053 ENSG00000226816.2 AC005082.12 4.73 4.98e-06 0.00295 0.4 0.36 Cerebrospinal fluid biomarker levels; chr7:23115906 chr7:23206013~23208045:+ PAAD cis rs17023223 0.537 rs3934789 ENSG00000231365.4 RP11-418J17.1 -4.73 4.99e-06 0.00295 -0.39 -0.36 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119140440 chr1:119140396~119275973:+ PAAD cis rs73173548 0.502 rs10505856 ENSG00000247828.6 TMEM161B-AS1 4.73 4.99e-06 0.00295 0.29 0.36 Macular telangiectasia type 2; chr5:88440636 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs10452479 ENSG00000247828.6 TMEM161B-AS1 4.73 4.99e-06 0.00295 0.29 0.36 Macular telangiectasia type 2; chr5:88445131 chr5:88268895~88436685:+ PAAD cis rs61270009 0.738 rs73171756 ENSG00000247828.6 TMEM161B-AS1 4.73 4.99e-06 0.00295 0.29 0.36 Depressive symptoms; chr5:88446454 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs12516483 ENSG00000247828.6 TMEM161B-AS1 4.73 4.99e-06 0.00295 0.29 0.36 Macular telangiectasia type 2; chr5:88454718 chr5:88268895~88436685:+ PAAD cis rs6921919 0.583 rs4254981 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28403625 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs6928771 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28407432 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs6928773 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28407433 chr6:28943877~28944537:+ PAAD cis rs6921919 0.525 rs6929825 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28411182 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs35599905 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28411886 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs1124131 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28412471 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs6899389 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28413363 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs6922374 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28413495 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs6899603 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28413528 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs6922429 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28413568 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs6922169 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28415155 chr6:28943877~28944537:+ PAAD cis rs6921919 0.559 rs13210866 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28416065 chr6:28943877~28944537:+ PAAD cis rs6921919 0.609 rs36018474 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28417752 chr6:28943877~28944537:+ PAAD cis rs6921919 0.583 rs13201726 ENSG00000204709.4 LINC01556 4.73 4.99e-06 0.00296 0.51 0.36 Autism spectrum disorder or schizophrenia; chr6:28417774 chr6:28943877~28944537:+ PAAD cis rs2882667 0.522 rs7731574 ENSG00000253404.1 AC034243.1 -4.73 4.99e-06 0.00296 -0.4 -0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139118503 chr5:138744434~138753309:- PAAD cis rs7772486 0.686 rs9373473 ENSG00000235652.6 RP11-545I5.3 4.73 5e-06 0.00296 0.3 0.36 Lobe attachment (rater-scored or self-reported); chr6:145761146 chr6:145799409~145886585:+ PAAD cis rs6921919 0.789 rs6912584 ENSG00000216901.1 AL022393.7 4.73 5e-06 0.00296 0.54 0.36 Autism spectrum disorder or schizophrenia; chr6:28341813 chr6:28176188~28176674:+ PAAD cis rs453301 0.631 rs11780774 ENSG00000253893.2 FAM85B 4.73 5e-06 0.00296 0.5 0.36 Joint mobility (Beighton score); chr8:8941601 chr8:8167819~8226614:- PAAD cis rs2717559 0.522 rs2949872 ENSG00000253741.1 CTD-2292P10.4 -4.73 5e-06 0.00296 -0.48 -0.36 Urinary tract infection frequency; chr8:142791488 chr8:142702252~142726973:- PAAD cis rs1075265 0.587 rs2542585 ENSG00000233266.1 HMGB1P31 4.73 5.01e-06 0.00297 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:53786407 chr2:54051334~54051760:+ PAAD cis rs9531006 0.636 rs36063327 ENSG00000227676.3 LINC01068 4.73 5.01e-06 0.00297 0.57 0.36 Sleep duration; chr13:79934233 chr13:79566727~79571436:+ PAAD cis rs12134133 1 rs6668683 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207285846 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs10494889 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207286963 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs1429904 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207288539 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2782854 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207289369 chr1:207372559~207373252:+ PAAD cis rs12134133 0.962 rs2564970 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207290696 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2782851 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207291717 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2782850 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207292092 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2782848 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207293407 chr1:207372559~207373252:+ PAAD cis rs12134133 0.962 rs2039543 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207294228 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2802232 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207294806 chr1:207372559~207373252:+ PAAD cis rs12134133 0.962 rs2782847 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207295766 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2802235 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207298454 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2782846 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207300495 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2802237 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207300825 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2490261 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207304124 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs2782840 ENSG00000274245.1 RP11-357P18.2 4.73 5.01e-06 0.00297 0.55 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310838 chr1:207372559~207373252:+ PAAD cis rs6496044 0.507 rs7175731 ENSG00000202081.1 RNU6-1280P -4.73 5.01e-06 0.00297 -0.42 -0.36 Interstitial lung disease; chr15:85611115 chr15:85651522~85651628:- PAAD cis rs6496044 0.507 rs1471455 ENSG00000202081.1 RNU6-1280P -4.73 5.01e-06 0.00297 -0.42 -0.36 Interstitial lung disease; chr15:85611496 chr15:85651522~85651628:- PAAD cis rs6496044 0.507 rs62022863 ENSG00000202081.1 RNU6-1280P -4.73 5.01e-06 0.00297 -0.42 -0.36 Interstitial lung disease; chr15:85618822 chr15:85651522~85651628:- PAAD cis rs2281636 0.894 rs7077070 ENSG00000233690.1 EBAG9P1 4.73 5.01e-06 0.00297 0.38 0.36 Obesity-related traits; chr10:99692220 chr10:99697407~99697949:- PAAD cis rs4835473 0.838 rs56033497 ENSG00000251600.4 RP11-673E1.1 -4.73 5.02e-06 0.00297 -0.4 -0.36 Immature fraction of reticulocytes; chr4:143792341 chr4:143912331~143982454:+ PAAD cis rs1122900 1 rs56039629 ENSG00000250155.1 CTD-2353F22.1 4.73 5.02e-06 0.00297 0.37 0.36 Aggressive periodontitis; chr5:36683801 chr5:36666214~36725195:- PAAD cis rs75422866 0.541 rs12425816 ENSG00000257433.4 RP1-197B17.3 4.73 5.02e-06 0.00297 0.69 0.36 Pneumonia; chr12:47731419 chr12:47706085~47742294:+ PAAD cis rs62229266 0.625 rs62230813 ENSG00000231106.2 LINC01436 4.73 5.03e-06 0.00297 0.51 0.36 Mitral valve prolapse; chr21:36031134 chr21:36005338~36007838:+ PAAD cis rs2408955 0.715 rs1793957 ENSG00000240399.1 RP1-228P16.1 4.73 5.03e-06 0.00297 0.37 0.36 Glycated hemoglobin levels; chr12:47999041 chr12:48054813~48055591:- PAAD cis rs7646881 1 rs73015651 ENSG00000240207.5 RP11-379F4.4 -4.73 5.03e-06 0.00298 -0.53 -0.36 Tetralogy of Fallot; chr3:158733133 chr3:158732263~158784070:+ PAAD cis rs12908161 0.96 rs17599989 ENSG00000259728.4 LINC00933 4.73 5.03e-06 0.00298 0.47 0.36 Schizophrenia; chr15:84742305 chr15:84570649~84580175:+ PAAD cis rs8396 0.883 rs67481496 ENSG00000271817.2 U3 4.73 5.04e-06 0.00298 0.42 0.36 Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits; chr4:158701758 chr4:158700691~158700909:+ PAAD cis rs7397814 0.558 rs4764447 ENSG00000256673.1 RP11-599J14.2 4.73 5.05e-06 0.00299 0.41 0.36 IgG glycosylation; chr12:9426513 chr12:9398355~9414851:- PAAD cis rs160451 0.934 rs160422 ENSG00000251136.7 RP11-37B2.1 4.73 5.05e-06 0.00299 0.33 0.36 Leprosy; chr8:89657610 chr8:89609409~89757727:- PAAD cis rs875971 0.545 rs221986 ENSG00000226824.5 RP4-756H11.3 4.73 5.05e-06 0.00299 0.5 0.36 Aortic root size; chr7:66105323 chr7:66654538~66669855:+ PAAD cis rs6921919 0.887 rs7766356 ENSG00000216901.1 AL022393.7 4.73 5.05e-06 0.00299 0.57 0.36 Autism spectrum disorder or schizophrenia; chr6:28432761 chr6:28176188~28176674:+ PAAD cis rs61270009 0.863 rs35339529 ENSG00000247828.6 TMEM161B-AS1 4.73 5.05e-06 0.00299 0.3 0.36 Depressive symptoms; chr5:88360284 chr5:88268895~88436685:+ PAAD cis rs9556958 0.527 rs9517313 ENSG00000231194.1 FARP1-AS1 4.73 5.06e-06 0.00299 0.39 0.36 Educational attainment (years of education); chr13:98453638 chr13:98435405~98435840:- PAAD cis rs992157 0.56 rs4674275 ENSG00000261338.2 RP11-378A13.1 -4.73 5.06e-06 0.00299 -0.41 -0.36 Colorectal cancer; chr2:218233015 chr2:218255319~218257366:+ PAAD cis rs992157 0.585 rs62182795 ENSG00000261338.2 RP11-378A13.1 -4.73 5.06e-06 0.00299 -0.41 -0.36 Colorectal cancer; chr2:218235479 chr2:218255319~218257366:+ PAAD cis rs7945705 0.846 rs905290 ENSG00000254860.4 TMEM9B-AS1 -4.73 5.06e-06 0.00299 -0.41 -0.36 Hemoglobin concentration; chr11:8732182 chr11:8964675~8977527:+ PAAD cis rs4865169 0.595 rs4865165 ENSG00000269949.1 RP11-738E22.3 -4.73 5.07e-06 0.00299 -0.47 -0.36 Breast cancer; chr4:56899380 chr4:56960927~56961373:- PAAD cis rs989978 0.583 rs2902288 ENSG00000257582.4 LINC01475 4.73 5.07e-06 0.003 0.6 0.36 Red blood cell count; chr10:99564608 chr10:99526350~99531177:- PAAD cis rs4835473 0.808 rs1984810 ENSG00000251600.4 RP11-673E1.1 4.73 5.07e-06 0.003 0.39 0.36 Immature fraction of reticulocytes; chr4:143824970 chr4:143912331~143982454:+ PAAD cis rs4835473 0.831 rs1984809 ENSG00000251600.4 RP11-673E1.1 4.73 5.07e-06 0.003 0.39 0.36 Immature fraction of reticulocytes; chr4:143825018 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs10857413 ENSG00000251600.4 RP11-673E1.1 4.73 5.07e-06 0.003 0.39 0.36 Immature fraction of reticulocytes; chr4:143827752 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6828935 ENSG00000251600.4 RP11-673E1.1 4.73 5.07e-06 0.003 0.39 0.36 Immature fraction of reticulocytes; chr4:143829113 chr4:143912331~143982454:+ PAAD cis rs9322193 0.607 rs6925151 ENSG00000223701.3 RAET1E-AS1 4.73 5.08e-06 0.003 0.47 0.36 Lung cancer; chr6:149889587 chr6:149884431~149919508:+ PAAD cis rs7615952 0.546 rs2979307 ENSG00000171084.14 FAM86JP -4.73 5.08e-06 0.003 -0.52 -0.36 Blood pressure (smoking interaction); chr3:125590730 chr3:125916620~125930024:+ PAAD cis rs2486288 0.656 rs7171312 ENSG00000259433.2 CTD-2651B20.4 4.73 5.08e-06 0.003 0.39 0.36 Glomerular filtration rate; chr15:45278027 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs6493143 ENSG00000259433.2 CTD-2651B20.4 4.73 5.08e-06 0.003 0.39 0.36 Glomerular filtration rate; chr15:45278583 chr15:45330209~45332634:- PAAD cis rs11098499 0.739 rs9996382 ENSG00000245958.5 RP11-33B1.1 -4.73 5.09e-06 0.003 -0.28 -0.36 Corneal astigmatism; chr4:119229857 chr4:119454791~119552025:+ PAAD cis rs2283792 0.765 rs2283793 ENSG00000224086.5 LL22NC03-86G7.1 -4.73 5.09e-06 0.00301 -0.37 -0.36 Multiple sclerosis; chr22:21827189 chr22:21938293~21977632:+ PAAD cis rs2283792 0.765 rs9607298 ENSG00000224086.5 LL22NC03-86G7.1 -4.73 5.09e-06 0.00301 -0.37 -0.36 Multiple sclerosis; chr22:21829844 chr22:21938293~21977632:+ PAAD cis rs1075265 0.54 rs2542587 ENSG00000233266.1 HMGB1P31 4.73 5.09e-06 0.00301 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:53788839 chr2:54051334~54051760:+ PAAD cis rs1075265 0.563 rs2692537 ENSG00000233266.1 HMGB1P31 4.73 5.09e-06 0.00301 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:53788840 chr2:54051334~54051760:+ PAAD cis rs12817211 0.502 rs7307230 ENSG00000272368.2 RP4-605O3.4 4.73 5.1e-06 0.00301 0.34 0.36 Colorectal or endometrial cancer; chr12:50118849 chr12:50112197~50165618:+ PAAD cis rs8062405 0.54 rs151226 ENSG00000259982.1 CDC37P1 4.73 5.1e-06 0.00301 0.37 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28538502 chr16:28700294~28701540:- PAAD cis rs8062405 0.558 rs151228 ENSG00000259982.1 CDC37P1 4.73 5.1e-06 0.00301 0.37 0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28551705 chr16:28700294~28701540:- PAAD cis rs17301013 0.507 rs11810824 ENSG00000227373.4 RP11-160H22.5 -4.73 5.11e-06 0.00301 -0.49 -0.36 Systemic lupus erythematosus; chr1:174408223 chr1:174115300~174160004:- PAAD cis rs11673344 0.528 rs578655 ENSG00000226686.6 LINC01535 4.73 5.11e-06 0.00302 0.48 0.36 Obesity-related traits; chr19:36919855 chr19:37251912~37265535:+ PAAD cis rs11159086 0.793 rs4903229 ENSG00000259005.1 RP3-449M8.6 4.73 5.11e-06 0.00302 0.47 0.36 Advanced glycation end-product levels; chr14:74489865 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs8016972 ENSG00000259005.1 RP3-449M8.6 4.73 5.11e-06 0.00302 0.47 0.36 Advanced glycation end-product levels; chr14:74491833 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs8015894 ENSG00000259005.1 RP3-449M8.6 4.73 5.11e-06 0.00302 0.47 0.36 Advanced glycation end-product levels; chr14:74491917 chr14:74474007~74474864:- PAAD cis rs7829975 0.774 rs1703982 ENSG00000253893.2 FAM85B 4.73 5.11e-06 0.00302 0.52 0.36 Mood instability; chr8:8740878 chr8:8167819~8226614:- PAAD cis rs7646881 0.904 rs112493023 ENSG00000240207.5 RP11-379F4.4 -4.73 5.12e-06 0.00302 -0.53 -0.36 Tetralogy of Fallot; chr3:158730487 chr3:158732263~158784070:+ PAAD cis rs10740039 0.67 rs7088798 ENSG00000254271.1 RP11-131N11.4 4.73 5.13e-06 0.00303 0.41 0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60716147 chr10:60734342~60741828:+ PAAD cis rs6782228 1 rs12495411 ENSG00000242551.2 POU5F1P6 4.73 5.13e-06 0.00303 0.47 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128676852 chr3:128674735~128677005:- PAAD cis rs6782228 1 rs6775011 ENSG00000242551.2 POU5F1P6 4.73 5.13e-06 0.00303 0.47 0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128677640 chr3:128674735~128677005:- PAAD cis rs36051354 0.592 rs2710332 ENSG00000242142.1 SERBP1P3 4.73 5.13e-06 0.00303 0.47 0.36 Intelligence (multi-trait analysis); chr3:52944675 chr3:53064283~53065091:- PAAD cis rs498872 0.507 rs10892247 ENSG00000255239.1 AP002954.6 -4.73 5.13e-06 0.00303 -0.47 -0.36 Glioma; chr11:118619361 chr11:118688039~118690600:- PAAD cis rs1823913 0.637 rs4853584 ENSG00000280083.1 RP11-317J9.1 4.73 5.13e-06 0.00303 0.43 0.36 Obesity-related traits; chr2:191310596 chr2:191154118~191156070:- PAAD cis rs1823913 0.614 rs12616167 ENSG00000280083.1 RP11-317J9.1 4.73 5.13e-06 0.00303 0.43 0.36 Obesity-related traits; chr2:191311274 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs4613316 ENSG00000280083.1 RP11-317J9.1 -4.73 5.14e-06 0.00303 -0.43 -0.36 Obesity-related traits; chr2:191326074 chr2:191154118~191156070:- PAAD cis rs2274273 1 rs3742566 ENSG00000258413.1 RP11-665C16.6 -4.73 5.14e-06 0.00303 -0.47 -0.36 Protein biomarker; chr14:55129121 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs1047556 ENSG00000258413.1 RP11-665C16.6 -4.73 5.14e-06 0.00303 -0.47 -0.36 Protein biomarker; chr14:55133564 chr14:55262767~55272075:- PAAD cis rs62229266 0.633 rs743420 ENSG00000231106.2 LINC01436 4.73 5.15e-06 0.00303 0.51 0.36 Mitral valve prolapse; chr21:36015104 chr21:36005338~36007838:+ PAAD cis rs4664293 1 rs10184034 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159648916 chr2:159670708~159712435:- PAAD cis rs4664293 1 rs4664293 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159649241 chr2:159670708~159712435:- PAAD cis rs4664293 1 rs10193402 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159651271 chr2:159670708~159712435:- PAAD cis rs4664293 1 rs11676412 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159651560 chr2:159670708~159712435:- PAAD cis rs4664293 0.934 rs7604482 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159657315 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs10176436 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159658883 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs7559127 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159659424 chr2:159670708~159712435:- PAAD cis rs6751744 0.514 rs12386214 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Dysphagia; chr2:159675012 chr2:159670708~159712435:- PAAD cis rs4664293 0.932 rs4665104 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159675847 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs7595639 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159676533 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs7597482 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159690580 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs7597488 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159690585 chr2:159670708~159712435:- PAAD cis rs4664293 0.902 rs13391919 ENSG00000226266.5 AC009961.3 -4.73 5.15e-06 0.00303 -0.44 -0.36 Monocyte percentage of white cells; chr2:159703649 chr2:159670708~159712435:- PAAD cis rs2337406 0.704 rs1858679 ENSG00000274576.2 IGHV2-70 -4.73 5.15e-06 0.00304 -0.48 -0.36 Alzheimer's disease (late onset); chr14:106706726 chr14:106770577~106771020:- PAAD cis rs7923609 0.967 rs10740134 ENSG00000232075.1 MRPL35P2 -4.73 5.16e-06 0.00304 -0.44 -0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63555673 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs2393986 ENSG00000232075.1 MRPL35P2 -4.73 5.16e-06 0.00304 -0.44 -0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63560246 chr10:63634317~63634827:- PAAD cis rs9287719 1 rs9679122 ENSG00000234818.1 AC092687.5 4.73 5.16e-06 0.00304 0.4 0.36 Prostate cancer; chr2:10611584 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs9679581 ENSG00000234818.1 AC092687.5 4.73 5.16e-06 0.00304 0.4 0.36 Prostate cancer; chr2:10611610 chr2:10589166~10604830:+ PAAD cis rs748404 0.69 rs2467737 ENSG00000205771.5 CATSPER2P1 -4.73 5.16e-06 0.00304 -0.49 -0.36 Lung cancer; chr15:43444990 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs2439846 ENSG00000205771.5 CATSPER2P1 -4.73 5.16e-06 0.00304 -0.49 -0.36 Lung cancer; chr15:43448772 chr15:43726918~43747094:- PAAD cis rs11079159 0.606 rs4239192 ENSG00000263096.1 RP11-515O17.2 4.73 5.17e-06 0.00305 0.43 0.36 QRS duration; chr17:55299143 chr17:55271504~55273653:- PAAD cis rs748404 0.56 rs1060939 ENSG00000205771.5 CATSPER2P1 -4.73 5.17e-06 0.00305 -0.5 -0.36 Lung cancer; chr15:43524719 chr15:43726918~43747094:- PAAD cis rs160451 0.811 rs2735886 ENSG00000251136.7 RP11-37B2.1 4.73 5.17e-06 0.00305 0.35 0.36 Leprosy; chr8:89639406 chr8:89609409~89757727:- PAAD cis rs992157 0.56 rs12987130 ENSG00000261338.2 RP11-378A13.1 -4.73 5.18e-06 0.00305 -0.41 -0.36 Colorectal cancer; chr2:218240267 chr2:218255319~218257366:+ PAAD cis rs992157 0.56 rs6738394 ENSG00000261338.2 RP11-378A13.1 -4.73 5.18e-06 0.00305 -0.41 -0.36 Colorectal cancer; chr2:218245902 chr2:218255319~218257366:+ PAAD cis rs992157 0.56 rs6436047 ENSG00000261338.2 RP11-378A13.1 4.73 5.18e-06 0.00305 0.41 0.36 Colorectal cancer; chr2:218244190 chr2:218255319~218257366:+ PAAD cis rs58873874 1 rs58873874 ENSG00000251405.2 CTB-109A12.1 4.73 5.18e-06 0.00305 0.7 0.36 Bipolar disorder (body mass index interaction); chr5:157518140 chr5:157362615~157460078:- PAAD cis rs6921919 0.789 rs11970439 ENSG00000216901.1 AL022393.7 4.73 5.2e-06 0.00306 0.54 0.36 Autism spectrum disorder or schizophrenia; chr6:28335687 chr6:28176188~28176674:+ PAAD cis rs7188445 0.736 rs4243177 ENSG00000261390.4 RP11-345M22.2 4.72 5.2e-06 0.00306 0.47 0.36 Urate levels; chr16:79669932 chr16:79715232~79770563:- PAAD cis rs111580313 0.685 rs7206713 ENSG00000270020.1 RP11-463O9.9 4.72 5.2e-06 0.00306 0.96 0.36 Systemic juvenile idiopathic arthritis; chr16:86564438 chr16:86520383~86523897:- PAAD cis rs111580313 0.685 rs79667308 ENSG00000270020.1 RP11-463O9.9 4.72 5.2e-06 0.00306 0.96 0.36 Systemic juvenile idiopathic arthritis; chr16:86564444 chr16:86520383~86523897:- PAAD cis rs16828019 0.929 rs111309254 ENSG00000235358.1 RP11-399E6.1 4.72 5.2e-06 0.00306 0.67 0.36 Intelligence (multi-trait analysis); chr1:41270328 chr1:41242373~41284861:+ PAAD cis rs16828019 0.929 rs4131949 ENSG00000235358.1 RP11-399E6.1 4.72 5.2e-06 0.00306 0.67 0.36 Intelligence (multi-trait analysis); chr1:41272965 chr1:41242373~41284861:+ PAAD cis rs16828019 0.929 rs35813191 ENSG00000235358.1 RP11-399E6.1 4.72 5.2e-06 0.00306 0.67 0.36 Intelligence (multi-trait analysis); chr1:41277128 chr1:41242373~41284861:+ PAAD cis rs4728142 0.604 rs13242262 ENSG00000275106.1 RP11-309L24.10 -4.72 5.2e-06 0.00306 -0.49 -0.36 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128951310 chr7:128952527~128953316:- PAAD cis rs74233809 1 rs11191582 ENSG00000213277.3 MARCKSL1P1 4.72 5.21e-06 0.00307 0.63 0.36 Birth weight; chr10:103153896 chr10:103175554~103176094:+ PAAD cis rs1545257 0.55 rs66943245 ENSG00000242628.4 AC009228.1 4.72 5.21e-06 0.00307 0.41 0.36 Sjögren's syndrome; chr2:24408206 chr2:24214381~24221516:+ PAAD cis rs10754283 0.967 rs10922680 ENSG00000231613.1 RP5-943J3.1 -4.72 5.21e-06 0.00307 -0.38 -0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89635767 chr1:89788914~89790492:+ PAAD cis rs2486288 0.656 rs11637364 ENSG00000259433.2 CTD-2651B20.4 4.72 5.22e-06 0.00307 0.4 0.36 Glomerular filtration rate; chr15:45287040 chr15:45330209~45332634:- PAAD cis rs4273100 1 rs16960158 ENSG00000228157.4 AC007952.5 4.72 5.22e-06 0.00307 0.58 0.36 Schizophrenia; chr17:19259739 chr17:19092974~19096837:+ PAAD cis rs7829975 0.714 rs6994038 ENSG00000253893.2 FAM85B -4.72 5.23e-06 0.00308 -0.49 -0.36 Mood instability; chr8:8803028 chr8:8167819~8226614:- PAAD cis rs950880 0.71 rs55927292 ENSG00000234389.1 AC007278.3 -4.72 5.25e-06 0.00309 -0.36 -0.36 Serum protein levels (sST2); chr2:102348401 chr2:102438713~102440475:+ PAAD cis rs1545257 0.537 rs2339948 ENSG00000242628.4 AC009228.1 4.72 5.26e-06 0.00309 0.41 0.36 Sjögren's syndrome; chr2:24418143 chr2:24214381~24221516:+ PAAD cis rs889398 0.967 rs12599391 ENSG00000226232.7 RP11-419C5.2 -4.72 5.26e-06 0.00309 -0.29 -0.36 Body mass index; chr16:69571446 chr16:69976388~69996188:- PAAD cis rs4927850 1 rs4927850 ENSG00000231464.1 AC024937.4 -4.72 5.26e-06 0.00309 -0.42 -0.36 Pancreatic cancer; chr3:196024759 chr3:195996738~195998233:+ PAAD cis rs8100891 0.506 rs4804992 ENSG00000267213.4 AC007773.2 -4.72 5.27e-06 0.00309 -0.57 -0.36 Neuroticism; chr19:32367885 chr19:32390050~32405560:- PAAD cis rs2111504 0.945 rs1861780 ENSG00000267213.4 AC007773.2 -4.72 5.27e-06 0.00309 -0.57 -0.36 Bipolar disorder; chr19:32372138 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs4805755 ENSG00000267213.4 AC007773.2 4.72 5.27e-06 0.00309 0.57 0.36 Neuroticism; chr19:32363564 chr19:32390050~32405560:- PAAD cis rs1185460 0.967 rs1177563 ENSG00000271751.1 RP11-110I1.14 -4.72 5.27e-06 0.00309 -0.47 -0.36 Coronary artery disease; chr11:119078373 chr11:119065263~119065677:- PAAD cis rs160451 0.84 rs216990 ENSG00000251136.7 RP11-37B2.1 4.72 5.27e-06 0.0031 0.36 0.36 Leprosy; chr8:89664572 chr8:89609409~89757727:- PAAD cis rs160451 0.782 rs218892 ENSG00000251136.7 RP11-37B2.1 4.72 5.27e-06 0.0031 0.36 0.36 Leprosy; chr8:89685582 chr8:89609409~89757727:- PAAD cis rs160451 0.782 rs10956226 ENSG00000251136.7 RP11-37B2.1 4.72 5.27e-06 0.0031 0.36 0.36 Leprosy; chr8:89687131 chr8:89609409~89757727:- PAAD cis rs1823913 0.599 rs35892286 ENSG00000280083.1 RP11-317J9.1 -4.72 5.28e-06 0.0031 -0.42 -0.36 Obesity-related traits; chr2:191269010 chr2:191154118~191156070:- PAAD cis rs12468226 1 rs16839090 ENSG00000273456.1 RP11-686O6.2 4.72 5.28e-06 0.0031 0.54 0.36 Urate levels; chr2:202348338 chr2:202374932~202375604:- PAAD cis rs12468226 1 rs58288071 ENSG00000273456.1 RP11-686O6.2 4.72 5.28e-06 0.0031 0.54 0.36 Urate levels; chr2:202350016 chr2:202374932~202375604:- PAAD cis rs7772486 0.713 rs2328704 ENSG00000235652.6 RP11-545I5.3 -4.72 5.28e-06 0.0031 -0.3 -0.36 Lobe attachment (rater-scored or self-reported); chr6:145699358 chr6:145799409~145886585:+ PAAD cis rs7772486 0.743 rs62433835 ENSG00000235652.6 RP11-545I5.3 -4.72 5.28e-06 0.0031 -0.3 -0.36 Lobe attachment (rater-scored or self-reported); chr6:145711552 chr6:145799409~145886585:+ PAAD cis rs7772486 0.743 rs2092262 ENSG00000235652.6 RP11-545I5.3 -4.72 5.28e-06 0.0031 -0.3 -0.36 Lobe attachment (rater-scored or self-reported); chr6:145715969 chr6:145799409~145886585:+ PAAD cis rs7772486 0.682 rs1337840 ENSG00000235652.6 RP11-545I5.3 -4.72 5.28e-06 0.0031 -0.3 -0.36 Lobe attachment (rater-scored or self-reported); chr6:145721422 chr6:145799409~145886585:+ PAAD cis rs6908034 0.769 rs6916589 ENSG00000228412.5 RP4-625H18.2 4.72 5.28e-06 0.0031 0.64 0.36 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19761132 chr6:19802164~19804752:- PAAD cis rs4835473 0.897 rs1817027 ENSG00000251600.4 RP11-673E1.1 -4.72 5.29e-06 0.0031 -0.4 -0.36 Immature fraction of reticulocytes; chr4:143713336 chr4:143912331~143982454:+ PAAD cis rs4835473 0.801 rs999049 ENSG00000251600.4 RP11-673E1.1 -4.72 5.29e-06 0.0031 -0.4 -0.36 Immature fraction of reticulocytes; chr4:143715440 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs11735341 ENSG00000251600.4 RP11-673E1.1 -4.72 5.29e-06 0.0031 -0.4 -0.36 Immature fraction of reticulocytes; chr4:143716030 chr4:143912331~143982454:+ PAAD cis rs9637599 0.967 rs7661312 ENSG00000246375.2 RP11-10L7.1 4.72 5.29e-06 0.00311 0.43 0.36 Metabolite levels (small molecules and protein measures); chr4:88279855 chr4:88284942~88331421:+ PAAD cis rs17684571 0.751 rs4415160 ENSG00000231441.1 RP11-472M19.2 -4.72 5.29e-06 0.00311 -0.65 -0.36 Schizophrenia; chr6:56821424 chr6:56844002~56864078:+ PAAD cis rs17684571 0.751 rs7775182 ENSG00000231441.1 RP11-472M19.2 4.72 5.29e-06 0.00311 0.65 0.36 Schizophrenia; chr6:56831848 chr6:56844002~56864078:+ PAAD cis rs6496044 0.507 rs8034676 ENSG00000202081.1 RNU6-1280P 4.72 5.29e-06 0.00311 0.42 0.36 Interstitial lung disease; chr15:85616031 chr15:85651522~85651628:- PAAD cis rs6921919 0.945 rs7765989 ENSG00000204709.4 LINC01556 4.72 5.29e-06 0.00311 0.62 0.36 Autism spectrum disorder or schizophrenia; chr6:28432518 chr6:28943877~28944537:+ PAAD cis rs6921919 0.887 rs16894116 ENSG00000204709.4 LINC01556 4.72 5.29e-06 0.00311 0.62 0.36 Autism spectrum disorder or schizophrenia; chr6:28447190 chr6:28943877~28944537:+ PAAD cis rs2980439 0.525 rs2980508 ENSG00000173295.6 FAM86B3P 4.72 5.29e-06 0.00311 0.37 0.36 Neuroticism; chr8:8314210 chr8:8228595~8244865:+ PAAD cis rs1823913 0.637 rs6722183 ENSG00000280083.1 RP11-317J9.1 4.72 5.3e-06 0.00311 0.43 0.36 Obesity-related traits; chr2:191333203 chr2:191154118~191156070:- PAAD cis rs4879677 0.96 rs9695050 ENSG00000260390.1 RP11-575I8.1 4.72 5.3e-06 0.00311 0.43 0.36 Gut microbiome composition (summer and winter); chr9:27671900 chr9:27829276~27844481:+ PAAD cis rs7829975 0.684 rs488904 ENSG00000253893.2 FAM85B 4.72 5.3e-06 0.00311 0.52 0.36 Mood instability; chr8:8730061 chr8:8167819~8226614:- PAAD cis rs2115630 0.764 rs11073716 ENSG00000225151.9 GOLGA2P7 4.72 5.31e-06 0.00312 0.44 0.36 P wave terminal force; chr15:84792543 chr15:84199311~84230136:- PAAD cis rs7119038 0.509 rs10790261 ENSG00000255239.1 AP002954.6 4.72 5.31e-06 0.00312 0.47 0.36 Sjögren's syndrome; chr11:118709038 chr11:118688039~118690600:- PAAD cis rs11654699 0.806 rs59725932 ENSG00000274341.1 RP11-227G15.10 4.72 5.31e-06 0.00312 0.34 0.36 Neurofibrillary tangles; chr17:32601694 chr17:32408013~32408309:+ PAAD cis rs11654699 0.806 rs1112170 ENSG00000274341.1 RP11-227G15.10 4.72 5.31e-06 0.00312 0.34 0.36 Neurofibrillary tangles; chr17:32601872 chr17:32408013~32408309:+ PAAD cis rs11654699 0.773 rs2055091 ENSG00000274341.1 RP11-227G15.10 4.72 5.31e-06 0.00312 0.34 0.36 Neurofibrillary tangles; chr17:32610729 chr17:32408013~32408309:+ PAAD cis rs2277027 0.518 rs11134774 ENSG00000251405.2 CTB-109A12.1 4.72 5.31e-06 0.00312 0.45 0.36 Pulmonary function;Pulmonary function (smoking interaction); chr5:157504266 chr5:157362615~157460078:- PAAD cis rs79040073 0.563 rs73392233 ENSG00000259531.2 RP11-295H24.3 4.72 5.31e-06 0.00312 0.53 0.36 Lung cancer in ever smokers; chr15:49214881 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs79452929 ENSG00000259531.2 RP11-295H24.3 4.72 5.31e-06 0.00312 0.53 0.36 Lung cancer in ever smokers; chr15:49216166 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs57560518 ENSG00000259531.2 RP11-295H24.3 4.72 5.31e-06 0.00312 0.53 0.36 Lung cancer in ever smokers; chr15:49218760 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs8025550 ENSG00000259531.2 RP11-295H24.3 -4.72 5.31e-06 0.00312 -0.53 -0.36 Lung cancer in ever smokers; chr15:49222870 chr15:49365124~49366685:- PAAD cis rs17826219 0.585 rs8064302 ENSG00000266490.1 CTD-2349P21.9 -4.72 5.32e-06 0.00312 -0.42 -0.36 Body mass index; chr17:30397920 chr17:30792372~30792833:+ PAAD cis rs710913 0.618 rs6587 ENSG00000237624.1 OXCT2P1 4.72 5.32e-06 0.00312 0.43 0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39624273 chr1:39514956~39516490:+ PAAD cis rs9531006 0.636 rs9601293 ENSG00000227676.3 LINC01068 4.72 5.32e-06 0.00312 0.56 0.36 Sleep duration; chr13:79934759 chr13:79566727~79571436:+ PAAD cis rs8100891 0.537 rs738093 ENSG00000267213.4 AC007773.2 -4.72 5.33e-06 0.00312 -0.59 -0.36 Neuroticism; chr19:32439601 chr19:32390050~32405560:- PAAD cis rs321358 0.945 rs7931995 ENSG00000271390.1 RP11-89C3.3 4.72 5.35e-06 0.00314 0.55 0.36 Body mass index; chr11:111117691 chr11:111089870~111090368:- PAAD cis rs6844153 0.752 rs73811400 ENSG00000240005.4 RP11-293A21.1 -4.72 5.35e-06 0.00314 -0.5 -0.36 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26887701 chr4:26859806~26860599:- PAAD cis rs10510102 0.935 rs79360006 ENSG00000276742.1 RP11-500G22.4 4.72 5.35e-06 0.00314 0.53 0.36 Breast cancer; chr10:121912856 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200252 ENSG00000276742.1 RP11-500G22.4 4.72 5.35e-06 0.00314 0.53 0.36 Breast cancer; chr10:121914728 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12254184 ENSG00000276742.1 RP11-500G22.4 4.72 5.35e-06 0.00314 0.53 0.36 Breast cancer; chr10:121914971 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200253 ENSG00000276742.1 RP11-500G22.4 4.72 5.35e-06 0.00314 0.53 0.36 Breast cancer; chr10:121915114 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200254 ENSG00000276742.1 RP11-500G22.4 4.72 5.35e-06 0.00314 0.53 0.36 Breast cancer; chr10:121915241 chr10:121956782~121957098:+ PAAD cis rs8100891 0.537 rs4805754 ENSG00000267213.4 AC007773.2 -4.72 5.35e-06 0.00314 -0.58 -0.36 Neuroticism; chr19:32346260 chr19:32390050~32405560:- PAAD cis rs10740039 0.583 rs10740042 ENSG00000254271.1 RP11-131N11.4 4.72 5.35e-06 0.00314 0.43 0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60736828 chr10:60734342~60741828:+ PAAD cis rs992157 0.764 rs10932774 ENSG00000261338.2 RP11-378A13.1 4.72 5.35e-06 0.00314 0.43 0.36 Colorectal cancer; chr2:218326846 chr2:218255319~218257366:+ PAAD cis rs62103177 0.525 rs62101233 ENSG00000261126.6 RP11-795F19.1 4.72 5.35e-06 0.00314 0.49 0.36 Opioid sensitivity; chr18:79964288 chr18:80046900~80095482:+ PAAD cis rs4664293 0.967 rs13032135 ENSG00000226266.5 AC009961.3 -4.72 5.36e-06 0.00314 -0.44 -0.36 Monocyte percentage of white cells; chr2:159675588 chr2:159670708~159712435:- PAAD cis rs4664293 0.934 rs4380179 ENSG00000226266.5 AC009961.3 -4.72 5.36e-06 0.00314 -0.44 -0.36 Monocyte percentage of white cells; chr2:159685064 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs10803758 ENSG00000226266.5 AC009961.3 -4.72 5.36e-06 0.00314 -0.44 -0.36 Monocyte percentage of white cells; chr2:159691708 chr2:159670708~159712435:- PAAD cis rs7773456 0.576 rs4140624 ENSG00000228412.5 RP4-625H18.2 -4.72 5.37e-06 0.00315 -0.5 -0.36 Lupus nephritis in systemic lupus erythematosus; chr6:19818329 chr6:19802164~19804752:- PAAD cis rs9828933 0.752 rs13433909 ENSG00000280620.1 SCAANT1 4.72 5.37e-06 0.00315 0.6 0.36 Type 2 diabetes; chr3:63962933 chr3:63911518~63911772:- PAAD cis rs4713118 0.516 rs6931858 ENSG00000280107.1 AL022393.9 -4.72 5.38e-06 0.00315 -0.59 -0.36 Parkinson's disease; chr6:28110633 chr6:28170845~28172521:+ PAAD cis rs853679 0.55 rs1237875 ENSG00000226314.6 ZNF192P1 4.72 5.38e-06 0.00315 0.61 0.36 Depression; chr6:28205232 chr6:28161781~28169594:+ PAAD cis rs35160687 0.623 rs7569654 ENSG00000273080.1 RP11-301O19.1 -4.72 5.38e-06 0.00316 -0.42 -0.36 Night sleep phenotypes; chr2:86250899 chr2:86195590~86196049:+ PAAD cis rs1075265 0.901 rs2112124 ENSG00000233266.1 HMGB1P31 4.72 5.39e-06 0.00316 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:54137385 chr2:54051334~54051760:+ PAAD cis rs6723226 0.572 rs176411 ENSG00000276334.1 AL133243.1 4.72 5.39e-06 0.00316 0.41 0.36 Intelligence (multi-trait analysis); chr2:32418460 chr2:32521927~32523547:+ PAAD cis rs6538678 0.864 rs10777747 ENSG00000258343.1 RP11-536G4.2 -4.72 5.39e-06 0.00316 -0.46 -0.36 Lupus nephritis in systemic lupus erythematosus; chr12:95870192 chr12:95795345~95858839:- PAAD cis rs2412819 0.571 rs12443084 ENSG00000205771.5 CATSPER2P1 4.72 5.39e-06 0.00316 0.55 0.36 Lung cancer; chr15:43748767 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs10163069 ENSG00000205771.5 CATSPER2P1 4.72 5.39e-06 0.00316 0.55 0.36 Lung cancer; chr15:43755372 chr15:43726918~43747094:- PAAD cis rs2929278 0.617 rs3986209 ENSG00000205771.5 CATSPER2P1 4.72 5.39e-06 0.00316 0.55 0.36 Schizophrenia; chr15:43758675 chr15:43726918~43747094:- PAAD cis rs1823913 0.599 rs10497713 ENSG00000280083.1 RP11-317J9.1 -4.72 5.4e-06 0.00316 -0.42 -0.36 Obesity-related traits; chr2:191279312 chr2:191154118~191156070:- PAAD cis rs9584850 0.834 rs12463 ENSG00000231194.1 FARP1-AS1 4.72 5.4e-06 0.00316 0.46 0.36 Neuroticism; chr13:98453048 chr13:98435405~98435840:- PAAD cis rs9584850 0.834 rs8481 ENSG00000231194.1 FARP1-AS1 4.72 5.4e-06 0.00316 0.46 0.36 Neuroticism; chr13:98453141 chr13:98435405~98435840:- PAAD cis rs61270009 0.955 rs4916905 ENSG00000247828.6 TMEM161B-AS1 4.72 5.4e-06 0.00316 0.29 0.36 Depressive symptoms; chr5:88362244 chr5:88268895~88436685:+ PAAD cis rs875971 0.545 rs73376394 ENSG00000226824.5 RP4-756H11.3 -4.72 5.41e-06 0.00317 -0.5 -0.36 Aortic root size; chr7:66172694 chr7:66654538~66669855:+ PAAD cis rs11123170 0.542 rs11123169 ENSG00000189223.12 PAX8-AS1 4.72 5.41e-06 0.00317 0.45 0.36 Renal function-related traits (BUN); chr2:113209498 chr2:113211522~113276581:+ PAAD cis rs9531006 0.636 rs7332417 ENSG00000227676.3 LINC01068 4.72 5.42e-06 0.00318 0.56 0.36 Sleep duration; chr13:79920719 chr13:79566727~79571436:+ PAAD cis rs9531006 0.636 rs4885683 ENSG00000227676.3 LINC01068 4.72 5.42e-06 0.00318 0.56 0.36 Sleep duration; chr13:79923049 chr13:79566727~79571436:+ PAAD cis rs9531006 0.636 rs9593420 ENSG00000227676.3 LINC01068 -4.72 5.42e-06 0.00318 -0.56 -0.36 Sleep duration; chr13:79905269 chr13:79566727~79571436:+ PAAD cis rs9531006 0.636 rs9593421 ENSG00000227676.3 LINC01068 -4.72 5.42e-06 0.00318 -0.56 -0.36 Sleep duration; chr13:79915151 chr13:79566727~79571436:+ PAAD cis rs2665103 0.589 rs2134046 ENSG00000278603.1 RP13-608F4.5 4.72 5.42e-06 0.00318 0.45 0.36 Intelligence (multi-trait analysis); chr15:82232203 chr15:82472203~82472426:+ PAAD cis rs875971 0.895 rs12698520 ENSG00000237310.1 GS1-124K5.4 4.71 5.43e-06 0.00318 0.35 0.36 Aortic root size; chr7:66453720 chr7:66493706~66495474:+ PAAD cis rs8100891 0.537 rs73034207 ENSG00000267213.4 AC007773.2 -4.71 5.43e-06 0.00318 -0.59 -0.36 Neuroticism; chr19:32384863 chr19:32390050~32405560:- PAAD cis rs7923609 0.935 rs10995477 ENSG00000232075.1 MRPL35P2 -4.71 5.43e-06 0.00318 -0.44 -0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63250912 chr10:63634317~63634827:- PAAD cis rs7923609 0.756 rs7910951 ENSG00000232075.1 MRPL35P2 4.71 5.44e-06 0.00318 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63578544 chr10:63634317~63634827:- PAAD cis rs7923609 0.756 rs7911761 ENSG00000232075.1 MRPL35P2 4.71 5.44e-06 0.00318 0.43 0.36 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63578993 chr10:63634317~63634827:- PAAD cis rs7829975 0.522 rs6601689 ENSG00000253893.2 FAM85B -4.71 5.44e-06 0.00318 -0.48 -0.36 Mood instability; chr8:8314761 chr8:8167819~8226614:- PAAD cis rs7829975 0.533 rs35900578 ENSG00000253893.2 FAM85B -4.71 5.45e-06 0.00319 -0.5 -0.36 Mood instability; chr8:8862003 chr8:8167819~8226614:- PAAD cis rs453301 0.686 rs6601281 ENSG00000253893.2 FAM85B 4.71 5.45e-06 0.00319 0.51 0.36 Joint mobility (Beighton score); chr8:9053494 chr8:8167819~8226614:- PAAD cis rs2404602 0.735 rs4886495 ENSG00000259422.1 RP11-593F23.1 4.71 5.45e-06 0.00319 0.44 0.36 Blood metabolite levels; chr15:76446618 chr15:76174891~76181486:- PAAD cis rs7188445 0.712 rs6564688 ENSG00000261390.4 RP11-345M22.2 4.71 5.46e-06 0.00319 0.47 0.36 Urate levels; chr16:79680061 chr16:79715232~79770563:- PAAD cis rs1075265 0.587 rs2949812 ENSG00000233266.1 HMGB1P31 4.71 5.46e-06 0.00319 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:53797190 chr2:54051334~54051760:+ PAAD cis rs2564921 0.704 rs2336720 ENSG00000242142.1 SERBP1P3 -4.71 5.46e-06 0.00319 -0.41 -0.36 Height; chr3:52994045 chr3:53064283~53065091:- PAAD cis rs2564921 0.73 rs56384586 ENSG00000242142.1 SERBP1P3 -4.71 5.46e-06 0.00319 -0.41 -0.36 Height; chr3:52994990 chr3:53064283~53065091:- PAAD cis rs7119038 0.509 rs10892258 ENSG00000255239.1 AP002954.6 4.71 5.47e-06 0.0032 0.46 0.36 Sjögren's syndrome; chr11:118709156 chr11:118688039~118690600:- PAAD cis rs7119038 0.509 rs11216961 ENSG00000255239.1 AP002954.6 -4.71 5.47e-06 0.0032 -0.46 -0.36 Sjögren's syndrome; chr11:118709629 chr11:118688039~118690600:- PAAD cis rs496547 0.52 rs11216963 ENSG00000255239.1 AP002954.6 -4.71 5.47e-06 0.0032 -0.46 -0.36 Hip minimal joint space width; chr11:118710105 chr11:118688039~118690600:- PAAD cis rs7119038 0.509 rs11216964 ENSG00000255239.1 AP002954.6 -4.71 5.47e-06 0.0032 -0.46 -0.36 Sjögren's syndrome; chr11:118711186 chr11:118688039~118690600:- PAAD cis rs7119038 0.509 rs10892259 ENSG00000255239.1 AP002954.6 -4.71 5.47e-06 0.0032 -0.46 -0.36 Sjögren's syndrome; chr11:118712293 chr11:118688039~118690600:- PAAD cis rs7189233 0.531 rs9931702 ENSG00000279344.1 RP11-44F14.7 4.71 5.47e-06 0.0032 0.28 0.36 Intelligence (multi-trait analysis); chr16:53492639 chr16:53478957~53481550:- PAAD cis rs41157 0.528 rs15888 ENSG00000279159.1 RP3-394A18.1 4.71 5.47e-06 0.0032 0.35 0.36 Cerebrospinal P-tau181p levels; chr22:30030346 chr22:29978950~30028236:- PAAD cis rs10740039 0.734 rs10821831 ENSG00000254271.1 RP11-131N11.4 4.71 5.48e-06 0.00321 0.42 0.36 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60720717 chr10:60734342~60741828:+ PAAD cis rs12594515 0.694 rs2068294 ENSG00000273972.1 CTD-2306A12.1 -4.71 5.48e-06 0.00321 -0.42 -0.36 Weight;Waist circumference; chr15:45693350 chr15:45702640~45703183:+ PAAD cis rs6540731 0.754 rs2358452 ENSG00000229983.1 RP11-15I11.2 4.71 5.49e-06 0.00321 0.42 0.36 Intelligence (childhood); chr1:212185707 chr1:212168207~212190259:+ PAAD cis rs8062405 0.728 rs11642449 ENSG00000251417.2 RP11-1348G14.4 -4.71 5.49e-06 0.00321 -0.33 -0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28884694 chr16:28802743~28817828:+ PAAD cis rs9368481 0.743 rs9368480 ENSG00000241549.7 GUSBP2 4.71 5.5e-06 0.00321 0.37 0.36 Autism spectrum disorder or schizophrenia; chr6:26987971 chr6:26871484~26956554:- PAAD cis rs2564921 0.693 rs2336721 ENSG00000242142.1 SERBP1P3 -4.71 5.5e-06 0.00322 -0.41 -0.36 Height; chr3:52994359 chr3:53064283~53065091:- PAAD cis rs897984 0.609 rs55979739 ENSG00000260911.2 RP11-196G11.2 4.71 5.51e-06 0.00322 0.33 0.36 Dementia with Lewy bodies; chr16:31037834 chr16:31043150~31049868:+ PAAD cis rs897984 0.609 rs732173 ENSG00000260911.2 RP11-196G11.2 4.71 5.51e-06 0.00322 0.33 0.36 Dementia with Lewy bodies; chr16:31038702 chr16:31043150~31049868:+ PAAD cis rs897984 0.609 rs732172 ENSG00000260911.2 RP11-196G11.2 4.71 5.51e-06 0.00322 0.33 0.36 Dementia with Lewy bodies; chr16:31038712 chr16:31043150~31049868:+ PAAD cis rs897984 0.609 rs1108431 ENSG00000260911.2 RP11-196G11.2 4.71 5.51e-06 0.00322 0.33 0.36 Dementia with Lewy bodies; chr16:31043286 chr16:31043150~31049868:+ PAAD cis rs12134133 1 rs7522618 ENSG00000274245.1 RP11-357P18.2 4.71 5.51e-06 0.00322 0.58 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207244081 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs11580382 ENSG00000274245.1 RP11-357P18.2 4.71 5.51e-06 0.00322 0.58 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207245047 chr1:207372559~207373252:+ PAAD cis rs4664293 0.967 rs12999124 ENSG00000226266.5 AC009961.3 -4.71 5.51e-06 0.00322 -0.44 -0.36 Monocyte percentage of white cells; chr2:159674817 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs35975814 ENSG00000226266.5 AC009961.3 -4.71 5.51e-06 0.00322 -0.44 -0.36 Monocyte percentage of white cells; chr2:159691280 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs9646765 ENSG00000226266.5 AC009961.3 -4.71 5.51e-06 0.00322 -0.44 -0.36 Monocyte percentage of white cells; chr2:159709137 chr2:159670708~159712435:- PAAD cis rs7684253 1 rs7684253 ENSG00000269949.1 RP11-738E22.3 4.71 5.52e-06 0.00323 0.46 0.36 Migraine; chr4:56861145 chr4:56960927~56961373:- PAAD cis rs10129255 0.589 rs78599641 ENSG00000223648.3 IGHV3-64 4.71 5.53e-06 0.00323 0.38 0.36 Kawasaki disease; chr14:106637576 chr14:106643132~106658258:- PAAD cis rs210138 0.832 rs375555 ENSG00000197251.3 LINC00336 4.71 5.54e-06 0.00324 0.53 0.36 Testicular germ cell tumor; chr6:33589964 chr6:33586106~33593338:- PAAD cis rs9494145 0.59 rs9376090 ENSG00000232876.1 CTA-212D2.2 -4.71 5.54e-06 0.00324 -0.44 -0.36 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135090090 chr6:135055033~135060550:+ PAAD cis rs6921919 0.583 rs9468355 ENSG00000216901.1 AL022393.7 4.71 5.55e-06 0.00324 0.48 0.36 Autism spectrum disorder or schizophrenia; chr6:28374100 chr6:28176188~28176674:+ PAAD cis rs12134133 1 rs12134133 ENSG00000274245.1 RP11-357P18.2 4.71 5.56e-06 0.00324 0.54 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207284500 chr1:207372559~207373252:+ PAAD cis rs2283792 0.967 rs11704205 ENSG00000228050.1 TOP3BP1 4.71 5.56e-06 0.00324 0.38 0.36 Multiple sclerosis; chr22:21790964 chr22:22223187~22224566:- PAAD cis rs8059260 0.736 rs7200623 ENSG00000274038.1 RP11-66H6.4 -4.71 5.57e-06 0.00325 -0.6 -0.36 Alcohol consumption over the past year; chr16:11001188 chr16:11056556~11057034:+ PAAD cis rs35160687 0.644 rs4832276 ENSG00000273080.1 RP11-301O19.1 4.71 5.57e-06 0.00325 0.42 0.36 Night sleep phenotypes; chr2:86317895 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs11680025 ENSG00000273080.1 RP11-301O19.1 -4.71 5.57e-06 0.00325 -0.42 -0.36 Night sleep phenotypes; chr2:86318215 chr2:86195590~86196049:+ PAAD cis rs10486158 0.521 rs1294645 ENSG00000155070.8 UNC93B2 -4.71 5.57e-06 0.00325 -0.43 -0.36 Bipolar disorder and schizophrenia; chr7:7392109 chr7:6855485~6859830:- PAAD cis rs62229266 0.659 rs2835258 ENSG00000231106.2 LINC01436 4.71 5.57e-06 0.00325 0.51 0.36 Mitral valve prolapse; chr21:36052067 chr21:36005338~36007838:+ PAAD cis rs6723162 0.51 rs4852238 ENSG00000237751.2 LINC01143 4.71 5.58e-06 0.00325 0.48 0.36 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70925370 chr2:70887871~70889959:+ PAAD cis rs12134133 1 rs7521457 ENSG00000274245.1 RP11-357P18.2 4.71 5.58e-06 0.00325 0.54 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207283802 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs7553157 ENSG00000274245.1 RP11-357P18.2 4.71 5.58e-06 0.00325 0.54 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207283922 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs7553339 ENSG00000274245.1 RP11-357P18.2 4.71 5.58e-06 0.00325 0.54 0.36 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207284075 chr1:207372559~207373252:+ PAAD cis rs3169166 0.5 rs12901552 ENSG00000259562.2 RP11-762H8.2 -4.71 5.58e-06 0.00325 -0.31 -0.36 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78269818 chr15:78290527~78291221:- PAAD cis rs9531006 0.636 rs12323035 ENSG00000227676.3 LINC01068 4.71 5.59e-06 0.00326 0.55 0.36 Sleep duration; chr13:79902481 chr13:79566727~79571436:+ PAAD cis rs7580658 0.545 rs12477559 ENSG00000236682.1 AC068282.3 -4.71 5.59e-06 0.00326 -0.44 -0.36 Protein C levels; chr2:127194221 chr2:127389130~127400580:+ PAAD cis rs964611 0.938 rs8032357 ENSG00000259488.2 RP11-154J22.1 -4.71 5.59e-06 0.00326 -0.39 -0.36 Metabolite levels (Pyroglutamine); chr15:48326622 chr15:48312353~48331856:- PAAD cis rs10754283 0.935 rs1934046 ENSG00000231613.1 RP5-943J3.1 -4.71 5.59e-06 0.00326 -0.38 -0.36 Amyotrophic lateral sclerosis (sporadic); chr1:89653731 chr1:89788914~89790492:+ PAAD cis rs7615952 0.932 rs1976458 ENSG00000241288.6 RP11-379B18.5 -4.71 5.59e-06 0.00326 -0.39 -0.36 Blood pressure (smoking interaction); chr3:125928669 chr3:125827238~125916384:- PAAD cis rs10129255 0.53 rs8008811 ENSG00000223648.3 IGHV3-64 4.71 5.6e-06 0.00326 0.39 0.36 Kawasaki disease; chr14:106652273 chr14:106643132~106658258:- PAAD cis rs10129255 0.542 rs8009795 ENSG00000223648.3 IGHV3-64 4.71 5.6e-06 0.00326 0.39 0.36 Kawasaki disease; chr14:106652287 chr14:106643132~106658258:- PAAD cis rs10129255 0.528 rs8008831 ENSG00000223648.3 IGHV3-64 4.71 5.6e-06 0.00326 0.39 0.36 Kawasaki disease; chr14:106652290 chr14:106643132~106658258:- PAAD cis rs10129255 0.584 rs11161001 ENSG00000223648.3 IGHV3-64 4.71 5.6e-06 0.00326 0.39 0.36 Kawasaki disease; chr14:106652664 chr14:106643132~106658258:- PAAD cis rs10129255 0.507 rs58656539 ENSG00000223648.3 IGHV3-64 4.71 5.6e-06 0.00326 0.39 0.36 Kawasaki disease; chr14:106653262 chr14:106643132~106658258:- PAAD cis rs12817211 0.502 rs59262224 ENSG00000272368.2 RP4-605O3.4 -4.71 5.61e-06 0.00327 -0.34 -0.36 Colorectal or endometrial cancer; chr12:50117164 chr12:50112197~50165618:+ PAAD cis rs12817211 0.502 rs7135322 ENSG00000272368.2 RP4-605O3.4 -4.71 5.61e-06 0.00327 -0.34 -0.36 Colorectal or endometrial cancer; chr12:50118065 chr12:50112197~50165618:+ PAAD cis rs9487605 1 rs9487605 ENSG00000230177.1 RP5-1112D6.4 -4.71 5.62e-06 0.00327 -0.31 -0.36 Inflammatory skin disease; chr6:111261682 chr6:111277932~111278742:+ PAAD cis rs9532669 0.926 rs4942014 ENSG00000176268.5 CYCSP34 4.71 5.62e-06 0.00327 0.32 0.36 Cervical cancer; chr13:40966366 chr13:40863599~40863902:- PAAD cis rs55665837 0.701 rs1522633 ENSG00000251991.1 RNU7-49P 4.71 5.63e-06 0.00327 0.42 0.36 Vitamin D levels; chr11:14623692 chr11:14478892~14478953:+ PAAD cis rs875971 0.545 rs313830 ENSG00000164669.11 INTS4P1 4.71 5.63e-06 0.00327 0.52 0.36 Aortic root size; chr7:66086944 chr7:65141225~65234216:+ PAAD cis rs875971 0.545 rs313828 ENSG00000164669.11 INTS4P1 4.71 5.63e-06 0.00327 0.52 0.36 Aortic root size; chr7:66087627 chr7:65141225~65234216:+ PAAD cis rs875971 0.571 rs160647 ENSG00000164669.11 INTS4P1 4.71 5.63e-06 0.00327 0.52 0.36 Aortic root size; chr7:66089365 chr7:65141225~65234216:+ PAAD cis rs875971 0.52 rs160645 ENSG00000164669.11 INTS4P1 4.71 5.63e-06 0.00327 0.52 0.36 Aortic root size; chr7:66091320 chr7:65141225~65234216:+ PAAD cis rs875971 0.789 rs28815324 ENSG00000164669.11 INTS4P1 4.71 5.63e-06 0.00327 0.52 0.36 Aortic root size; chr7:66100789 chr7:65141225~65234216:+ PAAD cis rs875971 0.545 rs73136346 ENSG00000164669.11 INTS4P1 4.71 5.63e-06 0.00327 0.52 0.36 Aortic root size; chr7:66101095 chr7:65141225~65234216:+ PAAD cis rs755249 0.501 rs2490945 ENSG00000261798.1 RP1-118J21.25 4.71 5.64e-06 0.00328 0.43 0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39371672 chr1:39788976~39790171:+ PAAD cis rs755249 0.501 rs621807 ENSG00000261798.1 RP1-118J21.25 4.71 5.64e-06 0.00328 0.43 0.36 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39376771 chr1:39788976~39790171:+ PAAD cis rs7580658 0.75 rs6731176 ENSG00000236682.1 AC068282.3 -4.71 5.65e-06 0.00328 -0.45 -0.36 Protein C levels; chr2:127313427 chr2:127389130~127400580:+ PAAD cis rs7916697 0.628 rs10998036 ENSG00000233590.1 RP11-153K11.3 4.71 5.65e-06 0.00328 0.49 0.36 Optic disc area; chr10:68256921 chr10:68233251~68242379:- PAAD cis rs2255336 0.938 rs9651850 ENSG00000245648.1 RP11-277P12.20 -4.71 5.66e-06 0.00329 -0.58 -0.36 Blood protein levels; chr12:10490533 chr12:10363769~10398506:+ PAAD cis rs2255336 0.873 rs12301897 ENSG00000245648.1 RP11-277P12.20 -4.71 5.66e-06 0.00329 -0.58 -0.36 Blood protein levels; chr12:10491974 chr12:10363769~10398506:+ PAAD cis rs1823913 0.599 rs17346475 ENSG00000280083.1 RP11-317J9.1 4.7 5.68e-06 0.00329 0.43 0.36 Obesity-related traits; chr2:191288488 chr2:191154118~191156070:- PAAD cis rs4728142 0.564 rs10954213 ENSG00000275106.1 RP11-309L24.10 -4.7 5.68e-06 0.0033 -0.49 -0.36 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:128949373 chr7:128952527~128953316:- PAAD cis rs2274273 0.967 rs8013027 ENSG00000258413.1 RP11-665C16.6 -4.7 5.68e-06 0.0033 -0.47 -0.36 Protein biomarker; chr14:55144222 chr14:55262767~55272075:- PAAD cis rs11089937 0.597 rs11089925 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22137267 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs5757024 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22137415 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs5757026 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22137556 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs2213156 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22137852 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs2213157 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22137997 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs9622955 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22138343 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs4821781 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22138845 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs5750589 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22139655 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs5757038 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22140149 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs5757056 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22142491 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs4145535 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22143981 chr22:22162199~22162681:+ PAAD cis rs11089937 0.626 rs9622968 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22144916 chr22:22162199~22162681:+ PAAD cis rs11089937 0.667 rs5757081 ENSG00000211639.2 IGLV4-60 4.7 5.69e-06 0.0033 0.37 0.36 Periodontitis (PAL4Q3); chr22:22146272 chr22:22162199~22162681:+ PAAD cis rs35160687 0.712 rs1863057 ENSG00000273080.1 RP11-301O19.1 -4.7 5.7e-06 0.0033 -0.42 -0.36 Night sleep phenotypes; chr2:86274978 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs11687392 ENSG00000273080.1 RP11-301O19.1 -4.7 5.7e-06 0.0033 -0.42 -0.36 Night sleep phenotypes; chr2:86275540 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs1863058 ENSG00000273080.1 RP11-301O19.1 -4.7 5.7e-06 0.0033 -0.42 -0.36 Night sleep phenotypes; chr2:86282144 chr2:86195590~86196049:+ PAAD cis rs35160687 0.623 rs1863060 ENSG00000273080.1 RP11-301O19.1 -4.7 5.7e-06 0.0033 -0.42 -0.36 Night sleep phenotypes; chr2:86284333 chr2:86195590~86196049:+ PAAD cis rs9322193 0.923 rs9371207 ENSG00000268592.3 RAET1E-AS1 4.7 5.7e-06 0.0033 0.44 0.36 Lung cancer; chr6:149858087 chr6:149863494~149919507:+ PAAD cis rs3779195 0.697 rs13232861 ENSG00000272950.1 RP11-307C18.1 4.7 5.7e-06 0.00331 0.59 0.36 Sex hormone-binding globulin levels; chr7:98299769 chr7:98322853~98323430:+ PAAD cis rs1322639 0.614 rs4708414 ENSG00000261039.2 RP11-417E7.2 -4.7 5.71e-06 0.00331 -0.4 -0.36 Pulse pressure; chr6:169174049 chr6:169175304~169182740:- PAAD cis rs11893307 0.599 rs11900857 ENSG00000235852.1 AC005540.3 4.7 5.71e-06 0.00331 0.53 0.36 Mean platelet volume; chr2:190794285 chr2:190880797~190882059:- PAAD cis rs11893307 0.599 rs12617417 ENSG00000235852.1 AC005540.3 4.7 5.71e-06 0.00331 0.53 0.36 Mean platelet volume; chr2:190798845 chr2:190880797~190882059:- PAAD cis rs11893307 0.599 rs13423600 ENSG00000235852.1 AC005540.3 4.7 5.71e-06 0.00331 0.53 0.36 Mean platelet volume; chr2:190803575 chr2:190880797~190882059:- PAAD cis rs35160687 0.644 rs9309635 ENSG00000273080.1 RP11-301O19.1 4.7 5.71e-06 0.00331 0.42 0.36 Night sleep phenotypes; chr2:86272279 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs1863061 ENSG00000273080.1 RP11-301O19.1 -4.7 5.71e-06 0.00331 -0.42 -0.36 Night sleep phenotypes; chr2:86285784 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs17738058 ENSG00000273080.1 RP11-301O19.1 -4.7 5.71e-06 0.00331 -0.42 -0.36 Night sleep phenotypes; chr2:86286080 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs4832272 ENSG00000273080.1 RP11-301O19.1 -4.7 5.71e-06 0.00331 -0.42 -0.36 Night sleep phenotypes; chr2:86289088 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs57270703 ENSG00000273080.1 RP11-301O19.1 -4.7 5.71e-06 0.00331 -0.42 -0.36 Night sleep phenotypes; chr2:86289750 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs2113615 ENSG00000273080.1 RP11-301O19.1 -4.7 5.71e-06 0.00331 -0.42 -0.36 Night sleep phenotypes; chr2:86290479 chr2:86195590~86196049:+ PAAD cis rs453301 0.597 rs7001187 ENSG00000253893.2 FAM85B 4.7 5.72e-06 0.00331 0.48 0.36 Joint mobility (Beighton score); chr8:8935272 chr8:8167819~8226614:- PAAD cis rs453301 0.631 rs13250781 ENSG00000253893.2 FAM85B 4.7 5.72e-06 0.00331 0.48 0.36 Joint mobility (Beighton score); chr8:8935833 chr8:8167819~8226614:- PAAD cis rs748404 0.697 rs493177 ENSG00000249839.1 AC011330.5 -4.7 5.72e-06 0.00331 -0.48 -0.36 Lung cancer; chr15:43251060 chr15:43663654~43684339:- PAAD cis rs58873874 0.737 rs112160357 ENSG00000251405.2 CTB-109A12.1 4.7 5.72e-06 0.00331 0.73 0.36 Bipolar disorder (body mass index interaction); chr5:157501696 chr5:157362615~157460078:- PAAD cis rs1075265 0.621 rs2542593 ENSG00000233266.1 HMGB1P31 4.7 5.72e-06 0.00331 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:53804299 chr2:54051334~54051760:+ PAAD cis rs6540731 0.754 rs6679064 ENSG00000229983.1 RP11-15I11.2 4.7 5.72e-06 0.00332 0.42 0.36 Intelligence (childhood); chr1:212186366 chr1:212168207~212190259:+ PAAD cis rs4835473 0.932 rs2323200 ENSG00000251600.4 RP11-673E1.1 4.7 5.73e-06 0.00332 0.39 0.36 Immature fraction of reticulocytes; chr4:143765448 chr4:143912331~143982454:+ PAAD cis rs10510102 0.935 rs7083278 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121853758 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs78369301 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121858527 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs75339296 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121859895 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12262776 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121884532 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12244866 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121886013 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12266597 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121886062 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12245018 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121886195 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200217 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121886372 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200218 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121886410 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs10887008 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121886714 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12268872 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121887426 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs9630107 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121887713 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs10887010 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121888542 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12251175 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121889015 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11200220 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121889949 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200221 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121890134 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs10887011 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121890203 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs10887012 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121890454 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11200222 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121891177 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200223 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121891416 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs10887013 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121891546 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11200225 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121891948 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200226 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121891988 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs10887014 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121892322 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs11818735 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121892472 chr10:121956782~121957098:+ PAAD cis rs10510102 0.81 rs12259902 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121893017 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200228 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121893358 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200229 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121893519 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs10887016 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121893830 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs10887018 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121894457 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200230 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121895117 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200234 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121895851 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12244951 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121896879 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs74362676 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121898216 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs3750837 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121899080 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs3750836 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121899087 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200237 ENSG00000276742.1 RP11-500G22.4 4.7 5.74e-06 0.00332 0.53 0.36 Breast cancer; chr10:121900715 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11818001 ENSG00000276742.1 RP11-500G22.4 -4.7 5.74e-06 0.00332 -0.53 -0.36 Breast cancer; chr10:121884830 chr10:121956782~121957098:+ PAAD cis rs1823913 0.599 rs17412094 ENSG00000280083.1 RP11-317J9.1 -4.7 5.74e-06 0.00332 -0.43 -0.36 Obesity-related traits; chr2:191284202 chr2:191154118~191156070:- PAAD cis rs2015599 0.623 rs1072724 ENSG00000257176.2 RP11-996F15.2 4.7 5.74e-06 0.00332 0.36 0.36 Platelet count;Mean platelet volume; chr12:29289205 chr12:29280418~29317848:- PAAD cis rs8062405 0.728 rs8056890 ENSG00000251417.2 RP11-1348G14.4 -4.7 5.74e-06 0.00332 -0.33 -0.36 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28886131 chr16:28802743~28817828:+ PAAD cis rs80285556 1 rs76812330 ENSG00000161643.11 SIGLEC16 4.7 5.75e-06 0.00333 0.86 0.36 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50028603 chr19:49969673~49975814:+ PAAD cis rs748404 0.589 rs62020616 ENSG00000249839.1 AC011330.5 -4.7 5.75e-06 0.00333 -0.63 -0.36 Lung cancer; chr15:43558554 chr15:43663654~43684339:- PAAD cis rs748404 0.626 rs60367691 ENSG00000249839.1 AC011330.5 -4.7 5.75e-06 0.00333 -0.63 -0.36 Lung cancer; chr15:43559201 chr15:43663654~43684339:- PAAD cis rs9287719 0.935 rs61424402 ENSG00000234818.1 AC092687.5 4.7 5.76e-06 0.00333 0.4 0.36 Prostate cancer; chr2:10618245 chr2:10589166~10604830:+ PAAD cis rs1075265 0.626 rs805320 ENSG00000233266.1 HMGB1P31 4.7 5.76e-06 0.00333 0.45 0.36 Chronotype;Morning vs. evening chronotype; chr2:53911305 chr2:54051334~54051760:+ PAAD cis rs12817211 0.502 rs17124432 ENSG00000272368.2 RP4-605O3.4 4.7 5.77e-06 0.00334 0.34 0.36 Colorectal or endometrial cancer; chr12:50116994 chr12:50112197~50165618:+ PAAD cis rs12817211 0.502 rs7294618 ENSG00000272368.2 RP4-605O3.4 -4.7 5.77e-06 0.00334 -0.34 -0.36 Colorectal or endometrial cancer; chr12:50119192 chr12:50112197~50165618:+ PAAD cis rs12817211 0.502 rs7961112 ENSG00000272368.2 RP4-605O3.4 -4.7 5.77e-06 0.00334 -0.34 -0.36 Colorectal or endometrial cancer; chr12:50119736 chr12:50112197~50165618:+ PAAD cis rs12701220 0.522 rs1881116 ENSG00000229043.2 AC091729.9 -4.7 5.78e-06 0.00334 -0.43 -0.36 Bronchopulmonary dysplasia; chr7:1014322 chr7:1160374~1165267:+ PAAD cis rs66887589 0.748 rs28439855 ENSG00000248280.1 RP11-33B1.2 4.7 5.79e-06 0.00335 0.32 0.36 Diastolic blood pressure; chr4:119341101 chr4:119440561~119450157:- PAAD cis rs748404 0.66 rs493377 ENSG00000205771.5 CATSPER2P1 -4.7 5.79e-06 0.00335 -0.5 -0.36 Lung cancer; chr15:43481269 chr15:43726918~43747094:- PAAD cis rs10050311 0.746 rs969734 ENSG00000251411.1 RP11-397E7.4 -4.7 5.79e-06 0.00335 -0.42 -0.36 Insulin-related traits; chr4:86744231 chr4:86913266~86914817:- PAAD cis rs6782228 0.606 rs2811500 ENSG00000242551.2 POU5F1P6 -4.7 5.8e-06 0.00335 -0.42 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128647413 chr3:128674735~128677005:- PAAD cis rs7773456 0.74 rs6917179 ENSG00000228412.5 RP4-625H18.2 -4.7 5.8e-06 0.00335 -0.48 -0.36 Lupus nephritis in systemic lupus erythematosus; chr6:19817570 chr6:19802164~19804752:- PAAD cis rs2658782 0.951 rs2608214 ENSG00000279684.1 RP11-755E23.2 -4.7 5.8e-06 0.00335 -0.61 -0.36 Pulmonary function decline; chr11:93415499 chr11:93286629~93288903:- PAAD cis rs11673344 0.502 rs62108306 ENSG00000267422.1 CTD-2554C21.1 4.7 5.81e-06 0.00336 0.47 0.36 Obesity-related traits; chr19:37691789 chr19:37779686~37792865:+ PAAD cis rs11673344 0.536 rs7259272 ENSG00000267422.1 CTD-2554C21.1 4.7 5.81e-06 0.00336 0.47 0.36 Obesity-related traits; chr19:37692214 chr19:37779686~37792865:+ PAAD cis rs3096299 0.503 rs4785677 ENSG00000261253.2 AC137932.6 4.7 5.82e-06 0.00336 0.39 0.36 Multiple myeloma (IgH translocation); chr16:89488693 chr16:89321133~89325110:+ PAAD cis rs35160687 0.623 rs11689971 ENSG00000273080.1 RP11-301O19.1 -4.7 5.82e-06 0.00336 -0.42 -0.36 Night sleep phenotypes; chr2:86247348 chr2:86195590~86196049:+ PAAD cis rs35160687 0.623 rs11127021 ENSG00000273080.1 RP11-301O19.1 -4.7 5.82e-06 0.00336 -0.42 -0.36 Night sleep phenotypes; chr2:86247796 chr2:86195590~86196049:+ PAAD cis rs3779195 0.524 rs76976120 ENSG00000272950.1 RP11-307C18.1 -4.7 5.82e-06 0.00336 -0.64 -0.36 Sex hormone-binding globulin levels; chr7:98264860 chr7:98322853~98323430:+ PAAD cis rs35160687 0.623 rs718292 ENSG00000273080.1 RP11-301O19.1 4.7 5.82e-06 0.00336 0.42 0.36 Night sleep phenotypes; chr2:86246617 chr2:86195590~86196049:+ PAAD cis rs4835473 0.9 rs10032963 ENSG00000251600.4 RP11-673E1.1 4.7 5.82e-06 0.00336 0.39 0.36 Immature fraction of reticulocytes; chr4:143733068 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs28796049 ENSG00000251600.4 RP11-673E1.1 4.7 5.82e-06 0.00336 0.39 0.36 Immature fraction of reticulocytes; chr4:143733990 chr4:143912331~143982454:+ PAAD cis rs4664293 0.967 rs13000070 ENSG00000226266.5 AC009961.3 -4.7 5.83e-06 0.00336 -0.44 -0.36 Monocyte percentage of white cells; chr2:159669263 chr2:159670708~159712435:- PAAD cis rs11723261 0.582 rs11735742 ENSG00000275426.1 CH17-262A2.1 -4.7 5.83e-06 0.00337 -0.56 -0.36 Immune response to smallpox vaccine (IL-6); chr4:148766 chr4:149738~150317:+ PAAD cis rs853679 0.55 rs1150689 ENSG00000226314.6 ZNF192P1 -4.7 5.83e-06 0.00337 -0.6 -0.36 Depression; chr6:28197321 chr6:28161781~28169594:+ PAAD cis rs853679 0.55 rs1225599 ENSG00000226314.6 ZNF192P1 -4.7 5.83e-06 0.00337 -0.6 -0.36 Depression; chr6:28197412 chr6:28161781~28169594:+ PAAD cis rs10510102 0.935 rs11200257 ENSG00000276742.1 RP11-500G22.4 4.7 5.83e-06 0.00337 0.53 0.36 Breast cancer; chr10:121917232 chr10:121956782~121957098:+ PAAD cis rs633715 0.959 rs2094510 ENSG00000254154.7 RP4-798P15.3 -4.7 5.84e-06 0.00337 -0.34 -0.36 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177874344 chr1:177928788~178038007:- PAAD cis rs871012 0.502 rs17658198 ENSG00000251405.2 CTB-109A12.1 -4.7 5.84e-06 0.00337 -0.45 -0.36 IgG glycosylation; chr5:157458669 chr5:157362615~157460078:- PAAD cis rs4835473 0.932 rs35164917 ENSG00000251600.4 RP11-673E1.1 4.7 5.84e-06 0.00337 0.39 0.36 Immature fraction of reticulocytes; chr4:143748891 chr4:143912331~143982454:+ PAAD cis rs1823913 0.599 rs2124093 ENSG00000280083.1 RP11-317J9.1 -4.7 5.85e-06 0.00337 -0.42 -0.36 Obesity-related traits; chr2:191288280 chr2:191154118~191156070:- PAAD cis rs2729354 0.768 rs1001956 ENSG00000265566.2 RN7SL605P -4.7 5.85e-06 0.00338 -0.45 -0.36 Blood protein levels; chr11:57499476 chr11:57528085~57528365:- PAAD cis rs1185460 0.967 rs1786141 ENSG00000271751.1 RP11-110I1.14 -4.7 5.85e-06 0.00338 -0.45 -0.36 Coronary artery disease; chr11:119067604 chr11:119065263~119065677:- PAAD cis rs2274273 1 rs3825613 ENSG00000258413.1 RP11-665C16.6 -4.7 5.85e-06 0.00338 -0.47 -0.36 Protein biomarker; chr14:55126454 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs2147972 ENSG00000258413.1 RP11-665C16.6 -4.7 5.85e-06 0.00338 -0.47 -0.36 Protein biomarker; chr14:55131312 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs57970196 ENSG00000258413.1 RP11-665C16.6 -4.7 5.85e-06 0.00338 -0.47 -0.36 Protein biomarker; chr14:55133687 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs4644 ENSG00000258413.1 RP11-665C16.6 -4.7 5.85e-06 0.00338 -0.47 -0.36 Protein biomarker; chr14:55138217 chr14:55262767~55272075:- PAAD cis rs2274273 1 rs2075603 ENSG00000258413.1 RP11-665C16.6 -4.7 5.85e-06 0.00338 -0.47 -0.36 Protein biomarker; chr14:55143237 chr14:55262767~55272075:- PAAD cis rs7188445 0.736 rs4888043 ENSG00000261390.4 RP11-345M22.2 4.7 5.86e-06 0.00338 0.46 0.36 Urate levels; chr16:79668744 chr16:79715232~79770563:- PAAD cis rs2283792 0.765 rs9607285 ENSG00000224086.5 LL22NC03-86G7.1 -4.7 5.86e-06 0.00338 -0.36 -0.36 Multiple sclerosis; chr22:21808704 chr22:21938293~21977632:+ PAAD cis rs2283792 0.765 rs2266969 ENSG00000224086.5 LL22NC03-86G7.1 -4.7 5.86e-06 0.00338 -0.36 -0.36 Multiple sclerosis; chr22:21819618 chr22:21938293~21977632:+ PAAD cis rs4273100 1 rs4924986 ENSG00000228157.4 AC007952.5 -4.7 5.87e-06 0.00338 -0.59 -0.36 Schizophrenia; chr17:19339154 chr17:19092974~19096837:+ PAAD cis rs2858942 0.602 rs1211375 ENSG00000268836.1 LA16c-OS12.2 -4.7 5.87e-06 0.00339 -0.31 -0.36 Mean corpuscular hemoglobin; chr16:190281 chr16:185748~186294:- PAAD cis rs2404602 0.684 rs11854850 ENSG00000259422.1 RP11-593F23.1 -4.7 5.88e-06 0.00339 -0.44 -0.36 Blood metabolite levels; chr15:76552230 chr15:76174891~76181486:- PAAD cis rs3096299 0.802 rs3102336 ENSG00000274627.1 RP11-104N10.2 4.7 5.88e-06 0.00339 0.31 0.36 Multiple myeloma (IgH translocation); chr16:89375598 chr16:89516797~89522217:+ PAAD cis rs3096299 0.679 rs3102338 ENSG00000274627.1 RP11-104N10.2 4.7 5.88e-06 0.00339 0.31 0.36 Multiple myeloma (IgH translocation); chr16:89375842 chr16:89516797~89522217:+ PAAD cis rs61776719 0.875 rs10890238 ENSG00000212541.1 RNU6-510P -4.7 5.88e-06 0.00339 -0.38 -0.36 Coronary artery disease; chr1:37979982 chr1:37991462~37991569:+ PAAD cis rs8059260 0.673 rs7188928 ENSG00000274038.1 RP11-66H6.4 -4.7 5.89e-06 0.00339 -0.57 -0.36 Alcohol consumption over the past year; chr16:10964896 chr16:11056556~11057034:+ PAAD cis rs7580658 0.509 rs12477653 ENSG00000236682.1 AC068282.3 -4.7 5.89e-06 0.00339 -0.44 -0.36 Protein C levels; chr2:127194505 chr2:127389130~127400580:+ PAAD cis rs7580658 0.545 rs13001179 ENSG00000236682.1 AC068282.3 -4.7 5.89e-06 0.00339 -0.44 -0.36 Protein C levels; chr2:127194617 chr2:127389130~127400580:+ PAAD cis rs7580658 0.545 rs13001184 ENSG00000236682.1 AC068282.3 -4.7 5.89e-06 0.00339 -0.44 -0.36 Protein C levels; chr2:127194630 chr2:127389130~127400580:+ PAAD cis rs9287719 0.967 rs4669593 ENSG00000234818.1 AC092687.5 4.7 5.89e-06 0.00339 0.4 0.36 Prostate cancer; chr2:10561782 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs3814388 ENSG00000234818.1 AC092687.5 4.7 5.89e-06 0.00339 0.4 0.36 Prostate cancer; chr2:10561973 chr2:10589166~10604830:+ PAAD cis rs4268898 1 rs6746005 ENSG00000242628.4 AC009228.1 -4.7 5.89e-06 0.0034 -0.43 -0.36 Asthma; chr2:24211476 chr2:24214381~24221516:+ PAAD cis rs4268898 1 rs10195436 ENSG00000242628.4 AC009228.1 -4.7 5.89e-06 0.0034 -0.43 -0.36 Asthma; chr2:24213243 chr2:24214381~24221516:+ PAAD cis rs160451 0.811 rs216986 ENSG00000251136.7 RP11-37B2.1 4.7 5.9e-06 0.0034 0.35 0.36 Leprosy; chr8:89642601 chr8:89609409~89757727:- PAAD cis rs964611 0.882 rs11629725 ENSG00000259488.2 RP11-154J22.1 4.7 5.91e-06 0.0034 0.38 0.36 Metabolite levels (Pyroglutamine); chr15:48347986 chr15:48312353~48331856:- PAAD cis rs6782228 0.585 rs2811492 ENSG00000242551.2 POU5F1P6 -4.69 5.92e-06 0.00341 -0.42 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128637436 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs1697 ENSG00000242551.2 POU5F1P6 -4.69 5.92e-06 0.00341 -0.42 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128638009 chr3:128674735~128677005:- PAAD cis rs6782228 0.585 rs3122175 ENSG00000242551.2 POU5F1P6 -4.69 5.92e-06 0.00341 -0.42 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128642433 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs2811497 ENSG00000242551.2 POU5F1P6 -4.69 5.92e-06 0.00341 -0.42 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128644489 chr3:128674735~128677005:- PAAD cis rs7580658 0.545 rs13006847 ENSG00000236682.1 AC068282.3 4.69 5.92e-06 0.00341 0.43 0.36 Protein C levels; chr2:127194687 chr2:127389130~127400580:+ PAAD cis rs2658782 0.789 rs3020076 ENSG00000279684.1 RP11-755E23.2 -4.69 5.93e-06 0.00341 -0.58 -0.36 Pulmonary function decline; chr11:93407892 chr11:93286629~93288903:- PAAD cis rs7208859 0.673 rs999797 ENSG00000266490.1 CTD-2349P21.9 4.69 5.94e-06 0.00342 0.49 0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832311 chr17:30792372~30792833:+ PAAD cis rs748404 0.631 rs2412781 ENSG00000205771.5 CATSPER2P1 4.69 5.94e-06 0.00342 0.48 0.36 Lung cancer; chr15:43375702 chr15:43726918~43747094:- PAAD cis rs7829975 0.714 rs60315134 ENSG00000253893.2 FAM85B -4.69 5.94e-06 0.00342 -0.49 -0.36 Mood instability; chr8:8813089 chr8:8167819~8226614:- PAAD cis rs601999 1 rs601999 ENSG00000108785.7 HSD17B1P1 4.69 5.94e-06 0.00342 0.34 0.36 Parkinson's disease; chr17:42546140 chr17:42546764~42548706:+ PAAD cis rs2337406 0.866 rs79901786 ENSG00000211974.3 IGHV2-70 -4.69 5.95e-06 0.00342 -0.46 -0.36 Alzheimer's disease (late onset); chr14:106777623 chr14:106723574~106724093:- PAAD cis rs9287719 0.967 rs12464817 ENSG00000234818.1 AC092687.5 4.69 5.96e-06 0.00343 0.4 0.36 Prostate cancer; chr2:10567086 chr2:10589166~10604830:+ PAAD cis rs9287719 1 rs9287719 ENSG00000234818.1 AC092687.5 4.69 5.96e-06 0.00343 0.4 0.36 Prostate cancer; chr2:10570604 chr2:10589166~10604830:+ PAAD cis rs875971 0.571 rs160641 ENSG00000226824.5 RP4-756H11.3 4.69 5.96e-06 0.00343 0.49 0.36 Aortic root size; chr7:66112359 chr7:66654538~66669855:+ PAAD cis rs10050311 0.698 rs3775238 ENSG00000251411.1 RP11-397E7.4 -4.69 5.96e-06 0.00343 -0.43 -0.36 Insulin-related traits; chr4:86712231 chr4:86913266~86914817:- PAAD cis rs1075265 0.73 rs7601692 ENSG00000233266.1 HMGB1P31 4.69 5.97e-06 0.00344 0.46 0.36 Chronotype;Morning vs. evening chronotype; chr2:53705532 chr2:54051334~54051760:+ PAAD cis rs4268898 0.965 rs4665673 ENSG00000242628.4 AC009228.1 -4.69 5.98e-06 0.00344 -0.44 -0.36 Asthma; chr2:24236868 chr2:24214381~24221516:+ PAAD cis rs734999 0.588 rs876938 ENSG00000225931.3 RP3-395M20.7 4.69 5.98e-06 0.00344 0.35 0.36 Ulcerative colitis; chr1:2591773 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs745368 ENSG00000225931.3 RP3-395M20.7 4.69 5.98e-06 0.00344 0.35 0.36 Ulcerative colitis; chr1:2592766 chr1:2566410~2569888:+ PAAD cis rs734999 0.566 rs10752747 ENSG00000225931.3 RP3-395M20.7 4.69 5.98e-06 0.00344 0.35 0.36 Ulcerative colitis; chr1:2593476 chr1:2566410~2569888:+ PAAD cis rs10050311 0.858 rs55698195 ENSG00000251411.1 RP11-397E7.4 -4.69 5.99e-06 0.00344 -0.44 -0.36 Insulin-related traits; chr4:86872297 chr4:86913266~86914817:- PAAD cis rs2188561 0.666 rs13231387 ENSG00000241764.3 AC002467.7 4.69 5.99e-06 0.00344 0.46 0.36 Alcohol consumption; chr7:107749534 chr7:107742817~107744581:- PAAD cis rs2188561 0.615 rs13226711 ENSG00000241764.3 AC002467.7 4.69 5.99e-06 0.00344 0.46 0.36 Alcohol consumption; chr7:107754897 chr7:107742817~107744581:- PAAD cis rs2188561 0.697 rs12705421 ENSG00000241764.3 AC002467.7 4.69 5.99e-06 0.00344 0.46 0.36 Alcohol consumption; chr7:107760984 chr7:107742817~107744581:- PAAD cis rs58873874 0.737 rs11745566 ENSG00000251405.2 CTB-109A12.1 4.69 5.99e-06 0.00344 0.72 0.36 Bipolar disorder (body mass index interaction); chr5:157464945 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs10476050 ENSG00000251405.2 CTB-109A12.1 4.69 5.99e-06 0.00344 0.72 0.36 Bipolar disorder (body mass index interaction); chr5:157471866 chr5:157362615~157460078:- PAAD cis rs875971 0.54 rs35510581 ENSG00000237310.1 GS1-124K5.4 -4.69 5.99e-06 0.00345 -0.33 -0.36 Aortic root size; chr7:66113790 chr7:66493706~66495474:+ PAAD cis rs875971 0.577 rs35072105 ENSG00000237310.1 GS1-124K5.4 -4.69 5.99e-06 0.00345 -0.33 -0.36 Aortic root size; chr7:66144830 chr7:66493706~66495474:+ PAAD cis rs9322193 0.884 rs1108889 ENSG00000268592.3 RAET1E-AS1 4.69 5.99e-06 0.00345 0.44 0.36 Lung cancer; chr6:149845433 chr6:149863494~149919507:+ PAAD cis rs6921919 0.848 rs56131013 ENSG00000216901.1 AL022393.7 4.69 6e-06 0.00345 0.54 0.36 Autism spectrum disorder or schizophrenia; chr6:28352900 chr6:28176188~28176674:+ PAAD cis rs6921919 0.848 rs6903652 ENSG00000216901.1 AL022393.7 4.69 6e-06 0.00345 0.54 0.36 Autism spectrum disorder or schizophrenia; chr6:28354343 chr6:28176188~28176674:+ PAAD cis rs6921919 0.848 rs6903823 ENSG00000216901.1 AL022393.7 4.69 6e-06 0.00345 0.54 0.36 Autism spectrum disorder or schizophrenia; chr6:28354519 chr6:28176188~28176674:+ PAAD cis rs380904 0.552 rs10099003 ENSG00000254859.1 RP11-661A12.5 -4.69 6e-06 0.00345 -0.6 -0.36 Venous thromboembolism (SNP x SNP interaction); chr8:143563290 chr8:143541973~143549729:- PAAD cis rs11089937 0.825 rs4820339 ENSG00000211639.2 IGLV4-60 4.69 6e-06 0.00345 0.34 0.36 Periodontitis (PAL4Q3); chr22:22166765 chr22:22162199~22162681:+ PAAD cis rs3096299 0.967 rs28689480 ENSG00000274627.1 RP11-104N10.2 4.69 6e-06 0.00345 0.32 0.36 Multiple myeloma (IgH translocation); chr16:89393685 chr16:89516797~89522217:+ PAAD cis rs1823913 0.599 rs13001899 ENSG00000280083.1 RP11-317J9.1 -4.69 6.02e-06 0.00346 -0.43 -0.36 Obesity-related traits; chr2:191285442 chr2:191154118~191156070:- PAAD cis rs62229266 0.659 rs7275820 ENSG00000231106.2 LINC01436 4.69 6.03e-06 0.00346 0.5 0.36 Mitral valve prolapse; chr21:36037116 chr21:36005338~36007838:+ PAAD cis rs62229266 0.652 rs7280551 ENSG00000231106.2 LINC01436 4.69 6.03e-06 0.00346 0.5 0.36 Mitral valve prolapse; chr21:36037311 chr21:36005338~36007838:+ PAAD cis rs62229266 0.659 rs2255734 ENSG00000231106.2 LINC01436 4.69 6.03e-06 0.00346 0.5 0.36 Mitral valve prolapse; chr21:36039611 chr21:36005338~36007838:+ PAAD cis rs62229266 0.659 rs2835242 ENSG00000231106.2 LINC01436 4.69 6.03e-06 0.00346 0.5 0.36 Mitral valve prolapse; chr21:36041234 chr21:36005338~36007838:+ PAAD cis rs62229266 0.659 rs2835243 ENSG00000231106.2 LINC01436 4.69 6.03e-06 0.00346 0.5 0.36 Mitral valve prolapse; chr21:36041648 chr21:36005338~36007838:+ PAAD cis rs62229266 0.659 rs2835245 ENSG00000231106.2 LINC01436 4.69 6.03e-06 0.00346 0.5 0.36 Mitral valve prolapse; chr21:36044410 chr21:36005338~36007838:+ PAAD cis rs62229266 0.609 rs12482541 ENSG00000231106.2 LINC01436 4.69 6.03e-06 0.00346 0.5 0.36 Mitral valve prolapse; chr21:36047445 chr21:36005338~36007838:+ PAAD cis rs62229266 0.609 rs2835253 ENSG00000231106.2 LINC01436 4.69 6.03e-06 0.00346 0.5 0.36 Mitral valve prolapse; chr21:36047447 chr21:36005338~36007838:+ PAAD cis rs11893307 0.536 rs6719798 ENSG00000235852.1 AC005540.3 4.69 6.03e-06 0.00346 0.53 0.36 Mean platelet volume; chr2:190812938 chr2:190880797~190882059:- PAAD cis rs2658782 0.688 rs2658768 ENSG00000279684.1 RP11-755E23.2 -4.69 6.03e-06 0.00346 -0.58 -0.36 Pulmonary function decline; chr11:93517661 chr11:93286629~93288903:- PAAD cis rs2658782 0.724 rs2658769 ENSG00000279684.1 RP11-755E23.2 -4.69 6.03e-06 0.00346 -0.58 -0.36 Pulmonary function decline; chr11:93518864 chr11:93286629~93288903:- PAAD cis rs1823913 0.895 rs10931491 ENSG00000280083.1 RP11-317J9.1 4.69 6.03e-06 0.00347 0.45 0.36 Obesity-related traits; chr2:191256087 chr2:191154118~191156070:- PAAD cis rs1823913 1 rs11681777 ENSG00000280083.1 RP11-317J9.1 4.69 6.03e-06 0.00347 0.45 0.36 Obesity-related traits; chr2:191256741 chr2:191154118~191156070:- PAAD cis rs7615952 0.546 rs2979340 ENSG00000171084.14 FAM86JP 4.69 6.04e-06 0.00347 0.52 0.36 Blood pressure (smoking interaction); chr3:125622540 chr3:125916620~125930024:+ PAAD cis rs7615952 0.546 rs2979338 ENSG00000171084.14 FAM86JP 4.69 6.04e-06 0.00347 0.52 0.36 Blood pressure (smoking interaction); chr3:125624282 chr3:125916620~125930024:+ PAAD cis rs7615952 0.546 rs2922171 ENSG00000171084.14 FAM86JP 4.69 6.04e-06 0.00347 0.52 0.36 Blood pressure (smoking interaction); chr3:125624349 chr3:125916620~125930024:+ PAAD cis rs7615952 0.546 rs112919177 ENSG00000171084.14 FAM86JP 4.69 6.04e-06 0.00347 0.52 0.36 Blood pressure (smoking interaction); chr3:125627226 chr3:125916620~125930024:+ PAAD cis rs2283792 0.765 rs9610374 ENSG00000224086.5 LL22NC03-86G7.1 -4.69 6.04e-06 0.00347 -0.36 -0.36 Multiple sclerosis; chr22:21832514 chr22:21938293~21977632:+ PAAD cis rs2283792 0.765 rs5999752 ENSG00000224086.5 LL22NC03-86G7.1 -4.69 6.04e-06 0.00347 -0.36 -0.36 Multiple sclerosis; chr22:21833894 chr22:21938293~21977632:+ PAAD cis rs4273100 0.646 rs4924990 ENSG00000228157.4 AC007952.5 -4.69 6.05e-06 0.00347 -0.55 -0.36 Schizophrenia; chr17:19391511 chr17:19092974~19096837:+ PAAD cis rs8059260 0.668 rs74737820 ENSG00000274038.1 RP11-66H6.4 -4.69 6.05e-06 0.00347 -0.6 -0.36 Alcohol consumption over the past year; chr16:10972240 chr16:11056556~11057034:+ PAAD cis rs3096299 0.9 rs4785663 ENSG00000274627.1 RP11-104N10.2 4.69 6.05e-06 0.00348 0.31 0.36 Multiple myeloma (IgH translocation); chr16:89368480 chr16:89516797~89522217:+ PAAD cis rs66887589 0.87 rs2389875 ENSG00000248280.1 RP11-33B1.2 -4.69 6.06e-06 0.00348 -0.32 -0.36 Diastolic blood pressure; chr4:119635859 chr4:119440561~119450157:- PAAD cis rs9322193 0.884 rs7769115 ENSG00000268592.3 RAET1E-AS1 4.69 6.07e-06 0.00348 0.44 0.36 Lung cancer; chr6:149848796 chr6:149863494~149919507:+ PAAD cis rs2729354 0.817 rs2649667 ENSG00000265566.2 RN7SL605P -4.69 6.07e-06 0.00348 -0.44 -0.36 Blood protein levels; chr11:57503036 chr11:57528085~57528365:- PAAD cis rs12554020 0.892 rs59483310 ENSG00000227603.1 RP11-165J3.6 4.69 6.07e-06 0.00348 0.56 0.36 Schizophrenia; chr9:93503318 chr9:93435332~93437121:- PAAD cis rs6860540 0.687 rs6871720 ENSG00000251405.2 CTB-109A12.1 -4.69 6.08e-06 0.00349 -0.46 -0.36 Inflammatory skin disease; chr5:157447457 chr5:157362615~157460078:- PAAD cis rs2562456 0.793 rs2562474 ENSG00000213976.4 CTD-2561J22.2 4.69 6.09e-06 0.00349 0.4 0.36 Pain; chr19:21463480 chr19:21382865~21387177:+ PAAD cis rs308403 0.509 rs6811183 ENSG00000224786.1 CETN4P 4.69 6.09e-06 0.00349 0.42 0.36 Blood protein levels; chr4:122750396 chr4:122730548~122732193:- PAAD cis rs308403 0.509 rs9990804 ENSG00000224786.1 CETN4P 4.69 6.09e-06 0.00349 0.42 0.36 Blood protein levels; chr4:122750829 chr4:122730548~122732193:- PAAD cis rs308403 0.509 rs10016979 ENSG00000224786.1 CETN4P 4.69 6.09e-06 0.00349 0.42 0.36 Blood protein levels; chr4:122752037 chr4:122730548~122732193:- PAAD cis rs308403 0.509 rs1849430 ENSG00000224786.1 CETN4P 4.69 6.09e-06 0.00349 0.42 0.36 Blood protein levels; chr4:122753546 chr4:122730548~122732193:- PAAD cis rs9531006 0.636 rs12583645 ENSG00000227676.3 LINC01068 4.69 6.09e-06 0.00349 0.56 0.36 Sleep duration; chr13:79929175 chr13:79566727~79571436:+ PAAD cis rs453301 0.686 rs6601280 ENSG00000253893.2 FAM85B -4.69 6.1e-06 0.00349 -0.5 -0.36 Joint mobility (Beighton score); chr8:9051726 chr8:8167819~8226614:- PAAD cis rs2348418 0.864 rs7304776 ENSG00000247934.4 RP11-967K21.1 4.69 6.1e-06 0.00349 0.34 0.36 Lung function (FEV1);Lung function (FVC); chr12:28560634 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs11049714 ENSG00000247934.4 RP11-967K21.1 4.69 6.1e-06 0.00349 0.34 0.36 Lung function (FEV1);Lung function (FVC); chr12:28561162 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7960369 ENSG00000247934.4 RP11-967K21.1 4.69 6.1e-06 0.00349 0.34 0.36 Lung function (FEV1);Lung function (FVC); chr12:28561569 chr12:28163298~28190738:- PAAD cis rs111580313 0.685 rs4843160 ENSG00000270020.1 RP11-463O9.9 4.69 6.1e-06 0.00349 0.95 0.36 Systemic juvenile idiopathic arthritis; chr16:86565140 chr16:86520383~86523897:- PAAD cis rs6751744 0.513 rs10173538 ENSG00000226266.5 AC009961.3 -4.69 6.1e-06 0.0035 -0.44 -0.36 Dysphagia; chr2:159712765 chr2:159670708~159712435:- PAAD cis rs66887589 0.777 rs2017058 ENSG00000248280.1 RP11-33B1.2 4.69 6.11e-06 0.0035 0.31 0.36 Diastolic blood pressure; chr4:119336584 chr4:119440561~119450157:- PAAD cis rs66887589 0.777 rs1814815 ENSG00000248280.1 RP11-33B1.2 4.69 6.11e-06 0.0035 0.31 0.36 Diastolic blood pressure; chr4:119336936 chr4:119440561~119450157:- PAAD cis rs6782228 0.606 rs7627549 ENSG00000242551.2 POU5F1P6 -4.69 6.11e-06 0.0035 -0.42 -0.36 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128634236 chr3:128674735~128677005:- PAAD cis rs8100891 0.537 rs10410770 ENSG00000267213.4 AC007773.2 -4.69 6.12e-06 0.00351 -0.58 -0.36 Neuroticism; chr19:32411498 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs28729153 ENSG00000267213.4 AC007773.2 -4.69 6.12e-06 0.00351 -0.58 -0.36 Neuroticism; chr19:32416672 chr19:32390050~32405560:- PAAD cis rs17772222 0.565 rs845759 ENSG00000258983.2 RP11-507K2.2 -4.69 6.13e-06 0.00351 -0.43 -0.36 Coronary artery calcification; chr14:88415538 chr14:88499334~88515502:+ PAAD cis rs9322193 0.884 rs7744105 ENSG00000268592.3 RAET1E-AS1 4.69 6.13e-06 0.00351 0.44 0.36 Lung cancer; chr6:149849308 chr6:149863494~149919507:+ PAAD cis rs1075265 0.868 rs4671872 ENSG00000233266.1 HMGB1P31 4.69 6.13e-06 0.00351 0.47 0.36 Chronotype;Morning vs. evening chronotype; chr2:54134035 chr2:54051334~54051760:+ PAAD cis rs875971 0.54 rs1723268 ENSG00000237310.1 GS1-124K5.4 4.69 6.13e-06 0.00351 0.34 0.36 Aortic root size; chr7:66008093 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs1701760 ENSG00000237310.1 GS1-124K5.4 4.69 6.13e-06 0.00351 0.34 0.36 Aortic root size; chr7:66008701 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs2949690 ENSG00000237310.1 GS1-124K5.4 -4.69 6.13e-06 0.00351 -0.34 -0.36 Aortic root size; chr7:66018255 chr7:66493706~66495474:+ PAAD cis rs11992186 0.505 rs7845203 ENSG00000253981.4 ALG1L13P 4.69 6.14e-06 0.00352 0.43 0.36 Neuroticism; chr8:8287918 chr8:8236003~8244667:- PAAD cis rs2882667 0.537 rs6887866 ENSG00000253404.1 AC034243.1 4.69 6.14e-06 0.00352 0.39 0.36 Age-related hearing impairment (SNP x SNP interaction); chr5:139102007 chr5:138744434~138753309:- PAAD cis rs733592 0.504 rs2261608 ENSG00000240399.1 RP1-228P16.1 4.69 6.14e-06 0.00352 0.32 0.36 Plateletcrit; chr12:48327851 chr12:48054813~48055591:- PAAD cis rs9980 0.657 rs62052820 ENSG00000226232.7 RP11-419C5.2 -4.69 6.14e-06 0.00352 -0.34 -0.36 Blood osmolality (transformed sodium); chr16:69541335 chr16:69976388~69996188:- PAAD cis rs6540731 0.728 rs12746096 ENSG00000229983.1 RP11-15I11.2 4.69 6.15e-06 0.00352 0.42 0.36 Intelligence (childhood); chr1:212190424 chr1:212168207~212190259:+ PAAD cis rs7119038 0.509 rs11216956 ENSG00000255239.1 AP002954.6 -4.69 6.16e-06 0.00353 -0.46 -0.36 Sjögren's syndrome; chr11:118704617 chr11:118688039~118690600:- PAAD cis rs6565180 1 rs8049108 ENSG00000183604.13 SMG1P5 -4.68 6.18e-06 0.00354 -0.39 -0.36 Tonsillectomy; chr16:30365165 chr16:30267553~30335374:- PAAD cis rs7208859 0.673 rs9889755 ENSG00000266490.1 CTD-2349P21.9 -4.68 6.18e-06 0.00354 -0.45 -0.36 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30907487 chr17:30792372~30792833:+ PAAD cis rs2348418 0.864 rs2203088 ENSG00000247934.4 RP11-967K21.1 4.68 6.2e-06 0.00355 0.34 0.36 Lung function (FEV1);Lung function (FVC); chr12:28556767 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs6487687 ENSG00000247934.4 RP11-967K21.1 4.68 6.2e-06 0.00355 0.34 0.36 Lung function (FEV1);Lung function (FVC); chr12:28558230 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs6487689 ENSG00000247934.4 RP11-967K21.1 4.68 6.2e-06 0.00355 0.34 0.36 Lung function (FEV1);Lung function (FVC); chr12:28560101 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs6487690 ENSG00000247934.4 RP11-967K21.1 4.68 6.2e-06 0.00355 0.34 0.36 Lung function (FEV1);Lung function (FVC); chr12:28560407 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7304540 ENSG00000247934.4 RP11-967K21.1 4.68 6.2e-06 0.00355 0.34 0.36 Lung function (FEV1);Lung function (FVC); chr12:28560489 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs2137073 ENSG00000247934.4 RP11-967K21.1 -4.68 6.2e-06 0.00355 -0.34 -0.36 Lung function (FEV1);Lung function (FVC); chr12:28564151 chr12:28163298~28190738:- PAAD cis rs62229266 0.839 rs11088335 ENSG00000231106.2 LINC01436 4.68 6.2e-06 0.00355 0.5 0.36 Mitral valve prolapse; chr21:36098037 chr21:36005338~36007838:+ PAAD cis rs1823913 0.599 rs1378156 ENSG00000280083.1 RP11-317J9.1 4.68 6.2e-06 0.00355 0.42 0.36 Obesity-related traits; chr2:191272466 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs17511445 ENSG00000280083.1 RP11-317J9.1 4.68 6.2e-06 0.00355 0.42 0.36 Obesity-related traits; chr2:191279831 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs13002286 ENSG00000280083.1 RP11-317J9.1 4.68 6.2e-06 0.00355 0.42 0.36 Obesity-related traits; chr2:191285626 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs56328712 ENSG00000280083.1 RP11-317J9.1 -4.68 6.2e-06 0.00355 -0.42 -0.36 Obesity-related traits; chr2:191273807 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs55862924 ENSG00000280083.1 RP11-317J9.1 -4.68 6.2e-06 0.00355 -0.42 -0.36 Obesity-related traits; chr2:191273809 chr2:191154118~191156070:- PAAD cis rs1823913 0.561 rs60479498 ENSG00000280083.1 RP11-317J9.1 -4.68 6.2e-06 0.00355 -0.42 -0.36 Obesity-related traits; chr2:191275197 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs12989203 ENSG00000280083.1 RP11-317J9.1 -4.68 6.2e-06 0.00355 -0.42 -0.36 Obesity-related traits; chr2:191276617 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs17511410 ENSG00000280083.1 RP11-317J9.1 -4.68 6.2e-06 0.00355 -0.42 -0.36 Obesity-related traits; chr2:191278043 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs34262638 ENSG00000280083.1 RP11-317J9.1 -4.68 6.2e-06 0.00355 -0.42 -0.36 Obesity-related traits; chr2:191279442 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs34100174 ENSG00000280083.1 RP11-317J9.1 -4.68 6.2e-06 0.00355 -0.42 -0.36 Obesity-related traits; chr2:191283579 chr2:191154118~191156070:- PAAD cis rs763567 0.935 rs1234275 ENSG00000271811.1 RP1-79C4.4 -4.68 6.21e-06 0.00355 -0.33 -0.36 Tonsillectomy; chr1:170627117 chr1:170667381~170669425:+ PAAD cis rs7712401 0.601 rs36180885 ENSG00000263432.2 RN7SL689P -4.68 6.21e-06 0.00355 -0.46 -0.36 Mean platelet volume; chr5:123020708 chr5:123022487~123022783:- PAAD cis rs2486288 0.656 rs7162022 ENSG00000259433.2 CTD-2651B20.4 4.68 6.22e-06 0.00356 0.39 0.36 Glomerular filtration rate; chr15:45273055 chr15:45330209~45332634:- PAAD cis rs270601 0.721 rs270621 ENSG00000233006.5 AC034220.3 4.68 6.23e-06 0.00356 0.3 0.36 Acylcarnitine levels; chr5:132270128 chr5:132311285~132369916:- PAAD cis rs270601 0.721 rs162894 ENSG00000233006.5 AC034220.3 4.68 6.23e-06 0.00356 0.3 0.36 Acylcarnitine levels; chr5:132276179 chr5:132311285~132369916:- PAAD cis rs875971 0.522 rs709604 ENSG00000237310.1 GS1-124K5.4 -4.68 6.25e-06 0.00357 -0.33 -0.36 Aortic root size; chr7:66032447 chr7:66493706~66495474:+ PAAD cis rs867529 0.695 rs335115 ENSG00000230006.6 ANKRD36BP2 4.68 6.26e-06 0.00357 0.3 0.35 Height; chr2:88728129 chr2:88765807~88806612:+ PAAD cis rs3813579 0.654 rs4480821 ENSG00000261390.4 RP11-345M22.2 -4.68 6.26e-06 0.00358 -0.46 -0.35 Thyroid volume; chr16:79711416 chr16:79715232~79770563:- PAAD cis rs62229266 0.633 rs34259635 ENSG00000231106.2 LINC01436 4.68 6.27e-06 0.00358 0.5 0.35 Mitral valve prolapse; chr21:36031272 chr21:36005338~36007838:+ PAAD cis rs12134133 1 rs6658718 ENSG00000274245.1 RP11-357P18.2 4.68 6.29e-06 0.00359 0.53 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207285561 chr1:207372559~207373252:+ PAAD cis rs807029 0.758 rs807025 ENSG00000272572.1 RP11-179B2.2 -4.68 6.3e-06 0.0036 -0.44 -0.35 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:101005064 chr10:100911103~100912739:- PAAD cis rs2115630 0.791 rs2008262 ENSG00000225151.9 GOLGA2P7 4.68 6.3e-06 0.0036 0.44 0.35 P wave terminal force; chr15:84762039 chr15:84199311~84230136:- PAAD cis rs6844153 0.752 rs12650172 ENSG00000240005.4 RP11-293A21.1 -4.68 6.3e-06 0.0036 -0.52 -0.35 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26872784 chr4:26859806~26860599:- PAAD cis rs6844153 0.752 rs12641261 ENSG00000240005.4 RP11-293A21.1 -4.68 6.3e-06 0.0036 -0.52 -0.35 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26872814 chr4:26859806~26860599:- PAAD cis rs12439619 0.739 rs4778988 ENSG00000255769.6 GOLGA2P10 -4.68 6.31e-06 0.0036 -0.41 -0.35 Intelligence (multi-trait analysis); chr15:82247996 chr15:82472993~82513950:- PAAD cis rs748404 0.631 rs28702649 ENSG00000249839.1 AC011330.5 -4.68 6.31e-06 0.0036 -0.52 -0.35 Lung cancer; chr15:43356431 chr15:43663654~43684339:- PAAD cis rs10510102 0.872 rs12264046 ENSG00000276742.1 RP11-500G22.4 4.68 6.31e-06 0.0036 0.53 0.35 Breast cancer; chr10:121894996 chr10:121956782~121957098:+ PAAD cis rs2348418 0.864 rs7314984 ENSG00000247934.4 RP11-967K21.1 4.68 6.32e-06 0.00361 0.34 0.35 Lung function (FEV1);Lung function (FVC); chr12:28557936 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7312339 ENSG00000247934.4 RP11-967K21.1 4.68 6.32e-06 0.00361 0.34 0.35 Lung function (FEV1);Lung function (FVC); chr12:28558751 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs1343859 ENSG00000247934.4 RP11-967K21.1 4.68 6.32e-06 0.00361 0.34 0.35 Lung function (FEV1);Lung function (FVC); chr12:28559537 chr12:28163298~28190738:- PAAD cis rs7188445 0.736 rs8048539 ENSG00000261390.4 RP11-345M22.2 4.68 6.33e-06 0.00361 0.48 0.35 Urate levels; chr16:79670255 chr16:79715232~79770563:- PAAD cis rs74233809 1 rs79237883 ENSG00000213277.3 MARCKSL1P1 4.68 6.34e-06 0.00362 0.61 0.35 Birth weight; chr10:103181189 chr10:103175554~103176094:+ PAAD cis rs2658782 0.756 rs3019205 ENSG00000279684.1 RP11-755E23.2 -4.68 6.34e-06 0.00362 -0.58 -0.35 Pulmonary function decline; chr11:93376387 chr11:93286629~93288903:- PAAD cis rs60733400 0.509 rs56814247 ENSG00000225931.3 RP3-395M20.7 -4.68 6.35e-06 0.00362 -0.35 -0.35 Multiple sclerosis; chr1:2691050 chr1:2566410~2569888:+ PAAD cis rs189798 0.845 rs330904 ENSG00000254340.1 RP11-10A14.3 -4.68 6.35e-06 0.00362 -0.46 -0.35 Myopia (pathological); chr8:9134315 chr8:9141424~9145435:+ PAAD cis rs2599510 0.811 rs176410 ENSG00000276334.1 AL133243.1 -4.68 6.35e-06 0.00362 -0.42 -0.35 Interleukin-18 levels; chr2:32418369 chr2:32521927~32523547:+ PAAD cis rs2348418 0.831 rs1581074 ENSG00000247934.4 RP11-967K21.1 4.68 6.35e-06 0.00362 0.35 0.35 Lung function (FEV1);Lung function (FVC); chr12:28571031 chr12:28163298~28190738:- PAAD cis rs35160687 0.644 rs11127024 ENSG00000273080.1 RP11-301O19.1 -4.68 6.35e-06 0.00362 -0.41 -0.35 Night sleep phenotypes; chr2:86278330 chr2:86195590~86196049:+ PAAD cis rs9595908 0.931 rs9595617 ENSG00000212293.1 SNORA16 4.68 6.36e-06 0.00363 0.41 0.35 Body mass index; chr13:32483208 chr13:32420390~32420516:- PAAD cis rs9595908 0.895 rs9591012 ENSG00000212293.1 SNORA16 4.68 6.36e-06 0.00363 0.41 0.35 Body mass index; chr13:32484196 chr13:32420390~32420516:- PAAD cis rs9595908 0.931 rs9595628 ENSG00000212293.1 SNORA16 4.68 6.36e-06 0.00363 0.41 0.35 Body mass index; chr13:32491021 chr13:32420390~32420516:- PAAD cis rs9595908 0.931 rs35555940 ENSG00000212293.1 SNORA16 4.68 6.36e-06 0.00363 0.41 0.35 Body mass index; chr13:32492975 chr13:32420390~32420516:- PAAD cis rs9595908 0.931 rs9315167 ENSG00000212293.1 SNORA16 4.68 6.36e-06 0.00363 0.41 0.35 Body mass index; chr13:32495051 chr13:32420390~32420516:- PAAD cis rs2412819 0.597 rs2412821 ENSG00000205771.5 CATSPER2P1 -4.68 6.37e-06 0.00363 -0.52 -0.35 Lung cancer; chr15:43864966 chr15:43726918~43747094:- PAAD cis rs5758659 0.652 rs133347 ENSG00000273366.1 CTA-989H11.1 -4.68 6.38e-06 0.00364 -0.43 -0.35 Cognitive function; chr22:42027641 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133349 ENSG00000273366.1 CTA-989H11.1 -4.68 6.38e-06 0.00364 -0.43 -0.35 Cognitive function; chr22:42032723 chr22:42278188~42278846:+ PAAD cis rs308403 0.533 rs12644866 ENSG00000224786.1 CETN4P 4.68 6.38e-06 0.00364 0.42 0.35 Blood protein levels; chr4:122746449 chr4:122730548~122732193:- PAAD cis rs2948294 0.524 rs13270062 ENSG00000253893.2 FAM85B -4.68 6.39e-06 0.00364 -0.49 -0.35 Red cell distribution width; chr8:8255128 chr8:8167819~8226614:- PAAD cis rs12025262 0.546 rs10754539 ENSG00000227671.4 RP11-488L18.4 -4.68 6.39e-06 0.00364 -0.2 -0.35 Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50); chr1:247202128 chr1:247189851~247210856:- PAAD cis rs2581828 0.646 rs2564944 ENSG00000242142.1 SERBP1P3 4.68 6.39e-06 0.00364 0.43 0.35 Crohn's disease; chr3:53114439 chr3:53064283~53065091:- PAAD cis rs4853012 0.752 rs13413795 ENSG00000257800.1 FNBP1P1 4.68 6.4e-06 0.00365 0.48 0.35 Gestational age at birth (maternal effect); chr2:74122712 chr2:74120680~74123218:+ PAAD cis rs2404602 0.647 rs11072626 ENSG00000259422.1 RP11-593F23.1 -4.68 6.4e-06 0.00365 -0.43 -0.35 Blood metabolite levels; chr15:76798485 chr15:76174891~76181486:- PAAD cis rs17495987 0.871 rs73061231 ENSG00000219545.8 UMAD1 4.68 6.4e-06 0.00365 0.48 0.35 Tonsillectomy; chr7:7864765 chr7:7640711~8004059:+ PAAD cis rs858239 0.632 rs6952947 ENSG00000226816.2 AC005082.12 -4.68 6.4e-06 0.00365 -0.4 -0.35 Cerebrospinal fluid biomarker levels; chr7:23081423 chr7:23206013~23208045:+ PAAD cis rs8100891 0.537 rs16967057 ENSG00000267213.4 AC007773.2 4.68 6.4e-06 0.00365 0.57 0.35 Neuroticism; chr19:32423172 chr19:32390050~32405560:- PAAD cis rs4835473 0.932 rs12505628 ENSG00000251600.4 RP11-673E1.1 -4.68 6.41e-06 0.00365 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143758468 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs12505663 ENSG00000251600.4 RP11-673E1.1 -4.68 6.41e-06 0.00365 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143758491 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs12513078 ENSG00000251600.4 RP11-673E1.1 -4.68 6.41e-06 0.00365 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143758494 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs12505665 ENSG00000251600.4 RP11-673E1.1 -4.68 6.41e-06 0.00365 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143758515 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs12509716 ENSG00000251600.4 RP11-673E1.1 -4.68 6.41e-06 0.00365 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143758520 chr4:143912331~143982454:+ PAAD cis rs7826238 0.653 rs2979202 ENSG00000253893.2 FAM85B -4.68 6.42e-06 0.00365 -0.48 -0.35 Systolic blood pressure; chr8:8486617 chr8:8167819~8226614:- PAAD cis rs2658782 0.724 rs2248655 ENSG00000279684.1 RP11-755E23.2 -4.68 6.42e-06 0.00365 -0.58 -0.35 Pulmonary function decline; chr11:93521446 chr11:93286629~93288903:- PAAD cis rs7615952 0.932 rs7630077 ENSG00000241288.6 RP11-379B18.5 -4.68 6.42e-06 0.00365 -0.37 -0.35 Blood pressure (smoking interaction); chr3:125930833 chr3:125827238~125916384:- PAAD cis rs4835473 0.897 rs2590034 ENSG00000251600.4 RP11-673E1.1 4.68 6.42e-06 0.00365 0.41 0.35 Immature fraction of reticulocytes; chr4:143926778 chr4:143912331~143982454:+ PAAD cis rs17495987 0.871 rs73057784 ENSG00000219545.8 UMAD1 4.68 6.43e-06 0.00366 0.49 0.35 Tonsillectomy; chr7:7857074 chr7:7640711~8004059:+ PAAD cis rs13178541 0.752 rs66533013 ENSG00000250378.1 RP11-119J18.1 -4.67 6.44e-06 0.00367 -0.56 -0.35 IgG glycosylation; chr5:135788933 chr5:135812667~135826582:+ PAAD cis rs8059260 0.736 rs7192695 ENSG00000274038.1 RP11-66H6.4 -4.67 6.45e-06 0.00367 -0.59 -0.35 Alcohol consumption over the past year; chr16:11005395 chr16:11056556~11057034:+ PAAD cis rs5758659 0.652 rs5758553 ENSG00000273366.1 CTA-989H11.1 -4.67 6.45e-06 0.00367 -0.43 -0.35 Cognitive function; chr22:42035425 chr22:42278188~42278846:+ PAAD cis rs9532669 0.926 rs9532691 ENSG00000176268.5 CYCSP34 -4.67 6.45e-06 0.00367 -0.33 -0.35 Cervical cancer; chr13:40969358 chr13:40863599~40863902:- PAAD cis rs2278034 0.502 rs3747672 ENSG00000271662.1 RP11-141C7.3 -4.67 6.45e-06 0.00367 -0.4 -0.35 Bronchopulmonary dysplasia; chr3:195885163 chr3:195650146~195651472:- PAAD cis rs10916248 0.511 rs10916489 ENSG00000232628.4 RP11-365O16.3 -4.67 6.46e-06 0.00367 -0.52 -0.35 QT interval (drug interaction); chr1:224215164 chr1:224208747~224213279:- PAAD cis rs9928842 1 rs7202566 ENSG00000280152.1 RP11-331F4.5 4.67 6.47e-06 0.00368 0.48 0.35 Alcoholic chronic pancreatitis; chr16:75213746 chr16:75245994~75250077:- PAAD cis rs734999 0.588 rs3748818 ENSG00000225931.3 RP3-395M20.7 4.67 6.48e-06 0.00368 0.34 0.35 Ulcerative colitis; chr1:2594221 chr1:2566410~2569888:+ PAAD cis rs4664293 0.967 rs1006192 ENSG00000226266.5 AC009961.3 -4.67 6.48e-06 0.00368 -0.44 -0.35 Monocyte percentage of white cells; chr2:159711078 chr2:159670708~159712435:- PAAD cis rs4835473 0.897 rs34425128 ENSG00000251600.4 RP11-673E1.1 -4.67 6.48e-06 0.00368 -0.4 -0.35 Immature fraction of reticulocytes; chr4:143725191 chr4:143912331~143982454:+ PAAD cis rs61270009 0.955 rs454693 ENSG00000247828.6 TMEM161B-AS1 4.67 6.48e-06 0.00368 0.28 0.35 Depressive symptoms; chr5:88248396 chr5:88268895~88436685:+ PAAD cis rs7078219 0.524 rs6584277 ENSG00000257582.4 LINC01475 -4.67 6.48e-06 0.00369 -0.38 -0.35 Dental caries; chr10:99518298 chr10:99526350~99531177:- PAAD cis rs9322193 0.607 rs12204653 ENSG00000268592.3 RAET1E-AS1 4.67 6.48e-06 0.00369 0.48 0.35 Lung cancer; chr6:149891885 chr6:149863494~149919507:+ PAAD cis rs633715 0.766 rs11586243 ENSG00000254154.7 RP4-798P15.3 -4.67 6.49e-06 0.00369 -0.34 -0.35 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177829702 chr1:177928788~178038007:- PAAD cis rs2882667 0.537 rs7701338 ENSG00000253404.1 AC034243.1 4.67 6.49e-06 0.00369 0.4 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139070305 chr5:138744434~138753309:- PAAD cis rs879620 0.929 rs2238435 ENSG00000262888.1 RP11-462G12.2 -4.67 6.51e-06 0.0037 -0.47 -0.35 Hip circumference;Body mass index; chr16:3964281 chr16:3931217~3946305:- PAAD cis rs8005677 0.828 rs12437151 ENSG00000279656.1 RP11-298I3.6 4.67 6.51e-06 0.0037 0.42 0.35 Cognitive ability (multi-trait analysis); chr14:22903704 chr14:23023083~23024217:- PAAD cis rs2274273 0.686 rs68083077 ENSG00000258413.1 RP11-665C16.6 -4.67 6.51e-06 0.0037 -0.47 -0.35 Protein biomarker; chr14:55107710 chr14:55262767~55272075:- PAAD cis rs4835473 0.897 rs6537170 ENSG00000251600.4 RP11-673E1.1 4.67 6.51e-06 0.0037 0.39 0.35 Immature fraction of reticulocytes; chr4:143691747 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs1450246 ENSG00000251600.4 RP11-673E1.1 4.67 6.51e-06 0.0037 0.39 0.35 Immature fraction of reticulocytes; chr4:143702954 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs1545437 ENSG00000251600.4 RP11-673E1.1 -4.67 6.51e-06 0.0037 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143696689 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs61427459 ENSG00000251600.4 RP11-673E1.1 -4.67 6.51e-06 0.0037 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143699605 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs7657088 ENSG00000251600.4 RP11-673E1.1 -4.67 6.51e-06 0.0037 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143701877 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs4835333 ENSG00000251600.4 RP11-673E1.1 -4.67 6.51e-06 0.0037 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143703174 chr4:143912331~143982454:+ PAAD cis rs11893307 0.851 rs62182472 ENSG00000235852.1 AC005540.3 4.67 6.52e-06 0.0037 0.54 0.35 Mean platelet volume; chr2:190868102 chr2:190880797~190882059:- PAAD cis rs2117029 0.727 rs10875910 ENSG00000258017.1 RP11-386G11.10 -4.67 6.52e-06 0.0037 -0.47 -0.35 Intelligence (multi-trait analysis); chr12:49008610 chr12:49127782~49147869:+ PAAD cis rs2274273 0.868 rs1572611 ENSG00000258413.1 RP11-665C16.6 -4.67 6.52e-06 0.0037 -0.46 -0.35 Protein biomarker; chr14:55367156 chr14:55262767~55272075:- PAAD cis rs9876781 0.835 rs12487765 ENSG00000229759.1 MRPS18AP1 -4.67 6.53e-06 0.00371 -0.37 -0.35 Longevity; chr3:48370245 chr3:48256350~48256938:- PAAD cis rs1322639 0.614 rs9455889 ENSG00000261039.2 RP11-417E7.2 -4.67 6.53e-06 0.00371 -0.58 -0.35 Pulse pressure; chr6:169165992 chr6:169175304~169182740:- PAAD cis rs2015599 0.623 rs3782510 ENSG00000257176.2 RP11-996F15.2 4.67 6.54e-06 0.00371 0.35 0.35 Platelet count;Mean platelet volume; chr12:29301176 chr12:29280418~29317848:- PAAD cis rs2882667 0.537 rs7701116 ENSG00000253404.1 AC034243.1 4.67 6.55e-06 0.00372 0.39 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139070389 chr5:138744434~138753309:- PAAD cis rs2882667 0.537 rs11743534 ENSG00000253404.1 AC034243.1 4.67 6.55e-06 0.00372 0.39 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139073318 chr5:138744434~138753309:- PAAD cis rs4728142 0.604 rs4731541 ENSG00000275106.1 RP11-309L24.10 -4.67 6.55e-06 0.00372 -0.49 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129038182 chr7:128952527~128953316:- PAAD cis rs9322193 0.884 rs7743823 ENSG00000268592.3 RAET1E-AS1 4.67 6.55e-06 0.00372 0.44 0.35 Lung cancer; chr6:149849744 chr6:149863494~149919507:+ PAAD cis rs8031584 0.958 rs34909055 ENSG00000260382.1 RP11-540B6.2 4.67 6.55e-06 0.00372 0.44 0.35 Huntington's disease progression; chr15:30991967 chr15:30882267~30883231:- PAAD cis rs13178541 0.638 rs34295073 ENSG00000250378.1 RP11-119J18.1 -4.67 6.56e-06 0.00372 -0.55 -0.35 IgG glycosylation; chr5:135785964 chr5:135812667~135826582:+ PAAD cis rs902774 0.597 rs7299694 ENSG00000278185.1 RP11-153F5.7 4.67 6.57e-06 0.00372 0.47 0.35 Prostate cancer; chr12:52958788 chr12:52946614~52947125:- PAAD cis rs11159086 0.793 rs10136668 ENSG00000259005.1 RP3-449M8.6 4.67 6.57e-06 0.00373 0.47 0.35 Advanced glycation end-product levels; chr14:74492183 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs10139029 ENSG00000259005.1 RP3-449M8.6 4.67 6.57e-06 0.00373 0.47 0.35 Advanced glycation end-product levels; chr14:74492284 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs10139122 ENSG00000259005.1 RP3-449M8.6 4.67 6.57e-06 0.00373 0.47 0.35 Advanced glycation end-product levels; chr14:74492353 chr14:74474007~74474864:- PAAD cis rs734999 0.588 rs867435 ENSG00000225931.3 RP3-395M20.7 4.67 6.57e-06 0.00373 0.34 0.35 Ulcerative colitis; chr1:2592267 chr1:2566410~2569888:+ PAAD cis rs6782228 0.606 rs6439135 ENSG00000242551.2 POU5F1P6 -4.67 6.57e-06 0.00373 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128639790 chr3:128674735~128677005:- PAAD cis rs6782228 0.509 rs2811495 ENSG00000242551.2 POU5F1P6 -4.67 6.57e-06 0.00373 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128641114 chr3:128674735~128677005:- PAAD cis rs6782228 0.565 rs2811496 ENSG00000242551.2 POU5F1P6 -4.67 6.57e-06 0.00373 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128641115 chr3:128674735~128677005:- PAAD cis rs17023223 0.508 rs12096448 ENSG00000231365.4 RP11-418J17.1 -4.67 6.59e-06 0.00374 -0.38 -0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119140767 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs4508058 ENSG00000231365.4 RP11-418J17.1 -4.67 6.59e-06 0.00374 -0.38 -0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119141627 chr1:119140396~119275973:+ PAAD cis rs748404 0.589 rs3862138 ENSG00000249839.1 AC011330.5 -4.67 6.59e-06 0.00374 -0.63 -0.35 Lung cancer; chr15:43523801 chr15:43663654~43684339:- PAAD cis rs748404 0.55 rs12912505 ENSG00000249839.1 AC011330.5 -4.67 6.59e-06 0.00374 -0.63 -0.35 Lung cancer; chr15:43525206 chr15:43663654~43684339:- PAAD cis rs4835473 0.932 rs13130345 ENSG00000251600.4 RP11-673E1.1 4.67 6.6e-06 0.00374 0.41 0.35 Immature fraction of reticulocytes; chr4:143920939 chr4:143912331~143982454:+ PAAD cis rs9601248 0.756 rs7997134 ENSG00000227354.5 RBM26-AS1 -4.67 6.6e-06 0.00374 -0.35 -0.35 Major depressive disorder; chr13:79619594 chr13:79406309~79424328:+ PAAD cis rs2333194 0.772 rs8016034 ENSG00000258695.2 RP3-414A15.2 -4.67 6.6e-06 0.00374 -0.39 -0.35 Bipolar disorder with mood-incongruent psychosis; chr14:73345480 chr14:73522878~73530610:+ PAAD cis rs62229266 0.659 rs62230814 ENSG00000231106.2 LINC01436 4.67 6.61e-06 0.00375 0.5 0.35 Mitral valve prolapse; chr21:36031248 chr21:36005338~36007838:+ PAAD cis rs6921919 0.887 rs7766356 ENSG00000204709.4 LINC01556 4.67 6.62e-06 0.00375 0.62 0.35 Autism spectrum disorder or schizophrenia; chr6:28432761 chr6:28943877~28944537:+ PAAD cis rs11654699 0.869 rs7225208 ENSG00000274341.1 RP11-227G15.10 4.67 6.62e-06 0.00375 0.34 0.35 Neurofibrillary tangles; chr17:32595766 chr17:32408013~32408309:+ PAAD cis rs308403 0.509 rs13117125 ENSG00000224786.1 CETN4P 4.67 6.63e-06 0.00376 0.42 0.35 Blood protein levels; chr4:122749669 chr4:122730548~122732193:- PAAD cis rs308403 0.509 rs7690133 ENSG00000224786.1 CETN4P 4.67 6.63e-06 0.00376 0.42 0.35 Blood protein levels; chr4:122752654 chr4:122730548~122732193:- PAAD cis rs308403 0.509 rs1849431 ENSG00000224786.1 CETN4P 4.67 6.63e-06 0.00376 0.42 0.35 Blood protein levels; chr4:122753607 chr4:122730548~122732193:- PAAD cis rs9287719 0.967 rs6432112 ENSG00000234818.1 AC092687.5 -4.67 6.64e-06 0.00376 -0.39 -0.35 Prostate cancer; chr2:10604748 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs6432113 ENSG00000234818.1 AC092687.5 -4.67 6.64e-06 0.00376 -0.39 -0.35 Prostate cancer; chr2:10604763 chr2:10589166~10604830:+ PAAD cis rs7208859 0.673 rs9915139 ENSG00000266490.1 CTD-2349P21.9 4.67 6.65e-06 0.00377 0.45 0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831497 chr17:30792372~30792833:+ PAAD cis rs3758785 0.621 rs7128673 ENSG00000255893.1 RP11-685N10.1 -4.67 6.65e-06 0.00377 -0.39 -0.35 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy); chr11:94453072 chr11:94472908~94473570:- PAAD cis rs72802342 0.541 rs185052 ENSG00000261783.1 RP11-252K23.2 4.67 6.66e-06 0.00377 0.55 0.35 Advanced age-related macular degeneration; chr16:75433165 chr16:75379818~75381260:- PAAD cis rs847577 0.609 rs6465658 ENSG00000272950.1 RP11-307C18.1 4.67 6.66e-06 0.00377 0.45 0.35 Breast cancer; chr7:98187326 chr7:98322853~98323430:+ PAAD cis rs9473147 0.516 rs9369695 ENSG00000270761.1 RP11-385F7.1 -4.67 6.67e-06 0.00378 -0.35 -0.35 Platelet distribution width;Mean platelet volume; chr6:47472829 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs4715018 ENSG00000270761.1 RP11-385F7.1 -4.67 6.67e-06 0.00378 -0.35 -0.35 Platelet distribution width;Mean platelet volume; chr6:47474135 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs1931837 ENSG00000270761.1 RP11-385F7.1 -4.67 6.67e-06 0.00378 -0.35 -0.35 Platelet distribution width;Mean platelet volume; chr6:47474641 chr6:47477243~47477572:- PAAD cis rs9473147 0.516 rs9381564 ENSG00000270761.1 RP11-385F7.1 -4.67 6.67e-06 0.00378 -0.35 -0.35 Platelet distribution width;Mean platelet volume; chr6:47476070 chr6:47477243~47477572:- PAAD cis rs2564921 0.704 rs62253604 ENSG00000242142.1 SERBP1P3 -4.67 6.67e-06 0.00378 -0.43 -0.35 Height; chr3:52941053 chr3:53064283~53065091:- PAAD cis rs992157 0.71 rs10167446 ENSG00000261338.2 RP11-378A13.1 4.67 6.68e-06 0.00378 0.4 0.35 Colorectal cancer; chr2:218192143 chr2:218255319~218257366:+ PAAD cis rs12817211 0.524 rs10876000 ENSG00000272368.2 RP4-605O3.4 -4.67 6.68e-06 0.00378 -0.35 -0.35 Colorectal or endometrial cancer; chr12:50128431 chr12:50112197~50165618:+ PAAD cis rs12817211 0.524 rs2204683 ENSG00000272368.2 RP4-605O3.4 -4.67 6.68e-06 0.00378 -0.35 -0.35 Colorectal or endometrial cancer; chr12:50128593 chr12:50112197~50165618:+ PAAD cis rs6504950 0.925 rs2787497 ENSG00000275710.1 RP11-257O5.4 -4.67 6.69e-06 0.00379 -0.47 -0.35 Breast cancer; chr17:55098850 chr17:54964474~54964679:+ PAAD cis rs6504950 0.925 rs181727 ENSG00000275710.1 RP11-257O5.4 4.67 6.69e-06 0.00379 0.47 0.35 Breast cancer; chr17:55113634 chr17:54964474~54964679:+ PAAD cis rs6504950 0.925 rs244358 ENSG00000275710.1 RP11-257O5.4 4.67 6.69e-06 0.00379 0.47 0.35 Breast cancer; chr17:55114870 chr17:54964474~54964679:+ PAAD cis rs734999 0.588 rs2764841 ENSG00000225931.3 RP3-395M20.7 -4.67 6.69e-06 0.00379 -0.33 -0.35 Ulcerative colitis; chr1:2597921 chr1:2566410~2569888:+ PAAD cis rs13178541 0.81 rs11748975 ENSG00000250378.1 RP11-119J18.1 -4.67 6.7e-06 0.00379 -0.55 -0.35 IgG glycosylation; chr5:135768875 chr5:135812667~135826582:+ PAAD cis rs13178541 0.688 rs12189128 ENSG00000250378.1 RP11-119J18.1 -4.67 6.7e-06 0.00379 -0.55 -0.35 IgG glycosylation; chr5:135770662 chr5:135812667~135826582:+ PAAD cis rs453301 0.657 rs36056437 ENSG00000253893.2 FAM85B 4.67 6.7e-06 0.00379 0.47 0.35 Joint mobility (Beighton score); chr8:8935355 chr8:8167819~8226614:- PAAD cis rs4728142 0.604 rs7783384 ENSG00000275106.1 RP11-309L24.10 -4.67 6.71e-06 0.00379 -0.48 -0.35 Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus; chr7:129041243 chr7:128952527~128953316:- PAAD cis rs2274273 1 rs72718804 ENSG00000258413.1 RP11-665C16.6 -4.67 6.71e-06 0.0038 -0.47 -0.35 Protein biomarker; chr14:55163892 chr14:55262767~55272075:- PAAD cis rs453301 0.686 rs2409120 ENSG00000253893.2 FAM85B 4.67 6.71e-06 0.0038 0.48 0.35 Joint mobility (Beighton score); chr8:9025061 chr8:8167819~8226614:- PAAD cis rs2274273 0.905 rs2147961 ENSG00000258413.1 RP11-665C16.6 -4.67 6.71e-06 0.0038 -0.44 -0.35 Protein biomarker; chr14:55118663 chr14:55262767~55272075:- PAAD cis rs2348418 0.966 rs11049694 ENSG00000247934.4 RP11-967K21.1 4.66 6.72e-06 0.0038 0.35 0.35 Lung function (FEV1);Lung function (FVC); chr12:28527925 chr12:28163298~28190738:- PAAD cis rs9531006 0.636 rs1811362 ENSG00000227676.3 LINC01068 4.66 6.73e-06 0.00381 0.53 0.35 Sleep duration; chr13:79901570 chr13:79566727~79571436:+ PAAD cis rs807029 0.533 rs2863095 ENSG00000272572.1 RP11-179B2.2 -4.66 6.73e-06 0.00381 -0.43 -0.35 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100986746 chr10:100911103~100912739:- PAAD cis rs1185460 0.967 rs3825061 ENSG00000271751.1 RP11-110I1.14 -4.66 6.75e-06 0.00382 -0.44 -0.35 Coronary artery disease; chr11:119073965 chr11:119065263~119065677:- PAAD cis rs807029 0.533 rs67692077 ENSG00000272572.1 RP11-179B2.2 -4.66 6.75e-06 0.00382 -0.43 -0.35 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100980514 chr10:100911103~100912739:- PAAD cis rs807029 0.533 rs12571302 ENSG00000272572.1 RP11-179B2.2 -4.66 6.75e-06 0.00382 -0.43 -0.35 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100983006 chr10:100911103~100912739:- PAAD cis rs2274273 1 rs67805055 ENSG00000258413.1 RP11-665C16.6 -4.66 6.76e-06 0.00382 -0.46 -0.35 Protein biomarker; chr14:55120834 chr14:55262767~55272075:- PAAD cis rs7208859 0.623 rs9914242 ENSG00000266490.1 CTD-2349P21.9 4.66 6.76e-06 0.00382 0.47 0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889227 chr17:30792372~30792833:+ PAAD cis rs6991838 0.612 rs7842162 ENSG00000200714.1 Y_RNA 4.66 6.77e-06 0.00383 0.41 0.35 Intelligence (multi-trait analysis); chr8:65644057 chr8:65592731~65592820:+ PAAD cis rs11654699 0.806 rs8067382 ENSG00000274341.1 RP11-227G15.10 4.66 6.77e-06 0.00383 0.33 0.35 Neurofibrillary tangles; chr17:32600945 chr17:32408013~32408309:+ PAAD cis rs308403 0.509 rs7690409 ENSG00000224786.1 CETN4P 4.66 6.78e-06 0.00383 0.42 0.35 Blood protein levels; chr4:122745602 chr4:122730548~122732193:- PAAD cis rs61270009 0.955 rs768705 ENSG00000247828.6 TMEM161B-AS1 4.66 6.78e-06 0.00383 0.29 0.35 Depressive symptoms; chr5:88272893 chr5:88268895~88436685:+ PAAD cis rs4794202 0.717 rs6503897 ENSG00000264920.1 RP11-6N17.4 4.66 6.79e-06 0.00383 0.52 0.35 Alzheimer's disease (cognitive decline); chr17:47879683 chr17:47891255~47895812:- PAAD cis rs6504950 0.705 rs9899602 ENSG00000275710.1 RP11-257O5.4 -4.66 6.79e-06 0.00384 -0.46 -0.35 Breast cancer; chr17:54909547 chr17:54964474~54964679:+ PAAD cis rs4950322 0.57 rs11800580 ENSG00000278811.3 LINC00624 -4.66 6.79e-06 0.00384 -0.37 -0.35 Protein quantitative trait loci; chr1:147261053 chr1:147258885~147517875:- PAAD cis rs875971 0.54 rs781152 ENSG00000237310.1 GS1-124K5.4 4.66 6.8e-06 0.00384 0.34 0.35 Aortic root size; chr7:66014585 chr7:66493706~66495474:+ PAAD cis rs17711722 0.727 rs781151 ENSG00000237310.1 GS1-124K5.4 4.66 6.8e-06 0.00384 0.34 0.35 Calcium levels; chr7:66014891 chr7:66493706~66495474:+ PAAD cis rs7580658 0.864 rs10928761 ENSG00000236682.1 AC068282.3 -4.66 6.81e-06 0.00385 -0.47 -0.35 Protein C levels; chr2:127245671 chr2:127389130~127400580:+ PAAD cis rs7580658 0.521 rs35577992 ENSG00000236682.1 AC068282.3 -4.66 6.81e-06 0.00385 -0.44 -0.35 Protein C levels; chr2:127183748 chr2:127389130~127400580:+ PAAD cis rs9987353 0.589 rs1053036 ENSG00000253893.2 FAM85B 4.66 6.82e-06 0.00385 0.47 0.35 Recombination measurement; chr8:9202567 chr8:8167819~8226614:- PAAD cis rs964611 0.882 rs3784616 ENSG00000259488.2 RP11-154J22.1 -4.66 6.83e-06 0.00386 -0.37 -0.35 Metabolite levels (Pyroglutamine); chr15:48278381 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs7175172 ENSG00000259488.2 RP11-154J22.1 -4.66 6.83e-06 0.00386 -0.37 -0.35 Metabolite levels (Pyroglutamine); chr15:48280021 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs8040405 ENSG00000259488.2 RP11-154J22.1 -4.66 6.83e-06 0.00386 -0.37 -0.35 Metabolite levels (Pyroglutamine); chr15:48280640 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs7179027 ENSG00000259488.2 RP11-154J22.1 -4.66 6.83e-06 0.00386 -0.37 -0.35 Metabolite levels (Pyroglutamine); chr15:48287279 chr15:48312353~48331856:- PAAD cis rs964611 0.882 rs12442530 ENSG00000259488.2 RP11-154J22.1 -4.66 6.83e-06 0.00386 -0.37 -0.35 Metabolite levels (Pyroglutamine); chr15:48288376 chr15:48312353~48331856:- PAAD cis rs2486288 0.656 rs1706768 ENSG00000259433.2 CTD-2651B20.4 4.66 6.85e-06 0.00387 0.38 0.35 Glomerular filtration rate; chr15:45277245 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs2461705 ENSG00000259433.2 CTD-2651B20.4 4.66 6.85e-06 0.00387 0.38 0.35 Glomerular filtration rate; chr15:45278043 chr15:45330209~45332634:- PAAD cis rs216345 0.7 rs1760822 ENSG00000230074.1 RP11-195F19.9 4.66 6.86e-06 0.00387 0.47 0.35 Bipolar disorder; chr9:34025952 chr9:34665665~34681298:+ PAAD cis rs77372450 0.636 rs6556105 ENSG00000251405.2 CTB-109A12.1 4.66 6.86e-06 0.00387 0.56 0.35 Bipolar disorder (body mass index interaction); chr5:157595856 chr5:157362615~157460078:- PAAD cis rs1910358 0.566 rs320572 ENSG00000248874.4 C5orf17 -4.66 6.86e-06 0.00387 -0.53 -0.35 Venous thromboembolism (SNP x SNP interaction); chr5:23848157 chr5:23951348~24178263:+ PAAD cis rs7712401 0.601 rs34126945 ENSG00000263432.2 RN7SL689P -4.66 6.86e-06 0.00387 -0.45 -0.35 Mean platelet volume; chr5:122994034 chr5:123022487~123022783:- PAAD cis rs2255336 0.938 rs1478309 ENSG00000245648.1 RP11-277P12.20 4.66 6.86e-06 0.00387 0.54 0.35 Blood protein levels; chr12:10389146 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs2045876 ENSG00000245648.1 RP11-277P12.20 4.66 6.86e-06 0.00387 0.54 0.35 Blood protein levels; chr12:10389233 chr12:10363769~10398506:+ PAAD cis rs9601248 0.756 rs9601251 ENSG00000227354.5 RBM26-AS1 -4.66 6.87e-06 0.00388 -0.35 -0.35 Major depressive disorder; chr13:79615582 chr13:79406309~79424328:+ PAAD cis rs9601248 0.756 rs9601252 ENSG00000227354.5 RBM26-AS1 -4.66 6.87e-06 0.00388 -0.35 -0.35 Major depressive disorder; chr13:79615607 chr13:79406309~79424328:+ PAAD cis rs2404602 0.647 rs35710279 ENSG00000259422.1 RP11-593F23.1 -4.66 6.88e-06 0.00388 -0.43 -0.35 Blood metabolite levels; chr15:76789893 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11855296 ENSG00000259422.1 RP11-593F23.1 -4.66 6.88e-06 0.00388 -0.43 -0.35 Blood metabolite levels; chr15:76800621 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11072628 ENSG00000259422.1 RP11-593F23.1 -4.66 6.88e-06 0.00388 -0.43 -0.35 Blood metabolite levels; chr15:76815420 chr15:76174891~76181486:- PAAD cis rs12134133 1 rs6660557 ENSG00000274245.1 RP11-357P18.2 4.66 6.88e-06 0.00388 0.54 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207281251 chr1:207372559~207373252:+ PAAD cis rs17826219 0.789 rs4794873 ENSG00000266490.1 CTD-2349P21.9 4.66 6.89e-06 0.00388 0.41 0.35 Body mass index; chr17:30421334 chr17:30792372~30792833:+ PAAD cis rs8031584 0.918 rs1425292 ENSG00000260382.1 RP11-540B6.2 4.66 6.89e-06 0.00389 0.45 0.35 Huntington's disease progression; chr15:30993219 chr15:30882267~30883231:- PAAD cis rs2337406 0.789 rs60000589 ENSG00000211974.3 IGHV2-70 -4.66 6.9e-06 0.00389 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106782459 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs111881598 ENSG00000211974.3 IGHV2-70 -4.66 6.9e-06 0.00389 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106783113 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs61164979 ENSG00000211974.3 IGHV2-70 -4.66 6.9e-06 0.00389 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106783133 chr14:106723574~106724093:- PAAD cis rs2946504 0.822 rs2977095 ENSG00000251468.2 RP11-369K16.1 4.66 6.9e-06 0.00389 0.41 0.35 Type 2 diabetes; chr8:12947706 chr8:12958387~12962200:+ PAAD cis rs858239 0.867 rs10250602 ENSG00000226816.2 AC005082.12 4.66 6.9e-06 0.00389 0.4 0.35 Cerebrospinal fluid biomarker levels; chr7:23264082 chr7:23206013~23208045:+ PAAD cis rs9649213 0.574 rs7802560 ENSG00000272950.1 RP11-307C18.1 -4.66 6.91e-06 0.00389 -0.41 -0.35 Prostate cancer (SNP x SNP interaction); chr7:98274494 chr7:98322853~98323430:+ PAAD cis rs2348418 0.966 rs11049698 ENSG00000247934.4 RP11-967K21.1 4.66 6.91e-06 0.0039 0.35 0.35 Lung function (FEV1);Lung function (FVC); chr12:28535354 chr12:28163298~28190738:- PAAD cis rs875971 0.838 rs2173570 ENSG00000237310.1 GS1-124K5.4 -4.66 6.91e-06 0.0039 -0.34 -0.35 Aortic root size; chr7:66297976 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs937495 ENSG00000237310.1 GS1-124K5.4 -4.66 6.91e-06 0.0039 -0.34 -0.35 Aortic root size; chr7:66314811 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs2036264 ENSG00000237310.1 GS1-124K5.4 -4.66 6.91e-06 0.0039 -0.34 -0.35 Aortic root size; chr7:66334917 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs7783613 ENSG00000237310.1 GS1-124K5.4 -4.66 6.91e-06 0.0039 -0.34 -0.35 Aortic root size; chr7:66340274 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs778735 ENSG00000237310.1 GS1-124K5.4 4.66 6.91e-06 0.0039 0.34 0.35 Aortic root size; chr7:66349822 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6979382 ENSG00000237310.1 GS1-124K5.4 4.66 6.91e-06 0.0039 0.34 0.35 Aortic root size; chr7:66421388 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6961990 ENSG00000237310.1 GS1-124K5.4 4.66 6.91e-06 0.0039 0.34 0.35 Aortic root size; chr7:66423583 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs4718358 ENSG00000237310.1 GS1-124K5.4 4.66 6.91e-06 0.0039 0.34 0.35 Aortic root size; chr7:66508681 chr7:66493706~66495474:+ PAAD cis rs17711722 0.522 rs62469933 ENSG00000237310.1 GS1-124K5.4 4.66 6.92e-06 0.0039 0.34 0.35 Calcium levels; chr7:65800652 chr7:66493706~66495474:+ PAAD cis rs964611 0.882 rs12903327 ENSG00000259488.2 RP11-154J22.1 4.66 6.92e-06 0.0039 0.4 0.35 Metabolite levels (Pyroglutamine); chr15:48355466 chr15:48312353~48331856:- PAAD cis rs950169 0.881 rs150965 ENSG00000259295.5 CSPG4P12 4.66 6.93e-06 0.0039 0.39 0.35 Schizophrenia; chr15:84537296 chr15:85191438~85213905:+ PAAD cis rs6921919 0.583 rs7764722 ENSG00000216901.1 AL022393.7 4.66 6.93e-06 0.0039 0.45 0.35 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28176188~28176674:+ PAAD cis rs4853525 0.59 rs2355576 ENSG00000235852.1 AC005540.3 4.66 6.93e-06 0.0039 0.53 0.35 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190850374 chr2:190880797~190882059:- PAAD cis rs4853525 0.561 rs17746911 ENSG00000235852.1 AC005540.3 4.66 6.93e-06 0.0039 0.53 0.35 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190854640 chr2:190880797~190882059:- PAAD cis rs4853525 0.59 rs12614693 ENSG00000235852.1 AC005540.3 4.66 6.93e-06 0.0039 0.53 0.35 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190854882 chr2:190880797~190882059:- PAAD cis rs4853525 0.59 rs1921911 ENSG00000235852.1 AC005540.3 4.66 6.93e-06 0.0039 0.53 0.35 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190855644 chr2:190880797~190882059:- PAAD cis rs1075265 0.704 rs805410 ENSG00000233266.1 HMGB1P31 4.66 6.93e-06 0.0039 0.45 0.35 Chronotype;Morning vs. evening chronotype; chr2:53893360 chr2:54051334~54051760:+ PAAD cis rs9828933 0.752 rs28675788 ENSG00000280620.1 SCAANT1 4.66 6.93e-06 0.00391 0.59 0.35 Type 2 diabetes; chr3:63956512 chr3:63911518~63911772:- PAAD cis rs889398 0.967 rs244415 ENSG00000226232.7 RP11-419C5.2 4.66 6.93e-06 0.00391 0.29 0.35 Body mass index; chr16:69632780 chr16:69976388~69996188:- PAAD cis rs889398 0.967 rs1437134 ENSG00000226232.7 RP11-419C5.2 -4.66 6.93e-06 0.00391 -0.29 -0.35 Body mass index; chr16:69696523 chr16:69976388~69996188:- PAAD cis rs889398 0.967 rs7359336 ENSG00000226232.7 RP11-419C5.2 -4.66 6.93e-06 0.00391 -0.29 -0.35 Body mass index; chr16:69699557 chr16:69976388~69996188:- PAAD cis rs2117029 0.767 rs12580349 ENSG00000258017.1 RP11-386G11.10 4.66 6.93e-06 0.00391 0.46 0.35 Intelligence (multi-trait analysis); chr12:49042941 chr12:49127782~49147869:+ PAAD cis rs7829975 0.684 rs546603 ENSG00000253893.2 FAM85B 4.66 6.94e-06 0.00391 0.52 0.35 Mood instability; chr8:8738328 chr8:8167819~8226614:- PAAD cis rs13178541 0.873 rs11749405 ENSG00000250378.1 RP11-119J18.1 -4.66 6.94e-06 0.00391 -0.56 -0.35 IgG glycosylation; chr5:135804386 chr5:135812667~135826582:+ PAAD cis rs7712401 0.601 rs30045 ENSG00000263432.2 RN7SL689P 4.66 6.95e-06 0.00391 0.45 0.35 Mean platelet volume; chr5:122935924 chr5:123022487~123022783:- PAAD cis rs7762018 0.514 rs60671539 ENSG00000231690.2 LINC00574 -4.66 6.96e-06 0.00392 -0.43 -0.35 Thiazide-induced adverse metabolic effects in hypertensive patients; chr6:169765885 chr6:169790321~169802873:+ PAAD cis rs853679 0.517 rs9393896 ENSG00000226314.6 ZNF192P1 -4.66 6.97e-06 0.00393 -0.6 -0.35 Depression; chr6:28159925 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393897 ENSG00000226314.6 ZNF192P1 -4.66 6.97e-06 0.00393 -0.6 -0.35 Depression; chr6:28159932 chr6:28161781~28169594:+ PAAD cis rs11168351 1 rs11168351 ENSG00000240399.1 RP1-228P16.1 4.66 6.98e-06 0.00393 0.37 0.35 Bipolar disorder and schizophrenia; chr12:48009982 chr12:48054813~48055591:- PAAD cis rs4664293 0.707 rs7563956 ENSG00000226266.5 AC009961.3 4.66 6.99e-06 0.00393 0.43 0.35 Monocyte percentage of white cells; chr2:159815943 chr2:159670708~159712435:- PAAD cis rs1707322 0.686 rs1084086 ENSG00000280836.1 AL355480.1 4.66 6.99e-06 0.00394 0.43 0.35 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45575428 chr1:45581219~45581321:- PAAD cis rs6480314 0.522 rs4746754 ENSG00000233590.1 RP11-153K11.3 4.66 7e-06 0.00394 0.56 0.35 Optic nerve measurement (disc area); chr10:68289862 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs10762204 ENSG00000233590.1 RP11-153K11.3 4.66 7e-06 0.00394 0.56 0.35 Optic nerve measurement (disc area); chr10:68290006 chr10:68233251~68242379:- PAAD cis rs12571093 0.571 rs10762205 ENSG00000233590.1 RP11-153K11.3 4.66 7e-06 0.00394 0.56 0.35 Optic nerve measurement (disc area); chr10:68290145 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs10762210 ENSG00000233590.1 RP11-153K11.3 4.66 7e-06 0.00394 0.56 0.35 Optic nerve measurement (disc area); chr10:68290860 chr10:68233251~68242379:- PAAD cis rs12571093 0.571 rs7899387 ENSG00000233590.1 RP11-153K11.3 4.66 7e-06 0.00394 0.56 0.35 Optic nerve measurement (disc area); chr10:68293278 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs10733841 ENSG00000233590.1 RP11-153K11.3 4.66 7e-06 0.00394 0.56 0.35 Optic nerve measurement (disc area); chr10:68293520 chr10:68233251~68242379:- PAAD cis rs875971 0.54 rs736270 ENSG00000237310.1 GS1-124K5.4 4.66 7e-06 0.00394 0.34 0.35 Aortic root size; chr7:65963835 chr7:66493706~66495474:+ PAAD cis rs17507216 1 rs17507216 ENSG00000255769.6 GOLGA2P10 4.65 7.01e-06 0.00394 0.45 0.35 Excessive daytime sleepiness; chr15:82558175 chr15:82472993~82513950:- PAAD cis rs8177376 1 rs8177376 ENSG00000254905.1 RP11-712L6.7 4.65 7.02e-06 0.00395 0.48 0.35 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126293717 chr11:126292922~126294254:- PAAD cis rs1185460 0.967 rs2509121 ENSG00000271751.1 RP11-110I1.14 -4.65 7.02e-06 0.00395 -0.45 -0.35 Coronary artery disease; chr11:119057542 chr11:119065263~119065677:- PAAD cis rs7208859 0.673 rs216435 ENSG00000266490.1 CTD-2349P21.9 4.65 7.03e-06 0.00395 0.42 0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30595719 chr17:30792372~30792833:+ PAAD cis rs7580658 0.534 rs2089109 ENSG00000236682.1 AC068282.3 -4.65 7.04e-06 0.00396 -0.43 -0.35 Protein C levels; chr2:127193882 chr2:127389130~127400580:+ PAAD cis rs2283792 0.765 rs9610338 ENSG00000224086.5 LL22NC03-86G7.1 4.65 7.04e-06 0.00396 0.35 0.35 Multiple sclerosis; chr22:21797532 chr22:21938293~21977632:+ PAAD cis rs853679 0.517 rs16893666 ENSG00000280107.1 AL022393.9 4.65 7.04e-06 0.00396 0.57 0.35 Depression; chr6:28086929 chr6:28170845~28172521:+ PAAD cis rs1185460 0.934 rs10892328 ENSG00000271751.1 RP11-110I1.14 -4.65 7.05e-06 0.00396 -0.44 -0.35 Coronary artery disease; chr11:119071944 chr11:119065263~119065677:- PAAD cis rs10510102 0.935 rs78525391 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121901102 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs4627017 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121901878 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs7098562 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121902148 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs7098822 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121902157 chr10:121956782~121957098:+ PAAD cis rs10510102 0.81 rs11200240 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121903265 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs74914751 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121904496 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200242 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121905378 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12246704 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121906165 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200243 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121906888 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200244 ENSG00000276742.1 RP11-500G22.4 4.65 7.05e-06 0.00396 0.52 0.35 Breast cancer; chr10:121906944 chr10:121956782~121957098:+ PAAD cis rs10463554 0.853 rs246902 ENSG00000175749.11 EIF3KP1 4.65 7.06e-06 0.00396 0.46 0.35 Parkinson's disease; chr5:103253553 chr5:103032376~103033031:+ PAAD cis rs11893307 0.566 rs62179714 ENSG00000235852.1 AC005540.3 4.65 7.06e-06 0.00396 0.52 0.35 Mean platelet volume; chr2:190702815 chr2:190880797~190882059:- PAAD cis rs6504950 0.925 rs8082622 ENSG00000275710.1 RP11-257O5.4 -4.65 7.06e-06 0.00397 -0.46 -0.35 Breast cancer; chr17:55100206 chr17:54964474~54964679:+ PAAD cis rs6504950 0.925 rs244377 ENSG00000275710.1 RP11-257O5.4 -4.65 7.06e-06 0.00397 -0.46 -0.35 Breast cancer; chr17:55105718 chr17:54964474~54964679:+ PAAD cis rs734999 0.588 rs2260976 ENSG00000225931.3 RP3-395M20.7 -4.65 7.07e-06 0.00397 -0.34 -0.35 Ulcerative colitis; chr1:2596239 chr1:2566410~2569888:+ PAAD cis rs7615952 0.575 rs35949599 ENSG00000239804.1 RP11-379B18.1 4.65 7.09e-06 0.00398 0.48 0.35 Blood pressure (smoking interaction); chr3:125825359 chr3:125787888~125788146:- PAAD cis rs1823913 0.927 rs13013390 ENSG00000280083.1 RP11-317J9.1 -4.65 7.09e-06 0.00398 -0.44 -0.35 Obesity-related traits; chr2:191262001 chr2:191154118~191156070:- PAAD cis rs7078219 0.543 rs7092009 ENSG00000257582.4 LINC01475 -4.65 7.09e-06 0.00398 -0.38 -0.35 Dental caries; chr10:99517482 chr10:99526350~99531177:- PAAD cis rs2404602 0.622 rs1567671 ENSG00000259422.1 RP11-593F23.1 -4.65 7.12e-06 0.004 -0.43 -0.35 Blood metabolite levels; chr15:76916859 chr15:76174891~76181486:- PAAD cis rs4723738 1 rs11766341 ENSG00000227191.5 TRGC2 -4.65 7.12e-06 0.004 -0.31 -0.35 Treatment response for severe sepsis; chr7:38188147 chr7:38239580~38368091:- PAAD cis rs12908161 0.515 rs12907646 ENSG00000275120.1 RP11-182J1.17 4.65 7.14e-06 0.00401 0.41 0.35 Schizophrenia; chr15:84860265 chr15:84599434~84606463:- PAAD cis rs526231 0.543 rs34804 ENSG00000175749.11 EIF3KP1 4.65 7.15e-06 0.00401 0.48 0.35 Primary biliary cholangitis; chr5:103092535 chr5:103032376~103033031:+ PAAD cis rs9739640 1 rs9739640 ENSG00000257379.1 RP11-793H13.8 4.65 7.17e-06 0.00402 0.5 0.35 Reticulocyte count; chr12:53389390 chr12:53441741~53467528:+ PAAD cis rs2243480 1 rs1618893 ENSG00000226824.5 RP4-756H11.3 -4.65 7.18e-06 0.00402 -0.6 -0.35 Diabetic kidney disease; chr7:66631132 chr7:66654538~66669855:+ PAAD cis rs2599510 0.84 rs466146 ENSG00000276334.1 AL133243.1 4.65 7.18e-06 0.00403 0.43 0.35 Interleukin-18 levels; chr2:32314167 chr2:32521927~32523547:+ PAAD cis rs16846053 0.71 rs13022437 ENSG00000227403.1 AC009299.3 -4.65 7.19e-06 0.00403 -0.55 -0.35 Blood osmolality (transformed sodium); chr2:161765775 chr2:161244739~161249050:+ PAAD cis rs755249 0.51 rs599892 ENSG00000237624.1 OXCT2P1 4.65 7.19e-06 0.00403 0.47 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39457212 chr1:39514956~39516490:+ PAAD cis rs6565180 1 rs11863150 ENSG00000183604.13 SMG1P5 4.65 7.19e-06 0.00403 0.37 0.35 Tonsillectomy; chr16:30374182 chr16:30267553~30335374:- PAAD cis rs871012 0.502 rs951959 ENSG00000251405.2 CTB-109A12.1 -4.65 7.2e-06 0.00403 -0.45 -0.35 IgG glycosylation; chr5:157462211 chr5:157362615~157460078:- PAAD cis rs871012 0.502 rs57064749 ENSG00000251405.2 CTB-109A12.1 -4.65 7.2e-06 0.00403 -0.45 -0.35 IgG glycosylation; chr5:157462690 chr5:157362615~157460078:- PAAD cis rs734999 0.545 rs4074789 ENSG00000225931.3 RP3-395M20.7 4.65 7.2e-06 0.00404 0.34 0.35 Ulcerative colitis; chr1:2606025 chr1:2566410~2569888:+ PAAD cis rs734999 0.505 rs10797437 ENSG00000225931.3 RP3-395M20.7 4.65 7.2e-06 0.00404 0.34 0.35 Ulcerative colitis; chr1:2607567 chr1:2566410~2569888:+ PAAD cis rs734999 0.505 rs10910107 ENSG00000225931.3 RP3-395M20.7 4.65 7.2e-06 0.00404 0.34 0.35 Ulcerative colitis; chr1:2607742 chr1:2566410~2569888:+ PAAD cis rs734999 0.505 rs4073286 ENSG00000225931.3 RP3-395M20.7 4.65 7.2e-06 0.00404 0.34 0.35 Ulcerative colitis; chr1:2608462 chr1:2566410~2569888:+ PAAD cis rs734999 0.505 rs10797438 ENSG00000225931.3 RP3-395M20.7 4.65 7.2e-06 0.00404 0.34 0.35 Ulcerative colitis; chr1:2608823 chr1:2566410~2569888:+ PAAD cis rs6667605 0.527 rs12046118 ENSG00000225931.3 RP3-395M20.7 4.65 7.2e-06 0.00404 0.34 0.35 Ulcerative colitis;Inflammatory bowel disease; chr1:2608904 chr1:2566410~2569888:+ PAAD cis rs734999 0.505 rs10797439 ENSG00000225931.3 RP3-395M20.7 4.65 7.2e-06 0.00404 0.34 0.35 Ulcerative colitis; chr1:2608925 chr1:2566410~2569888:+ PAAD cis rs6667605 0.506 rs10797440 ENSG00000225931.3 RP3-395M20.7 4.65 7.2e-06 0.00404 0.34 0.35 Ulcerative colitis;Inflammatory bowel disease; chr1:2609830 chr1:2566410~2569888:+ PAAD cis rs4723738 1 rs4723734 ENSG00000227191.5 TRGC2 -4.65 7.2e-06 0.00404 -0.31 -0.35 Treatment response for severe sepsis; chr7:38192459 chr7:38239580~38368091:- PAAD cis rs12134133 0.962 rs6682586 ENSG00000274245.1 RP11-357P18.2 4.65 7.2e-06 0.00404 0.58 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207243122 chr1:207372559~207373252:+ PAAD cis rs12134133 0.962 rs6668560 ENSG00000274245.1 RP11-357P18.2 4.65 7.2e-06 0.00404 0.58 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207243462 chr1:207372559~207373252:+ PAAD cis rs992157 0.56 rs7605980 ENSG00000261338.2 RP11-378A13.1 4.65 7.2e-06 0.00404 0.4 0.35 Colorectal cancer; chr2:218236146 chr2:218255319~218257366:+ PAAD cis rs2255336 0.938 rs59906810 ENSG00000245648.1 RP11-277P12.20 -4.65 7.21e-06 0.00404 -0.55 -0.35 Blood protein levels; chr12:10446021 chr12:10363769~10398506:+ PAAD cis rs734999 0.505 rs4445406 ENSG00000225931.3 RP3-395M20.7 4.65 7.22e-06 0.00404 0.34 0.35 Ulcerative colitis; chr1:2607961 chr1:2566410~2569888:+ PAAD cis rs6921919 0.945 rs16901847 ENSG00000204709.4 LINC01556 4.65 7.22e-06 0.00404 0.61 0.35 Autism spectrum disorder or schizophrenia; chr6:28408074 chr6:28943877~28944537:+ PAAD cis rs10754283 0.967 rs10922685 ENSG00000231613.1 RP5-943J3.1 4.65 7.22e-06 0.00405 0.38 0.35 Amyotrophic lateral sclerosis (sporadic); chr1:89652761 chr1:89788914~89790492:+ PAAD cis rs6472235 1 rs6981354 ENSG00000200714.1 Y_RNA 4.65 7.23e-06 0.00405 0.46 0.35 Plateletcrit;Myopia (pathological); chr8:65952948 chr8:65592731~65592820:+ PAAD cis rs2283792 0.765 rs9610328 ENSG00000224086.5 LL22NC03-86G7.1 -4.65 7.24e-06 0.00405 -0.35 -0.35 Multiple sclerosis; chr22:21793085 chr22:21938293~21977632:+ PAAD cis rs853679 0.517 rs1340004 ENSG00000280107.1 AL022393.9 -4.65 7.24e-06 0.00405 -0.58 -0.35 Depression; chr6:28135913 chr6:28170845~28172521:+ PAAD cis rs12220777 0.748 rs11201641 ENSG00000230091.5 TMEM254-AS1 4.65 7.25e-06 0.00406 0.53 0.35 Chronic obstructive pulmonary disease-related biomarkers; chr10:80091975 chr10:80046860~80078912:- PAAD cis rs734999 0.545 rs4474198 ENSG00000225931.3 RP3-395M20.7 4.65 7.25e-06 0.00406 0.33 0.35 Ulcerative colitis; chr1:2622319 chr1:2566410~2569888:+ PAAD cis rs9531006 0.603 rs9601288 ENSG00000227676.3 LINC01068 4.65 7.26e-06 0.00406 0.55 0.35 Sleep duration; chr13:79893120 chr13:79566727~79571436:+ PAAD cis rs9531006 0.602 rs9601289 ENSG00000227676.3 LINC01068 4.65 7.26e-06 0.00406 0.55 0.35 Sleep duration; chr13:79893972 chr13:79566727~79571436:+ PAAD cis rs9531006 0.636 rs9601290 ENSG00000227676.3 LINC01068 4.65 7.26e-06 0.00406 0.55 0.35 Sleep duration; chr13:79895192 chr13:79566727~79571436:+ PAAD cis rs12134133 1 rs10494890 ENSG00000274245.1 RP11-357P18.2 -4.65 7.26e-06 0.00406 -0.56 -0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207251041 chr1:207372559~207373252:+ PAAD cis rs889398 0.933 rs6499240 ENSG00000226232.7 RP11-419C5.2 -4.65 7.26e-06 0.00406 -0.29 -0.35 Body mass index; chr16:69653009 chr16:69976388~69996188:- PAAD cis rs11098499 0.588 rs2389874 ENSG00000248280.1 RP11-33B1.2 -4.65 7.27e-06 0.00407 -0.33 -0.35 Corneal astigmatism; chr4:119633836 chr4:119440561~119450157:- PAAD cis rs932287 0.536 rs10840160 ENSG00000254860.4 TMEM9B-AS1 4.65 7.27e-06 0.00407 0.38 0.35 Colonoscopy-negative controls vs population controls; chr11:9031989 chr11:8964675~8977527:+ PAAD cis rs6667605 0.527 rs6673993 ENSG00000225931.3 RP3-395M20.7 4.65 7.27e-06 0.00407 0.33 0.35 Ulcerative colitis;Inflammatory bowel disease; chr1:2620632 chr1:2566410~2569888:+ PAAD cis rs2658782 0.901 rs2605611 ENSG00000279684.1 RP11-755E23.2 -4.65 7.28e-06 0.00407 -0.61 -0.35 Pulmonary function decline; chr11:93496153 chr11:93286629~93288903:- PAAD cis rs7615952 0.673 rs3811677 ENSG00000241288.6 RP11-379B18.5 -4.65 7.28e-06 0.00407 -0.37 -0.35 Blood pressure (smoking interaction); chr3:125929237 chr3:125827238~125916384:- PAAD cis rs7615952 0.932 rs3811679 ENSG00000241288.6 RP11-379B18.5 -4.65 7.28e-06 0.00407 -0.37 -0.35 Blood pressure (smoking interaction); chr3:125929440 chr3:125827238~125916384:- PAAD cis rs694739 0.595 rs11542299 ENSG00000236935.1 AP003774.1 4.65 7.28e-06 0.00407 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64371333 chr11:64325050~64329504:- PAAD cis rs694739 0.726 rs17857342 ENSG00000236935.1 AP003774.1 4.65 7.28e-06 0.00407 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64371433 chr11:64325050~64329504:- PAAD cis rs6782228 0.606 rs2712417 ENSG00000242551.2 POU5F1P6 -4.65 7.29e-06 0.00408 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128626336 chr3:128674735~128677005:- PAAD cis rs6782228 0.527 rs2712371 ENSG00000242551.2 POU5F1P6 -4.65 7.29e-06 0.00408 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128627371 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs2811490 ENSG00000242551.2 POU5F1P6 -4.65 7.29e-06 0.00408 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128632912 chr3:128674735~128677005:- PAAD cis rs10932679 0.654 rs35169442 ENSG00000229352.1 AC007563.3 4.65 7.3e-06 0.00408 0.45 0.35 Pulse pressure; chr2:216814704 chr2:216799608~216805335:+ PAAD cis rs6867913 0.561 rs249663 ENSG00000280047.1 CTC-463A16.1 -4.65 7.3e-06 0.00408 -0.34 -0.35 Asthma; chr5:142194607 chr5:142165767~142168387:+ PAAD cis rs12468226 0.938 rs55668474 ENSG00000273456.1 RP11-686O6.2 4.65 7.3e-06 0.00408 0.5 0.35 Urate levels; chr2:202265559 chr2:202374932~202375604:- PAAD cis rs6504622 0.791 rs758392 ENSG00000262539.1 RP11-259G18.3 -4.65 7.31e-06 0.00408 -0.46 -0.35 Orofacial clefts; chr17:46940493 chr17:46259551~46260606:- PAAD cis rs875971 0.895 rs7788984 ENSG00000237310.1 GS1-124K5.4 4.65 7.31e-06 0.00408 0.35 0.35 Aortic root size; chr7:66450629 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1981798 ENSG00000237310.1 GS1-124K5.4 4.65 7.31e-06 0.00408 0.35 0.35 Aortic root size; chr7:66489916 chr7:66493706~66495474:+ PAAD cis rs1124769 0.502 rs12911207 ENSG00000259306.2 RP11-108K3.2 -4.65 7.31e-06 0.00408 -0.45 -0.35 Cognitive performance; chr15:50777099 chr15:51315841~51321996:+ PAAD cis rs8059260 0.736 rs16957872 ENSG00000274038.1 RP11-66H6.4 -4.64 7.32e-06 0.00409 -0.57 -0.35 Alcohol consumption over the past year; chr16:10988835 chr16:11056556~11057034:+ PAAD cis rs734999 0.505 rs10910108 ENSG00000225931.3 RP3-395M20.7 4.64 7.32e-06 0.00409 0.34 0.35 Ulcerative colitis; chr1:2608093 chr1:2566410~2569888:+ PAAD cis rs734999 0.505 rs4278312 ENSG00000225931.3 RP3-395M20.7 4.64 7.32e-06 0.00409 0.34 0.35 Ulcerative colitis; chr1:2608116 chr1:2566410~2569888:+ PAAD cis rs6667605 0.527 rs4422947 ENSG00000225931.3 RP3-395M20.7 4.64 7.32e-06 0.00409 0.34 0.35 Ulcerative colitis;Inflammatory bowel disease; chr1:2608151 chr1:2566410~2569888:+ PAAD cis rs9828933 0.701 rs7621544 ENSG00000280620.1 SCAANT1 4.64 7.32e-06 0.00409 0.6 0.35 Type 2 diabetes; chr3:63943005 chr3:63911518~63911772:- PAAD cis rs9531006 0.636 rs2329003 ENSG00000227676.3 LINC01068 4.64 7.32e-06 0.00409 0.54 0.35 Sleep duration; chr13:79927065 chr13:79566727~79571436:+ PAAD cis rs77372450 0.636 rs11465226 ENSG00000251405.2 CTB-109A12.1 -4.64 7.33e-06 0.00409 -0.56 -0.35 Bipolar disorder (body mass index interaction); chr5:157576643 chr5:157362615~157460078:- PAAD cis rs7567389 0.51 rs1473623 ENSG00000236682.1 AC068282.3 4.64 7.33e-06 0.00409 0.47 0.35 Self-rated health; chr2:127438644 chr2:127389130~127400580:+ PAAD cis rs9584850 0.874 rs9168 ENSG00000231194.1 FARP1-AS1 4.64 7.34e-06 0.0041 0.45 0.35 Neuroticism; chr13:98449329 chr13:98435405~98435840:- PAAD cis rs9584850 0.874 rs3742137 ENSG00000231194.1 FARP1-AS1 4.64 7.34e-06 0.0041 0.45 0.35 Neuroticism; chr13:98450195 chr13:98435405~98435840:- PAAD cis rs9584850 0.874 rs7988959 ENSG00000231194.1 FARP1-AS1 4.64 7.34e-06 0.0041 0.45 0.35 Neuroticism; chr13:98451750 chr13:98435405~98435840:- PAAD cis rs8062405 0.72 rs9926245 ENSG00000251417.2 RP11-1348G14.4 -4.64 7.35e-06 0.0041 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544385 chr16:28802743~28817828:+ PAAD cis rs8062405 0.823 rs7202948 ENSG00000251417.2 RP11-1348G14.4 -4.64 7.35e-06 0.0041 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28546968 chr16:28802743~28817828:+ PAAD cis rs8062405 0.824 rs7191618 ENSG00000251417.2 RP11-1348G14.4 -4.64 7.35e-06 0.0041 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554346 chr16:28802743~28817828:+ PAAD cis rs8062405 0.754 rs3859172 ENSG00000251417.2 RP11-1348G14.4 -4.64 7.35e-06 0.0041 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554837 chr16:28802743~28817828:+ PAAD cis rs9322193 0.607 rs10457852 ENSG00000223701.3 RAET1E-AS1 4.64 7.35e-06 0.0041 0.45 0.35 Lung cancer; chr6:149880584 chr6:149884431~149919508:+ PAAD cis rs11079159 0.606 rs876720 ENSG00000263096.1 RP11-515O17.2 -4.64 7.36e-06 0.00411 -0.43 -0.35 QRS duration; chr17:55289154 chr17:55271504~55273653:- PAAD cis rs8091660 0.624 rs907547 ENSG00000278983.1 RP11-426J5.3 4.64 7.37e-06 0.00411 0.43 0.35 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48549725 chr18:48564795~48568342:+ PAAD cis rs734999 0.545 rs10910111 ENSG00000225931.3 RP3-395M20.7 4.64 7.37e-06 0.00412 0.34 0.35 Ulcerative colitis; chr1:2611214 chr1:2566410~2569888:+ PAAD cis rs2581828 0.618 rs6777975 ENSG00000242142.1 SERBP1P3 -4.64 7.37e-06 0.00412 -0.43 -0.35 Crohn's disease; chr3:53132119 chr3:53064283~53065091:- PAAD cis rs6061231 0.675 rs755726 ENSG00000273619.1 RP5-908M14.9 -4.64 7.38e-06 0.00412 -0.29 -0.35 Colorectal cancer; chr20:62387568 chr20:62386303~62386970:- PAAD cis rs9322193 0.607 rs7764677 ENSG00000268592.3 RAET1E-AS1 4.64 7.38e-06 0.00412 0.46 0.35 Lung cancer; chr6:149906197 chr6:149863494~149919507:+ PAAD cis rs7773456 1 rs7773456 ENSG00000228412.5 RP4-625H18.2 4.64 7.38e-06 0.00412 0.44 0.35 Lupus nephritis in systemic lupus erythematosus; chr6:19823007 chr6:19802164~19804752:- PAAD cis rs10129255 0.613 rs36005652 ENSG00000223648.3 IGHV3-64 4.64 7.39e-06 0.00413 0.39 0.35 Kawasaki disease; chr14:106651223 chr14:106643132~106658258:- PAAD cis rs10129255 0.53 rs35069612 ENSG00000223648.3 IGHV3-64 4.64 7.39e-06 0.00413 0.39 0.35 Kawasaki disease; chr14:106651364 chr14:106643132~106658258:- PAAD cis rs6504950 0.679 rs9897646 ENSG00000275710.1 RP11-257O5.4 4.64 7.4e-06 0.00413 0.45 0.35 Breast cancer; chr17:54907990 chr17:54964474~54964679:+ PAAD cis rs875971 0.522 rs4718285 ENSG00000234585.5 CCT6P3 4.64 7.4e-06 0.00413 0.28 0.35 Aortic root size; chr7:65827018 chr7:65038354~65074713:+ PAAD cis rs875971 0.522 rs4502988 ENSG00000234585.5 CCT6P3 4.64 7.4e-06 0.00413 0.28 0.35 Aortic root size; chr7:65832759 chr7:65038354~65074713:+ PAAD cis rs17711722 0.64 rs13237956 ENSG00000234585.5 CCT6P3 4.64 7.4e-06 0.00413 0.28 0.35 Calcium levels; chr7:65853042 chr7:65038354~65074713:+ PAAD cis rs2976388 0.692 rs2978983 ENSG00000253741.1 CTD-2292P10.4 -4.64 7.41e-06 0.00413 -0.4 -0.35 Urinary tract infection frequency; chr8:142684424 chr8:142702252~142726973:- PAAD cis rs10483853 0.579 rs66992833 ENSG00000258695.2 RP3-414A15.2 -4.64 7.43e-06 0.00414 -0.53 -0.35 Coronary artery calcification; chr14:73471638 chr14:73522878~73530610:+ PAAD cis rs380904 0.519 rs10102146 ENSG00000254859.1 RP11-661A12.5 4.64 7.43e-06 0.00414 0.65 0.35 Venous thromboembolism (SNP x SNP interaction); chr8:143566986 chr8:143541973~143549729:- PAAD cis rs11123170 0.543 rs12472361 ENSG00000274877.1 RP11-65I12.1 -4.64 7.43e-06 0.00415 -0.46 -0.35 Renal function-related traits (BUN); chr2:113223068 chr2:113237595~113240825:+ PAAD cis rs11123170 0.543 rs4849180 ENSG00000274877.1 RP11-65I12.1 -4.64 7.43e-06 0.00415 -0.46 -0.35 Renal function-related traits (BUN); chr2:113227609 chr2:113237595~113240825:+ PAAD cis rs11123170 0.543 rs35222158 ENSG00000274877.1 RP11-65I12.1 -4.64 7.43e-06 0.00415 -0.46 -0.35 Renal function-related traits (BUN); chr2:113229052 chr2:113237595~113240825:+ PAAD cis rs11123170 0.543 rs2863242 ENSG00000274877.1 RP11-65I12.1 -4.64 7.43e-06 0.00415 -0.46 -0.35 Renal function-related traits (BUN); chr2:113231659 chr2:113237595~113240825:+ PAAD cis rs9828933 0.766 rs704361 ENSG00000280620.1 SCAANT1 -4.64 7.43e-06 0.00415 -0.59 -0.35 Type 2 diabetes; chr3:63897995 chr3:63911518~63911772:- PAAD cis rs6504950 0.886 rs2541236 ENSG00000275710.1 RP11-257O5.4 -4.64 7.44e-06 0.00415 -0.46 -0.35 Breast cancer; chr17:55082471 chr17:54964474~54964679:+ PAAD cis rs2739330 0.587 rs4820571 ENSG00000231271.1 AP000350.8 4.64 7.44e-06 0.00415 0.49 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23949918~23954042:+ PAAD cis rs453301 0.624 rs6987558 ENSG00000254340.1 RP11-10A14.3 4.64 7.44e-06 0.00415 0.42 0.35 Joint mobility (Beighton score); chr8:9005011 chr8:9141424~9145435:+ PAAD cis rs11673344 0.528 rs573294 ENSG00000226686.6 LINC01535 4.64 7.44e-06 0.00415 0.48 0.35 Obesity-related traits; chr19:36919260 chr19:37251912~37265535:+ PAAD cis rs11673344 0.528 rs476194 ENSG00000226686.6 LINC01535 4.64 7.44e-06 0.00415 0.48 0.35 Obesity-related traits; chr19:36919831 chr19:37251912~37265535:+ PAAD cis rs11673344 0.528 rs579452 ENSG00000226686.6 LINC01535 4.64 7.44e-06 0.00415 0.48 0.35 Obesity-related traits; chr19:36919936 chr19:37251912~37265535:+ PAAD cis rs11673344 0.528 rs491326 ENSG00000226686.6 LINC01535 4.64 7.44e-06 0.00415 0.48 0.35 Obesity-related traits; chr19:36920037 chr19:37251912~37265535:+ PAAD cis rs11673344 0.528 rs563786 ENSG00000226686.6 LINC01535 4.64 7.44e-06 0.00415 0.48 0.35 Obesity-related traits; chr19:36922012 chr19:37251912~37265535:+ PAAD cis rs875971 0.545 rs10950029 ENSG00000226824.5 RP4-756H11.3 -4.64 7.44e-06 0.00415 -0.49 -0.35 Aortic root size; chr7:66169334 chr7:66654538~66669855:+ PAAD cis rs5760092 0.618 rs5996631 ENSG00000206090.4 AP000350.7 -4.64 7.45e-06 0.00415 -0.48 -0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23939998~23942798:+ PAAD cis rs8100891 0.537 rs58591218 ENSG00000267213.4 AC007773.2 -4.64 7.45e-06 0.00415 -0.59 -0.35 Neuroticism; chr19:32399876 chr19:32390050~32405560:- PAAD cis rs74233809 1 rs11191548 ENSG00000213277.3 MARCKSL1P1 -4.64 7.45e-06 0.00415 -0.6 -0.35 Birth weight; chr10:103086421 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191531 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103047141 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12219027 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103051446 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12219901 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103081210 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs10458729 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103081722 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191551 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103091078 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs17094683 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103091544 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12220743 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103092155 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs9633712 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103114004 chr10:103175554~103176094:+ PAAD cis rs74233809 0.786 rs11191564 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103118786 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs1060240 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103123580 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs10883835 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103124451 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191575 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103138580 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs79993475 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103141274 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191587 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103169959 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191593 ENSG00000213277.3 MARCKSL1P1 4.64 7.45e-06 0.00415 0.6 0.35 Birth weight; chr10:103179458 chr10:103175554~103176094:+ PAAD cis rs4664293 0.836 rs10190704 ENSG00000226266.5 AC009961.3 -4.64 7.46e-06 0.00416 -0.43 -0.35 Monocyte percentage of white cells; chr2:159738451 chr2:159670708~159712435:- PAAD cis rs17711722 0.565 rs4717276 ENSG00000236529.1 RP13-254B10.1 4.64 7.48e-06 0.00416 0.39 0.35 Calcium levels; chr7:65829754 chr7:65840212~65840596:+ PAAD cis rs6545883 0.542 rs7584500 ENSG00000273302.1 RP11-493E12.2 4.64 7.48e-06 0.00416 0.31 0.35 Tuberculosis; chr2:61464980 chr2:61199979~61200769:+ PAAD cis rs10754283 0.967 rs7546518 ENSG00000231613.1 RP5-943J3.1 4.64 7.49e-06 0.00417 0.37 0.35 Amyotrophic lateral sclerosis (sporadic); chr1:89644397 chr1:89788914~89790492:+ PAAD cis rs7829975 0.582 rs6982832 ENSG00000254340.1 RP11-10A14.3 -4.64 7.49e-06 0.00417 -0.42 -0.35 Mood instability; chr8:8934707 chr8:9141424~9145435:+ PAAD cis rs7829975 0.582 rs6983150 ENSG00000254340.1 RP11-10A14.3 -4.64 7.49e-06 0.00417 -0.42 -0.35 Mood instability; chr8:8934916 chr8:9141424~9145435:+ PAAD cis rs8059260 0.668 rs8055893 ENSG00000274038.1 RP11-66H6.4 -4.64 7.51e-06 0.00418 -0.59 -0.35 Alcohol consumption over the past year; chr16:10977938 chr16:11056556~11057034:+ PAAD cis rs321358 0.945 rs17537367 ENSG00000271390.1 RP11-89C3.3 4.64 7.52e-06 0.00418 0.54 0.35 Body mass index; chr11:111117008 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs17458885 ENSG00000271390.1 RP11-89C3.3 4.64 7.52e-06 0.00418 0.54 0.35 Body mass index; chr11:111117222 chr11:111089870~111090368:- PAAD cis rs889398 0.874 rs2917677 ENSG00000226232.7 RP11-419C5.2 4.64 7.52e-06 0.00418 0.29 0.35 Body mass index; chr16:69716946 chr16:69976388~69996188:- PAAD cis rs7119038 0.509 rs11216960 ENSG00000255239.1 AP002954.6 -4.64 7.53e-06 0.00419 -0.45 -0.35 Sjögren's syndrome; chr11:118707164 chr11:118688039~118690600:- PAAD cis rs7119038 0.509 rs10892256 ENSG00000255239.1 AP002954.6 -4.64 7.53e-06 0.00419 -0.45 -0.35 Sjögren's syndrome; chr11:118707996 chr11:118688039~118690600:- PAAD cis rs7119038 0.509 rs10892257 ENSG00000255239.1 AP002954.6 -4.64 7.53e-06 0.00419 -0.45 -0.35 Sjögren's syndrome; chr11:118708618 chr11:118688039~118690600:- PAAD cis rs7829975 0.742 rs1533059 ENSG00000253893.2 FAM85B 4.64 7.54e-06 0.00419 0.47 0.35 Mood instability; chr8:8827443 chr8:8167819~8226614:- PAAD cis rs7727544 0.735 rs272860 ENSG00000233006.5 AC034220.3 4.64 7.56e-06 0.0042 0.29 0.35 Blood metabolite levels; chr5:132348482 chr5:132311285~132369916:- PAAD cis rs2281636 0.894 rs1541598 ENSG00000233690.1 EBAG9P1 -4.64 7.56e-06 0.0042 -0.37 -0.35 Obesity-related traits; chr10:99630733 chr10:99697407~99697949:- PAAD cis rs2281636 0.894 rs1332103 ENSG00000233690.1 EBAG9P1 4.64 7.56e-06 0.0042 0.37 0.35 Obesity-related traits; chr10:99616139 chr10:99697407~99697949:- PAAD cis rs2281636 0.894 rs12782208 ENSG00000233690.1 EBAG9P1 4.64 7.56e-06 0.0042 0.37 0.35 Obesity-related traits; chr10:99617219 chr10:99697407~99697949:- PAAD cis rs2564921 0.73 rs62253602 ENSG00000242142.1 SERBP1P3 -4.64 7.56e-06 0.0042 -0.43 -0.35 Height; chr3:52936861 chr3:53064283~53065091:- PAAD cis rs2564921 0.704 rs62253603 ENSG00000242142.1 SERBP1P3 -4.64 7.56e-06 0.0042 -0.43 -0.35 Height; chr3:52938846 chr3:53064283~53065091:- PAAD cis rs2274273 0.673 rs2209808 ENSG00000258413.1 RP11-665C16.6 -4.64 7.57e-06 0.00421 -0.45 -0.35 Protein biomarker; chr14:55340977 chr14:55262767~55272075:- PAAD cis rs8059260 0.544 rs7205916 ENSG00000274038.1 RP11-66H6.4 -4.64 7.57e-06 0.00421 -0.54 -0.35 Alcohol consumption over the past year; chr16:11095399 chr16:11056556~11057034:+ PAAD cis rs17711722 0.522 rs6957759 ENSG00000236529.1 RP13-254B10.1 4.64 7.57e-06 0.00421 0.39 0.35 Calcium levels; chr7:65806798 chr7:65840212~65840596:+ PAAD cis rs10510102 0.872 rs56108883 ENSG00000276742.1 RP11-500G22.4 4.64 7.58e-06 0.00421 0.53 0.35 Breast cancer; chr10:121825567 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200183 ENSG00000276742.1 RP11-500G22.4 4.64 7.58e-06 0.00421 0.53 0.35 Breast cancer; chr10:121829908 chr10:121956782~121957098:+ PAAD cis rs853679 0.55 rs6901017 ENSG00000226314.6 ZNF192P1 -4.64 7.58e-06 0.00421 -0.58 -0.35 Depression; chr6:28184805 chr6:28161781~28169594:+ PAAD cis rs16828019 0.852 rs3820090 ENSG00000235358.1 RP11-399E6.1 4.64 7.58e-06 0.00421 0.67 0.35 Intelligence (multi-trait analysis); chr1:41107980 chr1:41242373~41284861:+ PAAD cis rs34375054 0.641 rs34624329 ENSG00000279233.1 RP11-158L12.4 4.64 7.59e-06 0.00422 0.3 0.35 Post bronchodilator FEV1/FVC ratio; chr12:125123482 chr12:125138245~125141711:+ PAAD cis rs17711722 1 rs17711722 ENSG00000234585.5 CCT6P3 -4.64 7.59e-06 0.00422 -0.28 -0.35 Calcium levels; chr7:65806210 chr7:65038354~65074713:+ PAAD cis rs17711722 0.675 rs6947132 ENSG00000234585.5 CCT6P3 -4.64 7.59e-06 0.00422 -0.28 -0.35 Calcium levels; chr7:65808508 chr7:65038354~65074713:+ PAAD cis rs9287719 0.967 rs6721739 ENSG00000234818.1 AC092687.5 -4.64 7.59e-06 0.00422 -0.39 -0.35 Prostate cancer; chr2:10611120 chr2:10589166~10604830:+ PAAD cis rs2274273 0.934 rs17740741 ENSG00000258413.1 RP11-665C16.6 -4.64 7.61e-06 0.00423 -0.45 -0.35 Protein biomarker; chr14:55295994 chr14:55262767~55272075:- PAAD cis rs2274273 0.901 rs68046603 ENSG00000258413.1 RP11-665C16.6 -4.64 7.61e-06 0.00423 -0.45 -0.35 Protein biomarker; chr14:55296085 chr14:55262767~55272075:- PAAD cis rs2274273 0.901 rs12050099 ENSG00000258413.1 RP11-665C16.6 -4.64 7.61e-06 0.00423 -0.45 -0.35 Protein biomarker; chr14:55297613 chr14:55262767~55272075:- PAAD cis rs2274273 0.934 rs10140869 ENSG00000258413.1 RP11-665C16.6 -4.64 7.61e-06 0.00423 -0.45 -0.35 Protein biomarker; chr14:55328565 chr14:55262767~55272075:- PAAD cis rs853679 0.517 rs6932109 ENSG00000280107.1 AL022393.9 4.64 7.61e-06 0.00423 0.57 0.35 Depression; chr6:28110525 chr6:28170845~28172521:+ PAAD cis rs13403656 1 rs13403656 ENSG00000240350.2 AC017002.1 4.64 7.62e-06 0.00423 0.62 0.35 Allergic disease (asthma, hay fever or eczema); chr2:111511550 chr2:111491273~111570974:+ PAAD cis rs5760092 0.842 rs5751763 ENSG00000231271.1 AP000350.8 4.64 7.63e-06 0.00423 0.6 0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23905606 chr22:23949918~23954042:+ PAAD cis rs6565180 0.962 rs6565183 ENSG00000183604.13 SMG1P5 -4.64 7.63e-06 0.00423 -0.38 -0.35 Tonsillectomy; chr16:30371434 chr16:30267553~30335374:- PAAD cis rs858239 0.899 rs5850 ENSG00000226816.2 AC005082.12 4.63 7.63e-06 0.00423 0.4 0.35 Cerebrospinal fluid biomarker levels; chr7:23274928 chr7:23206013~23208045:+ PAAD cis rs3096299 0.967 rs2965827 ENSG00000274627.1 RP11-104N10.2 -4.63 7.64e-06 0.00424 -0.31 -0.35 Multiple myeloma (IgH translocation); chr16:89390942 chr16:89516797~89522217:+ PAAD cis rs9322193 0.884 rs9397036 ENSG00000268592.3 RAET1E-AS1 4.63 7.64e-06 0.00424 0.44 0.35 Lung cancer; chr6:149851787 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs9383864 ENSG00000268592.3 RAET1E-AS1 4.63 7.64e-06 0.00424 0.44 0.35 Lung cancer; chr6:149851969 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs9383865 ENSG00000268592.3 RAET1E-AS1 4.63 7.64e-06 0.00424 0.44 0.35 Lung cancer; chr6:149852043 chr6:149863494~149919507:+ PAAD cis rs7773456 0.533 rs9350190 ENSG00000228412.5 RP4-625H18.2 -4.63 7.65e-06 0.00424 -0.49 -0.35 Lupus nephritis in systemic lupus erythematosus; chr6:19811429 chr6:19802164~19804752:- PAAD cis rs7773456 0.576 rs6924929 ENSG00000228412.5 RP4-625H18.2 -4.63 7.65e-06 0.00424 -0.49 -0.35 Lupus nephritis in systemic lupus erythematosus; chr6:19812381 chr6:19802164~19804752:- PAAD cis rs9326246 0.556 rs662799 ENSG00000254851.1 RP11-109L13.1 -4.63 7.65e-06 0.00424 -0.76 -0.35 Coronary artery disease; chr11:116792991 chr11:117135528~117138582:+ PAAD cis rs807029 0.758 rs807027 ENSG00000272572.1 RP11-179B2.2 -4.63 7.65e-06 0.00425 -0.44 -0.35 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:101004850 chr10:100911103~100912739:- PAAD cis rs5760092 0.755 rs4585126 ENSG00000099984.9 GSTT2 4.63 7.67e-06 0.00426 0.5 0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23980123~23983911:+ PAAD cis rs12220777 0.748 rs7920814 ENSG00000230091.5 TMEM254-AS1 4.63 7.67e-06 0.00426 0.53 0.35 Chronic obstructive pulmonary disease-related biomarkers; chr10:80095713 chr10:80046860~80078912:- PAAD cis rs12220777 0.748 rs6584955 ENSG00000230091.5 TMEM254-AS1 4.63 7.67e-06 0.00426 0.53 0.35 Chronic obstructive pulmonary disease-related biomarkers; chr10:80100568 chr10:80046860~80078912:- PAAD cis rs4835473 0.9 rs4257605 ENSG00000251600.4 RP11-673E1.1 -4.63 7.67e-06 0.00426 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143740081 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4498094 ENSG00000251600.4 RP11-673E1.1 -4.63 7.67e-06 0.00426 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143740097 chr4:143912331~143982454:+ PAAD cis rs919433 1 rs6741380 ENSG00000231621.1 AC013264.2 -4.63 7.68e-06 0.00426 -0.34 -0.35 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197300397 chr2:197197991~197199273:+ PAAD cis rs12134133 1 rs1782468 ENSG00000274245.1 RP11-357P18.2 4.63 7.69e-06 0.00426 0.53 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207297070 chr1:207372559~207373252:+ PAAD cis rs7712401 0.601 rs30039 ENSG00000263432.2 RN7SL689P -4.63 7.69e-06 0.00427 -0.46 -0.35 Mean platelet volume; chr5:122941484 chr5:123022487~123022783:- PAAD cis rs9828933 0.752 rs73117082 ENSG00000280620.1 SCAANT1 4.63 7.7e-06 0.00427 0.59 0.35 Type 2 diabetes; chr3:63961889 chr3:63911518~63911772:- PAAD cis rs7773456 0.533 rs9368127 ENSG00000228412.5 RP4-625H18.2 -4.63 7.7e-06 0.00427 -0.49 -0.35 Lupus nephritis in systemic lupus erythematosus; chr6:19811760 chr6:19802164~19804752:- PAAD cis rs1124769 0.525 rs11070812 ENSG00000259306.2 RP11-108K3.2 -4.63 7.7e-06 0.00427 -0.45 -0.35 Cognitive performance; chr15:50770295 chr15:51315841~51321996:+ PAAD cis rs1124769 0.502 rs35088194 ENSG00000259306.2 RP11-108K3.2 -4.63 7.7e-06 0.00427 -0.45 -0.35 Cognitive performance; chr15:50773717 chr15:51315841~51321996:+ PAAD cis rs2658782 0.901 rs11601056 ENSG00000279684.1 RP11-755E23.2 4.63 7.71e-06 0.00427 0.62 0.35 Pulmonary function decline; chr11:93495995 chr11:93286629~93288903:- PAAD cis rs1729407 0.695 rs1263176 ENSG00000254851.1 RP11-109L13.1 -4.63 7.72e-06 0.00428 -0.43 -0.35 Apolipoprotein A-IV levels; chr11:116819407 chr11:117135528~117138582:+ PAAD cis rs74233809 1 rs77787671 ENSG00000213277.3 MARCKSL1P1 4.63 7.72e-06 0.00428 0.6 0.35 Birth weight; chr10:103016448 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191519 ENSG00000213277.3 MARCKSL1P1 4.63 7.72e-06 0.00428 0.6 0.35 Birth weight; chr10:103025161 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs76752100 ENSG00000213277.3 MARCKSL1P1 4.63 7.72e-06 0.00428 0.6 0.35 Birth weight; chr10:103034329 chr10:103175554~103176094:+ PAAD cis rs11159086 0.793 rs3784035 ENSG00000259005.1 RP3-449M8.6 4.63 7.73e-06 0.00428 0.47 0.35 Advanced glycation end-product levels; chr14:74482221 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs12433382 ENSG00000259005.1 RP3-449M8.6 4.63 7.73e-06 0.00428 0.47 0.35 Advanced glycation end-product levels; chr14:74482940 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs10148268 ENSG00000259005.1 RP3-449M8.6 4.63 7.73e-06 0.00428 0.47 0.35 Advanced glycation end-product levels; chr14:74484261 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs9285594 ENSG00000259005.1 RP3-449M8.6 4.63 7.73e-06 0.00428 0.47 0.35 Advanced glycation end-product levels; chr14:74489253 chr14:74474007~74474864:- PAAD cis rs6844153 0.752 rs12644073 ENSG00000240005.4 RP11-293A21.1 -4.63 7.73e-06 0.00428 -0.5 -0.35 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26895436 chr4:26859806~26860599:- PAAD cis rs6844153 0.752 rs28520489 ENSG00000240005.4 RP11-293A21.1 -4.63 7.73e-06 0.00428 -0.5 -0.35 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26896082 chr4:26859806~26860599:- PAAD cis rs7309 0.622 rs4664395 ENSG00000227403.1 AC009299.3 -4.63 7.73e-06 0.00429 -0.47 -0.35 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161044790 chr2:161244739~161249050:+ PAAD cis rs453301 0.686 rs3989373 ENSG00000253893.2 FAM85B 4.63 7.73e-06 0.00429 0.49 0.35 Joint mobility (Beighton score); chr8:9053798 chr8:8167819~8226614:- PAAD cis rs875971 1 rs11971949 ENSG00000237310.1 GS1-124K5.4 -4.63 7.74e-06 0.00429 -0.34 -0.35 Aortic root size; chr7:66161027 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs11974264 ENSG00000237310.1 GS1-124K5.4 -4.63 7.74e-06 0.00429 -0.34 -0.35 Aortic root size; chr7:66182595 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1540651 ENSG00000237310.1 GS1-124K5.4 -4.63 7.74e-06 0.00429 -0.34 -0.35 Aortic root size; chr7:66185134 chr7:66493706~66495474:+ PAAD cis rs875971 0.898 rs6977501 ENSG00000237310.1 GS1-124K5.4 -4.63 7.74e-06 0.00429 -0.34 -0.35 Aortic root size; chr7:66228355 chr7:66493706~66495474:+ PAAD cis rs875971 0.965 rs6971509 ENSG00000237310.1 GS1-124K5.4 -4.63 7.74e-06 0.00429 -0.34 -0.35 Aortic root size; chr7:66249983 chr7:66493706~66495474:+ PAAD cis rs526231 0.543 rs246905 ENSG00000175749.11 EIF3KP1 4.63 7.74e-06 0.00429 0.46 0.35 Primary biliary cholangitis; chr5:103255242 chr5:103032376~103033031:+ PAAD cis rs2658782 0.951 rs2608215 ENSG00000279684.1 RP11-755E23.2 -4.63 7.75e-06 0.00429 -0.59 -0.35 Pulmonary function decline; chr11:93415651 chr11:93286629~93288903:- PAAD cis rs6991838 0.584 rs10089708 ENSG00000200714.1 Y_RNA 4.63 7.75e-06 0.00429 0.41 0.35 Intelligence (multi-trait analysis); chr8:65642927 chr8:65592731~65592820:+ PAAD cis rs6991838 0.584 rs6991731 ENSG00000200714.1 Y_RNA 4.63 7.75e-06 0.00429 0.41 0.35 Intelligence (multi-trait analysis); chr8:65643232 chr8:65592731~65592820:+ PAAD cis rs734999 0.566 rs4648658 ENSG00000225931.3 RP3-395M20.7 -4.63 7.75e-06 0.00429 -0.33 -0.35 Ulcerative colitis; chr1:2629443 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs12749591 ENSG00000225931.3 RP3-395M20.7 -4.63 7.75e-06 0.00429 -0.33 -0.35 Ulcerative colitis; chr1:2631811 chr1:2566410~2569888:+ PAAD cis rs6782228 0.527 rs2811491 ENSG00000242551.2 POU5F1P6 -4.63 7.75e-06 0.00429 -0.42 -0.35 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128635107 chr3:128674735~128677005:- PAAD cis rs367615 0.552 rs2115511 ENSG00000249476.1 CTD-2587M2.1 -4.63 7.75e-06 0.00429 -0.37 -0.35 Colorectal cancer (SNP x SNP interaction); chr5:109389702 chr5:109237120~109326369:- PAAD cis rs367615 0.552 rs2963022 ENSG00000249476.1 CTD-2587M2.1 -4.63 7.75e-06 0.00429 -0.37 -0.35 Colorectal cancer (SNP x SNP interaction); chr5:109391484 chr5:109237120~109326369:- PAAD cis rs34164109 1 rs34164109 ENSG00000232876.1 CTA-212D2.2 -4.63 7.76e-06 0.0043 -0.44 -0.35 Red blood cell count;Reticulocyte fraction of red cells; chr6:135100038 chr6:135055033~135060550:+ PAAD cis rs2274273 0.868 rs9919926 ENSG00000258413.1 RP11-665C16.6 -4.63 7.76e-06 0.0043 -0.46 -0.35 Protein biomarker; chr14:55347172 chr14:55262767~55272075:- PAAD cis rs2274273 0.934 rs10144418 ENSG00000258413.1 RP11-665C16.6 -4.63 7.76e-06 0.0043 -0.46 -0.35 Protein biomarker; chr14:55350990 chr14:55262767~55272075:- PAAD cis rs2274273 0.901 rs7147136 ENSG00000258413.1 RP11-665C16.6 -4.63 7.76e-06 0.0043 -0.46 -0.35 Protein biomarker; chr14:55359970 chr14:55262767~55272075:- PAAD cis rs2274273 0.901 rs17674563 ENSG00000258413.1 RP11-665C16.6 -4.63 7.76e-06 0.0043 -0.46 -0.35 Protein biomarker; chr14:55364407 chr14:55262767~55272075:- PAAD cis rs2274273 0.934 rs10137307 ENSG00000258413.1 RP11-665C16.6 -4.63 7.76e-06 0.0043 -0.46 -0.35 Protein biomarker; chr14:55378467 chr14:55262767~55272075:- PAAD cis rs160451 0.811 rs160418 ENSG00000251136.7 RP11-37B2.1 4.63 7.76e-06 0.0043 0.34 0.35 Leprosy; chr8:89631300 chr8:89609409~89757727:- PAAD cis rs35160687 0.644 rs4832274 ENSG00000273080.1 RP11-301O19.1 -4.63 7.77e-06 0.0043 -0.41 -0.35 Night sleep phenotypes; chr2:86301961 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs2367232 ENSG00000273080.1 RP11-301O19.1 -4.63 7.77e-06 0.0043 -0.41 -0.35 Night sleep phenotypes; chr2:86314368 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs36079379 ENSG00000273080.1 RP11-301O19.1 -4.63 7.77e-06 0.0043 -0.41 -0.35 Night sleep phenotypes; chr2:86318837 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs4832036 ENSG00000273080.1 RP11-301O19.1 -4.63 7.77e-06 0.0043 -0.41 -0.35 Night sleep phenotypes; chr2:86324179 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs4610056 ENSG00000273080.1 RP11-301O19.1 -4.63 7.77e-06 0.0043 -0.41 -0.35 Night sleep phenotypes; chr2:86326127 chr2:86195590~86196049:+ PAAD cis rs35160687 0.644 rs7595785 ENSG00000273080.1 RP11-301O19.1 -4.63 7.77e-06 0.0043 -0.41 -0.35 Night sleep phenotypes; chr2:86329282 chr2:86195590~86196049:+ PAAD cis rs2658782 0.724 rs2605627 ENSG00000279684.1 RP11-755E23.2 -4.63 7.77e-06 0.0043 -0.57 -0.35 Pulmonary function decline; chr11:93526349 chr11:93286629~93288903:- PAAD cis rs4664293 0.51 rs2042776 ENSG00000226266.5 AC009961.3 4.63 7.78e-06 0.00431 0.57 0.35 Monocyte percentage of white cells; chr2:159653793 chr2:159670708~159712435:- PAAD cis rs8062405 0.824 rs153106 ENSG00000251417.2 RP11-1348G14.4 -4.63 7.79e-06 0.00431 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28515576 chr16:28802743~28817828:+ PAAD cis rs2153535 0.563 rs7739249 ENSG00000230939.1 RP11-314C16.1 -4.63 7.8e-06 0.00432 -0.37 -0.35 Motion sickness; chr6:8534357 chr6:8784178~8785445:+ PAAD cis rs2882667 0.505 rs7721110 ENSG00000253404.1 AC034243.1 4.63 7.82e-06 0.00433 0.39 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139146817 chr5:138744434~138753309:- PAAD cis rs11159086 0.838 rs10147963 ENSG00000259005.1 RP3-449M8.6 4.63 7.82e-06 0.00433 0.47 0.35 Advanced glycation end-product levels; chr14:74476091 chr14:74474007~74474864:- PAAD cis rs12134133 1 rs2661357 ENSG00000274245.1 RP11-357P18.2 4.63 7.83e-06 0.00433 0.53 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310593 chr1:207372559~207373252:+ PAAD cis rs1075265 0.575 rs2692531 ENSG00000233266.1 HMGB1P31 4.63 7.83e-06 0.00433 0.46 0.35 Chronotype;Morning vs. evening chronotype; chr2:53776640 chr2:54051334~54051760:+ PAAD cis rs867529 0.722 rs13014673 ENSG00000230006.6 ANKRD36BP2 -4.63 7.83e-06 0.00433 -0.29 -0.35 Height; chr2:88689483 chr2:88765807~88806612:+ PAAD cis rs11079159 0.606 rs4239193 ENSG00000263096.1 RP11-515O17.2 4.63 7.83e-06 0.00433 0.44 0.35 QRS duration; chr17:55299163 chr17:55271504~55273653:- PAAD cis rs17826219 0.733 rs7221691 ENSG00000266490.1 CTD-2349P21.9 -4.63 7.85e-06 0.00434 -0.41 -0.35 Body mass index; chr17:30396601 chr17:30792372~30792833:+ PAAD cis rs17826219 0.562 rs719600 ENSG00000266490.1 CTD-2349P21.9 -4.63 7.85e-06 0.00434 -0.41 -0.35 Body mass index; chr17:30404244 chr17:30792372~30792833:+ PAAD cis rs12908161 0.959 rs17534709 ENSG00000259728.4 LINC00933 4.63 7.86e-06 0.00434 0.48 0.35 Schizophrenia; chr15:84771166 chr15:84570649~84580175:+ PAAD cis rs2283792 0.691 rs11913721 ENSG00000224086.5 LL22NC03-86G7.1 -4.63 7.86e-06 0.00435 -0.36 -0.35 Multiple sclerosis; chr22:21855846 chr22:21938293~21977632:+ PAAD cis rs2015599 0.623 rs7964831 ENSG00000257176.2 RP11-996F15.2 -4.63 7.87e-06 0.00435 -0.35 -0.35 Platelet count;Mean platelet volume; chr12:29286655 chr12:29280418~29317848:- PAAD cis rs8100891 0.537 rs10415744 ENSG00000267213.4 AC007773.2 -4.63 7.87e-06 0.00435 -0.58 -0.35 Neuroticism; chr19:32389674 chr19:32390050~32405560:- PAAD cis rs950169 0.922 rs2033284 ENSG00000259295.5 CSPG4P12 4.63 7.87e-06 0.00435 0.39 0.35 Schizophrenia; chr15:84391575 chr15:85191438~85213905:+ PAAD cis rs2404602 0.647 rs12440965 ENSG00000259422.1 RP11-593F23.1 -4.63 7.88e-06 0.00436 -0.43 -0.35 Blood metabolite levels; chr15:76666250 chr15:76174891~76181486:- PAAD cis rs2729354 0.779 rs2454663 ENSG00000265566.2 RN7SL605P -4.63 7.89e-06 0.00436 -0.48 -0.35 Blood protein levels; chr11:57590610 chr11:57528085~57528365:- PAAD cis rs2665103 0.61 rs56398167 ENSG00000278603.1 RP13-608F4.5 4.63 7.89e-06 0.00436 0.44 0.35 Intelligence (multi-trait analysis); chr15:82237482 chr15:82472203~82472426:+ PAAD cis rs2665103 0.589 rs3858953 ENSG00000278603.1 RP13-608F4.5 4.63 7.89e-06 0.00436 0.44 0.35 Intelligence (multi-trait analysis); chr15:82238049 chr15:82472203~82472426:+ PAAD cis rs2665103 0.61 rs1972460 ENSG00000278603.1 RP13-608F4.5 4.63 7.89e-06 0.00436 0.44 0.35 Intelligence (multi-trait analysis); chr15:82238289 chr15:82472203~82472426:+ PAAD cis rs4664293 0.625 rs7595852 ENSG00000226266.5 AC009961.3 4.63 7.89e-06 0.00436 0.45 0.35 Monocyte percentage of white cells; chr2:159683656 chr2:159670708~159712435:- PAAD cis rs780094 0.564 rs4665978 ENSG00000234072.1 AC074117.10 -4.63 7.9e-06 0.00436 -0.28 -0.35 Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels; chr2:27425859 chr2:27356246~27367622:+ PAAD cis rs17711722 0.727 rs1880555 ENSG00000234585.5 CCT6P3 4.63 7.9e-06 0.00437 0.28 0.35 Calcium levels; chr7:65967580 chr7:65038354~65074713:+ PAAD cis rs17711722 0.701 rs781143 ENSG00000234585.5 CCT6P3 4.63 7.9e-06 0.00437 0.28 0.35 Calcium levels; chr7:65974892 chr7:65038354~65074713:+ PAAD cis rs17711722 0.701 rs781145 ENSG00000234585.5 CCT6P3 4.63 7.9e-06 0.00437 0.28 0.35 Calcium levels; chr7:65975383 chr7:65038354~65074713:+ PAAD cis rs17711722 0.727 rs2658585 ENSG00000234585.5 CCT6P3 4.63 7.9e-06 0.00437 0.28 0.35 Calcium levels; chr7:65996954 chr7:65038354~65074713:+ PAAD cis rs919433 0.68 rs8539 ENSG00000231621.1 AC013264.2 -4.63 7.91e-06 0.00437 -0.35 -0.35 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197497294 chr2:197197991~197199273:+ PAAD cis rs871012 0.632 rs1862384 ENSG00000248544.2 CTB-47B11.3 -4.63 7.91e-06 0.00437 -0.45 -0.35 IgG glycosylation; chr5:157389995 chr5:157375741~157384950:- PAAD cis rs12554020 0.786 rs6479495 ENSG00000227603.1 RP11-165J3.6 4.63 7.91e-06 0.00437 0.53 0.35 Schizophrenia; chr9:93572320 chr9:93435332~93437121:- PAAD cis rs853679 0.55 rs1233704 ENSG00000226314.6 ZNF192P1 4.63 7.92e-06 0.00437 0.59 0.35 Depression; chr6:28199145 chr6:28161781~28169594:+ PAAD cis rs6584283 0.744 rs1332099 ENSG00000228778.1 RP11-129J12.1 -4.63 7.92e-06 0.00437 -0.39 -0.35 Ulcerative colitis; chr10:99538694 chr10:99527081~99528261:+ PAAD cis rs9309711 0.961 rs35067331 ENSG00000225234.1 TRAPPC12-AS1 -4.63 7.92e-06 0.00438 -0.38 -0.35 Neurofibrillary tangles; chr2:3470314 chr2:3481242~3482409:- PAAD cis rs7712401 0.601 rs431878 ENSG00000263432.2 RN7SL689P -4.63 7.93e-06 0.00438 -0.45 -0.35 Mean platelet volume; chr5:122926096 chr5:123022487~123022783:- PAAD cis rs147858478 1 rs147858478 ENSG00000233006.5 AC034220.3 4.63 7.94e-06 0.00438 0.29 0.35 High light scatter reticulocyte percentage of red cells; chr5:132347099 chr5:132311285~132369916:- PAAD cis rs11690935 0.632 rs12991740 ENSG00000228389.1 AC068039.4 -4.63 7.95e-06 0.00439 -0.43 -0.35 Schizophrenia; chr2:172021092 chr2:171773482~171775844:+ PAAD cis rs11089937 0.597 rs5757005 ENSG00000211639.2 IGLV4-60 4.62 7.97e-06 0.0044 0.37 0.35 Periodontitis (PAL4Q3); chr22:22134775 chr22:22162199~22162681:+ PAAD cis rs9326248 0.817 rs6589598 ENSG00000280143.1 AP000892.6 4.62 7.97e-06 0.0044 0.46 0.35 Blood protein levels; chr11:117131687 chr11:117204967~117210292:+ PAAD cis rs950027 0.572 rs12910764 ENSG00000259433.2 CTD-2651B20.4 4.62 7.98e-06 0.00441 0.39 0.35 Response to fenofibrate (adiponectin levels); chr15:45317162 chr15:45330209~45332634:- PAAD cis rs2274273 0.84 rs10142448 ENSG00000258413.1 RP11-665C16.6 4.62 7.99e-06 0.00441 0.42 0.35 Protein biomarker; chr14:55371390 chr14:55262767~55272075:- PAAD cis rs6504622 0.818 rs11079742 ENSG00000262539.1 RP11-259G18.3 -4.62 8.01e-06 0.00442 -0.46 -0.35 Orofacial clefts; chr17:46942762 chr17:46259551~46260606:- PAAD cis rs6570726 0.935 rs432086 ENSG00000235652.6 RP11-545I5.3 -4.62 8.02e-06 0.00442 -0.29 -0.35 Lobe attachment (rater-scored or self-reported); chr6:145520457 chr6:145799409~145886585:+ PAAD cis rs858239 0.6 rs10266123 ENSG00000226816.2 AC005082.12 4.62 8.02e-06 0.00442 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23096868 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6461691 ENSG00000226816.2 AC005082.12 4.62 8.02e-06 0.00442 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23099726 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs10241208 ENSG00000226816.2 AC005082.12 4.62 8.02e-06 0.00442 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23105295 chr7:23206013~23208045:+ PAAD cis rs2404602 0.684 rs965818 ENSG00000259422.1 RP11-593F23.1 -4.62 8.02e-06 0.00442 -0.43 -0.35 Blood metabolite levels; chr15:76574444 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs11072602 ENSG00000259422.1 RP11-593F23.1 -4.62 8.02e-06 0.00442 -0.43 -0.35 Blood metabolite levels; chr15:76581126 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs4886816 ENSG00000259422.1 RP11-593F23.1 -4.62 8.02e-06 0.00442 -0.43 -0.35 Blood metabolite levels; chr15:76582366 chr15:76174891~76181486:- PAAD cis rs4664293 0.647 rs6734085 ENSG00000226266.5 AC009961.3 -4.62 8.03e-06 0.00443 -0.44 -0.35 Monocyte percentage of white cells; chr2:159595711 chr2:159670708~159712435:- PAAD cis rs12554020 0.892 rs6479494 ENSG00000227603.1 RP11-165J3.6 -4.62 8.03e-06 0.00443 -0.52 -0.35 Schizophrenia; chr9:93568217 chr9:93435332~93437121:- PAAD cis rs11089937 0.597 rs5757027 ENSG00000211639.2 IGLV4-60 4.62 8.04e-06 0.00443 0.36 0.35 Periodontitis (PAL4Q3); chr22:22137683 chr22:22162199~22162681:+ PAAD cis rs2404602 0.647 rs11072612 ENSG00000259422.1 RP11-593F23.1 -4.62 8.04e-06 0.00443 -0.43 -0.35 Blood metabolite levels; chr15:76668643 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs12910820 ENSG00000259422.1 RP11-593F23.1 -4.62 8.04e-06 0.00443 -0.43 -0.35 Blood metabolite levels; chr15:76730484 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs12910081 ENSG00000259422.1 RP11-593F23.1 -4.62 8.04e-06 0.00443 -0.43 -0.35 Blood metabolite levels; chr15:76730618 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs10851889 ENSG00000259422.1 RP11-593F23.1 -4.62 8.04e-06 0.00443 -0.43 -0.35 Blood metabolite levels; chr15:76730995 chr15:76174891~76181486:- PAAD cis rs9322193 0.516 rs1999632 ENSG00000268592.3 RAET1E-AS1 4.62 8.04e-06 0.00443 0.47 0.35 Lung cancer; chr6:149866737 chr6:149863494~149919507:+ PAAD cis rs2281636 0.931 rs2300984 ENSG00000233690.1 EBAG9P1 4.62 8.05e-06 0.00444 0.37 0.35 Obesity-related traits; chr10:99717100 chr10:99697407~99697949:- PAAD cis rs2281636 0.894 rs2300985 ENSG00000233690.1 EBAG9P1 4.62 8.05e-06 0.00444 0.37 0.35 Obesity-related traits; chr10:99717148 chr10:99697407~99697949:- PAAD cis rs992157 0.661 rs10171839 ENSG00000261338.2 RP11-378A13.1 4.62 8.05e-06 0.00444 0.39 0.35 Colorectal cancer; chr2:218186591 chr2:218255319~218257366:+ PAAD cis rs10050311 0.746 rs17420607 ENSG00000251411.1 RP11-397E7.4 -4.62 8.05e-06 0.00444 -0.42 -0.35 Insulin-related traits; chr4:86749048 chr4:86913266~86914817:- PAAD cis rs10050311 0.586 rs2054592 ENSG00000251411.1 RP11-397E7.4 -4.62 8.05e-06 0.00444 -0.42 -0.35 Insulin-related traits; chr4:86752292 chr4:86913266~86914817:- PAAD cis rs10050311 0.746 rs17454662 ENSG00000251411.1 RP11-397E7.4 -4.62 8.05e-06 0.00444 -0.42 -0.35 Insulin-related traits; chr4:86752611 chr4:86913266~86914817:- PAAD cis rs10050311 0.746 rs72665791 ENSG00000251411.1 RP11-397E7.4 -4.62 8.05e-06 0.00444 -0.42 -0.35 Insulin-related traits; chr4:86757634 chr4:86913266~86914817:- PAAD cis rs633715 0.918 rs532504 ENSG00000254154.7 RP4-798P15.3 -4.62 8.06e-06 0.00444 -0.32 -0.35 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177909798 chr1:177928788~178038007:- PAAD cis rs34375054 0.672 rs58416336 ENSG00000279233.1 RP11-158L12.4 4.62 8.06e-06 0.00444 0.29 0.35 Post bronchodilator FEV1/FVC ratio; chr12:125121882 chr12:125138245~125141711:+ PAAD cis rs2790457 0.518 rs2993984 ENSG00000254635.4 WAC-AS1 -4.62 8.08e-06 0.00445 -0.34 -0.35 Multiple myeloma; chr10:28509727 chr10:28522652~28532743:- PAAD cis rs4927850 1 rs7625570 ENSG00000231464.1 AC024937.4 4.62 8.09e-06 0.00446 0.42 0.35 Pancreatic cancer; chr3:196020527 chr3:195996738~195998233:+ PAAD cis rs4927850 0.881 rs7624638 ENSG00000231464.1 AC024937.4 4.62 8.09e-06 0.00446 0.42 0.35 Pancreatic cancer; chr3:196021858 chr3:195996738~195998233:+ PAAD cis rs4927850 1 rs10881564 ENSG00000231464.1 AC024937.4 4.62 8.09e-06 0.00446 0.42 0.35 Pancreatic cancer; chr3:196023455 chr3:195996738~195998233:+ PAAD cis rs1823913 0.614 rs4853576 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191296618 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs12623156 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191299661 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs1349938 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191299970 chr2:191154118~191156070:- PAAD cis rs1823913 0.592 rs1349939 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191300079 chr2:191154118~191156070:- PAAD cis rs1823913 0.614 rs6434459 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191300886 chr2:191154118~191156070:- PAAD cis rs1823913 0.592 rs7588555 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191300912 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs4853581 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191301533 chr2:191154118~191156070:- PAAD cis rs1823913 0.614 rs7565987 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191301815 chr2:191154118~191156070:- PAAD cis rs1823913 0.614 rs1973067 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191302021 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs1973068 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191302227 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs7569231 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191302373 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs6434461 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191302661 chr2:191154118~191156070:- PAAD cis rs1823913 0.614 rs6434462 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191302705 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs6750360 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191303089 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs11677694 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191303203 chr2:191154118~191156070:- PAAD cis rs1823913 0.571 rs6737307 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191303247 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs4853582 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191303483 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs35200176 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191303534 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs17348013 ENSG00000280083.1 RP11-317J9.1 4.62 8.1e-06 0.00446 0.42 0.35 Obesity-related traits; chr2:191303726 chr2:191154118~191156070:- PAAD cis rs964611 0.882 rs6493316 ENSG00000259488.2 RP11-154J22.1 -4.62 8.11e-06 0.00447 -0.37 -0.35 Metabolite levels (Pyroglutamine); chr15:48275280 chr15:48312353~48331856:- PAAD cis rs694739 0.628 rs508168 ENSG00000236935.1 AP003774.1 4.62 8.12e-06 0.00447 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64367963 chr11:64325050~64329504:- PAAD cis rs694739 0.595 rs11606015 ENSG00000236935.1 AP003774.1 4.62 8.12e-06 0.00447 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64369405 chr11:64325050~64329504:- PAAD cis rs694739 0.628 rs11606081 ENSG00000236935.1 AP003774.1 4.62 8.12e-06 0.00447 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64370403 chr11:64325050~64329504:- PAAD cis rs6496044 0.507 rs2467096 ENSG00000202081.1 RNU6-1280P -4.62 8.12e-06 0.00447 -0.4 -0.35 Interstitial lung disease; chr15:85667447 chr15:85651522~85651628:- PAAD cis rs2108622 1 rs2108622 ENSG00000267453.5 AC004791.2 -4.62 8.12e-06 0.00447 -0.54 -0.35 Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels; chr19:15879621 chr19:15851993~15864904:- PAAD cis rs13178541 0.81 rs7378848 ENSG00000250378.1 RP11-119J18.1 4.62 8.12e-06 0.00447 0.55 0.35 IgG glycosylation; chr5:135751336 chr5:135812667~135826582:+ PAAD cis rs4835473 0.808 rs2060653 ENSG00000251600.4 RP11-673E1.1 -4.62 8.12e-06 0.00447 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143739132 chr4:143912331~143982454:+ PAAD cis rs11089937 0.963 rs2073454 ENSG00000211639.2 IGLV4-60 4.62 8.12e-06 0.00447 0.33 0.35 Periodontitis (PAL4Q3); chr22:22163086 chr22:22162199~22162681:+ PAAD cis rs11654699 0.806 rs4795711 ENSG00000274341.1 RP11-227G15.10 4.62 8.13e-06 0.00447 0.32 0.35 Neurofibrillary tangles; chr17:32592080 chr17:32408013~32408309:+ PAAD cis rs2658782 0.738 rs2605628 ENSG00000279684.1 RP11-755E23.2 -4.62 8.13e-06 0.00447 -0.58 -0.35 Pulmonary function decline; chr11:93528394 chr11:93286629~93288903:- PAAD cis rs10510102 0.872 rs3862129 ENSG00000276742.1 RP11-500G22.4 4.62 8.13e-06 0.00447 0.51 0.35 Breast cancer; chr10:121824460 chr10:121956782~121957098:+ PAAD cis rs17711722 0.565 rs4275112 ENSG00000236529.1 RP13-254B10.1 -4.62 8.14e-06 0.00448 -0.39 -0.35 Calcium levels; chr7:65733651 chr7:65840212~65840596:+ PAAD cis rs6504950 0.72 rs2877634 ENSG00000275710.1 RP11-257O5.4 4.62 8.15e-06 0.00448 0.42 0.35 Breast cancer; chr17:54910184 chr17:54964474~54964679:+ PAAD cis rs2427308 0.643 rs477859 ENSG00000273619.1 RP5-908M14.9 4.62 8.16e-06 0.00449 0.32 0.35 Colorectal cancer; chr20:62362541 chr20:62386303~62386970:- PAAD cis rs12571093 0.803 rs17297418 ENSG00000233590.1 RP11-153K11.3 4.62 8.16e-06 0.00449 0.54 0.35 Optic nerve measurement (disc area); chr10:68271894 chr10:68233251~68242379:- PAAD cis rs8062405 0.755 rs17707300 ENSG00000251417.2 RP11-1348G14.4 -4.62 8.17e-06 0.00449 -0.32 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582026 chr16:28802743~28817828:+ PAAD cis rs1823913 0.637 rs4853577 ENSG00000280083.1 RP11-317J9.1 4.62 8.18e-06 0.0045 0.42 0.35 Obesity-related traits; chr2:191297118 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs4853578 ENSG00000280083.1 RP11-317J9.1 -4.62 8.18e-06 0.0045 -0.42 -0.35 Obesity-related traits; chr2:191297215 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs4853579 ENSG00000280083.1 RP11-317J9.1 4.62 8.18e-06 0.0045 0.42 0.35 Obesity-related traits; chr2:191297413 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs12622194 ENSG00000280083.1 RP11-317J9.1 4.62 8.18e-06 0.0045 0.42 0.35 Obesity-related traits; chr2:191298680 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs13019567 ENSG00000280083.1 RP11-317J9.1 4.62 8.18e-06 0.0045 0.42 0.35 Obesity-related traits; chr2:191298736 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs1947456 ENSG00000280083.1 RP11-317J9.1 4.62 8.18e-06 0.0045 0.42 0.35 Obesity-related traits; chr2:191298759 chr2:191154118~191156070:- PAAD cis rs1823913 0.614 rs11693878 ENSG00000280083.1 RP11-317J9.1 4.62 8.18e-06 0.0045 0.42 0.35 Obesity-related traits; chr2:191299399 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs10931494 ENSG00000280083.1 RP11-317J9.1 4.62 8.18e-06 0.0045 0.42 0.35 Obesity-related traits; chr2:191299442 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs10931495 ENSG00000280083.1 RP11-317J9.1 4.62 8.18e-06 0.0045 0.42 0.35 Obesity-related traits; chr2:191299447 chr2:191154118~191156070:- PAAD cis rs11159086 0.793 rs11845370 ENSG00000259005.1 RP3-449M8.6 4.62 8.18e-06 0.0045 0.47 0.35 Advanced glycation end-product levels; chr14:74481587 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs11850070 ENSG00000259005.1 RP3-449M8.6 4.62 8.18e-06 0.0045 0.47 0.35 Advanced glycation end-product levels; chr14:74487575 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs28378078 ENSG00000259005.1 RP3-449M8.6 4.62 8.18e-06 0.0045 0.47 0.35 Advanced glycation end-product levels; chr14:74487940 chr14:74474007~74474864:- PAAD cis rs2486288 0.656 rs9921035 ENSG00000259433.2 CTD-2651B20.4 4.62 8.18e-06 0.0045 0.39 0.35 Glomerular filtration rate; chr15:45254462 chr15:45330209~45332634:- PAAD cis rs10875746 0.551 rs1471997 ENSG00000240399.1 RP1-228P16.1 -4.62 8.18e-06 0.0045 -0.36 -0.35 Longevity (90 years and older); chr12:48329812 chr12:48054813~48055591:- PAAD cis rs79040073 0.53 rs113085328 ENSG00000259531.2 RP11-295H24.3 4.62 8.19e-06 0.0045 0.52 0.35 Lung cancer in ever smokers; chr15:49223704 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs73392262 ENSG00000259531.2 RP11-295H24.3 4.62 8.19e-06 0.0045 0.52 0.35 Lung cancer in ever smokers; chr15:49229513 chr15:49365124~49366685:- PAAD cis rs79040073 0.563 rs7167852 ENSG00000259531.2 RP11-295H24.3 4.62 8.19e-06 0.0045 0.52 0.35 Lung cancer in ever smokers; chr15:49250004 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs17396612 ENSG00000259531.2 RP11-295H24.3 4.62 8.19e-06 0.0045 0.52 0.35 Lung cancer in ever smokers; chr15:49257746 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs17475228 ENSG00000259531.2 RP11-295H24.3 4.62 8.19e-06 0.0045 0.52 0.35 Lung cancer in ever smokers; chr15:49269619 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs8029506 ENSG00000259531.2 RP11-295H24.3 4.62 8.19e-06 0.0045 0.52 0.35 Lung cancer in ever smokers; chr15:49274543 chr15:49365124~49366685:- PAAD cis rs12134133 0.888 rs11580394 ENSG00000274245.1 RP11-357P18.2 4.62 8.2e-06 0.00451 0.57 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207238567 chr1:207372559~207373252:+ PAAD cis rs12134133 0.962 rs11120512 ENSG00000274245.1 RP11-357P18.2 -4.62 8.2e-06 0.00451 -0.57 -0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207240370 chr1:207372559~207373252:+ PAAD cis rs12134133 0.962 rs7516416 ENSG00000274245.1 RP11-357P18.2 4.62 8.2e-06 0.00451 0.57 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241050 chr1:207372559~207373252:+ PAAD cis rs12134133 0.962 rs17258843 ENSG00000274245.1 RP11-357P18.2 4.62 8.2e-06 0.00451 0.57 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241387 chr1:207372559~207373252:+ PAAD cis rs12134133 0.962 rs6673890 ENSG00000274245.1 RP11-357P18.2 4.62 8.2e-06 0.00451 0.57 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207241788 chr1:207372559~207373252:+ PAAD cis rs875971 0.54 rs4717275 ENSG00000234585.5 CCT6P3 -4.62 8.2e-06 0.00451 -0.28 -0.35 Aortic root size; chr7:65800193 chr7:65038354~65074713:+ PAAD cis rs11763147 1 rs11763147 ENSG00000234585.5 CCT6P3 -4.62 8.2e-06 0.00451 -0.28 -0.35 Corneal structure; chr7:65861834 chr7:65038354~65074713:+ PAAD cis rs875971 0.522 rs10807697 ENSG00000234585.5 CCT6P3 4.62 8.2e-06 0.00451 0.28 0.35 Aortic root size; chr7:65951183 chr7:65038354~65074713:+ PAAD cis rs875971 0.522 rs2008188 ENSG00000234585.5 CCT6P3 4.62 8.2e-06 0.00451 0.28 0.35 Aortic root size; chr7:65964026 chr7:65038354~65074713:+ PAAD cis rs7923609 0.812 rs10761753 ENSG00000232075.1 MRPL35P2 -4.62 8.22e-06 0.00452 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63402143 chr10:63634317~63634827:- PAAD cis rs4268898 0.722 rs11680491 ENSG00000242628.4 AC009228.1 -4.62 8.22e-06 0.00452 -0.41 -0.35 Asthma; chr2:24193423 chr2:24214381~24221516:+ PAAD cis rs12817211 0.502 rs11169282 ENSG00000272368.2 RP4-605O3.4 4.62 8.23e-06 0.00452 0.34 0.35 Colorectal or endometrial cancer; chr12:50136188 chr12:50112197~50165618:+ PAAD cis rs763567 0.869 rs629234 ENSG00000271811.1 RP1-79C4.4 4.62 8.24e-06 0.00452 0.35 0.35 Tonsillectomy; chr1:170662622 chr1:170667381~170669425:+ PAAD cis rs2562456 0.833 rs8106025 ENSG00000213976.4 CTD-2561J22.2 4.62 8.24e-06 0.00453 0.39 0.35 Pain; chr19:21451922 chr19:21382865~21387177:+ PAAD cis rs2115630 0.755 rs7169629 ENSG00000259728.4 LINC00933 4.62 8.24e-06 0.00453 0.42 0.35 P wave terminal force; chr15:84648043 chr15:84570649~84580175:+ PAAD cis rs950880 0.71 rs1474309 ENSG00000234389.1 AC007278.3 -4.62 8.25e-06 0.00453 -0.35 -0.35 Serum protein levels (sST2); chr2:102474542 chr2:102438713~102440475:+ PAAD cis rs8059260 0.736 rs76818150 ENSG00000274038.1 RP11-66H6.4 -4.62 8.26e-06 0.00453 -0.63 -0.35 Alcohol consumption over the past year; chr16:10955006 chr16:11056556~11057034:+ PAAD cis rs189798 0.807 rs330912 ENSG00000253893.2 FAM85B -4.62 8.26e-06 0.00453 -0.55 -0.35 Myopia (pathological); chr8:9138784 chr8:8167819~8226614:- PAAD cis rs367615 0.552 rs3828603 ENSG00000249476.1 CTD-2587M2.1 -4.62 8.27e-06 0.00454 -0.37 -0.35 Colorectal cancer (SNP x SNP interaction); chr5:109376367 chr5:109237120~109326369:- PAAD cis rs367615 0.552 rs10042721 ENSG00000249476.1 CTD-2587M2.1 -4.62 8.27e-06 0.00454 -0.37 -0.35 Colorectal cancer (SNP x SNP interaction); chr5:109378269 chr5:109237120~109326369:- PAAD cis rs11654699 0.84 rs4794929 ENSG00000274341.1 RP11-227G15.10 4.62 8.28e-06 0.00454 0.33 0.35 Neurofibrillary tangles; chr17:32595055 chr17:32408013~32408309:+ PAAD cis rs3096299 0.967 rs3102341 ENSG00000274627.1 RP11-104N10.2 4.62 8.29e-06 0.00455 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89384336 chr16:89516797~89522217:+ PAAD cis rs3096299 0.933 rs3114848 ENSG00000274627.1 RP11-104N10.2 4.62 8.29e-06 0.00455 0.31 0.35 Multiple myeloma (IgH translocation); chr16:89386363 chr16:89516797~89522217:+ PAAD cis rs734999 0.588 rs2985859 ENSG00000225931.3 RP3-395M20.7 -4.62 8.3e-06 0.00455 -0.33 -0.35 Ulcerative colitis; chr1:2600977 chr1:2566410~2569888:+ PAAD cis rs11098499 0.739 rs10031033 ENSG00000245958.5 RP11-33B1.1 -4.61 8.31e-06 0.00456 -0.28 -0.35 Corneal astigmatism; chr4:119230297 chr4:119454791~119552025:+ PAAD cis rs734999 0.588 rs2764848 ENSG00000225931.3 RP3-395M20.7 -4.61 8.33e-06 0.00457 -0.33 -0.35 Ulcerative colitis; chr1:2599255 chr1:2566410~2569888:+ PAAD cis rs9326248 0.52 rs236919 ENSG00000280143.1 AP000892.6 4.61 8.33e-06 0.00457 0.39 0.35 Blood protein levels; chr11:117224645 chr11:117204967~117210292:+ PAAD cis rs710913 0.566 rs879037 ENSG00000243970.1 PPIEL -4.61 8.33e-06 0.00457 -0.32 -0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39509736 chr1:39531838~39558707:- PAAD cis rs2486288 0.656 rs12911861 ENSG00000259433.2 CTD-2651B20.4 4.61 8.33e-06 0.00457 0.38 0.35 Glomerular filtration rate; chr15:45274520 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs12908818 ENSG00000259433.2 CTD-2651B20.4 4.61 8.33e-06 0.00457 0.38 0.35 Glomerular filtration rate; chr15:45279470 chr15:45330209~45332634:- PAAD cis rs2486288 0.586 rs12909625 ENSG00000259433.2 CTD-2651B20.4 4.61 8.33e-06 0.00457 0.38 0.35 Glomerular filtration rate; chr15:45279855 chr15:45330209~45332634:- PAAD cis rs2486288 0.586 rs12909883 ENSG00000259433.2 CTD-2651B20.4 4.61 8.33e-06 0.00457 0.38 0.35 Glomerular filtration rate; chr15:45279856 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs12910009 ENSG00000259433.2 CTD-2651B20.4 4.61 8.33e-06 0.00457 0.38 0.35 Glomerular filtration rate; chr15:45280210 chr15:45330209~45332634:- PAAD cis rs875971 0.545 rs4718348 ENSG00000226824.5 RP4-756H11.3 -4.61 8.35e-06 0.00458 -0.49 -0.35 Aortic root size; chr7:66441589 chr7:66654538~66669855:+ PAAD cis rs694739 0.657 rs11231770 ENSG00000236935.1 AP003774.1 4.61 8.35e-06 0.00458 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373153 chr11:64325050~64329504:- PAAD cis rs694739 0.687 rs11231771 ENSG00000236935.1 AP003774.1 4.61 8.35e-06 0.00458 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373170 chr11:64325050~64329504:- PAAD cis rs694739 0.628 rs10897487 ENSG00000236935.1 AP003774.1 4.61 8.35e-06 0.00458 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373232 chr11:64325050~64329504:- PAAD cis rs694739 0.654 rs10897488 ENSG00000236935.1 AP003774.1 4.61 8.35e-06 0.00458 0.37 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373334 chr11:64325050~64329504:- PAAD cis rs853679 0.723 rs9366718 ENSG00000226314.6 ZNF192P1 -4.61 8.36e-06 0.00458 -0.56 -0.35 Depression; chr6:28237724 chr6:28161781~28169594:+ PAAD cis rs4950322 0.518 rs56151278 ENSG00000278811.3 LINC00624 4.61 8.36e-06 0.00458 0.35 0.35 Protein quantitative trait loci; chr1:147117421 chr1:147258885~147517875:- PAAD cis rs4950322 0.518 rs4950306 ENSG00000278811.3 LINC00624 4.61 8.36e-06 0.00458 0.35 0.35 Protein quantitative trait loci; chr1:147117838 chr1:147258885~147517875:- PAAD cis rs55665837 0.502 rs4757269 ENSG00000251991.1 RNU7-49P 4.61 8.36e-06 0.00458 0.42 0.35 Vitamin D levels; chr11:14814646 chr11:14478892~14478953:+ PAAD cis rs2274273 0.967 rs67756714 ENSG00000258413.1 RP11-665C16.6 -4.61 8.36e-06 0.00458 -0.45 -0.35 Protein biomarker; chr14:55123105 chr14:55262767~55272075:- PAAD cis rs7615952 1 rs7616044 ENSG00000241288.6 RP11-379B18.5 -4.61 8.36e-06 0.00458 -0.37 -0.35 Blood pressure (smoking interaction); chr3:125930511 chr3:125827238~125916384:- PAAD cis rs7615952 0.932 rs7629977 ENSG00000241288.6 RP11-379B18.5 -4.61 8.36e-06 0.00458 -0.37 -0.35 Blood pressure (smoking interaction); chr3:125930730 chr3:125827238~125916384:- PAAD cis rs7615952 1 rs7615952 ENSG00000241288.6 RP11-379B18.5 4.61 8.36e-06 0.00458 0.37 0.35 Blood pressure (smoking interaction); chr3:125930560 chr3:125827238~125916384:- PAAD cis rs7615952 0.932 rs6438948 ENSG00000241288.6 RP11-379B18.5 4.61 8.36e-06 0.00458 0.37 0.35 Blood pressure (smoking interaction); chr3:125931202 chr3:125827238~125916384:- PAAD cis rs12134133 1 rs4844590 ENSG00000274245.1 RP11-357P18.2 4.61 8.38e-06 0.00459 0.58 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207322784 chr1:207372559~207373252:+ PAAD cis rs12134133 1 rs28371597 ENSG00000274245.1 RP11-357P18.2 4.61 8.38e-06 0.00459 0.58 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207323551 chr1:207372559~207373252:+ PAAD cis rs2904804 0.641 rs2904802 ENSG00000224251.5 RP11-499O7.7 4.61 8.41e-06 0.00461 0.39 0.35 Economic and political preferences (immigration/crime); chr10:4967172 chr10:4995488~4997380:+ PAAD cis rs858239 0.6 rs10256359 ENSG00000226816.2 AC005082.12 4.61 8.41e-06 0.00461 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23084258 chr7:23206013~23208045:+ PAAD cis rs11098499 0.562 rs58583086 ENSG00000248280.1 RP11-33B1.2 -4.61 8.41e-06 0.00461 -0.33 -0.35 Corneal astigmatism; chr4:119635207 chr4:119440561~119450157:- PAAD cis rs11098499 0.615 rs59867181 ENSG00000248280.1 RP11-33B1.2 -4.61 8.41e-06 0.00461 -0.33 -0.35 Corneal astigmatism; chr4:119635312 chr4:119440561~119450157:- PAAD cis rs11098499 0.562 rs2389879 ENSG00000248280.1 RP11-33B1.2 -4.61 8.41e-06 0.00461 -0.33 -0.35 Corneal astigmatism; chr4:119636529 chr4:119440561~119450157:- PAAD cis rs2188561 0.697 rs10808154 ENSG00000241764.3 AC002467.7 4.61 8.41e-06 0.00461 0.45 0.35 Alcohol consumption; chr7:107745951 chr7:107742817~107744581:- PAAD cis rs2188561 0.697 rs6956243 ENSG00000241764.3 AC002467.7 4.61 8.41e-06 0.00461 0.45 0.35 Alcohol consumption; chr7:107748466 chr7:107742817~107744581:- PAAD cis rs2188561 0.697 rs12539555 ENSG00000241764.3 AC002467.7 4.61 8.41e-06 0.00461 0.45 0.35 Alcohol consumption; chr7:107764028 chr7:107742817~107744581:- PAAD cis rs11690935 0.595 rs788170 ENSG00000228389.1 AC068039.4 -4.61 8.42e-06 0.00461 -0.4 -0.35 Schizophrenia; chr2:172055230 chr2:171773482~171775844:+ PAAD cis rs11690935 0.595 rs788171 ENSG00000228389.1 AC068039.4 -4.61 8.42e-06 0.00461 -0.4 -0.35 Schizophrenia; chr2:172057104 chr2:171773482~171775844:+ PAAD cis rs5760092 0.627 rs6519489 ENSG00000099984.9 GSTT2 4.61 8.42e-06 0.00461 0.53 0.35 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23980123~23983911:+ PAAD cis rs7182621 0.546 rs12906587 ENSG00000259363.4 CTD-2054N24.2 4.61 8.42e-06 0.00461 0.43 0.35 Colonoscopy-negative controls vs population controls; chr15:99837114 chr15:99807023~99877148:+ PAAD cis rs2404602 0.622 rs9635380 ENSG00000259422.1 RP11-593F23.1 -4.61 8.42e-06 0.00461 -0.43 -0.35 Blood metabolite levels; chr15:76811138 chr15:76174891~76181486:- PAAD cis rs889398 0.869 rs862320 ENSG00000226232.7 RP11-419C5.2 4.61 8.44e-06 0.00462 0.29 0.35 Body mass index; chr16:69617963 chr16:69976388~69996188:- PAAD cis rs889398 0.935 rs244420 ENSG00000226232.7 RP11-419C5.2 4.61 8.44e-06 0.00462 0.29 0.35 Body mass index; chr16:69624093 chr16:69976388~69996188:- PAAD cis rs889398 0.967 rs244417 ENSG00000226232.7 RP11-419C5.2 4.61 8.44e-06 0.00462 0.29 0.35 Body mass index; chr16:69629616 chr16:69976388~69996188:- PAAD cis rs8100891 0.537 rs7258196 ENSG00000267213.4 AC007773.2 -4.61 8.44e-06 0.00462 -0.57 -0.35 Neuroticism; chr19:32453659 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs4805762 ENSG00000267213.4 AC007773.2 -4.61 8.44e-06 0.00462 -0.57 -0.35 Neuroticism; chr19:32473048 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs7253039 ENSG00000267213.4 AC007773.2 -4.61 8.44e-06 0.00462 -0.57 -0.35 Neuroticism; chr19:32482171 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs1057395 ENSG00000267213.4 AC007773.2 -4.61 8.44e-06 0.00462 -0.57 -0.35 Neuroticism; chr19:32483832 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs1057397 ENSG00000267213.4 AC007773.2 -4.61 8.44e-06 0.00462 -0.57 -0.35 Neuroticism; chr19:32484007 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs737093 ENSG00000267213.4 AC007773.2 -4.61 8.44e-06 0.00462 -0.57 -0.35 Neuroticism; chr19:32486500 chr19:32390050~32405560:- PAAD cis rs27524 0.734 rs27037 ENSG00000272109.1 CTD-2260A17.3 -4.61 8.44e-06 0.00462 -0.46 -0.35 Hodgkin's lymphoma;Psoriasis; chr5:96758990 chr5:96804353~96806105:+ PAAD cis rs950880 0.71 rs56043441 ENSG00000234389.1 AC007278.3 -4.61 8.45e-06 0.00463 -0.34 -0.35 Serum protein levels (sST2); chr2:102470923 chr2:102438713~102440475:+ PAAD cis rs1665050 0.749 rs8037569 ENSG00000277144.1 RP11-59H7.4 -4.61 8.45e-06 0.00463 -0.41 -0.35 Atopic dermatitis; chr15:59010263 chr15:59115547~59116089:- PAAD cis rs4835473 0.932 rs1375986 ENSG00000251600.4 RP11-673E1.1 -4.61 8.46e-06 0.00463 -0.4 -0.35 Immature fraction of reticulocytes; chr4:143746048 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs35420625 ENSG00000251600.4 RP11-673E1.1 -4.61 8.46e-06 0.00463 -0.4 -0.35 Immature fraction of reticulocytes; chr4:143746089 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs4835009 ENSG00000251600.4 RP11-673E1.1 -4.61 8.46e-06 0.00463 -0.4 -0.35 Immature fraction of reticulocytes; chr4:143746130 chr4:143912331~143982454:+ PAAD cis rs74233809 1 rs12413409 ENSG00000213277.3 MARCKSL1P1 4.61 8.46e-06 0.00463 0.62 0.35 Birth weight; chr10:102959339 chr10:103175554~103176094:+ PAAD cis rs6860806 0.507 rs169256 ENSG00000233006.5 AC034220.3 4.61 8.47e-06 0.00463 0.31 0.35 Breast cancer; chr5:132352840 chr5:132311285~132369916:- PAAD cis rs7923609 0.756 rs12768534 ENSG00000232075.1 MRPL35P2 -4.61 8.47e-06 0.00463 -0.42 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63581137 chr10:63634317~63634827:- PAAD cis rs7923609 0.756 rs6479908 ENSG00000232075.1 MRPL35P2 4.61 8.47e-06 0.00463 0.42 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63573888 chr10:63634317~63634827:- PAAD cis rs7923609 0.756 rs7090758 ENSG00000232075.1 MRPL35P2 4.61 8.47e-06 0.00463 0.42 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63575555 chr10:63634317~63634827:- PAAD cis rs7923609 0.756 rs7077256 ENSG00000232075.1 MRPL35P2 4.61 8.47e-06 0.00463 0.42 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63576425 chr10:63634317~63634827:- PAAD cis rs7923609 0.729 rs7902616 ENSG00000232075.1 MRPL35P2 4.61 8.47e-06 0.00463 0.42 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63576613 chr10:63634317~63634827:- PAAD cis rs7923609 0.756 rs10822183 ENSG00000232075.1 MRPL35P2 4.61 8.47e-06 0.00463 0.42 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63577381 chr10:63634317~63634827:- PAAD cis rs12817211 0.549 rs6580728 ENSG00000272368.2 RP4-605O3.4 -4.61 8.47e-06 0.00464 -0.34 -0.35 Colorectal or endometrial cancer; chr12:50147344 chr12:50112197~50165618:+ PAAD cis rs12817211 0.549 rs7398567 ENSG00000272368.2 RP4-605O3.4 4.61 8.47e-06 0.00464 0.34 0.35 Colorectal or endometrial cancer; chr12:50157375 chr12:50112197~50165618:+ PAAD cis rs12817211 0.549 rs10783338 ENSG00000272368.2 RP4-605O3.4 4.61 8.47e-06 0.00464 0.34 0.35 Colorectal or endometrial cancer; chr12:50158746 chr12:50112197~50165618:+ PAAD cis rs4664293 0.764 rs1425044 ENSG00000226266.5 AC009961.3 -4.61 8.48e-06 0.00464 -0.44 -0.35 Monocyte percentage of white cells; chr2:159618426 chr2:159670708~159712435:- PAAD cis rs11089937 0.597 rs6001072 ENSG00000211639.2 IGLV4-60 4.61 8.49e-06 0.00464 0.37 0.35 Periodontitis (PAL4Q3); chr22:22133629 chr22:22162199~22162681:+ PAAD cis rs11089937 0.512 rs6001073 ENSG00000211639.2 IGLV4-60 4.61 8.49e-06 0.00464 0.37 0.35 Periodontitis (PAL4Q3); chr22:22133650 chr22:22162199~22162681:+ PAAD cis rs11089937 0.539 rs6001075 ENSG00000211639.2 IGLV4-60 4.61 8.49e-06 0.00464 0.37 0.35 Periodontitis (PAL4Q3); chr22:22133765 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs6001076 ENSG00000211639.2 IGLV4-60 4.61 8.49e-06 0.00464 0.37 0.35 Periodontitis (PAL4Q3); chr22:22133873 chr22:22162199~22162681:+ PAAD cis rs11089937 0.597 rs5995560 ENSG00000211639.2 IGLV4-60 4.61 8.49e-06 0.00464 0.37 0.35 Periodontitis (PAL4Q3); chr22:22133989 chr22:22162199~22162681:+ PAAD cis rs11089937 0.568 rs6001078 ENSG00000211639.2 IGLV4-60 4.61 8.49e-06 0.00464 0.37 0.35 Periodontitis (PAL4Q3); chr22:22134365 chr22:22162199~22162681:+ PAAD cis rs4268898 0.722 rs7563958 ENSG00000242628.4 AC009228.1 -4.61 8.5e-06 0.00465 -0.4 -0.35 Asthma; chr2:24199512 chr2:24214381~24221516:+ PAAD cis rs964611 0.751 rs58922278 ENSG00000259488.2 RP11-154J22.1 -4.61 8.5e-06 0.00465 -0.38 -0.35 Metabolite levels (Pyroglutamine); chr15:48257357 chr15:48312353~48331856:- PAAD cis rs2599510 0.811 rs2710628 ENSG00000276334.1 AL133243.1 4.61 8.5e-06 0.00465 0.42 0.35 Interleukin-18 levels; chr2:32533286 chr2:32521927~32523547:+ PAAD cis rs2283792 0.765 rs6518968 ENSG00000224086.5 LL22NC03-86G7.1 -4.61 8.51e-06 0.00465 -0.36 -0.35 Multiple sclerosis; chr22:21793327 chr22:21938293~21977632:+ PAAD cis rs2283792 0.765 rs7290469 ENSG00000224086.5 LL22NC03-86G7.1 -4.61 8.51e-06 0.00465 -0.36 -0.35 Multiple sclerosis; chr22:21796693 chr22:21938293~21977632:+ PAAD cis rs10463554 0.716 rs152136 ENSG00000175749.11 EIF3KP1 4.61 8.51e-06 0.00465 0.44 0.35 Parkinson's disease; chr5:103248167 chr5:103032376~103033031:+ PAAD cis rs17684571 0.751 rs35081015 ENSG00000231441.1 RP11-472M19.2 4.61 8.51e-06 0.00465 0.64 0.35 Schizophrenia; chr6:56819757 chr6:56844002~56864078:+ PAAD cis rs17684571 0.751 rs10498813 ENSG00000231441.1 RP11-472M19.2 4.61 8.51e-06 0.00465 0.64 0.35 Schizophrenia; chr6:56819921 chr6:56844002~56864078:+ PAAD cis rs17684571 0.751 rs13190854 ENSG00000231441.1 RP11-472M19.2 4.61 8.51e-06 0.00465 0.64 0.35 Schizophrenia; chr6:56827020 chr6:56844002~56864078:+ PAAD cis rs8177376 1 rs657361 ENSG00000254905.1 RP11-712L6.7 4.61 8.51e-06 0.00465 0.47 0.35 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126241196 chr11:126292922~126294254:- PAAD cis rs8177376 0.953 rs529328 ENSG00000254905.1 RP11-712L6.7 4.61 8.51e-06 0.00465 0.47 0.35 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126263746 chr11:126292922~126294254:- PAAD cis rs875971 0.505 rs6955582 ENSG00000234585.5 CCT6P3 4.61 8.52e-06 0.00465 0.28 0.35 Aortic root size; chr7:65966699 chr7:65038354~65074713:+ PAAD cis rs6480314 0.522 rs2120900 ENSG00000233590.1 RP11-153K11.3 4.61 8.53e-06 0.00466 0.55 0.35 Optic nerve measurement (disc area); chr10:68296052 chr10:68233251~68242379:- PAAD cis rs9532669 0.963 rs9566607 ENSG00000176268.5 CYCSP34 -4.61 8.53e-06 0.00466 -0.36 -0.35 Cervical cancer; chr13:40921788 chr13:40863599~40863902:- PAAD cis rs2281636 0.824 rs2160620 ENSG00000233690.1 EBAG9P1 4.61 8.53e-06 0.00466 0.37 0.35 Obesity-related traits; chr10:99627261 chr10:99697407~99697949:- PAAD cis rs338389 0.586 rs338387 ENSG00000260657.2 RP11-315D16.4 4.61 8.54e-06 0.00466 0.39 0.35 Survival in rectal cancer; chr15:67968644 chr15:68267792~68277994:- PAAD cis rs2658782 0.901 rs10466368 ENSG00000279684.1 RP11-755E23.2 -4.61 8.54e-06 0.00466 -0.61 -0.35 Pulmonary function decline; chr11:93496590 chr11:93286629~93288903:- PAAD cis rs367615 0.552 rs2963023 ENSG00000249476.1 CTD-2587M2.1 -4.61 8.54e-06 0.00466 -0.37 -0.35 Colorectal cancer (SNP x SNP interaction); chr5:109394369 chr5:109237120~109326369:- PAAD cis rs367615 0.552 rs2963025 ENSG00000249476.1 CTD-2587M2.1 -4.61 8.54e-06 0.00466 -0.37 -0.35 Colorectal cancer (SNP x SNP interaction); chr5:109397555 chr5:109237120~109326369:- PAAD cis rs367615 0.552 rs2416210 ENSG00000249476.1 CTD-2587M2.1 -4.61 8.54e-06 0.00466 -0.37 -0.35 Colorectal cancer (SNP x SNP interaction); chr5:109405436 chr5:109237120~109326369:- PAAD cis rs1322639 0.614 rs9294967 ENSG00000261039.2 RP11-417E7.2 4.61 8.56e-06 0.00467 0.56 0.35 Pulse pressure; chr6:169165311 chr6:169175304~169182740:- PAAD cis rs9928842 0.824 rs889515 ENSG00000280152.1 RP11-331F4.5 4.61 8.57e-06 0.00467 0.46 0.35 Alcoholic chronic pancreatitis; chr16:75217401 chr16:75245994~75250077:- PAAD cis rs7829975 0.606 rs11776838 ENSG00000254340.1 RP11-10A14.3 -4.61 8.57e-06 0.00468 -0.42 -0.35 Mood instability; chr8:8937291 chr8:9141424~9145435:+ PAAD cis rs734999 0.545 rs6666430 ENSG00000225931.3 RP3-395M20.7 4.61 8.57e-06 0.00468 0.33 0.35 Ulcerative colitis; chr1:2782407 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs4648356 ENSG00000225931.3 RP3-395M20.7 4.61 8.57e-06 0.00468 0.33 0.35 Ulcerative colitis; chr1:2792599 chr1:2566410~2569888:+ PAAD cis rs1823913 0.637 rs4853574 ENSG00000280083.1 RP11-317J9.1 4.61 8.58e-06 0.00468 0.42 0.35 Obesity-related traits; chr2:191296113 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs4853575 ENSG00000280083.1 RP11-317J9.1 4.61 8.58e-06 0.00468 0.42 0.35 Obesity-related traits; chr2:191296149 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs4853583 ENSG00000280083.1 RP11-317J9.1 4.61 8.58e-06 0.00468 0.42 0.35 Obesity-related traits; chr2:191304648 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs10931497 ENSG00000280083.1 RP11-317J9.1 4.61 8.58e-06 0.00468 0.42 0.35 Obesity-related traits; chr2:191306254 chr2:191154118~191156070:- PAAD cis rs11123170 0.543 rs2166421 ENSG00000274877.1 RP11-65I12.1 -4.61 8.58e-06 0.00468 -0.46 -0.35 Renal function-related traits (BUN); chr2:113232665 chr2:113237595~113240825:+ PAAD cis rs12439619 0.508 rs8032033 ENSG00000255769.6 GOLGA2P10 -4.61 8.59e-06 0.00468 -0.37 -0.35 Intelligence (multi-trait analysis); chr15:82165555 chr15:82472993~82513950:- PAAD cis rs12439619 0.53 rs28883606 ENSG00000255769.6 GOLGA2P10 -4.61 8.59e-06 0.00468 -0.37 -0.35 Intelligence (multi-trait analysis); chr15:82216713 chr15:82472993~82513950:- PAAD cis rs12439619 0.693 rs28665836 ENSG00000255769.6 GOLGA2P10 -4.61 8.59e-06 0.00468 -0.37 -0.35 Intelligence (multi-trait analysis); chr15:82218955 chr15:82472993~82513950:- PAAD cis rs2284378 0.506 rs6142059 ENSG00000276073.1 RP5-1125A11.7 -4.61 8.59e-06 0.00468 -0.38 -0.35 Breast cancer; chr20:33956521 chr20:33985617~33988989:- PAAD cis rs7829975 0.514 rs2979151 ENSG00000253893.2 FAM85B 4.61 8.59e-06 0.00468 0.47 0.35 Mood instability; chr8:8400509 chr8:8167819~8226614:- PAAD cis rs734999 0.588 rs2843401 ENSG00000225931.3 RP3-395M20.7 -4.61 8.59e-06 0.00468 -0.33 -0.35 Ulcerative colitis; chr1:2596694 chr1:2566410~2569888:+ PAAD cis rs10276381 0.786 rs73300665 ENSG00000234336.5 JAZF1-AS1 -4.61 8.6e-06 0.00469 -0.52 -0.35 Crohn's disease; chr7:28187405 chr7:28180322~28243917:+ PAAD cis rs748404 0.626 rs57938858 ENSG00000205771.5 CATSPER2P1 -4.61 8.6e-06 0.00469 -0.59 -0.35 Lung cancer; chr15:43520259 chr15:43726918~43747094:- PAAD cis rs748404 0.589 rs62020612 ENSG00000205771.5 CATSPER2P1 -4.61 8.6e-06 0.00469 -0.59 -0.35 Lung cancer; chr15:43525881 chr15:43726918~43747094:- PAAD cis rs734999 0.588 rs3748819 ENSG00000225931.3 RP3-395M20.7 4.61 8.62e-06 0.0047 0.34 0.35 Ulcerative colitis; chr1:2593527 chr1:2566410~2569888:+ PAAD cis rs8023057 0.803 rs72695000 ENSG00000252481.1 SCARNA13 -4.61 8.62e-06 0.0047 -0.44 -0.35 Prostate-specific antigen levels; chr14:94638408 chr14:95533355~95533629:- PAAD cis rs17772222 0.701 rs845757 ENSG00000258983.2 RP11-507K2.2 -4.61 8.62e-06 0.0047 -0.43 -0.35 Coronary artery calcification; chr14:88455372 chr14:88499334~88515502:+ PAAD cis rs10888838 0.756 rs11589005 ENSG00000198711.5 SSBP3-AS1 4.61 8.62e-06 0.0047 0.44 0.35 Mitochondrial DNA levels; chr1:54227752 chr1:54236440~54239063:+ PAAD cis rs10888838 0.756 rs11206309 ENSG00000198711.5 SSBP3-AS1 4.61 8.62e-06 0.0047 0.44 0.35 Mitochondrial DNA levels; chr1:54228581 chr1:54236440~54239063:+ PAAD cis rs453301 0.592 rs4841084 ENSG00000254340.1 RP11-10A14.3 4.61 8.65e-06 0.00472 0.42 0.35 Joint mobility (Beighton score); chr8:9026395 chr8:9141424~9145435:+ PAAD cis rs453301 0.653 rs2956244 ENSG00000254340.1 RP11-10A14.3 4.61 8.65e-06 0.00472 0.42 0.35 Joint mobility (Beighton score); chr8:9027656 chr8:9141424~9145435:+ PAAD cis rs8005677 0.828 rs2295682 ENSG00000279656.1 RP11-298I3.6 4.6 8.67e-06 0.00472 0.41 0.35 Cognitive ability (multi-trait analysis); chr14:22905653 chr14:23023083~23024217:- PAAD cis rs2902193 0.645 rs12953580 ENSG00000267325.1 LINC01415 4.6 8.67e-06 0.00472 0.34 0.35 Cancer; chr18:55977847 chr18:55776727~55781721:- PAAD cis rs2902193 0.667 rs12455343 ENSG00000267325.1 LINC01415 4.6 8.67e-06 0.00472 0.34 0.35 Cancer; chr18:55980838 chr18:55776727~55781721:- PAAD cis rs4950322 0.57 rs72691012 ENSG00000278811.3 LINC00624 4.6 8.67e-06 0.00472 0.35 0.35 Protein quantitative trait loci; chr1:147239751 chr1:147258885~147517875:- PAAD cis rs7829975 0.606 rs6422352 ENSG00000254340.1 RP11-10A14.3 -4.6 8.68e-06 0.00472 -0.42 -0.35 Mood instability; chr8:8936683 chr8:9141424~9145435:+ PAAD cis rs7829975 0.606 rs891570 ENSG00000254340.1 RP11-10A14.3 -4.6 8.68e-06 0.00472 -0.42 -0.35 Mood instability; chr8:8936944 chr8:9141424~9145435:+ PAAD cis rs875971 1 rs709595 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66352346 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs811880 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66353659 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs778726 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66363744 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs778723 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66364510 chr7:66493706~66495474:+ PAAD cis rs875971 0.767 rs1695815 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66366357 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs778685 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66371189 chr7:66493706~66495474:+ PAAD cis rs875971 0.929 rs778682 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66372947 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs11765965 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66377234 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs1643388 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66379575 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs778722 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66379841 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs778721 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66380410 chr7:66493706~66495474:+ PAAD cis rs875971 0.929 rs778712 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66384991 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs778710 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66389847 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs778708 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66391332 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs778706 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66395437 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs778700 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66401463 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs778699 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66403303 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs778696 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66405826 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs778694 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66406571 chr7:66493706~66495474:+ PAAD cis rs875971 0.929 rs778692 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66407462 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs4718343 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66409301 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs4718344 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66409394 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1968225 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66409786 chr7:66493706~66495474:+ PAAD cis rs875971 0.737 rs7803424 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66415618 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs7799834 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66415707 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6460295 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66417741 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs6978721 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66418217 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs3857684 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66473171 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs6978429 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66494889 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs4718357 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66495891 chr7:66493706~66495474:+ PAAD cis rs875971 0.929 rs12535036 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66499076 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs12533997 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66500390 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs12532998 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66502472 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs12698523 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66503126 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6970030 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66503692 chr7:66493706~66495474:+ PAAD cis rs875971 0.928 rs6970357 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66503891 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs3735148 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66506022 chr7:66493706~66495474:+ PAAD cis rs875971 0.929 rs10950041 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66508888 chr7:66493706~66495474:+ PAAD cis rs875971 0.929 rs6970860 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66511647 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6957199 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66513532 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6958271 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66514344 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6958277 ENSG00000237310.1 GS1-124K5.4 4.6 8.68e-06 0.00472 0.33 0.35 Aortic root size; chr7:66514362 chr7:66493706~66495474:+ PAAD cis rs875971 0.965 rs10267430 ENSG00000237310.1 GS1-124K5.4 -4.6 8.68e-06 0.00472 -0.33 -0.35 Aortic root size; chr7:66278036 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs10257427 ENSG00000237310.1 GS1-124K5.4 -4.6 8.68e-06 0.00472 -0.33 -0.35 Aortic root size; chr7:66278221 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs10215948 ENSG00000237310.1 GS1-124K5.4 -4.6 8.68e-06 0.00472 -0.33 -0.35 Aortic root size; chr7:66282799 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs55748098 ENSG00000237310.1 GS1-124K5.4 -4.6 8.68e-06 0.00472 -0.33 -0.35 Aortic root size; chr7:66298631 chr7:66493706~66495474:+ PAAD cis rs875971 0.965 rs9969301 ENSG00000237310.1 GS1-124K5.4 -4.6 8.68e-06 0.00472 -0.33 -0.35 Aortic root size; chr7:66316668 chr7:66493706~66495474:+ PAAD cis rs875971 0.867 rs1002053 ENSG00000237310.1 GS1-124K5.4 -4.6 8.68e-06 0.00472 -0.33 -0.35 Aortic root size; chr7:66333558 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6460292 ENSG00000237310.1 GS1-124K5.4 -4.6 8.68e-06 0.00472 -0.33 -0.35 Aortic root size; chr7:66345088 chr7:66493706~66495474:+ PAAD cis rs10740039 0.768 rs1596197 ENSG00000254271.1 RP11-131N11.4 4.6 8.69e-06 0.00473 0.41 0.35 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60708921 chr10:60734342~60741828:+ PAAD cis rs10740039 0.768 rs1816799 ENSG00000254271.1 RP11-131N11.4 4.6 8.69e-06 0.00473 0.41 0.35 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60711381 chr10:60734342~60741828:+ PAAD cis rs10740039 0.804 rs2393677 ENSG00000254271.1 RP11-131N11.4 4.6 8.69e-06 0.00473 0.41 0.35 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60711385 chr10:60734342~60741828:+ PAAD cis rs74233809 0.901 rs4409766 ENSG00000213277.3 MARCKSL1P1 4.6 8.69e-06 0.00473 0.58 0.35 Birth weight; chr10:102856906 chr10:103175554~103176094:+ PAAD cis rs12571093 0.803 rs61854839 ENSG00000233590.1 RP11-153K11.3 -4.6 8.71e-06 0.00474 -0.55 -0.35 Optic nerve measurement (disc area); chr10:68284859 chr10:68233251~68242379:- PAAD cis rs60733400 0.644 rs28774982 ENSG00000225931.3 RP3-395M20.7 -4.6 8.72e-06 0.00474 -0.34 -0.35 Multiple sclerosis; chr1:2689913 chr1:2566410~2569888:+ PAAD cis rs2281636 0.754 rs7087826 ENSG00000233690.1 EBAG9P1 4.6 8.72e-06 0.00474 0.38 0.35 Obesity-related traits; chr10:99604588 chr10:99697407~99697949:- PAAD cis rs2281636 0.754 rs4919364 ENSG00000233690.1 EBAG9P1 4.6 8.72e-06 0.00474 0.38 0.35 Obesity-related traits; chr10:99604947 chr10:99697407~99697949:- PAAD cis rs2281636 0.754 rs7092699 ENSG00000233690.1 EBAG9P1 4.6 8.72e-06 0.00474 0.38 0.35 Obesity-related traits; chr10:99605545 chr10:99697407~99697949:- PAAD cis rs2404602 0.647 rs10152247 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76649911 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs62026898 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76652030 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11631394 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76680868 chr15:76174891~76181486:- PAAD cis rs2404602 0.622 rs11632670 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76681714 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11632765 ENSG00000259422.1 RP11-593F23.1 4.6 8.73e-06 0.00474 0.43 0.35 Blood metabolite levels; chr15:76681920 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11072616 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76692928 chr15:76174891~76181486:- PAAD cis rs2404602 0.684 rs1011083 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76715186 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs920712 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76741593 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11631959 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76747707 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11072619 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76750901 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11072620 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76756429 chr15:76174891~76181486:- PAAD cis rs2404602 0.61 rs28823285 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76758054 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11634266 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76801120 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs7178250 ENSG00000259422.1 RP11-593F23.1 -4.6 8.73e-06 0.00474 -0.43 -0.35 Blood metabolite levels; chr15:76806766 chr15:76174891~76181486:- PAAD cis rs780094 0.544 rs780110 ENSG00000234072.1 AC074117.10 -4.6 8.73e-06 0.00474 -0.28 -0.35 Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels; chr2:27462521 chr2:27356246~27367622:+ PAAD cis rs11098499 0.588 rs2389874 ENSG00000245958.5 RP11-33B1.1 4.6 8.74e-06 0.00475 0.26 0.35 Corneal astigmatism; chr4:119633836 chr4:119454791~119552025:+ PAAD cis rs17214007 0.518 rs8047940 ENSG00000263335.1 AF001548.5 -4.6 8.74e-06 0.00475 -0.47 -0.35 Cognitive function; chr16:15691787 chr16:15726674~15732993:+ PAAD cis rs7829975 0.606 rs10112585 ENSG00000254340.1 RP11-10A14.3 -4.6 8.74e-06 0.00475 -0.42 -0.35 Mood instability; chr8:8937520 chr8:9141424~9145435:+ PAAD cis rs2858942 0.575 rs2858011 ENSG00000268836.1 LA16c-OS12.2 4.6 8.74e-06 0.00475 0.32 0.35 Mean corpuscular hemoglobin; chr16:197939 chr16:185748~186294:- PAAD cis rs12134133 1 rs28371583 ENSG00000274245.1 RP11-357P18.2 4.6 8.74e-06 0.00475 0.53 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207321334 chr1:207372559~207373252:+ PAAD cis rs797680 0.786 rs12133576 ENSG00000223745.6 RP4-717I23.3 -4.6 8.75e-06 0.00475 -0.28 -0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93350843 chr1:93262186~93346025:- PAAD cis rs4664293 0.715 rs13002625 ENSG00000226266.5 AC009961.3 4.6 8.76e-06 0.00476 0.44 0.35 Monocyte percentage of white cells; chr2:159648114 chr2:159670708~159712435:- PAAD cis rs875971 0.505 rs1167386 ENSG00000237310.1 GS1-124K5.4 -4.6 8.76e-06 0.00476 -0.33 -0.35 Aortic root size; chr7:66048109 chr7:66493706~66495474:+ PAAD cis rs4853525 0.59 rs4513327 ENSG00000235852.1 AC005540.3 4.6 8.78e-06 0.00477 0.53 0.35 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190850695 chr2:190880797~190882059:- PAAD cis rs2976388 0.647 rs2572898 ENSG00000253741.1 CTD-2292P10.4 -4.6 8.78e-06 0.00477 -0.4 -0.35 Urinary tract infection frequency; chr8:142700856 chr8:142702252~142726973:- PAAD cis rs2404602 0.647 rs4312276 ENSG00000259422.1 RP11-593F23.1 -4.6 8.8e-06 0.00478 -0.43 -0.35 Blood metabolite levels; chr15:76872020 chr15:76174891~76181486:- PAAD cis rs2288884 0.515 rs73053909 ENSG00000275055.1 CTC-471J1.11 -4.6 8.83e-06 0.00479 -0.46 -0.35 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52032864 chr19:52049007~52049754:+ PAAD cis rs2288884 0.537 rs7254131 ENSG00000275055.1 CTC-471J1.11 -4.6 8.83e-06 0.00479 -0.46 -0.35 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52035774 chr19:52049007~52049754:+ PAAD cis rs2288884 0.515 rs17779341 ENSG00000275055.1 CTC-471J1.11 -4.6 8.83e-06 0.00479 -0.46 -0.35 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52047148 chr19:52049007~52049754:+ PAAD cis rs2288884 0.537 rs9636140 ENSG00000275055.1 CTC-471J1.11 -4.6 8.83e-06 0.00479 -0.46 -0.35 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52056610 chr19:52049007~52049754:+ PAAD cis rs160451 0.745 rs218898 ENSG00000251136.7 RP11-37B2.1 -4.6 8.83e-06 0.00479 -0.35 -0.35 Leprosy; chr8:89717140 chr8:89609409~89757727:- PAAD cis rs11155671 0.546 rs1999633 ENSG00000223701.3 RAET1E-AS1 4.6 8.83e-06 0.00479 0.44 0.35 Testicular germ cell tumor; chr6:149866576 chr6:149884431~149919508:+ PAAD cis rs858239 0.899 rs28635122 ENSG00000226816.2 AC005082.12 4.6 8.83e-06 0.00479 0.4 0.35 Cerebrospinal fluid biomarker levels; chr7:23270562 chr7:23206013~23208045:+ PAAD cis rs17023223 0.537 rs10923767 ENSG00000231365.4 RP11-418J17.1 -4.6 8.86e-06 0.0048 -0.38 -0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119189724 chr1:119140396~119275973:+ PAAD cis rs61270009 0.818 rs6452786 ENSG00000247828.6 TMEM161B-AS1 4.6 8.86e-06 0.00481 0.28 0.35 Depressive symptoms; chr5:88409022 chr5:88268895~88436685:+ PAAD cis rs201673768 1 rs201673768 ENSG00000240399.1 RP1-228P16.1 4.6 8.87e-06 0.00481 0.32 0.35 Platelet count; chr12:48305834 chr12:48054813~48055591:- PAAD cis rs2902193 0.667 rs10163561 ENSG00000267325.1 LINC01415 4.6 8.87e-06 0.00481 0.34 0.35 Cancer; chr18:55983946 chr18:55776727~55781721:- PAAD cis rs2277027 0.518 rs2863747 ENSG00000251405.2 CTB-109A12.1 4.6 8.88e-06 0.00481 0.44 0.35 Pulmonary function;Pulmonary function (smoking interaction); chr5:157503776 chr5:157362615~157460078:- PAAD cis rs61270009 0.955 rs2410766 ENSG00000247828.6 TMEM161B-AS1 4.6 8.89e-06 0.00482 0.28 0.35 Depressive symptoms; chr5:88405666 chr5:88268895~88436685:+ PAAD cis rs3761847 0.5 rs10760132 ENSG00000226752.6 PSMD5-AS1 -4.6 8.9e-06 0.00482 -0.39 -0.35 Rheumatoid arthritis; chr9:120977715 chr9:120824828~120854385:+ PAAD cis rs9531006 0.602 rs3898550 ENSG00000227676.3 LINC01068 4.6 8.91e-06 0.00483 0.54 0.35 Sleep duration; chr13:79895562 chr13:79566727~79571436:+ PAAD cis rs9531006 0.636 rs3898551 ENSG00000227676.3 LINC01068 4.6 8.91e-06 0.00483 0.54 0.35 Sleep duration; chr13:79895630 chr13:79566727~79571436:+ PAAD cis rs4853525 0.544 rs61187415 ENSG00000235852.1 AC005540.3 4.6 8.91e-06 0.00483 0.52 0.35 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190846184 chr2:190880797~190882059:- PAAD cis rs453301 0.653 rs7016139 ENSG00000254340.1 RP11-10A14.3 -4.6 8.92e-06 0.00483 -0.41 -0.35 Joint mobility (Beighton score); chr8:9037960 chr8:9141424~9145435:+ PAAD cis rs2337406 0.866 rs2027901 ENSG00000211974.3 IGHV2-70 -4.6 8.93e-06 0.00484 -0.48 -0.35 Alzheimer's disease (late onset); chr14:106807164 chr14:106723574~106724093:- PAAD cis rs73110464 0.562 rs2363634 ENSG00000278185.1 RP11-153F5.7 4.6 8.93e-06 0.00484 0.46 0.35 Cancer (pleiotropy); chr12:52960899 chr12:52946614~52947125:- PAAD cis rs950880 0.71 rs17027255 ENSG00000234389.1 AC007278.3 -4.6 8.95e-06 0.00485 -0.34 -0.35 Serum protein levels (sST2); chr2:102473668 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs17027258 ENSG00000234389.1 AC007278.3 -4.6 8.95e-06 0.00485 -0.34 -0.35 Serum protein levels (sST2); chr2:102475081 chr2:102438713~102440475:+ PAAD cis rs453301 0.631 rs7843369 ENSG00000253893.2 FAM85B 4.6 8.96e-06 0.00485 0.47 0.35 Joint mobility (Beighton score); chr8:8940276 chr8:8167819~8226614:- PAAD cis rs453301 0.631 rs11779804 ENSG00000253893.2 FAM85B 4.6 8.96e-06 0.00485 0.47 0.35 Joint mobility (Beighton score); chr8:8940442 chr8:8167819~8226614:- PAAD cis rs6061231 0.63 rs62196294 ENSG00000273619.1 RP5-908M14.9 -4.6 8.96e-06 0.00485 -0.29 -0.35 Colorectal cancer; chr20:62398376 chr20:62386303~62386970:- PAAD cis rs11123170 0.569 rs1049137 ENSG00000274877.1 RP11-65I12.1 -4.6 8.96e-06 0.00485 -0.45 -0.35 Renal function-related traits (BUN); chr2:113217533 chr2:113237595~113240825:+ PAAD cis rs8023057 0.755 rs61976131 ENSG00000252481.1 SCARNA13 -4.6 8.96e-06 0.00485 -0.44 -0.35 Prostate-specific antigen levels; chr14:94638883 chr14:95533355~95533629:- PAAD cis rs950169 0.922 rs62029585 ENSG00000259295.5 CSPG4P12 4.6 8.97e-06 0.00485 0.39 0.35 Schizophrenia; chr15:84397176 chr15:85191438~85213905:+ PAAD cis rs964611 0.706 rs4775755 ENSG00000259488.2 RP11-154J22.1 4.6 8.97e-06 0.00485 0.4 0.35 Metabolite levels (Pyroglutamine); chr15:48370282 chr15:48312353~48331856:- PAAD cis rs734999 0.545 rs9970196 ENSG00000225931.3 RP3-395M20.7 -4.6 8.97e-06 0.00486 -0.34 -0.35 Ulcerative colitis; chr1:2642639 chr1:2566410~2569888:+ PAAD cis rs12468226 0.938 rs7585867 ENSG00000273456.1 RP11-686O6.2 4.6 8.98e-06 0.00486 0.5 0.35 Urate levels; chr2:202287040 chr2:202374932~202375604:- PAAD cis rs7829975 0.572 rs7005000 ENSG00000254340.1 RP11-10A14.3 -4.6 8.98e-06 0.00486 -0.42 -0.35 Mood instability; chr8:8939092 chr8:9141424~9145435:+ PAAD cis rs4273100 1 rs12602286 ENSG00000228157.4 AC007952.5 -4.6 8.99e-06 0.00487 -0.57 -0.35 Schizophrenia; chr17:19333641 chr17:19092974~19096837:+ PAAD cis rs871012 0.502 rs11951889 ENSG00000251405.2 CTB-109A12.1 -4.6 9e-06 0.00487 -0.45 -0.35 IgG glycosylation; chr5:157449776 chr5:157362615~157460078:- PAAD cis rs871012 0.502 rs17599812 ENSG00000251405.2 CTB-109A12.1 -4.6 9e-06 0.00487 -0.45 -0.35 IgG glycosylation; chr5:157450982 chr5:157362615~157460078:- PAAD cis rs875971 0.895 rs4718349 ENSG00000237310.1 GS1-124K5.4 4.6 9e-06 0.00487 0.34 0.35 Aortic root size; chr7:66444024 chr7:66493706~66495474:+ PAAD cis rs2281636 0.755 rs2111324 ENSG00000233690.1 EBAG9P1 4.6 9e-06 0.00487 0.36 0.35 Obesity-related traits; chr10:99636807 chr10:99697407~99697949:- PAAD cis rs2281636 0.894 rs10883396 ENSG00000233690.1 EBAG9P1 4.6 9e-06 0.00487 0.36 0.35 Obesity-related traits; chr10:99647135 chr10:99697407~99697949:- PAAD cis rs2281636 0.894 rs12771048 ENSG00000233690.1 EBAG9P1 4.6 9e-06 0.00487 0.36 0.35 Obesity-related traits; chr10:99649691 chr10:99697407~99697949:- PAAD cis rs858239 0.6 rs9691762 ENSG00000226816.2 AC005082.12 4.6 9.01e-06 0.00487 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23086303 chr7:23206013~23208045:+ PAAD cis rs4835473 0.932 rs7683686 ENSG00000251600.4 RP11-673E1.1 -4.6 9.03e-06 0.00488 -0.36 -0.35 Immature fraction of reticulocytes; chr4:143784352 chr4:143912331~143982454:+ PAAD cis rs9987353 0.566 rs34389718 ENSG00000253893.2 FAM85B 4.59 9.05e-06 0.00489 0.47 0.35 Recombination measurement; chr8:9208015 chr8:8167819~8226614:- PAAD cis rs7829975 0.714 rs59046059 ENSG00000253893.2 FAM85B -4.59 9.05e-06 0.00489 -0.49 -0.35 Mood instability; chr8:8813226 chr8:8167819~8226614:- PAAD cis rs2348418 0.579 rs2126896 ENSG00000247934.4 RP11-967K21.1 -4.59 9.06e-06 0.0049 -0.34 -0.35 Lung function (FEV1);Lung function (FVC); chr12:28239701 chr12:28163298~28190738:- PAAD cis rs748404 0.518 rs480108 ENSG00000205771.5 CATSPER2P1 -4.59 9.07e-06 0.0049 -0.48 -0.35 Lung cancer; chr15:43525208 chr15:43726918~43747094:- PAAD cis rs748404 0.56 rs572837 ENSG00000205771.5 CATSPER2P1 -4.59 9.07e-06 0.0049 -0.48 -0.35 Lung cancer; chr15:43531615 chr15:43726918~43747094:- PAAD cis rs748404 0.56 rs570933 ENSG00000205771.5 CATSPER2P1 -4.59 9.07e-06 0.0049 -0.48 -0.35 Lung cancer; chr15:43531832 chr15:43726918~43747094:- PAAD cis rs748404 0.56 rs689797 ENSG00000205771.5 CATSPER2P1 -4.59 9.07e-06 0.0049 -0.48 -0.35 Lung cancer; chr15:43534359 chr15:43726918~43747094:- PAAD cis rs7849973 0.524 rs10118643 ENSG00000224549.1 RP11-370B11.3 4.59 9.07e-06 0.0049 0.41 0.35 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22807219 chr9:22767175~22768316:+ PAAD cis rs7712401 0.601 rs154502 ENSG00000263432.2 RN7SL689P 4.59 9.07e-06 0.0049 0.44 0.35 Mean platelet volume; chr5:122871351 chr5:123022487~123022783:- PAAD cis rs734999 0.549 rs60733400 ENSG00000225931.3 RP3-395M20.7 4.59 9.07e-06 0.00491 0.34 0.35 Ulcerative colitis; chr1:2585342 chr1:2566410~2569888:+ PAAD cis rs853679 0.55 rs1225598 ENSG00000226314.6 ZNF192P1 -4.59 9.09e-06 0.00491 -0.59 -0.35 Depression; chr6:28193021 chr6:28161781~28169594:+ PAAD cis rs8062405 0.723 rs4788077 ENSG00000251417.2 RP11-1348G14.4 -4.59 9.09e-06 0.00491 -0.34 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558443 chr16:28802743~28817828:+ PAAD cis rs853679 0.517 rs9380058 ENSG00000226314.6 ZNF192P1 -4.59 9.09e-06 0.00491 -0.59 -0.35 Depression; chr6:28159666 chr6:28161781~28169594:+ PAAD cis rs853679 0.517 rs9393898 ENSG00000226314.6 ZNF192P1 -4.59 9.09e-06 0.00491 -0.59 -0.35 Depression; chr6:28162598 chr6:28161781~28169594:+ PAAD cis rs734999 0.545 rs3890745 ENSG00000225931.3 RP3-395M20.7 -4.59 9.09e-06 0.00491 -0.33 -0.35 Ulcerative colitis; chr1:2622185 chr1:2566410~2569888:+ PAAD cis rs79040073 0.637 rs73392256 ENSG00000259531.2 RP11-295H24.3 4.59 9.1e-06 0.00492 0.58 0.35 Lung cancer in ever smokers; chr15:49228379 chr15:49365124~49366685:- PAAD cis rs2274273 0.805 rs60972460 ENSG00000258413.1 RP11-665C16.6 -4.59 9.1e-06 0.00492 -0.43 -0.35 Protein biomarker; chr14:55105055 chr14:55262767~55272075:- PAAD cis rs2274273 0.905 rs28429419 ENSG00000258413.1 RP11-665C16.6 -4.59 9.1e-06 0.00492 -0.43 -0.35 Protein biomarker; chr14:55108075 chr14:55262767~55272075:- PAAD cis rs11654699 0.806 rs62068381 ENSG00000274341.1 RP11-227G15.10 4.59 9.11e-06 0.00492 0.32 0.35 Neurofibrillary tangles; chr17:32592731 chr17:32408013~32408309:+ PAAD cis rs11654699 0.773 rs62068382 ENSG00000274341.1 RP11-227G15.10 4.59 9.11e-06 0.00492 0.32 0.35 Neurofibrillary tangles; chr17:32592865 chr17:32408013~32408309:+ PAAD cis rs1823913 0.637 rs4853573 ENSG00000280083.1 RP11-317J9.1 4.59 9.11e-06 0.00492 0.42 0.35 Obesity-related traits; chr2:191295866 chr2:191154118~191156070:- PAAD cis rs1823913 0.614 rs4853466 ENSG00000280083.1 RP11-317J9.1 4.59 9.11e-06 0.00492 0.42 0.35 Obesity-related traits; chr2:191295943 chr2:191154118~191156070:- PAAD cis rs4835473 0.864 rs57648439 ENSG00000251600.4 RP11-673E1.1 -4.59 9.11e-06 0.00492 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143691519 chr4:143912331~143982454:+ PAAD cis rs2283792 0.715 rs56036797 ENSG00000224086.5 LL22NC03-86G7.1 -4.59 9.12e-06 0.00493 -0.36 -0.35 Multiple sclerosis; chr22:21860875 chr22:21938293~21977632:+ PAAD cis rs2283792 0.74 rs11912377 ENSG00000224086.5 LL22NC03-86G7.1 -4.59 9.12e-06 0.00493 -0.36 -0.35 Multiple sclerosis; chr22:21864332 chr22:21938293~21977632:+ PAAD cis rs6061231 0.631 rs927133 ENSG00000273619.1 RP5-908M14.9 -4.59 9.13e-06 0.00493 -0.29 -0.35 Colorectal cancer; chr20:62397053 chr20:62386303~62386970:- PAAD cis rs6538678 0.833 rs1898178 ENSG00000258343.1 RP11-536G4.2 -4.59 9.13e-06 0.00493 -0.44 -0.35 Lupus nephritis in systemic lupus erythematosus; chr12:95887554 chr12:95795345~95858839:- PAAD cis rs6538678 0.833 rs1898177 ENSG00000258343.1 RP11-536G4.2 -4.59 9.13e-06 0.00493 -0.44 -0.35 Lupus nephritis in systemic lupus erythematosus; chr12:95887568 chr12:95795345~95858839:- PAAD cis rs6921919 1 rs35875412 ENSG00000216901.1 AL022393.7 4.59 9.13e-06 0.00493 0.55 0.35 Autism spectrum disorder or schizophrenia; chr6:28364041 chr6:28176188~28176674:+ PAAD cis rs858239 0.601 rs2141307 ENSG00000226816.2 AC005082.12 4.59 9.14e-06 0.00493 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23151805 chr7:23206013~23208045:+ PAAD cis rs9876781 0.53 rs11708617 ENSG00000229759.1 MRPS18AP1 4.59 9.14e-06 0.00494 0.36 0.35 Longevity; chr3:48354819 chr3:48256350~48256938:- PAAD cis rs875971 1 rs2077593 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66427543 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6460296 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66430152 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs4717292 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66430611 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs2420591 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66447394 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs10755833 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66448930 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs1833495 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66456608 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs6945019 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66457471 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs6945032 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66457499 chr7:66493706~66495474:+ PAAD cis rs875971 0.929 rs12673810 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66458866 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs35149210 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66464938 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs2042133 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66466935 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs2161065 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66467918 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6961155 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66468308 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs7789768 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66473993 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs12698521 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66474502 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1363055 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66478288 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs9691480 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66479319 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs7789554 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66481051 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs4717300 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66482393 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs1974769 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66485627 chr7:66493706~66495474:+ PAAD cis rs875971 0.895 rs6460300 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66487937 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs7803416 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66489212 chr7:66493706~66495474:+ PAAD cis rs875971 0.862 rs1981799 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66490572 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs2277911 ENSG00000237310.1 GS1-124K5.4 4.59 9.16e-06 0.00495 0.34 0.35 Aortic root size; chr7:66493638 chr7:66493706~66495474:+ PAAD cis rs9637599 1 rs9637599 ENSG00000246375.2 RP11-10L7.1 4.59 9.17e-06 0.00495 0.43 0.35 Metabolite levels (small molecules and protein measures); chr4:88285078 chr4:88284942~88331421:+ PAAD cis rs2337406 0.866 rs112089985 ENSG00000211974.3 IGHV2-70 -4.59 9.17e-06 0.00495 -0.45 -0.35 Alzheimer's disease (late onset); chr14:106780074 chr14:106723574~106724093:- PAAD cis rs919433 1 rs6761919 ENSG00000231621.1 AC013264.2 4.59 9.18e-06 0.00495 0.33 0.35 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197298604 chr2:197197991~197199273:+ PAAD cis rs919433 1 rs2889363 ENSG00000231621.1 AC013264.2 4.59 9.18e-06 0.00495 0.33 0.35 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197298975 chr2:197197991~197199273:+ PAAD cis rs919433 1 rs1346649 ENSG00000231621.1 AC013264.2 4.59 9.18e-06 0.00495 0.33 0.35 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197301393 chr2:197197991~197199273:+ PAAD cis rs7923609 1 rs7923609 ENSG00000232075.1 MRPL35P2 -4.59 9.18e-06 0.00495 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63374062 chr10:63634317~63634827:- PAAD cis rs7923609 0.934 rs2893919 ENSG00000232075.1 MRPL35P2 -4.59 9.18e-06 0.00495 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63375018 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs2393966 ENSG00000232075.1 MRPL35P2 -4.59 9.18e-06 0.00495 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63375054 chr10:63634317~63634827:- PAAD cis rs11893307 0.566 rs10170782 ENSG00000235852.1 AC005540.3 4.59 9.19e-06 0.00496 0.51 0.35 Mean platelet volume; chr2:190758510 chr2:190880797~190882059:- PAAD cis rs7727544 0.684 rs272889 ENSG00000233006.5 AC034220.3 4.59 9.2e-06 0.00496 0.28 0.35 Blood metabolite levels; chr5:132329685 chr5:132311285~132369916:- PAAD cis rs4927850 0.958 rs1975582 ENSG00000231464.1 AC024937.4 4.59 9.2e-06 0.00496 0.41 0.35 Pancreatic cancer; chr3:196024568 chr3:195996738~195998233:+ PAAD cis rs4927850 0.957 rs4927851 ENSG00000231464.1 AC024937.4 4.59 9.2e-06 0.00496 0.41 0.35 Pancreatic cancer; chr3:196024982 chr3:195996738~195998233:+ PAAD cis rs4927850 0.918 rs4361313 ENSG00000231464.1 AC024937.4 4.59 9.2e-06 0.00496 0.41 0.35 Pancreatic cancer; chr3:196025389 chr3:195996738~195998233:+ PAAD cis rs4927850 1 rs7627706 ENSG00000231464.1 AC024937.4 4.59 9.2e-06 0.00496 0.41 0.35 Pancreatic cancer; chr3:196026482 chr3:195996738~195998233:+ PAAD cis rs4927850 0.881 rs7630489 ENSG00000231464.1 AC024937.4 4.59 9.2e-06 0.00496 0.41 0.35 Pancreatic cancer; chr3:196026530 chr3:195996738~195998233:+ PAAD cis rs4927850 1 rs7614767 ENSG00000231464.1 AC024937.4 4.59 9.2e-06 0.00496 0.41 0.35 Pancreatic cancer; chr3:196026580 chr3:195996738~195998233:+ PAAD cis rs4927850 1 rs7627868 ENSG00000231464.1 AC024937.4 4.59 9.2e-06 0.00496 0.41 0.35 Pancreatic cancer; chr3:196026602 chr3:195996738~195998233:+ PAAD cis rs4927850 1 rs7630875 ENSG00000231464.1 AC024937.4 4.59 9.2e-06 0.00496 0.41 0.35 Pancreatic cancer; chr3:196026895 chr3:195996738~195998233:+ PAAD cis rs6921919 0.583 rs9468370 ENSG00000216901.1 AL022393.7 4.59 9.21e-06 0.00496 0.45 0.35 Autism spectrum disorder or schizophrenia; chr6:28401163 chr6:28176188~28176674:+ PAAD cis rs11079159 1 rs10445344 ENSG00000263096.1 RP11-515O17.2 4.59 9.21e-06 0.00497 0.47 0.35 QRS duration; chr17:55290427 chr17:55271504~55273653:- PAAD cis rs2921073 0.604 rs2979140 ENSG00000253893.2 FAM85B -4.59 9.21e-06 0.00497 -0.49 -0.35 Parkinson's disease; chr8:8409692 chr8:8167819~8226614:- PAAD cis rs6991838 0.671 rs13251307 ENSG00000200714.1 Y_RNA 4.59 9.23e-06 0.00498 0.41 0.35 Intelligence (multi-trait analysis); chr8:65664911 chr8:65592731~65592820:+ PAAD cis rs6991838 0.733 rs10111844 ENSG00000200714.1 Y_RNA 4.59 9.23e-06 0.00498 0.41 0.35 Intelligence (multi-trait analysis); chr8:65690374 chr8:65592731~65592820:+ PAAD cis rs8177376 1 rs17656 ENSG00000254905.1 RP11-712L6.7 4.59 9.24e-06 0.00498 0.46 0.35 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126263287 chr11:126292922~126294254:- PAAD cis rs875971 0.545 rs221986 ENSG00000164669.11 INTS4P1 4.59 9.24e-06 0.00498 0.51 0.35 Aortic root size; chr7:66105323 chr7:65141225~65234216:+ PAAD cis rs2255336 0.938 rs2733845 ENSG00000245648.1 RP11-277P12.20 -4.59 9.24e-06 0.00498 -0.53 -0.35 Blood protein levels; chr12:10387216 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs2617151 ENSG00000245648.1 RP11-277P12.20 4.59 9.24e-06 0.00498 0.53 0.35 Blood protein levels; chr12:10379835 chr12:10363769~10398506:+ PAAD cis rs160451 0.782 rs2132348 ENSG00000251136.7 RP11-37B2.1 4.59 9.25e-06 0.00498 0.35 0.35 Leprosy; chr8:89694545 chr8:89609409~89757727:- PAAD cis rs160451 0.782 rs218920 ENSG00000251136.7 RP11-37B2.1 4.59 9.25e-06 0.00498 0.35 0.35 Leprosy; chr8:89696607 chr8:89609409~89757727:- PAAD cis rs160451 0.782 rs7828553 ENSG00000251136.7 RP11-37B2.1 4.59 9.25e-06 0.00498 0.35 0.35 Leprosy; chr8:89700193 chr8:89609409~89757727:- PAAD cis rs160451 0.782 rs1603288 ENSG00000251136.7 RP11-37B2.1 -4.59 9.25e-06 0.00498 -0.35 -0.35 Leprosy; chr8:89701036 chr8:89609409~89757727:- PAAD cis rs950027 0.549 rs12909409 ENSG00000259433.2 CTD-2651B20.4 4.59 9.25e-06 0.00498 0.38 0.35 Response to fenofibrate (adiponectin levels); chr15:45316384 chr15:45330209~45332634:- PAAD cis rs7923609 1 rs4399232 ENSG00000232075.1 MRPL35P2 -4.59 9.26e-06 0.00499 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63239730 chr10:63634317~63634827:- PAAD cis rs4453827 0.955 rs2029331 ENSG00000271916.1 RP11-884K10.6 -4.59 9.27e-06 0.00499 -0.36 -0.35 Blood protein levels; chr3:53733662 chr3:53797764~53798019:- PAAD cis rs11976180 1 rs11976037 ENSG00000273234.1 OR2A13P -4.59 9.27e-06 0.00499 -0.43 -0.35 Obesity-related traits; chr7:144043931 chr7:144142009~144142938:+ PAAD cis rs9494145 0.531 rs9399136 ENSG00000232876.1 CTA-212D2.2 -4.59 9.27e-06 0.00499 -0.44 -0.35 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135081201 chr6:135055033~135060550:+ PAAD cis rs7923609 0.936 rs10822160 ENSG00000232075.1 MRPL35P2 -4.59 9.27e-06 0.00499 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63353036 chr10:63634317~63634827:- PAAD cis rs453301 0.686 rs1045527 ENSG00000253893.2 FAM85B 4.59 9.27e-06 0.00499 0.47 0.35 Joint mobility (Beighton score); chr8:9032531 chr8:8167819~8226614:- PAAD cis rs7923609 1 rs4400684 ENSG00000232075.1 MRPL35P2 -4.59 9.27e-06 0.00499 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63252927 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs4454603 ENSG00000232075.1 MRPL35P2 -4.59 9.27e-06 0.00499 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63252990 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs4595427 ENSG00000232075.1 MRPL35P2 -4.59 9.27e-06 0.00499 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63253184 chr10:63634317~63634827:- PAAD cis rs7923609 0.936 rs4405189 ENSG00000232075.1 MRPL35P2 -4.59 9.27e-06 0.00499 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63254175 chr10:63634317~63634827:- PAAD cis rs2658782 0.789 rs2658776 ENSG00000279684.1 RP11-755E23.2 -4.59 9.28e-06 0.005 -0.58 -0.35 Pulmonary function decline; chr11:93414761 chr11:93286629~93288903:- PAAD cis rs2658782 0.756 rs2658777 ENSG00000279684.1 RP11-755E23.2 -4.59 9.28e-06 0.005 -0.58 -0.35 Pulmonary function decline; chr11:93415257 chr11:93286629~93288903:- PAAD cis rs2153535 0.563 rs6942177 ENSG00000230939.1 RP11-314C16.1 4.59 9.29e-06 0.005 0.37 0.35 Motion sickness; chr6:8534227 chr6:8784178~8785445:+ PAAD cis rs875971 0.505 rs1723275 ENSG00000237310.1 GS1-124K5.4 -4.59 9.29e-06 0.005 -0.33 -0.35 Aortic root size; chr7:66039646 chr7:66493706~66495474:+ PAAD cis rs875971 0.505 rs2462573 ENSG00000237310.1 GS1-124K5.4 -4.59 9.29e-06 0.005 -0.33 -0.35 Aortic root size; chr7:66042405 chr7:66493706~66495474:+ PAAD cis rs875971 0.505 rs1167385 ENSG00000237310.1 GS1-124K5.4 -4.59 9.29e-06 0.005 -0.33 -0.35 Aortic root size; chr7:66048321 chr7:66493706~66495474:+ PAAD cis rs4835473 0.897 rs34380794 ENSG00000251600.4 RP11-673E1.1 -4.59 9.29e-06 0.005 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143735800 chr4:143912331~143982454:+ PAAD cis rs4835473 0.75 rs56372690 ENSG00000251600.4 RP11-673E1.1 -4.59 9.29e-06 0.005 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143735816 chr4:143912331~143982454:+ PAAD cis rs7923609 1 rs4379723 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63203689 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs10822149 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63227652 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs10761727 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63235733 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs10761729 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63235844 chr10:63634317~63634827:- PAAD cis rs7923609 0.934 rs10822153 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63297053 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs7070296 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63310678 chr10:63634317~63634827:- PAAD cis rs7923609 0.87 rs10822156 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63320967 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs10761742 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63325288 chr10:63634317~63634827:- PAAD cis rs7923609 0.902 rs10822158 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63334623 chr10:63634317~63634827:- PAAD cis rs7923609 0.846 rs10740115 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63335230 chr10:63634317~63634827:- PAAD cis rs7923609 0.846 rs10740116 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63335232 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs10822161 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63358443 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs10822163 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63364338 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs6479896 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63367072 chr10:63634317~63634827:- PAAD cis rs10761750 1 rs10761750 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Vascular endothelial growth factor levels; chr10:63368859 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs4310508 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63378813 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs7910927 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63379150 chr10:63634317~63634827:- PAAD cis rs7923609 1 rs1935 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63168063 chr10:63634317~63634827:- PAAD cis rs10822145 1 rs10822145 ENSG00000232075.1 MRPL35P2 -4.59 9.3e-06 0.005 -0.43 -0.35 Triglycerides; chr10:63174788 chr10:63634317~63634827:- PAAD cis rs7429990 0.864 rs1403579 ENSG00000229759.1 MRPS18AP1 4.59 9.31e-06 0.00501 0.39 0.35 Educational attainment (years of education); chr3:47617889 chr3:48256350~48256938:- PAAD cis rs2739330 0.685 rs4822453 ENSG00000206090.4 AP000350.7 4.59 9.31e-06 0.00501 0.44 0.35 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23939998~23942798:+ PAAD cis rs295490 0.748 rs10513063 ENSG00000272656.1 RP11-219D15.3 4.59 9.31e-06 0.00501 0.94 0.35 PR interval in Tripanosoma cruzi seropositivity; chr3:139341586 chr3:139349024~139349371:- PAAD cis rs73110464 0.609 rs11170348 ENSG00000278185.1 RP11-153F5.7 4.59 9.34e-06 0.00502 0.46 0.35 Cancer (pleiotropy); chr12:52961804 chr12:52946614~52947125:- PAAD cis rs7572733 0.534 rs1983359 ENSG00000231621.1 AC013264.2 -4.59 9.34e-06 0.00502 -0.35 -0.35 Dermatomyositis; chr2:197940374 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs11887138 ENSG00000231621.1 AC013264.2 -4.59 9.34e-06 0.00502 -0.35 -0.35 Dermatomyositis; chr2:197941114 chr2:197197991~197199273:+ PAAD cis rs700651 0.754 rs1518367 ENSG00000231621.1 AC013264.2 -4.59 9.34e-06 0.00502 -0.35 -0.35 Intracranial aneurysm; chr2:197942291 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1518365 ENSG00000231621.1 AC013264.2 -4.59 9.34e-06 0.00502 -0.35 -0.35 Dermatomyositis; chr2:197944686 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1518363 ENSG00000231621.1 AC013264.2 -4.59 9.34e-06 0.00502 -0.35 -0.35 Dermatomyositis; chr2:197945407 chr2:197197991~197199273:+ PAAD cis rs853679 0.55 rs1233701 ENSG00000226314.6 ZNF192P1 4.59 9.36e-06 0.00503 0.59 0.35 Depression; chr6:28200948 chr6:28161781~28169594:+ PAAD cis rs853679 0.574 rs1233705 ENSG00000226314.6 ZNF192P1 -4.59 9.36e-06 0.00503 -0.59 -0.35 Depression; chr6:28198669 chr6:28161781~28169594:+ PAAD cis rs853679 0.55 rs1233699 ENSG00000226314.6 ZNF192P1 -4.59 9.36e-06 0.00503 -0.59 -0.35 Depression; chr6:28201380 chr6:28161781~28169594:+ PAAD cis rs853679 0.55 rs1233707 ENSG00000226314.6 ZNF192P1 -4.59 9.36e-06 0.00503 -0.59 -0.35 Depression; chr6:28205175 chr6:28161781~28169594:+ PAAD cis rs160451 0.782 rs160410 ENSG00000251136.7 RP11-37B2.1 -4.59 9.37e-06 0.00503 -0.34 -0.35 Leprosy; chr8:89636500 chr8:89609409~89757727:- PAAD cis rs77372450 0.636 rs11465233 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157574945 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs11465225 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157576841 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs11465222 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157577159 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs6879751 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157580398 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs10066998 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157581502 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs11949232 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157583993 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs60855017 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157585709 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs13356635 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157587113 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs6889910 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157587904 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs73305048 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157590839 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs10072471 ENSG00000251405.2 CTB-109A12.1 4.59 9.39e-06 0.00504 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157595199 chr5:157362615~157460078:- PAAD cis rs2281636 0.823 rs11190225 ENSG00000233690.1 EBAG9P1 4.59 9.41e-06 0.00506 0.36 0.35 Obesity-related traits; chr10:99657156 chr10:99697407~99697949:- PAAD cis rs11089937 0.647 rs743516 ENSG00000211639.2 IGLV4-60 4.59 9.42e-06 0.00506 0.34 0.35 Periodontitis (PAL4Q3); chr22:22167105 chr22:22162199~22162681:+ PAAD cis rs889398 0.933 rs244418 ENSG00000226232.7 RP11-419C5.2 4.58 9.42e-06 0.00506 0.28 0.35 Body mass index; chr16:69588859 chr16:69976388~69996188:- PAAD cis rs853679 0.55 rs1225598 ENSG00000204709.4 LINC01556 4.58 9.43e-06 0.00506 0.6 0.35 Depression; chr6:28193021 chr6:28943877~28944537:+ PAAD cis rs11098499 0.588 rs6534149 ENSG00000248280.1 RP11-33B1.2 -4.58 9.43e-06 0.00506 -0.33 -0.35 Corneal astigmatism; chr4:119638137 chr4:119440561~119450157:- PAAD cis rs11159086 0.793 rs8021664 ENSG00000259005.1 RP3-449M8.6 4.58 9.43e-06 0.00506 0.46 0.35 Advanced glycation end-product levels; chr14:74476592 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs1860108 ENSG00000259005.1 RP3-449M8.6 4.58 9.43e-06 0.00506 0.46 0.35 Advanced glycation end-product levels; chr14:74478562 chr14:74474007~74474864:- PAAD cis rs6504950 0.886 rs12449538 ENSG00000275710.1 RP11-257O5.4 -4.58 9.44e-06 0.00506 -0.42 -0.35 Breast cancer; chr17:55033760 chr17:54964474~54964679:+ PAAD cis rs13178541 0.745 rs3963615 ENSG00000250378.1 RP11-119J18.1 -4.58 9.44e-06 0.00506 -0.54 -0.35 IgG glycosylation; chr5:135750292 chr5:135812667~135826582:+ PAAD cis rs13178541 0.745 rs7380109 ENSG00000250378.1 RP11-119J18.1 -4.58 9.44e-06 0.00506 -0.54 -0.35 IgG glycosylation; chr5:135751385 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs62365677 ENSG00000250378.1 RP11-119J18.1 -4.58 9.44e-06 0.00506 -0.54 -0.35 IgG glycosylation; chr5:135752861 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs7380576 ENSG00000250378.1 RP11-119J18.1 -4.58 9.44e-06 0.00506 -0.54 -0.35 IgG glycosylation; chr5:135752903 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs7380618 ENSG00000250378.1 RP11-119J18.1 -4.58 9.44e-06 0.00506 -0.54 -0.35 IgG glycosylation; chr5:135753120 chr5:135812667~135826582:+ PAAD cis rs2337406 0.929 rs12050233 ENSG00000211974.3 IGHV2-70 -4.58 9.44e-06 0.00506 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106781123 chr14:106723574~106724093:- PAAD cis rs2337406 0.852 rs12050466 ENSG00000211974.3 IGHV2-70 -4.58 9.44e-06 0.00506 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106781131 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs61419485 ENSG00000211974.3 IGHV2-70 -4.58 9.44e-06 0.00506 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106783374 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs8015361 ENSG00000211974.3 IGHV2-70 -4.58 9.44e-06 0.00506 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106783991 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74090151 ENSG00000211974.3 IGHV2-70 -4.58 9.44e-06 0.00506 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106785377 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs11488879 ENSG00000211974.3 IGHV2-70 -4.58 9.44e-06 0.00506 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106786097 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs8012619 ENSG00000211974.3 IGHV2-70 -4.58 9.44e-06 0.00506 -0.46 -0.35 Alzheimer's disease (late onset); chr14:106793907 chr14:106723574~106724093:- PAAD cis rs2115630 1 rs4633690 ENSG00000225151.9 GOLGA2P7 4.58 9.44e-06 0.00506 0.41 0.35 P wave terminal force; chr15:84818729 chr15:84199311~84230136:- PAAD cis rs2041895 0.527 rs10861681 ENSG00000260329.1 RP11-412D9.4 -4.58 9.44e-06 0.00506 -0.33 -0.35 Glaucoma (low intraocular pressure); chr12:106940484 chr12:106954029~106955497:- PAAD cis rs60733400 0.5 rs72644697 ENSG00000225931.3 RP3-395M20.7 4.58 9.44e-06 0.00506 0.33 0.35 Multiple sclerosis; chr1:2602166 chr1:2566410~2569888:+ PAAD cis rs4660214 0.666 rs6698791 ENSG00000237624.1 OXCT2P1 -4.58 9.45e-06 0.00507 -0.46 -0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39469104 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs10888788 ENSG00000237624.1 OXCT2P1 -4.58 9.45e-06 0.00507 -0.46 -0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39472024 chr1:39514956~39516490:+ PAAD cis rs62229266 0.618 rs11088334 ENSG00000231106.2 LINC01436 4.58 9.46e-06 0.00507 0.52 0.35 Mitral valve prolapse; chr21:36094531 chr21:36005338~36007838:+ PAAD cis rs61270009 0.955 rs12654702 ENSG00000247828.6 TMEM161B-AS1 4.58 9.46e-06 0.00507 0.28 0.35 Depressive symptoms; chr5:88402882 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs4269995 ENSG00000247828.6 TMEM161B-AS1 4.58 9.46e-06 0.00507 0.28 0.35 Depressive symptoms; chr5:88405406 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs6874182 ENSG00000247828.6 TMEM161B-AS1 4.58 9.46e-06 0.00507 0.28 0.35 Depressive symptoms; chr5:88407268 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs12523282 ENSG00000247828.6 TMEM161B-AS1 4.58 9.46e-06 0.00507 0.28 0.35 Depressive symptoms; chr5:88407679 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs12651891 ENSG00000247828.6 TMEM161B-AS1 4.58 9.46e-06 0.00507 0.28 0.35 Depressive symptoms; chr5:88408187 chr5:88268895~88436685:+ PAAD cis rs8059260 0.736 rs113433437 ENSG00000274038.1 RP11-66H6.4 -4.58 9.46e-06 0.00507 -0.62 -0.35 Alcohol consumption over the past year; chr16:10959438 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs8046423 ENSG00000274038.1 RP11-66H6.4 -4.58 9.46e-06 0.00507 -0.62 -0.35 Alcohol consumption over the past year; chr16:10964016 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs77599345 ENSG00000274038.1 RP11-66H6.4 -4.58 9.46e-06 0.00507 -0.62 -0.35 Alcohol consumption over the past year; chr16:10964707 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs79361721 ENSG00000274038.1 RP11-66H6.4 -4.58 9.46e-06 0.00507 -0.62 -0.35 Alcohol consumption over the past year; chr16:10968082 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs74391397 ENSG00000274038.1 RP11-66H6.4 -4.58 9.46e-06 0.00507 -0.62 -0.35 Alcohol consumption over the past year; chr16:10975570 chr16:11056556~11057034:+ PAAD cis rs8059260 0.736 rs16957854 ENSG00000274038.1 RP11-66H6.4 -4.58 9.46e-06 0.00507 -0.62 -0.35 Alcohol consumption over the past year; chr16:10976466 chr16:11056556~11057034:+ PAAD cis rs17772222 0.71 rs1028455 ENSG00000258983.2 RP11-507K2.2 4.58 9.46e-06 0.00507 0.42 0.35 Coronary artery calcification; chr14:88363631 chr14:88499334~88515502:+ PAAD cis rs6921919 1 rs6922111 ENSG00000216901.1 AL022393.7 4.58 9.47e-06 0.00507 0.53 0.35 Autism spectrum disorder or schizophrenia; chr6:28357531 chr6:28176188~28176674:+ PAAD cis rs2564921 0.704 rs35671032 ENSG00000242142.1 SERBP1P3 -4.58 9.48e-06 0.00508 -0.42 -0.35 Height; chr3:52972039 chr3:53064283~53065091:- PAAD cis rs871012 0.524 rs11952499 ENSG00000251405.2 CTB-109A12.1 -4.58 9.48e-06 0.00508 -0.44 -0.35 IgG glycosylation; chr5:157455626 chr5:157362615~157460078:- PAAD cis rs9601248 0.756 rs2146592 ENSG00000227354.5 RBM26-AS1 -4.58 9.49e-06 0.00508 -0.35 -0.35 Major depressive disorder; chr13:79606146 chr13:79406309~79424328:+ PAAD cis rs3096299 0.503 rs9940093 ENSG00000261253.2 AC137932.6 4.58 9.51e-06 0.00509 0.39 0.35 Multiple myeloma (IgH translocation); chr16:89492297 chr16:89321133~89325110:+ PAAD cis rs875971 1 rs2420168 ENSG00000237310.1 GS1-124K5.4 -4.58 9.51e-06 0.00509 -0.33 -0.35 Aortic root size; chr7:66165644 chr7:66493706~66495474:+ PAAD cis rs75804782 0.572 rs76939124 ENSG00000186235.9 AC016757.3 4.58 9.52e-06 0.0051 0.87 0.35 Chronotype;Morning vs. evening chronotype; chr2:238314837 chr2:238224552~238231677:- PAAD cis rs734999 0.588 rs3001837 ENSG00000225931.3 RP3-395M20.7 -4.58 9.54e-06 0.0051 -0.33 -0.35 Ulcerative colitis; chr1:2601067 chr1:2566410~2569888:+ PAAD cis rs871012 0.632 rs889035 ENSG00000248544.2 CTB-47B11.3 -4.58 9.54e-06 0.00511 -0.45 -0.35 IgG glycosylation; chr5:157389514 chr5:157375741~157384950:- PAAD cis rs9584850 0.874 rs3742136 ENSG00000231194.1 FARP1-AS1 4.58 9.54e-06 0.00511 0.45 0.35 Neuroticism; chr13:98450353 chr13:98435405~98435840:- PAAD cis rs6504950 0.8 rs12952253 ENSG00000275710.1 RP11-257O5.4 4.58 9.55e-06 0.00511 0.42 0.35 Breast cancer; chr17:54928355 chr17:54964474~54964679:+ PAAD cis rs6504950 0.8 rs7208123 ENSG00000275710.1 RP11-257O5.4 4.58 9.55e-06 0.00511 0.42 0.35 Breast cancer; chr17:54928978 chr17:54964474~54964679:+ PAAD cis rs6504950 0.8 rs72829484 ENSG00000275710.1 RP11-257O5.4 4.58 9.55e-06 0.00511 0.42 0.35 Breast cancer; chr17:54931919 chr17:54964474~54964679:+ PAAD cis rs6504950 0.8 rs17745183 ENSG00000275710.1 RP11-257O5.4 4.58 9.55e-06 0.00511 0.42 0.35 Breast cancer; chr17:54936234 chr17:54964474~54964679:+ PAAD cis rs3169166 0.521 rs62007839 ENSG00000259562.2 RP11-762H8.2 4.58 9.55e-06 0.00511 0.29 0.35 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78278533 chr15:78290527~78291221:- PAAD cis rs73186030 0.546 rs6791616 ENSG00000272758.4 RP11-299J3.8 4.58 9.56e-06 0.00512 0.47 0.35 Serum parathyroid hormone levels; chr3:122388388 chr3:122416207~122443180:+ PAAD cis rs950169 0.544 rs12913702 ENSG00000259295.5 CSPG4P12 4.58 9.57e-06 0.00512 0.39 0.35 Schizophrenia; chr15:84609953 chr15:85191438~85213905:+ PAAD cis rs673078 0.607 rs4767671 ENSG00000275759.1 RP11-131L12.3 -4.58 9.59e-06 0.00513 -0.57 -0.35 Glucose homeostasis traits; chr12:118396038 chr12:118428281~118428870:+ PAAD cis rs673078 0.607 rs7312555 ENSG00000275759.1 RP11-131L12.3 -4.58 9.59e-06 0.00513 -0.57 -0.35 Glucose homeostasis traits; chr12:118414120 chr12:118428281~118428870:+ PAAD cis rs6539288 0.677 rs10778518 ENSG00000260329.1 RP11-412D9.4 4.58 9.59e-06 0.00513 0.3 0.35 Total body bone mineral density; chr12:106950172 chr12:106954029~106955497:- PAAD cis rs1167827 0.71 rs1167836 ENSG00000205583.12 STAG3L1 4.58 9.6e-06 0.00513 0.39 0.35 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75539580 chr7:75359194~75395383:+ PAAD cis rs4835473 0.932 rs6813011 ENSG00000251600.4 RP11-673E1.1 4.58 9.6e-06 0.00513 0.4 0.35 Immature fraction of reticulocytes; chr4:143914496 chr4:143912331~143982454:+ PAAD cis rs9257809 1 rs9257809 ENSG00000243753.4 HLA-L -4.58 9.6e-06 0.00513 -0.87 -0.35 Barrett's esophagus;Breast cancer;Barrett's esophagus or Esophageal adenocarcinoma; chr6:29388554 chr6:30259584~30293014:+ PAAD cis rs858239 0.6 rs4628176 ENSG00000226816.2 AC005082.12 4.58 9.61e-06 0.00514 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23102947 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs10488077 ENSG00000226816.2 AC005082.12 4.58 9.61e-06 0.00514 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23104563 chr7:23206013~23208045:+ PAAD cis rs2274273 0.905 rs8007944 ENSG00000258413.1 RP11-665C16.6 -4.58 9.61e-06 0.00514 -0.43 -0.35 Protein biomarker; chr14:55110098 chr14:55262767~55272075:- PAAD cis rs2274273 0.905 rs17128183 ENSG00000258413.1 RP11-665C16.6 4.58 9.61e-06 0.00514 0.43 0.35 Protein biomarker; chr14:55112795 chr14:55262767~55272075:- PAAD cis rs2274273 0.967 rs8009670 ENSG00000258413.1 RP11-665C16.6 -4.58 9.61e-06 0.00514 -0.43 -0.35 Protein biomarker; chr14:55116759 chr14:55262767~55272075:- PAAD cis rs10129255 0.556 rs9324093 ENSG00000211972.2 IGHV3-66 4.58 9.61e-06 0.00514 0.27 0.35 Kawasaki disease; chr14:106683893 chr14:106675017~106675544:- PAAD cis rs7829975 0.617 rs4841072 ENSG00000254340.1 RP11-10A14.3 -4.58 9.62e-06 0.00514 -0.41 -0.35 Mood instability; chr8:8933743 chr8:9141424~9145435:+ PAAD cis rs7646881 0.812 rs6788069 ENSG00000240207.5 RP11-379F4.4 4.58 9.62e-06 0.00514 0.56 0.35 Tetralogy of Fallot; chr3:158741670 chr3:158732263~158784070:+ PAAD cis rs2253762 0.54 rs4752631 ENSG00000276742.1 RP11-500G22.4 4.58 9.62e-06 0.00514 0.48 0.35 Breast cancer; chr10:121996442 chr10:121956782~121957098:+ PAAD cis rs2253762 0.54 rs11200313 ENSG00000276742.1 RP11-500G22.4 4.58 9.62e-06 0.00514 0.48 0.35 Breast cancer; chr10:121996523 chr10:121956782~121957098:+ PAAD cis rs2253762 0.54 rs10887036 ENSG00000276742.1 RP11-500G22.4 4.58 9.62e-06 0.00514 0.48 0.35 Breast cancer; chr10:121997570 chr10:121956782~121957098:+ PAAD cis rs2253762 0.54 rs10887037 ENSG00000276742.1 RP11-500G22.4 4.58 9.62e-06 0.00514 0.48 0.35 Breast cancer; chr10:121997572 chr10:121956782~121957098:+ PAAD cis rs4664293 0.967 rs1346325 ENSG00000226266.5 AC009961.3 -4.58 9.63e-06 0.00515 -0.43 -0.35 Monocyte percentage of white cells; chr2:159685995 chr2:159670708~159712435:- PAAD cis rs8100891 0.537 rs10405382 ENSG00000267213.4 AC007773.2 -4.58 9.65e-06 0.00516 -0.57 -0.35 Neuroticism; chr19:32405810 chr19:32390050~32405560:- PAAD cis rs2115630 0.967 rs10438428 ENSG00000225151.9 GOLGA2P7 4.58 9.66e-06 0.00516 0.4 0.35 P wave terminal force; chr15:84787514 chr15:84199311~84230136:- PAAD cis rs4218 0.689 rs35066133 ENSG00000277144.1 RP11-59H7.4 -4.58 9.66e-06 0.00516 -0.46 -0.35 Social communication problems; chr15:59081917 chr15:59115547~59116089:- PAAD cis rs875971 1 rs6961717 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66122550 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs2087647 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66128201 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6958484 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66134459 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs4718307 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66146001 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs7801282 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66148700 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs875971 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66152608 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs55962648 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66160764 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs11974219 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66182423 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1565531 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66198126 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs6963646 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66220780 chr7:66493706~66495474:+ PAAD cis rs875971 0.965 rs28682868 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66224822 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs9986696 ENSG00000237310.1 GS1-124K5.4 -4.58 9.66e-06 0.00516 -0.33 -0.35 Aortic root size; chr7:66239589 chr7:66493706~66495474:+ PAAD cis rs2412819 0.545 rs654276 ENSG00000205771.5 CATSPER2P1 4.58 9.68e-06 0.00517 0.56 0.35 Lung cancer; chr15:43798656 chr15:43726918~43747094:- PAAD cis rs66887589 0.627 rs3872807 ENSG00000248280.1 RP11-33B1.2 4.58 9.68e-06 0.00517 0.31 0.35 Diastolic blood pressure; chr4:119439096 chr4:119440561~119450157:- PAAD cis rs66887589 0.56 rs9684327 ENSG00000248280.1 RP11-33B1.2 4.58 9.68e-06 0.00517 0.31 0.35 Diastolic blood pressure; chr4:119444286 chr4:119440561~119450157:- PAAD cis rs66887589 0.807 rs13134517 ENSG00000248280.1 RP11-33B1.2 4.58 9.68e-06 0.00517 0.31 0.35 Diastolic blood pressure; chr4:119484107 chr4:119440561~119450157:- PAAD cis rs66887589 0.807 rs7694483 ENSG00000248280.1 RP11-33B1.2 4.58 9.68e-06 0.00517 0.31 0.35 Diastolic blood pressure; chr4:119484774 chr4:119440561~119450157:- PAAD cis rs66887589 0.837 rs6534135 ENSG00000248280.1 RP11-33B1.2 4.58 9.68e-06 0.00517 0.31 0.35 Diastolic blood pressure; chr4:119485147 chr4:119440561~119450157:- PAAD cis rs66887589 0.837 rs7661498 ENSG00000248280.1 RP11-33B1.2 4.58 9.68e-06 0.00517 0.31 0.35 Diastolic blood pressure; chr4:119486953 chr4:119440561~119450157:- PAAD cis rs66887589 0.774 rs9307477 ENSG00000248280.1 RP11-33B1.2 4.58 9.68e-06 0.00517 0.31 0.35 Diastolic blood pressure; chr4:119500654 chr4:119440561~119450157:- PAAD cis rs1233491 1 rs1233491 ENSG00000243753.4 HLA-L -4.58 9.71e-06 0.00518 -0.87 -0.35 Cutaneous lupus erythematosus; chr6:29493953 chr6:30259584~30293014:+ PAAD cis rs9309711 0.883 rs13429373 ENSG00000225234.1 TRAPPC12-AS1 -4.58 9.71e-06 0.00518 -0.38 -0.35 Neurofibrillary tangles; chr2:3473243 chr2:3481242~3482409:- PAAD cis rs9601248 0.756 rs928640 ENSG00000227354.5 RBM26-AS1 -4.58 9.71e-06 0.00518 -0.35 -0.35 Major depressive disorder; chr13:79603348 chr13:79406309~79424328:+ PAAD cis rs526231 0.547 rs72783895 ENSG00000175749.11 EIF3KP1 4.58 9.71e-06 0.00518 0.47 0.35 Primary biliary cholangitis; chr5:102951792 chr5:103032376~103033031:+ PAAD cis rs11690935 0.549 rs796839 ENSG00000228389.1 AC068039.4 -4.58 9.74e-06 0.00519 -0.41 -0.35 Schizophrenia; chr2:172051486 chr2:171773482~171775844:+ PAAD cis rs11690935 0.549 rs2129475 ENSG00000228389.1 AC068039.4 -4.58 9.74e-06 0.00519 -0.41 -0.35 Schizophrenia; chr2:172052044 chr2:171773482~171775844:+ PAAD cis rs6480314 0.542 rs7078967 ENSG00000233590.1 RP11-153K11.3 -4.58 9.74e-06 0.0052 -0.54 -0.35 Optic nerve measurement (disc area); chr10:68266564 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs17231644 ENSG00000233590.1 RP11-153K11.3 4.58 9.74e-06 0.0052 0.54 0.35 Optic nerve measurement (disc area); chr10:68270301 chr10:68233251~68242379:- PAAD cis rs116927879 1 rs116927879 ENSG00000272556.1 RP11-638I8.1 -4.58 9.76e-06 0.00521 -0.42 -0.35 Subjective response to lithium treatment in bipolar disorder; chr7:45825128 chr7:45814602~45815263:+ PAAD cis rs6538678 0.864 rs4762249 ENSG00000258343.1 RP11-536G4.2 4.58 9.78e-06 0.00522 0.44 0.35 Lupus nephritis in systemic lupus erythematosus; chr12:95884183 chr12:95795345~95858839:- PAAD cis rs2564921 0.704 rs62253606 ENSG00000242142.1 SERBP1P3 -4.58 9.78e-06 0.00522 -0.42 -0.35 Height; chr3:52949886 chr3:53064283~53065091:- PAAD cis rs3781264 0.595 rs7094783 ENSG00000273450.1 RP11-76P2.4 4.58 9.78e-06 0.00522 0.47 0.35 Esophageal cancer and gastric cancer; chr10:94321380 chr10:94314907~94315327:- PAAD cis rs6570726 0.791 rs6918814 ENSG00000235652.6 RP11-545I5.3 4.58 9.79e-06 0.00522 0.28 0.35 Lobe attachment (rater-scored or self-reported); chr6:145584892 chr6:145799409~145886585:+ PAAD cis rs1185460 0.967 rs11217137 ENSG00000271751.1 RP11-110I1.14 -4.58 9.79e-06 0.00522 -0.43 -0.35 Coronary artery disease; chr11:119060319 chr11:119065263~119065677:- PAAD cis rs4950322 0.857 rs72693002 ENSG00000278811.3 LINC00624 4.58 9.8e-06 0.00523 0.36 0.35 Protein quantitative trait loci; chr1:147357593 chr1:147258885~147517875:- PAAD cis rs4950322 0.857 rs72694703 ENSG00000278811.3 LINC00624 4.58 9.8e-06 0.00523 0.36 0.35 Protein quantitative trait loci; chr1:147358427 chr1:147258885~147517875:- PAAD cis rs4950322 0.802 rs72694705 ENSG00000278811.3 LINC00624 4.58 9.8e-06 0.00523 0.36 0.35 Protein quantitative trait loci; chr1:147362313 chr1:147258885~147517875:- PAAD cis rs4950322 0.857 rs55790545 ENSG00000278811.3 LINC00624 4.58 9.8e-06 0.00523 0.36 0.35 Protein quantitative trait loci; chr1:147366649 chr1:147258885~147517875:- PAAD cis rs4950322 0.857 rs7522219 ENSG00000278811.3 LINC00624 4.58 9.8e-06 0.00523 0.36 0.35 Protein quantitative trait loci; chr1:147366904 chr1:147258885~147517875:- PAAD cis rs6991838 0.701 rs7829434 ENSG00000200714.1 Y_RNA 4.57 9.82e-06 0.00524 0.41 0.35 Intelligence (multi-trait analysis); chr8:65716909 chr8:65592731~65592820:+ PAAD cis rs700651 0.752 rs1850631 ENSG00000231621.1 AC013264.2 -4.57 9.83e-06 0.00524 -0.35 -0.35 Intracranial aneurysm; chr2:197964744 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs6752458 ENSG00000231621.1 AC013264.2 -4.57 9.83e-06 0.00524 -0.35 -0.35 Dermatomyositis; chr2:197970382 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs1356542 ENSG00000231621.1 AC013264.2 -4.57 9.83e-06 0.00524 -0.35 -0.35 Dermatomyositis; chr2:197970978 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs1518368 ENSG00000231621.1 AC013264.2 -4.57 9.83e-06 0.00524 -0.35 -0.35 Dermatomyositis; chr2:197974421 chr2:197197991~197199273:+ PAAD cis rs2115630 1 rs2879828 ENSG00000225151.9 GOLGA2P7 4.57 9.83e-06 0.00524 0.41 0.35 P wave terminal force; chr15:84818746 chr15:84199311~84230136:- PAAD cis rs394563 0.967 rs369643 ENSG00000231760.4 RP11-350J20.5 4.57 9.84e-06 0.00524 0.45 0.35 Dupuytren's disease; chr6:149478662 chr6:149796151~149826294:- PAAD cis rs79040073 0.563 rs17478618 ENSG00000259531.2 RP11-295H24.3 -4.57 9.84e-06 0.00525 -0.56 -0.35 Lung cancer in ever smokers; chr15:49444621 chr15:49365124~49366685:- PAAD cis rs79040073 0.607 rs17400706 ENSG00000259531.2 RP11-295H24.3 4.57 9.84e-06 0.00525 0.56 0.35 Lung cancer in ever smokers; chr15:49455148 chr15:49365124~49366685:- PAAD cis rs10050311 0.858 rs1010903 ENSG00000251411.1 RP11-397E7.4 -4.57 9.85e-06 0.00525 -0.43 -0.35 Insulin-related traits; chr4:86898040 chr4:86913266~86914817:- PAAD cis rs6867913 0.561 rs249658 ENSG00000280047.1 CTC-463A16.1 -4.57 9.85e-06 0.00525 -0.33 -0.35 Asthma; chr5:142198447 chr5:142165767~142168387:+ PAAD cis rs1322639 0.614 rs6908401 ENSG00000261039.2 RP11-417E7.2 4.57 9.86e-06 0.00525 0.58 0.35 Pulse pressure; chr6:169164621 chr6:169175304~169182740:- PAAD cis rs812925 0.555 rs12616433 ENSG00000273302.1 RP11-493E12.2 4.57 9.86e-06 0.00525 0.3 0.35 Immature fraction of reticulocytes; chr2:61469353 chr2:61199979~61200769:+ PAAD cis rs3864261 0.515 rs57149385 ENSG00000272081.1 CTD-2376I4.2 4.57 9.86e-06 0.00525 0.41 0.35 Discordance in emotional problems in monozygotic twins; chr5:73060354 chr5:72955206~72955699:- PAAD cis rs3864261 0.515 rs10942539 ENSG00000272081.1 CTD-2376I4.2 4.57 9.86e-06 0.00525 0.41 0.35 Discordance in emotional problems in monozygotic twins; chr5:73061259 chr5:72955206~72955699:- PAAD cis rs3781264 0.595 rs11187901 ENSG00000273450.1 RP11-76P2.4 4.57 9.88e-06 0.00526 0.46 0.35 Esophageal cancer and gastric cancer; chr10:94355251 chr10:94314907~94315327:- PAAD cis rs2115630 0.936 rs8033459 ENSG00000225151.9 GOLGA2P7 4.57 9.88e-06 0.00526 0.41 0.35 P wave terminal force; chr15:84710027 chr15:84199311~84230136:- PAAD cis rs13178541 0.745 rs11948578 ENSG00000250378.1 RP11-119J18.1 -4.57 9.89e-06 0.00527 -0.55 -0.35 IgG glycosylation; chr5:135794511 chr5:135812667~135826582:+ PAAD cis rs7176527 0.5 rs895571 ENSG00000230373.7 GOLGA6L5P 4.57 9.9e-06 0.00527 0.35 0.35 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84573922 chr15:84507885~84516814:- PAAD cis rs2283792 1 rs2266967 ENSG00000228050.1 TOP3BP1 4.57 9.92e-06 0.00528 0.37 0.35 Multiple sclerosis; chr22:21802500 chr22:22223187~22224566:- PAAD cis rs12134133 0.962 rs7526658 ENSG00000274245.1 RP11-357P18.2 4.57 9.92e-06 0.00528 0.57 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207240098 chr1:207372559~207373252:+ PAAD cis rs919433 1 rs2195510 ENSG00000231621.1 AC013264.2 4.57 9.93e-06 0.00528 0.33 0.35 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197296471 chr2:197197991~197199273:+ PAAD cis rs4218 0.681 rs6494069 ENSG00000277144.1 RP11-59H7.4 -4.57 9.94e-06 0.00529 -0.47 -0.35 Social communication problems; chr15:59094151 chr15:59115547~59116089:- PAAD cis rs11159086 0.793 rs10150696 ENSG00000259005.1 RP3-449M8.6 4.57 9.94e-06 0.00529 0.47 0.35 Advanced glycation end-product levels; chr14:74476723 chr14:74474007~74474864:- PAAD cis rs10754283 0.967 rs10754285 ENSG00000231613.1 RP5-943J3.1 4.57 9.94e-06 0.00529 0.37 0.35 Amyotrophic lateral sclerosis (sporadic); chr1:89651028 chr1:89788914~89790492:+ PAAD cis rs2882667 0.537 rs7704790 ENSG00000253404.1 AC034243.1 4.57 9.94e-06 0.00529 0.39 0.35 Age-related hearing impairment (SNP x SNP interaction); chr5:139074407 chr5:138744434~138753309:- PAAD cis rs4835473 0.838 rs4271960 ENSG00000251600.4 RP11-673E1.1 -4.57 9.95e-06 0.00529 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143763591 chr4:143912331~143982454:+ PAAD cis rs4835473 0.808 rs2323198 ENSG00000251600.4 RP11-673E1.1 -4.57 9.95e-06 0.00529 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143763595 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs2323199 ENSG00000251600.4 RP11-673E1.1 -4.57 9.95e-06 0.00529 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143763606 chr4:143912331~143982454:+ PAAD cis rs2599510 0.811 rs2710615 ENSG00000276334.1 AL133243.1 4.57 9.95e-06 0.0053 0.42 0.35 Interleukin-18 levels; chr2:32566155 chr2:32521927~32523547:+ PAAD cis rs116139393 0.536 rs13247186 ENSG00000187953.9 PMS2CL -4.57 1e-05 0.00531 -0.42 -0.35 Alzheimer's disease (APOE e4 interaction); chr7:6729524 chr7:6710128~6753862:+ PAAD cis rs5758511 0.689 rs17002947 ENSG00000205702.9 CYP2D7 -4.57 1e-05 0.00531 -0.32 -0.35 Birth weight; chr22:42292526 chr22:42140203~42144577:- PAAD cis rs2283792 1 rs5999521 ENSG00000228050.1 TOP3BP1 4.57 1e-05 0.00532 0.37 0.35 Multiple sclerosis; chr22:21792110 chr22:22223187~22224566:- PAAD cis rs17772222 0.958 rs1123421 ENSG00000258983.2 RP11-507K2.2 4.57 1e-05 0.00532 0.48 0.35 Coronary artery calcification; chr14:88524651 chr14:88499334~88515502:+ PAAD cis rs2985684 0.948 rs6572592 ENSG00000259113.1 RP11-406H23.2 -4.57 1e-05 0.00532 -0.48 -0.35 Carotid intima media thickness; chr14:49614153 chr14:50448807~50456742:+ PAAD cis rs2115630 0.936 rs11073663 ENSG00000225151.9 GOLGA2P7 4.57 1e-05 0.00532 0.4 0.35 P wave terminal force; chr15:84717037 chr15:84199311~84230136:- PAAD cis rs453301 0.653 rs1045529 ENSG00000254340.1 RP11-10A14.3 -4.57 1e-05 0.00532 -0.42 -0.35 Joint mobility (Beighton score); chr8:9032588 chr8:9141424~9145435:+ PAAD cis rs3823536 0.583 rs7789423 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:128981150 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs6948928 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:128983043 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs3807302 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:129004803 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs11760442 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:129016066 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs3847099 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:129016777 chr7:128952527~128953316:- PAAD cis rs3823536 0.604 rs3857852 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:129017223 chr7:128952527~128953316:- PAAD cis rs3823536 0.604 rs13221560 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:129023121 chr7:128952527~128953316:- PAAD cis rs3823536 0.544 rs12532542 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:129027358 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs4731540 ENSG00000275106.1 RP11-309L24.10 -4.57 1e-05 0.00532 -0.47 -0.35 Sjögren's syndrome; chr7:129028196 chr7:128952527~128953316:- PAAD cis rs453301 0.631 rs17700611 ENSG00000253893.2 FAM85B 4.57 1e-05 0.00532 0.47 0.35 Joint mobility (Beighton score); chr8:8936144 chr8:8167819~8226614:- PAAD cis rs17711722 0.565 rs4717276 ENSG00000237310.1 GS1-124K5.4 4.57 1e-05 0.00533 0.34 0.35 Calcium levels; chr7:65829754 chr7:66493706~66495474:+ PAAD cis rs8177376 1 rs692955 ENSG00000254905.1 RP11-712L6.7 4.57 1e-05 0.00533 0.47 0.35 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126214601 chr11:126292922~126294254:- PAAD cis rs1665050 0.625 rs8028764 ENSG00000277144.1 RP11-59H7.4 -4.57 1e-05 0.00534 -0.39 -0.35 Atopic dermatitis; chr15:59012436 chr15:59115547~59116089:- PAAD cis rs7829975 0.572 rs28730413 ENSG00000254340.1 RP11-10A14.3 -4.57 1.01e-05 0.00534 -0.41 -0.35 Mood instability; chr8:8937937 chr8:9141424~9145435:+ PAAD cis rs4273100 0.834 rs59415593 ENSG00000228157.4 AC007952.5 4.57 1.01e-05 0.00534 0.59 0.35 Schizophrenia; chr17:19319911 chr17:19092974~19096837:+ PAAD cis rs4664293 0.642 rs6732598 ENSG00000226266.5 AC009961.3 4.57 1.01e-05 0.00534 0.42 0.35 Monocyte percentage of white cells; chr2:159790370 chr2:159670708~159712435:- PAAD cis rs453301 0.579 rs10096850 ENSG00000253893.2 FAM85B 4.57 1.01e-05 0.00536 0.47 0.35 Joint mobility (Beighton score); chr8:8940712 chr8:8167819~8226614:- PAAD cis rs2412819 0.545 rs35822148 ENSG00000249839.1 AC011330.5 -4.57 1.01e-05 0.00536 -0.59 -0.35 Lung cancer; chr15:43808084 chr15:43663654~43684339:- PAAD cis rs6452524 0.766 rs2252179 ENSG00000249664.1 CTD-2227C6.2 -4.57 1.01e-05 0.00537 -0.41 -0.35 Hypertension (SNP x SNP interaction); chr5:83145630 chr5:83012285~83013109:- PAAD cis rs6452524 0.692 rs1382367 ENSG00000249664.1 CTD-2227C6.2 -4.57 1.01e-05 0.00537 -0.41 -0.35 Hypertension (SNP x SNP interaction); chr5:83155393 chr5:83012285~83013109:- PAAD cis rs2599510 0.783 rs2710626 ENSG00000276334.1 AL133243.1 4.57 1.01e-05 0.00537 0.41 0.35 Interleukin-18 levels; chr2:32533687 chr2:32521927~32523547:+ PAAD cis rs11673344 0.864 rs8110696 ENSG00000226686.6 LINC01535 4.57 1.01e-05 0.00538 0.49 0.35 Obesity-related traits; chr19:37009449 chr19:37251912~37265535:+ PAAD cis rs113835537 0.808 rs10896128 ENSG00000255517.5 CTD-3074O7.5 -4.57 1.02e-05 0.00538 -0.57 -0.35 Airway imaging phenotypes; chr11:66557058 chr11:66473490~66480233:- PAAD cis rs4835473 0.932 rs5015760 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143737955 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs5016158 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143738472 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs5016157 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143738587 chr4:143912331~143982454:+ PAAD cis rs4835473 0.808 rs2060652 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143739129 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs2060654 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143739155 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2060655 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143739159 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2060656 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143739330 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs67749935 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143739852 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs66934100 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143739872 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4325971 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143740167 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4615131 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143740295 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4499657 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143740316 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4443230 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143740372 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4637344 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143740434 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs56277406 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143740620 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13143879 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143740901 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs36086465 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143742738 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs873430 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143742953 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs873431 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143743035 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs899903 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143743551 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2323191 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143744472 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs1375982 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143745764 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs4835237 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143746349 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs56084616 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143746697 chr4:143912331~143982454:+ PAAD cis rs4835473 0.966 rs11722639 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143746884 chr4:143912331~143982454:+ PAAD cis rs4835473 0.966 rs11722673 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143746946 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6821979 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143748091 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6838887 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143748130 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1982392 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143748604 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1982393 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143748736 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs9683880 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143748787 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs7687976 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143749171 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs7683287 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143749270 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2218791 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143749300 chr4:143912331~143982454:+ PAAD cis rs4835473 0.712 rs2198000 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143750005 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs2198002 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143750028 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6853460 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143750392 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6853676 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143750495 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6848393 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143750537 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs971390 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143751264 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs971391 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143751324 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs971392 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143751384 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs35978782 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143751713 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34060266 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143751766 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35300159 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143751768 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13139419 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143751862 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs13106052 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143751995 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13134401 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752008 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13106287 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752091 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13134679 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752187 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13108134 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752213 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs34406317 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752237 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6836896 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752404 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2874983 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752589 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2874984 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752622 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs2323192 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752646 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2323193 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143752812 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34152627 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143753205 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35670108 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143753280 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs6832005 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143754284 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs55963933 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143755048 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs35243309 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143755116 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs34790336 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143755284 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35740243 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143755395 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4395452 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143755678 chr4:143912331~143982454:+ PAAD cis rs4835473 0.741 rs6537180 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143755984 chr4:143912331~143982454:+ PAAD cis rs4835473 0.741 rs6537181 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143755995 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs6814065 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143756233 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs6816347 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143756674 chr4:143912331~143982454:+ PAAD cis rs4835473 0.808 rs6847256 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143757032 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs57413073 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143757852 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34732468 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143758009 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs12510395 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143758107 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs12513087 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143758551 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs12513119 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143758619 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs12513130 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143758666 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs7681891 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143759289 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs7681903 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143759326 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs7656753 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143759414 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs7656786 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143759455 chr4:143912331~143982454:+ PAAD cis rs4835473 0.771 rs34069296 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143759656 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs7687915 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143759801 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1993015 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143760202 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs1993016 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143760217 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1993017 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143760285 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs1375983 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143760423 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1375984 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143760510 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1375985 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143760556 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs17018200 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143760866 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11100805 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143760979 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs56115009 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761073 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs10857406 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761216 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs10857407 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761226 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs10857408 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761333 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs10857409 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761461 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs10857410 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761566 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs10857411 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761599 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1006406 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761710 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1562776 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143761999 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34697602 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143762499 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34618381 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143762612 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11100808 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143762728 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7661407 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143762982 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1562777 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143763676 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1562778 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143763816 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1562779 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143763999 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1597441 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143764158 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1597442 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143764359 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1597443 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143764406 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1597444 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143764547 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs60038202 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143764662 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1450230 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143765118 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs72946226 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143765238 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34230433 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143765253 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7696869 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143765855 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7698287 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143765859 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11721495 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143767216 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6858195 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143768444 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs7689374 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143769567 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6537183 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143770441 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs12512202 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143771248 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6843671 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143772041 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs35395070 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143772283 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs34614750 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143772369 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35002497 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143772952 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13119630 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143773901 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1450233 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143774710 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4308330 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143774761 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11725708 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143775683 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs17762299 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143777196 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs17694797 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143778812 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35947975 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143778969 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1375987 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143779622 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7687151 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143781681 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1450236 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143783069 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs62339581 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143785172 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7666368 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143785372 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7690428 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143785400 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34781605 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143785486 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs11100810 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143787518 chr4:143912331~143982454:+ PAAD cis rs4835473 0.808 rs62339607 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143791474 chr4:143912331~143982454:+ PAAD cis rs4835473 0.801 rs35839125 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143792351 chr4:143912331~143982454:+ PAAD cis rs4835473 0.75 rs12498381 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143793928 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs6832094 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143795388 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs17018500 ENSG00000251600.4 RP11-673E1.1 -4.57 1.02e-05 0.00538 -0.38 -0.35 Immature fraction of reticulocytes; chr4:143824849 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13147386 ENSG00000251600.4 RP11-673E1.1 4.57 1.02e-05 0.00538 0.38 0.35 Immature fraction of reticulocytes; chr4:143736586 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13135034 ENSG00000251600.4 RP11-673E1.1 4.57 1.02e-05 0.00538 0.38 0.35 Immature fraction of reticulocytes; chr4:143738247 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs5016159 ENSG00000251600.4 RP11-673E1.1 4.57 1.02e-05 0.00538 0.38 0.35 Immature fraction of reticulocytes; chr4:143738362 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13134327 ENSG00000251600.4 RP11-673E1.1 4.57 1.02e-05 0.00538 0.38 0.35 Immature fraction of reticulocytes; chr4:143738642 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11100806 ENSG00000251600.4 RP11-673E1.1 4.57 1.02e-05 0.00538 0.38 0.35 Immature fraction of reticulocytes; chr4:143761006 chr4:143912331~143982454:+ PAAD cis rs7615952 0.866 rs6438949 ENSG00000241288.6 RP11-379B18.5 -4.57 1.02e-05 0.00539 -0.36 -0.35 Blood pressure (smoking interaction); chr3:125931221 chr3:125827238~125916384:- PAAD cis rs2717559 0.542 rs2585156 ENSG00000253741.1 CTD-2292P10.4 4.57 1.02e-05 0.00539 0.46 0.35 Urinary tract infection frequency; chr8:142798379 chr8:142702252~142726973:- PAAD cis rs1823913 0.637 rs10931493 ENSG00000280083.1 RP11-317J9.1 -4.57 1.02e-05 0.0054 -0.42 -0.35 Obesity-related traits; chr2:191288142 chr2:191154118~191156070:- PAAD cis rs7202877 0.706 rs247443 ENSG00000261783.1 RP11-252K23.2 4.57 1.02e-05 0.0054 0.54 0.35 Type 1 diabetes;Type 2 diabetes; chr16:75431175 chr16:75379818~75381260:- PAAD cis rs853679 0.76 rs9357067 ENSG00000226314.6 ZNF192P1 -4.57 1.02e-05 0.0054 -0.55 -0.35 Depression; chr6:28242515 chr6:28161781~28169594:+ PAAD cis rs61270009 0.955 rs12655529 ENSG00000247828.6 TMEM161B-AS1 4.57 1.02e-05 0.00541 0.28 0.35 Depressive symptoms; chr5:88280980 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs4916897 ENSG00000247828.6 TMEM161B-AS1 4.57 1.02e-05 0.00541 0.28 0.35 Depressive symptoms; chr5:88285771 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs410354 ENSG00000247828.6 TMEM161B-AS1 -4.57 1.02e-05 0.00541 -0.28 -0.35 Depressive symptoms; chr5:88254467 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs780404 ENSG00000247828.6 TMEM161B-AS1 -4.57 1.02e-05 0.00541 -0.28 -0.35 Depressive symptoms; chr5:88256675 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs375514 ENSG00000247828.6 TMEM161B-AS1 -4.57 1.02e-05 0.00541 -0.28 -0.35 Depressive symptoms; chr5:88259477 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs377958 ENSG00000247828.6 TMEM161B-AS1 -4.57 1.02e-05 0.00541 -0.28 -0.35 Depressive symptoms; chr5:88267571 chr5:88268895~88436685:+ PAAD cis rs61270009 0.913 rs402114 ENSG00000247828.6 TMEM161B-AS1 -4.57 1.02e-05 0.00541 -0.28 -0.35 Depressive symptoms; chr5:88268106 chr5:88268895~88436685:+ PAAD cis rs9494145 0.652 rs9399137 ENSG00000232876.1 CTA-212D2.2 -4.57 1.02e-05 0.00541 -0.43 -0.35 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135097880 chr6:135055033~135060550:+ PAAD cis rs9494145 0.567 rs35786788 ENSG00000232876.1 CTA-212D2.2 -4.57 1.02e-05 0.00541 -0.43 -0.35 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135097904 chr6:135055033~135060550:+ PAAD cis rs1322639 0.614 rs9689800 ENSG00000261039.2 RP11-417E7.2 4.57 1.02e-05 0.00541 0.39 0.35 Pulse pressure; chr6:169172850 chr6:169175304~169182740:- PAAD cis rs2404602 0.684 rs2454451 ENSG00000259422.1 RP11-593F23.1 4.57 1.02e-05 0.00541 0.43 0.35 Blood metabolite levels; chr15:76569120 chr15:76174891~76181486:- PAAD cis rs526231 0.578 rs17154889 ENSG00000175749.11 EIF3KP1 4.57 1.02e-05 0.00541 0.46 0.35 Primary biliary cholangitis; chr5:102969361 chr5:103032376~103033031:+ PAAD cis rs853679 1 rs2799077 ENSG00000226314.6 ZNF192P1 -4.56 1.02e-05 0.00542 -0.6 -0.35 Depression; chr6:28266819 chr6:28161781~28169594:+ PAAD cis rs950027 0.62 rs1719245 ENSG00000259433.2 CTD-2651B20.4 -4.56 1.02e-05 0.00542 -0.4 -0.35 Response to fenofibrate (adiponectin levels); chr15:45331584 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs6493145 ENSG00000259433.2 CTD-2651B20.4 4.56 1.02e-05 0.00542 0.38 0.35 Glomerular filtration rate; chr15:45281664 chr15:45330209~45332634:- PAAD cis rs17023223 0.537 rs12085308 ENSG00000231365.4 RP11-418J17.1 -4.56 1.03e-05 0.00542 -0.37 -0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119134930 chr1:119140396~119275973:+ PAAD cis rs7208859 0.725 rs9891656 ENSG00000266490.1 CTD-2349P21.9 4.56 1.03e-05 0.00542 0.41 0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30792372~30792833:+ PAAD cis rs116139393 0.54 rs12539942 ENSG00000187953.9 PMS2CL -4.56 1.03e-05 0.00542 -0.43 -0.35 Alzheimer's disease (APOE e4 interaction); chr7:6736954 chr7:6710128~6753862:+ PAAD cis rs950169 0.763 rs35372971 ENSG00000259295.5 CSPG4P12 4.56 1.03e-05 0.00542 0.38 0.35 Schizophrenia; chr15:84387097 chr15:85191438~85213905:+ PAAD cis rs2283792 1 rs6518986 ENSG00000228050.1 TOP3BP1 4.56 1.03e-05 0.00543 0.37 0.35 Multiple sclerosis; chr22:21831058 chr22:22223187~22224566:- PAAD cis rs2283792 1 rs1892846 ENSG00000228050.1 TOP3BP1 4.56 1.03e-05 0.00543 0.37 0.35 Multiple sclerosis; chr22:21832190 chr22:22223187~22224566:- PAAD cis rs2283792 1 rs1892848 ENSG00000228050.1 TOP3BP1 4.56 1.03e-05 0.00543 0.37 0.35 Multiple sclerosis; chr22:21832273 chr22:22223187~22224566:- PAAD cis rs2599510 0.807 rs176416 ENSG00000276334.1 AL133243.1 -4.56 1.03e-05 0.00543 -0.42 -0.35 Interleukin-18 levels; chr2:32427155 chr2:32521927~32523547:+ PAAD cis rs7078219 1 rs7081330 ENSG00000257582.4 LINC01475 -4.56 1.03e-05 0.00543 -0.37 -0.35 Dental caries; chr10:99514708 chr10:99526350~99531177:- PAAD cis rs7923609 1 rs7073746 ENSG00000232075.1 MRPL35P2 -4.56 1.03e-05 0.00543 -0.43 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63144311 chr10:63634317~63634827:- PAAD cis rs7246657 0.525 rs1667351 ENSG00000226686.6 LINC01535 -4.56 1.03e-05 0.00543 -0.58 -0.35 Coronary artery calcification; chr19:36987125 chr19:37251912~37265535:+ PAAD cis rs2562456 0.72 rs6511250 ENSG00000213976.4 CTD-2561J22.2 4.56 1.03e-05 0.00543 0.38 0.35 Pain; chr19:21473244 chr19:21382865~21387177:+ PAAD cis rs11690935 0.632 rs12987931 ENSG00000228389.1 AC068039.4 -4.56 1.03e-05 0.00543 -0.41 -0.35 Schizophrenia; chr2:172036045 chr2:171773482~171775844:+ PAAD cis rs2946504 0.906 rs2946511 ENSG00000251468.2 RP11-369K16.1 4.56 1.03e-05 0.00543 0.4 0.35 Type 2 diabetes; chr8:12949796 chr8:12958387~12962200:+ PAAD cis rs9531006 0.636 rs13378771 ENSG00000227676.3 LINC01068 4.56 1.03e-05 0.00544 0.53 0.35 Sleep duration; chr13:79885396 chr13:79566727~79571436:+ PAAD cis rs7665090 0.743 rs228626 ENSG00000246560.2 RP11-10L12.4 -4.56 1.03e-05 0.00544 -0.39 -0.35 Primary biliary cholangitis; chr4:102651789 chr4:102828055~102844075:+ PAAD cis rs9918079 0.506 rs10214 ENSG00000273133.1 RP11-799M12.2 4.56 1.03e-05 0.00544 0.41 0.35 Obesity-related traits; chr4:15604808 chr4:15563698~15564253:- PAAD cis rs875971 0.545 rs313830 ENSG00000226824.5 RP4-756H11.3 4.56 1.03e-05 0.00544 0.49 0.35 Aortic root size; chr7:66086944 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs313828 ENSG00000226824.5 RP4-756H11.3 4.56 1.03e-05 0.00544 0.49 0.35 Aortic root size; chr7:66087627 chr7:66654538~66669855:+ PAAD cis rs875971 0.571 rs160647 ENSG00000226824.5 RP4-756H11.3 4.56 1.03e-05 0.00544 0.49 0.35 Aortic root size; chr7:66089365 chr7:66654538~66669855:+ PAAD cis rs875971 0.52 rs160645 ENSG00000226824.5 RP4-756H11.3 4.56 1.03e-05 0.00544 0.49 0.35 Aortic root size; chr7:66091320 chr7:66654538~66669855:+ PAAD cis rs875971 0.789 rs28815324 ENSG00000226824.5 RP4-756H11.3 4.56 1.03e-05 0.00544 0.49 0.35 Aortic root size; chr7:66100789 chr7:66654538~66669855:+ PAAD cis rs875971 0.545 rs73136346 ENSG00000226824.5 RP4-756H11.3 4.56 1.03e-05 0.00544 0.49 0.35 Aortic root size; chr7:66101095 chr7:66654538~66669855:+ PAAD cis rs10129255 0.5 rs2027902 ENSG00000211972.2 IGHV3-66 4.56 1.03e-05 0.00545 0.26 0.35 Kawasaki disease; chr14:106807157 chr14:106675017~106675544:- PAAD cis rs858239 0.6 rs7341483 ENSG00000226816.2 AC005082.12 -4.56 1.03e-05 0.00545 -0.39 -0.35 Cerebrospinal fluid biomarker levels; chr7:23088038 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs7799422 ENSG00000226816.2 AC005082.12 4.56 1.03e-05 0.00545 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23088794 chr7:23206013~23208045:+ PAAD cis rs7188445 0.736 rs4889012 ENSG00000261390.4 RP11-345M22.2 4.56 1.03e-05 0.00545 0.45 0.35 Urate levels; chr16:79667485 chr16:79715232~79770563:- PAAD cis rs4683346 0.616 rs11129976 ENSG00000173811.9 CCDC13-AS1 -4.56 1.03e-05 0.00545 -0.38 -0.35 Granulocyte percentage of myeloid white cells; chr3:42808873 chr3:42732575~42746768:+ PAAD cis rs858239 0.6 rs2003555 ENSG00000226816.2 AC005082.12 4.56 1.04e-05 0.00546 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23083296 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs7784929 ENSG00000226816.2 AC005082.12 4.56 1.04e-05 0.00546 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23084658 chr7:23206013~23208045:+ PAAD cis rs11976180 1 rs2961134 ENSG00000273234.1 OR2A13P -4.56 1.04e-05 0.00546 -0.42 -0.35 Obesity-related traits; chr7:144073969 chr7:144142009~144142938:+ PAAD cis rs2253762 0.507 rs4752630 ENSG00000276742.1 RP11-500G22.4 4.56 1.04e-05 0.00546 0.47 0.35 Breast cancer; chr10:121991440 chr10:121956782~121957098:+ PAAD cis rs858239 0.601 rs764533 ENSG00000226816.2 AC005082.12 4.56 1.04e-05 0.00546 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23114256 chr7:23206013~23208045:+ PAAD cis rs77372450 0.636 rs6876128 ENSG00000251405.2 CTB-109A12.1 4.56 1.04e-05 0.00546 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157567429 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs6875939 ENSG00000251405.2 CTB-109A12.1 4.56 1.04e-05 0.00546 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157567458 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs6860257 ENSG00000251405.2 CTB-109A12.1 4.56 1.04e-05 0.00546 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157568861 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs28621556 ENSG00000251405.2 CTB-109A12.1 4.56 1.04e-05 0.00546 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157570315 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs6556089 ENSG00000251405.2 CTB-109A12.1 4.56 1.04e-05 0.00546 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157573846 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs6556090 ENSG00000251405.2 CTB-109A12.1 4.56 1.04e-05 0.00546 0.54 0.35 Bipolar disorder (body mass index interaction); chr5:157574175 chr5:157362615~157460078:- PAAD cis rs2790457 0.958 rs2790454 ENSG00000254635.4 WAC-AS1 -4.56 1.04e-05 0.00546 -0.34 -0.35 Multiple myeloma; chr10:28553103 chr10:28522652~28532743:- PAAD cis rs2790457 0.958 rs2790455 ENSG00000254635.4 WAC-AS1 -4.56 1.04e-05 0.00546 -0.34 -0.35 Multiple myeloma; chr10:28558148 chr10:28522652~28532743:- PAAD cis rs2790457 1 rs2790457 ENSG00000254635.4 WAC-AS1 -4.56 1.04e-05 0.00546 -0.34 -0.35 Multiple myeloma; chr10:28567890 chr10:28522652~28532743:- PAAD cis rs2790457 0.958 rs2532742 ENSG00000254635.4 WAC-AS1 -4.56 1.04e-05 0.00546 -0.34 -0.35 Multiple myeloma; chr10:28578291 chr10:28522652~28532743:- PAAD cis rs2790457 0.917 rs2790462 ENSG00000254635.4 WAC-AS1 -4.56 1.04e-05 0.00546 -0.34 -0.35 Multiple myeloma; chr10:28584273 chr10:28522652~28532743:- PAAD cis rs2446066 0.872 rs10876451 ENSG00000257379.1 RP11-793H13.8 4.56 1.04e-05 0.00546 0.53 0.35 Red blood cell count; chr12:53419640 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs57676448 ENSG00000257379.1 RP11-793H13.8 4.56 1.04e-05 0.00547 0.51 0.35 Red blood cell count; chr12:53401003 chr12:53441741~53467528:+ PAAD cis rs9531006 0.571 rs6563150 ENSG00000227676.3 LINC01068 4.56 1.04e-05 0.00549 0.54 0.35 Sleep duration; chr13:79926969 chr13:79566727~79571436:+ PAAD cis rs797680 0.93 rs1474927 ENSG00000223745.6 RP4-717I23.3 4.56 1.04e-05 0.00549 0.27 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93104811 chr1:93262186~93346025:- PAAD cis rs7572733 0.534 rs1464209 ENSG00000231621.1 AC013264.2 -4.56 1.04e-05 0.00549 -0.35 -0.35 Dermatomyositis; chr2:197949672 chr2:197197991~197199273:+ PAAD cis rs9494145 0.667 rs1331309 ENSG00000232876.1 CTA-212D2.2 -4.56 1.04e-05 0.0055 -0.43 -0.35 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135085040 chr6:135055033~135060550:+ PAAD cis rs9487094 0.645 rs1322818 ENSG00000260273.1 RP11-425D10.10 4.56 1.05e-05 0.0055 0.49 0.35 Height; chr6:109369898 chr6:109382795~109383666:+ PAAD cis rs950169 0.84 rs62029595 ENSG00000259295.5 CSPG4P12 4.56 1.05e-05 0.0055 0.38 0.35 Schizophrenia; chr15:84400603 chr15:85191438~85213905:+ PAAD cis rs858239 0.601 rs11984129 ENSG00000226816.2 AC005082.12 4.56 1.05e-05 0.0055 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23113058 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs6969733 ENSG00000226816.2 AC005082.12 4.56 1.05e-05 0.0055 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23128758 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs4440529 ENSG00000226816.2 AC005082.12 4.56 1.05e-05 0.0055 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23129132 chr7:23206013~23208045:+ PAAD cis rs858239 0.571 rs6953020 ENSG00000226816.2 AC005082.12 4.56 1.05e-05 0.0055 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23132513 chr7:23206013~23208045:+ PAAD cis rs7829975 0.522 rs6601689 ENSG00000253981.4 ALG1L13P 4.56 1.05e-05 0.00551 0.4 0.35 Mood instability; chr8:8314761 chr8:8236003~8244667:- PAAD cis rs4355801 0.536 rs3103995 ENSG00000281641.1 SAMD12-AS1 4.56 1.05e-05 0.00551 0.36 0.35 Bone mineral density; chr8:118860712 chr8:118621001~118858218:+ PAAD cis rs9309711 0.506 rs9284794 ENSG00000225234.1 TRAPPC12-AS1 -4.56 1.05e-05 0.00551 -0.37 -0.35 Neurofibrillary tangles; chr2:3488281 chr2:3481242~3482409:- PAAD cis rs9322193 0.607 rs4869755 ENSG00000268592.3 RAET1E-AS1 4.56 1.05e-05 0.00551 0.47 0.35 Lung cancer; chr6:149886347 chr6:149863494~149919507:+ PAAD cis rs9322193 0.639 rs4869756 ENSG00000268592.3 RAET1E-AS1 4.56 1.05e-05 0.00551 0.47 0.35 Lung cancer; chr6:149886360 chr6:149863494~149919507:+ PAAD cis rs7567389 0.51 rs6755028 ENSG00000236682.1 AC068282.3 4.56 1.05e-05 0.00552 0.47 0.35 Self-rated health; chr2:127437866 chr2:127389130~127400580:+ PAAD cis rs321358 0.945 rs10502129 ENSG00000271390.1 RP11-89C3.3 4.56 1.05e-05 0.00552 0.53 0.35 Body mass index; chr11:111107405 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs10502130 ENSG00000271390.1 RP11-89C3.3 4.56 1.05e-05 0.00552 0.53 0.35 Body mass index; chr11:111107437 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs73017109 ENSG00000271390.1 RP11-89C3.3 4.56 1.05e-05 0.00552 0.53 0.35 Body mass index; chr11:111108484 chr11:111089870~111090368:- PAAD cis rs321358 0.887 rs1470537 ENSG00000271390.1 RP11-89C3.3 4.56 1.05e-05 0.00552 0.53 0.35 Body mass index; chr11:111109328 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs12421769 ENSG00000271390.1 RP11-89C3.3 4.56 1.05e-05 0.00552 0.53 0.35 Body mass index; chr11:111109500 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs73017114 ENSG00000271390.1 RP11-89C3.3 4.56 1.05e-05 0.00552 0.53 0.35 Body mass index; chr11:111111582 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs17458493 ENSG00000271390.1 RP11-89C3.3 4.56 1.05e-05 0.00552 0.53 0.35 Body mass index; chr11:111112156 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs17458541 ENSG00000271390.1 RP11-89C3.3 4.56 1.05e-05 0.00552 0.53 0.35 Body mass index; chr11:111113182 chr11:111089870~111090368:- PAAD cis rs919433 0.963 rs12617117 ENSG00000231621.1 AC013264.2 4.56 1.05e-05 0.00552 0.34 0.35 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197290446 chr2:197197991~197199273:+ PAAD cis rs11723261 0.621 rs6599306 ENSG00000275426.1 CH17-262A2.1 -4.56 1.05e-05 0.00552 -0.54 -0.35 Immune response to smallpox vaccine (IL-6); chr4:149655 chr4:149738~150317:+ PAAD cis rs42490 0.652 rs374957 ENSG00000251136.7 RP11-37B2.1 -4.56 1.05e-05 0.00552 -0.32 -0.35 Leprosy; chr8:89825402 chr8:89609409~89757727:- PAAD cis rs8062405 0.625 rs8060365 ENSG00000251417.2 RP11-1348G14.4 4.56 1.05e-05 0.00553 0.33 0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28899988 chr16:28802743~28817828:+ PAAD cis rs8062405 0.698 rs8046545 ENSG00000251417.2 RP11-1348G14.4 4.56 1.05e-05 0.00553 0.33 0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28903896 chr16:28802743~28817828:+ PAAD cis rs8062405 0.698 rs10499 ENSG00000251417.2 RP11-1348G14.4 4.56 1.05e-05 0.00553 0.33 0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28904206 chr16:28802743~28817828:+ PAAD cis rs9918079 0.56 rs7685083 ENSG00000273133.1 RP11-799M12.2 4.56 1.05e-05 0.00553 0.41 0.35 Obesity-related traits; chr4:15609148 chr4:15563698~15564253:- PAAD cis rs9918079 0.56 rs13147590 ENSG00000273133.1 RP11-799M12.2 4.56 1.05e-05 0.00553 0.41 0.35 Obesity-related traits; chr4:15619565 chr4:15563698~15564253:- PAAD cis rs79040073 0.637 rs77813839 ENSG00000259531.2 RP11-295H24.3 4.56 1.05e-05 0.00553 0.59 0.35 Lung cancer in ever smokers; chr15:49172799 chr15:49365124~49366685:- PAAD cis rs3738443 0.594 rs6664697 ENSG00000259865.1 RP11-488L18.10 -4.56 1.05e-05 0.00553 -0.3 -0.35 Alcohol dependence; chr1:247217308 chr1:247187281~247188526:- PAAD cis rs2599510 0.703 rs762023 ENSG00000276334.1 AL133243.1 4.56 1.05e-05 0.00553 0.42 0.35 Interleukin-18 levels; chr2:32488103 chr2:32521927~32523547:+ PAAD cis rs9287719 0.967 rs6744599 ENSG00000234818.1 AC092687.5 -4.56 1.05e-05 0.00553 -0.39 -0.35 Prostate cancer; chr2:10606887 chr2:10589166~10604830:+ PAAD cis rs7829975 0.511 rs2980512 ENSG00000253981.4 ALG1L13P 4.56 1.05e-05 0.00553 0.44 0.35 Mood instability; chr8:8283379 chr8:8236003~8244667:- PAAD cis rs7829975 0.539 rs35571782 ENSG00000253981.4 ALG1L13P 4.56 1.05e-05 0.00553 0.44 0.35 Mood instability; chr8:8284301 chr8:8236003~8244667:- PAAD cis rs9494145 0.68 rs4895441 ENSG00000232876.1 CTA-212D2.2 4.56 1.05e-05 0.00553 0.43 0.35 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135105435 chr6:135055033~135060550:+ PAAD cis rs7773456 0.74 rs4140625 ENSG00000228412.5 RP4-625H18.2 -4.56 1.05e-05 0.00554 -0.47 -0.35 Lupus nephritis in systemic lupus erythematosus; chr6:19818109 chr6:19802164~19804752:- PAAD cis rs35160687 0.623 rs2276625 ENSG00000273080.1 RP11-301O19.1 4.56 1.05e-05 0.00554 0.4 0.35 Night sleep phenotypes; chr2:86254712 chr2:86195590~86196049:+ PAAD cis rs2253762 0.507 rs12264894 ENSG00000276742.1 RP11-500G22.4 4.56 1.06e-05 0.00554 0.48 0.35 Breast cancer; chr10:121992087 chr10:121956782~121957098:+ PAAD cis rs2253762 0.507 rs10159582 ENSG00000276742.1 RP11-500G22.4 4.56 1.06e-05 0.00554 0.48 0.35 Breast cancer; chr10:121993110 chr10:121956782~121957098:+ PAAD cis rs2253762 0.507 rs10159583 ENSG00000276742.1 RP11-500G22.4 4.56 1.06e-05 0.00554 0.48 0.35 Breast cancer; chr10:121993154 chr10:121956782~121957098:+ PAAD cis rs2253762 0.507 rs75383663 ENSG00000276742.1 RP11-500G22.4 4.56 1.06e-05 0.00554 0.48 0.35 Breast cancer; chr10:121993340 chr10:121956782~121957098:+ PAAD cis rs2253762 0.507 rs10159998 ENSG00000276742.1 RP11-500G22.4 4.56 1.06e-05 0.00554 0.48 0.35 Breast cancer; chr10:121994550 chr10:121956782~121957098:+ PAAD cis rs2253762 0.54 rs11200311 ENSG00000276742.1 RP11-500G22.4 4.56 1.06e-05 0.00554 0.48 0.35 Breast cancer; chr10:121995094 chr10:121956782~121957098:+ PAAD cis rs2253762 0.54 rs79069897 ENSG00000276742.1 RP11-500G22.4 4.56 1.06e-05 0.00554 0.48 0.35 Breast cancer; chr10:121995680 chr10:121956782~121957098:+ PAAD cis rs2253762 0.54 rs77032313 ENSG00000276742.1 RP11-500G22.4 4.56 1.06e-05 0.00554 0.48 0.35 Breast cancer; chr10:121995687 chr10:121956782~121957098:+ PAAD cis rs2253762 0.54 rs10159634 ENSG00000276742.1 RP11-500G22.4 -4.56 1.06e-05 0.00554 -0.48 -0.35 Breast cancer; chr10:121994520 chr10:121956782~121957098:+ PAAD cis rs9918079 0.56 rs10008975 ENSG00000273133.1 RP11-799M12.2 -4.56 1.06e-05 0.00555 -0.41 -0.35 Obesity-related traits; chr4:15622948 chr4:15563698~15564253:- PAAD cis rs9918079 0.56 rs7438356 ENSG00000273133.1 RP11-799M12.2 -4.56 1.06e-05 0.00555 -0.41 -0.35 Obesity-related traits; chr4:15623147 chr4:15563698~15564253:- PAAD cis rs9918079 0.542 rs6414765 ENSG00000273133.1 RP11-799M12.2 -4.56 1.06e-05 0.00555 -0.41 -0.35 Obesity-related traits; chr4:15624870 chr4:15563698~15564253:- PAAD cis rs9918079 0.56 rs4698402 ENSG00000273133.1 RP11-799M12.2 -4.56 1.06e-05 0.00555 -0.41 -0.35 Obesity-related traits; chr4:15628180 chr4:15563698~15564253:- PAAD cis rs9918079 0.56 rs7662032 ENSG00000273133.1 RP11-799M12.2 -4.56 1.06e-05 0.00555 -0.41 -0.35 Obesity-related traits; chr4:15633791 chr4:15563698~15564253:- PAAD cis rs9918079 0.56 rs12651550 ENSG00000273133.1 RP11-799M12.2 -4.56 1.06e-05 0.00555 -0.41 -0.35 Obesity-related traits; chr4:15639395 chr4:15563698~15564253:- PAAD cis rs9918079 0.506 rs7696127 ENSG00000273133.1 RP11-799M12.2 -4.56 1.06e-05 0.00555 -0.41 -0.35 Obesity-related traits; chr4:15641330 chr4:15563698~15564253:- PAAD cis rs2348418 0.733 rs2169752 ENSG00000247934.4 RP11-967K21.1 -4.56 1.06e-05 0.00555 -0.35 -0.35 Lung function (FEV1);Lung function (FVC); chr12:28239279 chr12:28163298~28190738:- PAAD cis rs730566 0.714 rs2889854 ENSG00000229759.1 MRPS18AP1 4.56 1.06e-05 0.00555 0.46 0.35 Prion diseases; chr3:48227019 chr3:48256350~48256938:- PAAD cis rs875971 0.964 rs12668936 ENSG00000237310.1 GS1-124K5.4 4.56 1.06e-05 0.00555 0.34 0.35 Aortic root size; chr7:66449417 chr7:66493706~66495474:+ PAAD cis rs1823913 0.599 rs1823912 ENSG00000280083.1 RP11-317J9.1 -4.56 1.06e-05 0.00556 -0.4 -0.35 Obesity-related traits; chr2:191266388 chr2:191154118~191156070:- PAAD cis rs732716 0.889 rs11666856 ENSG00000267769.1 CTB-50L17.9 -4.56 1.06e-05 0.00556 -0.45 -0.35 Mean corpuscular volume; chr19:4437453 chr19:4454014~4455286:+ PAAD cis rs6991838 0.673 rs7462352 ENSG00000200714.1 Y_RNA 4.56 1.06e-05 0.00556 0.4 0.35 Intelligence (multi-trait analysis); chr8:65584378 chr8:65592731~65592820:+ PAAD cis rs858239 0.699 rs858260 ENSG00000226816.2 AC005082.12 4.56 1.06e-05 0.00556 0.4 0.35 Cerebrospinal fluid biomarker levels; chr7:23173315 chr7:23206013~23208045:+ PAAD cis rs2564921 0.73 rs1811351 ENSG00000242142.1 SERBP1P3 -4.56 1.06e-05 0.00557 -0.44 -0.35 Height; chr3:53064759 chr3:53064283~53065091:- PAAD cis rs8062405 0.755 rs12447461 ENSG00000251417.2 RP11-1348G14.4 -4.56 1.06e-05 0.00558 -0.32 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28571620 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs111693583 ENSG00000251417.2 RP11-1348G14.4 -4.56 1.06e-05 0.00558 -0.32 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28572289 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs55792032 ENSG00000251417.2 RP11-1348G14.4 -4.56 1.06e-05 0.00558 -0.32 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28588090 chr16:28802743~28817828:+ PAAD cis rs694739 0.541 rs61886926 ENSG00000236935.1 AP003774.1 4.56 1.07e-05 0.00559 0.36 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64366080 chr11:64325050~64329504:- PAAD cis rs694739 0.628 rs617051 ENSG00000236935.1 AP003774.1 4.56 1.07e-05 0.00559 0.36 0.35 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64366166 chr11:64325050~64329504:- PAAD cis rs9368481 0.672 rs3931463 ENSG00000241549.7 GUSBP2 4.56 1.07e-05 0.00559 0.37 0.35 Autism spectrum disorder or schizophrenia; chr6:26972018 chr6:26871484~26956554:- PAAD cis rs216345 0.7 rs307660 ENSG00000230074.1 RP11-195F19.9 -4.56 1.07e-05 0.00559 -0.46 -0.35 Bipolar disorder; chr9:33942932 chr9:34665665~34681298:+ PAAD cis rs6570726 0.846 rs446031 ENSG00000235652.6 RP11-545I5.3 4.55 1.07e-05 0.0056 0.28 0.35 Lobe attachment (rater-scored or self-reported); chr6:145564456 chr6:145799409~145886585:+ PAAD cis rs7727544 0.735 rs273913 ENSG00000233006.5 AC034220.3 4.55 1.07e-05 0.0056 0.29 0.35 Blood metabolite levels; chr5:132325463 chr5:132311285~132369916:- PAAD cis rs6480314 0.522 rs80326649 ENSG00000233590.1 RP11-153K11.3 -4.55 1.07e-05 0.00561 -0.58 -0.35 Optic nerve measurement (disc area); chr10:68285667 chr10:68233251~68242379:- PAAD cis rs17123764 0.71 rs2278068 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49550805 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs7953911 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49554717 chr12:49442424~49442652:- PAAD cis rs17123764 0.892 rs13906 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49558611 chr12:49442424~49442652:- PAAD cis rs17123764 1 rs73305012 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49568854 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs12311839 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49569622 chr12:49442424~49442652:- PAAD cis rs17123764 1 rs11169069 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49572751 chr12:49442424~49442652:- PAAD cis rs17123764 0.71 rs12320556 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49579228 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs7973389 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49586962 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs876889 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49589595 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs11169082 ENSG00000257464.1 RP11-161H23.8 -4.55 1.07e-05 0.00562 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49591625 chr12:49442424~49442652:- PAAD cis rs7572733 0.534 rs11890137 ENSG00000231621.1 AC013264.2 -4.55 1.07e-05 0.00562 -0.35 -0.35 Dermatomyositis; chr2:197951938 chr2:197197991~197199273:+ PAAD cis rs2274273 0.837 rs11625968 ENSG00000258413.1 RP11-665C16.6 -4.55 1.07e-05 0.00562 -0.43 -0.35 Protein biomarker; chr14:55334286 chr14:55262767~55272075:- PAAD cis rs875971 0.522 rs1617484 ENSG00000234585.5 CCT6P3 4.55 1.07e-05 0.00563 0.28 0.35 Aortic root size; chr7:65998108 chr7:65038354~65074713:+ PAAD cis rs1185460 0.904 rs1003081 ENSG00000271751.1 RP11-110I1.14 4.55 1.07e-05 0.00563 0.45 0.35 Coronary artery disease; chr11:119043282 chr11:119065263~119065677:- PAAD cis rs9531006 0.636 rs11843138 ENSG00000227676.3 LINC01068 -4.55 1.07e-05 0.00563 -0.54 -0.35 Sleep duration; chr13:79910289 chr13:79566727~79571436:+ PAAD cis rs2832077 0.689 rs2832052 ENSG00000176054.6 RPL23P2 -4.55 1.08e-05 0.00563 -0.38 -0.35 Cognitive test performance; chr21:28757751 chr21:28997613~28998033:- PAAD cis rs58873874 0.737 rs11746314 ENSG00000251405.2 CTB-109A12.1 4.55 1.08e-05 0.00564 0.76 0.35 Bipolar disorder (body mass index interaction); chr5:157325949 chr5:157362615~157460078:- PAAD cis rs9494145 0.648 rs7758845 ENSG00000232876.1 CTA-212D2.2 -4.55 1.08e-05 0.00564 -0.43 -0.35 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135107399 chr6:135055033~135060550:+ PAAD cis rs2188561 0.697 rs739518 ENSG00000241764.3 AC002467.7 4.55 1.08e-05 0.00564 0.44 0.35 Alcohol consumption; chr7:107743682 chr7:107742817~107744581:- PAAD cis rs4604732 0.536 rs12058821 ENSG00000227135.1 GCSAML-AS1 -4.55 1.08e-05 0.00564 -0.52 -0.35 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247486349 chr1:247524679~247526752:- PAAD cis rs11098499 0.562 rs13101722 ENSG00000248280.1 RP11-33B1.2 -4.55 1.08e-05 0.00564 -0.33 -0.35 Corneal astigmatism; chr4:119634820 chr4:119440561~119450157:- PAAD cis rs2337406 0.789 rs9324095 ENSG00000211974.3 IGHV2-70 -4.55 1.08e-05 0.00565 -0.45 -0.35 Alzheimer's disease (late onset); chr14:106795885 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs58154560 ENSG00000211974.3 IGHV2-70 -4.55 1.08e-05 0.00565 -0.45 -0.35 Alzheimer's disease (late onset); chr14:106799601 chr14:106723574~106724093:- PAAD cis rs4664293 0.667 rs6432562 ENSG00000226266.5 AC009961.3 -4.55 1.08e-05 0.00565 -0.42 -0.35 Monocyte percentage of white cells; chr2:159791495 chr2:159670708~159712435:- PAAD cis rs7712401 0.601 rs448505 ENSG00000263432.2 RN7SL689P -4.55 1.08e-05 0.00565 -0.45 -0.35 Mean platelet volume; chr5:123000995 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs2164773 ENSG00000263432.2 RN7SL689P -4.55 1.08e-05 0.00565 -0.45 -0.35 Mean platelet volume; chr5:123003222 chr5:123022487~123022783:- PAAD cis rs950880 0.71 rs17027006 ENSG00000234389.1 AC007278.3 4.55 1.08e-05 0.00565 0.35 0.35 Serum protein levels (sST2); chr2:102348872 chr2:102438713~102440475:+ PAAD cis rs11662586 1 rs8093291 ENSG00000267270.4 PARD6G-AS1 -4.55 1.08e-05 0.00566 -0.47 -0.35 Exploratory eye movement dysfunction in schizophrenia (responsive search score); chr18:79941294 chr18:80147924~80178432:+ PAAD cis rs3781264 0.557 rs10882437 ENSG00000273450.1 RP11-76P2.4 4.55 1.08e-05 0.00566 0.46 0.35 Esophageal cancer and gastric cancer; chr10:94362073 chr10:94314907~94315327:- PAAD cis rs8100891 0.506 rs10408437 ENSG00000267213.4 AC007773.2 -4.55 1.08e-05 0.00566 -0.56 -0.35 Neuroticism; chr19:32497094 chr19:32390050~32405560:- PAAD cis rs10510102 0.935 rs12243529 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121880321 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12250677 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121880575 chr10:121956782~121957098:+ PAAD cis rs10510102 0.872 rs12243874 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121880788 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs7921873 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121881736 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12258426 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121882189 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12266380 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121882559 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200212 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121883145 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs11200213 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121883228 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs12247749 ENSG00000276742.1 RP11-500G22.4 4.55 1.08e-05 0.00566 0.51 0.35 Breast cancer; chr10:121884196 chr10:121956782~121957098:+ PAAD cis rs748404 0.697 rs513970 ENSG00000249839.1 AC011330.5 -4.55 1.08e-05 0.00566 -0.49 -0.35 Lung cancer; chr15:43287368 chr15:43663654~43684339:- PAAD cis rs4938303 0.589 rs11601584 ENSG00000254851.1 RP11-109L13.1 4.55 1.09e-05 0.00567 0.49 0.35 Triglycerides; chr11:116700568 chr11:117135528~117138582:+ PAAD cis rs4938303 0.589 rs11216100 ENSG00000254851.1 RP11-109L13.1 4.55 1.09e-05 0.00567 0.49 0.35 Triglycerides; chr11:116701814 chr11:117135528~117138582:+ PAAD cis rs35160687 0.509 rs13024436 ENSG00000273080.1 RP11-301O19.1 -4.55 1.09e-05 0.00567 -0.41 -0.35 Night sleep phenotypes; chr2:86307398 chr2:86195590~86196049:+ PAAD cis rs35160687 0.509 rs35723061 ENSG00000273080.1 RP11-301O19.1 -4.55 1.09e-05 0.00567 -0.41 -0.35 Night sleep phenotypes; chr2:86321965 chr2:86195590~86196049:+ PAAD cis rs35160687 0.545 rs1863050 ENSG00000273080.1 RP11-301O19.1 -4.55 1.09e-05 0.00567 -0.41 -0.35 Night sleep phenotypes; chr2:86331253 chr2:86195590~86196049:+ PAAD cis rs9368481 0.761 rs7775041 ENSG00000241549.7 GUSBP2 -4.55 1.09e-05 0.00567 -0.36 -0.35 Autism spectrum disorder or schizophrenia; chr6:27041733 chr6:26871484~26956554:- PAAD cis rs7923609 0.811 rs12245367 ENSG00000232075.1 MRPL35P2 4.55 1.09e-05 0.00567 0.41 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63561704 chr10:63634317~63634827:- PAAD cis rs7923609 0.811 rs7899657 ENSG00000232075.1 MRPL35P2 4.55 1.09e-05 0.00567 0.41 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63563505 chr10:63634317~63634827:- PAAD cis rs7923609 0.783 rs4746203 ENSG00000232075.1 MRPL35P2 4.55 1.09e-05 0.00567 0.41 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63564237 chr10:63634317~63634827:- PAAD cis rs7923609 0.811 rs10822181 ENSG00000232075.1 MRPL35P2 4.55 1.09e-05 0.00567 0.41 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63565366 chr10:63634317~63634827:- PAAD cis rs7923609 0.811 rs4746204 ENSG00000232075.1 MRPL35P2 4.55 1.09e-05 0.00567 0.41 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63568758 chr10:63634317~63634827:- PAAD cis rs7923609 0.783 rs7907451 ENSG00000232075.1 MRPL35P2 4.55 1.09e-05 0.00567 0.41 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63568980 chr10:63634317~63634827:- PAAD cis rs7923609 0.783 rs7100409 ENSG00000232075.1 MRPL35P2 4.55 1.09e-05 0.00567 0.41 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63570435 chr10:63634317~63634827:- PAAD cis rs7923609 0.703 rs7100413 ENSG00000232075.1 MRPL35P2 4.55 1.09e-05 0.00567 0.41 0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63570448 chr10:63634317~63634827:- PAAD cis rs6504950 0.886 rs2787500 ENSG00000275710.1 RP11-257O5.4 -4.55 1.09e-05 0.00567 -0.42 -0.35 Breast cancer; chr17:55092445 chr17:54964474~54964679:+ PAAD cis rs8062405 0.691 rs743590 ENSG00000251417.2 RP11-1348G14.4 -4.55 1.09e-05 0.00568 -0.32 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28596909 chr16:28802743~28817828:+ PAAD cis rs3813579 0.606 rs3813583 ENSG00000261390.4 RP11-345M22.2 -4.55 1.09e-05 0.00569 -0.46 -0.35 Thyroid volume; chr16:79721183 chr16:79715232~79770563:- PAAD cis rs2946504 0.861 rs2946497 ENSG00000251468.2 RP11-369K16.1 -4.55 1.09e-05 0.00569 -0.43 -0.35 Type 2 diabetes; chr8:12960804 chr8:12958387~12962200:+ PAAD cis rs8059260 0.673 rs8056854 ENSG00000274038.1 RP11-66H6.4 -4.55 1.09e-05 0.0057 -0.66 -0.35 Alcohol consumption over the past year; chr16:10947858 chr16:11056556~11057034:+ PAAD cis rs10510102 0.935 rs10510101 ENSG00000276742.1 RP11-500G22.4 4.55 1.09e-05 0.0057 0.51 0.35 Breast cancer; chr10:121898614 chr10:121956782~121957098:+ PAAD cis rs10510102 0.935 rs7906667 ENSG00000276742.1 RP11-500G22.4 4.55 1.09e-05 0.0057 0.51 0.35 Breast cancer; chr10:121909142 chr10:121956782~121957098:+ PAAD cis rs10028773 0.546 rs13117947 ENSG00000248280.1 RP11-33B1.2 4.55 1.09e-05 0.0057 0.31 0.35 Educational attainment; chr4:119335905 chr4:119440561~119450157:- PAAD cis rs4950322 0.518 rs61838951 ENSG00000278811.3 LINC00624 4.55 1.09e-05 0.00571 0.34 0.35 Protein quantitative trait loci; chr1:147116081 chr1:147258885~147517875:- PAAD cis rs1930961 1 rs59226697 ENSG00000100058.11 CRYBB2P1 4.55 1.09e-05 0.00571 0.75 0.35 Bipolar disorder with mood-incongruent psychosis; chr22:25474070 chr22:25448105~25520854:+ PAAD cis rs2115630 0.905 rs1975277 ENSG00000225151.9 GOLGA2P7 4.55 1.1e-05 0.00571 0.39 0.35 P wave terminal force; chr15:84786327 chr15:84199311~84230136:- PAAD cis rs61270009 0.955 rs12657757 ENSG00000247828.6 TMEM161B-AS1 -4.55 1.1e-05 0.00571 -0.27 -0.35 Depressive symptoms; chr5:88280952 chr5:88268895~88436685:+ PAAD cis rs780094 0.544 rs780108 ENSG00000234072.1 AC074117.10 -4.55 1.1e-05 0.00571 -0.28 -0.35 Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels; chr2:27462090 chr2:27356246~27367622:+ PAAD cis rs853679 0.699 rs9468318 ENSG00000226314.6 ZNF192P1 -4.55 1.1e-05 0.00572 -0.55 -0.35 Depression; chr6:28241753 chr6:28161781~28169594:+ PAAD cis rs2729354 0.817 rs2250673 ENSG00000265566.2 RN7SL605P -4.55 1.1e-05 0.00572 -0.42 -0.35 Blood protein levels; chr11:57500697 chr11:57528085~57528365:- PAAD cis rs9847710 0.545 rs2952830 ENSG00000242142.1 SERBP1P3 4.55 1.1e-05 0.00572 0.46 0.35 Ulcerative colitis; chr3:52948280 chr3:53064283~53065091:- PAAD cis rs7615952 0.611 rs78137633 ENSG00000171084.14 FAM86JP 4.55 1.1e-05 0.00572 0.73 0.35 Blood pressure (smoking interaction); chr3:126056218 chr3:125916620~125930024:+ PAAD cis rs308403 0.509 rs13122636 ENSG00000224786.1 CETN4P 4.55 1.1e-05 0.00572 0.41 0.35 Blood protein levels; chr4:122749890 chr4:122730548~122732193:- PAAD cis rs780094 0.544 rs2303370 ENSG00000234072.1 AC074117.10 -4.55 1.1e-05 0.00572 -0.27 -0.35 Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels; chr2:27428508 chr2:27356246~27367622:+ PAAD cis rs4268898 0.931 rs55642516 ENSG00000242628.4 AC009228.1 4.55 1.1e-05 0.00572 0.42 0.35 Asthma; chr2:24279436 chr2:24214381~24221516:+ PAAD cis rs4268898 0.931 rs34504814 ENSG00000242628.4 AC009228.1 4.55 1.1e-05 0.00572 0.42 0.35 Asthma; chr2:24280897 chr2:24214381~24221516:+ PAAD cis rs7712401 0.601 rs442427 ENSG00000263432.2 RN7SL689P -4.55 1.1e-05 0.00573 -0.45 -0.35 Mean platelet volume; chr5:122986570 chr5:123022487~123022783:- PAAD cis rs710913 0.618 rs12030495 ENSG00000237624.1 OXCT2P1 4.55 1.1e-05 0.00573 0.42 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39623923 chr1:39514956~39516490:+ PAAD cis rs12571093 0.541 rs7893837 ENSG00000233590.1 RP11-153K11.3 -4.55 1.1e-05 0.00575 -0.57 -0.35 Optic nerve measurement (disc area); chr10:68295578 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs11816028 ENSG00000233590.1 RP11-153K11.3 -4.55 1.1e-05 0.00575 -0.57 -0.35 Optic nerve measurement (disc area); chr10:68296566 chr10:68233251~68242379:- PAAD cis rs12134133 1 rs7526831 ENSG00000274245.1 RP11-357P18.2 4.55 1.1e-05 0.00575 0.57 0.35 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207265261 chr1:207372559~207373252:+ PAAD cis rs858239 0.6 rs28483572 ENSG00000226816.2 AC005082.12 4.55 1.1e-05 0.00575 0.38 0.35 Cerebrospinal fluid biomarker levels; chr7:23092166 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6961406 ENSG00000226816.2 AC005082.12 4.55 1.1e-05 0.00575 0.38 0.35 Cerebrospinal fluid biomarker levels; chr7:23095272 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6461690 ENSG00000226816.2 AC005082.12 4.55 1.1e-05 0.00575 0.38 0.35 Cerebrospinal fluid biomarker levels; chr7:23095915 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6967419 ENSG00000226816.2 AC005082.12 4.55 1.1e-05 0.00575 0.38 0.35 Cerebrospinal fluid biomarker levels; chr7:23096691 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs1468592 ENSG00000226816.2 AC005082.12 -4.55 1.1e-05 0.00575 -0.38 -0.35 Cerebrospinal fluid biomarker levels; chr7:23101028 chr7:23206013~23208045:+ PAAD cis rs17123764 1 rs7131915 ENSG00000257464.1 RP11-161H23.8 -4.55 1.1e-05 0.00575 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49573877 chr12:49442424~49442652:- PAAD cis rs4722166 0.532 rs4719711 ENSG00000179428.2 AC073072.5 4.55 1.1e-05 0.00575 0.31 0.35 Lung cancer; chr7:22716069 chr7:22725395~22727620:- PAAD cis rs9494145 0.68 rs35959442 ENSG00000232876.1 CTA-212D2.2 -4.55 1.11e-05 0.00576 -0.43 -0.35 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135103041 chr6:135055033~135060550:+ PAAD cis rs7429990 1 rs319680 ENSG00000228638.1 FCF1P2 -4.55 1.11e-05 0.00576 -0.41 -0.35 Educational attainment (years of education); chr3:47856817 chr3:48290793~48291375:- PAAD cis rs7429990 1 rs7429990 ENSG00000228638.1 FCF1P2 -4.55 1.11e-05 0.00576 -0.41 -0.35 Educational attainment (years of education); chr3:47860313 chr3:48290793~48291375:- PAAD cis rs4268898 0.931 rs2551121 ENSG00000242628.4 AC009228.1 4.55 1.11e-05 0.00577 0.42 0.35 Asthma; chr2:24317098 chr2:24214381~24221516:+ PAAD cis rs2412819 0.597 rs514311 ENSG00000205771.5 CATSPER2P1 -4.55 1.11e-05 0.00577 -0.51 -0.35 Lung cancer; chr15:43869376 chr15:43726918~43747094:- PAAD cis rs7572733 0.534 rs1518361 ENSG00000231621.1 AC013264.2 -4.55 1.11e-05 0.00577 -0.35 -0.35 Dermatomyositis; chr2:197948150 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1464211 ENSG00000231621.1 AC013264.2 -4.55 1.11e-05 0.00578 -0.35 -0.35 Dermatomyositis; chr2:197933906 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1607375 ENSG00000231621.1 AC013264.2 -4.55 1.11e-05 0.00578 -0.35 -0.35 Dermatomyositis; chr2:197935663 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1607374 ENSG00000231621.1 AC013264.2 -4.55 1.11e-05 0.00578 -0.35 -0.35 Dermatomyositis; chr2:197935716 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs4369854 ENSG00000231621.1 AC013264.2 -4.55 1.11e-05 0.00578 -0.35 -0.35 Dermatomyositis; chr2:197935906 chr2:197197991~197199273:+ PAAD cis rs73110464 0.609 rs727266 ENSG00000278185.1 RP11-153F5.7 4.55 1.11e-05 0.00578 0.46 0.35 Cancer (pleiotropy); chr12:52962627 chr12:52946614~52947125:- PAAD cis rs7829975 0.511 rs2980426 ENSG00000173295.6 FAM86B3P 4.55 1.11e-05 0.00579 0.38 0.35 Mood instability; chr8:8288087 chr8:8228595~8244865:+ PAAD cis rs7826238 0.526 rs876955 ENSG00000253893.2 FAM85B -4.55 1.11e-05 0.00579 -0.5 -0.35 Systolic blood pressure; chr8:8453374 chr8:8167819~8226614:- PAAD cis rs2117029 1 rs11168827 ENSG00000258017.1 RP11-386G11.10 4.55 1.11e-05 0.00579 0.45 0.35 Intelligence (multi-trait analysis); chr12:49025894 chr12:49127782~49147869:+ PAAD cis rs807029 0.533 rs722435 ENSG00000272572.1 RP11-179B2.2 -4.54 1.11e-05 0.0058 -0.42 -0.35 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100985305 chr10:100911103~100912739:- PAAD cis rs62381364 1 rs62381364 ENSG00000240250.3 RN7SL541P 4.54 1.11e-05 0.0058 0.72 0.35 Eosinophil counts; chr5:134284275 chr5:134517810~134518092:+ PAAD cis rs2902193 0.589 rs11151485 ENSG00000267325.1 LINC01415 4.54 1.11e-05 0.0058 0.33 0.35 Cancer; chr18:56000856 chr18:55776727~55781721:- PAAD cis rs2239557 0.581 rs12100961 ENSG00000259065.1 RP5-1021I20.1 -4.54 1.11e-05 0.0058 -0.45 -0.35 Common traits (Other); chr14:73815667 chr14:73787360~73803270:+ PAAD cis rs1729407 0.741 rs1263177 ENSG00000254851.1 RP11-109L13.1 -4.54 1.11e-05 0.0058 -0.42 -0.35 Apolipoprotein A-IV levels; chr11:116819996 chr11:117135528~117138582:+ PAAD cis rs807029 0.533 rs67813203 ENSG00000272572.1 RP11-179B2.2 -4.54 1.12e-05 0.0058 -0.42 -0.35 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100978794 chr10:100911103~100912739:- PAAD cis rs807029 0.533 rs2295716 ENSG00000272572.1 RP11-179B2.2 -4.54 1.12e-05 0.0058 -0.42 -0.35 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100984457 chr10:100911103~100912739:- PAAD cis rs2337406 0.636 rs74090069 ENSG00000211974.3 IGHV2-70 -4.54 1.12e-05 0.00581 -0.45 -0.35 Alzheimer's disease (late onset); chr14:106777532 chr14:106723574~106724093:- PAAD cis rs2337406 0.866 rs74090071 ENSG00000211974.3 IGHV2-70 -4.54 1.12e-05 0.00581 -0.45 -0.35 Alzheimer's disease (late onset); chr14:106777533 chr14:106723574~106724093:- PAAD cis rs11976180 1 rs11975942 ENSG00000273234.1 OR2A13P -4.54 1.12e-05 0.00582 -0.43 -0.35 Obesity-related traits; chr7:144043487 chr7:144142009~144142938:+ PAAD cis rs11159086 0.793 rs28612392 ENSG00000259005.1 RP3-449M8.6 4.54 1.12e-05 0.00582 0.46 0.35 Advanced glycation end-product levels; chr14:74467894 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs1029703 ENSG00000259005.1 RP3-449M8.6 4.54 1.12e-05 0.00582 0.46 0.35 Advanced glycation end-product levels; chr14:74473899 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs12432412 ENSG00000259005.1 RP3-449M8.6 4.54 1.12e-05 0.00582 0.46 0.35 Advanced glycation end-product levels; chr14:74474294 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs1029700 ENSG00000259005.1 RP3-449M8.6 4.54 1.12e-05 0.00582 0.46 0.35 Advanced glycation end-product levels; chr14:74474309 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs1029699 ENSG00000259005.1 RP3-449M8.6 4.54 1.12e-05 0.00582 0.46 0.35 Advanced glycation end-product levels; chr14:74474790 chr14:74474007~74474864:- PAAD cis rs11159086 0.729 rs8015872 ENSG00000259005.1 RP3-449M8.6 4.54 1.12e-05 0.00582 0.46 0.35 Advanced glycation end-product levels; chr14:74475529 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs10147316 ENSG00000259005.1 RP3-449M8.6 4.54 1.12e-05 0.00582 0.46 0.35 Advanced glycation end-product levels; chr14:74475688 chr14:74474007~74474864:- PAAD cis rs2262909 0.962 rs11673195 ENSG00000279377.1 AC003973.3 -4.54 1.12e-05 0.00582 -0.33 -0.35 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22131012 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs73021832 ENSG00000279377.1 AC003973.3 -4.54 1.12e-05 0.00582 -0.33 -0.35 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22133342 chr19:21965708~21968529:- PAAD cis rs755249 0.567 rs72661961 ENSG00000261798.1 RP1-118J21.25 4.54 1.12e-05 0.00583 0.44 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39366096 chr1:39788976~39790171:+ PAAD cis rs755249 0.532 rs61779277 ENSG00000261798.1 RP1-118J21.25 4.54 1.12e-05 0.00583 0.44 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39367863 chr1:39788976~39790171:+ PAAD cis rs755249 0.532 rs61779278 ENSG00000261798.1 RP1-118J21.25 4.54 1.12e-05 0.00583 0.44 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39368945 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs2296172 ENSG00000261798.1 RP1-118J21.25 4.54 1.12e-05 0.00583 0.44 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39370145 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs61779279 ENSG00000261798.1 RP1-118J21.25 4.54 1.12e-05 0.00583 0.44 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39371430 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs76111861 ENSG00000261798.1 RP1-118J21.25 4.54 1.12e-05 0.00583 0.44 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39377018 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs72661965 ENSG00000261798.1 RP1-118J21.25 4.54 1.12e-05 0.00583 0.44 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380918 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs61779284 ENSG00000261798.1 RP1-118J21.25 4.54 1.12e-05 0.00583 0.44 0.35 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39389505 chr1:39788976~39790171:+ PAAD cis rs7208859 0.673 rs28588622 ENSG00000266490.1 CTD-2349P21.9 4.54 1.12e-05 0.00583 0.47 0.35 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30918681 chr17:30792372~30792833:+ PAAD cis rs734999 0.588 rs2843404 ENSG00000225931.3 RP3-395M20.7 -4.54 1.12e-05 0.00583 -0.33 -0.35 Ulcerative colitis; chr1:2599119 chr1:2566410~2569888:+ PAAD cis rs734999 0.55 rs2985855 ENSG00000225931.3 RP3-395M20.7 -4.54 1.12e-05 0.00583 -0.33 -0.35 Ulcerative colitis; chr1:2599933 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs6689711 ENSG00000225931.3 RP3-395M20.7 -4.54 1.12e-05 0.00583 -0.33 -0.35 Ulcerative colitis; chr1:2600028 chr1:2566410~2569888:+ PAAD cis rs6504950 0.566 rs12937360 ENSG00000275710.1 RP11-257O5.4 4.54 1.12e-05 0.00583 0.39 0.35 Breast cancer; chr17:54968937 chr17:54964474~54964679:+ PAAD cis rs6504950 0.566 rs7226272 ENSG00000275710.1 RP11-257O5.4 4.54 1.12e-05 0.00583 0.39 0.35 Breast cancer; chr17:54969086 chr17:54964474~54964679:+ PAAD cis rs6504950 0.566 rs7208403 ENSG00000275710.1 RP11-257O5.4 4.54 1.12e-05 0.00583 0.39 0.35 Breast cancer; chr17:54969306 chr17:54964474~54964679:+ PAAD cis rs801193 0.967 rs34356500 ENSG00000237310.1 GS1-124K5.4 4.54 1.12e-05 0.00584 0.32 0.35 Aortic root size; chr7:66771620 chr7:66493706~66495474:+ PAAD cis rs10510102 0.688 rs56094144 ENSG00000276742.1 RP11-500G22.4 4.54 1.12e-05 0.00584 0.51 0.35 Breast cancer; chr10:121903941 chr10:121956782~121957098:+ PAAD cis rs812925 0.502 rs6545868 ENSG00000273302.1 RP11-493E12.2 -4.54 1.12e-05 0.00584 -0.3 -0.35 Immature fraction of reticulocytes; chr2:61428230 chr2:61199979~61200769:+ PAAD cis rs8062405 0.824 rs4788085 ENSG00000251417.2 RP11-1348G14.4 -4.54 1.13e-05 0.00585 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523682 chr16:28802743~28817828:+ PAAD cis rs8062405 0.824 rs28772958 ENSG00000251417.2 RP11-1348G14.4 -4.54 1.13e-05 0.00585 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28523984 chr16:28802743~28817828:+ PAAD cis rs2348418 0.701 rs6487670 ENSG00000247934.4 RP11-967K21.1 -4.54 1.13e-05 0.00586 -0.35 -0.35 Lung function (FEV1);Lung function (FVC); chr12:28210856 chr12:28163298~28190738:- PAAD cis rs2486288 0.656 rs11637838 ENSG00000259433.2 CTD-2651B20.4 4.54 1.13e-05 0.00586 0.38 0.35 Glomerular filtration rate; chr15:45258459 chr15:45330209~45332634:- PAAD cis rs6921919 0.945 rs7765989 ENSG00000216901.1 AL022393.7 4.54 1.13e-05 0.00586 0.54 0.35 Autism spectrum disorder or schizophrenia; chr6:28432518 chr6:28176188~28176674:+ PAAD cis rs6921919 0.887 rs16894116 ENSG00000216901.1 AL022393.7 4.54 1.13e-05 0.00586 0.54 0.35 Autism spectrum disorder or schizophrenia; chr6:28447190 chr6:28176188~28176674:+ PAAD cis rs17023223 0.537 rs17023185 ENSG00000231365.4 RP11-418J17.1 -4.54 1.13e-05 0.00586 -0.41 -0.35 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119068164 chr1:119140396~119275973:+ PAAD cis rs10888838 0.941 rs11206305 ENSG00000198711.5 SSBP3-AS1 4.54 1.13e-05 0.00586 0.42 0.35 Mitochondrial DNA levels; chr1:54222538 chr1:54236440~54239063:+ PAAD cis rs2562456 0.755 rs1879234 ENSG00000213976.4 CTD-2561J22.2 4.54 1.13e-05 0.00586 0.39 0.35 Pain; chr19:21521677 chr19:21382865~21387177:+ PAAD cis rs4683346 0.616 rs6779561 ENSG00000173811.9 CCDC13-AS1 4.54 1.13e-05 0.00586 0.38 0.35 Granulocyte percentage of myeloid white cells; chr3:42808326 chr3:42732575~42746768:+ PAAD cis rs1185460 0.967 rs11217133 ENSG00000271751.1 RP11-110I1.14 -4.54 1.13e-05 0.00586 -0.44 -0.35 Coronary artery disease; chr11:119057538 chr11:119065263~119065677:- PAAD cis rs2564921 0.704 rs62253649 ENSG00000242142.1 SERBP1P3 -4.54 1.13e-05 0.00587 -0.42 -0.35 Height; chr3:52967831 chr3:53064283~53065091:- PAAD cis rs2564921 0.704 rs57916015 ENSG00000242142.1 SERBP1P3 -4.54 1.13e-05 0.00587 -0.42 -0.35 Height; chr3:52971094 chr3:53064283~53065091:- PAAD cis rs17711722 0.565 rs4275112 ENSG00000237310.1 GS1-124K5.4 -4.54 1.13e-05 0.00587 -0.34 -0.35 Calcium levels; chr7:65733651 chr7:66493706~66495474:+ PAAD cis rs2658782 0.951 rs72972357 ENSG00000279684.1 RP11-755E23.2 4.54 1.13e-05 0.00588 0.58 0.35 Pulmonary function decline; chr11:93385674 chr11:93286629~93288903:- PAAD cis rs732716 0.74 rs78869060 ENSG00000267769.1 CTB-50L17.9 -4.54 1.13e-05 0.00588 -0.45 -0.35 Mean corpuscular volume; chr19:4444745 chr19:4454014~4455286:+ PAAD cis rs2412819 0.597 rs541871 ENSG00000205771.5 CATSPER2P1 -4.54 1.13e-05 0.00588 -0.5 -0.35 Lung cancer; chr15:43868656 chr15:43726918~43747094:- PAAD cis rs6570726 0.967 rs7772286 ENSG00000235652.6 RP11-545I5.3 -4.54 1.13e-05 0.00588 -0.29 -0.35 Lobe attachment (rater-scored or self-reported); chr6:145609287 chr6:145799409~145886585:+ PAAD cis rs6844153 0.752 rs7681462 ENSG00000240005.4 RP11-293A21.1 -4.54 1.13e-05 0.00588 -0.5 -0.35 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26894272 chr4:26859806~26860599:- PAAD cis rs12480328 1 rs17790938 ENSG00000203999.7 LINC01270 4.54 1.14e-05 0.00589 0.75 0.35 Prostate cancer; chr20:50892647 chr20:50292720~50314922:+ PAAD cis rs12908161 0.959 rs3748376 ENSG00000259728.4 LINC00933 4.54 1.14e-05 0.00589 0.44 0.35 Schizophrenia; chr15:84785121 chr15:84570649~84580175:+ PAAD cis rs2658782 0.789 rs2259633 ENSG00000279684.1 RP11-755E23.2 -4.54 1.14e-05 0.0059 -0.58 -0.35 Pulmonary function decline; chr11:93408414 chr11:93286629~93288903:- PAAD cis rs8177376 1 rs563011 ENSG00000254905.1 RP11-712L6.7 -4.54 1.14e-05 0.00591 -0.46 -0.35 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126281527 chr11:126292922~126294254:- PAAD cis rs11893307 0.566 rs10203824 ENSG00000235852.1 AC005540.3 4.54 1.14e-05 0.00591 0.51 0.35 Mean platelet volume; chr2:190731124 chr2:190880797~190882059:- PAAD cis rs4835473 0.932 rs4092718 ENSG00000251600.4 RP11-673E1.1 -4.54 1.14e-05 0.00591 -0.41 -0.35 Immature fraction of reticulocytes; chr4:143799637 chr4:143912331~143982454:+ PAAD cis rs919433 0.963 rs4850786 ENSG00000231621.1 AC013264.2 -4.54 1.14e-05 0.00592 -0.32 -0.35 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197313884 chr2:197197991~197199273:+ PAAD cis rs8062405 0.789 rs240704 ENSG00000251417.2 RP11-1348G14.4 -4.54 1.14e-05 0.00592 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28518628 chr16:28802743~28817828:+ PAAD cis rs8062405 0.824 rs240702 ENSG00000251417.2 RP11-1348G14.4 -4.54 1.14e-05 0.00592 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28520032 chr16:28802743~28817828:+ PAAD cis rs8062405 0.824 rs62034319 ENSG00000251417.2 RP11-1348G14.4 -4.54 1.14e-05 0.00592 -0.3 -0.35 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28520867 chr16:28802743~28817828:+ PAAD cis rs8100891 0.537 rs2012353 ENSG00000267213.4 AC007773.2 -4.54 1.14e-05 0.00592 -0.56 -0.35 Neuroticism; chr19:32408387 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs28562777 ENSG00000267213.4 AC007773.2 -4.54 1.14e-05 0.00592 -0.56 -0.35 Neuroticism; chr19:32409913 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs2302772 ENSG00000267213.4 AC007773.2 -4.54 1.14e-05 0.00592 -0.56 -0.35 Neuroticism; chr19:32411144 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs28672356 ENSG00000267213.4 AC007773.2 -4.54 1.14e-05 0.00592 -0.56 -0.35 Neuroticism; chr19:32416937 chr19:32390050~32405560:- PAAD cis rs8100891 0.537 rs2111504 ENSG00000267213.4 AC007773.2 -4.54 1.14e-05 0.00592 -0.56 -0.35 Neuroticism; chr19:32426549 chr19:32390050~32405560:- PAAD cis rs4835473 0.932 rs34886773 ENSG00000251600.4 RP11-673E1.1 -4.54 1.14e-05 0.00592 -0.39 -0.35 Immature fraction of reticulocytes; chr4:143764678 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs5016160 ENSG00000251600.4 RP11-673E1.1 4.54 1.14e-05 0.00592 0.39 0.35 Immature fraction of reticulocytes; chr4:143738305 chr4:143912331~143982454:+ PAAD cis rs16828019 0.704 rs12743340 ENSG00000235358.1 RP11-399E6.1 4.54 1.14e-05 0.00593 0.73 0.35 Intelligence (multi-trait analysis); chr1:40990360 chr1:41242373~41284861:+ PAAD cis rs10050311 1 rs10050311 ENSG00000251411.1 RP11-397E7.4 -4.54 1.14e-05 0.00593 -0.45 -0.35 Insulin-related traits; chr4:86833266 chr4:86913266~86914817:- PAAD cis rs8031584 0.541 rs2955797 ENSG00000260382.1 RP11-540B6.2 -4.54 1.14e-05 0.00593 -0.44 -0.35 Huntington's disease progression; chr15:30918778 chr15:30882267~30883231:- PAAD cis rs60733400 0.818 rs10909839 ENSG00000225931.3 RP3-395M20.7 4.54 1.14e-05 0.00593 0.33 0.35 Multiple sclerosis; chr1:2791865 chr1:2566410~2569888:+ PAAD cis rs3743162 0.553 rs12900463 ENSG00000275120.1 RP11-182J1.17 4.54 1.15e-05 0.00594 0.4 0.35 Alzheimer's disease (age of onset); chr15:84872155 chr15:84599434~84606463:- PAAD cis rs3743162 0.553 rs12915656 ENSG00000275120.1 RP11-182J1.17 4.54 1.15e-05 0.00594 0.4 0.35 Alzheimer's disease (age of onset); chr15:84872349 chr15:84599434~84606463:- PAAD cis rs2658782 0.654 rs2605617 ENSG00000279684.1 RP11-755E23.2 -4.54 1.15e-05 0.00594 -0.55 -0.35 Pulmonary function decline; chr11:93510167 chr11:93286629~93288903:- PAAD cis rs734999 0.524 rs4648448 ENSG00000225931.3 RP3-395M20.7 4.54 1.15e-05 0.00594 0.33 0.35 Ulcerative colitis; chr1:2779144 chr1:2566410~2569888:+ PAAD cis rs3738443 0.672 rs6691539 ENSG00000259865.1 RP11-488L18.10 4.54 1.15e-05 0.00594 0.3 0.35 Alcohol dependence; chr1:247209370 chr1:247187281~247188526:- PAAD cis rs17123764 0.818 rs73305008 ENSG00000257464.1 RP11-161H23.8 -4.54 1.15e-05 0.00595 -0.58 -0.35 Intelligence (multi-trait analysis); chr12:49565128 chr12:49442424~49442652:- PAAD cis rs734999 0.588 rs2843402 ENSG00000225931.3 RP3-395M20.7 -4.54 1.15e-05 0.00595 -0.33 -0.35 Ulcerative colitis; chr1:2597243 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs2764842 ENSG00000225931.3 RP3-395M20.7 -4.54 1.15e-05 0.00595 -0.33 -0.35 Ulcerative colitis; chr1:2597753 chr1:2566410~2569888:+ PAAD cis rs2412819 0.571 rs11070411 ENSG00000205771.5 CATSPER2P1 4.54 1.15e-05 0.00596 0.51 0.35 Lung cancer; chr15:43766436 chr15:43726918~43747094:- PAAD cis rs7923609 0.934 rs10761756 ENSG00000232075.1 MRPL35P2 -4.54 1.15e-05 0.00596 -0.42 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63412568 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs10761758 ENSG00000232075.1 MRPL35P2 -4.54 1.15e-05 0.00596 -0.42 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63412987 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs7909269 ENSG00000232075.1 MRPL35P2 -4.54 1.15e-05 0.00596 -0.42 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63418006 chr10:63634317~63634827:- PAAD cis rs58873874 0.737 rs11744671 ENSG00000251405.2 CTB-109A12.1 4.54 1.15e-05 0.00598 0.71 0.35 Bipolar disorder (body mass index interaction); chr5:157494223 chr5:157362615~157460078:- PAAD cis rs748404 0.589 rs3862138 ENSG00000205771.5 CATSPER2P1 -4.54 1.15e-05 0.00598 -0.58 -0.35 Lung cancer; chr15:43523801 chr15:43726918~43747094:- PAAD cis rs748404 0.55 rs12912505 ENSG00000205771.5 CATSPER2P1 -4.54 1.15e-05 0.00598 -0.58 -0.35 Lung cancer; chr15:43525206 chr15:43726918~43747094:- PAAD cis rs875971 1 rs7781698 ENSG00000237310.1 GS1-124K5.4 4.54 1.15e-05 0.00598 0.34 0.35 Aortic root size; chr7:66431325 chr7:66493706~66495474:+ PAAD cis rs9494145 0.652 rs9376091 ENSG00000232876.1 CTA-212D2.2 -4.54 1.16e-05 0.00598 -0.43 -0.35 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135098498 chr6:135055033~135060550:+ PAAD cis rs10050311 0.858 rs76283582 ENSG00000251411.1 RP11-397E7.4 -4.54 1.16e-05 0.00599 -0.43 -0.35 Insulin-related traits; chr4:86878202 chr4:86913266~86914817:- PAAD cis rs10050311 0.858 rs72667703 ENSG00000251411.1 RP11-397E7.4 -4.54 1.16e-05 0.00599 -0.43 -0.35 Insulin-related traits; chr4:86891825 chr4:86913266~86914817:- PAAD cis rs10050311 0.858 rs72667705 ENSG00000251411.1 RP11-397E7.4 -4.54 1.16e-05 0.00599 -0.43 -0.35 Insulin-related traits; chr4:86892986 chr4:86913266~86914817:- PAAD cis rs10050311 0.858 rs1010902 ENSG00000251411.1 RP11-397E7.4 -4.54 1.16e-05 0.00599 -0.43 -0.35 Insulin-related traits; chr4:86898002 chr4:86913266~86914817:- PAAD cis rs10050311 0.858 rs1985944 ENSG00000251411.1 RP11-397E7.4 -4.54 1.16e-05 0.00599 -0.43 -0.35 Insulin-related traits; chr4:86898130 chr4:86913266~86914817:- PAAD cis rs8100891 0.537 rs3746016 ENSG00000267213.4 AC007773.2 -4.54 1.16e-05 0.00599 -0.55 -0.35 Neuroticism; chr19:32386353 chr19:32390050~32405560:- PAAD cis rs71403859 0.803 rs10500562 ENSG00000260886.1 TAT-AS1 4.54 1.16e-05 0.00599 0.58 0.35 Post bronchodilator FEV1; chr16:71593828 chr16:71565789~71578187:+ PAAD cis rs7923609 0.841 rs10761786 ENSG00000232075.1 MRPL35P2 -4.54 1.16e-05 0.006 -0.42 -0.35 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63576447 chr10:63634317~63634827:- PAAD cis rs62229266 0.625 rs2051395 ENSG00000231106.2 LINC01436 -4.54 1.16e-05 0.006 -0.49 -0.35 Mitral valve prolapse; chr21:36058967 chr21:36005338~36007838:+ PAAD cis rs875971 0.522 rs1917563 ENSG00000237310.1 GS1-124K5.4 -4.54 1.16e-05 0.006 -0.32 -0.35 Aortic root size; chr7:65950660 chr7:66493706~66495474:+ PAAD cis rs74233809 0.892 rs11191447 ENSG00000213277.3 MARCKSL1P1 4.54 1.16e-05 0.006 0.62 0.35 Birth weight; chr10:102892566 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs74233296 ENSG00000213277.3 MARCKSL1P1 4.54 1.16e-05 0.006 0.62 0.35 Birth weight; chr10:102895593 chr10:103175554~103176094:+ PAAD cis rs797680 0.856 rs12118262 ENSG00000223745.6 RP4-717I23.3 -4.54 1.16e-05 0.006 -0.28 -0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93185990 chr1:93262186~93346025:- PAAD cis rs2255336 0.938 rs1382264 ENSG00000245648.1 RP11-277P12.20 -4.53 1.16e-05 0.00601 -0.51 -0.35 Blood protein levels; chr12:10390740 chr12:10363769~10398506:+ PAAD cis rs797680 0.786 rs1559828 ENSG00000223745.6 RP4-717I23.3 4.53 1.16e-05 0.00601 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93360081 chr1:93262186~93346025:- PAAD cis rs7429990 0.932 rs12486714 ENSG00000228638.1 FCF1P2 4.53 1.16e-05 0.00602 0.39 0.35 Educational attainment (years of education); chr3:48107210 chr3:48290793~48291375:- PAAD cis rs7429990 0.901 rs6442102 ENSG00000228638.1 FCF1P2 4.53 1.16e-05 0.00602 0.39 0.35 Educational attainment (years of education); chr3:48111072 chr3:48290793~48291375:- PAAD cis rs7429990 0.932 rs2361684 ENSG00000228638.1 FCF1P2 4.53 1.16e-05 0.00602 0.39 0.35 Educational attainment (years of education); chr3:48111128 chr3:48290793~48291375:- PAAD cis rs7429990 0.803 rs11714518 ENSG00000228638.1 FCF1P2 4.53 1.16e-05 0.00602 0.39 0.35 Educational attainment (years of education); chr3:48115145 chr3:48290793~48291375:- PAAD cis rs7429990 0.896 rs7427648 ENSG00000228638.1 FCF1P2 4.53 1.16e-05 0.00602 0.39 0.35 Educational attainment (years of education); chr3:48116749 chr3:48290793~48291375:- PAAD cis rs853679 0.76 rs967005 ENSG00000226314.6 ZNF192P1 -4.53 1.16e-05 0.00602 -0.55 -0.35 Depression; chr6:28242910 chr6:28161781~28169594:+ PAAD cis rs8100891 0.537 rs11883143 ENSG00000267213.4 AC007773.2 -4.53 1.17e-05 0.00603 -0.54 -0.35 Neuroticism; chr19:32478350 chr19:32390050~32405560:- PAAD cis rs700651 0.786 rs58224025 ENSG00000231621.1 AC013264.2 -4.53 1.17e-05 0.00604 -0.35 -0.35 Intracranial aneurysm; chr2:197957264 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs1401096 ENSG00000231621.1 AC013264.2 -4.53 1.17e-05 0.00604 -0.35 -0.35 Dermatomyositis; chr2:197959104 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs13408411 ENSG00000231621.1 AC013264.2 -4.53 1.17e-05 0.00604 -0.35 -0.35 Dermatomyositis; chr2:197960738 chr2:197197991~197199273:+ PAAD cis rs6061231 1 rs6061231 ENSG00000275437.1 RP5-908M14.10 4.53 1.17e-05 0.00604 0.31 0.35 Colorectal cancer; chr20:62381861 chr20:62402236~62405935:- PAAD cis rs797680 0.822 rs1057257 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93155926 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs10874759 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93164615 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs10874762 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93173544 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs6688230 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93175567 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs7553465 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93178853 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs1335679 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93179625 chr1:93262186~93346025:- PAAD cis rs797680 0.822 rs2297707 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93180650 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs6682670 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93184175 chr1:93262186~93346025:- PAAD cis rs797680 0.754 rs12118230 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93185904 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs12124011 ENSG00000223745.6 RP4-717I23.3 4.53 1.17e-05 0.00604 0.28 0.35 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93186987 chr1:93262186~93346025:- PAAD cis rs2412819 0.571 rs2729494 ENSG00000205771.5 CATSPER2P1 4.53 1.17e-05 0.00605 0.5 0.35 Lung cancer; chr15:43837395 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs528764 ENSG00000205771.5 CATSPER2P1 4.53 1.17e-05 0.00605 0.5 0.35 Lung cancer; chr15:43838650 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs495880 ENSG00000205771.5 CATSPER2P1 4.53 1.17e-05 0.00605 0.5 0.35 Lung cancer; chr15:43855067 chr15:43726918~43747094:- PAAD cis rs950880 0.71 rs67723747 ENSG00000234389.1 AC007278.3 -4.53 1.17e-05 0.00605 -0.36 -0.35 Serum protein levels (sST2); chr2:102353347 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs56386507 ENSG00000234389.1 AC007278.3 -4.53 1.17e-05 0.00605 -0.36 -0.35 Serum protein levels (sST2); chr2:102354705 chr2:102438713~102440475:+ PAAD cis rs9287719 0.674 rs759399 ENSG00000234818.1 AC092687.5 -4.53 1.17e-05 0.00605 -0.38 -0.35 Prostate cancer; chr2:10656757 chr2:10589166~10604830:+ PAAD cis rs9287719 0.674 rs10929690 ENSG00000234818.1 AC092687.5 -4.53 1.17e-05 0.00605 -0.38 -0.35 Prostate cancer; chr2:10665848 chr2:10589166~10604830:+ PAAD cis rs9287719 0.674 rs6432130 ENSG00000234818.1 AC092687.5 -4.53 1.17e-05 0.00605 -0.38 -0.35 Prostate cancer; chr2:10681431 chr2:10589166~10604830:+ PAAD cis rs9287719 0.674 rs11691060 ENSG00000234818.1 AC092687.5 -4.53 1.17e-05 0.00605 -0.38 -0.35 Prostate cancer; chr2:10686935 chr2:10589166~10604830:+ PAAD cis rs9287719 0.674 rs11684157 ENSG00000234818.1 AC092687.5 -4.53 1.17e-05 0.00605 -0.38 -0.35 Prostate cancer; chr2:10687031 chr2:10589166~10604830:+ PAAD cis rs9287719 0.674 rs1387566 ENSG00000234818.1 AC092687.5 -4.53 1.17e-05 0.00605 -0.38 -0.35 Prostate cancer; chr2:10688524 chr2:10589166~10604830:+ PAAD cis rs11214589 0.747 rs11493880 ENSG00000270179.1 RP11-159N11.4 -4.53 1.17e-05 0.00605 -0.37 -0.35 Neuroticism; chr11:113354422 chr11:113368478~113369117:+ PAAD cis rs10754283 0.901 rs10047070 ENSG00000231613.1 RP5-943J3.1 4.53 1.17e-05 0.00605 0.37 0.35 Amyotrophic lateral sclerosis (sporadic); chr1:89633156 chr1:89788914~89790492:+ PAAD cis rs9649213 0.531 rs35216698 ENSG00000272950.1 RP11-307C18.1 4.53 1.17e-05 0.00606 0.4 0.35 Prostate cancer (SNP x SNP interaction); chr7:98266863 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs34830366 ENSG00000272950.1 RP11-307C18.1 4.53 1.17e-05 0.00606 0.4 0.35 Prostate cancer (SNP x SNP interaction); chr7:98270223 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs34776142 ENSG00000272950.1 RP11-307C18.1 4.53 1.17e-05 0.00606 0.4 0.35 Prostate cancer (SNP x SNP interaction); chr7:98270561 chr7:98322853~98323430:+ PAAD cis rs11079159 1 rs11079159 ENSG00000263096.1 RP11-515O17.2 4.53 1.17e-05 0.00606 0.45 0.35 QRS duration; chr17:55296189 chr17:55271504~55273653:- PAAD cis rs2188561 0.697 rs13224313 ENSG00000241764.3 AC002467.7 4.53 1.17e-05 0.00606 0.43 0.35 Alcohol consumption; chr7:107741907 chr7:107742817~107744581:- PAAD cis rs8100891 0.537 rs10424665 ENSG00000267213.4 AC007773.2 -4.53 1.17e-05 0.00607 -0.55 -0.35 Neuroticism; chr19:32404725 chr19:32390050~32405560:- PAAD cis rs858239 0.6 rs7776644 ENSG00000226816.2 AC005082.12 4.53 1.18e-05 0.00607 0.39 0.35 Cerebrospinal fluid biomarker levels; chr7:23079688 chr7:23206013~23208045:+ PAAD cis rs897984 0.684 rs6950 ENSG00000260911.2 RP11-196G11.2 -4.53 1.18e-05 0.00607 -0.31 -0.35 Dementia with Lewy bodies; chr16:30984348 chr16:31043150~31049868:+ PAAD cis rs897984 0.645 rs9938550 ENSG00000260911.2 RP11-196G11.2 -4.53 1.18e-05 0.00607 -0.31 -0.35 Dementia with Lewy bodies; chr16:30987821 chr16:31043150~31049868:+ PAAD cis rs897984 0.762 rs2305880 ENSG00000260911.2 RP11-196G11.2 -4.53 1.18e-05 0.00607 -0.31 -0.35 Dementia with Lewy bodies; chr16:30988141 chr16:31043150~31049868:+ PAAD cis rs897984 0.759 rs13708 ENSG00000260911.2 RP11-196G11.2 -4.53 1.18e-05 0.00607 -0.31 -0.35 Dementia with Lewy bodies; chr16:30989488 chr16:31043150~31049868:+ PAAD cis rs4950322 0.518 rs4950305 ENSG00000278811.3 LINC00624 4.53 1.18e-05 0.00608 0.34 0.34 Protein quantitative trait loci; chr1:147117711 chr1:147258885~147517875:- PAAD cis rs871012 0.593 rs59666316 ENSG00000248544.2 CTB-47B11.3 -4.53 1.18e-05 0.00609 -0.44 -0.34 IgG glycosylation; chr5:157391833 chr5:157375741~157384950:- PAAD cis rs871012 0.632 rs62387479 ENSG00000248544.2 CTB-47B11.3 -4.53 1.18e-05 0.00609 -0.44 -0.34 IgG glycosylation; chr5:157392370 chr5:157375741~157384950:- PAAD cis rs871012 0.609 rs57047471 ENSG00000248544.2 CTB-47B11.3 -4.53 1.18e-05 0.00609 -0.44 -0.34 IgG glycosylation; chr5:157392605 chr5:157375741~157384950:- PAAD cis rs710913 0.566 rs879037 ENSG00000237624.1 OXCT2P1 -4.53 1.18e-05 0.00609 -0.44 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39509736 chr1:39514956~39516490:+ PAAD cis rs10276381 0.786 rs10255700 ENSG00000234336.5 JAZF1-AS1 -4.53 1.18e-05 0.0061 -0.49 -0.34 Crohn's disease; chr7:28180609 chr7:28180322~28243917:+ PAAD cis rs1124769 0.502 rs34354799 ENSG00000259306.2 RP11-108K3.2 -4.53 1.18e-05 0.0061 -0.44 -0.34 Cognitive performance; chr15:50774380 chr15:51315841~51321996:+ PAAD cis rs1124769 0.502 rs8042982 ENSG00000259306.2 RP11-108K3.2 -4.53 1.18e-05 0.0061 -0.44 -0.34 Cognitive performance; chr15:50774816 chr15:51315841~51321996:+ PAAD cis rs1124769 0.502 rs737031 ENSG00000259306.2 RP11-108K3.2 -4.53 1.18e-05 0.0061 -0.44 -0.34 Cognitive performance; chr15:50775340 chr15:51315841~51321996:+ PAAD cis rs7646881 0.767 rs58152433 ENSG00000240207.5 RP11-379F4.4 -4.53 1.18e-05 0.0061 -0.53 -0.34 Tetralogy of Fallot; chr3:158738851 chr3:158732263~158784070:+ PAAD cis rs801193 1 rs62466793 ENSG00000237310.1 GS1-124K5.4 4.53 1.18e-05 0.0061 0.32 0.34 Aortic root size; chr7:66726530 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs62466794 ENSG00000237310.1 GS1-124K5.4 4.53 1.18e-05 0.0061 0.32 0.34 Aortic root size; chr7:66726592 chr7:66493706~66495474:+ PAAD cis rs4722166 0.597 rs2002792 ENSG00000179428.2 AC073072.5 -4.53 1.18e-05 0.0061 -0.31 -0.34 Lung cancer; chr7:22724226 chr7:22725395~22727620:- PAAD cis rs2404602 0.647 rs12440511 ENSG00000259422.1 RP11-593F23.1 -4.53 1.18e-05 0.0061 -0.42 -0.34 Blood metabolite levels; chr15:76700794 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs11072631 ENSG00000259422.1 RP11-593F23.1 -4.53 1.18e-05 0.0061 -0.42 -0.34 Blood metabolite levels; chr15:76840568 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs55778276 ENSG00000259422.1 RP11-593F23.1 -4.53 1.18e-05 0.0061 -0.42 -0.34 Blood metabolite levels; chr15:76844249 chr15:76174891~76181486:- PAAD cis rs8062405 0.824 rs4788083 ENSG00000251417.2 RP11-1348G14.4 -4.53 1.19e-05 0.00611 -0.3 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28534128 chr16:28802743~28817828:+ PAAD cis rs780096 0.546 rs1260320 ENSG00000234072.1 AC074117.10 4.53 1.19e-05 0.00612 0.27 0.34 Total body bone mineral density; chr2:27499549 chr2:27356246~27367622:+ PAAD cis rs9584850 1 rs9584850 ENSG00000231194.1 FARP1-AS1 4.53 1.19e-05 0.00612 0.45 0.34 Neuroticism; chr13:98449172 chr13:98435405~98435840:- PAAD cis rs9584850 0.915 rs7983438 ENSG00000231194.1 FARP1-AS1 4.53 1.19e-05 0.00612 0.45 0.34 Neuroticism; chr13:98451063 chr13:98435405~98435840:- PAAD cis rs2486288 0.656 rs9921025 ENSG00000259433.2 CTD-2651B20.4 4.53 1.19e-05 0.00613 0.38 0.34 Glomerular filtration rate; chr15:45254404 chr15:45330209~45332634:- PAAD cis rs10740039 0.768 rs920646 ENSG00000254271.1 RP11-131N11.4 4.53 1.19e-05 0.00613 0.41 0.34 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60703767 chr10:60734342~60741828:+ PAAD cis rs4835473 0.897 rs11727223 ENSG00000251600.4 RP11-673E1.1 4.53 1.19e-05 0.00613 0.38 0.34 Immature fraction of reticulocytes; chr4:143707090 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs13144504 ENSG00000251600.4 RP11-673E1.1 -4.53 1.19e-05 0.00613 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143707402 chr4:143912331~143982454:+ PAAD cis rs875971 0.502 rs2946580 ENSG00000226824.5 RP4-756H11.3 4.53 1.19e-05 0.00614 0.49 0.34 Aortic root size; chr7:66066855 chr7:66654538~66669855:+ PAAD cis rs7078219 0.965 rs11190141 ENSG00000257582.4 LINC01475 -4.53 1.19e-05 0.00614 -0.37 -0.34 Dental caries; chr10:99532633 chr10:99526350~99531177:- PAAD cis rs6472235 1 rs6994725 ENSG00000200714.1 Y_RNA -4.53 1.19e-05 0.00614 -0.45 -0.34 Plateletcrit;Myopia (pathological); chr8:65932508 chr8:65592731~65592820:+ PAAD cis rs62103177 0.525 rs8086024 ENSG00000261126.6 RP11-795F19.1 -4.53 1.19e-05 0.00615 -0.45 -0.34 Opioid sensitivity; chr18:79986623 chr18:80046900~80095482:+ PAAD cis rs2985684 0.948 rs12886130 ENSG00000259113.1 RP11-406H23.2 -4.53 1.2e-05 0.00615 -0.48 -0.34 Carotid intima media thickness; chr14:49616035 chr14:50448807~50456742:+ PAAD cis rs2985684 0.948 rs11623263 ENSG00000259113.1 RP11-406H23.2 -4.53 1.2e-05 0.00615 -0.48 -0.34 Carotid intima media thickness; chr14:49616577 chr14:50448807~50456742:+ PAAD cis rs8062405 0.789 rs2106480 ENSG00000251417.2 RP11-1348G14.4 -4.53 1.2e-05 0.00616 -0.3 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28526650 chr16:28802743~28817828:+ PAAD cis rs871012 0.502 rs56259240 ENSG00000251405.2 CTB-109A12.1 -4.53 1.2e-05 0.00616 -0.44 -0.34 IgG glycosylation; chr5:157464523 chr5:157362615~157460078:- PAAD cis rs453301 0.598 rs2921383 ENSG00000254340.1 RP11-10A14.3 4.53 1.2e-05 0.00616 0.41 0.34 Joint mobility (Beighton score); chr8:9034711 chr8:9141424~9145435:+ PAAD cis rs8062405 0.755 rs56272201 ENSG00000251417.2 RP11-1348G14.4 -4.53 1.2e-05 0.00617 -0.33 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569364 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs62034355 ENSG00000251417.2 RP11-1348G14.4 -4.53 1.2e-05 0.00617 -0.33 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28569717 chr16:28802743~28817828:+ PAAD cis rs8023057 0.755 rs61976132 ENSG00000252481.1 SCARNA13 -4.53 1.2e-05 0.00618 -0.43 -0.34 Prostate-specific antigen levels; chr14:94645758 chr14:95533355~95533629:- PAAD cis rs2882667 0.505 rs6596465 ENSG00000253404.1 AC034243.1 -4.53 1.2e-05 0.00618 -0.38 -0.34 Age-related hearing impairment (SNP x SNP interaction); chr5:139147337 chr5:138744434~138753309:- PAAD cis rs9357354 0.929 rs12193066 ENSG00000218809.1 RP1-229K20.5 4.53 1.2e-05 0.00618 0.39 0.34 Telomere length; chr6:41343629 chr6:41269875~41270239:- PAAD cis rs950880 0.614 rs60038017 ENSG00000234389.1 AC007278.3 -4.53 1.2e-05 0.00618 -0.34 -0.34 Serum protein levels (sST2); chr2:102459541 chr2:102438713~102440475:+ PAAD cis rs2505998 0.833 rs2251674 ENSG00000273008.1 RP11-351D16.3 4.53 1.2e-05 0.00618 0.3 0.34 Hirschsprung disease; chr10:43109944 chr10:43136824~43138334:- PAAD cis rs6540731 0.782 rs10436976 ENSG00000229983.1 RP11-15I11.2 4.53 1.2e-05 0.00618 0.41 0.34 Intelligence (childhood); chr1:212187066 chr1:212168207~212190259:+ PAAD cis rs792448 0.743 rs3767863 ENSG00000229983.1 RP11-15I11.2 4.53 1.2e-05 0.00619 0.41 0.34 White blood cell count (basophil); chr1:212364365 chr1:212168207~212190259:+ PAAD cis rs453301 0.522 rs2929455 ENSG00000253893.2 FAM85B 4.53 1.2e-05 0.00619 0.49 0.34 Joint mobility (Beighton score); chr8:9225923 chr8:8167819~8226614:- PAAD cis rs453301 0.522 rs2929309 ENSG00000253893.2 FAM85B 4.53 1.2e-05 0.00619 0.49 0.34 Joint mobility (Beighton score); chr8:9226261 chr8:8167819~8226614:- PAAD cis rs2427308 0.607 rs1741635 ENSG00000273619.1 RP5-908M14.9 4.53 1.2e-05 0.00619 0.32 0.34 Colorectal cancer; chr20:62363141 chr20:62386303~62386970:- PAAD cis rs748404 0.69 rs1079309 ENSG00000205771.5 CATSPER2P1 -4.53 1.2e-05 0.00619 -0.49 -0.34 Lung cancer; chr15:43490966 chr15:43726918~43747094:- PAAD cis rs748404 0.69 rs2924369 ENSG00000205771.5 CATSPER2P1 4.53 1.2e-05 0.00619 0.49 0.34 Lung cancer; chr15:43485787 chr15:43726918~43747094:- PAAD cis rs8062405 0.755 rs17640009 ENSG00000251417.2 RP11-1348G14.4 -4.53 1.2e-05 0.00619 -0.32 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28584379 chr16:28802743~28817828:+ PAAD cis rs7727544 0.735 rs274559 ENSG00000233006.5 AC034220.3 -4.53 1.2e-05 0.0062 -0.28 -0.34 Blood metabolite levels; chr5:132384378 chr5:132311285~132369916:- PAAD cis rs11023332 0.832 rs10832289 ENSG00000251991.1 RNU7-49P -4.53 1.21e-05 0.00621 -0.41 -0.34 Vitamin D levels;Adiponectin levels; chr11:14647950 chr11:14478892~14478953:+ PAAD cis rs12134133 1 rs2782842 ENSG00000274245.1 RP11-357P18.2 4.53 1.21e-05 0.00621 0.53 0.34 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207310231 chr1:207372559~207373252:+ PAAD cis rs10759883 0.525 rs1556026 ENSG00000175611.10 LINC00476 4.53 1.21e-05 0.00621 0.34 0.34 Nicotine dependence; chr9:96046454 chr9:95759231~95875977:- PAAD cis rs2581828 0.58 rs9872260 ENSG00000242142.1 SERBP1P3 -4.53 1.21e-05 0.00622 -0.43 -0.34 Crohn's disease; chr3:53136158 chr3:53064283~53065091:- PAAD cis rs74233809 1 rs732998 ENSG00000213277.3 MARCKSL1P1 -4.53 1.21e-05 0.00622 -0.59 -0.34 Birth weight; chr10:103138144 chr10:103175554~103176094:+ PAAD cis rs526231 0.543 rs72785717 ENSG00000175749.11 EIF3KP1 4.53 1.21e-05 0.00622 0.47 0.34 Primary biliary cholangitis; chr5:102997401 chr5:103032376~103033031:+ PAAD cis rs2564921 0.73 rs56026870 ENSG00000242142.1 SERBP1P3 -4.53 1.21e-05 0.00622 -0.4 -0.34 Height; chr3:52998472 chr3:53064283~53065091:- PAAD cis rs367615 0.552 rs2963024 ENSG00000249476.1 CTD-2587M2.1 -4.53 1.21e-05 0.00622 -0.37 -0.34 Colorectal cancer (SNP x SNP interaction); chr5:109395072 chr5:109237120~109326369:- PAAD cis rs79349575 0.756 rs2291726 ENSG00000270781.1 RP11-501C14.9 4.52 1.21e-05 0.00623 0.39 0.34 Type 2 diabetes; chr17:48961892 chr17:48899131~48899748:+ PAAD cis rs17772222 0.917 rs2004329 ENSG00000258983.2 RP11-507K2.2 4.52 1.21e-05 0.00623 0.47 0.34 Coronary artery calcification; chr14:88532965 chr14:88499334~88515502:+ PAAD cis rs7923609 0.811 rs3847326 ENSG00000232075.1 MRPL35P2 4.52 1.21e-05 0.00623 0.41 0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63572099 chr10:63634317~63634827:- PAAD cis rs17772222 0.727 rs3179969 ENSG00000258983.2 RP11-507K2.2 4.52 1.21e-05 0.00624 0.42 0.34 Coronary artery calcification; chr14:88396185 chr14:88499334~88515502:+ PAAD cis rs9322193 0.607 rs10457852 ENSG00000268592.3 RAET1E-AS1 4.52 1.21e-05 0.00624 0.45 0.34 Lung cancer; chr6:149880584 chr6:149863494~149919507:+ PAAD cis rs321358 0.836 rs17458597 ENSG00000271390.1 RP11-89C3.3 4.52 1.22e-05 0.00625 0.53 0.34 Body mass index; chr11:111113599 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs73017176 ENSG00000271390.1 RP11-89C3.3 4.52 1.22e-05 0.00625 0.53 0.34 Body mass index; chr11:111113879 chr11:111089870~111090368:- PAAD cis rs321358 0.887 rs80221187 ENSG00000271390.1 RP11-89C3.3 4.52 1.22e-05 0.00625 0.53 0.34 Body mass index; chr11:111113977 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs73017177 ENSG00000271390.1 RP11-89C3.3 4.52 1.22e-05 0.00625 0.53 0.34 Body mass index; chr11:111114034 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs73017179 ENSG00000271390.1 RP11-89C3.3 4.52 1.22e-05 0.00625 0.53 0.34 Body mass index; chr11:111114037 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs1356411 ENSG00000271390.1 RP11-89C3.3 4.52 1.22e-05 0.00625 0.53 0.34 Body mass index; chr11:111115371 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs12420595 ENSG00000271390.1 RP11-89C3.3 4.52 1.22e-05 0.00625 0.53 0.34 Body mass index; chr11:111115871 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs17537360 ENSG00000271390.1 RP11-89C3.3 4.52 1.22e-05 0.00625 0.53 0.34 Body mass index; chr11:111116921 chr11:111089870~111090368:- PAAD cis rs858239 0.6 rs2072368 ENSG00000226816.2 AC005082.12 4.52 1.22e-05 0.00625 0.39 0.34 Cerebrospinal fluid biomarker levels; chr7:23106493 chr7:23206013~23208045:+ PAAD cis rs12468226 1 rs16824599 ENSG00000273456.1 RP11-686O6.2 4.52 1.22e-05 0.00625 0.52 0.34 Urate levels; chr2:202358243 chr2:202374932~202375604:- PAAD cis rs8177376 0.834 rs12287976 ENSG00000254905.1 RP11-712L6.7 4.52 1.22e-05 0.00626 0.43 0.34 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126302693 chr11:126292922~126294254:- PAAD cis rs8062405 0.824 rs28698667 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.22e-05 0.00626 -0.3 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28521750 chr16:28802743~28817828:+ PAAD cis rs8062405 0.754 rs62034323 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.22e-05 0.00626 -0.3 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525152 chr16:28802743~28817828:+ PAAD cis rs8062405 0.824 rs62034324 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.22e-05 0.00626 -0.3 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28525441 chr16:28802743~28817828:+ PAAD cis rs8062405 0.824 rs62034326 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.22e-05 0.00626 -0.3 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28527972 chr16:28802743~28817828:+ PAAD cis rs8062405 0.824 rs4788084 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.22e-05 0.00626 -0.3 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28528527 chr16:28802743~28817828:+ PAAD cis rs8062405 0.792 rs12446550 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.22e-05 0.00626 -0.3 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28532060 chr16:28802743~28817828:+ PAAD cis rs7615952 0.932 rs13314869 ENSG00000241288.6 RP11-379B18.5 -4.52 1.22e-05 0.00626 -0.36 -0.34 Blood pressure (smoking interaction); chr3:125925826 chr3:125827238~125916384:- PAAD cis rs7615952 0.741 rs13314845 ENSG00000241288.6 RP11-379B18.5 -4.52 1.22e-05 0.00626 -0.36 -0.34 Blood pressure (smoking interaction); chr3:125925939 chr3:125827238~125916384:- PAAD cis rs7615952 0.733 rs13314847 ENSG00000241288.6 RP11-379B18.5 -4.52 1.22e-05 0.00626 -0.36 -0.34 Blood pressure (smoking interaction); chr3:125925945 chr3:125827238~125916384:- PAAD cis rs7615952 0.932 rs13086087 ENSG00000241288.6 RP11-379B18.5 -4.52 1.22e-05 0.00626 -0.36 -0.34 Blood pressure (smoking interaction); chr3:125927438 chr3:125827238~125916384:- PAAD cis rs7615952 0.8 rs13086460 ENSG00000241288.6 RP11-379B18.5 -4.52 1.22e-05 0.00626 -0.36 -0.34 Blood pressure (smoking interaction); chr3:125927574 chr3:125827238~125916384:- PAAD cis rs7615952 0.866 rs1976459 ENSG00000241288.6 RP11-379B18.5 -4.52 1.22e-05 0.00626 -0.36 -0.34 Blood pressure (smoking interaction); chr3:125928643 chr3:125827238~125916384:- PAAD cis rs6061231 0.624 rs8668 ENSG00000273619.1 RP5-908M14.9 4.52 1.22e-05 0.00626 0.3 0.34 Colorectal cancer; chr20:62389008 chr20:62386303~62386970:- PAAD cis rs797680 0.856 rs687394 ENSG00000223745.6 RP4-717I23.3 -4.52 1.22e-05 0.00626 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93248360 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs7512911 ENSG00000223745.6 RP4-717I23.3 -4.52 1.22e-05 0.00626 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93250261 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs637646 ENSG00000223745.6 RP4-717I23.3 -4.52 1.22e-05 0.00626 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93250826 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs797681 ENSG00000223745.6 RP4-717I23.3 -4.52 1.22e-05 0.00626 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93252189 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs682514 ENSG00000223745.6 RP4-717I23.3 -4.52 1.22e-05 0.00626 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93253873 chr1:93262186~93346025:- PAAD cis rs7665090 0.51 rs223498 ENSG00000246560.2 RP11-10L12.4 -4.52 1.22e-05 0.00626 -0.38 -0.34 Primary biliary cholangitis; chr4:102730805 chr4:102828055~102844075:+ PAAD cis rs6840258 0.547 rs4693795 ENSG00000251411.1 RP11-397E7.4 -4.52 1.22e-05 0.00626 -0.41 -0.34 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86946904 chr4:86913266~86914817:- PAAD cis rs11690935 0.632 rs12052246 ENSG00000228389.1 AC068039.4 -4.52 1.22e-05 0.00627 -0.41 -0.34 Schizophrenia; chr2:172030703 chr2:171773482~171775844:+ PAAD cis rs12439619 0.705 rs17354185 ENSG00000255769.6 GOLGA2P10 4.52 1.22e-05 0.00628 0.46 0.34 Intelligence (multi-trait analysis); chr15:82133829 chr15:82472993~82513950:- PAAD cis rs6921919 0.525 rs16894095 ENSG00000204709.4 LINC01556 4.52 1.22e-05 0.00628 0.49 0.34 Autism spectrum disorder or schizophrenia; chr6:28422453 chr6:28943877~28944537:+ PAAD cis rs8100891 0.537 rs1030094 ENSG00000267213.4 AC007773.2 -4.52 1.22e-05 0.00628 -0.54 -0.34 Neuroticism; chr19:32419525 chr19:32390050~32405560:- PAAD cis rs4835473 0.932 rs34683160 ENSG00000251600.4 RP11-673E1.1 -4.52 1.23e-05 0.00629 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143765227 chr4:143912331~143982454:+ PAAD cis rs2946504 0.861 rs2946494 ENSG00000251468.2 RP11-369K16.1 -4.52 1.23e-05 0.00629 -0.45 -0.34 Type 2 diabetes; chr8:12962601 chr8:12958387~12962200:+ PAAD cis rs7923609 0.811 rs3847325 ENSG00000232075.1 MRPL35P2 4.52 1.23e-05 0.0063 0.41 0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63571751 chr10:63634317~63634827:- PAAD cis rs9918079 0.56 rs10008376 ENSG00000273133.1 RP11-799M12.2 4.52 1.23e-05 0.0063 0.41 0.34 Obesity-related traits; chr4:15622332 chr4:15563698~15564253:- PAAD cis rs2348418 0.765 rs12368743 ENSG00000247934.4 RP11-967K21.1 -4.52 1.23e-05 0.0063 -0.34 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28192409 chr12:28163298~28190738:- PAAD cis rs2348418 0.8 rs6487667 ENSG00000247934.4 RP11-967K21.1 -4.52 1.23e-05 0.0063 -0.34 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28195643 chr12:28163298~28190738:- PAAD cis rs2348418 0.765 rs4931734 ENSG00000247934.4 RP11-967K21.1 -4.52 1.23e-05 0.0063 -0.34 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28196661 chr12:28163298~28190738:- PAAD cis rs2348418 0.733 rs1824769 ENSG00000247934.4 RP11-967K21.1 -4.52 1.23e-05 0.0063 -0.34 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28202322 chr12:28163298~28190738:- PAAD cis rs2348418 0.671 rs2169753 ENSG00000247934.4 RP11-967K21.1 -4.52 1.23e-05 0.0063 -0.34 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28203481 chr12:28163298~28190738:- PAAD cis rs2348418 0.733 rs4931078 ENSG00000247934.4 RP11-967K21.1 -4.52 1.23e-05 0.0063 -0.34 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28215067 chr12:28163298~28190738:- PAAD cis rs9531006 0.636 rs7330635 ENSG00000227676.3 LINC01068 4.52 1.23e-05 0.00631 0.52 0.34 Sleep duration; chr13:79895804 chr13:79566727~79571436:+ PAAD cis rs889398 0.9 rs4783722 ENSG00000226232.7 RP11-419C5.2 4.52 1.23e-05 0.00631 0.28 0.34 Body mass index; chr16:69548009 chr16:69976388~69996188:- PAAD cis rs2486288 0.656 rs11629807 ENSG00000259433.2 CTD-2651B20.4 4.52 1.23e-05 0.00631 0.38 0.34 Glomerular filtration rate; chr15:45254839 chr15:45330209~45332634:- PAAD cis rs2486288 0.587 rs12899942 ENSG00000259433.2 CTD-2651B20.4 4.52 1.23e-05 0.00631 0.38 0.34 Glomerular filtration rate; chr15:45255082 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs12899058 ENSG00000259433.2 CTD-2651B20.4 4.52 1.23e-05 0.00631 0.38 0.34 Glomerular filtration rate; chr15:45255126 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs12904150 ENSG00000259433.2 CTD-2651B20.4 4.52 1.23e-05 0.00631 0.38 0.34 Glomerular filtration rate; chr15:45255407 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs9920290 ENSG00000259433.2 CTD-2651B20.4 4.52 1.23e-05 0.00631 0.38 0.34 Glomerular filtration rate; chr15:45255837 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11854325 ENSG00000259433.2 CTD-2651B20.4 4.52 1.23e-05 0.00631 0.38 0.34 Glomerular filtration rate; chr15:45256761 chr15:45330209~45332634:- PAAD cis rs6782228 0.606 rs7650156 ENSG00000242551.2 POU5F1P6 -4.52 1.23e-05 0.00631 -0.42 -0.34 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128642712 chr3:128674735~128677005:- PAAD cis rs2658782 0.789 rs2605580 ENSG00000279684.1 RP11-755E23.2 -4.52 1.23e-05 0.00631 -0.56 -0.34 Pulmonary function decline; chr11:93413888 chr11:93286629~93288903:- PAAD cis rs9494145 0.648 rs9373124 ENSG00000232876.1 CTA-212D2.2 -4.52 1.23e-05 0.00632 -0.43 -0.34 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135102071 chr6:135055033~135060550:+ PAAD cis rs12908161 0.959 rs34342559 ENSG00000259728.4 LINC00933 4.52 1.23e-05 0.00632 0.44 0.34 Schizophrenia; chr15:84788040 chr15:84570649~84580175:+ PAAD cis rs12908161 0.959 rs62019472 ENSG00000259728.4 LINC00933 4.52 1.23e-05 0.00632 0.44 0.34 Schizophrenia; chr15:84788262 chr15:84570649~84580175:+ PAAD cis rs12908161 0.959 rs35557864 ENSG00000259728.4 LINC00933 4.52 1.23e-05 0.00632 0.44 0.34 Schizophrenia; chr15:84788398 chr15:84570649~84580175:+ PAAD cis rs987724 0.57 rs4680318 ENSG00000240875.4 LINC00886 -4.52 1.23e-05 0.00632 -0.51 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156953850 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs4234315 ENSG00000240875.4 LINC00886 -4.52 1.23e-05 0.00632 -0.51 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156955749 chr3:156747346~156817062:- PAAD cis rs12817211 0.549 rs7138945 ENSG00000272368.2 RP4-605O3.4 -4.52 1.23e-05 0.00633 -0.34 -0.34 Colorectal or endometrial cancer; chr12:50145636 chr12:50112197~50165618:+ PAAD cis rs8062405 0.755 rs56209193 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.24e-05 0.00633 -0.32 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574315 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs7186573 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.24e-05 0.00633 -0.32 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576068 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs4788073 ENSG00000251417.2 RP11-1348G14.4 -4.52 1.24e-05 0.00633 -0.32 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28583228 chr16:28802743~28817828:+ PAAD cis rs964611 0.882 rs8025164 ENSG00000259488.2 RP11-154J22.1 4.52 1.24e-05 0.00633 0.38 0.34 Metabolite levels (Pyroglutamine); chr15:48346517 chr15:48312353~48331856:- PAAD cis rs797680 0.786 rs4847240 ENSG00000223745.6 RP4-717I23.3 4.52 1.24e-05 0.00634 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93352389 chr1:93262186~93346025:- PAAD cis rs797680 0.754 rs12044883 ENSG00000223745.6 RP4-717I23.3 4.52 1.24e-05 0.00634 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93355018 chr1:93262186~93346025:- PAAD cis rs7712401 0.601 rs35858098 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:122998670 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs13155907 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:122998938 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs62377430 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:122998993 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs34348084 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:122999419 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs35334805 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:122999566 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs13164134 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:123002246 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs13185741 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:123002315 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs418229 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:123005969 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs374403 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:123006018 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs446782 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:123006173 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs417268 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:123009317 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs398142 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:123009881 chr5:123022487~123022783:- PAAD cis rs7712401 0.58 rs383262 ENSG00000263432.2 RN7SL689P -4.52 1.24e-05 0.00634 -0.45 -0.34 Mean platelet volume; chr5:123009989 chr5:123022487~123022783:- PAAD cis rs6921919 0.789 rs17301128 ENSG00000216901.1 AL022393.7 4.52 1.24e-05 0.00634 0.53 0.34 Autism spectrum disorder or schizophrenia; chr6:28340257 chr6:28176188~28176674:+ PAAD cis rs3781264 0.557 rs7100430 ENSG00000273450.1 RP11-76P2.4 4.52 1.24e-05 0.00634 0.45 0.34 Esophageal cancer and gastric cancer; chr10:94362786 chr10:94314907~94315327:- PAAD cis rs2581828 0.549 rs7611386 ENSG00000242142.1 SERBP1P3 -4.52 1.24e-05 0.00634 -0.4 -0.34 Crohn's disease; chr3:53019386 chr3:53064283~53065091:- PAAD cis rs5850 0.602 rs1005786 ENSG00000226816.2 AC005082.12 4.52 1.24e-05 0.00635 0.37 0.34 Blood protein levels; chr7:23106218 chr7:23206013~23208045:+ PAAD cis rs6504950 0.8 rs9916547 ENSG00000275710.1 RP11-257O5.4 4.52 1.24e-05 0.00635 0.41 0.34 Breast cancer; chr17:54929529 chr17:54964474~54964679:+ PAAD cis rs17684571 0.751 rs17684941 ENSG00000231441.1 RP11-472M19.2 -4.52 1.24e-05 0.00635 -0.65 -0.34 Schizophrenia; chr6:56862636 chr6:56844002~56864078:+ PAAD cis rs58873874 0.737 rs10476052 ENSG00000251405.2 CTB-109A12.1 4.52 1.24e-05 0.00636 0.7 0.34 Bipolar disorder (body mass index interaction); chr5:157473526 chr5:157362615~157460078:- PAAD cis rs58873874 0.737 rs78832945 ENSG00000251405.2 CTB-109A12.1 4.52 1.24e-05 0.00636 0.7 0.34 Bipolar disorder (body mass index interaction); chr5:157475805 chr5:157362615~157460078:- PAAD cis rs6061231 0.701 rs6061505 ENSG00000273619.1 RP5-908M14.9 -4.52 1.24e-05 0.00636 -0.28 -0.34 Colorectal cancer; chr20:62385155 chr20:62386303~62386970:- PAAD cis rs1707322 0.686 rs1547924 ENSG00000280836.1 AL355480.1 -4.52 1.24e-05 0.00636 -0.42 -0.34 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619440 chr1:45581219~45581321:- PAAD cis rs875971 0.965 rs7794930 ENSG00000232559.3 GS1-124K5.12 -4.52 1.24e-05 0.00636 -0.37 -0.34 Aortic root size; chr7:66313559 chr7:66554588~66576923:- PAAD cis rs6052484 0.523 rs17315511 ENSG00000226948.1 RPS4XP2 -4.52 1.24e-05 0.00636 -0.52 -0.34 Sense of smell; chr20:4334714 chr20:4629427~4630219:- PAAD cis rs6052484 0.523 rs17315630 ENSG00000226948.1 RPS4XP2 -4.52 1.24e-05 0.00636 -0.52 -0.34 Sense of smell; chr20:4336810 chr20:4629427~4630219:- PAAD cis rs4835473 0.9 rs10025455 ENSG00000251600.4 RP11-673E1.1 -4.52 1.24e-05 0.00637 -0.41 -0.34 Immature fraction of reticulocytes; chr4:143998417 chr4:143912331~143982454:+ PAAD cis rs4835473 0.722 rs7662277 ENSG00000251600.4 RP11-673E1.1 -4.52 1.24e-05 0.00637 -0.41 -0.34 Immature fraction of reticulocytes; chr4:143999485 chr4:143912331~143982454:+ PAAD cis rs919433 0.68 rs787983 ENSG00000231621.1 AC013264.2 -4.52 1.24e-05 0.00637 -0.33 -0.34 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197481073 chr2:197197991~197199273:+ PAAD cis rs9918079 0.56 rs4270584 ENSG00000273133.1 RP11-799M12.2 4.52 1.24e-05 0.00637 0.41 0.34 Obesity-related traits; chr4:15599176 chr4:15563698~15564253:- PAAD cis rs7923609 0.841 rs10740131 ENSG00000232075.1 MRPL35P2 -4.52 1.24e-05 0.00637 -0.43 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63511728 chr10:63634317~63634827:- PAAD cis rs6504950 0.886 rs2787501 ENSG00000275710.1 RP11-257O5.4 4.52 1.24e-05 0.00637 0.42 0.34 Breast cancer; chr17:55016604 chr17:54964474~54964679:+ PAAD cis rs2486288 0.656 rs8024620 ENSG00000259433.2 CTD-2651B20.4 4.52 1.24e-05 0.00637 0.38 0.34 Glomerular filtration rate; chr15:45282131 chr15:45330209~45332634:- PAAD cis rs4423214 0.592 rs7120029 ENSG00000254682.1 RP11-660L16.2 -4.52 1.24e-05 0.00637 -0.57 -0.34 Vitamin D levels; chr11:71487911 chr11:71448674~71452157:+ PAAD cis rs131777 0.575 rs963980 ENSG00000205559.3 CHKB-AS1 -4.52 1.25e-05 0.00637 -0.43 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50583688 chr22:50583026~50583877:+ PAAD cis rs8062405 0.728 rs9931989 ENSG00000251417.2 RP11-1348G14.4 4.52 1.25e-05 0.00638 0.32 0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28894763 chr16:28802743~28817828:+ PAAD cis rs8062405 0.656 rs7189927 ENSG00000251417.2 RP11-1348G14.4 4.52 1.25e-05 0.00638 0.32 0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28902466 chr16:28802743~28817828:+ PAAD cis rs8062405 0.698 rs7188071 ENSG00000251417.2 RP11-1348G14.4 4.52 1.25e-05 0.00638 0.32 0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28906323 chr16:28802743~28817828:+ PAAD cis rs875971 0.577 rs34888281 ENSG00000237310.1 GS1-124K5.4 -4.52 1.25e-05 0.00638 -0.32 -0.34 Aortic root size; chr7:66120784 chr7:66493706~66495474:+ PAAD cis rs131777 0.575 rs131760 ENSG00000205559.3 CHKB-AS1 -4.52 1.25e-05 0.00638 -0.43 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50573507 chr22:50583026~50583877:+ PAAD cis rs3169166 0.546 rs4887029 ENSG00000259562.2 RP11-762H8.2 4.52 1.25e-05 0.00638 0.29 0.34 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78299168 chr15:78290527~78291221:- PAAD cis rs7712401 0.623 rs426877 ENSG00000263432.2 RN7SL689P -4.52 1.25e-05 0.00638 -0.44 -0.34 Mean platelet volume; chr5:122978940 chr5:123022487~123022783:- PAAD cis rs74233809 1 rs35125602 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102896282 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191453 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102900095 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12221193 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102905510 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs77180047 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102907000 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12221064 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102917369 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs17115213 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102921386 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs77602510 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102922845 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs78821730 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102924787 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs10509759 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102929908 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs5011520 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102937759 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs10883806 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102953319 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs10883808 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102961369 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs78260931 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102962205 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191479 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102963863 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs10883815 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102979422 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs112390216 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102981274 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs77860422 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:102988252 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191502 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:103005737 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs74444347 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:103009518 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12221335 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:103009635 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191514 ENSG00000213277.3 MARCKSL1P1 4.52 1.25e-05 0.00638 0.58 0.34 Birth weight; chr10:103013607 chr10:103175554~103176094:+ PAAD cis rs7208859 0.614 rs216477 ENSG00000266490.1 CTD-2349P21.9 -4.52 1.25e-05 0.00638 -0.39 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30539726 chr17:30792372~30792833:+ PAAD cis rs113835537 0.877 rs2275998 ENSG00000255517.5 CTD-3074O7.5 -4.52 1.25e-05 0.00639 -0.55 -0.34 Airway imaging phenotypes; chr11:66559110 chr11:66473490~66480233:- PAAD cis rs2946504 0.861 rs2946502 ENSG00000251468.2 RP11-369K16.1 -4.52 1.25e-05 0.00639 -0.43 -0.34 Type 2 diabetes; chr8:12955445 chr8:12958387~12962200:+ PAAD cis rs4218 0.531 rs1374156 ENSG00000277144.1 RP11-59H7.4 -4.52 1.25e-05 0.00639 -0.41 -0.34 Social communication problems; chr15:59046746 chr15:59115547~59116089:- PAAD cis rs853679 1 rs1936365 ENSG00000204709.4 LINC01556 -4.52 1.25e-05 0.00639 -0.6 -0.34 Depression; chr6:28300675 chr6:28943877~28944537:+ PAAD cis rs853679 1 rs853685 ENSG00000204709.4 LINC01556 4.52 1.25e-05 0.00639 0.6 0.34 Depression; chr6:28321008 chr6:28943877~28944537:+ PAAD cis rs853679 1 rs853679 ENSG00000204709.4 LINC01556 4.52 1.25e-05 0.00639 0.6 0.34 Depression; chr6:28329086 chr6:28943877~28944537:+ PAAD cis rs853679 1 rs853678 ENSG00000204709.4 LINC01556 4.52 1.25e-05 0.00639 0.6 0.34 Depression; chr6:28329536 chr6:28943877~28944537:+ PAAD cis rs9637599 0.967 rs4693209 ENSG00000246375.2 RP11-10L7.1 4.52 1.25e-05 0.00639 0.42 0.34 Metabolite levels (small molecules and protein measures); chr4:88265916 chr4:88284942~88331421:+ PAAD cis rs4835473 0.832 rs35763177 ENSG00000251600.4 RP11-673E1.1 -4.52 1.25e-05 0.0064 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143737717 chr4:143912331~143982454:+ PAAD cis rs6504950 0.8 rs8065361 ENSG00000275710.1 RP11-257O5.4 4.52 1.25e-05 0.0064 0.41 0.34 Breast cancer; chr17:54931492 chr17:54964474~54964679:+ PAAD cis rs6504950 0.745 rs12603899 ENSG00000275710.1 RP11-257O5.4 4.52 1.25e-05 0.0064 0.41 0.34 Breast cancer; chr17:54932737 chr17:54964474~54964679:+ PAAD cis rs6504950 0.8 rs9891704 ENSG00000275710.1 RP11-257O5.4 4.52 1.25e-05 0.0064 0.41 0.34 Breast cancer; chr17:54933394 chr17:54964474~54964679:+ PAAD cis rs6504950 0.8 rs9900816 ENSG00000275710.1 RP11-257O5.4 4.52 1.25e-05 0.0064 0.41 0.34 Breast cancer; chr17:54934696 chr17:54964474~54964679:+ PAAD cis rs6504950 0.8 rs9907961 ENSG00000275710.1 RP11-257O5.4 4.52 1.25e-05 0.0064 0.41 0.34 Breast cancer; chr17:54935566 chr17:54964474~54964679:+ PAAD cis rs2658782 1 rs2605583 ENSG00000279684.1 RP11-755E23.2 -4.52 1.25e-05 0.0064 -0.58 -0.34 Pulmonary function decline; chr11:93431791 chr11:93286629~93288903:- PAAD cis rs7615952 0.609 rs13088451 ENSG00000171084.14 FAM86JP 4.52 1.25e-05 0.0064 0.45 0.34 Blood pressure (smoking interaction); chr3:125834656 chr3:125916620~125930024:+ PAAD cis rs4453827 0.955 rs6800641 ENSG00000271916.1 RP11-884K10.6 4.52 1.25e-05 0.00641 0.35 0.34 Blood protein levels; chr3:53736561 chr3:53797764~53798019:- PAAD cis rs2658782 0.654 rs2605622 ENSG00000279684.1 RP11-755E23.2 -4.52 1.26e-05 0.00642 -0.55 -0.34 Pulmonary function decline; chr11:93515076 chr11:93286629~93288903:- PAAD cis rs6052484 0.523 rs17315602 ENSG00000226948.1 RPS4XP2 -4.52 1.26e-05 0.00642 -0.51 -0.34 Sense of smell; chr20:4336262 chr20:4629427~4630219:- PAAD cis rs77372450 0.636 rs73814834 ENSG00000251405.2 CTB-109A12.1 4.52 1.26e-05 0.00643 0.54 0.34 Bipolar disorder (body mass index interaction); chr5:157597451 chr5:157362615~157460078:- PAAD cis rs4835473 0.932 rs66474962 ENSG00000251600.4 RP11-673E1.1 -4.52 1.26e-05 0.00644 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143735145 chr4:143912331~143982454:+ PAAD cis rs9287719 0.967 rs7355649 ENSG00000234818.1 AC092687.5 4.52 1.26e-05 0.00644 0.39 0.34 Prostate cancer; chr2:10607968 chr2:10589166~10604830:+ PAAD cis rs2658782 0.724 rs2605626 ENSG00000279684.1 RP11-755E23.2 -4.52 1.26e-05 0.00644 -0.56 -0.34 Pulmonary function decline; chr11:93520737 chr11:93286629~93288903:- PAAD cis rs6061231 1 rs11908473 ENSG00000275437.1 RP5-908M14.10 4.52 1.26e-05 0.00644 0.31 0.34 Colorectal cancer; chr20:62382714 chr20:62402236~62405935:- PAAD cis rs6061231 1 rs67941642 ENSG00000275437.1 RP5-908M14.10 4.52 1.26e-05 0.00644 0.31 0.34 Colorectal cancer; chr20:62383052 chr20:62402236~62405935:- PAAD cis rs6061231 1 rs13043313 ENSG00000275437.1 RP5-908M14.10 4.52 1.26e-05 0.00644 0.31 0.34 Colorectal cancer; chr20:62383213 chr20:62402236~62405935:- PAAD cis rs7665090 0.84 rs228618 ENSG00000246560.2 RP11-10L12.4 -4.51 1.26e-05 0.00645 -0.39 -0.34 Primary biliary cholangitis; chr4:102646191 chr4:102828055~102844075:+ PAAD cis rs7826238 0.539 rs2945891 ENSG00000253981.4 ALG1L13P 4.51 1.26e-05 0.00645 0.41 0.34 Systolic blood pressure; chr8:8297953 chr8:8236003~8244667:- PAAD cis rs8091660 0.624 rs9952398 ENSG00000278983.1 RP11-426J5.3 4.51 1.26e-05 0.00645 0.42 0.34 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550407 chr18:48564795~48568342:+ PAAD cis rs7224610 0.898 rs4299205 ENSG00000263096.1 RP11-515O17.2 4.51 1.26e-05 0.00645 0.42 0.34 Urate levels; chr17:55288785 chr17:55271504~55273653:- PAAD cis rs6991838 0.702 rs10106749 ENSG00000200714.1 Y_RNA 4.51 1.26e-05 0.00645 0.41 0.34 Intelligence (multi-trait analysis); chr8:65692355 chr8:65592731~65592820:+ PAAD cis rs1185460 0.967 rs1168568 ENSG00000271751.1 RP11-110I1.14 -4.51 1.26e-05 0.00645 -0.44 -0.34 Coronary artery disease; chr11:119079089 chr11:119065263~119065677:- PAAD cis rs1185460 0.967 rs1307145 ENSG00000271751.1 RP11-110I1.14 -4.51 1.26e-05 0.00645 -0.44 -0.34 Coronary artery disease; chr11:119079507 chr11:119065263~119065677:- PAAD cis rs4759375 0.667 rs10846514 ENSG00000256092.2 RP13-942N8.1 4.51 1.27e-05 0.00646 0.55 0.34 HDL cholesterol; chr12:123315829 chr12:123363868~123366113:+ PAAD cis rs7923609 0.812 rs10822184 ENSG00000232075.1 MRPL35P2 4.51 1.27e-05 0.00646 0.42 0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63577393 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs6479891 ENSG00000232075.1 MRPL35P2 4.51 1.27e-05 0.00646 0.58 0.34 Arthritis (juvenile idiopathic); chr10:63246696 chr10:63634317~63634827:- PAAD cis rs2348418 0.864 rs6487688 ENSG00000247934.4 RP11-967K21.1 -4.51 1.27e-05 0.00646 -0.33 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28558278 chr12:28163298~28190738:- PAAD cis rs2729354 0.768 rs2584856 ENSG00000265566.2 RN7SL605P -4.51 1.27e-05 0.00647 -0.42 -0.34 Blood protein levels; chr11:57499839 chr11:57528085~57528365:- PAAD cis rs61270009 0.908 rs780405 ENSG00000247828.6 TMEM161B-AS1 -4.51 1.27e-05 0.00647 -0.28 -0.34 Depressive symptoms; chr5:88260522 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs12514004 ENSG00000247828.6 TMEM161B-AS1 4.51 1.27e-05 0.00647 0.28 0.34 Depressive symptoms; chr5:88269979 chr5:88268895~88436685:+ PAAD cis rs8059260 0.542 rs78319720 ENSG00000274038.1 RP11-66H6.4 -4.51 1.27e-05 0.00647 -0.7 -0.34 Alcohol consumption over the past year; chr16:11034573 chr16:11056556~11057034:+ PAAD cis rs2115630 0.754 rs12595321 ENSG00000225151.9 GOLGA2P7 4.51 1.27e-05 0.00647 0.42 0.34 P wave terminal force; chr15:84788038 chr15:84199311~84230136:- PAAD cis rs11098499 0.562 rs13101722 ENSG00000245958.5 RP11-33B1.1 4.51 1.27e-05 0.00647 0.25 0.34 Corneal astigmatism; chr4:119634820 chr4:119454791~119552025:+ PAAD cis rs807029 0.577 rs3740488 ENSG00000272572.1 RP11-179B2.2 -4.51 1.27e-05 0.00648 -0.41 -0.34 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100994276 chr10:100911103~100912739:- PAAD cis rs807029 0.577 rs11190787 ENSG00000272572.1 RP11-179B2.2 -4.51 1.27e-05 0.00648 -0.41 -0.34 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100998868 chr10:100911103~100912739:- PAAD cis rs2283792 0.73 rs56398890 ENSG00000224086.5 LL22NC03-86G7.1 -4.51 1.27e-05 0.00648 -0.35 -0.34 Multiple sclerosis; chr22:21836496 chr22:21938293~21977632:+ PAAD cis rs4664293 0.764 rs10195287 ENSG00000226266.5 AC009961.3 -4.51 1.27e-05 0.00648 -0.42 -0.34 Monocyte percentage of white cells; chr2:159604967 chr2:159670708~159712435:- PAAD cis rs875971 0.522 rs709604 ENSG00000234585.5 CCT6P3 -4.51 1.27e-05 0.00648 -0.27 -0.34 Aortic root size; chr7:66032447 chr7:65038354~65074713:+ PAAD cis rs62229266 0.839 rs11702763 ENSG00000231106.2 LINC01436 4.51 1.27e-05 0.00648 0.5 0.34 Mitral valve prolapse; chr21:36098406 chr21:36005338~36007838:+ PAAD cis rs9322193 0.607 rs3798763 ENSG00000268592.3 RAET1E-AS1 4.51 1.27e-05 0.00649 0.46 0.34 Lung cancer; chr6:149889964 chr6:149863494~149919507:+ PAAD cis rs4835473 0.932 rs35863996 ENSG00000251600.4 RP11-673E1.1 -4.51 1.27e-05 0.00649 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143752260 chr4:143912331~143982454:+ PAAD cis rs4835473 0.778 rs75562808 ENSG00000251600.4 RP11-673E1.1 -4.51 1.27e-05 0.00649 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143779065 chr4:143912331~143982454:+ PAAD cis rs4835473 0.808 rs4054643 ENSG00000251600.4 RP11-673E1.1 -4.51 1.27e-05 0.00649 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143787329 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs34819068 ENSG00000251600.4 RP11-673E1.1 -4.51 1.27e-05 0.00649 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143787330 chr4:143912331~143982454:+ PAAD cis rs193541 0.545 rs112390044 ENSG00000263432.2 RN7SL689P -4.51 1.27e-05 0.00649 -0.44 -0.34 Glucose homeostasis traits; chr5:122976307 chr5:123022487~123022783:- PAAD cis rs2404602 1 rs2896954 ENSG00000259422.1 RP11-593F23.1 4.51 1.28e-05 0.0065 0.4 0.34 Blood metabolite levels; chr15:76559351 chr15:76174891~76181486:- PAAD cis rs2404602 1 rs2404741 ENSG00000259422.1 RP11-593F23.1 4.51 1.28e-05 0.0065 0.4 0.34 Blood metabolite levels; chr15:76559394 chr15:76174891~76181486:- PAAD cis rs2404602 1 rs2404740 ENSG00000259422.1 RP11-593F23.1 4.51 1.28e-05 0.0065 0.4 0.34 Blood metabolite levels; chr15:76559802 chr15:76174891~76181486:- PAAD cis rs2658782 0.704 rs2658766 ENSG00000279684.1 RP11-755E23.2 -4.51 1.28e-05 0.0065 -0.55 -0.34 Pulmonary function decline; chr11:93499063 chr11:93286629~93288903:- PAAD cis rs6840258 0.66 rs72667737 ENSG00000251411.1 RP11-397E7.4 -4.51 1.28e-05 0.0065 -0.4 -0.34 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86955264 chr4:86913266~86914817:- PAAD cis rs6840258 0.66 rs72667739 ENSG00000251411.1 RP11-397E7.4 -4.51 1.28e-05 0.0065 -0.4 -0.34 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86956347 chr4:86913266~86914817:- PAAD cis rs10510102 0.516 rs3936070 ENSG00000276742.1 RP11-500G22.4 4.51 1.28e-05 0.0065 0.5 0.34 Breast cancer; chr10:121974440 chr10:121956782~121957098:+ PAAD cis rs6480314 0.706 rs2394465 ENSG00000233590.1 RP11-153K11.3 4.51 1.28e-05 0.0065 0.47 0.34 Optic nerve measurement (disc area); chr10:68224349 chr10:68233251~68242379:- PAAD cis rs6142102 0.923 rs2268078 ENSG00000276073.1 RP5-1125A11.7 -4.51 1.28e-05 0.00651 -0.37 -0.34 Skin pigmentation; chr20:34008898 chr20:33985617~33988989:- PAAD cis rs2255336 0.938 rs61917723 ENSG00000245648.1 RP11-277P12.20 -4.51 1.28e-05 0.00651 -0.55 -0.34 Blood protein levels; chr12:10472728 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs61917750 ENSG00000245648.1 RP11-277P12.20 -4.51 1.28e-05 0.00651 -0.55 -0.34 Blood protein levels; chr12:10480824 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs7953692 ENSG00000245648.1 RP11-277P12.20 -4.51 1.28e-05 0.00651 -0.55 -0.34 Blood protein levels; chr12:10482432 chr12:10363769~10398506:+ PAAD cis rs6538678 0.864 rs7308921 ENSG00000258343.1 RP11-536G4.2 4.51 1.28e-05 0.00651 0.43 0.34 Lupus nephritis in systemic lupus erythematosus; chr12:95870757 chr12:95795345~95858839:- PAAD cis rs2564921 0.73 rs58492539 ENSG00000242142.1 SERBP1P3 -4.51 1.28e-05 0.00652 -0.43 -0.34 Height; chr3:53052712 chr3:53064283~53065091:- PAAD cis rs8023057 0.755 rs17826595 ENSG00000252481.1 SCARNA13 -4.51 1.28e-05 0.00652 -0.43 -0.34 Prostate-specific antigen levels; chr14:94643496 chr14:95533355~95533629:- PAAD cis rs10129255 0.509 rs756583 ENSG00000211972.2 IGHV3-66 4.51 1.28e-05 0.00652 0.27 0.34 Kawasaki disease; chr14:106680002 chr14:106675017~106675544:- PAAD cis rs1075265 0.901 rs1118618 ENSG00000233266.1 HMGB1P31 4.51 1.28e-05 0.00653 0.45 0.34 Chronotype;Morning vs. evening chronotype; chr2:54099333 chr2:54051334~54051760:+ PAAD cis rs3823536 0.583 rs3778750 ENSG00000275106.1 RP11-309L24.10 -4.51 1.28e-05 0.00653 -0.46 -0.34 Sjögren's syndrome; chr7:128977035 chr7:128952527~128953316:- PAAD cis rs17772222 0.839 rs2274735 ENSG00000258983.2 RP11-507K2.2 4.51 1.28e-05 0.00653 0.42 0.34 Coronary artery calcification; chr14:88505414 chr14:88499334~88515502:+ PAAD cis rs17772222 0.682 rs7142053 ENSG00000258983.2 RP11-507K2.2 4.51 1.28e-05 0.00653 0.42 0.34 Coronary artery calcification; chr14:88511594 chr14:88499334~88515502:+ PAAD cis rs8062405 0.723 rs113208333 ENSG00000251417.2 RP11-1348G14.4 -4.51 1.28e-05 0.00653 -0.32 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28594839 chr16:28802743~28817828:+ PAAD cis rs9828933 0.766 rs864975 ENSG00000280620.1 SCAANT1 -4.51 1.28e-05 0.00654 -0.6 -0.34 Type 2 diabetes; chr3:63899939 chr3:63911518~63911772:- PAAD cis rs2946504 0.861 rs2954171 ENSG00000251468.2 RP11-369K16.1 -4.51 1.29e-05 0.00656 -0.43 -0.34 Type 2 diabetes; chr8:12956087 chr8:12958387~12962200:+ PAAD cis rs2946504 0.861 rs2977085 ENSG00000251468.2 RP11-369K16.1 -4.51 1.29e-05 0.00656 -0.43 -0.34 Type 2 diabetes; chr8:12956237 chr8:12958387~12962200:+ PAAD cis rs2946504 0.861 rs2977081 ENSG00000251468.2 RP11-369K16.1 -4.51 1.29e-05 0.00656 -0.43 -0.34 Type 2 diabetes; chr8:12958272 chr8:12958387~12962200:+ PAAD cis rs112721625 1 rs112721625 ENSG00000266992.1 DHX40P1 4.51 1.29e-05 0.00656 0.37 0.34 Monocyte count; chr17:59850066 chr17:59976009~60002384:- PAAD cis rs7923609 0.902 rs10733793 ENSG00000232075.1 MRPL35P2 -4.51 1.29e-05 0.00657 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63564049 chr10:63634317~63634827:- PAAD cis rs7923609 0.902 rs10822182 ENSG00000232075.1 MRPL35P2 -4.51 1.29e-05 0.00657 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63565718 chr10:63634317~63634827:- PAAD cis rs7923609 0.902 rs4633333 ENSG00000232075.1 MRPL35P2 -4.51 1.29e-05 0.00657 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63568779 chr10:63634317~63634827:- PAAD cis rs7923609 0.902 rs10740136 ENSG00000232075.1 MRPL35P2 -4.51 1.29e-05 0.00657 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63569862 chr10:63634317~63634827:- PAAD cis rs11123170 0.529 rs35606997 ENSG00000274877.1 RP11-65I12.1 -4.51 1.29e-05 0.00658 -0.45 -0.34 Renal function-related traits (BUN); chr2:113215773 chr2:113237595~113240825:+ PAAD cis rs7615952 0.688 rs9754526 ENSG00000239804.1 RP11-379B18.1 4.51 1.29e-05 0.00658 0.46 0.34 Blood pressure (smoking interaction); chr3:125824023 chr3:125787888~125788146:- PAAD cis rs7615952 0.512 rs34085484 ENSG00000239804.1 RP11-379B18.1 4.51 1.29e-05 0.00658 0.46 0.34 Blood pressure (smoking interaction); chr3:125825343 chr3:125787888~125788146:- PAAD cis rs7615952 0.608 rs35668111 ENSG00000239804.1 RP11-379B18.1 4.51 1.29e-05 0.00658 0.46 0.34 Blood pressure (smoking interaction); chr3:125825792 chr3:125787888~125788146:- PAAD cis rs2564921 0.73 rs6781896 ENSG00000242142.1 SERBP1P3 -4.51 1.29e-05 0.00658 -0.44 -0.34 Height; chr3:53047596 chr3:53064283~53065091:- PAAD cis rs7826238 0.594 rs2948285 ENSG00000253981.4 ALG1L13P 4.51 1.29e-05 0.00658 0.43 0.34 Systolic blood pressure; chr8:8273016 chr8:8236003~8244667:- PAAD cis rs7829975 0.511 rs2955578 ENSG00000253981.4 ALG1L13P 4.51 1.29e-05 0.00658 0.43 0.34 Mood instability; chr8:8279561 chr8:8236003~8244667:- PAAD cis rs17214007 0.877 rs4482303 ENSG00000263335.1 AF001548.5 -4.51 1.3e-05 0.00658 -0.49 -0.34 Cognitive function; chr16:15777020 chr16:15726674~15732993:+ PAAD cis rs7727544 0.735 rs274558 ENSG00000233006.5 AC034220.3 -4.51 1.3e-05 0.00659 -0.29 -0.34 Blood metabolite levels; chr5:132385482 chr5:132311285~132369916:- PAAD cis rs7727544 0.735 rs274557 ENSG00000233006.5 AC034220.3 -4.51 1.3e-05 0.00659 -0.29 -0.34 Blood metabolite levels; chr5:132385512 chr5:132311285~132369916:- PAAD cis rs4835473 0.9 rs4285038 ENSG00000251600.4 RP11-673E1.1 -4.51 1.3e-05 0.00659 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143763637 chr4:143912331~143982454:+ PAAD cis rs79040073 0.637 rs111375880 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49120197 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs17394420 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49128619 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs17473148 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49137213 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs74798636 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49143146 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs79455310 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49146918 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs79979867 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49177261 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs80214300 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49180767 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs79723325 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49193423 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs77815234 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49193495 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs77965410 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49194450 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs112792737 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49198849 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs75391491 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49210376 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs12913966 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49214290 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs75691966 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49214743 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs117582142 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49228624 chr15:49365124~49366685:- PAAD cis rs79040073 0.565 rs11638515 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49233530 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11632303 ENSG00000259531.2 RP11-295H24.3 4.51 1.3e-05 0.00659 0.58 0.34 Lung cancer in ever smokers; chr15:49238124 chr15:49365124~49366685:- PAAD cis rs875971 0.522 rs9530 ENSG00000237310.1 GS1-124K5.4 4.51 1.3e-05 0.00659 0.33 0.34 Aortic root size; chr7:65960907 chr7:66493706~66495474:+ PAAD cis rs10754283 0.967 rs1953821 ENSG00000231613.1 RP5-943J3.1 4.51 1.3e-05 0.00659 0.37 0.34 Amyotrophic lateral sclerosis (sporadic); chr1:89641539 chr1:89788914~89790492:+ PAAD cis rs77372450 0.636 rs6889203 ENSG00000251405.2 CTB-109A12.1 4.51 1.3e-05 0.0066 0.54 0.34 Bipolar disorder (body mass index interaction); chr5:157566863 chr5:157362615~157460078:- PAAD cis rs34375054 0.624 rs12826658 ENSG00000279233.1 RP11-158L12.4 4.51 1.3e-05 0.0066 0.28 0.34 Post bronchodilator FEV1/FVC ratio; chr12:125195691 chr12:125138245~125141711:+ PAAD cis rs34375054 0.624 rs12832525 ENSG00000279233.1 RP11-158L12.4 4.51 1.3e-05 0.0066 0.28 0.34 Post bronchodilator FEV1/FVC ratio; chr12:125195820 chr12:125138245~125141711:+ PAAD cis rs34375054 0.624 rs7295689 ENSG00000279233.1 RP11-158L12.4 4.51 1.3e-05 0.0066 0.28 0.34 Post bronchodilator FEV1/FVC ratio; chr12:125196376 chr12:125138245~125141711:+ PAAD cis rs4950322 0.58 rs7515160 ENSG00000278811.3 LINC00624 4.51 1.3e-05 0.0066 0.34 0.34 Protein quantitative trait loci; chr1:147120714 chr1:147258885~147517875:- PAAD cis rs875971 0.66 rs10215132 ENSG00000237310.1 GS1-124K5.4 -4.51 1.3e-05 0.0066 -0.32 -0.34 Aortic root size; chr7:66589419 chr7:66493706~66495474:+ PAAD cis rs4835473 0.897 rs1391189 ENSG00000251600.4 RP11-673E1.1 -4.51 1.3e-05 0.00661 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143690951 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs36083752 ENSG00000251600.4 RP11-673E1.1 -4.51 1.3e-05 0.00661 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143693377 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs35162238 ENSG00000251600.4 RP11-673E1.1 -4.51 1.3e-05 0.00661 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143693518 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs11100802 ENSG00000251600.4 RP11-673E1.1 -4.51 1.3e-05 0.00661 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143700046 chr4:143912331~143982454:+ PAAD cis rs4835473 0.863 rs7696828 ENSG00000251600.4 RP11-673E1.1 4.51 1.3e-05 0.00661 0.38 0.34 Immature fraction of reticulocytes; chr4:143700846 chr4:143912331~143982454:+ PAAD cis rs797680 0.789 rs35940311 ENSG00000223745.6 RP4-717I23.3 4.51 1.3e-05 0.00661 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93198047 chr1:93262186~93346025:- PAAD cis rs950169 0.656 rs748455 ENSG00000259295.5 CSPG4P12 4.51 1.3e-05 0.00662 0.39 0.34 Schizophrenia; chr15:84606344 chr15:85191438~85213905:+ PAAD cis rs216345 0.763 rs7033336 ENSG00000230074.1 RP11-195F19.9 4.51 1.3e-05 0.00662 0.47 0.34 Bipolar disorder; chr9:34012524 chr9:34665665~34681298:+ PAAD cis rs673078 0.562 rs61944668 ENSG00000275759.1 RP11-131L12.3 -4.51 1.3e-05 0.00662 -0.56 -0.34 Glucose homeostasis traits; chr12:118448446 chr12:118428281~118428870:+ PAAD cis rs2412819 0.52 rs17727763 ENSG00000249839.1 AC011330.5 -4.51 1.3e-05 0.00662 -0.62 -0.34 Lung cancer; chr15:43623873 chr15:43663654~43684339:- PAAD cis rs3743772 0.5 rs4784308 ENSG00000279344.1 RP11-44F14.7 4.51 1.31e-05 0.00663 0.37 0.34 Depressive symptoms (SSRI exposure interaction); chr16:53406387 chr16:53478957~53481550:- PAAD cis rs2274273 1 rs67098772 ENSG00000258413.1 RP11-665C16.6 -4.51 1.31e-05 0.00663 -0.45 -0.34 Protein biomarker; chr14:55128524 chr14:55262767~55272075:- PAAD cis rs16846053 0.71 rs13006199 ENSG00000227403.1 AC009299.3 4.51 1.31e-05 0.00663 0.54 0.34 Blood osmolality (transformed sodium); chr2:161770258 chr2:161244739~161249050:+ PAAD cis rs12908161 1 rs17601029 ENSG00000259728.4 LINC00933 4.51 1.31e-05 0.00663 0.44 0.34 Schizophrenia; chr15:84804478 chr15:84570649~84580175:+ PAAD cis rs4852324 0.536 rs6721042 ENSG00000217702.2 RP11-287D1.4 4.51 1.31e-05 0.00663 0.98 0.34 Systemic lupus erythematosus; chr2:73990156 chr2:74130583~74135395:+ PAAD cis rs797680 0.82 rs11164879 ENSG00000223745.6 RP4-717I23.3 4.51 1.31e-05 0.00663 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93189965 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs7541687 ENSG00000223745.6 RP4-717I23.3 4.51 1.31e-05 0.00663 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93191031 chr1:93262186~93346025:- PAAD cis rs797680 0.753 rs11164881 ENSG00000223745.6 RP4-717I23.3 4.51 1.31e-05 0.00663 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93193432 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs10874764 ENSG00000223745.6 RP4-717I23.3 4.51 1.31e-05 0.00663 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93195785 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs2031225 ENSG00000223745.6 RP4-717I23.3 -4.51 1.31e-05 0.00663 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93321157 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs6703310 ENSG00000223745.6 RP4-717I23.3 4.51 1.31e-05 0.00663 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93323183 chr1:93262186~93346025:- PAAD cis rs797680 0.821 rs2391254 ENSG00000223745.6 RP4-717I23.3 4.51 1.31e-05 0.00663 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93329609 chr1:93262186~93346025:- PAAD cis rs797680 0.82 rs10874773 ENSG00000223745.6 RP4-717I23.3 4.51 1.31e-05 0.00663 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93332939 chr1:93262186~93346025:- PAAD cis rs73110464 0.609 rs6580923 ENSG00000278185.1 RP11-153F5.7 4.51 1.31e-05 0.00663 0.46 0.34 Cancer (pleiotropy); chr12:52964568 chr12:52946614~52947125:- PAAD cis rs58873874 0.737 rs9313608 ENSG00000251405.2 CTB-109A12.1 -4.51 1.31e-05 0.00663 -0.69 -0.34 Bipolar disorder (body mass index interaction); chr5:157473039 chr5:157362615~157460078:- PAAD cis rs875971 0.619 rs12533585 ENSG00000237310.1 GS1-124K5.4 4.51 1.31e-05 0.00663 0.32 0.34 Aortic root size; chr7:66519618 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs12698534 ENSG00000237310.1 GS1-124K5.4 4.51 1.31e-05 0.00663 0.32 0.34 Aortic root size; chr7:66521858 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs28698552 ENSG00000237310.1 GS1-124K5.4 4.51 1.31e-05 0.00663 0.32 0.34 Aortic root size; chr7:66540031 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs62465434 ENSG00000237310.1 GS1-124K5.4 4.51 1.31e-05 0.00663 0.32 0.34 Aortic root size; chr7:66540165 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs13224319 ENSG00000237310.1 GS1-124K5.4 4.51 1.31e-05 0.00663 0.32 0.34 Aortic root size; chr7:66542376 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs801217 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66545590 chr7:66493706~66495474:+ PAAD cis rs875971 0.638 rs801216 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66546680 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs801211 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66550702 chr7:66493706~66495474:+ PAAD cis rs875971 0.638 rs801205 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66557157 chr7:66493706~66495474:+ PAAD cis rs875971 0.617 rs810400 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66557902 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs801193 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66565625 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs801192 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66566965 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs801190 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66568046 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs3857686 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66571204 chr7:66493706~66495474:+ PAAD cis rs875971 0.638 rs3898855 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66571411 chr7:66493706~66495474:+ PAAD cis rs875971 0.638 rs10278816 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66572000 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs10281080 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66577454 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs10950044 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66577989 chr7:66493706~66495474:+ PAAD cis rs875971 0.638 rs10249404 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66581737 chr7:66493706~66495474:+ PAAD cis rs875971 0.619 rs10278371 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66586553 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs1968127 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66591816 chr7:66493706~66495474:+ PAAD cis rs875971 0.638 rs6460305 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66595421 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs10272357 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66598087 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs79009421 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66603522 chr7:66493706~66495474:+ PAAD cis rs875971 0.638 rs6960778 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66606610 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs6460308 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66619753 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs7807930 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66622178 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs7807944 ENSG00000237310.1 GS1-124K5.4 -4.51 1.31e-05 0.00663 -0.32 -0.34 Aortic root size; chr7:66622208 chr7:66493706~66495474:+ PAAD cis rs858239 0.632 rs7811903 ENSG00000226816.2 AC005082.12 4.51 1.31e-05 0.00663 0.39 0.34 Cerebrospinal fluid biomarker levels; chr7:23079437 chr7:23206013~23208045:+ PAAD cis rs34435647 1 rs34435647 ENSG00000226266.5 AC009961.3 -4.51 1.31e-05 0.00664 -0.44 -0.34 Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells; chr2:159661779 chr2:159670708~159712435:- PAAD cis rs4835473 0.9 rs58106929 ENSG00000251600.4 RP11-673E1.1 4.51 1.31e-05 0.00665 0.38 0.34 Immature fraction of reticulocytes; chr4:143733166 chr4:143912331~143982454:+ PAAD cis rs79349575 0.756 rs937301 ENSG00000270781.1 RP11-501C14.9 4.51 1.32e-05 0.00666 0.38 0.34 Type 2 diabetes; chr17:48968914 chr17:48899131~48899748:+ PAAD cis rs853679 0.882 rs9380069 ENSG00000226314.6 ZNF192P1 -4.5 1.32e-05 0.00666 -0.56 -0.34 Depression; chr6:28235522 chr6:28161781~28169594:+ PAAD cis rs6142102 0.646 rs2223553 ENSG00000276073.1 RP5-1125A11.7 -4.5 1.32e-05 0.00666 -0.36 -0.34 Skin pigmentation; chr20:34121638 chr20:33985617~33988989:- PAAD cis rs7580658 0.545 rs885275 ENSG00000236682.1 AC068282.3 -4.5 1.32e-05 0.00667 -0.42 -0.34 Protein C levels; chr2:127193519 chr2:127389130~127400580:+ PAAD cis rs2980439 0.818 rs2948294 ENSG00000253981.4 ALG1L13P 4.5 1.32e-05 0.00667 0.43 0.34 Neuroticism; chr8:8237439 chr8:8236003~8244667:- PAAD cis rs2976388 0.647 rs2585154 ENSG00000253741.1 CTD-2292P10.4 -4.5 1.32e-05 0.00667 -0.4 -0.34 Urinary tract infection frequency; chr8:142702067 chr8:142702252~142726973:- PAAD cis rs797680 0.856 rs693737 ENSG00000223745.6 RP4-717I23.3 -4.5 1.32e-05 0.00667 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93259367 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs602204 ENSG00000223745.6 RP4-717I23.3 -4.5 1.32e-05 0.00667 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93262022 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs535760 ENSG00000223745.6 RP4-717I23.3 -4.5 1.32e-05 0.00667 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93263201 chr1:93262186~93346025:- PAAD cis rs12554020 0.786 rs7857183 ENSG00000227603.1 RP11-165J3.6 4.5 1.32e-05 0.00667 0.5 0.34 Schizophrenia; chr9:93569762 chr9:93435332~93437121:- PAAD cis rs9322193 0.566 rs12528243 ENSG00000268592.3 RAET1E-AS1 4.5 1.32e-05 0.00668 0.46 0.34 Lung cancer; chr6:149898491 chr6:149863494~149919507:+ PAAD cis rs17023223 0.581 rs10923750 ENSG00000231365.4 RP11-418J17.1 -4.5 1.32e-05 0.00668 -0.37 -0.34 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119108172 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs10923754 ENSG00000231365.4 RP11-418J17.1 -4.5 1.32e-05 0.00668 -0.37 -0.34 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119126017 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs10923756 ENSG00000231365.4 RP11-418J17.1 -4.5 1.32e-05 0.00668 -0.37 -0.34 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119132025 chr1:119140396~119275973:+ PAAD cis rs9584850 0.834 rs2031239 ENSG00000231194.1 FARP1-AS1 4.5 1.32e-05 0.00668 0.44 0.34 Neuroticism; chr13:98459306 chr13:98435405~98435840:- PAAD cis rs2717559 0.561 rs7841267 ENSG00000253741.1 CTD-2292P10.4 4.5 1.32e-05 0.00669 0.46 0.34 Urinary tract infection frequency; chr8:142800267 chr8:142702252~142726973:- PAAD cis rs748404 0.631 rs7167882 ENSG00000205771.5 CATSPER2P1 -4.5 1.32e-05 0.00669 -0.46 -0.34 Lung cancer; chr15:43386465 chr15:43726918~43747094:- PAAD cis rs9595908 0.931 rs9595630 ENSG00000212293.1 SNORA16 -4.5 1.32e-05 0.00669 -0.39 -0.34 Body mass index; chr13:32491306 chr13:32420390~32420516:- PAAD cis rs858239 0.665 rs6964665 ENSG00000226816.2 AC005082.12 4.5 1.32e-05 0.00669 0.39 0.34 Cerebrospinal fluid biomarker levels; chr7:23171733 chr7:23206013~23208045:+ PAAD cis rs748404 0.66 rs690367 ENSG00000205771.5 CATSPER2P1 4.5 1.33e-05 0.0067 0.48 0.34 Lung cancer; chr15:43456106 chr15:43726918~43747094:- PAAD cis rs73110464 0.609 rs4919752 ENSG00000278185.1 RP11-153F5.7 4.5 1.33e-05 0.0067 0.45 0.34 Cancer (pleiotropy); chr12:52965445 chr12:52946614~52947125:- PAAD cis rs1075265 0.656 rs2542574 ENSG00000233266.1 HMGB1P31 4.5 1.33e-05 0.00671 0.43 0.34 Chronotype;Morning vs. evening chronotype; chr2:53820295 chr2:54051334~54051760:+ PAAD cis rs871012 0.502 rs6891843 ENSG00000251405.2 CTB-109A12.1 -4.5 1.33e-05 0.00671 -0.44 -0.34 IgG glycosylation; chr5:157416739 chr5:157362615~157460078:- PAAD cis rs797680 0.856 rs627779 ENSG00000223745.6 RP4-717I23.3 -4.5 1.33e-05 0.00671 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93218532 chr1:93262186~93346025:- PAAD cis rs797680 0.796 rs797661 ENSG00000223745.6 RP4-717I23.3 -4.5 1.33e-05 0.00671 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93221534 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs12030549 ENSG00000223745.6 RP4-717I23.3 4.5 1.33e-05 0.00671 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93203661 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs531358 ENSG00000223745.6 RP4-717I23.3 4.5 1.33e-05 0.00671 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93210454 chr1:93262186~93346025:- PAAD cis rs797680 0.786 rs555161 ENSG00000223745.6 RP4-717I23.3 4.5 1.33e-05 0.00671 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93210757 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs2765545 ENSG00000223745.6 RP4-717I23.3 4.5 1.33e-05 0.00671 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93211712 chr1:93262186~93346025:- PAAD cis rs797680 0.786 rs10874772 ENSG00000223745.6 RP4-717I23.3 4.5 1.33e-05 0.00671 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93322213 chr1:93262186~93346025:- PAAD cis rs4950322 0.542 rs56080828 ENSG00000278811.3 LINC00624 4.5 1.33e-05 0.00671 0.35 0.34 Protein quantitative trait loci; chr1:147183447 chr1:147258885~147517875:- PAAD cis rs4950322 0.542 rs3766520 ENSG00000278811.3 LINC00624 4.5 1.33e-05 0.00671 0.35 0.34 Protein quantitative trait loci; chr1:147214658 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs79810882 ENSG00000278811.3 LINC00624 4.5 1.33e-05 0.00671 0.35 0.34 Protein quantitative trait loci; chr1:147235575 chr1:147258885~147517875:- PAAD cis rs2976388 0.669 rs2976391 ENSG00000253741.1 CTD-2292P10.4 -4.5 1.33e-05 0.00671 -0.39 -0.34 Urinary tract infection frequency; chr8:142681306 chr8:142702252~142726973:- PAAD cis rs7945705 0.791 rs10769958 ENSG00000254860.4 TMEM9B-AS1 4.5 1.33e-05 0.00671 0.36 0.34 Hemoglobin concentration; chr11:8793568 chr11:8964675~8977527:+ PAAD cis rs7945705 0.738 rs11042067 ENSG00000254860.4 TMEM9B-AS1 4.5 1.33e-05 0.00671 0.36 0.34 Hemoglobin concentration; chr11:8793906 chr11:8964675~8977527:+ PAAD cis rs13178541 0.81 rs9327728 ENSG00000250378.1 RP11-119J18.1 -4.5 1.33e-05 0.00671 -0.53 -0.34 IgG glycosylation; chr5:135760318 chr5:135812667~135826582:+ PAAD cis rs13178541 0.745 rs4605777 ENSG00000250378.1 RP11-119J18.1 -4.5 1.33e-05 0.00671 -0.53 -0.34 IgG glycosylation; chr5:135760855 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs4452549 ENSG00000250378.1 RP11-119J18.1 -4.5 1.33e-05 0.00671 -0.53 -0.34 IgG glycosylation; chr5:135762020 chr5:135812667~135826582:+ PAAD cis rs13178541 0.745 rs35767093 ENSG00000250378.1 RP11-119J18.1 -4.5 1.33e-05 0.00671 -0.53 -0.34 IgG glycosylation; chr5:135765243 chr5:135812667~135826582:+ PAAD cis rs13178541 0.745 rs10900833 ENSG00000250378.1 RP11-119J18.1 -4.5 1.33e-05 0.00671 -0.53 -0.34 IgG glycosylation; chr5:135765741 chr5:135812667~135826582:+ PAAD cis rs13178541 0.81 rs10900834 ENSG00000250378.1 RP11-119J18.1 -4.5 1.33e-05 0.00671 -0.53 -0.34 IgG glycosylation; chr5:135765792 chr5:135812667~135826582:+ PAAD cis rs13178541 0.745 rs7379919 ENSG00000250378.1 RP11-119J18.1 -4.5 1.33e-05 0.00671 -0.53 -0.34 IgG glycosylation; chr5:135767028 chr5:135812667~135826582:+ PAAD cis rs9652601 0.843 rs7204643 ENSG00000274038.1 RP11-66H6.4 4.5 1.33e-05 0.00672 0.39 0.34 Systemic lupus erythematosus; chr16:11073746 chr16:11056556~11057034:+ PAAD cis rs875971 1 rs709597 ENSG00000237310.1 GS1-124K5.4 -4.5 1.33e-05 0.00672 -0.33 -0.34 Aortic root size; chr7:66360996 chr7:66493706~66495474:+ PAAD cis rs2255336 0.938 rs73070926 ENSG00000245648.1 RP11-277P12.20 -4.5 1.33e-05 0.00672 -0.55 -0.34 Blood protein levels; chr12:10459717 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs7298494 ENSG00000245648.1 RP11-277P12.20 -4.5 1.33e-05 0.00672 -0.55 -0.34 Blood protein levels; chr12:10460666 chr12:10363769~10398506:+ PAAD cis rs4268898 0.932 rs7577964 ENSG00000242628.4 AC009228.1 -4.5 1.33e-05 0.00672 -0.41 -0.34 Asthma; chr2:24375410 chr2:24214381~24221516:+ PAAD cis rs2486288 0.656 rs12440356 ENSG00000259433.2 CTD-2651B20.4 -4.5 1.33e-05 0.00672 -0.37 -0.34 Glomerular filtration rate; chr15:45275331 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11639349 ENSG00000259433.2 CTD-2651B20.4 4.5 1.33e-05 0.00672 0.37 0.34 Glomerular filtration rate; chr15:45276062 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs1719232 ENSG00000259433.2 CTD-2651B20.4 4.5 1.33e-05 0.00672 0.37 0.34 Glomerular filtration rate; chr15:45279874 chr15:45330209~45332634:- PAAD cis rs748404 0.697 rs1814323 ENSG00000249839.1 AC011330.5 4.5 1.33e-05 0.00673 0.48 0.34 Lung cancer; chr15:43271039 chr15:43663654~43684339:- PAAD cis rs9368481 0.761 rs9348746 ENSG00000241549.7 GUSBP2 -4.5 1.33e-05 0.00673 -0.36 -0.34 Autism spectrum disorder or schizophrenia; chr6:27002578 chr6:26871484~26956554:- PAAD cis rs9368481 0.761 rs9357030 ENSG00000241549.7 GUSBP2 -4.5 1.33e-05 0.00673 -0.36 -0.34 Autism spectrum disorder or schizophrenia; chr6:27017247 chr6:26871484~26956554:- PAAD cis rs9368481 0.761 rs9379952 ENSG00000241549.7 GUSBP2 -4.5 1.33e-05 0.00673 -0.36 -0.34 Autism spectrum disorder or schizophrenia; chr6:27020121 chr6:26871484~26956554:- PAAD cis rs7208859 0.614 rs216412 ENSG00000266490.1 CTD-2349P21.9 -4.5 1.33e-05 0.00673 -0.4 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30576376 chr17:30792372~30792833:+ PAAD cis rs9309711 0.961 rs6739269 ENSG00000225234.1 TRAPPC12-AS1 -4.5 1.33e-05 0.00673 -0.38 -0.34 Neurofibrillary tangles; chr2:3467224 chr2:3481242~3482409:- PAAD cis rs9309711 0.961 rs11686236 ENSG00000225234.1 TRAPPC12-AS1 -4.5 1.33e-05 0.00673 -0.38 -0.34 Neurofibrillary tangles; chr2:3467778 chr2:3481242~3482409:- PAAD cis rs113835537 0.877 rs2229456 ENSG00000255517.5 CTD-3074O7.5 -4.5 1.33e-05 0.00673 -0.56 -0.34 Airway imaging phenotypes; chr11:66561270 chr11:66473490~66480233:- PAAD cis rs9649213 0.593 rs6944262 ENSG00000272950.1 RP11-307C18.1 4.5 1.34e-05 0.00674 0.4 0.34 Prostate cancer (SNP x SNP interaction); chr7:98356103 chr7:98322853~98323430:+ PAAD cis rs638893 0.617 rs4938558 ENSG00000278376.1 RP11-158I9.8 -4.5 1.34e-05 0.00674 -0.36 -0.34 Vitiligo; chr11:118847220 chr11:118791254~118793137:+ PAAD cis rs867371 1 rs867370 ENSG00000259429.4 UBE2Q2P2 4.5 1.34e-05 0.00674 0.27 0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82145921 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs867371 ENSG00000259429.4 UBE2Q2P2 4.5 1.34e-05 0.00674 0.27 0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82146005 chr15:82355142~82420075:+ PAAD cis rs7208859 0.673 rs216418 ENSG00000266490.1 CTD-2349P21.9 4.5 1.34e-05 0.00674 0.41 0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30609519 chr17:30792372~30792833:+ PAAD cis rs2904804 1 rs2904804 ENSG00000224251.5 RP11-499O7.7 -4.5 1.34e-05 0.00674 -0.38 -0.34 Economic and political preferences (immigration/crime); chr10:4967567 chr10:4995488~4997380:+ PAAD cis rs7849973 0.579 rs10965453 ENSG00000224549.1 RP11-370B11.3 4.5 1.34e-05 0.00675 0.41 0.34 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22778493 chr9:22767175~22768316:+ PAAD cis rs797680 0.856 rs6680107 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93305323 chr1:93262186~93346025:- PAAD cis rs797680 0.891 rs9432453 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93306072 chr1:93262186~93346025:- PAAD cis rs797680 0.927 rs1000607 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93306444 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs4240966 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93309255 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs7537403 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93312167 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs11164902 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93313237 chr1:93262186~93346025:- PAAD cis rs797680 0.786 rs9432465 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93315034 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs7547244 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93316211 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs7540025 ENSG00000223745.6 RP4-717I23.3 -4.5 1.34e-05 0.00675 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93293671 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs9432681 ENSG00000223745.6 RP4-717I23.3 -4.5 1.34e-05 0.00675 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93296339 chr1:93262186~93346025:- PAAD cis rs797680 0.964 rs1932314 ENSG00000223745.6 RP4-717I23.3 4.5 1.34e-05 0.00675 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93172843 chr1:93262186~93346025:- PAAD cis rs797680 0.93 rs622608 ENSG00000223745.6 RP4-717I23.3 -4.5 1.34e-05 0.00677 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93249662 chr1:93262186~93346025:- PAAD cis rs12554020 0.892 rs12341488 ENSG00000227603.1 RP11-165J3.6 4.5 1.34e-05 0.00677 0.5 0.34 Schizophrenia; chr9:93568889 chr9:93435332~93437121:- PAAD cis rs12468226 0.873 rs1474267 ENSG00000273456.1 RP11-686O6.2 -4.5 1.35e-05 0.00678 -0.55 -0.34 Urate levels; chr2:202178596 chr2:202374932~202375604:- PAAD cis rs4660214 0.666 rs1180383 ENSG00000237624.1 OXCT2P1 4.5 1.35e-05 0.00678 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380595 chr1:39514956~39516490:+ PAAD cis rs748404 0.578 rs2012467 ENSG00000205771.5 CATSPER2P1 -4.5 1.35e-05 0.00678 -0.47 -0.34 Lung cancer; chr15:43398367 chr15:43726918~43747094:- PAAD cis rs4323050 0.546 rs13124157 ENSG00000251600.4 RP11-673E1.1 4.5 1.35e-05 0.00679 0.4 0.34 High light scatter reticulocyte percentage of red cells; chr4:143975741 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13147170 ENSG00000251600.4 RP11-673E1.1 4.5 1.35e-05 0.00679 0.4 0.34 Immature fraction of reticulocytes; chr4:143975848 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13147184 ENSG00000251600.4 RP11-673E1.1 4.5 1.35e-05 0.00679 0.4 0.34 Immature fraction of reticulocytes; chr4:143975873 chr4:143912331~143982454:+ PAAD cis rs4835473 0.8 rs13124170 ENSG00000251600.4 RP11-673E1.1 4.5 1.35e-05 0.00679 0.4 0.34 Immature fraction of reticulocytes; chr4:143975951 chr4:143912331~143982454:+ PAAD cis rs28374715 0.629 rs2118740 ENSG00000247556.5 OIP5-AS1 4.5 1.35e-05 0.00679 0.38 0.34 Ulcerative colitis; chr15:41285034 chr15:41283990~41309737:+ PAAD cis rs6538678 0.864 rs10777749 ENSG00000258343.1 RP11-536G4.2 -4.5 1.35e-05 0.00679 -0.43 -0.34 Lupus nephritis in systemic lupus erythematosus; chr12:95883182 chr12:95795345~95858839:- PAAD cis rs2283792 0.967 rs5999550 ENSG00000228050.1 TOP3BP1 4.5 1.35e-05 0.00679 0.36 0.34 Multiple sclerosis; chr22:21796997 chr22:22223187~22224566:- PAAD cis rs2562456 0.874 rs2562417 ENSG00000213976.4 CTD-2561J22.2 4.5 1.35e-05 0.0068 0.38 0.34 Pain; chr19:21528400 chr19:21382865~21387177:+ PAAD cis rs950880 0.71 rs11123929 ENSG00000234389.1 AC007278.3 -4.5 1.35e-05 0.0068 -0.34 -0.34 Serum protein levels (sST2); chr2:102450683 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs17027230 ENSG00000234389.1 AC007278.3 -4.5 1.35e-05 0.0068 -0.34 -0.34 Serum protein levels (sST2); chr2:102462870 chr2:102438713~102440475:+ PAAD cis rs4879677 1 rs9695197 ENSG00000260390.1 RP11-575I8.1 -4.5 1.35e-05 0.0068 -0.44 -0.34 Gut microbiome composition (summer and winter); chr9:27672340 chr9:27829276~27844481:+ PAAD cis rs4865169 0.871 rs9918067 ENSG00000269949.1 RP11-738E22.3 -4.5 1.35e-05 0.0068 -0.44 -0.34 Breast cancer; chr4:57004378 chr4:56960927~56961373:- PAAD cis rs4865169 1 rs4865169 ENSG00000269949.1 RP11-738E22.3 -4.5 1.35e-05 0.0068 -0.44 -0.34 Breast cancer; chr4:57013626 chr4:56960927~56961373:- PAAD cis rs4865169 0.967 rs10023088 ENSG00000269949.1 RP11-738E22.3 4.5 1.35e-05 0.0068 0.44 0.34 Breast cancer; chr4:57018269 chr4:56960927~56961373:- PAAD cis rs4423214 0.592 rs10898186 ENSG00000254682.1 RP11-660L16.2 -4.5 1.35e-05 0.00681 -0.57 -0.34 Vitamin D levels; chr11:71477754 chr11:71448674~71452157:+ PAAD cis rs6052484 0.523 rs11087634 ENSG00000226948.1 RPS4XP2 -4.5 1.35e-05 0.00681 -0.51 -0.34 Sense of smell; chr20:4340734 chr20:4629427~4630219:- PAAD cis rs4660214 0.756 rs11205823 ENSG00000237624.1 OXCT2P1 -4.5 1.36e-05 0.00682 -0.46 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39248566 chr1:39514956~39516490:+ PAAD cis rs6480314 0.522 rs10733842 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68299286 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs7902936 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68299584 chr10:68233251~68242379:- PAAD cis rs12571093 0.571 rs7903251 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68299969 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs4746756 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68301188 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs10740294 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68301595 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs4363487 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68301809 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs10762214 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68302555 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs12769008 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68302836 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs61857263 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68303370 chr10:68233251~68242379:- PAAD cis rs12571093 0.571 rs4517412 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68303779 chr10:68233251~68242379:- PAAD cis rs12571093 0.571 rs7097498 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68303780 chr10:68233251~68242379:- PAAD cis rs6480314 0.614 rs7067601 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68304213 chr10:68233251~68242379:- PAAD cis rs12571093 0.571 rs10740295 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68304313 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs10733843 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68304752 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs4746760 ENSG00000233590.1 RP11-153K11.3 4.5 1.36e-05 0.00682 0.54 0.34 Optic nerve measurement (disc area); chr10:68306122 chr10:68233251~68242379:- PAAD cis rs2281636 0.894 rs2297446 ENSG00000233690.1 EBAG9P1 4.5 1.36e-05 0.00682 0.36 0.34 Obesity-related traits; chr10:99610258 chr10:99697407~99697949:- PAAD cis rs801193 1 rs2659915 ENSG00000237310.1 GS1-124K5.4 4.5 1.36e-05 0.00683 0.31 0.34 Aortic root size; chr7:66688114 chr7:66493706~66495474:+ PAAD cis rs4865169 0.934 rs12650737 ENSG00000269949.1 RP11-738E22.3 -4.5 1.36e-05 0.00683 -0.45 -0.34 Breast cancer; chr4:57026309 chr4:56960927~56961373:- PAAD cis rs875971 1 rs6956179 ENSG00000237310.1 GS1-124K5.4 -4.5 1.36e-05 0.00683 -0.33 -0.34 Aortic root size; chr7:66341672 chr7:66493706~66495474:+ PAAD cis rs7727544 0.735 rs2631370 ENSG00000233006.5 AC034220.3 -4.5 1.36e-05 0.00684 -0.28 -0.34 Blood metabolite levels; chr5:132368084 chr5:132311285~132369916:- PAAD cis rs7727544 0.709 rs272852 ENSG00000233006.5 AC034220.3 4.5 1.36e-05 0.00684 0.28 0.34 Blood metabolite levels; chr5:132353074 chr5:132311285~132369916:- PAAD cis rs7727544 0.661 rs273900 ENSG00000233006.5 AC034220.3 4.5 1.36e-05 0.00684 0.28 0.34 Blood metabolite levels; chr5:132358913 chr5:132311285~132369916:- PAAD cis rs11079757 0.604 rs72823425 ENSG00000262879.4 RP11-156P1.3 4.5 1.36e-05 0.00685 0.45 0.34 Erythema nodosum in inflammatory bowel disease; chr17:47111303 chr17:46984045~47100323:- PAAD cis rs7727544 0.684 rs272849 ENSG00000233006.5 AC034220.3 4.5 1.36e-05 0.00685 0.28 0.34 Blood metabolite levels; chr5:132354548 chr5:132311285~132369916:- PAAD cis rs7727544 0.684 rs274546 ENSG00000233006.5 AC034220.3 4.5 1.36e-05 0.00685 0.28 0.34 Blood metabolite levels; chr5:132364175 chr5:132311285~132369916:- PAAD cis rs2404602 0.647 rs12913024 ENSG00000259422.1 RP11-593F23.1 -4.5 1.36e-05 0.00685 -0.42 -0.34 Blood metabolite levels; chr15:76852875 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs10851892 ENSG00000259422.1 RP11-593F23.1 -4.5 1.36e-05 0.00685 -0.42 -0.34 Blood metabolite levels; chr15:76884150 chr15:76174891~76181486:- PAAD cis rs338389 0.542 rs7182139 ENSG00000260657.2 RP11-315D16.4 -4.5 1.37e-05 0.00686 -0.39 -0.34 Survival in rectal cancer; chr15:67993116 chr15:68267792~68277994:- PAAD cis rs9419788 0.65 rs4388804 ENSG00000233377.1 MTND4P20 4.5 1.37e-05 0.00686 0.3 0.34 Personality traits in bipolar disorder; chr10:94222648 chr10:94940253~94941121:- PAAD cis rs4664293 0.647 rs1425039 ENSG00000226266.5 AC009961.3 -4.5 1.37e-05 0.00686 -0.42 -0.34 Monocyte percentage of white cells; chr2:159571612 chr2:159670708~159712435:- PAAD cis rs853679 0.76 rs9393910 ENSG00000226314.6 ZNF192P1 -4.5 1.37e-05 0.00687 -0.54 -0.34 Depression; chr6:28240414 chr6:28161781~28169594:+ PAAD cis rs853679 0.76 rs9368563 ENSG00000226314.6 ZNF192P1 -4.5 1.37e-05 0.00687 -0.54 -0.34 Depression; chr6:28240780 chr6:28161781~28169594:+ PAAD cis rs853679 0.76 rs9295768 ENSG00000226314.6 ZNF192P1 -4.5 1.37e-05 0.00687 -0.54 -0.34 Depression; chr6:28241324 chr6:28161781~28169594:+ PAAD cis rs2790457 0.958 rs2807754 ENSG00000254635.4 WAC-AS1 -4.5 1.37e-05 0.00687 -0.34 -0.34 Multiple myeloma; chr10:28598263 chr10:28522652~28532743:- PAAD cis rs2790457 0.958 rs2772431 ENSG00000254635.4 WAC-AS1 -4.5 1.37e-05 0.00687 -0.34 -0.34 Multiple myeloma; chr10:28601231 chr10:28522652~28532743:- PAAD cis rs2790457 0.958 rs2772432 ENSG00000254635.4 WAC-AS1 -4.5 1.37e-05 0.00687 -0.34 -0.34 Multiple myeloma; chr10:28605366 chr10:28522652~28532743:- PAAD cis rs9584850 0.874 rs4584 ENSG00000231194.1 FARP1-AS1 4.5 1.37e-05 0.00688 0.44 0.34 Neuroticism; chr13:98449615 chr13:98435405~98435840:- PAAD cis rs4423214 0.592 rs78300366 ENSG00000254682.1 RP11-660L16.2 -4.5 1.37e-05 0.00688 -0.57 -0.34 Vitamin D levels; chr11:71494468 chr11:71448674~71452157:+ PAAD cis rs964611 0.938 rs12592157 ENSG00000259488.2 RP11-154J22.1 -4.5 1.37e-05 0.00688 -0.37 -0.34 Metabolite levels (Pyroglutamine); chr15:48331327 chr15:48312353~48331856:- PAAD cis rs8059260 0.668 rs16957839 ENSG00000274038.1 RP11-66H6.4 -4.5 1.37e-05 0.00688 -0.59 -0.34 Alcohol consumption over the past year; chr16:10962521 chr16:11056556~11057034:+ PAAD cis rs853679 0.55 rs1150689 ENSG00000204709.4 LINC01556 4.5 1.37e-05 0.00688 0.59 0.34 Depression; chr6:28197321 chr6:28943877~28944537:+ PAAD cis rs853679 0.55 rs1225599 ENSG00000204709.4 LINC01556 4.5 1.37e-05 0.00688 0.59 0.34 Depression; chr6:28197412 chr6:28943877~28944537:+ PAAD cis rs112744032 1 rs112744032 ENSG00000240350.2 AC017002.1 -4.5 1.37e-05 0.00688 -0.6 -0.34 Mean corpuscular hemoglobin; chr2:111521757 chr2:111491273~111570974:+ PAAD cis rs62162297 1 rs62162297 ENSG00000240350.2 AC017002.1 -4.5 1.37e-05 0.00688 -0.6 -0.34 Red blood cell count; chr2:111521758 chr2:111491273~111570974:+ PAAD cis rs4268898 0.931 rs7603997 ENSG00000242628.4 AC009228.1 4.5 1.37e-05 0.00688 0.42 0.34 Asthma; chr2:24302089 chr2:24214381~24221516:+ PAAD cis rs4268898 0.931 rs60716082 ENSG00000242628.4 AC009228.1 4.5 1.37e-05 0.00688 0.42 0.34 Asthma; chr2:24303396 chr2:24214381~24221516:+ PAAD cis rs10510102 0.516 rs78586895 ENSG00000276742.1 RP11-500G22.4 4.49 1.37e-05 0.00689 0.5 0.34 Breast cancer; chr10:121977081 chr10:121956782~121957098:+ PAAD cis rs3738443 0.594 rs60050650 ENSG00000259865.1 RP11-488L18.10 4.49 1.37e-05 0.00689 0.3 0.34 Alcohol dependence; chr1:247213474 chr1:247187281~247188526:- PAAD cis rs12701220 0.503 rs12702047 ENSG00000229043.2 AC091729.9 -4.49 1.37e-05 0.00689 -0.48 -0.34 Bronchopulmonary dysplasia; chr7:1093084 chr7:1160374~1165267:+ PAAD cis rs4938303 0.633 rs12799441 ENSG00000254851.1 RP11-109L13.1 4.49 1.37e-05 0.00689 0.57 0.34 Triglycerides; chr11:116687799 chr11:117135528~117138582:+ PAAD cis rs12571093 0.773 rs61854802 ENSG00000233590.1 RP11-153K11.3 -4.49 1.37e-05 0.0069 -0.56 -0.34 Optic nerve measurement (disc area); chr10:68249815 chr10:68233251~68242379:- PAAD cis rs919433 0.963 rs1366837 ENSG00000231621.1 AC013264.2 4.49 1.38e-05 0.00691 0.33 0.34 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197295777 chr2:197197991~197199273:+ PAAD cis rs1729407 0.709 rs2098453 ENSG00000254851.1 RP11-109L13.1 -4.49 1.38e-05 0.00691 -0.42 -0.34 Apolipoprotein A-IV levels; chr11:116825964 chr11:117135528~117138582:+ PAAD cis rs1729407 0.625 rs2727789 ENSG00000254851.1 RP11-109L13.1 -4.49 1.38e-05 0.00691 -0.42 -0.34 Apolipoprotein A-IV levels; chr11:116826171 chr11:117135528~117138582:+ PAAD cis rs1729407 0.649 rs2849176 ENSG00000254851.1 RP11-109L13.1 4.49 1.38e-05 0.00691 0.42 0.34 Apolipoprotein A-IV levels; chr11:116826205 chr11:117135528~117138582:+ PAAD cis rs2412819 0.571 rs66903736 ENSG00000205771.5 CATSPER2P1 -4.49 1.38e-05 0.00691 -0.57 -0.34 Lung cancer; chr15:43619435 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs66749753 ENSG00000205771.5 CATSPER2P1 -4.49 1.38e-05 0.00691 -0.57 -0.34 Lung cancer; chr15:43619601 chr15:43726918~43747094:- PAAD cis rs4950322 0.58 rs1813002 ENSG00000278811.3 LINC00624 4.49 1.38e-05 0.00691 0.33 0.34 Protein quantitative trait loci; chr1:147112579 chr1:147258885~147517875:- PAAD cis rs853679 0.55 rs1233704 ENSG00000204709.4 LINC01556 -4.49 1.38e-05 0.00692 -0.58 -0.34 Depression; chr6:28199145 chr6:28943877~28944537:+ PAAD cis rs8100891 0.537 rs10417152 ENSG00000267213.4 AC007773.2 -4.49 1.38e-05 0.00692 -0.56 -0.34 Neuroticism; chr19:32397994 chr19:32390050~32405560:- PAAD cis rs1789 0.592 rs1558572 ENSG00000273133.1 RP11-799M12.2 -4.49 1.38e-05 0.00693 -0.48 -0.34 Blood protein levels; chr4:15537121 chr4:15563698~15564253:- PAAD cis rs7646881 0.812 rs73017541 ENSG00000240207.5 RP11-379F4.4 -4.49 1.38e-05 0.00693 -0.53 -0.34 Tetralogy of Fallot; chr3:158743007 chr3:158732263~158784070:+ PAAD cis rs10129255 0.54 rs35046566 ENSG00000223648.3 IGHV3-64 4.49 1.38e-05 0.00694 0.37 0.34 Kawasaki disease; chr14:106651018 chr14:106643132~106658258:- PAAD cis rs4950322 0.58 rs972368 ENSG00000278811.3 LINC00624 4.49 1.39e-05 0.00695 0.35 0.34 Protein quantitative trait loci; chr1:147111142 chr1:147258885~147517875:- PAAD cis rs7487075 1 rs7487075 ENSG00000270429.1 KNOP1P2 4.49 1.39e-05 0.00695 0.38 0.34 Itch intensity from mosquito bite; chr12:46435135 chr12:45880950~45882266:- PAAD cis rs113835537 0.935 rs3867133 ENSG00000255517.5 CTD-3074O7.5 4.49 1.39e-05 0.00695 0.58 0.34 Airway imaging phenotypes; chr11:66684491 chr11:66473490~66480233:- PAAD cis rs10510102 0.935 rs11200203 ENSG00000276742.1 RP11-500G22.4 4.49 1.39e-05 0.00695 0.51 0.34 Breast cancer; chr10:121874014 chr10:121956782~121957098:+ PAAD cis rs734999 0.545 rs4648565 ENSG00000225931.3 RP3-395M20.7 -4.49 1.39e-05 0.00696 -0.33 -0.34 Ulcerative colitis; chr1:2638584 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs28690427 ENSG00000225931.3 RP3-395M20.7 -4.49 1.39e-05 0.00696 -0.33 -0.34 Ulcerative colitis; chr1:2640384 chr1:2566410~2569888:+ PAAD cis rs210138 1 rs210144 ENSG00000197251.3 LINC00336 4.49 1.39e-05 0.00696 0.52 0.34 Testicular germ cell tumor; chr6:33579653 chr6:33586106~33593338:- PAAD cis rs6860540 0.796 rs55635824 ENSG00000251405.2 CTB-109A12.1 -4.49 1.39e-05 0.00696 -0.44 -0.34 Inflammatory skin disease; chr5:157466414 chr5:157362615~157460078:- PAAD cis rs7580658 0.545 rs885276 ENSG00000236682.1 AC068282.3 -4.49 1.39e-05 0.00696 -0.42 -0.34 Protein C levels; chr2:127193328 chr2:127389130~127400580:+ PAAD cis rs8100891 0.537 rs73038232 ENSG00000267213.4 AC007773.2 -4.49 1.39e-05 0.00696 -0.57 -0.34 Neuroticism; chr19:32496747 chr19:32390050~32405560:- PAAD cis rs4835473 0.669 rs75704080 ENSG00000251600.4 RP11-673E1.1 -4.49 1.39e-05 0.00696 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143779066 chr4:143912331~143982454:+ PAAD cis rs919433 0.963 rs2043016 ENSG00000231621.1 AC013264.2 4.49 1.39e-05 0.00697 0.33 0.34 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197281657 chr2:197197991~197199273:+ PAAD cis rs9652601 0.959 rs11865121 ENSG00000274038.1 RP11-66H6.4 -4.49 1.39e-05 0.00698 -0.39 -0.34 Systemic lupus erythematosus; chr16:11072831 chr16:11056556~11057034:+ PAAD cis rs9652601 0.959 rs7198621 ENSG00000274038.1 RP11-66H6.4 -4.49 1.39e-05 0.00698 -0.39 -0.34 Systemic lupus erythematosus; chr16:11073601 chr16:11056556~11057034:+ PAAD cis rs797680 0.822 rs942196 ENSG00000223745.6 RP4-717I23.3 4.49 1.39e-05 0.00699 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93336707 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs4847410 ENSG00000223745.6 RP4-717I23.3 4.49 1.39e-05 0.00699 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93337224 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs1535699 ENSG00000223745.6 RP4-717I23.3 4.49 1.39e-05 0.00699 0.28 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93339395 chr1:93262186~93346025:- PAAD cis rs3096299 0.933 rs3096297 ENSG00000274627.1 RP11-104N10.2 4.49 1.4e-05 0.00699 0.3 0.34 Multiple myeloma (IgH translocation); chr16:89386747 chr16:89516797~89522217:+ PAAD cis rs2486288 0.656 rs11631021 ENSG00000259433.2 CTD-2651B20.4 4.49 1.4e-05 0.00699 0.37 0.34 Glomerular filtration rate; chr15:45264631 chr15:45330209~45332634:- PAAD cis rs9309711 0.922 rs13431788 ENSG00000225234.1 TRAPPC12-AS1 -4.49 1.4e-05 0.007 -0.37 -0.34 Neurofibrillary tangles; chr2:3479141 chr2:3481242~3482409:- PAAD cis rs9309711 0.922 rs13385119 ENSG00000225234.1 TRAPPC12-AS1 -4.49 1.4e-05 0.007 -0.37 -0.34 Neurofibrillary tangles; chr2:3480750 chr2:3481242~3482409:- PAAD cis rs66887589 0.87 rs59590064 ENSG00000248280.1 RP11-33B1.2 -4.49 1.4e-05 0.007 -0.31 -0.34 Diastolic blood pressure; chr4:119618598 chr4:119440561~119450157:- PAAD cis rs66887589 0.934 rs6817317 ENSG00000248280.1 RP11-33B1.2 -4.49 1.4e-05 0.007 -0.31 -0.34 Diastolic blood pressure; chr4:119621672 chr4:119440561~119450157:- PAAD cis rs66887589 0.934 rs7672519 ENSG00000248280.1 RP11-33B1.2 -4.49 1.4e-05 0.007 -0.31 -0.34 Diastolic blood pressure; chr4:119622957 chr4:119440561~119450157:- PAAD cis rs4813802 1 rs6140071 ENSG00000278192.1 RP5-1056H1.2 4.49 1.4e-05 0.007 0.37 0.34 Colorectal cancer; chr20:6725846 chr20:6065966~6067897:- PAAD cis rs494459 0.536 rs10790267 ENSG00000255422.1 AP002954.4 -4.49 1.4e-05 0.007 -0.37 -0.34 Height; chr11:118856460 chr11:118704607~118750263:+ PAAD cis rs494459 0.536 rs11217067 ENSG00000255422.1 AP002954.4 -4.49 1.4e-05 0.007 -0.37 -0.34 Height; chr11:118856623 chr11:118704607~118750263:+ PAAD cis rs2510897 0.675 rs4936442 ENSG00000255422.1 AP002954.4 -4.49 1.4e-05 0.007 -0.37 -0.34 Height; chr11:118857611 chr11:118704607~118750263:+ PAAD cis rs6751744 0.513 rs6738215 ENSG00000226266.5 AC009961.3 -4.49 1.4e-05 0.00701 -0.42 -0.34 Dysphagia; chr2:159596794 chr2:159670708~159712435:- PAAD cis rs1823913 0.637 rs1470962 ENSG00000280083.1 RP11-317J9.1 4.49 1.4e-05 0.00701 0.41 0.34 Obesity-related traits; chr2:191270271 chr2:191154118~191156070:- PAAD cis rs7829975 0.582 rs448231 ENSG00000254340.1 RP11-10A14.3 -4.49 1.4e-05 0.00701 -0.4 -0.34 Mood instability; chr8:8932549 chr8:9141424~9145435:+ PAAD cis rs2115630 1 rs6496441 ENSG00000225151.9 GOLGA2P7 4.49 1.4e-05 0.00702 0.41 0.34 P wave terminal force; chr15:84820117 chr15:84199311~84230136:- PAAD cis rs34375054 0.752 rs12582808 ENSG00000279233.1 RP11-158L12.4 4.49 1.4e-05 0.00702 0.31 0.34 Post bronchodilator FEV1/FVC ratio; chr12:125176913 chr12:125138245~125141711:+ PAAD cis rs10510102 0.872 rs12264952 ENSG00000276742.1 RP11-500G22.4 4.49 1.4e-05 0.00702 0.51 0.34 Breast cancer; chr10:121885673 chr10:121956782~121957098:+ PAAD cis rs2980439 0.525 rs2945238 ENSG00000173295.6 FAM86B3P 4.49 1.41e-05 0.00704 0.35 0.34 Neuroticism; chr8:8312614 chr8:8228595~8244865:+ PAAD cis rs7617773 0.78 rs13084616 ENSG00000228638.1 FCF1P2 4.49 1.41e-05 0.00705 0.38 0.34 Coronary artery disease; chr3:48298209 chr3:48290793~48291375:- PAAD cis rs3823536 0.583 rs10236569 ENSG00000275106.1 RP11-309L24.10 -4.49 1.41e-05 0.00705 -0.46 -0.34 Sjögren's syndrome; chr7:128957533 chr7:128952527~128953316:- PAAD cis rs9926296 0.585 rs8058009 ENSG00000260259.1 RP11-368I7.4 -4.49 1.41e-05 0.00706 -0.43 -0.34 Vitiligo; chr16:89790031 chr16:89682620~89686569:- PAAD cis rs6480314 0.542 rs17231637 ENSG00000233590.1 RP11-153K11.3 4.49 1.41e-05 0.00706 0.53 0.34 Optic nerve measurement (disc area); chr10:68270137 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs1007848 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68258549 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs61854807 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68258948 chr10:68233251~68242379:- PAAD cis rs6480314 0.616 rs12571093 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68259614 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs2120902 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68260465 chr10:68233251~68242379:- PAAD cis rs12571093 0.773 rs4142047 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68261498 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs61854809 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68262847 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs61854810 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68264139 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs61854811 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68264474 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs7079054 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68266404 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs12570281 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68267237 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs61854813 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68267464 chr10:68233251~68242379:- PAAD cis rs12571093 0.803 rs61854814 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68267639 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs4403687 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68268295 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs4592311 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68268492 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs79081413 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68268746 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs17231630 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68268960 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs61854816 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68269051 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs17297383 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68269106 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs10998044 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68269508 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs10998045 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68269626 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs10998046 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68269641 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs61854824 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68270438 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs12572954 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68270766 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs12572967 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68270873 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs12572960 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68270966 chr10:68233251~68242379:- PAAD cis rs12571093 0.803 rs2241969 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68271253 chr10:68233251~68242379:- PAAD cis rs12571093 0.803 rs61854825 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68271535 chr10:68233251~68242379:- PAAD cis rs12571093 0.803 rs61854826 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68271801 chr10:68233251~68242379:- PAAD cis rs12571093 0.803 rs36103935 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68273171 chr10:68233251~68242379:- PAAD cis rs12571093 0.803 rs61854829 ENSG00000233590.1 RP11-153K11.3 -4.49 1.41e-05 0.00706 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68273286 chr10:68233251~68242379:- PAAD cis rs875971 0.505 rs6955582 ENSG00000237310.1 GS1-124K5.4 4.49 1.41e-05 0.00706 0.32 0.34 Aortic root size; chr7:65966699 chr7:66493706~66495474:+ PAAD cis rs1075265 0.704 rs13417926 ENSG00000233266.1 HMGB1P31 4.49 1.41e-05 0.00707 0.43 0.34 Chronotype;Morning vs. evening chronotype; chr2:53825520 chr2:54051334~54051760:+ PAAD cis rs871012 0.542 rs58995342 ENSG00000251405.2 CTB-109A12.1 -4.49 1.42e-05 0.00707 -0.43 -0.34 IgG glycosylation; chr5:157401332 chr5:157362615~157460078:- PAAD cis rs2412819 0.571 rs678084 ENSG00000205771.5 CATSPER2P1 4.49 1.42e-05 0.00707 0.5 0.34 Lung cancer; chr15:43828361 chr15:43726918~43747094:- PAAD cis rs2486288 0.656 rs1706770 ENSG00000259433.2 CTD-2651B20.4 4.49 1.42e-05 0.00707 0.37 0.34 Glomerular filtration rate; chr15:45282864 chr15:45330209~45332634:- PAAD cis rs6921919 0.945 rs16901847 ENSG00000216901.1 AL022393.7 4.49 1.42e-05 0.00708 0.54 0.34 Autism spectrum disorder or schizophrenia; chr6:28408074 chr6:28176188~28176674:+ PAAD cis rs3096299 0.503 rs9925045 ENSG00000261253.2 AC137932.6 4.49 1.42e-05 0.00708 0.38 0.34 Multiple myeloma (IgH translocation); chr16:89490068 chr16:89321133~89325110:+ PAAD cis rs797680 0.789 rs531514 ENSG00000223745.6 RP4-717I23.3 -4.49 1.42e-05 0.00708 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93234655 chr1:93262186~93346025:- PAAD cis rs797680 0.789 rs797671 ENSG00000223745.6 RP4-717I23.3 -4.49 1.42e-05 0.00708 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93234806 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs797672 ENSG00000223745.6 RP4-717I23.3 -4.49 1.42e-05 0.00708 -0.28 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93236562 chr1:93262186~93346025:- PAAD cis rs11976180 0.569 rs12703565 ENSG00000170356.8 OR2A20P -4.49 1.42e-05 0.00708 -0.5 -0.34 Obesity-related traits; chr7:144057308 chr7:144250045~144252957:- PAAD cis rs10888838 0.938 rs11206304 ENSG00000198711.5 SSBP3-AS1 -4.49 1.42e-05 0.00708 -0.4 -0.34 Mitochondrial DNA levels; chr1:54213646 chr1:54236440~54239063:+ PAAD cis rs2980439 0.846 rs2980437 ENSG00000173295.6 FAM86B3P -4.49 1.42e-05 0.00708 -0.37 -0.34 Neuroticism; chr8:8237241 chr8:8228595~8244865:+ PAAD cis rs12908161 0.96 rs62019463 ENSG00000259728.4 LINC00933 4.49 1.42e-05 0.00709 0.44 0.34 Schizophrenia; chr15:84744856 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs62019464 ENSG00000259728.4 LINC00933 4.49 1.42e-05 0.00709 0.44 0.34 Schizophrenia; chr15:84751238 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs12910012 ENSG00000259728.4 LINC00933 4.49 1.42e-05 0.00709 0.44 0.34 Schizophrenia; chr15:84755431 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs12899981 ENSG00000259728.4 LINC00933 4.49 1.42e-05 0.00709 0.44 0.34 Schizophrenia; chr15:84759142 chr15:84570649~84580175:+ PAAD cis rs9322193 0.607 rs6557165 ENSG00000268592.3 RAET1E-AS1 -4.49 1.42e-05 0.00709 -0.43 -0.34 Lung cancer; chr6:149906883 chr6:149863494~149919507:+ PAAD cis rs7945705 0.791 rs12421789 ENSG00000254860.4 TMEM9B-AS1 4.49 1.42e-05 0.00709 0.36 0.34 Hemoglobin concentration; chr11:8792409 chr11:8964675~8977527:+ PAAD cis rs897984 0.806 rs11150600 ENSG00000260911.2 RP11-196G11.2 -4.49 1.42e-05 0.0071 -0.3 -0.34 Dementia with Lewy bodies; chr16:30929010 chr16:31043150~31049868:+ PAAD cis rs72615157 0.561 rs113401658 ENSG00000242294.5 STAG3L5P 4.49 1.42e-05 0.0071 0.28 0.34 Lung function (FEV1/FVC); chr7:100260882 chr7:100336079~100351900:+ PAAD cis rs4835473 0.897 rs7662736 ENSG00000251600.4 RP11-673E1.1 4.49 1.42e-05 0.0071 0.4 0.34 Immature fraction of reticulocytes; chr4:143958036 chr4:143912331~143982454:+ PAAD cis rs7208859 0.725 rs9897673 ENSG00000266490.1 CTD-2349P21.9 4.49 1.42e-05 0.00711 0.41 0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916348 chr17:30792372~30792833:+ PAAD cis rs2283792 0.776 rs9610458 ENSG00000228050.1 TOP3BP1 4.49 1.42e-05 0.00711 0.37 0.34 Multiple sclerosis; chr22:21851064 chr22:22223187~22224566:- PAAD cis rs763121 0.853 rs5750627 ENSG00000228274.3 RP3-508I15.9 -4.49 1.42e-05 0.00711 -0.33 -0.34 Menopause (age at onset); chr22:38586316 chr22:38667585~38681820:- PAAD cis rs2115630 1 rs11854291 ENSG00000225151.9 GOLGA2P7 4.49 1.42e-05 0.00711 0.41 0.34 P wave terminal force; chr15:84820477 chr15:84199311~84230136:- PAAD cis rs7208859 0.614 rs7216394 ENSG00000266490.1 CTD-2349P21.9 -4.49 1.43e-05 0.00712 -0.39 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30498738 chr17:30792372~30792833:+ PAAD cis rs7208859 0.614 rs4794874 ENSG00000266490.1 CTD-2349P21.9 -4.49 1.43e-05 0.00712 -0.39 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30514300 chr17:30792372~30792833:+ PAAD cis rs7923837 0.555 rs2497304 ENSG00000236493.2 EIF2S2P3 -4.49 1.43e-05 0.00713 -0.43 -0.34 Multiple sclerosis;Body mass index; chr10:92732959 chr10:92668745~92669743:- PAAD cis rs4218 0.531 rs8026611 ENSG00000277144.1 RP11-59H7.4 -4.48 1.43e-05 0.00713 -0.4 -0.34 Social communication problems; chr15:59048927 chr15:59115547~59116089:- PAAD cis rs1862618 0.853 rs832584 ENSG00000271828.1 CTD-2310F14.1 -4.48 1.43e-05 0.00714 -0.49 -0.34 Initial pursuit acceleration; chr5:56883385 chr5:56927874~56929573:+ PAAD cis rs12571093 0.571 rs10823175 ENSG00000233590.1 RP11-153K11.3 4.48 1.43e-05 0.00714 0.53 0.34 Optic nerve measurement (disc area); chr10:68306024 chr10:68233251~68242379:- PAAD cis rs6480314 0.522 rs4746759 ENSG00000233590.1 RP11-153K11.3 4.48 1.43e-05 0.00714 0.53 0.34 Optic nerve measurement (disc area); chr10:68306040 chr10:68233251~68242379:- PAAD cis rs858239 0.601 rs12539331 ENSG00000226816.2 AC005082.12 4.48 1.43e-05 0.00715 0.38 0.34 Cerebrospinal fluid biomarker levels; chr7:23111711 chr7:23206013~23208045:+ PAAD cis rs7182621 0.639 rs1561048 ENSG00000259363.4 CTD-2054N24.2 -4.48 1.43e-05 0.00715 -0.45 -0.34 Colonoscopy-negative controls vs population controls; chr15:99875369 chr15:99807023~99877148:+ PAAD cis rs3779195 0.585 rs73709460 ENSG00000272950.1 RP11-307C18.1 -4.48 1.43e-05 0.00715 -0.62 -0.34 Sex hormone-binding globulin levels; chr7:98265942 chr7:98322853~98323430:+ PAAD cis rs3779195 0.585 rs56694862 ENSG00000272950.1 RP11-307C18.1 -4.48 1.43e-05 0.00715 -0.62 -0.34 Sex hormone-binding globulin levels; chr7:98267808 chr7:98322853~98323430:+ PAAD cis rs338389 0.564 rs338393 ENSG00000260657.2 RP11-315D16.4 -4.48 1.43e-05 0.00715 -0.39 -0.34 Survival in rectal cancer; chr15:67964657 chr15:68267792~68277994:- PAAD cis rs338389 0.586 rs338390 ENSG00000260657.2 RP11-315D16.4 -4.48 1.43e-05 0.00715 -0.39 -0.34 Survival in rectal cancer; chr15:67966876 chr15:68267792~68277994:- PAAD cis rs875971 1 rs3981131 ENSG00000237310.1 GS1-124K5.4 4.48 1.43e-05 0.00715 0.33 0.34 Aortic root size; chr7:66486690 chr7:66493706~66495474:+ PAAD cis rs12571093 0.803 rs2241970 ENSG00000233590.1 RP11-153K11.3 4.48 1.44e-05 0.00716 0.54 0.34 Optic nerve measurement (disc area); chr10:68271310 chr10:68233251~68242379:- PAAD cis rs2281636 0.894 rs11190196 ENSG00000233690.1 EBAG9P1 4.48 1.44e-05 0.00716 0.35 0.34 Obesity-related traits; chr10:99626757 chr10:99697407~99697949:- PAAD cis rs7572733 0.534 rs7557203 ENSG00000231621.1 AC013264.2 -4.48 1.44e-05 0.00716 -0.34 -0.34 Dermatomyositis; chr2:197930926 chr2:197197991~197199273:+ PAAD cis rs7712401 0.601 rs386602 ENSG00000263432.2 RN7SL689P -4.48 1.44e-05 0.00716 -0.44 -0.34 Mean platelet volume; chr5:122986262 chr5:123022487~123022783:- PAAD cis rs7727544 0.645 rs272857 ENSG00000233006.5 AC034220.3 4.48 1.44e-05 0.00716 0.28 0.34 Blood metabolite levels; chr5:132349604 chr5:132311285~132369916:- PAAD cis rs79040073 0.637 rs73392288 ENSG00000259531.2 RP11-295H24.3 4.48 1.44e-05 0.00716 0.57 0.34 Lung cancer in ever smokers; chr15:49250842 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs17396747 ENSG00000259531.2 RP11-295H24.3 4.48 1.44e-05 0.00716 0.57 0.34 Lung cancer in ever smokers; chr15:49269330 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs75612464 ENSG00000259531.2 RP11-295H24.3 4.48 1.44e-05 0.00716 0.57 0.34 Lung cancer in ever smokers; chr15:49270727 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73394324 ENSG00000259531.2 RP11-295H24.3 4.48 1.44e-05 0.00716 0.57 0.34 Lung cancer in ever smokers; chr15:49274894 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs35692325 ENSG00000259531.2 RP11-295H24.3 4.48 1.44e-05 0.00716 0.57 0.34 Lung cancer in ever smokers; chr15:49316062 chr15:49365124~49366685:- PAAD cis rs8031584 0.541 rs2959037 ENSG00000260382.1 RP11-540B6.2 -4.48 1.44e-05 0.00718 -0.44 -0.34 Huntington's disease progression; chr15:30925961 chr15:30882267~30883231:- PAAD cis rs8031584 0.505 rs2959036 ENSG00000260382.1 RP11-540B6.2 -4.48 1.44e-05 0.00718 -0.44 -0.34 Huntington's disease progression; chr15:30927539 chr15:30882267~30883231:- PAAD cis rs8031584 0.541 rs2955777 ENSG00000260382.1 RP11-540B6.2 -4.48 1.44e-05 0.00718 -0.44 -0.34 Huntington's disease progression; chr15:30927585 chr15:30882267~30883231:- PAAD cis rs4664293 0.647 rs10192408 ENSG00000226266.5 AC009961.3 -4.48 1.44e-05 0.00718 -0.43 -0.34 Monocyte percentage of white cells; chr2:159568083 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs10196064 ENSG00000226266.5 AC009961.3 -4.48 1.44e-05 0.00718 -0.43 -0.34 Monocyte percentage of white cells; chr2:159569454 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs2162023 ENSG00000226266.5 AC009961.3 -4.48 1.44e-05 0.00718 -0.43 -0.34 Monocyte percentage of white cells; chr2:159569719 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs10202352 ENSG00000226266.5 AC009961.3 -4.48 1.44e-05 0.00718 -0.43 -0.34 Monocyte percentage of white cells; chr2:159571097 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs1425040 ENSG00000226266.5 AC009961.3 -4.48 1.44e-05 0.00718 -0.43 -0.34 Monocyte percentage of white cells; chr2:159571912 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs11693108 ENSG00000226266.5 AC009961.3 -4.48 1.44e-05 0.00718 -0.43 -0.34 Monocyte percentage of white cells; chr2:159572076 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs7575924 ENSG00000226266.5 AC009961.3 -4.48 1.44e-05 0.00718 -0.43 -0.34 Monocyte percentage of white cells; chr2:159573049 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs1549385 ENSG00000226266.5 AC009961.3 -4.48 1.44e-05 0.00718 -0.43 -0.34 Monocyte percentage of white cells; chr2:159582540 chr2:159670708~159712435:- PAAD cis rs2976388 0.632 rs2585139 ENSG00000253741.1 CTD-2292P10.4 -4.48 1.44e-05 0.00718 -0.4 -0.34 Urinary tract infection frequency; chr8:142726757 chr8:142702252~142726973:- PAAD cis rs4950322 0.518 rs4950304 ENSG00000278811.3 LINC00624 4.48 1.44e-05 0.00718 0.33 0.34 Protein quantitative trait loci; chr1:147116685 chr1:147258885~147517875:- PAAD cis rs4950322 0.518 rs11811023 ENSG00000278811.3 LINC00624 -4.48 1.44e-05 0.00718 -0.33 -0.34 Protein quantitative trait loci; chr1:147109536 chr1:147258885~147517875:- PAAD cis rs2980439 0.556 rs2921059 ENSG00000253981.4 ALG1L13P 4.48 1.44e-05 0.00718 0.41 0.34 Neuroticism; chr8:8460377 chr8:8236003~8244667:- PAAD cis rs2348418 0.966 rs11049699 ENSG00000247934.4 RP11-967K21.1 4.48 1.44e-05 0.00718 0.34 0.34 Lung function (FEV1);Lung function (FVC); chr12:28535487 chr12:28163298~28190738:- PAAD cis rs6496044 0.507 rs410522 ENSG00000202081.1 RNU6-1280P -4.48 1.44e-05 0.00718 -0.39 -0.34 Interstitial lung disease; chr15:85663813 chr15:85651522~85651628:- PAAD cis rs2281636 0.792 rs10883385 ENSG00000233690.1 EBAG9P1 4.48 1.44e-05 0.00718 0.36 0.34 Obesity-related traits; chr10:99621956 chr10:99697407~99697949:- PAAD cis rs1789 0.903 rs4453929 ENSG00000273133.1 RP11-799M12.2 -4.48 1.44e-05 0.0072 -0.42 -0.34 Blood protein levels; chr4:15670550 chr4:15563698~15564253:- PAAD cis rs1789 0.903 rs4616746 ENSG00000273133.1 RP11-799M12.2 -4.48 1.44e-05 0.0072 -0.42 -0.34 Blood protein levels; chr4:15671475 chr4:15563698~15564253:- PAAD cis rs1789 0.868 rs4631041 ENSG00000273133.1 RP11-799M12.2 -4.48 1.44e-05 0.0072 -0.42 -0.34 Blood protein levels; chr4:15671772 chr4:15563698~15564253:- PAAD cis rs1789 0.903 rs4470622 ENSG00000273133.1 RP11-799M12.2 -4.48 1.44e-05 0.0072 -0.42 -0.34 Blood protein levels; chr4:15672552 chr4:15563698~15564253:- PAAD cis rs1789 0.903 rs6850422 ENSG00000273133.1 RP11-799M12.2 -4.48 1.44e-05 0.0072 -0.42 -0.34 Blood protein levels; chr4:15680814 chr4:15563698~15564253:- PAAD cis rs28374715 0.733 rs7167706 ENSG00000247556.5 OIP5-AS1 4.48 1.45e-05 0.0072 0.36 0.34 Ulcerative colitis; chr15:41277446 chr15:41283990~41309737:+ PAAD cis rs763567 0.869 rs680084 ENSG00000271811.1 RP1-79C4.4 4.48 1.45e-05 0.0072 0.33 0.34 Tonsillectomy; chr1:170659114 chr1:170667381~170669425:+ PAAD cis rs7772486 0.902 rs2777480 ENSG00000235652.6 RP11-545I5.3 4.48 1.45e-05 0.0072 0.29 0.34 Lobe attachment (rater-scored or self-reported); chr6:145988847 chr6:145799409~145886585:+ PAAD cis rs4950322 0.542 rs4950384 ENSG00000278811.3 LINC00624 4.48 1.45e-05 0.0072 0.34 0.34 Protein quantitative trait loci; chr1:147177310 chr1:147258885~147517875:- PAAD cis rs4950322 0.542 rs17159924 ENSG00000278811.3 LINC00624 4.48 1.45e-05 0.0072 0.34 0.34 Protein quantitative trait loci; chr1:147199463 chr1:147258885~147517875:- PAAD cis rs4950322 0.542 rs28381210 ENSG00000278811.3 LINC00624 4.48 1.45e-05 0.0072 0.34 0.34 Protein quantitative trait loci; chr1:147201925 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs4593887 ENSG00000278811.3 LINC00624 4.48 1.45e-05 0.0072 0.34 0.34 Protein quantitative trait loci; chr1:147234246 chr1:147258885~147517875:- PAAD cis rs4950322 0.57 rs72691004 ENSG00000278811.3 LINC00624 4.48 1.45e-05 0.0072 0.34 0.34 Protein quantitative trait loci; chr1:147234309 chr1:147258885~147517875:- PAAD cis rs797680 0.822 rs6541401 ENSG00000223745.6 RP4-717I23.3 -4.48 1.45e-05 0.00721 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93273391 chr1:93262186~93346025:- PAAD cis rs797680 0.821 rs7551485 ENSG00000223745.6 RP4-717I23.3 -4.48 1.45e-05 0.00721 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93285723 chr1:93262186~93346025:- PAAD cis rs797680 0.822 rs7541304 ENSG00000223745.6 RP4-717I23.3 -4.48 1.45e-05 0.00721 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93292281 chr1:93262186~93346025:- PAAD cis rs875971 0.54 rs4717275 ENSG00000237310.1 GS1-124K5.4 -4.48 1.45e-05 0.00722 -0.32 -0.34 Aortic root size; chr7:65800193 chr7:66493706~66495474:+ PAAD cis rs11763147 1 rs11763147 ENSG00000237310.1 GS1-124K5.4 -4.48 1.45e-05 0.00722 -0.32 -0.34 Corneal structure; chr7:65861834 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs10807697 ENSG00000237310.1 GS1-124K5.4 4.48 1.45e-05 0.00722 0.32 0.34 Aortic root size; chr7:65951183 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs2008188 ENSG00000237310.1 GS1-124K5.4 4.48 1.45e-05 0.00722 0.32 0.34 Aortic root size; chr7:65964026 chr7:66493706~66495474:+ PAAD cis rs4713118 0.616 rs9348789 ENSG00000226314.6 ZNF192P1 -4.48 1.45e-05 0.00722 -0.57 -0.34 Parkinson's disease; chr6:28057708 chr6:28161781~28169594:+ PAAD cis rs7727544 0.735 rs274566 ENSG00000233006.5 AC034220.3 -4.48 1.45e-05 0.00723 -0.28 -0.34 Blood metabolite levels; chr5:132379319 chr5:132311285~132369916:- PAAD cis rs79040073 0.563 rs17479003 ENSG00000259531.2 RP11-295H24.3 4.48 1.45e-05 0.00723 0.56 0.34 Lung cancer in ever smokers; chr15:49453223 chr15:49365124~49366685:- PAAD cis rs4664293 1 rs4665083 ENSG00000226266.5 AC009961.3 4.48 1.46e-05 0.00725 0.43 0.34 Monocyte percentage of white cells; chr2:159573616 chr2:159670708~159712435:- PAAD cis rs4660214 0.666 rs4660550 ENSG00000237624.1 OXCT2P1 -4.48 1.46e-05 0.00725 -0.46 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39222787 chr1:39514956~39516490:+ PAAD cis rs2117029 0.767 rs10875912 ENSG00000258017.1 RP11-386G11.10 -4.48 1.46e-05 0.00725 -0.44 -0.34 Intelligence (multi-trait analysis); chr12:49023161 chr12:49127782~49147869:+ PAAD cis rs2348418 0.681 rs10771435 ENSG00000247934.4 RP11-967K21.1 4.48 1.46e-05 0.00726 0.33 0.34 Lung function (FEV1);Lung function (FVC); chr12:28582769 chr12:28163298~28190738:- PAAD cis rs42490 0.789 rs416324 ENSG00000251136.7 RP11-37B2.1 4.48 1.46e-05 0.00726 0.3 0.34 Leprosy; chr8:89803007 chr8:89609409~89757727:- PAAD cis rs7617773 0.78 rs13090538 ENSG00000228638.1 FCF1P2 -4.48 1.46e-05 0.00726 -0.38 -0.34 Coronary artery disease; chr3:48329279 chr3:48290793~48291375:- PAAD cis rs1150668 0.799 rs1150707 ENSG00000204709.4 LINC01556 4.48 1.46e-05 0.00727 0.44 0.34 Pubertal anthropometrics; chr6:28229827 chr6:28943877~28944537:+ PAAD cis rs1150668 0.768 rs1233713 ENSG00000204709.4 LINC01556 4.48 1.46e-05 0.00727 0.44 0.34 Pubertal anthropometrics; chr6:28230503 chr6:28943877~28944537:+ PAAD cis rs7712401 0.562 rs383638 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122988983 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs62377399 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122988984 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs415534 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122989606 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs442911 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122989856 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs425573 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122990313 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs364723 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122990769 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs35847506 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122991413 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs390234 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122995828 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs4555798 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122996419 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs62377424 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122996627 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs35699701 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122998061 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs35256179 ENSG00000263432.2 RN7SL689P -4.48 1.46e-05 0.00727 -0.44 -0.34 Mean platelet volume; chr5:122998560 chr5:123022487~123022783:- PAAD cis rs964611 0.671 rs11070639 ENSG00000259488.2 RP11-154J22.1 4.48 1.46e-05 0.00727 0.39 0.34 Metabolite levels (Pyroglutamine); chr15:48371908 chr15:48312353~48331856:- PAAD cis rs950169 0.509 rs71395455 ENSG00000259295.5 CSPG4P12 4.48 1.46e-05 0.00727 0.38 0.34 Schizophrenia; chr15:84610573 chr15:85191438~85213905:+ PAAD cis rs4835473 0.897 rs55635947 ENSG00000251600.4 RP11-673E1.1 -4.48 1.46e-05 0.00727 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143736218 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs56334914 ENSG00000251600.4 RP11-673E1.1 -4.48 1.46e-05 0.00727 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143736291 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs56324738 ENSG00000251600.4 RP11-673E1.1 -4.48 1.46e-05 0.00727 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143736297 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs55862664 ENSG00000251600.4 RP11-673E1.1 -4.48 1.46e-05 0.00727 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143736311 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs17693768 ENSG00000251600.4 RP11-673E1.1 -4.48 1.46e-05 0.00727 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143737503 chr4:143912331~143982454:+ PAAD cis rs4835473 0.832 rs35398499 ENSG00000251600.4 RP11-673E1.1 -4.48 1.46e-05 0.00727 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143737715 chr4:143912331~143982454:+ PAAD cis rs2253762 0.507 rs11200310 ENSG00000276742.1 RP11-500G22.4 4.48 1.46e-05 0.00728 0.47 0.34 Breast cancer; chr10:121989944 chr10:121956782~121957098:+ PAAD cis rs10510102 0.516 rs12244921 ENSG00000276742.1 RP11-500G22.4 4.48 1.46e-05 0.00728 0.47 0.34 Breast cancer; chr10:121990342 chr10:121956782~121957098:+ PAAD cis rs4835473 0.897 rs6537167 ENSG00000251600.4 RP11-673E1.1 4.48 1.47e-05 0.00729 0.35 0.34 Immature fraction of reticulocytes; chr4:143691323 chr4:143912331~143982454:+ PAAD cis rs7945705 0.791 rs4579928 ENSG00000254860.4 TMEM9B-AS1 -4.48 1.47e-05 0.00729 -0.36 -0.34 Hemoglobin concentration; chr11:8794157 chr11:8964675~8977527:+ PAAD cis rs4218 0.681 rs2121236 ENSG00000277144.1 RP11-59H7.4 -4.48 1.47e-05 0.00729 -0.46 -0.34 Social communication problems; chr15:59091923 chr15:59115547~59116089:- PAAD cis rs853679 0.527 rs853693 ENSG00000204709.4 LINC01556 4.48 1.47e-05 0.00729 0.47 0.34 Depression; chr6:28314871 chr6:28943877~28944537:+ PAAD cis rs2348418 0.798 rs4930826 ENSG00000247934.4 RP11-967K21.1 4.48 1.47e-05 0.0073 0.33 0.34 Lung function (FEV1);Lung function (FVC); chr12:28574385 chr12:28163298~28190738:- PAAD cis rs2658782 1 rs2658779 ENSG00000279684.1 RP11-755E23.2 4.48 1.47e-05 0.0073 0.58 0.34 Pulmonary function decline; chr11:93429971 chr11:93286629~93288903:- PAAD cis rs2658782 1 rs2608216 ENSG00000279684.1 RP11-755E23.2 -4.48 1.47e-05 0.0073 -0.58 -0.34 Pulmonary function decline; chr11:93416006 chr11:93286629~93288903:- PAAD cis rs2658782 0.95 rs2446061 ENSG00000279684.1 RP11-755E23.2 -4.48 1.47e-05 0.0073 -0.58 -0.34 Pulmonary function decline; chr11:93416111 chr11:93286629~93288903:- PAAD cis rs4664293 0.647 rs10199805 ENSG00000226266.5 AC009961.3 -4.48 1.47e-05 0.00731 -0.43 -0.34 Monocyte percentage of white cells; chr2:159570880 chr2:159670708~159712435:- PAAD cis rs4554975 0.689 rs4374015 ENSG00000274723.1 RP11-618L22.1 -4.48 1.47e-05 0.00731 -0.4 -0.34 Metabolite levels (small molecules and protein measures); chr12:46832877 chr12:46970504~46972155:+ PAAD cis rs4554975 0.689 rs4495962 ENSG00000274723.1 RP11-618L22.1 -4.48 1.47e-05 0.00731 -0.4 -0.34 Metabolite levels (small molecules and protein measures); chr12:46832903 chr12:46970504~46972155:+ PAAD cis rs4554975 0.689 rs11183625 ENSG00000274723.1 RP11-618L22.1 -4.48 1.47e-05 0.00731 -0.4 -0.34 Metabolite levels (small molecules and protein measures); chr12:46833239 chr12:46970504~46972155:+ PAAD cis rs9584850 0.915 rs9517310 ENSG00000231194.1 FARP1-AS1 4.48 1.47e-05 0.00731 0.44 0.34 Neuroticism; chr13:98448220 chr13:98435405~98435840:- PAAD cis rs8062405 0.755 rs4149398 ENSG00000251417.2 RP11-1348G14.4 -4.48 1.47e-05 0.00731 -0.33 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597617 chr16:28802743~28817828:+ PAAD cis rs7826238 0.566 rs2945886 ENSG00000173295.6 FAM86B3P 4.48 1.47e-05 0.00731 0.36 0.34 Systolic blood pressure; chr8:8290748 chr8:8228595~8244865:+ PAAD cis rs797680 0.856 rs2031226 ENSG00000223745.6 RP4-717I23.3 4.48 1.48e-05 0.00732 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93321207 chr1:93262186~93346025:- PAAD cis rs797680 0.897 rs6658257 ENSG00000223745.6 RP4-717I23.3 4.48 1.48e-05 0.00733 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93355127 chr1:93262186~93346025:- PAAD cis rs875971 0.522 rs781144 ENSG00000234585.5 CCT6P3 4.48 1.48e-05 0.00733 0.27 0.34 Aortic root size; chr7:65975357 chr7:65038354~65074713:+ PAAD cis rs875971 0.522 rs9530 ENSG00000234585.5 CCT6P3 4.48 1.48e-05 0.00733 0.27 0.34 Aortic root size; chr7:65960907 chr7:65038354~65074713:+ PAAD cis rs74233809 1 rs74233809 ENSG00000213277.3 MARCKSL1P1 4.48 1.48e-05 0.00733 0.6 0.34 Birth weight; chr10:103154183 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs12219304 ENSG00000213277.3 MARCKSL1P1 4.48 1.48e-05 0.00733 0.6 0.34 Birth weight; chr10:103171827 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs77420391 ENSG00000213277.3 MARCKSL1P1 4.48 1.48e-05 0.00733 0.6 0.34 Birth weight; chr10:103186066 chr10:103175554~103176094:+ PAAD cis rs74233809 1 rs11191607 ENSG00000213277.3 MARCKSL1P1 4.48 1.48e-05 0.00733 0.6 0.34 Birth weight; chr10:103199431 chr10:103175554~103176094:+ PAAD cis rs7923609 0.869 rs9971352 ENSG00000232075.1 MRPL35P2 -4.48 1.48e-05 0.00733 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63505348 chr10:63634317~63634827:- PAAD cis rs1075265 0.508 rs12621225 ENSG00000233266.1 HMGB1P31 4.48 1.48e-05 0.00734 0.46 0.34 Chronotype;Morning vs. evening chronotype; chr2:53710040 chr2:54051334~54051760:+ PAAD cis rs12134133 1 rs28371614 ENSG00000274245.1 RP11-357P18.2 4.48 1.48e-05 0.00734 0.52 0.34 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207331929 chr1:207372559~207373252:+ PAAD cis rs2486288 0.554 rs1719235 ENSG00000259433.2 CTD-2651B20.4 4.48 1.48e-05 0.00734 0.38 0.34 Glomerular filtration rate; chr15:45283910 chr15:45330209~45332634:- PAAD cis rs2790457 0.958 rs2772433 ENSG00000254635.4 WAC-AS1 4.48 1.48e-05 0.00734 0.33 0.34 Multiple myeloma; chr10:28607017 chr10:28522652~28532743:- PAAD cis rs1862618 0.853 rs252910 ENSG00000271828.1 CTD-2310F14.1 4.48 1.48e-05 0.00734 0.53 0.34 Initial pursuit acceleration; chr5:56897156 chr5:56927874~56929573:+ PAAD cis rs9828933 0.832 rs3774723 ENSG00000280620.1 SCAANT1 4.48 1.48e-05 0.00735 0.55 0.34 Type 2 diabetes; chr3:63976663 chr3:63911518~63911772:- PAAD cis rs897984 0.511 rs7196726 ENSG00000260911.2 RP11-196G11.2 4.48 1.48e-05 0.00735 0.31 0.34 Dementia with Lewy bodies; chr16:31080754 chr16:31043150~31049868:+ PAAD cis rs2564921 0.615 rs56129941 ENSG00000242142.1 SERBP1P3 -4.48 1.48e-05 0.00735 -0.43 -0.34 Height; chr3:53007328 chr3:53064283~53065091:- PAAD cis rs2564921 0.704 rs56155510 ENSG00000242142.1 SERBP1P3 -4.48 1.48e-05 0.00735 -0.43 -0.34 Height; chr3:53009621 chr3:53064283~53065091:- PAAD cis rs2564921 0.679 rs12635933 ENSG00000242142.1 SERBP1P3 -4.48 1.48e-05 0.00735 -0.43 -0.34 Height; chr3:53015087 chr3:53064283~53065091:- PAAD cis rs2564921 0.73 rs62255895 ENSG00000242142.1 SERBP1P3 -4.48 1.48e-05 0.00735 -0.43 -0.34 Height; chr3:53027969 chr3:53064283~53065091:- PAAD cis rs2564921 0.73 rs62255898 ENSG00000242142.1 SERBP1P3 -4.48 1.48e-05 0.00735 -0.43 -0.34 Height; chr3:53029908 chr3:53064283~53065091:- PAAD cis rs2564921 0.73 rs73079924 ENSG00000242142.1 SERBP1P3 -4.48 1.48e-05 0.00735 -0.43 -0.34 Height; chr3:53034139 chr3:53064283~53065091:- PAAD cis rs755249 0.529 rs4660732 ENSG00000261798.1 RP1-118J21.25 4.48 1.48e-05 0.00735 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39397543 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs61779285 ENSG00000261798.1 RP1-118J21.25 4.48 1.48e-05 0.00735 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39401383 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs3768301 ENSG00000261798.1 RP1-118J21.25 4.48 1.48e-05 0.00735 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39405121 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs113214136 ENSG00000261798.1 RP1-118J21.25 4.48 1.48e-05 0.00735 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39408867 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs3768302 ENSG00000261798.1 RP1-118J21.25 4.48 1.48e-05 0.00735 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39414647 chr1:39788976~39790171:+ PAAD cis rs755249 0.532 rs17343193 ENSG00000261798.1 RP1-118J21.25 4.48 1.48e-05 0.00735 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39415796 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs61779300 ENSG00000261798.1 RP1-118J21.25 4.48 1.48e-05 0.00735 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39420091 chr1:39788976~39790171:+ PAAD cis rs2562456 0.92 rs2650784 ENSG00000213976.4 CTD-2561J22.2 4.48 1.48e-05 0.00736 0.37 0.34 Pain; chr19:21483795 chr19:21382865~21387177:+ PAAD cis rs797680 0.927 rs797675 ENSG00000223745.6 RP4-717I23.3 4.48 1.49e-05 0.00736 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93208669 chr1:93262186~93346025:- PAAD cis rs987724 0.515 rs344079 ENSG00000240875.4 LINC00886 -4.48 1.49e-05 0.00737 -0.51 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156837783 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs344080 ENSG00000240875.4 LINC00886 -4.48 1.49e-05 0.00737 -0.51 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156837996 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs344082 ENSG00000240875.4 LINC00886 -4.48 1.49e-05 0.00737 -0.51 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156838290 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs344084 ENSG00000240875.4 LINC00886 -4.48 1.49e-05 0.00737 -0.51 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156838591 chr3:156747346~156817062:- PAAD cis rs812925 0.519 rs967968 ENSG00000273302.1 RP11-493E12.2 -4.48 1.49e-05 0.00737 -0.3 -0.34 Immature fraction of reticulocytes; chr2:61428921 chr2:61199979~61200769:+ PAAD cis rs7626444 0.585 rs860050 ENSG00000272359.1 U4 -4.48 1.49e-05 0.00738 -0.37 -0.34 Monocyte count; chr3:196747576 chr3:196747192~196747324:- PAAD cis rs1707322 0.717 rs1547925 ENSG00000280836.1 AL355480.1 4.47 1.49e-05 0.00738 0.41 0.34 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619684 chr1:45581219~45581321:- PAAD cis rs3169166 0.5 rs3743084 ENSG00000259562.2 RP11-762H8.2 -4.47 1.49e-05 0.00738 -0.29 -0.34 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78270351 chr15:78290527~78291221:- PAAD cis rs1873386 0.79 rs1490710 ENSG00000255910.1 RP11-405A12.2 4.47 1.49e-05 0.00739 0.5 0.34 Personality dimensions; chr12:18915365 chr12:19775451~20009937:+ PAAD cis rs858239 0.601 rs7805206 ENSG00000226816.2 AC005082.12 4.47 1.49e-05 0.0074 0.37 0.34 Cerebrospinal fluid biomarker levels; chr7:23120591 chr7:23206013~23208045:+ PAAD cis rs394563 1 rs394563 ENSG00000231760.4 RP11-350J20.5 4.47 1.49e-05 0.0074 0.44 0.34 Dupuytren's disease; chr6:149475878 chr6:149796151~149826294:- PAAD cis rs394563 0.967 rs444784 ENSG00000231760.4 RP11-350J20.5 4.47 1.49e-05 0.0074 0.44 0.34 Dupuytren's disease; chr6:149477230 chr6:149796151~149826294:- PAAD cis rs9926296 0.632 rs72807526 ENSG00000260259.1 RP11-368I7.4 4.47 1.49e-05 0.0074 0.4 0.34 Vitiligo; chr16:89709538 chr16:89682620~89686569:- PAAD cis rs3096299 0.504 rs4785574 ENSG00000261253.2 AC137932.6 4.47 1.5e-05 0.00741 0.38 0.34 Multiple myeloma (IgH translocation); chr16:89502467 chr16:89321133~89325110:+ PAAD cis rs7567389 0.74 rs4536600 ENSG00000236682.1 AC068282.3 -4.47 1.5e-05 0.00741 -0.46 -0.34 Self-rated health; chr2:127244996 chr2:127389130~127400580:+ PAAD cis rs867371 0.722 rs8033050 ENSG00000259429.4 UBE2Q2P2 -4.47 1.5e-05 0.00741 -0.27 -0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82269648 chr15:82355142~82420075:+ PAAD cis rs708547 0.575 rs6847086 ENSG00000280285.1 RP11-630A13.4 -4.47 1.5e-05 0.00741 -0.46 -0.34 Response to bleomycin (chromatid breaks); chr4:56925698 chr4:56662469~56665694:- PAAD cis rs858239 0.602 rs6953996 ENSG00000226816.2 AC005082.12 4.47 1.5e-05 0.00742 0.38 0.34 Cerebrospinal fluid biomarker levels; chr7:23136327 chr7:23206013~23208045:+ PAAD cis rs9649213 0.555 rs6955259 ENSG00000272950.1 RP11-307C18.1 4.47 1.5e-05 0.00742 0.4 0.34 Prostate cancer (SNP x SNP interaction); chr7:98263044 chr7:98322853~98323430:+ PAAD cis rs72634501 0.531 rs67758468 ENSG00000261798.1 RP1-118J21.25 4.47 1.5e-05 0.00743 0.4 0.34 HDL cholesterol; chr1:39156916 chr1:39788976~39790171:+ PAAD cis rs1928295 1 rs12001662 ENSG00000233569.1 RP11-500B12.1 4.47 1.5e-05 0.00743 0.4 0.34 Body mass index (joint analysis main effects and smoking interaction);BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index; chr9:117643731 chr9:117648606~117657027:+ PAAD cis rs7182621 0.639 rs35049216 ENSG00000182397.13 DNM1P46 4.47 1.5e-05 0.00743 0.45 0.34 Colonoscopy-negative controls vs population controls; chr15:99872562 chr15:99790156~99806927:- PAAD cis rs4713118 0.629 rs203887 ENSG00000204709.4 LINC01556 4.47 1.5e-05 0.00743 0.6 0.34 Parkinson's disease; chr6:28053491 chr6:28943877~28944537:+ PAAD cis rs2337406 0.789 rs112027230 ENSG00000211974.3 IGHV2-70 -4.47 1.5e-05 0.00743 -0.46 -0.34 Alzheimer's disease (late onset); chr14:106810329 chr14:106723574~106724093:- PAAD cis rs2243480 1 rs34815098 ENSG00000228409.4 CCT6P1 4.47 1.5e-05 0.00743 0.37 0.34 Diabetic kidney disease; chr7:65827267 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs7456042 ENSG00000228409.4 CCT6P1 4.47 1.5e-05 0.00743 0.37 0.34 Diabetic kidney disease; chr7:65834791 chr7:65751142~65763354:+ PAAD cis rs7923609 1 rs10761723 ENSG00000232075.1 MRPL35P2 -4.47 1.5e-05 0.00744 -0.43 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63195821 chr10:63634317~63634827:- PAAD cis rs4789693 0.518 rs6502117 ENSG00000265458.1 RP13-20L14.6 4.47 1.5e-05 0.00744 0.44 0.34 Glucocorticoid-induced osteonecrosis; chr17:82494716 chr17:82454273~82458521:- PAAD cis rs2412819 0.571 rs28410121 ENSG00000205771.5 CATSPER2P1 4.47 1.51e-05 0.00745 0.56 0.34 Lung cancer; chr15:43777831 chr15:43726918~43747094:- PAAD cis rs7829975 0.511 rs2980512 ENSG00000173295.6 FAM86B3P 4.47 1.51e-05 0.00745 0.38 0.34 Mood instability; chr8:8283379 chr8:8228595~8244865:+ PAAD cis rs7829975 0.539 rs35571782 ENSG00000173295.6 FAM86B3P 4.47 1.51e-05 0.00745 0.38 0.34 Mood instability; chr8:8284301 chr8:8228595~8244865:+ PAAD cis rs2274273 0.648 rs58553156 ENSG00000258413.1 RP11-665C16.6 -4.47 1.51e-05 0.00745 -0.44 -0.34 Protein biomarker; chr14:55115976 chr14:55262767~55272075:- PAAD cis rs1823913 0.637 rs4853465 ENSG00000280083.1 RP11-317J9.1 4.47 1.51e-05 0.00746 0.41 0.34 Obesity-related traits; chr2:191294768 chr2:191154118~191156070:- PAAD cis rs7626444 0.625 rs7648479 ENSG00000272359.1 U4 -4.47 1.51e-05 0.00746 -0.38 -0.34 Monocyte count; chr3:196750342 chr3:196747192~196747324:- PAAD cis rs61776719 0.875 rs4072980 ENSG00000212541.1 RNU6-510P 4.47 1.51e-05 0.00746 0.37 0.34 Coronary artery disease; chr1:37990434 chr1:37991462~37991569:+ PAAD cis rs9368481 0.645 rs10456350 ENSG00000241549.7 GUSBP2 4.47 1.51e-05 0.00746 0.36 0.34 Autism spectrum disorder or schizophrenia; chr6:27007802 chr6:26871484~26956554:- PAAD cis rs72615157 0.634 rs11762932 ENSG00000242294.5 STAG3L5P -4.47 1.51e-05 0.00747 -0.27 -0.34 Lung function (FEV1/FVC); chr7:100195043 chr7:100336079~100351900:+ PAAD cis rs6504950 0.925 rs2787481 ENSG00000275710.1 RP11-257O5.4 -4.47 1.51e-05 0.00747 -0.45 -0.34 Breast cancer; chr17:55133749 chr17:54964474~54964679:+ PAAD cis rs6504950 0.925 rs2787483 ENSG00000275710.1 RP11-257O5.4 4.47 1.51e-05 0.00747 0.45 0.34 Breast cancer; chr17:55132953 chr17:54964474~54964679:+ PAAD cis rs6504950 0.925 rs2628317 ENSG00000275710.1 RP11-257O5.4 4.47 1.51e-05 0.00747 0.45 0.34 Breast cancer; chr17:55135212 chr17:54964474~54964679:+ PAAD cis rs1275468 0.731 rs1627431 ENSG00000257497.2 RP11-585P4.5 -4.47 1.51e-05 0.00748 -0.53 -0.34 Polycystic ovary syndrome; chr12:75569132 chr12:75483454~75489820:- PAAD cis rs897984 0.542 rs3751855 ENSG00000260911.2 RP11-196G11.2 4.47 1.51e-05 0.00748 0.31 0.34 Dementia with Lewy bodies; chr16:31079888 chr16:31043150~31049868:+ PAAD cis rs897984 0.542 rs11865038 ENSG00000260911.2 RP11-196G11.2 4.47 1.51e-05 0.00748 0.31 0.34 Dementia with Lewy bodies; chr16:31083850 chr16:31043150~31049868:+ PAAD cis rs897984 0.542 rs11864806 ENSG00000260911.2 RP11-196G11.2 4.47 1.51e-05 0.00748 0.31 0.34 Dementia with Lewy bodies; chr16:31083883 chr16:31043150~31049868:+ PAAD cis rs897984 0.542 rs11864839 ENSG00000260911.2 RP11-196G11.2 4.47 1.51e-05 0.00748 0.31 0.34 Dementia with Lewy bodies; chr16:31083930 chr16:31043150~31049868:+ PAAD cis rs897984 0.542 rs7199949 ENSG00000260911.2 RP11-196G11.2 4.47 1.51e-05 0.00748 0.31 0.34 Dementia with Lewy bodies; chr16:31084843 chr16:31043150~31049868:+ PAAD cis rs897984 0.513 rs17839568 ENSG00000260911.2 RP11-196G11.2 4.47 1.51e-05 0.00748 0.31 0.34 Dementia with Lewy bodies; chr16:31088462 chr16:31043150~31049868:+ PAAD cis rs77372450 0.636 rs55699399 ENSG00000251405.2 CTB-109A12.1 4.47 1.51e-05 0.00748 0.54 0.34 Bipolar disorder (body mass index interaction); chr5:157601355 chr5:157362615~157460078:- PAAD cis rs55665837 0.54 rs4757261 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14648256 chr11:14478892~14478953:+ PAAD cis rs55665837 0.54 rs10128681 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14680030 chr11:14478892~14478953:+ PAAD cis rs55665837 0.54 rs7938266 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14687778 chr11:14478892~14478953:+ PAAD cis rs55665837 0.52 rs10766189 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14712377 chr11:14478892~14478953:+ PAAD cis rs55665837 0.54 rs10832294 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14725881 chr11:14478892~14478953:+ PAAD cis rs55665837 0.54 rs10219313 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14728303 chr11:14478892~14478953:+ PAAD cis rs55665837 0.54 rs4144487 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14728905 chr11:14478892~14478953:+ PAAD cis rs55665837 0.519 rs10832297 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14736191 chr11:14478892~14478953:+ PAAD cis rs55665837 0.54 rs12788030 ENSG00000251991.1 RNU7-49P 4.47 1.51e-05 0.00748 0.4 0.34 Vitamin D levels; chr11:14743138 chr11:14478892~14478953:+ PAAD cis rs2255336 0.938 rs12298043 ENSG00000245648.1 RP11-277P12.20 -4.47 1.51e-05 0.00748 -0.55 -0.34 Blood protein levels; chr12:10456883 chr12:10363769~10398506:+ PAAD cis rs6844153 0.938 rs12646473 ENSG00000240005.4 RP11-293A21.1 -4.47 1.51e-05 0.00749 -0.56 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26873833 chr4:26859806~26860599:- PAAD cis rs5758659 0.652 rs133358 ENSG00000273366.1 CTA-989H11.1 -4.47 1.52e-05 0.00749 -0.41 -0.34 Cognitive function; chr22:42046535 chr22:42278188~42278846:+ PAAD cis rs734999 0.545 rs7368072 ENSG00000225931.3 RP3-395M20.7 4.47 1.52e-05 0.0075 0.33 0.34 Ulcerative colitis; chr1:2624686 chr1:2566410~2569888:+ PAAD cis rs17123764 0.818 rs3887728 ENSG00000257464.1 RP11-161H23.8 -4.47 1.52e-05 0.0075 -0.58 -0.34 Intelligence (multi-trait analysis); chr12:49578549 chr12:49442424~49442652:- PAAD cis rs2404602 0.647 rs12904417 ENSG00000259422.1 RP11-593F23.1 4.47 1.52e-05 0.0075 0.42 0.34 Blood metabolite levels; chr15:76671811 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs7165053 ENSG00000259422.1 RP11-593F23.1 -4.47 1.52e-05 0.0075 -0.42 -0.34 Blood metabolite levels; chr15:76686577 chr15:76174891~76181486:- PAAD cis rs4950322 0.518 rs61838938 ENSG00000278811.3 LINC00624 4.47 1.52e-05 0.0075 0.33 0.34 Protein quantitative trait loci; chr1:147105943 chr1:147258885~147517875:- PAAD cis rs4950322 0.529 rs11809327 ENSG00000278811.3 LINC00624 4.47 1.52e-05 0.0075 0.33 0.34 Protein quantitative trait loci; chr1:147106679 chr1:147258885~147517875:- PAAD cis rs4950322 0.563 rs11809328 ENSG00000278811.3 LINC00624 4.47 1.52e-05 0.0075 0.33 0.34 Protein quantitative trait loci; chr1:147106681 chr1:147258885~147517875:- PAAD cis rs6844153 0.715 rs73813220 ENSG00000240005.4 RP11-293A21.1 -4.47 1.52e-05 0.0075 -0.48 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26920224 chr4:26859806~26860599:- PAAD cis rs9928842 0.882 rs4737 ENSG00000280152.1 RP11-331F4.5 -4.47 1.52e-05 0.0075 -0.47 -0.34 Alcoholic chronic pancreatitis; chr16:75204205 chr16:75245994~75250077:- PAAD cis rs4950322 0.542 rs3766519 ENSG00000278811.3 LINC00624 4.47 1.52e-05 0.00751 0.35 0.34 Protein quantitative trait loci; chr1:147214802 chr1:147258885~147517875:- PAAD cis rs7617773 0.78 rs11706277 ENSG00000228638.1 FCF1P2 -4.47 1.52e-05 0.00751 -0.4 -0.34 Coronary artery disease; chr3:48318943 chr3:48290793~48291375:- PAAD cis rs12468226 0.938 rs16824590 ENSG00000273456.1 RP11-686O6.2 4.47 1.52e-05 0.00752 0.49 0.34 Urate levels; chr2:202272624 chr2:202374932~202375604:- PAAD cis rs12468226 0.938 rs77018809 ENSG00000273456.1 RP11-686O6.2 4.47 1.52e-05 0.00752 0.49 0.34 Urate levels; chr2:202273166 chr2:202374932~202375604:- PAAD cis rs2404602 0.622 rs2280194 ENSG00000259422.1 RP11-593F23.1 -4.47 1.52e-05 0.00752 -0.43 -0.34 Blood metabolite levels; chr15:76947310 chr15:76174891~76181486:- PAAD cis rs6504950 0.886 rs4794551 ENSG00000275710.1 RP11-257O5.4 -4.47 1.52e-05 0.00752 -0.41 -0.34 Breast cancer; chr17:54998066 chr17:54964474~54964679:+ PAAD cis rs2562456 0.917 rs2650825 ENSG00000213976.4 CTD-2561J22.2 -4.47 1.52e-05 0.00753 -0.38 -0.34 Pain; chr19:21516423 chr19:21382865~21387177:+ PAAD cis rs4664293 0.541 rs1863218 ENSG00000226266.5 AC009961.3 4.47 1.52e-05 0.00753 0.43 0.34 Monocyte percentage of white cells; chr2:159512276 chr2:159670708~159712435:- PAAD cis rs4664293 0.541 rs1425047 ENSG00000226266.5 AC009961.3 4.47 1.52e-05 0.00753 0.43 0.34 Monocyte percentage of white cells; chr2:159517946 chr2:159670708~159712435:- PAAD cis rs9287719 0.967 rs1541573 ENSG00000234818.1 AC092687.5 4.47 1.52e-05 0.00753 0.38 0.34 Prostate cancer; chr2:10633259 chr2:10589166~10604830:+ PAAD cis rs9287719 0.967 rs1541574 ENSG00000234818.1 AC092687.5 4.47 1.52e-05 0.00753 0.38 0.34 Prostate cancer; chr2:10633382 chr2:10589166~10604830:+ PAAD cis rs4835473 0.932 rs62339580 ENSG00000251600.4 RP11-673E1.1 -4.47 1.52e-05 0.00753 -0.37 -0.34 Immature fraction of reticulocytes; chr4:143785090 chr4:143912331~143982454:+ PAAD cis rs12908161 0.959 rs17534709 ENSG00000225151.9 GOLGA2P7 -4.47 1.53e-05 0.00753 -0.45 -0.34 Schizophrenia; chr15:84771166 chr15:84199311~84230136:- PAAD cis rs9368481 0.761 rs12661756 ENSG00000241549.7 GUSBP2 4.47 1.53e-05 0.00754 0.36 0.34 Autism spectrum disorder or schizophrenia; chr6:27035704 chr6:26871484~26956554:- PAAD cis rs4835473 0.722 rs7666296 ENSG00000251600.4 RP11-673E1.1 -4.47 1.53e-05 0.00754 -0.41 -0.34 Immature fraction of reticulocytes; chr4:143999004 chr4:143912331~143982454:+ PAAD cis rs4835473 0.618 rs7666297 ENSG00000251600.4 RP11-673E1.1 -4.47 1.53e-05 0.00754 -0.41 -0.34 Immature fraction of reticulocytes; chr4:143999005 chr4:143912331~143982454:+ PAAD cis rs734999 0.588 rs4648652 ENSG00000225931.3 RP3-395M20.7 4.47 1.53e-05 0.00754 0.32 0.34 Ulcerative colitis; chr1:2604319 chr1:2566410~2569888:+ PAAD cis rs755249 0.567 rs16826069 ENSG00000261798.1 RP1-118J21.25 4.47 1.53e-05 0.00755 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39331383 chr1:39788976~39790171:+ PAAD cis rs4273100 1 rs57433322 ENSG00000228157.4 AC007952.5 4.47 1.53e-05 0.00755 0.56 0.34 Schizophrenia; chr17:19238269 chr17:19092974~19096837:+ PAAD cis rs160451 0.782 rs160409 ENSG00000251136.7 RP11-37B2.1 4.47 1.53e-05 0.00756 0.33 0.34 Leprosy; chr8:89636342 chr8:89609409~89757727:- PAAD cis rs2243480 0.522 rs12698511 ENSG00000226824.5 RP4-756H11.3 -4.47 1.53e-05 0.00756 -0.69 -0.34 Diabetic kidney disease; chr7:66009932 chr7:66654538~66669855:+ PAAD cis rs2243480 0.522 rs431168 ENSG00000226824.5 RP4-756H11.3 -4.47 1.53e-05 0.00756 -0.69 -0.34 Diabetic kidney disease; chr7:66046617 chr7:66654538~66669855:+ PAAD cis rs2243480 0.522 rs778717 ENSG00000226824.5 RP4-756H11.3 -4.47 1.53e-05 0.00756 -0.69 -0.34 Diabetic kidney disease; chr7:66383164 chr7:66654538~66669855:+ PAAD cis rs2243480 0.522 rs73150635 ENSG00000226824.5 RP4-756H11.3 -4.47 1.53e-05 0.00756 -0.69 -0.34 Diabetic kidney disease; chr7:66507503 chr7:66654538~66669855:+ PAAD cis rs2243480 0.522 rs1638736 ENSG00000226824.5 RP4-756H11.3 -4.47 1.53e-05 0.00756 -0.69 -0.34 Diabetic kidney disease; chr7:66627321 chr7:66654538~66669855:+ PAAD cis rs1499614 0.522 rs13247442 ENSG00000226824.5 RP4-756H11.3 -4.47 1.53e-05 0.00756 -0.69 -0.34 Gout; chr7:66723871 chr7:66654538~66669855:+ PAAD cis rs8105265 1 rs8105265 ENSG00000253392.2 AC006277.2 4.47 1.53e-05 0.00756 0.51 0.34 Dementia and core Alzheimer's disease neuropathologic changes; chr19:2920707 chr19:2915146~2926807:- PAAD cis rs321358 1 rs73021573 ENSG00000271390.1 RP11-89C3.3 4.47 1.53e-05 0.00756 0.51 0.34 Body mass index; chr11:111155508 chr11:111089870~111090368:- PAAD cis rs321358 1 rs73003503 ENSG00000271390.1 RP11-89C3.3 4.47 1.53e-05 0.00756 0.51 0.34 Body mass index; chr11:111158360 chr11:111089870~111090368:- PAAD cis rs321358 1 rs73003511 ENSG00000271390.1 RP11-89C3.3 4.47 1.53e-05 0.00756 0.51 0.34 Body mass index; chr11:111160478 chr11:111089870~111090368:- PAAD cis rs321358 1 rs73003514 ENSG00000271390.1 RP11-89C3.3 4.47 1.53e-05 0.00756 0.51 0.34 Body mass index; chr11:111160605 chr11:111089870~111090368:- PAAD cis rs58873874 1 rs75720504 ENSG00000251405.2 CTB-109A12.1 4.47 1.53e-05 0.00756 0.7 0.34 Bipolar disorder (body mass index interaction); chr5:157508965 chr5:157362615~157460078:- PAAD cis rs797680 0.964 rs2152358 ENSG00000223745.6 RP4-717I23.3 4.47 1.53e-05 0.00757 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93168452 chr1:93262186~93346025:- PAAD cis rs6991838 0.765 rs6472219 ENSG00000200714.1 Y_RNA 4.47 1.54e-05 0.00757 0.4 0.34 Intelligence (multi-trait analysis); chr8:65644487 chr8:65592731~65592820:+ PAAD cis rs8059260 0.736 rs77334546 ENSG00000274038.1 RP11-66H6.4 -4.47 1.54e-05 0.00758 -0.61 -0.34 Alcohol consumption over the past year; chr16:10970061 chr16:11056556~11057034:+ PAAD cis rs2337406 0.5 rs57619050 ENSG00000211974.3 IGHV2-70 -4.47 1.54e-05 0.00758 -0.49 -0.34 Alzheimer's disease (late onset); chr14:106820074 chr14:106723574~106724093:- PAAD cis rs4835473 0.897 rs35140014 ENSG00000251600.4 RP11-673E1.1 4.47 1.54e-05 0.00759 0.4 0.34 Immature fraction of reticulocytes; chr4:143964292 chr4:143912331~143982454:+ PAAD cis rs6844153 0.887 rs62302533 ENSG00000240005.4 RP11-293A21.1 -4.47 1.54e-05 0.00759 -0.53 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26955309 chr4:26859806~26860599:- PAAD cis rs7829975 0.617 rs4841071 ENSG00000254340.1 RP11-10A14.3 4.47 1.54e-05 0.0076 0.4 0.34 Mood instability; chr8:8933634 chr8:9141424~9145435:+ PAAD cis rs2946504 0.861 rs2946501 ENSG00000251468.2 RP11-369K16.1 4.47 1.54e-05 0.0076 0.43 0.34 Type 2 diabetes; chr8:12955922 chr8:12958387~12962200:+ PAAD cis rs2985684 1 rs8014170 ENSG00000259113.1 RP11-406H23.2 -4.47 1.54e-05 0.00761 -0.48 -0.34 Carotid intima media thickness; chr14:49604976 chr14:50448807~50456742:+ PAAD cis rs6480314 0.542 rs61854805 ENSG00000233590.1 RP11-153K11.3 -4.47 1.54e-05 0.00761 -0.53 -0.34 Optic nerve measurement (disc area); chr10:68255826 chr10:68233251~68242379:- PAAD cis rs55665837 0.54 rs11023302 ENSG00000251991.1 RNU7-49P 4.47 1.54e-05 0.00761 0.4 0.34 Vitamin D levels; chr11:14672389 chr11:14478892~14478953:+ PAAD cis rs9368481 0.761 rs4358615 ENSG00000241549.7 GUSBP2 4.47 1.54e-05 0.00761 0.36 0.34 Autism spectrum disorder or schizophrenia; chr6:27030788 chr6:26871484~26956554:- PAAD cis rs7617773 0.925 rs35942721 ENSG00000228638.1 FCF1P2 -4.47 1.55e-05 0.00762 -0.4 -0.34 Coronary artery disease; chr3:48131579 chr3:48290793~48291375:- PAAD cis rs3733829 0.925 rs12052092 ENSG00000233622.1 CYP2T1P -4.47 1.55e-05 0.00763 -0.46 -0.34 Smoking behavior; chr19:40812994 chr19:40808525~40811390:- PAAD cis rs79040073 0.637 rs73396235 ENSG00000259531.2 RP11-295H24.3 4.47 1.55e-05 0.00763 0.58 0.34 Lung cancer in ever smokers; chr15:49346956 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73396238 ENSG00000259531.2 RP11-295H24.3 4.47 1.55e-05 0.00763 0.58 0.34 Lung cancer in ever smokers; chr15:49347146 chr15:49365124~49366685:- PAAD cis rs2486288 0.656 rs2413771 ENSG00000259433.2 CTD-2651B20.4 4.47 1.55e-05 0.00763 0.37 0.34 Glomerular filtration rate; chr15:45260942 chr15:45330209~45332634:- PAAD cis rs1075265 0.73 rs4413193 ENSG00000233266.1 HMGB1P31 4.47 1.55e-05 0.00763 0.44 0.34 Chronotype;Morning vs. evening chronotype; chr2:53710901 chr2:54051334~54051760:+ PAAD cis rs1075265 0.655 rs13432632 ENSG00000233266.1 HMGB1P31 4.47 1.55e-05 0.00763 0.44 0.34 Chronotype;Morning vs. evening chronotype; chr2:53713586 chr2:54051334~54051760:+ PAAD cis rs755249 0.567 rs6668369 ENSG00000261798.1 RP1-118J21.25 4.47 1.55e-05 0.00763 0.44 0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39382675 chr1:39788976~39790171:+ PAAD cis rs6504622 0.818 rs758391 ENSG00000262539.1 RP11-259G18.3 4.47 1.55e-05 0.00763 0.45 0.34 Orofacial clefts; chr17:46939875 chr17:46259551~46260606:- PAAD cis rs30380 0.688 rs27524 ENSG00000272109.1 CTD-2260A17.3 -4.47 1.55e-05 0.00764 -0.41 -0.34 Cerebrospinal fluid biomarker levels; chr5:96766240 chr5:96804353~96806105:+ PAAD cis rs7712401 0.601 rs246321 ENSG00000263432.2 RN7SL689P 4.46 1.55e-05 0.00765 0.44 0.34 Mean platelet volume; chr5:122972604 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246320 ENSG00000263432.2 RN7SL689P 4.46 1.55e-05 0.00765 0.44 0.34 Mean platelet volume; chr5:122972886 chr5:123022487~123022783:- PAAD cis rs4664293 0.541 rs12692551 ENSG00000226266.5 AC009961.3 4.46 1.55e-05 0.00765 0.43 0.34 Monocyte percentage of white cells; chr2:159501263 chr2:159670708~159712435:- PAAD cis rs4664293 0.541 rs2113859 ENSG00000226266.5 AC009961.3 4.46 1.55e-05 0.00765 0.43 0.34 Monocyte percentage of white cells; chr2:159502199 chr2:159670708~159712435:- PAAD cis rs4664293 0.541 rs62173243 ENSG00000226266.5 AC009961.3 4.46 1.55e-05 0.00765 0.43 0.34 Monocyte percentage of white cells; chr2:159502693 chr2:159670708~159712435:- PAAD cis rs17772222 0.655 rs7160717 ENSG00000258983.2 RP11-507K2.2 4.46 1.55e-05 0.00765 0.43 0.34 Coronary artery calcification; chr14:88498232 chr14:88499334~88515502:+ PAAD cis rs1729407 0.786 rs5100 ENSG00000254851.1 RP11-109L13.1 -4.46 1.55e-05 0.00765 -0.42 -0.34 Apolipoprotein A-IV levels; chr11:116821978 chr11:117135528~117138582:+ PAAD cis rs1729407 0.786 rs5096 ENSG00000254851.1 RP11-109L13.1 -4.46 1.55e-05 0.00765 -0.42 -0.34 Apolipoprotein A-IV levels; chr11:116822379 chr11:117135528~117138582:+ PAAD cis rs763121 0.889 rs6001209 ENSG00000225450.1 RP3-508I15.14 4.46 1.55e-05 0.00765 0.28 0.34 Menopause (age at onset); chr22:38725247 chr22:38739003~38749041:+ PAAD cis rs6480314 0.542 rs7894859 ENSG00000233590.1 RP11-153K11.3 -4.46 1.55e-05 0.00765 -0.55 -0.34 Optic nerve measurement (disc area); chr10:68234620 chr10:68233251~68242379:- PAAD cis rs1150668 0.799 rs7206 ENSG00000204709.4 LINC01556 4.46 1.56e-05 0.00766 0.44 0.34 Pubertal anthropometrics; chr6:28233360 chr6:28943877~28944537:+ PAAD cis rs9517313 0.897 rs4772087 ENSG00000231194.1 FARP1-AS1 4.46 1.56e-05 0.00766 0.37 0.34 Neuroticism; chr13:98462787 chr13:98435405~98435840:- PAAD cis rs4423214 0.559 rs7949129 ENSG00000254682.1 RP11-660L16.2 -4.46 1.56e-05 0.00766 -0.56 -0.34 Vitamin D levels; chr11:71482089 chr11:71448674~71452157:+ PAAD cis rs4423214 0.592 rs3829251 ENSG00000254682.1 RP11-660L16.2 -4.46 1.56e-05 0.00766 -0.56 -0.34 Vitamin D levels; chr11:71483513 chr11:71448674~71452157:+ PAAD cis rs4423214 0.592 rs10898193 ENSG00000254682.1 RP11-660L16.2 4.46 1.56e-05 0.00766 0.56 0.34 Vitamin D levels; chr11:71486037 chr11:71448674~71452157:+ PAAD cis rs9309711 0.961 rs11678655 ENSG00000225234.1 TRAPPC12-AS1 -4.46 1.56e-05 0.00767 -0.37 -0.34 Neurofibrillary tangles; chr2:3472463 chr2:3481242~3482409:- PAAD cis rs9309711 0.961 rs11675119 ENSG00000225234.1 TRAPPC12-AS1 -4.46 1.56e-05 0.00767 -0.37 -0.34 Neurofibrillary tangles; chr2:3472651 chr2:3481242~3482409:- PAAD cis rs13256369 0.951 rs12679360 ENSG00000253981.4 ALG1L13P -4.46 1.56e-05 0.00767 -0.45 -0.34 Obesity-related traits; chr8:8708759 chr8:8236003~8244667:- PAAD cis rs4664293 0.967 rs10202187 ENSG00000226266.5 AC009961.3 -4.46 1.56e-05 0.00768 -0.42 -0.34 Monocyte percentage of white cells; chr2:159571135 chr2:159670708~159712435:- PAAD cis rs2658782 0.654 rs2605623 ENSG00000279684.1 RP11-755E23.2 -4.46 1.56e-05 0.00768 -0.54 -0.34 Pulmonary function decline; chr11:93516193 chr11:93286629~93288903:- PAAD cis rs17507216 0.958 rs28648832 ENSG00000255769.6 GOLGA2P10 -4.46 1.56e-05 0.00768 -0.45 -0.34 Excessive daytime sleepiness; chr15:82567642 chr15:82472993~82513950:- PAAD cis rs4604732 0.536 rs61184655 ENSG00000227135.1 GCSAML-AS1 -4.46 1.56e-05 0.00769 -0.52 -0.34 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247488040 chr1:247524679~247526752:- PAAD cis rs3096299 0.869 rs748941 ENSG00000274627.1 RP11-104N10.2 4.46 1.56e-05 0.00769 0.29 0.34 Multiple myeloma (IgH translocation); chr16:89374346 chr16:89516797~89522217:+ PAAD cis rs9649213 0.574 rs34817002 ENSG00000272950.1 RP11-307C18.1 4.46 1.56e-05 0.00769 0.4 0.34 Prostate cancer (SNP x SNP interaction); chr7:98257739 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs7789440 ENSG00000272950.1 RP11-307C18.1 4.46 1.56e-05 0.00769 0.4 0.34 Prostate cancer (SNP x SNP interaction); chr7:98259486 chr7:98322853~98323430:+ PAAD cis rs17495987 0.913 rs7804266 ENSG00000219545.8 UMAD1 4.46 1.56e-05 0.00769 0.47 0.34 Tonsillectomy; chr7:7853552 chr7:7640711~8004059:+ PAAD cis rs7626444 0.625 rs1798634 ENSG00000272359.1 U4 -4.46 1.56e-05 0.00769 -0.37 -0.34 Monocyte count; chr3:196747416 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs1798635 ENSG00000272359.1 U4 -4.46 1.56e-05 0.00769 -0.37 -0.34 Monocyte count; chr3:196747418 chr3:196747192~196747324:- PAAD cis rs889398 0.967 rs35967356 ENSG00000226232.7 RP11-419C5.2 4.46 1.57e-05 0.00771 0.28 0.34 Body mass index; chr16:69547451 chr16:69976388~69996188:- PAAD cis rs732716 0.813 rs760369 ENSG00000267769.1 CTB-50L17.9 4.46 1.57e-05 0.00771 0.44 0.34 Mean corpuscular volume; chr19:4449290 chr19:4454014~4455286:+ PAAD cis rs875971 0.558 rs4433015 ENSG00000237310.1 GS1-124K5.4 -4.46 1.57e-05 0.00772 -0.32 -0.34 Aortic root size; chr7:66174736 chr7:66493706~66495474:+ PAAD cis rs734999 0.545 rs6698817 ENSG00000225931.3 RP3-395M20.7 -4.46 1.57e-05 0.00772 -0.33 -0.34 Ulcerative colitis; chr1:2632744 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs12752515 ENSG00000225931.3 RP3-395M20.7 -4.46 1.57e-05 0.00772 -0.33 -0.34 Ulcerative colitis; chr1:2633026 chr1:2566410~2569888:+ PAAD cis rs6844153 0.752 rs10029307 ENSG00000240005.4 RP11-293A21.1 -4.46 1.57e-05 0.00772 -0.49 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26902591 chr4:26859806~26860599:- PAAD cis rs11723261 0.582 rs11248006 ENSG00000275426.1 CH17-262A2.1 4.46 1.57e-05 0.00773 0.55 0.34 Immune response to smallpox vaccine (IL-6); chr4:172914 chr4:149738~150317:+ PAAD cis rs797680 0.856 rs569414 ENSG00000223745.6 RP4-717I23.3 4.46 1.57e-05 0.00773 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93319344 chr1:93262186~93346025:- PAAD cis rs5760092 0.755 rs915589 ENSG00000231271.1 AP000350.8 -4.46 1.57e-05 0.00773 -0.53 -0.34 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23949918~23954042:+ PAAD cis rs11098499 0.588 rs6534149 ENSG00000245958.5 RP11-33B1.1 4.46 1.57e-05 0.00773 0.25 0.34 Corneal astigmatism; chr4:119638137 chr4:119454791~119552025:+ PAAD cis rs17711722 1 rs17711722 ENSG00000237310.1 GS1-124K5.4 -4.46 1.58e-05 0.00774 -0.32 -0.34 Calcium levels; chr7:65806210 chr7:66493706~66495474:+ PAAD cis rs17711722 0.675 rs6947132 ENSG00000237310.1 GS1-124K5.4 -4.46 1.58e-05 0.00774 -0.32 -0.34 Calcium levels; chr7:65808508 chr7:66493706~66495474:+ PAAD cis rs2717559 0.542 rs34147336 ENSG00000253741.1 CTD-2292P10.4 4.46 1.58e-05 0.00775 0.45 0.34 Urinary tract infection frequency; chr8:142803453 chr8:142702252~142726973:- PAAD cis rs875971 1 rs697970 ENSG00000232559.3 GS1-124K5.12 -4.46 1.58e-05 0.00775 -0.37 -0.34 Aortic root size; chr7:66095065 chr7:66554588~66576923:- PAAD cis rs10510102 0.516 rs10887034 ENSG00000276742.1 RP11-500G22.4 4.46 1.58e-05 0.00775 0.49 0.34 Breast cancer; chr10:121973996 chr10:121956782~121957098:+ PAAD cis rs7923609 0.875 rs10822143 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00775 -0.43 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63128096 chr10:63634317~63634827:- PAAD cis rs7615952 0.8 rs12489350 ENSG00000241288.6 RP11-379B18.5 -4.46 1.58e-05 0.00775 -0.36 -0.34 Blood pressure (smoking interaction); chr3:125925273 chr3:125827238~125916384:- PAAD cis rs853679 0.723 rs1736904 ENSG00000226314.6 ZNF192P1 -4.46 1.58e-05 0.00776 -0.53 -0.34 Depression; chr6:28251492 chr6:28161781~28169594:+ PAAD cis rs1964356 0.967 rs17701675 ENSG00000253893.2 FAM85B 4.46 1.58e-05 0.00776 0.44 0.34 Mean corpuscular volume; chr8:8993123 chr8:8167819~8226614:- PAAD cis rs4835473 0.868 rs4350958 ENSG00000251600.4 RP11-673E1.1 4.46 1.58e-05 0.00776 0.39 0.34 Immature fraction of reticulocytes; chr4:143744656 chr4:143912331~143982454:+ PAAD cis rs7923609 0.967 rs7085018 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63526907 chr10:63634317~63634827:- PAAD cis rs7923609 0.841 rs7920036 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63534100 chr10:63634317~63634827:- PAAD cis rs7923609 0.902 rs7897379 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63541965 chr10:63634317~63634827:- PAAD cis rs7923609 0.74 rs10761784 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63548990 chr10:63634317~63634827:- PAAD cis rs4664293 0.669 rs35299907 ENSG00000226266.5 AC009961.3 4.46 1.58e-05 0.00777 0.43 0.34 Monocyte percentage of white cells; chr2:159562142 chr2:159670708~159712435:- PAAD cis rs7626444 0.625 rs843535 ENSG00000272359.1 U4 -4.46 1.58e-05 0.00777 -0.37 -0.34 Monocyte count; chr3:196746193 chr3:196747192~196747324:- PAAD cis rs7923609 0.934 rs10761771 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63470404 chr10:63634317~63634827:- PAAD cis rs7923609 0.869 rs10733792 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63472779 chr10:63634317~63634827:- PAAD cis rs7923609 0.838 rs7909960 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63479417 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs7915779 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63484484 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs2393977 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63487849 chr10:63634317~63634827:- PAAD cis rs7923609 0.905 rs10740129 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63491048 chr10:63634317~63634827:- PAAD cis rs34524635 1 rs34524635 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Vascular endothelial growth factor levels; chr10:63501417 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs10509189 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63504366 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs4486511 ENSG00000232075.1 MRPL35P2 -4.46 1.58e-05 0.00777 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63504506 chr10:63634317~63634827:- PAAD cis rs11690935 0.632 rs1607254 ENSG00000228389.1 AC068039.4 -4.46 1.58e-05 0.00777 -0.42 -0.34 Schizophrenia; chr2:171770042 chr2:171773482~171775844:+ PAAD cis rs700651 0.789 rs6434949 ENSG00000231621.1 AC013264.2 -4.46 1.58e-05 0.00778 -0.35 -0.34 Intracranial aneurysm; chr2:197990786 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs6724526 ENSG00000231621.1 AC013264.2 -4.46 1.58e-05 0.00778 -0.35 -0.34 Dermatomyositis; chr2:197993677 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs893808 ENSG00000231621.1 AC013264.2 -4.46 1.58e-05 0.00778 -0.35 -0.34 Dermatomyositis; chr2:197996113 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs35730302 ENSG00000231621.1 AC013264.2 4.46 1.59e-05 0.0078 0.34 0.34 Dermatomyositis; chr2:197953902 chr2:197197991~197199273:+ PAAD cis rs7849973 1 rs7849973 ENSG00000224549.1 RP11-370B11.3 4.46 1.59e-05 0.0078 0.42 0.34 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22819577 chr9:22767175~22768316:+ PAAD cis rs7250849 0.79 rs7259861 ENSG00000273837.1 LLNLR-470E3.1 -4.46 1.59e-05 0.0078 -0.46 -0.34 Blood protein levels; chr19:51657490 chr19:51639478~51639931:- PAAD cis rs812925 0.855 rs6545851 ENSG00000271889.1 RP11-493E12.1 -4.46 1.59e-05 0.00781 -0.39 -0.34 Immature fraction of reticulocytes; chr2:61271222 chr2:61151433~61162105:- PAAD cis rs4835473 0.932 rs12512649 ENSG00000251600.4 RP11-673E1.1 -4.46 1.59e-05 0.00781 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143736745 chr4:143912331~143982454:+ PAAD cis rs11159086 0.793 rs1029701 ENSG00000259005.1 RP3-449M8.6 4.46 1.59e-05 0.00782 0.45 0.34 Advanced glycation end-product levels; chr14:74474112 chr14:74474007~74474864:- PAAD cis rs10754283 0.967 rs12058749 ENSG00000231613.1 RP5-943J3.1 4.46 1.6e-05 0.00783 0.36 0.34 Amyotrophic lateral sclerosis (sporadic); chr1:89640045 chr1:89788914~89790492:+ PAAD cis rs9288520 1 rs10932669 ENSG00000230838.1 AC093850.2 -4.46 1.6e-05 0.00783 -0.42 -0.34 Esophageal cancer (alcohol interaction); chr2:216615506 chr2:215718043~215719424:+ PAAD cis rs2348418 0.966 rs11049695 ENSG00000247934.4 RP11-967K21.1 4.46 1.6e-05 0.00783 0.34 0.34 Lung function (FEV1);Lung function (FVC); chr12:28527934 chr12:28163298~28190738:- PAAD cis rs2348418 0.966 rs7136139 ENSG00000247934.4 RP11-967K21.1 4.46 1.6e-05 0.00783 0.34 0.34 Lung function (FEV1);Lung function (FVC); chr12:28531087 chr12:28163298~28190738:- PAAD cis rs2348418 0.966 rs4144964 ENSG00000247934.4 RP11-967K21.1 4.46 1.6e-05 0.00783 0.34 0.34 Lung function (FEV1);Lung function (FVC); chr12:28531249 chr12:28163298~28190738:- PAAD cis rs964611 0.938 rs8039653 ENSG00000259488.2 RP11-154J22.1 -4.46 1.6e-05 0.00783 -0.36 -0.34 Metabolite levels (Pyroglutamine); chr15:48280438 chr15:48312353~48331856:- PAAD cis rs964611 0.938 rs7174204 ENSG00000259488.2 RP11-154J22.1 -4.46 1.6e-05 0.00783 -0.36 -0.34 Metabolite levels (Pyroglutamine); chr15:48286949 chr15:48312353~48331856:- PAAD cis rs2337406 0.714 rs7152055 ENSG00000211974.3 IGHV2-70 -4.46 1.6e-05 0.00783 -0.48 -0.34 Alzheimer's disease (late onset); chr14:106818996 chr14:106723574~106724093:- PAAD cis rs7646881 0.812 rs74618709 ENSG00000240207.5 RP11-379F4.4 -4.46 1.6e-05 0.00783 -0.52 -0.34 Tetralogy of Fallot; chr3:158737492 chr3:158732263~158784070:+ PAAD cis rs55665837 0.519 rs1451677 ENSG00000251991.1 RNU7-49P 4.46 1.6e-05 0.00784 0.4 0.34 Vitamin D levels; chr11:14724466 chr11:14478892~14478953:+ PAAD cis rs6504950 0.925 rs244348 ENSG00000275710.1 RP11-257O5.4 4.46 1.6e-05 0.00784 0.44 0.34 Breast cancer; chr17:55118930 chr17:54964474~54964679:+ PAAD cis rs6504950 0.925 rs244336 ENSG00000275710.1 RP11-257O5.4 4.46 1.6e-05 0.00784 0.44 0.34 Breast cancer; chr17:55124141 chr17:54964474~54964679:+ PAAD cis rs2283792 0.74 rs2283791 ENSG00000224086.5 LL22NC03-86G7.1 -4.46 1.6e-05 0.00784 -0.36 -0.34 Multiple sclerosis; chr22:21776656 chr22:21938293~21977632:+ PAAD cis rs10129255 0.5 rs10143242 ENSG00000211972.2 IGHV3-66 4.46 1.6e-05 0.00784 0.26 0.34 Kawasaki disease; chr14:106681814 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs2105991 ENSG00000211972.2 IGHV3-66 4.46 1.6e-05 0.00784 0.26 0.34 Kawasaki disease; chr14:106682022 chr14:106675017~106675544:- PAAD cis rs12550612 0.567 rs7834950 ENSG00000253616.4 RP11-875O11.3 4.46 1.6e-05 0.00785 0.48 0.34 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23084305 chr8:23071377~23074488:- PAAD cis rs12550612 0.614 rs11135696 ENSG00000253616.4 RP11-875O11.3 4.46 1.6e-05 0.00785 0.48 0.34 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23084410 chr8:23071377~23074488:- PAAD cis rs6142102 0.961 rs6120519 ENSG00000276073.1 RP5-1125A11.7 -4.46 1.6e-05 0.00785 -0.36 -0.34 Skin pigmentation; chr20:34100307 chr20:33985617~33988989:- PAAD cis rs6061231 0.631 rs2427317 ENSG00000273619.1 RP5-908M14.9 -4.46 1.6e-05 0.00785 -0.28 -0.34 Colorectal cancer; chr20:62400669 chr20:62386303~62386970:- PAAD cis rs6844153 0.887 rs62302532 ENSG00000240005.4 RP11-293A21.1 -4.46 1.6e-05 0.00786 -0.55 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26947150 chr4:26859806~26860599:- PAAD cis rs6844153 0.887 rs6448488 ENSG00000240005.4 RP11-293A21.1 -4.46 1.6e-05 0.00786 -0.55 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26949365 chr4:26859806~26860599:- PAAD cis rs6844153 0.887 rs62302535 ENSG00000240005.4 RP11-293A21.1 -4.46 1.6e-05 0.00786 -0.55 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26957254 chr4:26859806~26860599:- PAAD cis rs6844153 0.887 rs3792685 ENSG00000240005.4 RP11-293A21.1 -4.46 1.6e-05 0.00786 -0.55 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26957585 chr4:26859806~26860599:- PAAD cis rs6844153 0.887 rs6835631 ENSG00000240005.4 RP11-293A21.1 4.46 1.6e-05 0.00786 0.55 0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26946864 chr4:26859806~26860599:- PAAD cis rs2790457 0.958 rs2532741 ENSG00000254635.4 WAC-AS1 -4.46 1.6e-05 0.00786 -0.35 -0.34 Multiple myeloma; chr10:28574879 chr10:28522652~28532743:- PAAD cis rs7849973 0.552 rs9298841 ENSG00000224549.1 RP11-370B11.3 -4.46 1.6e-05 0.00786 -0.4 -0.34 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22811337 chr9:22767175~22768316:+ PAAD cis rs11214589 0.719 rs10891535 ENSG00000270179.1 RP11-159N11.4 -4.46 1.61e-05 0.00787 -0.37 -0.34 Neuroticism; chr11:113330558 chr11:113368478~113369117:+ PAAD cis rs875971 0.522 rs4718285 ENSG00000237310.1 GS1-124K5.4 4.46 1.61e-05 0.00788 0.32 0.34 Aortic root size; chr7:65827018 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs4502988 ENSG00000237310.1 GS1-124K5.4 4.46 1.61e-05 0.00788 0.32 0.34 Aortic root size; chr7:65832759 chr7:66493706~66495474:+ PAAD cis rs17711722 0.64 rs13237956 ENSG00000237310.1 GS1-124K5.4 4.46 1.61e-05 0.00788 0.32 0.34 Calcium levels; chr7:65853042 chr7:66493706~66495474:+ PAAD cis rs6570726 0.935 rs380433 ENSG00000235652.6 RP11-545I5.3 4.46 1.61e-05 0.00789 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145538465 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs367643 ENSG00000235652.6 RP11-545I5.3 4.46 1.61e-05 0.00789 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145538466 chr6:145799409~145886585:+ PAAD cis rs10461617 0.617 rs6874733 ENSG00000271828.1 CTD-2310F14.1 4.46 1.61e-05 0.0079 0.45 0.34 Type 2 diabetes; chr5:56773773 chr5:56927874~56929573:+ PAAD cis rs10510102 0.516 rs12256693 ENSG00000276742.1 RP11-500G22.4 4.46 1.61e-05 0.0079 0.49 0.34 Breast cancer; chr10:121976839 chr10:121956782~121957098:+ PAAD cis rs10510102 0.516 rs11200300 ENSG00000276742.1 RP11-500G22.4 4.46 1.61e-05 0.0079 0.49 0.34 Breast cancer; chr10:121977489 chr10:121956782~121957098:+ PAAD cis rs10510102 0.516 rs11200301 ENSG00000276742.1 RP11-500G22.4 4.46 1.61e-05 0.0079 0.49 0.34 Breast cancer; chr10:121977976 chr10:121956782~121957098:+ PAAD cis rs9314986 0.72 rs912396 ENSG00000238121.4 LINC00426 4.46 1.61e-05 0.00791 0.28 0.34 Biliary atresia; chr13:29869107 chr13:30340270~30377145:- PAAD cis rs7487637 0.529 rs11168245 ENSG00000276691.1 RP5-1057I20.5 4.46 1.61e-05 0.00791 0.4 0.34 Mononucleosis; chr12:47810716 chr12:47788426~47788971:+ PAAD cis rs7626444 0.625 rs1798636 ENSG00000272359.1 U4 -4.46 1.62e-05 0.00791 -0.37 -0.34 Monocyte count; chr3:196749733 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs1798637 ENSG00000272359.1 U4 -4.46 1.62e-05 0.00791 -0.37 -0.34 Monocyte count; chr3:196749768 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs7638090 ENSG00000272359.1 U4 -4.46 1.62e-05 0.00791 -0.37 -0.34 Monocyte count; chr3:196749965 chr3:196747192~196747324:- PAAD cis rs6480314 0.636 rs7914274 ENSG00000233590.1 RP11-153K11.3 -4.46 1.62e-05 0.00792 -0.55 -0.34 Optic nerve measurement (disc area); chr10:68240300 chr10:68233251~68242379:- PAAD cis rs6480314 0.573 rs12573244 ENSG00000233590.1 RP11-153K11.3 -4.46 1.62e-05 0.00792 -0.55 -0.34 Optic nerve measurement (disc area); chr10:68241488 chr10:68233251~68242379:- PAAD cis rs6480314 0.542 rs11814858 ENSG00000233590.1 RP11-153K11.3 -4.46 1.62e-05 0.00792 -0.55 -0.34 Optic nerve measurement (disc area); chr10:68241950 chr10:68233251~68242379:- PAAD cis rs6480314 0.636 rs61854788 ENSG00000233590.1 RP11-153K11.3 -4.46 1.62e-05 0.00792 -0.55 -0.34 Optic nerve measurement (disc area); chr10:68241980 chr10:68233251~68242379:- PAAD cis rs6480314 0.636 rs34888891 ENSG00000233590.1 RP11-153K11.3 -4.46 1.62e-05 0.00792 -0.55 -0.34 Optic nerve measurement (disc area); chr10:68242351 chr10:68233251~68242379:- PAAD cis rs6480314 0.636 rs61854790 ENSG00000233590.1 RP11-153K11.3 -4.46 1.62e-05 0.00792 -0.55 -0.34 Optic nerve measurement (disc area); chr10:68242491 chr10:68233251~68242379:- PAAD cis rs4950322 0.58 rs2083720 ENSG00000278811.3 LINC00624 4.46 1.62e-05 0.00792 0.35 0.34 Protein quantitative trait loci; chr1:147122296 chr1:147258885~147517875:- PAAD cis rs4950322 0.58 rs72706441 ENSG00000278811.3 LINC00624 4.46 1.62e-05 0.00792 0.35 0.34 Protein quantitative trait loci; chr1:147122601 chr1:147258885~147517875:- PAAD cis rs4950322 0.547 rs17355509 ENSG00000278811.3 LINC00624 4.46 1.62e-05 0.00792 0.35 0.34 Protein quantitative trait loci; chr1:147123139 chr1:147258885~147517875:- PAAD cis rs2562456 0.874 rs2562408 ENSG00000213976.4 CTD-2561J22.2 4.46 1.62e-05 0.00792 0.38 0.34 Pain; chr19:21527079 chr19:21382865~21387177:+ PAAD cis rs11662586 0.51 rs12960174 ENSG00000267270.4 PARD6G-AS1 -4.45 1.62e-05 0.00793 -0.49 -0.34 Exploratory eye movement dysfunction in schizophrenia (responsive search score); chr18:79832807 chr18:80147924~80178432:+ PAAD cis rs2255336 0.817 rs12318583 ENSG00000245648.1 RP11-277P12.20 -4.45 1.62e-05 0.00793 -0.52 -0.34 Blood protein levels; chr12:10426485 chr12:10363769~10398506:+ PAAD cis rs66887589 0.807 rs9799664 ENSG00000248280.1 RP11-33B1.2 4.45 1.62e-05 0.00793 0.3 0.34 Diastolic blood pressure; chr4:119405523 chr4:119440561~119450157:- PAAD cis rs11098499 0.575 rs9996586 ENSG00000248280.1 RP11-33B1.2 4.45 1.62e-05 0.00793 0.3 0.34 Corneal astigmatism; chr4:119405787 chr4:119440561~119450157:- PAAD cis rs2486288 0.656 rs2413774 ENSG00000259433.2 CTD-2651B20.4 4.45 1.62e-05 0.00794 0.37 0.34 Glomerular filtration rate; chr15:45257225 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs2413773 ENSG00000259433.2 CTD-2651B20.4 4.45 1.62e-05 0.00794 0.37 0.34 Glomerular filtration rate; chr15:45257244 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs2413772 ENSG00000259433.2 CTD-2651B20.4 4.45 1.62e-05 0.00794 0.37 0.34 Glomerular filtration rate; chr15:45257664 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11632724 ENSG00000259433.2 CTD-2651B20.4 4.45 1.62e-05 0.00794 0.37 0.34 Glomerular filtration rate; chr15:45258593 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11632651 ENSG00000259433.2 CTD-2651B20.4 4.45 1.62e-05 0.00794 0.37 0.34 Glomerular filtration rate; chr15:45258640 chr15:45330209~45332634:- PAAD cis rs4713118 0.662 rs149970 ENSG00000226314.6 ZNF192P1 -4.45 1.62e-05 0.00794 -0.52 -0.34 Parkinson's disease; chr6:28012442 chr6:28161781~28169594:+ PAAD cis rs42490 0.664 rs376110 ENSG00000251136.7 RP11-37B2.1 -4.45 1.62e-05 0.00794 -0.31 -0.34 Leprosy; chr8:89819362 chr8:89609409~89757727:- PAAD cis rs897984 0.542 rs59061704 ENSG00000260911.2 RP11-196G11.2 4.45 1.62e-05 0.00794 0.32 0.34 Dementia with Lewy bodies; chr16:31051383 chr16:31043150~31049868:+ PAAD cis rs748404 1 rs12909095 ENSG00000249839.1 AC011330.5 -4.45 1.62e-05 0.00795 -0.53 -0.34 Lung cancer; chr15:43265944 chr15:43663654~43684339:- PAAD cis rs4813802 0.764 rs6085661 ENSG00000278192.1 RP5-1056H1.2 -4.45 1.62e-05 0.00795 -0.36 -0.34 Colorectal cancer; chr20:6712481 chr20:6065966~6067897:- PAAD cis rs867371 0.762 rs1846910 ENSG00000259429.4 UBE2Q2P2 -4.45 1.62e-05 0.00795 -0.27 -0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82279439 chr15:82355142~82420075:+ PAAD cis rs867371 0.762 rs12905578 ENSG00000259429.4 UBE2Q2P2 4.45 1.62e-05 0.00795 0.27 0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82288923 chr15:82355142~82420075:+ PAAD cis rs7829975 0.511 rs2980426 ENSG00000253981.4 ALG1L13P 4.45 1.62e-05 0.00795 0.42 0.34 Mood instability; chr8:8288087 chr8:8236003~8244667:- PAAD cis rs9287719 0.639 rs7595845 ENSG00000234818.1 AC092687.5 -4.45 1.63e-05 0.00796 -0.37 -0.34 Prostate cancer; chr2:10692734 chr2:10589166~10604830:+ PAAD cis rs9847710 0.566 rs2564951 ENSG00000242142.1 SERBP1P3 4.45 1.63e-05 0.00797 0.45 0.34 Ulcerative colitis; chr3:53026433 chr3:53064283~53065091:- PAAD cis rs1823913 0.599 rs4146103 ENSG00000280083.1 RP11-317J9.1 -4.45 1.63e-05 0.00797 -0.4 -0.34 Obesity-related traits; chr2:191272000 chr2:191154118~191156070:- PAAD cis rs4835473 0.9 rs7698963 ENSG00000251600.4 RP11-673E1.1 4.45 1.63e-05 0.00797 0.38 0.34 Immature fraction of reticulocytes; chr4:143733190 chr4:143912331~143982454:+ PAAD cis rs734999 0.545 rs41300092 ENSG00000225931.3 RP3-395M20.7 4.45 1.63e-05 0.00797 0.33 0.34 Ulcerative colitis; chr1:2606399 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs10910105 ENSG00000225931.3 RP3-395M20.7 4.45 1.63e-05 0.00797 0.33 0.34 Ulcerative colitis; chr1:2606770 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs10910106 ENSG00000225931.3 RP3-395M20.7 4.45 1.63e-05 0.00797 0.33 0.34 Ulcerative colitis; chr1:2607447 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs10752748 ENSG00000225931.3 RP3-395M20.7 4.45 1.63e-05 0.00797 0.33 0.34 Ulcerative colitis; chr1:2613201 chr1:2566410~2569888:+ PAAD cis rs4835473 0.864 rs5015762 ENSG00000251600.4 RP11-673E1.1 -4.45 1.63e-05 0.00797 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143737773 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs5015761 ENSG00000251600.4 RP11-673E1.1 -4.45 1.63e-05 0.00797 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143737791 chr4:143912331~143982454:+ PAAD cis rs6504950 0.72 rs9913784 ENSG00000275710.1 RP11-257O5.4 4.45 1.63e-05 0.00797 0.41 0.34 Breast cancer; chr17:54911710 chr17:54964474~54964679:+ PAAD cis rs4660214 0.666 rs11205839 ENSG00000237624.1 OXCT2P1 -4.45 1.63e-05 0.00798 -0.46 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39268061 chr1:39514956~39516490:+ PAAD cis rs2408955 0.522 rs10875721 ENSG00000240399.1 RP1-228P16.1 -4.45 1.63e-05 0.00798 -0.36 -0.34 Glycated hemoglobin levels; chr12:48019810 chr12:48054813~48055591:- PAAD cis rs2505998 1 rs2435357 ENSG00000273008.1 RP11-351D16.3 -4.45 1.63e-05 0.00798 -0.3 -0.34 Hirschsprung disease; chr10:43086608 chr10:43136824~43138334:- PAAD cis rs8059260 0.668 rs7206753 ENSG00000274038.1 RP11-66H6.4 -4.45 1.63e-05 0.00799 -0.55 -0.34 Alcohol consumption over the past year; chr16:10974987 chr16:11056556~11057034:+ PAAD cis rs7665090 0.87 rs228627 ENSG00000246560.2 RP11-10L12.4 -4.45 1.63e-05 0.00799 -0.38 -0.34 Primary biliary cholangitis; chr4:102651925 chr4:102828055~102844075:+ PAAD cis rs2380205 0.546 rs626344 ENSG00000232807.2 RP11-536K7.3 -4.45 1.64e-05 0.00799 -0.36 -0.34 Breast cancer; chr10:5908272 chr10:5934270~5945900:- PAAD cis rs17711722 0.727 rs1880555 ENSG00000237310.1 GS1-124K5.4 4.45 1.64e-05 0.00799 0.32 0.34 Calcium levels; chr7:65967580 chr7:66493706~66495474:+ PAAD cis rs17711722 0.701 rs781143 ENSG00000237310.1 GS1-124K5.4 4.45 1.64e-05 0.00799 0.32 0.34 Calcium levels; chr7:65974892 chr7:66493706~66495474:+ PAAD cis rs17711722 0.701 rs781145 ENSG00000237310.1 GS1-124K5.4 4.45 1.64e-05 0.00799 0.32 0.34 Calcium levels; chr7:65975383 chr7:66493706~66495474:+ PAAD cis rs17711722 0.727 rs2658585 ENSG00000237310.1 GS1-124K5.4 4.45 1.64e-05 0.00799 0.32 0.34 Calcium levels; chr7:65996954 chr7:66493706~66495474:+ PAAD cis rs916888 0.773 rs9896243 ENSG00000261575.2 RP11-259G18.1 4.45 1.64e-05 0.00799 0.52 0.34 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:46267037~46268694:+ PAAD cis rs2976388 0.647 rs2244163 ENSG00000253741.1 CTD-2292P10.4 -4.45 1.64e-05 0.00799 -0.39 -0.34 Urinary tract infection frequency; chr8:142703082 chr8:142702252~142726973:- PAAD cis rs2976388 0.647 rs2164307 ENSG00000253741.1 CTD-2292P10.4 -4.45 1.64e-05 0.00799 -0.39 -0.34 Urinary tract infection frequency; chr8:142707413 chr8:142702252~142726973:- PAAD cis rs2976388 0.573 rs1529865 ENSG00000253741.1 CTD-2292P10.4 -4.45 1.64e-05 0.00799 -0.39 -0.34 Urinary tract infection frequency; chr8:142707753 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs1560986 ENSG00000253741.1 CTD-2292P10.4 -4.45 1.64e-05 0.00799 -0.39 -0.34 Urinary tract infection frequency; chr8:142708357 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2376491 ENSG00000253741.1 CTD-2292P10.4 -4.45 1.64e-05 0.00799 -0.39 -0.34 Urinary tract infection frequency; chr8:142709516 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2585148 ENSG00000253741.1 CTD-2292P10.4 -4.45 1.64e-05 0.00799 -0.39 -0.34 Urinary tract infection frequency; chr8:142714775 chr8:142702252~142726973:- PAAD cis rs2976388 0.565 rs2572905 ENSG00000253741.1 CTD-2292P10.4 -4.45 1.64e-05 0.00799 -0.39 -0.34 Urinary tract infection frequency; chr8:142715686 chr8:142702252~142726973:- PAAD cis rs2976388 0.647 rs2572906 ENSG00000253741.1 CTD-2292P10.4 -4.45 1.64e-05 0.00799 -0.39 -0.34 Urinary tract infection frequency; chr8:142716851 chr8:142702252~142726973:- PAAD cis rs867371 0.717 rs3858954 ENSG00000259429.4 UBE2Q2P2 -4.45 1.64e-05 0.00799 -0.27 -0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82265693 chr15:82355142~82420075:+ PAAD cis rs11098499 0.562 rs58583086 ENSG00000245958.5 RP11-33B1.1 4.45 1.64e-05 0.008 0.25 0.34 Corneal astigmatism; chr4:119635207 chr4:119454791~119552025:+ PAAD cis rs11098499 0.615 rs59867181 ENSG00000245958.5 RP11-33B1.1 4.45 1.64e-05 0.008 0.25 0.34 Corneal astigmatism; chr4:119635312 chr4:119454791~119552025:+ PAAD cis rs11098499 0.562 rs2389879 ENSG00000245958.5 RP11-33B1.1 4.45 1.64e-05 0.008 0.25 0.34 Corneal astigmatism; chr4:119636529 chr4:119454791~119552025:+ PAAD cis rs1075232 1 rs12437749 ENSG00000215302.7 CTD-3092A11.1 -4.45 1.64e-05 0.008 -0.81 -0.34 Survival in colorectal cancer (non-distant metastatic); chr15:31357685 chr15:30470779~30507623:+ PAAD cis rs8023057 0.756 rs72696805 ENSG00000252481.1 SCARNA13 -4.45 1.64e-05 0.008 -0.43 -0.34 Prostate-specific antigen levels; chr14:94640590 chr14:95533355~95533629:- PAAD cis rs8023057 0.618 rs72696806 ENSG00000252481.1 SCARNA13 -4.45 1.64e-05 0.008 -0.43 -0.34 Prostate-specific antigen levels; chr14:94641022 chr14:95533355~95533629:- PAAD cis rs2243480 0.708 rs13242216 ENSG00000228409.4 CCT6P1 4.45 1.64e-05 0.008 0.38 0.34 Diabetic kidney disease; chr7:66433290 chr7:65751142~65763354:+ PAAD cis rs2243480 0.615 rs34363376 ENSG00000228409.4 CCT6P1 4.45 1.64e-05 0.008 0.38 0.34 Diabetic kidney disease; chr7:66474549 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs67536397 ENSG00000228409.4 CCT6P1 4.45 1.64e-05 0.008 0.38 0.34 Diabetic kidney disease; chr7:66482930 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs58669269 ENSG00000228409.4 CCT6P1 4.45 1.64e-05 0.008 0.38 0.34 Diabetic kidney disease; chr7:66486966 chr7:65751142~65763354:+ PAAD cis rs13178541 0.872 rs10900836 ENSG00000250378.1 RP11-119J18.1 -4.45 1.64e-05 0.008 -0.52 -0.34 IgG glycosylation; chr5:135788139 chr5:135812667~135826582:+ PAAD cis rs9926296 0.656 rs11861084 ENSG00000260259.1 RP11-368I7.4 4.45 1.64e-05 0.008 0.4 0.34 Vitiligo; chr16:89809302 chr16:89682620~89686569:- PAAD cis rs6479891 0.73 rs16918600 ENSG00000232075.1 MRPL35P2 4.45 1.64e-05 0.00801 0.53 0.34 Arthritis (juvenile idiopathic); chr10:63560690 chr10:63634317~63634827:- PAAD cis rs6479891 0.915 rs11812934 ENSG00000232075.1 MRPL35P2 4.45 1.64e-05 0.00801 0.53 0.34 Arthritis (juvenile idiopathic); chr10:63560970 chr10:63634317~63634827:- PAAD cis rs6479891 0.915 rs16918601 ENSG00000232075.1 MRPL35P2 4.45 1.64e-05 0.00801 0.53 0.34 Arthritis (juvenile idiopathic); chr10:63561291 chr10:63634317~63634827:- PAAD cis rs12935418 0.887 rs3743503 ENSG00000261838.4 RP11-303E16.6 4.45 1.64e-05 0.00801 0.63 0.34 Mean corpuscular volume; chr16:81022836 chr16:81069854~81076598:+ PAAD cis rs367615 0.506 rs246102 ENSG00000249476.1 CTD-2587M2.1 -4.45 1.64e-05 0.00801 -0.36 -0.34 Colorectal cancer (SNP x SNP interaction); chr5:109363994 chr5:109237120~109326369:- PAAD cis rs12908161 0.65 rs182517 ENSG00000225151.9 GOLGA2P7 -4.45 1.64e-05 0.00802 -0.43 -0.34 Schizophrenia; chr15:84846400 chr15:84199311~84230136:- PAAD cis rs2790457 0.958 rs2790444 ENSG00000254635.4 WAC-AS1 -4.45 1.64e-05 0.00802 -0.33 -0.34 Multiple myeloma; chr10:28536760 chr10:28522652~28532743:- PAAD cis rs9584850 0.834 rs4294654 ENSG00000231194.1 FARP1-AS1 4.45 1.65e-05 0.00804 0.43 0.34 Neuroticism; chr13:98467353 chr13:98435405~98435840:- PAAD cis rs9584850 0.834 rs12869627 ENSG00000231194.1 FARP1-AS1 4.45 1.65e-05 0.00804 0.43 0.34 Neuroticism; chr13:98468198 chr13:98435405~98435840:- PAAD cis rs9584850 0.834 rs745638 ENSG00000231194.1 FARP1-AS1 -4.45 1.65e-05 0.00804 -0.43 -0.34 Neuroticism; chr13:98467053 chr13:98435405~98435840:- PAAD cis rs9584850 0.834 rs7334078 ENSG00000231194.1 FARP1-AS1 -4.45 1.65e-05 0.00804 -0.43 -0.34 Neuroticism; chr13:98468230 chr13:98435405~98435840:- PAAD cis rs131777 0.577 rs5770928 ENSG00000205559.3 CHKB-AS1 -4.45 1.65e-05 0.00804 -0.41 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50590662 chr22:50583026~50583877:+ PAAD cis rs10129255 0.557 rs4043727 ENSG00000223648.3 IGHV3-64 4.45 1.65e-05 0.00804 0.37 0.34 Kawasaki disease; chr14:106649820 chr14:106643132~106658258:- PAAD cis rs6840258 0.66 rs10516786 ENSG00000251411.1 RP11-397E7.4 -4.45 1.65e-05 0.00804 -0.38 -0.34 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86971189 chr4:86913266~86914817:- PAAD cis rs6496044 0.963 rs7165300 ENSG00000202081.1 RNU6-1280P 4.45 1.65e-05 0.00804 0.38 0.34 Interstitial lung disease; chr15:85526838 chr15:85651522~85651628:- PAAD cis rs10740039 0.548 rs9415607 ENSG00000254271.1 RP11-131N11.4 -4.45 1.65e-05 0.00804 -0.41 -0.34 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60737616 chr10:60734342~60741828:+ PAAD cis rs116139393 0.656 rs10244591 ENSG00000187953.9 PMS2CL -4.45 1.65e-05 0.00804 -0.41 -0.34 Alzheimer's disease (APOE e4 interaction); chr7:6731467 chr7:6710128~6753862:+ PAAD cis rs734999 0.545 rs10797441 ENSG00000225931.3 RP3-395M20.7 4.45 1.65e-05 0.00805 0.33 0.34 Ulcerative colitis; chr1:2620221 chr1:2566410~2569888:+ PAAD cis rs6421571 0.564 rs11216972 ENSG00000255239.1 AP002954.6 -4.45 1.65e-05 0.00805 -0.44 -0.34 Primary biliary cholangitis; chr11:118715117 chr11:118688039~118690600:- PAAD cis rs2255336 0.938 rs2734561 ENSG00000245648.1 RP11-277P12.20 4.45 1.65e-05 0.00805 0.5 0.34 Blood protein levels; chr12:10402386 chr12:10363769~10398506:+ PAAD cis rs2255336 0.882 rs2246809 ENSG00000245648.1 RP11-277P12.20 4.45 1.65e-05 0.00805 0.5 0.34 Blood protein levels; chr12:10404445 chr12:10363769~10398506:+ PAAD cis rs11976180 1 rs2961144 ENSG00000273234.1 OR2A13P 4.45 1.65e-05 0.00807 0.42 0.34 Obesity-related traits; chr7:144050777 chr7:144142009~144142938:+ PAAD cis rs867371 1 rs7181655 ENSG00000259429.4 UBE2Q2P2 -4.45 1.65e-05 0.00807 -0.27 -0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163275 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs7180584 ENSG00000259429.4 UBE2Q2P2 -4.45 1.65e-05 0.00807 -0.27 -0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163493 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs6495642 ENSG00000259429.4 UBE2Q2P2 -4.45 1.65e-05 0.00807 -0.27 -0.34 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82165156 chr15:82355142~82420075:+ PAAD cis rs10510102 0.935 rs12253283 ENSG00000276742.1 RP11-500G22.4 -4.45 1.66e-05 0.00807 -0.5 -0.34 Breast cancer; chr10:121909740 chr10:121956782~121957098:+ PAAD cis rs7078219 0.505 rs7916751 ENSG00000228778.1 RP11-129J12.1 -4.45 1.66e-05 0.00808 -0.37 -0.34 Dental caries; chr10:99525893 chr10:99527081~99528261:+ PAAD cis rs6584283 0.846 rs7917446 ENSG00000228778.1 RP11-129J12.1 -4.45 1.66e-05 0.00808 -0.37 -0.34 Ulcerative colitis; chr10:99526450 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs6584281 ENSG00000228778.1 RP11-129J12.1 -4.45 1.66e-05 0.00808 -0.37 -0.34 Dental caries; chr10:99526723 chr10:99527081~99528261:+ PAAD cis rs4664293 0.647 rs4665082 ENSG00000226266.5 AC009961.3 -4.45 1.66e-05 0.00808 -0.42 -0.34 Monocyte percentage of white cells; chr2:159573455 chr2:159670708~159712435:- PAAD cis rs321358 0.945 rs7111445 ENSG00000271390.1 RP11-89C3.3 -4.45 1.66e-05 0.00808 -0.52 -0.34 Body mass index; chr11:111105787 chr11:111089870~111090368:- PAAD cis rs2790457 0.958 rs1265829 ENSG00000254635.4 WAC-AS1 -4.45 1.66e-05 0.00809 -0.33 -0.34 Multiple myeloma; chr10:28622374 chr10:28522652~28532743:- PAAD cis rs2790457 0.792 rs1265830 ENSG00000254635.4 WAC-AS1 4.45 1.66e-05 0.00809 0.33 0.34 Multiple myeloma; chr10:28623294 chr10:28522652~28532743:- PAAD cis rs9322193 0.884 rs880245 ENSG00000268592.3 RAET1E-AS1 -4.45 1.66e-05 0.00809 -0.41 -0.34 Lung cancer; chr6:149846262 chr6:149863494~149919507:+ PAAD cis rs7487637 0.529 rs11168244 ENSG00000276691.1 RP5-1057I20.5 4.45 1.66e-05 0.0081 0.4 0.34 Mononucleosis; chr12:47809158 chr12:47788426~47788971:+ PAAD cis rs321358 0.945 rs73015196 ENSG00000271390.1 RP11-89C3.3 4.45 1.66e-05 0.00811 0.52 0.34 Body mass index; chr11:111104608 chr11:111089870~111090368:- PAAD cis rs321358 0.945 rs73015199 ENSG00000271390.1 RP11-89C3.3 4.45 1.66e-05 0.00811 0.52 0.34 Body mass index; chr11:111104952 chr11:111089870~111090368:- PAAD cis rs10050311 0.698 rs4693780 ENSG00000251411.1 RP11-397E7.4 4.45 1.66e-05 0.00811 0.42 0.34 Insulin-related traits; chr4:86720066 chr4:86913266~86914817:- PAAD cis rs950880 0.71 rs10490203 ENSG00000234389.1 AC007278.3 -4.45 1.66e-05 0.00811 -0.34 -0.34 Serum protein levels (sST2); chr2:102442777 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs4851583 ENSG00000234389.1 AC007278.3 -4.45 1.66e-05 0.00811 -0.34 -0.34 Serum protein levels (sST2); chr2:102443840 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs11694360 ENSG00000234389.1 AC007278.3 -4.45 1.66e-05 0.00811 -0.34 -0.34 Serum protein levels (sST2); chr2:102444687 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs11123928 ENSG00000234389.1 AC007278.3 -4.45 1.66e-05 0.00811 -0.34 -0.34 Serum protein levels (sST2); chr2:102444826 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs7597017 ENSG00000234389.1 AC007278.3 -4.45 1.66e-05 0.00811 -0.34 -0.34 Serum protein levels (sST2); chr2:102445656 chr2:102438713~102440475:+ PAAD cis rs950880 0.677 rs4851585 ENSG00000234389.1 AC007278.3 -4.45 1.66e-05 0.00811 -0.34 -0.34 Serum protein levels (sST2); chr2:102446294 chr2:102438713~102440475:+ PAAD cis rs694739 0.628 rs475032 ENSG00000236935.1 AP003774.1 -4.45 1.67e-05 0.00812 -0.35 -0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64373265 chr11:64325050~64329504:- PAAD cis rs28374715 0.783 rs11635269 ENSG00000247556.5 OIP5-AS1 4.45 1.67e-05 0.00812 0.36 0.34 Ulcerative colitis; chr15:41278512 chr15:41283990~41309737:+ PAAD cis rs11690935 0.589 rs6729945 ENSG00000228389.1 AC068039.4 -4.45 1.67e-05 0.00812 -0.42 -0.34 Schizophrenia; chr2:171999788 chr2:171773482~171775844:+ PAAD cis rs11690935 0.55 rs62183784 ENSG00000228389.1 AC068039.4 -4.45 1.67e-05 0.00812 -0.42 -0.34 Schizophrenia; chr2:172001789 chr2:171773482~171775844:+ PAAD cis rs11690935 0.55 rs62183785 ENSG00000228389.1 AC068039.4 -4.45 1.67e-05 0.00812 -0.42 -0.34 Schizophrenia; chr2:172002068 chr2:171773482~171775844:+ PAAD cis rs11690935 0.531 rs62183800 ENSG00000228389.1 AC068039.4 -4.45 1.67e-05 0.00812 -0.42 -0.34 Schizophrenia; chr2:172002365 chr2:171773482~171775844:+ PAAD cis rs734999 0.588 rs10910098 ENSG00000225931.3 RP3-395M20.7 4.45 1.67e-05 0.00812 0.32 0.34 Ulcerative colitis; chr1:2601811 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs60520190 ENSG00000225931.3 RP3-395M20.7 4.45 1.67e-05 0.00812 0.32 0.34 Ulcerative colitis; chr1:2602267 chr1:2566410~2569888:+ PAAD cis rs734999 0.566 rs10797435 ENSG00000225931.3 RP3-395M20.7 4.45 1.67e-05 0.00812 0.32 0.34 Ulcerative colitis; chr1:2603362 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs4648562 ENSG00000225931.3 RP3-395M20.7 4.45 1.67e-05 0.00812 0.32 0.34 Ulcerative colitis; chr1:2604174 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs4648653 ENSG00000225931.3 RP3-395M20.7 4.45 1.67e-05 0.00812 0.32 0.34 Ulcerative colitis; chr1:2604456 chr1:2566410~2569888:+ PAAD cis rs734999 0.566 rs4648563 ENSG00000225931.3 RP3-395M20.7 4.45 1.67e-05 0.00812 0.32 0.34 Ulcerative colitis; chr1:2604563 chr1:2566410~2569888:+ PAAD cis rs734999 0.566 rs6424092 ENSG00000225931.3 RP3-395M20.7 -4.45 1.67e-05 0.00812 -0.32 -0.34 Ulcerative colitis; chr1:2601460 chr1:2566410~2569888:+ PAAD cis rs2412819 0.571 rs514255 ENSG00000205771.5 CATSPER2P1 -4.45 1.67e-05 0.00812 -0.51 -0.34 Lung cancer; chr15:43893134 chr15:43726918~43747094:- PAAD cis rs321358 0.945 rs7112932 ENSG00000271390.1 RP11-89C3.3 4.45 1.67e-05 0.00813 0.51 0.34 Body mass index; chr11:111101099 chr11:111089870~111090368:- PAAD cis rs8023057 0.755 rs56250610 ENSG00000252481.1 SCARNA13 -4.45 1.67e-05 0.00813 -0.43 -0.34 Prostate-specific antigen levels; chr14:94648887 chr14:95533355~95533629:- PAAD cis rs7712401 0.601 rs34233716 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122980670 chr5:123022487~123022783:- PAAD cis rs7712401 0.54 rs416763 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122981546 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs35339188 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122981990 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs36099390 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122982024 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs35157167 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122982506 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs396941 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122982570 chr5:123022487~123022783:- PAAD cis rs7712401 0.58 rs439739 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122982726 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs371604 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122982737 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs34707663 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122984768 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs385547 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122986138 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs454617 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122986232 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs436546 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122987095 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs397731 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122987264 chr5:123022487~123022783:- PAAD cis rs7712401 0.58 rs35902490 ENSG00000263432.2 RN7SL689P -4.45 1.67e-05 0.00813 -0.44 -0.34 Mean platelet volume; chr5:122987703 chr5:123022487~123022783:- PAAD cis rs853679 0.55 rs6901017 ENSG00000204709.4 LINC01556 4.45 1.67e-05 0.00813 0.57 0.34 Depression; chr6:28184805 chr6:28943877~28944537:+ PAAD cis rs6480314 0.522 rs61854800 ENSG00000233590.1 RP11-153K11.3 -4.45 1.67e-05 0.00813 -0.56 -0.34 Optic nerve measurement (disc area); chr10:68248271 chr10:68233251~68242379:- PAAD cis rs7182621 0.639 rs12906068 ENSG00000182397.13 DNM1P46 4.45 1.67e-05 0.00814 0.45 0.34 Colonoscopy-negative controls vs population controls; chr15:99873422 chr15:99790156~99806927:- PAAD cis rs7429990 1 rs1665982 ENSG00000228638.1 FCF1P2 4.45 1.67e-05 0.00814 0.41 0.34 Educational attainment (years of education); chr3:47863589 chr3:48290793~48291375:- PAAD cis rs42490 0.664 rs453266 ENSG00000251136.7 RP11-37B2.1 -4.45 1.67e-05 0.00814 -0.31 -0.34 Leprosy; chr8:89823789 chr8:89609409~89757727:- PAAD cis rs42490 0.638 rs369771 ENSG00000251136.7 RP11-37B2.1 -4.45 1.67e-05 0.00814 -0.31 -0.34 Leprosy; chr8:89823884 chr8:89609409~89757727:- PAAD cis rs6570726 0.902 rs373321 ENSG00000235652.6 RP11-545I5.3 4.45 1.67e-05 0.00814 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145533014 chr6:145799409~145886585:+ PAAD cis rs6570726 0.967 rs374728 ENSG00000235652.6 RP11-545I5.3 4.45 1.67e-05 0.00814 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145533462 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs368848 ENSG00000235652.6 RP11-545I5.3 4.45 1.67e-05 0.00814 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145534145 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs374000 ENSG00000235652.6 RP11-545I5.3 4.45 1.67e-05 0.00814 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145534154 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs369214 ENSG00000235652.6 RP11-545I5.3 4.45 1.67e-05 0.00814 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145535573 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs390252 ENSG00000235652.6 RP11-545I5.3 4.45 1.67e-05 0.00814 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145535760 chr6:145799409~145886585:+ PAAD cis rs6570726 0.875 rs373313 ENSG00000235652.6 RP11-545I5.3 4.45 1.67e-05 0.00814 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145536655 chr6:145799409~145886585:+ PAAD cis rs7202877 0.656 rs247427 ENSG00000261783.1 RP11-252K23.2 4.45 1.67e-05 0.00814 0.53 0.34 Type 1 diabetes;Type 2 diabetes; chr16:75405234 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs247434 ENSG00000261783.1 RP11-252K23.2 4.45 1.67e-05 0.00814 0.53 0.34 Type 1 diabetes;Type 2 diabetes; chr16:75411406 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs247436 ENSG00000261783.1 RP11-252K23.2 4.45 1.67e-05 0.00814 0.53 0.34 Type 1 diabetes;Type 2 diabetes; chr16:75412073 chr16:75379818~75381260:- PAAD cis rs8100891 0.537 rs73034216 ENSG00000267213.4 AC007773.2 -4.45 1.67e-05 0.00814 -0.56 -0.34 Neuroticism; chr19:32392510 chr19:32390050~32405560:- PAAD cis rs113835537 0.877 rs3867132 ENSG00000255517.5 CTD-3074O7.5 -4.45 1.67e-05 0.00814 -0.58 -0.34 Airway imaging phenotypes; chr11:66541798 chr11:66473490~66480233:- PAAD cis rs113835537 0.877 rs57127845 ENSG00000255517.5 CTD-3074O7.5 -4.45 1.67e-05 0.00814 -0.58 -0.34 Airway imaging phenotypes; chr11:66550854 chr11:66473490~66480233:- PAAD cis rs4713118 0.662 rs149900 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28046819 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs149961 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28047791 chr6:28161781~28169594:+ PAAD cis rs4713118 0.629 rs149899 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28052201 chr6:28161781~28169594:+ PAAD cis rs4713118 0.629 rs172165 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28053036 chr6:28161781~28169594:+ PAAD cis rs4713118 0.597 rs172166 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28053042 chr6:28161781~28169594:+ PAAD cis rs4713118 0.629 rs203888 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28053811 chr6:28161781~28169594:+ PAAD cis rs4713118 0.629 rs203889 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28053997 chr6:28161781~28169594:+ PAAD cis rs4713118 0.629 rs203890 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28054470 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9357060 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28056708 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9468271 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28056792 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9380045 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28057501 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9468274 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28058299 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9468275 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28058358 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9468276 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28059910 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9468277 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28060612 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9468278 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28060704 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs13218430 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28062059 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs9380046 ENSG00000226314.6 ZNF192P1 -4.45 1.68e-05 0.00815 -0.56 -0.34 Parkinson's disease; chr6:28062721 chr6:28161781~28169594:+ PAAD cis rs875971 0.54 rs736270 ENSG00000234585.5 CCT6P3 4.45 1.68e-05 0.00815 0.28 0.34 Aortic root size; chr7:65963835 chr7:65038354~65074713:+ PAAD cis rs7078219 0.523 rs10883366 ENSG00000228778.1 RP11-129J12.1 -4.45 1.68e-05 0.00817 -0.37 -0.34 Dental caries; chr10:99528028 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs10883367 ENSG00000228778.1 RP11-129J12.1 -4.45 1.68e-05 0.00817 -0.37 -0.34 Dental caries; chr10:99528233 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs7085798 ENSG00000228778.1 RP11-129J12.1 -4.45 1.68e-05 0.00817 -0.37 -0.34 Dental caries; chr10:99528590 chr10:99527081~99528261:+ PAAD cis rs7078219 0.524 rs1548963 ENSG00000228778.1 RP11-129J12.1 -4.45 1.68e-05 0.00817 -0.37 -0.34 Dental caries; chr10:99529946 chr10:99527081~99528261:+ PAAD cis rs6584283 0.875 rs1548962 ENSG00000228778.1 RP11-129J12.1 4.45 1.68e-05 0.00817 0.37 0.34 Ulcerative colitis; chr10:99529978 chr10:99527081~99528261:+ PAAD cis rs240993 0.909 rs11153279 ENSG00000230177.1 RP5-1112D6.4 4.45 1.68e-05 0.00817 0.3 0.34 Inflammatory skin disease;Psoriasis; chr6:111266063 chr6:111277932~111278742:+ PAAD cis rs42490 0.57 rs454561 ENSG00000251136.7 RP11-37B2.1 -4.45 1.68e-05 0.00818 -0.31 -0.34 Leprosy; chr8:89824387 chr8:89609409~89757727:- PAAD cis rs4950322 0.58 rs17359629 ENSG00000278811.3 LINC00624 4.45 1.68e-05 0.00818 0.34 0.34 Protein quantitative trait loci; chr1:147121537 chr1:147258885~147517875:- PAAD cis rs6504622 0.875 rs3785888 ENSG00000262879.4 RP11-156P1.3 -4.45 1.68e-05 0.00818 -0.37 -0.34 Orofacial clefts; chr17:46928337 chr17:46984045~47100323:- PAAD cis rs79040073 0.51 rs111307556 ENSG00000259531.2 RP11-295H24.3 4.44 1.69e-05 0.00819 0.57 0.34 Lung cancer in ever smokers; chr15:49339858 chr15:49365124~49366685:- PAAD cis rs4664293 1 rs12692554 ENSG00000226266.5 AC009961.3 -4.44 1.69e-05 0.00819 -0.42 -0.34 Monocyte percentage of white cells; chr2:159594777 chr2:159670708~159712435:- PAAD cis rs11214589 0.747 rs11214577 ENSG00000270179.1 RP11-159N11.4 4.44 1.69e-05 0.0082 0.36 0.34 Neuroticism; chr11:113333544 chr11:113368478~113369117:+ PAAD cis rs694739 0.628 rs645078 ENSG00000236935.1 AP003774.1 4.44 1.69e-05 0.0082 0.37 0.34 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64367826 chr11:64325050~64329504:- PAAD cis rs2486288 0.656 rs6493144 ENSG00000259433.2 CTD-2651B20.4 -4.44 1.69e-05 0.0082 -0.37 -0.34 Glomerular filtration rate; chr15:45281291 chr15:45330209~45332634:- PAAD cis rs7665090 0.87 rs228623 ENSG00000246560.2 RP11-10L12.4 -4.44 1.69e-05 0.0082 -0.38 -0.34 Primary biliary cholangitis; chr4:102651163 chr4:102828055~102844075:+ PAAD cis rs7665090 0.837 rs228624 ENSG00000246560.2 RP11-10L12.4 -4.44 1.69e-05 0.0082 -0.38 -0.34 Primary biliary cholangitis; chr4:102651283 chr4:102828055~102844075:+ PAAD cis rs7189233 0.531 rs8055642 ENSG00000279344.1 RP11-44F14.7 4.44 1.69e-05 0.00821 0.26 0.34 Intelligence (multi-trait analysis); chr16:53503669 chr16:53478957~53481550:- PAAD cis rs10510102 1 rs10510102 ENSG00000276742.1 RP11-500G22.4 -4.44 1.69e-05 0.00821 -0.49 -0.34 Breast cancer; chr10:121865675 chr10:121956782~121957098:+ PAAD cis rs875971 0.651 rs313829 ENSG00000164669.11 INTS4P1 4.44 1.69e-05 0.00822 0.46 0.34 Aortic root size; chr7:66087510 chr7:65141225~65234216:+ PAAD cis rs4925386 0.808 rs1741634 ENSG00000273619.1 RP5-908M14.9 4.44 1.7e-05 0.00824 0.28 0.34 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62350923 chr20:62386303~62386970:- PAAD cis rs4925386 0.808 rs1760073 ENSG00000273619.1 RP5-908M14.9 4.44 1.7e-05 0.00824 0.28 0.34 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62351050 chr20:62386303~62386970:- PAAD cis rs9287719 0.572 rs1038690 ENSG00000234818.1 AC092687.5 -4.44 1.7e-05 0.00824 -0.38 -0.34 Prostate cancer; chr2:10673118 chr2:10589166~10604830:+ PAAD cis rs6539288 0.933 rs1822736 ENSG00000260329.1 RP11-412D9.4 4.44 1.7e-05 0.00826 0.28 0.34 Total body bone mineral density; chr12:106915481 chr12:106954029~106955497:- PAAD cis rs9494145 0.68 rs9376092 ENSG00000232876.1 CTA-212D2.2 4.44 1.7e-05 0.00826 0.43 0.34 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135106006 chr6:135055033~135060550:+ PAAD cis rs9926296 0.744 rs164746 ENSG00000260259.1 RP11-368I7.4 4.44 1.7e-05 0.00826 0.46 0.34 Vitiligo; chr16:89642611 chr16:89682620~89686569:- PAAD cis rs8005677 0.828 rs712486 ENSG00000279656.1 RP11-298I3.6 4.44 1.71e-05 0.00827 0.4 0.34 Cognitive ability (multi-trait analysis); chr14:22955832 chr14:23023083~23024217:- PAAD cis rs7829975 0.593 rs2921061 ENSG00000253981.4 ALG1L13P 4.44 1.71e-05 0.00828 0.4 0.34 Mood instability; chr8:8460105 chr8:8236003~8244667:- PAAD cis rs613391 0.522 rs1031289 ENSG00000224549.1 RP11-370B11.3 4.44 1.71e-05 0.00829 0.4 0.34 Quantitative traits; chr9:22731107 chr9:22767175~22768316:+ PAAD cis rs440932 0.757 rs330943 ENSG00000254340.1 RP11-10A14.3 4.44 1.71e-05 0.00829 0.43 0.34 High light scatter reticulocyte percentage of red cells; chr8:9163516 chr8:9141424~9145435:+ PAAD cis rs394563 0.901 rs448874 ENSG00000231760.4 RP11-350J20.5 4.44 1.71e-05 0.0083 0.44 0.34 Dupuytren's disease; chr6:149475831 chr6:149796151~149826294:- PAAD cis rs2404602 0.647 rs3812908 ENSG00000259422.1 RP11-593F23.1 4.44 1.71e-05 0.0083 0.42 0.34 Blood metabolite levels; chr15:76883817 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs8025991 ENSG00000259422.1 RP11-593F23.1 -4.44 1.71e-05 0.0083 -0.42 -0.34 Blood metabolite levels; chr15:76862927 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs4886837 ENSG00000259422.1 RP11-593F23.1 -4.44 1.71e-05 0.0083 -0.42 -0.34 Blood metabolite levels; chr15:76864076 chr15:76174891~76181486:- PAAD cis rs9322193 0.566 rs9397070 ENSG00000268592.3 RAET1E-AS1 -4.44 1.71e-05 0.00831 -0.44 -0.34 Lung cancer; chr6:149922073 chr6:149863494~149919507:+ PAAD cis rs2564921 0.666 rs62253656 ENSG00000242142.1 SERBP1P3 -4.44 1.72e-05 0.00832 -0.42 -0.34 Height; chr3:52989412 chr3:53064283~53065091:- PAAD cis rs2564921 0.666 rs11130335 ENSG00000242142.1 SERBP1P3 -4.44 1.72e-05 0.00832 -0.42 -0.34 Height; chr3:52989619 chr3:53064283~53065091:- PAAD cis rs755249 0.501 rs4660669 ENSG00000261798.1 RP1-118J21.25 -4.44 1.72e-05 0.00832 -0.41 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39341786 chr1:39788976~39790171:+ PAAD cis rs4554975 0.838 rs11183620 ENSG00000274723.1 RP11-618L22.1 -4.44 1.72e-05 0.00833 -0.4 -0.34 Metabolite levels (small molecules and protein measures); chr12:46818587 chr12:46970504~46972155:+ PAAD cis rs394563 0.967 rs420099 ENSG00000231760.4 RP11-350J20.5 4.44 1.72e-05 0.00833 0.44 0.34 Dupuytren's disease; chr6:149473154 chr6:149796151~149826294:- PAAD cis rs7615952 0.932 rs13321217 ENSG00000241288.6 RP11-379B18.5 -4.44 1.72e-05 0.00833 -0.36 -0.34 Blood pressure (smoking interaction); chr3:125912928 chr3:125827238~125916384:- PAAD cis rs79040073 0.607 rs10519227 ENSG00000259531.2 RP11-295H24.3 4.44 1.72e-05 0.00833 0.52 0.34 Lung cancer in ever smokers; chr15:49454167 chr15:49365124~49366685:- PAAD cis rs7580658 0.545 rs59318157 ENSG00000236682.1 AC068282.3 -4.44 1.72e-05 0.00833 -0.41 -0.34 Protein C levels; chr2:127192498 chr2:127389130~127400580:+ PAAD cis rs3738443 0.645 rs11811599 ENSG00000259865.1 RP11-488L18.10 4.44 1.72e-05 0.00833 0.29 0.34 Alcohol dependence; chr1:247203133 chr1:247187281~247188526:- PAAD cis rs3020264 0.579 rs1256 ENSG00000271743.1 CTD-2541M15.3 -4.44 1.72e-05 0.00834 -0.5 -0.34 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6615835 chr8:6615604~6617198:- PAAD cis rs9652601 0.881 rs11860603 ENSG00000274038.1 RP11-66H6.4 -4.44 1.72e-05 0.00835 -0.39 -0.34 Systemic lupus erythematosus; chr16:11071160 chr16:11056556~11057034:+ PAAD cis rs9652601 0.959 rs9934969 ENSG00000274038.1 RP11-66H6.4 -4.44 1.72e-05 0.00835 -0.39 -0.34 Systemic lupus erythematosus; chr16:11072145 chr16:11056556~11057034:+ PAAD cis rs34375054 0.624 rs7132026 ENSG00000279233.1 RP11-158L12.4 -4.44 1.72e-05 0.00835 -0.28 -0.34 Post bronchodilator FEV1/FVC ratio; chr12:125193550 chr12:125138245~125141711:+ PAAD cis rs4664293 1 rs6432540 ENSG00000226266.5 AC009961.3 -4.44 1.72e-05 0.00835 -0.42 -0.34 Monocyte percentage of white cells; chr2:159594192 chr2:159670708~159712435:- PAAD cis rs2348418 0.966 rs7315631 ENSG00000247934.4 RP11-967K21.1 4.44 1.73e-05 0.00835 0.33 0.34 Lung function (FEV1);Lung function (FVC); chr12:28545311 chr12:28163298~28190738:- PAAD cis rs2348418 0.966 rs7316351 ENSG00000247934.4 RP11-967K21.1 4.44 1.73e-05 0.00835 0.33 0.34 Lung function (FEV1);Lung function (FVC); chr12:28545595 chr12:28163298~28190738:- PAAD cis rs2412819 0.571 rs4923964 ENSG00000249839.1 AC011330.5 4.44 1.73e-05 0.00837 0.55 0.34 Lung cancer; chr15:43722882 chr15:43663654~43684339:- PAAD cis rs6584283 0.875 rs10748783 ENSG00000228778.1 RP11-129J12.1 -4.44 1.73e-05 0.00837 -0.37 -0.34 Ulcerative colitis; chr10:99526115 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs6584282 ENSG00000228778.1 RP11-129J12.1 -4.44 1.73e-05 0.00837 -0.37 -0.34 Dental caries; chr10:99526738 chr10:99527081~99528261:+ PAAD cis rs6584283 0.846 rs11190135 ENSG00000228778.1 RP11-129J12.1 -4.44 1.73e-05 0.00837 -0.37 -0.34 Ulcerative colitis; chr10:99527091 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs10883362 ENSG00000228778.1 RP11-129J12.1 -4.44 1.73e-05 0.00837 -0.37 -0.34 Dental caries; chr10:99527227 chr10:99527081~99528261:+ PAAD cis rs2911132 1 rs2911140 ENSG00000248734.2 CTD-2260A17.1 4.44 1.73e-05 0.00837 0.32 0.34 Urate levels (BMI interaction); chr5:96844240 chr5:96784777~96785999:+ PAAD cis rs11690935 0.632 rs62183783 ENSG00000228389.1 AC068039.4 -4.44 1.73e-05 0.00837 -0.41 -0.34 Schizophrenia; chr2:172000868 chr2:171773482~171775844:+ PAAD cis rs2348418 0.648 rs11049730 ENSG00000247934.4 RP11-967K21.1 4.44 1.73e-05 0.00837 0.33 0.34 Lung function (FEV1);Lung function (FVC); chr12:28586912 chr12:28163298~28190738:- PAAD cis rs797680 0.754 rs3767964 ENSG00000223745.6 RP4-717I23.3 4.44 1.73e-05 0.00838 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93349933 chr1:93262186~93346025:- PAAD cis rs11690935 0.632 rs6433323 ENSG00000228389.1 AC068039.4 4.44 1.73e-05 0.00838 0.41 0.34 Schizophrenia; chr2:172008155 chr2:171773482~171775844:+ PAAD cis rs111580313 0.685 rs78689656 ENSG00000270020.1 RP11-463O9.9 4.44 1.73e-05 0.00838 0.89 0.34 Systemic juvenile idiopathic arthritis; chr16:86571787 chr16:86520383~86523897:- PAAD cis rs111580313 0.685 rs74870060 ENSG00000270020.1 RP11-463O9.9 4.44 1.73e-05 0.00838 0.89 0.34 Systemic juvenile idiopathic arthritis; chr16:86572158 chr16:86520383~86523897:- PAAD cis rs111580313 0.685 rs4843167 ENSG00000270020.1 RP11-463O9.9 4.44 1.73e-05 0.00838 0.89 0.34 Systemic juvenile idiopathic arthritis; chr16:86573157 chr16:86520383~86523897:- PAAD cis rs111580313 0.685 rs79088793 ENSG00000270020.1 RP11-463O9.9 4.44 1.73e-05 0.00838 0.89 0.34 Systemic juvenile idiopathic arthritis; chr16:86573421 chr16:86520383~86523897:- PAAD cis rs2902193 0.645 rs10048306 ENSG00000267325.1 LINC01415 -4.44 1.73e-05 0.00839 -0.33 -0.34 Cancer; chr18:55986789 chr18:55776727~55781721:- PAAD cis rs34375054 0.672 rs10400509 ENSG00000279233.1 RP11-158L12.4 4.44 1.73e-05 0.00839 0.29 0.34 Post bronchodilator FEV1/FVC ratio; chr12:125107627 chr12:125138245~125141711:+ PAAD cis rs9649213 0.574 rs60077733 ENSG00000272950.1 RP11-307C18.1 4.44 1.74e-05 0.00839 0.39 0.34 Prostate cancer (SNP x SNP interaction); chr7:98340825 chr7:98322853~98323430:+ PAAD cis rs4888378 0.576 rs8050367 ENSG00000261783.1 RP11-252K23.2 4.44 1.74e-05 0.0084 0.52 0.34 Coronary artery disease; chr16:75279360 chr16:75379818~75381260:- PAAD cis rs12908161 0.92 rs35758837 ENSG00000259728.4 LINC00933 4.44 1.74e-05 0.0084 0.43 0.34 Schizophrenia; chr15:84768151 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs36033486 ENSG00000259728.4 LINC00933 4.44 1.74e-05 0.0084 0.43 0.34 Schizophrenia; chr15:84776461 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs12908549 ENSG00000259728.4 LINC00933 4.44 1.74e-05 0.0084 0.43 0.34 Schizophrenia; chr15:84779120 chr15:84570649~84580175:+ PAAD cis rs17027258 0.697 rs1468789 ENSG00000234389.1 AC007278.3 -4.44 1.74e-05 0.00841 -0.34 -0.34 White blood cell types; chr2:102476044 chr2:102438713~102440475:+ PAAD cis rs2348418 0.733 rs1904386 ENSG00000247934.4 RP11-967K21.1 -4.44 1.74e-05 0.00841 -0.34 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28202321 chr12:28163298~28190738:- PAAD cis rs17684571 0.751 rs6918949 ENSG00000231441.1 RP11-472M19.2 -4.44 1.74e-05 0.00841 -0.63 -0.34 Schizophrenia; chr6:56845183 chr6:56844002~56864078:+ PAAD cis rs131777 0.526 rs86337 ENSG00000205559.3 CHKB-AS1 -4.44 1.74e-05 0.00841 -0.39 -0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50582239 chr22:50583026~50583877:+ PAAD cis rs950169 0.544 rs2036949 ENSG00000259728.4 LINC00933 4.44 1.74e-05 0.00841 0.43 0.34 Schizophrenia; chr15:84620374 chr15:84570649~84580175:+ PAAD cis rs11893307 0.566 rs13412750 ENSG00000235852.1 AC005540.3 4.44 1.74e-05 0.00842 0.5 0.34 Mean platelet volume; chr2:190770232 chr2:190880797~190882059:- PAAD cis rs12550612 0.614 rs4268128 ENSG00000253616.4 RP11-875O11.3 4.44 1.74e-05 0.00842 0.46 0.34 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23080343 chr8:23071377~23074488:- PAAD cis rs875971 0.522 rs1880556 ENSG00000234585.5 CCT6P3 4.44 1.74e-05 0.00842 0.27 0.34 Aortic root size; chr7:65967557 chr7:65038354~65074713:+ PAAD cis rs4835473 0.669 rs56112476 ENSG00000251600.4 RP11-673E1.1 -4.44 1.74e-05 0.00842 -0.4 -0.34 Immature fraction of reticulocytes; chr4:143948716 chr4:143912331~143982454:+ PAAD cis rs4664293 0.867 rs6432553 ENSG00000226266.5 AC009961.3 -4.44 1.74e-05 0.00843 -0.42 -0.34 Monocyte percentage of white cells; chr2:159720499 chr2:159670708~159712435:- PAAD cis rs77372450 0.636 rs28712355 ENSG00000251405.2 CTB-109A12.1 4.44 1.75e-05 0.00843 0.53 0.34 Bipolar disorder (body mass index interaction); chr5:157596500 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs11749144 ENSG00000251405.2 CTB-109A12.1 4.44 1.75e-05 0.00843 0.53 0.34 Bipolar disorder (body mass index interaction); chr5:157599988 chr5:157362615~157460078:- PAAD cis rs2115630 1 rs55646601 ENSG00000225151.9 GOLGA2P7 4.44 1.75e-05 0.00843 0.4 0.34 P wave terminal force; chr15:84780337 chr15:84199311~84230136:- PAAD cis rs853679 1 rs1778508 ENSG00000226314.6 ZNF192P1 4.44 1.75e-05 0.00843 0.57 0.34 Depression; chr6:28262103 chr6:28161781~28169594:+ PAAD cis rs6904897 0.563 rs6569976 ENSG00000232876.1 CTA-212D2.2 -4.44 1.75e-05 0.00843 -0.38 -0.34 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134903615 chr6:135055033~135060550:+ PAAD cis rs8072100 0.539 rs36043200 ENSG00000228782.6 CTD-2026D20.3 -4.44 1.75e-05 0.00843 -0.33 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47552040 chr17:47450568~47492492:- PAAD cis rs4664293 1 rs6745766 ENSG00000226266.5 AC009961.3 -4.44 1.75e-05 0.00843 -0.42 -0.34 Monocyte percentage of white cells; chr2:159598284 chr2:159670708~159712435:- PAAD cis rs1823913 0.637 rs4853569 ENSG00000280083.1 RP11-317J9.1 4.44 1.75e-05 0.00844 0.4 0.34 Obesity-related traits; chr2:191266970 chr2:191154118~191156070:- PAAD cis rs10853057 0.541 rs11656396 ENSG00000214174.7 AMZ2P1 4.44 1.75e-05 0.00845 0.53 0.34 White matter microstructure (global fractional anisotropy); chr17:65049958 chr17:64966550~64975576:- PAAD cis rs853679 1 rs853694 ENSG00000204709.4 LINC01556 4.44 1.75e-05 0.00845 0.59 0.34 Depression; chr6:28311323 chr6:28943877~28944537:+ PAAD cis rs11123170 0.529 rs1015755 ENSG00000274877.1 RP11-65I12.1 -4.44 1.75e-05 0.00845 -0.45 -0.34 Renal function-related traits (BUN); chr2:113210730 chr2:113237595~113240825:+ PAAD cis rs4853525 0.561 rs11898764 ENSG00000235852.1 AC005540.3 -4.44 1.75e-05 0.00846 -0.52 -0.34 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190847844 chr2:190880797~190882059:- PAAD cis rs3020264 0.669 rs7005662 ENSG00000271743.1 CTD-2541M15.3 4.44 1.75e-05 0.00846 0.51 0.34 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6619105 chr8:6615604~6617198:- PAAD cis rs3131856 1 rs3131856 ENSG00000243753.4 HLA-L -4.44 1.75e-05 0.00846 -0.87 -0.34 Tuberculosis; chr6:29639324 chr6:30259584~30293014:+ PAAD cis rs3116813 1 rs3116813 ENSG00000243753.4 HLA-L -4.44 1.75e-05 0.00846 -0.87 -0.34 Breast cancer; chr6:29693039 chr6:30259584~30293014:+ PAAD cis rs3094146 1 rs3094146 ENSG00000243753.4 HLA-L -4.44 1.75e-05 0.00846 -0.87 -0.34 Breast cancer; chr6:30003183 chr6:30259584~30293014:+ PAAD cis rs7182621 0.774 rs12101368 ENSG00000182397.13 DNM1P46 4.44 1.75e-05 0.00846 0.4 0.34 Colonoscopy-negative controls vs population controls; chr15:99872475 chr15:99790156~99806927:- PAAD cis rs2412819 0.571 rs8038068 ENSG00000205771.5 CATSPER2P1 -4.44 1.75e-05 0.00847 -0.56 -0.34 Lung cancer; chr15:43622175 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs8030536 ENSG00000205771.5 CATSPER2P1 -4.44 1.75e-05 0.00847 -0.56 -0.34 Lung cancer; chr15:43627365 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs56246169 ENSG00000205771.5 CATSPER2P1 -4.44 1.75e-05 0.00847 -0.56 -0.34 Lung cancer; chr15:43628358 chr15:43726918~43747094:- PAAD cis rs79040073 0.607 rs17479205 ENSG00000259531.2 RP11-295H24.3 4.44 1.75e-05 0.00847 0.51 0.34 Lung cancer in ever smokers; chr15:49456065 chr15:49365124~49366685:- PAAD cis rs79040073 0.53 rs1055254 ENSG00000259469.1 RP11-227D13.4 -4.44 1.76e-05 0.00847 -0.47 -0.34 Lung cancer in ever smokers; chr15:49328003 chr15:48729080~48729844:- PAAD cis rs871012 0.502 rs60416963 ENSG00000251405.2 CTB-109A12.1 -4.44 1.76e-05 0.00847 -0.44 -0.34 IgG glycosylation; chr5:157441157 chr5:157362615~157460078:- PAAD cis rs9807989 0.507 rs6734762 ENSG00000234389.1 AC007278.3 4.43 1.76e-05 0.00848 0.34 0.34 Asthma; chr2:102446466 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs11465721 ENSG00000234389.1 AC007278.3 4.43 1.76e-05 0.00848 0.34 0.34 Asthma; chr2:102446780 chr2:102438713~102440475:+ PAAD cis rs8177376 0.953 rs4935964 ENSG00000254905.1 RP11-712L6.7 4.43 1.76e-05 0.00848 0.45 0.34 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126285289 chr11:126292922~126294254:- PAAD cis rs3096299 0.685 rs4785676 ENSG00000261253.2 AC137932.6 4.43 1.76e-05 0.00848 0.37 0.34 Multiple myeloma (IgH translocation); chr16:89487216 chr16:89321133~89325110:+ PAAD cis rs3096299 0.933 rs2965824 ENSG00000274627.1 RP11-104N10.2 4.43 1.76e-05 0.00849 0.3 0.34 Multiple myeloma (IgH translocation); chr16:89388898 chr16:89516797~89522217:+ PAAD cis rs7615952 0.688 rs12638240 ENSG00000239804.1 RP11-379B18.1 4.43 1.76e-05 0.00849 0.45 0.34 Blood pressure (smoking interaction); chr3:125822395 chr3:125787888~125788146:- PAAD cis rs7615952 0.688 rs12638224 ENSG00000239804.1 RP11-379B18.1 4.43 1.76e-05 0.00849 0.45 0.34 Blood pressure (smoking interaction); chr3:125822477 chr3:125787888~125788146:- PAAD cis rs853679 0.517 rs9380052 ENSG00000280107.1 AL022393.9 -4.43 1.76e-05 0.0085 -0.56 -0.34 Depression; chr6:28096845 chr6:28170845~28172521:+ PAAD cis rs216345 0.699 rs6476433 ENSG00000230074.1 RP11-195F19.9 4.43 1.76e-05 0.0085 0.46 0.34 Bipolar disorder; chr9:34042373 chr9:34665665~34681298:+ PAAD cis rs6142102 0.886 rs6142098 ENSG00000276073.1 RP5-1125A11.7 -4.43 1.77e-05 0.0085 -0.36 -0.34 Skin pigmentation; chr20:34100488 chr20:33985617~33988989:- PAAD cis rs7646881 0.812 rs75267618 ENSG00000240207.5 RP11-379F4.4 -4.43 1.77e-05 0.00851 -0.5 -0.34 Tetralogy of Fallot; chr3:158726027 chr3:158732263~158784070:+ PAAD cis rs4453827 1 rs17053417 ENSG00000271916.1 RP11-884K10.6 -4.43 1.77e-05 0.00851 -0.35 -0.34 Blood protein levels; chr3:53725362 chr3:53797764~53798019:- PAAD cis rs4453827 0.955 rs7628839 ENSG00000271916.1 RP11-884K10.6 4.43 1.77e-05 0.00851 0.35 0.34 Blood protein levels; chr3:53731421 chr3:53797764~53798019:- PAAD cis rs2380205 0.546 rs649537 ENSG00000232807.2 RP11-536K7.3 -4.43 1.77e-05 0.00852 -0.36 -0.34 Breast cancer; chr10:5903709 chr10:5934270~5945900:- PAAD cis rs7665090 0.87 rs228613 ENSG00000246560.2 RP11-10L12.4 -4.43 1.77e-05 0.00852 -0.38 -0.34 Primary biliary cholangitis; chr4:102656308 chr4:102828055~102844075:+ PAAD cis rs73086581 0.617 rs2300213 ENSG00000229539.1 RP11-119B16.2 -4.43 1.77e-05 0.00852 -0.42 -0.34 Response to antidepressants in depression; chr20:4006076 chr20:3888239~3888868:- PAAD cis rs12439619 0.693 rs28689861 ENSG00000255769.6 GOLGA2P10 -4.43 1.77e-05 0.00854 -0.41 -0.34 Intelligence (multi-trait analysis); chr15:82206369 chr15:82472993~82513950:- PAAD cis rs2262909 0.853 rs56207853 ENSG00000279377.1 AC003973.3 -4.43 1.78e-05 0.00854 -0.32 -0.34 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22109555 chr19:21965708~21968529:- PAAD cis rs7923609 0.967 rs10761751 ENSG00000232075.1 MRPL35P2 -4.43 1.78e-05 0.00855 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63395125 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs10761752 ENSG00000232075.1 MRPL35P2 -4.43 1.78e-05 0.00855 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63400561 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs7920058 ENSG00000232075.1 MRPL35P2 -4.43 1.78e-05 0.00855 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63534164 chr10:63634317~63634827:- PAAD cis rs2658782 0.724 rs1869914 ENSG00000279684.1 RP11-755E23.2 -4.43 1.78e-05 0.00855 -0.56 -0.34 Pulmonary function decline; chr11:93379326 chr11:93286629~93288903:- PAAD cis rs2348418 0.831 rs7299042 ENSG00000247934.4 RP11-967K21.1 4.43 1.78e-05 0.00855 0.33 0.34 Lung function (FEV1);Lung function (FVC); chr12:28571750 chr12:28163298~28190738:- PAAD cis rs9494145 0.68 rs4895440 ENSG00000232876.1 CTA-212D2.2 -4.43 1.78e-05 0.00856 -0.42 -0.34 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135105420 chr6:135055033~135060550:+ PAAD cis rs2486288 0.656 rs10519018 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45257067 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11637920 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45258707 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11632777 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45258847 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11632778 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45258858 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11632752 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45258942 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11632920 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45259066 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs12911186 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45259225 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs12915314 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45259293 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs8039138 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45259394 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs8039540 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45259644 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs8040185 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45259883 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs1060896 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45262069 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11632419 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45265258 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs2271438 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45265270 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11854365 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45265885 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11639420 ENSG00000259433.2 CTD-2651B20.4 4.43 1.78e-05 0.00856 0.37 0.34 Glomerular filtration rate; chr15:45267070 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs8039354 ENSG00000259433.2 CTD-2651B20.4 -4.43 1.78e-05 0.00856 -0.37 -0.34 Glomerular filtration rate; chr15:45259558 chr15:45330209~45332634:- PAAD cis rs964611 0.706 rs11070638 ENSG00000259488.2 RP11-154J22.1 4.43 1.78e-05 0.00856 0.38 0.34 Metabolite levels (Pyroglutamine); chr15:48371906 chr15:48312353~48331856:- PAAD cis rs6584283 1 rs6584283 ENSG00000228778.1 RP11-129J12.1 -4.43 1.78e-05 0.00857 -0.37 -0.34 Ulcerative colitis; chr10:99530544 chr10:99527081~99528261:+ PAAD cis rs2505998 0.833 rs1864403 ENSG00000273008.1 RP11-351D16.3 4.43 1.78e-05 0.00857 0.29 0.34 Hirschsprung disease; chr10:43109502 chr10:43136824~43138334:- PAAD cis rs2505998 0.833 rs1864404 ENSG00000273008.1 RP11-351D16.3 -4.43 1.78e-05 0.00857 -0.29 -0.34 Hirschsprung disease; chr10:43108942 chr10:43136824~43138334:- PAAD cis rs9487094 0.67 rs12192268 ENSG00000260273.1 RP11-425D10.10 4.43 1.78e-05 0.00857 0.41 0.34 Height; chr6:109690255 chr6:109382795~109383666:+ PAAD cis rs9487094 0.626 rs11153213 ENSG00000260273.1 RP11-425D10.10 4.43 1.78e-05 0.00857 0.41 0.34 Height; chr6:109693890 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12201356 ENSG00000260273.1 RP11-425D10.10 4.43 1.78e-05 0.00857 0.41 0.34 Height; chr6:109694672 chr6:109382795~109383666:+ PAAD cis rs9918079 0.542 rs12499412 ENSG00000273133.1 RP11-799M12.2 4.43 1.78e-05 0.00857 0.4 0.34 Obesity-related traits; chr4:15600629 chr4:15563698~15564253:- PAAD cis rs75804782 0.515 rs74409360 ENSG00000186235.9 AC016757.3 4.43 1.78e-05 0.00857 0.82 0.34 Chronotype;Morning vs. evening chronotype; chr2:238367637 chr2:238224552~238231677:- PAAD cis rs7923609 1 rs12355784 ENSG00000232075.1 MRPL35P2 -4.43 1.78e-05 0.00858 -0.42 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63361805 chr10:63634317~63634827:- PAAD cis rs77372450 0.636 rs6890471 ENSG00000251405.2 CTB-109A12.1 4.43 1.79e-05 0.00858 0.53 0.34 Bipolar disorder (body mass index interaction); chr5:157597024 chr5:157362615~157460078:- PAAD cis rs6991838 0.831 rs11992528 ENSG00000200714.1 Y_RNA 4.43 1.79e-05 0.00858 0.4 0.34 Intelligence (multi-trait analysis); chr8:65561644 chr8:65592731~65592820:+ PAAD cis rs9987353 0.566 rs13260067 ENSG00000253893.2 FAM85B 4.43 1.79e-05 0.00859 0.45 0.34 Recombination measurement; chr8:9213523 chr8:8167819~8226614:- PAAD cis rs2337406 0.714 rs7150993 ENSG00000211974.3 IGHV2-70 -4.43 1.79e-05 0.00859 -0.47 -0.34 Alzheimer's disease (late onset); chr14:106818515 chr14:106723574~106724093:- PAAD cis rs17772222 1 rs17772288 ENSG00000258983.2 RP11-507K2.2 4.43 1.79e-05 0.00859 0.46 0.34 Coronary artery calcification; chr14:88361022 chr14:88499334~88515502:+ PAAD cis rs7829975 0.714 rs11784052 ENSG00000253893.2 FAM85B -4.43 1.79e-05 0.0086 -0.47 -0.34 Mood instability; chr8:8814452 chr8:8167819~8226614:- PAAD cis rs950880 0.71 rs3732123 ENSG00000234389.1 AC007278.3 -4.43 1.79e-05 0.0086 -0.34 -0.34 Serum protein levels (sST2); chr2:102401617 chr2:102438713~102440475:+ PAAD cis rs2902193 0.589 rs12956596 ENSG00000267325.1 LINC01415 4.43 1.79e-05 0.0086 0.32 0.34 Cancer; chr18:56005382 chr18:55776727~55781721:- PAAD cis rs2902193 0.589 rs8085781 ENSG00000267325.1 LINC01415 4.43 1.79e-05 0.0086 0.32 0.34 Cancer; chr18:56005632 chr18:55776727~55781721:- PAAD cis rs453301 0.658 rs6986044 ENSG00000253893.2 FAM85B 4.43 1.79e-05 0.0086 0.46 0.34 Joint mobility (Beighton score); chr8:9017276 chr8:8167819~8226614:- PAAD cis rs520525 0.927 rs583006 ENSG00000271811.1 RP1-79C4.4 4.43 1.79e-05 0.00861 0.37 0.34 Atrial fibrillation; chr1:170659247 chr1:170667381~170669425:+ PAAD cis rs1823913 0.637 rs12624271 ENSG00000280083.1 RP11-317J9.1 4.43 1.8e-05 0.00863 0.4 0.34 Obesity-related traits; chr2:191288586 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs11686185 ENSG00000280083.1 RP11-317J9.1 4.43 1.8e-05 0.00863 0.4 0.34 Obesity-related traits; chr2:191289282 chr2:191154118~191156070:- PAAD cis rs812925 0.519 rs1186696 ENSG00000273302.1 RP11-493E12.2 4.43 1.8e-05 0.00863 0.29 0.34 Immature fraction of reticulocytes; chr2:61433348 chr2:61199979~61200769:+ PAAD cis rs4835473 0.77 rs4835096 ENSG00000251600.4 RP11-673E1.1 4.43 1.8e-05 0.00863 0.39 0.34 Immature fraction of reticulocytes; chr4:143960685 chr4:143912331~143982454:+ PAAD cis rs4664293 0.625 rs6745448 ENSG00000226266.5 AC009961.3 -4.43 1.8e-05 0.00863 -0.42 -0.34 Monocyte percentage of white cells; chr2:159699087 chr2:159670708~159712435:- PAAD cis rs4664293 0.647 rs918969 ENSG00000226266.5 AC009961.3 4.43 1.8e-05 0.00863 0.42 0.34 Monocyte percentage of white cells; chr2:159610145 chr2:159670708~159712435:- PAAD cis rs853679 0.517 rs9393896 ENSG00000204709.4 LINC01556 4.43 1.8e-05 0.00864 0.58 0.34 Depression; chr6:28159925 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393897 ENSG00000204709.4 LINC01556 4.43 1.8e-05 0.00864 0.58 0.34 Depression; chr6:28159932 chr6:28943877~28944537:+ PAAD cis rs55665837 0.54 rs10832299 ENSG00000251991.1 RNU7-49P 4.43 1.8e-05 0.00864 0.39 0.34 Vitamin D levels; chr11:14747846 chr11:14478892~14478953:+ PAAD cis rs748404 0.578 rs2244746 ENSG00000205771.5 CATSPER2P1 -4.43 1.8e-05 0.00864 -0.45 -0.34 Lung cancer; chr15:43402885 chr15:43726918~43747094:- PAAD cis rs55665837 0.54 rs1007392 ENSG00000251991.1 RNU7-49P 4.43 1.8e-05 0.00865 0.39 0.34 Vitamin D levels; chr11:14753045 chr11:14478892~14478953:+ PAAD cis rs55665837 0.523 rs10832301 ENSG00000251991.1 RNU7-49P 4.43 1.8e-05 0.00865 0.39 0.34 Vitamin D levels; chr11:14767418 chr11:14478892~14478953:+ PAAD cis rs55665837 0.54 rs12416696 ENSG00000251991.1 RNU7-49P 4.43 1.8e-05 0.00865 0.39 0.34 Vitamin D levels; chr11:14769343 chr11:14478892~14478953:+ PAAD cis rs55665837 0.54 rs10766192 ENSG00000251991.1 RNU7-49P 4.43 1.8e-05 0.00865 0.39 0.34 Vitamin D levels; chr11:14790140 chr11:14478892~14478953:+ PAAD cis rs12571093 0.773 rs10762197 ENSG00000233590.1 RP11-153K11.3 4.43 1.8e-05 0.00865 0.54 0.34 Optic nerve measurement (disc area); chr10:68249498 chr10:68233251~68242379:- PAAD cis rs919433 0.963 rs1429417 ENSG00000231621.1 AC013264.2 4.43 1.8e-05 0.00865 0.33 0.34 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197293447 chr2:197197991~197199273:+ PAAD cis rs7829975 0.533 rs1039917 ENSG00000253893.2 FAM85B -4.43 1.81e-05 0.00867 -0.46 -0.34 Mood instability; chr8:8861340 chr8:8167819~8226614:- PAAD cis rs16846053 0.71 rs11891026 ENSG00000227403.1 AC009299.3 4.43 1.81e-05 0.00867 0.53 0.34 Blood osmolality (transformed sodium); chr2:161735366 chr2:161244739~161249050:+ PAAD cis rs2303319 0.504 rs1551052 ENSG00000227403.1 AC009299.3 4.43 1.81e-05 0.00867 0.53 0.34 Cognitive function; chr2:161736144 chr2:161244739~161249050:+ PAAD cis rs16846053 0.71 rs1449629 ENSG00000227403.1 AC009299.3 4.43 1.81e-05 0.00867 0.53 0.34 Blood osmolality (transformed sodium); chr2:161738314 chr2:161244739~161249050:+ PAAD cis rs16846053 0.792 rs6714082 ENSG00000227403.1 AC009299.3 4.43 1.81e-05 0.00867 0.53 0.34 Blood osmolality (transformed sodium); chr2:161743646 chr2:161244739~161249050:+ PAAD cis rs16846053 0.71 rs6755071 ENSG00000227403.1 AC009299.3 4.43 1.81e-05 0.00867 0.53 0.34 Blood osmolality (transformed sodium); chr2:161748720 chr2:161244739~161249050:+ PAAD cis rs16846053 0.71 rs973940 ENSG00000227403.1 AC009299.3 4.43 1.81e-05 0.00867 0.53 0.34 Blood osmolality (transformed sodium); chr2:161750890 chr2:161244739~161249050:+ PAAD cis rs7176527 0.519 rs12148368 ENSG00000230373.7 GOLGA6L5P 4.43 1.81e-05 0.00868 0.34 0.34 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals; chr15:84563274 chr15:84507885~84516814:- PAAD cis rs875971 0.619 rs2302918 ENSG00000237310.1 GS1-124K5.4 4.43 1.81e-05 0.00868 0.32 0.34 Aortic root size; chr7:66535945 chr7:66493706~66495474:+ PAAD cis rs3169166 0.5 rs12909123 ENSG00000259562.2 RP11-762H8.2 -4.43 1.81e-05 0.00869 -0.28 -0.34 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78267501 chr15:78290527~78291221:- PAAD cis rs3169166 0.5 rs3813575 ENSG00000259562.2 RP11-762H8.2 4.43 1.81e-05 0.00869 0.28 0.34 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78268400 chr15:78290527~78291221:- PAAD cis rs11690935 0.655 rs17614941 ENSG00000228389.1 AC068039.4 -4.43 1.81e-05 0.00869 -0.41 -0.34 Schizophrenia; chr2:171684868 chr2:171773482~171775844:+ PAAD cis rs17214007 0.735 rs2075513 ENSG00000263335.1 AF001548.5 -4.43 1.81e-05 0.0087 -0.48 -0.34 Cognitive function; chr16:15782614 chr16:15726674~15732993:+ PAAD cis rs2262909 0.962 rs12610034 ENSG00000279377.1 AC003973.3 -4.43 1.82e-05 0.0087 -0.32 -0.34 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22131726 chr19:21965708~21968529:- PAAD cis rs11089937 0.568 rs5756988 ENSG00000211639.2 IGLV4-60 -4.43 1.82e-05 0.00871 -0.36 -0.34 Periodontitis (PAL4Q3); chr22:22132397 chr22:22162199~22162681:+ PAAD cis rs4218 0.531 rs12101733 ENSG00000277144.1 RP11-59H7.4 -4.43 1.82e-05 0.00872 -0.4 -0.34 Social communication problems; chr15:59047566 chr15:59115547~59116089:- PAAD cis rs2658782 0.951 rs72972364 ENSG00000279684.1 RP11-755E23.2 4.43 1.82e-05 0.00872 0.58 0.34 Pulmonary function decline; chr11:93388962 chr11:93286629~93288903:- PAAD cis rs9918079 0.58 rs13120905 ENSG00000273133.1 RP11-799M12.2 4.43 1.82e-05 0.00872 0.4 0.34 Obesity-related traits; chr4:15610665 chr4:15563698~15564253:- PAAD cis rs9652601 0.919 rs12924729 ENSG00000274038.1 RP11-66H6.4 -4.43 1.82e-05 0.00872 -0.39 -0.34 Systemic lupus erythematosus; chr16:11093926 chr16:11056556~11057034:+ PAAD cis rs453301 0.686 rs6748 ENSG00000253893.2 FAM85B 4.43 1.82e-05 0.00872 0.46 0.34 Joint mobility (Beighton score); chr8:9033292 chr8:8167819~8226614:- PAAD cis rs1045529 0.524 rs34251783 ENSG00000253893.2 FAM85B 4.43 1.82e-05 0.00872 0.46 0.34 Myopia (pathological);Myopia; chr8:9033866 chr8:8167819~8226614:- PAAD cis rs453301 0.719 rs34004903 ENSG00000253893.2 FAM85B 4.43 1.82e-05 0.00872 0.46 0.34 Joint mobility (Beighton score); chr8:9035094 chr8:8167819~8226614:- PAAD cis rs453301 0.686 rs10217044 ENSG00000253893.2 FAM85B 4.43 1.82e-05 0.00872 0.46 0.34 Joint mobility (Beighton score); chr8:9037242 chr8:8167819~8226614:- PAAD cis rs5760092 0.755 rs915589 ENSG00000099984.9 GSTT2 4.43 1.82e-05 0.00872 0.51 0.34 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23980123~23983911:+ PAAD cis rs2243480 0.901 rs35256305 ENSG00000228409.4 CCT6P1 4.43 1.82e-05 0.00873 0.36 0.34 Diabetic kidney disease; chr7:65841418 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35825738 ENSG00000228409.4 CCT6P1 4.43 1.82e-05 0.00873 0.36 0.34 Diabetic kidney disease; chr7:65853040 chr7:65751142~65763354:+ PAAD cis rs2946504 0.861 rs6986271 ENSG00000251468.2 RP11-369K16.1 -4.43 1.82e-05 0.00873 -0.42 -0.34 Type 2 diabetes; chr8:12959345 chr8:12958387~12962200:+ PAAD cis rs2412819 0.571 rs2930531 ENSG00000205771.5 CATSPER2P1 4.43 1.82e-05 0.00874 0.51 0.34 Lung cancer; chr15:43829372 chr15:43726918~43747094:- PAAD cis rs11673344 0.548 rs2058852 ENSG00000267422.1 CTD-2554C21.1 4.43 1.83e-05 0.00875 0.43 0.34 Obesity-related traits; chr19:37673701 chr19:37779686~37792865:+ PAAD cis rs62103177 0.525 rs4799117 ENSG00000261126.6 RP11-795F19.1 -4.43 1.83e-05 0.00875 -0.46 -0.34 Opioid sensitivity; chr18:79996604 chr18:80046900~80095482:+ PAAD cis rs62103177 0.525 rs4283293 ENSG00000261126.6 RP11-795F19.1 -4.43 1.83e-05 0.00875 -0.46 -0.34 Opioid sensitivity; chr18:79999582 chr18:80046900~80095482:+ PAAD cis rs897984 0.542 rs4468641 ENSG00000260911.2 RP11-196G11.2 4.43 1.83e-05 0.00876 0.31 0.34 Dementia with Lewy bodies; chr16:31085555 chr16:31043150~31049868:+ PAAD cis rs858239 0.6 rs10256361 ENSG00000226816.2 AC005082.12 4.43 1.83e-05 0.00876 0.38 0.34 Cerebrospinal fluid biomarker levels; chr7:23084266 chr7:23206013~23208045:+ PAAD cis rs6904897 0.538 rs4639353 ENSG00000232876.1 CTA-212D2.2 4.43 1.83e-05 0.00876 0.38 0.34 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134903190 chr6:135055033~135060550:+ PAAD cis rs2404602 0.532 rs744336 ENSG00000259422.1 RP11-593F23.1 4.42 1.83e-05 0.00877 0.39 0.34 Blood metabolite levels; chr15:76382283 chr15:76174891~76181486:- PAAD cis rs2115630 1 rs58581703 ENSG00000225151.9 GOLGA2P7 4.42 1.83e-05 0.00877 0.4 0.34 P wave terminal force; chr15:84733704 chr15:84199311~84230136:- PAAD cis rs2115630 0.967 rs8028490 ENSG00000225151.9 GOLGA2P7 4.42 1.83e-05 0.00877 0.4 0.34 P wave terminal force; chr15:84734657 chr15:84199311~84230136:- PAAD cis rs5758511 0.689 rs56906457 ENSG00000226450.2 CYP2D8P 4.42 1.83e-05 0.00877 0.43 0.34 Birth weight; chr22:42232329 chr22:42149886~42155001:- PAAD cis rs7189233 0.513 rs8044091 ENSG00000279344.1 RP11-44F14.7 4.42 1.83e-05 0.00877 0.25 0.34 Intelligence (multi-trait analysis); chr16:53487086 chr16:53478957~53481550:- PAAD cis rs1823913 0.637 rs6741454 ENSG00000280083.1 RP11-317J9.1 4.42 1.83e-05 0.00877 0.4 0.34 Obesity-related traits; chr2:191269520 chr2:191154118~191156070:- PAAD cis rs1823913 0.614 rs6755243 ENSG00000280083.1 RP11-317J9.1 4.42 1.83e-05 0.00877 0.4 0.34 Obesity-related traits; chr2:191269810 chr2:191154118~191156070:- PAAD cis rs2564921 0.73 rs12633064 ENSG00000242142.1 SERBP1P3 -4.42 1.83e-05 0.00877 -0.43 -0.34 Height; chr3:53027361 chr3:53064283~53065091:- PAAD cis rs4266144 0.558 rs7623382 ENSG00000244515.1 KRT18P34 -4.42 1.83e-05 0.00877 -0.4 -0.34 Coronary artery disease; chr3:157115105 chr3:157162663~157163932:- PAAD cis rs2243480 1 rs1723267 ENSG00000228409.4 CCT6P1 4.42 1.83e-05 0.00878 0.36 0.34 Diabetic kidney disease; chr7:66008327 chr7:65751142~65763354:+ PAAD cis rs1862618 0.853 rs252898 ENSG00000271828.1 CTD-2310F14.1 4.42 1.84e-05 0.00878 0.5 0.34 Initial pursuit acceleration; chr5:56893104 chr5:56927874~56929573:+ PAAD cis rs1862618 0.802 rs194058 ENSG00000271828.1 CTD-2310F14.1 4.42 1.84e-05 0.00878 0.5 0.34 Initial pursuit acceleration; chr5:56893150 chr5:56927874~56929573:+ PAAD cis rs7646881 0.812 rs61387735 ENSG00000240207.5 RP11-379F4.4 -4.42 1.84e-05 0.00879 -0.52 -0.34 Tetralogy of Fallot; chr3:158738372 chr3:158732263~158784070:+ PAAD cis rs7646881 0.767 rs73015669 ENSG00000240207.5 RP11-379F4.4 -4.42 1.84e-05 0.00879 -0.52 -0.34 Tetralogy of Fallot; chr3:158738529 chr3:158732263~158784070:+ PAAD cis rs11089937 0.626 rs9619811 ENSG00000211639.2 IGLV4-60 4.42 1.84e-05 0.00879 0.36 0.34 Periodontitis (PAL4Q3); chr22:22159186 chr22:22162199~22162681:+ PAAD cis rs17214007 0.877 rs11075281 ENSG00000263335.1 AF001548.5 -4.42 1.84e-05 0.0088 -0.49 -0.34 Cognitive function; chr16:15780585 chr16:15726674~15732993:+ PAAD cis rs73173548 0.502 rs12189501 ENSG00000247828.6 TMEM161B-AS1 -4.42 1.84e-05 0.0088 -0.27 -0.34 Macular telangiectasia type 2; chr5:88462208 chr5:88268895~88436685:+ PAAD cis rs875971 1 rs697970 ENSG00000237310.1 GS1-124K5.4 -4.42 1.84e-05 0.0088 -0.33 -0.34 Aortic root size; chr7:66095065 chr7:66493706~66495474:+ PAAD cis rs7772486 0.712 rs1292335 ENSG00000235652.6 RP11-545I5.3 4.42 1.84e-05 0.00881 0.29 0.34 Lobe attachment (rater-scored or self-reported); chr6:145646741 chr6:145799409~145886585:+ PAAD cis rs1876905 0.68 rs9384787 ENSG00000230177.1 RP5-1112D6.4 4.42 1.84e-05 0.00881 0.34 0.34 Mean corpuscular hemoglobin; chr6:111113707 chr6:111277932~111278742:+ PAAD cis rs9649213 0.537 rs6465663 ENSG00000272950.1 RP11-307C18.1 4.42 1.84e-05 0.00881 0.39 0.34 Prostate cancer (SNP x SNP interaction); chr7:98289571 chr7:98322853~98323430:+ PAAD cis rs734999 0.588 rs11585048 ENSG00000225931.3 RP3-395M20.7 4.42 1.85e-05 0.00883 0.32 0.34 Ulcerative colitis; chr1:2602648 chr1:2566410~2569888:+ PAAD cis rs734999 0.566 rs6664969 ENSG00000225931.3 RP3-395M20.7 4.42 1.85e-05 0.00883 0.32 0.34 Ulcerative colitis; chr1:2603539 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs78506337 ENSG00000225931.3 RP3-395M20.7 4.42 1.85e-05 0.00883 0.32 0.34 Ulcerative colitis; chr1:2605656 chr1:2566410~2569888:+ PAAD cis rs321358 1 rs321352 ENSG00000271390.1 RP11-89C3.3 4.42 1.85e-05 0.00883 0.51 0.34 Body mass index; chr11:111123001 chr11:111089870~111090368:- PAAD cis rs321358 1 rs167683 ENSG00000271390.1 RP11-89C3.3 4.42 1.85e-05 0.00883 0.51 0.34 Body mass index; chr11:111123131 chr11:111089870~111090368:- PAAD cis rs6844153 0.68 rs61047003 ENSG00000240005.4 RP11-293A21.1 -4.42 1.85e-05 0.00883 -0.47 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26937139 chr4:26859806~26860599:- PAAD cis rs6472235 1 rs60258162 ENSG00000200714.1 Y_RNA -4.42 1.85e-05 0.00883 -0.44 -0.34 Plateletcrit;Myopia (pathological); chr8:65933651 chr8:65592731~65592820:+ PAAD cis rs12908161 0.959 rs12906348 ENSG00000259728.4 LINC00933 4.42 1.85e-05 0.00883 0.43 0.34 Schizophrenia; chr15:84786190 chr15:84570649~84580175:+ PAAD cis rs2906856 0.526 rs2906852 ENSG00000255733.4 IFNG-AS1 4.42 1.85e-05 0.00883 0.36 0.34 Mosquito bite size; chr12:67985701 chr12:67989445~68234686:+ PAAD cis rs797680 0.897 rs3767962 ENSG00000223745.6 RP4-717I23.3 4.42 1.85e-05 0.00883 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93348854 chr1:93262186~93346025:- PAAD cis rs6844153 1 rs74356465 ENSG00000240005.4 RP11-293A21.1 -4.42 1.85e-05 0.00884 -0.57 -0.34 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26902405 chr4:26859806~26860599:- PAAD cis rs17772222 0.655 rs1152376 ENSG00000258983.2 RP11-507K2.2 -4.42 1.85e-05 0.00885 -0.41 -0.34 Coronary artery calcification; chr14:88495121 chr14:88499334~88515502:+ PAAD cis rs528301 0.642 rs895632 ENSG00000259439.2 RP11-89K21.1 4.42 1.85e-05 0.00885 0.45 0.34 Alcohol and nicotine co-dependence; chr2:44937906 chr2:44921077~44939199:- PAAD cis rs1167827 0.68 rs1167796 ENSG00000205583.12 STAG3L1 -4.42 1.85e-05 0.00885 -0.37 -0.34 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75543861 chr7:75359194~75395383:+ PAAD cis rs66887589 0.776 rs10518337 ENSG00000248280.1 RP11-33B1.2 -4.42 1.85e-05 0.00886 -0.3 -0.34 Diastolic blood pressure; chr4:119653719 chr4:119440561~119450157:- PAAD cis rs111580313 0.685 rs60808032 ENSG00000270020.1 RP11-463O9.9 4.42 1.85e-05 0.00886 0.88 0.34 Systemic juvenile idiopathic arthritis; chr16:86571971 chr16:86520383~86523897:- PAAD cis rs2412819 0.545 rs35822148 ENSG00000205771.5 CATSPER2P1 -4.42 1.85e-05 0.00886 -0.55 -0.34 Lung cancer; chr15:43808084 chr15:43726918~43747094:- PAAD cis rs11227306 0.934 rs7940691 ENSG00000255468.5 RP11-867G23.8 4.42 1.85e-05 0.00887 0.3 0.34 DNA methylation (variation); chr11:65873435 chr11:66347950~66364804:+ PAAD cis rs144447022 1 rs144447022 ENSG00000243753.4 HLA-L -4.42 1.86e-05 0.00887 -0.84 -0.34 Schizophrenia;Intelligence (multi-trait analysis); chr6:29276442 chr6:30259584~30293014:+ PAAD cis rs3130834 1 rs3130834 ENSG00000243753.4 HLA-L -4.42 1.86e-05 0.00887 -0.84 -0.34 Breast cancer; chr6:29280372 chr6:30259584~30293014:+ PAAD cis rs3129682 1 rs3129682 ENSG00000243753.4 HLA-L -4.42 1.86e-05 0.00887 -0.84 -0.34 Blood protein levels; chr6:29315895 chr6:30259584~30293014:+ PAAD cis rs6480314 0.522 rs61857273 ENSG00000233590.1 RP11-153K11.3 -4.42 1.86e-05 0.00888 -0.56 -0.34 Optic nerve measurement (disc area); chr10:68307530 chr10:68233251~68242379:- PAAD cis rs7189233 0.513 rs1344491 ENSG00000279344.1 RP11-44F14.7 4.42 1.86e-05 0.00888 0.26 0.34 Intelligence (multi-trait analysis); chr16:53405497 chr16:53478957~53481550:- PAAD cis rs801193 0.636 rs10233806 ENSG00000232559.3 GS1-124K5.12 -4.42 1.86e-05 0.00888 -0.37 -0.34 Aortic root size; chr7:66653261 chr7:66554588~66576923:- PAAD cis rs801193 0.66 rs2659897 ENSG00000232559.3 GS1-124K5.12 -4.42 1.86e-05 0.00888 -0.37 -0.34 Aortic root size; chr7:66722728 chr7:66554588~66576923:- PAAD cis rs875971 1 rs10244498 ENSG00000232559.3 GS1-124K5.12 4.42 1.86e-05 0.00888 0.37 0.34 Aortic root size; chr7:66651069 chr7:66554588~66576923:- PAAD cis rs801193 0.613 rs2659900 ENSG00000232559.3 GS1-124K5.12 4.42 1.86e-05 0.00888 0.37 0.34 Aortic root size; chr7:66719456 chr7:66554588~66576923:- PAAD cis rs801193 0.636 rs2659895 ENSG00000232559.3 GS1-124K5.12 4.42 1.86e-05 0.00888 0.37 0.34 Aortic root size; chr7:66731484 chr7:66554588~66576923:- PAAD cis rs801193 0.66 rs974239 ENSG00000232559.3 GS1-124K5.12 4.42 1.86e-05 0.00888 0.37 0.34 Aortic root size; chr7:66748504 chr7:66554588~66576923:- PAAD cis rs801193 0.66 rs1016265 ENSG00000232559.3 GS1-124K5.12 4.42 1.86e-05 0.00888 0.37 0.34 Aortic root size; chr7:66749580 chr7:66554588~66576923:- PAAD cis rs801193 0.66 rs4610622 ENSG00000232559.3 GS1-124K5.12 4.42 1.86e-05 0.00888 0.37 0.34 Aortic root size; chr7:66759510 chr7:66554588~66576923:- PAAD cis rs6751744 0.513 rs7563368 ENSG00000226266.5 AC009961.3 4.42 1.86e-05 0.00888 0.42 0.34 Dysphagia; chr2:159600564 chr2:159670708~159712435:- PAAD cis rs4664293 1 rs6432542 ENSG00000226266.5 AC009961.3 -4.42 1.86e-05 0.00888 -0.42 -0.34 Monocyte percentage of white cells; chr2:159624025 chr2:159670708~159712435:- PAAD cis rs2599510 0.729 rs1135484 ENSG00000276334.1 AL133243.1 4.42 1.86e-05 0.00888 0.41 0.34 Interleukin-18 levels; chr2:32523993 chr2:32521927~32523547:+ PAAD cis rs61270009 0.955 rs10214154 ENSG00000247828.6 TMEM161B-AS1 -4.42 1.86e-05 0.00888 -0.28 -0.34 Depressive symptoms; chr5:88249502 chr5:88268895~88436685:+ PAAD cis rs710913 0.816 rs1180341 ENSG00000243970.1 PPIEL -4.42 1.86e-05 0.00888 -0.3 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527136 chr1:39531838~39558707:- PAAD cis rs9584850 0.794 rs72655609 ENSG00000231194.1 FARP1-AS1 4.42 1.86e-05 0.00889 0.44 0.34 Neuroticism; chr13:98476368 chr13:98435405~98435840:- PAAD cis rs6570726 0.967 rs1396648 ENSG00000235652.6 RP11-545I5.3 -4.42 1.86e-05 0.00889 -0.28 -0.34 Lobe attachment (rater-scored or self-reported); chr6:145464112 chr6:145799409~145886585:+ PAAD cis rs6570726 0.902 rs9390326 ENSG00000235652.6 RP11-545I5.3 -4.42 1.86e-05 0.00889 -0.28 -0.34 Lobe attachment (rater-scored or self-reported); chr6:145470086 chr6:145799409~145886585:+ PAAD cis rs16846053 0.71 rs11901817 ENSG00000227403.1 AC009299.3 4.42 1.86e-05 0.00889 0.53 0.34 Blood osmolality (transformed sodium); chr2:161732331 chr2:161244739~161249050:+ PAAD cis rs2348418 0.733 rs7294486 ENSG00000247934.4 RP11-967K21.1 -4.42 1.86e-05 0.0089 -0.34 -0.34 Lung function (FEV1);Lung function (FVC); chr12:28181989 chr12:28163298~28190738:- PAAD cis rs6570726 0.818 rs437978 ENSG00000235652.6 RP11-545I5.3 4.42 1.87e-05 0.00891 0.27 0.34 Lobe attachment (rater-scored or self-reported); chr6:145487998 chr6:145799409~145886585:+ PAAD cis rs6570726 0.818 rs399516 ENSG00000235652.6 RP11-545I5.3 4.42 1.87e-05 0.00891 0.27 0.34 Lobe attachment (rater-scored or self-reported); chr6:145489713 chr6:145799409~145886585:+ PAAD cis rs2919917 1 rs1466526 ENSG00000254352.1 RP11-578O24.2 -4.42 1.87e-05 0.00891 -0.35 -0.34 Lymphocyte counts; chr8:78643239 chr8:78723796~78724136:- PAAD cis rs1707322 0.682 rs12037459 ENSG00000280836.1 AL355480.1 -4.42 1.87e-05 0.00892 -0.41 -0.34 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629287 chr1:45581219~45581321:- PAAD cis rs797680 1 rs797680 ENSG00000223745.6 RP4-717I23.3 -4.42 1.87e-05 0.00892 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93251417 chr1:93262186~93346025:- PAAD cis rs2976388 0.609 rs2244152 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142703467 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2585153 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142703927 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2572899 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142704131 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2585152 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142704796 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2717550 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142706390 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2263092 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142708548 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs1594999 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142709156 chr8:142702252~142726973:- PAAD cis rs2976388 0.506 rs2572902 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142709969 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2572904 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142710775 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2585150 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142711251 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2585149 ENSG00000253741.1 CTD-2292P10.4 -4.42 1.87e-05 0.00892 -0.39 -0.34 Urinary tract infection frequency; chr8:142711902 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2164308 ENSG00000253741.1 CTD-2292P10.4 4.42 1.87e-05 0.00892 0.39 0.34 Urinary tract infection frequency; chr8:142704241 chr8:142702252~142726973:- PAAD cis rs11976180 0.569 rs12703565 ENSG00000273234.1 OR2A13P -4.42 1.87e-05 0.00892 -0.49 -0.34 Obesity-related traits; chr7:144057308 chr7:144142009~144142938:+ PAAD cis rs3738443 0.569 rs6704060 ENSG00000259865.1 RP11-488L18.10 4.42 1.87e-05 0.00892 0.29 0.34 Alcohol dependence; chr1:247218222 chr1:247187281~247188526:- PAAD cis rs3738443 0.52 rs1771932 ENSG00000259865.1 RP11-488L18.10 4.42 1.87e-05 0.00892 0.29 0.34 Alcohol dependence; chr1:247218747 chr1:247187281~247188526:- PAAD cis rs8072100 0.84 rs11079774 ENSG00000228782.6 CTD-2026D20.3 4.42 1.87e-05 0.00893 0.35 0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402340 chr17:47450568~47492492:- PAAD cis rs1930961 1 rs59226697 ENSG00000272977.1 CTA-390C10.10 -4.42 1.87e-05 0.00894 -0.79 -0.34 Bipolar disorder with mood-incongruent psychosis; chr22:25474070 chr22:25476218~25479971:+ PAAD cis rs8072100 0.84 rs12452796 ENSG00000228782.6 CTD-2026D20.3 -4.42 1.87e-05 0.00894 -0.35 -0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402367 chr17:47450568~47492492:- PAAD cis rs8072100 0.807 rs2175290 ENSG00000228782.6 CTD-2026D20.3 4.42 1.87e-05 0.00894 0.35 0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402551 chr17:47450568~47492492:- PAAD cis rs6570726 0.875 rs416243 ENSG00000235652.6 RP11-545I5.3 4.42 1.87e-05 0.00894 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145546945 chr6:145799409~145886585:+ PAAD cis rs131777 0.708 rs131749 ENSG00000205559.3 CHKB-AS1 4.42 1.88e-05 0.00895 0.42 0.34 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586195 chr22:50583026~50583877:+ PAAD cis rs801193 0.904 rs4718405 ENSG00000237310.1 GS1-124K5.4 4.42 1.88e-05 0.00895 0.31 0.34 Aortic root size; chr7:66789659 chr7:66493706~66495474:+ PAAD cis rs9326248 0.603 rs7396061 ENSG00000280143.1 AP000892.6 4.42 1.88e-05 0.00895 0.39 0.34 Blood protein levels; chr11:116880158 chr11:117204967~117210292:+ PAAD cis rs7923609 0.967 rs7082470 ENSG00000232075.1 MRPL35P2 -4.42 1.88e-05 0.00895 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63517266 chr10:63634317~63634827:- PAAD cis rs7923609 0.846 rs7075901 ENSG00000232075.1 MRPL35P2 -4.42 1.88e-05 0.00895 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63521234 chr10:63634317~63634827:- PAAD cis rs321358 1 rs321355 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00895 0.51 0.34 Body mass index; chr11:111124273 chr11:111089870~111090368:- PAAD cis rs321358 1 rs12419222 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00895 0.51 0.34 Body mass index; chr11:111128439 chr11:111089870~111090368:- PAAD cis rs919433 0.617 rs10931791 ENSG00000231621.1 AC013264.2 4.42 1.88e-05 0.00895 0.33 0.34 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197708888 chr2:197197991~197199273:+ PAAD cis rs7829975 0.593 rs2921077 ENSG00000253981.4 ALG1L13P 4.42 1.88e-05 0.00896 0.39 0.34 Mood instability; chr8:8446992 chr8:8236003~8244667:- PAAD cis rs748404 0.589 rs62020616 ENSG00000205771.5 CATSPER2P1 -4.42 1.88e-05 0.00896 -0.57 -0.34 Lung cancer; chr15:43558554 chr15:43726918~43747094:- PAAD cis rs748404 0.626 rs60367691 ENSG00000205771.5 CATSPER2P1 -4.42 1.88e-05 0.00896 -0.57 -0.34 Lung cancer; chr15:43559201 chr15:43726918~43747094:- PAAD cis rs4950322 0.518 rs61838936 ENSG00000278811.3 LINC00624 4.42 1.88e-05 0.00896 0.33 0.34 Protein quantitative trait loci; chr1:147098422 chr1:147258885~147517875:- PAAD cis rs710913 0.738 rs1180347 ENSG00000243970.1 PPIEL -4.42 1.88e-05 0.00896 -0.31 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39531044 chr1:39531838~39558707:- PAAD cis rs321358 1 rs321357 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00896 0.51 0.34 Body mass index; chr11:111125002 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321358 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00896 0.51 0.34 Body mass index; chr11:111125247 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321359 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00896 0.51 0.34 Body mass index; chr11:111125257 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321360 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00896 0.51 0.34 Body mass index; chr11:111125346 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321361 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00896 0.51 0.34 Body mass index; chr11:111125495 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321362 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00896 0.51 0.34 Body mass index; chr11:111125754 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321363 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00896 0.51 0.34 Body mass index; chr11:111125929 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321365 ENSG00000271390.1 RP11-89C3.3 4.42 1.88e-05 0.00896 0.51 0.34 Body mass index; chr11:111126676 chr11:111089870~111090368:- PAAD cis rs748404 0.588 rs2255410 ENSG00000205771.5 CATSPER2P1 -4.42 1.88e-05 0.00896 -0.47 -0.34 Lung cancer; chr15:43538899 chr15:43726918~43747094:- PAAD cis rs7916410 0.512 rs61854783 ENSG00000233590.1 RP11-153K11.3 -4.42 1.88e-05 0.00897 -0.54 -0.34 Optic disc area; chr10:68236307 chr10:68233251~68242379:- PAAD cis rs7923609 0.936 rs10761778 ENSG00000232075.1 MRPL35P2 -4.42 1.88e-05 0.00897 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63514022 chr10:63634317~63634827:- PAAD cis rs1823913 0.614 rs4853463 ENSG00000280083.1 RP11-317J9.1 4.42 1.88e-05 0.00897 0.4 0.34 Obesity-related traits; chr2:191278699 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs897197 ENSG00000280083.1 RP11-317J9.1 4.42 1.88e-05 0.00897 0.4 0.34 Obesity-related traits; chr2:191281456 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs2883912 ENSG00000280083.1 RP11-317J9.1 4.42 1.88e-05 0.00897 0.4 0.34 Obesity-related traits; chr2:191284290 chr2:191154118~191156070:- PAAD cis rs1823913 0.637 rs921737 ENSG00000280083.1 RP11-317J9.1 4.42 1.88e-05 0.00897 0.4 0.34 Obesity-related traits; chr2:191286097 chr2:191154118~191156070:- PAAD cis rs1823913 0.599 rs6736071 ENSG00000280083.1 RP11-317J9.1 4.42 1.88e-05 0.00897 0.4 0.34 Obesity-related traits; chr2:191287265 chr2:191154118~191156070:- PAAD cis rs748404 0.66 rs2467741 ENSG00000205771.5 CATSPER2P1 -4.42 1.88e-05 0.00898 -0.47 -0.34 Lung cancer; chr15:43450428 chr15:43726918~43747094:- PAAD cis rs9322193 0.607 rs9322229 ENSG00000268592.3 RAET1E-AS1 4.42 1.88e-05 0.00898 0.43 0.34 Lung cancer; chr6:149908949 chr6:149863494~149919507:+ PAAD cis rs1322639 0.571 rs13204417 ENSG00000261039.2 RP11-417E7.2 4.42 1.88e-05 0.00898 0.38 0.34 Pulse pressure; chr6:169175260 chr6:169175304~169182740:- PAAD cis rs11089937 0.597 rs5757005 ENSG00000211638.2 IGLV8-61 -4.42 1.89e-05 0.00899 -0.32 -0.34 Periodontitis (PAL4Q3); chr22:22134775 chr22:22098700~22099212:+ PAAD cis rs8100891 0.537 rs10409835 ENSG00000267213.4 AC007773.2 -4.42 1.89e-05 0.00899 -0.53 -0.34 Neuroticism; chr19:32397754 chr19:32390050~32405560:- PAAD cis rs28374715 0.783 rs11630656 ENSG00000247556.5 OIP5-AS1 4.42 1.89e-05 0.00899 0.36 0.34 Ulcerative colitis; chr15:41278711 chr15:41283990~41309737:+ PAAD cis rs9368481 0.729 rs9379950 ENSG00000241549.7 GUSBP2 -4.42 1.89e-05 0.00899 -0.35 -0.34 Autism spectrum disorder or schizophrenia; chr6:26993769 chr6:26871484~26956554:- PAAD cis rs9368481 1 rs9368481 ENSG00000241549.7 GUSBP2 -4.42 1.89e-05 0.00899 -0.35 -0.34 Autism spectrum disorder or schizophrenia; chr6:26993982 chr6:26871484~26956554:- PAAD cis rs9368481 0.554 rs2754603 ENSG00000241549.7 GUSBP2 -4.42 1.89e-05 0.00899 -0.35 -0.34 Autism spectrum disorder or schizophrenia; chr6:26997360 chr6:26871484~26956554:- PAAD cis rs9368481 0.761 rs9357028 ENSG00000241549.7 GUSBP2 -4.42 1.89e-05 0.00899 -0.35 -0.34 Autism spectrum disorder or schizophrenia; chr6:26999445 chr6:26871484~26956554:- PAAD cis rs4326844 0.59 rs7967622 ENSG00000248265.1 FLJ12825 4.42 1.89e-05 0.009 0.37 0.34 Platelet count; chr12:54284196 chr12:54058254~54122234:+ PAAD cis rs216345 0.642 rs307675 ENSG00000230074.1 RP11-195F19.9 -4.42 1.89e-05 0.009 -0.45 -0.34 Bipolar disorder; chr9:33969354 chr9:34665665~34681298:+ PAAD cis rs216345 0.7 rs844305 ENSG00000230074.1 RP11-195F19.9 -4.42 1.89e-05 0.009 -0.45 -0.34 Bipolar disorder; chr9:33976579 chr9:34665665~34681298:+ PAAD cis rs216345 0.67 rs307703 ENSG00000230074.1 RP11-195F19.9 -4.42 1.89e-05 0.009 -0.45 -0.34 Bipolar disorder; chr9:33985467 chr9:34665665~34681298:+ PAAD cis rs66887589 0.934 rs41464847 ENSG00000248280.1 RP11-33B1.2 -4.42 1.89e-05 0.009 -0.31 -0.34 Diastolic blood pressure; chr4:119611246 chr4:119440561~119450157:- PAAD cis rs66887589 0.934 rs7681980 ENSG00000248280.1 RP11-33B1.2 -4.42 1.89e-05 0.009 -0.31 -0.34 Diastolic blood pressure; chr4:119612068 chr4:119440561~119450157:- PAAD cis rs394563 0.69 rs372205 ENSG00000231760.4 RP11-350J20.5 4.42 1.89e-05 0.009 0.47 0.34 Dupuytren's disease; chr6:149454131 chr6:149796151~149826294:- PAAD cis rs4853525 0.59 rs2280235 ENSG00000235852.1 AC005540.3 4.42 1.89e-05 0.00901 0.5 0.34 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190979104 chr2:190880797~190882059:- PAAD cis rs2564921 0.704 rs55950520 ENSG00000242142.1 SERBP1P3 -4.42 1.89e-05 0.00901 -0.43 -0.34 Height; chr3:53094335 chr3:53064283~53065091:- PAAD cis rs42490 0.664 rs40457 ENSG00000251136.7 RP11-37B2.1 -4.42 1.89e-05 0.00901 -0.3 -0.34 Leprosy; chr8:89811459 chr8:89609409~89757727:- PAAD cis rs748404 0.723 rs512431 ENSG00000249839.1 AC011330.5 4.42 1.89e-05 0.00901 0.46 0.34 Lung cancer; chr15:43249741 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs530188 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43253116 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs475227 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43254248 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs572959 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43258304 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs554001 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43259721 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs501884 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43261784 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs504417 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43262028 chr15:43663654~43684339:- PAAD cis rs748404 0.723 rs560134 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43263501 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs546170 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43272651 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs493444 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43274272 chr15:43663654~43684339:- PAAD cis rs748404 0.65 rs556851 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43279021 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs567357 ENSG00000249839.1 AC011330.5 -4.42 1.89e-05 0.00901 -0.46 -0.34 Lung cancer; chr15:43279192 chr15:43663654~43684339:- PAAD cis rs3781264 0.677 rs7100870 ENSG00000273450.1 RP11-76P2.4 4.42 1.89e-05 0.00901 0.46 0.34 Esophageal cancer and gastric cancer; chr10:94363069 chr10:94314907~94315327:- PAAD cis rs3096299 0.748 rs3102339 ENSG00000274627.1 RP11-104N10.2 4.42 1.89e-05 0.00902 0.29 0.34 Multiple myeloma (IgH translocation); chr16:89376303 chr16:89516797~89522217:+ PAAD cis rs950027 0.549 rs1719250 ENSG00000259433.2 CTD-2651B20.4 -4.42 1.89e-05 0.00902 -0.37 -0.34 Response to fenofibrate (adiponectin levels); chr15:45317575 chr15:45330209~45332634:- PAAD cis rs763121 0.813 rs4821807 ENSG00000228274.3 RP3-508I15.9 -4.42 1.89e-05 0.00902 -0.32 -0.34 Menopause (age at onset); chr22:38669577 chr22:38667585~38681820:- PAAD cis rs875971 0.965 rs697968 ENSG00000237310.1 GS1-124K5.4 -4.42 1.89e-05 0.00902 -0.32 -0.34 Aortic root size; chr7:66070046 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1167411 ENSG00000237310.1 GS1-124K5.4 -4.42 1.89e-05 0.00902 -0.32 -0.34 Aortic root size; chr7:66074277 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1183245 ENSG00000237310.1 GS1-124K5.4 -4.42 1.89e-05 0.00902 -0.32 -0.34 Aortic root size; chr7:66076198 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1144895 ENSG00000237310.1 GS1-124K5.4 -4.42 1.89e-05 0.00902 -0.32 -0.34 Aortic root size; chr7:66076320 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1144894 ENSG00000237310.1 GS1-124K5.4 -4.42 1.89e-05 0.00902 -0.32 -0.34 Aortic root size; chr7:66077907 chr7:66493706~66495474:+ PAAD cis rs2790457 0.917 rs1265831 ENSG00000254635.4 WAC-AS1 -4.42 1.9e-05 0.00902 -0.33 -0.34 Multiple myeloma; chr10:28623921 chr10:28522652~28532743:- PAAD cis rs4266144 0.558 rs34696078 ENSG00000244515.1 KRT18P34 -4.42 1.9e-05 0.00903 -0.4 -0.34 Coronary artery disease; chr3:157114875 chr3:157162663~157163932:- PAAD cis rs2658782 0.704 rs2605614 ENSG00000279684.1 RP11-755E23.2 -4.42 1.9e-05 0.00903 -0.54 -0.34 Pulmonary function decline; chr11:93499579 chr11:93286629~93288903:- PAAD cis rs2658782 0.615 rs2605615 ENSG00000279684.1 RP11-755E23.2 -4.42 1.9e-05 0.00903 -0.54 -0.34 Pulmonary function decline; chr11:93499902 chr11:93286629~93288903:- PAAD cis rs7712401 0.601 rs30048 ENSG00000263432.2 RN7SL689P 4.42 1.9e-05 0.00904 0.43 0.34 Mean platelet volume; chr5:122934698 chr5:123022487~123022783:- PAAD cis rs12571093 0.773 rs3740588 ENSG00000233590.1 RP11-153K11.3 4.42 1.9e-05 0.00904 0.52 0.34 Optic nerve measurement (disc area); chr10:68261079 chr10:68233251~68242379:- PAAD cis rs11976180 1 rs2961120 ENSG00000273234.1 OR2A13P -4.42 1.9e-05 0.00904 -0.42 -0.34 Obesity-related traits; chr7:144059492 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2951360 ENSG00000273234.1 OR2A13P -4.42 1.9e-05 0.00904 -0.42 -0.34 Obesity-related traits; chr7:144060256 chr7:144142009~144142938:+ PAAD cis rs4664293 0.669 rs1549387 ENSG00000226266.5 AC009961.3 4.42 1.9e-05 0.00904 0.42 0.34 Monocyte percentage of white cells; chr2:159561029 chr2:159670708~159712435:- PAAD cis rs4664293 0.669 rs1863219 ENSG00000226266.5 AC009961.3 4.42 1.9e-05 0.00904 0.42 0.34 Monocyte percentage of white cells; chr2:159561660 chr2:159670708~159712435:- PAAD cis rs394563 0.663 rs415434 ENSG00000231760.4 RP11-350J20.5 4.42 1.9e-05 0.00904 0.47 0.34 Dupuytren's disease; chr6:149451509 chr6:149796151~149826294:- PAAD cis rs8028182 0.537 rs4371118 ENSG00000260269.4 CTD-2323K18.1 -4.42 1.9e-05 0.00904 -0.46 -0.34 Sudden cardiac arrest; chr15:75606549 chr15:75527150~75601205:- PAAD cis rs897984 0.542 rs6565217 ENSG00000260911.2 RP11-196G11.2 4.42 1.9e-05 0.00904 0.3 0.34 Dementia with Lewy bodies; chr16:31072003 chr16:31043150~31049868:+ PAAD cis rs10129255 0.536 rs17113249 ENSG00000211972.2 IGHV3-66 4.42 1.9e-05 0.00904 0.26 0.34 Kawasaki disease; chr14:106678273 chr14:106675017~106675544:- PAAD cis rs987724 0.515 rs4315647 ENSG00000240875.4 LINC00886 -4.42 1.9e-05 0.00905 -0.5 -0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156941199 chr3:156747346~156817062:- PAAD cis rs13392177 0.672 rs1877715 ENSG00000261338.2 RP11-378A13.1 4.42 1.9e-05 0.00905 0.39 0.34 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218187823 chr2:218255319~218257366:+ PAAD cis rs4664293 1 rs10204535 ENSG00000226266.5 AC009961.3 -4.42 1.9e-05 0.00905 -0.42 -0.34 Monocyte percentage of white cells; chr2:159607181 chr2:159670708~159712435:- PAAD cis rs7826238 0.594 rs2948285 ENSG00000173295.6 FAM86B3P 4.41 1.91e-05 0.00907 0.38 0.34 Systolic blood pressure; chr8:8273016 chr8:8228595~8244865:+ PAAD cis rs7829975 0.511 rs2955578 ENSG00000173295.6 FAM86B3P 4.41 1.91e-05 0.00907 0.38 0.34 Mood instability; chr8:8279561 chr8:8228595~8244865:+ PAAD cis rs9584850 0.794 rs9630321 ENSG00000231194.1 FARP1-AS1 4.41 1.91e-05 0.00908 0.44 0.34 Neuroticism; chr13:98454725 chr13:98435405~98435840:- PAAD cis rs17772222 0.958 rs60878614 ENSG00000258983.2 RP11-507K2.2 4.41 1.91e-05 0.00909 0.46 0.34 Coronary artery calcification; chr14:88513871 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs10143767 ENSG00000258983.2 RP11-507K2.2 4.41 1.91e-05 0.00909 0.46 0.34 Coronary artery calcification; chr14:88514867 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs76559451 ENSG00000258983.2 RP11-507K2.2 4.41 1.91e-05 0.00909 0.46 0.34 Coronary artery calcification; chr14:88523193 chr14:88499334~88515502:+ PAAD cis rs4660214 0.666 rs7554206 ENSG00000237624.1 OXCT2P1 -4.41 1.91e-05 0.00909 -0.45 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39463568 chr1:39514956~39516490:+ PAAD cis rs55665837 0.701 rs12286408 ENSG00000251991.1 RNU7-49P 4.41 1.91e-05 0.00909 0.39 0.34 Vitamin D levels; chr11:14557830 chr11:14478892~14478953:+ PAAD cis rs987724 0.515 rs344073 ENSG00000240875.4 LINC00886 4.41 1.91e-05 0.00909 0.51 0.34 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156829224 chr3:156747346~156817062:- PAAD cis rs6991838 0.8 rs28547533 ENSG00000200714.1 Y_RNA 4.41 1.91e-05 0.0091 0.4 0.34 Intelligence (multi-trait analysis); chr8:65559318 chr8:65592731~65592820:+ PAAD cis rs6991838 0.8 rs28626262 ENSG00000200714.1 Y_RNA 4.41 1.91e-05 0.0091 0.4 0.34 Intelligence (multi-trait analysis); chr8:65559335 chr8:65592731~65592820:+ PAAD cis rs6991838 0.8 rs28709439 ENSG00000200714.1 Y_RNA 4.41 1.91e-05 0.0091 0.4 0.34 Intelligence (multi-trait analysis); chr8:65559337 chr8:65592731~65592820:+ PAAD cis rs11690935 0.55 rs7584187 ENSG00000228389.1 AC068039.4 4.41 1.91e-05 0.0091 0.42 0.34 Schizophrenia; chr2:172001198 chr2:171773482~171775844:+ PAAD cis rs453301 0.624 rs2915251 ENSG00000254340.1 RP11-10A14.3 4.41 1.92e-05 0.0091 0.41 0.34 Joint mobility (Beighton score); chr8:9009901 chr8:9141424~9145435:+ PAAD cis rs5760092 0.627 rs6519489 ENSG00000231271.1 AP000350.8 -4.41 1.92e-05 0.00911 -0.52 -0.34 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23949918~23954042:+ PAAD cis rs4554975 0.869 rs10881002 ENSG00000274723.1 RP11-618L22.1 -4.41 1.92e-05 0.00911 -0.39 -0.34 Metabolite levels (small molecules and protein measures); chr12:46813270 chr12:46970504~46972155:+ PAAD cis rs6480314 0.522 rs10047388 ENSG00000233590.1 RP11-153K11.3 4.41 1.92e-05 0.00911 0.52 0.34 Optic nerve measurement (disc area); chr10:68300456 chr10:68233251~68242379:- PAAD cis rs4713118 0.662 rs149901 ENSG00000226314.6 ZNF192P1 -4.41 1.92e-05 0.00911 -0.55 -0.34 Parkinson's disease; chr6:27997725 chr6:28161781~28169594:+ PAAD cis rs4268898 0.862 rs11125549 ENSG00000242628.4 AC009228.1 -4.41 1.92e-05 0.00912 -0.4 -0.34 Asthma; chr2:24353371 chr2:24214381~24221516:+ PAAD cis rs801193 0.66 rs10950049 ENSG00000232559.3 GS1-124K5.12 4.41 1.92e-05 0.00912 0.37 0.34 Aortic root size; chr7:66765873 chr7:66554588~66576923:- PAAD cis rs812925 0.502 rs2053750 ENSG00000273302.1 RP11-493E12.2 -4.41 1.92e-05 0.00913 -0.3 -0.34 Immature fraction of reticulocytes; chr2:61429138 chr2:61199979~61200769:+ PAAD cis rs3761847 0.5 rs7037673 ENSG00000226752.6 PSMD5-AS1 -4.41 1.92e-05 0.00913 -0.38 -0.34 Rheumatoid arthritis; chr9:120978206 chr9:120824828~120854385:+ PAAD cis rs66887589 0.777 rs10015883 ENSG00000248280.1 RP11-33B1.2 4.41 1.92e-05 0.00913 0.3 0.34 Diastolic blood pressure; chr4:119346991 chr4:119440561~119450157:- PAAD cis rs748404 0.534 rs489509 ENSG00000249839.1 AC011330.5 -4.41 1.93e-05 0.00914 -0.5 -0.34 Lung cancer; chr15:43294709 chr15:43663654~43684339:- PAAD cis rs4834770 0.765 rs1511016 ENSG00000245958.5 RP11-33B1.1 -4.41 1.93e-05 0.00915 -0.27 -0.34 Blood protein levels; chr4:119249200 chr4:119454791~119552025:+ PAAD cis rs6991838 0.771 rs13282323 ENSG00000200714.1 Y_RNA 4.41 1.93e-05 0.00915 0.4 0.34 Intelligence (multi-trait analysis); chr8:65560557 chr8:65592731~65592820:+ PAAD cis rs6991838 0.831 rs4394432 ENSG00000200714.1 Y_RNA 4.41 1.93e-05 0.00915 0.4 0.34 Intelligence (multi-trait analysis); chr8:65560939 chr8:65592731~65592820:+ PAAD cis rs897984 0.609 rs72800847 ENSG00000260911.2 RP11-196G11.2 4.41 1.93e-05 0.00915 0.31 0.34 Dementia with Lewy bodies; chr16:31011318 chr16:31043150~31049868:+ PAAD cis rs79040073 0.637 rs11635005 ENSG00000259531.2 RP11-295H24.3 4.41 1.93e-05 0.00915 0.56 0.34 Lung cancer in ever smokers; chr15:49309228 chr15:49365124~49366685:- PAAD cis rs797680 0.964 rs1060622 ENSG00000223745.6 RP4-717I23.3 4.41 1.93e-05 0.00915 0.27 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93154836 chr1:93262186~93346025:- PAAD cis rs2255336 0.706 rs4415856 ENSG00000245648.1 RP11-277P12.20 -4.41 1.93e-05 0.00915 -0.48 -0.34 Blood protein levels; chr12:10448069 chr12:10363769~10398506:+ PAAD cis rs7829975 0.567 rs6601273 ENSG00000254340.1 RP11-10A14.3 -4.41 1.93e-05 0.00915 -0.4 -0.34 Mood instability; chr8:8939009 chr8:9141424~9145435:+ PAAD cis rs7829975 0.606 rs7819827 ENSG00000254340.1 RP11-10A14.3 -4.41 1.93e-05 0.00915 -0.4 -0.34 Mood instability; chr8:8939545 chr8:9141424~9145435:+ PAAD cis rs7829975 0.509 rs7838674 ENSG00000254340.1 RP11-10A14.3 -4.41 1.93e-05 0.00915 -0.4 -0.34 Mood instability; chr8:8939563 chr8:9141424~9145435:+ PAAD cis rs7829975 0.573 rs7842359 ENSG00000254340.1 RP11-10A14.3 -4.41 1.93e-05 0.00915 -0.4 -0.34 Mood instability; chr8:8939568 chr8:9141424~9145435:+ PAAD cis rs113835537 0.735 rs519380 ENSG00000255517.5 CTD-3074O7.5 -4.41 1.93e-05 0.00916 -0.49 -0.34 Airway imaging phenotypes; chr11:66641938 chr11:66473490~66480233:- PAAD cis rs853679 0.574 rs1233705 ENSG00000204709.4 LINC01556 4.41 1.93e-05 0.00917 0.57 0.34 Depression; chr6:28198669 chr6:28943877~28944537:+ PAAD cis rs853679 0.55 rs1233701 ENSG00000204709.4 LINC01556 -4.41 1.93e-05 0.00917 -0.57 -0.34 Depression; chr6:28200948 chr6:28943877~28944537:+ PAAD cis rs853679 0.55 rs1233699 ENSG00000204709.4 LINC01556 4.41 1.93e-05 0.00917 0.57 0.34 Depression; chr6:28201380 chr6:28943877~28944537:+ PAAD cis rs853679 0.55 rs1233707 ENSG00000204709.4 LINC01556 4.41 1.93e-05 0.00917 0.57 0.34 Depression; chr6:28205175 chr6:28943877~28944537:+ PAAD cis rs1035539 1 rs1035539 ENSG00000280152.1 RP11-331F4.5 4.41 1.93e-05 0.00917 0.34 0.34 Alcoholic chronic pancreatitis; chr16:75242877 chr16:75245994~75250077:- PAAD cis rs6472235 0.681 rs4129057 ENSG00000200714.1 Y_RNA -4.41 1.93e-05 0.00917 -0.44 -0.34 Plateletcrit;Myopia (pathological); chr8:65943911 chr8:65592731~65592820:+ PAAD cis rs10411161 0.702 rs892039 ENSG00000270248.1 CTC-471J1.10 4.41 1.93e-05 0.00918 0.59 0.34 Breast cancer; chr19:51893288 chr19:52110318~52110726:- PAAD cis rs10411161 0.702 rs2867319 ENSG00000270248.1 CTC-471J1.10 4.41 1.93e-05 0.00918 0.59 0.34 Breast cancer; chr19:51893907 chr19:52110318~52110726:- PAAD cis rs74233809 0.901 rs3824755 ENSG00000213277.3 MARCKSL1P1 4.41 1.94e-05 0.00919 0.54 0.34 Birth weight; chr10:102836092 chr10:103175554~103176094:+ PAAD cis rs2729354 0.903 rs1846568 ENSG00000265566.2 RN7SL605P -4.41 1.94e-05 0.00919 -0.45 -0.34 Blood protein levels; chr11:57590241 chr11:57528085~57528365:- PAAD cis rs575908 0.773 rs671596 ENSG00000254154.7 RP4-798P15.3 -4.41 1.94e-05 0.00919 -0.25 -0.34 Breast cancer; chr1:177900152 chr1:177928788~178038007:- PAAD cis rs633715 0.531 rs604388 ENSG00000254154.7 RP4-798P15.3 -4.41 1.94e-05 0.00919 -0.25 -0.34 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177908844 chr1:177928788~178038007:- PAAD cis rs633715 0.531 rs617763 ENSG00000254154.7 RP4-798P15.3 -4.41 1.94e-05 0.00919 -0.25 -0.34 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177916103 chr1:177928788~178038007:- PAAD cis rs633715 0.513 rs512898 ENSG00000254154.7 RP4-798P15.3 -4.41 1.94e-05 0.00919 -0.25 -0.34 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177919294 chr1:177928788~178038007:- PAAD cis rs2404602 0.647 rs2404600 ENSG00000259422.1 RP11-593F23.1 -4.41 1.94e-05 0.0092 -0.41 -0.34 Blood metabolite levels; chr15:76881216 chr15:76174891~76181486:- PAAD cis rs75804782 0.63 rs56328549 ENSG00000186235.9 AC016757.3 4.41 1.94e-05 0.0092 0.81 0.34 Chronotype;Morning vs. evening chronotype; chr2:238317912 chr2:238224552~238231677:- PAAD cis rs6570726 0.935 rs585292 ENSG00000235652.6 RP11-545I5.3 4.41 1.94e-05 0.0092 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145541092 chr6:145799409~145886585:+ PAAD cis rs6570726 0.837 rs419991 ENSG00000235652.6 RP11-545I5.3 4.41 1.94e-05 0.0092 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145543076 chr6:145799409~145886585:+ PAAD cis rs6570726 0.875 rs12524077 ENSG00000235652.6 RP11-545I5.3 4.41 1.94e-05 0.0092 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145545197 chr6:145799409~145886585:+ PAAD cis rs9918079 0.56 rs4557256 ENSG00000273133.1 RP11-799M12.2 -4.41 1.94e-05 0.0092 -0.4 -0.34 Obesity-related traits; chr4:15625024 chr4:15563698~15564253:- PAAD cis rs1789 0.839 rs9997068 ENSG00000273133.1 RP11-799M12.2 -4.41 1.94e-05 0.0092 -0.4 -0.34 Blood protein levels; chr4:15649367 chr4:15563698~15564253:- PAAD cis rs9918079 0.56 rs6414767 ENSG00000273133.1 RP11-799M12.2 -4.41 1.94e-05 0.0092 -0.4 -0.34 Obesity-related traits; chr4:15654098 chr4:15563698~15564253:- PAAD cis rs2243480 0.706 rs34466769 ENSG00000232546.1 RP11-458F8.1 -4.41 1.94e-05 0.00921 -0.36 -0.34 Diabetic kidney disease; chr7:65988305 chr7:66848496~66858136:+ PAAD cis rs748404 0.66 rs548704 ENSG00000205771.5 CATSPER2P1 -4.41 1.94e-05 0.00921 -0.47 -0.34 Lung cancer; chr15:43499508 chr15:43726918~43747094:- PAAD cis rs3738443 0.52 rs6699577 ENSG00000259865.1 RP11-488L18.10 4.41 1.94e-05 0.00921 0.29 0.34 Alcohol dependence; chr1:247224152 chr1:247187281~247188526:- PAAD cis rs3738443 0.545 rs12566906 ENSG00000259865.1 RP11-488L18.10 4.41 1.94e-05 0.00921 0.29 0.34 Alcohol dependence; chr1:247224904 chr1:247187281~247188526:- PAAD cis rs7617773 0.817 rs6796490 ENSG00000228638.1 FCF1P2 -4.41 1.94e-05 0.00922 -0.37 -0.34 Coronary artery disease; chr3:48195614 chr3:48290793~48291375:- PAAD cis rs17214007 0.877 rs7201553 ENSG00000263335.1 AF001548.5 -4.41 1.94e-05 0.00922 -0.48 -0.34 Cognitive function; chr16:15781186 chr16:15726674~15732993:+ PAAD cis rs720064 0.586 rs12957815 ENSG00000264745.1 TTC39C-AS1 4.41 1.95e-05 0.00923 0.41 0.34 Strep throat; chr18:23976626 chr18:23994213~24015339:- PAAD cis rs2380205 0.546 rs633928 ENSG00000232807.2 RP11-536K7.3 -4.41 1.95e-05 0.00924 -0.35 -0.34 Breast cancer; chr10:5902547 chr10:5934270~5945900:- PAAD cis rs4835473 0.801 rs76574827 ENSG00000251600.4 RP11-673E1.1 -4.41 1.95e-05 0.00924 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143737303 chr4:143912331~143982454:+ PAAD cis rs4835473 0.832 rs62337616 ENSG00000251600.4 RP11-673E1.1 -4.41 1.95e-05 0.00924 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143737307 chr4:143912331~143982454:+ PAAD cis rs4835473 0.832 rs66717029 ENSG00000251600.4 RP11-673E1.1 -4.41 1.95e-05 0.00924 -0.38 -0.34 Immature fraction of reticulocytes; chr4:143737318 chr4:143912331~143982454:+ PAAD cis rs9649213 0.511 rs6950994 ENSG00000272950.1 RP11-307C18.1 4.41 1.95e-05 0.00924 0.39 0.34 Prostate cancer (SNP x SNP interaction); chr7:98258560 chr7:98322853~98323430:+ PAAD cis rs2243480 1 rs4548056 ENSG00000228409.4 CCT6P1 4.41 1.95e-05 0.00924 0.37 0.34 Diabetic kidney disease; chr7:65833886 chr7:65751142~65763354:+ PAAD cis rs6472235 0.656 rs11995784 ENSG00000200714.1 Y_RNA -4.41 1.95e-05 0.00924 -0.45 -0.34 Plateletcrit;Myopia (pathological); chr8:65967906 chr8:65592731~65592820:+ PAAD cis rs6472235 0.656 rs11993927 ENSG00000200714.1 Y_RNA -4.41 1.95e-05 0.00924 -0.45 -0.34 Plateletcrit;Myopia (pathological); chr8:65969407 chr8:65592731~65592820:+ PAAD cis rs6472235 0.656 rs11994927 ENSG00000200714.1 Y_RNA -4.41 1.95e-05 0.00924 -0.45 -0.34 Plateletcrit;Myopia (pathological); chr8:65970615 chr8:65592731~65592820:+ PAAD cis rs6472235 0.609 rs11985589 ENSG00000200714.1 Y_RNA -4.41 1.95e-05 0.00924 -0.45 -0.34 Plateletcrit;Myopia (pathological); chr8:65972076 chr8:65592731~65592820:+ PAAD cis rs801193 0.935 rs2659916 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66686365 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs6958520 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66686466 chr7:66493706~66495474:+ PAAD cis rs801193 0.967 rs2707849 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66687725 chr7:66493706~66495474:+ PAAD cis rs801193 0.967 rs2707841 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66692033 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2659912 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66693012 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2707836 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66695448 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs4717310 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66696020 chr7:66493706~66495474:+ PAAD cis rs801193 0.844 rs7779971 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66696803 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2659906 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66700323 chr7:66493706~66495474:+ PAAD cis rs801193 0.935 rs2659899 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66721734 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs1553609 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66732152 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs1553610 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66732246 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2707845 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66733811 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2707850 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66738883 chr7:66493706~66495474:+ PAAD cis rs801193 0.967 rs1110414 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66740595 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs7783924 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66744070 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs7789184 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66745208 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2707856 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66746023 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2707854 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66747610 chr7:66493706~66495474:+ PAAD cis rs801193 0.967 rs2707853 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66749023 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2659889 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66752125 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs3800812 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66758474 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs4279493 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66761633 chr7:66493706~66495474:+ PAAD cis rs801193 0.761 rs2659888 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66765184 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs4717319 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66777606 chr7:66493706~66495474:+ PAAD cis rs801193 0.904 rs4718403 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66777742 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs3778909 ENSG00000237310.1 GS1-124K5.4 4.41 1.95e-05 0.00925 0.31 0.34 Aortic root size; chr7:66790659 chr7:66493706~66495474:+ PAAD cis rs875971 0.638 rs7793569 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66651646 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs6975195 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66659787 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs3857688 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66662819 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2286684 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66664843 chr7:66493706~66495474:+ PAAD cis rs801193 0.935 rs2286683 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66664856 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs10274773 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66668591 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs7785213 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66673991 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs11773829 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66676087 chr7:66493706~66495474:+ PAAD cis rs801193 0.935 rs3800820 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66682191 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2003301 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66682669 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs7788576 ENSG00000237310.1 GS1-124K5.4 -4.41 1.95e-05 0.00925 -0.31 -0.34 Aortic root size; chr7:66683315 chr7:66493706~66495474:+ PAAD cis rs10740039 0.768 rs7895268 ENSG00000254271.1 RP11-131N11.4 4.41 1.95e-05 0.00925 0.39 0.34 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60703479 chr10:60734342~60741828:+ PAAD cis rs73219805 0.793 rs1564576 ENSG00000228451.3 SDAD1P1 -4.41 1.95e-05 0.00925 -0.5 -0.34 Schizophrenia; chr8:26333320 chr8:26379259~26382953:- PAAD cis rs950880 0.71 rs3771172 ENSG00000234389.1 AC007278.3 -4.41 1.95e-05 0.00925 -0.35 -0.34 Serum protein levels (sST2); chr2:102369352 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs3771171 ENSG00000234389.1 AC007278.3 -4.41 1.95e-05 0.00925 -0.35 -0.34 Serum protein levels (sST2); chr2:102369490 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs2160202 ENSG00000234389.1 AC007278.3 -4.41 1.95e-05 0.00925 -0.35 -0.34 Serum protein levels (sST2); chr2:102369694 chr2:102438713~102440475:+ PAAD cis rs4835473 0.868 rs7683365 ENSG00000251600.4 RP11-673E1.1 -4.41 1.95e-05 0.00925 -0.41 -0.34 Immature fraction of reticulocytes; chr4:143999443 chr4:143912331~143982454:+ PAAD cis rs17684571 0.872 rs34587484 ENSG00000216854.2 RPL17P26 4.41 1.96e-05 0.00926 0.68 0.34 Schizophrenia; chr6:56742926 chr6:56871191~56871743:+ PAAD cis rs17684571 0.872 rs34465210 ENSG00000216854.2 RPL17P26 4.41 1.96e-05 0.00926 0.68 0.34 Schizophrenia; chr6:56742930 chr6:56871191~56871743:+ PAAD cis rs6052484 0.523 rs4569542 ENSG00000226948.1 RPS4XP2 -4.41 1.96e-05 0.00927 -0.51 -0.34 Sense of smell; chr20:4338546 chr20:4629427~4630219:- PAAD cis rs6052484 0.523 rs4283491 ENSG00000226948.1 RPS4XP2 -4.41 1.96e-05 0.00927 -0.51 -0.34 Sense of smell; chr20:4338575 chr20:4629427~4630219:- PAAD cis rs6052484 0.523 rs10854263 ENSG00000226948.1 RPS4XP2 -4.41 1.96e-05 0.00927 -0.51 -0.34 Sense of smell; chr20:4339157 chr20:4629427~4630219:- PAAD cis rs2117029 1 rs3782357 ENSG00000258017.1 RP11-386G11.10 -4.41 1.96e-05 0.00927 -0.43 -0.34 Intelligence (multi-trait analysis); chr12:49033869 chr12:49127782~49147869:+ PAAD cis rs2980439 0.525 rs1850511 ENSG00000173295.6 FAM86B3P 4.41 1.96e-05 0.00928 0.34 0.34 Neuroticism; chr8:8312807 chr8:8228595~8244865:+ PAAD cis rs2019137 0.539 rs4849181 ENSG00000274877.1 RP11-65I12.1 -4.41 1.96e-05 0.00929 -0.39 -0.34 Lymphocyte counts; chr2:113234393 chr2:113237595~113240825:+ PAAD cis rs7646881 0.812 rs79303235 ENSG00000240207.5 RP11-379F4.4 -4.41 1.96e-05 0.00929 -0.51 -0.34 Tetralogy of Fallot; chr3:158727004 chr3:158732263~158784070:+ PAAD cis rs4950322 0.634 rs4950415 ENSG00000278811.3 LINC00624 4.41 1.96e-05 0.00929 0.34 0.34 Protein quantitative trait loci; chr1:147350951 chr1:147258885~147517875:- PAAD cis rs889398 0.935 rs1364063 ENSG00000226232.7 RP11-419C5.2 4.41 1.97e-05 0.0093 0.27 0.34 Body mass index; chr16:69554669 chr16:69976388~69996188:- PAAD cis rs11690935 0.55 rs62183801 ENSG00000228389.1 AC068039.4 -4.41 1.97e-05 0.00931 -0.42 -0.34 Schizophrenia; chr2:172002567 chr2:171773482~171775844:+ PAAD cis rs11690935 0.55 rs6718013 ENSG00000228389.1 AC068039.4 -4.41 1.97e-05 0.00931 -0.42 -0.34 Schizophrenia; chr2:172004277 chr2:171773482~171775844:+ PAAD cis rs2658782 1 rs2605582 ENSG00000279684.1 RP11-755E23.2 -4.41 1.97e-05 0.00932 -0.57 -0.34 Pulmonary function decline; chr11:93430633 chr11:93286629~93288903:- PAAD cis rs8005677 0.77 rs56180741 ENSG00000279656.1 RP11-298I3.6 4.41 1.97e-05 0.00933 0.4 0.34 Cognitive ability (multi-trait analysis); chr14:22908037 chr14:23023083~23024217:- PAAD cis rs8005677 0.828 rs3794452 ENSG00000279656.1 RP11-298I3.6 4.41 1.97e-05 0.00933 0.4 0.34 Cognitive ability (multi-trait analysis); chr14:22917473 chr14:23023083~23024217:- PAAD cis rs8005677 0.828 rs4981450 ENSG00000279656.1 RP11-298I3.6 4.41 1.97e-05 0.00933 0.4 0.34 Cognitive ability (multi-trait analysis); chr14:22920095 chr14:23023083~23024217:- PAAD cis rs853679 0.55 rs1150692 ENSG00000226314.6 ZNF192P1 -4.41 1.98e-05 0.00934 -0.57 -0.34 Depression; chr6:28206179 chr6:28161781~28169594:+ PAAD cis rs4664293 0.967 rs12611922 ENSG00000226266.5 AC009961.3 -4.41 1.98e-05 0.00934 -0.42 -0.34 Monocyte percentage of white cells; chr2:159606238 chr2:159670708~159712435:- PAAD cis rs4664293 0.967 rs13020365 ENSG00000226266.5 AC009961.3 -4.41 1.98e-05 0.00934 -0.42 -0.34 Monocyte percentage of white cells; chr2:159619893 chr2:159670708~159712435:- PAAD cis rs4664293 1 rs13014418 ENSG00000226266.5 AC009961.3 -4.41 1.98e-05 0.00934 -0.42 -0.34 Monocyte percentage of white cells; chr2:159627174 chr2:159670708~159712435:- PAAD cis rs10888838 1 rs6621 ENSG00000198711.5 SSBP3-AS1 4.41 1.98e-05 0.00934 0.4 0.34 Mitochondrial DNA levels; chr1:54218252 chr1:54236440~54239063:+ PAAD cis rs10888838 1 rs33988698 ENSG00000198711.5 SSBP3-AS1 4.41 1.98e-05 0.00934 0.4 0.34 Mitochondrial DNA levels; chr1:54220182 chr1:54236440~54239063:+ PAAD cis rs7712401 0.601 rs154501 ENSG00000263432.2 RN7SL689P 4.41 1.98e-05 0.00935 0.43 0.34 Mean platelet volume; chr5:122875899 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs154500 ENSG00000263432.2 RN7SL689P 4.41 1.98e-05 0.00935 0.43 0.34 Mean platelet volume; chr5:122876296 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246271 ENSG00000263432.2 RN7SL689P 4.41 1.98e-05 0.00935 0.43 0.34 Mean platelet volume; chr5:122877127 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs257813 ENSG00000263432.2 RN7SL689P 4.41 1.98e-05 0.00935 0.43 0.34 Mean platelet volume; chr5:122881473 chr5:123022487~123022783:- PAAD cis rs734999 0.545 rs28568531 ENSG00000225931.3 RP3-395M20.7 4.41 1.98e-05 0.00935 0.32 0.34 Ulcerative colitis; chr1:2624201 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs7368105 ENSG00000225931.3 RP3-395M20.7 4.41 1.98e-05 0.00935 0.32 0.34 Ulcerative colitis; chr1:2625109 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs7364820 ENSG00000225931.3 RP3-395M20.7 4.41 1.98e-05 0.00935 0.32 0.34 Ulcerative colitis; chr1:2625270 chr1:2566410~2569888:+ PAAD cis rs734999 0.588 rs6668149 ENSG00000225931.3 RP3-395M20.7 -4.41 1.98e-05 0.00935 -0.32 -0.34 Ulcerative colitis; chr1:2626869 chr1:2566410~2569888:+ PAAD cis rs734999 0.566 rs12748729 ENSG00000225931.3 RP3-395M20.7 -4.41 1.98e-05 0.00935 -0.32 -0.34 Ulcerative colitis; chr1:2627301 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs12730932 ENSG00000225931.3 RP3-395M20.7 -4.41 1.98e-05 0.00935 -0.32 -0.34 Ulcerative colitis; chr1:2628150 chr1:2566410~2569888:+ PAAD cis rs3096299 0.685 rs8050512 ENSG00000261253.2 AC137932.6 4.41 1.98e-05 0.00936 0.36 0.34 Multiple myeloma (IgH translocation); chr16:89485912 chr16:89321133~89325110:+ PAAD cis rs6504622 0.818 rs3851784 ENSG00000262879.4 RP11-156P1.3 4.41 1.98e-05 0.00936 0.36 0.34 Orofacial clefts; chr17:46962751 chr17:46984045~47100323:- PAAD cis rs2281636 1 rs10786569 ENSG00000233690.1 EBAG9P1 4.41 1.99e-05 0.00937 0.35 0.34 Obesity-related traits; chr10:99753828 chr10:99697407~99697949:- PAAD cis rs10761482 0.566 rs10159663 ENSG00000254271.1 RP11-131N11.4 -4.4 1.99e-05 0.00937 -0.43 -0.34 Schizophrenia; chr10:60448659 chr10:60734342~60741828:+ PAAD cis rs526231 0.575 rs26822 ENSG00000175749.11 EIF3KP1 4.4 1.99e-05 0.00938 0.43 0.34 Primary biliary cholangitis; chr5:103183094 chr5:103032376~103033031:+ PAAD cis rs7487075 0.93 rs6582656 ENSG00000270429.1 KNOP1P2 4.4 1.99e-05 0.00939 0.37 0.34 Itch intensity from mosquito bite; chr12:46449633 chr12:45880950~45882266:- PAAD cis rs6472235 1 rs6472238 ENSG00000200714.1 Y_RNA -4.4 1.99e-05 0.00939 -0.44 -0.34 Plateletcrit;Myopia (pathological); chr8:65937968 chr8:65592731~65592820:+ PAAD cis rs6472235 1 rs11984618 ENSG00000200714.1 Y_RNA -4.4 1.99e-05 0.00939 -0.44 -0.34 Plateletcrit;Myopia (pathological); chr8:65939229 chr8:65592731~65592820:+ PAAD cis rs6472235 1 rs11984566 ENSG00000200714.1 Y_RNA -4.4 1.99e-05 0.00939 -0.44 -0.34 Plateletcrit;Myopia (pathological); chr8:65939237 chr8:65592731~65592820:+ PAAD cis rs6472235 1 rs7817474 ENSG00000200714.1 Y_RNA -4.4 1.99e-05 0.00939 -0.44 -0.34 Plateletcrit;Myopia (pathological); chr8:65939683 chr8:65592731~65592820:+ PAAD cis rs11654699 0.84 rs8079280 ENSG00000274341.1 RP11-227G15.10 4.4 1.99e-05 0.0094 0.32 0.34 Neurofibrillary tangles; chr17:32591164 chr17:32408013~32408309:+ PAAD cis rs748404 0.66 rs690446 ENSG00000205771.5 CATSPER2P1 -4.4 1.99e-05 0.0094 -0.47 -0.34 Lung cancer; chr15:43469066 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs518288 ENSG00000205771.5 CATSPER2P1 -4.4 1.99e-05 0.0094 -0.47 -0.34 Lung cancer; chr15:43471801 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs690472 ENSG00000205771.5 CATSPER2P1 -4.4 1.99e-05 0.0094 -0.47 -0.34 Lung cancer; chr15:43472170 chr15:43726918~43747094:- PAAD cis rs748404 0.631 rs560191 ENSG00000205771.5 CATSPER2P1 -4.4 1.99e-05 0.0094 -0.47 -0.34 Lung cancer; chr15:43475576 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs2444251 ENSG00000205771.5 CATSPER2P1 -4.4 1.99e-05 0.0094 -0.47 -0.34 Lung cancer; chr15:43496397 chr15:43726918~43747094:- PAAD cis rs42490 0.789 rs51331 ENSG00000251136.7 RP11-37B2.1 -4.4 1.99e-05 0.00941 -0.29 -0.34 Leprosy; chr8:89801900 chr8:89609409~89757727:- PAAD cis rs9487094 0.626 rs3799845 ENSG00000260273.1 RP11-425D10.10 4.4 2e-05 0.00941 0.41 0.34 Height; chr6:109706514 chr6:109382795~109383666:+ PAAD cis rs4423214 0.592 rs10898191 ENSG00000254682.1 RP11-660L16.2 -4.4 2e-05 0.00945 -0.56 -0.34 Vitamin D levels; chr11:71483555 chr11:71448674~71452157:+ PAAD cis rs9368481 0.729 rs10946881 ENSG00000241549.7 GUSBP2 4.4 2e-05 0.00945 0.35 0.34 Autism spectrum disorder or schizophrenia; chr6:26946832 chr6:26871484~26956554:- PAAD cis rs10510102 0.935 rs7907871 ENSG00000276742.1 RP11-500G22.4 4.4 2.01e-05 0.00945 0.53 0.34 Breast cancer; chr10:121878185 chr10:121956782~121957098:+ PAAD cis rs42490 0.664 rs39516 ENSG00000251136.7 RP11-37B2.1 -4.4 2.01e-05 0.00945 -0.3 -0.34 Leprosy; chr8:89822157 chr8:89609409~89757727:- PAAD cis rs595244 1 rs363820 ENSG00000259705.1 RP11-227D13.1 -4.4 2.01e-05 0.00945 -0.54 -0.34 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48436833 chr15:48645951~48652016:+ PAAD cis rs797680 0.964 rs2296558 ENSG00000223745.6 RP4-717I23.3 -4.4 2.01e-05 0.00946 -0.26 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93270998 chr1:93262186~93346025:- PAAD cis rs7189233 0.531 rs9302648 ENSG00000279344.1 RP11-44F14.7 4.4 2.01e-05 0.00947 0.26 0.34 Intelligence (multi-trait analysis); chr16:53493869 chr16:53478957~53481550:- PAAD cis rs734999 0.545 rs6684865 ENSG00000225931.3 RP3-395M20.7 -4.4 2.01e-05 0.00947 -0.32 -0.34 Ulcerative colitis; chr1:2614790 chr1:2566410~2569888:+ PAAD cis rs11123170 0.529 rs112692022 ENSG00000274877.1 RP11-65I12.1 -4.4 2.01e-05 0.00947 -0.45 -0.34 Renal function-related traits (BUN); chr2:113212605 chr2:113237595~113240825:+ PAAD cis rs189798 0.807 rs12785 ENSG00000253893.2 FAM85B -4.4 2.01e-05 0.00947 -0.5 -0.34 Myopia (pathological); chr8:9137426 chr8:8167819~8226614:- PAAD cis rs189798 0.807 rs330909 ENSG00000253893.2 FAM85B -4.4 2.01e-05 0.00947 -0.5 -0.34 Myopia (pathological); chr8:9137877 chr8:8167819~8226614:- PAAD cis rs55665837 0.701 rs10160597 ENSG00000251991.1 RNU7-49P 4.4 2.01e-05 0.00948 0.39 0.34 Vitamin D levels; chr11:14582446 chr11:14478892~14478953:+ PAAD cis rs55665837 0.701 rs11023265 ENSG00000251991.1 RNU7-49P 4.4 2.01e-05 0.00948 0.39 0.34 Vitamin D levels; chr11:14594492 chr11:14478892~14478953:+ PAAD cis rs55665837 0.701 rs11023272 ENSG00000251991.1 RNU7-49P 4.4 2.01e-05 0.00948 0.39 0.34 Vitamin D levels; chr11:14608824 chr11:14478892~14478953:+ PAAD cis rs55665837 0.665 rs11023273 ENSG00000251991.1 RNU7-49P 4.4 2.01e-05 0.00948 0.39 0.34 Vitamin D levels; chr11:14609273 chr11:14478892~14478953:+ PAAD cis rs11723261 0.621 rs61794960 ENSG00000275426.1 CH17-262A2.1 4.4 2.01e-05 0.00948 0.54 0.34 Immune response to smallpox vaccine (IL-6); chr4:156661 chr4:149738~150317:+ PAAD cis rs2554380 0.55 rs62025822 ENSG00000230373.7 GOLGA6L5P 4.4 2.01e-05 0.00949 0.32 0.34 Height; chr15:83870162 chr15:84507885~84516814:- PAAD cis rs2554380 0.55 rs56159777 ENSG00000230373.7 GOLGA6L5P 4.4 2.01e-05 0.00949 0.32 0.34 Height; chr15:83870527 chr15:84507885~84516814:- PAAD cis rs2554380 0.55 rs4842919 ENSG00000230373.7 GOLGA6L5P 4.4 2.01e-05 0.00949 0.32 0.34 Height; chr15:83870668 chr15:84507885~84516814:- PAAD cis rs2554380 0.55 rs62025825 ENSG00000230373.7 GOLGA6L5P 4.4 2.01e-05 0.00949 0.32 0.34 Height; chr15:83872285 chr15:84507885~84516814:- PAAD cis rs7580658 0.521 rs2404535 ENSG00000236682.1 AC068282.3 4.4 2.01e-05 0.00949 0.42 0.34 Protein C levels; chr2:127190133 chr2:127389130~127400580:+ PAAD cis rs875971 0.666 rs13242072 ENSG00000237310.1 GS1-124K5.4 -4.4 2.01e-05 0.00949 -0.31 -0.34 Aortic root size; chr7:66301001 chr7:66493706~66495474:+ PAAD cis rs1707322 0.721 rs10890333 ENSG00000280836.1 AL355480.1 -4.4 2.02e-05 0.00949 -0.39 -0.34 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634650 chr1:45581219~45581321:- PAAD cis rs2562456 0.617 rs34203148 ENSG00000213976.4 CTD-2561J22.2 -4.4 2.02e-05 0.0095 -0.38 -0.34 Pain; chr19:21590743 chr19:21382865~21387177:+ PAAD cis rs8062405 0.69 rs7187604 ENSG00000251417.2 RP11-1348G14.4 -4.4 2.02e-05 0.0095 -0.32 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554632 chr16:28802743~28817828:+ PAAD cis rs79040073 0.679 rs78135084 ENSG00000259531.2 RP11-295H24.3 4.4 2.02e-05 0.0095 0.57 0.34 Lung cancer in ever smokers; chr15:49169895 chr15:49365124~49366685:- PAAD cis rs2262909 0.962 rs11669110 ENSG00000279377.1 AC003973.3 -4.4 2.02e-05 0.00951 -0.32 -0.34 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22113683 chr19:21965708~21968529:- PAAD cis rs8100891 0.537 rs10403370 ENSG00000267213.4 AC007773.2 -4.4 2.02e-05 0.00951 -0.55 -0.34 Neuroticism; chr19:32501949 chr19:32390050~32405560:- PAAD cis rs7829975 0.564 rs2921060 ENSG00000253981.4 ALG1L13P -4.4 2.02e-05 0.00951 -0.39 -0.34 Mood instability; chr8:8460307 chr8:8236003~8244667:- PAAD cis rs4835473 0.932 rs62337619 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143742083 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13152443 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143742492 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs9685306 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143748843 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13107719 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143752034 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs2323194 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143752879 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35055653 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143754836 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35017645 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143760196 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13129993 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143763076 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13117421 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143769405 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6826665 ENSG00000251600.4 RP11-673E1.1 -4.4 2.02e-05 0.00952 -0.39 -0.34 Immature fraction of reticulocytes; chr4:143795140 chr4:143912331~143982454:+ PAAD cis rs11673344 0.526 rs8101610 ENSG00000267422.1 CTD-2554C21.1 -4.4 2.02e-05 0.00953 -0.45 -0.34 Obesity-related traits; chr19:37566604 chr19:37779686~37792865:+ PAAD cis rs12554020 0.792 rs11975 ENSG00000227603.1 RP11-165J3.6 4.4 2.03e-05 0.00953 0.51 0.34 Schizophrenia; chr9:93565409 chr9:93435332~93437121:- PAAD cis rs12554020 0.892 rs7870210 ENSG00000227603.1 RP11-165J3.6 4.4 2.03e-05 0.00953 0.51 0.34 Schizophrenia; chr9:93569534 chr9:93435332~93437121:- PAAD cis rs12554020 0.892 rs7860098 ENSG00000227603.1 RP11-165J3.6 4.4 2.03e-05 0.00953 0.51 0.34 Schizophrenia; chr9:93569562 chr9:93435332~93437121:- PAAD cis rs919433 1 rs112572902 ENSG00000231621.1 AC013264.2 4.4 2.03e-05 0.00954 0.32 0.34 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197310455 chr2:197197991~197199273:+ PAAD cis rs919433 0.817 rs10931780 ENSG00000231621.1 AC013264.2 4.4 2.03e-05 0.00954 0.32 0.34 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197310573 chr2:197197991~197199273:+ PAAD cis rs4834770 0.792 rs7676969 ENSG00000245958.5 RP11-33B1.1 -4.4 2.03e-05 0.00956 -0.27 -0.34 Blood protein levels; chr4:119252569 chr4:119454791~119552025:+ PAAD cis rs4834770 0.685 rs4496567 ENSG00000245958.5 RP11-33B1.1 -4.4 2.03e-05 0.00956 -0.27 -0.34 Blood protein levels; chr4:119254470 chr4:119454791~119552025:+ PAAD cis rs4834770 0.792 rs6823331 ENSG00000245958.5 RP11-33B1.1 -4.4 2.03e-05 0.00956 -0.27 -0.34 Blood protein levels; chr4:119259635 chr4:119454791~119552025:+ PAAD cis rs11089937 0.651 rs2330015 ENSG00000211640.3 IGLV6-57 -4.4 2.03e-05 0.00956 -0.22 -0.34 Periodontitis (PAL4Q3); chr22:22182566 chr22:22195713~22196460:+ PAAD cis rs875971 0.929 rs4122249 ENSG00000237310.1 GS1-124K5.4 4.4 2.03e-05 0.00956 0.33 0.34 Aortic root size; chr7:66455949 chr7:66493706~66495474:+ PAAD cis rs7189233 0.531 rs3929 ENSG00000279344.1 RP11-44F14.7 -4.4 2.03e-05 0.00956 -0.25 -0.34 Intelligence (multi-trait analysis); chr16:53490396 chr16:53478957~53481550:- PAAD cis rs79349575 0.756 rs3848460 ENSG00000270781.1 RP11-501C14.9 4.4 2.04e-05 0.00958 0.38 0.34 Type 2 diabetes; chr17:48969752 chr17:48899131~48899748:+ PAAD cis rs1823913 0.637 rs2356354 ENSG00000280083.1 RP11-317J9.1 4.4 2.04e-05 0.00958 0.4 0.34 Obesity-related traits; chr2:191270970 chr2:191154118~191156070:- PAAD cis rs10461617 0.592 rs6450403 ENSG00000271828.1 CTD-2310F14.1 4.4 2.04e-05 0.00958 0.45 0.34 Type 2 diabetes; chr5:56766910 chr5:56927874~56929573:+ PAAD cis rs2985684 0.895 rs4900940 ENSG00000259113.1 RP11-406H23.2 -4.4 2.04e-05 0.00958 -0.47 -0.34 Carotid intima media thickness; chr14:49608592 chr14:50448807~50456742:+ PAAD cis rs2599510 0.783 rs2568464 ENSG00000276334.1 AL133243.1 -4.4 2.04e-05 0.00959 -0.4 -0.34 Interleukin-18 levels; chr2:32623591 chr2:32521927~32523547:+ PAAD cis rs7394190 0.935 rs12570126 ENSG00000272140.2 RP11-574K11.29 4.4 2.04e-05 0.0096 0.37 0.34 Incident atrial fibrillation; chr10:73657031 chr10:73703735~73713581:- PAAD cis rs10916248 0.511 rs10916515 ENSG00000232628.4 RP11-365O16.3 4.4 2.04e-05 0.0096 0.5 0.34 QT interval (drug interaction); chr1:224222121 chr1:224208747~224213279:- PAAD cis rs79040073 0.679 rs76231511 ENSG00000259531.2 RP11-295H24.3 4.4 2.04e-05 0.0096 0.57 0.34 Lung cancer in ever smokers; chr15:49222243 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs17396119 ENSG00000259531.2 RP11-295H24.3 4.4 2.04e-05 0.0096 0.57 0.34 Lung cancer in ever smokers; chr15:49242167 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73392277 ENSG00000259531.2 RP11-295H24.3 4.4 2.04e-05 0.0096 0.57 0.34 Lung cancer in ever smokers; chr15:49243772 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs79311354 ENSG00000259531.2 RP11-295H24.3 4.4 2.04e-05 0.0096 0.57 0.34 Lung cancer in ever smokers; chr15:49255987 chr15:49365124~49366685:- PAAD cis rs79040073 0.599 rs17396536 ENSG00000259531.2 RP11-295H24.3 4.4 2.04e-05 0.0096 0.57 0.34 Lung cancer in ever smokers; chr15:49256871 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs78881953 ENSG00000259531.2 RP11-295H24.3 4.4 2.04e-05 0.0096 0.57 0.34 Lung cancer in ever smokers; chr15:49269019 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11634636 ENSG00000259531.2 RP11-295H24.3 4.4 2.04e-05 0.0096 0.57 0.34 Lung cancer in ever smokers; chr15:49315407 chr15:49365124~49366685:- PAAD cis rs79040073 0.636 rs74339964 ENSG00000259531.2 RP11-295H24.3 4.4 2.04e-05 0.0096 0.57 0.34 Lung cancer in ever smokers; chr15:49329916 chr15:49365124~49366685:- PAAD cis rs9584850 0.834 rs7339274 ENSG00000231194.1 FARP1-AS1 -4.4 2.04e-05 0.0096 -0.42 -0.34 Neuroticism; chr13:98468018 chr13:98435405~98435840:- PAAD cis rs1153858 0.562 rs8025019 ENSG00000259520.4 CTD-2651B20.3 -4.4 2.04e-05 0.0096 -0.66 -0.34 Homoarginine levels; chr15:45443667 chr15:45251580~45279251:- PAAD cis rs34375054 0.573 rs12581367 ENSG00000279233.1 RP11-158L12.4 4.4 2.05e-05 0.00961 0.32 0.34 Post bronchodilator FEV1/FVC ratio; chr12:125170095 chr12:125138245~125141711:+ PAAD cis rs1823913 0.599 rs7598639 ENSG00000280083.1 RP11-317J9.1 -4.4 2.05e-05 0.00961 -0.39 -0.34 Obesity-related traits; chr2:191267958 chr2:191154118~191156070:- PAAD cis rs2404602 0.647 rs11072636 ENSG00000259422.1 RP11-593F23.1 -4.4 2.05e-05 0.00962 -0.41 -0.34 Blood metabolite levels; chr15:76893445 chr15:76174891~76181486:- PAAD cis rs4453827 0.955 rs11708934 ENSG00000271916.1 RP11-884K10.6 4.4 2.05e-05 0.00962 0.34 0.34 Blood protein levels; chr3:53736230 chr3:53797764~53798019:- PAAD cis rs62341639 0.525 rs4861610 ENSG00000270426.1 RP11-326I11.5 4.4 2.05e-05 0.00962 0.36 0.34 Acute kidney injury in critical illness; chr4:184217264 chr4:184471924~184472609:- PAAD cis rs6539288 0.677 rs1348566 ENSG00000260329.1 RP11-412D9.4 -4.4 2.05e-05 0.00965 -0.3 -0.34 Total body bone mineral density; chr12:106931870 chr12:106954029~106955497:- PAAD cis rs4423214 0.592 rs11233977 ENSG00000254682.1 RP11-660L16.2 -4.4 2.06e-05 0.00965 -0.54 -0.34 Vitamin D levels; chr11:71510559 chr11:71448674~71452157:+ PAAD cis rs79040073 0.637 rs113885253 ENSG00000259531.2 RP11-295H24.3 4.4 2.06e-05 0.00965 0.57 0.34 Lung cancer in ever smokers; chr15:49402615 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73398250 ENSG00000259531.2 RP11-295H24.3 4.4 2.06e-05 0.00965 0.57 0.34 Lung cancer in ever smokers; chr15:49404829 chr15:49365124~49366685:- PAAD cis rs12468226 0.808 rs73992849 ENSG00000273456.1 RP11-686O6.2 4.4 2.06e-05 0.00966 0.53 0.34 Urate levels; chr2:202152444 chr2:202374932~202375604:- PAAD cis rs1864400 0.605 rs12360493 ENSG00000273008.1 RP11-351D16.3 4.4 2.06e-05 0.00967 0.31 0.34 Hirschsprung disease; chr10:43223165 chr10:43136824~43138334:- PAAD cis rs2446066 0.872 rs34148420 ENSG00000257379.1 RP11-793H13.8 4.4 2.06e-05 0.00967 0.48 0.34 Red blood cell count; chr12:53405024 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs114075368 ENSG00000257379.1 RP11-793H13.8 4.4 2.06e-05 0.00967 0.48 0.34 Red blood cell count; chr12:53407960 chr12:53441741~53467528:+ PAAD cis rs9649213 0.574 rs7794187 ENSG00000272950.1 RP11-307C18.1 4.4 2.06e-05 0.00968 0.39 0.34 Prostate cancer (SNP x SNP interaction); chr7:98260446 chr7:98322853~98323430:+ PAAD cis rs6480314 0.636 rs61854792 ENSG00000233590.1 RP11-153K11.3 -4.4 2.06e-05 0.00968 -0.54 -0.34 Optic nerve measurement (disc area); chr10:68243902 chr10:68233251~68242379:- PAAD cis rs6480314 0.636 rs77760458 ENSG00000233590.1 RP11-153K11.3 -4.4 2.06e-05 0.00968 -0.54 -0.34 Optic nerve measurement (disc area); chr10:68244248 chr10:68233251~68242379:- PAAD cis rs6480314 0.636 rs61854797 ENSG00000233590.1 RP11-153K11.3 -4.4 2.06e-05 0.00968 -0.54 -0.34 Optic nerve measurement (disc area); chr10:68245854 chr10:68233251~68242379:- PAAD cis rs7572733 0.515 rs6726506 ENSG00000231621.1 AC013264.2 -4.4 2.07e-05 0.00968 -0.35 -0.34 Dermatomyositis; chr2:197981762 chr2:197197991~197199273:+ PAAD cis rs7169304 0.559 rs117818498 ENSG00000259531.2 RP11-295H24.3 4.4 2.07e-05 0.00969 0.58 0.34 Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma; chr15:49436685 chr15:49365124~49366685:- PAAD cis rs77204473 0.557 rs9971422 ENSG00000254851.1 RP11-109L13.1 4.39 2.07e-05 0.0097 0.71 0.34 Sum eosinophil basophil counts;Eosinophil counts; chr11:116966657 chr11:117135528~117138582:+ PAAD cis rs8072100 0.84 rs2136751 ENSG00000228782.6 CTD-2026D20.3 4.39 2.07e-05 0.00971 0.35 0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47378727 chr17:47450568~47492492:- PAAD cis rs8072100 0.84 rs9895746 ENSG00000228782.6 CTD-2026D20.3 4.39 2.07e-05 0.00971 0.35 0.34 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47401733 chr17:47450568~47492492:- PAAD cis rs11690935 0.589 rs62183782 ENSG00000228389.1 AC068039.4 -4.39 2.07e-05 0.00971 -0.43 -0.34 Schizophrenia; chr2:172000102 chr2:171773482~171775844:+ PAAD cis rs853679 0.517 rs1340004 ENSG00000204709.4 LINC01556 4.39 2.07e-05 0.00971 0.57 0.34 Depression; chr6:28135913 chr6:28943877~28944537:+ PAAD cis rs8031584 0.781 rs4779498 ENSG00000260382.1 RP11-540B6.2 4.39 2.07e-05 0.00972 0.42 0.34 Huntington's disease progression; chr15:30885273 chr15:30882267~30883231:- PAAD cis rs4835473 0.897 rs28701142 ENSG00000251600.4 RP11-673E1.1 4.39 2.08e-05 0.00972 0.39 0.34 Immature fraction of reticulocytes; chr4:143945730 chr4:143912331~143982454:+ PAAD cis rs2858942 0.527 rs7185345 ENSG00000268836.1 LA16c-OS12.2 4.39 2.08e-05 0.00973 0.31 0.34 Mean corpuscular hemoglobin; chr16:192771 chr16:185748~186294:- PAAD cis rs4950322 0.57 rs4950315 ENSG00000278811.3 LINC00624 -4.39 2.08e-05 0.00973 -0.36 -0.34 Protein quantitative trait loci; chr1:147264433 chr1:147258885~147517875:- PAAD cis rs7078219 0.505 rs10883372 ENSG00000228778.1 RP11-129J12.1 -4.39 2.08e-05 0.00973 -0.37 -0.34 Dental caries; chr10:99532726 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs10883373 ENSG00000228778.1 RP11-129J12.1 -4.39 2.08e-05 0.00973 -0.37 -0.34 Dental caries; chr10:99532727 chr10:99527081~99528261:+ PAAD cis rs7712401 0.601 rs2126935 ENSG00000263432.2 RN7SL689P -4.39 2.08e-05 0.00973 -0.43 -0.34 Mean platelet volume; chr5:122977876 chr5:123022487~123022783:- PAAD cis rs2980439 0.818 rs2945249 ENSG00000253981.4 ALG1L13P 4.39 2.08e-05 0.00973 0.42 0.34 Neuroticism; chr8:8237204 chr8:8236003~8244667:- PAAD cis rs11134654 0.627 rs4868033 ENSG00000253966.1 CTC-455F18.3 -4.39 2.08e-05 0.00974 -0.53 -0.34 Smooth-surface caries; chr5:170807260 chr5:170896929~170904461:+ PAAD cis rs11690935 0.55 rs55653103 ENSG00000228389.1 AC068039.4 -4.39 2.08e-05 0.00974 -0.43 -0.34 Schizophrenia; chr2:171996909 chr2:171773482~171775844:+ PAAD cis rs4423214 0.559 rs10898203 ENSG00000254682.1 RP11-660L16.2 -4.39 2.08e-05 0.00974 -0.55 -0.34 Vitamin D levels; chr11:71492390 chr11:71448674~71452157:+ PAAD cis rs113835537 0.877 rs77239910 ENSG00000255517.5 CTD-3074O7.5 -4.39 2.08e-05 0.00974 -0.56 -0.34 Airway imaging phenotypes; chr11:66562168 chr11:66473490~66480233:- PAAD cis rs2505998 0.833 rs2505536 ENSG00000273008.1 RP11-351D16.3 4.39 2.08e-05 0.00975 0.29 0.34 Hirschsprung disease; chr10:43096756 chr10:43136824~43138334:- PAAD cis rs1729407 0.706 rs1268354 ENSG00000254851.1 RP11-109L13.1 -4.39 2.09e-05 0.00977 -0.4 -0.34 Apolipoprotein A-IV levels; chr11:116819862 chr11:117135528~117138582:+ PAAD cis rs710913 0.745 rs67563067 ENSG00000243970.1 PPIEL -4.39 2.09e-05 0.00978 -0.29 -0.34 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39581323 chr1:39531838~39558707:- PAAD cis rs2505998 0.833 rs2742243 ENSG00000273008.1 RP11-351D16.3 -4.39 2.09e-05 0.00978 -0.29 -0.34 Hirschsprung disease; chr10:43106301 chr10:43136824~43138334:- PAAD cis rs2505998 0.833 rs2742244 ENSG00000273008.1 RP11-351D16.3 -4.39 2.09e-05 0.00978 -0.29 -0.34 Hirschsprung disease; chr10:43108144 chr10:43136824~43138334:- PAAD cis rs2505998 0.833 rs1864405 ENSG00000273008.1 RP11-351D16.3 -4.39 2.09e-05 0.00978 -0.29 -0.34 Hirschsprung disease; chr10:43108700 chr10:43136824~43138334:- PAAD cis rs3781264 0.724 rs12780491 ENSG00000273450.1 RP11-76P2.4 4.39 2.09e-05 0.00979 0.45 0.34 Esophageal cancer and gastric cancer; chr10:94361265 chr10:94314907~94315327:- PAAD cis rs6479891 1 rs12412012 ENSG00000232075.1 MRPL35P2 4.39 2.09e-05 0.00979 0.52 0.34 Arthritis (juvenile idiopathic); chr10:63556003 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs61579729 ENSG00000232075.1 MRPL35P2 4.39 2.09e-05 0.00979 0.52 0.34 Arthritis (juvenile idiopathic); chr10:63559553 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12411988 ENSG00000232075.1 MRPL35P2 -4.39 2.09e-05 0.00979 -0.52 -0.34 Arthritis (juvenile idiopathic); chr10:63555637 chr10:63634317~63634827:- PAAD cis rs748404 0.631 rs6493083 ENSG00000249839.1 AC011330.5 -4.39 2.09e-05 0.00979 -0.47 -0.34 Lung cancer; chr15:43345787 chr15:43663654~43684339:- PAAD cis rs7712401 0.601 rs35479600 ENSG00000263432.2 RN7SL689P -4.39 2.1e-05 0.0098 -0.44 -0.34 Mean platelet volume; chr5:122988775 chr5:123022487~123022783:- PAAD cis rs42490 0.664 rs43227 ENSG00000251136.7 RP11-37B2.1 -4.39 2.1e-05 0.0098 -0.3 -0.34 Leprosy; chr8:89809351 chr8:89609409~89757727:- PAAD cis rs42490 0.638 rs28144 ENSG00000251136.7 RP11-37B2.1 -4.39 2.1e-05 0.0098 -0.3 -0.34 Leprosy; chr8:89810531 chr8:89609409~89757727:- PAAD cis rs42490 0.638 rs40637 ENSG00000251136.7 RP11-37B2.1 -4.39 2.1e-05 0.0098 -0.3 -0.34 Leprosy; chr8:89811082 chr8:89609409~89757727:- PAAD cis rs42490 0.664 rs394108 ENSG00000251136.7 RP11-37B2.1 -4.39 2.1e-05 0.0098 -0.3 -0.34 Leprosy; chr8:89812991 chr8:89609409~89757727:- PAAD cis rs270601 0.69 rs162904 ENSG00000233006.5 AC034220.3 -4.39 2.1e-05 0.00981 -0.28 -0.34 Acylcarnitine levels; chr5:132260091 chr5:132311285~132369916:- PAAD cis rs4835473 0.708 rs7655939 ENSG00000251600.4 RP11-673E1.1 4.39 2.1e-05 0.00981 0.39 0.34 Immature fraction of reticulocytes; chr4:143956889 chr4:143912331~143982454:+ PAAD cis rs7665090 0.87 rs228625 ENSG00000246560.2 RP11-10L12.4 -4.39 2.1e-05 0.00981 -0.38 -0.34 Primary biliary cholangitis; chr4:102651594 chr4:102828055~102844075:+ PAAD cis rs10740039 0.583 rs9415611 ENSG00000254271.1 RP11-131N11.4 -4.39 2.1e-05 0.00981 -0.4 -0.34 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60743440 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs9415612 ENSG00000254271.1 RP11-131N11.4 -4.39 2.1e-05 0.00981 -0.4 -0.34 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60746638 chr10:60734342~60741828:+ PAAD cis rs9926296 0.581 rs12598477 ENSG00000260259.1 RP11-368I7.4 -4.39 2.1e-05 0.00982 -0.42 -0.34 Vitiligo; chr16:89836074 chr16:89682620~89686569:- PAAD cis rs8062405 0.723 rs762633 ENSG00000251417.2 RP11-1348G14.4 -4.39 2.1e-05 0.00982 -0.32 -0.34 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597020 chr16:28802743~28817828:+ PAAD cis rs12554020 0.786 rs60076242 ENSG00000227603.1 RP11-165J3.6 4.39 2.1e-05 0.00983 0.51 0.34 Schizophrenia; chr9:93571634 chr9:93435332~93437121:- PAAD cis rs3823536 0.583 rs10279821 ENSG00000275106.1 RP11-309L24.10 -4.39 2.1e-05 0.00983 -0.45 -0.34 Sjögren's syndrome; chr7:129043493 chr7:128952527~128953316:- PAAD cis rs8059260 0.668 rs7199305 ENSG00000274038.1 RP11-66H6.4 4.39 2.1e-05 0.00984 0.56 0.34 Alcohol consumption over the past year; chr16:11006476 chr16:11056556~11057034:+ PAAD cis rs871012 0.524 rs11952499 ENSG00000248544.2 CTB-47B11.3 -4.39 2.11e-05 0.00984 -0.43 -0.34 IgG glycosylation; chr5:157455626 chr5:157375741~157384950:- PAAD cis rs700651 0.789 rs1976772 ENSG00000231621.1 AC013264.2 -4.39 2.11e-05 0.00984 -0.34 -0.34 Intracranial aneurysm; chr2:198003477 chr2:197197991~197199273:+ PAAD cis rs700651 0.757 rs6748683 ENSG00000231621.1 AC013264.2 -4.39 2.11e-05 0.00984 -0.34 -0.34 Intracranial aneurysm; chr2:198013284 chr2:197197991~197199273:+ PAAD cis rs700651 0.789 rs62277902 ENSG00000231621.1 AC013264.2 4.39 2.11e-05 0.00984 0.34 0.34 Intracranial aneurysm; chr2:198014719 chr2:197197991~197199273:+ PAAD cis rs2911132 1 rs2549803 ENSG00000248734.2 CTD-2260A17.1 4.39 2.11e-05 0.00985 0.32 0.34 Urate levels (BMI interaction); chr5:96839226 chr5:96784777~96785999:+ PAAD cis rs10740039 0.583 rs9415608 ENSG00000254271.1 RP11-131N11.4 -4.39 2.11e-05 0.00985 -0.4 -0.34 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60737680 chr10:60734342~60741828:+ PAAD cis rs73186030 0.546 rs67931976 ENSG00000272758.4 RP11-299J3.8 4.39 2.11e-05 0.00985 0.46 0.34 Serum parathyroid hormone levels; chr3:122386868 chr3:122416207~122443180:+ PAAD cis rs8023057 0.755 rs8014793 ENSG00000252481.1 SCARNA13 4.39 2.11e-05 0.00986 0.41 0.34 Prostate-specific antigen levels; chr14:94647595 chr14:95533355~95533629:- PAAD cis rs797680 0.964 rs4000699 ENSG00000223745.6 RP4-717I23.3 4.39 2.11e-05 0.00986 0.26 0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93314248 chr1:93262186~93346025:- PAAD cis rs7078219 0.505 rs10883365 ENSG00000228778.1 RP11-129J12.1 -4.39 2.11e-05 0.00986 -0.36 -0.34 Dental caries; chr10:99528007 chr10:99527081~99528261:+ PAAD cis rs7646881 0.812 rs61696028 ENSG00000240207.5 RP11-379F4.4 -4.39 2.11e-05 0.00986 -0.52 -0.34 Tetralogy of Fallot; chr3:158737914 chr3:158732263~158784070:+ PAAD cis rs12908161 1 rs35630683 ENSG00000259728.4 LINC00933 4.39 2.11e-05 0.00987 0.43 0.34 Schizophrenia; chr15:84806000 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs56864281 ENSG00000259728.4 LINC00933 4.39 2.11e-05 0.00987 0.43 0.34 Schizophrenia; chr15:84814418 chr15:84570649~84580175:+ PAAD cis rs9584850 0.834 rs3783005 ENSG00000231194.1 FARP1-AS1 -4.39 2.11e-05 0.00987 -0.43 -0.34 Neuroticism; chr13:98459083 chr13:98435405~98435840:- PAAD cis rs2281636 1 rs10883409 ENSG00000233690.1 EBAG9P1 4.39 2.12e-05 0.00988 0.35 0.34 Obesity-related traits; chr10:99758108 chr10:99697407~99697949:- PAAD cis rs1075265 0.756 rs2160931 ENSG00000233266.1 HMGB1P31 4.39 2.12e-05 0.00989 0.43 0.34 Chronotype;Morning vs. evening chronotype; chr2:53712411 chr2:54051334~54051760:+ PAAD cis rs2658782 1 rs2658778 ENSG00000279684.1 RP11-755E23.2 -4.39 2.12e-05 0.00989 -0.57 -0.34 Pulmonary function decline; chr11:93415782 chr11:93286629~93288903:- PAAD cis rs28386778 0.897 rs2727327 ENSG00000240280.5 TCAM1P -4.39 2.12e-05 0.0099 -0.47 -0.34 Prudent dietary pattern; chr17:63846062 chr17:63849292~63864379:+ PAAD cis rs28386778 0.831 rs2584618 ENSG00000240280.5 TCAM1P -4.39 2.12e-05 0.0099 -0.47 -0.34 Prudent dietary pattern; chr17:63846251 chr17:63849292~63864379:+ PAAD cis rs889398 0.934 rs12923231 ENSG00000226232.7 RP11-419C5.2 4.39 2.12e-05 0.0099 0.28 0.34 Body mass index; chr16:69538989 chr16:69976388~69996188:- PAAD cis rs4813802 1 rs4813802 ENSG00000278192.1 RP5-1056H1.2 -4.39 2.12e-05 0.0099 -0.35 -0.34 Colorectal cancer; chr20:6718948 chr20:6065966~6067897:- PAAD cis rs853679 0.517 rs17711344 ENSG00000280107.1 AL022393.9 4.39 2.12e-05 0.00991 0.56 0.34 Depression; chr6:28109824 chr6:28170845~28172521:+ PAAD cis rs60733400 0.782 rs4648564 ENSG00000225931.3 RP3-395M20.7 -4.39 2.12e-05 0.00991 -0.32 -0.34 Multiple sclerosis; chr1:2630730 chr1:2566410~2569888:+ PAAD cis rs494459 0.536 rs57719838 ENSG00000255422.1 AP002954.4 -4.39 2.12e-05 0.00991 -0.37 -0.34 Height; chr11:118854014 chr11:118704607~118750263:+ PAAD cis rs494459 0.536 rs11217063 ENSG00000255422.1 AP002954.4 -4.39 2.12e-05 0.00991 -0.37 -0.34 Height; chr11:118855233 chr11:118704607~118750263:+ PAAD cis rs494459 0.536 rs11217065 ENSG00000255422.1 AP002954.4 -4.39 2.12e-05 0.00991 -0.37 -0.34 Height; chr11:118855938 chr11:118704607~118750263:+ PAAD cis rs494459 0.504 rs7929520 ENSG00000255422.1 AP002954.4 -4.39 2.12e-05 0.00991 -0.37 -0.34 Height; chr11:118859432 chr11:118704607~118750263:+ PAAD cis rs494459 0.536 rs34561290 ENSG00000255422.1 AP002954.4 -4.39 2.12e-05 0.00991 -0.37 -0.34 Height; chr11:118860890 chr11:118704607~118750263:+ PAAD cis rs494459 0.536 rs11217072 ENSG00000255422.1 AP002954.4 -4.39 2.12e-05 0.00991 -0.37 -0.34 Height; chr11:118861053 chr11:118704607~118750263:+ PAAD cis rs875971 0.66 rs3764903 ENSG00000237310.1 GS1-124K5.4 -4.39 2.13e-05 0.00992 -0.31 -0.34 Aortic root size; chr7:66633495 chr7:66493706~66495474:+ PAAD cis rs875971 0.66 rs1860470 ENSG00000237310.1 GS1-124K5.4 -4.39 2.13e-05 0.00992 -0.31 -0.34 Aortic root size; chr7:66638707 chr7:66493706~66495474:+ PAAD cis rs35797862 1 rs35797862 ENSG00000223745.6 RP4-717I23.3 -4.39 2.13e-05 0.00992 -0.26 -0.34 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts; chr1:93272958 chr1:93262186~93346025:- PAAD cis rs797680 0.894 rs7418101 ENSG00000223745.6 RP4-717I23.3 -4.39 2.13e-05 0.00992 -0.26 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93290635 chr1:93262186~93346025:- PAAD cis rs720064 0.555 rs11873358 ENSG00000264745.1 TTC39C-AS1 4.39 2.13e-05 0.00993 0.42 0.34 Strep throat; chr18:23951942 chr18:23994213~24015339:- PAAD cis rs10461617 0.535 rs7709874 ENSG00000271828.1 CTD-2310F14.1 4.39 2.13e-05 0.00993 0.46 0.34 Type 2 diabetes; chr5:56751624 chr5:56927874~56929573:+ PAAD cis rs10461617 0.512 rs7715746 ENSG00000271828.1 CTD-2310F14.1 4.39 2.13e-05 0.00993 0.46 0.34 Type 2 diabetes; chr5:56753010 chr5:56927874~56929573:+ PAAD cis rs734999 0.505 rs4648659 ENSG00000225931.3 RP3-395M20.7 -4.39 2.13e-05 0.00993 -0.32 -0.34 Ulcerative colitis; chr1:2629464 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs28532547 ENSG00000225931.3 RP3-395M20.7 -4.39 2.13e-05 0.00993 -0.32 -0.34 Ulcerative colitis; chr1:2629847 chr1:2566410~2569888:+ PAAD cis rs734999 0.545 rs6666788 ENSG00000225931.3 RP3-395M20.7 -4.39 2.13e-05 0.00993 -0.32 -0.34 Ulcerative colitis; chr1:2636061 chr1:2566410~2569888:+ PAAD cis rs7829975 0.511 rs2948286 ENSG00000253981.4 ALG1L13P 4.39 2.13e-05 0.00993 0.42 0.34 Mood instability; chr8:8272638 chr8:8236003~8244667:- PAAD cis rs79349575 0.721 rs4794004 ENSG00000270781.1 RP11-501C14.9 -4.39 2.13e-05 0.00993 -0.38 -0.34 Type 2 diabetes; chr17:48961109 chr17:48899131~48899748:+ PAAD cis rs797680 0.861 rs612037 ENSG00000223745.6 RP4-717I23.3 -4.39 2.13e-05 0.00994 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93217321 chr1:93262186~93346025:- PAAD cis rs797680 0.964 rs624131 ENSG00000223745.6 RP4-717I23.3 -4.39 2.13e-05 0.00994 -0.27 -0.34 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93217653 chr1:93262186~93346025:- PAAD cis rs60733400 0.817 rs4648657 ENSG00000225931.3 RP3-395M20.7 -4.39 2.13e-05 0.00994 -0.32 -0.34 Multiple sclerosis; chr1:2629296 chr1:2566410~2569888:+ PAAD cis rs6860540 0.687 rs6871720 ENSG00000248544.2 CTB-47B11.3 -4.39 2.13e-05 0.00994 -0.44 -0.34 Inflammatory skin disease; chr5:157447457 chr5:157375741~157384950:- PAAD cis rs950880 0.71 rs12905 ENSG00000234389.1 AC007278.3 -4.39 2.14e-05 0.00996 -0.34 -0.34 Serum protein levels (sST2); chr2:102343547 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs3821204 ENSG00000234389.1 AC007278.3 -4.39 2.14e-05 0.00996 -0.34 -0.34 Serum protein levels (sST2); chr2:102343821 chr2:102438713~102440475:+ PAAD cis rs964611 0.882 rs12909148 ENSG00000259488.2 RP11-154J22.1 4.39 2.14e-05 0.00997 0.37 0.34 Metabolite levels (Pyroglutamine); chr15:48356800 chr15:48312353~48331856:- PAAD cis rs62103177 0.564 rs55867755 ENSG00000261126.6 RP11-795F19.1 4.39 2.14e-05 0.00997 0.47 0.34 Opioid sensitivity; chr18:79963434 chr18:80046900~80095482:+ PAAD cis rs62103177 0.564 rs59188178 ENSG00000261126.6 RP11-795F19.1 4.39 2.14e-05 0.00997 0.47 0.34 Opioid sensitivity; chr18:79963435 chr18:80046900~80095482:+ PAAD cis rs12554020 0.786 rs10429558 ENSG00000227603.1 RP11-165J3.6 4.39 2.14e-05 0.00997 0.51 0.34 Schizophrenia; chr9:93574508 chr9:93435332~93437121:- PAAD cis rs6479901 0.557 rs1009984 ENSG00000232075.1 MRPL35P2 -4.39 2.14e-05 0.00997 -0.52 -0.34 Intelligence (multi-trait analysis); chr10:63156709 chr10:63634317~63634827:- PAAD cis rs7572733 0.515 rs11891555 ENSG00000231621.1 AC013264.2 -4.39 2.14e-05 0.00997 -0.34 -0.34 Dermatomyositis; chr2:197988816 chr2:197197991~197199273:+ PAAD cis rs3096299 0.874 rs3102342 ENSG00000274627.1 RP11-104N10.2 4.39 2.14e-05 0.00997 0.3 0.34 Multiple myeloma (IgH translocation); chr16:89385167 chr16:89516797~89522217:+ PAAD cis rs3096299 0.933 rs28608022 ENSG00000274627.1 RP11-104N10.2 4.39 2.14e-05 0.00997 0.3 0.34 Multiple myeloma (IgH translocation); chr16:89387884 chr16:89516797~89522217:+ PAAD cis rs3096299 0.933 rs2965823 ENSG00000274627.1 RP11-104N10.2 4.39 2.14e-05 0.00997 0.3 0.34 Multiple myeloma (IgH translocation); chr16:89388516 chr16:89516797~89522217:+ PAAD cis rs2262909 0.889 rs61268244 ENSG00000279377.1 AC003973.3 -4.39 2.14e-05 0.00998 -0.32 -0.34 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22127328 chr19:21965708~21968529:- PAAD cis rs7189233 0.55 rs17193176 ENSG00000279344.1 RP11-44F14.7 4.39 2.14e-05 0.00998 0.25 0.34 Intelligence (multi-trait analysis); chr16:53484316 chr16:53478957~53481550:- PAAD cis rs9309711 0.922 rs11679058 ENSG00000225234.1 TRAPPC12-AS1 -4.39 2.14e-05 0.00999 -0.37 -0.34 Neurofibrillary tangles; chr2:3480042 chr2:3481242~3482409:- PAAD cis rs17214007 0.735 rs8045778 ENSG00000263335.1 AF001548.5 4.39 2.14e-05 0.00999 0.46 0.34 Cognitive function; chr16:15784395 chr16:15726674~15732993:+ PAAD cis rs4761702 1 rs4761701 ENSG00000258171.1 RP11-511B23.3 -4.39 2.14e-05 0.00999 -0.42 -0.34 Immature fraction of reticulocytes; chr12:93315956 chr12:93174366~93181832:+ PAAD cis rs12429206 0.547 rs75419800 ENSG00000233672.5 RNASEH2B-AS1 -4.39 2.15e-05 0.00999 -0.43 -0.34 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50898897 chr13:50862172~50910764:- PAAD cis rs12429206 0.52 rs75594262 ENSG00000233672.5 RNASEH2B-AS1 -4.39 2.15e-05 0.00999 -0.43 -0.34 Prostate-specific antigen levels (conditioned on lead SNPs); chr13:50900249 chr13:50862172~50910764:- PAAD cis rs9322193 0.607 rs6925151 ENSG00000268592.3 RAET1E-AS1 4.39 2.15e-05 0.00999 0.45 0.34 Lung cancer; chr6:149889587 chr6:149863494~149919507:+ PAAD cis rs1823913 0.599 rs13427761 ENSG00000280083.1 RP11-317J9.1 4.39 2.15e-05 0.00999 0.39 0.34 Obesity-related traits; chr2:191269256 chr2:191154118~191156070:- PAAD cis rs1167827 0.68 rs1167796 ENSG00000278416.1 PMS2L2 -4.39 2.15e-05 0.00999 -0.39 -0.34 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75543861 chr7:75344015~75359550:- PAAD cis rs3020264 0.962 rs1974946 ENSG00000271743.1 CTD-2541M15.3 -4.39 2.15e-05 0.00999 -0.51 -0.34 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6631266 chr8:6615604~6617198:- PAAD cis rs7829975 0.539 rs71537846 ENSG00000253893.2 FAM85B 4.39 2.15e-05 0.01 0.48 0.34 Mood instability; chr8:8684610 chr8:8167819~8226614:- PAAD cis rs7829975 0.511 rs1543238 ENSG00000253981.4 ALG1L13P 4.39 2.15e-05 0.01 0.42 0.34 Mood instability; chr8:8277287 chr8:8236003~8244667:- PAAD cis rs7829975 0.511 rs1401390 ENSG00000253981.4 ALG1L13P 4.39 2.15e-05 0.01 0.42 0.34 Mood instability; chr8:8278888 chr8:8236003~8244667:- PAAD cis rs4683346 0.616 rs4683332 ENSG00000173811.9 CCDC13-AS1 -4.39 2.15e-05 0.01 -0.37 -0.34 Granulocyte percentage of myeloid white cells; chr3:42785945 chr3:42732575~42746768:+ PAAD cis rs11654699 0.84 rs8067122 ENSG00000274341.1 RP11-227G15.10 4.39 2.15e-05 0.01 0.31 0.34 Neurofibrillary tangles; chr17:32592530 chr17:32408013~32408309:+ PAAD cis rs4218 0.681 rs10518996 ENSG00000277144.1 RP11-59H7.4 -4.39 2.15e-05 0.01 -0.45 -0.34 Social communication problems; chr15:59085247 chr15:59115547~59116089:- PAAD cis rs4218 0.638 rs12437587 ENSG00000277144.1 RP11-59H7.4 -4.39 2.15e-05 0.01 -0.45 -0.34 Social communication problems; chr15:59072785 chr15:59115547~59116089:- PAAD cis rs321358 1 rs321353 ENSG00000271390.1 RP11-89C3.3 -4.39 2.15e-05 0.01 -0.51 -0.34 Body mass index; chr11:111123841 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321368 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111129033 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321369 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111129797 chr11:111089870~111090368:- PAAD cis rs321358 1 rs321370 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111129959 chr11:111089870~111090368:- PAAD cis rs321358 1 rs73019214 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111131680 chr11:111089870~111090368:- PAAD cis rs321358 1 rs419633 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111132187 chr11:111089870~111090368:- PAAD cis rs321358 1 rs429803 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111132263 chr11:111089870~111090368:- PAAD cis rs321358 0.943 rs402820 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111132480 chr11:111089870~111090368:- PAAD cis rs321358 0.943 rs17537987 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111134144 chr11:111089870~111090368:- PAAD cis rs321358 1 rs73019218 ENSG00000271390.1 RP11-89C3.3 4.39 2.15e-05 0.01 0.51 0.34 Body mass index; chr11:111134521 chr11:111089870~111090368:- PAAD cis rs7923609 0.967 rs7912893 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63402240 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs7896783 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63402393 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs10761762 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63424957 chr10:63634317~63634827:- PAAD cis rs7923609 0.934 rs10761763 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63428558 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs10761766 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63430567 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs3740331 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63432528 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs3956912 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63446121 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs10509186 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63447258 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs7085621 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63449166 chr10:63634317~63634827:- PAAD cis rs7923609 0.936 rs10740125 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63449849 chr10:63634317~63634827:- PAAD cis rs7923609 0.967 rs10740126 ENSG00000232075.1 MRPL35P2 -4.38 2.16e-05 0.01 -0.41 -0.34 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63451175 chr10:63634317~63634827:- PAAD cis rs1832886 1 rs1832886 ENSG00000236493.2 EIF2S2P3 4.38 2.16e-05 0.01 0.43 0.34 Body mass index; chr10:92717782 chr10:92668745~92669743:- PAAD cis rs2562456 0.917 rs2562466 ENSG00000213976.4 CTD-2561J22.2 4.38 2.16e-05 0.01 0.37 0.34 Pain; chr19:21531402 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs2562468 ENSG00000213976.4 CTD-2561J22.2 4.38 2.16e-05 0.01 0.37 0.34 Pain; chr19:21532048 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs2562471 ENSG00000213976.4 CTD-2561J22.2 4.38 2.16e-05 0.01 0.37 0.34 Pain; chr19:21533017 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs2681377 ENSG00000213976.4 CTD-2561J22.2 4.38 2.16e-05 0.01 0.37 0.34 Pain; chr19:21533718 chr19:21382865~21387177:+ PAAD cis rs4835473 0.932 rs10025527 ENSG00000251600.4 RP11-673E1.1 4.38 2.16e-05 0.01 0.39 0.34 Immature fraction of reticulocytes; chr4:143968391 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs3872 ENSG00000251600.4 RP11-673E1.1 4.38 2.16e-05 0.01 0.39 0.34 Immature fraction of reticulocytes; chr4:143968788 chr4:143912331~143982454:+ PAAD cis rs12908161 1 rs11637142 ENSG00000259728.4 LINC00933 4.38 2.16e-05 0.01 0.43 0.34 Schizophrenia; chr15:84752696 chr15:84570649~84580175:+ PAAD cis rs7219451 0.655 rs4527073 ENSG00000222881.1 Y_RNA -4.38 2.16e-05 0.01 -0.42 -0.34 Glucose homeostasis traits; chr17:40798651 chr17:40391232~40391338:- PAAD cis rs6570726 0.902 rs396681 ENSG00000235652.6 RP11-545I5.3 4.38 2.16e-05 0.01 0.28 0.34 Lobe attachment (rater-scored or self-reported); chr6:145532467 chr6:145799409~145886585:+ PAAD cis rs193541 0.593 rs1035372 ENSG00000263432.2 RN7SL689P 4.38 2.16e-05 0.0101 0.43 0.34 Glucose homeostasis traits; chr5:122833753 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs7735618 ENSG00000263432.2 RN7SL689P 4.38 2.16e-05 0.0101 0.43 0.34 Glucose homeostasis traits; chr5:122840550 chr5:123022487~123022783:- PAAD cis rs7911264 0.967 rs2497318 ENSG00000236493.2 EIF2S2P3 -4.38 2.17e-05 0.0101 -0.43 -0.34 Inflammatory bowel disease; chr10:92672243 chr10:92668745~92669743:- PAAD cis rs3738443 0.678 rs57861883 ENSG00000259865.1 RP11-488L18.10 4.38 2.17e-05 0.0101 0.29 0.34 Alcohol dependence; chr1:247214089 chr1:247187281~247188526:- PAAD cis rs17711722 0.653 rs2460421 ENSG00000236529.1 RP13-254B10.1 -4.38 2.17e-05 0.0101 -0.37 -0.34 Calcium levels; chr7:66026136 chr7:65840212~65840596:+ PAAD cis rs28386778 0.897 rs2665795 ENSG00000240280.5 TCAM1P 4.38 2.17e-05 0.0101 0.46 0.34 Prudent dietary pattern; chr17:63847912 chr17:63849292~63864379:+ PAAD cis rs9652601 0.959 rs741172 ENSG00000274038.1 RP11-66H6.4 -4.38 2.17e-05 0.0101 -0.38 -0.34 Systemic lupus erythematosus; chr16:11106941 chr16:11056556~11057034:+ PAAD cis rs2554380 0.55 rs12904106 ENSG00000230373.7 GOLGA6L5P -4.38 2.17e-05 0.0101 -0.33 -0.34 Height; chr15:83842571 chr15:84507885~84516814:- PAAD cis rs2554380 0.55 rs11853949 ENSG00000230373.7 GOLGA6L5P -4.38 2.17e-05 0.0101 -0.33 -0.34 Height; chr15:83848152 chr15:84507885~84516814:- PAAD cis rs2554380 0.55 rs6602997 ENSG00000230373.7 GOLGA6L5P -4.38 2.17e-05 0.0101 -0.33 -0.34 Height; chr15:83852646 chr15:84507885~84516814:- PAAD cis rs2348418 0.733 rs2169754 ENSG00000247934.4 RP11-967K21.1 -4.38 2.17e-05 0.0101 -0.34 -0.33 Lung function (FEV1);Lung function (FVC); chr12:28187712 chr12:28163298~28190738:- PAAD cis rs11673344 0.536 rs62108291 ENSG00000267422.1 CTD-2554C21.1 4.38 2.17e-05 0.0101 0.44 0.33 Obesity-related traits; chr19:37659457 chr19:37779686~37792865:+ PAAD cis rs4761702 1 rs4761702 ENSG00000258171.1 RP11-511B23.3 -4.38 2.17e-05 0.0101 -0.42 -0.33 Immature fraction of reticulocytes; chr12:93316116 chr12:93174366~93181832:+ PAAD cis rs875971 0.964 rs60193905 ENSG00000237310.1 GS1-124K5.4 4.38 2.17e-05 0.0101 0.32 0.33 Aortic root size; chr7:66506273 chr7:66493706~66495474:+ PAAD cis rs9652601 0.959 rs2058531 ENSG00000274038.1 RP11-66H6.4 -4.38 2.17e-05 0.0101 -0.38 -0.33 Systemic lupus erythematosus; chr16:11078252 chr16:11056556~11057034:+ PAAD cis rs889398 0.9 rs62052815 ENSG00000226232.7 RP11-419C5.2 4.38 2.18e-05 0.0101 0.28 0.33 Body mass index; chr16:69527923 chr16:69976388~69996188:- PAAD cis rs17772222 0.958 rs59136503 ENSG00000258983.2 RP11-507K2.2 4.38 2.18e-05 0.0101 0.46 0.33 Coronary artery calcification; chr14:88501921 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs1816372 ENSG00000258983.2 RP11-507K2.2 4.38 2.18e-05 0.0101 0.46 0.33 Coronary artery calcification; chr14:88507033 chr14:88499334~88515502:+ PAAD cis rs1665050 0.842 rs1665049 ENSG00000277144.1 RP11-59H7.4 4.38 2.18e-05 0.0101 0.41 0.33 Atopic dermatitis; chr15:58998453 chr15:59115547~59116089:- PAAD cis rs2243480 1 rs35735127 ENSG00000228409.4 CCT6P1 4.38 2.18e-05 0.0101 0.36 0.33 Diabetic kidney disease; chr7:65835436 chr7:65751142~65763354:+ PAAD cis rs9368481 0.761 rs3931464 ENSG00000241549.7 GUSBP2 4.38 2.18e-05 0.0101 0.35 0.33 Autism spectrum disorder or schizophrenia; chr6:26972077 chr6:26871484~26956554:- PAAD cis rs9368481 0.729 rs9379948 ENSG00000241549.7 GUSBP2 4.38 2.18e-05 0.0101 0.35 0.33 Autism spectrum disorder or schizophrenia; chr6:26977004 chr6:26871484~26956554:- PAAD cis rs17772222 1 rs61977058 ENSG00000258983.2 RP11-507K2.2 4.38 2.18e-05 0.0101 0.46 0.33 Coronary artery calcification; chr14:88415571 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs11159856 ENSG00000258983.2 RP11-507K2.2 4.38 2.18e-05 0.0101 0.46 0.33 Coronary artery calcification; chr14:88417585 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs17124652 ENSG00000258983.2 RP11-507K2.2 4.38 2.18e-05 0.0101 0.46 0.33 Coronary artery calcification; chr14:88424384 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs2295135 ENSG00000258983.2 RP11-507K2.2 4.38 2.18e-05 0.0101 0.46 0.33 Coronary artery calcification; chr14:88427866 chr14:88499334~88515502:+ PAAD cis rs17772222 0.876 rs4375590 ENSG00000258983.2 RP11-507K2.2 4.38 2.18e-05 0.0101 0.46 0.33 Coronary artery calcification; chr14:88451334 chr14:88499334~88515502:+ PAAD cis rs4835473 0.932 rs4835279 ENSG00000251600.4 RP11-673E1.1 -4.38 2.19e-05 0.0101 -0.38 -0.33 Immature fraction of reticulocytes; chr4:143788917 chr4:143912331~143982454:+ PAAD cis rs734999 0.505 rs60687045 ENSG00000225931.3 RP3-395M20.7 4.38 2.19e-05 0.0101 0.32 0.33 Ulcerative colitis; chr1:2608164 chr1:2566410~2569888:+ PAAD cis rs6570726 1 rs444564 ENSG00000235652.6 RP11-545I5.3 4.38 2.19e-05 0.0101 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145538659 chr6:145799409~145886585:+ PAAD cis rs7829975 0.572 rs28446104 ENSG00000254340.1 RP11-10A14.3 -4.38 2.19e-05 0.0101 -0.4 -0.33 Mood instability; chr8:8938391 chr8:9141424~9145435:+ PAAD cis rs4835473 0.932 rs10857415 ENSG00000251600.4 RP11-673E1.1 4.38 2.19e-05 0.0101 0.39 0.33 Immature fraction of reticulocytes; chr4:143908753 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1973608 ENSG00000251600.4 RP11-673E1.1 4.38 2.19e-05 0.0101 0.39 0.33 Immature fraction of reticulocytes; chr4:143913057 chr4:143912331~143982454:+ PAAD cis rs3020264 0.579 rs2454517 ENSG00000271743.1 CTD-2541M15.3 -4.38 2.19e-05 0.0101 -0.49 -0.33 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6616237 chr8:6615604~6617198:- PAAD cis rs797680 0.964 rs547866 ENSG00000223745.6 RP4-717I23.3 -4.38 2.19e-05 0.0101 -0.27 -0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93259496 chr1:93262186~93346025:- PAAD cis rs2658782 1 rs2658781 ENSG00000279684.1 RP11-755E23.2 4.38 2.19e-05 0.0101 0.57 0.33 Pulmonary function decline; chr11:93433202 chr11:93286629~93288903:- PAAD cis rs11159086 1 rs4899516 ENSG00000259005.1 RP3-449M8.6 4.38 2.19e-05 0.0101 0.46 0.33 Advanced glycation end-product levels; chr14:74492825 chr14:74474007~74474864:- PAAD cis rs1823913 0.599 rs13399251 ENSG00000280083.1 RP11-317J9.1 -4.38 2.19e-05 0.0101 -0.39 -0.33 Obesity-related traits; chr2:191268758 chr2:191154118~191156070:- PAAD cis rs919433 0.68 rs1961558 ENSG00000231621.1 AC013264.2 -4.38 2.19e-05 0.0101 -0.33 -0.33 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197622554 chr2:197197991~197199273:+ PAAD cis rs7923609 0.812 rs10822155 ENSG00000232075.1 MRPL35P2 -4.38 2.19e-05 0.0101 -0.41 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63311455 chr10:63634317~63634827:- PAAD cis rs2505998 0.833 rs2565204 ENSG00000273008.1 RP11-351D16.3 -4.38 2.19e-05 0.0101 -0.29 -0.33 Hirschsprung disease; chr10:43107725 chr10:43136824~43138334:- PAAD cis rs2486288 0.656 rs7167146 ENSG00000259433.2 CTD-2651B20.4 -4.38 2.19e-05 0.0102 -0.37 -0.33 Glomerular filtration rate; chr15:45279188 chr15:45330209~45332634:- PAAD cis rs10740039 0.549 rs9414741 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60738510 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs1904399 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739240 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs1904400 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739361 chr10:60734342~60741828:+ PAAD cis rs10740039 0.515 rs9414742 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739769 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs9415609 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60739832 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs4948263 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740132 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs4948264 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740484 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs4948265 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740495 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs7917700 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740596 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs2170005 ENSG00000254271.1 RP11-131N11.4 4.38 2.19e-05 0.0102 0.4 0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740842 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs2127348 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740945 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs2127349 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60740947 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs2127350 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741079 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs2127351 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741425 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs2127352 ENSG00000254271.1 RP11-131N11.4 -4.38 2.19e-05 0.0102 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60742129 chr10:60734342~60741828:+ PAAD cis rs2790457 0.874 rs1265840 ENSG00000254635.4 WAC-AS1 -4.38 2.2e-05 0.0102 -0.32 -0.33 Multiple myeloma; chr10:28630712 chr10:28522652~28532743:- PAAD cis rs950880 0.71 rs2270298 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102375619 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs17027037 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102378424 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs2080289 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102378560 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs11683700 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102380345 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs3821203 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102380412 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs3771162 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102380714 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs11465633 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102381273 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs56258475 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102382852 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs1035130 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102384942 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs4851570 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102389927 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs17027060 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102391107 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs66919607 ENSG00000234389.1 AC007278.3 -4.38 2.2e-05 0.0102 -0.34 -0.33 Serum protein levels (sST2); chr2:102392509 chr2:102438713~102440475:+ PAAD cis rs2505998 0.957 rs2435359 ENSG00000273008.1 RP11-351D16.3 -4.38 2.2e-05 0.0102 -0.29 -0.33 Hirschsprung disease; chr10:43084567 chr10:43136824~43138334:- PAAD cis rs2505998 0.879 rs2435358 ENSG00000273008.1 RP11-351D16.3 -4.38 2.2e-05 0.0102 -0.29 -0.33 Hirschsprung disease; chr10:43084767 chr10:43136824~43138334:- PAAD cis rs2505998 0.843 rs2506008 ENSG00000273008.1 RP11-351D16.3 -4.38 2.2e-05 0.0102 -0.29 -0.33 Hirschsprung disease; chr10:43084776 chr10:43136824~43138334:- PAAD cis rs797680 0.93 rs12124771 ENSG00000223745.6 RP4-717I23.3 4.38 2.21e-05 0.0102 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93333682 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs1535701 ENSG00000223745.6 RP4-717I23.3 4.38 2.21e-05 0.0102 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93339644 chr1:93262186~93346025:- PAAD cis rs1275411 0.511 rs2012752 ENSG00000259062.2 ACTN1-AS1 4.38 2.21e-05 0.0102 0.41 0.33 Neuroticism; chr14:68973553 chr14:68979682~68987463:+ PAAD cis rs2243480 1 rs464895 ENSG00000232546.1 RP11-458F8.1 -4.38 2.21e-05 0.0102 -0.41 -0.33 Diabetic kidney disease; chr7:66062119 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs160633 ENSG00000232546.1 RP11-458F8.1 -4.38 2.21e-05 0.0102 -0.41 -0.33 Diabetic kidney disease; chr7:66063241 chr7:66848496~66858136:+ PAAD cis rs7182621 0.512 rs71403471 ENSG00000259363.4 CTD-2054N24.2 -4.38 2.21e-05 0.0102 -0.43 -0.33 Colonoscopy-negative controls vs population controls; chr15:99870656 chr15:99807023~99877148:+ PAAD cis rs10028773 0.515 rs9994488 ENSG00000248280.1 RP11-33B1.2 4.38 2.21e-05 0.0102 0.33 0.33 Educational attainment; chr4:119666626 chr4:119440561~119450157:- PAAD cis rs4761702 0.922 rs7960229 ENSG00000258171.1 RP11-511B23.3 -4.38 2.21e-05 0.0102 -0.41 -0.33 Immature fraction of reticulocytes; chr12:93323943 chr12:93174366~93181832:+ PAAD cis rs801193 0.935 rs11772264 ENSG00000237310.1 GS1-124K5.4 4.38 2.21e-05 0.0102 0.31 0.33 Aortic root size; chr7:66711400 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs7782320 ENSG00000237310.1 GS1-124K5.4 4.38 2.21e-05 0.0102 0.31 0.33 Aortic root size; chr7:66712111 chr7:66493706~66495474:+ PAAD cis rs8062405 0.723 rs62031562 ENSG00000251417.2 RP11-1348G14.4 -4.38 2.21e-05 0.0102 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28598008 chr16:28802743~28817828:+ PAAD cis rs2243480 1 rs709607 ENSG00000232546.1 RP11-458F8.1 4.38 2.21e-05 0.0102 0.4 0.33 Diabetic kidney disease; chr7:65984554 chr7:66848496~66858136:+ PAAD cis rs950880 0.71 rs11693955 ENSG00000234389.1 AC007278.3 -4.38 2.21e-05 0.0102 -0.33 -0.33 Serum protein levels (sST2); chr2:102412705 chr2:102438713~102440475:+ PAAD cis rs950880 0.744 rs3771156 ENSG00000234389.1 AC007278.3 -4.38 2.21e-05 0.0102 -0.33 -0.33 Serum protein levels (sST2); chr2:102420217 chr2:102438713~102440475:+ PAAD cis rs2337406 0.866 rs4773949 ENSG00000211974.3 IGHV2-70 4.38 2.21e-05 0.0102 0.43 0.33 Alzheimer's disease (late onset); chr14:106808070 chr14:106723574~106724093:- PAAD cis rs2115630 0.905 rs6496401 ENSG00000225151.9 GOLGA2P7 4.38 2.21e-05 0.0102 0.39 0.33 P wave terminal force; chr15:84754562 chr15:84199311~84230136:- PAAD cis rs2115630 0.967 rs11073702 ENSG00000225151.9 GOLGA2P7 4.38 2.21e-05 0.0102 0.39 0.33 P wave terminal force; chr15:84766840 chr15:84199311~84230136:- PAAD cis rs6480314 0.636 rs61854782 ENSG00000233590.1 RP11-153K11.3 -4.38 2.21e-05 0.0102 -0.54 -0.33 Optic nerve measurement (disc area); chr10:68231992 chr10:68233251~68242379:- PAAD cis rs2288884 0.559 rs8111873 ENSG00000275055.1 CTC-471J1.11 -4.38 2.22e-05 0.0102 -0.41 -0.33 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52014267 chr19:52049007~52049754:+ PAAD cis rs8072100 0.875 rs62073966 ENSG00000228782.6 CTD-2026D20.3 -4.38 2.22e-05 0.0102 -0.33 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47522647 chr17:47450568~47492492:- PAAD cis rs2980439 0.517 rs793753 ENSG00000253981.4 ALG1L13P -4.38 2.22e-05 0.0102 -0.4 -0.33 Neuroticism; chr8:8247837 chr8:8236003~8244667:- PAAD cis rs338389 0.542 rs62002423 ENSG00000260657.2 RP11-315D16.4 4.38 2.22e-05 0.0103 0.39 0.33 Survival in rectal cancer; chr15:67976709 chr15:68267792~68277994:- PAAD cis rs875971 0.66 rs2013222 ENSG00000237310.1 GS1-124K5.4 -4.38 2.22e-05 0.0103 -0.31 -0.33 Aortic root size; chr7:66570949 chr7:66493706~66495474:+ PAAD cis rs734999 0.572 rs2985857 ENSG00000225931.3 RP3-395M20.7 -4.38 2.22e-05 0.0103 -0.32 -0.33 Ulcerative colitis; chr1:2601185 chr1:2566410~2569888:+ PAAD cis rs9419788 0.769 rs7914268 ENSG00000233377.1 MTND4P20 4.38 2.22e-05 0.0103 0.3 0.33 Personality traits in bipolar disorder; chr10:94219769 chr10:94940253~94941121:- PAAD cis rs944722 0.749 rs8081248 ENSG00000266786.1 LGALS9DP 4.38 2.23e-05 0.0103 0.37 0.33 Fractional exhaled nitric oxide (childhood); chr17:27754938 chr17:27746132~27754954:+ PAAD cis rs3825776 1 rs3825776 ENSG00000274719.1 RP11-86K22.2 4.38 2.23e-05 0.0103 0.43 0.33 Amyotrophic lateral sclerosis; chr15:58454631 chr15:57990217~57990636:- PAAD cis rs897984 0.542 rs7197717 ENSG00000260911.2 RP11-196G11.2 4.38 2.23e-05 0.0103 0.3 0.33 Dementia with Lewy bodies; chr16:31071754 chr16:31043150~31049868:+ PAAD cis rs6991838 0.67 rs869151 ENSG00000200714.1 Y_RNA 4.38 2.23e-05 0.0103 0.4 0.33 Intelligence (multi-trait analysis); chr8:65726487 chr8:65592731~65592820:+ PAAD cis rs797680 0.822 rs1572343 ENSG00000223745.6 RP4-717I23.3 4.38 2.23e-05 0.0103 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93150645 chr1:93262186~93346025:- PAAD cis rs2250402 0.51 rs2291621 ENSG00000245849.5 RAD51-AS1 -4.38 2.23e-05 0.0103 -0.41 -0.33 Corneal curvature; chr15:40032636 chr15:40686724~40695107:- PAAD cis rs858239 0.6 rs7790157 ENSG00000226816.2 AC005082.12 4.38 2.23e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23087379 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6960001 ENSG00000226816.2 AC005082.12 4.38 2.23e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23091257 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs10237755 ENSG00000226816.2 AC005082.12 4.38 2.23e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23091945 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6961131 ENSG00000226816.2 AC005082.12 4.38 2.23e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23095171 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs1115941 ENSG00000226816.2 AC005082.12 4.38 2.23e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23097569 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs7787110 ENSG00000226816.2 AC005082.12 4.38 2.23e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23098855 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs28646184 ENSG00000226816.2 AC005082.12 4.38 2.23e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23099976 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs10256524 ENSG00000226816.2 AC005082.12 4.38 2.23e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23105328 chr7:23206013~23208045:+ PAAD cis rs8072100 0.84 rs4968319 ENSG00000228782.6 CTD-2026D20.3 4.38 2.23e-05 0.0103 0.35 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47387601 chr17:47450568~47492492:- PAAD cis rs2911132 1 rs2617433 ENSG00000248734.2 CTD-2260A17.1 4.38 2.23e-05 0.0103 0.32 0.33 Urate levels (BMI interaction); chr5:96840738 chr5:96784777~96785999:+ PAAD cis rs11089937 0.597 rs6001072 ENSG00000211638.2 IGLV8-61 -4.38 2.23e-05 0.0103 -0.32 -0.33 Periodontitis (PAL4Q3); chr22:22133629 chr22:22098700~22099212:+ PAAD cis rs11089937 0.512 rs6001073 ENSG00000211638.2 IGLV8-61 -4.38 2.23e-05 0.0103 -0.32 -0.33 Periodontitis (PAL4Q3); chr22:22133650 chr22:22098700~22099212:+ PAAD cis rs11089937 0.539 rs6001075 ENSG00000211638.2 IGLV8-61 -4.38 2.23e-05 0.0103 -0.32 -0.33 Periodontitis (PAL4Q3); chr22:22133765 chr22:22098700~22099212:+ PAAD cis rs11089937 0.597 rs6001076 ENSG00000211638.2 IGLV8-61 -4.38 2.23e-05 0.0103 -0.32 -0.33 Periodontitis (PAL4Q3); chr22:22133873 chr22:22098700~22099212:+ PAAD cis rs11089937 0.597 rs5995560 ENSG00000211638.2 IGLV8-61 -4.38 2.23e-05 0.0103 -0.32 -0.33 Periodontitis (PAL4Q3); chr22:22133989 chr22:22098700~22099212:+ PAAD cis rs11089937 0.568 rs6001078 ENSG00000211638.2 IGLV8-61 -4.38 2.23e-05 0.0103 -0.32 -0.33 Periodontitis (PAL4Q3); chr22:22134365 chr22:22098700~22099212:+ PAAD cis rs2278034 0.502 rs3747672 ENSG00000231443.2 AC024937.6 -4.38 2.23e-05 0.0103 -0.29 -0.33 Bronchopulmonary dysplasia; chr3:195885163 chr3:195937243~195938739:+ PAAD cis rs2921073 0.605 rs2976933 ENSG00000253893.2 FAM85B -4.38 2.23e-05 0.0103 -0.48 -0.33 Parkinson's disease; chr8:8397365 chr8:8167819~8226614:- PAAD cis rs2115630 1 rs10220733 ENSG00000225151.9 GOLGA2P7 4.38 2.23e-05 0.0103 0.39 0.33 P wave terminal force; chr15:84737633 chr15:84199311~84230136:- PAAD cis rs2115630 1 rs1030863 ENSG00000225151.9 GOLGA2P7 4.38 2.23e-05 0.0103 0.39 0.33 P wave terminal force; chr15:84739404 chr15:84199311~84230136:- PAAD cis rs79040073 0.637 rs57252806 ENSG00000259531.2 RP11-295H24.3 4.38 2.23e-05 0.0103 0.57 0.33 Lung cancer in ever smokers; chr15:49352188 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11633981 ENSG00000259531.2 RP11-295H24.3 4.38 2.23e-05 0.0103 0.57 0.33 Lung cancer in ever smokers; chr15:49360903 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11633282 ENSG00000259531.2 RP11-295H24.3 4.38 2.23e-05 0.0103 0.57 0.33 Lung cancer in ever smokers; chr15:49372472 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11638606 ENSG00000259531.2 RP11-295H24.3 4.38 2.23e-05 0.0103 0.57 0.33 Lung cancer in ever smokers; chr15:49372564 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs77408643 ENSG00000259531.2 RP11-295H24.3 4.38 2.23e-05 0.0103 0.57 0.33 Lung cancer in ever smokers; chr15:49377226 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73398223 ENSG00000259531.2 RP11-295H24.3 4.38 2.23e-05 0.0103 0.57 0.33 Lung cancer in ever smokers; chr15:49379505 chr15:49365124~49366685:- PAAD cis rs62355901 0.545 rs6882255 ENSG00000271828.1 CTD-2310F14.1 4.38 2.23e-05 0.0103 0.61 0.33 Breast cancer; chr5:56762344 chr5:56927874~56929573:+ PAAD cis rs62355900 0.636 rs12654584 ENSG00000271828.1 CTD-2310F14.1 4.38 2.23e-05 0.0103 0.61 0.33 Endometriosis; chr5:56762588 chr5:56927874~56929573:+ PAAD cis rs577676 0.586 rs549449 ENSG00000271811.1 RP1-79C4.4 4.38 2.23e-05 0.0103 0.36 0.33 Prevalent atrial fibrillation; chr1:170641569 chr1:170667381~170669425:+ PAAD cis rs577676 0.586 rs639720 ENSG00000271811.1 RP1-79C4.4 4.38 2.23e-05 0.0103 0.36 0.33 Prevalent atrial fibrillation; chr1:170643785 chr1:170667381~170669425:+ PAAD cis rs577676 0.586 rs666419 ENSG00000271811.1 RP1-79C4.4 4.38 2.23e-05 0.0103 0.36 0.33 Prevalent atrial fibrillation; chr1:170645103 chr1:170667381~170669425:+ PAAD cis rs577676 0.586 rs593173 ENSG00000271811.1 RP1-79C4.4 4.38 2.23e-05 0.0103 0.36 0.33 Prevalent atrial fibrillation; chr1:170646719 chr1:170667381~170669425:+ PAAD cis rs10050311 0.698 rs67867077 ENSG00000251411.1 RP11-397E7.4 -4.38 2.23e-05 0.0103 -0.41 -0.33 Insulin-related traits; chr4:86722593 chr4:86913266~86914817:- PAAD cis rs871012 0.593 rs59666316 ENSG00000251405.2 CTB-109A12.1 -4.38 2.23e-05 0.0103 -0.42 -0.33 IgG glycosylation; chr5:157391833 chr5:157362615~157460078:- PAAD cis rs871012 0.632 rs62387479 ENSG00000251405.2 CTB-109A12.1 -4.38 2.23e-05 0.0103 -0.42 -0.33 IgG glycosylation; chr5:157392370 chr5:157362615~157460078:- PAAD cis rs871012 0.609 rs57047471 ENSG00000251405.2 CTB-109A12.1 -4.38 2.23e-05 0.0103 -0.42 -0.33 IgG glycosylation; chr5:157392605 chr5:157362615~157460078:- PAAD cis rs7727544 0.684 rs274560 ENSG00000233006.5 AC034220.3 -4.38 2.24e-05 0.0103 -0.27 -0.33 Blood metabolite levels; chr5:132383758 chr5:132311285~132369916:- PAAD cis rs6743226 0.603 rs11675957 ENSG00000266621.1 AC104841.1 -4.38 2.24e-05 0.0103 -0.39 -0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241269377 chr2:241245202~241245299:- PAAD cis rs7078219 0.505 rs1548964 ENSG00000228778.1 RP11-129J12.1 4.38 2.24e-05 0.0103 0.37 0.33 Dental caries; chr10:99529896 chr10:99527081~99528261:+ PAAD cis rs6142102 0.961 rs2377957 ENSG00000276073.1 RP5-1125A11.7 -4.38 2.24e-05 0.0103 -0.36 -0.33 Skin pigmentation; chr20:33966667 chr20:33985617~33988989:- PAAD cis rs858239 0.6 rs2014768 ENSG00000226816.2 AC005082.12 4.38 2.24e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23082821 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs6978827 ENSG00000226816.2 AC005082.12 4.38 2.24e-05 0.0103 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23085925 chr7:23206013~23208045:+ PAAD cis rs9584850 0.708 rs4411372 ENSG00000231194.1 FARP1-AS1 4.38 2.24e-05 0.0103 0.43 0.33 Neuroticism; chr13:98478169 chr13:98435405~98435840:- PAAD cis rs4759375 0.667 rs11057266 ENSG00000256092.2 RP13-942N8.1 4.38 2.24e-05 0.0103 0.61 0.33 HDL cholesterol; chr12:123322998 chr12:123363868~123366113:+ PAAD cis rs4835473 0.831 rs4323050 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143992106 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs4423826 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143992165 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1849128 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143992582 chr4:143912331~143982454:+ PAAD cis rs4835473 0.715 rs4538428 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143992751 chr4:143912331~143982454:+ PAAD cis rs4835473 0.771 rs2175452 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143992887 chr4:143912331~143982454:+ PAAD cis rs4835473 0.8 rs2175451 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143992964 chr4:143912331~143982454:+ PAAD cis rs4323050 0.51 rs4254715 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 High light scatter reticulocyte percentage of red cells; chr4:143993140 chr4:143912331~143982454:+ PAAD cis rs4323050 0.51 rs4273414 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 High light scatter reticulocyte percentage of red cells; chr4:143993142 chr4:143912331~143982454:+ PAAD cis rs4835473 0.831 rs1912743 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143993705 chr4:143912331~143982454:+ PAAD cis rs4835473 0.614 rs4487293 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143993880 chr4:143912331~143982454:+ PAAD cis rs4835473 0.742 rs6537238 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143996463 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1473055 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143997714 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4835126 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143997740 chr4:143912331~143982454:+ PAAD cis rs4835473 0.699 rs4835127 ENSG00000251600.4 RP11-673E1.1 4.38 2.24e-05 0.0103 0.4 0.33 Immature fraction of reticulocytes; chr4:143997972 chr4:143912331~143982454:+ PAAD cis rs2911132 1 rs2911130 ENSG00000248734.2 CTD-2260A17.1 4.38 2.24e-05 0.0103 0.32 0.33 Urate levels (BMI interaction); chr5:96847724 chr5:96784777~96785999:+ PAAD cis rs2729354 0.768 rs2848640 ENSG00000265566.2 RN7SL605P -4.38 2.24e-05 0.0103 -0.42 -0.33 Blood protein levels; chr11:57495207 chr11:57528085~57528365:- PAAD cis rs7849973 0.7 rs7865016 ENSG00000224549.1 RP11-370B11.3 -4.38 2.24e-05 0.0103 -0.39 -0.33 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22819408 chr9:22767175~22768316:+ PAAD cis rs797680 0.964 rs797668 ENSG00000223745.6 RP4-717I23.3 -4.37 2.25e-05 0.0103 -0.27 -0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93229232 chr1:93262186~93346025:- PAAD cis rs11089937 0.597 rs11704434 ENSG00000211638.2 IGLV8-61 -4.37 2.25e-05 0.0103 -0.32 -0.33 Periodontitis (PAL4Q3); chr22:22131715 chr22:22098700~22099212:+ PAAD cis rs6723226 0.75 rs762019 ENSG00000276334.1 AL133243.1 4.37 2.25e-05 0.0104 0.39 0.33 Intelligence (multi-trait analysis); chr2:32463533 chr2:32521927~32523547:+ PAAD cis rs2976388 0.647 rs13272904 ENSG00000253741.1 CTD-2292P10.4 -4.37 2.25e-05 0.0104 -0.39 -0.33 Urinary tract infection frequency; chr8:142701196 chr8:142702252~142726973:- PAAD cis rs9309711 0.961 rs4296457 ENSG00000225234.1 TRAPPC12-AS1 -4.37 2.25e-05 0.0104 -0.38 -0.33 Neurofibrillary tangles; chr2:3466824 chr2:3481242~3482409:- PAAD cis rs6504950 0.8 rs7209926 ENSG00000275710.1 RP11-257O5.4 -4.37 2.25e-05 0.0104 -0.4 -0.33 Breast cancer; chr17:54928963 chr17:54964474~54964679:+ PAAD cis rs7615952 0.558 rs17334039 ENSG00000239804.1 RP11-379B18.1 4.37 2.26e-05 0.0104 0.45 0.33 Blood pressure (smoking interaction); chr3:125821465 chr3:125787888~125788146:- PAAD cis rs79349575 0.716 rs595767 ENSG00000270781.1 RP11-501C14.9 -4.37 2.26e-05 0.0104 -0.38 -0.33 Type 2 diabetes; chr17:48880625 chr17:48899131~48899748:+ PAAD cis rs919433 0.713 rs55642934 ENSG00000231621.1 AC013264.2 -4.37 2.26e-05 0.0104 -0.34 -0.33 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197626386 chr2:197197991~197199273:+ PAAD cis rs4835473 0.897 rs11728121 ENSG00000251600.4 RP11-673E1.1 4.37 2.26e-05 0.0104 0.38 0.33 Immature fraction of reticulocytes; chr4:143707079 chr4:143912331~143982454:+ PAAD cis rs2288884 0.559 rs8104890 ENSG00000275055.1 CTC-471J1.11 -4.37 2.26e-05 0.0104 -0.42 -0.33 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52016355 chr19:52049007~52049754:+ PAAD cis rs111580313 0.792 rs79430710 ENSG00000270020.1 RP11-463O9.9 4.37 2.26e-05 0.0104 0.87 0.33 Systemic juvenile idiopathic arthritis; chr16:86575505 chr16:86520383~86523897:- PAAD cis rs111580313 0.685 rs78285663 ENSG00000270020.1 RP11-463O9.9 4.37 2.26e-05 0.0104 0.87 0.33 Systemic juvenile idiopathic arthritis; chr16:86575638 chr16:86520383~86523897:- PAAD cis rs1387259 0.759 rs7960122 ENSG00000258273.1 RP11-370I10.4 4.37 2.26e-05 0.0104 0.43 0.33 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48383217 chr12:48333755~48333901:- PAAD cis rs889398 0.967 rs2032912 ENSG00000226232.7 RP11-419C5.2 4.37 2.26e-05 0.0104 0.28 0.33 Body mass index; chr16:69534400 chr16:69976388~69996188:- PAAD cis rs7615952 1 rs9289275 ENSG00000241288.6 RP11-379B18.5 -4.37 2.26e-05 0.0104 -0.36 -0.33 Blood pressure (smoking interaction); chr3:125929816 chr3:125827238~125916384:- PAAD cis rs4835473 0.868 rs1828503 ENSG00000251600.4 RP11-673E1.1 -4.37 2.27e-05 0.0104 -0.4 -0.33 Immature fraction of reticulocytes; chr4:143993354 chr4:143912331~143982454:+ PAAD cis rs2562456 0.917 rs2650793 ENSG00000213976.4 CTD-2561J22.2 4.37 2.27e-05 0.0104 0.36 0.33 Pain; chr19:21493313 chr19:21382865~21387177:+ PAAD cis rs1075265 0.62 rs10192626 ENSG00000233266.1 HMGB1P31 4.37 2.27e-05 0.0104 0.44 0.33 Chronotype;Morning vs. evening chronotype; chr2:53760885 chr2:54051334~54051760:+ PAAD cis rs193541 0.632 rs6595413 ENSG00000263432.2 RN7SL689P 4.37 2.27e-05 0.0104 0.44 0.33 Glucose homeostasis traits; chr5:122821254 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs1363200 ENSG00000263432.2 RN7SL689P 4.37 2.27e-05 0.0104 0.44 0.33 Glucose homeostasis traits; chr5:122828107 chr5:123022487~123022783:- PAAD cis rs2712184 0.875 rs35925637 ENSG00000229352.1 AC007563.3 4.37 2.27e-05 0.0104 0.33 0.33 Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine); chr2:216811905 chr2:216799608~216805335:+ PAAD cis rs2729354 0.768 rs2729384 ENSG00000265566.2 RN7SL605P -4.37 2.27e-05 0.0104 -0.41 -0.33 Blood protein levels; chr11:57491144 chr11:57528085~57528365:- PAAD cis rs1113500 0.836 rs2801220 ENSG00000226822.1 RP11-356N1.2 -4.37 2.27e-05 0.0104 -0.4 -0.33 Growth-regulated protein alpha levels; chr1:108042027 chr1:108071482~108074519:+ PAAD cis rs2288073 0.619 rs6713263 ENSG00000242628.4 AC009228.1 4.37 2.27e-05 0.0104 0.36 0.33 Venous thromboembolism (SNP x SNP interaction); chr2:24152593 chr2:24214381~24221516:+ PAAD cis rs710913 0.738 rs755247 ENSG00000243970.1 PPIEL -4.37 2.28e-05 0.0104 -0.3 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39528873 chr1:39531838~39558707:- PAAD cis rs9926296 0.632 rs1800286 ENSG00000260259.1 RP11-368I7.4 -4.37 2.28e-05 0.0104 -0.39 -0.33 Vitiligo; chr16:89803353 chr16:89682620~89686569:- PAAD cis rs710913 0.816 rs1727098 ENSG00000243970.1 PPIEL -4.37 2.28e-05 0.0104 -0.3 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39523655 chr1:39531838~39558707:- PAAD cis rs875971 1 rs2220626 ENSG00000237310.1 GS1-124K5.4 -4.37 2.28e-05 0.0105 -0.32 -0.33 Aortic root size; chr7:66081075 chr7:66493706~66495474:+ PAAD cis rs875971 0.964 rs697969 ENSG00000237310.1 GS1-124K5.4 -4.37 2.28e-05 0.0105 -0.32 -0.33 Aortic root size; chr7:66093491 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs1182882 ENSG00000237310.1 GS1-124K5.4 -4.37 2.28e-05 0.0105 -0.32 -0.33 Aortic root size; chr7:66097076 chr7:66493706~66495474:+ PAAD cis rs6584283 0.846 rs10883370 ENSG00000228778.1 RP11-129J12.1 -4.37 2.28e-05 0.0105 -0.37 -0.33 Ulcerative colitis; chr10:99531715 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs11190140 ENSG00000228778.1 RP11-129J12.1 -4.37 2.28e-05 0.0105 -0.37 -0.33 Dental caries; chr10:99531836 chr10:99527081~99528261:+ PAAD cis rs853679 0.55 rs9295762 ENSG00000280107.1 AL022393.9 4.37 2.28e-05 0.0105 0.55 0.33 Depression; chr6:28187640 chr6:28170845~28172521:+ PAAD cis rs12118297 0.771 rs6691205 ENSG00000236915.1 RP4-651E10.4 -4.37 2.28e-05 0.0105 -0.51 -0.33 Breast cancer; chr1:87298519 chr1:86571181~86693203:- PAAD cis rs12118297 0.657 rs6696960 ENSG00000236915.1 RP4-651E10.4 -4.37 2.28e-05 0.0105 -0.51 -0.33 Breast cancer; chr1:87299234 chr1:86571181~86693203:- PAAD cis rs2832077 0.943 rs2832084 ENSG00000176054.6 RPL23P2 -4.37 2.28e-05 0.0105 -0.38 -0.33 Cognitive test performance; chr21:28782476 chr21:28997613~28998033:- PAAD cis rs2832077 0.943 rs2832091 ENSG00000176054.6 RPL23P2 -4.37 2.28e-05 0.0105 -0.38 -0.33 Cognitive test performance; chr21:28790533 chr21:28997613~28998033:- PAAD cis rs797680 0.93 rs2295423 ENSG00000223745.6 RP4-717I23.3 4.37 2.28e-05 0.0105 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93115467 chr1:93262186~93346025:- PAAD cis rs6480314 0.542 rs61854804 ENSG00000233590.1 RP11-153K11.3 -4.37 2.28e-05 0.0105 -0.52 -0.33 Optic nerve measurement (disc area); chr10:68255819 chr10:68233251~68242379:- PAAD cis rs4835473 0.618 rs12499907 ENSG00000251600.4 RP11-673E1.1 -4.37 2.29e-05 0.0105 -0.4 -0.33 Immature fraction of reticulocytes; chr4:143999748 chr4:143912331~143982454:+ PAAD cis rs7189233 0.55 rs1861350 ENSG00000279344.1 RP11-44F14.7 4.37 2.29e-05 0.0105 0.25 0.33 Intelligence (multi-trait analysis); chr16:53499430 chr16:53478957~53481550:- PAAD cis rs12439619 0.693 rs17269819 ENSG00000255769.6 GOLGA2P10 -4.37 2.29e-05 0.0105 -0.4 -0.33 Intelligence (multi-trait analysis); chr15:82174660 chr15:82472993~82513950:- PAAD cis rs12439619 0.693 rs8034801 ENSG00000255769.6 GOLGA2P10 -4.37 2.29e-05 0.0105 -0.4 -0.33 Intelligence (multi-trait analysis); chr15:82183996 chr15:82472993~82513950:- PAAD cis rs4218 0.681 rs1074701 ENSG00000277144.1 RP11-59H7.4 -4.37 2.29e-05 0.0105 -0.45 -0.33 Social communication problems; chr15:59073862 chr15:59115547~59116089:- PAAD cis rs2255336 0.616 rs6488285 ENSG00000245648.1 RP11-277P12.20 4.37 2.29e-05 0.0105 0.59 0.33 Blood protein levels; chr12:10366107 chr12:10363769~10398506:+ PAAD cis rs2255336 0.608 rs7957681 ENSG00000245648.1 RP11-277P12.20 4.37 2.29e-05 0.0105 0.59 0.33 Blood protein levels; chr12:10366223 chr12:10363769~10398506:+ PAAD cis rs2255336 0.608 rs7958658 ENSG00000245648.1 RP11-277P12.20 4.37 2.29e-05 0.0105 0.59 0.33 Blood protein levels; chr12:10366229 chr12:10363769~10398506:+ PAAD cis rs2255336 0.702 rs7964772 ENSG00000245648.1 RP11-277P12.20 4.37 2.29e-05 0.0105 0.59 0.33 Blood protein levels; chr12:10367498 chr12:10363769~10398506:+ PAAD cis rs2658782 0.593 rs2243410 ENSG00000279684.1 RP11-755E23.2 -4.37 2.29e-05 0.0105 -0.53 -0.33 Pulmonary function decline; chr11:93522353 chr11:93286629~93288903:- PAAD cis rs17711722 0.653 rs2460421 ENSG00000234585.5 CCT6P3 -4.37 2.29e-05 0.0105 -0.27 -0.33 Calcium levels; chr7:66026136 chr7:65038354~65074713:+ PAAD cis rs2564921 0.704 rs12053904 ENSG00000242142.1 SERBP1P3 -4.37 2.3e-05 0.0105 -0.42 -0.33 Height; chr3:52991821 chr3:53064283~53065091:- PAAD cis rs2564921 0.679 rs2115779 ENSG00000242142.1 SERBP1P3 -4.37 2.3e-05 0.0105 -0.42 -0.33 Height; chr3:52992698 chr3:53064283~53065091:- PAAD cis rs494459 0.838 rs555649 ENSG00000278376.1 RP11-158I9.8 -4.37 2.3e-05 0.0105 -0.3 -0.33 Height; chr11:118781100 chr11:118791254~118793137:+ PAAD cis rs919433 0.89 rs979020 ENSG00000231621.1 AC013264.2 4.37 2.3e-05 0.0105 0.31 0.33 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197305025 chr2:197197991~197199273:+ PAAD cis rs10028773 0.515 rs9994651 ENSG00000248280.1 RP11-33B1.2 4.37 2.3e-05 0.0105 0.32 0.33 Educational attainment; chr4:119666648 chr4:119440561~119450157:- PAAD cis rs8059260 0.673 rs77240340 ENSG00000274038.1 RP11-66H6.4 -4.37 2.3e-05 0.0105 -0.6 -0.33 Alcohol consumption over the past year; chr16:10945778 chr16:11056556~11057034:+ PAAD cis rs79040073 0.637 rs11632575 ENSG00000259531.2 RP11-295H24.3 4.37 2.3e-05 0.0105 0.57 0.33 Lung cancer in ever smokers; chr15:49380758 chr15:49365124~49366685:- PAAD cis rs79040073 0.594 rs59112977 ENSG00000259531.2 RP11-295H24.3 4.37 2.3e-05 0.0105 0.57 0.33 Lung cancer in ever smokers; chr15:49382342 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs8027094 ENSG00000259531.2 RP11-295H24.3 4.37 2.3e-05 0.0105 0.57 0.33 Lung cancer in ever smokers; chr15:49388639 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs8030457 ENSG00000259531.2 RP11-295H24.3 4.37 2.3e-05 0.0105 0.57 0.33 Lung cancer in ever smokers; chr15:49392809 chr15:49365124~49366685:- PAAD cis rs79040073 0.599 rs17477722 ENSG00000259531.2 RP11-295H24.3 4.37 2.3e-05 0.0105 0.57 0.33 Lung cancer in ever smokers; chr15:49394220 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73398243 ENSG00000259531.2 RP11-295H24.3 4.37 2.3e-05 0.0105 0.57 0.33 Lung cancer in ever smokers; chr15:49394344 chr15:49365124~49366685:- PAAD cis rs9652601 0.959 rs9746695 ENSG00000274038.1 RP11-66H6.4 4.37 2.3e-05 0.0105 0.37 0.33 Systemic lupus erythematosus; chr16:11114037 chr16:11056556~11057034:+ PAAD cis rs6142102 0.961 rs2268089 ENSG00000276073.1 RP5-1125A11.7 -4.37 2.3e-05 0.0105 -0.36 -0.33 Skin pigmentation; chr20:34079492 chr20:33985617~33988989:- PAAD cis rs4950322 0.58 rs7514970 ENSG00000278811.3 LINC00624 4.37 2.32e-05 0.0106 0.33 0.33 Protein quantitative trait loci; chr1:147120516 chr1:147258885~147517875:- PAAD cis rs748404 1 rs17779494 ENSG00000249839.1 AC011330.5 4.37 2.32e-05 0.0106 0.53 0.33 Lung cancer; chr15:43287025 chr15:43663654~43684339:- PAAD cis rs11098499 0.78 rs7692994 ENSG00000248280.1 RP11-33B1.2 4.37 2.32e-05 0.0106 0.33 0.33 Corneal astigmatism; chr4:119506334 chr4:119440561~119450157:- PAAD cis rs8062405 0.723 rs35175818 ENSG00000251417.2 RP11-1348G14.4 -4.37 2.32e-05 0.0106 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28597425 chr16:28802743~28817828:+ PAAD cis rs6472235 0.632 rs6981089 ENSG00000200714.1 Y_RNA -4.37 2.32e-05 0.0106 -0.46 -0.33 Plateletcrit;Myopia (pathological); chr8:65895118 chr8:65592731~65592820:+ PAAD cis rs3738443 0.678 rs61636449 ENSG00000259865.1 RP11-488L18.10 4.37 2.32e-05 0.0106 0.29 0.33 Alcohol dependence; chr1:247213758 chr1:247187281~247188526:- PAAD cis rs853679 1 rs10456362 ENSG00000226314.6 ZNF192P1 4.37 2.32e-05 0.0106 0.6 0.33 Depression; chr6:28254038 chr6:28161781~28169594:+ PAAD cis rs9322193 0.566 rs6912330 ENSG00000268592.3 RAET1E-AS1 -4.37 2.33e-05 0.0106 -0.44 -0.33 Lung cancer; chr6:149908811 chr6:149863494~149919507:+ PAAD cis rs8005677 0.828 rs12589539 ENSG00000279656.1 RP11-298I3.6 4.37 2.33e-05 0.0106 0.4 0.33 Cognitive ability (multi-trait analysis); chr14:22927471 chr14:23023083~23024217:- PAAD cis rs2243480 1 rs34703416 ENSG00000228409.4 CCT6P1 4.37 2.33e-05 0.0106 0.36 0.33 Diabetic kidney disease; chr7:65835655 chr7:65751142~65763354:+ PAAD cis rs131777 0.532 rs131747 ENSG00000205559.3 CHKB-AS1 -4.37 2.33e-05 0.0106 -0.38 -0.33 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50586645 chr22:50583026~50583877:+ PAAD cis rs897984 0.574 rs11647284 ENSG00000260911.2 RP11-196G11.2 4.37 2.33e-05 0.0106 0.31 0.33 Dementia with Lewy bodies; chr16:31066014 chr16:31043150~31049868:+ PAAD cis rs2486288 0.656 rs8037583 ENSG00000259433.2 CTD-2651B20.4 4.37 2.33e-05 0.0106 0.37 0.33 Glomerular filtration rate; chr15:45254180 chr15:45330209~45332634:- PAAD cis rs9876781 0.559 rs7630053 ENSG00000229759.1 MRPS18AP1 4.37 2.33e-05 0.0106 0.34 0.33 Longevity; chr3:48357096 chr3:48256350~48256938:- PAAD cis rs9876781 0.559 rs11130167 ENSG00000229759.1 MRPS18AP1 4.37 2.33e-05 0.0106 0.34 0.33 Longevity; chr3:48358570 chr3:48256350~48256938:- PAAD cis rs9876781 0.559 rs13073692 ENSG00000229759.1 MRPS18AP1 4.37 2.33e-05 0.0106 0.34 0.33 Longevity; chr3:48361812 chr3:48256350~48256938:- PAAD cis rs9876781 0.559 rs7611415 ENSG00000229759.1 MRPS18AP1 4.37 2.33e-05 0.0106 0.34 0.33 Longevity; chr3:48363659 chr3:48256350~48256938:- PAAD cis rs1124769 0.502 rs12148865 ENSG00000259306.2 RP11-108K3.2 -4.37 2.33e-05 0.0106 -0.42 -0.33 Cognitive performance; chr15:50786400 chr15:51315841~51321996:+ PAAD cis rs1124769 0.502 rs28565448 ENSG00000259306.2 RP11-108K3.2 -4.37 2.33e-05 0.0106 -0.42 -0.33 Cognitive performance; chr15:50787773 chr15:51315841~51321996:+ PAAD cis rs3169166 0.527 rs1996625 ENSG00000259562.2 RP11-762H8.2 -4.37 2.33e-05 0.0106 -0.29 -0.33 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78308752 chr15:78290527~78291221:- PAAD cis rs61776719 0.747 rs28428561 ENSG00000212541.1 RNU6-510P 4.37 2.33e-05 0.0106 0.36 0.33 Coronary artery disease; chr1:37968634 chr1:37991462~37991569:+ PAAD cis rs7580658 0.864 rs1566823 ENSG00000236682.1 AC068282.3 -4.37 2.33e-05 0.0106 -0.44 -0.33 Protein C levels; chr2:127260616 chr2:127389130~127400580:+ PAAD cis rs7580658 0.895 rs9636237 ENSG00000236682.1 AC068282.3 -4.37 2.33e-05 0.0106 -0.44 -0.33 Protein C levels; chr2:127318446 chr2:127389130~127400580:+ PAAD cis rs7580658 0.857 rs11890187 ENSG00000236682.1 AC068282.3 -4.37 2.33e-05 0.0106 -0.44 -0.33 Protein C levels; chr2:127326162 chr2:127389130~127400580:+ PAAD cis rs919433 0.963 rs10199410 ENSG00000231621.1 AC013264.2 4.37 2.33e-05 0.0106 0.32 0.33 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197291052 chr2:197197991~197199273:+ PAAD cis rs7923837 1 rs10748582 ENSG00000236493.2 EIF2S2P3 4.37 2.34e-05 0.0107 0.42 0.33 Multiple sclerosis;Body mass index; chr10:92717462 chr10:92668745~92669743:- PAAD cis rs7923837 0.964 rs10882106 ENSG00000236493.2 EIF2S2P3 4.36 2.34e-05 0.0107 0.42 0.33 Multiple sclerosis;Body mass index; chr10:92720577 chr10:92668745~92669743:- PAAD cis rs61270009 0.955 rs780399 ENSG00000247828.6 TMEM161B-AS1 -4.36 2.34e-05 0.0107 -0.27 -0.33 Depressive symptoms; chr5:88237160 chr5:88268895~88436685:+ PAAD cis rs61270009 0.913 rs380670 ENSG00000247828.6 TMEM161B-AS1 -4.36 2.34e-05 0.0107 -0.27 -0.33 Depressive symptoms; chr5:88243132 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs379430 ENSG00000247828.6 TMEM161B-AS1 -4.36 2.34e-05 0.0107 -0.27 -0.33 Depressive symptoms; chr5:88243275 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs383385 ENSG00000247828.6 TMEM161B-AS1 -4.36 2.34e-05 0.0107 -0.27 -0.33 Depressive symptoms; chr5:88246065 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs396702 ENSG00000247828.6 TMEM161B-AS1 -4.36 2.34e-05 0.0107 -0.27 -0.33 Depressive symptoms; chr5:88247486 chr5:88268895~88436685:+ PAAD cis rs7078219 0.505 rs10883371 ENSG00000228778.1 RP11-129J12.1 -4.36 2.34e-05 0.0107 -0.36 -0.33 Dental caries; chr10:99532698 chr10:99527081~99528261:+ PAAD cis rs2562456 0.874 rs9304986 ENSG00000213976.4 CTD-2561J22.2 4.36 2.34e-05 0.0107 0.37 0.33 Pain; chr19:21499260 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs2650805 ENSG00000213976.4 CTD-2561J22.2 4.36 2.34e-05 0.0107 0.37 0.33 Pain; chr19:21505137 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs6511256 ENSG00000213976.4 CTD-2561J22.2 4.36 2.34e-05 0.0107 0.37 0.33 Pain; chr19:21510513 chr19:21382865~21387177:+ PAAD cis rs2581828 0.632 rs891369 ENSG00000242142.1 SERBP1P3 -4.36 2.35e-05 0.0107 -0.42 -0.33 Crohn's disease; chr3:53102535 chr3:53064283~53065091:- PAAD cis rs6840258 0.66 rs72667736 ENSG00000251411.1 RP11-397E7.4 -4.36 2.35e-05 0.0107 -0.4 -0.33 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86954803 chr4:86913266~86914817:- PAAD cis rs7646881 0.812 rs73015665 ENSG00000240207.5 RP11-379F4.4 -4.36 2.35e-05 0.0107 -0.5 -0.33 Tetralogy of Fallot; chr3:158736145 chr3:158732263~158784070:+ PAAD cis rs748404 0.66 rs2467742 ENSG00000205771.5 CATSPER2P1 -4.36 2.35e-05 0.0107 -0.47 -0.33 Lung cancer; chr15:43458039 chr15:43726918~43747094:- PAAD cis rs748404 0.69 rs2244981 ENSG00000205771.5 CATSPER2P1 -4.36 2.35e-05 0.0107 -0.47 -0.33 Lung cancer; chr15:43460553 chr15:43726918~43747094:- PAAD cis rs748404 0.66 rs694725 ENSG00000205771.5 CATSPER2P1 -4.36 2.35e-05 0.0107 -0.47 -0.33 Lung cancer; chr15:43464012 chr15:43726918~43747094:- PAAD cis rs494459 0.838 rs555639 ENSG00000278376.1 RP11-158I9.8 4.36 2.35e-05 0.0107 0.29 0.33 Height; chr11:118758322 chr11:118791254~118793137:+ PAAD cis rs2262909 0.925 rs56073035 ENSG00000279377.1 AC003973.3 -4.36 2.35e-05 0.0107 -0.31 -0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22093496 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs73019889 ENSG00000279377.1 AC003973.3 -4.36 2.35e-05 0.0107 -0.31 -0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22095024 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs17459246 ENSG00000279377.1 AC003973.3 -4.36 2.35e-05 0.0107 -0.31 -0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22095319 chr19:21965708~21968529:- PAAD cis rs2262909 0.925 rs73019900 ENSG00000279377.1 AC003973.3 -4.36 2.35e-05 0.0107 -0.31 -0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22103878 chr19:21965708~21968529:- PAAD cis rs2564921 0.693 rs2581798 ENSG00000242142.1 SERBP1P3 4.36 2.35e-05 0.0107 0.42 0.33 Height; chr3:53073584 chr3:53064283~53065091:- PAAD cis rs638893 0.673 rs538645 ENSG00000278376.1 RP11-158I9.8 4.36 2.35e-05 0.0107 0.36 0.33 Vitiligo; chr11:118840360 chr11:118791254~118793137:+ PAAD cis rs6479901 0.895 rs67963837 ENSG00000232075.1 MRPL35P2 -4.36 2.35e-05 0.0107 -0.48 -0.33 Intelligence (multi-trait analysis); chr10:63247111 chr10:63634317~63634827:- PAAD cis rs734999 0.545 rs10797436 ENSG00000225931.3 RP3-395M20.7 4.36 2.35e-05 0.0107 0.32 0.33 Ulcerative colitis; chr1:2606910 chr1:2566410~2569888:+ PAAD cis rs9487094 0.813 rs13203252 ENSG00000260273.1 RP11-425D10.10 4.36 2.35e-05 0.0107 0.46 0.33 Height; chr6:109351533 chr6:109382795~109383666:+ PAAD cis rs6480314 0.542 rs7476012 ENSG00000233590.1 RP11-153K11.3 -4.36 2.35e-05 0.0107 -0.52 -0.33 Optic nerve measurement (disc area); chr10:68259950 chr10:68233251~68242379:- PAAD cis rs4988958 0.565 rs3755265 ENSG00000234389.1 AC007278.3 4.36 2.36e-05 0.0107 0.34 0.33 Asthma (childhood onset); chr2:102436356 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs4479442 ENSG00000234389.1 AC007278.3 4.36 2.36e-05 0.0107 0.34 0.33 Asthma; chr2:102437614 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs2058659 ENSG00000234389.1 AC007278.3 -4.36 2.36e-05 0.0107 -0.34 -0.33 Asthma; chr2:102438096 chr2:102438713~102440475:+ PAAD cis rs2505998 0.957 rs2506005 ENSG00000273008.1 RP11-351D16.3 -4.36 2.36e-05 0.0107 -0.29 -0.33 Hirschsprung disease; chr10:43086532 chr10:43136824~43138334:- PAAD cis rs2505998 0.843 rs2506004 ENSG00000273008.1 RP11-351D16.3 -4.36 2.36e-05 0.0107 -0.29 -0.33 Hirschsprung disease; chr10:43086825 chr10:43136824~43138334:- PAAD cis rs2412819 0.571 rs4923965 ENSG00000205771.5 CATSPER2P1 4.36 2.36e-05 0.0107 0.53 0.33 Lung cancer; chr15:43790232 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs6493090 ENSG00000205771.5 CATSPER2P1 4.36 2.36e-05 0.0107 0.53 0.33 Lung cancer; chr15:43792084 chr15:43726918~43747094:- PAAD cis rs2412819 0.571 rs4644832 ENSG00000205771.5 CATSPER2P1 4.36 2.36e-05 0.0107 0.53 0.33 Lung cancer; chr15:43792507 chr15:43726918~43747094:- PAAD cis rs7189233 0.955 rs72801817 ENSG00000279722.1 RP11-44F14.6 -4.36 2.36e-05 0.0107 -0.36 -0.33 Intelligence (multi-trait analysis); chr16:53440656 chr16:53487607~53489943:- PAAD cis rs10129255 0.536 rs3944157 ENSG00000211972.2 IGHV3-66 4.36 2.36e-05 0.0107 0.26 0.33 Kawasaki disease; chr14:106682286 chr14:106675017~106675544:- PAAD cis rs889398 0.967 rs62052816 ENSG00000226232.7 RP11-419C5.2 4.36 2.36e-05 0.0108 0.28 0.33 Body mass index; chr16:69529503 chr16:69976388~69996188:- PAAD cis rs889398 0.967 rs12929503 ENSG00000226232.7 RP11-419C5.2 4.36 2.36e-05 0.0108 0.28 0.33 Body mass index; chr16:69531558 chr16:69976388~69996188:- PAAD cis rs889398 0.935 rs12933292 ENSG00000226232.7 RP11-419C5.2 4.36 2.36e-05 0.0108 0.28 0.33 Body mass index; chr16:69532406 chr16:69976388~69996188:- PAAD cis rs875971 1 rs1167612 ENSG00000237310.1 GS1-124K5.4 -4.36 2.36e-05 0.0108 -0.32 -0.33 Aortic root size; chr7:66102989 chr7:66493706~66495474:+ PAAD cis rs7202877 0.656 rs3851736 ENSG00000261783.1 RP11-252K23.2 -4.36 2.36e-05 0.0108 -0.52 -0.33 Type 1 diabetes;Type 2 diabetes; chr16:75353434 chr16:75379818~75381260:- PAAD cis rs7202877 0.572 rs8051611 ENSG00000261783.1 RP11-252K23.2 -4.36 2.36e-05 0.0108 -0.52 -0.33 Type 1 diabetes;Type 2 diabetes; chr16:75355035 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs4993971 ENSG00000261783.1 RP11-252K23.2 4.36 2.36e-05 0.0108 0.52 0.33 Type 1 diabetes;Type 2 diabetes; chr16:75377736 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs8046184 ENSG00000261783.1 RP11-252K23.2 -4.36 2.36e-05 0.0108 -0.52 -0.33 Type 1 diabetes;Type 2 diabetes; chr16:75377827 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs247438 ENSG00000261783.1 RP11-252K23.2 4.36 2.36e-05 0.0108 0.52 0.33 Type 1 diabetes;Type 2 diabetes; chr16:75398751 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs247447 ENSG00000261783.1 RP11-252K23.2 4.36 2.37e-05 0.0108 0.54 0.33 Type 1 diabetes;Type 2 diabetes; chr16:75452750 chr16:75379818~75381260:- PAAD cis rs2911132 1 rs2911132 ENSG00000248734.2 CTD-2260A17.1 4.36 2.37e-05 0.0108 0.32 0.33 Urate levels (BMI interaction); chr5:96851285 chr5:96784777~96785999:+ PAAD cis rs1862618 0.754 rs252899 ENSG00000271828.1 CTD-2310F14.1 4.36 2.37e-05 0.0108 0.5 0.33 Initial pursuit acceleration; chr5:56892742 chr5:56927874~56929573:+ PAAD cis rs987724 0.515 rs6787457 ENSG00000240875.4 LINC00886 -4.36 2.37e-05 0.0108 -0.5 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156891157 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs11914959 ENSG00000240875.4 LINC00886 -4.36 2.37e-05 0.0108 -0.5 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156898616 chr3:156747346~156817062:- PAAD cis rs987724 0.501 rs4680313 ENSG00000240875.4 LINC00886 -4.36 2.37e-05 0.0108 -0.5 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156901348 chr3:156747346~156817062:- PAAD cis rs1075232 0.826 rs16956738 ENSG00000215302.7 CTD-3092A11.1 4.36 2.37e-05 0.0108 0.83 0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31444028 chr15:30470779~30507623:+ PAAD cis rs7429990 0.932 rs936428 ENSG00000228638.1 FCF1P2 4.36 2.37e-05 0.0108 0.37 0.33 Educational attainment (years of education); chr3:48125791 chr3:48290793~48291375:- PAAD cis rs7429990 0.901 rs7374482 ENSG00000228638.1 FCF1P2 4.36 2.37e-05 0.0108 0.37 0.33 Educational attainment (years of education); chr3:48126900 chr3:48290793~48291375:- PAAD cis rs858239 0.601 rs987257 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23108221 chr7:23206013~23208045:+ PAAD cis rs858239 0.57 rs10235467 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23109189 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs6980224 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23109518 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs1558313 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23116460 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs6962526 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23118614 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs6971673 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23119904 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs10278700 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23120910 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs10263110 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23120932 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs11982002 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23123651 chr7:23206013~23208045:+ PAAD cis rs858239 0.541 rs4624924 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23129224 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs6948469 ENSG00000226816.2 AC005082.12 4.36 2.37e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23135147 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs6461693 ENSG00000226816.2 AC005082.12 -4.36 2.37e-05 0.0108 -0.38 -0.33 Cerebrospinal fluid biomarker levels; chr7:23120514 chr7:23206013~23208045:+ PAAD cis rs748404 0.697 rs505249 ENSG00000249839.1 AC011330.5 -4.36 2.37e-05 0.0108 -0.46 -0.33 Lung cancer; chr15:43267762 chr15:43663654~43684339:- PAAD cis rs6142102 0.961 rs4911405 ENSG00000276073.1 RP5-1125A11.7 -4.36 2.38e-05 0.0108 -0.36 -0.33 Skin pigmentation; chr20:34087161 chr20:33985617~33988989:- PAAD cis rs4713118 0.587 rs61471148 ENSG00000204709.4 LINC01556 4.36 2.38e-05 0.0108 0.57 0.33 Parkinson's disease; chr6:28069254 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393884 ENSG00000204709.4 LINC01556 4.36 2.38e-05 0.0108 0.57 0.33 Depression; chr6:28079011 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393887 ENSG00000204709.4 LINC01556 4.36 2.38e-05 0.0108 0.57 0.33 Depression; chr6:28091242 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs6922063 ENSG00000204709.4 LINC01556 4.36 2.38e-05 0.0108 0.57 0.33 Depression; chr6:28126588 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs2275508 ENSG00000204709.4 LINC01556 4.36 2.38e-05 0.0108 0.57 0.33 Depression; chr6:28126953 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs1904841 ENSG00000204709.4 LINC01556 4.36 2.38e-05 0.0108 0.57 0.33 Depression; chr6:28140307 chr6:28943877~28944537:+ PAAD cis rs6472235 1 rs11986631 ENSG00000200714.1 Y_RNA -4.36 2.38e-05 0.0108 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65908091 chr8:65592731~65592820:+ PAAD cis rs6472235 0.934 rs7461470 ENSG00000200714.1 Y_RNA -4.36 2.38e-05 0.0108 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65914661 chr8:65592731~65592820:+ PAAD cis rs6472235 0.872 rs6472236 ENSG00000200714.1 Y_RNA -4.36 2.38e-05 0.0108 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65920446 chr8:65592731~65592820:+ PAAD cis rs6472235 0.903 rs7841181 ENSG00000200714.1 Y_RNA -4.36 2.38e-05 0.0108 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65923319 chr8:65592731~65592820:+ PAAD cis rs6472235 1 rs11986470 ENSG00000200714.1 Y_RNA -4.36 2.38e-05 0.0108 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65924048 chr8:65592731~65592820:+ PAAD cis rs2564921 0.73 rs73082047 ENSG00000242142.1 SERBP1P3 -4.36 2.38e-05 0.0108 -0.42 -0.33 Height; chr3:53070344 chr3:53064283~53065091:- PAAD cis rs867529 1 rs1606803 ENSG00000230006.6 ANKRD36BP2 -4.36 2.38e-05 0.0108 -0.29 -0.33 Height; chr2:88633798 chr2:88765807~88806612:+ PAAD cis rs12935418 0.83 rs12448368 ENSG00000261061.1 RP11-303E16.2 4.36 2.38e-05 0.0108 0.52 0.33 Mean corpuscular volume; chr16:81011342 chr16:81030770~81031485:+ PAAD cis rs797680 0.754 rs4847419 ENSG00000223745.6 RP4-717I23.3 4.36 2.38e-05 0.0108 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93380098 chr1:93262186~93346025:- PAAD cis rs797680 0.664 rs4847420 ENSG00000223745.6 RP4-717I23.3 4.36 2.38e-05 0.0108 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93380117 chr1:93262186~93346025:- PAAD cis rs797680 0.786 rs1593512 ENSG00000223745.6 RP4-717I23.3 4.36 2.38e-05 0.0108 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93392817 chr1:93262186~93346025:- PAAD cis rs62103177 0.525 rs10438902 ENSG00000261126.6 RP11-795F19.1 -4.36 2.38e-05 0.0108 -0.45 -0.33 Opioid sensitivity; chr18:79985640 chr18:80046900~80095482:+ PAAD cis rs2408955 0.521 rs1476607 ENSG00000240399.1 RP1-228P16.1 -4.36 2.38e-05 0.0108 -0.36 -0.33 Glycated hemoglobin levels; chr12:48131021 chr12:48054813~48055591:- PAAD cis rs858239 0.512 rs55788996 ENSG00000226816.2 AC005082.12 4.36 2.38e-05 0.0108 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23153230 chr7:23206013~23208045:+ PAAD cis rs1665050 0.598 rs8041221 ENSG00000277144.1 RP11-59H7.4 -4.36 2.38e-05 0.0108 -0.39 -0.33 Atopic dermatitis; chr15:59042609 chr15:59115547~59116089:- PAAD cis rs6570726 1 rs404229 ENSG00000235652.6 RP11-545I5.3 4.36 2.39e-05 0.0108 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145547064 chr6:145799409~145886585:+ PAAD cis rs633715 0.531 rs618759 ENSG00000254154.7 RP4-798P15.3 -4.36 2.39e-05 0.0108 -0.25 -0.33 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177916353 chr1:177928788~178038007:- PAAD cis rs17772222 0.682 rs2297129 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88469581 chr14:88499334~88515502:+ PAAD cis rs17772222 0.682 rs61542857 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88470358 chr14:88499334~88515502:+ PAAD cis rs17772222 0.637 rs7161660 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88471832 chr14:88499334~88515502:+ PAAD cis rs17772222 0.682 rs7141363 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88471879 chr14:88499334~88515502:+ PAAD cis rs17772222 0.682 rs2274736 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88472308 chr14:88499334~88515502:+ PAAD cis rs17772222 0.682 rs3783889 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88475637 chr14:88499334~88515502:+ PAAD cis rs17772222 0.637 rs879932 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88479247 chr14:88499334~88515502:+ PAAD cis rs17772222 0.682 rs8017689 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88483442 chr14:88499334~88515502:+ PAAD cis rs17772222 0.682 rs28371093 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88486112 chr14:88499334~88515502:+ PAAD cis rs17772222 0.655 rs10150594 ENSG00000258983.2 RP11-507K2.2 4.36 2.39e-05 0.0108 0.41 0.33 Coronary artery calcification; chr14:88489613 chr14:88499334~88515502:+ PAAD cis rs7120173 0.915 rs12786797 ENSG00000254851.1 RP11-109L13.1 -4.36 2.39e-05 0.0108 -0.52 -0.33 Visceral adipose tissue adjusted for BMI; chr11:117017035 chr11:117135528~117138582:+ PAAD cis rs79040073 0.637 rs73398272 ENSG00000259531.2 RP11-295H24.3 4.36 2.39e-05 0.0108 0.56 0.33 Lung cancer in ever smokers; chr15:49416426 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73398276 ENSG00000259531.2 RP11-295H24.3 4.36 2.39e-05 0.0108 0.56 0.33 Lung cancer in ever smokers; chr15:49418782 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11635308 ENSG00000259531.2 RP11-295H24.3 4.36 2.39e-05 0.0108 0.56 0.33 Lung cancer in ever smokers; chr15:49426531 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs61259878 ENSG00000259531.2 RP11-295H24.3 4.36 2.39e-05 0.0108 0.56 0.33 Lung cancer in ever smokers; chr15:49432564 chr15:49365124~49366685:- PAAD cis rs8062405 0.755 rs4788076 ENSG00000251417.2 RP11-1348G14.4 -4.36 2.39e-05 0.0108 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28558684 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs7193402 ENSG00000251417.2 RP11-1348G14.4 -4.36 2.39e-05 0.0108 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28574806 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs62034358 ENSG00000251417.2 RP11-1348G14.4 -4.36 2.39e-05 0.0108 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576276 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs12445823 ENSG00000251417.2 RP11-1348G14.4 -4.36 2.39e-05 0.0108 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28576728 chr16:28802743~28817828:+ PAAD cis rs8062405 0.723 rs12445744 ENSG00000251417.2 RP11-1348G14.4 -4.36 2.39e-05 0.0108 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28577074 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs4787455 ENSG00000251417.2 RP11-1348G14.4 -4.36 2.39e-05 0.0108 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28578134 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs4788074 ENSG00000251417.2 RP11-1348G14.4 4.36 2.39e-05 0.0108 0.32 0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28582276 chr16:28802743~28817828:+ PAAD cis rs858239 0.601 rs10239760 ENSG00000226816.2 AC005082.12 4.36 2.39e-05 0.0108 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23110331 chr7:23206013~23208045:+ PAAD cis rs66887589 0.934 rs2389873 ENSG00000248280.1 RP11-33B1.2 -4.36 2.39e-05 0.0109 -0.3 -0.33 Diastolic blood pressure; chr4:119633559 chr4:119440561~119450157:- PAAD cis rs66887589 0.934 rs4834792 ENSG00000248280.1 RP11-33B1.2 -4.36 2.39e-05 0.0109 -0.3 -0.33 Diastolic blood pressure; chr4:119634541 chr4:119440561~119450157:- PAAD cis rs2404602 0.647 rs3812909 ENSG00000259422.1 RP11-593F23.1 -4.36 2.39e-05 0.0109 -0.41 -0.33 Blood metabolite levels; chr15:76883859 chr15:76174891~76181486:- PAAD cis rs2404602 0.647 rs4886840 ENSG00000259422.1 RP11-593F23.1 -4.36 2.39e-05 0.0109 -0.41 -0.33 Blood metabolite levels; chr15:76886661 chr15:76174891~76181486:- PAAD cis rs4660214 0.666 rs1537818 ENSG00000237624.1 OXCT2P1 -4.36 2.39e-05 0.0109 -0.44 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39181366 chr1:39514956~39516490:+ PAAD cis rs853679 0.55 rs6901017 ENSG00000280107.1 AL022393.9 -4.36 2.4e-05 0.0109 -0.55 -0.33 Depression; chr6:28184805 chr6:28170845~28172521:+ PAAD cis rs440932 0.565 rs19334 ENSG00000254340.1 RP11-10A14.3 4.36 2.4e-05 0.0109 0.41 0.33 High light scatter reticulocyte percentage of red cells; chr8:9152396 chr8:9141424~9145435:+ PAAD cis rs7646881 0.812 rs7635704 ENSG00000240207.5 RP11-379F4.4 -4.36 2.4e-05 0.0109 -0.51 -0.33 Tetralogy of Fallot; chr3:158741931 chr3:158732263~158784070:+ PAAD cis rs7646881 0.812 rs7624161 ENSG00000240207.5 RP11-379F4.4 -4.36 2.4e-05 0.0109 -0.51 -0.33 Tetralogy of Fallot; chr3:158742125 chr3:158732263~158784070:+ PAAD cis rs7646881 0.812 rs113166116 ENSG00000240207.5 RP11-379F4.4 -4.36 2.4e-05 0.0109 -0.51 -0.33 Tetralogy of Fallot; chr3:158742467 chr3:158732263~158784070:+ PAAD cis rs7429990 0.932 rs13085054 ENSG00000228638.1 FCF1P2 4.36 2.4e-05 0.0109 0.37 0.33 Educational attainment (years of education); chr3:48092647 chr3:48290793~48291375:- PAAD cis rs7429990 0.87 rs13089844 ENSG00000228638.1 FCF1P2 4.36 2.4e-05 0.0109 0.37 0.33 Educational attainment (years of education); chr3:48098741 chr3:48290793~48291375:- PAAD cis rs7429990 0.932 rs11130155 ENSG00000228638.1 FCF1P2 4.36 2.4e-05 0.0109 0.37 0.33 Educational attainment (years of education); chr3:48098938 chr3:48290793~48291375:- PAAD cis rs7429990 0.932 rs12493348 ENSG00000228638.1 FCF1P2 4.36 2.4e-05 0.0109 0.37 0.33 Educational attainment (years of education); chr3:48102048 chr3:48290793~48291375:- PAAD cis rs1789 0.592 rs1125378 ENSG00000273133.1 RP11-799M12.2 -4.36 2.4e-05 0.0109 -0.45 -0.33 Blood protein levels; chr4:15538867 chr4:15563698~15564253:- PAAD cis rs950880 0.71 rs55645612 ENSG00000234389.1 AC007278.3 -4.36 2.4e-05 0.0109 -0.33 -0.33 Serum protein levels (sST2); chr2:102439201 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs56166614 ENSG00000234389.1 AC007278.3 -4.36 2.4e-05 0.0109 -0.33 -0.33 Serum protein levels (sST2); chr2:102439636 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs17027179 ENSG00000234389.1 AC007278.3 -4.36 2.4e-05 0.0109 -0.33 -0.33 Serum protein levels (sST2); chr2:102440699 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs11123927 ENSG00000234389.1 AC007278.3 -4.36 2.4e-05 0.0109 -0.33 -0.33 Serum protein levels (sST2); chr2:102442343 chr2:102438713~102440475:+ PAAD cis rs950880 0.645 rs56044378 ENSG00000234389.1 AC007278.3 -4.36 2.4e-05 0.0109 -0.33 -0.33 Serum protein levels (sST2); chr2:102448907 chr2:102438713~102440475:+ PAAD cis rs694739 0.861 rs479552 ENSG00000236935.1 AP003774.1 4.36 2.41e-05 0.0109 0.37 0.33 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64343211 chr11:64325050~64329504:- PAAD cis rs6844153 1 rs80197589 ENSG00000240005.4 RP11-293A21.1 -4.36 2.41e-05 0.0109 -0.56 -0.33 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26887030 chr4:26859806~26860599:- PAAD cis rs6844153 1 rs7655686 ENSG00000240005.4 RP11-293A21.1 -4.36 2.41e-05 0.0109 -0.56 -0.33 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26897955 chr4:26859806~26860599:- PAAD cis rs2976388 0.609 rs2717605 ENSG00000253741.1 CTD-2292P10.4 -4.36 2.41e-05 0.0109 -0.38 -0.33 Urinary tract infection frequency; chr8:142719597 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2572907 ENSG00000253741.1 CTD-2292P10.4 -4.36 2.41e-05 0.0109 -0.38 -0.33 Urinary tract infection frequency; chr8:142720520 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2572908 ENSG00000253741.1 CTD-2292P10.4 -4.36 2.41e-05 0.0109 -0.38 -0.33 Urinary tract infection frequency; chr8:142721218 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2717602 ENSG00000253741.1 CTD-2292P10.4 -4.36 2.41e-05 0.0109 -0.38 -0.33 Urinary tract infection frequency; chr8:142724265 chr8:142702252~142726973:- PAAD cis rs12480328 1 rs73909824 ENSG00000203999.7 LINC01270 4.36 2.41e-05 0.0109 0.71 0.33 Prostate cancer; chr20:50880816 chr20:50292720~50314922:+ PAAD cis rs6840258 0.66 rs74784659 ENSG00000251411.1 RP11-397E7.4 -4.36 2.41e-05 0.0109 -0.38 -0.33 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86967777 chr4:86913266~86914817:- PAAD cis rs6840258 0.66 rs17012213 ENSG00000251411.1 RP11-397E7.4 -4.36 2.41e-05 0.0109 -0.38 -0.33 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86968015 chr4:86913266~86914817:- PAAD cis rs6840258 0.66 rs17012216 ENSG00000251411.1 RP11-397E7.4 -4.36 2.41e-05 0.0109 -0.38 -0.33 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86968285 chr4:86913266~86914817:- PAAD cis rs6840258 0.66 rs72667741 ENSG00000251411.1 RP11-397E7.4 -4.36 2.41e-05 0.0109 -0.38 -0.33 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86970923 chr4:86913266~86914817:- PAAD cis rs6840258 0.66 rs17012200 ENSG00000251411.1 RP11-397E7.4 4.36 2.41e-05 0.0109 0.38 0.33 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86963494 chr4:86913266~86914817:- PAAD cis rs42490 0.59 rs39771 ENSG00000251136.7 RP11-37B2.1 -4.36 2.41e-05 0.0109 -0.32 -0.33 Leprosy; chr8:89826378 chr8:89609409~89757727:- PAAD cis rs42490 0.625 rs43229 ENSG00000251136.7 RP11-37B2.1 -4.36 2.41e-05 0.0109 -0.32 -0.33 Leprosy; chr8:89826558 chr8:89609409~89757727:- PAAD cis rs2243480 1 rs34702770 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65879836 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs35480979 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65892097 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34637256 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65895144 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35391607 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65895842 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs13220979 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65898217 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34974928 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65899019 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs67728539 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65913137 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34136756 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65916269 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs78803505 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65917585 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34933526 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65918212 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34577383 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65920739 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6949812 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65922114 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs55895244 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65922691 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6970243 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65923503 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs7794661 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65924743 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs7795242 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65925107 chr7:65751142~65763354:+ PAAD cis rs2243480 0.708 rs35310401 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65925372 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35058610 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65925938 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2177703 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65926730 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35432774 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65928032 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs56985706 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65929575 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs60683927 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65929781 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs58062456 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65929865 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34529418 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65938222 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs35087093 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65940221 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35046236 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65943626 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs36068983 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65944004 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs68189316 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65944182 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs34804747 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65947955 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs59794892 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65950886 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs36004293 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65951525 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs35268390 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65951549 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs12698509 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65953889 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs11538349 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65956884 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs937108 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65963465 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35542501 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65966228 chr7:65751142~65763354:+ PAAD cis rs2243480 0.711 rs1626926 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65970805 chr7:65751142~65763354:+ PAAD cis rs2243480 0.708 rs781141 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65973566 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs781142 ENSG00000228409.4 CCT6P1 4.36 2.41e-05 0.0109 0.36 0.33 Diabetic kidney disease; chr7:65973791 chr7:65751142~65763354:+ PAAD cis rs2243480 0.831 rs7806717 ENSG00000228409.4 CCT6P1 -4.36 2.41e-05 0.0109 -0.36 -0.33 Diabetic kidney disease; chr7:65928187 chr7:65751142~65763354:+ PAAD cis rs950880 0.71 rs4851011 ENSG00000234389.1 AC007278.3 4.36 2.41e-05 0.0109 0.34 0.33 Serum protein levels (sST2); chr2:102473219 chr2:102438713~102440475:+ PAAD cis rs6061231 0.544 rs2427314 ENSG00000273619.1 RP5-908M14.9 -4.36 2.42e-05 0.0109 -0.29 -0.33 Colorectal cancer; chr20:62398610 chr20:62386303~62386970:- PAAD cis rs6504622 0.818 rs9303532 ENSG00000262539.1 RP11-259G18.3 -4.36 2.42e-05 0.0109 -0.44 -0.33 Orofacial clefts; chr17:46956636 chr17:46259551~46260606:- PAAD cis rs6504622 0.818 rs9910899 ENSG00000262539.1 RP11-259G18.3 4.36 2.42e-05 0.0109 0.44 0.33 Orofacial clefts; chr17:46956976 chr17:46259551~46260606:- PAAD cis rs6504622 0.818 rs9912794 ENSG00000262539.1 RP11-259G18.3 4.36 2.42e-05 0.0109 0.44 0.33 Orofacial clefts; chr17:46957075 chr17:46259551~46260606:- PAAD cis rs6504622 0.818 rs9898527 ENSG00000262539.1 RP11-259G18.3 4.36 2.42e-05 0.0109 0.44 0.33 Orofacial clefts; chr17:46958844 chr17:46259551~46260606:- PAAD cis rs6504622 0.791 rs61671555 ENSG00000262539.1 RP11-259G18.3 4.36 2.42e-05 0.0109 0.44 0.33 Orofacial clefts; chr17:46960491 chr17:46259551~46260606:- PAAD cis rs6540731 0.782 rs10436962 ENSG00000229983.1 RP11-15I11.2 4.36 2.42e-05 0.0109 0.39 0.33 Intelligence (childhood); chr1:212188280 chr1:212168207~212190259:+ PAAD cis rs867529 0.695 rs62157805 ENSG00000230006.6 ANKRD36BP2 -4.36 2.42e-05 0.0109 -0.28 -0.33 Height; chr2:88715210 chr2:88765807~88806612:+ PAAD cis rs875971 1 rs2220626 ENSG00000232559.3 GS1-124K5.12 -4.36 2.42e-05 0.0109 -0.35 -0.33 Aortic root size; chr7:66081075 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs697969 ENSG00000232559.3 GS1-124K5.12 -4.36 2.42e-05 0.0109 -0.35 -0.33 Aortic root size; chr7:66093491 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1182882 ENSG00000232559.3 GS1-124K5.12 -4.36 2.42e-05 0.0109 -0.35 -0.33 Aortic root size; chr7:66097076 chr7:66554588~66576923:- PAAD cis rs11976180 1 rs11976180 ENSG00000273234.1 OR2A13P -4.36 2.42e-05 0.0109 -0.42 -0.33 Obesity-related traits; chr7:144044487 chr7:144142009~144142938:+ PAAD cis rs2337406 0.714 rs2337463 ENSG00000211974.3 IGHV2-70 -4.36 2.42e-05 0.0109 -0.46 -0.33 Alzheimer's disease (late onset); chr14:106816066 chr14:106723574~106724093:- PAAD cis rs2505998 0.833 rs2565203 ENSG00000273008.1 RP11-351D16.3 -4.36 2.42e-05 0.0109 -0.29 -0.33 Hirschsprung disease; chr10:43108287 chr10:43136824~43138334:- PAAD cis rs9494145 0.68 rs11759553 ENSG00000232876.1 CTA-212D2.2 -4.36 2.42e-05 0.0109 -0.42 -0.33 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135101158 chr6:135055033~135060550:+ PAAD cis rs1075265 0.933 rs918357 ENSG00000233266.1 HMGB1P31 4.36 2.42e-05 0.011 0.41 0.33 Chronotype;Morning vs. evening chronotype; chr2:54108826 chr2:54051334~54051760:+ PAAD cis rs12908161 1 rs12903134 ENSG00000259728.4 LINC00933 4.36 2.42e-05 0.011 0.43 0.33 Schizophrenia; chr15:84794468 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs35726233 ENSG00000259728.4 LINC00933 4.36 2.42e-05 0.011 0.43 0.33 Schizophrenia; chr15:84794569 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs35960805 ENSG00000259728.4 LINC00933 4.36 2.42e-05 0.011 0.43 0.33 Schizophrenia; chr15:84800749 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs12912388 ENSG00000259728.4 LINC00933 4.36 2.42e-05 0.011 0.43 0.33 Schizophrenia; chr15:84801319 chr15:84570649~84580175:+ PAAD cis rs5758511 0.68 rs5758651 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42213142 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs5758652 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42216402 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs5758657 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42222663 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs1033459 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42223061 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs1033460 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42223302 chr22:42149886~42155001:- PAAD cis rs5758511 0.679 rs55867855 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42227252 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs58654759 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42246570 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs5758682 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42249196 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs5758684 ENSG00000226450.2 CYP2D8P 4.36 2.43e-05 0.011 0.35 0.33 Birth weight; chr22:42253503 chr22:42149886~42155001:- PAAD cis rs4713118 0.621 rs9295755 ENSG00000204709.4 LINC01556 -4.36 2.43e-05 0.011 -0.56 -0.33 Parkinson's disease; chr6:28065396 chr6:28943877~28944537:+ PAAD cis rs4713118 0.621 rs10484403 ENSG00000204709.4 LINC01556 4.36 2.43e-05 0.011 0.56 0.33 Parkinson's disease; chr6:28065745 chr6:28943877~28944537:+ PAAD cis rs4713118 0.621 rs4713132 ENSG00000204709.4 LINC01556 4.36 2.43e-05 0.011 0.56 0.33 Parkinson's disease; chr6:28066257 chr6:28943877~28944537:+ PAAD cis rs4713118 0.621 rs4713133 ENSG00000204709.4 LINC01556 4.36 2.43e-05 0.011 0.56 0.33 Parkinson's disease; chr6:28066263 chr6:28943877~28944537:+ PAAD cis rs4713118 0.621 rs4713134 ENSG00000204709.4 LINC01556 4.36 2.43e-05 0.011 0.56 0.33 Parkinson's disease; chr6:28066343 chr6:28943877~28944537:+ PAAD cis rs1823913 0.599 rs6732976 ENSG00000280083.1 RP11-317J9.1 4.36 2.43e-05 0.011 0.39 0.33 Obesity-related traits; chr2:191281004 chr2:191154118~191156070:- PAAD cis rs3096299 0.632 rs4399533 ENSG00000261253.2 AC137932.6 4.36 2.43e-05 0.011 0.35 0.33 Multiple myeloma (IgH translocation); chr16:89472974 chr16:89321133~89325110:+ PAAD cis rs3096299 0.685 rs4785675 ENSG00000261253.2 AC137932.6 4.36 2.43e-05 0.011 0.35 0.33 Multiple myeloma (IgH translocation); chr16:89473566 chr16:89321133~89325110:+ PAAD cis rs3096299 0.685 rs4238830 ENSG00000261253.2 AC137932.6 4.36 2.43e-05 0.011 0.35 0.33 Multiple myeloma (IgH translocation); chr16:89473833 chr16:89321133~89325110:+ PAAD cis rs6472235 0.967 rs11996694 ENSG00000200714.1 Y_RNA -4.36 2.43e-05 0.011 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65947329 chr8:65592731~65592820:+ PAAD cis rs6472235 0.934 rs56389721 ENSG00000200714.1 Y_RNA -4.36 2.43e-05 0.011 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65951903 chr8:65592731~65592820:+ PAAD cis rs216345 0.7 rs307652 ENSG00000230074.1 RP11-195F19.9 -4.36 2.43e-05 0.011 -0.43 -0.33 Bipolar disorder; chr9:33935738 chr9:34665665~34681298:+ PAAD cis rs748404 0.56 rs529611 ENSG00000205771.5 CATSPER2P1 -4.36 2.43e-05 0.011 -0.47 -0.33 Lung cancer; chr15:43513790 chr15:43726918~43747094:- PAAD cis rs2486288 0.656 rs2413768 ENSG00000259433.2 CTD-2651B20.4 4.36 2.43e-05 0.011 0.36 0.33 Glomerular filtration rate; chr15:45269786 chr15:45330209~45332634:- PAAD cis rs2505998 0.796 rs2505537 ENSG00000273008.1 RP11-351D16.3 -4.36 2.43e-05 0.011 -0.29 -0.33 Hirschsprung disease; chr10:43096710 chr10:43136824~43138334:- PAAD cis rs2505998 0.833 rs2505535 ENSG00000273008.1 RP11-351D16.3 -4.36 2.43e-05 0.011 -0.29 -0.33 Hirschsprung disease; chr10:43097595 chr10:43136824~43138334:- PAAD cis rs2505998 0.833 rs2505533 ENSG00000273008.1 RP11-351D16.3 -4.36 2.43e-05 0.011 -0.29 -0.33 Hirschsprung disease; chr10:43099005 chr10:43136824~43138334:- PAAD cis rs2505998 0.833 rs1800858 ENSG00000273008.1 RP11-351D16.3 -4.36 2.43e-05 0.011 -0.29 -0.33 Hirschsprung disease; chr10:43100520 chr10:43136824~43138334:- PAAD cis rs6570726 0.935 rs447818 ENSG00000235652.6 RP11-545I5.3 4.36 2.43e-05 0.011 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145547860 chr6:145799409~145886585:+ PAAD cis rs7826238 0.566 rs2945886 ENSG00000253981.4 ALG1L13P 4.35 2.44e-05 0.011 0.4 0.33 Systolic blood pressure; chr8:8290748 chr8:8236003~8244667:- PAAD cis rs1529672 0.825 rs1153587 ENSG00000213871.3 TAF9BP1 -4.35 2.44e-05 0.011 -0.5 -0.33 Pulmonary function;Pulmonary function (smoking interaction);Chronic obstructive pulmonary disease; chr3:25508868 chr3:25754925~25755670:+ PAAD cis rs338389 0.586 rs338402 ENSG00000260657.2 RP11-315D16.4 -4.35 2.44e-05 0.011 -0.38 -0.33 Survival in rectal cancer; chr15:67961613 chr15:68267792~68277994:- PAAD cis rs338389 0.586 rs338400 ENSG00000260657.2 RP11-315D16.4 -4.35 2.44e-05 0.011 -0.38 -0.33 Survival in rectal cancer; chr15:67961818 chr15:68267792~68277994:- PAAD cis rs950880 0.71 rs12469506 ENSG00000234389.1 AC007278.3 -4.35 2.44e-05 0.011 -0.34 -0.33 Serum protein levels (sST2); chr2:102349411 chr2:102438713~102440475:+ PAAD cis rs9419788 0.869 rs3980310 ENSG00000233377.1 MTND4P20 4.35 2.44e-05 0.011 0.3 0.33 Personality traits in bipolar disorder; chr10:94222258 chr10:94940253~94941121:- PAAD cis rs3096299 0.591 rs748940 ENSG00000274627.1 RP11-104N10.2 4.35 2.44e-05 0.011 0.29 0.33 Multiple myeloma (IgH translocation); chr16:89374349 chr16:89516797~89522217:+ PAAD cis rs9652601 1 rs9652601 ENSG00000274038.1 RP11-66H6.4 -4.35 2.44e-05 0.011 -0.39 -0.33 Systemic lupus erythematosus; chr16:11080508 chr16:11056556~11057034:+ PAAD cis rs7923609 0.905 rs7092784 ENSG00000232075.1 MRPL35P2 -4.35 2.44e-05 0.011 -0.41 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63454989 chr10:63634317~63634827:- PAAD cis rs6570726 0.967 rs373704 ENSG00000235652.6 RP11-545I5.3 4.35 2.45e-05 0.011 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145539482 chr6:145799409~145886585:+ PAAD cis rs6479901 0.895 rs1904296 ENSG00000232075.1 MRPL35P2 -4.35 2.45e-05 0.0111 -0.49 -0.33 Intelligence (multi-trait analysis); chr10:63173019 chr10:63634317~63634827:- PAAD cis rs216345 0.615 rs2994032 ENSG00000230074.1 RP11-195F19.9 -4.35 2.45e-05 0.0111 -0.43 -0.33 Bipolar disorder; chr9:33824587 chr9:34665665~34681298:+ PAAD cis rs12530845 0.943 rs58577912 ENSG00000223718.3 AC093107.7 4.35 2.45e-05 0.0111 0.54 0.33 Red blood cell traits; chr7:135644521 chr7:135660039~135660647:+ PAAD cis rs12530845 0.943 rs55889179 ENSG00000223718.3 AC093107.7 4.35 2.45e-05 0.0111 0.54 0.33 Red blood cell traits; chr7:135646883 chr7:135660039~135660647:+ PAAD cis rs12530845 0.943 rs11984203 ENSG00000223718.3 AC093107.7 -4.35 2.45e-05 0.0111 -0.54 -0.33 Red blood cell traits; chr7:135641199 chr7:135660039~135660647:+ PAAD cis rs4835473 0.712 rs12509607 ENSG00000251600.4 RP11-673E1.1 -4.35 2.45e-05 0.0111 -0.38 -0.33 Immature fraction of reticulocytes; chr4:143736894 chr4:143912331~143982454:+ PAAD cis rs4835473 0.712 rs12498218 ENSG00000251600.4 RP11-673E1.1 -4.35 2.45e-05 0.0111 -0.38 -0.33 Immature fraction of reticulocytes; chr4:143736900 chr4:143912331~143982454:+ PAAD cis rs8014671 0.597 rs8021180 ENSG00000274330.1 RP11-486O13.5 -4.35 2.45e-05 0.0111 -0.4 -0.33 Prostate cancer; chr14:70317226 chr14:70230224~70232426:+ PAAD cis rs801193 0.591 rs2707839 ENSG00000232559.3 GS1-124K5.12 4.35 2.45e-05 0.0111 0.36 0.33 Aortic root size; chr7:66728097 chr7:66554588~66576923:- PAAD cis rs42490 0.625 rs438485 ENSG00000251136.7 RP11-37B2.1 -4.35 2.46e-05 0.0111 -0.32 -0.33 Leprosy; chr8:89831190 chr8:89609409~89757727:- PAAD cis rs875971 0.964 rs778735 ENSG00000232559.3 GS1-124K5.12 4.35 2.46e-05 0.0111 0.36 0.33 Aortic root size; chr7:66349822 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6979382 ENSG00000232559.3 GS1-124K5.12 4.35 2.46e-05 0.0111 0.36 0.33 Aortic root size; chr7:66421388 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6961990 ENSG00000232559.3 GS1-124K5.12 4.35 2.46e-05 0.0111 0.36 0.33 Aortic root size; chr7:66423583 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs4718358 ENSG00000232559.3 GS1-124K5.12 4.35 2.46e-05 0.0111 0.36 0.33 Aortic root size; chr7:66508681 chr7:66554588~66576923:- PAAD cis rs875971 0.838 rs2173570 ENSG00000232559.3 GS1-124K5.12 -4.35 2.46e-05 0.0111 -0.36 -0.33 Aortic root size; chr7:66297976 chr7:66554588~66576923:- PAAD cis rs875971 1 rs937495 ENSG00000232559.3 GS1-124K5.12 -4.35 2.46e-05 0.0111 -0.36 -0.33 Aortic root size; chr7:66314811 chr7:66554588~66576923:- PAAD cis rs875971 1 rs2036264 ENSG00000232559.3 GS1-124K5.12 -4.35 2.46e-05 0.0111 -0.36 -0.33 Aortic root size; chr7:66334917 chr7:66554588~66576923:- PAAD cis rs875971 1 rs7783613 ENSG00000232559.3 GS1-124K5.12 -4.35 2.46e-05 0.0111 -0.36 -0.33 Aortic root size; chr7:66340274 chr7:66554588~66576923:- PAAD cis rs748404 0.666 rs8027748 ENSG00000205771.5 CATSPER2P1 -4.35 2.46e-05 0.0111 -0.55 -0.33 Lung cancer; chr15:43447622 chr15:43726918~43747094:- PAAD cis rs7182621 0.512 rs34151878 ENSG00000259363.4 CTD-2054N24.2 -4.35 2.46e-05 0.0111 -0.43 -0.33 Colonoscopy-negative controls vs population controls; chr15:99869179 chr15:99807023~99877148:+ PAAD cis rs7182621 0.512 rs12903892 ENSG00000259363.4 CTD-2054N24.2 -4.35 2.46e-05 0.0111 -0.43 -0.33 Colonoscopy-negative controls vs population controls; chr15:99869662 chr15:99807023~99877148:+ PAAD cis rs801193 0.66 rs2659914 ENSG00000232559.3 GS1-124K5.12 4.35 2.46e-05 0.0111 0.36 0.33 Aortic root size; chr7:66691927 chr7:66554588~66576923:- PAAD cis rs7580658 0.554 rs2069915 ENSG00000236682.1 AC068282.3 -4.35 2.46e-05 0.0111 -0.43 -0.33 Protein C levels; chr2:127420802 chr2:127389130~127400580:+ PAAD cis rs7580658 0.588 rs2069920 ENSG00000236682.1 AC068282.3 -4.35 2.46e-05 0.0111 -0.43 -0.33 Protein C levels; chr2:127422070 chr2:127389130~127400580:+ PAAD cis rs1729407 0.659 rs2542050 ENSG00000254851.1 RP11-109L13.1 -4.35 2.46e-05 0.0111 -0.4 -0.33 Apolipoprotein A-IV levels; chr11:116826401 chr11:117135528~117138582:+ PAAD cis rs1729407 0.565 rs2849173 ENSG00000254851.1 RP11-109L13.1 -4.35 2.46e-05 0.0111 -0.4 -0.33 Apolipoprotein A-IV levels; chr11:116826605 chr11:117135528~117138582:+ PAAD cis rs2564921 0.704 rs56058643 ENSG00000242142.1 SERBP1P3 -4.35 2.47e-05 0.0111 -0.42 -0.33 Height; chr3:53093751 chr3:53064283~53065091:- PAAD cis rs2243480 0.901 rs57126451 ENSG00000228409.4 CCT6P1 4.35 2.47e-05 0.0111 0.36 0.33 Diabetic kidney disease; chr7:65951319 chr7:65751142~65763354:+ PAAD cis rs9368481 0.7 rs6911401 ENSG00000241549.7 GUSBP2 4.35 2.47e-05 0.0111 0.35 0.33 Autism spectrum disorder or schizophrenia; chr6:26945435 chr6:26871484~26956554:- PAAD cis rs807029 0.533 rs3740485 ENSG00000272572.1 RP11-179B2.2 -4.35 2.47e-05 0.0111 -0.4 -0.33 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100990864 chr10:100911103~100912739:- PAAD cis rs807029 0.533 rs3740486 ENSG00000272572.1 RP11-179B2.2 -4.35 2.47e-05 0.0111 -0.4 -0.33 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100990866 chr10:100911103~100912739:- PAAD cis rs807029 0.533 rs3740487 ENSG00000272572.1 RP11-179B2.2 -4.35 2.47e-05 0.0111 -0.4 -0.33 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100991026 chr10:100911103~100912739:- PAAD cis rs807029 0.533 rs3824783 ENSG00000272572.1 RP11-179B2.2 -4.35 2.47e-05 0.0111 -0.4 -0.33 Ejection fraction in Tripanosoma cruzi seropositivity; chr10:100991094 chr10:100911103~100912739:- PAAD cis rs1075232 1 rs72722829 ENSG00000215302.7 CTD-3092A11.1 -4.35 2.47e-05 0.0111 -0.78 -0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31346911 chr15:30470779~30507623:+ PAAD cis rs1075232 1 rs16956707 ENSG00000215302.7 CTD-3092A11.1 -4.35 2.47e-05 0.0111 -0.78 -0.33 Survival in colorectal cancer (non-distant metastatic); chr15:31349430 chr15:30470779~30507623:+ PAAD cis rs2599510 0.783 rs2038534 ENSG00000276334.1 AL133243.1 4.35 2.47e-05 0.0111 0.4 0.33 Interleukin-18 levels; chr2:32434421 chr2:32521927~32523547:+ PAAD cis rs11690935 0.632 rs6737308 ENSG00000228389.1 AC068039.4 -4.35 2.47e-05 0.0111 -0.41 -0.33 Schizophrenia; chr2:172007137 chr2:171773482~171775844:+ PAAD cis rs4950322 0.515 rs11239954 ENSG00000278811.3 LINC00624 4.35 2.47e-05 0.0111 0.33 0.33 Protein quantitative trait loci; chr1:147246045 chr1:147258885~147517875:- PAAD cis rs4950322 0.515 rs76327075 ENSG00000278811.3 LINC00624 4.35 2.47e-05 0.0111 0.33 0.33 Protein quantitative trait loci; chr1:147246319 chr1:147258885~147517875:- PAAD cis rs4950322 0.515 rs11239958 ENSG00000278811.3 LINC00624 4.35 2.47e-05 0.0111 0.33 0.33 Protein quantitative trait loci; chr1:147247454 chr1:147258885~147517875:- PAAD cis rs4950322 0.515 rs12060046 ENSG00000278811.3 LINC00624 4.35 2.47e-05 0.0111 0.33 0.33 Protein quantitative trait loci; chr1:147249278 chr1:147258885~147517875:- PAAD cis rs875971 0.83 rs427973 ENSG00000237310.1 GS1-124K5.4 4.35 2.47e-05 0.0111 0.32 0.33 Aortic root size; chr7:66061661 chr7:66493706~66495474:+ PAAD cis rs875971 0.793 rs460678 ENSG00000237310.1 GS1-124K5.4 4.35 2.47e-05 0.0111 0.32 0.33 Aortic root size; chr7:66062213 chr7:66493706~66495474:+ PAAD cis rs13178541 0.638 rs11242276 ENSG00000250378.1 RP11-119J18.1 -4.35 2.47e-05 0.0111 -0.51 -0.33 IgG glycosylation; chr5:135777323 chr5:135812667~135826582:+ PAAD cis rs17123764 0.818 rs3815832 ENSG00000257464.1 RP11-161H23.8 -4.35 2.47e-05 0.0112 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49554322 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs7970241 ENSG00000257464.1 RP11-161H23.8 -4.35 2.47e-05 0.0112 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49554976 chr12:49442424~49442652:- PAAD cis rs17123764 1 rs2241418 ENSG00000257464.1 RP11-161H23.8 -4.35 2.47e-05 0.0112 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49557449 chr12:49442424~49442652:- PAAD cis rs17123764 0.792 rs11169073 ENSG00000257464.1 RP11-161H23.8 -4.35 2.47e-05 0.0112 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49574643 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs7977389 ENSG00000257464.1 RP11-161H23.8 -4.35 2.47e-05 0.0112 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49587939 chr12:49442424~49442652:- PAAD cis rs7119038 0.629 rs10892271 ENSG00000255239.1 AP002954.6 -4.35 2.48e-05 0.0112 -0.46 -0.33 Sjögren's syndrome; chr11:118727835 chr11:118688039~118690600:- PAAD cis rs875971 1 rs6945843 ENSG00000232559.3 GS1-124K5.12 -4.35 2.48e-05 0.0112 -0.35 -0.33 Aortic root size; chr7:66269796 chr7:66554588~66576923:- PAAD cis rs4950322 0.58 rs2014106 ENSG00000278811.3 LINC00624 4.35 2.48e-05 0.0112 0.33 0.33 Protein quantitative trait loci; chr1:147118499 chr1:147258885~147517875:- PAAD cis rs4950322 0.58 rs17355474 ENSG00000278811.3 LINC00624 4.35 2.48e-05 0.0112 0.33 0.33 Protein quantitative trait loci; chr1:147120541 chr1:147258885~147517875:- PAAD cis rs5758511 0.68 rs5758681 ENSG00000226450.2 CYP2D8P 4.35 2.48e-05 0.0112 0.35 0.33 Birth weight; chr22:42249085 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs34107327 ENSG00000226450.2 CYP2D8P 4.35 2.48e-05 0.0112 0.35 0.33 Birth weight; chr22:42252347 chr22:42149886~42155001:- PAAD cis rs3169166 0.546 rs2280366 ENSG00000259562.2 RP11-762H8.2 -4.35 2.48e-05 0.0112 -0.28 -0.33 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78293556 chr15:78290527~78291221:- PAAD cis rs10510102 0.516 rs12242799 ENSG00000276742.1 RP11-500G22.4 4.35 2.48e-05 0.0112 0.48 0.33 Breast cancer; chr10:121980067 chr10:121956782~121957098:+ PAAD cis rs10510102 0.516 rs79528809 ENSG00000276742.1 RP11-500G22.4 4.35 2.48e-05 0.0112 0.48 0.33 Breast cancer; chr10:121980309 chr10:121956782~121957098:+ PAAD cis rs2243480 1 rs2243480 ENSG00000228409.4 CCT6P1 4.35 2.48e-05 0.0112 0.35 0.33 Diabetic kidney disease; chr7:66134209 chr7:65751142~65763354:+ PAAD cis rs2288884 0.559 rs61287503 ENSG00000275055.1 CTC-471J1.11 -4.35 2.48e-05 0.0112 -0.4 -0.33 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52017939 chr19:52049007~52049754:+ PAAD cis rs2288884 0.559 rs73052102 ENSG00000275055.1 CTC-471J1.11 -4.35 2.48e-05 0.0112 -0.4 -0.33 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52021748 chr19:52049007~52049754:+ PAAD cis rs875971 0.964 rs160635 ENSG00000237310.1 GS1-124K5.4 4.35 2.48e-05 0.0112 0.32 0.33 Aortic root size; chr7:66063931 chr7:66493706~66495474:+ PAAD cis rs10510102 1 rs6585764 ENSG00000276742.1 RP11-500G22.4 4.35 2.48e-05 0.0112 0.46 0.33 Breast cancer; chr10:121837308 chr10:121956782~121957098:+ PAAD cis rs2742417 0.967 rs2742427 ENSG00000244357.3 RN7SL145P -4.35 2.49e-05 0.0112 -0.31 -0.33 Response to anti-depressant treatment in major depressive disorder; chr3:45694931 chr3:45742675~45742970:+ PAAD cis rs6142102 0.961 rs2235596 ENSG00000276073.1 RP5-1125A11.7 4.35 2.49e-05 0.0112 0.36 0.33 Skin pigmentation; chr20:34096503 chr20:33985617~33988989:- PAAD cis rs2739330 0.796 rs1006771 ENSG00000231271.1 AP000350.8 4.35 2.49e-05 0.0112 0.45 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23949918~23954042:+ PAAD cis rs6991838 0.798 rs6994889 ENSG00000200714.1 Y_RNA 4.35 2.49e-05 0.0112 0.39 0.33 Intelligence (multi-trait analysis); chr8:65562547 chr8:65592731~65592820:+ PAAD cis rs17836934 0.845 rs7135166 ENSG00000258302.2 RP11-981P6.1 4.35 2.49e-05 0.0112 0.29 0.33 Total body bone mineral density; chr12:90150155 chr12:89561129~89594878:+ PAAD cis rs8072100 0.967 rs9894905 ENSG00000228782.6 CTD-2026D20.3 4.35 2.49e-05 0.0112 0.33 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47408616 chr17:47450568~47492492:- PAAD cis rs9322193 0.607 rs915140 ENSG00000268592.3 RAET1E-AS1 4.35 2.49e-05 0.0112 0.45 0.33 Lung cancer; chr6:149899674 chr6:149863494~149919507:+ PAAD cis rs748404 1 rs66651343 ENSG00000249839.1 AC011330.5 -4.35 2.49e-05 0.0112 -0.52 -0.33 Lung cancer; chr15:43265806 chr15:43663654~43684339:- PAAD cis rs748404 1 rs748404 ENSG00000249839.1 AC011330.5 -4.35 2.49e-05 0.0112 -0.52 -0.33 Lung cancer; chr15:43267033 chr15:43663654~43684339:- PAAD cis rs748404 1 rs12911132 ENSG00000249839.1 AC011330.5 -4.35 2.49e-05 0.0112 -0.52 -0.33 Lung cancer; chr15:43268238 chr15:43663654~43684339:- PAAD cis rs858239 0.899 rs10262243 ENSG00000226816.2 AC005082.12 4.35 2.49e-05 0.0112 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23251368 chr7:23206013~23208045:+ PAAD cis rs858239 0.899 rs1881203 ENSG00000226816.2 AC005082.12 4.35 2.49e-05 0.0112 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23253189 chr7:23206013~23208045:+ PAAD cis rs7923609 0.967 rs7095571 ENSG00000232075.1 MRPL35P2 -4.35 2.49e-05 0.0112 -0.41 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63391199 chr10:63634317~63634827:- PAAD cis rs4664293 1 rs2357382 ENSG00000226266.5 AC009961.3 -4.35 2.5e-05 0.0112 -0.42 -0.33 Monocyte percentage of white cells; chr2:159636614 chr2:159670708~159712435:- PAAD cis rs4938303 0.633 rs17092638 ENSG00000254851.1 RP11-109L13.1 4.35 2.5e-05 0.0112 0.56 0.33 Triglycerides; chr11:116685520 chr11:117135528~117138582:+ PAAD cis rs4423214 0.559 rs10898228 ENSG00000254682.1 RP11-660L16.2 -4.35 2.5e-05 0.0112 -0.54 -0.33 Vitamin D levels; chr11:71517312 chr11:71448674~71452157:+ PAAD cis rs4423214 0.592 rs79634040 ENSG00000254682.1 RP11-660L16.2 -4.35 2.5e-05 0.0112 -0.54 -0.33 Vitamin D levels; chr11:71519123 chr11:71448674~71452157:+ PAAD cis rs4423214 0.592 rs11234027 ENSG00000254682.1 RP11-660L16.2 -4.35 2.5e-05 0.0112 -0.54 -0.33 Vitamin D levels; chr11:71523061 chr11:71448674~71452157:+ PAAD cis rs4423214 0.592 rs7114252 ENSG00000254682.1 RP11-660L16.2 -4.35 2.5e-05 0.0112 -0.54 -0.33 Vitamin D levels; chr11:71526560 chr11:71448674~71452157:+ PAAD cis rs11997175 0.766 rs7387133 ENSG00000240738.1 RP1-273G13.1 -4.35 2.5e-05 0.0112 -0.37 -0.33 Body mass index; chr8:33869527 chr8:33859480~33860223:- PAAD cis rs8062405 0.755 rs2077031 ENSG00000251417.2 RP11-1348G14.4 -4.35 2.5e-05 0.0112 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28591847 chr16:28802743~28817828:+ PAAD cis rs8062405 0.69 rs762634 ENSG00000251417.2 RP11-1348G14.4 -4.35 2.5e-05 0.0112 -0.32 -0.33 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28592014 chr16:28802743~28817828:+ PAAD cis rs62034325 0.697 rs710410 ENSG00000251417.2 RP11-1348G14.4 -4.35 2.5e-05 0.0112 -0.32 -0.33 Body mass index; chr16:28592021 chr16:28802743~28817828:+ PAAD cis rs2348418 0.831 rs2348416 ENSG00000247934.4 RP11-967K21.1 4.35 2.5e-05 0.0112 0.32 0.33 Lung function (FEV1);Lung function (FVC); chr12:28556283 chr12:28163298~28190738:- PAAD cis rs17772222 0.682 rs28711639 ENSG00000258983.2 RP11-507K2.2 4.35 2.5e-05 0.0112 0.41 0.33 Coronary artery calcification; chr14:88482277 chr14:88499334~88515502:+ PAAD cis rs858239 0.899 rs28458177 ENSG00000226816.2 AC005082.12 4.35 2.5e-05 0.0112 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23255253 chr7:23206013~23208045:+ PAAD cis rs9595908 0.929 rs34916533 ENSG00000212293.1 SNORA16 4.35 2.5e-05 0.0113 0.4 0.33 Body mass index; chr13:32500537 chr13:32420390~32420516:- PAAD cis rs9595908 0.965 rs2239748 ENSG00000212293.1 SNORA16 4.35 2.5e-05 0.0113 0.4 0.33 Body mass index; chr13:32527680 chr13:32420390~32420516:- PAAD cis rs6977955 0.627 rs1513275 ENSG00000234336.5 JAZF1-AS1 4.35 2.5e-05 0.0113 0.43 0.33 Allergic disease (asthma, hay fever or eczema); chr7:28219614 chr7:28180322~28243917:+ PAAD cis rs34375054 0.573 rs12811438 ENSG00000279233.1 RP11-158L12.4 4.35 2.5e-05 0.0113 0.31 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125168944 chr12:125138245~125141711:+ PAAD cis rs2564921 0.73 rs56386026 ENSG00000242142.1 SERBP1P3 -4.35 2.5e-05 0.0113 -0.42 -0.33 Height; chr3:53080524 chr3:53064283~53065091:- PAAD cis rs3864261 0.515 rs55769858 ENSG00000272081.1 CTD-2376I4.2 4.35 2.51e-05 0.0113 0.4 0.33 Discordance in emotional problems in monozygotic twins; chr5:72984937 chr5:72955206~72955699:- PAAD cis rs6570726 0.837 rs636894 ENSG00000235652.6 RP11-545I5.3 4.35 2.51e-05 0.0113 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145542986 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs382910 ENSG00000235652.6 RP11-545I5.3 4.35 2.51e-05 0.0113 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145544805 chr6:145799409~145886585:+ PAAD cis rs7224610 1 rs7224610 ENSG00000263096.1 RP11-515O17.2 4.35 2.51e-05 0.0113 0.4 0.33 Urate levels; chr17:55287427 chr17:55271504~55273653:- PAAD cis rs9926296 0.656 rs7191144 ENSG00000260259.1 RP11-368I7.4 -4.35 2.51e-05 0.0113 -0.39 -0.33 Vitiligo; chr16:89756985 chr16:89682620~89686569:- PAAD cis rs7182621 0.546 rs11635811 ENSG00000259363.4 CTD-2054N24.2 -4.35 2.52e-05 0.0113 -0.41 -0.33 Colonoscopy-negative controls vs population controls; chr15:99839918 chr15:99807023~99877148:+ PAAD cis rs8072100 0.967 rs4338849 ENSG00000228782.6 CTD-2026D20.3 4.35 2.52e-05 0.0113 0.33 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47435117 chr17:47450568~47492492:- PAAD cis rs2790457 0.958 rs2532744 ENSG00000254635.4 WAC-AS1 -4.35 2.52e-05 0.0113 -0.33 -0.33 Multiple myeloma; chr10:28613689 chr10:28522652~28532743:- PAAD cis rs2283792 1 rs2006893 ENSG00000228050.1 TOP3BP1 4.35 2.52e-05 0.0113 0.36 0.33 Multiple sclerosis; chr22:21774389 chr22:22223187~22224566:- PAAD cis rs2729354 0.768 rs2581922 ENSG00000265566.2 RN7SL605P -4.35 2.52e-05 0.0113 -0.41 -0.33 Blood protein levels; chr11:57497927 chr11:57528085~57528365:- PAAD cis rs42490 0.664 rs421411 ENSG00000251136.7 RP11-37B2.1 -4.35 2.52e-05 0.0113 -0.3 -0.33 Leprosy; chr8:89808665 chr8:89609409~89757727:- PAAD cis rs42490 0.664 rs43226 ENSG00000251136.7 RP11-37B2.1 -4.35 2.52e-05 0.0113 -0.3 -0.33 Leprosy; chr8:89809048 chr8:89609409~89757727:- PAAD cis rs42490 0.664 rs422559 ENSG00000251136.7 RP11-37B2.1 -4.35 2.52e-05 0.0113 -0.3 -0.33 Leprosy; chr8:89809121 chr8:89609409~89757727:- PAAD cis rs42490 0.625 rs39519 ENSG00000251136.7 RP11-37B2.1 4.35 2.52e-05 0.0113 0.32 0.33 Leprosy; chr8:89833814 chr8:89609409~89757727:- PAAD cis rs6540731 0.782 rs12038888 ENSG00000229983.1 RP11-15I11.2 4.35 2.52e-05 0.0113 0.39 0.33 Intelligence (childhood); chr1:212192711 chr1:212168207~212190259:+ PAAD cis rs7712401 0.601 rs1990890 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0113 0.42 0.33 Mean platelet volume; chr5:122847275 chr5:123022487~123022783:- PAAD cis rs858239 0.6 rs7776649 ENSG00000226816.2 AC005082.12 4.35 2.53e-05 0.0113 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23079698 chr7:23206013~23208045:+ PAAD cis rs4218 0.505 rs6494064 ENSG00000277144.1 RP11-59H7.4 4.35 2.53e-05 0.0114 0.39 0.33 Social communication problems; chr15:59053192 chr15:59115547~59116089:- PAAD cis rs55665837 0.701 rs12787709 ENSG00000251991.1 RNU7-49P 4.35 2.53e-05 0.0114 0.39 0.33 Vitamin D levels; chr11:14617711 chr11:14478892~14478953:+ PAAD cis rs7712401 0.601 rs152039 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0114 0.42 0.33 Mean platelet volume; chr5:122884970 chr5:123022487~123022783:- PAAD cis rs7712401 0.645 rs154497 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0114 0.42 0.33 Mean platelet volume; chr5:122885725 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs154496 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0114 0.42 0.33 Mean platelet volume; chr5:122886036 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs144597 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0114 0.42 0.33 Mean platelet volume; chr5:122887537 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246282 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0114 0.42 0.33 Mean platelet volume; chr5:122889910 chr5:123022487~123022783:- PAAD cis rs7712401 0.623 rs538424 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0114 0.42 0.33 Mean platelet volume; chr5:122893068 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246275 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0114 0.42 0.33 Mean platelet volume; chr5:122895718 chr5:123022487~123022783:- PAAD cis rs7712401 0.623 rs30032 ENSG00000263432.2 RN7SL689P 4.35 2.53e-05 0.0114 0.42 0.33 Mean platelet volume; chr5:122902692 chr5:123022487~123022783:- PAAD cis rs9357354 0.929 rs6458216 ENSG00000218809.1 RP1-229K20.5 4.35 2.53e-05 0.0114 0.37 0.33 Telomere length; chr6:41344998 chr6:41269875~41270239:- PAAD cis rs227932 0.764 rs6461725 ENSG00000234286.1 AC006026.13 -4.34 2.54e-05 0.0114 -0.56 -0.33 Schizophrenia; chr7:23690555 chr7:23680195~23680786:- PAAD cis rs2599510 0.811 rs2754523 ENSG00000276334.1 AL133243.1 4.34 2.54e-05 0.0114 0.4 0.33 Interleukin-18 levels; chr2:32612043 chr2:32521927~32523547:+ PAAD cis rs3131082 1 rs3131082 ENSG00000281831.1 HCP5B 4.34 2.54e-05 0.0114 0.72 0.33 Tuberculosis; chr6:29015497 chr6:29871895~29873783:- PAAD cis rs11089937 0.626 rs737841 ENSG00000211639.2 IGLV4-60 4.34 2.54e-05 0.0114 0.37 0.33 Periodontitis (PAL4Q3); chr22:22162769 chr22:22162199~22162681:+ PAAD cis rs79040073 0.637 rs17476361 ENSG00000259531.2 RP11-295H24.3 4.34 2.54e-05 0.0114 0.56 0.33 Lung cancer in ever smokers; chr15:49302255 chr15:49365124~49366685:- PAAD cis rs4713118 0.516 rs7739216 ENSG00000280107.1 AL022393.9 -4.34 2.54e-05 0.0114 -0.56 -0.33 Parkinson's disease; chr6:28112168 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs35512245 ENSG00000280107.1 AL022393.9 -4.34 2.54e-05 0.0114 -0.56 -0.33 Depression; chr6:28112175 chr6:28170845~28172521:+ PAAD cis rs1113500 0.799 rs1777459 ENSG00000226822.1 RP11-356N1.2 -4.34 2.54e-05 0.0114 -0.39 -0.33 Growth-regulated protein alpha levels; chr1:108042377 chr1:108071482~108074519:+ PAAD cis rs12220777 0.748 rs12259239 ENSG00000230091.5 TMEM254-AS1 4.34 2.54e-05 0.0114 0.51 0.33 Chronic obstructive pulmonary disease-related biomarkers; chr10:80103265 chr10:80046860~80078912:- PAAD cis rs875971 0.522 rs1617484 ENSG00000236529.1 RP13-254B10.1 4.34 2.54e-05 0.0114 0.37 0.33 Aortic root size; chr7:65998108 chr7:65840212~65840596:+ PAAD cis rs10740039 0.583 rs1904404 ENSG00000254271.1 RP11-131N11.4 -4.34 2.54e-05 0.0114 -0.41 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60742428 chr10:60734342~60741828:+ PAAD cis rs58873874 1 rs11740562 ENSG00000251405.2 CTB-109A12.1 -4.34 2.54e-05 0.0114 -0.63 -0.33 Bipolar disorder (body mass index interaction); chr5:157515277 chr5:157362615~157460078:- PAAD cis rs9357354 0.929 rs6916897 ENSG00000218809.1 RP1-229K20.5 4.34 2.55e-05 0.0114 0.37 0.33 Telomere length; chr6:41344681 chr6:41269875~41270239:- PAAD cis rs2882667 0.556 rs6873733 ENSG00000253404.1 AC034243.1 4.34 2.55e-05 0.0114 0.37 0.33 Age-related hearing impairment (SNP x SNP interaction); chr5:139067628 chr5:138744434~138753309:- PAAD cis rs9876781 0.56 rs2362451 ENSG00000229759.1 MRPS18AP1 -4.34 2.55e-05 0.0114 -0.35 -0.33 Longevity; chr3:48358338 chr3:48256350~48256938:- PAAD cis rs9876781 0.507 rs1824362 ENSG00000229759.1 MRPS18AP1 -4.34 2.55e-05 0.0114 -0.35 -0.33 Longevity; chr3:48360459 chr3:48256350~48256938:- PAAD cis rs867529 1 rs11681299 ENSG00000230006.6 ANKRD36BP2 -4.34 2.55e-05 0.0114 -0.29 -0.33 Height; chr2:88602214 chr2:88765807~88806612:+ PAAD cis rs58873874 0.737 rs11746837 ENSG00000251405.2 CTB-109A12.1 4.34 2.55e-05 0.0114 0.67 0.33 Bipolar disorder (body mass index interaction); chr5:157491138 chr5:157362615~157460078:- PAAD cis rs853679 0.517 rs16893666 ENSG00000204709.4 LINC01556 -4.34 2.55e-05 0.0114 -0.55 -0.33 Depression; chr6:28086929 chr6:28943877~28944537:+ PAAD cis rs5758659 0.652 rs1063392 ENSG00000273366.1 CTA-989H11.1 4.34 2.55e-05 0.0114 0.39 0.33 Cognitive function; chr22:42058946 chr22:42278188~42278846:+ PAAD cis rs1707322 0.752 rs11211145 ENSG00000280836.1 AL355480.1 -4.34 2.56e-05 0.0115 -0.4 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642819 chr1:45581219~45581321:- PAAD cis rs7429990 0.864 rs6777081 ENSG00000228638.1 FCF1P2 4.34 2.56e-05 0.0115 0.37 0.33 Educational attainment (years of education); chr3:48114079 chr3:48290793~48291375:- PAAD cis rs6504950 0.924 rs187242 ENSG00000275710.1 RP11-257O5.4 4.34 2.56e-05 0.0115 0.4 0.33 Breast cancer; chr17:55115585 chr17:54964474~54964679:+ PAAD cis rs6504950 0.732 rs244373 ENSG00000275710.1 RP11-257O5.4 -4.34 2.56e-05 0.0115 -0.4 -0.33 Breast cancer; chr17:55107588 chr17:54964474~54964679:+ PAAD cis rs6504950 0.924 rs244353 ENSG00000275710.1 RP11-257O5.4 -4.34 2.56e-05 0.0115 -0.4 -0.33 Breast cancer; chr17:55117408 chr17:54964474~54964679:+ PAAD cis rs8031584 0.918 rs11639169 ENSG00000260382.1 RP11-540B6.2 4.34 2.56e-05 0.0115 0.42 0.33 Huntington's disease progression; chr15:30963235 chr15:30882267~30883231:- PAAD cis rs2717559 0.542 rs2717560 ENSG00000253741.1 CTD-2292P10.4 4.34 2.56e-05 0.0115 0.44 0.33 Urinary tract infection frequency; chr8:142800254 chr8:142702252~142726973:- PAAD cis rs17772222 1 rs12589480 ENSG00000258983.2 RP11-507K2.2 4.34 2.56e-05 0.0115 0.46 0.33 Coronary artery calcification; chr14:88414926 chr14:88499334~88515502:+ PAAD cis rs17772222 0.674 rs112788894 ENSG00000258983.2 RP11-507K2.2 4.34 2.56e-05 0.0115 0.46 0.33 Coronary artery calcification; chr14:88442850 chr14:88499334~88515502:+ PAAD cis rs10783487 0.947 rs1920606 ENSG00000257542.4 OR7E47P -4.34 2.56e-05 0.0115 -0.46 -0.33 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52088244 chr12:52079696~52108261:+ PAAD cis rs812925 0.502 rs2084318 ENSG00000273302.1 RP11-493E12.2 -4.34 2.56e-05 0.0115 -0.28 -0.33 Immature fraction of reticulocytes; chr2:61425466 chr2:61199979~61200769:+ PAAD cis rs11123170 0.503 rs28679654 ENSG00000274877.1 RP11-65I12.1 -4.34 2.57e-05 0.0115 -0.44 -0.33 Renal function-related traits (BUN); chr2:113210040 chr2:113237595~113240825:+ PAAD cis rs5758511 0.689 rs45441993 ENSG00000226450.2 CYP2D8P 4.34 2.57e-05 0.0115 0.42 0.33 Birth weight; chr22:42075734 chr22:42149886~42155001:- PAAD cis rs7712401 0.601 rs246265 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122919255 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs246267 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122920409 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246268 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122920647 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246269 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122921046 chr5:123022487~123022783:- PAAD cis rs7712401 0.607 rs246270 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122922954 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs377316 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122924180 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs438196 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122927368 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs401729 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122928590 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs2910140 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122928700 chr5:123022487~123022783:- PAAD cis rs7712401 0.645 rs246316 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122930502 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246315 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122930743 chr5:123022487~123022783:- PAAD cis rs7712401 0.525 rs246312 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122933760 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246308 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122934395 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30047 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122934829 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs30046 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122935538 chr5:123022487~123022783:- PAAD cis rs7712401 0.623 rs30044 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122936385 chr5:123022487~123022783:- PAAD cis rs7712401 0.623 rs30043 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122936598 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs185009 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122938072 chr5:123022487~123022783:- PAAD cis rs7712401 0.541 rs42537 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122938993 chr5:123022487~123022783:- PAAD cis rs7712401 0.58 rs185008 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122939039 chr5:123022487~123022783:- PAAD cis rs7712401 0.58 rs30041 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122939658 chr5:123022487~123022783:- PAAD cis rs7712401 0.58 rs42536 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122940728 chr5:123022487~123022783:- PAAD cis rs7712401 0.584 rs30037 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122942295 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30035 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122942850 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246306 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122943523 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs2927639 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122943971 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246274 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122945108 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246273 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122945280 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30028 ENSG00000263432.2 RN7SL689P 4.34 2.57e-05 0.0115 0.43 0.33 Mean platelet volume; chr5:122947574 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30029 ENSG00000263432.2 RN7SL689P -4.34 2.57e-05 0.0115 -0.43 -0.33 Mean platelet volume; chr5:122947475 chr5:123022487~123022783:- PAAD cis rs7923837 1 rs7923866 ENSG00000236493.2 EIF2S2P3 4.34 2.57e-05 0.0115 0.42 0.33 Multiple sclerosis;Body mass index; chr10:92722319 chr10:92668745~92669743:- PAAD cis rs6142102 0.961 rs6087557 ENSG00000276073.1 RP5-1125A11.7 -4.34 2.57e-05 0.0115 -0.36 -0.33 Skin pigmentation; chr20:34110469 chr20:33985617~33988989:- PAAD cis rs79040073 0.637 rs60594237 ENSG00000259531.2 RP11-295H24.3 4.34 2.57e-05 0.0115 0.57 0.33 Lung cancer in ever smokers; chr15:49379916 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs77296528 ENSG00000259531.2 RP11-295H24.3 4.34 2.57e-05 0.0115 0.57 0.33 Lung cancer in ever smokers; chr15:49381827 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs79365293 ENSG00000259531.2 RP11-295H24.3 4.34 2.57e-05 0.0115 0.57 0.33 Lung cancer in ever smokers; chr15:49402268 chr15:49365124~49366685:- PAAD cis rs732716 0.889 rs62129355 ENSG00000267769.1 CTB-50L17.9 -4.34 2.58e-05 0.0115 -0.43 -0.33 Mean corpuscular volume; chr19:4397037 chr19:4454014~4455286:+ PAAD cis rs2262909 0.962 rs1526884 ENSG00000279377.1 AC003973.3 -4.34 2.58e-05 0.0115 -0.31 -0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22120849 chr19:21965708~21968529:- PAAD cis rs3738443 1 rs61839991 ENSG00000259865.1 RP11-488L18.10 4.34 2.58e-05 0.0115 0.32 0.33 Alcohol dependence; chr1:247186284 chr1:247187281~247188526:- PAAD cis rs3738443 0.953 rs56065612 ENSG00000259865.1 RP11-488L18.10 4.34 2.58e-05 0.0115 0.32 0.33 Alcohol dependence; chr1:247194812 chr1:247187281~247188526:- PAAD cis rs3738443 0.953 rs61839997 ENSG00000259865.1 RP11-488L18.10 4.34 2.58e-05 0.0115 0.32 0.33 Alcohol dependence; chr1:247197867 chr1:247187281~247188526:- PAAD cis rs9322193 0.607 rs12209310 ENSG00000268592.3 RAET1E-AS1 4.34 2.58e-05 0.0115 0.44 0.33 Lung cancer; chr6:149904882 chr6:149863494~149919507:+ PAAD cis rs9322193 0.607 rs12210822 ENSG00000268592.3 RAET1E-AS1 4.34 2.58e-05 0.0115 0.44 0.33 Lung cancer; chr6:149905356 chr6:149863494~149919507:+ PAAD cis rs2729354 0.953 rs1846567 ENSG00000265566.2 RN7SL605P -4.34 2.58e-05 0.0115 -0.45 -0.33 Blood protein levels; chr11:57590120 chr11:57528085~57528365:- PAAD cis rs7189233 0.955 rs72801821 ENSG00000279722.1 RP11-44F14.6 -4.34 2.58e-05 0.0115 -0.36 -0.33 Intelligence (multi-trait analysis); chr16:53445740 chr16:53487607~53489943:- PAAD cis rs11159086 0.793 rs17100414 ENSG00000259005.1 RP3-449M8.6 4.34 2.58e-05 0.0116 0.44 0.33 Advanced glycation end-product levels; chr14:74467918 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs11625502 ENSG00000259005.1 RP3-449M8.6 4.34 2.58e-05 0.0116 0.44 0.33 Advanced glycation end-product levels; chr14:74468309 chr14:74474007~74474864:- PAAD cis rs11159086 0.793 rs1029702 ENSG00000259005.1 RP3-449M8.6 4.34 2.58e-05 0.0116 0.44 0.33 Advanced glycation end-product levels; chr14:74473909 chr14:74474007~74474864:- PAAD cis rs227932 0.681 rs7776862 ENSG00000234800.2 PCMTD1P3 -4.34 2.59e-05 0.0116 -0.55 -0.33 Schizophrenia; chr7:23736607 chr7:23721311~23721782:- PAAD cis rs957448 1 rs1055800 ENSG00000253704.1 RP11-267M23.4 -4.34 2.59e-05 0.0116 -0.41 -0.33 Nonsyndromic cleft lip with cleft palate; chr8:94510810 chr8:94553722~94569745:+ PAAD cis rs6504622 0.818 rs3851784 ENSG00000262539.1 RP11-259G18.3 4.34 2.59e-05 0.0116 0.42 0.33 Orofacial clefts; chr17:46962751 chr17:46259551~46260606:- PAAD cis rs2188561 0.697 rs34986332 ENSG00000241764.3 AC002467.7 4.34 2.59e-05 0.0116 0.42 0.33 Alcohol consumption; chr7:107739010 chr7:107742817~107744581:- PAAD cis rs2188561 0.638 rs28690459 ENSG00000241764.3 AC002467.7 4.34 2.59e-05 0.0116 0.42 0.33 Alcohol consumption; chr7:107740258 chr7:107742817~107744581:- PAAD cis rs4938303 0.549 rs12785990 ENSG00000254851.1 RP11-109L13.1 4.34 2.59e-05 0.0116 0.48 0.33 Triglycerides; chr11:116692990 chr11:117135528~117138582:+ PAAD cis rs6723226 0.75 rs3769597 ENSG00000276334.1 AL133243.1 4.34 2.59e-05 0.0116 0.39 0.33 Intelligence (multi-trait analysis); chr2:32466332 chr2:32521927~32523547:+ PAAD cis rs11159086 0.793 rs11621693 ENSG00000259005.1 RP3-449M8.6 4.34 2.59e-05 0.0116 0.44 0.33 Advanced glycation end-product levels; chr14:74472631 chr14:74474007~74474864:- PAAD cis rs4835473 0.932 rs12503900 ENSG00000251600.4 RP11-673E1.1 -4.34 2.59e-05 0.0116 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143812459 chr4:143912331~143982454:+ PAAD cis rs2250402 0.51 rs937215 ENSG00000245849.5 RAD51-AS1 -4.34 2.59e-05 0.0116 -0.4 -0.33 Corneal curvature; chr15:40038492 chr15:40686724~40695107:- PAAD cis rs950880 0.71 rs17027071 ENSG00000234389.1 AC007278.3 -4.34 2.59e-05 0.0116 -0.33 -0.33 Serum protein levels (sST2); chr2:102396214 chr2:102438713~102440475:+ PAAD cis rs2658782 0.789 rs2658775 ENSG00000279684.1 RP11-755E23.2 -4.34 2.59e-05 0.0116 -0.55 -0.33 Pulmonary function decline; chr11:93393633 chr11:93286629~93288903:- PAAD cis rs2658782 0.789 rs2658773 ENSG00000279684.1 RP11-755E23.2 -4.34 2.59e-05 0.0116 -0.55 -0.33 Pulmonary function decline; chr11:93393748 chr11:93286629~93288903:- PAAD cis rs453301 0.686 rs11785634 ENSG00000253893.2 FAM85B 4.34 2.59e-05 0.0116 0.46 0.33 Joint mobility (Beighton score); chr8:9035087 chr8:8167819~8226614:- PAAD cis rs7829975 0.511 rs1543238 ENSG00000173295.6 FAM86B3P 4.34 2.6e-05 0.0116 0.37 0.33 Mood instability; chr8:8277287 chr8:8228595~8244865:+ PAAD cis rs7829975 0.511 rs1401390 ENSG00000173295.6 FAM86B3P 4.34 2.6e-05 0.0116 0.37 0.33 Mood instability; chr8:8278888 chr8:8228595~8244865:+ PAAD cis rs7078219 1 rs61872688 ENSG00000257582.4 LINC01475 -4.34 2.6e-05 0.0116 -0.35 -0.33 Dental caries; chr10:99513789 chr10:99526350~99531177:- PAAD cis rs7078219 0.965 rs10883358 ENSG00000257582.4 LINC01475 -4.34 2.6e-05 0.0116 -0.35 -0.33 Dental caries; chr10:99514100 chr10:99526350~99531177:- PAAD cis rs858239 0.6 rs7785842 ENSG00000226816.2 AC005082.12 4.34 2.6e-05 0.0116 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23102087 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs7456915 ENSG00000226816.2 AC005082.12 4.34 2.6e-05 0.0116 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23103430 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs13438179 ENSG00000226816.2 AC005082.12 4.34 2.6e-05 0.0116 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23104232 chr7:23206013~23208045:+ PAAD cis rs6061231 0.631 rs2427318 ENSG00000273619.1 RP5-908M14.9 -4.34 2.6e-05 0.0116 -0.28 -0.33 Colorectal cancer; chr20:62400671 chr20:62386303~62386970:- PAAD cis rs2188561 0.697 rs7782475 ENSG00000241764.3 AC002467.7 -4.34 2.61e-05 0.0116 -0.42 -0.33 Alcohol consumption; chr7:107745806 chr7:107742817~107744581:- PAAD cis rs7182621 0.639 rs34701806 ENSG00000182397.13 DNM1P46 4.34 2.61e-05 0.0116 0.44 0.33 Colonoscopy-negative controls vs population controls; chr15:99872953 chr15:99790156~99806927:- PAAD cis rs1150668 0.796 rs9468372 ENSG00000219891.2 ZSCAN12P1 4.34 2.61e-05 0.0116 0.42 0.33 Pubertal anthropometrics; chr6:28411584 chr6:28091154~28093664:+ PAAD cis rs9901225 1 rs9901225 ENSG00000108785.7 HSD17B1P1 -4.34 2.61e-05 0.0116 -0.29 -0.33 Colorectal or endometrial cancer; chr17:42603793 chr17:42546764~42548706:+ PAAD cis rs17772222 1 rs17124700 ENSG00000258983.2 RP11-507K2.2 4.34 2.61e-05 0.0117 0.46 0.33 Coronary artery calcification; chr14:88439285 chr14:88499334~88515502:+ PAAD cis rs1185460 0.967 rs1177562 ENSG00000271751.1 RP11-110I1.14 -4.34 2.61e-05 0.0117 -0.43 -0.33 Coronary artery disease; chr11:119078621 chr11:119065263~119065677:- PAAD cis rs7829975 0.511 rs2948286 ENSG00000173295.6 FAM86B3P 4.34 2.61e-05 0.0117 0.37 0.33 Mood instability; chr8:8272638 chr8:8228595~8244865:+ PAAD cis rs6683071 0.557 rs2378605 ENSG00000272750.1 RP11-378J18.8 -4.34 2.62e-05 0.0117 -0.47 -0.33 Cognitive performance; chr1:222732211 chr1:222658867~222661512:- PAAD cis rs12468226 0.808 rs77251002 ENSG00000273456.1 RP11-686O6.2 4.34 2.62e-05 0.0117 0.52 0.33 Urate levels; chr2:202150236 chr2:202374932~202375604:- PAAD cis rs2581828 0.58 rs9834111 ENSG00000242142.1 SERBP1P3 -4.34 2.62e-05 0.0117 -0.41 -0.33 Crohn's disease; chr3:53136028 chr3:53064283~53065091:- PAAD cis rs2581828 0.58 rs9817467 ENSG00000242142.1 SERBP1P3 -4.34 2.62e-05 0.0117 -0.41 -0.33 Crohn's disease; chr3:53136609 chr3:53064283~53065091:- PAAD cis rs5758511 0.68 rs5751243 ENSG00000226450.2 CYP2D8P 4.34 2.62e-05 0.0117 0.35 0.33 Birth weight; chr22:42221171 chr22:42149886~42155001:- PAAD cis rs6921919 1 rs6921919 ENSG00000216901.1 AL022393.7 4.34 2.63e-05 0.0117 0.51 0.33 Autism spectrum disorder or schizophrenia; chr6:28357424 chr6:28176188~28176674:+ PAAD cis rs2564921 0.704 rs11130333 ENSG00000242142.1 SERBP1P3 -4.34 2.63e-05 0.0117 -0.42 -0.33 Height; chr3:52977358 chr3:53064283~53065091:- PAAD cis rs12908161 1 rs17600551 ENSG00000259728.4 LINC00933 4.34 2.63e-05 0.0117 0.43 0.33 Schizophrenia; chr15:84776027 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs62019469 ENSG00000259728.4 LINC00933 4.34 2.63e-05 0.0117 0.43 0.33 Schizophrenia; chr15:84777989 chr15:84570649~84580175:+ PAAD cis rs875971 0.66 rs1860468 ENSG00000237310.1 GS1-124K5.4 -4.34 2.63e-05 0.0117 -0.31 -0.33 Aortic root size; chr7:66642265 chr7:66493706~66495474:+ PAAD cis rs1150668 0.796 rs1005125 ENSG00000219891.2 ZSCAN12P1 4.34 2.63e-05 0.0117 0.43 0.33 Pubertal anthropometrics; chr6:28399578 chr6:28091154~28093664:+ PAAD cis rs6472235 0.656 rs11987304 ENSG00000200714.1 Y_RNA -4.34 2.63e-05 0.0117 -0.44 -0.33 Plateletcrit;Myopia (pathological); chr8:65957778 chr8:65592731~65592820:+ PAAD cis rs2243480 1 rs73142121 ENSG00000228409.4 CCT6P1 4.34 2.63e-05 0.0117 0.35 0.33 Diabetic kidney disease; chr7:65846219 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs34004500 ENSG00000228409.4 CCT6P1 4.34 2.63e-05 0.0117 0.35 0.33 Diabetic kidney disease; chr7:65847191 chr7:65751142~65763354:+ PAAD cis rs12701220 0.817 rs59471534 ENSG00000229043.2 AC091729.9 -4.34 2.63e-05 0.0117 -0.46 -0.33 Bronchopulmonary dysplasia; chr7:1045588 chr7:1160374~1165267:+ PAAD cis rs9368481 0.678 rs62402024 ENSG00000241549.7 GUSBP2 4.34 2.63e-05 0.0117 0.35 0.33 Autism spectrum disorder or schizophrenia; chr6:26956197 chr6:26871484~26956554:- PAAD cis rs321358 1 rs321356 ENSG00000271390.1 RP11-89C3.3 -4.34 2.63e-05 0.0117 -0.5 -0.33 Body mass index; chr11:111124957 chr11:111089870~111090368:- PAAD cis rs2564921 0.654 rs73087044 ENSG00000242142.1 SERBP1P3 -4.34 2.63e-05 0.0117 -0.41 -0.33 Height; chr3:52975027 chr3:53064283~53065091:- PAAD cis rs7646881 0.812 rs59192661 ENSG00000240207.5 RP11-379F4.4 -4.34 2.64e-05 0.0117 -0.52 -0.33 Tetralogy of Fallot; chr3:158741238 chr3:158732263~158784070:+ PAAD cis rs7646881 0.812 rs7624408 ENSG00000240207.5 RP11-379F4.4 -4.34 2.64e-05 0.0117 -0.52 -0.33 Tetralogy of Fallot; chr3:158742269 chr3:158732263~158784070:+ PAAD cis rs7646881 0.812 rs7636023 ENSG00000240207.5 RP11-379F4.4 -4.34 2.64e-05 0.0117 -0.52 -0.33 Tetralogy of Fallot; chr3:158742270 chr3:158732263~158784070:+ PAAD cis rs7646881 0.812 rs73017536 ENSG00000240207.5 RP11-379F4.4 -4.34 2.64e-05 0.0117 -0.52 -0.33 Tetralogy of Fallot; chr3:158742813 chr3:158732263~158784070:+ PAAD cis rs7646881 0.812 rs73017539 ENSG00000240207.5 RP11-379F4.4 -4.34 2.64e-05 0.0117 -0.52 -0.33 Tetralogy of Fallot; chr3:158742954 chr3:158732263~158784070:+ PAAD cis rs7646881 0.812 rs73017540 ENSG00000240207.5 RP11-379F4.4 -4.34 2.64e-05 0.0117 -0.52 -0.33 Tetralogy of Fallot; chr3:158742999 chr3:158732263~158784070:+ PAAD cis rs1275411 0.511 rs4899275 ENSG00000259062.2 ACTN1-AS1 4.34 2.64e-05 0.0118 0.41 0.33 Neuroticism; chr14:68970841 chr14:68979682~68987463:+ PAAD cis rs4950322 0.515 rs17160050 ENSG00000278811.3 LINC00624 4.34 2.64e-05 0.0118 0.34 0.33 Protein quantitative trait loci; chr1:147255558 chr1:147258885~147517875:- PAAD cis rs2739330 0.652 rs2000469 ENSG00000231271.1 AP000350.8 4.33 2.64e-05 0.0118 0.47 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23949918~23954042:+ PAAD cis rs7189233 0.955 rs11540358 ENSG00000279722.1 RP11-44F14.6 -4.33 2.64e-05 0.0118 -0.36 -0.33 Intelligence (multi-trait analysis); chr16:53470031 chr16:53487607~53489943:- PAAD cis rs8026198 0.929 rs3743006 ENSG00000260571.1 BNIP3P5 -4.33 2.64e-05 0.0118 -0.54 -0.33 Fibrinogen levels; chr15:42353570 chr15:42313687~42314386:+ PAAD cis rs4835473 0.932 rs1450235 ENSG00000251600.4 RP11-673E1.1 4.33 2.64e-05 0.0118 0.39 0.33 Immature fraction of reticulocytes; chr4:143782927 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7670010 ENSG00000251600.4 RP11-673E1.1 4.33 2.64e-05 0.0118 0.39 0.33 Immature fraction of reticulocytes; chr4:143821679 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs5025156 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143738025 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1580002 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143766507 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs34521499 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143777628 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs71612420 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143779107 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs34264936 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143780294 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13140028 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143782195 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13134869 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143782301 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34324222 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143784572 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs12508285 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143792642 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs7667544 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143793802 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6849896 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143794927 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs35998817 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143795355 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13134808 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143798339 chr4:143912331~143982454:+ PAAD cis rs4835473 0.808 rs6831401 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143801038 chr4:143912331~143982454:+ PAAD cis rs4835473 0.808 rs6836630 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143801068 chr4:143912331~143982454:+ PAAD cis rs4835473 0.778 rs6853798 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143801153 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13101541 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143806590 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs12502940 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143812117 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs12503074 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143812560 chr4:143912331~143982454:+ PAAD cis rs4835473 0.778 rs2622380 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143814571 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35792820 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143814806 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs62337300 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143815897 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7697498 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143816854 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7656455 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143817005 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13133239 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143818894 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13106488 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143818969 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13105102 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143819046 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs13105118 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143819077 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35271123 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143819629 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1383443 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143819940 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs17695238 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143820720 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7669198 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143821229 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs6834494 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143822257 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11734290 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143823636 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11734383 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143824093 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs11735295 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143824150 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs35809032 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143824797 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs6838981 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143826484 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs17763107 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143828512 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs17695782 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143830311 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34917094 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143832003 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11736609 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143832876 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11730929 ENSG00000251600.4 RP11-673E1.1 -4.33 2.64e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143834795 chr4:143912331~143982454:+ PAAD cis rs10170846 0.893 rs11692810 ENSG00000261428.2 RP11-16P6.1 -4.33 2.64e-05 0.0118 -0.44 -0.33 Schizophrenia (inflammation and infection response interaction); chr2:222679377 chr2:222566899~222569719:- PAAD cis rs2404602 0.532 rs284892 ENSG00000259422.1 RP11-593F23.1 4.33 2.65e-05 0.0118 0.38 0.33 Blood metabolite levels; chr15:76428696 chr15:76174891~76181486:- PAAD cis rs6504950 0.745 rs12949718 ENSG00000275710.1 RP11-257O5.4 -4.33 2.65e-05 0.0118 -0.4 -0.33 Breast cancer; chr17:54904492 chr17:54964474~54964679:+ PAAD cis rs17772222 0.682 rs2401751 ENSG00000258983.2 RP11-507K2.2 -4.33 2.65e-05 0.0118 -0.4 -0.33 Coronary artery calcification; chr14:88480278 chr14:88499334~88515502:+ PAAD cis rs10740039 0.842 rs7069157 ENSG00000254271.1 RP11-131N11.4 4.33 2.65e-05 0.0118 0.4 0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60629475 chr10:60734342~60741828:+ PAAD cis rs10740039 0.583 rs1904401 ENSG00000254271.1 RP11-131N11.4 -4.33 2.65e-05 0.0118 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60741809 chr10:60734342~60741828:+ PAAD cis rs6479891 1 rs4746149 ENSG00000232075.1 MRPL35P2 -4.33 2.66e-05 0.0118 -0.52 -0.33 Arthritis (juvenile idiopathic); chr10:63497633 chr10:63634317~63634827:- PAAD cis rs4835473 0.868 rs62337303 ENSG00000251600.4 RP11-673E1.1 -4.33 2.66e-05 0.0118 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143824967 chr4:143912331~143982454:+ PAAD cis rs755249 0.567 rs41270807 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39336143 chr1:39788976~39790171:+ PAAD cis rs755249 0.53 rs16826087 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39346846 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs3754346 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39349288 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs16826093 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39349471 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs41270811 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39349672 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs61779274 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39351269 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs17264671 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39352380 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs4660690 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39353831 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs61779275 ENSG00000261798.1 RP1-118J21.25 4.33 2.66e-05 0.0118 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39354638 chr1:39788976~39790171:+ PAAD cis rs8177376 1 rs8177365 ENSG00000254905.1 RP11-712L6.7 4.33 2.66e-05 0.0118 0.44 0.33 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126289965 chr11:126292922~126294254:- PAAD cis rs797680 0.897 rs2114273 ENSG00000223745.6 RP4-717I23.3 4.33 2.66e-05 0.0118 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93388960 chr1:93262186~93346025:- PAAD cis rs5758659 0.845 rs5758645 ENSG00000273366.1 CTA-989H11.1 -4.33 2.66e-05 0.0118 -0.43 -0.33 Cognitive function; chr22:42202945 chr22:42278188~42278846:+ PAAD cis rs2019137 0.589 rs7560701 ENSG00000189223.12 PAX8-AS1 -4.33 2.66e-05 0.0118 -0.39 -0.33 Lymphocyte counts; chr2:113269305 chr2:113211522~113276581:+ PAAD cis rs7189233 0.531 rs7203132 ENSG00000279344.1 RP11-44F14.7 -4.33 2.66e-05 0.0118 -0.25 -0.33 Intelligence (multi-trait analysis); chr16:53395863 chr16:53478957~53481550:- PAAD cis rs79040073 0.682 rs12592277 ENSG00000259531.2 RP11-295H24.3 4.33 2.66e-05 0.0118 0.53 0.33 Lung cancer in ever smokers; chr15:49436562 chr15:49365124~49366685:- PAAD cis rs875971 1 rs6946143 ENSG00000237310.1 GS1-124K5.4 4.33 2.67e-05 0.0118 0.31 0.33 Aortic root size; chr7:66114735 chr7:66493706~66495474:+ PAAD cis rs2658782 0.789 rs3020057 ENSG00000279684.1 RP11-755E23.2 -4.33 2.67e-05 0.0118 -0.53 -0.33 Pulmonary function decline; chr11:93385349 chr11:93286629~93288903:- PAAD cis rs1233491 1 rs1233491 ENSG00000281831.1 HCP5B 4.33 2.67e-05 0.0119 0.72 0.33 Cutaneous lupus erythematosus; chr6:29493953 chr6:29871895~29873783:- PAAD cis rs17214007 0.877 rs11075280 ENSG00000263335.1 AF001548.5 -4.33 2.67e-05 0.0119 -0.47 -0.33 Cognitive function; chr16:15776630 chr16:15726674~15732993:+ PAAD cis rs17214007 0.877 rs1569300 ENSG00000263335.1 AF001548.5 -4.33 2.67e-05 0.0119 -0.47 -0.33 Cognitive function; chr16:15776891 chr16:15726674~15732993:+ PAAD cis rs4664293 0.967 rs3940435 ENSG00000226266.5 AC009961.3 -4.33 2.67e-05 0.0119 -0.41 -0.33 Monocyte percentage of white cells; chr2:159638272 chr2:159670708~159712435:- PAAD cis rs1075265 0.68 rs805396 ENSG00000233266.1 HMGB1P31 4.33 2.68e-05 0.0119 0.43 0.33 Chronotype;Morning vs. evening chronotype; chr2:53882314 chr2:54051334~54051760:+ PAAD cis rs9419788 0.708 rs4113810 ENSG00000233377.1 MTND4P20 4.33 2.68e-05 0.0119 0.29 0.33 Personality traits in bipolar disorder; chr10:94218018 chr10:94940253~94941121:- PAAD cis rs9419788 0.708 rs7085875 ENSG00000233377.1 MTND4P20 4.33 2.68e-05 0.0119 0.29 0.33 Personality traits in bipolar disorder; chr10:94218824 chr10:94940253~94941121:- PAAD cis rs9652601 0.879 rs8062322 ENSG00000274038.1 RP11-66H6.4 -4.33 2.68e-05 0.0119 -0.39 -0.33 Systemic lupus erythematosus; chr16:10998462 chr16:11056556~11057034:+ PAAD cis rs2117029 1 rs2117029 ENSG00000258017.1 RP11-386G11.10 -4.33 2.68e-05 0.0119 -0.43 -0.33 Intelligence (multi-trait analysis); chr12:49014657 chr12:49127782~49147869:+ PAAD cis rs3785888 0.548 rs11079744 ENSG00000262539.1 RP11-259G18.3 4.33 2.68e-05 0.0119 0.47 0.33 Cleft lip with or without cleft palate; chr17:46949753 chr17:46259551~46260606:- PAAD cis rs3785888 0.548 rs3885731 ENSG00000262539.1 RP11-259G18.3 4.33 2.68e-05 0.0119 0.47 0.33 Cleft lip with or without cleft palate; chr17:46955944 chr17:46259551~46260606:- PAAD cis rs28386778 0.863 rs6504178 ENSG00000240280.5 TCAM1P 4.33 2.68e-05 0.0119 0.46 0.33 Prudent dietary pattern; chr17:63735373 chr17:63849292~63864379:+ PAAD cis rs35828350 1 rs35828350 ENSG00000259728.4 LINC00933 4.33 2.68e-05 0.0119 0.43 0.33 Autism spectrum disorder or schizophrenia; chr15:84812610 chr15:84570649~84580175:+ PAAD cis rs13256369 0.802 rs34762800 ENSG00000253981.4 ALG1L13P 4.33 2.68e-05 0.0119 0.46 0.33 Obesity-related traits; chr8:8701784 chr8:8236003~8244667:- PAAD cis rs7189233 0.531 rs9929873 ENSG00000279344.1 RP11-44F14.7 4.33 2.69e-05 0.0119 0.25 0.33 Intelligence (multi-trait analysis); chr16:53456764 chr16:53478957~53481550:- PAAD cis rs216345 0.705 rs307661 ENSG00000230074.1 RP11-195F19.9 -4.33 2.69e-05 0.0119 -0.45 -0.33 Bipolar disorder; chr9:33960154 chr9:34665665~34681298:+ PAAD cis rs10740039 0.583 rs2127353 ENSG00000254271.1 RP11-131N11.4 -4.33 2.69e-05 0.0119 -0.4 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60750206 chr10:60734342~60741828:+ PAAD cis rs1062177 1 rs12654573 ENSG00000253921.1 CTB-113P19.3 -4.33 2.69e-05 0.0119 -0.41 -0.33 Preschool internalizing problems; chr5:151827912 chr5:151753992~151767247:+ PAAD cis rs2255336 0.938 rs2617169 ENSG00000245648.1 RP11-277P12.20 4.33 2.69e-05 0.0119 0.52 0.33 Blood protein levels; chr12:10408225 chr12:10363769~10398506:+ PAAD cis rs2255336 0.938 rs2617172 ENSG00000245648.1 RP11-277P12.20 4.33 2.69e-05 0.0119 0.52 0.33 Blood protein levels; chr12:10409887 chr12:10363769~10398506:+ PAAD cis rs3790645 1 rs188158 ENSG00000225159.1 NPM1P39 4.33 2.69e-05 0.0119 0.44 0.33 Glucose homeostasis traits; chr1:26571651 chr1:27206930~27207796:+ PAAD cis rs1665050 0.901 rs1665051 ENSG00000277144.1 RP11-59H7.4 -4.33 2.69e-05 0.0119 -0.39 -0.33 Atopic dermatitis; chr15:59003025 chr15:59115547~59116089:- PAAD cis rs6570726 0.935 rs110289 ENSG00000235652.6 RP11-545I5.3 4.33 2.69e-05 0.0119 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145544040 chr6:145799409~145886585:+ PAAD cis rs4683346 0.549 rs6442067 ENSG00000173811.9 CCDC13-AS1 4.33 2.69e-05 0.0119 0.36 0.33 Granulocyte percentage of myeloid white cells; chr3:42783623 chr3:42732575~42746768:+ PAAD cis rs1150668 0.764 rs9368565 ENSG00000219891.2 ZSCAN12P1 -4.33 2.7e-05 0.012 -0.43 -0.33 Pubertal anthropometrics; chr6:28377433 chr6:28091154~28093664:+ PAAD cis rs10761482 0.601 rs10733764 ENSG00000254271.1 RP11-131N11.4 4.33 2.7e-05 0.012 0.42 0.33 Schizophrenia; chr10:60450587 chr10:60734342~60741828:+ PAAD cis rs2562456 0.55 rs4809143 ENSG00000213976.4 CTD-2561J22.2 -4.33 2.7e-05 0.012 -0.38 -0.33 Pain; chr19:21589926 chr19:21382865~21387177:+ PAAD cis rs2562456 0.583 rs4809144 ENSG00000213976.4 CTD-2561J22.2 -4.33 2.7e-05 0.012 -0.38 -0.33 Pain; chr19:21589928 chr19:21382865~21387177:+ PAAD cis rs2562456 0.652 rs62110214 ENSG00000213976.4 CTD-2561J22.2 -4.33 2.7e-05 0.012 -0.38 -0.33 Pain; chr19:21592406 chr19:21382865~21387177:+ PAAD cis rs227932 0.681 rs79586340 ENSG00000234800.2 PCMTD1P3 4.33 2.7e-05 0.012 0.56 0.33 Schizophrenia; chr7:23746122 chr7:23721311~23721782:- PAAD cis rs227932 0.681 rs75405201 ENSG00000234800.2 PCMTD1P3 4.33 2.7e-05 0.012 0.56 0.33 Schizophrenia; chr7:23746123 chr7:23721311~23721782:- PAAD cis rs2599510 0.748 rs6718214 ENSG00000276334.1 AL133243.1 -4.33 2.7e-05 0.012 -0.41 -0.33 Interleukin-18 levels; chr2:32325416 chr2:32521927~32523547:+ PAAD cis rs718314 0.507 rs9442 ENSG00000256234.1 RP11-283G6.4 -4.33 2.7e-05 0.012 -0.38 -0.33 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index; chr12:26335572 chr12:26211164~26335856:- PAAD cis rs7727544 0.684 rs2516788 ENSG00000233006.5 AC034220.3 -4.33 2.7e-05 0.012 -0.27 -0.33 Blood metabolite levels; chr5:132379873 chr5:132311285~132369916:- PAAD cis rs7727544 0.66 rs274563 ENSG00000233006.5 AC034220.3 -4.33 2.7e-05 0.012 -0.27 -0.33 Blood metabolite levels; chr5:132382167 chr5:132311285~132369916:- PAAD cis rs72843506 0.656 rs28622601 ENSG00000189423.10 USP32P3 4.33 2.7e-05 0.012 0.47 0.33 Schizophrenia; chr17:20055341 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs16960660 ENSG00000189423.10 USP32P3 4.33 2.7e-05 0.012 0.47 0.33 Schizophrenia; chr17:20062274 chr17:20415547~20431008:+ PAAD cis rs2742417 1 rs2742436 ENSG00000244357.3 RN7SL145P 4.33 2.7e-05 0.012 0.31 0.33 Response to anti-depressant treatment in major depressive disorder; chr3:45699905 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742437 ENSG00000244357.3 RN7SL145P 4.33 2.7e-05 0.012 0.31 0.33 Response to anti-depressant treatment in major depressive disorder; chr3:45701785 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673039 ENSG00000244357.3 RN7SL145P 4.33 2.7e-05 0.012 0.31 0.33 Response to anti-depressant treatment in major depressive disorder; chr3:45706943 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2249357 ENSG00000244357.3 RN7SL145P 4.33 2.7e-05 0.012 0.31 0.33 Response to anti-depressant treatment in major depressive disorder; chr3:45716889 chr3:45742675~45742970:+ PAAD cis rs17836934 0.754 rs2118803 ENSG00000258302.2 RP11-981P6.1 4.33 2.7e-05 0.012 0.29 0.33 Total body bone mineral density; chr12:90153750 chr12:89561129~89594878:+ PAAD cis rs4835473 0.897 rs35598237 ENSG00000251600.4 RP11-673E1.1 -4.33 2.71e-05 0.012 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735961 chr4:143912331~143982454:+ PAAD cis rs7646881 0.812 rs73015644 ENSG00000240207.5 RP11-379F4.4 -4.33 2.71e-05 0.012 -0.51 -0.33 Tetralogy of Fallot; chr3:158729955 chr3:158732263~158784070:+ PAAD cis rs944722 0.628 rs4795051 ENSG00000266786.1 LGALS9DP 4.33 2.71e-05 0.012 0.36 0.33 Fractional exhaled nitric oxide (childhood); chr17:27752471 chr17:27746132~27754954:+ PAAD cis rs9584850 0.789 rs7988345 ENSG00000231194.1 FARP1-AS1 4.33 2.71e-05 0.012 0.42 0.33 Neuroticism; chr13:98465431 chr13:98435405~98435840:- PAAD cis rs17772222 0.958 rs61579615 ENSG00000258983.2 RP11-507K2.2 4.33 2.71e-05 0.012 0.46 0.33 Coronary artery calcification; chr14:88400054 chr14:88499334~88515502:+ PAAD cis rs2253762 0.54 rs79547192 ENSG00000276742.1 RP11-500G22.4 4.33 2.71e-05 0.012 0.46 0.33 Breast cancer; chr10:121998664 chr10:121956782~121957098:+ PAAD cis rs6570726 0.935 rs446242 ENSG00000235652.6 RP11-545I5.3 4.33 2.71e-05 0.012 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145522730 chr6:145799409~145886585:+ PAAD cis rs10875746 0.517 rs12721420 ENSG00000240399.1 RP1-228P16.1 -4.33 2.71e-05 0.012 -0.36 -0.33 Longevity (90 years and older); chr12:47965011 chr12:48054813~48055591:- PAAD cis rs10129255 0.518 rs7143784 ENSG00000211972.2 IGHV3-66 4.33 2.71e-05 0.012 0.25 0.33 Kawasaki disease; chr14:106687277 chr14:106675017~106675544:- PAAD cis rs6840258 0.66 rs55851914 ENSG00000251411.1 RP11-397E7.4 -4.33 2.72e-05 0.012 -0.4 -0.33 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86955903 chr4:86913266~86914817:- PAAD cis rs4423214 0.592 rs10898211 ENSG00000254682.1 RP11-660L16.2 -4.33 2.72e-05 0.012 -0.55 -0.33 Vitamin D levels; chr11:71499631 chr11:71448674~71452157:+ PAAD cis rs4423214 0.592 rs10898223 ENSG00000254682.1 RP11-660L16.2 -4.33 2.72e-05 0.012 -0.55 -0.33 Vitamin D levels; chr11:71508218 chr11:71448674~71452157:+ PAAD cis rs131777 0.547 rs131753 ENSG00000205559.3 CHKB-AS1 -4.33 2.72e-05 0.012 -0.41 -0.33 Mean corpuscular hemoglobin;Mean corpuscular volume; chr22:50584433 chr22:50583026~50583877:+ PAAD cis rs42490 0.635 rs42186 ENSG00000251136.7 RP11-37B2.1 -4.33 2.72e-05 0.012 -0.32 -0.33 Leprosy; chr8:89827257 chr8:89609409~89757727:- PAAD cis rs9309711 0.813 rs11690865 ENSG00000225234.1 TRAPPC12-AS1 -4.33 2.72e-05 0.012 -0.36 -0.33 Neurofibrillary tangles; chr2:3468179 chr2:3481242~3482409:- PAAD cis rs9326246 0.598 rs481843 ENSG00000254851.1 RP11-109L13.1 4.33 2.72e-05 0.012 0.65 0.33 Coronary artery disease; chr11:116655150 chr11:117135528~117138582:+ PAAD cis rs7829975 0.511 rs2976906 ENSG00000254340.1 RP11-10A14.3 4.33 2.73e-05 0.0121 0.41 0.33 Mood instability; chr8:8484905 chr8:9141424~9145435:+ PAAD cis rs7078219 0.505 rs4129132 ENSG00000228778.1 RP11-129J12.1 -4.33 2.73e-05 0.0121 -0.37 -0.33 Dental caries; chr10:99524880 chr10:99527081~99528261:+ PAAD cis rs7829975 0.5 rs7841082 ENSG00000173295.6 FAM86B3P -4.33 2.73e-05 0.0121 -0.35 -0.33 Mood instability; chr8:8311465 chr8:8228595~8244865:+ PAAD cis rs6479891 0.908 rs4746201 ENSG00000232075.1 MRPL35P2 4.33 2.73e-05 0.0121 0.53 0.33 Arthritis (juvenile idiopathic); chr10:63562621 chr10:63634317~63634827:- PAAD cis rs6479891 0.908 rs61853655 ENSG00000232075.1 MRPL35P2 4.33 2.73e-05 0.0121 0.53 0.33 Arthritis (juvenile idiopathic); chr10:63570645 chr10:63634317~63634827:- PAAD cis rs2348418 0.733 rs7137557 ENSG00000247934.4 RP11-967K21.1 4.33 2.73e-05 0.0121 0.33 0.33 Lung function (FEV1);Lung function (FVC); chr12:28221259 chr12:28163298~28190738:- PAAD cis rs2348418 0.733 rs2019011 ENSG00000247934.4 RP11-967K21.1 4.33 2.73e-05 0.0121 0.33 0.33 Lung function (FEV1);Lung function (FVC); chr12:28228144 chr12:28163298~28190738:- PAAD cis rs2348418 0.733 rs12425200 ENSG00000247934.4 RP11-967K21.1 4.33 2.73e-05 0.0121 0.33 0.33 Lung function (FEV1);Lung function (FVC); chr12:28237896 chr12:28163298~28190738:- PAAD cis rs7189233 0.955 rs7184800 ENSG00000279722.1 RP11-44F14.6 -4.33 2.73e-05 0.0121 -0.36 -0.33 Intelligence (multi-trait analysis); chr16:53475219 chr16:53487607~53489943:- PAAD cis rs453301 0.624 rs4841083 ENSG00000254340.1 RP11-10A14.3 4.33 2.73e-05 0.0121 0.4 0.33 Joint mobility (Beighton score); chr8:9012918 chr8:9141424~9145435:+ PAAD cis rs950880 0.668 rs3732126 ENSG00000234389.1 AC007278.3 -4.33 2.74e-05 0.0121 -0.33 -0.33 Serum protein levels (sST2); chr2:102397502 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs3732125 ENSG00000234389.1 AC007278.3 -4.33 2.74e-05 0.0121 -0.33 -0.33 Serum protein levels (sST2); chr2:102397503 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs1135354 ENSG00000234389.1 AC007278.3 -4.33 2.74e-05 0.0121 -0.33 -0.33 Serum protein levels (sST2); chr2:102397842 chr2:102438713~102440475:+ PAAD cis rs950880 0.677 rs17027087 ENSG00000234389.1 AC007278.3 -4.33 2.74e-05 0.0121 -0.33 -0.33 Serum protein levels (sST2); chr2:102399458 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs55742125 ENSG00000234389.1 AC007278.3 -4.33 2.74e-05 0.0121 -0.33 -0.33 Serum protein levels (sST2); chr2:102403322 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs55883125 ENSG00000234389.1 AC007278.3 -4.33 2.74e-05 0.0121 -0.33 -0.33 Serum protein levels (sST2); chr2:102407871 chr2:102438713~102440475:+ PAAD cis rs950880 0.645 rs4851006 ENSG00000234389.1 AC007278.3 -4.33 2.74e-05 0.0121 -0.33 -0.33 Serum protein levels (sST2); chr2:102408278 chr2:102438713~102440475:+ PAAD cis rs55665837 0.54 rs3206554 ENSG00000251991.1 RNU7-49P 4.33 2.74e-05 0.0121 0.39 0.33 Vitamin D levels; chr11:14776399 chr11:14478892~14478953:+ PAAD cis rs3738443 0.678 rs6680707 ENSG00000259865.1 RP11-488L18.10 4.33 2.74e-05 0.0121 0.29 0.33 Alcohol dependence; chr1:247213648 chr1:247187281~247188526:- PAAD cis rs7712401 0.601 rs30038 ENSG00000263432.2 RN7SL689P 4.33 2.74e-05 0.0121 0.42 0.33 Mean platelet volume; chr5:122941667 chr5:123022487~123022783:- PAAD cis rs1211375 0.607 rs1203978 ENSG00000268836.1 LA16c-OS12.2 -4.33 2.74e-05 0.0121 -0.3 -0.33 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:207212 chr16:185748~186294:- PAAD cis rs528301 0.642 rs895632 ENSG00000274520.1 Six3os1_1 4.33 2.74e-05 0.0121 0.38 0.33 Alcohol and nicotine co-dependence; chr2:44937906 chr2:44932320~44932406:+ PAAD cis rs27434 0.66 rs27043 ENSG00000272109.1 CTD-2260A17.3 4.33 2.74e-05 0.0121 0.53 0.33 Ankylosing spondylitis; chr5:96781596 chr5:96804353~96806105:+ PAAD cis rs27434 0.605 rs39840 ENSG00000272109.1 CTD-2260A17.3 -4.33 2.74e-05 0.0121 -0.53 -0.33 Ankylosing spondylitis; chr5:96784350 chr5:96804353~96806105:+ PAAD cis rs27434 0.66 rs42398 ENSG00000272109.1 CTD-2260A17.3 -4.33 2.74e-05 0.0121 -0.53 -0.33 Ankylosing spondylitis; chr5:96784751 chr5:96804353~96806105:+ PAAD cis rs853679 0.506 rs1150693 ENSG00000226314.6 ZNF192P1 -4.33 2.74e-05 0.0121 -0.56 -0.33 Depression; chr6:28206812 chr6:28161781~28169594:+ PAAD cis rs9926296 0.643 rs2159114 ENSG00000260259.1 RP11-368I7.4 -4.33 2.74e-05 0.0121 -0.38 -0.33 Vitiligo; chr16:89765433 chr16:89682620~89686569:- PAAD cis rs4713118 0.587 rs61471148 ENSG00000280107.1 AL022393.9 -4.33 2.74e-05 0.0121 -0.55 -0.33 Parkinson's disease; chr6:28069254 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393884 ENSG00000280107.1 AL022393.9 -4.33 2.74e-05 0.0121 -0.55 -0.33 Depression; chr6:28079011 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393887 ENSG00000280107.1 AL022393.9 -4.33 2.74e-05 0.0121 -0.55 -0.33 Depression; chr6:28091242 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs6922063 ENSG00000280107.1 AL022393.9 -4.33 2.74e-05 0.0121 -0.55 -0.33 Depression; chr6:28126588 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs2275508 ENSG00000280107.1 AL022393.9 -4.33 2.74e-05 0.0121 -0.55 -0.33 Depression; chr6:28126953 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs1904841 ENSG00000280107.1 AL022393.9 -4.33 2.74e-05 0.0121 -0.55 -0.33 Depression; chr6:28140307 chr6:28170845~28172521:+ PAAD cis rs6504950 0.888 rs244319 ENSG00000275710.1 RP11-257O5.4 4.33 2.74e-05 0.0121 0.4 0.33 Breast cancer; chr17:55145513 chr17:54964474~54964679:+ PAAD cis rs6504950 0.888 rs244320 ENSG00000275710.1 RP11-257O5.4 4.33 2.74e-05 0.0121 0.4 0.33 Breast cancer; chr17:55145559 chr17:54964474~54964679:+ PAAD cis rs6504950 0.813 rs244321 ENSG00000275710.1 RP11-257O5.4 4.33 2.74e-05 0.0121 0.4 0.33 Breast cancer; chr17:55146637 chr17:54964474~54964679:+ PAAD cis rs6504950 0.854 rs244322 ENSG00000275710.1 RP11-257O5.4 4.33 2.74e-05 0.0121 0.4 0.33 Breast cancer; chr17:55147398 chr17:54964474~54964679:+ PAAD cis rs3096299 0.685 rs4329923 ENSG00000261253.2 AC137932.6 4.33 2.74e-05 0.0121 0.37 0.33 Multiple myeloma (IgH translocation); chr16:89493770 chr16:89321133~89325110:+ PAAD cis rs964611 0.882 rs12917438 ENSG00000259488.2 RP11-154J22.1 4.33 2.74e-05 0.0121 0.37 0.33 Metabolite levels (Pyroglutamine); chr15:48347540 chr15:48312353~48331856:- PAAD cis rs3096299 0.748 rs2965822 ENSG00000274627.1 RP11-104N10.2 4.33 2.74e-05 0.0121 0.29 0.33 Multiple myeloma (IgH translocation); chr16:89378269 chr16:89516797~89522217:+ PAAD cis rs4683346 0.523 rs12491179 ENSG00000173811.9 CCDC13-AS1 -4.33 2.75e-05 0.0121 -0.4 -0.33 Granulocyte percentage of myeloid white cells; chr3:42732470 chr3:42732575~42746768:+ PAAD cis rs7712401 0.601 rs173480 ENSG00000263432.2 RN7SL689P 4.33 2.75e-05 0.0121 0.43 0.33 Mean platelet volume; chr5:122918436 chr5:123022487~123022783:- PAAD cis rs7646881 1 rs7646987 ENSG00000240207.5 RP11-379F4.4 4.33 2.75e-05 0.0121 0.48 0.33 Tetralogy of Fallot; chr3:158735653 chr3:158732263~158784070:+ PAAD cis rs79040073 0.637 rs57749497 ENSG00000259531.2 RP11-295H24.3 4.32 2.75e-05 0.0121 0.55 0.33 Lung cancer in ever smokers; chr15:49297661 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73394355 ENSG00000259531.2 RP11-295H24.3 4.32 2.75e-05 0.0121 0.55 0.33 Lung cancer in ever smokers; chr15:49299893 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73394359 ENSG00000259531.2 RP11-295H24.3 4.32 2.75e-05 0.0121 0.55 0.33 Lung cancer in ever smokers; chr15:49300941 chr15:49365124~49366685:- PAAD cis rs6570726 0.935 rs366621 ENSG00000235652.6 RP11-545I5.3 4.32 2.75e-05 0.0121 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145540139 chr6:145799409~145886585:+ PAAD cis rs6472235 0.632 rs11985554 ENSG00000200714.1 Y_RNA -4.32 2.75e-05 0.0121 -0.46 -0.33 Plateletcrit;Myopia (pathological); chr8:65972004 chr8:65592731~65592820:+ PAAD cis rs2446066 0.872 rs10876449 ENSG00000257379.1 RP11-793H13.8 4.32 2.75e-05 0.0122 0.47 0.33 Red blood cell count; chr12:53385991 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs11170525 ENSG00000257379.1 RP11-793H13.8 4.32 2.75e-05 0.0122 0.47 0.33 Red blood cell count; chr12:53388844 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs12368491 ENSG00000257379.1 RP11-793H13.8 4.32 2.75e-05 0.0122 0.47 0.33 Red blood cell count; chr12:53389175 chr12:53441741~53467528:+ PAAD cis rs2446066 0.818 rs7315782 ENSG00000257379.1 RP11-793H13.8 4.32 2.75e-05 0.0122 0.47 0.33 Red blood cell count; chr12:53391129 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs11170532 ENSG00000257379.1 RP11-793H13.8 4.32 2.75e-05 0.0122 0.47 0.33 Red blood cell count; chr12:53394551 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs7300593 ENSG00000257379.1 RP11-793H13.8 4.32 2.75e-05 0.0122 0.47 0.33 Red blood cell count; chr12:53396666 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs7133236 ENSG00000257379.1 RP11-793H13.8 4.32 2.75e-05 0.0122 0.47 0.33 Red blood cell count; chr12:53397201 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs74090765 ENSG00000257379.1 RP11-793H13.8 4.32 2.75e-05 0.0122 0.47 0.33 Red blood cell count; chr12:53399130 chr12:53441741~53467528:+ PAAD cis rs2281636 1 rs11190263 ENSG00000233690.1 EBAG9P1 4.32 2.76e-05 0.0122 0.35 0.33 Obesity-related traits; chr10:99746626 chr10:99697407~99697949:- PAAD cis rs867371 1 rs13380317 ENSG00000259429.4 UBE2Q2P2 4.32 2.76e-05 0.0122 0.26 0.33 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214449 chr15:82355142~82420075:+ PAAD cis rs11123170 0.64 rs2863240 ENSG00000274877.1 RP11-65I12.1 4.32 2.76e-05 0.0122 0.4 0.33 Renal function-related traits (BUN); chr2:113212539 chr2:113237595~113240825:+ PAAD cis rs9926296 0.557 rs11076618 ENSG00000260259.1 RP11-368I7.4 -4.32 2.76e-05 0.0122 -0.39 -0.33 Vitiligo; chr16:89741297 chr16:89682620~89686569:- PAAD cis rs12480328 1 rs73909823 ENSG00000203999.7 LINC01270 4.32 2.76e-05 0.0122 0.73 0.33 Prostate cancer; chr20:50880508 chr20:50292720~50314922:+ PAAD cis rs6723162 0.51 rs6722245 ENSG00000237751.2 LINC01143 -4.32 2.76e-05 0.0122 -0.43 -0.33 Neurocognitive impairment in HIV-1 infection (dichotomous); chr2:70910516 chr2:70887871~70889959:+ PAAD cis rs950880 0.71 rs4140785 ENSG00000234389.1 AC007278.3 -4.32 2.77e-05 0.0122 -0.33 -0.33 Serum protein levels (sST2); chr2:102472057 chr2:102438713~102440475:+ PAAD cis rs6782228 0.606 rs2712404 ENSG00000242551.2 POU5F1P6 4.32 2.77e-05 0.0122 0.4 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613836 chr3:128674735~128677005:- PAAD cis rs9584850 0.834 rs7985565 ENSG00000231194.1 FARP1-AS1 4.32 2.77e-05 0.0122 0.41 0.33 Neuroticism; chr13:98461217 chr13:98435405~98435840:- PAAD cis rs10932679 0.543 rs2014998 ENSG00000229352.1 AC007563.3 4.32 2.77e-05 0.0122 0.37 0.33 Pulse pressure; chr2:216817238 chr2:216799608~216805335:+ PAAD cis rs10916248 0.559 rs116083281 ENSG00000232628.4 RP11-365O16.3 4.32 2.77e-05 0.0122 0.52 0.33 QT interval (drug interaction); chr1:224199365 chr1:224208747~224213279:- PAAD cis rs73173548 0.528 rs6872276 ENSG00000247828.6 TMEM161B-AS1 4.32 2.77e-05 0.0122 0.28 0.33 Macular telangiectasia type 2; chr5:88473903 chr5:88268895~88436685:+ PAAD cis rs73173548 0.557 rs71580759 ENSG00000247828.6 TMEM161B-AS1 4.32 2.77e-05 0.0122 0.28 0.33 Macular telangiectasia type 2; chr5:88474306 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs74429030 ENSG00000247828.6 TMEM161B-AS1 4.32 2.77e-05 0.0122 0.28 0.33 Macular telangiectasia type 2; chr5:88474689 chr5:88268895~88436685:+ PAAD cis rs73173548 0.528 rs80083342 ENSG00000247828.6 TMEM161B-AS1 4.32 2.77e-05 0.0122 0.28 0.33 Macular telangiectasia type 2; chr5:88476921 chr5:88268895~88436685:+ PAAD cis rs1862618 0.853 rs252922 ENSG00000271828.1 CTD-2310F14.1 4.32 2.78e-05 0.0122 0.5 0.33 Initial pursuit acceleration; chr5:56840516 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs252921 ENSG00000271828.1 CTD-2310F14.1 4.32 2.78e-05 0.0122 0.5 0.33 Initial pursuit acceleration; chr5:56841960 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs33325 ENSG00000271828.1 CTD-2310F14.1 4.32 2.78e-05 0.0122 0.5 0.33 Initial pursuit acceleration; chr5:56846720 chr5:56927874~56929573:+ PAAD cis rs1862618 0.802 rs42769 ENSG00000271828.1 CTD-2310F14.1 4.32 2.78e-05 0.0122 0.5 0.33 Initial pursuit acceleration; chr5:56848325 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs860580 ENSG00000271828.1 CTD-2310F14.1 -4.32 2.78e-05 0.0122 -0.5 -0.33 Initial pursuit acceleration; chr5:56853602 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs832578 ENSG00000271828.1 CTD-2310F14.1 4.32 2.78e-05 0.0122 0.5 0.33 Initial pursuit acceleration; chr5:56868396 chr5:56927874~56929573:+ PAAD cis rs11676348 0.818 rs7426289 ENSG00000261338.2 RP11-378A13.1 -4.32 2.78e-05 0.0122 -0.38 -0.33 Ulcerative colitis; chr2:218101592 chr2:218255319~218257366:+ PAAD cis rs9652601 0.779 rs12708716 ENSG00000274038.1 RP11-66H6.4 4.32 2.78e-05 0.0122 0.36 0.33 Systemic lupus erythematosus; chr16:11086016 chr16:11056556~11057034:+ PAAD cis rs9487094 0.677 rs35452836 ENSG00000260273.1 RP11-425D10.10 4.32 2.78e-05 0.0122 0.46 0.33 Height; chr6:109378243 chr6:109382795~109383666:+ PAAD cis rs321358 1 rs321366 ENSG00000271390.1 RP11-89C3.3 4.32 2.78e-05 0.0122 0.49 0.33 Body mass index; chr11:111128003 chr11:111089870~111090368:- PAAD cis rs28386778 0.897 rs11654841 ENSG00000240280.5 TCAM1P -4.32 2.78e-05 0.0123 -0.46 -0.33 Prudent dietary pattern; chr17:63760899 chr17:63849292~63864379:+ PAAD cis rs9322193 0.962 rs9688412 ENSG00000268592.3 RAET1E-AS1 -4.32 2.78e-05 0.0123 -0.39 -0.33 Lung cancer; chr6:149803147 chr6:149863494~149919507:+ PAAD cis rs10510102 0.516 rs11200306 ENSG00000276742.1 RP11-500G22.4 4.32 2.79e-05 0.0123 0.49 0.33 Breast cancer; chr10:121980862 chr10:121956782~121957098:+ PAAD cis rs6952407 1 rs6952407 ENSG00000237310.1 GS1-124K5.4 -4.32 2.79e-05 0.0123 -0.3 -0.33 Cotinine glucuronidation; chr7:66580525 chr7:66493706~66495474:+ PAAD cis rs2505998 0.833 rs1864402 ENSG00000273008.1 RP11-351D16.3 -4.32 2.79e-05 0.0123 -0.3 -0.33 Hirschsprung disease; chr10:43110412 chr10:43136824~43138334:- PAAD cis rs2505998 0.716 rs1864401 ENSG00000273008.1 RP11-351D16.3 -4.32 2.79e-05 0.0123 -0.3 -0.33 Hirschsprung disease; chr10:43110454 chr10:43136824~43138334:- PAAD cis rs2554380 0.55 rs17296856 ENSG00000230373.7 GOLGA6L5P 4.32 2.79e-05 0.0123 0.31 0.33 Height; chr15:83888698 chr15:84507885~84516814:- PAAD cis rs2776353 0.836 rs2849691 ENSG00000280109.1 PLAC4 -4.32 2.79e-05 0.0123 -0.34 -0.33 Basal cell carcinoma; chr21:41665910 chr21:41175231~41185239:- PAAD cis rs1665050 0.652 rs62002516 ENSG00000277144.1 RP11-59H7.4 -4.32 2.79e-05 0.0123 -0.38 -0.33 Atopic dermatitis; chr15:59009703 chr15:59115547~59116089:- PAAD cis rs9326246 0.643 rs651821 ENSG00000254851.1 RP11-109L13.1 -4.32 2.8e-05 0.0123 -0.72 -0.33 Coronary artery disease; chr11:116791863 chr11:117135528~117138582:+ PAAD cis rs4925166 1 rs4925166 ENSG00000273018.4 CTD-2303H24.2 -4.32 2.8e-05 0.0123 -0.44 -0.33 Multiple sclerosis; chr17:18307496 chr17:18511221~18551705:- PAAD cis rs34375054 0.724 rs4517581 ENSG00000279233.1 RP11-158L12.4 4.32 2.8e-05 0.0123 0.29 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125182848 chr12:125138245~125141711:+ PAAD cis rs2554380 0.55 rs4842918 ENSG00000230373.7 GOLGA6L5P 4.32 2.8e-05 0.0123 0.31 0.33 Height; chr15:83868247 chr15:84507885~84516814:- PAAD cis rs9531006 0.636 rs12876835 ENSG00000227676.3 LINC01068 -4.32 2.8e-05 0.0123 -0.49 -0.33 Sleep duration; chr13:79903644 chr13:79566727~79571436:+ PAAD cis rs16846053 0.71 rs7581747 ENSG00000227403.1 AC009299.3 -4.32 2.8e-05 0.0123 -0.52 -0.33 Blood osmolality (transformed sodium); chr2:161758605 chr2:161244739~161249050:+ PAAD cis rs6142102 0.961 rs1883524 ENSG00000276073.1 RP5-1125A11.7 -4.32 2.8e-05 0.0123 -0.35 -0.33 Skin pigmentation; chr20:34038301 chr20:33985617~33988989:- PAAD cis rs4660214 0.666 rs61783383 ENSG00000237624.1 OXCT2P1 -4.32 2.8e-05 0.0123 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39341346 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs6704246 ENSG00000237624.1 OXCT2P1 -4.32 2.8e-05 0.0123 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39343612 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs597311 ENSG00000237624.1 OXCT2P1 4.32 2.8e-05 0.0123 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39355254 chr1:39514956~39516490:+ PAAD cis rs4660214 0.615 rs597708 ENSG00000237624.1 OXCT2P1 4.32 2.8e-05 0.0123 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39355291 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs636156 ENSG00000237624.1 OXCT2P1 4.32 2.8e-05 0.0123 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39356065 chr1:39514956~39516490:+ PAAD cis rs875971 0.522 rs1880556 ENSG00000237310.1 GS1-124K5.4 4.32 2.81e-05 0.0123 0.31 0.33 Aortic root size; chr7:65967557 chr7:66493706~66495474:+ PAAD cis rs7188445 0.651 rs4889014 ENSG00000261390.4 RP11-345M22.2 4.32 2.81e-05 0.0123 0.44 0.33 Urate levels; chr16:79684556 chr16:79715232~79770563:- PAAD cis rs7188445 0.688 rs4889015 ENSG00000261390.4 RP11-345M22.2 4.32 2.81e-05 0.0123 0.44 0.33 Urate levels; chr16:79684833 chr16:79715232~79770563:- PAAD cis rs17772222 0.682 rs10132554 ENSG00000258983.2 RP11-507K2.2 4.32 2.81e-05 0.0123 0.41 0.33 Coronary artery calcification; chr14:88473090 chr14:88499334~88515502:+ PAAD cis rs860554 0.515 rs16848196 ENSG00000249007.1 RP11-510N19.5 4.32 2.81e-05 0.0124 0.26 0.33 Panic disorder; chr1:201275301 chr1:202011370~202015657:+ PAAD cis rs7712401 0.601 rs2910136 ENSG00000263432.2 RN7SL689P -4.32 2.82e-05 0.0124 -0.42 -0.33 Mean platelet volume; chr5:122918322 chr5:123022487~123022783:- PAAD cis rs3743772 0.5 rs28671196 ENSG00000279344.1 RP11-44F14.7 4.32 2.82e-05 0.0124 0.35 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53404024 chr16:53478957~53481550:- PAAD cis rs5742933 0.557 rs6756571 ENSG00000273240.1 RP11-455J20.3 4.32 2.82e-05 0.0124 0.41 0.33 Ferritin levels; chr2:189640971 chr2:189763859~189764456:- PAAD cis rs763121 0.785 rs5750646 ENSG00000228274.3 RP3-508I15.9 -4.32 2.82e-05 0.0124 -0.32 -0.33 Menopause (age at onset); chr22:38617825 chr22:38667585~38681820:- PAAD cis rs853679 0.517 rs9380058 ENSG00000204709.4 LINC01556 4.32 2.82e-05 0.0124 0.57 0.33 Depression; chr6:28159666 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393898 ENSG00000204709.4 LINC01556 4.32 2.82e-05 0.0124 0.57 0.33 Depression; chr6:28162598 chr6:28943877~28944537:+ PAAD cis rs2243480 1 rs160634 ENSG00000232546.1 RP11-458F8.1 4.32 2.82e-05 0.0124 0.4 0.33 Diabetic kidney disease; chr7:66063677 chr7:66848496~66858136:+ PAAD cis rs6570726 0.791 rs448939 ENSG00000235652.6 RP11-545I5.3 4.32 2.82e-05 0.0124 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145487184 chr6:145799409~145886585:+ PAAD cis rs4950322 0.58 rs4950371 ENSG00000278811.3 LINC00624 4.32 2.82e-05 0.0124 0.33 0.33 Protein quantitative trait loci; chr1:147114243 chr1:147258885~147517875:- PAAD cis rs950880 1 rs1420101 ENSG00000234389.1 AC007278.3 -4.32 2.82e-05 0.0124 -0.32 -0.33 Serum protein levels (sST2); chr2:102341256 chr2:102438713~102440475:+ PAAD cis rs10050311 0.8 rs2230600 ENSG00000251411.1 RP11-397E7.4 4.32 2.82e-05 0.0124 0.4 0.33 Insulin-related traits; chr4:86769845 chr4:86913266~86914817:- PAAD cis rs7182621 0.546 rs11632596 ENSG00000259363.4 CTD-2054N24.2 -4.32 2.82e-05 0.0124 -0.41 -0.33 Colonoscopy-negative controls vs population controls; chr15:99834385 chr15:99807023~99877148:+ PAAD cis rs2348418 0.966 rs7316797 ENSG00000247934.4 RP11-967K21.1 4.32 2.82e-05 0.0124 0.33 0.33 Lung function (FEV1);Lung function (FVC); chr12:28529776 chr12:28163298~28190738:- PAAD cis rs12480328 1 rs6096186 ENSG00000203999.7 LINC01270 -4.32 2.83e-05 0.0124 -0.7 -0.33 Prostate cancer; chr20:50917412 chr20:50292720~50314922:+ PAAD cis rs1862618 0.853 rs2548665 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56835978 chr5:56927874~56929573:+ PAAD cis rs1862618 0.802 rs2591949 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56836800 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs2548664 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56837728 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs3099459 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56841343 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs43184 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56845950 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs33326 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56846774 chr5:56927874~56929573:+ PAAD cis rs1862618 0.802 rs33327 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56846866 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs832565 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56854976 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs832568 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56857949 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs832569 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56858757 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs2113079 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56862124 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs252887 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56870361 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs33322 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56879399 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs832582 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56881916 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs832583 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56882390 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs832551 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56884285 chr5:56927874~56929573:+ PAAD cis rs1862618 0.713 rs832550 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56886762 chr5:56927874~56929573:+ PAAD cis rs1862618 0.713 rs832549 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56887715 chr5:56927874~56929573:+ PAAD cis rs1862618 0.756 rs832548 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56887810 chr5:56927874~56929573:+ PAAD cis rs1862618 0.802 rs832547 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56888114 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs866222 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56888617 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs861283 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56888783 chr5:56927874~56929573:+ PAAD cis rs1862618 0.802 rs252900 ENSG00000271828.1 CTD-2310F14.1 4.32 2.83e-05 0.0124 0.5 0.33 Initial pursuit acceleration; chr5:56889454 chr5:56927874~56929573:+ PAAD cis rs11976180 1 rs1919951 ENSG00000273234.1 OR2A13P -4.32 2.83e-05 0.0124 -0.41 -0.33 Obesity-related traits; chr7:144071798 chr7:144142009~144142938:+ PAAD cis rs875971 0.522 rs781144 ENSG00000237310.1 GS1-124K5.4 4.32 2.83e-05 0.0124 0.31 0.33 Aortic root size; chr7:65975357 chr7:66493706~66495474:+ PAAD cis rs113835537 0.877 rs2229455 ENSG00000255517.5 CTD-3074O7.5 -4.32 2.83e-05 0.0124 -0.53 -0.33 Airway imaging phenotypes; chr11:66560584 chr11:66473490~66480233:- PAAD cis rs919433 0.929 rs1366836 ENSG00000231621.1 AC013264.2 4.32 2.83e-05 0.0124 0.31 0.33 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197307424 chr2:197197991~197199273:+ PAAD cis rs3169166 0.546 rs4887027 ENSG00000259562.2 RP11-762H8.2 4.32 2.83e-05 0.0124 0.28 0.33 Reticulocyte fraction of red cells;Reticulocyte count; chr15:78287599 chr15:78290527~78291221:- PAAD cis rs875971 1 rs7792762 ENSG00000237310.1 GS1-124K5.4 4.32 2.83e-05 0.0124 0.32 0.33 Aortic root size; chr7:66539151 chr7:66493706~66495474:+ PAAD cis rs2921036 0.545 rs4840975 ENSG00000253893.2 FAM85B 4.32 2.84e-05 0.0124 0.51 0.33 Neuroticism; chr8:8505748 chr8:8167819~8226614:- PAAD cis rs453301 0.624 rs2979256 ENSG00000254340.1 RP11-10A14.3 4.32 2.84e-05 0.0124 0.4 0.33 Joint mobility (Beighton score); chr8:9014200 chr8:9141424~9145435:+ PAAD cis rs2562456 0.917 rs10420016 ENSG00000213976.4 CTD-2561J22.2 4.32 2.84e-05 0.0124 0.37 0.33 Pain; chr19:21505800 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs2681389 ENSG00000213976.4 CTD-2561J22.2 4.32 2.84e-05 0.0124 0.37 0.33 Pain; chr19:21509773 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs2681392 ENSG00000213976.4 CTD-2561J22.2 4.32 2.84e-05 0.0124 0.37 0.33 Pain; chr19:21513185 chr19:21382865~21387177:+ PAAD cis rs338389 0.542 rs12594726 ENSG00000260657.2 RP11-315D16.4 -4.32 2.84e-05 0.0124 -0.38 -0.33 Survival in rectal cancer; chr15:67994440 chr15:68267792~68277994:- PAAD cis rs2041895 0.509 rs1035236 ENSG00000260329.1 RP11-412D9.4 -4.32 2.84e-05 0.0124 -0.32 -0.33 Glaucoma (low intraocular pressure); chr12:106917019 chr12:106954029~106955497:- PAAD cis rs2041895 0.509 rs10861676 ENSG00000260329.1 RP11-412D9.4 -4.32 2.84e-05 0.0124 -0.32 -0.33 Glaucoma (low intraocular pressure); chr12:106917457 chr12:106954029~106955497:- PAAD cis rs2041895 0.509 rs7970139 ENSG00000260329.1 RP11-412D9.4 -4.32 2.84e-05 0.0124 -0.32 -0.33 Glaucoma (low intraocular pressure); chr12:106918652 chr12:106954029~106955497:- PAAD cis rs1665050 0.652 rs9302206 ENSG00000277144.1 RP11-59H7.4 -4.32 2.84e-05 0.0124 -0.38 -0.33 Atopic dermatitis; chr15:59017274 chr15:59115547~59116089:- PAAD cis rs7665090 0.87 rs228616 ENSG00000246560.2 RP11-10L12.4 -4.32 2.84e-05 0.0125 -0.36 -0.33 Primary biliary cholangitis; chr4:102658534 chr4:102828055~102844075:+ PAAD cis rs55665837 0.539 rs10766196 ENSG00000251991.1 RNU7-49P 4.32 2.84e-05 0.0125 0.39 0.33 Vitamin D levels; chr11:14891585 chr11:14478892~14478953:+ PAAD cis rs55665837 0.539 rs12794714 ENSG00000251991.1 RNU7-49P 4.32 2.84e-05 0.0125 0.39 0.33 Vitamin D levels; chr11:14892029 chr11:14478892~14478953:+ PAAD cis rs4660214 0.666 rs1180376 ENSG00000237624.1 OXCT2P1 4.32 2.84e-05 0.0125 0.44 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39418761 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs625384 ENSG00000237624.1 OXCT2P1 4.32 2.84e-05 0.0125 0.44 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39427421 chr1:39514956~39516490:+ PAAD cis rs9876781 0.559 rs7610524 ENSG00000229759.1 MRPS18AP1 4.32 2.84e-05 0.0125 0.34 0.33 Longevity; chr3:48353882 chr3:48256350~48256938:- PAAD cis rs216345 0.7 rs307654 ENSG00000230074.1 RP11-195F19.9 -4.32 2.85e-05 0.0125 -0.44 -0.33 Bipolar disorder; chr9:33948654 chr9:34665665~34681298:+ PAAD cis rs216345 0.7 rs307656 ENSG00000230074.1 RP11-195F19.9 -4.32 2.85e-05 0.0125 -0.44 -0.33 Bipolar disorder; chr9:33949722 chr9:34665665~34681298:+ PAAD cis rs2404602 0.647 rs35940181 ENSG00000259422.1 RP11-593F23.1 -4.32 2.85e-05 0.0125 -0.41 -0.33 Blood metabolite levels; chr15:76887678 chr15:76174891~76181486:- PAAD cis rs755249 0.567 rs61783378 ENSG00000261798.1 RP1-118J21.25 4.32 2.85e-05 0.0125 0.42 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39311487 chr1:39788976~39790171:+ PAAD cis rs3096299 0.658 rs3934737 ENSG00000261253.2 AC137932.6 4.32 2.85e-05 0.0125 0.36 0.33 Multiple myeloma (IgH translocation); chr16:89493801 chr16:89321133~89325110:+ PAAD cis rs34375054 0.573 rs12581813 ENSG00000279233.1 RP11-158L12.4 4.32 2.85e-05 0.0125 0.31 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125171856 chr12:125138245~125141711:+ PAAD cis rs1707322 0.752 rs11211152 ENSG00000280836.1 AL355480.1 -4.32 2.85e-05 0.0125 -0.39 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648485 chr1:45581219~45581321:- PAAD cis rs710913 0.717 rs2068473 ENSG00000243970.1 PPIEL -4.32 2.86e-05 0.0125 -0.29 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572925 chr1:39531838~39558707:- PAAD cis rs10411161 0.702 rs11879436 ENSG00000270248.1 CTC-471J1.10 4.32 2.86e-05 0.0125 0.59 0.33 Breast cancer; chr19:51894562 chr19:52110318~52110726:- PAAD cis rs10411161 0.702 rs10420224 ENSG00000270248.1 CTC-471J1.10 4.32 2.86e-05 0.0125 0.59 0.33 Breast cancer; chr19:51895702 chr19:52110318~52110726:- PAAD cis rs10411161 0.702 rs75647161 ENSG00000270248.1 CTC-471J1.10 4.32 2.86e-05 0.0125 0.59 0.33 Breast cancer; chr19:51895731 chr19:52110318~52110726:- PAAD cis rs10411161 0.702 rs17778790 ENSG00000270248.1 CTC-471J1.10 4.32 2.86e-05 0.0125 0.59 0.33 Breast cancer; chr19:51896306 chr19:52110318~52110726:- PAAD cis rs6142102 0.961 rs1055857 ENSG00000276073.1 RP5-1125A11.7 -4.31 2.87e-05 0.0125 -0.35 -0.33 Skin pigmentation; chr20:34026067 chr20:33985617~33988989:- PAAD cis rs4834770 1 rs878374 ENSG00000245958.5 RP11-33B1.1 -4.31 2.87e-05 0.0125 -0.25 -0.33 Blood protein levels; chr4:119316409 chr4:119454791~119552025:+ PAAD cis rs4834770 1 rs4834770 ENSG00000245958.5 RP11-33B1.1 -4.31 2.87e-05 0.0125 -0.25 -0.33 Blood protein levels; chr4:119320694 chr4:119454791~119552025:+ PAAD cis rs4834770 1 rs6823963 ENSG00000245958.5 RP11-33B1.1 -4.31 2.87e-05 0.0125 -0.25 -0.33 Blood protein levels; chr4:119321009 chr4:119454791~119552025:+ PAAD cis rs4834770 1 rs4834771 ENSG00000245958.5 RP11-33B1.1 -4.31 2.87e-05 0.0125 -0.25 -0.33 Blood protein levels; chr4:119321617 chr4:119454791~119552025:+ PAAD cis rs4834770 1 rs1397613 ENSG00000245958.5 RP11-33B1.1 -4.31 2.87e-05 0.0125 -0.25 -0.33 Blood protein levels; chr4:119321774 chr4:119454791~119552025:+ PAAD cis rs4834770 1 rs6857641 ENSG00000245958.5 RP11-33B1.1 -4.31 2.87e-05 0.0125 -0.25 -0.33 Blood protein levels; chr4:119322356 chr4:119454791~119552025:+ PAAD cis rs4834770 1 rs2282688 ENSG00000245958.5 RP11-33B1.1 -4.31 2.87e-05 0.0125 -0.25 -0.33 Blood protein levels; chr4:119322567 chr4:119454791~119552025:+ PAAD cis rs4834770 1 rs10034579 ENSG00000245958.5 RP11-33B1.1 -4.31 2.87e-05 0.0125 -0.25 -0.33 Blood protein levels; chr4:119322874 chr4:119454791~119552025:+ PAAD cis rs4664293 1 rs10432413 ENSG00000226266.5 AC009961.3 -4.31 2.87e-05 0.0125 -0.41 -0.33 Monocyte percentage of white cells; chr2:159639243 chr2:159670708~159712435:- PAAD cis rs4950322 0.58 rs7541393 ENSG00000278811.3 LINC00624 4.31 2.87e-05 0.0126 0.32 0.33 Protein quantitative trait loci; chr1:147117186 chr1:147258885~147517875:- PAAD cis rs6472235 0.681 rs34174890 ENSG00000200714.1 Y_RNA -4.31 2.87e-05 0.0126 -0.44 -0.33 Plateletcrit;Myopia (pathological); chr8:65954892 chr8:65592731~65592820:+ PAAD cis rs6472235 0.681 rs67768803 ENSG00000200714.1 Y_RNA -4.31 2.87e-05 0.0126 -0.44 -0.33 Plateletcrit;Myopia (pathological); chr8:65955957 chr8:65592731~65592820:+ PAAD cis rs6472235 0.681 rs66644630 ENSG00000200714.1 Y_RNA -4.31 2.87e-05 0.0126 -0.44 -0.33 Plateletcrit;Myopia (pathological); chr8:65956483 chr8:65592731~65592820:+ PAAD cis rs9326246 0.598 rs480823 ENSG00000254851.1 RP11-109L13.1 4.31 2.87e-05 0.0126 0.63 0.33 Coronary artery disease; chr11:116655013 chr11:117135528~117138582:+ PAAD cis rs8091660 0.624 rs2175565 ENSG00000278983.1 RP11-426J5.3 -4.31 2.87e-05 0.0126 -0.4 -0.33 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48553481 chr18:48564795~48568342:+ PAAD cis rs889398 1 rs889398 ENSG00000226232.7 RP11-419C5.2 4.31 2.88e-05 0.0126 0.28 0.33 Body mass index; chr16:69522812 chr16:69976388~69996188:- PAAD cis rs1113500 0.897 rs11185263 ENSG00000226822.1 RP11-356N1.2 4.31 2.88e-05 0.0126 0.38 0.33 Growth-regulated protein alpha levels; chr1:108097182 chr1:108071482~108074519:+ PAAD cis rs2115630 1 rs2115630 ENSG00000225151.9 GOLGA2P7 4.31 2.88e-05 0.0126 0.39 0.33 P wave terminal force; chr15:84821285 chr15:84199311~84230136:- PAAD cis rs8177376 0.681 rs240548 ENSG00000254905.1 RP11-712L6.7 4.31 2.88e-05 0.0126 0.42 0.33 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126335072 chr11:126292922~126294254:- PAAD cis rs7078219 0.505 rs4409764 ENSG00000228778.1 RP11-129J12.1 -4.31 2.88e-05 0.0126 -0.37 -0.33 Dental caries; chr10:99524480 chr10:99527081~99528261:+ PAAD cis rs7078219 0.523 rs4129134 ENSG00000228778.1 RP11-129J12.1 -4.31 2.88e-05 0.0126 -0.37 -0.33 Dental caries; chr10:99524588 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs4129133 ENSG00000228778.1 RP11-129J12.1 -4.31 2.88e-05 0.0126 -0.37 -0.33 Dental caries; chr10:99524813 chr10:99527081~99528261:+ PAAD cis rs62103177 0.525 rs9949598 ENSG00000261126.6 RP11-795F19.1 -4.31 2.88e-05 0.0126 -0.44 -0.33 Opioid sensitivity; chr18:79993037 chr18:80046900~80095482:+ PAAD cis rs897984 0.806 rs9319588 ENSG00000260911.2 RP11-196G11.2 -4.31 2.88e-05 0.0126 -0.29 -0.33 Dementia with Lewy bodies; chr16:30919662 chr16:31043150~31049868:+ PAAD cis rs3823536 0.583 rs10954214 ENSG00000275106.1 RP11-309L24.10 -4.31 2.89e-05 0.0126 -0.45 -0.33 Sjögren's syndrome; chr7:128949579 chr7:128952527~128953316:- PAAD cis rs748404 0.56 rs1869258 ENSG00000205771.5 CATSPER2P1 -4.31 2.89e-05 0.0126 -0.47 -0.33 Lung cancer; chr15:43511423 chr15:43726918~43747094:- PAAD cis rs8177376 0.953 rs73017399 ENSG00000254905.1 RP11-712L6.7 4.31 2.89e-05 0.0126 0.46 0.33 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126316417 chr11:126292922~126294254:- PAAD cis rs12439619 0.508 rs8042665 ENSG00000255769.6 GOLGA2P10 -4.31 2.89e-05 0.0126 -0.35 -0.33 Intelligence (multi-trait analysis); chr15:82189008 chr15:82472993~82513950:- PAAD cis rs79040073 0.681 rs4775800 ENSG00000259531.2 RP11-295H24.3 4.31 2.89e-05 0.0126 0.59 0.33 Lung cancer in ever smokers; chr15:49117270 chr15:49365124~49366685:- PAAD cis rs394563 0.967 rs438852 ENSG00000231760.4 RP11-350J20.5 -4.31 2.89e-05 0.0126 -0.43 -0.33 Dupuytren's disease; chr6:149473397 chr6:149796151~149826294:- PAAD cis rs17772222 0.682 rs28482235 ENSG00000258983.2 RP11-507K2.2 4.31 2.89e-05 0.0126 0.41 0.33 Coronary artery calcification; chr14:88472857 chr14:88499334~88515502:+ PAAD cis rs2505998 0.957 rs2435366 ENSG00000273008.1 RP11-351D16.3 -4.31 2.89e-05 0.0126 -0.29 -0.33 Hirschsprung disease; chr10:43076540 chr10:43136824~43138334:- PAAD cis rs2505998 1 rs1864410 ENSG00000273008.1 RP11-351D16.3 -4.31 2.89e-05 0.0126 -0.29 -0.33 Hirschsprung disease; chr10:43080177 chr10:43136824~43138334:- PAAD cis rs4683346 0.616 rs7641046 ENSG00000173811.9 CCDC13-AS1 -4.31 2.89e-05 0.0126 -0.36 -0.33 Granulocyte percentage of myeloid white cells; chr3:42789838 chr3:42732575~42746768:+ PAAD cis rs4683346 0.585 rs11129975 ENSG00000173811.9 CCDC13-AS1 -4.31 2.89e-05 0.0126 -0.36 -0.33 Granulocyte percentage of myeloid white cells; chr3:42794493 chr3:42732575~42746768:+ PAAD cis rs4683346 0.616 rs13096498 ENSG00000173811.9 CCDC13-AS1 -4.31 2.89e-05 0.0126 -0.36 -0.33 Granulocyte percentage of myeloid white cells; chr3:42795494 chr3:42732575~42746768:+ PAAD cis rs17772222 1 rs7145588 ENSG00000258983.2 RP11-507K2.2 4.31 2.9e-05 0.0127 0.46 0.33 Coronary artery calcification; chr14:88360452 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs61977049 ENSG00000258983.2 RP11-507K2.2 4.31 2.9e-05 0.0127 0.46 0.33 Coronary artery calcification; chr14:88360656 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs12587386 ENSG00000258983.2 RP11-507K2.2 4.31 2.9e-05 0.0127 0.46 0.33 Coronary artery calcification; chr14:88361420 chr14:88499334~88515502:+ PAAD cis rs42490 0.727 rs42481 ENSG00000251136.7 RP11-37B2.1 4.31 2.9e-05 0.0127 0.3 0.33 Leprosy; chr8:89825486 chr8:89609409~89757727:- PAAD cis rs9876781 0.592 rs9817960 ENSG00000229759.1 MRPS18AP1 -4.31 2.9e-05 0.0127 -0.35 -0.33 Longevity; chr3:48369284 chr3:48256350~48256938:- PAAD cis rs7712401 0.601 rs27976 ENSG00000263432.2 RN7SL689P -4.31 2.9e-05 0.0127 -0.43 -0.33 Mean platelet volume; chr5:122870765 chr5:123022487~123022783:- PAAD cis rs12682352 0.602 rs11783966 ENSG00000253893.2 FAM85B 4.31 2.91e-05 0.0127 0.48 0.33 Neuroticism; chr8:8807637 chr8:8167819~8226614:- PAAD cis rs7189233 0.531 rs8063294 ENSG00000279344.1 RP11-44F14.7 4.31 2.91e-05 0.0127 0.25 0.33 Intelligence (multi-trait analysis); chr16:53412845 chr16:53478957~53481550:- PAAD cis rs673078 0.607 rs17441214 ENSG00000275759.1 RP11-131L12.3 -4.31 2.91e-05 0.0127 -0.54 -0.33 Glucose homeostasis traits; chr12:118436721 chr12:118428281~118428870:+ PAAD cis rs61270009 0.955 rs780401 ENSG00000247828.6 TMEM161B-AS1 -4.31 2.91e-05 0.0127 -0.27 -0.33 Depressive symptoms; chr5:88244393 chr5:88268895~88436685:+ PAAD cis rs6860540 0.796 rs10475585 ENSG00000251405.2 CTB-109A12.1 -4.31 2.91e-05 0.0127 -0.42 -0.33 Inflammatory skin disease; chr5:157488080 chr5:157362615~157460078:- PAAD cis rs6570726 1 rs1935617 ENSG00000235652.6 RP11-545I5.3 4.31 2.91e-05 0.0127 0.28 0.33 Lobe attachment (rater-scored or self-reported); chr6:145622190 chr6:145799409~145886585:+ PAAD cis rs7182621 0.639 rs12906050 ENSG00000182397.13 DNM1P46 4.31 2.91e-05 0.0127 0.44 0.33 Colonoscopy-negative controls vs population controls; chr15:99873384 chr15:99790156~99806927:- PAAD cis rs7182621 0.639 rs35248328 ENSG00000182397.13 DNM1P46 4.31 2.91e-05 0.0127 0.44 0.33 Colonoscopy-negative controls vs population controls; chr15:99873399 chr15:99790156~99806927:- PAAD cis rs9322193 0.962 rs2065664 ENSG00000268592.3 RAET1E-AS1 4.31 2.91e-05 0.0127 0.4 0.33 Lung cancer; chr6:149762485 chr6:149863494~149919507:+ PAAD cis rs897984 0.806 rs8050588 ENSG00000260911.2 RP11-196G11.2 4.31 2.91e-05 0.0127 0.29 0.33 Dementia with Lewy bodies; chr16:30926478 chr16:31043150~31049868:+ PAAD cis rs897984 0.806 rs1458202 ENSG00000260911.2 RP11-196G11.2 4.31 2.91e-05 0.0127 0.29 0.33 Dementia with Lewy bodies; chr16:30941881 chr16:31043150~31049868:+ PAAD cis rs897984 0.77 rs12930657 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30920647 chr16:31043150~31049868:+ PAAD cis rs897984 0.77 rs3813020 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30922754 chr16:31043150~31049868:+ PAAD cis rs897984 0.762 rs12930545 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30927490 chr16:31043150~31049868:+ PAAD cis rs897984 0.806 rs10782001 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30931304 chr16:31043150~31049868:+ PAAD cis rs897984 0.806 rs12928852 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30932667 chr16:31043150~31049868:+ PAAD cis rs897984 0.806 rs10782002 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30935185 chr16:31043150~31049868:+ PAAD cis rs897984 0.806 rs4889571 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30937726 chr16:31043150~31049868:+ PAAD cis rs897984 0.806 rs11640534 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30938194 chr16:31043150~31049868:+ PAAD cis rs897984 0.762 rs7206511 ENSG00000260911.2 RP11-196G11.2 -4.31 2.91e-05 0.0127 -0.29 -0.33 Dementia with Lewy bodies; chr16:30939031 chr16:31043150~31049868:+ PAAD cis rs9992667 0.704 rs3900761 ENSG00000231160.8 KLF3-AS1 -4.31 2.92e-05 0.0127 -0.41 -0.33 Eosinophil percentage of granulocytes; chr4:38609961 chr4:38612701~38664883:- PAAD cis rs694739 0.726 rs516124 ENSG00000236935.1 AP003774.1 4.31 2.92e-05 0.0127 0.35 0.33 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64360951 chr11:64325050~64329504:- PAAD cis rs4713118 0.516 rs7739216 ENSG00000204709.4 LINC01556 4.31 2.92e-05 0.0127 0.56 0.33 Parkinson's disease; chr6:28112168 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs35512245 ENSG00000204709.4 LINC01556 4.31 2.92e-05 0.0127 0.56 0.33 Depression; chr6:28112175 chr6:28943877~28944537:+ PAAD cis rs5758659 0.652 rs133335 ENSG00000273366.1 CTA-989H11.1 4.31 2.93e-05 0.0128 0.39 0.33 Cognitive function; chr22:42020052 chr22:42278188~42278846:+ PAAD cis rs7202877 0.706 rs1540 ENSG00000261783.1 RP11-252K23.2 4.31 2.93e-05 0.0128 0.53 0.33 Type 1 diabetes;Type 2 diabetes; chr16:75447287 chr16:75379818~75381260:- PAAD cis rs9487094 0.626 rs2025148 ENSG00000260273.1 RP11-425D10.10 4.31 2.93e-05 0.0128 0.4 0.33 Height; chr6:109706740 chr6:109382795~109383666:+ PAAD cis rs453301 0.686 rs6987107 ENSG00000253893.2 FAM85B 4.31 2.93e-05 0.0128 0.45 0.33 Joint mobility (Beighton score); chr8:9036071 chr8:8167819~8226614:- PAAD cis rs42490 0.59 rs441547 ENSG00000251136.7 RP11-37B2.1 -4.31 2.93e-05 0.0128 -0.3 -0.33 Leprosy; chr8:89807954 chr8:89609409~89757727:- PAAD cis rs42490 0.614 rs441548 ENSG00000251136.7 RP11-37B2.1 -4.31 2.93e-05 0.0128 -0.3 -0.33 Leprosy; chr8:89807955 chr8:89609409~89757727:- PAAD cis rs42490 0.614 rs402434 ENSG00000251136.7 RP11-37B2.1 -4.31 2.93e-05 0.0128 -0.3 -0.33 Leprosy; chr8:89808088 chr8:89609409~89757727:- PAAD cis rs42490 0.614 rs452694 ENSG00000251136.7 RP11-37B2.1 -4.31 2.93e-05 0.0128 -0.3 -0.33 Leprosy; chr8:89808293 chr8:89609409~89757727:- PAAD cis rs42490 0.614 rs445172 ENSG00000251136.7 RP11-37B2.1 -4.31 2.93e-05 0.0128 -0.3 -0.33 Leprosy; chr8:89808322 chr8:89609409~89757727:- PAAD cis rs42490 0.59 rs447611 ENSG00000251136.7 RP11-37B2.1 -4.31 2.93e-05 0.0128 -0.3 -0.33 Leprosy; chr8:89808359 chr8:89609409~89757727:- PAAD cis rs6782228 0.565 rs67445542 ENSG00000242551.2 POU5F1P6 -4.31 2.93e-05 0.0128 -0.39 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611683 chr3:128674735~128677005:- PAAD cis rs17772222 0.701 rs1627444 ENSG00000258983.2 RP11-507K2.2 -4.31 2.93e-05 0.0128 -0.41 -0.33 Coronary artery calcification; chr14:88413784 chr14:88499334~88515502:+ PAAD cis rs2562456 0.917 rs6511253 ENSG00000213976.4 CTD-2561J22.2 4.31 2.93e-05 0.0128 0.36 0.33 Pain; chr19:21495996 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs2650804 ENSG00000213976.4 CTD-2561J22.2 -4.31 2.93e-05 0.0128 -0.36 -0.33 Pain; chr19:21497382 chr19:21382865~21387177:+ PAAD cis rs2562456 0.917 rs9304987 ENSG00000213976.4 CTD-2561J22.2 4.31 2.93e-05 0.0128 0.36 0.33 Pain; chr19:21499472 chr19:21382865~21387177:+ PAAD cis rs17123764 0.71 rs2278069 ENSG00000257464.1 RP11-161H23.8 -4.31 2.93e-05 0.0128 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49550725 chr12:49442424~49442652:- PAAD cis rs4660214 0.724 rs10888683 ENSG00000237624.1 OXCT2P1 4.31 2.93e-05 0.0128 0.41 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39157997 chr1:39514956~39516490:+ PAAD cis rs17772222 0.545 rs1758846 ENSG00000258983.2 RP11-507K2.2 -4.31 2.93e-05 0.0128 -0.41 -0.33 Coronary artery calcification; chr14:88449288 chr14:88499334~88515502:+ PAAD cis rs7826238 0.601 rs2979206 ENSG00000254340.1 RP11-10A14.3 4.31 2.93e-05 0.0128 0.39 0.33 Systolic blood pressure; chr8:8488071 chr8:9141424~9145435:+ PAAD cis rs2945232 1 rs2945232 ENSG00000253981.4 ALG1L13P 4.31 2.93e-05 0.0128 0.4 0.33 Schizophrenia; chr8:8240516 chr8:8236003~8244667:- PAAD cis rs2404602 0.532 rs12591100 ENSG00000259422.1 RP11-593F23.1 -4.31 2.94e-05 0.0128 -0.38 -0.33 Blood metabolite levels; chr15:76408460 chr15:76174891~76181486:- PAAD cis rs7923837 1 rs7923837 ENSG00000236493.2 EIF2S2P3 4.31 2.94e-05 0.0128 0.42 0.33 Multiple sclerosis;Body mass index; chr10:92722160 chr10:92668745~92669743:- PAAD cis rs4925386 1 rs4925386 ENSG00000273619.1 RP5-908M14.9 -4.31 2.94e-05 0.0128 -0.27 -0.33 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345988 chr20:62386303~62386970:- PAAD cis rs8072100 0.871 rs7206971 ENSG00000228782.6 CTD-2026D20.3 -4.31 2.94e-05 0.0128 -0.33 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47347749 chr17:47450568~47492492:- PAAD cis rs9487094 0.813 rs12524502 ENSG00000260273.1 RP11-425D10.10 4.31 2.94e-05 0.0128 0.47 0.33 Height; chr6:109333018 chr6:109382795~109383666:+ PAAD cis rs867371 0.502 rs8025964 ENSG00000278603.1 RP13-608F4.5 4.31 2.95e-05 0.0128 0.4 0.33 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82229429 chr15:82472203~82472426:+ PAAD cis rs7189233 0.531 rs7199401 ENSG00000279344.1 RP11-44F14.7 4.31 2.95e-05 0.0128 0.24 0.33 Intelligence (multi-trait analysis); chr16:53483038 chr16:53478957~53481550:- PAAD cis rs1113500 0.565 rs1777455 ENSG00000226822.1 RP11-356N1.2 -4.31 2.95e-05 0.0128 -0.41 -0.33 Growth-regulated protein alpha levels; chr1:108047666 chr1:108071482~108074519:+ PAAD cis rs8014671 0.597 rs1044527 ENSG00000274330.1 RP11-486O13.5 -4.31 2.95e-05 0.0129 -0.39 -0.33 Prostate cancer; chr14:70367102 chr14:70230224~70232426:+ PAAD cis rs1729407 0.632 rs2071523 ENSG00000254851.1 RP11-109L13.1 -4.31 2.95e-05 0.0129 -0.4 -0.33 Apolipoprotein A-IV levels; chr11:116826628 chr11:117135528~117138582:+ PAAD cis rs6570726 0.967 rs365515 ENSG00000235652.6 RP11-545I5.3 -4.31 2.95e-05 0.0129 -0.27 -0.33 Lobe attachment (rater-scored or self-reported); chr6:145481697 chr6:145799409~145886585:+ PAAD cis rs7665090 0.806 rs434644 ENSG00000246560.2 RP11-10L12.4 -4.31 2.95e-05 0.0129 -0.36 -0.33 Primary biliary cholangitis; chr4:102662032 chr4:102828055~102844075:+ PAAD cis rs7665090 0.806 rs413967 ENSG00000246560.2 RP11-10L12.4 -4.31 2.95e-05 0.0129 -0.36 -0.33 Primary biliary cholangitis; chr4:102662039 chr4:102828055~102844075:+ PAAD cis rs7665090 0.806 rs404574 ENSG00000246560.2 RP11-10L12.4 -4.31 2.95e-05 0.0129 -0.36 -0.33 Primary biliary cholangitis; chr4:102662051 chr4:102828055~102844075:+ PAAD cis rs7260598 0.581 rs17311328 ENSG00000268442.1 CTD-2027I19.2 4.31 2.96e-05 0.0129 0.56 0.33 Response to taxane treatment (placlitaxel); chr19:24186640 chr19:24162370~24163425:- PAAD cis rs2243480 0.708 rs13242216 ENSG00000226824.5 RP4-756H11.3 -4.31 2.96e-05 0.0129 -0.62 -0.33 Diabetic kidney disease; chr7:66433290 chr7:66654538~66669855:+ PAAD cis rs2243480 0.615 rs34363376 ENSG00000226824.5 RP4-756H11.3 -4.31 2.96e-05 0.0129 -0.62 -0.33 Diabetic kidney disease; chr7:66474549 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs67536397 ENSG00000226824.5 RP4-756H11.3 -4.31 2.96e-05 0.0129 -0.62 -0.33 Diabetic kidney disease; chr7:66482930 chr7:66654538~66669855:+ PAAD cis rs2243480 1 rs58669269 ENSG00000226824.5 RP4-756H11.3 -4.31 2.96e-05 0.0129 -0.62 -0.33 Diabetic kidney disease; chr7:66486966 chr7:66654538~66669855:+ PAAD cis rs79040073 0.637 rs11635354 ENSG00000259531.2 RP11-295H24.3 4.31 2.96e-05 0.0129 0.56 0.33 Lung cancer in ever smokers; chr15:49419413 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11638314 ENSG00000259531.2 RP11-295H24.3 4.31 2.96e-05 0.0129 0.56 0.33 Lung cancer in ever smokers; chr15:49421747 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs78323502 ENSG00000259531.2 RP11-295H24.3 4.31 2.96e-05 0.0129 0.56 0.33 Lung cancer in ever smokers; chr15:49436634 chr15:49365124~49366685:- PAAD cis rs79040073 0.517 rs118069527 ENSG00000259531.2 RP11-295H24.3 4.31 2.96e-05 0.0129 0.56 0.33 Lung cancer in ever smokers; chr15:49436684 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs79404431 ENSG00000259531.2 RP11-295H24.3 4.31 2.96e-05 0.0129 0.56 0.33 Lung cancer in ever smokers; chr15:49436689 chr15:49365124~49366685:- PAAD cis rs4835473 0.742 rs7654409 ENSG00000251600.4 RP11-673E1.1 4.31 2.96e-05 0.0129 0.38 0.33 Immature fraction of reticulocytes; chr4:143956842 chr4:143912331~143982454:+ PAAD cis rs2283792 0.967 rs5749998 ENSG00000228050.1 TOP3BP1 4.31 2.96e-05 0.0129 0.35 0.33 Multiple sclerosis; chr22:21808085 chr22:22223187~22224566:- PAAD cis rs2283792 1 rs9607287 ENSG00000228050.1 TOP3BP1 4.31 2.96e-05 0.0129 0.35 0.33 Multiple sclerosis; chr22:21809136 chr22:22223187~22224566:- PAAD cis rs73219805 0.671 rs13267955 ENSG00000228451.3 SDAD1P1 -4.31 2.96e-05 0.0129 -0.47 -0.33 Schizophrenia; chr8:26367077 chr8:26379259~26382953:- PAAD cis rs73219805 0.838 rs17055172 ENSG00000228451.3 SDAD1P1 -4.31 2.96e-05 0.0129 -0.47 -0.33 Schizophrenia; chr8:26368096 chr8:26379259~26382953:- PAAD cis rs11790994 0.915 rs10991145 ENSG00000271384.1 RP11-435O5.7 -4.31 2.96e-05 0.0129 -0.67 -0.33 Inattentive symptoms; chr9:95662260 chr9:95406990~95407662:- PAAD cis rs734999 0.505 rs4073285 ENSG00000225931.3 RP3-395M20.7 4.31 2.97e-05 0.0129 0.32 0.33 Ulcerative colitis; chr1:2608357 chr1:2566410~2569888:+ PAAD cis rs7580658 0.895 rs62157549 ENSG00000236682.1 AC068282.3 -4.31 2.97e-05 0.0129 -0.44 -0.33 Protein C levels; chr2:127308431 chr2:127389130~127400580:+ PAAD cis rs6570726 0.967 rs441364 ENSG00000235652.6 RP11-545I5.3 4.31 2.97e-05 0.0129 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145532526 chr6:145799409~145886585:+ PAAD cis rs1862618 0.853 rs832554 ENSG00000271828.1 CTD-2310F14.1 4.31 2.97e-05 0.0129 0.49 0.33 Initial pursuit acceleration; chr5:56819209 chr5:56927874~56929573:+ PAAD cis rs7078219 0.543 rs10786557 ENSG00000228778.1 RP11-129J12.1 -4.31 2.97e-05 0.0129 -0.37 -0.33 Dental caries; chr10:99523571 chr10:99527081~99528261:+ PAAD cis rs6142102 0.961 rs2284389 ENSG00000276073.1 RP5-1125A11.7 -4.31 2.98e-05 0.0129 -0.35 -0.33 Skin pigmentation; chr20:34069035 chr20:33985617~33988989:- PAAD cis rs17684571 0.751 rs28360570 ENSG00000231441.1 RP11-472M19.2 4.31 2.98e-05 0.013 0.62 0.33 Schizophrenia; chr6:56852832 chr6:56844002~56864078:+ PAAD cis rs5760092 0.618 rs4461358 ENSG00000231271.1 AP000350.8 -4.31 2.98e-05 0.013 -0.47 -0.33 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23949918~23954042:+ PAAD cis rs3096299 0.967 rs3102383 ENSG00000274627.1 RP11-104N10.2 4.3 2.98e-05 0.013 0.31 0.33 Multiple myeloma (IgH translocation); chr16:89344887 chr16:89516797~89522217:+ PAAD cis rs2562456 0.792 rs2562398 ENSG00000213976.4 CTD-2561J22.2 4.3 2.98e-05 0.013 0.37 0.33 Pain; chr19:21540147 chr19:21382865~21387177:+ PAAD cis rs7580658 0.857 rs17015199 ENSG00000236682.1 AC068282.3 -4.3 2.98e-05 0.013 -0.44 -0.33 Protein C levels; chr2:127336477 chr2:127389130~127400580:+ PAAD cis rs7580658 0.895 rs4662722 ENSG00000236682.1 AC068282.3 -4.3 2.98e-05 0.013 -0.44 -0.33 Protein C levels; chr2:127344993 chr2:127389130~127400580:+ PAAD cis rs7580658 0.895 rs4662580 ENSG00000236682.1 AC068282.3 -4.3 2.98e-05 0.013 -0.44 -0.33 Protein C levels; chr2:127345230 chr2:127389130~127400580:+ PAAD cis rs7580658 0.864 rs34832797 ENSG00000236682.1 AC068282.3 -4.3 2.98e-05 0.013 -0.44 -0.33 Protein C levels; chr2:127361865 chr2:127389130~127400580:+ PAAD cis rs7580658 0.895 rs7589451 ENSG00000236682.1 AC068282.3 -4.3 2.98e-05 0.013 -0.44 -0.33 Protein C levels; chr2:127371199 chr2:127389130~127400580:+ PAAD cis rs7580658 0.857 rs2896980 ENSG00000236682.1 AC068282.3 -4.3 2.98e-05 0.013 -0.44 -0.33 Protein C levels; chr2:127382383 chr2:127389130~127400580:+ PAAD cis rs2439831 1 rs537115 ENSG00000275601.1 AC011330.13 -4.3 2.98e-05 0.013 -0.57 -0.33 Lung cancer in ever smokers; chr15:43437750 chr15:43642389~43643023:- PAAD cis rs2439831 1 rs2245908 ENSG00000275601.1 AC011330.13 -4.3 2.98e-05 0.013 -0.57 -0.33 Lung cancer in ever smokers; chr15:43439256 chr15:43642389~43643023:- PAAD cis rs780096 0.565 rs813592 ENSG00000234072.1 AC074117.10 -4.3 2.98e-05 0.013 -0.26 -0.33 Total body bone mineral density; chr2:27499104 chr2:27356246~27367622:+ PAAD cis rs10421328 0.821 rs4808976 ENSG00000259242.2 AC002306.1 4.3 2.99e-05 0.013 0.5 0.33 Parental longevity (combined parental age at death); chr19:19648490 chr19:19606350~19608660:+ PAAD cis rs3743772 0.5 rs11859135 ENSG00000279344.1 RP11-44F14.7 4.3 2.99e-05 0.013 0.36 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53404267 chr16:53478957~53481550:- PAAD cis rs6472235 0.656 rs72650541 ENSG00000200714.1 Y_RNA -4.3 2.99e-05 0.013 -0.44 -0.33 Plateletcrit;Myopia (pathological); chr8:65966056 chr8:65592731~65592820:+ PAAD cis rs6472235 0.656 rs62506593 ENSG00000200714.1 Y_RNA -4.3 2.99e-05 0.013 -0.44 -0.33 Plateletcrit;Myopia (pathological); chr8:65966114 chr8:65592731~65592820:+ PAAD cis rs17123764 0.818 rs12321819 ENSG00000257464.1 RP11-161H23.8 -4.3 2.99e-05 0.013 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49548214 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs12314878 ENSG00000257464.1 RP11-161H23.8 -4.3 2.99e-05 0.013 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49548425 chr12:49442424~49442652:- PAAD cis rs871012 0.502 rs11951889 ENSG00000248544.2 CTB-47B11.3 -4.3 2.99e-05 0.013 -0.43 -0.33 IgG glycosylation; chr5:157449776 chr5:157375741~157384950:- PAAD cis rs871012 0.502 rs17599812 ENSG00000248544.2 CTB-47B11.3 -4.3 2.99e-05 0.013 -0.43 -0.33 IgG glycosylation; chr5:157450982 chr5:157375741~157384950:- PAAD cis rs7646881 0.812 rs9864589 ENSG00000240207.5 RP11-379F4.4 -4.3 2.99e-05 0.013 -0.49 -0.33 Tetralogy of Fallot; chr3:158712917 chr3:158732263~158784070:+ PAAD cis rs6951245 1 rs6951245 ENSG00000229043.2 AC091729.9 -4.3 2.99e-05 0.013 -0.52 -0.33 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1018557 chr7:1160374~1165267:+ PAAD cis rs6951245 0.872 rs75280240 ENSG00000229043.2 AC091729.9 -4.3 2.99e-05 0.013 -0.52 -0.33 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1018875 chr7:1160374~1165267:+ PAAD cis rs11098499 0.604 rs2389882 ENSG00000245958.5 RP11-33B1.1 -4.3 2.99e-05 0.013 -0.28 -0.33 Corneal astigmatism; chr4:119645578 chr4:119454791~119552025:+ PAAD cis rs11098499 0.604 rs2389887 ENSG00000245958.5 RP11-33B1.1 -4.3 2.99e-05 0.013 -0.28 -0.33 Corneal astigmatism; chr4:119649489 chr4:119454791~119552025:+ PAAD cis rs11098499 0.604 rs34278750 ENSG00000245958.5 RP11-33B1.1 -4.3 2.99e-05 0.013 -0.28 -0.33 Corneal astigmatism; chr4:119649981 chr4:119454791~119552025:+ PAAD cis rs11098499 0.604 rs10022185 ENSG00000245958.5 RP11-33B1.1 -4.3 2.99e-05 0.013 -0.28 -0.33 Corneal astigmatism; chr4:119650610 chr4:119454791~119552025:+ PAAD cis rs11098499 0.604 rs12642411 ENSG00000245958.5 RP11-33B1.1 -4.3 2.99e-05 0.013 -0.28 -0.33 Corneal astigmatism; chr4:119659370 chr4:119454791~119552025:+ PAAD cis rs1275468 0.518 rs1552040 ENSG00000257497.2 RP11-585P4.5 -4.3 3e-05 0.013 -0.49 -0.33 Polycystic ovary syndrome; chr12:75528437 chr12:75483454~75489820:- PAAD cis rs453301 0.538 rs7830804 ENSG00000254340.1 RP11-10A14.3 -4.3 3e-05 0.013 -0.41 -0.33 Joint mobility (Beighton score); chr8:9113252 chr8:9141424~9145435:+ PAAD cis rs2717559 0.522 rs35816096 ENSG00000253741.1 CTD-2292P10.4 4.3 3e-05 0.013 0.43 0.33 Urinary tract infection frequency; chr8:142803522 chr8:142702252~142726973:- PAAD cis rs8072100 0.846 rs4264433 ENSG00000228782.6 CTD-2026D20.3 -4.3 3e-05 0.013 -0.32 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47659909 chr17:47450568~47492492:- PAAD cis rs801193 0.548 rs2659904 ENSG00000232559.3 GS1-124K5.12 4.3 3e-05 0.013 0.36 0.33 Aortic root size; chr7:66713615 chr7:66554588~66576923:- PAAD cis rs8072100 0.744 rs34537623 ENSG00000228782.6 CTD-2026D20.3 4.3 3e-05 0.013 0.34 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47452837 chr17:47450568~47492492:- PAAD cis rs8072100 0.777 rs9914653 ENSG00000228782.6 CTD-2026D20.3 4.3 3e-05 0.013 0.34 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47460029 chr17:47450568~47492492:- PAAD cis rs6991838 0.584 rs7842085 ENSG00000200714.1 Y_RNA 4.3 3e-05 0.013 0.41 0.33 Intelligence (multi-trait analysis); chr8:65636787 chr8:65592731~65592820:+ PAAD cis rs3785888 0.548 rs3890958 ENSG00000262539.1 RP11-259G18.3 4.3 3e-05 0.013 0.48 0.33 Cleft lip with or without cleft palate; chr17:46969499 chr17:46259551~46260606:- PAAD cis rs8005677 0.798 rs4982713 ENSG00000279656.1 RP11-298I3.6 4.3 3e-05 0.013 0.39 0.33 Cognitive ability (multi-trait analysis); chr14:22934893 chr14:23023083~23024217:- PAAD cis rs8005677 0.798 rs35615180 ENSG00000279656.1 RP11-298I3.6 4.3 3e-05 0.013 0.39 0.33 Cognitive ability (multi-trait analysis); chr14:22935180 chr14:23023083~23024217:- PAAD cis rs172166 0.516 rs1225710 ENSG00000219891.2 ZSCAN12P1 -4.3 3.01e-05 0.013 -0.44 -0.33 Cardiac Troponin-T levels; chr6:28132862 chr6:28091154~28093664:+ PAAD cis rs7189233 0.955 rs7189726 ENSG00000279722.1 RP11-44F14.6 -4.3 3.01e-05 0.013 -0.36 -0.33 Intelligence (multi-trait analysis); chr16:53463862 chr16:53487607~53489943:- PAAD cis rs2337406 1 rs7145172 ENSG00000274576.2 IGHV2-70 -4.3 3.01e-05 0.0131 -0.44 -0.33 Alzheimer's disease (late onset); chr14:106704924 chr14:106770577~106771020:- PAAD cis rs2337406 1 rs1858677 ENSG00000274576.2 IGHV2-70 -4.3 3.01e-05 0.0131 -0.44 -0.33 Alzheimer's disease (late onset); chr14:106706828 chr14:106770577~106771020:- PAAD cis rs1150668 0.796 rs213236 ENSG00000219891.2 ZSCAN12P1 4.3 3.01e-05 0.0131 0.41 0.33 Pubertal anthropometrics; chr6:28356620 chr6:28091154~28093664:+ PAAD cis rs17214007 0.877 rs2075515 ENSG00000263335.1 AF001548.5 -4.3 3.01e-05 0.0131 -0.46 -0.33 Cognitive function; chr16:15778462 chr16:15726674~15732993:+ PAAD cis rs17214007 0.877 rs2075514 ENSG00000263335.1 AF001548.5 -4.3 3.01e-05 0.0131 -0.46 -0.33 Cognitive function; chr16:15778752 chr16:15726674~15732993:+ PAAD cis rs17214007 0.877 rs11644832 ENSG00000263335.1 AF001548.5 -4.3 3.01e-05 0.0131 -0.46 -0.33 Cognitive function; chr16:15778891 chr16:15726674~15732993:+ PAAD cis rs17214007 0.877 rs11645883 ENSG00000263335.1 AF001548.5 -4.3 3.01e-05 0.0131 -0.46 -0.33 Cognitive function; chr16:15778950 chr16:15726674~15732993:+ PAAD cis rs17214007 0.877 rs10852376 ENSG00000263335.1 AF001548.5 4.3 3.01e-05 0.0131 0.46 0.33 Cognitive function; chr16:15778216 chr16:15726674~15732993:+ PAAD cis rs4835473 0.9 rs35230778 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734336 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs34772566 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734355 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs35419968 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734583 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs66634585 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734608 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs35016507 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734617 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs67600034 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734670 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35655934 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734697 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs35515006 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734705 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34525847 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143734970 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35277115 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735001 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34653324 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735058 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35947648 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735092 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs35800634 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735199 chr4:143912331~143982454:+ PAAD cis rs4835473 0.838 rs34505330 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735206 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4597770 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735239 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs4629390 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735302 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs13117932 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735873 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34257944 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143736443 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13119602 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143736621 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs12509642 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143737080 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs17750354 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143737352 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs5015759 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143738050 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs5015758 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143738052 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs34569841 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143738060 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34950821 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143738174 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2323190 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143744282 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11721523 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143767301 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs62337291 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143807903 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13121861 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143814007 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs4835303 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143821533 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4835034 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143821538 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6827971 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143822126 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4835305 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143823646 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11721700 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143824264 chr4:143912331~143982454:+ PAAD cis rs4835473 0.778 rs6856553 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143825973 chr4:143912331~143982454:+ PAAD cis rs4835473 0.868 rs11737787 ENSG00000251600.4 RP11-673E1.1 -4.3 3.01e-05 0.0131 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143826498 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs5015757 ENSG00000251600.4 RP11-673E1.1 4.3 3.01e-05 0.0131 0.37 0.33 Immature fraction of reticulocytes; chr4:143738144 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13133444 ENSG00000251600.4 RP11-673E1.1 4.3 3.01e-05 0.0131 0.37 0.33 Immature fraction of reticulocytes; chr4:143738191 chr4:143912331~143982454:+ PAAD cis rs3781264 0.595 rs6583937 ENSG00000273450.1 RP11-76P2.4 4.3 3.02e-05 0.0131 0.44 0.33 Esophageal cancer and gastric cancer; chr10:94323695 chr10:94314907~94315327:- PAAD cis rs3781264 0.595 rs10882424 ENSG00000273450.1 RP11-76P2.4 4.3 3.02e-05 0.0131 0.44 0.33 Esophageal cancer and gastric cancer; chr10:94326321 chr10:94314907~94315327:- PAAD cis rs3781264 0.595 rs7096037 ENSG00000273450.1 RP11-76P2.4 4.3 3.02e-05 0.0131 0.44 0.33 Esophageal cancer and gastric cancer; chr10:94329950 chr10:94314907~94315327:- PAAD cis rs3781264 0.595 rs11187876 ENSG00000273450.1 RP11-76P2.4 4.3 3.02e-05 0.0131 0.44 0.33 Esophageal cancer and gastric cancer; chr10:94330382 chr10:94314907~94315327:- PAAD cis rs3781264 0.595 rs10882430 ENSG00000273450.1 RP11-76P2.4 4.3 3.02e-05 0.0131 0.44 0.33 Esophageal cancer and gastric cancer; chr10:94330915 chr10:94314907~94315327:- PAAD cis rs9652601 0.959 rs7200940 ENSG00000274038.1 RP11-66H6.4 4.3 3.02e-05 0.0131 0.38 0.33 Systemic lupus erythematosus; chr16:11070710 chr16:11056556~11057034:+ PAAD cis rs6570726 0.818 rs398812 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145496135 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs12663204 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145497237 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs12663205 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145497242 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs12663211 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145497291 chr6:145799409~145886585:+ PAAD cis rs6570726 0.934 rs430003 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145498370 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs395948 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145499049 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs452552 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145499645 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs451349 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145499758 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs406799 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145500701 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs1883406 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145502069 chr6:145799409~145886585:+ PAAD cis rs6570726 0.87 rs370653 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145502506 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs391524 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145502708 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs429306 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145505880 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs428659 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145505903 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs376991 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145506937 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs379164 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145507957 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs413916 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145510264 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs401888 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145510399 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs414646 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145510549 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs454614 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145511497 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs411468 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145511656 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs425731 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145513015 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs421690 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145513458 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs399169 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145515217 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs377130 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145515496 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs422540 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145516679 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs408723 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145517399 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs425717 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145517484 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs409121 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145518657 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs424263 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145518937 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs419575 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145519038 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs409725 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145519204 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs386823 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145520229 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs397418 ENSG00000235652.6 RP11-545I5.3 4.3 3.02e-05 0.0131 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145521226 chr6:145799409~145886585:+ PAAD cis rs12571093 0.656 rs3858147 ENSG00000233590.1 RP11-153K11.3 -4.3 3.02e-05 0.0131 -0.51 -0.33 Optic nerve measurement (disc area); chr10:68253507 chr10:68233251~68242379:- PAAD cis rs9487094 0.813 rs67857472 ENSG00000260273.1 RP11-425D10.10 4.3 3.02e-05 0.0131 0.45 0.33 Height; chr6:109359125 chr6:109382795~109383666:+ PAAD cis rs1508798 0.539 rs3798092 ENSG00000250786.1 SNHG18 -4.3 3.03e-05 0.0131 -0.42 -0.33 Coronary artery disease; chr5:9541581 chr5:9546200~9550609:+ PAAD cis rs8177376 0.906 rs487450 ENSG00000254905.1 RP11-712L6.7 4.3 3.03e-05 0.0131 0.46 0.33 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126188474 chr11:126292922~126294254:- PAAD cis rs4718428 0.705 rs2901311 ENSG00000273142.1 RP11-458F8.4 -4.3 3.03e-05 0.0131 -0.24 -0.33 Corneal structure; chr7:66950082 chr7:66902857~66906297:+ PAAD cis rs9326248 0.559 rs482371 ENSG00000280143.1 AP000892.6 4.3 3.03e-05 0.0131 0.38 0.33 Blood protein levels; chr11:116881447 chr11:117204967~117210292:+ PAAD cis rs9326248 0.559 rs1269329 ENSG00000280143.1 AP000892.6 4.3 3.03e-05 0.0131 0.38 0.33 Blood protein levels; chr11:116884325 chr11:117204967~117210292:+ PAAD cis rs8072100 0.84 rs9912311 ENSG00000228782.6 CTD-2026D20.3 4.3 3.03e-05 0.0131 0.34 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469766 chr17:47450568~47492492:- PAAD cis rs11976180 1 rs2951364 ENSG00000273234.1 OR2A13P -4.3 3.03e-05 0.0131 -0.41 -0.33 Obesity-related traits; chr7:144057390 chr7:144142009~144142938:+ PAAD cis rs113835537 0.935 rs117480267 ENSG00000255517.5 CTD-3074O7.5 -4.3 3.03e-05 0.0131 -0.53 -0.33 Airway imaging phenotypes; chr11:66631125 chr11:66473490~66480233:- PAAD cis rs633715 0.766 rs12730934 ENSG00000254154.7 RP4-798P15.3 -4.3 3.04e-05 0.0132 -0.31 -0.33 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177848531 chr1:177928788~178038007:- PAAD cis rs633715 0.766 rs12757638 ENSG00000254154.7 RP4-798P15.3 4.3 3.04e-05 0.0132 0.31 0.33 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177846634 chr1:177928788~178038007:- PAAD cis rs2274273 0.624 rs2026633 ENSG00000258413.1 RP11-665C16.6 -4.3 3.04e-05 0.0132 -0.43 -0.33 Protein biomarker; chr14:55322459 chr14:55262767~55272075:- PAAD cis rs1823913 0.66 rs1454752 ENSG00000280083.1 RP11-317J9.1 4.3 3.04e-05 0.0132 0.4 0.33 Obesity-related traits; chr2:191298668 chr2:191154118~191156070:- PAAD cis rs9649213 0.593 rs6465675 ENSG00000272950.1 RP11-307C18.1 -4.3 3.04e-05 0.0132 -0.38 -0.33 Prostate cancer (SNP x SNP interaction); chr7:98352791 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6949718 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98295171 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6970990 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98296070 chr7:98322853~98323430:+ PAAD cis rs9649213 0.555 rs34695842 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98301750 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7807555 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98328205 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7807455 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98328310 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6465667 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98328573 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6949214 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98330921 chr7:98322853~98323430:+ PAAD cis rs9649213 0.537 rs35997266 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98336254 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6945554 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98343634 chr7:98322853~98323430:+ PAAD cis rs9649213 0.613 rs6961129 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98346230 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7795176 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98348975 chr7:98322853~98323430:+ PAAD cis rs9649213 0.537 rs6971825 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98350236 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs62478200 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98350733 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs1859482 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98354462 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs2240349 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98355351 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs13307593 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98356834 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs13246868 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98357141 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs12672092 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98357245 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs1468340 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98358364 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6969234 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98358674 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs3801256 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98362783 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7776638 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98364194 chr7:98322853~98323430:+ PAAD cis rs9649213 0.555 rs6956686 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98368633 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs3801255 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98371617 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs36099592 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98373019 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs13246843 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98373349 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs2394854 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98397994 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs3801251 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98398306 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs3779193 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98399154 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs12704989 ENSG00000272950.1 RP11-307C18.1 4.3 3.04e-05 0.0132 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98400126 chr7:98322853~98323430:+ PAAD cis rs950880 0.593 rs887971 ENSG00000234389.1 AC007278.3 -4.3 3.05e-05 0.0132 -0.33 -0.33 Serum protein levels (sST2); chr2:102424707 chr2:102438713~102440475:+ PAAD cis rs847577 0.609 rs6965016 ENSG00000272950.1 RP11-307C18.1 4.3 3.05e-05 0.0132 0.42 0.33 Breast cancer; chr7:98178570 chr7:98322853~98323430:+ PAAD cis rs847577 0.609 rs6465657 ENSG00000272950.1 RP11-307C18.1 4.3 3.05e-05 0.0132 0.42 0.33 Breast cancer; chr7:98187015 chr7:98322853~98323430:+ PAAD cis rs734999 0.588 rs10910099 ENSG00000225931.3 RP3-395M20.7 -4.3 3.05e-05 0.0132 -0.31 -0.33 Ulcerative colitis; chr1:2602113 chr1:2566410~2569888:+ PAAD cis rs3893377 0.573 rs10000290 ENSG00000214846.4 RP11-115L11.1 4.3 3.05e-05 0.0132 0.56 0.33 Current cigarettes per day in chronic obstructive pulmonary disease; chr4:15751676 chr4:15730962~15731627:- PAAD cis rs2717559 0.542 rs11774823 ENSG00000253741.1 CTD-2292P10.4 4.3 3.05e-05 0.0132 0.44 0.33 Urinary tract infection frequency; chr8:142806152 chr8:142702252~142726973:- PAAD cis rs8005677 0.828 rs35085068 ENSG00000279656.1 RP11-298I3.6 4.3 3.05e-05 0.0132 0.39 0.33 Cognitive ability (multi-trait analysis); chr14:22940700 chr14:23023083~23024217:- PAAD cis rs8005677 0.828 rs4981451 ENSG00000279656.1 RP11-298I3.6 4.3 3.05e-05 0.0132 0.39 0.33 Cognitive ability (multi-trait analysis); chr14:22941072 chr14:23023083~23024217:- PAAD cis rs8005677 0.798 rs4536383 ENSG00000279656.1 RP11-298I3.6 4.3 3.05e-05 0.0132 0.39 0.33 Cognitive ability (multi-trait analysis); chr14:22941717 chr14:23023083~23024217:- PAAD cis rs8005677 0.828 rs34584578 ENSG00000279656.1 RP11-298I3.6 4.3 3.05e-05 0.0132 0.39 0.33 Cognitive ability (multi-trait analysis); chr14:22942481 chr14:23023083~23024217:- PAAD cis rs7224610 0.966 rs3794748 ENSG00000263096.1 RP11-515O17.2 4.3 3.05e-05 0.0132 0.4 0.33 Urate levels; chr17:55287811 chr17:55271504~55273653:- PAAD cis rs11976180 1 rs1540894 ENSG00000273234.1 OR2A13P -4.3 3.05e-05 0.0132 -0.41 -0.33 Obesity-related traits; chr7:144070583 chr7:144142009~144142938:+ PAAD cis rs4660214 0.614 rs6688708 ENSG00000237624.1 OXCT2P1 -4.3 3.05e-05 0.0132 -0.44 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39293321 chr1:39514956~39516490:+ PAAD cis rs2348418 0.864 rs1949978 ENSG00000247934.4 RP11-967K21.1 4.3 3.05e-05 0.0132 0.32 0.33 Lung function (FEV1);Lung function (FVC); chr12:28443951 chr12:28163298~28190738:- PAAD cis rs2348418 0.831 rs10843173 ENSG00000247934.4 RP11-967K21.1 4.3 3.05e-05 0.0132 0.32 0.33 Lung function (FEV1);Lung function (FVC); chr12:28453092 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs10843174 ENSG00000247934.4 RP11-967K21.1 4.3 3.05e-05 0.0132 0.32 0.33 Lung function (FEV1);Lung function (FVC); chr12:28453135 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs7299039 ENSG00000247934.4 RP11-967K21.1 4.3 3.05e-05 0.0132 0.32 0.33 Lung function (FEV1);Lung function (FVC); chr12:28454083 chr12:28163298~28190738:- PAAD cis rs2243480 1 rs35820085 ENSG00000232546.1 RP11-458F8.1 -4.3 3.06e-05 0.0132 -0.4 -0.33 Diabetic kidney disease; chr7:65977771 chr7:66848496~66858136:+ PAAD cis rs2911132 1 rs2911131 ENSG00000248734.2 CTD-2260A17.1 -4.3 3.06e-05 0.0132 -0.31 -0.33 Urate levels (BMI interaction); chr5:96850246 chr5:96784777~96785999:+ PAAD cis rs950169 0.58 rs11635597 ENSG00000259728.4 LINC00933 4.3 3.06e-05 0.0132 0.42 0.33 Schizophrenia; chr15:84622468 chr15:84570649~84580175:+ PAAD cis rs1862618 0.511 rs2591952 ENSG00000271828.1 CTD-2310F14.1 4.3 3.06e-05 0.0132 0.49 0.33 Initial pursuit acceleration; chr5:56824942 chr5:56927874~56929573:+ PAAD cis rs9926296 0.586 rs1800359 ENSG00000260259.1 RP11-368I7.4 -4.3 3.06e-05 0.0132 -0.39 -0.33 Vitiligo; chr16:89738853 chr16:89682620~89686569:- PAAD cis rs62402013 1 rs62402013 ENSG00000241549.7 GUSBP2 4.3 3.06e-05 0.0132 0.34 0.33 Schizophrenia; chr6:26947221 chr6:26871484~26956554:- PAAD cis rs6969780 0.722 rs3823764 ENSG00000233429.8 HOTAIRM1 -4.3 3.06e-05 0.0132 -0.45 -0.33 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27148134 chr7:27095647~27100265:+ PAAD cis rs2976388 0.609 rs2717601 ENSG00000253741.1 CTD-2292P10.4 -4.3 3.06e-05 0.0132 -0.39 -0.33 Urinary tract infection frequency; chr8:142726506 chr8:142702252~142726973:- PAAD cis rs66887589 0.967 rs1155577 ENSG00000248280.1 RP11-33B1.2 -4.3 3.06e-05 0.0132 -0.3 -0.33 Diastolic blood pressure; chr4:119528655 chr4:119440561~119450157:- PAAD cis rs6142102 0.923 rs4911394 ENSG00000276073.1 RP5-1125A11.7 -4.3 3.06e-05 0.0132 -0.36 -0.33 Skin pigmentation; chr20:33989521 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs6119447 ENSG00000276073.1 RP5-1125A11.7 -4.3 3.07e-05 0.0132 -0.35 -0.33 Skin pigmentation; chr20:34080770 chr20:33985617~33988989:- PAAD cis rs1113500 0.836 rs1122158 ENSG00000226822.1 RP11-356N1.2 4.3 3.07e-05 0.0132 0.38 0.33 Growth-regulated protein alpha levels; chr1:108046046 chr1:108071482~108074519:+ PAAD cis rs7554672 0.961 rs12124230 ENSG00000232679.1 RP11-400N13.3 4.3 3.07e-05 0.0132 0.35 0.33 Hypertension; chr1:221188045 chr1:222041705~222064763:- PAAD cis rs10740039 0.81 rs1006956 ENSG00000254271.1 RP11-131N11.4 -4.3 3.07e-05 0.0132 -0.41 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60608218 chr10:60734342~60741828:+ PAAD cis rs28386778 0.897 rs968719 ENSG00000240280.5 TCAM1P -4.3 3.07e-05 0.0132 -0.46 -0.33 Prudent dietary pattern; chr17:63830911 chr17:63849292~63864379:+ PAAD cis rs2348418 0.733 rs9651832 ENSG00000247934.4 RP11-967K21.1 -4.3 3.08e-05 0.0133 -0.34 -0.33 Lung function (FEV1);Lung function (FVC); chr12:28242489 chr12:28163298~28190738:- PAAD cis rs6743226 0.603 rs3771343 ENSG00000266621.1 AC104841.1 4.3 3.08e-05 0.0133 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241264871 chr2:241245202~241245299:- PAAD cis rs9649213 0.502 rs6465680 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98376466 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6961438 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98376537 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7787858 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98380602 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs3779194 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98380965 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs3801254 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98381499 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs55825602 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98383727 chr7:98322853~98323430:+ PAAD cis rs9649213 0.555 rs67132564 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98385588 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6465682 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98387105 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs56286037 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98390210 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs62478233 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98393780 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6465683 ENSG00000272950.1 RP11-307C18.1 4.3 3.08e-05 0.0133 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98396780 chr7:98322853~98323430:+ PAAD cis rs5742933 0.597 rs6756913 ENSG00000273240.1 RP11-455J20.3 4.3 3.08e-05 0.0133 0.41 0.33 Ferritin levels; chr2:189641040 chr2:189763859~189764456:- PAAD cis rs2134046 0.587 rs11854289 ENSG00000278603.1 RP13-608F4.5 -4.3 3.08e-05 0.0133 -0.39 -0.33 Cognitive ability; chr15:82266461 chr15:82472203~82472426:+ PAAD cis rs7626444 0.625 rs843539 ENSG00000272359.1 U4 -4.3 3.08e-05 0.0133 -0.35 -0.33 Monocyte count; chr3:196747985 chr3:196747192~196747324:- PAAD cis rs73219805 1 rs17310286 ENSG00000228451.3 SDAD1P1 4.3 3.08e-05 0.0133 0.47 0.33 Schizophrenia; chr8:26411516 chr8:26379259~26382953:- PAAD cis rs728616 0.764 rs12413678 ENSG00000225484.5 NUTM2B-AS1 -4.3 3.08e-05 0.0133 -0.63 -0.33 Chronic obstructive pulmonary disease-related biomarkers; chr10:79927343 chr10:79663088~79826594:- PAAD cis rs56046484 0.871 rs7177110 ENSG00000259295.5 CSPG4P12 4.3 3.08e-05 0.0133 0.46 0.33 Testicular germ cell tumor; chr15:85128524 chr15:85191438~85213905:+ PAAD cis rs6991838 0.765 rs10957358 ENSG00000200714.1 Y_RNA 4.3 3.08e-05 0.0133 0.38 0.33 Intelligence (multi-trait analysis); chr8:65590067 chr8:65592731~65592820:+ PAAD cis rs6991838 0.733 rs13281981 ENSG00000200714.1 Y_RNA 4.3 3.08e-05 0.0133 0.38 0.33 Intelligence (multi-trait analysis); chr8:65611649 chr8:65592731~65592820:+ PAAD cis rs964611 0.938 rs12592155 ENSG00000259488.2 RP11-154J22.1 -4.3 3.08e-05 0.0133 -0.36 -0.33 Metabolite levels (Pyroglutamine); chr15:48331303 chr15:48312353~48331856:- PAAD cis rs8072100 0.84 rs9893901 ENSG00000228782.6 CTD-2026D20.3 4.3 3.09e-05 0.0133 0.34 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47429316 chr17:47450568~47492492:- PAAD cis rs7572733 0.534 rs13026569 ENSG00000231621.1 AC013264.2 4.3 3.09e-05 0.0133 0.33 0.33 Dermatomyositis; chr2:197918606 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs4850815 ENSG00000231621.1 AC013264.2 4.3 3.09e-05 0.0133 0.33 0.33 Dermatomyositis; chr2:197921443 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs12619300 ENSG00000231621.1 AC013264.2 4.3 3.09e-05 0.0133 0.33 0.33 Dermatomyositis; chr2:197921766 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1401091 ENSG00000231621.1 AC013264.2 4.3 3.09e-05 0.0133 0.33 0.33 Dermatomyositis; chr2:197925699 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1401092 ENSG00000231621.1 AC013264.2 4.3 3.09e-05 0.0133 0.33 0.33 Dermatomyositis; chr2:197927596 chr2:197197991~197199273:+ PAAD cis rs3130844 1 rs3130844 ENSG00000281831.1 HCP5B 4.3 3.09e-05 0.0133 0.71 0.33 Urinary tract infection frequency; chr6:28948817 chr6:29871895~29873783:- PAAD cis rs148696809 1 rs148696809 ENSG00000281831.1 HCP5B 4.3 3.09e-05 0.0133 0.71 0.33 Lung cancer;Squamous cell lung carcinoma; chr6:28966575 chr6:29871895~29873783:- PAAD cis rs3131085 1 rs3131085 ENSG00000281831.1 HCP5B 4.3 3.09e-05 0.0133 0.71 0.33 Blood protein levels; chr6:29076924 chr6:29871895~29873783:- PAAD cis rs3129178 1 rs3129178 ENSG00000281831.1 HCP5B 4.3 3.09e-05 0.0133 0.71 0.33 Breast cancer; chr6:29107311 chr6:29871895~29873783:- PAAD cis rs3130746 1 rs3130746 ENSG00000281831.1 HCP5B 4.3 3.09e-05 0.0133 0.71 0.33 Tuberculosis; chr6:29185378 chr6:29871895~29873783:- PAAD cis rs144447022 1 rs144447022 ENSG00000281831.1 HCP5B 4.3 3.09e-05 0.0133 0.71 0.33 Schizophrenia;Intelligence (multi-trait analysis); chr6:29276442 chr6:29871895~29873783:- PAAD cis rs3130834 1 rs3130834 ENSG00000281831.1 HCP5B 4.3 3.09e-05 0.0133 0.71 0.33 Breast cancer; chr6:29280372 chr6:29871895~29873783:- PAAD cis rs3129682 1 rs3129682 ENSG00000281831.1 HCP5B 4.3 3.09e-05 0.0133 0.71 0.33 Blood protein levels; chr6:29315895 chr6:29871895~29873783:- PAAD cis rs1150668 0.796 rs1052215 ENSG00000219891.2 ZSCAN12P1 -4.3 3.09e-05 0.0133 -0.43 -0.33 Pubertal anthropometrics; chr6:28380381 chr6:28091154~28093664:+ PAAD cis rs7712401 0.601 rs246322 ENSG00000263432.2 RN7SL689P -4.3 3.09e-05 0.0133 -0.42 -0.33 Mean platelet volume; chr5:122971574 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30026 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122948873 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30022 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122950021 chr5:123022487~123022783:- PAAD cis rs7712401 0.546 rs30021 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122950199 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs246328 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122951933 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs30073 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122954814 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30072 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122956525 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30069 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122957331 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30067 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122957973 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs187405 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122959300 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs40818 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122959378 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs30062 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122960681 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30060 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122961005 chr5:123022487~123022783:- PAAD cis rs7712401 0.525 rs2910150 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122961050 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30059 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122961814 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30058 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122962008 chr5:123022487~123022783:- PAAD cis rs7712401 0.623 rs30057 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122962423 chr5:123022487~123022783:- PAAD cis rs7712401 0.584 rs39820 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122964226 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30055 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122965384 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs39819 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122965981 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30054 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122966304 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs30053 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122967948 chr5:123022487~123022783:- PAAD cis rs7712401 0.562 rs30052 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122969314 chr5:123022487~123022783:- PAAD cis rs7712401 0.601 rs30049 ENSG00000263432.2 RN7SL689P 4.3 3.09e-05 0.0133 0.42 0.33 Mean platelet volume; chr5:122970402 chr5:123022487~123022783:- PAAD cis rs11675119 0.501 rs9309716 ENSG00000225234.1 TRAPPC12-AS1 -4.3 3.09e-05 0.0133 -0.35 -0.33 Neurofibrillary tangles; chr2:3489584 chr2:3481242~3482409:- PAAD cis rs2739330 0.76 rs5751761 ENSG00000099984.9 GSTT2 4.3 3.09e-05 0.0133 0.43 0.33 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23980123~23983911:+ PAAD cis rs6782228 1 rs35604103 ENSG00000242551.2 POU5F1P6 4.3 3.09e-05 0.0133 0.43 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128616009 chr3:128674735~128677005:- PAAD cis rs9876781 1 rs2362452 ENSG00000229759.1 MRPS18AP1 -4.3 3.09e-05 0.0133 -0.35 -0.33 Longevity; chr3:48376724 chr3:48256350~48256938:- PAAD cis rs6479901 0.841 rs10733787 ENSG00000232075.1 MRPL35P2 -4.3 3.1e-05 0.0133 -0.48 -0.33 Intelligence (multi-trait analysis); chr10:63147078 chr10:63634317~63634827:- PAAD cis rs6479901 0.67 rs12240740 ENSG00000232075.1 MRPL35P2 -4.3 3.1e-05 0.0133 -0.48 -0.33 Intelligence (multi-trait analysis); chr10:63147478 chr10:63634317~63634827:- PAAD cis rs4713118 0.662 rs9393881 ENSG00000204709.4 LINC01556 4.3 3.1e-05 0.0133 0.55 0.33 Parkinson's disease; chr6:28055973 chr6:28943877~28944537:+ PAAD cis rs7580658 0.817 rs6761447 ENSG00000236682.1 AC068282.3 -4.3 3.1e-05 0.0133 -0.44 -0.33 Protein C levels; chr2:127316997 chr2:127389130~127400580:+ PAAD cis rs6782228 0.585 rs9841161 ENSG00000242551.2 POU5F1P6 -4.3 3.1e-05 0.0133 -0.39 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613027 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs2712405 ENSG00000242551.2 POU5F1P6 -4.3 3.1e-05 0.0133 -0.39 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128613239 chr3:128674735~128677005:- PAAD cis rs6782228 0.606 rs9828893 ENSG00000242551.2 POU5F1P6 -4.3 3.1e-05 0.0133 -0.39 -0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128614082 chr3:128674735~128677005:- PAAD cis rs6446731 0.568 rs4488885 ENSG00000261643.1 RP11-529E10.6 -4.3 3.1e-05 0.0133 -0.39 -0.33 Mean platelet volume; chr4:3284226 chr4:3503597~3504457:- PAAD cis rs8005677 0.851 rs8010804 ENSG00000279656.1 RP11-298I3.6 4.3 3.1e-05 0.0133 0.41 0.33 Cognitive ability (multi-trait analysis); chr14:22927271 chr14:23023083~23024217:- PAAD cis rs41369048 0.669 rs11589654 ENSG00000238078.1 LINC01352 -4.3 3.1e-05 0.0133 -0.46 -0.33 Eosinophil counts;Sum eosinophil basophil counts; chr1:220866646 chr1:220829255~220832429:+ PAAD cis rs6860540 0.796 rs57229403 ENSG00000251405.2 CTB-109A12.1 -4.29 3.11e-05 0.0133 -0.42 -0.33 Inflammatory skin disease; chr5:157489634 chr5:157362615~157460078:- PAAD cis rs950880 0.593 rs887972 ENSG00000234389.1 AC007278.3 -4.29 3.11e-05 0.0133 -0.33 -0.33 Serum protein levels (sST2); chr2:102424485 chr2:102438713~102440475:+ PAAD cis rs7617773 0.744 rs2125482 ENSG00000228638.1 FCF1P2 -4.29 3.11e-05 0.0134 -0.37 -0.33 Coronary artery disease; chr3:48281643 chr3:48290793~48291375:- PAAD cis rs8177376 0.727 rs4937121 ENSG00000254905.1 RP11-712L6.7 4.29 3.11e-05 0.0134 0.42 0.33 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126330659 chr11:126292922~126294254:- PAAD cis rs6472235 0.681 rs58881093 ENSG00000200714.1 Y_RNA -4.29 3.11e-05 0.0134 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65952396 chr8:65592731~65592820:+ PAAD cis rs10510102 1 rs7923678 ENSG00000276742.1 RP11-500G22.4 4.29 3.11e-05 0.0134 0.46 0.33 Breast cancer; chr10:121832546 chr10:121956782~121957098:+ PAAD cis rs12935418 0.672 rs9925780 ENSG00000261061.1 RP11-303E16.2 -4.29 3.11e-05 0.0134 -0.41 -0.33 Mean corpuscular volume; chr16:81011571 chr16:81030770~81031485:+ PAAD cis rs10411161 0.702 rs79180893 ENSG00000270248.1 CTC-471J1.10 4.29 3.11e-05 0.0134 0.59 0.33 Breast cancer; chr19:51892362 chr19:52110318~52110726:- PAAD cis rs8177876 0.822 rs12444137 ENSG00000261838.4 RP11-303E16.6 4.29 3.11e-05 0.0134 0.77 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81076746 chr16:81069854~81076598:+ PAAD cis rs8177876 0.731 rs76093926 ENSG00000261838.4 RP11-303E16.6 4.29 3.11e-05 0.0134 0.77 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81078920 chr16:81069854~81076598:+ PAAD cis rs8177876 0.731 rs10514512 ENSG00000261838.4 RP11-303E16.6 4.29 3.11e-05 0.0134 0.77 0.33 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81080350 chr16:81069854~81076598:+ PAAD cis rs10510102 1 rs11200181 ENSG00000276742.1 RP11-500G22.4 4.29 3.11e-05 0.0134 0.46 0.33 Breast cancer; chr10:121828528 chr10:121956782~121957098:+ PAAD cis rs6951245 1 rs11763020 ENSG00000229043.2 AC091729.9 -4.29 3.12e-05 0.0134 -0.52 -0.33 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1020652 chr7:1160374~1165267:+ PAAD cis rs7829975 1 rs7829975 ENSG00000254340.1 RP11-10A14.3 -4.29 3.12e-05 0.0134 -0.43 -0.33 Mood instability; chr8:8690607 chr8:9141424~9145435:+ PAAD cis rs4713118 0.586 rs9468290 ENSG00000280107.1 AL022393.9 -4.29 3.12e-05 0.0134 -0.55 -0.33 Parkinson's disease; chr6:28119896 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393894 ENSG00000280107.1 AL022393.9 -4.29 3.12e-05 0.0134 -0.55 -0.33 Depression; chr6:28144784 chr6:28170845~28172521:+ PAAD cis rs4835473 0.932 rs11724752 ENSG00000251600.4 RP11-673E1.1 -4.29 3.12e-05 0.0134 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143769473 chr4:143912331~143982454:+ PAAD cis rs8059260 0.668 rs74423828 ENSG00000274038.1 RP11-66H6.4 -4.29 3.12e-05 0.0134 -0.56 -0.33 Alcohol consumption over the past year; chr16:10975574 chr16:11056556~11057034:+ PAAD cis rs4835473 0.932 rs9997931 ENSG00000251600.4 RP11-673E1.1 4.29 3.12e-05 0.0134 0.37 0.33 Immature fraction of reticulocytes; chr4:143904601 chr4:143912331~143982454:+ PAAD cis rs853679 0.506 rs1150711 ENSG00000204709.4 LINC01556 4.29 3.12e-05 0.0134 0.45 0.33 Depression; chr6:28240757 chr6:28943877~28944537:+ PAAD cis rs4835473 0.932 rs17750042 ENSG00000251600.4 RP11-673E1.1 -4.29 3.13e-05 0.0134 -0.38 -0.33 Immature fraction of reticulocytes; chr4:143726691 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1375989 ENSG00000251600.4 RP11-673E1.1 -4.29 3.13e-05 0.0134 -0.38 -0.33 Immature fraction of reticulocytes; chr4:143726893 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs35598827 ENSG00000251600.4 RP11-673E1.1 -4.29 3.13e-05 0.0134 -0.38 -0.33 Immature fraction of reticulocytes; chr4:143729605 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34570929 ENSG00000251600.4 RP11-673E1.1 -4.29 3.13e-05 0.0134 -0.38 -0.33 Immature fraction of reticulocytes; chr4:143730766 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs17750172 ENSG00000251600.4 RP11-673E1.1 -4.29 3.13e-05 0.0134 -0.38 -0.33 Immature fraction of reticulocytes; chr4:143731094 chr4:143912331~143982454:+ PAAD cis rs9928842 0.941 rs1808427 ENSG00000280152.1 RP11-331F4.5 4.29 3.13e-05 0.0134 0.45 0.33 Alcoholic chronic pancreatitis; chr16:75207496 chr16:75245994~75250077:- PAAD cis rs9928842 1 rs9928842 ENSG00000280152.1 RP11-331F4.5 4.29 3.13e-05 0.0134 0.45 0.33 Alcoholic chronic pancreatitis; chr16:75208969 chr16:75245994~75250077:- PAAD cis rs7580658 0.864 rs4150454 ENSG00000236682.1 AC068282.3 -4.29 3.13e-05 0.0134 -0.44 -0.33 Protein C levels; chr2:127280968 chr2:127389130~127400580:+ PAAD cis rs12935418 0.561 rs2287991 ENSG00000261061.1 RP11-303E16.2 -4.29 3.13e-05 0.0134 -0.41 -0.33 Mean corpuscular volume; chr16:81006950 chr16:81030770~81031485:+ PAAD cis rs801193 0.967 rs2420827 ENSG00000237310.1 GS1-124K5.4 -4.29 3.13e-05 0.0134 -0.31 -0.33 Aortic root size; chr7:66682114 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2055682 ENSG00000237310.1 GS1-124K5.4 4.29 3.13e-05 0.0134 0.31 0.33 Aortic root size; chr7:66795302 chr7:66493706~66495474:+ PAAD cis rs2348418 0.868 rs12302861 ENSG00000247934.4 RP11-967K21.1 4.29 3.13e-05 0.0134 0.33 0.33 Lung function (FEV1);Lung function (FVC); chr12:28516269 chr12:28163298~28190738:- PAAD cis rs9926296 0.609 rs4785709 ENSG00000260259.1 RP11-368I7.4 4.29 3.13e-05 0.0134 0.38 0.33 Vitiligo; chr16:89730257 chr16:89682620~89686569:- PAAD cis rs2948294 0.566 rs13274039 ENSG00000253893.2 FAM85B -4.29 3.13e-05 0.0134 -0.45 -0.33 Red cell distribution width; chr8:8254137 chr8:8167819~8226614:- PAAD cis rs2948294 0.566 rs13261997 ENSG00000253893.2 FAM85B -4.29 3.13e-05 0.0134 -0.45 -0.33 Red cell distribution width; chr8:8254773 chr8:8167819~8226614:- PAAD cis rs2243480 1 rs316330 ENSG00000228409.4 CCT6P1 4.29 3.13e-05 0.0134 0.35 0.33 Diabetic kidney disease; chr7:66140385 chr7:65751142~65763354:+ PAAD cis rs9652601 0.959 rs9652582 ENSG00000274038.1 RP11-66H6.4 -4.29 3.13e-05 0.0134 -0.38 -0.33 Systemic lupus erythematosus; chr16:11080707 chr16:11056556~11057034:+ PAAD cis rs9652601 0.959 rs2041670 ENSG00000274038.1 RP11-66H6.4 -4.29 3.13e-05 0.0134 -0.38 -0.33 Systemic lupus erythematosus; chr16:11080795 chr16:11056556~11057034:+ PAAD cis rs9652601 0.959 rs9931397 ENSG00000274038.1 RP11-66H6.4 -4.29 3.13e-05 0.0134 -0.38 -0.33 Systemic lupus erythematosus; chr16:11083537 chr16:11056556~11057034:+ PAAD cis rs9652601 0.959 rs12708715 ENSG00000274038.1 RP11-66H6.4 -4.29 3.13e-05 0.0134 -0.38 -0.33 Systemic lupus erythematosus; chr16:11083967 chr16:11056556~11057034:+ PAAD cis rs113835537 0.935 rs11550057 ENSG00000255517.5 CTD-3074O7.5 -4.29 3.13e-05 0.0135 -0.53 -0.33 Airway imaging phenotypes; chr11:66625409 chr11:66473490~66480233:- PAAD cis rs113835537 0.935 rs15969 ENSG00000255517.5 CTD-3074O7.5 -4.29 3.13e-05 0.0135 -0.53 -0.33 Airway imaging phenotypes; chr11:66626916 chr11:66473490~66480233:- PAAD cis rs6504622 0.875 rs3785888 ENSG00000262539.1 RP11-259G18.3 -4.29 3.13e-05 0.0135 -0.42 -0.33 Orofacial clefts; chr17:46928337 chr17:46259551~46260606:- PAAD cis rs11723261 0.621 rs7440274 ENSG00000275426.1 CH17-262A2.1 -4.29 3.13e-05 0.0135 -0.51 -0.33 Immune response to smallpox vaccine (IL-6); chr4:161923 chr4:149738~150317:+ PAAD cis rs2262909 0.849 rs10420483 ENSG00000279377.1 AC003973.3 4.29 3.13e-05 0.0135 0.31 0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22007576 chr19:21965708~21968529:- PAAD cis rs7626444 0.625 rs2686596 ENSG00000272359.1 U4 -4.29 3.14e-05 0.0135 -0.35 -0.33 Monocyte count; chr3:196748248 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs2686595 ENSG00000272359.1 U4 -4.29 3.14e-05 0.0135 -0.35 -0.33 Monocyte count; chr3:196748271 chr3:196747192~196747324:- PAAD cis rs7626444 0.647 rs844546 ENSG00000272359.1 U4 -4.29 3.14e-05 0.0135 -0.35 -0.33 Monocyte count; chr3:196748403 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs843540 ENSG00000272359.1 U4 -4.29 3.14e-05 0.0135 -0.35 -0.33 Monocyte count; chr3:196748442 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs1104375 ENSG00000272359.1 U4 -4.29 3.14e-05 0.0135 -0.35 -0.33 Monocyte count; chr3:196749172 chr3:196747192~196747324:- PAAD cis rs3823536 0.583 rs1874327 ENSG00000275106.1 RP11-309L24.10 -4.29 3.14e-05 0.0135 -0.46 -0.33 Sjögren's syndrome; chr7:128945322 chr7:128952527~128953316:- PAAD cis rs2505998 1 rs2506006 ENSG00000273008.1 RP11-351D16.3 -4.29 3.14e-05 0.0135 -0.28 -0.33 Hirschsprung disease; chr10:43086053 chr10:43136824~43138334:- PAAD cis rs12908161 0.96 rs34452033 ENSG00000259295.5 CSPG4P12 4.29 3.14e-05 0.0135 0.37 0.33 Schizophrenia; chr15:84678762 chr15:85191438~85213905:+ PAAD cis rs7923609 0.905 rs7088799 ENSG00000232075.1 MRPL35P2 -4.29 3.14e-05 0.0135 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63256414 chr10:63634317~63634827:- PAAD cis rs7923609 0.756 rs7080386 ENSG00000232075.1 MRPL35P2 -4.29 3.14e-05 0.0135 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63288546 chr10:63634317~63634827:- PAAD cis rs7923609 0.778 rs7075195 ENSG00000232075.1 MRPL35P2 -4.29 3.14e-05 0.0135 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63290899 chr10:63634317~63634827:- PAAD cis rs17711722 0.565 rs73372653 ENSG00000237310.1 GS1-124K5.4 4.29 3.15e-05 0.0135 0.32 0.33 Calcium levels; chr7:65977808 chr7:66493706~66495474:+ PAAD cis rs79040073 0.607 rs17479289 ENSG00000259531.2 RP11-295H24.3 4.29 3.15e-05 0.0135 0.51 0.33 Lung cancer in ever smokers; chr15:49456416 chr15:49365124~49366685:- PAAD cis rs394563 0.934 rs384334 ENSG00000231760.4 RP11-350J20.5 4.29 3.15e-05 0.0135 0.43 0.33 Dupuytren's disease; chr6:149475036 chr6:149796151~149826294:- PAAD cis rs10411161 1 rs10411161 ENSG00000269483.1 AC006272.1 4.29 3.15e-05 0.0135 0.57 0.33 Breast cancer; chr19:51869723 chr19:51839924~51843324:- PAAD cis rs11976180 1 rs1320893 ENSG00000273234.1 OR2A13P -4.29 3.15e-05 0.0135 -0.4 -0.33 Obesity-related traits; chr7:144055019 chr7:144142009~144142938:+ PAAD cis rs7592578 0.599 rs62180992 ENSG00000231858.4 AC067945.4 -4.29 3.15e-05 0.0135 -0.41 -0.33 Diastolic blood pressure; chr2:190421006 chr2:191021526~191032314:+ PAAD cis rs10779751 0.762 rs1074078 ENSG00000238199.1 UBE2V2P3 4.29 3.15e-05 0.0135 0.38 0.33 Body mass index; chr1:11266731 chr1:11278616~11279351:- PAAD cis rs11690935 0.61 rs59844139 ENSG00000228389.1 AC068039.4 -4.29 3.15e-05 0.0135 -0.41 -0.33 Schizophrenia; chr2:171875473 chr2:171773482~171775844:+ PAAD cis rs66823261 0.741 rs7841786 ENSG00000253166.2 RP11-585F1.6 -4.29 3.16e-05 0.0135 -0.45 -0.33 Breast cancer (estrogen-receptor negative);Breast cancer; chr8:241746 chr8:202660~202897:- PAAD cis rs4660214 0.666 rs2256614 ENSG00000237624.1 OXCT2P1 4.29 3.16e-05 0.0135 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39359046 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs596062 ENSG00000237624.1 OXCT2P1 4.29 3.16e-05 0.0135 0.43 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39360333 chr1:39514956~39516490:+ PAAD cis rs8181477 0.764 rs11014484 ENSG00000240291.1 RP11-499P20.2 -4.29 3.16e-05 0.0135 -0.28 -0.33 Obesity-related traits; chr10:18490395 chr10:18513115~18545651:- PAAD cis rs6142102 0.923 rs6059635 ENSG00000276073.1 RP5-1125A11.7 -4.29 3.16e-05 0.0135 -0.35 -0.33 Skin pigmentation; chr20:34025687 chr20:33985617~33988989:- PAAD cis rs3743772 0.5 rs8045574 ENSG00000279344.1 RP11-44F14.7 -4.29 3.16e-05 0.0136 -0.36 -0.33 Depressive symptoms (SSRI exposure interaction); chr16:53395293 chr16:53478957~53481550:- PAAD cis rs871012 0.502 rs60416963 ENSG00000248544.2 CTB-47B11.3 -4.29 3.16e-05 0.0136 -0.43 -0.33 IgG glycosylation; chr5:157441157 chr5:157375741~157384950:- PAAD cis rs10779751 1 rs11121703 ENSG00000238199.1 UBE2V2P3 4.29 3.17e-05 0.0136 0.39 0.33 Body mass index; chr1:11233735 chr1:11278616~11279351:- PAAD cis rs2832077 0.527 rs11088095 ENSG00000176054.6 RPL23P2 -4.29 3.17e-05 0.0136 -0.33 -0.33 Cognitive test performance; chr21:28850866 chr21:28997613~28998033:- PAAD cis rs2832077 0.527 rs2142375 ENSG00000176054.6 RPL23P2 -4.29 3.17e-05 0.0136 -0.33 -0.33 Cognitive test performance; chr21:28851420 chr21:28997613~28998033:- PAAD cis rs2832077 0.527 rs9980449 ENSG00000176054.6 RPL23P2 -4.29 3.17e-05 0.0136 -0.33 -0.33 Cognitive test performance; chr21:28852567 chr21:28997613~28998033:- PAAD cis rs2832077 0.527 rs59730679 ENSG00000176054.6 RPL23P2 -4.29 3.17e-05 0.0136 -0.33 -0.33 Cognitive test performance; chr21:28853922 chr21:28997613~28998033:- PAAD cis rs2832077 0.527 rs2832116 ENSG00000176054.6 RPL23P2 -4.29 3.17e-05 0.0136 -0.33 -0.33 Cognitive test performance; chr21:28856046 chr21:28997613~28998033:- PAAD cis rs7626444 0.625 rs843541 ENSG00000272359.1 U4 -4.29 3.17e-05 0.0136 -0.35 -0.33 Monocyte count; chr3:196748879 chr3:196747192~196747324:- PAAD cis rs8005677 0.828 rs8016027 ENSG00000279656.1 RP11-298I3.6 4.29 3.17e-05 0.0136 0.39 0.33 Cognitive ability (multi-trait analysis); chr14:22950944 chr14:23023083~23024217:- PAAD cis rs577676 0.586 rs578928 ENSG00000271811.1 RP1-79C4.4 4.29 3.17e-05 0.0136 0.35 0.33 Prevalent atrial fibrillation; chr1:170640602 chr1:170667381~170669425:+ PAAD cis rs7646881 0.767 rs73015629 ENSG00000240207.5 RP11-379F4.4 -4.29 3.17e-05 0.0136 -0.5 -0.33 Tetralogy of Fallot; chr3:158716051 chr3:158732263~158784070:+ PAAD cis rs17772222 0.755 rs12435019 ENSG00000258983.2 RP11-507K2.2 4.29 3.17e-05 0.0136 0.37 0.33 Coronary artery calcification; chr14:88365074 chr14:88499334~88515502:+ PAAD cis rs9649213 0.574 rs62478236 ENSG00000272950.1 RP11-307C18.1 4.29 3.17e-05 0.0136 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98401065 chr7:98322853~98323430:+ PAAD cis rs6908034 0.66 rs12525506 ENSG00000228412.5 RP4-625H18.2 4.29 3.18e-05 0.0136 0.69 0.33 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19794003 chr6:19802164~19804752:- PAAD cis rs4218 0.681 rs1867757 ENSG00000277144.1 RP11-59H7.4 -4.29 3.18e-05 0.0136 -0.44 -0.33 Social communication problems; chr15:59072315 chr15:59115547~59116089:- PAAD cis rs496547 0.719 rs598373 ENSG00000278376.1 RP11-158I9.8 -4.29 3.18e-05 0.0136 -0.29 -0.33 Hip minimal joint space width; chr11:118793668 chr11:118791254~118793137:+ PAAD cis rs6951245 1 rs74652290 ENSG00000229043.2 AC091729.9 -4.29 3.18e-05 0.0136 -0.49 -0.33 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1050473 chr7:1160374~1165267:+ PAAD cis rs1167827 0.71 rs1167836 ENSG00000278416.1 PMS2L2 4.29 3.18e-05 0.0136 0.38 0.33 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75539580 chr7:75344015~75359550:- PAAD cis rs12682352 0.715 rs332039 ENSG00000253893.2 FAM85B -4.29 3.18e-05 0.0136 -0.44 -0.33 Neuroticism; chr8:8866141 chr8:8167819~8226614:- PAAD cis rs7615952 0.575 rs35949599 ENSG00000171084.14 FAM86JP 4.29 3.19e-05 0.0136 0.45 0.33 Blood pressure (smoking interaction); chr3:125825359 chr3:125916620~125930024:+ PAAD cis rs2243480 1 rs437889 ENSG00000232546.1 RP11-458F8.1 -4.29 3.19e-05 0.0136 -0.4 -0.33 Diabetic kidney disease; chr7:66044247 chr7:66848496~66858136:+ PAAD cis rs2976388 0.609 rs2572909 ENSG00000253741.1 CTD-2292P10.4 -4.29 3.19e-05 0.0137 -0.39 -0.33 Urinary tract infection frequency; chr8:142725046 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2585140 ENSG00000253741.1 CTD-2292P10.4 -4.29 3.19e-05 0.0137 -0.39 -0.33 Urinary tract infection frequency; chr8:142725478 chr8:142702252~142726973:- PAAD cis rs10800713 0.908 rs6686605 ENSG00000260088.1 RP11-92G12.3 -4.29 3.19e-05 0.0137 -0.44 -0.33 Tandem gait; chr1:200539440 chr1:200669507~200694250:+ PAAD cis rs12908161 1 rs12908161 ENSG00000259728.4 LINC00933 4.29 3.19e-05 0.0137 0.41 0.33 Schizophrenia; chr15:84664594 chr15:84570649~84580175:+ PAAD cis rs2117029 1 rs10875913 ENSG00000258017.1 RP11-386G11.10 -4.29 3.19e-05 0.0137 -0.42 -0.33 Intelligence (multi-trait analysis); chr12:49025525 chr12:49127782~49147869:+ PAAD cis rs4713118 0.662 rs9393881 ENSG00000226314.6 ZNF192P1 -4.29 3.19e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28055973 chr6:28161781~28169594:+ PAAD cis rs797680 0.964 rs12139009 ENSG00000223745.6 RP4-717I23.3 4.29 3.2e-05 0.0137 0.26 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93107936 chr1:93262186~93346025:- PAAD cis rs797680 0.964 rs4847398 ENSG00000223745.6 RP4-717I23.3 4.29 3.2e-05 0.0137 0.26 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93112845 chr1:93262186~93346025:- PAAD cis rs797680 0.897 rs2295424 ENSG00000223745.6 RP4-717I23.3 4.29 3.2e-05 0.0137 0.26 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93115322 chr1:93262186~93346025:- PAAD cis rs797680 0.891 rs4847399 ENSG00000223745.6 RP4-717I23.3 4.29 3.2e-05 0.0137 0.26 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93119049 chr1:93262186~93346025:- PAAD cis rs172166 0.543 rs1150691 ENSG00000219891.2 ZSCAN12P1 4.29 3.2e-05 0.0137 0.45 0.33 Cardiac Troponin-T levels; chr6:28200255 chr6:28091154~28093664:+ PAAD cis rs780096 0.546 rs8179225 ENSG00000234072.1 AC074117.10 -4.29 3.2e-05 0.0137 -0.25 -0.33 Total body bone mineral density; chr2:27514314 chr2:27356246~27367622:+ PAAD cis rs11123170 0.542 rs28522253 ENSG00000274877.1 RP11-65I12.1 -4.29 3.2e-05 0.0137 -0.44 -0.33 Renal function-related traits (BUN); chr2:113209810 chr2:113237595~113240825:+ PAAD cis rs7826238 0.601 rs2976907 ENSG00000254340.1 RP11-10A14.3 4.29 3.2e-05 0.0137 0.39 0.33 Systolic blood pressure; chr8:8487658 chr8:9141424~9145435:+ PAAD cis rs58873874 0.737 rs78738433 ENSG00000248544.2 CTB-47B11.3 4.29 3.2e-05 0.0137 0.71 0.33 Bipolar disorder (body mass index interaction); chr5:157386503 chr5:157375741~157384950:- PAAD cis rs7826238 0.535 rs2979179 ENSG00000253981.4 ALG1L13P 4.29 3.2e-05 0.0137 0.39 0.33 Systolic blood pressure; chr8:8462519 chr8:8236003~8244667:- PAAD cis rs718433 1 rs718433 ENSG00000256379.1 TRAV8-5 -4.29 3.2e-05 0.0137 -0.29 -0.33 Intraocular pressure; chr14:21767650 chr14:21903077~21903598:+ PAAD cis rs4266144 0.581 rs1806867 ENSG00000244515.1 KRT18P34 -4.29 3.21e-05 0.0137 -0.39 -0.33 Coronary artery disease; chr3:157110513 chr3:157162663~157163932:- PAAD cis rs7626444 0.625 rs843530 ENSG00000272359.1 U4 -4.29 3.21e-05 0.0137 -0.36 -0.33 Monocyte count; chr3:196754153 chr3:196747192~196747324:- PAAD cis rs8005677 0.798 rs61977741 ENSG00000279656.1 RP11-298I3.6 4.29 3.21e-05 0.0137 0.39 0.33 Cognitive ability (multi-trait analysis); chr14:22931770 chr14:23023083~23024217:- PAAD cis rs889398 0.904 rs4783721 ENSG00000226232.7 RP11-419C5.2 4.29 3.21e-05 0.0137 0.27 0.33 Body mass index; chr16:69527253 chr16:69976388~69996188:- PAAD cis rs853679 0.517 rs868987 ENSG00000280107.1 AL022393.9 4.29 3.21e-05 0.0137 0.55 0.33 Depression; chr6:28142370 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9283884 ENSG00000280107.1 AL022393.9 4.29 3.21e-05 0.0137 0.55 0.33 Depression; chr6:28167882 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380047 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28070115 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs7755442 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28071237 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713135 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28071808 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs12174753 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28074687 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs55747925 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28076559 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs56310871 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28076704 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs34716816 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28078391 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380049 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28080757 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380050 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28080760 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393885 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28082231 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393886 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28082261 chr6:28170845~28172521:+ PAAD cis rs4713118 0.515 rs9368549 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28082269 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs56364346 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28082984 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9357061 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28083994 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368550 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28084025 chr6:28170845~28172521:+ PAAD cis rs853679 0.542 rs2295594 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28085319 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs2273564 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28089816 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs1853097 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28090857 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393888 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28091439 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs3734573 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28091659 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9357063 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28092227 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs3823180 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28093966 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368551 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28094014 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393890 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28096077 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9366715 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28096855 chr6:28170845~28172521:+ PAAD cis rs853679 0.598 rs9380054 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28099759 chr6:28170845~28172521:+ PAAD cis rs4713118 0.547 rs2116981 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28100173 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368552 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28100648 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs2281588 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28104824 chr6:28170845~28172521:+ PAAD cis rs853679 0.542 rs34131763 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28107222 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs35193936 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28108492 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs36078605 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28110254 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393891 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28111382 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9468286 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28111650 chr6:28170845~28172521:+ PAAD cis rs853679 0.542 rs9393892 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28113616 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380055 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28113851 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368553 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28114487 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368554 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28114933 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713137 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28115743 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9348793 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28116411 chr6:28170845~28172521:+ PAAD cis rs4713118 0.586 rs6905516 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28118700 chr6:28170845~28172521:+ PAAD cis rs4713118 0.586 rs6905522 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28118701 chr6:28170845~28172521:+ PAAD cis rs853679 0.542 rs6934769 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28123153 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs17711801 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28124529 chr6:28170845~28172521:+ PAAD cis rs4713118 0.527 rs9461433 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28127394 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9468292 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28127577 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs1947863 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28131566 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713141 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28133900 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380056 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28136698 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380057 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28136856 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs1947862 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28137418 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs6941992 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28138363 chr6:28170845~28172521:+ PAAD cis rs4713118 0.516 rs4713142 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28138569 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713143 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28138981 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713144 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28139012 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713145 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28139049 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs3757187 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28139876 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs3757185 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28139998 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs1904840 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28140454 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368555 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28141189 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393893 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28141484 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713146 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28143758 chr6:28170845~28172521:+ PAAD cis rs853679 0.513 rs9468296 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28145952 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4711164 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28147378 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4711165 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28147406 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713148 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28148143 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9348794 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28149979 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9468297 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28151096 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9295758 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28152885 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs17774663 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28153120 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9468298 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28154567 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9295759 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28156691 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9348796 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28158424 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs11552219 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28159056 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393895 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28159843 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9357065 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28161802 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9357066 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28162053 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368556 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28163375 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368557 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28163759 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380059 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28164580 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380060 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28164825 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs35227624 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28164948 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380061 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28165025 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9368558 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28165528 chr6:28170845~28172521:+ PAAD cis rs4713118 0.587 rs9393899 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28165750 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713150 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28168434 chr6:28170845~28172521:+ PAAD cis rs4713118 0.527 rs4713151 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Parkinson's disease; chr6:28168578 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393901 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28169019 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs3173443 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28169249 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs4713152 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28169676 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9348797 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28169755 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380062 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28169791 chr6:28170845~28172521:+ PAAD cis rs853679 0.542 rs9380063 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28170075 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs12332979 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28173770 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs67878650 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28174809 chr6:28170845~28172521:+ PAAD cis rs853679 0.569 rs9348798 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28175233 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9380065 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28176973 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9295761 ENSG00000280107.1 AL022393.9 -4.29 3.21e-05 0.0137 -0.55 -0.33 Depression; chr6:28180209 chr6:28170845~28172521:+ PAAD cis rs79040073 0.599 rs73394331 ENSG00000259531.2 RP11-295H24.3 4.29 3.21e-05 0.0137 0.56 0.33 Lung cancer in ever smokers; chr15:49278236 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73394333 ENSG00000259531.2 RP11-295H24.3 4.29 3.21e-05 0.0137 0.56 0.33 Lung cancer in ever smokers; chr15:49278719 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs76069611 ENSG00000259531.2 RP11-295H24.3 4.29 3.21e-05 0.0137 0.56 0.33 Lung cancer in ever smokers; chr15:49281322 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs78050772 ENSG00000259531.2 RP11-295H24.3 4.29 3.21e-05 0.0137 0.56 0.33 Lung cancer in ever smokers; chr15:49286380 chr15:49365124~49366685:- PAAD cis rs10853057 0.618 rs12947222 ENSG00000214174.7 AMZ2P1 4.29 3.21e-05 0.0137 0.52 0.33 White matter microstructure (global fractional anisotropy); chr17:65005160 chr17:64966550~64975576:- PAAD cis rs9595908 0.965 rs9595877 ENSG00000212293.1 SNORA16 4.29 3.21e-05 0.0137 0.38 0.33 Body mass index; chr13:32589512 chr13:32420390~32420516:- PAAD cis rs17772222 0.917 rs1998670 ENSG00000258983.2 RP11-507K2.2 4.29 3.21e-05 0.0137 0.46 0.33 Coronary artery calcification; chr14:88504581 chr14:88499334~88515502:+ PAAD cis rs10129255 0.576 rs2157616 ENSG00000211972.2 IGHV3-66 4.29 3.21e-05 0.0137 0.25 0.33 Kawasaki disease; chr14:106767802 chr14:106675017~106675544:- PAAD cis rs9649213 0.593 rs3823740 ENSG00000272950.1 RP11-307C18.1 4.29 3.22e-05 0.0137 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98327792 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs35535338 ENSG00000272950.1 RP11-307C18.1 4.29 3.22e-05 0.0137 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98333007 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs36017146 ENSG00000272950.1 RP11-307C18.1 4.29 3.22e-05 0.0137 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98345305 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs1468341 ENSG00000272950.1 RP11-307C18.1 4.29 3.22e-05 0.0137 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98358384 chr7:98322853~98323430:+ PAAD cis rs780096 0.546 rs715325 ENSG00000234072.1 AC074117.10 -4.29 3.22e-05 0.0137 -0.26 -0.33 Total body bone mineral density; chr2:27502705 chr2:27356246~27367622:+ PAAD cis rs3813579 0.679 rs4329928 ENSG00000261390.4 RP11-345M22.2 4.29 3.22e-05 0.0137 0.42 0.33 Thyroid volume; chr16:79713988 chr16:79715232~79770563:- PAAD cis rs7554672 0.961 rs12120171 ENSG00000232679.1 RP11-400N13.3 4.29 3.22e-05 0.0137 0.35 0.33 Hypertension; chr1:221184625 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs12128432 ENSG00000232679.1 RP11-400N13.3 4.29 3.22e-05 0.0137 0.35 0.33 Hypertension; chr1:221185115 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs9431431 ENSG00000232679.1 RP11-400N13.3 4.29 3.22e-05 0.0137 0.35 0.33 Hypertension; chr1:221185454 chr1:222041705~222064763:- PAAD cis rs72627509 0.857 rs2227901 ENSG00000269949.1 RP11-738E22.3 -4.29 3.22e-05 0.0137 -0.52 -0.33 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56932023 chr4:56960927~56961373:- PAAD cis rs74233809 0.748 rs10786736 ENSG00000213277.3 MARCKSL1P1 4.29 3.22e-05 0.0137 0.5 0.33 Birth weight; chr10:103089359 chr10:103175554~103176094:+ PAAD cis rs13178541 0.81 rs11959218 ENSG00000250378.1 RP11-119J18.1 -4.29 3.22e-05 0.0137 -0.52 -0.33 IgG glycosylation; chr5:135809526 chr5:135812667~135826582:+ PAAD cis rs853679 0.517 rs9380047 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28070115 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs7755442 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28071237 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713135 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28071808 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs12174753 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28074687 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs55747925 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28076559 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs56310871 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28076704 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs34716816 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28078391 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380049 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28080757 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380050 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28080760 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393885 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28082231 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393886 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28082261 chr6:28943877~28944537:+ PAAD cis rs4713118 0.515 rs9368549 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Parkinson's disease; chr6:28082269 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs56364346 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28082984 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9357061 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28083994 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368550 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28084025 chr6:28943877~28944537:+ PAAD cis rs853679 0.542 rs2295594 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28085319 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs2273564 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28089816 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs1853097 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28090857 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393888 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28091439 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs3734573 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28091659 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9357063 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28092227 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs3823180 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28093966 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368551 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28094014 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393890 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28096077 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9366715 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28096855 chr6:28943877~28944537:+ PAAD cis rs853679 0.598 rs9380054 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28099759 chr6:28943877~28944537:+ PAAD cis rs4713118 0.547 rs2116981 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Parkinson's disease; chr6:28100173 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368552 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28100648 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs2281588 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28104824 chr6:28943877~28944537:+ PAAD cis rs853679 0.542 rs34131763 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28107222 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs35193936 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28108492 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs36078605 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28110254 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393891 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28111382 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9468286 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28111650 chr6:28943877~28944537:+ PAAD cis rs853679 0.542 rs9393892 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28113616 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380055 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28113851 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368553 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28114487 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368554 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28114933 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713137 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28115743 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9348793 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28116411 chr6:28943877~28944537:+ PAAD cis rs4713118 0.586 rs6905516 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Parkinson's disease; chr6:28118700 chr6:28943877~28944537:+ PAAD cis rs4713118 0.586 rs6905522 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Parkinson's disease; chr6:28118701 chr6:28943877~28944537:+ PAAD cis rs853679 0.542 rs6934769 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28123153 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs17711801 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28124529 chr6:28943877~28944537:+ PAAD cis rs4713118 0.527 rs9461433 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Parkinson's disease; chr6:28127394 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9468292 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28127577 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs1947863 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28131566 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713141 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28133900 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380056 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28136698 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380057 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28136856 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs1947862 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28137418 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs6941992 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28138363 chr6:28943877~28944537:+ PAAD cis rs4713118 0.516 rs4713142 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Parkinson's disease; chr6:28138569 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713143 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28138981 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713144 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28139012 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713145 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28139049 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs3757187 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28139876 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs3757185 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28139998 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs1904840 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28140454 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368555 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28141189 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393893 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28141484 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713146 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28143758 chr6:28943877~28944537:+ PAAD cis rs853679 0.513 rs9468296 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28145952 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4711164 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28147378 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4711165 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28147406 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713148 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28148143 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9348794 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28149979 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9468297 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28151096 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9295758 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28152885 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs17774663 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28153120 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9468298 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28154567 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9295759 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28156691 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9348796 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28158424 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs11552219 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28159056 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393895 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28159843 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9357065 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28161802 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9357066 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28162053 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368556 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28163375 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368557 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28163759 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380059 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28164580 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380060 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28164825 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs35227624 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28164948 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380061 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28165025 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9368558 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28165528 chr6:28943877~28944537:+ PAAD cis rs4713118 0.587 rs9393899 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Parkinson's disease; chr6:28165750 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713150 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28168434 chr6:28943877~28944537:+ PAAD cis rs4713118 0.527 rs4713151 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Parkinson's disease; chr6:28168578 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393901 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28169019 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs3173443 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28169249 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs4713152 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28169676 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9348797 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28169755 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380062 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28169791 chr6:28943877~28944537:+ PAAD cis rs853679 0.542 rs9380063 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28170075 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs12332979 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28173770 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs67878650 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28174809 chr6:28943877~28944537:+ PAAD cis rs853679 0.569 rs9348798 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28175233 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9380065 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28176973 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9295761 ENSG00000204709.4 LINC01556 4.29 3.22e-05 0.0137 0.56 0.33 Depression; chr6:28180209 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs868987 ENSG00000204709.4 LINC01556 -4.29 3.22e-05 0.0137 -0.56 -0.33 Depression; chr6:28142370 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9283884 ENSG00000204709.4 LINC01556 -4.29 3.22e-05 0.0137 -0.56 -0.33 Depression; chr6:28167882 chr6:28943877~28944537:+ PAAD cis rs28374715 0.783 rs1866399 ENSG00000247556.5 OIP5-AS1 4.29 3.23e-05 0.0137 0.35 0.33 Ulcerative colitis; chr15:41278941 chr15:41283990~41309737:+ PAAD cis rs13217239 0.646 rs35691005 ENSG00000241549.7 GUSBP2 4.29 3.23e-05 0.0138 0.33 0.33 Schizophrenia; chr6:27004291 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs10946891 ENSG00000241549.7 GUSBP2 4.29 3.23e-05 0.0138 0.33 0.33 Schizophrenia; chr6:27005436 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs12201393 ENSG00000241549.7 GUSBP2 4.29 3.23e-05 0.0138 0.33 0.33 Schizophrenia; chr6:27007911 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs12209886 ENSG00000241549.7 GUSBP2 4.29 3.23e-05 0.0138 0.33 0.33 Schizophrenia; chr6:27016978 chr6:26871484~26956554:- PAAD cis rs6940638 0.531 rs12211984 ENSG00000241549.7 GUSBP2 4.29 3.23e-05 0.0138 0.33 0.33 Intelligence (multi-trait analysis); chr6:27018275 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs10456351 ENSG00000241549.7 GUSBP2 4.29 3.23e-05 0.0138 0.33 0.33 Schizophrenia; chr6:27019013 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs10456352 ENSG00000241549.7 GUSBP2 4.29 3.23e-05 0.0138 0.33 0.33 Schizophrenia; chr6:27022579 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs4583981 ENSG00000241549.7 GUSBP2 4.29 3.23e-05 0.0138 0.33 0.33 Schizophrenia; chr6:27024244 chr6:26871484~26956554:- PAAD cis rs394563 0.602 rs409099 ENSG00000231760.4 RP11-350J20.5 4.28 3.23e-05 0.0138 0.46 0.33 Dupuytren's disease; chr6:149445727 chr6:149796151~149826294:- PAAD cis rs7189233 0.55 rs3803657 ENSG00000279344.1 RP11-44F14.7 4.28 3.23e-05 0.0138 0.24 0.33 Intelligence (multi-trait analysis); chr16:53482047 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs4783813 ENSG00000279344.1 RP11-44F14.7 4.28 3.23e-05 0.0138 0.24 0.33 Intelligence (multi-trait analysis); chr16:53484458 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs8046307 ENSG00000279344.1 RP11-44F14.7 4.28 3.23e-05 0.0138 0.24 0.33 Intelligence (multi-trait analysis); chr16:53484774 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs13337544 ENSG00000279344.1 RP11-44F14.7 4.28 3.23e-05 0.0138 0.24 0.33 Intelligence (multi-trait analysis); chr16:53485123 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs8055279 ENSG00000279344.1 RP11-44F14.7 4.28 3.23e-05 0.0138 0.24 0.33 Intelligence (multi-trait analysis); chr16:53488837 chr16:53478957~53481550:- PAAD cis rs8072100 0.84 rs9900360 ENSG00000228782.6 CTD-2026D20.3 4.28 3.23e-05 0.0138 0.34 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47414613 chr17:47450568~47492492:- PAAD cis rs8072100 0.84 rs56952963 ENSG00000228782.6 CTD-2026D20.3 4.28 3.23e-05 0.0138 0.34 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47416460 chr17:47450568~47492492:- PAAD cis rs13178541 0.577 rs11748103 ENSG00000250378.1 RP11-119J18.1 -4.28 3.23e-05 0.0138 -0.48 -0.33 IgG glycosylation; chr5:135789066 chr5:135812667~135826582:+ PAAD cis rs13178541 0.511 rs11744702 ENSG00000250378.1 RP11-119J18.1 -4.28 3.23e-05 0.0138 -0.48 -0.33 IgG glycosylation; chr5:135789114 chr5:135812667~135826582:+ PAAD cis rs13178541 0.542 rs35475457 ENSG00000250378.1 RP11-119J18.1 -4.28 3.23e-05 0.0138 -0.48 -0.33 IgG glycosylation; chr5:135789389 chr5:135812667~135826582:+ PAAD cis rs13178541 0.577 rs67655763 ENSG00000250378.1 RP11-119J18.1 -4.28 3.23e-05 0.0138 -0.48 -0.33 IgG glycosylation; chr5:135789541 chr5:135812667~135826582:+ PAAD cis rs720064 0.586 rs12956330 ENSG00000264745.1 TTC39C-AS1 4.28 3.23e-05 0.0138 0.41 0.33 Strep throat; chr18:23981536 chr18:23994213~24015339:- PAAD cis rs1198872 0.571 rs902130 ENSG00000272275.1 RP11-791G15.2 -4.28 3.23e-05 0.0138 -0.43 -0.33 Cardiac Troponin-T levels; chr2:10770843 chr2:10767875~10770058:- PAAD cis rs9309473 0.847 rs4547554 ENSG00000163016.8 ALMS1P 4.28 3.24e-05 0.0138 0.49 0.33 Metabolite levels; chr2:73640735 chr2:73644919~73685576:+ PAAD cis rs9309473 0.847 rs13538 ENSG00000163016.8 ALMS1P 4.28 3.24e-05 0.0138 0.49 0.33 Metabolite levels; chr2:73641201 chr2:73644919~73685576:+ PAAD cis rs9649213 0.593 rs1076272 ENSG00000272950.1 RP11-307C18.1 4.28 3.24e-05 0.0138 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98401693 chr7:98322853~98323430:+ PAAD cis rs10779751 1 rs2300094 ENSG00000238199.1 UBE2V2P3 -4.28 3.24e-05 0.0138 -0.4 -0.33 Body mass index; chr1:11205987 chr1:11278616~11279351:- PAAD cis rs801193 1 rs2420824 ENSG00000237310.1 GS1-124K5.4 -4.28 3.24e-05 0.0138 -0.3 -0.33 Aortic root size; chr7:66666129 chr7:66493706~66495474:+ PAAD cis rs801193 1 rs2659909 ENSG00000237310.1 GS1-124K5.4 4.28 3.24e-05 0.0138 0.3 0.33 Aortic root size; chr7:66695292 chr7:66493706~66495474:+ PAAD cis rs12480328 1 rs16995626 ENSG00000203999.7 LINC01270 4.28 3.24e-05 0.0138 0.74 0.33 Prostate cancer; chr20:50924388 chr20:50292720~50314922:+ PAAD cis rs8031584 0.752 rs1852035 ENSG00000260382.1 RP11-540B6.2 4.28 3.24e-05 0.0138 0.44 0.33 Huntington's disease progression; chr15:30892600 chr15:30882267~30883231:- PAAD cis rs2283792 1 rs3788332 ENSG00000228050.1 TOP3BP1 4.28 3.24e-05 0.0138 0.35 0.33 Multiple sclerosis; chr22:21817278 chr22:22223187~22224566:- PAAD cis rs3781264 0.557 rs10882442 ENSG00000273450.1 RP11-76P2.4 4.28 3.24e-05 0.0138 0.43 0.33 Esophageal cancer and gastric cancer; chr10:94368824 chr10:94314907~94315327:- PAAD cis rs2906856 0.524 rs56236103 ENSG00000255733.4 IFNG-AS1 4.28 3.25e-05 0.0138 0.37 0.33 Mosquito bite size; chr12:67937437 chr12:67989445~68234686:+ PAAD cis rs5758511 0.689 rs55906806 ENSG00000226450.2 CYP2D8P 4.28 3.25e-05 0.0138 0.41 0.33 Birth weight; chr22:42248465 chr22:42149886~42155001:- PAAD cis rs6782228 0.876 rs34198449 ENSG00000242551.2 POU5F1P6 4.28 3.25e-05 0.0138 0.43 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128662427 chr3:128674735~128677005:- PAAD cis rs321358 0.895 rs6589210 ENSG00000271390.1 RP11-89C3.3 4.28 3.25e-05 0.0138 0.45 0.33 Body mass index; chr11:111088408 chr11:111089870~111090368:- PAAD cis rs11976180 1 rs13243677 ENSG00000273234.1 OR2A13P -4.28 3.25e-05 0.0138 -0.4 -0.33 Obesity-related traits; chr7:144049479 chr7:144142009~144142938:+ PAAD cis rs8031584 0.918 rs35396566 ENSG00000260382.1 RP11-540B6.2 4.28 3.25e-05 0.0138 0.43 0.33 Huntington's disease progression; chr15:30970854 chr15:30882267~30883231:- PAAD cis rs8031584 1 rs35607976 ENSG00000260382.1 RP11-540B6.2 4.28 3.25e-05 0.0138 0.43 0.33 Huntington's disease progression; chr15:30985585 chr15:30882267~30883231:- PAAD cis rs6538678 0.895 rs1436124 ENSG00000258343.1 RP11-536G4.2 -4.28 3.25e-05 0.0138 -0.43 -0.33 Lupus nephritis in systemic lupus erythematosus; chr12:95889654 chr12:95795345~95858839:- PAAD cis rs6860540 0.796 rs3734029 ENSG00000251405.2 CTB-109A12.1 -4.28 3.25e-05 0.0138 -0.42 -0.33 Inflammatory skin disease; chr5:157473742 chr5:157362615~157460078:- PAAD cis rs6860540 0.796 rs10404 ENSG00000251405.2 CTB-109A12.1 -4.28 3.25e-05 0.0138 -0.42 -0.33 Inflammatory skin disease; chr5:157477625 chr5:157362615~157460078:- PAAD cis rs17772222 0.701 rs376698 ENSG00000258983.2 RP11-507K2.2 -4.28 3.25e-05 0.0138 -0.41 -0.33 Coronary artery calcification; chr14:88391886 chr14:88499334~88515502:+ PAAD cis rs9649213 0.593 rs6973775 ENSG00000272950.1 RP11-307C18.1 4.28 3.26e-05 0.0138 0.38 0.33 Prostate cancer (SNP x SNP interaction); chr7:98375373 chr7:98322853~98323430:+ PAAD cis rs6061231 0.597 rs624313 ENSG00000273619.1 RP5-908M14.9 4.28 3.26e-05 0.0138 0.28 0.33 Colorectal cancer; chr20:62352356 chr20:62386303~62386970:- PAAD cis rs2041895 0.509 rs10861674 ENSG00000260329.1 RP11-412D9.4 -4.28 3.26e-05 0.0138 -0.32 -0.33 Glaucoma (low intraocular pressure); chr12:106910259 chr12:106954029~106955497:- PAAD cis rs2041895 0.509 rs2072559 ENSG00000260329.1 RP11-412D9.4 -4.28 3.26e-05 0.0138 -0.32 -0.33 Glaucoma (low intraocular pressure); chr12:106913509 chr12:106954029~106955497:- PAAD cis rs4950322 0.58 rs4950308 ENSG00000278811.3 LINC00624 4.28 3.26e-05 0.0139 0.32 0.33 Protein quantitative trait loci; chr1:147120092 chr1:147258885~147517875:- PAAD cis rs7302981 0.681 rs706792 ENSG00000272368.2 RP4-605O3.4 4.28 3.26e-05 0.0139 0.33 0.33 Systolic blood pressure; chr12:50073861 chr12:50112197~50165618:+ PAAD cis rs6472235 0.656 rs16932382 ENSG00000200714.1 Y_RNA -4.28 3.26e-05 0.0139 -0.43 -0.33 Plateletcrit;Myopia (pathological); chr8:65966241 chr8:65592731~65592820:+ PAAD cis rs2408955 0.522 rs6580650 ENSG00000240399.1 RP1-228P16.1 -4.28 3.26e-05 0.0139 -0.35 -0.33 Glycated hemoglobin levels; chr12:48024773 chr12:48054813~48055591:- PAAD cis rs812925 0.859 rs2593624 ENSG00000271889.1 RP11-493E12.1 -4.28 3.26e-05 0.0139 -0.39 -0.33 Immature fraction of reticulocytes; chr2:61325349 chr2:61151433~61162105:- PAAD cis rs1862618 0.853 rs252915 ENSG00000271828.1 CTD-2310F14.1 -4.28 3.26e-05 0.0139 -0.49 -0.33 Initial pursuit acceleration; chr5:56825927 chr5:56927874~56929573:+ PAAD cis rs8031584 0.752 rs34722914 ENSG00000260382.1 RP11-540B6.2 4.28 3.26e-05 0.0139 0.44 0.33 Huntington's disease progression; chr15:30899788 chr15:30882267~30883231:- PAAD cis rs12480328 1 rs76454304 ENSG00000203999.7 LINC01270 4.28 3.27e-05 0.0139 0.73 0.33 Prostate cancer; chr20:50896753 chr20:50292720~50314922:+ PAAD cis rs2658782 0.789 rs2605574 ENSG00000279684.1 RP11-755E23.2 -4.28 3.27e-05 0.0139 -0.53 -0.33 Pulmonary function decline; chr11:93403278 chr11:93286629~93288903:- PAAD cis rs17030434 0.627 rs17371643 ENSG00000280241.2 RP11-290O12.2 4.28 3.27e-05 0.0139 0.33 0.33 Electrocardiographic conduction measures; chr4:153848220 chr4:154142122~154298819:+ PAAD cis rs7923609 0.846 rs10761739 ENSG00000232075.1 MRPL35P2 4.28 3.27e-05 0.0139 0.4 0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63302248 chr10:63634317~63634827:- PAAD cis rs7923609 0.875 rs10740118 ENSG00000232075.1 MRPL35P2 4.28 3.27e-05 0.0139 0.4 0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63341447 chr10:63634317~63634827:- PAAD cis rs7923609 0.846 rs7073753 ENSG00000232075.1 MRPL35P2 -4.28 3.27e-05 0.0139 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63303060 chr10:63634317~63634827:- PAAD cis rs7923609 0.875 rs10761741 ENSG00000232075.1 MRPL35P2 -4.28 3.27e-05 0.0139 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63306426 chr10:63634317~63634827:- PAAD cis rs7923609 0.818 rs10822159 ENSG00000232075.1 MRPL35P2 -4.28 3.27e-05 0.0139 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63336490 chr10:63634317~63634827:- PAAD cis rs7923609 0.846 rs7896518 ENSG00000232075.1 MRPL35P2 -4.28 3.27e-05 0.0139 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63344740 chr10:63634317~63634827:- PAAD cis rs4660214 0.666 rs587404 ENSG00000237624.1 OXCT2P1 4.28 3.27e-05 0.0139 0.44 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39442834 chr1:39514956~39516490:+ PAAD cis rs6565180 0.926 rs12446288 ENSG00000183604.13 SMG1P5 4.28 3.27e-05 0.0139 0.36 0.33 Tonsillectomy; chr16:30377388 chr16:30267553~30335374:- PAAD cis rs2243480 0.706 rs34466769 ENSG00000273142.1 RP11-458F8.4 -4.28 3.27e-05 0.0139 -0.27 -0.33 Diabetic kidney disease; chr7:65988305 chr7:66902857~66906297:+ PAAD cis rs11089937 0.626 rs10483106 ENSG00000211638.2 IGLV8-61 -4.28 3.27e-05 0.0139 -0.33 -0.33 Periodontitis (PAL4Q3); chr22:22149240 chr22:22098700~22099212:+ PAAD cis rs5758511 0.68 rs17002902 ENSG00000226450.2 CYP2D8P 4.28 3.27e-05 0.0139 0.35 0.33 Birth weight; chr22:42229503 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs5758662 ENSG00000226450.2 CYP2D8P 4.28 3.27e-05 0.0139 0.35 0.33 Birth weight; chr22:42232082 chr22:42149886~42155001:- PAAD cis rs11079159 0.917 rs12452367 ENSG00000263096.1 RP11-515O17.2 4.28 3.28e-05 0.0139 0.42 0.33 QRS duration; chr17:55297249 chr17:55271504~55273653:- PAAD cis rs1075265 0.756 rs3821081 ENSG00000233266.1 HMGB1P31 -4.28 3.28e-05 0.0139 -0.42 -0.33 Chronotype;Morning vs. evening chronotype; chr2:53738252 chr2:54051334~54051760:+ PAAD cis rs812925 0.519 rs1186706 ENSG00000273302.1 RP11-493E12.2 4.28 3.28e-05 0.0139 0.28 0.33 Immature fraction of reticulocytes; chr2:61446259 chr2:61199979~61200769:+ PAAD cis rs4273100 0.85 rs11204306 ENSG00000228157.4 AC007952.5 4.28 3.28e-05 0.0139 0.54 0.33 Schizophrenia; chr17:19364058 chr17:19092974~19096837:+ PAAD cis rs4273100 0.79 rs2048230 ENSG00000228157.4 AC007952.5 4.28 3.28e-05 0.0139 0.54 0.33 Schizophrenia; chr17:19372886 chr17:19092974~19096837:+ PAAD cis rs4273100 0.79 rs60606605 ENSG00000228157.4 AC007952.5 4.28 3.28e-05 0.0139 0.54 0.33 Schizophrenia; chr17:19373831 chr17:19092974~19096837:+ PAAD cis rs4273100 0.79 rs60166680 ENSG00000228157.4 AC007952.5 4.28 3.28e-05 0.0139 0.54 0.33 Schizophrenia; chr17:19374231 chr17:19092974~19096837:+ PAAD cis rs8091660 0.624 rs8099285 ENSG00000278983.1 RP11-426J5.3 4.28 3.28e-05 0.0139 0.4 0.33 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48551434 chr18:48564795~48568342:+ PAAD cis rs28386778 0.897 rs2727326 ENSG00000240280.5 TCAM1P -4.28 3.28e-05 0.0139 -0.46 -0.33 Prudent dietary pattern; chr17:63845656 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2727328 ENSG00000240280.5 TCAM1P -4.28 3.28e-05 0.0139 -0.46 -0.33 Prudent dietary pattern; chr17:63846204 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2665796 ENSG00000240280.5 TCAM1P -4.28 3.28e-05 0.0139 -0.46 -0.33 Prudent dietary pattern; chr17:63846356 chr17:63849292~63864379:+ PAAD cis rs4664293 0.667 rs2042782 ENSG00000226266.5 AC009961.3 4.28 3.28e-05 0.0139 0.4 0.33 Monocyte percentage of white cells; chr2:159789781 chr2:159670708~159712435:- PAAD cis rs13217239 0.646 rs10946897 ENSG00000241549.7 GUSBP2 4.28 3.28e-05 0.0139 0.33 0.33 Schizophrenia; chr6:27027472 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs4403259 ENSG00000241549.7 GUSBP2 4.28 3.28e-05 0.0139 0.33 0.33 Schizophrenia; chr6:27029838 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs6937880 ENSG00000241549.7 GUSBP2 4.28 3.28e-05 0.0139 0.33 0.33 Schizophrenia; chr6:27032457 chr6:26871484~26956554:- PAAD cis rs13217239 0.621 rs12527231 ENSG00000241549.7 GUSBP2 4.28 3.28e-05 0.0139 0.33 0.33 Schizophrenia; chr6:27033509 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs12523820 ENSG00000241549.7 GUSBP2 4.28 3.28e-05 0.0139 0.33 0.33 Schizophrenia; chr6:27033723 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs10946898 ENSG00000241549.7 GUSBP2 4.28 3.28e-05 0.0139 0.33 0.33 Schizophrenia; chr6:27036105 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs12527111 ENSG00000241549.7 GUSBP2 4.28 3.28e-05 0.0139 0.33 0.33 Schizophrenia; chr6:27038696 chr6:26871484~26956554:- PAAD cis rs11690935 0.655 rs12052995 ENSG00000228389.1 AC068039.4 -4.28 3.28e-05 0.0139 -0.4 -0.33 Schizophrenia; chr2:171680702 chr2:171773482~171775844:+ PAAD cis rs5015933 0.788 rs568409 ENSG00000232630.1 PRPS1P2 -4.28 3.29e-05 0.014 -0.29 -0.33 Body mass index; chr9:125309994 chr9:125150653~125151589:+ PAAD cis rs9549328 0.837 rs9549330 ENSG00000267868.1 RP11-120K24.3 4.28 3.29e-05 0.014 0.37 0.33 Systolic blood pressure; chr13:112994090 chr13:112964835~112966131:- PAAD cis rs9549328 0.917 rs4907573 ENSG00000267868.1 RP11-120K24.3 4.28 3.29e-05 0.014 0.37 0.33 Systolic blood pressure; chr13:112994428 chr13:112964835~112966131:- PAAD cis rs9549328 0.837 rs7988967 ENSG00000267868.1 RP11-120K24.3 4.28 3.29e-05 0.014 0.37 0.33 Systolic blood pressure; chr13:112996846 chr13:112964835~112966131:- PAAD cis rs871012 0.502 rs17658198 ENSG00000248544.2 CTB-47B11.3 -4.28 3.29e-05 0.014 -0.43 -0.33 IgG glycosylation; chr5:157458669 chr5:157375741~157384950:- PAAD cis rs7712401 0.601 rs193539 ENSG00000263432.2 RN7SL689P 4.28 3.29e-05 0.014 0.42 0.33 Mean platelet volume; chr5:122921922 chr5:123022487~123022783:- PAAD cis rs6570726 0.935 rs388394 ENSG00000235652.6 RP11-545I5.3 4.28 3.29e-05 0.014 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145531553 chr6:145799409~145886585:+ PAAD cis rs4835473 0.864 rs13145791 ENSG00000251600.4 RP11-673E1.1 -4.28 3.3e-05 0.014 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143735688 chr4:143912331~143982454:+ PAAD cis rs7202877 0.656 rs9923834 ENSG00000261783.1 RP11-252K23.2 -4.28 3.3e-05 0.014 -0.52 -0.33 Type 1 diabetes;Type 2 diabetes; chr16:75473355 chr16:75379818~75381260:- PAAD cis rs153852 0.811 rs36727 ENSG00000243806.1 RPL7P18 -4.28 3.3e-05 0.014 -0.39 -0.33 Cancer; chr5:94824464 chr5:94825961~94826694:- PAAD cis rs153852 0.892 rs36731 ENSG00000243806.1 RPL7P18 -4.28 3.3e-05 0.014 -0.39 -0.33 Cancer; chr5:94827967 chr5:94825961~94826694:- PAAD cis rs2742417 1 rs2742392 ENSG00000244357.3 RN7SL145P 4.28 3.3e-05 0.014 0.3 0.33 Response to anti-depressant treatment in major depressive disorder; chr3:45715790 chr3:45742675~45742970:+ PAAD cis rs7849973 0.637 rs12349560 ENSG00000224549.1 RP11-370B11.3 -4.28 3.3e-05 0.014 -0.43 -0.33 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22763159 chr9:22767175~22768316:+ PAAD cis rs2243480 1 rs313814 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66038306 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs402418 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66044482 chr7:66848496~66858136:+ PAAD cis rs2243480 0.803 rs423187 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66044512 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs431318 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66046610 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs313803 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66049744 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs313802 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66051386 chr7:66848496~66858136:+ PAAD cis rs2243480 0.803 rs403089 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66052736 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs458291 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66055492 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs466983 ENSG00000232546.1 RP11-458F8.1 -4.28 3.3e-05 0.014 -0.4 -0.33 Diabetic kidney disease; chr7:66055509 chr7:66848496~66858136:+ PAAD cis rs1150668 0.796 rs1124132 ENSG00000219891.2 ZSCAN12P1 4.28 3.3e-05 0.014 0.43 0.33 Pubertal anthropometrics; chr6:28412544 chr6:28091154~28093664:+ PAAD cis rs1150668 0.796 rs2531832 ENSG00000219891.2 ZSCAN12P1 4.28 3.3e-05 0.014 0.43 0.33 Pubertal anthropometrics; chr6:28421445 chr6:28091154~28093664:+ PAAD cis rs3743772 0.5 rs35346613 ENSG00000279344.1 RP11-44F14.7 4.28 3.3e-05 0.014 0.35 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53408246 chr16:53478957~53481550:- PAAD cis rs3743772 0.5 rs28804772 ENSG00000279344.1 RP11-44F14.7 4.28 3.3e-05 0.014 0.35 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53411252 chr16:53478957~53481550:- PAAD cis rs3743772 0.5 rs62048485 ENSG00000279344.1 RP11-44F14.7 4.28 3.3e-05 0.014 0.35 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53414065 chr16:53478957~53481550:- PAAD cis rs7712401 0.601 rs418562 ENSG00000263432.2 RN7SL689P -4.28 3.3e-05 0.014 -0.43 -0.33 Mean platelet volume; chr5:123004567 chr5:123022487~123022783:- PAAD cis rs10779751 0.762 rs6671083 ENSG00000238199.1 UBE2V2P3 4.28 3.3e-05 0.014 0.37 0.33 Body mass index; chr1:11265853 chr1:11278616~11279351:- PAAD cis rs7712401 0.601 rs28892 ENSG00000263432.2 RN7SL689P -4.28 3.3e-05 0.014 -0.43 -0.33 Mean platelet volume; chr5:122948131 chr5:123022487~123022783:- PAAD cis rs4761702 0.857 rs1135400 ENSG00000258171.1 RP11-511B23.3 4.28 3.31e-05 0.014 0.4 0.33 Immature fraction of reticulocytes; chr12:93315763 chr12:93174366~93181832:+ PAAD cis rs394563 0.602 rs409111 ENSG00000231760.4 RP11-350J20.5 4.28 3.31e-05 0.014 0.46 0.33 Dupuytren's disease; chr6:149445724 chr6:149796151~149826294:- PAAD cis rs216345 0.666 rs1749268 ENSG00000230074.1 RP11-195F19.9 -4.28 3.31e-05 0.014 -0.43 -0.33 Bipolar disorder; chr9:33837332 chr9:34665665~34681298:+ PAAD cis rs812925 0.502 rs13028833 ENSG00000273302.1 RP11-493E12.2 -4.28 3.31e-05 0.014 -0.28 -0.33 Immature fraction of reticulocytes; chr2:61417194 chr2:61199979~61200769:+ PAAD cis rs6545883 0.558 rs7587389 ENSG00000273302.1 RP11-493E12.2 -4.28 3.31e-05 0.014 -0.28 -0.33 Tuberculosis; chr2:61422656 chr2:61199979~61200769:+ PAAD cis rs2243480 0.901 rs2949697 ENSG00000232546.1 RP11-458F8.1 -4.28 3.31e-05 0.014 -0.39 -0.33 Diabetic kidney disease; chr7:65999249 chr7:66848496~66858136:+ PAAD cis rs4819052 0.765 rs2838868 ENSG00000223768.1 LINC00205 4.28 3.31e-05 0.014 0.35 0.33 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45294726 chr21:45293285~45297354:+ PAAD cis rs2980439 0.517 rs17594065 ENSG00000253981.4 ALG1L13P -4.28 3.32e-05 0.0141 -0.4 -0.33 Neuroticism; chr8:8247883 chr8:8236003~8244667:- PAAD cis rs6479891 1 rs16918599 ENSG00000232075.1 MRPL35P2 4.28 3.32e-05 0.0141 0.52 0.33 Arthritis (juvenile idiopathic); chr10:63560319 chr10:63634317~63634827:- PAAD cis rs12073837 0.5 rs2807845 ENSG00000221571.3 RNU6ATAC35P -4.28 3.32e-05 0.0141 -0.41 -0.33 F-cell distribution; chr1:220822945 chr1:220825620~220826063:+ PAAD cis rs2599510 0.811 rs2583713 ENSG00000276334.1 AL133243.1 4.28 3.32e-05 0.0141 0.4 0.33 Interleukin-18 levels; chr2:32597662 chr2:32521927~32523547:+ PAAD cis rs4888378 0.535 rs9319483 ENSG00000261783.1 RP11-252K23.2 4.28 3.32e-05 0.0141 0.48 0.33 Coronary artery disease; chr16:75311893 chr16:75379818~75381260:- PAAD cis rs853679 0.55 rs1150689 ENSG00000280107.1 AL022393.9 -4.28 3.32e-05 0.0141 -0.55 -0.33 Depression; chr6:28197321 chr6:28170845~28172521:+ PAAD cis rs853679 0.55 rs1225599 ENSG00000280107.1 AL022393.9 -4.28 3.32e-05 0.0141 -0.55 -0.33 Depression; chr6:28197412 chr6:28170845~28172521:+ PAAD cis rs7202877 0.706 rs4888393 ENSG00000261783.1 RP11-252K23.2 -4.28 3.32e-05 0.0141 -0.51 -0.33 Type 1 diabetes;Type 2 diabetes; chr16:75379775 chr16:75379818~75381260:- PAAD cis rs7202877 0.656 rs4888394 ENSG00000261783.1 RP11-252K23.2 -4.28 3.32e-05 0.0141 -0.51 -0.33 Type 1 diabetes;Type 2 diabetes; chr16:75379811 chr16:75379818~75381260:- PAAD cis rs7202877 0.611 rs4888395 ENSG00000261783.1 RP11-252K23.2 -4.28 3.32e-05 0.0141 -0.51 -0.33 Type 1 diabetes;Type 2 diabetes; chr16:75379817 chr16:75379818~75381260:- PAAD cis rs919433 0.963 rs1896854 ENSG00000231621.1 AC013264.2 4.28 3.32e-05 0.0141 0.32 0.33 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197283052 chr2:197197991~197199273:+ PAAD cis rs812925 0.537 rs2593620 ENSG00000273302.1 RP11-493E12.2 -4.28 3.32e-05 0.0141 -0.28 -0.33 Immature fraction of reticulocytes; chr2:61386126 chr2:61199979~61200769:+ PAAD cis rs7572733 0.576 rs6734781 ENSG00000231621.1 AC013264.2 -4.28 3.32e-05 0.0141 -0.32 -0.33 Dermatomyositis; chr2:197895249 chr2:197197991~197199273:+ PAAD cis rs3781264 0.595 rs11187881 ENSG00000273450.1 RP11-76P2.4 4.28 3.33e-05 0.0141 0.44 0.33 Esophageal cancer and gastric cancer; chr10:94335697 chr10:94314907~94315327:- PAAD cis rs1707322 0.686 rs3014251 ENSG00000280836.1 AL355480.1 4.28 3.33e-05 0.0141 0.39 0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45611756 chr1:45581219~45581321:- PAAD cis rs6743226 0.603 rs62186419 ENSG00000266621.1 AC104841.1 4.28 3.33e-05 0.0141 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241307450 chr2:241245202~241245299:- PAAD cis rs6743226 0.557 rs62186420 ENSG00000266621.1 AC104841.1 4.28 3.33e-05 0.0141 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241307460 chr2:241245202~241245299:- PAAD cis rs227932 0.764 rs76349338 ENSG00000234286.1 AC006026.13 -4.28 3.33e-05 0.0141 -0.56 -0.33 Schizophrenia; chr7:23709138 chr7:23680195~23680786:- PAAD cis rs227932 0.618 rs3807888 ENSG00000234286.1 AC006026.13 -4.28 3.33e-05 0.0141 -0.56 -0.33 Schizophrenia; chr7:23710213 chr7:23680195~23680786:- PAAD cis rs1729407 0.706 rs595049 ENSG00000254851.1 RP11-109L13.1 -4.28 3.33e-05 0.0141 -0.4 -0.33 Apolipoprotein A-IV levels; chr11:116828729 chr11:117135528~117138582:+ PAAD cis rs6142102 0.923 rs3787230 ENSG00000276073.1 RP5-1125A11.7 -4.28 3.34e-05 0.0141 -0.35 -0.33 Skin pigmentation; chr20:34052466 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2284386 ENSG00000276073.1 RP5-1125A11.7 -4.28 3.34e-05 0.0141 -0.35 -0.33 Skin pigmentation; chr20:34056590 chr20:33985617~33988989:- PAAD cis rs113835537 0.935 rs1127145 ENSG00000255517.5 CTD-3074O7.5 -4.28 3.34e-05 0.0141 -0.54 -0.33 Airway imaging phenotypes; chr11:66605834 chr11:66473490~66480233:- PAAD cis rs4660214 0.666 rs598415 ENSG00000261798.1 RP1-118J21.25 4.28 3.34e-05 0.0141 0.4 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39366735 chr1:39788976~39790171:+ PAAD cis rs17123764 1 rs7301209 ENSG00000257464.1 RP11-161H23.8 -4.28 3.34e-05 0.0141 -0.56 -0.33 Intelligence (multi-trait analysis); chr12:49552268 chr12:49442424~49442652:- PAAD cis rs8072100 0.967 rs4580230 ENSG00000228782.6 CTD-2026D20.3 4.28 3.34e-05 0.0141 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47661495 chr17:47450568~47492492:- PAAD cis rs6951245 0.935 rs11763765 ENSG00000229043.2 AC091729.9 -4.28 3.34e-05 0.0141 -0.52 -0.33 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1020874 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs78185558 ENSG00000229043.2 AC091729.9 -4.28 3.34e-05 0.0141 -0.49 -0.33 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1050547 chr7:1160374~1165267:+ PAAD cis rs17023223 0.553 rs72691108 ENSG00000231365.4 RP11-418J17.1 -4.28 3.34e-05 0.0142 -0.39 -0.33 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119219552 chr1:119140396~119275973:+ PAAD cis rs10779751 1 rs2253213 ENSG00000238199.1 UBE2V2P3 -4.28 3.35e-05 0.0142 -0.4 -0.33 Body mass index; chr1:11205728 chr1:11278616~11279351:- PAAD cis rs2250402 0.51 rs2898984 ENSG00000245849.5 RAD51-AS1 -4.28 3.35e-05 0.0142 -0.41 -0.33 Corneal curvature; chr15:40031874 chr15:40686724~40695107:- PAAD cis rs2250402 0.51 rs7535 ENSG00000245849.5 RAD51-AS1 -4.28 3.35e-05 0.0142 -0.41 -0.33 Corneal curvature; chr15:40036374 chr15:40686724~40695107:- PAAD cis rs10461617 0.617 rs1423623 ENSG00000271828.1 CTD-2310F14.1 -4.28 3.35e-05 0.0142 -0.43 -0.33 Type 2 diabetes; chr5:56769748 chr5:56927874~56929573:+ PAAD cis rs216345 0.7 rs2196 ENSG00000230074.1 RP11-195F19.9 -4.28 3.35e-05 0.0142 -0.43 -0.33 Bipolar disorder; chr9:33914310 chr9:34665665~34681298:+ PAAD cis rs871012 0.632 rs1862384 ENSG00000251405.2 CTB-109A12.1 -4.28 3.35e-05 0.0142 -0.41 -0.33 IgG glycosylation; chr5:157389995 chr5:157362615~157460078:- PAAD cis rs2011013 0.6 rs17370572 ENSG00000230373.7 GOLGA6L5P 4.28 3.35e-05 0.0142 0.42 0.33 Sitting height ratio; chr15:83947961 chr15:84507885~84516814:- PAAD cis rs651386 0.529 rs2206063 ENSG00000271811.1 RP1-79C4.4 -4.28 3.36e-05 0.0142 -0.35 -0.33 Atrial fibrillation; chr1:170615956 chr1:170667381~170669425:+ PAAD cis rs577676 0.586 rs2022373 ENSG00000271811.1 RP1-79C4.4 4.28 3.36e-05 0.0142 0.35 0.33 Prevalent atrial fibrillation; chr1:170619453 chr1:170667381~170669425:+ PAAD cis rs577676 0.586 rs10489231 ENSG00000271811.1 RP1-79C4.4 -4.28 3.36e-05 0.0142 -0.35 -0.33 Prevalent atrial fibrillation; chr1:170620296 chr1:170667381~170669425:+ PAAD cis rs577676 0.586 rs12068805 ENSG00000271811.1 RP1-79C4.4 4.28 3.36e-05 0.0142 0.35 0.33 Prevalent atrial fibrillation; chr1:170632172 chr1:170667381~170669425:+ PAAD cis rs577676 0.586 rs12566725 ENSG00000271811.1 RP1-79C4.4 4.28 3.36e-05 0.0142 0.35 0.33 Prevalent atrial fibrillation; chr1:170632794 chr1:170667381~170669425:+ PAAD cis rs577676 0.564 rs644784 ENSG00000271811.1 RP1-79C4.4 4.28 3.36e-05 0.0142 0.35 0.33 Prevalent atrial fibrillation; chr1:170636945 chr1:170667381~170669425:+ PAAD cis rs577676 0.586 rs656539 ENSG00000271811.1 RP1-79C4.4 4.28 3.36e-05 0.0142 0.35 0.33 Prevalent atrial fibrillation; chr1:170637213 chr1:170667381~170669425:+ PAAD cis rs2935183 1 rs2935183 ENSG00000228782.6 CTD-2026D20.3 -4.28 3.36e-05 0.0142 -0.33 -0.33 Multiple sclerosis or amyotrophic lateral sclerosis; chr17:47530206 chr17:47450568~47492492:- PAAD cis rs2337406 0.641 rs10133227 ENSG00000211974.3 IGHV2-70 4.28 3.36e-05 0.0142 0.45 0.33 Alzheimer's disease (late onset); chr14:106814260 chr14:106723574~106724093:- PAAD cis rs2337406 0.714 rs8022729 ENSG00000211974.3 IGHV2-70 4.28 3.36e-05 0.0142 0.45 0.33 Alzheimer's disease (late onset); chr14:106816928 chr14:106723574~106724093:- PAAD cis rs13178541 0.688 rs4246802 ENSG00000250378.1 RP11-119J18.1 -4.28 3.36e-05 0.0142 -0.51 -0.33 IgG glycosylation; chr5:135864020 chr5:135812667~135826582:+ PAAD cis rs7302981 0.746 rs706793 ENSG00000272368.2 RP4-605O3.4 4.28 3.36e-05 0.0142 0.33 0.33 Systolic blood pressure; chr12:50073986 chr12:50112197~50165618:+ PAAD cis rs9326248 0.581 rs10892063 ENSG00000280143.1 AP000892.6 4.27 3.36e-05 0.0142 0.37 0.33 Blood protein levels; chr11:117025439 chr11:117204967~117210292:+ PAAD cis rs9326248 0.559 rs10892064 ENSG00000280143.1 AP000892.6 4.27 3.36e-05 0.0142 0.37 0.33 Blood protein levels; chr11:117025837 chr11:117204967~117210292:+ PAAD cis rs9326248 0.539 rs10892065 ENSG00000280143.1 AP000892.6 4.27 3.36e-05 0.0142 0.37 0.33 Blood protein levels; chr11:117026308 chr11:117204967~117210292:+ PAAD cis rs897984 0.542 rs8061047 ENSG00000260911.2 RP11-196G11.2 4.27 3.37e-05 0.0142 0.3 0.33 Dementia with Lewy bodies; chr16:31057639 chr16:31043150~31049868:+ PAAD cis rs4889609 0.834 rs72785520 ENSG00000260911.2 RP11-196G11.2 4.27 3.37e-05 0.0142 0.3 0.33 Response to metformin (IC50); chr16:31059457 chr16:31043150~31049868:+ PAAD cis rs10276381 0.786 rs10272155 ENSG00000234336.5 JAZF1-AS1 -4.27 3.37e-05 0.0142 -0.46 -0.33 Crohn's disease; chr7:28207370 chr7:28180322~28243917:+ PAAD cis rs7567389 0.704 rs4662714 ENSG00000236682.1 AC068282.3 4.27 3.37e-05 0.0142 0.44 0.33 Self-rated health; chr2:127237637 chr2:127389130~127400580:+ PAAD cis rs7567389 0.74 rs1604817 ENSG00000236682.1 AC068282.3 4.27 3.37e-05 0.0142 0.44 0.33 Self-rated health; chr2:127242345 chr2:127389130~127400580:+ PAAD cis rs7626444 0.647 rs843537 ENSG00000272359.1 U4 -4.27 3.37e-05 0.0142 -0.36 -0.33 Monocyte count; chr3:196746532 chr3:196747192~196747324:- PAAD cis rs801193 0.967 rs3800823 ENSG00000237310.1 GS1-124K5.4 -4.27 3.37e-05 0.0142 -0.31 -0.33 Aortic root size; chr7:66682123 chr7:66493706~66495474:+ PAAD cis rs4660214 0.666 rs2275188 ENSG00000237624.1 OXCT2P1 -4.27 3.37e-05 0.0142 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39283249 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs1984143 ENSG00000237624.1 OXCT2P1 -4.27 3.37e-05 0.0142 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39290645 chr1:39514956~39516490:+ PAAD cis rs3823536 0.505 rs3925323 ENSG00000275106.1 RP11-309L24.10 -4.27 3.37e-05 0.0143 -0.45 -0.33 Sjögren's syndrome; chr7:128952187 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs7800687 ENSG00000275106.1 RP11-309L24.10 -4.27 3.37e-05 0.0143 -0.45 -0.33 Sjögren's syndrome; chr7:128953665 chr7:128952527~128953316:- PAAD cis rs3823536 0.583 rs2280714 ENSG00000275106.1 RP11-309L24.10 -4.27 3.37e-05 0.0143 -0.45 -0.33 Sjögren's syndrome; chr7:128954671 chr7:128952527~128953316:- PAAD cis rs7189233 0.955 rs8044205 ENSG00000279722.1 RP11-44F14.6 -4.27 3.38e-05 0.0143 -0.35 -0.33 Intelligence (multi-trait analysis); chr16:53481181 chr16:53487607~53489943:- PAAD cis rs7189233 0.955 rs8058684 ENSG00000279722.1 RP11-44F14.6 -4.27 3.38e-05 0.0143 -0.35 -0.33 Intelligence (multi-trait analysis); chr16:53481206 chr16:53487607~53489943:- PAAD cis rs7189233 0.955 rs72801853 ENSG00000279722.1 RP11-44F14.6 -4.27 3.38e-05 0.0143 -0.35 -0.33 Intelligence (multi-trait analysis); chr16:53482912 chr16:53487607~53489943:- PAAD cis rs7189233 0.911 rs72801854 ENSG00000279722.1 RP11-44F14.6 -4.27 3.38e-05 0.0143 -0.35 -0.33 Intelligence (multi-trait analysis); chr16:53483330 chr16:53487607~53489943:- PAAD cis rs7078219 0.965 rs11190134 ENSG00000257582.4 LINC01475 -4.27 3.38e-05 0.0143 -0.34 -0.33 Dental caries; chr10:99522443 chr10:99526350~99531177:- PAAD cis rs12280210 0.557 rs12284696 ENSG00000254851.1 RP11-109L13.1 4.27 3.39e-05 0.0143 0.73 0.33 Lobe attachment (rater-scored or self-reported); chr11:117008803 chr11:117135528~117138582:+ PAAD cis rs77372450 1 rs11738723 ENSG00000251405.2 CTB-109A12.1 4.27 3.39e-05 0.0143 0.72 0.33 Bipolar disorder (body mass index interaction); chr5:157572090 chr5:157362615~157460078:- PAAD cis rs41369048 0.844 rs2807844 ENSG00000257551.1 HLX-AS1 -4.27 3.39e-05 0.0143 -0.52 -0.33 Eosinophil counts;Sum eosinophil basophil counts; chr1:220874239 chr1:220832763~220880140:- PAAD cis rs2581828 0.58 rs57514626 ENSG00000242142.1 SERBP1P3 -4.27 3.39e-05 0.0143 -0.41 -0.33 Crohn's disease; chr3:53135286 chr3:53064283~53065091:- PAAD cis rs2581828 0.58 rs61296683 ENSG00000242142.1 SERBP1P3 -4.27 3.39e-05 0.0143 -0.41 -0.33 Crohn's disease; chr3:53135307 chr3:53064283~53065091:- PAAD cis rs2581828 0.58 rs9867590 ENSG00000242142.1 SERBP1P3 -4.27 3.39e-05 0.0143 -0.41 -0.33 Crohn's disease; chr3:53135635 chr3:53064283~53065091:- PAAD cis rs2581828 0.58 rs9845021 ENSG00000242142.1 SERBP1P3 -4.27 3.39e-05 0.0143 -0.41 -0.33 Crohn's disease; chr3:53138096 chr3:53064283~53065091:- PAAD cis rs75422866 0.541 rs61918136 ENSG00000257433.4 RP1-197B17.3 4.27 3.39e-05 0.0143 0.75 0.33 Pneumonia; chr12:47566798 chr12:47706085~47742294:+ PAAD cis rs1075265 0.756 rs698854 ENSG00000233266.1 HMGB1P31 4.27 3.39e-05 0.0143 0.42 0.33 Chronotype;Morning vs. evening chronotype; chr2:53826784 chr2:54051334~54051760:+ PAAD cis rs2188561 0.708 rs9718496 ENSG00000241764.3 AC002467.7 4.27 3.4e-05 0.0143 0.42 0.33 Alcohol consumption; chr7:107730187 chr7:107742817~107744581:- PAAD cis rs1707322 0.721 rs12043945 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45641250 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs12091503 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45642196 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs10890336 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645384 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs11211151 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45647080 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs12045096 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45648756 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs4609469 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651513 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs12049027 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45652512 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs10789467 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45653073 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs10890337 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658855 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs3811435 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660118 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs9793568 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664701 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs11211157 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667172 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs11211158 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45667178 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs6429575 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668544 chr1:45581219~45581321:- PAAD cis rs1707322 0.685 rs6690926 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669306 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs8179402 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45676794 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs8179296 ENSG00000280836.1 AL355480.1 -4.27 3.4e-05 0.0143 -0.38 -0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45678119 chr1:45581219~45581321:- PAAD cis rs7202877 0.706 rs247450 ENSG00000261783.1 RP11-252K23.2 4.27 3.4e-05 0.0143 0.53 0.33 Type 1 diabetes;Type 2 diabetes; chr16:75456119 chr16:75379818~75381260:- PAAD cis rs72843506 0.656 rs80250684 ENSG00000189423.10 USP32P3 4.27 3.4e-05 0.0143 0.46 0.33 Schizophrenia; chr17:20054983 chr17:20415547~20431008:+ PAAD cis rs72843506 0.586 rs75048432 ENSG00000189423.10 USP32P3 4.27 3.4e-05 0.0143 0.46 0.33 Schizophrenia; chr17:20057571 chr17:20415547~20431008:+ PAAD cis rs613391 0.508 rs10965431 ENSG00000224549.1 RP11-370B11.3 -4.27 3.4e-05 0.0144 -0.39 -0.33 Quantitative traits; chr9:22725850 chr9:22767175~22768316:+ PAAD cis rs2253762 0.54 rs7358186 ENSG00000276742.1 RP11-500G22.4 4.27 3.4e-05 0.0144 0.45 0.33 Breast cancer; chr10:122000816 chr10:121956782~121957098:+ PAAD cis rs2976388 0.647 rs2082801 ENSG00000253741.1 CTD-2292P10.4 -4.27 3.4e-05 0.0144 -0.37 -0.33 Urinary tract infection frequency; chr8:142705043 chr8:142702252~142726973:- PAAD cis rs10783487 0.762 rs11169995 ENSG00000257542.4 OR7E47P -4.27 3.4e-05 0.0144 -0.41 -0.33 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52084513 chr12:52079696~52108261:+ PAAD cis rs5760092 0.842 rs5760103 ENSG00000231271.1 AP000350.8 4.27 3.41e-05 0.0144 0.57 0.33 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23906594 chr22:23949918~23954042:+ PAAD cis rs2115630 1 rs56074163 ENSG00000225151.9 GOLGA2P7 4.27 3.41e-05 0.0144 0.39 0.33 P wave terminal force; chr15:84808101 chr15:84199311~84230136:- PAAD cis rs2832077 0.527 rs2738953 ENSG00000176054.6 RPL23P2 4.27 3.41e-05 0.0144 0.32 0.33 Cognitive test performance; chr21:28866041 chr21:28997613~28998033:- PAAD cis rs2832077 0.527 rs2705690 ENSG00000176054.6 RPL23P2 4.27 3.41e-05 0.0144 0.32 0.33 Cognitive test performance; chr21:28866923 chr21:28997613~28998033:- PAAD cis rs13178541 0.577 rs67427688 ENSG00000250378.1 RP11-119J18.1 -4.27 3.42e-05 0.0144 -0.47 -0.33 IgG glycosylation; chr5:135789248 chr5:135812667~135826582:+ PAAD cis rs7017914 0.652 rs10957533 ENSG00000254031.4 RP11-326E22.1 -4.27 3.42e-05 0.0144 -0.35 -0.33 Bone mineral density; chr8:70912872 chr8:71155457~71204223:+ PAAD cis rs2115630 0.967 rs12595786 ENSG00000225151.9 GOLGA2P7 4.27 3.42e-05 0.0144 0.39 0.33 P wave terminal force; chr15:84793439 chr15:84199311~84230136:- PAAD cis rs79349575 0.783 rs58591767 ENSG00000270781.1 RP11-501C14.9 -4.27 3.42e-05 0.0144 -0.37 -0.33 Type 2 diabetes; chr17:48948714 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs59270107 ENSG00000270781.1 RP11-501C14.9 -4.27 3.42e-05 0.0144 -0.37 -0.33 Type 2 diabetes; chr17:48948823 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs62078370 ENSG00000270781.1 RP11-501C14.9 -4.27 3.42e-05 0.0144 -0.37 -0.33 Type 2 diabetes; chr17:48949474 chr17:48899131~48899748:+ PAAD cis rs1862618 0.756 rs13356762 ENSG00000271828.1 CTD-2310F14.1 4.27 3.42e-05 0.0144 0.49 0.33 Initial pursuit acceleration; chr5:56815165 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs832553 ENSG00000271828.1 CTD-2310F14.1 4.27 3.42e-05 0.0144 0.49 0.33 Initial pursuit acceleration; chr5:56818959 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs2432195 ENSG00000271828.1 CTD-2310F14.1 4.27 3.42e-05 0.0144 0.49 0.33 Initial pursuit acceleration; chr5:56824586 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs252916 ENSG00000271828.1 CTD-2310F14.1 4.27 3.42e-05 0.0144 0.49 0.33 Initial pursuit acceleration; chr5:56825961 chr5:56927874~56929573:+ PAAD cis rs1862618 0.802 rs832560 ENSG00000271828.1 CTD-2310F14.1 4.27 3.42e-05 0.0144 0.49 0.33 Initial pursuit acceleration; chr5:56828596 chr5:56927874~56929573:+ PAAD cis rs6480314 0.522 rs17231602 ENSG00000233590.1 RP11-153K11.3 -4.27 3.42e-05 0.0144 -0.54 -0.33 Optic nerve measurement (disc area); chr10:68252532 chr10:68233251~68242379:- PAAD cis rs17772222 1 rs17772222 ENSG00000258983.2 RP11-507K2.2 -4.27 3.42e-05 0.0144 -0.45 -0.33 Coronary artery calcification; chr14:88360138 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs61977053 ENSG00000258983.2 RP11-507K2.2 4.27 3.42e-05 0.0144 0.45 0.33 Coronary artery calcification; chr14:88380876 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs3814855 ENSG00000258983.2 RP11-507K2.2 4.27 3.42e-05 0.0144 0.45 0.33 Coronary artery calcification; chr14:88467016 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs2274737 ENSG00000258983.2 RP11-507K2.2 4.27 3.42e-05 0.0144 0.45 0.33 Coronary artery calcification; chr14:88469307 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs2297128 ENSG00000258983.2 RP11-507K2.2 4.27 3.42e-05 0.0144 0.45 0.33 Coronary artery calcification; chr14:88469910 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs74074098 ENSG00000258983.2 RP11-507K2.2 4.27 3.42e-05 0.0144 0.45 0.33 Coronary artery calcification; chr14:88484213 chr14:88499334~88515502:+ PAAD cis rs17772222 0.876 rs12587528 ENSG00000258983.2 RP11-507K2.2 4.27 3.42e-05 0.0144 0.45 0.33 Coronary artery calcification; chr14:88487652 chr14:88499334~88515502:+ PAAD cis rs17772222 0.837 rs1864748 ENSG00000258983.2 RP11-507K2.2 4.27 3.42e-05 0.0144 0.45 0.33 Coronary artery calcification; chr14:88488847 chr14:88499334~88515502:+ PAAD cis rs17772222 0.916 rs77306894 ENSG00000258983.2 RP11-507K2.2 4.27 3.42e-05 0.0144 0.45 0.33 Coronary artery calcification; chr14:88494507 chr14:88499334~88515502:+ PAAD cis rs2348418 0.703 rs10843122 ENSG00000247934.4 RP11-967K21.1 -4.27 3.43e-05 0.0144 -0.33 -0.33 Lung function (FEV1);Lung function (FVC); chr12:28174153 chr12:28163298~28190738:- PAAD cis rs2348418 0.765 rs2078016 ENSG00000247934.4 RP11-967K21.1 -4.27 3.43e-05 0.0144 -0.33 -0.33 Lung function (FEV1);Lung function (FVC); chr12:28180174 chr12:28163298~28190738:- PAAD cis rs7712401 0.601 rs154506 ENSG00000263432.2 RN7SL689P 4.27 3.43e-05 0.0144 0.42 0.33 Mean platelet volume; chr5:122867086 chr5:123022487~123022783:- PAAD cis rs3096299 0.658 rs12443705 ENSG00000261253.2 AC137932.6 4.27 3.43e-05 0.0144 0.35 0.33 Multiple myeloma (IgH translocation); chr16:89480646 chr16:89321133~89325110:+ PAAD cis rs7923609 0.936 rs10761779 ENSG00000232075.1 MRPL35P2 -4.27 3.43e-05 0.0145 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63515167 chr10:63634317~63634827:- PAAD cis rs11723261 0.621 rs11733385 ENSG00000275426.1 CH17-262A2.1 4.27 3.43e-05 0.0145 0.53 0.33 Immune response to smallpox vaccine (IL-6); chr4:146677 chr4:149738~150317:+ PAAD cis rs11723261 0.546 rs4315728 ENSG00000275426.1 CH17-262A2.1 4.27 3.43e-05 0.0145 0.53 0.33 Immune response to smallpox vaccine (IL-6); chr4:147237 chr4:149738~150317:+ PAAD cis rs2554380 0.55 rs62025831 ENSG00000230373.7 GOLGA6L5P 4.27 3.43e-05 0.0145 0.31 0.33 Height; chr15:83876933 chr15:84507885~84516814:- PAAD cis rs2554380 0.55 rs62025854 ENSG00000230373.7 GOLGA6L5P 4.27 3.43e-05 0.0145 0.31 0.33 Height; chr15:83883763 chr15:84507885~84516814:- PAAD cis rs9309711 0.56 rs6548164 ENSG00000225234.1 TRAPPC12-AS1 4.27 3.43e-05 0.0145 0.34 0.33 Neurofibrillary tangles; chr2:3468894 chr2:3481242~3482409:- PAAD cis rs853679 0.55 rs1225598 ENSG00000280107.1 AL022393.9 -4.27 3.44e-05 0.0145 -0.55 -0.33 Depression; chr6:28193021 chr6:28170845~28172521:+ PAAD cis rs2262909 0.925 rs73019838 ENSG00000279377.1 AC003973.3 -4.27 3.44e-05 0.0145 -0.31 -0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22064930 chr19:21965708~21968529:- PAAD cis rs2505998 0.957 rs1864408 ENSG00000273008.1 RP11-351D16.3 -4.27 3.44e-05 0.0145 -0.29 -0.33 Hirschsprung disease; chr10:43080435 chr10:43136824~43138334:- PAAD cis rs2505998 1 rs2435362 ENSG00000273008.1 RP11-351D16.3 -4.27 3.44e-05 0.0145 -0.29 -0.33 Hirschsprung disease; chr10:43083331 chr10:43136824~43138334:- PAAD cis rs891378 0.793 rs12021745 ENSG00000274245.1 RP11-357P18.2 4.27 3.44e-05 0.0145 0.45 0.33 Spherical equivalent (joint analysis main effects and education interaction); chr1:207293254 chr1:207372559~207373252:+ PAAD cis rs7246657 0.551 rs62108899 ENSG00000267422.1 CTD-2554C21.1 -4.27 3.44e-05 0.0145 -0.64 -0.33 Coronary artery calcification; chr19:37104281 chr19:37779686~37792865:+ PAAD cis rs8031584 0.56 rs7171208 ENSG00000260382.1 RP11-540B6.2 -4.27 3.44e-05 0.0145 -0.42 -0.33 Huntington's disease progression; chr15:30906726 chr15:30882267~30883231:- PAAD cis rs6061231 0.518 rs639836 ENSG00000273619.1 RP5-908M14.9 4.27 3.44e-05 0.0145 0.27 0.33 Colorectal cancer; chr20:62351167 chr20:62386303~62386970:- PAAD cis rs6061231 0.571 rs482010 ENSG00000273619.1 RP5-908M14.9 4.27 3.44e-05 0.0145 0.27 0.33 Colorectal cancer; chr20:62352495 chr20:62386303~62386970:- PAAD cis rs2337406 0.714 rs7145254 ENSG00000211974.3 IGHV2-70 -4.27 3.44e-05 0.0145 -0.44 -0.33 Alzheimer's disease (late onset); chr14:106817783 chr14:106723574~106724093:- PAAD cis rs10129255 0.5 rs8014529 ENSG00000211972.2 IGHV3-66 4.27 3.44e-05 0.0145 0.25 0.33 Kawasaki disease; chr14:106784065 chr14:106675017~106675544:- PAAD cis rs3823536 0.583 rs10156169 ENSG00000275106.1 RP11-309L24.10 -4.27 3.45e-05 0.0145 -0.44 -0.33 Sjögren's syndrome; chr7:129044517 chr7:128952527~128953316:- PAAD cis rs6539288 0.677 rs7315989 ENSG00000260329.1 RP11-412D9.4 -4.27 3.45e-05 0.0145 -0.29 -0.33 Total body bone mineral density; chr12:106946010 chr12:106954029~106955497:- PAAD cis rs6539288 0.641 rs12318060 ENSG00000260329.1 RP11-412D9.4 -4.27 3.45e-05 0.0145 -0.29 -0.33 Total body bone mineral density; chr12:106946834 chr12:106954029~106955497:- PAAD cis rs12571093 0.773 rs7895164 ENSG00000233590.1 RP11-153K11.3 -4.27 3.45e-05 0.0145 -0.5 -0.33 Optic nerve measurement (disc area); chr10:68225658 chr10:68233251~68242379:- PAAD cis rs2281636 0.929 rs7913190 ENSG00000233690.1 EBAG9P1 4.27 3.46e-05 0.0146 0.34 0.33 Obesity-related traits; chr10:99738639 chr10:99697407~99697949:- PAAD cis rs3743772 0.5 rs9924562 ENSG00000279344.1 RP11-44F14.7 4.27 3.46e-05 0.0146 0.36 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53415152 chr16:53478957~53481550:- PAAD cis rs12439619 0.53 rs7162177 ENSG00000255769.6 GOLGA2P10 -4.27 3.46e-05 0.0146 -0.34 -0.33 Intelligence (multi-trait analysis); chr15:82181728 chr15:82472993~82513950:- PAAD cis rs2117029 0.862 rs10875915 ENSG00000258017.1 RP11-386G11.10 -4.27 3.46e-05 0.0146 -0.42 -0.33 Intelligence (multi-trait analysis); chr12:49036311 chr12:49127782~49147869:+ PAAD cis rs875971 0.895 rs7788984 ENSG00000232559.3 GS1-124K5.12 4.27 3.46e-05 0.0146 0.36 0.33 Aortic root size; chr7:66450629 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1981798 ENSG00000232559.3 GS1-124K5.12 4.27 3.46e-05 0.0146 0.36 0.33 Aortic root size; chr7:66489916 chr7:66554588~66576923:- PAAD cis rs17030434 0.749 rs1125228 ENSG00000280241.2 RP11-290O12.2 4.27 3.47e-05 0.0146 0.33 0.33 Electrocardiographic conduction measures; chr4:153847900 chr4:154142122~154298819:+ PAAD cis rs7202877 0.706 rs42472 ENSG00000261783.1 RP11-252K23.2 4.27 3.47e-05 0.0146 0.52 0.33 Type 1 diabetes;Type 2 diabetes; chr16:75439422 chr16:75379818~75381260:- PAAD cis rs494459 0.838 rs567680 ENSG00000278376.1 RP11-158I9.8 -4.27 3.47e-05 0.0146 -0.29 -0.33 Height; chr11:118737823 chr11:118791254~118793137:+ PAAD cis rs494459 0.838 rs566733 ENSG00000278376.1 RP11-158I9.8 -4.27 3.47e-05 0.0146 -0.29 -0.33 Height; chr11:118737916 chr11:118791254~118793137:+ PAAD cis rs2412819 0.571 rs28410121 ENSG00000249839.1 AC011330.5 4.27 3.47e-05 0.0146 0.56 0.33 Lung cancer; chr15:43777831 chr15:43663654~43684339:- PAAD cis rs4835473 0.932 rs13103072 ENSG00000251600.4 RP11-673E1.1 -4.27 3.47e-05 0.0146 -0.39 -0.33 Immature fraction of reticulocytes; chr4:143952116 chr4:143912331~143982454:+ PAAD cis rs7626444 0.625 rs2669637 ENSG00000272359.1 U4 -4.27 3.47e-05 0.0146 -0.35 -0.33 Monocyte count; chr3:196750498 chr3:196747192~196747324:- PAAD cis rs7626444 0.627 rs5021326 ENSG00000272359.1 U4 -4.27 3.47e-05 0.0146 -0.35 -0.33 Monocyte count; chr3:196750757 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs1718410 ENSG00000272359.1 U4 -4.27 3.47e-05 0.0146 -0.35 -0.33 Monocyte count; chr3:196750789 chr3:196747192~196747324:- PAAD cis rs2262909 0.962 rs409439 ENSG00000279377.1 AC003973.3 4.27 3.48e-05 0.0146 0.3 0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22044630 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs425781 ENSG00000279377.1 AC003973.3 4.27 3.48e-05 0.0146 0.3 0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22046504 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs390730 ENSG00000279377.1 AC003973.3 4.27 3.48e-05 0.0146 0.3 0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22050707 chr19:21965708~21968529:- PAAD cis rs10129255 0.5 rs8011115 ENSG00000211972.2 IGHV3-66 4.27 3.48e-05 0.0146 0.25 0.33 Kawasaki disease; chr14:106786292 chr14:106675017~106675544:- PAAD cis rs3020264 1 rs3020264 ENSG00000271743.1 CTD-2541M15.3 4.27 3.48e-05 0.0146 0.48 0.33 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6631056 chr8:6615604~6617198:- PAAD cis rs812925 0.537 rs778139 ENSG00000273302.1 RP11-493E12.2 -4.27 3.48e-05 0.0146 -0.29 -0.33 Immature fraction of reticulocytes; chr2:61457429 chr2:61199979~61200769:+ PAAD cis rs12439619 0.705 rs4778665 ENSG00000276710.3 CSPG4P8 -4.27 3.48e-05 0.0146 -0.37 -0.33 Intelligence (multi-trait analysis); chr15:82144163 chr15:82459472~82477258:+ PAAD cis rs9928842 0.765 rs8055472 ENSG00000280152.1 RP11-331F4.5 4.27 3.48e-05 0.0146 0.43 0.33 Alcoholic chronic pancreatitis; chr16:75191650 chr16:75245994~75250077:- PAAD cis rs12908161 1 rs12905057 ENSG00000259728.4 LINC00933 4.27 3.48e-05 0.0146 0.41 0.33 Schizophrenia; chr15:84667534 chr15:84570649~84580175:+ PAAD cis rs2564921 0.704 rs17304694 ENSG00000242142.1 SERBP1P3 -4.27 3.48e-05 0.0146 -0.41 -0.33 Height; chr3:53017561 chr3:53064283~53065091:- PAAD cis rs2564921 0.666 rs55796351 ENSG00000242142.1 SERBP1P3 -4.27 3.48e-05 0.0146 -0.41 -0.33 Height; chr3:53020134 chr3:53064283~53065091:- PAAD cis rs17772222 0.651 rs865285 ENSG00000258983.2 RP11-507K2.2 -4.27 3.49e-05 0.0147 -0.39 -0.33 Coronary artery calcification; chr14:88391138 chr14:88499334~88515502:+ PAAD cis rs11690935 0.55 rs6746701 ENSG00000228389.1 AC068039.4 -4.27 3.49e-05 0.0147 -0.42 -0.33 Schizophrenia; chr2:172004347 chr2:171773482~171775844:+ PAAD cis rs6504950 0.745 rs9914088 ENSG00000275710.1 RP11-257O5.4 4.27 3.49e-05 0.0147 0.4 0.33 Breast cancer; chr17:54902624 chr17:54964474~54964679:+ PAAD cis rs6570726 1 rs405622 ENSG00000235652.6 RP11-545I5.3 4.27 3.49e-05 0.0147 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145550761 chr6:145799409~145886585:+ PAAD cis rs6570726 1 rs455109 ENSG00000235652.6 RP11-545I5.3 4.27 3.49e-05 0.0147 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145551529 chr6:145799409~145886585:+ PAAD cis rs6570726 1 rs373778 ENSG00000235652.6 RP11-545I5.3 4.27 3.49e-05 0.0147 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145552116 chr6:145799409~145886585:+ PAAD cis rs61841072 0.961 rs12131267 ENSG00000253326.2 RP11-261C10.7 -4.27 3.49e-05 0.0147 -0.47 -0.33 Schizophrenia; chr1:242975034 chr1:243054861~243056394:- PAAD cis rs7216064 0.953 rs1599859 ENSG00000278219.1 AC145343.1 -4.27 3.49e-05 0.0147 -0.51 -0.33 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67841077 chr17:68101538~68101639:+ PAAD cis rs3743772 0.5 rs11866060 ENSG00000279344.1 RP11-44F14.7 4.27 3.5e-05 0.0147 0.36 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53394937 chr16:53478957~53481550:- PAAD cis rs919433 0.929 rs7592511 ENSG00000231621.1 AC013264.2 4.27 3.5e-05 0.0147 0.31 0.33 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197313250 chr2:197197991~197199273:+ PAAD cis rs919433 0.929 rs4850788 ENSG00000231621.1 AC013264.2 4.27 3.5e-05 0.0147 0.31 0.33 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197318216 chr2:197197991~197199273:+ PAAD cis rs10411161 1 rs72626249 ENSG00000269483.1 AC006272.1 4.27 3.5e-05 0.0147 0.58 0.33 Breast cancer; chr19:51861622 chr19:51839924~51843324:- PAAD cis rs5742933 0.597 rs12471663 ENSG00000253559.1 OSGEPL1-AS1 4.26 3.5e-05 0.0147 0.35 0.33 Ferritin levels; chr2:189642372 chr2:189762704~189765556:+ PAAD cis rs5742933 0.597 rs6761923 ENSG00000253559.1 OSGEPL1-AS1 4.26 3.5e-05 0.0147 0.35 0.33 Ferritin levels; chr2:189642873 chr2:189762704~189765556:+ PAAD cis rs797680 0.786 rs6694508 ENSG00000223745.6 RP4-717I23.3 4.26 3.5e-05 0.0147 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93376466 chr1:93262186~93346025:- PAAD cis rs7646881 0.812 rs59957986 ENSG00000240207.5 RP11-379F4.4 -4.26 3.5e-05 0.0147 -0.51 -0.33 Tetralogy of Fallot; chr3:158741124 chr3:158732263~158784070:+ PAAD cis rs10050311 0.79 rs76583174 ENSG00000251411.1 RP11-397E7.4 -4.26 3.5e-05 0.0147 -0.39 -0.33 Insulin-related traits; chr4:86917234 chr4:86913266~86914817:- PAAD cis rs853679 0.55 rs1233701 ENSG00000280107.1 AL022393.9 4.26 3.5e-05 0.0147 0.54 0.33 Depression; chr6:28200948 chr6:28170845~28172521:+ PAAD cis rs853679 0.574 rs1233705 ENSG00000280107.1 AL022393.9 -4.26 3.5e-05 0.0147 -0.54 -0.33 Depression; chr6:28198669 chr6:28170845~28172521:+ PAAD cis rs853679 0.55 rs1233699 ENSG00000280107.1 AL022393.9 -4.26 3.5e-05 0.0147 -0.54 -0.33 Depression; chr6:28201380 chr6:28170845~28172521:+ PAAD cis rs853679 0.55 rs1233707 ENSG00000280107.1 AL022393.9 -4.26 3.5e-05 0.0147 -0.54 -0.33 Depression; chr6:28205175 chr6:28170845~28172521:+ PAAD cis rs10851478 0.558 rs17478694 ENSG00000259531.2 RP11-295H24.3 -4.26 3.5e-05 0.0147 -0.44 -0.33 Oral cavity cancer; chr15:49446345 chr15:49365124~49366685:- PAAD cis rs10851478 0.558 rs17478785 ENSG00000259531.2 RP11-295H24.3 -4.26 3.5e-05 0.0147 -0.44 -0.33 Oral cavity cancer; chr15:49448107 chr15:49365124~49366685:- PAAD cis rs10851478 0.558 rs4389093 ENSG00000259531.2 RP11-295H24.3 -4.26 3.5e-05 0.0147 -0.44 -0.33 Oral cavity cancer; chr15:49450872 chr15:49365124~49366685:- PAAD cis rs6951245 0.58 rs77101766 ENSG00000229043.2 AC091729.9 -4.26 3.51e-05 0.0147 -0.45 -0.33 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1082802 chr7:1160374~1165267:+ PAAD cis rs748404 0.631 rs7163288 ENSG00000205771.5 CATSPER2P1 -4.26 3.51e-05 0.0147 -0.45 -0.33 Lung cancer; chr15:43379157 chr15:43726918~43747094:- PAAD cis rs2262909 0.745 rs1989120 ENSG00000279377.1 AC003973.3 4.26 3.51e-05 0.0147 0.31 0.33 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22022726 chr19:21965708~21968529:- PAAD cis rs3738443 0.599 rs1934986 ENSG00000259865.1 RP11-488L18.10 4.26 3.51e-05 0.0147 0.29 0.33 Alcohol dependence; chr1:247235696 chr1:247187281~247188526:- PAAD cis rs11690935 0.589 rs62182403 ENSG00000228389.1 AC068039.4 -4.26 3.51e-05 0.0147 -0.41 -0.33 Schizophrenia; chr2:171890672 chr2:171773482~171775844:+ PAAD cis rs13178541 0.745 rs7379714 ENSG00000250378.1 RP11-119J18.1 -4.26 3.51e-05 0.0147 -0.5 -0.33 IgG glycosylation; chr5:135757447 chr5:135812667~135826582:+ PAAD cis rs2348418 0.932 rs7968515 ENSG00000247934.4 RP11-967K21.1 4.26 3.51e-05 0.0147 0.32 0.33 Lung function (FEV1);Lung function (FVC); chr12:28542914 chr12:28163298~28190738:- PAAD cis rs2348418 0.966 rs2881910 ENSG00000247934.4 RP11-967K21.1 4.26 3.51e-05 0.0147 0.32 0.33 Lung function (FEV1);Lung function (FVC); chr12:28544459 chr12:28163298~28190738:- PAAD cis rs763121 0.853 rs2267393 ENSG00000228274.3 RP3-508I15.9 -4.26 3.52e-05 0.0148 -0.31 -0.33 Menopause (age at onset); chr22:38705614 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2267394 ENSG00000228274.3 RP3-508I15.9 -4.26 3.52e-05 0.0148 -0.31 -0.33 Menopause (age at onset); chr22:38705628 chr22:38667585~38681820:- PAAD cis rs5760092 0.618 rs5996631 ENSG00000231271.1 AP000350.8 -4.26 3.52e-05 0.0148 -0.46 -0.33 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23949918~23954042:+ PAAD cis rs7299940 0.694 rs12296337 ENSG00000256250.1 RP11-989F5.1 4.26 3.52e-05 0.0148 0.36 0.33 Panic disorder; chr12:130891406 chr12:130810606~130812438:+ PAAD cis rs11089937 0.651 rs1543779 ENSG00000211640.3 IGLV6-57 -4.26 3.53e-05 0.0148 -0.22 -0.33 Periodontitis (PAL4Q3); chr22:22194092 chr22:22195713~22196460:+ PAAD cis rs2243480 1 rs316315 ENSG00000273142.1 RP11-458F8.4 4.26 3.53e-05 0.0148 0.26 0.33 Diabetic kidney disease; chr7:66126218 chr7:66902857~66906297:+ PAAD cis rs792448 0.501 rs11119880 ENSG00000229983.1 RP11-15I11.2 4.26 3.53e-05 0.0148 0.38 0.33 White blood cell count (basophil); chr1:212205143 chr1:212168207~212190259:+ PAAD cis rs4853012 0.793 rs6723185 ENSG00000257800.1 FNBP1P1 4.26 3.53e-05 0.0148 0.46 0.33 Gestational age at birth (maternal effect); chr2:74117757 chr2:74120680~74123218:+ PAAD cis rs3738443 1 rs3738443 ENSG00000259865.1 RP11-488L18.10 -4.26 3.53e-05 0.0148 -0.31 -0.33 Alcohol dependence; chr1:247184887 chr1:247187281~247188526:- PAAD cis rs113835537 0.935 rs75863187 ENSG00000255517.5 CTD-3074O7.5 -4.26 3.53e-05 0.0148 -0.53 -0.33 Airway imaging phenotypes; chr11:66675990 chr11:66473490~66480233:- PAAD cis rs6479891 0.908 rs11817901 ENSG00000232075.1 MRPL35P2 4.26 3.54e-05 0.0148 0.55 0.33 Arthritis (juvenile idiopathic); chr10:63580123 chr10:63634317~63634827:- PAAD cis rs889398 0.741 rs8049373 ENSG00000226232.7 RP11-419C5.2 -4.26 3.54e-05 0.0148 -0.26 -0.33 Body mass index; chr16:69905802 chr16:69976388~69996188:- PAAD cis rs2250402 1 rs2250402 ENSG00000245849.5 RAD51-AS1 -4.26 3.54e-05 0.0148 -0.41 -0.33 Corneal curvature; chr15:40030351 chr15:40686724~40695107:- PAAD cis rs2250402 0.51 rs8031319 ENSG00000245849.5 RAD51-AS1 -4.26 3.54e-05 0.0148 -0.41 -0.33 Corneal curvature; chr15:40031491 chr15:40686724~40695107:- PAAD cis rs2250402 0.51 rs6492926 ENSG00000245849.5 RAD51-AS1 -4.26 3.54e-05 0.0148 -0.41 -0.33 Corneal curvature; chr15:40033628 chr15:40686724~40695107:- PAAD cis rs2250402 0.51 rs2291619 ENSG00000245849.5 RAD51-AS1 4.26 3.54e-05 0.0148 0.41 0.33 Corneal curvature; chr15:40036832 chr15:40686724~40695107:- PAAD cis rs55665837 0.524 rs61884009 ENSG00000251991.1 RNU7-49P 4.26 3.54e-05 0.0148 0.4 0.33 Vitamin D levels; chr11:14404916 chr11:14478892~14478953:+ PAAD cis rs2729354 0.953 rs2848625 ENSG00000265566.2 RN7SL605P -4.26 3.54e-05 0.0148 -0.44 -0.33 Blood protein levels; chr11:57563177 chr11:57528085~57528365:- PAAD cis rs1862618 0.853 rs9283717 ENSG00000271828.1 CTD-2310F14.1 4.26 3.54e-05 0.0148 0.46 0.33 Initial pursuit acceleration; chr5:56782832 chr5:56927874~56929573:+ PAAD cis rs4925386 1 rs1889201 ENSG00000273619.1 RP5-908M14.9 4.26 3.54e-05 0.0149 0.27 0.33 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62348019 chr20:62386303~62386970:- PAAD cis rs4835473 0.932 rs7696106 ENSG00000251600.4 RP11-673E1.1 -4.26 3.55e-05 0.0149 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143765454 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7680045 ENSG00000251600.4 RP11-673E1.1 -4.26 3.55e-05 0.0149 -0.37 -0.33 Immature fraction of reticulocytes; chr4:143765470 chr4:143912331~143982454:+ PAAD cis rs17772222 0.675 rs845769 ENSG00000258983.2 RP11-507K2.2 -4.26 3.55e-05 0.0149 -0.4 -0.33 Coronary artery calcification; chr14:88461455 chr14:88499334~88515502:+ PAAD cis rs4718428 0.672 rs4718412 ENSG00000273142.1 RP11-458F8.4 4.26 3.55e-05 0.0149 0.22 0.33 Corneal structure; chr7:66821880 chr7:66902857~66906297:+ PAAD cis rs8031584 0.56 rs1056118 ENSG00000260382.1 RP11-540B6.2 -4.26 3.55e-05 0.0149 -0.42 -0.33 Huntington's disease progression; chr15:30911583 chr15:30882267~30883231:- PAAD cis rs875971 0.522 rs4718286 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Aortic root size; chr7:65827777 chr7:66493706~66495474:+ PAAD cis rs17711722 0.585 rs6942660 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Calcium levels; chr7:65837419 chr7:66493706~66495474:+ PAAD cis rs875971 0.516 rs6945322 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Aortic root size; chr7:65871069 chr7:66493706~66495474:+ PAAD cis rs17711722 0.701 rs55773927 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Calcium levels; chr7:65872915 chr7:66493706~66495474:+ PAAD cis rs17711722 0.727 rs35850374 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Calcium levels; chr7:65892789 chr7:66493706~66495474:+ PAAD cis rs17711722 0.701 rs4467826 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Calcium levels; chr7:65903721 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs7784623 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Aortic root size; chr7:65930047 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs34973832 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Aortic root size; chr7:65931217 chr7:66493706~66495474:+ PAAD cis rs17711722 0.74 rs7809991 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Calcium levels; chr7:65941231 chr7:66493706~66495474:+ PAAD cis rs875971 0.522 rs6960048 ENSG00000237310.1 GS1-124K5.4 4.26 3.55e-05 0.0149 0.31 0.33 Aortic root size; chr7:65943052 chr7:66493706~66495474:+ PAAD cis rs6570726 0.935 rs398060 ENSG00000235652.6 RP11-545I5.3 -4.26 3.55e-05 0.0149 -0.26 -0.33 Lobe attachment (rater-scored or self-reported); chr6:145520379 chr6:145799409~145886585:+ PAAD cis rs889398 0.741 rs3790075 ENSG00000226232.7 RP11-419C5.2 -4.26 3.55e-05 0.0149 -0.26 -0.33 Body mass index; chr16:69873908 chr16:69976388~69996188:- PAAD cis rs889398 0.741 rs7190013 ENSG00000226232.7 RP11-419C5.2 -4.26 3.55e-05 0.0149 -0.26 -0.33 Body mass index; chr16:69874345 chr16:69976388~69996188:- PAAD cis rs889398 0.683 rs8047682 ENSG00000226232.7 RP11-419C5.2 -4.26 3.55e-05 0.0149 -0.26 -0.33 Body mass index; chr16:69879543 chr16:69976388~69996188:- PAAD cis rs889398 0.741 rs6499270 ENSG00000226232.7 RP11-419C5.2 4.26 3.55e-05 0.0149 0.26 0.33 Body mass index; chr16:69883837 chr16:69976388~69996188:- PAAD cis rs889398 0.741 rs4146819 ENSG00000226232.7 RP11-419C5.2 -4.26 3.55e-05 0.0149 -0.26 -0.33 Body mass index; chr16:69889660 chr16:69976388~69996188:- PAAD cis rs889398 0.741 rs7193038 ENSG00000226232.7 RP11-419C5.2 -4.26 3.55e-05 0.0149 -0.26 -0.33 Body mass index; chr16:69892231 chr16:69976388~69996188:- PAAD cis rs889398 0.741 rs7192213 ENSG00000226232.7 RP11-419C5.2 -4.26 3.55e-05 0.0149 -0.26 -0.33 Body mass index; chr16:69892377 chr16:69976388~69996188:- PAAD cis rs889398 0.741 rs10852461 ENSG00000226232.7 RP11-419C5.2 -4.26 3.55e-05 0.0149 -0.26 -0.33 Body mass index; chr16:69894943 chr16:69976388~69996188:- PAAD cis rs30380 0.734 rs27044 ENSG00000272109.1 CTD-2260A17.3 -4.26 3.55e-05 0.0149 -0.41 -0.33 Cerebrospinal fluid biomarker levels; chr5:96783148 chr5:96804353~96806105:+ PAAD cis rs30380 0.69 rs27432 ENSG00000272109.1 CTD-2260A17.3 -4.26 3.55e-05 0.0149 -0.41 -0.33 Cerebrospinal fluid biomarker levels; chr5:96783569 chr5:96804353~96806105:+ PAAD cis rs30380 0.734 rs30376 ENSG00000272109.1 CTD-2260A17.3 -4.26 3.55e-05 0.0149 -0.41 -0.33 Cerebrospinal fluid biomarker levels; chr5:96784555 chr5:96804353~96806105:+ PAAD cis rs916888 0.773 rs538628 ENSG00000261575.2 RP11-259G18.1 4.26 3.55e-05 0.0149 0.5 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46267037~46268694:+ PAAD cis rs11690935 0.655 rs1028127 ENSG00000228389.1 AC068039.4 -4.26 3.55e-05 0.0149 -0.4 -0.33 Schizophrenia; chr2:171673526 chr2:171773482~171775844:+ PAAD cis rs11690935 0.632 rs12998411 ENSG00000228389.1 AC068039.4 -4.26 3.55e-05 0.0149 -0.4 -0.33 Schizophrenia; chr2:171674197 chr2:171773482~171775844:+ PAAD cis rs394563 0.775 rs412894 ENSG00000231760.4 RP11-350J20.5 4.26 3.56e-05 0.0149 0.45 0.33 Dupuytren's disease; chr6:149460039 chr6:149796151~149826294:- PAAD cis rs394563 0.717 rs548848 ENSG00000231760.4 RP11-350J20.5 4.26 3.56e-05 0.0149 0.45 0.33 Dupuytren's disease; chr6:149460873 chr6:149796151~149826294:- PAAD cis rs9487094 0.961 rs12528822 ENSG00000260273.1 RP11-425D10.10 4.26 3.56e-05 0.0149 0.42 0.33 Height; chr6:109340338 chr6:109382795~109383666:+ PAAD cis rs338389 0.542 rs8036189 ENSG00000260657.2 RP11-315D16.4 -4.26 3.56e-05 0.0149 -0.37 -0.33 Survival in rectal cancer; chr15:68000614 chr15:68267792~68277994:- PAAD cis rs338389 0.542 rs6494709 ENSG00000260657.2 RP11-315D16.4 -4.26 3.56e-05 0.0149 -0.37 -0.33 Survival in rectal cancer; chr15:68001672 chr15:68267792~68277994:- PAAD cis rs338389 0.542 rs7494835 ENSG00000260657.2 RP11-315D16.4 -4.26 3.56e-05 0.0149 -0.37 -0.33 Survival in rectal cancer; chr15:68001993 chr15:68267792~68277994:- PAAD cis rs7727544 0.709 rs441969 ENSG00000233006.5 AC034220.3 4.26 3.56e-05 0.0149 0.27 0.33 Blood metabolite levels; chr5:132366428 chr5:132311285~132369916:- PAAD cis rs867371 0.929 rs1045508 ENSG00000259429.4 UBE2Q2P2 4.26 3.56e-05 0.0149 0.25 0.33 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82157565 chr15:82355142~82420075:+ PAAD cis rs6061231 0.74 rs11698650 ENSG00000273619.1 RP5-908M14.9 -4.26 3.57e-05 0.0149 -0.26 -0.33 Colorectal cancer; chr20:62383318 chr20:62386303~62386970:- PAAD cis rs4660214 0.639 rs6699928 ENSG00000237624.1 OXCT2P1 -4.26 3.57e-05 0.0149 -0.44 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39267827 chr1:39514956~39516490:+ PAAD cis rs8072100 0.807 rs4561509 ENSG00000228782.6 CTD-2026D20.3 4.26 3.57e-05 0.0149 0.33 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47704433 chr17:47450568~47492492:- PAAD cis rs3743772 0.5 rs2388117 ENSG00000279344.1 RP11-44F14.7 4.26 3.57e-05 0.0149 0.35 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53413692 chr16:53478957~53481550:- PAAD cis rs3743772 0.5 rs28415605 ENSG00000279344.1 RP11-44F14.7 4.26 3.57e-05 0.0149 0.35 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53415274 chr16:53478957~53481550:- PAAD cis rs3743772 0.5 rs2160290 ENSG00000279344.1 RP11-44F14.7 4.26 3.57e-05 0.0149 0.35 0.33 Depressive symptoms (SSRI exposure interaction); chr16:53415763 chr16:53478957~53481550:- PAAD cis rs1873386 0.79 rs7971554 ENSG00000255910.1 RP11-405A12.2 4.26 3.57e-05 0.0149 0.48 0.33 Personality dimensions; chr12:18914184 chr12:19775451~20009937:+ PAAD cis rs916888 0.773 rs199447 ENSG00000261575.2 RP11-259G18.1 4.26 3.57e-05 0.0149 0.5 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46267037~46268694:+ PAAD cis rs9257809 1 rs9257809 ENSG00000281831.1 HCP5B 4.26 3.57e-05 0.0149 0.71 0.33 Barrett's esophagus;Breast cancer;Barrett's esophagus or Esophageal adenocarcinoma; chr6:29388554 chr6:29871895~29873783:- PAAD cis rs13256369 0.802 rs12541520 ENSG00000253981.4 ALG1L13P 4.26 3.57e-05 0.015 0.44 0.33 Obesity-related traits; chr8:8706636 chr8:8236003~8244667:- PAAD cis rs7923609 0.934 rs7923544 ENSG00000232075.1 MRPL35P2 -4.26 3.58e-05 0.015 -0.4 -0.33 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63422496 chr10:63634317~63634827:- PAAD cis rs801193 1 rs17566701 ENSG00000237310.1 GS1-124K5.4 4.26 3.58e-05 0.015 0.3 0.33 Aortic root size; chr7:66728196 chr7:66493706~66495474:+ PAAD cis rs7626444 0.625 rs2669638 ENSG00000272359.1 U4 -4.26 3.58e-05 0.015 -0.35 -0.33 Monocyte count; chr3:196750527 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs2686593 ENSG00000272359.1 U4 -4.26 3.58e-05 0.015 -0.35 -0.33 Monocyte count; chr3:196750530 chr3:196747192~196747324:- PAAD cis rs2729354 1 rs2511983 ENSG00000265566.2 RN7SL605P -4.26 3.58e-05 0.015 -0.44 -0.33 Blood protein levels; chr11:57579401 chr11:57528085~57528365:- PAAD cis rs205611 0.709 rs12151610 ENSG00000204792.2 LINC01291 -4.26 3.58e-05 0.015 -0.63 -0.33 Iris characteristics; chr2:74798726 chr2:74918148~74938418:+ PAAD cis rs4664293 0.625 rs7590617 ENSG00000226266.5 AC009961.3 4.26 3.59e-05 0.015 0.4 0.33 Monocyte percentage of white cells; chr2:159775437 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs7564585 ENSG00000226266.5 AC009961.3 4.26 3.59e-05 0.015 0.4 0.33 Monocyte percentage of white cells; chr2:159775582 chr2:159670708~159712435:- PAAD cis rs4664293 0.546 rs7564399 ENSG00000226266.5 AC009961.3 4.26 3.59e-05 0.015 0.4 0.33 Monocyte percentage of white cells; chr2:159775608 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs35481084 ENSG00000226266.5 AC009961.3 4.26 3.59e-05 0.015 0.4 0.33 Monocyte percentage of white cells; chr2:159777729 chr2:159670708~159712435:- PAAD cis rs4664293 0.625 rs10460300 ENSG00000226266.5 AC009961.3 4.26 3.59e-05 0.015 0.4 0.33 Monocyte percentage of white cells; chr2:159778210 chr2:159670708~159712435:- PAAD cis rs79040073 0.607 rs7168316 ENSG00000259531.2 RP11-295H24.3 4.26 3.59e-05 0.015 0.5 0.33 Lung cancer in ever smokers; chr15:49441549 chr15:49365124~49366685:- PAAD cis rs10851478 0.529 rs9920722 ENSG00000259531.2 RP11-295H24.3 4.26 3.59e-05 0.015 0.42 0.33 Oral cavity cancer; chr15:49442915 chr15:49365124~49366685:- PAAD cis rs2115630 0.967 rs11073731 ENSG00000225151.9 GOLGA2P7 4.26 3.59e-05 0.015 0.39 0.33 P wave terminal force; chr15:84811882 chr15:84199311~84230136:- PAAD cis rs2115630 1 rs8037423 ENSG00000225151.9 GOLGA2P7 4.26 3.59e-05 0.015 0.39 0.33 P wave terminal force; chr15:84812263 chr15:84199311~84230136:- PAAD cis rs7202877 0.706 rs247425 ENSG00000261783.1 RP11-252K23.2 4.26 3.6e-05 0.015 0.51 0.33 Type 1 diabetes;Type 2 diabetes; chr16:75426504 chr16:75379818~75381260:- PAAD cis rs6570726 0.905 rs1355146 ENSG00000235652.6 RP11-545I5.3 -4.26 3.6e-05 0.015 -0.27 -0.33 Lobe attachment (rater-scored or self-reported); chr6:145460605 chr6:145799409~145886585:+ PAAD cis rs6570726 0.902 rs973855 ENSG00000235652.6 RP11-545I5.3 -4.26 3.6e-05 0.015 -0.27 -0.33 Lobe attachment (rater-scored or self-reported); chr6:145460714 chr6:145799409~145886585:+ PAAD cis rs2581828 0.58 rs6799837 ENSG00000242142.1 SERBP1P3 -4.26 3.6e-05 0.015 -0.41 -0.33 Crohn's disease; chr3:53133838 chr3:53064283~53065091:- PAAD cis rs12439619 0.693 rs4778989 ENSG00000255769.6 GOLGA2P10 -4.26 3.6e-05 0.0151 -0.4 -0.33 Intelligence (multi-trait analysis); chr15:82276963 chr15:82472993~82513950:- PAAD cis rs11123170 0.529 rs1015753 ENSG00000274877.1 RP11-65I12.1 -4.26 3.61e-05 0.0151 -0.43 -0.33 Renal function-related traits (BUN); chr2:113211226 chr2:113237595~113240825:+ PAAD cis rs2505998 0.843 rs2435344 ENSG00000273008.1 RP11-351D16.3 -4.26 3.61e-05 0.0151 -0.28 -0.33 Hirschsprung disease; chr10:43090426 chr10:43136824~43138334:- PAAD cis rs2505998 0.833 rs752977 ENSG00000273008.1 RP11-351D16.3 -4.26 3.61e-05 0.0151 -0.28 -0.33 Hirschsprung disease; chr10:43092933 chr10:43136824~43138334:- PAAD cis rs2505998 0.833 rs12767776 ENSG00000273008.1 RP11-351D16.3 -4.26 3.61e-05 0.0151 -0.28 -0.33 Hirschsprung disease; chr10:43094065 chr10:43136824~43138334:- PAAD cis rs7829975 0.593 rs2921051 ENSG00000253981.4 ALG1L13P 4.26 3.61e-05 0.0151 0.38 0.33 Mood instability; chr8:8462594 chr8:8236003~8244667:- PAAD cis rs2243480 1 rs160655 ENSG00000228409.4 CCT6P1 4.26 3.61e-05 0.0151 0.34 0.33 Diabetic kidney disease; chr7:66068227 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs160649 ENSG00000228409.4 CCT6P1 4.26 3.61e-05 0.0151 0.34 0.33 Diabetic kidney disease; chr7:66078212 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs160648 ENSG00000228409.4 CCT6P1 4.26 3.61e-05 0.0151 0.34 0.33 Diabetic kidney disease; chr7:66078397 chr7:65751142~65763354:+ PAAD cis rs9807989 0.507 rs7584093 ENSG00000234389.1 AC007278.3 4.26 3.61e-05 0.0151 0.33 0.33 Asthma; chr2:102381261 chr2:102438713~102440475:+ PAAD cis rs7225151 1 rs4456560 ENSG00000234327.6 AC012146.7 -4.26 3.61e-05 0.0151 -0.34 -0.33 Alzheimer's disease (late onset); chr17:5237104 chr17:5111468~5115004:+ PAAD cis rs853679 0.55 rs1237875 ENSG00000280107.1 AL022393.9 4.26 3.61e-05 0.0151 0.55 0.33 Depression; chr6:28205232 chr6:28170845~28172521:+ PAAD cis rs733592 0.599 rs12819124 ENSG00000240399.1 RP1-228P16.1 4.26 3.61e-05 0.0151 0.32 0.33 Plateletcrit; chr12:48015271 chr12:48054813~48055591:- PAAD cis rs710913 0.717 rs11206377 ENSG00000243970.1 PPIEL 4.26 3.61e-05 0.0151 0.28 0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39583432 chr1:39531838~39558707:- PAAD cis rs801193 1 rs10234018 ENSG00000237310.1 GS1-124K5.4 -4.26 3.62e-05 0.0151 -0.31 -0.33 Aortic root size; chr7:66681297 chr7:66493706~66495474:+ PAAD cis rs763121 0.853 rs1013338 ENSG00000228274.3 RP3-508I15.9 -4.26 3.62e-05 0.0151 -0.31 -0.33 Menopause (age at onset); chr22:38578149 chr22:38667585~38681820:- PAAD cis rs871012 0.502 rs951959 ENSG00000248544.2 CTB-47B11.3 -4.26 3.62e-05 0.0151 -0.43 -0.33 IgG glycosylation; chr5:157462211 chr5:157375741~157384950:- PAAD cis rs871012 0.502 rs57064749 ENSG00000248544.2 CTB-47B11.3 -4.26 3.62e-05 0.0151 -0.43 -0.33 IgG glycosylation; chr5:157462690 chr5:157375741~157384950:- PAAD cis rs34375054 0.573 rs35698828 ENSG00000279233.1 RP11-158L12.4 4.26 3.62e-05 0.0151 0.31 0.33 Post bronchodilator FEV1/FVC ratio; chr12:125174057 chr12:125138245~125141711:+ PAAD cis rs4938303 0.587 rs10892017 ENSG00000254851.1 RP11-109L13.1 4.26 3.62e-05 0.0151 0.47 0.33 Triglycerides; chr11:116697165 chr11:117135528~117138582:+ PAAD cis rs4725617 0.686 rs1804527 ENSG00000176510.4 OR10AC1 -4.26 3.62e-05 0.0151 -0.67 -0.33 Blood protein levels; chr7:143391730 chr7:143510933~143511911:- PAAD cis rs10888838 1 rs10888840 ENSG00000198711.5 SSBP3-AS1 4.26 3.63e-05 0.0151 0.38 0.33 Mitochondrial DNA levels; chr1:54217740 chr1:54236440~54239063:+ PAAD cis rs10888838 1 rs2026045 ENSG00000198711.5 SSBP3-AS1 4.26 3.63e-05 0.0151 0.38 0.33 Mitochondrial DNA levels; chr1:54219522 chr1:54236440~54239063:+ PAAD cis rs9928842 0.823 rs12918452 ENSG00000280152.1 RP11-331F4.5 4.26 3.63e-05 0.0151 0.44 0.33 Alcoholic chronic pancreatitis; chr16:75201536 chr16:75245994~75250077:- PAAD cis rs78579285 0.507 rs1061247 ENSG00000278341.1 RP5-1142A6.10 -4.26 3.63e-05 0.0151 -0.56 -0.33 Joint mobility (Beighton score); chr16:88715383 chr16:88708956~88710437:- PAAD cis rs9807989 0.507 rs6758936 ENSG00000234389.1 AC007278.3 -4.26 3.63e-05 0.0151 -0.33 -0.33 Asthma; chr2:102374909 chr2:102438713~102440475:+ PAAD cis rs2134046 0.555 rs11854483 ENSG00000278603.1 RP13-608F4.5 4.26 3.63e-05 0.0151 0.4 0.33 Cognitive ability; chr15:82267217 chr15:82472203~82472426:+ PAAD cis rs6539288 0.677 rs11113144 ENSG00000260329.1 RP11-412D9.4 -4.26 3.63e-05 0.0151 -0.29 -0.33 Total body bone mineral density; chr12:106929644 chr12:106954029~106955497:- PAAD cis rs6539288 0.677 rs2216221 ENSG00000260329.1 RP11-412D9.4 -4.26 3.63e-05 0.0151 -0.29 -0.33 Total body bone mineral density; chr12:106933453 chr12:106954029~106955497:- PAAD cis rs6539288 0.677 rs1348565 ENSG00000260329.1 RP11-412D9.4 -4.26 3.63e-05 0.0151 -0.29 -0.33 Total body bone mineral density; chr12:106935326 chr12:106954029~106955497:- PAAD cis rs10779751 0.77 rs10864490 ENSG00000238199.1 UBE2V2P3 -4.26 3.63e-05 0.0151 -0.41 -0.33 Body mass index; chr1:11176353 chr1:11278616~11279351:- PAAD cis rs7182621 0.639 rs1561047 ENSG00000182397.13 DNM1P46 4.26 3.63e-05 0.0151 0.43 0.33 Colonoscopy-negative controls vs population controls; chr15:99874606 chr15:99790156~99806927:- PAAD cis rs17772222 0.958 rs60213984 ENSG00000258983.2 RP11-507K2.2 4.26 3.63e-05 0.0152 0.45 0.33 Coronary artery calcification; chr14:88401473 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs55722539 ENSG00000258983.2 RP11-507K2.2 4.26 3.63e-05 0.0152 0.45 0.33 Coronary artery calcification; chr14:88411691 chr14:88499334~88515502:+ PAAD cis rs875971 0.638 rs35986979 ENSG00000237310.1 GS1-124K5.4 -4.26 3.64e-05 0.0152 -0.3 -0.33 Aortic root size; chr7:66624003 chr7:66493706~66495474:+ PAAD cis rs3096299 0.838 rs3096319 ENSG00000274627.1 RP11-104N10.2 4.26 3.64e-05 0.0152 0.29 0.33 Multiple myeloma (IgH translocation); chr16:89336226 chr16:89516797~89522217:+ PAAD cis rs4660214 0.724 rs3931300 ENSG00000261798.1 RP1-118J21.25 -4.26 3.64e-05 0.0152 -0.39 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39195175 chr1:39788976~39790171:+ PAAD cis rs4713118 0.621 rs9368548 ENSG00000204709.4 LINC01556 4.26 3.64e-05 0.0152 0.56 0.33 Parkinson's disease; chr6:28066959 chr6:28943877~28944537:+ PAAD cis rs12480328 1 rs6091236 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50900458 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs4449196 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50905118 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs16995592 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50907914 chr20:50292720~50314922:+ PAAD cis rs12480328 0.85 rs16984523 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50908064 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs6091237 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50909450 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs73909829 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50909760 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs73909831 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50909948 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs78860779 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50910834 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs12480328 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50911385 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs41274692 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50914391 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs2870024 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50922384 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs2870025 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50922521 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs73909841 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50932270 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs73909842 ENSG00000203999.7 LINC01270 4.26 3.64e-05 0.0152 0.73 0.33 Prostate cancer; chr20:50934277 chr20:50292720~50314922:+ PAAD cis rs4638749 0.588 rs13401731 ENSG00000261209.1 RP11-443K8.1 4.25 3.64e-05 0.0152 0.35 0.33 Blood pressure; chr2:108268884 chr2:108317725~108318611:+ PAAD cis rs12550612 0.614 rs6983885 ENSG00000253616.4 RP11-875O11.3 4.25 3.64e-05 0.0152 0.46 0.33 Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts; chr8:23087574 chr8:23071377~23074488:- PAAD cis rs4713118 0.5 rs9461434 ENSG00000226314.6 ZNF192P1 -4.25 3.65e-05 0.0152 -0.58 -0.33 Parkinson's disease; chr6:28134687 chr6:28161781~28169594:+ PAAD cis rs4794202 0.891 rs2074185 ENSG00000264920.1 RP11-6N17.4 -4.25 3.65e-05 0.0152 -0.48 -0.33 Alzheimer's disease (cognitive decline); chr17:47853218 chr17:47891255~47895812:- PAAD cis rs453301 0.686 rs13252797 ENSG00000253893.2 FAM85B -4.25 3.65e-05 0.0152 -0.44 -0.33 Joint mobility (Beighton score); chr8:9003920 chr8:8167819~8226614:- PAAD cis rs7615952 0.688 rs17334074 ENSG00000239804.1 RP11-379B18.1 -4.25 3.66e-05 0.0152 -0.42 -0.33 Blood pressure (smoking interaction); chr3:125821617 chr3:125787888~125788146:- PAAD cis rs4660214 0.666 rs7414381 ENSG00000237624.1 OXCT2P1 -4.25 3.66e-05 0.0152 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39275848 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs3116387 ENSG00000237624.1 OXCT2P1 -4.25 3.66e-05 0.0152 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39277197 chr1:39514956~39516490:+ PAAD cis rs4660214 0.614 rs1537815 ENSG00000237624.1 OXCT2P1 -4.25 3.66e-05 0.0152 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39278946 chr1:39514956~39516490:+ PAAD cis rs4660214 0.789 rs1984142 ENSG00000237624.1 OXCT2P1 -4.25 3.66e-05 0.0152 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39279936 chr1:39514956~39516490:+ PAAD cis rs847577 0.609 rs7791463 ENSG00000272950.1 RP11-307C18.1 4.25 3.66e-05 0.0152 0.41 0.33 Breast cancer; chr7:98189735 chr7:98322853~98323430:+ PAAD cis rs847577 0.609 rs11765552 ENSG00000272950.1 RP11-307C18.1 4.25 3.66e-05 0.0152 0.41 0.33 Breast cancer; chr7:98192803 chr7:98322853~98323430:+ PAAD cis rs847577 0.63 rs3801294 ENSG00000272950.1 RP11-307C18.1 4.25 3.66e-05 0.0152 0.41 0.33 Breast cancer; chr7:98192898 chr7:98322853~98323430:+ PAAD cis rs847577 0.63 rs11764933 ENSG00000272950.1 RP11-307C18.1 4.25 3.66e-05 0.0152 0.41 0.33 Breast cancer; chr7:98195876 chr7:98322853~98323430:+ PAAD cis rs847577 0.63 rs2132276 ENSG00000272950.1 RP11-307C18.1 4.25 3.66e-05 0.0152 0.41 0.33 Breast cancer; chr7:98197028 chr7:98322853~98323430:+ PAAD cis rs2283792 0.905 rs5755694 ENSG00000228050.1 TOP3BP1 4.25 3.66e-05 0.0153 0.35 0.33 Multiple sclerosis; chr22:21846241 chr22:22223187~22224566:- PAAD cis rs710913 0.717 rs2243761 ENSG00000243970.1 PPIEL -4.25 3.67e-05 0.0153 -0.28 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39585944 chr1:39531838~39558707:- PAAD cis rs875971 1 rs11971949 ENSG00000232559.3 GS1-124K5.12 -4.25 3.67e-05 0.0153 -0.35 -0.33 Aortic root size; chr7:66161027 chr7:66554588~66576923:- PAAD cis rs875971 1 rs11974264 ENSG00000232559.3 GS1-124K5.12 -4.25 3.67e-05 0.0153 -0.35 -0.33 Aortic root size; chr7:66182595 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1540651 ENSG00000232559.3 GS1-124K5.12 -4.25 3.67e-05 0.0153 -0.35 -0.33 Aortic root size; chr7:66185134 chr7:66554588~66576923:- PAAD cis rs875971 0.898 rs6977501 ENSG00000232559.3 GS1-124K5.12 -4.25 3.67e-05 0.0153 -0.35 -0.33 Aortic root size; chr7:66228355 chr7:66554588~66576923:- PAAD cis rs875971 0.965 rs6971509 ENSG00000232559.3 GS1-124K5.12 -4.25 3.67e-05 0.0153 -0.35 -0.33 Aortic root size; chr7:66249983 chr7:66554588~66576923:- PAAD cis rs74233809 1 rs3740390 ENSG00000213277.3 MARCKSL1P1 4.25 3.67e-05 0.0153 0.6 0.33 Birth weight; chr10:102878723 chr10:103175554~103176094:+ PAAD cis rs7615952 0.736 rs11921945 ENSG00000241288.6 RP11-379B18.5 -4.25 3.67e-05 0.0153 -0.35 -0.33 Blood pressure (smoking interaction); chr3:125924876 chr3:125827238~125916384:- PAAD cis rs12439619 0.693 rs7165536 ENSG00000255769.6 GOLGA2P10 -4.25 3.67e-05 0.0153 -0.4 -0.33 Intelligence (multi-trait analysis); chr15:82273743 chr15:82472993~82513950:- PAAD cis rs2255336 0.671 rs7301582 ENSG00000245648.1 RP11-277P12.20 -4.25 3.67e-05 0.0153 -0.47 -0.33 Blood protein levels; chr12:10449091 chr12:10363769~10398506:+ PAAD cis rs6570726 0.934 rs9484995 ENSG00000235652.6 RP11-545I5.3 -4.25 3.68e-05 0.0153 -0.27 -0.33 Lobe attachment (rater-scored or self-reported); chr6:145459978 chr6:145799409~145886585:+ PAAD cis rs7078219 0.965 rs11190126 ENSG00000257582.4 LINC01475 -4.25 3.68e-05 0.0153 -0.35 -0.33 Dental caries; chr10:99512032 chr10:99526350~99531177:- PAAD cis rs9652601 0.779 rs7186106 ENSG00000274038.1 RP11-66H6.4 -4.25 3.68e-05 0.0153 -0.35 -0.33 Systemic lupus erythematosus; chr16:11116974 chr16:11056556~11057034:+ PAAD cis rs897984 0.806 rs8052245 ENSG00000260911.2 RP11-196G11.2 -4.25 3.68e-05 0.0153 -0.29 -0.33 Dementia with Lewy bodies; chr16:30905109 chr16:31043150~31049868:+ PAAD cis rs4664293 0.667 rs3815876 ENSG00000226266.5 AC009961.3 -4.25 3.68e-05 0.0153 -0.4 -0.33 Monocyte percentage of white cells; chr2:159783640 chr2:159670708~159712435:- PAAD cis rs7829975 0.755 rs3789849 ENSG00000254340.1 RP11-10A14.3 4.25 3.68e-05 0.0153 0.39 0.33 Mood instability; chr8:8829544 chr8:9141424~9145435:+ PAAD cis rs9926296 0.607 rs11076629 ENSG00000260259.1 RP11-368I7.4 -4.25 3.68e-05 0.0153 -0.38 -0.33 Vitiligo; chr16:89808851 chr16:89682620~89686569:- PAAD cis rs987724 0.515 rs344087 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156842608 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs4680309 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156865807 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs2874488 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156868027 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs6765353 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156868755 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs7638330 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156869976 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs6441101 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156875409 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs9870137 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156898867 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs1574980 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156917639 chr3:156747346~156817062:- PAAD cis rs987724 0.501 rs2321293 ENSG00000240875.4 LINC00886 -4.25 3.68e-05 0.0153 -0.48 -0.33 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156931311 chr3:156747346~156817062:- PAAD cis rs875971 0.8 rs427557 ENSG00000237310.1 GS1-124K5.4 4.25 3.69e-05 0.0153 0.31 0.33 Aortic root size; chr7:66054263 chr7:66493706~66495474:+ PAAD cis rs875971 0.83 rs587360 ENSG00000237310.1 GS1-124K5.4 4.25 3.69e-05 0.0153 0.31 0.33 Aortic root size; chr7:66057711 chr7:66493706~66495474:+ PAAD cis rs2985684 1 rs2147712 ENSG00000259113.1 RP11-406H23.2 -4.25 3.69e-05 0.0153 -0.47 -0.33 Carotid intima media thickness; chr14:49624966 chr14:50448807~50456742:+ PAAD cis rs2985684 0.779 rs12160 ENSG00000259113.1 RP11-406H23.2 -4.25 3.69e-05 0.0153 -0.47 -0.33 Carotid intima media thickness; chr14:49625214 chr14:50448807~50456742:+ PAAD cis rs875971 1 rs709595 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66352346 chr7:66554588~66576923:- PAAD cis rs875971 1 rs811880 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66353659 chr7:66554588~66576923:- PAAD cis rs875971 1 rs778726 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66363744 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs778723 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66364510 chr7:66554588~66576923:- PAAD cis rs875971 0.767 rs1695815 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66366357 chr7:66554588~66576923:- PAAD cis rs875971 1 rs778685 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66371189 chr7:66554588~66576923:- PAAD cis rs875971 0.929 rs778682 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66372947 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs11765965 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66377234 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs1643388 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66379575 chr7:66554588~66576923:- PAAD cis rs875971 1 rs778722 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66379841 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs778721 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66380410 chr7:66554588~66576923:- PAAD cis rs875971 0.929 rs778712 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66384991 chr7:66554588~66576923:- PAAD cis rs875971 1 rs778710 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66389847 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs778708 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66391332 chr7:66554588~66576923:- PAAD cis rs875971 1 rs778706 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66395437 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs778700 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66401463 chr7:66554588~66576923:- PAAD cis rs875971 1 rs778699 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66403303 chr7:66554588~66576923:- PAAD cis rs875971 1 rs778696 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66405826 chr7:66554588~66576923:- PAAD cis rs875971 1 rs778694 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66406571 chr7:66554588~66576923:- PAAD cis rs875971 0.929 rs778692 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66407462 chr7:66554588~66576923:- PAAD cis rs875971 1 rs4718343 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66409301 chr7:66554588~66576923:- PAAD cis rs875971 1 rs4718344 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66409394 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1968225 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66409786 chr7:66554588~66576923:- PAAD cis rs875971 0.737 rs7803424 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66415618 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs7799834 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66415707 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6460295 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66417741 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs6978721 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66418217 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs3857684 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66473171 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs6978429 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66494889 chr7:66554588~66576923:- PAAD cis rs875971 1 rs4718357 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66495891 chr7:66554588~66576923:- PAAD cis rs875971 0.929 rs12535036 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66499076 chr7:66554588~66576923:- PAAD cis rs875971 1 rs12533997 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66500390 chr7:66554588~66576923:- PAAD cis rs875971 1 rs12532998 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66502472 chr7:66554588~66576923:- PAAD cis rs875971 1 rs12698523 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66503126 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6970030 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66503692 chr7:66554588~66576923:- PAAD cis rs875971 0.928 rs6970357 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66503891 chr7:66554588~66576923:- PAAD cis rs875971 1 rs3735148 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66506022 chr7:66554588~66576923:- PAAD cis rs875971 0.929 rs10950041 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66508888 chr7:66554588~66576923:- PAAD cis rs875971 0.929 rs6970860 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66511647 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6957199 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66513532 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6958271 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66514344 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6958277 ENSG00000232559.3 GS1-124K5.12 4.25 3.69e-05 0.0153 0.34 0.33 Aortic root size; chr7:66514362 chr7:66554588~66576923:- PAAD cis rs875971 0.965 rs10267430 ENSG00000232559.3 GS1-124K5.12 -4.25 3.69e-05 0.0153 -0.34 -0.33 Aortic root size; chr7:66278036 chr7:66554588~66576923:- PAAD cis rs875971 1 rs10257427 ENSG00000232559.3 GS1-124K5.12 -4.25 3.69e-05 0.0153 -0.34 -0.33 Aortic root size; chr7:66278221 chr7:66554588~66576923:- PAAD cis rs875971 1 rs10215948 ENSG00000232559.3 GS1-124K5.12 -4.25 3.69e-05 0.0153 -0.34 -0.33 Aortic root size; chr7:66282799 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs55748098 ENSG00000232559.3 GS1-124K5.12 -4.25 3.69e-05 0.0153 -0.34 -0.33 Aortic root size; chr7:66298631 chr7:66554588~66576923:- PAAD cis rs875971 0.965 rs9969301 ENSG00000232559.3 GS1-124K5.12 -4.25 3.69e-05 0.0153 -0.34 -0.33 Aortic root size; chr7:66316668 chr7:66554588~66576923:- PAAD cis rs875971 0.867 rs1002053 ENSG00000232559.3 GS1-124K5.12 -4.25 3.69e-05 0.0153 -0.34 -0.33 Aortic root size; chr7:66333558 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6460292 ENSG00000232559.3 GS1-124K5.12 -4.25 3.69e-05 0.0153 -0.34 -0.33 Aortic root size; chr7:66345088 chr7:66554588~66576923:- PAAD cis rs858239 0.601 rs6461702 ENSG00000226816.2 AC005082.12 4.25 3.69e-05 0.0153 0.38 0.33 Cerebrospinal fluid biomarker levels; chr7:23209654 chr7:23206013~23208045:+ PAAD cis rs7120173 0.779 rs7103842 ENSG00000254851.1 RP11-109L13.1 -4.25 3.69e-05 0.0153 -0.5 -0.33 Visceral adipose tissue adjusted for BMI; chr11:117087312 chr11:117135528~117138582:+ PAAD cis rs7078219 0.965 rs7081858 ENSG00000257582.4 LINC01475 -4.25 3.69e-05 0.0153 -0.35 -0.33 Dental caries; chr10:99514808 chr10:99526350~99531177:- PAAD cis rs7078219 1 rs11190130 ENSG00000257582.4 LINC01475 -4.25 3.69e-05 0.0153 -0.35 -0.33 Dental caries; chr10:99515449 chr10:99526350~99531177:- PAAD cis rs7078219 1 rs6584278 ENSG00000257582.4 LINC01475 -4.25 3.69e-05 0.0153 -0.35 -0.33 Dental caries; chr10:99518342 chr10:99526350~99531177:- PAAD cis rs7772486 0.875 rs2777482 ENSG00000235652.6 RP11-545I5.3 4.25 3.69e-05 0.0153 0.26 0.33 Lobe attachment (rater-scored or self-reported); chr6:145999205 chr6:145799409~145886585:+ PAAD cis rs3096299 0.967 rs753852 ENSG00000274627.1 RP11-104N10.2 4.25 3.69e-05 0.0153 0.29 0.33 Multiple myeloma (IgH translocation); chr16:89380011 chr16:89516797~89522217:+ PAAD cis rs3096299 0.967 rs753853 ENSG00000274627.1 RP11-104N10.2 4.25 3.69e-05 0.0153 0.29 0.33 Multiple myeloma (IgH translocation); chr16:89380117 chr16:89516797~89522217:+ PAAD cis rs12439619 0.508 rs8023960 ENSG00000255769.6 GOLGA2P10 -4.25 3.69e-05 0.0153 -0.34 -0.33 Intelligence (multi-trait analysis); chr15:82206704 chr15:82472993~82513950:- PAAD cis rs11155671 0.546 rs1999633 ENSG00000268592.3 RAET1E-AS1 4.25 3.69e-05 0.0153 0.42 0.33 Testicular germ cell tumor; chr6:149866576 chr6:149863494~149919507:+ PAAD cis rs17684571 0.7 rs17752002 ENSG00000231441.1 RP11-472M19.2 4.25 3.69e-05 0.0153 0.6 0.33 Schizophrenia; chr6:56812209 chr6:56844002~56864078:+ PAAD cis rs17684571 0.7 rs4299824 ENSG00000231441.1 RP11-472M19.2 4.25 3.69e-05 0.0153 0.6 0.33 Schizophrenia; chr6:56815697 chr6:56844002~56864078:+ PAAD cis rs17684571 0.7 rs17684802 ENSG00000231441.1 RP11-472M19.2 -4.25 3.69e-05 0.0153 -0.6 -0.33 Schizophrenia; chr6:56813854 chr6:56844002~56864078:+ PAAD cis rs17772222 0.92 rs61975260 ENSG00000258983.2 RP11-507K2.2 4.25 3.7e-05 0.0154 0.46 0.33 Coronary artery calcification; chr14:88429597 chr14:88499334~88515502:+ PAAD cis rs9531006 0.611 rs7336725 ENSG00000227676.3 LINC01068 4.25 3.7e-05 0.0154 0.49 0.33 Sleep duration; chr13:79926494 chr13:79566727~79571436:+ PAAD cis rs10129255 0.5 rs59939897 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106783414 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs6576231 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106783693 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs12101190 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106784149 chr14:106675017~106675544:- PAAD cis rs10129255 0.518 rs8004895 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106785139 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs8004923 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106785926 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs6576232 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106787090 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs10131875 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106792798 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs11628999 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106800208 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs7157975 ENSG00000211972.2 IGHV3-66 4.25 3.7e-05 0.0154 0.25 0.33 Kawasaki disease; chr14:106804049 chr14:106675017~106675544:- PAAD cis rs1707322 0.686 rs1541131 ENSG00000280836.1 AL355480.1 4.25 3.7e-05 0.0154 0.39 0.33 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45619262 chr1:45581219~45581321:- PAAD cis rs9926296 0.656 rs2376884 ENSG00000260259.1 RP11-368I7.4 -4.25 3.7e-05 0.0154 -0.38 -0.33 Vitiligo; chr16:89760514 chr16:89682620~89686569:- PAAD cis rs9926296 0.656 rs2376883 ENSG00000260259.1 RP11-368I7.4 -4.25 3.7e-05 0.0154 -0.38 -0.33 Vitiligo; chr16:89760518 chr16:89682620~89686569:- PAAD cis rs6683071 0.557 rs4240934 ENSG00000272750.1 RP11-378J18.8 4.25 3.7e-05 0.0154 0.46 0.33 Cognitive performance; chr1:222730956 chr1:222658867~222661512:- PAAD cis rs797680 0.786 rs7525248 ENSG00000223745.6 RP4-717I23.3 4.25 3.71e-05 0.0154 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93362966 chr1:93262186~93346025:- PAAD cis rs797680 0.786 rs4847412 ENSG00000223745.6 RP4-717I23.3 4.25 3.71e-05 0.0154 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93363691 chr1:93262186~93346025:- PAAD cis rs577676 0.524 rs601938 ENSG00000271811.1 RP1-79C4.4 4.25 3.71e-05 0.0154 0.35 0.33 Prevalent atrial fibrillation; chr1:170661118 chr1:170667381~170669425:+ PAAD cis rs1862618 0.853 rs252902 ENSG00000271828.1 CTD-2310F14.1 4.25 3.71e-05 0.0154 0.48 0.33 Initial pursuit acceleration; chr5:56820258 chr5:56927874~56929573:+ PAAD cis rs13178541 0.542 rs11748092 ENSG00000250378.1 RP11-119J18.1 -4.25 3.71e-05 0.0154 -0.47 -0.33 IgG glycosylation; chr5:135789035 chr5:135812667~135826582:+ PAAD cis rs2041895 0.527 rs10861678 ENSG00000260329.1 RP11-412D9.4 -4.25 3.71e-05 0.0154 -0.31 -0.33 Glaucoma (low intraocular pressure); chr12:106925883 chr12:106954029~106955497:- PAAD cis rs1862618 0.853 rs11739344 ENSG00000271828.1 CTD-2310F14.1 4.25 3.71e-05 0.0154 0.49 0.33 Initial pursuit acceleration; chr5:56815260 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs252909 ENSG00000271828.1 CTD-2310F14.1 4.25 3.71e-05 0.0154 0.49 0.33 Initial pursuit acceleration; chr5:56825304 chr5:56927874~56929573:+ PAAD cis rs1862618 0.853 rs252919 ENSG00000271828.1 CTD-2310F14.1 4.25 3.71e-05 0.0154 0.49 0.33 Initial pursuit acceleration; chr5:56828284 chr5:56927874~56929573:+ PAAD cis rs10740039 0.729 rs6479728 ENSG00000254271.1 RP11-131N11.4 -4.25 3.71e-05 0.0154 -0.39 -0.33 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60731043 chr10:60734342~60741828:+ PAAD cis rs7759001 0.681 rs6918131 ENSG00000271755.1 RP1-153G14.4 4.25 3.71e-05 0.0154 0.39 0.33 Glomerular filtration rate (creatinine); chr6:27513138 chr6:27404010~27406964:- PAAD cis rs7759001 0.681 rs7776338 ENSG00000271755.1 RP1-153G14.4 4.25 3.71e-05 0.0154 0.39 0.33 Glomerular filtration rate (creatinine); chr6:27513892 chr6:27404010~27406964:- PAAD cis rs17772222 1 rs74071851 ENSG00000258983.2 RP11-507K2.2 4.25 3.72e-05 0.0154 0.45 0.33 Coronary artery calcification; chr14:88415858 chr14:88499334~88515502:+ PAAD cis rs7772486 0.712 rs6570726 ENSG00000235652.6 RP11-545I5.3 4.25 3.72e-05 0.0154 0.27 0.33 Lobe attachment (rater-scored or self-reported); chr6:145838324 chr6:145799409~145886585:+ PAAD cis rs896655 0.541 rs7023329 ENSG00000266446.1 RP11-149I2.4 -4.25 3.72e-05 0.0154 -0.4 -0.33 Coronary artery disease; chr9:21816529 chr9:21995482~21996013:+ PAAD cis rs748404 0.646 rs2253268 ENSG00000205771.5 CATSPER2P1 -4.25 3.72e-05 0.0154 -0.46 -0.33 Lung cancer; chr15:43508770 chr15:43726918~43747094:- PAAD cis rs950880 0.71 rs2287035 ENSG00000234389.1 AC007278.3 -4.25 3.72e-05 0.0154 -0.34 -0.33 Serum protein levels (sST2); chr2:102394070 chr2:102438713~102440475:+ PAAD cis rs891378 0.837 rs11120688 ENSG00000274245.1 RP11-357P18.2 4.25 3.72e-05 0.0154 0.45 0.33 Spherical equivalent (joint analysis main effects and education interaction); chr1:207312770 chr1:207372559~207373252:+ PAAD cis rs720064 0.555 rs7244601 ENSG00000264745.1 TTC39C-AS1 4.25 3.73e-05 0.0155 0.42 0.33 Strep throat; chr18:23929704 chr18:23994213~24015339:- PAAD cis rs28386778 0.897 rs2584617 ENSG00000240280.5 TCAM1P -4.25 3.73e-05 0.0155 -0.46 -0.33 Prudent dietary pattern; chr17:63847938 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584615 ENSG00000240280.5 TCAM1P -4.25 3.73e-05 0.0155 -0.46 -0.33 Prudent dietary pattern; chr17:63850414 chr17:63849292~63864379:+ PAAD cis rs875971 0.642 rs35526611 ENSG00000237310.1 GS1-124K5.4 -4.25 3.73e-05 0.0155 -0.3 -0.33 Aortic root size; chr7:66629021 chr7:66493706~66495474:+ PAAD cis rs2976388 0.609 rs1469811 ENSG00000253741.1 CTD-2292P10.4 -4.25 3.73e-05 0.0155 -0.38 -0.33 Urinary tract infection frequency; chr8:142706581 chr8:142702252~142726973:- PAAD cis rs11654699 0.84 rs4795712 ENSG00000274341.1 RP11-227G15.10 -4.25 3.73e-05 0.0155 -0.3 -0.33 Neurofibrillary tangles; chr17:32592089 chr17:32408013~32408309:+ PAAD cis rs3781264 0.848 rs10882422 ENSG00000273450.1 RP11-76P2.4 -4.25 3.74e-05 0.0155 -0.43 -0.33 Esophageal cancer and gastric cancer; chr10:94313806 chr10:94314907~94315327:- PAAD cis rs3781264 0.595 rs10786161 ENSG00000273450.1 RP11-76P2.4 4.25 3.74e-05 0.0155 0.43 0.33 Esophageal cancer and gastric cancer; chr10:94347914 chr10:94314907~94315327:- PAAD cis rs3781264 0.595 rs7084988 ENSG00000273450.1 RP11-76P2.4 4.25 3.74e-05 0.0155 0.43 0.33 Esophageal cancer and gastric cancer; chr10:94349085 chr10:94314907~94315327:- PAAD cis rs3781264 0.595 rs7085378 ENSG00000273450.1 RP11-76P2.4 4.25 3.74e-05 0.0155 0.43 0.33 Esophageal cancer and gastric cancer; chr10:94349568 chr10:94314907~94315327:- PAAD cis rs2404602 0.503 rs284909 ENSG00000259422.1 RP11-593F23.1 4.25 3.74e-05 0.0155 0.37 0.33 Blood metabolite levels; chr15:76444287 chr15:76174891~76181486:- PAAD cis rs9876781 0.624 rs12491849 ENSG00000229759.1 MRPS18AP1 4.25 3.75e-05 0.0155 0.37 0.33 Longevity; chr3:48489975 chr3:48256350~48256938:- PAAD cis rs889398 0.741 rs11075744 ENSG00000226232.7 RP11-419C5.2 -4.25 3.75e-05 0.0155 -0.26 -0.33 Body mass index; chr16:69875212 chr16:69976388~69996188:- PAAD cis rs2243480 1 rs13247184 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65893941 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs35283677 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65894246 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs35421653 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65898442 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs73142162 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65909309 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs73142166 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65910845 chr7:66848496~66858136:+ PAAD cis rs2243480 0.908 rs55876148 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65914813 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs56016656 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65918494 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs56291018 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65925352 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs36033484 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65925571 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34193460 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65928123 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34560516 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65939105 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs57057549 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65940751 chr7:66848496~66858136:+ PAAD cis rs2243480 0.808 rs12698508 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65946971 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2961102 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65959671 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34970380 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65966506 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs73148097 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65966800 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs906134 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65979301 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs73150014 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:65985932 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1723270 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:66004843 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1723269 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:66007799 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs781150 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:66015986 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs313798 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:66028044 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs35396113 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:66030474 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs313809 ENSG00000232546.1 RP11-458F8.1 -4.25 3.75e-05 0.0155 -0.39 -0.33 Diabetic kidney disease; chr7:66034996 chr7:66848496~66858136:+ PAAD cis rs6743226 0.521 rs12474449 ENSG00000266621.1 AC104841.1 4.25 3.75e-05 0.0155 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241279274 chr2:241245202~241245299:- PAAD cis rs6743226 0.519 rs12475374 ENSG00000266621.1 AC104841.1 4.25 3.75e-05 0.0155 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241279347 chr2:241245202~241245299:- PAAD cis rs6743226 0.59 rs6733962 ENSG00000266621.1 AC104841.1 4.25 3.75e-05 0.0155 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241280254 chr2:241245202~241245299:- PAAD cis rs6743226 0.566 rs59065053 ENSG00000266621.1 AC104841.1 4.25 3.75e-05 0.0155 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241281151 chr2:241245202~241245299:- PAAD cis rs6743226 0.566 rs34006413 ENSG00000266621.1 AC104841.1 4.25 3.75e-05 0.0155 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241282044 chr2:241245202~241245299:- PAAD cis rs6743226 0.566 rs6724257 ENSG00000266621.1 AC104841.1 4.25 3.75e-05 0.0155 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241282982 chr2:241245202~241245299:- PAAD cis rs6743226 0.542 rs62186397 ENSG00000266621.1 AC104841.1 4.25 3.75e-05 0.0155 0.39 0.33 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241284497 chr2:241245202~241245299:- PAAD cis rs13217239 0.646 rs11756275 ENSG00000241549.7 GUSBP2 -4.25 3.75e-05 0.0155 -0.33 -0.33 Schizophrenia; chr6:27039334 chr6:26871484~26956554:- PAAD cis rs4853012 0.838 rs4452177 ENSG00000257800.1 FNBP1P1 4.25 3.75e-05 0.0155 0.45 0.33 Gestational age at birth (maternal effect); chr2:74118079 chr2:74120680~74123218:+ PAAD cis rs4853012 0.838 rs60705299 ENSG00000257800.1 FNBP1P1 4.25 3.75e-05 0.0155 0.45 0.33 Gestational age at birth (maternal effect); chr2:74118243 chr2:74120680~74123218:+ PAAD cis rs12908161 1 rs11638290 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84684405 chr15:84570649~84580175:+ PAAD cis rs12908161 0.959 rs34028043 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84688354 chr15:84570649~84580175:+ PAAD cis rs12908161 0.959 rs34784022 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84688675 chr15:84570649~84580175:+ PAAD cis rs12908161 0.959 rs12908699 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84697172 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs35316992 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84704902 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs4643294 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84707022 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs62021219 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84712928 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs34900908 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84714368 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs35524990 ENSG00000259728.4 LINC00933 4.25 3.75e-05 0.0155 0.41 0.33 Schizophrenia; chr15:84714972 chr15:84570649~84580175:+ PAAD cis rs11089937 1 rs6001121 ENSG00000211639.2 IGLV4-60 4.25 3.76e-05 0.0155 0.3 0.33 Periodontitis (PAL4Q3); chr22:22149505 chr22:22162199~22162681:+ PAAD cis rs7617773 0.817 rs13094727 ENSG00000228638.1 FCF1P2 -4.25 3.76e-05 0.0155 -0.36 -0.33 Coronary artery disease; chr3:48281999 chr3:48290793~48291375:- PAAD cis rs780096 0.546 rs4425043 ENSG00000234072.1 AC074117.10 -4.25 3.76e-05 0.0156 -0.25 -0.33 Total body bone mineral density; chr2:27510585 chr2:27356246~27367622:+ PAAD cis rs780096 0.527 rs12471703 ENSG00000234072.1 AC074117.10 -4.25 3.76e-05 0.0156 -0.25 -0.33 Total body bone mineral density; chr2:27515987 chr2:27356246~27367622:+ PAAD cis rs9549328 0.756 rs2993291 ENSG00000267868.1 RP11-120K24.3 4.25 3.76e-05 0.0156 0.36 0.33 Systolic blood pressure; chr13:112999532 chr13:112964835~112966131:- PAAD cis rs8072100 1 rs11870935 ENSG00000228782.6 CTD-2026D20.3 -4.25 3.77e-05 0.0156 -0.32 -0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47655239 chr17:47450568~47492492:- PAAD cis rs7572733 0.534 rs4850813 ENSG00000231621.1 AC013264.2 4.25 3.77e-05 0.0156 0.33 0.33 Dermatomyositis; chr2:197911258 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs10931794 ENSG00000231621.1 AC013264.2 4.25 3.77e-05 0.0156 0.33 0.33 Dermatomyositis; chr2:197911416 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs2341778 ENSG00000231621.1 AC013264.2 4.25 3.77e-05 0.0156 0.33 0.33 Dermatomyositis; chr2:197911822 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1401095 ENSG00000231621.1 AC013264.2 4.25 3.77e-05 0.0156 0.33 0.33 Dermatomyositis; chr2:197915143 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs10211202 ENSG00000231621.1 AC013264.2 -4.25 3.77e-05 0.0156 -0.33 -0.33 Dermatomyositis; chr2:197907217 chr2:197197991~197199273:+ PAAD cis rs2243480 1 rs160652 ENSG00000232546.1 RP11-458F8.1 -4.25 3.77e-05 0.0156 -0.4 -0.33 Diabetic kidney disease; chr7:66073444 chr7:66848496~66858136:+ PAAD cis rs4713118 0.662 rs464312 ENSG00000226314.6 ZNF192P1 -4.25 3.77e-05 0.0156 -0.53 -0.33 Parkinson's disease; chr6:27999813 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs469228 ENSG00000226314.6 ZNF192P1 -4.25 3.77e-05 0.0156 -0.53 -0.33 Parkinson's disease; chr6:28002926 chr6:28161781~28169594:+ PAAD cis rs4713118 0.54 rs469227 ENSG00000226314.6 ZNF192P1 -4.25 3.77e-05 0.0156 -0.53 -0.33 Parkinson's disease; chr6:28002927 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs149948 ENSG00000226314.6 ZNF192P1 -4.25 3.77e-05 0.0156 -0.53 -0.33 Parkinson's disease; chr6:28007039 chr6:28161781~28169594:+ PAAD cis rs7078219 0.897 rs10883360 ENSG00000257582.4 LINC01475 -4.25 3.77e-05 0.0156 -0.35 -0.33 Dental caries; chr10:99521401 chr10:99526350~99531177:- PAAD cis rs1150668 0.799 rs9301 ENSG00000219891.2 ZSCAN12P1 4.25 3.77e-05 0.0156 0.42 0.33 Pubertal anthropometrics; chr6:28324929 chr6:28091154~28093664:+ PAAD cis rs1150668 0.799 rs853684 ENSG00000219891.2 ZSCAN12P1 4.25 3.77e-05 0.0156 0.42 0.33 Pubertal anthropometrics; chr6:28326773 chr6:28091154~28093664:+ PAAD cis rs9876781 0.62 rs11130168 ENSG00000229759.1 MRPS18AP1 4.25 3.77e-05 0.0156 0.34 0.33 Longevity; chr3:48368010 chr3:48256350~48256938:- PAAD cis rs718314 0.719 rs11048447 ENSG00000255750.4 RP11-283G6.5 4.25 3.77e-05 0.0156 0.41 0.33 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index; chr12:26291164 chr12:26230819~26319720:- PAAD cis rs7615952 0.736 rs13063122 ENSG00000241288.6 RP11-379B18.5 -4.25 3.77e-05 0.0156 -0.35 -0.33 Blood pressure (smoking interaction); chr3:125925017 chr3:125827238~125916384:- PAAD cis rs2278034 0.578 rs881753 ENSG00000271662.1 RP11-141C7.3 4.25 3.77e-05 0.0156 0.36 0.33 Bronchopulmonary dysplasia; chr3:195879899 chr3:195650146~195651472:- PAAD cis rs11976180 1 rs1320894 ENSG00000273234.1 OR2A13P -4.25 3.78e-05 0.0156 -0.4 -0.33 Obesity-related traits; chr7:144054709 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2951369 ENSG00000273234.1 OR2A13P -4.25 3.78e-05 0.0156 -0.4 -0.33 Obesity-related traits; chr7:144055545 chr7:144142009~144142938:+ PAAD cis rs79040073 0.593 rs11632038 ENSG00000259531.2 RP11-295H24.3 4.25 3.78e-05 0.0156 0.55 0.33 Lung cancer in ever smokers; chr15:49314101 chr15:49365124~49366685:- PAAD cis rs2117029 1 rs10783299 ENSG00000258017.1 RP11-386G11.10 -4.25 3.78e-05 0.0156 -0.43 -0.33 Intelligence (multi-trait analysis); chr12:48996894 chr12:49127782~49147869:+ PAAD cis rs7078219 1 rs7078219 ENSG00000257582.4 LINC01475 4.25 3.78e-05 0.0156 0.35 0.33 Dental caries; chr10:99514608 chr10:99526350~99531177:- PAAD cis rs4453827 1 rs11719179 ENSG00000271916.1 RP11-884K10.6 4.25 3.78e-05 0.0156 0.36 0.33 Blood protein levels; chr3:53725694 chr3:53797764~53798019:- PAAD cis rs42490 0.7 rs40250 ENSG00000251136.7 RP11-37B2.1 -4.25 3.78e-05 0.0156 -0.31 -0.33 Leprosy; chr8:89828779 chr8:89609409~89757727:- PAAD cis rs42490 0.7 rs419890 ENSG00000251136.7 RP11-37B2.1 -4.25 3.78e-05 0.0156 -0.31 -0.33 Leprosy; chr8:89829012 chr8:89609409~89757727:- PAAD cis rs7617773 0.743 rs6804986 ENSG00000228638.1 FCF1P2 -4.25 3.78e-05 0.0156 -0.37 -0.33 Coronary artery disease; chr3:48322105 chr3:48290793~48291375:- PAAD cis rs7617773 0.815 rs9825637 ENSG00000228638.1 FCF1P2 -4.25 3.78e-05 0.0156 -0.37 -0.33 Coronary artery disease; chr3:48330792 chr3:48290793~48291375:- PAAD cis rs7260598 0.792 rs17620029 ENSG00000268442.1 CTD-2027I19.2 4.25 3.79e-05 0.0156 0.52 0.33 Response to taxane treatment (placlitaxel); chr19:24171510 chr19:24162370~24163425:- PAAD cis rs8072100 1 rs4375701 ENSG00000228782.6 CTD-2026D20.3 4.25 3.79e-05 0.0156 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47634852 chr17:47450568~47492492:- PAAD cis rs5742933 0.597 rs7568449 ENSG00000253559.1 OSGEPL1-AS1 4.24 3.79e-05 0.0157 0.35 0.33 Ferritin levels; chr2:189656328 chr2:189762704~189765556:+ PAAD cis rs7615952 0.8 rs2062773 ENSG00000241288.6 RP11-379B18.5 -4.24 3.79e-05 0.0157 -0.34 -0.33 Blood pressure (smoking interaction); chr3:125920805 chr3:125827238~125916384:- PAAD cis rs7615952 0.799 rs13315434 ENSG00000241288.6 RP11-379B18.5 -4.24 3.79e-05 0.0157 -0.34 -0.33 Blood pressure (smoking interaction); chr3:125922551 chr3:125827238~125916384:- PAAD cis rs7615952 0.866 rs13063119 ENSG00000241288.6 RP11-379B18.5 -4.24 3.79e-05 0.0157 -0.34 -0.33 Blood pressure (smoking interaction); chr3:125925004 chr3:125827238~125916384:- PAAD cis rs2581828 0.646 rs3796351 ENSG00000242142.1 SERBP1P3 4.24 3.79e-05 0.0157 0.41 0.33 Crohn's disease; chr3:53122049 chr3:53064283~53065091:- PAAD cis rs9926296 0.632 rs4785590 ENSG00000260259.1 RP11-368I7.4 4.24 3.79e-05 0.0157 0.38 0.33 Vitiligo; chr16:89723759 chr16:89682620~89686569:- PAAD cis rs10540 1 rs12417570 ENSG00000255237.1 RP13-317D12.3 4.24 3.8e-05 0.0157 0.51 0.33 Body mass index; chr11:462684 chr11:462930~463899:- PAAD cis rs8177376 0.906 rs240559 ENSG00000254905.1 RP11-712L6.7 4.24 3.8e-05 0.0157 0.44 0.33 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126321217 chr11:126292922~126294254:- PAAD cis rs2505998 0.719 rs10900296 ENSG00000273008.1 RP11-351D16.3 -4.24 3.8e-05 0.0157 -0.28 -0.33 Hirschsprung disease; chr10:43077059 chr10:43136824~43138334:- PAAD cis rs5758511 0.633 rs5758689 ENSG00000226450.2 CYP2D8P 4.24 3.8e-05 0.0157 0.33 0.33 Birth weight; chr22:42268966 chr22:42149886~42155001:- PAAD cis rs718314 0.719 rs11048447 ENSG00000256234.1 RP11-283G6.4 4.24 3.8e-05 0.0157 0.37 0.33 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index; chr12:26291164 chr12:26211164~26335856:- PAAD cis rs875971 0.83 rs427575 ENSG00000237310.1 GS1-124K5.4 4.24 3.8e-05 0.0157 0.31 0.33 Aortic root size; chr7:66054232 chr7:66493706~66495474:+ PAAD cis rs5742933 0.557 rs6756571 ENSG00000253559.1 OSGEPL1-AS1 4.24 3.81e-05 0.0157 0.35 0.33 Ferritin levels; chr2:189640971 chr2:189762704~189765556:+ PAAD cis rs28386778 0.829 rs1877317 ENSG00000240280.5 TCAM1P -4.24 3.81e-05 0.0157 -0.46 -0.33 Prudent dietary pattern; chr17:63699119 chr17:63849292~63864379:+ PAAD cis rs9487094 0.813 rs12528712 ENSG00000260273.1 RP11-425D10.10 4.24 3.81e-05 0.0157 0.45 0.33 Height; chr6:109339681 chr6:109382795~109383666:+ PAAD cis rs9326248 0.581 rs10892053 ENSG00000280143.1 AP000892.6 4.24 3.81e-05 0.0157 0.36 0.33 Blood protein levels; chr11:116986287 chr11:117204967~117210292:+ PAAD cis rs8072100 0.905 rs9895274 ENSG00000228782.6 CTD-2026D20.3 4.24 3.82e-05 0.0157 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47461751 chr17:47450568~47492492:- PAAD cis rs12908161 1 rs60957376 ENSG00000259728.4 LINC00933 4.24 3.82e-05 0.0157 0.41 0.33 Schizophrenia; chr15:84737561 chr15:84570649~84580175:+ PAAD cis rs7674212 1 rs7691873 ENSG00000246560.2 RP11-10L12.4 -4.24 3.82e-05 0.0157 -0.35 -0.33 Type 2 diabetes; chr4:103066742 chr4:102828055~102844075:+ PAAD cis rs12908161 1 rs11632465 ENSG00000259728.4 LINC00933 4.24 3.82e-05 0.0157 0.41 0.33 Schizophrenia; chr15:84738814 chr15:84570649~84580175:+ PAAD cis rs812925 0.502 rs778150 ENSG00000273302.1 RP11-493E12.2 -4.24 3.82e-05 0.0158 -0.28 -0.33 Immature fraction of reticulocytes; chr2:61381237 chr2:61199979~61200769:+ PAAD cis rs6479901 0.841 rs10761721 ENSG00000232075.1 MRPL35P2 -4.24 3.82e-05 0.0158 -0.47 -0.33 Intelligence (multi-trait analysis); chr10:63178644 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs3211105 ENSG00000232075.1 MRPL35P2 -4.24 3.82e-05 0.0158 -0.47 -0.33 Intelligence (multi-trait analysis); chr10:63185604 chr10:63634317~63634827:- PAAD cis rs6479901 0.841 rs10822148 ENSG00000232075.1 MRPL35P2 -4.24 3.82e-05 0.0158 -0.47 -0.33 Intelligence (multi-trait analysis); chr10:63219487 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs10761728 ENSG00000232075.1 MRPL35P2 -4.24 3.82e-05 0.0158 -0.47 -0.33 Intelligence (multi-trait analysis); chr10:63235808 chr10:63634317~63634827:- PAAD cis rs4355801 0.558 rs3103970 ENSG00000281641.1 SAMD12-AS1 -4.24 3.82e-05 0.0158 -0.33 -0.33 Bone mineral density; chr8:118847519 chr8:118621001~118858218:+ PAAD cis rs6479891 0.908 rs16918638 ENSG00000232075.1 MRPL35P2 4.24 3.82e-05 0.0158 0.55 0.33 Arthritis (juvenile idiopathic); chr10:63583371 chr10:63634317~63634827:- PAAD cis rs17772222 0.63 rs2778936 ENSG00000258983.2 RP11-507K2.2 -4.24 3.82e-05 0.0158 -0.39 -0.33 Coronary artery calcification; chr14:88505959 chr14:88499334~88515502:+ PAAD cis rs2115630 1 rs11854313 ENSG00000225151.9 GOLGA2P7 4.24 3.82e-05 0.0158 0.39 0.33 P wave terminal force; chr15:84760817 chr15:84199311~84230136:- PAAD cis rs6479901 0.895 rs10733788 ENSG00000232075.1 MRPL35P2 -4.24 3.82e-05 0.0158 -0.47 -0.33 Intelligence (multi-trait analysis); chr10:63158105 chr10:63634317~63634827:- PAAD cis rs7592578 0.766 rs12472081 ENSG00000231858.4 AC067945.4 -4.24 3.83e-05 0.0158 -0.39 -0.33 Diastolic blood pressure; chr2:190533819 chr2:191021526~191032314:+ PAAD cis rs8072100 0.817 rs9892497 ENSG00000228782.6 CTD-2026D20.3 4.24 3.83e-05 0.0158 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47468553 chr17:47450568~47492492:- PAAD cis rs8072100 0.817 rs9905581 ENSG00000228782.6 CTD-2026D20.3 4.24 3.83e-05 0.0158 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469819 chr17:47450568~47492492:- PAAD cis rs8072100 0.817 rs12449647 ENSG00000228782.6 CTD-2026D20.3 4.24 3.83e-05 0.0158 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47471592 chr17:47450568~47492492:- PAAD cis rs8072100 0.748 rs9908016 ENSG00000228782.6 CTD-2026D20.3 4.24 3.83e-05 0.0158 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47473995 chr17:47450568~47492492:- PAAD cis rs8072100 0.782 rs28507314 ENSG00000228782.6 CTD-2026D20.3 4.24 3.83e-05 0.0158 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47474036 chr17:47450568~47492492:- PAAD cis rs8072100 0.748 rs9912592 ENSG00000228782.6 CTD-2026D20.3 4.24 3.83e-05 0.0158 0.32 0.33 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47479579 chr17:47450568~47492492:- PAAD cis rs7617773 0.779 rs11718329 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48268338 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs6442111 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48270570 chr3:48290793~48291375:- PAAD cis rs7617773 0.851 rs6775179 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48271928 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs6800492 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48282400 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs9818937 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48283791 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs6801801 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48284943 chr3:48290793~48291375:- PAAD cis rs7617773 0.779 rs9833309 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48285960 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs9853804 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48286239 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs9834095 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48286261 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs4131361 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48287322 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs4131362 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48287546 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs6791930 ENSG00000228638.1 FCF1P2 -4.24 3.83e-05 0.0158 -0.37 -0.33 Coronary artery disease; chr3:48288410 chr3:48290793~48291375:- PAAD cis rs613391 0.522 rs7043015 ENSG00000224549.1 RP11-370B11.3 -4.24 3.83e-05 0.0158 -0.39 -0.33 Quantitative traits; chr9:22729025 chr9:22767175~22768316:+ PAAD cis rs613391 0.522 rs1992926 ENSG00000224549.1 RP11-370B11.3 -4.24 3.83e-05 0.0158 -0.39 -0.33 Quantitative traits; chr9:22730294 chr9:22767175~22768316:+ PAAD cis rs613391 0.522 rs1667083 ENSG00000224549.1 RP11-370B11.3 -4.24 3.83e-05 0.0158 -0.39 -0.33 Quantitative traits; chr9:22730548 chr9:22767175~22768316:+ PAAD cis rs613391 0.522 rs1470616 ENSG00000224549.1 RP11-370B11.3 -4.24 3.83e-05 0.0158 -0.39 -0.33 Quantitative traits; chr9:22730733 chr9:22767175~22768316:+ PAAD cis rs613391 0.522 rs491563 ENSG00000224549.1 RP11-370B11.3 -4.24 3.83e-05 0.0158 -0.39 -0.33 Quantitative traits; chr9:22730788 chr9:22767175~22768316:+ PAAD cis rs72843506 0.528 rs73981803 ENSG00000189423.10 USP32P3 4.24 3.83e-05 0.0158 0.47 0.33 Schizophrenia; chr17:20088952 chr17:20415547~20431008:+ PAAD cis rs12701220 0.522 rs868833 ENSG00000229043.2 AC091729.9 -4.24 3.83e-05 0.0158 -0.39 -0.33 Bronchopulmonary dysplasia; chr7:1015337 chr7:1160374~1165267:+ PAAD cis rs875971 1 rs1167612 ENSG00000232559.3 GS1-124K5.12 -4.24 3.83e-05 0.0158 -0.34 -0.33 Aortic root size; chr7:66102989 chr7:66554588~66576923:- PAAD cis rs5742933 0.597 rs7568449 ENSG00000273240.1 RP11-455J20.3 4.24 3.83e-05 0.0158 0.4 0.33 Ferritin levels; chr2:189656328 chr2:189763859~189764456:- PAAD cis rs7927592 0.913 rs7106339 ENSG00000212093.1 AP000807.1 4.24 3.83e-05 0.0158 0.39 0.33 Total body bone mineral density; chr11:68472773 chr11:68506083~68506166:- PAAD cis rs2985684 1 rs1957977 ENSG00000259113.1 RP11-406H23.2 -4.24 3.83e-05 0.0158 -0.47 -0.33 Carotid intima media thickness; chr14:49623885 chr14:50448807~50456742:+ PAAD cis rs797680 0.856 rs6685271 ENSG00000223745.6 RP4-717I23.3 4.24 3.83e-05 0.0158 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93169033 chr1:93262186~93346025:- PAAD cis rs4660214 0.568 rs6692769 ENSG00000237624.1 OXCT2P1 -4.24 3.83e-05 0.0158 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39217503 chr1:39514956~39516490:+ PAAD cis rs4660214 0.614 rs11205802 ENSG00000237624.1 OXCT2P1 -4.24 3.83e-05 0.0158 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39233442 chr1:39514956~39516490:+ PAAD cis rs4660214 0.614 rs10888715 ENSG00000237624.1 OXCT2P1 -4.24 3.83e-05 0.0158 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39233572 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs7553009 ENSG00000237624.1 OXCT2P1 -4.24 3.83e-05 0.0158 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39247441 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs10493087 ENSG00000237624.1 OXCT2P1 -4.24 3.83e-05 0.0158 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39251584 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs11205828 ENSG00000237624.1 OXCT2P1 -4.24 3.83e-05 0.0158 -0.43 -0.33 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39253674 chr1:39514956~39516490:+ PAAD cis rs916888 0.773 rs199457 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46267037~46268694:+ PAAD cis rs916888 0.687 rs199456 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46267037~46268694:+ PAAD cis rs916888 0.773 rs199451 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46267037~46268694:+ PAAD cis rs916888 0.773 rs199448 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46267037~46268694:+ PAAD cis rs916888 0.773 rs199445 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46267037~46268694:+ PAAD cis rs916888 0.773 rs199443 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46267037~46268694:+ PAAD cis rs916888 0.773 rs199535 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46267037~46268694:+ PAAD cis rs916888 0.779 rs199528 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs199525 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs70600 ENSG00000261575.2 RP11-259G18.1 4.24 3.84e-05 0.0158 0.49 0.33 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46267037~46268694:+ PAAD cis rs858239 0.738 rs13225593 ENSG00000226816.2 AC005082.12 4.24 3.84e-05 0.0158 0.37 0.33 Cerebrospinal fluid biomarker levels; chr7:23220688 chr7:23206013~23208045:+ PAAD cis rs2337406 1 rs78857163 ENSG00000274576.2 IGHV2-70 -4.24 3.84e-05 0.0158 -0.44 -0.33 Alzheimer's disease (late onset); chr14:106707435 chr14:106770577~106771020:- PAAD cis rs17772222 0.651 rs1950280 ENSG00000258983.2 RP11-507K2.2 -4.24 3.84e-05 0.0158 -0.38 -0.33 Coronary artery calcification; chr14:88366259 chr14:88499334~88515502:+ PAAD cis rs2041895 0.509 rs1838445 ENSG00000260329.1 RP11-412D9.4 -4.24 3.84e-05 0.0158 -0.32 -0.33 Glaucoma (low intraocular pressure); chr12:106920807 chr12:106954029~106955497:- PAAD cis rs7182621 0.639 rs35049216 ENSG00000259363.4 CTD-2054N24.2 -4.24 3.84e-05 0.0158 -0.43 -0.33 Colonoscopy-negative controls vs population controls; chr15:99872562 chr15:99807023~99877148:+ PAAD cis rs7189233 0.513 rs28759393 ENSG00000279344.1 RP11-44F14.7 4.24 3.84e-05 0.0158 0.25 0.33 Intelligence (multi-trait analysis); chr16:53411446 chr16:53478957~53481550:- PAAD cis rs2599510 0.811 rs2243844 ENSG00000276334.1 AL133243.1 4.24 3.84e-05 0.0158 0.39 0.33 Interleukin-18 levels; chr2:32550917 chr2:32521927~32523547:+ PAAD cis rs6479901 0.895 rs9629895 ENSG00000232075.1 MRPL35P2 -4.24 3.84e-05 0.0158 -0.47 -0.33 Intelligence (multi-trait analysis); chr10:63363027 chr10:63634317~63634827:- PAAD cis rs797680 0.897 rs12752223 ENSG00000223745.6 RP4-717I23.3 4.24 3.85e-05 0.0158 0.27 0.33 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93371576 chr1:93262186~93346025:- PAAD cis rs6570726 0.935 rs387965 ENSG00000235652.6 RP11-545I5.3 4.24 3.85e-05 0.0158 0.26 0.33 Lobe attachment (rater-scored or self-reported); chr6:145548230 chr6:145799409~145886585:+ PAAD cis rs1167827 0.68 rs1167800 ENSG00000278416.1 PMS2L2 4.24 3.85e-05 0.0159 0.38 0.33 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75546898 chr7:75344015~75359550:- PAAD cis rs9926296 0.632 rs8048331 ENSG00000260259.1 RP11-368I7.4 4.24 3.85e-05 0.0159 0.38 0.33 Vitiligo; chr16:89726634 chr16:89682620~89686569:- PAAD cis rs7617773 0.817 rs9830016 ENSG00000228638.1 FCF1P2 -4.24 3.85e-05 0.0159 -0.37 -0.33 Coronary artery disease; chr3:48241004 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs9847953 ENSG00000228638.1 FCF1P2 -4.24 3.85e-05 0.0159 -0.37 -0.33 Coronary artery disease; chr3:48241205 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs11928691 ENSG00000228638.1 FCF1P2 -4.24 3.85e-05 0.0159 -0.37 -0.33 Coronary artery disease; chr3:48245275 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs9311421 ENSG00000228638.1 FCF1P2 -4.24 3.85e-05 0.0159 -0.37 -0.33 Coronary artery disease; chr3:48251588 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs11710861 ENSG00000228638.1 FCF1P2 -4.24 3.85e-05 0.0159 -0.37 -0.33 Coronary artery disease; chr3:48256070 chr3:48290793~48291375:- PAAD cis rs7617773 0.784 rs9850672 ENSG00000228638.1 FCF1P2 -4.24 3.85e-05 0.0159 -0.37 -0.33 Coronary artery disease; chr3:48259682 chr3:48290793~48291375:- PAAD cis rs10129255 0.5 rs2027903 ENSG00000211972.2 IGHV3-66 4.24 3.86e-05 0.0159 0.25 0.33 Kawasaki disease; chr14:106807047 chr14:106675017~106675544:- PAAD cis rs4925386 1 rs4925389 ENSG00000273619.1 RP5-908M14.9 4.24 3.86e-05 0.0159 0.26 0.33 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62347456 chr20:62386303~62386970:- PAAD cis rs4759375 0.667 rs10846509 ENSG00000256092.2 RP13-942N8.1 4.24 3.86e-05 0.0159 0.63 0.33 HDL cholesterol; chr12:123308301 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs10846510 ENSG00000256092.2 RP13-942N8.1 4.24 3.86e-05 0.0159 0.63 0.33 HDL cholesterol; chr12:123310010 chr12:123363868~123366113:+ PAAD cis rs55665837 0.559 rs9667144 ENSG00000251991.1 RNU7-49P -4.24 3.86e-05 0.0159 -0.39 -0.33 Vitamin D levels; chr11:14399555 chr11:14478892~14478953:+ PAAD cis rs10761482 0.601 rs1954117 ENSG00000254271.1 RP11-131N11.4 4.24 3.86e-05 0.0159 0.42 0.33 Schizophrenia; chr10:60450830 chr10:60734342~60741828:+ PAAD cis rs10761482 0.639 rs2067612 ENSG00000254271.1 RP11-131N11.4 4.24 3.86e-05 0.0159 0.42 0.33 Schizophrenia; chr10:60452576 chr10:60734342~60741828:+ PAAD cis rs871012 0.632 rs889035 ENSG00000251405.2 CTB-109A12.1 -4.24 3.86e-05 0.0159 -0.41 -0.33 IgG glycosylation; chr5:157389514 chr5:157362615~157460078:- PAAD cis rs7829975 0.501 rs2980769 ENSG00000253981.4 ALG1L13P 4.24 3.87e-05 0.0159 0.39 0.33 Mood instability; chr8:8462781 chr8:8236003~8244667:- PAAD cis rs9876781 0.62 rs17648188 ENSG00000229759.1 MRPS18AP1 4.24 3.87e-05 0.0159 0.34 0.33 Longevity; chr3:48368851 chr3:48256350~48256938:- PAAD cis rs763121 0.853 rs4821810 ENSG00000228274.3 RP3-508I15.9 -4.24 3.87e-05 0.0159 -0.31 -0.33 Menopause (age at onset); chr22:38676093 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757234 ENSG00000228274.3 RP3-508I15.9 -4.24 3.87e-05 0.0159 -0.31 -0.33 Menopause (age at onset); chr22:38676681 chr22:38667585~38681820:- PAAD cis rs7260598 0.685 rs73524177 ENSG00000268442.1 CTD-2027I19.2 4.24 3.87e-05 0.0159 0.52 0.33 Response to taxane treatment (placlitaxel); chr19:24156376 chr19:24162370~24163425:- PAAD cis rs6782228 1 rs6782407 ENSG00000242551.2 POU5F1P6 4.24 3.87e-05 0.0159 0.42 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128619905 chr3:128674735~128677005:- PAAD cis rs9652601 0.959 rs12925642 ENSG00000274038.1 RP11-66H6.4 -4.24 3.87e-05 0.0159 -0.37 -0.33 Systemic lupus erythematosus; chr16:11077745 chr16:11056556~11057034:+ PAAD cis rs6142102 0.961 rs4911392 ENSG00000276073.1 RP5-1125A11.7 -4.24 3.87e-05 0.0159 -0.35 -0.33 Skin pigmentation; chr20:33982712 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs4911393 ENSG00000276073.1 RP5-1125A11.7 -4.24 3.87e-05 0.0159 -0.35 -0.33 Skin pigmentation; chr20:33983120 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2300204 ENSG00000276073.1 RP5-1125A11.7 -4.24 3.87e-05 0.0159 -0.35 -0.33 Skin pigmentation; chr20:34000967 chr20:33985617~33988989:- PAAD cis rs1150668 0.83 rs2531831 ENSG00000219891.2 ZSCAN12P1 4.24 3.88e-05 0.016 0.41 0.33 Pubertal anthropometrics; chr6:28420988 chr6:28091154~28093664:+ PAAD cis rs7615952 0.551 rs58274173 ENSG00000171084.14 FAM86JP 4.24 3.88e-05 0.016 0.68 0.33 Blood pressure (smoking interaction); chr3:126081857 chr3:125916620~125930024:+ PAAD cis rs1665050 0.534 rs11858479 ENSG00000277144.1 RP11-59H7.4 -4.24 3.88e-05 0.016 -0.39 -0.33 Atopic dermatitis; chr15:58950507 chr15:59115547~59116089:- PAAD cis rs8091660 0.624 rs1028010 ENSG00000278983.1 RP11-426J5.3 4.24 3.88e-05 0.016 0.39 0.33 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48559459 chr18:48564795~48568342:+ PAAD cis rs216345 0.73 rs12555291 ENSG00000230074.1 RP11-195F19.9 4.24 3.88e-05 0.016 0.44 0.33 Bipolar disorder; chr9:34011393 chr9:34665665~34681298:+ PAAD cis rs2439831 1 rs690002 ENSG00000275601.1 AC011330.13 -4.24 3.89e-05 0.016 -0.56 -0.33 Lung cancer in ever smokers; chr15:43437151 chr15:43642389~43643023:- PAAD cis rs10129255 0.5 rs11627315 ENSG00000211972.2 IGHV3-66 4.24 3.89e-05 0.016 0.25 0.33 Kawasaki disease; chr14:106802182 chr14:106675017~106675544:- PAAD cis rs9326248 0.581 rs10892061 ENSG00000280143.1 AP000892.6 4.24 3.89e-05 0.016 0.36 0.33 Blood protein levels; chr11:117015398 chr11:117204967~117210292:+ PAAD cis rs9326248 0.581 rs11216242 ENSG00000280143.1 AP000892.6 4.24 3.89e-05 0.016 0.36 0.33 Blood protein levels; chr11:117030833 chr11:117204967~117210292:+ PAAD cis rs9326248 0.581 rs12804122 ENSG00000280143.1 AP000892.6 4.24 3.89e-05 0.016 0.36 0.33 Blood protein levels; chr11:117031900 chr11:117204967~117210292:+ PAAD cis rs9876781 0.588 rs11715932 ENSG00000229759.1 MRPS18AP1 4.24 3.89e-05 0.016 0.34 0.33 Longevity; chr3:48366855 chr3:48256350~48256938:- PAAD cis rs6570726 0.935 rs407721 ENSG00000235652.6 RP11-545I5.3 4.24 3.9e-05 0.016 0.26 0.33 Lobe attachment (rater-scored or self-reported); chr6:145550218 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs408768 ENSG00000235652.6 RP11-545I5.3 4.24 3.9e-05 0.016 0.26 0.33 Lobe attachment (rater-scored or self-reported); chr6:145550599 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs430248 ENSG00000235652.6 RP11-545I5.3 4.24 3.9e-05 0.016 0.26 0.33 Lobe attachment (rater-scored or self-reported); chr6:145552968 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs406343 ENSG00000235652.6 RP11-545I5.3 4.24 3.9e-05 0.016 0.26 0.33 Lobe attachment (rater-scored or self-reported); chr6:145553252 chr6:145799409~145886585:+ PAAD cis rs8100891 0.537 rs1001446 ENSG00000267213.4 AC007773.2 -4.24 3.9e-05 0.016 -0.51 -0.33 Neuroticism; chr19:32410051 chr19:32390050~32405560:- PAAD cis rs58873874 0.737 rs80320835 ENSG00000248544.2 CTB-47B11.3 4.24 3.9e-05 0.016 0.7 0.33 Bipolar disorder (body mass index interaction); chr5:157389887 chr5:157375741~157384950:- PAAD cis rs11700536 1 rs11700536 ENSG00000236663.1 AP001631.9 -4.24 3.9e-05 0.016 -0.36 -0.33 Interleukin-18 levels; chr21:43138577 chr21:43140523~43141092:- PAAD cis rs12507634 1 rs12507634 ENSG00000251216.1 RP11-161D15.3 4.24 3.9e-05 0.016 0.36 0.33 Thiazide-induced adverse metabolic effects in hypertensive patients; chr4:174150451 chr4:173924207~173990861:- PAAD cis rs7849973 0.864 rs4571809 ENSG00000224549.1 RP11-370B11.3 -4.24 3.9e-05 0.016 -0.38 -0.33 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22819065 chr9:22767175~22768316:+ PAAD cis rs9217 1 rs11658168 ENSG00000233223.2 AC113189.5 4.24 3.9e-05 0.016 0.36 0.33 Height; chr17:7502815 chr17:7581964~7584072:- PAAD cis rs12701220 0.817 rs1058729 ENSG00000229043.2 AC091729.9 -4.24 3.91e-05 0.016 -0.45 -0.33 Bronchopulmonary dysplasia; chr7:1047647 chr7:1160374~1165267:+ PAAD cis rs2303759 0.874 rs8108669 ENSG00000268686.1 AC010524.2 -4.24 3.91e-05 0.016 -0.44 -0.33 Multiple sclerosis; chr19:49342638 chr19:49368705~49388081:- PAAD cis rs6782228 1 rs35871360 ENSG00000242551.2 POU5F1P6 4.24 3.91e-05 0.0161 0.43 0.33 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128617286 chr3:128674735~128677005:- PAAD cis rs2348418 0.669 rs7959641 ENSG00000247934.4 RP11-967K21.1 4.24 3.91e-05 0.0161 0.33 0.33 Lung function (FEV1);Lung function (FVC); chr12:28237267 chr12:28163298~28190738:- PAAD cis rs7260598 0.539 rs57417281 ENSG00000268442.1 CTD-2027I19.2 4.24 3.91e-05 0.0161 0.54 0.33 Response to taxane treatment (placlitaxel); chr19:23877968 chr19:24162370~24163425:- PAAD cis rs6479891 0.915 rs10740110 ENSG00000232075.1 MRPL35P2 -4.24 3.91e-05 0.0161 -0.51 -0.32 Arthritis (juvenile idiopathic); chr10:63283461 chr10:63634317~63634827:- PAAD cis rs595244 0.764 rs6493333 ENSG00000259705.1 RP11-227D13.1 -4.24 3.92e-05 0.0161 -0.41 -0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48646849 chr15:48645951~48652016:+ PAAD cis rs7216064 0.531 rs6504573 ENSG00000278219.1 AC145343.1 -4.24 3.92e-05 0.0161 -0.45 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68019847 chr17:68101538~68101639:+ PAAD cis rs17123764 0.748 rs55686423 ENSG00000257464.1 RP11-161H23.8 -4.24 3.92e-05 0.0161 -0.59 -0.32 Intelligence (multi-trait analysis); chr12:49569751 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs57916875 ENSG00000257464.1 RP11-161H23.8 -4.24 3.92e-05 0.0161 -0.59 -0.32 Intelligence (multi-trait analysis); chr12:49595553 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs52824916 ENSG00000257464.1 RP11-161H23.8 -4.24 3.92e-05 0.0161 -0.59 -0.32 Intelligence (multi-trait analysis); chr12:49599895 chr12:49442424~49442652:- PAAD cis rs897984 0.683 rs729482 ENSG00000260911.2 RP11-196G11.2 4.24 3.93e-05 0.0161 0.3 0.32 Dementia with Lewy bodies; chr16:31005649 chr16:31043150~31049868:+ PAAD cis rs10779751 0.922 rs2295079 ENSG00000238199.1 UBE2V2P3 -4.24 3.93e-05 0.0161 -0.4 -0.32 Body mass index; chr1:11262508 chr1:11278616~11279351:- PAAD cis rs79040073 0.607 rs73400205 ENSG00000259531.2 RP11-295H24.3 4.24 3.93e-05 0.0161 0.52 0.32 Lung cancer in ever smokers; chr15:49442346 chr15:49365124~49366685:- PAAD cis rs6504950 0.679 rs9908752 ENSG00000275710.1 RP11-257O5.4 4.24 3.93e-05 0.0161 0.4 0.32 Breast cancer; chr17:54905855 chr17:54964474~54964679:+ PAAD cis rs6504950 0.72 rs9895901 ENSG00000275710.1 RP11-257O5.4 4.24 3.93e-05 0.0161 0.4 0.32 Breast cancer; chr17:54907524 chr17:54964474~54964679:+ PAAD cis rs7849973 0.579 rs12335498 ENSG00000224549.1 RP11-370B11.3 -4.24 3.94e-05 0.0161 -0.4 -0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22763089 chr9:22767175~22768316:+ PAAD cis rs7849973 0.579 rs13285009 ENSG00000224549.1 RP11-370B11.3 -4.24 3.94e-05 0.0161 -0.4 -0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22763642 chr9:22767175~22768316:+ PAAD cis rs9926296 0.542 rs12599531 ENSG00000260259.1 RP11-368I7.4 4.24 3.94e-05 0.0161 0.42 0.32 Vitiligo; chr16:89842993 chr16:89682620~89686569:- PAAD cis rs577676 0.586 rs533603 ENSG00000271811.1 RP1-79C4.4 4.24 3.94e-05 0.0161 0.35 0.32 Prevalent atrial fibrillation; chr1:170639527 chr1:170667381~170669425:+ PAAD cis rs10853057 0.541 rs4239089 ENSG00000214174.7 AMZ2P1 -4.24 3.94e-05 0.0161 -0.51 -0.32 White matter microstructure (global fractional anisotropy); chr17:65005864 chr17:64966550~64975576:- PAAD cis rs10853057 0.618 rs12939956 ENSG00000214174.7 AMZ2P1 -4.24 3.94e-05 0.0161 -0.51 -0.32 White matter microstructure (global fractional anisotropy); chr17:65006264 chr17:64966550~64975576:- PAAD cis rs7617773 0.817 rs9837228 ENSG00000228638.1 FCF1P2 4.23 3.94e-05 0.0161 0.36 0.32 Coronary artery disease; chr3:48282976 chr3:48290793~48291375:- PAAD cis rs11089937 0.651 rs928894 ENSG00000211640.3 IGLV6-57 4.23 3.94e-05 0.0161 0.22 0.32 Periodontitis (PAL4Q3); chr22:22185882 chr22:22195713~22196460:+ PAAD cis rs11089937 0.523 rs4821832 ENSG00000211640.3 IGLV6-57 4.23 3.94e-05 0.0161 0.22 0.32 Periodontitis (PAL4Q3); chr22:22188499 chr22:22195713~22196460:+ PAAD cis rs11089937 0.523 rs4820352 ENSG00000211640.3 IGLV6-57 4.23 3.94e-05 0.0161 0.22 0.32 Periodontitis (PAL4Q3); chr22:22189203 chr22:22195713~22196460:+ PAAD cis rs1150668 0.796 rs213237 ENSG00000219891.2 ZSCAN12P1 4.23 3.94e-05 0.0161 0.41 0.32 Pubertal anthropometrics; chr6:28356161 chr6:28091154~28093664:+ PAAD cis rs9649213 0.593 rs13246942 ENSG00000272950.1 RP11-307C18.1 4.23 3.95e-05 0.0162 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98285709 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6968144 ENSG00000272950.1 RP11-307C18.1 4.23 3.95e-05 0.0162 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98286385 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs62479853 ENSG00000272950.1 RP11-307C18.1 4.23 3.95e-05 0.0162 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98287846 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs12728 ENSG00000272950.1 RP11-307C18.1 4.23 3.95e-05 0.0162 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98293539 chr7:98322853~98323430:+ PAAD cis rs6479891 1 rs7070052 ENSG00000232075.1 MRPL35P2 -4.23 3.95e-05 0.0162 -0.51 -0.32 Arthritis (juvenile idiopathic); chr10:63144054 chr10:63634317~63634827:- PAAD cis rs9322193 0.962 rs9322206 ENSG00000268592.3 RAET1E-AS1 4.23 3.95e-05 0.0162 0.37 0.32 Lung cancer; chr6:149641481 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9688750 ENSG00000268592.3 RAET1E-AS1 4.23 3.95e-05 0.0162 0.37 0.32 Lung cancer; chr6:149657633 chr6:149863494~149919507:+ PAAD cis rs7829975 0.577 rs940032 ENSG00000253893.2 FAM85B 4.23 3.95e-05 0.0162 0.49 0.32 Mood instability; chr8:8688833 chr8:8167819~8226614:- PAAD cis rs8072100 1 rs11650372 ENSG00000228782.6 CTD-2026D20.3 4.23 3.96e-05 0.0162 0.32 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47644429 chr17:47450568~47492492:- PAAD cis rs8072100 1 rs8065669 ENSG00000228782.6 CTD-2026D20.3 4.23 3.96e-05 0.0162 0.32 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47647630 chr17:47450568~47492492:- PAAD cis rs2337406 1 rs7145100 ENSG00000274576.2 IGHV2-70 -4.23 3.96e-05 0.0162 -0.44 -0.32 Alzheimer's disease (late onset); chr14:106704673 chr14:106770577~106771020:- PAAD cis rs10421328 0.821 rs2288867 ENSG00000259242.2 AC002306.1 4.23 3.96e-05 0.0162 0.49 0.32 Parental longevity (combined parental age at death); chr19:19654759 chr19:19606350~19608660:+ PAAD cis rs8177376 0.727 rs645852 ENSG00000254905.1 RP11-712L6.7 4.23 3.96e-05 0.0162 0.42 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327509 chr11:126292922~126294254:- PAAD cis rs8177376 0.727 rs646775 ENSG00000254905.1 RP11-712L6.7 4.23 3.96e-05 0.0162 0.42 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327704 chr11:126292922~126294254:- PAAD cis rs7829975 0.682 rs7013471 ENSG00000253893.2 FAM85B 4.23 3.96e-05 0.0162 0.43 0.32 Mood instability; chr8:8829815 chr8:8167819~8226614:- PAAD cis rs9595908 0.965 rs9337 ENSG00000212293.1 SNORA16 4.23 3.97e-05 0.0162 0.39 0.32 Body mass index; chr13:32517104 chr13:32420390~32420516:- PAAD cis rs28386778 0.897 rs1877318 ENSG00000240280.5 TCAM1P -4.23 3.97e-05 0.0162 -0.45 -0.32 Prudent dietary pattern; chr17:63742600 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs8079818 ENSG00000240280.5 TCAM1P -4.23 3.97e-05 0.0162 -0.45 -0.32 Prudent dietary pattern; chr17:63747307 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs4638645 ENSG00000240280.5 TCAM1P -4.23 3.97e-05 0.0162 -0.45 -0.32 Prudent dietary pattern; chr17:63750989 chr17:63849292~63864379:+ PAAD cis rs28386778 0.805 rs9911714 ENSG00000240280.5 TCAM1P -4.23 3.97e-05 0.0162 -0.45 -0.32 Prudent dietary pattern; chr17:63751592 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs7212196 ENSG00000240280.5 TCAM1P -4.23 3.97e-05 0.0162 -0.45 -0.32 Prudent dietary pattern; chr17:63757621 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs4968599 ENSG00000240280.5 TCAM1P -4.23 3.97e-05 0.0162 -0.45 -0.32 Prudent dietary pattern; chr17:63758632 chr17:63849292~63864379:+ PAAD cis rs216345 0.7 rs2248910 ENSG00000230074.1 RP11-195F19.9 -4.23 3.97e-05 0.0162 -0.42 -0.32 Bipolar disorder; chr9:33838477 chr9:34665665~34681298:+ PAAD cis rs216345 0.734 rs2265040 ENSG00000230074.1 RP11-195F19.9 -4.23 3.97e-05 0.0162 -0.42 -0.32 Bipolar disorder; chr9:33844757 chr9:34665665~34681298:+ PAAD cis rs216345 0.642 rs471371 ENSG00000230074.1 RP11-195F19.9 -4.23 3.97e-05 0.0162 -0.42 -0.32 Bipolar disorder; chr9:33870846 chr9:34665665~34681298:+ PAAD cis rs6570726 1 rs386678 ENSG00000235652.6 RP11-545I5.3 4.23 3.97e-05 0.0162 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145547874 chr6:145799409~145886585:+ PAAD cis rs7202877 0.61 rs4888381 ENSG00000261783.1 RP11-252K23.2 -4.23 3.98e-05 0.0162 -0.52 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75322949 chr16:75379818~75381260:- PAAD cis rs4938303 0.633 rs567209 ENSG00000254851.1 RP11-109L13.1 4.23 3.98e-05 0.0162 0.55 0.32 Triglycerides; chr11:116664111 chr11:117135528~117138582:+ PAAD cis rs7580658 0.864 rs4150441 ENSG00000236682.1 AC068282.3 -4.23 3.98e-05 0.0163 -0.43 -0.32 Protein C levels; chr2:127283339 chr2:127389130~127400580:+ PAAD cis rs745080 1 rs729931 ENSG00000261208.1 RP11-452D12.1 4.23 3.98e-05 0.0163 0.39 0.32 Orofacial clefts; chr14:52521867 chr14:52286797~52289268:+ PAAD cis rs745080 1 rs745080 ENSG00000261208.1 RP11-452D12.1 -4.23 3.98e-05 0.0163 -0.39 -0.32 Orofacial clefts; chr14:52522510 chr14:52286797~52289268:+ PAAD cis rs2117029 0.898 rs10875914 ENSG00000258017.1 RP11-386G11.10 -4.23 3.98e-05 0.0163 -0.42 -0.32 Intelligence (multi-trait analysis); chr12:49028311 chr12:49127782~49147869:+ PAAD cis rs9584850 0.834 rs17574378 ENSG00000231194.1 FARP1-AS1 4.23 3.98e-05 0.0163 0.41 0.32 Neuroticism; chr13:98464130 chr13:98435405~98435840:- PAAD cis rs9584850 0.834 rs3803253 ENSG00000231194.1 FARP1-AS1 4.23 3.98e-05 0.0163 0.41 0.32 Neuroticism; chr13:98464895 chr13:98435405~98435840:- PAAD cis rs9584850 0.834 rs9584854 ENSG00000231194.1 FARP1-AS1 4.23 3.98e-05 0.0163 0.41 0.32 Neuroticism; chr13:98466336 chr13:98435405~98435840:- PAAD cis rs9584850 0.834 rs745639 ENSG00000231194.1 FARP1-AS1 4.23 3.98e-05 0.0163 0.41 0.32 Neuroticism; chr13:98467025 chr13:98435405~98435840:- PAAD cis rs987724 0.519 rs9820830 ENSG00000240875.4 LINC00886 -4.23 3.99e-05 0.0163 -0.4 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156824915 chr3:156747346~156817062:- PAAD cis rs2985684 1 rs2985696 ENSG00000259113.1 RP11-406H23.2 -4.23 3.99e-05 0.0163 -0.47 -0.32 Carotid intima media thickness; chr14:49628195 chr14:50448807~50456742:+ PAAD cis rs2278796 0.789 rs1078719 ENSG00000226330.1 RP11-739N20.2 -4.23 3.99e-05 0.0163 -0.26 -0.32 Mean platelet volume; chr1:204993277 chr1:204377850~204435846:+ PAAD cis rs9595908 0.965 rs9595903 ENSG00000212293.1 SNORA16 4.23 4e-05 0.0163 0.38 0.32 Body mass index; chr13:32608003 chr13:32420390~32420516:- PAAD cis rs2739330 0.76 rs5751761 ENSG00000206090.4 AP000350.7 -4.23 4e-05 0.0163 -0.41 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23939998~23942798:+ PAAD cis rs11089937 0.626 rs737840 ENSG00000211639.2 IGLV4-60 4.23 4e-05 0.0163 0.36 0.32 Periodontitis (PAL4Q3); chr22:22162743 chr22:22162199~22162681:+ PAAD cis rs6840258 0.6 rs1447994 ENSG00000251411.1 RP11-397E7.4 4.23 4e-05 0.0163 0.38 0.32 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86966902 chr4:86913266~86914817:- PAAD cis rs6840258 0.66 rs10015639 ENSG00000251411.1 RP11-397E7.4 4.23 4e-05 0.0163 0.38 0.32 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86970413 chr4:86913266~86914817:- PAAD cis rs1832007 0.554 rs34179396 ENSG00000224034.1 RP11-445P17.8 -4.23 4e-05 0.0163 -0.47 -0.32 Triglyceride levels;Triglycerides; chr10:5278817 chr10:5266033~5271236:- PAAD cis rs867371 1 rs1392976 ENSG00000259429.4 UBE2Q2P2 4.23 4e-05 0.0163 0.26 0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82153834 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs1174543 ENSG00000259429.4 UBE2Q2P2 4.23 4e-05 0.0163 0.26 0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82155732 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs11855089 ENSG00000259429.4 UBE2Q2P2 -4.23 4e-05 0.0163 -0.26 -0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82154924 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs9944197 ENSG00000259429.4 UBE2Q2P2 -4.23 4e-05 0.0163 -0.26 -0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82158261 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs8037224 ENSG00000259429.4 UBE2Q2P2 -4.23 4e-05 0.0163 -0.26 -0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82172189 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs7166570 ENSG00000259429.4 UBE2Q2P2 -4.23 4e-05 0.0163 -0.26 -0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82173880 chr15:82355142~82420075:+ PAAD cis rs496547 0.654 rs688161 ENSG00000278376.1 RP11-158I9.8 -4.23 4e-05 0.0163 -0.29 -0.32 Hip minimal joint space width; chr11:118807001 chr11:118791254~118793137:+ PAAD cis rs6723226 0.75 rs1033751 ENSG00000276334.1 AL133243.1 4.23 4.01e-05 0.0164 0.38 0.32 Intelligence (multi-trait analysis); chr2:32470691 chr2:32521927~32523547:+ PAAD cis rs6024905 0.722 rs2275954 ENSG00000275401.1 RP4-564F22.7 -4.23 4.01e-05 0.0164 -0.35 -0.32 Bipolar disorder and schizophrenia; chr20:38334265 chr20:38418483~38419202:- PAAD cis rs4950322 0.58 rs17355419 ENSG00000278811.3 LINC00624 4.23 4.01e-05 0.0164 0.32 0.32 Protein quantitative trait loci; chr1:147110094 chr1:147258885~147517875:- PAAD cis rs4950322 0.58 rs72706428 ENSG00000278811.3 LINC00624 4.23 4.01e-05 0.0164 0.32 0.32 Protein quantitative trait loci; chr1:147110219 chr1:147258885~147517875:- PAAD cis rs4950322 0.563 rs61838944 ENSG00000278811.3 LINC00624 4.23 4.01e-05 0.0164 0.32 0.32 Protein quantitative trait loci; chr1:147110275 chr1:147258885~147517875:- PAAD cis rs4950322 0.547 rs61838945 ENSG00000278811.3 LINC00624 4.23 4.01e-05 0.0164 0.32 0.32 Protein quantitative trait loci; chr1:147111477 chr1:147258885~147517875:- PAAD cis rs4950322 0.563 rs6686480 ENSG00000278811.3 LINC00624 4.23 4.01e-05 0.0164 0.32 0.32 Protein quantitative trait loci; chr1:147111986 chr1:147258885~147517875:- PAAD cis rs4950322 0.563 rs6700783 ENSG00000278811.3 LINC00624 4.23 4.01e-05 0.0164 0.32 0.32 Protein quantitative trait loci; chr1:147111987 chr1:147258885~147517875:- PAAD cis rs6565180 0.926 rs8046445 ENSG00000183604.13 SMG1P5 -4.23 4.01e-05 0.0164 -0.36 -0.32 Tonsillectomy; chr16:30374941 chr16:30267553~30335374:- PAAD cis rs9595908 1 rs7999125 ENSG00000212293.1 SNORA16 4.23 4.01e-05 0.0164 0.37 0.32 Body mass index; chr13:32571858 chr13:32420390~32420516:- PAAD cis rs447735 0.565 rs10852626 ENSG00000260259.1 RP11-368I7.4 -4.23 4.02e-05 0.0164 -0.43 -0.32 Hemoglobin concentration; chr16:89848225 chr16:89682620~89686569:- PAAD cis rs9322193 0.962 rs7818 ENSG00000268592.3 RAET1E-AS1 4.23 4.02e-05 0.0164 0.39 0.32 Lung cancer; chr6:149810956 chr6:149863494~149919507:+ PAAD cis rs875971 0.564 rs313804 ENSG00000237310.1 GS1-124K5.4 4.23 4.02e-05 0.0164 0.31 0.32 Aortic root size; chr7:66049635 chr7:66493706~66495474:+ PAAD cis rs875971 0.662 rs448725 ENSG00000237310.1 GS1-124K5.4 4.23 4.02e-05 0.0164 0.31 0.32 Aortic root size; chr7:66049641 chr7:66493706~66495474:+ PAAD cis rs875971 0.658 rs432667 ENSG00000237310.1 GS1-124K5.4 4.23 4.02e-05 0.0164 0.31 0.32 Aortic root size; chr7:66049646 chr7:66493706~66495474:+ PAAD cis rs4794202 0.836 rs11079798 ENSG00000264920.1 RP11-6N17.4 -4.23 4.02e-05 0.0164 -0.5 -0.32 Alzheimer's disease (cognitive decline); chr17:47859521 chr17:47891255~47895812:- PAAD cis rs763121 0.853 rs138709 ENSG00000228274.3 RP3-508I15.9 -4.23 4.02e-05 0.0164 -0.32 -0.32 Menopause (age at onset); chr22:38743211 chr22:38667585~38681820:- PAAD cis rs8062405 0.757 rs2411453 ENSG00000251417.2 RP11-1348G14.4 4.23 4.02e-05 0.0164 0.3 0.32 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620700 chr16:28802743~28817828:+ PAAD cis rs2638953 0.853 rs3782515 ENSG00000247934.4 RP11-967K21.1 -4.23 4.03e-05 0.0164 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28310511 chr12:28163298~28190738:- PAAD cis rs73173548 0.528 rs34857793 ENSG00000247828.6 TMEM161B-AS1 4.23 4.03e-05 0.0164 0.27 0.32 Macular telangiectasia type 2; chr5:88467749 chr5:88268895~88436685:+ PAAD cis rs4853525 0.884 rs34303278 ENSG00000235852.1 AC005540.3 4.23 4.03e-05 0.0164 0.45 0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190866744 chr2:190880797~190882059:- PAAD cis rs4853525 0.923 rs13397788 ENSG00000235852.1 AC005540.3 4.23 4.03e-05 0.0164 0.45 0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190866777 chr2:190880797~190882059:- PAAD cis rs4813802 0.569 rs990930 ENSG00000278192.1 RP5-1056H1.2 -4.23 4.03e-05 0.0164 -0.36 -0.32 Colorectal cancer; chr20:6712931 chr20:6065966~6067897:- PAAD cis rs10129255 0.5 rs8022547 ENSG00000211972.2 IGHV3-66 4.23 4.03e-05 0.0164 0.25 0.32 Kawasaki disease; chr14:106781985 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs8006888 ENSG00000211972.2 IGHV3-66 4.23 4.03e-05 0.0164 0.25 0.32 Kawasaki disease; chr14:106782219 chr14:106675017~106675544:- PAAD cis rs7182621 0.639 rs1561047 ENSG00000259363.4 CTD-2054N24.2 -4.23 4.04e-05 0.0165 -0.43 -0.32 Colonoscopy-negative controls vs population controls; chr15:99874606 chr15:99807023~99877148:+ PAAD cis rs6860806 0.507 rs2631372 ENSG00000233006.5 AC034220.3 4.23 4.04e-05 0.0165 0.3 0.32 Breast cancer; chr5:132367886 chr5:132311285~132369916:- PAAD cis rs5758659 0.789 rs2413684 ENSG00000273366.1 CTA-989H11.1 -4.23 4.04e-05 0.0165 -0.41 -0.32 Cognitive function; chr22:42178824 chr22:42278188~42278846:+ PAAD cis rs1873386 0.79 rs7972258 ENSG00000255910.1 RP11-405A12.2 4.23 4.04e-05 0.0165 0.47 0.32 Personality dimensions; chr12:18914773 chr12:19775451~20009937:+ PAAD cis rs8100891 0.734 rs8104048 ENSG00000267213.4 AC007773.2 -4.23 4.04e-05 0.0165 -0.43 -0.32 Neuroticism; chr19:32338400 chr19:32390050~32405560:- PAAD cis rs1823913 0.599 rs34840299 ENSG00000280083.1 RP11-317J9.1 -4.23 4.04e-05 0.0165 -0.38 -0.32 Obesity-related traits; chr2:191280379 chr2:191154118~191156070:- PAAD cis rs7923609 0.841 rs10822186 ENSG00000232075.1 MRPL35P2 -4.23 4.05e-05 0.0165 -0.39 -0.32 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63590623 chr10:63634317~63634827:- PAAD cis rs3892715 0.521 rs2676884 ENSG00000214145.5 LINC00887 4.23 4.05e-05 0.0165 0.39 0.32 Attention deficit hyperactivity disorder (time to onset); chr3:195044816 chr3:194296465~194312803:- PAAD cis rs9487094 0.71 rs71558370 ENSG00000260273.1 RP11-425D10.10 4.23 4.05e-05 0.0165 0.47 0.32 Height; chr6:109455700 chr6:109382795~109383666:+ PAAD cis rs2117029 0.965 rs2293446 ENSG00000258017.1 RP11-386G11.10 -4.23 4.05e-05 0.0165 -0.42 -0.32 Intelligence (multi-trait analysis); chr12:49018926 chr12:49127782~49147869:+ PAAD cis rs6840258 0.547 rs2053771 ENSG00000251411.1 RP11-397E7.4 -4.23 4.05e-05 0.0165 -0.39 -0.32 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86937396 chr4:86913266~86914817:- PAAD cis rs875971 0.66 rs10263935 ENSG00000237310.1 GS1-124K5.4 4.23 4.05e-05 0.0165 0.29 0.32 Aortic root size; chr7:66631041 chr7:66493706~66495474:+ PAAD cis rs17772222 0.701 rs453112 ENSG00000258983.2 RP11-507K2.2 -4.23 4.05e-05 0.0165 -0.4 -0.32 Coronary artery calcification; chr14:88392657 chr14:88499334~88515502:+ PAAD cis rs950880 0.71 rs56117144 ENSG00000234389.1 AC007278.3 -4.23 4.05e-05 0.0165 -0.32 -0.32 Serum protein levels (sST2); chr2:102458191 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs57081652 ENSG00000234389.1 AC007278.3 -4.23 4.05e-05 0.0165 -0.32 -0.32 Serum protein levels (sST2); chr2:102458921 chr2:102438713~102440475:+ PAAD cis rs7487637 0.529 rs56389811 ENSG00000276691.1 RP5-1057I20.5 4.23 4.06e-05 0.0165 0.39 0.32 Mononucleosis; chr12:47811575 chr12:47788426~47788971:+ PAAD cis rs28374715 0.681 rs7162231 ENSG00000247556.5 OIP5-AS1 4.23 4.06e-05 0.0165 0.34 0.32 Ulcerative colitis; chr15:41299661 chr15:41283990~41309737:+ PAAD cis rs28374715 0.681 rs28687846 ENSG00000247556.5 OIP5-AS1 4.23 4.06e-05 0.0165 0.34 0.32 Ulcerative colitis; chr15:41307704 chr15:41283990~41309737:+ PAAD cis rs34375054 0.687 rs35540170 ENSG00000279233.1 RP11-158L12.4 4.23 4.06e-05 0.0165 0.29 0.32 Post bronchodilator FEV1/FVC ratio; chr12:125184576 chr12:125138245~125141711:+ PAAD cis rs8026198 0.929 rs633934 ENSG00000260571.1 BNIP3P5 -4.23 4.06e-05 0.0165 -0.52 -0.32 Fibrinogen levels; chr15:42172545 chr15:42313687~42314386:+ PAAD cis rs6142102 0.961 rs4911146 ENSG00000276073.1 RP5-1125A11.7 -4.23 4.06e-05 0.0165 -0.35 -0.32 Skin pigmentation; chr20:34052241 chr20:33985617~33988989:- PAAD cis rs2243480 1 rs10807702 ENSG00000232546.1 RP11-458F8.1 -4.23 4.06e-05 0.0165 -0.4 -0.32 Diabetic kidney disease; chr7:66302856 chr7:66848496~66858136:+ PAAD cis rs79040073 0.53 rs2078024 ENSG00000259469.1 RP11-227D13.4 -4.23 4.06e-05 0.0166 -0.45 -0.32 Lung cancer in ever smokers; chr15:49329413 chr15:48729080~48729844:- PAAD cis rs2262909 0.962 rs55728714 ENSG00000279377.1 AC003973.3 -4.23 4.06e-05 0.0166 -0.31 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22080097 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs12609368 ENSG00000279377.1 AC003973.3 -4.23 4.06e-05 0.0166 -0.31 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22081194 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs56369285 ENSG00000279377.1 AC003973.3 -4.23 4.06e-05 0.0166 -0.31 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22084383 chr19:21965708~21968529:- PAAD cis rs62341639 0.525 rs17679896 ENSG00000270426.1 RP11-326I11.5 4.23 4.07e-05 0.0166 0.34 0.32 Acute kidney injury in critical illness; chr4:184206942 chr4:184471924~184472609:- PAAD cis rs2638953 0.886 rs11049594 ENSG00000247934.4 RP11-967K21.1 4.23 4.07e-05 0.0166 0.35 0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28430368 chr12:28163298~28190738:- PAAD cis rs8005677 1 rs1043209 ENSG00000279656.1 RP11-298I3.6 -4.23 4.07e-05 0.0166 -0.39 -0.32 Cognitive ability (multi-trait analysis); chr14:22904777 chr14:23023083~23024217:- PAAD cis rs9309473 0.861 rs6546857 ENSG00000163016.8 ALMS1P 4.23 4.07e-05 0.0166 0.48 0.32 Metabolite levels; chr2:73610828 chr2:73644919~73685576:+ PAAD cis rs1113500 0.836 rs1539553 ENSG00000226822.1 RP11-356N1.2 -4.23 4.07e-05 0.0166 -0.37 -0.32 Growth-regulated protein alpha levels; chr1:108047376 chr1:108071482~108074519:+ PAAD cis rs812925 0.519 rs2463099 ENSG00000273302.1 RP11-493E12.2 -4.23 4.07e-05 0.0166 -0.27 -0.32 Immature fraction of reticulocytes; chr2:61391176 chr2:61199979~61200769:+ PAAD cis rs33998987 0.637 rs2068330 ENSG00000226121.2 AC009487.6 4.23 4.08e-05 0.0166 0.4 0.32 Coronary artery disease; chr2:162380880 chr2:161500885~161507705:- PAAD cis rs8072100 0.544 rs9284377 ENSG00000228782.6 CTD-2026D20.3 4.23 4.08e-05 0.0166 0.33 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309046 chr17:47450568~47492492:- PAAD cis rs2708377 0.789 rs3911150 ENSG00000212125.2 TAS2R15P -4.23 4.08e-05 0.0166 -0.52 -0.32 Bitter taste perception; chr12:11049649 chr12:10964425~10965352:- PAAD cis rs9517313 0.615 rs4772079 ENSG00000231194.1 FARP1-AS1 -4.23 4.09e-05 0.0166 -0.37 -0.32 Neuroticism; chr13:98438583 chr13:98435405~98435840:- PAAD cis rs17772222 0.675 rs1099698 ENSG00000258983.2 RP11-507K2.2 -4.23 4.09e-05 0.0166 -0.4 -0.32 Coronary artery calcification; chr14:88414904 chr14:88499334~88515502:+ PAAD cis rs28374715 0.578 rs10518717 ENSG00000247556.5 OIP5-AS1 4.23 4.09e-05 0.0166 0.35 0.32 Ulcerative colitis; chr15:41331170 chr15:41283990~41309737:+ PAAD cis rs28374715 0.578 rs72739630 ENSG00000247556.5 OIP5-AS1 4.23 4.09e-05 0.0166 0.35 0.32 Ulcerative colitis; chr15:41338866 chr15:41283990~41309737:+ PAAD cis rs34375054 1 rs3751178 ENSG00000279233.1 RP11-158L12.4 -4.23 4.09e-05 0.0166 -0.28 -0.32 Post bronchodilator FEV1/FVC ratio; chr12:125179811 chr12:125138245~125141711:+ PAAD cis rs964611 0.882 rs12441867 ENSG00000259488.2 RP11-154J22.1 4.23 4.09e-05 0.0166 0.35 0.32 Metabolite levels (Pyroglutamine); chr15:48343856 chr15:48312353~48331856:- PAAD cis rs9326248 0.559 rs12808524 ENSG00000280143.1 AP000892.6 4.23 4.09e-05 0.0166 0.37 0.32 Blood protein levels; chr11:117020277 chr11:117204967~117210292:+ PAAD cis rs1707322 0.717 rs1135812 ENSG00000280836.1 AL355480.1 -4.23 4.09e-05 0.0166 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45629600 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs6703748 ENSG00000280836.1 AL355480.1 -4.23 4.09e-05 0.0166 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45630304 chr1:45581219~45581321:- PAAD cis rs728616 0.867 rs7893241 ENSG00000225484.5 NUTM2B-AS1 -4.23 4.1e-05 0.0167 -0.6 -0.32 Chronic obstructive pulmonary disease-related biomarkers; chr10:80194582 chr10:79663088~79826594:- PAAD cis rs2564921 0.73 rs2564939 ENSG00000242142.1 SERBP1P3 4.23 4.1e-05 0.0167 0.4 0.32 Height; chr3:53072864 chr3:53064283~53065091:- PAAD cis rs17023223 0.537 rs10802075 ENSG00000231365.4 RP11-418J17.1 -4.23 4.1e-05 0.0167 -0.36 -0.32 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119084604 chr1:119140396~119275973:+ PAAD cis rs10050311 0.79 rs55831707 ENSG00000251411.1 RP11-397E7.4 -4.23 4.1e-05 0.0167 -0.39 -0.32 Insulin-related traits; chr4:86918376 chr4:86913266~86914817:- PAAD cis rs6840258 0.547 rs72667721 ENSG00000251411.1 RP11-397E7.4 -4.23 4.1e-05 0.0167 -0.39 -0.32 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86919644 chr4:86913266~86914817:- PAAD cis rs10050311 0.79 rs4693154 ENSG00000251411.1 RP11-397E7.4 -4.23 4.1e-05 0.0167 -0.39 -0.32 Insulin-related traits; chr4:86922109 chr4:86913266~86914817:- PAAD cis rs10050311 0.79 rs72667724 ENSG00000251411.1 RP11-397E7.4 -4.23 4.1e-05 0.0167 -0.39 -0.32 Insulin-related traits; chr4:86929931 chr4:86913266~86914817:- PAAD cis rs902774 0.554 rs4503623 ENSG00000278185.1 RP11-153F5.7 4.22 4.1e-05 0.0167 0.43 0.32 Prostate cancer; chr12:52959975 chr12:52946614~52947125:- PAAD cis rs496547 0.686 rs540180 ENSG00000278376.1 RP11-158I9.8 -4.22 4.11e-05 0.0167 -0.29 -0.32 Hip minimal joint space width; chr11:118782920 chr11:118791254~118793137:+ PAAD cis rs496547 0.686 rs2508916 ENSG00000278376.1 RP11-158I9.8 -4.22 4.11e-05 0.0167 -0.29 -0.32 Hip minimal joint space width; chr11:118783942 chr11:118791254~118793137:+ PAAD cis rs2858942 0.527 rs7198029 ENSG00000268836.1 LA16c-OS12.2 4.22 4.11e-05 0.0167 0.29 0.32 Mean corpuscular hemoglobin; chr16:199465 chr16:185748~186294:- PAAD cis rs11089937 0.584 rs6001213 ENSG00000211640.3 IGLV6-57 4.22 4.11e-05 0.0167 0.21 0.32 Periodontitis (PAL4Q3); chr22:22182108 chr22:22195713~22196460:+ PAAD cis rs62355901 0.545 rs16886256 ENSG00000271828.1 CTD-2310F14.1 -4.22 4.11e-05 0.0167 -0.58 -0.32 Breast cancer; chr5:56765737 chr5:56927874~56929573:+ PAAD cis rs2787486 1 rs2787486 ENSG00000275710.1 RP11-257O5.4 4.22 4.12e-05 0.0167 0.39 0.32 Breast cancer; chr17:55132413 chr17:54964474~54964679:+ PAAD cis rs520525 0.963 rs600093 ENSG00000271811.1 RP1-79C4.4 4.22 4.12e-05 0.0167 0.34 0.32 Atrial fibrillation; chr1:170660697 chr1:170667381~170669425:+ PAAD cis rs2179367 0.959 rs521845 ENSG00000231760.4 RP11-350J20.5 -4.22 4.12e-05 0.0167 -0.42 -0.32 Dupuytren's disease; chr6:149350562 chr6:149796151~149826294:- PAAD cis rs4660214 0.666 rs588326 ENSG00000237624.1 OXCT2P1 4.22 4.12e-05 0.0167 0.42 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39443054 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs1775656 ENSG00000237624.1 OXCT2P1 4.22 4.12e-05 0.0167 0.42 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39445329 chr1:39514956~39516490:+ PAAD cis rs2658782 0.906 rs2658791 ENSG00000279684.1 RP11-755E23.2 -4.22 4.12e-05 0.0168 -0.56 -0.32 Pulmonary function decline; chr11:93465817 chr11:93286629~93288903:- PAAD cis rs4660214 0.59 rs11205885 ENSG00000237624.1 OXCT2P1 -4.22 4.12e-05 0.0168 -0.42 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39306633 chr1:39514956~39516490:+ PAAD cis rs4835473 0.9 rs35311036 ENSG00000251600.4 RP11-673E1.1 -4.22 4.13e-05 0.0168 -0.37 -0.32 Immature fraction of reticulocytes; chr4:143734397 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs35906127 ENSG00000251600.4 RP11-673E1.1 -4.22 4.13e-05 0.0168 -0.37 -0.32 Immature fraction of reticulocytes; chr4:143734400 chr4:143912331~143982454:+ PAAD cis rs10740039 0.732 rs10160182 ENSG00000254271.1 RP11-131N11.4 4.22 4.13e-05 0.0168 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60602693 chr10:60734342~60741828:+ PAAD cis rs10740039 0.768 rs10159993 ENSG00000254271.1 RP11-131N11.4 4.22 4.13e-05 0.0168 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60602788 chr10:60734342~60741828:+ PAAD cis rs10740039 0.768 rs1372710 ENSG00000254271.1 RP11-131N11.4 4.22 4.13e-05 0.0168 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60603200 chr10:60734342~60741828:+ PAAD cis rs10740039 0.81 rs7098097 ENSG00000254271.1 RP11-131N11.4 4.22 4.13e-05 0.0168 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60605233 chr10:60734342~60741828:+ PAAD cis rs10740039 0.81 rs10740036 ENSG00000254271.1 RP11-131N11.4 4.22 4.13e-05 0.0168 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60606216 chr10:60734342~60741828:+ PAAD cis rs10740039 0.81 rs10821800 ENSG00000254271.1 RP11-131N11.4 4.22 4.13e-05 0.0168 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60607812 chr10:60734342~60741828:+ PAAD cis rs1153858 0.673 rs117332547 ENSG00000259520.4 CTD-2651B20.3 -4.22 4.13e-05 0.0168 -0.67 -0.32 Homoarginine levels; chr15:45403565 chr15:45251580~45279251:- PAAD cis rs755249 0.529 rs604316 ENSG00000237624.1 OXCT2P1 4.22 4.13e-05 0.0168 0.43 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39413694 chr1:39514956~39516490:+ PAAD cis rs7849973 0.517 rs10811772 ENSG00000224549.1 RP11-370B11.3 -4.22 4.13e-05 0.0168 -0.41 -0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22775513 chr9:22767175~22768316:+ PAAD cis rs7849973 0.517 rs12345463 ENSG00000224549.1 RP11-370B11.3 -4.22 4.13e-05 0.0168 -0.41 -0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22776096 chr9:22767175~22768316:+ PAAD cis rs160451 0.739 rs218904 ENSG00000251136.7 RP11-37B2.1 -4.22 4.13e-05 0.0168 -0.33 -0.32 Leprosy; chr8:89722278 chr8:89609409~89757727:- PAAD cis rs6570726 0.935 rs380883 ENSG00000235652.6 RP11-545I5.3 4.22 4.13e-05 0.0168 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145501856 chr6:145799409~145886585:+ PAAD cis rs6539288 0.933 rs10746070 ENSG00000260329.1 RP11-412D9.4 -4.22 4.13e-05 0.0168 -0.27 -0.32 Total body bone mineral density; chr12:106910681 chr12:106954029~106955497:- PAAD cis rs1823913 0.637 rs979967 ENSG00000280083.1 RP11-317J9.1 -4.22 4.13e-05 0.0168 -0.4 -0.32 Obesity-related traits; chr2:191304695 chr2:191154118~191156070:- PAAD cis rs8005677 1 rs8014936 ENSG00000279656.1 RP11-298I3.6 4.22 4.13e-05 0.0168 0.39 0.32 Cognitive ability (multi-trait analysis); chr14:22905936 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs8016061 ENSG00000279656.1 RP11-298I3.6 4.22 4.13e-05 0.0168 0.39 0.32 Cognitive ability (multi-trait analysis); chr14:22906600 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs8005677 ENSG00000279656.1 RP11-298I3.6 4.22 4.13e-05 0.0168 0.39 0.32 Cognitive ability (multi-trait analysis); chr14:22907469 chr14:23023083~23024217:- PAAD cis rs812925 0.659 rs2167565 ENSG00000271889.1 RP11-493E12.1 -4.22 4.13e-05 0.0168 -0.36 -0.32 Immature fraction of reticulocytes; chr2:61249323 chr2:61151433~61162105:- PAAD cis rs1665050 0.534 rs35124643 ENSG00000277144.1 RP11-59H7.4 -4.22 4.14e-05 0.0168 -0.38 -0.32 Atopic dermatitis; chr15:58949802 chr15:59115547~59116089:- PAAD cis rs9876781 1 rs2885510 ENSG00000229759.1 MRPS18AP1 -4.22 4.14e-05 0.0168 -0.35 -0.32 Longevity; chr3:48376736 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs725309 ENSG00000229759.1 MRPS18AP1 -4.22 4.14e-05 0.0168 -0.35 -0.32 Longevity; chr3:48377218 chr3:48256350~48256938:- PAAD cis rs7826238 0.653 rs2979202 ENSG00000254340.1 RP11-10A14.3 4.22 4.14e-05 0.0168 0.4 0.32 Systolic blood pressure; chr8:8486617 chr8:9141424~9145435:+ PAAD cis rs453301 0.624 rs2979265 ENSG00000254340.1 RP11-10A14.3 4.22 4.14e-05 0.0168 0.39 0.32 Joint mobility (Beighton score); chr8:9001207 chr8:9141424~9145435:+ PAAD cis rs964611 0.882 rs3784619 ENSG00000259488.2 RP11-154J22.1 4.22 4.14e-05 0.0168 0.37 0.32 Metabolite levels (Pyroglutamine); chr15:48333741 chr15:48312353~48331856:- PAAD cis rs6782228 1 rs6782228 ENSG00000242551.2 POU5F1P6 4.22 4.14e-05 0.0168 0.43 0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128604581 chr3:128674735~128677005:- PAAD cis rs28386778 0.734 rs7210724 ENSG00000240280.5 TCAM1P -4.22 4.14e-05 0.0168 -0.45 -0.32 Prudent dietary pattern; chr17:63721838 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs1470697 ENSG00000240280.5 TCAM1P -4.22 4.14e-05 0.0168 -0.45 -0.32 Prudent dietary pattern; chr17:63722480 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs57108948 ENSG00000240280.5 TCAM1P -4.22 4.14e-05 0.0168 -0.45 -0.32 Prudent dietary pattern; chr17:63725018 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs7501614 ENSG00000240280.5 TCAM1P -4.22 4.14e-05 0.0168 -0.45 -0.32 Prudent dietary pattern; chr17:63725252 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2137144 ENSG00000240280.5 TCAM1P -4.22 4.14e-05 0.0168 -0.45 -0.32 Prudent dietary pattern; chr17:63728247 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs10221279 ENSG00000240280.5 TCAM1P -4.22 4.14e-05 0.0168 -0.45 -0.32 Prudent dietary pattern; chr17:63728778 chr17:63849292~63864379:+ PAAD cis rs28386778 0.687 rs59596917 ENSG00000240280.5 TCAM1P -4.22 4.14e-05 0.0168 -0.45 -0.32 Prudent dietary pattern; chr17:63728904 chr17:63849292~63864379:+ PAAD cis rs853679 0.527 rs1997660 ENSG00000219891.2 ZSCAN12P1 4.22 4.14e-05 0.0168 0.44 0.32 Depression; chr6:28301886 chr6:28091154~28093664:+ PAAD cis rs853679 0.527 rs9468333 ENSG00000219891.2 ZSCAN12P1 4.22 4.14e-05 0.0168 0.44 0.32 Depression; chr6:28303421 chr6:28091154~28093664:+ PAAD cis rs6903823 0.527 rs4713158 ENSG00000219891.2 ZSCAN12P1 4.22 4.14e-05 0.0168 0.44 0.32 Pulmonary function; chr6:28309994 chr6:28091154~28093664:+ PAAD cis rs2736345 0.747 rs1478901 ENSG00000251402.3 FAM90A25P 4.22 4.14e-05 0.0168 0.42 0.32 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11490324 chr8:12415080~12418090:- PAAD cis rs10096908 1 rs10096908 ENSG00000254165.1 RP11-503E24.2 -4.22 4.15e-05 0.0168 -0.54 -0.32 Blood pressure traits (multi-trait analysis);Hypertension;Systolic blood pressure; chr8:41784039 chr8:42537529~42538304:- PAAD cis rs2348418 0.832 rs1405811 ENSG00000247934.4 RP11-967K21.1 4.22 4.15e-05 0.0168 0.31 0.32 Lung function (FEV1);Lung function (FVC); chr12:28428169 chr12:28163298~28190738:- PAAD cis rs11089937 0.626 rs11704092 ENSG00000211638.2 IGLV8-61 -4.22 4.15e-05 0.0168 -0.31 -0.32 Periodontitis (PAL4Q3); chr22:22135815 chr22:22098700~22099212:+ PAAD cis rs13256369 0.95 rs13255655 ENSG00000253981.4 ALG1L13P 4.22 4.15e-05 0.0168 0.45 0.32 Obesity-related traits; chr8:8720226 chr8:8236003~8244667:- PAAD cis rs9876781 1 rs13071337 ENSG00000229759.1 MRPS18AP1 4.22 4.16e-05 0.0169 0.36 0.32 Longevity; chr3:48396724 chr3:48256350~48256938:- PAAD cis rs1113500 0.541 rs11185240 ENSG00000226822.1 RP11-356N1.2 4.22 4.16e-05 0.0169 0.4 0.32 Growth-regulated protein alpha levels; chr1:108040188 chr1:108071482~108074519:+ PAAD cis rs1113500 0.541 rs11185241 ENSG00000226822.1 RP11-356N1.2 4.22 4.16e-05 0.0169 0.4 0.32 Growth-regulated protein alpha levels; chr1:108040403 chr1:108071482~108074519:+ PAAD cis rs8177376 0.727 rs240555 ENSG00000254905.1 RP11-712L6.7 4.22 4.16e-05 0.0169 0.41 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126332190 chr11:126292922~126294254:- PAAD cis rs7829975 0.5 rs7841082 ENSG00000253981.4 ALG1L13P -4.22 4.16e-05 0.0169 -0.38 -0.32 Mood instability; chr8:8311465 chr8:8236003~8244667:- PAAD cis rs62103177 0.564 rs1864529 ENSG00000261126.6 RP11-795F19.1 -4.22 4.16e-05 0.0169 -0.45 -0.32 Opioid sensitivity; chr18:79988975 chr18:80046900~80095482:+ PAAD cis rs3020264 0.962 rs3020263 ENSG00000271743.1 CTD-2541M15.3 -4.22 4.16e-05 0.0169 -0.5 -0.32 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6629928 chr8:6615604~6617198:- PAAD cis rs780096 0.546 rs1528533 ENSG00000234072.1 AC074117.10 -4.22 4.17e-05 0.0169 -0.25 -0.32 Total body bone mineral density; chr2:27372889 chr2:27356246~27367622:+ PAAD cis rs780096 0.505 rs12475426 ENSG00000234072.1 AC074117.10 -4.22 4.17e-05 0.0169 -0.25 -0.32 Total body bone mineral density; chr2:27376265 chr2:27356246~27367622:+ PAAD cis rs73173548 0.528 rs12189274 ENSG00000247828.6 TMEM161B-AS1 -4.22 4.17e-05 0.0169 -0.27 -0.32 Macular telangiectasia type 2; chr5:88468669 chr5:88268895~88436685:+ PAAD cis rs17711722 0.528 rs73138179 ENSG00000226824.5 RP4-756H11.3 -4.22 4.17e-05 0.0169 -0.38 -0.32 Calcium levels; chr7:65829495 chr7:66654538~66669855:+ PAAD cis rs7202877 0.706 rs467780 ENSG00000261783.1 RP11-252K23.2 4.22 4.17e-05 0.0169 0.5 0.32 Type 1 diabetes;Type 2 diabetes; chr16:75403240 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs247423 ENSG00000261783.1 RP11-252K23.2 4.22 4.17e-05 0.0169 0.5 0.32 Type 1 diabetes;Type 2 diabetes; chr16:75422733 chr16:75379818~75381260:- PAAD cis rs73186030 0.591 rs28630628 ENSG00000272758.4 RP11-299J3.8 4.22 4.17e-05 0.0169 0.44 0.32 Serum parathyroid hormone levels; chr3:122386769 chr3:122416207~122443180:+ PAAD cis rs9807989 0.507 rs2287033 ENSG00000234389.1 AC007278.3 -4.22 4.17e-05 0.0169 -0.32 -0.32 Asthma; chr2:102394777 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs6710528 ENSG00000234389.1 AC007278.3 -4.22 4.17e-05 0.0169 -0.32 -0.32 Asthma; chr2:102399682 chr2:102438713~102440475:+ PAAD cis rs1150668 0.835 rs203869 ENSG00000219891.2 ZSCAN12P1 4.22 4.17e-05 0.0169 0.43 0.32 Pubertal anthropometrics; chr6:28073041 chr6:28091154~28093664:+ PAAD cis rs172166 0.56 rs203878 ENSG00000219891.2 ZSCAN12P1 4.22 4.17e-05 0.0169 0.43 0.32 Cardiac Troponin-T levels; chr6:28081218 chr6:28091154~28093664:+ PAAD cis rs2439831 0.681 rs1837960 ENSG00000275601.1 AC011330.13 -4.22 4.18e-05 0.0169 -0.55 -0.32 Lung cancer in ever smokers; chr15:43406404 chr15:43642389~43643023:- PAAD cis rs2439831 0.681 rs1837959 ENSG00000275601.1 AC011330.13 -4.22 4.18e-05 0.0169 -0.55 -0.32 Lung cancer in ever smokers; chr15:43406481 chr15:43642389~43643023:- PAAD cis rs4944571 0.664 rs1452134 ENSG00000255471.1 RP11-736K20.5 -4.22 4.18e-05 0.0169 -0.3 -0.32 Urate levels in obese individuals; chr11:86422374 chr11:86892214~86925037:- PAAD cis rs494459 0.838 rs632124 ENSG00000278376.1 RP11-158I9.8 -4.22 4.18e-05 0.0169 -0.29 -0.32 Height; chr11:118742526 chr11:118791254~118793137:+ PAAD cis rs2408955 0.521 rs10875749 ENSG00000240399.1 RP1-228P16.1 -4.22 4.18e-05 0.0169 -0.35 -0.32 Glycated hemoglobin levels; chr12:48138134 chr12:48054813~48055591:- PAAD cis rs2408955 0.541 rs11168428 ENSG00000240399.1 RP1-228P16.1 -4.22 4.18e-05 0.0169 -0.35 -0.32 Glycated hemoglobin levels; chr12:48153345 chr12:48054813~48055591:- PAAD cis rs2408955 0.501 rs8716 ENSG00000240399.1 RP1-228P16.1 4.22 4.18e-05 0.0169 0.35 0.32 Glycated hemoglobin levels; chr12:48145699 chr12:48054813~48055591:- PAAD cis rs2408955 0.521 rs7301003 ENSG00000240399.1 RP1-228P16.1 4.22 4.18e-05 0.0169 0.35 0.32 Glycated hemoglobin levels; chr12:48156444 chr12:48054813~48055591:- PAAD cis rs2408955 0.521 rs10875753 ENSG00000240399.1 RP1-228P16.1 4.22 4.18e-05 0.0169 0.35 0.32 Glycated hemoglobin levels; chr12:48163358 chr12:48054813~48055591:- PAAD cis rs2408955 0.5 rs12816820 ENSG00000240399.1 RP1-228P16.1 4.22 4.18e-05 0.0169 0.35 0.32 Glycated hemoglobin levels; chr12:48164542 chr12:48054813~48055591:- PAAD cis rs1387259 0.57 rs12368659 ENSG00000240399.1 RP1-228P16.1 4.22 4.18e-05 0.0169 0.35 0.32 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48168516 chr12:48054813~48055591:- PAAD cis rs41369048 0.844 rs2807844 ENSG00000238078.1 LINC01352 -4.22 4.19e-05 0.0169 -0.49 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220874239 chr1:220829255~220832429:+ PAAD cis rs9584850 0.834 rs9584855 ENSG00000231194.1 FARP1-AS1 -4.22 4.19e-05 0.017 -0.4 -0.32 Neuroticism; chr13:98466746 chr13:98435405~98435840:- PAAD cis rs28386778 0.897 rs1982400 ENSG00000240280.5 TCAM1P -4.22 4.19e-05 0.017 -0.44 -0.32 Prudent dietary pattern; chr17:63716458 chr17:63849292~63864379:+ PAAD cis rs2638953 0.962 rs11049539 ENSG00000247934.4 RP11-967K21.1 -4.22 4.19e-05 0.017 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28335953 chr12:28163298~28190738:- PAAD cis rs7615952 0.512 rs4679430 ENSG00000171084.14 FAM86JP 4.22 4.19e-05 0.017 0.44 0.32 Blood pressure (smoking interaction); chr3:125639049 chr3:125916620~125930024:+ PAAD cis rs7615952 0.512 rs34651730 ENSG00000171084.14 FAM86JP 4.22 4.19e-05 0.017 0.44 0.32 Blood pressure (smoking interaction); chr3:125639796 chr3:125916620~125930024:+ PAAD cis rs7615952 0.512 rs2979334 ENSG00000171084.14 FAM86JP 4.22 4.19e-05 0.017 0.44 0.32 Blood pressure (smoking interaction); chr3:125639980 chr3:125916620~125930024:+ PAAD cis rs7615952 0.512 rs11929125 ENSG00000171084.14 FAM86JP 4.22 4.19e-05 0.017 0.44 0.32 Blood pressure (smoking interaction); chr3:125640599 chr3:125916620~125930024:+ PAAD cis rs7615952 0.512 rs11921452 ENSG00000171084.14 FAM86JP 4.22 4.19e-05 0.017 0.44 0.32 Blood pressure (smoking interaction); chr3:125640906 chr3:125916620~125930024:+ PAAD cis rs7615952 0.512 rs2922175 ENSG00000171084.14 FAM86JP 4.22 4.19e-05 0.017 0.44 0.32 Blood pressure (smoking interaction); chr3:125642516 chr3:125916620~125930024:+ PAAD cis rs7615952 0.512 rs2979351 ENSG00000171084.14 FAM86JP 4.22 4.19e-05 0.017 0.44 0.32 Blood pressure (smoking interaction); chr3:125644755 chr3:125916620~125930024:+ PAAD cis rs4713118 0.662 rs149900 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28046819 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs149961 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28047791 chr6:28943877~28944537:+ PAAD cis rs4713118 0.629 rs149899 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28052201 chr6:28943877~28944537:+ PAAD cis rs4713118 0.629 rs172165 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28053036 chr6:28943877~28944537:+ PAAD cis rs4713118 0.597 rs172166 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28053042 chr6:28943877~28944537:+ PAAD cis rs4713118 0.629 rs203888 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28053811 chr6:28943877~28944537:+ PAAD cis rs4713118 0.629 rs203889 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28053997 chr6:28943877~28944537:+ PAAD cis rs4713118 0.629 rs203890 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28054470 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9357060 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28056708 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9468271 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28056792 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9380045 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28057501 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9468274 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28058299 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9468275 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28058358 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9468276 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28059910 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9468277 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28060612 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9468278 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28060704 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs13218430 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28062059 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs9380046 ENSG00000204709.4 LINC01556 4.22 4.2e-05 0.017 0.54 0.32 Parkinson's disease; chr6:28062721 chr6:28943877~28944537:+ PAAD cis rs4660214 0.666 rs587404 ENSG00000228060.1 RP11-69E11.8 -4.22 4.2e-05 0.017 -0.31 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39442834 chr1:39565160~39573203:+ PAAD cis rs2581828 0.646 rs9867023 ENSG00000242142.1 SERBP1P3 4.22 4.2e-05 0.017 0.41 0.32 Crohn's disease; chr3:53126116 chr3:53064283~53065091:- PAAD cis rs4218 0.681 rs7178935 ENSG00000277144.1 RP11-59H7.4 -4.22 4.2e-05 0.017 -0.44 -0.32 Social communication problems; chr15:59075968 chr15:59115547~59116089:- PAAD cis rs11976180 1 rs6464573 ENSG00000273234.1 OR2A13P 4.22 4.2e-05 0.017 0.4 0.32 Obesity-related traits; chr7:144051005 chr7:144142009~144142938:+ PAAD cis rs748404 0.697 rs1814323 ENSG00000205771.5 CATSPER2P1 4.22 4.2e-05 0.017 0.43 0.32 Lung cancer; chr15:43271039 chr15:43726918~43747094:- PAAD cis rs1707322 0.717 rs1972410 ENSG00000280836.1 AL355480.1 -4.22 4.2e-05 0.017 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615275 chr1:45581219~45581321:- PAAD cis rs7712401 0.601 rs246303 ENSG00000263432.2 RN7SL689P 4.22 4.2e-05 0.017 0.42 0.32 Mean platelet volume; chr5:122916022 chr5:123022487~123022783:- PAAD cis rs6436017 0.589 rs1424918 ENSG00000273466.1 RP11-548H3.1 -4.22 4.2e-05 0.017 -0.29 -0.32 Breast cancer; chr2:217876772 chr2:218633256~218634014:- PAAD cis rs4853525 0.522 rs62179715 ENSG00000235852.1 AC005540.3 4.22 4.2e-05 0.017 0.45 0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190705346 chr2:190880797~190882059:- PAAD cis rs7246657 0.551 rs4806413 ENSG00000267422.1 CTD-2554C21.1 -4.22 4.21e-05 0.017 -0.61 -0.32 Coronary artery calcification; chr19:37126814 chr19:37779686~37792865:+ PAAD cis rs2658782 1 rs2658782 ENSG00000279684.1 RP11-755E23.2 -4.22 4.21e-05 0.017 -0.54 -0.32 Pulmonary function decline; chr11:93433565 chr11:93286629~93288903:- PAAD cis rs6504950 0.888 rs2628315 ENSG00000275710.1 RP11-257O5.4 4.22 4.21e-05 0.017 0.39 0.32 Breast cancer; chr17:55149261 chr17:54964474~54964679:+ PAAD cis rs4218 0.681 rs17302163 ENSG00000277144.1 RP11-59H7.4 -4.22 4.21e-05 0.017 -0.44 -0.32 Social communication problems; chr15:59076773 chr15:59115547~59116089:- PAAD cis rs2303759 0.918 rs2288480 ENSG00000268686.1 AC010524.2 -4.22 4.21e-05 0.017 -0.44 -0.32 Multiple sclerosis; chr19:49363759 chr19:49368705~49388081:- PAAD cis rs2303759 1 rs2303759 ENSG00000268686.1 AC010524.2 -4.22 4.21e-05 0.017 -0.44 -0.32 Multiple sclerosis; chr19:49365794 chr19:49368705~49388081:- PAAD cis rs6860540 0.796 rs6879450 ENSG00000251405.2 CTB-109A12.1 -4.22 4.21e-05 0.017 -0.42 -0.32 Inflammatory skin disease; chr5:157471959 chr5:157362615~157460078:- PAAD cis rs4664293 0.747 rs7600347 ENSG00000226266.5 AC009961.3 -4.22 4.21e-05 0.017 -0.42 -0.32 Monocyte percentage of white cells; chr2:159800981 chr2:159670708~159712435:- PAAD cis rs9368481 0.761 rs4713062 ENSG00000241549.7 GUSBP2 -4.22 4.21e-05 0.017 -0.34 -0.32 Autism spectrum disorder or schizophrenia; chr6:26980416 chr6:26871484~26956554:- PAAD cis rs76963786 0.515 rs1779715 ENSG00000223722.3 RP11-467L13.5 4.22 4.21e-05 0.017 0.51 0.32 Interleukin-9 levels; chr12:31912955 chr12:31754720~31755121:+ PAAD cis rs11690935 0.55 rs6730085 ENSG00000228389.1 AC068039.4 -4.22 4.22e-05 0.0171 -0.4 -0.32 Schizophrenia; chr2:171999938 chr2:171773482~171775844:+ PAAD cis rs5758511 0.633 rs5758690 ENSG00000226450.2 CYP2D8P 4.22 4.22e-05 0.0171 0.32 0.32 Birth weight; chr22:42272289 chr22:42149886~42155001:- PAAD cis rs2980439 0.557 rs2976876 ENSG00000253981.4 ALG1L13P 4.22 4.22e-05 0.0171 0.39 0.32 Neuroticism; chr8:8461340 chr8:8236003~8244667:- PAAD cis rs2945232 1 rs2945232 ENSG00000254340.1 RP11-10A14.3 4.22 4.22e-05 0.0171 0.41 0.32 Schizophrenia; chr8:8240516 chr8:9141424~9145435:+ PAAD cis rs853679 0.55 rs1233704 ENSG00000280107.1 AL022393.9 4.22 4.22e-05 0.0171 0.53 0.32 Depression; chr6:28199145 chr6:28170845~28172521:+ PAAD cis rs748404 0.578 rs1058298 ENSG00000205771.5 CATSPER2P1 -4.22 4.23e-05 0.0171 -0.43 -0.32 Lung cancer; chr15:43408732 chr15:43726918~43747094:- PAAD cis rs11098499 0.604 rs2389886 ENSG00000245958.5 RP11-33B1.1 -4.22 4.23e-05 0.0171 -0.28 -0.32 Corneal astigmatism; chr4:119649267 chr4:119454791~119552025:+ PAAD cis rs7617773 0.817 rs6794644 ENSG00000228638.1 FCF1P2 -4.22 4.23e-05 0.0171 -0.36 -0.32 Coronary artery disease; chr3:48288547 chr3:48290793~48291375:- PAAD cis rs3738443 0.645 rs55768801 ENSG00000259865.1 RP11-488L18.10 4.22 4.24e-05 0.0171 0.28 0.32 Alcohol dependence; chr1:247199688 chr1:247187281~247188526:- PAAD cis rs357618 0.531 rs152389 ENSG00000271795.1 CTC-251D13.1 4.22 4.24e-05 0.0171 0.39 0.32 Basophil percentage of white cells; chr5:151482619 chr5:151509453~151512769:+ PAAD cis rs2243480 1 rs313813 ENSG00000232546.1 RP11-458F8.1 -4.22 4.24e-05 0.0171 -0.39 -0.32 Diabetic kidney disease; chr7:66038513 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs427044 ENSG00000232546.1 RP11-458F8.1 -4.22 4.24e-05 0.0171 -0.39 -0.32 Diabetic kidney disease; chr7:66043558 chr7:66848496~66858136:+ PAAD cis rs10129255 0.536 rs10139058 ENSG00000211972.2 IGHV3-66 4.22 4.24e-05 0.0171 0.25 0.32 Kawasaki disease; chr14:106685899 chr14:106675017~106675544:- PAAD cis rs10129255 0.536 rs8004835 ENSG00000211972.2 IGHV3-66 4.22 4.24e-05 0.0171 0.25 0.32 Kawasaki disease; chr14:106686361 chr14:106675017~106675544:- PAAD cis rs2581828 0.618 rs1560332 ENSG00000242142.1 SERBP1P3 4.22 4.24e-05 0.0171 0.4 0.32 Crohn's disease; chr3:53130787 chr3:53064283~53065091:- PAAD cis rs9649213 0.593 rs6465666 ENSG00000272950.1 RP11-307C18.1 -4.22 4.24e-05 0.0171 -0.37 -0.32 Prostate cancer (SNP x SNP interaction); chr7:98307946 chr7:98322853~98323430:+ PAAD cis rs2581828 0.646 rs13433700 ENSG00000242142.1 SERBP1P3 -4.22 4.24e-05 0.0171 -0.41 -0.32 Crohn's disease; chr3:53113870 chr3:53064283~53065091:- PAAD cis rs919433 0.926 rs787997 ENSG00000231621.1 AC013264.2 -4.22 4.24e-05 0.0171 -0.31 -0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197351547 chr2:197197991~197199273:+ PAAD cis rs1113500 0.933 rs4593854 ENSG00000226822.1 RP11-356N1.2 4.22 4.25e-05 0.0171 0.38 0.32 Growth-regulated protein alpha levels; chr1:108095897 chr1:108071482~108074519:+ PAAD cis rs79349575 0.783 rs15563 ENSG00000270781.1 RP11-501C14.9 -4.22 4.25e-05 0.0171 -0.36 -0.32 Type 2 diabetes; chr17:48927831 chr17:48899131~48899748:+ PAAD cis rs7684446 1 rs7684446 ENSG00000273133.1 RP11-799M12.2 4.22 4.25e-05 0.0171 0.38 0.32 Red blood cell count; chr4:15591241 chr4:15563698~15564253:- PAAD cis rs1789 0.653 rs13142069 ENSG00000273133.1 RP11-799M12.2 4.22 4.25e-05 0.0171 0.38 0.32 Blood protein levels; chr4:15592069 chr4:15563698~15564253:- PAAD cis rs7216064 1 rs4790908 ENSG00000278219.1 AC145343.1 -4.22 4.25e-05 0.0171 -0.5 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67856791 chr17:68101538~68101639:+ PAAD cis rs2562456 0.917 rs2681376 ENSG00000213976.4 CTD-2561J22.2 4.22 4.26e-05 0.0172 0.37 0.32 Pain; chr19:21532723 chr19:21382865~21387177:+ PAAD cis rs494459 0.838 rs607125 ENSG00000278376.1 RP11-158I9.8 -4.22 4.26e-05 0.0172 -0.29 -0.32 Height; chr11:118746590 chr11:118791254~118793137:+ PAAD cis rs6991838 0.702 rs34496943 ENSG00000200714.1 Y_RNA 4.21 4.27e-05 0.0172 0.38 0.32 Intelligence (multi-trait analysis); chr8:65676978 chr8:65592731~65592820:+ PAAD cis rs6991838 0.733 rs13281090 ENSG00000200714.1 Y_RNA 4.21 4.27e-05 0.0172 0.38 0.32 Intelligence (multi-trait analysis); chr8:65678244 chr8:65592731~65592820:+ PAAD cis rs6991838 0.701 rs17395275 ENSG00000200714.1 Y_RNA 4.21 4.27e-05 0.0172 0.38 0.32 Intelligence (multi-trait analysis); chr8:65679003 chr8:65592731~65592820:+ PAAD cis rs2562456 0.834 rs2173727 ENSG00000213976.4 CTD-2561J22.2 4.21 4.28e-05 0.0172 0.36 0.32 Pain; chr19:21491155 chr19:21382865~21387177:+ PAAD cis rs10779751 1 rs2300093 ENSG00000238199.1 UBE2V2P3 -4.21 4.28e-05 0.0172 -0.39 -0.32 Body mass index; chr1:11206335 chr1:11278616~11279351:- PAAD cis rs10779751 0.959 rs2300091 ENSG00000238199.1 UBE2V2P3 -4.21 4.28e-05 0.0172 -0.39 -0.32 Body mass index; chr1:11206654 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs11121698 ENSG00000238199.1 UBE2V2P3 -4.21 4.28e-05 0.0172 -0.39 -0.32 Body mass index; chr1:11207226 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs742824 ENSG00000238199.1 UBE2V2P3 -4.21 4.28e-05 0.0172 -0.39 -0.32 Body mass index; chr1:11213965 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs4845856 ENSG00000238199.1 UBE2V2P3 -4.21 4.28e-05 0.0172 -0.39 -0.32 Body mass index; chr1:11214490 chr1:11278616~11279351:- PAAD cis rs28386778 0.897 rs3744293 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63764428 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs6504184 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63765048 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs8081454 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63765286 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs58269663 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63765770 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs8067102 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63771419 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs6504185 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63771432 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs8077013 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63773032 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs9906247 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63779954 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs7221853 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63782476 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs7207005 ENSG00000240280.5 TCAM1P -4.21 4.28e-05 0.0172 -0.45 -0.32 Prudent dietary pattern; chr17:63782995 chr17:63849292~63864379:+ PAAD cis rs2739330 0.734 rs2000467 ENSG00000231271.1 AP000350.8 -4.21 4.28e-05 0.0172 -0.46 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23949918~23954042:+ PAAD cis rs116139393 0.561 rs62439737 ENSG00000187953.9 PMS2CL -4.21 4.28e-05 0.0172 -0.4 -0.32 Alzheimer's disease (APOE e4 interaction); chr7:6740179 chr7:6710128~6753862:+ PAAD cis rs7849270 0.879 rs10819461 ENSG00000268707.1 RP11-247A12.7 -4.21 4.28e-05 0.0172 -0.41 -0.32 Blood metabolite ratios; chr9:129079608 chr9:129170434~129170940:+ PAAD cis rs700651 0.789 rs2196176 ENSG00000231621.1 AC013264.2 -4.21 4.28e-05 0.0172 -0.33 -0.32 Intracranial aneurysm; chr2:198040190 chr2:197197991~197199273:+ PAAD cis rs700651 0.789 rs892514 ENSG00000231621.1 AC013264.2 -4.21 4.28e-05 0.0172 -0.33 -0.32 Intracranial aneurysm; chr2:198040546 chr2:197197991~197199273:+ PAAD cis rs858239 0.601 rs3735228 ENSG00000226816.2 AC005082.12 4.21 4.28e-05 0.0172 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23130808 chr7:23206013~23208045:+ PAAD cis rs9326248 0.581 rs10502222 ENSG00000280143.1 AP000892.6 4.21 4.28e-05 0.0172 0.36 0.32 Blood protein levels; chr11:116963014 chr11:117204967~117210292:+ PAAD cis rs9326248 0.559 rs10892052 ENSG00000280143.1 AP000892.6 4.21 4.28e-05 0.0172 0.36 0.32 Blood protein levels; chr11:116963597 chr11:117204967~117210292:+ PAAD cis rs2911132 0.967 rs2042380 ENSG00000248734.2 CTD-2260A17.1 4.21 4.29e-05 0.0172 0.3 0.32 Urate levels (BMI interaction); chr5:96851563 chr5:96784777~96785999:+ PAAD cis rs875971 0.522 rs2949690 ENSG00000234585.5 CCT6P3 -4.21 4.29e-05 0.0172 -0.26 -0.32 Aortic root size; chr7:66018255 chr7:65038354~65074713:+ PAAD cis rs875971 0.54 rs1723268 ENSG00000234585.5 CCT6P3 4.21 4.29e-05 0.0172 0.26 0.32 Aortic root size; chr7:66008093 chr7:65038354~65074713:+ PAAD cis rs875971 0.522 rs1701760 ENSG00000234585.5 CCT6P3 4.21 4.29e-05 0.0172 0.26 0.32 Aortic root size; chr7:66008701 chr7:65038354~65074713:+ PAAD cis rs5015933 0.815 rs10114168 ENSG00000232630.1 PRPS1P2 -4.21 4.29e-05 0.0172 -0.29 -0.32 Body mass index; chr9:125273170 chr9:125150653~125151589:+ PAAD cis rs9926296 0.656 rs2376882 ENSG00000260259.1 RP11-368I7.4 -4.21 4.29e-05 0.0173 -0.38 -0.32 Vitiligo; chr16:89760594 chr16:89682620~89686569:- PAAD cis rs8081395 0.651 rs1292067 ENSG00000266992.1 DHX40P1 -4.21 4.29e-05 0.0173 -0.35 -0.32 White blood cell count; chr17:59853285 chr17:59976009~60002384:- PAAD cis rs6052484 0.523 rs56309952 ENSG00000226948.1 RPS4XP2 -4.21 4.29e-05 0.0173 -0.49 -0.32 Sense of smell; chr20:4342230 chr20:4629427~4630219:- PAAD cis rs6052484 0.523 rs61330129 ENSG00000226948.1 RPS4XP2 -4.21 4.29e-05 0.0173 -0.49 -0.32 Sense of smell; chr20:4343931 chr20:4629427~4630219:- PAAD cis rs494459 0.838 rs488219 ENSG00000278376.1 RP11-158I9.8 -4.21 4.29e-05 0.0173 -0.28 -0.32 Height; chr11:118749988 chr11:118791254~118793137:+ PAAD cis rs1990950 0.933 rs11747685 ENSG00000251405.2 CTB-109A12.1 -4.21 4.29e-05 0.0173 -0.39 -0.32 Lung function (FEV1/FVC); chr5:157476582 chr5:157362615~157460078:- PAAD cis rs2980439 0.557 rs2921056 ENSG00000253981.4 ALG1L13P 4.21 4.29e-05 0.0173 0.39 0.32 Neuroticism; chr8:8461672 chr8:8236003~8244667:- PAAD cis rs7826238 0.524 rs2921055 ENSG00000253981.4 ALG1L13P 4.21 4.29e-05 0.0173 0.39 0.32 Systolic blood pressure; chr8:8461832 chr8:8236003~8244667:- PAAD cis rs1873386 0.79 rs7971887 ENSG00000255910.1 RP11-405A12.2 4.21 4.29e-05 0.0173 0.47 0.32 Personality dimensions; chr12:18914405 chr12:19775451~20009937:+ PAAD cis rs2505998 1 rs2435356 ENSG00000273008.1 RP11-351D16.3 4.21 4.3e-05 0.0173 0.28 0.32 Hirschsprung disease; chr10:43087702 chr10:43136824~43138334:- PAAD cis rs6545883 0.56 rs11677775 ENSG00000273302.1 RP11-493E12.2 -4.21 4.3e-05 0.0173 -0.29 -0.32 Tuberculosis; chr2:61275975 chr2:61199979~61200769:+ PAAD cis rs12935418 0.672 rs78895138 ENSG00000261061.1 RP11-303E16.2 -4.21 4.3e-05 0.0173 -0.4 -0.32 Mean corpuscular volume; chr16:81014820 chr16:81030770~81031485:+ PAAD cis rs2153535 0.562 rs10458225 ENSG00000230939.1 RP11-314C16.1 4.21 4.3e-05 0.0173 0.34 0.32 Motion sickness; chr6:8385771 chr6:8784178~8785445:+ PAAD cis rs4423214 0.592 rs11233933 ENSG00000254682.1 RP11-660L16.2 -4.21 4.3e-05 0.0173 -0.55 -0.32 Vitamin D levels; chr11:71499024 chr11:71448674~71452157:+ PAAD cis rs6909229 0.74 rs2502607 ENSG00000233893.1 EZR-AS1 4.21 4.3e-05 0.0173 0.45 0.32 Lipoprotein (a) levels; chr6:158110136 chr6:158818011~158820593:+ PAAD cis rs9807989 0.524 rs6759479 ENSG00000234389.1 AC007278.3 4.21 4.3e-05 0.0173 0.32 0.32 Asthma; chr2:102423587 chr2:102438713~102440475:+ PAAD cis rs6570726 1 rs951143 ENSG00000235652.6 RP11-545I5.3 4.21 4.31e-05 0.0173 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145611440 chr6:145799409~145886585:+ PAAD cis rs7637701 0.818 rs10936038 ENSG00000240875.4 LINC00886 -4.21 4.31e-05 0.0173 -0.39 -0.32 Breast cancer; chr3:156814877 chr3:156747346~156817062:- PAAD cis rs7637701 0.818 rs11711674 ENSG00000240875.4 LINC00886 -4.21 4.31e-05 0.0173 -0.39 -0.32 Breast cancer; chr3:156815164 chr3:156747346~156817062:- PAAD cis rs7637701 0.818 rs1560415 ENSG00000240875.4 LINC00886 -4.21 4.31e-05 0.0173 -0.39 -0.32 Breast cancer; chr3:156819569 chr3:156747346~156817062:- PAAD cis rs7637701 0.818 rs1560416 ENSG00000240875.4 LINC00886 -4.21 4.31e-05 0.0173 -0.39 -0.32 Breast cancer; chr3:156819630 chr3:156747346~156817062:- PAAD cis rs7637701 0.818 rs9837271 ENSG00000240875.4 LINC00886 -4.21 4.31e-05 0.0173 -0.39 -0.32 Breast cancer; chr3:156820949 chr3:156747346~156817062:- PAAD cis rs780096 0.587 rs6743819 ENSG00000234072.1 AC074117.10 -4.21 4.31e-05 0.0173 -0.25 -0.32 Total body bone mineral density; chr2:27344540 chr2:27356246~27367622:+ PAAD cis rs780096 0.587 rs10205219 ENSG00000234072.1 AC074117.10 -4.21 4.31e-05 0.0173 -0.25 -0.32 Total body bone mineral density; chr2:27345698 chr2:27356246~27367622:+ PAAD cis rs7637701 0.967 rs9837038 ENSG00000240875.4 LINC00886 4.21 4.31e-05 0.0173 0.39 0.32 Breast cancer; chr3:156850680 chr3:156747346~156817062:- PAAD cis rs6436017 0.589 rs4674220 ENSG00000273466.1 RP11-548H3.1 4.21 4.31e-05 0.0173 0.29 0.32 Breast cancer; chr2:217877279 chr2:218633256~218634014:- PAAD cis rs858239 0.6 rs10235786 ENSG00000226816.2 AC005082.12 4.21 4.31e-05 0.0173 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23100321 chr7:23206013~23208045:+ PAAD cis rs858239 0.6 rs10233039 ENSG00000226816.2 AC005082.12 4.21 4.31e-05 0.0173 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23103494 chr7:23206013~23208045:+ PAAD cis rs2945232 1 rs2945232 ENSG00000173295.6 FAM86B3P 4.21 4.31e-05 0.0173 0.35 0.32 Schizophrenia; chr8:8240516 chr8:8228595~8244865:+ PAAD cis rs28386778 0.897 rs6504176 ENSG00000240280.5 TCAM1P -4.21 4.31e-05 0.0173 -0.45 -0.32 Prudent dietary pattern; chr17:63734560 chr17:63849292~63864379:+ PAAD cis rs6479891 0.908 rs16918603 ENSG00000232075.1 MRPL35P2 4.21 4.32e-05 0.0173 0.52 0.32 Arthritis (juvenile idiopathic); chr10:63561712 chr10:63634317~63634827:- PAAD cis rs8177376 0.727 rs240552 ENSG00000254905.1 RP11-712L6.7 4.21 4.32e-05 0.0173 0.42 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126333818 chr11:126292922~126294254:- PAAD cis rs797680 0.897 rs12133907 ENSG00000223745.6 RP4-717I23.3 4.21 4.32e-05 0.0173 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93384726 chr1:93262186~93346025:- PAAD cis rs4927850 0.501 rs9881504 ENSG00000231464.1 AC024937.4 4.21 4.32e-05 0.0174 0.41 0.32 Pancreatic cancer; chr3:195929743 chr3:195996738~195998233:+ PAAD cis rs2281636 0.858 rs7068079 ENSG00000233690.1 EBAG9P1 -4.21 4.32e-05 0.0174 -0.35 -0.32 Obesity-related traits; chr10:99607558 chr10:99697407~99697949:- PAAD cis rs9876781 1 rs4858817 ENSG00000229759.1 MRPS18AP1 -4.21 4.33e-05 0.0174 -0.35 -0.32 Longevity; chr3:48375266 chr3:48256350~48256938:- PAAD cis rs4853525 1 rs4853525 ENSG00000235852.1 AC005540.3 4.21 4.33e-05 0.0174 0.43 0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190872738 chr2:190880797~190882059:- PAAD cis rs1707322 0.716 rs6694889 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45636134 chr1:45581219~45581321:- PAAD cis rs1707322 0.682 rs12041197 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638792 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs11211146 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644122 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs11211147 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45644422 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs4660313 ENSG00000280836.1 AL355480.1 4.21 4.33e-05 0.0174 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645169 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs11211149 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45646546 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs4607935 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651489 chr1:45581219~45581321:- PAAD cis rs1707322 0.681 rs12048866 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45651820 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs3811436 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45660208 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs12024590 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45661824 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs12027622 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45664580 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs4415615 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45666437 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs7529699 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668962 chr1:45581219~45581321:- PAAD cis rs1707322 0.716 rs6699444 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45669448 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs10430105 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45673204 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs10890341 ENSG00000280836.1 AL355480.1 -4.21 4.33e-05 0.0174 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45681568 chr1:45581219~45581321:- PAAD cis rs338389 0.542 rs11071972 ENSG00000260657.2 RP11-315D16.4 -4.21 4.33e-05 0.0174 -0.37 -0.32 Survival in rectal cancer; chr15:67984005 chr15:68267792~68277994:- PAAD cis rs812925 0.784 rs6735081 ENSG00000271889.1 RP11-493E12.1 -4.21 4.33e-05 0.0174 -0.36 -0.32 Immature fraction of reticulocytes; chr2:61233582 chr2:61151433~61162105:- PAAD cis rs812925 0.784 rs7588041 ENSG00000271889.1 RP11-493E12.1 -4.21 4.33e-05 0.0174 -0.36 -0.32 Immature fraction of reticulocytes; chr2:61234277 chr2:61151433~61162105:- PAAD cis rs2486288 0.656 rs8039352 ENSG00000259433.2 CTD-2651B20.4 4.21 4.34e-05 0.0174 0.36 0.32 Glomerular filtration rate; chr15:45259592 chr15:45330209~45332634:- PAAD cis rs6570726 0.935 rs400968 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145498582 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs391820 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145500148 chr6:145799409~145886585:+ PAAD cis rs6570726 0.875 rs1883407 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145502296 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs421032 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145506635 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs9390329 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145506890 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs367612 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145507851 chr6:145799409~145886585:+ PAAD cis rs6570726 0.902 rs406979 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145517847 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs375692 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145519232 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs371744 ENSG00000235652.6 RP11-545I5.3 4.21 4.35e-05 0.0174 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145519888 chr6:145799409~145886585:+ PAAD cis rs2564921 0.704 rs62255931 ENSG00000242142.1 SERBP1P3 -4.21 4.35e-05 0.0174 -0.41 -0.32 Height; chr3:53097932 chr3:53064283~53065091:- PAAD cis rs7617773 0.817 rs9819094 ENSG00000228638.1 FCF1P2 -4.21 4.35e-05 0.0174 -0.37 -0.32 Coronary artery disease; chr3:48278068 chr3:48290793~48291375:- PAAD cis rs9487094 0.961 rs9487068 ENSG00000260273.1 RP11-425D10.10 4.21 4.35e-05 0.0174 0.42 0.32 Height; chr6:109350642 chr6:109382795~109383666:+ PAAD cis rs694739 0.628 rs538147 ENSG00000236935.1 AP003774.1 4.21 4.35e-05 0.0174 0.34 0.32 Alopecia areata;Crohn's disease;Psoriasis vulgaris; chr11:64362250 chr11:64325050~64329504:- PAAD cis rs5742933 0.597 rs12471663 ENSG00000273240.1 RP11-455J20.3 4.21 4.35e-05 0.0174 0.4 0.32 Ferritin levels; chr2:189642372 chr2:189763859~189764456:- PAAD cis rs5742933 0.597 rs6761923 ENSG00000273240.1 RP11-455J20.3 4.21 4.35e-05 0.0174 0.4 0.32 Ferritin levels; chr2:189642873 chr2:189763859~189764456:- PAAD cis rs3738443 1 rs61840059 ENSG00000259865.1 RP11-488L18.10 4.21 4.35e-05 0.0174 0.3 0.32 Alcohol dependence; chr1:247207676 chr1:247187281~247188526:- PAAD cis rs3738443 1 rs75028588 ENSG00000259865.1 RP11-488L18.10 4.21 4.35e-05 0.0174 0.3 0.32 Alcohol dependence; chr1:247208350 chr1:247187281~247188526:- PAAD cis rs3738443 1 rs56340510 ENSG00000259865.1 RP11-488L18.10 4.21 4.35e-05 0.0174 0.3 0.32 Alcohol dependence; chr1:247208707 chr1:247187281~247188526:- PAAD cis rs113835537 0.935 rs76228630 ENSG00000255517.5 CTD-3074O7.5 -4.21 4.35e-05 0.0174 -0.53 -0.32 Airway imaging phenotypes; chr11:66691205 chr11:66473490~66480233:- PAAD cis rs9584850 0.718 rs6491427 ENSG00000231194.1 FARP1-AS1 4.21 4.36e-05 0.0175 0.41 0.32 Neuroticism; chr13:98460912 chr13:98435405~98435840:- PAAD cis rs440932 0.887 rs398801 ENSG00000254340.1 RP11-10A14.3 -4.21 4.36e-05 0.0175 -0.4 -0.32 High light scatter reticulocyte percentage of red cells; chr8:9174194 chr8:9141424~9145435:+ PAAD cis rs4664293 0.632 rs7588230 ENSG00000226266.5 AC009961.3 4.21 4.36e-05 0.0175 0.4 0.32 Monocyte percentage of white cells; chr2:159797209 chr2:159670708~159712435:- PAAD cis rs9876781 1 rs9849509 ENSG00000229759.1 MRPS18AP1 4.21 4.36e-05 0.0175 0.35 0.32 Longevity; chr3:48442021 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs60512868 ENSG00000229759.1 MRPS18AP1 4.21 4.36e-05 0.0175 0.35 0.32 Longevity; chr3:48442035 chr3:48256350~48256938:- PAAD cis rs193541 0.632 rs1903260 ENSG00000263432.2 RN7SL689P 4.21 4.36e-05 0.0175 0.42 0.32 Glucose homeostasis traits; chr5:122799493 chr5:123022487~123022783:- PAAD cis rs17711722 0.51 rs11767457 ENSG00000226824.5 RP4-756H11.3 -4.21 4.36e-05 0.0175 -0.38 -0.32 Calcium levels; chr7:65825628 chr7:66654538~66669855:+ PAAD cis rs6904897 0.563 rs4896117 ENSG00000232876.1 CTA-212D2.2 4.21 4.37e-05 0.0175 0.37 0.32 Mean corpuscular volume;Mean corpuscular hemoglobin; chr6:134908262 chr6:135055033~135060550:+ PAAD cis rs2581828 0.609 rs73088342 ENSG00000242142.1 SERBP1P3 -4.21 4.37e-05 0.0175 -0.4 -0.32 Crohn's disease; chr3:53117648 chr3:53064283~53065091:- PAAD cis rs2581828 0.646 rs9878875 ENSG00000242142.1 SERBP1P3 -4.21 4.37e-05 0.0175 -0.4 -0.32 Crohn's disease; chr3:53122851 chr3:53064283~53065091:- PAAD cis rs889398 0.771 rs1566453 ENSG00000226232.7 RP11-419C5.2 -4.21 4.37e-05 0.0175 -0.25 -0.32 Body mass index; chr16:69865884 chr16:69976388~69996188:- PAAD cis rs2243480 1 rs383402 ENSG00000273142.1 RP11-458F8.4 4.21 4.37e-05 0.0175 0.3 0.32 Diabetic kidney disease; chr7:66121666 chr7:66902857~66906297:+ PAAD cis rs6743226 0.603 rs55659209 ENSG00000266621.1 AC104841.1 4.21 4.37e-05 0.0175 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241314902 chr2:241245202~241245299:- PAAD cis rs858239 0.539 rs4559148 ENSG00000226816.2 AC005082.12 4.21 4.37e-05 0.0175 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23146348 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs4377861 ENSG00000226816.2 AC005082.12 4.21 4.37e-05 0.0175 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23146350 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs6975852 ENSG00000226816.2 AC005082.12 4.21 4.37e-05 0.0175 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23147035 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs10247268 ENSG00000226816.2 AC005082.12 4.21 4.37e-05 0.0175 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23147560 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs6461694 ENSG00000226816.2 AC005082.12 4.21 4.37e-05 0.0175 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23148160 chr7:23206013~23208045:+ PAAD cis rs858239 0.508 rs7805071 ENSG00000226816.2 AC005082.12 4.21 4.37e-05 0.0175 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23150593 chr7:23206013~23208045:+ PAAD cis rs858239 0.508 rs7805085 ENSG00000226816.2 AC005082.12 4.21 4.37e-05 0.0175 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23150624 chr7:23206013~23208045:+ PAAD cis rs858239 0.508 rs2390754 ENSG00000226816.2 AC005082.12 4.21 4.37e-05 0.0175 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23150875 chr7:23206013~23208045:+ PAAD cis rs7849973 0.551 rs10117155 ENSG00000224549.1 RP11-370B11.3 4.21 4.37e-05 0.0175 0.38 0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22809464 chr9:22767175~22768316:+ PAAD cis rs812925 0.537 rs778146 ENSG00000273302.1 RP11-493E12.2 -4.21 4.37e-05 0.0175 -0.28 -0.32 Immature fraction of reticulocytes; chr2:61379340 chr2:61199979~61200769:+ PAAD cis rs7759001 0.744 rs10946933 ENSG00000271755.1 RP1-153G14.4 4.21 4.38e-05 0.0175 0.39 0.32 Glomerular filtration rate (creatinine); chr6:27503319 chr6:27404010~27406964:- PAAD cis rs6472235 1 rs60120959 ENSG00000200714.1 Y_RNA -4.21 4.38e-05 0.0175 -0.42 -0.32 Plateletcrit;Myopia (pathological); chr8:65887471 chr8:65592731~65592820:+ PAAD cis rs4794202 1 rs4794202 ENSG00000264920.1 RP11-6N17.4 -4.21 4.38e-05 0.0175 -0.48 -0.32 Alzheimer's disease (cognitive decline); chr17:47853173 chr17:47891255~47895812:- PAAD cis rs748404 0.697 rs493177 ENSG00000205771.5 CATSPER2P1 -4.21 4.38e-05 0.0175 -0.42 -0.32 Lung cancer; chr15:43251060 chr15:43726918~43747094:- PAAD cis rs5015933 0.815 rs10819041 ENSG00000232630.1 PRPS1P2 -4.21 4.38e-05 0.0175 -0.29 -0.32 Body mass index; chr9:125268558 chr9:125150653~125151589:+ PAAD cis rs2262909 0.893 rs4244912 ENSG00000279377.1 AC003973.3 4.21 4.38e-05 0.0175 0.31 0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22020435 chr19:21965708~21968529:- PAAD cis rs2262909 0.924 rs11085509 ENSG00000279377.1 AC003973.3 4.21 4.38e-05 0.0175 0.31 0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22021771 chr19:21965708~21968529:- PAAD cis rs2262909 1 rs2359821 ENSG00000279377.1 AC003973.3 4.21 4.38e-05 0.0175 0.31 0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22025512 chr19:21965708~21968529:- PAAD cis rs2262909 1 rs2017962 ENSG00000279377.1 AC003973.3 4.21 4.38e-05 0.0175 0.31 0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22025949 chr19:21965708~21968529:- PAAD cis rs2262909 1 rs2078089 ENSG00000279377.1 AC003973.3 4.21 4.38e-05 0.0175 0.31 0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22026951 chr19:21965708~21968529:- PAAD cis rs2262909 1 rs436039 ENSG00000279377.1 AC003973.3 4.21 4.38e-05 0.0175 0.31 0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22032071 chr19:21965708~21968529:- PAAD cis rs2262909 0.925 rs404822 ENSG00000279377.1 AC003973.3 4.21 4.38e-05 0.0175 0.31 0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22033165 chr19:21965708~21968529:- PAAD cis rs2230624 1 rs76823085 ENSG00000242349.4 NPPA-AS1 -4.21 4.38e-05 0.0175 -0.65 -0.32 Mosquito bite size; chr1:11823491 chr1:11841017~11848079:+ PAAD cis rs9876781 1 rs28824259 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48384185 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs12487542 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48384586 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs9864371 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48385276 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs73074358 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48385757 chr3:48256350~48256938:- PAAD cis rs9876781 0.967 rs34761139 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48386489 chr3:48256350~48256938:- PAAD cis rs9876781 0.868 rs9875280 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48387420 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs6796491 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48388977 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs6804774 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48389129 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs9826195 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48392157 chr3:48256350~48256938:- PAAD cis rs9876781 0.967 rs9864815 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48392588 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs9809843 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48392923 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs11712561 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48393807 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs1563736 ENSG00000229759.1 MRPS18AP1 4.21 4.38e-05 0.0175 0.35 0.32 Longevity; chr3:48395329 chr3:48256350~48256938:- PAAD cis rs42490 0.7 rs40459 ENSG00000251136.7 RP11-37B2.1 4.21 4.38e-05 0.0175 0.3 0.32 Leprosy; chr8:89833998 chr8:89609409~89757727:- PAAD cis rs7617773 0.817 rs936426 ENSG00000228638.1 FCF1P2 -4.21 4.39e-05 0.0175 -0.36 -0.32 Coronary artery disease; chr3:48173763 chr3:48290793~48291375:- PAAD cis rs4725617 0.686 rs41277428 ENSG00000176510.4 OR10AC1 4.21 4.39e-05 0.0175 0.68 0.32 Blood protein levels; chr7:143388729 chr7:143510933~143511911:- PAAD cis rs7202877 0.61 rs3844219 ENSG00000261783.1 RP11-252K23.2 -4.21 4.39e-05 0.0176 -0.5 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75336332 chr16:75379818~75381260:- PAAD cis rs748404 0.587 rs9920879 ENSG00000205771.5 CATSPER2P1 -4.21 4.39e-05 0.0176 -0.44 -0.32 Lung cancer; chr15:43347572 chr15:43726918~43747094:- PAAD cis rs748404 0.631 rs7166812 ENSG00000205771.5 CATSPER2P1 -4.21 4.39e-05 0.0176 -0.44 -0.32 Lung cancer; chr15:43352562 chr15:43726918~43747094:- PAAD cis rs11096990 0.593 rs4580660 ENSG00000249207.1 RP11-360F5.1 -4.21 4.39e-05 0.0176 -0.33 -0.32 Cognitive function; chr4:39152216 chr4:39112677~39126818:- PAAD cis rs11096990 0.551 rs11724855 ENSG00000249207.1 RP11-360F5.1 -4.21 4.39e-05 0.0176 -0.33 -0.32 Cognitive function; chr4:39163379 chr4:39112677~39126818:- PAAD cis rs394563 0.69 rs237009 ENSG00000231760.4 RP11-350J20.5 4.21 4.39e-05 0.0176 0.45 0.32 Dupuytren's disease; chr6:149438416 chr6:149796151~149826294:- PAAD cis rs270601 0.69 rs162907 ENSG00000233006.5 AC034220.3 -4.21 4.4e-05 0.0176 -0.27 -0.32 Acylcarnitine levels; chr5:132244459 chr5:132311285~132369916:- PAAD cis rs270601 0.71 rs371709 ENSG00000233006.5 AC034220.3 4.21 4.4e-05 0.0176 0.27 0.32 Acylcarnitine levels; chr5:132247547 chr5:132311285~132369916:- PAAD cis rs2832077 0.527 rs2250141 ENSG00000176054.6 RPL23P2 4.21 4.4e-05 0.0176 0.31 0.32 Cognitive test performance; chr21:28869662 chr21:28997613~28998033:- PAAD cis rs8072100 1 rs8072100 ENSG00000228782.6 CTD-2026D20.3 -4.21 4.4e-05 0.0176 -0.31 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47597321 chr17:47450568~47492492:- PAAD cis rs700651 0.789 rs1813106 ENSG00000231621.1 AC013264.2 -4.21 4.4e-05 0.0176 -0.32 -0.32 Intracranial aneurysm; chr2:198015865 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs1836234 ENSG00000231621.1 AC013264.2 -4.21 4.4e-05 0.0176 -0.32 -0.32 Dermatomyositis; chr2:198018149 chr2:197197991~197199273:+ PAAD cis rs700651 0.789 rs116165148 ENSG00000231621.1 AC013264.2 -4.21 4.4e-05 0.0176 -0.32 -0.32 Intracranial aneurysm; chr2:198023623 chr2:197197991~197199273:+ PAAD cis rs700651 0.789 rs1978889 ENSG00000231621.1 AC013264.2 -4.21 4.4e-05 0.0176 -0.32 -0.32 Intracranial aneurysm; chr2:198024642 chr2:197197991~197199273:+ PAAD cis rs700651 0.789 rs10184395 ENSG00000231621.1 AC013264.2 -4.21 4.4e-05 0.0176 -0.32 -0.32 Intracranial aneurysm; chr2:198029561 chr2:197197991~197199273:+ PAAD cis rs700651 0.789 rs6715070 ENSG00000231621.1 AC013264.2 4.21 4.4e-05 0.0176 0.32 0.32 Intracranial aneurysm; chr2:198033541 chr2:197197991~197199273:+ PAAD cis rs2337406 0.714 rs115401799 ENSG00000211974.3 IGHV2-70 -4.21 4.4e-05 0.0176 -0.45 -0.32 Alzheimer's disease (late onset); chr14:106813739 chr14:106723574~106724093:- PAAD cis rs950169 0.544 rs2036949 ENSG00000259295.5 CSPG4P12 4.21 4.4e-05 0.0176 0.36 0.32 Schizophrenia; chr15:84620374 chr15:85191438~85213905:+ PAAD cis rs6991838 0.733 rs7822627 ENSG00000200714.1 Y_RNA 4.21 4.41e-05 0.0176 0.38 0.32 Intelligence (multi-trait analysis); chr8:65714139 chr8:65592731~65592820:+ PAAD cis rs916888 0.773 rs199534 ENSG00000261575.2 RP11-259G18.1 4.21 4.41e-05 0.0176 0.49 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46267037~46268694:+ PAAD cis rs10759883 0.539 rs10115110 ENSG00000175611.10 LINC00476 4.21 4.41e-05 0.0176 0.32 0.32 Nicotine dependence; chr9:96033023 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs690286 ENSG00000175611.10 LINC00476 4.21 4.41e-05 0.0176 0.32 0.32 Nicotine dependence; chr9:96034685 chr9:95759231~95875977:- PAAD cis rs2985684 1 rs3007030 ENSG00000259113.1 RP11-406H23.2 -4.21 4.41e-05 0.0176 -0.46 -0.32 Carotid intima media thickness; chr14:49619845 chr14:50448807~50456742:+ PAAD cis rs801193 1 rs13239306 ENSG00000237310.1 GS1-124K5.4 -4.21 4.41e-05 0.0176 -0.3 -0.32 Aortic root size; chr7:66671030 chr7:66493706~66495474:+ PAAD cis rs10178409 1 rs10178409 ENSG00000163016.8 ALMS1P 4.21 4.42e-05 0.0176 0.48 0.32 Urinary metabolites; chr2:73628380 chr2:73644919~73685576:+ PAAD cis rs7829975 0.684 rs474892 ENSG00000253893.2 FAM85B 4.21 4.42e-05 0.0176 0.47 0.32 Mood instability; chr8:8739221 chr8:8167819~8226614:- PAAD cis rs4713118 0.586 rs9468290 ENSG00000204709.4 LINC01556 4.21 4.42e-05 0.0176 0.55 0.32 Parkinson's disease; chr6:28119896 chr6:28943877~28944537:+ PAAD cis rs853679 0.517 rs9393894 ENSG00000204709.4 LINC01556 4.21 4.42e-05 0.0176 0.55 0.32 Depression; chr6:28144784 chr6:28943877~28944537:+ PAAD cis rs6479901 0.789 rs7081614 ENSG00000232075.1 MRPL35P2 -4.21 4.42e-05 0.0176 -0.47 -0.32 Intelligence (multi-trait analysis); chr10:63252088 chr10:63634317~63634827:- PAAD cis rs6479901 0.894 rs10761732 ENSG00000232075.1 MRPL35P2 -4.21 4.42e-05 0.0176 -0.47 -0.32 Intelligence (multi-trait analysis); chr10:63268497 chr10:63634317~63634827:- PAAD cis rs6479901 0.793 rs10761733 ENSG00000232075.1 MRPL35P2 -4.21 4.42e-05 0.0176 -0.47 -0.32 Intelligence (multi-trait analysis); chr10:63275024 chr10:63634317~63634827:- PAAD cis rs2446066 0.524 rs2947337 ENSG00000257379.1 RP11-793H13.8 4.21 4.42e-05 0.0176 0.47 0.32 Red blood cell count; chr12:53403214 chr12:53441741~53467528:+ PAAD cis rs2742417 0.967 rs9311378 ENSG00000244357.3 RN7SL145P 4.21 4.42e-05 0.0176 0.3 0.32 Response to anti-depressant treatment in major depressive disorder; chr3:45721643 chr3:45742675~45742970:+ PAAD cis rs4988958 0.565 rs6732138 ENSG00000234389.1 AC007278.3 4.21 4.42e-05 0.0176 0.32 0.32 Asthma (childhood onset); chr2:102393202 chr2:102438713~102440475:+ PAAD cis rs5758511 0.68 rs5758686 ENSG00000226450.2 CYP2D8P 4.21 4.43e-05 0.0176 0.32 0.32 Birth weight; chr22:42259371 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs5758687 ENSG00000226450.2 CYP2D8P 4.21 4.43e-05 0.0176 0.32 0.32 Birth weight; chr22:42260582 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs739146 ENSG00000226450.2 CYP2D8P 4.21 4.43e-05 0.0176 0.32 0.32 Birth weight; chr22:42264408 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs5758688 ENSG00000226450.2 CYP2D8P 4.21 4.43e-05 0.0176 0.32 0.32 Birth weight; chr22:42266495 chr22:42149886~42155001:- PAAD cis rs5758511 0.633 rs5751258 ENSG00000226450.2 CYP2D8P 4.21 4.43e-05 0.0176 0.32 0.32 Birth weight; chr22:42267865 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs56111723 ENSG00000226450.2 CYP2D8P 4.21 4.43e-05 0.0176 0.32 0.32 Birth weight; chr22:42268877 chr22:42149886~42155001:- PAAD cis rs5758511 0.596 rs55644935 ENSG00000226450.2 CYP2D8P 4.21 4.43e-05 0.0176 0.32 0.32 Birth weight; chr22:42270063 chr22:42149886~42155001:- PAAD cis rs867371 0.502 rs3759800 ENSG00000278603.1 RP13-608F4.5 -4.21 4.43e-05 0.0176 -0.38 -0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82240622 chr15:82472203~82472426:+ PAAD cis rs780096 0.546 rs1104 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Total body bone mineral density; chr2:27377008 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs4582 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Total body bone mineral density; chr2:27381412 chr2:27356246~27367622:+ PAAD cis rs780096 0.546 rs1647284 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Total body bone mineral density; chr2:27385248 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs7594812 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Total body bone mineral density; chr2:27388602 chr2:27356246~27367622:+ PAAD cis rs704795 0.805 rs1728926 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Menopause (age at onset); chr2:27390070 chr2:27356246~27367622:+ PAAD cis rs704795 0.836 rs1647281 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Menopause (age at onset); chr2:27390071 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs809058 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Total body bone mineral density; chr2:27393923 chr2:27356246~27367622:+ PAAD cis rs704795 0.836 rs1083865 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Menopause (age at onset); chr2:27397960 chr2:27356246~27367622:+ PAAD cis rs780096 0.546 rs2911712 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Total body bone mineral density; chr2:27404078 chr2:27356246~27367622:+ PAAD cis rs704795 0.867 rs7566052 ENSG00000234072.1 AC074117.10 -4.21 4.43e-05 0.0176 -0.25 -0.32 Menopause (age at onset); chr2:27405768 chr2:27356246~27367622:+ PAAD cis rs9322193 0.923 rs9766004 ENSG00000268592.3 RAET1E-AS1 4.21 4.44e-05 0.0176 0.36 0.32 Lung cancer; chr6:149754363 chr6:149863494~149919507:+ PAAD cis rs9652601 0.92 rs12923098 ENSG00000274038.1 RP11-66H6.4 -4.21 4.44e-05 0.0176 -0.37 -0.32 Systemic lupus erythematosus; chr16:11083196 chr16:11056556~11057034:+ PAAD cis rs42490 0.689 rs43228 ENSG00000251136.7 RP11-37B2.1 -4.21 4.44e-05 0.0176 -0.29 -0.32 Leprosy; chr8:89816790 chr8:89609409~89757727:- PAAD cis rs7617773 0.817 rs936427 ENSG00000228638.1 FCF1P2 4.21 4.44e-05 0.0176 0.36 0.32 Coronary artery disease; chr3:48259584 chr3:48290793~48291375:- PAAD cis rs2736345 0.742 rs4840568 ENSG00000251402.3 FAM90A25P 4.21 4.44e-05 0.0176 0.41 0.32 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11493510 chr8:12415080~12418090:- PAAD cis rs1832007 0.529 rs17306779 ENSG00000224034.1 RP11-445P17.8 4.2 4.45e-05 0.0177 0.48 0.32 Triglyceride levels;Triglycerides; chr10:5200201 chr10:5266033~5271236:- PAAD cis rs7829975 0.564 rs2921057 ENSG00000253981.4 ALG1L13P 4.2 4.45e-05 0.0177 0.38 0.32 Mood instability; chr8:8461157 chr8:8236003~8244667:- PAAD cis rs2446066 0.872 rs10876452 ENSG00000257379.1 RP11-793H13.8 4.2 4.45e-05 0.0177 0.48 0.32 Red blood cell count; chr12:53420474 chr12:53441741~53467528:+ PAAD cis rs79349575 0.783 rs11079844 ENSG00000270781.1 RP11-501C14.9 -4.2 4.45e-05 0.0177 -0.37 -0.32 Type 2 diabetes; chr17:48950972 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs62078372 ENSG00000270781.1 RP11-501C14.9 -4.2 4.45e-05 0.0177 -0.37 -0.32 Type 2 diabetes; chr17:48951627 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs12602933 ENSG00000270781.1 RP11-501C14.9 -4.2 4.45e-05 0.0177 -0.37 -0.32 Type 2 diabetes; chr17:48951918 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4794003 ENSG00000270781.1 RP11-501C14.9 -4.2 4.45e-05 0.0177 -0.37 -0.32 Type 2 diabetes; chr17:48952542 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs12602746 ENSG00000270781.1 RP11-501C14.9 -4.2 4.45e-05 0.0177 -0.37 -0.32 Type 2 diabetes; chr17:48954379 chr17:48899131~48899748:+ PAAD cis rs12935418 0.672 rs9938541 ENSG00000261061.1 RP11-303E16.2 -4.2 4.45e-05 0.0177 -0.4 -0.32 Mean corpuscular volume; chr16:81011623 chr16:81030770~81031485:+ PAAD cis rs12935418 0.616 rs9936366 ENSG00000261061.1 RP11-303E16.2 -4.2 4.45e-05 0.0177 -0.4 -0.32 Mean corpuscular volume; chr16:81011657 chr16:81030770~81031485:+ PAAD cis rs10740039 0.729 rs6479721 ENSG00000254271.1 RP11-131N11.4 4.2 4.45e-05 0.0177 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60613364 chr10:60734342~60741828:+ PAAD cis rs1707322 0.717 rs12023439 ENSG00000280836.1 AL355480.1 -4.2 4.45e-05 0.0177 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45638964 chr1:45581219~45581321:- PAAD cis rs9876781 1 rs7636782 ENSG00000229759.1 MRPS18AP1 4.2 4.46e-05 0.0177 0.34 0.32 Longevity; chr3:48379897 chr3:48256350~48256938:- PAAD cis rs891378 1 rs12095015 ENSG00000274245.1 RP11-357P18.2 4.2 4.46e-05 0.0177 0.46 0.32 Spherical equivalent (joint analysis main effects and education interaction); chr1:207283129 chr1:207372559~207373252:+ PAAD cis rs2729354 1 rs2649662 ENSG00000265566.2 RN7SL605P 4.2 4.46e-05 0.0177 0.43 0.32 Blood protein levels; chr11:57585089 chr11:57528085~57528365:- PAAD cis rs2729354 1 rs2729355 ENSG00000265566.2 RN7SL605P -4.2 4.46e-05 0.0177 -0.43 -0.32 Blood protein levels; chr11:57586510 chr11:57528085~57528365:- PAAD cis rs2729354 1 rs2729354 ENSG00000265566.2 RN7SL605P -4.2 4.46e-05 0.0177 -0.43 -0.32 Blood protein levels; chr11:57588497 chr11:57528085~57528365:- PAAD cis rs2729354 1 rs2848630 ENSG00000265566.2 RN7SL605P -4.2 4.46e-05 0.0177 -0.43 -0.32 Blood protein levels; chr11:57589434 chr11:57528085~57528365:- PAAD cis rs2729354 0.953 rs2649663 ENSG00000265566.2 RN7SL605P -4.2 4.46e-05 0.0177 -0.43 -0.32 Blood protein levels; chr11:57589832 chr11:57528085~57528365:- PAAD cis rs4683346 0.616 rs35584330 ENSG00000173811.9 CCDC13-AS1 -4.2 4.46e-05 0.0177 -0.36 -0.32 Granulocyte percentage of myeloid white cells; chr3:42769748 chr3:42732575~42746768:+ PAAD cis rs11892454 0.544 rs7599961 ENSG00000217643.1 PTGES3P2 -4.2 4.46e-05 0.0177 -0.34 -0.32 Heschl's gyrus morphology; chr2:25783610 chr2:25822469~25822950:+ PAAD cis rs897984 0.76 rs11076 ENSG00000260911.2 RP11-196G11.2 -4.2 4.46e-05 0.0177 -0.28 -0.32 Dementia with Lewy bodies; chr16:30984207 chr16:31043150~31049868:+ PAAD cis rs10779751 1 rs1205592 ENSG00000238199.1 UBE2V2P3 -4.2 4.46e-05 0.0177 -0.39 -0.32 Body mass index; chr1:11245606 chr1:11278616~11279351:- PAAD cis rs950169 0.544 rs62021193 ENSG00000259728.4 LINC00933 4.2 4.47e-05 0.0177 0.4 0.32 Schizophrenia; chr15:84627352 chr15:84570649~84580175:+ PAAD cis rs950169 0.58 rs17598114 ENSG00000259728.4 LINC00933 4.2 4.47e-05 0.0177 0.4 0.32 Schizophrenia; chr15:84628086 chr15:84570649~84580175:+ PAAD cis rs950169 0.58 rs17532346 ENSG00000259728.4 LINC00933 4.2 4.47e-05 0.0177 0.4 0.32 Schizophrenia; chr15:84628264 chr15:84570649~84580175:+ PAAD cis rs950169 0.58 rs11634322 ENSG00000259728.4 LINC00933 4.2 4.47e-05 0.0177 0.4 0.32 Schizophrenia; chr15:84628978 chr15:84570649~84580175:+ PAAD cis rs950169 0.58 rs4603535 ENSG00000259728.4 LINC00933 4.2 4.47e-05 0.0177 0.4 0.32 Schizophrenia; chr15:84630641 chr15:84570649~84580175:+ PAAD cis rs950169 0.541 rs10795 ENSG00000259728.4 LINC00933 4.2 4.47e-05 0.0177 0.4 0.32 Schizophrenia; chr15:84634066 chr15:84570649~84580175:+ PAAD cis rs950169 0.58 rs36126054 ENSG00000259728.4 LINC00933 4.2 4.47e-05 0.0177 0.4 0.32 Schizophrenia; chr15:84634492 chr15:84570649~84580175:+ PAAD cis rs950169 0.58 rs11633762 ENSG00000259728.4 LINC00933 4.2 4.47e-05 0.0177 0.4 0.32 Schizophrenia; chr15:84643921 chr15:84570649~84580175:+ PAAD cis rs853679 0.55 rs1237875 ENSG00000204709.4 LINC01556 -4.2 4.47e-05 0.0177 -0.55 -0.32 Depression; chr6:28205232 chr6:28943877~28944537:+ PAAD cis rs2505998 1 rs2505998 ENSG00000273008.1 RP11-351D16.3 -4.2 4.47e-05 0.0177 -0.28 -0.32 Hirschsprung disease; chr10:43075477 chr10:43136824~43138334:- PAAD cis rs6570726 0.935 rs386344 ENSG00000235652.6 RP11-545I5.3 4.2 4.47e-05 0.0177 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145534486 chr6:145799409~145886585:+ PAAD cis rs66887589 0.775 rs6843229 ENSG00000248280.1 RP11-33B1.2 4.2 4.47e-05 0.0177 0.29 0.32 Diastolic blood pressure; chr4:119502932 chr4:119440561~119450157:- PAAD cis rs77372450 0.636 rs10057597 ENSG00000251405.2 CTB-109A12.1 4.2 4.47e-05 0.0178 0.5 0.32 Bipolar disorder (body mass index interaction); chr5:157585862 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs10066519 ENSG00000251405.2 CTB-109A12.1 4.2 4.47e-05 0.0178 0.5 0.32 Bipolar disorder (body mass index interaction); chr5:157590421 chr5:157362615~157460078:- PAAD cis rs4660214 0.666 rs3116398 ENSG00000237624.1 OXCT2P1 -4.2 4.48e-05 0.0178 -0.42 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39314130 chr1:39514956~39516490:+ PAAD cis rs7923837 0.634 rs1544210 ENSG00000236493.2 EIF2S2P3 -4.2 4.48e-05 0.0178 -0.41 -0.32 Multiple sclerosis;Body mass index; chr10:92728044 chr10:92668745~92669743:- PAAD cis rs7189233 0.531 rs11859538 ENSG00000279344.1 RP11-44F14.7 4.2 4.48e-05 0.0178 0.24 0.32 Intelligence (multi-trait analysis); chr16:53463133 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs1072911 ENSG00000279344.1 RP11-44F14.7 4.2 4.48e-05 0.0178 0.24 0.32 Intelligence (multi-trait analysis); chr16:53465813 chr16:53478957~53481550:- PAAD cis rs12935418 0.672 rs12448656 ENSG00000261061.1 RP11-303E16.2 -4.2 4.49e-05 0.0178 -0.4 -0.32 Mean corpuscular volume; chr16:81008876 chr16:81030770~81031485:+ PAAD cis rs12935418 0.672 rs12446810 ENSG00000261061.1 RP11-303E16.2 -4.2 4.49e-05 0.0178 -0.4 -0.32 Mean corpuscular volume; chr16:81009369 chr16:81030770~81031485:+ PAAD cis rs7189233 0.571 rs4146344 ENSG00000279344.1 RP11-44F14.7 4.2 4.49e-05 0.0178 0.24 0.32 Intelligence (multi-trait analysis); chr16:53435050 chr16:53478957~53481550:- PAAD cis rs4794202 0.891 rs59715174 ENSG00000264920.1 RP11-6N17.4 -4.2 4.49e-05 0.0178 -0.48 -0.32 Alzheimer's disease (cognitive decline); chr17:47854047 chr17:47891255~47895812:- PAAD cis rs2412819 0.545 rs3862143 ENSG00000205771.5 CATSPER2P1 4.2 4.49e-05 0.0178 0.51 0.32 Lung cancer; chr15:43779282 chr15:43726918~43747094:- PAAD cis rs792448 0.527 rs11119887 ENSG00000229983.1 RP11-15I11.2 4.2 4.49e-05 0.0178 0.38 0.32 White blood cell count (basophil); chr1:212234220 chr1:212168207~212190259:+ PAAD cis rs9419788 0.708 rs4477375 ENSG00000233377.1 MTND4P20 4.2 4.5e-05 0.0178 0.29 0.32 Personality traits in bipolar disorder; chr10:94223553 chr10:94940253~94941121:- PAAD cis rs55665837 0.54 rs12290926 ENSG00000251991.1 RNU7-49P 4.2 4.5e-05 0.0178 0.37 0.32 Vitamin D levels; chr11:14673500 chr11:14478892~14478953:+ PAAD cis rs28386778 0.897 rs896064 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63783572 chr17:63849292~63864379:+ PAAD cis rs28386778 0.83 rs2665841 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63783859 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2727320 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63787965 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584635 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63788574 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs9915552 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63791735 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2665844 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63797095 chr17:63849292~63864379:+ PAAD cis rs28386778 0.83 rs2597637 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63797706 chr17:63849292~63864379:+ PAAD cis rs28386778 0.83 rs2597636 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63798650 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2597634 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63800784 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs1062787 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63818644 chr17:63849292~63864379:+ PAAD cis rs28386778 0.799 rs2665836 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63820775 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584627 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63824079 chr17:63849292~63864379:+ PAAD cis rs28386778 0.83 rs2584625 ENSG00000240280.5 TCAM1P -4.2 4.5e-05 0.0178 -0.45 -0.32 Prudent dietary pattern; chr17:63826085 chr17:63849292~63864379:+ PAAD cis rs1275468 0.731 rs1679384 ENSG00000257497.2 RP11-585P4.5 -4.2 4.5e-05 0.0178 -0.51 -0.32 Polycystic ovary syndrome; chr12:75567552 chr12:75483454~75489820:- PAAD cis rs2243480 1 rs313813 ENSG00000228409.4 CCT6P1 4.2 4.5e-05 0.0178 0.35 0.32 Diabetic kidney disease; chr7:66038513 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs427044 ENSG00000228409.4 CCT6P1 4.2 4.5e-05 0.0178 0.35 0.32 Diabetic kidney disease; chr7:66043558 chr7:65751142~65763354:+ PAAD cis rs8177376 0.727 rs586566 ENSG00000254905.1 RP11-712L6.7 4.2 4.51e-05 0.0179 0.41 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126329723 chr11:126292922~126294254:- PAAD cis rs8177376 0.681 rs678422 ENSG00000254905.1 RP11-712L6.7 4.2 4.51e-05 0.0179 0.41 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126330009 chr11:126292922~126294254:- PAAD cis rs8177376 0.727 rs667469 ENSG00000254905.1 RP11-712L6.7 4.2 4.51e-05 0.0179 0.41 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126330171 chr11:126292922~126294254:- PAAD cis rs8177376 0.727 rs651983 ENSG00000254905.1 RP11-712L6.7 4.2 4.51e-05 0.0179 0.41 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126331343 chr11:126292922~126294254:- PAAD cis rs8177376 0.727 rs651922 ENSG00000254905.1 RP11-712L6.7 4.2 4.51e-05 0.0179 0.41 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126331395 chr11:126292922~126294254:- PAAD cis rs8177376 0.727 rs616360 ENSG00000254905.1 RP11-712L6.7 4.2 4.51e-05 0.0179 0.41 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126331508 chr11:126292922~126294254:- PAAD cis rs2505998 0.787 rs28502801 ENSG00000273008.1 RP11-351D16.3 -4.2 4.51e-05 0.0179 -0.28 -0.32 Hirschsprung disease; chr10:43088591 chr10:43136824~43138334:- PAAD cis rs9876781 1 rs7630741 ENSG00000229759.1 MRPS18AP1 4.2 4.51e-05 0.0179 0.35 0.32 Longevity; chr3:48378233 chr3:48256350~48256938:- PAAD cis rs2348418 0.765 rs6487665 ENSG00000247934.4 RP11-967K21.1 4.2 4.51e-05 0.0179 0.33 0.32 Lung function (FEV1);Lung function (FVC); chr12:28177726 chr12:28163298~28190738:- PAAD cis rs12468579 0.77 rs13395505 ENSG00000235852.1 AC005540.3 -4.2 4.51e-05 0.0179 -0.4 -0.32 JT interval (sulfonylurea treatment interaction); chr2:190973788 chr2:190880797~190882059:- PAAD cis rs496547 0.721 rs2508570 ENSG00000278376.1 RP11-158I9.8 -4.2 4.51e-05 0.0179 -0.29 -0.32 Hip minimal joint space width; chr11:118807900 chr11:118791254~118793137:+ PAAD cis rs496547 0.686 rs591756 ENSG00000278376.1 RP11-158I9.8 -4.2 4.51e-05 0.0179 -0.29 -0.32 Hip minimal joint space width; chr11:118808172 chr11:118791254~118793137:+ PAAD cis rs9487094 0.645 rs12529505 ENSG00000260273.1 RP11-425D10.10 -4.2 4.51e-05 0.0179 -0.44 -0.32 Height; chr6:109625358 chr6:109382795~109383666:+ PAAD cis rs7772486 0.774 rs6930181 ENSG00000235652.6 RP11-545I5.3 -4.2 4.52e-05 0.0179 -0.27 -0.32 Lobe attachment (rater-scored or self-reported); chr6:145859838 chr6:145799409~145886585:+ PAAD cis rs9487094 0.645 rs34533653 ENSG00000260273.1 RP11-425D10.10 4.2 4.52e-05 0.0179 0.46 0.32 Height; chr6:109479488 chr6:109382795~109383666:+ PAAD cis rs6991838 0.8 rs11786598 ENSG00000200714.1 Y_RNA -4.2 4.52e-05 0.0179 -0.38 -0.32 Intelligence (multi-trait analysis); chr8:65559944 chr8:65592731~65592820:+ PAAD cis rs12444979 0.517 rs75594829 ENSG00000261195.1 CTD-2380F24.1 -4.2 4.52e-05 0.0179 -0.51 -0.32 Body mass index; chr16:19783001 chr16:19761172~19766099:- PAAD cis rs12446554 0.528 rs117650757 ENSG00000261195.1 CTD-2380F24.1 -4.2 4.52e-05 0.0179 -0.51 -0.32 Obesity; chr16:19783003 chr16:19761172~19766099:- PAAD cis rs28386778 0.897 rs2584608 ENSG00000240280.5 TCAM1P -4.2 4.52e-05 0.0179 -0.45 -0.32 Prudent dietary pattern; chr17:63859350 chr17:63849292~63864379:+ PAAD cis rs8072100 0.817 rs9912101 ENSG00000228782.6 CTD-2026D20.3 4.2 4.52e-05 0.0179 0.32 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47469712 chr17:47450568~47492492:- PAAD cis rs66887589 0.967 rs1480933 ENSG00000248280.1 RP11-33B1.2 4.2 4.53e-05 0.0179 0.29 0.32 Diastolic blood pressure; chr4:119512093 chr4:119440561~119450157:- PAAD cis rs9876781 0.559 rs1903144 ENSG00000229759.1 MRPS18AP1 4.2 4.53e-05 0.0179 0.33 0.32 Longevity; chr3:48364907 chr3:48256350~48256938:- PAAD cis rs28374715 0.578 rs17730589 ENSG00000247556.5 OIP5-AS1 4.2 4.53e-05 0.0179 0.34 0.32 Ulcerative colitis; chr15:41308680 chr15:41283990~41309737:+ PAAD cis rs77372450 1 rs115992025 ENSG00000251405.2 CTB-109A12.1 4.2 4.53e-05 0.0179 0.82 0.32 Bipolar disorder (body mass index interaction); chr5:157702974 chr5:157362615~157460078:- PAAD cis rs2446066 0.872 rs10876450 ENSG00000257379.1 RP11-793H13.8 -4.2 4.53e-05 0.0179 -0.47 -0.32 Red blood cell count; chr12:53417250 chr12:53441741~53467528:+ PAAD cis rs3096299 0.685 rs12446145 ENSG00000261253.2 AC137932.6 4.2 4.53e-05 0.0179 0.34 0.32 Multiple myeloma (IgH translocation); chr16:89476287 chr16:89321133~89325110:+ PAAD cis rs9807989 0.507 rs10208196 ENSG00000234389.1 AC007278.3 4.2 4.54e-05 0.018 0.32 0.32 Asthma; chr2:102379885 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs3213732 ENSG00000234389.1 AC007278.3 4.2 4.54e-05 0.018 0.32 0.32 Asthma; chr2:102381819 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs10204757 ENSG00000234389.1 AC007278.3 4.2 4.54e-05 0.018 0.32 0.32 Asthma; chr2:102382514 chr2:102438713~102440475:+ PAAD cis rs9807989 0.524 rs7591246 ENSG00000234389.1 AC007278.3 4.2 4.54e-05 0.018 0.32 0.32 Asthma; chr2:102382943 chr2:102438713~102440475:+ PAAD cis rs4988958 0.565 rs6760621 ENSG00000234389.1 AC007278.3 4.2 4.54e-05 0.018 0.32 0.32 Asthma (childhood onset); chr2:102383492 chr2:102438713~102440475:+ PAAD cis rs4988958 0.527 rs11465641 ENSG00000234389.1 AC007278.3 4.2 4.54e-05 0.018 0.32 0.32 Asthma (childhood onset); chr2:102384408 chr2:102438713~102440475:+ PAAD cis rs7554672 0.961 rs6667902 ENSG00000232679.1 RP11-400N13.3 4.2 4.54e-05 0.018 0.33 0.32 Hypertension; chr1:221152071 chr1:222041705~222064763:- PAAD cis rs4604732 0.578 rs12040725 ENSG00000227135.1 GCSAML-AS1 -4.2 4.54e-05 0.018 -0.48 -0.32 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247481395 chr1:247524679~247526752:- PAAD cis rs4604732 0.536 rs10925056 ENSG00000227135.1 GCSAML-AS1 -4.2 4.54e-05 0.018 -0.48 -0.32 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247487170 chr1:247524679~247526752:- PAAD cis rs897984 0.762 rs2054213 ENSG00000260911.2 RP11-196G11.2 -4.2 4.54e-05 0.018 -0.28 -0.32 Dementia with Lewy bodies; chr16:30960489 chr16:31043150~31049868:+ PAAD cis rs17836934 0.845 rs10777222 ENSG00000258302.2 RP11-981P6.1 -4.2 4.54e-05 0.018 -0.28 -0.32 Total body bone mineral density; chr12:90050964 chr12:89561129~89594878:+ PAAD cis rs4423214 0.592 rs10898234 ENSG00000254682.1 RP11-660L16.2 -4.2 4.55e-05 0.018 -0.53 -0.32 Vitamin D levels; chr11:71525638 chr11:71448674~71452157:+ PAAD cis rs11146838 1 rs11146838 ENSG00000263064.2 RP11-291L22.7 4.2 4.55e-05 0.018 0.38 0.32 Breast cancer; chr10:38856846 chr10:38448689~38448949:+ PAAD cis rs3779195 0.929 rs4268041 ENSG00000272950.1 RP11-307C18.1 -4.2 4.55e-05 0.018 -0.5 -0.32 Sex hormone-binding globulin levels; chr7:98376226 chr7:98322853~98323430:+ PAAD cis rs2599510 0.744 rs4952212 ENSG00000276334.1 AL133243.1 -4.2 4.55e-05 0.018 -0.39 -0.32 Interleukin-18 levels; chr2:32393425 chr2:32521927~32523547:+ PAAD cis rs7712401 0.623 rs26372 ENSG00000263432.2 RN7SL689P -4.2 4.55e-05 0.018 -0.42 -0.32 Mean platelet volume; chr5:122870752 chr5:123022487~123022783:- PAAD cis rs6500550 0.851 rs11646287 ENSG00000276754.1 RP11-461A8.5 4.2 4.55e-05 0.018 0.35 0.32 Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count; chr16:3669343 chr16:3686998~3687380:+ PAAD cis rs4834770 0.718 rs4833618 ENSG00000245958.5 RP11-33B1.1 4.2 4.56e-05 0.018 0.25 0.32 Blood protein levels; chr4:119388345 chr4:119454791~119552025:+ PAAD cis rs2337406 0.85 rs11161008 ENSG00000211974.3 IGHV2-70 -4.2 4.56e-05 0.018 -0.46 -0.32 Alzheimer's disease (late onset); chr14:106705261 chr14:106723574~106724093:- PAAD cis rs6487679 1 rs7298108 ENSG00000111788.10 RP11-22B23.1 -4.2 4.56e-05 0.018 -0.36 -0.32 Non-alcoholic fatty liver disease histology (AST); chr12:9223572 chr12:9277235~9313241:+ PAAD cis rs12554020 0.579 rs59326991 ENSG00000227603.1 RP11-165J3.6 4.2 4.56e-05 0.018 0.57 0.32 Schizophrenia; chr9:93473603 chr9:93435332~93437121:- PAAD cis rs494459 0.657 rs614554 ENSG00000278376.1 RP11-158I9.8 -4.2 4.57e-05 0.018 -0.28 -0.32 Height; chr11:118764443 chr11:118791254~118793137:+ PAAD cis rs2581828 0.659 rs4282053 ENSG00000242142.1 SERBP1P3 -4.2 4.57e-05 0.0181 -0.41 -0.32 Crohn's disease; chr3:53107949 chr3:53064283~53065091:- PAAD cis rs2581828 0.659 rs9845352 ENSG00000242142.1 SERBP1P3 -4.2 4.57e-05 0.0181 -0.41 -0.32 Crohn's disease; chr3:53108205 chr3:53064283~53065091:- PAAD cis rs2581828 0.659 rs9845484 ENSG00000242142.1 SERBP1P3 -4.2 4.57e-05 0.0181 -0.41 -0.32 Crohn's disease; chr3:53108240 chr3:53064283~53065091:- PAAD cis rs987724 0.964 rs1995425 ENSG00000240875.4 LINC00886 -4.2 4.57e-05 0.0181 -0.39 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156944020 chr3:156747346~156817062:- PAAD cis rs3738443 0.951 rs61840056 ENSG00000259865.1 RP11-488L18.10 4.2 4.57e-05 0.0181 0.3 0.32 Alcohol dependence; chr1:247205930 chr1:247187281~247188526:- PAAD cis rs3738443 1 rs61840057 ENSG00000259865.1 RP11-488L18.10 4.2 4.57e-05 0.0181 0.3 0.32 Alcohol dependence; chr1:247206054 chr1:247187281~247188526:- PAAD cis rs10888838 0.938 rs747753 ENSG00000198711.5 SSBP3-AS1 4.2 4.58e-05 0.0181 0.39 0.32 Mitochondrial DNA levels; chr1:54216816 chr1:54236440~54239063:+ PAAD cis rs6570726 0.935 rs411641 ENSG00000235652.6 RP11-545I5.3 4.2 4.58e-05 0.0181 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145506396 chr6:145799409~145886585:+ PAAD cis rs7829975 0.517 rs12542733 ENSG00000254340.1 RP11-10A14.3 -4.2 4.58e-05 0.0181 -0.37 -0.32 Mood instability; chr8:8967348 chr8:9141424~9145435:+ PAAD cis rs17123764 0.818 rs17123808 ENSG00000257464.1 RP11-161H23.8 -4.2 4.58e-05 0.0181 -0.54 -0.32 Intelligence (multi-trait analysis); chr12:49585630 chr12:49442424~49442652:- PAAD cis rs520525 0.963 rs627848 ENSG00000271811.1 RP1-79C4.4 4.2 4.58e-05 0.0181 0.34 0.32 Atrial fibrillation; chr1:170662279 chr1:170667381~170669425:+ PAAD cis rs6545883 0.56 rs11677776 ENSG00000273302.1 RP11-493E12.2 -4.2 4.58e-05 0.0181 -0.29 -0.32 Tuberculosis; chr2:61275978 chr2:61199979~61200769:+ PAAD cis rs919433 0.927 rs13032495 ENSG00000231621.1 AC013264.2 4.2 4.58e-05 0.0181 0.31 0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197324622 chr2:197197991~197199273:+ PAAD cis rs5015933 0.788 rs466614 ENSG00000232630.1 PRPS1P2 -4.2 4.58e-05 0.0181 -0.29 -0.32 Body mass index; chr9:125265428 chr9:125150653~125151589:+ PAAD cis rs62355901 0.545 rs6895844 ENSG00000271828.1 CTD-2310F14.1 4.2 4.58e-05 0.0181 0.57 0.32 Breast cancer; chr5:56762113 chr5:56927874~56929573:+ PAAD cis rs9807989 0.507 rs6745614 ENSG00000234389.1 AC007278.3 4.2 4.58e-05 0.0181 0.32 0.32 Asthma; chr2:102374753 chr2:102438713~102440475:+ PAAD cis rs6479901 0.557 rs12773283 ENSG00000232075.1 MRPL35P2 -4.2 4.58e-05 0.0181 -0.5 -0.32 Intelligence (multi-trait analysis); chr10:63298464 chr10:63634317~63634827:- PAAD cis rs2742417 1 rs2742454 ENSG00000244357.3 RN7SL145P 4.2 4.58e-05 0.0181 0.3 0.32 Response to anti-depressant treatment in major depressive disorder; chr3:45724730 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs767280 ENSG00000244357.3 RN7SL145P 4.2 4.58e-05 0.0181 0.3 0.32 Response to anti-depressant treatment in major depressive disorder; chr3:45730109 chr3:45742675~45742970:+ PAAD cis rs2742417 0.935 rs1468543 ENSG00000244357.3 RN7SL145P 4.2 4.58e-05 0.0181 0.3 0.32 Response to anti-depressant treatment in major depressive disorder; chr3:45735408 chr3:45742675~45742970:+ PAAD cis rs7617773 0.817 rs11709691 ENSG00000228638.1 FCF1P2 -4.2 4.59e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48262179 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs13072018 ENSG00000228638.1 FCF1P2 -4.2 4.59e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48278842 chr3:48290793~48291375:- PAAD cis rs7617773 0.779 rs77957078 ENSG00000228638.1 FCF1P2 -4.2 4.59e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48289796 chr3:48290793~48291375:- PAAD cis rs2729354 0.729 rs2581923 ENSG00000265566.2 RN7SL605P -4.2 4.59e-05 0.0181 -0.4 -0.32 Blood protein levels; chr11:57482518 chr11:57528085~57528365:- PAAD cis rs2729354 0.729 rs2848634 ENSG00000265566.2 RN7SL605P -4.2 4.59e-05 0.0181 -0.4 -0.32 Blood protein levels; chr11:57484855 chr11:57528085~57528365:- PAAD cis rs9807989 0.507 rs10439410 ENSG00000234389.1 AC007278.3 -4.2 4.59e-05 0.0181 -0.32 -0.32 Asthma; chr2:102374328 chr2:102438713~102440475:+ PAAD cis rs4988958 0.525 rs3771159 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma (childhood onset); chr2:102388498 chr2:102438713~102440475:+ PAAD cis rs9807989 0.501 rs11903946 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102388870 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs6706002 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102389644 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs6749014 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102389988 chr2:102438713~102440475:+ PAAD cis rs4988958 0.565 rs12712146 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma (childhood onset); chr2:102392254 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs1420097 ENSG00000234389.1 AC007278.3 -4.2 4.59e-05 0.0181 -0.32 -0.32 Asthma; chr2:102392894 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs4851004 ENSG00000234389.1 AC007278.3 -4.2 4.59e-05 0.0181 -0.32 -0.32 Asthma; chr2:102393077 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs1420096 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102394452 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs1420094 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102399227 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs3732124 ENSG00000234389.1 AC007278.3 -4.2 4.59e-05 0.0181 -0.32 -0.32 Asthma; chr2:102401592 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs4851571 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102402540 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs4851572 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102402571 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs1035129 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102403325 chr2:102438713~102440475:+ PAAD cis rs9807989 0.524 rs2110662 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102403679 chr2:102438713~102440475:+ PAAD cis rs9807989 0.524 rs7594402 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102404807 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs6710034 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102407218 chr2:102438713~102440475:+ PAAD cis rs4988958 0.584 rs7589142 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma (childhood onset); chr2:102408200 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs1420105 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102418659 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs2293224 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102419319 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs6743516 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma; chr2:102419875 chr2:102438713~102440475:+ PAAD cis rs4988958 0.565 rs1420100 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma (childhood onset); chr2:102420542 chr2:102438713~102440475:+ PAAD cis rs4988958 0.527 rs3771155 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma (childhood onset); chr2:102421366 chr2:102438713~102440475:+ PAAD cis rs4988958 0.565 rs10206291 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma (childhood onset); chr2:102422403 chr2:102438713~102440475:+ PAAD cis rs4988958 0.565 rs885088 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma (childhood onset); chr2:102422584 chr2:102438713~102440475:+ PAAD cis rs4988958 0.565 rs3771154 ENSG00000234389.1 AC007278.3 4.2 4.59e-05 0.0181 0.32 0.32 Asthma (childhood onset); chr2:102422900 chr2:102438713~102440475:+ PAAD cis rs11098499 0.739 rs9884728 ENSG00000245958.5 RP11-33B1.1 4.2 4.59e-05 0.0181 0.26 0.32 Corneal astigmatism; chr4:119205924 chr4:119454791~119552025:+ PAAD cis rs11098499 0.739 rs6534130 ENSG00000245958.5 RP11-33B1.1 4.2 4.59e-05 0.0181 0.26 0.32 Corneal astigmatism; chr4:119210184 chr4:119454791~119552025:+ PAAD cis rs11098499 0.739 rs2203039 ENSG00000245958.5 RP11-33B1.1 4.2 4.59e-05 0.0181 0.26 0.32 Corneal astigmatism; chr4:119211192 chr4:119454791~119552025:+ PAAD cis rs11098499 0.739 rs7441137 ENSG00000245958.5 RP11-33B1.1 4.2 4.59e-05 0.0181 0.26 0.32 Corneal astigmatism; chr4:119212066 chr4:119454791~119552025:+ PAAD cis rs11098499 0.739 rs4833612 ENSG00000245958.5 RP11-33B1.1 4.2 4.59e-05 0.0181 0.26 0.32 Corneal astigmatism; chr4:119226441 chr4:119454791~119552025:+ PAAD cis rs11098499 0.739 rs10013032 ENSG00000245958.5 RP11-33B1.1 4.2 4.59e-05 0.0181 0.26 0.32 Corneal astigmatism; chr4:119228264 chr4:119454791~119552025:+ PAAD cis rs11098499 0.739 rs951570 ENSG00000245958.5 RP11-33B1.1 4.2 4.59e-05 0.0181 0.26 0.32 Corneal astigmatism; chr4:119229312 chr4:119454791~119552025:+ PAAD cis rs12444979 0.515 rs8046628 ENSG00000261195.1 CTD-2380F24.1 -4.2 4.59e-05 0.0181 -0.51 -0.32 Body mass index; chr16:19770638 chr16:19761172~19766099:- PAAD cis rs11997175 0.766 rs6983113 ENSG00000240738.1 RP1-273G13.1 4.2 4.59e-05 0.0181 0.36 0.32 Body mass index; chr8:33841995 chr8:33859480~33860223:- PAAD cis rs6472235 1 rs56080166 ENSG00000200714.1 Y_RNA -4.2 4.59e-05 0.0181 -0.42 -0.32 Plateletcrit;Myopia (pathological); chr8:65882963 chr8:65592731~65592820:+ PAAD cis rs1211375 0.628 rs3859141 ENSG00000268836.1 LA16c-OS12.2 4.2 4.59e-05 0.0181 0.29 0.32 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:195080 chr16:185748~186294:- PAAD cis rs7615952 0.605 rs34865555 ENSG00000171084.14 FAM86JP 4.2 4.6e-05 0.0181 0.52 0.32 Blood pressure (smoking interaction); chr3:125585290 chr3:125916620~125930024:+ PAAD cis rs2581828 0.632 rs73088322 ENSG00000242142.1 SERBP1P3 -4.2 4.6e-05 0.0181 -0.41 -0.32 Crohn's disease; chr3:53107500 chr3:53064283~53065091:- PAAD cis rs2581828 0.659 rs73088327 ENSG00000242142.1 SERBP1P3 -4.2 4.6e-05 0.0181 -0.41 -0.32 Crohn's disease; chr3:53107533 chr3:53064283~53065091:- PAAD cis rs7617773 0.851 rs7647817 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48195017 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs11707606 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48195597 chr3:48290793~48291375:- PAAD cis rs7617773 0.71 rs36064160 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48201611 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs17786132 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48207930 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs35456569 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48209409 chr3:48290793~48291375:- PAAD cis rs7617773 0.784 rs11715799 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48213730 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs34728236 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48217618 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs79310258 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48218177 chr3:48290793~48291375:- PAAD cis rs7617773 0.746 rs6796343 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48240531 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs13100815 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48245959 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs13059037 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48246389 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs35414021 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48252034 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs13068265 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48260124 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs3197223 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48294367 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs13067450 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48295716 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs4479622 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48296683 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs34946886 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48296997 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs13079728 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48297870 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs34589064 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48298059 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs2541 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48298128 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs13085251 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48298555 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs35297395 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48301392 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs36075665 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48301597 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs34630841 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48301771 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs35190747 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48301800 chr3:48290793~48291375:- PAAD cis rs7617773 0.743 rs7621785 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48302218 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs4511915 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48302368 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs13066758 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48302387 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs4392440 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48302430 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs13082859 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48303185 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs36121690 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48304021 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs35778847 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48305495 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs34749846 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48305678 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs7632297 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48306673 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs79089926 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48307074 chr3:48290793~48291375:- PAAD cis rs7617773 0.643 rs78159520 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48307533 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs77044321 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48307824 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs4511916 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48308876 chr3:48290793~48291375:- PAAD cis rs7617773 0.815 rs7624450 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48308885 chr3:48290793~48291375:- PAAD cis rs7617773 0.815 rs6793150 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48310070 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs6793239 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48310128 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs6782166 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48310193 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs4130522 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48310823 chr3:48290793~48291375:- PAAD cis rs7617773 0.746 rs4371540 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48312053 chr3:48290793~48291375:- PAAD cis rs7617773 0.674 rs13069029 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48313534 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs13081169 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48315307 chr3:48290793~48291375:- PAAD cis rs7617773 0.743 rs13081633 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48315791 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs35411187 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48318527 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs11714176 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48319372 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs11718350 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48319502 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs7653152 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48320607 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs7645425 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48320879 chr3:48290793~48291375:- PAAD cis rs7617773 0.743 rs11716371 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48321260 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs6793223 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48322611 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs4541431 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48323728 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs11714944 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48325481 chr3:48290793~48291375:- PAAD cis rs7617773 0.743 rs13071960 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48326047 chr3:48290793~48291375:- PAAD cis rs7617773 0.743 rs4632568 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48326329 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs11130164 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48327544 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs7653336 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48327974 chr3:48290793~48291375:- PAAD cis rs7617773 0.747 rs34076262 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48328926 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs13082158 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48330980 chr3:48290793~48291375:- PAAD cis rs7617773 0.676 rs13060020 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48331156 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs11710257 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48331724 chr3:48290793~48291375:- PAAD cis rs7617773 0.707 rs13061269 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48331853 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs71323395 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48332587 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs71323396 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48333244 chr3:48290793~48291375:- PAAD cis rs7617773 0.743 rs71323397 ENSG00000228638.1 FCF1P2 -4.2 4.6e-05 0.0181 -0.36 -0.32 Coronary artery disease; chr3:48333384 chr3:48290793~48291375:- PAAD cis rs4660214 0.666 rs598415 ENSG00000237624.1 OXCT2P1 4.2 4.6e-05 0.0182 0.43 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39366735 chr1:39514956~39516490:+ PAAD cis rs11687659 0.515 rs6725611 ENSG00000235852.1 AC005540.3 4.2 4.6e-05 0.0182 0.45 0.32 Immature fraction of reticulocytes; chr2:190714299 chr2:190880797~190882059:- PAAD cis rs3781264 0.595 rs12220125 ENSG00000273450.1 RP11-76P2.4 4.2 4.61e-05 0.0182 0.44 0.32 Esophageal cancer and gastric cancer; chr10:94315182 chr10:94314907~94315327:- PAAD cis rs9435732 0.697 rs9435671 ENSG00000235241.1 RP11-108M9.5 4.2 4.61e-05 0.0182 0.39 0.32 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:17013444 chr1:16889095~16889602:+ PAAD cis rs6570726 0.935 rs421268 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145524422 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs384519 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145524881 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs454370 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145525593 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs434298 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145525737 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs416987 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145525869 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs452770 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145526026 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs442254 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145527982 chr6:145799409~145886585:+ PAAD cis rs6570726 0.846 rs441575 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145528069 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs436212 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145528264 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs414222 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145529346 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs385134 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145529869 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs415590 ENSG00000235652.6 RP11-545I5.3 4.2 4.61e-05 0.0182 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145530108 chr6:145799409~145886585:+ PAAD cis rs10510102 0.516 rs10219133 ENSG00000276742.1 RP11-500G22.4 4.2 4.61e-05 0.0182 0.5 0.32 Breast cancer; chr10:121987898 chr10:121956782~121957098:+ PAAD cis rs17684571 0.938 rs17751682 ENSG00000231441.1 RP11-472M19.2 -4.2 4.62e-05 0.0182 -0.54 -0.32 Schizophrenia; chr6:56695732 chr6:56844002~56864078:+ PAAD cis rs6570726 0.967 rs450973 ENSG00000235652.6 RP11-545I5.3 4.2 4.62e-05 0.0182 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145541929 chr6:145799409~145886585:+ PAAD cis rs39841 1 rs39841 ENSG00000272109.1 CTD-2260A17.3 -4.2 4.62e-05 0.0182 -0.41 -0.32 Inflammatory skin disease; chr5:96784466 chr5:96804353~96806105:+ PAAD cis rs2303759 0.918 rs8107548 ENSG00000268686.1 AC010524.2 -4.19 4.62e-05 0.0182 -0.45 -0.32 Multiple sclerosis; chr19:49367386 chr19:49368705~49388081:- PAAD cis rs7260598 0.792 rs73021412 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24070755 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs73021416 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24081849 chr19:24162370~24163425:- PAAD cis rs7260598 0.685 rs73021420 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24082833 chr19:24162370~24163425:- PAAD cis rs7260598 0.685 rs73021424 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24090897 chr19:24162370~24163425:- PAAD cis rs7260598 0.685 rs11667970 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24094893 chr19:24162370~24163425:- PAAD cis rs7260598 0.581 rs73021432 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24101827 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs11672468 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24119770 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs73021445 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24121306 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs7252836 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24122787 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs61737180 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24127230 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs11671960 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24135019 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs73021461 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24140154 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs59756985 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24141664 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs73021467 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24142863 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs4019979 ENSG00000268442.1 CTD-2027I19.2 4.19 4.62e-05 0.0182 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24143881 chr19:24162370~24163425:- PAAD cis rs2348418 0.83 rs4930821 ENSG00000247934.4 RP11-967K21.1 4.19 4.62e-05 0.0182 0.31 0.32 Lung function (FEV1);Lung function (FVC); chr12:28410948 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs11049578 ENSG00000247934.4 RP11-967K21.1 4.19 4.62e-05 0.0182 0.31 0.32 Lung function (FEV1);Lung function (FVC); chr12:28414520 chr12:28163298~28190738:- PAAD cis rs2348418 0.864 rs11049580 ENSG00000247934.4 RP11-967K21.1 4.19 4.62e-05 0.0182 0.31 0.32 Lung function (FEV1);Lung function (FVC); chr12:28414696 chr12:28163298~28190738:- PAAD cis rs61270009 0.955 rs415302 ENSG00000247828.6 TMEM161B-AS1 -4.19 4.63e-05 0.0182 -0.26 -0.32 Depressive symptoms; chr5:88231628 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs780398 ENSG00000247828.6 TMEM161B-AS1 -4.19 4.63e-05 0.0182 -0.26 -0.32 Depressive symptoms; chr5:88234112 chr5:88268895~88436685:+ PAAD cis rs6540731 0.521 rs10779572 ENSG00000226251.4 RP11-15I11.3 4.19 4.63e-05 0.0182 0.43 0.32 Intelligence (childhood); chr1:212181070 chr1:212225278~212238977:- PAAD cis rs748404 0.631 rs1133395 ENSG00000205771.5 CATSPER2P1 -4.19 4.63e-05 0.0182 -0.44 -0.32 Lung cancer; chr15:43358186 chr15:43726918~43747094:- PAAD cis rs748404 0.631 rs3809482 ENSG00000205771.5 CATSPER2P1 -4.19 4.63e-05 0.0182 -0.44 -0.32 Lung cancer; chr15:43369604 chr15:43726918~43747094:- PAAD cis rs853679 0.527 rs853690 ENSG00000219891.2 ZSCAN12P1 4.19 4.63e-05 0.0182 0.44 0.32 Depression; chr6:28317705 chr6:28091154~28093664:+ PAAD cis rs853679 0.527 rs707907 ENSG00000219891.2 ZSCAN12P1 4.19 4.63e-05 0.0182 0.44 0.32 Depression; chr6:28323463 chr6:28091154~28093664:+ PAAD cis rs853679 0.527 rs853683 ENSG00000219891.2 ZSCAN12P1 4.19 4.63e-05 0.0182 0.44 0.32 Depression; chr6:28327262 chr6:28091154~28093664:+ PAAD cis rs10779751 1 rs11121706 ENSG00000238199.1 UBE2V2P3 -4.19 4.63e-05 0.0182 -0.38 -0.32 Body mass index; chr1:11242008 chr1:11278616~11279351:- PAAD cis rs17111230 0.617 rs1176965 ENSG00000251363.2 RP11-129M6.1 4.19 4.63e-05 0.0182 0.51 0.32 Congenital heart disease (inherited effect); chr14:40956893 chr14:40954898~40975877:+ PAAD cis rs6052484 0.523 rs605191 ENSG00000226948.1 RPS4XP2 -4.19 4.63e-05 0.0182 -0.47 -0.32 Sense of smell; chr20:4342329 chr20:4629427~4630219:- PAAD cis rs2742417 0.935 rs2673028 ENSG00000244357.3 RN7SL145P 4.19 4.63e-05 0.0183 0.3 0.32 Response to anti-depressant treatment in major depressive disorder; chr3:45718162 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742406 ENSG00000244357.3 RN7SL145P 4.19 4.63e-05 0.0183 0.3 0.32 Response to anti-depressant treatment in major depressive disorder; chr3:45719108 chr3:45742675~45742970:+ PAAD cis rs896655 0.747 rs10811585 ENSG00000266446.1 RP11-149I2.4 -4.19 4.64e-05 0.0183 -0.39 -0.32 Coronary artery disease; chr9:21701535 chr9:21995482~21996013:+ PAAD cis rs2581828 0.646 rs6783748 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53119415 chr3:53064283~53065091:- PAAD cis rs2581828 0.646 rs12630819 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53123286 chr3:53064283~53065091:- PAAD cis rs2581828 0.646 rs12638996 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53123530 chr3:53064283~53065091:- PAAD cis rs2581828 0.646 rs6769931 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53126177 chr3:53064283~53065091:- PAAD cis rs2581828 0.646 rs6809973 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53126200 chr3:53064283~53065091:- PAAD cis rs2581828 0.608 rs6769944 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53126227 chr3:53064283~53065091:- PAAD cis rs2581828 0.646 rs9858469 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53128390 chr3:53064283~53065091:- PAAD cis rs2581828 0.646 rs9820324 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53128429 chr3:53064283~53065091:- PAAD cis rs2581828 0.646 rs28501212 ENSG00000242142.1 SERBP1P3 -4.19 4.64e-05 0.0183 -0.4 -0.32 Crohn's disease; chr3:53129041 chr3:53064283~53065091:- PAAD cis rs2638953 0.924 rs11049620 ENSG00000247934.4 RP11-967K21.1 -4.19 4.64e-05 0.0183 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28454698 chr12:28163298~28190738:- PAAD cis rs9876781 1 rs9311423 ENSG00000229759.1 MRPS18AP1 4.19 4.64e-05 0.0183 0.35 0.32 Longevity; chr3:48378818 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs7634377 ENSG00000229759.1 MRPS18AP1 4.19 4.64e-05 0.0183 0.35 0.32 Longevity; chr3:48379768 chr3:48256350~48256938:- PAAD cis rs9876781 0.967 rs2885509 ENSG00000229759.1 MRPS18AP1 -4.19 4.64e-05 0.0183 -0.35 -0.32 Longevity; chr3:48376729 chr3:48256350~48256938:- PAAD cis rs11048434 0.518 rs7136274 ENSG00000256720.1 RP11-436I9.6 4.19 4.65e-05 0.0183 0.3 0.32 Sjögren's syndrome; chr12:9022360 chr12:9135084~9135591:+ PAAD cis rs2153535 0.606 rs11243253 ENSG00000230939.1 RP11-314C16.1 4.19 4.65e-05 0.0183 0.34 0.32 Motion sickness; chr6:8379960 chr6:8784178~8785445:+ PAAD cis rs987724 0.501 rs9851913 ENSG00000240875.4 LINC00886 -4.19 4.65e-05 0.0183 -0.47 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156883165 chr3:156747346~156817062:- PAAD cis rs12439619 0.768 rs28694364 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82208119 chr15:82459472~82477258:+ PAAD cis rs12439619 0.81 rs28876157 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82216708 chr15:82459472~82477258:+ PAAD cis rs12439619 0.739 rs62012046 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82236824 chr15:82459472~82477258:+ PAAD cis rs12439619 0.774 rs62012047 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82236852 chr15:82459472~82477258:+ PAAD cis rs12439619 0.81 rs62012049 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82237722 chr15:82459472~82477258:+ PAAD cis rs12439619 0.846 rs28470877 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82245797 chr15:82459472~82477258:+ PAAD cis rs12439619 0.846 rs62012056 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82247278 chr15:82459472~82477258:+ PAAD cis rs12439619 0.846 rs62012059 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82251669 chr15:82459472~82477258:+ PAAD cis rs12439619 0.774 rs2867649 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82262331 chr15:82459472~82477258:+ PAAD cis rs12439619 0.846 rs28697264 ENSG00000276710.3 CSPG4P8 -4.19 4.65e-05 0.0183 -0.36 -0.32 Intelligence (multi-trait analysis); chr15:82265559 chr15:82459472~82477258:+ PAAD cis rs6570726 0.935 rs419854 ENSG00000235652.6 RP11-545I5.3 4.19 4.66e-05 0.0183 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145522949 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs365658 ENSG00000235652.6 RP11-545I5.3 4.19 4.66e-05 0.0183 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145523452 chr6:145799409~145886585:+ PAAD cis rs494459 0.838 rs1784543 ENSG00000278376.1 RP11-158I9.8 -4.19 4.66e-05 0.0183 -0.28 -0.32 Height; chr11:118760944 chr11:118791254~118793137:+ PAAD cis rs7829975 0.577 rs7816329 ENSG00000253893.2 FAM85B 4.19 4.66e-05 0.0183 0.48 0.32 Mood instability; chr8:8686333 chr8:8167819~8226614:- PAAD cis rs2262909 0.962 rs55735642 ENSG00000279377.1 AC003973.3 -4.19 4.66e-05 0.0183 -0.3 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22058374 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs4932952 ENSG00000279377.1 AC003973.3 -4.19 4.66e-05 0.0183 -0.3 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22063986 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs73019842 ENSG00000279377.1 AC003973.3 -4.19 4.66e-05 0.0183 -0.3 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22067107 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs73019844 ENSG00000279377.1 AC003973.3 -4.19 4.66e-05 0.0183 -0.3 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22067123 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs11667209 ENSG00000279377.1 AC003973.3 -4.19 4.66e-05 0.0183 -0.3 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22076665 chr19:21965708~21968529:- PAAD cis rs797680 0.964 rs7517363 ENSG00000223745.6 RP4-717I23.3 4.19 4.66e-05 0.0183 0.27 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93187228 chr1:93262186~93346025:- PAAD cis rs2832077 0.527 rs9981922 ENSG00000176054.6 RPL23P2 -4.19 4.66e-05 0.0183 -0.32 -0.32 Cognitive test performance; chr21:28840396 chr21:28997613~28998033:- PAAD cis rs9926296 0.572 rs2079671 ENSG00000260259.1 RP11-368I7.4 -4.19 4.66e-05 0.0183 -0.38 -0.32 Vitiligo; chr16:89818573 chr16:89682620~89686569:- PAAD cis rs710913 0.618 rs6587 ENSG00000243970.1 PPIEL 4.19 4.66e-05 0.0183 0.28 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39624273 chr1:39531838~39558707:- PAAD cis rs17684571 0.751 rs7771085 ENSG00000231441.1 RP11-472M19.2 4.19 4.66e-05 0.0183 0.6 0.32 Schizophrenia; chr6:56818631 chr6:56844002~56864078:+ PAAD cis rs4835473 0.838 rs4583708 ENSG00000251600.4 RP11-673E1.1 -4.19 4.67e-05 0.0184 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143735610 chr4:143912331~143982454:+ PAAD cis rs4813802 0.569 rs990928 ENSG00000278192.1 RP5-1056H1.2 -4.19 4.67e-05 0.0184 -0.35 -0.32 Colorectal cancer; chr20:6713232 chr20:6065966~6067897:- PAAD cis rs7772486 0.743 rs111332144 ENSG00000235652.6 RP11-545I5.3 -4.19 4.68e-05 0.0184 -0.27 -0.32 Lobe attachment (rater-scored or self-reported); chr6:145735545 chr6:145799409~145886585:+ PAAD cis rs11159086 1 rs8006909 ENSG00000259005.1 RP3-449M8.6 4.19 4.68e-05 0.0184 0.44 0.32 Advanced glycation end-product levels; chr14:74478085 chr14:74474007~74474864:- PAAD cis rs11159086 1 rs8006958 ENSG00000259005.1 RP3-449M8.6 4.19 4.68e-05 0.0184 0.44 0.32 Advanced glycation end-product levels; chr14:74478148 chr14:74474007~74474864:- PAAD cis rs9918079 0.56 rs4698409 ENSG00000273133.1 RP11-799M12.2 -4.19 4.68e-05 0.0184 -0.38 -0.32 Obesity-related traits; chr4:15658143 chr4:15563698~15564253:- PAAD cis rs9918079 0.542 rs1789 ENSG00000273133.1 RP11-799M12.2 -4.19 4.68e-05 0.0184 -0.38 -0.32 Obesity-related traits; chr4:15662912 chr4:15563698~15564253:- PAAD cis rs498136 0.864 rs582635 ENSG00000250508.1 RP11-757G1.6 4.19 4.68e-05 0.0184 0.42 0.32 Cutaneous malignant melanoma;Melanoma; chr11:69539716 chr11:68870664~68874542:+ PAAD cis rs2564921 0.73 rs2564929 ENSG00000242142.1 SERBP1P3 -4.19 4.68e-05 0.0184 -0.39 -0.32 Height; chr3:53084188 chr3:53064283~53065091:- PAAD cis rs9807989 0.507 rs6543133 ENSG00000234389.1 AC007278.3 4.19 4.69e-05 0.0184 0.33 0.32 Asthma; chr2:102423717 chr2:102438713~102440475:+ PAAD cis rs11089937 0.568 rs5756988 ENSG00000211638.2 IGLV8-61 4.19 4.69e-05 0.0184 0.3 0.32 Periodontitis (PAL4Q3); chr22:22132397 chr22:22098700~22099212:+ PAAD cis rs7923609 0.967 rs3999089 ENSG00000232075.1 MRPL35P2 4.19 4.69e-05 0.0184 0.39 0.32 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63444048 chr10:63634317~63634827:- PAAD cis rs9326248 0.559 rs476399 ENSG00000280143.1 AP000892.6 4.19 4.69e-05 0.0184 0.37 0.32 Blood protein levels; chr11:116863012 chr11:117204967~117210292:+ PAAD cis rs6993244 1 rs6993244 ENSG00000254340.1 RP11-10A14.3 4.19 4.69e-05 0.0184 0.39 0.32 Mean corpuscular hemoglobin; chr8:9005549 chr8:9141424~9145435:+ PAAD cis rs853679 0.517 rs9393896 ENSG00000280107.1 AL022393.9 -4.19 4.69e-05 0.0184 -0.54 -0.32 Depression; chr6:28159925 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393897 ENSG00000280107.1 AL022393.9 -4.19 4.69e-05 0.0184 -0.54 -0.32 Depression; chr6:28159932 chr6:28170845~28172521:+ PAAD cis rs858239 0.539 rs2390757 ENSG00000226816.2 AC005082.12 4.19 4.7e-05 0.0185 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23151873 chr7:23206013~23208045:+ PAAD cis rs875971 1 rs1544549 ENSG00000232559.3 GS1-124K5.12 -4.19 4.7e-05 0.0185 -0.36 -0.32 Aortic root size; chr7:66625676 chr7:66554588~66576923:- PAAD cis rs5758511 0.508 rs2854827 ENSG00000205702.9 CYP2D7 4.19 4.7e-05 0.0185 0.3 0.32 Birth weight; chr22:42065914 chr22:42140203~42144577:- PAAD cis rs797680 0.786 rs7532195 ENSG00000223745.6 RP4-717I23.3 4.19 4.7e-05 0.0185 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93151846 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs4847235 ENSG00000223745.6 RP4-717I23.3 4.19 4.7e-05 0.0185 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93162170 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs11164876 ENSG00000223745.6 RP4-717I23.3 4.19 4.7e-05 0.0185 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93164953 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs12044657 ENSG00000223745.6 RP4-717I23.3 4.19 4.7e-05 0.0185 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93174039 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs7535628 ENSG00000223745.6 RP4-717I23.3 4.19 4.7e-05 0.0185 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93183171 chr1:93262186~93346025:- PAAD cis rs2739330 0.828 rs4822451 ENSG00000206090.4 AP000350.7 4.19 4.7e-05 0.0185 0.42 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905979 chr22:23939998~23942798:+ PAAD cis rs2739330 0.828 rs5760099 ENSG00000206090.4 AP000350.7 4.19 4.7e-05 0.0185 0.42 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906227 chr22:23939998~23942798:+ PAAD cis rs2729354 0.693 rs2584862 ENSG00000265566.2 RN7SL605P -4.19 4.7e-05 0.0185 -0.41 -0.32 Blood protein levels; chr11:57474483 chr11:57528085~57528365:- PAAD cis rs1150668 0.796 rs2531825 ENSG00000219891.2 ZSCAN12P1 4.19 4.7e-05 0.0185 0.41 0.32 Pubertal anthropometrics; chr6:28381487 chr6:28091154~28093664:+ PAAD cis rs77372450 0.636 rs7707786 ENSG00000251405.2 CTB-109A12.1 -4.19 4.71e-05 0.0185 -0.5 -0.32 Bipolar disorder (body mass index interaction); chr5:157569750 chr5:157362615~157460078:- PAAD cis rs858239 0.899 rs10085838 ENSG00000226816.2 AC005082.12 4.19 4.71e-05 0.0185 0.38 0.32 Cerebrospinal fluid biomarker levels; chr7:23258796 chr7:23206013~23208045:+ PAAD cis rs9531006 0.752 rs3850061 ENSG00000227676.3 LINC01068 4.19 4.71e-05 0.0185 0.51 0.32 Sleep duration; chr13:79944751 chr13:79566727~79571436:+ PAAD cis rs9531006 0.752 rs3850062 ENSG00000227676.3 LINC01068 4.19 4.71e-05 0.0185 0.51 0.32 Sleep duration; chr13:79945171 chr13:79566727~79571436:+ PAAD cis rs9531006 0.711 rs3850064 ENSG00000227676.3 LINC01068 4.19 4.71e-05 0.0185 0.51 0.32 Sleep duration; chr13:79949727 chr13:79566727~79571436:+ PAAD cis rs10050311 0.585 rs113536481 ENSG00000251411.1 RP11-397E7.4 -4.19 4.71e-05 0.0185 -0.38 -0.32 Insulin-related traits; chr4:86943979 chr4:86913266~86914817:- PAAD cis rs10421328 0.821 rs10423311 ENSG00000259242.2 AC002306.1 4.19 4.71e-05 0.0185 0.49 0.32 Parental longevity (combined parental age at death); chr19:19646453 chr19:19606350~19608660:+ PAAD cis rs638893 0.617 rs7933007 ENSG00000278376.1 RP11-158I9.8 4.19 4.71e-05 0.0185 0.34 0.32 Vitiligo; chr11:118859960 chr11:118791254~118793137:+ PAAD cis rs6584283 0.766 rs7911680 ENSG00000228778.1 RP11-129J12.1 -4.19 4.71e-05 0.0185 -0.36 -0.32 Ulcerative colitis; chr10:99533711 chr10:99527081~99528261:+ PAAD cis rs6479891 0.915 rs10761744 ENSG00000232075.1 MRPL35P2 -4.19 4.71e-05 0.0185 -0.53 -0.32 Arthritis (juvenile idiopathic); chr10:63341266 chr10:63634317~63634827:- PAAD cis rs4664293 0.667 rs10169681 ENSG00000226266.5 AC009961.3 4.19 4.72e-05 0.0185 0.39 0.32 Monocyte percentage of white cells; chr2:159782065 chr2:159670708~159712435:- PAAD cis rs72634501 0.54 rs16826036 ENSG00000261798.1 RP1-118J21.25 4.19 4.72e-05 0.0185 0.41 0.32 HDL cholesterol; chr1:39292127 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs16826038 ENSG00000261798.1 RP1-118J21.25 4.19 4.72e-05 0.0185 0.41 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39292962 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs61782157 ENSG00000261798.1 RP1-118J21.25 4.19 4.72e-05 0.0185 0.41 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39297217 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs41270803 ENSG00000261798.1 RP1-118J21.25 4.19 4.72e-05 0.0185 0.41 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39300369 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs61783376 ENSG00000261798.1 RP1-118J21.25 4.19 4.72e-05 0.0185 0.41 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39303328 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs4660636 ENSG00000261798.1 RP1-118J21.25 4.19 4.72e-05 0.0185 0.41 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39304555 chr1:39788976~39790171:+ PAAD cis rs7120173 0.779 rs7103842 ENSG00000231865.1 SIK3-IT1 -4.19 4.72e-05 0.0185 -0.43 -0.32 Visceral adipose tissue adjusted for BMI; chr11:117087312 chr11:116886046~116890721:- PAAD cis rs4554975 0.689 rs10881004 ENSG00000274723.1 RP11-618L22.1 -4.19 4.72e-05 0.0185 -0.36 -0.32 Metabolite levels (small molecules and protein measures); chr12:46842788 chr12:46970504~46972155:+ PAAD cis rs4660214 0.789 rs1180375 ENSG00000237624.1 OXCT2P1 4.19 4.72e-05 0.0185 0.42 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39415368 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs663892 ENSG00000237624.1 OXCT2P1 4.19 4.72e-05 0.0185 0.42 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39424005 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs1180384 ENSG00000237624.1 OXCT2P1 4.19 4.72e-05 0.0185 0.42 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39427102 chr1:39514956~39516490:+ PAAD cis rs9309473 0.95 rs10206899 ENSG00000163016.8 ALMS1P 4.19 4.72e-05 0.0185 0.48 0.32 Metabolite levels; chr2:73673773 chr2:73644919~73685576:+ PAAD cis rs55894132 1 rs55894132 ENSG00000279656.1 RP11-298I3.6 4.19 4.73e-05 0.0185 0.38 0.32 Intelligence (multi-trait analysis); chr14:22939628 chr14:23023083~23024217:- PAAD cis rs875971 0.545 rs221986 ENSG00000222364.1 RNU6-96P 4.19 4.73e-05 0.0185 0.43 0.32 Aortic root size; chr7:66105323 chr7:66395191~66395286:+ PAAD cis rs633715 0.766 rs12097393 ENSG00000254154.7 RP4-798P15.3 -4.19 4.73e-05 0.0185 -0.3 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177846708 chr1:177928788~178038007:- PAAD cis rs633715 0.702 rs36055936 ENSG00000254154.7 RP4-798P15.3 -4.19 4.73e-05 0.0185 -0.3 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177847661 chr1:177928788~178038007:- PAAD cis rs7626444 0.625 rs2931210 ENSG00000272359.1 U4 -4.19 4.73e-05 0.0186 -0.35 -0.32 Monocyte count; chr3:196749805 chr3:196747192~196747324:- PAAD cis rs4660214 0.666 rs1180376 ENSG00000261798.1 RP1-118J21.25 4.19 4.73e-05 0.0186 0.39 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39418761 chr1:39788976~39790171:+ PAAD cis rs4660214 0.666 rs625384 ENSG00000261798.1 RP1-118J21.25 4.19 4.73e-05 0.0186 0.39 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39427421 chr1:39788976~39790171:+ PAAD cis rs7617773 0.817 rs3937 ENSG00000228638.1 FCF1P2 -4.19 4.73e-05 0.0186 -0.37 -0.32 Coronary artery disease; chr3:48270912 chr3:48290793~48291375:- PAAD cis rs1964356 0.524 rs7839585 ENSG00000253893.2 FAM85B 4.19 4.73e-05 0.0186 0.44 0.32 Mean corpuscular volume; chr8:8996725 chr8:8167819~8226614:- PAAD cis rs7615952 0.543 rs4645102 ENSG00000171084.14 FAM86JP 4.19 4.73e-05 0.0186 0.44 0.32 Blood pressure (smoking interaction); chr3:125705597 chr3:125916620~125930024:+ PAAD cis rs494459 0.536 rs7103067 ENSG00000255422.1 AP002954.4 -4.19 4.73e-05 0.0186 -0.36 -0.32 Height; chr11:118852670 chr11:118704607~118750263:+ PAAD cis rs6539288 0.677 rs10735418 ENSG00000260329.1 RP11-412D9.4 -4.19 4.74e-05 0.0186 -0.29 -0.32 Total body bone mineral density; chr12:106949598 chr12:106954029~106955497:- PAAD cis rs72615157 0.612 rs7786505 ENSG00000242294.5 STAG3L5P 4.19 4.74e-05 0.0186 0.26 0.32 Lung function (FEV1/FVC); chr7:100219962 chr7:100336079~100351900:+ PAAD cis rs72615157 0.664 rs6953580 ENSG00000242294.5 STAG3L5P 4.19 4.74e-05 0.0186 0.26 0.32 Lung function (FEV1/FVC); chr7:100227652 chr7:100336079~100351900:+ PAAD cis rs1075265 0.59 rs810909 ENSG00000233266.1 HMGB1P31 4.19 4.74e-05 0.0186 0.4 0.32 Chronotype;Morning vs. evening chronotype; chr2:53846034 chr2:54051334~54051760:+ PAAD cis rs4660214 0.724 rs7554301 ENSG00000237624.1 OXCT2P1 -4.19 4.74e-05 0.0186 -0.42 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39177792 chr1:39514956~39516490:+ PAAD cis rs2562456 0.652 rs4809145 ENSG00000213976.4 CTD-2561J22.2 -4.19 4.74e-05 0.0186 -0.37 -0.32 Pain; chr19:21597907 chr19:21382865~21387177:+ PAAD cis rs10129255 0.5 rs4774189 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106768275 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs7161740 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106776119 chr14:106675017~106675544:- PAAD cis rs10129255 0.556 rs6576222 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106776442 chr14:106675017~106675544:- PAAD cis rs10129255 0.536 rs6576223 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106776448 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs988134 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106776698 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs988133 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106776724 chr14:106675017~106675544:- PAAD cis rs10129255 0.518 rs8009594 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106777494 chr14:106675017~106675544:- PAAD cis rs10129255 0.518 rs8009612 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106777510 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs6576225 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106778120 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs6576226 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106778135 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs6576230 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106778539 chr14:106675017~106675544:- PAAD cis rs10129255 0.518 rs11847766 ENSG00000211972.2 IGHV3-66 4.19 4.75e-05 0.0186 0.25 0.32 Kawasaki disease; chr14:106779186 chr14:106675017~106675544:- PAAD cis rs10129255 0.518 rs12590732 ENSG00000211972.2 IGHV3-66 -4.19 4.75e-05 0.0186 -0.25 -0.32 Kawasaki disease; chr14:106779612 chr14:106675017~106675544:- PAAD cis rs7617773 0.709 rs4404473 ENSG00000228638.1 FCF1P2 -4.19 4.75e-05 0.0186 -0.37 -0.32 Coronary artery disease; chr3:48312136 chr3:48290793~48291375:- PAAD cis rs7572733 0.576 rs1865586 ENSG00000231621.1 AC013264.2 4.19 4.75e-05 0.0186 0.31 0.32 Dermatomyositis; chr2:197894144 chr2:197197991~197199273:+ PAAD cis rs9419788 0.708 rs2860749 ENSG00000233377.1 MTND4P20 4.19 4.75e-05 0.0186 0.29 0.32 Personality traits in bipolar disorder; chr10:94226238 chr10:94940253~94941121:- PAAD cis rs9487094 0.67 rs2277114 ENSG00000260273.1 RP11-425D10.10 4.19 4.75e-05 0.0186 0.41 0.32 Height; chr6:109506513 chr6:109382795~109383666:+ PAAD cis rs394563 0.775 rs399673 ENSG00000231760.4 RP11-350J20.5 4.19 4.75e-05 0.0186 0.44 0.32 Dupuytren's disease; chr6:149462085 chr6:149796151~149826294:- PAAD cis rs394563 0.81 rs480870 ENSG00000231760.4 RP11-350J20.5 4.19 4.75e-05 0.0186 0.44 0.32 Dupuytren's disease; chr6:149463682 chr6:149796151~149826294:- PAAD cis rs394563 0.775 rs420430 ENSG00000231760.4 RP11-350J20.5 4.19 4.75e-05 0.0186 0.44 0.32 Dupuytren's disease; chr6:149464403 chr6:149796151~149826294:- PAAD cis rs394563 0.775 rs448420 ENSG00000231760.4 RP11-350J20.5 4.19 4.75e-05 0.0186 0.44 0.32 Dupuytren's disease; chr6:149464666 chr6:149796151~149826294:- PAAD cis rs338389 0.934 rs338404 ENSG00000260657.2 RP11-315D16.4 -4.19 4.75e-05 0.0186 -0.33 -0.32 Survival in rectal cancer; chr15:67959337 chr15:68267792~68277994:- PAAD cis rs338389 0.934 rs338403 ENSG00000260657.2 RP11-315D16.4 -4.19 4.75e-05 0.0186 -0.33 -0.32 Survival in rectal cancer; chr15:67959349 chr15:68267792~68277994:- PAAD cis rs8072100 0.869 rs4439799 ENSG00000228782.6 CTD-2026D20.3 4.19 4.76e-05 0.0186 0.32 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47704233 chr17:47450568~47492492:- PAAD cis rs5758511 0.689 rs5758691 ENSG00000226450.2 CYP2D8P 4.19 4.76e-05 0.0186 0.32 0.32 Birth weight; chr22:42272498 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs5758692 ENSG00000226450.2 CYP2D8P 4.19 4.76e-05 0.0186 0.32 0.32 Birth weight; chr22:42273023 chr22:42149886~42155001:- PAAD cis rs5758511 0.68 rs1001586 ENSG00000226450.2 CYP2D8P 4.19 4.76e-05 0.0186 0.32 0.32 Birth weight; chr22:42274287 chr22:42149886~42155001:- PAAD cis rs77372450 0.636 rs10052322 ENSG00000251405.2 CTB-109A12.1 4.19 4.76e-05 0.0186 0.51 0.32 Bipolar disorder (body mass index interaction); chr5:157587412 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs77291311 ENSG00000251405.2 CTB-109A12.1 4.19 4.76e-05 0.0186 0.51 0.32 Bipolar disorder (body mass index interaction); chr5:157591642 chr5:157362615~157460078:- PAAD cis rs9309473 0.95 rs2947860 ENSG00000163016.8 ALMS1P 4.19 4.76e-05 0.0186 0.47 0.32 Metabolite levels; chr2:73628259 chr2:73644919~73685576:+ PAAD cis rs9309473 0.898 rs10201159 ENSG00000163016.8 ALMS1P 4.19 4.76e-05 0.0186 0.47 0.32 Metabolite levels; chr2:73631838 chr2:73644919~73685576:+ PAAD cis rs2522056 0.808 rs7704457 ENSG00000233006.5 AC034220.3 4.19 4.76e-05 0.0186 0.29 0.32 Fibrinogen;Lymphocyte counts; chr5:132409098 chr5:132311285~132369916:- PAAD cis rs7592578 0.713 rs60915953 ENSG00000231858.4 AC067945.4 -4.19 4.76e-05 0.0186 -0.39 -0.32 Diastolic blood pressure; chr2:190466578 chr2:191021526~191032314:+ PAAD cis rs7260598 0.792 rs11669251 ENSG00000268442.1 CTD-2027I19.2 4.19 4.76e-05 0.0186 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24154192 chr19:24162370~24163425:- PAAD cis rs7572733 0.534 rs700678 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197841096 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700681 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197846778 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700682 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197847586 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700683 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197847608 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700684 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197848375 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs7604700 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197853906 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs1435569 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197853943 chr2:197197991~197199273:+ PAAD cis rs7572733 0.514 rs700686 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197856330 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700687 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197856836 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs696817 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197857501 chr2:197197991~197199273:+ PAAD cis rs700651 0.821 rs770661 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Intracranial aneurysm; chr2:197860720 chr2:197197991~197199273:+ PAAD cis rs700651 0.821 rs700690 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Intracranial aneurysm; chr2:197862902 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700692 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197863776 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs770662 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197864559 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1436131 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197866506 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs1435570 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197866647 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs11899188 ENSG00000231621.1 AC013264.2 -4.19 4.76e-05 0.0186 -0.32 -0.32 Dermatomyositis; chr2:197875397 chr2:197197991~197199273:+ PAAD cis rs6743226 0.603 rs12619677 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241273780 chr2:241245202~241245299:- PAAD cis rs6743226 0.626 rs59542139 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241274234 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs60515663 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241274843 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs10933546 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241286583 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs11896191 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241287336 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs67625947 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241287985 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs58226367 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241288132 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs62186405 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241292738 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs62186406 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241294041 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs10933548 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241295422 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs62186408 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241296236 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs62186410 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241296443 chr2:241245202~241245299:- PAAD cis rs6743226 0.626 rs12612578 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241297245 chr2:241245202~241245299:- PAAD cis rs6743226 0.58 rs11677414 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241298382 chr2:241245202~241245299:- PAAD cis rs6743226 0.58 rs11884197 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241303371 chr2:241245202~241245299:- PAAD cis rs6743226 0.515 rs56061376 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241304020 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs62186421 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241309357 chr2:241245202~241245299:- PAAD cis rs6743226 0.58 rs12619620 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241310679 chr2:241245202~241245299:- PAAD cis rs6743226 0.603 rs1106523 ENSG00000266621.1 AC104841.1 4.19 4.76e-05 0.0186 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241312124 chr2:241245202~241245299:- PAAD cis rs875971 1 rs2420820 ENSG00000232559.3 GS1-124K5.12 -4.19 4.77e-05 0.0187 -0.36 -0.32 Aortic root size; chr7:66626920 chr7:66554588~66576923:- PAAD cis rs6545883 0.507 rs4672427 ENSG00000273302.1 RP11-493E12.2 -4.19 4.77e-05 0.0187 -0.28 -0.32 Tuberculosis; chr2:61242115 chr2:61199979~61200769:+ PAAD cis rs2243480 1 rs1039664 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:65984729 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1964692 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:65989196 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs2456483 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:65996588 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1701750 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66002158 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1701758 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66005214 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs1701759 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66005945 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2462569 ENSG00000232546.1 RP11-458F8.1 4.19 4.77e-05 0.0187 0.39 0.32 Diabetic kidney disease; chr7:66009859 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs781157 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66013324 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs781156 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66014154 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs781149 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66016297 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs451396 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66019087 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs58207111 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66021736 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1167613 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66022452 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1715235 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66023407 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs313799 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66029343 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs313807 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66034494 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs313808 ENSG00000232546.1 RP11-458F8.1 -4.19 4.77e-05 0.0187 -0.39 -0.32 Diabetic kidney disease; chr7:66034886 chr7:66848496~66858136:+ PAAD cis rs9876781 0.53 rs35516531 ENSG00000229759.1 MRPS18AP1 4.19 4.77e-05 0.0187 0.33 0.32 Longevity; chr3:48364275 chr3:48256350~48256938:- PAAD cis rs77505915 0.512 rs12921808 ENSG00000261783.1 RP11-252K23.2 4.19 4.77e-05 0.0187 0.47 0.32 Migraine; chr16:75350086 chr16:75379818~75381260:- PAAD cis rs79349575 0.594 rs1985785 ENSG00000270781.1 RP11-501C14.9 -4.19 4.77e-05 0.0187 -0.37 -0.32 Type 2 diabetes; chr17:48890426 chr17:48899131~48899748:+ PAAD cis rs79349575 0.685 rs1124829 ENSG00000270781.1 RP11-501C14.9 -4.19 4.77e-05 0.0187 -0.37 -0.32 Type 2 diabetes; chr17:48890435 chr17:48899131~48899748:+ PAAD cis rs79349575 0.721 rs1008834 ENSG00000270781.1 RP11-501C14.9 -4.19 4.77e-05 0.0187 -0.37 -0.32 Type 2 diabetes; chr17:48890646 chr17:48899131~48899748:+ PAAD cis rs79349575 0.721 rs9904645 ENSG00000270781.1 RP11-501C14.9 -4.19 4.77e-05 0.0187 -0.37 -0.32 Type 2 diabetes; chr17:48892303 chr17:48899131~48899748:+ PAAD cis rs2115630 1 rs7183401 ENSG00000225151.9 GOLGA2P7 4.19 4.78e-05 0.0187 0.38 0.32 P wave terminal force; chr15:84828713 chr15:84199311~84230136:- PAAD cis rs79040073 0.637 rs11632211 ENSG00000259531.2 RP11-295H24.3 4.19 4.78e-05 0.0187 0.53 0.32 Lung cancer in ever smokers; chr15:49159178 chr15:49365124~49366685:- PAAD cis rs79349575 0.87 rs12941262 ENSG00000270781.1 RP11-501C14.9 -4.19 4.78e-05 0.0187 -0.37 -0.32 Type 2 diabetes; chr17:48889675 chr17:48899131~48899748:+ PAAD cis rs79349575 0.778 rs12950328 ENSG00000270781.1 RP11-501C14.9 -4.19 4.78e-05 0.0187 -0.37 -0.32 Type 2 diabetes; chr17:48889699 chr17:48899131~48899748:+ PAAD cis rs10779751 0.96 rs4845857 ENSG00000238199.1 UBE2V2P3 -4.19 4.78e-05 0.0187 -0.39 -0.32 Body mass index; chr1:11225623 chr1:11278616~11279351:- PAAD cis rs10779751 0.922 rs4845985 ENSG00000238199.1 UBE2V2P3 -4.19 4.78e-05 0.0187 -0.39 -0.32 Body mass index; chr1:11228561 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs4845986 ENSG00000238199.1 UBE2V2P3 -4.19 4.78e-05 0.0187 -0.39 -0.32 Body mass index; chr1:11228576 chr1:11278616~11279351:- PAAD cis rs10779751 0.96 rs6661859 ENSG00000238199.1 UBE2V2P3 -4.19 4.78e-05 0.0187 -0.39 -0.32 Body mass index; chr1:11241006 chr1:11278616~11279351:- PAAD cis rs10779751 0.887 rs6686835 ENSG00000238199.1 UBE2V2P3 -4.19 4.78e-05 0.0187 -0.39 -0.32 Body mass index; chr1:11245259 chr1:11278616~11279351:- PAAD cis rs4835473 0.8 rs1849117 ENSG00000251600.4 RP11-673E1.1 4.19 4.78e-05 0.0187 0.38 0.32 Immature fraction of reticulocytes; chr4:143989791 chr4:143912331~143982454:+ PAAD cis rs858239 0.601 rs6971002 ENSG00000226816.2 AC005082.12 4.19 4.78e-05 0.0187 0.37 0.32 Cerebrospinal fluid biomarker levels; chr7:23132685 chr7:23206013~23208045:+ PAAD cis rs4266144 0.544 rs7340627 ENSG00000244515.1 KRT18P34 -4.19 4.78e-05 0.0187 -0.37 -0.32 Coronary artery disease; chr3:157114604 chr3:157162663~157163932:- PAAD cis rs4266144 0.544 rs13080798 ENSG00000244515.1 KRT18P34 -4.19 4.78e-05 0.0187 -0.37 -0.32 Coronary artery disease; chr3:157114612 chr3:157162663~157163932:- PAAD cis rs2638953 0.962 rs10506029 ENSG00000247934.4 RP11-967K21.1 -4.19 4.78e-05 0.0187 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28320302 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049530 ENSG00000247934.4 RP11-967K21.1 -4.19 4.78e-05 0.0187 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28322220 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049531 ENSG00000247934.4 RP11-967K21.1 -4.19 4.78e-05 0.0187 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28322797 chr12:28163298~28190738:- PAAD cis rs2638953 1 rs11049532 ENSG00000247934.4 RP11-967K21.1 -4.19 4.78e-05 0.0187 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28323979 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs10843154 ENSG00000247934.4 RP11-967K21.1 -4.19 4.78e-05 0.0187 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28326824 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049537 ENSG00000247934.4 RP11-967K21.1 -4.19 4.78e-05 0.0187 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28331239 chr12:28163298~28190738:- PAAD cis rs2638953 0.889 rs10843155 ENSG00000247934.4 RP11-967K21.1 -4.19 4.78e-05 0.0187 -0.37 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28334920 chr12:28163298~28190738:- PAAD cis rs72615157 0.716 rs75779608 ENSG00000242294.5 STAG3L5P 4.19 4.78e-05 0.0187 0.26 0.32 Lung function (FEV1/FVC); chr7:100171334 chr7:100336079~100351900:+ PAAD cis rs11098499 0.71 rs6851130 ENSG00000245958.5 RP11-33B1.1 4.19 4.78e-05 0.0187 0.26 0.32 Corneal astigmatism; chr4:119212557 chr4:119454791~119552025:+ PAAD cis rs1707322 0.686 rs2275085 ENSG00000280836.1 AL355480.1 4.19 4.79e-05 0.0187 0.39 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620180 chr1:45581219~45581321:- PAAD cis rs12701220 0.625 rs12701499 ENSG00000229043.2 AC091729.9 -4.19 4.79e-05 0.0187 -0.42 -0.32 Bronchopulmonary dysplasia; chr7:1022168 chr7:1160374~1165267:+ PAAD cis rs853679 0.55 rs1150692 ENSG00000204709.4 LINC01556 4.19 4.79e-05 0.0187 0.55 0.32 Depression; chr6:28206179 chr6:28943877~28944537:+ PAAD cis rs2736345 0.788 rs9693589 ENSG00000251402.3 FAM90A25P 4.19 4.79e-05 0.0187 0.42 0.32 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11491452 chr8:12415080~12418090:- PAAD cis rs2736345 0.788 rs13277113 ENSG00000251402.3 FAM90A25P 4.19 4.79e-05 0.0187 0.42 0.32 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11491677 chr8:12415080~12418090:- PAAD cis rs73173548 0.528 rs16903177 ENSG00000247828.6 TMEM161B-AS1 4.19 4.79e-05 0.0187 0.27 0.32 Macular telangiectasia type 2; chr5:88480416 chr5:88268895~88436685:+ PAAD cis rs6921919 0.789 rs6456814 ENSG00000204709.4 LINC01556 4.19 4.79e-05 0.0187 0.51 0.32 Autism spectrum disorder or schizophrenia; chr6:28338035 chr6:28943877~28944537:+ PAAD cis rs6921919 0.789 rs13210258 ENSG00000204709.4 LINC01556 4.19 4.79e-05 0.0187 0.51 0.32 Autism spectrum disorder or schizophrenia; chr6:28340894 chr6:28943877~28944537:+ PAAD cis rs7772486 0.774 rs2247571 ENSG00000235652.6 RP11-545I5.3 4.19 4.8e-05 0.0188 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145898397 chr6:145799409~145886585:+ PAAD cis rs2117029 1 rs2293445 ENSG00000258017.1 RP11-386G11.10 -4.19 4.8e-05 0.0188 -0.42 -0.32 Intelligence (multi-trait analysis); chr12:49005079 chr12:49127782~49147869:+ PAAD cis rs7189233 0.91 rs3809634 ENSG00000279722.1 RP11-44F14.6 -4.19 4.8e-05 0.0188 -0.34 -0.32 Intelligence (multi-trait analysis); chr16:53504245 chr16:53487607~53489943:- PAAD cis rs950169 0.58 rs1061737 ENSG00000259728.4 LINC00933 4.19 4.8e-05 0.0188 0.4 0.32 Schizophrenia; chr15:84640559 chr15:84570649~84580175:+ PAAD cis rs1555322 0.932 rs1205411 ENSG00000279253.1 RP4-614O4.13 -4.19 4.8e-05 0.0188 -0.41 -0.32 Attention deficit hyperactivity disorder; chr20:35269439 chr20:35262727~35264187:- PAAD cis rs6570726 0.935 rs419847 ENSG00000235652.6 RP11-545I5.3 4.19 4.8e-05 0.0188 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145506142 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs419850 ENSG00000235652.6 RP11-545I5.3 4.19 4.8e-05 0.0188 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145506145 chr6:145799409~145886585:+ PAAD cis rs7712401 0.601 rs246287 ENSG00000263432.2 RN7SL689P 4.18 4.81e-05 0.0188 0.42 0.32 Mean platelet volume; chr5:122909731 chr5:123022487~123022783:- PAAD cis rs10888838 1 rs1410896 ENSG00000198711.5 SSBP3-AS1 4.18 4.81e-05 0.0188 0.38 0.32 Mitochondrial DNA levels; chr1:54217341 chr1:54236440~54239063:+ PAAD cis rs964611 0.786 rs5020564 ENSG00000259488.2 RP11-154J22.1 -4.18 4.81e-05 0.0188 -0.37 -0.32 Metabolite levels (Pyroglutamine); chr15:48372356 chr15:48312353~48331856:- PAAD cis rs9807989 0.507 rs1833174 ENSG00000234389.1 AC007278.3 4.18 4.81e-05 0.0188 0.32 0.32 Asthma; chr2:102418383 chr2:102438713~102440475:+ PAAD cis rs79040073 0.637 rs61442055 ENSG00000259469.1 RP11-227D13.4 -4.18 4.81e-05 0.0188 -0.5 -0.32 Lung cancer in ever smokers; chr15:49156901 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs73390343 ENSG00000259469.1 RP11-227D13.4 -4.18 4.81e-05 0.0188 -0.5 -0.32 Lung cancer in ever smokers; chr15:49164026 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs73390360 ENSG00000259469.1 RP11-227D13.4 -4.18 4.81e-05 0.0188 -0.5 -0.32 Lung cancer in ever smokers; chr15:49171265 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs73390362 ENSG00000259469.1 RP11-227D13.4 -4.18 4.81e-05 0.0188 -0.5 -0.32 Lung cancer in ever smokers; chr15:49172292 chr15:48729080~48729844:- PAAD cis rs896655 0.71 rs751158 ENSG00000266446.1 RP11-149I2.4 -4.18 4.81e-05 0.0188 -0.38 -0.32 Coronary artery disease; chr9:21706796 chr9:21995482~21996013:+ PAAD cis rs6743226 0.603 rs72484048 ENSG00000266621.1 AC104841.1 4.18 4.81e-05 0.0188 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241287944 chr2:241245202~241245299:- PAAD cis rs9487094 0.67 rs34928881 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109526846 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs10782163 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109533040 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs10457195 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109534269 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12194061 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109546439 chr6:109382795~109383666:+ PAAD cis rs6920372 0.731 rs2357124 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109551060 chr6:109382795~109383666:+ PAAD cis rs9487094 0.696 rs11153188 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109558247 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs11752791 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109564443 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs4490694 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109571489 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12214639 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109576414 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs11754340 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109584789 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs11755641 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109586733 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs13199135 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109588639 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12193719 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109589051 chr6:109382795~109383666:+ PAAD cis rs9487094 0.644 rs1960325 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109592105 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12528781 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109608105 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs7767525 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109646187 chr6:109382795~109383666:+ PAAD cis rs9487094 0.504 rs71541003 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109652694 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs3899233 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109655791 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12197838 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109672088 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs6911700 ENSG00000260273.1 RP11-425D10.10 4.18 4.81e-05 0.0188 0.39 0.32 Height; chr6:109676091 chr6:109382795~109383666:+ PAAD cis rs10510102 0.608 rs4486560 ENSG00000276742.1 RP11-500G22.4 4.18 4.81e-05 0.0188 0.4 0.32 Breast cancer; chr10:121844840 chr10:121956782~121957098:+ PAAD cis rs2790457 0.792 rs1265841 ENSG00000254635.4 WAC-AS1 -4.18 4.82e-05 0.0188 -0.32 -0.32 Multiple myeloma; chr10:28631772 chr10:28522652~28532743:- PAAD cis rs748404 1 rs17779494 ENSG00000205771.5 CATSPER2P1 4.18 4.82e-05 0.0188 0.48 0.32 Lung cancer; chr15:43287025 chr15:43726918~43747094:- PAAD cis rs700651 0.821 rs4850812 ENSG00000231621.1 AC013264.2 4.18 4.82e-05 0.0188 0.32 0.32 Intracranial aneurysm; chr2:197878931 chr2:197197991~197199273:+ PAAD cis rs2985684 0.748 rs2985686 ENSG00000259113.1 RP11-406H23.2 -4.18 4.82e-05 0.0188 -0.46 -0.32 Carotid intima media thickness; chr14:49633965 chr14:50448807~50456742:+ PAAD cis rs9357354 0.927 rs34440489 ENSG00000218809.1 RP1-229K20.5 4.18 4.82e-05 0.0188 0.35 0.32 Telomere length; chr6:41343900 chr6:41269875~41270239:- PAAD cis rs7688540 0.511 rs61794965 ENSG00000275426.1 CH17-262A2.1 4.18 4.82e-05 0.0188 0.52 0.32 Facial morphology (factor 6, height of vermillion lower lip); chr4:177880 chr4:149738~150317:+ PAAD cis rs7688540 0.511 rs11731927 ENSG00000275426.1 CH17-262A2.1 4.18 4.82e-05 0.0188 0.52 0.32 Facial morphology (factor 6, height of vermillion lower lip); chr4:180316 chr4:149738~150317:+ PAAD cis rs453301 0.624 rs2288671 ENSG00000254340.1 RP11-10A14.3 4.18 4.82e-05 0.0188 0.39 0.32 Joint mobility (Beighton score); chr8:9003384 chr8:9141424~9145435:+ PAAD cis rs9876781 1 rs7635522 ENSG00000229759.1 MRPS18AP1 4.18 4.83e-05 0.0188 0.34 0.32 Longevity; chr3:48382166 chr3:48256350~48256938:- PAAD cis rs6479891 1 rs4746974 ENSG00000232075.1 MRPL35P2 4.18 4.83e-05 0.0188 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63132292 chr10:63634317~63634827:- PAAD cis rs6977955 1 rs6977955 ENSG00000234336.5 JAZF1-AS1 4.18 4.83e-05 0.0189 0.38 0.32 Allergic disease (asthma, hay fever or eczema); chr7:28117268 chr7:28180322~28243917:+ PAAD cis rs6570726 0.967 rs9497316 ENSG00000235652.6 RP11-545I5.3 -4.18 4.83e-05 0.0189 -0.26 -0.32 Lobe attachment (rater-scored or self-reported); chr6:145471251 chr6:145799409~145886585:+ PAAD cis rs875971 0.895 rs4718349 ENSG00000232559.3 GS1-124K5.12 4.18 4.84e-05 0.0189 0.35 0.32 Aortic root size; chr7:66444024 chr7:66554588~66576923:- PAAD cis rs2280018 0.526 rs2966128 ENSG00000188599.16 NPIPP1 -4.18 4.84e-05 0.0189 -0.3 -0.32 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059532 chr16:15104312~15123498:- PAAD cis rs9549328 0.796 rs7993665 ENSG00000267868.1 RP11-120K24.3 4.18 4.84e-05 0.0189 0.36 0.32 Systolic blood pressure; chr13:112996818 chr13:112964835~112966131:- PAAD cis rs2976388 0.609 rs2585145 ENSG00000253741.1 CTD-2292P10.4 -4.18 4.84e-05 0.0189 -0.38 -0.32 Urinary tract infection frequency; chr8:142718039 chr8:142702252~142726973:- PAAD cis rs2976388 0.587 rs2717606 ENSG00000253741.1 CTD-2292P10.4 -4.18 4.84e-05 0.0189 -0.38 -0.32 Urinary tract infection frequency; chr8:142718078 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2585144 ENSG00000253741.1 CTD-2292P10.4 -4.18 4.84e-05 0.0189 -0.38 -0.32 Urinary tract infection frequency; chr8:142718851 chr8:142702252~142726973:- PAAD cis rs2976388 0.609 rs2717603 ENSG00000253741.1 CTD-2292P10.4 -4.18 4.84e-05 0.0189 -0.38 -0.32 Urinary tract infection frequency; chr8:142721775 chr8:142702252~142726973:- PAAD cis rs4268898 0.896 rs2702042 ENSG00000242628.4 AC009228.1 4.18 4.84e-05 0.0189 0.39 0.32 Asthma; chr2:24323673 chr2:24214381~24221516:+ PAAD cis rs7189233 0.513 rs2908797 ENSG00000279344.1 RP11-44F14.7 4.18 4.84e-05 0.0189 0.24 0.32 Intelligence (multi-trait analysis); chr16:53395261 chr16:53478957~53481550:- PAAD cis rs4722166 0.704 rs4321884 ENSG00000179428.2 AC073072.5 -4.18 4.85e-05 0.0189 -0.32 -0.32 Lung cancer; chr7:22701840 chr7:22725395~22727620:- PAAD cis rs9652601 0.959 rs9888908 ENSG00000274038.1 RP11-66H6.4 -4.18 4.85e-05 0.0189 -0.37 -0.32 Systemic lupus erythematosus; chr16:11087387 chr16:11056556~11057034:+ PAAD cis rs7829975 0.557 rs7816427 ENSG00000253893.2 FAM85B 4.18 4.85e-05 0.0189 0.49 0.32 Mood instability; chr8:8688374 chr8:8167819~8226614:- PAAD cis rs9926296 0.656 rs2376881 ENSG00000260259.1 RP11-368I7.4 -4.18 4.86e-05 0.0189 -0.38 -0.32 Vitiligo; chr16:89760603 chr16:89682620~89686569:- PAAD cis rs919433 0.889 rs787995 ENSG00000231621.1 AC013264.2 -4.18 4.86e-05 0.0189 -0.31 -0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197352129 chr2:197197991~197199273:+ PAAD cis rs651386 0.505 rs10919441 ENSG00000271811.1 RP1-79C4.4 4.18 4.86e-05 0.0189 0.34 0.32 Atrial fibrillation; chr1:170609948 chr1:170667381~170669425:+ PAAD cis rs494459 0.838 rs581045 ENSG00000278376.1 RP11-158I9.8 -4.18 4.86e-05 0.0189 -0.28 -0.32 Height; chr11:118761813 chr11:118791254~118793137:+ PAAD cis rs797680 0.786 rs1426318 ENSG00000223745.6 RP4-717I23.3 4.18 4.86e-05 0.0189 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93381863 chr1:93262186~93346025:- PAAD cis rs797680 0.786 rs59417472 ENSG00000223745.6 RP4-717I23.3 4.18 4.86e-05 0.0189 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93382956 chr1:93262186~93346025:- PAAD cis rs797680 0.786 rs12406245 ENSG00000223745.6 RP4-717I23.3 4.18 4.86e-05 0.0189 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93395068 chr1:93262186~93346025:- PAAD cis rs4713118 0.616 rs9348789 ENSG00000204709.4 LINC01556 4.18 4.86e-05 0.0189 0.54 0.32 Parkinson's disease; chr6:28057708 chr6:28943877~28944537:+ PAAD cis rs8072100 0.967 rs12452315 ENSG00000228782.6 CTD-2026D20.3 -4.18 4.86e-05 0.019 -0.32 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47402080 chr17:47450568~47492492:- PAAD cis rs73086581 0.592 rs2300217 ENSG00000229539.1 RP11-119B16.2 4.18 4.87e-05 0.019 0.4 0.32 Response to antidepressants in depression; chr20:3957928 chr20:3888239~3888868:- PAAD cis rs1113500 0.933 rs10881497 ENSG00000226822.1 RP11-356N1.2 -4.18 4.87e-05 0.019 -0.37 -0.32 Growth-regulated protein alpha levels; chr1:108091893 chr1:108071482~108074519:+ PAAD cis rs34375054 0.573 rs34579346 ENSG00000279233.1 RP11-158L12.4 4.18 4.88e-05 0.019 0.31 0.32 Post bronchodilator FEV1/FVC ratio; chr12:125173628 chr12:125138245~125141711:+ PAAD cis rs10510102 0.608 rs4077606 ENSG00000276742.1 RP11-500G22.4 -4.18 4.88e-05 0.019 -0.4 -0.32 Breast cancer; chr10:121849907 chr10:121956782~121957098:+ PAAD cis rs1873386 0.79 rs11044352 ENSG00000255910.1 RP11-405A12.2 4.18 4.88e-05 0.019 0.47 0.32 Personality dimensions; chr12:18911582 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs11044353 ENSG00000255910.1 RP11-405A12.2 4.18 4.88e-05 0.019 0.47 0.32 Personality dimensions; chr12:18911792 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs11044354 ENSG00000255910.1 RP11-405A12.2 4.18 4.88e-05 0.019 0.47 0.32 Personality dimensions; chr12:18912071 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs11044355 ENSG00000255910.1 RP11-405A12.2 4.18 4.88e-05 0.019 0.47 0.32 Personality dimensions; chr12:18912102 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs12300665 ENSG00000255910.1 RP11-405A12.2 4.18 4.88e-05 0.019 0.47 0.32 Personality dimensions; chr12:18912552 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs12830179 ENSG00000255910.1 RP11-405A12.2 4.18 4.88e-05 0.019 0.47 0.32 Personality dimensions; chr12:18913442 chr12:19775451~20009937:+ PAAD cis rs1873386 0.74 rs7967977 ENSG00000255910.1 RP11-405A12.2 4.18 4.88e-05 0.019 0.47 0.32 Personality dimensions; chr12:18913572 chr12:19775451~20009937:+ PAAD cis rs916888 0.738 rs199515 ENSG00000261575.2 RP11-259G18.1 -4.18 4.88e-05 0.019 -0.47 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46267037~46268694:+ PAAD cis rs9926296 0.632 rs2011925 ENSG00000260259.1 RP11-368I7.4 -4.18 4.88e-05 0.019 -0.37 -0.32 Vitiligo; chr16:89747656 chr16:89682620~89686569:- PAAD cis rs9926296 0.681 rs12923946 ENSG00000260259.1 RP11-368I7.4 -4.18 4.88e-05 0.019 -0.37 -0.32 Vitiligo; chr16:89754672 chr16:89682620~89686569:- PAAD cis rs6687821 0.773 rs12097495 ENSG00000267734.1 RP4-604K5.3 4.18 4.89e-05 0.019 0.52 0.32 Yeast infection; chr1:86749925 chr1:86932199~86934891:- PAAD cis rs2034650 0.506 rs1984793 ENSG00000223313.1 RNU6-516P 4.18 4.89e-05 0.019 0.41 0.32 Interstitial lung disease; chr15:40407172 chr15:40529570~40529673:+ PAAD cis rs4835473 0.742 rs1838519 ENSG00000251600.4 RP11-673E1.1 4.18 4.89e-05 0.019 0.38 0.32 Immature fraction of reticulocytes; chr4:143972242 chr4:143912331~143982454:+ PAAD cis rs11118620 0.622 rs11118618 ENSG00000257551.1 HLX-AS1 4.18 4.89e-05 0.019 0.38 0.32 Heart failure; chr1:220838204 chr1:220832763~220880140:- PAAD cis rs28386778 0.897 rs2044125 ENSG00000240280.5 TCAM1P 4.18 4.89e-05 0.0191 0.45 0.32 Prudent dietary pattern; chr17:63785824 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2665831 ENSG00000240280.5 TCAM1P -4.18 4.89e-05 0.0191 -0.45 -0.32 Prudent dietary pattern; chr17:63835032 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2028567 ENSG00000240280.5 TCAM1P -4.18 4.89e-05 0.0191 -0.45 -0.32 Prudent dietary pattern; chr17:63837966 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs6504187 ENSG00000240280.5 TCAM1P -4.18 4.89e-05 0.0191 -0.45 -0.32 Prudent dietary pattern; chr17:63839739 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2859619 ENSG00000240280.5 TCAM1P -4.18 4.89e-05 0.0191 -0.45 -0.32 Prudent dietary pattern; chr17:63840326 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584610 ENSG00000240280.5 TCAM1P -4.18 4.89e-05 0.0191 -0.45 -0.32 Prudent dietary pattern; chr17:63857423 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs2584637 ENSG00000240280.5 TCAM1P -4.18 4.89e-05 0.0191 -0.45 -0.32 Prudent dietary pattern; chr17:63865592 chr17:63849292~63864379:+ PAAD cis rs28386778 0.724 rs35092235 ENSG00000240280.5 TCAM1P -4.18 4.89e-05 0.0191 -0.45 -0.32 Prudent dietary pattern; chr17:63867261 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2854213 ENSG00000240280.5 TCAM1P -4.18 4.89e-05 0.0191 -0.45 -0.32 Prudent dietary pattern; chr17:63868271 chr17:63849292~63864379:+ PAAD cis rs11997175 0.74 rs4733462 ENSG00000240738.1 RP1-273G13.1 4.18 4.9e-05 0.0191 0.37 0.32 Body mass index; chr8:33822386 chr8:33859480~33860223:- PAAD cis rs11997175 0.766 rs4733178 ENSG00000240738.1 RP1-273G13.1 4.18 4.9e-05 0.0191 0.36 0.32 Body mass index; chr8:33834381 chr8:33859480~33860223:- PAAD cis rs11997175 0.74 rs4467902 ENSG00000240738.1 RP1-273G13.1 4.18 4.9e-05 0.0191 0.36 0.32 Body mass index; chr8:33835897 chr8:33859480~33860223:- PAAD cis rs11997175 0.704 rs11775534 ENSG00000240738.1 RP1-273G13.1 4.18 4.9e-05 0.0191 0.36 0.32 Body mass index; chr8:33837714 chr8:33859480~33860223:- PAAD cis rs11997175 0.766 rs4273817 ENSG00000240738.1 RP1-273G13.1 4.18 4.9e-05 0.0191 0.36 0.32 Body mass index; chr8:33845168 chr8:33859480~33860223:- PAAD cis rs11997175 0.766 rs6995220 ENSG00000240738.1 RP1-273G13.1 4.18 4.9e-05 0.0191 0.36 0.32 Body mass index; chr8:33851401 chr8:33859480~33860223:- PAAD cis rs792448 0.692 rs351407 ENSG00000229983.1 RP11-15I11.2 4.18 4.9e-05 0.0191 0.38 0.32 White blood cell count (basophil); chr1:212264100 chr1:212168207~212190259:+ PAAD cis rs7225151 0.611 rs6502851 ENSG00000234327.6 AC012146.7 4.18 4.9e-05 0.0191 0.26 0.32 Alzheimer's disease (late onset); chr17:5247358 chr17:5111468~5115004:+ PAAD cis rs2581828 0.646 rs9861233 ENSG00000242142.1 SERBP1P3 -4.18 4.9e-05 0.0191 -0.4 -0.32 Crohn's disease; chr3:53124815 chr3:53064283~53065091:- PAAD cis rs2902193 0.627 rs7242353 ENSG00000267325.1 LINC01415 4.18 4.91e-05 0.0191 0.31 0.32 Cancer; chr18:55995537 chr18:55776727~55781721:- PAAD cis rs2581828 0.608 rs9868263 ENSG00000242142.1 SERBP1P3 -4.18 4.91e-05 0.0191 -0.4 -0.32 Crohn's disease; chr3:53130078 chr3:53064283~53065091:- PAAD cis rs2581828 0.618 rs9868406 ENSG00000242142.1 SERBP1P3 -4.18 4.91e-05 0.0191 -0.4 -0.32 Crohn's disease; chr3:53130177 chr3:53064283~53065091:- PAAD cis rs853679 0.55 rs1150692 ENSG00000280107.1 AL022393.9 -4.18 4.91e-05 0.0191 -0.54 -0.32 Depression; chr6:28206179 chr6:28170845~28172521:+ PAAD cis rs2243480 1 rs10807702 ENSG00000273142.1 RP11-458F8.4 -4.18 4.91e-05 0.0191 -0.3 -0.32 Diabetic kidney disease; chr7:66302856 chr7:66902857~66906297:+ PAAD cis rs853679 0.723 rs9366718 ENSG00000280107.1 AL022393.9 -4.18 4.91e-05 0.0191 -0.5 -0.32 Depression; chr6:28237724 chr6:28170845~28172521:+ PAAD cis rs5015933 0.788 rs372225 ENSG00000232630.1 PRPS1P2 -4.18 4.91e-05 0.0191 -0.29 -0.32 Body mass index; chr9:125261770 chr9:125150653~125151589:+ PAAD cis rs5015933 0.788 rs490978 ENSG00000232630.1 PRPS1P2 -4.18 4.91e-05 0.0191 -0.29 -0.32 Body mass index; chr9:125265972 chr9:125150653~125151589:+ PAAD cis rs9918079 0.542 rs7688984 ENSG00000273133.1 RP11-799M12.2 -4.18 4.92e-05 0.0191 -0.39 -0.32 Obesity-related traits; chr4:15655630 chr4:15563698~15564253:- PAAD cis rs875971 0.545 rs12670811 ENSG00000222364.1 RNU6-96P -4.18 4.92e-05 0.0191 -0.42 -0.32 Aortic root size; chr7:66358032 chr7:66395191~66395286:+ PAAD cis rs11997175 0.545 rs4733457 ENSG00000240738.1 RP1-273G13.1 4.18 4.92e-05 0.0191 0.38 0.32 Body mass index; chr8:33803718 chr8:33859480~33860223:- PAAD cis rs11997175 0.545 rs4733458 ENSG00000240738.1 RP1-273G13.1 4.18 4.92e-05 0.0191 0.38 0.32 Body mass index; chr8:33804024 chr8:33859480~33860223:- PAAD cis rs1665050 0.546 rs7175490 ENSG00000277144.1 RP11-59H7.4 -4.18 4.92e-05 0.0191 -0.4 -0.32 Atopic dermatitis; chr15:59041735 chr15:59115547~59116089:- PAAD cis rs10779751 1 rs12120734 ENSG00000238199.1 UBE2V2P3 -4.18 4.92e-05 0.0191 -0.39 -0.32 Body mass index; chr1:11201963 chr1:11278616~11279351:- PAAD cis rs1871045 0.517 rs3112438 ENSG00000267191.1 RP11-15A1.2 -4.18 4.92e-05 0.0191 -0.5 -0.32 Waist-to-hip circumference ratio (smoking years interaction); chr19:44856313 chr19:43902001~43926545:+ PAAD cis rs2243480 0.803 rs55700941 ENSG00000232546.1 RP11-458F8.1 -4.18 4.92e-05 0.0191 -0.39 -0.32 Diabetic kidney disease; chr7:65924813 chr7:66848496~66858136:+ PAAD cis rs4722166 0.532 rs4719713 ENSG00000179428.2 AC073072.5 -4.18 4.92e-05 0.0191 -0.29 -0.32 Lung cancer; chr7:22719192 chr7:22725395~22727620:- PAAD cis rs871012 0.502 rs56259240 ENSG00000248544.2 CTB-47B11.3 -4.18 4.92e-05 0.0191 -0.42 -0.32 IgG glycosylation; chr5:157464523 chr5:157375741~157384950:- PAAD cis rs4853525 0.923 rs2204859 ENSG00000235852.1 AC005540.3 4.18 4.92e-05 0.0191 0.45 0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190872147 chr2:190880797~190882059:- PAAD cis rs6061231 0.755 rs11699160 ENSG00000273619.1 RP5-908M14.9 -4.18 4.92e-05 0.0191 -0.26 -0.32 Colorectal cancer; chr20:62383595 chr20:62386303~62386970:- PAAD cis rs9595908 1 rs9591143 ENSG00000212293.1 SNORA16 4.18 4.93e-05 0.0191 0.36 0.32 Body mass index; chr13:32585301 chr13:32420390~32420516:- PAAD cis rs9595908 1 rs9591145 ENSG00000212293.1 SNORA16 4.18 4.93e-05 0.0191 0.36 0.32 Body mass index; chr13:32587322 chr13:32420390~32420516:- PAAD cis rs9595908 1 rs3742320 ENSG00000212293.1 SNORA16 4.18 4.93e-05 0.0191 0.36 0.32 Body mass index; chr13:32590281 chr13:32420390~32420516:- PAAD cis rs9595908 0.965 rs9595893 ENSG00000212293.1 SNORA16 4.18 4.93e-05 0.0191 0.36 0.32 Body mass index; chr13:32601656 chr13:32420390~32420516:- PAAD cis rs9595908 1 rs7992980 ENSG00000212293.1 SNORA16 4.18 4.93e-05 0.0191 0.36 0.32 Body mass index; chr13:32607005 chr13:32420390~32420516:- PAAD cis rs9326248 0.539 rs660443 ENSG00000280143.1 AP000892.6 4.18 4.93e-05 0.0191 0.37 0.32 Blood protein levels; chr11:116889977 chr11:117204967~117210292:+ PAAD cis rs2281636 1 rs2804417 ENSG00000233690.1 EBAG9P1 -4.18 4.93e-05 0.0192 -0.34 -0.32 Obesity-related traits; chr10:99756458 chr10:99697407~99697949:- PAAD cis rs10129255 0.518 rs28378320 ENSG00000211972.2 IGHV3-66 4.18 4.93e-05 0.0192 0.25 0.32 Kawasaki disease; chr14:106808609 chr14:106675017~106675544:- PAAD cis rs4835473 0.798 rs34353812 ENSG00000251600.4 RP11-673E1.1 4.18 4.93e-05 0.0192 0.38 0.32 Immature fraction of reticulocytes; chr4:143973949 chr4:143912331~143982454:+ PAAD cis rs7688540 0.511 rs11735723 ENSG00000275426.1 CH17-262A2.1 4.18 4.94e-05 0.0192 0.54 0.32 Facial morphology (factor 6, height of vermillion lower lip); chr4:205848 chr4:149738~150317:+ PAAD cis rs494459 0.688 rs1048040 ENSG00000278376.1 RP11-158I9.8 -4.18 4.94e-05 0.0192 -0.28 -0.32 Height; chr11:118747911 chr11:118791254~118793137:+ PAAD cis rs3829251 0.786 rs7103591 ENSG00000254682.1 RP11-660L16.2 -4.18 4.94e-05 0.0192 -0.53 -0.32 Vitamin D levels; chr11:71526573 chr11:71448674~71452157:+ PAAD cis rs4423214 0.559 rs11234042 ENSG00000254682.1 RP11-660L16.2 -4.18 4.94e-05 0.0192 -0.53 -0.32 Vitamin D levels; chr11:71528040 chr11:71448674~71452157:+ PAAD cis rs792448 0.701 rs1774247 ENSG00000229983.1 RP11-15I11.2 4.18 4.94e-05 0.0192 0.39 0.32 White blood cell count (basophil); chr1:212376015 chr1:212168207~212190259:+ PAAD cis rs763121 0.776 rs5757177 ENSG00000228274.3 RP3-508I15.9 -4.18 4.95e-05 0.0192 -0.31 -0.32 Menopause (age at onset); chr22:38611169 chr22:38667585~38681820:- PAAD cis rs2739330 0.753 rs4822452 ENSG00000206090.4 AP000350.7 4.18 4.95e-05 0.0192 0.41 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23939998~23942798:+ PAAD cis rs5758659 0.594 rs739292 ENSG00000273366.1 CTA-989H11.1 -4.18 4.95e-05 0.0192 -0.39 -0.32 Cognitive function; chr22:41972853 chr22:42278188~42278846:+ PAAD cis rs3785888 0.548 rs197922 ENSG00000262539.1 RP11-259G18.3 4.18 4.95e-05 0.0192 0.45 0.32 Cleft lip with or without cleft palate; chr17:46931204 chr17:46259551~46260606:- PAAD cis rs172166 0.538 rs1150686 ENSG00000219891.2 ZSCAN12P1 4.18 4.95e-05 0.0192 0.42 0.32 Cardiac Troponin-T levels; chr6:28193493 chr6:28091154~28093664:+ PAAD cis rs1150688 1 rs1150688 ENSG00000219891.2 ZSCAN12P1 4.18 4.95e-05 0.0192 0.42 0.32 Autism spectrum disorder or schizophrenia; chr6:28195002 chr6:28091154~28093664:+ PAAD cis rs172166 0.516 rs2622322 ENSG00000219891.2 ZSCAN12P1 4.18 4.95e-05 0.0192 0.42 0.32 Cardiac Troponin-T levels; chr6:28149665 chr6:28091154~28093664:+ PAAD cis rs172166 0.516 rs1225618 ENSG00000219891.2 ZSCAN12P1 4.18 4.95e-05 0.0192 0.42 0.32 Cardiac Troponin-T levels; chr6:28161935 chr6:28091154~28093664:+ PAAD cis rs172166 0.516 rs1150670 ENSG00000219891.2 ZSCAN12P1 4.18 4.95e-05 0.0192 0.42 0.32 Cardiac Troponin-T levels; chr6:28162781 chr6:28091154~28093664:+ PAAD cis rs172166 0.516 rs2021826 ENSG00000219891.2 ZSCAN12P1 4.18 4.95e-05 0.0192 0.42 0.32 Cardiac Troponin-T levels; chr6:28164978 chr6:28091154~28093664:+ PAAD cis rs1150668 0.835 rs1233696 ENSG00000219891.2 ZSCAN12P1 4.18 4.95e-05 0.0192 0.42 0.32 Pubertal anthropometrics; chr6:28175232 chr6:28091154~28093664:+ PAAD cis rs875971 0.628 rs6974355 ENSG00000237310.1 GS1-124K5.4 4.18 4.95e-05 0.0192 0.3 0.32 Aortic root size; chr7:66376994 chr7:66493706~66495474:+ PAAD cis rs875971 0.706 rs1643374 ENSG00000237310.1 GS1-124K5.4 4.18 4.95e-05 0.0192 0.3 0.32 Aortic root size; chr7:66407695 chr7:66493706~66495474:+ PAAD cis rs7592578 0.766 rs35818159 ENSG00000231858.4 AC067945.4 -4.18 4.95e-05 0.0192 -0.39 -0.32 Diastolic blood pressure; chr2:190544890 chr2:191021526~191032314:+ PAAD cis rs2412819 0.597 rs2412821 ENSG00000249839.1 AC011330.5 -4.18 4.96e-05 0.0193 -0.5 -0.32 Lung cancer; chr15:43864966 chr15:43663654~43684339:- PAAD cis rs10951983 0.821 rs4724801 ENSG00000272719.1 CTB-161C1.1 -4.18 4.96e-05 0.0193 -0.39 -0.32 Coronary artery disease; chr7:6372482 chr7:5556731~5557245:+ PAAD cis rs10951983 0.821 rs33999234 ENSG00000272719.1 CTB-161C1.1 -4.18 4.96e-05 0.0193 -0.39 -0.32 Coronary artery disease; chr7:6372756 chr7:5556731~5557245:+ PAAD cis rs6479891 1 rs868798 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63135250 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12416113 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63136717 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs61853336 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63140115 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs4746994 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63145564 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12415984 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63150528 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs11814792 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63157799 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12413415 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63159751 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs4747045 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63166722 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs4466712 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63173508 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs72829170 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63180529 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs61855465 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63196847 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12413730 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63204388 chr10:63634317~63634827:- PAAD cis rs6479891 0.908 rs11819167 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63216409 chr10:63634317~63634827:- PAAD cis rs6479901 0.512 rs7082090 ENSG00000232075.1 MRPL35P2 4.18 4.96e-05 0.0193 0.51 0.32 Intelligence (multi-trait analysis); chr10:63239252 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs11817689 ENSG00000232075.1 MRPL35P2 -4.18 4.96e-05 0.0193 -0.51 -0.32 Arthritis (juvenile idiopathic); chr10:63164457 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs1904295 ENSG00000232075.1 MRPL35P2 -4.18 4.96e-05 0.0193 -0.51 -0.32 Arthritis (juvenile idiopathic); chr10:63223116 chr10:63634317~63634827:- PAAD cis rs6479901 0.512 rs6415875 ENSG00000232075.1 MRPL35P2 -4.18 4.96e-05 0.0193 -0.51 -0.32 Intelligence (multi-trait analysis); chr10:63226657 chr10:63634317~63634827:- PAAD cis rs6479891 0.915 rs4281380 ENSG00000232075.1 MRPL35P2 -4.18 4.96e-05 0.0193 -0.51 -0.32 Arthritis (juvenile idiopathic); chr10:63227938 chr10:63634317~63634827:- PAAD cis rs6479901 0.512 rs4439410 ENSG00000232075.1 MRPL35P2 -4.18 4.96e-05 0.0193 -0.51 -0.32 Intelligence (multi-trait analysis); chr10:63239012 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9414788 ENSG00000232075.1 MRPL35P2 -4.18 4.96e-05 0.0193 -0.51 -0.32 Arthritis (juvenile idiopathic); chr10:63296952 chr10:63634317~63634827:- PAAD cis rs7626444 0.625 rs2686590 ENSG00000272359.1 U4 -4.18 4.97e-05 0.0193 -0.37 -0.32 Monocyte count; chr3:196765568 chr3:196747192~196747324:- PAAD cis rs7260598 0.685 rs73021422 ENSG00000268442.1 CTD-2027I19.2 4.18 4.97e-05 0.0193 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24082919 chr19:24162370~24163425:- PAAD cis rs7260598 0.685 rs11671000 ENSG00000268442.1 CTD-2027I19.2 4.18 4.97e-05 0.0193 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24110025 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs73021454 ENSG00000268442.1 CTD-2027I19.2 4.18 4.97e-05 0.0193 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24133074 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs11672981 ENSG00000268442.1 CTD-2027I19.2 4.18 4.97e-05 0.0193 0.53 0.32 Response to taxane treatment (placlitaxel); chr19:24144735 chr19:24162370~24163425:- PAAD cis rs10783487 0.803 rs2272484 ENSG00000257542.4 OR7E47P -4.18 4.97e-05 0.0193 -0.43 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52087533 chr12:52079696~52108261:+ PAAD cis rs7119038 0.607 rs12365699 ENSG00000255239.1 AP002954.6 -4.18 4.97e-05 0.0193 -0.51 -0.32 Sjögren's syndrome; chr11:118872577 chr11:118688039~118690600:- PAAD cis rs6504950 0.85 rs2628321 ENSG00000275710.1 RP11-257O5.4 4.18 4.97e-05 0.0193 0.38 0.32 Breast cancer; chr17:55128556 chr17:54964474~54964679:+ PAAD cis rs453301 0.686 rs28482034 ENSG00000253893.2 FAM85B 4.18 4.97e-05 0.0193 0.44 0.32 Joint mobility (Beighton score); chr8:9012154 chr8:8167819~8226614:- PAAD cis rs72843506 0.722 rs74658636 ENSG00000154898.14 CCDC144CP 4.18 4.98e-05 0.0193 0.59 0.32 Schizophrenia; chr17:20294669 chr17:20321164~20403557:+ PAAD cis rs6504950 0.924 rs244342 ENSG00000275710.1 RP11-257O5.4 4.18 4.98e-05 0.0193 0.38 0.32 Breast cancer; chr17:55121046 chr17:54964474~54964679:+ PAAD cis rs6504950 0.924 rs244338 ENSG00000275710.1 RP11-257O5.4 4.18 4.98e-05 0.0193 0.38 0.32 Breast cancer; chr17:55123057 chr17:54964474~54964679:+ PAAD cis rs453301 0.598 rs1025395 ENSG00000254340.1 RP11-10A14.3 4.18 4.98e-05 0.0193 0.37 0.32 Joint mobility (Beighton score); chr8:8979093 chr8:9141424~9145435:+ PAAD cis rs9473147 0.747 rs9395288 ENSG00000270761.1 RP11-385F7.1 -4.18 4.99e-05 0.0193 -0.34 -0.32 Platelet distribution width;Mean platelet volume; chr6:47630389 chr6:47477243~47477572:- PAAD cis rs3743162 0.644 rs4842996 ENSG00000275120.1 RP11-182J1.17 -4.18 4.99e-05 0.0193 -0.38 -0.32 Alzheimer's disease (age of onset); chr15:84876267 chr15:84599434~84606463:- PAAD cis rs950880 0.71 rs11678975 ENSG00000234389.1 AC007278.3 -4.18 4.99e-05 0.0193 -0.32 -0.32 Serum protein levels (sST2); chr2:102427279 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs66566526 ENSG00000234389.1 AC007278.3 -4.18 4.99e-05 0.0193 -0.32 -0.32 Serum protein levels (sST2); chr2:102431342 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs56331791 ENSG00000234389.1 AC007278.3 -4.18 4.99e-05 0.0193 -0.32 -0.32 Serum protein levels (sST2); chr2:102431697 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs11681718 ENSG00000234389.1 AC007278.3 -4.18 4.99e-05 0.0193 -0.32 -0.32 Serum protein levels (sST2); chr2:102434684 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs4851582 ENSG00000234389.1 AC007278.3 -4.18 4.99e-05 0.0193 -0.32 -0.32 Serum protein levels (sST2); chr2:102435098 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs10490204 ENSG00000234389.1 AC007278.3 -4.18 4.99e-05 0.0193 -0.32 -0.32 Serum protein levels (sST2); chr2:102440074 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs3771150 ENSG00000234389.1 AC007278.3 -4.18 4.99e-05 0.0193 -0.32 -0.32 Serum protein levels (sST2); chr2:102444391 chr2:102438713~102440475:+ PAAD cis rs11893307 0.566 rs7558832 ENSG00000235852.1 AC005540.3 4.18 4.99e-05 0.0193 0.47 0.32 Mean platelet volume; chr2:190695863 chr2:190880797~190882059:- PAAD cis rs9652601 0.779 rs725613 ENSG00000274038.1 RP11-66H6.4 -4.18 4.99e-05 0.0194 -0.35 -0.32 Systemic lupus erythematosus; chr16:11075826 chr16:11056556~11057034:+ PAAD cis rs2554380 0.55 rs56258128 ENSG00000230373.7 GOLGA6L5P 4.18 4.99e-05 0.0194 0.31 0.32 Height; chr15:83874234 chr15:84507885~84516814:- PAAD cis rs4604732 0.536 rs4433437 ENSG00000227135.1 GCSAML-AS1 -4.18 4.99e-05 0.0194 -0.47 -0.32 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247473278 chr1:247524679~247526752:- PAAD cis rs9487094 0.626 rs12204548 ENSG00000260273.1 RP11-425D10.10 4.18 5e-05 0.0194 0.39 0.32 Height; chr6:109715504 chr6:109382795~109383666:+ PAAD cis rs6479891 1 rs9414780 ENSG00000232075.1 MRPL35P2 4.18 5e-05 0.0194 0.52 0.32 Arthritis (juvenile idiopathic); chr10:63241673 chr10:63634317~63634827:- PAAD cis rs792448 0.926 rs701905 ENSG00000229983.1 RP11-15I11.2 4.18 5e-05 0.0194 0.39 0.32 White blood cell count (basophil); chr1:212379769 chr1:212168207~212190259:+ PAAD cis rs6504340 0.689 rs4793951 ENSG00000263766.4 RP11-580I16.2 4.18 5e-05 0.0194 0.53 0.32 Primary tooth development (number of teeth); chr17:48601452 chr17:47603860~47649420:- PAAD cis rs9487094 0.553 rs11968891 ENSG00000260273.1 RP11-425D10.10 4.18 5e-05 0.0194 0.45 0.32 Height; chr6:109548647 chr6:109382795~109383666:+ PAAD cis rs2581828 0.618 rs6792345 ENSG00000242142.1 SERBP1P3 -4.18 5e-05 0.0194 -0.4 -0.32 Crohn's disease; chr3:53131178 chr3:53064283~53065091:- PAAD cis rs2581828 0.618 rs6792363 ENSG00000242142.1 SERBP1P3 -4.18 5e-05 0.0194 -0.4 -0.32 Crohn's disease; chr3:53131247 chr3:53064283~53065091:- PAAD cis rs2581828 0.618 rs6445565 ENSG00000242142.1 SERBP1P3 -4.18 5e-05 0.0194 -0.4 -0.32 Crohn's disease; chr3:53131448 chr3:53064283~53065091:- PAAD cis rs2581828 0.591 rs6445566 ENSG00000242142.1 SERBP1P3 -4.18 5e-05 0.0194 -0.4 -0.32 Crohn's disease; chr3:53131611 chr3:53064283~53065091:- PAAD cis rs2581828 0.618 rs13319872 ENSG00000242142.1 SERBP1P3 -4.18 5e-05 0.0194 -0.4 -0.32 Crohn's disease; chr3:53132082 chr3:53064283~53065091:- PAAD cis rs2581828 0.618 rs6784207 ENSG00000242142.1 SERBP1P3 -4.18 5e-05 0.0194 -0.4 -0.32 Crohn's disease; chr3:53133458 chr3:53064283~53065091:- PAAD cis rs71403859 0.73 rs12931191 ENSG00000260886.1 TAT-AS1 -4.18 5e-05 0.0194 -0.51 -0.32 Post bronchodilator FEV1; chr16:71587470 chr16:71565789~71578187:+ PAAD cis rs71403859 0.803 rs8063455 ENSG00000260886.1 TAT-AS1 4.18 5e-05 0.0194 0.51 0.32 Post bronchodilator FEV1; chr16:71566074 chr16:71565789~71578187:+ PAAD cis rs41369048 0.925 rs11588625 ENSG00000238078.1 LINC01352 -4.17 5e-05 0.0194 -0.46 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220885504 chr1:220829255~220832429:+ PAAD cis rs9876781 0.539 rs9809695 ENSG00000229759.1 MRPS18AP1 -4.17 5.01e-05 0.0194 -0.34 -0.32 Longevity; chr3:48364654 chr3:48256350~48256938:- PAAD cis rs17684571 0.751 rs7761729 ENSG00000231441.1 RP11-472M19.2 4.17 5.01e-05 0.0194 0.57 0.32 Schizophrenia; chr6:56846478 chr6:56844002~56864078:+ PAAD cis rs6435957 0.568 rs10211289 ENSG00000233143.1 DIRC3-AS1 4.17 5.01e-05 0.0194 0.41 0.32 Primary tooth development (number of teeth); chr2:217027648 chr2:217282739~217336120:+ PAAD cis rs79040073 0.637 rs77813839 ENSG00000259469.1 RP11-227D13.4 -4.17 5.01e-05 0.0194 -0.51 -0.32 Lung cancer in ever smokers; chr15:49172799 chr15:48729080~48729844:- PAAD cis rs8177376 0.861 rs604255 ENSG00000254905.1 RP11-712L6.7 4.17 5.01e-05 0.0194 0.45 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327131 chr11:126292922~126294254:- PAAD cis rs919433 0.889 rs788004 ENSG00000231621.1 AC013264.2 -4.17 5.01e-05 0.0194 -0.31 -0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197354308 chr2:197197991~197199273:+ PAAD cis rs5758511 0.68 rs739147 ENSG00000226450.2 CYP2D8P 4.17 5.01e-05 0.0194 0.32 0.32 Birth weight; chr22:42275060 chr22:42149886~42155001:- PAAD cis rs210138 0.591 rs1408711 ENSG00000197251.3 LINC00336 -4.17 5.01e-05 0.0194 -0.51 -0.32 Testicular germ cell tumor; chr6:33652231 chr6:33586106~33593338:- PAAD cis rs2034650 0.563 rs12914315 ENSG00000223313.1 RNU6-516P -4.17 5.01e-05 0.0194 -0.41 -0.32 Interstitial lung disease; chr15:40421679 chr15:40529570~40529673:+ PAAD cis rs853679 0.513 rs13437444 ENSG00000226314.6 ZNF192P1 -4.17 5.02e-05 0.0194 -0.57 -0.32 Depression; chr6:28103220 chr6:28161781~28169594:+ PAAD cis rs11159086 1 rs17100451 ENSG00000259005.1 RP3-449M8.6 4.17 5.02e-05 0.0194 0.43 0.32 Advanced glycation end-product levels; chr14:74476210 chr14:74474007~74474864:- PAAD cis rs728616 0.558 rs61859793 ENSG00000225484.5 NUTM2B-AS1 -4.17 5.02e-05 0.0194 -0.6 -0.32 Chronic obstructive pulmonary disease-related biomarkers; chr10:79927007 chr10:79663088~79826594:- PAAD cis rs867529 0.62 rs335121 ENSG00000230006.6 ANKRD36BP2 4.17 5.02e-05 0.0194 0.27 0.32 Height; chr2:88784810 chr2:88765807~88806612:+ PAAD cis rs780096 0.565 rs10169261 ENSG00000234072.1 AC074117.10 -4.17 5.02e-05 0.0195 -0.25 -0.32 Total body bone mineral density; chr2:27504447 chr2:27356246~27367622:+ PAAD cis rs9419788 0.74 rs11187825 ENSG00000233377.1 MTND4P20 4.17 5.02e-05 0.0195 0.29 0.32 Personality traits in bipolar disorder; chr10:94227556 chr10:94940253~94941121:- PAAD cis rs17711722 1 rs17711722 ENSG00000236529.1 RP13-254B10.1 -4.17 5.03e-05 0.0195 -0.35 -0.32 Calcium levels; chr7:65806210 chr7:65840212~65840596:+ PAAD cis rs17711722 0.675 rs6947132 ENSG00000236529.1 RP13-254B10.1 -4.17 5.03e-05 0.0195 -0.35 -0.32 Calcium levels; chr7:65808508 chr7:65840212~65840596:+ PAAD cis rs848490 0.532 rs6965245 ENSG00000213542.3 RP11-467H10.1 4.17 5.03e-05 0.0195 0.34 0.32 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77700426 chr7:77115399~77116192:- PAAD cis rs897984 0.762 rs4889599 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30957268 chr16:31043150~31049868:+ PAAD cis rs897984 0.721 rs2305884 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30959420 chr16:31043150~31049868:+ PAAD cis rs897984 0.762 rs11150601 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30966478 chr16:31043150~31049868:+ PAAD cis rs897984 0.762 rs897986 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30969581 chr16:31043150~31049868:+ PAAD cis rs897984 0.721 rs28360557 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30971939 chr16:31043150~31049868:+ PAAD cis rs897984 0.762 rs7204459 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30972891 chr16:31043150~31049868:+ PAAD cis rs897984 0.762 rs4889604 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30974673 chr16:31043150~31049868:+ PAAD cis rs897984 0.762 rs12931046 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30975823 chr16:31043150~31049868:+ PAAD cis rs897984 0.721 rs4889525 ENSG00000260911.2 RP11-196G11.2 -4.17 5.03e-05 0.0195 -0.28 -0.32 Dementia with Lewy bodies; chr16:30978537 chr16:31043150~31049868:+ PAAD cis rs916888 0.773 rs199533 ENSG00000261575.2 RP11-259G18.1 4.17 5.03e-05 0.0195 0.48 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46267037~46268694:+ PAAD cis rs2980439 0.517 rs712253 ENSG00000253981.4 ALG1L13P -4.17 5.03e-05 0.0195 -0.39 -0.32 Neuroticism; chr8:8246260 chr8:8236003~8244667:- PAAD cis rs11023332 1 rs11023332 ENSG00000251991.1 RNU7-49P 4.17 5.03e-05 0.0195 0.38 0.32 Vitamin D levels;Adiponectin levels; chr11:14762564 chr11:14478892~14478953:+ PAAD cis rs10096908 0.892 rs9886512 ENSG00000254165.1 RP11-503E24.2 -4.17 5.03e-05 0.0195 -0.53 -0.32 Blood pressure traits (multi-trait analysis);Hypertension;Systolic blood pressure; chr8:41784646 chr8:42537529~42538304:- PAAD cis rs919433 0.68 rs6434930 ENSG00000231621.1 AC013264.2 -4.17 5.03e-05 0.0195 -0.31 -0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197504646 chr2:197197991~197199273:+ PAAD cis rs2717559 0.542 rs11777634 ENSG00000253741.1 CTD-2292P10.4 4.17 5.04e-05 0.0195 0.43 0.32 Urinary tract infection frequency; chr8:142806541 chr8:142702252~142726973:- PAAD cis rs7839040 0.535 rs7830287 ENSG00000253334.1 RP13-923O23.6 4.17 5.04e-05 0.0195 0.38 0.32 Response to methotrexate in juvenile idiopathic arthritis; chr8:82004774 chr8:81791823~81815714:+ PAAD cis rs792448 0.501 rs2307128 ENSG00000229983.1 RP11-15I11.2 4.17 5.04e-05 0.0195 0.37 0.32 White blood cell count (basophil); chr1:212226474 chr1:212168207~212190259:+ PAAD cis rs216345 0.67 rs307664 ENSG00000230074.1 RP11-195F19.9 -4.17 5.04e-05 0.0195 -0.43 -0.32 Bipolar disorder; chr9:33961354 chr9:34665665~34681298:+ PAAD cis rs6570726 0.967 rs439017 ENSG00000235652.6 RP11-545I5.3 4.17 5.04e-05 0.0195 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145484987 chr6:145799409~145886585:+ PAAD cis rs3738443 0.868 rs6660351 ENSG00000259865.1 RP11-488L18.10 4.17 5.05e-05 0.0195 0.3 0.32 Alcohol dependence; chr1:247184526 chr1:247187281~247188526:- PAAD cis rs10916814 1 rs10916814 ENSG00000226396.1 RP5-1056L3.3 4.17 5.05e-05 0.0195 0.26 0.32 Age-related hearing impairment (SNP x SNP interaction); chr1:20566438 chr1:19608114~19608568:+ PAAD cis rs748404 0.516 rs523156 ENSG00000205771.5 CATSPER2P1 4.17 5.05e-05 0.0195 0.46 0.32 Lung cancer; chr15:43519645 chr15:43726918~43747094:- PAAD cis rs847577 0.609 rs11763970 ENSG00000272950.1 RP11-307C18.1 4.17 5.05e-05 0.0195 0.41 0.32 Breast cancer; chr7:98188009 chr7:98322853~98323430:+ PAAD cis rs858239 0.738 rs7807879 ENSG00000226816.2 AC005082.12 4.17 5.05e-05 0.0195 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23220969 chr7:23206013~23208045:+ PAAD cis rs7665090 0.87 rs228615 ENSG00000246560.2 RP11-10L12.4 -4.17 5.05e-05 0.0196 -0.35 -0.32 Primary biliary cholangitis; chr4:102658303 chr4:102828055~102844075:+ PAAD cis rs10888838 0.941 rs10888841 ENSG00000198711.5 SSBP3-AS1 4.17 5.06e-05 0.0196 0.38 0.32 Mitochondrial DNA levels; chr1:54221392 chr1:54236440~54239063:+ PAAD cis rs10888838 0.941 rs11585887 ENSG00000198711.5 SSBP3-AS1 4.17 5.06e-05 0.0196 0.38 0.32 Mitochondrial DNA levels; chr1:54221850 chr1:54236440~54239063:+ PAAD cis rs2179367 0.959 rs4895788 ENSG00000231760.4 RP11-350J20.5 4.17 5.06e-05 0.0196 0.41 0.32 Dupuytren's disease; chr6:149426955 chr6:149796151~149826294:- PAAD cis rs2688608 0.592 rs7908825 ENSG00000271816.1 BMS1P4 -4.17 5.06e-05 0.0196 -0.33 -0.32 Inflammatory bowel disease; chr10:73794783 chr10:73699151~73730487:- PAAD cis rs1881744 0.588 rs78808618 ENSG00000257433.4 RP1-197B17.3 4.17 5.06e-05 0.0196 0.73 0.32 Metabolite levels (HVA/5-HIAA ratio); chr12:47567624 chr12:47706085~47742294:+ PAAD cis rs6908034 0.556 rs113071446 ENSG00000228412.5 RP4-625H18.2 4.17 5.06e-05 0.0196 0.64 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19810604 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs77386860 ENSG00000228412.5 RP4-625H18.2 4.17 5.06e-05 0.0196 0.64 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19814524 chr6:19802164~19804752:- PAAD cis rs4268898 0.931 rs2111882 ENSG00000242628.4 AC009228.1 -4.17 5.06e-05 0.0196 -0.39 -0.32 Asthma; chr2:24211555 chr2:24214381~24221516:+ PAAD cis rs1707322 0.662 rs11211160 ENSG00000280836.1 AL355480.1 -4.17 5.06e-05 0.0196 -0.37 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680557 chr1:45581219~45581321:- PAAD cis rs763121 0.853 rs6001173 ENSG00000228274.3 RP3-508I15.9 -4.17 5.06e-05 0.0196 -0.3 -0.32 Menopause (age at onset); chr22:38619297 chr22:38667585~38681820:- PAAD cis rs5742933 0.597 rs6756913 ENSG00000253559.1 OSGEPL1-AS1 4.17 5.07e-05 0.0196 0.34 0.32 Ferritin levels; chr2:189641040 chr2:189762704~189765556:+ PAAD cis rs8072100 1 rs8065437 ENSG00000228782.6 CTD-2026D20.3 4.17 5.07e-05 0.0196 0.32 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47644287 chr17:47450568~47492492:- PAAD cis rs8072100 0.967 rs2317826 ENSG00000228782.6 CTD-2026D20.3 4.17 5.07e-05 0.0196 0.32 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47653533 chr17:47450568~47492492:- PAAD cis rs7182621 0.639 rs12906068 ENSG00000259363.4 CTD-2054N24.2 -4.17 5.07e-05 0.0196 -0.43 -0.32 Colonoscopy-negative controls vs population controls; chr15:99873422 chr15:99807023~99877148:+ PAAD cis rs710913 0.717 rs1180349 ENSG00000243970.1 PPIEL -4.17 5.07e-05 0.0196 -0.28 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39540380 chr1:39531838~39558707:- PAAD cis rs710913 0.691 rs1180351 ENSG00000243970.1 PPIEL -4.17 5.07e-05 0.0196 -0.28 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39541605 chr1:39531838~39558707:- PAAD cis rs710913 0.717 rs1180352 ENSG00000243970.1 PPIEL -4.17 5.07e-05 0.0196 -0.28 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39542157 chr1:39531838~39558707:- PAAD cis rs710913 0.745 rs1180334 ENSG00000243970.1 PPIEL -4.17 5.07e-05 0.0196 -0.28 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39555972 chr1:39531838~39558707:- PAAD cis rs287982 0.932 rs58521916 ENSG00000269973.1 RP11-95D17.1 -4.17 5.07e-05 0.0196 -0.38 -0.32 Nonsyndromic cleft lip with cleft palate; chr2:9826341 chr2:9936360~9939590:+ PAAD cis rs9876781 1 rs7653691 ENSG00000229759.1 MRPS18AP1 -4.17 5.07e-05 0.0196 -0.35 -0.32 Longevity; chr3:48378199 chr3:48256350~48256938:- PAAD cis rs1275468 0.731 rs1630753 ENSG00000257497.2 RP11-585P4.5 -4.17 5.08e-05 0.0196 -0.5 -0.32 Polycystic ovary syndrome; chr12:75569518 chr12:75483454~75489820:- PAAD cis rs1910358 0.621 rs6871540 ENSG00000248874.4 C5orf17 -4.17 5.08e-05 0.0196 -0.46 -0.32 Venous thromboembolism (SNP x SNP interaction); chr5:23860955 chr5:23951348~24178263:+ PAAD cis rs3785888 0.548 rs197923 ENSG00000262539.1 RP11-259G18.3 4.17 5.08e-05 0.0196 0.46 0.32 Cleft lip with or without cleft palate; chr17:46931376 chr17:46259551~46260606:- PAAD cis rs2790457 0.833 rs1265843 ENSG00000254635.4 WAC-AS1 -4.17 5.08e-05 0.0196 -0.31 -0.32 Multiple myeloma; chr10:28636088 chr10:28522652~28532743:- PAAD cis rs2408955 0.522 rs11168408 ENSG00000240399.1 RP1-228P16.1 -4.17 5.09e-05 0.0197 -0.34 -0.32 Glycated hemoglobin levels; chr12:48104544 chr12:48054813~48055591:- PAAD cis rs7617773 0.817 rs3731513 ENSG00000228638.1 FCF1P2 -4.17 5.09e-05 0.0197 -0.36 -0.32 Coronary artery disease; chr3:48178047 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs3731497 ENSG00000228638.1 FCF1P2 -4.17 5.09e-05 0.0197 -0.36 -0.32 Coronary artery disease; chr3:48185063 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs3731489 ENSG00000228638.1 FCF1P2 -4.17 5.09e-05 0.0197 -0.36 -0.32 Coronary artery disease; chr3:48187416 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs3729577 ENSG00000228638.1 FCF1P2 -4.17 5.09e-05 0.0197 -0.36 -0.32 Coronary artery disease; chr3:48187504 chr3:48290793~48291375:- PAAD cis rs7617773 0.779 rs3731487 ENSG00000228638.1 FCF1P2 -4.17 5.09e-05 0.0197 -0.36 -0.32 Coronary artery disease; chr3:48188134 chr3:48290793~48291375:- PAAD cis rs11089937 0.512 rs34963809 ENSG00000211638.2 IGLV8-61 -4.17 5.09e-05 0.0197 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22130737 chr22:22098700~22099212:+ PAAD cis rs11089937 0.568 rs35626600 ENSG00000211638.2 IGLV8-61 -4.17 5.09e-05 0.0197 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22130811 chr22:22098700~22099212:+ PAAD cis rs11089937 0.539 rs34228957 ENSG00000211638.2 IGLV8-61 -4.17 5.09e-05 0.0197 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22130838 chr22:22098700~22099212:+ PAAD cis rs11089937 0.512 rs13054756 ENSG00000211638.2 IGLV8-61 -4.17 5.09e-05 0.0197 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22130948 chr22:22098700~22099212:+ PAAD cis rs11089937 0.597 rs4821768 ENSG00000211638.2 IGLV8-61 -4.17 5.09e-05 0.0197 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22131047 chr22:22098700~22099212:+ PAAD cis rs11089937 0.597 rs4821770 ENSG00000211638.2 IGLV8-61 -4.17 5.09e-05 0.0197 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22131281 chr22:22098700~22099212:+ PAAD cis rs11089937 0.568 rs4821771 ENSG00000211638.2 IGLV8-61 -4.17 5.09e-05 0.0197 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22131287 chr22:22098700~22099212:+ PAAD cis rs11089937 0.597 rs4821773 ENSG00000211638.2 IGLV8-61 -4.17 5.09e-05 0.0197 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22131434 chr22:22098700~22099212:+ PAAD cis rs10761482 0.566 rs4505011 ENSG00000254271.1 RP11-131N11.4 4.17 5.09e-05 0.0197 0.41 0.32 Schizophrenia; chr10:60440550 chr10:60734342~60741828:+ PAAD cis rs9807989 0.507 rs10203558 ENSG00000234389.1 AC007278.3 4.17 5.1e-05 0.0197 0.32 0.32 Asthma; chr2:102411180 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs10200952 ENSG00000234389.1 AC007278.3 4.17 5.1e-05 0.0197 0.32 0.32 Asthma; chr2:102411191 chr2:102438713~102440475:+ PAAD cis rs3892715 0.502 rs2676885 ENSG00000214145.5 LINC00887 4.17 5.1e-05 0.0197 0.38 0.32 Attention deficit hyperactivity disorder (time to onset); chr3:195043802 chr3:194296465~194312803:- PAAD cis rs28386778 1 rs2955241 ENSG00000240280.5 TCAM1P -4.17 5.1e-05 0.0197 -0.46 -0.32 Prudent dietary pattern; chr17:63890753 chr17:63849292~63864379:+ PAAD cis rs11893307 0.537 rs6731208 ENSG00000235852.1 AC005540.3 4.17 5.11e-05 0.0197 0.48 0.32 Mean platelet volume; chr2:190638499 chr2:190880797~190882059:- PAAD cis rs17711722 0.727 rs1880555 ENSG00000236529.1 RP13-254B10.1 4.17 5.11e-05 0.0197 0.35 0.32 Calcium levels; chr7:65967580 chr7:65840212~65840596:+ PAAD cis rs17711722 0.701 rs781143 ENSG00000236529.1 RP13-254B10.1 4.17 5.11e-05 0.0197 0.35 0.32 Calcium levels; chr7:65974892 chr7:65840212~65840596:+ PAAD cis rs17711722 0.701 rs781145 ENSG00000236529.1 RP13-254B10.1 4.17 5.11e-05 0.0197 0.35 0.32 Calcium levels; chr7:65975383 chr7:65840212~65840596:+ PAAD cis rs17711722 0.727 rs2658585 ENSG00000236529.1 RP13-254B10.1 4.17 5.11e-05 0.0197 0.35 0.32 Calcium levels; chr7:65996954 chr7:65840212~65840596:+ PAAD cis rs2115630 1 rs11073730 ENSG00000225151.9 GOLGA2P7 4.17 5.11e-05 0.0197 0.38 0.32 P wave terminal force; chr15:84811365 chr15:84199311~84230136:- PAAD cis rs7617773 0.78 rs34523942 ENSG00000228638.1 FCF1P2 -4.17 5.11e-05 0.0197 -0.36 -0.32 Coronary artery disease; chr3:48301179 chr3:48290793~48291375:- PAAD cis rs4722166 0.568 rs1880241 ENSG00000179428.2 AC073072.5 -4.17 5.11e-05 0.0197 -0.3 -0.32 Lung cancer; chr7:22719850 chr7:22725395~22727620:- PAAD cis rs875971 1 rs2420168 ENSG00000232559.3 GS1-124K5.12 -4.17 5.13e-05 0.0198 -0.34 -0.32 Aortic root size; chr7:66165644 chr7:66554588~66576923:- PAAD cis rs875971 1 rs2077593 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66427543 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6460296 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66430152 chr7:66554588~66576923:- PAAD cis rs875971 1 rs4717292 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66430611 chr7:66554588~66576923:- PAAD cis rs875971 1 rs2420591 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66447394 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs10755833 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66448930 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs1833495 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66456608 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs6945019 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66457471 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs6945032 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66457499 chr7:66554588~66576923:- PAAD cis rs875971 0.929 rs12673810 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66458866 chr7:66554588~66576923:- PAAD cis rs875971 1 rs35149210 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66464938 chr7:66554588~66576923:- PAAD cis rs875971 1 rs2042133 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66466935 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs2161065 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66467918 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6961155 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66468308 chr7:66554588~66576923:- PAAD cis rs875971 1 rs7789768 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66473993 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs12698521 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66474502 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1363055 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66478288 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs9691480 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66479319 chr7:66554588~66576923:- PAAD cis rs875971 1 rs7789554 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66481051 chr7:66554588~66576923:- PAAD cis rs875971 1 rs4717300 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66482393 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs1974769 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66485627 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs6460300 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66487937 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs7803416 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66489212 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs1981799 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66490572 chr7:66554588~66576923:- PAAD cis rs875971 0.964 rs2277911 ENSG00000232559.3 GS1-124K5.12 4.17 5.13e-05 0.0198 0.34 0.32 Aortic root size; chr7:66493638 chr7:66554588~66576923:- PAAD cis rs11098499 0.566 rs17051356 ENSG00000245958.5 RP11-33B1.1 -4.17 5.13e-05 0.0198 -0.28 -0.32 Corneal astigmatism; chr4:119664153 chr4:119454791~119552025:+ PAAD cis rs66887589 0.616 rs11098498 ENSG00000248280.1 RP11-33B1.2 4.17 5.13e-05 0.0198 0.3 0.32 Diastolic blood pressure; chr4:119265964 chr4:119440561~119450157:- PAAD cis rs148406912 1 rs148406912 ENSG00000254851.1 RP11-109L13.1 4.17 5.14e-05 0.0198 0.68 0.32 Lobe attachment (rater-scored or self-reported); chr11:116967001 chr11:117135528~117138582:+ PAAD cis rs5758511 0.634 rs1001587 ENSG00000226450.2 CYP2D8P 4.17 5.14e-05 0.0198 0.32 0.32 Birth weight; chr22:42274105 chr22:42149886~42155001:- PAAD cis rs7615952 0.932 rs13325495 ENSG00000241288.6 RP11-379B18.5 -4.17 5.14e-05 0.0198 -0.35 -0.32 Blood pressure (smoking interaction); chr3:125918573 chr3:125827238~125916384:- PAAD cis rs41369048 0.858 rs11578466 ENSG00000238078.1 LINC01352 -4.17 5.14e-05 0.0198 -0.46 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220884397 chr1:220829255~220832429:+ PAAD cis rs875971 0.54 rs4717275 ENSG00000236529.1 RP13-254B10.1 -4.17 5.14e-05 0.0198 -0.35 -0.32 Aortic root size; chr7:65800193 chr7:65840212~65840596:+ PAAD cis rs11763147 1 rs11763147 ENSG00000236529.1 RP13-254B10.1 -4.17 5.14e-05 0.0198 -0.35 -0.32 Corneal structure; chr7:65861834 chr7:65840212~65840596:+ PAAD cis rs875971 0.522 rs10807697 ENSG00000236529.1 RP13-254B10.1 4.17 5.14e-05 0.0198 0.35 0.32 Aortic root size; chr7:65951183 chr7:65840212~65840596:+ PAAD cis rs875971 0.522 rs2008188 ENSG00000236529.1 RP13-254B10.1 4.17 5.14e-05 0.0198 0.35 0.32 Aortic root size; chr7:65964026 chr7:65840212~65840596:+ PAAD cis rs4853525 0.923 rs4853521 ENSG00000235852.1 AC005540.3 4.17 5.14e-05 0.0198 0.44 0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190865458 chr2:190880797~190882059:- PAAD cis rs8177376 0.906 rs1613842 ENSG00000254905.1 RP11-712L6.7 4.17 5.15e-05 0.0198 0.43 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126326015 chr11:126292922~126294254:- PAAD cis rs8177376 0.906 rs1695739 ENSG00000254905.1 RP11-712L6.7 4.17 5.15e-05 0.0198 0.43 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126326280 chr11:126292922~126294254:- PAAD cis rs3790645 1 rs282175 ENSG00000225159.1 NPM1P39 4.17 5.15e-05 0.0198 0.42 0.32 Glucose homeostasis traits; chr1:26569311 chr1:27206930~27207796:+ PAAD cis rs7727544 0.507 rs11741341 ENSG00000233006.5 AC034220.3 4.17 5.15e-05 0.0199 0.27 0.32 Blood metabolite levels; chr5:132234525 chr5:132311285~132369916:- PAAD cis rs7727544 0.507 rs10051679 ENSG00000233006.5 AC034220.3 4.17 5.15e-05 0.0199 0.27 0.32 Blood metabolite levels; chr5:132235238 chr5:132311285~132369916:- PAAD cis rs1075265 0.563 rs2542588 ENSG00000233266.1 HMGB1P31 -4.17 5.15e-05 0.0199 -0.42 -0.32 Chronotype;Morning vs. evening chronotype; chr2:53791787 chr2:54051334~54051760:+ PAAD cis rs1707322 0.752 rs4660880 ENSG00000280836.1 AL355480.1 -4.17 5.15e-05 0.0199 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45645368 chr1:45581219~45581321:- PAAD cis rs2280018 0.526 rs2966129 ENSG00000188599.16 NPIPP1 4.17 5.15e-05 0.0199 0.3 0.32 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059070 chr16:15104312~15123498:- PAAD cis rs871012 0.542 rs951958 ENSG00000251405.2 CTB-109A12.1 -4.17 5.16e-05 0.0199 -0.4 -0.32 IgG glycosylation; chr5:157462089 chr5:157362615~157460078:- PAAD cis rs41369048 0.858 rs2807866 ENSG00000238078.1 LINC01352 -4.17 5.16e-05 0.0199 -0.43 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220907587 chr1:220829255~220832429:+ PAAD cis rs9876781 0.62 rs34571806 ENSG00000229759.1 MRPS18AP1 4.17 5.16e-05 0.0199 0.33 0.32 Longevity; chr3:48368594 chr3:48256350~48256938:- PAAD cis rs591584 0.73 rs11020847 ENSG00000255893.1 RP11-685N10.1 4.17 5.16e-05 0.0199 0.41 0.32 Macrophage Migration Inhibitory Factor levels; chr11:94590746 chr11:94472908~94473570:- PAAD cis rs7927592 0.913 rs11228292 ENSG00000212093.1 AP000807.1 4.17 5.17e-05 0.0199 0.38 0.32 Total body bone mineral density; chr11:68612304 chr11:68506083~68506166:- PAAD cis rs6597981 0.543 rs3901233 ENSG00000255142.1 AP006621.6 4.17 5.17e-05 0.0199 0.26 0.32 Breast cancer; chr11:749452 chr11:781645~782105:+ PAAD cis rs7429990 0.901 rs9825114 ENSG00000228638.1 FCF1P2 4.17 5.17e-05 0.0199 0.36 0.32 Educational attainment (years of education); chr3:48096592 chr3:48290793~48291375:- PAAD cis rs7429990 0.932 rs11720151 ENSG00000228638.1 FCF1P2 4.17 5.17e-05 0.0199 0.36 0.32 Educational attainment (years of education); chr3:48099144 chr3:48290793~48291375:- PAAD cis rs7429990 0.932 rs6766641 ENSG00000228638.1 FCF1P2 4.17 5.17e-05 0.0199 0.36 0.32 Educational attainment (years of education); chr3:48103734 chr3:48290793~48291375:- PAAD cis rs6908034 0.607 rs76413455 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19808733 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs76525593 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19808939 chr6:19802164~19804752:- PAAD cis rs6908034 0.546 rs74514942 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19810289 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs78402429 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19811459 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs77791009 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19812371 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs75060331 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19812725 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs77753186 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19812749 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs79162793 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19812834 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs76245225 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19812957 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs75110577 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19814292 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs79406203 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19815990 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs74559916 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19818486 chr6:19802164~19804752:- PAAD cis rs6908034 0.505 rs76391302 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19818885 chr6:19802164~19804752:- PAAD cis rs6908034 0.505 rs77880623 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19819223 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs12526109 ENSG00000228412.5 RP4-625H18.2 4.17 5.17e-05 0.0199 0.63 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19819858 chr6:19802164~19804752:- PAAD cis rs17741873 1 rs17741873 ENSG00000207327.1 RNU6-883P -4.17 5.17e-05 0.0199 -0.5 -0.32 Paclitaxel disposition in epithelial ovarian cancer; chr10:73894042 chr10:73529051~73529157:- PAAD cis rs17741873 0.943 rs11000802 ENSG00000207327.1 RNU6-883P -4.17 5.17e-05 0.0199 -0.5 -0.32 Paclitaxel disposition in epithelial ovarian cancer; chr10:73894409 chr10:73529051~73529157:- PAAD cis rs875971 1 rs7792762 ENSG00000232559.3 GS1-124K5.12 4.17 5.17e-05 0.0199 0.35 0.32 Aortic root size; chr7:66539151 chr7:66554588~66576923:- PAAD cis rs2337406 0.704 rs1858679 ENSG00000211974.3 IGHV2-70 -4.17 5.18e-05 0.0199 -0.45 -0.32 Alzheimer's disease (late onset); chr14:106706726 chr14:106723574~106724093:- PAAD cis rs853679 0.628 rs9368560 ENSG00000226314.6 ZNF192P1 -4.17 5.18e-05 0.0199 -0.55 -0.32 Depression; chr6:28192182 chr6:28161781~28169594:+ PAAD cis rs1113500 1 rs1777483 ENSG00000226822.1 RP11-356N1.2 -4.17 5.18e-05 0.0199 -0.37 -0.32 Growth-regulated protein alpha levels; chr1:108066786 chr1:108071482~108074519:+ PAAD cis rs9487094 0.626 rs1980591 ENSG00000260273.1 RP11-425D10.10 4.17 5.18e-05 0.02 0.39 0.32 Height; chr6:109618620 chr6:109382795~109383666:+ PAAD cis rs9487094 0.696 rs12191353 ENSG00000260273.1 RP11-425D10.10 4.17 5.18e-05 0.02 0.39 0.32 Height; chr6:109620772 chr6:109382795~109383666:+ PAAD cis rs9487094 0.626 rs12192776 ENSG00000260273.1 RP11-425D10.10 4.17 5.18e-05 0.02 0.39 0.32 Height; chr6:109634150 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12194157 ENSG00000260273.1 RP11-425D10.10 4.17 5.18e-05 0.02 0.39 0.32 Height; chr6:109640141 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12197950 ENSG00000260273.1 RP11-425D10.10 4.17 5.18e-05 0.02 0.39 0.32 Height; chr6:109642186 chr6:109382795~109383666:+ PAAD cis rs7189233 0.531 rs1131220 ENSG00000279344.1 RP11-44F14.7 4.17 5.18e-05 0.02 0.24 0.32 Intelligence (multi-trait analysis); chr16:53470022 chr16:53478957~53481550:- PAAD cis rs9326248 0.581 rs7120706 ENSG00000280143.1 AP000892.6 -4.17 5.19e-05 0.02 -0.36 -0.32 Blood protein levels; chr11:116959371 chr11:117204967~117210292:+ PAAD cis rs9652601 0.959 rs12927355 ENSG00000274038.1 RP11-66H6.4 -4.17 5.19e-05 0.02 -0.37 -0.32 Systemic lupus erythematosus; chr16:11100914 chr16:11056556~11057034:+ PAAD cis rs9807989 0.507 rs6755905 ENSG00000234389.1 AC007278.3 4.17 5.19e-05 0.02 0.33 0.32 Asthma; chr2:102431747 chr2:102438713~102440475:+ PAAD cis rs4988958 0.527 rs6756161 ENSG00000234389.1 AC007278.3 4.17 5.19e-05 0.02 0.33 0.32 Asthma (childhood onset); chr2:102431957 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs6726985 ENSG00000234389.1 AC007278.3 4.17 5.19e-05 0.02 0.33 0.32 Asthma; chr2:102432120 chr2:102438713~102440475:+ PAAD cis rs11079159 1 rs876719 ENSG00000263096.1 RP11-515O17.2 4.17 5.2e-05 0.02 0.42 0.32 QRS duration; chr17:55289205 chr17:55271504~55273653:- PAAD cis rs10838687 0.736 rs2279238 ENSG00000255007.1 CTD-2589M5.4 4.16 5.2e-05 0.02 0.39 0.32 Proinsulin levels; chr11:47260473 chr11:46256355~46274547:- PAAD cis rs638893 0.617 rs4938561 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118847776 chr11:118791254~118793137:+ PAAD cis rs638893 0.617 rs2156750 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118848545 chr11:118791254~118793137:+ PAAD cis rs638893 0.561 rs2156749 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118848696 chr11:118791254~118793137:+ PAAD cis rs638893 0.617 rs7116715 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118849033 chr11:118791254~118793137:+ PAAD cis rs638893 0.617 rs4938564 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118849881 chr11:118791254~118793137:+ PAAD cis rs638893 0.588 rs4936440 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118849975 chr11:118791254~118793137:+ PAAD cis rs638893 0.588 rs4938566 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118850480 chr11:118791254~118793137:+ PAAD cis rs638893 0.617 rs4938567 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118850540 chr11:118791254~118793137:+ PAAD cis rs638893 0.617 rs11217059 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118852378 chr11:118791254~118793137:+ PAAD cis rs638893 0.617 rs7103314 ENSG00000278376.1 RP11-158I9.8 -4.16 5.2e-05 0.02 -0.34 -0.32 Vitiligo; chr11:118852828 chr11:118791254~118793137:+ PAAD cis rs6545883 0.507 rs6545855 ENSG00000271889.1 RP11-493E12.1 -4.16 5.2e-05 0.02 -0.34 -0.32 Tuberculosis; chr2:61305725 chr2:61151433~61162105:- PAAD cis rs17772222 0.63 rs816069 ENSG00000258983.2 RP11-507K2.2 -4.16 5.21e-05 0.02 -0.4 -0.32 Coronary artery calcification; chr14:88500992 chr14:88499334~88515502:+ PAAD cis rs4835473 0.9 rs3856989 ENSG00000251600.4 RP11-673E1.1 4.16 5.21e-05 0.02 0.36 0.32 Immature fraction of reticulocytes; chr4:143921752 chr4:143912331~143982454:+ PAAD cis rs10129255 0.518 rs10136903 ENSG00000211972.2 IGHV3-66 4.16 5.21e-05 0.02 0.25 0.32 Kawasaki disease; chr14:106778866 chr14:106675017~106675544:- PAAD cis rs7182621 0.639 rs34701806 ENSG00000259363.4 CTD-2054N24.2 -4.16 5.21e-05 0.02 -0.43 -0.32 Colonoscopy-negative controls vs population controls; chr15:99872953 chr15:99807023~99877148:+ PAAD cis rs10759883 0.539 rs7847393 ENSG00000175611.10 LINC00476 4.16 5.21e-05 0.02 0.32 0.32 Nicotine dependence; chr9:96033431 chr9:95759231~95875977:- PAAD cis rs12439619 0.508 rs11856561 ENSG00000255769.6 GOLGA2P10 -4.16 5.21e-05 0.02 -0.34 -0.32 Intelligence (multi-trait analysis); chr15:82161415 chr15:82472993~82513950:- PAAD cis rs9876781 1 rs6442117 ENSG00000229759.1 MRPS18AP1 -4.16 5.21e-05 0.0201 -0.35 -0.32 Longevity; chr3:48378407 chr3:48256350~48256938:- PAAD cis rs875971 0.505 rs6955582 ENSG00000236529.1 RP13-254B10.1 4.16 5.22e-05 0.0201 0.35 0.32 Aortic root size; chr7:65966699 chr7:65840212~65840596:+ PAAD cis rs11997175 0.766 rs4442096 ENSG00000240738.1 RP1-273G13.1 4.16 5.22e-05 0.0201 0.36 0.32 Body mass index; chr8:33833521 chr8:33859480~33860223:- PAAD cis rs2446066 0.872 rs36065378 ENSG00000257379.1 RP11-793H13.8 4.16 5.22e-05 0.0201 0.46 0.32 Red blood cell count; chr12:53380995 chr12:53441741~53467528:+ PAAD cis rs797680 0.789 rs7539307 ENSG00000223745.6 RP4-717I23.3 4.16 5.22e-05 0.0201 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93187146 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs11164880 ENSG00000223745.6 RP4-717I23.3 4.16 5.22e-05 0.0201 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93192539 chr1:93262186~93346025:- PAAD cis rs797680 0.856 rs7513705 ENSG00000223745.6 RP4-717I23.3 4.16 5.22e-05 0.0201 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93200792 chr1:93262186~93346025:- PAAD cis rs11690935 0.632 rs62184165 ENSG00000228389.1 AC068039.4 -4.16 5.22e-05 0.0201 -0.39 -0.32 Schizophrenia; chr2:171701818 chr2:171773482~171775844:+ PAAD cis rs11690935 0.632 rs2292816 ENSG00000228389.1 AC068039.4 -4.16 5.22e-05 0.0201 -0.39 -0.32 Schizophrenia; chr2:171730204 chr2:171773482~171775844:+ PAAD cis rs2412819 0.571 rs12443084 ENSG00000249839.1 AC011330.5 4.16 5.22e-05 0.0201 0.52 0.32 Lung cancer; chr15:43748767 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs10163069 ENSG00000249839.1 AC011330.5 4.16 5.22e-05 0.0201 0.52 0.32 Lung cancer; chr15:43755372 chr15:43663654~43684339:- PAAD cis rs2929278 0.617 rs3986209 ENSG00000249839.1 AC011330.5 4.16 5.22e-05 0.0201 0.52 0.32 Schizophrenia; chr15:43758675 chr15:43663654~43684339:- PAAD cis rs9322193 0.962 rs3805748 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149772542 chr6:149863494~149919507:+ PAAD cis rs9322193 0.736 rs10457851 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149775216 chr6:149863494~149919507:+ PAAD cis rs9322193 0.886 rs10872652 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149775303 chr6:149863494~149919507:+ PAAD cis rs9322193 0.886 rs12525871 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149775882 chr6:149863494~149919507:+ PAAD cis rs9322193 0.886 rs17672976 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149776207 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs2184369 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149776681 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs2342861 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149777561 chr6:149863494~149919507:+ PAAD cis rs9322193 0.926 rs2342860 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149777641 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs10872653 ENSG00000268592.3 RAET1E-AS1 4.16 5.22e-05 0.0201 0.38 0.32 Lung cancer; chr6:149778907 chr6:149863494~149919507:+ PAAD cis rs8031584 0.958 rs61997076 ENSG00000260382.1 RP11-540B6.2 4.16 5.22e-05 0.0201 0.42 0.32 Huntington's disease progression; chr15:30924022 chr15:30882267~30883231:- PAAD cis rs6545883 0.56 rs11677776 ENSG00000271889.1 RP11-493E12.1 -4.16 5.22e-05 0.0201 -0.34 -0.32 Tuberculosis; chr2:61275978 chr2:61151433~61162105:- PAAD cis rs5003154 0.58 rs4739785 ENSG00000253334.1 RP13-923O23.6 4.16 5.22e-05 0.0201 0.36 0.32 Bladder cancer; chr8:81097896 chr8:81791823~81815714:+ PAAD cis rs2034650 0.563 rs11070270 ENSG00000223313.1 RNU6-516P -4.16 5.22e-05 0.0201 -0.41 -0.32 Interstitial lung disease; chr15:40416223 chr15:40529570~40529673:+ PAAD cis rs1707322 0.686 rs2050376 ENSG00000280836.1 AL355480.1 -4.16 5.22e-05 0.0201 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45612958 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs2230658 ENSG00000280836.1 AL355480.1 4.16 5.22e-05 0.0201 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613182 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs2230659 ENSG00000280836.1 AL355480.1 4.16 5.22e-05 0.0201 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613212 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs2991987 ENSG00000280836.1 AL355480.1 4.16 5.22e-05 0.0201 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615750 chr1:45581219~45581321:- PAAD cis rs6782228 1 rs6801509 ENSG00000242551.2 POU5F1P6 4.16 5.23e-05 0.0201 0.42 0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128645426 chr3:128674735~128677005:- PAAD cis rs853679 0.513 rs13437444 ENSG00000204709.4 LINC01556 4.16 5.23e-05 0.0201 0.58 0.32 Depression; chr6:28103220 chr6:28943877~28944537:+ PAAD cis rs77372450 0.591 rs11958568 ENSG00000251405.2 CTB-109A12.1 4.16 5.23e-05 0.0201 0.51 0.32 Bipolar disorder (body mass index interaction); chr5:157553332 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs55704016 ENSG00000251405.2 CTB-109A12.1 4.16 5.23e-05 0.0201 0.51 0.32 Bipolar disorder (body mass index interaction); chr5:157557419 chr5:157362615~157460078:- PAAD cis rs9595908 0.965 rs35193668 ENSG00000212293.1 SNORA16 4.16 5.23e-05 0.0201 0.38 0.32 Body mass index; chr13:32518792 chr13:32420390~32420516:- PAAD cis rs2188561 0.697 rs3735606 ENSG00000241764.3 AC002467.7 4.16 5.23e-05 0.0201 0.41 0.32 Alcohol consumption; chr7:107743864 chr7:107742817~107744581:- PAAD cis rs7189233 0.531 rs4281707 ENSG00000279344.1 RP11-44F14.7 4.16 5.23e-05 0.0201 0.24 0.32 Intelligence (multi-trait analysis); chr16:53468034 chr16:53478957~53481550:- PAAD cis rs7119038 0.865 rs4936443 ENSG00000255239.1 AP002954.6 4.16 5.24e-05 0.0201 0.47 0.32 Sjögren's syndrome; chr11:118870155 chr11:118688039~118690600:- PAAD cis rs7119038 0.818 rs4938572 ENSG00000255239.1 AP002954.6 4.16 5.24e-05 0.0201 0.47 0.32 Sjögren's syndrome; chr11:118870222 chr11:118688039~118690600:- PAAD cis rs763121 0.853 rs4821798 ENSG00000228274.3 RP3-508I15.9 -4.16 5.24e-05 0.0201 -0.3 -0.32 Menopause (age at onset); chr22:38625160 chr22:38667585~38681820:- PAAD cis rs55665837 0.559 rs11023210 ENSG00000251991.1 RNU7-49P -4.16 5.24e-05 0.0201 -0.38 -0.32 Vitamin D levels; chr11:14401216 chr11:14478892~14478953:+ PAAD cis rs11690935 0.632 rs6723259 ENSG00000228389.1 AC068039.4 -4.16 5.24e-05 0.0201 -0.39 -0.32 Schizophrenia; chr2:171766017 chr2:171773482~171775844:+ PAAD cis rs11690935 0.632 rs11690807 ENSG00000228389.1 AC068039.4 -4.16 5.24e-05 0.0201 -0.39 -0.32 Schizophrenia; chr2:171771610 chr2:171773482~171775844:+ PAAD cis rs9326248 0.559 rs484646 ENSG00000280143.1 AP000892.6 4.16 5.24e-05 0.0201 0.37 0.32 Blood protein levels; chr11:116862140 chr11:117204967~117210292:+ PAAD cis rs9326248 0.509 rs533556 ENSG00000280143.1 AP000892.6 4.16 5.24e-05 0.0201 0.37 0.32 Blood protein levels; chr11:116870856 chr11:117204967~117210292:+ PAAD cis rs780096 0.545 rs2280737 ENSG00000234072.1 AC074117.10 -4.16 5.24e-05 0.0201 -0.25 -0.32 Total body bone mineral density; chr2:27366943 chr2:27356246~27367622:+ PAAD cis rs871012 0.502 rs2112691 ENSG00000251405.2 CTB-109A12.1 -4.16 5.25e-05 0.0201 -0.4 -0.32 IgG glycosylation; chr5:157456328 chr5:157362615~157460078:- PAAD cis rs871012 0.502 rs62388483 ENSG00000251405.2 CTB-109A12.1 -4.16 5.25e-05 0.0201 -0.4 -0.32 IgG glycosylation; chr5:157456829 chr5:157362615~157460078:- PAAD cis rs72615157 0.561 rs113844570 ENSG00000242294.5 STAG3L5P 4.16 5.25e-05 0.0202 0.27 0.32 Lung function (FEV1/FVC); chr7:100276155 chr7:100336079~100351900:+ PAAD cis rs4938573 0.526 rs11216973 ENSG00000255239.1 AP002954.6 -4.16 5.25e-05 0.0202 -0.43 -0.32 Follicular lymphoma; chr11:118716292 chr11:118688039~118690600:- PAAD cis rs6421571 0.565 rs10892263 ENSG00000255239.1 AP002954.6 -4.16 5.25e-05 0.0202 -0.43 -0.32 Primary biliary cholangitis; chr11:118716610 chr11:118688039~118690600:- PAAD cis rs891378 0.785 rs6540876 ENSG00000274245.1 RP11-357P18.2 -4.16 5.25e-05 0.0202 -0.44 -0.32 Spherical equivalent (joint analysis main effects and education interaction); chr1:207222873 chr1:207372559~207373252:+ PAAD cis rs9807989 0.507 rs3755266 ENSG00000234389.1 AC007278.3 4.16 5.25e-05 0.0202 0.33 0.32 Asthma; chr2:102426252 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs2110659 ENSG00000234389.1 AC007278.3 4.16 5.25e-05 0.0202 0.33 0.32 Asthma; chr2:102427407 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs7605284 ENSG00000234389.1 AC007278.3 4.16 5.25e-05 0.0202 0.33 0.32 Asthma; chr2:102427715 chr2:102438713~102440475:+ PAAD cis rs4988958 0.584 rs12712149 ENSG00000234389.1 AC007278.3 4.16 5.25e-05 0.0202 0.33 0.32 Asthma (childhood onset); chr2:102428733 chr2:102438713~102440475:+ PAAD cis rs4988958 0.584 rs7559845 ENSG00000234389.1 AC007278.3 4.16 5.25e-05 0.0202 0.33 0.32 Asthma (childhood onset); chr2:102429754 chr2:102438713~102440475:+ PAAD cis rs9322193 0.962 rs17673294 ENSG00000268592.3 RAET1E-AS1 4.16 5.25e-05 0.0202 0.38 0.32 Lung cancer; chr6:149813857 chr6:149863494~149919507:+ PAAD cis rs7646881 0.504 rs61080878 ENSG00000240207.5 RP11-379F4.4 -4.16 5.25e-05 0.0202 -0.43 -0.32 Tetralogy of Fallot; chr3:158745108 chr3:158732263~158784070:+ PAAD cis rs7646881 0.504 rs4264773 ENSG00000240207.5 RP11-379F4.4 -4.16 5.25e-05 0.0202 -0.43 -0.32 Tetralogy of Fallot; chr3:158745436 chr3:158732263~158784070:+ PAAD cis rs7646881 0.504 rs67305172 ENSG00000240207.5 RP11-379F4.4 -4.16 5.25e-05 0.0202 -0.43 -0.32 Tetralogy of Fallot; chr3:158746485 chr3:158732263~158784070:+ PAAD cis rs12468226 0.873 rs2350358 ENSG00000273456.1 RP11-686O6.2 -4.16 5.26e-05 0.0202 -0.45 -0.32 Urate levels; chr2:202199771 chr2:202374932~202375604:- PAAD cis rs1113500 0.541 rs9803640 ENSG00000226822.1 RP11-356N1.2 -4.16 5.26e-05 0.0202 -0.4 -0.32 Growth-regulated protein alpha levels; chr1:108033645 chr1:108071482~108074519:+ PAAD cis rs9876781 1 rs6810060 ENSG00000229759.1 MRPS18AP1 4.16 5.26e-05 0.0202 0.35 0.32 Longevity; chr3:48393284 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs6770470 ENSG00000229759.1 MRPS18AP1 4.16 5.26e-05 0.0202 0.35 0.32 Longevity; chr3:48393659 chr3:48256350~48256938:- PAAD cis rs812925 0.537 rs2463097 ENSG00000273302.1 RP11-493E12.2 -4.16 5.26e-05 0.0202 -0.27 -0.32 Immature fraction of reticulocytes; chr2:61387166 chr2:61199979~61200769:+ PAAD cis rs763121 0.819 rs5750629 ENSG00000228274.3 RP3-508I15.9 -4.16 5.27e-05 0.0202 -0.31 -0.32 Menopause (age at onset); chr22:38589060 chr22:38667585~38681820:- PAAD cis rs812925 0.515 rs1177308 ENSG00000271889.1 RP11-493E12.1 4.16 5.27e-05 0.0202 0.35 0.32 Immature fraction of reticulocytes; chr2:61160119 chr2:61151433~61162105:- PAAD cis rs812925 0.553 rs1177307 ENSG00000271889.1 RP11-493E12.1 4.16 5.27e-05 0.0202 0.35 0.32 Immature fraction of reticulocytes; chr2:61160253 chr2:61151433~61162105:- PAAD cis rs812925 0.512 rs1729674 ENSG00000271889.1 RP11-493E12.1 4.16 5.27e-05 0.0202 0.35 0.32 Immature fraction of reticulocytes; chr2:61162602 chr2:61151433~61162105:- PAAD cis rs150992 0.742 rs34495 ENSG00000248489.1 CTD-2007H13.3 4.16 5.27e-05 0.0202 0.35 0.32 Body mass index; chr5:98930103 chr5:98929171~98995013:+ PAAD cis rs10129255 0.518 rs8010020 ENSG00000211972.2 IGHV3-66 4.16 5.27e-05 0.0202 0.25 0.32 Kawasaki disease; chr14:106778016 chr14:106675017~106675544:- PAAD cis rs9876781 0.559 rs1841178 ENSG00000229759.1 MRPS18AP1 4.16 5.27e-05 0.0202 0.33 0.32 Longevity; chr3:48355556 chr3:48256350~48256938:- PAAD cis rs8072100 0.84 rs12453233 ENSG00000228782.6 CTD-2026D20.3 4.16 5.27e-05 0.0202 0.33 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47377204 chr17:47450568~47492492:- PAAD cis rs8072100 0.84 rs1912482 ENSG00000228782.6 CTD-2026D20.3 4.16 5.27e-05 0.0202 0.33 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47377517 chr17:47450568~47492492:- PAAD cis rs10761482 0.601 rs7922622 ENSG00000254271.1 RP11-131N11.4 -4.16 5.27e-05 0.0202 -0.41 -0.32 Schizophrenia; chr10:60447765 chr10:60734342~60741828:+ PAAD cis rs3743772 0.5 rs8045574 ENSG00000279722.1 RP11-44F14.6 -4.16 5.28e-05 0.0202 -0.45 -0.32 Depressive symptoms (SSRI exposure interaction); chr16:53395293 chr16:53487607~53489943:- PAAD cis rs763121 0.853 rs2235230 ENSG00000225450.1 RP3-508I15.14 4.16 5.28e-05 0.0202 0.27 0.32 Menopause (age at onset); chr22:38728462 chr22:38739003~38749041:+ PAAD cis rs2736345 0.672 rs2618473 ENSG00000251402.3 FAM90A25P 4.16 5.28e-05 0.0202 0.4 0.32 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11486618 chr8:12415080~12418090:- PAAD cis rs42490 0.789 rs383592 ENSG00000251136.7 RP11-37B2.1 -4.16 5.28e-05 0.0203 -0.28 -0.32 Leprosy; chr8:89792100 chr8:89609409~89757727:- PAAD cis rs9926296 0.656 rs4522419 ENSG00000260259.1 RP11-368I7.4 -4.16 5.28e-05 0.0203 -0.37 -0.32 Vitiligo; chr16:89786899 chr16:89682620~89686569:- PAAD cis rs916888 0.697 rs199516 ENSG00000261575.2 RP11-259G18.1 -4.16 5.29e-05 0.0203 -0.48 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs199514 ENSG00000261575.2 RP11-259G18.1 -4.16 5.29e-05 0.0203 -0.48 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs199513 ENSG00000261575.2 RP11-259G18.1 -4.16 5.29e-05 0.0203 -0.48 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs199512 ENSG00000261575.2 RP11-259G18.1 -4.16 5.29e-05 0.0203 -0.48 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs199509 ENSG00000261575.2 RP11-259G18.1 -4.16 5.29e-05 0.0203 -0.48 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs199507 ENSG00000261575.2 RP11-259G18.1 -4.16 5.29e-05 0.0203 -0.48 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs199505 ENSG00000261575.2 RP11-259G18.1 -4.16 5.29e-05 0.0203 -0.48 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46267037~46268694:+ PAAD cis rs916888 0.821 rs70602 ENSG00000261575.2 RP11-259G18.1 -4.16 5.29e-05 0.0203 -0.48 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46267037~46268694:+ PAAD cis rs9649213 0.593 rs11760930 ENSG00000272950.1 RP11-307C18.1 4.16 5.29e-05 0.0203 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98286477 chr7:98322853~98323430:+ PAAD cis rs2904804 0.792 rs2904795 ENSG00000224251.5 RP11-499O7.7 4.16 5.29e-05 0.0203 0.36 0.32 Economic and political preferences (immigration/crime); chr10:4962125 chr10:4995488~4997380:+ PAAD cis rs858239 0.6 rs2072369 ENSG00000226816.2 AC005082.12 4.16 5.29e-05 0.0203 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23106570 chr7:23206013~23208045:+ PAAD cis rs10411161 1 rs10414104 ENSG00000269483.1 AC006272.1 4.16 5.29e-05 0.0203 0.57 0.32 Breast cancer; chr19:51864879 chr19:51839924~51843324:- PAAD cis rs10411161 0.935 rs8107422 ENSG00000269483.1 AC006272.1 4.16 5.29e-05 0.0203 0.57 0.32 Breast cancer; chr19:51865522 chr19:51839924~51843324:- PAAD cis rs7615952 0.558 rs17334039 ENSG00000171084.14 FAM86JP 4.16 5.3e-05 0.0203 0.43 0.32 Blood pressure (smoking interaction); chr3:125821465 chr3:125916620~125930024:+ PAAD cis rs2985684 0.948 rs2883437 ENSG00000259113.1 RP11-406H23.2 -4.16 5.3e-05 0.0203 -0.44 -0.32 Carotid intima media thickness; chr14:49564948 chr14:50448807~50456742:+ PAAD cis rs1707322 0.686 rs3014242 ENSG00000280836.1 AL355480.1 4.16 5.3e-05 0.0203 0.39 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621905 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs3014239 ENSG00000280836.1 AL355480.1 4.16 5.3e-05 0.0203 0.39 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624129 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs3014236 ENSG00000280836.1 AL355480.1 4.16 5.3e-05 0.0203 0.39 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625633 chr1:45581219~45581321:- PAAD cis rs498136 0.831 rs546597 ENSG00000250508.1 RP11-757G1.6 -4.16 5.3e-05 0.0203 -0.43 -0.32 Cutaneous malignant melanoma;Melanoma; chr11:69537143 chr11:68870664~68874542:+ PAAD cis rs710913 0.527 rs2004330 ENSG00000237624.1 OXCT2P1 -4.16 5.3e-05 0.0203 -0.4 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39498201 chr1:39514956~39516490:+ PAAD cis rs755249 1 rs4660293 ENSG00000228060.1 RP11-69E11.8 4.16 5.3e-05 0.0203 0.32 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39562508 chr1:39565160~39573203:+ PAAD cis rs7849973 0.551 rs7850461 ENSG00000224549.1 RP11-370B11.3 -4.16 5.31e-05 0.0203 -0.37 -0.32 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined); chr9:22809451 chr9:22767175~22768316:+ PAAD cis rs1387259 0.723 rs2732488 ENSG00000258273.1 RP11-370I10.4 -4.16 5.31e-05 0.0203 -0.39 -0.32 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48377661 chr12:48333755~48333901:- PAAD cis rs1387259 0.758 rs2634670 ENSG00000258273.1 RP11-370I10.4 -4.16 5.31e-05 0.0203 -0.39 -0.32 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48378094 chr12:48333755~48333901:- PAAD cis rs3738443 0.644 rs2799177 ENSG00000259865.1 RP11-488L18.10 -4.16 5.31e-05 0.0204 -0.29 -0.32 Alcohol dependence; chr1:247235898 chr1:247187281~247188526:- PAAD cis rs494459 0.726 rs1784300 ENSG00000278376.1 RP11-158I9.8 -4.16 5.32e-05 0.0204 -0.28 -0.32 Height; chr11:118808920 chr11:118791254~118793137:+ PAAD cis rs919433 1 rs1429414 ENSG00000231621.1 AC013264.2 4.16 5.32e-05 0.0204 0.3 0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197297706 chr2:197197991~197199273:+ PAAD cis rs58873874 0.737 rs11466784 ENSG00000251405.2 CTB-109A12.1 4.16 5.32e-05 0.0204 0.64 0.32 Bipolar disorder (body mass index interaction); chr5:157494643 chr5:157362615~157460078:- PAAD cis rs797680 0.598 rs3754186 ENSG00000223745.6 RP4-717I23.3 4.16 5.32e-05 0.0204 0.25 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93246225 chr1:93262186~93346025:- PAAD cis rs12468226 0.689 rs17651413 ENSG00000273456.1 RP11-686O6.2 4.16 5.32e-05 0.0204 0.5 0.32 Urate levels; chr2:202104086 chr2:202374932~202375604:- PAAD cis rs12468226 0.689 rs73989731 ENSG00000273456.1 RP11-686O6.2 4.16 5.32e-05 0.0204 0.5 0.32 Urate levels; chr2:202109309 chr2:202374932~202375604:- PAAD cis rs12468226 0.689 rs60584169 ENSG00000273456.1 RP11-686O6.2 4.16 5.32e-05 0.0204 0.5 0.32 Urate levels; chr2:202111695 chr2:202374932~202375604:- PAAD cis rs12468226 0.689 rs73989733 ENSG00000273456.1 RP11-686O6.2 4.16 5.32e-05 0.0204 0.5 0.32 Urate levels; chr2:202115241 chr2:202374932~202375604:- PAAD cis rs12439619 0.705 rs17354185 ENSG00000276710.3 CSPG4P8 4.16 5.32e-05 0.0204 0.36 0.32 Intelligence (multi-trait analysis); chr15:82133829 chr15:82459472~82477258:+ PAAD cis rs11651753 0.935 rs2525109 ENSG00000264920.1 RP11-6N17.4 4.16 5.32e-05 0.0204 0.36 0.32 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47964961 chr17:47891255~47895812:- PAAD cis rs11651753 0.935 rs2525110 ENSG00000264920.1 RP11-6N17.4 4.16 5.32e-05 0.0204 0.36 0.32 Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1); chr17:47964999 chr17:47891255~47895812:- PAAD cis rs72634501 0.642 rs67452844 ENSG00000261798.1 RP1-118J21.25 4.16 5.33e-05 0.0204 0.37 0.32 HDL cholesterol; chr1:39150610 chr1:39788976~39790171:+ PAAD cis rs755249 0.508 rs586057 ENSG00000237624.1 OXCT2P1 4.16 5.33e-05 0.0204 0.42 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39393122 chr1:39514956~39516490:+ PAAD cis rs755249 0.508 rs624971 ENSG00000237624.1 OXCT2P1 4.16 5.33e-05 0.0204 0.42 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39393275 chr1:39514956~39516490:+ PAAD cis rs916888 0.773 rs169201 ENSG00000261575.2 RP11-259G18.1 4.16 5.33e-05 0.0204 0.49 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46267037~46268694:+ PAAD cis rs916888 0.773 rs199439 ENSG00000261575.2 RP11-259G18.1 4.16 5.33e-05 0.0204 0.49 0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46267037~46268694:+ PAAD cis rs61270009 0.955 rs415449 ENSG00000247828.6 TMEM161B-AS1 -4.16 5.33e-05 0.0204 -0.26 -0.32 Depressive symptoms; chr5:88231533 chr5:88268895~88436685:+ PAAD cis rs700651 0.752 rs7592556 ENSG00000231621.1 AC013264.2 -4.16 5.33e-05 0.0204 -0.32 -0.32 Intracranial aneurysm; chr2:198026297 chr2:197197991~197199273:+ PAAD cis rs700651 0.753 rs10207232 ENSG00000231621.1 AC013264.2 -4.16 5.33e-05 0.0204 -0.32 -0.32 Intracranial aneurysm; chr2:198029089 chr2:197197991~197199273:+ PAAD cis rs6545883 0.56 rs11677775 ENSG00000271889.1 RP11-493E12.1 -4.16 5.33e-05 0.0204 -0.34 -0.32 Tuberculosis; chr2:61275975 chr2:61151433~61162105:- PAAD cis rs17123764 0.818 rs59960493 ENSG00000257464.1 RP11-161H23.8 -4.16 5.33e-05 0.0204 -0.57 -0.32 Intelligence (multi-trait analysis); chr12:49548096 chr12:49442424~49442652:- PAAD cis rs6743226 0.603 rs3755324 ENSG00000266621.1 AC104841.1 4.16 5.33e-05 0.0204 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241263805 chr2:241245202~241245299:- PAAD cis rs6921919 0.848 rs9468350 ENSG00000204709.4 LINC01556 4.16 5.34e-05 0.0204 0.51 0.32 Autism spectrum disorder or schizophrenia; chr6:28351330 chr6:28943877~28944537:+ PAAD cis rs875971 0.545 rs1796222 ENSG00000222364.1 RNU6-96P 4.16 5.34e-05 0.0204 0.42 0.32 Aortic root size; chr7:66592167 chr7:66395191~66395286:+ PAAD cis rs3738443 0.951 rs61840467 ENSG00000259865.1 RP11-488L18.10 4.16 5.34e-05 0.0204 0.29 0.32 Alcohol dependence; chr1:247216936 chr1:247187281~247188526:- PAAD cis rs28386778 0.787 rs2665827 ENSG00000240280.5 TCAM1P -4.16 5.34e-05 0.0205 -0.46 -0.32 Prudent dietary pattern; chr17:63883990 chr17:63849292~63864379:+ PAAD cis rs7572733 0.534 rs700662 ENSG00000231621.1 AC013264.2 -4.16 5.35e-05 0.0205 -0.32 -0.32 Dermatomyositis; chr2:197804027 chr2:197197991~197199273:+ PAAD cis rs7572733 0.514 rs770659 ENSG00000231621.1 AC013264.2 -4.16 5.35e-05 0.0205 -0.32 -0.32 Dermatomyositis; chr2:197805030 chr2:197197991~197199273:+ PAAD cis rs700651 0.821 rs700663 ENSG00000231621.1 AC013264.2 -4.16 5.35e-05 0.0205 -0.32 -0.32 Intracranial aneurysm; chr2:197805754 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700664 ENSG00000231621.1 AC013264.2 -4.16 5.35e-05 0.0205 -0.32 -0.32 Dermatomyositis; chr2:197806421 chr2:197197991~197199273:+ PAAD cis rs700651 0.821 rs700666 ENSG00000231621.1 AC013264.2 -4.16 5.35e-05 0.0205 -0.32 -0.32 Intracranial aneurysm; chr2:197808820 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs770657 ENSG00000231621.1 AC013264.2 -4.16 5.35e-05 0.0205 -0.32 -0.32 Dermatomyositis; chr2:197809460 chr2:197197991~197199273:+ PAAD cis rs700651 0.821 rs771005 ENSG00000231621.1 AC013264.2 -4.16 5.35e-05 0.0205 -0.32 -0.32 Intracranial aneurysm; chr2:197811224 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700667 ENSG00000231621.1 AC013264.2 -4.16 5.35e-05 0.0205 -0.32 -0.32 Dermatomyositis; chr2:197812784 chr2:197197991~197199273:+ PAAD cis rs10129255 0.627 rs115739224 ENSG00000211972.2 IGHV3-66 4.16 5.35e-05 0.0205 0.3 0.32 Kawasaki disease; chr14:106718758 chr14:106675017~106675544:- PAAD cis rs9876781 1 rs725310 ENSG00000229759.1 MRPS18AP1 -4.16 5.35e-05 0.0205 -0.35 -0.32 Longevity; chr3:48377081 chr3:48256350~48256938:- PAAD cis rs3785888 0.569 rs1838105 ENSG00000262539.1 RP11-259G18.3 -4.16 5.35e-05 0.0205 -0.45 -0.32 Cleft lip with or without cleft palate; chr17:46931569 chr17:46259551~46260606:- PAAD cis rs440932 0.565 rs19334 ENSG00000253893.2 FAM85B -4.16 5.35e-05 0.0205 -0.44 -0.32 High light scatter reticulocyte percentage of red cells; chr8:9152396 chr8:8167819~8226614:- PAAD cis rs633715 0.766 rs1854289 ENSG00000254154.7 RP4-798P15.3 -4.16 5.35e-05 0.0205 -0.29 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177834028 chr1:177928788~178038007:- PAAD cis rs7617773 0.817 rs745116 ENSG00000228638.1 FCF1P2 -4.16 5.35e-05 0.0205 -0.36 -0.32 Coronary artery disease; chr3:48231046 chr3:48290793~48291375:- PAAD cis rs496547 0.719 rs1790189 ENSG00000278376.1 RP11-158I9.8 -4.16 5.36e-05 0.0205 -0.29 -0.32 Hip minimal joint space width; chr11:118781617 chr11:118791254~118793137:+ PAAD cis rs7216064 1 rs1976054 ENSG00000278219.1 AC145343.1 -4.16 5.36e-05 0.0205 -0.5 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67837108 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs8074078 ENSG00000278219.1 AC145343.1 -4.16 5.36e-05 0.0205 -0.5 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67842627 chr17:68101538~68101639:+ PAAD cis rs9926296 0.572 rs8046872 ENSG00000260259.1 RP11-368I7.4 -4.16 5.36e-05 0.0205 -0.37 -0.32 Vitiligo; chr16:89775144 chr16:89682620~89686569:- PAAD cis rs1665050 0.534 rs4600408 ENSG00000277144.1 RP11-59H7.4 -4.16 5.36e-05 0.0205 -0.38 -0.32 Atopic dermatitis; chr15:58954601 chr15:59115547~59116089:- PAAD cis rs1665050 0.534 rs4465553 ENSG00000277144.1 RP11-59H7.4 -4.16 5.36e-05 0.0205 -0.38 -0.32 Atopic dermatitis; chr15:58954621 chr15:59115547~59116089:- PAAD cis rs1707322 0.717 rs2253862 ENSG00000280836.1 AL355480.1 4.16 5.36e-05 0.0205 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616288 chr1:45581219~45581321:- PAAD cis rs1707322 0.717 rs2991988 ENSG00000280836.1 AL355480.1 4.16 5.36e-05 0.0205 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45616759 chr1:45581219~45581321:- PAAD cis rs1707322 0.717 rs2991989 ENSG00000280836.1 AL355480.1 4.16 5.36e-05 0.0205 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45617293 chr1:45581219~45581321:- PAAD cis rs10740039 0.81 rs6479720 ENSG00000254271.1 RP11-131N11.4 4.16 5.37e-05 0.0205 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60610935 chr10:60734342~60741828:+ PAAD cis rs3131856 1 rs3131856 ENSG00000281831.1 HCP5B 4.16 5.37e-05 0.0205 0.71 0.32 Tuberculosis; chr6:29639324 chr6:29871895~29873783:- PAAD cis rs3116813 1 rs3116813 ENSG00000281831.1 HCP5B 4.16 5.37e-05 0.0205 0.71 0.32 Breast cancer; chr6:29693039 chr6:29871895~29873783:- PAAD cis rs3094146 1 rs3094146 ENSG00000281831.1 HCP5B 4.16 5.37e-05 0.0205 0.71 0.32 Breast cancer; chr6:30003183 chr6:29871895~29873783:- PAAD cis rs919433 0.929 rs10931779 ENSG00000231621.1 AC013264.2 4.16 5.37e-05 0.0205 0.3 0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197302101 chr2:197197991~197199273:+ PAAD cis rs6547741 0.816 rs10201652 ENSG00000234072.1 AC074117.10 -4.16 5.37e-05 0.0205 -0.26 -0.32 Oral cavity cancer; chr2:27651465 chr2:27356246~27367622:+ PAAD cis rs6547741 0.788 rs7595739 ENSG00000234072.1 AC074117.10 -4.16 5.37e-05 0.0205 -0.26 -0.32 Oral cavity cancer; chr2:27651696 chr2:27356246~27367622:+ PAAD cis rs1167827 0.68 rs1167800 ENSG00000205583.12 STAG3L1 4.16 5.37e-05 0.0205 0.36 0.32 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75546898 chr7:75359194~75395383:+ PAAD cis rs2736345 0.788 rs998683 ENSG00000255518.1 RP11-148O21.4 4.16 5.38e-05 0.0205 0.3 0.32 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11495491 chr8:11556251~11558022:- PAAD cis rs10497394 0.66 rs6744344 ENSG00000270460.1 RP11-796E10.1 4.16 5.38e-05 0.0205 0.33 0.32 Otitis media (chronic/recurrent); chr2:173431901 chr2:173811076~173811392:+ PAAD cis rs453301 0.686 rs11785819 ENSG00000253893.2 FAM85B 4.16 5.38e-05 0.0205 0.44 0.32 Joint mobility (Beighton score); chr8:9012868 chr8:8167819~8226614:- PAAD cis rs6545883 0.524 rs2694619 ENSG00000271889.1 RP11-493E12.1 -4.16 5.38e-05 0.0205 -0.33 -0.32 Tuberculosis; chr2:61309766 chr2:61151433~61162105:- PAAD cis rs4835473 0.932 rs1849113 ENSG00000251600.4 RP11-673E1.1 -4.16 5.38e-05 0.0205 -0.38 -0.32 Immature fraction of reticulocytes; chr4:143962512 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4585249 ENSG00000251600.4 RP11-673E1.1 -4.16 5.38e-05 0.0205 -0.38 -0.32 Immature fraction of reticulocytes; chr4:143981173 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1877235 ENSG00000251600.4 RP11-673E1.1 -4.16 5.38e-05 0.0205 -0.38 -0.32 Immature fraction of reticulocytes; chr4:143986961 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4305468 ENSG00000251600.4 RP11-673E1.1 -4.16 5.38e-05 0.0205 -0.38 -0.32 Immature fraction of reticulocytes; chr4:143987315 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs2089835 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143965127 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7693772 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143965614 chr4:143912331~143982454:+ PAAD cis rs4835473 0.639 rs28674022 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143966409 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs28423022 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143966416 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs35888177 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143966863 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs10033382 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143967103 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7667092 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143968604 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs3874 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143968795 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs2323417 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143969108 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs2323418 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143969141 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs11931330 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143970808 chr4:143912331~143982454:+ PAAD cis rs4835473 0.549 rs11940719 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143970855 chr4:143912331~143982454:+ PAAD cis rs4835473 0.83 rs7692672 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143971048 chr4:143912331~143982454:+ PAAD cis rs4835473 0.766 rs6537222 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143971459 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs6537223 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143971541 chr4:143912331~143982454:+ PAAD cis rs4835473 0.615 rs6857432 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143971912 chr4:143912331~143982454:+ PAAD cis rs4835473 0.831 rs4452380 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143972856 chr4:143912331~143982454:+ PAAD cis rs4835473 0.831 rs10428468 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143974104 chr4:143912331~143982454:+ PAAD cis rs4835473 0.75 rs57610804 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143974341 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs13148097 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143976238 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs28377887 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143977075 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6826862 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143978180 chr4:143912331~143982454:+ PAAD cis rs4835473 0.8 rs1849122 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143978699 chr4:143912331~143982454:+ PAAD cis rs4835473 0.663 rs4835115 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143979308 chr4:143912331~143982454:+ PAAD cis rs4835473 0.771 rs4261935 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143979751 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs4257604 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143980261 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs35599924 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143980602 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4516663 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143980791 chr4:143912331~143982454:+ PAAD cis rs4835473 0.8 rs2089839 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143980955 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4835118 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143981994 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4835471 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143982153 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs4835119 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143982210 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4835120 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143982370 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4835472 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143982398 chr4:143912331~143982454:+ PAAD cis rs4835473 1 rs4835473 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143982419 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs4835474 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143982444 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6847869 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143982881 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs6846984 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143983098 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs34617134 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143983606 chr4:143912331~143982454:+ PAAD cis rs4835473 0.736 rs11724009 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143984291 chr4:143912331~143982454:+ PAAD cis rs4323050 0.514 rs28647406 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 High light scatter reticulocyte percentage of red cells; chr4:143984437 chr4:143912331~143982454:+ PAAD cis rs4835473 0.604 rs11938387 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143984476 chr4:143912331~143982454:+ PAAD cis rs4835473 0.798 rs11100829 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143984761 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1511425 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143985122 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1849120 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143985337 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4835476 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143985517 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1828502 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143985797 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs7668698 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143986333 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6537231 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143986489 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1877234 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143986774 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs6852502 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143987174 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4260486 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143987556 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4287958 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143987719 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs4125545 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143988650 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs12649594 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143989307 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs13101482 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143989463 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs13135472 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143989465 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1849118 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143989822 chr4:143912331~143982454:+ PAAD cis rs4835473 0.663 rs1511423 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143990136 chr4:143912331~143982454:+ PAAD cis rs4835473 0.639 rs5029916 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143990684 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs1988206 ENSG00000251600.4 RP11-673E1.1 4.16 5.38e-05 0.0205 0.38 0.32 Immature fraction of reticulocytes; chr4:143991344 chr4:143912331~143982454:+ PAAD cis rs748404 0.666 rs12900259 ENSG00000205771.5 CATSPER2P1 -4.16 5.38e-05 0.0205 -0.52 -0.32 Lung cancer; chr15:43427369 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs34921640 ENSG00000205771.5 CATSPER2P1 -4.16 5.38e-05 0.0205 -0.52 -0.32 Lung cancer; chr15:43429187 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs62020574 ENSG00000205771.5 CATSPER2P1 -4.16 5.38e-05 0.0205 -0.52 -0.32 Lung cancer; chr15:43429380 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs16957730 ENSG00000205771.5 CATSPER2P1 -4.16 5.38e-05 0.0205 -0.52 -0.32 Lung cancer; chr15:43438288 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs12913977 ENSG00000205771.5 CATSPER2P1 -4.16 5.38e-05 0.0205 -0.52 -0.32 Lung cancer; chr15:43438913 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs12914122 ENSG00000205771.5 CATSPER2P1 -4.16 5.38e-05 0.0205 -0.52 -0.32 Lung cancer; chr15:43438956 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs34697113 ENSG00000205771.5 CATSPER2P1 -4.16 5.38e-05 0.0205 -0.52 -0.32 Lung cancer; chr15:43442041 chr15:43726918~43747094:- PAAD cis rs987724 0.515 rs9876148 ENSG00000240875.4 LINC00886 -4.16 5.38e-05 0.0205 -0.47 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156894349 chr3:156747346~156817062:- PAAD cis rs987724 0.515 rs6762708 ENSG00000240875.4 LINC00886 4.16 5.38e-05 0.0205 0.47 0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156973815 chr3:156747346~156817062:- PAAD cis rs2708377 0.656 rs116607079 ENSG00000212125.2 TAS2R15P 4.16 5.38e-05 0.0205 0.51 0.32 Bitter taste perception; chr12:11109445 chr12:10964425~10965352:- PAAD cis rs2708377 0.929 rs73066828 ENSG00000212125.2 TAS2R15P 4.16 5.38e-05 0.0205 0.51 0.32 Bitter taste perception; chr12:11118055 chr12:10964425~10965352:- PAAD cis rs2708377 0.656 rs73066852 ENSG00000212125.2 TAS2R15P 4.16 5.38e-05 0.0205 0.51 0.32 Bitter taste perception; chr12:11123942 chr12:10964425~10965352:- PAAD cis rs2708377 0.858 rs117212341 ENSG00000212125.2 TAS2R15P 4.16 5.38e-05 0.0205 0.51 0.32 Bitter taste perception; chr12:11129957 chr12:10964425~10965352:- PAAD cis rs2708377 0.858 rs68045377 ENSG00000212125.2 TAS2R15P 4.16 5.38e-05 0.0205 0.51 0.32 Bitter taste perception; chr12:11141853 chr12:10964425~10965352:- PAAD cis rs2708377 0.858 rs115781584 ENSG00000212125.2 TAS2R15P 4.16 5.38e-05 0.0205 0.51 0.32 Bitter taste perception; chr12:11151961 chr12:10964425~10965352:- PAAD cis rs9326248 0.559 rs573549 ENSG00000280143.1 AP000892.6 4.16 5.39e-05 0.0206 0.37 0.32 Blood protein levels; chr11:116865963 chr11:117204967~117210292:+ PAAD cis rs9847710 0.67 rs36051354 ENSG00000242142.1 SERBP1P3 4.16 5.39e-05 0.0206 0.39 0.32 Ulcerative colitis; chr3:52951996 chr3:53064283~53065091:- PAAD cis rs4835473 0.897 rs7676614 ENSG00000251600.4 RP11-673E1.1 -4.16 5.39e-05 0.0206 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143695213 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs7681559 ENSG00000251600.4 RP11-673E1.1 -4.16 5.39e-05 0.0206 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143695248 chr4:143912331~143982454:+ PAAD cis rs4835473 0.832 rs55935372 ENSG00000251600.4 RP11-673E1.1 -4.16 5.39e-05 0.0206 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143700626 chr4:143912331~143982454:+ PAAD cis rs10740039 0.81 rs2165691 ENSG00000254271.1 RP11-131N11.4 4.16 5.39e-05 0.0206 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60611891 chr10:60734342~60741828:+ PAAD cis rs10740039 0.768 rs10821801 ENSG00000254271.1 RP11-131N11.4 4.16 5.39e-05 0.0206 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60612017 chr10:60734342~60741828:+ PAAD cis rs10740039 0.81 rs1442543 ENSG00000254271.1 RP11-131N11.4 4.16 5.39e-05 0.0206 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60613704 chr10:60734342~60741828:+ PAAD cis rs10740039 0.81 rs4440977 ENSG00000254271.1 RP11-131N11.4 4.16 5.39e-05 0.0206 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60618163 chr10:60734342~60741828:+ PAAD cis rs875971 0.54 rs781152 ENSG00000234585.5 CCT6P3 4.16 5.4e-05 0.0206 0.26 0.32 Aortic root size; chr7:66014585 chr7:65038354~65074713:+ PAAD cis rs17711722 0.727 rs781151 ENSG00000234585.5 CCT6P3 4.16 5.4e-05 0.0206 0.26 0.32 Calcium levels; chr7:66014891 chr7:65038354~65074713:+ PAAD cis rs875971 1 rs6961717 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66122550 chr7:66554588~66576923:- PAAD cis rs875971 1 rs2087647 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66128201 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6958484 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66134459 chr7:66554588~66576923:- PAAD cis rs875971 1 rs4718307 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66146001 chr7:66554588~66576923:- PAAD cis rs875971 1 rs7801282 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66148700 chr7:66554588~66576923:- PAAD cis rs875971 1 rs875971 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66152608 chr7:66554588~66576923:- PAAD cis rs875971 1 rs55962648 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66160764 chr7:66554588~66576923:- PAAD cis rs875971 1 rs11974219 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66182423 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1565531 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66198126 chr7:66554588~66576923:- PAAD cis rs875971 1 rs6963646 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66220780 chr7:66554588~66576923:- PAAD cis rs875971 0.965 rs28682868 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66224822 chr7:66554588~66576923:- PAAD cis rs875971 1 rs9986696 ENSG00000232559.3 GS1-124K5.12 -4.16 5.4e-05 0.0206 -0.34 -0.32 Aortic root size; chr7:66239589 chr7:66554588~66576923:- PAAD cis rs9326248 0.581 rs4938331 ENSG00000280143.1 AP000892.6 4.16 5.4e-05 0.0206 0.35 0.32 Blood protein levels; chr11:117059966 chr11:117204967~117210292:+ PAAD cis rs9326248 0.51 rs4938332 ENSG00000280143.1 AP000892.6 4.16 5.4e-05 0.0206 0.35 0.32 Blood protein levels; chr11:117060082 chr11:117204967~117210292:+ PAAD cis rs9326248 0.559 rs4938334 ENSG00000280143.1 AP000892.6 4.16 5.4e-05 0.0206 0.35 0.32 Blood protein levels; chr11:117060326 chr11:117204967~117210292:+ PAAD cis rs8072100 0.935 rs12150231 ENSG00000228782.6 CTD-2026D20.3 -4.16 5.4e-05 0.0206 -0.31 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47639725 chr17:47450568~47492492:- PAAD cis rs4268898 0.582 rs1559472 ENSG00000242628.4 AC009228.1 -4.16 5.41e-05 0.0206 -0.37 -0.32 Asthma; chr2:24232961 chr2:24214381~24221516:+ PAAD cis rs9813712 0.595 rs12490957 ENSG00000228252.7 COL6A4P2 4.15 5.41e-05 0.0206 0.39 0.32 Response to amphetamines; chr3:130287851 chr3:130212823~130273806:+ PAAD cis rs6437061 0.614 rs1000837 ENSG00000238062.4 SPATA3-AS1 -4.15 5.41e-05 0.0206 -0.41 -0.32 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction); chr2:231955461 chr2:230984368~230996032:- PAAD cis rs2281636 1 rs2231675 ENSG00000233690.1 EBAG9P1 -4.15 5.41e-05 0.0206 -0.34 -0.32 Obesity-related traits; chr10:99732484 chr10:99697407~99697949:- PAAD cis rs2281636 1 rs2281636 ENSG00000233690.1 EBAG9P1 -4.15 5.41e-05 0.0206 -0.34 -0.32 Obesity-related traits; chr10:99732646 chr10:99697407~99697949:- PAAD cis rs2281636 0.965 rs2006077 ENSG00000233690.1 EBAG9P1 -4.15 5.41e-05 0.0206 -0.34 -0.32 Obesity-related traits; chr10:99733076 chr10:99697407~99697949:- PAAD cis rs494459 0.691 rs607472 ENSG00000278376.1 RP11-158I9.8 -4.15 5.41e-05 0.0206 -0.28 -0.32 Height; chr11:118809363 chr11:118791254~118793137:+ PAAD cis rs1799810 0.523 rs11683986 ENSG00000236682.1 AC068282.3 4.15 5.42e-05 0.0206 0.45 0.32 Self-rated health; chr2:127438822 chr2:127389130~127400580:+ PAAD cis rs2739330 0.796 rs2154594 ENSG00000206090.4 AP000350.7 -4.15 5.42e-05 0.0207 -0.41 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23939998~23942798:+ PAAD cis rs10510102 0.623 rs10159856 ENSG00000276742.1 RP11-500G22.4 4.15 5.42e-05 0.0207 0.46 0.32 Breast cancer; chr10:121988292 chr10:121956782~121957098:+ PAAD cis rs2408955 0.542 rs7975632 ENSG00000240399.1 RP1-228P16.1 4.15 5.43e-05 0.0207 0.34 0.32 Glycated hemoglobin levels; chr12:48049265 chr12:48054813~48055591:- PAAD cis rs2739330 0.828 rs2186366 ENSG00000206090.4 AP000350.7 -4.15 5.43e-05 0.0207 -0.4 -0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23939998~23942798:+ PAAD cis rs2904804 0.506 rs10751995 ENSG00000224251.5 RP11-499O7.7 4.15 5.43e-05 0.0207 0.35 0.32 Economic and political preferences (immigration/crime); chr10:4925954 chr10:4995488~4997380:+ PAAD cis rs2904804 0.506 rs4427477 ENSG00000224251.5 RP11-499O7.7 4.15 5.43e-05 0.0207 0.35 0.32 Economic and political preferences (immigration/crime); chr10:4926905 chr10:4995488~4997380:+ PAAD cis rs10740039 0.81 rs10761528 ENSG00000254271.1 RP11-131N11.4 4.15 5.44e-05 0.0207 0.4 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60607902 chr10:60734342~60741828:+ PAAD cis rs9326248 0.731 rs90192 ENSG00000280143.1 AP000892.6 4.15 5.44e-05 0.0207 0.44 0.32 Blood protein levels; chr11:117188631 chr11:117204967~117210292:+ PAAD cis rs4853525 0.859 rs11897136 ENSG00000235852.1 AC005540.3 4.15 5.44e-05 0.0207 0.42 0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190846354 chr2:190880797~190882059:- PAAD cis rs2188561 0.673 rs2712218 ENSG00000241764.3 AC002467.7 4.15 5.44e-05 0.0207 0.42 0.32 Alcohol consumption; chr7:107716314 chr7:107742817~107744581:- PAAD cis rs7216064 0.953 rs4791046 ENSG00000278219.1 AC145343.1 -4.15 5.44e-05 0.0207 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67855857 chr17:68101538~68101639:+ PAAD cis rs496547 0.686 rs524590 ENSG00000278376.1 RP11-158I9.8 -4.15 5.44e-05 0.0207 -0.29 -0.32 Hip minimal joint space width; chr11:118769354 chr11:118791254~118793137:+ PAAD cis rs7487075 1 rs12832425 ENSG00000270429.1 KNOP1P2 4.15 5.44e-05 0.0207 0.37 0.32 Itch intensity from mosquito bite; chr12:46429035 chr12:45880950~45882266:- PAAD cis rs7487075 1 rs12814341 ENSG00000270429.1 KNOP1P2 4.15 5.44e-05 0.0207 0.37 0.32 Itch intensity from mosquito bite; chr12:46429489 chr12:45880950~45882266:- PAAD cis rs7487075 0.93 rs4768121 ENSG00000270429.1 KNOP1P2 4.15 5.44e-05 0.0207 0.37 0.32 Itch intensity from mosquito bite; chr12:46436069 chr12:45880950~45882266:- PAAD cis rs7487075 1 rs7301001 ENSG00000270429.1 KNOP1P2 4.15 5.44e-05 0.0207 0.37 0.32 Itch intensity from mosquito bite; chr12:46437058 chr12:45880950~45882266:- PAAD cis rs9322193 0.962 rs6899661 ENSG00000268592.3 RAET1E-AS1 4.15 5.45e-05 0.0208 0.38 0.32 Lung cancer; chr6:149818093 chr6:149863494~149919507:+ PAAD cis rs10050311 0.79 rs72667716 ENSG00000251411.1 RP11-397E7.4 -4.15 5.45e-05 0.0208 -0.38 -0.32 Insulin-related traits; chr4:86912775 chr4:86913266~86914817:- PAAD cis rs10050311 0.79 rs61651372 ENSG00000251411.1 RP11-397E7.4 -4.15 5.45e-05 0.0208 -0.38 -0.32 Insulin-related traits; chr4:86912903 chr4:86913266~86914817:- PAAD cis rs2708377 0.789 rs3911150 ENSG00000247157.5 LINC01252 -4.15 5.45e-05 0.0208 -0.55 -0.32 Bitter taste perception; chr12:11049649 chr12:11548030~11590369:+ PAAD cis rs896655 1 rs10811590 ENSG00000266446.1 RP11-149I2.4 -4.15 5.45e-05 0.0208 -0.4 -0.32 Coronary artery disease; chr9:21708884 chr9:21995482~21996013:+ PAAD cis rs58123204 1 rs58123204 ENSG00000257379.1 RP11-793H13.8 4.15 5.45e-05 0.0208 0.48 0.32 Mean corpuscular hemoglobin; chr12:53366378 chr12:53441741~53467528:+ PAAD cis rs763121 0.706 rs3827356 ENSG00000228274.3 RP3-508I15.9 4.15 5.45e-05 0.0208 0.3 0.32 Menopause (age at onset); chr22:38668801 chr22:38667585~38681820:- PAAD cis rs9487094 0.67 rs749517 ENSG00000260273.1 RP11-425D10.10 -4.15 5.45e-05 0.0208 -0.38 -0.32 Height; chr6:109531713 chr6:109382795~109383666:+ PAAD cis rs6061231 0.546 rs482220 ENSG00000273619.1 RP5-908M14.9 4.15 5.45e-05 0.0208 0.27 0.32 Colorectal cancer; chr20:62352426 chr20:62386303~62386970:- PAAD cis rs2522056 1 rs10900807 ENSG00000233006.5 AC034220.3 -4.15 5.45e-05 0.0208 -0.29 -0.32 Fibrinogen;Lymphocyte counts; chr5:132421788 chr5:132311285~132369916:- PAAD cis rs2729354 0.729 rs2258835 ENSG00000265566.2 RN7SL605P -4.15 5.46e-05 0.0208 -0.4 -0.32 Blood protein levels; chr11:57476115 chr11:57528085~57528365:- PAAD cis rs2638953 0.889 rs11049538 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28335801 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049540 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28337959 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049541 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28341781 chr12:28163298~28190738:- PAAD cis rs2638953 0.889 rs11049543 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28342124 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049544 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28342348 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs11049545 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28344965 chr12:28163298~28190738:- PAAD cis rs2638953 0.889 rs10843157 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28346417 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049547 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28346945 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049548 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28350789 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs10843159 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28354597 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs11049549 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28357808 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049550 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28358591 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049552 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28361466 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049553 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28361611 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049554 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28362819 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs12371222 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28363245 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049555 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28364919 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049556 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28365626 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049558 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28371438 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs11049563 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28376041 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs61920565 ENSG00000247934.4 RP11-967K21.1 -4.15 5.46e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28377192 chr12:28163298~28190738:- PAAD cis rs7202877 0.561 rs2865532 ENSG00000261783.1 RP11-252K23.2 -4.15 5.46e-05 0.0208 -0.51 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75317077 chr16:75379818~75381260:- PAAD cis rs6743226 0.603 rs11678750 ENSG00000266621.1 AC104841.1 4.15 5.46e-05 0.0208 0.38 0.32 Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in non-smokers; chr2:241261504 chr2:241245202~241245299:- PAAD cis rs7572733 0.534 rs700680 ENSG00000231621.1 AC013264.2 4.15 5.46e-05 0.0208 0.32 0.32 Dermatomyositis; chr2:197843226 chr2:197197991~197199273:+ PAAD cis rs2439831 0.85 rs12702 ENSG00000205771.5 CATSPER2P1 4.15 5.46e-05 0.0208 0.43 0.32 Lung cancer in ever smokers; chr15:43801729 chr15:43726918~43747094:- PAAD cis rs72843506 0.656 rs73981807 ENSG00000189423.10 USP32P3 4.15 5.47e-05 0.0208 0.46 0.32 Schizophrenia; chr17:20092917 chr17:20415547~20431008:+ PAAD cis rs4853012 0.838 rs6707729 ENSG00000257800.1 FNBP1P1 4.15 5.47e-05 0.0208 0.44 0.32 Gestational age at birth (maternal effect); chr2:74117558 chr2:74120680~74123218:+ PAAD cis rs3747517 0.651 rs1549020 ENSG00000226121.2 AC009487.6 -4.15 5.47e-05 0.0208 -0.39 -0.32 Psoriasis; chr2:162384337 chr2:161500885~161507705:- PAAD cis rs1275411 0.511 rs4902683 ENSG00000259062.2 ACTN1-AS1 4.15 5.47e-05 0.0208 0.4 0.32 Neuroticism; chr14:68976131 chr14:68979682~68987463:+ PAAD cis rs2638953 0.64 rs11049721 ENSG00000247934.4 RP11-967K21.1 -4.15 5.47e-05 0.0208 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28573743 chr12:28163298~28190738:- PAAD cis rs11997175 0.692 rs6995075 ENSG00000240738.1 RP1-273G13.1 4.15 5.47e-05 0.0208 0.37 0.32 Body mass index; chr8:33816298 chr8:33859480~33860223:- PAAD cis rs6479891 1 rs9415705 ENSG00000232075.1 MRPL35P2 4.15 5.48e-05 0.0208 0.51 0.32 Arthritis (juvenile idiopathic); chr10:63401790 chr10:63634317~63634827:- PAAD cis rs8005677 1 rs4982712 ENSG00000279656.1 RP11-298I3.6 4.15 5.48e-05 0.0209 0.39 0.32 Cognitive ability (multi-trait analysis); chr14:22934519 chr14:23023083~23024217:- PAAD cis rs75804782 0.63 rs57033609 ENSG00000186235.9 AC016757.3 4.15 5.48e-05 0.0209 0.75 0.32 Chronotype;Morning vs. evening chronotype; chr2:238319871 chr2:238224552~238231677:- PAAD cis rs7712401 0.562 rs2407403 ENSG00000263432.2 RN7SL689P 4.15 5.48e-05 0.0209 0.39 0.32 Mean platelet volume; chr5:122838336 chr5:123022487~123022783:- PAAD cis rs11089937 0.651 rs6001216 ENSG00000211640.3 IGLV6-57 4.15 5.48e-05 0.0209 0.21 0.32 Periodontitis (PAL4Q3); chr22:22183755 chr22:22195713~22196460:+ PAAD cis rs11089937 0.651 rs6001217 ENSG00000211640.3 IGLV6-57 4.15 5.48e-05 0.0209 0.21 0.32 Periodontitis (PAL4Q3); chr22:22183804 chr22:22195713~22196460:+ PAAD cis rs11089937 0.521 rs6001221 ENSG00000211640.3 IGLV6-57 4.15 5.48e-05 0.0209 0.21 0.32 Periodontitis (PAL4Q3); chr22:22185176 chr22:22195713~22196460:+ PAAD cis rs10276381 0.786 rs10281102 ENSG00000234336.5 JAZF1-AS1 -4.15 5.48e-05 0.0209 -0.45 -0.32 Crohn's disease; chr7:28203854 chr7:28180322~28243917:+ PAAD cis rs12439619 0.883 rs62012045 ENSG00000255769.6 GOLGA2P10 -4.15 5.48e-05 0.0209 -0.37 -0.32 Intelligence (multi-trait analysis); chr15:82229366 chr15:82472993~82513950:- PAAD cis rs12439619 0.921 rs56042848 ENSG00000255769.6 GOLGA2P10 -4.15 5.48e-05 0.0209 -0.37 -0.32 Intelligence (multi-trait analysis); chr15:82235244 chr15:82472993~82513950:- PAAD cis rs7615952 0.688 rs12638240 ENSG00000171084.14 FAM86JP 4.15 5.49e-05 0.0209 0.43 0.32 Blood pressure (smoking interaction); chr3:125822395 chr3:125916620~125930024:+ PAAD cis rs7615952 0.688 rs12638224 ENSG00000171084.14 FAM86JP 4.15 5.49e-05 0.0209 0.43 0.32 Blood pressure (smoking interaction); chr3:125822477 chr3:125916620~125930024:+ PAAD cis rs7182621 0.512 rs34151878 ENSG00000182397.13 DNM1P46 4.15 5.49e-05 0.0209 0.4 0.32 Colonoscopy-negative controls vs population controls; chr15:99869179 chr15:99790156~99806927:- PAAD cis rs7182621 0.512 rs12903892 ENSG00000182397.13 DNM1P46 4.15 5.49e-05 0.0209 0.4 0.32 Colonoscopy-negative controls vs population controls; chr15:99869662 chr15:99790156~99806927:- PAAD cis rs1113500 0.836 rs1618973 ENSG00000226822.1 RP11-356N1.2 -4.15 5.49e-05 0.0209 -0.37 -0.32 Growth-regulated protein alpha levels; chr1:108044145 chr1:108071482~108074519:+ PAAD cis rs12908161 1 rs12911736 ENSG00000259728.4 LINC00933 4.15 5.49e-05 0.0209 0.4 0.32 Schizophrenia; chr15:84696777 chr15:84570649~84580175:+ PAAD cis rs10740039 0.583 rs9415613 ENSG00000254271.1 RP11-131N11.4 -4.15 5.49e-05 0.0209 -0.43 -0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60747636 chr10:60734342~60741828:+ PAAD cis rs9847710 0.696 rs62253605 ENSG00000242142.1 SERBP1P3 4.15 5.49e-05 0.0209 0.39 0.32 Ulcerative colitis; chr3:52944402 chr3:53064283~53065091:- PAAD cis rs4853012 0.838 rs2177707 ENSG00000257800.1 FNBP1P1 4.15 5.49e-05 0.0209 0.47 0.32 Gestational age at birth (maternal effect); chr2:74129723 chr2:74120680~74123218:+ PAAD cis rs4853012 0.887 rs2280642 ENSG00000257800.1 FNBP1P1 4.15 5.49e-05 0.0209 0.47 0.32 Gestational age at birth (maternal effect); chr2:74131125 chr2:74120680~74123218:+ PAAD cis rs41369048 0.858 rs1572384 ENSG00000238078.1 LINC01352 -4.15 5.49e-05 0.0209 -0.43 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220907383 chr1:220829255~220832429:+ PAAD cis rs41369048 0.858 rs2784273 ENSG00000238078.1 LINC01352 -4.15 5.49e-05 0.0209 -0.43 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220907744 chr1:220829255~220832429:+ PAAD cis rs638893 0.588 rs2156755 ENSG00000278376.1 RP11-158I9.8 -4.15 5.49e-05 0.0209 -0.34 -0.32 Vitiligo; chr11:118855521 chr11:118791254~118793137:+ PAAD cis rs755249 0.501 rs2484749 ENSG00000261798.1 RP1-118J21.25 -4.15 5.5e-05 0.0209 -0.38 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39293283 chr1:39788976~39790171:+ PAAD cis rs9322193 0.962 rs12175575 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149763351 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs4869966 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149763714 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs1112730 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149766383 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs1112729 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149766491 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs10452626 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149767481 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs62441303 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149767547 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9765929 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149769680 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs11155683 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149779341 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9372044 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149780867 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs11155685 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149781649 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9322220 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149782897 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs10214845 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149783124 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9767122 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149783553 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs1413654 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149783956 chr6:149863494~149919507:+ PAAD cis rs9322193 0.683 rs113281309 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149787289 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9688809 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149787920 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9689242 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149787970 chr6:149863494~149919507:+ PAAD cis rs9322193 1 rs9767077 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149788479 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9688938 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149788941 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9688940 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149788977 chr6:149863494~149919507:+ PAAD cis rs9322193 0.632 rs3828700 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149791033 chr6:149863494~149919507:+ PAAD cis rs9322193 0.736 rs3828701 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149791063 chr6:149863494~149919507:+ PAAD cis rs9322193 0.736 rs3805750 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149791065 chr6:149863494~149919507:+ PAAD cis rs9322193 0.926 rs3805751 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149791193 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9689269 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149791861 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs62441335 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149792658 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs4816 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149793609 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs3805753 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149795662 chr6:149863494~149919507:+ PAAD cis rs9322193 0.926 rs952166 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149798774 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs952165 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149798900 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs10872656 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149799444 chr6:149863494~149919507:+ PAAD cis rs9322193 0.926 rs9285525 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149801253 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs2342858 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149805967 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs6914319 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149806304 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs2095375 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149807037 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs4869730 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149808187 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs11155689 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149808470 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs2151913 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149809506 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs933055 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149809701 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs4869731 ENSG00000268592.3 RAET1E-AS1 4.15 5.5e-05 0.0209 0.38 0.32 Lung cancer; chr6:149810072 chr6:149863494~149919507:+ PAAD cis rs9649213 0.593 rs1132971 ENSG00000272950.1 RP11-307C18.1 4.15 5.5e-05 0.0209 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98292221 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6465664 ENSG00000272950.1 RP11-307C18.1 4.15 5.5e-05 0.0209 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98292522 chr7:98322853~98323430:+ PAAD cis rs7219451 0.655 rs11869809 ENSG00000222881.1 Y_RNA -4.15 5.5e-05 0.0209 -0.39 -0.32 Glucose homeostasis traits; chr17:40804870 chr17:40391232~40391338:- PAAD cis rs7260598 0.792 rs11669295 ENSG00000268442.1 CTD-2027I19.2 4.15 5.51e-05 0.0209 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24154184 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs11670299 ENSG00000268442.1 CTD-2027I19.2 4.15 5.51e-05 0.0209 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24154959 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs11670331 ENSG00000268442.1 CTD-2027I19.2 4.15 5.51e-05 0.0209 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24155040 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs11671489 ENSG00000268442.1 CTD-2027I19.2 4.15 5.51e-05 0.0209 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24156070 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs60773823 ENSG00000268442.1 CTD-2027I19.2 4.15 5.51e-05 0.0209 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24156730 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs10500223 ENSG00000268442.1 CTD-2027I19.2 4.15 5.51e-05 0.0209 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24163222 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs73029291 ENSG00000268442.1 CTD-2027I19.2 4.15 5.51e-05 0.0209 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24171866 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs17620048 ENSG00000268442.1 CTD-2027I19.2 4.15 5.51e-05 0.0209 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24174677 chr19:24162370~24163425:- PAAD cis rs12439619 0.693 rs9944185 ENSG00000255769.6 GOLGA2P10 -4.15 5.51e-05 0.0209 -0.37 -0.32 Intelligence (multi-trait analysis); chr15:82157927 chr15:82472993~82513950:- PAAD cis rs2776353 0.513 rs2309100 ENSG00000280109.1 PLAC4 -4.15 5.51e-05 0.0209 -0.34 -0.32 Basal cell carcinoma; chr21:41665830 chr21:41175231~41185239:- PAAD cis rs9419788 0.845 rs10882407 ENSG00000233377.1 MTND4P20 4.15 5.51e-05 0.0209 0.29 0.32 Personality traits in bipolar disorder; chr10:94217254 chr10:94940253~94941121:- PAAD cis rs2638953 0.962 rs10506032 ENSG00000247934.4 RP11-967K21.1 -4.15 5.51e-05 0.021 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28384177 chr12:28163298~28190738:- PAAD cis rs12682352 0.602 rs4841044 ENSG00000253893.2 FAM85B 4.15 5.52e-05 0.021 0.47 0.32 Neuroticism; chr8:8807430 chr8:8167819~8226614:- PAAD cis rs3096299 0.563 rs4600467 ENSG00000261253.2 AC137932.6 4.15 5.52e-05 0.021 0.35 0.32 Multiple myeloma (IgH translocation); chr16:89496108 chr16:89321133~89325110:+ PAAD cis rs11070836 1 rs11070836 ENSG00000259240.1 RP11-108K3.1 -4.15 5.52e-05 0.021 -0.35 -0.32 Airway wall thickness; chr15:51144200 chr15:51037488~51293912:+ PAAD cis rs11070836 1 rs11070837 ENSG00000259240.1 RP11-108K3.1 -4.15 5.52e-05 0.021 -0.35 -0.32 Airway wall thickness; chr15:51148690 chr15:51037488~51293912:+ PAAD cis rs28374715 0.609 rs8043237 ENSG00000247556.5 OIP5-AS1 4.15 5.52e-05 0.021 0.33 0.32 Ulcerative colitis; chr15:41222100 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs72737792 ENSG00000247556.5 OIP5-AS1 4.15 5.52e-05 0.021 0.33 0.32 Ulcerative colitis; chr15:41223391 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs72737793 ENSG00000247556.5 OIP5-AS1 4.15 5.52e-05 0.021 0.33 0.32 Ulcerative colitis; chr15:41224625 chr15:41283990~41309737:+ PAAD cis rs6908034 0.654 rs6456272 ENSG00000228412.5 RP4-625H18.2 -4.15 5.53e-05 0.021 -0.53 -0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19804805 chr6:19802164~19804752:- PAAD cis rs3738443 0.904 rs12569090 ENSG00000259865.1 RP11-488L18.10 4.15 5.53e-05 0.021 0.29 0.32 Alcohol dependence; chr1:247234370 chr1:247187281~247188526:- PAAD cis rs11089937 0.626 rs5757011 ENSG00000211638.2 IGLV8-61 -4.15 5.53e-05 0.021 -0.3 -0.32 Periodontitis (PAL4Q3); chr22:22135336 chr22:22098700~22099212:+ PAAD cis rs11089937 0.626 rs5757013 ENSG00000211638.2 IGLV8-61 -4.15 5.53e-05 0.021 -0.3 -0.32 Periodontitis (PAL4Q3); chr22:22135544 chr22:22098700~22099212:+ PAAD cis rs11089937 0.626 rs5757014 ENSG00000211638.2 IGLV8-61 -4.15 5.53e-05 0.021 -0.3 -0.32 Periodontitis (PAL4Q3); chr22:22135612 chr22:22098700~22099212:+ PAAD cis rs7712401 0.601 rs30027 ENSG00000263432.2 RN7SL689P 4.15 5.53e-05 0.021 0.41 0.32 Mean platelet volume; chr5:122947695 chr5:123022487~123022783:- PAAD cis rs8072100 0.905 rs8077106 ENSG00000228782.6 CTD-2026D20.3 -4.15 5.54e-05 0.021 -0.31 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47575925 chr17:47450568~47492492:- PAAD cis rs8072100 0.754 rs8081717 ENSG00000228782.6 CTD-2026D20.3 -4.15 5.54e-05 0.021 -0.31 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47576555 chr17:47450568~47492492:- PAAD cis rs4660214 0.666 rs2275186 ENSG00000237624.1 OXCT2P1 -4.15 5.54e-05 0.021 -0.41 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39300383 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs12025847 ENSG00000237624.1 OXCT2P1 -4.15 5.54e-05 0.021 -0.41 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39300977 chr1:39514956~39516490:+ PAAD cis rs9807989 0.507 rs2310300 ENSG00000234389.1 AC007278.3 4.15 5.54e-05 0.021 0.33 0.32 Asthma; chr2:102432614 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs7581119 ENSG00000234389.1 AC007278.3 4.15 5.54e-05 0.021 0.33 0.32 Asthma; chr2:102433405 chr2:102438713~102440475:+ PAAD cis rs748404 0.586 rs2584700 ENSG00000205771.5 CATSPER2P1 -4.15 5.54e-05 0.021 -0.44 -0.32 Lung cancer; chr15:43393134 chr15:43726918~43747094:- PAAD cis rs7617773 0.694 rs13099560 ENSG00000228638.1 FCF1P2 4.15 5.54e-05 0.021 0.35 0.32 Coronary artery disease; chr3:48163278 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs11130163 ENSG00000228638.1 FCF1P2 -4.15 5.54e-05 0.021 -0.35 -0.32 Coronary artery disease; chr3:48271168 chr3:48290793~48291375:- PAAD cis rs763121 0.853 rs2267395 ENSG00000228274.3 RP3-508I15.9 -4.15 5.54e-05 0.021 -0.31 -0.32 Menopause (age at onset); chr22:38717898 chr22:38667585~38681820:- PAAD cis rs633715 0.531 rs527065 ENSG00000254154.7 RP4-798P15.3 -4.15 5.54e-05 0.021 -0.24 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177899747 chr1:177928788~178038007:- PAAD cis rs633715 0.531 rs685233 ENSG00000254154.7 RP4-798P15.3 -4.15 5.54e-05 0.021 -0.24 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177900806 chr1:177928788~178038007:- PAAD cis rs633715 0.531 rs623130 ENSG00000254154.7 RP4-798P15.3 -4.15 5.54e-05 0.021 -0.24 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177902751 chr1:177928788~178038007:- PAAD cis rs633715 0.531 rs576101 ENSG00000254154.7 RP4-798P15.3 -4.15 5.54e-05 0.021 -0.24 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177904248 chr1:177928788~178038007:- PAAD cis rs498136 0.8 rs659612 ENSG00000250508.1 RP11-757G1.6 4.15 5.55e-05 0.0211 0.43 0.32 Cutaneous malignant melanoma;Melanoma; chr11:69535460 chr11:68870664~68874542:+ PAAD cis rs6142102 0.961 rs8119937 ENSG00000276073.1 RP5-1125A11.7 -4.15 5.55e-05 0.0211 -0.34 -0.32 Skin pigmentation; chr20:34057745 chr20:33985617~33988989:- PAAD cis rs12480328 1 rs6091233 ENSG00000203999.7 LINC01270 4.15 5.55e-05 0.0211 0.7 0.32 Prostate cancer; chr20:50895370 chr20:50292720~50314922:+ PAAD cis rs7712401 0.54 rs27617 ENSG00000263432.2 RN7SL689P 4.15 5.55e-05 0.0211 0.41 0.32 Mean platelet volume; chr5:122900839 chr5:123022487~123022783:- PAAD cis rs28386778 0.897 rs4968597 ENSG00000240280.5 TCAM1P -4.15 5.56e-05 0.0211 -0.44 -0.32 Prudent dietary pattern; chr17:63728387 chr17:63849292~63864379:+ PAAD cis rs11976180 1 rs2951363 ENSG00000273234.1 OR2A13P -4.15 5.56e-05 0.0211 -0.39 -0.32 Obesity-related traits; chr7:144057631 chr7:144142009~144142938:+ PAAD cis rs1707322 0.682 rs10890334 ENSG00000280836.1 AL355480.1 -4.15 5.56e-05 0.0211 -0.37 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634706 chr1:45581219~45581321:- PAAD cis rs1707322 0.682 rs10890335 ENSG00000280836.1 AL355480.1 -4.15 5.56e-05 0.0211 -0.37 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634722 chr1:45581219~45581321:- PAAD cis rs6046396 1 rs6046396 ENSG00000275142.1 RP5-999L4.2 4.15 5.56e-05 0.0211 0.43 0.32 Bipolar disorder and schizophrenia; chr20:19871859 chr20:19871891~19872284:+ PAAD cis rs7615952 0.932 rs11922218 ENSG00000241288.6 RP11-379B18.5 -4.15 5.56e-05 0.0211 -0.34 -0.32 Blood pressure (smoking interaction); chr3:125912446 chr3:125827238~125916384:- PAAD cis rs7615952 0.866 rs11922276 ENSG00000241288.6 RP11-379B18.5 -4.15 5.56e-05 0.0211 -0.34 -0.32 Blood pressure (smoking interaction); chr3:125912483 chr3:125827238~125916384:- PAAD cis rs7572733 0.534 rs700670 ENSG00000231621.1 AC013264.2 -4.15 5.56e-05 0.0211 -0.32 -0.32 Dermatomyositis; chr2:197822560 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs700671 ENSG00000231621.1 AC013264.2 -4.15 5.56e-05 0.0211 -0.32 -0.32 Dermatomyositis; chr2:197825277 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs771009 ENSG00000231621.1 AC013264.2 -4.15 5.56e-05 0.0211 -0.32 -0.32 Dermatomyositis; chr2:197826358 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700672 ENSG00000231621.1 AC013264.2 -4.15 5.56e-05 0.0211 -0.32 -0.32 Dermatomyositis; chr2:197826731 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700673 ENSG00000231621.1 AC013264.2 -4.15 5.56e-05 0.0211 -0.32 -0.32 Dermatomyositis; chr2:197828205 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs700674 ENSG00000231621.1 AC013264.2 -4.15 5.56e-05 0.0211 -0.32 -0.32 Dermatomyositis; chr2:197828979 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs700675 ENSG00000231621.1 AC013264.2 -4.15 5.56e-05 0.0211 -0.32 -0.32 Dermatomyositis; chr2:197835492 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs2574832 ENSG00000231621.1 AC013264.2 -4.15 5.56e-05 0.0211 -0.32 -0.32 Dermatomyositis; chr2:197840094 chr2:197197991~197199273:+ PAAD cis rs42490 0.625 rs427854 ENSG00000251136.7 RP11-37B2.1 -4.15 5.57e-05 0.0211 -0.3 -0.32 Leprosy; chr8:89843518 chr8:89609409~89757727:- PAAD cis rs4853012 0.887 rs2122290 ENSG00000257800.1 FNBP1P1 4.15 5.57e-05 0.0211 0.47 0.32 Gestational age at birth (maternal effect); chr2:74131774 chr2:74120680~74123218:+ PAAD cis rs2333194 1 rs177377 ENSG00000258695.2 RP3-414A15.2 -4.15 5.57e-05 0.0211 -0.36 -0.32 Bipolar disorder with mood-incongruent psychosis; chr14:73286811 chr14:73522878~73530610:+ PAAD cis rs72627509 0.951 rs72627508 ENSG00000269949.1 RP11-738E22.3 4.15 5.57e-05 0.0211 0.49 0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56965398 chr4:56960927~56961373:- PAAD cis rs12701220 0.522 rs12701455 ENSG00000229043.2 AC091729.9 -4.15 5.57e-05 0.0211 -0.39 -0.32 Bronchopulmonary dysplasia; chr7:1015773 chr7:1160374~1165267:+ PAAD cis rs792448 0.545 rs7519168 ENSG00000229983.1 RP11-15I11.2 -4.15 5.57e-05 0.0212 -0.37 -0.32 White blood cell count (basophil); chr1:212220043 chr1:212168207~212190259:+ PAAD cis rs111580313 0.685 rs77563985 ENSG00000270020.1 RP11-463O9.9 4.15 5.58e-05 0.0212 0.83 0.32 Systemic juvenile idiopathic arthritis; chr16:86572414 chr16:86520383~86523897:- PAAD cis rs7617773 0.817 rs11720622 ENSG00000228638.1 FCF1P2 -4.15 5.58e-05 0.0212 -0.35 -0.32 Coronary artery disease; chr3:48205189 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs11130162 ENSG00000228638.1 FCF1P2 -4.15 5.58e-05 0.0212 -0.35 -0.32 Coronary artery disease; chr3:48256121 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs6787500 ENSG00000228638.1 FCF1P2 -4.15 5.58e-05 0.0212 -0.35 -0.32 Coronary artery disease; chr3:48257949 chr3:48290793~48291375:- PAAD cis rs11700536 1 rs4919965 ENSG00000236663.1 AP001631.9 -4.15 5.58e-05 0.0212 -0.35 -0.32 Interleukin-18 levels; chr21:43137961 chr21:43140523~43141092:- PAAD cis rs2832077 0.943 rs4816332 ENSG00000176054.6 RPL23P2 -4.15 5.58e-05 0.0212 -0.37 -0.32 Cognitive test performance; chr21:28829384 chr21:28997613~28998033:- PAAD cis rs2832077 0.824 rs4816333 ENSG00000176054.6 RPL23P2 -4.15 5.58e-05 0.0212 -0.37 -0.32 Cognitive test performance; chr21:28829455 chr21:28997613~28998033:- PAAD cis rs9487094 0.553 rs13191995 ENSG00000260273.1 RP11-425D10.10 4.15 5.59e-05 0.0212 0.45 0.32 Height; chr6:109645257 chr6:109382795~109383666:+ PAAD cis rs2380205 0.546 rs636578 ENSG00000232807.2 RP11-536K7.3 -4.15 5.59e-05 0.0212 -0.34 -0.32 Breast cancer; chr10:5896581 chr10:5934270~5945900:- PAAD cis rs700651 0.789 rs1371663 ENSG00000231621.1 AC013264.2 4.15 5.59e-05 0.0212 0.32 0.32 Intracranial aneurysm; chr2:198035581 chr2:197197991~197199273:+ PAAD cis rs9595908 1 rs718444 ENSG00000212293.1 SNORA16 4.15 5.6e-05 0.0212 0.37 0.32 Body mass index; chr13:32572915 chr13:32420390~32420516:- PAAD cis rs9595908 1 rs7332115 ENSG00000212293.1 SNORA16 4.15 5.6e-05 0.0212 0.37 0.32 Body mass index; chr13:32573411 chr13:32420390~32420516:- PAAD cis rs9595908 1 rs7332763 ENSG00000212293.1 SNORA16 4.15 5.6e-05 0.0212 0.37 0.32 Body mass index; chr13:32573751 chr13:32420390~32420516:- PAAD cis rs9595908 1 rs9591134 ENSG00000212293.1 SNORA16 4.15 5.6e-05 0.0212 0.37 0.32 Body mass index; chr13:32574079 chr13:32420390~32420516:- PAAD cis rs780096 0.587 rs4665969 ENSG00000234072.1 AC074117.10 4.15 5.6e-05 0.0212 0.24 0.32 Total body bone mineral density; chr2:27352086 chr2:27356246~27367622:+ PAAD cis rs71403859 0.803 rs7203606 ENSG00000260886.1 TAT-AS1 4.15 5.6e-05 0.0212 0.51 0.32 Post bronchodilator FEV1; chr16:71556608 chr16:71565789~71578187:+ PAAD cis rs2288884 0.515 rs11882053 ENSG00000275055.1 CTC-471J1.11 -4.15 5.61e-05 0.0213 -0.43 -0.32 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52047687 chr19:52049007~52049754:+ PAAD cis rs17772222 0.682 rs1864744 ENSG00000258983.2 RP11-507K2.2 -4.15 5.61e-05 0.0213 -0.38 -0.32 Coronary artery calcification; chr14:88484662 chr14:88499334~88515502:+ PAAD cis rs302972 0.826 rs303011 ENSG00000168405.13 CMAHP -4.15 5.61e-05 0.0213 -0.46 -0.32 Creatinine levels in ischemic stroke; chr6:25080620 chr6:25081068~25166555:- PAAD cis rs11214589 0.747 rs10502172 ENSG00000270179.1 RP11-159N11.4 -4.15 5.61e-05 0.0213 -0.35 -0.32 Neuroticism; chr11:113328424 chr11:113368478~113369117:+ PAAD cis rs10506328 0.509 rs1140681 ENSG00000248265.1 FLJ12825 4.15 5.62e-05 0.0213 0.27 0.32 Mean platelet volume; chr12:54257687 chr12:54058254~54122234:+ PAAD cis rs6908034 0.607 rs78774173 ENSG00000228412.5 RP4-625H18.2 4.15 5.62e-05 0.0213 0.72 0.32 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19820455 chr6:19802164~19804752:- PAAD cis rs853679 1 rs1679709 ENSG00000280107.1 AL022393.9 4.15 5.62e-05 0.0213 0.56 0.32 Depression; chr6:28260564 chr6:28170845~28172521:+ PAAD cis rs853679 1 rs1778511 ENSG00000280107.1 AL022393.9 4.15 5.62e-05 0.0213 0.56 0.32 Depression; chr6:28261633 chr6:28170845~28172521:+ PAAD cis rs453301 0.686 rs7017868 ENSG00000253893.2 FAM85B 4.15 5.62e-05 0.0213 0.43 0.32 Joint mobility (Beighton score); chr8:9015783 chr8:8167819~8226614:- PAAD cis rs453301 0.686 rs3895823 ENSG00000253893.2 FAM85B 4.15 5.62e-05 0.0213 0.43 0.32 Joint mobility (Beighton score); chr8:9016136 chr8:8167819~8226614:- PAAD cis rs375066 0.935 rs396973 ENSG00000267058.1 RP11-15A1.3 4.14 5.63e-05 0.0213 0.28 0.32 Breast cancer; chr19:43895154 chr19:43891804~43901805:- PAAD cis rs2348418 0.832 rs4931080 ENSG00000247934.4 RP11-967K21.1 4.14 5.63e-05 0.0213 0.3 0.32 Lung function (FEV1);Lung function (FVC); chr12:28433843 chr12:28163298~28190738:- PAAD cis rs2348418 0.832 rs4244844 ENSG00000247934.4 RP11-967K21.1 4.14 5.63e-05 0.0213 0.3 0.32 Lung function (FEV1);Lung function (FVC); chr12:28434062 chr12:28163298~28190738:- PAAD cis rs6951245 0.935 rs11766669 ENSG00000229043.2 AC091729.9 -4.14 5.63e-05 0.0213 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1023957 chr7:1160374~1165267:+ PAAD cis rs6951245 0.935 rs79067319 ENSG00000229043.2 AC091729.9 -4.14 5.63e-05 0.0213 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1025912 chr7:1160374~1165267:+ PAAD cis rs6951245 0.872 rs74360401 ENSG00000229043.2 AC091729.9 -4.14 5.63e-05 0.0213 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1027767 chr7:1160374~1165267:+ PAAD cis rs2243480 1 rs3885839 ENSG00000228409.4 CCT6P1 4.14 5.63e-05 0.0213 0.34 0.32 Diabetic kidney disease; chr7:65825416 chr7:65751142~65763354:+ PAAD cis rs12446554 0.509 rs56100071 ENSG00000261195.1 CTD-2380F24.1 -4.14 5.64e-05 0.0213 -0.52 -0.32 Obesity; chr16:19698429 chr16:19761172~19766099:- PAAD cis rs12444979 0.517 rs720173 ENSG00000261195.1 CTD-2380F24.1 -4.14 5.64e-05 0.0213 -0.52 -0.32 Body mass index; chr16:19710484 chr16:19761172~19766099:- PAAD cis rs8177376 0.727 rs601985 ENSG00000254905.1 RP11-712L6.7 4.14 5.64e-05 0.0214 0.41 0.32 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126327662 chr11:126292922~126294254:- PAAD cis rs7216064 1 rs6504542 ENSG00000278219.1 AC145343.1 -4.14 5.64e-05 0.0214 -0.5 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67840526 chr17:68101538~68101639:+ PAAD cis rs7216064 0.953 rs1966410 ENSG00000278219.1 AC145343.1 -4.14 5.64e-05 0.0214 -0.5 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67841099 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs8067892 ENSG00000278219.1 AC145343.1 -4.14 5.64e-05 0.0214 -0.5 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67841867 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs7223930 ENSG00000278219.1 AC145343.1 -4.14 5.64e-05 0.0214 -0.5 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67846070 chr17:68101538~68101639:+ PAAD cis rs3781264 0.761 rs11187893 ENSG00000273450.1 RP11-76P2.4 -4.14 5.64e-05 0.0214 -0.43 -0.32 Esophageal cancer and gastric cancer; chr10:94346222 chr10:94314907~94315327:- PAAD cis rs9876781 1 rs9815103 ENSG00000229759.1 MRPS18AP1 4.14 5.64e-05 0.0214 0.34 0.32 Longevity; chr3:48372725 chr3:48256350~48256938:- PAAD cis rs6504622 0.818 rs11079742 ENSG00000214401.4 KANSL1-AS1 -4.14 5.65e-05 0.0214 -0.41 -0.32 Orofacial clefts; chr17:46942762 chr17:46193576~46196723:+ PAAD cis rs6991838 0.67 rs13275168 ENSG00000200714.1 Y_RNA 4.14 5.65e-05 0.0214 0.37 0.32 Intelligence (multi-trait analysis); chr8:65685107 chr8:65592731~65592820:+ PAAD cis rs7189233 0.531 rs13332071 ENSG00000279344.1 RP11-44F14.7 4.14 5.65e-05 0.0214 0.24 0.32 Intelligence (multi-trait analysis); chr16:53409724 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs6499617 ENSG00000279344.1 RP11-44F14.7 4.14 5.65e-05 0.0214 0.24 0.32 Intelligence (multi-trait analysis); chr16:53433810 chr16:53478957~53481550:- PAAD cis rs9487094 0.778 rs11757877 ENSG00000260273.1 RP11-425D10.10 4.14 5.65e-05 0.0214 0.44 0.32 Height; chr6:109360679 chr6:109382795~109383666:+ PAAD cis rs9487094 0.813 rs61233650 ENSG00000260273.1 RP11-425D10.10 4.14 5.65e-05 0.0214 0.44 0.32 Height; chr6:109365409 chr6:109382795~109383666:+ PAAD cis rs9487094 0.813 rs3799835 ENSG00000260273.1 RP11-425D10.10 4.14 5.65e-05 0.0214 0.44 0.32 Height; chr6:109372084 chr6:109382795~109383666:+ PAAD cis rs9487094 0.813 rs11753645 ENSG00000260273.1 RP11-425D10.10 4.14 5.65e-05 0.0214 0.44 0.32 Height; chr6:109373851 chr6:109382795~109383666:+ PAAD cis rs9487094 0.813 rs34131679 ENSG00000260273.1 RP11-425D10.10 4.14 5.65e-05 0.0214 0.44 0.32 Height; chr6:109375848 chr6:109382795~109383666:+ PAAD cis rs2404602 0.622 rs11637296 ENSG00000259422.1 RP11-593F23.1 -4.14 5.65e-05 0.0214 -0.39 -0.32 Blood metabolite levels; chr15:76915544 chr15:76174891~76181486:- PAAD cis rs2303759 0.881 rs10412811 ENSG00000268686.1 AC010524.2 -4.14 5.65e-05 0.0214 -0.45 -0.32 Multiple sclerosis; chr19:49381238 chr19:49368705~49388081:- PAAD cis rs17684571 0.7 rs13220618 ENSG00000231441.1 RP11-472M19.2 4.14 5.65e-05 0.0214 0.6 0.32 Schizophrenia; chr6:56819388 chr6:56844002~56864078:+ PAAD cis rs950880 0.71 rs17026974 ENSG00000234389.1 AC007278.3 4.14 5.66e-05 0.0214 0.31 0.32 Serum protein levels (sST2); chr2:102335900 chr2:102438713~102440475:+ PAAD cis rs28386778 0.897 rs5020097 ENSG00000240280.5 TCAM1P -4.14 5.66e-05 0.0214 -0.45 -0.32 Prudent dietary pattern; chr17:63736838 chr17:63849292~63864379:+ PAAD cis rs150992 0.504 rs11745405 ENSG00000248489.1 CTD-2007H13.3 -4.14 5.66e-05 0.0214 -0.36 -0.32 Body mass index; chr5:99047700 chr5:98929171~98995013:+ PAAD cis rs4660214 0.666 rs683135 ENSG00000228060.1 RP11-69E11.8 -4.14 5.66e-05 0.0214 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39429788 chr1:39565160~39573203:+ PAAD cis rs732716 0.853 rs62129349 ENSG00000267769.1 CTB-50L17.9 -4.14 5.67e-05 0.0215 -0.42 -0.32 Mean corpuscular volume; chr19:4385662 chr19:4454014~4455286:+ PAAD cis rs732716 0.889 rs11085074 ENSG00000267769.1 CTB-50L17.9 -4.14 5.67e-05 0.0215 -0.42 -0.32 Mean corpuscular volume; chr19:4386355 chr19:4454014~4455286:+ PAAD cis rs875971 0.522 rs4718285 ENSG00000236529.1 RP13-254B10.1 4.14 5.67e-05 0.0215 0.35 0.32 Aortic root size; chr7:65827018 chr7:65840212~65840596:+ PAAD cis rs875971 0.522 rs4502988 ENSG00000236529.1 RP13-254B10.1 4.14 5.67e-05 0.0215 0.35 0.32 Aortic root size; chr7:65832759 chr7:65840212~65840596:+ PAAD cis rs17711722 0.64 rs13237956 ENSG00000236529.1 RP13-254B10.1 4.14 5.67e-05 0.0215 0.35 0.32 Calcium levels; chr7:65853042 chr7:65840212~65840596:+ PAAD cis rs496547 0.686 rs477014 ENSG00000278376.1 RP11-158I9.8 -4.14 5.67e-05 0.0215 -0.28 -0.32 Hip minimal joint space width; chr11:118808277 chr11:118791254~118793137:+ PAAD cis rs496547 0.588 rs473298 ENSG00000278376.1 RP11-158I9.8 -4.14 5.67e-05 0.0215 -0.28 -0.32 Hip minimal joint space width; chr11:118808678 chr11:118791254~118793137:+ PAAD cis rs496547 0.557 rs516719 ENSG00000278376.1 RP11-158I9.8 -4.14 5.67e-05 0.0215 -0.28 -0.32 Hip minimal joint space width; chr11:118808736 chr11:118791254~118793137:+ PAAD cis rs10888838 0.652 rs12410868 ENSG00000198711.5 SSBP3-AS1 4.14 5.67e-05 0.0215 0.4 0.32 Mitochondrial DNA levels; chr1:54230646 chr1:54236440~54239063:+ PAAD cis rs4713118 0.662 rs175954 ENSG00000204709.4 LINC01556 4.14 5.67e-05 0.0215 0.53 0.32 Parkinson's disease; chr6:28043807 chr6:28943877~28944537:+ PAAD cis rs72627509 0.951 rs6554401 ENSG00000269949.1 RP11-738E22.3 4.14 5.68e-05 0.0215 0.49 0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56959170 chr4:56960927~56961373:- PAAD cis rs4938303 0.633 rs77835865 ENSG00000254851.1 RP11-109L13.1 4.14 5.68e-05 0.0215 0.53 0.32 Triglycerides; chr11:116684713 chr11:117135528~117138582:+ PAAD cis rs2243480 1 rs2462569 ENSG00000228409.4 CCT6P1 -4.14 5.68e-05 0.0215 -0.34 -0.32 Diabetic kidney disease; chr7:66009859 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1039664 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:65984729 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1964692 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:65989196 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs2456483 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:65996588 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1701750 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66002158 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1701758 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66005214 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs1701759 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66005945 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs781157 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66013324 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs781156 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66014154 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs781149 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66016297 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs451396 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66019087 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs58207111 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66021736 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1167613 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66022452 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1715235 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66023407 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313799 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66029343 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313807 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66034494 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs313808 ENSG00000228409.4 CCT6P1 4.14 5.68e-05 0.0215 0.34 0.32 Diabetic kidney disease; chr7:66034886 chr7:65751142~65763354:+ PAAD cis rs11048470 0.569 rs4963983 ENSG00000256625.1 RP11-582E3.4 -4.14 5.68e-05 0.0215 -0.39 -0.32 Waist-hip ratio; chr12:26334725 chr12:27121910~27147664:+ PAAD cis rs10861661 0.569 rs10778514 ENSG00000260329.1 RP11-412D9.4 -4.14 5.68e-05 0.0215 -0.31 -0.32 Triglyceride levels; chr12:106909799 chr12:106954029~106955497:- PAAD cis rs2638953 0.853 rs10843195 ENSG00000247934.4 RP11-967K21.1 -4.14 5.68e-05 0.0215 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28513633 chr12:28163298~28190738:- PAAD cis rs2638953 0.853 rs10843196 ENSG00000247934.4 RP11-967K21.1 -4.14 5.68e-05 0.0215 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28513660 chr12:28163298~28190738:- PAAD cis rs520525 1 rs520525 ENSG00000271811.1 RP1-79C4.4 4.14 5.69e-05 0.0215 0.34 0.32 Atrial fibrillation; chr1:170669192 chr1:170667381~170669425:+ PAAD cis rs867529 0.6 rs335120 ENSG00000230006.6 ANKRD36BP2 4.14 5.69e-05 0.0215 0.27 0.32 Height; chr2:88773214 chr2:88765807~88806612:+ PAAD cis rs34375054 0.624 rs4073534 ENSG00000279233.1 RP11-158L12.4 4.14 5.69e-05 0.0215 0.28 0.32 Post bronchodilator FEV1/FVC ratio; chr12:125187254 chr12:125138245~125141711:+ PAAD cis rs2562456 1 rs2562456 ENSG00000213976.4 CTD-2561J22.2 -4.14 5.69e-05 0.0215 -0.33 -0.32 Pain; chr19:21483408 chr19:21382865~21387177:+ PAAD cis rs7120173 0.915 rs12786797 ENSG00000231865.1 SIK3-IT1 -4.14 5.7e-05 0.0215 -0.43 -0.32 Visceral adipose tissue adjusted for BMI; chr11:117017035 chr11:116886046~116890721:- PAAD cis rs3858145 0.506 rs10762224 ENSG00000233590.1 RP11-153K11.3 4.14 5.7e-05 0.0215 0.46 0.32 Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area; chr10:68326556 chr10:68233251~68242379:- PAAD cis rs6570726 0.935 rs7757387 ENSG00000235652.6 RP11-545I5.3 4.14 5.7e-05 0.0216 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145495590 chr6:145799409~145886585:+ PAAD cis rs10951983 0.562 rs71531381 ENSG00000272719.1 CTB-161C1.1 -4.14 5.7e-05 0.0216 -0.38 -0.32 Coronary artery disease; chr7:6376729 chr7:5556731~5557245:+ PAAD cis rs10951983 0.821 rs7456834 ENSG00000272719.1 CTB-161C1.1 -4.14 5.7e-05 0.0216 -0.38 -0.32 Coronary artery disease; chr7:6376957 chr7:5556731~5557245:+ PAAD cis rs10951983 0.821 rs7455288 ENSG00000272719.1 CTB-161C1.1 -4.14 5.7e-05 0.0216 -0.38 -0.32 Coronary artery disease; chr7:6376984 chr7:5556731~5557245:+ PAAD cis rs9322193 0.961 rs9027 ENSG00000268592.3 RAET1E-AS1 4.14 5.71e-05 0.0216 0.37 0.32 Lung cancer; chr6:149594921 chr6:149863494~149919507:+ PAAD cis rs66823261 0.778 rs2906332 ENSG00000253166.2 RP11-585F1.6 -4.14 5.71e-05 0.0216 -0.43 -0.32 Breast cancer (estrogen-receptor negative);Breast cancer; chr8:244943 chr8:202660~202897:- PAAD cis rs797680 0.754 rs10874777 ENSG00000223745.6 RP4-717I23.3 4.14 5.71e-05 0.0216 0.26 0.32 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93396463 chr1:93262186~93346025:- PAAD cis rs11673344 0.526 rs17303902 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37551912 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs55754546 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37552860 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs17244713 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37559938 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs17244769 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37562031 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs8111790 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37565861 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs55909413 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37578663 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs55865869 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37578683 chr19:37779686~37792865:+ PAAD cis rs11673344 0.502 rs17304703 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37582646 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs73033122 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37586006 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs2306201 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37586573 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs2291001 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37594431 chr19:37779686~37792865:+ PAAD cis rs11673344 0.518 rs73033134 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37596046 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs17305193 ENSG00000267422.1 CTD-2554C21.1 4.14 5.71e-05 0.0216 0.43 0.32 Obesity-related traits; chr19:37598764 chr19:37779686~37792865:+ PAAD cis rs3743162 0.553 rs4842994 ENSG00000275120.1 RP11-182J1.17 -4.14 5.72e-05 0.0216 -0.37 -0.32 Alzheimer's disease (age of onset); chr15:84872568 chr15:84599434~84606463:- PAAD cis rs950169 0.509 rs71395455 ENSG00000275120.1 RP11-182J1.17 4.14 5.72e-05 0.0216 0.34 0.32 Schizophrenia; chr15:84610573 chr15:84599434~84606463:- PAAD cis rs11673344 0.526 rs35153242 ENSG00000267422.1 CTD-2554C21.1 -4.14 5.72e-05 0.0216 -0.43 -0.32 Obesity-related traits; chr19:37660841 chr19:37779686~37792865:+ PAAD cis rs8072100 0.934 rs8067286 ENSG00000228782.6 CTD-2026D20.3 -4.14 5.72e-05 0.0216 -0.31 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47517224 chr17:47450568~47492492:- PAAD cis rs8072100 0.935 rs78551919 ENSG00000228782.6 CTD-2026D20.3 -4.14 5.72e-05 0.0216 -0.31 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47548636 chr17:47450568~47492492:- PAAD cis rs7202877 0.61 rs468079 ENSG00000261783.1 RP11-252K23.2 4.14 5.72e-05 0.0216 0.49 0.32 Type 1 diabetes;Type 2 diabetes; chr16:75394576 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs247437 ENSG00000261783.1 RP11-252K23.2 4.14 5.72e-05 0.0216 0.49 0.32 Type 1 diabetes;Type 2 diabetes; chr16:75397377 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs1074961 ENSG00000261783.1 RP11-252K23.2 -4.14 5.72e-05 0.0216 -0.49 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75355586 chr16:75379818~75381260:- PAAD cis rs7202877 0.656 rs8048677 ENSG00000261783.1 RP11-252K23.2 -4.14 5.72e-05 0.0216 -0.49 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75358130 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs8055609 ENSG00000261783.1 RP11-252K23.2 -4.14 5.72e-05 0.0216 -0.49 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75368190 chr16:75379818~75381260:- PAAD cis rs7202877 0.706 rs8054586 ENSG00000261783.1 RP11-252K23.2 -4.14 5.72e-05 0.0216 -0.49 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75376807 chr16:75379818~75381260:- PAAD cis rs6565180 0.632 rs8050812 ENSG00000183604.13 SMG1P5 -4.14 5.73e-05 0.0216 -0.36 -0.32 Tonsillectomy; chr16:30374516 chr16:30267553~30335374:- PAAD cis rs10421328 0.784 rs8107058 ENSG00000259242.2 AC002306.1 4.14 5.73e-05 0.0216 0.48 0.32 Parental longevity (combined parental age at death); chr19:19648842 chr19:19606350~19608660:+ PAAD cis rs763121 0.853 rs5750671 ENSG00000228274.3 RP3-508I15.9 -4.14 5.73e-05 0.0216 -0.3 -0.32 Menopause (age at onset); chr22:38698614 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs926299 ENSG00000228274.3 RP3-508I15.9 -4.14 5.73e-05 0.0216 -0.3 -0.32 Menopause (age at onset); chr22:38699693 chr22:38667585~38681820:- PAAD cis rs763121 0.785 rs6001203 ENSG00000228274.3 RP3-508I15.9 -4.14 5.73e-05 0.0216 -0.3 -0.32 Menopause (age at onset); chr22:38703597 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs6001204 ENSG00000228274.3 RP3-508I15.9 -4.14 5.73e-05 0.0216 -0.3 -0.32 Menopause (age at onset); chr22:38704234 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757253 ENSG00000228274.3 RP3-508I15.9 -4.14 5.73e-05 0.0216 -0.3 -0.32 Menopause (age at onset); chr22:38708315 chr22:38667585~38681820:- PAAD cis rs72843506 0.586 rs75128113 ENSG00000189423.10 USP32P3 4.14 5.73e-05 0.0216 0.49 0.32 Schizophrenia; chr17:20000172 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs79773274 ENSG00000189423.10 USP32P3 4.14 5.73e-05 0.0216 0.49 0.32 Schizophrenia; chr17:20002618 chr17:20415547~20431008:+ PAAD cis rs7829975 0.523 rs9644774 ENSG00000253893.2 FAM85B 4.14 5.73e-05 0.0216 0.46 0.32 Mood instability; chr8:8702322 chr8:8167819~8226614:- PAAD cis rs13256369 0.802 rs11995449 ENSG00000253981.4 ALG1L13P 4.14 5.73e-05 0.0216 0.43 0.32 Obesity-related traits; chr8:8702388 chr8:8236003~8244667:- PAAD cis rs8059260 1 rs7205474 ENSG00000274038.1 RP11-66H6.4 -4.14 5.73e-05 0.0216 -0.48 -0.32 Alcohol consumption over the past year; chr16:10949556 chr16:11056556~11057034:+ PAAD cis rs4718428 0.705 rs4718422 ENSG00000273142.1 RP11-458F8.4 -4.14 5.73e-05 0.0216 -0.22 -0.32 Corneal structure; chr7:66894282 chr7:66902857~66906297:+ PAAD cis rs4718428 0.705 rs13231140 ENSG00000273142.1 RP11-458F8.4 -4.14 5.73e-05 0.0216 -0.22 -0.32 Corneal structure; chr7:66896631 chr7:66902857~66906297:+ PAAD cis rs7626444 0.626 rs5021325 ENSG00000272359.1 U4 -4.14 5.74e-05 0.0216 -0.35 -0.32 Monocyte count; chr3:196750758 chr3:196747192~196747324:- PAAD cis rs2739330 0.796 rs5760097 ENSG00000206090.4 AP000350.7 4.14 5.74e-05 0.0217 0.41 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23905607 chr22:23939998~23942798:+ PAAD cis rs2739330 0.828 rs5760098 ENSG00000206090.4 AP000350.7 4.14 5.74e-05 0.0217 0.41 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23906127 chr22:23939998~23942798:+ PAAD cis rs7615952 0.688 rs9754526 ENSG00000171084.14 FAM86JP 4.14 5.74e-05 0.0217 0.44 0.32 Blood pressure (smoking interaction); chr3:125824023 chr3:125916620~125930024:+ PAAD cis rs7615952 0.512 rs34085484 ENSG00000171084.14 FAM86JP 4.14 5.74e-05 0.0217 0.44 0.32 Blood pressure (smoking interaction); chr3:125825343 chr3:125916620~125930024:+ PAAD cis rs7615952 0.608 rs35668111 ENSG00000171084.14 FAM86JP 4.14 5.74e-05 0.0217 0.44 0.32 Blood pressure (smoking interaction); chr3:125825792 chr3:125916620~125930024:+ PAAD cis rs9649213 0.593 rs6967457 ENSG00000272950.1 RP11-307C18.1 4.14 5.74e-05 0.0217 0.36 0.32 Prostate cancer (SNP x SNP interaction); chr7:98282909 chr7:98322853~98323430:+ PAAD cis rs2281636 0.931 rs2804419 ENSG00000233690.1 EBAG9P1 -4.14 5.75e-05 0.0217 -0.34 -0.32 Obesity-related traits; chr10:99749356 chr10:99697407~99697949:- PAAD cis rs2281636 1 rs2804418 ENSG00000233690.1 EBAG9P1 -4.14 5.75e-05 0.0217 -0.34 -0.32 Obesity-related traits; chr10:99752337 chr10:99697407~99697949:- PAAD cis rs10888838 0.941 rs10888842 ENSG00000198711.5 SSBP3-AS1 4.14 5.75e-05 0.0217 0.38 0.32 Mitochondrial DNA levels; chr1:54223229 chr1:54236440~54239063:+ PAAD cis rs748404 1 rs12909095 ENSG00000205771.5 CATSPER2P1 -4.14 5.76e-05 0.0217 -0.47 -0.32 Lung cancer; chr15:43265944 chr15:43726918~43747094:- PAAD cis rs153852 0.859 rs36732 ENSG00000243806.1 RPL7P18 -4.14 5.76e-05 0.0217 -0.37 -0.32 Cancer; chr5:94829386 chr5:94825961~94826694:- PAAD cis rs950169 0.922 rs11638445 ENSG00000275120.1 RP11-182J1.17 4.14 5.76e-05 0.0217 0.33 0.32 Schizophrenia; chr15:84594463 chr15:84599434~84606463:- PAAD cis rs897984 0.542 rs7294 ENSG00000260911.2 RP11-196G11.2 -4.14 5.76e-05 0.0217 -0.3 -0.32 Dementia with Lewy bodies; chr16:31091000 chr16:31043150~31049868:+ PAAD cis rs494459 0.838 rs2510897 ENSG00000278376.1 RP11-158I9.8 -4.14 5.77e-05 0.0217 -0.28 -0.32 Height; chr11:118773873 chr11:118791254~118793137:+ PAAD cis rs6570726 1 rs6570699 ENSG00000235652.6 RP11-545I5.3 4.14 5.77e-05 0.0217 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145599596 chr6:145799409~145886585:+ PAAD cis rs6570726 1 rs1935615 ENSG00000235652.6 RP11-545I5.3 4.14 5.77e-05 0.0217 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145599981 chr6:145799409~145886585:+ PAAD cis rs2243480 1 rs160643 ENSG00000226824.5 RP4-756H11.3 -4.14 5.77e-05 0.0218 -0.55 -0.32 Diabetic kidney disease; chr7:66093235 chr7:66654538~66669855:+ PAAD cis rs6991838 0.702 rs7007987 ENSG00000200714.1 Y_RNA 4.14 5.78e-05 0.0218 0.38 0.32 Intelligence (multi-trait analysis); chr8:65700754 chr8:65592731~65592820:+ PAAD cis rs9487094 0.67 rs1476388 ENSG00000260273.1 RP11-425D10.10 4.14 5.78e-05 0.0218 0.39 0.32 Height; chr6:109518783 chr6:109382795~109383666:+ PAAD cis rs2408955 0.522 rs4760679 ENSG00000240399.1 RP1-228P16.1 -4.14 5.78e-05 0.0218 -0.34 -0.32 Glycated hemoglobin levels; chr12:48067852 chr12:48054813~48055591:- PAAD cis rs2408955 0.561 rs9971924 ENSG00000240399.1 RP1-228P16.1 -4.14 5.78e-05 0.0218 -0.34 -0.32 Glycated hemoglobin levels; chr12:48086049 chr12:48054813~48055591:- PAAD cis rs2408955 0.522 rs7139330 ENSG00000240399.1 RP1-228P16.1 -4.14 5.78e-05 0.0218 -0.34 -0.32 Glycated hemoglobin levels; chr12:48089701 chr12:48054813~48055591:- PAAD cis rs2408955 0.522 rs2051851 ENSG00000240399.1 RP1-228P16.1 -4.14 5.78e-05 0.0218 -0.34 -0.32 Glycated hemoglobin levels; chr12:48092157 chr12:48054813~48055591:- PAAD cis rs2408955 0.522 rs973398 ENSG00000240399.1 RP1-228P16.1 -4.14 5.78e-05 0.0218 -0.34 -0.32 Glycated hemoglobin levels; chr12:48097265 chr12:48054813~48055591:- PAAD cis rs11168351 0.864 rs12228750 ENSG00000240399.1 RP1-228P16.1 -4.14 5.78e-05 0.0218 -0.34 -0.32 Bipolar disorder and schizophrenia; chr12:48103214 chr12:48054813~48055591:- PAAD cis rs11168351 0.864 rs10875743 ENSG00000240399.1 RP1-228P16.1 -4.14 5.78e-05 0.0218 -0.34 -0.32 Bipolar disorder and schizophrenia; chr12:48104630 chr12:48054813~48055591:- PAAD cis rs2408955 0.568 rs12099462 ENSG00000240399.1 RP1-228P16.1 -4.14 5.78e-05 0.0218 -0.34 -0.32 Glycated hemoglobin levels; chr12:48109321 chr12:48054813~48055591:- PAAD cis rs8031584 0.752 rs2001686 ENSG00000260382.1 RP11-540B6.2 4.14 5.79e-05 0.0218 0.42 0.32 Huntington's disease progression; chr15:30893569 chr15:30882267~30883231:- PAAD cis rs4835473 0.932 rs9308176 ENSG00000251600.4 RP11-673E1.1 -4.14 5.79e-05 0.0218 -0.36 -0.32 Immature fraction of reticulocytes; chr4:144072718 chr4:143912331~143982454:+ PAAD cis rs2985684 0.947 rs1952013 ENSG00000259113.1 RP11-406H23.2 -4.14 5.79e-05 0.0218 -0.46 -0.32 Carotid intima media thickness; chr14:49620639 chr14:50448807~50456742:+ PAAD cis rs28374715 0.578 rs7169543 ENSG00000247556.5 OIP5-AS1 4.14 5.79e-05 0.0218 0.34 0.32 Ulcerative colitis; chr15:41328207 chr15:41283990~41309737:+ PAAD cis rs28374715 0.528 rs7181982 ENSG00000247556.5 OIP5-AS1 4.14 5.79e-05 0.0218 0.34 0.32 Ulcerative colitis; chr15:41330822 chr15:41283990~41309737:+ PAAD cis rs28374715 0.528 rs28492932 ENSG00000247556.5 OIP5-AS1 4.14 5.79e-05 0.0218 0.34 0.32 Ulcerative colitis; chr15:41332199 chr15:41283990~41309737:+ PAAD cis rs28374715 0.578 rs13313520 ENSG00000247556.5 OIP5-AS1 4.14 5.79e-05 0.0218 0.34 0.32 Ulcerative colitis; chr15:41336929 chr15:41283990~41309737:+ PAAD cis rs28374715 0.578 rs8036026 ENSG00000247556.5 OIP5-AS1 4.14 5.79e-05 0.0218 0.34 0.32 Ulcerative colitis; chr15:41338301 chr15:41283990~41309737:+ PAAD cis rs28374715 0.528 rs7178360 ENSG00000247556.5 OIP5-AS1 4.14 5.79e-05 0.0218 0.34 0.32 Ulcerative colitis; chr15:41338977 chr15:41283990~41309737:+ PAAD cis rs28374715 0.578 rs7165914 ENSG00000247556.5 OIP5-AS1 4.14 5.79e-05 0.0218 0.34 0.32 Ulcerative colitis; chr15:41340253 chr15:41283990~41309737:+ PAAD cis rs2581828 0.539 rs114317830 ENSG00000242142.1 SERBP1P3 -4.14 5.79e-05 0.0218 -0.4 -0.32 Crohn's disease; chr3:53126253 chr3:53064283~53065091:- PAAD cis rs2581828 0.539 rs114670283 ENSG00000242142.1 SERBP1P3 -4.14 5.79e-05 0.0218 -0.4 -0.32 Crohn's disease; chr3:53126254 chr3:53064283~53065091:- PAAD cis rs1823913 0.637 rs11688994 ENSG00000280083.1 RP11-317J9.1 -4.14 5.8e-05 0.0218 -0.37 -0.32 Obesity-related traits; chr2:191266242 chr2:191154118~191156070:- PAAD cis rs287982 0.8 rs13429581 ENSG00000269973.1 RP11-95D17.1 -4.14 5.8e-05 0.0218 -0.38 -0.32 Nonsyndromic cleft lip with cleft palate; chr2:9823314 chr2:9936360~9939590:+ PAAD cis rs6929812 0.664 rs3918438 ENSG00000271755.1 RP1-153G14.4 4.14 5.8e-05 0.0218 0.36 0.32 Neuroticism (multi-trait analysis); chr6:27430354 chr6:27404010~27406964:- PAAD cis rs4713118 0.621 rs9295756 ENSG00000204709.4 LINC01556 4.14 5.81e-05 0.0219 0.54 0.32 Parkinson's disease; chr6:28065618 chr6:28943877~28944537:+ PAAD cis rs9595066 0.548 rs9562537 ENSG00000227258.4 SMIM2-AS1 4.14 5.81e-05 0.0219 0.48 0.32 Schizophrenia; chr13:44181651 chr13:44110451~44240517:+ PAAD cis rs72843506 0.656 rs10459970 ENSG00000189423.10 USP32P3 4.14 5.82e-05 0.0219 0.49 0.32 Schizophrenia; chr17:20034028 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs2385960 ENSG00000189423.10 USP32P3 4.14 5.82e-05 0.0219 0.49 0.32 Schizophrenia; chr17:20034904 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs8073875 ENSG00000189423.10 USP32P3 4.14 5.82e-05 0.0219 0.49 0.32 Schizophrenia; chr17:20035746 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs57040439 ENSG00000189423.10 USP32P3 4.14 5.82e-05 0.0219 0.49 0.32 Schizophrenia; chr17:20036522 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs58313980 ENSG00000189423.10 USP32P3 4.14 5.82e-05 0.0219 0.49 0.32 Schizophrenia; chr17:20036737 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs73984559 ENSG00000189423.10 USP32P3 4.14 5.82e-05 0.0219 0.49 0.32 Schizophrenia; chr17:20043203 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs77090106 ENSG00000189423.10 USP32P3 4.14 5.82e-05 0.0219 0.49 0.32 Schizophrenia; chr17:20044832 chr17:20415547~20431008:+ PAAD cis rs720064 0.586 rs2241643 ENSG00000264745.1 TTC39C-AS1 4.14 5.82e-05 0.0219 0.41 0.32 Strep throat; chr18:23949758 chr18:23994213~24015339:- PAAD cis rs875971 0.964 rs12668936 ENSG00000232559.3 GS1-124K5.12 4.14 5.83e-05 0.0219 0.34 0.32 Aortic root size; chr7:66449417 chr7:66554588~66576923:- PAAD cis rs12908161 0.96 rs34452033 ENSG00000259728.4 LINC00933 4.14 5.83e-05 0.0219 0.4 0.32 Schizophrenia; chr15:84678762 chr15:84570649~84580175:+ PAAD cis rs3790645 1 rs444482 ENSG00000225159.1 NPM1P39 4.14 5.84e-05 0.0219 0.41 0.32 Glucose homeostasis traits; chr1:26564157 chr1:27206930~27207796:+ PAAD cis rs3790645 1 rs392814 ENSG00000225159.1 NPM1P39 4.14 5.84e-05 0.0219 0.41 0.32 Glucose homeostasis traits; chr1:26565518 chr1:27206930~27207796:+ PAAD cis rs3790645 1 rs657227 ENSG00000225159.1 NPM1P39 4.14 5.84e-05 0.0219 0.41 0.32 Glucose homeostasis traits; chr1:26565613 chr1:27206930~27207796:+ PAAD cis rs3790645 1 rs396997 ENSG00000225159.1 NPM1P39 4.14 5.84e-05 0.0219 0.41 0.32 Glucose homeostasis traits; chr1:26566576 chr1:27206930~27207796:+ PAAD cis rs3790645 1 rs369385 ENSG00000225159.1 NPM1P39 4.14 5.84e-05 0.0219 0.41 0.32 Glucose homeostasis traits; chr1:26566738 chr1:27206930~27207796:+ PAAD cis rs7665090 0.87 rs228614 ENSG00000246560.2 RP11-10L12.4 -4.14 5.84e-05 0.0219 -0.35 -0.32 Primary biliary cholangitis; chr4:102657480 chr4:102828055~102844075:+ PAAD cis rs7615952 0.512 rs4234285 ENSG00000171084.14 FAM86JP 4.14 5.84e-05 0.0219 0.44 0.32 Blood pressure (smoking interaction); chr3:125685633 chr3:125916620~125930024:+ PAAD cis rs7615952 0.546 rs2976733 ENSG00000171084.14 FAM86JP 4.14 5.84e-05 0.0219 0.44 0.32 Blood pressure (smoking interaction); chr3:125695294 chr3:125916620~125930024:+ PAAD cis rs302972 0.826 rs303010 ENSG00000168405.13 CMAHP -4.14 5.84e-05 0.022 -0.43 -0.32 Creatinine levels in ischemic stroke; chr6:25081877 chr6:25081068~25166555:- PAAD cis rs5758511 0.689 rs56906457 ENSG00000205702.9 CYP2D7 4.14 5.85e-05 0.022 0.34 0.32 Birth weight; chr22:42232329 chr22:42140203~42144577:- PAAD cis rs496547 0.721 rs2508570 ENSG00000255239.1 AP002954.6 4.14 5.85e-05 0.022 0.38 0.32 Hip minimal joint space width; chr11:118807900 chr11:118688039~118690600:- PAAD cis rs496547 0.686 rs591756 ENSG00000255239.1 AP002954.6 4.14 5.85e-05 0.022 0.38 0.32 Hip minimal joint space width; chr11:118808172 chr11:118688039~118690600:- PAAD cis rs792448 0.743 rs351373 ENSG00000229983.1 RP11-15I11.2 4.13 5.85e-05 0.022 0.38 0.32 White blood cell count (basophil); chr1:212253289 chr1:212168207~212190259:+ PAAD cis rs4722166 0.532 rs6963866 ENSG00000179428.2 AC073072.5 -4.13 5.86e-05 0.022 -0.29 -0.32 Lung cancer; chr7:22717722 chr7:22725395~22727620:- PAAD cis rs11048434 0.518 rs7311509 ENSG00000256720.1 RP11-436I9.6 -4.13 5.86e-05 0.022 -0.3 -0.32 Sjögren's syndrome; chr12:9026438 chr12:9135084~9135591:+ PAAD cis rs17597773 0.527 rs1537806 ENSG00000238078.1 LINC01352 -4.13 5.86e-05 0.022 -0.31 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr1:220910880 chr1:220829255~220832429:+ PAAD cis rs7216064 1 rs11079707 ENSG00000278219.1 AC145343.1 4.13 5.86e-05 0.022 0.48 0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67839501 chr17:68101538~68101639:+ PAAD cis rs17597773 0.527 rs2484698 ENSG00000238078.1 LINC01352 4.13 5.86e-05 0.022 0.31 0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr1:220912723 chr1:220829255~220832429:+ PAAD cis rs9322193 1 rs9322193 ENSG00000268592.3 RAET1E-AS1 4.13 5.86e-05 0.022 0.37 0.32 Lung cancer; chr6:149598007 chr6:149863494~149919507:+ PAAD cis rs6472235 0.656 rs57683289 ENSG00000200714.1 Y_RNA -4.13 5.87e-05 0.022 -0.42 -0.32 Plateletcrit;Myopia (pathological); chr8:65973204 chr8:65592731~65592820:+ PAAD cis rs4853525 0.522 rs6434412 ENSG00000235852.1 AC005540.3 4.13 5.87e-05 0.0221 0.44 0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190720549 chr2:190880797~190882059:- PAAD cis rs633715 0.766 rs1815367 ENSG00000254154.7 RP4-798P15.3 -4.13 5.87e-05 0.0221 -0.3 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177839607 chr1:177928788~178038007:- PAAD cis rs780096 0.587 rs1049817 ENSG00000234072.1 AC074117.10 -4.13 5.87e-05 0.0221 -0.25 -0.32 Total body bone mineral density; chr2:27328100 chr2:27356246~27367622:+ PAAD cis rs10510102 0.608 rs4752607 ENSG00000276742.1 RP11-500G22.4 -4.13 5.87e-05 0.0221 -0.39 -0.32 Breast cancer; chr10:121835426 chr10:121956782~121957098:+ PAAD cis rs897984 0.542 rs750952 ENSG00000260911.2 RP11-196G11.2 4.13 5.88e-05 0.0221 0.29 0.32 Dementia with Lewy bodies; chr16:31082633 chr16:31043150~31049868:+ PAAD cis rs801193 0.569 rs2659908 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66695835 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs2659907 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66699045 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs7782587 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66701485 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs4717315 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66713338 chr7:66554588~66576923:- PAAD cis rs801193 0.527 rs2707837 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66716086 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs2707824 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66724256 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs2659893 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66735006 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs2659892 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66735318 chr7:66554588~66576923:- PAAD cis rs801193 0.548 rs2659891 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66736127 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs2707847 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66737884 chr7:66554588~66576923:- PAAD cis rs801193 0.548 rs7805152 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66744266 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs11772819 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66752983 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs11761542 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66753209 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs7800620 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66758701 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs10950050 ENSG00000232559.3 GS1-124K5.12 4.13 5.88e-05 0.0221 0.35 0.32 Aortic root size; chr7:66774601 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10274883 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66651104 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs881285 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66654433 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs3846973 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66655048 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs2013908 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66656082 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs13242290 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66656898 chr7:66554588~66576923:- PAAD cis rs801193 0.548 rs2109297 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66657397 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs6978178 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66658097 chr7:66554588~66576923:- PAAD cis rs801193 0.591 rs721717 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66665305 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs6951302 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66667525 chr7:66554588~66576923:- PAAD cis rs801193 0.591 rs4506088 ENSG00000232559.3 GS1-124K5.12 -4.13 5.88e-05 0.0221 -0.35 -0.32 Aortic root size; chr7:66670470 chr7:66554588~66576923:- PAAD cis rs12681963 0.536 rs7814629 ENSG00000272375.1 RP11-51J9.6 4.13 5.89e-05 0.0221 0.49 0.32 Migraine; chr8:30257784 chr8:30197404~30198048:+ PAAD cis rs891378 0.785 rs7516468 ENSG00000274245.1 RP11-357P18.2 -4.13 5.89e-05 0.0221 -0.44 -0.32 Spherical equivalent (joint analysis main effects and education interaction); chr1:207235943 chr1:207372559~207373252:+ PAAD cis rs875971 0.965 rs7794930 ENSG00000237310.1 GS1-124K5.4 -4.13 5.89e-05 0.0221 -0.31 -0.32 Aortic root size; chr7:66313559 chr7:66493706~66495474:+ PAAD cis rs9425766 0.639 rs10798295 ENSG00000227373.4 RP11-160H22.5 4.13 5.89e-05 0.0221 0.4 0.32 Life satisfaction; chr1:173714815 chr1:174115300~174160004:- PAAD cis rs4606360 1 rs4606360 ENSG00000227373.4 RP11-160H22.5 4.13 5.89e-05 0.0221 0.4 0.32 Subjective well-being; chr1:173729868 chr1:174115300~174160004:- PAAD cis rs9425766 0.511 rs10912676 ENSG00000227373.4 RP11-160H22.5 4.13 5.89e-05 0.0221 0.4 0.32 Life satisfaction; chr1:173740477 chr1:174115300~174160004:- PAAD cis rs11893307 0.509 rs17465200 ENSG00000235852.1 AC005540.3 4.13 5.89e-05 0.0221 0.47 0.32 Mean platelet volume; chr2:190684910 chr2:190880797~190882059:- PAAD cis rs4266144 0.544 rs6805781 ENSG00000244515.1 KRT18P34 4.13 5.89e-05 0.0221 0.36 0.32 Coronary artery disease; chr3:157112780 chr3:157162663~157163932:- PAAD cis rs755249 1 rs2293476 ENSG00000228060.1 RP11-69E11.8 4.13 5.9e-05 0.0221 0.32 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39571175 chr1:39565160~39573203:+ PAAD cis rs6570726 0.935 rs453609 ENSG00000235652.6 RP11-545I5.3 4.13 5.9e-05 0.0221 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145491196 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs447247 ENSG00000235652.6 RP11-545I5.3 4.13 5.9e-05 0.0221 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145491542 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs369458 ENSG00000235652.6 RP11-545I5.3 4.13 5.9e-05 0.0221 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145491673 chr6:145799409~145886585:+ PAAD cis rs9649213 0.613 rs7777415 ENSG00000272950.1 RP11-307C18.1 4.13 5.9e-05 0.0221 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98329902 chr7:98322853~98323430:+ PAAD cis rs748404 1 rs66651343 ENSG00000205771.5 CATSPER2P1 -4.13 5.91e-05 0.0221 -0.47 -0.32 Lung cancer; chr15:43265806 chr15:43726918~43747094:- PAAD cis rs748404 1 rs748404 ENSG00000205771.5 CATSPER2P1 -4.13 5.91e-05 0.0221 -0.47 -0.32 Lung cancer; chr15:43267033 chr15:43726918~43747094:- PAAD cis rs748404 1 rs12911132 ENSG00000205771.5 CATSPER2P1 -4.13 5.91e-05 0.0221 -0.47 -0.32 Lung cancer; chr15:43268238 chr15:43726918~43747094:- PAAD cis rs613391 0.561 rs682908 ENSG00000224549.1 RP11-370B11.3 -4.13 5.91e-05 0.0221 -0.38 -0.32 Quantitative traits; chr9:22721975 chr9:22767175~22768316:+ PAAD cis rs6570726 0.902 rs4895678 ENSG00000235652.6 RP11-545I5.3 4.13 5.91e-05 0.0222 0.27 0.32 Lobe attachment (rater-scored or self-reported); chr6:145614374 chr6:145799409~145886585:+ PAAD cis rs9309473 0.95 rs13431529 ENSG00000163016.8 ALMS1P 4.13 5.91e-05 0.0222 0.47 0.32 Metabolite levels; chr2:73648914 chr2:73644919~73685576:+ PAAD cis rs9309473 0.95 rs13408433 ENSG00000163016.8 ALMS1P 4.13 5.91e-05 0.0222 0.47 0.32 Metabolite levels; chr2:73655945 chr2:73644919~73685576:+ PAAD cis rs7208859 0.573 rs8070182 ENSG00000264538.5 SUZ12P1 -4.13 5.91e-05 0.0222 -0.3 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30808576 chr17:30709299~30790908:+ PAAD cis rs853679 0.506 rs1150693 ENSG00000280107.1 AL022393.9 -4.13 5.91e-05 0.0222 -0.53 -0.32 Depression; chr6:28206812 chr6:28170845~28172521:+ PAAD cis rs11168351 0.833 rs6580652 ENSG00000240399.1 RP1-228P16.1 -4.13 5.92e-05 0.0222 -0.33 -0.32 Bipolar disorder and schizophrenia; chr12:48053322 chr12:48054813~48055591:- PAAD cis rs28386778 0.897 rs1043127 ENSG00000240280.5 TCAM1P -4.13 5.92e-05 0.0222 -0.44 -0.32 Prudent dietary pattern; chr17:63713850 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2036911 ENSG00000240280.5 TCAM1P -4.13 5.92e-05 0.0222 -0.44 -0.32 Prudent dietary pattern; chr17:63717479 chr17:63849292~63864379:+ PAAD cis rs7260598 0.792 rs11669171 ENSG00000268442.1 CTD-2027I19.2 4.13 5.92e-05 0.0222 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:24153957 chr19:24162370~24163425:- PAAD cis rs9847710 0.733 rs2581790 ENSG00000242142.1 SERBP1P3 4.13 5.92e-05 0.0222 0.39 0.32 Ulcerative colitis; chr3:53067764 chr3:53064283~53065091:- PAAD cis rs2904804 0.555 rs4300303 ENSG00000224251.5 RP11-499O7.7 4.13 5.93e-05 0.0222 0.36 0.32 Economic and political preferences (immigration/crime); chr10:4944761 chr10:4995488~4997380:+ PAAD cis rs919433 1 rs1560277 ENSG00000231621.1 AC013264.2 -4.13 5.93e-05 0.0222 -0.31 -0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197323179 chr2:197197991~197199273:+ PAAD cis rs853679 0.517 rs6932109 ENSG00000204709.4 LINC01556 -4.13 5.93e-05 0.0222 -0.53 -0.32 Depression; chr6:28110525 chr6:28943877~28944537:+ PAAD cis rs4835473 0.897 rs7682204 ENSG00000251600.4 RP11-673E1.1 4.13 5.93e-05 0.0222 0.38 0.32 Immature fraction of reticulocytes; chr4:143966306 chr4:143912331~143982454:+ PAAD cis rs7225151 1 rs7225151 ENSG00000234327.6 AC012146.7 -4.13 5.93e-05 0.0222 -0.34 -0.32 Alzheimer's disease (late onset); chr17:5233752 chr17:5111468~5115004:+ PAAD cis rs8072100 1 rs4794048 ENSG00000228782.6 CTD-2026D20.3 4.13 5.93e-05 0.0222 0.31 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47685707 chr17:47450568~47492492:- PAAD cis rs9652601 0.959 rs12928537 ENSG00000274038.1 RP11-66H6.4 -4.13 5.93e-05 0.0222 -0.36 -0.32 Systemic lupus erythematosus; chr16:11097543 chr16:11056556~11057034:+ PAAD cis rs1800795 0.599 rs1546762 ENSG00000179428.2 AC073072.5 -4.13 5.94e-05 0.0222 -0.28 -0.32 Cerebrospinal fluid clusterin levels in APOEe4- carriers; chr7:22717884 chr7:22725395~22727620:- PAAD cis rs4722166 0.532 rs1546763 ENSG00000179428.2 AC073072.5 -4.13 5.94e-05 0.0222 -0.28 -0.32 Lung cancer; chr7:22718224 chr7:22725395~22727620:- PAAD cis rs4722166 0.532 rs1880242 ENSG00000179428.2 AC073072.5 4.13 5.94e-05 0.0222 0.28 0.32 Lung cancer; chr7:22719988 chr7:22725395~22727620:- PAAD cis rs17711722 0.503 rs453835 ENSG00000226824.5 RP4-756H11.3 4.13 5.94e-05 0.0222 0.38 0.32 Calcium levels; chr7:66046172 chr7:66654538~66669855:+ PAAD cis rs6479891 1 rs6479899 ENSG00000232075.1 MRPL35P2 -4.13 5.94e-05 0.0222 -0.51 -0.32 Arthritis (juvenile idiopathic); chr10:63379287 chr10:63634317~63634827:- PAAD cis rs66573146 0.572 rs68169399 ENSG00000272620.1 AFAP1-AS1 -4.13 5.94e-05 0.0223 -0.61 -0.32 Granulocyte percentage of myeloid white cells; chr4:6950764 chr4:7754090~7778928:+ PAAD cis rs66573146 0.572 rs66611116 ENSG00000272620.1 AFAP1-AS1 -4.13 5.94e-05 0.0223 -0.61 -0.32 Granulocyte percentage of myeloid white cells; chr4:6951543 chr4:7754090~7778928:+ PAAD cis rs66573146 0.572 rs55740475 ENSG00000272620.1 AFAP1-AS1 -4.13 5.94e-05 0.0223 -0.61 -0.32 Granulocyte percentage of myeloid white cells; chr4:6952365 chr4:7754090~7778928:+ PAAD cis rs66573146 0.572 rs67922134 ENSG00000272620.1 AFAP1-AS1 -4.13 5.94e-05 0.0223 -0.61 -0.32 Granulocyte percentage of myeloid white cells; chr4:6954045 chr4:7754090~7778928:+ PAAD cis rs66573146 0.572 rs73199995 ENSG00000272620.1 AFAP1-AS1 -4.13 5.94e-05 0.0223 -0.61 -0.32 Granulocyte percentage of myeloid white cells; chr4:6954074 chr4:7754090~7778928:+ PAAD cis rs66573146 0.656 rs56094305 ENSG00000272620.1 AFAP1-AS1 -4.13 5.94e-05 0.0223 -0.61 -0.32 Granulocyte percentage of myeloid white cells; chr4:6954359 chr4:7754090~7778928:+ PAAD cis rs172166 0.516 rs2791333 ENSG00000219891.2 ZSCAN12P1 4.13 5.94e-05 0.0223 0.41 0.32 Cardiac Troponin-T levels; chr6:28143336 chr6:28091154~28093664:+ PAAD cis rs10779751 1 rs1135172 ENSG00000238199.1 UBE2V2P3 4.13 5.94e-05 0.0223 0.38 0.32 Body mass index; chr1:11241657 chr1:11278616~11279351:- PAAD cis rs13256369 0.802 rs12681925 ENSG00000253981.4 ALG1L13P 4.13 5.95e-05 0.0223 0.43 0.32 Obesity-related traits; chr8:8704139 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs12680019 ENSG00000253981.4 ALG1L13P 4.13 5.95e-05 0.0223 0.43 0.32 Obesity-related traits; chr8:8704188 chr8:8236003~8244667:- PAAD cis rs5760092 0.618 rs5996631 ENSG00000099984.9 GSTT2 4.13 5.95e-05 0.0223 0.44 0.32 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23980123~23983911:+ PAAD cis rs7759001 0.681 rs13212050 ENSG00000271755.1 RP1-153G14.4 4.13 5.95e-05 0.0223 0.37 0.32 Glomerular filtration rate (creatinine); chr6:27511830 chr6:27404010~27406964:- PAAD cis rs7759001 0.681 rs7756377 ENSG00000271755.1 RP1-153G14.4 4.13 5.95e-05 0.0223 0.37 0.32 Glomerular filtration rate (creatinine); chr6:27513882 chr6:27404010~27406964:- PAAD cis rs270601 0.683 rs81598 ENSG00000233006.5 AC034220.3 4.13 5.95e-05 0.0223 0.28 0.32 Acylcarnitine levels; chr5:132252267 chr5:132311285~132369916:- PAAD cis rs1862618 0.853 rs10461617 ENSG00000271828.1 CTD-2310F14.1 4.13 5.95e-05 0.0223 0.46 0.32 Initial pursuit acceleration; chr5:56808481 chr5:56927874~56929573:+ PAAD cis rs812925 0.537 rs778153 ENSG00000273302.1 RP11-493E12.2 -4.13 5.96e-05 0.0223 -0.27 -0.32 Immature fraction of reticulocytes; chr2:61381517 chr2:61199979~61200769:+ PAAD cis rs889398 0.741 rs3790076 ENSG00000226232.7 RP11-419C5.2 4.13 5.96e-05 0.0223 0.26 0.32 Body mass index; chr16:69873542 chr16:69976388~69996188:- PAAD cis rs34375054 0.573 rs12831151 ENSG00000279233.1 RP11-158L12.4 4.13 5.96e-05 0.0223 0.3 0.32 Post bronchodilator FEV1/FVC ratio; chr12:125171717 chr12:125138245~125141711:+ PAAD cis rs1862618 0.853 rs190414 ENSG00000271828.1 CTD-2310F14.1 4.13 5.97e-05 0.0223 0.48 0.32 Initial pursuit acceleration; chr5:56820945 chr5:56927874~56929573:+ PAAD cis rs9926296 0.643 rs12596429 ENSG00000260259.1 RP11-368I7.4 -4.13 5.97e-05 0.0223 -0.37 -0.32 Vitiligo; chr16:89774966 chr16:89682620~89686569:- PAAD cis rs9601248 0.627 rs2146593 ENSG00000227354.5 RBM26-AS1 4.13 5.97e-05 0.0223 0.33 0.32 Major depressive disorder; chr13:79605977 chr13:79406309~79424328:+ PAAD cis rs4938303 0.549 rs11216096 ENSG00000254851.1 RP11-109L13.1 4.13 5.97e-05 0.0223 0.46 0.32 Triglycerides; chr11:116691864 chr11:117135528~117138582:+ PAAD cis rs4938303 0.549 rs12785772 ENSG00000254851.1 RP11-109L13.1 4.13 5.97e-05 0.0223 0.46 0.32 Triglycerides; chr11:116692892 chr11:117135528~117138582:+ PAAD cis rs4938303 0.549 rs12420888 ENSG00000254851.1 RP11-109L13.1 4.13 5.97e-05 0.0223 0.46 0.32 Triglycerides; chr11:116693106 chr11:117135528~117138582:+ PAAD cis rs878939 0.625 rs2193352 ENSG00000233690.1 EBAG9P1 4.13 5.97e-05 0.0223 0.41 0.32 Warfarin maintenance dose; chr10:99586852 chr10:99697407~99697949:- PAAD cis rs4759375 0.667 rs28397122 ENSG00000256092.2 RP13-942N8.1 4.13 5.97e-05 0.0223 0.59 0.32 HDL cholesterol; chr12:123364349 chr12:123363868~123366113:+ PAAD cis rs7189233 0.531 rs9932007 ENSG00000279344.1 RP11-44F14.7 4.13 5.97e-05 0.0223 0.24 0.32 Intelligence (multi-trait analysis); chr16:53422749 chr16:53478957~53481550:- PAAD cis rs6570726 0.935 rs906774 ENSG00000235652.6 RP11-545I5.3 4.13 5.97e-05 0.0223 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145492634 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs366308 ENSG00000235652.6 RP11-545I5.3 4.13 5.97e-05 0.0223 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145493396 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs384806 ENSG00000235652.6 RP11-545I5.3 4.13 5.97e-05 0.0223 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145493753 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs385185 ENSG00000235652.6 RP11-545I5.3 4.13 5.97e-05 0.0223 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145493856 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs384453 ENSG00000235652.6 RP11-545I5.3 4.13 5.97e-05 0.0223 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145494009 chr6:145799409~145886585:+ PAAD cis rs6570726 0.935 rs372378 ENSG00000235652.6 RP11-545I5.3 4.13 5.97e-05 0.0223 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145495091 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs388728 ENSG00000235652.6 RP11-545I5.3 4.13 5.97e-05 0.0223 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145495283 chr6:145799409~145886585:+ PAAD cis rs11089937 0.597 rs4821772 ENSG00000211638.2 IGLV8-61 4.13 5.98e-05 0.0224 0.29 0.32 Periodontitis (PAL4Q3); chr22:22131383 chr22:22098700~22099212:+ PAAD cis rs2115630 0.967 rs28595395 ENSG00000225151.9 GOLGA2P7 4.13 5.98e-05 0.0224 0.37 0.32 P wave terminal force; chr15:84791721 chr15:84199311~84230136:- PAAD cis rs10759883 0.627 rs13294931 ENSG00000175611.10 LINC00476 -4.13 5.98e-05 0.0224 -0.31 -0.32 Nicotine dependence; chr9:95833220 chr9:95759231~95875977:- PAAD cis rs7678555 0.863 rs11098553 ENSG00000178636.7 RP11-455G16.1 4.13 5.98e-05 0.0224 0.4 0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease; chr4:119976692 chr4:119192773~119212644:- PAAD cis rs10838687 0.736 rs12574081 ENSG00000255007.1 CTD-2589M5.4 4.13 5.98e-05 0.0224 0.41 0.32 Proinsulin levels; chr11:47264863 chr11:46256355~46274547:- PAAD cis rs748404 0.697 rs1095389 ENSG00000205771.5 CATSPER2P1 -4.13 5.98e-05 0.0224 -0.41 -0.32 Lung cancer; chr15:43274473 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs473554 ENSG00000205771.5 CATSPER2P1 -4.13 5.98e-05 0.0224 -0.41 -0.32 Lung cancer; chr15:43276009 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs498227 ENSG00000205771.5 CATSPER2P1 -4.13 5.98e-05 0.0224 -0.41 -0.32 Lung cancer; chr15:43280854 chr15:43726918~43747094:- PAAD cis rs748404 0.65 rs518234 ENSG00000205771.5 CATSPER2P1 -4.13 5.98e-05 0.0224 -0.41 -0.32 Lung cancer; chr15:43281223 chr15:43726918~43747094:- PAAD cis rs748404 0.65 rs518261 ENSG00000205771.5 CATSPER2P1 -4.13 5.98e-05 0.0224 -0.41 -0.32 Lung cancer; chr15:43281231 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs530683 ENSG00000205771.5 CATSPER2P1 4.13 5.98e-05 0.0224 0.41 0.32 Lung cancer; chr15:43276801 chr15:43726918~43747094:- PAAD cis rs42490 0.664 rs39515 ENSG00000251136.7 RP11-37B2.1 -4.13 5.98e-05 0.0224 -0.29 -0.32 Leprosy; chr8:89816761 chr8:89609409~89757727:- PAAD cis rs11089937 0.597 rs5756991 ENSG00000211638.2 IGLV8-61 -4.13 5.99e-05 0.0224 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22132541 chr22:22098700~22099212:+ PAAD cis rs11089937 0.54 rs5756992 ENSG00000211638.2 IGLV8-61 -4.13 5.99e-05 0.0224 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22132636 chr22:22098700~22099212:+ PAAD cis rs11089937 0.597 rs9622919 ENSG00000211638.2 IGLV8-61 -4.13 5.99e-05 0.0224 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22132863 chr22:22098700~22099212:+ PAAD cis rs11089937 0.597 rs9619793 ENSG00000211638.2 IGLV8-61 -4.13 5.99e-05 0.0224 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22132952 chr22:22098700~22099212:+ PAAD cis rs2832077 0.943 rs2832100 ENSG00000176054.6 RPL23P2 -4.13 5.99e-05 0.0224 -0.37 -0.32 Cognitive test performance; chr21:28803305 chr21:28997613~28998033:- PAAD cis rs1555322 1 rs2425032 ENSG00000279253.1 RP4-614O4.13 -4.13 5.99e-05 0.0224 -0.4 -0.32 Attention deficit hyperactivity disorder; chr20:35267651 chr20:35262727~35264187:- PAAD cis rs10888838 0.652 rs11577661 ENSG00000198711.5 SSBP3-AS1 4.13 5.99e-05 0.0224 0.4 0.32 Mitochondrial DNA levels; chr1:54227863 chr1:54236440~54239063:+ PAAD cis rs9322193 0.926 rs9766562 ENSG00000268592.3 RAET1E-AS1 4.13 5.99e-05 0.0224 0.38 0.32 Lung cancer; chr6:149788709 chr6:149863494~149919507:+ PAAD cis rs1707322 0.752 rs12062535 ENSG00000280836.1 AL355480.1 -4.13 5.99e-05 0.0224 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45757208 chr1:45581219~45581321:- PAAD cis rs13178541 0.81 rs4327594 ENSG00000250378.1 RP11-119J18.1 -4.13 6e-05 0.0224 -0.49 -0.32 IgG glycosylation; chr5:135774638 chr5:135812667~135826582:+ PAAD cis rs28386778 0.863 rs3826341 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63741862 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs11079510 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63743542 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs3760256 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63743801 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs8069969 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63744863 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs3785572 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63752629 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs4968662 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63757177 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs4968598 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63758219 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs4968663 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63758243 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs7222189 ENSG00000240280.5 TCAM1P -4.13 6e-05 0.0224 -0.44 -0.32 Prudent dietary pattern; chr17:63759012 chr17:63849292~63864379:+ PAAD cis rs7927592 0.913 rs12283755 ENSG00000212093.1 AP000807.1 4.13 6e-05 0.0224 0.38 0.32 Total body bone mineral density; chr11:68604190 chr11:68506083~68506166:- PAAD cis rs10951983 0.821 rs34106847 ENSG00000272719.1 CTB-161C1.1 -4.13 6e-05 0.0224 -0.39 -0.32 Coronary artery disease; chr7:6375101 chr7:5556731~5557245:+ PAAD cis rs11089937 0.597 rs11704434 ENSG00000211639.2 IGLV4-60 4.13 6e-05 0.0224 0.34 0.32 Periodontitis (PAL4Q3); chr22:22131715 chr22:22162199~22162681:+ PAAD cis rs113835537 0.935 rs79106199 ENSG00000255517.5 CTD-3074O7.5 -4.13 6e-05 0.0224 -0.52 -0.32 Airway imaging phenotypes; chr11:66653047 chr11:66473490~66480233:- PAAD cis rs113835537 0.935 rs117131621 ENSG00000255517.5 CTD-3074O7.5 -4.13 6e-05 0.0224 -0.52 -0.32 Airway imaging phenotypes; chr11:66654863 chr11:66473490~66480233:- PAAD cis rs113835537 0.935 rs57043177 ENSG00000255517.5 CTD-3074O7.5 -4.13 6e-05 0.0224 -0.52 -0.32 Airway imaging phenotypes; chr11:66655676 chr11:66473490~66480233:- PAAD cis rs1113500 0.933 rs61797344 ENSG00000226822.1 RP11-356N1.2 4.13 6.01e-05 0.0224 0.38 0.32 Growth-regulated protein alpha levels; chr1:108079958 chr1:108071482~108074519:+ PAAD cis rs17684571 0.687 rs34083827 ENSG00000231441.1 RP11-472M19.2 4.13 6.01e-05 0.0224 0.61 0.32 Schizophrenia; chr6:56866498 chr6:56844002~56864078:+ PAAD cis rs6951245 1 rs78308415 ENSG00000229043.2 AC091729.9 -4.13 6.01e-05 0.0224 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1032998 chr7:1160374~1165267:+ PAAD cis rs2446066 1 rs2446066 ENSG00000257379.1 RP11-793H13.8 4.13 6.01e-05 0.0224 0.46 0.32 Red blood cell count; chr12:53384866 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs2683522 ENSG00000257379.1 RP11-793H13.8 4.13 6.01e-05 0.0224 0.46 0.32 Red blood cell count; chr12:53389612 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs2694847 ENSG00000257379.1 RP11-793H13.8 4.13 6.01e-05 0.0224 0.46 0.32 Red blood cell count; chr12:53391244 chr12:53441741~53467528:+ PAAD cis rs2460882 1 rs2460882 ENSG00000257379.1 RP11-793H13.8 4.13 6.01e-05 0.0224 0.46 0.32 Percentage gas trapping; chr12:53394169 chr12:53441741~53467528:+ PAAD cis rs2446066 0.872 rs2608302 ENSG00000257379.1 RP11-793H13.8 4.13 6.01e-05 0.0224 0.46 0.32 Red blood cell count; chr12:53396512 chr12:53441741~53467528:+ PAAD cis rs6921919 0.609 rs9461455 ENSG00000219891.2 ZSCAN12P1 4.13 6.02e-05 0.0225 0.44 0.32 Autism spectrum disorder or schizophrenia; chr6:28361954 chr6:28091154~28093664:+ PAAD cis rs6921919 0.551 rs13201753 ENSG00000219891.2 ZSCAN12P1 4.13 6.02e-05 0.0225 0.44 0.32 Autism spectrum disorder or schizophrenia; chr6:28363351 chr6:28091154~28093664:+ PAAD cis rs11893307 0.509 rs2109958 ENSG00000235852.1 AC005540.3 4.13 6.02e-05 0.0225 0.47 0.32 Mean platelet volume; chr2:190668388 chr2:190880797~190882059:- PAAD cis rs11893307 0.509 rs11895262 ENSG00000235852.1 AC005540.3 4.13 6.02e-05 0.0225 0.47 0.32 Mean platelet volume; chr2:190669136 chr2:190880797~190882059:- PAAD cis rs6142102 0.961 rs6120487 ENSG00000276073.1 RP5-1125A11.7 -4.13 6.02e-05 0.0225 -0.34 -0.32 Skin pigmentation; chr20:34034802 chr20:33985617~33988989:- PAAD cis rs1113500 0.541 rs6692571 ENSG00000226822.1 RP11-356N1.2 4.13 6.02e-05 0.0225 0.39 0.32 Growth-regulated protein alpha levels; chr1:108034062 chr1:108071482~108074519:+ PAAD cis rs2806561 0.704 rs2806570 ENSG00000215381.3 RP5-1057J7.1 -4.13 6.03e-05 0.0225 -0.39 -0.32 Height; chr1:23200512 chr1:23244765~23245224:+ PAAD cis rs17772222 0.655 rs816072 ENSG00000258983.2 RP11-507K2.2 -4.13 6.04e-05 0.0225 -0.39 -0.32 Coronary artery calcification; chr14:88484335 chr14:88499334~88515502:+ PAAD cis rs17772222 0.682 rs1152377 ENSG00000258983.2 RP11-507K2.2 -4.13 6.04e-05 0.0225 -0.39 -0.32 Coronary artery calcification; chr14:88496243 chr14:88499334~88515502:+ PAAD cis rs950169 0.656 rs748455 ENSG00000275120.1 RP11-182J1.17 4.13 6.04e-05 0.0225 0.34 0.32 Schizophrenia; chr15:84606344 chr15:84599434~84606463:- PAAD cis rs755249 0.727 rs12028034 ENSG00000243970.1 PPIEL -4.13 6.04e-05 0.0225 -0.29 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39574035 chr1:39531838~39558707:- PAAD cis rs755249 0.567 rs1537817 ENSG00000261798.1 RP1-118J21.25 -4.13 6.04e-05 0.0225 -0.4 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39173981 chr1:39788976~39790171:+ PAAD cis rs7617773 0.817 rs3731555 ENSG00000228638.1 FCF1P2 -4.13 6.04e-05 0.0225 -0.35 -0.32 Coronary artery disease; chr3:48164612 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs3731550 ENSG00000228638.1 FCF1P2 -4.13 6.04e-05 0.0225 -0.35 -0.32 Coronary artery disease; chr3:48165093 chr3:48290793~48291375:- PAAD cis rs7617773 0.817 rs3731534 ENSG00000228638.1 FCF1P2 -4.13 6.04e-05 0.0225 -0.35 -0.32 Coronary artery disease; chr3:48170287 chr3:48290793~48291375:- PAAD cis rs7394190 0.935 rs4746140 ENSG00000272140.2 RP11-574K11.29 -4.13 6.04e-05 0.0225 -0.34 -0.32 Incident atrial fibrillation; chr10:73657491 chr10:73703735~73713581:- PAAD cis rs302972 0.826 rs79229624 ENSG00000168405.13 CMAHP 4.13 6.04e-05 0.0225 0.46 0.32 Creatinine levels in ischemic stroke; chr6:25074428 chr6:25081068~25166555:- PAAD cis rs8181477 1 rs11014504 ENSG00000240291.1 RP11-499P20.2 -4.13 6.04e-05 0.0225 -0.25 -0.32 Obesity-related traits; chr10:18495059 chr10:18513115~18545651:- PAAD cis rs889398 0.802 rs8050414 ENSG00000226232.7 RP11-419C5.2 -4.13 6.05e-05 0.0225 -0.25 -0.32 Body mass index; chr16:69852910 chr16:69976388~69996188:- PAAD cis rs889398 0.802 rs8051168 ENSG00000226232.7 RP11-419C5.2 -4.13 6.05e-05 0.0225 -0.25 -0.32 Body mass index; chr16:69853371 chr16:69976388~69996188:- PAAD cis rs889398 0.774 rs6499263 ENSG00000226232.7 RP11-419C5.2 -4.13 6.05e-05 0.0225 -0.25 -0.32 Body mass index; chr16:69856246 chr16:69976388~69996188:- PAAD cis rs889398 0.771 rs4985448 ENSG00000226232.7 RP11-419C5.2 -4.13 6.05e-05 0.0225 -0.25 -0.32 Body mass index; chr16:69865492 chr16:69976388~69996188:- PAAD cis rs889398 0.771 rs1566454 ENSG00000226232.7 RP11-419C5.2 -4.13 6.05e-05 0.0225 -0.25 -0.32 Body mass index; chr16:69866180 chr16:69976388~69996188:- PAAD cis rs889398 0.651 rs1566455 ENSG00000226232.7 RP11-419C5.2 -4.13 6.05e-05 0.0225 -0.25 -0.32 Body mass index; chr16:69866261 chr16:69976388~69996188:- PAAD cis rs889398 0.741 rs6499268 ENSG00000226232.7 RP11-419C5.2 -4.13 6.05e-05 0.0225 -0.25 -0.32 Body mass index; chr16:69872626 chr16:69976388~69996188:- PAAD cis rs4722166 0.532 rs1404008 ENSG00000179428.2 AC073072.5 -4.13 6.05e-05 0.0226 -0.28 -0.32 Lung cancer; chr7:22716381 chr7:22725395~22727620:- PAAD cis rs7189233 0.531 rs17801498 ENSG00000279344.1 RP11-44F14.7 4.13 6.05e-05 0.0226 0.24 0.32 Intelligence (multi-trait analysis); chr16:53479540 chr16:53478957~53481550:- PAAD cis rs1555322 0.929 rs2247828 ENSG00000279253.1 RP4-614O4.13 4.13 6.05e-05 0.0226 0.4 0.32 Attention deficit hyperactivity disorder; chr20:35252136 chr20:35262727~35264187:- PAAD cis rs7202877 0.706 rs37605 ENSG00000261783.1 RP11-252K23.2 4.13 6.05e-05 0.0226 0.5 0.32 Type 1 diabetes;Type 2 diabetes; chr16:75472674 chr16:75379818~75381260:- PAAD cis rs9326248 0.581 rs10892048 ENSG00000280143.1 AP000892.6 4.13 6.05e-05 0.0226 0.36 0.32 Blood protein levels; chr11:116943880 chr11:117204967~117210292:+ PAAD cis rs919433 0.889 rs788001 ENSG00000231621.1 AC013264.2 -4.13 6.05e-05 0.0226 -0.3 -0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197348996 chr2:197197991~197199273:+ PAAD cis rs12908161 0.959 rs2175567 ENSG00000259728.4 LINC00933 4.13 6.05e-05 0.0226 0.4 0.32 Schizophrenia; chr15:84657715 chr15:84570649~84580175:+ PAAD cis rs4853525 0.859 rs6434425 ENSG00000235852.1 AC005540.3 -4.13 6.05e-05 0.0226 -0.42 -0.32 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190857590 chr2:190880797~190882059:- PAAD cis rs11976180 1 rs7777389 ENSG00000273234.1 OR2A13P -4.13 6.05e-05 0.0226 -0.39 -0.32 Obesity-related traits; chr7:144047709 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs67239267 ENSG00000273234.1 OR2A13P -4.13 6.05e-05 0.0226 -0.39 -0.32 Obesity-related traits; chr7:144048023 chr7:144142009~144142938:+ PAAD cis rs858239 0.509 rs6962213 ENSG00000226816.2 AC005082.12 4.13 6.06e-05 0.0226 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23148490 chr7:23206013~23208045:+ PAAD cis rs6479891 1 rs10761730 ENSG00000232075.1 MRPL35P2 -4.13 6.06e-05 0.0226 -0.5 -0.32 Arthritis (juvenile idiopathic); chr10:63257293 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9415680 ENSG00000232075.1 MRPL35P2 -4.13 6.06e-05 0.0226 -0.5 -0.32 Arthritis (juvenile idiopathic); chr10:63261130 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs7916282 ENSG00000232075.1 MRPL35P2 -4.13 6.06e-05 0.0226 -0.5 -0.32 Arthritis (juvenile idiopathic); chr10:63272051 chr10:63634317~63634827:- PAAD cis rs6479891 0.915 rs9415682 ENSG00000232075.1 MRPL35P2 -4.13 6.06e-05 0.0226 -0.5 -0.32 Arthritis (juvenile idiopathic); chr10:63274057 chr10:63634317~63634827:- PAAD cis rs6479891 0.778 rs10761735 ENSG00000232075.1 MRPL35P2 -4.13 6.06e-05 0.0226 -0.5 -0.32 Arthritis (juvenile idiopathic); chr10:63284158 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9414786 ENSG00000232075.1 MRPL35P2 -4.13 6.06e-05 0.0226 -0.5 -0.32 Arthritis (juvenile idiopathic); chr10:63284562 chr10:63634317~63634827:- PAAD cis rs6479891 0.822 rs6479892 ENSG00000232075.1 MRPL35P2 -4.13 6.06e-05 0.0226 -0.5 -0.32 Arthritis (juvenile idiopathic); chr10:63292472 chr10:63634317~63634827:- PAAD cis rs2581828 0.608 rs9830353 ENSG00000242142.1 SERBP1P3 -4.13 6.06e-05 0.0226 -0.39 -0.32 Crohn's disease; chr3:53129937 chr3:53064283~53065091:- PAAD cis rs10129255 0.5 rs1024350 ENSG00000211972.2 IGHV3-66 4.13 6.06e-05 0.0226 0.24 0.32 Kawasaki disease; chr14:106685105 chr14:106675017~106675544:- PAAD cis rs6964833 1 rs17515241 ENSG00000277053.3 GTF2IP1 4.13 6.06e-05 0.0226 0.42 0.32 Menarche (age at onset); chr7:74717695 chr7:75185385~75237696:- PAAD cis rs10779751 1 rs7549109 ENSG00000238199.1 UBE2V2P3 4.13 6.06e-05 0.0226 0.38 0.32 Body mass index; chr1:11218756 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs12124983 ENSG00000238199.1 UBE2V2P3 4.13 6.06e-05 0.0226 0.38 0.32 Body mass index; chr1:11226121 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs2076655 ENSG00000238199.1 UBE2V2P3 4.13 6.06e-05 0.0226 0.38 0.32 Body mass index; chr1:11229104 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs7544489 ENSG00000238199.1 UBE2V2P3 4.13 6.06e-05 0.0226 0.38 0.32 Body mass index; chr1:11239454 chr1:11278616~11279351:- PAAD cis rs10779751 0.879 rs7543400 ENSG00000238199.1 UBE2V2P3 -4.13 6.06e-05 0.0226 -0.38 -0.32 Body mass index; chr1:11223907 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs12730522 ENSG00000238199.1 UBE2V2P3 -4.13 6.06e-05 0.0226 -0.38 -0.32 Body mass index; chr1:11224034 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs4845987 ENSG00000238199.1 UBE2V2P3 -4.13 6.06e-05 0.0226 -0.38 -0.32 Body mass index; chr1:11246222 chr1:11278616~11279351:- PAAD cis rs1124769 0.525 rs11070812 ENSG00000259240.1 RP11-108K3.1 -4.13 6.07e-05 0.0226 -0.41 -0.32 Cognitive performance; chr15:50770295 chr15:51037488~51293912:+ PAAD cis rs1124769 0.502 rs35088194 ENSG00000259240.1 RP11-108K3.1 -4.13 6.07e-05 0.0226 -0.41 -0.32 Cognitive performance; chr15:50773717 chr15:51037488~51293912:+ PAAD cis rs916888 0.821 rs199506 ENSG00000261575.2 RP11-259G18.1 -4.13 6.07e-05 0.0226 -0.47 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46267037~46268694:+ PAAD cis rs10486158 0.901 rs1294614 ENSG00000233264.2 AC006042.8 4.13 6.08e-05 0.0226 0.4 0.32 Bipolar disorder and schizophrenia; chr7:7327333 chr7:7980312~7982228:+ PAAD cis rs12908161 1 rs58416181 ENSG00000259728.4 LINC00933 4.13 6.08e-05 0.0226 0.4 0.32 Schizophrenia; chr15:84721230 chr15:84570649~84580175:+ PAAD cis rs287982 1 rs287976 ENSG00000269973.1 RP11-95D17.1 4.13 6.08e-05 0.0226 0.36 0.32 Nonsyndromic cleft lip with cleft palate; chr2:9829559 chr2:9936360~9939590:+ PAAD cis rs287982 1 rs287979 ENSG00000269973.1 RP11-95D17.1 4.13 6.08e-05 0.0226 0.36 0.32 Nonsyndromic cleft lip with cleft palate; chr2:9830838 chr2:9936360~9939590:+ PAAD cis rs287982 1 rs287980 ENSG00000269973.1 RP11-95D17.1 4.13 6.08e-05 0.0226 0.36 0.32 Nonsyndromic cleft lip with cleft palate; chr2:9831237 chr2:9936360~9939590:+ PAAD cis rs287982 1 rs287981 ENSG00000269973.1 RP11-95D17.1 4.13 6.08e-05 0.0226 0.36 0.32 Nonsyndromic cleft lip with cleft palate; chr2:9831433 chr2:9936360~9939590:+ PAAD cis rs2188561 0.697 rs2237679 ENSG00000241764.3 AC002467.7 4.13 6.08e-05 0.0226 0.41 0.32 Alcohol consumption; chr7:107693581 chr7:107742817~107744581:- PAAD cis rs2188561 0.697 rs2072064 ENSG00000241764.3 AC002467.7 4.13 6.08e-05 0.0226 0.41 0.32 Alcohol consumption; chr7:107694068 chr7:107742817~107744581:- PAAD cis rs72843506 0.656 rs111249650 ENSG00000189423.10 USP32P3 4.12 6.08e-05 0.0227 0.49 0.32 Schizophrenia; chr17:20008517 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs79406817 ENSG00000189423.10 USP32P3 4.12 6.08e-05 0.0227 0.49 0.32 Schizophrenia; chr17:20011814 chr17:20415547~20431008:+ PAAD cis rs1124769 0.525 rs8033807 ENSG00000259306.2 RP11-108K3.2 -4.12 6.08e-05 0.0227 -0.39 -0.32 Cognitive performance; chr15:50778531 chr15:51315841~51321996:+ PAAD cis rs4683346 0.616 rs3843369 ENSG00000173811.9 CCDC13-AS1 -4.12 6.08e-05 0.0227 -0.36 -0.32 Granulocyte percentage of myeloid white cells; chr3:42765556 chr3:42732575~42746768:+ PAAD cis rs2658782 1 rs2019814 ENSG00000279684.1 RP11-755E23.2 -4.12 6.09e-05 0.0227 -0.53 -0.32 Pulmonary function decline; chr11:93435719 chr11:93286629~93288903:- PAAD cis rs1113500 0.933 rs11185250 ENSG00000226822.1 RP11-356N1.2 4.12 6.09e-05 0.0227 0.38 0.32 Growth-regulated protein alpha levels; chr1:108073795 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs1419003 ENSG00000226822.1 RP11-356N1.2 4.12 6.09e-05 0.0227 0.38 0.32 Growth-regulated protein alpha levels; chr1:108074333 chr1:108071482~108074519:+ PAAD cis rs858239 0.57 rs10271613 ENSG00000226816.2 AC005082.12 4.12 6.09e-05 0.0227 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23122967 chr7:23206013~23208045:+ PAAD cis rs858239 0.57 rs10242166 ENSG00000226816.2 AC005082.12 4.12 6.09e-05 0.0227 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23123180 chr7:23206013~23208045:+ PAAD cis rs858239 0.57 rs6968242 ENSG00000226816.2 AC005082.12 4.12 6.09e-05 0.0227 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23127792 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs1981665 ENSG00000226816.2 AC005082.12 4.12 6.09e-05 0.0227 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23128350 chr7:23206013~23208045:+ PAAD cis rs875971 0.522 rs709604 ENSG00000236529.1 RP13-254B10.1 -4.12 6.09e-05 0.0227 -0.34 -0.32 Aortic root size; chr7:66032447 chr7:65840212~65840596:+ PAAD cis rs28386778 0.863 rs9897229 ENSG00000240280.5 TCAM1P -4.12 6.09e-05 0.0227 -0.43 -0.32 Prudent dietary pattern; chr17:63704965 chr17:63849292~63864379:+ PAAD cis rs172166 0.637 rs1225592 ENSG00000204709.4 LINC01556 4.12 6.09e-05 0.0227 0.49 0.32 Cardiac Troponin-T levels; chr6:28182464 chr6:28943877~28944537:+ PAAD cis rs172166 0.637 rs1225595 ENSG00000204709.4 LINC01556 4.12 6.09e-05 0.0227 0.49 0.32 Cardiac Troponin-T levels; chr6:28183562 chr6:28943877~28944537:+ PAAD cis rs453301 0.658 rs9650616 ENSG00000253893.2 FAM85B 4.12 6.1e-05 0.0227 0.43 0.32 Joint mobility (Beighton score); chr8:9011689 chr8:8167819~8226614:- PAAD cis rs9876781 0.56 rs4558783 ENSG00000229759.1 MRPS18AP1 -4.12 6.1e-05 0.0227 -0.34 -0.32 Longevity; chr3:48365972 chr3:48256350~48256938:- PAAD cis rs8026198 0.929 rs2918461 ENSG00000260571.1 BNIP3P5 -4.12 6.1e-05 0.0227 -0.51 -0.32 Fibrinogen levels; chr15:42328283 chr15:42313687~42314386:+ PAAD cis rs4266144 0.558 rs4680339 ENSG00000244515.1 KRT18P34 4.12 6.1e-05 0.0227 0.36 0.32 Coronary artery disease; chr3:157117630 chr3:157162663~157163932:- PAAD cis rs1387259 0.69 rs1601985 ENSG00000258273.1 RP11-370I10.4 -4.12 6.1e-05 0.0227 -0.39 -0.32 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48368131 chr12:48333755~48333901:- PAAD cis rs12682352 0.602 rs13260419 ENSG00000253893.2 FAM85B -4.12 6.1e-05 0.0227 -0.46 -0.32 Neuroticism; chr8:8817666 chr8:8167819~8226614:- PAAD cis rs9357354 0.927 rs34512993 ENSG00000218809.1 RP1-229K20.5 4.12 6.1e-05 0.0227 0.35 0.32 Telomere length; chr6:41343918 chr6:41269875~41270239:- PAAD cis rs1707322 0.717 rs2275086 ENSG00000280836.1 AL355480.1 4.12 6.11e-05 0.0227 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620207 chr1:45581219~45581321:- PAAD cis rs12439619 0.846 rs7496227 ENSG00000276710.3 CSPG4P8 -4.12 6.11e-05 0.0227 -0.35 -0.32 Intelligence (multi-trait analysis); chr15:82275241 chr15:82459472~82477258:+ PAAD cis rs9309473 0.95 rs10189885 ENSG00000163016.8 ALMS1P 4.12 6.11e-05 0.0227 0.47 0.32 Metabolite levels; chr2:73649928 chr2:73644919~73685576:+ PAAD cis rs919433 0.889 rs12693816 ENSG00000231621.1 AC013264.2 4.12 6.11e-05 0.0227 0.3 0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197343696 chr2:197197991~197199273:+ PAAD cis rs4835473 0.897 rs13135627 ENSG00000251600.4 RP11-673E1.1 -4.12 6.11e-05 0.0227 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143691099 chr4:143912331~143982454:+ PAAD cis rs4722166 0.532 rs4719712 ENSG00000179428.2 AC073072.5 -4.12 6.12e-05 0.0228 -0.28 -0.32 Lung cancer; chr7:22716188 chr7:22725395~22727620:- PAAD cis rs4835473 0.9 rs10027246 ENSG00000251600.4 RP11-673E1.1 -4.12 6.12e-05 0.0228 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143935069 chr4:143912331~143982454:+ PAAD cis rs4835473 0.808 rs11725413 ENSG00000251600.4 RP11-673E1.1 -4.12 6.12e-05 0.0228 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143943366 chr4:143912331~143982454:+ PAAD cis rs17711722 0.583 rs10085415 ENSG00000236529.1 RP13-254B10.1 -4.12 6.12e-05 0.0228 -0.36 -0.32 Calcium levels; chr7:65628655 chr7:65840212~65840596:+ PAAD cis rs720064 0.558 rs7245197 ENSG00000264745.1 TTC39C-AS1 4.12 6.12e-05 0.0228 0.41 0.32 Strep throat; chr18:23926339 chr18:23994213~24015339:- PAAD cis rs720064 0.586 rs12958287 ENSG00000264745.1 TTC39C-AS1 4.12 6.12e-05 0.0228 0.41 0.32 Strep throat; chr18:23927465 chr18:23994213~24015339:- PAAD cis rs79349575 0.811 rs60708039 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48922011 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs55771415 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48922575 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs2088139 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48922748 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4793991 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48924439 chr17:48899131~48899748:+ PAAD cis rs79349575 0.715 rs62075844 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48925027 chr17:48899131~48899748:+ PAAD cis rs79349575 0.749 rs957557 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48925859 chr17:48899131~48899748:+ PAAD cis rs79349575 0.749 rs12601672 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48929131 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs17635252 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48929588 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs56046215 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48931395 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4399576 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48932473 chr17:48899131~48899748:+ PAAD cis rs79349575 0.687 rs12602179 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48932672 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs17708633 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48934258 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs9747646 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48939520 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs62075852 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48939814 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs12601858 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48940115 chr17:48899131~48899748:+ PAAD cis rs79349575 0.715 rs55724082 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48940517 chr17:48899131~48899748:+ PAAD cis rs79349575 0.749 rs8182364 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48940663 chr17:48899131~48899748:+ PAAD cis rs79349575 0.681 rs56080003 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48941687 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4793995 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48942037 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4793996 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48942235 chr17:48899131~48899748:+ PAAD cis rs79349575 0.715 rs4793997 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48942310 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4793998 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48942537 chr17:48899131~48899748:+ PAAD cis rs79349575 0.749 rs2270574 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48944908 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4794000 ENSG00000270781.1 RP11-501C14.9 -4.12 6.12e-05 0.0228 -0.36 -0.32 Type 2 diabetes; chr17:48945393 chr17:48899131~48899748:+ PAAD cis rs11690935 0.589 rs2271758 ENSG00000228389.1 AC068039.4 -4.12 6.12e-05 0.0228 -0.38 -0.32 Schizophrenia; chr2:171844647 chr2:171773482~171775844:+ PAAD cis rs2985684 0.894 rs4581611 ENSG00000259113.1 RP11-406H23.2 -4.12 6.12e-05 0.0228 -0.44 -0.32 Carotid intima media thickness; chr14:49576802 chr14:50448807~50456742:+ PAAD cis rs12935418 0.672 rs12446304 ENSG00000261061.1 RP11-303E16.2 -4.12 6.13e-05 0.0228 -0.39 -0.32 Mean corpuscular volume; chr16:81012730 chr16:81030770~81031485:+ PAAD cis rs12935418 0.672 rs9923948 ENSG00000261061.1 RP11-303E16.2 -4.12 6.13e-05 0.0228 -0.39 -0.32 Mean corpuscular volume; chr16:81013814 chr16:81030770~81031485:+ PAAD cis rs2638953 0.924 rs11049606 ENSG00000247934.4 RP11-967K21.1 -4.12 6.13e-05 0.0228 -0.35 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28444213 chr12:28163298~28190738:- PAAD cis rs2522056 1 rs2057655 ENSG00000233006.5 AC034220.3 4.12 6.13e-05 0.0228 0.29 0.32 Fibrinogen;Lymphocyte counts; chr5:132471932 chr5:132311285~132369916:- PAAD cis rs7189233 0.531 rs1861351 ENSG00000279344.1 RP11-44F14.7 4.12 6.13e-05 0.0228 0.24 0.32 Intelligence (multi-trait analysis); chr16:53499315 chr16:53478957~53481550:- PAAD cis rs216345 0.667 rs7357700 ENSG00000230074.1 RP11-195F19.9 -4.12 6.13e-05 0.0228 -0.42 -0.32 Bipolar disorder; chr9:33892533 chr9:34665665~34681298:+ PAAD cis rs216345 0.731 rs4879734 ENSG00000230074.1 RP11-195F19.9 -4.12 6.13e-05 0.0228 -0.42 -0.32 Bipolar disorder; chr9:33915906 chr9:34665665~34681298:+ PAAD cis rs7727544 0.904 rs7736102 ENSG00000233006.5 AC034220.3 4.12 6.13e-05 0.0228 0.24 0.32 Blood metabolite levels; chr5:132268564 chr5:132311285~132369916:- PAAD cis rs7727544 0.904 rs6897575 ENSG00000233006.5 AC034220.3 4.12 6.13e-05 0.0228 0.24 0.32 Blood metabolite levels; chr5:132268842 chr5:132311285~132369916:- PAAD cis rs853679 0.527 rs213228 ENSG00000219891.2 ZSCAN12P1 4.12 6.13e-05 0.0228 0.44 0.32 Depression; chr6:28363475 chr6:28091154~28093664:+ PAAD cis rs732716 0.889 rs55637375 ENSG00000267769.1 CTB-50L17.9 -4.12 6.13e-05 0.0228 -0.42 -0.32 Mean corpuscular volume; chr19:4386848 chr19:4454014~4455286:+ PAAD cis rs2019137 0.868 rs6755639 ENSG00000274877.1 RP11-65I12.1 -4.12 6.14e-05 0.0228 -0.36 -0.32 Lymphocyte counts; chr2:113224233 chr2:113237595~113240825:+ PAAD cis rs10129255 0.5 rs8021941 ENSG00000211972.2 IGHV3-66 4.12 6.14e-05 0.0228 0.25 0.32 Kawasaki disease; chr14:106781490 chr14:106675017~106675544:- PAAD cis rs812925 0.533 rs60997156 ENSG00000271889.1 RP11-493E12.1 4.12 6.14e-05 0.0228 0.34 0.32 Immature fraction of reticulocytes; chr2:61169404 chr2:61151433~61162105:- PAAD cis rs812925 0.533 rs35507645 ENSG00000271889.1 RP11-493E12.1 4.12 6.14e-05 0.0228 0.34 0.32 Immature fraction of reticulocytes; chr2:61169631 chr2:61151433~61162105:- PAAD cis rs801193 0.569 rs13226966 ENSG00000232559.3 GS1-124K5.12 4.12 6.15e-05 0.0228 0.35 0.32 Aortic root size; chr7:66768636 chr7:66554588~66576923:- PAAD cis rs7647973 0.6 rs12631989 ENSG00000226913.1 BSN-AS2 -4.12 6.15e-05 0.0228 -0.35 -0.32 Menarche (age at onset); chr3:49236563 chr3:49549306~49554366:- PAAD cis rs7647973 0.6 rs13064780 ENSG00000226913.1 BSN-AS2 -4.12 6.15e-05 0.0228 -0.35 -0.32 Menarche (age at onset); chr3:49237393 chr3:49549306~49554366:- PAAD cis rs11976180 1 rs13226728 ENSG00000273234.1 OR2A13P -4.12 6.15e-05 0.0228 -0.39 -0.32 Obesity-related traits; chr7:144049485 chr7:144142009~144142938:+ PAAD cis rs12134133 0.752 rs6673080 ENSG00000274245.1 RP11-357P18.2 4.12 6.15e-05 0.0228 0.53 0.32 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207216859 chr1:207372559~207373252:+ PAAD cis rs12134133 0.752 rs6540874 ENSG00000274245.1 RP11-357P18.2 4.12 6.15e-05 0.0228 0.53 0.32 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207221638 chr1:207372559~207373252:+ PAAD cis rs12134133 0.752 rs6683677 ENSG00000274245.1 RP11-357P18.2 4.12 6.15e-05 0.0228 0.53 0.32 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207228335 chr1:207372559~207373252:+ PAAD cis rs72627509 0.951 rs17087335 ENSG00000269949.1 RP11-738E22.3 4.12 6.15e-05 0.0228 0.49 0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56972417 chr4:56960927~56961373:- PAAD cis rs72627509 1 rs72627509 ENSG00000269949.1 RP11-738E22.3 4.12 6.15e-05 0.0228 0.49 0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56972885 chr4:56960927~56961373:- PAAD cis rs72627509 1 rs57265257 ENSG00000269949.1 RP11-738E22.3 4.12 6.15e-05 0.0228 0.49 0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56973114 chr4:56960927~56961373:- PAAD cis rs2333194 1 rs2333194 ENSG00000258695.2 RP3-414A15.2 -4.12 6.15e-05 0.0228 -0.35 -0.32 Bipolar disorder with mood-incongruent psychosis; chr14:73300506 chr14:73522878~73530610:+ PAAD cis rs2262909 0.962 rs422344 ENSG00000279377.1 AC003973.3 -4.12 6.15e-05 0.0229 -0.3 -0.32 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22048154 chr19:21965708~21968529:- PAAD cis rs755249 0.567 rs4660603 ENSG00000261798.1 RP1-118J21.25 -4.12 6.16e-05 0.0229 -0.4 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39270662 chr1:39788976~39790171:+ PAAD cis rs7617773 0.78 rs13066044 ENSG00000228638.1 FCF1P2 -4.12 6.16e-05 0.0229 -0.35 -0.32 Coronary artery disease; chr3:48335786 chr3:48290793~48291375:- PAAD cis rs7617773 0.778 rs11715776 ENSG00000228638.1 FCF1P2 -4.12 6.16e-05 0.0229 -0.35 -0.32 Coronary artery disease; chr3:48336121 chr3:48290793~48291375:- PAAD cis rs7617773 0.778 rs11707997 ENSG00000228638.1 FCF1P2 -4.12 6.16e-05 0.0229 -0.35 -0.32 Coronary artery disease; chr3:48336385 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs11720026 ENSG00000228638.1 FCF1P2 -4.12 6.16e-05 0.0229 -0.35 -0.32 Coronary artery disease; chr3:48336431 chr3:48290793~48291375:- PAAD cis rs7617773 0.743 rs11715876 ENSG00000228638.1 FCF1P2 -4.12 6.16e-05 0.0229 -0.35 -0.32 Coronary artery disease; chr3:48336432 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs35297486 ENSG00000228638.1 FCF1P2 -4.12 6.16e-05 0.0229 -0.35 -0.32 Coronary artery disease; chr3:48336657 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs11716848 ENSG00000228638.1 FCF1P2 -4.12 6.16e-05 0.0229 -0.35 -0.32 Coronary artery disease; chr3:48337010 chr3:48290793~48291375:- PAAD cis rs12571093 0.504 rs4443961 ENSG00000233590.1 RP11-153K11.3 4.12 6.16e-05 0.0229 0.51 0.32 Optic nerve measurement (disc area); chr10:68285725 chr10:68233251~68242379:- PAAD cis rs6844153 0.68 rs11729927 ENSG00000240005.4 RP11-293A21.1 -4.12 6.16e-05 0.0229 -0.46 -0.32 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26922178 chr4:26859806~26860599:- PAAD cis rs875971 0.862 rs6971059 ENSG00000232559.3 GS1-124K5.12 -4.12 6.17e-05 0.0229 -0.36 -0.32 Aortic root size; chr7:66602045 chr7:66554588~66576923:- PAAD cis rs875971 0.755 rs76288834 ENSG00000232559.3 GS1-124K5.12 -4.12 6.17e-05 0.0229 -0.36 -0.32 Aortic root size; chr7:66604815 chr7:66554588~66576923:- PAAD cis rs875971 0.789 rs7808013 ENSG00000232559.3 GS1-124K5.12 -4.12 6.17e-05 0.0229 -0.36 -0.32 Aortic root size; chr7:66606209 chr7:66554588~66576923:- PAAD cis rs875971 0.825 rs7384021 ENSG00000232559.3 GS1-124K5.12 -4.12 6.17e-05 0.0229 -0.36 -0.32 Aortic root size; chr7:66612917 chr7:66554588~66576923:- PAAD cis rs875971 0.825 rs66981195 ENSG00000232559.3 GS1-124K5.12 -4.12 6.17e-05 0.0229 -0.36 -0.32 Aortic root size; chr7:66614048 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs3926380 ENSG00000232559.3 GS1-124K5.12 -4.12 6.17e-05 0.0229 -0.36 -0.32 Aortic root size; chr7:66615658 chr7:66554588~66576923:- PAAD cis rs875971 0.825 rs1860472 ENSG00000232559.3 GS1-124K5.12 -4.12 6.17e-05 0.0229 -0.36 -0.32 Aortic root size; chr7:66617736 chr7:66554588~66576923:- PAAD cis rs2412819 0.597 rs514311 ENSG00000249839.1 AC011330.5 -4.12 6.17e-05 0.0229 -0.49 -0.32 Lung cancer; chr15:43869376 chr15:43663654~43684339:- PAAD cis rs72843506 0.656 rs77314146 ENSG00000189423.10 USP32P3 4.12 6.17e-05 0.0229 0.49 0.32 Schizophrenia; chr17:20003827 chr17:20415547~20431008:+ PAAD cis rs9649213 0.574 rs7791321 ENSG00000272950.1 RP11-307C18.1 4.12 6.17e-05 0.0229 0.37 0.32 Prostate cancer (SNP x SNP interaction); chr7:98314813 chr7:98322853~98323430:+ PAAD cis rs919433 0.617 rs13018267 ENSG00000231621.1 AC013264.2 4.12 6.17e-05 0.0229 0.31 0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197680868 chr2:197197991~197199273:+ PAAD cis rs919433 0.927 rs6759834 ENSG00000231621.1 AC013264.2 4.12 6.18e-05 0.0229 0.31 0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197340136 chr2:197197991~197199273:+ PAAD cis rs2439831 0.867 rs2447208 ENSG00000275601.1 AC011330.13 -4.12 6.18e-05 0.0229 -0.51 -0.32 Lung cancer in ever smokers; chr15:43641697 chr15:43642389~43643023:- PAAD cis rs287982 1 rs287977 ENSG00000269973.1 RP11-95D17.1 4.12 6.18e-05 0.0229 0.36 0.32 Nonsyndromic cleft lip with cleft palate; chr2:9829889 chr2:9936360~9939590:+ PAAD cis rs801193 0.901 rs4273746 ENSG00000237310.1 GS1-124K5.4 -4.12 6.18e-05 0.023 -0.3 -0.32 Aortic root size; chr7:66836124 chr7:66493706~66495474:+ PAAD cis rs6539288 0.677 rs10778515 ENSG00000260329.1 RP11-412D9.4 -4.12 6.19e-05 0.023 -0.29 -0.32 Total body bone mineral density; chr12:106938703 chr12:106954029~106955497:- PAAD cis rs7824557 0.767 rs6985460 ENSG00000205879.4 FAM90A2P 4.12 6.19e-05 0.023 0.41 0.32 Retinal vascular caliber; chr8:11313578 chr8:12172202~12178575:- PAAD cis rs867371 0.929 rs7173852 ENSG00000259429.4 UBE2Q2P2 -4.12 6.19e-05 0.023 -0.25 -0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82169512 chr15:82355142~82420075:+ PAAD cis rs7189233 0.531 rs9921587 ENSG00000279344.1 RP11-44F14.7 4.12 6.19e-05 0.023 0.24 0.32 Intelligence (multi-trait analysis); chr16:53441738 chr16:53478957~53481550:- PAAD cis rs11079159 0.565 rs4794563 ENSG00000263096.1 RP11-515O17.2 4.12 6.19e-05 0.023 0.39 0.32 QRS duration; chr17:55304524 chr17:55271504~55273653:- PAAD cis rs3096299 0.685 rs4785568 ENSG00000261253.2 AC137932.6 4.12 6.19e-05 0.023 0.35 0.32 Multiple myeloma (IgH translocation); chr16:89487299 chr16:89321133~89325110:+ PAAD cis rs6479901 0.895 rs7916224 ENSG00000232075.1 MRPL35P2 -4.12 6.19e-05 0.023 -0.46 -0.32 Intelligence (multi-trait analysis); chr10:63144843 chr10:63634317~63634827:- PAAD cis rs4834770 1 rs878375 ENSG00000245958.5 RP11-33B1.1 -4.12 6.19e-05 0.023 -0.24 -0.32 Blood protein levels; chr4:119316419 chr4:119454791~119552025:+ PAAD cis rs9487094 0.71 rs10499052 ENSG00000260273.1 RP11-425D10.10 4.12 6.2e-05 0.023 0.45 0.32 Height; chr6:109564272 chr6:109382795~109383666:+ PAAD cis rs8012947 0.651 rs74055634 ENSG00000257621.6 PSMA3-AS1 4.12 6.2e-05 0.023 0.18 0.32 Alcohol consumption in current drinkers; chr14:58361359 chr14:58265365~58298134:- PAAD cis rs338389 0.586 rs10851782 ENSG00000260657.2 RP11-315D16.4 -4.12 6.2e-05 0.023 -0.36 -0.32 Survival in rectal cancer; chr15:67972711 chr15:68267792~68277994:- PAAD cis rs713477 0.631 rs7145182 ENSG00000258413.1 RP11-665C16.6 4.12 6.2e-05 0.023 0.38 0.32 Pediatric bone mineral content (femoral neck); chr14:55438513 chr14:55262767~55272075:- PAAD cis rs17772222 0.958 rs12436326 ENSG00000258983.2 RP11-507K2.2 4.12 6.21e-05 0.023 0.43 0.32 Coronary artery calcification; chr14:88533632 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs17203789 ENSG00000258983.2 RP11-507K2.2 4.12 6.21e-05 0.023 0.43 0.32 Coronary artery calcification; chr14:88541362 chr14:88499334~88515502:+ PAAD cis rs7759001 0.744 rs6920733 ENSG00000271755.1 RP1-153G14.4 4.12 6.21e-05 0.023 0.38 0.32 Glomerular filtration rate (creatinine); chr6:27466608 chr6:27404010~27406964:- PAAD cis rs875971 0.862 rs10282433 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66256452 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10276077 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66263424 chr7:66554588~66576923:- PAAD cis rs875971 0.825 rs4587224 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66271195 chr7:66554588~66576923:- PAAD cis rs875971 0.792 rs6971752 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66272999 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10950033 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66274686 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs11760844 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66274896 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs4149461 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66279745 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs4236208 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66284091 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10261398 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66285177 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10224872 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66294786 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs949930 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66301835 chr7:66554588~66576923:- PAAD cis rs875971 0.825 rs1000464 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66312922 chr7:66554588~66576923:- PAAD cis rs875971 0.928 rs2036263 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66335210 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10240949 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66339430 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs7782704 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66340379 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6460290 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66344119 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6959268 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66347979 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778720 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66381288 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs11773628 ENSG00000232559.3 GS1-124K5.12 -4.12 6.21e-05 0.023 -0.35 -0.32 Aortic root size; chr7:66517644 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs12537823 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66255897 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778734 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66349862 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778724 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66364304 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778686 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66370923 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778684 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66371416 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778680 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66375427 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs11769079 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66377141 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs1695820 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66379576 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs778715 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66384222 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs809025 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66384832 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778702 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66399848 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs1643375 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66407690 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6962717 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66418748 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6460302 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66495270 chr7:66554588~66576923:- PAAD cis rs875971 0.798 rs6460304 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66499741 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6945775 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66503987 chr7:66554588~66576923:- PAAD cis rs875971 0.798 rs57739047 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66507579 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs6950137 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66511623 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs11763189 ENSG00000232559.3 GS1-124K5.12 4.12 6.21e-05 0.023 0.35 0.32 Aortic root size; chr7:66518542 chr7:66554588~66576923:- PAAD cis rs2408955 0.522 rs3997 ENSG00000240399.1 RP1-228P16.1 -4.12 6.21e-05 0.023 -0.33 -0.32 Glycated hemoglobin levels; chr12:48087804 chr12:48054813~48055591:- PAAD cis rs7189233 0.531 rs62048526 ENSG00000279344.1 RP11-44F14.7 4.12 6.21e-05 0.023 0.24 0.32 Intelligence (multi-trait analysis); chr16:53478014 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs8062535 ENSG00000279344.1 RP11-44F14.7 4.12 6.21e-05 0.023 0.24 0.32 Intelligence (multi-trait analysis); chr16:53478576 chr16:53478957~53481550:- PAAD cis rs11168351 0.927 rs10875716 ENSG00000240399.1 RP1-228P16.1 4.12 6.22e-05 0.023 0.34 0.32 Bipolar disorder and schizophrenia; chr12:47995240 chr12:48054813~48055591:- PAAD cis rs6782228 1 rs7429360 ENSG00000242551.2 POU5F1P6 4.12 6.22e-05 0.023 0.41 0.32 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128645954 chr3:128674735~128677005:- PAAD cis rs2243480 0.901 rs73142137 ENSG00000232546.1 RP11-458F8.1 -4.12 6.22e-05 0.0231 -0.38 -0.32 Diabetic kidney disease; chr7:65878455 chr7:66848496~66858136:+ PAAD cis rs755249 0.567 rs2018212 ENSG00000261798.1 RP1-118J21.25 4.12 6.22e-05 0.0231 0.4 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39439916 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs4660751 ENSG00000261798.1 RP1-118J21.25 4.12 6.22e-05 0.0231 0.4 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39440201 chr1:39788976~39790171:+ PAAD cis rs755249 0.532 rs2296173 ENSG00000261798.1 RP1-118J21.25 4.12 6.22e-05 0.0231 0.4 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39447679 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs3118014 ENSG00000261798.1 RP1-118J21.25 4.12 6.22e-05 0.0231 0.4 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39448418 chr1:39788976~39790171:+ PAAD cis rs780096 0.546 rs7563162 ENSG00000234072.1 AC074117.10 -4.12 6.22e-05 0.0231 -0.25 -0.32 Total body bone mineral density; chr2:27408324 chr2:27356246~27367622:+ PAAD cis rs780096 0.546 rs1060525 ENSG00000234072.1 AC074117.10 -4.12 6.22e-05 0.0231 -0.25 -0.32 Total body bone mineral density; chr2:27412715 chr2:27356246~27367622:+ PAAD cis rs780096 0.546 rs12473776 ENSG00000234072.1 AC074117.10 -4.12 6.22e-05 0.0231 -0.25 -0.32 Total body bone mineral density; chr2:27413607 chr2:27356246~27367622:+ PAAD cis rs780096 0.546 rs4665976 ENSG00000234072.1 AC074117.10 -4.12 6.22e-05 0.0231 -0.25 -0.32 Total body bone mineral density; chr2:27417458 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs2911713 ENSG00000234072.1 AC074117.10 -4.12 6.22e-05 0.0231 -0.25 -0.32 Total body bone mineral density; chr2:27418113 chr2:27356246~27367622:+ PAAD cis rs780096 0.506 rs1728922 ENSG00000234072.1 AC074117.10 -4.12 6.22e-05 0.0231 -0.25 -0.32 Total body bone mineral density; chr2:27421597 chr2:27356246~27367622:+ PAAD cis rs780096 0.546 rs6547626 ENSG00000234072.1 AC074117.10 -4.12 6.22e-05 0.0231 -0.25 -0.32 Total body bone mineral density; chr2:27423903 chr2:27356246~27367622:+ PAAD cis rs891378 1 rs2184476 ENSG00000274245.1 RP11-357P18.2 -4.12 6.22e-05 0.0231 -0.44 -0.32 Spherical equivalent (joint analysis main effects and education interaction); chr1:207331324 chr1:207372559~207373252:+ PAAD cis rs891378 0.959 rs1507757 ENSG00000274245.1 RP11-357P18.2 -4.12 6.22e-05 0.0231 -0.44 -0.32 Spherical equivalent (joint analysis main effects and education interaction); chr1:207331403 chr1:207372559~207373252:+ PAAD cis rs6142102 0.527 rs1015362 ENSG00000276073.1 RP5-1125A11.7 4.12 6.23e-05 0.0231 0.37 0.32 Skin pigmentation; chr20:34150806 chr20:33985617~33988989:- PAAD cis rs72627509 0.904 rs7687767 ENSG00000269949.1 RP11-738E22.3 -4.12 6.23e-05 0.0231 -0.49 -0.32 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56958766 chr4:56960927~56961373:- PAAD cis rs7224610 0.931 rs7223342 ENSG00000263096.1 RP11-515O17.2 4.12 6.23e-05 0.0231 0.39 0.32 Urate levels; chr17:55292233 chr17:55271504~55273653:- PAAD cis rs7727544 0.836 rs10463892 ENSG00000233006.5 AC034220.3 4.12 6.23e-05 0.0231 0.24 0.32 Blood metabolite levels; chr5:132263012 chr5:132311285~132369916:- PAAD cis rs7727544 0.901 rs55633655 ENSG00000233006.5 AC034220.3 4.12 6.23e-05 0.0231 0.24 0.32 Blood metabolite levels; chr5:132263063 chr5:132311285~132369916:- PAAD cis rs7727544 0.904 rs58835386 ENSG00000233006.5 AC034220.3 4.12 6.23e-05 0.0231 0.24 0.32 Blood metabolite levels; chr5:132264866 chr5:132311285~132369916:- PAAD cis rs763121 0.819 rs5757160 ENSG00000228274.3 RP3-508I15.9 -4.12 6.24e-05 0.0231 -0.3 -0.32 Menopause (age at onset); chr22:38593641 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5750633 ENSG00000228274.3 RP3-508I15.9 -4.12 6.24e-05 0.0231 -0.3 -0.32 Menopause (age at onset); chr22:38597462 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757166 ENSG00000228274.3 RP3-508I15.9 -4.12 6.24e-05 0.0231 -0.3 -0.32 Menopause (age at onset); chr22:38599380 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs1569716 ENSG00000228274.3 RP3-508I15.9 -4.12 6.24e-05 0.0231 -0.3 -0.32 Menopause (age at onset); chr22:38602514 chr22:38667585~38681820:- PAAD cis rs763121 0.819 rs5757169 ENSG00000228274.3 RP3-508I15.9 -4.12 6.24e-05 0.0231 -0.3 -0.32 Menopause (age at onset); chr22:38607490 chr22:38667585~38681820:- PAAD cis rs3096299 0.658 rs4291902 ENSG00000261253.2 AC137932.6 4.12 6.24e-05 0.0231 0.34 0.32 Multiple myeloma (IgH translocation); chr16:89493907 chr16:89321133~89325110:+ PAAD cis rs7202877 0.611 rs56092808 ENSG00000261783.1 RP11-252K23.2 -4.12 6.24e-05 0.0231 -0.51 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75278818 chr16:75379818~75381260:- PAAD cis rs894157 0.92 rs4932240 ENSG00000255571.5 LINC00925 4.12 6.24e-05 0.0231 0.45 0.32 Obesity-related traits; chr15:89649674 chr15:89361579~89398487:+ PAAD cis rs9322193 0.923 rs2342857 ENSG00000268592.3 RAET1E-AS1 4.12 6.25e-05 0.0231 0.38 0.32 Lung cancer; chr6:149809537 chr6:149863494~149919507:+ PAAD cis rs227932 0.681 rs79586340 ENSG00000234286.1 AC006026.13 -4.12 6.25e-05 0.0232 -0.54 -0.32 Schizophrenia; chr7:23746122 chr7:23680195~23680786:- PAAD cis rs227932 0.681 rs75405201 ENSG00000234286.1 AC006026.13 -4.12 6.25e-05 0.0232 -0.54 -0.32 Schizophrenia; chr7:23746123 chr7:23680195~23680786:- PAAD cis rs3096299 0.559 rs9931073 ENSG00000261253.2 AC137932.6 4.12 6.26e-05 0.0232 0.34 0.32 Multiple myeloma (IgH translocation); chr16:89502105 chr16:89321133~89325110:+ PAAD cis rs66573146 0.656 rs41410847 ENSG00000272620.1 AFAP1-AS1 -4.12 6.26e-05 0.0232 -0.6 -0.32 Granulocyte percentage of myeloid white cells; chr4:6955605 chr4:7754090~7778928:+ PAAD cis rs12908161 0.92 rs35738019 ENSG00000259728.4 LINC00933 4.12 6.26e-05 0.0232 0.4 0.32 Schizophrenia; chr15:84736979 chr15:84570649~84580175:+ PAAD cis rs12908161 1 rs34570071 ENSG00000259728.4 LINC00933 4.12 6.26e-05 0.0232 0.4 0.32 Schizophrenia; chr15:84736981 chr15:84570649~84580175:+ PAAD cis rs4423214 0.547 rs11234030 ENSG00000254682.1 RP11-660L16.2 -4.12 6.26e-05 0.0232 -0.52 -0.32 Vitamin D levels; chr11:71525921 chr11:71448674~71452157:+ PAAD cis rs4423214 0.592 rs7130829 ENSG00000254682.1 RP11-660L16.2 -4.12 6.26e-05 0.0232 -0.52 -0.32 Vitamin D levels; chr11:71526656 chr11:71448674~71452157:+ PAAD cis rs17382119 0.518 rs344031 ENSG00000240875.4 LINC00886 -4.12 6.27e-05 0.0232 -0.6 -0.32 Clozapine-induced cytotoxicity; chr3:156746262 chr3:156747346~156817062:- PAAD cis rs6860540 0.796 rs11466790 ENSG00000251405.2 CTB-109A12.1 -4.12 6.27e-05 0.0232 -0.41 -0.32 Inflammatory skin disease; chr5:157491979 chr5:157362615~157460078:- PAAD cis rs4835473 0.864 rs28609839 ENSG00000251600.4 RP11-673E1.1 -4.12 6.27e-05 0.0232 -0.37 -0.32 Immature fraction of reticulocytes; chr4:143954160 chr4:143912331~143982454:+ PAAD cis rs7829975 0.54 rs2976909 ENSG00000254340.1 RP11-10A14.3 -4.12 6.27e-05 0.0232 -0.38 -0.32 Mood instability; chr8:8489180 chr8:9141424~9145435:+ PAAD cis rs591584 0.73 rs11020836 ENSG00000255893.1 RP11-685N10.1 -4.12 6.28e-05 0.0232 -0.4 -0.32 Macrophage Migration Inhibitory Factor levels; chr11:94575726 chr11:94472908~94473570:- PAAD cis rs77372450 0.636 rs6865742 ENSG00000251405.2 CTB-109A12.1 4.12 6.28e-05 0.0232 0.49 0.32 Bipolar disorder (body mass index interaction); chr5:157596254 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs11750662 ENSG00000251405.2 CTB-109A12.1 4.12 6.28e-05 0.0232 0.49 0.32 Bipolar disorder (body mass index interaction); chr5:157600710 chr5:157362615~157460078:- PAAD cis rs7202877 0.656 rs977986 ENSG00000261783.1 RP11-252K23.2 -4.12 6.28e-05 0.0232 -0.5 -0.32 Type 1 diabetes;Type 2 diabetes; chr16:75472798 chr16:75379818~75381260:- PAAD cis rs13217239 0.646 rs7768407 ENSG00000241549.7 GUSBP2 4.12 6.28e-05 0.0232 0.33 0.32 Schizophrenia; chr6:27049016 chr6:26871484~26956554:- PAAD cis rs2554380 0.55 rs4572348 ENSG00000230373.7 GOLGA6L5P -4.12 6.29e-05 0.0233 -0.3 -0.32 Height; chr15:83871411 chr15:84507885~84516814:- PAAD cis rs9322193 0.962 rs3763162 ENSG00000268592.3 RAET1E-AS1 -4.12 6.29e-05 0.0233 -0.37 -0.32 Lung cancer; chr6:149819674 chr6:149863494~149919507:+ PAAD cis rs4660214 0.666 rs683135 ENSG00000237624.1 OXCT2P1 4.12 6.29e-05 0.0233 0.41 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39429788 chr1:39514956~39516490:+ PAAD cis rs2712184 0.846 rs7598172 ENSG00000229352.1 AC007563.3 -4.12 6.29e-05 0.0233 -0.31 -0.32 Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine); chr2:216813276 chr2:216799608~216805335:+ PAAD cis rs3738443 1 rs74152976 ENSG00000259865.1 RP11-488L18.10 4.12 6.29e-05 0.0233 0.3 0.32 Alcohol dependence; chr1:247183504 chr1:247187281~247188526:- PAAD cis rs6504950 0.925 rs244315 ENSG00000275710.1 RP11-257O5.4 4.12 6.29e-05 0.0233 0.42 0.32 Breast cancer; chr17:55137293 chr17:54964474~54964679:+ PAAD cis rs4660214 0.666 rs2256614 ENSG00000228060.1 RP11-69E11.8 -4.12 6.3e-05 0.0233 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39359046 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs596062 ENSG00000228060.1 RP11-69E11.8 -4.12 6.3e-05 0.0233 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39360333 chr1:39565160~39573203:+ PAAD cis rs72843506 0.656 rs74648067 ENSG00000189423.10 USP32P3 4.12 6.3e-05 0.0233 0.49 0.32 Schizophrenia; chr17:20022938 chr17:20415547~20431008:+ PAAD cis rs6539288 0.63 rs3759316 ENSG00000260329.1 RP11-412D9.4 -4.12 6.3e-05 0.0233 -0.29 -0.32 Total body bone mineral density; chr12:106976432 chr12:106954029~106955497:- PAAD cis rs12602901 1 rs12602901 ENSG00000234327.6 AC012146.7 4.12 6.31e-05 0.0233 0.3 0.32 Blood metabolite levels; chr17:4921330 chr17:5111468~5115004:+ PAAD cis rs8059260 0.877 rs111352543 ENSG00000274038.1 RP11-66H6.4 -4.12 6.31e-05 0.0233 -0.48 -0.32 Alcohol consumption over the past year; chr16:10949603 chr16:11056556~11057034:+ PAAD cis rs875971 0.767 rs1643394 ENSG00000232559.3 GS1-124K5.12 4.12 6.31e-05 0.0233 0.35 0.32 Aortic root size; chr7:66371107 chr7:66554588~66576923:- PAAD cis rs498136 0.734 rs631683 ENSG00000250508.1 RP11-757G1.6 4.12 6.31e-05 0.0233 0.4 0.32 Cutaneous malignant melanoma;Melanoma; chr11:69532570 chr11:68870664~68874542:+ PAAD cis rs3738443 0.951 rs4269806 ENSG00000259865.1 RP11-488L18.10 4.12 6.32e-05 0.0234 0.29 0.32 Alcohol dependence; chr1:247211721 chr1:247187281~247188526:- PAAD cis rs3738443 0.951 rs4551629 ENSG00000259865.1 RP11-488L18.10 4.12 6.32e-05 0.0234 0.29 0.32 Alcohol dependence; chr1:247211748 chr1:247187281~247188526:- PAAD cis rs3738443 0.951 rs41315860 ENSG00000259865.1 RP11-488L18.10 4.12 6.32e-05 0.0234 0.29 0.32 Alcohol dependence; chr1:247212558 chr1:247187281~247188526:- PAAD cis rs4853012 0.838 rs72915068 ENSG00000257800.1 FNBP1P1 4.11 6.33e-05 0.0234 0.44 0.32 Gestational age at birth (maternal effect); chr2:74129058 chr2:74120680~74123218:+ PAAD cis rs7766910 1 rs13209180 ENSG00000234261.2 RP11-146I2.1 4.11 6.33e-05 0.0234 0.39 0.32 Pediatric bone mineral content (radius); chr6:14099852 chr6:14661829~15090003:- PAAD cis rs28386778 0.897 rs2854214 ENSG00000240280.5 TCAM1P 4.11 6.33e-05 0.0234 0.44 0.32 Prudent dietary pattern; chr17:63868089 chr17:63849292~63864379:+ PAAD cis rs9487094 0.689 rs9480936 ENSG00000260273.1 RP11-425D10.10 4.11 6.33e-05 0.0234 0.38 0.32 Height; chr6:109358227 chr6:109382795~109383666:+ PAAD cis rs7829975 0.688 rs6601703 ENSG00000173295.6 FAM86B3P 4.11 6.33e-05 0.0234 0.32 0.32 Mood instability; chr8:8522714 chr8:8228595~8244865:+ PAAD cis rs7927592 0.913 rs7116994 ENSG00000212093.1 AP000807.1 4.11 6.33e-05 0.0234 0.37 0.32 Total body bone mineral density; chr11:68487159 chr11:68506083~68506166:- PAAD cis rs79040073 0.6 rs57785991 ENSG00000259531.2 RP11-295H24.3 4.11 6.33e-05 0.0234 0.52 0.32 Lung cancer in ever smokers; chr15:49188443 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11635814 ENSG00000259531.2 RP11-295H24.3 4.11 6.33e-05 0.0234 0.52 0.32 Lung cancer in ever smokers; chr15:49195028 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73392236 ENSG00000259531.2 RP11-295H24.3 4.11 6.33e-05 0.0234 0.52 0.32 Lung cancer in ever smokers; chr15:49216829 chr15:49365124~49366685:- PAAD cis rs9473147 0.843 rs6904933 ENSG00000270761.1 RP11-385F7.1 -4.11 6.34e-05 0.0234 -0.32 -0.32 Platelet distribution width;Mean platelet volume; chr6:47660822 chr6:47477243~47477572:- PAAD cis rs73173548 0.502 rs12189343 ENSG00000247828.6 TMEM161B-AS1 4.11 6.34e-05 0.0234 0.26 0.32 Macular telangiectasia type 2; chr5:88447510 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs13180798 ENSG00000247828.6 TMEM161B-AS1 4.11 6.34e-05 0.0234 0.27 0.32 Macular telangiectasia type 2; chr5:88425633 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs13163266 ENSG00000247828.6 TMEM161B-AS1 4.11 6.34e-05 0.0234 0.27 0.32 Macular telangiectasia type 2; chr5:88425703 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs13180932 ENSG00000247828.6 TMEM161B-AS1 4.11 6.34e-05 0.0234 0.27 0.32 Macular telangiectasia type 2; chr5:88425720 chr5:88268895~88436685:+ PAAD cis rs13217239 0.646 rs10946888 ENSG00000241549.7 GUSBP2 4.11 6.34e-05 0.0234 0.32 0.32 Schizophrenia; chr6:26983899 chr6:26871484~26956554:- PAAD cis rs74233809 0.901 rs7098825 ENSG00000213277.3 MARCKSL1P1 4.11 6.35e-05 0.0234 0.54 0.32 Birth weight; chr10:102868477 chr10:103175554~103176094:+ PAAD cis rs812925 0.511 rs11886950 ENSG00000271889.1 RP11-493E12.1 4.11 6.35e-05 0.0234 0.34 0.32 Immature fraction of reticulocytes; chr2:61172182 chr2:61151433~61162105:- PAAD cis rs35934224 0.891 rs13054713 ENSG00000232926.1 AC000078.5 4.11 6.35e-05 0.0234 0.44 0.32 Glaucoma (primary open-angle); chr22:19880391 chr22:19887289~19887970:+ PAAD cis rs35934224 0.891 rs33997573 ENSG00000232926.1 AC000078.5 4.11 6.35e-05 0.0234 0.44 0.32 Glaucoma (primary open-angle); chr22:19881428 chr22:19887289~19887970:+ PAAD cis rs35934224 0.831 rs8141610 ENSG00000232926.1 AC000078.5 -4.11 6.35e-05 0.0234 -0.44 -0.32 Glaucoma (primary open-angle); chr22:19882624 chr22:19887289~19887970:+ PAAD cis rs73081554 0.611 rs4681852 ENSG00000272360.1 RP11-359I18.5 -4.11 6.35e-05 0.0234 -0.51 -0.32 Rheumatoid arthritis; chr3:58423446 chr3:58490830~58491291:- PAAD cis rs41369048 0.8 rs2784252 ENSG00000238078.1 LINC01352 -4.11 6.35e-05 0.0234 -0.43 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220889342 chr1:220829255~220832429:+ PAAD cis rs710913 0.604 rs1180343 ENSG00000237624.1 OXCT2P1 -4.11 6.35e-05 0.0234 -0.4 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527760 chr1:39514956~39516490:+ PAAD cis rs9322193 0.923 rs9688350 ENSG00000268592.3 RAET1E-AS1 4.11 6.36e-05 0.0235 0.37 0.32 Lung cancer; chr6:149730977 chr6:149863494~149919507:+ PAAD cis rs7189233 0.592 rs2024449 ENSG00000279344.1 RP11-44F14.7 4.11 6.36e-05 0.0235 0.23 0.32 Intelligence (multi-trait analysis); chr16:53460705 chr16:53478957~53481550:- PAAD cis rs3096299 0.506 rs3114863 ENSG00000274627.1 RP11-104N10.2 4.11 6.36e-05 0.0235 0.29 0.32 Multiple myeloma (IgH translocation); chr16:89372259 chr16:89516797~89522217:+ PAAD cis rs302972 0.826 rs7740534 ENSG00000168405.13 CMAHP 4.11 6.36e-05 0.0235 0.45 0.32 Creatinine levels in ischemic stroke; chr6:25076951 chr6:25081068~25166555:- PAAD cis rs2638953 0.924 rs11049418 ENSG00000247934.4 RP11-967K21.1 -4.11 6.36e-05 0.0235 -0.35 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28192154 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs12367188 ENSG00000247934.4 RP11-967K21.1 -4.11 6.36e-05 0.0235 -0.35 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28192511 chr12:28163298~28190738:- PAAD cis rs7572733 0.534 rs734037 ENSG00000231621.1 AC013264.2 -4.11 6.36e-05 0.0235 -0.31 -0.32 Dermatomyositis; chr2:197884545 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs13395030 ENSG00000231621.1 AC013264.2 -4.11 6.36e-05 0.0235 -0.31 -0.32 Dermatomyositis; chr2:197886082 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs2060488 ENSG00000231621.1 AC013264.2 -4.11 6.36e-05 0.0235 -0.31 -0.32 Dermatomyositis; chr2:197886913 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs6434943 ENSG00000231621.1 AC013264.2 -4.11 6.36e-05 0.0235 -0.31 -0.32 Dermatomyositis; chr2:197897468 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs6729473 ENSG00000231621.1 AC013264.2 -4.11 6.36e-05 0.0235 -0.31 -0.32 Dermatomyositis; chr2:197899204 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs6760891 ENSG00000231621.1 AC013264.2 -4.11 6.36e-05 0.0235 -0.31 -0.32 Dermatomyositis; chr2:197903442 chr2:197197991~197199273:+ PAAD cis rs7572733 0.534 rs7572123 ENSG00000231621.1 AC013264.2 -4.11 6.36e-05 0.0235 -0.31 -0.32 Dermatomyositis; chr2:197904913 chr2:197197991~197199273:+ PAAD cis rs2239557 0.5 rs7157723 ENSG00000259065.1 RP5-1021I20.1 4.11 6.36e-05 0.0235 0.4 0.32 Common traits (Other); chr14:73999497 chr14:73787360~73803270:+ PAAD cis rs6539288 0.899 rs6539290 ENSG00000260329.1 RP11-412D9.4 -4.11 6.36e-05 0.0235 -0.27 -0.32 Total body bone mineral density; chr12:106915871 chr12:106954029~106955497:- PAAD cis rs748404 0.697 rs530683 ENSG00000249839.1 AC011330.5 4.11 6.37e-05 0.0235 0.43 0.32 Lung cancer; chr15:43276801 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs1095389 ENSG00000249839.1 AC011330.5 -4.11 6.37e-05 0.0235 -0.43 -0.32 Lung cancer; chr15:43274473 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs473554 ENSG00000249839.1 AC011330.5 -4.11 6.37e-05 0.0235 -0.43 -0.32 Lung cancer; chr15:43276009 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs498227 ENSG00000249839.1 AC011330.5 -4.11 6.37e-05 0.0235 -0.43 -0.32 Lung cancer; chr15:43280854 chr15:43663654~43684339:- PAAD cis rs748404 0.65 rs518234 ENSG00000249839.1 AC011330.5 -4.11 6.37e-05 0.0235 -0.43 -0.32 Lung cancer; chr15:43281223 chr15:43663654~43684339:- PAAD cis rs748404 0.65 rs518261 ENSG00000249839.1 AC011330.5 -4.11 6.37e-05 0.0235 -0.43 -0.32 Lung cancer; chr15:43281231 chr15:43663654~43684339:- PAAD cis rs633715 0.788 rs630372 ENSG00000254154.7 RP4-798P15.3 -4.11 6.37e-05 0.0235 -0.26 -0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177916627 chr1:177928788~178038007:- PAAD cis rs1113500 0.933 rs61797345 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108081106 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs1414674 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108083325 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs11185256 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108091335 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs10881498 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108092362 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs12035689 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108094134 chr1:108071482~108074519:+ PAAD cis rs1113500 0.862 rs3853494 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108094712 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs4517375 ENSG00000226822.1 RP11-356N1.2 -4.11 6.37e-05 0.0235 -0.37 -0.32 Growth-regulated protein alpha levels; chr1:108095708 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs4590700 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108095722 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs11185261 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108096081 chr1:108071482~108074519:+ PAAD cis rs1113500 0.897 rs4628530 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108096086 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs10881500 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108096273 chr1:108071482~108074519:+ PAAD cis rs1113500 0.897 rs10785832 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108096277 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs10785833 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108096460 chr1:108071482~108074519:+ PAAD cis rs1113500 0.897 rs55980437 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108096876 chr1:108071482~108074519:+ PAAD cis rs1113500 0.702 rs11185262 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108097120 chr1:108071482~108074519:+ PAAD cis rs1113500 0.862 rs2336129 ENSG00000226822.1 RP11-356N1.2 -4.11 6.37e-05 0.0235 -0.37 -0.32 Growth-regulated protein alpha levels; chr1:108098047 chr1:108071482~108074519:+ PAAD cis rs1113500 0.862 rs2336128 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108098117 chr1:108071482~108074519:+ PAAD cis rs1113500 0.897 rs2336127 ENSG00000226822.1 RP11-356N1.2 4.11 6.37e-05 0.0235 0.37 0.32 Growth-regulated protein alpha levels; chr1:108098248 chr1:108071482~108074519:+ PAAD cis rs4938303 0.633 rs61906081 ENSG00000254851.1 RP11-109L13.1 4.11 6.37e-05 0.0235 0.53 0.32 Triglycerides; chr11:116666342 chr11:117135528~117138582:+ PAAD cis rs4938303 0.633 rs1960036 ENSG00000254851.1 RP11-109L13.1 4.11 6.37e-05 0.0235 0.53 0.32 Triglycerides; chr11:116676692 chr11:117135528~117138582:+ PAAD cis rs4938303 0.633 rs12801136 ENSG00000254851.1 RP11-109L13.1 4.11 6.37e-05 0.0235 0.53 0.32 Triglycerides; chr11:116677632 chr11:117135528~117138582:+ PAAD cis rs4938303 0.633 rs35963862 ENSG00000254851.1 RP11-109L13.1 4.11 6.37e-05 0.0235 0.53 0.32 Triglycerides; chr11:116679180 chr11:117135528~117138582:+ PAAD cis rs4938303 0.633 rs61906104 ENSG00000254851.1 RP11-109L13.1 4.11 6.37e-05 0.0235 0.53 0.32 Triglycerides; chr11:116679398 chr11:117135528~117138582:+ PAAD cis rs4938303 0.671 rs35352977 ENSG00000254851.1 RP11-109L13.1 4.11 6.37e-05 0.0235 0.53 0.32 Triglycerides; chr11:116681756 chr11:117135528~117138582:+ PAAD cis rs4938303 0.633 rs35681250 ENSG00000254851.1 RP11-109L13.1 4.11 6.37e-05 0.0235 0.53 0.32 Triglycerides; chr11:116684670 chr11:117135528~117138582:+ PAAD cis rs2739330 0.828 rs2877178 ENSG00000206090.4 AP000350.7 4.11 6.37e-05 0.0235 0.4 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23939998~23942798:+ PAAD cis rs2739330 0.828 rs2154593 ENSG00000206090.4 AP000350.7 4.11 6.37e-05 0.0235 0.4 0.32 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23939998~23942798:+ PAAD cis rs2599510 0.693 rs2754514 ENSG00000276334.1 AL133243.1 4.11 6.38e-05 0.0235 0.39 0.32 Interleukin-18 levels; chr2:32563769 chr2:32521927~32523547:+ PAAD cis rs6951245 0.935 rs118132455 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1028596 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs78628466 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1028817 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs11768761 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1030171 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs76833820 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1030642 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs28379681 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1030903 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs28528096 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1031276 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs74369356 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1032075 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs77083167 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1032187 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs74347384 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1032804 chr7:1160374~1165267:+ PAAD cis rs6951245 0.872 rs75493422 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1033254 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs118059236 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1033566 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs113858334 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1033840 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs79765398 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1034128 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs79443843 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1035609 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs78896566 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040546 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs79422648 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040605 chr7:1160374~1165267:+ PAAD cis rs6951245 0.872 rs113119264 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1040928 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs76804143 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1042385 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs1997243 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1044141 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs77760339 ENSG00000229043.2 AC091729.9 -4.11 6.38e-05 0.0235 -0.5 -0.32 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1044291 chr7:1160374~1165267:+ PAAD cis rs4938303 0.549 rs12291024 ENSG00000254851.1 RP11-109L13.1 4.11 6.38e-05 0.0235 0.46 0.32 Triglycerides; chr11:116689951 chr11:117135528~117138582:+ PAAD cis rs28374715 0.662 rs72737786 ENSG00000247556.5 OIP5-AS1 4.11 6.38e-05 0.0235 0.33 0.32 Ulcerative colitis; chr15:41208163 chr15:41283990~41309737:+ PAAD cis rs812925 0.714 rs1900573 ENSG00000271889.1 RP11-493E12.1 -4.11 6.38e-05 0.0235 -0.36 -0.32 Immature fraction of reticulocytes; chr2:61369777 chr2:61151433~61162105:- PAAD cis rs28386778 0.966 rs2854161 ENSG00000240280.5 TCAM1P 4.11 6.39e-05 0.0235 0.45 0.32 Prudent dietary pattern; chr17:63898733 chr17:63849292~63864379:+ PAAD cis rs1927790 0.643 rs9556570 ENSG00000247400.3 DNAJC3-AS1 4.11 6.39e-05 0.0235 0.3 0.32 Body mass index; chr13:96346839 chr13:95648733~95676925:- PAAD cis rs7189233 0.531 rs7202621 ENSG00000279344.1 RP11-44F14.7 4.11 6.39e-05 0.0235 0.24 0.32 Intelligence (multi-trait analysis); chr16:53452125 chr16:53478957~53481550:- PAAD cis rs4835473 0.715 rs1849124 ENSG00000251600.4 RP11-673E1.1 4.11 6.39e-05 0.0235 0.38 0.32 Immature fraction of reticulocytes; chr4:143978494 chr4:143912331~143982454:+ PAAD cis rs4835473 0.689 rs1849123 ENSG00000251600.4 RP11-673E1.1 4.11 6.39e-05 0.0235 0.38 0.32 Immature fraction of reticulocytes; chr4:143978495 chr4:143912331~143982454:+ PAAD cis rs12439619 0.846 rs62011975 ENSG00000276710.3 CSPG4P8 -4.11 6.39e-05 0.0235 -0.35 -0.32 Intelligence (multi-trait analysis); chr15:82159213 chr15:82459472~82477258:+ PAAD cis rs12439619 0.846 rs62012003 ENSG00000276710.3 CSPG4P8 -4.11 6.39e-05 0.0235 -0.35 -0.32 Intelligence (multi-trait analysis); chr15:82183236 chr15:82459472~82477258:+ PAAD cis rs12439619 0.846 rs62012004 ENSG00000276710.3 CSPG4P8 -4.11 6.39e-05 0.0235 -0.35 -0.32 Intelligence (multi-trait analysis); chr15:82183924 chr15:82459472~82477258:+ PAAD cis rs12439619 0.846 rs62013464 ENSG00000276710.3 CSPG4P8 -4.11 6.39e-05 0.0235 -0.35 -0.32 Intelligence (multi-trait analysis); chr15:82288250 chr15:82459472~82477258:+ PAAD cis rs12439619 0.846 rs62010071 ENSG00000276710.3 CSPG4P8 -4.11 6.39e-05 0.0235 -0.35 -0.32 Intelligence (multi-trait analysis); chr15:82289442 chr15:82459472~82477258:+ PAAD cis rs2243480 0.901 rs57126451 ENSG00000232546.1 RP11-458F8.1 -4.11 6.39e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65951319 chr7:66848496~66858136:+ PAAD cis rs11790994 1 rs11790994 ENSG00000271384.1 RP11-435O5.7 -4.11 6.4e-05 0.0236 -0.62 -0.32 Inattentive symptoms; chr9:95666984 chr9:95406990~95407662:- PAAD cis rs7759001 0.779 rs4711153 ENSG00000271755.1 RP1-153G14.4 4.11 6.4e-05 0.0236 0.38 0.32 Glomerular filtration rate (creatinine); chr6:27467130 chr6:27404010~27406964:- PAAD cis rs151234 0.741 rs151227 ENSG00000259982.1 CDC37P1 -4.11 6.4e-05 0.0236 -0.56 -0.32 Platelet distribution width; chr16:28538187 chr16:28700294~28701540:- PAAD cis rs1862618 0.853 rs6450408 ENSG00000271828.1 CTD-2310F14.1 4.11 6.41e-05 0.0236 0.46 0.32 Initial pursuit acceleration; chr5:56802319 chr5:56927874~56929573:+ PAAD cis rs6840258 0.66 rs6531941 ENSG00000251411.1 RP11-397E7.4 4.11 6.41e-05 0.0236 0.37 0.32 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86974808 chr4:86913266~86914817:- PAAD cis rs17772222 1 rs12589467 ENSG00000258983.2 RP11-507K2.2 4.11 6.41e-05 0.0236 0.44 0.32 Coronary artery calcification; chr14:88357239 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs12433464 ENSG00000258983.2 RP11-507K2.2 4.11 6.41e-05 0.0236 0.44 0.32 Coronary artery calcification; chr14:88357671 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs1955599 ENSG00000258983.2 RP11-507K2.2 4.11 6.41e-05 0.0236 0.44 0.32 Coronary artery calcification; chr14:88358788 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs1955600 ENSG00000258983.2 RP11-507K2.2 4.11 6.41e-05 0.0236 0.44 0.32 Coronary artery calcification; chr14:88359040 chr14:88499334~88515502:+ PAAD cis rs858239 0.601 rs929507 ENSG00000226816.2 AC005082.12 4.11 6.41e-05 0.0236 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23127045 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs929508 ENSG00000226816.2 AC005082.12 4.11 6.41e-05 0.0236 0.36 0.32 Cerebrospinal fluid biomarker levels; chr7:23127090 chr7:23206013~23208045:+ PAAD cis rs916888 0.821 rs199504 ENSG00000261575.2 RP11-259G18.1 -4.11 6.42e-05 0.0236 -0.47 -0.32 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46267037~46268694:+ PAAD cis rs2243480 1 rs34702770 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65879836 chr7:66848496~66858136:+ PAAD cis rs2243480 0.803 rs35480979 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65892097 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34637256 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65895144 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs35391607 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65895842 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs13220979 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65898217 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34974928 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65899019 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs67728539 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65913137 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34136756 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65916269 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs78803505 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65917585 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34933526 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65918212 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34577383 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65920739 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6949812 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65922114 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs55895244 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65922691 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6970243 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65923503 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs7794661 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65924743 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs7795242 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65925107 chr7:66848496~66858136:+ PAAD cis rs2243480 0.708 rs35310401 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65925372 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs35058610 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65925938 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2177703 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65926730 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs35432774 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65928032 chr7:66848496~66858136:+ PAAD cis rs2243480 0.831 rs7806717 ENSG00000232546.1 RP11-458F8.1 4.11 6.42e-05 0.0236 0.38 0.32 Diabetic kidney disease; chr7:65928187 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs56985706 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65929575 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs60683927 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65929781 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs58062456 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65929865 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34529418 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65938222 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs35087093 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65940221 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs35046236 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65943626 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs36068983 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65944004 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs68189316 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65944182 chr7:66848496~66858136:+ PAAD cis rs2243480 0.803 rs34804747 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65947955 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs59794892 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65950886 chr7:66848496~66858136:+ PAAD cis rs2243480 0.803 rs36004293 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65951525 chr7:66848496~66858136:+ PAAD cis rs2243480 0.803 rs35268390 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65951549 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs12698509 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65953889 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs11538349 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65956884 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs937108 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65963465 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs35542501 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65966228 chr7:66848496~66858136:+ PAAD cis rs2243480 0.711 rs1626926 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65970805 chr7:66848496~66858136:+ PAAD cis rs2243480 0.708 rs781141 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65973566 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs781142 ENSG00000232546.1 RP11-458F8.1 -4.11 6.42e-05 0.0236 -0.38 -0.32 Diabetic kidney disease; chr7:65973791 chr7:66848496~66858136:+ PAAD cis rs9487094 0.67 rs2024850 ENSG00000260273.1 RP11-425D10.10 -4.11 6.42e-05 0.0236 -0.39 -0.32 Height; chr6:109497253 chr6:109382795~109383666:+ PAAD cis rs79040073 0.911 rs11638981 ENSG00000259531.2 RP11-295H24.3 4.11 6.42e-05 0.0236 0.48 0.32 Lung cancer in ever smokers; chr15:49029332 chr15:49365124~49366685:- PAAD cis rs853679 0.55 rs9295762 ENSG00000204709.4 LINC01556 -4.11 6.43e-05 0.0237 -0.53 -0.32 Depression; chr6:28187640 chr6:28943877~28944537:+ PAAD cis rs494459 0.756 rs570806 ENSG00000278376.1 RP11-158I9.8 -4.11 6.43e-05 0.0237 -0.28 -0.32 Height; chr11:118786602 chr11:118791254~118793137:+ PAAD cis rs494459 0.838 rs12796102 ENSG00000278376.1 RP11-158I9.8 -4.11 6.43e-05 0.0237 -0.28 -0.32 Height; chr11:118791319 chr11:118791254~118793137:+ PAAD cis rs11893307 0.537 rs1558473 ENSG00000235852.1 AC005540.3 4.11 6.43e-05 0.0237 0.48 0.32 Mean platelet volume; chr2:190639338 chr2:190880797~190882059:- PAAD cis rs13178541 0.542 rs12653449 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135789750 chr5:135812667~135826582:+ PAAD cis rs13178541 0.577 rs12653452 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135789785 chr5:135812667~135826582:+ PAAD cis rs13178541 0.577 rs12653438 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135789834 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs4532359 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135790641 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs4976457 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135790948 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs9637921 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135791175 chr5:135812667~135826582:+ PAAD cis rs13178541 0.606 rs9637922 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135791514 chr5:135812667~135826582:+ PAAD cis rs13178541 0.671 rs9637923 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135791532 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs11242290 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135791660 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs12654633 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135791677 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs12656771 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135791696 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs10060930 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135791965 chr5:135812667~135826582:+ PAAD cis rs13178541 0.606 rs10069058 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135792227 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs4499826 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135792619 chr5:135812667~135826582:+ PAAD cis rs13178541 0.574 rs9637925 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135792982 chr5:135812667~135826582:+ PAAD cis rs13178541 0.574 rs11242292 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135793829 chr5:135812667~135826582:+ PAAD cis rs13178541 0.574 rs11242293 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135793846 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs11954354 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135793998 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs11955110 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135794353 chr5:135812667~135826582:+ PAAD cis rs13178541 0.606 rs11958506 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135794373 chr5:135812667~135826582:+ PAAD cis rs13178541 0.574 rs11958557 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135794527 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs11948583 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135794589 chr5:135812667~135826582:+ PAAD cis rs13178541 0.574 rs55798589 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135794616 chr5:135812667~135826582:+ PAAD cis rs13178541 0.574 rs11748719 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135794979 chr5:135812667~135826582:+ PAAD cis rs13178541 0.574 rs11745326 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135795200 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs10069265 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135795700 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs10077045 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135795798 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs62364709 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135796257 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs11242294 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135797027 chr5:135812667~135826582:+ PAAD cis rs13178541 0.606 rs11242295 ENSG00000250378.1 RP11-119J18.1 -4.11 6.44e-05 0.0237 -0.47 -0.32 IgG glycosylation; chr5:135797217 chr5:135812667~135826582:+ PAAD cis rs73081554 0.611 rs4681851 ENSG00000272360.1 RP11-359I18.5 -4.11 6.44e-05 0.0237 -0.51 -0.32 Rheumatoid arthritis; chr3:58410164 chr3:58490830~58491291:- PAAD cis rs720475 1 rs720475 ENSG00000204959.4 ARHGEF34P -4.11 6.44e-05 0.0237 -0.38 -0.32 Breast cancer; chr7:144377836 chr7:144272445~144286966:- PAAD cis rs633715 0.733 rs10913445 ENSG00000254154.7 RP4-798P15.3 4.11 6.44e-05 0.0237 0.36 0.32 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177840425 chr1:177928788~178038007:- PAAD cis rs933117 0.892 rs8128745 ENSG00000232687.1 RPL12P9 4.11 6.45e-05 0.0237 0.66 0.32 Body mass index; chr21:29679216 chr21:29127701~29128188:- PAAD cis rs933117 0.892 rs113628239 ENSG00000232687.1 RPL12P9 4.11 6.45e-05 0.0237 0.66 0.32 Body mass index; chr21:29684546 chr21:29127701~29128188:- PAAD cis rs780096 0.545 rs11695549 ENSG00000234072.1 AC074117.10 -4.11 6.45e-05 0.0237 -0.25 -0.32 Total body bone mineral density; chr2:27363288 chr2:27356246~27367622:+ PAAD cis rs4950322 0.744 rs2353987 ENSG00000278811.3 LINC00624 4.11 6.45e-05 0.0237 0.32 0.32 Protein quantitative trait loci; chr1:147355845 chr1:147258885~147517875:- PAAD cis rs72843506 0.591 rs74319100 ENSG00000154898.14 CCDC144CP 4.11 6.45e-05 0.0237 0.56 0.32 Schizophrenia; chr17:20318079 chr17:20321164~20403557:+ PAAD cis rs13178541 0.688 rs10079688 ENSG00000250378.1 RP11-119J18.1 -4.11 6.45e-05 0.0237 -0.5 -0.32 IgG glycosylation; chr5:135858587 chr5:135812667~135826582:+ PAAD cis rs9322193 0.962 rs9689447 ENSG00000268592.3 RAET1E-AS1 4.11 6.45e-05 0.0237 0.38 0.32 Lung cancer; chr6:149789350 chr6:149863494~149919507:+ PAAD cis rs496547 0.686 rs487728 ENSG00000278376.1 RP11-158I9.8 -4.11 6.46e-05 0.0237 -0.29 -0.32 Hip minimal joint space width; chr11:118750785 chr11:118791254~118793137:+ PAAD cis rs875971 0.964 rs60193905 ENSG00000232559.3 GS1-124K5.12 4.11 6.46e-05 0.0237 0.33 0.32 Aortic root size; chr7:66506273 chr7:66554588~66576923:- PAAD cis rs875971 0.522 rs1917563 ENSG00000234585.5 CCT6P3 -4.11 6.46e-05 0.0237 -0.25 -0.32 Aortic root size; chr7:65950660 chr7:65038354~65074713:+ PAAD cis rs9322193 0.923 rs12526675 ENSG00000268592.3 RAET1E-AS1 -4.11 6.46e-05 0.0237 -0.37 -0.32 Lung cancer; chr6:149729540 chr6:149863494~149919507:+ PAAD cis rs889398 0.741 rs6499269 ENSG00000226232.7 RP11-419C5.2 -4.11 6.46e-05 0.0237 -0.25 -0.32 Body mass index; chr16:69875015 chr16:69976388~69996188:- PAAD cis rs875971 0.545 rs1547529 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66258859 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs2420456 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66280619 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs7783889 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66283366 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs1909508 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66301366 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs11767262 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66302237 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs66594357 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66327797 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs10950036 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66353241 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs75840613 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66376399 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs73148639 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66390342 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs6460298 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66442783 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs35459055 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66479399 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs75577046 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66493729 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs3735147 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66505541 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs6950988 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66511428 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs73152714 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66534641 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs4718364 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66536353 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs6961853 ENSG00000222364.1 RNU6-96P -4.11 6.46e-05 0.0237 -0.41 -0.32 Aortic root size; chr7:66537035 chr7:66395191~66395286:+ PAAD cis rs875971 0.528 rs801213 ENSG00000222364.1 RNU6-96P 4.11 6.46e-05 0.0237 0.41 0.32 Aortic root size; chr7:66549931 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs801212 ENSG00000222364.1 RNU6-96P 4.11 6.46e-05 0.0237 0.41 0.32 Aortic root size; chr7:66550643 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs801199 ENSG00000222364.1 RNU6-96P 4.11 6.46e-05 0.0237 0.41 0.32 Aortic root size; chr7:66560286 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs1638724 ENSG00000222364.1 RNU6-96P 4.11 6.46e-05 0.0237 0.41 0.32 Aortic root size; chr7:66575494 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs1267814 ENSG00000222364.1 RNU6-96P 4.11 6.46e-05 0.0237 0.41 0.32 Aortic root size; chr7:66579422 chr7:66395191~66395286:+ PAAD cis rs891378 0.675 rs7543002 ENSG00000274245.1 RP11-357P18.2 -4.11 6.46e-05 0.0237 -0.45 -0.32 Spherical equivalent (joint analysis main effects and education interaction); chr1:207205496 chr1:207372559~207373252:+ PAAD cis rs891378 0.785 rs7554219 ENSG00000274245.1 RP11-357P18.2 -4.11 6.46e-05 0.0237 -0.45 -0.32 Spherical equivalent (joint analysis main effects and education interaction); chr1:207205712 chr1:207372559~207373252:+ PAAD cis rs891378 0.785 rs6700846 ENSG00000274245.1 RP11-357P18.2 -4.11 6.46e-05 0.0237 -0.45 -0.32 Spherical equivalent (joint analysis main effects and education interaction); chr1:207228799 chr1:207372559~207373252:+ PAAD cis rs908366 0.826 rs1254947 ENSG00000273599.1 RP11-59C5.3 4.11 6.47e-05 0.0238 0.21 0.32 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin); chr10:124466230 chr10:124996064~125001491:+ PAAD cis rs41369048 0.925 rs2738756 ENSG00000238078.1 LINC01352 -4.11 6.47e-05 0.0238 -0.45 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220884717 chr1:220829255~220832429:+ PAAD cis rs7216064 1 rs8081517 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67849581 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs60432293 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67864291 chr17:68101538~68101639:+ PAAD cis rs7216064 0.953 rs4790905 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67867234 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs9912084 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67871919 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs9912770 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67872117 chr17:68101538~68101639:+ PAAD cis rs7216064 0.953 rs9890629 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67875443 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs9915108 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67878347 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs9913471 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67878379 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs73352808 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67879041 chr17:68101538~68101639:+ PAAD cis rs7216064 0.861 rs73352810 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67879068 chr17:68101538~68101639:+ PAAD cis rs7216064 0.906 rs8074644 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67882101 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs3935969 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67885843 chr17:68101538~68101639:+ PAAD cis rs7216064 1 rs7208663 ENSG00000278219.1 AC145343.1 -4.11 6.47e-05 0.0238 -0.49 -0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67889055 chr17:68101538~68101639:+ PAAD cis rs897984 0.542 rs35713203 ENSG00000260911.2 RP11-196G11.2 4.11 6.47e-05 0.0238 0.29 0.32 Dementia with Lewy bodies; chr16:31079086 chr16:31043150~31049868:+ PAAD cis rs897984 0.542 rs73530203 ENSG00000260911.2 RP11-196G11.2 4.11 6.47e-05 0.0238 0.29 0.32 Dementia with Lewy bodies; chr16:31088538 chr16:31043150~31049868:+ PAAD cis rs28386778 0.83 rs67905415 ENSG00000240280.5 TCAM1P -4.11 6.47e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63763876 chr17:63849292~63864379:+ PAAD cis rs28386778 0.797 rs4968664 ENSG00000240280.5 TCAM1P -4.11 6.47e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63774006 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs9913323 ENSG00000240280.5 TCAM1P -4.11 6.47e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63774125 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs3760254 ENSG00000240280.5 TCAM1P -4.11 6.47e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63774391 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs7221573 ENSG00000240280.5 TCAM1P -4.11 6.47e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63782030 chr17:63849292~63864379:+ PAAD cis rs73219805 0.838 rs7840859 ENSG00000228451.3 SDAD1P1 -4.11 6.47e-05 0.0238 -0.46 -0.32 Schizophrenia; chr8:26377501 chr8:26379259~26382953:- PAAD cis rs13256369 0.802 rs11249884 ENSG00000253981.4 ALG1L13P -4.11 6.48e-05 0.0238 -0.43 -0.32 Obesity-related traits; chr8:8704042 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs1060107 ENSG00000253981.4 ALG1L13P 4.11 6.48e-05 0.0238 0.43 0.32 Obesity-related traits; chr8:8703889 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs4840350 ENSG00000253981.4 ALG1L13P 4.11 6.48e-05 0.0238 0.43 0.32 Obesity-related traits; chr8:8703932 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs1060106 ENSG00000253981.4 ALG1L13P 4.11 6.48e-05 0.0238 0.43 0.32 Obesity-related traits; chr8:8703942 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs11249883 ENSG00000253981.4 ALG1L13P 4.11 6.48e-05 0.0238 0.43 0.32 Obesity-related traits; chr8:8704027 chr8:8236003~8244667:- PAAD cis rs75422866 0.85 rs73111220 ENSG00000274902.1 RP1-197B17.4 4.11 6.48e-05 0.0238 0.96 0.32 Pneumonia; chr12:47578764 chr12:47731908~47732351:+ PAAD cis rs2303759 0.918 rs1054770 ENSG00000268686.1 AC010524.2 -4.11 6.48e-05 0.0238 -0.44 -0.32 Multiple sclerosis; chr19:49374858 chr19:49368705~49388081:- PAAD cis rs12480328 1 rs6067584 ENSG00000203999.7 LINC01270 4.11 6.48e-05 0.0238 0.71 0.32 Prostate cancer; chr20:50894815 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs6091234 ENSG00000203999.7 LINC01270 4.11 6.48e-05 0.0238 0.71 0.32 Prostate cancer; chr20:50895780 chr20:50292720~50314922:+ PAAD cis rs2412819 0.52 rs17727763 ENSG00000205771.5 CATSPER2P1 -4.11 6.48e-05 0.0238 -0.54 -0.32 Lung cancer; chr15:43623873 chr15:43726918~43747094:- PAAD cis rs763121 0.853 rs138702 ENSG00000228274.3 RP3-508I15.9 4.11 6.48e-05 0.0238 0.31 0.32 Menopause (age at onset); chr22:38736596 chr22:38667585~38681820:- PAAD cis rs11893307 0.537 rs7571572 ENSG00000235852.1 AC005540.3 4.11 6.48e-05 0.0238 0.46 0.32 Mean platelet volume; chr2:190688911 chr2:190880797~190882059:- PAAD cis rs7301826 0.504 rs11061164 ENSG00000256299.1 RP11-989F5.3 -4.11 6.48e-05 0.0238 -0.34 -0.32 Plasma plasminogen activator levels; chr12:130839724 chr12:130810821~130812622:- PAAD cis rs74233809 0.901 rs17878846 ENSG00000213277.3 MARCKSL1P1 4.11 6.48e-05 0.0238 0.55 0.32 Birth weight; chr10:102870655 chr10:103175554~103176094:+ PAAD cis rs7189233 0.531 rs1978337 ENSG00000279344.1 RP11-44F14.7 4.11 6.48e-05 0.0238 0.24 0.32 Intelligence (multi-trait analysis); chr16:53425833 chr16:53478957~53481550:- PAAD cis rs867371 0.964 rs7169961 ENSG00000259429.4 UBE2Q2P2 -4.11 6.48e-05 0.0238 -0.25 -0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82186588 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs6495643 ENSG00000259429.4 UBE2Q2P2 -4.11 6.48e-05 0.0238 -0.25 -0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82186913 chr15:82355142~82420075:+ PAAD cis rs11997175 0.655 rs72630922 ENSG00000240738.1 RP1-273G13.1 4.11 6.48e-05 0.0238 0.35 0.32 Body mass index; chr8:33804883 chr8:33859480~33860223:- PAAD cis rs11997175 0.655 rs72630923 ENSG00000240738.1 RP1-273G13.1 4.11 6.48e-05 0.0238 0.35 0.32 Body mass index; chr8:33804886 chr8:33859480~33860223:- PAAD cis rs31872 0.678 rs702390 ENSG00000273557.1 CTD-2024I7.18 -4.11 6.48e-05 0.0238 -0.44 -0.32 Visceral adipose tissue adjusted for BMI; chr5:141062624 chr5:141468465~141471528:+ PAAD cis rs31872 0.526 rs810277 ENSG00000273557.1 CTD-2024I7.18 -4.11 6.48e-05 0.0238 -0.44 -0.32 Visceral adipose tissue adjusted for BMI; chr5:141072909 chr5:141468465~141471528:+ PAAD cis rs4453827 0.955 rs723540 ENSG00000271916.1 RP11-884K10.6 4.11 6.48e-05 0.0238 0.33 0.32 Blood protein levels; chr3:53721926 chr3:53797764~53798019:- PAAD cis rs28386778 0.897 rs9912557 ENSG00000240280.5 TCAM1P -4.11 6.49e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63707603 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs7210443 ENSG00000240280.5 TCAM1P -4.11 6.49e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63708014 chr17:63849292~63864379:+ PAAD cis rs6496044 0.963 rs11853972 ENSG00000202081.1 RNU6-1280P 4.11 6.49e-05 0.0238 0.35 0.32 Interstitial lung disease; chr15:85519209 chr15:85651522~85651628:- PAAD cis rs6496044 1 rs6496044 ENSG00000202081.1 RNU6-1280P 4.11 6.49e-05 0.0238 0.35 0.32 Interstitial lung disease; chr15:85524075 chr15:85651522~85651628:- PAAD cis rs1862618 0.802 rs4389648 ENSG00000271828.1 CTD-2310F14.1 4.11 6.49e-05 0.0238 0.46 0.32 Initial pursuit acceleration; chr5:56807775 chr5:56927874~56929573:+ PAAD cis rs10461617 0.617 rs79742142 ENSG00000271828.1 CTD-2310F14.1 4.11 6.49e-05 0.0238 0.46 0.32 Type 2 diabetes; chr5:56808550 chr5:56927874~56929573:+ PAAD cis rs7829975 0.688 rs7837587 ENSG00000173295.6 FAM86B3P 4.11 6.49e-05 0.0238 0.32 0.32 Mood instability; chr8:8521482 chr8:8228595~8244865:+ PAAD cis rs7829975 0.688 rs7826654 ENSG00000173295.6 FAM86B3P 4.11 6.49e-05 0.0238 0.32 0.32 Mood instability; chr8:8521596 chr8:8228595~8244865:+ PAAD cis rs7829975 0.688 rs7826660 ENSG00000173295.6 FAM86B3P 4.11 6.49e-05 0.0238 0.32 0.32 Mood instability; chr8:8521597 chr8:8228595~8244865:+ PAAD cis rs9322193 0.923 rs12175504 ENSG00000268592.3 RAET1E-AS1 4.11 6.49e-05 0.0238 0.36 0.32 Lung cancer; chr6:149664079 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs35443312 ENSG00000268592.3 RAET1E-AS1 4.11 6.49e-05 0.0238 0.36 0.32 Lung cancer; chr6:149670625 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs62439843 ENSG00000268592.3 RAET1E-AS1 4.11 6.49e-05 0.0238 0.36 0.32 Lung cancer; chr6:149676521 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs35031906 ENSG00000268592.3 RAET1E-AS1 4.11 6.49e-05 0.0238 0.36 0.32 Lung cancer; chr6:149677438 chr6:149863494~149919507:+ PAAD cis rs28386778 0.83 rs6504180 ENSG00000240280.5 TCAM1P -4.11 6.49e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63735809 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs8066754 ENSG00000240280.5 TCAM1P -4.11 6.49e-05 0.0238 -0.44 -0.32 Prudent dietary pattern; chr17:63739230 chr17:63849292~63864379:+ PAAD cis rs5758659 0.652 rs6519301 ENSG00000273366.1 CTA-989H11.1 -4.11 6.49e-05 0.0238 -0.37 -0.32 Cognitive function; chr22:41989963 chr22:42278188~42278846:+ PAAD cis rs11079159 0.651 rs2287223 ENSG00000263096.1 RP11-515O17.2 4.11 6.5e-05 0.0238 0.41 0.32 QRS duration; chr17:55315491 chr17:55271504~55273653:- PAAD cis rs6903823 0.508 rs1150726 ENSG00000204709.4 LINC01556 4.11 6.5e-05 0.0238 0.41 0.32 Pulmonary function; chr6:28275265 chr6:28943877~28944537:+ PAAD cis rs7839040 0.507 rs13272064 ENSG00000253334.1 RP13-923O23.6 -4.11 6.5e-05 0.0239 -0.38 -0.32 Response to methotrexate in juvenile idiopathic arthritis; chr8:82030296 chr8:81791823~81815714:+ PAAD cis rs4835473 0.9 rs35670120 ENSG00000251600.4 RP11-673E1.1 -4.11 6.5e-05 0.0239 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143787041 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs4054634 ENSG00000251600.4 RP11-673E1.1 -4.11 6.5e-05 0.0239 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143787045 chr4:143912331~143982454:+ PAAD cis rs34375054 0.66 rs12578446 ENSG00000279233.1 RP11-158L12.4 4.11 6.51e-05 0.0239 0.27 0.32 Post bronchodilator FEV1/FVC ratio; chr12:125121341 chr12:125138245~125141711:+ PAAD cis rs8005677 0.798 rs4982711 ENSG00000279656.1 RP11-298I3.6 4.11 6.52e-05 0.0239 0.38 0.32 Cognitive ability (multi-trait analysis); chr14:22929781 chr14:23023083~23024217:- PAAD cis rs8072100 0.934 rs9905583 ENSG00000228782.6 CTD-2026D20.3 4.11 6.52e-05 0.0239 0.31 0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47663650 chr17:47450568~47492492:- PAAD cis rs987724 0.515 rs453219 ENSG00000240875.4 LINC00886 -4.11 6.52e-05 0.0239 -0.47 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156856463 chr3:156747346~156817062:- PAAD cis rs338389 0.542 rs338342 ENSG00000260657.2 RP11-315D16.4 4.11 6.53e-05 0.0239 0.35 0.32 Survival in rectal cancer; chr15:67979714 chr15:68267792~68277994:- PAAD cis rs720064 0.586 rs2288592 ENSG00000264745.1 TTC39C-AS1 4.11 6.53e-05 0.024 0.4 0.32 Strep throat; chr18:23946123 chr18:23994213~24015339:- PAAD cis rs10888838 0.756 rs11206306 ENSG00000198711.5 SSBP3-AS1 4.11 6.53e-05 0.024 0.39 0.32 Mitochondrial DNA levels; chr1:54224092 chr1:54236440~54239063:+ PAAD cis rs10888838 0.756 rs11206307 ENSG00000198711.5 SSBP3-AS1 4.11 6.53e-05 0.024 0.39 0.32 Mitochondrial DNA levels; chr1:54224289 chr1:54236440~54239063:+ PAAD cis rs5015933 0.788 rs558352 ENSG00000232630.1 PRPS1P2 -4.11 6.54e-05 0.024 -0.29 -0.32 Body mass index; chr9:125258497 chr9:125150653~125151589:+ PAAD cis rs5015933 0.788 rs662637 ENSG00000232630.1 PRPS1P2 -4.11 6.54e-05 0.024 -0.29 -0.32 Body mass index; chr9:125258887 chr9:125150653~125151589:+ PAAD cis rs17684571 0.687 rs13214893 ENSG00000231441.1 RP11-472M19.2 4.11 6.54e-05 0.024 0.61 0.32 Schizophrenia; chr6:56865425 chr6:56844002~56864078:+ PAAD cis rs7927592 0.956 rs12365160 ENSG00000212093.1 AP000807.1 4.11 6.54e-05 0.024 0.37 0.32 Total body bone mineral density; chr11:68482951 chr11:68506083~68506166:- PAAD cis rs7927592 0.956 rs11228256 ENSG00000212093.1 AP000807.1 4.11 6.54e-05 0.024 0.37 0.32 Total body bone mineral density; chr11:68483992 chr11:68506083~68506166:- PAAD cis rs72843506 0.656 rs78325601 ENSG00000189423.10 USP32P3 4.11 6.55e-05 0.024 0.49 0.32 Schizophrenia; chr17:20018486 chr17:20415547~20431008:+ PAAD cis rs780676 0.958 rs780679 ENSG00000230526.1 RP11-472G21.2 4.11 6.55e-05 0.024 0.44 0.32 Gestational age at birth (child effect); chr10:71354752 chr10:71878356~71879107:+ PAAD cis rs6840258 0.547 rs72667727 ENSG00000251411.1 RP11-397E7.4 -4.11 6.55e-05 0.024 -0.39 -0.32 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86936370 chr4:86913266~86914817:- PAAD cis rs6840258 0.547 rs17012170 ENSG00000251411.1 RP11-397E7.4 -4.11 6.55e-05 0.024 -0.39 -0.32 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86939692 chr4:86913266~86914817:- PAAD cis rs4835473 0.9 rs13137885 ENSG00000251600.4 RP11-673E1.1 -4.11 6.55e-05 0.024 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143734212 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13105550 ENSG00000251600.4 RP11-673E1.1 -4.11 6.55e-05 0.024 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143734220 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13105571 ENSG00000251600.4 RP11-673E1.1 -4.11 6.55e-05 0.024 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143734241 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs36083417 ENSG00000251600.4 RP11-673E1.1 -4.11 6.55e-05 0.024 -0.36 -0.32 Immature fraction of reticulocytes; chr4:143734253 chr4:143912331~143982454:+ PAAD cis rs1789 0.786 rs6414768 ENSG00000273133.1 RP11-799M12.2 -4.11 6.55e-05 0.024 -0.39 -0.32 Blood protein levels; chr4:15693740 chr4:15563698~15564253:- PAAD cis rs6686842 0.689 rs2885697 ENSG00000235358.1 RP11-399E6.1 -4.11 6.56e-05 0.024 -0.4 -0.32 Height; chr1:41078607 chr1:41242373~41284861:+ PAAD cis rs9487094 0.67 rs7755941 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109494148 chr6:109382795~109383666:+ PAAD cis rs9487094 0.626 rs7773950 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109494237 chr6:109382795~109383666:+ PAAD cis rs9487094 0.626 rs12195904 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109494760 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs1406899 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109495102 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs11153183 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109496073 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs11754455 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109496680 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs2024849 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109497088 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs2024852 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109498586 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs2024853 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109498751 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs13203587 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109499759 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12197180 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109500687 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12212476 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109501402 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs12198938 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109501429 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs13220915 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109503623 chr6:109382795~109383666:+ PAAD cis rs9487094 0.626 rs10457192 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109507271 chr6:109382795~109383666:+ PAAD cis rs9487094 0.6 rs10457193 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109507364 chr6:109382795~109383666:+ PAAD cis rs9487094 0.558 rs10457194 ENSG00000260273.1 RP11-425D10.10 4.11 6.56e-05 0.024 0.39 0.32 Height; chr6:109507366 chr6:109382795~109383666:+ PAAD cis rs41369048 0.669 rs111238725 ENSG00000238078.1 LINC01352 -4.11 6.56e-05 0.024 -0.45 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220860320 chr1:220829255~220832429:+ PAAD cis rs41369048 0.669 rs6660867 ENSG00000238078.1 LINC01352 -4.11 6.56e-05 0.024 -0.45 -0.32 Eosinophil counts;Sum eosinophil basophil counts; chr1:220864097 chr1:220829255~220832429:+ PAAD cis rs7189233 0.55 rs9938788 ENSG00000279344.1 RP11-44F14.7 4.11 6.56e-05 0.024 0.24 0.32 Intelligence (multi-trait analysis); chr16:53447510 chr16:53478957~53481550:- PAAD cis rs10129255 0.5 rs988132 ENSG00000211972.2 IGHV3-66 4.11 6.56e-05 0.024 0.25 0.32 Kawasaki disease; chr14:106776758 chr14:106675017~106675544:- PAAD cis rs9876781 1 rs922075 ENSG00000229759.1 MRPS18AP1 -4.11 6.57e-05 0.0241 -0.34 -0.32 Longevity; chr3:48447994 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs2045554 ENSG00000229759.1 MRPS18AP1 -4.11 6.57e-05 0.0241 -0.34 -0.32 Longevity; chr3:48453142 chr3:48256350~48256938:- PAAD cis rs9876781 0.967 rs1870444 ENSG00000229759.1 MRPS18AP1 4.11 6.57e-05 0.0241 0.34 0.32 Longevity; chr3:48445369 chr3:48256350~48256938:- PAAD cis rs496547 0.654 rs688161 ENSG00000255239.1 AP002954.6 4.11 6.57e-05 0.0241 0.38 0.32 Hip minimal joint space width; chr11:118807001 chr11:118688039~118690600:- PAAD cis rs700651 0.789 rs10190226 ENSG00000231621.1 AC013264.2 4.11 6.57e-05 0.0241 0.31 0.32 Intracranial aneurysm; chr2:198036840 chr2:197197991~197199273:+ PAAD cis rs2638953 0.962 rs10843150 ENSG00000247934.4 RP11-967K21.1 4.11 6.57e-05 0.0241 0.36 0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28304869 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049521 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28310976 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049524 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28311956 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049525 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28313227 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs12371974 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28313969 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049526 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28314751 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049527 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28317667 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs11049528 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28317914 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs10843151 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28318386 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs10843152 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28319090 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs10843153 ENSG00000247934.4 RP11-967K21.1 -4.11 6.57e-05 0.0241 -0.36 -0.32 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28319168 chr12:28163298~28190738:- PAAD cis rs2243480 0.901 rs73142137 ENSG00000228409.4 CCT6P1 4.11 6.58e-05 0.0241 0.34 0.32 Diabetic kidney disease; chr7:65878455 chr7:65751142~65763354:+ PAAD cis rs72843506 0.722 rs9897161 ENSG00000154898.14 CCDC144CP 4.11 6.58e-05 0.0241 0.57 0.32 Schizophrenia; chr17:20130957 chr17:20321164~20403557:+ PAAD cis rs72843506 0.722 rs9897168 ENSG00000154898.14 CCDC144CP 4.11 6.58e-05 0.0241 0.57 0.32 Schizophrenia; chr17:20130961 chr17:20321164~20403557:+ PAAD cis rs72843506 0.656 rs9913018 ENSG00000154898.14 CCDC144CP 4.11 6.58e-05 0.0241 0.57 0.32 Schizophrenia; chr17:20160759 chr17:20321164~20403557:+ PAAD cis rs6504950 0.695 rs9904377 ENSG00000275710.1 RP11-257O5.4 4.1 6.58e-05 0.0241 0.38 0.32 Breast cancer; chr17:54908621 chr17:54964474~54964679:+ PAAD cis rs394563 0.69 rs237010 ENSG00000231760.4 RP11-350J20.5 4.1 6.58e-05 0.0241 0.44 0.32 Dupuytren's disease; chr6:149437614 chr6:149796151~149826294:- PAAD cis rs6061231 0.724 rs1570027 ENSG00000275437.1 RP5-908M14.10 4.1 6.58e-05 0.0241 0.33 0.32 Colorectal cancer; chr20:62393540 chr20:62402236~62405935:- PAAD cis rs7829975 0.688 rs13270194 ENSG00000173295.6 FAM86B3P 4.1 6.59e-05 0.0241 0.32 0.32 Mood instability; chr8:8520592 chr8:8228595~8244865:+ PAAD cis rs7020651 1 rs7020689 ENSG00000215221.2 UBA52P6 -4.1 6.6e-05 0.0241 -0.58 -0.32 Cannabis use (initiation); chr9:22972986 chr9:22012155~22012536:+ PAAD cis rs1707322 0.717 rs3014246 ENSG00000280836.1 AL355480.1 4.1 6.6e-05 0.0242 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45620405 chr1:45581219~45581321:- PAAD cis rs9487094 0.67 rs1998811 ENSG00000260273.1 RP11-425D10.10 4.1 6.6e-05 0.0242 0.39 0.32 Height; chr6:109490935 chr6:109382795~109383666:+ PAAD cis rs66887589 0.66 rs4833613 ENSG00000248280.1 RP11-33B1.2 -4.1 6.6e-05 0.0242 -0.3 -0.32 Diastolic blood pressure; chr4:119229001 chr4:119440561~119450157:- PAAD cis rs79349575 0.783 rs12603969 ENSG00000270781.1 RP11-501C14.9 -4.1 6.61e-05 0.0242 -0.36 -0.32 Type 2 diabetes; chr17:48957057 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs12601955 ENSG00000270781.1 RP11-501C14.9 -4.1 6.61e-05 0.0242 -0.36 -0.32 Type 2 diabetes; chr17:48957058 chr17:48899131~48899748:+ PAAD cis rs9322193 0.923 rs6913486 ENSG00000268592.3 RAET1E-AS1 -4.1 6.61e-05 0.0242 -0.38 -0.32 Lung cancer; chr6:149705060 chr6:149863494~149919507:+ PAAD cis rs591584 0.73 rs7342170 ENSG00000255893.1 RP11-685N10.1 -4.1 6.61e-05 0.0242 -0.4 -0.32 Macrophage Migration Inhibitory Factor levels; chr11:94581311 chr11:94472908~94473570:- PAAD cis rs28374715 0.532 rs28463309 ENSG00000247556.5 OIP5-AS1 4.1 6.61e-05 0.0242 0.32 0.32 Ulcerative colitis; chr15:41374518 chr15:41283990~41309737:+ PAAD cis rs42490 0.664 rs368812 ENSG00000251136.7 RP11-37B2.1 -4.1 6.61e-05 0.0242 -0.28 -0.32 Leprosy; chr8:89822269 chr8:89609409~89757727:- PAAD cis rs1124769 0.502 rs12911207 ENSG00000259240.1 RP11-108K3.1 -4.1 6.61e-05 0.0242 -0.41 -0.32 Cognitive performance; chr15:50777099 chr15:51037488~51293912:+ PAAD cis rs9357354 0.927 rs12530182 ENSG00000218809.1 RP1-229K20.5 4.1 6.62e-05 0.0242 0.35 0.32 Telomere length; chr6:41344154 chr6:41269875~41270239:- PAAD cis rs4713118 0.662 rs156744 ENSG00000226314.6 ZNF192P1 -4.1 6.62e-05 0.0242 -0.52 -0.32 Parkinson's disease; chr6:27999496 chr6:28161781~28169594:+ PAAD cis rs9876781 1 rs2362450 ENSG00000229759.1 MRPS18AP1 4.1 6.62e-05 0.0242 0.33 0.32 Longevity; chr3:48419904 chr3:48256350~48256938:- PAAD cis rs9876781 0.967 rs1459249 ENSG00000229759.1 MRPS18AP1 4.1 6.62e-05 0.0242 0.33 0.32 Longevity; chr3:48438208 chr3:48256350~48256938:- PAAD cis rs10783487 0.895 rs7964071 ENSG00000257542.4 OR7E47P -4.1 6.62e-05 0.0242 -0.43 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52072266 chr12:52079696~52108261:+ PAAD cis rs950169 0.58 rs1061737 ENSG00000259295.5 CSPG4P12 4.1 6.62e-05 0.0242 0.35 0.32 Schizophrenia; chr15:84640559 chr15:85191438~85213905:+ PAAD cis rs2412819 0.571 rs514255 ENSG00000249839.1 AC011330.5 -4.1 6.63e-05 0.0242 -0.5 -0.32 Lung cancer; chr15:43893134 chr15:43663654~43684339:- PAAD cis rs1707322 0.506 rs2991983 ENSG00000280836.1 AL355480.1 4.1 6.63e-05 0.0242 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613719 chr1:45581219~45581321:- PAAD cis rs189798 1 rs189798 ENSG00000254340.1 RP11-10A14.3 -4.1 6.63e-05 0.0242 -0.4 -0.32 Myopia (pathological); chr8:9133067 chr8:9141424~9145435:+ PAAD cis rs7615952 0.558 rs7641353 ENSG00000171084.14 FAM86JP 4.1 6.63e-05 0.0242 0.42 0.32 Blood pressure (smoking interaction); chr3:125621035 chr3:125916620~125930024:+ PAAD cis rs2524005 1 rs2524005 ENSG00000272236.1 XXbac-BPG170G13.32 -4.1 6.63e-05 0.0242 -0.49 -0.32 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29751965~29752207:- PAAD cis rs270601 0.77 rs932019 ENSG00000233006.5 AC034220.3 4.1 6.64e-05 0.0243 0.26 0.32 Acylcarnitine levels; chr5:132263677 chr5:132311285~132369916:- PAAD cis rs270601 0.77 rs4361510 ENSG00000233006.5 AC034220.3 4.1 6.64e-05 0.0243 0.26 0.32 Acylcarnitine levels; chr5:132263954 chr5:132311285~132369916:- PAAD cis rs270601 0.77 rs61352298 ENSG00000233006.5 AC034220.3 4.1 6.64e-05 0.0243 0.26 0.32 Acylcarnitine levels; chr5:132264896 chr5:132311285~132369916:- PAAD cis rs270601 0.739 rs1979981 ENSG00000233006.5 AC034220.3 4.1 6.64e-05 0.0243 0.26 0.32 Acylcarnitine levels; chr5:132266027 chr5:132311285~132369916:- PAAD cis rs270601 0.77 rs1007602 ENSG00000233006.5 AC034220.3 4.1 6.64e-05 0.0243 0.26 0.32 Acylcarnitine levels; chr5:132266473 chr5:132311285~132369916:- PAAD cis rs270601 0.71 rs4705852 ENSG00000233006.5 AC034220.3 4.1 6.64e-05 0.0243 0.26 0.32 Acylcarnitine levels; chr5:132267114 chr5:132311285~132369916:- PAAD cis rs8072100 1 rs4794016 ENSG00000228782.6 CTD-2026D20.3 -4.1 6.64e-05 0.0243 -0.31 -0.32 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47648565 chr17:47450568~47492492:- PAAD cis rs7637701 0.818 rs4680305 ENSG00000240875.4 LINC00886 -4.1 6.64e-05 0.0243 -0.39 -0.32 Breast cancer; chr3:156815614 chr3:156747346~156817062:- PAAD cis rs11159086 0.793 rs10136668 ENSG00000270000.1 RP3-449M8.9 4.1 6.64e-05 0.0243 0.46 0.32 Advanced glycation end-product levels; chr14:74492183 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs10139029 ENSG00000270000.1 RP3-449M8.9 4.1 6.64e-05 0.0243 0.46 0.32 Advanced glycation end-product levels; chr14:74492284 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs10139122 ENSG00000270000.1 RP3-449M8.9 4.1 6.64e-05 0.0243 0.46 0.32 Advanced glycation end-product levels; chr14:74492353 chr14:74471930~74472360:- PAAD cis rs11976180 1 rs2951308 ENSG00000273234.1 OR2A13P 4.1 6.65e-05 0.0243 0.39 0.32 Obesity-related traits; chr7:144070056 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2961119 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144058759 chr7:144142009~144142938:+ PAAD cis rs11976180 0.953 rs2951355 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144063469 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2951354 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144063908 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2961125 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144064677 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2961126 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144065643 chr7:144142009~144142938:+ PAAD cis rs11976180 0.953 rs2961127 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144065644 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs1919948 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144065750 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2961128 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144066390 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2371248 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144067096 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs1533268 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144069265 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs1533267 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144069347 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs1533266 ENSG00000273234.1 OR2A13P -4.1 6.65e-05 0.0243 -0.39 -0.32 Obesity-related traits; chr7:144069621 chr7:144142009~144142938:+ PAAD cis rs7208859 0.673 rs9912122 ENSG00000264538.5 SUZ12P1 -4.1 6.65e-05 0.0243 -0.28 -0.32 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813698 chr17:30709299~30790908:+ PAAD cis rs9326248 0.581 rs12225187 ENSG00000280143.1 AP000892.6 4.1 6.65e-05 0.0243 0.36 0.32 Blood protein levels; chr11:116922515 chr11:117204967~117210292:+ PAAD cis rs11668609 0.515 rs61308481 ENSG00000268442.1 CTD-2027I19.2 4.1 6.65e-05 0.0243 0.52 0.32 Response to taxane treatment (docetaxel); chr19:23882545 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs59175483 ENSG00000268442.1 CTD-2027I19.2 4.1 6.65e-05 0.0243 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:23882740 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs61693040 ENSG00000268442.1 CTD-2027I19.2 4.1 6.65e-05 0.0243 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:23883370 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs57061964 ENSG00000268442.1 CTD-2027I19.2 4.1 6.65e-05 0.0243 0.52 0.32 Response to taxane treatment (placlitaxel); chr19:23883476 chr19:24162370~24163425:- PAAD cis rs748404 0.706 rs35975365 ENSG00000249839.1 AC011330.5 -4.1 6.65e-05 0.0243 -0.54 -0.32 Lung cancer; chr15:43379347 chr15:43663654~43684339:- PAAD cis rs12654437 0.506 rs35082563 ENSG00000263361.1 MIR378H -4.1 6.66e-05 0.0243 -0.39 -0.32 Cognitive decline (age-related); chr5:155428926 chr5:154829458~154829540:+ PAAD cis rs10740039 0.842 rs7080024 ENSG00000254271.1 RP11-131N11.4 -4.1 6.66e-05 0.0243 -0.38 -0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60632033 chr10:60734342~60741828:+ PAAD cis rs4660456 0.529 rs61779237 ENSG00000272145.1 NFYC-AS1 -4.1 6.66e-05 0.0243 -0.25 -0.32 Platelet count; chr1:40685300 chr1:40690380~40692066:- PAAD cis rs919433 0.68 rs1116734 ENSG00000231621.1 AC013264.2 -4.1 6.66e-05 0.0243 -0.31 -0.32 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197500319 chr2:197197991~197199273:+ PAAD cis rs2446066 0.728 rs10876444 ENSG00000257379.1 RP11-793H13.8 4.1 6.66e-05 0.0243 0.46 0.32 Red blood cell count; chr12:53358697 chr12:53441741~53467528:+ PAAD cis rs216345 0.902 rs216353 ENSG00000230074.1 RP11-195F19.9 -4.1 6.66e-05 0.0243 -0.42 -0.32 Bipolar disorder; chr9:33804169 chr9:34665665~34681298:+ PAAD cis rs950169 0.544 rs62021193 ENSG00000259295.5 CSPG4P12 4.1 6.67e-05 0.0243 0.35 0.32 Schizophrenia; chr15:84627352 chr15:85191438~85213905:+ PAAD cis rs950169 0.58 rs17598114 ENSG00000259295.5 CSPG4P12 4.1 6.67e-05 0.0243 0.35 0.32 Schizophrenia; chr15:84628086 chr15:85191438~85213905:+ PAAD cis rs950169 0.58 rs17532346 ENSG00000259295.5 CSPG4P12 4.1 6.67e-05 0.0243 0.35 0.32 Schizophrenia; chr15:84628264 chr15:85191438~85213905:+ PAAD cis rs950169 0.58 rs11634322 ENSG00000259295.5 CSPG4P12 4.1 6.67e-05 0.0243 0.35 0.32 Schizophrenia; chr15:84628978 chr15:85191438~85213905:+ PAAD cis rs950169 0.58 rs4603535 ENSG00000259295.5 CSPG4P12 4.1 6.67e-05 0.0243 0.35 0.32 Schizophrenia; chr15:84630641 chr15:85191438~85213905:+ PAAD cis rs950169 0.541 rs10795 ENSG00000259295.5 CSPG4P12 4.1 6.67e-05 0.0243 0.35 0.32 Schizophrenia; chr15:84634066 chr15:85191438~85213905:+ PAAD cis rs950169 0.58 rs36126054 ENSG00000259295.5 CSPG4P12 4.1 6.67e-05 0.0243 0.35 0.32 Schizophrenia; chr15:84634492 chr15:85191438~85213905:+ PAAD cis rs950169 0.58 rs11633762 ENSG00000259295.5 CSPG4P12 4.1 6.67e-05 0.0243 0.35 0.32 Schizophrenia; chr15:84643921 chr15:85191438~85213905:+ PAAD cis rs10888838 0.938 rs12033727 ENSG00000198711.5 SSBP3-AS1 4.1 6.67e-05 0.0243 0.37 0.32 Mitochondrial DNA levels; chr1:54214083 chr1:54236440~54239063:+ PAAD cis rs11997175 0.655 rs7833512 ENSG00000240738.1 RP1-273G13.1 4.1 6.67e-05 0.0243 0.35 0.32 Body mass index; chr8:33805366 chr8:33859480~33860223:- PAAD cis rs11997175 0.655 rs4380889 ENSG00000240738.1 RP1-273G13.1 4.1 6.67e-05 0.0243 0.35 0.32 Body mass index; chr8:33805863 chr8:33859480~33860223:- PAAD cis rs11997175 0.609 rs4733459 ENSG00000240738.1 RP1-273G13.1 4.1 6.67e-05 0.0243 0.35 0.32 Body mass index; chr8:33806275 chr8:33859480~33860223:- PAAD cis rs2278034 0.516 rs9829709 ENSG00000231443.2 AC024937.6 -4.1 6.67e-05 0.0243 -0.28 -0.32 Bronchopulmonary dysplasia; chr3:195889802 chr3:195937243~195938739:+ PAAD cis rs9595066 0.627 rs4942290 ENSG00000227258.4 SMIM2-AS1 4.1 6.67e-05 0.0244 0.47 0.32 Schizophrenia; chr13:44183203 chr13:44110451~44240517:+ PAAD cis rs4660214 0.666 rs61783383 ENSG00000228060.1 RP11-69E11.8 4.1 6.68e-05 0.0244 0.3 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39341346 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs6704246 ENSG00000228060.1 RP11-69E11.8 4.1 6.68e-05 0.0244 0.3 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39343612 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs597311 ENSG00000228060.1 RP11-69E11.8 -4.1 6.68e-05 0.0244 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39355254 chr1:39565160~39573203:+ PAAD cis rs4660214 0.615 rs597708 ENSG00000228060.1 RP11-69E11.8 -4.1 6.68e-05 0.0244 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39355291 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs636156 ENSG00000228060.1 RP11-69E11.8 -4.1 6.68e-05 0.0244 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39356065 chr1:39565160~39573203:+ PAAD cis rs11893307 0.509 rs62182902 ENSG00000235852.1 AC005540.3 4.1 6.68e-05 0.0244 0.47 0.32 Mean platelet volume; chr2:190638041 chr2:190880797~190882059:- PAAD cis rs62103177 0.525 rs4799116 ENSG00000261126.6 RP11-795F19.1 -4.1 6.68e-05 0.0244 -0.42 -0.32 Opioid sensitivity; chr18:79976735 chr18:80046900~80095482:+ PAAD cis rs792448 0.743 rs351408 ENSG00000229983.1 RP11-15I11.2 4.1 6.68e-05 0.0244 0.38 0.32 White blood cell count (basophil); chr1:212267786 chr1:212168207~212190259:+ PAAD cis rs303386 0.689 rs3931165 ENSG00000223656.1 HMGB3P10 -4.1 6.69e-05 0.0244 -0.41 -0.32 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin); chr1:99131621 chr1:99698242~99699178:+ PAAD cis rs875971 0.522 rs781144 ENSG00000236529.1 RP13-254B10.1 4.1 6.69e-05 0.0244 0.34 0.32 Aortic root size; chr7:65975357 chr7:65840212~65840596:+ PAAD cis rs7923609 1 rs2393969 ENSG00000232075.1 MRPL35P2 -4.1 6.69e-05 0.0244 -0.39 -0.32 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63380680 chr10:63634317~63634827:- PAAD cis rs6545883 0.524 rs4599092 ENSG00000271889.1 RP11-493E12.1 -4.1 6.69e-05 0.0244 -0.33 -0.32 Tuberculosis; chr2:61271833 chr2:61151433~61162105:- PAAD cis rs6545883 0.524 rs12713435 ENSG00000271889.1 RP11-493E12.1 -4.1 6.69e-05 0.0244 -0.33 -0.32 Tuberculosis; chr2:61272654 chr2:61151433~61162105:- PAAD cis rs875971 1 rs709597 ENSG00000232559.3 GS1-124K5.12 -4.1 6.69e-05 0.0244 -0.33 -0.32 Aortic root size; chr7:66360996 chr7:66554588~66576923:- PAAD cis rs7189233 0.55 rs9927982 ENSG00000279344.1 RP11-44F14.7 4.1 6.7e-05 0.0244 0.24 0.32 Intelligence (multi-trait analysis); chr16:53440196 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs17800577 ENSG00000279344.1 RP11-44F14.7 4.1 6.7e-05 0.0244 0.24 0.32 Intelligence (multi-trait analysis); chr16:53442892 chr16:53478957~53481550:- PAAD cis rs11662586 0.517 rs11663082 ENSG00000267270.4 PARD6G-AS1 -4.1 6.7e-05 0.0244 -0.43 -0.32 Exploratory eye movement dysfunction in schizophrenia (responsive search score); chr18:79953494 chr18:80147924~80178432:+ PAAD cis rs11662586 0.517 rs11662894 ENSG00000267270.4 PARD6G-AS1 -4.1 6.7e-05 0.0244 -0.43 -0.32 Exploratory eye movement dysfunction in schizophrenia (responsive search score); chr18:79953591 chr18:80147924~80178432:+ PAAD cis rs4759375 0.667 rs10773007 ENSG00000256092.2 RP13-942N8.1 4.1 6.7e-05 0.0244 0.61 0.32 HDL cholesterol; chr12:123316205 chr12:123363868~123366113:+ PAAD cis rs780096 0.526 rs7602534 ENSG00000234072.1 AC074117.10 -4.1 6.7e-05 0.0244 -0.24 -0.32 Total body bone mineral density; chr2:27369556 chr2:27356246~27367622:+ PAAD cis rs3743772 0.881 rs62048523 ENSG00000279344.1 RP11-44F14.7 4.1 6.7e-05 0.0244 0.47 0.32 Depressive symptoms (SSRI exposure interaction); chr16:53471465 chr16:53478957~53481550:- PAAD cis rs7727544 1 rs7727038 ENSG00000233006.5 AC034220.3 4.1 6.71e-05 0.0245 0.24 0.32 Blood metabolite levels; chr5:132254564 chr5:132311285~132369916:- PAAD cis rs7727544 1 rs7727544 ENSG00000233006.5 AC034220.3 4.1 6.71e-05 0.0245 0.24 0.32 Blood metabolite levels; chr5:132254841 chr5:132311285~132369916:- PAAD cis rs7727544 1 rs10076701 ENSG00000233006.5 AC034220.3 4.1 6.71e-05 0.0245 0.24 0.32 Blood metabolite levels; chr5:132260726 chr5:132311285~132369916:- PAAD cis rs4794202 0.523 rs11871969 ENSG00000264920.1 RP11-6N17.4 -4.1 6.71e-05 0.0245 -0.51 -0.32 Alzheimer's disease (cognitive decline); chr17:47915256 chr17:47891255~47895812:- PAAD cis rs4660214 0.666 rs7554206 ENSG00000228060.1 RP11-69E11.8 4.1 6.71e-05 0.0245 0.3 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39463568 chr1:39565160~39573203:+ PAAD cis rs5760092 0.618 rs4461358 ENSG00000099984.9 GSTT2 4.1 6.72e-05 0.0245 0.44 0.32 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23917919 chr22:23980123~23983911:+ PAAD cis rs7688540 0.511 rs10003260 ENSG00000275426.1 CH17-262A2.1 4.1 6.72e-05 0.0245 0.51 0.32 Facial morphology (factor 6, height of vermillion lower lip); chr4:191053 chr4:149738~150317:+ PAAD cis rs11081761 0.79 rs11876773 ENSG00000265008.1 RP11-53I6.3 4.1 6.72e-05 0.0245 0.56 0.32 Resting heart rate; chr18:32357113 chr18:32091295~32092119:- PAAD cis rs11089937 0.626 rs11704092 ENSG00000211639.2 IGLV4-60 4.1 6.73e-05 0.0245 0.34 0.32 Periodontitis (PAL4Q3); chr22:22135815 chr22:22162199~22162681:+ PAAD cis rs683250 0.599 rs7110564 ENSG00000227097.5 RPS28P7 4.1 6.73e-05 0.0245 0.4 0.32 Subcortical brain region volumes; chr11:83367576 chr11:82689559~82689768:+ PAAD cis rs9309711 0.772 rs9752251 ENSG00000225234.1 TRAPPC12-AS1 -4.1 6.73e-05 0.0245 -0.35 -0.32 Neurofibrillary tangles; chr2:3486098 chr2:3481242~3482409:- PAAD cis rs9309711 0.772 rs9309714 ENSG00000225234.1 TRAPPC12-AS1 -4.1 6.73e-05 0.0245 -0.35 -0.32 Neurofibrillary tangles; chr2:3488059 chr2:3481242~3482409:- PAAD cis rs4853012 0.941 rs60291089 ENSG00000257800.1 FNBP1P1 4.1 6.73e-05 0.0245 0.42 0.32 Gestational age at birth (maternal effect); chr2:74117763 chr2:74120680~74123218:+ PAAD cis rs4853012 0.838 rs58759652 ENSG00000257800.1 FNBP1P1 4.1 6.73e-05 0.0245 0.42 0.32 Gestational age at birth (maternal effect); chr2:74117775 chr2:74120680~74123218:+ PAAD cis rs1150668 0.83 rs2023493 ENSG00000219891.2 ZSCAN12P1 4.1 6.73e-05 0.0245 0.41 0.32 Pubertal anthropometrics; chr6:28432385 chr6:28091154~28093664:+ PAAD cis rs8031584 0.736 rs11635775 ENSG00000260382.1 RP11-540B6.2 4.1 6.74e-05 0.0245 0.42 0.32 Huntington's disease progression; chr15:30868437 chr15:30882267~30883231:- PAAD cis rs8031584 0.678 rs4779790 ENSG00000260382.1 RP11-540B6.2 4.1 6.74e-05 0.0245 0.42 0.32 Huntington's disease progression; chr15:30872392 chr15:30882267~30883231:- PAAD cis rs8031584 0.678 rs8035703 ENSG00000260382.1 RP11-540B6.2 4.1 6.74e-05 0.0245 0.42 0.32 Huntington's disease progression; chr15:30876269 chr15:30882267~30883231:- PAAD cis rs11893307 0.509 rs12612904 ENSG00000235852.1 AC005540.3 4.1 6.74e-05 0.0245 0.47 0.32 Mean platelet volume; chr2:190670121 chr2:190880797~190882059:- PAAD cis rs11893307 0.509 rs2109957 ENSG00000235852.1 AC005540.3 4.1 6.74e-05 0.0245 0.47 0.32 Mean platelet volume; chr2:190670585 chr2:190880797~190882059:- PAAD cis rs11893307 0.509 rs4368360 ENSG00000235852.1 AC005540.3 4.1 6.74e-05 0.0245 0.47 0.32 Mean platelet volume; chr2:190671327 chr2:190880797~190882059:- PAAD cis rs950169 0.922 rs4586394 ENSG00000275120.1 RP11-182J1.17 -4.1 6.74e-05 0.0246 -0.33 -0.32 Schizophrenia; chr15:84153633 chr15:84599434~84606463:- PAAD cis rs61270009 0.955 rs430943 ENSG00000247828.6 TMEM161B-AS1 -4.1 6.75e-05 0.0246 -0.26 -0.32 Depressive symptoms; chr5:88251306 chr5:88268895~88436685:+ PAAD cis rs61270009 0.913 rs373845 ENSG00000247828.6 TMEM161B-AS1 -4.1 6.75e-05 0.0246 -0.26 -0.32 Depressive symptoms; chr5:88253893 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs454830 ENSG00000247828.6 TMEM161B-AS1 -4.1 6.75e-05 0.0246 -0.26 -0.32 Depressive symptoms; chr5:88254678 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs75214722 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88269908 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs895295 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88271529 chr5:88268895~88436685:+ PAAD cis rs61270009 0.913 rs16903040 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88273220 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs12163987 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88276209 chr5:88268895~88436685:+ PAAD cis rs61270009 1 rs61270009 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88280322 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs16903057 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88292603 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs34241164 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88293189 chr5:88268895~88436685:+ PAAD cis rs13177755 1 rs13177755 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms (multi-trait analysis); chr5:88296420 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs13159835 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88305576 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs10942528 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88314098 chr5:88268895~88436685:+ PAAD cis rs61270009 0.913 rs13190179 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88314755 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs11738675 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88315360 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs60331678 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88315547 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs10462333 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88315871 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs6872897 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88322248 chr5:88268895~88436685:+ PAAD cis rs61270009 0.908 rs16903077 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88323008 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs10462472 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88346652 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs11748798 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88354925 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs11740836 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88356311 chr5:88268895~88436685:+ PAAD cis rs61270009 0.913 rs13154590 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88357208 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs2115884 ENSG00000247828.6 TMEM161B-AS1 4.1 6.75e-05 0.0246 0.26 0.32 Depressive symptoms; chr5:88358839 chr5:88268895~88436685:+ PAAD cis rs7182621 0.546 rs11635811 ENSG00000182397.13 DNM1P46 4.1 6.75e-05 0.0246 0.39 0.32 Colonoscopy-negative controls vs population controls; chr15:99839918 chr15:99790156~99806927:- PAAD cis rs17655730 0.52 rs2178798 ENSG00000277290.1 RP11-326C3.16 -4.1 6.75e-05 0.0246 -0.25 -0.32 Mean platelet volume; chr11:254869 chr11:243099~243483:- PAAD cis rs7083 0.875 rs536648 ENSG00000254851.1 RP11-109L13.1 4.1 6.75e-05 0.0246 0.37 0.32 Blood protein levels; chr11:117272469 chr11:117135528~117138582:+ PAAD cis rs12935418 0.733 rs12448615 ENSG00000261061.1 RP11-303E16.2 -4.1 6.75e-05 0.0246 -0.51 -0.32 Mean corpuscular volume; chr16:80947132 chr16:81030770~81031485:+ PAAD cis rs9595908 0.9 rs7994229 ENSG00000212293.1 SNORA16 4.1 6.75e-05 0.0246 0.36 0.32 Body mass index; chr13:32586568 chr13:32420390~32420516:- PAAD cis rs9595908 1 rs9595905 ENSG00000212293.1 SNORA16 4.1 6.75e-05 0.0246 0.36 0.32 Body mass index; chr13:32609266 chr13:32420390~32420516:- PAAD cis rs28386778 0.863 rs9207 ENSG00000240280.5 TCAM1P -4.1 6.75e-05 0.0246 -0.44 -0.32 Prudent dietary pattern; chr17:63746539 chr17:63849292~63864379:+ PAAD cis rs755249 1 rs61779359 ENSG00000228060.1 RP11-69E11.8 -4.1 6.76e-05 0.0246 -0.32 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39544563 chr1:39565160~39573203:+ PAAD cis rs755249 0.959 rs61781363 ENSG00000228060.1 RP11-69E11.8 -4.1 6.76e-05 0.0246 -0.32 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39546761 chr1:39565160~39573203:+ PAAD cis rs755249 1 rs4660808 ENSG00000228060.1 RP11-69E11.8 -4.1 6.76e-05 0.0246 -0.32 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39552837 chr1:39565160~39573203:+ PAAD cis rs755249 1 rs61781364 ENSG00000228060.1 RP11-69E11.8 -4.1 6.76e-05 0.0246 -0.32 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39553919 chr1:39565160~39573203:+ PAAD cis rs1707322 0.717 rs1135850 ENSG00000280836.1 AL355480.1 -4.1 6.76e-05 0.0246 -0.38 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628020 chr1:45581219~45581321:- PAAD cis rs1707322 0.682 rs3014241 ENSG00000280836.1 AL355480.1 4.1 6.76e-05 0.0246 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45622207 chr1:45581219~45581321:- PAAD cis rs1707322 0.655 rs3014240 ENSG00000280836.1 AL355480.1 4.1 6.76e-05 0.0246 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45623553 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs3014235 ENSG00000280836.1 AL355480.1 4.1 6.76e-05 0.0246 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45625840 chr1:45581219~45581321:- PAAD cis rs1707322 0.656 rs9429172 ENSG00000280836.1 AL355480.1 4.1 6.76e-05 0.0246 0.38 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45626804 chr1:45581219~45581321:- PAAD cis rs755249 0.529 rs3768299 ENSG00000261798.1 RP1-118J21.25 4.1 6.77e-05 0.0246 0.41 0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39391520 chr1:39788976~39790171:+ PAAD cis rs6479901 0.841 rs7913332 ENSG00000232075.1 MRPL35P2 -4.1 6.77e-05 0.0246 -0.45 -0.32 Intelligence (multi-trait analysis); chr10:63293890 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs7093899 ENSG00000232075.1 MRPL35P2 -4.1 6.77e-05 0.0246 -0.45 -0.32 Intelligence (multi-trait analysis); chr10:63294576 chr10:63634317~63634827:- PAAD cis rs755249 0.508 rs586057 ENSG00000228060.1 RP11-69E11.8 -4.1 6.77e-05 0.0246 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39393122 chr1:39565160~39573203:+ PAAD cis rs755249 0.508 rs624971 ENSG00000228060.1 RP11-69E11.8 -4.1 6.77e-05 0.0246 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39393275 chr1:39565160~39573203:+ PAAD cis rs9652601 0.845 rs7184615 ENSG00000274038.1 RP11-66H6.4 -4.1 6.77e-05 0.0246 -0.34 -0.32 Systemic lupus erythematosus; chr16:11071685 chr16:11056556~11057034:+ PAAD cis rs763121 0.853 rs138704 ENSG00000228274.3 RP3-508I15.9 -4.1 6.78e-05 0.0246 -0.31 -0.32 Menopause (age at onset); chr22:38737405 chr22:38667585~38681820:- PAAD cis rs2712184 0.875 rs1015784 ENSG00000229352.1 AC007563.3 -4.1 6.78e-05 0.0246 -0.31 -0.32 Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine); chr2:216817110 chr2:216799608~216805335:+ PAAD cis rs526231 0.697 rs253759 ENSG00000175749.11 EIF3KP1 4.1 6.78e-05 0.0247 0.45 0.32 Primary biliary cholangitis; chr5:103279974 chr5:103032376~103033031:+ PAAD cis rs950027 0.62 rs1145077 ENSG00000259433.2 CTD-2651B20.4 4.1 6.78e-05 0.0247 0.36 0.32 Response to fenofibrate (adiponectin levels); chr15:45391597 chr15:45330209~45332634:- PAAD cis rs987724 0.778 rs35874547 ENSG00000240875.4 LINC00886 -4.1 6.78e-05 0.0247 -0.39 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156972867 chr3:156747346~156817062:- PAAD cis rs987724 0.929 rs2321455 ENSG00000240875.4 LINC00886 -4.1 6.78e-05 0.0247 -0.39 -0.32 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156975806 chr3:156747346~156817062:- PAAD cis rs28386778 0.897 rs2584640 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63786128 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584639 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63786372 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs2597633 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63795511 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2727333 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63798663 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs2251164 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63806760 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2727290 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63817368 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs1062788 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63818767 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs1062790 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63819095 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs1062791 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63819127 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs894408 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63819454 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs2727288 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63823837 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs894407 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63824281 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs894406 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63824297 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs716880 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63825462 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584626 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63825819 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584624 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63827186 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs2665834 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63827364 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2727287 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63827368 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2665833 ENSG00000240280.5 TCAM1P -4.1 6.79e-05 0.0247 -0.44 -0.32 Prudent dietary pattern; chr17:63829486 chr17:63849292~63864379:+ PAAD cis rs189798 0.738 rs330911 ENSG00000253893.2 FAM85B -4.1 6.79e-05 0.0247 -0.47 -0.32 Myopia (pathological); chr8:9138763 chr8:8167819~8226614:- PAAD cis rs6570726 1 rs374464 ENSG00000235652.6 RP11-545I5.3 4.1 6.79e-05 0.0247 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145525543 chr6:145799409~145886585:+ PAAD cis rs6570726 1 rs436066 ENSG00000235652.6 RP11-545I5.3 4.1 6.79e-05 0.0247 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145525991 chr6:145799409~145886585:+ PAAD cis rs6570726 1 rs450076 ENSG00000235652.6 RP11-545I5.3 4.1 6.79e-05 0.0247 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145526519 chr6:145799409~145886585:+ PAAD cis rs6570726 1 rs441477 ENSG00000235652.6 RP11-545I5.3 4.1 6.79e-05 0.0247 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145527107 chr6:145799409~145886585:+ PAAD cis rs812925 0.519 rs2922089 ENSG00000273302.1 RP11-493E12.2 -4.1 6.79e-05 0.0247 -0.27 -0.32 Immature fraction of reticulocytes; chr2:61397994 chr2:61199979~61200769:+ PAAD cis rs812925 0.519 rs2694627 ENSG00000273302.1 RP11-493E12.2 -4.1 6.79e-05 0.0247 -0.27 -0.32 Immature fraction of reticulocytes; chr2:61398371 chr2:61199979~61200769:+ PAAD cis rs7615952 0.512 rs2979336 ENSG00000171084.14 FAM86JP 4.1 6.79e-05 0.0247 0.43 0.32 Blood pressure (smoking interaction); chr3:125638626 chr3:125916620~125930024:+ PAAD cis rs2985684 0.901 rs7146248 ENSG00000259113.1 RP11-406H23.2 -4.1 6.79e-05 0.0247 -0.43 -0.32 Carotid intima media thickness; chr14:49645349 chr14:50448807~50456742:+ PAAD cis rs12935418 0.83 rs12448368 ENSG00000261838.4 RP11-303E16.6 -4.1 6.8e-05 0.0247 -0.57 -0.32 Mean corpuscular volume; chr16:81011342 chr16:81069854~81076598:+ PAAD cis rs7216064 0.553 rs62084690 ENSG00000278219.1 AC145343.1 4.1 6.8e-05 0.0247 0.43 0.32 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:68039295 chr17:68101538~68101639:+ PAAD cis rs1862618 0.756 rs9292125 ENSG00000271828.1 CTD-2310F14.1 4.1 6.8e-05 0.0247 0.46 0.32 Initial pursuit acceleration; chr5:56811373 chr5:56927874~56929573:+ PAAD cis rs1862618 0.802 rs986049 ENSG00000271828.1 CTD-2310F14.1 4.1 6.8e-05 0.0247 0.46 0.32 Initial pursuit acceleration; chr5:56814406 chr5:56927874~56929573:+ PAAD cis rs9595908 0.897 rs10083285 ENSG00000212293.1 SNORA16 4.1 6.8e-05 0.0247 0.36 0.32 Body mass index; chr13:32557205 chr13:32420390~32420516:- PAAD cis rs867371 0.502 rs7176926 ENSG00000278603.1 RP13-608F4.5 4.1 6.8e-05 0.0247 0.38 0.32 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82245753 chr15:82472203~82472426:+ PAAD cis rs2665103 0.632 rs3902959 ENSG00000278603.1 RP13-608F4.5 4.1 6.8e-05 0.0247 0.38 0.32 Intelligence (multi-trait analysis); chr15:82252586 chr15:82472203~82472426:+ PAAD cis rs5015933 0.815 rs4991998 ENSG00000232630.1 PRPS1P2 -4.1 6.8e-05 0.0247 -0.28 -0.32 Body mass index; chr9:125314702 chr9:125150653~125151589:+ PAAD cis rs5015933 0.815 rs12338077 ENSG00000232630.1 PRPS1P2 -4.1 6.8e-05 0.0247 -0.28 -0.32 Body mass index; chr9:125345427 chr9:125150653~125151589:+ PAAD cis rs5015933 0.815 rs10986716 ENSG00000232630.1 PRPS1P2 -4.1 6.8e-05 0.0247 -0.28 -0.32 Body mass index; chr9:125345606 chr9:125150653~125151589:+ PAAD cis rs5015933 0.815 rs13291322 ENSG00000232630.1 PRPS1P2 -4.1 6.8e-05 0.0247 -0.28 -0.32 Body mass index; chr9:125348076 chr9:125150653~125151589:+ PAAD cis rs5015933 0.815 rs13291655 ENSG00000232630.1 PRPS1P2 -4.1 6.8e-05 0.0247 -0.28 -0.32 Body mass index; chr9:125348274 chr9:125150653~125151589:+ PAAD cis rs1707322 0.686 rs1250 ENSG00000280836.1 AL355480.1 -4.1 6.8e-05 0.0247 -0.39 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45628355 chr1:45581219~45581321:- PAAD cis rs6479901 0.895 rs7902187 ENSG00000232075.1 MRPL35P2 -4.1 6.81e-05 0.0247 -0.46 -0.32 Intelligence (multi-trait analysis); chr10:63333375 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs10761746 ENSG00000232075.1 MRPL35P2 -4.1 6.81e-05 0.0247 -0.46 -0.32 Intelligence (multi-trait analysis); chr10:63345134 chr10:63634317~63634827:- PAAD cis rs6479901 0.894 rs10761748 ENSG00000232075.1 MRPL35P2 -4.1 6.81e-05 0.0247 -0.46 -0.32 Intelligence (multi-trait analysis); chr10:63350216 chr10:63634317~63634827:- PAAD cis rs6479901 0.846 rs7082926 ENSG00000232075.1 MRPL35P2 -4.1 6.81e-05 0.0247 -0.46 -0.32 Intelligence (multi-trait analysis); chr10:63355771 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs10740119 ENSG00000232075.1 MRPL35P2 -4.1 6.81e-05 0.0247 -0.46 -0.32 Intelligence (multi-trait analysis); chr10:63365477 chr10:63634317~63634827:- PAAD cis rs4660214 0.666 rs588326 ENSG00000228060.1 RP11-69E11.8 -4.1 6.81e-05 0.0247 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39443054 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs1775656 ENSG00000228060.1 RP11-69E11.8 -4.1 6.81e-05 0.0247 -0.3 -0.32 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39445329 chr1:39565160~39573203:+ PAAD cis rs11976180 0.517 rs6949375 ENSG00000273234.1 OR2A13P -4.1 6.81e-05 0.0248 -0.47 -0.32 Obesity-related traits; chr7:144076758 chr7:144142009~144142938:+ PAAD cis rs5015933 0.815 rs16928051 ENSG00000232630.1 PRPS1P2 -4.1 6.82e-05 0.0248 -0.28 -0.32 Body mass index; chr9:125308738 chr9:125150653~125151589:+ PAAD cis rs1707322 0.721 rs4660883 ENSG00000280836.1 AL355480.1 -4.1 6.82e-05 0.0248 -0.37 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45770426 chr1:45581219~45581321:- PAAD cis rs2446066 0.872 rs10876447 ENSG00000257379.1 RP11-793H13.8 4.1 6.82e-05 0.0248 0.46 0.32 Red blood cell count; chr12:53377157 chr12:53441741~53467528:+ PAAD cis rs6977955 1 rs11495981 ENSG00000234336.5 JAZF1-AS1 4.1 6.82e-05 0.0248 0.38 0.32 Allergic disease (asthma, hay fever or eczema); chr7:28137682 chr7:28180322~28243917:+ PAAD cis rs748404 0.631 rs8042688 ENSG00000205771.5 CATSPER2P1 -4.1 6.82e-05 0.0248 -0.42 -0.32 Lung cancer; chr15:43346327 chr15:43726918~43747094:- PAAD cis rs748404 0.631 rs4296223 ENSG00000205771.5 CATSPER2P1 -4.1 6.82e-05 0.0248 -0.42 -0.32 Lung cancer; chr15:43353048 chr15:43726918~43747094:- PAAD cis rs748404 0.631 rs11070399 ENSG00000205771.5 CATSPER2P1 -4.1 6.82e-05 0.0248 -0.42 -0.32 Lung cancer; chr15:43354149 chr15:43726918~43747094:- PAAD cis rs748404 0.631 rs6493086 ENSG00000205771.5 CATSPER2P1 -4.1 6.82e-05 0.0248 -0.42 -0.32 Lung cancer; chr15:43363196 chr15:43726918~43747094:- PAAD cis rs9847710 0.683 rs2581818 ENSG00000242142.1 SERBP1P3 4.1 6.83e-05 0.0248 0.39 0.32 Ulcerative colitis; chr3:53037636 chr3:53064283~53065091:- PAAD cis rs9847710 0.733 rs9818819 ENSG00000242142.1 SERBP1P3 4.1 6.83e-05 0.0248 0.39 0.32 Ulcerative colitis; chr3:53042739 chr3:53064283~53065091:- PAAD cis rs11089937 0.568 rs11089919 ENSG00000211638.2 IGLV8-61 -4.1 6.83e-05 0.0248 -0.29 -0.32 Periodontitis (PAL4Q3); chr22:22131648 chr22:22098700~22099212:+ PAAD cis rs7554672 0.961 rs12123182 ENSG00000232679.1 RP11-400N13.3 4.1 6.83e-05 0.0248 0.32 0.32 Hypertension; chr1:221157173 chr1:222041705~222064763:- PAAD cis rs2188561 1 rs2712207 ENSG00000241764.3 AC002467.7 4.1 6.83e-05 0.0248 0.42 0.32 Alcohol consumption; chr7:107711672 chr7:107742817~107744581:- PAAD cis rs2288884 0.515 rs3752118 ENSG00000275055.1 CTC-471J1.11 -4.1 6.83e-05 0.0248 -0.43 -0.32 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52048233 chr19:52049007~52049754:+ PAAD cis rs9876781 1 rs1459242 ENSG00000229759.1 MRPS18AP1 -4.1 6.83e-05 0.0248 -0.34 -0.32 Longevity; chr3:48372047 chr3:48256350~48256938:- PAAD cis rs10129255 0.536 rs6576201 ENSG00000211967.3 IGHV3-53 4.1 6.84e-05 0.0248 0.23 0.32 Kawasaki disease; chr14:106683696 chr14:106592676~106593347:- PAAD cis rs763121 0.626 rs5750643 ENSG00000228274.3 RP3-508I15.9 -4.1 6.84e-05 0.0248 -0.3 -0.32 Menopause (age at onset); chr22:38613012 chr22:38667585~38681820:- PAAD cis rs28386778 0.863 rs6919 ENSG00000240280.5 TCAM1P 4.09 6.84e-05 0.0248 0.44 0.32 Prudent dietary pattern; chr17:63832125 chr17:63849292~63864379:+ PAAD cis rs1707322 0.721 rs10890346 ENSG00000280836.1 AL355480.1 4.09 6.84e-05 0.0248 0.37 0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45758220 chr1:45581219~45581321:- PAAD cis rs1707322 0.685 rs56177313 ENSG00000280836.1 AL355480.1 -4.09 6.84e-05 0.0248 -0.37 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760134 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs11211178 ENSG00000280836.1 AL355480.1 -4.09 6.84e-05 0.0248 -0.37 -0.32 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45761894 chr1:45581219~45581321:- PAAD cis rs9918079 0.524 rs4235379 ENSG00000273133.1 RP11-799M12.2 -4.09 6.84e-05 0.0248 -0.38 -0.32 Obesity-related traits; chr4:15657655 chr4:15563698~15564253:- PAAD cis rs9322193 0.923 rs9479810 ENSG00000268592.3 RAET1E-AS1 4.09 6.84e-05 0.0248 0.37 0.32 Lung cancer; chr6:149751359 chr6:149863494~149919507:+ PAAD cis rs950169 0.58 rs2271431 ENSG00000259295.5 CSPG4P12 4.09 6.84e-05 0.0248 0.35 0.32 Schizophrenia; chr15:84646233 chr15:85191438~85213905:+ PAAD cis rs287982 0.932 rs11887231 ENSG00000269973.1 RP11-95D17.1 -4.09 6.84e-05 0.0248 -0.37 -0.32 Nonsyndromic cleft lip with cleft palate; chr2:9826987 chr2:9936360~9939590:+ PAAD cis rs287982 1 rs13404815 ENSG00000269973.1 RP11-95D17.1 -4.09 6.84e-05 0.0248 -0.37 -0.32 Nonsyndromic cleft lip with cleft palate; chr2:9827637 chr2:9936360~9939590:+ PAAD cis rs287982 1 rs2656329 ENSG00000269973.1 RP11-95D17.1 -4.09 6.84e-05 0.0248 -0.37 -0.32 Nonsyndromic cleft lip with cleft palate; chr2:9828215 chr2:9936360~9939590:+ PAAD cis rs287982 1 rs56154233 ENSG00000269973.1 RP11-95D17.1 -4.09 6.84e-05 0.0248 -0.37 -0.32 Nonsyndromic cleft lip with cleft palate; chr2:9829098 chr2:9936360~9939590:+ PAAD cis rs3785888 0.553 rs10853086 ENSG00000262539.1 RP11-259G18.3 -4.09 6.84e-05 0.0248 -0.45 -0.32 Cleft lip with or without cleft palate; chr17:46928743 chr17:46259551~46260606:- PAAD cis rs792448 0.581 rs1663626 ENSG00000226251.4 RP11-15I11.3 -4.09 6.84e-05 0.0248 -0.41 -0.32 White blood cell count (basophil); chr1:212249225 chr1:212225278~212238977:- PAAD cis rs6570726 0.935 rs392014 ENSG00000235652.6 RP11-545I5.3 4.09 6.84e-05 0.0248 0.26 0.32 Lobe attachment (rater-scored or self-reported); chr6:145522555 chr6:145799409~145886585:+ PAAD cis rs11089937 0.667 rs9622981 ENSG00000211638.2 IGLV8-61 -4.09 6.85e-05 0.0248 -0.3 -0.32 Periodontitis (PAL4Q3); chr22:22150100 chr22:22098700~22099212:+ PAAD cis rs7512552 0.525 rs2298161 ENSG00000234232.5 RP11-353N4.5 4.09 6.85e-05 0.0249 0.36 0.32 Allergic disease (asthma, hay fever or eczema);Atopic dermatitis; chr1:150265224 chr1:149677498~149747812:- PAAD cis rs10759883 0.563 rs10819720 ENSG00000175611.10 LINC00476 4.09 6.85e-05 0.0249 0.31 0.32 Nicotine dependence; chr9:96021506 chr9:95759231~95875977:- PAAD cis rs1789 0.592 rs1558572 ENSG00000247624.5 CPEB2-AS1 -4.09 6.86e-05 0.0249 -0.42 -0.32 Blood protein levels; chr4:15537121 chr4:14909961~15002045:- PAAD cis rs7617773 0.746 rs4130995 ENSG00000228638.1 FCF1P2 -4.09 6.86e-05 0.0249 -0.35 -0.32 Coronary artery disease; chr3:48316765 chr3:48290793~48291375:- PAAD cis rs12439619 1 rs12439619 ENSG00000276710.3 CSPG4P8 -4.09 6.86e-05 0.0249 -0.31 -0.32 Intelligence (multi-trait analysis); chr15:82254605 chr15:82459472~82477258:+ PAAD cis rs6479901 0.841 rs10995453 ENSG00000232075.1 MRPL35P2 -4.09 6.86e-05 0.0249 -0.46 -0.32 Intelligence (multi-trait analysis); chr10:63174571 chr10:63634317~63634827:- PAAD cis rs5758511 0.68 rs5758667 ENSG00000226450.2 CYP2D8P 4.09 6.87e-05 0.0249 0.34 0.32 Birth weight; chr22:42237198 chr22:42149886~42155001:- PAAD cis rs7182621 0.639 rs12906050 ENSG00000259363.4 CTD-2054N24.2 -4.09 6.87e-05 0.0249 -0.42 -0.32 Colonoscopy-negative controls vs population controls; chr15:99873384 chr15:99807023~99877148:+ PAAD cis rs7182621 0.639 rs35248328 ENSG00000259363.4 CTD-2054N24.2 -4.09 6.87e-05 0.0249 -0.42 -0.32 Colonoscopy-negative controls vs population controls; chr15:99873399 chr15:99807023~99877148:+ PAAD cis rs5758511 0.508 rs2413667 ENSG00000205702.9 CYP2D7 4.09 6.87e-05 0.0249 0.3 0.32 Birth weight; chr22:42076233 chr22:42140203~42144577:- PAAD cis rs5758511 0.689 rs45441993 ENSG00000205702.9 CYP2D7 4.09 6.88e-05 0.0249 0.34 0.32 Birth weight; chr22:42075734 chr22:42140203~42144577:- PAAD cis rs3785888 0.569 rs11655668 ENSG00000262539.1 RP11-259G18.3 -4.09 6.88e-05 0.0249 -0.45 -0.32 Cleft lip with or without cleft palate; chr17:46930266 chr17:46259551~46260606:- PAAD cis rs1862618 0.853 rs2113078 ENSG00000271828.1 CTD-2310F14.1 4.09 6.88e-05 0.0249 0.46 0.32 Initial pursuit acceleration; chr5:56791363 chr5:56927874~56929573:+ PAAD cis rs72843506 0.586 rs74811834 ENSG00000189423.10 USP32P3 4.09 6.88e-05 0.0249 0.48 0.32 Schizophrenia; chr17:19982271 chr17:20415547~20431008:+ PAAD cis rs72843506 0.52 rs78178505 ENSG00000189423.10 USP32P3 4.09 6.88e-05 0.0249 0.48 0.32 Schizophrenia; chr17:19984410 chr17:20415547~20431008:+ PAAD cis rs10740039 0.883 rs1561850 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60631583 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs34168977 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60632916 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7088404 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60633320 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs1837946 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60633676 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs1837945 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60633757 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7089287 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60634006 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7089720 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60634063 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7093573 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60634611 chr10:60734342~60741828:+ PAAD cis rs10740039 0.804 rs7093882 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60634863 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7097818 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60635106 chr10:60734342~60741828:+ PAAD cis rs10740039 0.842 rs2119913 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60635631 chr10:60734342~60741828:+ PAAD cis rs10740039 0.586 rs7068462 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60636240 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7068934 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60636490 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7069814 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60637001 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs10821809 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60637612 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs10740037 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60637747 chr10:60734342~60741828:+ PAAD cis rs10740039 0.804 rs10761531 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60638177 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs10761533 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60638573 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs10994446 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60639433 chr10:60734342~60741828:+ PAAD cis rs10740039 0.846 rs2165690 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60639609 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs2119912 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60639754 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs2119911 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60639808 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs10740038 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60643479 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7918897 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60643754 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7902632 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60643811 chr10:60734342~60741828:+ PAAD cis rs10740039 0.804 rs7902456 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60643937 chr10:60734342~60741828:+ PAAD cis rs10740039 0.96 rs10761536 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60644657 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs10994455 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60645589 chr10:60734342~60741828:+ PAAD cis rs10740039 0.96 rs10443928 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60645718 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs10443929 ENSG00000254271.1 RP11-131N11.4 4.09 6.88e-05 0.0249 0.38 0.32 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60645852 chr10:60734342~60741828:+ PAAD cis rs5003154 0.58 rs4739787 ENSG00000253334.1 RP13-923O23.6 4.09 6.89e-05 0.025 0.35 0.32 Bladder cancer; chr8:81098298 chr8:81791823~81815714:+ PAAD cis rs12908161 1 rs12908161 ENSG00000259295.5 CSPG4P12 4.09 6.89e-05 0.025 0.35 0.32 Schizophrenia; chr15:84664594 chr15:85191438~85213905:+ PAAD cis rs1275411 0.54 rs1983700 ENSG00000259062.2 ACTN1-AS1 4.09 6.89e-05 0.025 0.39 0.32 Neuroticism; chr14:68978401 chr14:68979682~68987463:+ PAAD cis rs2729354 0.817 rs2467327 ENSG00000265566.2 RN7SL605P -4.09 6.89e-05 0.025 -0.4 -0.32 Blood protein levels; chr11:57511755 chr11:57528085~57528365:- PAAD cis rs62392365 0.543 rs1665820 ENSG00000168405.13 CMAHP 4.09 6.9e-05 0.025 0.46 0.32 Intelligence (multi-trait analysis);Schizophrenia; chr6:25070610 chr6:25081068~25166555:- PAAD cis rs9487094 0.744 rs13204787 ENSG00000260273.1 RP11-425D10.10 4.09 6.9e-05 0.025 0.44 0.32 Height; chr6:109618283 chr6:109382795~109383666:+ PAAD cis rs453301 0.686 rs28665409 ENSG00000253893.2 FAM85B 4.09 6.9e-05 0.025 0.43 0.32 Joint mobility (Beighton score); chr8:9011767 chr8:8167819~8226614:- PAAD cis rs4554975 0.514 rs10881009 ENSG00000274723.1 RP11-618L22.1 -4.09 6.9e-05 0.025 -0.36 -0.32 Metabolite levels (small molecules and protein measures); chr12:46906861 chr12:46970504~46972155:+ PAAD cis rs12446554 0.509 rs56108048 ENSG00000261195.1 CTD-2380F24.1 -4.09 6.9e-05 0.025 -0.51 -0.32 Obesity; chr16:19698457 chr16:19761172~19766099:- PAAD cis rs12444979 0.517 rs720176 ENSG00000261195.1 CTD-2380F24.1 -4.09 6.9e-05 0.025 -0.51 -0.32 Body mass index; chr16:19710193 chr16:19761172~19766099:- PAAD cis rs2243480 1 rs313814 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66038306 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs402418 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66044482 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs423187 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66044512 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs431318 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66046610 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313803 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66049744 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313802 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66051386 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs403089 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66052736 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs458291 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66055492 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs466983 ENSG00000228409.4 CCT6P1 4.09 6.9e-05 0.025 0.34 0.32 Diabetic kidney disease; chr7:66055509 chr7:65751142~65763354:+ PAAD cis rs4554975 0.514 rs7963326 ENSG00000274723.1 RP11-618L22.1 -4.09 6.9e-05 0.025 -0.36 -0.32 Metabolite levels (small molecules and protein measures); chr12:46908278 chr12:46970504~46972155:+ PAAD cis rs11098499 0.566 rs7664440 ENSG00000245958.5 RP11-33B1.1 -4.09 6.9e-05 0.025 -0.27 -0.32 Corneal astigmatism; chr4:119657385 chr4:119454791~119552025:+ PAAD cis rs12908161 1 rs3803403 ENSG00000259728.4 LINC00933 4.09 6.9e-05 0.025 0.42 0.32 Schizophrenia; chr15:84839914 chr15:84570649~84580175:+ PAAD cis rs5015933 0.815 rs3896021 ENSG00000232630.1 PRPS1P2 -4.09 6.91e-05 0.025 -0.28 -0.32 Body mass index; chr9:125262019 chr9:125150653~125151589:+ PAAD cis rs5015933 0.815 rs35216121 ENSG00000232630.1 PRPS1P2 -4.09 6.91e-05 0.025 -0.28 -0.32 Body mass index; chr9:125263999 chr9:125150653~125151589:+ PAAD cis rs5015933 0.778 rs867547 ENSG00000232630.1 PRPS1P2 -4.09 6.91e-05 0.025 -0.28 -0.32 Body mass index; chr9:125269184 chr9:125150653~125151589:+ PAAD cis rs4718428 0.705 rs4718424 ENSG00000273142.1 RP11-458F8.4 -4.09 6.91e-05 0.025 -0.21 -0.32 Corneal structure; chr7:66911108 chr7:66902857~66906297:+ PAAD cis rs11233413 0.874 rs17504704 ENSG00000247137.7 RP11-727A23.5 -4.09 6.91e-05 0.025 -0.28 -0.32 Economic and political preferences (feminism/equality); chr11:83034485 chr11:83184491~83193794:- PAAD cis rs710216 0.536 rs710222 ENSG00000227533.4 SLC2A1-AS1 4.09 6.91e-05 0.025 0.34 0.32 Red cell distribution width; chr1:42947982 chr1:42959049~42983358:+ PAAD cis rs11976180 1 rs2951372 ENSG00000273234.1 OR2A13P -4.09 6.91e-05 0.025 -0.39 -0.32 Obesity-related traits; chr7:144052410 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2951368 ENSG00000273234.1 OR2A13P -4.09 6.91e-05 0.025 -0.39 -0.32 Obesity-related traits; chr7:144055728 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2961115 ENSG00000273234.1 OR2A13P -4.09 6.91e-05 0.025 -0.39 -0.32 Obesity-related traits; chr7:144056278 chr7:144142009~144142938:+ PAAD cis rs4759375 0.831 rs4281511 ENSG00000256092.2 RP13-942N8.1 4.09 6.92e-05 0.025 0.61 0.32 HDL cholesterol; chr12:123296566 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs11057250 ENSG00000256092.2 RP13-942N8.1 4.09 6.92e-05 0.025 0.61 0.32 HDL cholesterol; chr12:123303264 chr12:123363868~123366113:+ PAAD cis rs9595908 0.965 rs9595795 ENSG00000212293.1 SNORA16 4.09 6.92e-05 0.0251 0.37 0.32 Body mass index; chr13:32548658 chr13:32420390~32420516:- PAAD cis rs55726902 1 rs73107993 ENSG00000276691.1 RP5-1057I20.5 4.09 6.92e-05 0.0251 0.36 0.31 Allergic disease (asthma, hay fever or eczema); chr12:47802090 chr12:47788426~47788971:+ PAAD cis rs4853012 0.838 rs59570457 ENSG00000257800.1 FNBP1P1 4.09 6.93e-05 0.0251 0.44 0.31 Gestational age at birth (maternal effect); chr2:74117155 chr2:74120680~74123218:+ PAAD cis rs270601 0.661 rs10036208 ENSG00000233006.5 AC034220.3 4.09 6.93e-05 0.0251 0.27 0.31 Acylcarnitine levels; chr5:132235630 chr5:132311285~132369916:- PAAD cis rs270601 0.633 rs733300 ENSG00000233006.5 AC034220.3 4.09 6.93e-05 0.0251 0.27 0.31 Acylcarnitine levels; chr5:132236550 chr5:132311285~132369916:- PAAD cis rs270601 0.633 rs4535443 ENSG00000233006.5 AC034220.3 4.09 6.93e-05 0.0251 0.27 0.31 Acylcarnitine levels; chr5:132236868 chr5:132311285~132369916:- PAAD cis rs10421328 0.784 rs12983292 ENSG00000259242.2 AC002306.1 4.09 6.93e-05 0.0251 0.47 0.31 Parental longevity (combined parental age at death); chr19:19676958 chr19:19606350~19608660:+ PAAD cis rs2404602 0.532 rs206205 ENSG00000259422.1 RP11-593F23.1 4.09 6.93e-05 0.0251 0.36 0.31 Blood metabolite levels; chr15:76443750 chr15:76174891~76181486:- PAAD cis rs633715 0.766 rs72698507 ENSG00000254154.7 RP4-798P15.3 -4.09 6.93e-05 0.0251 -0.3 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177828212 chr1:177928788~178038007:- PAAD cis rs4835473 0.932 rs1849112 ENSG00000251600.4 RP11-673E1.1 4.09 6.94e-05 0.0251 0.37 0.31 Immature fraction of reticulocytes; chr4:143962502 chr4:143912331~143982454:+ PAAD cis rs4835473 0.831 rs4125544 ENSG00000251600.4 RP11-673E1.1 4.09 6.94e-05 0.0251 0.37 0.31 Immature fraction of reticulocytes; chr4:143962542 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs12507633 ENSG00000251600.4 RP11-673E1.1 4.09 6.94e-05 0.0251 0.37 0.31 Immature fraction of reticulocytes; chr4:143962730 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs11100824 ENSG00000251600.4 RP11-673E1.1 4.09 6.94e-05 0.0251 0.37 0.31 Immature fraction of reticulocytes; chr4:143964845 chr4:143912331~143982454:+ PAAD cis rs4835473 0.592 rs11100825 ENSG00000251600.4 RP11-673E1.1 4.09 6.94e-05 0.0251 0.37 0.31 Immature fraction of reticulocytes; chr4:143964903 chr4:143912331~143982454:+ PAAD cis rs4273100 0.646 rs4924990 ENSG00000279825.1 CTC-457L16.1 -4.09 6.94e-05 0.0251 -0.38 -0.31 Schizophrenia; chr17:19391511 chr17:19030857~19033529:+ PAAD cis rs35000415 0.688 rs35429892 ENSG00000281490.1 CICP14 -4.09 6.94e-05 0.0251 -0.35 -0.31 Systemic lupus erythematosus; chr7:129073576 chr7:128655962~128658791:- PAAD cis rs6479891 0.524 rs10740107 ENSG00000232075.1 MRPL35P2 -4.09 6.94e-05 0.0251 -0.48 -0.31 Arthritis (juvenile idiopathic); chr10:63184557 chr10:63634317~63634827:- PAAD cis rs875971 0.522 rs1880556 ENSG00000236529.1 RP13-254B10.1 4.09 6.94e-05 0.0251 0.34 0.31 Aortic root size; chr7:65967557 chr7:65840212~65840596:+ PAAD cis rs7208859 0.673 rs2470251 ENSG00000264538.5 SUZ12P1 -4.09 6.95e-05 0.0251 -0.28 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30768043 chr17:30709299~30790908:+ PAAD cis rs7208859 0.673 rs11652370 ENSG00000264538.5 SUZ12P1 -4.09 6.95e-05 0.0251 -0.28 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770205 chr17:30709299~30790908:+ PAAD cis rs7208859 0.673 rs56846352 ENSG00000264538.5 SUZ12P1 -4.09 6.95e-05 0.0251 -0.28 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792170 chr17:30709299~30790908:+ PAAD cis rs7208859 0.673 rs7211776 ENSG00000264538.5 SUZ12P1 -4.09 6.95e-05 0.0251 -0.28 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793178 chr17:30709299~30790908:+ PAAD cis rs7208859 0.573 rs8078182 ENSG00000264538.5 SUZ12P1 -4.09 6.95e-05 0.0251 -0.28 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822646 chr17:30709299~30790908:+ PAAD cis rs10740039 0.81 rs9415605 ENSG00000254271.1 RP11-131N11.4 -4.09 6.95e-05 0.0251 -0.41 -0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60616809 chr10:60734342~60741828:+ PAAD cis rs891378 1 rs6700168 ENSG00000274245.1 RP11-357P18.2 4.09 6.95e-05 0.0251 0.44 0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207329189 chr1:207372559~207373252:+ PAAD cis rs6940638 0.513 rs4424065 ENSG00000241549.7 GUSBP2 -4.09 6.95e-05 0.0251 -0.33 -0.31 Intelligence (multi-trait analysis); chr6:27068677 chr6:26871484~26956554:- PAAD cis rs9322193 0.884 rs1125 ENSG00000223701.3 RAET1E-AS1 4.09 6.96e-05 0.0252 0.38 0.31 Lung cancer; chr6:149658280 chr6:149884431~149919508:+ PAAD cis rs55665837 0.559 rs11023209 ENSG00000251991.1 RNU7-49P 4.09 6.97e-05 0.0252 0.38 0.31 Vitamin D levels; chr11:14401054 chr11:14478892~14478953:+ PAAD cis rs9322193 0.923 rs9322197 ENSG00000268592.3 RAET1E-AS1 4.09 6.97e-05 0.0252 0.36 0.31 Lung cancer; chr6:149622577 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs9688858 ENSG00000268592.3 RAET1E-AS1 4.09 6.97e-05 0.0252 0.36 0.31 Lung cancer; chr6:149637911 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs1934534 ENSG00000223701.3 RAET1E-AS1 4.09 6.97e-05 0.0252 0.35 0.31 Lung cancer; chr6:149711896 chr6:149884431~149919508:+ PAAD cis rs950169 0.58 rs11635597 ENSG00000259295.5 CSPG4P12 4.09 6.97e-05 0.0252 0.35 0.31 Schizophrenia; chr15:84622468 chr15:85191438~85213905:+ PAAD cis rs1789 0.786 rs6449161 ENSG00000273133.1 RP11-799M12.2 -4.09 6.97e-05 0.0252 -0.39 -0.31 Blood protein levels; chr4:15691331 chr4:15563698~15564253:- PAAD cis rs12554020 1 rs55766809 ENSG00000227603.1 RP11-165J3.6 4.09 6.98e-05 0.0252 0.46 0.31 Schizophrenia; chr9:93428436 chr9:93435332~93437121:- PAAD cis rs7554672 0.961 rs12119108 ENSG00000232679.1 RP11-400N13.3 4.09 6.98e-05 0.0252 0.33 0.31 Hypertension; chr1:221153558 chr1:222041705~222064763:- PAAD cis rs7189233 0.513 rs10748 ENSG00000279344.1 RP11-44F14.7 4.09 6.98e-05 0.0252 0.24 0.31 Intelligence (multi-trait analysis); chr16:53470809 chr16:53478957~53481550:- PAAD cis rs8005677 0.828 rs2295680 ENSG00000279656.1 RP11-298I3.6 -4.09 6.98e-05 0.0252 -0.36 -0.31 Cognitive ability (multi-trait analysis); chr14:22905226 chr14:23023083~23024217:- PAAD cis rs1113500 0.966 rs11185249 ENSG00000226822.1 RP11-356N1.2 4.09 6.99e-05 0.0253 0.37 0.31 Growth-regulated protein alpha levels; chr1:108069024 chr1:108071482~108074519:+ PAAD cis rs7626444 0.625 rs843531 ENSG00000272359.1 U4 -4.09 6.99e-05 0.0253 -0.34 -0.31 Monocyte count; chr3:196754900 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs9877495 ENSG00000272359.1 U4 -4.09 6.99e-05 0.0253 -0.34 -0.31 Monocyte count; chr3:196756409 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs2686599 ENSG00000272359.1 U4 -4.09 6.99e-05 0.0253 -0.34 -0.31 Monocyte count; chr3:196756923 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs1403101 ENSG00000272359.1 U4 -4.09 6.99e-05 0.0253 -0.34 -0.31 Monocyte count; chr3:196758203 chr3:196747192~196747324:- PAAD cis rs7626444 0.628 rs1684464 ENSG00000272359.1 U4 -4.09 6.99e-05 0.0253 -0.34 -0.31 Monocyte count; chr3:196758643 chr3:196747192~196747324:- PAAD cis rs7626444 0.625 rs1486358 ENSG00000272359.1 U4 -4.09 6.99e-05 0.0253 -0.34 -0.31 Monocyte count; chr3:196758719 chr3:196747192~196747324:- PAAD cis rs75804782 0.63 rs75651012 ENSG00000186235.9 AC016757.3 4.09 7e-05 0.0253 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238325755 chr2:238224552~238231677:- PAAD cis rs780096 0.506 rs2950834 ENSG00000234072.1 AC074117.10 -4.09 7e-05 0.0253 -0.25 -0.31 Total body bone mineral density; chr2:27404499 chr2:27356246~27367622:+ PAAD cis rs867371 0.502 rs1846908 ENSG00000278603.1 RP13-608F4.5 4.09 7e-05 0.0253 0.38 0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82230185 chr15:82472203~82472426:+ PAAD cis rs2665103 0.655 rs1501367 ENSG00000278603.1 RP13-608F4.5 4.09 7e-05 0.0253 0.38 0.31 Intelligence (multi-trait analysis); chr15:82230475 chr15:82472203~82472426:+ PAAD cis rs867371 0.502 rs28610286 ENSG00000278603.1 RP13-608F4.5 4.09 7e-05 0.0253 0.38 0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82233314 chr15:82472203~82472426:+ PAAD cis rs867371 0.502 rs2047679 ENSG00000278603.1 RP13-608F4.5 4.09 7e-05 0.0253 0.38 0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82239540 chr15:82472203~82472426:+ PAAD cis rs2677744 1 rs1550636 ENSG00000278370.1 RP11-387D10.4 -4.09 7e-05 0.0253 -0.41 -0.31 Attention deficit hyperactivity disorder; chr15:90934231 chr15:90650631~90651103:+ PAAD cis rs4660214 0.666 rs950805 ENSG00000237624.1 OXCT2P1 -4.09 7.01e-05 0.0253 -0.42 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39239786 chr1:39514956~39516490:+ PAAD cis rs897984 0.806 rs12924903 ENSG00000260911.2 RP11-196G11.2 4.09 7.01e-05 0.0253 0.28 0.31 Dementia with Lewy bodies; chr16:30917649 chr16:31043150~31049868:+ PAAD cis rs5758659 0.652 rs133340 ENSG00000273366.1 CTA-989H11.1 4.09 7.01e-05 0.0253 0.37 0.31 Cognitive function; chr22:42021683 chr22:42278188~42278846:+ PAAD cis rs17772222 0.958 rs17798341 ENSG00000258983.2 RP11-507K2.2 4.09 7.01e-05 0.0253 0.42 0.31 Coronary artery calcification; chr14:88548201 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs10134008 ENSG00000258983.2 RP11-507K2.2 4.09 7.01e-05 0.0253 0.42 0.31 Coronary artery calcification; chr14:88549183 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs891750 ENSG00000258983.2 RP11-507K2.2 4.09 7.01e-05 0.0253 0.42 0.31 Coronary artery calcification; chr14:88550856 chr14:88499334~88515502:+ PAAD cis rs17772222 0.958 rs891749 ENSG00000258983.2 RP11-507K2.2 4.09 7.01e-05 0.0253 0.42 0.31 Coronary artery calcification; chr14:88550893 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs61984683 ENSG00000258983.2 RP11-507K2.2 4.09 7.01e-05 0.0253 0.42 0.31 Coronary artery calcification; chr14:88553162 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs61984684 ENSG00000258983.2 RP11-507K2.2 4.09 7.01e-05 0.0253 0.42 0.31 Coronary artery calcification; chr14:88559104 chr14:88499334~88515502:+ PAAD cis rs2658782 1 rs2605585 ENSG00000279684.1 RP11-755E23.2 -4.09 7.01e-05 0.0253 -0.53 -0.31 Pulmonary function decline; chr11:93438696 chr11:93286629~93288903:- PAAD cis rs2894969 0.664 rs11252705 ENSG00000225269.2 LINC00705 4.09 7.01e-05 0.0253 0.31 0.31 Major depressive disorder; chr10:4753157 chr10:4655427~4662419:+ PAAD cis rs6977955 0.877 rs9648346 ENSG00000234336.5 JAZF1-AS1 -4.09 7.01e-05 0.0253 -0.37 -0.31 Allergic disease (asthma, hay fever or eczema); chr7:28120494 chr7:28180322~28243917:+ PAAD cis rs2403083 0.505 rs4740047 ENSG00000258256.1 RP11-219B4.5 -4.09 7.02e-05 0.0254 -0.35 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85281577 chr8:85222446~85245717:- PAAD cis rs4759375 0.588 rs10846490 ENSG00000256092.2 RP13-942N8.1 4.09 7.02e-05 0.0254 0.61 0.31 HDL cholesterol; chr12:123266447 chr12:123363868~123366113:+ PAAD cis rs17684571 0.938 rs17751695 ENSG00000231441.1 RP11-472M19.2 4.09 7.02e-05 0.0254 0.52 0.31 Schizophrenia; chr6:56695966 chr6:56844002~56864078:+ PAAD cis rs193541 0.632 rs34486978 ENSG00000263432.2 RN7SL689P -4.09 7.02e-05 0.0254 -0.41 -0.31 Glucose homeostasis traits; chr5:122976848 chr5:123022487~123022783:- PAAD cis rs4664293 1 rs6753181 ENSG00000226266.5 AC009961.3 -4.09 7.02e-05 0.0254 -0.4 -0.31 Monocyte percentage of white cells; chr2:159635927 chr2:159670708~159712435:- PAAD cis rs4950322 0.542 rs1932977 ENSG00000278811.3 LINC00624 4.09 7.03e-05 0.0254 0.31 0.31 Protein quantitative trait loci; chr1:147217371 chr1:147258885~147517875:- PAAD cis rs3738443 0.904 rs12562191 ENSG00000259865.1 RP11-488L18.10 4.09 7.03e-05 0.0254 0.29 0.31 Alcohol dependence; chr1:247234227 chr1:247187281~247188526:- PAAD cis rs73019876 0.747 rs7258834 ENSG00000279377.1 AC003973.3 4.09 7.03e-05 0.0254 0.26 0.31 Testicular germ cell tumor; chr19:22045319 chr19:21965708~21968529:- PAAD cis rs5758511 0.689 rs17478227 ENSG00000226450.2 CYP2D8P -4.09 7.03e-05 0.0254 -0.37 -0.31 Birth weight; chr22:42258321 chr22:42149886~42155001:- PAAD cis rs17772222 0.63 rs12437422 ENSG00000258983.2 RP11-507K2.2 -4.09 7.03e-05 0.0254 -0.39 -0.31 Coronary artery calcification; chr14:88529621 chr14:88499334~88515502:+ PAAD cis rs17772222 0.605 rs4899955 ENSG00000258983.2 RP11-507K2.2 -4.09 7.03e-05 0.0254 -0.39 -0.31 Coronary artery calcification; chr14:88530381 chr14:88499334~88515502:+ PAAD cis rs867371 0.892 rs4344697 ENSG00000259429.4 UBE2Q2P2 -4.09 7.04e-05 0.0254 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82252873 chr15:82355142~82420075:+ PAAD cis rs10540 1 rs61876333 ENSG00000255237.1 RP13-317D12.3 4.09 7.04e-05 0.0254 0.48 0.31 Body mass index; chr11:487136 chr11:462930~463899:- PAAD cis rs4478147 0.51 rs1031739 ENSG00000251411.1 RP11-397E7.4 -4.09 7.04e-05 0.0254 -0.32 -0.31 Migraine - clinic-based; chr4:86308524 chr4:86913266~86914817:- PAAD cis rs11159086 1 rs11626856 ENSG00000259005.1 RP3-449M8.6 4.09 7.05e-05 0.0254 0.43 0.31 Advanced glycation end-product levels; chr14:74469665 chr14:74474007~74474864:- PAAD cis rs2188561 0.697 rs6947099 ENSG00000241764.3 AC002467.7 4.09 7.05e-05 0.0254 0.4 0.31 Alcohol consumption; chr7:107720471 chr7:107742817~107744581:- PAAD cis rs858239 0.601 rs1034963 ENSG00000226816.2 AC005082.12 4.09 7.05e-05 0.0254 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23108854 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs73272048 ENSG00000226816.2 AC005082.12 4.09 7.05e-05 0.0254 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23113034 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs15775 ENSG00000226816.2 AC005082.12 4.09 7.05e-05 0.0254 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23125082 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs4599714 ENSG00000226816.2 AC005082.12 4.09 7.05e-05 0.0254 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23129182 chr7:23206013~23208045:+ PAAD cis rs858239 0.601 rs10278776 ENSG00000226816.2 AC005082.12 4.09 7.05e-05 0.0254 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23130140 chr7:23206013~23208045:+ PAAD cis rs858239 0.632 rs13438452 ENSG00000226816.2 AC005082.12 4.09 7.05e-05 0.0254 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23134563 chr7:23206013~23208045:+ PAAD cis rs6052484 0.523 rs6052515 ENSG00000226948.1 RPS4XP2 -4.09 7.05e-05 0.0254 -0.48 -0.31 Sense of smell; chr20:4332667 chr20:4629427~4630219:- PAAD cis rs17214007 0.877 rs4541094 ENSG00000263335.1 AF001548.5 -4.09 7.06e-05 0.0255 -0.45 -0.31 Cognitive function; chr16:15776878 chr16:15726674~15732993:+ PAAD cis rs919433 0.889 rs12472355 ENSG00000231621.1 AC013264.2 4.09 7.06e-05 0.0255 0.3 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197341116 chr2:197197991~197199273:+ PAAD cis rs919433 0.889 rs6711624 ENSG00000231621.1 AC013264.2 4.09 7.06e-05 0.0255 0.3 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197342883 chr2:197197991~197199273:+ PAAD cis rs2882667 0.518 rs10041986 ENSG00000253404.1 AC034243.1 4.09 7.06e-05 0.0255 0.34 0.31 Age-related hearing impairment (SNP x SNP interaction); chr5:139088748 chr5:138744434~138753309:- PAAD cis rs61270009 0.955 rs10514299 ENSG00000247828.6 TMEM161B-AS1 4.09 7.06e-05 0.0255 0.26 0.31 Depressive symptoms; chr5:88367793 chr5:88268895~88436685:+ PAAD cis rs4666002 0.789 rs13030973 ENSG00000234072.1 AC074117.10 4.09 7.07e-05 0.0255 0.3 0.31 Phospholipid levels (plasma); chr2:27705930 chr2:27356246~27367622:+ PAAD cis rs9807989 0.507 rs2041739 ENSG00000234389.1 AC007278.3 -4.09 7.07e-05 0.0255 -0.31 -0.31 Asthma; chr2:102377873 chr2:102438713~102440475:+ PAAD cis rs9847710 0.733 rs7613013 ENSG00000242142.1 SERBP1P3 4.09 7.07e-05 0.0255 0.39 0.31 Ulcerative colitis; chr3:53043790 chr3:53064283~53065091:- PAAD cis rs9847710 0.708 rs2581811 ENSG00000242142.1 SERBP1P3 4.09 7.07e-05 0.0255 0.39 0.31 Ulcerative colitis; chr3:53051785 chr3:53064283~53065091:- PAAD cis rs9847710 0.733 rs2581808 ENSG00000242142.1 SERBP1P3 4.09 7.07e-05 0.0255 0.39 0.31 Ulcerative colitis; chr3:53055429 chr3:53064283~53065091:- PAAD cis rs9847710 0.733 rs2581809 ENSG00000242142.1 SERBP1P3 4.09 7.07e-05 0.0255 0.39 0.31 Ulcerative colitis; chr3:53055667 chr3:53064283~53065091:- PAAD cis rs72627509 0.904 rs17081933 ENSG00000269949.1 RP11-738E22.3 4.09 7.07e-05 0.0255 0.5 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56956703 chr4:56960927~56961373:- PAAD cis rs72627509 0.904 rs17081935 ENSG00000269949.1 RP11-738E22.3 4.09 7.07e-05 0.0255 0.5 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56957310 chr4:56960927~56961373:- PAAD cis rs6844153 0.713 rs11734308 ENSG00000240005.4 RP11-293A21.1 -4.09 7.07e-05 0.0255 -0.44 -0.31 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26934877 chr4:26859806~26860599:- PAAD cis rs2562456 1 rs2359155 ENSG00000213976.4 CTD-2561J22.2 4.09 7.08e-05 0.0255 0.34 0.31 Pain; chr19:21489067 chr19:21382865~21387177:+ PAAD cis rs2179367 0.959 rs652807 ENSG00000231760.4 RP11-350J20.5 -4.09 7.08e-05 0.0255 -0.4 -0.31 Dupuytren's disease; chr6:149416359 chr6:149796151~149826294:- PAAD cis rs4713118 0.662 rs464312 ENSG00000204709.4 LINC01556 4.09 7.08e-05 0.0255 0.52 0.31 Parkinson's disease; chr6:27999813 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs469228 ENSG00000204709.4 LINC01556 4.09 7.08e-05 0.0255 0.52 0.31 Parkinson's disease; chr6:28002926 chr6:28943877~28944537:+ PAAD cis rs4713118 0.54 rs469227 ENSG00000204709.4 LINC01556 4.09 7.08e-05 0.0255 0.52 0.31 Parkinson's disease; chr6:28002927 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs149948 ENSG00000204709.4 LINC01556 4.09 7.08e-05 0.0255 0.52 0.31 Parkinson's disease; chr6:28007039 chr6:28943877~28944537:+ PAAD cis rs6504622 0.791 rs758392 ENSG00000214401.4 KANSL1-AS1 -4.09 7.09e-05 0.0255 -0.41 -0.31 Orofacial clefts; chr17:46940493 chr17:46193576~46196723:+ PAAD cis rs6951245 0.935 rs112554101 ENSG00000229043.2 AC091729.9 -4.09 7.09e-05 0.0256 -0.45 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1025899 chr7:1160374~1165267:+ PAAD cis rs3096299 0.582 rs12935119 ENSG00000261253.2 AC137932.6 4.09 7.09e-05 0.0256 0.34 0.31 Multiple myeloma (IgH translocation); chr16:89476466 chr16:89321133~89325110:+ PAAD cis rs7617773 0.817 rs17647717 ENSG00000228638.1 FCF1P2 -4.09 7.09e-05 0.0256 -0.36 -0.31 Coronary artery disease; chr3:48263966 chr3:48290793~48291375:- PAAD cis rs72615157 0.634 rs74774557 ENSG00000242294.5 STAG3L5P 4.09 7.1e-05 0.0256 0.25 0.31 Lung function (FEV1/FVC); chr7:100212802 chr7:100336079~100351900:+ PAAD cis rs2403083 0.505 rs4609189 ENSG00000258256.1 RP11-219B4.5 -4.09 7.1e-05 0.0256 -0.34 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85277940 chr8:85222446~85245717:- PAAD cis rs2403083 0.505 rs4617148 ENSG00000258256.1 RP11-219B4.5 -4.09 7.1e-05 0.0256 -0.34 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85282132 chr8:85222446~85245717:- PAAD cis rs2403083 0.505 rs9329908 ENSG00000258256.1 RP11-219B4.5 -4.09 7.1e-05 0.0256 -0.34 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85286992 chr8:85222446~85245717:- PAAD cis rs2015599 0.623 rs2288128 ENSG00000275476.1 RP11-996F15.4 4.09 7.1e-05 0.0256 0.3 0.31 Platelet count;Mean platelet volume; chr12:29316054 chr12:29277397~29277882:- PAAD cis rs2015599 0.584 rs2288129 ENSG00000275476.1 RP11-996F15.4 4.09 7.1e-05 0.0256 0.3 0.31 Platelet count;Mean platelet volume; chr12:29316355 chr12:29277397~29277882:- PAAD cis rs2015599 0.623 rs10843385 ENSG00000275476.1 RP11-996F15.4 -4.09 7.1e-05 0.0256 -0.3 -0.31 Platelet count;Mean platelet volume; chr12:29323100 chr12:29277397~29277882:- PAAD cis rs79040073 0.637 rs17473568 ENSG00000259531.2 RP11-295H24.3 4.09 7.1e-05 0.0256 0.53 0.31 Lung cancer in ever smokers; chr15:49149326 chr15:49365124~49366685:- PAAD cis rs6504950 0.888 rs244294 ENSG00000275710.1 RP11-257O5.4 4.09 7.1e-05 0.0256 0.38 0.31 Breast cancer; chr17:55151182 chr17:54964474~54964679:+ PAAD cis rs1113500 0.933 rs745795 ENSG00000226822.1 RP11-356N1.2 4.09 7.1e-05 0.0256 0.37 0.31 Growth-regulated protein alpha levels; chr1:108086723 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs2077259 ENSG00000226822.1 RP11-356N1.2 4.09 7.1e-05 0.0256 0.37 0.31 Growth-regulated protein alpha levels; chr1:108086929 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs3909076 ENSG00000226822.1 RP11-356N1.2 4.09 7.1e-05 0.0256 0.37 0.31 Growth-regulated protein alpha levels; chr1:108089138 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs3893034 ENSG00000226822.1 RP11-356N1.2 4.09 7.1e-05 0.0256 0.37 0.31 Growth-regulated protein alpha levels; chr1:108089556 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs12132785 ENSG00000226822.1 RP11-356N1.2 4.09 7.1e-05 0.0256 0.37 0.31 Growth-regulated protein alpha levels; chr1:108090461 chr1:108071482~108074519:+ PAAD cis rs1113500 0.933 rs11185255 ENSG00000226822.1 RP11-356N1.2 4.09 7.1e-05 0.0256 0.37 0.31 Growth-regulated protein alpha levels; chr1:108090569 chr1:108071482~108074519:+ PAAD cis rs7189233 0.55 rs4783811 ENSG00000279344.1 RP11-44F14.7 4.09 7.1e-05 0.0256 0.24 0.31 Intelligence (multi-trait analysis); chr16:53449464 chr16:53478957~53481550:- PAAD cis rs3743772 1 rs62048488 ENSG00000279344.1 RP11-44F14.7 4.09 7.11e-05 0.0256 0.46 0.31 Depressive symptoms (SSRI exposure interaction); chr16:53420027 chr16:53478957~53481550:- PAAD cis rs7759001 0.744 rs7771590 ENSG00000271755.1 RP1-153G14.4 4.09 7.11e-05 0.0256 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27500117 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs10946932 ENSG00000271755.1 RP1-153G14.4 4.09 7.11e-05 0.0256 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27502334 chr6:27404010~27406964:- PAAD cis rs17123764 0.818 rs1902330 ENSG00000257464.1 RP11-161H23.8 -4.08 7.11e-05 0.0256 -0.54 -0.31 Intelligence (multi-trait analysis); chr12:49546170 chr12:49442424~49442652:- PAAD cis rs9487094 0.67 rs12199154 ENSG00000260273.1 RP11-425D10.10 -4.08 7.11e-05 0.0256 -0.39 -0.31 Height; chr6:109501793 chr6:109382795~109383666:+ PAAD cis rs2904804 0.555 rs7067963 ENSG00000224251.5 RP11-499O7.7 4.08 7.12e-05 0.0256 0.36 0.31 Economic and political preferences (immigration/crime); chr10:4947800 chr10:4995488~4997380:+ PAAD cis rs11893307 0.537 rs3771319 ENSG00000235852.1 AC005540.3 4.08 7.12e-05 0.0256 0.47 0.31 Mean platelet volume; chr2:190660507 chr2:190880797~190882059:- PAAD cis rs875971 0.505 rs1723275 ENSG00000236529.1 RP13-254B10.1 -4.08 7.12e-05 0.0256 -0.34 -0.31 Aortic root size; chr7:66039646 chr7:65840212~65840596:+ PAAD cis rs875971 0.505 rs2462573 ENSG00000236529.1 RP13-254B10.1 -4.08 7.12e-05 0.0256 -0.34 -0.31 Aortic root size; chr7:66042405 chr7:65840212~65840596:+ PAAD cis rs875971 0.505 rs1167385 ENSG00000236529.1 RP13-254B10.1 -4.08 7.12e-05 0.0256 -0.34 -0.31 Aortic root size; chr7:66048321 chr7:65840212~65840596:+ PAAD cis rs10050311 0.8 rs17420966 ENSG00000251411.1 RP11-397E7.4 -4.08 7.12e-05 0.0256 -0.39 -0.31 Insulin-related traits; chr4:86770976 chr4:86913266~86914817:- PAAD cis rs7626444 0.584 rs844542 ENSG00000272359.1 U4 -4.08 7.12e-05 0.0256 -0.34 -0.31 Monocyte count; chr3:196752432 chr3:196747192~196747324:- PAAD cis rs7626444 0.543 rs843528 ENSG00000272359.1 U4 -4.08 7.12e-05 0.0256 -0.34 -0.31 Monocyte count; chr3:196753464 chr3:196747192~196747324:- PAAD cis rs9847710 0.733 rs11923593 ENSG00000242142.1 SERBP1P3 4.08 7.13e-05 0.0257 0.39 0.31 Ulcerative colitis; chr3:53054774 chr3:53064283~53065091:- PAAD cis rs875971 0.597 rs11763224 ENSG00000222364.1 RNU6-96P -4.08 7.13e-05 0.0257 -0.41 -0.31 Aortic root size; chr7:66518628 chr7:66395191~66395286:+ PAAD cis rs7189233 0.531 rs1362429 ENSG00000279344.1 RP11-44F14.7 4.08 7.13e-05 0.0257 0.23 0.31 Intelligence (multi-trait analysis); chr16:53445172 chr16:53478957~53481550:- PAAD cis rs2599510 0.783 rs62136349 ENSG00000276334.1 AL133243.1 4.08 7.13e-05 0.0257 0.38 0.31 Interleukin-18 levels; chr2:32602437 chr2:32521927~32523547:+ PAAD cis rs12908161 1 rs35808647 ENSG00000259728.4 LINC00933 4.08 7.14e-05 0.0257 0.41 0.31 Schizophrenia; chr15:84834210 chr15:84570649~84580175:+ PAAD cis rs7402982 0.625 rs4966011 ENSG00000278022.1 RP11-35O15.2 -4.08 7.14e-05 0.0257 -0.4 -0.31 Birth weight; chr15:98660777 chr15:98660210~98660668:+ PAAD cis rs2348418 0.798 rs11049486 ENSG00000247934.4 RP11-967K21.1 -4.08 7.14e-05 0.0257 -0.3 -0.31 Lung function (FEV1);Lung function (FVC); chr12:28253224 chr12:28163298~28190738:- PAAD cis rs2348418 0.767 rs1478332 ENSG00000247934.4 RP11-967K21.1 -4.08 7.14e-05 0.0257 -0.3 -0.31 Lung function (FEV1);Lung function (FVC); chr12:28255432 chr12:28163298~28190738:- PAAD cis rs10129255 0.536 rs10139058 ENSG00000211967.3 IGHV3-53 -4.08 7.15e-05 0.0257 -0.23 -0.31 Kawasaki disease; chr14:106685899 chr14:106592676~106593347:- PAAD cis rs10129255 0.536 rs8004835 ENSG00000211967.3 IGHV3-53 -4.08 7.15e-05 0.0257 -0.23 -0.31 Kawasaki disease; chr14:106686361 chr14:106592676~106593347:- PAAD cis rs5758511 0.689 rs55906806 ENSG00000205702.9 CYP2D7 4.08 7.16e-05 0.0257 0.34 0.31 Birth weight; chr22:42248465 chr22:42140203~42144577:- PAAD cis rs7839040 0.535 rs7830040 ENSG00000253334.1 RP13-923O23.6 -4.08 7.16e-05 0.0258 -0.39 -0.31 Response to methotrexate in juvenile idiopathic arthritis; chr8:82004718 chr8:81791823~81815714:+ PAAD cis rs321358 0.945 rs17458235 ENSG00000271390.1 RP11-89C3.3 -4.08 7.16e-05 0.0258 -0.45 -0.31 Body mass index; chr11:111106114 chr11:111089870~111090368:- PAAD cis rs17836934 0.804 rs59313167 ENSG00000258302.2 RP11-981P6.1 4.08 7.16e-05 0.0258 0.27 0.31 Total body bone mineral density; chr12:90129715 chr12:89561129~89594878:+ PAAD cis rs17836934 0.838 rs7970711 ENSG00000258302.2 RP11-981P6.1 4.08 7.16e-05 0.0258 0.27 0.31 Total body bone mineral density; chr12:90134908 chr12:89561129~89594878:+ PAAD cis rs17836934 0.845 rs7979050 ENSG00000258302.2 RP11-981P6.1 4.08 7.16e-05 0.0258 0.27 0.31 Total body bone mineral density; chr12:90136962 chr12:89561129~89594878:+ PAAD cis rs7923837 0.963 rs11187141 ENSG00000236493.2 EIF2S2P3 4.08 7.16e-05 0.0258 0.41 0.31 Multiple sclerosis;Body mass index; chr10:92707388 chr10:92668745~92669743:- PAAD cis rs66573146 0.572 rs66734745 ENSG00000272620.1 AFAP1-AS1 -4.08 7.17e-05 0.0258 -0.59 -0.31 Granulocyte percentage of myeloid white cells; chr4:6947038 chr4:7754090~7778928:+ PAAD cis rs755249 1 rs4660303 ENSG00000228060.1 RP11-69E11.8 -4.08 7.17e-05 0.0258 -0.32 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39594801 chr1:39565160~39573203:+ PAAD cis rs2243480 1 rs1618893 ENSG00000228409.4 CCT6P1 4.08 7.17e-05 0.0258 0.32 0.31 Diabetic kidney disease; chr7:66631132 chr7:65751142~65763354:+ PAAD cis rs4666002 0.636 rs2272406 ENSG00000234072.1 AC074117.10 4.08 7.17e-05 0.0258 0.3 0.31 Phospholipid levels (plasma); chr2:27669156 chr2:27356246~27367622:+ PAAD cis rs7539624 0.577 rs1222081 ENSG00000272645.2 RP11-504P24.8 -4.08 7.17e-05 0.0258 -0.27 -0.31 Schizophrenia; chr1:223790954 chr1:223951388~223953439:- PAAD cis rs7216064 1 rs9915591 ENSG00000278219.1 AC145343.1 -4.08 7.17e-05 0.0258 -0.51 -0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67829974 chr17:68101538~68101639:+ PAAD cis rs72627509 0.904 rs3796529 ENSG00000269949.1 RP11-738E22.3 4.08 7.17e-05 0.0258 0.5 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56931248 chr4:56960927~56961373:- PAAD cis rs10888838 0.756 rs2282332 ENSG00000198711.5 SSBP3-AS1 4.08 7.18e-05 0.0258 0.39 0.31 Mitochondrial DNA levels; chr1:54224364 chr1:54236440~54239063:+ PAAD cis rs891378 1 rs10864231 ENSG00000274245.1 RP11-357P18.2 -4.08 7.18e-05 0.0258 -0.44 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207332984 chr1:207372559~207373252:+ PAAD cis rs4660214 0.789 rs1180375 ENSG00000228060.1 RP11-69E11.8 -4.08 7.18e-05 0.0258 -0.3 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39415368 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs663892 ENSG00000228060.1 RP11-69E11.8 -4.08 7.18e-05 0.0258 -0.3 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39424005 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs1180384 ENSG00000228060.1 RP11-69E11.8 -4.08 7.18e-05 0.0258 -0.3 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39427102 chr1:39565160~39573203:+ PAAD cis rs9322193 0.923 rs9371486 ENSG00000223701.3 RAET1E-AS1 4.08 7.18e-05 0.0258 0.39 0.31 Lung cancer; chr6:149832090 chr6:149884431~149919508:+ PAAD cis rs919433 0.713 rs6714697 ENSG00000231621.1 AC013264.2 -4.08 7.19e-05 0.0258 -0.31 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197619762 chr2:197197991~197199273:+ PAAD cis rs7646881 0.812 rs75107964 ENSG00000240207.5 RP11-379F4.4 -4.08 7.19e-05 0.0258 -0.51 -0.31 Tetralogy of Fallot; chr3:158740962 chr3:158732263~158784070:+ PAAD cis rs7189233 0.531 rs8045674 ENSG00000279344.1 RP11-44F14.7 4.08 7.19e-05 0.0258 0.24 0.31 Intelligence (multi-trait analysis); chr16:53476024 chr16:53478957~53481550:- PAAD cis rs3738443 0.904 rs61840474 ENSG00000259865.1 RP11-488L18.10 4.08 7.19e-05 0.0259 0.29 0.31 Alcohol dependence; chr1:247225109 chr1:247187281~247188526:- PAAD cis rs3738443 0.904 rs61840475 ENSG00000259865.1 RP11-488L18.10 4.08 7.19e-05 0.0259 0.29 0.31 Alcohol dependence; chr1:247225818 chr1:247187281~247188526:- PAAD cis rs950169 0.544 rs12913702 ENSG00000275120.1 RP11-182J1.17 4.08 7.2e-05 0.0259 0.34 0.31 Schizophrenia; chr15:84609953 chr15:84599434~84606463:- PAAD cis rs1113500 0.933 rs10494089 ENSG00000226822.1 RP11-356N1.2 4.08 7.2e-05 0.0259 0.37 0.31 Growth-regulated protein alpha levels; chr1:108084073 chr1:108071482~108074519:+ PAAD cis rs17836934 0.583 rs7311631 ENSG00000258302.2 RP11-981P6.1 4.08 7.2e-05 0.0259 0.29 0.31 Total body bone mineral density; chr12:90035251 chr12:89561129~89594878:+ PAAD cis rs17836934 0.654 rs6538218 ENSG00000258302.2 RP11-981P6.1 4.08 7.2e-05 0.0259 0.29 0.31 Total body bone mineral density; chr12:90039790 chr12:89561129~89594878:+ PAAD cis rs9322193 0.923 rs7753812 ENSG00000268592.3 RAET1E-AS1 4.08 7.2e-05 0.0259 0.37 0.31 Lung cancer; chr6:149690150 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs12195866 ENSG00000268592.3 RAET1E-AS1 4.08 7.2e-05 0.0259 0.37 0.31 Lung cancer; chr6:149693334 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9285524 ENSG00000268592.3 RAET1E-AS1 4.08 7.2e-05 0.0259 0.37 0.31 Lung cancer; chr6:149694122 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs10872645 ENSG00000268592.3 RAET1E-AS1 4.08 7.2e-05 0.0259 0.37 0.31 Lung cancer; chr6:149742840 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs12211511 ENSG00000268592.3 RAET1E-AS1 4.08 7.2e-05 0.0259 0.37 0.31 Lung cancer; chr6:149745206 chr6:149863494~149919507:+ PAAD cis rs4835473 0.831 rs7689328 ENSG00000251600.4 RP11-673E1.1 4.08 7.21e-05 0.0259 0.37 0.31 Immature fraction of reticulocytes; chr4:143973768 chr4:143912331~143982454:+ PAAD cis rs4835473 0.831 rs7694353 ENSG00000251600.4 RP11-673E1.1 4.08 7.21e-05 0.0259 0.37 0.31 Immature fraction of reticulocytes; chr4:143973787 chr4:143912331~143982454:+ PAAD cis rs2243480 1 rs1723267 ENSG00000232546.1 RP11-458F8.1 -4.08 7.21e-05 0.0259 -0.38 -0.31 Diabetic kidney disease; chr7:66008327 chr7:66848496~66858136:+ PAAD cis rs11997175 0.692 rs6468202 ENSG00000240738.1 RP1-273G13.1 4.08 7.21e-05 0.0259 0.37 0.31 Body mass index; chr8:33890202 chr8:33859480~33860223:- PAAD cis rs8072100 1 rs3809868 ENSG00000228782.6 CTD-2026D20.3 -4.08 7.21e-05 0.0259 -0.31 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47673230 chr17:47450568~47492492:- PAAD cis rs8072100 1 rs7210738 ENSG00000228782.6 CTD-2026D20.3 -4.08 7.21e-05 0.0259 -0.31 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47680232 chr17:47450568~47492492:- PAAD cis rs72615157 0.629 rs55839153 ENSG00000242294.5 STAG3L5P 4.08 7.21e-05 0.0259 0.26 0.31 Lung function (FEV1/FVC); chr7:100154943 chr7:100336079~100351900:+ PAAD cis rs2243480 1 rs437889 ENSG00000228409.4 CCT6P1 4.08 7.21e-05 0.0259 0.34 0.31 Diabetic kidney disease; chr7:66044247 chr7:65751142~65763354:+ PAAD cis rs10129255 0.536 rs10142951 ENSG00000211972.2 IGHV3-66 4.08 7.22e-05 0.0259 0.24 0.31 Kawasaki disease; chr14:106782337 chr14:106675017~106675544:- PAAD cis rs6951245 0.554 rs4724294 ENSG00000229043.2 AC091729.9 -4.08 7.22e-05 0.026 -0.43 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1100059 chr7:1160374~1165267:+ PAAD cis rs4759375 0.597 rs11531106 ENSG00000256092.2 RP13-942N8.1 4.08 7.22e-05 0.026 0.61 0.31 HDL cholesterol; chr12:123249508 chr12:123363868~123366113:+ PAAD cis rs6479901 0.947 rs6479897 ENSG00000232075.1 MRPL35P2 -4.08 7.23e-05 0.026 -0.46 -0.31 Intelligence (multi-trait analysis); chr10:63376868 chr10:63634317~63634827:- PAAD cis rs10411161 0.702 rs7250193 ENSG00000270248.1 CTC-471J1.10 -4.08 7.23e-05 0.026 -0.57 -0.31 Breast cancer; chr19:51882267 chr19:52110318~52110726:- PAAD cis rs829883 0.738 rs249846 ENSG00000245017.2 RP11-181C3.1 -4.08 7.23e-05 0.026 -0.31 -0.31 Colorectal adenoma (advanced); chr12:98474961 chr12:98485544~98503855:- PAAD cis rs7592578 0.766 rs62182865 ENSG00000231858.4 AC067945.4 -4.08 7.23e-05 0.026 -0.38 -0.31 Diastolic blood pressure; chr2:190569454 chr2:191021526~191032314:+ PAAD cis rs10783487 0.947 rs4762048 ENSG00000257542.4 OR7E47P -4.08 7.24e-05 0.026 -0.43 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52074492 chr12:52079696~52108261:+ PAAD cis rs10783487 0.947 rs12830246 ENSG00000257542.4 OR7E47P -4.08 7.24e-05 0.026 -0.43 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52074787 chr12:52079696~52108261:+ PAAD cis rs10783487 0.947 rs1882120 ENSG00000257542.4 OR7E47P -4.08 7.24e-05 0.026 -0.43 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52074972 chr12:52079696~52108261:+ PAAD cis rs153852 0.715 rs36729 ENSG00000243806.1 RPL7P18 -4.08 7.24e-05 0.026 -0.37 -0.31 Cancer; chr5:94827001 chr5:94825961~94826694:- PAAD cis rs748404 0.631 rs6493084 ENSG00000205771.5 CATSPER2P1 -4.08 7.25e-05 0.026 -0.43 -0.31 Lung cancer; chr15:43355429 chr15:43726918~43747094:- PAAD cis rs748404 0.631 rs12905772 ENSG00000205771.5 CATSPER2P1 -4.08 7.25e-05 0.026 -0.43 -0.31 Lung cancer; chr15:43356246 chr15:43726918~43747094:- PAAD cis rs748404 0.676 rs4401024 ENSG00000205771.5 CATSPER2P1 -4.08 7.25e-05 0.026 -0.43 -0.31 Lung cancer; chr15:43358137 chr15:43726918~43747094:- PAAD cis rs35934224 0.542 rs8139091 ENSG00000232926.1 AC000078.5 4.08 7.25e-05 0.026 0.36 0.31 Glaucoma (primary open-angle); chr22:19857760 chr22:19887289~19887970:+ PAAD cis rs1707322 0.686 rs2991986 ENSG00000280836.1 AL355480.1 4.08 7.25e-05 0.026 0.38 0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45615610 chr1:45581219~45581321:- PAAD cis rs4853525 0.923 rs1882398 ENSG00000235852.1 AC005540.3 4.08 7.25e-05 0.026 0.43 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190859734 chr2:190880797~190882059:- PAAD cis rs4853525 0.923 rs2355575 ENSG00000235852.1 AC005540.3 4.08 7.25e-05 0.026 0.43 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190863678 chr2:190880797~190882059:- PAAD cis rs4853525 0.923 rs7582941 ENSG00000235852.1 AC005540.3 4.08 7.25e-05 0.026 0.43 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190864174 chr2:190880797~190882059:- PAAD cis rs9322193 0.923 rs9767652 ENSG00000268592.3 RAET1E-AS1 4.08 7.25e-05 0.026 0.37 0.31 Lung cancer; chr6:149734502 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs10782314 ENSG00000268592.3 RAET1E-AS1 4.08 7.25e-05 0.026 0.37 0.31 Lung cancer; chr6:149735527 chr6:149863494~149919507:+ PAAD cis rs919433 0.68 rs2565163 ENSG00000231621.1 AC013264.2 -4.08 7.26e-05 0.026 -0.31 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197489690 chr2:197197991~197199273:+ PAAD cis rs919433 0.68 rs7605813 ENSG00000231621.1 AC013264.2 -4.08 7.26e-05 0.026 -0.31 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197510605 chr2:197197991~197199273:+ PAAD cis rs9487094 0.744 rs13220304 ENSG00000260273.1 RP11-425D10.10 4.08 7.26e-05 0.026 0.43 0.31 Height; chr6:109331033 chr6:109382795~109383666:+ PAAD cis rs2929278 0.617 rs533143 ENSG00000275601.1 AC011330.13 -4.08 7.26e-05 0.026 -0.34 -0.31 Schizophrenia; chr15:43896656 chr15:43642389~43643023:- PAAD cis rs2736345 0.788 rs998683 ENSG00000251402.3 FAM90A25P -4.08 7.26e-05 0.0261 -0.4 -0.31 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11495491 chr8:12415080~12418090:- PAAD cis rs9322193 0.923 rs57938011 ENSG00000268592.3 RAET1E-AS1 4.08 7.27e-05 0.0261 0.37 0.31 Lung cancer; chr6:149642969 chr6:149863494~149919507:+ PAAD cis rs867371 0.929 rs1501371 ENSG00000259429.4 UBE2Q2P2 -4.08 7.27e-05 0.0261 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82168099 chr15:82355142~82420075:+ PAAD cis rs8031584 0.541 rs1983459 ENSG00000260382.1 RP11-540B6.2 4.08 7.27e-05 0.0261 0.4 0.31 Huntington's disease progression; chr15:30916546 chr15:30882267~30883231:- PAAD cis rs453301 0.686 rs6748 ENSG00000254340.1 RP11-10A14.3 -4.08 7.27e-05 0.0261 -0.39 -0.31 Joint mobility (Beighton score); chr8:9033292 chr8:9141424~9145435:+ PAAD cis rs1045529 0.524 rs34251783 ENSG00000254340.1 RP11-10A14.3 -4.08 7.27e-05 0.0261 -0.39 -0.31 Myopia (pathological);Myopia; chr8:9033866 chr8:9141424~9145435:+ PAAD cis rs453301 0.719 rs34004903 ENSG00000254340.1 RP11-10A14.3 -4.08 7.27e-05 0.0261 -0.39 -0.31 Joint mobility (Beighton score); chr8:9035094 chr8:9141424~9145435:+ PAAD cis rs453301 0.686 rs10217044 ENSG00000254340.1 RP11-10A14.3 -4.08 7.27e-05 0.0261 -0.39 -0.31 Joint mobility (Beighton score); chr8:9037242 chr8:9141424~9145435:+ PAAD cis rs683257 0.673 rs72990126 ENSG00000234147.1 RP3-460G2.2 -4.08 7.27e-05 0.0261 -0.55 -0.31 Facial emotion recognition (angry faces); chr6:140850534 chr6:140845958~140852924:- PAAD cis rs683257 0.636 rs6934165 ENSG00000234147.1 RP3-460G2.2 -4.08 7.27e-05 0.0261 -0.55 -0.31 Facial emotion recognition (angry faces); chr6:140851191 chr6:140845958~140852924:- PAAD cis rs683257 0.636 rs56295525 ENSG00000234147.1 RP3-460G2.2 -4.08 7.27e-05 0.0261 -0.55 -0.31 Facial emotion recognition (angry faces); chr6:140853380 chr6:140845958~140852924:- PAAD cis rs792448 0.603 rs4951588 ENSG00000229983.1 RP11-15I11.2 4.08 7.27e-05 0.0261 0.37 0.31 White blood cell count (basophil); chr1:212327091 chr1:212168207~212190259:+ PAAD cis rs9549260 0.709 rs4943795 ENSG00000214222.2 TUBBP2 4.08 7.27e-05 0.0261 0.45 0.31 Red blood cell count; chr13:40599296 chr13:41384773~41385183:- PAAD cis rs4853525 0.923 rs7578618 ENSG00000235852.1 AC005540.3 4.08 7.28e-05 0.0261 0.43 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190868631 chr2:190880797~190882059:- PAAD cis rs61270009 0.955 rs13189889 ENSG00000247828.6 TMEM161B-AS1 4.08 7.28e-05 0.0261 0.26 0.31 Depressive symptoms; chr5:88365589 chr5:88268895~88436685:+ PAAD cis rs1862618 0.853 rs6885541 ENSG00000271828.1 CTD-2310F14.1 4.08 7.28e-05 0.0261 0.46 0.31 Initial pursuit acceleration; chr5:56815030 chr5:56927874~56929573:+ PAAD cis rs6964833 1 rs4717907 ENSG00000277053.3 GTF2IP1 -4.08 7.29e-05 0.0261 -0.4 -0.31 Menarche (age at onset); chr7:74672169 chr7:75185385~75237696:- PAAD cis rs2288884 0.515 rs8112458 ENSG00000275055.1 CTC-471J1.11 -4.08 7.29e-05 0.0261 -0.43 -0.31 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52030052 chr19:52049007~52049754:+ PAAD cis rs875971 0.545 rs6979636 ENSG00000222364.1 RNU6-96P -4.08 7.29e-05 0.0261 -0.41 -0.31 Aortic root size; chr7:66276638 chr7:66395191~66395286:+ PAAD cis rs7017914 0.934 rs7814274 ENSG00000254031.4 RP11-326E22.1 -4.08 7.29e-05 0.0261 -0.32 -0.31 Bone mineral density; chr8:70658176 chr8:71155457~71204223:+ PAAD cis rs28374715 0.662 rs521890 ENSG00000247556.5 OIP5-AS1 4.08 7.3e-05 0.0262 0.32 0.31 Ulcerative colitis; chr15:41180945 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs691906 ENSG00000247556.5 OIP5-AS1 -4.08 7.3e-05 0.0262 -0.32 -0.31 Ulcerative colitis; chr15:41182438 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs691907 ENSG00000247556.5 OIP5-AS1 -4.08 7.3e-05 0.0262 -0.32 -0.31 Ulcerative colitis; chr15:41182459 chr15:41283990~41309737:+ PAAD cis rs6539288 0.866 rs6539286 ENSG00000260329.1 RP11-412D9.4 -4.08 7.3e-05 0.0262 -0.27 -0.31 Total body bone mineral density; chr12:106903845 chr12:106954029~106955497:- PAAD cis rs6539288 0.899 rs6539287 ENSG00000260329.1 RP11-412D9.4 -4.08 7.3e-05 0.0262 -0.27 -0.31 Total body bone mineral density; chr12:106903872 chr12:106954029~106955497:- PAAD cis rs6539288 1 rs6539288 ENSG00000260329.1 RP11-412D9.4 -4.08 7.3e-05 0.0262 -0.27 -0.31 Total body bone mineral density; chr12:106904084 chr12:106954029~106955497:- PAAD cis rs7617773 0.746 rs7619865 ENSG00000228638.1 FCF1P2 -4.08 7.3e-05 0.0262 -0.34 -0.31 Coronary artery disease; chr3:48329090 chr3:48290793~48291375:- PAAD cis rs7617773 0.78 rs9846818 ENSG00000228638.1 FCF1P2 -4.08 7.3e-05 0.0262 -0.34 -0.31 Coronary artery disease; chr3:48334195 chr3:48290793~48291375:- PAAD cis rs2742417 1 rs2742435 ENSG00000244357.3 RN7SL145P 4.08 7.3e-05 0.0262 0.29 0.31 Response to anti-depressant treatment in major depressive disorder; chr3:45699371 chr3:45742675~45742970:+ PAAD cis rs13383928 0.826 rs115488691 ENSG00000222317.1 RNA5SP118 4.08 7.3e-05 0.0262 0.47 0.31 Lung cancer (asbestos exposure interaction); chr2:208774023 chr2:209721913~209722021:- PAAD cis rs1275468 0.731 rs1795380 ENSG00000257497.2 RP11-585P4.5 -4.08 7.31e-05 0.0262 -0.49 -0.31 Polycystic ovary syndrome; chr12:75559432 chr12:75483454~75489820:- PAAD cis rs1275468 0.678 rs2620687 ENSG00000257497.2 RP11-585P4.5 -4.08 7.31e-05 0.0262 -0.49 -0.31 Polycystic ovary syndrome; chr12:75560395 chr12:75483454~75489820:- PAAD cis rs1275468 0.68 rs1697753 ENSG00000257497.2 RP11-585P4.5 -4.08 7.31e-05 0.0262 -0.49 -0.31 Polycystic ovary syndrome; chr12:75562074 chr12:75483454~75489820:- PAAD cis rs613391 0.561 rs694541 ENSG00000224549.1 RP11-370B11.3 -4.08 7.31e-05 0.0262 -0.38 -0.31 Quantitative traits; chr9:22722357 chr9:22767175~22768316:+ PAAD cis rs613391 0.578 rs7874257 ENSG00000224549.1 RP11-370B11.3 -4.08 7.31e-05 0.0262 -0.38 -0.31 Quantitative traits; chr9:22723026 chr9:22767175~22768316:+ PAAD cis rs4853525 0.522 rs62179717 ENSG00000235852.1 AC005540.3 4.08 7.31e-05 0.0262 0.44 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190726087 chr2:190880797~190882059:- PAAD cis rs72843506 0.656 rs73984564 ENSG00000189423.10 USP32P3 4.08 7.31e-05 0.0262 0.45 0.31 Schizophrenia; chr17:20068535 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs77540008 ENSG00000189423.10 USP32P3 4.08 7.31e-05 0.0262 0.45 0.31 Schizophrenia; chr17:20069886 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs13339684 ENSG00000189423.10 USP32P3 4.08 7.31e-05 0.0262 0.45 0.31 Schizophrenia; chr17:20073898 chr17:20415547~20431008:+ PAAD cis rs72843506 0.656 rs73984568 ENSG00000189423.10 USP32P3 4.08 7.31e-05 0.0262 0.45 0.31 Schizophrenia; chr17:20074301 chr17:20415547~20431008:+ PAAD cis rs4938303 0.756 rs4938301 ENSG00000254851.1 RP11-109L13.1 4.08 7.31e-05 0.0262 0.5 0.31 Triglycerides; chr11:116704757 chr11:117135528~117138582:+ PAAD cis rs4835473 0.868 rs1822841 ENSG00000251600.4 RP11-673E1.1 4.08 7.31e-05 0.0262 0.37 0.31 Immature fraction of reticulocytes; chr4:143921485 chr4:143912331~143982454:+ PAAD cis rs10888838 1 rs10888838 ENSG00000198711.5 SSBP3-AS1 4.08 7.31e-05 0.0262 0.38 0.31 Mitochondrial DNA levels; chr1:54207424 chr1:54236440~54239063:+ PAAD cis rs10411161 1 rs4514789 ENSG00000269483.1 AC006272.1 4.08 7.32e-05 0.0262 0.55 0.31 Breast cancer; chr19:51862401 chr19:51839924~51843324:- PAAD cis rs613391 0.522 rs525532 ENSG00000224549.1 RP11-370B11.3 -4.08 7.32e-05 0.0262 -0.38 -0.31 Quantitative traits; chr9:22732228 chr9:22767175~22768316:+ PAAD cis rs12364620 1 rs12364620 ENSG00000212093.1 AP000807.1 4.08 7.32e-05 0.0262 0.37 0.31 Total body bone mineral density (age 0-15); chr11:68484655 chr11:68506083~68506166:- PAAD cis rs11998649 0.69 rs876888 ENSG00000253930.1 RP11-1149O23.2 4.08 7.33e-05 0.0262 0.34 0.31 Visceral fat; chr8:22776777 chr8:23189279~23190675:+ PAAD cis rs829883 0.763 rs249843 ENSG00000245017.2 RP11-181C3.1 -4.08 7.33e-05 0.0263 -0.31 -0.31 Colorectal adenoma (advanced); chr12:98477209 chr12:98485544~98503855:- PAAD cis rs12468579 1 rs12468579 ENSG00000235852.1 AC005540.3 4.08 7.33e-05 0.0263 0.39 0.31 JT interval (sulfonylurea treatment interaction); chr2:190967538 chr2:190880797~190882059:- PAAD cis rs13392177 0.637 rs61041183 ENSG00000261338.2 RP11-378A13.1 4.08 7.33e-05 0.0263 0.37 0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218191657 chr2:218255319~218257366:+ PAAD cis rs2348418 0.83 rs7977418 ENSG00000247934.4 RP11-967K21.1 4.08 7.33e-05 0.0263 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28435309 chr12:28163298~28190738:- PAAD cis rs3738443 0.678 rs4314914 ENSG00000259865.1 RP11-488L18.10 4.08 7.33e-05 0.0263 0.27 0.31 Alcohol dependence; chr1:247210326 chr1:247187281~247188526:- PAAD cis rs10779751 1 rs7526649 ENSG00000238199.1 UBE2V2P3 -4.08 7.34e-05 0.0263 -0.38 -0.31 Body mass index; chr1:11218106 chr1:11278616~11279351:- PAAD cis rs12291225 0.535 rs16930126 ENSG00000251991.1 RNU7-49P -4.08 7.34e-05 0.0263 -0.37 -0.31 Sense of smell; chr11:14383437 chr11:14478892~14478953:+ PAAD cis rs28386778 0.897 rs2665832 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63834901 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs894413 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63838987 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs894414 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63839024 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs8076760 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63843137 chr17:63849292~63864379:+ PAAD cis rs28386778 0.83 rs2665798 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63844037 chr17:63849292~63864379:+ PAAD cis rs28386778 0.799 rs2727322 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63844346 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2727323 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63844639 chr17:63849292~63864379:+ PAAD cis rs28386778 0.865 rs2727276 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63852349 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs2727355 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63854430 chr17:63849292~63864379:+ PAAD cis rs28386778 0.799 rs2584612 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63854844 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2156903 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63859819 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2236737 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63860740 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2236736 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63860888 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584601 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63863617 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2854221 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63864085 chr17:63849292~63864379:+ PAAD cis rs28386778 0.897 rs2584642 ENSG00000240280.5 TCAM1P -4.08 7.34e-05 0.0263 -0.44 -0.31 Prudent dietary pattern; chr17:63865067 chr17:63849292~63864379:+ PAAD cis rs4660214 0.666 rs2275187 ENSG00000237624.1 OXCT2P1 -4.08 7.35e-05 0.0263 -0.41 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39297570 chr1:39514956~39516490:+ PAAD cis rs7849270 0.959 rs1107329 ENSG00000268707.1 RP11-247A12.7 4.08 7.35e-05 0.0263 0.4 0.31 Blood metabolite ratios; chr9:129155435 chr9:129170434~129170940:+ PAAD cis rs871012 0.502 rs4704865 ENSG00000251405.2 CTB-109A12.1 -4.08 7.35e-05 0.0263 -0.39 -0.31 IgG glycosylation; chr5:157465802 chr5:157362615~157460078:- PAAD cis rs1873386 0.79 rs34405951 ENSG00000255910.1 RP11-405A12.2 4.08 7.36e-05 0.0263 0.45 0.31 Personality dimensions; chr12:18908112 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs12312662 ENSG00000255910.1 RP11-405A12.2 4.08 7.36e-05 0.0263 0.45 0.31 Personality dimensions; chr12:18908302 chr12:19775451~20009937:+ PAAD cis rs293748 0.54 rs6879284 ENSG00000250155.1 CTD-2353F22.1 -4.08 7.36e-05 0.0263 -0.4 -0.31 Obesity-related traits; chr5:37230185 chr5:36666214~36725195:- PAAD cis rs3096299 0.658 rs4785679 ENSG00000261253.2 AC137932.6 4.08 7.36e-05 0.0263 0.34 0.31 Multiple myeloma (IgH translocation); chr16:89499705 chr16:89321133~89325110:+ PAAD cis rs6479901 0.895 rs907 ENSG00000232075.1 MRPL35P2 -4.08 7.38e-05 0.0264 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63176919 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs7082066 ENSG00000232075.1 MRPL35P2 -4.08 7.38e-05 0.0264 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63239211 chr10:63634317~63634827:- PAAD cis rs6539288 0.901 rs4964193 ENSG00000260329.1 RP11-412D9.4 -4.08 7.38e-05 0.0264 -0.27 -0.31 Total body bone mineral density; chr12:106927970 chr12:106954029~106955497:- PAAD cis rs755249 0.51 rs613511 ENSG00000237624.1 OXCT2P1 4.08 7.38e-05 0.0264 0.41 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39367801 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs629093 ENSG00000237624.1 OXCT2P1 4.08 7.38e-05 0.0264 0.41 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39367831 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs2490946 ENSG00000237624.1 OXCT2P1 4.08 7.38e-05 0.0264 0.41 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39371955 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs663449 ENSG00000237624.1 OXCT2P1 4.08 7.38e-05 0.0264 0.41 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39378286 chr1:39514956~39516490:+ PAAD cis rs755249 0.51 rs1184716 ENSG00000237624.1 OXCT2P1 4.08 7.38e-05 0.0264 0.41 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380817 chr1:39514956~39516490:+ PAAD cis rs6142102 0.59 rs6059691 ENSG00000276073.1 RP5-1125A11.7 4.08 7.38e-05 0.0264 0.36 0.31 Skin pigmentation; chr20:34149161 chr20:33985617~33988989:- PAAD cis rs7202877 0.706 rs40217 ENSG00000261783.1 RP11-252K23.2 4.08 7.38e-05 0.0264 0.5 0.31 Type 1 diabetes;Type 2 diabetes; chr16:75446168 chr16:75379818~75381260:- PAAD cis rs2015599 0.601 rs17715086 ENSG00000275476.1 RP11-996F15.4 -4.08 7.38e-05 0.0264 -0.3 -0.31 Platelet count;Mean platelet volume; chr12:29329073 chr12:29277397~29277882:- PAAD cis rs9487094 0.6 rs9372213 ENSG00000260273.1 RP11-425D10.10 4.08 7.38e-05 0.0264 0.37 0.31 Height; chr6:109370985 chr6:109382795~109383666:+ PAAD cis rs858239 0.806 rs10268610 ENSG00000226816.2 AC005082.12 4.08 7.38e-05 0.0264 0.36 0.31 Cerebrospinal fluid biomarker levels; chr7:23235145 chr7:23206013~23208045:+ PAAD cis rs12908161 1 rs3803405 ENSG00000259728.4 LINC00933 4.08 7.38e-05 0.0264 0.42 0.31 Schizophrenia; chr15:84840409 chr15:84570649~84580175:+ PAAD cis rs9584850 0.794 rs17574433 ENSG00000231194.1 FARP1-AS1 -4.08 7.38e-05 0.0264 -0.41 -0.31 Neuroticism; chr13:98485803 chr13:98435405~98435840:- PAAD cis rs7626444 0.625 rs9826214 ENSG00000272359.1 U4 -4.08 7.39e-05 0.0264 -0.34 -0.31 Monocyte count; chr3:196751342 chr3:196747192~196747324:- PAAD cis rs7617773 0.925 rs34513961 ENSG00000228638.1 FCF1P2 -4.08 7.39e-05 0.0264 -0.37 -0.31 Coronary artery disease; chr3:48132163 chr3:48290793~48291375:- PAAD cis rs8072100 0.875 rs7208530 ENSG00000228782.6 CTD-2026D20.3 4.08 7.39e-05 0.0264 0.31 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47466741 chr17:47450568~47492492:- PAAD cis rs8072100 0.875 rs12451409 ENSG00000228782.6 CTD-2026D20.3 4.08 7.39e-05 0.0264 0.31 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47467490 chr17:47450568~47492492:- PAAD cis rs6479901 0.895 rs10761722 ENSG00000232075.1 MRPL35P2 -4.08 7.39e-05 0.0264 -0.46 -0.31 Intelligence (multi-trait analysis); chr10:63195287 chr10:63634317~63634827:- PAAD cis rs12439619 0.508 rs17354842 ENSG00000255769.6 GOLGA2P10 4.07 7.4e-05 0.0264 0.32 0.31 Intelligence (multi-trait analysis); chr15:82177259 chr15:82472993~82513950:- PAAD cis rs4925166 1 rs4925166 ENSG00000233327.9 USP32P2 -4.07 7.4e-05 0.0264 -0.39 -0.31 Multiple sclerosis; chr17:18307496 chr17:18511262~18525930:- PAAD cis rs1927790 0.643 rs7328493 ENSG00000247400.3 DNAJC3-AS1 -4.07 7.4e-05 0.0265 -0.29 -0.31 Body mass index; chr13:96348244 chr13:95648733~95676925:- PAAD cis rs1927790 0.643 rs1475296 ENSG00000247400.3 DNAJC3-AS1 -4.07 7.4e-05 0.0265 -0.29 -0.31 Body mass index; chr13:96352019 chr13:95648733~95676925:- PAAD cis rs1927790 0.643 rs927710 ENSG00000247400.3 DNAJC3-AS1 -4.07 7.4e-05 0.0265 -0.29 -0.31 Body mass index; chr13:96352542 chr13:95648733~95676925:- PAAD cis rs55665837 0.539 rs10500804 ENSG00000251991.1 RNU7-49P 4.07 7.41e-05 0.0265 0.36 0.31 Vitamin D levels; chr11:14888727 chr11:14478892~14478953:+ PAAD cis rs4925386 0.959 rs4925385 ENSG00000273619.1 RP5-908M14.9 4.07 7.41e-05 0.0265 0.26 0.31 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345568 chr20:62386303~62386970:- PAAD cis rs4925386 0.921 rs11204472 ENSG00000273619.1 RP5-908M14.9 4.07 7.41e-05 0.0265 0.26 0.31 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62345831 chr20:62386303~62386970:- PAAD cis rs950880 0.71 rs2287034 ENSG00000234389.1 AC007278.3 4.07 7.41e-05 0.0265 0.31 0.31 Serum protein levels (sST2); chr2:102394128 chr2:102438713~102440475:+ PAAD cis rs933117 0.892 rs75975774 ENSG00000232687.1 RPL12P9 4.07 7.42e-05 0.0265 0.66 0.31 Body mass index; chr21:29685600 chr21:29127701~29128188:- PAAD cis rs748404 0.697 rs546722 ENSG00000249839.1 AC011330.5 -4.07 7.42e-05 0.0265 -0.44 -0.31 Lung cancer; chr15:43288621 chr15:43663654~43684339:- PAAD cis rs950169 0.922 rs17531523 ENSG00000275120.1 RP11-182J1.17 4.07 7.42e-05 0.0265 0.33 0.31 Schizophrenia; chr15:84589218 chr15:84599434~84606463:- PAAD cis rs2337406 1 rs17113331 ENSG00000211974.3 IGHV2-70 -4.07 7.42e-05 0.0265 -0.43 -0.31 Alzheimer's disease (late onset); chr14:106703843 chr14:106723574~106724093:- PAAD cis rs7103648 0.669 rs7131262 ENSG00000252874.2 Y_RNA -4.07 7.42e-05 0.0265 -0.4 -0.31 Systolic blood pressure;Diastolic blood pressure; chr11:47814750 chr11:47820200~47820289:- PAAD cis rs6951245 1 rs2363286 ENSG00000229043.2 AC091729.9 -4.07 7.42e-05 0.0265 -0.47 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1051989 chr7:1160374~1165267:+ PAAD cis rs16828019 0.929 rs35883594 ENSG00000235358.1 RP11-399E6.1 4.07 7.42e-05 0.0265 0.66 0.31 Intelligence (multi-trait analysis); chr1:41278421 chr1:41242373~41284861:+ PAAD cis rs916888 0.773 rs1378358 ENSG00000261575.2 RP11-259G18.1 4.07 7.42e-05 0.0265 0.47 0.31 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46267037~46268694:+ PAAD cis rs700651 0.789 rs882954 ENSG00000231621.1 AC013264.2 -4.07 7.43e-05 0.0265 -0.32 -0.31 Intracranial aneurysm; chr2:198042720 chr2:197197991~197199273:+ PAAD cis rs700651 0.789 rs5007118 ENSG00000231621.1 AC013264.2 -4.07 7.43e-05 0.0265 -0.32 -0.31 Intracranial aneurysm; chr2:198045014 chr2:197197991~197199273:+ PAAD cis rs700651 0.789 rs10497812 ENSG00000231621.1 AC013264.2 4.07 7.43e-05 0.0265 0.32 0.31 Intracranial aneurysm; chr2:198046521 chr2:197197991~197199273:+ PAAD cis rs79040073 0.53 rs17476940 ENSG00000259469.1 RP11-227D13.4 4.07 7.43e-05 0.0265 0.44 0.31 Lung cancer in ever smokers; chr15:49332587 chr15:48729080~48729844:- PAAD cis rs1665050 0.545 rs2414617 ENSG00000277144.1 RP11-59H7.4 -4.07 7.43e-05 0.0265 -0.43 -0.31 Atopic dermatitis; chr15:58981686 chr15:59115547~59116089:- PAAD cis rs338389 0.521 rs8031161 ENSG00000260657.2 RP11-315D16.4 -4.07 7.43e-05 0.0265 -0.36 -0.31 Survival in rectal cancer; chr15:67990789 chr15:68267792~68277994:- PAAD cis rs11690935 0.632 rs34242651 ENSG00000228389.1 AC068039.4 -4.07 7.43e-05 0.0265 -0.39 -0.31 Schizophrenia; chr2:171697489 chr2:171773482~171775844:+ PAAD cis rs957448 1 rs12679345 ENSG00000253704.1 RP11-267M23.4 4.07 7.44e-05 0.0266 0.39 0.31 Nonsyndromic cleft lip with cleft palate; chr8:94552305 chr8:94553722~94569745:+ PAAD cis rs17711722 0.653 rs2460421 ENSG00000224316.1 RP11-479O9.2 -4.07 7.44e-05 0.0266 -0.32 -0.31 Calcium levels; chr7:66026136 chr7:65773620~65802067:+ PAAD cis rs8030379 0.667 rs4842921 ENSG00000225151.9 GOLGA2P7 -4.07 7.44e-05 0.0266 -0.35 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83887871 chr15:84199311~84230136:- PAAD cis rs6840258 0.607 rs56023922 ENSG00000251411.1 RP11-397E7.4 -4.07 7.44e-05 0.0266 -0.39 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86994934 chr4:86913266~86914817:- PAAD cis rs6840258 0.66 rs55816619 ENSG00000251411.1 RP11-397E7.4 -4.07 7.44e-05 0.0266 -0.39 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87038653 chr4:86913266~86914817:- PAAD cis rs17772222 0.582 rs1288122 ENSG00000258983.2 RP11-507K2.2 -4.07 7.45e-05 0.0266 -0.39 -0.31 Coronary artery calcification; chr14:88472736 chr14:88499334~88515502:+ PAAD cis rs10779751 0.96 rs12739368 ENSG00000238199.1 UBE2V2P3 -4.07 7.45e-05 0.0266 -0.38 -0.31 Body mass index; chr1:11228190 chr1:11278616~11279351:- PAAD cis rs1150668 0.796 rs2247002 ENSG00000219891.2 ZSCAN12P1 4.07 7.45e-05 0.0266 0.39 0.31 Pubertal anthropometrics; chr6:28430174 chr6:28091154~28093664:+ PAAD cis rs1150668 0.83 rs2859365 ENSG00000219891.2 ZSCAN12P1 -4.07 7.45e-05 0.0266 -0.39 -0.31 Pubertal anthropometrics; chr6:28423688 chr6:28091154~28093664:+ PAAD cis rs10740039 0.883 rs7476720 ENSG00000254271.1 RP11-131N11.4 4.07 7.46e-05 0.0266 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60650610 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs1975442 ENSG00000254271.1 RP11-131N11.4 4.07 7.46e-05 0.0266 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60651161 chr10:60734342~60741828:+ PAAD cis rs10740039 0.842 rs7090892 ENSG00000254271.1 RP11-131N11.4 4.07 7.46e-05 0.0266 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60652093 chr10:60734342~60741828:+ PAAD cis rs10740039 0.804 rs7094818 ENSG00000254271.1 RP11-131N11.4 4.07 7.46e-05 0.0266 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60652213 chr10:60734342~60741828:+ PAAD cis rs2985684 1 rs11157696 ENSG00000259113.1 RP11-406H23.2 4.07 7.46e-05 0.0266 0.42 0.31 Carotid intima media thickness; chr14:49639028 chr14:50448807~50456742:+ PAAD cis rs878939 0.625 rs7476059 ENSG00000233690.1 EBAG9P1 4.07 7.46e-05 0.0266 0.41 0.31 Warfarin maintenance dose; chr10:99587281 chr10:99697407~99697949:- PAAD cis rs11676348 0.791 rs4133195 ENSG00000261338.2 RP11-378A13.1 4.07 7.46e-05 0.0266 0.36 0.31 Ulcerative colitis; chr2:218086522 chr2:218255319~218257366:+ PAAD cis rs9517313 0.77 rs9517301 ENSG00000231194.1 FARP1-AS1 -4.07 7.47e-05 0.0266 -0.34 -0.31 Neuroticism; chr13:98442834 chr13:98435405~98435840:- PAAD cis rs11997175 0.646 rs55898196 ENSG00000240738.1 RP1-273G13.1 4.07 7.47e-05 0.0266 0.37 0.31 Body mass index; chr8:33908344 chr8:33859480~33860223:- PAAD cis rs13256369 0.708 rs11783670 ENSG00000253981.4 ALG1L13P 4.07 7.47e-05 0.0266 0.43 0.31 Obesity-related traits; chr8:8701884 chr8:8236003~8244667:- PAAD cis rs13256369 0.755 rs11776987 ENSG00000253981.4 ALG1L13P 4.07 7.47e-05 0.0266 0.43 0.31 Obesity-related traits; chr8:8701891 chr8:8236003~8244667:- PAAD cis rs2243480 0.901 rs2949697 ENSG00000228409.4 CCT6P1 4.07 7.47e-05 0.0267 0.33 0.31 Diabetic kidney disease; chr7:65999249 chr7:65751142~65763354:+ PAAD cis rs2041895 0.509 rs2024518 ENSG00000260329.1 RP11-412D9.4 -4.07 7.47e-05 0.0267 -0.3 -0.31 Glaucoma (low intraocular pressure); chr12:106903124 chr12:106954029~106955497:- PAAD cis rs6570726 0.935 rs449377 ENSG00000235652.6 RP11-545I5.3 4.07 7.47e-05 0.0267 0.26 0.31 Lobe attachment (rater-scored or self-reported); chr6:145531301 chr6:145799409~145886585:+ PAAD cis rs75804782 0.572 rs56400267 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238338572 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs55762325 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238342082 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs56304316 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238344625 chr2:238224552~238231677:- PAAD cis rs75804782 0.572 rs55764347 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238344888 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs56354063 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238345278 chr2:238224552~238231677:- PAAD cis rs75804782 0.572 rs56330821 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238365308 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs56108200 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238368247 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs75921156 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238370992 chr2:238224552~238231677:- PAAD cis rs75804782 0.566 rs56314406 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238371736 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs113725999 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238379010 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs55708222 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238379052 chr2:238224552~238231677:- PAAD cis rs75804782 0.515 rs75251934 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238379746 chr2:238224552~238231677:- PAAD cis rs75804782 0.572 rs111233411 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238380400 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs79693451 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238387832 chr2:238224552~238231677:- PAAD cis rs75804782 0.515 rs79557340 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238389311 chr2:238224552~238231677:- PAAD cis rs75804782 0.572 rs112551758 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238391129 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs74404946 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238392131 chr2:238224552~238231677:- PAAD cis rs75804782 0.572 rs76084375 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238392552 chr2:238224552~238231677:- PAAD cis rs75804782 0.572 rs74979875 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238393927 chr2:238224552~238231677:- PAAD cis rs61332075 0.503 rs113377546 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Lung function (FEV1/FVC); chr2:238395229 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs3739070 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238397627 chr2:238224552~238231677:- PAAD cis rs75804782 0.572 rs77008212 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238398472 chr2:238224552~238231677:- PAAD cis rs75804782 0.572 rs11900963 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238399408 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs11895642 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238399639 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs13024052 ENSG00000186235.9 AC016757.3 4.07 7.48e-05 0.0267 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238399815 chr2:238224552~238231677:- PAAD cis rs12935418 0.616 rs77336552 ENSG00000261061.1 RP11-303E16.2 -4.07 7.48e-05 0.0267 -0.51 -0.31 Mean corpuscular volume; chr16:80942989 chr16:81030770~81031485:+ PAAD cis rs1075265 0.62 rs2542584 ENSG00000233266.1 HMGB1P31 4.07 7.48e-05 0.0267 0.41 0.31 Chronotype;Morning vs. evening chronotype; chr2:53782707 chr2:54051334~54051760:+ PAAD cis rs867371 0.519 rs1566560 ENSG00000278603.1 RP13-608F4.5 4.07 7.49e-05 0.0267 0.38 0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82232116 chr15:82472203~82472426:+ PAAD cis rs867371 0.519 rs1566559 ENSG00000278603.1 RP13-608F4.5 4.07 7.49e-05 0.0267 0.38 0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82232120 chr15:82472203~82472426:+ PAAD cis rs4713118 0.516 rs6931858 ENSG00000204709.4 LINC01556 4.07 7.49e-05 0.0267 0.53 0.31 Parkinson's disease; chr6:28110633 chr6:28943877~28944537:+ PAAD cis rs6052484 0.523 rs11698498 ENSG00000226948.1 RPS4XP2 -4.07 7.49e-05 0.0267 -0.48 -0.31 Sense of smell; chr20:4342528 chr20:4629427~4630219:- PAAD cis rs6052484 0.523 rs62212298 ENSG00000226948.1 RPS4XP2 -4.07 7.49e-05 0.0267 -0.48 -0.31 Sense of smell; chr20:4345884 chr20:4629427~4630219:- PAAD cis rs6052484 0.523 rs62212299 ENSG00000226948.1 RPS4XP2 -4.07 7.49e-05 0.0267 -0.48 -0.31 Sense of smell; chr20:4347401 chr20:4629427~4630219:- PAAD cis rs72615157 0.613 rs56089143 ENSG00000242294.5 STAG3L5P 4.07 7.5e-05 0.0267 0.25 0.31 Lung function (FEV1/FVC); chr7:100222221 chr7:100336079~100351900:+ PAAD cis rs858239 0.601 rs28673077 ENSG00000226816.2 AC005082.12 4.07 7.5e-05 0.0267 0.37 0.31 Cerebrospinal fluid biomarker levels; chr7:23211235 chr7:23206013~23208045:+ PAAD cis rs10129255 0.536 rs6576201 ENSG00000211972.2 IGHV3-66 -4.07 7.5e-05 0.0267 -0.24 -0.31 Kawasaki disease; chr14:106683696 chr14:106675017~106675544:- PAAD cis rs5758659 0.652 rs133300 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:41993835 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133301 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:41994089 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133305 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:41999956 chr22:42278188~42278846:+ PAAD cis rs5758659 0.682 rs133306 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42000146 chr22:42278188~42278846:+ PAAD cis rs5758659 0.519 rs133307 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42000564 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs5758537 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42001038 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133313 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42005745 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133314 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42005837 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133321 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42009318 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133323 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42009918 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133324 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42010367 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133327 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42011685 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133330 ENSG00000273366.1 CTA-989H11.1 -4.07 7.51e-05 0.0268 -0.37 -0.31 Cognitive function; chr22:42013452 chr22:42278188~42278846:+ PAAD cis rs6951245 1 rs78158942 ENSG00000229043.2 AC091729.9 -4.07 7.51e-05 0.0268 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1050804 chr7:1160374~1165267:+ PAAD cis rs2348418 0.932 rs61922464 ENSG00000247934.4 RP11-967K21.1 4.07 7.51e-05 0.0268 0.31 0.31 Lung function (FEV1);Lung function (FVC); chr12:28485665 chr12:28163298~28190738:- PAAD cis rs2348418 0.932 rs11049661 ENSG00000247934.4 RP11-967K21.1 4.07 7.51e-05 0.0268 0.31 0.31 Lung function (FEV1);Lung function (FVC); chr12:28486215 chr12:28163298~28190738:- PAAD cis rs2348418 0.932 rs11049662 ENSG00000247934.4 RP11-967K21.1 4.07 7.51e-05 0.0268 0.31 0.31 Lung function (FEV1);Lung function (FVC); chr12:28487344 chr12:28163298~28190738:- PAAD cis rs2348418 0.932 rs7306581 ENSG00000247934.4 RP11-967K21.1 4.07 7.51e-05 0.0268 0.31 0.31 Lung function (FEV1);Lung function (FVC); chr12:28488641 chr12:28163298~28190738:- PAAD cis rs2348418 0.932 rs6487685 ENSG00000247934.4 RP11-967K21.1 4.07 7.51e-05 0.0268 0.31 0.31 Lung function (FEV1);Lung function (FVC); chr12:28505417 chr12:28163298~28190738:- PAAD cis rs2348418 0.932 rs10843190 ENSG00000247934.4 RP11-967K21.1 4.07 7.51e-05 0.0268 0.31 0.31 Lung function (FEV1);Lung function (FVC); chr12:28507412 chr12:28163298~28190738:- PAAD cis rs172166 0.694 rs1225716 ENSG00000204709.4 LINC01556 4.07 7.51e-05 0.0268 0.48 0.31 Cardiac Troponin-T levels; chr6:28145968 chr6:28943877~28944537:+ PAAD cis rs7927592 0.913 rs10896329 ENSG00000212093.1 AP000807.1 4.07 7.51e-05 0.0268 0.37 0.31 Total body bone mineral density; chr11:68482561 chr11:68506083~68506166:- PAAD cis rs2524005 1 rs2524005 ENSG00000227766.1 HCG4P5 -4.07 7.51e-05 0.0268 -0.54 -0.31 Bipolar disorder and schizophrenia; chr6:29931900 chr6:29942075~29943067:- PAAD cis rs28386778 0.863 rs4968661 ENSG00000240280.5 TCAM1P -4.07 7.52e-05 0.0268 -0.43 -0.31 Prudent dietary pattern; chr17:63718946 chr17:63849292~63864379:+ PAAD cis rs889398 0.741 rs2362642 ENSG00000226232.7 RP11-419C5.2 -4.07 7.52e-05 0.0268 -0.25 -0.31 Body mass index; chr16:69897555 chr16:69976388~69996188:- PAAD cis rs496547 0.719 rs598373 ENSG00000255239.1 AP002954.6 4.07 7.53e-05 0.0268 0.37 0.31 Hip minimal joint space width; chr11:118793668 chr11:118688039~118690600:- PAAD cis rs7712401 0.546 rs10044921 ENSG00000263432.2 RN7SL689P 4.07 7.53e-05 0.0268 0.39 0.31 Mean platelet volume; chr5:122843662 chr5:123022487~123022783:- PAAD cis rs17772222 1 rs56987357 ENSG00000258983.2 RP11-507K2.2 4.07 7.53e-05 0.0268 0.43 0.31 Coronary artery calcification; chr14:88358019 chr14:88499334~88515502:+ PAAD cis rs1873386 0.79 rs12810703 ENSG00000255910.1 RP11-405A12.2 4.07 7.54e-05 0.0269 0.46 0.31 Personality dimensions; chr12:18917759 chr12:19775451~20009937:+ PAAD cis rs66573146 0.572 rs66819208 ENSG00000272620.1 AFAP1-AS1 -4.07 7.54e-05 0.0269 -0.59 -0.31 Granulocyte percentage of myeloid white cells; chr4:6944401 chr4:7754090~7778928:+ PAAD cis rs66573146 0.572 rs67252699 ENSG00000272620.1 AFAP1-AS1 -4.07 7.54e-05 0.0269 -0.59 -0.31 Granulocyte percentage of myeloid white cells; chr4:6944684 chr4:7754090~7778928:+ PAAD cis rs853679 0.506 rs1150693 ENSG00000204709.4 LINC01556 4.07 7.55e-05 0.0269 0.54 0.31 Depression; chr6:28206812 chr6:28943877~28944537:+ PAAD cis rs889398 0.771 rs12927431 ENSG00000226232.7 RP11-419C5.2 4.07 7.55e-05 0.0269 0.25 0.31 Body mass index; chr16:69823144 chr16:69976388~69996188:- PAAD cis rs829883 0.664 rs829864 ENSG00000245017.2 RP11-181C3.1 -4.07 7.55e-05 0.0269 -0.32 -0.31 Colorectal adenoma (advanced); chr12:98456417 chr12:98485544~98503855:- PAAD cis rs829883 0.664 rs1096148 ENSG00000245017.2 RP11-181C3.1 -4.07 7.55e-05 0.0269 -0.32 -0.31 Colorectal adenoma (advanced); chr12:98457227 chr12:98485544~98503855:- PAAD cis rs829883 0.664 rs865509 ENSG00000245017.2 RP11-181C3.1 -4.07 7.55e-05 0.0269 -0.32 -0.31 Colorectal adenoma (advanced); chr12:98460666 chr12:98485544~98503855:- PAAD cis rs829883 0.639 rs829898 ENSG00000245017.2 RP11-181C3.1 -4.07 7.55e-05 0.0269 -0.32 -0.31 Colorectal adenoma (advanced); chr12:98463897 chr12:98485544~98503855:- PAAD cis rs4664293 0.867 rs3771719 ENSG00000226266.5 AC009961.3 4.07 7.55e-05 0.0269 0.37 0.31 Monocyte percentage of white cells; chr2:159774453 chr2:159670708~159712435:- PAAD cis rs6479901 0.512 rs11817169 ENSG00000232075.1 MRPL35P2 4.07 7.56e-05 0.0269 0.52 0.31 Intelligence (multi-trait analysis); chr10:63596549 chr10:63634317~63634827:- PAAD cis rs4718428 0.705 rs12536410 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66789303 chr7:66902857~66906297:+ PAAD cis rs4718428 0.705 rs3800817 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66798563 chr7:66902857~66906297:+ PAAD cis rs4718428 0.705 rs12698547 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66813271 chr7:66902857~66906297:+ PAAD cis rs4718428 0.705 rs62465692 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66830758 chr7:66902857~66906297:+ PAAD cis rs4718428 0.672 rs13241598 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66835665 chr7:66902857~66906297:+ PAAD cis rs4718428 0.662 rs34577323 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66845054 chr7:66902857~66906297:+ PAAD cis rs4718428 0.705 rs4717328 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66887678 chr7:66902857~66906297:+ PAAD cis rs4718428 0.705 rs4717331 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66913899 chr7:66902857~66906297:+ PAAD cis rs4718428 0.672 rs12530806 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66925737 chr7:66902857~66906297:+ PAAD cis rs4718428 0.705 rs10267335 ENSG00000273142.1 RP11-458F8.4 -4.07 7.56e-05 0.0269 -0.21 -0.31 Corneal structure; chr7:66938233 chr7:66902857~66906297:+ PAAD cis rs4718428 0.705 rs13220977 ENSG00000273142.1 RP11-458F8.4 4.07 7.56e-05 0.0269 0.21 0.31 Corneal structure; chr7:66872661 chr7:66902857~66906297:+ PAAD cis rs7260598 0.642 rs67908565 ENSG00000268442.1 CTD-2027I19.2 4.07 7.56e-05 0.0269 0.47 0.31 Response to taxane treatment (placlitaxel); chr19:23998579 chr19:24162370~24163425:- PAAD cis rs2243480 1 rs35820085 ENSG00000228409.4 CCT6P1 4.07 7.56e-05 0.0269 0.33 0.31 Diabetic kidney disease; chr7:65977771 chr7:65751142~65763354:+ PAAD cis rs755249 0.509 rs710913 ENSG00000243970.1 PPIEL -4.07 7.57e-05 0.0269 -0.27 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39524254 chr1:39531838~39558707:- PAAD cis rs9368481 0.761 rs6918835 ENSG00000241549.7 GUSBP2 -4.07 7.57e-05 0.0269 -0.34 -0.31 Autism spectrum disorder or schizophrenia; chr6:27050048 chr6:26871484~26956554:- PAAD cis rs2255336 0.817 rs7310643 ENSG00000245648.1 RP11-277P12.20 4.07 7.57e-05 0.0269 0.56 0.31 Blood protein levels; chr12:10365501 chr12:10363769~10398506:+ PAAD cis rs7120173 0.693 rs12799198 ENSG00000254851.1 RP11-109L13.1 -4.07 7.57e-05 0.027 -0.49 -0.31 Visceral adipose tissue adjusted for BMI; chr11:116930706 chr11:117135528~117138582:+ PAAD cis rs17772222 0.675 rs845758 ENSG00000258983.2 RP11-507K2.2 -4.07 7.57e-05 0.027 -0.37 -0.31 Coronary artery calcification; chr14:88433746 chr14:88499334~88515502:+ PAAD cis rs4683346 0.584 rs339731 ENSG00000173811.9 CCDC13-AS1 -4.07 7.58e-05 0.027 -0.36 -0.31 Granulocyte percentage of myeloid white cells; chr3:42725867 chr3:42732575~42746768:+ PAAD cis rs2015599 0.623 rs3782505 ENSG00000275476.1 RP11-996F15.4 4.07 7.58e-05 0.027 0.29 0.31 Platelet count;Mean platelet volume; chr12:29292236 chr12:29277397~29277882:- PAAD cis rs2015599 0.549 rs7134796 ENSG00000275476.1 RP11-996F15.4 4.07 7.58e-05 0.027 0.29 0.31 Platelet count;Mean platelet volume; chr12:29294361 chr12:29277397~29277882:- PAAD cis rs338389 0.543 rs449487 ENSG00000260657.2 RP11-315D16.4 -4.07 7.58e-05 0.027 -0.37 -0.31 Survival in rectal cancer; chr15:67948410 chr15:68267792~68277994:- PAAD cis rs189798 0.738 rs330908 ENSG00000253893.2 FAM85B -4.07 7.59e-05 0.027 -0.45 -0.31 Myopia (pathological); chr8:9137656 chr8:8167819~8226614:- PAAD cis rs2985684 0.846 rs11157693 ENSG00000259113.1 RP11-406H23.2 -4.07 7.59e-05 0.027 -0.43 -0.31 Carotid intima media thickness; chr14:49581708 chr14:50448807~50456742:+ PAAD cis rs28386778 1 rs28386778 ENSG00000240280.5 TCAM1P -4.07 7.59e-05 0.027 -0.45 -0.31 Prudent dietary pattern; chr17:63887455 chr17:63849292~63864379:+ PAAD cis rs28386778 0.901 rs2665855 ENSG00000240280.5 TCAM1P -4.07 7.59e-05 0.027 -0.45 -0.31 Prudent dietary pattern; chr17:63887783 chr17:63849292~63864379:+ PAAD cis rs10050311 0.79 rs17751557 ENSG00000251411.1 RP11-397E7.4 -4.07 7.59e-05 0.027 -0.37 -0.31 Insulin-related traits; chr4:86913454 chr4:86913266~86914817:- PAAD cis rs8030379 0.967 rs7182563 ENSG00000230373.7 GOLGA6L5P -4.07 7.6e-05 0.027 -0.25 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83879994 chr15:84507885~84516814:- PAAD cis rs8030379 0.967 rs11629657 ENSG00000230373.7 GOLGA6L5P -4.07 7.6e-05 0.027 -0.25 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83880228 chr15:84507885~84516814:- PAAD cis rs6860540 0.796 rs55635824 ENSG00000248544.2 CTB-47B11.3 -4.07 7.6e-05 0.027 -0.41 -0.31 Inflammatory skin disease; chr5:157466414 chr5:157375741~157384950:- PAAD cis rs11690935 0.632 rs34531723 ENSG00000228389.1 AC068039.4 -4.07 7.6e-05 0.027 -0.38 -0.31 Schizophrenia; chr2:171707584 chr2:171773482~171775844:+ PAAD cis rs11690935 0.655 rs12997093 ENSG00000228389.1 AC068039.4 -4.07 7.6e-05 0.027 -0.38 -0.31 Schizophrenia; chr2:171707928 chr2:171773482~171775844:+ PAAD cis rs11690935 0.731 rs10930491 ENSG00000228389.1 AC068039.4 -4.07 7.6e-05 0.027 -0.38 -0.31 Schizophrenia; chr2:171713314 chr2:171773482~171775844:+ PAAD cis rs7569084 0.687 rs6755006 ENSG00000281920.1 RP11-418H16.1 -4.07 7.6e-05 0.027 -0.36 -0.31 Sum eosinophil basophil counts; chr2:65426008 chr2:65623272~65628424:+ PAAD cis rs7569084 0.687 rs6755128 ENSG00000281920.1 RP11-418H16.1 -4.07 7.6e-05 0.027 -0.36 -0.31 Sum eosinophil basophil counts; chr2:65426065 chr2:65623272~65628424:+ PAAD cis rs9876781 0.967 rs9876891 ENSG00000229759.1 MRPS18AP1 4.07 7.61e-05 0.0271 0.34 0.31 Longevity; chr3:48440024 chr3:48256350~48256938:- PAAD cis rs160451 0.774 rs218896 ENSG00000251136.7 RP11-37B2.1 -4.07 7.61e-05 0.0271 -0.3 -0.31 Leprosy; chr8:89714370 chr8:89609409~89757727:- PAAD cis rs7829975 0.536 rs2980439 ENSG00000254340.1 RP11-10A14.3 4.07 7.61e-05 0.0271 0.4 0.31 Mood instability; chr8:8237348 chr8:9141424~9145435:+ PAAD cis rs728616 0.867 rs56198874 ENSG00000225484.5 NUTM2B-AS1 -4.07 7.62e-05 0.0271 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79926732 chr10:79663088~79826594:- PAAD cis rs728616 0.867 rs12413715 ENSG00000225484.5 NUTM2B-AS1 -4.07 7.62e-05 0.0271 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79927604 chr10:79663088~79826594:- PAAD cis rs728616 0.867 rs17884637 ENSG00000225484.5 NUTM2B-AS1 -4.07 7.62e-05 0.0271 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79928166 chr10:79663088~79826594:- PAAD cis rs728616 1 rs12414891 ENSG00000225484.5 NUTM2B-AS1 -4.07 7.62e-05 0.0271 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79930629 chr10:79663088~79826594:- PAAD cis rs728616 0.717 rs12415523 ENSG00000225484.5 NUTM2B-AS1 -4.07 7.62e-05 0.0271 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79932220 chr10:79663088~79826594:- PAAD cis rs5758659 0.652 rs5751195 ENSG00000273366.1 CTA-989H11.1 -4.07 7.62e-05 0.0271 -0.37 -0.31 Cognitive function; chr22:41983997 chr22:42278188~42278846:+ PAAD cis rs79040073 0.563 rs73392233 ENSG00000259469.1 RP11-227D13.4 -4.07 7.62e-05 0.0271 -0.43 -0.31 Lung cancer in ever smokers; chr15:49214881 chr15:48729080~48729844:- PAAD cis rs79040073 0.53 rs79452929 ENSG00000259469.1 RP11-227D13.4 -4.07 7.62e-05 0.0271 -0.43 -0.31 Lung cancer in ever smokers; chr15:49216166 chr15:48729080~48729844:- PAAD cis rs79040073 0.53 rs57560518 ENSG00000259469.1 RP11-227D13.4 -4.07 7.62e-05 0.0271 -0.43 -0.31 Lung cancer in ever smokers; chr15:49218760 chr15:48729080~48729844:- PAAD cis rs79040073 0.53 rs8025550 ENSG00000259469.1 RP11-227D13.4 4.07 7.62e-05 0.0271 0.43 0.31 Lung cancer in ever smokers; chr15:49222870 chr15:48729080~48729844:- PAAD cis rs12468226 0.752 rs77319662 ENSG00000273456.1 RP11-686O6.2 4.07 7.62e-05 0.0271 0.49 0.31 Urate levels; chr2:202126928 chr2:202374932~202375604:- PAAD cis rs12468226 0.752 rs79058237 ENSG00000273456.1 RP11-686O6.2 4.07 7.62e-05 0.0271 0.49 0.31 Urate levels; chr2:202140247 chr2:202374932~202375604:- PAAD cis rs12468226 0.702 rs114634431 ENSG00000273456.1 RP11-686O6.2 4.07 7.62e-05 0.0271 0.49 0.31 Urate levels; chr2:202142530 chr2:202374932~202375604:- PAAD cis rs9876781 1 rs9883759 ENSG00000229759.1 MRPS18AP1 4.07 7.62e-05 0.0271 0.34 0.31 Longevity; chr3:48422209 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs6442120 ENSG00000229759.1 MRPS18AP1 4.07 7.62e-05 0.0271 0.34 0.31 Longevity; chr3:48423094 chr3:48256350~48256938:- PAAD cis rs9876781 0.9 rs1037773 ENSG00000229759.1 MRPS18AP1 4.07 7.62e-05 0.0271 0.34 0.31 Longevity; chr3:48426493 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs2279077 ENSG00000229759.1 MRPS18AP1 4.07 7.62e-05 0.0271 0.34 0.31 Longevity; chr3:48432839 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs1109227 ENSG00000229759.1 MRPS18AP1 4.07 7.62e-05 0.0271 0.34 0.31 Longevity; chr3:48437797 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs3774808 ENSG00000229759.1 MRPS18AP1 4.07 7.62e-05 0.0271 0.34 0.31 Longevity; chr3:48440237 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs9881491 ENSG00000229759.1 MRPS18AP1 4.07 7.62e-05 0.0271 0.34 0.31 Longevity; chr3:48446507 chr3:48256350~48256938:- PAAD cis rs12352894 1 rs12352894 ENSG00000225345.3 SNX18P3 4.07 7.63e-05 0.0271 0.52 0.31 Post bronchodilator FEV1 in COPD; chr9:38197387 chr9:38566260~38568211:- PAAD cis rs875971 0.502 rs11769702 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66255529 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs6970498 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66275908 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs73146609 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66302477 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs2173571 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66305392 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs11770063 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66318029 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs3936065 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66325577 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs4718335 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66339619 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs2279757 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66363676 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs6969224 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66370011 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs11766183 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66374173 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs1065265 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66376216 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs7811204 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66387213 chr7:66395191~66395286:+ PAAD cis rs875971 0.571 rs78668714 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66474464 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs73150604 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66480545 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs7810213 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66481592 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs2420612 ENSG00000222364.1 RNU6-96P -4.07 7.63e-05 0.0271 -0.41 -0.31 Aortic root size; chr7:66536825 chr7:66395191~66395286:+ PAAD cis rs6479901 0.894 rs10822165 ENSG00000232075.1 MRPL35P2 -4.07 7.63e-05 0.0271 -0.46 -0.31 Intelligence (multi-trait analysis); chr10:63387199 chr10:63634317~63634827:- PAAD cis rs780096 0.506 rs1262430 ENSG00000234072.1 AC074117.10 -4.07 7.63e-05 0.0271 -0.24 -0.31 Total body bone mineral density; chr2:27450931 chr2:27356246~27367622:+ PAAD cis rs2337406 0.866 rs112089985 ENSG00000223648.3 IGHV3-64 4.07 7.63e-05 0.0271 0.35 0.31 Alzheimer's disease (late onset); chr14:106780074 chr14:106643132~106658258:- PAAD cis rs780096 0.506 rs780100 ENSG00000234072.1 AC074117.10 -4.07 7.63e-05 0.0271 -0.25 -0.31 Total body bone mineral density; chr2:27429286 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs704795 ENSG00000234072.1 AC074117.10 -4.07 7.63e-05 0.0271 -0.25 -0.31 Total body bone mineral density; chr2:27493627 chr2:27356246~27367622:+ PAAD cis rs4713118 0.621 rs9295755 ENSG00000280107.1 AL022393.9 4.07 7.63e-05 0.0271 0.52 0.31 Parkinson's disease; chr6:28065396 chr6:28170845~28172521:+ PAAD cis rs4713118 0.621 rs10484403 ENSG00000280107.1 AL022393.9 -4.07 7.63e-05 0.0271 -0.52 -0.31 Parkinson's disease; chr6:28065745 chr6:28170845~28172521:+ PAAD cis rs4713118 0.621 rs4713132 ENSG00000280107.1 AL022393.9 -4.07 7.63e-05 0.0271 -0.52 -0.31 Parkinson's disease; chr6:28066257 chr6:28170845~28172521:+ PAAD cis rs4713118 0.621 rs4713133 ENSG00000280107.1 AL022393.9 -4.07 7.63e-05 0.0271 -0.52 -0.31 Parkinson's disease; chr6:28066263 chr6:28170845~28172521:+ PAAD cis rs4713118 0.621 rs4713134 ENSG00000280107.1 AL022393.9 -4.07 7.63e-05 0.0271 -0.52 -0.31 Parkinson's disease; chr6:28066343 chr6:28170845~28172521:+ PAAD cis rs9326248 0.581 rs6589582 ENSG00000280143.1 AP000892.6 4.07 7.63e-05 0.0271 0.35 0.31 Blood protein levels; chr11:116958484 chr11:117204967~117210292:+ PAAD cis rs9595908 0.965 rs7335710 ENSG00000212293.1 SNORA16 4.07 7.63e-05 0.0271 0.36 0.31 Body mass index; chr13:32561287 chr13:32420390~32420516:- PAAD cis rs10761482 0.544 rs1938544 ENSG00000254271.1 RP11-131N11.4 4.07 7.64e-05 0.0271 0.37 0.31 Schizophrenia; chr10:60524901 chr10:60734342~60741828:+ PAAD cis rs10761482 0.5 rs1938543 ENSG00000254271.1 RP11-131N11.4 4.07 7.64e-05 0.0271 0.37 0.31 Schizophrenia; chr10:60524902 chr10:60734342~60741828:+ PAAD cis rs71403859 0.803 rs17282500 ENSG00000260886.1 TAT-AS1 4.07 7.64e-05 0.0271 0.54 0.31 Post bronchodilator FEV1; chr16:71599750 chr16:71565789~71578187:+ PAAD cis rs1062177 1 rs62377945 ENSG00000253921.1 CTB-113P19.3 -4.07 7.64e-05 0.0271 -0.4 -0.31 Preschool internalizing problems; chr5:151828443 chr5:151753992~151767247:+ PAAD cis rs7260598 0.642 rs7256265 ENSG00000268442.1 CTD-2027I19.2 4.07 7.64e-05 0.0271 0.44 0.31 Response to taxane treatment (placlitaxel); chr19:23950901 chr19:24162370~24163425:- PAAD cis rs11089937 0.667 rs78549985 ENSG00000211638.2 IGLV8-61 -4.07 7.64e-05 0.0271 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22139152 chr22:22098700~22099212:+ PAAD cis rs11089937 0.626 rs9619800 ENSG00000211638.2 IGLV8-61 -4.07 7.64e-05 0.0271 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22141088 chr22:22098700~22099212:+ PAAD cis rs11089937 0.626 rs2213161 ENSG00000211638.2 IGLV8-61 -4.07 7.64e-05 0.0271 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22143005 chr22:22098700~22099212:+ PAAD cis rs11089937 0.626 rs4821784 ENSG00000211638.2 IGLV8-61 -4.07 7.64e-05 0.0271 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22143513 chr22:22098700~22099212:+ PAAD cis rs11089937 0.626 rs11089933 ENSG00000211638.2 IGLV8-61 -4.07 7.64e-05 0.0271 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22145708 chr22:22098700~22099212:+ PAAD cis rs6545883 0.524 rs778159 ENSG00000273302.1 RP11-493E12.2 -4.07 7.64e-05 0.0271 -0.28 -0.31 Tuberculosis; chr2:61329609 chr2:61199979~61200769:+ PAAD cis rs2348418 1 rs2348418 ENSG00000247934.4 RP11-967K21.1 4.07 7.65e-05 0.0272 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28536581 chr12:28163298~28190738:- PAAD cis rs6840258 1 rs55787557 ENSG00000251411.1 RP11-397E7.4 -4.07 7.65e-05 0.0272 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87029673 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs72667759 ENSG00000251411.1 RP11-397E7.4 -4.07 7.65e-05 0.0272 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87031047 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs56201818 ENSG00000251411.1 RP11-397E7.4 -4.07 7.65e-05 0.0272 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87031481 chr4:86913266~86914817:- PAAD cis rs6840258 0.825 rs79998318 ENSG00000251411.1 RP11-397E7.4 -4.07 7.65e-05 0.0272 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87033014 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs56395939 ENSG00000251411.1 RP11-397E7.4 -4.07 7.65e-05 0.0272 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87042481 chr4:86913266~86914817:- PAAD cis rs539096 0.54 rs3011217 ENSG00000200913.1 SNORD46 4.07 7.66e-05 0.0272 0.35 0.31 Intelligence (multi-trait analysis); chr1:43837594 chr1:44776490~44776593:+ PAAD cis rs10129255 0.5 rs9324092 ENSG00000211972.2 IGHV3-66 -4.07 7.66e-05 0.0272 -0.24 -0.31 Kawasaki disease; chr14:106683806 chr14:106675017~106675544:- PAAD cis rs9652601 0.779 rs7203793 ENSG00000274038.1 RP11-66H6.4 -4.07 7.66e-05 0.0272 -0.34 -0.31 Systemic lupus erythematosus; chr16:11088277 chr16:11056556~11057034:+ PAAD cis rs9326248 0.581 rs6589590 ENSG00000280143.1 AP000892.6 4.07 7.66e-05 0.0272 0.34 0.31 Blood protein levels; chr11:117065365 chr11:117204967~117210292:+ PAAD cis rs1555322 0.872 rs2425046 ENSG00000279253.1 RP4-614O4.13 -4.07 7.67e-05 0.0272 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35283858 chr20:35262727~35264187:- PAAD cis rs1555322 0.872 rs2425048 ENSG00000279253.1 RP4-614O4.13 -4.07 7.67e-05 0.0272 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35284920 chr20:35262727~35264187:- PAAD cis rs6969780 0.673 rs2301721 ENSG00000233429.8 HOTAIRM1 -4.07 7.67e-05 0.0272 -0.42 -0.31 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27156494 chr7:27095647~27100265:+ PAAD cis rs66887589 0.616 rs11098497 ENSG00000248280.1 RP11-33B1.2 4.07 7.67e-05 0.0272 0.3 0.31 Diastolic blood pressure; chr4:119265913 chr4:119440561~119450157:- PAAD cis rs66887589 0.616 rs10032299 ENSG00000248280.1 RP11-33B1.2 4.07 7.67e-05 0.0272 0.3 0.31 Diastolic blood pressure; chr4:119285264 chr4:119440561~119450157:- PAAD cis rs11089937 0.568 rs5756989 ENSG00000211638.2 IGLV8-61 -4.07 7.67e-05 0.0272 -0.29 -0.31 Periodontitis (PAL4Q3); chr22:22132415 chr22:22098700~22099212:+ PAAD cis rs34375054 0.66 rs57491100 ENSG00000279233.1 RP11-158L12.4 4.07 7.67e-05 0.0272 0.28 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125108464 chr12:125138245~125141711:+ PAAD cis rs34375054 0.66 rs57031290 ENSG00000279233.1 RP11-158L12.4 4.07 7.67e-05 0.0272 0.28 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125108507 chr12:125138245~125141711:+ PAAD cis rs79040073 0.637 rs61442055 ENSG00000259531.2 RP11-295H24.3 4.07 7.68e-05 0.0272 0.53 0.31 Lung cancer in ever smokers; chr15:49156901 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73390343 ENSG00000259531.2 RP11-295H24.3 4.07 7.68e-05 0.0272 0.53 0.31 Lung cancer in ever smokers; chr15:49164026 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73390360 ENSG00000259531.2 RP11-295H24.3 4.07 7.68e-05 0.0272 0.53 0.31 Lung cancer in ever smokers; chr15:49171265 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs73390362 ENSG00000259531.2 RP11-295H24.3 4.07 7.68e-05 0.0272 0.53 0.31 Lung cancer in ever smokers; chr15:49172292 chr15:49365124~49366685:- PAAD cis rs12908161 0.92 rs12904605 ENSG00000259728.4 LINC00933 4.07 7.68e-05 0.0273 0.39 0.31 Schizophrenia; chr15:84658188 chr15:84570649~84580175:+ PAAD cis rs6142102 0.923 rs6059586 ENSG00000276073.1 RP5-1125A11.7 -4.06 7.68e-05 0.0273 -0.34 -0.31 Skin pigmentation; chr20:33952695 chr20:33985617~33988989:- PAAD cis rs6977955 1 rs917117 ENSG00000234336.5 JAZF1-AS1 -4.06 7.68e-05 0.0273 -0.37 -0.31 Allergic disease (asthma, hay fever or eczema); chr7:28136686 chr7:28180322~28243917:+ PAAD cis rs34526934 0.566 rs34028621 ENSG00000226363.3 HAGLROS 4.06 7.69e-05 0.0273 0.44 0.31 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176178051 chr2:176177717~176179008:+ PAAD cis rs34526934 0.566 rs1374325 ENSG00000226363.3 HAGLROS 4.06 7.69e-05 0.0273 0.44 0.31 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176179243 chr2:176177717~176179008:+ PAAD cis rs10783487 0.895 rs10876230 ENSG00000257542.4 OR7E47P -4.06 7.69e-05 0.0273 -0.43 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52072398 chr12:52079696~52108261:+ PAAD cis rs10783487 0.895 rs10876231 ENSG00000257542.4 OR7E47P -4.06 7.69e-05 0.0273 -0.43 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52072421 chr12:52079696~52108261:+ PAAD cis rs10783487 0.895 rs10876232 ENSG00000257542.4 OR7E47P -4.06 7.69e-05 0.0273 -0.43 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52072572 chr12:52079696~52108261:+ PAAD cis rs10783487 0.895 rs7979353 ENSG00000257542.4 OR7E47P -4.06 7.69e-05 0.0273 -0.43 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52072655 chr12:52079696~52108261:+ PAAD cis rs1113500 0.933 rs10785834 ENSG00000226822.1 RP11-356N1.2 4.06 7.69e-05 0.0273 0.37 0.31 Growth-regulated protein alpha levels; chr1:108096479 chr1:108071482~108074519:+ PAAD cis rs74233809 1 rs11191499 ENSG00000213277.3 MARCKSL1P1 4.06 7.69e-05 0.0273 0.52 0.31 Birth weight; chr10:103004514 chr10:103175554~103176094:+ PAAD cis rs5758511 0.68 rs5758699 ENSG00000205702.9 CYP2D7 4.06 7.69e-05 0.0273 0.26 0.31 Birth weight; chr22:42292028 chr22:42140203~42144577:- PAAD cis rs8072100 0.512 rs9674670 ENSG00000228782.6 CTD-2026D20.3 4.06 7.69e-05 0.0273 0.31 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47308791 chr17:47450568~47492492:- PAAD cis rs17684571 0.7 rs17684784 ENSG00000231441.1 RP11-472M19.2 -4.06 7.69e-05 0.0273 -0.58 -0.31 Schizophrenia; chr6:56813644 chr6:56844002~56864078:+ PAAD cis rs13178541 0.641 rs4976532 ENSG00000250378.1 RP11-119J18.1 -4.06 7.7e-05 0.0273 -0.46 -0.31 IgG glycosylation; chr5:135798385 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs4976534 ENSG00000250378.1 RP11-119J18.1 -4.06 7.7e-05 0.0273 -0.46 -0.31 IgG glycosylation; chr5:135798716 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs10900839 ENSG00000250378.1 RP11-119J18.1 -4.06 7.7e-05 0.0273 -0.46 -0.31 IgG glycosylation; chr5:135798845 chr5:135812667~135826582:+ PAAD cis rs13178541 0.574 rs11738505 ENSG00000250378.1 RP11-119J18.1 -4.06 7.7e-05 0.0273 -0.46 -0.31 IgG glycosylation; chr5:135800107 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs10076272 ENSG00000250378.1 RP11-119J18.1 -4.06 7.7e-05 0.0273 -0.46 -0.31 IgG glycosylation; chr5:135800540 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs2159660 ENSG00000250378.1 RP11-119J18.1 -4.06 7.7e-05 0.0273 -0.46 -0.31 IgG glycosylation; chr5:135801356 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs2109670 ENSG00000250378.1 RP11-119J18.1 -4.06 7.7e-05 0.0273 -0.46 -0.31 IgG glycosylation; chr5:135801529 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs2109669 ENSG00000250378.1 RP11-119J18.1 -4.06 7.7e-05 0.0273 -0.46 -0.31 IgG glycosylation; chr5:135801688 chr5:135812667~135826582:+ PAAD cis rs7592578 0.766 rs62181052 ENSG00000231858.4 AC067945.4 -4.06 7.7e-05 0.0273 -0.38 -0.31 Diastolic blood pressure; chr2:190523132 chr2:191021526~191032314:+ PAAD cis rs7182621 0.546 rs12906587 ENSG00000182397.13 DNM1P46 -4.06 7.7e-05 0.0273 -0.38 -0.31 Colonoscopy-negative controls vs population controls; chr15:99837114 chr15:99790156~99806927:- PAAD cis rs1707322 0.65 rs4553239 ENSG00000280836.1 AL355480.1 -4.06 7.71e-05 0.0273 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684814 chr1:45581219~45581321:- PAAD cis rs6723226 0.572 rs176404 ENSG00000276334.1 AL133243.1 -4.06 7.71e-05 0.0273 -0.36 -0.31 Intelligence (multi-trait analysis); chr2:32413778 chr2:32521927~32523547:+ PAAD cis rs10181042 0.612 rs1177282 ENSG00000271889.1 RP11-493E12.1 4.06 7.71e-05 0.0273 0.35 0.31 Crohn's disease; chr2:61130642 chr2:61151433~61162105:- PAAD cis rs4835473 0.932 rs7697916 ENSG00000251600.4 RP11-673E1.1 -4.06 7.71e-05 0.0273 -0.37 -0.31 Immature fraction of reticulocytes; chr4:143765628 chr4:143912331~143982454:+ PAAD cis rs62103177 0.564 rs3930043 ENSG00000261126.6 RP11-795F19.1 4.06 7.72e-05 0.0274 0.43 0.31 Opioid sensitivity; chr18:79963832 chr18:80046900~80095482:+ PAAD cis rs62103177 0.564 rs3930042 ENSG00000261126.6 RP11-795F19.1 4.06 7.72e-05 0.0274 0.43 0.31 Opioid sensitivity; chr18:79963843 chr18:80046900~80095482:+ PAAD cis rs2638953 0.925 rs11049520 ENSG00000247934.4 RP11-967K21.1 -4.06 7.72e-05 0.0274 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28310656 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs9645730 ENSG00000247934.4 RP11-967K21.1 -4.06 7.72e-05 0.0274 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28317151 chr12:28163298~28190738:- PAAD cis rs9322193 0.923 rs12529698 ENSG00000268592.3 RAET1E-AS1 4.06 7.72e-05 0.0274 0.36 0.31 Lung cancer; chr6:149650951 chr6:149863494~149919507:+ PAAD cis rs867371 0.896 rs8033831 ENSG00000259429.4 UBE2Q2P2 -4.06 7.72e-05 0.0274 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82220953 chr15:82355142~82420075:+ PAAD cis rs6840258 1 rs7682652 ENSG00000251411.1 RP11-397E7.4 -4.06 7.72e-05 0.0274 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86992292 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs7695426 ENSG00000251411.1 RP11-397E7.4 -4.06 7.72e-05 0.0274 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87000125 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs72667752 ENSG00000251411.1 RP11-397E7.4 -4.06 7.72e-05 0.0274 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87018379 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs72667753 ENSG00000251411.1 RP11-397E7.4 -4.06 7.72e-05 0.0274 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87019860 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs72667754 ENSG00000251411.1 RP11-397E7.4 -4.06 7.72e-05 0.0274 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87020909 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs56050898 ENSG00000251411.1 RP11-397E7.4 -4.06 7.72e-05 0.0274 -0.35 -0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87024223 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs17012234 ENSG00000251411.1 RP11-397E7.4 4.06 7.72e-05 0.0274 0.35 0.31 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:86990539 chr4:86913266~86914817:- PAAD cis rs11089937 0.651 rs2330015 ENSG00000211648.2 IGLV1-47 -4.06 7.73e-05 0.0274 -0.18 -0.31 Periodontitis (PAL4Q3); chr22:22182566 chr22:22357739~22358260:+ PAAD cis rs4853525 0.923 rs4853523 ENSG00000235852.1 AC005540.3 4.06 7.73e-05 0.0274 0.43 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190868053 chr2:190880797~190882059:- PAAD cis rs13178541 0.577 rs67621798 ENSG00000250378.1 RP11-119J18.1 -4.06 7.73e-05 0.0274 -0.47 -0.31 IgG glycosylation; chr5:135789568 chr5:135812667~135826582:+ PAAD cis rs919433 0.617 rs10931793 ENSG00000231621.1 AC013264.2 4.06 7.73e-05 0.0274 0.31 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197712861 chr2:197197991~197199273:+ PAAD cis rs919433 0.617 rs4850809 ENSG00000231621.1 AC013264.2 4.06 7.73e-05 0.0274 0.31 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197718679 chr2:197197991~197199273:+ PAAD cis rs919433 0.617 rs2037590 ENSG00000231621.1 AC013264.2 4.06 7.73e-05 0.0274 0.31 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197720051 chr2:197197991~197199273:+ PAAD cis rs780096 0.526 rs1647267 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27428187 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs10182937 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27428826 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs704791 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27434300 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs780102 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27436624 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs1260341 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27440348 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs1260342 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27440549 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs780112 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27442494 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs4803 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27444430 chr2:27356246~27367622:+ PAAD cis rs780096 0.565 rs780104 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27454824 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs780106 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27458731 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs780107 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27461867 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs1647276 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27465734 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs1406295 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27466833 chr2:27356246~27367622:+ PAAD cis rs780096 0.506 rs1647265 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27469394 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs1647266 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27470618 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs780117 ENSG00000234072.1 AC074117.10 -4.06 7.73e-05 0.0274 -0.24 -0.31 Total body bone mineral density; chr2:27475476 chr2:27356246~27367622:+ PAAD cis rs9928842 0.765 rs6564223 ENSG00000280152.1 RP11-331F4.5 4.06 7.74e-05 0.0274 0.45 0.31 Alcoholic chronic pancreatitis; chr16:75192001 chr16:75245994~75250077:- PAAD cis rs801193 1 rs10252765 ENSG00000237310.1 GS1-124K5.4 4.06 7.74e-05 0.0274 0.29 0.31 Aortic root size; chr7:66763745 chr7:66493706~66495474:+ PAAD cis rs6547741 0.717 rs2178197 ENSG00000234072.1 AC074117.10 4.06 7.75e-05 0.0274 0.25 0.31 Oral cavity cancer; chr2:27637684 chr2:27356246~27367622:+ PAAD cis rs2742417 1 rs2673035 ENSG00000244357.3 RN7SL145P 4.06 7.75e-05 0.0274 0.29 0.31 Response to anti-depressant treatment in major depressive disorder; chr3:45712173 chr3:45742675~45742970:+ PAAD cis rs41369048 0.8 rs2784254 ENSG00000238078.1 LINC01352 -4.06 7.75e-05 0.0274 -0.43 -0.31 Eosinophil counts;Sum eosinophil basophil counts; chr1:220891002 chr1:220829255~220832429:+ PAAD cis rs919433 0.51 rs34631382 ENSG00000231621.1 AC013264.2 -4.06 7.76e-05 0.0275 -0.31 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197525285 chr2:197197991~197199273:+ PAAD cis rs919433 0.589 rs7601800 ENSG00000231621.1 AC013264.2 -4.06 7.76e-05 0.0275 -0.31 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197530375 chr2:197197991~197199273:+ PAAD cis rs728616 0.867 rs726289 ENSG00000225484.5 NUTM2B-AS1 -4.06 7.76e-05 0.0275 -0.58 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79947195 chr10:79663088~79826594:- PAAD cis rs9807989 0.507 rs13021177 ENSG00000234389.1 AC007278.3 4.06 7.76e-05 0.0275 0.31 0.31 Asthma; chr2:102440033 chr2:102438713~102440475:+ PAAD cis rs11233413 0.874 rs4943870 ENSG00000247137.7 RP11-727A23.5 -4.06 7.77e-05 0.0275 -0.28 -0.31 Economic and political preferences (feminism/equality); chr11:83042198 chr11:83184491~83193794:- PAAD cis rs11233413 0.874 rs12422142 ENSG00000247137.7 RP11-727A23.5 -4.06 7.77e-05 0.0275 -0.28 -0.31 Economic and political preferences (feminism/equality); chr11:83043119 chr11:83184491~83193794:- PAAD cis rs6435957 0.568 rs2372937 ENSG00000233143.1 DIRC3-AS1 4.06 7.77e-05 0.0275 0.4 0.31 Primary tooth development (number of teeth); chr2:217027991 chr2:217282739~217336120:+ PAAD cis rs919433 0.889 rs787998 ENSG00000231621.1 AC013264.2 -4.06 7.78e-05 0.0275 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197351368 chr2:197197991~197199273:+ PAAD cis rs889398 0.769 rs12927052 ENSG00000226232.7 RP11-419C5.2 4.06 7.78e-05 0.0275 0.25 0.31 Body mass index; chr16:69823140 chr16:69976388~69996188:- PAAD cis rs10486158 1 rs6955140 ENSG00000233264.2 AC006042.8 4.06 7.79e-05 0.0275 0.38 0.31 Bipolar disorder and schizophrenia; chr7:7335192 chr7:7980312~7982228:+ PAAD cis rs964611 1 rs964611 ENSG00000259488.2 RP11-154J22.1 -4.06 7.8e-05 0.0276 -0.35 -0.31 Metabolite levels (Pyroglutamine); chr15:48305317 chr15:48312353~48331856:- PAAD cis rs1555322 1 rs2425031 ENSG00000279253.1 RP4-614O4.13 -4.06 7.8e-05 0.0276 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35267481 chr20:35262727~35264187:- PAAD cis rs1555322 1 rs2425034 ENSG00000279253.1 RP4-614O4.13 -4.06 7.8e-05 0.0276 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35268011 chr20:35262727~35264187:- PAAD cis rs1555322 0.858 rs2425035 ENSG00000279253.1 RP4-614O4.13 -4.06 7.8e-05 0.0276 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35268016 chr20:35262727~35264187:- PAAD cis rs1555322 1 rs2425036 ENSG00000279253.1 RP4-614O4.13 -4.06 7.8e-05 0.0276 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35268178 chr20:35262727~35264187:- PAAD cis rs763121 0.853 rs2284073 ENSG00000228274.3 RP3-508I15.9 -4.06 7.8e-05 0.0276 -0.3 -0.31 Menopause (age at onset); chr22:38709943 chr22:38667585~38681820:- PAAD cis rs2638953 0.672 rs10843203 ENSG00000247934.4 RP11-967K21.1 -4.06 7.8e-05 0.0276 -0.36 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28563555 chr12:28163298~28190738:- PAAD cis rs720064 0.586 rs9963697 ENSG00000264745.1 TTC39C-AS1 4.06 7.81e-05 0.0276 0.4 0.31 Strep throat; chr18:23944796 chr18:23994213~24015339:- PAAD cis rs520525 0.963 rs501680 ENSG00000271811.1 RP1-79C4.4 4.06 7.81e-05 0.0276 0.33 0.31 Atrial fibrillation; chr1:170656726 chr1:170667381~170669425:+ PAAD cis rs520525 0.963 rs663887 ENSG00000271811.1 RP1-79C4.4 4.06 7.81e-05 0.0276 0.33 0.31 Atrial fibrillation; chr1:170657812 chr1:170667381~170669425:+ PAAD cis rs520525 0.963 rs524877 ENSG00000271811.1 RP1-79C4.4 4.06 7.81e-05 0.0276 0.33 0.31 Atrial fibrillation; chr1:170659294 chr1:170667381~170669425:+ PAAD cis rs9876781 1 rs6776700 ENSG00000229759.1 MRPS18AP1 4.06 7.81e-05 0.0276 0.34 0.31 Longevity; chr3:48455358 chr3:48256350~48256938:- PAAD cis rs9876781 0.967 rs7618883 ENSG00000229759.1 MRPS18AP1 4.06 7.81e-05 0.0276 0.34 0.31 Longevity; chr3:48457056 chr3:48256350~48256938:- PAAD cis rs7189233 0.955 rs60420081 ENSG00000279722.1 RP11-44F14.6 -4.06 7.81e-05 0.0276 -0.34 -0.31 Intelligence (multi-trait analysis); chr16:53486892 chr16:53487607~53489943:- PAAD cis rs5015933 0.815 rs10819044 ENSG00000232630.1 PRPS1P2 -4.06 7.81e-05 0.0276 -0.28 -0.31 Body mass index; chr9:125278750 chr9:125150653~125151589:+ PAAD cis rs72615157 0.634 rs79986079 ENSG00000242294.5 STAG3L5P 4.06 7.81e-05 0.0276 0.25 0.31 Lung function (FEV1/FVC); chr7:100204421 chr7:100336079~100351900:+ PAAD cis rs28374715 0.662 rs522063 ENSG00000247556.5 OIP5-AS1 -4.06 7.82e-05 0.0276 -0.32 -0.31 Ulcerative colitis; chr15:41184011 chr15:41283990~41309737:+ PAAD cis rs763121 0.853 rs138706 ENSG00000228274.3 RP3-508I15.9 -4.06 7.82e-05 0.0276 -0.31 -0.31 Menopause (age at onset); chr22:38741829 chr22:38667585~38681820:- PAAD cis rs3781264 0.595 rs3818432 ENSG00000273450.1 RP11-76P2.4 4.06 7.82e-05 0.0276 0.43 0.31 Esophageal cancer and gastric cancer; chr10:94304411 chr10:94314907~94315327:- PAAD cis rs2412819 0.597 rs541871 ENSG00000249839.1 AC011330.5 -4.06 7.82e-05 0.0276 -0.48 -0.31 Lung cancer; chr15:43868656 chr15:43663654~43684339:- PAAD cis rs6669008 1 rs6669008 ENSG00000232450.1 RP4-730K3.3 -4.06 7.82e-05 0.0276 -0.37 -0.31 Bacteremia; chr1:113623939 chr1:113698884~113699631:- PAAD cis rs683257 0.636 rs17070386 ENSG00000234147.1 RP3-460G2.2 4.06 7.83e-05 0.0276 0.55 0.31 Facial emotion recognition (angry faces); chr6:140850424 chr6:140845958~140852924:- PAAD cis rs9649213 0.555 rs6948346 ENSG00000272950.1 RP11-307C18.1 4.06 7.83e-05 0.0276 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98330644 chr7:98322853~98323430:+ PAAD cis rs4713118 0.662 rs149901 ENSG00000204709.4 LINC01556 4.06 7.83e-05 0.0277 0.51 0.31 Parkinson's disease; chr6:27997725 chr6:28943877~28944537:+ PAAD cis rs10740039 0.842 rs7915540 ENSG00000254271.1 RP11-131N11.4 4.06 7.84e-05 0.0277 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60646538 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7905018 ENSG00000254271.1 RP11-131N11.4 4.06 7.84e-05 0.0277 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60647585 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs7920170 ENSG00000254271.1 RP11-131N11.4 4.06 7.84e-05 0.0277 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60647766 chr10:60734342~60741828:+ PAAD cis rs10740039 0.842 rs10761537 ENSG00000254271.1 RP11-131N11.4 4.06 7.84e-05 0.0277 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60649263 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs10761538 ENSG00000254271.1 RP11-131N11.4 4.06 7.84e-05 0.0277 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60649463 chr10:60734342~60741828:+ PAAD cis rs9595908 0.965 rs4941612 ENSG00000212293.1 SNORA16 4.06 7.84e-05 0.0277 0.37 0.31 Body mass index; chr13:32549791 chr13:32420390~32420516:- PAAD cis rs9595908 0.965 rs12323094 ENSG00000212293.1 SNORA16 4.06 7.84e-05 0.0277 0.37 0.31 Body mass index; chr13:32569227 chr13:32420390~32420516:- PAAD cis rs9595908 0.965 rs12323101 ENSG00000212293.1 SNORA16 4.06 7.84e-05 0.0277 0.37 0.31 Body mass index; chr13:32569269 chr13:32420390~32420516:- PAAD cis rs9595908 0.965 rs1123462 ENSG00000212293.1 SNORA16 4.06 7.84e-05 0.0277 0.37 0.31 Body mass index; chr13:32571325 chr13:32420390~32420516:- PAAD cis rs9595908 0.897 rs12429688 ENSG00000212293.1 SNORA16 4.06 7.84e-05 0.0277 0.37 0.31 Body mass index; chr13:32572075 chr13:32420390~32420516:- PAAD cis rs7759001 0.744 rs12529839 ENSG00000271755.1 RP1-153G14.4 4.06 7.84e-05 0.0277 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27456187 chr6:27404010~27406964:- PAAD cis rs4835473 0.864 rs2089837 ENSG00000251600.4 RP11-673E1.1 4.06 7.84e-05 0.0277 0.37 0.31 Immature fraction of reticulocytes; chr4:143965038 chr4:143912331~143982454:+ PAAD cis rs6570726 0.967 rs9403706 ENSG00000235652.6 RP11-545I5.3 -4.06 7.84e-05 0.0277 -0.26 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145474051 chr6:145799409~145886585:+ PAAD cis rs2638953 0.777 rs11049689 ENSG00000247934.4 RP11-967K21.1 -4.06 7.84e-05 0.0277 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28519177 chr12:28163298~28190738:- PAAD cis rs2638953 0.815 rs61922546 ENSG00000247934.4 RP11-967K21.1 -4.06 7.84e-05 0.0277 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28524632 chr12:28163298~28190738:- PAAD cis rs950880 0.71 rs873022 ENSG00000234389.1 AC007278.3 -4.06 7.84e-05 0.0277 -0.31 -0.31 Serum protein levels (sST2); chr2:102339223 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs3771177 ENSG00000234389.1 AC007278.3 -4.06 7.84e-05 0.0277 -0.31 -0.31 Serum protein levels (sST2); chr2:102339400 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs3732129 ENSG00000234389.1 AC007278.3 -4.06 7.84e-05 0.0277 -0.31 -0.31 Serum protein levels (sST2); chr2:102341072 chr2:102438713~102440475:+ PAAD cis rs1876905 0.764 rs9398265 ENSG00000230177.1 RP5-1112D6.4 -4.06 7.85e-05 0.0277 -0.35 -0.31 Mean corpuscular hemoglobin; chr6:111101399 chr6:111277932~111278742:+ PAAD cis rs453301 0.686 rs11785634 ENSG00000254340.1 RP11-10A14.3 -4.06 7.85e-05 0.0277 -0.39 -0.31 Joint mobility (Beighton score); chr8:9035087 chr8:9141424~9145435:+ PAAD cis rs496547 0.686 rs477014 ENSG00000255239.1 AP002954.6 4.06 7.85e-05 0.0277 0.37 0.31 Hip minimal joint space width; chr11:118808277 chr11:118688039~118690600:- PAAD cis rs496547 0.588 rs473298 ENSG00000255239.1 AP002954.6 4.06 7.85e-05 0.0277 0.37 0.31 Hip minimal joint space width; chr11:118808678 chr11:118688039~118690600:- PAAD cis rs496547 0.557 rs516719 ENSG00000255239.1 AP002954.6 4.06 7.85e-05 0.0277 0.37 0.31 Hip minimal joint space width; chr11:118808736 chr11:118688039~118690600:- PAAD cis rs4835473 0.771 rs4443231 ENSG00000251600.4 RP11-673E1.1 4.06 7.85e-05 0.0277 0.37 0.31 Immature fraction of reticulocytes; chr4:143979501 chr4:143912331~143982454:+ PAAD cis rs3096299 0.838 rs3102384 ENSG00000274627.1 RP11-104N10.2 4.06 7.86e-05 0.0277 0.28 0.31 Multiple myeloma (IgH translocation); chr16:89345253 chr16:89516797~89522217:+ PAAD cis rs867371 0.896 rs6495647 ENSG00000259429.4 UBE2Q2P2 -4.06 7.86e-05 0.0277 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82244708 chr15:82355142~82420075:+ PAAD cis rs683250 0.599 rs5003308 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83358762 chr11:82689559~82689768:+ PAAD cis rs683250 0.567 rs11233582 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83359384 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs7123856 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83363669 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs1943737 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83365985 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs12788709 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83366511 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs35615759 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83367021 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs7110308 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83367410 chr11:82689559~82689768:+ PAAD cis rs683250 0.63 rs1943739 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83368709 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs1943740 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83368932 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs1943742 ENSG00000227097.5 RPS28P7 -4.06 7.86e-05 0.0277 -0.39 -0.31 Subcortical brain region volumes; chr11:83369540 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs2226415 ENSG00000227097.5 RPS28P7 4.06 7.86e-05 0.0277 0.39 0.31 Subcortical brain region volumes; chr11:83369776 chr11:82689559~82689768:+ PAAD cis rs7208859 0.778 rs6505219 ENSG00000266490.1 CTD-2349P21.9 4.06 7.86e-05 0.0277 0.34 0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30938603 chr17:30792372~30792833:+ PAAD cis rs9487094 0.677 rs4428538 ENSG00000260273.1 RP11-425D10.10 4.06 7.86e-05 0.0277 0.45 0.31 Height; chr6:109409645 chr6:109382795~109383666:+ PAAD cis rs8059260 1 rs8057540 ENSG00000274038.1 RP11-66H6.4 -4.06 7.87e-05 0.0277 -0.46 -0.31 Alcohol consumption over the past year; chr16:10951985 chr16:11056556~11057034:+ PAAD cis rs948562 0.657 rs11229574 ENSG00000255299.4 RP11-655C2.3 -4.06 7.87e-05 0.0277 -0.35 -0.31 Lymphoma; chr11:58667837 chr11:58497888~58505758:- PAAD cis rs2404602 0.655 rs10444809 ENSG00000259422.1 RP11-593F23.1 -4.06 7.87e-05 0.0278 -0.35 -0.31 Blood metabolite levels; chr15:76832195 chr15:76174891~76181486:- PAAD cis rs6929812 0.577 rs2294308 ENSG00000271755.1 RP1-153G14.4 4.06 7.87e-05 0.0278 0.35 0.31 Neuroticism (multi-trait analysis); chr6:27515481 chr6:27404010~27406964:- PAAD cis rs28374715 0.662 rs111522288 ENSG00000247556.5 OIP5-AS1 4.06 7.87e-05 0.0278 0.33 0.31 Ulcerative colitis; chr15:41187971 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs113913466 ENSG00000247556.5 OIP5-AS1 4.06 7.87e-05 0.0278 0.33 0.31 Ulcerative colitis; chr15:41190902 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs28493087 ENSG00000247556.5 OIP5-AS1 4.06 7.87e-05 0.0278 0.33 0.31 Ulcerative colitis; chr15:41194306 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs28382348 ENSG00000247556.5 OIP5-AS1 4.06 7.87e-05 0.0278 0.33 0.31 Ulcerative colitis; chr15:41195736 chr15:41283990~41309737:+ PAAD cis rs6539288 0.933 rs10778513 ENSG00000260329.1 RP11-412D9.4 -4.06 7.88e-05 0.0278 -0.26 -0.31 Total body bone mineral density; chr12:106908405 chr12:106954029~106955497:- PAAD cis rs2337406 0.636 rs74090069 ENSG00000223648.3 IGHV3-64 4.06 7.88e-05 0.0278 0.35 0.31 Alzheimer's disease (late onset); chr14:106777532 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74090071 ENSG00000223648.3 IGHV3-64 4.06 7.88e-05 0.0278 0.35 0.31 Alzheimer's disease (late onset); chr14:106777533 chr14:106643132~106658258:- PAAD cis rs812925 0.519 rs10199672 ENSG00000273302.1 RP11-493E12.2 -4.06 7.88e-05 0.0278 -0.27 -0.31 Immature fraction of reticulocytes; chr2:61400499 chr2:61199979~61200769:+ PAAD cis rs6539288 0.63 rs10778519 ENSG00000260329.1 RP11-412D9.4 -4.06 7.88e-05 0.0278 -0.29 -0.31 Total body bone mineral density; chr12:106963551 chr12:106954029~106955497:- PAAD cis rs11723261 0.582 rs61792238 ENSG00000275426.1 CH17-262A2.1 4.06 7.88e-05 0.0278 0.5 0.31 Immune response to smallpox vaccine (IL-6); chr4:112398 chr4:149738~150317:+ PAAD cis rs2348418 0.966 rs1527578 ENSG00000247934.4 RP11-967K21.1 4.06 7.88e-05 0.0278 0.31 0.31 Lung function (FEV1);Lung function (FVC); chr12:28536903 chr12:28163298~28190738:- PAAD cis rs2348418 0.966 rs16932891 ENSG00000247934.4 RP11-967K21.1 4.06 7.88e-05 0.0278 0.31 0.31 Lung function (FEV1);Lung function (FVC); chr12:28537055 chr12:28163298~28190738:- PAAD cis rs748404 0.666 rs16957680 ENSG00000205771.5 CATSPER2P1 -4.06 7.89e-05 0.0278 -0.51 -0.31 Lung cancer; chr15:43396207 chr15:43726918~43747094:- PAAD cis rs1075265 0.605 rs805373 ENSG00000233266.1 HMGB1P31 4.06 7.89e-05 0.0278 0.42 0.31 Chronotype;Morning vs. evening chronotype; chr2:53859458 chr2:54051334~54051760:+ PAAD cis rs11089937 0.597 rs4821774 ENSG00000211638.2 IGLV8-61 -4.06 7.89e-05 0.0278 -0.29 -0.31 Periodontitis (PAL4Q3); chr22:22131536 chr22:22098700~22099212:+ PAAD cis rs13256369 0.755 rs12680167 ENSG00000253981.4 ALG1L13P 4.06 7.89e-05 0.0278 0.42 0.31 Obesity-related traits; chr8:8704957 chr8:8236003~8244667:- PAAD cis rs2303759 0.918 rs10405465 ENSG00000268686.1 AC010524.2 -4.06 7.9e-05 0.0278 -0.43 -0.31 Multiple sclerosis; chr19:49366041 chr19:49368705~49388081:- PAAD cis rs2736345 0.755 rs2736340 ENSG00000251402.3 FAM90A25P 4.06 7.9e-05 0.0278 0.4 0.31 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11486464 chr8:12415080~12418090:- PAAD cis rs11159086 0.793 rs4903229 ENSG00000270000.1 RP3-449M8.9 4.06 7.9e-05 0.0278 0.46 0.31 Advanced glycation end-product levels; chr14:74489865 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs8016972 ENSG00000270000.1 RP3-449M8.9 4.06 7.9e-05 0.0278 0.46 0.31 Advanced glycation end-product levels; chr14:74491833 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs8015894 ENSG00000270000.1 RP3-449M8.9 4.06 7.9e-05 0.0278 0.46 0.31 Advanced glycation end-product levels; chr14:74491917 chr14:74471930~74472360:- PAAD cis rs875971 0.571 rs160641 ENSG00000222364.1 RNU6-96P 4.06 7.9e-05 0.0278 0.41 0.31 Aortic root size; chr7:66112359 chr7:66395191~66395286:+ PAAD cis rs7429990 0.813 rs7627568 ENSG00000228638.1 FCF1P2 4.06 7.9e-05 0.0278 0.35 0.31 Educational attainment (years of education); chr3:48051562 chr3:48290793~48291375:- PAAD cis rs1707322 0.717 rs3014245 ENSG00000280836.1 AL355480.1 4.06 7.9e-05 0.0278 0.38 0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45621241 chr1:45581219~45581321:- PAAD cis rs28386778 0.897 rs8073515 ENSG00000240280.5 TCAM1P -4.06 7.91e-05 0.0279 -0.43 -0.31 Prudent dietary pattern; chr17:63717968 chr17:63849292~63864379:+ PAAD cis rs28386778 0.863 rs11649912 ENSG00000240280.5 TCAM1P -4.06 7.91e-05 0.0279 -0.43 -0.31 Prudent dietary pattern; chr17:63720155 chr17:63849292~63864379:+ PAAD cis rs950169 0.84 rs12905223 ENSG00000275120.1 RP11-182J1.17 4.06 7.91e-05 0.0279 0.33 0.31 Schizophrenia; chr15:84571037 chr15:84599434~84606463:- PAAD cis rs28374715 0.733 rs9568 ENSG00000247556.5 OIP5-AS1 4.06 7.91e-05 0.0279 0.33 0.31 Ulcerative colitis; chr15:41281414 chr15:41283990~41309737:+ PAAD cis rs894157 1 rs894157 ENSG00000255571.5 LINC00925 4.06 7.91e-05 0.0279 0.5 0.31 Obesity-related traits; chr15:89624877 chr15:89361579~89398487:+ PAAD cis rs7824557 0.767 rs2164272 ENSG00000205879.4 FAM90A2P 4.06 7.91e-05 0.0279 0.41 0.31 Retinal vascular caliber; chr8:11304987 chr8:12172202~12178575:- PAAD cis rs7824557 0.701 rs2060465 ENSG00000205879.4 FAM90A2P 4.06 7.91e-05 0.0279 0.41 0.31 Retinal vascular caliber; chr8:11305100 chr8:12172202~12178575:- PAAD cis rs7824557 0.767 rs17797443 ENSG00000205879.4 FAM90A2P 4.06 7.91e-05 0.0279 0.41 0.31 Retinal vascular caliber; chr8:11306503 chr8:12172202~12178575:- PAAD cis rs11690935 0.55 rs11676438 ENSG00000228389.1 AC068039.4 -4.06 7.91e-05 0.0279 -0.39 -0.31 Schizophrenia; chr2:171970147 chr2:171773482~171775844:+ PAAD cis rs5758511 0.508 rs28715885 ENSG00000205702.9 CYP2D7 4.06 7.92e-05 0.0279 0.29 0.31 Birth weight; chr22:42045087 chr22:42140203~42144577:- PAAD cis rs812925 0.537 rs10208769 ENSG00000273302.1 RP11-493E12.2 -4.06 7.92e-05 0.0279 -0.27 -0.31 Immature fraction of reticulocytes; chr2:61378479 chr2:61199979~61200769:+ PAAD cis rs13178541 0.641 rs10062107 ENSG00000250378.1 RP11-119J18.1 -4.06 7.92e-05 0.0279 -0.45 -0.31 IgG glycosylation; chr5:135804913 chr5:135812667~135826582:+ PAAD cis rs6142102 0.961 rs4911407 ENSG00000276073.1 RP5-1125A11.7 -4.06 7.92e-05 0.0279 -0.34 -0.31 Skin pigmentation; chr20:34095759 chr20:33985617~33988989:- PAAD cis rs6479901 0.895 rs1579045 ENSG00000232075.1 MRPL35P2 -4.06 7.92e-05 0.0279 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63210688 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs7920159 ENSG00000232075.1 MRPL35P2 -4.06 7.92e-05 0.0279 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63212416 chr10:63634317~63634827:- PAAD cis rs6479901 0.846 rs7907462 ENSG00000232075.1 MRPL35P2 -4.06 7.92e-05 0.0279 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63295773 chr10:63634317~63634827:- PAAD cis rs6968419 0.788 rs10953810 ENSG00000237870.5 AC073130.1 4.06 7.93e-05 0.0279 0.42 0.31 Intraocular pressure; chr7:116172324 chr7:116275606~116286734:- PAAD cis rs11098499 0.82 rs11737395 ENSG00000248280.1 RP11-33B1.2 4.06 7.93e-05 0.0279 0.35 0.31 Corneal astigmatism; chr4:119599549 chr4:119440561~119450157:- PAAD cis rs10759883 0.539 rs10117340 ENSG00000175611.10 LINC00476 -4.06 7.93e-05 0.0279 -0.31 -0.31 Nicotine dependence; chr9:96032530 chr9:95759231~95875977:- PAAD cis rs5758659 0.652 rs133303 ENSG00000273366.1 CTA-989H11.1 -4.06 7.93e-05 0.0279 -0.37 -0.31 Cognitive function; chr22:41999238 chr22:42278188~42278846:+ PAAD cis rs5758659 0.622 rs129856 ENSG00000273366.1 CTA-989H11.1 -4.06 7.93e-05 0.0279 -0.37 -0.31 Cognitive function; chr22:42003392 chr22:42278188~42278846:+ PAAD cis rs5758659 0.652 rs133322 ENSG00000273366.1 CTA-989H11.1 -4.06 7.93e-05 0.0279 -0.37 -0.31 Cognitive function; chr22:42009655 chr22:42278188~42278846:+ PAAD cis rs5758659 0.623 rs133328 ENSG00000273366.1 CTA-989H11.1 -4.06 7.93e-05 0.0279 -0.37 -0.31 Cognitive function; chr22:42012075 chr22:42278188~42278846:+ PAAD cis rs2243480 0.908 rs313822 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66108952 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313820 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66109479 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs160639 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66115000 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313824 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66116220 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs186378 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66117071 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs160637 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66119331 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs422164 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66121618 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316313 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66128561 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316312 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66131504 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs419603 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66132354 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs387676 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66133233 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs13310597 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66133553 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs431076 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66135333 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2257790 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66135463 chr7:65751142~65763354:+ PAAD cis rs2243480 0.764 rs2460423 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66136229 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2460422 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66136518 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316334 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66137139 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316332 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66139312 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316331 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66139635 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316329 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66143429 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316326 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66144466 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316325 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66144531 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316322 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66146246 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316321 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66146626 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316318 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66147917 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316317 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66148650 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316304 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66151907 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2465120 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66155987 chr7:65751142~65763354:+ PAAD cis rs2243480 0.908 rs2460431 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66157859 chr7:65751142~65763354:+ PAAD cis rs2243480 0.711 rs2460426 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66158142 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs4718309 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66162777 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6460274 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66163497 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs7787230 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66164112 chr7:65751142~65763354:+ PAAD cis rs2243480 0.711 rs2420172 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66170354 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2420171 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66172773 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6974723 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66172952 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs9769882 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66177938 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6966322 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66181767 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs4145008 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66182524 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs4718315 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66183554 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs4718316 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66183744 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1873494 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66184912 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6959002 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66185509 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1546059 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66189722 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2420170 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66191066 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6958289 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66192124 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs7804223 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66199572 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs12530490 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66226660 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs7778911 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66229519 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1979823 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66239626 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6964245 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66253730 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs10807701 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66259699 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1499614 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66265811 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1499613 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66265873 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1553174 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66266207 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs10950032 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66273604 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6958420 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66286184 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1392104 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66294120 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs4718333 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66307771 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs7792391 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66308442 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs10247526 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66315709 chr7:65751142~65763354:+ PAAD cis rs2243480 0.908 rs1532573 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Diabetic kidney disease; chr7:66333815 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs778729 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66359432 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs4149468 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66360703 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs778687 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66370832 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs778679 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66375924 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs778704 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66398480 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs778693 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66407358 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs778691 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66408105 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs13235972 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66418618 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34192067 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66422670 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs34807232 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66500146 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs35823062 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66500834 chr7:65751142~65763354:+ PAAD cis rs2243480 0.708 rs35825036 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66521515 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs13224048 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66528779 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs13237037 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66532895 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1796228 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66568097 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1267820 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66585308 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2533288 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66591724 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2707844 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66594522 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1796220 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66597113 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2707831 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Diabetic kidney disease; chr7:66597524 chr7:65751142~65763354:+ PAAD cis rs1499614 0.803 rs1796229 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66654674 chr7:65751142~65763354:+ PAAD cis rs1499614 0.901 rs3936 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66661502 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2707832 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66671562 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs1638731 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66679692 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs1882655 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Gout; chr7:66682070 chr7:65751142~65763354:+ PAAD cis rs1499614 0.831 rs3800822 ENSG00000228409.4 CCT6P1 -4.06 7.93e-05 0.0279 -0.33 -0.31 Gout; chr7:66682162 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2659913 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66692349 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2707840 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66693028 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2659911 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66693433 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2707838 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66694214 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs60326618 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66701371 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2707830 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66702658 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2707828 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66706390 chr7:65751142~65763354:+ PAAD cis rs1499614 0.803 rs1922723 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66710076 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2659903 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66715944 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs2141924 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66721259 chr7:65751142~65763354:+ PAAD cis rs1499614 0.901 rs2178742 ENSG00000228409.4 CCT6P1 4.06 7.93e-05 0.0279 0.33 0.31 Gout; chr7:66732812 chr7:65751142~65763354:+ PAAD cis rs858239 0.601 rs4140959 ENSG00000226816.2 AC005082.12 4.06 7.94e-05 0.0279 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23131157 chr7:23206013~23208045:+ PAAD cis rs5758511 0.637 rs5751244 ENSG00000226450.2 CYP2D8P 4.06 7.94e-05 0.0279 0.34 0.31 Birth weight; chr22:42221405 chr22:42149886~42155001:- PAAD cis rs5758659 0.652 rs133326 ENSG00000273366.1 CTA-989H11.1 -4.06 7.95e-05 0.0279 -0.37 -0.31 Cognitive function; chr22:42010881 chr22:42278188~42278846:+ PAAD cis rs9649213 0.555 rs7785612 ENSG00000272950.1 RP11-307C18.1 4.06 7.96e-05 0.028 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98304555 chr7:98322853~98323430:+ PAAD cis rs2980439 0.517 rs17594093 ENSG00000253893.2 FAM85B 4.06 7.96e-05 0.028 0.46 0.31 Neuroticism; chr8:8248884 chr8:8167819~8226614:- PAAD cis rs867529 1 rs62157778 ENSG00000230006.6 ANKRD36BP2 -4.06 7.96e-05 0.028 -0.29 -0.31 Height; chr2:88634572 chr2:88765807~88806612:+ PAAD cis rs7078219 0.505 rs41290504 ENSG00000228778.1 RP11-129J12.1 -4.06 7.96e-05 0.028 -0.35 -0.31 Dental caries; chr10:99533278 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs7908704 ENSG00000228778.1 RP11-129J12.1 -4.06 7.96e-05 0.028 -0.35 -0.31 Dental caries; chr10:99533561 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs7893840 ENSG00000228778.1 RP11-129J12.1 -4.06 7.96e-05 0.028 -0.35 -0.31 Dental caries; chr10:99533584 chr10:99527081~99528261:+ PAAD cis rs2638953 0.886 rs11049572 ENSG00000247934.4 RP11-967K21.1 -4.06 7.96e-05 0.028 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28397268 chr12:28163298~28190738:- PAAD cis rs28374715 0.681 rs28712264 ENSG00000247556.5 OIP5-AS1 4.06 7.97e-05 0.028 0.34 0.31 Ulcerative colitis; chr15:41296599 chr15:41283990~41309737:+ PAAD cis rs2708377 0.79 rs73051387 ENSG00000212125.2 TAS2R15P 4.06 7.97e-05 0.028 0.5 0.31 Bitter taste perception; chr12:11161864 chr12:10964425~10965352:- PAAD cis rs755249 0.567 rs67408364 ENSG00000261798.1 RP1-118J21.25 4.06 7.97e-05 0.028 0.39 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39152884 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs66531516 ENSG00000261798.1 RP1-118J21.25 4.06 7.97e-05 0.028 0.39 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39163390 chr1:39788976~39790171:+ PAAD cis rs287982 0.935 rs287978 ENSG00000269973.1 RP11-95D17.1 4.06 7.97e-05 0.028 0.35 0.31 Nonsyndromic cleft lip with cleft palate; chr2:9830405 chr2:9936360~9939590:+ PAAD cis rs287982 1 rs287982 ENSG00000269973.1 RP11-95D17.1 4.06 7.97e-05 0.028 0.35 0.31 Nonsyndromic cleft lip with cleft palate; chr2:9832313 chr2:9936360~9939590:+ PAAD cis rs7759001 0.744 rs2893917 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27462962 chr6:27404010~27406964:- PAAD cis rs7759001 0.711 rs10807025 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27464049 chr6:27404010~27406964:- PAAD cis rs7759001 0.711 rs10946921 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27464076 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs4358616 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27465069 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs13201443 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27465634 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs13201965 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27465816 chr6:27404010~27406964:- PAAD cis rs7759001 0.652 rs6920010 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27466057 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs6920408 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27466441 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs6921071 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27466663 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs4713104 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27467000 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs2272814 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27467928 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs12213598 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27468466 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs11970336 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27469245 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs2049944 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27470852 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs2049945 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27470869 chr6:27404010~27406964:- PAAD cis rs7759001 0.652 rs7741031 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27470962 chr6:27404010~27406964:- PAAD cis rs7759001 0.652 rs7745380 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27471142 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs2179154 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27471152 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs2142705 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27471346 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs7750795 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27472225 chr6:27404010~27406964:- PAAD cis rs7759001 0.652 rs2272815 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27472763 chr6:27404010~27406964:- PAAD cis rs7759001 0.6 rs2272816 ENSG00000271755.1 RP1-153G14.4 4.06 7.97e-05 0.028 0.38 0.31 Glomerular filtration rate (creatinine); chr6:27472766 chr6:27404010~27406964:- PAAD cis rs1910358 0.554 rs4235528 ENSG00000248874.4 C5orf17 -4.06 7.98e-05 0.028 -0.44 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23808329 chr5:23951348~24178263:+ PAAD cis rs11673344 0.526 rs73035160 ENSG00000267422.1 CTD-2554C21.1 4.06 7.98e-05 0.028 0.42 0.31 Obesity-related traits; chr19:37655135 chr19:37779686~37792865:+ PAAD cis rs11673344 0.526 rs1871196 ENSG00000267422.1 CTD-2554C21.1 4.06 7.98e-05 0.028 0.42 0.31 Obesity-related traits; chr19:37656022 chr19:37779686~37792865:+ PAAD cis rs10506328 0.509 rs6580979 ENSG00000248265.1 FLJ12825 4.06 7.98e-05 0.028 0.28 0.31 Mean platelet volume; chr12:54253137 chr12:54058254~54122234:+ PAAD cis rs7487075 0.751 rs10880947 ENSG00000258181.1 RP11-493L12.4 -4.06 7.98e-05 0.028 -0.34 -0.31 Itch intensity from mosquito bite; chr12:46283501 chr12:47248124~47257539:+ PAAD cis rs7759001 0.779 rs12212293 ENSG00000271755.1 RP1-153G14.4 4.06 7.98e-05 0.028 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27425410 chr6:27404010~27406964:- PAAD cis rs7759001 0.711 rs7747283 ENSG00000271755.1 RP1-153G14.4 4.06 7.98e-05 0.028 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27425826 chr6:27404010~27406964:- PAAD cis rs3743772 0.5 rs11866060 ENSG00000279722.1 RP11-44F14.6 4.06 7.98e-05 0.028 0.44 0.31 Depressive symptoms (SSRI exposure interaction); chr16:53394937 chr16:53487607~53489943:- PAAD cis rs9487094 0.665 rs13207864 ENSG00000260273.1 RP11-425D10.10 4.05 7.99e-05 0.0281 0.43 0.31 Height; chr6:109708527 chr6:109382795~109383666:+ PAAD cis rs12118297 0.657 rs6656790 ENSG00000236915.1 RP4-651E10.4 -4.05 7.99e-05 0.0281 -0.48 -0.31 Breast cancer; chr1:87299232 chr1:86571181~86693203:- PAAD cis rs528301 0.833 rs340498 ENSG00000259439.2 RP11-89K21.1 4.05 8e-05 0.0281 0.4 0.31 Alcohol and nicotine co-dependence; chr2:44908746 chr2:44921077~44939199:- PAAD cis rs58873874 0.737 rs75326191 ENSG00000248544.2 CTB-47B11.3 4.05 8e-05 0.0281 0.67 0.31 Bipolar disorder (body mass index interaction); chr5:157445797 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs75022277 ENSG00000248544.2 CTB-47B11.3 4.05 8e-05 0.0281 0.67 0.31 Bipolar disorder (body mass index interaction); chr5:157454954 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs78565801 ENSG00000248544.2 CTB-47B11.3 4.05 8e-05 0.0281 0.67 0.31 Bipolar disorder (body mass index interaction); chr5:157459326 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs79951742 ENSG00000248544.2 CTB-47B11.3 4.05 8e-05 0.0281 0.67 0.31 Bipolar disorder (body mass index interaction); chr5:157459705 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs76634949 ENSG00000248544.2 CTB-47B11.3 4.05 8e-05 0.0281 0.67 0.31 Bipolar disorder (body mass index interaction); chr5:157463391 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs79339674 ENSG00000248544.2 CTB-47B11.3 4.05 8e-05 0.0281 0.67 0.31 Bipolar disorder (body mass index interaction); chr5:157464318 chr5:157375741~157384950:- PAAD cis rs17836934 0.874 rs7966278 ENSG00000258302.2 RP11-981P6.1 4.05 8e-05 0.0281 0.27 0.31 Total body bone mineral density; chr12:90112140 chr12:89561129~89594878:+ PAAD cis rs7945705 0.774 rs6486060 ENSG00000254860.4 TMEM9B-AS1 -4.05 8e-05 0.0281 -0.34 -0.31 Hemoglobin concentration; chr11:9003083 chr11:8964675~8977527:+ PAAD cis rs10800713 0.954 rs10800710 ENSG00000260088.1 RP11-92G12.3 -4.05 8.01e-05 0.0281 -0.43 -0.31 Tandem gait; chr1:200569240 chr1:200669507~200694250:+ PAAD cis rs10800713 0.954 rs10800711 ENSG00000260088.1 RP11-92G12.3 -4.05 8.01e-05 0.0281 -0.43 -0.31 Tandem gait; chr1:200569757 chr1:200669507~200694250:+ PAAD cis rs10800713 0.954 rs12092148 ENSG00000260088.1 RP11-92G12.3 -4.05 8.01e-05 0.0281 -0.43 -0.31 Tandem gait; chr1:200570655 chr1:200669507~200694250:+ PAAD cis rs10800713 0.826 rs11586257 ENSG00000260088.1 RP11-92G12.3 -4.05 8.01e-05 0.0281 -0.43 -0.31 Tandem gait; chr1:200572236 chr1:200669507~200694250:+ PAAD cis rs10800713 0.954 rs10800712 ENSG00000260088.1 RP11-92G12.3 -4.05 8.01e-05 0.0281 -0.43 -0.31 Tandem gait; chr1:200576059 chr1:200669507~200694250:+ PAAD cis rs10800713 0.908 rs10919978 ENSG00000260088.1 RP11-92G12.3 -4.05 8.01e-05 0.0281 -0.43 -0.31 Tandem gait; chr1:200576923 chr1:200669507~200694250:+ PAAD cis rs287982 0.932 rs9973654 ENSG00000269973.1 RP11-95D17.1 -4.05 8.01e-05 0.0281 -0.37 -0.31 Nonsyndromic cleft lip with cleft palate; chr2:9822439 chr2:9936360~9939590:+ PAAD cis rs9487094 1 rs10872032 ENSG00000260273.1 RP11-425D10.10 4.05 8.01e-05 0.0281 0.39 0.31 Height; chr6:109355573 chr6:109382795~109383666:+ PAAD cis rs1113500 0.862 rs11185264 ENSG00000226822.1 RP11-356N1.2 4.05 8.01e-05 0.0281 0.36 0.31 Growth-regulated protein alpha levels; chr1:108097884 chr1:108071482~108074519:+ PAAD cis rs4835473 0.932 rs36018946 ENSG00000251600.4 RP11-673E1.1 -4.05 8.02e-05 0.0281 -0.37 -0.31 Immature fraction of reticulocytes; chr4:143980942 chr4:143912331~143982454:+ PAAD cis rs4835473 0.9 rs13101531 ENSG00000251600.4 RP11-673E1.1 -4.05 8.02e-05 0.0281 -0.37 -0.31 Immature fraction of reticulocytes; chr4:143982197 chr4:143912331~143982454:+ PAAD cis rs4835473 0.932 rs28668841 ENSG00000251600.4 RP11-673E1.1 -4.05 8.02e-05 0.0281 -0.37 -0.31 Immature fraction of reticulocytes; chr4:143982530 chr4:143912331~143982454:+ PAAD cis rs950169 0.922 rs8037078 ENSG00000275120.1 RP11-182J1.17 -4.05 8.02e-05 0.0281 -0.33 -0.31 Schizophrenia; chr15:84150119 chr15:84599434~84606463:- PAAD cis rs10129255 0.957 rs11847726 ENSG00000211972.2 IGHV3-66 4.05 8.02e-05 0.0281 0.27 0.31 Kawasaki disease; chr14:106779116 chr14:106675017~106675544:- PAAD cis rs3096299 0.632 rs8051537 ENSG00000261253.2 AC137932.6 4.05 8.02e-05 0.0281 0.33 0.31 Multiple myeloma (IgH translocation); chr16:89477976 chr16:89321133~89325110:+ PAAD cis rs3096299 0.685 rs3803682 ENSG00000261253.2 AC137932.6 4.05 8.02e-05 0.0281 0.33 0.31 Multiple myeloma (IgH translocation); chr16:89478228 chr16:89321133~89325110:+ PAAD cis rs3096299 0.685 rs3803681 ENSG00000261253.2 AC137932.6 4.05 8.02e-05 0.0281 0.33 0.31 Multiple myeloma (IgH translocation); chr16:89478348 chr16:89321133~89325110:+ PAAD cis rs160451 0.811 rs218945 ENSG00000251136.7 RP11-37B2.1 -4.05 8.02e-05 0.0281 -0.3 -0.31 Leprosy; chr8:89701884 chr8:89609409~89757727:- PAAD cis rs780096 0.546 rs35073769 ENSG00000234072.1 AC074117.10 -4.05 8.02e-05 0.0281 -0.24 -0.31 Total body bone mineral density; chr2:27508509 chr2:27356246~27367622:+ PAAD cis rs10411161 1 rs8106929 ENSG00000269483.1 AC006272.1 4.05 8.02e-05 0.0281 0.54 0.31 Breast cancer; chr19:51865214 chr19:51839924~51843324:- PAAD cis rs858239 0.601 rs10255228 ENSG00000226816.2 AC005082.12 4.05 8.02e-05 0.0281 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23119244 chr7:23206013~23208045:+ PAAD cis rs2688608 0.592 rs10762559 ENSG00000271816.1 BMS1P4 4.05 8.02e-05 0.0281 0.32 0.31 Inflammatory bowel disease; chr10:73726695 chr10:73699151~73730487:- PAAD cis rs875971 0.66 rs10229345 ENSG00000237310.1 GS1-124K5.4 4.05 8.03e-05 0.0281 0.29 0.31 Aortic root size; chr7:66517181 chr7:66493706~66495474:+ PAAD cis rs10740039 0.81 rs1372709 ENSG00000254271.1 RP11-131N11.4 4.05 8.03e-05 0.0281 0.39 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60621666 chr10:60734342~60741828:+ PAAD cis rs10740039 0.768 rs10994432 ENSG00000254271.1 RP11-131N11.4 4.05 8.03e-05 0.0281 0.39 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60623831 chr10:60734342~60741828:+ PAAD cis rs9652601 0.879 rs9926367 ENSG00000274038.1 RP11-66H6.4 -4.05 8.03e-05 0.0282 -0.36 -0.31 Systemic lupus erythematosus; chr16:10999322 chr16:11056556~11057034:+ PAAD cis rs10540 0.915 rs35389167 ENSG00000255237.1 RP13-317D12.3 4.05 8.03e-05 0.0282 0.47 0.31 Body mass index; chr11:460765 chr11:462930~463899:- PAAD cis rs9807989 0.524 rs6543126 ENSG00000234389.1 AC007278.3 4.05 8.03e-05 0.0282 0.31 0.31 Asthma; chr2:102410644 chr2:102438713~102440475:+ PAAD cis rs4128527 0.813 rs13249262 ENSG00000253317.1 RP11-142A23.1 4.05 8.03e-05 0.0282 0.39 0.31 Late-onset myasthenia gravis; chr8:71758473 chr8:72196334~72202269:+ PAAD cis rs1707322 0.717 rs3014249 ENSG00000280836.1 AL355480.1 4.05 8.04e-05 0.0282 0.37 0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45613821 chr1:45581219~45581321:- PAAD cis rs5758659 0.569 rs133293 ENSG00000273366.1 CTA-989H11.1 -4.05 8.04e-05 0.0282 -0.37 -0.31 Cognitive function; chr22:41986793 chr22:42278188~42278846:+ PAAD cis rs5758659 0.569 rs133294 ENSG00000273366.1 CTA-989H11.1 -4.05 8.04e-05 0.0282 -0.37 -0.31 Cognitive function; chr22:41986801 chr22:42278188~42278846:+ PAAD cis rs875971 0.862 rs1167390 ENSG00000232559.3 GS1-124K5.12 -4.05 8.04e-05 0.0282 -0.35 -0.31 Aortic root size; chr7:66110906 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs35034167 ENSG00000232559.3 GS1-124K5.12 -4.05 8.04e-05 0.0282 -0.35 -0.31 Aortic root size; chr7:66115179 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs28470208 ENSG00000232559.3 GS1-124K5.12 -4.05 8.04e-05 0.0282 -0.35 -0.31 Aortic root size; chr7:66119713 chr7:66554588~66576923:- PAAD cis rs7189233 0.531 rs7204496 ENSG00000279344.1 RP11-44F14.7 -4.05 8.05e-05 0.0282 -0.23 -0.31 Intelligence (multi-trait analysis); chr16:53462686 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs7204758 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53448453 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs9921627 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53448780 chr16:53478957~53481550:- PAAD cis rs1861353 0.863 rs16952252 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53450068 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs9941254 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53453306 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs7194730 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53455278 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs13332406 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53455793 chr16:53478957~53481550:- PAAD cis rs7189233 0.55 rs4784312 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53464490 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs1072910 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53465687 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs56126229 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53476775 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs8049033 ENSG00000279344.1 RP11-44F14.7 4.05 8.05e-05 0.0282 0.23 0.31 Intelligence (multi-trait analysis); chr16:53479143 chr16:53478957~53481550:- PAAD cis rs56046484 0.797 rs907260 ENSG00000259295.5 CSPG4P12 -4.05 8.05e-05 0.0282 -0.44 -0.31 Testicular germ cell tumor; chr15:85133526 chr15:85191438~85213905:+ PAAD cis rs748404 0.697 rs471122 ENSG00000249839.1 AC011330.5 4.05 8.05e-05 0.0282 0.42 0.31 Lung cancer; chr15:43266376 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs555001 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43253530 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs475261 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43254258 chr15:43663654~43684339:- PAAD cis rs748404 0.723 rs573169 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43258383 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs524547 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43258825 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs564946 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43264074 chr15:43663654~43684339:- PAAD cis rs748404 0.723 rs565658 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43264109 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs579651 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43266178 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs473016 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43266625 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs531910 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43268409 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs491804 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43268627 chr15:43663654~43684339:- PAAD cis rs748404 0.697 rs492743 ENSG00000249839.1 AC011330.5 -4.05 8.05e-05 0.0282 -0.42 -0.31 Lung cancer; chr15:43268747 chr15:43663654~43684339:- PAAD cis rs950169 0.881 rs150965 ENSG00000275120.1 RP11-182J1.17 4.05 8.05e-05 0.0282 0.33 0.31 Schizophrenia; chr15:84537296 chr15:84599434~84606463:- PAAD cis rs4718428 0.705 rs68168107 ENSG00000273142.1 RP11-458F8.4 -4.05 8.06e-05 0.0282 -0.21 -0.31 Corneal structure; chr7:66790251 chr7:66902857~66906297:+ PAAD cis rs7487075 0.93 rs12814298 ENSG00000270429.1 KNOP1P2 4.05 8.06e-05 0.0282 0.36 0.31 Itch intensity from mosquito bite; chr12:46443841 chr12:45880950~45882266:- PAAD cis rs1387259 0.839 rs7487682 ENSG00000240399.1 RP1-228P16.1 -4.05 8.06e-05 0.0282 -0.33 -0.31 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48185882 chr12:48054813~48055591:- PAAD cis rs62229266 0.557 rs4817761 ENSG00000231106.2 LINC01436 4.05 8.06e-05 0.0282 0.49 0.31 Mitral valve prolapse; chr21:36023258 chr21:36005338~36007838:+ PAAD cis rs950880 0.553 rs3755272 ENSG00000234389.1 AC007278.3 -4.05 8.06e-05 0.0282 -0.36 -0.31 Serum protein levels (sST2); chr2:102417365 chr2:102438713~102440475:+ PAAD cis rs950880 0.553 rs2293225 ENSG00000234389.1 AC007278.3 -4.05 8.06e-05 0.0282 -0.36 -0.31 Serum protein levels (sST2); chr2:102419429 chr2:102438713~102440475:+ PAAD cis rs755249 0.958 rs2068663 ENSG00000228060.1 RP11-69E11.8 -4.05 8.07e-05 0.0282 -0.32 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572899 chr1:39565160~39573203:+ PAAD cis rs6539288 0.674 rs4964494 ENSG00000260329.1 RP11-412D9.4 -4.05 8.07e-05 0.0282 -0.27 -0.31 Total body bone mineral density; chr12:106890682 chr12:106954029~106955497:- PAAD cis rs12682352 0.65 rs13265731 ENSG00000253893.2 FAM85B -4.05 8.07e-05 0.0282 -0.46 -0.31 Neuroticism; chr8:8815810 chr8:8167819~8226614:- PAAD cis rs227932 0.764 rs4722246 ENSG00000234286.1 AC006026.13 4.05 8.07e-05 0.0282 0.52 0.31 Schizophrenia; chr7:23682359 chr7:23680195~23680786:- PAAD cis rs227932 0.614 rs12700458 ENSG00000234286.1 AC006026.13 4.05 8.07e-05 0.0282 0.52 0.31 Schizophrenia; chr7:23682525 chr7:23680195~23680786:- PAAD cis rs338389 0.521 rs338381 ENSG00000260657.2 RP11-315D16.4 -4.05 8.07e-05 0.0283 -0.37 -0.31 Survival in rectal cancer; chr15:67951850 chr15:68267792~68277994:- PAAD cis rs2348418 0.932 rs16932850 ENSG00000247934.4 RP11-967K21.1 4.05 8.07e-05 0.0283 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28457941 chr12:28163298~28190738:- PAAD cis rs2348418 0.932 rs11049623 ENSG00000247934.4 RP11-967K21.1 4.05 8.07e-05 0.0283 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28458374 chr12:28163298~28190738:- PAAD cis rs2348418 0.932 rs7136429 ENSG00000247934.4 RP11-967K21.1 4.05 8.07e-05 0.0283 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28460306 chr12:28163298~28190738:- PAAD cis rs2348418 0.932 rs7136886 ENSG00000247934.4 RP11-967K21.1 4.05 8.07e-05 0.0283 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28460684 chr12:28163298~28190738:- PAAD cis rs7646881 0.504 rs7617304 ENSG00000240207.5 RP11-379F4.4 -4.05 8.08e-05 0.0283 -0.43 -0.31 Tetralogy of Fallot; chr3:158745312 chr3:158732263~158784070:+ PAAD cis rs2243480 1 rs1638734 ENSG00000228409.4 CCT6P1 4.05 8.08e-05 0.0283 0.33 0.31 Diabetic kidney disease; chr7:66632552 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs1267818 ENSG00000228409.4 CCT6P1 4.05 8.08e-05 0.0283 0.33 0.31 Gout; chr7:66642037 chr7:65751142~65763354:+ PAAD cis rs1499614 1 rs1267817 ENSG00000228409.4 CCT6P1 4.05 8.08e-05 0.0283 0.33 0.31 Gout; chr7:66645053 chr7:65751142~65763354:+ PAAD cis rs12900463 0.813 rs187316 ENSG00000275120.1 RP11-182J1.17 4.05 8.08e-05 0.0283 0.34 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine); chr15:84862764 chr15:84599434~84606463:- PAAD cis rs4835473 0.524 rs4404495 ENSG00000251600.4 RP11-673E1.1 4.05 8.08e-05 0.0283 0.37 0.31 Immature fraction of reticulocytes; chr4:143979791 chr4:143912331~143982454:+ PAAD cis rs987724 0.927 rs6803064 ENSG00000240875.4 LINC00886 -4.05 8.08e-05 0.0283 -0.38 -0.31 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156960821 chr3:156747346~156817062:- PAAD cis rs987724 0.964 rs9814813 ENSG00000240875.4 LINC00886 -4.05 8.08e-05 0.0283 -0.38 -0.31 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156962229 chr3:156747346~156817062:- PAAD cis rs6700559 0.716 rs12140579 ENSG00000260088.1 RP11-92G12.3 4.05 8.08e-05 0.0283 0.42 0.31 Coronary artery disease; chr1:200655368 chr1:200669507~200694250:+ PAAD cis rs9322193 0.962 rs1413655 ENSG00000268592.3 RAET1E-AS1 4.05 8.08e-05 0.0283 0.37 0.31 Lung cancer; chr6:149821815 chr6:149863494~149919507:+ PAAD cis rs9322193 0.926 rs9383546 ENSG00000268592.3 RAET1E-AS1 4.05 8.08e-05 0.0283 0.37 0.31 Lung cancer; chr6:149822743 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs2151912 ENSG00000268592.3 RAET1E-AS1 4.05 8.08e-05 0.0283 0.37 0.31 Lung cancer; chr6:149831772 chr6:149863494~149919507:+ PAAD cis rs7572733 0.555 rs6434953 ENSG00000231621.1 AC013264.2 -4.05 8.09e-05 0.0283 -0.33 -0.31 Dermatomyositis; chr2:198064969 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs6434954 ENSG00000231621.1 AC013264.2 -4.05 8.09e-05 0.0283 -0.33 -0.31 Dermatomyositis; chr2:198064992 chr2:197197991~197199273:+ PAAD cis rs919433 0.926 rs787996 ENSG00000231621.1 AC013264.2 -4.05 8.09e-05 0.0283 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197352081 chr2:197197991~197199273:+ PAAD cis rs4718428 0.705 rs11028 ENSG00000273142.1 RP11-458F8.4 -4.05 8.09e-05 0.0283 -0.21 -0.31 Corneal structure; chr7:66811230 chr7:66902857~66906297:+ PAAD cis rs6908034 0.607 rs79842087 ENSG00000228412.5 RP4-625H18.2 4.05 8.1e-05 0.0283 0.72 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19821085 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs12527834 ENSG00000228412.5 RP4-625H18.2 4.05 8.1e-05 0.0283 0.72 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19821550 chr6:19802164~19804752:- PAAD cis rs755249 0.51 rs613511 ENSG00000228060.1 RP11-69E11.8 -4.05 8.1e-05 0.0283 -0.29 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39367801 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs629093 ENSG00000228060.1 RP11-69E11.8 -4.05 8.1e-05 0.0283 -0.29 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39367831 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs2490946 ENSG00000228060.1 RP11-69E11.8 -4.05 8.1e-05 0.0283 -0.29 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39371955 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs663449 ENSG00000228060.1 RP11-69E11.8 -4.05 8.1e-05 0.0283 -0.29 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39378286 chr1:39565160~39573203:+ PAAD cis rs755249 0.51 rs1184716 ENSG00000228060.1 RP11-69E11.8 -4.05 8.1e-05 0.0283 -0.29 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380817 chr1:39565160~39573203:+ PAAD cis rs2928148 0.5 rs12912887 ENSG00000223313.1 RNU6-516P 4.05 8.12e-05 0.0284 0.42 0.31 Glomerular filtration rate in non diabetics (creatinine); chr15:40965410 chr15:40529570~40529673:+ PAAD cis rs2928148 0.522 rs11070318 ENSG00000223313.1 RNU6-516P 4.05 8.12e-05 0.0284 0.42 0.31 Glomerular filtration rate in non diabetics (creatinine); chr15:40965656 chr15:40529570~40529673:+ PAAD cis rs2243480 1 rs160655 ENSG00000232546.1 RP11-458F8.1 -4.05 8.12e-05 0.0284 -0.36 -0.31 Diabetic kidney disease; chr7:66068227 chr7:66848496~66858136:+ PAAD cis rs2243480 0.803 rs160649 ENSG00000232546.1 RP11-458F8.1 -4.05 8.12e-05 0.0284 -0.36 -0.31 Diabetic kidney disease; chr7:66078212 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs160648 ENSG00000232546.1 RP11-458F8.1 -4.05 8.12e-05 0.0284 -0.36 -0.31 Diabetic kidney disease; chr7:66078397 chr7:66848496~66858136:+ PAAD cis rs193541 0.564 rs407230 ENSG00000263432.2 RN7SL689P -4.05 8.12e-05 0.0284 -0.41 -0.31 Glucose homeostasis traits; chr5:123010032 chr5:123022487~123022783:- PAAD cis rs453301 0.686 rs6987107 ENSG00000254340.1 RP11-10A14.3 -4.05 8.12e-05 0.0284 -0.39 -0.31 Joint mobility (Beighton score); chr8:9036071 chr8:9141424~9145435:+ PAAD cis rs3781264 0.761 rs11187894 ENSG00000273450.1 RP11-76P2.4 4.05 8.12e-05 0.0284 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94346268 chr10:94314907~94315327:- PAAD cis rs3781264 0.724 rs10882435 ENSG00000273450.1 RP11-76P2.4 4.05 8.12e-05 0.0284 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94348110 chr10:94314907~94315327:- PAAD cis rs3781264 0.761 rs11187899 ENSG00000273450.1 RP11-76P2.4 4.05 8.12e-05 0.0284 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94348345 chr10:94314907~94315327:- PAAD cis rs3781264 0.687 rs11187900 ENSG00000273450.1 RP11-76P2.4 4.05 8.12e-05 0.0284 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94348607 chr10:94314907~94315327:- PAAD cis rs3781264 0.687 rs10882436 ENSG00000273450.1 RP11-76P2.4 4.05 8.12e-05 0.0284 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94349043 chr10:94314907~94315327:- PAAD cis rs889398 0.802 rs12919094 ENSG00000226232.7 RP11-419C5.2 4.05 8.12e-05 0.0284 0.25 0.31 Body mass index; chr16:69809454 chr16:69976388~69996188:- PAAD cis rs3738443 0.951 rs55914345 ENSG00000259865.1 RP11-488L18.10 4.05 8.13e-05 0.0284 0.29 0.31 Alcohol dependence; chr1:247216105 chr1:247187281~247188526:- PAAD cis rs7078219 0.543 rs4919342 ENSG00000228778.1 RP11-129J12.1 -4.05 8.13e-05 0.0284 -0.34 -0.31 Dental caries; chr10:99522796 chr10:99527081~99528261:+ PAAD cis rs7824557 0.679 rs10110008 ENSG00000254527.1 ENPP7P12 -4.05 8.13e-05 0.0284 -0.36 -0.31 Retinal vascular caliber; chr8:11276227 chr8:12205759~12206389:- PAAD cis rs8177376 0.906 rs522486 ENSG00000254905.1 RP11-712L6.7 4.05 8.13e-05 0.0284 0.43 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126190054 chr11:126292922~126294254:- PAAD cis rs6570726 0.967 rs373527 ENSG00000235652.6 RP11-545I5.3 4.05 8.14e-05 0.0284 0.26 0.31 Lobe attachment (rater-scored or self-reported); chr6:145480725 chr6:145799409~145886585:+ PAAD cis rs6570726 0.967 rs413880 ENSG00000235652.6 RP11-545I5.3 4.05 8.14e-05 0.0284 0.26 0.31 Lobe attachment (rater-scored or self-reported); chr6:145483686 chr6:145799409~145886585:+ PAAD cis rs6570726 0.967 rs403584 ENSG00000235652.6 RP11-545I5.3 4.05 8.14e-05 0.0284 0.26 0.31 Lobe attachment (rater-scored or self-reported); chr6:145485874 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs377143 ENSG00000235652.6 RP11-545I5.3 4.05 8.14e-05 0.0284 0.26 0.31 Lobe attachment (rater-scored or self-reported); chr6:145513084 chr6:145799409~145886585:+ PAAD cis rs11723261 0.621 rs3829 ENSG00000275426.1 CH17-262A2.1 4.05 8.14e-05 0.0284 0.5 0.31 Immune response to smallpox vaccine (IL-6); chr4:141070 chr4:149738~150317:+ PAAD cis rs11723261 0.621 rs57013142 ENSG00000275426.1 CH17-262A2.1 4.05 8.14e-05 0.0284 0.5 0.31 Immune response to smallpox vaccine (IL-6); chr4:141956 chr4:149738~150317:+ PAAD cis rs633715 0.766 rs12760319 ENSG00000254154.7 RP4-798P15.3 -4.05 8.14e-05 0.0284 -0.29 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177835056 chr1:177928788~178038007:- PAAD cis rs633715 0.766 rs17360224 ENSG00000254154.7 RP4-798P15.3 -4.05 8.14e-05 0.0284 -0.29 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177835105 chr1:177928788~178038007:- PAAD cis rs9494145 0.838 rs9483788 ENSG00000232876.1 CTA-212D2.2 -4.05 8.15e-05 0.0285 -0.43 -0.31 Mean platelet volume;Red blood cell traits;Fetal hemoglobin levels in sickle cell anemia;Platelet count; chr6:135114363 chr6:135055033~135060550:+ PAAD cis rs11159086 1 rs11159086 ENSG00000259005.1 RP3-449M8.6 4.05 8.15e-05 0.0285 0.42 0.31 Advanced glycation end-product levels; chr14:74495572 chr14:74474007~74474864:- PAAD cis rs858239 0.539 rs2178140 ENSG00000226816.2 AC005082.12 4.05 8.15e-05 0.0285 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23152006 chr7:23206013~23208045:+ PAAD cis rs77372450 0.688 rs11465228 ENSG00000251405.2 CTB-109A12.1 4.05 8.15e-05 0.0285 0.66 0.31 Bipolar disorder (body mass index interaction); chr5:157575687 chr5:157362615~157460078:- PAAD cis rs950169 0.881 rs72750843 ENSG00000275120.1 RP11-182J1.17 4.05 8.16e-05 0.0285 0.32 0.31 Schizophrenia; chr15:84592552 chr15:84599434~84606463:- PAAD cis rs17836934 0.771 rs7488228 ENSG00000258302.2 RP11-981P6.1 -4.05 8.16e-05 0.0285 -0.27 -0.31 Total body bone mineral density; chr12:90077187 chr12:89561129~89594878:+ PAAD cis rs9322193 0.923 rs14314 ENSG00000268592.3 RAET1E-AS1 4.05 8.16e-05 0.0285 0.37 0.31 Lung cancer; chr6:149820395 chr6:149863494~149919507:+ PAAD cis rs4423214 0.524 rs4944046 ENSG00000254682.1 RP11-660L16.2 4.05 8.16e-05 0.0285 0.4 0.31 Vitamin D levels; chr11:71412748 chr11:71448674~71452157:+ PAAD cis rs17597773 0.527 rs2484699 ENSG00000238078.1 LINC01352 -4.05 8.16e-05 0.0285 -0.3 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr1:220910410 chr1:220829255~220832429:+ PAAD cis rs4713118 0.629 rs203887 ENSG00000226314.6 ZNF192P1 -4.05 8.16e-05 0.0285 -0.54 -0.31 Parkinson's disease; chr6:28053491 chr6:28161781~28169594:+ PAAD cis rs5015933 0.815 rs10124754 ENSG00000232630.1 PRPS1P2 -4.05 8.17e-05 0.0285 -0.28 -0.31 Body mass index; chr9:125327479 chr9:125150653~125151589:+ PAAD cis rs5015933 0.705 rs13288223 ENSG00000232630.1 PRPS1P2 -4.05 8.17e-05 0.0285 -0.28 -0.31 Body mass index; chr9:125335388 chr9:125150653~125151589:+ PAAD cis rs4718428 0.672 rs36038499 ENSG00000273142.1 RP11-458F8.4 -4.05 8.17e-05 0.0285 -0.21 -0.31 Corneal structure; chr7:66824628 chr7:66902857~66906297:+ PAAD cis rs720064 0.586 rs8099403 ENSG00000264745.1 TTC39C-AS1 -4.05 8.18e-05 0.0286 -0.39 -0.31 Strep throat; chr18:23933031 chr18:23994213~24015339:- PAAD cis rs2688608 0.588 rs10128205 ENSG00000271816.1 BMS1P4 4.05 8.18e-05 0.0286 0.32 0.31 Inflammatory bowel disease; chr10:73709890 chr10:73699151~73730487:- PAAD cis rs11893307 0.509 rs6726273 ENSG00000235852.1 AC005540.3 4.05 8.18e-05 0.0286 0.47 0.31 Mean platelet volume; chr2:190664970 chr2:190880797~190882059:- PAAD cis rs11893307 0.509 rs62179690 ENSG00000235852.1 AC005540.3 4.05 8.18e-05 0.0286 0.47 0.31 Mean platelet volume; chr2:190665147 chr2:190880797~190882059:- PAAD cis rs1275468 0.689 rs1795382 ENSG00000257497.2 RP11-585P4.5 -4.05 8.18e-05 0.0286 -0.49 -0.31 Polycystic ovary syndrome; chr12:75586113 chr12:75483454~75489820:- PAAD cis rs6991838 0.725 rs6995134 ENSG00000200714.1 Y_RNA 4.05 8.18e-05 0.0286 0.37 0.31 Intelligence (multi-trait analysis); chr8:65555472 chr8:65592731~65592820:+ PAAD cis rs7182621 0.512 rs71403471 ENSG00000182397.13 DNM1P46 4.05 8.18e-05 0.0286 0.4 0.31 Colonoscopy-negative controls vs population controls; chr15:99870656 chr15:99790156~99806927:- PAAD cis rs2403083 0.505 rs2279700 ENSG00000258256.1 RP11-219B4.5 -4.05 8.19e-05 0.0286 -0.34 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85298621 chr8:85222446~85245717:- PAAD cis rs12935418 0.887 rs3743503 ENSG00000261061.1 RP11-303E16.2 -4.05 8.19e-05 0.0286 -0.49 -0.31 Mean corpuscular volume; chr16:81022836 chr16:81030770~81031485:+ PAAD cis rs7923609 0.846 rs7090111 ENSG00000232075.1 MRPL35P2 -4.05 8.19e-05 0.0286 -0.38 -0.31 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63318234 chr10:63634317~63634827:- PAAD cis rs763121 0.962 rs6001159 ENSG00000228274.3 RP3-508I15.9 -4.05 8.19e-05 0.0286 -0.29 -0.31 Menopause (age at onset); chr22:38570482 chr22:38667585~38681820:- PAAD cis rs6046396 1 rs6112627 ENSG00000275142.1 RP5-999L4.2 -4.05 8.19e-05 0.0286 -0.43 -0.31 Bipolar disorder and schizophrenia; chr20:19877342 chr20:19871891~19872284:+ PAAD cis rs889398 0.771 rs8048550 ENSG00000226232.7 RP11-419C5.2 -4.05 8.2e-05 0.0286 -0.25 -0.31 Body mass index; chr16:69857856 chr16:69976388~69996188:- PAAD cis rs3738443 0.868 rs56029850 ENSG00000259865.1 RP11-488L18.10 4.05 8.21e-05 0.0286 0.28 0.31 Alcohol dependence; chr1:247201027 chr1:247187281~247188526:- PAAD cis rs3738443 0.868 rs55643126 ENSG00000259865.1 RP11-488L18.10 4.05 8.21e-05 0.0286 0.28 0.31 Alcohol dependence; chr1:247201042 chr1:247187281~247188526:- PAAD cis rs3738443 0.868 rs12569042 ENSG00000259865.1 RP11-488L18.10 4.05 8.21e-05 0.0286 0.28 0.31 Alcohol dependence; chr1:247203078 chr1:247187281~247188526:- PAAD cis rs875971 0.862 rs1167408 ENSG00000232559.3 GS1-124K5.12 -4.05 8.21e-05 0.0286 -0.35 -0.31 Aortic root size; chr7:66091121 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs1167406 ENSG00000232559.3 GS1-124K5.12 -4.05 8.21e-05 0.0286 -0.35 -0.31 Aortic root size; chr7:66091949 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs709609 ENSG00000232559.3 GS1-124K5.12 -4.05 8.21e-05 0.0286 -0.35 -0.31 Aortic root size; chr7:66095574 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs1167399 ENSG00000232559.3 GS1-124K5.12 -4.05 8.21e-05 0.0286 -0.35 -0.31 Aortic root size; chr7:66096890 chr7:66554588~66576923:- PAAD cis rs755249 1 rs17513135 ENSG00000228060.1 RP11-69E11.8 -4.05 8.21e-05 0.0286 -0.32 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39570014 chr1:39565160~39573203:+ PAAD cis rs4888378 0.6 rs729109 ENSG00000261783.1 RP11-252K23.2 4.05 8.21e-05 0.0287 0.48 0.31 Coronary artery disease; chr16:75282176 chr16:75379818~75381260:- PAAD cis rs12264252 0.623 rs12773636 ENSG00000230091.5 TMEM254-AS1 -4.05 8.21e-05 0.0287 -0.38 -0.31 Coronary artery disease; chr10:80502651 chr10:80046860~80078912:- PAAD cis rs6951245 0.554 rs58210047 ENSG00000229043.2 AC091729.9 -4.05 8.21e-05 0.0287 -0.43 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1109745 chr7:1160374~1165267:+ PAAD cis rs61270009 0.955 rs13171573 ENSG00000247828.6 TMEM161B-AS1 4.05 8.21e-05 0.0287 0.26 0.31 Depressive symptoms; chr5:88383625 chr5:88268895~88436685:+ PAAD cis rs453301 0.653 rs1562211 ENSG00000254340.1 RP11-10A14.3 -4.05 8.22e-05 0.0287 -0.38 -0.31 Joint mobility (Beighton score); chr8:9044914 chr8:9141424~9145435:+ PAAD cis rs889398 0.77 rs8052225 ENSG00000226232.7 RP11-419C5.2 -4.05 8.22e-05 0.0287 -0.25 -0.31 Body mass index; chr16:69849750 chr16:69976388~69996188:- PAAD cis rs28374715 0.532 rs11070328 ENSG00000247556.5 OIP5-AS1 4.05 8.22e-05 0.0287 0.32 0.31 Ulcerative colitis; chr15:41359371 chr15:41283990~41309737:+ PAAD cis rs28374715 0.532 rs28535540 ENSG00000247556.5 OIP5-AS1 4.05 8.22e-05 0.0287 0.32 0.31 Ulcerative colitis; chr15:41367079 chr15:41283990~41309737:+ PAAD cis rs2439831 0.867 rs45585139 ENSG00000275601.1 AC011330.13 -4.05 8.22e-05 0.0287 -0.58 -0.31 Lung cancer in ever smokers; chr15:43408229 chr15:43642389~43643023:- PAAD cis rs33998987 0.664 rs984971 ENSG00000226121.2 AC009487.6 4.05 8.22e-05 0.0287 0.38 0.31 Coronary artery disease; chr2:162368011 chr2:161500885~161507705:- PAAD cis rs1075265 0.553 rs2692532 ENSG00000233266.1 HMGB1P31 4.05 8.23e-05 0.0287 0.41 0.31 Chronotype;Morning vs. evening chronotype; chr2:53778962 chr2:54051334~54051760:+ PAAD cis rs4660214 0.666 rs7538300 ENSG00000237624.1 OXCT2P1 -4.05 8.23e-05 0.0287 -0.41 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39187092 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs11205739 ENSG00000237624.1 OXCT2P1 -4.05 8.23e-05 0.0287 -0.41 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39190729 chr1:39514956~39516490:+ PAAD cis rs755249 0.508 rs12023553 ENSG00000237624.1 OXCT2P1 -4.05 8.23e-05 0.0287 -0.41 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39205820 chr1:39514956~39516490:+ PAAD cis rs4660214 0.694 rs16866216 ENSG00000237624.1 OXCT2P1 -4.05 8.23e-05 0.0287 -0.41 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39208916 chr1:39514956~39516490:+ PAAD cis rs2011013 0.6 rs34047645 ENSG00000230373.7 GOLGA6L5P 4.05 8.23e-05 0.0287 0.4 0.31 Sitting height ratio; chr15:83942615 chr15:84507885~84516814:- PAAD cis rs889398 0.802 rs2291959 ENSG00000226232.7 RP11-419C5.2 -4.05 8.23e-05 0.0287 -0.25 -0.31 Body mass index; chr16:69840089 chr16:69976388~69996188:- PAAD cis rs889398 0.802 rs2937121 ENSG00000226232.7 RP11-419C5.2 4.05 8.23e-05 0.0287 0.25 0.31 Body mass index; chr16:69836506 chr16:69976388~69996188:- PAAD cis rs4326844 0.583 rs10506328 ENSG00000248265.1 FLJ12825 4.05 8.24e-05 0.0287 0.32 0.31 Platelet count; chr12:54293448 chr12:54058254~54122234:+ PAAD cis rs875971 0.522 rs2949690 ENSG00000236529.1 RP13-254B10.1 -4.05 8.24e-05 0.0287 -0.34 -0.31 Aortic root size; chr7:66018255 chr7:65840212~65840596:+ PAAD cis rs875971 0.54 rs1723268 ENSG00000236529.1 RP13-254B10.1 4.05 8.24e-05 0.0287 0.34 0.31 Aortic root size; chr7:66008093 chr7:65840212~65840596:+ PAAD cis rs875971 0.522 rs1701760 ENSG00000236529.1 RP13-254B10.1 4.05 8.24e-05 0.0287 0.34 0.31 Aortic root size; chr7:66008701 chr7:65840212~65840596:+ PAAD cis rs829883 0.738 rs249854 ENSG00000245017.2 RP11-181C3.1 -4.05 8.25e-05 0.0288 -0.31 -0.31 Colorectal adenoma (advanced); chr12:98468994 chr12:98485544~98503855:- PAAD cis rs867371 1 rs7173339 ENSG00000259429.4 UBE2Q2P2 -4.05 8.25e-05 0.0288 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82175253 chr15:82355142~82420075:+ PAAD cis rs4554975 0.689 rs2263487 ENSG00000274723.1 RP11-618L22.1 4.05 8.25e-05 0.0288 0.36 0.31 Metabolite levels (small molecules and protein measures); chr12:46857044 chr12:46970504~46972155:+ PAAD cis rs4554975 0.714 rs2465213 ENSG00000274723.1 RP11-618L22.1 4.05 8.25e-05 0.0288 0.36 0.31 Metabolite levels (small molecules and protein measures); chr12:46857179 chr12:46970504~46972155:+ PAAD cis rs4554975 0.689 rs2465211 ENSG00000274723.1 RP11-618L22.1 4.05 8.25e-05 0.0288 0.36 0.31 Metabolite levels (small molecules and protein measures); chr12:46859159 chr12:46970504~46972155:+ PAAD cis rs4554975 0.626 rs2465210 ENSG00000274723.1 RP11-618L22.1 4.05 8.25e-05 0.0288 0.36 0.31 Metabolite levels (small molecules and protein measures); chr12:46862765 chr12:46970504~46972155:+ PAAD cis rs4554975 0.689 rs2465208 ENSG00000274723.1 RP11-618L22.1 4.05 8.25e-05 0.0288 0.36 0.31 Metabolite levels (small molecules and protein measures); chr12:46876759 chr12:46970504~46972155:+ PAAD cis rs4660214 0.666 rs1180383 ENSG00000228060.1 RP11-69E11.8 -4.05 8.25e-05 0.0288 -0.29 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380595 chr1:39565160~39573203:+ PAAD cis rs9309473 0.948 rs7607892 ENSG00000163016.8 ALMS1P 4.05 8.26e-05 0.0288 0.43 0.31 Metabolite levels; chr2:73591580 chr2:73644919~73685576:+ PAAD cis rs1124769 0.502 rs12148865 ENSG00000259240.1 RP11-108K3.1 -4.05 8.26e-05 0.0288 -0.4 -0.31 Cognitive performance; chr15:50786400 chr15:51037488~51293912:+ PAAD cis rs1124769 0.502 rs28565448 ENSG00000259240.1 RP11-108K3.1 -4.05 8.26e-05 0.0288 -0.4 -0.31 Cognitive performance; chr15:50787773 chr15:51037488~51293912:+ PAAD cis rs2188561 0.697 rs13242107 ENSG00000241764.3 AC002467.7 4.05 8.26e-05 0.0288 0.4 0.31 Alcohol consumption; chr7:107734800 chr7:107742817~107744581:- PAAD cis rs812925 0.512 rs7558954 ENSG00000271889.1 RP11-493E12.1 4.05 8.26e-05 0.0288 0.34 0.31 Immature fraction of reticulocytes; chr2:61157771 chr2:61151433~61162105:- PAAD cis rs12468579 0.74 rs12693588 ENSG00000235852.1 AC005540.3 4.05 8.26e-05 0.0288 0.38 0.31 JT interval (sulfonylurea treatment interaction); chr2:190967766 chr2:190880797~190882059:- PAAD cis rs10506328 0.509 rs4759073 ENSG00000248265.1 FLJ12825 4.05 8.26e-05 0.0288 0.28 0.31 Mean platelet volume; chr12:54259474 chr12:54058254~54122234:+ PAAD cis rs6446731 0.568 rs732869 ENSG00000261643.1 RP11-529E10.6 -4.05 8.26e-05 0.0288 -0.36 -0.31 Mean platelet volume; chr4:3285074 chr4:3503597~3504457:- PAAD cis rs7554672 1 rs61817985 ENSG00000232679.1 RP11-400N13.3 4.05 8.27e-05 0.0288 0.31 0.31 Hypertension; chr1:221128930 chr1:222041705~222064763:- PAAD cis rs2911132 0.714 rs13167972 ENSG00000248734.2 CTD-2260A17.1 4.05 8.27e-05 0.0288 0.3 0.31 Urate levels (BMI interaction); chr5:96761124 chr5:96784777~96785999:+ PAAD cis rs13256369 0.802 rs35382339 ENSG00000253981.4 ALG1L13P 4.05 8.27e-05 0.0288 0.42 0.31 Obesity-related traits; chr8:8701745 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs11781257 ENSG00000253981.4 ALG1L13P 4.05 8.27e-05 0.0288 0.42 0.31 Obesity-related traits; chr8:8702153 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs2280560 ENSG00000253981.4 ALG1L13P 4.05 8.27e-05 0.0288 0.42 0.31 Obesity-related traits; chr8:8703092 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs12153 ENSG00000253981.4 ALG1L13P 4.05 8.27e-05 0.0288 0.42 0.31 Obesity-related traits; chr8:8703399 chr8:8236003~8244667:- PAAD cis rs2179367 0.959 rs9285519 ENSG00000231760.4 RP11-350J20.5 4.05 8.27e-05 0.0288 0.4 0.31 Dupuytren's disease; chr6:149371799 chr6:149796151~149826294:- PAAD cis rs2486288 0.656 rs8041702 ENSG00000259433.2 CTD-2651B20.4 4.05 8.29e-05 0.0289 0.35 0.31 Glomerular filtration rate; chr15:45254895 chr15:45330209~45332634:- PAAD cis rs8177376 0.727 rs651034 ENSG00000254905.1 RP11-712L6.7 4.05 8.29e-05 0.0289 0.41 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126331563 chr11:126292922~126294254:- PAAD cis rs496547 0.719 rs1790189 ENSG00000255239.1 AP002954.6 4.05 8.29e-05 0.0289 0.38 0.31 Hip minimal joint space width; chr11:118781617 chr11:118688039~118690600:- PAAD cis rs61270009 0.687 rs10942530 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Depressive symptoms; chr5:88414221 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs10942531 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88414280 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs10505857 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88420376 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs71639110 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88422222 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs71639111 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88428788 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs13185071 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88429895 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs4601863 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88433804 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs34634636 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88435989 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs34394411 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88436903 chr5:88268895~88436685:+ PAAD cis rs73173548 0.528 rs34182576 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88438321 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs4423262 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88438609 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs10505855 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88440962 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs4129235 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88441465 chr5:88268895~88436685:+ PAAD cis rs61270009 0.731 rs13189022 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Depressive symptoms; chr5:88445017 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs6867204 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88446423 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs34933255 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88446492 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs12188494 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88447747 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs6865869 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88449645 chr5:88268895~88436685:+ PAAD cis rs61270009 0.738 rs12659772 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Depressive symptoms; chr5:88451917 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs12659818 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88451964 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs12653074 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88452920 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs76393802 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88455311 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs10942532 ENSG00000247828.6 TMEM161B-AS1 4.05 8.29e-05 0.0289 0.26 0.31 Macular telangiectasia type 2; chr5:88462015 chr5:88268895~88436685:+ PAAD cis rs7202877 0.706 rs2059257 ENSG00000261783.1 RP11-252K23.2 -4.04 8.3e-05 0.0289 -0.49 -0.31 Type 1 diabetes;Type 2 diabetes; chr16:75362478 chr16:75379818~75381260:- PAAD cis rs11168351 0.927 rs7971880 ENSG00000240399.1 RP1-228P16.1 4.04 8.3e-05 0.0289 0.33 0.31 Bipolar disorder and schizophrenia; chr12:47997272 chr12:48054813~48055591:- PAAD cis rs10779751 0.96 rs4845860 ENSG00000238199.1 UBE2V2P3 -4.04 8.3e-05 0.0289 -0.37 -0.31 Body mass index; chr1:11264136 chr1:11278616~11279351:- PAAD cis rs10838687 0.736 rs3781619 ENSG00000255007.1 CTD-2589M5.4 4.04 8.3e-05 0.0289 0.37 0.31 Proinsulin levels; chr11:47233766 chr11:46256355~46274547:- PAAD cis rs3015497 0.763 rs2934689 ENSG00000270062.1 RP11-248J18.3 4.04 8.3e-05 0.0289 0.29 0.31 Mean platelet volume; chr14:50651609 chr14:50723777~50724272:- PAAD cis rs4853525 0.859 rs1882396 ENSG00000235852.1 AC005540.3 4.04 8.3e-05 0.0289 0.41 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190851286 chr2:190880797~190882059:- PAAD cis rs4853525 0.859 rs1894775 ENSG00000235852.1 AC005540.3 4.04 8.3e-05 0.0289 0.41 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190851980 chr2:190880797~190882059:- PAAD cis rs4853525 0.818 rs4853520 ENSG00000235852.1 AC005540.3 4.04 8.3e-05 0.0289 0.41 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190854772 chr2:190880797~190882059:- PAAD cis rs4853525 0.859 rs1882397 ENSG00000235852.1 AC005540.3 4.04 8.3e-05 0.0289 0.41 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190855406 chr2:190880797~190882059:- PAAD cis rs227932 0.764 rs78660981 ENSG00000234286.1 AC006026.13 -4.04 8.3e-05 0.0289 -0.51 -0.31 Schizophrenia; chr7:23719296 chr7:23680195~23680786:- PAAD cis rs780096 0.527 rs11127044 ENSG00000234072.1 AC074117.10 -4.04 8.31e-05 0.0289 -0.24 -0.31 Total body bone mineral density; chr2:27517537 chr2:27356246~27367622:+ PAAD cis rs6700559 0.703 rs10919993 ENSG00000260088.1 RP11-92G12.3 4.04 8.31e-05 0.0289 0.42 0.31 Coronary artery disease; chr1:200658184 chr1:200669507~200694250:+ PAAD cis rs2486288 0.656 rs1719236 ENSG00000259433.2 CTD-2651B20.4 4.04 8.31e-05 0.0289 0.35 0.31 Glomerular filtration rate; chr15:45285585 chr15:45330209~45332634:- PAAD cis rs7617773 0.817 rs6806112 ENSG00000228638.1 FCF1P2 -4.04 8.31e-05 0.0289 -0.34 -0.31 Coronary artery disease; chr3:48234587 chr3:48290793~48291375:- PAAD cis rs4713118 0.662 rs149946 ENSG00000204709.4 LINC01556 -4.04 8.31e-05 0.0289 -0.52 -0.31 Parkinson's disease; chr6:28002253 chr6:28943877~28944537:+ PAAD cis rs4713118 0.662 rs149947 ENSG00000204709.4 LINC01556 4.04 8.31e-05 0.0289 0.52 0.31 Parkinson's disease; chr6:28004655 chr6:28943877~28944537:+ PAAD cis rs919433 0.68 rs2605039 ENSG00000231621.1 AC013264.2 -4.04 8.32e-05 0.029 -0.31 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197498127 chr2:197197991~197199273:+ PAAD cis rs9322193 0.566 rs5024811 ENSG00000268592.3 RAET1E-AS1 -4.04 8.32e-05 0.029 -0.4 -0.31 Lung cancer; chr6:149924898 chr6:149863494~149919507:+ PAAD cis rs1275468 0.731 rs2652022 ENSG00000257497.2 RP11-585P4.5 -4.04 8.32e-05 0.029 -0.49 -0.31 Polycystic ovary syndrome; chr12:75586771 chr12:75483454~75489820:- PAAD cis rs7429990 0.965 rs1550914 ENSG00000228638.1 FCF1P2 -4.04 8.32e-05 0.029 -0.35 -0.31 Educational attainment (years of education); chr3:47953678 chr3:48290793~48291375:- PAAD cis rs12507634 0.6 rs7687806 ENSG00000251216.1 RP11-161D15.3 -4.04 8.32e-05 0.029 -0.36 -0.31 Thiazide-induced adverse metabolic effects in hypertensive patients; chr4:174138117 chr4:173924207~173990861:- PAAD cis rs12507634 0.6 rs4695912 ENSG00000251216.1 RP11-161D15.3 -4.04 8.32e-05 0.029 -0.36 -0.31 Thiazide-induced adverse metabolic effects in hypertensive patients; chr4:174138232 chr4:173924207~173990861:- PAAD cis rs2439831 0.85 rs8042868 ENSG00000275601.1 AC011330.13 -4.04 8.33e-05 0.029 -0.56 -0.31 Lung cancer in ever smokers; chr15:43647444 chr15:43642389~43643023:- PAAD cis rs2522056 0.808 rs1016988 ENSG00000233006.5 AC034220.3 -4.04 8.33e-05 0.029 -0.29 -0.31 Fibrinogen;Lymphocyte counts; chr5:132408882 chr5:132311285~132369916:- PAAD cis rs950169 0.58 rs2271431 ENSG00000259728.4 LINC00933 4.04 8.35e-05 0.029 0.39 0.31 Schizophrenia; chr15:84646233 chr15:84570649~84580175:+ PAAD cis rs6909229 0.778 rs1946390 ENSG00000233893.1 EZR-AS1 -4.04 8.35e-05 0.029 -0.43 -0.31 Lipoprotein (a) levels; chr6:158134598 chr6:158818011~158820593:+ PAAD cis rs12908161 0.959 rs2175567 ENSG00000259295.5 CSPG4P12 4.04 8.35e-05 0.029 0.35 0.31 Schizophrenia; chr15:84657715 chr15:85191438~85213905:+ PAAD cis rs6991838 0.798 rs62507575 ENSG00000200714.1 Y_RNA 4.04 8.36e-05 0.0291 0.36 0.31 Intelligence (multi-trait analysis); chr8:65566486 chr8:65592731~65592820:+ PAAD cis rs10779751 1 rs11121711 ENSG00000238199.1 UBE2V2P3 -4.04 8.36e-05 0.0291 -0.38 -0.31 Body mass index; chr1:11257604 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs7525957 ENSG00000238199.1 UBE2V2P3 -4.04 8.36e-05 0.0291 -0.38 -0.31 Body mass index; chr1:11258179 chr1:11278616~11279351:- PAAD cis rs728616 0.764 rs75385771 ENSG00000225484.5 NUTM2B-AS1 -4.04 8.36e-05 0.0291 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79933023 chr10:79663088~79826594:- PAAD cis rs728616 0.867 rs17883671 ENSG00000225484.5 NUTM2B-AS1 -4.04 8.36e-05 0.0291 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79935437 chr10:79663088~79826594:- PAAD cis rs728616 0.867 rs17885031 ENSG00000225484.5 NUTM2B-AS1 -4.04 8.36e-05 0.0291 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79936335 chr10:79663088~79826594:- PAAD cis rs728616 0.867 rs3088308 ENSG00000225484.5 NUTM2B-AS1 -4.04 8.36e-05 0.0291 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79938112 chr10:79663088~79826594:- PAAD cis rs728616 0.867 rs17879726 ENSG00000225484.5 NUTM2B-AS1 -4.04 8.36e-05 0.0291 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79938967 chr10:79663088~79826594:- PAAD cis rs12439619 0.921 rs4778672 ENSG00000255769.6 GOLGA2P10 4.04 8.37e-05 0.0291 0.36 0.31 Intelligence (multi-trait analysis); chr15:82245013 chr15:82472993~82513950:- PAAD cis rs950880 0.553 rs2241116 ENSG00000234389.1 AC007278.3 -4.04 8.37e-05 0.0291 -0.37 -0.31 Serum protein levels (sST2); chr2:102386805 chr2:102438713~102440475:+ PAAD cis rs12908161 0.959 rs1051168 ENSG00000259728.4 LINC00933 4.04 8.37e-05 0.0291 0.39 0.31 Schizophrenia; chr15:84657289 chr15:84570649~84580175:+ PAAD cis rs17201317 0.64 rs10505036 ENSG00000272037.1 KB-431C1.5 4.04 8.37e-05 0.0291 0.26 0.31 Small vessel stroke; chr8:103103452 chr8:102256392~102257821:+ PAAD cis rs2688608 0.592 rs7923045 ENSG00000271816.1 BMS1P4 4.04 8.37e-05 0.0291 0.31 0.31 Inflammatory bowel disease; chr10:73727740 chr10:73699151~73730487:- PAAD cis rs73173548 0.502 rs13165428 ENSG00000247828.6 TMEM161B-AS1 -4.04 8.38e-05 0.0291 -0.25 -0.31 Macular telangiectasia type 2; chr5:88443945 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs34743961 ENSG00000247828.6 TMEM161B-AS1 4.04 8.38e-05 0.0291 0.25 0.31 Macular telangiectasia type 2; chr5:88435952 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs4129236 ENSG00000247828.6 TMEM161B-AS1 4.04 8.38e-05 0.0291 0.25 0.31 Macular telangiectasia type 2; chr5:88441542 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs36077166 ENSG00000247828.6 TMEM161B-AS1 4.04 8.38e-05 0.0291 0.25 0.31 Macular telangiectasia type 2; chr5:88441770 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs13165211 ENSG00000247828.6 TMEM161B-AS1 4.04 8.38e-05 0.0291 0.25 0.31 Macular telangiectasia type 2; chr5:88443772 chr5:88268895~88436685:+ PAAD cis rs73173548 0.528 rs68019847 ENSG00000247828.6 TMEM161B-AS1 4.04 8.38e-05 0.0291 0.25 0.31 Macular telangiectasia type 2; chr5:88446795 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs34969608 ENSG00000247828.6 TMEM161B-AS1 4.04 8.38e-05 0.0291 0.25 0.31 Macular telangiectasia type 2; chr5:88448606 chr5:88268895~88436685:+ PAAD cis rs73173548 0.502 rs6885165 ENSG00000247828.6 TMEM161B-AS1 4.04 8.38e-05 0.0291 0.25 0.31 Macular telangiectasia type 2; chr5:88449705 chr5:88268895~88436685:+ PAAD cis rs7189233 0.531 rs8061398 ENSG00000279344.1 RP11-44F14.7 4.04 8.38e-05 0.0291 0.23 0.31 Intelligence (multi-trait analysis); chr16:53420239 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs8056349 ENSG00000279344.1 RP11-44F14.7 4.04 8.38e-05 0.0291 0.23 0.31 Intelligence (multi-trait analysis); chr16:53434114 chr16:53478957~53481550:- PAAD cis rs13256369 0.802 rs13281933 ENSG00000253981.4 ALG1L13P 4.04 8.39e-05 0.0291 0.42 0.31 Obesity-related traits; chr8:8705155 chr8:8236003~8244667:- PAAD cis rs858239 0.509 rs57611130 ENSG00000226816.2 AC005082.12 4.04 8.39e-05 0.0292 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23144933 chr7:23206013~23208045:+ PAAD cis rs908366 0.756 rs1254946 ENSG00000273599.1 RP11-59C5.3 4.04 8.39e-05 0.0292 0.21 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin); chr10:124466266 chr10:124996064~125001491:+ PAAD cis rs17772222 0.63 rs7141608 ENSG00000258983.2 RP11-507K2.2 -4.04 8.39e-05 0.0292 -0.38 -0.31 Coronary artery calcification; chr14:88514045 chr14:88499334~88515502:+ PAAD cis rs7911264 0.905 rs7918084 ENSG00000236493.2 EIF2S2P3 4.04 8.4e-05 0.0292 0.4 0.31 Inflammatory bowel disease; chr10:92669710 chr10:92668745~92669743:- PAAD cis rs919433 0.68 rs1563340 ENSG00000231621.1 AC013264.2 -4.04 8.4e-05 0.0292 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197549989 chr2:197197991~197199273:+ PAAD cis rs7120173 0.693 rs12799198 ENSG00000231865.1 SIK3-IT1 -4.04 8.4e-05 0.0292 -0.42 -0.31 Visceral adipose tissue adjusted for BMI; chr11:116930706 chr11:116886046~116890721:- PAAD cis rs875971 0.929 rs34406470 ENSG00000232559.3 GS1-124K5.12 4.04 8.41e-05 0.0292 0.34 0.31 Aortic root size; chr7:66464969 chr7:66554588~66576923:- PAAD cis rs12118297 0.882 rs6689223 ENSG00000236915.1 RP4-651E10.4 -4.04 8.42e-05 0.0292 -0.48 -0.31 Breast cancer; chr1:87301704 chr1:86571181~86693203:- PAAD cis rs6545883 0.507 rs2123111 ENSG00000271889.1 RP11-493E12.1 -4.04 8.42e-05 0.0292 -0.33 -0.31 Tuberculosis; chr2:61223319 chr2:61151433~61162105:- PAAD cis rs2638953 0.815 rs11049696 ENSG00000247934.4 RP11-967K21.1 -4.04 8.42e-05 0.0292 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28528922 chr12:28163298~28190738:- PAAD cis rs1062177 1 rs12515762 ENSG00000253921.1 CTB-113P19.3 -4.04 8.42e-05 0.0292 -0.4 -0.31 Preschool internalizing problems; chr5:151830361 chr5:151753992~151767247:+ PAAD cis rs1275468 0.731 rs1480002 ENSG00000257497.2 RP11-585P4.5 -4.04 8.42e-05 0.0292 -0.49 -0.31 Polycystic ovary syndrome; chr12:75587184 chr12:75483454~75489820:- PAAD cis rs10506328 0.509 rs57281063 ENSG00000248265.1 FLJ12825 4.04 8.42e-05 0.0292 0.27 0.31 Mean platelet volume; chr12:54266643 chr12:54058254~54122234:+ PAAD cis rs10506328 0.509 rs4759074 ENSG00000248265.1 FLJ12825 4.04 8.42e-05 0.0292 0.27 0.31 Mean platelet volume; chr12:54270313 chr12:54058254~54122234:+ PAAD cis rs72615157 0.697 rs2056726 ENSG00000242294.5 STAG3L5P 4.04 8.42e-05 0.0292 0.25 0.31 Lung function (FEV1/FVC); chr7:100182660 chr7:100336079~100351900:+ PAAD cis rs1862618 0.853 rs10051747 ENSG00000271828.1 CTD-2310F14.1 4.04 8.43e-05 0.0292 0.45 0.31 Initial pursuit acceleration; chr5:56787462 chr5:56927874~56929573:+ PAAD cis rs1862618 0.715 rs6866779 ENSG00000271828.1 CTD-2310F14.1 4.04 8.43e-05 0.0292 0.45 0.31 Initial pursuit acceleration; chr5:56794173 chr5:56927874~56929573:+ PAAD cis rs42490 0.716 rs42346 ENSG00000251136.7 RP11-37B2.1 4.04 8.43e-05 0.0292 0.28 0.31 Leprosy; chr8:89816829 chr8:89609409~89757727:- PAAD cis rs13178541 0.872 rs7447059 ENSG00000250378.1 RP11-119J18.1 -4.04 8.43e-05 0.0293 -0.48 -0.31 IgG glycosylation; chr5:135790308 chr5:135812667~135826582:+ PAAD cis rs13178541 0.817 rs7449192 ENSG00000250378.1 RP11-119J18.1 -4.04 8.43e-05 0.0293 -0.48 -0.31 IgG glycosylation; chr5:135793068 chr5:135812667~135826582:+ PAAD cis rs13178541 0.873 rs11745158 ENSG00000250378.1 RP11-119J18.1 -4.04 8.43e-05 0.0293 -0.48 -0.31 IgG glycosylation; chr5:135794701 chr5:135812667~135826582:+ PAAD cis rs11892454 0.515 rs11888036 ENSG00000217643.1 PTGES3P2 4.04 8.43e-05 0.0293 0.33 0.31 Heschl's gyrus morphology; chr2:25840906 chr2:25822469~25822950:+ PAAD cis rs520525 0.963 rs552277 ENSG00000271811.1 RP1-79C4.4 4.04 8.43e-05 0.0293 0.33 0.31 Atrial fibrillation; chr1:170658653 chr1:170667381~170669425:+ PAAD cis rs9876781 1 rs13091785 ENSG00000229759.1 MRPS18AP1 4.04 8.44e-05 0.0293 0.34 0.31 Longevity; chr3:48452692 chr3:48256350~48256938:- PAAD cis rs6908034 0.66 rs74795718 ENSG00000228412.5 RP4-625H18.2 4.04 8.44e-05 0.0293 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19782068 chr6:19802164~19804752:- PAAD cis rs6908034 0.556 rs79028848 ENSG00000228412.5 RP4-625H18.2 4.04 8.44e-05 0.0293 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19782922 chr6:19802164~19804752:- PAAD cis rs6908034 0.66 rs6918235 ENSG00000228412.5 RP4-625H18.2 4.04 8.44e-05 0.0293 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19788196 chr6:19802164~19804752:- PAAD cis rs41369048 0.669 rs80327434 ENSG00000238078.1 LINC01352 -4.04 8.44e-05 0.0293 -0.45 -0.31 Eosinophil counts;Sum eosinophil basophil counts; chr1:220850961 chr1:220829255~220832429:+ PAAD cis rs41369048 0.669 rs77986094 ENSG00000238078.1 LINC01352 -4.04 8.44e-05 0.0293 -0.45 -0.31 Eosinophil counts;Sum eosinophil basophil counts; chr1:220854514 chr1:220829255~220832429:+ PAAD cis rs41369048 0.669 rs11586003 ENSG00000238078.1 LINC01352 -4.04 8.44e-05 0.0293 -0.45 -0.31 Eosinophil counts;Sum eosinophil basophil counts; chr1:220866816 chr1:220829255~220832429:+ PAAD cis rs160451 0.782 rs6999425 ENSG00000251136.7 RP11-37B2.1 4.04 8.45e-05 0.0293 0.3 0.31 Leprosy; chr8:89694952 chr8:89609409~89757727:- PAAD cis rs160451 0.811 rs218943 ENSG00000251136.7 RP11-37B2.1 -4.04 8.45e-05 0.0293 -0.3 -0.31 Leprosy; chr8:89701113 chr8:89609409~89757727:- PAAD cis rs919433 0.854 rs13013049 ENSG00000231621.1 AC013264.2 4.04 8.45e-05 0.0293 0.3 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197343940 chr2:197197991~197199273:+ PAAD cis rs780096 0.587 rs6760828 ENSG00000234072.1 AC074117.10 -4.04 8.45e-05 0.0293 -0.24 -0.31 Total body bone mineral density; chr2:27356364 chr2:27356246~27367622:+ PAAD cis rs847577 0.609 rs17435590 ENSG00000272950.1 RP11-307C18.1 4.04 8.45e-05 0.0293 0.39 0.31 Breast cancer; chr7:98154749 chr7:98322853~98323430:+ PAAD cis rs847577 0.609 rs34320230 ENSG00000272950.1 RP11-307C18.1 4.04 8.45e-05 0.0293 0.39 0.31 Breast cancer; chr7:98156188 chr7:98322853~98323430:+ PAAD cis rs847577 0.588 rs12666406 ENSG00000272950.1 RP11-307C18.1 4.04 8.45e-05 0.0293 0.39 0.31 Breast cancer; chr7:98161679 chr7:98322853~98323430:+ PAAD cis rs847577 0.609 rs17435847 ENSG00000272950.1 RP11-307C18.1 4.04 8.45e-05 0.0293 0.39 0.31 Breast cancer; chr7:98163508 chr7:98322853~98323430:+ PAAD cis rs2985684 0.74 rs2883438 ENSG00000259113.1 RP11-406H23.2 -4.04 8.46e-05 0.0293 -0.43 -0.31 Carotid intima media thickness; chr14:49577674 chr14:50448807~50456742:+ PAAD cis rs9595908 1 rs9595908 ENSG00000212293.1 SNORA16 4.04 8.46e-05 0.0293 0.36 0.31 Body mass index; chr13:32610151 chr13:32420390~32420516:- PAAD cis rs3781264 0.595 rs11187853 ENSG00000273450.1 RP11-76P2.4 4.04 8.46e-05 0.0293 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94312471 chr10:94314907~94315327:- PAAD cis rs875971 0.965 rs697968 ENSG00000232559.3 GS1-124K5.12 -4.04 8.46e-05 0.0293 -0.33 -0.31 Aortic root size; chr7:66070046 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1167411 ENSG00000232559.3 GS1-124K5.12 -4.04 8.46e-05 0.0293 -0.33 -0.31 Aortic root size; chr7:66074277 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1183245 ENSG00000232559.3 GS1-124K5.12 -4.04 8.46e-05 0.0293 -0.33 -0.31 Aortic root size; chr7:66076198 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1144895 ENSG00000232559.3 GS1-124K5.12 -4.04 8.46e-05 0.0293 -0.33 -0.31 Aortic root size; chr7:66076320 chr7:66554588~66576923:- PAAD cis rs875971 1 rs1144894 ENSG00000232559.3 GS1-124K5.12 -4.04 8.46e-05 0.0293 -0.33 -0.31 Aortic root size; chr7:66077907 chr7:66554588~66576923:- PAAD cis rs7586673 0.621 rs4999196 ENSG00000227403.1 AC009299.3 -4.04 8.46e-05 0.0293 -0.55 -0.31 Intelligence (multi-trait analysis); chr2:161114824 chr2:161244739~161249050:+ PAAD cis rs7189233 0.55 rs13330182 ENSG00000279344.1 RP11-44F14.7 4.04 8.47e-05 0.0294 0.23 0.31 Intelligence (multi-trait analysis); chr16:53438473 chr16:53478957~53481550:- PAAD cis rs7189233 0.531 rs16952246 ENSG00000279344.1 RP11-44F14.7 4.04 8.47e-05 0.0294 0.23 0.31 Intelligence (multi-trait analysis); chr16:53446797 chr16:53478957~53481550:- PAAD cis rs950169 0.922 rs12910334 ENSG00000275120.1 RP11-182J1.17 4.04 8.48e-05 0.0294 0.33 0.31 Schizophrenia; chr15:84403620 chr15:84599434~84606463:- PAAD cis rs2288884 0.515 rs11084133 ENSG00000275055.1 CTC-471J1.11 -4.04 8.48e-05 0.0294 -0.42 -0.31 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52041125 chr19:52049007~52049754:+ PAAD cis rs2288884 0.537 rs12151130 ENSG00000275055.1 CTC-471J1.11 -4.04 8.48e-05 0.0294 -0.42 -0.31 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52060531 chr19:52049007~52049754:+ PAAD cis rs11089937 0.667 rs10483107 ENSG00000211638.2 IGLV8-61 -4.04 8.48e-05 0.0294 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22151036 chr22:22098700~22099212:+ PAAD cis rs11089937 0.667 rs11704024 ENSG00000211638.2 IGLV8-61 -4.04 8.48e-05 0.0294 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22151195 chr22:22098700~22099212:+ PAAD cis rs11089937 0.667 rs10483108 ENSG00000211638.2 IGLV8-61 -4.04 8.48e-05 0.0294 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22152664 chr22:22098700~22099212:+ PAAD cis rs10411161 0.702 rs10403189 ENSG00000270248.1 CTC-471J1.10 -4.04 8.48e-05 0.0294 -0.56 -0.31 Breast cancer; chr19:51897420 chr19:52110318~52110726:- PAAD cis rs72843506 0.722 rs16964352 ENSG00000154898.14 CCDC144CP 4.04 8.48e-05 0.0294 0.55 0.31 Schizophrenia; chr17:20245095 chr17:20321164~20403557:+ PAAD cis rs11098499 0.954 rs6820115 ENSG00000248280.1 RP11-33B1.2 4.04 8.48e-05 0.0294 0.3 0.31 Corneal astigmatism; chr4:119477027 chr4:119440561~119450157:- PAAD cis rs11096990 0.613 rs1451821 ENSG00000249685.1 RP11-360F5.3 -4.04 8.48e-05 0.0294 -0.32 -0.31 Cognitive function; chr4:39178797 chr4:39133913~39135608:+ PAAD cis rs2243480 1 rs6964530 ENSG00000273142.1 RP11-458F8.4 4.04 8.49e-05 0.0294 0.28 0.31 Diabetic kidney disease; chr7:66253864 chr7:66902857~66906297:+ PAAD cis rs6472235 0.967 rs59282311 ENSG00000200714.1 Y_RNA -4.04 8.49e-05 0.0294 -0.41 -0.31 Plateletcrit;Myopia (pathological); chr8:65974221 chr8:65592731~65592820:+ PAAD cis rs6472235 0.967 rs7000670 ENSG00000200714.1 Y_RNA -4.04 8.49e-05 0.0294 -0.41 -0.31 Plateletcrit;Myopia (pathological); chr8:65975261 chr8:65592731~65592820:+ PAAD cis rs6472235 0.967 rs56249745 ENSG00000200714.1 Y_RNA -4.04 8.49e-05 0.0294 -0.41 -0.31 Plateletcrit;Myopia (pathological); chr8:65976359 chr8:65592731~65592820:+ PAAD cis rs6472235 0.967 rs7012332 ENSG00000200714.1 Y_RNA -4.04 8.49e-05 0.0294 -0.41 -0.31 Plateletcrit;Myopia (pathological); chr8:65977849 chr8:65592731~65592820:+ PAAD cis rs2188561 0.697 rs4730258 ENSG00000241764.3 AC002467.7 4.04 8.49e-05 0.0294 0.4 0.31 Alcohol consumption; chr7:107755787 chr7:107742817~107744581:- PAAD cis rs1841770 0.521 rs1870000 ENSG00000241627.3 UBQLN4P1 -4.04 8.5e-05 0.0294 -0.39 -0.31 Multiple sclerosis; chr3:148069804 chr3:148985868~148987668:- PAAD cis rs2243480 0.908 rs4718273 ENSG00000228409.4 CCT6P1 -4.04 8.5e-05 0.0294 -0.33 -0.31 Diabetic kidney disease; chr7:65751112 chr7:65751142~65763354:+ PAAD cis rs34375054 0.624 rs73233307 ENSG00000279233.1 RP11-158L12.4 4.04 8.5e-05 0.0294 0.27 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125191327 chr12:125138245~125141711:+ PAAD cis rs34375054 0.624 rs12580033 ENSG00000279233.1 RP11-158L12.4 4.04 8.5e-05 0.0294 0.27 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125191537 chr12:125138245~125141711:+ PAAD cis rs5167 0.539 rs4803783 ENSG00000280087.1 CTB-129P6.7 -4.04 8.5e-05 0.0294 -0.39 -0.31 Blood protein levels; chr19:44967201 chr19:44909375~44914968:+ PAAD cis rs6951245 1 rs74785791 ENSG00000229043.2 AC091729.9 -4.04 8.5e-05 0.0294 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1048858 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs74366004 ENSG00000229043.2 AC091729.9 -4.04 8.5e-05 0.0294 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1048994 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs77702926 ENSG00000229043.2 AC091729.9 -4.04 8.5e-05 0.0294 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1049202 chr7:1160374~1165267:+ PAAD cis rs6951245 0.935 rs78573577 ENSG00000229043.2 AC091729.9 -4.04 8.5e-05 0.0294 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1049451 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs76129108 ENSG00000229043.2 AC091729.9 -4.04 8.5e-05 0.0294 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1049523 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs78523927 ENSG00000229043.2 AC091729.9 -4.04 8.5e-05 0.0294 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1049822 chr7:1160374~1165267:+ PAAD cis rs748404 0.626 rs62021176 ENSG00000205771.5 CATSPER2P1 -4.04 8.5e-05 0.0294 -0.51 -0.31 Lung cancer; chr15:43388014 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs35158584 ENSG00000205771.5 CATSPER2P1 -4.04 8.5e-05 0.0294 -0.51 -0.31 Lung cancer; chr15:43392876 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs7180812 ENSG00000205771.5 CATSPER2P1 -4.04 8.5e-05 0.0294 -0.51 -0.31 Lung cancer; chr15:43403033 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs12908460 ENSG00000205771.5 CATSPER2P1 -4.04 8.5e-05 0.0294 -0.51 -0.31 Lung cancer; chr15:43413472 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs2230451 ENSG00000205771.5 CATSPER2P1 -4.04 8.5e-05 0.0294 -0.51 -0.31 Lung cancer; chr15:43415610 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs16957715 ENSG00000205771.5 CATSPER2P1 -4.04 8.5e-05 0.0294 -0.51 -0.31 Lung cancer; chr15:43416539 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs62021180 ENSG00000205771.5 CATSPER2P1 -4.04 8.5e-05 0.0294 -0.51 -0.31 Lung cancer; chr15:43420139 chr15:43726918~43747094:- PAAD cis rs193541 0.632 rs4835896 ENSG00000263432.2 RN7SL689P -4.04 8.51e-05 0.0295 -0.4 -0.31 Glucose homeostasis traits; chr5:122785545 chr5:123022487~123022783:- PAAD cis rs4664293 0.565 rs10165197 ENSG00000226266.5 AC009961.3 4.04 8.51e-05 0.0295 0.41 0.31 Monocyte percentage of white cells; chr2:159537137 chr2:159670708~159712435:- PAAD cis rs62103177 0.535 rs34299914 ENSG00000261126.6 RP11-795F19.1 4.04 8.51e-05 0.0295 0.43 0.31 Opioid sensitivity; chr18:80191353 chr18:80046900~80095482:+ PAAD cis rs1707322 0.752 rs11488313 ENSG00000280836.1 AL355480.1 -4.04 8.51e-05 0.0295 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45759108 chr1:45581219~45581321:- PAAD cis rs1707322 0.685 rs11211177 ENSG00000280836.1 AL355480.1 -4.04 8.51e-05 0.0295 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45760677 chr1:45581219~45581321:- PAAD cis rs2739330 0.828 rs5760108 ENSG00000206090.4 AP000350.7 4.04 8.52e-05 0.0295 0.39 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23939998~23942798:+ PAAD cis rs6545883 0.507 rs4672427 ENSG00000271889.1 RP11-493E12.1 -4.04 8.52e-05 0.0295 -0.33 -0.31 Tuberculosis; chr2:61242115 chr2:61151433~61162105:- PAAD cis rs1062177 0.826 rs2915879 ENSG00000253921.1 CTB-113P19.3 -4.04 8.52e-05 0.0295 -0.39 -0.31 Preschool internalizing problems; chr5:151767881 chr5:151753992~151767247:+ PAAD cis rs8026198 0.929 rs6493027 ENSG00000260571.1 BNIP3P5 4.04 8.52e-05 0.0295 0.5 0.31 Fibrinogen levels; chr15:42258247 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs12917101 ENSG00000260571.1 BNIP3P5 4.04 8.52e-05 0.0295 0.5 0.31 Fibrinogen levels; chr15:42263673 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs10851407 ENSG00000260571.1 BNIP3P5 4.04 8.52e-05 0.0295 0.5 0.31 Fibrinogen levels; chr15:42267595 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs10851408 ENSG00000260571.1 BNIP3P5 4.04 8.52e-05 0.0295 0.5 0.31 Fibrinogen levels; chr15:42269660 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs4244587 ENSG00000260571.1 BNIP3P5 4.04 8.52e-05 0.0295 0.5 0.31 Fibrinogen levels; chr15:42272171 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs2412682 ENSG00000260571.1 BNIP3P5 4.04 8.52e-05 0.0295 0.5 0.31 Fibrinogen levels; chr15:42274789 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs4924648 ENSG00000260571.1 BNIP3P5 4.04 8.52e-05 0.0295 0.5 0.31 Fibrinogen levels; chr15:42275306 chr15:42313687~42314386:+ PAAD cis rs7182621 0.546 rs11632596 ENSG00000182397.13 DNM1P46 4.04 8.52e-05 0.0295 0.38 0.31 Colonoscopy-negative controls vs population controls; chr15:99834385 chr15:99790156~99806927:- PAAD cis rs896655 0.71 rs10811587 ENSG00000266446.1 RP11-149I2.4 -4.04 8.53e-05 0.0295 -0.37 -0.31 Coronary artery disease; chr9:21703290 chr9:21995482~21996013:+ PAAD cis rs9487094 0.626 rs3799849 ENSG00000260273.1 RP11-425D10.10 4.04 8.53e-05 0.0295 0.38 0.31 Height; chr6:109715560 chr6:109382795~109383666:+ PAAD cis rs7429990 0.866 rs3732529 ENSG00000228638.1 FCF1P2 -4.04 8.54e-05 0.0296 -0.35 -0.31 Educational attainment (years of education); chr3:47928619 chr3:48290793~48291375:- PAAD cis rs7429990 0.932 rs60446735 ENSG00000228638.1 FCF1P2 -4.04 8.54e-05 0.0296 -0.35 -0.31 Educational attainment (years of education); chr3:47929958 chr3:48290793~48291375:- PAAD cis rs7615952 0.611 rs9681518 ENSG00000239804.1 RP11-379B18.1 4.04 8.54e-05 0.0296 0.54 0.31 Blood pressure (smoking interaction); chr3:125896287 chr3:125787888~125788146:- PAAD cis rs2348418 0.832 rs4930822 ENSG00000247934.4 RP11-967K21.1 4.04 8.54e-05 0.0296 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28421789 chr12:28163298~28190738:- PAAD cis rs2348418 0.832 rs4930823 ENSG00000247934.4 RP11-967K21.1 4.04 8.54e-05 0.0296 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28421892 chr12:28163298~28190738:- PAAD cis rs6142102 0.886 rs4911147 ENSG00000276073.1 RP5-1125A11.7 -4.04 8.55e-05 0.0296 -0.33 -0.31 Skin pigmentation; chr20:34079801 chr20:33985617~33988989:- PAAD cis rs1927790 0.759 rs4771935 ENSG00000247400.3 DNAJC3-AS1 -4.04 8.55e-05 0.0296 -0.29 -0.31 Body mass index; chr13:96344648 chr13:95648733~95676925:- PAAD cis rs1927790 0.759 rs9554345 ENSG00000247400.3 DNAJC3-AS1 -4.04 8.55e-05 0.0296 -0.29 -0.31 Body mass index; chr13:96344879 chr13:95648733~95676925:- PAAD cis rs6540731 1 rs11119885 ENSG00000229983.1 RP11-15I11.2 4.04 8.55e-05 0.0296 0.36 0.31 Intelligence (childhood); chr1:212227656 chr1:212168207~212190259:+ PAAD cis rs11997175 0.766 rs60855034 ENSG00000240738.1 RP1-273G13.1 4.04 8.56e-05 0.0296 0.35 0.31 Body mass index; chr8:33827214 chr8:33859480~33860223:- PAAD cis rs11997175 0.766 rs4733176 ENSG00000240738.1 RP1-273G13.1 4.04 8.56e-05 0.0296 0.35 0.31 Body mass index; chr8:33827816 chr8:33859480~33860223:- PAAD cis rs11997175 0.766 rs56803376 ENSG00000240738.1 RP1-273G13.1 4.04 8.56e-05 0.0296 0.35 0.31 Body mass index; chr8:33830158 chr8:33859480~33860223:- PAAD cis rs303386 0.689 rs302749 ENSG00000223656.1 HMGB3P10 4.04 8.56e-05 0.0296 0.41 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin); chr1:99132094 chr1:99698242~99699178:+ PAAD cis rs9649213 0.574 rs7802541 ENSG00000272950.1 RP11-307C18.1 4.04 8.57e-05 0.0296 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98304543 chr7:98322853~98323430:+ PAAD cis rs755249 0.508 rs10888688 ENSG00000237624.1 OXCT2P1 -4.04 8.57e-05 0.0296 -0.4 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39171633 chr1:39514956~39516490:+ PAAD cis rs889398 1 rs889399 ENSG00000226232.7 RP11-419C5.2 4.04 8.57e-05 0.0296 0.26 0.31 Body mass index; chr16:69522680 chr16:69976388~69996188:- PAAD cis rs867371 1 rs8042464 ENSG00000259429.4 UBE2Q2P2 -4.04 8.57e-05 0.0296 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82173195 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs8041868 ENSG00000259429.4 UBE2Q2P2 -4.04 8.57e-05 0.0296 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82179985 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs8041924 ENSG00000259429.4 UBE2Q2P2 -4.04 8.57e-05 0.0296 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82181320 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs2088858 ENSG00000259429.4 UBE2Q2P2 -4.04 8.57e-05 0.0296 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82182408 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs4778982 ENSG00000259429.4 UBE2Q2P2 -4.04 8.57e-05 0.0296 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82182931 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs2867579 ENSG00000259429.4 UBE2Q2P2 -4.04 8.57e-05 0.0296 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82183043 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs881308 ENSG00000259429.4 UBE2Q2P2 -4.04 8.57e-05 0.0296 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82183456 chr15:82355142~82420075:+ PAAD cis rs10170846 0.53 rs56353541 ENSG00000261428.2 RP11-16P6.1 4.04 8.57e-05 0.0296 0.43 0.31 Schizophrenia (inflammation and infection response interaction); chr2:222556468 chr2:222566899~222569719:- PAAD cis rs9531006 0.76 rs7982819 ENSG00000227676.3 LINC01068 -4.04 8.58e-05 0.0296 -0.45 -0.31 Sleep duration; chr13:79939943 chr13:79566727~79571436:+ PAAD cis rs891378 0.785 rs1346720 ENSG00000274245.1 RP11-357P18.2 4.04 8.58e-05 0.0296 0.44 0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207214421 chr1:207372559~207373252:+ PAAD cis rs1799955 1 rs1799955 ENSG00000279314.1 RP1-257C22.2 4.04 8.58e-05 0.0297 0.34 0.31 LDL cholesterol levels; chr13:32355095 chr13:31960325~31961946:- PAAD cis rs17772222 0.606 rs449338 ENSG00000258983.2 RP11-507K2.2 -4.04 8.58e-05 0.0297 -0.37 -0.31 Coronary artery calcification; chr14:88411690 chr14:88499334~88515502:+ PAAD cis rs6921919 0.583 rs7764722 ENSG00000219891.2 ZSCAN12P1 4.04 8.58e-05 0.0297 0.43 0.31 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28091154~28093664:+ PAAD cis rs6539288 0.933 rs1444581 ENSG00000260329.1 RP11-412D9.4 -4.04 8.58e-05 0.0297 -0.26 -0.31 Total body bone mineral density; chr12:106920473 chr12:106954029~106955497:- PAAD cis rs10779751 0.762 rs6540965 ENSG00000238199.1 UBE2V2P3 4.04 8.58e-05 0.0297 0.35 0.31 Body mass index; chr1:11265464 chr1:11278616~11279351:- PAAD cis rs7119038 0.58 rs7123726 ENSG00000255239.1 AP002954.6 -4.04 8.59e-05 0.0297 -0.45 -0.31 Sjögren's syndrome; chr11:118823838 chr11:118688039~118690600:- PAAD cis rs4660214 0.756 rs11205823 ENSG00000228060.1 RP11-69E11.8 4.04 8.59e-05 0.0297 0.3 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39248566 chr1:39565160~39573203:+ PAAD cis rs11098499 0.866 rs10518329 ENSG00000248280.1 RP11-33B1.2 4.04 8.6e-05 0.0297 0.3 0.31 Corneal astigmatism; chr4:119480680 chr4:119440561~119450157:- PAAD cis rs11098499 0.866 rs7665125 ENSG00000248280.1 RP11-33B1.2 4.04 8.6e-05 0.0297 0.3 0.31 Corneal astigmatism; chr4:119480924 chr4:119440561~119450157:- PAAD cis rs10740039 0.842 rs10761539 ENSG00000254271.1 RP11-131N11.4 4.04 8.6e-05 0.0297 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60649733 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs1442546 ENSG00000254271.1 RP11-131N11.4 4.04 8.6e-05 0.0297 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60650240 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs1442545 ENSG00000254271.1 RP11-131N11.4 4.04 8.6e-05 0.0297 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60650268 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs1470237 ENSG00000254271.1 RP11-131N11.4 4.04 8.6e-05 0.0297 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60653381 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs1442540 ENSG00000254271.1 RP11-131N11.4 -4.04 8.6e-05 0.0297 -0.38 -0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60653548 chr10:60734342~60741828:+ PAAD cis rs11089937 0.553 rs35336247 ENSG00000211638.2 IGLV8-61 -4.04 8.6e-05 0.0297 -0.29 -0.31 Periodontitis (PAL4Q3); chr22:22131593 chr22:22098700~22099212:+ PAAD cis rs11089937 0.553 rs34088081 ENSG00000211638.2 IGLV8-61 -4.04 8.6e-05 0.0297 -0.29 -0.31 Periodontitis (PAL4Q3); chr22:22131601 chr22:22098700~22099212:+ PAAD cis rs8072100 0.934 rs6504872 ENSG00000228782.6 CTD-2026D20.3 4.04 8.61e-05 0.0297 0.31 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47361586 chr17:47450568~47492492:- PAAD cis rs2739330 0.587 rs4820571 ENSG00000206090.4 AP000350.7 4.04 8.61e-05 0.0297 0.41 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23939998~23942798:+ PAAD cis rs2638953 0.962 rs61920564 ENSG00000247934.4 RP11-967K21.1 -4.04 8.61e-05 0.0297 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28357000 chr12:28163298~28190738:- PAAD cis rs73219805 1 rs1042992 ENSG00000228451.3 SDAD1P1 4.04 8.61e-05 0.0297 0.44 0.31 Schizophrenia; chr8:26411675 chr8:26379259~26382953:- PAAD cis rs35934224 0.891 rs34249993 ENSG00000232926.1 AC000078.5 4.04 8.62e-05 0.0298 0.43 0.31 Glaucoma (primary open-angle); chr22:19884647 chr22:19887289~19887970:+ PAAD cis rs6479901 0.793 rs7070693 ENSG00000232075.1 MRPL35P2 -4.03 8.62e-05 0.0298 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63256402 chr10:63634317~63634827:- PAAD cis rs13178541 0.641 rs10900841 ENSG00000250378.1 RP11-119J18.1 -4.03 8.63e-05 0.0298 -0.46 -0.31 IgG glycosylation; chr5:135799020 chr5:135812667~135826582:+ PAAD cis rs6071524 1 rs2103655 ENSG00000277581.1 RP4-616B8.6 4.03 8.63e-05 0.0298 0.4 0.31 Autism spectrum disorder or schizophrenia; chr20:38797315 chr20:38962472~38962993:+ PAAD cis rs6071524 1 rs6071524 ENSG00000277581.1 RP4-616B8.6 4.03 8.63e-05 0.0298 0.4 0.31 Autism spectrum disorder or schizophrenia; chr20:38797937 chr20:38962472~38962993:+ PAAD cis rs6071524 0.963 rs6124079 ENSG00000277581.1 RP4-616B8.6 4.03 8.63e-05 0.0298 0.4 0.31 Autism spectrum disorder or schizophrenia; chr20:38810181 chr20:38962472~38962993:+ PAAD cis rs9992667 0.955 rs9998440 ENSG00000231160.8 KLF3-AS1 -4.03 8.63e-05 0.0298 -0.35 -0.31 Eosinophil percentage of granulocytes; chr4:38606180 chr4:38612701~38664883:- PAAD cis rs8005677 1 rs8006396 ENSG00000279656.1 RP11-298I3.6 4.03 8.63e-05 0.0298 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22911641 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs4981446 ENSG00000279656.1 RP11-298I3.6 4.03 8.63e-05 0.0298 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22912204 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs4982706 ENSG00000279656.1 RP11-298I3.6 4.03 8.63e-05 0.0298 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22912488 chr14:23023083~23024217:- PAAD cis rs8005677 0.926 rs34344888 ENSG00000279656.1 RP11-298I3.6 4.03 8.63e-05 0.0298 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22918376 chr14:23023083~23024217:- PAAD cis rs8005677 0.962 rs34917191 ENSG00000279656.1 RP11-298I3.6 4.03 8.63e-05 0.0298 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22918419 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs1951119 ENSG00000279656.1 RP11-298I3.6 4.03 8.63e-05 0.0298 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22919117 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs2295683 ENSG00000279656.1 RP11-298I3.6 4.03 8.63e-05 0.0298 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22919173 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs4981449 ENSG00000279656.1 RP11-298I3.6 4.03 8.63e-05 0.0298 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22919662 chr14:23023083~23024217:- PAAD cis rs9918079 0.56 rs6449153 ENSG00000273133.1 RP11-799M12.2 -4.03 8.64e-05 0.0298 -0.38 -0.31 Obesity-related traits; chr4:15629593 chr4:15563698~15564253:- PAAD cis rs9918079 0.56 rs4698406 ENSG00000273133.1 RP11-799M12.2 -4.03 8.64e-05 0.0298 -0.38 -0.31 Obesity-related traits; chr4:15638994 chr4:15563698~15564253:- PAAD cis rs7178375 0.678 rs34678577 ENSG00000270055.1 CTD-3092A11.2 -4.03 8.64e-05 0.0298 -0.41 -0.31 Hypertriglyceridemia; chr15:30885262 chr15:30487963~30490313:+ PAAD cis rs2562456 0.837 rs62110205 ENSG00000213976.4 CTD-2561J22.2 -4.03 8.64e-05 0.0298 -0.35 -0.31 Pain; chr19:21577269 chr19:21382865~21387177:+ PAAD cis rs5758659 0.622 rs5758527 ENSG00000273366.1 CTA-989H11.1 -4.03 8.64e-05 0.0298 -0.37 -0.31 Cognitive function; chr22:41979757 chr22:42278188~42278846:+ PAAD cis rs2243480 1 rs2243480 ENSG00000232546.1 RP11-458F8.1 -4.03 8.64e-05 0.0298 -0.37 -0.31 Diabetic kidney disease; chr7:66134209 chr7:66848496~66858136:+ PAAD cis rs11690935 0.55 rs4280427 ENSG00000228389.1 AC068039.4 -4.03 8.65e-05 0.0298 -0.39 -0.31 Schizophrenia; chr2:171956692 chr2:171773482~171775844:+ PAAD cis rs11690935 0.531 rs4280428 ENSG00000228389.1 AC068039.4 -4.03 8.65e-05 0.0298 -0.39 -0.31 Schizophrenia; chr2:171956693 chr2:171773482~171775844:+ PAAD cis rs10759883 0.539 rs689744 ENSG00000175611.10 LINC00476 4.03 8.65e-05 0.0298 0.31 0.31 Nicotine dependence; chr9:96040417 chr9:95759231~95875977:- PAAD cis rs10759883 0.539 rs2296858 ENSG00000175611.10 LINC00476 4.03 8.65e-05 0.0298 0.31 0.31 Nicotine dependence; chr9:96041126 chr9:95759231~95875977:- PAAD cis rs7615952 0.688 rs7624806 ENSG00000241288.6 RP11-379B18.5 -4.03 8.65e-05 0.0298 -0.34 -0.31 Blood pressure (smoking interaction); chr3:125880231 chr3:125827238~125916384:- PAAD cis rs2911132 0.66 rs754615 ENSG00000248734.2 CTD-2260A17.1 4.03 8.66e-05 0.0299 0.29 0.31 Urate levels (BMI interaction); chr5:96750630 chr5:96784777~96785999:+ PAAD cis rs2243480 1 rs4718269 ENSG00000228409.4 CCT6P1 -4.03 8.66e-05 0.0299 -0.33 -0.31 Diabetic kidney disease; chr7:65735810 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6460260 ENSG00000228409.4 CCT6P1 -4.03 8.66e-05 0.0299 -0.33 -0.31 Diabetic kidney disease; chr7:65750468 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs6460261 ENSG00000228409.4 CCT6P1 -4.03 8.66e-05 0.0299 -0.33 -0.31 Diabetic kidney disease; chr7:65750593 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs4718270 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65737415 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs2900904 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65739282 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs13247184 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65893941 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35283677 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65894246 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35421653 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65898442 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs73142162 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65909309 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs73142166 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65910845 chr7:65751142~65763354:+ PAAD cis rs2243480 0.908 rs55876148 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65914813 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs56016656 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65918494 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs56291018 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65925352 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs36033484 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65925571 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34193460 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65928123 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34560516 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65939105 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs57057549 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65940751 chr7:65751142~65763354:+ PAAD cis rs2243480 0.808 rs12698508 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65946971 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs2961102 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65959671 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs34970380 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65966506 chr7:65751142~65763354:+ PAAD cis rs2243480 0.901 rs73148097 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65966800 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs906134 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65979301 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs73150014 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:65985932 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1723270 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:66004843 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs1723269 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:66007799 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs781150 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:66015986 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313798 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:66028044 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs35396113 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:66030474 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313809 ENSG00000228409.4 CCT6P1 4.03 8.66e-05 0.0299 0.33 0.31 Diabetic kidney disease; chr7:66034996 chr7:65751142~65763354:+ PAAD cis rs2273156 0.673 rs12887885 ENSG00000258738.1 RP11-73E17.2 -4.03 8.67e-05 0.0299 -0.45 -0.31 Immunoglobulin light chain (AL) amyloidosis; chr14:34906876 chr14:34874343~34876459:+ PAAD cis rs9807989 0.524 rs4851576 ENSG00000234389.1 AC007278.3 4.03 8.67e-05 0.0299 0.31 0.31 Asthma; chr2:102412435 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs4851577 ENSG00000234389.1 AC007278.3 4.03 8.67e-05 0.0299 0.31 0.31 Asthma; chr2:102412461 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs4851579 ENSG00000234389.1 AC007278.3 4.03 8.67e-05 0.0299 0.31 0.31 Asthma; chr2:102412524 chr2:102438713~102440475:+ PAAD cis rs1841770 0.521 rs6440527 ENSG00000241627.3 UBQLN4P1 -4.03 8.67e-05 0.0299 -0.39 -0.31 Multiple sclerosis; chr3:148058082 chr3:148985868~148987668:- PAAD cis rs12908161 1 rs12905057 ENSG00000259295.5 CSPG4P12 4.03 8.67e-05 0.0299 0.35 0.31 Schizophrenia; chr15:84667534 chr15:85191438~85213905:+ PAAD cis rs160451 0.774 rs4961159 ENSG00000251136.7 RP11-37B2.1 4.03 8.67e-05 0.0299 0.3 0.31 Leprosy; chr8:89691677 chr8:89609409~89757727:- PAAD cis rs13256369 0.802 rs13280101 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8705263 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs13255789 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8705281 chr8:8236003~8244667:- PAAD cis rs13256369 0.756 rs13282580 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8705393 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs13256404 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8705464 chr8:8236003~8244667:- PAAD cis rs13256369 0.756 rs13280759 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8705485 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs13258283 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8706120 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs13249700 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8706127 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs13254997 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8706243 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs13255061 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8706324 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs12541477 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8706385 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs13266562 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8706555 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs13256611 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8706831 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs11786125 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8707060 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs11249888 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8707424 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs11249889 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8707482 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs11249890 ENSG00000253981.4 ALG1L13P 4.03 8.67e-05 0.0299 0.42 0.31 Obesity-related traits; chr8:8707735 chr8:8236003~8244667:- PAAD cis rs8100891 0.734 rs4804990 ENSG00000267213.4 AC007773.2 -4.03 8.67e-05 0.0299 -0.41 -0.31 Neuroticism; chr19:32346523 chr19:32390050~32405560:- PAAD cis rs7927592 0.913 rs10896330 ENSG00000212093.1 AP000807.1 4.03 8.68e-05 0.0299 0.36 0.31 Total body bone mineral density; chr11:68487530 chr11:68506083~68506166:- PAAD cis rs7927592 0.956 rs12274114 ENSG00000212093.1 AP000807.1 4.03 8.68e-05 0.0299 0.36 0.31 Total body bone mineral density; chr11:68488109 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs12294029 ENSG00000212093.1 AP000807.1 4.03 8.68e-05 0.0299 0.36 0.31 Total body bone mineral density; chr11:68489591 chr11:68506083~68506166:- PAAD cis rs7927592 0.956 rs7126340 ENSG00000212093.1 AP000807.1 4.03 8.68e-05 0.0299 0.36 0.31 Total body bone mineral density; chr11:68489825 chr11:68506083~68506166:- PAAD cis rs919433 0.617 rs12619333 ENSG00000231621.1 AC013264.2 4.03 8.68e-05 0.0299 0.31 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197702914 chr2:197197991~197199273:+ PAAD cis rs919433 0.617 rs4850807 ENSG00000231621.1 AC013264.2 4.03 8.68e-05 0.0299 0.31 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197711251 chr2:197197991~197199273:+ PAAD cis rs10779751 1 rs10779751 ENSG00000238199.1 UBE2V2P3 -4.03 8.68e-05 0.0299 -0.37 -0.31 Body mass index; chr1:11224279 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs12032364 ENSG00000238199.1 UBE2V2P3 -4.03 8.68e-05 0.0299 -0.37 -0.31 Body mass index; chr1:11226815 chr1:11278616~11279351:- PAAD cis rs9322193 0.566 rs3922947 ENSG00000268592.3 RAET1E-AS1 -4.03 8.68e-05 0.0299 -0.41 -0.31 Lung cancer; chr6:149924856 chr6:149863494~149919507:+ PAAD cis rs2243480 1 rs464895 ENSG00000228409.4 CCT6P1 4.03 8.68e-05 0.0299 0.34 0.31 Diabetic kidney disease; chr7:66062119 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs160633 ENSG00000228409.4 CCT6P1 4.03 8.68e-05 0.0299 0.34 0.31 Diabetic kidney disease; chr7:66063241 chr7:65751142~65763354:+ PAAD cis rs2117029 0.782 rs6580699 ENSG00000258017.1 RP11-386G11.10 4.03 8.68e-05 0.0299 0.39 0.31 Intelligence (multi-trait analysis); chr12:49085029 chr12:49127782~49147869:+ PAAD cis rs5758659 0.81 rs5758623 ENSG00000273366.1 CTA-989H11.1 -4.03 8.69e-05 0.0299 -0.39 -0.31 Cognitive function; chr22:42170308 chr22:42278188~42278846:+ PAAD cis rs2439831 1 rs2467426 ENSG00000275601.1 AC011330.13 -4.03 8.7e-05 0.03 -0.57 -0.31 Lung cancer in ever smokers; chr15:43697320 chr15:43642389~43643023:- PAAD cis rs11159086 1 rs58384818 ENSG00000259005.1 RP3-449M8.6 4.03 8.7e-05 0.03 0.43 0.31 Advanced glycation end-product levels; chr14:74487045 chr14:74474007~74474864:- PAAD cis rs11159086 1 rs17100588 ENSG00000259005.1 RP3-449M8.6 4.03 8.7e-05 0.03 0.43 0.31 Advanced glycation end-product levels; chr14:74487624 chr14:74474007~74474864:- PAAD cis rs4713118 0.621 rs9368548 ENSG00000280107.1 AL022393.9 -4.03 8.7e-05 0.03 -0.52 -0.31 Parkinson's disease; chr6:28066959 chr6:28170845~28172521:+ PAAD cis rs7849270 0.959 rs4836641 ENSG00000268707.1 RP11-247A12.7 4.03 8.71e-05 0.03 0.38 0.31 Blood metabolite ratios; chr9:129149953 chr9:129170434~129170940:+ PAAD cis rs5015933 0.815 rs1333055 ENSG00000232630.1 PRPS1P2 -4.03 8.72e-05 0.03 -0.28 -0.31 Body mass index; chr9:125307948 chr9:125150653~125151589:+ PAAD cis rs5015933 0.815 rs12553785 ENSG00000232630.1 PRPS1P2 -4.03 8.72e-05 0.03 -0.28 -0.31 Body mass index; chr9:125314262 chr9:125150653~125151589:+ PAAD cis rs11089937 0.597 rs9619794 ENSG00000211638.2 IGLV8-61 -4.03 8.72e-05 0.03 -0.29 -0.31 Periodontitis (PAL4Q3); chr22:22132999 chr22:22098700~22099212:+ PAAD cis rs763121 0.853 rs5750649 ENSG00000228274.3 RP3-508I15.9 -4.03 8.72e-05 0.03 -0.3 -0.31 Menopause (age at onset); chr22:38640764 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs6519124 ENSG00000228274.3 RP3-508I15.9 -4.03 8.72e-05 0.03 -0.3 -0.31 Menopause (age at onset); chr22:38649094 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5750652 ENSG00000228274.3 RP3-508I15.9 -4.03 8.72e-05 0.03 -0.3 -0.31 Menopause (age at onset); chr22:38652311 chr22:38667585~38681820:- PAAD cis rs763121 0.814 rs5757212 ENSG00000228274.3 RP3-508I15.9 -4.03 8.72e-05 0.03 -0.3 -0.31 Menopause (age at onset); chr22:38657752 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757187 ENSG00000228274.3 RP3-508I15.9 4.03 8.73e-05 0.03 0.3 0.31 Menopause (age at onset); chr22:38625517 chr22:38667585~38681820:- PAAD cis rs853679 0.882 rs9380069 ENSG00000219392.1 RP1-265C24.5 -4.03 8.73e-05 0.03 -0.43 -0.31 Depression; chr6:28235522 chr6:28115628~28116551:+ PAAD cis rs9322193 0.923 rs10782317 ENSG00000268592.3 RAET1E-AS1 -4.03 8.73e-05 0.03 -0.36 -0.31 Lung cancer; chr6:149753911 chr6:149863494~149919507:+ PAAD cis rs8031584 0.678 rs35098644 ENSG00000260382.1 RP11-540B6.2 4.03 8.73e-05 0.03 0.42 0.31 Huntington's disease progression; chr15:30853237 chr15:30882267~30883231:- PAAD cis rs13256369 1 rs4840352 ENSG00000253981.4 ALG1L13P 4.03 8.74e-05 0.0301 0.42 0.31 Obesity-related traits; chr8:8715998 chr8:8236003~8244667:- PAAD cis rs6860540 0.796 rs10475585 ENSG00000248544.2 CTB-47B11.3 -4.03 8.74e-05 0.0301 -0.41 -0.31 Inflammatory skin disease; chr5:157488080 chr5:157375741~157384950:- PAAD cis rs6991838 0.806 rs11777025 ENSG00000200714.1 Y_RNA -4.03 8.74e-05 0.0301 -0.36 -0.31 Intelligence (multi-trait analysis); chr8:65551438 chr8:65592731~65592820:+ PAAD cis rs11676348 0.818 rs6436031 ENSG00000261338.2 RP11-378A13.1 -4.03 8.74e-05 0.0301 -0.36 -0.31 Ulcerative colitis; chr2:218114536 chr2:218255319~218257366:+ PAAD cis rs79040073 0.637 rs73408143 ENSG00000259469.1 RP11-227D13.4 -4.03 8.74e-05 0.0301 -0.48 -0.31 Lung cancer in ever smokers; chr15:49126771 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs3088333 ENSG00000259469.1 RP11-227D13.4 -4.03 8.74e-05 0.0301 -0.48 -0.31 Lung cancer in ever smokers; chr15:49140891 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs17394970 ENSG00000259469.1 RP11-227D13.4 -4.03 8.74e-05 0.0301 -0.48 -0.31 Lung cancer in ever smokers; chr15:49145371 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs11635455 ENSG00000259469.1 RP11-227D13.4 -4.03 8.74e-05 0.0301 -0.48 -0.31 Lung cancer in ever smokers; chr15:49147216 chr15:48729080~48729844:- PAAD cis rs79040073 0.599 rs73390384 ENSG00000259469.1 RP11-227D13.4 -4.03 8.74e-05 0.0301 -0.48 -0.31 Lung cancer in ever smokers; chr15:49180905 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs7177624 ENSG00000259469.1 RP11-227D13.4 -4.03 8.74e-05 0.0301 -0.48 -0.31 Lung cancer in ever smokers; chr15:49189515 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs78298181 ENSG00000259469.1 RP11-227D13.4 -4.03 8.74e-05 0.0301 -0.48 -0.31 Lung cancer in ever smokers; chr15:49213350 chr15:48729080~48729844:- PAAD cis rs172166 0.538 rs149956 ENSG00000219891.2 ZSCAN12P1 4.03 8.75e-05 0.0301 0.42 0.31 Cardiac Troponin-T levels; chr6:28068473 chr6:28091154~28093664:+ PAAD cis rs853679 0.538 rs13199081 ENSG00000219891.2 ZSCAN12P1 4.03 8.75e-05 0.0301 0.45 0.31 Depression; chr6:28364057 chr6:28091154~28093664:+ PAAD cis rs2894969 0.664 rs11252708 ENSG00000225269.2 LINC00705 4.03 8.75e-05 0.0301 0.31 0.31 Major depressive disorder; chr10:4753232 chr10:4655427~4662419:+ PAAD cis rs633715 0.766 rs4509539 ENSG00000254154.7 RP4-798P15.3 -4.03 8.76e-05 0.0301 -0.29 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177830753 chr1:177928788~178038007:- PAAD cis rs1387259 0.839 rs7486941 ENSG00000240399.1 RP1-228P16.1 -4.03 8.76e-05 0.0301 -0.33 -0.31 Obstructive sleep apnea trait (apnea hypopnea index); chr12:48184848 chr12:48054813~48055591:- PAAD cis rs7923609 0.846 rs7098181 ENSG00000232075.1 MRPL35P2 -4.03 8.76e-05 0.0301 -0.39 -0.31 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63267383 chr10:63634317~63634827:- PAAD cis rs7923609 0.846 rs10761731 ENSG00000232075.1 MRPL35P2 -4.03 8.76e-05 0.0301 -0.39 -0.31 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63267850 chr10:63634317~63634827:- PAAD cis rs7923609 0.846 rs9787438 ENSG00000232075.1 MRPL35P2 -4.03 8.76e-05 0.0301 -0.39 -0.31 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63278270 chr10:63634317~63634827:- PAAD cis rs804280 1 rs804280 ENSG00000254866.2 DEFB109P3 -4.03 8.77e-05 0.0301 -0.43 -0.31 Myopia (pathological); chr8:11755189 chr8:12150895~12151134:- PAAD cis rs6496044 0.963 rs6496050 ENSG00000202081.1 RNU6-1280P 4.03 8.77e-05 0.0301 0.35 0.31 Interstitial lung disease; chr15:85526019 chr15:85651522~85651628:- PAAD cis rs2439831 1 rs690263 ENSG00000275601.1 AC011330.13 -4.03 8.77e-05 0.0302 -0.53 -0.31 Lung cancer in ever smokers; chr15:43412267 chr15:43642389~43643023:- PAAD cis rs2439831 1 rs2254321 ENSG00000275601.1 AC011330.13 -4.03 8.77e-05 0.0302 -0.53 -0.31 Lung cancer in ever smokers; chr15:43415344 chr15:43642389~43643023:- PAAD cis rs6951245 0.554 rs11544331 ENSG00000229043.2 AC091729.9 -4.03 8.77e-05 0.0302 -0.43 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1091775 chr7:1160374~1165267:+ PAAD cis rs919433 0.927 rs1429412 ENSG00000231621.1 AC013264.2 4.03 8.77e-05 0.0302 0.3 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197326170 chr2:197197991~197199273:+ PAAD cis rs919433 0.927 rs3843857 ENSG00000231621.1 AC013264.2 4.03 8.77e-05 0.0302 0.3 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197331241 chr2:197197991~197199273:+ PAAD cis rs3015497 0.616 rs7154131 ENSG00000270062.1 RP11-248J18.3 4.03 8.78e-05 0.0302 0.3 0.31 Mean platelet volume; chr14:50579808 chr14:50723777~50724272:- PAAD cis rs28374715 0.662 rs1554445 ENSG00000247556.5 OIP5-AS1 4.03 8.79e-05 0.0302 0.33 0.31 Ulcerative colitis; chr15:41211000 chr15:41283990~41309737:+ PAAD cis rs41369048 1 rs2738751 ENSG00000238078.1 LINC01352 -4.03 8.79e-05 0.0302 -0.44 -0.31 Eosinophil counts;Sum eosinophil basophil counts; chr1:220878371 chr1:220829255~220832429:+ PAAD cis rs2403083 0.505 rs1845892 ENSG00000258256.1 RP11-219B4.5 -4.03 8.79e-05 0.0302 -0.34 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85260388 chr8:85222446~85245717:- PAAD cis rs2403083 0.505 rs7839129 ENSG00000258256.1 RP11-219B4.5 -4.03 8.79e-05 0.0302 -0.34 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85273995 chr8:85222446~85245717:- PAAD cis rs7759001 0.652 rs7756216 ENSG00000271755.1 RP1-153G14.4 4.03 8.79e-05 0.0302 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27473153 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs62401365 ENSG00000271755.1 RP1-153G14.4 4.03 8.79e-05 0.0302 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27473751 chr6:27404010~27406964:- PAAD cis rs6570726 0.846 rs397311 ENSG00000235652.6 RP11-545I5.3 -4.03 8.79e-05 0.0302 -0.25 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145485565 chr6:145799409~145886585:+ PAAD cis rs7260598 0.539 rs11665842 ENSG00000268442.1 CTD-2027I19.2 4.03 8.8e-05 0.0302 0.51 0.31 Response to taxane treatment (placlitaxel); chr19:23911846 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs7250219 ENSG00000268442.1 CTD-2027I19.2 4.03 8.8e-05 0.0302 0.51 0.31 Response to taxane treatment (placlitaxel); chr19:23912809 chr19:24162370~24163425:- PAAD cis rs6539288 0.901 rs1444580 ENSG00000260329.1 RP11-412D9.4 -4.03 8.8e-05 0.0302 -0.26 -0.31 Total body bone mineral density; chr12:106920780 chr12:106954029~106955497:- PAAD cis rs919433 0.617 rs700643 ENSG00000231621.1 AC013264.2 -4.03 8.8e-05 0.0302 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197736646 chr2:197197991~197199273:+ PAAD cis rs919433 0.617 rs700645 ENSG00000231621.1 AC013264.2 -4.03 8.8e-05 0.0302 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197740790 chr2:197197991~197199273:+ PAAD cis rs919433 0.617 rs700646 ENSG00000231621.1 AC013264.2 -4.03 8.8e-05 0.0302 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197743787 chr2:197197991~197199273:+ PAAD cis rs4683346 0.652 rs339671 ENSG00000173811.9 CCDC13-AS1 -4.03 8.81e-05 0.0302 -0.34 -0.31 Granulocyte percentage of myeloid white cells; chr3:42760420 chr3:42732575~42746768:+ PAAD cis rs5758659 0.652 rs129857 ENSG00000273366.1 CTA-989H11.1 4.03 8.81e-05 0.0303 0.37 0.31 Cognitive function; chr22:42003682 chr22:42278188~42278846:+ PAAD cis rs2408955 0.522 rs4760612 ENSG00000240399.1 RP1-228P16.1 -4.03 8.82e-05 0.0303 -0.33 -0.31 Glycated hemoglobin levels; chr12:48028073 chr12:48054813~48055591:- PAAD cis rs6061231 0.798 rs2427308 ENSG00000275437.1 RP5-908M14.10 4.03 8.82e-05 0.0303 0.32 0.31 Colorectal cancer; chr20:62394395 chr20:62402236~62405935:- PAAD cis rs2832191 1 rs2832191 ENSG00000215533.7 LINC00189 4.03 8.82e-05 0.0303 0.38 0.31 Dental caries; chr21:29116979 chr21:29193480~29288205:+ PAAD cis rs9326248 0.581 rs10892072 ENSG00000280143.1 AP000892.6 4.03 8.83e-05 0.0303 0.34 0.31 Blood protein levels; chr11:117089597 chr11:117204967~117210292:+ PAAD cis rs11676348 0.846 rs7607437 ENSG00000261338.2 RP11-378A13.1 -4.03 8.83e-05 0.0303 -0.36 -0.31 Ulcerative colitis; chr2:218143669 chr2:218255319~218257366:+ PAAD cis rs763121 0.853 rs9610986 ENSG00000228274.3 RP3-508I15.9 -4.03 8.83e-05 0.0303 -0.3 -0.31 Menopause (age at onset); chr22:38629272 chr22:38667585~38681820:- PAAD cis rs453301 0.653 rs7005133 ENSG00000254340.1 RP11-10A14.3 4.03 8.83e-05 0.0303 0.38 0.31 Joint mobility (Beighton score); chr8:9043712 chr8:9141424~9145435:+ PAAD cis rs2832191 1 rs8131214 ENSG00000215533.7 LINC00189 4.03 8.84e-05 0.0303 0.38 0.31 Dental caries; chr21:29111065 chr21:29193480~29288205:+ PAAD cis rs261902 0.779 rs171886 ENSG00000255867.1 DENND5B-AS1 4.03 8.84e-05 0.0303 0.48 0.31 Normalized brain volume; chr12:32324057 chr12:31589923~31615666:+ PAAD cis rs11723261 0.509 rs61792240 ENSG00000275426.1 CH17-262A2.1 4.03 8.84e-05 0.0303 0.5 0.31 Immune response to smallpox vaccine (IL-6); chr4:134876 chr4:149738~150317:+ PAAD cis rs11723261 0.564 rs61792258 ENSG00000275426.1 CH17-262A2.1 4.03 8.84e-05 0.0303 0.5 0.31 Immune response to smallpox vaccine (IL-6); chr4:143482 chr4:149738~150317:+ PAAD cis rs13256369 0.708 rs11249886 ENSG00000253981.4 ALG1L13P 4.03 8.84e-05 0.0303 0.42 0.31 Obesity-related traits; chr8:8704511 chr8:8236003~8244667:- PAAD cis rs13256369 0.802 rs11249887 ENSG00000253981.4 ALG1L13P 4.03 8.84e-05 0.0303 0.42 0.31 Obesity-related traits; chr8:8704674 chr8:8236003~8244667:- PAAD cis rs13256369 0.755 rs12550057 ENSG00000253981.4 ALG1L13P 4.03 8.84e-05 0.0303 0.42 0.31 Obesity-related traits; chr8:8704758 chr8:8236003~8244667:- PAAD cis rs919433 0.653 rs700651 ENSG00000231621.1 AC013264.2 -4.03 8.84e-05 0.0303 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197766990 chr2:197197991~197199273:+ PAAD cis rs8062405 0.755 rs1074631 ENSG00000251417.2 RP11-1348G14.4 4.03 8.85e-05 0.0304 0.3 0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28542787 chr16:28802743~28817828:+ PAAD cis rs7820074 0.778 rs1848184 ENSG00000253334.1 RP13-923O23.6 4.03 8.85e-05 0.0304 0.37 0.31 Orofacial clefts; chr8:82014893 chr8:81791823~81815714:+ PAAD cis rs2262909 0.962 rs409835 ENSG00000279377.1 AC003973.3 4.03 8.85e-05 0.0304 0.29 0.31 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22047869 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs411020 ENSG00000279377.1 AC003973.3 4.03 8.85e-05 0.0304 0.29 0.31 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22048300 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs408687 ENSG00000279377.1 AC003973.3 4.03 8.85e-05 0.0304 0.29 0.31 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22048321 chr19:21965708~21968529:- PAAD cis rs2262909 0.962 rs436662 ENSG00000279377.1 AC003973.3 4.03 8.85e-05 0.0304 0.29 0.31 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22049305 chr19:21965708~21968529:- PAAD cis rs1910358 0.554 rs1826235 ENSG00000248874.4 C5orf17 -4.03 8.85e-05 0.0304 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23805259 chr5:23951348~24178263:+ PAAD cis rs2980439 0.807 rs2980438 ENSG00000253981.4 ALG1L13P 4.03 8.85e-05 0.0304 0.38 0.31 Neuroticism; chr8:8237303 chr8:8236003~8244667:- PAAD cis rs6479901 0.846 rs10761761 ENSG00000232075.1 MRPL35P2 -4.03 8.85e-05 0.0304 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63419398 chr10:63634317~63634827:- PAAD cis rs7216064 0.861 rs62084252 ENSG00000278219.1 AC145343.1 -4.03 8.85e-05 0.0304 -0.48 -0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67883462 chr17:68101538~68101639:+ PAAD cis rs763121 0.853 rs4821816 ENSG00000228274.3 RP3-508I15.9 -4.03 8.85e-05 0.0304 -0.3 -0.31 Menopause (age at onset); chr22:38717129 chr22:38667585~38681820:- PAAD cis rs792448 0.743 rs3767861 ENSG00000229983.1 RP11-15I11.2 4.03 8.85e-05 0.0304 0.36 0.31 White blood cell count (basophil); chr1:212364211 chr1:212168207~212190259:+ PAAD cis rs792448 0.743 rs3767862 ENSG00000229983.1 RP11-15I11.2 4.03 8.85e-05 0.0304 0.36 0.31 White blood cell count (basophil); chr1:212364360 chr1:212168207~212190259:+ PAAD cis rs792448 0.701 rs3099112 ENSG00000229983.1 RP11-15I11.2 4.03 8.85e-05 0.0304 0.36 0.31 White blood cell count (basophil); chr1:212369068 chr1:212168207~212190259:+ PAAD cis rs761772 0.81 rs429216 ENSG00000267737.1 AC061992.2 -4.03 8.85e-05 0.0304 -0.51 -0.31 Glycated hemoglobin levels; chr17:78130123 chr17:78315729~78347798:+ PAAD cis rs17382119 0.518 rs391833 ENSG00000240875.4 LINC00886 4.03 8.86e-05 0.0304 0.54 0.31 Clozapine-induced cytotoxicity; chr3:156762474 chr3:156747346~156817062:- PAAD cis rs9322193 0.923 rs11155670 ENSG00000268592.3 RAET1E-AS1 4.03 8.86e-05 0.0304 0.36 0.31 Lung cancer; chr6:149644992 chr6:149863494~149919507:+ PAAD cis rs875971 0.505 rs1167386 ENSG00000236529.1 RP13-254B10.1 -4.03 8.86e-05 0.0304 -0.34 -0.31 Aortic root size; chr7:66048109 chr7:65840212~65840596:+ PAAD cis rs287982 0.8 rs9973905 ENSG00000269973.1 RP11-95D17.1 -4.03 8.86e-05 0.0304 -0.37 -0.31 Nonsyndromic cleft lip with cleft palate; chr2:9820726 chr2:9936360~9939590:+ PAAD cis rs1124769 0.502 rs34354799 ENSG00000259240.1 RP11-108K3.1 -4.03 8.87e-05 0.0304 -0.4 -0.31 Cognitive performance; chr15:50774380 chr15:51037488~51293912:+ PAAD cis rs1124769 0.502 rs8042982 ENSG00000259240.1 RP11-108K3.1 -4.03 8.87e-05 0.0304 -0.4 -0.31 Cognitive performance; chr15:50774816 chr15:51037488~51293912:+ PAAD cis rs1124769 0.502 rs737031 ENSG00000259240.1 RP11-108K3.1 -4.03 8.87e-05 0.0304 -0.4 -0.31 Cognitive performance; chr15:50775340 chr15:51037488~51293912:+ PAAD cis rs875971 0.895 rs4145009 ENSG00000232559.3 GS1-124K5.12 -4.03 8.87e-05 0.0304 -0.35 -0.31 Aortic root size; chr7:66261628 chr7:66554588~66576923:- PAAD cis rs2658782 0.789 rs1456238 ENSG00000279684.1 RP11-755E23.2 -4.03 8.87e-05 0.0304 -0.53 -0.31 Pulmonary function decline; chr11:93384204 chr11:93286629~93288903:- PAAD cis rs875971 0.862 rs57866200 ENSG00000232559.3 GS1-124K5.12 -4.03 8.87e-05 0.0304 -0.35 -0.31 Aortic root size; chr7:66100405 chr7:66554588~66576923:- PAAD cis rs10936632 0.565 rs9865021 ENSG00000242578.1 RP11-469J4.3 -4.03 8.87e-05 0.0304 -0.35 -0.31 Prostate cancer; chr3:170429093 chr3:170410512~170418615:+ PAAD cis rs11893307 0.509 rs2356126 ENSG00000235852.1 AC005540.3 4.03 8.87e-05 0.0304 0.45 0.31 Mean platelet volume; chr2:190677788 chr2:190880797~190882059:- PAAD cis rs11893307 0.509 rs12618075 ENSG00000235852.1 AC005540.3 4.03 8.87e-05 0.0304 0.45 0.31 Mean platelet volume; chr2:190681095 chr2:190880797~190882059:- PAAD cis rs11893307 0.537 rs57780226 ENSG00000235852.1 AC005540.3 4.03 8.87e-05 0.0304 0.45 0.31 Mean platelet volume; chr2:190683139 chr2:190880797~190882059:- PAAD cis rs7394190 0.935 rs6480708 ENSG00000272140.2 RP11-574K11.29 -4.03 8.87e-05 0.0304 -0.34 -0.31 Incident atrial fibrillation; chr10:73660356 chr10:73703735~73713581:- PAAD cis rs6435957 0.568 rs4583440 ENSG00000233143.1 DIRC3-AS1 -4.03 8.87e-05 0.0304 -0.4 -0.31 Primary tooth development (number of teeth); chr2:217034529 chr2:217282739~217336120:+ PAAD cis rs11079757 0.847 rs16941684 ENSG00000263142.4 LRRC37A17P 4.03 8.87e-05 0.0304 0.35 0.31 Erythema nodosum in inflammatory bowel disease; chr17:47225320 chr17:46978481~47054569:+ PAAD cis rs9876781 1 rs6442123 ENSG00000229759.1 MRPS18AP1 4.03 8.87e-05 0.0304 0.33 0.31 Longevity; chr3:48458887 chr3:48256350~48256938:- PAAD cis rs896655 0.71 rs1987458 ENSG00000266446.1 RP11-149I2.4 -4.03 8.87e-05 0.0304 -0.37 -0.31 Coronary artery disease; chr9:21704874 chr9:21995482~21996013:+ PAAD cis rs4853525 0.859 rs6434424 ENSG00000235852.1 AC005540.3 4.03 8.88e-05 0.0304 0.41 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190857400 chr2:190880797~190882059:- PAAD cis rs2243480 1 rs4718317 ENSG00000232546.1 RP11-458F8.1 4.03 8.88e-05 0.0304 0.37 0.31 Diabetic kidney disease; chr7:66183914 chr7:66848496~66858136:+ PAAD cis rs66887589 0.87 rs10518336 ENSG00000248280.1 RP11-33B1.2 4.03 8.88e-05 0.0304 0.3 0.31 Diastolic blood pressure; chr4:119601779 chr4:119440561~119450157:- PAAD cis rs2380205 0.546 rs635532 ENSG00000232807.2 RP11-536K7.3 -4.03 8.88e-05 0.0304 -0.33 -0.31 Breast cancer; chr10:5928365 chr10:5934270~5945900:- PAAD cis rs7309 0.622 rs4664396 ENSG00000227403.1 AC009299.3 4.03 8.89e-05 0.0304 0.41 0.31 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161045139 chr2:161244739~161249050:+ PAAD cis rs6539288 0.834 rs1545097 ENSG00000260329.1 RP11-412D9.4 -4.03 8.89e-05 0.0304 -0.26 -0.31 Total body bone mineral density; chr12:106919918 chr12:106954029~106955497:- PAAD cis rs6539288 0.899 rs6539292 ENSG00000260329.1 RP11-412D9.4 -4.03 8.89e-05 0.0304 -0.26 -0.31 Total body bone mineral density; chr12:106919935 chr12:106954029~106955497:- PAAD cis rs7246657 0.551 rs10404069 ENSG00000267422.1 CTD-2554C21.1 -4.03 8.89e-05 0.0305 -0.57 -0.31 Coronary artery calcification; chr19:37147502 chr19:37779686~37792865:+ PAAD cis rs2179367 0.959 rs579789 ENSG00000231760.4 RP11-350J20.5 4.03 8.9e-05 0.0305 0.39 0.31 Dupuytren's disease; chr6:149358235 chr6:149796151~149826294:- PAAD cis rs9322193 0.607 rs9383941 ENSG00000268592.3 RAET1E-AS1 -4.03 8.9e-05 0.0305 -0.39 -0.31 Lung cancer; chr6:149912100 chr6:149863494~149919507:+ PAAD cis rs9876781 1 rs11130171 ENSG00000229759.1 MRPS18AP1 4.03 8.9e-05 0.0305 0.33 0.31 Longevity; chr3:48421052 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs9883927 ENSG00000229759.1 MRPS18AP1 4.03 8.9e-05 0.0305 0.33 0.31 Longevity; chr3:48422302 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs9817615 ENSG00000229759.1 MRPS18AP1 4.03 8.9e-05 0.0305 0.33 0.31 Longevity; chr3:48429347 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs2290822 ENSG00000229759.1 MRPS18AP1 4.03 8.9e-05 0.0305 0.33 0.31 Longevity; chr3:48431794 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs13076076 ENSG00000229759.1 MRPS18AP1 4.03 8.9e-05 0.0305 0.33 0.31 Longevity; chr3:48437629 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs7636044 ENSG00000229759.1 MRPS18AP1 4.03 8.9e-05 0.0305 0.33 0.31 Longevity; chr3:48443151 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs4490383 ENSG00000229759.1 MRPS18AP1 4.03 8.9e-05 0.0305 0.33 0.31 Longevity; chr3:48443275 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs9876781 ENSG00000229759.1 MRPS18AP1 4.03 8.9e-05 0.0305 0.33 0.31 Longevity; chr3:48445934 chr3:48256350~48256938:- PAAD cis rs2243480 1 rs35825738 ENSG00000232546.1 RP11-458F8.1 -4.03 8.9e-05 0.0305 -0.38 -0.31 Diabetic kidney disease; chr7:65853040 chr7:66848496~66858136:+ PAAD cis rs28386778 0.897 rs2665823 ENSG00000240280.5 TCAM1P -4.03 8.9e-05 0.0305 -0.44 -0.31 Prudent dietary pattern; chr17:63808557 chr17:63849292~63864379:+ PAAD cis rs172166 0.637 rs1225597 ENSG00000204709.4 LINC01556 4.03 8.9e-05 0.0305 0.48 0.31 Cardiac Troponin-T levels; chr6:28194309 chr6:28943877~28944537:+ PAAD cis rs613391 0.536 rs682022 ENSG00000224549.1 RP11-370B11.3 -4.03 8.91e-05 0.0305 -0.37 -0.31 Quantitative traits; chr9:22722160 chr9:22767175~22768316:+ PAAD cis rs252152 0.652 rs2906077 ENSG00000280047.1 CTC-463A16.1 4.03 8.91e-05 0.0305 0.29 0.31 Squamous cell lung carcinoma; chr5:142191759 chr5:142165767~142168387:+ PAAD cis rs17772222 0.651 rs12586714 ENSG00000258983.2 RP11-507K2.2 4.03 8.91e-05 0.0305 0.37 0.31 Coronary artery calcification; chr14:88360497 chr14:88499334~88515502:+ PAAD cis rs950169 0.58 rs11636189 ENSG00000259728.4 LINC00933 4.03 8.91e-05 0.0305 0.39 0.31 Schizophrenia; chr15:84650323 chr15:84570649~84580175:+ PAAD cis rs950169 0.58 rs35516100 ENSG00000259728.4 LINC00933 4.03 8.91e-05 0.0305 0.39 0.31 Schizophrenia; chr15:84652199 chr15:84570649~84580175:+ PAAD cis rs950169 0.58 rs62021208 ENSG00000259728.4 LINC00933 4.03 8.91e-05 0.0305 0.39 0.31 Schizophrenia; chr15:84653013 chr15:84570649~84580175:+ PAAD cis rs875971 0.83 rs6976714 ENSG00000232559.3 GS1-124K5.12 4.03 8.91e-05 0.0305 0.35 0.31 Aortic root size; chr7:66426474 chr7:66554588~66576923:- PAAD cis rs875971 0.651 rs2420596 ENSG00000232559.3 GS1-124K5.12 4.03 8.91e-05 0.0305 0.35 0.31 Aortic root size; chr7:66450996 chr7:66554588~66576923:- PAAD cis rs875971 0.52 rs2420597 ENSG00000232559.3 GS1-124K5.12 4.03 8.91e-05 0.0305 0.35 0.31 Aortic root size; chr7:66450999 chr7:66554588~66576923:- PAAD cis rs7572733 0.534 rs1435568 ENSG00000231621.1 AC013264.2 -4.03 8.91e-05 0.0305 -0.31 -0.31 Dermatomyositis; chr2:197898155 chr2:197197991~197199273:+ PAAD cis rs10050311 0.79 rs17751427 ENSG00000251411.1 RP11-397E7.4 -4.03 8.92e-05 0.0305 -0.38 -0.31 Insulin-related traits; chr4:86909939 chr4:86913266~86914817:- PAAD cis rs11079159 0.637 rs4147524 ENSG00000263096.1 RP11-515O17.2 4.03 8.92e-05 0.0305 0.47 0.31 QRS duration; chr17:55274249 chr17:55271504~55273653:- PAAD cis rs77372450 0.636 rs11746670 ENSG00000251405.2 CTB-109A12.1 4.03 8.92e-05 0.0305 0.48 0.31 Bipolar disorder (body mass index interaction); chr5:157600697 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs6879084 ENSG00000251405.2 CTB-109A12.1 4.03 8.92e-05 0.0305 0.48 0.31 Bipolar disorder (body mass index interaction); chr5:157602180 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs11748443 ENSG00000251405.2 CTB-109A12.1 4.03 8.92e-05 0.0305 0.48 0.31 Bipolar disorder (body mass index interaction); chr5:157602449 chr5:157362615~157460078:- PAAD cis rs77372450 0.636 rs6877434 ENSG00000251405.2 CTB-109A12.1 -4.03 8.92e-05 0.0305 -0.48 -0.31 Bipolar disorder (body mass index interaction); chr5:157601939 chr5:157362615~157460078:- PAAD cis rs11976180 1 rs1919949 ENSG00000273234.1 OR2A13P -4.03 8.92e-05 0.0305 -0.39 -0.31 Obesity-related traits; chr7:144070630 chr7:144142009~144142938:+ PAAD cis rs6951245 1 rs113575110 ENSG00000229043.2 AC091729.9 -4.03 8.92e-05 0.0305 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1044758 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs1881123 ENSG00000229043.2 AC091729.9 -4.03 8.92e-05 0.0305 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1045070 chr7:1160374~1165267:+ PAAD cis rs6951245 0.872 rs77569514 ENSG00000229043.2 AC091729.9 -4.03 8.92e-05 0.0305 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1045872 chr7:1160374~1165267:+ PAAD cis rs6951245 1 rs11770909 ENSG00000229043.2 AC091729.9 -4.03 8.92e-05 0.0305 -0.49 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1047080 chr7:1160374~1165267:+ PAAD cis rs9309711 0.961 rs11890651 ENSG00000225234.1 TRAPPC12-AS1 -4.03 8.93e-05 0.0306 -0.34 -0.31 Neurofibrillary tangles; chr2:3479025 chr2:3481242~3482409:- PAAD cis rs11123170 0.64 rs931472 ENSG00000274877.1 RP11-65I12.1 4.03 8.93e-05 0.0306 0.37 0.31 Renal function-related traits (BUN); chr2:113212371 chr2:113237595~113240825:+ PAAD cis rs11089937 0.609 rs9622980 ENSG00000211638.2 IGLV8-61 -4.03 8.93e-05 0.0306 -0.29 -0.31 Periodontitis (PAL4Q3); chr22:22149888 chr22:22098700~22099212:+ PAAD cis rs17772222 0.56 rs3742681 ENSG00000258983.2 RP11-507K2.2 -4.03 8.93e-05 0.0306 -0.39 -0.31 Coronary artery calcification; chr14:88554903 chr14:88499334~88515502:+ PAAD cis rs1275468 0.731 rs1383098 ENSG00000257497.2 RP11-585P4.5 -4.03 8.93e-05 0.0306 -0.49 -0.31 Polycystic ovary syndrome; chr12:75588107 chr12:75483454~75489820:- PAAD cis rs375066 0.935 rs368089 ENSG00000267058.1 RP11-15A1.3 -4.03 8.93e-05 0.0306 -0.28 -0.31 Breast cancer; chr19:43894932 chr19:43891804~43901805:- PAAD cis rs6479891 1 rs9415692 ENSG00000232075.1 MRPL35P2 4.03 8.93e-05 0.0306 0.5 0.31 Arthritis (juvenile idiopathic); chr10:63355392 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9414799 ENSG00000232075.1 MRPL35P2 4.03 8.93e-05 0.0306 0.5 0.31 Arthritis (juvenile idiopathic); chr10:63369842 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs4746119 ENSG00000232075.1 MRPL35P2 4.03 8.93e-05 0.0306 0.5 0.31 Arthritis (juvenile idiopathic); chr10:63370157 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9414800 ENSG00000232075.1 MRPL35P2 4.03 8.93e-05 0.0306 0.5 0.31 Arthritis (juvenile idiopathic); chr10:63371522 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9415696 ENSG00000232075.1 MRPL35P2 4.03 8.93e-05 0.0306 0.5 0.31 Arthritis (juvenile idiopathic); chr10:63374588 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9415697 ENSG00000232075.1 MRPL35P2 4.03 8.93e-05 0.0306 0.5 0.31 Arthritis (juvenile idiopathic); chr10:63375377 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs724553 ENSG00000232075.1 MRPL35P2 4.03 8.93e-05 0.0306 0.5 0.31 Arthritis (juvenile idiopathic); chr10:63380624 chr10:63634317~63634827:- PAAD cis rs6479891 0.841 rs7092504 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63329679 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs4133250 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63332645 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs10995506 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63334706 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs10740117 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63338517 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs6479894 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63338981 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs10733790 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63340574 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs10761745 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63341311 chr10:63634317~63634827:- PAAD cis rs6479891 0.915 rs7091664 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63342040 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs7081275 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63346791 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs7895348 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63349781 chr10:63634317~63634827:- PAAD cis rs6479891 0.915 rs9415699 ENSG00000232075.1 MRPL35P2 -4.03 8.93e-05 0.0306 -0.5 -0.31 Arthritis (juvenile idiopathic); chr10:63383798 chr10:63634317~63634827:- PAAD cis rs7520050 0.966 rs1085243 ENSG00000280836.1 AL355480.1 4.03 8.93e-05 0.0306 0.35 0.31 Reticulocyte count;Red blood cell count; chr1:46079096 chr1:45581219~45581321:- PAAD cis rs72615157 0.634 rs74742883 ENSG00000242294.5 STAG3L5P 4.03 8.94e-05 0.0306 0.24 0.31 Lung function (FEV1/FVC); chr7:100188142 chr7:100336079~100351900:+ PAAD cis rs9595908 0.863 rs11616287 ENSG00000212293.1 SNORA16 4.03 8.95e-05 0.0306 0.34 0.31 Body mass index; chr13:32580139 chr13:32420390~32420516:- PAAD cis rs6539288 0.933 rs6539291 ENSG00000260329.1 RP11-412D9.4 -4.03 8.95e-05 0.0306 -0.26 -0.31 Total body bone mineral density; chr12:106916033 chr12:106954029~106955497:- PAAD cis rs9649213 0.593 rs6465673 ENSG00000272950.1 RP11-307C18.1 4.03 8.95e-05 0.0306 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98339575 chr7:98322853~98323430:+ PAAD cis rs17201317 0.565 rs16870094 ENSG00000272037.1 KB-431C1.5 -4.03 8.95e-05 0.0306 -0.25 -0.31 Small vessel stroke; chr8:103104950 chr8:102256392~102257821:+ PAAD cis rs9393813 0.506 rs4713105 ENSG00000271755.1 RP1-153G14.4 4.03 8.96e-05 0.0306 0.36 0.31 Bipolar disorder; chr6:27467141 chr6:27404010~27406964:- PAAD cis rs577676 0.564 rs619699 ENSG00000271811.1 RP1-79C4.4 4.03 8.96e-05 0.0306 0.34 0.31 Prevalent atrial fibrillation; chr1:170648238 chr1:170667381~170669425:+ PAAD cis rs4666002 0.75 rs13021208 ENSG00000234072.1 AC074117.10 4.03 8.96e-05 0.0306 0.29 0.31 Phospholipid levels (plasma); chr2:27678861 chr2:27356246~27367622:+ PAAD cis rs4666002 0.789 rs12998770 ENSG00000234072.1 AC074117.10 4.03 8.96e-05 0.0306 0.29 0.31 Phospholipid levels (plasma); chr2:27690321 chr2:27356246~27367622:+ PAAD cis rs9876781 1 rs9838618 ENSG00000229759.1 MRPS18AP1 4.02 8.96e-05 0.0306 0.34 0.31 Longevity; chr3:48445949 chr3:48256350~48256938:- PAAD cis rs11048434 0.518 rs11048496 ENSG00000256720.1 RP11-436I9.6 -4.02 8.96e-05 0.0307 -0.29 -0.31 Sjögren's syndrome; chr12:9019825 chr12:9135084~9135591:+ PAAD cis rs801193 0.66 rs1962050 ENSG00000232559.3 GS1-124K5.12 -4.02 8.97e-05 0.0307 -0.35 -0.31 Aortic root size; chr7:66775021 chr7:66554588~66576923:- PAAD cis rs357618 0.581 rs165359 ENSG00000271795.1 CTC-251D13.1 4.02 8.97e-05 0.0307 0.39 0.31 Basophil percentage of white cells; chr5:151481475 chr5:151509453~151512769:+ PAAD cis rs321358 0.895 rs73015171 ENSG00000271390.1 RP11-89C3.3 4.02 8.98e-05 0.0307 0.43 0.31 Body mass index; chr11:111087535 chr11:111089870~111090368:- PAAD cis rs7260598 0.792 rs17620072 ENSG00000268442.1 CTD-2027I19.2 4.02 8.98e-05 0.0307 0.51 0.31 Response to taxane treatment (placlitaxel); chr19:24177850 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs7260592 ENSG00000268442.1 CTD-2027I19.2 4.02 8.98e-05 0.0307 0.51 0.31 Response to taxane treatment (placlitaxel); chr19:24178786 chr19:24162370~24163425:- PAAD cis rs7520050 0.865 rs785515 ENSG00000280836.1 AL355480.1 4.02 8.98e-05 0.0307 0.35 0.31 Reticulocyte count;Red blood cell count; chr1:46096990 chr1:45581219~45581321:- PAAD cis rs4950322 0.547 rs6660507 ENSG00000278811.3 LINC00624 4.02 8.99e-05 0.0307 0.31 0.31 Protein quantitative trait loci; chr1:147148574 chr1:147258885~147517875:- PAAD cis rs2034650 0.544 rs2289331 ENSG00000223313.1 RNU6-516P 4.02 8.99e-05 0.0307 0.4 0.31 Interstitial lung disease; chr15:40407739 chr15:40529570~40529673:+ PAAD cis rs2034650 0.563 rs2412523 ENSG00000223313.1 RNU6-516P 4.02 8.99e-05 0.0307 0.4 0.31 Interstitial lung disease; chr15:40417487 chr15:40529570~40529673:+ PAAD cis rs1056107 0.763 rs10759529 ENSG00000225513.1 RP11-165N19.2 -4.02 8.99e-05 0.0307 -0.39 -0.31 Colorectal cancer; chr9:112176651 chr9:112173522~112173971:- PAAD cis rs453301 0.653 rs11784393 ENSG00000254340.1 RP11-10A14.3 4.02 8.99e-05 0.0307 0.38 0.31 Joint mobility (Beighton score); chr8:9045624 chr8:9141424~9145435:+ PAAD cis rs2638953 0.64 rs11049718 ENSG00000247934.4 RP11-967K21.1 -4.02 9e-05 0.0308 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28565739 chr12:28163298~28190738:- PAAD cis rs2348418 0.832 rs7136426 ENSG00000247934.4 RP11-967K21.1 4.02 9e-05 0.0308 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28400129 chr12:28163298~28190738:- PAAD cis rs287982 1 rs1119633 ENSG00000269973.1 RP11-95D17.1 -4.02 9e-05 0.0308 -0.36 -0.31 Nonsyndromic cleft lip with cleft palate; chr2:9827403 chr2:9936360~9939590:+ PAAD cis rs287982 0.935 rs1119632 ENSG00000269973.1 RP11-95D17.1 -4.02 9e-05 0.0308 -0.36 -0.31 Nonsyndromic cleft lip with cleft palate; chr2:9827535 chr2:9936360~9939590:+ PAAD cis rs7487075 1 rs12827740 ENSG00000270429.1 KNOP1P2 4.02 9.01e-05 0.0308 0.36 0.31 Itch intensity from mosquito bite; chr12:46454332 chr12:45880950~45882266:- PAAD cis rs11997175 0.679 rs10954935 ENSG00000240738.1 RP1-273G13.1 4.02 9.01e-05 0.0308 0.35 0.31 Body mass index; chr8:33812861 chr8:33859480~33860223:- PAAD cis rs4853525 0.923 rs7570775 ENSG00000235852.1 AC005540.3 4.02 9.01e-05 0.0308 0.43 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190864428 chr2:190880797~190882059:- PAAD cis rs9601248 0.627 rs9545151 ENSG00000227354.5 RBM26-AS1 -4.02 9.01e-05 0.0308 -0.32 -0.31 Major depressive disorder; chr13:79608400 chr13:79406309~79424328:+ PAAD cis rs9601248 0.627 rs2876741 ENSG00000227354.5 RBM26-AS1 -4.02 9.01e-05 0.0308 -0.32 -0.31 Major depressive disorder; chr13:79612577 chr13:79406309~79424328:+ PAAD cis rs9487094 0.677 rs13203636 ENSG00000260273.1 RP11-425D10.10 4.02 9.01e-05 0.0308 0.44 0.31 Height; chr6:109741085 chr6:109382795~109383666:+ PAAD cis rs7923609 0.871 rs10761787 ENSG00000232075.1 MRPL35P2 -4.02 9.01e-05 0.0308 -0.38 -0.31 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63593995 chr10:63634317~63634827:- PAAD cis rs10932679 1 rs10932679 ENSG00000229352.1 AC007563.3 4.02 9.01e-05 0.0308 0.38 0.31 Pulse pressure; chr2:216787868 chr2:216799608~216805335:+ PAAD cis rs10932679 0.901 rs12465693 ENSG00000229352.1 AC007563.3 4.02 9.01e-05 0.0308 0.38 0.31 Pulse pressure; chr2:216788844 chr2:216799608~216805335:+ PAAD cis rs10932679 0.901 rs13027512 ENSG00000229352.1 AC007563.3 4.02 9.01e-05 0.0308 0.38 0.31 Pulse pressure; chr2:216792041 chr2:216799608~216805335:+ PAAD cis rs10932679 0.901 rs6435954 ENSG00000229352.1 AC007563.3 4.02 9.01e-05 0.0308 0.38 0.31 Pulse pressure; chr2:216793857 chr2:216799608~216805335:+ PAAD cis rs10761482 0.515 rs2393642 ENSG00000254271.1 RP11-131N11.4 4.02 9.01e-05 0.0308 0.37 0.31 Schizophrenia; chr10:60522732 chr10:60734342~60741828:+ PAAD cis rs11089937 0.637 rs988200 ENSG00000211638.2 IGLV8-61 -4.02 9.02e-05 0.0308 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22154715 chr22:22098700~22099212:+ PAAD cis rs7078219 0.543 rs7096296 ENSG00000228778.1 RP11-129J12.1 4.02 9.02e-05 0.0308 0.34 0.31 Dental caries; chr10:99518059 chr10:99527081~99528261:+ PAAD cis rs2115630 0.641 rs11073613 ENSG00000275120.1 RP11-182J1.17 -4.02 9.02e-05 0.0308 -0.31 -0.31 P wave terminal force; chr15:84642662 chr15:84599434~84606463:- PAAD cis rs338389 0.867 rs7402193 ENSG00000260657.2 RP11-315D16.4 -4.02 9.03e-05 0.0308 -0.32 -0.31 Survival in rectal cancer; chr15:67984513 chr15:68267792~68277994:- PAAD cis rs2404602 0.583 rs12592501 ENSG00000259422.1 RP11-593F23.1 4.02 9.03e-05 0.0308 0.36 0.31 Blood metabolite levels; chr15:76262449 chr15:76174891~76181486:- PAAD cis rs950880 0.71 rs11693204 ENSG00000234389.1 AC007278.3 -4.02 9.03e-05 0.0308 -0.3 -0.31 Serum protein levels (sST2); chr2:102319514 chr2:102438713~102440475:+ PAAD cis rs950880 0.645 rs11679889 ENSG00000234389.1 AC007278.3 -4.02 9.03e-05 0.0308 -0.3 -0.31 Serum protein levels (sST2); chr2:102324549 chr2:102438713~102440475:+ PAAD cis rs10740039 0.768 rs10761549 ENSG00000254271.1 RP11-131N11.4 4.02 9.03e-05 0.0308 0.36 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60701902 chr10:60734342~60741828:+ PAAD cis rs919433 0.68 rs3792160 ENSG00000231621.1 AC013264.2 -4.02 9.04e-05 0.0309 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197538795 chr2:197197991~197199273:+ PAAD cis rs919433 0.68 rs11680291 ENSG00000231621.1 AC013264.2 -4.02 9.04e-05 0.0309 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197545160 chr2:197197991~197199273:+ PAAD cis rs919433 0.648 rs6434933 ENSG00000231621.1 AC013264.2 -4.02 9.04e-05 0.0309 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197562236 chr2:197197991~197199273:+ PAAD cis rs919433 0.68 rs67580728 ENSG00000231621.1 AC013264.2 -4.02 9.04e-05 0.0309 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197566534 chr2:197197991~197199273:+ PAAD cis rs919433 0.68 rs6434934 ENSG00000231621.1 AC013264.2 -4.02 9.04e-05 0.0309 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197572662 chr2:197197991~197199273:+ PAAD cis rs4835473 0.9 rs10003922 ENSG00000251600.4 RP11-673E1.1 -4.02 9.05e-05 0.0309 -0.36 -0.31 Immature fraction of reticulocytes; chr4:143921235 chr4:143912331~143982454:+ PAAD cis rs891378 1 rs10864180 ENSG00000274245.1 RP11-357P18.2 -4.02 9.06e-05 0.0309 -0.43 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207272416 chr1:207372559~207373252:+ PAAD cis rs13392177 0.672 rs4674270 ENSG00000261338.2 RP11-378A13.1 -4.02 9.06e-05 0.0309 -0.36 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218188418 chr2:218255319~218257366:+ PAAD cis rs748404 0.723 rs11853991 ENSG00000205771.5 CATSPER2P1 -4.02 9.07e-05 0.031 -0.41 -0.31 Lung cancer; chr15:43265351 chr15:43726918~43747094:- PAAD cis rs8026198 0.929 rs8037020 ENSG00000260571.1 BNIP3P5 4.02 9.07e-05 0.031 0.51 0.31 Fibrinogen levels; chr15:42280869 chr15:42313687~42314386:+ PAAD cis rs633715 0.76 rs12731430 ENSG00000254154.7 RP4-798P15.3 -4.02 9.08e-05 0.031 -0.29 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177839985 chr1:177928788~178038007:- PAAD cis rs633715 0.733 rs12737338 ENSG00000254154.7 RP4-798P15.3 -4.02 9.08e-05 0.031 -0.29 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177842804 chr1:177928788~178038007:- PAAD cis rs9649213 0.593 rs10953257 ENSG00000272950.1 RP11-307C18.1 -4.02 9.08e-05 0.031 -0.36 -0.31 Prostate cancer (SNP x SNP interaction); chr7:98331352 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6969731 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98295259 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6970801 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98295928 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6975156 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98296222 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs12704982 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98296741 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs34129434 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98297152 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs12704983 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98297733 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7781916 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98300426 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs736753 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98302177 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs736754 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98302247 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs13232181 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98306359 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs3801264 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98321308 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs1468338 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98321806 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs2158553 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98321819 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs10808107 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98322359 chr7:98322853~98323430:+ PAAD cis rs9649213 0.613 rs10953256 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98322574 chr7:98322853~98323430:+ PAAD cis rs9649213 0.613 rs2286074 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98322699 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7458551 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98322855 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7789380 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98326868 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6948540 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98330754 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs6979373 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98332532 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs34717219 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98332959 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs62478177 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98335299 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs3801263 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98335704 chr7:98322853~98323430:+ PAAD cis rs9649213 0.555 rs12667634 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98336130 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs3801257 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98362480 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7803372 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98362945 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6465677 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98374240 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6465678 ENSG00000272950.1 RP11-307C18.1 4.02 9.08e-05 0.031 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98374745 chr7:98322853~98323430:+ PAAD cis rs2739330 0.828 rs5751770 ENSG00000206090.4 AP000350.7 4.02 9.08e-05 0.031 0.39 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23939998~23942798:+ PAAD cis rs526231 0.697 rs422115 ENSG00000175749.11 EIF3KP1 4.02 9.08e-05 0.031 0.45 0.31 Primary biliary cholangitis; chr5:103298639 chr5:103032376~103033031:+ PAAD cis rs4819052 0.851 rs2838865 ENSG00000223768.1 LINC00205 -4.02 9.09e-05 0.031 -0.32 -0.31 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45292384 chr21:45293285~45297354:+ PAAD cis rs440932 1 rs378974 ENSG00000254340.1 RP11-10A14.3 4.02 9.09e-05 0.031 0.4 0.31 High light scatter reticulocyte percentage of red cells; chr8:9169129 chr8:9141424~9145435:+ PAAD cis rs2348418 0.832 rs11049587 ENSG00000247934.4 RP11-967K21.1 4.02 9.09e-05 0.031 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28418090 chr12:28163298~28190738:- PAAD cis rs2980439 0.846 rs2980437 ENSG00000253981.4 ALG1L13P -4.02 9.09e-05 0.031 -0.38 -0.31 Neuroticism; chr8:8237241 chr8:8236003~8244667:- PAAD cis rs7202877 0.61 rs7202284 ENSG00000261783.1 RP11-252K23.2 -4.02 9.09e-05 0.031 -0.48 -0.31 Type 1 diabetes;Type 2 diabetes; chr16:75340448 chr16:75379818~75381260:- PAAD cis rs79040073 0.637 rs111375880 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49120197 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs17394420 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49128619 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs17473148 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49137213 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs74798636 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49143146 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs79455310 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49146918 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs79979867 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49177261 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs80214300 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49180767 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs79723325 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49193423 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs77815234 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49193495 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs77965410 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49194450 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs112792737 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49198849 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs75391491 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49210376 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs12913966 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49214290 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs75691966 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49214743 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs117582142 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49228624 chr15:48729080~48729844:- PAAD cis rs79040073 0.565 rs11638515 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49233530 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs11632303 ENSG00000259469.1 RP11-227D13.4 -4.02 9.09e-05 0.031 -0.49 -0.31 Lung cancer in ever smokers; chr15:49238124 chr15:48729080~48729844:- PAAD cis rs116139393 0.54 rs13224907 ENSG00000187953.9 PMS2CL -4.02 9.1e-05 0.031 -0.38 -0.31 Alzheimer's disease (APOE e4 interaction); chr7:6734261 chr7:6710128~6753862:+ PAAD cis rs1707322 0.721 rs4660314 ENSG00000280836.1 AL355480.1 -4.02 9.1e-05 0.031 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764213 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs12069121 ENSG00000280836.1 AL355480.1 -4.02 9.1e-05 0.031 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45766312 chr1:45581219~45581321:- PAAD cis rs1707322 0.686 rs61784833 ENSG00000280836.1 AL355480.1 -4.02 9.1e-05 0.031 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45768100 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs7519900 ENSG00000280836.1 AL355480.1 -4.02 9.1e-05 0.031 -0.37 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769275 chr1:45581219~45581321:- PAAD cis rs950169 0.84 rs12905223 ENSG00000259683.1 RP11-182J1.14 4.02 9.1e-05 0.031 0.25 0.31 Schizophrenia; chr15:84571037 chr15:84389729~84395903:+ PAAD cis rs2255336 0.808 rs59611026 ENSG00000245648.1 RP11-277P12.20 -4.02 9.11e-05 0.031 -0.45 -0.31 Blood protein levels; chr12:10445387 chr12:10363769~10398506:+ PAAD cis rs6545883 0.524 rs4599092 ENSG00000273302.1 RP11-493E12.2 -4.02 9.11e-05 0.031 -0.27 -0.31 Tuberculosis; chr2:61271833 chr2:61199979~61200769:+ PAAD cis rs6545883 0.524 rs12713435 ENSG00000273302.1 RP11-493E12.2 -4.02 9.11e-05 0.031 -0.27 -0.31 Tuberculosis; chr2:61272654 chr2:61199979~61200769:+ PAAD cis rs6908034 0.505 rs76709285 ENSG00000228412.5 RP4-625H18.2 4.02 9.11e-05 0.031 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19804099 chr6:19802164~19804752:- PAAD cis rs7927592 0.913 rs12363722 ENSG00000212093.1 AP000807.1 4.02 9.11e-05 0.031 0.38 0.31 Total body bone mineral density; chr11:68468823 chr11:68506083~68506166:- PAAD cis rs7927592 0.871 rs12360903 ENSG00000212093.1 AP000807.1 4.02 9.11e-05 0.031 0.38 0.31 Total body bone mineral density; chr11:68468846 chr11:68506083~68506166:- PAAD cis rs2729354 0.768 rs2848635 ENSG00000265566.2 RN7SL605P -4.02 9.11e-05 0.0311 -0.39 -0.31 Blood protein levels; chr11:57486458 chr11:57528085~57528365:- PAAD cis rs9322193 0.607 rs9371228 ENSG00000268592.3 RAET1E-AS1 -4.02 9.11e-05 0.0311 -0.41 -0.31 Lung cancer; chr6:149921977 chr6:149863494~149919507:+ PAAD cis rs9322193 0.566 rs4870118 ENSG00000268592.3 RAET1E-AS1 -4.02 9.11e-05 0.0311 -0.41 -0.31 Lung cancer; chr6:149923877 chr6:149863494~149919507:+ PAAD cis rs9322193 0.566 rs4869767 ENSG00000268592.3 RAET1E-AS1 -4.02 9.11e-05 0.0311 -0.41 -0.31 Lung cancer; chr6:149923974 chr6:149863494~149919507:+ PAAD cis rs9322193 0.566 rs4869768 ENSG00000268592.3 RAET1E-AS1 -4.02 9.11e-05 0.0311 -0.41 -0.31 Lung cancer; chr6:149924067 chr6:149863494~149919507:+ PAAD cis rs498136 0.966 rs652190 ENSG00000250508.1 RP11-757G1.6 4.02 9.12e-05 0.0311 0.39 0.31 Cutaneous malignant melanoma;Melanoma; chr11:69573375 chr11:68870664~68874542:+ PAAD cis rs9309711 0.922 rs13399524 ENSG00000225234.1 TRAPPC12-AS1 -4.02 9.12e-05 0.0311 -0.34 -0.31 Neurofibrillary tangles; chr2:3476435 chr2:3481242~3482409:- PAAD cis rs6570726 0.935 rs430561 ENSG00000235652.6 RP11-545I5.3 4.02 9.12e-05 0.0311 0.25 0.31 Lobe attachment (rater-scored or self-reported); chr6:145492004 chr6:145799409~145886585:+ PAAD cis rs6504622 0.818 rs3851784 ENSG00000214401.4 KANSL1-AS1 4.02 9.12e-05 0.0311 0.39 0.31 Orofacial clefts; chr17:46962751 chr17:46193576~46196723:+ PAAD cis rs7829975 0.627 rs2979172 ENSG00000253981.4 ALG1L13P 4.02 9.12e-05 0.0311 0.36 0.31 Mood instability; chr8:8452998 chr8:8236003~8244667:- PAAD cis rs2243480 1 rs316330 ENSG00000273142.1 RP11-458F8.4 -4.02 9.12e-05 0.0311 -0.28 -0.31 Diabetic kidney disease; chr7:66140385 chr7:66902857~66906297:+ PAAD cis rs858239 0.539 rs2103281 ENSG00000226816.2 AC005082.12 4.02 9.13e-05 0.0311 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23154612 chr7:23206013~23208045:+ PAAD cis rs17711722 0.565 rs4275112 ENSG00000213640.3 EEF1DP4 4.02 9.13e-05 0.0311 0.32 0.31 Calcium levels; chr7:65733651 chr7:64862999~64864370:+ PAAD cis rs858239 0.568 rs6970694 ENSG00000226816.2 AC005082.12 4.02 9.14e-05 0.0311 0.36 0.31 Cerebrospinal fluid biomarker levels; chr7:23211209 chr7:23206013~23208045:+ PAAD cis rs6921919 0.638 rs1416920 ENSG00000204709.4 LINC01556 4.02 9.14e-05 0.0311 0.45 0.31 Autism spectrum disorder or schizophrenia; chr6:28335007 chr6:28943877~28944537:+ PAAD cis rs6921919 0.525 rs1361386 ENSG00000204709.4 LINC01556 4.02 9.14e-05 0.0311 0.45 0.31 Autism spectrum disorder or schizophrenia; chr6:28337827 chr6:28943877~28944537:+ PAAD cis rs6921919 0.638 rs6456815 ENSG00000204709.4 LINC01556 4.02 9.14e-05 0.0311 0.45 0.31 Autism spectrum disorder or schizophrenia; chr6:28338360 chr6:28943877~28944537:+ PAAD cis rs6921919 0.638 rs2108926 ENSG00000204709.4 LINC01556 4.02 9.14e-05 0.0311 0.45 0.31 Autism spectrum disorder or schizophrenia; chr6:28340970 chr6:28943877~28944537:+ PAAD cis rs9876781 1 rs6784322 ENSG00000229759.1 MRPS18AP1 4.02 9.14e-05 0.0311 0.35 0.31 Longevity; chr3:48380745 chr3:48256350~48256938:- PAAD cis rs7829975 0.593 rs2979241 ENSG00000253981.4 ALG1L13P 4.02 9.14e-05 0.0311 0.37 0.31 Mood instability; chr8:8445843 chr8:8236003~8244667:- PAAD cis rs4713118 0.662 rs156744 ENSG00000204709.4 LINC01556 4.02 9.14e-05 0.0311 0.51 0.31 Parkinson's disease; chr6:27999496 chr6:28943877~28944537:+ PAAD cis rs5742933 0.817 rs1233297 ENSG00000253559.1 OSGEPL1-AS1 -4.02 9.14e-05 0.0311 -0.32 -0.31 Ferritin levels; chr2:189829449 chr2:189762704~189765556:+ PAAD cis rs6479901 0.841 rs1904297 ENSG00000232075.1 MRPL35P2 -4.02 9.15e-05 0.0312 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63255428 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs10822150 ENSG00000232075.1 MRPL35P2 -4.02 9.15e-05 0.0312 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63257736 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs7909555 ENSG00000232075.1 MRPL35P2 -4.02 9.15e-05 0.0312 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63273348 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs4417159 ENSG00000232075.1 MRPL35P2 -4.02 9.15e-05 0.0312 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63285938 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs10995493 ENSG00000232075.1 MRPL35P2 -4.02 9.15e-05 0.0312 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63287266 chr10:63634317~63634827:- PAAD cis rs1665050 1 rs1665050 ENSG00000277144.1 RP11-59H7.4 4.02 9.15e-05 0.0312 0.36 0.31 Atopic dermatitis; chr15:59001406 chr15:59115547~59116089:- PAAD cis rs2243480 1 rs2243480 ENSG00000273142.1 RP11-458F8.4 -4.02 9.15e-05 0.0312 -0.28 -0.31 Diabetic kidney disease; chr7:66134209 chr7:66902857~66906297:+ PAAD cis rs10129255 0.518 rs10150460 ENSG00000211972.2 IGHV3-66 -4.02 9.15e-05 0.0312 -0.24 -0.31 Kawasaki disease; chr14:106677179 chr14:106675017~106675544:- PAAD cis rs875971 0.893 rs62465470 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66136231 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs4368860 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66143495 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs908915 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66149664 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs7809814 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66150410 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs7786892 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66163889 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs2420174 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66180374 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs2420173 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66180412 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs4718319 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66187797 chr7:66554588~66576923:- PAAD cis rs875971 0.723 rs28391294 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66189328 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs6967708 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66192326 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs7782806 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66192910 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs880166 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66205775 chr7:66554588~66576923:- PAAD cis rs875971 0.756 rs4718328 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66228350 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs4718330 ENSG00000232559.3 GS1-124K5.12 -4.02 9.15e-05 0.0312 -0.34 -0.31 Aortic root size; chr7:66250256 chr7:66554588~66576923:- PAAD cis rs9649213 0.593 rs10953255 ENSG00000272950.1 RP11-307C18.1 4.02 9.16e-05 0.0312 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98293886 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs6961790 ENSG00000272950.1 RP11-307C18.1 4.02 9.16e-05 0.0312 0.36 0.31 Prostate cancer (SNP x SNP interaction); chr7:98378681 chr7:98322853~98323430:+ PAAD cis rs3906453 1 rs9957265 ENSG00000277324.1 RP11-850A17.1 -4.02 9.16e-05 0.0312 -0.39 -0.31 Response to exercise (triglyceride level interaction); chr18:53714401 chr18:54268346~54270028:- PAAD cis rs12130219 0.588 rs2282302 ENSG00000237975.5 FLG-AS1 4.02 9.16e-05 0.0312 0.37 0.31 Inflammatory skin disease; chr1:152356893 chr1:152168125~152445456:+ PAAD cis rs755249 0.51 rs599892 ENSG00000228060.1 RP11-69E11.8 -4.02 9.17e-05 0.0312 -0.3 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39457212 chr1:39565160~39573203:+ PAAD cis rs10750441 0.571 rs1628692 ENSG00000255455.2 RP11-890B15.3 4.02 9.17e-05 0.0312 0.28 0.31 Pulse pressure; chr11:130558398 chr11:130866254~130870247:- PAAD cis rs75804782 0.63 rs11900807 ENSG00000186235.9 AC016757.3 4.02 9.17e-05 0.0312 0.72 0.31 Chronotype;Morning vs. evening chronotype; chr2:238401348 chr2:238224552~238231677:- PAAD cis rs75804782 0.63 rs57435966 ENSG00000186235.9 AC016757.3 4.02 9.17e-05 0.0312 0.72 0.31 Chronotype;Morning vs. evening chronotype; chr2:238402728 chr2:238224552~238231677:- PAAD cis rs75804782 0.515 rs11897824 ENSG00000186235.9 AC016757.3 4.02 9.17e-05 0.0312 0.72 0.31 Chronotype;Morning vs. evening chronotype; chr2:238402804 chr2:238224552~238231677:- PAAD cis rs710216 0.536 rs710221 ENSG00000227533.4 SLC2A1-AS1 4.02 9.17e-05 0.0312 0.34 0.31 Red cell distribution width; chr1:42948529 chr1:42959049~42983358:+ PAAD cis rs801193 0.66 rs10950049 ENSG00000237310.1 GS1-124K5.4 4.02 9.18e-05 0.0312 0.3 0.31 Aortic root size; chr7:66765873 chr7:66493706~66495474:+ PAAD cis rs10779751 0.708 rs2746640 ENSG00000238199.1 UBE2V2P3 -4.02 9.18e-05 0.0312 -0.37 -0.31 Body mass index; chr1:11232895 chr1:11278616~11279351:- PAAD cis rs79040073 0.637 rs73408143 ENSG00000259531.2 RP11-295H24.3 4.02 9.18e-05 0.0312 0.52 0.31 Lung cancer in ever smokers; chr15:49126771 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs3088333 ENSG00000259531.2 RP11-295H24.3 4.02 9.18e-05 0.0312 0.52 0.31 Lung cancer in ever smokers; chr15:49140891 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs17394970 ENSG00000259531.2 RP11-295H24.3 4.02 9.18e-05 0.0312 0.52 0.31 Lung cancer in ever smokers; chr15:49145371 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11635455 ENSG00000259531.2 RP11-295H24.3 4.02 9.18e-05 0.0312 0.52 0.31 Lung cancer in ever smokers; chr15:49147216 chr15:49365124~49366685:- PAAD cis rs79040073 0.599 rs73390384 ENSG00000259531.2 RP11-295H24.3 4.02 9.18e-05 0.0312 0.52 0.31 Lung cancer in ever smokers; chr15:49180905 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs7177624 ENSG00000259531.2 RP11-295H24.3 4.02 9.18e-05 0.0312 0.52 0.31 Lung cancer in ever smokers; chr15:49189515 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs78298181 ENSG00000259531.2 RP11-295H24.3 4.02 9.18e-05 0.0312 0.52 0.31 Lung cancer in ever smokers; chr15:49213350 chr15:49365124~49366685:- PAAD cis rs1150668 0.83 rs213240 ENSG00000219891.2 ZSCAN12P1 4.02 9.19e-05 0.0313 0.4 0.31 Pubertal anthropometrics; chr6:28348098 chr6:28091154~28093664:+ PAAD cis rs10779751 1 rs4845858 ENSG00000238199.1 UBE2V2P3 -4.02 9.19e-05 0.0313 -0.37 -0.31 Body mass index; chr1:11244663 chr1:11278616~11279351:- PAAD cis rs853679 0.825 rs8180562 ENSG00000226314.6 ZNF192P1 -4.02 9.19e-05 0.0313 -0.6 -0.31 Depression; chr6:28173682 chr6:28161781~28169594:+ PAAD cis rs853679 0.882 rs9380064 ENSG00000226314.6 ZNF192P1 -4.02 9.19e-05 0.0313 -0.6 -0.31 Depression; chr6:28175340 chr6:28161781~28169594:+ PAAD cis rs6547741 0.752 rs7562863 ENSG00000234072.1 AC074117.10 -4.02 9.19e-05 0.0313 -0.26 -0.31 Oral cavity cancer; chr2:27669827 chr2:27356246~27367622:+ PAAD cis rs6844153 0.752 rs58968032 ENSG00000240005.4 RP11-293A21.1 -4.02 9.19e-05 0.0313 -0.49 -0.31 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26884674 chr4:26859806~26860599:- PAAD cis rs2832191 1 rs2832189 ENSG00000215533.7 LINC00189 4.02 9.2e-05 0.0313 0.38 0.31 Dental caries; chr21:29115093 chr21:29193480~29288205:+ PAAD cis rs2832191 1 rs6516891 ENSG00000215533.7 LINC00189 4.02 9.2e-05 0.0313 0.38 0.31 Dental caries; chr21:29110749 chr21:29193480~29288205:+ PAAD cis rs2832191 1 rs2832184 ENSG00000215533.7 LINC00189 4.02 9.2e-05 0.0313 0.38 0.31 Dental caries; chr21:29110944 chr21:29193480~29288205:+ PAAD cis rs2832191 1 rs2832185 ENSG00000215533.7 LINC00189 4.02 9.2e-05 0.0313 0.38 0.31 Dental caries; chr21:29111440 chr21:29193480~29288205:+ PAAD cis rs72843506 0.656 rs28567541 ENSG00000189423.10 USP32P3 4.02 9.2e-05 0.0313 0.44 0.31 Schizophrenia; chr17:20051789 chr17:20415547~20431008:+ PAAD cis rs76747430 0.504 rs8138982 ENSG00000227413.1 RP5-1042K10.12 -4.02 9.21e-05 0.0313 -0.36 -0.31 Facial morphology (factor 20); chr22:40214394 chr22:40433136~40433641:+ PAAD cis rs5757906 0.889 rs138019 ENSG00000227413.1 RP5-1042K10.12 -4.02 9.21e-05 0.0313 -0.36 -0.31 Neutrophil percentage of white cells; chr22:40215624 chr22:40433136~40433641:+ PAAD cis rs7216064 0.861 rs12449312 ENSG00000278219.1 AC145343.1 -4.02 9.21e-05 0.0313 -0.5 -0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67833242 chr17:68101538~68101639:+ PAAD cis rs4835473 0.897 rs2036880 ENSG00000251600.4 RP11-673E1.1 4.02 9.21e-05 0.0313 0.34 0.31 Immature fraction of reticulocytes; chr4:143907834 chr4:143912331~143982454:+ PAAD cis rs2404602 0.735 rs2468130 ENSG00000259422.1 RP11-593F23.1 -4.02 9.22e-05 0.0313 -0.37 -0.31 Blood metabolite levels; chr15:76504155 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs2048856 ENSG00000259422.1 RP11-593F23.1 -4.02 9.22e-05 0.0313 -0.37 -0.31 Blood metabolite levels; chr15:76507742 chr15:76174891~76181486:- PAAD cis rs6723226 0.521 rs1991626 ENSG00000276334.1 AL133243.1 -4.02 9.22e-05 0.0313 -0.36 -0.31 Intelligence (multi-trait analysis); chr2:32377382 chr2:32521927~32523547:+ PAAD cis rs526231 0.697 rs253754 ENSG00000175749.11 EIF3KP1 4.02 9.22e-05 0.0313 0.44 0.31 Primary biliary cholangitis; chr5:103296261 chr5:103032376~103033031:+ PAAD cis rs950169 0.96 rs12905475 ENSG00000275120.1 RP11-182J1.17 4.02 9.22e-05 0.0313 0.34 0.31 Schizophrenia; chr15:84131743 chr15:84599434~84606463:- PAAD cis rs13256369 0.951 rs10503394 ENSG00000253981.4 ALG1L13P 4.02 9.22e-05 0.0314 0.42 0.31 Obesity-related traits; chr8:8708265 chr8:8236003~8244667:- PAAD cis rs6539288 0.63 rs10778520 ENSG00000260329.1 RP11-412D9.4 4.02 9.22e-05 0.0314 0.28 0.31 Total body bone mineral density; chr12:106971095 chr12:106954029~106955497:- PAAD cis rs6908034 0.66 rs74457659 ENSG00000228412.5 RP4-625H18.2 4.02 9.22e-05 0.0314 0.61 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19760494 chr6:19802164~19804752:- PAAD cis rs34375054 0.66 rs35941060 ENSG00000279233.1 RP11-158L12.4 4.02 9.23e-05 0.0314 0.28 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125109699 chr12:125138245~125141711:+ PAAD cis rs7772486 0.742 rs4896851 ENSG00000235652.6 RP11-545I5.3 -4.02 9.23e-05 0.0314 -0.27 -0.31 Lobe attachment (rater-scored or self-reported); chr6:145957823 chr6:145799409~145886585:+ PAAD cis rs5015933 0.815 rs3861866 ENSG00000232630.1 PRPS1P2 -4.02 9.23e-05 0.0314 -0.28 -0.31 Body mass index; chr9:125258595 chr9:125150653~125151589:+ PAAD cis rs8030379 0.967 rs2401171 ENSG00000230373.7 GOLGA6L5P -4.02 9.23e-05 0.0314 -0.25 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83888924 chr15:84507885~84516814:- PAAD cis rs2243480 1 rs6964530 ENSG00000228409.4 CCT6P1 -4.02 9.24e-05 0.0314 -0.33 -0.31 Diabetic kidney disease; chr7:66253864 chr7:65751142~65763354:+ PAAD cis rs7759001 0.744 rs13217798 ENSG00000271755.1 RP1-153G14.4 4.02 9.24e-05 0.0314 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27414801 chr6:27404010~27406964:- PAAD cis rs7759001 0.779 rs7754977 ENSG00000271755.1 RP1-153G14.4 4.02 9.24e-05 0.0314 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27417991 chr6:27404010~27406964:- PAAD cis rs7216064 1 rs7221651 ENSG00000278219.1 AC145343.1 4.02 9.25e-05 0.0314 0.48 0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67836274 chr17:68101538~68101639:+ PAAD cis rs1873386 0.79 rs12580023 ENSG00000255910.1 RP11-405A12.2 4.02 9.25e-05 0.0314 0.44 0.31 Personality dimensions; chr12:18912337 chr12:19775451~20009937:+ PAAD cis rs6951245 0.554 rs118191017 ENSG00000229043.2 AC091729.9 -4.02 9.25e-05 0.0314 -0.4 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1116210 chr7:1160374~1165267:+ PAAD cis rs12935418 0.616 rs8045512 ENSG00000261061.1 RP11-303E16.2 -4.02 9.26e-05 0.0315 -0.42 -0.31 Mean corpuscular volume; chr16:80952410 chr16:81030770~81031485:+ PAAD cis rs12935418 0.616 rs718954 ENSG00000261061.1 RP11-303E16.2 -4.02 9.26e-05 0.0315 -0.42 -0.31 Mean corpuscular volume; chr16:80953219 chr16:81030770~81031485:+ PAAD cis rs7520050 0.966 rs1707321 ENSG00000280836.1 AL355480.1 4.02 9.26e-05 0.0315 0.35 0.31 Reticulocyte count;Red blood cell count; chr1:46039637 chr1:45581219~45581321:- PAAD cis rs58521262 0.546 rs73031452 ENSG00000241282.1 RPL34P33 4.02 9.27e-05 0.0315 0.56 0.31 Testicular germ cell tumor; chr19:23166429 chr19:22699352~22699685:+ PAAD cis rs9487094 0.922 rs2275650 ENSG00000260273.1 RP11-425D10.10 4.02 9.28e-05 0.0315 0.4 0.31 Height; chr6:109347085 chr6:109382795~109383666:+ PAAD cis rs9487094 0.885 rs3818934 ENSG00000260273.1 RP11-425D10.10 4.02 9.28e-05 0.0315 0.4 0.31 Height; chr6:109347277 chr6:109382795~109383666:+ PAAD cis rs9487094 0.961 rs1040284 ENSG00000260273.1 RP11-425D10.10 4.02 9.28e-05 0.0315 0.4 0.31 Height; chr6:109352730 chr6:109382795~109383666:+ PAAD cis rs9487094 0.961 rs34202013 ENSG00000260273.1 RP11-425D10.10 4.02 9.28e-05 0.0315 0.4 0.31 Height; chr6:109353355 chr6:109382795~109383666:+ PAAD cis rs11992186 0.505 rs7845203 ENSG00000253893.2 FAM85B -4.02 9.28e-05 0.0315 -0.43 -0.31 Neuroticism; chr8:8287918 chr8:8167819~8226614:- PAAD cis rs2015599 0.563 rs11050168 ENSG00000275476.1 RP11-996F15.4 4.02 9.28e-05 0.0315 0.29 0.31 Platelet count;Mean platelet volume; chr12:29273760 chr12:29277397~29277882:- PAAD cis rs2179367 0.959 rs489551 ENSG00000231760.4 RP11-350J20.5 4.02 9.28e-05 0.0315 0.39 0.31 Dupuytren's disease; chr6:149368321 chr6:149796151~149826294:- PAAD cis rs2243480 0.901 rs3813708 ENSG00000228409.4 CCT6P1 4.02 9.29e-05 0.0315 0.33 0.31 Diabetic kidney disease; chr7:65840645 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs73142122 ENSG00000228409.4 CCT6P1 4.02 9.29e-05 0.0315 0.33 0.31 Diabetic kidney disease; chr7:65846311 chr7:65751142~65763354:+ PAAD cis rs891378 1 rs10864181 ENSG00000274245.1 RP11-357P18.2 -4.02 9.29e-05 0.0316 -0.44 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207274706 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs971317 ENSG00000274245.1 RP11-357P18.2 -4.02 9.29e-05 0.0316 -0.44 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207302695 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs2802238 ENSG00000274245.1 RP11-357P18.2 -4.02 9.29e-05 0.0316 -0.44 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207302796 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs2564978 ENSG00000274245.1 RP11-357P18.2 -4.02 9.29e-05 0.0316 -0.44 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207321071 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs2782828 ENSG00000274245.1 RP11-357P18.2 -4.02 9.29e-05 0.0316 -0.44 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207323654 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs2802236 ENSG00000274245.1 RP11-357P18.2 4.02 9.29e-05 0.0316 0.44 0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207298844 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs971318 ENSG00000274245.1 RP11-357P18.2 4.02 9.29e-05 0.0316 0.44 0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207302251 chr1:207372559~207373252:+ PAAD cis rs3096299 0.685 rs12935112 ENSG00000261253.2 AC137932.6 -4.02 9.3e-05 0.0316 -0.32 -0.31 Multiple myeloma (IgH translocation); chr16:89476450 chr16:89321133~89325110:+ PAAD cis rs12468579 0.74 rs11894425 ENSG00000235852.1 AC005540.3 4.02 9.3e-05 0.0316 0.38 0.31 JT interval (sulfonylurea treatment interaction); chr2:190973115 chr2:190880797~190882059:- PAAD cis rs9926296 0.618 rs8058179 ENSG00000260259.1 RP11-368I7.4 4.02 9.3e-05 0.0316 0.36 0.31 Vitiligo; chr16:89780579 chr16:89682620~89686569:- PAAD cis rs8072100 0.688 rs12602134 ENSG00000228782.6 CTD-2026D20.3 -4.02 9.3e-05 0.0316 -0.3 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47504770 chr17:47450568~47492492:- PAAD cis rs3738443 0.817 rs6698690 ENSG00000259865.1 RP11-488L18.10 4.02 9.3e-05 0.0316 0.28 0.31 Alcohol dependence; chr1:247199176 chr1:247187281~247188526:- PAAD cis rs812925 0.537 rs10865324 ENSG00000273302.1 RP11-493E12.2 -4.02 9.3e-05 0.0316 -0.27 -0.31 Immature fraction of reticulocytes; chr2:61394172 chr2:61199979~61200769:+ PAAD cis rs496547 0.719 rs472641 ENSG00000278376.1 RP11-158I9.8 -4.02 9.3e-05 0.0316 -0.28 -0.31 Hip minimal joint space width; chr11:118746835 chr11:118791254~118793137:+ PAAD cis rs10759883 0.612 rs2943532 ENSG00000175611.10 LINC00476 4.02 9.31e-05 0.0316 0.31 0.31 Nicotine dependence; chr9:96024975 chr9:95759231~95875977:- PAAD cis rs7592578 0.766 rs62182885 ENSG00000231858.4 AC067945.4 -4.02 9.31e-05 0.0316 -0.37 -0.31 Diastolic blood pressure; chr2:190572298 chr2:191021526~191032314:+ PAAD cis rs1910358 0.554 rs10057796 ENSG00000248874.4 C5orf17 4.02 9.31e-05 0.0316 0.44 0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23759637 chr5:23951348~24178263:+ PAAD cis rs1167827 1 rs1167827 ENSG00000205583.12 STAG3L1 4.01 9.31e-05 0.0316 0.34 0.31 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75533848 chr7:75359194~75395383:+ PAAD cis rs526231 0.697 rs168820 ENSG00000175749.11 EIF3KP1 4.01 9.32e-05 0.0316 0.45 0.31 Primary biliary cholangitis; chr5:103306972 chr5:103032376~103033031:+ PAAD cis rs7219451 0.655 rs8067028 ENSG00000222881.1 Y_RNA -4.01 9.32e-05 0.0316 -0.37 -0.31 Glucose homeostasis traits; chr17:40817777 chr17:40391232~40391338:- PAAD cis rs1969253 0.803 rs843362 ENSG00000205955.4 HSP90AA5P -4.01 9.32e-05 0.0316 -0.39 -0.31 Major depressive disorder; chr3:184146241 chr3:184115352~184117898:+ PAAD cis rs7927592 0.956 rs7106259 ENSG00000212093.1 AP000807.1 4.01 9.32e-05 0.0316 0.35 0.31 Total body bone mineral density; chr11:68531044 chr11:68506083~68506166:- PAAD cis rs683250 0.538 rs11233584 ENSG00000227097.5 RPS28P7 4.01 9.33e-05 0.0316 0.39 0.31 Subcortical brain region volumes; chr11:83362214 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs12795811 ENSG00000227097.5 RPS28P7 4.01 9.33e-05 0.0316 0.39 0.31 Subcortical brain region volumes; chr11:83366943 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs1943741 ENSG00000227097.5 RPS28P7 4.01 9.33e-05 0.0316 0.39 0.31 Subcortical brain region volumes; chr11:83369295 chr11:82689559~82689768:+ PAAD cis rs8062405 0.69 rs62034351 ENSG00000251417.2 RP11-1348G14.4 -4.01 9.33e-05 0.0316 -0.3 -0.31 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28554168 chr16:28802743~28817828:+ PAAD cis rs10853057 0.85 rs8076385 ENSG00000214174.7 AMZ2P1 4.01 9.33e-05 0.0316 0.59 0.31 White matter microstructure (global fractional anisotropy); chr17:65002369 chr17:64966550~64975576:- PAAD cis rs683257 0.636 rs6918856 ENSG00000234147.1 RP3-460G2.2 -4.01 9.33e-05 0.0317 -0.54 -0.31 Facial emotion recognition (angry faces); chr6:140851609 chr6:140845958~140852924:- PAAD cis rs17772222 0.837 rs57118463 ENSG00000258983.2 RP11-507K2.2 4.01 9.34e-05 0.0317 0.4 0.31 Coronary artery calcification; chr14:88665822 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs17260380 ENSG00000258983.2 RP11-507K2.2 4.01 9.34e-05 0.0317 0.4 0.31 Coronary artery calcification; chr14:88682142 chr14:88499334~88515502:+ PAAD cis rs17772222 0.876 rs12436982 ENSG00000258983.2 RP11-507K2.2 4.01 9.34e-05 0.0317 0.4 0.31 Coronary artery calcification; chr14:88689862 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs58984912 ENSG00000258983.2 RP11-507K2.2 4.01 9.34e-05 0.0317 0.4 0.31 Coronary artery calcification; chr14:88698172 chr14:88499334~88515502:+ PAAD cis rs72627509 0.951 rs72606404 ENSG00000269949.1 RP11-738E22.3 4.01 9.34e-05 0.0317 0.48 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56975047 chr4:56960927~56961373:- PAAD cis rs7617773 0.817 rs34225441 ENSG00000228638.1 FCF1P2 -4.01 9.34e-05 0.0317 -0.35 -0.31 Coronary artery disease; chr3:48267401 chr3:48290793~48291375:- PAAD cis rs748404 0.578 rs2584701 ENSG00000205771.5 CATSPER2P1 -4.01 9.35e-05 0.0317 -0.41 -0.31 Lung cancer; chr15:43392741 chr15:43726918~43747094:- PAAD cis rs7945705 0.935 rs2251536 ENSG00000254860.4 TMEM9B-AS1 -4.01 9.35e-05 0.0317 -0.35 -0.31 Hemoglobin concentration; chr11:8831630 chr11:8964675~8977527:+ PAAD cis rs2243480 1 rs1404147 ENSG00000228409.4 CCT6P1 4.01 9.36e-05 0.0317 0.32 0.31 Diabetic kidney disease; chr7:65799537 chr7:65751142~65763354:+ PAAD cis rs2638953 0.924 rs11049582 ENSG00000247934.4 RP11-967K21.1 -4.01 9.36e-05 0.0317 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28416392 chr12:28163298~28190738:- PAAD cis rs2638953 0.814 rs10843164 ENSG00000247934.4 RP11-967K21.1 -4.01 9.36e-05 0.0317 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28416781 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049583 ENSG00000247934.4 RP11-967K21.1 -4.01 9.36e-05 0.0317 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28417238 chr12:28163298~28190738:- PAAD cis rs4660456 0.572 rs10789191 ENSG00000272145.1 NFYC-AS1 -4.01 9.36e-05 0.0317 -0.24 -0.31 Platelet count; chr1:40690819 chr1:40690380~40692066:- PAAD cis rs4660456 0.572 rs1008204 ENSG00000272145.1 NFYC-AS1 -4.01 9.36e-05 0.0317 -0.24 -0.31 Platelet count; chr1:40700189 chr1:40690380~40692066:- PAAD cis rs10411161 1 rs10402988 ENSG00000269483.1 AC006272.1 4.01 9.37e-05 0.0318 0.55 0.31 Breast cancer; chr19:51859851 chr19:51839924~51843324:- PAAD cis rs10411161 1 rs2867318 ENSG00000269483.1 AC006272.1 4.01 9.37e-05 0.0318 0.55 0.31 Breast cancer; chr19:51860219 chr19:51839924~51843324:- PAAD cis rs10411161 1 rs6509581 ENSG00000269483.1 AC006272.1 4.01 9.37e-05 0.0318 0.55 0.31 Breast cancer; chr19:51860629 chr19:51839924~51843324:- PAAD cis rs10411161 1 rs8108477 ENSG00000269483.1 AC006272.1 4.01 9.37e-05 0.0318 0.55 0.31 Breast cancer; chr19:51861649 chr19:51839924~51843324:- PAAD cis rs10411161 1 rs8109345 ENSG00000269483.1 AC006272.1 4.01 9.37e-05 0.0318 0.55 0.31 Breast cancer; chr19:51861680 chr19:51839924~51843324:- PAAD cis rs10411161 1 rs8108583 ENSG00000269483.1 AC006272.1 4.01 9.37e-05 0.0318 0.55 0.31 Breast cancer; chr19:51861724 chr19:51839924~51843324:- PAAD cis rs987724 0.927 rs7616633 ENSG00000240875.4 LINC00886 -4.01 9.37e-05 0.0318 -0.39 -0.31 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156863245 chr3:156747346~156817062:- PAAD cis rs950169 0.922 rs6603022 ENSG00000275120.1 RP11-182J1.17 -4.01 9.37e-05 0.0318 -0.33 -0.31 Schizophrenia; chr15:84161418 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs4842940 ENSG00000275120.1 RP11-182J1.17 -4.01 9.37e-05 0.0318 -0.33 -0.31 Schizophrenia; chr15:84162473 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs4842941 ENSG00000275120.1 RP11-182J1.17 -4.01 9.37e-05 0.0318 -0.33 -0.31 Schizophrenia; chr15:84162560 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs12911223 ENSG00000275120.1 RP11-182J1.17 -4.01 9.37e-05 0.0318 -0.33 -0.31 Schizophrenia; chr15:84162919 chr15:84599434~84606463:- PAAD cis rs8012947 0.916 rs12433823 ENSG00000279636.2 LINC00216 4.01 9.37e-05 0.0318 0.29 0.31 Alcohol consumption in current drinkers; chr14:58378959 chr14:58288033~58289158:+ PAAD cis rs801193 0.636 rs10233806 ENSG00000237310.1 GS1-124K5.4 -4.01 9.37e-05 0.0318 -0.3 -0.31 Aortic root size; chr7:66653261 chr7:66493706~66495474:+ PAAD cis rs801193 0.66 rs2659897 ENSG00000237310.1 GS1-124K5.4 -4.01 9.37e-05 0.0318 -0.3 -0.31 Aortic root size; chr7:66722728 chr7:66493706~66495474:+ PAAD cis rs875971 1 rs10244498 ENSG00000237310.1 GS1-124K5.4 4.01 9.37e-05 0.0318 0.3 0.31 Aortic root size; chr7:66651069 chr7:66493706~66495474:+ PAAD cis rs801193 0.613 rs2659900 ENSG00000237310.1 GS1-124K5.4 4.01 9.37e-05 0.0318 0.3 0.31 Aortic root size; chr7:66719456 chr7:66493706~66495474:+ PAAD cis rs801193 0.636 rs2659895 ENSG00000237310.1 GS1-124K5.4 4.01 9.37e-05 0.0318 0.3 0.31 Aortic root size; chr7:66731484 chr7:66493706~66495474:+ PAAD cis rs801193 0.66 rs974239 ENSG00000237310.1 GS1-124K5.4 4.01 9.37e-05 0.0318 0.3 0.31 Aortic root size; chr7:66748504 chr7:66493706~66495474:+ PAAD cis rs801193 0.66 rs1016265 ENSG00000237310.1 GS1-124K5.4 4.01 9.37e-05 0.0318 0.3 0.31 Aortic root size; chr7:66749580 chr7:66493706~66495474:+ PAAD cis rs801193 0.66 rs4610622 ENSG00000237310.1 GS1-124K5.4 4.01 9.37e-05 0.0318 0.3 0.31 Aortic root size; chr7:66759510 chr7:66493706~66495474:+ PAAD cis rs755249 0.958 rs17264866 ENSG00000228060.1 RP11-69E11.8 -4.01 9.38e-05 0.0318 -0.31 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557105 chr1:39565160~39573203:+ PAAD cis rs2412819 0.597 rs7181912 ENSG00000205771.5 CATSPER2P1 4.01 9.38e-05 0.0318 0.49 0.31 Lung cancer; chr15:43770676 chr15:43726918~43747094:- PAAD cis rs8030379 0.967 rs7181926 ENSG00000230373.7 GOLGA6L5P -4.01 9.38e-05 0.0318 -0.25 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83880676 chr15:84507885~84516814:- PAAD cis rs8030379 0.967 rs6603000 ENSG00000230373.7 GOLGA6L5P -4.01 9.38e-05 0.0318 -0.25 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83883142 chr15:84507885~84516814:- PAAD cis rs8030379 0.967 rs12916223 ENSG00000230373.7 GOLGA6L5P -4.01 9.38e-05 0.0318 -0.25 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83883742 chr15:84507885~84516814:- PAAD cis rs8030379 0.875 rs28801104 ENSG00000230373.7 GOLGA6L5P -4.01 9.38e-05 0.0318 -0.25 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83884091 chr15:84507885~84516814:- PAAD cis rs8030379 0.967 rs12900412 ENSG00000230373.7 GOLGA6L5P -4.01 9.38e-05 0.0318 -0.25 -0.31 Waist circumference;Waist circumference adjusted for body mass index; chr15:83884314 chr15:84507885~84516814:- PAAD cis rs9322193 0.923 rs9478291 ENSG00000268592.3 RAET1E-AS1 4.01 9.38e-05 0.0318 0.36 0.31 Lung cancer; chr6:149729434 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9479494 ENSG00000268592.3 RAET1E-AS1 4.01 9.38e-05 0.0318 0.36 0.31 Lung cancer; chr6:149739108 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9800806 ENSG00000268592.3 RAET1E-AS1 4.01 9.38e-05 0.0318 0.36 0.31 Lung cancer; chr6:149740350 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9688517 ENSG00000268592.3 RAET1E-AS1 4.01 9.38e-05 0.0318 0.36 0.31 Lung cancer; chr6:149740655 chr6:149863494~149919507:+ PAAD cis rs748404 0.666 rs10518812 ENSG00000205771.5 CATSPER2P1 4.01 9.38e-05 0.0318 0.51 0.31 Lung cancer; chr15:43360739 chr15:43726918~43747094:- PAAD cis rs10779751 1 rs2016559 ENSG00000238199.1 UBE2V2P3 -4.01 9.39e-05 0.0318 -0.37 -0.31 Body mass index; chr1:11209860 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs4845982 ENSG00000238199.1 UBE2V2P3 -4.01 9.39e-05 0.0318 -0.37 -0.31 Body mass index; chr1:11211519 chr1:11278616~11279351:- PAAD cis rs10779751 0.922 rs2746637 ENSG00000238199.1 UBE2V2P3 -4.01 9.39e-05 0.0318 -0.37 -0.31 Body mass index; chr1:11215531 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs1064261 ENSG00000238199.1 UBE2V2P3 -4.01 9.39e-05 0.0318 -0.37 -0.31 Body mass index; chr1:11228701 chr1:11278616~11279351:- PAAD cis rs7189233 0.531 rs1074182 ENSG00000279344.1 RP11-44F14.7 4.01 9.39e-05 0.0318 0.23 0.31 Intelligence (multi-trait analysis); chr16:53437445 chr16:53478957~53481550:- PAAD cis rs2677744 0.626 rs12915155 ENSG00000259704.1 CTD-3094K11.1 -4.01 9.39e-05 0.0318 -0.41 -0.31 Attention deficit hyperactivity disorder; chr15:90947664 chr15:90839724~90841378:+ PAAD cis rs12899811 0.512 rs7164916 ENSG00000214432.8 AC068831.10 -4.01 9.39e-05 0.0318 -0.41 -0.31 Type 2 diabetes; chr15:91018216 chr15:91022619~91036611:+ PAAD cis rs12908161 1 rs12911736 ENSG00000259295.5 CSPG4P12 4.01 9.4e-05 0.0318 0.35 0.31 Schizophrenia; chr15:84696777 chr15:85191438~85213905:+ PAAD cis rs526231 0.584 rs246914 ENSG00000175749.11 EIF3KP1 4.01 9.4e-05 0.0319 0.45 0.31 Primary biliary cholangitis; chr5:103223706 chr5:103032376~103033031:+ PAAD cis rs4660214 0.724 rs3931300 ENSG00000243970.1 PPIEL -4.01 9.41e-05 0.0319 -0.3 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39195175 chr1:39531838~39558707:- PAAD cis rs303386 0.689 rs302748 ENSG00000223656.1 HMGB3P10 4.01 9.41e-05 0.0319 0.4 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin); chr1:99131772 chr1:99698242~99699178:+ PAAD cis rs638893 0.617 rs4938565 ENSG00000278376.1 RP11-158I9.8 4.01 9.41e-05 0.0319 0.32 0.31 Vitiligo; chr11:118850289 chr11:118791254~118793137:+ PAAD cis rs875971 0.862 rs709596 ENSG00000232559.3 GS1-124K5.12 4.01 9.42e-05 0.0319 0.34 0.31 Aortic root size; chr7:66360926 chr7:66554588~66576923:- PAAD cis rs10276381 0.786 rs740261 ENSG00000234336.5 JAZF1-AS1 -4.01 9.42e-05 0.0319 -0.44 -0.31 Crohn's disease; chr7:28201657 chr7:28180322~28243917:+ PAAD cis rs9326248 0.581 rs7120963 ENSG00000280143.1 AP000892.6 -4.01 9.42e-05 0.0319 -0.34 -0.31 Blood protein levels; chr11:116959545 chr11:117204967~117210292:+ PAAD cis rs6081541 0.689 rs6081546 ENSG00000179447.2 RP5-1027G4.3 -4.01 9.42e-05 0.0319 -0.42 -0.31 Psychosis (atypical); chr20:19240785 chr20:19242302~19284596:- PAAD cis rs12908161 1 rs11638290 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84684405 chr15:85191438~85213905:+ PAAD cis rs12908161 0.959 rs34028043 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84688354 chr15:85191438~85213905:+ PAAD cis rs12908161 0.959 rs34784022 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84688675 chr15:85191438~85213905:+ PAAD cis rs12908161 0.959 rs12908699 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84697172 chr15:85191438~85213905:+ PAAD cis rs12908161 1 rs35316992 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84704902 chr15:85191438~85213905:+ PAAD cis rs12908161 1 rs4643294 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84707022 chr15:85191438~85213905:+ PAAD cis rs12908161 1 rs62021219 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84712928 chr15:85191438~85213905:+ PAAD cis rs12908161 1 rs34900908 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84714368 chr15:85191438~85213905:+ PAAD cis rs12908161 1 rs35524990 ENSG00000259295.5 CSPG4P12 4.01 9.43e-05 0.0319 0.35 0.31 Schizophrenia; chr15:84714972 chr15:85191438~85213905:+ PAAD cis rs2776353 0.846 rs2776348 ENSG00000280109.1 PLAC4 -4.01 9.43e-05 0.0319 -0.32 -0.31 Basal cell carcinoma; chr21:41666784 chr21:41175231~41185239:- PAAD cis rs875971 0.522 rs9530 ENSG00000236529.1 RP13-254B10.1 4.01 9.43e-05 0.0319 0.34 0.31 Aortic root size; chr7:65960907 chr7:65840212~65840596:+ PAAD cis rs11048434 0.518 rs2377678 ENSG00000256720.1 RP11-436I9.6 -4.01 9.44e-05 0.0319 -0.29 -0.31 Sjögren's syndrome; chr12:9021562 chr12:9135084~9135591:+ PAAD cis rs11048434 0.518 rs2377679 ENSG00000256720.1 RP11-436I9.6 -4.01 9.44e-05 0.0319 -0.29 -0.31 Sjögren's syndrome; chr12:9023874 chr12:9135084~9135591:+ PAAD cis rs2243480 0.808 rs11769505 ENSG00000228409.4 CCT6P1 -4.01 9.44e-05 0.032 -0.34 -0.31 Diabetic kidney disease; chr7:65778268 chr7:65751142~65763354:+ PAAD cis rs2562456 0.876 rs62110202 ENSG00000213976.4 CTD-2561J22.2 -4.01 9.44e-05 0.032 -0.35 -0.31 Pain; chr19:21571799 chr19:21382865~21387177:+ PAAD cis rs13178541 0.641 rs12153181 ENSG00000250378.1 RP11-119J18.1 -4.01 9.44e-05 0.032 -0.46 -0.31 IgG glycosylation; chr5:135793126 chr5:135812667~135826582:+ PAAD cis rs13178541 0.671 rs12153176 ENSG00000250378.1 RP11-119J18.1 -4.01 9.44e-05 0.032 -0.46 -0.31 IgG glycosylation; chr5:135793155 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs12153182 ENSG00000250378.1 RP11-119J18.1 -4.01 9.44e-05 0.032 -0.46 -0.31 IgG glycosylation; chr5:135793165 chr5:135812667~135826582:+ PAAD cis rs17772222 0.917 rs12588535 ENSG00000258983.2 RP11-507K2.2 4.01 9.45e-05 0.032 0.4 0.31 Coronary artery calcification; chr14:88781900 chr14:88499334~88515502:+ PAAD cis rs2243480 1 rs160634 ENSG00000228409.4 CCT6P1 -4.01 9.45e-05 0.032 -0.33 -0.31 Diabetic kidney disease; chr7:66063677 chr7:65751142~65763354:+ PAAD cis rs79040073 0.53 rs73396206 ENSG00000259469.1 RP11-227D13.4 -4.01 9.45e-05 0.032 -0.42 -0.31 Lung cancer in ever smokers; chr15:49323632 chr15:48729080~48729844:- PAAD cis rs1555322 0.872 rs6579227 ENSG00000279253.1 RP4-614O4.13 -4.01 9.45e-05 0.032 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35291403 chr20:35262727~35264187:- PAAD cis rs748404 0.697 rs574065 ENSG00000249839.1 AC011330.5 4.01 9.45e-05 0.032 0.42 0.31 Lung cancer; chr15:43258457 chr15:43663654~43684339:- PAAD cis rs151234 0.8 rs231972 ENSG00000259982.1 CDC37P1 -4.01 9.45e-05 0.032 -0.59 -0.31 Platelet distribution width; chr16:28527015 chr16:28700294~28701540:- PAAD cis rs151234 0.8 rs231974 ENSG00000259982.1 CDC37P1 -4.01 9.45e-05 0.032 -0.59 -0.31 Platelet distribution width; chr16:28529001 chr16:28700294~28701540:- PAAD cis rs1075265 0.563 rs2692536 ENSG00000233266.1 HMGB1P31 4.01 9.45e-05 0.032 0.4 0.31 Chronotype;Morning vs. evening chronotype; chr2:53788266 chr2:54051334~54051760:+ PAAD cis rs17772222 0.876 rs61983303 ENSG00000258983.2 RP11-507K2.2 4.01 9.45e-05 0.032 0.4 0.31 Coronary artery calcification; chr14:88764459 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs7157149 ENSG00000258983.2 RP11-507K2.2 4.01 9.45e-05 0.032 0.4 0.31 Coronary artery calcification; chr14:88765501 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs2224333 ENSG00000258983.2 RP11-507K2.2 4.01 9.45e-05 0.032 0.4 0.31 Coronary artery calcification; chr14:88768748 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs12590826 ENSG00000258983.2 RP11-507K2.2 4.01 9.45e-05 0.032 0.4 0.31 Coronary artery calcification; chr14:88769357 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs57889459 ENSG00000258983.2 RP11-507K2.2 4.01 9.45e-05 0.032 0.4 0.31 Coronary artery calcification; chr14:88770820 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs61982733 ENSG00000258983.2 RP11-507K2.2 4.01 9.45e-05 0.032 0.4 0.31 Coronary artery calcification; chr14:88776244 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs2145120 ENSG00000258983.2 RP11-507K2.2 4.01 9.45e-05 0.032 0.4 0.31 Coronary artery calcification; chr14:88777699 chr14:88499334~88515502:+ PAAD cis rs17684571 0.938 rs62412526 ENSG00000231441.1 RP11-472M19.2 4.01 9.46e-05 0.032 0.51 0.31 Schizophrenia; chr6:56689171 chr6:56844002~56864078:+ PAAD cis rs2904524 1 rs7980085 ENSG00000257815.4 RP11-611E13.2 4.01 9.46e-05 0.032 0.32 0.31 Amyotrophic lateral sclerosis (age of onset); chr12:70293850 chr12:69904033~70243360:- PAAD cis rs34761973 0.569 rs7223411 ENSG00000272911.1 RP11-74E22.6 4.01 9.46e-05 0.032 0.4 0.31 Depressive symptoms (multi-trait analysis);Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis); chr17:2673883 chr17:2688473~2688960:+ PAAD cis rs9595908 0.865 rs743760 ENSG00000212293.1 SNORA16 -4.01 9.46e-05 0.032 -0.38 -0.31 Body mass index; chr13:32496990 chr13:32420390~32420516:- PAAD cis rs79349575 0.783 rs903567 ENSG00000270781.1 RP11-501C14.9 -4.01 9.46e-05 0.032 -0.36 -0.31 Type 2 diabetes; chr17:48902956 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs62075818 ENSG00000270781.1 RP11-501C14.9 -4.01 9.46e-05 0.032 -0.36 -0.31 Type 2 diabetes; chr17:48904965 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs9912829 ENSG00000270781.1 RP11-501C14.9 -4.01 9.46e-05 0.032 -0.36 -0.31 Type 2 diabetes; chr17:48905387 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs62075820 ENSG00000270781.1 RP11-501C14.9 -4.01 9.46e-05 0.032 -0.36 -0.31 Type 2 diabetes; chr17:48905809 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4294857 ENSG00000270781.1 RP11-501C14.9 -4.01 9.46e-05 0.032 -0.36 -0.31 Type 2 diabetes; chr17:48906029 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs61576918 ENSG00000270781.1 RP11-501C14.9 -4.01 9.46e-05 0.032 -0.36 -0.31 Type 2 diabetes; chr17:48908231 chr17:48899131~48899748:+ PAAD cis rs42490 0.716 rs40636 ENSG00000251136.7 RP11-37B2.1 -4.01 9.46e-05 0.032 -0.27 -0.31 Leprosy; chr8:89809079 chr8:89609409~89757727:- PAAD cis rs2904804 0.522 rs10904378 ENSG00000224251.5 RP11-499O7.7 4.01 9.47e-05 0.032 0.35 0.31 Economic and political preferences (immigration/crime); chr10:4945047 chr10:4995488~4997380:+ PAAD cis rs4853525 0.522 rs1860167 ENSG00000235852.1 AC005540.3 4.01 9.47e-05 0.032 0.43 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190717661 chr2:190880797~190882059:- PAAD cis rs4853525 0.522 rs7574840 ENSG00000235852.1 AC005540.3 4.01 9.47e-05 0.032 0.43 0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190719510 chr2:190880797~190882059:- PAAD cis rs11893307 0.507 rs1465303 ENSG00000235852.1 AC005540.3 4.01 9.47e-05 0.032 0.43 0.31 Mean platelet volume; chr2:190720714 chr2:190880797~190882059:- PAAD cis rs4853525 0.522 rs6744420 ENSG00000235852.1 AC005540.3 -4.01 9.47e-05 0.032 -0.43 -0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190724356 chr2:190880797~190882059:- PAAD cis rs2404602 0.735 rs2461871 ENSG00000259422.1 RP11-593F23.1 -4.01 9.47e-05 0.032 -0.37 -0.31 Blood metabolite levels; chr15:76530077 chr15:76174891~76181486:- PAAD cis rs5015933 0.815 rs937482 ENSG00000232630.1 PRPS1P2 -4.01 9.48e-05 0.032 -0.28 -0.31 Body mass index; chr9:125354538 chr9:125150653~125151589:+ PAAD cis rs34375054 0.66 rs58624919 ENSG00000279233.1 RP11-158L12.4 4.01 9.48e-05 0.0321 0.27 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125111912 chr12:125138245~125141711:+ PAAD cis rs4722166 0.532 rs6461662 ENSG00000179428.2 AC073072.5 -4.01 9.48e-05 0.0321 -0.28 -0.31 Lung cancer; chr7:22717470 chr7:22725395~22727620:- PAAD cis rs2638953 0.924 rs12368745 ENSG00000247934.4 RP11-967K21.1 -4.01 9.48e-05 0.0321 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28396198 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs10843162 ENSG00000247934.4 RP11-967K21.1 -4.01 9.48e-05 0.0321 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28410985 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049575 ENSG00000247934.4 RP11-967K21.1 -4.01 9.48e-05 0.0321 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28411328 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs2348235 ENSG00000247934.4 RP11-967K21.1 -4.01 9.48e-05 0.0321 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28414019 chr12:28163298~28190738:- PAAD cis rs2638953 0.886 rs11049577 ENSG00000247934.4 RP11-967K21.1 -4.01 9.48e-05 0.0321 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28414437 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049579 ENSG00000247934.4 RP11-967K21.1 -4.01 9.48e-05 0.0321 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28414693 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs10843163 ENSG00000247934.4 RP11-967K21.1 -4.01 9.48e-05 0.0321 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28415541 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs10843169 ENSG00000247934.4 RP11-967K21.1 4.01 9.48e-05 0.0321 0.34 0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28430051 chr12:28163298~28190738:- PAAD cis rs9393813 0.528 rs4713109 ENSG00000271755.1 RP1-153G14.4 4.01 9.49e-05 0.0321 0.36 0.31 Bipolar disorder; chr6:27508489 chr6:27404010~27406964:- PAAD cis rs812925 0.519 rs2694638 ENSG00000273302.1 RP11-493E12.2 -4.01 9.49e-05 0.0321 -0.27 -0.31 Immature fraction of reticulocytes; chr2:61408228 chr2:61199979~61200769:+ PAAD cis rs3781264 0.848 rs6583935 ENSG00000273450.1 RP11-76P2.4 4.01 9.49e-05 0.0321 0.4 0.31 Esophageal cancer and gastric cancer; chr10:94313568 chr10:94314907~94315327:- PAAD cis rs6504622 0.905 rs736603 ENSG00000262539.1 RP11-259G18.3 4.01 9.49e-05 0.0321 0.38 0.31 Orofacial clefts; chr17:46947379 chr17:46259551~46260606:- PAAD cis rs6504622 0.905 rs736604 ENSG00000262539.1 RP11-259G18.3 4.01 9.49e-05 0.0321 0.38 0.31 Orofacial clefts; chr17:46947443 chr17:46259551~46260606:- PAAD cis rs4356975 0.899 rs7677996 ENSG00000250696.4 RP11-704M14.1 4.01 9.5e-05 0.0321 0.36 0.31 Obesity-related traits; chr4:69075473 chr4:69182100~69216766:+ PAAD cis rs763121 0.853 rs2179142 ENSG00000228274.3 RP3-508I15.9 -4.01 9.5e-05 0.0321 -0.3 -0.31 Menopause (age at onset); chr22:38641949 chr22:38667585~38681820:- PAAD cis rs1910358 0.621 rs12109110 ENSG00000248874.4 C5orf17 -4.01 9.5e-05 0.0321 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23845772 chr5:23951348~24178263:+ PAAD cis rs1910358 0.621 rs6891863 ENSG00000248874.4 C5orf17 -4.01 9.5e-05 0.0321 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23852557 chr5:23951348~24178263:+ PAAD cis rs1910358 0.621 rs7734054 ENSG00000248874.4 C5orf17 -4.01 9.5e-05 0.0321 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23858070 chr5:23951348~24178263:+ PAAD cis rs1910358 0.621 rs2055140 ENSG00000248874.4 C5orf17 -4.01 9.5e-05 0.0321 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23859035 chr5:23951348~24178263:+ PAAD cis rs1873386 0.79 rs12579184 ENSG00000255910.1 RP11-405A12.2 4.01 9.51e-05 0.0321 0.45 0.31 Personality dimensions; chr12:18918713 chr12:19775451~20009937:+ PAAD cis rs1789 0.592 rs1125378 ENSG00000247624.5 CPEB2-AS1 -4.01 9.51e-05 0.0321 -0.4 -0.31 Blood protein levels; chr4:15538867 chr4:14909961~15002045:- PAAD cis rs4834770 1 rs4336213 ENSG00000245958.5 RP11-33B1.1 -4.01 9.51e-05 0.0321 -0.24 -0.31 Blood protein levels; chr4:119315314 chr4:119454791~119552025:+ PAAD cis rs7637701 0.78 rs9858158 ENSG00000240875.4 LINC00886 -4.01 9.51e-05 0.0321 -0.37 -0.31 Breast cancer; chr3:156845538 chr3:156747346~156817062:- PAAD cis rs2086824 0.702 rs3114891 ENSG00000274627.1 RP11-104N10.2 4.01 9.51e-05 0.0321 0.28 0.31 Multiple myeloma (IgH translocation); chr16:89333047 chr16:89516797~89522217:+ PAAD cis rs6472866 0.654 rs35990825 ENSG00000254288.1 RP11-6I2.3 -4.01 9.51e-05 0.0321 -0.33 -0.31 Protein quantitative trait loci; chr8:74574785 chr8:74052340~74099853:+ PAAD cis rs6472866 0.654 rs1425762 ENSG00000254288.1 RP11-6I2.3 -4.01 9.51e-05 0.0321 -0.33 -0.31 Protein quantitative trait loci; chr8:74575010 chr8:74052340~74099853:+ PAAD cis rs6472866 0.654 rs1425761 ENSG00000254288.1 RP11-6I2.3 -4.01 9.51e-05 0.0321 -0.33 -0.31 Protein quantitative trait loci; chr8:74575053 chr8:74052340~74099853:+ PAAD cis rs889398 0.771 rs3790080 ENSG00000226232.7 RP11-419C5.2 -4.01 9.52e-05 0.0322 -0.24 -0.31 Body mass index; chr16:69868236 chr16:69976388~69996188:- PAAD cis rs889398 0.771 rs1500337 ENSG00000226232.7 RP11-419C5.2 4.01 9.52e-05 0.0322 0.24 0.31 Body mass index; chr16:69867981 chr16:69976388~69996188:- PAAD cis rs7119038 0.818 rs4936441 ENSG00000255239.1 AP002954.6 4.01 9.53e-05 0.0322 0.45 0.31 Sjögren's syndrome; chr11:118854951 chr11:118688039~118690600:- PAAD cis rs10790268 1 rs10790268 ENSG00000255239.1 AP002954.6 4.01 9.53e-05 0.0322 0.45 0.31 Rheumatoid arthritis; chr11:118858682 chr11:118688039~118690600:- PAAD cis rs7119038 0.73 rs10790269 ENSG00000255239.1 AP002954.6 4.01 9.53e-05 0.0322 0.45 0.31 Sjögren's syndrome; chr11:118858747 chr11:118688039~118690600:- PAAD cis rs7119038 0.865 rs10892299 ENSG00000255239.1 AP002954.6 -4.01 9.53e-05 0.0322 -0.45 -0.31 Sjögren's syndrome; chr11:118856134 chr11:118688039~118690600:- PAAD cis rs7923837 1 rs4933736 ENSG00000236493.2 EIF2S2P3 4.01 9.53e-05 0.0322 0.4 0.31 Multiple sclerosis;Body mass index; chr10:92711838 chr10:92668745~92669743:- PAAD cis rs2348418 0.801 rs7298379 ENSG00000247934.4 RP11-967K21.1 4.01 9.53e-05 0.0322 0.3 0.31 Lung function (FEV1);Lung function (FVC); chr12:28270541 chr12:28163298~28190738:- PAAD cis rs55702914 0.628 rs3849362 ENSG00000231621.1 AC013264.2 4.01 9.53e-05 0.0322 0.29 0.31 Major depression and alcohol dependence; chr2:197443536 chr2:197197991~197199273:+ PAAD cis rs79349575 0.749 rs519537 ENSG00000270781.1 RP11-501C14.9 -4.01 9.53e-05 0.0322 -0.36 -0.31 Type 2 diabetes; chr17:48893778 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs832410 ENSG00000270781.1 RP11-501C14.9 -4.01 9.53e-05 0.0322 -0.36 -0.31 Type 2 diabetes; chr17:48895503 chr17:48899131~48899748:+ PAAD cis rs498136 0.864 rs661178 ENSG00000250508.1 RP11-757G1.6 4.01 9.53e-05 0.0322 0.39 0.31 Cutaneous malignant melanoma;Melanoma; chr11:69537636 chr11:68870664~68874542:+ PAAD cis rs9487094 0.961 rs1358998 ENSG00000260273.1 RP11-425D10.10 -4.01 9.53e-05 0.0322 -0.4 -0.31 Height; chr6:109380015 chr6:109382795~109383666:+ PAAD cis rs3096299 0.838 rs3102376 ENSG00000274627.1 RP11-104N10.2 4.01 9.53e-05 0.0322 0.28 0.31 Multiple myeloma (IgH translocation); chr16:89336065 chr16:89516797~89522217:+ PAAD cis rs4718428 0.705 rs28648401 ENSG00000273142.1 RP11-458F8.4 -4.01 9.53e-05 0.0322 -0.21 -0.31 Corneal structure; chr7:66902145 chr7:66902857~66906297:+ PAAD cis rs4718428 0.607 rs66954441 ENSG00000273142.1 RP11-458F8.4 -4.01 9.53e-05 0.0322 -0.21 -0.31 Corneal structure; chr7:66904222 chr7:66902857~66906297:+ PAAD cis rs10411161 1 rs3764540 ENSG00000269483.1 AC006272.1 4.01 9.54e-05 0.0322 0.59 0.31 Breast cancer; chr19:51877428 chr19:51839924~51843324:- PAAD cis rs858239 0.537 rs2286272 ENSG00000226816.2 AC005082.12 4.01 9.54e-05 0.0322 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23184748 chr7:23206013~23208045:+ PAAD cis rs858239 0.537 rs6955115 ENSG00000226816.2 AC005082.12 4.01 9.54e-05 0.0322 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23187525 chr7:23206013~23208045:+ PAAD cis rs858239 0.537 rs10279691 ENSG00000226816.2 AC005082.12 4.01 9.54e-05 0.0322 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23188768 chr7:23206013~23208045:+ PAAD cis rs58873874 1 rs58873874 ENSG00000248544.2 CTB-47B11.3 4.01 9.54e-05 0.0322 0.63 0.31 Bipolar disorder (body mass index interaction); chr5:157518140 chr5:157375741~157384950:- PAAD cis rs9487094 0.626 rs4947016 ENSG00000260273.1 RP11-425D10.10 4.01 9.54e-05 0.0322 0.37 0.31 Height; chr6:109740895 chr6:109382795~109383666:+ PAAD cis rs12935418 0.55 rs35595567 ENSG00000261061.1 RP11-303E16.2 -4.01 9.55e-05 0.0322 -0.42 -0.31 Mean corpuscular volume; chr16:80999761 chr16:81030770~81031485:+ PAAD cis rs4925386 0.959 rs6121989 ENSG00000273619.1 RP5-908M14.9 4.01 9.55e-05 0.0322 0.26 0.31 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62341657 chr20:62386303~62386970:- PAAD cis rs4853012 0.838 rs6715351 ENSG00000257800.1 FNBP1P1 4.01 9.55e-05 0.0322 0.43 0.31 Gestational age at birth (maternal effect); chr2:74118992 chr2:74120680~74123218:+ PAAD cis rs4853012 0.838 rs61521879 ENSG00000257800.1 FNBP1P1 4.01 9.55e-05 0.0322 0.43 0.31 Gestational age at birth (maternal effect); chr2:74119081 chr2:74120680~74123218:+ PAAD cis rs710913 0.618 rs12030495 ENSG00000243970.1 PPIEL 4.01 9.56e-05 0.0323 0.27 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39623923 chr1:39531838~39558707:- PAAD cis rs2717559 0.522 rs10956987 ENSG00000253741.1 CTD-2292P10.4 4.01 9.56e-05 0.0323 0.41 0.31 Urinary tract infection frequency; chr8:142805197 chr8:142702252~142726973:- PAAD cis rs193541 0.632 rs1460040 ENSG00000263432.2 RN7SL689P 4.01 9.57e-05 0.0323 0.4 0.31 Glucose homeostasis traits; chr5:122769537 chr5:123022487~123022783:- PAAD cis rs79349575 0.594 rs62078375 ENSG00000270781.1 RP11-501C14.9 -4.01 9.58e-05 0.0323 -0.36 -0.31 Type 2 diabetes; chr17:48957612 chr17:48899131~48899748:+ PAAD cis rs10951983 0.904 rs3729790 ENSG00000272719.1 CTB-161C1.1 -4.01 9.59e-05 0.0323 -0.38 -0.31 Coronary artery disease; chr7:6387323 chr7:5556731~5557245:+ PAAD cis rs11834862 0.77 rs10444603 ENSG00000256576.2 RP13-977J11.2 -4.01 9.59e-05 0.0323 -0.41 -0.31 Anti-saccade response; chr12:132210365 chr12:132186735~132189695:- PAAD cis rs79349575 0.729 rs62075824 ENSG00000270781.1 RP11-501C14.9 -4.01 9.59e-05 0.0323 -0.36 -0.31 Type 2 diabetes; chr17:48909317 chr17:48899131~48899748:+ PAAD cis rs79349575 0.749 rs46521 ENSG00000270781.1 RP11-501C14.9 -4.01 9.59e-05 0.0323 -0.36 -0.31 Type 2 diabetes; chr17:48911167 chr17:48899131~48899748:+ PAAD cis rs79349575 0.749 rs318093 ENSG00000270781.1 RP11-501C14.9 -4.01 9.59e-05 0.0323 -0.36 -0.31 Type 2 diabetes; chr17:48911992 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs28409394 ENSG00000270781.1 RP11-501C14.9 -4.01 9.59e-05 0.0323 -0.36 -0.31 Type 2 diabetes; chr17:48920756 chr17:48899131~48899748:+ PAAD cis rs10800713 0.954 rs4353125 ENSG00000260088.1 RP11-92G12.3 -4.01 9.59e-05 0.0324 -0.43 -0.31 Tandem gait; chr1:200582178 chr1:200669507~200694250:+ PAAD cis rs10800713 0.908 rs6670625 ENSG00000260088.1 RP11-92G12.3 -4.01 9.59e-05 0.0324 -0.43 -0.31 Tandem gait; chr1:200587514 chr1:200669507~200694250:+ PAAD cis rs10951983 0.898 rs11767078 ENSG00000272719.1 CTB-161C1.1 -4.01 9.6e-05 0.0324 -0.41 -0.31 Coronary artery disease; chr7:6425157 chr7:5556731~5557245:+ PAAD cis rs10951983 0.898 rs11760556 ENSG00000272719.1 CTB-161C1.1 -4.01 9.6e-05 0.0324 -0.41 -0.31 Coronary artery disease; chr7:6425205 chr7:5556731~5557245:+ PAAD cis rs10951983 0.898 rs11760562 ENSG00000272719.1 CTB-161C1.1 -4.01 9.6e-05 0.0324 -0.41 -0.31 Coronary artery disease; chr7:6425252 chr7:5556731~5557245:+ PAAD cis rs10951983 0.847 rs2272157 ENSG00000272719.1 CTB-161C1.1 -4.01 9.6e-05 0.0324 -0.41 -0.31 Coronary artery disease; chr7:6425810 chr7:5556731~5557245:+ PAAD cis rs2688608 0.587 rs2894040 ENSG00000271816.1 BMS1P4 4.01 9.6e-05 0.0324 0.31 0.31 Inflammatory bowel disease; chr10:73718401 chr10:73699151~73730487:- PAAD cis rs2688608 0.592 rs3849967 ENSG00000271816.1 BMS1P4 4.01 9.6e-05 0.0324 0.31 0.31 Inflammatory bowel disease; chr10:73723608 chr10:73699151~73730487:- PAAD cis rs2688608 0.592 rs7909802 ENSG00000271816.1 BMS1P4 4.01 9.6e-05 0.0324 0.31 0.31 Inflammatory bowel disease; chr10:73724428 chr10:73699151~73730487:- PAAD cis rs2688608 0.592 rs11000757 ENSG00000271816.1 BMS1P4 4.01 9.6e-05 0.0324 0.31 0.31 Inflammatory bowel disease; chr10:73727057 chr10:73699151~73730487:- PAAD cis rs5760092 0.755 rs915589 ENSG00000206090.4 AP000350.7 -4.01 9.6e-05 0.0324 -0.46 -0.31 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23918817 chr22:23939998~23942798:+ PAAD cis rs6539288 0.691 rs10746071 ENSG00000260329.1 RP11-412D9.4 4.01 9.6e-05 0.0324 0.27 0.31 Total body bone mineral density; chr12:106959817 chr12:106954029~106955497:- PAAD cis rs42490 0.716 rs40547 ENSG00000251136.7 RP11-37B2.1 -4.01 9.6e-05 0.0324 -0.27 -0.31 Leprosy; chr8:89817685 chr8:89609409~89757727:- PAAD cis rs42490 0.716 rs43135 ENSG00000251136.7 RP11-37B2.1 -4.01 9.6e-05 0.0324 -0.27 -0.31 Leprosy; chr8:89823722 chr8:89609409~89757727:- PAAD cis rs72843506 0.722 rs9908032 ENSG00000154898.14 CCDC144CP 4.01 9.62e-05 0.0324 0.55 0.31 Schizophrenia; chr17:20204871 chr17:20321164~20403557:+ PAAD cis rs72843506 0.591 rs75925580 ENSG00000154898.14 CCDC144CP 4.01 9.62e-05 0.0324 0.55 0.31 Schizophrenia; chr17:20211700 chr17:20321164~20403557:+ PAAD cis rs72843506 0.722 rs12051550 ENSG00000154898.14 CCDC144CP 4.01 9.62e-05 0.0324 0.55 0.31 Schizophrenia; chr17:20226233 chr17:20321164~20403557:+ PAAD cis rs72843506 0.722 rs9901484 ENSG00000154898.14 CCDC144CP 4.01 9.62e-05 0.0324 0.55 0.31 Schizophrenia; chr17:20229581 chr17:20321164~20403557:+ PAAD cis rs72843506 0.656 rs16959946 ENSG00000154898.14 CCDC144CP 4.01 9.62e-05 0.0324 0.55 0.31 Schizophrenia; chr17:20269134 chr17:20321164~20403557:+ PAAD cis rs72843506 0.722 rs5025290 ENSG00000154898.14 CCDC144CP 4.01 9.62e-05 0.0324 0.55 0.31 Schizophrenia; chr17:20302504 chr17:20321164~20403557:+ PAAD cis rs72843506 0.722 rs9895177 ENSG00000154898.14 CCDC144CP 4.01 9.62e-05 0.0324 0.55 0.31 Schizophrenia; chr17:20304281 chr17:20321164~20403557:+ PAAD cis rs12935418 0.733 rs11150329 ENSG00000261061.1 RP11-303E16.2 -4.01 9.62e-05 0.0324 -0.5 -0.31 Mean corpuscular volume; chr16:80945189 chr16:81030770~81031485:+ PAAD cis rs2333194 0.844 rs17182286 ENSG00000258695.2 RP3-414A15.2 -4.01 9.62e-05 0.0324 -0.35 -0.31 Bipolar disorder with mood-incongruent psychosis; chr14:73282200 chr14:73522878~73530610:+ PAAD cis rs17711722 0.565 rs4717276 ENSG00000213640.3 EEF1DP4 -4.01 9.63e-05 0.0324 -0.32 -0.31 Calcium levels; chr7:65829754 chr7:64862999~64864370:+ PAAD cis rs2412819 0.571 rs2930529 ENSG00000249839.1 AC011330.5 4.01 9.63e-05 0.0325 0.47 0.31 Lung cancer; chr15:43819467 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs2930530 ENSG00000249839.1 AC011330.5 4.01 9.63e-05 0.0325 0.47 0.31 Lung cancer; chr15:43823268 chr15:43663654~43684339:- PAAD cis rs42490 0.716 rs40638 ENSG00000251136.7 RP11-37B2.1 -4.01 9.65e-05 0.0325 -0.27 -0.31 Leprosy; chr8:89815824 chr8:89609409~89757727:- PAAD cis rs42490 0.716 rs370282 ENSG00000251136.7 RP11-37B2.1 -4.01 9.65e-05 0.0325 -0.27 -0.31 Leprosy; chr8:89816117 chr8:89609409~89757727:- PAAD cis rs8031584 0.679 rs34017474 ENSG00000269930.1 RP11-932O9.9 -4.01 9.65e-05 0.0325 -0.37 -0.31 Huntington's disease progression; chr15:30938408 chr15:30616958~30617749:+ PAAD cis rs1707322 0.717 rs11211161 ENSG00000280836.1 AL355480.1 -4.01 9.65e-05 0.0325 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45682466 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs61784793 ENSG00000280836.1 AL355480.1 -4.01 9.65e-05 0.0325 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45683613 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs4586014 ENSG00000280836.1 AL355480.1 -4.01 9.65e-05 0.0325 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45684771 chr1:45581219~45581321:- PAAD cis rs1707322 0.648 rs4439382 ENSG00000280836.1 AL355480.1 -4.01 9.65e-05 0.0325 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45685133 chr1:45581219~45581321:- PAAD cis rs9595908 0.9 rs9595883 ENSG00000212293.1 SNORA16 4.01 9.65e-05 0.0325 0.34 0.31 Body mass index; chr13:32593563 chr13:32420390~32420516:- PAAD cis rs9595908 0.9 rs9595890 ENSG00000212293.1 SNORA16 4.01 9.65e-05 0.0325 0.34 0.31 Body mass index; chr13:32597518 chr13:32420390~32420516:- PAAD cis rs9595908 0.9 rs1324415 ENSG00000212293.1 SNORA16 4.01 9.65e-05 0.0325 0.34 0.31 Body mass index; chr13:32600186 chr13:32420390~32420516:- PAAD cis rs4468007 0.898 rs7032484 ENSG00000235865.2 GSN-AS1 4.01 9.65e-05 0.0325 0.3 0.31 Educational attainment; chr9:121855640 chr9:121280768~121285530:- PAAD cis rs28714278 0.909 rs7178419 ENSG00000248508.5 SRP14-AS1 4.01 9.65e-05 0.0325 0.34 0.31 Mean corpuscular hemoglobin; chr15:39992322 chr15:40039311~40067290:+ PAAD cis rs2739330 0.652 rs2000469 ENSG00000206090.4 AP000350.7 4.01 9.66e-05 0.0325 0.41 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23903105 chr22:23939998~23942798:+ PAAD cis rs718433 0.866 rs4982498 ENSG00000256379.1 TRAV8-5 4.01 9.67e-05 0.0325 0.27 0.31 Intraocular pressure; chr14:21760486 chr14:21903077~21903598:+ PAAD cis rs6903823 0.508 rs1150718 ENSG00000204709.4 LINC01556 4.01 9.67e-05 0.0326 0.41 0.31 Pulmonary function; chr6:28289170 chr6:28943877~28944537:+ PAAD cis rs6903823 0.508 rs1233660 ENSG00000204709.4 LINC01556 4.01 9.67e-05 0.0326 0.41 0.31 Pulmonary function; chr6:28292472 chr6:28943877~28944537:+ PAAD cis rs17507216 0.718 rs17158403 ENSG00000255769.6 GOLGA2P10 -4.01 9.67e-05 0.0326 -0.42 -0.31 Excessive daytime sleepiness; chr15:82572478 chr15:82472993~82513950:- PAAD cis rs79040073 0.637 rs73392249 ENSG00000259531.2 RP11-295H24.3 4.01 9.67e-05 0.0326 0.51 0.31 Lung cancer in ever smokers; chr15:49224264 chr15:49365124~49366685:- PAAD cis rs79040073 0.637 rs11630318 ENSG00000259531.2 RP11-295H24.3 -4.01 9.67e-05 0.0326 -0.51 -0.31 Lung cancer in ever smokers; chr15:49312606 chr15:49365124~49366685:- PAAD cis rs6061231 0.793 rs2427320 ENSG00000275437.1 RP5-908M14.10 4 9.67e-05 0.0326 0.32 0.31 Colorectal cancer; chr20:62401667 chr20:62402236~62405935:- PAAD cis rs6061231 0.793 rs6061512 ENSG00000275437.1 RP5-908M14.10 4 9.67e-05 0.0326 0.32 0.31 Colorectal cancer; chr20:62401873 chr20:62402236~62405935:- PAAD cis rs6061231 0.837 rs6061235 ENSG00000275437.1 RP5-908M14.10 4 9.67e-05 0.0326 0.32 0.31 Colorectal cancer; chr20:62403468 chr20:62402236~62405935:- PAAD cis rs56046484 0.956 rs2174218 ENSG00000259295.5 CSPG4P12 -4 9.69e-05 0.0326 -0.43 -0.31 Testicular germ cell tumor; chr15:85081425 chr15:85191438~85213905:+ PAAD cis rs56046484 0.956 rs35885781 ENSG00000259295.5 CSPG4P12 4 9.69e-05 0.0326 0.43 0.31 Testicular germ cell tumor; chr15:85047852 chr15:85191438~85213905:+ PAAD cis rs56046484 0.956 rs34105012 ENSG00000259295.5 CSPG4P12 4 9.69e-05 0.0326 0.43 0.31 Testicular germ cell tumor; chr15:85048455 chr15:85191438~85213905:+ PAAD cis rs56046484 0.956 rs34054841 ENSG00000259295.5 CSPG4P12 4 9.69e-05 0.0326 0.43 0.31 Testicular germ cell tumor; chr15:85058115 chr15:85191438~85213905:+ PAAD cis rs56046484 0.956 rs12908535 ENSG00000259295.5 CSPG4P12 4 9.69e-05 0.0326 0.43 0.31 Testicular germ cell tumor; chr15:85058294 chr15:85191438~85213905:+ PAAD cis rs56046484 0.956 rs12904410 ENSG00000259295.5 CSPG4P12 4 9.69e-05 0.0326 0.43 0.31 Testicular germ cell tumor; chr15:85066557 chr15:85191438~85213905:+ PAAD cis rs56046484 1 rs12911330 ENSG00000259295.5 CSPG4P12 4 9.69e-05 0.0326 0.43 0.31 Testicular germ cell tumor; chr15:85087103 chr15:85191438~85213905:+ PAAD cis rs56046484 0.956 rs34919315 ENSG00000259295.5 CSPG4P12 4 9.69e-05 0.0326 0.43 0.31 Testicular germ cell tumor; chr15:85088675 chr15:85191438~85213905:+ PAAD cis rs7829975 0.577 rs7816329 ENSG00000173295.6 FAM86B3P -4 9.69e-05 0.0326 -0.35 -0.31 Mood instability; chr8:8686333 chr8:8228595~8244865:+ PAAD cis rs4662986 0.579 rs3108975 ENSG00000229536.1 AC079776.1 4 9.69e-05 0.0326 0.59 0.31 Age at smoking initiation in chronic obstructive pulmonary disease; chr2:129608160 chr2:129869193~129877553:- PAAD cis rs12900463 0.813 rs186266 ENSG00000275120.1 RP11-182J1.17 4 9.7e-05 0.0326 0.34 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine); chr15:84859564 chr15:84599434~84606463:- PAAD cis rs16846053 0.642 rs971284 ENSG00000227403.1 AC009299.3 4 9.7e-05 0.0326 0.48 0.31 Blood osmolality (transformed sodium); chr2:161751944 chr2:161244739~161249050:+ PAAD cis rs16849225 0.548 rs6748298 ENSG00000277998.1 RP11-452N17.1 -4 9.7e-05 0.0326 -0.35 -0.31 Systolic blood pressure;Blood pressure; chr2:163977170 chr2:164573741~164574054:+ PAAD cis rs7572733 0.534 rs4550664 ENSG00000231621.1 AC013264.2 -4 9.7e-05 0.0326 -0.31 -0.31 Dermatomyositis; chr2:197826681 chr2:197197991~197199273:+ PAAD cis rs10779751 0.922 rs2295080 ENSG00000238199.1 UBE2V2P3 -4 9.71e-05 0.0327 -0.37 -0.31 Body mass index; chr1:11262571 chr1:11278616~11279351:- PAAD cis rs3738443 0.868 rs61840048 ENSG00000259865.1 RP11-488L18.10 4 9.71e-05 0.0327 0.28 0.31 Alcohol dependence; chr1:247199829 chr1:247187281~247188526:- PAAD cis rs3738443 0.868 rs7551871 ENSG00000259865.1 RP11-488L18.10 4 9.71e-05 0.0327 0.28 0.31 Alcohol dependence; chr1:247199888 chr1:247187281~247188526:- PAAD cis rs3738443 0.868 rs2892054 ENSG00000259865.1 RP11-488L18.10 4 9.71e-05 0.0327 0.28 0.31 Alcohol dependence; chr1:247203803 chr1:247187281~247188526:- PAAD cis rs3738443 0.817 rs61840052 ENSG00000259865.1 RP11-488L18.10 4 9.71e-05 0.0327 0.28 0.31 Alcohol dependence; chr1:247204036 chr1:247187281~247188526:- PAAD cis rs7260598 0.792 rs73031010 ENSG00000268442.1 CTD-2027I19.2 4 9.71e-05 0.0327 0.51 0.31 Response to taxane treatment (placlitaxel); chr19:24178160 chr19:24162370~24163425:- PAAD cis rs7260598 0.792 rs73031013 ENSG00000268442.1 CTD-2027I19.2 4 9.71e-05 0.0327 0.51 0.31 Response to taxane treatment (placlitaxel); chr19:24182049 chr19:24162370~24163425:- PAAD cis rs7120173 1 rs7120173 ENSG00000254851.1 RP11-109L13.1 4 9.71e-05 0.0327 0.47 0.31 Visceral adipose tissue adjusted for BMI; chr11:116958937 chr11:117135528~117138582:+ PAAD cis rs10506328 0.509 rs2293602 ENSG00000248265.1 FLJ12825 4 9.71e-05 0.0327 0.27 0.31 Mean platelet volume; chr12:54242062 chr12:54058254~54122234:+ PAAD cis rs8177376 0.953 rs73017385 ENSG00000254905.1 RP11-712L6.7 4 9.72e-05 0.0327 0.43 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126309680 chr11:126292922~126294254:- PAAD cis rs875971 1 rs6956179 ENSG00000232559.3 GS1-124K5.12 -4 9.72e-05 0.0327 -0.33 -0.31 Aortic root size; chr7:66341672 chr7:66554588~66576923:- PAAD cis rs10936632 0.565 rs6794467 ENSG00000242578.1 RP11-469J4.3 -4 9.72e-05 0.0327 -0.34 -0.31 Prostate cancer; chr3:170430203 chr3:170410512~170418615:+ PAAD cis rs2832191 0.967 rs2898160 ENSG00000215533.7 LINC00189 4 9.72e-05 0.0327 0.37 0.31 Dental caries; chr21:29115175 chr21:29193480~29288205:+ PAAD cis rs2832191 1 rs2832190 ENSG00000215533.7 LINC00189 4 9.72e-05 0.0327 0.37 0.31 Dental caries; chr21:29115905 chr21:29193480~29288205:+ PAAD cis rs2832191 1 rs9984793 ENSG00000215533.7 LINC00189 4 9.73e-05 0.0327 0.37 0.31 Dental caries; chr21:29114150 chr21:29193480~29288205:+ PAAD cis rs2832191 0.903 rs11700687 ENSG00000215533.7 LINC00189 4 9.73e-05 0.0327 0.37 0.31 Dental caries; chr21:29114446 chr21:29193480~29288205:+ PAAD cis rs4713118 0.662 rs149969 ENSG00000219392.1 RP1-265C24.5 -4 9.73e-05 0.0327 -0.43 -0.31 Parkinson's disease; chr6:28009959 chr6:28115628~28116551:+ PAAD cis rs4950322 0.542 rs17159914 ENSG00000278811.3 LINC00624 -4 9.73e-05 0.0327 -0.3 -0.31 Protein quantitative trait loci; chr1:147183226 chr1:147258885~147517875:- PAAD cis rs4950322 0.542 rs115179956 ENSG00000278811.3 LINC00624 4 9.73e-05 0.0327 0.3 0.31 Protein quantitative trait loci; chr1:147172620 chr1:147258885~147517875:- PAAD cis rs4950322 0.542 rs4950382 ENSG00000278811.3 LINC00624 4 9.73e-05 0.0327 0.3 0.31 Protein quantitative trait loci; chr1:147176645 chr1:147258885~147517875:- PAAD cis rs4950322 0.542 rs2883434 ENSG00000278811.3 LINC00624 4 9.73e-05 0.0327 0.3 0.31 Protein quantitative trait loci; chr1:147177505 chr1:147258885~147517875:- PAAD cis rs4950322 0.542 rs12046706 ENSG00000278811.3 LINC00624 4 9.73e-05 0.0327 0.3 0.31 Protein quantitative trait loci; chr1:147189758 chr1:147258885~147517875:- PAAD cis rs6539288 0.933 rs10861673 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106906293 chr12:106954029~106955497:- PAAD cis rs6539288 0.899 rs7956807 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106906748 chr12:106954029~106955497:- PAAD cis rs6539288 0.899 rs7298423 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106908202 chr12:106954029~106955497:- PAAD cis rs6539288 0.933 rs1037012 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106908899 chr12:106954029~106955497:- PAAD cis rs6539288 0.933 rs1037011 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106909000 chr12:106954029~106955497:- PAAD cis rs6539288 0.933 rs4964497 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106910711 chr12:106954029~106955497:- PAAD cis rs6539288 0.899 rs2053206 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106912401 chr12:106954029~106955497:- PAAD cis rs6539288 0.933 rs2053205 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106912489 chr12:106954029~106955497:- PAAD cis rs6539288 0.933 rs759605 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106913401 chr12:106954029~106955497:- PAAD cis rs6539288 0.933 rs759604 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106913518 chr12:106954029~106955497:- PAAD cis rs6539288 0.899 rs759603 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106913613 chr12:106954029~106955497:- PAAD cis rs6539288 0.933 rs2075289 ENSG00000260329.1 RP11-412D9.4 -4 9.73e-05 0.0327 -0.26 -0.31 Total body bone mineral density; chr12:106913860 chr12:106954029~106955497:- PAAD cis rs116139393 0.505 rs3801033 ENSG00000187953.9 PMS2CL 4 9.73e-05 0.0327 0.32 0.31 Alzheimer's disease (APOE e4 interaction); chr7:6694472 chr7:6710128~6753862:+ PAAD cis rs2403083 0.505 rs2279701 ENSG00000258256.1 RP11-219B4.5 -4 9.73e-05 0.0327 -0.34 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85298046 chr8:85222446~85245717:- PAAD cis rs10129255 0.518 rs2006284 ENSG00000211972.2 IGHV3-66 4 9.73e-05 0.0327 0.24 0.31 Kawasaki disease; chr14:106676185 chr14:106675017~106675544:- PAAD cis rs2243480 1 rs316330 ENSG00000232546.1 RP11-458F8.1 -4 9.73e-05 0.0327 -0.37 -0.31 Diabetic kidney disease; chr7:66140385 chr7:66848496~66858136:+ PAAD cis rs950169 0.8 rs34302901 ENSG00000259683.1 RP11-182J1.14 4 9.74e-05 0.0327 0.25 0.31 Schizophrenia; chr15:84567712 chr15:84389729~84395903:+ PAAD cis rs111580313 0.534 rs4843170 ENSG00000270020.1 RP11-463O9.9 4 9.75e-05 0.0327 0.64 0.31 Systemic juvenile idiopathic arthritis; chr16:86576660 chr16:86520383~86523897:- PAAD cis rs728616 0.571 rs113030473 ENSG00000225484.5 NUTM2B-AS1 -4 9.75e-05 0.0327 -0.61 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79889275 chr10:79663088~79826594:- PAAD cis rs950169 0.922 rs62021167 ENSG00000275120.1 RP11-182J1.17 4 9.76e-05 0.0328 0.33 0.31 Schizophrenia; chr15:84574820 chr15:84599434~84606463:- PAAD cis rs11233413 0.874 rs5018628 ENSG00000247137.7 RP11-727A23.5 -4 9.76e-05 0.0328 -0.28 -0.31 Economic and political preferences (feminism/equality); chr11:83041195 chr11:83184491~83193794:- PAAD cis rs10540 1 rs35996687 ENSG00000255237.1 RP13-317D12.3 4 9.76e-05 0.0328 0.49 0.31 Body mass index; chr11:458595 chr11:462930~463899:- PAAD cis rs896655 0.631 rs1335511 ENSG00000266446.1 RP11-149I2.4 4 9.76e-05 0.0328 0.37 0.31 Coronary artery disease; chr9:21757917 chr9:21995482~21996013:+ PAAD cis rs6539288 0.899 rs4964192 ENSG00000260329.1 RP11-412D9.4 -4 9.76e-05 0.0328 -0.26 -0.31 Total body bone mineral density; chr12:106915014 chr12:106954029~106955497:- PAAD cis rs7712401 0.562 rs384483 ENSG00000263432.2 RN7SL689P -4 9.77e-05 0.0328 -0.4 -0.31 Mean platelet volume; chr5:122925878 chr5:123022487~123022783:- PAAD cis rs2404602 0.647 rs907593 ENSG00000259422.1 RP11-593F23.1 -4 9.78e-05 0.0328 -0.39 -0.31 Blood metabolite levels; chr15:76904612 chr15:76174891~76181486:- PAAD cis rs9584850 0.794 rs17470961 ENSG00000231194.1 FARP1-AS1 4 9.78e-05 0.0328 0.39 0.31 Neuroticism; chr13:98483060 chr13:98435405~98435840:- PAAD cis rs5003154 0.555 rs4739786 ENSG00000253334.1 RP13-923O23.6 4 9.79e-05 0.0329 0.34 0.31 Bladder cancer; chr8:81098188 chr8:81791823~81815714:+ PAAD cis rs10951983 0.847 rs12537894 ENSG00000272719.1 CTB-161C1.1 -4 9.79e-05 0.0329 -0.41 -0.31 Coronary artery disease; chr7:6427820 chr7:5556731~5557245:+ PAAD cis rs10951983 0.847 rs35444732 ENSG00000272719.1 CTB-161C1.1 -4 9.79e-05 0.0329 -0.41 -0.31 Coronary artery disease; chr7:6434333 chr7:5556731~5557245:+ PAAD cis rs10951983 0.847 rs12538142 ENSG00000272719.1 CTB-161C1.1 -4 9.79e-05 0.0329 -0.41 -0.31 Coronary artery disease; chr7:6436168 chr7:5556731~5557245:+ PAAD cis rs10951983 0.847 rs3750038 ENSG00000272719.1 CTB-161C1.1 -4 9.79e-05 0.0329 -0.41 -0.31 Coronary artery disease; chr7:6436606 chr7:5556731~5557245:+ PAAD cis rs5769765 0.908 rs138880 ENSG00000278869.1 CITF22-49E9.3 4 9.79e-05 0.0329 0.45 0.31 Schizophrenia; chr22:49824963 chr22:49933198~49934074:- PAAD cis rs11676348 0.755 rs6436026 ENSG00000261338.2 RP11-378A13.1 -4 9.79e-05 0.0329 -0.36 -0.31 Ulcerative colitis; chr2:218087015 chr2:218255319~218257366:+ PAAD cis rs11676348 0.791 rs6726126 ENSG00000261338.2 RP11-378A13.1 -4 9.79e-05 0.0329 -0.36 -0.31 Ulcerative colitis; chr2:218087510 chr2:218255319~218257366:+ PAAD cis rs193541 0.632 rs2407402 ENSG00000263432.2 RN7SL689P 4 9.8e-05 0.0329 0.4 0.31 Glucose homeostasis traits; chr5:122771410 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs7729834 ENSG00000263432.2 RN7SL689P 4 9.8e-05 0.0329 0.4 0.31 Glucose homeostasis traits; chr5:122786464 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs10037044 ENSG00000263432.2 RN7SL689P -4 9.8e-05 0.0329 -0.4 -0.31 Glucose homeostasis traits; chr5:122787604 chr5:123022487~123022783:- PAAD cis rs14165 0.67 rs2359133 ENSG00000271916.1 RP11-884K10.6 4 9.81e-05 0.0329 0.26 0.31 Refractive error; chr3:53802715 chr3:53797764~53798019:- PAAD cis rs13392177 0.684 rs11682371 ENSG00000261338.2 RP11-378A13.1 -4 9.81e-05 0.0329 -0.37 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218214790 chr2:218255319~218257366:+ PAAD cis rs13392177 0.684 rs6720105 ENSG00000261338.2 RP11-378A13.1 -4 9.81e-05 0.0329 -0.37 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218215995 chr2:218255319~218257366:+ PAAD cis rs13392177 0.684 rs6720449 ENSG00000261338.2 RP11-378A13.1 -4 9.81e-05 0.0329 -0.37 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218216255 chr2:218255319~218257366:+ PAAD cis rs11048470 0.638 rs2570 ENSG00000256234.1 RP11-283G6.4 4 9.81e-05 0.0329 0.36 0.31 Waist-hip ratio; chr12:26338905 chr12:26211164~26335856:- PAAD cis rs3738443 0.868 rs35229190 ENSG00000259865.1 RP11-488L18.10 4 9.81e-05 0.0329 0.28 0.31 Alcohol dependence; chr1:247202339 chr1:247187281~247188526:- PAAD cis rs950169 1 rs79318564 ENSG00000259683.1 RP11-182J1.14 4 9.82e-05 0.0329 0.26 0.31 Schizophrenia; chr15:84117398 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs1911155 ENSG00000259683.1 RP11-182J1.14 4 9.82e-05 0.0329 0.26 0.31 Schizophrenia; chr15:84118883 chr15:84389729~84395903:+ PAAD cis rs13178541 0.511 rs28373574 ENSG00000250378.1 RP11-119J18.1 -4 9.82e-05 0.0329 -0.46 -0.31 IgG glycosylation; chr5:135789626 chr5:135812667~135826582:+ PAAD cis rs2188561 0.697 rs7787927 ENSG00000241764.3 AC002467.7 4 9.82e-05 0.0329 0.39 0.31 Alcohol consumption; chr7:107763915 chr7:107742817~107744581:- PAAD cis rs8026198 0.714 rs1062038 ENSG00000260571.1 BNIP3P5 -4 9.82e-05 0.0329 -0.53 -0.31 Fibrinogen levels; chr15:42415645 chr15:42313687~42314386:+ PAAD cis rs12908161 0.959 rs1051168 ENSG00000259295.5 CSPG4P12 4 9.83e-05 0.033 0.34 0.31 Schizophrenia; chr15:84657289 chr15:85191438~85213905:+ PAAD cis rs71403859 0.685 rs12444890 ENSG00000260886.1 TAT-AS1 4 9.83e-05 0.033 0.53 0.31 Post bronchodilator FEV1; chr16:71602123 chr16:71565789~71578187:+ PAAD cis rs71403859 1 rs71403859 ENSG00000260886.1 TAT-AS1 4 9.83e-05 0.033 0.53 0.31 Post bronchodilator FEV1; chr16:71606304 chr16:71565789~71578187:+ PAAD cis rs71403859 0.803 rs34381861 ENSG00000260886.1 TAT-AS1 4 9.83e-05 0.033 0.53 0.31 Post bronchodilator FEV1; chr16:71606327 chr16:71565789~71578187:+ PAAD cis rs2688608 0.618 rs28553894 ENSG00000271816.1 BMS1P4 4 9.83e-05 0.033 0.32 0.31 Inflammatory bowel disease; chr10:73730085 chr10:73699151~73730487:- PAAD cis rs2688608 0.618 rs28718766 ENSG00000271816.1 BMS1P4 4 9.83e-05 0.033 0.32 0.31 Inflammatory bowel disease; chr10:73730086 chr10:73699151~73730487:- PAAD cis rs919433 0.519 rs700656 ENSG00000231621.1 AC013264.2 -4 9.83e-05 0.033 -0.31 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197788943 chr2:197197991~197199273:+ PAAD cis rs867371 1 rs13380319 ENSG00000259429.4 UBE2Q2P2 -4 9.83e-05 0.033 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82214526 chr15:82355142~82420075:+ PAAD cis rs4853012 0.838 rs12619982 ENSG00000257800.1 FNBP1P1 4 9.83e-05 0.033 0.43 0.31 Gestational age at birth (maternal effect); chr2:74128895 chr2:74120680~74123218:+ PAAD cis rs6908034 0.66 rs111509549 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19798139 chr6:19802164~19804752:- PAAD cis rs6908034 0.6 rs79733895 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19799310 chr6:19802164~19804752:- PAAD cis rs6908034 0.66 rs76322282 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19801429 chr6:19802164~19804752:- PAAD cis rs6908034 0.66 rs111231540 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19801995 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs111533721 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19803514 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs112824001 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19804460 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs73376650 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19805275 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs112599867 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19805301 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs73376651 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19805328 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs73376655 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19805433 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs73376657 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19805729 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs74573060 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19805801 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs113592672 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19805832 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs113894708 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19805835 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs62404179 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19806041 chr6:19802164~19804752:- PAAD cis rs6908034 0.546 rs73376662 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19806109 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs12529148 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19806566 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs112659166 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19807178 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs34109983 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19807811 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs73376680 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19807868 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs73376681 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19807944 chr6:19802164~19804752:- PAAD cis rs6908034 0.607 rs80355837 ENSG00000228412.5 RP4-625H18.2 4 9.83e-05 0.033 0.65 0.31 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19808112 chr6:19802164~19804752:- PAAD cis rs11098499 0.604 rs17051352 ENSG00000245958.5 RP11-33B1.1 -4 9.84e-05 0.033 -0.27 -0.31 Corneal astigmatism; chr4:119660272 chr4:119454791~119552025:+ PAAD cis rs6452524 0.544 rs2126989 ENSG00000249664.1 CTD-2227C6.2 -4 9.84e-05 0.033 -0.37 -0.31 Hypertension (SNP x SNP interaction); chr5:83092120 chr5:83012285~83013109:- PAAD cis rs3790645 1 rs282177 ENSG00000225159.1 NPM1P39 4 9.84e-05 0.033 0.4 0.31 Glucose homeostasis traits; chr1:26572634 chr1:27206930~27207796:+ PAAD cis rs2688608 0.592 rs3933085 ENSG00000271816.1 BMS1P4 4 9.85e-05 0.033 0.31 0.31 Inflammatory bowel disease; chr10:73723573 chr10:73699151~73730487:- PAAD cis rs2688608 0.592 rs7909544 ENSG00000271816.1 BMS1P4 4 9.85e-05 0.033 0.31 0.31 Inflammatory bowel disease; chr10:73724246 chr10:73699151~73730487:- PAAD cis rs10411161 0.702 rs7247017 ENSG00000270248.1 CTC-471J1.10 4 9.85e-05 0.033 0.56 0.31 Breast cancer; chr19:51888516 chr19:52110318~52110726:- PAAD cis rs10411161 0.702 rs7256926 ENSG00000270248.1 CTC-471J1.10 4 9.85e-05 0.033 0.56 0.31 Breast cancer; chr19:51888735 chr19:52110318~52110726:- PAAD cis rs7824557 0.767 rs7003241 ENSG00000205879.4 FAM90A2P 4 9.85e-05 0.033 0.4 0.31 Retinal vascular caliber; chr8:11311566 chr8:12172202~12178575:- PAAD cis rs7824557 0.767 rs1897950 ENSG00000205879.4 FAM90A2P 4 9.85e-05 0.033 0.4 0.31 Retinal vascular caliber; chr8:11312042 chr8:12172202~12178575:- PAAD cis rs7824557 0.767 rs1897951 ENSG00000205879.4 FAM90A2P 4 9.85e-05 0.033 0.4 0.31 Retinal vascular caliber; chr8:11312345 chr8:12172202~12178575:- PAAD cis rs7824557 0.767 rs11250127 ENSG00000205879.4 FAM90A2P 4 9.85e-05 0.033 0.4 0.31 Retinal vascular caliber; chr8:11312700 chr8:12172202~12178575:- PAAD cis rs867371 0.82 rs12443224 ENSG00000259767.1 RP11-90B9.2 4 9.86e-05 0.033 0.26 0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82203269 chr15:83022236~83024336:- PAAD cis rs6543140 0.964 rs6543143 ENSG00000234389.1 AC007278.3 4 9.86e-05 0.033 0.34 0.31 Blood protein levels; chr2:102468960 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs13383602 ENSG00000234389.1 AC007278.3 4 9.86e-05 0.033 0.34 0.31 Blood protein levels; chr2:102469502 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs4851592 ENSG00000234389.1 AC007278.3 4 9.86e-05 0.033 0.34 0.31 Blood protein levels; chr2:102471181 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs10193485 ENSG00000234389.1 AC007278.3 4 9.86e-05 0.033 0.34 0.31 Blood protein levels; chr2:102473114 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs10196334 ENSG00000234389.1 AC007278.3 4 9.86e-05 0.033 0.34 0.31 Blood protein levels; chr2:102473582 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs10200081 ENSG00000234389.1 AC007278.3 4 9.86e-05 0.033 0.34 0.31 Blood protein levels; chr2:102475097 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs4851593 ENSG00000234389.1 AC007278.3 -4 9.86e-05 0.033 -0.34 -0.31 Blood protein levels; chr2:102472767 chr2:102438713~102440475:+ PAAD cis rs4660214 0.666 rs2275188 ENSG00000228060.1 RP11-69E11.8 4 9.86e-05 0.033 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39283249 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs1984143 ENSG00000228060.1 RP11-69E11.8 4 9.86e-05 0.033 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39290645 chr1:39565160~39573203:+ PAAD cis rs7260598 0.642 rs11667315 ENSG00000268442.1 CTD-2027I19.2 4 9.86e-05 0.033 0.44 0.31 Response to taxane treatment (placlitaxel); chr19:23932336 chr19:24162370~24163425:- PAAD cis rs79349575 0.745 rs170319 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48914169 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs318090 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48914390 chr17:48899131~48899748:+ PAAD cis rs79349575 0.651 rs4378658 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48916008 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs12453374 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48917484 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs12453394 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48917608 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs62075838 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48919070 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs62075839 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48919072 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs4255820 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48919221 chr17:48899131~48899748:+ PAAD cis rs79349575 0.811 rs12601072 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48920636 chr17:48899131~48899748:+ PAAD cis rs79349575 0.749 rs58838744 ENSG00000270781.1 RP11-501C14.9 -4 9.86e-05 0.033 -0.35 -0.31 Type 2 diabetes; chr17:48921540 chr17:48899131~48899748:+ PAAD cis rs8100891 0.665 rs7259259 ENSG00000267213.4 AC007773.2 -4 9.86e-05 0.033 -0.41 -0.31 Neuroticism; chr19:32328935 chr19:32390050~32405560:- PAAD cis rs730566 0.619 rs3731529 ENSG00000229759.1 MRPS18AP1 -4 9.87e-05 0.033 -0.43 -0.31 Prion diseases; chr3:48172008 chr3:48256350~48256938:- PAAD cis rs13178541 0.566 rs6879940 ENSG00000250378.1 RP11-119J18.1 -4 9.87e-05 0.033 -0.4 -0.31 IgG glycosylation; chr5:135718040 chr5:135812667~135826582:+ PAAD cis rs7216064 1 rs4791212 ENSG00000278219.1 AC145343.1 -4 9.87e-05 0.0331 -0.47 -0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67979269 chr17:68101538~68101639:+ PAAD cis rs17507216 0.718 rs4779034 ENSG00000255769.6 GOLGA2P10 -4 9.87e-05 0.0331 -0.41 -0.31 Excessive daytime sleepiness; chr15:82576799 chr15:82472993~82513950:- PAAD cis rs17507216 0.671 rs28582623 ENSG00000255769.6 GOLGA2P10 -4 9.87e-05 0.0331 -0.41 -0.31 Excessive daytime sleepiness; chr15:82577381 chr15:82472993~82513950:- PAAD cis rs7829975 0.688 rs7827182 ENSG00000173295.6 FAM86B3P 4 9.87e-05 0.0331 0.31 0.31 Mood instability; chr8:8522961 chr8:8228595~8244865:+ PAAD cis rs8059260 1 rs6498138 ENSG00000274038.1 RP11-66H6.4 4 9.87e-05 0.0331 0.45 0.31 Alcohol consumption over the past year; chr16:10951421 chr16:11056556~11057034:+ PAAD cis rs847577 0.569 rs7804318 ENSG00000272950.1 RP11-307C18.1 -4 9.88e-05 0.0331 -0.39 -0.31 Breast cancer; chr7:98167323 chr7:98322853~98323430:+ PAAD cis rs4722166 0.532 rs6963591 ENSG00000179428.2 AC073072.5 4 9.88e-05 0.0331 0.28 0.31 Lung cancer; chr7:22717651 chr7:22725395~22727620:- PAAD cis rs7202877 0.561 rs9933956 ENSG00000261783.1 RP11-252K23.2 -4 9.88e-05 0.0331 -0.49 -0.31 Type 1 diabetes;Type 2 diabetes; chr16:75328915 chr16:75379818~75381260:- PAAD cis rs2439831 0.85 rs558656 ENSG00000275601.1 AC011330.13 -4 9.89e-05 0.0331 -0.54 -0.31 Lung cancer in ever smokers; chr15:43431316 chr15:43642389~43643023:- PAAD cis rs2243480 1 rs160652 ENSG00000228409.4 CCT6P1 4 9.89e-05 0.0331 0.33 0.31 Diabetic kidney disease; chr7:66073444 chr7:65751142~65763354:+ PAAD cis rs8026198 0.734 rs7163986 ENSG00000260571.1 BNIP3P5 -4 9.89e-05 0.0331 -0.51 -0.31 Fibrinogen levels; chr15:42403960 chr15:42313687~42314386:+ PAAD cis rs633715 0.766 rs2902200 ENSG00000254154.7 RP4-798P15.3 -4 9.89e-05 0.0331 -0.28 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177837703 chr1:177928788~178038007:- PAAD cis rs34375054 0.66 rs12305181 ENSG00000279233.1 RP11-158L12.4 4 9.89e-05 0.0331 0.27 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125109610 chr12:125138245~125141711:+ PAAD cis rs60065504 1 rs60065504 ENSG00000251022.5 THAP9-AS1 -4 9.89e-05 0.0331 -0.23 -0.31 Lymphocyte percentage of white cells; chr4:82964057 chr4:82893009~82900960:- PAAD cis rs73081554 0.611 rs13071861 ENSG00000272360.1 RP11-359I18.5 -4 9.9e-05 0.0331 -0.5 -0.31 Rheumatoid arthritis; chr3:58385605 chr3:58490830~58491291:- PAAD cis rs891378 1 rs891378 ENSG00000274245.1 RP11-357P18.2 -4 9.9e-05 0.0331 -0.44 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207316974 chr1:207372559~207373252:+ PAAD cis rs3096299 0.685 rs4785568 ENSG00000261118.1 RP11-104N10.1 4 9.9e-05 0.0331 0.27 0.31 Multiple myeloma (IgH translocation); chr16:89487299 chr16:89492017~89504460:- PAAD cis rs889398 0.742 rs12446197 ENSG00000226232.7 RP11-419C5.2 4 9.9e-05 0.0331 0.25 0.31 Body mass index; chr16:69820966 chr16:69976388~69996188:- PAAD cis rs889398 0.802 rs12921407 ENSG00000226232.7 RP11-419C5.2 4 9.9e-05 0.0331 0.25 0.31 Body mass index; chr16:69827030 chr16:69976388~69996188:- PAAD cis rs2904524 1 rs4761189 ENSG00000257815.4 RP11-611E13.2 -4 9.9e-05 0.0331 -0.33 -0.31 Amyotrophic lateral sclerosis (age of onset); chr12:70247078 chr12:69904033~70243360:- PAAD cis rs2439831 1 rs7173487 ENSG00000275601.1 AC011330.13 -4 9.91e-05 0.0331 -0.58 -0.31 Lung cancer in ever smokers; chr15:43458041 chr15:43642389~43643023:- PAAD cis rs7216064 0.648 rs61676547 ENSG00000278219.1 AC145343.1 -4 9.91e-05 0.0332 -0.49 -0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67896391 chr17:68101538~68101639:+ PAAD cis rs4853525 0.961 rs11687659 ENSG00000235852.1 AC005540.3 -4 9.91e-05 0.0332 -0.41 -0.31 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190876471 chr2:190880797~190882059:- PAAD cis rs4660214 0.666 rs11205839 ENSG00000228060.1 RP11-69E11.8 4 9.91e-05 0.0332 0.3 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39268061 chr1:39565160~39573203:+ PAAD cis rs8072100 0.512 rs9303533 ENSG00000228782.6 CTD-2026D20.3 4 9.92e-05 0.0332 0.31 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47309174 chr17:47450568~47492492:- PAAD cis rs1910358 0.554 rs2172050 ENSG00000248874.4 C5orf17 -4 9.92e-05 0.0332 -0.42 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23804461 chr5:23951348~24178263:+ PAAD cis rs1910358 0.554 rs7705749 ENSG00000248874.4 C5orf17 -4 9.92e-05 0.0332 -0.42 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23805116 chr5:23951348~24178263:+ PAAD cis rs9309473 0.95 rs11126412 ENSG00000163016.8 ALMS1P 4 9.93e-05 0.0332 0.45 0.31 Metabolite levels; chr2:73660507 chr2:73644919~73685576:+ PAAD cis rs321358 0.731 rs516110 ENSG00000271390.1 RP11-89C3.3 4 9.93e-05 0.0332 0.4 0.31 Body mass index; chr11:111166525 chr11:111089870~111090368:- PAAD cis rs950169 0.922 rs11639244 ENSG00000275120.1 RP11-182J1.17 4 9.93e-05 0.0332 0.32 0.31 Schizophrenia; chr15:84163898 chr15:84599434~84606463:- PAAD cis rs950169 0.845 rs4106951 ENSG00000275120.1 RP11-182J1.17 4 9.93e-05 0.0332 0.32 0.31 Schizophrenia; chr15:84164642 chr15:84599434~84606463:- PAAD cis rs10740039 0.883 rs2393676 ENSG00000254271.1 RP11-131N11.4 4 9.93e-05 0.0332 0.38 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60630500 chr10:60734342~60741828:+ PAAD cis rs17772222 0.682 rs4904452 ENSG00000258983.2 RP11-507K2.2 -4 9.93e-05 0.0332 -0.38 -0.31 Coronary artery calcification; chr14:88517329 chr14:88499334~88515502:+ PAAD cis rs303386 0.515 rs303393 ENSG00000223656.1 HMGB3P10 4 9.94e-05 0.0332 0.39 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin); chr1:99127536 chr1:99698242~99699178:+ PAAD cis rs2929278 0.617 rs694461 ENSG00000275601.1 AC011330.13 4 9.95e-05 0.0333 0.35 0.31 Schizophrenia; chr15:43803865 chr15:43642389~43643023:- PAAD cis rs10761482 0.5 rs7072229 ENSG00000254271.1 RP11-131N11.4 4 9.95e-05 0.0333 0.37 0.31 Schizophrenia; chr10:60524462 chr10:60734342~60741828:+ PAAD cis rs10761482 0.5 rs10821790 ENSG00000254271.1 RP11-131N11.4 4 9.95e-05 0.0333 0.37 0.31 Schizophrenia; chr10:60529009 chr10:60734342~60741828:+ PAAD cis rs728616 0.867 rs56365235 ENSG00000225484.5 NUTM2B-AS1 -4 9.96e-05 0.0333 -0.59 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:80134983 chr10:79663088~79826594:- PAAD cis rs9309711 0.698 rs9750503 ENSG00000225234.1 TRAPPC12-AS1 4 9.97e-05 0.0333 0.34 0.31 Neurofibrillary tangles; chr2:3488001 chr2:3481242~3482409:- PAAD cis rs7189233 1 rs16952251 ENSG00000279722.1 RP11-44F14.6 -4 9.97e-05 0.0333 -0.33 -0.31 Intelligence (multi-trait analysis); chr16:53449226 chr16:53487607~53489943:- PAAD cis rs7189233 1 rs62048520 ENSG00000279722.1 RP11-44F14.6 -4 9.97e-05 0.0333 -0.33 -0.31 Intelligence (multi-trait analysis); chr16:53457183 chr16:53487607~53489943:- PAAD cis rs7216064 0.734 rs11653507 ENSG00000278219.1 AC145343.1 -4 9.99e-05 0.0334 -0.44 -0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67895948 chr17:68101538~68101639:+ PAAD cis rs1873386 0.79 rs7312069 ENSG00000255910.1 RP11-405A12.2 4 9.99e-05 0.0334 0.44 0.31 Personality dimensions; chr12:18908743 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs7312198 ENSG00000255910.1 RP11-405A12.2 4 9.99e-05 0.0334 0.44 0.31 Personality dimensions; chr12:18908847 chr12:19775451~20009937:+ PAAD cis rs1873386 0.739 rs12828164 ENSG00000255910.1 RP11-405A12.2 4 9.99e-05 0.0334 0.44 0.31 Personality dimensions; chr12:18909280 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs12826776 ENSG00000255910.1 RP11-405A12.2 4 9.99e-05 0.0334 0.44 0.31 Personality dimensions; chr12:18909367 chr12:19775451~20009937:+ PAAD cis rs1873386 0.79 rs12826952 ENSG00000255910.1 RP11-405A12.2 4 9.99e-05 0.0334 0.44 0.31 Personality dimensions; chr12:18909389 chr12:19775451~20009937:+ PAAD cis rs2361718 0.501 rs8065486 ENSG00000279259.1 RP11-334C17.3 -4 9.99e-05 0.0334 -0.35 -0.31 Yeast infection; chr17:80164397 chr17:80147250~80148596:+ PAAD cis rs9322193 0.923 rs9800686 ENSG00000268592.3 RAET1E-AS1 4 9.99e-05 0.0334 0.36 0.31 Lung cancer; chr6:149634464 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs55849538 ENSG00000268592.3 RAET1E-AS1 4 9.99e-05 0.0334 0.36 0.31 Lung cancer; chr6:149635330 chr6:149863494~149919507:+ PAAD cis rs853679 0.517 rs9380058 ENSG00000280107.1 AL022393.9 -4 1e-04 0.0334 -0.51 -0.31 Depression; chr6:28159666 chr6:28170845~28172521:+ PAAD cis rs853679 0.517 rs9393898 ENSG00000280107.1 AL022393.9 -4 1e-04 0.0334 -0.51 -0.31 Depression; chr6:28162598 chr6:28170845~28172521:+ PAAD cis rs13392177 0.684 rs11695527 ENSG00000261338.2 RP11-378A13.1 4 1e-04 0.0334 0.37 0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218203380 chr2:218255319~218257366:+ PAAD cis rs13392177 0.647 rs6718220 ENSG00000261338.2 RP11-378A13.1 -4 1e-04 0.0334 -0.37 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218201795 chr2:218255319~218257366:+ PAAD cis rs2446066 0.872 rs7955418 ENSG00000257379.1 RP11-793H13.8 4 1e-04 0.0334 0.44 0.31 Red blood cell count; chr12:53397846 chr12:53441741~53467528:+ PAAD cis rs755249 0.501 rs661316 ENSG00000261798.1 RP1-118J21.25 4 1e-04 0.0335 0.36 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39165625 chr1:39788976~39790171:+ PAAD cis rs5015933 0.815 rs359597 ENSG00000232630.1 PRPS1P2 -4 1e-04 0.0335 -0.28 -0.31 Body mass index; chr9:125274312 chr9:125150653~125151589:+ PAAD cis rs5015933 0.815 rs10819043 ENSG00000232630.1 PRPS1P2 -4 1e-04 0.0335 -0.28 -0.31 Body mass index; chr9:125274966 chr9:125150653~125151589:+ PAAD cis rs6479901 0.793 rs10822154 ENSG00000232075.1 MRPL35P2 -4 1e-04 0.0335 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63299284 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs7897326 ENSG00000232075.1 MRPL35P2 -4 1e-04 0.0335 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63306059 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs7092139 ENSG00000232075.1 MRPL35P2 -4 1e-04 0.0335 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63306540 chr10:63634317~63634827:- PAAD cis rs6479901 1 rs7092539 ENSG00000232075.1 MRPL35P2 -4 1e-04 0.0335 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63306749 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs10740113 ENSG00000232075.1 MRPL35P2 -4 1e-04 0.0335 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63322516 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs10740114 ENSG00000232075.1 MRPL35P2 -4 1e-04 0.0335 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63322659 chr10:63634317~63634827:- PAAD cis rs2255336 0.938 rs61610254 ENSG00000245648.1 RP11-277P12.20 -4 1e-04 0.0335 -0.44 -0.31 Blood protein levels; chr12:10446176 chr12:10363769~10398506:+ PAAD cis rs710913 0.966 rs3738676 ENSG00000243970.1 PPIEL 4 1e-04 0.0335 0.27 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39525916 chr1:39531838~39558707:- PAAD cis rs853679 0.824 rs34712084 ENSG00000226314.6 ZNF192P1 -4 1e-04 0.0335 -0.6 -0.31 Depression; chr6:28076050 chr6:28161781~28169594:+ PAAD cis rs853679 0.824 rs1321505 ENSG00000226314.6 ZNF192P1 -4 1e-04 0.0335 -0.6 -0.31 Depression; chr6:28085045 chr6:28161781~28169594:+ PAAD cis rs853679 0.882 rs9468287 ENSG00000226314.6 ZNF192P1 -4 1e-04 0.0335 -0.6 -0.31 Depression; chr6:28111963 chr6:28161781~28169594:+ PAAD cis rs853679 0.882 rs9461432 ENSG00000226314.6 ZNF192P1 -4 1e-04 0.0335 -0.6 -0.31 Depression; chr6:28119105 chr6:28161781~28169594:+ PAAD cis rs853679 0.882 rs4713139 ENSG00000226314.6 ZNF192P1 -4 1e-04 0.0335 -0.6 -0.31 Depression; chr6:28124907 chr6:28161781~28169594:+ PAAD cis rs853679 0.882 rs4713140 ENSG00000226314.6 ZNF192P1 -4 1e-04 0.0335 -0.6 -0.31 Depression; chr6:28129415 chr6:28161781~28169594:+ PAAD cis rs853679 0.882 rs3757188 ENSG00000226314.6 ZNF192P1 -4 1e-04 0.0335 -0.6 -0.31 Depression; chr6:28139579 chr6:28161781~28169594:+ PAAD cis rs853679 0.882 rs9468300 ENSG00000226314.6 ZNF192P1 -4 1e-04 0.0335 -0.6 -0.31 Depression; chr6:28159062 chr6:28161781~28169594:+ PAAD cis rs591584 0.73 rs10765688 ENSG00000255893.1 RP11-685N10.1 -4 1e-04 0.0335 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94576693 chr11:94472908~94473570:- PAAD cis rs591584 0.73 rs72963850 ENSG00000255893.1 RP11-685N10.1 -4 1e-04 0.0335 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94577566 chr11:94472908~94473570:- PAAD cis rs591584 0.73 rs11020840 ENSG00000255893.1 RP11-685N10.1 -4 1e-04 0.0335 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94580348 chr11:94472908~94473570:- PAAD cis rs7615952 0.611 rs2971298 ENSG00000239804.1 RP11-379B18.1 4 1e-04 0.0335 0.53 0.31 Blood pressure (smoking interaction); chr3:125883870 chr3:125787888~125788146:- PAAD cis rs1113500 0.933 rs11185260 ENSG00000226822.1 RP11-356N1.2 -4 1e-04 0.0335 -0.36 -0.31 Growth-regulated protein alpha levels; chr1:108092457 chr1:108071482~108074519:+ PAAD cis rs7923609 0.54 rs10733789 ENSG00000232075.1 MRPL35P2 4 1e-04 0.0336 0.39 0.31 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63188924 chr10:63634317~63634827:- PAAD cis rs2034650 0.525 rs11790 ENSG00000223313.1 RNU6-516P 3.99 0.000101 0.0336 0.4 0.31 Interstitial lung disease; chr15:40420538 chr15:40529570~40529673:+ PAAD cis rs304029 0.716 rs2307068 ENSG00000231249.1 ITPR1-AS1 3.99 0.000101 0.0336 0.28 0.31 Diabetic kidney disease; chr3:4491276 chr3:4490891~4493163:- PAAD cis rs8081395 0.836 rs2063353 ENSG00000266992.1 DHX40P1 -3.99 0.000101 0.0336 -0.31 -0.31 White blood cell count; chr17:59811831 chr17:59976009~60002384:- PAAD cis rs2712184 0.875 rs2541381 ENSG00000229352.1 AC007563.3 -3.99 0.000101 0.0336 -0.3 -0.31 Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine); chr2:216819113 chr2:216799608~216805335:+ PAAD cis rs9531006 0.76 rs11840740 ENSG00000227676.3 LINC01068 3.99 0.000101 0.0336 0.44 0.31 Sleep duration; chr13:79911555 chr13:79566727~79571436:+ PAAD cis rs293748 0.571 rs13177573 ENSG00000250155.1 CTD-2353F22.1 3.99 0.000101 0.0336 0.41 0.31 Obesity-related traits; chr5:37233335 chr5:36666214~36725195:- PAAD cis rs7554672 0.961 rs7515181 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221155004 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs12121213 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221155664 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs7522861 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221158453 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs59098418 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221158906 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs12140672 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221161335 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs6670400 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221164368 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs9431425 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221165927 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs3920857 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221165952 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs17009529 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221165990 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs17009536 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221166132 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs4420085 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221170808 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs2039956 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221171187 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs7539794 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221174113 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs12122167 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221177270 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs11118663 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221177904 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs1341619 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221178056 chr1:222041705~222064763:- PAAD cis rs7554672 0.922 rs11118664 ENSG00000232679.1 RP11-400N13.3 3.99 0.000101 0.0336 0.32 0.31 Hypertension; chr1:221182246 chr1:222041705~222064763:- PAAD cis rs13256369 0.901 rs4841015 ENSG00000253981.4 ALG1L13P 3.99 0.000101 0.0336 0.41 0.31 Obesity-related traits; chr8:8709630 chr8:8236003~8244667:- PAAD cis rs858239 0.539 rs10254544 ENSG00000226816.2 AC005082.12 3.99 0.000101 0.0336 0.35 0.31 Cerebrospinal fluid biomarker levels; chr7:23180616 chr7:23206013~23208045:+ PAAD cis rs6563695 1 rs6563695 ENSG00000275149.1 RP11-427J23.1 -3.99 0.000101 0.0336 -0.7 -0.31 Preeclampsia; chr13:39329106 chr13:40079106~40273509:- PAAD cis rs1910358 0.621 rs10454885 ENSG00000248874.4 C5orf17 -3.99 0.000101 0.0336 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23844704 chr5:23951348~24178263:+ PAAD cis rs7829975 0.593 rs2921077 ENSG00000173295.6 FAM86B3P 3.99 0.000101 0.0336 0.31 0.31 Mood instability; chr8:8446992 chr8:8228595~8244865:+ PAAD cis rs1150668 0.699 rs12214383 ENSG00000204709.4 LINC01556 -3.99 0.000101 0.0337 -0.38 -0.31 Pubertal anthropometrics; chr6:28255953 chr6:28943877~28944537:+ PAAD cis rs1150668 0.699 rs1736895 ENSG00000204709.4 LINC01556 3.99 0.000101 0.0337 0.38 0.31 Pubertal anthropometrics; chr6:28252048 chr6:28943877~28944537:+ PAAD cis rs7849270 0.801 rs10819474 ENSG00000204054.10 LINC00963 3.99 0.000101 0.0337 0.43 0.31 Blood metabolite ratios; chr9:129168215 chr9:129483451~129513683:+ PAAD cis rs3743162 0.553 rs12900463 ENSG00000259728.4 LINC00933 3.99 0.000101 0.0337 0.42 0.31 Alzheimer's disease (age of onset); chr15:84872155 chr15:84570649~84580175:+ PAAD cis rs3743162 0.553 rs12915656 ENSG00000259728.4 LINC00933 3.99 0.000101 0.0337 0.42 0.31 Alzheimer's disease (age of onset); chr15:84872349 chr15:84570649~84580175:+ PAAD cis rs2677744 0.626 rs868547 ENSG00000259704.1 CTD-3094K11.1 -3.99 0.000101 0.0337 -0.38 -0.31 Attention deficit hyperactivity disorder; chr15:90955530 chr15:90839724~90841378:+ PAAD cis rs2581828 0.618 rs9824325 ENSG00000242142.1 SERBP1P3 -3.99 0.000101 0.0337 -0.38 -0.31 Crohn's disease; chr3:53132494 chr3:53064283~53065091:- PAAD cis rs79040073 0.598 rs11636296 ENSG00000259531.2 RP11-295H24.3 3.99 0.000101 0.0337 0.53 0.31 Lung cancer in ever smokers; chr15:49034864 chr15:49365124~49366685:- PAAD cis rs6951245 0.554 rs11761322 ENSG00000229043.2 AC091729.9 -3.99 0.000101 0.0337 -0.42 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112021 chr7:1160374~1165267:+ PAAD cis rs6951245 0.554 rs10270249 ENSG00000229043.2 AC091729.9 -3.99 0.000101 0.0337 -0.42 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112250 chr7:1160374~1165267:+ PAAD cis rs17772222 0.917 rs61983300 ENSG00000258983.2 RP11-507K2.2 3.99 0.000101 0.0337 0.4 0.31 Coronary artery calcification; chr14:88754047 chr14:88499334~88515502:+ PAAD cis rs17772222 0.876 rs78068036 ENSG00000258983.2 RP11-507K2.2 3.99 0.000101 0.0337 0.4 0.31 Coronary artery calcification; chr14:88754817 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs11159868 ENSG00000258983.2 RP11-507K2.2 3.99 0.000101 0.0337 0.4 0.31 Coronary artery calcification; chr14:88760528 chr14:88499334~88515502:+ PAAD cis rs11089937 0.597 rs9619812 ENSG00000211638.2 IGLV8-61 -3.99 0.000101 0.0337 -0.3 -0.31 Periodontitis (PAL4Q3); chr22:22163945 chr22:22098700~22099212:+ PAAD cis rs8031584 0.678 rs798086 ENSG00000260382.1 RP11-540B6.2 -3.99 0.000101 0.0337 -0.4 -0.31 Huntington's disease progression; chr15:30837008 chr15:30882267~30883231:- PAAD cis rs7665090 0.692 rs227276 ENSG00000246560.2 RP11-10L12.4 -3.99 0.000101 0.0337 -0.34 -0.31 Primary biliary cholangitis; chr4:102673761 chr4:102828055~102844075:+ PAAD cis rs7665090 0.728 rs227278 ENSG00000246560.2 RP11-10L12.4 -3.99 0.000101 0.0337 -0.34 -0.31 Primary biliary cholangitis; chr4:102674494 chr4:102828055~102844075:+ PAAD cis rs1707322 0.721 rs6699418 ENSG00000280836.1 AL355480.1 -3.99 0.000101 0.0337 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45634509 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs4431884 ENSG00000280836.1 AL355480.1 -3.99 0.000101 0.0337 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45635651 chr1:45581219~45581321:- PAAD cis rs1707322 0.65 rs4660879 ENSG00000280836.1 AL355480.1 -3.99 0.000101 0.0337 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45639729 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs10789468 ENSG00000280836.1 AL355480.1 -3.99 0.000101 0.0337 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45658886 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs6429574 ENSG00000280836.1 AL355480.1 -3.99 0.000101 0.0337 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45668382 chr1:45581219~45581321:- PAAD cis rs4218 0.681 rs4531679 ENSG00000277144.1 RP11-59H7.4 -3.99 0.000101 0.0337 -0.41 -0.31 Social communication problems; chr15:59083246 chr15:59115547~59116089:- PAAD cis rs950880 0.961 rs13020553 ENSG00000234389.1 AC007278.3 -3.99 0.000101 0.0338 -0.29 -0.31 Serum protein levels (sST2); chr2:102315366 chr2:102438713~102440475:+ PAAD cis rs950880 1 rs950880 ENSG00000234389.1 AC007278.3 -3.99 0.000101 0.0338 -0.29 -0.31 Serum protein levels (sST2); chr2:102316102 chr2:102438713~102440475:+ PAAD cis rs4660214 0.59 rs11205885 ENSG00000228060.1 RP11-69E11.8 3.99 0.000101 0.0338 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39306633 chr1:39565160~39573203:+ PAAD cis rs7615952 0.604 rs9837847 ENSG00000239804.1 RP11-379B18.1 3.99 0.000101 0.0338 0.52 0.31 Blood pressure (smoking interaction); chr3:125905076 chr3:125787888~125788146:- PAAD cis rs7615952 0.673 rs35955861 ENSG00000239804.1 RP11-379B18.1 3.99 0.000101 0.0338 0.52 0.31 Blood pressure (smoking interaction); chr3:125907358 chr3:125787888~125788146:- PAAD cis rs7615952 0.673 rs35001498 ENSG00000239804.1 RP11-379B18.1 3.99 0.000101 0.0338 0.52 0.31 Blood pressure (smoking interaction); chr3:125909801 chr3:125787888~125788146:- PAAD cis rs12446554 0.511 rs72769544 ENSG00000261195.1 CTD-2380F24.1 -3.99 0.000101 0.0338 -0.48 -0.31 Obesity; chr16:19765915 chr16:19761172~19766099:- PAAD cis rs6545883 0.524 rs778159 ENSG00000271889.1 RP11-493E12.1 -3.99 0.000101 0.0338 -0.33 -0.31 Tuberculosis; chr2:61329609 chr2:61151433~61162105:- PAAD cis rs12908161 1 rs35808647 ENSG00000275120.1 RP11-182J1.17 3.99 0.000101 0.0338 0.34 0.31 Schizophrenia; chr15:84834210 chr15:84599434~84606463:- PAAD cis rs12908161 1 rs3803405 ENSG00000275120.1 RP11-182J1.17 3.99 0.000101 0.0338 0.35 0.31 Schizophrenia; chr15:84840409 chr15:84599434~84606463:- PAAD cis rs780676 1 rs780678 ENSG00000230526.1 RP11-472G21.2 3.99 0.000101 0.0338 0.43 0.31 Gestational age at birth (child effect); chr10:71354729 chr10:71878356~71879107:+ PAAD cis rs13392177 0.66 rs62185964 ENSG00000261338.2 RP11-378A13.1 -3.99 0.000101 0.0338 -0.37 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209022 chr2:218255319~218257366:+ PAAD cis rs13392177 0.684 rs62185965 ENSG00000261338.2 RP11-378A13.1 -3.99 0.000101 0.0338 -0.37 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209056 chr2:218255319~218257366:+ PAAD cis rs13392177 0.66 rs10932762 ENSG00000261338.2 RP11-378A13.1 -3.99 0.000101 0.0338 -0.37 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218211490 chr2:218255319~218257366:+ PAAD cis rs6942756 1 rs6467235 ENSG00000276988.1 Metazoa_SRP 3.99 0.000101 0.0338 0.44 0.31 White matter hyperintensity burden; chr7:129299309 chr7:128483907~128484158:- PAAD cis rs2273156 0.673 rs12878219 ENSG00000258738.1 RP11-73E17.2 -3.99 0.000101 0.0338 -0.46 -0.31 Immunoglobulin light chain (AL) amyloidosis; chr14:34911931 chr14:34874343~34876459:+ PAAD cis rs4759375 0.667 rs61953413 ENSG00000256092.2 RP13-942N8.1 3.99 0.000101 0.0338 0.59 0.31 HDL cholesterol; chr12:123282239 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs73231946 ENSG00000256092.2 RP13-942N8.1 3.99 0.000101 0.0338 0.59 0.31 HDL cholesterol; chr12:123282374 chr12:123363868~123366113:+ PAAD cis rs4759375 0.588 rs10846501 ENSG00000256092.2 RP13-942N8.1 3.99 0.000101 0.0338 0.59 0.31 HDL cholesterol; chr12:123283558 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs11057240 ENSG00000256092.2 RP13-942N8.1 3.99 0.000101 0.0338 0.59 0.31 HDL cholesterol; chr12:123283717 chr12:123363868~123366113:+ PAAD cis rs3096299 0.658 rs4291902 ENSG00000261118.1 RP11-104N10.1 3.99 0.000101 0.0338 0.27 0.31 Multiple myeloma (IgH translocation); chr16:89493907 chr16:89492017~89504460:- PAAD cis rs35000415 0.506 rs34288126 ENSG00000281490.1 CICP14 -3.99 0.000101 0.0338 -0.36 -0.31 Systemic lupus erythematosus; chr7:129095384 chr7:128655962~128658791:- PAAD cis rs2034650 0.544 rs2289330 ENSG00000223313.1 RNU6-516P 3.99 0.000101 0.0338 0.4 0.31 Interstitial lung disease; chr15:40412906 chr15:40529570~40529673:+ PAAD cis rs755249 1 rs76841360 ENSG00000228060.1 RP11-69E11.8 -3.99 0.000101 0.0338 -0.32 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39594353 chr1:39565160~39573203:+ PAAD cis rs5758511 0.689 rs17478227 ENSG00000233903.2 Z83851.4 -3.99 0.000101 0.0338 -0.5 -0.31 Birth weight; chr22:42258321 chr22:42276355~42277052:+ PAAD cis rs4660214 0.666 rs3116398 ENSG00000228060.1 RP11-69E11.8 3.99 0.000101 0.0338 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39314130 chr1:39565160~39573203:+ PAAD cis rs10783487 0.947 rs7138000 ENSG00000257542.4 OR7E47P -3.99 0.000101 0.0338 -0.42 -0.31 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52076325 chr12:52079696~52108261:+ PAAD cis rs2729354 0.729 rs2729353 ENSG00000265566.2 RN7SL605P -3.99 0.000101 0.0338 -0.39 -0.31 Blood protein levels; chr11:57480530 chr11:57528085~57528365:- PAAD cis rs2729354 0.52 rs2729377 ENSG00000265566.2 RN7SL605P -3.99 0.000101 0.0338 -0.39 -0.31 Blood protein levels; chr11:57482611 chr11:57528085~57528365:- PAAD cis rs5758511 0.68 rs1107553 ENSG00000226450.2 CYP2D8P 3.99 0.000102 0.0338 0.31 0.31 Birth weight; chr22:42271467 chr22:42149886~42155001:- PAAD cis rs860554 0.545 rs56252940 ENSG00000249007.1 RP11-510N19.5 3.99 0.000102 0.0338 0.25 0.31 Panic disorder; chr1:201281600 chr1:202011370~202015657:+ PAAD cis rs5758511 0.68 rs1107553 ENSG00000205702.9 CYP2D7 3.99 0.000102 0.0338 0.26 0.31 Birth weight; chr22:42271467 chr22:42140203~42144577:- PAAD cis rs12908161 0.96 rs17599989 ENSG00000259295.5 CSPG4P12 3.99 0.000102 0.0339 0.36 0.31 Schizophrenia; chr15:84742305 chr15:85191438~85213905:+ PAAD cis rs7202877 0.61 rs4536500 ENSG00000261783.1 RP11-252K23.2 3.99 0.000102 0.0339 0.49 0.31 Type 1 diabetes;Type 2 diabetes; chr16:75309299 chr16:75379818~75381260:- PAAD cis rs2562456 0.917 rs11085463 ENSG00000213976.4 CTD-2561J22.2 -3.99 0.000102 0.0339 -0.34 -0.31 Pain; chr19:21568500 chr19:21382865~21387177:+ PAAD cis rs763121 0.853 rs8140617 ENSG00000225450.1 RP3-508I15.14 3.99 0.000102 0.0339 0.26 0.31 Menopause (age at onset); chr22:38574434 chr22:38739003~38749041:+ PAAD cis rs2921036 0.503 rs7817832 ENSG00000253893.2 FAM85B -3.99 0.000102 0.0339 -0.51 -0.31 Neuroticism; chr8:8523311 chr8:8167819~8226614:- PAAD cis rs10951983 0.904 rs17196595 ENSG00000272719.1 CTB-161C1.1 -3.99 0.000102 0.0339 -0.38 -0.31 Coronary artery disease; chr7:6378747 chr7:5556731~5557245:+ PAAD cis rs5015933 1 rs5015933 ENSG00000232630.1 PRPS1P2 -3.99 0.000102 0.0339 -0.28 -0.31 Body mass index; chr9:125375139 chr9:125150653~125151589:+ PAAD cis rs227932 0.681 rs7776862 ENSG00000234286.1 AC006026.13 3.99 0.000102 0.0339 0.51 0.31 Schizophrenia; chr7:23736607 chr7:23680195~23680786:- PAAD cis rs2581828 0.646 rs9757079 ENSG00000242142.1 SERBP1P3 -3.99 0.000102 0.0339 -0.39 -0.31 Crohn's disease; chr3:53121142 chr3:53064283~53065091:- PAAD cis rs710913 0.557 rs1180320 ENSG00000243970.1 PPIEL 3.99 0.000102 0.0339 0.27 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39616330 chr1:39531838~39558707:- PAAD cis rs11893307 0.509 rs12611764 ENSG00000235852.1 AC005540.3 3.99 0.000102 0.0339 0.45 0.31 Mean platelet volume; chr2:190672417 chr2:190880797~190882059:- PAAD cis rs11159086 1 rs3759745 ENSG00000259005.1 RP3-449M8.6 3.99 0.000102 0.0339 0.42 0.31 Advanced glycation end-product levels; chr14:74495967 chr14:74474007~74474864:- PAAD cis rs11159086 1 rs4903232 ENSG00000259005.1 RP3-449M8.6 3.99 0.000102 0.0339 0.42 0.31 Advanced glycation end-product levels; chr14:74496585 chr14:74474007~74474864:- PAAD cis rs867371 1 rs1501372 ENSG00000259429.4 UBE2Q2P2 -3.99 0.000102 0.0339 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82176114 chr15:82355142~82420075:+ PAAD cis rs867371 1 rs1846911 ENSG00000259429.4 UBE2Q2P2 -3.99 0.000102 0.0339 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82176309 chr15:82355142~82420075:+ PAAD cis rs867371 0.929 rs7176075 ENSG00000259429.4 UBE2Q2P2 -3.99 0.000102 0.0339 -0.25 -0.31 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82178998 chr15:82355142~82420075:+ PAAD cis rs700651 0.685 rs976180 ENSG00000231621.1 AC013264.2 3.99 0.000102 0.034 0.31 0.31 Intracranial aneurysm; chr2:198015719 chr2:197197991~197199273:+ PAAD cis rs853679 0.882 rs9380069 ENSG00000280107.1 AL022393.9 -3.99 0.000102 0.034 -0.49 -0.31 Depression; chr6:28235522 chr6:28170845~28172521:+ PAAD cis rs7202877 0.706 rs4888375 ENSG00000261783.1 RP11-252K23.2 -3.99 0.000102 0.034 -0.48 -0.31 Type 1 diabetes;Type 2 diabetes; chr16:75288458 chr16:75379818~75381260:- PAAD cis rs321358 0.895 rs73015151 ENSG00000271390.1 RP11-89C3.3 3.99 0.000102 0.034 0.43 0.31 Body mass index; chr11:111084669 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs17535886 ENSG00000271390.1 RP11-89C3.3 3.99 0.000102 0.034 0.43 0.31 Body mass index; chr11:111084852 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs17457375 ENSG00000271390.1 RP11-89C3.3 3.99 0.000102 0.034 0.43 0.31 Body mass index; chr11:111085100 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs17535942 ENSG00000271390.1 RP11-89C3.3 3.99 0.000102 0.034 0.43 0.31 Body mass index; chr11:111085233 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs17457430 ENSG00000271390.1 RP11-89C3.3 3.99 0.000102 0.034 0.43 0.31 Body mass index; chr11:111085279 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs7101466 ENSG00000271390.1 RP11-89C3.3 3.99 0.000102 0.034 0.43 0.31 Body mass index; chr11:111085729 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs7101576 ENSG00000271390.1 RP11-89C3.3 3.99 0.000102 0.034 0.43 0.31 Body mass index; chr11:111085795 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs17457658 ENSG00000271390.1 RP11-89C3.3 3.99 0.000102 0.034 0.43 0.31 Body mass index; chr11:111089448 chr11:111089870~111090368:- PAAD cis rs453301 0.598 rs10104303 ENSG00000254340.1 RP11-10A14.3 3.99 0.000102 0.034 0.35 0.31 Joint mobility (Beighton score); chr8:8977018 chr8:9141424~9145435:+ PAAD cis rs10129255 0.556 rs8010005 ENSG00000211972.2 IGHV3-66 3.99 0.000102 0.034 0.24 0.31 Kawasaki disease; chr14:106777987 chr14:106675017~106675544:- PAAD cis rs10129255 0.556 rs6576224 ENSG00000211972.2 IGHV3-66 3.99 0.000102 0.034 0.24 0.31 Kawasaki disease; chr14:106777997 chr14:106675017~106675544:- PAAD cis rs9393813 0.528 rs6911865 ENSG00000271755.1 RP1-153G14.4 3.99 0.000102 0.034 0.35 0.31 Bipolar disorder; chr6:27502999 chr6:27404010~27406964:- PAAD cis rs6929812 0.613 rs9468140 ENSG00000271755.1 RP1-153G14.4 3.99 0.000102 0.034 0.35 0.31 Neuroticism (multi-trait analysis); chr6:27503736 chr6:27404010~27406964:- PAAD cis rs9393813 0.528 rs9468141 ENSG00000271755.1 RP1-153G14.4 3.99 0.000102 0.034 0.35 0.31 Bipolar disorder; chr6:27506748 chr6:27404010~27406964:- PAAD cis rs4948275 0.55 rs7082786 ENSG00000237233.2 TMEM26-AS1 3.99 0.000102 0.034 0.37 0.31 Night sleep phenotypes; chr10:61417232 chr10:61452639~61481956:+ PAAD cis rs1062177 1 rs2915878 ENSG00000253921.1 CTB-113P19.3 -3.99 0.000102 0.034 -0.38 -0.31 Preschool internalizing problems; chr5:151770101 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs6890099 ENSG00000253921.1 CTB-113P19.3 -3.99 0.000102 0.034 -0.38 -0.31 Preschool internalizing problems; chr5:151772401 chr5:151753992~151767247:+ PAAD cis rs1832007 0.554 rs7101071 ENSG00000224034.1 RP11-445P17.8 -3.99 0.000102 0.034 -0.45 -0.31 Triglyceride levels;Triglycerides; chr10:5200674 chr10:5266033~5271236:- PAAD cis rs2688608 0.56 rs10128354 ENSG00000271816.1 BMS1P4 3.99 0.000102 0.034 0.31 0.31 Inflammatory bowel disease; chr10:73710287 chr10:73699151~73730487:- PAAD cis rs2688608 0.592 rs12253482 ENSG00000271816.1 BMS1P4 3.99 0.000102 0.034 0.31 0.31 Inflammatory bowel disease; chr10:73736372 chr10:73699151~73730487:- PAAD cis rs1910358 0.621 rs1490761 ENSG00000248874.4 C5orf17 -3.99 0.000102 0.034 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23838237 chr5:23951348~24178263:+ PAAD cis rs4761702 0.661 rs12423139 ENSG00000258171.1 RP11-511B23.3 -3.99 0.000102 0.034 -0.36 -0.31 Immature fraction of reticulocytes; chr12:93336482 chr12:93174366~93181832:+ PAAD cis rs4761702 0.629 rs7966997 ENSG00000258171.1 RP11-511B23.3 -3.99 0.000102 0.034 -0.36 -0.31 Immature fraction of reticulocytes; chr12:93337570 chr12:93174366~93181832:+ PAAD cis rs11976180 1 rs1919950 ENSG00000273234.1 OR2A13P -3.99 0.000102 0.034 -0.38 -0.31 Obesity-related traits; chr7:144070805 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2961132 ENSG00000273234.1 OR2A13P -3.99 0.000102 0.034 -0.38 -0.31 Obesity-related traits; chr7:144071035 chr7:144142009~144142938:+ PAAD cis rs950880 0.767 rs6543119 ENSG00000234389.1 AC007278.3 -3.99 0.000102 0.034 -0.29 -0.31 Serum protein levels (sST2); chr2:102346612 chr2:102438713~102440475:+ PAAD cis rs950880 0.767 rs13017455 ENSG00000234389.1 AC007278.3 -3.99 0.000102 0.034 -0.29 -0.31 Serum protein levels (sST2); chr2:102348282 chr2:102438713~102440475:+ PAAD cis rs4759375 0.667 rs11057222 ENSG00000256092.2 RP13-942N8.1 3.99 0.000102 0.034 0.59 0.31 HDL cholesterol; chr12:123268358 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs10846495 ENSG00000256092.2 RP13-942N8.1 3.99 0.000102 0.034 0.59 0.31 HDL cholesterol; chr12:123276182 chr12:123363868~123366113:+ PAAD cis rs4759375 0.588 rs10846496 ENSG00000256092.2 RP13-942N8.1 3.99 0.000102 0.034 0.59 0.31 HDL cholesterol; chr12:123276958 chr12:123363868~123366113:+ PAAD cis rs73219805 0.818 rs117325001 ENSG00000228451.3 SDAD1P1 -3.99 0.000102 0.0341 -0.44 -0.31 Schizophrenia; chr8:26384756 chr8:26379259~26382953:- PAAD cis rs73219805 1 rs3808581 ENSG00000228451.3 SDAD1P1 -3.99 0.000102 0.0341 -0.44 -0.31 Schizophrenia; chr8:26392531 chr8:26379259~26382953:- PAAD cis rs73219805 1 rs73217798 ENSG00000228451.3 SDAD1P1 -3.99 0.000102 0.0341 -0.44 -0.31 Schizophrenia; chr8:26406847 chr8:26379259~26382953:- PAAD cis rs3096299 0.606 rs4785573 ENSG00000274627.1 RP11-104N10.2 3.99 0.000102 0.0341 0.3 0.31 Multiple myeloma (IgH translocation); chr16:89498995 chr16:89516797~89522217:+ PAAD cis rs9847710 0.696 rs2581821 ENSG00000242142.1 SERBP1P3 3.99 0.000102 0.0341 0.38 0.31 Ulcerative colitis; chr3:52987572 chr3:53064283~53065091:- PAAD cis rs7766910 1 rs2235368 ENSG00000234261.2 RP11-146I2.1 3.99 0.000102 0.0341 0.39 0.31 Pediatric bone mineral content (radius); chr6:14117907 chr6:14661829~15090003:- PAAD cis rs113835537 0.935 rs79496339 ENSG00000255517.5 CTD-3074O7.5 -3.99 0.000102 0.0341 -0.51 -0.31 Airway imaging phenotypes; chr11:66700298 chr11:66473490~66480233:- PAAD cis rs1841770 0.503 rs2319546 ENSG00000241627.3 UBQLN4P1 -3.99 0.000102 0.0341 -0.39 -0.31 Multiple sclerosis; chr3:148072457 chr3:148985868~148987668:- PAAD cis rs8031584 0.723 rs11632229 ENSG00000260382.1 RP11-540B6.2 -3.99 0.000102 0.0341 -0.39 -0.31 Huntington's disease progression; chr15:30887331 chr15:30882267~30883231:- PAAD cis rs7216064 0.906 rs7223643 ENSG00000278219.1 AC145343.1 -3.99 0.000103 0.0341 -0.5 -0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67834166 chr17:68101538~68101639:+ PAAD cis rs1876905 0.764 rs6934341 ENSG00000230177.1 RP5-1112D6.4 -3.99 0.000103 0.0341 -0.35 -0.31 Mean corpuscular hemoglobin; chr6:111098387 chr6:111277932~111278742:+ PAAD cis rs12999616 0.55 rs35358137 ENSG00000228486.8 LINC01125 -3.99 0.000103 0.0341 -0.28 -0.31 Colorectal cancer; chr2:97885738 chr2:97664217~97703064:+ PAAD cis rs17270561 0.514 rs10946805 ENSG00000272462.2 U91328.19 -3.99 0.000103 0.0341 -0.42 -0.31 Iron status biomarkers; chr6:26077663 chr6:25992662~26001775:+ PAAD cis rs2985684 0.841 rs12894785 ENSG00000259113.1 RP11-406H23.2 -3.99 0.000103 0.0341 -0.42 -0.31 Carotid intima media thickness; chr14:49583037 chr14:50448807~50456742:+ PAAD cis rs6903823 0.508 rs1778484 ENSG00000204709.4 LINC01556 3.99 0.000103 0.0341 0.4 0.31 Pulmonary function; chr6:28273021 chr6:28943877~28944537:+ PAAD cis rs7759001 0.857 rs980960 ENSG00000271755.1 RP1-153G14.4 3.99 0.000103 0.0341 0.39 0.31 Glomerular filtration rate (creatinine); chr6:27393263 chr6:27404010~27406964:- PAAD cis rs7554672 0.849 rs12129495 ENSG00000232679.1 RP11-400N13.3 3.99 0.000103 0.0341 0.32 0.31 Hypertension; chr1:221189769 chr1:222041705~222064763:- PAAD cis rs7554672 0.849 rs6664892 ENSG00000232679.1 RP11-400N13.3 3.99 0.000103 0.0341 0.32 0.31 Hypertension; chr1:221190653 chr1:222041705~222064763:- PAAD cis rs7989336 0.515 rs6491287 ENSG00000247400.3 DNAJC3-AS1 -3.99 0.000103 0.0342 -0.29 -0.31 Obesity; chr13:96374769 chr13:95648733~95676925:- PAAD cis rs7927592 0.956 rs11228258 ENSG00000212093.1 AP000807.1 -3.99 0.000103 0.0342 -0.35 -0.31 Total body bone mineral density; chr11:68486860 chr11:68506083~68506166:- PAAD cis rs79349575 0.811 rs1057897 ENSG00000270781.1 RP11-501C14.9 -3.99 0.000103 0.0342 -0.35 -0.31 Type 2 diabetes; chr17:48928147 chr17:48899131~48899748:+ PAAD cis rs6472827 0.794 rs4439117 ENSG00000253983.2 RP1-16A9.1 3.99 0.000103 0.0342 0.46 0.31 Uterine fibroids; chr8:74207475 chr8:74199396~74208441:+ PAAD cis rs6472827 0.953 rs7827128 ENSG00000253983.2 RP1-16A9.1 3.99 0.000103 0.0342 0.46 0.31 Uterine fibroids; chr8:74209641 chr8:74199396~74208441:+ PAAD cis rs4660214 0.666 rs7414381 ENSG00000228060.1 RP11-69E11.8 3.99 0.000103 0.0342 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39275848 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs3116387 ENSG00000228060.1 RP11-69E11.8 3.99 0.000103 0.0342 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39277197 chr1:39565160~39573203:+ PAAD cis rs4660214 0.614 rs1537815 ENSG00000228060.1 RP11-69E11.8 3.99 0.000103 0.0342 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39278946 chr1:39565160~39573203:+ PAAD cis rs4660214 0.789 rs1984142 ENSG00000228060.1 RP11-69E11.8 3.99 0.000103 0.0342 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39279936 chr1:39565160~39573203:+ PAAD cis rs8081395 0.899 rs2645477 ENSG00000266992.1 DHX40P1 -3.99 0.000103 0.0342 -0.32 -0.31 White blood cell count; chr17:59768263 chr17:59976009~60002384:- PAAD cis rs1150668 0.745 rs213238 ENSG00000219891.2 ZSCAN12P1 3.99 0.000103 0.0342 0.39 0.31 Pubertal anthropometrics; chr6:28354216 chr6:28091154~28093664:+ PAAD cis rs79040073 0.765 rs7169304 ENSG00000259531.2 RP11-295H24.3 3.99 0.000103 0.0342 0.46 0.31 Lung cancer in ever smokers; chr15:49186829 chr15:49365124~49366685:- PAAD cis rs1150668 0.796 rs728122 ENSG00000219891.2 ZSCAN12P1 3.99 0.000103 0.0342 0.39 0.31 Pubertal anthropometrics; chr6:28431347 chr6:28091154~28093664:+ PAAD cis rs12701220 0.69 rs10243973 ENSG00000229043.2 AC091729.9 -3.99 0.000103 0.0342 -0.42 -0.31 Bronchopulmonary dysplasia; chr7:1025347 chr7:1160374~1165267:+ PAAD cis rs4879656 1 rs4879656 ENSG00000231193.1 RP11-462B18.2 3.99 0.000103 0.0342 0.36 0.31 Menopause (age at onset); chr9:33012384 chr9:32840598~32841762:- PAAD cis rs9393813 0.566 rs12662076 ENSG00000271755.1 RP1-153G14.4 3.99 0.000103 0.0342 0.35 0.31 Bipolar disorder; chr6:27395358 chr6:27404010~27406964:- PAAD cis rs11089937 0.54 rs9622920 ENSG00000211638.2 IGLV8-61 3.99 0.000103 0.0343 0.29 0.31 Periodontitis (PAL4Q3); chr22:22133024 chr22:22098700~22099212:+ PAAD cis rs72627509 0.904 rs58408429 ENSG00000269949.1 RP11-738E22.3 3.99 0.000103 0.0343 0.48 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56903658 chr4:56960927~56961373:- PAAD cis rs7617773 0.539 rs35460860 ENSG00000228638.1 FCF1P2 -3.99 0.000103 0.0343 -0.34 -0.31 Coronary artery disease; chr3:48350595 chr3:48290793~48291375:- PAAD cis rs7617773 0.563 rs13082269 ENSG00000228638.1 FCF1P2 -3.99 0.000103 0.0343 -0.34 -0.31 Coronary artery disease; chr3:48350784 chr3:48290793~48291375:- PAAD cis rs2980439 0.525 rs2945238 ENSG00000253981.4 ALG1L13P 3.99 0.000103 0.0343 0.36 0.31 Neuroticism; chr8:8312614 chr8:8236003~8244667:- PAAD cis rs79349575 0.721 rs3744608 ENSG00000270781.1 RP11-501C14.9 -3.99 0.000103 0.0343 -0.35 -0.31 Type 2 diabetes; chr17:48915871 chr17:48899131~48899748:+ PAAD cis rs12701220 0.894 rs12701348 ENSG00000229043.2 AC091729.9 -3.99 0.000103 0.0343 -0.41 -0.31 Bronchopulmonary dysplasia; chr7:999821 chr7:1160374~1165267:+ PAAD cis rs10181042 0.581 rs1177285 ENSG00000271889.1 RP11-493E12.1 3.99 0.000103 0.0343 0.35 0.31 Crohn's disease; chr2:61123002 chr2:61151433~61162105:- PAAD cis rs2188561 0.697 rs66560125 ENSG00000241764.3 AC002467.7 3.99 0.000103 0.0343 0.39 0.31 Alcohol consumption; chr7:107729589 chr7:107742817~107744581:- PAAD cis rs5015933 0.778 rs10819045 ENSG00000232630.1 PRPS1P2 -3.99 0.000103 0.0343 -0.28 -0.31 Body mass index; chr9:125321886 chr9:125150653~125151589:+ PAAD cis rs5015933 0.788 rs10114684 ENSG00000232630.1 PRPS1P2 -3.99 0.000103 0.0343 -0.28 -0.31 Body mass index; chr9:125340586 chr9:125150653~125151589:+ PAAD cis rs5015933 0.778 rs10819046 ENSG00000232630.1 PRPS1P2 -3.99 0.000103 0.0343 -0.28 -0.31 Body mass index; chr9:125349961 chr9:125150653~125151589:+ PAAD cis rs5015933 0.815 rs10986718 ENSG00000232630.1 PRPS1P2 -3.99 0.000103 0.0343 -0.28 -0.31 Body mass index; chr9:125350617 chr9:125150653~125151589:+ PAAD cis rs111321694 1 rs111321694 ENSG00000271390.1 RP11-89C3.3 3.99 0.000103 0.0343 0.44 0.31 Educational attainment (years of education); chr11:111079662 chr11:111089870~111090368:- PAAD cis rs321358 0.895 rs17457076 ENSG00000271390.1 RP11-89C3.3 3.99 0.000103 0.0343 0.44 0.31 Body mass index; chr11:111081030 chr11:111089870~111090368:- PAAD cis rs28386778 0.591 rs2584619 ENSG00000240280.5 TCAM1P -3.99 0.000103 0.0343 -0.43 -0.31 Prudent dietary pattern; chr17:63835855 chr17:63849292~63864379:+ PAAD cis rs28374715 0.662 rs28827035 ENSG00000247556.5 OIP5-AS1 3.99 0.000103 0.0343 0.32 0.31 Ulcerative colitis; chr15:41200092 chr15:41283990~41309737:+ PAAD cis rs6951245 0.554 rs75075857 ENSG00000229043.2 AC091729.9 -3.99 0.000103 0.0343 -0.42 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1100662 chr7:1160374~1165267:+ PAAD cis rs6951245 0.529 rs10262070 ENSG00000229043.2 AC091729.9 -3.99 0.000103 0.0343 -0.42 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1102102 chr7:1160374~1165267:+ PAAD cis rs6951245 0.638 rs4720486 ENSG00000229043.2 AC091729.9 -3.99 0.000103 0.0343 -0.42 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1107128 chr7:1160374~1165267:+ PAAD cis rs7812879 0.543 rs2409766 ENSG00000254507.2 RP11-481A20.10 -3.99 0.000104 0.0344 -0.56 -0.31 Systemic lupus erythematosus; chr8:11446277 chr8:12003400~12004082:- PAAD cis rs9322193 0.923 rs10872644 ENSG00000268592.3 RAET1E-AS1 3.99 0.000104 0.0344 0.36 0.31 Lung cancer; chr6:149741819 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs1572229 ENSG00000268592.3 RAET1E-AS1 3.99 0.000104 0.0344 0.36 0.31 Lung cancer; chr6:149743841 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs10872646 ENSG00000268592.3 RAET1E-AS1 3.99 0.000104 0.0344 0.36 0.31 Lung cancer; chr6:149746539 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs12528279 ENSG00000268592.3 RAET1E-AS1 3.99 0.000104 0.0344 0.36 0.31 Lung cancer; chr6:149750892 chr6:149863494~149919507:+ PAAD cis rs9322193 0.809 rs9479808 ENSG00000268592.3 RAET1E-AS1 3.99 0.000104 0.0344 0.36 0.31 Lung cancer; chr6:149751328 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs62441284 ENSG00000268592.3 RAET1E-AS1 3.99 0.000104 0.0344 0.36 0.31 Lung cancer; chr6:149751542 chr6:149863494~149919507:+ PAAD cis rs7120173 1 rs7120173 ENSG00000231865.1 SIK3-IT1 3.99 0.000104 0.0344 0.41 0.31 Visceral adipose tissue adjusted for BMI; chr11:116958937 chr11:116886046~116890721:- PAAD cis rs755249 0.917 rs61779331 ENSG00000237624.1 OXCT2P1 3.99 0.000104 0.0344 0.43 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39505256 chr1:39514956~39516490:+ PAAD cis rs2243480 0.901 rs13237344 ENSG00000228409.4 CCT6P1 3.99 0.000104 0.0344 0.33 0.31 Diabetic kidney disease; chr7:66557269 chr7:65751142~65763354:+ PAAD cis rs8081395 0.834 rs11650106 ENSG00000266992.1 DHX40P1 -3.99 0.000104 0.0344 -0.31 -0.31 White blood cell count; chr17:59772890 chr17:59976009~60002384:- PAAD cis rs2638953 0.924 rs11049415 ENSG00000247934.4 RP11-967K21.1 -3.99 0.000104 0.0344 -0.33 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28190188 chr12:28163298~28190738:- PAAD cis rs30380 1 rs469758 ENSG00000272109.1 CTD-2260A17.3 -3.99 0.000104 0.0344 -0.37 -0.31 Cerebrospinal fluid biomarker levels; chr5:96786011 chr5:96804353~96806105:+ PAAD cis rs496547 0.686 rs540180 ENSG00000255239.1 AP002954.6 3.99 0.000104 0.0344 0.37 0.31 Hip minimal joint space width; chr11:118782920 chr11:118688039~118690600:- PAAD cis rs496547 0.686 rs2508916 ENSG00000255239.1 AP002954.6 3.99 0.000104 0.0344 0.37 0.31 Hip minimal joint space width; chr11:118783942 chr11:118688039~118690600:- PAAD cis rs2243480 0.901 rs13237344 ENSG00000273142.1 RP11-458F8.4 -3.99 0.000104 0.0344 -0.28 -0.31 Diabetic kidney disease; chr7:66557269 chr7:66902857~66906297:+ PAAD cis rs891378 0.651 rs7546693 ENSG00000274245.1 RP11-357P18.2 -3.99 0.000104 0.0344 -0.42 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207192864 chr1:207372559~207373252:+ PAAD cis rs891378 0.755 rs7411168 ENSG00000274245.1 RP11-357P18.2 -3.99 0.000104 0.0344 -0.42 -0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207201970 chr1:207372559~207373252:+ PAAD cis rs10435719 0.902 rs6601633 ENSG00000227888.4 FAM66A -3.99 0.000104 0.0344 -0.36 -0.31 C-reactive protein levels or triglyceride levels (pleiotropy); chr8:11947664 chr8:12362019~12388296:+ PAAD cis rs216345 1 rs216345 ENSG00000230074.1 RP11-195F19.9 3.99 0.000104 0.0345 0.41 0.31 Bipolar disorder; chr9:33799372 chr9:34665665~34681298:+ PAAD cis rs2832077 0.943 rs11701445 ENSG00000176054.6 RPL23P2 -3.99 0.000104 0.0345 -0.35 -0.31 Cognitive test performance; chr21:28788485 chr21:28997613~28998033:- PAAD cis rs2243480 1 rs316327 ENSG00000232546.1 RP11-458F8.1 3.99 0.000104 0.0345 0.37 0.31 Diabetic kidney disease; chr7:66144214 chr7:66848496~66858136:+ PAAD cis rs7615952 0.611 rs7632305 ENSG00000239804.1 RP11-379B18.1 3.99 0.000104 0.0345 0.53 0.31 Blood pressure (smoking interaction); chr3:125915924 chr3:125787888~125788146:- PAAD cis rs7615952 0.673 rs9841194 ENSG00000239804.1 RP11-379B18.1 3.99 0.000104 0.0345 0.53 0.31 Blood pressure (smoking interaction); chr3:125916896 chr3:125787888~125788146:- PAAD cis rs7615952 0.673 rs9289270 ENSG00000239804.1 RP11-379B18.1 3.99 0.000104 0.0345 0.53 0.31 Blood pressure (smoking interaction); chr3:125918136 chr3:125787888~125788146:- PAAD cis rs9309711 0.544 rs9752130 ENSG00000271868.1 RP11-1293J14.1 -3.99 0.000104 0.0345 -0.38 -0.31 Neurofibrillary tangles; chr2:3484731 chr2:3496956~3497428:+ PAAD cis rs748404 0.588 rs506120 ENSG00000205771.5 CATSPER2P1 -3.99 0.000104 0.0345 -0.44 -0.31 Lung cancer; chr15:43509826 chr15:43726918~43747094:- PAAD cis rs12908161 1 rs3803403 ENSG00000275120.1 RP11-182J1.17 3.99 0.000104 0.0345 0.35 0.31 Schizophrenia; chr15:84839914 chr15:84599434~84606463:- PAAD cis rs9535307 0.522 rs55732704 ENSG00000274270.1 RP11-34F20.7 3.99 0.000104 0.0345 0.44 0.31 Obesity-related traits; chr13:49840069 chr13:50125816~50128463:+ PAAD cis rs9535307 0.522 rs9596200 ENSG00000274270.1 RP11-34F20.7 3.99 0.000104 0.0345 0.44 0.31 Obesity-related traits; chr13:49842234 chr13:50125816~50128463:+ PAAD cis rs2985684 0.894 rs2281837 ENSG00000259113.1 RP11-406H23.2 -3.99 0.000104 0.0345 -0.43 -0.31 Carotid intima media thickness; chr14:49598641 chr14:50448807~50456742:+ PAAD cis rs12654437 0.574 rs2872328 ENSG00000263361.1 MIR378H -3.99 0.000104 0.0345 -0.38 -0.31 Cognitive decline (age-related); chr5:155420959 chr5:154829458~154829540:+ PAAD cis rs12999616 0.602 rs17489259 ENSG00000228486.8 LINC01125 -3.99 0.000104 0.0345 -0.27 -0.31 Colorectal cancer; chr2:97775839 chr2:97664217~97703064:+ PAAD cis rs56046484 1 rs2304416 ENSG00000259295.5 CSPG4P12 -3.99 0.000104 0.0345 -0.42 -0.31 Testicular germ cell tumor; chr15:85075651 chr15:85191438~85213905:+ PAAD cis rs9928842 0.664 rs8053265 ENSG00000280152.1 RP11-331F4.5 3.99 0.000104 0.0345 0.39 0.31 Alcoholic chronic pancreatitis; chr16:75187953 chr16:75245994~75250077:- PAAD cis rs9652601 0.779 rs9929994 ENSG00000274038.1 RP11-66H6.4 -3.99 0.000104 0.0345 -0.34 -0.31 Systemic lupus erythematosus; chr16:11084388 chr16:11056556~11057034:+ PAAD cis rs11233413 0.874 rs11233440 ENSG00000247137.7 RP11-727A23.5 -3.99 0.000104 0.0345 -0.28 -0.31 Economic and political preferences (feminism/equality); chr11:83047195 chr11:83184491~83193794:- PAAD cis rs12291225 0.585 rs34171876 ENSG00000251991.1 RNU7-49P 3.99 0.000104 0.0345 0.36 0.31 Sense of smell; chr11:14332411 chr11:14478892~14478953:+ PAAD cis rs3743772 0.5 rs4784308 ENSG00000279722.1 RP11-44F14.6 3.99 0.000104 0.0345 0.44 0.31 Depressive symptoms (SSRI exposure interaction); chr16:53406387 chr16:53487607~53489943:- PAAD cis rs9649213 0.593 rs6955647 ENSG00000272950.1 RP11-307C18.1 3.99 0.000104 0.0345 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98375250 chr7:98322853~98323430:+ PAAD cis rs7927592 0.913 rs7107622 ENSG00000212093.1 AP000807.1 3.99 0.000104 0.0345 0.35 0.31 Total body bone mineral density; chr11:68606715 chr11:68506083~68506166:- PAAD cis rs17772222 0.917 rs61986670 ENSG00000258983.2 RP11-507K2.2 3.99 0.000104 0.0346 0.4 0.31 Coronary artery calcification; chr14:88730875 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs61986671 ENSG00000258983.2 RP11-507K2.2 3.99 0.000104 0.0346 0.4 0.31 Coronary artery calcification; chr14:88732917 chr14:88499334~88515502:+ PAAD cis rs9322193 0.884 rs9371201 ENSG00000223701.3 RAET1E-AS1 3.99 0.000104 0.0346 0.38 0.31 Lung cancer; chr6:149823865 chr6:149884431~149919508:+ PAAD cis rs2739330 0.828 rs4822454 ENSG00000206090.4 AP000350.7 3.99 0.000104 0.0346 0.39 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23939998~23942798:+ PAAD cis rs2688608 0.592 rs11814282 ENSG00000271816.1 BMS1P4 3.99 0.000104 0.0346 0.31 0.31 Inflammatory bowel disease; chr10:73730459 chr10:73699151~73730487:- PAAD cis rs2675662 0.525 rs12264025 ENSG00000271816.1 BMS1P4 3.99 0.000104 0.0346 0.31 0.31 Psoriasis vulgaris;Psoriasis; chr10:73734692 chr10:73699151~73730487:- PAAD cis rs2688608 0.592 rs10762560 ENSG00000271816.1 BMS1P4 3.99 0.000104 0.0346 0.31 0.31 Inflammatory bowel disease; chr10:73735647 chr10:73699151~73730487:- PAAD cis rs2688608 0.62 rs12253408 ENSG00000271816.1 BMS1P4 3.99 0.000104 0.0346 0.31 0.31 Inflammatory bowel disease; chr10:73736198 chr10:73699151~73730487:- PAAD cis rs2688608 0.592 rs12253429 ENSG00000271816.1 BMS1P4 3.99 0.000104 0.0346 0.31 0.31 Inflammatory bowel disease; chr10:73736403 chr10:73699151~73730487:- PAAD cis rs10540 1 rs79440439 ENSG00000255237.1 RP13-317D12.3 3.99 0.000104 0.0346 0.47 0.31 Body mass index; chr11:478147 chr11:462930~463899:- PAAD cis rs858239 0.72 rs10227559 ENSG00000226816.2 AC005082.12 3.99 0.000104 0.0346 0.37 0.31 Cerebrospinal fluid biomarker levels; chr7:23232525 chr7:23206013~23208045:+ PAAD cis rs10740039 0.804 rs1372714 ENSG00000254271.1 RP11-131N11.4 3.99 0.000104 0.0346 0.36 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60686640 chr10:60734342~60741828:+ PAAD cis rs10740039 0.671 rs7919726 ENSG00000254271.1 RP11-131N11.4 3.99 0.000104 0.0346 0.36 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60689748 chr10:60734342~60741828:+ PAAD cis rs10740039 0.804 rs10821824 ENSG00000254271.1 RP11-131N11.4 3.99 0.000104 0.0346 0.36 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60690449 chr10:60734342~60741828:+ PAAD cis rs3096299 0.658 rs34590044 ENSG00000261253.2 AC137932.6 3.98 0.000104 0.0346 0.33 0.31 Multiple myeloma (IgH translocation); chr16:89476749 chr16:89321133~89325110:+ PAAD cis rs2742417 0.967 rs6800556 ENSG00000244357.3 RN7SL145P 3.98 0.000104 0.0346 0.28 0.31 Response to anti-depressant treatment in major depressive disorder; chr3:45710737 chr3:45742675~45742970:+ PAAD cis rs2902193 1 rs1820283 ENSG00000267325.1 LINC01415 3.98 0.000105 0.0346 0.29 0.31 Cancer; chr18:55982861 chr18:55776727~55781721:- PAAD cis rs7665090 0.87 rs227361 ENSG00000246560.2 RP11-10L12.4 3.98 0.000105 0.0346 0.33 0.31 Primary biliary cholangitis; chr4:102665820 chr4:102828055~102844075:+ PAAD cis rs13256369 0.802 rs12681326 ENSG00000253981.4 ALG1L13P 3.98 0.000105 0.0346 0.41 0.31 Obesity-related traits; chr8:8708879 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs13267036 ENSG00000253981.4 ALG1L13P 3.98 0.000105 0.0346 0.41 0.31 Obesity-related traits; chr8:8709175 chr8:8236003~8244667:- PAAD cis rs11668609 0.81 rs9305015 ENSG00000268442.1 CTD-2027I19.2 -3.98 0.000105 0.0346 -0.45 -0.31 Response to taxane treatment (docetaxel); chr19:24157700 chr19:24162370~24163425:- PAAD cis rs10853057 0.85 rs62065479 ENSG00000214174.7 AMZ2P1 3.98 0.000105 0.0347 0.59 0.31 White matter microstructure (global fractional anisotropy); chr17:65002593 chr17:64966550~64975576:- PAAD cis rs4879656 0.735 rs10733465 ENSG00000231193.1 RP11-462B18.2 -3.98 0.000105 0.0347 -0.37 -0.31 Menopause (age at onset); chr9:32932196 chr9:32840598~32841762:- PAAD cis rs4722166 1 rs4722166 ENSG00000179428.2 AC073072.5 -3.98 0.000105 0.0347 -0.34 -0.31 Lung cancer; chr7:22699143 chr7:22725395~22727620:- PAAD cis rs10740039 0.734 rs10821815 ENSG00000254271.1 RP11-131N11.4 3.98 0.000105 0.0347 0.37 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60644843 chr10:60734342~60741828:+ PAAD cis rs875971 0.545 rs4441996 ENSG00000222364.1 RNU6-96P 3.98 0.000105 0.0347 0.4 0.31 Aortic root size; chr7:66123233 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs316324 ENSG00000222364.1 RNU6-96P 3.98 0.000105 0.0347 0.4 0.31 Aortic root size; chr7:66145627 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs316323 ENSG00000222364.1 RNU6-96P 3.98 0.000105 0.0347 0.4 0.31 Aortic root size; chr7:66146002 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs316316 ENSG00000222364.1 RNU6-96P 3.98 0.000105 0.0347 0.4 0.31 Aortic root size; chr7:66149270 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs316305 ENSG00000222364.1 RNU6-96P 3.98 0.000105 0.0347 0.4 0.31 Aortic root size; chr7:66152984 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs316306 ENSG00000222364.1 RNU6-96P 3.98 0.000105 0.0347 0.4 0.31 Aortic root size; chr7:66153687 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs2460427 ENSG00000222364.1 RNU6-96P 3.98 0.000105 0.0347 0.4 0.31 Aortic root size; chr7:66154218 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs10950025 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66158946 chr7:66395191~66395286:+ PAAD cis rs875971 0.52 rs12666485 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66160135 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs67688847 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66161064 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs7787063 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66164012 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs12673308 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66166374 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs67397473 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66168318 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs10950027 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66169164 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs73376401 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66174841 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs6460276 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66182290 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs67775320 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66193792 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs17138149 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66228193 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs17138156 ENSG00000222364.1 RNU6-96P -3.98 0.000105 0.0347 -0.4 -0.31 Aortic root size; chr7:66249708 chr7:66395191~66395286:+ PAAD cis rs75804782 0.63 rs80271258 ENSG00000186235.9 AC016757.3 3.98 0.000105 0.0347 0.71 0.31 Chronotype;Morning vs. evening chronotype; chr2:238402864 chr2:238224552~238231677:- PAAD cis rs4713118 0.866 rs9468217 ENSG00000226314.6 ZNF192P1 -3.98 0.000105 0.0347 -0.43 -0.31 Parkinson's disease; chr6:27758688 chr6:28161781~28169594:+ PAAD cis rs4713118 0.911 rs9295746 ENSG00000226314.6 ZNF192P1 -3.98 0.000105 0.0347 -0.43 -0.31 Parkinson's disease; chr6:27762285 chr6:28161781~28169594:+ PAAD cis rs4713118 0.911 rs9461406 ENSG00000226314.6 ZNF192P1 3.98 0.000105 0.0347 0.43 0.31 Parkinson's disease; chr6:27751985 chr6:28161781~28169594:+ PAAD cis rs4666002 0.789 rs13023094 ENSG00000234072.1 AC074117.10 -3.98 0.000105 0.0347 -0.29 -0.31 Phospholipid levels (plasma); chr2:27687839 chr2:27356246~27367622:+ PAAD cis rs950880 0.767 rs13001714 ENSG00000234389.1 AC007278.3 -3.98 0.000105 0.0347 -0.3 -0.31 Serum protein levels (sST2); chr2:102344025 chr2:102438713~102440475:+ PAAD cis rs950027 0.967 rs2486280 ENSG00000259433.2 CTD-2651B20.4 -3.98 0.000105 0.0347 -0.37 -0.31 Response to fenofibrate (adiponectin levels); chr15:45459691 chr15:45330209~45332634:- PAAD cis rs7665147 1 rs7665147 ENSG00000269949.1 RP11-738E22.3 3.98 0.000105 0.0347 0.48 0.31 Platelet count; chr4:56901161 chr4:56960927~56961373:- PAAD cis rs151234 0.741 rs11644791 ENSG00000259982.1 CDC37P1 -3.98 0.000105 0.0347 -0.58 -0.31 Platelet distribution width; chr16:28589865 chr16:28700294~28701540:- PAAD cis rs151234 0.741 rs3194168 ENSG00000259982.1 CDC37P1 -3.98 0.000105 0.0347 -0.58 -0.31 Platelet distribution width; chr16:28591691 chr16:28700294~28701540:- PAAD cis rs595244 1 rs8026752 ENSG00000259705.1 RP11-227D13.1 -3.98 0.000105 0.0347 -0.45 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48531573 chr15:48645951~48652016:+ PAAD cis rs683250 0.599 rs11233578 ENSG00000227097.5 RPS28P7 3.98 0.000105 0.0347 0.39 0.31 Subcortical brain region volumes; chr11:83357066 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs11233579 ENSG00000227097.5 RPS28P7 3.98 0.000105 0.0347 0.39 0.31 Subcortical brain region volumes; chr11:83357261 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs11233580 ENSG00000227097.5 RPS28P7 3.98 0.000105 0.0347 0.39 0.31 Subcortical brain region volumes; chr11:83357329 chr11:82689559~82689768:+ PAAD cis rs683250 0.57 rs11512910 ENSG00000227097.5 RPS28P7 3.98 0.000105 0.0347 0.39 0.31 Subcortical brain region volumes; chr11:83357426 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs4944434 ENSG00000227097.5 RPS28P7 3.98 0.000105 0.0347 0.39 0.31 Subcortical brain region volumes; chr11:83357726 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs4944435 ENSG00000227097.5 RPS28P7 3.98 0.000105 0.0347 0.39 0.31 Subcortical brain region volumes; chr11:83358089 chr11:82689559~82689768:+ PAAD cis rs4835473 0.643 rs34680080 ENSG00000251600.4 RP11-673E1.1 -3.98 0.000105 0.0347 -0.35 -0.31 Immature fraction of reticulocytes; chr4:143797290 chr4:143912331~143982454:+ PAAD cis rs755249 0.917 rs61779331 ENSG00000228060.1 RP11-69E11.8 -3.98 0.000105 0.0348 -0.31 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39505256 chr1:39565160~39573203:+ PAAD cis rs950027 0.967 rs3120975 ENSG00000259433.2 CTD-2651B20.4 -3.98 0.000105 0.0348 -0.37 -0.31 Response to fenofibrate (adiponectin levels); chr15:45452927 chr15:45330209~45332634:- PAAD cis rs6669008 1 rs55912359 ENSG00000232450.1 RP4-730K3.3 -3.98 0.000105 0.0348 -0.37 -0.31 Bacteremia; chr1:113624477 chr1:113698884~113699631:- PAAD cis rs321358 0.79 rs4635115 ENSG00000271390.1 RP11-89C3.3 3.98 0.000105 0.0348 0.42 0.31 Body mass index; chr11:111076352 chr11:111089870~111090368:- PAAD cis rs2902193 1 rs2902193 ENSG00000267325.1 LINC01415 3.98 0.000105 0.0348 0.29 0.31 Cancer; chr18:55983078 chr18:55776727~55781721:- PAAD cis rs72843506 0.722 rs9908418 ENSG00000154898.14 CCDC144CP 3.98 0.000105 0.0348 0.54 0.31 Schizophrenia; chr17:20311252 chr17:20321164~20403557:+ PAAD cis rs61270009 0.955 rs34148755 ENSG00000247828.6 TMEM161B-AS1 3.98 0.000105 0.0348 0.25 0.31 Depressive symptoms; chr5:88394130 chr5:88268895~88436685:+ PAAD cis rs10129255 0.53 rs11624912 ENSG00000211972.2 IGHV3-66 3.98 0.000105 0.0348 0.24 0.31 Kawasaki disease; chr14:106673891 chr14:106675017~106675544:- PAAD cis rs10483853 0.689 rs11623977 ENSG00000258695.2 RP3-414A15.2 -3.98 0.000105 0.0348 -0.44 -0.31 Coronary artery calcification; chr14:73370662 chr14:73522878~73530610:+ PAAD cis rs8059260 1 rs6498139 ENSG00000274038.1 RP11-66H6.4 -3.98 0.000105 0.0349 -0.45 -0.31 Alcohol consumption over the past year; chr16:10954066 chr16:11056556~11057034:+ PAAD cis rs8059260 1 rs7185978 ENSG00000274038.1 RP11-66H6.4 -3.98 0.000105 0.0349 -0.45 -0.31 Alcohol consumption over the past year; chr16:10954417 chr16:11056556~11057034:+ PAAD cis rs5769765 1 rs2319458 ENSG00000278869.1 CITF22-49E9.3 3.98 0.000105 0.0349 0.45 0.31 Schizophrenia; chr22:49842658 chr22:49933198~49934074:- PAAD cis rs5769765 0.954 rs6009900 ENSG00000278869.1 CITF22-49E9.3 3.98 0.000105 0.0349 0.45 0.31 Schizophrenia; chr22:49842962 chr22:49933198~49934074:- PAAD cis rs9326248 0.861 rs7120309 ENSG00000280143.1 AP000892.6 3.98 0.000105 0.0349 0.4 0.31 Blood protein levels; chr11:117172100 chr11:117204967~117210292:+ PAAD cis rs9326248 0.861 rs7120449 ENSG00000280143.1 AP000892.6 3.98 0.000105 0.0349 0.4 0.31 Blood protein levels; chr11:117172183 chr11:117204967~117210292:+ PAAD cis rs193541 0.632 rs154504 ENSG00000263432.2 RN7SL689P 3.98 0.000106 0.0349 0.4 0.31 Glucose homeostasis traits; chr5:122868391 chr5:123022487~123022783:- PAAD cis rs11992162 0.508 rs7003792 ENSG00000254866.2 DEFB109P3 3.98 0.000106 0.0349 0.4 0.31 Monocyte count; chr8:11923955 chr8:12150895~12151134:- PAAD cis rs4554975 0.624 rs2263486 ENSG00000274723.1 RP11-618L22.1 3.98 0.000106 0.0349 0.36 0.31 Metabolite levels (small molecules and protein measures); chr12:46858534 chr12:46970504~46972155:+ PAAD cis rs853679 0.599 rs202906 ENSG00000204709.4 LINC01556 -3.98 0.000106 0.0349 -0.61 -0.31 Depression; chr6:28043874 chr6:28943877~28944537:+ PAAD cis rs11723261 0.621 rs11721745 ENSG00000275426.1 CH17-262A2.1 3.98 0.000106 0.0349 0.49 0.31 Immune response to smallpox vaccine (IL-6); chr4:115052 chr4:149738~150317:+ PAAD cis rs9326248 0.813 rs7115562 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117149754 chr11:117204967~117210292:+ PAAD cis rs9326248 0.727 rs4938347 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117151043 chr11:117204967~117210292:+ PAAD cis rs9326248 0.861 rs4938348 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117151161 chr11:117204967~117210292:+ PAAD cis rs9326248 0.813 rs4938350 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117151560 chr11:117204967~117210292:+ PAAD cis rs9326248 0.652 rs7128382 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117152771 chr11:117204967~117210292:+ PAAD cis rs9326248 0.768 rs4936366 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117156169 chr11:117204967~117210292:+ PAAD cis rs9326248 0.861 rs4938352 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117156765 chr11:117204967~117210292:+ PAAD cis rs9326248 0.861 rs7931335 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117166089 chr11:117204967~117210292:+ PAAD cis rs9326248 0.861 rs4938353 ENSG00000280143.1 AP000892.6 3.98 0.000106 0.0349 0.4 0.31 Blood protein levels; chr11:117175481 chr11:117204967~117210292:+ PAAD cis rs12999616 0.602 rs905484 ENSG00000228486.8 LINC01125 -3.98 0.000106 0.0349 -0.27 -0.31 Colorectal cancer; chr2:97973620 chr2:97664217~97703064:+ PAAD cis rs1113500 0.932 rs1343205 ENSG00000226822.1 RP11-356N1.2 3.98 0.000106 0.0349 0.36 0.31 Growth-regulated protein alpha levels; chr1:108055251 chr1:108071482~108074519:+ PAAD cis rs2015599 0.623 rs7358667 ENSG00000275476.1 RP11-996F15.4 3.98 0.000106 0.0349 0.29 0.31 Platelet count;Mean platelet volume; chr12:29290236 chr12:29277397~29277882:- PAAD cis rs6951245 0.882 rs11764817 ENSG00000229043.2 AC091729.9 -3.98 0.000106 0.0349 -0.44 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1024974 chr7:1160374~1165267:+ PAAD cis rs7260598 0.892 rs67180860 ENSG00000268442.1 CTD-2027I19.2 3.98 0.000106 0.0349 0.52 0.31 Response to taxane treatment (placlitaxel); chr19:24023433 chr19:24162370~24163425:- PAAD cis rs193541 0.593 rs154499 ENSG00000263432.2 RN7SL689P 3.98 0.000106 0.0349 0.4 0.31 Glucose homeostasis traits; chr5:122883971 chr5:123022487~123022783:- PAAD cis rs6991838 0.806 rs17302392 ENSG00000200714.1 Y_RNA 3.98 0.000106 0.0349 0.36 0.31 Intelligence (multi-trait analysis); chr8:65551073 chr8:65592731~65592820:+ PAAD cis rs4266144 0.569 rs729257 ENSG00000244515.1 KRT18P34 -3.98 0.000106 0.0349 -0.35 -0.31 Coronary artery disease; chr3:157111034 chr3:157162663~157163932:- PAAD cis rs189798 0.807 rs330905 ENSG00000253893.2 FAM85B -3.98 0.000106 0.035 -0.43 -0.31 Myopia (pathological); chr8:9136041 chr8:8167819~8226614:- PAAD cis rs10129255 0.5 rs34326748 ENSG00000211972.2 IGHV3-66 3.98 0.000106 0.035 0.24 0.31 Kawasaki disease; chr14:106782523 chr14:106675017~106675544:- PAAD cis rs10129255 0.5 rs10143385 ENSG00000211972.2 IGHV3-66 3.98 0.000106 0.035 0.24 0.31 Kawasaki disease; chr14:106782559 chr14:106675017~106675544:- PAAD cis rs2688608 0.592 rs11000759 ENSG00000271816.1 BMS1P4 3.98 0.000106 0.035 0.32 0.31 Inflammatory bowel disease; chr10:73733968 chr10:73699151~73730487:- PAAD cis rs2412819 0.571 rs11070411 ENSG00000249839.1 AC011330.5 3.98 0.000106 0.035 0.48 0.31 Lung cancer; chr15:43766436 chr15:43663654~43684339:- PAAD cis rs7078012 1 rs7078012 ENSG00000272489.1 RP11-182L21.5 -3.98 0.000106 0.035 -0.47 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79945677 chr10:79663192~79664786:+ PAAD cis rs7078012 0.915 rs726287 ENSG00000272489.1 RP11-182L21.5 -3.98 0.000106 0.035 -0.47 -0.31 Chronic obstructive pulmonary disease-related biomarkers; chr10:79947037 chr10:79663192~79664786:+ PAAD cis rs4794202 0.741 rs9903904 ENSG00000264920.1 RP11-6N17.4 -3.98 0.000106 0.035 -0.45 -0.31 Alzheimer's disease (cognitive decline); chr17:47851803 chr17:47891255~47895812:- PAAD cis rs6539288 0.933 rs4964498 ENSG00000260329.1 RP11-412D9.4 -3.98 0.000106 0.035 -0.26 -0.31 Total body bone mineral density; chr12:106912945 chr12:106954029~106955497:- PAAD cis rs7246657 0.943 rs7255785 ENSG00000267422.1 CTD-2554C21.1 -3.98 0.000106 0.035 -0.53 -0.31 Coronary artery calcification; chr19:37480781 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs7255996 ENSG00000267422.1 CTD-2554C21.1 -3.98 0.000106 0.035 -0.53 -0.31 Coronary artery calcification; chr19:37480797 chr19:37779686~37792865:+ PAAD cis rs8020941 0.585 rs7149193 ENSG00000227051.5 C14orf132 -3.98 0.000106 0.035 -0.36 -0.31 Diabetic kidney disease; chr14:97038762 chr14:96039324~96094080:+ PAAD cis rs8072100 0.875 rs4794047 ENSG00000228782.6 CTD-2026D20.3 -3.98 0.000106 0.035 -0.33 -0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47685639 chr17:47450568~47492492:- PAAD cis rs17211409 0.655 rs79179849 ENSG00000255250.1 CTD-2005H7.2 3.98 0.000106 0.035 0.73 0.31 JT interval (sulfonylurea treatment interaction); chr11:86663182 chr11:86727355~86765265:+ PAAD cis rs28386778 0.897 rs2665797 ENSG00000240280.5 TCAM1P 3.98 0.000106 0.035 0.43 0.31 Prudent dietary pattern; chr17:63845125 chr17:63849292~63864379:+ PAAD cis rs3015497 0.789 rs3015502 ENSG00000270062.1 RP11-248J18.3 3.98 0.000106 0.035 0.29 0.31 Mean platelet volume; chr14:50641709 chr14:50723777~50724272:- PAAD cis rs3015497 0.789 rs3015500 ENSG00000270062.1 RP11-248J18.3 3.98 0.000106 0.035 0.29 0.31 Mean platelet volume; chr14:50642159 chr14:50723777~50724272:- PAAD cis rs3015497 0.789 rs3015498 ENSG00000270062.1 RP11-248J18.3 3.98 0.000106 0.035 0.29 0.31 Mean platelet volume; chr14:50646106 chr14:50723777~50724272:- PAAD cis rs3015497 0.789 rs3015496 ENSG00000270062.1 RP11-248J18.3 3.98 0.000106 0.035 0.29 0.31 Mean platelet volume; chr14:50647333 chr14:50723777~50724272:- PAAD cis rs1555322 1 rs2425040 ENSG00000279253.1 RP4-614O4.13 -3.98 0.000106 0.035 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35271075 chr20:35262727~35264187:- PAAD cis rs1555322 1 rs6058219 ENSG00000279253.1 RP4-614O4.13 -3.98 0.000106 0.035 -0.4 -0.31 Attention deficit hyperactivity disorder; chr20:35271441 chr20:35262727~35264187:- PAAD cis rs3096299 1 rs3096299 ENSG00000274627.1 RP11-104N10.2 3.98 0.000106 0.035 0.28 0.31 Multiple myeloma (IgH translocation); chr16:89382255 chr16:89516797~89522217:+ PAAD cis rs8072100 0.745 rs7214410 ENSG00000228782.6 CTD-2026D20.3 3.98 0.000106 0.035 0.32 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47345262 chr17:47450568~47492492:- PAAD cis rs6545883 0.507 rs59981505 ENSG00000271889.1 RP11-493E12.1 -3.98 0.000106 0.035 -0.33 -0.31 Tuberculosis; chr2:61353394 chr2:61151433~61162105:- PAAD cis rs12530845 0.887 rs73725434 ENSG00000223718.3 AC093107.7 3.98 0.000106 0.035 0.52 0.31 Red blood cell traits; chr7:135628909 chr7:135660039~135660647:+ PAAD cis rs12530845 0.887 rs4492299 ENSG00000223718.3 AC093107.7 3.98 0.000106 0.035 0.52 0.31 Red blood cell traits; chr7:135630942 chr7:135660039~135660647:+ PAAD cis rs12530845 0.887 rs79100776 ENSG00000223718.3 AC093107.7 3.98 0.000106 0.035 0.52 0.31 Red blood cell traits; chr7:135631069 chr7:135660039~135660647:+ PAAD cis rs8077577 0.945 rs8065026 ENSG00000273018.4 CTD-2303H24.2 -3.98 0.000106 0.035 -0.47 -0.31 Obesity-related traits; chr17:18142976 chr17:18511221~18551705:- PAAD cis rs2243480 1 rs316331 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66139635 chr7:66902857~66906297:+ PAAD cis rs2243480 0.908 rs2460431 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66157859 chr7:66902857~66906297:+ PAAD cis rs2243480 0.711 rs2460426 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66158142 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs4718309 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66162777 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs6460274 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66163497 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs7787230 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66164112 chr7:66902857~66906297:+ PAAD cis rs2243480 0.711 rs2420172 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66170354 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs2420171 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66172773 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs6974723 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66172952 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs9769882 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66177938 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs6966322 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66181767 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs4145008 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66182524 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs4718315 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66183554 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs4718316 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66183744 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1873494 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66184912 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs6959002 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66185509 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1546059 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66189722 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs2420170 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66191066 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs6958289 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66192124 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs7804223 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66199572 chr7:66902857~66906297:+ PAAD cis rs2243480 0.901 rs12530490 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66226660 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs7778911 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66229519 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1979823 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66239626 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs6964245 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66253730 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs10807701 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66259699 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1499613 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66265873 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1553174 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66266207 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs10950032 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66273604 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs6958420 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66286184 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1392104 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66294120 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs4718333 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66307771 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs7792391 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66308442 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs10247526 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66315709 chr7:66902857~66906297:+ PAAD cis rs2243480 0.908 rs1532573 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Diabetic kidney disease; chr7:66333815 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs1882655 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Gout; chr7:66682070 chr7:66902857~66906297:+ PAAD cis rs1499614 0.831 rs3800822 ENSG00000273142.1 RP11-458F8.4 3.98 0.000106 0.035 0.28 0.31 Gout; chr7:66682162 chr7:66902857~66906297:+ PAAD cis rs2243480 0.908 rs313822 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66108952 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs313820 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66109479 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs160639 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66115000 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs313824 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66116220 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs186378 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66117071 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs160637 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66119331 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs422164 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66121618 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316313 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66128561 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316312 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66131504 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs419603 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66132354 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs387676 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66133233 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs13310597 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66133553 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs431076 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66135333 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs2257790 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66135463 chr7:66902857~66906297:+ PAAD cis rs2243480 0.764 rs2460423 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66136229 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs2460422 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66136518 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316334 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66137139 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316332 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66139312 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316329 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66143429 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316326 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66144466 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316325 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66144531 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316322 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66146246 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316321 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66146626 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316318 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66147917 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316317 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66148650 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316304 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66151907 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs2465120 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66155987 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1499614 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66265811 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs778729 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66359432 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs4149468 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66360703 chr7:66902857~66906297:+ PAAD cis rs2243480 0.901 rs778687 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66370832 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs778679 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66375924 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs778704 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66398480 chr7:66902857~66906297:+ PAAD cis rs2243480 0.901 rs778693 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66407358 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs778691 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66408105 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs13235972 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66418618 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs34192067 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66422670 chr7:66902857~66906297:+ PAAD cis rs2243480 0.901 rs34807232 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66500146 chr7:66902857~66906297:+ PAAD cis rs2243480 0.901 rs35823062 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66500834 chr7:66902857~66906297:+ PAAD cis rs2243480 0.708 rs35825036 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66521515 chr7:66902857~66906297:+ PAAD cis rs2243480 0.803 rs13224048 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66528779 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs13237037 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66532895 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1796228 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66568097 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1267820 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66585308 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs2533288 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66591724 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs2707844 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66594522 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs1796220 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66597113 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs2707831 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Diabetic kidney disease; chr7:66597524 chr7:66902857~66906297:+ PAAD cis rs1499614 0.803 rs1796229 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66654674 chr7:66902857~66906297:+ PAAD cis rs1499614 0.901 rs3936 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66661502 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2707832 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66671562 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs1638731 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66679692 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2659913 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66692349 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2707840 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66693028 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2659911 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66693433 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2707838 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66694214 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs60326618 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66701371 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2707830 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66702658 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2707828 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66706390 chr7:66902857~66906297:+ PAAD cis rs1499614 0.803 rs1922723 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66710076 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2659903 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66715944 chr7:66902857~66906297:+ PAAD cis rs1499614 1 rs2141924 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66721259 chr7:66902857~66906297:+ PAAD cis rs1499614 0.901 rs2178742 ENSG00000273142.1 RP11-458F8.4 -3.98 0.000106 0.035 -0.28 -0.31 Gout; chr7:66732812 chr7:66902857~66906297:+ PAAD cis rs2581828 0.618 rs9828221 ENSG00000242142.1 SERBP1P3 -3.98 0.000106 0.035 -0.38 -0.31 Crohn's disease; chr3:53132643 chr3:53064283~53065091:- PAAD cis rs919433 0.68 rs7568250 ENSG00000231621.1 AC013264.2 -3.98 0.000106 0.0351 -0.3 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197544887 chr2:197197991~197199273:+ PAAD cis rs72627509 0.904 rs56281640 ENSG00000269949.1 RP11-738E22.3 3.98 0.000106 0.0351 0.48 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56899650 chr4:56960927~56961373:- PAAD cis rs7119038 0.779 rs11217045 ENSG00000255239.1 AP002954.6 -3.98 0.000106 0.0351 -0.46 -0.31 Sjögren's syndrome; chr11:118827156 chr11:118688039~118690600:- PAAD cis rs7119038 0.865 rs11217046 ENSG00000255239.1 AP002954.6 -3.98 0.000106 0.0351 -0.46 -0.31 Sjögren's syndrome; chr11:118828198 chr11:118688039~118690600:- PAAD cis rs4266290 0.597 rs2286879 ENSG00000214846.4 RP11-115L11.1 3.98 0.000106 0.0351 0.42 0.31 Parkinson's disease; chr4:15739257 chr4:15730962~15731627:- PAAD cis rs526231 0.667 rs187580 ENSG00000175749.11 EIF3KP1 3.98 0.000107 0.0351 0.45 0.31 Primary biliary cholangitis; chr5:103291654 chr5:103032376~103033031:+ PAAD cis rs8072100 0.811 rs1912483 ENSG00000228782.6 CTD-2026D20.3 3.98 0.000107 0.0351 0.32 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47366128 chr17:47450568~47492492:- PAAD cis rs8072100 0.811 rs9889709 ENSG00000228782.6 CTD-2026D20.3 3.98 0.000107 0.0351 0.32 0.31 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47367863 chr17:47450568~47492492:- PAAD cis rs2729354 0.909 rs2729374 ENSG00000265566.2 RN7SL605P -3.98 0.000107 0.0351 -0.4 -0.31 Blood protein levels; chr11:57559454 chr11:57528085~57528365:- PAAD cis rs2688608 0.53 rs71507081 ENSG00000271816.1 BMS1P4 3.98 0.000107 0.0351 0.31 0.31 Inflammatory bowel disease; chr10:73733378 chr10:73699151~73730487:- PAAD cis rs2688608 0.592 rs11000758 ENSG00000271816.1 BMS1P4 3.98 0.000107 0.0351 0.31 0.31 Inflammatory bowel disease; chr10:73733852 chr10:73699151~73730487:- PAAD cis rs1729407 0.814 rs2071521 ENSG00000254851.1 RP11-109L13.1 3.98 0.000107 0.0351 0.38 0.31 Apolipoprotein A-IV levels; chr11:116827132 chr11:117135528~117138582:+ PAAD cis rs12908161 0.92 rs12904605 ENSG00000259295.5 CSPG4P12 3.98 0.000107 0.0351 0.34 0.31 Schizophrenia; chr15:84658188 chr15:85191438~85213905:+ PAAD cis rs8005677 0.828 rs57822749 ENSG00000279656.1 RP11-298I3.6 3.98 0.000107 0.0351 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22940758 chr14:23023083~23024217:- PAAD cis rs2522056 0.932 rs2522064 ENSG00000233006.5 AC034220.3 -3.98 0.000107 0.0351 -0.27 -0.31 Fibrinogen;Lymphocyte counts; chr5:132470796 chr5:132311285~132369916:- PAAD cis rs17507216 0.56 rs2871011 ENSG00000255769.6 GOLGA2P10 -3.98 0.000107 0.0351 -0.32 -0.31 Excessive daytime sleepiness; chr15:82560792 chr15:82472993~82513950:- PAAD cis rs10129255 0.589 rs78599641 ENSG00000224373.3 IGHV4-59 3.98 0.000107 0.0351 0.26 0.31 Kawasaki disease; chr14:106637576 chr14:106627249~106627825:- PAAD cis rs9487094 0.744 rs13211604 ENSG00000260273.1 RP11-425D10.10 3.98 0.000107 0.0351 0.42 0.31 Height; chr6:109712525 chr6:109382795~109383666:+ PAAD cis rs9487094 0.744 rs13212535 ENSG00000260273.1 RP11-425D10.10 3.98 0.000107 0.0351 0.42 0.31 Height; chr6:109713188 chr6:109382795~109383666:+ PAAD cis rs12477438 0.52 rs2290255 ENSG00000273306.1 RP11-527J8.1 3.98 0.000107 0.0351 0.34 0.31 Chronic sinus infection; chr2:99382634 chr2:99405218~99405843:+ PAAD cis rs7202877 0.656 rs4887812 ENSG00000261783.1 RP11-252K23.2 -3.98 0.000107 0.0351 -0.48 -0.31 Type 1 diabetes;Type 2 diabetes; chr16:75276154 chr16:75379818~75381260:- PAAD cis rs2337406 0.866 rs79901786 ENSG00000223648.3 IGHV3-64 3.98 0.000107 0.0351 0.34 0.31 Alzheimer's disease (late onset); chr14:106777623 chr14:106643132~106658258:- PAAD cis rs9322193 0.923 rs4421206 ENSG00000268592.3 RAET1E-AS1 3.98 0.000107 0.0352 0.36 0.31 Lung cancer; chr6:149682891 chr6:149863494~149919507:+ PAAD cis rs7923837 0.687 rs11187139 ENSG00000236493.2 EIF2S2P3 3.98 0.000107 0.0352 0.39 0.31 Multiple sclerosis;Body mass index; chr10:92706670 chr10:92668745~92669743:- PAAD cis rs7923837 0.687 rs10882102 ENSG00000236493.2 EIF2S2P3 3.98 0.000107 0.0352 0.39 0.31 Multiple sclerosis;Body mass index; chr10:92706738 chr10:92668745~92669743:- PAAD cis rs12940030 0.794 rs1558274 ENSG00000236088.8 COX10-AS1 -3.98 0.000107 0.0352 -0.3 -0.31 Corneal structure; chr17:14673135 chr17:13756478~14069495:- PAAD cis rs2638953 0.924 rs7955118 ENSG00000247934.4 RP11-967K21.1 -3.98 0.000107 0.0352 -0.36 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28157159 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs7955237 ENSG00000247934.4 RP11-967K21.1 -3.98 0.000107 0.0352 -0.36 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28157272 chr12:28163298~28190738:- PAAD cis rs595244 1 rs4775769 ENSG00000259705.1 RP11-227D13.1 -3.98 0.000107 0.0352 -0.55 -0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48647691 chr15:48645951~48652016:+ PAAD cis rs7617773 0.962 rs6797587 ENSG00000228638.1 FCF1P2 3.98 0.000107 0.0352 0.35 0.31 Coronary artery disease; chr3:48156124 chr3:48290793~48291375:- PAAD cis rs6543140 0.964 rs6543136 ENSG00000234389.1 AC007278.3 3.98 0.000107 0.0352 0.34 0.31 Blood protein levels; chr2:102449087 chr2:102438713~102440475:+ PAAD cis rs9487094 0.626 rs4141930 ENSG00000260273.1 RP11-425D10.10 3.98 0.000107 0.0352 0.37 0.31 Height; chr6:109739615 chr6:109382795~109383666:+ PAAD cis rs7829975 0.628 rs1109618 ENSG00000253893.2 FAM85B 3.98 0.000107 0.0352 0.46 0.31 Mood instability; chr8:8713854 chr8:8167819~8226614:- PAAD cis rs2638953 0.815 rs1534340 ENSG00000247934.4 RP11-967K21.1 -3.98 0.000107 0.0352 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28515550 chr12:28163298~28190738:- PAAD cis rs1113500 1 rs1113500 ENSG00000226822.1 RP11-356N1.2 -3.98 0.000107 0.0352 -0.36 -0.31 Growth-regulated protein alpha levels; chr1:108052820 chr1:108071482~108074519:+ PAAD cis rs1910358 0.579 rs7730970 ENSG00000248874.4 C5orf17 -3.98 0.000107 0.0352 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23757455 chr5:23951348~24178263:+ PAAD cis rs7170668 0.597 rs17493093 ENSG00000259134.4 LINC00924 3.98 0.000107 0.0352 0.37 0.31 Motion sickness; chr15:95506447 chr15:95433095~95507847:+ PAAD cis rs2736345 0.89 rs4840565 ENSG00000251402.3 FAM90A25P 3.98 0.000107 0.0352 0.38 0.31 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11488036 chr8:12415080~12418090:- PAAD cis rs7402982 0.647 rs34038360 ENSG00000278022.1 RP11-35O15.2 -3.98 0.000107 0.0353 -0.4 -0.31 Birth weight; chr15:98658344 chr15:98660210~98660668:+ PAAD cis rs2243480 1 rs316315 ENSG00000232546.1 RP11-458F8.1 3.98 0.000107 0.0353 0.32 0.31 Diabetic kidney disease; chr7:66126218 chr7:66848496~66858136:+ PAAD cis rs763121 0.853 rs6001175 ENSG00000228274.3 RP3-508I15.9 -3.98 0.000107 0.0353 -0.29 -0.31 Menopause (age at onset); chr22:38622329 chr22:38667585~38681820:- PAAD cis rs11096990 0.551 rs2060005 ENSG00000249685.1 RP11-360F5.3 3.98 0.000107 0.0353 0.32 0.31 Cognitive function; chr4:39160901 chr4:39133913~39135608:+ PAAD cis rs1061377 0.501 rs62308278 ENSG00000249685.1 RP11-360F5.3 3.98 0.000107 0.0353 0.32 0.31 Uric acid levels; chr4:39161038 chr4:39133913~39135608:+ PAAD cis rs9652601 0.626 rs887864 ENSG00000274038.1 RP11-66H6.4 3.98 0.000107 0.0353 0.34 0.31 Systemic lupus erythematosus; chr16:11065028 chr16:11056556~11057034:+ PAAD cis rs3892715 0.581 rs2676889 ENSG00000214145.5 LINC00887 3.98 0.000107 0.0353 0.36 0.31 Attention deficit hyperactivity disorder (time to onset); chr3:195042872 chr3:194296465~194312803:- PAAD cis rs1476587 0.92 rs71562738 ENSG00000224046.1 AC005076.5 3.98 0.000107 0.0353 0.44 0.31 Brachial circumference; chr7:87054733 chr7:87151423~87152420:- PAAD cis rs1476587 0.92 rs71562739 ENSG00000224046.1 AC005076.5 3.98 0.000107 0.0353 0.44 0.31 Brachial circumference; chr7:87055587 chr7:87151423~87152420:- PAAD cis rs1476587 0.92 rs35595157 ENSG00000224046.1 AC005076.5 3.98 0.000107 0.0353 0.44 0.31 Brachial circumference; chr7:87055611 chr7:87151423~87152420:- PAAD cis rs17772222 0.874 rs78077739 ENSG00000258983.2 RP11-507K2.2 3.98 0.000107 0.0353 0.4 0.31 Coronary artery calcification; chr14:88741176 chr14:88499334~88515502:+ PAAD cis rs377457 0.623 rs1053328 ENSG00000270159.1 RP11-568J23.6 -3.98 0.000107 0.0353 -0.37 -0.31 Type 2 diabetes; chr16:85678254 chr16:85792415~85792933:+ PAAD cis rs1275468 0.724 rs1611928 ENSG00000257497.2 RP11-585P4.5 -3.98 0.000107 0.0353 -0.48 -0.31 Polycystic ovary syndrome; chr12:75561705 chr12:75483454~75489820:- PAAD cis rs3738443 0.951 rs4582838 ENSG00000259865.1 RP11-488L18.10 3.98 0.000108 0.0353 0.29 0.31 Alcohol dependence; chr1:247210269 chr1:247187281~247188526:- PAAD cis rs7759001 0.711 rs13217248 ENSG00000271755.1 RP1-153G14.4 3.98 0.000108 0.0353 0.36 0.31 Glomerular filtration rate (creatinine); chr6:27509170 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs13217162 ENSG00000271755.1 RP1-153G14.4 3.98 0.000108 0.0353 0.36 0.31 Glomerular filtration rate (creatinine); chr6:27509320 chr6:27404010~27406964:- PAAD cis rs6951245 0.554 rs35126802 ENSG00000229043.2 AC091729.9 -3.98 0.000108 0.0354 -0.42 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1095206 chr7:1160374~1165267:+ PAAD cis rs6951245 0.554 rs78999139 ENSG00000229043.2 AC091729.9 -3.98 0.000108 0.0354 -0.42 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1098889 chr7:1160374~1165267:+ PAAD cis rs6951245 0.58 rs78894484 ENSG00000229043.2 AC091729.9 -3.98 0.000108 0.0354 -0.42 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1099085 chr7:1160374~1165267:+ PAAD cis rs9925964 0.9 rs9934438 ENSG00000232748.3 RP11-196G11.6 3.98 0.000108 0.0354 0.37 0.31 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31093557 chr16:31056460~31062803:+ PAAD cis rs9595066 0.627 rs4941486 ENSG00000227258.4 SMIM2-AS1 3.98 0.000108 0.0354 0.46 0.31 Schizophrenia; chr13:44175021 chr13:44110451~44240517:+ PAAD cis rs4660214 0.666 rs6698791 ENSG00000228060.1 RP11-69E11.8 3.98 0.000108 0.0354 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39469104 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs10888788 ENSG00000228060.1 RP11-69E11.8 3.98 0.000108 0.0354 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39472024 chr1:39565160~39573203:+ PAAD cis rs6479891 1 rs7099425 ENSG00000232075.1 MRPL35P2 -3.98 0.000108 0.0354 -0.48 -0.31 Arthritis (juvenile idiopathic); chr10:63200957 chr10:63634317~63634827:- PAAD cis rs28374715 0.662 rs10851403 ENSG00000247556.5 OIP5-AS1 3.98 0.000108 0.0354 0.32 0.31 Ulcerative colitis; chr15:41173889 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs13329579 ENSG00000247556.5 OIP5-AS1 3.98 0.000108 0.0354 0.32 0.31 Ulcerative colitis; chr15:41175237 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs8038983 ENSG00000247556.5 OIP5-AS1 3.98 0.000108 0.0354 0.32 0.31 Ulcerative colitis; chr15:41181118 chr15:41283990~41309737:+ PAAD cis rs950169 0.922 rs11633075 ENSG00000275120.1 RP11-182J1.17 3.98 0.000108 0.0354 0.32 0.31 Schizophrenia; chr15:84570741 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs12912934 ENSG00000275120.1 RP11-182J1.17 3.98 0.000108 0.0354 0.32 0.31 Schizophrenia; chr15:84571216 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs11633534 ENSG00000275120.1 RP11-182J1.17 3.98 0.000108 0.0354 0.32 0.31 Schizophrenia; chr15:84581411 chr15:84599434~84606463:- PAAD cis rs2348418 0.703 rs12368149 ENSG00000247934.4 RP11-967K21.1 -3.98 0.000108 0.0354 -0.31 -0.31 Lung function (FEV1);Lung function (FVC); chr12:28168625 chr12:28163298~28190738:- PAAD cis rs4835473 0.932 rs1849115 ENSG00000251600.4 RP11-673E1.1 3.98 0.000108 0.0354 0.36 0.31 Immature fraction of reticulocytes; chr4:143989687 chr4:143912331~143982454:+ PAAD cis rs7202877 0.656 rs6564245 ENSG00000261783.1 RP11-252K23.2 3.98 0.000108 0.0354 0.48 0.31 Type 1 diabetes;Type 2 diabetes; chr16:75275001 chr16:75379818~75381260:- PAAD cis rs7202877 0.561 rs4888369 ENSG00000261783.1 RP11-252K23.2 -3.98 0.000108 0.0354 -0.48 -0.31 Type 1 diabetes;Type 2 diabetes; chr16:75273379 chr16:75379818~75381260:- PAAD cis rs4218 0.689 rs11853828 ENSG00000259732.1 RP11-59H7.3 -3.98 0.000108 0.0354 -0.42 -0.31 Social communication problems; chr15:59136031 chr15:59121034~59133250:+ PAAD cis rs72627509 0.857 rs55762216 ENSG00000269949.1 RP11-738E22.3 3.98 0.000108 0.0354 0.48 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56899565 chr4:56960927~56961373:- PAAD cis rs2404602 0.735 rs2461870 ENSG00000259422.1 RP11-593F23.1 -3.98 0.000108 0.0354 -0.36 -0.31 Blood metabolite levels; chr15:76521579 chr15:76174891~76181486:- PAAD cis rs2404602 0.735 rs2454454 ENSG00000259422.1 RP11-593F23.1 -3.98 0.000108 0.0354 -0.36 -0.31 Blood metabolite levels; chr15:76531306 chr15:76174891~76181486:- PAAD cis rs801193 0.591 rs2707839 ENSG00000237310.1 GS1-124K5.4 3.98 0.000108 0.0355 0.3 0.31 Aortic root size; chr7:66728097 chr7:66493706~66495474:+ PAAD cis rs897984 0.806 rs1046276 ENSG00000260911.2 RP11-196G11.2 -3.98 0.000108 0.0355 -0.28 -0.31 Dementia with Lewy bodies; chr16:30903305 chr16:31043150~31049868:+ PAAD cis rs896655 0.775 rs10114559 ENSG00000266446.1 RP11-149I2.4 -3.98 0.000108 0.0355 -0.39 -0.31 Coronary artery disease; chr9:21816638 chr9:21995482~21996013:+ PAAD cis rs12352894 0.583 rs10973703 ENSG00000204860.4 FAM201A -3.98 0.000108 0.0355 -0.45 -0.31 Post bronchodilator FEV1 in COPD; chr9:38198632 chr9:38620474~38624990:+ PAAD cis rs10779751 0.922 rs2746638 ENSG00000238199.1 UBE2V2P3 -3.98 0.000108 0.0355 -0.37 -0.31 Body mass index; chr1:11218068 chr1:11278616~11279351:- PAAD cis rs780096 0.526 rs2010087 ENSG00000234072.1 AC074117.10 -3.98 0.000108 0.0355 -0.24 -0.31 Total body bone mineral density; chr2:27414368 chr2:27356246~27367622:+ PAAD cis rs780096 0.525 rs13388159 ENSG00000234072.1 AC074117.10 -3.98 0.000108 0.0355 -0.24 -0.31 Total body bone mineral density; chr2:27425417 chr2:27356246~27367622:+ PAAD cis rs3781264 0.761 rs12781451 ENSG00000273450.1 RP11-76P2.4 3.98 0.000108 0.0355 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94324163 chr10:94314907~94315327:- PAAD cis rs3781264 0.761 rs11187869 ENSG00000273450.1 RP11-76P2.4 3.98 0.000108 0.0355 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94327740 chr10:94314907~94315327:- PAAD cis rs10779751 0.959 rs2092642 ENSG00000238199.1 UBE2V2P3 -3.98 0.000108 0.0355 -0.37 -0.31 Body mass index; chr1:11257263 chr1:11278616~11279351:- PAAD cis rs10779751 0.96 rs2076657 ENSG00000238199.1 UBE2V2P3 -3.98 0.000108 0.0355 -0.37 -0.31 Body mass index; chr1:11258706 chr1:11278616~11279351:- PAAD cis rs10779751 0.96 rs4845988 ENSG00000238199.1 UBE2V2P3 -3.98 0.000108 0.0355 -0.37 -0.31 Body mass index; chr1:11259530 chr1:11278616~11279351:- PAAD cis rs10779751 0.96 rs11121712 ENSG00000238199.1 UBE2V2P3 -3.98 0.000108 0.0355 -0.37 -0.31 Body mass index; chr1:11260272 chr1:11278616~11279351:- PAAD cis rs453301 0.686 rs4840389 ENSG00000254340.1 RP11-10A14.3 -3.98 0.000108 0.0355 -0.38 -0.31 Joint mobility (Beighton score); chr8:9026993 chr8:9141424~9145435:+ PAAD cis rs453301 0.658 rs13271797 ENSG00000254340.1 RP11-10A14.3 -3.98 0.000108 0.0355 -0.38 -0.31 Joint mobility (Beighton score); chr8:9028444 chr8:9141424~9145435:+ PAAD cis rs7260598 0.539 rs11670289 ENSG00000269397.1 CTB-92J24.2 3.98 0.000108 0.0356 0.6 0.31 Response to taxane treatment (placlitaxel); chr19:23884154 chr19:23927788~23929287:+ PAAD cis rs5758659 0.652 rs133336 ENSG00000273366.1 CTA-989H11.1 -3.98 0.000108 0.0356 -0.36 -0.31 Cognitive function; chr22:42020299 chr22:42278188~42278846:+ PAAD cis rs6142102 0.961 rs8123521 ENSG00000276073.1 RP5-1125A11.7 -3.98 0.000108 0.0356 -0.33 -0.31 Skin pigmentation; chr20:34081079 chr20:33985617~33988989:- PAAD cis rs2179367 0.887 rs2789488 ENSG00000231760.4 RP11-350J20.5 -3.97 0.000108 0.0356 -0.4 -0.31 Dupuytren's disease; chr6:149404154 chr6:149796151~149826294:- PAAD cis rs6977955 0.838 rs2189966 ENSG00000234336.5 JAZF1-AS1 3.97 0.000109 0.0356 0.38 0.31 Allergic disease (asthma, hay fever or eczema); chr7:28132447 chr7:28180322~28243917:+ PAAD cis rs28374715 0.662 rs28587487 ENSG00000247556.5 OIP5-AS1 3.97 0.000109 0.0356 0.32 0.31 Ulcerative colitis; chr15:41203262 chr15:41283990~41309737:+ PAAD cis rs9425766 0.888 rs1799876 ENSG00000227373.4 RP11-160H22.5 3.97 0.000109 0.0356 0.41 0.31 Life satisfaction; chr1:173909333 chr1:174115300~174160004:- PAAD cis rs1910358 0.596 rs1121277 ENSG00000248874.4 C5orf17 -3.97 0.000109 0.0356 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23835358 chr5:23951348~24178263:+ PAAD cis rs1910358 0.621 rs7714949 ENSG00000248874.4 C5orf17 -3.97 0.000109 0.0356 -0.43 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23836146 chr5:23951348~24178263:+ PAAD cis rs2243480 1 rs313832 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66085904 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs313831 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66086239 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs160646 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66091293 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs465359 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66093177 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs462853 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66093180 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs160644 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66093199 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs160642 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66093386 chr7:65751142~65763354:+ PAAD cis rs2243480 0.614 rs34032527 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66100154 chr7:65751142~65763354:+ PAAD cis rs2243480 0.803 rs36127118 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66100518 chr7:65751142~65763354:+ PAAD cis rs2243480 1 rs316307 ENSG00000228409.4 CCT6P1 3.97 0.000109 0.0357 0.33 0.31 Diabetic kidney disease; chr7:66105184 chr7:65751142~65763354:+ PAAD cis rs797680 0.856 rs4847408 ENSG00000223745.6 RP4-717I23.3 -3.97 0.000109 0.0357 -0.25 -0.31 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93325880 chr1:93262186~93346025:- PAAD cis rs7923837 0.893 rs10882104 ENSG00000236493.2 EIF2S2P3 3.97 0.000109 0.0357 0.4 0.31 Multiple sclerosis;Body mass index; chr10:92710758 chr10:92668745~92669743:- PAAD cis rs3015497 1 rs4075253 ENSG00000270062.1 RP11-248J18.3 3.97 0.000109 0.0357 0.28 0.31 Mean platelet volume; chr14:50641019 chr14:50723777~50724272:- PAAD cis rs7939886 0.92 rs7124734 ENSG00000274150.1 FADS2P1 3.97 0.000109 0.0357 0.64 0.31 Myopia (pathological); chr11:56192863 chr11:56890613~56927885:+ PAAD cis rs12134133 1 rs10494890 ENSG00000237074.1 RP11-6J21.2 -3.97 0.000109 0.0357 -0.47 -0.31 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207251041 chr1:207249067~207309121:+ PAAD cis rs2439831 0.85 rs60883262 ENSG00000275601.1 AC011330.13 -3.97 0.000109 0.0357 -0.53 -0.31 Lung cancer in ever smokers; chr15:43784305 chr15:43642389~43643023:- PAAD cis rs950169 0.92 rs12915390 ENSG00000259683.1 RP11-182J1.14 3.97 0.000109 0.0358 0.26 0.31 Schizophrenia; chr15:84123317 chr15:84389729~84395903:+ PAAD cis rs6479891 1 rs12414796 ENSG00000232075.1 MRPL35P2 3.97 0.000109 0.0358 0.49 0.31 Arthritis (juvenile idiopathic); chr10:63543327 chr10:63634317~63634827:- PAAD cis rs7759001 0.779 rs12215117 ENSG00000271755.1 RP1-153G14.4 3.97 0.000109 0.0358 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27479517 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs13220155 ENSG00000271755.1 RP1-153G14.4 3.97 0.000109 0.0358 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27483331 chr6:27404010~27406964:- PAAD cis rs7759001 0.711 rs10946929 ENSG00000271755.1 RP1-153G14.4 3.97 0.000109 0.0358 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27488027 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs10946931 ENSG00000271755.1 RP1-153G14.4 3.97 0.000109 0.0358 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27494167 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs10452601 ENSG00000271755.1 RP1-153G14.4 3.97 0.000109 0.0358 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27494437 chr6:27404010~27406964:- PAAD cis rs7759001 0.744 rs6650992 ENSG00000271755.1 RP1-153G14.4 3.97 0.000109 0.0358 0.37 0.31 Glomerular filtration rate (creatinine); chr6:27494606 chr6:27404010~27406964:- PAAD cis rs17507216 1 rs17356118 ENSG00000276710.3 CSPG4P8 -3.97 0.000109 0.0358 -0.34 -0.31 Excessive daytime sleepiness; chr15:82569149 chr15:82459472~82477258:+ PAAD cis rs72627509 0.638 rs7658601 ENSG00000269949.1 RP11-738E22.3 3.97 0.000109 0.0358 0.49 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56915181 chr4:56960927~56961373:- PAAD cis rs10129255 0.957 rs10140904 ENSG00000211972.2 IGHV3-66 3.97 0.000109 0.0358 0.27 0.31 Kawasaki disease; chr14:106776558 chr14:106675017~106675544:- PAAD cis rs10740039 0.732 rs10159808 ENSG00000254271.1 RP11-131N11.4 3.97 0.000109 0.0358 0.39 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60602432 chr10:60734342~60741828:+ PAAD cis rs1707322 0.752 rs6662164 ENSG00000280836.1 AL355480.1 -3.97 0.000109 0.0358 -0.35 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45680558 chr1:45581219~45581321:- PAAD cis rs72627509 0.904 rs781663 ENSG00000269949.1 RP11-738E22.3 3.97 0.000109 0.0358 0.49 0.31 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56915588 chr4:56960927~56961373:- PAAD cis rs12682352 0.602 rs28399241 ENSG00000253893.2 FAM85B -3.97 0.000109 0.0358 -0.45 -0.31 Neuroticism; chr8:8805705 chr8:8167819~8226614:- PAAD cis rs7829975 0.582 rs11783950 ENSG00000253893.2 FAM85B 3.97 0.000109 0.0358 0.44 0.31 Mood instability; chr8:8740321 chr8:8167819~8226614:- PAAD cis rs17507216 0.56 rs28493687 ENSG00000278603.1 RP13-608F4.5 3.97 0.000109 0.0358 0.4 0.31 Excessive daytime sleepiness; chr15:82560062 chr15:82472203~82472426:+ PAAD cis rs8012947 0.565 rs12891852 ENSG00000257621.6 PSMA3-AS1 -3.97 0.000109 0.0358 -0.18 -0.31 Alcohol consumption in current drinkers; chr14:58330922 chr14:58265365~58298134:- PAAD cis rs3813579 0.517 rs9928324 ENSG00000261390.4 RP11-345M22.2 3.97 0.000109 0.0358 0.44 0.31 Thyroid volume; chr16:79711089 chr16:79715232~79770563:- PAAD cis rs496547 0.719 rs476246 ENSG00000278376.1 RP11-158I9.8 3.97 0.000109 0.0359 0.28 0.31 Hip minimal joint space width; chr11:118747211 chr11:118791254~118793137:+ PAAD cis rs4809324 0.551 rs2297437 ENSG00000275620.1 FLJ16779 3.97 0.000109 0.0359 0.49 0.31 Glioma (high-grade); chr20:63673921 chr20:63253978~63261615:+ PAAD cis rs2777491 0.874 rs11633799 ENSG00000247556.5 OIP5-AS1 3.97 0.000109 0.0359 0.29 0.31 Ulcerative colitis; chr15:41284340 chr15:41283990~41309737:+ PAAD cis rs804280 1 rs804281 ENSG00000254866.2 DEFB109P3 -3.97 0.000109 0.0359 -0.43 -0.31 Myopia (pathological); chr8:11754356 chr8:12150895~12151134:- PAAD cis rs338389 0.967 rs338395 ENSG00000260657.2 RP11-315D16.4 3.97 0.000109 0.0359 0.31 0.31 Survival in rectal cancer; chr15:67962938 chr15:68267792~68277994:- PAAD cis rs11723261 0.582 rs11732336 ENSG00000275426.1 CH17-262A2.1 3.97 0.00011 0.0359 0.48 0.31 Immune response to smallpox vaccine (IL-6); chr4:146728 chr4:149738~150317:+ PAAD cis rs4266144 0.544 rs6805781 ENSG00000241135.4 LINC00881 -3.97 0.00011 0.0359 -0.39 -0.31 Coronary artery disease; chr3:157112780 chr3:157089881~157101135:+ PAAD cis rs591584 0.73 rs112062277 ENSG00000255893.1 RP11-685N10.1 -3.97 0.00011 0.0359 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94581107 chr11:94472908~94473570:- PAAD cis rs2412819 0.571 rs4923965 ENSG00000249839.1 AC011330.5 3.97 0.00011 0.0359 0.52 0.31 Lung cancer; chr15:43790232 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs6493090 ENSG00000249839.1 AC011330.5 3.97 0.00011 0.0359 0.52 0.31 Lung cancer; chr15:43792084 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs4644832 ENSG00000249839.1 AC011330.5 3.97 0.00011 0.0359 0.52 0.31 Lung cancer; chr15:43792507 chr15:43663654~43684339:- PAAD cis rs7189233 0.911 rs8057808 ENSG00000279722.1 RP11-44F14.6 -3.97 0.00011 0.0359 -0.33 -0.31 Intelligence (multi-trait analysis); chr16:53486701 chr16:53487607~53489943:- PAAD cis rs4713118 0.662 rs149969 ENSG00000204709.4 LINC01556 3.97 0.00011 0.0359 0.5 0.31 Parkinson's disease; chr6:28009959 chr6:28943877~28944537:+ PAAD cis rs11668609 0.506 rs8113480 ENSG00000269397.1 CTB-92J24.2 -3.97 0.00011 0.0359 -0.59 -0.31 Response to taxane treatment (docetaxel); chr19:23878217 chr19:23927788~23929287:+ PAAD cis rs7429990 0.965 rs62260764 ENSG00000228638.1 FCF1P2 -3.97 0.00011 0.0359 -0.37 -0.31 Educational attainment (years of education); chr3:47949010 chr3:48290793~48291375:- PAAD cis rs7429990 0.932 rs7630685 ENSG00000228638.1 FCF1P2 3.97 0.00011 0.0359 0.35 0.31 Educational attainment (years of education); chr3:48089680 chr3:48290793~48291375:- PAAD cis rs79040073 1 rs79040073 ENSG00000259531.2 RP11-295H24.3 3.97 0.00011 0.036 0.49 0.31 Lung cancer in ever smokers; chr15:49038657 chr15:49365124~49366685:- PAAD cis rs13178541 0.638 rs34465140 ENSG00000250378.1 RP11-119J18.1 -3.97 0.00011 0.036 -0.39 -0.31 IgG glycosylation; chr5:135713707 chr5:135812667~135826582:+ PAAD cis rs7927592 0.956 rs12271290 ENSG00000212093.1 AP000807.1 -3.97 0.00011 0.036 -0.36 -0.31 Total body bone mineral density; chr11:68558768 chr11:68506083~68506166:- PAAD cis rs7927592 0.956 rs12277225 ENSG00000212093.1 AP000807.1 3.97 0.00011 0.036 0.36 0.31 Total body bone mineral density; chr11:68573499 chr11:68506083~68506166:- PAAD cis rs7927592 1 rs7927592 ENSG00000212093.1 AP000807.1 3.97 0.00011 0.036 0.36 0.31 Total body bone mineral density; chr11:68602492 chr11:68506083~68506166:- PAAD cis rs7727544 0.507 rs9791170 ENSG00000233006.5 AC034220.3 3.97 0.00011 0.036 0.25 0.31 Blood metabolite levels; chr5:132233934 chr5:132311285~132369916:- PAAD cis rs4925386 1 rs6121990 ENSG00000273619.1 RP5-908M14.9 3.97 0.00011 0.036 0.26 0.31 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62344207 chr20:62386303~62386970:- PAAD cis rs11690935 0.632 rs9789538 ENSG00000228389.1 AC068039.4 -3.97 0.00011 0.036 -0.38 -0.31 Schizophrenia; chr2:171761964 chr2:171773482~171775844:+ PAAD cis rs950169 0.763 rs35372971 ENSG00000275120.1 RP11-182J1.17 3.97 0.00011 0.036 0.32 0.31 Schizophrenia; chr15:84387097 chr15:84599434~84606463:- PAAD cis rs11159086 1 rs4903233 ENSG00000259005.1 RP3-449M8.6 3.97 0.00011 0.036 0.41 0.31 Advanced glycation end-product levels; chr14:74497291 chr14:74474007~74474864:- PAAD cis rs875971 0.522 rs1617484 ENSG00000237310.1 GS1-124K5.4 3.97 0.00011 0.036 0.29 0.31 Aortic root size; chr7:65998108 chr7:66493706~66495474:+ PAAD cis rs2243480 1 rs958550 ENSG00000273142.1 RP11-458F8.4 3.97 0.00011 0.036 0.28 0.31 Diabetic kidney disease; chr7:66170692 chr7:66902857~66906297:+ PAAD cis rs10083777 0.551 rs111889995 ENSG00000261061.1 RP11-303E16.2 -3.97 0.00011 0.036 -0.63 -0.31 Metabolite levels (small molecules and protein measures); chr16:81000166 chr16:81030770~81031485:+ PAAD cis rs17360053 0.519 rs1014985 ENSG00000218510.5 LINC00339 -3.97 0.00011 0.036 -0.36 -0.31 Obesity-related traits; chr1:22172762 chr1:22025188~22031223:+ PAAD cis rs2742234 0.541 rs11238490 ENSG00000273008.1 RP11-351D16.3 3.97 0.00011 0.036 0.3 0.31 Hirschsprung disease; chr10:43252150 chr10:43136824~43138334:- PAAD cis rs7103648 0.669 rs12577383 ENSG00000252874.2 Y_RNA -3.97 0.00011 0.036 -0.39 -0.31 Systolic blood pressure;Diastolic blood pressure; chr11:47752686 chr11:47820200~47820289:- PAAD cis rs7103648 0.669 rs7927445 ENSG00000252874.2 Y_RNA -3.97 0.00011 0.036 -0.39 -0.31 Systolic blood pressure;Diastolic blood pressure; chr11:47759202 chr11:47820200~47820289:- PAAD cis rs7103648 0.695 rs12223593 ENSG00000252874.2 Y_RNA -3.97 0.00011 0.036 -0.39 -0.31 Systolic blood pressure;Diastolic blood pressure; chr11:47767530 chr11:47820200~47820289:- PAAD cis rs7103648 0.669 rs7114011 ENSG00000252874.2 Y_RNA -3.97 0.00011 0.036 -0.39 -0.31 Systolic blood pressure;Diastolic blood pressure; chr11:47789757 chr11:47820200~47820289:- PAAD cis rs12999616 0.571 rs35263587 ENSG00000228486.8 LINC01125 -3.97 0.00011 0.0361 -0.27 -0.31 Colorectal cancer; chr2:97890443 chr2:97664217~97703064:+ PAAD cis rs7202877 0.61 rs8053632 ENSG00000261783.1 RP11-252K23.2 -3.97 0.00011 0.0361 -0.47 -0.31 Type 1 diabetes;Type 2 diabetes; chr16:75331042 chr16:75379818~75381260:- PAAD cis rs72802342 0.51 rs12932952 ENSG00000261783.1 RP11-252K23.2 -3.97 0.00011 0.0361 -0.47 -0.31 Advanced age-related macular degeneration; chr16:75331588 chr16:75379818~75381260:- PAAD cis rs6545883 0.507 rs59981505 ENSG00000273302.1 RP11-493E12.2 -3.97 0.00011 0.0361 -0.27 -0.31 Tuberculosis; chr2:61353394 chr2:61199979~61200769:+ PAAD cis rs10779751 0.77 rs11581010 ENSG00000238199.1 UBE2V2P3 3.97 0.00011 0.0361 0.4 0.31 Body mass index; chr1:11152401 chr1:11278616~11279351:- PAAD cis rs3790645 0.958 rs2290589 ENSG00000225159.1 NPM1P39 3.97 0.00011 0.0361 0.4 0.31 Glucose homeostasis traits; chr1:26553797 chr1:27206930~27207796:+ PAAD cis rs3790645 0.831 rs873151 ENSG00000225159.1 NPM1P39 3.97 0.00011 0.0361 0.4 0.31 Glucose homeostasis traits; chr1:26554498 chr1:27206930~27207796:+ PAAD cis rs76963786 0.515 rs1150982 ENSG00000223722.3 RP11-467L13.5 3.97 0.00011 0.0361 0.49 0.31 Interleukin-9 levels; chr12:31907406 chr12:31754720~31755121:+ PAAD cis rs9322193 0.962 rs9478848 ENSG00000268592.3 RAET1E-AS1 3.97 0.00011 0.0361 0.36 0.31 Lung cancer; chr6:149825080 chr6:149863494~149919507:+ PAAD cis rs5758511 0.68 rs5758698 ENSG00000226450.2 CYP2D8P 3.97 0.00011 0.0361 0.3 0.31 Birth weight; chr22:42288812 chr22:42149886~42155001:- PAAD cis rs2894969 0.664 rs10904335 ENSG00000225269.2 LINC00705 3.97 0.000111 0.0361 0.31 0.31 Major depressive disorder; chr10:4759968 chr10:4655427~4662419:+ PAAD cis rs7615952 0.673 rs34209763 ENSG00000239804.1 RP11-379B18.1 3.97 0.000111 0.0361 0.53 0.31 Blood pressure (smoking interaction); chr3:125880752 chr3:125787888~125788146:- PAAD cis rs7615952 0.611 rs35321002 ENSG00000239804.1 RP11-379B18.1 3.97 0.000111 0.0361 0.53 0.31 Blood pressure (smoking interaction); chr3:125893222 chr3:125787888~125788146:- PAAD cis rs303386 0.689 rs303391 ENSG00000223656.1 HMGB3P10 3.97 0.000111 0.0362 0.4 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin); chr1:99127031 chr1:99698242~99699178:+ PAAD cis rs303386 0.639 rs302746 ENSG00000223656.1 HMGB3P10 3.97 0.000111 0.0362 0.4 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin); chr1:99131344 chr1:99698242~99699178:+ PAAD cis rs303386 0.681 rs302747 ENSG00000223656.1 HMGB3P10 3.97 0.000111 0.0362 0.4 0.31 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin); chr1:99131607 chr1:99698242~99699178:+ PAAD cis rs7539624 0.577 rs1153950 ENSG00000272645.2 RP11-504P24.8 -3.97 0.000111 0.0362 -0.26 -0.31 Schizophrenia; chr1:223772094 chr1:223951388~223953439:- PAAD cis rs950169 0.58 rs11634320 ENSG00000259295.5 CSPG4P12 -3.97 0.000111 0.0362 -0.34 -0.31 Schizophrenia; chr15:84628952 chr15:85191438~85213905:+ PAAD cis rs792448 0.743 rs351398 ENSG00000229983.1 RP11-15I11.2 3.97 0.000111 0.0362 0.36 0.31 White blood cell count (basophil); chr1:212292897 chr1:212168207~212190259:+ PAAD cis rs8005677 1 rs1956880 ENSG00000279656.1 RP11-298I3.6 3.97 0.000111 0.0362 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22924798 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs1956881 ENSG00000279656.1 RP11-298I3.6 3.97 0.000111 0.0362 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22924860 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs8006409 ENSG00000279656.1 RP11-298I3.6 3.97 0.000111 0.0362 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22927302 chr14:23023083~23024217:- PAAD cis rs8005677 0.962 rs10130756 ENSG00000279656.1 RP11-298I3.6 3.97 0.000111 0.0362 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22927391 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs2295685 ENSG00000279656.1 RP11-298I3.6 3.97 0.000111 0.0362 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22928944 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs4982710 ENSG00000279656.1 RP11-298I3.6 3.97 0.000111 0.0362 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22929693 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs7145494 ENSG00000279656.1 RP11-298I3.6 3.97 0.000111 0.0362 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22930581 chr14:23023083~23024217:- PAAD cis rs8005677 1 rs7155857 ENSG00000279656.1 RP11-298I3.6 3.97 0.000111 0.0362 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22930850 chr14:23023083~23024217:- PAAD cis rs6991838 0.806 rs35284121 ENSG00000200714.1 Y_RNA 3.97 0.000111 0.0362 0.36 0.31 Intelligence (multi-trait analysis); chr8:65551230 chr8:65592731~65592820:+ PAAD cis rs6991838 0.751 rs35553155 ENSG00000200714.1 Y_RNA 3.97 0.000111 0.0362 0.36 0.31 Intelligence (multi-trait analysis); chr8:65551232 chr8:65592731~65592820:+ PAAD cis rs6991838 0.806 rs35024820 ENSG00000200714.1 Y_RNA 3.97 0.000111 0.0362 0.36 0.31 Intelligence (multi-trait analysis); chr8:65551296 chr8:65592731~65592820:+ PAAD cis rs28374715 0.635 rs8023530 ENSG00000247556.5 OIP5-AS1 3.97 0.000111 0.0362 0.31 0.31 Ulcerative colitis; chr15:41355577 chr15:41283990~41309737:+ PAAD cis rs28374715 0.681 rs28728213 ENSG00000247556.5 OIP5-AS1 3.97 0.000111 0.0362 0.31 0.31 Ulcerative colitis; chr15:41361404 chr15:41283990~41309737:+ PAAD cis rs28374715 0.635 rs28557159 ENSG00000247556.5 OIP5-AS1 3.97 0.000111 0.0362 0.31 0.31 Ulcerative colitis; chr15:41365155 chr15:41283990~41309737:+ PAAD cis rs28374715 0.662 rs513280 ENSG00000247556.5 OIP5-AS1 -3.97 0.000111 0.0362 -0.32 -0.31 Ulcerative colitis; chr15:41190602 chr15:41283990~41309737:+ PAAD cis rs4660214 0.724 rs10788933 ENSG00000237624.1 OXCT2P1 -3.97 0.000111 0.0362 -0.4 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39229483 chr1:39514956~39516490:+ PAAD cis rs10483853 0.54 rs2108552 ENSG00000258695.2 RP3-414A15.2 -3.97 0.000111 0.0362 -0.44 -0.31 Coronary artery calcification; chr14:73410218 chr14:73522878~73530610:+ PAAD cis rs763121 0.853 rs8142098 ENSG00000228274.3 RP3-508I15.9 -3.97 0.000111 0.0362 -0.3 -0.31 Menopause (age at onset); chr22:38662752 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2413544 ENSG00000228274.3 RP3-508I15.9 -3.97 0.000111 0.0362 -0.3 -0.31 Menopause (age at onset); chr22:38663399 chr22:38667585~38681820:- PAAD cis rs763121 0.752 rs5757222 ENSG00000228274.3 RP3-508I15.9 -3.97 0.000111 0.0362 -0.3 -0.31 Menopause (age at onset); chr22:38664468 chr22:38667585~38681820:- PAAD cis rs763121 0.819 rs5750658 ENSG00000228274.3 RP3-508I15.9 -3.97 0.000111 0.0362 -0.3 -0.31 Menopause (age at onset); chr22:38664912 chr22:38667585~38681820:- PAAD cis rs763121 0.819 rs8137829 ENSG00000228274.3 RP3-508I15.9 -3.97 0.000111 0.0362 -0.3 -0.31 Menopause (age at onset); chr22:38665025 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs6001188 ENSG00000228274.3 RP3-508I15.9 -3.97 0.000111 0.0362 -0.3 -0.31 Menopause (age at onset); chr22:38666189 chr22:38667585~38681820:- PAAD cis rs9487094 0.813 rs3799840 ENSG00000260273.1 RP11-425D10.10 3.97 0.000111 0.0362 0.42 0.31 Height; chr6:109381443 chr6:109382795~109383666:+ PAAD cis rs9487094 0.744 rs2275652 ENSG00000260273.1 RP11-425D10.10 3.97 0.000111 0.0362 0.42 0.31 Height; chr6:109382480 chr6:109382795~109383666:+ PAAD cis rs9487094 0.744 rs13199519 ENSG00000260273.1 RP11-425D10.10 3.97 0.000111 0.0362 0.42 0.31 Height; chr6:109387972 chr6:109382795~109383666:+ PAAD cis rs9322193 0.884 rs62439837 ENSG00000268592.3 RAET1E-AS1 3.97 0.000111 0.0362 0.36 0.31 Lung cancer; chr6:149670380 chr6:149863494~149919507:+ PAAD cis rs12474201 0.588 rs3768719 ENSG00000234690.5 AC073283.4 3.97 0.000111 0.0362 0.33 0.31 Height; chr2:46760796 chr2:47192405~47345074:- PAAD cis rs4453827 0.625 rs3774573 ENSG00000271916.1 RP11-884K10.6 3.97 0.000111 0.0362 0.3 0.31 Blood protein levels; chr3:53765933 chr3:53797764~53798019:- PAAD cis rs12480328 1 rs76685994 ENSG00000203999.7 LINC01270 3.97 0.000111 0.0362 0.68 0.31 Prostate cancer; chr20:50947674 chr20:50292720~50314922:+ PAAD cis rs12480328 1 rs73909848 ENSG00000203999.7 LINC01270 3.97 0.000111 0.0362 0.68 0.31 Prostate cancer; chr20:50953866 chr20:50292720~50314922:+ PAAD cis rs1838105 0.714 rs2317376 ENSG00000262539.1 RP11-259G18.3 3.97 0.000111 0.0362 0.44 0.31 Nonsyndromic cleft lip with cleft palate; chr17:47093682 chr17:46259551~46260606:- PAAD cis rs9531006 0.772 rs9545268 ENSG00000227676.3 LINC01068 -3.97 0.000111 0.0362 -0.45 -0.31 Sleep duration; chr13:79927860 chr13:79566727~79571436:+ PAAD cis rs3015497 0.789 rs2356457 ENSG00000270062.1 RP11-248J18.3 3.97 0.000111 0.0362 0.28 0.31 Mean platelet volume; chr14:50650145 chr14:50723777~50724272:- PAAD cis rs56145559 1 rs56145559 ENSG00000163016.8 ALMS1P 3.97 0.000111 0.0362 0.43 0.31 Schizophrenia; chr2:73396311 chr2:73644919~73685576:+ PAAD cis rs2412819 0.571 rs2729494 ENSG00000249839.1 AC011330.5 3.97 0.000111 0.0362 0.47 0.31 Lung cancer; chr15:43837395 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs528764 ENSG00000249839.1 AC011330.5 3.97 0.000111 0.0362 0.47 0.31 Lung cancer; chr15:43838650 chr15:43663654~43684339:- PAAD cis rs2412819 0.571 rs495880 ENSG00000249839.1 AC011330.5 3.97 0.000111 0.0362 0.47 0.31 Lung cancer; chr15:43855067 chr15:43663654~43684339:- PAAD cis rs6479891 1 rs10437345 ENSG00000232075.1 MRPL35P2 -3.97 0.000111 0.0362 -0.49 -0.31 Arthritis (juvenile idiopathic); chr10:63443186 chr10:63634317~63634827:- PAAD cis rs6479891 0.908 rs7078456 ENSG00000232075.1 MRPL35P2 -3.97 0.000111 0.0362 -0.49 -0.31 Arthritis (juvenile idiopathic); chr10:63509719 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs7087279 ENSG00000232075.1 MRPL35P2 -3.97 0.000111 0.0362 -0.49 -0.31 Arthritis (juvenile idiopathic); chr10:63532176 chr10:63634317~63634827:- PAAD cis rs4660214 0.666 rs10888682 ENSG00000237624.1 OXCT2P1 -3.97 0.000111 0.0363 -0.39 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39157635 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs11205698 ENSG00000237624.1 OXCT2P1 -3.97 0.000111 0.0363 -0.39 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39158708 chr1:39514956~39516490:+ PAAD cis rs755249 0.508 rs6703800 ENSG00000237624.1 OXCT2P1 -3.97 0.000111 0.0363 -0.39 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39160970 chr1:39514956~39516490:+ PAAD cis rs4660214 0.724 rs12117785 ENSG00000237624.1 OXCT2P1 -3.97 0.000111 0.0363 -0.39 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39162739 chr1:39514956~39516490:+ PAAD cis rs6570726 0.811 rs375873 ENSG00000235652.6 RP11-545I5.3 3.97 0.000111 0.0363 0.25 0.31 Lobe attachment (rater-scored or self-reported); chr6:145491235 chr6:145799409~145886585:+ PAAD cis rs6570726 0.875 rs368744 ENSG00000235652.6 RP11-545I5.3 3.97 0.000111 0.0363 0.25 0.31 Lobe attachment (rater-scored or self-reported); chr6:145491486 chr6:145799409~145886585:+ PAAD cis rs9925964 0.9 rs56813533 ENSG00000232748.3 RP11-196G11.6 3.97 0.000111 0.0363 0.37 0.31 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31059160 chr16:31056460~31062803:+ PAAD cis rs9925964 0.933 rs2303223 ENSG00000232748.3 RP11-196G11.6 3.97 0.000111 0.0363 0.37 0.31 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31063854 chr16:31056460~31062803:+ PAAD cis rs9925964 0.933 rs881929 ENSG00000232748.3 RP11-196G11.6 3.97 0.000111 0.0363 0.37 0.31 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31068050 chr16:31056460~31062803:+ PAAD cis rs7224610 0.932 rs10852974 ENSG00000263096.1 RP11-515O17.2 3.97 0.000111 0.0363 0.38 0.31 Urate levels; chr17:55295205 chr17:55271504~55273653:- PAAD cis rs2806561 0.704 rs674386 ENSG00000215381.3 RP5-1057J7.1 3.97 0.000111 0.0363 0.4 0.31 Height; chr1:23195342 chr1:23244765~23245224:+ PAAD cis rs2806561 0.704 rs663942 ENSG00000215381.3 RP5-1057J7.1 3.97 0.000111 0.0363 0.4 0.31 Height; chr1:23195983 chr1:23244765~23245224:+ PAAD cis rs2806561 0.704 rs664301 ENSG00000215381.3 RP5-1057J7.1 3.97 0.000111 0.0363 0.4 0.31 Height; chr1:23196029 chr1:23244765~23245224:+ PAAD cis rs2806561 0.704 rs636940 ENSG00000215381.3 RP5-1057J7.1 3.97 0.000111 0.0363 0.4 0.31 Height; chr1:23196474 chr1:23244765~23245224:+ PAAD cis rs2806561 0.704 rs588387 ENSG00000215381.3 RP5-1057J7.1 3.97 0.000111 0.0363 0.4 0.31 Height; chr1:23197196 chr1:23244765~23245224:+ PAAD cis rs2806561 0.704 rs856510 ENSG00000215381.3 RP5-1057J7.1 3.97 0.000111 0.0363 0.4 0.31 Height; chr1:23197914 chr1:23244765~23245224:+ PAAD cis rs2806561 0.704 rs2746560 ENSG00000215381.3 RP5-1057J7.1 3.97 0.000111 0.0363 0.4 0.31 Height; chr1:23199786 chr1:23244765~23245224:+ PAAD cis rs896655 0.738 rs4615669 ENSG00000266446.1 RP11-149I2.4 -3.97 0.000111 0.0363 -0.39 -0.31 Coronary artery disease; chr9:21818675 chr9:21995482~21996013:+ PAAD cis rs13178541 0.593 rs6862956 ENSG00000250378.1 RP11-119J18.1 -3.97 0.000111 0.0363 -0.39 -0.31 IgG glycosylation; chr5:135706119 chr5:135812667~135826582:+ PAAD cis rs13178541 0.593 rs6860305 ENSG00000250378.1 RP11-119J18.1 -3.97 0.000111 0.0363 -0.39 -0.31 IgG glycosylation; chr5:135710654 chr5:135812667~135826582:+ PAAD cis rs13178541 0.593 rs5027775 ENSG00000250378.1 RP11-119J18.1 -3.97 0.000111 0.0363 -0.39 -0.31 IgG glycosylation; chr5:135710995 chr5:135812667~135826582:+ PAAD cis rs950169 0.58 rs11630887 ENSG00000259295.5 CSPG4P12 3.97 0.000111 0.0363 0.34 0.31 Schizophrenia; chr15:84649784 chr15:85191438~85213905:+ PAAD cis rs6545883 0.524 rs2463101 ENSG00000271889.1 RP11-493E12.1 -3.97 0.000111 0.0363 -0.33 -0.31 Tuberculosis; chr2:61347287 chr2:61151433~61162105:- PAAD cis rs287982 0.932 rs9973577 ENSG00000269973.1 RP11-95D17.1 -3.97 0.000111 0.0363 -0.37 -0.31 Nonsyndromic cleft lip with cleft palate; chr2:9820574 chr2:9936360~9939590:+ PAAD cis rs10483853 0.806 rs10135747 ENSG00000258695.2 RP3-414A15.2 -3.97 0.000111 0.0363 -0.4 -0.31 Coronary artery calcification; chr14:73422744 chr14:73522878~73530610:+ PAAD cis rs10483853 0.767 rs60274183 ENSG00000258695.2 RP3-414A15.2 -3.97 0.000111 0.0363 -0.4 -0.31 Coronary artery calcification; chr14:73445698 chr14:73522878~73530610:+ PAAD cis rs3738443 0.817 rs61840053 ENSG00000259865.1 RP11-488L18.10 3.97 0.000111 0.0363 0.27 0.31 Alcohol dependence; chr1:247204038 chr1:247187281~247188526:- PAAD cis rs189798 0.592 rs10111263 ENSG00000254340.1 RP11-10A14.3 -3.97 0.000111 0.0364 -0.38 -0.31 Myopia (pathological); chr8:9111923 chr8:9141424~9145435:+ PAAD cis rs2736345 1 rs922483 ENSG00000251402.3 FAM90A25P 3.97 0.000112 0.0364 0.37 0.31 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11494403 chr8:12415080~12418090:- PAAD cis rs13256369 0.951 rs13260947 ENSG00000253981.4 ALG1L13P 3.97 0.000112 0.0364 0.41 0.31 Obesity-related traits; chr8:8708373 chr8:8236003~8244667:- PAAD cis rs13256369 0.951 rs13259955 ENSG00000253981.4 ALG1L13P 3.97 0.000112 0.0364 0.41 0.31 Obesity-related traits; chr8:8708375 chr8:8236003~8244667:- PAAD cis rs13256369 0.901 rs12679831 ENSG00000253981.4 ALG1L13P 3.97 0.000112 0.0364 0.41 0.31 Obesity-related traits; chr8:8708901 chr8:8236003~8244667:- PAAD cis rs13256369 0.901 rs12681327 ENSG00000253981.4 ALG1L13P 3.97 0.000112 0.0364 0.41 0.31 Obesity-related traits; chr8:8708904 chr8:8236003~8244667:- PAAD cis rs13256369 0.951 rs13270852 ENSG00000253981.4 ALG1L13P 3.97 0.000112 0.0364 0.41 0.31 Obesity-related traits; chr8:8709343 chr8:8236003~8244667:- PAAD cis rs13256369 0.851 rs13271698 ENSG00000253981.4 ALG1L13P 3.97 0.000112 0.0364 0.41 0.31 Obesity-related traits; chr8:8710029 chr8:8236003~8244667:- PAAD cis rs13256369 1 rs12550458 ENSG00000253981.4 ALG1L13P 3.97 0.000112 0.0364 0.41 0.31 Obesity-related traits; chr8:8710322 chr8:8236003~8244667:- PAAD cis rs13256369 1 rs12545771 ENSG00000253981.4 ALG1L13P 3.97 0.000112 0.0364 0.41 0.31 Obesity-related traits; chr8:8710467 chr8:8236003~8244667:- PAAD cis rs7820074 0.751 rs1995678 ENSG00000253334.1 RP13-923O23.6 3.97 0.000112 0.0364 0.36 0.31 Orofacial clefts; chr8:82041730 chr8:81791823~81815714:+ PAAD cis rs7911264 0.967 rs9419741 ENSG00000236493.2 EIF2S2P3 -3.97 0.000112 0.0364 -0.38 -0.31 Inflammatory bowel disease; chr10:92670768 chr10:92668745~92669743:- PAAD cis rs10411161 1 rs8111316 ENSG00000269483.1 AC006272.1 3.97 0.000112 0.0364 0.54 0.31 Breast cancer; chr19:51865816 chr19:51839924~51843324:- PAAD cis rs10411161 1 rs10402727 ENSG00000269483.1 AC006272.1 3.97 0.000112 0.0364 0.54 0.31 Breast cancer; chr19:51867126 chr19:51839924~51843324:- PAAD cis rs10411161 1 rs10409331 ENSG00000269483.1 AC006272.1 3.97 0.000112 0.0364 0.54 0.31 Breast cancer; chr19:51867709 chr19:51839924~51843324:- PAAD cis rs9595908 0.965 rs9591180 ENSG00000212293.1 SNORA16 3.97 0.000112 0.0364 0.35 0.31 Body mass index; chr13:32622864 chr13:32420390~32420516:- PAAD cis rs31872 1 rs31872 ENSG00000273557.1 CTD-2024I7.18 -3.97 0.000112 0.0364 -0.43 -0.31 Visceral adipose tissue adjusted for BMI; chr5:140992637 chr5:141468465~141471528:+ PAAD cis rs10506328 0.689 rs4759348 ENSG00000248576.1 RP11-834C11.8 3.97 0.000112 0.0364 0.42 0.31 Mean platelet volume; chr12:54236733 chr12:54163139~54168595:+ PAAD cis rs28374715 0.681 rs7165396 ENSG00000247556.5 OIP5-AS1 3.97 0.000112 0.0364 0.33 0.31 Ulcerative colitis; chr15:41294749 chr15:41283990~41309737:+ PAAD cis rs755249 0.567 rs4660543 ENSG00000261798.1 RP1-118J21.25 3.97 0.000112 0.0364 0.39 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39213318 chr1:39788976~39790171:+ PAAD cis rs9595908 0.827 rs9595885 ENSG00000212293.1 SNORA16 3.97 0.000112 0.0364 0.35 0.31 Body mass index; chr13:32593913 chr13:32420390~32420516:- PAAD cis rs613391 0.561 rs589423 ENSG00000224549.1 RP11-370B11.3 -3.97 0.000112 0.0365 -0.37 -0.31 Quantitative traits; chr9:22721049 chr9:22767175~22768316:+ PAAD cis rs3015497 0.789 rs11621971 ENSG00000270062.1 RP11-248J18.3 -3.97 0.000112 0.0365 -0.29 -0.31 Mean platelet volume; chr14:50657809 chr14:50723777~50724272:- PAAD cis rs683250 0.599 rs11233585 ENSG00000227097.5 RPS28P7 3.97 0.000112 0.0365 0.39 0.31 Subcortical brain region volumes; chr11:83365128 chr11:82689559~82689768:+ PAAD cis rs7246657 0.551 rs12972146 ENSG00000267422.1 CTD-2554C21.1 -3.97 0.000112 0.0365 -0.58 -0.31 Coronary artery calcification; chr19:37135193 chr19:37779686~37792865:+ PAAD cis rs11096990 0.613 rs12505690 ENSG00000249685.1 RP11-360F5.3 3.97 0.000112 0.0365 0.31 0.31 Cognitive function; chr4:39167425 chr4:39133913~39135608:+ PAAD cis rs9925964 0.933 rs8050894 ENSG00000232748.3 RP11-196G11.6 3.97 0.000112 0.0365 0.36 0.31 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31093188 chr16:31056460~31062803:+ PAAD cis rs8005677 1 rs11157930 ENSG00000279656.1 RP11-298I3.6 3.97 0.000112 0.0365 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22933962 chr14:23023083~23024217:- PAAD cis rs8005677 0.962 rs11157931 ENSG00000279656.1 RP11-298I3.6 3.97 0.000112 0.0365 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22933984 chr14:23023083~23024217:- PAAD cis rs12908161 0.853 rs12912342 ENSG00000225151.9 GOLGA2P7 -3.97 0.000112 0.0365 -0.36 -0.31 Schizophrenia; chr15:84704985 chr15:84199311~84230136:- PAAD cis rs6504249 0.893 rs2521827 ENSG00000270714.1 MINOS1P2 -3.97 0.000112 0.0365 -0.41 -0.31 Joint mobility (Beighton score); chr17:64696610 chr17:64747264~64747492:- PAAD cis rs1832007 0.529 rs4612705 ENSG00000224034.1 RP11-445P17.8 -3.97 0.000112 0.0365 -0.46 -0.31 Triglyceride levels;Triglycerides; chr10:5201635 chr10:5266033~5271236:- PAAD cis rs2403083 0.505 rs11261469 ENSG00000258256.1 RP11-219B4.5 -3.97 0.000112 0.0365 -0.34 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85277470 chr8:85222446~85245717:- PAAD cis rs2243480 0.803 rs55700941 ENSG00000228409.4 CCT6P1 3.97 0.000112 0.0365 0.33 0.31 Diabetic kidney disease; chr7:65924813 chr7:65751142~65763354:+ PAAD cis rs12291225 0.585 rs4757250 ENSG00000251991.1 RNU7-49P 3.97 0.000112 0.0365 0.36 0.31 Sense of smell; chr11:14354137 chr11:14478892~14478953:+ PAAD cis rs6570726 0.905 rs442435 ENSG00000235652.6 RP11-545I5.3 3.97 0.000112 0.0365 0.25 0.31 Lobe attachment (rater-scored or self-reported); chr6:145494423 chr6:145799409~145886585:+ PAAD cis rs6570726 0.905 rs396492 ENSG00000235652.6 RP11-545I5.3 3.97 0.000112 0.0365 0.25 0.31 Lobe attachment (rater-scored or self-reported); chr6:145495044 chr6:145799409~145886585:+ PAAD cis rs748404 0.626 rs62021176 ENSG00000249839.1 AC011330.5 -3.97 0.000112 0.0365 -0.52 -0.31 Lung cancer; chr15:43388014 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs35158584 ENSG00000249839.1 AC011330.5 -3.97 0.000112 0.0365 -0.52 -0.31 Lung cancer; chr15:43392876 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs7180812 ENSG00000249839.1 AC011330.5 -3.97 0.000112 0.0365 -0.52 -0.31 Lung cancer; chr15:43403033 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs12908460 ENSG00000249839.1 AC011330.5 -3.97 0.000112 0.0365 -0.52 -0.31 Lung cancer; chr15:43413472 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs2230451 ENSG00000249839.1 AC011330.5 -3.97 0.000112 0.0365 -0.52 -0.31 Lung cancer; chr15:43415610 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs16957715 ENSG00000249839.1 AC011330.5 -3.97 0.000112 0.0365 -0.52 -0.31 Lung cancer; chr15:43416539 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs62021180 ENSG00000249839.1 AC011330.5 -3.97 0.000112 0.0365 -0.52 -0.31 Lung cancer; chr15:43420139 chr15:43663654~43684339:- PAAD cis rs10750441 0.571 rs1627019 ENSG00000255455.2 RP11-890B15.3 3.97 0.000112 0.0365 0.28 0.31 Pulse pressure; chr11:130558215 chr11:130866254~130870247:- PAAD cis rs9847710 0.696 rs2581822 ENSG00000242142.1 SERBP1P3 3.97 0.000112 0.0365 0.37 0.31 Ulcerative colitis; chr3:52987733 chr3:53064283~53065091:- PAAD cis rs9847710 0.67 rs2564933 ENSG00000242142.1 SERBP1P3 3.97 0.000112 0.0365 0.37 0.31 Ulcerative colitis; chr3:52989357 chr3:53064283~53065091:- PAAD cis rs2179367 0.959 rs544947 ENSG00000231760.4 RP11-350J20.5 3.97 0.000112 0.0365 0.39 0.31 Dupuytren's disease; chr6:149402412 chr6:149796151~149826294:- PAAD cis rs9649213 0.574 rs7790229 ENSG00000272950.1 RP11-307C18.1 3.97 0.000112 0.0365 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98290026 chr7:98322853~98323430:+ PAAD cis rs2337406 1 rs11161002 ENSG00000211974.3 IGHV2-70 -3.97 0.000112 0.0366 -0.42 -0.31 Alzheimer's disease (late onset); chr14:106702202 chr14:106723574~106724093:- PAAD cis rs79040073 0.911 rs17393193 ENSG00000259531.2 RP11-295H24.3 3.97 0.000112 0.0366 0.46 0.31 Lung cancer in ever smokers; chr15:49039882 chr15:49365124~49366685:- PAAD cis rs4835473 0.838 rs12507468 ENSG00000251600.4 RP11-673E1.1 -3.97 0.000112 0.0366 -0.36 -0.31 Immature fraction of reticulocytes; chr4:143908061 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs4054616 ENSG00000251600.4 RP11-673E1.1 3.97 0.000112 0.0366 0.36 0.31 Immature fraction of reticulocytes; chr4:143837472 chr4:143912331~143982454:+ PAAD cis rs4835473 0.897 rs2323325 ENSG00000251600.4 RP11-673E1.1 3.97 0.000112 0.0366 0.36 0.31 Immature fraction of reticulocytes; chr4:143837561 chr4:143912331~143982454:+ PAAD cis rs633715 0.959 rs6670873 ENSG00000254154.7 RP4-798P15.3 -3.97 0.000112 0.0366 -0.28 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177872550 chr1:177928788~178038007:- PAAD cis rs10740039 0.842 rs1442541 ENSG00000254271.1 RP11-131N11.4 3.97 0.000113 0.0366 0.37 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60626285 chr10:60734342~60741828:+ PAAD cis rs10740039 0.883 rs1867081 ENSG00000254271.1 RP11-131N11.4 3.97 0.000113 0.0366 0.37 0.31 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60626569 chr10:60734342~60741828:+ PAAD cis rs11676348 0.783 rs13035513 ENSG00000261338.2 RP11-378A13.1 -3.97 0.000113 0.0366 -0.35 -0.31 Ulcerative colitis; chr2:218095957 chr2:218255319~218257366:+ PAAD cis rs7216064 1 rs2052187 ENSG00000278219.1 AC145343.1 -3.97 0.000113 0.0366 -0.48 -0.31 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67838621 chr17:68101538~68101639:+ PAAD cis rs1411478 1 rs1044595 ENSG00000243155.1 RP11-46A10.5 -3.96 0.000113 0.0367 -0.32 -0.31 Menopause (age at onset);Progressive supranuclear palsy; chr1:180974393 chr1:180944042~180976482:- PAAD cis rs2638953 0.85 rs10843167 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28429860 chr12:28163298~28190738:- PAAD cis rs2638953 0.886 rs10843168 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28430038 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs10843170 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28430118 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049600 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28439061 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs11049604 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28443092 chr12:28163298~28190738:- PAAD cis rs2638953 0.711 rs11049605 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28443132 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs9669509 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28443507 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049608 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28445528 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049609 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28445732 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049612 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28449160 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049613 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28449859 chr12:28163298~28190738:- PAAD cis rs2638953 0.886 rs11049617 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28453344 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049618 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28453371 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs60703205 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28454371 chr12:28163298~28190738:- PAAD cis rs2638953 0.85 rs59879751 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28454490 chr12:28163298~28190738:- PAAD cis rs2638953 0.814 rs60960895 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28454499 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs59193275 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000113 0.0367 -0.34 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28454560 chr12:28163298~28190738:- PAAD cis rs58873874 0.737 rs11739062 ENSG00000248544.2 CTB-47B11.3 3.96 0.000113 0.0367 0.66 0.31 Bipolar disorder (body mass index interaction); chr5:157474693 chr5:157375741~157384950:- PAAD cis rs2929278 0.617 rs663214 ENSG00000275601.1 AC011330.13 3.96 0.000113 0.0367 0.34 0.31 Schizophrenia; chr15:43821584 chr15:43642389~43643023:- PAAD cis rs2739330 0.734 rs2000467 ENSG00000206090.4 AP000350.7 -3.96 0.000113 0.0367 -0.41 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23939998~23942798:+ PAAD cis rs7911264 0.739 rs10786050 ENSG00000236493.2 EIF2S2P3 3.96 0.000113 0.0367 0.39 0.31 Inflammatory bowel disease; chr10:92607473 chr10:92668745~92669743:- PAAD cis rs11992162 0.636 rs35995176 ENSG00000254866.2 DEFB109P3 3.96 0.000113 0.0367 0.41 0.31 Monocyte count; chr8:11952138 chr8:12150895~12151134:- PAAD cis rs3015497 0.616 rs11157759 ENSG00000270062.1 RP11-248J18.3 3.96 0.000113 0.0367 0.3 0.31 Mean platelet volume; chr14:50620545 chr14:50723777~50724272:- PAAD cis rs7829975 0.56 rs56094035 ENSG00000253893.2 FAM85B 3.96 0.000113 0.0367 0.45 0.31 Mood instability; chr8:8694112 chr8:8167819~8226614:- PAAD cis rs7829975 0.539 rs4841012 ENSG00000253893.2 FAM85B 3.96 0.000113 0.0367 0.45 0.31 Mood instability; chr8:8694200 chr8:8167819~8226614:- PAAD cis rs7829975 0.56 rs4841013 ENSG00000253893.2 FAM85B 3.96 0.000113 0.0367 0.45 0.31 Mood instability; chr8:8694503 chr8:8167819~8226614:- PAAD cis rs7626444 0.565 rs7613010 ENSG00000272359.1 U4 -3.96 0.000113 0.0367 -0.34 -0.31 Monocyte count; chr3:196763350 chr3:196747192~196747324:- PAAD cis rs7626444 0.605 rs7642801 ENSG00000272359.1 U4 -3.96 0.000113 0.0367 -0.34 -0.31 Monocyte count; chr3:196763435 chr3:196747192~196747324:- PAAD cis rs7626444 0.584 rs7633044 ENSG00000272359.1 U4 -3.96 0.000113 0.0367 -0.34 -0.31 Monocyte count; chr3:196763772 chr3:196747192~196747324:- PAAD cis rs2188561 1 rs2188561 ENSG00000241764.3 AC002467.7 3.96 0.000113 0.0367 0.41 0.31 Alcohol consumption; chr7:107695613 chr7:107742817~107744581:- PAAD cis rs2188561 1 rs2712208 ENSG00000241764.3 AC002467.7 3.96 0.000113 0.0367 0.41 0.31 Alcohol consumption; chr7:107703317 chr7:107742817~107744581:- PAAD cis rs3731570 0.818 rs66730758 ENSG00000231621.1 AC013264.2 -3.96 0.000113 0.0367 -0.29 -0.31 Morning vs. evening chronotype; chr2:197476277 chr2:197197991~197199273:+ PAAD cis rs55702914 0.628 rs11883902 ENSG00000231621.1 AC013264.2 -3.96 0.000113 0.0367 -0.29 -0.31 Major depression and alcohol dependence; chr2:197476601 chr2:197197991~197199273:+ PAAD cis rs55702914 0.628 rs17730989 ENSG00000231621.1 AC013264.2 -3.96 0.000113 0.0367 -0.29 -0.31 Major depression and alcohol dependence; chr2:197497800 chr2:197197991~197199273:+ PAAD cis rs9393813 0.506 rs13201985 ENSG00000271755.1 RP1-153G14.4 3.96 0.000113 0.0368 0.35 0.31 Bipolar disorder; chr6:27465854 chr6:27404010~27406964:- PAAD cis rs9393813 0.528 rs6899950 ENSG00000271755.1 RP1-153G14.4 3.96 0.000113 0.0368 0.35 0.31 Bipolar disorder; chr6:27466216 chr6:27404010~27406964:- PAAD cis rs4988958 0.548 rs6543127 ENSG00000234389.1 AC007278.3 3.96 0.000113 0.0368 0.31 0.31 Asthma (childhood onset); chr2:102411841 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs1592459 ENSG00000234389.1 AC007278.3 3.96 0.000113 0.0368 0.31 0.31 Asthma; chr2:102415109 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs1592458 ENSG00000234389.1 AC007278.3 3.96 0.000113 0.0368 0.31 0.31 Asthma; chr2:102415289 chr2:102438713~102440475:+ PAAD cis rs4988958 0.565 rs1035125 ENSG00000234389.1 AC007278.3 3.96 0.000113 0.0368 0.31 0.31 Asthma (childhood onset); chr2:102417379 chr2:102438713~102440475:+ PAAD cis rs9807989 0.507 rs2160201 ENSG00000234389.1 AC007278.3 3.96 0.000113 0.0368 0.31 0.31 Asthma; chr2:102417501 chr2:102438713~102440475:+ PAAD cis rs1707322 0.752 rs6678444 ENSG00000280836.1 AL355480.1 -3.96 0.000113 0.0368 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45764175 chr1:45581219~45581321:- PAAD cis rs1707322 0.752 rs7541962 ENSG00000280836.1 AL355480.1 -3.96 0.000113 0.0368 -0.36 -0.31 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45769445 chr1:45581219~45581321:- PAAD cis rs12280210 0.557 rs11216225 ENSG00000254851.1 RP11-109L13.1 3.96 0.000113 0.0368 0.66 0.31 Lobe attachment (rater-scored or self-reported); chr11:117007298 chr11:117135528~117138582:+ PAAD cis rs12280210 0.557 rs7112937 ENSG00000254851.1 RP11-109L13.1 3.96 0.000113 0.0368 0.66 0.31 Lobe attachment (rater-scored or self-reported); chr11:117009740 chr11:117135528~117138582:+ PAAD cis rs77204473 0.549 rs12280210 ENSG00000254851.1 RP11-109L13.1 3.96 0.000113 0.0368 0.66 0.31 Sum eosinophil basophil counts;Eosinophil counts; chr11:117069733 chr11:117135528~117138582:+ PAAD cis rs153916 0.706 rs153917 ENSG00000250551.1 RP11-254I22.1 3.96 0.000113 0.0368 0.4 0.31 Pulmonary function; chr5:95701399 chr5:96050115~96215519:+ PAAD cis rs2742417 1 rs2742390 ENSG00000244357.3 RN7SL145P -3.96 0.000113 0.0368 -0.28 -0.31 Response to anti-depressant treatment in major depressive disorder; chr3:45715230 chr3:45742675~45742970:+ PAAD cis rs2717559 0.542 rs10956986 ENSG00000253741.1 CTD-2292P10.4 3.96 0.000113 0.0368 0.4 0.31 Urinary tract infection frequency; chr8:142805185 chr8:142702252~142726973:- PAAD cis rs55702914 0.628 rs6745660 ENSG00000231621.1 AC013264.2 -3.96 0.000113 0.0368 -0.29 -0.31 Major depression and alcohol dependence; chr2:197484812 chr2:197197991~197199273:+ PAAD cis rs7246657 1 rs34544865 ENSG00000267422.1 CTD-2554C21.1 -3.96 0.000113 0.0368 -0.56 -0.31 Coronary artery calcification; chr19:37310340 chr19:37779686~37792865:+ PAAD cis rs9595908 0.869 rs7337687 ENSG00000212293.1 SNORA16 -3.96 0.000113 0.0368 -0.34 -0.31 Body mass index; chr13:32595560 chr13:32420390~32420516:- PAAD cis rs10779751 0.96 rs1883965 ENSG00000238199.1 UBE2V2P3 -3.96 0.000113 0.0368 -0.36 -0.31 Body mass index; chr1:11262099 chr1:11278616~11279351:- PAAD cis rs11098499 0.722 rs1814814 ENSG00000248280.1 RP11-33B1.2 3.96 0.000113 0.0368 0.28 0.31 Corneal astigmatism; chr4:119336969 chr4:119440561~119450157:- PAAD cis rs897984 0.762 rs1870293 ENSG00000260911.2 RP11-196G11.2 -3.96 0.000113 0.0368 -0.28 -0.31 Dementia with Lewy bodies; chr16:30959620 chr16:31043150~31049868:+ PAAD cis rs67517081 1 rs67517081 ENSG00000260911.2 RP11-196G11.2 -3.96 0.000113 0.0368 -0.28 -0.31 Mean corpuscular hemoglobin; chr16:30976060 chr16:31043150~31049868:+ PAAD cis rs72843506 0.652 rs28550747 ENSG00000154898.14 CCDC144CP 3.96 0.000113 0.0368 0.54 0.31 Schizophrenia; chr17:20274999 chr17:20321164~20403557:+ PAAD cis rs651386 0.506 rs12027180 ENSG00000271811.1 RP1-79C4.4 3.96 0.000113 0.0368 0.34 0.31 Atrial fibrillation; chr1:170594064 chr1:170667381~170669425:+ PAAD cis rs3781264 0.687 rs12217597 ENSG00000273450.1 RP11-76P2.4 -3.96 0.000113 0.0368 -0.42 -0.31 Esophageal cancer and gastric cancer; chr10:94351055 chr10:94314907~94315327:- PAAD cis rs7487075 0.93 rs4076484 ENSG00000270429.1 KNOP1P2 3.96 0.000113 0.0368 0.35 0.31 Itch intensity from mosquito bite; chr12:46440129 chr12:45880950~45882266:- PAAD cis rs7487075 0.823 rs34472481 ENSG00000270429.1 KNOP1P2 3.96 0.000113 0.0368 0.35 0.31 Itch intensity from mosquito bite; chr12:46442565 chr12:45880950~45882266:- PAAD cis rs1341320 1 rs1341320 ENSG00000229887.3 HNRNPA1P6 3.96 0.000113 0.0369 0.64 0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr1:57500856 chr1:58048175~58049291:- PAAD cis rs8177376 0.953 rs3862627 ENSG00000254905.1 RP11-712L6.7 3.96 0.000114 0.0369 0.43 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126311697 chr11:126292922~126294254:- PAAD cis rs8177376 0.953 rs73017394 ENSG00000254905.1 RP11-712L6.7 3.96 0.000114 0.0369 0.43 0.31 Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes; chr11:126311952 chr11:126292922~126294254:- PAAD cis rs720064 0.589 rs10502441 ENSG00000264745.1 TTC39C-AS1 3.96 0.000114 0.0369 0.39 0.31 Strep throat; chr18:23923207 chr18:23994213~24015339:- PAAD cis rs10951983 0.847 rs58072643 ENSG00000272719.1 CTB-161C1.1 -3.96 0.000114 0.0369 -0.4 -0.31 Coronary artery disease; chr7:6436869 chr7:5556731~5557245:+ PAAD cis rs10951983 0.847 rs12535659 ENSG00000272719.1 CTB-161C1.1 -3.96 0.000114 0.0369 -0.4 -0.31 Coronary artery disease; chr7:6437284 chr7:5556731~5557245:+ PAAD cis rs10951983 0.797 rs13221129 ENSG00000272719.1 CTB-161C1.1 -3.96 0.000114 0.0369 -0.4 -0.31 Coronary artery disease; chr7:6437505 chr7:5556731~5557245:+ PAAD cis rs11723261 0.564 rs60994255 ENSG00000275426.1 CH17-262A2.1 3.96 0.000114 0.0369 0.52 0.31 Immune response to smallpox vaccine (IL-6); chr4:77554 chr4:149738~150317:+ PAAD cis rs11159086 1 rs4903233 ENSG00000270000.1 RP3-449M8.9 3.96 0.000114 0.0369 0.46 0.31 Advanced glycation end-product levels; chr14:74497291 chr14:74471930~74472360:- PAAD cis rs2638953 0.924 rs17801436 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000114 0.0369 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28165421 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049385 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000114 0.0369 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28167559 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049387 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000114 0.0369 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28167609 chr12:28163298~28190738:- PAAD cis rs2638953 0.886 rs12371462 ENSG00000247934.4 RP11-967K21.1 -3.96 0.000114 0.0369 -0.35 -0.31 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28168770 chr12:28163298~28190738:- PAAD cis rs11893307 0.507 rs1465305 ENSG00000235852.1 AC005540.3 3.96 0.000114 0.0369 0.43 0.31 Mean platelet volume; chr2:190720666 chr2:190880797~190882059:- PAAD cis rs11893307 0.507 rs1465304 ENSG00000235852.1 AC005540.3 3.96 0.000114 0.0369 0.43 0.31 Mean platelet volume; chr2:190720672 chr2:190880797~190882059:- PAAD cis rs5760092 0.842 rs5751763 ENSG00000206090.4 AP000350.7 3.96 0.000114 0.0369 0.5 0.31 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23905606 chr22:23939998~23942798:+ PAAD cis rs73219805 1 rs73219805 ENSG00000228451.3 SDAD1P1 -3.96 0.000114 0.0369 -0.44 -0.31 Schizophrenia; chr8:26415252 chr8:26379259~26382953:- PAAD cis rs3785888 0.548 rs3890958 ENSG00000214401.4 KANSL1-AS1 3.96 0.000114 0.0369 0.44 0.31 Cleft lip with or without cleft palate; chr17:46969499 chr17:46193576~46196723:+ PAAD cis rs748404 0.697 rs505249 ENSG00000205771.5 CATSPER2P1 -3.96 0.000114 0.0369 -0.4 -0.31 Lung cancer; chr15:43267762 chr15:43726918~43747094:- PAAD cis rs2403083 0.505 rs7001359 ENSG00000258256.1 RP11-219B4.5 -3.96 0.000114 0.0369 -0.33 -0.31 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85297334 chr8:85222446~85245717:- PAAD cis rs2404602 0.716 rs117129193 ENSG00000259422.1 RP11-593F23.1 3.96 0.000114 0.037 0.35 0.31 Blood metabolite levels; chr15:76364462 chr15:76174891~76181486:- PAAD cis rs9487094 0.885 rs11153214 ENSG00000260273.1 RP11-425D10.10 3.96 0.000114 0.037 0.4 0.31 Height; chr6:109694120 chr6:109382795~109383666:+ PAAD cis rs853679 0.766 rs9368561 ENSG00000226314.6 ZNF192P1 -3.96 0.000114 0.037 -0.59 -0.31 Depression; chr6:28200565 chr6:28161781~28169594:+ PAAD cis rs7487075 0.93 rs7308910 ENSG00000270429.1 KNOP1P2 3.96 0.000114 0.037 0.34 0.31 Itch intensity from mosquito bite; chr12:46444459 chr12:45880950~45882266:- PAAD cis rs2255336 0.748 rs60110638 ENSG00000245648.1 RP11-277P12.20 -3.96 0.000114 0.037 -0.44 -0.31 Blood protein levels; chr12:10444712 chr12:10363769~10398506:+ PAAD cis rs10129255 0.5 rs4600373 ENSG00000280411.1 IGHV1-69-2 -3.96 0.000114 0.037 -0.26 -0.31 Kawasaki disease; chr14:106704809 chr14:106762092~106762588:- PAAD cis rs7766910 1 rs7738797 ENSG00000234261.2 RP11-146I2.1 3.96 0.000114 0.037 0.38 0.31 Pediatric bone mineral content (radius); chr6:14115590 chr6:14661829~15090003:- PAAD cis rs79040073 0.679 rs78135084 ENSG00000259469.1 RP11-227D13.4 -3.96 0.000114 0.037 -0.48 -0.31 Lung cancer in ever smokers; chr15:49169895 chr15:48729080~48729844:- PAAD cis rs9487094 0.626 rs12215077 ENSG00000260273.1 RP11-425D10.10 -3.96 0.000114 0.037 -0.37 -0.31 Height; chr6:109731677 chr6:109382795~109383666:+ PAAD cis rs9487094 0.626 rs11153215 ENSG00000260273.1 RP11-425D10.10 3.96 0.000114 0.037 0.37 0.31 Height; chr6:109732518 chr6:109382795~109383666:+ PAAD cis rs9487094 0.626 rs12201444 ENSG00000260273.1 RP11-425D10.10 3.96 0.000114 0.037 0.37 0.31 Height; chr6:109738751 chr6:109382795~109383666:+ PAAD cis rs950169 0.881 rs150965 ENSG00000259683.1 RP11-182J1.14 3.96 0.000114 0.037 0.25 0.31 Schizophrenia; chr15:84537296 chr15:84389729~84395903:+ PAAD cis rs17684571 0.872 rs13219942 ENSG00000216854.2 RPL17P26 3.96 0.000114 0.037 0.63 0.31 Schizophrenia; chr6:56713977 chr6:56871191~56871743:+ PAAD cis rs17684571 0.872 rs35326806 ENSG00000216854.2 RPL17P26 3.96 0.000114 0.037 0.63 0.31 Schizophrenia; chr6:56714216 chr6:56871191~56871743:+ PAAD cis rs17684571 0.872 rs35494794 ENSG00000216854.2 RPL17P26 3.96 0.000114 0.037 0.63 0.31 Schizophrenia; chr6:56716124 chr6:56871191~56871743:+ PAAD cis rs10838687 0.736 rs2306353 ENSG00000255007.1 CTD-2589M5.4 3.96 0.000114 0.037 0.37 0.31 Proinsulin levels; chr11:47235157 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs3824866 ENSG00000255007.1 CTD-2589M5.4 3.96 0.000114 0.037 0.37 0.31 Proinsulin levels; chr11:47237302 chr11:46256355~46274547:- PAAD cis rs2288884 0.537 rs7254254 ENSG00000275055.1 CTC-471J1.11 -3.96 0.000114 0.037 -0.41 -0.31 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52035824 chr19:52049007~52049754:+ PAAD cis rs2288884 0.537 rs12151270 ENSG00000275055.1 CTC-471J1.11 -3.96 0.000114 0.037 -0.41 -0.31 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52058984 chr19:52049007~52049754:+ PAAD cis rs17123764 0.818 rs7975599 ENSG00000257464.1 RP11-161H23.8 -3.96 0.000114 0.037 -0.52 -0.31 Intelligence (multi-trait analysis); chr12:49551143 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs13066 ENSG00000257464.1 RP11-161H23.8 -3.96 0.000114 0.037 -0.52 -0.31 Intelligence (multi-trait analysis); chr12:49566768 chr12:49442424~49442652:- PAAD cis rs17123764 0.71 rs7296281 ENSG00000257464.1 RP11-161H23.8 -3.96 0.000114 0.037 -0.52 -0.31 Intelligence (multi-trait analysis); chr12:49570775 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs11169076 ENSG00000257464.1 RP11-161H23.8 -3.96 0.000114 0.037 -0.52 -0.31 Intelligence (multi-trait analysis); chr12:49581625 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs2005195 ENSG00000257464.1 RP11-161H23.8 -3.96 0.000114 0.037 -0.52 -0.31 Intelligence (multi-trait analysis); chr12:49589696 chr12:49442424~49442652:- PAAD cis rs17123764 0.818 rs11169081 ENSG00000257464.1 RP11-161H23.8 -3.96 0.000114 0.037 -0.52 -0.31 Intelligence (multi-trait analysis); chr12:49591427 chr12:49442424~49442652:- PAAD cis rs591584 0.73 rs2155098 ENSG00000255893.1 RP11-685N10.1 -3.96 0.000114 0.037 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94588886 chr11:94472908~94473570:- PAAD cis rs591584 0.693 rs11020845 ENSG00000255893.1 RP11-685N10.1 -3.96 0.000114 0.037 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94589186 chr11:94472908~94473570:- PAAD cis rs591584 0.693 rs11020846 ENSG00000255893.1 RP11-685N10.1 -3.96 0.000114 0.037 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94589187 chr11:94472908~94473570:- PAAD cis rs792448 0.603 rs12024665 ENSG00000229983.1 RP11-15I11.2 3.96 0.000114 0.037 0.36 0.31 White blood cell count (basophil); chr1:212326553 chr1:212168207~212190259:+ PAAD cis rs9813712 0.595 rs1901787 ENSG00000228252.7 COL6A4P2 3.96 0.000114 0.0371 0.37 0.31 Response to amphetamines; chr3:130288678 chr3:130212823~130273806:+ PAAD cis rs9813712 0.547 rs6807290 ENSG00000228252.7 COL6A4P2 3.96 0.000114 0.0371 0.37 0.31 Response to amphetamines; chr3:130297952 chr3:130212823~130273806:+ PAAD cis rs8005677 0.962 rs8003934 ENSG00000279656.1 RP11-298I3.6 3.96 0.000114 0.0371 0.37 0.31 Cognitive ability (multi-trait analysis); chr14:22931933 chr14:23023083~23024217:- PAAD cis rs950880 0.677 rs56224165 ENSG00000234389.1 AC007278.3 -3.96 0.000114 0.0371 -0.29 -0.31 Serum protein levels (sST2); chr2:102308763 chr2:102438713~102440475:+ PAAD cis rs950880 0.71 rs12470867 ENSG00000234389.1 AC007278.3 -3.96 0.000114 0.0371 -0.29 -0.31 Serum protein levels (sST2); chr2:102309906 chr2:102438713~102440475:+ PAAD cis rs2688608 0.617 rs6480709 ENSG00000271816.1 BMS1P4 3.96 0.000115 0.0371 0.31 0.31 Inflammatory bowel disease; chr10:73719367 chr10:73699151~73730487:- PAAD cis rs6940729 1 rs6940729 ENSG00000270761.1 RP11-385F7.1 -3.96 0.000115 0.0371 -0.27 -0.31 Plasma homocysteine levels; chr6:47585184 chr6:47477243~47477572:- PAAD cis rs4820834 0.808 rs17738020 ENSG00000273350.1 RP4-539M6.20 -3.96 0.000115 0.0371 -0.65 -0.31 Coronary artery calcification; chr22:30465928 chr22:30420512~30420912:+ PAAD cis rs8026198 0.929 rs4924645 ENSG00000260571.1 BNIP3P5 3.96 0.000115 0.0371 0.5 0.31 Fibrinogen levels; chr15:42260389 chr15:42313687~42314386:+ PAAD cis rs755249 0.701 rs1180342 ENSG00000243970.1 PPIEL -3.96 0.000115 0.0372 -0.29 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527206 chr1:39531838~39558707:- PAAD cis rs7829975 0.514 rs2976926 ENSG00000253981.4 ALG1L13P 3.96 0.000115 0.0372 0.36 0.31 Mood instability; chr8:8404114 chr8:8236003~8244667:- PAAD cis rs5750854 0.503 rs5757756 ENSG00000227188.1 MGAT3-AS1 -3.96 0.000115 0.0372 -0.39 -0.31 Intelligence (multi-trait analysis); chr22:39634472 chr22:39475807~39476822:- PAAD cis rs875971 0.54 rs736270 ENSG00000236529.1 RP13-254B10.1 3.96 0.000115 0.0372 0.34 0.31 Aortic root size; chr7:65963835 chr7:65840212~65840596:+ PAAD cis rs11676348 0.818 rs6436033 ENSG00000261338.2 RP11-378A13.1 -3.96 0.000115 0.0372 -0.35 -0.31 Ulcerative colitis; chr2:218119040 chr2:218255319~218257366:+ PAAD cis rs28386778 0.965 rs2854154 ENSG00000240280.5 TCAM1P 3.96 0.000115 0.0372 0.44 0.31 Prudent dietary pattern; chr17:63904336 chr17:63849292~63864379:+ PAAD cis rs2486288 0.656 rs11629858 ENSG00000259433.2 CTD-2651B20.4 3.96 0.000115 0.0372 0.35 0.31 Glomerular filtration rate; chr15:45254916 chr15:45330209~45332634:- PAAD cis rs2486288 0.656 rs11629859 ENSG00000259433.2 CTD-2651B20.4 3.96 0.000115 0.0372 0.35 0.31 Glomerular filtration rate; chr15:45254923 chr15:45330209~45332634:- PAAD cis rs11159086 1 rs4899516 ENSG00000270000.1 RP3-449M8.9 3.96 0.000115 0.0373 0.46 0.31 Advanced glycation end-product levels; chr14:74492825 chr14:74471930~74472360:- PAAD cis rs188759467 1 rs188759467 ENSG00000184084.7 CTD-2372A4.1 3.96 0.000115 0.0373 0.75 0.31 Interferon gamma-induced protein 10 levels; chr5:73807422 chr5:73803296~73803599:- PAAD cis rs10129255 0.5 rs10142931 ENSG00000211972.2 IGHV3-66 3.96 0.000115 0.0373 0.24 0.31 Kawasaki disease; chr14:106782288 chr14:106675017~106675544:- PAAD cis rs2404602 0.716 rs17460201 ENSG00000259422.1 RP11-593F23.1 -3.96 0.000115 0.0373 -0.35 -0.31 Blood metabolite levels; chr15:76381286 chr15:76174891~76181486:- PAAD cis rs2404602 0.716 rs12917430 ENSG00000259422.1 RP11-593F23.1 3.96 0.000115 0.0373 0.35 0.31 Blood metabolite levels; chr15:76382019 chr15:76174891~76181486:- PAAD cis rs2404602 0.716 rs12907805 ENSG00000259422.1 RP11-593F23.1 3.96 0.000115 0.0373 0.35 0.31 Blood metabolite levels; chr15:76398265 chr15:76174891~76181486:- PAAD cis rs2404602 0.716 rs4079681 ENSG00000259422.1 RP11-593F23.1 3.96 0.000115 0.0373 0.35 0.31 Blood metabolite levels; chr15:76402889 chr15:76174891~76181486:- PAAD cis rs2404602 0.716 rs7179142 ENSG00000259422.1 RP11-593F23.1 3.96 0.000115 0.0373 0.35 0.31 Blood metabolite levels; chr15:76405927 chr15:76174891~76181486:- PAAD cis rs2404602 0.716 rs8039545 ENSG00000259422.1 RP11-593F23.1 3.96 0.000115 0.0373 0.35 0.31 Blood metabolite levels; chr15:76414906 chr15:76174891~76181486:- PAAD cis rs2404602 0.716 rs7164060 ENSG00000259422.1 RP11-593F23.1 3.96 0.000115 0.0373 0.35 0.31 Blood metabolite levels; chr15:76415353 chr15:76174891~76181486:- PAAD cis rs2404602 0.716 rs7164813 ENSG00000259422.1 RP11-593F23.1 3.96 0.000115 0.0373 0.35 0.31 Blood metabolite levels; chr15:76415725 chr15:76174891~76181486:- PAAD cis rs1910358 0.53 rs7732852 ENSG00000248874.4 C5orf17 -3.96 0.000115 0.0373 -0.42 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23780287 chr5:23951348~24178263:+ PAAD cis rs1910358 0.554 rs13189504 ENSG00000248874.4 C5orf17 -3.96 0.000115 0.0373 -0.42 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23780803 chr5:23951348~24178263:+ PAAD cis rs1910358 0.53 rs1027680 ENSG00000248874.4 C5orf17 -3.96 0.000115 0.0373 -0.42 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23792950 chr5:23951348~24178263:+ PAAD cis rs1910358 0.554 rs4701399 ENSG00000248874.4 C5orf17 -3.96 0.000115 0.0373 -0.42 -0.31 Venous thromboembolism (SNP x SNP interaction); chr5:23795804 chr5:23951348~24178263:+ PAAD cis rs7429990 1 rs1684942 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47859213 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs800762 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47864080 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs2631721 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47881807 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs319692 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47882827 chr3:48290793~48291375:- PAAD cis rs319690 1 rs319690 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Diastolic blood pressure;Systolic blood pressure;Blood pressure; chr3:47885994 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs319685 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47890494 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs319684 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47890784 chr3:48290793~48291375:- PAAD cis rs7429990 0.932 rs810334 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47893813 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs796566 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47896864 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs34380889 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47905692 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs4858871 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47911915 chr3:48290793~48291375:- PAAD cis rs7429990 0.965 rs6772396 ENSG00000228638.1 FCF1P2 -3.96 0.000115 0.0373 -0.35 -0.31 Educational attainment (years of education); chr3:47918280 chr3:48290793~48291375:- PAAD cis rs875971 0.522 rs1917563 ENSG00000236529.1 RP13-254B10.1 -3.96 0.000115 0.0373 -0.33 -0.31 Aortic root size; chr7:65950660 chr7:65840212~65840596:+ PAAD cis rs2348418 0.832 rs11049512 ENSG00000247934.4 RP11-967K21.1 3.96 0.000115 0.0373 0.29 0.31 Lung function (FEV1);Lung function (FVC); chr12:28295880 chr12:28163298~28190738:- PAAD cis rs10916814 1 rs10916820 ENSG00000226396.1 RP5-1056L3.3 -3.96 0.000115 0.0373 -0.26 -0.31 Age-related hearing impairment (SNP x SNP interaction); chr1:20577299 chr1:19608114~19608568:+ PAAD cis rs72843506 0.591 rs75334890 ENSG00000154898.14 CCDC144CP 3.96 0.000115 0.0373 0.54 0.31 Schizophrenia; chr17:20318087 chr17:20321164~20403557:+ PAAD cis rs9322193 0.651 rs9322188 ENSG00000223701.3 RAET1E-AS1 -3.96 0.000115 0.0373 -0.35 -0.31 Lung cancer; chr6:149588355 chr6:149884431~149919508:+ PAAD cis rs9649213 0.593 rs13246725 ENSG00000272950.1 RP11-307C18.1 3.96 0.000115 0.0373 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98285586 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs11766808 ENSG00000272950.1 RP11-307C18.1 3.96 0.000115 0.0373 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98286064 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs35983874 ENSG00000272950.1 RP11-307C18.1 3.96 0.000115 0.0373 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98287149 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs6465662 ENSG00000272950.1 RP11-307C18.1 3.96 0.000115 0.0373 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98288489 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs35941058 ENSG00000272950.1 RP11-307C18.1 3.96 0.000115 0.0373 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98288847 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs7778015 ENSG00000272950.1 RP11-307C18.1 3.96 0.000115 0.0373 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98290958 chr7:98322853~98323430:+ PAAD cis rs9649213 0.593 rs34534766 ENSG00000272950.1 RP11-307C18.1 3.96 0.000115 0.0373 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98291559 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs12873 ENSG00000272950.1 RP11-307C18.1 3.96 0.000115 0.0373 0.35 0.31 Prostate cancer (SNP x SNP interaction); chr7:98293461 chr7:98322853~98323430:+ PAAD cis rs13217239 0.572 rs9379958 ENSG00000241549.7 GUSBP2 -3.96 0.000115 0.0373 -0.31 -0.31 Schizophrenia; chr6:27098384 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs9393789 ENSG00000241549.7 GUSBP2 -3.96 0.000115 0.0373 -0.31 -0.31 Schizophrenia; chr6:27099249 chr6:26871484~26956554:- PAAD cis rs13217239 0.646 rs6456767 ENSG00000241549.7 GUSBP2 -3.96 0.000115 0.0373 -0.31 -0.31 Schizophrenia; chr6:27102764 chr6:26871484~26956554:- PAAD cis rs6479901 0.588 rs10740105 ENSG00000232075.1 MRPL35P2 -3.96 0.000115 0.0373 -0.46 -0.31 Intelligence (multi-trait analysis); chr10:63129957 chr10:63634317~63634827:- PAAD cis rs10995505 0.578 rs1533068 ENSG00000232075.1 MRPL35P2 -3.96 0.000115 0.0373 -0.46 -0.31 Intelligence (multi-trait analysis); chr10:63132407 chr10:63634317~63634827:- PAAD cis rs2023634 0.509 rs807741 ENSG00000241527.1 CA15P1 3.96 0.000115 0.0373 0.69 0.31 Metabolic traits; chr22:19115785 chr22:19031564~19034564:- PAAD cis rs591584 0.666 rs1939139 ENSG00000255893.1 RP11-685N10.1 -3.96 0.000115 0.0373 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94573836 chr11:94472908~94473570:- PAAD cis rs591584 0.73 rs72963846 ENSG00000255893.1 RP11-685N10.1 -3.96 0.000115 0.0373 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94574596 chr11:94472908~94473570:- PAAD cis rs9322193 0.923 rs9800736 ENSG00000268592.3 RAET1E-AS1 3.96 0.000115 0.0373 0.35 0.31 Lung cancer; chr6:149661281 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs12660304 ENSG00000268592.3 RAET1E-AS1 3.96 0.000115 0.0373 0.35 0.31 Lung cancer; chr6:149739647 chr6:149863494~149919507:+ PAAD cis rs2698530 0.535 rs2114432 ENSG00000225889.6 AC074289.1 -3.96 0.000115 0.0373 -0.36 -0.31 Iron status biomarkers; chr2:64258678 chr2:64143239~64252859:+ PAAD cis rs11233413 0.874 rs4515990 ENSG00000247137.7 RP11-727A23.5 -3.96 0.000115 0.0374 -0.27 -0.31 Economic and political preferences (feminism/equality); chr11:83041420 chr11:83184491~83193794:- PAAD cis rs2243480 0.831 rs57294491 ENSG00000228409.4 CCT6P1 -3.96 0.000116 0.0374 -0.32 -0.31 Diabetic kidney disease; chr7:66219914 chr7:65751142~65763354:+ PAAD cis rs17772222 0.917 rs61986664 ENSG00000258983.2 RP11-507K2.2 3.96 0.000116 0.0374 0.4 0.31 Coronary artery calcification; chr14:88711251 chr14:88499334~88515502:+ PAAD cis rs17772222 0.876 rs61986665 ENSG00000258983.2 RP11-507K2.2 3.96 0.000116 0.0374 0.4 0.31 Coronary artery calcification; chr14:88711354 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs8018755 ENSG00000258983.2 RP11-507K2.2 3.96 0.000116 0.0374 0.4 0.31 Coronary artery calcification; chr14:88714249 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs8018630 ENSG00000258983.2 RP11-507K2.2 3.96 0.000116 0.0374 0.4 0.31 Coronary artery calcification; chr14:88714250 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs8020072 ENSG00000258983.2 RP11-507K2.2 3.96 0.000116 0.0374 0.4 0.31 Coronary artery calcification; chr14:88714332 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs12589982 ENSG00000258983.2 RP11-507K2.2 3.96 0.000116 0.0374 0.4 0.31 Coronary artery calcification; chr14:88716861 chr14:88499334~88515502:+ PAAD cis rs7119038 0.818 rs10892293 ENSG00000255239.1 AP002954.6 -3.96 0.000116 0.0374 -0.44 -0.31 Sjögren's syndrome; chr11:118794866 chr11:118688039~118690600:- PAAD cis rs2658782 0.654 rs2605620 ENSG00000279684.1 RP11-755E23.2 -3.96 0.000116 0.0374 -0.48 -0.31 Pulmonary function decline; chr11:93514480 chr11:93286629~93288903:- PAAD cis rs7260598 0.642 rs10403746 ENSG00000268442.1 CTD-2027I19.2 3.96 0.000116 0.0374 0.44 0.31 Response to taxane treatment (placlitaxel); chr19:23924452 chr19:24162370~24163425:- PAAD cis rs7260598 0.685 rs67534545 ENSG00000268442.1 CTD-2027I19.2 3.96 0.000116 0.0374 0.44 0.31 Response to taxane treatment (placlitaxel); chr19:23927339 chr19:24162370~24163425:- PAAD cis rs7260598 0.642 rs28537609 ENSG00000268442.1 CTD-2027I19.2 3.96 0.000116 0.0374 0.44 0.31 Response to taxane treatment (placlitaxel); chr19:23928662 chr19:24162370~24163425:- PAAD cis rs9487094 0.626 rs2273752 ENSG00000260273.1 RP11-425D10.10 3.96 0.000116 0.0374 0.37 0.31 Height; chr6:109738307 chr6:109382795~109383666:+ PAAD cis rs7254192 0.506 rs2305797 ENSG00000233622.1 CYP2T1P -3.96 0.000116 0.0374 -0.43 -0.31 Post bronchodilator FEV1; chr19:40763171 chr19:40808525~40811390:- PAAD cis rs919433 0.679 rs13000656 ENSG00000231621.1 AC013264.2 3.96 0.000116 0.0374 0.3 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197657402 chr2:197197991~197199273:+ PAAD cis rs11676348 0.818 rs1126579 ENSG00000261338.2 RP11-378A13.1 -3.96 0.000116 0.0374 -0.35 -0.31 Ulcerative colitis; chr2:218136011 chr2:218255319~218257366:+ PAAD cis rs11676348 0.846 rs4674260 ENSG00000261338.2 RP11-378A13.1 -3.96 0.000116 0.0374 -0.35 -0.31 Ulcerative colitis; chr2:218137653 chr2:218255319~218257366:+ PAAD cis rs11676348 0.846 rs6723449 ENSG00000261338.2 RP11-378A13.1 3.96 0.000116 0.0374 0.35 0.31 Ulcerative colitis; chr2:218132857 chr2:218255319~218257366:+ PAAD cis rs10771431 0.782 rs10771415 ENSG00000111788.10 RP11-22B23.1 3.96 0.000116 0.0374 0.28 0.31 Breast size; chr12:9205627 chr12:9277235~9313241:+ PAAD cis rs6061231 1 rs11696991 ENSG00000275437.1 RP5-908M14.10 3.96 0.000116 0.0375 0.28 0.31 Colorectal cancer; chr20:62384638 chr20:62402236~62405935:- PAAD cis rs9487094 0.922 rs10782162 ENSG00000260273.1 RP11-425D10.10 -3.96 0.000116 0.0375 -0.4 -0.31 Height; chr6:109485060 chr6:109382795~109383666:+ PAAD cis rs4853012 0.887 rs77148265 ENSG00000257800.1 FNBP1P1 3.96 0.000116 0.0375 0.45 0.31 Gestational age at birth (maternal effect); chr2:74112392 chr2:74120680~74123218:+ PAAD cis rs4853012 0.887 rs6737314 ENSG00000257800.1 FNBP1P1 3.96 0.000116 0.0375 0.45 0.31 Gestational age at birth (maternal effect); chr2:74112459 chr2:74120680~74123218:+ PAAD cis rs6601327 0.602 rs7820917 ENSG00000254340.1 RP11-10A14.3 3.96 0.000116 0.0375 0.38 0.31 Multiple myeloma (hyperdiploidy); chr8:9790358 chr8:9141424~9145435:+ PAAD cis rs7915414 0.543 rs67941743 ENSG00000230338.1 MTND4P19 3.96 0.000116 0.0375 0.37 0.31 Clopidogrel active metabolite levels; chr10:94630015 chr10:94774156~94774633:- PAAD cis rs7915414 0.585 rs749745 ENSG00000230338.1 MTND4P19 3.96 0.000116 0.0375 0.37 0.31 Clopidogrel active metabolite levels; chr10:94646759 chr10:94774156~94774633:- PAAD cis rs7915414 0.585 rs7089349 ENSG00000230338.1 MTND4P19 3.96 0.000116 0.0375 0.37 0.31 Clopidogrel active metabolite levels; chr10:94647595 chr10:94774156~94774633:- PAAD cis rs7915414 0.585 rs12784245 ENSG00000230338.1 MTND4P19 3.96 0.000116 0.0375 0.37 0.31 Clopidogrel active metabolite levels; chr10:94668194 chr10:94774156~94774633:- PAAD cis rs7299940 1 rs6486613 ENSG00000256250.1 RP11-989F5.1 3.96 0.000116 0.0375 0.36 0.31 Panic disorder; chr12:130909133 chr12:130810606~130812438:+ PAAD cis rs2243480 1 rs709607 ENSG00000228409.4 CCT6P1 -3.96 0.000116 0.0375 -0.32 -0.31 Diabetic kidney disease; chr7:65984554 chr7:65751142~65763354:+ PAAD cis rs79040073 0.53 rs73394357 ENSG00000259469.1 RP11-227D13.4 -3.96 0.000116 0.0375 -0.42 -0.31 Lung cancer in ever smokers; chr15:49300314 chr15:48729080~48729844:- PAAD cis rs79040073 0.53 rs3784630 ENSG00000259469.1 RP11-227D13.4 -3.96 0.000116 0.0375 -0.42 -0.31 Lung cancer in ever smokers; chr15:49322952 chr15:48729080~48729844:- PAAD cis rs7169304 0.531 rs59356430 ENSG00000259469.1 RP11-227D13.4 -3.96 0.000116 0.0375 -0.42 -0.31 Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma; chr15:49324835 chr15:48729080~48729844:- PAAD cis rs453301 0.686 rs1045527 ENSG00000254340.1 RP11-10A14.3 -3.96 0.000116 0.0375 -0.37 -0.31 Joint mobility (Beighton score); chr8:9032531 chr8:9141424~9145435:+ PAAD cis rs12935418 0.616 rs62054238 ENSG00000261061.1 RP11-303E16.2 -3.96 0.000116 0.0375 -0.42 -0.31 Mean corpuscular volume; chr16:80965753 chr16:81030770~81031485:+ PAAD cis rs12935418 0.616 rs62054239 ENSG00000261061.1 RP11-303E16.2 -3.96 0.000116 0.0375 -0.42 -0.31 Mean corpuscular volume; chr16:80966287 chr16:81030770~81031485:+ PAAD cis rs7829975 0.539 rs71537846 ENSG00000173295.6 FAM86B3P -3.96 0.000116 0.0375 -0.34 -0.31 Mood instability; chr8:8684610 chr8:8228595~8244865:+ PAAD cis rs755249 0.761 rs61781390 ENSG00000228060.1 RP11-69E11.8 -3.96 0.000116 0.0375 -0.31 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39610222 chr1:39565160~39573203:+ PAAD cis rs755249 0.876 rs61781391 ENSG00000228060.1 RP11-69E11.8 -3.96 0.000116 0.0375 -0.31 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39611865 chr1:39565160~39573203:+ PAAD cis rs755249 0.917 rs61781392 ENSG00000228060.1 RP11-69E11.8 -3.96 0.000116 0.0375 -0.31 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39617969 chr1:39565160~39573203:+ PAAD cis rs755249 0.917 rs61232586 ENSG00000228060.1 RP11-69E11.8 -3.96 0.000116 0.0375 -0.31 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39620685 chr1:39565160~39573203:+ PAAD cis rs755249 0.917 rs61781393 ENSG00000228060.1 RP11-69E11.8 -3.96 0.000116 0.0375 -0.31 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39622092 chr1:39565160~39573203:+ PAAD cis rs633715 0.819 rs585944 ENSG00000254154.7 RP4-798P15.3 -3.96 0.000116 0.0376 -0.26 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177913651 chr1:177928788~178038007:- PAAD cis rs61270009 0.955 rs17548339 ENSG00000247828.6 TMEM161B-AS1 3.96 0.000116 0.0376 0.25 0.31 Depressive symptoms; chr5:88391761 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs16903122 ENSG00000247828.6 TMEM161B-AS1 3.96 0.000116 0.0376 0.25 0.31 Depressive symptoms; chr5:88397744 chr5:88268895~88436685:+ PAAD cis rs61270009 0.955 rs10514300 ENSG00000247828.6 TMEM161B-AS1 3.96 0.000116 0.0376 0.25 0.31 Depressive symptoms; chr5:88409465 chr5:88268895~88436685:+ PAAD cis rs61270009 0.913 rs3733809 ENSG00000247828.6 TMEM161B-AS1 3.96 0.000116 0.0376 0.25 0.31 Depressive symptoms; chr5:88410112 chr5:88268895~88436685:+ PAAD cis rs7911264 0.739 rs4933734 ENSG00000236493.2 EIF2S2P3 3.96 0.000116 0.0376 0.39 0.31 Inflammatory bowel disease; chr10:92654810 chr10:92668745~92669743:- PAAD cis rs55702914 0.655 rs787982 ENSG00000231621.1 AC013264.2 -3.96 0.000116 0.0376 -0.29 -0.31 Major depression and alcohol dependence; chr2:197450810 chr2:197197991~197199273:+ PAAD cis rs55702914 0.628 rs11902195 ENSG00000231621.1 AC013264.2 -3.96 0.000116 0.0376 -0.29 -0.31 Major depression and alcohol dependence; chr2:197451646 chr2:197197991~197199273:+ PAAD cis rs55702914 0.539 rs787990 ENSG00000231621.1 AC013264.2 -3.96 0.000116 0.0376 -0.29 -0.31 Major depression and alcohol dependence; chr2:197460266 chr2:197197991~197199273:+ PAAD cis rs591584 0.73 rs72963868 ENSG00000255893.1 RP11-685N10.1 -3.96 0.000116 0.0376 -0.39 -0.31 Macrophage Migration Inhibitory Factor levels; chr11:94584543 chr11:94472908~94473570:- PAAD cis rs9813712 0.595 rs1453238 ENSG00000228252.7 COL6A4P2 3.96 0.000116 0.0376 0.37 0.31 Response to amphetamines; chr3:130290494 chr3:130212823~130273806:+ PAAD cis rs10266483 0.562 rs10949887 ENSG00000234585.5 CCT6P3 3.96 0.000116 0.0376 0.3 0.31 Response to statin therapy; chr7:64291702 chr7:65038354~65074713:+ PAAD cis rs7554672 0.885 rs1935157 ENSG00000232679.1 RP11-400N13.3 3.96 0.000117 0.0376 0.31 0.31 Hypertension; chr1:221143916 chr1:222041705~222064763:- PAAD cis rs4268898 0.828 rs2702121 ENSG00000242628.4 AC009228.1 -3.96 0.000117 0.0376 -0.38 -0.31 Asthma; chr2:24387523 chr2:24214381~24221516:+ PAAD cis rs2262909 0.962 rs2017521 ENSG00000279377.1 AC003973.3 3.96 0.000117 0.0376 0.3 0.31 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:21943336 chr19:21965708~21968529:- PAAD cis rs2262909 1 rs2175366 ENSG00000279377.1 AC003973.3 3.96 0.000117 0.0376 0.3 0.31 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:21945477 chr19:21965708~21968529:- PAAD cis rs2262909 0.849 rs2666447 ENSG00000279377.1 AC003973.3 3.96 0.000117 0.0376 0.3 0.31 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:21950066 chr19:21965708~21968529:- PAAD cis rs7260598 0.792 rs4635459 ENSG00000268442.1 CTD-2027I19.2 3.96 0.000117 0.0376 0.45 0.31 Response to taxane treatment (placlitaxel); chr19:23999020 chr19:24162370~24163425:- PAAD cis rs2739330 0.828 rs4820572 ENSG00000206090.4 AP000350.7 3.96 0.000117 0.0376 0.39 0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23939998~23942798:+ PAAD cis rs30380 0.573 rs469783 ENSG00000272109.1 CTD-2260A17.3 -3.96 0.000117 0.0377 -0.38 -0.31 Cerebrospinal fluid biomarker levels; chr5:96785820 chr5:96804353~96806105:+ PAAD cis rs4759375 0.667 rs10773009 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123333460 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs10773010 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123339138 chr12:123363868~123366113:+ PAAD cis rs4759375 0.588 rs10846521 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123340610 chr12:123363868~123366113:+ PAAD cis rs4759375 0.51 rs10846522 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123343682 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs10773014 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123358350 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs28660661 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123363908 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs28646185 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123365082 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs28376696 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123365316 chr12:123363868~123366113:+ PAAD cis rs4759375 0.667 rs61955088 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123365994 chr12:123363868~123366113:+ PAAD cis rs4759375 0.588 rs28421567 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123368635 chr12:123363868~123366113:+ PAAD cis rs4759375 0.585 rs28898283 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123370219 chr12:123363868~123366113:+ PAAD cis rs4759375 0.51 rs28454135 ENSG00000256092.2 RP13-942N8.1 3.96 0.000117 0.0377 0.57 0.31 HDL cholesterol; chr12:123373139 chr12:123363868~123366113:+ PAAD cis rs13178541 0.542 rs10900837 ENSG00000250378.1 RP11-119J18.1 -3.96 0.000117 0.0377 -0.45 -0.31 IgG glycosylation; chr5:135790074 chr5:135812667~135826582:+ PAAD cis rs13178541 0.577 rs10900838 ENSG00000250378.1 RP11-119J18.1 -3.96 0.000117 0.0377 -0.45 -0.31 IgG glycosylation; chr5:135790078 chr5:135812667~135826582:+ PAAD cis rs4660214 0.639 rs6699928 ENSG00000228060.1 RP11-69E11.8 3.96 0.000117 0.0377 0.29 0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39267827 chr1:39565160~39573203:+ PAAD cis rs6479891 1 rs4469774 ENSG00000232075.1 MRPL35P2 3.96 0.000117 0.0377 0.47 0.31 Arthritis (juvenile idiopathic); chr10:63550017 chr10:63634317~63634827:- PAAD cis rs9322193 0.962 rs4552 ENSG00000268592.3 RAET1E-AS1 3.96 0.000117 0.0377 0.36 0.31 Lung cancer; chr6:149811183 chr6:149863494~149919507:+ PAAD cis rs9992667 0.91 rs10019144 ENSG00000231160.8 KLF3-AS1 3.96 0.000117 0.0377 0.34 0.31 Eosinophil percentage of granulocytes; chr4:38684784 chr4:38612701~38664883:- PAAD cis rs9992667 0.91 rs28681431 ENSG00000231160.8 KLF3-AS1 3.96 0.000117 0.0377 0.34 0.31 Eosinophil percentage of granulocytes; chr4:38686307 chr4:38612701~38664883:- PAAD cis rs9992667 0.91 rs4535339 ENSG00000231160.8 KLF3-AS1 3.96 0.000117 0.0377 0.34 0.31 Eosinophil percentage of granulocytes; chr4:38687607 chr4:38612701~38664883:- PAAD cis rs17507216 0.56 rs28493687 ENSG00000255769.6 GOLGA2P10 -3.96 0.000117 0.0377 -0.32 -0.31 Excessive daytime sleepiness; chr15:82560062 chr15:82472993~82513950:- PAAD cis rs7829975 0.606 rs6601274 ENSG00000254340.1 RP11-10A14.3 -3.96 0.000117 0.0377 -0.37 -0.31 Mood instability; chr8:8941549 chr8:9141424~9145435:+ PAAD cis rs28386778 0.83 rs2854210 ENSG00000240280.5 TCAM1P -3.96 0.000117 0.0377 -0.44 -0.31 Prudent dietary pattern; chr17:63868978 chr17:63849292~63864379:+ PAAD cis rs7713065 0.531 rs2522051 ENSG00000233006.5 AC034220.3 3.96 0.000117 0.0377 0.24 0.31 Lung function (FEV1/FVC); chr5:132461886 chr5:132311285~132369916:- PAAD cis rs10761482 0.5 rs1890926 ENSG00000254271.1 RP11-131N11.4 3.96 0.000117 0.0377 0.37 0.31 Schizophrenia; chr10:60530347 chr10:60734342~60741828:+ PAAD cis rs10761482 0.5 rs1892547 ENSG00000254271.1 RP11-131N11.4 3.96 0.000117 0.0377 0.37 0.31 Schizophrenia; chr10:60533200 chr10:60734342~60741828:+ PAAD cis rs7246657 0.551 rs11084873 ENSG00000267422.1 CTD-2554C21.1 -3.96 0.000117 0.0377 -0.58 -0.31 Coronary artery calcification; chr19:37093008 chr19:37779686~37792865:+ PAAD cis rs7246657 0.551 rs10419174 ENSG00000267422.1 CTD-2554C21.1 -3.96 0.000117 0.0377 -0.58 -0.31 Coronary artery calcification; chr19:37114439 chr19:37779686~37792865:+ PAAD cis rs7246657 0.509 rs10426093 ENSG00000267422.1 CTD-2554C21.1 -3.96 0.000117 0.0377 -0.58 -0.31 Coronary artery calcification; chr19:37124727 chr19:37779686~37792865:+ PAAD cis rs755249 0.959 rs72663520 ENSG00000228060.1 RP11-69E11.8 -3.95 0.000117 0.0377 -0.31 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39537738 chr1:39565160~39573203:+ PAAD cis rs718314 0.719 rs11048447 ENSG00000256625.1 RP11-582E3.4 3.95 0.000117 0.0377 0.37 0.31 Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Renal cell carcinoma;Waist circumference adjusted for body mass index; chr12:26291164 chr12:27121910~27147664:+ PAAD cis rs2117029 0.638 rs7296288 ENSG00000258017.1 RP11-386G11.10 -3.95 0.000117 0.0378 -0.4 -0.31 Intelligence (multi-trait analysis); chr12:49086185 chr12:49127782~49147869:+ PAAD cis rs7824557 0.767 rs2164273 ENSG00000205879.4 FAM90A2P 3.95 0.000117 0.0378 0.4 0.31 Retinal vascular caliber; chr8:11310990 chr8:12172202~12178575:- PAAD cis rs5758511 0.514 rs5751222 ENSG00000205702.9 CYP2D7 3.95 0.000117 0.0378 0.27 0.31 Birth weight; chr22:42121918 chr22:42140203~42144577:- PAAD cis rs11998649 0.64 rs6557592 ENSG00000253986.1 CTC-756D1.3 -3.95 0.000117 0.0378 -0.42 -0.31 Visceral fat; chr8:22773534 chr8:23493009~23494198:- PAAD cis rs11998649 0.64 rs7812430 ENSG00000253986.1 CTC-756D1.3 -3.95 0.000117 0.0378 -0.42 -0.31 Visceral fat; chr8:22773836 chr8:23493009~23494198:- PAAD cis rs6479901 0.894 rs4518976 ENSG00000232075.1 MRPL35P2 -3.95 0.000117 0.0378 -0.45 -0.31 Intelligence (multi-trait analysis); chr10:63319017 chr10:63634317~63634827:- PAAD cis rs6951245 1 rs28399710 ENSG00000229043.2 AC091729.9 -3.95 0.000117 0.0378 -0.48 -0.31 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1030995 chr7:1160374~1165267:+ PAAD cis rs2739330 0.796 rs5760106 ENSG00000206090.4 AP000350.7 -3.95 0.000117 0.0378 -0.39 -0.31 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23939998~23942798:+ PAAD cis rs891378 0.958 rs1354942 ENSG00000274245.1 RP11-357P18.2 3.95 0.000117 0.0378 0.44 0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207335147 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs1507761 ENSG00000274245.1 RP11-357P18.2 3.95 0.000117 0.0378 0.44 0.31 Spherical equivalent (joint analysis main effects and education interaction); chr1:207336454 chr1:207372559~207373252:+ PAAD cis rs755249 0.529 rs604316 ENSG00000228060.1 RP11-69E11.8 -3.95 0.000117 0.0378 -0.29 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39413694 chr1:39565160~39573203:+ PAAD cis rs9926296 0.706 rs2159115 ENSG00000260259.1 RP11-368I7.4 -3.95 0.000117 0.0378 -0.35 -0.31 Vitiligo; chr16:89765411 chr16:89682620~89686569:- PAAD cis rs8031584 0.679 rs34017474 ENSG00000270015.1 RP11-540B6.6 -3.95 0.000117 0.0378 -0.24 -0.31 Huntington's disease progression; chr15:30938408 chr15:30926514~30928407:+ PAAD cis rs9652601 0.779 rs12935413 ENSG00000274038.1 RP11-66H6.4 -3.95 0.000117 0.0378 -0.32 -0.31 Systemic lupus erythematosus; chr16:11116590 chr16:11056556~11057034:+ PAAD cis rs792448 0.743 rs351380 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212309510 chr1:212168207~212190259:+ PAAD cis rs792448 0.66 rs12035647 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212313969 chr1:212168207~212190259:+ PAAD cis rs792448 0.743 rs7519959 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212325310 chr1:212168207~212190259:+ PAAD cis rs792448 0.743 rs4951589 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212327351 chr1:212168207~212190259:+ PAAD cis rs792448 0.798 rs7521853 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212330862 chr1:212168207~212190259:+ PAAD cis rs792448 0.743 rs7415843 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212336420 chr1:212168207~212190259:+ PAAD cis rs792448 0.743 rs12033246 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212339906 chr1:212168207~212190259:+ PAAD cis rs792448 0.728 rs2252044 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212342903 chr1:212168207~212190259:+ PAAD cis rs792448 0.743 rs10019 ENSG00000229983.1 RP11-15I11.2 3.95 0.000117 0.0378 0.36 0.31 White blood cell count (basophil); chr1:212361035 chr1:212168207~212190259:+ PAAD cis rs792448 0.743 rs351393 ENSG00000229983.1 RP11-15I11.2 -3.95 0.000117 0.0378 -0.36 -0.31 White blood cell count (basophil); chr1:212303177 chr1:212168207~212190259:+ PAAD cis rs7617773 0.851 rs13068288 ENSG00000228638.1 FCF1P2 -3.95 0.000117 0.0378 -0.35 -0.31 Coronary artery disease; chr3:48290261 chr3:48290793~48291375:- PAAD cis rs950169 0.8 rs4842847 ENSG00000275120.1 RP11-182J1.17 3.95 0.000117 0.0378 0.32 0.31 Schizophrenia; chr15:84262447 chr15:84599434~84606463:- PAAD cis rs5769765 1 rs2295408 ENSG00000278869.1 CITF22-49E9.3 -3.95 0.000117 0.0378 -0.43 -0.31 Schizophrenia; chr22:49867403 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs2295409 ENSG00000278869.1 CITF22-49E9.3 -3.95 0.000117 0.0378 -0.43 -0.31 Schizophrenia; chr22:49867412 chr22:49933198~49934074:- PAAD cis rs2688608 0.592 rs11000760 ENSG00000271816.1 BMS1P4 3.95 0.000117 0.0378 0.31 0.31 Inflammatory bowel disease; chr10:73733976 chr10:73699151~73730487:- PAAD cis rs3015497 0.846 rs1565839 ENSG00000270062.1 RP11-248J18.3 3.95 0.000117 0.0378 0.28 0.31 Mean platelet volume; chr14:50617307 chr14:50723777~50724272:- PAAD cis rs11070836 1 rs11070836 ENSG00000259306.2 RP11-108K3.2 -3.95 0.000117 0.0378 -0.33 -0.31 Airway wall thickness; chr15:51144200 chr15:51315841~51321996:+ PAAD cis rs11070836 1 rs11070837 ENSG00000259306.2 RP11-108K3.2 -3.95 0.000117 0.0378 -0.33 -0.31 Airway wall thickness; chr15:51148690 chr15:51315841~51321996:+ PAAD cis rs13392177 0.66 rs12988046 ENSG00000261338.2 RP11-378A13.1 -3.95 0.000118 0.0378 -0.37 -0.31 Pyoderma gangrenosum in inflammatory bowel disease; chr2:218209081 chr2:218255319~218257366:+ PAAD cis rs9487094 0.961 rs11967108 ENSG00000260273.1 RP11-425D10.10 3.95 0.000118 0.0378 0.4 0.31 Height; chr6:109354040 chr6:109382795~109383666:+ PAAD cis rs9487094 0.961 rs12206928 ENSG00000260273.1 RP11-425D10.10 3.95 0.000118 0.0378 0.4 0.31 Height; chr6:109357908 chr6:109382795~109383666:+ PAAD cis rs9487094 0.885 rs1590306 ENSG00000260273.1 RP11-425D10.10 3.95 0.000118 0.0378 0.4 0.31 Height; chr6:109359747 chr6:109382795~109383666:+ PAAD cis rs848486 0.902 rs7795371 ENSG00000213542.3 RP11-467H10.1 3.95 0.000118 0.0378 0.33 0.31 Glomerular filtration rate; chr7:77733187 chr7:77115399~77116192:- PAAD cis rs7820074 0.751 rs6999579 ENSG00000253334.1 RP13-923O23.6 3.95 0.000118 0.0378 0.37 0.31 Orofacial clefts; chr8:82034501 chr8:81791823~81815714:+ PAAD cis rs6545883 0.524 rs2694618 ENSG00000271889.1 RP11-493E12.1 3.95 0.000118 0.0378 0.32 0.31 Tuberculosis; chr2:61309849 chr2:61151433~61162105:- PAAD cis rs10771431 0.81 rs10771418 ENSG00000111788.10 RP11-22B23.1 3.95 0.000118 0.0378 0.28 0.31 Breast size; chr12:9206399 chr12:9277235~9313241:+ PAAD cis rs7119038 0.818 rs1048024 ENSG00000255239.1 AP002954.6 -3.95 0.000118 0.0379 -0.44 -0.31 Sjögren's syndrome; chr11:118748067 chr11:118688039~118690600:- PAAD cis rs2998286 0.862 rs2486637 ENSG00000254635.4 WAC-AS1 -3.95 0.000118 0.0379 -0.37 -0.31 Sum eosinophil basophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Eosinophil counts; chr10:28505085 chr10:28522652~28532743:- PAAD cis rs3747517 0.759 rs3788964 ENSG00000226121.2 AC009487.6 -3.95 0.000118 0.0379 -0.49 -0.31 Psoriasis; chr2:162350970 chr2:161500885~161507705:- PAAD cis rs1862618 0.853 rs252904 ENSG00000271828.1 CTD-2310F14.1 3.95 0.000118 0.0379 0.45 0.31 Initial pursuit acceleration; chr5:56822906 chr5:56927874~56929573:+ PAAD cis rs5769765 0.862 rs138897 ENSG00000278869.1 CITF22-49E9.3 3.95 0.000118 0.0379 0.45 0.31 Schizophrenia; chr22:49837419 chr22:49933198~49934074:- PAAD cis rs4725617 0.686 rs6967117 ENSG00000176510.4 OR10AC1 3.95 0.000118 0.0379 0.64 0.31 Blood protein levels; chr7:143391774 chr7:143510933~143511911:- PAAD cis rs79349575 0.716 rs46522 ENSG00000270781.1 RP11-501C14.9 -3.95 0.000118 0.0379 -0.35 -0.31 Type 2 diabetes; chr17:48911235 chr17:48899131~48899748:+ PAAD cis rs748404 0.578 rs4547312 ENSG00000205771.5 CATSPER2P1 -3.95 0.000118 0.0379 -0.43 -0.31 Lung cancer; chr15:43339940 chr15:43726918~43747094:- PAAD cis rs2439831 0.702 rs2467402 ENSG00000275601.1 AC011330.13 3.95 0.000118 0.0379 0.51 0.31 Lung cancer in ever smokers; chr15:43732292 chr15:43642389~43643023:- PAAD cis rs889398 0.904 rs6499244 ENSG00000226232.7 RP11-419C5.2 -3.95 0.000118 0.038 -0.24 -0.31 Body mass index; chr16:69701368 chr16:69976388~69996188:- PAAD cis rs9595908 0.9 rs1324414 ENSG00000212293.1 SNORA16 3.95 0.000118 0.038 0.34 0.31 Body mass index; chr13:32600088 chr13:32420390~32420516:- PAAD cis rs2303759 0.914 rs2288481 ENSG00000268686.1 AC010524.2 -3.95 0.000118 0.038 -0.44 -0.31 Multiple sclerosis; chr19:49374939 chr19:49368705~49388081:- PAAD cis rs1015362 0.869 rs6088411 ENSG00000276073.1 RP5-1125A11.7 3.95 0.000118 0.038 0.35 0.31 Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling; chr20:34152101 chr20:33985617~33988989:- PAAD cis rs4802666 1 rs56354891 ENSG00000161643.11 SIGLEC16 -3.95 0.000118 0.038 -0.43 -0.31 Disc degeneration (lumbar); chr19:50224253 chr19:49969673~49975814:+ PAAD cis rs6921919 0.806 rs213230 ENSG00000204709.4 LINC01556 3.95 0.000118 0.0381 0.51 0.31 Autism spectrum disorder or schizophrenia; chr6:28362487 chr6:28943877~28944537:+ PAAD cis rs755249 0.501 rs1889830 ENSG00000261798.1 RP1-118J21.25 -3.95 0.000118 0.0381 -0.37 -0.31 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39264500 chr1:39788976~39790171:+ PAAD cis rs595244 1 rs16960886 ENSG00000259705.1 RP11-227D13.1 3.95 0.000118 0.0381 0.52 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48407289 chr15:48645951~48652016:+ PAAD cis rs9925964 0.933 rs749671 ENSG00000232748.3 RP11-196G11.6 3.95 0.000118 0.0381 0.36 0.31 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31077026 chr16:31056460~31062803:+ PAAD cis rs9925964 0.869 rs749670 ENSG00000232748.3 RP11-196G11.6 3.95 0.000118 0.0381 0.36 0.31 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31077304 chr16:31056460~31062803:+ PAAD cis rs6479901 0.947 rs10740123 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63404755 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs10761767 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63432671 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs10761768 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63434369 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs12573212 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63458665 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7074735 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63459519 chr10:63634317~63634827:- PAAD cis rs6479901 0.802 rs7075205 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63459834 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs10995540 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63460170 chr10:63634317~63634827:- PAAD cis rs6479901 0.894 rs1061259 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63465484 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs10995541 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63473575 chr10:63634317~63634827:- PAAD cis rs6479901 0.894 rs10761773 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63480322 chr10:63634317~63634827:- PAAD cis rs6479901 0.894 rs2393978 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63482050 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs10822173 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63483842 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7085862 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63486687 chr10:63634317~63634827:- PAAD cis rs6479901 0.894 rs9919452 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63488812 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs10761776 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63491217 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7910662 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63493940 chr10:63634317~63634827:- PAAD cis rs6479901 0.624 rs10822175 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63495414 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7083823 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63510912 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7097698 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63513635 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7068144 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63514500 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7082076 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63517185 chr10:63634317~63634827:- PAAD cis rs6479901 1 rs10740133 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63517676 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs10822179 ENSG00000232075.1 MRPL35P2 -3.95 0.000118 0.0381 -0.44 -0.31 Intelligence (multi-trait analysis); chr10:63520404 chr10:63634317~63634827:- PAAD cis rs2439831 1 rs1814538 ENSG00000275601.1 AC011330.13 3.95 0.000119 0.0381 0.55 0.31 Lung cancer in ever smokers; chr15:43467576 chr15:43642389~43643023:- PAAD cis rs1275468 0.731 rs1480001 ENSG00000257497.2 RP11-585P4.5 -3.95 0.000119 0.0381 -0.48 -0.31 Polycystic ovary syndrome; chr12:75586939 chr12:75483454~75489820:- PAAD cis rs17772222 0.876 rs58655091 ENSG00000258983.2 RP11-507K2.2 3.95 0.000119 0.0381 0.4 0.31 Coronary artery calcification; chr14:88748567 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs1956406 ENSG00000258983.2 RP11-507K2.2 3.95 0.000119 0.0381 0.4 0.31 Coronary artery calcification; chr14:88749711 chr14:88499334~88515502:+ PAAD cis rs763121 0.819 rs4560233 ENSG00000228274.3 RP3-508I15.9 -3.95 0.000119 0.0381 -0.29 -0.31 Menopause (age at onset); chr22:38586437 chr22:38667585~38681820:- PAAD cis rs5760092 0.755 rs4585126 ENSG00000206090.4 AP000350.7 -3.95 0.000119 0.0381 -0.43 -0.31 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23927818 chr22:23939998~23942798:+ PAAD cis rs7246657 0.551 rs28462002 ENSG00000267422.1 CTD-2554C21.1 -3.95 0.000119 0.0381 -0.57 -0.31 Coronary artery calcification; chr19:37143560 chr19:37779686~37792865:+ PAAD cis rs2243480 1 rs4718334 ENSG00000228409.4 CCT6P1 -3.95 0.000119 0.0381 -0.32 -0.31 Diabetic kidney disease; chr7:66324467 chr7:65751142~65763354:+ PAAD cis rs9322193 0.923 rs66516768 ENSG00000268592.3 RAET1E-AS1 3.95 0.000119 0.0381 0.35 0.31 Lung cancer; chr6:149671999 chr6:149863494~149919507:+ PAAD cis rs4266144 0.544 rs7340627 ENSG00000241135.4 LINC00881 3.95 0.000119 0.0381 0.39 0.31 Coronary artery disease; chr3:157114604 chr3:157089881~157101135:+ PAAD cis rs4266144 0.544 rs13080798 ENSG00000241135.4 LINC00881 3.95 0.000119 0.0381 0.39 0.31 Coronary artery disease; chr3:157114612 chr3:157089881~157101135:+ PAAD cis rs11048434 0.518 rs4883206 ENSG00000256720.1 RP11-436I9.6 -3.95 0.000119 0.0381 -0.28 -0.31 Sjögren's syndrome; chr12:9021169 chr12:9135084~9135591:+ PAAD cis rs7688540 0.511 rs75433628 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:184563 chr4:149738~150317:+ PAAD cis rs7688540 0.511 rs4522818 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:187973 chr4:149738~150317:+ PAAD cis rs7688540 0.511 rs61794969 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:194242 chr4:149738~150317:+ PAAD cis rs7688540 0.511 rs77815676 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:196080 chr4:149738~150317:+ PAAD cis rs7688540 0.547 rs11728864 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:197518 chr4:149738~150317:+ PAAD cis rs7688540 0.511 rs76125013 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:201493 chr4:149738~150317:+ PAAD cis rs11723261 0.545 rs6812799 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Immune response to smallpox vaccine (IL-6); chr4:203545 chr4:149738~150317:+ PAAD cis rs7688540 0.511 rs6841415 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:203594 chr4:149738~150317:+ PAAD cis rs7688540 0.511 rs61794991 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:204418 chr4:149738~150317:+ PAAD cis rs7688540 0.511 rs11731623 ENSG00000275426.1 CH17-262A2.1 3.95 0.000119 0.0381 0.49 0.31 Facial morphology (factor 6, height of vermillion lower lip); chr4:207221 chr4:149738~150317:+ PAAD cis rs875971 0.522 rs4718286 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Aortic root size; chr7:65827777 chr7:65840212~65840596:+ PAAD cis rs17711722 0.585 rs6942660 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Calcium levels; chr7:65837419 chr7:65840212~65840596:+ PAAD cis rs875971 0.516 rs6945322 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Aortic root size; chr7:65871069 chr7:65840212~65840596:+ PAAD cis rs17711722 0.701 rs55773927 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Calcium levels; chr7:65872915 chr7:65840212~65840596:+ PAAD cis rs17711722 0.727 rs35850374 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Calcium levels; chr7:65892789 chr7:65840212~65840596:+ PAAD cis rs17711722 0.701 rs4467826 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Calcium levels; chr7:65903721 chr7:65840212~65840596:+ PAAD cis rs875971 0.522 rs7784623 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Aortic root size; chr7:65930047 chr7:65840212~65840596:+ PAAD cis rs875971 0.522 rs34973832 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Aortic root size; chr7:65931217 chr7:65840212~65840596:+ PAAD cis rs17711722 0.74 rs7809991 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Calcium levels; chr7:65941231 chr7:65840212~65840596:+ PAAD cis rs875971 0.522 rs6960048 ENSG00000236529.1 RP13-254B10.1 3.95 0.000119 0.0382 0.33 0.31 Aortic root size; chr7:65943052 chr7:65840212~65840596:+ PAAD cis rs6144337 1 rs6144337 ENSG00000255007.1 CTD-2589M5.4 3.95 0.000119 0.0382 0.37 0.31 Lymphocyte percentage of white cells; chr11:47262763 chr11:46256355~46274547:- PAAD cis rs34375054 0.573 rs12579211 ENSG00000279233.1 RP11-158L12.4 3.95 0.000119 0.0382 0.29 0.31 Post bronchodilator FEV1/FVC ratio; chr12:125163206 chr12:125138245~125141711:+ PAAD cis rs950169 1 rs1818950 ENSG00000275120.1 RP11-182J1.17 3.95 0.000119 0.0382 0.32 0.31 Schizophrenia; chr15:84053769 chr15:84599434~84606463:- PAAD cis rs1113500 0.965 rs10881495 ENSG00000226822.1 RP11-356N1.2 3.95 0.000119 0.0382 0.36 0.31 Growth-regulated protein alpha levels; chr1:108068364 chr1:108071482~108074519:+ PAAD cis rs7923837 0.656 rs2497306 ENSG00000236493.2 EIF2S2P3 -3.95 0.000119 0.0382 -0.38 -0.31 Multiple sclerosis;Body mass index; chr10:92725454 chr10:92668745~92669743:- PAAD cis rs293748 0.882 rs158802 ENSG00000250155.1 CTD-2353F22.1 -3.95 0.000119 0.0382 -0.47 -0.31 Obesity-related traits; chr5:36941446 chr5:36666214~36725195:- PAAD cis rs293748 0.882 rs293774 ENSG00000250155.1 CTD-2353F22.1 -3.95 0.000119 0.0382 -0.47 -0.31 Obesity-related traits; chr5:36943166 chr5:36666214~36725195:- PAAD cis rs633715 0.766 rs4609391 ENSG00000254154.7 RP4-798P15.3 -3.95 0.000119 0.0382 -0.29 -0.31 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177825882 chr1:177928788~178038007:- PAAD cis rs2288884 0.515 rs2869602 ENSG00000275055.1 CTC-471J1.11 -3.95 0.000119 0.0382 -0.41 -0.31 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52072324 chr19:52049007~52049754:+ PAAD cis rs10779751 0.77 rs2258621 ENSG00000238199.1 UBE2V2P3 -3.95 0.000119 0.0382 -0.39 -0.31 Body mass index; chr1:11081130 chr1:11278616~11279351:- PAAD cis rs4853012 0.838 rs4429500 ENSG00000257800.1 FNBP1P1 3.95 0.000119 0.0383 0.42 0.31 Gestational age at birth (maternal effect); chr2:74118209 chr2:74120680~74123218:+ PAAD cis rs10951983 0.904 rs34884077 ENSG00000272719.1 CTB-161C1.1 -3.95 0.000119 0.0383 -0.38 -0.31 Coronary artery disease; chr7:6381963 chr7:5556731~5557245:+ PAAD cis rs35934224 0.542 rs8139091 ENSG00000272682.1 AC004471.10 3.95 0.000119 0.0383 0.46 0.31 Glaucoma (primary open-angle); chr22:19857760 chr22:19124309~19128449:- PAAD cis rs853679 0.76 rs9468317 ENSG00000226314.6 ZNF192P1 -3.95 0.000119 0.0383 -0.49 -0.31 Depression; chr6:28230678 chr6:28161781~28169594:+ PAAD cis rs17772222 0.874 rs61984746 ENSG00000258983.2 RP11-507K2.2 3.95 0.000119 0.0383 0.4 0.31 Coronary artery calcification; chr14:88668136 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs17188207 ENSG00000258983.2 RP11-507K2.2 3.95 0.000119 0.0383 0.4 0.31 Coronary artery calcification; chr14:88699579 chr14:88499334~88515502:+ PAAD cis rs7615952 0.673 rs9821905 ENSG00000239804.1 RP11-379B18.1 -3.95 0.000119 0.0383 -0.53 -0.31 Blood pressure (smoking interaction); chr3:125902007 chr3:125787888~125788146:- PAAD cis rs13178541 0.641 rs10053928 ENSG00000250378.1 RP11-119J18.1 -3.95 0.000119 0.0383 -0.44 -0.31 IgG glycosylation; chr5:135795501 chr5:135812667~135826582:+ PAAD cis rs2243480 0.901 rs778730 ENSG00000273142.1 RP11-458F8.4 -3.95 0.000119 0.0383 -0.27 -0.31 Diabetic kidney disease; chr7:66358338 chr7:66902857~66906297:+ PAAD cis rs853679 0.517 rs9380052 ENSG00000204709.4 LINC01556 3.95 0.000119 0.0383 0.51 0.31 Depression; chr6:28096845 chr6:28943877~28944537:+ PAAD cis rs62103177 0.568 rs2365388 ENSG00000261126.6 RP11-795F19.1 3.95 0.000119 0.0383 0.41 0.31 Opioid sensitivity; chr18:80215819 chr18:80046900~80095482:+ PAAD cis rs116139393 0.611 rs7792579 ENSG00000187953.9 PMS2CL -3.95 0.000119 0.0383 -0.38 -0.31 Alzheimer's disease (APOE e4 interaction); chr7:6725962 chr7:6710128~6753862:+ PAAD cis rs9322193 0.923 rs4870509 ENSG00000268592.3 RAET1E-AS1 3.95 0.000119 0.0383 0.36 0.31 Lung cancer; chr6:149702212 chr6:149863494~149919507:+ PAAD cis rs1555322 1 rs1555322 ENSG00000279253.1 RP4-614O4.13 -3.95 0.000119 0.0383 -0.39 -0.31 Attention deficit hyperactivity disorder; chr20:35261376 chr20:35262727~35264187:- PAAD cis rs1555322 1 rs2425027 ENSG00000279253.1 RP4-614O4.13 -3.95 0.000119 0.0383 -0.39 -0.31 Attention deficit hyperactivity disorder; chr20:35261587 chr20:35262727~35264187:- PAAD cis rs7824557 0.767 rs3808509 ENSG00000205879.4 FAM90A2P 3.95 0.00012 0.0383 0.4 0.31 Retinal vascular caliber; chr8:11305747 chr8:12172202~12178575:- PAAD cis rs7824557 0.736 rs35392635 ENSG00000205879.4 FAM90A2P 3.95 0.00012 0.0383 0.4 0.31 Retinal vascular caliber; chr8:11306840 chr8:12172202~12178575:- PAAD cis rs7824557 0.767 rs11775635 ENSG00000205879.4 FAM90A2P 3.95 0.00012 0.0383 0.4 0.31 Retinal vascular caliber; chr8:11307356 chr8:12172202~12178575:- PAAD cis rs7824557 0.767 rs28507159 ENSG00000205879.4 FAM90A2P 3.95 0.00012 0.0383 0.4 0.31 Retinal vascular caliber; chr8:11308567 chr8:12172202~12178575:- PAAD cis rs2041895 0.509 rs12368448 ENSG00000260329.1 RP11-412D9.4 3.95 0.00012 0.0383 0.29 0.31 Glaucoma (low intraocular pressure); chr12:106923018 chr12:106954029~106955497:- PAAD cis rs1876905 1 rs1876905 ENSG00000230177.1 RP5-1112D6.4 -3.95 0.00012 0.0383 -0.34 -0.31 Mean corpuscular hemoglobin; chr6:111096756 chr6:111277932~111278742:+ PAAD cis rs10540 1 rs71487292 ENSG00000255237.1 RP13-317D12.3 3.95 0.00012 0.0383 0.48 0.31 Body mass index; chr11:486076 chr11:462930~463899:- PAAD cis rs11123170 0.64 rs1015754 ENSG00000274877.1 RP11-65I12.1 3.95 0.00012 0.0383 0.37 0.31 Renal function-related traits (BUN); chr2:113210413 chr2:113237595~113240825:+ PAAD cis rs6543140 0.964 rs6543142 ENSG00000234389.1 AC007278.3 3.95 0.00012 0.0384 0.34 0.31 Blood protein levels; chr2:102465546 chr2:102438713~102440475:+ PAAD cis rs6543140 0.929 rs6742530 ENSG00000234389.1 AC007278.3 3.95 0.00012 0.0384 0.34 0.31 Blood protein levels; chr2:102465820 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs2141781 ENSG00000234389.1 AC007278.3 3.95 0.00012 0.0384 0.34 0.31 Blood protein levels; chr2:102466446 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs11903551 ENSG00000234389.1 AC007278.3 3.95 0.00012 0.0384 0.34 0.31 Blood protein levels; chr2:102467721 chr2:102438713~102440475:+ PAAD cis rs79349575 0.749 rs1057902 ENSG00000270781.1 RP11-501C14.9 -3.95 0.00012 0.0384 -0.35 -0.31 Type 2 diabetes; chr17:48928226 chr17:48899131~48899748:+ PAAD cis rs10838687 0.673 rs77532017 ENSG00000255007.1 CTD-2589M5.4 3.95 0.00012 0.0384 0.37 0.31 Proinsulin levels; chr11:47262766 chr11:46256355~46274547:- PAAD cis rs3785888 0.548 rs11079744 ENSG00000214401.4 KANSL1-AS1 3.95 0.00012 0.0384 0.43 0.31 Cleft lip with or without cleft palate; chr17:46949753 chr17:46193576~46196723:+ PAAD cis rs3785888 0.548 rs3885731 ENSG00000214401.4 KANSL1-AS1 3.95 0.00012 0.0384 0.43 0.31 Cleft lip with or without cleft palate; chr17:46955944 chr17:46193576~46196723:+ PAAD cis rs12908161 0.959 rs17598603 ENSG00000259683.1 RP11-182J1.14 -3.95 0.00012 0.0384 -0.25 -0.31 Schizophrenia; chr15:84656980 chr15:84389729~84395903:+ PAAD cis rs595244 1 rs56286136 ENSG00000259705.1 RP11-227D13.1 3.95 0.00012 0.0384 0.49 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48463617 chr15:48645951~48652016:+ PAAD cis rs595244 1 rs55999498 ENSG00000259705.1 RP11-227D13.1 3.95 0.00012 0.0384 0.49 0.31 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48466330 chr15:48645951~48652016:+ PAAD cis rs10083777 0.551 rs79378252 ENSG00000261061.1 RP11-303E16.2 -3.95 0.00012 0.0384 -0.63 -0.31 Metabolite levels (small molecules and protein measures); chr16:81014554 chr16:81030770~81031485:+ PAAD cis rs4438643 1 rs6782743 ENSG00000263826.1 RP11-573D15.9 3.95 0.00012 0.0384 0.26 0.31 Methadone dose in opioid dependence; chr3:186441341 chr3:186781780~186784179:- PAAD cis rs7829975 0.539 rs883647 ENSG00000253893.2 FAM85B 3.95 0.00012 0.0384 0.45 0.31 Mood instability; chr8:8712214 chr8:8167819~8226614:- PAAD cis rs3781264 0.724 rs11558740 ENSG00000273450.1 RP11-76P2.4 3.95 0.00012 0.0384 0.42 0.31 Esophageal cancer and gastric cancer; chr10:94333618 chr10:94314907~94315327:- PAAD cis rs4403732 1 rs4237333 ENSG00000230526.1 RP11-472G21.2 3.95 0.00012 0.0384 0.56 0.31 Coronary artery disease; chr10:71877468 chr10:71878356~71879107:+ PAAD cis rs8062405 0.755 rs62031607 ENSG00000251417.2 RP11-1348G14.4 -3.95 0.00012 0.0385 -0.29 -0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28620209 chr16:28802743~28817828:+ PAAD cis rs3781264 0.761 rs7077192 ENSG00000273450.1 RP11-76P2.4 3.95 0.00012 0.0385 0.41 0.3 Esophageal cancer and gastric cancer; chr10:94365407 chr10:94314907~94315327:- PAAD cis rs3781264 0.761 rs12219063 ENSG00000273450.1 RP11-76P2.4 3.95 0.00012 0.0385 0.41 0.3 Esophageal cancer and gastric cancer; chr10:94366173 chr10:94314907~94315327:- PAAD cis rs1707322 0.721 rs11211165 ENSG00000280836.1 AL355480.1 -3.95 0.00012 0.0385 -0.36 -0.3 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45692234 chr1:45581219~45581321:- PAAD cis rs1707322 0.721 rs4559551 ENSG00000280836.1 AL355480.1 -3.95 0.00012 0.0385 -0.36 -0.3 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45701861 chr1:45581219~45581321:- PAAD cis rs801193 0.66 rs2659914 ENSG00000237310.1 GS1-124K5.4 3.95 0.00012 0.0385 0.3 0.3 Aortic root size; chr7:66691927 chr7:66493706~66495474:+ PAAD cis rs28374715 0.787 rs11856169 ENSG00000247556.5 OIP5-AS1 3.95 0.00012 0.0385 0.33 0.3 Ulcerative colitis; chr15:41255740 chr15:41283990~41309737:+ PAAD cis rs193541 0.632 rs400207 ENSG00000263432.2 RN7SL689P -3.95 0.00012 0.0385 -0.4 -0.3 Glucose homeostasis traits; chr5:122982802 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs415417 ENSG00000263432.2 RN7SL689P -3.95 0.00012 0.0385 -0.4 -0.3 Glucose homeostasis traits; chr5:122987189 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs62377425 ENSG00000263432.2 RN7SL689P -3.95 0.00012 0.0385 -0.4 -0.3 Glucose homeostasis traits; chr5:122996930 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs34714850 ENSG00000263432.2 RN7SL689P -3.95 0.00012 0.0385 -0.4 -0.3 Glucose homeostasis traits; chr5:122997000 chr5:123022487~123022783:- PAAD cis rs11159086 1 rs3759745 ENSG00000270000.1 RP3-449M8.9 3.95 0.00012 0.0385 0.46 0.3 Advanced glycation end-product levels; chr14:74495967 chr14:74471930~74472360:- PAAD cis rs11159086 1 rs4903232 ENSG00000270000.1 RP3-449M8.9 3.95 0.00012 0.0385 0.46 0.3 Advanced glycation end-product levels; chr14:74496585 chr14:74471930~74472360:- PAAD cis rs11992162 0.506 rs55948474 ENSG00000254866.2 DEFB109P3 3.95 0.00012 0.0385 0.41 0.3 Monocyte count; chr8:11952153 chr8:12150895~12151134:- PAAD cis rs55702914 0.628 rs12151767 ENSG00000231621.1 AC013264.2 -3.95 0.00012 0.0385 -0.29 -0.3 Major depression and alcohol dependence; chr2:197410205 chr2:197197991~197199273:+ PAAD cis rs55702914 0.628 rs55658871 ENSG00000231621.1 AC013264.2 -3.95 0.00012 0.0385 -0.29 -0.3 Major depression and alcohol dependence; chr2:197413847 chr2:197197991~197199273:+ PAAD cis rs55702914 0.602 rs2564372 ENSG00000231621.1 AC013264.2 -3.95 0.00012 0.0385 -0.29 -0.3 Major depression and alcohol dependence; chr2:197443089 chr2:197197991~197199273:+ PAAD cis rs710913 0.618 rs11206437 ENSG00000243970.1 PPIEL 3.95 0.00012 0.0385 0.27 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39613039 chr1:39531838~39558707:- PAAD cis rs683250 0.599 rs10501539 ENSG00000227097.5 RPS28P7 3.95 0.00012 0.0385 0.38 0.3 Subcortical brain region volumes; chr11:83355533 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs11233576 ENSG00000227097.5 RPS28P7 3.95 0.00012 0.0385 0.38 0.3 Subcortical brain region volumes; chr11:83356330 chr11:82689559~82689768:+ PAAD cis rs683250 0.569 rs11233577 ENSG00000227097.5 RPS28P7 3.95 0.00012 0.0385 0.38 0.3 Subcortical brain region volumes; chr11:83356345 chr11:82689559~82689768:+ PAAD cis rs683250 0.569 rs4617618 ENSG00000227097.5 RPS28P7 3.95 0.00012 0.0385 0.38 0.3 Subcortical brain region volumes; chr11:83356502 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs4590895 ENSG00000227097.5 RPS28P7 3.95 0.00012 0.0385 0.38 0.3 Subcortical brain region volumes; chr11:83356617 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs4445661 ENSG00000227097.5 RPS28P7 3.95 0.00012 0.0385 0.38 0.3 Subcortical brain region volumes; chr11:83356829 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs4590896 ENSG00000227097.5 RPS28P7 3.95 0.00012 0.0385 0.38 0.3 Subcortical brain region volumes; chr11:83356907 chr11:82689559~82689768:+ PAAD cis rs683250 0.599 rs4619176 ENSG00000227097.5 RPS28P7 3.95 0.00012 0.0385 0.38 0.3 Subcortical brain region volumes; chr11:83356954 chr11:82689559~82689768:+ PAAD cis rs748404 0.631 rs6493083 ENSG00000205771.5 CATSPER2P1 -3.95 0.00012 0.0385 -0.41 -0.3 Lung cancer; chr15:43345787 chr15:43726918~43747094:- PAAD cis rs2742417 1 rs1534876 ENSG00000244357.3 RN7SL145P 3.95 0.00012 0.0385 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45699765 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673034 ENSG00000244357.3 RN7SL145P 3.95 0.00012 0.0385 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45713646 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742386 ENSG00000244357.3 RN7SL145P 3.95 0.00012 0.0385 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45714818 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742389 ENSG00000244357.3 RN7SL145P 3.95 0.00012 0.0385 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45715191 chr3:45742675~45742970:+ PAAD cis rs8026198 0.705 rs4583208 ENSG00000260571.1 BNIP3P5 3.95 0.00012 0.0386 0.59 0.3 Fibrinogen levels; chr15:42264559 chr15:42313687~42314386:+ PAAD cis rs878939 0.625 rs17493485 ENSG00000233690.1 EBAG9P1 3.95 0.000121 0.0386 0.4 0.3 Warfarin maintenance dose; chr10:99584123 chr10:99697407~99697949:- PAAD cis rs11790994 0.915 rs1335050 ENSG00000271384.1 RP11-435O5.7 -3.95 0.000121 0.0386 -0.6 -0.3 Inattentive symptoms; chr9:95664357 chr9:95406990~95407662:- PAAD cis rs9287719 0.649 rs6721857 ENSG00000243819.4 RN7SL832P -3.95 0.000121 0.0386 -0.29 -0.3 Prostate cancer; chr2:10581084 chr2:10690344~10692099:+ PAAD cis rs55702914 0.628 rs788016 ENSG00000231621.1 AC013264.2 3.95 0.000121 0.0386 0.29 0.3 Major depression and alcohol dependence; chr2:197487569 chr2:197197991~197199273:+ PAAD cis rs9322193 0.81 rs62439811 ENSG00000268592.3 RAET1E-AS1 3.95 0.000121 0.0386 0.36 0.3 Lung cancer; chr6:149640416 chr6:149863494~149919507:+ PAAD cis rs3015497 0.648 rs10144512 ENSG00000270062.1 RP11-248J18.3 3.95 0.000121 0.0386 0.29 0.3 Mean platelet volume; chr14:50615553 chr14:50723777~50724272:- PAAD cis rs3015497 0.616 rs34061700 ENSG00000270062.1 RP11-248J18.3 3.95 0.000121 0.0386 0.29 0.3 Mean platelet volume; chr14:50618142 chr14:50723777~50724272:- PAAD cis rs9595908 0.9 rs9591137 ENSG00000212293.1 SNORA16 3.95 0.000121 0.0386 0.34 0.3 Body mass index; chr13:32578345 chr13:32420390~32420516:- PAAD cis rs848486 0.846 rs13237154 ENSG00000213542.3 RP11-467H10.1 3.95 0.000121 0.0386 0.33 0.3 Glomerular filtration rate; chr7:77720619 chr7:77115399~77116192:- PAAD cis rs848486 0.905 rs6963486 ENSG00000213542.3 RP11-467H10.1 3.95 0.000121 0.0386 0.33 0.3 Glomerular filtration rate; chr7:77720630 chr7:77115399~77116192:- PAAD cis rs6479901 0.639 rs10995450 ENSG00000232075.1 MRPL35P2 3.95 0.000121 0.0386 0.46 0.3 Intelligence (multi-trait analysis); chr10:63129151 chr10:63634317~63634827:- PAAD cis rs867529 0.924 rs6547787 ENSG00000230006.6 ANKRD36BP2 -3.95 0.000121 0.0386 -0.25 -0.3 Height; chr2:88630218 chr2:88765807~88806612:+ PAAD cis rs867529 0.924 rs11684404 ENSG00000230006.6 ANKRD36BP2 3.95 0.000121 0.0386 0.25 0.3 Height; chr2:88625104 chr2:88765807~88806612:+ PAAD cis rs1910358 0.554 rs13356462 ENSG00000248874.4 C5orf17 -3.95 0.000121 0.0387 -0.41 -0.3 Venous thromboembolism (SNP x SNP interaction); chr5:23819849 chr5:23951348~24178263:+ PAAD cis rs4453827 0.612 rs3774583 ENSG00000271916.1 RP11-884K10.6 3.95 0.000121 0.0387 0.3 0.3 Blood protein levels; chr3:53769236 chr3:53797764~53798019:- PAAD cis rs812925 0.559 rs2600667 ENSG00000271889.1 RP11-493E12.1 3.95 0.000121 0.0387 0.35 0.3 Immature fraction of reticulocytes; chr2:61177796 chr2:61151433~61162105:- PAAD cis rs66887589 0.72 rs2036858 ENSG00000248280.1 RP11-33B1.2 3.95 0.000121 0.0387 0.29 0.3 Diastolic blood pressure; chr4:119328082 chr4:119440561~119450157:- PAAD cis rs13256369 1 rs1109619 ENSG00000253981.4 ALG1L13P 3.95 0.000121 0.0387 0.41 0.3 Obesity-related traits; chr8:8714106 chr8:8236003~8244667:- PAAD cis rs11668609 0.81 rs9305015 ENSG00000269397.1 CTB-92J24.2 -3.95 0.000121 0.0387 -0.53 -0.3 Response to taxane treatment (docetaxel); chr19:24157700 chr19:23927788~23929287:+ PAAD cis rs763121 0.889 rs2267390 ENSG00000228274.3 RP3-508I15.9 -3.95 0.000121 0.0387 -0.29 -0.3 Menopause (age at onset); chr22:38493652 chr22:38667585~38681820:- PAAD cis rs2739330 0.828 rs2330635 ENSG00000206090.4 AP000350.7 3.95 0.000121 0.0387 0.39 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23939998~23942798:+ PAAD cis rs28386778 0.863 rs1376110 ENSG00000240280.5 TCAM1P -3.95 0.000121 0.0387 -0.42 -0.3 Prudent dietary pattern; chr17:63702567 chr17:63849292~63864379:+ PAAD cis rs1707322 0.717 rs3014237 ENSG00000280836.1 AL355480.1 3.95 0.000121 0.0387 0.37 0.3 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45624580 chr1:45581219~45581321:- PAAD cis rs10779751 0.77 rs12097293 ENSG00000238199.1 UBE2V2P3 3.95 0.000121 0.0387 0.39 0.3 Body mass index; chr1:11137410 chr1:11278616~11279351:- PAAD cis rs10779751 0.77 rs11121695 ENSG00000238199.1 UBE2V2P3 3.95 0.000121 0.0387 0.39 0.3 Body mass index; chr1:11169458 chr1:11278616~11279351:- PAAD cis rs13256369 1 rs873064 ENSG00000253981.4 ALG1L13P 3.95 0.000121 0.0388 0.4 0.3 Obesity-related traits; chr8:8714870 chr8:8236003~8244667:- PAAD cis rs13256369 1 rs873063 ENSG00000253981.4 ALG1L13P 3.95 0.000121 0.0388 0.4 0.3 Obesity-related traits; chr8:8714937 chr8:8236003~8244667:- PAAD cis rs13256369 1 rs10103769 ENSG00000253981.4 ALG1L13P 3.95 0.000121 0.0388 0.4 0.3 Obesity-related traits; chr8:8715526 chr8:8236003~8244667:- PAAD cis rs7688540 0.511 rs6845131 ENSG00000275426.1 CH17-262A2.1 3.95 0.000121 0.0388 0.49 0.3 Facial morphology (factor 6, height of vermillion lower lip); chr4:206358 chr4:149738~150317:+ PAAD cis rs12940030 0.794 rs2191197 ENSG00000236088.8 COX10-AS1 -3.95 0.000121 0.0388 -0.29 -0.3 Corneal structure; chr17:14660522 chr17:13756478~14069495:- PAAD cis rs10779751 1 rs11121702 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11233090 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs718206 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11234417 chr1:11278616~11279351:- PAAD cis rs10779751 0.96 rs1883964 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11234885 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs7524202 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11237705 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs2024627 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11238733 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs4845859 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11244816 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs6679878 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11246825 chr1:11278616~11279351:- PAAD cis rs10779751 0.922 rs11121708 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11247196 chr1:11278616~11279351:- PAAD cis rs10779751 1 rs6670821 ENSG00000238199.1 UBE2V2P3 -3.95 0.000121 0.0388 -0.36 -0.3 Body mass index; chr1:11248705 chr1:11278616~11279351:- PAAD cis rs9322193 0.923 rs62439840 ENSG00000268592.3 RAET1E-AS1 3.95 0.000121 0.0388 0.36 0.3 Lung cancer; chr6:149674639 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9393175 ENSG00000268592.3 RAET1E-AS1 3.95 0.000121 0.0388 0.36 0.3 Lung cancer; chr6:149677587 chr6:149863494~149919507:+ PAAD cis rs9287719 0.649 rs10207885 ENSG00000243819.4 RN7SL832P 3.95 0.000121 0.0388 0.29 0.3 Prostate cancer; chr2:10593062 chr2:10690344~10692099:+ PAAD cis rs453301 0.686 rs7814328 ENSG00000254340.1 RP11-10A14.3 -3.95 0.000121 0.0388 -0.38 -0.3 Joint mobility (Beighton score); chr8:9018719 chr8:9141424~9145435:+ PAAD cis rs12291225 0.535 rs11023203 ENSG00000251991.1 RNU7-49P 3.95 0.000121 0.0388 0.37 0.3 Sense of smell; chr11:14388269 chr11:14478892~14478953:+ PAAD cis rs55665837 0.583 rs78843135 ENSG00000251991.1 RNU7-49P 3.95 0.000121 0.0388 0.37 0.3 Vitamin D levels; chr11:14389708 chr11:14478892~14478953:+ PAAD cis rs12291225 0.535 rs12806025 ENSG00000251991.1 RNU7-49P 3.95 0.000121 0.0388 0.37 0.3 Sense of smell; chr11:14392271 chr11:14478892~14478953:+ PAAD cis rs55665837 0.524 rs2882128 ENSG00000251991.1 RNU7-49P 3.95 0.000121 0.0388 0.37 0.3 Vitamin D levels; chr11:14393088 chr11:14478892~14478953:+ PAAD cis rs10761482 0.5 rs1938524 ENSG00000254271.1 RP11-131N11.4 3.95 0.000121 0.0388 0.37 0.3 Schizophrenia; chr10:60543815 chr10:60734342~60741828:+ PAAD cis rs755249 0.567 rs16825887 ENSG00000261798.1 RP1-118J21.25 -3.95 0.000121 0.0388 -0.39 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39177710 chr1:39788976~39790171:+ PAAD cis rs11997175 0.646 rs6468197 ENSG00000240738.1 RP1-273G13.1 3.95 0.000122 0.0388 0.36 0.3 Body mass index; chr8:33877376 chr8:33859480~33860223:- PAAD cis rs11997175 0.646 rs28785323 ENSG00000240738.1 RP1-273G13.1 3.95 0.000122 0.0388 0.36 0.3 Body mass index; chr8:33878586 chr8:33859480~33860223:- PAAD cis rs11997175 0.646 rs67480501 ENSG00000240738.1 RP1-273G13.1 3.95 0.000122 0.0388 0.36 0.3 Body mass index; chr8:33878797 chr8:33859480~33860223:- PAAD cis rs151234 0.741 rs56236750 ENSG00000259982.1 CDC37P1 -3.94 0.000122 0.0388 -0.58 -0.3 Platelet distribution width; chr16:28583390 chr16:28700294~28701540:- PAAD cis rs72615157 0.539 rs2261360 ENSG00000078319.8 PMS2P1 -3.94 0.000122 0.0388 -0.43 -0.3 Lung function (FEV1/FVC); chr7:100095370 chr7:100320992~100341908:- PAAD cis rs6840258 1 rs6819155 ENSG00000251411.1 RP11-397E7.4 -3.94 0.000122 0.0388 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87055026 chr4:86913266~86914817:- PAAD cis rs6545883 0.507 rs6545855 ENSG00000273302.1 RP11-493E12.2 -3.94 0.000122 0.0388 -0.27 -0.3 Tuberculosis; chr2:61305725 chr2:61199979~61200769:+ PAAD cis rs2283792 0.764 rs2298432 ENSG00000228050.1 TOP3BP1 3.94 0.000122 0.0388 0.34 0.3 Multiple sclerosis; chr22:21768900 chr22:22223187~22224566:- PAAD cis rs11089937 0.626 rs737840 ENSG00000211638.2 IGLV8-61 -3.94 0.000122 0.0389 -0.3 -0.3 Periodontitis (PAL4Q3); chr22:22162743 chr22:22098700~22099212:+ PAAD cis rs6472235 1 rs28407694 ENSG00000200714.1 Y_RNA -3.94 0.000122 0.0389 -0.4 -0.3 Plateletcrit;Myopia (pathological); chr8:65949503 chr8:65592731~65592820:+ PAAD cis rs10421328 0.784 rs11667828 ENSG00000259242.2 AC002306.1 -3.94 0.000122 0.0389 -0.45 -0.3 Parental longevity (combined parental age at death); chr19:19657665 chr19:19606350~19608660:+ PAAD cis rs10129255 0.5 rs4774008 ENSG00000211972.2 IGHV3-66 3.94 0.000122 0.0389 0.24 0.3 Kawasaki disease; chr14:106681273 chr14:106675017~106675544:- PAAD cis rs6723226 0.557 rs62136260 ENSG00000276334.1 AL133243.1 -3.94 0.000122 0.0389 -0.38 -0.3 Intelligence (multi-trait analysis); chr2:32350379 chr2:32521927~32523547:+ PAAD cis rs875971 0.862 rs2909688 ENSG00000232559.3 GS1-124K5.12 3.94 0.000122 0.0389 0.34 0.3 Aortic root size; chr7:66376625 chr7:66554588~66576923:- PAAD cis rs780096 0.546 rs2293571 ENSG00000234072.1 AC074117.10 -3.94 0.000122 0.0389 -0.23 -0.3 Total body bone mineral density; chr2:27506613 chr2:27356246~27367622:+ PAAD cis rs8062405 0.722 rs3785354 ENSG00000251417.2 RP11-1348G14.4 -3.94 0.000122 0.0389 -0.3 -0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28539346 chr16:28802743~28817828:+ PAAD cis rs8062405 0.755 rs4787457 ENSG00000251417.2 RP11-1348G14.4 -3.94 0.000122 0.0389 -0.3 -0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28544079 chr16:28802743~28817828:+ PAAD cis rs13256369 1 rs4840351 ENSG00000253981.4 ALG1L13P 3.94 0.000122 0.0389 0.4 0.3 Obesity-related traits; chr8:8715638 chr8:8236003~8244667:- PAAD cis rs301901 0.683 rs34485458 ENSG00000250155.1 CTD-2353F22.1 -3.94 0.000122 0.0389 -0.31 -0.3 Height; chr5:36861889 chr5:36666214~36725195:- PAAD cis rs7119038 0.818 rs10892280 ENSG00000255239.1 AP002954.6 -3.94 0.000122 0.039 -0.44 -0.3 Sjögren's syndrome; chr11:118741108 chr11:118688039~118690600:- PAAD cis rs7119038 0.818 rs56758835 ENSG00000255239.1 AP002954.6 -3.94 0.000122 0.039 -0.44 -0.3 Sjögren's syndrome; chr11:118744631 chr11:118688039~118690600:- PAAD cis rs28714278 0.762 rs12050884 ENSG00000248508.5 SRP14-AS1 -3.94 0.000122 0.039 -0.33 -0.3 Mean corpuscular hemoglobin; chr15:40014133 chr15:40039311~40067290:+ PAAD cis rs9322193 0.962 rs9505974 ENSG00000268592.3 RAET1E-AS1 3.94 0.000122 0.039 0.36 0.3 Lung cancer; chr6:149779294 chr6:149863494~149919507:+ PAAD cis rs7989336 0.501 rs7985691 ENSG00000247400.3 DNAJC3-AS1 -3.94 0.000122 0.039 -0.27 -0.3 Obesity; chr13:96354909 chr13:95648733~95676925:- PAAD cis rs7989336 0.501 rs1925107 ENSG00000247400.3 DNAJC3-AS1 3.94 0.000122 0.039 0.27 0.3 Obesity; chr13:96358413 chr13:95648733~95676925:- PAAD cis rs9322193 0.884 rs9480009 ENSG00000268592.3 RAET1E-AS1 3.94 0.000122 0.039 0.36 0.3 Lung cancer; chr6:149758502 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9480031 ENSG00000268592.3 RAET1E-AS1 3.94 0.000122 0.039 0.36 0.3 Lung cancer; chr6:149758875 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs10872649 ENSG00000268592.3 RAET1E-AS1 3.94 0.000122 0.039 0.36 0.3 Lung cancer; chr6:149759454 chr6:149863494~149919507:+ PAAD cis rs4713118 0.662 rs149969 ENSG00000226314.6 ZNF192P1 -3.94 0.000122 0.039 -0.49 -0.3 Parkinson's disease; chr6:28009959 chr6:28161781~28169594:+ PAAD cis rs61270009 0.955 rs390856 ENSG00000247828.6 TMEM161B-AS1 3.94 0.000122 0.039 0.25 0.3 Depressive symptoms; chr5:88251742 chr5:88268895~88436685:+ PAAD cis rs7945705 0.935 rs2243566 ENSG00000254860.4 TMEM9B-AS1 -3.94 0.000122 0.039 -0.34 -0.3 Hemoglobin concentration; chr11:8830692 chr11:8964675~8977527:+ PAAD cis rs7945705 0.935 rs2568064 ENSG00000254860.4 TMEM9B-AS1 -3.94 0.000122 0.039 -0.34 -0.3 Hemoglobin concentration; chr11:8831138 chr11:8964675~8977527:+ PAAD cis rs9876781 1 rs6794875 ENSG00000229759.1 MRPS18AP1 3.94 0.000122 0.039 0.33 0.3 Longevity; chr3:48414217 chr3:48256350~48256938:- PAAD cis rs7580658 0.614 rs7585198 ENSG00000236682.1 AC068282.3 3.94 0.000122 0.039 0.4 0.3 Protein C levels; chr2:127205059 chr2:127389130~127400580:+ PAAD cis rs10740039 0.81 rs10159646 ENSG00000254271.1 RP11-131N11.4 3.94 0.000122 0.039 0.38 0.3 Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes; chr10:60620366 chr10:60734342~60741828:+ PAAD cis rs801193 0.548 rs6975044 ENSG00000232559.3 GS1-124K5.12 3.94 0.000122 0.039 0.34 0.3 Aortic root size; chr7:66762495 chr7:66554588~66576923:- PAAD cis rs801193 0.569 rs35070132 ENSG00000232559.3 GS1-124K5.12 3.94 0.000122 0.039 0.34 0.3 Aortic root size; chr7:66773096 chr7:66554588~66576923:- PAAD cis rs8012947 0.916 rs78350060 ENSG00000279636.2 LINC00216 3.94 0.000122 0.039 0.3 0.3 Alcohol consumption in current drinkers; chr14:58381595 chr14:58288033~58289158:+ PAAD cis rs950169 0.881 rs4842852 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84387263 chr15:84599434~84606463:- PAAD cis rs950169 0.84 rs4842853 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84387606 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs4842946 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84387633 chr15:84599434~84606463:- PAAD cis rs950169 0.84 rs4842854 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84387641 chr15:84599434~84606463:- PAAD cis rs950169 0.84 rs2896002 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84390423 chr15:84599434~84606463:- PAAD cis rs950169 0.887 rs3860265 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84390487 chr15:84599434~84606463:- PAAD cis rs950169 0.724 rs11632668 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84393989 chr15:84599434~84606463:- PAAD cis rs950169 0.881 rs34591918 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84396135 chr15:84599434~84606463:- PAAD cis rs950169 0.887 rs12903946 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84399732 chr15:84599434~84606463:- PAAD cis rs950169 0.887 rs35986397 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84400409 chr15:84599434~84606463:- PAAD cis rs950169 0.887 rs62029593 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84400482 chr15:84599434~84606463:- PAAD cis rs950169 0.81 rs62029594 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84400554 chr15:84599434~84606463:- PAAD cis rs950169 0.881 rs62029596 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84400736 chr15:84599434~84606463:- PAAD cis rs950169 0.881 rs4081123 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84401537 chr15:84599434~84606463:- PAAD cis rs950169 0.881 rs62029599 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84401867 chr15:84599434~84606463:- PAAD cis rs950169 0.8 rs4099846 ENSG00000275120.1 RP11-182J1.17 3.94 0.000122 0.039 0.32 0.3 Schizophrenia; chr15:84402196 chr15:84599434~84606463:- PAAD cis rs7829975 0.577 rs17684466 ENSG00000253893.2 FAM85B 3.94 0.000122 0.039 0.46 0.3 Mood instability; chr8:8687723 chr8:8167819~8226614:- PAAD cis rs10916248 0.511 rs10916512 ENSG00000232628.4 RP11-365O16.3 3.94 0.000122 0.039 0.47 0.3 QT interval (drug interaction); chr1:224220968 chr1:224208747~224213279:- PAAD cis rs853679 0.517 rs17711344 ENSG00000204709.4 LINC01556 -3.94 0.000122 0.039 -0.52 -0.3 Depression; chr6:28109824 chr6:28943877~28944537:+ PAAD cis rs72843506 0.656 rs9901357 ENSG00000154898.14 CCDC144CP 3.94 0.000122 0.039 0.53 0.3 Schizophrenia; chr17:20105729 chr17:20321164~20403557:+ PAAD cis rs7402982 0.625 rs4966009 ENSG00000278022.1 RP11-35O15.2 -3.94 0.000122 0.039 -0.39 -0.3 Birth weight; chr15:98660267 chr15:98660210~98660668:+ PAAD cis rs12291225 0.585 rs12270374 ENSG00000251991.1 RNU7-49P 3.94 0.000122 0.039 0.36 0.3 Sense of smell; chr11:14353533 chr11:14478892~14478953:+ PAAD cis rs12291225 0.585 rs10832246 ENSG00000251991.1 RNU7-49P 3.94 0.000122 0.039 0.36 0.3 Sense of smell; chr11:14359282 chr11:14478892~14478953:+ PAAD cis rs12291225 0.585 rs4517475 ENSG00000251991.1 RNU7-49P 3.94 0.000122 0.039 0.36 0.3 Sense of smell; chr11:14364599 chr11:14478892~14478953:+ PAAD cis rs150992 0.886 rs161948 ENSG00000248489.1 CTD-2007H13.3 3.94 0.000122 0.039 0.34 0.3 Body mass index; chr5:98932333 chr5:98929171~98995013:+ PAAD cis rs9900062 0.507 rs7225993 ENSG00000270714.1 MINOS1P2 -3.94 0.000122 0.0391 -0.42 -0.3 QT interval; chr17:64712166 chr17:64747264~64747492:- PAAD cis rs4578769 0.55 rs7237400 ENSG00000266850.1 RP11-370A5.1 3.94 0.000123 0.0391 0.4 0.3 Eosinophil percentage of white cells; chr18:22986533 chr18:22723491~22907721:- PAAD cis rs17772222 0.876 rs12587598 ENSG00000258983.2 RP11-507K2.2 3.94 0.000123 0.0391 0.4 0.3 Coronary artery calcification; chr14:88729474 chr14:88499334~88515502:+ PAAD cis rs683250 0.599 rs11233581 ENSG00000227097.5 RPS28P7 3.94 0.000123 0.0391 0.38 0.3 Subcortical brain region volumes; chr11:83359316 chr11:82689559~82689768:+ PAAD cis rs950169 0.65 rs12902052 ENSG00000275120.1 RP11-182J1.17 3.94 0.000123 0.0391 0.32 0.3 Schizophrenia; chr15:84582607 chr15:84599434~84606463:- PAAD cis rs9322193 0.923 rs9766004 ENSG00000223701.3 RAET1E-AS1 3.94 0.000123 0.0391 0.33 0.3 Lung cancer; chr6:149754363 chr6:149884431~149919508:+ PAAD cis rs12554020 1 rs12335532 ENSG00000227603.1 RP11-165J3.6 3.94 0.000123 0.0391 0.44 0.3 Schizophrenia; chr9:93431673 chr9:93435332~93437121:- PAAD cis rs13217239 0.646 rs62401067 ENSG00000241549.7 GUSBP2 3.94 0.000123 0.0391 0.31 0.3 Schizophrenia; chr6:27050322 chr6:26871484~26956554:- PAAD cis rs4853012 1 rs2280643 ENSG00000257800.1 FNBP1P1 3.94 0.000123 0.0391 0.45 0.3 Gestational age at birth (maternal effect); chr2:74131159 chr2:74120680~74123218:+ PAAD cis rs4853012 0.887 rs2280644 ENSG00000257800.1 FNBP1P1 3.94 0.000123 0.0391 0.45 0.3 Gestational age at birth (maternal effect); chr2:74131284 chr2:74120680~74123218:+ PAAD cis rs2288884 0.559 rs6509611 ENSG00000275055.1 CTC-471J1.11 -3.94 0.000123 0.0391 -0.38 -0.3 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52006953 chr19:52049007~52049754:+ PAAD cis rs2288884 0.559 rs7257830 ENSG00000275055.1 CTC-471J1.11 -3.94 0.000123 0.0391 -0.38 -0.3 Bronchodilator response in asthma (inhaled corticosteroid treatment interaction); chr19:52005392 chr19:52049007~52049754:+ PAAD cis rs6142102 0.961 rs1555075 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34022595 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs4911144 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34026565 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2056990 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34035658 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs6059649 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34056071 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2284387 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34056782 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs6059651 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34057246 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs909884 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34058257 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2268088 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34061258 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2284388 ENSG00000276073.1 RP5-1125A11.7 -3.94 0.000123 0.0391 -0.33 -0.3 Skin pigmentation; chr20:34067935 chr20:33985617~33988989:- PAAD cis rs9322193 0.884 rs2064521 ENSG00000268592.3 RAET1E-AS1 -3.94 0.000123 0.0391 -0.35 -0.3 Lung cancer; chr6:149625336 chr6:149863494~149919507:+ PAAD cis rs6539288 0.865 rs2888893 ENSG00000260329.1 RP11-412D9.4 -3.94 0.000123 0.0392 -0.27 -0.3 Total body bone mineral density; chr12:106944853 chr12:106954029~106955497:- PAAD cis rs6539288 0.901 rs7974499 ENSG00000260329.1 RP11-412D9.4 -3.94 0.000123 0.0392 -0.27 -0.3 Total body bone mineral density; chr12:106947607 chr12:106954029~106955497:- PAAD cis rs6539288 0.901 rs4964505 ENSG00000260329.1 RP11-412D9.4 -3.94 0.000123 0.0392 -0.27 -0.3 Total body bone mineral density; chr12:106948062 chr12:106954029~106955497:- PAAD cis rs10838687 0.736 rs3781620 ENSG00000255007.1 CTD-2589M5.4 3.94 0.000123 0.0392 0.36 0.3 Proinsulin levels; chr11:47237713 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs7933246 ENSG00000255007.1 CTD-2589M5.4 3.94 0.000123 0.0392 0.36 0.3 Proinsulin levels; chr11:47241097 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs11039144 ENSG00000255007.1 CTD-2589M5.4 3.94 0.000123 0.0392 0.36 0.3 Proinsulin levels; chr11:47242493 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs7120158 ENSG00000255007.1 CTD-2589M5.4 3.94 0.000123 0.0392 0.36 0.3 Proinsulin levels; chr11:47243643 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs2242262 ENSG00000255007.1 CTD-2589M5.4 3.94 0.000123 0.0392 0.36 0.3 Proinsulin levels; chr11:47244989 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs2242261 ENSG00000255007.1 CTD-2589M5.4 3.94 0.000123 0.0392 0.36 0.3 Proinsulin levels; chr11:47245257 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs16938581 ENSG00000255007.1 CTD-2589M5.4 3.94 0.000123 0.0392 0.36 0.3 Proinsulin levels; chr11:47249488 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs11039148 ENSG00000255007.1 CTD-2589M5.4 3.94 0.000123 0.0392 0.36 0.3 Proinsulin levels; chr11:47252575 chr11:46256355~46274547:- PAAD cis rs40363 0.68 rs4010628 ENSG00000261613.2 RP11-20I23.13 -3.94 0.000123 0.0392 -0.64 -0.3 Tuberculosis; chr16:3479779 chr16:2554060~2556060:- PAAD cis rs40363 0.68 rs72778116 ENSG00000261613.2 RP11-20I23.13 -3.94 0.000123 0.0392 -0.64 -0.3 Tuberculosis; chr16:3480752 chr16:2554060~2556060:- PAAD cis rs12999616 0.571 rs34635139 ENSG00000228486.8 LINC01125 -3.94 0.000123 0.0392 -0.28 -0.3 Colorectal cancer; chr2:97747944 chr2:97664217~97703064:+ PAAD cis rs12701220 0.689 rs12701824 ENSG00000229043.2 AC091729.9 -3.94 0.000123 0.0392 -0.44 -0.3 Bronchopulmonary dysplasia; chr7:1062728 chr7:1160374~1165267:+ PAAD cis rs891378 0.785 rs10158940 ENSG00000274245.1 RP11-357P18.2 -3.94 0.000123 0.0392 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207191575 chr1:207372559~207373252:+ PAAD cis rs2446066 0.872 rs12582170 ENSG00000257379.1 RP11-793H13.8 -3.94 0.000123 0.0392 -0.44 -0.3 Red blood cell count; chr12:53364047 chr12:53441741~53467528:+ PAAD cis rs1832007 0.554 rs11596429 ENSG00000224034.1 RP11-445P17.8 -3.94 0.000123 0.0392 -0.44 -0.3 Triglyceride levels;Triglycerides; chr10:5203345 chr10:5266033~5271236:- PAAD cis rs7119038 0.865 rs11217044 ENSG00000255239.1 AP002954.6 -3.94 0.000123 0.0392 -0.43 -0.3 Sjögren's syndrome; chr11:118825313 chr11:118688039~118690600:- PAAD cis rs3020264 0.74 rs2515563 ENSG00000271743.1 CTD-2541M15.3 -3.94 0.000123 0.0392 -0.44 -0.3 Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks); chr8:6637329 chr8:6615604~6617198:- PAAD cis rs4820834 0.867 rs35617977 ENSG00000273350.1 RP4-539M6.20 -3.94 0.000123 0.0392 -0.64 -0.3 Coronary artery calcification; chr22:30463549 chr22:30420512~30420912:+ PAAD cis rs11233413 0.874 rs12146474 ENSG00000247137.7 RP11-727A23.5 -3.94 0.000123 0.0392 -0.27 -0.3 Economic and political preferences (feminism/equality); chr11:83067408 chr11:83184491~83193794:- PAAD cis rs763121 0.719 rs9610995 ENSG00000228274.3 RP3-508I15.9 -3.94 0.000123 0.0392 -0.3 -0.3 Menopause (age at onset); chr22:38661758 chr22:38667585~38681820:- PAAD cis rs829883 0.664 rs829874 ENSG00000245017.2 RP11-181C3.1 -3.94 0.000123 0.0393 -0.31 -0.3 Colorectal adenoma (advanced); chr12:98446837 chr12:98485544~98503855:- PAAD cis rs4218 0.648 rs877269 ENSG00000259732.1 RP11-59H7.3 -3.94 0.000123 0.0393 -0.42 -0.3 Social communication problems; chr15:59081595 chr15:59121034~59133250:+ PAAD cis rs6565653 1 rs6565653 ENSG00000262580.4 RP11-334C17.5 3.94 0.000123 0.0393 0.23 0.3 Ischemic stroke; chr17:80227984 chr17:80200673~80205949:- PAAD cis rs11089937 0.651 rs2330015 ENSG00000211639.2 IGLV4-60 -3.94 0.000123 0.0393 -0.29 -0.3 Periodontitis (PAL4Q3); chr22:22182566 chr22:22162199~22162681:+ PAAD cis rs17836934 0.765 rs7132441 ENSG00000258302.2 RP11-981P6.1 3.94 0.000123 0.0393 0.27 0.3 Total body bone mineral density; chr12:90084513 chr12:89561129~89594878:+ PAAD cis rs2064219 0.554 rs6914846 ENSG00000271755.1 RP1-153G14.4 3.94 0.000124 0.0393 0.35 0.3 Depressive symptoms;Depressive symptoms (multi-trait analysis); chr6:27442900 chr6:27404010~27406964:- PAAD cis rs950169 0.8 rs34302901 ENSG00000275120.1 RP11-182J1.17 3.94 0.000124 0.0393 0.32 0.3 Schizophrenia; chr15:84567712 chr15:84599434~84606463:- PAAD cis rs2742417 1 rs2673067 ENSG00000244357.3 RN7SL145P 3.94 0.000124 0.0393 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45728595 chr3:45742675~45742970:+ PAAD cis rs4853012 0.838 rs4563249 ENSG00000257800.1 FNBP1P1 3.94 0.000124 0.0393 0.42 0.3 Gestational age at birth (maternal effect); chr2:74126889 chr2:74120680~74123218:+ PAAD cis rs7260598 0.539 rs11672512 ENSG00000269397.1 CTB-92J24.2 3.94 0.000124 0.0393 0.6 0.3 Response to taxane treatment (placlitaxel); chr19:23885948 chr19:23927788~23929287:+ PAAD cis rs2904524 0.867 rs17107870 ENSG00000257815.4 RP11-611E13.2 -3.94 0.000124 0.0393 -0.33 -0.3 Amyotrophic lateral sclerosis (age of onset); chr12:70251669 chr12:69904033~70243360:- PAAD cis rs34375054 0.66 rs900411 ENSG00000279233.1 RP11-158L12.4 3.94 0.000124 0.0393 0.26 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125128293 chr12:125138245~125141711:+ PAAD cis rs6504622 1 rs4968286 ENSG00000262539.1 RP11-259G18.3 -3.94 0.000124 0.0394 -0.36 -0.3 Orofacial clefts; chr17:46940279 chr17:46259551~46260606:- PAAD cis rs755249 1 rs755249 ENSG00000228060.1 RP11-69E11.8 -3.94 0.000124 0.0394 -0.31 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39529402 chr1:39565160~39573203:+ PAAD cis rs950169 0.922 rs2033284 ENSG00000275120.1 RP11-182J1.17 3.94 0.000124 0.0394 0.32 0.3 Schizophrenia; chr15:84391575 chr15:84599434~84606463:- PAAD cis rs748404 0.723 rs512431 ENSG00000205771.5 CATSPER2P1 3.94 0.000124 0.0394 0.4 0.3 Lung cancer; chr15:43249741 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs530188 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43253116 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs475227 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43254248 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs572959 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43258304 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs554001 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43259721 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs501884 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43261784 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs504417 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43262028 chr15:43726918~43747094:- PAAD cis rs748404 0.723 rs560134 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43263501 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs546170 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43272651 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs493444 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43274272 chr15:43726918~43747094:- PAAD cis rs748404 0.65 rs556851 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43279021 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs567357 ENSG00000205771.5 CATSPER2P1 -3.94 0.000124 0.0394 -0.4 -0.3 Lung cancer; chr15:43279192 chr15:43726918~43747094:- PAAD cis rs9309473 1 rs56672945 ENSG00000163016.8 ALMS1P 3.94 0.000124 0.0394 0.42 0.3 Metabolite levels; chr2:73395535 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs60844734 ENSG00000163016.8 ALMS1P 3.94 0.000124 0.0394 0.42 0.3 Metabolite levels; chr2:73396077 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs11899902 ENSG00000163016.8 ALMS1P 3.94 0.000124 0.0394 0.42 0.3 Metabolite levels; chr2:73404436 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs13428235 ENSG00000163016.8 ALMS1P 3.94 0.000124 0.0394 0.42 0.3 Metabolite levels; chr2:73406302 chr2:73644919~73685576:+ PAAD cis rs11098499 0.691 rs12510133 ENSG00000248280.1 RP11-33B1.2 3.94 0.000124 0.0394 0.28 0.3 Corneal astigmatism; chr4:119350189 chr4:119440561~119450157:- PAAD cis rs11098499 0.754 rs12506487 ENSG00000248280.1 RP11-33B1.2 3.94 0.000124 0.0394 0.28 0.3 Corneal astigmatism; chr4:119350206 chr4:119440561~119450157:- PAAD cis rs950169 0.922 rs11630760 ENSG00000275120.1 RP11-182J1.17 3.94 0.000124 0.0394 0.32 0.3 Schizophrenia; chr15:84570106 chr15:84599434~84606463:- PAAD cis rs950169 0.887 rs71395453 ENSG00000275120.1 RP11-182J1.17 3.94 0.000124 0.0394 0.32 0.3 Schizophrenia; chr15:84570259 chr15:84599434~84606463:- PAAD cis rs17826219 0.5 rs117560728 ENSG00000266490.1 CTD-2349P21.9 3.94 0.000124 0.0394 0.48 0.3 Body mass index; chr17:30743920 chr17:30792372~30792833:+ PAAD cis rs8031584 0.652 rs2691683 ENSG00000260382.1 RP11-540B6.2 -3.94 0.000124 0.0394 -0.41 -0.3 Huntington's disease progression; chr15:30842857 chr15:30882267~30883231:- PAAD cis rs8031584 0.578 rs1088473 ENSG00000260382.1 RP11-540B6.2 -3.94 0.000124 0.0394 -0.41 -0.3 Huntington's disease progression; chr15:30847095 chr15:30882267~30883231:- PAAD cis rs8031584 0.678 rs4779496 ENSG00000260382.1 RP11-540B6.2 3.94 0.000124 0.0394 0.41 0.3 Huntington's disease progression; chr15:30858851 chr15:30882267~30883231:- PAAD cis rs8031584 0.678 rs4779497 ENSG00000260382.1 RP11-540B6.2 3.94 0.000124 0.0394 0.41 0.3 Huntington's disease progression; chr15:30859162 chr15:30882267~30883231:- PAAD cis rs8031584 0.678 rs8028173 ENSG00000260382.1 RP11-540B6.2 3.94 0.000124 0.0394 0.41 0.3 Huntington's disease progression; chr15:30863546 chr15:30882267~30883231:- PAAD cis rs8031584 0.706 rs2177670 ENSG00000260382.1 RP11-540B6.2 3.94 0.000124 0.0394 0.41 0.3 Huntington's disease progression; chr15:30865548 chr15:30882267~30883231:- PAAD cis rs8031584 0.678 rs36047941 ENSG00000260382.1 RP11-540B6.2 3.94 0.000124 0.0394 0.41 0.3 Huntington's disease progression; chr15:30867032 chr15:30882267~30883231:- PAAD cis rs7819412 0.745 rs6601569 ENSG00000205879.4 FAM90A2P -3.94 0.000124 0.0395 -0.38 -0.3 Triglycerides; chr8:11216069 chr8:12172202~12178575:- PAAD cis rs12646107 0.943 rs10025117 ENSG00000261672.1 RP11-475B2.1 -3.94 0.000124 0.0395 -0.47 -0.3 Response to amphetamines; chr4:173594754 chr4:173593672~173594556:+ PAAD cis rs755249 0.567 rs3818806 ENSG00000261798.1 RP1-118J21.25 3.94 0.000124 0.0395 0.39 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39282599 chr1:39788976~39790171:+ PAAD cis rs755249 0.567 rs41270799 ENSG00000261798.1 RP1-118J21.25 3.94 0.000124 0.0395 0.39 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39282990 chr1:39788976~39790171:+ PAAD cis rs780096 0.546 rs2293572 ENSG00000234072.1 AC074117.10 3.94 0.000124 0.0395 0.23 0.3 Total body bone mineral density; chr2:27505910 chr2:27356246~27367622:+ PAAD cis rs6968419 0.788 rs4276607 ENSG00000237870.5 AC073130.1 3.94 0.000124 0.0395 0.41 0.3 Intraocular pressure; chr7:116181554 chr7:116275606~116286734:- PAAD cis rs2729354 0.817 rs2848626 ENSG00000265566.2 RN7SL605P -3.94 0.000124 0.0395 -0.41 -0.3 Blood protein levels; chr11:57516515 chr11:57528085~57528365:- PAAD cis rs4820834 0.808 rs35074129 ENSG00000273350.1 RP4-539M6.20 -3.94 0.000124 0.0395 -0.64 -0.3 Coronary artery calcification; chr22:30470484 chr22:30420512~30420912:+ PAAD cis rs10916814 0.959 rs12037522 ENSG00000226396.1 RP5-1056L3.3 -3.94 0.000124 0.0395 -0.26 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr1:20573691 chr1:19608114~19608568:+ PAAD cis rs10916814 1 rs72649163 ENSG00000226396.1 RP5-1056L3.3 -3.94 0.000124 0.0395 -0.26 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr1:20574099 chr1:19608114~19608568:+ PAAD cis rs10916814 1 rs12145310 ENSG00000226396.1 RP5-1056L3.3 -3.94 0.000124 0.0395 -0.26 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr1:20574571 chr1:19608114~19608568:+ PAAD cis rs10916814 1 rs12145351 ENSG00000226396.1 RP5-1056L3.3 -3.94 0.000124 0.0395 -0.26 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr1:20574688 chr1:19608114~19608568:+ PAAD cis rs10916814 0.959 rs2101731 ENSG00000226396.1 RP5-1056L3.3 -3.94 0.000124 0.0395 -0.26 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr1:20575429 chr1:19608114~19608568:+ PAAD cis rs10916814 1 rs4654863 ENSG00000226396.1 RP5-1056L3.3 -3.94 0.000124 0.0395 -0.26 -0.3 Age-related hearing impairment (SNP x SNP interaction); chr1:20575751 chr1:19608114~19608568:+ PAAD cis rs6539288 0.677 rs4964509 ENSG00000260329.1 RP11-412D9.4 -3.94 0.000124 0.0395 -0.27 -0.3 Total body bone mineral density; chr12:106963280 chr12:106954029~106955497:- PAAD cis rs875971 0.545 rs73142233 ENSG00000222364.1 RNU6-96P -3.94 0.000124 0.0395 -0.4 -0.3 Aortic root size; chr7:66221293 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs73142245 ENSG00000222364.1 RNU6-96P -3.94 0.000124 0.0395 -0.4 -0.3 Aortic root size; chr7:66226662 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs73142265 ENSG00000222364.1 RNU6-96P -3.94 0.000124 0.0395 -0.4 -0.3 Aortic root size; chr7:66234510 chr7:66395191~66395286:+ PAAD cis rs2742234 0.794 rs17153156 ENSG00000273008.1 RP11-351D16.3 3.94 0.000124 0.0395 0.27 0.3 Hirschsprung disease; chr10:43209189 chr10:43136824~43138334:- PAAD cis rs2742234 0.759 rs12241923 ENSG00000273008.1 RP11-351D16.3 3.94 0.000124 0.0395 0.27 0.3 Hirschsprung disease; chr10:43217599 chr10:43136824~43138334:- PAAD cis rs7119038 0.818 rs2077579 ENSG00000255239.1 AP002954.6 -3.94 0.000124 0.0395 -0.44 -0.3 Sjögren's syndrome; chr11:118748338 chr11:118688039~118690600:- PAAD cis rs7119038 0.774 rs2004781 ENSG00000255239.1 AP002954.6 -3.94 0.000124 0.0395 -0.44 -0.3 Sjögren's syndrome; chr11:118748544 chr11:118688039~118690600:- PAAD cis rs7119038 0.818 rs3889239 ENSG00000255239.1 AP002954.6 -3.94 0.000124 0.0395 -0.44 -0.3 Sjögren's syndrome; chr11:118749251 chr11:118688039~118690600:- PAAD cis rs10761482 0.5 rs10740030 ENSG00000254271.1 RP11-131N11.4 3.94 0.000124 0.0395 0.37 0.3 Schizophrenia; chr10:60532054 chr10:60734342~60741828:+ PAAD cis rs10761482 0.5 rs1892546 ENSG00000254271.1 RP11-131N11.4 3.94 0.000124 0.0395 0.37 0.3 Schizophrenia; chr10:60534258 chr10:60734342~60741828:+ PAAD cis rs10761482 0.5 rs1574466 ENSG00000254271.1 RP11-131N11.4 3.94 0.000124 0.0395 0.37 0.3 Schizophrenia; chr10:60534634 chr10:60734342~60741828:+ PAAD cis rs10761482 0.5 rs1938538 ENSG00000254271.1 RP11-131N11.4 3.94 0.000124 0.0395 0.37 0.3 Schizophrenia; chr10:60538475 chr10:60734342~60741828:+ PAAD cis rs10761482 0.5 rs7080540 ENSG00000254271.1 RP11-131N11.4 3.94 0.000124 0.0395 0.37 0.3 Schizophrenia; chr10:60538828 chr10:60734342~60741828:+ PAAD cis rs11976180 1 rs2961118 ENSG00000273234.1 OR2A13P -3.94 0.000124 0.0395 -0.37 -0.3 Obesity-related traits; chr7:144058350 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2371244 ENSG00000273234.1 OR2A13P -3.94 0.000124 0.0395 -0.37 -0.3 Obesity-related traits; chr7:144060518 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs4726669 ENSG00000273234.1 OR2A13P -3.94 0.000124 0.0395 -0.37 -0.3 Obesity-related traits; chr7:144061098 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2951353 ENSG00000273234.1 OR2A13P -3.94 0.000124 0.0395 -0.37 -0.3 Obesity-related traits; chr7:144064023 chr7:144142009~144142938:+ PAAD cis rs11976180 1 rs2371247 ENSG00000273234.1 OR2A13P -3.94 0.000124 0.0395 -0.37 -0.3 Obesity-related traits; chr7:144067086 chr7:144142009~144142938:+ PAAD cis rs4660214 0.666 rs4660550 ENSG00000261798.1 RP1-118J21.25 -3.94 0.000125 0.0396 -0.37 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39222787 chr1:39788976~39790171:+ PAAD cis rs875971 0.545 rs313830 ENSG00000222364.1 RNU6-96P 3.94 0.000125 0.0396 0.41 0.3 Aortic root size; chr7:66086944 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs313828 ENSG00000222364.1 RNU6-96P 3.94 0.000125 0.0396 0.41 0.3 Aortic root size; chr7:66087627 chr7:66395191~66395286:+ PAAD cis rs875971 0.571 rs160647 ENSG00000222364.1 RNU6-96P 3.94 0.000125 0.0396 0.41 0.3 Aortic root size; chr7:66089365 chr7:66395191~66395286:+ PAAD cis rs875971 0.52 rs160645 ENSG00000222364.1 RNU6-96P 3.94 0.000125 0.0396 0.41 0.3 Aortic root size; chr7:66091320 chr7:66395191~66395286:+ PAAD cis rs875971 0.789 rs28815324 ENSG00000222364.1 RNU6-96P 3.94 0.000125 0.0396 0.41 0.3 Aortic root size; chr7:66100789 chr7:66395191~66395286:+ PAAD cis rs875971 0.545 rs73136346 ENSG00000222364.1 RNU6-96P 3.94 0.000125 0.0396 0.41 0.3 Aortic root size; chr7:66101095 chr7:66395191~66395286:+ PAAD cis rs2976388 0.669 rs2585135 ENSG00000253741.1 CTD-2292P10.4 3.94 0.000125 0.0396 0.37 0.3 Urinary tract infection frequency; chr8:142732775 chr8:142702252~142726973:- PAAD cis rs111580313 0.792 rs4843171 ENSG00000270020.1 RP11-463O9.9 3.94 0.000125 0.0396 0.83 0.3 Systemic juvenile idiopathic arthritis; chr16:86576879 chr16:86520383~86523897:- PAAD cis rs111580313 0.792 rs8064031 ENSG00000270020.1 RP11-463O9.9 3.94 0.000125 0.0396 0.83 0.3 Systemic juvenile idiopathic arthritis; chr16:86576974 chr16:86520383~86523897:- PAAD cis rs11159086 1 rs4899514 ENSG00000259005.1 RP3-449M8.6 -3.94 0.000125 0.0396 -0.42 -0.3 Advanced glycation end-product levels; chr14:74473467 chr14:74474007~74474864:- PAAD cis rs11159086 0.941 rs12434836 ENSG00000259005.1 RP3-449M8.6 3.94 0.000125 0.0396 0.42 0.3 Advanced glycation end-product levels; chr14:74468887 chr14:74474007~74474864:- PAAD cis rs11159086 1 rs11159086 ENSG00000270000.1 RP3-449M8.9 3.94 0.000125 0.0396 0.46 0.3 Advanced glycation end-product levels; chr14:74495572 chr14:74471930~74472360:- PAAD cis rs713477 0.654 rs955257 ENSG00000258413.1 RP11-665C16.6 3.94 0.000125 0.0396 0.36 0.3 Pediatric bone mineral content (femoral neck); chr14:55453079 chr14:55262767~55272075:- PAAD cis rs9322193 0.923 rs12174716 ENSG00000268592.3 RAET1E-AS1 3.94 0.000125 0.0396 0.35 0.3 Lung cancer; chr6:149644487 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9800871 ENSG00000268592.3 RAET1E-AS1 3.94 0.000125 0.0396 0.35 0.3 Lung cancer; chr6:149644540 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9689723 ENSG00000268592.3 RAET1E-AS1 3.94 0.000125 0.0396 0.35 0.3 Lung cancer; chr6:149655935 chr6:149863494~149919507:+ PAAD cis rs5769765 1 rs5769760 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49866048 chr22:49933198~49934074:- PAAD cis rs5769765 0.955 rs2295406 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49866521 chr22:49933198~49934074:- PAAD cis rs5769765 0.955 rs8139758 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49867475 chr22:49933198~49934074:- PAAD cis rs5769765 0.913 rs2319462 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49869722 chr22:49933198~49934074:- PAAD cis rs5769765 0.955 rs5769761 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49869993 chr22:49933198~49934074:- PAAD cis rs5769765 0.954 rs5769762 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49870394 chr22:49933198~49934074:- PAAD cis rs5769765 0.955 rs2319465 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49872136 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs34774661 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49873860 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs4824106 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49874174 chr22:49933198~49934074:- PAAD cis rs5769765 0.954 rs5770739 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49874366 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs5770741 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49876567 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs5770742 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49876661 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs4597652 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49876922 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs5769764 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49877136 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs5769765 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49877528 chr22:49933198~49934074:- PAAD cis rs5769765 0.865 rs4824108 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49877780 chr22:49933198~49934074:- PAAD cis rs5769765 0.908 rs4824109 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49877812 chr22:49933198~49934074:- PAAD cis rs5769765 0.837 rs4824110 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49877983 chr22:49933198~49934074:- PAAD cis rs5769765 1 rs8184990 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49879526 chr22:49933198~49934074:- PAAD cis rs5769765 0.955 rs5769767 ENSG00000278869.1 CITF22-49E9.3 -3.94 0.000125 0.0396 -0.43 -0.3 Schizophrenia; chr22:49883261 chr22:49933198~49934074:- PAAD cis rs17772222 0.917 rs58550317 ENSG00000258983.2 RP11-507K2.2 3.94 0.000125 0.0396 0.39 0.3 Coronary artery calcification; chr14:88775243 chr14:88499334~88515502:+ PAAD cis rs2985684 1 rs2985697 ENSG00000259113.1 RP11-406H23.2 -3.94 0.000125 0.0396 -0.44 -0.3 Carotid intima media thickness; chr14:49626184 chr14:50448807~50456742:+ PAAD cis rs4853012 0.838 rs72911122 ENSG00000257800.1 FNBP1P1 3.94 0.000125 0.0396 0.43 0.3 Gestational age at birth (maternal effect); chr2:74116992 chr2:74120680~74123218:+ PAAD cis rs11089937 0.616 rs4145537 ENSG00000211660.3 IGLV2-23 -3.94 0.000125 0.0396 -0.22 -0.3 Periodontitis (PAL4Q3); chr22:22182550 chr22:22697789~22698407:+ PAAD cis rs7567389 0.505 rs56273408 ENSG00000236682.1 AC068282.3 -3.94 0.000125 0.0396 -0.42 -0.3 Self-rated health; chr2:127338012 chr2:127389130~127400580:+ PAAD cis rs1799810 0.64 rs55998444 ENSG00000236682.1 AC068282.3 -3.94 0.000125 0.0396 -0.42 -0.3 Self-rated health; chr2:127362270 chr2:127389130~127400580:+ PAAD cis rs7567389 0.505 rs1518760 ENSG00000236682.1 AC068282.3 -3.94 0.000125 0.0396 -0.42 -0.3 Self-rated health; chr2:127382924 chr2:127389130~127400580:+ PAAD cis rs7299940 0.967 rs9738957 ENSG00000256250.1 RP11-989F5.1 3.94 0.000125 0.0396 0.35 0.3 Panic disorder; chr12:130904256 chr12:130810606~130812438:+ PAAD cis rs655766 0.609 rs7917848 ENSG00000254635.4 WAC-AS1 3.94 0.000125 0.0396 0.29 0.3 Percentage gas trapping; chr10:28705933 chr10:28522652~28532743:- PAAD cis rs2404602 0.71 rs2469541 ENSG00000259422.1 RP11-593F23.1 -3.94 0.000125 0.0396 -0.37 -0.3 Blood metabolite levels; chr15:76269777 chr15:76174891~76181486:- PAAD cis rs6545883 0.501 rs935860 ENSG00000271889.1 RP11-493E12.1 3.94 0.000125 0.0397 0.32 0.3 Tuberculosis; chr2:61179426 chr2:61151433~61162105:- PAAD cis rs919433 0.519 rs700658 ENSG00000231621.1 AC013264.2 -3.94 0.000125 0.0397 -0.3 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197790283 chr2:197197991~197199273:+ PAAD cis rs2115630 1 rs6496452 ENSG00000225151.9 GOLGA2P7 3.94 0.000125 0.0397 0.36 0.3 P wave terminal force; chr15:84829414 chr15:84199311~84230136:- PAAD cis rs2404602 0.647 rs907594 ENSG00000259422.1 RP11-593F23.1 -3.94 0.000125 0.0397 -0.38 -0.3 Blood metabolite levels; chr15:76905404 chr15:76174891~76181486:- PAAD cis rs4725617 0.686 rs41277428 ENSG00000229153.4 EPHA1-AS1 3.94 0.000125 0.0397 0.69 0.3 Blood protein levels; chr7:143388729 chr7:143407813~143523449:+ PAAD cis rs9287719 0.649 rs10186984 ENSG00000243819.4 RN7SL832P -3.94 0.000125 0.0397 -0.29 -0.3 Prostate cancer; chr2:10594066 chr2:10690344~10692099:+ PAAD cis rs13217239 0.646 rs4269366 ENSG00000241549.7 GUSBP2 3.94 0.000125 0.0397 0.31 0.3 Schizophrenia; chr6:27048634 chr6:26871484~26956554:- PAAD cis rs6545883 0.524 rs17482440 ENSG00000271889.1 RP11-493E12.1 -3.94 0.000125 0.0397 -0.32 -0.3 Tuberculosis; chr2:61321722 chr2:61151433~61162105:- PAAD cis rs11997175 0.624 rs7016783 ENSG00000240738.1 RP1-273G13.1 3.94 0.000125 0.0397 0.36 0.3 Body mass index; chr8:33839313 chr8:33859480~33860223:- PAAD cis rs613391 0.561 rs496615 ENSG00000224549.1 RP11-370B11.3 -3.94 0.000125 0.0397 -0.37 -0.3 Quantitative traits; chr9:22718466 chr9:22767175~22768316:+ PAAD cis rs4666002 0.564 rs13030345 ENSG00000234072.1 AC074117.10 -3.94 0.000125 0.0397 -0.3 -0.3 Phospholipid levels (plasma); chr2:27780307 chr2:27356246~27367622:+ PAAD cis rs950169 0.919 rs12915589 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84065712 chr15:84389729~84395903:+ PAAD cis rs950169 0.959 rs66801143 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84067905 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs35648189 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84071996 chr15:84389729~84395903:+ PAAD cis rs950169 0.92 rs17300048 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84080725 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs1848093 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84086775 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs12915234 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84089549 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs34751999 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84089667 chr15:84389729~84395903:+ PAAD cis rs950169 0.919 rs17300292 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84093816 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs12916348 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84096775 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs35297609 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84104144 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs62026530 ENSG00000259683.1 RP11-182J1.14 3.94 0.000125 0.0397 0.25 0.3 Schizophrenia; chr15:84107088 chr15:84389729~84395903:+ PAAD cis rs7927592 0.871 rs55953412 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68560815 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs7102898 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68561402 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs7109294 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68564625 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs2282563 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68565732 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs3740631 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68574254 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs3824850 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68574405 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs3740629 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68576125 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs11228287 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68582286 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs10896346 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68585203 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs10896347 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68585659 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs6591344 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68593405 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs7127948 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68595594 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs3758643 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68599725 chr11:68506083~68506166:- PAAD cis rs7927592 0.871 rs17603185 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68608773 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs2236708 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68610577 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs4988291 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68614139 chr11:68506083~68506166:- PAAD cis rs7927592 0.871 rs12941 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68614725 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs11228293 ENSG00000212093.1 AP000807.1 3.94 0.000125 0.0397 0.36 0.3 Total body bone mineral density; chr11:68617178 chr11:68506083~68506166:- PAAD cis rs853679 0.766 rs9368561 ENSG00000204709.4 LINC01556 3.94 0.000125 0.0397 0.59 0.3 Depression; chr6:28200565 chr6:28943877~28944537:+ PAAD cis rs2288073 1 rs2288073 ENSG00000242628.4 AC009228.1 -3.94 0.000125 0.0397 -0.36 -0.3 Venous thromboembolism (SNP x SNP interaction); chr2:24190429 chr2:24214381~24221516:+ PAAD cis rs950169 0.922 rs62028133 ENSG00000275120.1 RP11-182J1.17 3.94 0.000125 0.0398 0.32 0.3 Schizophrenia; chr15:84250623 chr15:84599434~84606463:- PAAD cis rs950169 0.723 rs17589320 ENSG00000275120.1 RP11-182J1.17 3.94 0.000125 0.0398 0.32 0.3 Schizophrenia; chr15:84251244 chr15:84599434~84606463:- PAAD cis rs950169 0.845 rs4502182 ENSG00000275120.1 RP11-182J1.17 3.94 0.000125 0.0398 0.32 0.3 Schizophrenia; chr15:84254768 chr15:84599434~84606463:- PAAD cis rs1056107 0.763 rs7024998 ENSG00000225513.1 RP11-165N19.2 -3.94 0.000125 0.0398 -0.38 -0.3 Colorectal cancer; chr9:112175379 chr9:112173522~112173971:- PAAD cis rs755249 0.727 rs2242500 ENSG00000243970.1 PPIEL 3.94 0.000125 0.0398 0.28 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572230 chr1:39531838~39558707:- PAAD cis rs755249 0.727 rs16826349 ENSG00000243970.1 PPIEL 3.94 0.000125 0.0398 0.28 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39573264 chr1:39531838~39558707:- PAAD cis rs61270009 0.874 rs780403 ENSG00000247828.6 TMEM161B-AS1 -3.94 0.000126 0.0398 -0.25 -0.3 Depressive symptoms; chr5:88244989 chr5:88268895~88436685:+ PAAD cis rs11089937 0.857 rs5750578 ENSG00000211644.2 IGLV1-51 3.94 0.000126 0.0398 0.18 0.3 Periodontitis (PAL4Q3); chr22:22136444 chr22:22322472~22322980:+ PAAD cis rs6840258 1 rs75550773 ENSG00000251411.1 RP11-397E7.4 -3.94 0.000126 0.0398 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87034271 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs767315 ENSG00000251411.1 RP11-397E7.4 -3.94 0.000126 0.0398 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87039283 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs10516788 ENSG00000251411.1 RP11-397E7.4 -3.94 0.000126 0.0398 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87039705 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs114701347 ENSG00000251411.1 RP11-397E7.4 -3.94 0.000126 0.0398 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87043849 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs72667765 ENSG00000251411.1 RP11-397E7.4 -3.94 0.000126 0.0398 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87044790 chr4:86913266~86914817:- PAAD cis rs1529672 0.808 rs1286645 ENSG00000213871.3 TAF9BP1 3.94 0.000126 0.0398 0.44 0.3 Pulmonary function;Pulmonary function (smoking interaction);Chronic obstructive pulmonary disease; chr3:25507083 chr3:25754925~25755670:+ PAAD cis rs7260598 0.642 rs66750293 ENSG00000268442.1 CTD-2027I19.2 3.94 0.000126 0.0398 0.45 0.3 Response to taxane treatment (placlitaxel); chr19:23997819 chr19:24162370~24163425:- PAAD cis rs7189233 0.955 rs16952242 ENSG00000279722.1 RP11-44F14.6 -3.94 0.000126 0.0398 -0.33 -0.3 Intelligence (multi-trait analysis); chr16:53440338 chr16:53487607~53489943:- PAAD cis rs9287719 0.649 rs7589694 ENSG00000243819.4 RN7SL832P 3.94 0.000126 0.0399 0.29 0.3 Prostate cancer; chr2:10560748 chr2:10690344~10692099:+ PAAD cis rs4660214 0.666 rs587404 ENSG00000261798.1 RP1-118J21.25 3.94 0.000126 0.0399 0.36 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39442834 chr1:39788976~39790171:+ PAAD cis rs2243480 1 rs313832 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66085904 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs313831 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66086239 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs160646 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66091293 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs465359 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66093177 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs462853 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66093180 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs160644 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66093199 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs160642 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66093386 chr7:66902857~66906297:+ PAAD cis rs2243480 0.614 rs34032527 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66100154 chr7:66902857~66906297:+ PAAD cis rs2243480 0.803 rs36127118 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66100518 chr7:66902857~66906297:+ PAAD cis rs2243480 1 rs316307 ENSG00000273142.1 RP11-458F8.4 -3.94 0.000126 0.0399 -0.28 -0.3 Diabetic kidney disease; chr7:66105184 chr7:66902857~66906297:+ PAAD cis rs6951245 0.872 rs11768895 ENSG00000229043.2 AC091729.9 -3.94 0.000126 0.0399 -0.44 -0.3 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1024055 chr7:1160374~1165267:+ PAAD cis rs528301 0.737 rs83995 ENSG00000259439.2 RP11-89K21.1 3.94 0.000126 0.0399 0.39 0.3 Alcohol and nicotine co-dependence; chr2:44940431 chr2:44921077~44939199:- PAAD cis rs7078219 0.543 rs7095491 ENSG00000228778.1 RP11-129J12.1 -3.94 0.000126 0.0399 -0.33 -0.3 Dental caries; chr10:99514301 chr10:99527081~99528261:+ PAAD cis rs7078219 0.543 rs10786556 ENSG00000228778.1 RP11-129J12.1 -3.94 0.000126 0.0399 -0.33 -0.3 Dental caries; chr10:99518567 chr10:99527081~99528261:+ PAAD cis rs7078219 0.505 rs7077040 ENSG00000228778.1 RP11-129J12.1 -3.94 0.000126 0.0399 -0.33 -0.3 Dental caries; chr10:99521257 chr10:99527081~99528261:+ PAAD cis rs453301 0.686 rs2409120 ENSG00000254340.1 RP11-10A14.3 -3.94 0.000126 0.0399 -0.37 -0.3 Joint mobility (Beighton score); chr8:9025061 chr8:9141424~9145435:+ PAAD cis rs7617773 0.539 rs13087050 ENSG00000228638.1 FCF1P2 -3.94 0.000126 0.0399 -0.34 -0.3 Coronary artery disease; chr3:48351310 chr3:48290793~48291375:- PAAD cis rs8005677 1 rs4982709 ENSG00000279656.1 RP11-298I3.6 3.94 0.000126 0.0399 0.36 0.3 Cognitive ability (multi-trait analysis); chr14:22925490 chr14:23023083~23024217:- PAAD cis rs9309473 0.95 rs7596773 ENSG00000163016.8 ALMS1P 3.94 0.000126 0.04 0.45 0.3 Metabolite levels; chr2:73618873 chr2:73644919~73685576:+ PAAD cis rs303386 0.594 rs2807994 ENSG00000223656.1 HMGB3P10 3.94 0.000126 0.04 0.39 0.3 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin); chr1:99139338 chr1:99698242~99699178:+ PAAD cis rs4660214 0.568 rs6692769 ENSG00000228060.1 RP11-69E11.8 3.93 0.000126 0.04 0.29 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39217503 chr1:39565160~39573203:+ PAAD cis rs4660214 0.614 rs11205802 ENSG00000228060.1 RP11-69E11.8 3.93 0.000126 0.04 0.29 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39233442 chr1:39565160~39573203:+ PAAD cis rs4660214 0.614 rs10888715 ENSG00000228060.1 RP11-69E11.8 3.93 0.000126 0.04 0.29 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39233572 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs7553009 ENSG00000228060.1 RP11-69E11.8 3.93 0.000126 0.04 0.29 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39247441 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs10493087 ENSG00000228060.1 RP11-69E11.8 3.93 0.000126 0.04 0.29 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39251584 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs11205828 ENSG00000228060.1 RP11-69E11.8 3.93 0.000126 0.04 0.29 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39253674 chr1:39565160~39573203:+ PAAD cis rs858239 0.539 rs7791200 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23142502 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs57864591 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23144805 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs4294098 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23146376 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs4504540 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23146579 chr7:23206013~23208045:+ PAAD cis rs858239 0.509 rs6975524 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23146833 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs6955726 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23147072 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs6955969 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23147080 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs6976957 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23147714 chr7:23206013~23208045:+ PAAD cis rs858239 0.539 rs6956828 ENSG00000226816.2 AC005082.12 3.93 0.000126 0.04 0.34 0.3 Cerebrospinal fluid biomarker levels; chr7:23147728 chr7:23206013~23208045:+ PAAD cis rs6860540 0.796 rs868988 ENSG00000251405.2 CTB-109A12.1 -3.93 0.000126 0.04 -0.39 -0.3 Inflammatory skin disease; chr5:157507379 chr5:157362615~157460078:- PAAD cis rs2337406 0.85 rs10131280 ENSG00000223648.3 IGHV3-64 3.93 0.000126 0.04 0.4 0.3 Alzheimer's disease (late onset); chr14:106665591 chr14:106643132~106658258:- PAAD cis rs875971 0.929 rs4122249 ENSG00000232559.3 GS1-124K5.12 3.93 0.000126 0.04 0.33 0.3 Aortic root size; chr7:66455949 chr7:66554588~66576923:- PAAD cis rs2179367 0.959 rs536203 ENSG00000231760.4 RP11-350J20.5 3.93 0.000126 0.04 0.38 0.3 Dupuytren's disease; chr6:149330128 chr6:149796151~149826294:- PAAD cis rs2179367 0.959 rs9322178 ENSG00000231760.4 RP11-350J20.5 3.93 0.000126 0.04 0.39 0.3 Dupuytren's disease; chr6:149372131 chr6:149796151~149826294:- PAAD cis rs357618 0.581 rs165363 ENSG00000271795.1 CTC-251D13.1 3.93 0.000126 0.04 0.37 0.3 Basophil percentage of white cells; chr5:151486257 chr5:151509453~151512769:+ PAAD cis rs357618 0.581 rs165366 ENSG00000271795.1 CTC-251D13.1 3.93 0.000126 0.04 0.37 0.3 Basophil percentage of white cells; chr5:151487347 chr5:151509453~151512769:+ PAAD cis rs7927592 0.956 rs10896334 ENSG00000212093.1 AP000807.1 3.93 0.000126 0.04 0.36 0.3 Total body bone mineral density; chr11:68514026 chr11:68506083~68506166:- PAAD cis rs10888838 0.938 rs12031348 ENSG00000198711.5 SSBP3-AS1 3.93 0.000126 0.04 0.36 0.3 Mitochondrial DNA levels; chr1:54203106 chr1:54236440~54239063:+ PAAD cis rs950880 1 rs13019081 ENSG00000234389.1 AC007278.3 3.93 0.000126 0.04 0.29 0.3 Serum protein levels (sST2); chr2:102334362 chr2:102438713~102440475:+ PAAD cis rs2777491 0.872 rs11267024 ENSG00000247556.5 OIP5-AS1 3.93 0.000127 0.04 0.28 0.3 Ulcerative colitis; chr15:41284043 chr15:41283990~41309737:+ PAAD cis rs35851103 0.627 rs6601644 ENSG00000227888.4 FAM66A 3.93 0.000127 0.04 0.38 0.3 Neuroticism; chr8:11989569 chr8:12362019~12388296:+ PAAD cis rs9322193 0.884 rs9688699 ENSG00000268592.3 RAET1E-AS1 3.93 0.000127 0.04 0.36 0.3 Lung cancer; chr6:149733680 chr6:149863494~149919507:+ PAAD cis rs2677744 0.534 rs6496739 ENSG00000259704.1 CTD-3094K11.1 -3.93 0.000127 0.04 -0.39 -0.3 Attention deficit hyperactivity disorder; chr15:90951200 chr15:90839724~90841378:+ PAAD cis rs42490 0.589 rs39772 ENSG00000251136.7 RP11-37B2.1 -3.93 0.000127 0.0401 -0.29 -0.3 Leprosy; chr8:89831636 chr8:89609409~89757727:- PAAD cis rs780096 0.526 rs13391837 ENSG00000234072.1 AC074117.10 -3.93 0.000127 0.0401 -0.24 -0.3 Total body bone mineral density; chr2:27426508 chr2:27356246~27367622:+ PAAD cis rs780096 0.526 rs3845687 ENSG00000234072.1 AC074117.10 -3.93 0.000127 0.0401 -0.24 -0.3 Total body bone mineral density; chr2:27467032 chr2:27356246~27367622:+ PAAD cis rs780096 0.506 rs8395 ENSG00000234072.1 AC074117.10 -3.93 0.000127 0.0401 -0.24 -0.3 Total body bone mineral density; chr2:27492340 chr2:27356246~27367622:+ PAAD cis rs4266144 0.569 rs729257 ENSG00000241135.4 LINC00881 3.93 0.000127 0.0401 0.39 0.3 Coronary artery disease; chr3:157111034 chr3:157089881~157101135:+ PAAD cis rs6951245 0.554 rs76243429 ENSG00000229043.2 AC091729.9 -3.93 0.000127 0.0401 -0.42 -0.3 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112907 chr7:1160374~1165267:+ PAAD cis rs7182621 0.846 rs12915935 ENSG00000182397.13 DNM1P46 3.93 0.000127 0.0401 0.36 0.3 Colonoscopy-negative controls vs population controls; chr15:99871875 chr15:99790156~99806927:- PAAD cis rs6570726 0.967 rs418662 ENSG00000235652.6 RP11-545I5.3 3.93 0.000127 0.0401 0.25 0.3 Lobe attachment (rater-scored or self-reported); chr6:145527696 chr6:145799409~145886585:+ PAAD cis rs848490 0.515 rs6465825 ENSG00000213542.3 RP11-467H10.1 3.93 0.000127 0.0401 0.33 0.3 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77787122 chr7:77115399~77116192:- PAAD cis rs10779751 1 rs2300092 ENSG00000238199.1 UBE2V2P3 -3.93 0.000127 0.0401 -0.37 -0.3 Body mass index; chr1:11206407 chr1:11278616~11279351:- PAAD cis rs853679 1 rs7740487 ENSG00000280107.1 AL022393.9 -3.93 0.000127 0.0401 -0.54 -0.3 Depression; chr6:28248708 chr6:28170845~28172521:+ PAAD cis rs853679 1 rs68141011 ENSG00000280107.1 AL022393.9 -3.93 0.000127 0.0401 -0.54 -0.3 Depression; chr6:28250019 chr6:28170845~28172521:+ PAAD cis rs853679 1 rs13200462 ENSG00000280107.1 AL022393.9 -3.93 0.000127 0.0401 -0.54 -0.3 Depression; chr6:28250421 chr6:28170845~28172521:+ PAAD cis rs853679 1 rs9986596 ENSG00000280107.1 AL022393.9 -3.93 0.000127 0.0401 -0.54 -0.3 Depression; chr6:28251883 chr6:28170845~28172521:+ PAAD cis rs853679 1 rs1679732 ENSG00000280107.1 AL022393.9 3.93 0.000127 0.0401 0.54 0.3 Depression; chr6:28253486 chr6:28170845~28172521:+ PAAD cis rs9322193 0.962 rs2275046 ENSG00000268592.3 RAET1E-AS1 3.93 0.000127 0.0401 0.36 0.3 Lung cancer; chr6:149835865 chr6:149863494~149919507:+ PAAD cis rs61270009 0.955 rs780402 ENSG00000247828.6 TMEM161B-AS1 -3.93 0.000127 0.0401 -0.25 -0.3 Depressive symptoms; chr5:88244890 chr5:88268895~88436685:+ PAAD cis rs2015599 0.584 rs7299283 ENSG00000275476.1 RP11-996F15.4 3.93 0.000127 0.0401 0.29 0.3 Platelet count;Mean platelet volume; chr12:29277442 chr12:29277397~29277882:- PAAD cis rs9357354 0.929 rs9381050 ENSG00000218809.1 RP1-229K20.5 -3.93 0.000127 0.0401 -0.34 -0.3 Telomere length; chr6:41345738 chr6:41269875~41270239:- PAAD cis rs1056107 0.763 rs60623018 ENSG00000225513.1 RP11-165N19.2 -3.93 0.000127 0.0402 -0.38 -0.3 Colorectal cancer; chr9:112175922 chr9:112173522~112173971:- PAAD cis rs1927790 0.727 rs16953068 ENSG00000247400.3 DNAJC3-AS1 -3.93 0.000127 0.0402 -0.28 -0.3 Body mass index; chr13:96297073 chr13:95648733~95676925:- PAAD cis rs755249 0.917 rs61779330 ENSG00000237624.1 OXCT2P1 3.93 0.000127 0.0402 0.43 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39501551 chr1:39514956~39516490:+ PAAD cis rs755249 0.876 rs72662001 ENSG00000237624.1 OXCT2P1 3.93 0.000127 0.0402 0.43 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39501608 chr1:39514956~39516490:+ PAAD cis rs227932 0.764 rs76349338 ENSG00000234800.2 PCMTD1P3 3.93 0.000127 0.0402 0.51 0.3 Schizophrenia; chr7:23709138 chr7:23721311~23721782:- PAAD cis rs227932 0.618 rs3807888 ENSG00000234800.2 PCMTD1P3 3.93 0.000127 0.0402 0.51 0.3 Schizophrenia; chr7:23710213 chr7:23721311~23721782:- PAAD cis rs4639966 0.836 rs10892282 ENSG00000255239.1 AP002954.6 3.93 0.000127 0.0402 0.43 0.3 Systemic lupus erythematosus; chr11:118757069 chr11:118688039~118690600:- PAAD cis rs2816938 1 rs2816938 ENSG00000236468.1 RP11-104D3.2 3.93 0.000127 0.0402 0.35 0.3 Pancreatic cancer; chr1:200016240 chr1:199387141~199388475:+ PAAD cis rs950169 1 rs11638394 ENSG00000259683.1 RP11-182J1.14 3.93 0.000127 0.0402 0.25 0.3 Schizophrenia; chr15:84110176 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs35658069 ENSG00000259683.1 RP11-182J1.14 3.93 0.000127 0.0402 0.25 0.3 Schizophrenia; chr15:84111394 chr15:84389729~84395903:+ PAAD cis rs6929812 0.577 rs2294309 ENSG00000271755.1 RP1-153G14.4 3.93 0.000127 0.0402 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27516037 chr6:27404010~27406964:- PAAD cis rs75804782 0.566 rs77693902 ENSG00000186235.9 AC016757.3 3.93 0.000127 0.0402 0.71 0.3 Chronotype;Morning vs. evening chronotype; chr2:238351836 chr2:238224552~238231677:- PAAD cis rs12530845 0.887 rs61360007 ENSG00000223718.3 AC093107.7 3.93 0.000127 0.0402 0.51 0.3 Red blood cell traits; chr7:135632131 chr7:135660039~135660647:+ PAAD cis rs12530845 0.887 rs78641973 ENSG00000223718.3 AC093107.7 3.93 0.000127 0.0402 0.51 0.3 Red blood cell traits; chr7:135639563 chr7:135660039~135660647:+ PAAD cis rs6840258 0.943 rs72667748 ENSG00000251411.1 RP11-397E7.4 -3.93 0.000127 0.0402 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87005882 chr4:86913266~86914817:- PAAD cis rs6840258 0.825 rs72667751 ENSG00000251411.1 RP11-397E7.4 -3.93 0.000127 0.0402 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87015227 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs56390363 ENSG00000251411.1 RP11-397E7.4 -3.93 0.000127 0.0402 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87021935 chr4:86913266~86914817:- PAAD cis rs4725617 0.686 rs7780371 ENSG00000176510.4 OR10AC1 -3.93 0.000127 0.0402 -0.64 -0.3 Blood protein levels; chr7:143395825 chr7:143510933~143511911:- PAAD cis rs710913 0.531 rs1180331 ENSG00000237624.1 OXCT2P1 -3.93 0.000127 0.0402 -0.39 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39546512 chr1:39514956~39516490:+ PAAD cis rs4660214 0.724 rs2484751 ENSG00000261798.1 RP1-118J21.25 -3.93 0.000127 0.0402 -0.36 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39282867 chr1:39788976~39790171:+ PAAD cis rs7759001 0.744 rs4478400 ENSG00000271755.1 RP1-153G14.4 3.93 0.000127 0.0402 0.37 0.3 Glomerular filtration rate (creatinine); chr6:27518524 chr6:27404010~27406964:- PAAD cis rs3738443 0.868 rs7546908 ENSG00000259865.1 RP11-488L18.10 -3.93 0.000127 0.0402 -0.27 -0.3 Alcohol dependence; chr1:247200531 chr1:247187281~247188526:- PAAD cis rs3790645 1 rs3127013 ENSG00000225159.1 NPM1P39 3.93 0.000127 0.0402 0.4 0.3 Glucose homeostasis traits; chr1:26564869 chr1:27206930~27207796:+ PAAD cis rs3790645 0.874 rs9438508 ENSG00000225159.1 NPM1P39 3.93 0.000127 0.0402 0.4 0.3 Glucose homeostasis traits; chr1:26566578 chr1:27206930~27207796:+ PAAD cis rs3790645 1 rs383913 ENSG00000225159.1 NPM1P39 3.93 0.000127 0.0402 0.4 0.3 Glucose homeostasis traits; chr1:26566815 chr1:27206930~27207796:+ PAAD cis rs4604732 0.631 rs34924545 ENSG00000227135.1 GCSAML-AS1 -3.93 0.000127 0.0402 -0.46 -0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463590 chr1:247524679~247526752:- PAAD cis rs4604732 0.631 rs34443739 ENSG00000227135.1 GCSAML-AS1 -3.93 0.000127 0.0402 -0.46 -0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247463611 chr1:247524679~247526752:- PAAD cis rs17023223 0.537 rs2794310 ENSG00000231365.4 RP11-418J17.1 -3.93 0.000127 0.0402 -0.35 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119019307 chr1:119140396~119275973:+ PAAD cis rs9322193 0.923 rs9800736 ENSG00000223701.3 RAET1E-AS1 3.93 0.000127 0.0402 0.34 0.3 Lung cancer; chr6:149661281 chr6:149884431~149919508:+ PAAD cis rs9322193 0.923 rs12660304 ENSG00000223701.3 RAET1E-AS1 3.93 0.000127 0.0402 0.34 0.3 Lung cancer; chr6:149739647 chr6:149884431~149919508:+ PAAD cis rs7503807 0.967 rs12940622 ENSG00000232083.3 RPL31P7 3.93 0.000127 0.0403 0.36 0.3 Obesity; chr17:80641771 chr17:80602549~80602926:- PAAD cis rs891378 0.785 rs55957981 ENSG00000274245.1 RP11-357P18.2 -3.93 0.000128 0.0403 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207205594 chr1:207372559~207373252:+ PAAD cis rs891378 0.755 rs6703809 ENSG00000274245.1 RP11-357P18.2 -3.93 0.000128 0.0403 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207228650 chr1:207372559~207373252:+ PAAD cis rs6061231 0.834 rs2427307 ENSG00000275437.1 RP5-908M14.10 3.93 0.000128 0.0403 0.28 0.3 Colorectal cancer; chr20:62391630 chr20:62402236~62405935:- PAAD cis rs17836934 0.74 rs7303035 ENSG00000258302.2 RP11-981P6.1 3.93 0.000128 0.0403 0.27 0.3 Total body bone mineral density; chr12:90061403 chr12:89561129~89594878:+ PAAD cis rs7923837 0.634 rs61862780 ENSG00000236493.2 EIF2S2P3 -3.93 0.000128 0.0403 -0.39 -0.3 Multiple sclerosis;Body mass index; chr10:92708886 chr10:92668745~92669743:- PAAD cis rs3015497 0.753 rs4643225 ENSG00000270062.1 RP11-248J18.3 3.93 0.000128 0.0403 0.28 0.3 Mean platelet volume; chr14:50655487 chr14:50723777~50724272:- PAAD cis rs3015497 0.789 rs923908 ENSG00000270062.1 RP11-248J18.3 3.93 0.000128 0.0403 0.28 0.3 Mean platelet volume; chr14:50656877 chr14:50723777~50724272:- PAAD cis rs2115630 0.641 rs11073613 ENSG00000225151.9 GOLGA2P7 3.93 0.000128 0.0403 0.35 0.3 P wave terminal force; chr15:84642662 chr15:84199311~84230136:- PAAD cis rs9309711 0.961 rs11692184 ENSG00000225234.1 TRAPPC12-AS1 -3.93 0.000128 0.0403 -0.33 -0.3 Neurofibrillary tangles; chr2:3476939 chr2:3481242~3482409:- PAAD cis rs12319113 1 rs12319113 ENSG00000255910.1 RP11-405A12.2 3.93 0.000128 0.0403 0.57 0.3 QRS duration in Tripanosoma cruzi seropositivity;Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr12:18871624 chr12:19775451~20009937:+ PAAD cis rs9309711 0.77 rs13409323 ENSG00000225234.1 TRAPPC12-AS1 -3.93 0.000128 0.0403 -0.34 -0.3 Neurofibrillary tangles; chr2:3484413 chr2:3481242~3482409:- PAAD cis rs919433 0.617 rs700642 ENSG00000231621.1 AC013264.2 3.93 0.000128 0.0403 0.29 0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197736006 chr2:197197991~197199273:+ PAAD cis rs3015497 0.934 rs2934691 ENSG00000270062.1 RP11-248J18.3 3.93 0.000128 0.0404 0.28 0.3 Mean platelet volume; chr14:50654615 chr14:50723777~50724272:- PAAD cis rs12602901 0.528 rs12601694 ENSG00000244184.1 RP11-314A20.2 -3.93 0.000128 0.0404 -0.46 -0.3 Blood metabolite levels; chr17:5077086 chr17:4704230~4705529:+ PAAD cis rs780096 0.506 rs72819512 ENSG00000234072.1 AC074117.10 -3.93 0.000128 0.0404 -0.24 -0.3 Total body bone mineral density; chr2:27391582 chr2:27356246~27367622:+ PAAD cis rs878939 0.625 rs1035209 ENSG00000233690.1 EBAG9P1 3.93 0.000128 0.0404 0.39 0.3 Warfarin maintenance dose; chr10:99585609 chr10:99697407~99697949:- PAAD cis rs4468007 0.839 rs10760198 ENSG00000235865.2 GSN-AS1 3.93 0.000128 0.0404 0.33 0.3 Educational attainment; chr9:121848257 chr9:121280768~121285530:- PAAD cis rs9322193 0.923 rs10872650 ENSG00000268592.3 RAET1E-AS1 3.93 0.000128 0.0404 0.36 0.3 Lung cancer; chr6:149760959 chr6:149863494~149919507:+ PAAD cis rs6844153 0.887 rs60890366 ENSG00000240005.4 RP11-293A21.1 -3.93 0.000128 0.0404 -0.48 -0.3 Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid); chr4:26938615 chr4:26859806~26860599:- PAAD cis rs812925 0.537 rs10196146 ENSG00000273302.1 RP11-493E12.2 -3.93 0.000128 0.0404 -0.26 -0.3 Immature fraction of reticulocytes; chr2:61378244 chr2:61199979~61200769:+ PAAD cis rs9322193 0.923 rs9800614 ENSG00000268592.3 RAET1E-AS1 3.93 0.000128 0.0404 0.35 0.3 Lung cancer; chr6:149644604 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9689716 ENSG00000268592.3 RAET1E-AS1 3.93 0.000128 0.0404 0.35 0.3 Lung cancer; chr6:149655662 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9322207 ENSG00000268592.3 RAET1E-AS1 3.93 0.000128 0.0404 0.35 0.3 Lung cancer; chr6:149657185 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9968911 ENSG00000268592.3 RAET1E-AS1 3.93 0.000128 0.0404 0.35 0.3 Lung cancer; chr6:149657419 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs9322208 ENSG00000268592.3 RAET1E-AS1 3.93 0.000128 0.0404 0.35 0.3 Lung cancer; chr6:149658547 chr6:149863494~149919507:+ PAAD cis rs4713118 0.662 rs149946 ENSG00000226314.6 ZNF192P1 3.93 0.000128 0.0404 0.5 0.3 Parkinson's disease; chr6:28002253 chr6:28161781~28169594:+ PAAD cis rs4713118 0.662 rs149947 ENSG00000226314.6 ZNF192P1 -3.93 0.000128 0.0404 -0.5 -0.3 Parkinson's disease; chr6:28004655 chr6:28161781~28169594:+ PAAD cis rs523395 0.63 rs616111 ENSG00000224238.2 WARS2-IT1 3.93 0.000128 0.0405 0.32 0.3 Red blood cell count; chr1:119727368 chr1:119047405~119064785:+ PAAD cis rs5769765 0.908 rs2319464 ENSG00000278869.1 CITF22-49E9.3 -3.93 0.000128 0.0405 -0.43 -0.3 Schizophrenia; chr22:49872129 chr22:49933198~49934074:- PAAD cis rs11089937 0.626 rs737841 ENSG00000211638.2 IGLV8-61 -3.93 0.000128 0.0405 -0.3 -0.3 Periodontitis (PAL4Q3); chr22:22162769 chr22:22098700~22099212:+ PAAD cis rs2742417 0.603 rs2673032 ENSG00000244357.3 RN7SL145P 3.93 0.000128 0.0405 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45715435 chr3:45742675~45742970:+ PAAD cis rs2742417 0.565 rs2673031 ENSG00000244357.3 RN7SL145P 3.93 0.000128 0.0405 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45715494 chr3:45742675~45742970:+ PAAD cis rs2742417 0.624 rs2742394 ENSG00000244357.3 RN7SL145P 3.93 0.000128 0.0405 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45716099 chr3:45742675~45742970:+ PAAD cis rs2742417 0.624 rs2673030 ENSG00000244357.3 RN7SL145P 3.93 0.000128 0.0405 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45716408 chr3:45742675~45742970:+ PAAD cis rs2742417 0.624 rs2673029 ENSG00000244357.3 RN7SL145P 3.93 0.000128 0.0405 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45717375 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs2064063 ENSG00000244357.3 RN7SL145P 3.93 0.000128 0.0405 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45718432 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs2064062 ENSG00000244357.3 RN7SL145P 3.93 0.000128 0.0405 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45719623 chr3:45742675~45742970:+ PAAD cis rs4948102 0.595 rs7793921 ENSG00000273720.1 RP11-613E4.4 -3.93 0.000128 0.0405 -0.38 -0.3 Plasma homocysteine levels (post-methionine load test); chr7:56053188 chr7:55743073~55743457:+ PAAD cis rs4948102 0.595 rs10255049 ENSG00000273720.1 RP11-613E4.4 -3.93 0.000128 0.0405 -0.38 -0.3 Plasma homocysteine levels (post-methionine load test); chr7:56053611 chr7:55743073~55743457:+ PAAD cis rs4459386 0.509 rs10876020 ENSG00000272368.2 RP4-605O3.4 3.93 0.000128 0.0405 0.3 0.3 Schizophrenia; chr12:50342482 chr12:50112197~50165618:+ PAAD cis rs6472827 0.904 rs2956031 ENSG00000253983.2 RP1-16A9.1 3.93 0.000128 0.0405 0.45 0.3 Uterine fibroids; chr8:74203074 chr8:74199396~74208441:+ PAAD cis rs6472827 0.953 rs2936686 ENSG00000253983.2 RP1-16A9.1 3.93 0.000128 0.0405 0.45 0.3 Uterine fibroids; chr8:74203974 chr8:74199396~74208441:+ PAAD cis rs6472827 0.762 rs2936687 ENSG00000253983.2 RP1-16A9.1 3.93 0.000128 0.0405 0.45 0.3 Uterine fibroids; chr8:74205136 chr8:74199396~74208441:+ PAAD cis rs6472827 0.762 rs77058572 ENSG00000253983.2 RP1-16A9.1 3.93 0.000128 0.0405 0.45 0.3 Uterine fibroids; chr8:74205137 chr8:74199396~74208441:+ PAAD cis rs7911264 0.765 rs7092522 ENSG00000232709.1 MARK2P9 -3.93 0.000129 0.0405 -0.39 -0.3 Inflammatory bowel disease; chr10:92583226 chr10:92418667~92420875:+ PAAD cis rs7911264 0.765 rs2421941 ENSG00000232709.1 MARK2P9 -3.93 0.000129 0.0405 -0.39 -0.3 Inflammatory bowel disease; chr10:92586152 chr10:92418667~92420875:+ PAAD cis rs6540731 1 rs6540733 ENSG00000229983.1 RP11-15I11.2 3.93 0.000129 0.0406 0.35 0.3 Intelligence (childhood); chr1:212219611 chr1:212168207~212190259:+ PAAD cis rs79040073 0.637 rs17473568 ENSG00000259469.1 RP11-227D13.4 -3.93 0.000129 0.0406 -0.47 -0.3 Lung cancer in ever smokers; chr15:49149326 chr15:48729080~48729844:- PAAD cis rs1832007 0.58 rs72772226 ENSG00000224034.1 RP11-445P17.8 -3.93 0.000129 0.0406 -0.45 -0.3 Triglyceride levels;Triglycerides; chr10:5203048 chr10:5266033~5271236:- PAAD cis rs10761482 0.5 rs6479716 ENSG00000254271.1 RP11-131N11.4 3.93 0.000129 0.0406 0.37 0.3 Schizophrenia; chr10:60542800 chr10:60734342~60741828:+ PAAD cis rs10761482 0.5 rs10994411 ENSG00000254271.1 RP11-131N11.4 3.93 0.000129 0.0406 0.37 0.3 Schizophrenia; chr10:60545050 chr10:60734342~60741828:+ PAAD cis rs950880 1 rs13001325 ENSG00000234389.1 AC007278.3 -3.93 0.000129 0.0406 -0.29 -0.3 Serum protein levels (sST2); chr2:102322576 chr2:102438713~102440475:+ PAAD cis rs950880 1 rs12479210 ENSG00000234389.1 AC007278.3 -3.93 0.000129 0.0406 -0.29 -0.3 Serum protein levels (sST2); chr2:102332701 chr2:102438713~102440475:+ PAAD cis rs3096299 0.838 rs4785561 ENSG00000274627.1 RP11-104N10.2 3.93 0.000129 0.0406 0.28 0.3 Multiple myeloma (IgH translocation); chr16:89362644 chr16:89516797~89522217:+ PAAD cis rs1873386 0.79 rs7966585 ENSG00000255910.1 RP11-405A12.2 3.93 0.000129 0.0406 0.44 0.3 Personality dimensions; chr12:18918447 chr12:19775451~20009937:+ PAAD cis rs10486158 0.857 rs4724976 ENSG00000233264.2 AC006042.8 3.93 0.000129 0.0406 0.37 0.3 Bipolar disorder and schizophrenia; chr7:7359543 chr7:7980312~7982228:+ PAAD cis rs8081395 0.801 rs2777895 ENSG00000266992.1 DHX40P1 -3.93 0.000129 0.0407 -0.31 -0.3 White blood cell count; chr17:59802249 chr17:59976009~60002384:- PAAD cis rs8081395 0.769 rs12449331 ENSG00000266992.1 DHX40P1 -3.93 0.000129 0.0407 -0.31 -0.3 White blood cell count; chr17:59806285 chr17:59976009~60002384:- PAAD cis rs293748 0.882 rs13177875 ENSG00000250155.1 CTD-2353F22.1 -3.93 0.000129 0.0407 -0.47 -0.3 Obesity-related traits; chr5:37078226 chr5:36666214~36725195:- PAAD cis rs7617773 0.925 rs7374376 ENSG00000228638.1 FCF1P2 3.93 0.000129 0.0407 0.34 0.3 Coronary artery disease; chr3:48131197 chr3:48290793~48291375:- PAAD cis rs4713118 0.662 rs175954 ENSG00000226314.6 ZNF192P1 -3.93 0.000129 0.0407 -0.5 -0.3 Parkinson's disease; chr6:28043807 chr6:28161781~28169594:+ PAAD cis rs3015497 0.616 rs7152874 ENSG00000270062.1 RP11-248J18.3 3.93 0.000129 0.0407 0.29 0.3 Mean platelet volume; chr14:50579322 chr14:50723777~50724272:- PAAD cis rs3015497 0.526 rs10136630 ENSG00000270062.1 RP11-248J18.3 3.93 0.000129 0.0407 0.29 0.3 Mean platelet volume; chr14:50579756 chr14:50723777~50724272:- PAAD cis rs875971 0.895 rs12698520 ENSG00000232559.3 GS1-124K5.12 3.93 0.000129 0.0407 0.33 0.3 Aortic root size; chr7:66453720 chr7:66554588~66576923:- PAAD cis rs4713118 0.512 rs2622319 ENSG00000204709.4 LINC01556 3.93 0.000129 0.0407 0.47 0.3 Parkinson's disease; chr6:28152623 chr6:28943877~28944537:+ PAAD cis rs172166 0.694 rs1150666 ENSG00000204709.4 LINC01556 3.93 0.000129 0.0407 0.47 0.3 Cardiac Troponin-T levels; chr6:28156150 chr6:28943877~28944537:+ PAAD cis rs172166 0.694 rs9295760 ENSG00000204709.4 LINC01556 3.93 0.000129 0.0407 0.47 0.3 Cardiac Troponin-T levels; chr6:28179607 chr6:28943877~28944537:+ PAAD cis rs30380 1 rs30378 ENSG00000272109.1 CTD-2260A17.3 -3.93 0.000129 0.0407 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96786290 chr5:96804353~96806105:+ PAAD cis rs30380 1 rs30379 ENSG00000272109.1 CTD-2260A17.3 -3.93 0.000129 0.0407 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96786556 chr5:96804353~96806105:+ PAAD cis rs30380 1 rs30380 ENSG00000272109.1 CTD-2260A17.3 -3.93 0.000129 0.0407 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96786577 chr5:96804353~96806105:+ PAAD cis rs30380 1 rs246454 ENSG00000272109.1 CTD-2260A17.3 -3.93 0.000129 0.0407 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96787561 chr5:96804353~96806105:+ PAAD cis rs30380 0.922 rs246453 ENSG00000272109.1 CTD-2260A17.3 -3.93 0.000129 0.0407 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96787633 chr5:96804353~96806105:+ PAAD cis rs30380 1 rs151964 ENSG00000272109.1 CTD-2260A17.3 -3.93 0.000129 0.0407 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96787963 chr5:96804353~96806105:+ PAAD cis rs30380 1 rs30187 ENSG00000272109.1 CTD-2260A17.3 -3.93 0.000129 0.0407 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96788627 chr5:96804353~96806105:+ PAAD cis rs7119038 0.818 rs715412 ENSG00000255239.1 AP002954.6 -3.93 0.00013 0.0408 -0.43 -0.3 Sjögren's syndrome; chr11:118813901 chr11:118688039~118690600:- PAAD cis rs2439831 0.85 rs524417 ENSG00000275601.1 AC011330.13 -3.93 0.00013 0.0408 -0.56 -0.3 Lung cancer in ever smokers; chr15:43480176 chr15:43642389~43643023:- PAAD cis rs9595908 0.827 rs7321262 ENSG00000212293.1 SNORA16 3.93 0.00013 0.0408 0.34 0.3 Body mass index; chr13:32597942 chr13:32420390~32420516:- PAAD cis rs9595908 0.9 rs731414 ENSG00000212293.1 SNORA16 3.93 0.00013 0.0408 0.34 0.3 Body mass index; chr13:32601160 chr13:32420390~32420516:- PAAD cis rs6545883 0.507 rs2123111 ENSG00000273302.1 RP11-493E12.2 -3.93 0.00013 0.0408 -0.27 -0.3 Tuberculosis; chr2:61223319 chr2:61199979~61200769:+ PAAD cis rs2412819 0.545 rs3862143 ENSG00000249839.1 AC011330.5 3.93 0.00013 0.0408 0.51 0.3 Lung cancer; chr15:43779282 chr15:43663654~43684339:- PAAD cis rs10800713 0.954 rs6665951 ENSG00000260088.1 RP11-92G12.3 -3.93 0.00013 0.0409 -0.42 -0.3 Tandem gait; chr1:200589235 chr1:200669507~200694250:+ PAAD cis rs10800713 0.954 rs6427835 ENSG00000260088.1 RP11-92G12.3 -3.93 0.00013 0.0409 -0.42 -0.3 Tandem gait; chr1:200591725 chr1:200669507~200694250:+ PAAD cis rs6479901 0.895 rs10822157 ENSG00000232075.1 MRPL35P2 -3.93 0.00013 0.0409 -0.44 -0.3 Intelligence (multi-trait analysis); chr10:63329720 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs7918743 ENSG00000232075.1 MRPL35P2 -3.93 0.00013 0.0409 -0.44 -0.3 Intelligence (multi-trait analysis); chr10:63333302 chr10:63634317~63634827:- PAAD cis rs9322193 0.926 rs9689036 ENSG00000268592.3 RAET1E-AS1 3.93 0.00013 0.0409 0.36 0.3 Lung cancer; chr6:149780563 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9322218 ENSG00000268592.3 RAET1E-AS1 3.93 0.00013 0.0409 0.36 0.3 Lung cancer; chr6:149782183 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9322219 ENSG00000268592.3 RAET1E-AS1 3.93 0.00013 0.0409 0.36 0.3 Lung cancer; chr6:149782263 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs13215691 ENSG00000268592.3 RAET1E-AS1 3.93 0.00013 0.0409 0.36 0.3 Lung cancer; chr6:149792666 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9322223 ENSG00000268592.3 RAET1E-AS1 3.93 0.00013 0.0409 0.36 0.3 Lung cancer; chr6:149801509 chr6:149863494~149919507:+ PAAD cis rs9435732 0.945 rs2311528 ENSG00000235241.1 RP11-108M9.5 3.93 0.00013 0.0409 0.4 0.3 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:16983045 chr1:16889095~16889602:+ PAAD cis rs6840258 1 rs17701999 ENSG00000251411.1 RP11-397E7.4 -3.93 0.00013 0.0409 -0.34 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87034392 chr4:86913266~86914817:- PAAD cis rs2333021 0.78 rs28619241 ENSG00000258376.2 RP4-647C14.2 -3.93 0.00013 0.0409 -0.34 -0.3 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72972902 chr14:73242651~73245979:- PAAD cis rs2333021 0.78 rs12931 ENSG00000258376.2 RP4-647C14.2 -3.93 0.00013 0.0409 -0.34 -0.3 Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous); chr14:72974156 chr14:73242651~73245979:- PAAD cis rs2735413 0.563 rs2072663 ENSG00000276007.1 RP11-358L22.3 3.93 0.00013 0.0409 0.44 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78030836 chr16:78123243~78124332:+ PAAD cis rs1062177 1 rs2915882 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151765875 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs2915880 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151767773 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs2915877 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151771040 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs2964576 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151771041 chr5:151753992~151767247:+ PAAD cis rs1062177 0.906 rs2964573 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151780561 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs2964571 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151791695 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs2915869 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151791948 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs2347596 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151799638 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs892006 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151801329 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs72802204 ENSG00000253921.1 CTB-113P19.3 -3.93 0.00013 0.0409 -0.38 -0.3 Preschool internalizing problems; chr5:151803622 chr5:151753992~151767247:+ PAAD cis rs1062177 1 rs17741826 ENSG00000253921.1 CTB-113P19.3 3.93 0.00013 0.0409 0.38 0.3 Preschool internalizing problems; chr5:151769701 chr5:151753992~151767247:+ PAAD cis rs375066 0.901 rs1978723 ENSG00000267058.1 RP11-15A1.3 3.93 0.00013 0.0409 0.27 0.3 Breast cancer; chr19:43879648 chr19:43891804~43901805:- PAAD cis rs7429990 0.965 rs319682 ENSG00000228638.1 FCF1P2 -3.93 0.00013 0.0409 -0.35 -0.3 Educational attainment (years of education); chr3:47873628 chr3:48290793~48291375:- PAAD cis rs2638953 0.853 rs2141203 ENSG00000247934.4 RP11-967K21.1 -3.93 0.00013 0.0409 -0.32 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28461928 chr12:28163298~28190738:- PAAD cis rs357618 0.531 rs7723079 ENSG00000271795.1 CTC-251D13.1 -3.93 0.00013 0.041 -0.38 -0.3 Basophil percentage of white cells; chr5:151507055 chr5:151509453~151512769:+ PAAD cis rs293748 0.882 rs16903459 ENSG00000250155.1 CTD-2353F22.1 -3.93 0.00013 0.041 -0.47 -0.3 Obesity-related traits; chr5:37031314 chr5:36666214~36725195:- PAAD cis rs10838687 0.736 rs326224 ENSG00000255007.1 CTD-2589M5.4 -3.93 0.00013 0.041 -0.38 -0.3 Proinsulin levels; chr11:47234047 chr11:46256355~46274547:- PAAD cis rs7216064 1 rs7209675 ENSG00000278219.1 AC145343.1 -3.93 0.00013 0.041 -0.48 -0.3 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67835142 chr17:68101538~68101639:+ PAAD cis rs2976388 0.507 rs7813604 ENSG00000253741.1 CTD-2292P10.4 -3.93 0.00013 0.041 -0.37 -0.3 Urinary tract infection frequency; chr8:142756644 chr8:142702252~142726973:- PAAD cis rs2976388 0.525 rs2016749 ENSG00000253741.1 CTD-2292P10.4 3.93 0.00013 0.041 0.37 0.3 Urinary tract infection frequency; chr8:142754700 chr8:142702252~142726973:- PAAD cis rs950169 0.84 rs72748702 ENSG00000275120.1 RP11-182J1.17 3.93 0.00013 0.041 0.32 0.3 Schizophrenia; chr15:84246494 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs4338765 ENSG00000275120.1 RP11-182J1.17 3.93 0.00013 0.041 0.32 0.3 Schizophrenia; chr15:84248084 chr15:84599434~84606463:- PAAD cis rs4713118 0.869 rs4713121 ENSG00000226314.6 ZNF192P1 -3.93 0.00013 0.041 -0.42 -0.3 Parkinson's disease; chr6:27754285 chr6:28161781~28169594:+ PAAD cis rs4268898 0.795 rs12470303 ENSG00000242628.4 AC009228.1 3.93 0.00013 0.041 0.36 0.3 Asthma; chr2:24397014 chr2:24214381~24221516:+ PAAD cis rs6547741 0.775 rs11692692 ENSG00000234072.1 AC074117.10 -3.93 0.00013 0.041 -0.25 -0.3 Oral cavity cancer; chr2:27638840 chr2:27356246~27367622:+ PAAD cis rs8020941 0.585 rs80028507 ENSG00000227051.5 C14orf132 -3.93 0.00013 0.041 -0.36 -0.3 Diabetic kidney disease; chr14:97034001 chr14:96039324~96094080:+ PAAD cis rs8020941 0.585 rs76103642 ENSG00000227051.5 C14orf132 -3.93 0.00013 0.041 -0.36 -0.3 Diabetic kidney disease; chr14:97034812 chr14:96039324~96094080:+ PAAD cis rs8020941 0.585 rs80318300 ENSG00000227051.5 C14orf132 -3.93 0.00013 0.041 -0.36 -0.3 Diabetic kidney disease; chr14:97034907 chr14:96039324~96094080:+ PAAD cis rs8020941 0.585 rs78662326 ENSG00000227051.5 C14orf132 -3.93 0.00013 0.041 -0.36 -0.3 Diabetic kidney disease; chr14:97035506 chr14:96039324~96094080:+ PAAD cis rs8020941 0.585 rs77418493 ENSG00000227051.5 C14orf132 -3.93 0.00013 0.041 -0.36 -0.3 Diabetic kidney disease; chr14:97035884 chr14:96039324~96094080:+ PAAD cis rs763121 0.962 rs5757130 ENSG00000228274.3 RP3-508I15.9 -3.93 0.00013 0.041 -0.29 -0.3 Menopause (age at onset); chr22:38541789 chr22:38667585~38681820:- PAAD cis rs2243480 0.901 rs778730 ENSG00000228409.4 CCT6P1 3.93 0.00013 0.041 0.32 0.3 Diabetic kidney disease; chr7:66358338 chr7:65751142~65763354:+ PAAD cis rs1665050 0.534 rs7167050 ENSG00000277144.1 RP11-59H7.4 -3.93 0.000131 0.041 -0.35 -0.3 Atopic dermatitis; chr15:58948602 chr15:59115547~59116089:- PAAD cis rs10838687 0.61 rs4647737 ENSG00000255007.1 CTD-2589M5.4 3.93 0.000131 0.041 0.37 0.3 Proinsulin levels; chr11:47231693 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs4647741 ENSG00000255007.1 CTD-2589M5.4 3.93 0.000131 0.041 0.37 0.3 Proinsulin levels; chr11:47232459 chr11:46256355~46274547:- PAAD cis rs11690935 0.632 rs17581284 ENSG00000228389.1 AC068039.4 -3.93 0.000131 0.041 -0.37 -0.3 Schizophrenia; chr2:171802866 chr2:171773482~171775844:+ PAAD cis rs10759883 0.587 rs2405134 ENSG00000175611.10 LINC00476 -3.93 0.000131 0.041 -0.3 -0.3 Nicotine dependence; chr9:95795179 chr9:95759231~95875977:- PAAD cis rs7246657 0.882 rs10422667 ENSG00000267422.1 CTD-2554C21.1 -3.93 0.000131 0.041 -0.52 -0.3 Coronary artery calcification; chr19:37446974 chr19:37779686~37792865:+ PAAD cis rs7487075 0.751 rs10880947 ENSG00000257261.4 RP11-96H19.1 -3.93 0.000131 0.0411 -0.4 -0.3 Itch intensity from mosquito bite; chr12:46283501 chr12:46383679~46876159:+ PAAD cis rs950169 0.58 rs11634320 ENSG00000259728.4 LINC00933 -3.93 0.000131 0.0411 -0.38 -0.3 Schizophrenia; chr15:84628952 chr15:84570649~84580175:+ PAAD cis rs4835473 0.8 rs4835330 ENSG00000251600.4 RP11-673E1.1 3.93 0.000131 0.0411 0.36 0.3 Immature fraction of reticulocytes; chr4:143846303 chr4:143912331~143982454:+ PAAD cis rs4835473 0.736 rs6851661 ENSG00000251600.4 RP11-673E1.1 3.93 0.000131 0.0411 0.36 0.3 Immature fraction of reticulocytes; chr4:143850587 chr4:143912331~143982454:+ PAAD cis rs4835473 0.864 rs4835343 ENSG00000251600.4 RP11-673E1.1 3.93 0.000131 0.0411 0.36 0.3 Immature fraction of reticulocytes; chr4:143866038 chr4:143912331~143982454:+ PAAD cis rs2742417 0.967 rs1969625 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45693483 chr3:45742675~45742970:+ PAAD cis rs2742417 0.967 rs1609553 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45693650 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs1609554 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45693700 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673058 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45694126 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673057 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45694238 chr3:45742675~45742970:+ PAAD cis rs2742417 0.967 rs2742426 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45694409 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742432 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45695975 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673056 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45696310 chr3:45742675~45742970:+ PAAD cis rs2742417 0.967 rs9825559 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45698786 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs9829631 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45699066 chr3:45742675~45742970:+ PAAD cis rs2742417 0.967 rs1534875 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45699551 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673047 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45701621 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742438 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45701898 chr3:45742675~45742970:+ PAAD cis rs2742417 0.967 rs2742439 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45702756 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs938363 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45704872 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs938362 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45704873 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs1969626 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45705344 chr3:45742675~45742970:+ PAAD cis rs2742417 0.904 rs2373047 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45706005 chr3:45742675~45742970:+ PAAD cis rs2742417 0.967 rs2742441 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45706937 chr3:45742675~45742970:+ PAAD cis rs2742417 0.935 rs2742442 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45707107 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673038 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45707140 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673037 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45707602 chr3:45742675~45742970:+ PAAD cis rs2742417 0.967 rs1883096 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45708523 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742368 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45710801 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673036 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45710979 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs1877934 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45711803 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs1877933 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45711995 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs1877932 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45712047 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742369 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45712995 chr3:45742675~45742970:+ PAAD cis rs2742417 0.935 rs2248991 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45713257 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742385 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45714778 chr3:45742675~45742970:+ PAAD cis rs2742417 0.935 rs2742393 ENSG00000244357.3 RN7SL145P 3.93 0.000131 0.0411 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45715925 chr3:45742675~45742970:+ PAAD cis rs227275 0.526 rs223497 ENSG00000248971.2 KRT8P46 -3.93 0.000131 0.0411 -0.31 -0.3 Allergic disease (asthma, hay fever or eczema); chr4:102732819 chr4:102728746~102730171:- PAAD cis rs17023223 0.537 rs2765534 ENSG00000231365.4 RP11-418J17.1 -3.93 0.000131 0.0411 -0.34 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119055169 chr1:119140396~119275973:+ PAAD cis rs4809324 0.636 rs56227019 ENSG00000275620.1 FLJ16779 3.93 0.000131 0.0411 0.48 0.3 Glioma (high-grade); chr20:63669453 chr20:63253978~63261615:+ PAAD cis rs4809324 0.551 rs6062485 ENSG00000275620.1 FLJ16779 3.93 0.000131 0.0411 0.48 0.3 Glioma (high-grade); chr20:63670760 chr20:63253978~63261615:+ PAAD cis rs12908161 0.959 rs17598603 ENSG00000259295.5 CSPG4P12 -3.93 0.000131 0.0411 -0.34 -0.3 Schizophrenia; chr15:84656980 chr15:85191438~85213905:+ PAAD cis rs7572733 0.534 rs700685 ENSG00000231621.1 AC013264.2 -3.93 0.000131 0.0411 -0.3 -0.3 Dermatomyositis; chr2:197851248 chr2:197197991~197199273:+ PAAD cis rs17123764 0.579 rs74089551 ENSG00000257464.1 RP11-161H23.8 -3.92 0.000131 0.0412 -0.58 -0.3 Intelligence (multi-trait analysis); chr12:49522590 chr12:49442424~49442652:- PAAD cis rs1395103 0.959 rs9853008 ENSG00000237485.4 SGOL1-AS1 3.92 0.000131 0.0412 0.36 0.3 Bipolar disorder and schizophrenia; chr3:20552488 chr3:20174244~20186427:+ PAAD cis rs2015599 0.623 rs1006410 ENSG00000275476.1 RP11-996F15.4 3.92 0.000131 0.0412 0.29 0.3 Platelet count;Mean platelet volume; chr12:29282682 chr12:29277397~29277882:- PAAD cis rs28386778 0.769 rs6504179 ENSG00000240280.5 TCAM1P -3.92 0.000131 0.0412 -0.43 -0.3 Prudent dietary pattern; chr17:63735635 chr17:63849292~63864379:+ PAAD cis rs748404 0.666 rs72709850 ENSG00000205771.5 CATSPER2P1 -3.92 0.000131 0.0412 -0.5 -0.3 Lung cancer; chr15:43462486 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs34633582 ENSG00000205771.5 CATSPER2P1 -3.92 0.000131 0.0412 -0.5 -0.3 Lung cancer; chr15:43462683 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs12905220 ENSG00000205771.5 CATSPER2P1 -3.92 0.000131 0.0412 -0.5 -0.3 Lung cancer; chr15:43465641 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs36078097 ENSG00000205771.5 CATSPER2P1 -3.92 0.000131 0.0412 -0.5 -0.3 Lung cancer; chr15:43466209 chr15:43726918~43747094:- PAAD cis rs748404 0.666 rs12906481 ENSG00000205771.5 CATSPER2P1 -3.92 0.000131 0.0412 -0.5 -0.3 Lung cancer; chr15:43467356 chr15:43726918~43747094:- PAAD cis rs13256369 1 rs4841016 ENSG00000253981.4 ALG1L13P 3.92 0.000131 0.0412 0.4 0.3 Obesity-related traits; chr8:8715051 chr8:8236003~8244667:- PAAD cis rs17772222 1 rs60310240 ENSG00000258983.2 RP11-507K2.2 3.92 0.000131 0.0412 0.42 0.3 Coronary artery calcification; chr14:88356365 chr14:88499334~88515502:+ PAAD cis rs17772222 1 rs17772064 ENSG00000258983.2 RP11-507K2.2 3.92 0.000131 0.0412 0.42 0.3 Coronary artery calcification; chr14:88356527 chr14:88499334~88515502:+ PAAD cis rs7637701 0.901 rs13071598 ENSG00000240875.4 LINC00886 -3.92 0.000131 0.0412 -0.37 -0.3 Breast cancer; chr3:156854426 chr3:156747346~156817062:- PAAD cis rs6142102 0.961 rs4911401 ENSG00000276073.1 RP5-1125A11.7 -3.92 0.000131 0.0412 -0.33 -0.3 Skin pigmentation; chr20:34066756 chr20:33985617~33988989:- PAAD cis rs11159086 0.793 rs3784035 ENSG00000270000.1 RP3-449M8.9 3.92 0.000131 0.0412 0.45 0.3 Advanced glycation end-product levels; chr14:74482221 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs12433382 ENSG00000270000.1 RP3-449M8.9 3.92 0.000131 0.0412 0.45 0.3 Advanced glycation end-product levels; chr14:74482940 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs10148268 ENSG00000270000.1 RP3-449M8.9 3.92 0.000131 0.0412 0.45 0.3 Advanced glycation end-product levels; chr14:74484261 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs9285594 ENSG00000270000.1 RP3-449M8.9 3.92 0.000131 0.0412 0.45 0.3 Advanced glycation end-product levels; chr14:74489253 chr14:74471930~74472360:- PAAD cis rs755249 0.917 rs72663503 ENSG00000237624.1 OXCT2P1 3.92 0.000131 0.0412 0.42 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39503387 chr1:39514956~39516490:+ PAAD cis rs7829975 0.593 rs2921051 ENSG00000254340.1 RP11-10A14.3 3.92 0.000131 0.0412 0.37 0.3 Mood instability; chr8:8462594 chr8:9141424~9145435:+ PAAD cis rs11790994 0.822 rs10820734 ENSG00000271384.1 RP11-435O5.7 -3.92 0.000131 0.0412 -0.61 -0.3 Inattentive symptoms; chr9:95668582 chr9:95406990~95407662:- PAAD cis rs4622329 0.636 rs4764836 ENSG00000257202.1 RP11-512N21.3 3.92 0.000131 0.0412 0.36 0.3 Systemic lupus erythematosus; chr12:101893925 chr12:101923410~101924719:- PAAD cis rs4478147 0.548 rs4693140 ENSG00000251411.1 RP11-397E7.4 -3.92 0.000132 0.0413 -0.31 -0.3 Migraine - clinic-based; chr4:86319646 chr4:86913266~86914817:- PAAD cis rs9322193 0.923 rs66516768 ENSG00000223701.3 RAET1E-AS1 3.92 0.000132 0.0413 0.34 0.3 Lung cancer; chr6:149671999 chr6:149884431~149919508:+ PAAD cis rs72615157 0.634 rs7789890 ENSG00000242294.5 STAG3L5P 3.92 0.000132 0.0413 0.24 0.3 Lung function (FEV1/FVC); chr7:100202936 chr7:100336079~100351900:+ PAAD cis rs35934224 0.504 rs10372 ENSG00000232926.1 AC000078.5 3.92 0.000132 0.0413 0.42 0.3 Glaucoma (primary open-angle); chr22:19849775 chr22:19887289~19887970:+ PAAD cis rs2348418 0.832 rs1032391 ENSG00000247934.4 RP11-967K21.1 3.92 0.000132 0.0413 0.29 0.3 Lung function (FEV1);Lung function (FVC); chr12:28383775 chr12:28163298~28190738:- PAAD cis rs7216064 1 rs62084214 ENSG00000278219.1 AC145343.1 -3.92 0.000132 0.0413 -0.49 -0.3 EGFR mutation-positive lung adenocarcinoma;Lung adenocarcinoma;Lung cancer; chr17:67847209 chr17:68101538~68101639:+ PAAD cis rs987724 0.593 rs13322318 ENSG00000240875.4 LINC00886 -3.92 0.000132 0.0413 -0.36 -0.3 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156906481 chr3:156747346~156817062:- PAAD cis rs4604732 0.631 rs12038793 ENSG00000227135.1 GCSAML-AS1 3.92 0.000132 0.0413 0.46 0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247460960 chr1:247524679~247526752:- PAAD cis rs6717918 0.924 rs6718438 ENSG00000251791.1 SCARNA6 3.92 0.000132 0.0413 0.35 0.3 Height; chr2:232290856 chr2:233288676~233288940:+ PAAD cis rs5769765 0.74 rs2103932 ENSG00000278869.1 CITF22-49E9.3 -3.92 0.000132 0.0413 -0.42 -0.3 Schizophrenia; chr22:49878867 chr22:49933198~49934074:- PAAD cis rs9549328 0.837 rs4907572 ENSG00000267868.1 RP11-120K24.3 3.92 0.000132 0.0413 0.35 0.3 Systolic blood pressure; chr13:112993007 chr13:112964835~112966131:- PAAD cis rs875971 0.825 rs1129531 ENSG00000232559.3 GS1-124K5.12 -3.92 0.000132 0.0413 -0.34 -0.3 Aortic root size; chr7:66154117 chr7:66554588~66576923:- PAAD cis rs3015497 0.616 rs6572678 ENSG00000270062.1 RP11-248J18.3 3.92 0.000132 0.0414 0.29 0.3 Mean platelet volume; chr14:50623397 chr14:50723777~50724272:- PAAD cis rs3015497 0.616 rs4901044 ENSG00000270062.1 RP11-248J18.3 3.92 0.000132 0.0414 0.29 0.3 Mean platelet volume; chr14:50623577 chr14:50723777~50724272:- PAAD cis rs3015497 0.586 rs12587821 ENSG00000270062.1 RP11-248J18.3 3.92 0.000132 0.0414 0.29 0.3 Mean platelet volume; chr14:50625836 chr14:50723777~50724272:- PAAD cis rs3015497 0.586 rs12587842 ENSG00000270062.1 RP11-248J18.3 3.92 0.000132 0.0414 0.29 0.3 Mean platelet volume; chr14:50625844 chr14:50723777~50724272:- PAAD cis rs902774 0.53 rs11834907 ENSG00000278185.1 RP11-153F5.7 3.92 0.000132 0.0414 0.61 0.3 Prostate cancer; chr12:52957201 chr12:52946614~52947125:- PAAD cis rs902774 0.53 rs12819597 ENSG00000278185.1 RP11-153F5.7 3.92 0.000132 0.0414 0.61 0.3 Prostate cancer; chr12:52960172 chr12:52946614~52947125:- PAAD cis rs902774 0.585 rs7399070 ENSG00000278185.1 RP11-153F5.7 3.92 0.000132 0.0414 0.61 0.3 Prostate cancer; chr12:52961894 chr12:52946614~52947125:- PAAD cis rs7264396 0.58 rs6119655 ENSG00000207635.1 MIR499A -3.92 0.000132 0.0414 -0.4 -0.3 Total cholesterol levels; chr20:35824127 chr20:34990376~34990497:+ PAAD cis rs748404 0.534 rs489509 ENSG00000205771.5 CATSPER2P1 -3.92 0.000132 0.0414 -0.42 -0.3 Lung cancer; chr15:43294709 chr15:43726918~43747094:- PAAD cis rs74233809 0.636 rs284851 ENSG00000213277.3 MARCKSL1P1 3.92 0.000132 0.0414 0.45 0.3 Birth weight; chr10:102818774 chr10:103175554~103176094:+ PAAD cis rs74233809 0.636 rs284861 ENSG00000213277.3 MARCKSL1P1 -3.92 0.000132 0.0414 -0.45 -0.3 Birth weight; chr10:102812519 chr10:103175554~103176094:+ PAAD cis rs35934224 0.504 rs7288631 ENSG00000232926.1 AC000078.5 3.92 0.000132 0.0414 0.48 0.3 Glaucoma (primary open-angle); chr22:19848625 chr22:19887289~19887970:+ PAAD cis rs2115630 0.755 rs7169629 ENSG00000275120.1 RP11-182J1.17 3.92 0.000132 0.0414 0.31 0.3 P wave terminal force; chr15:84648043 chr15:84599434~84606463:- PAAD cis rs801193 0.548 rs2659904 ENSG00000237310.1 GS1-124K5.4 3.92 0.000132 0.0414 0.3 0.3 Aortic root size; chr7:66713615 chr7:66493706~66495474:+ PAAD cis rs2115630 0.936 rs8033459 ENSG00000275120.1 RP11-182J1.17 -3.92 0.000132 0.0414 -0.31 -0.3 P wave terminal force; chr15:84710027 chr15:84599434~84606463:- PAAD cis rs2638953 0.853 rs11049678 ENSG00000247934.4 RP11-967K21.1 -3.92 0.000132 0.0414 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28505546 chr12:28163298~28190738:- PAAD cis rs4948275 0.53 rs2393853 ENSG00000237233.2 TMEM26-AS1 3.92 0.000132 0.0414 0.36 0.3 Night sleep phenotypes; chr10:61407930 chr10:61452639~61481956:+ PAAD cis rs12586317 0.508 rs8015350 ENSG00000258704.4 SRP54-AS1 -3.92 0.000132 0.0414 -0.29 -0.3 Psoriasis; chr14:35166024 chr14:34920858~34982532:- PAAD cis rs950169 0.922 rs12906983 ENSG00000275120.1 RP11-182J1.17 3.92 0.000132 0.0414 0.32 0.3 Schizophrenia; chr15:84262270 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs62021167 ENSG00000259683.1 RP11-182J1.14 3.92 0.000132 0.0414 0.25 0.3 Schizophrenia; chr15:84574820 chr15:84389729~84395903:+ PAAD cis rs755249 1 rs12037222 ENSG00000228060.1 RP11-69E11.8 -3.92 0.000132 0.0414 -0.31 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39599289 chr1:39565160~39573203:+ PAAD cis rs2439831 0.85 rs2439832 ENSG00000275601.1 AC011330.13 -3.92 0.000132 0.0414 -0.56 -0.3 Lung cancer in ever smokers; chr15:43487488 chr15:43642389~43643023:- PAAD cis rs7078219 0.524 rs6584277 ENSG00000228778.1 RP11-129J12.1 -3.92 0.000132 0.0414 -0.33 -0.3 Dental caries; chr10:99518298 chr10:99527081~99528261:+ PAAD cis rs12908161 1 rs11632465 ENSG00000259295.5 CSPG4P12 3.92 0.000132 0.0415 0.34 0.3 Schizophrenia; chr15:84738814 chr15:85191438~85213905:+ PAAD cis rs79040073 0.53 rs113085328 ENSG00000259469.1 RP11-227D13.4 -3.92 0.000132 0.0415 -0.41 -0.3 Lung cancer in ever smokers; chr15:49223704 chr15:48729080~48729844:- PAAD cis rs79040073 0.53 rs73392262 ENSG00000259469.1 RP11-227D13.4 -3.92 0.000132 0.0415 -0.41 -0.3 Lung cancer in ever smokers; chr15:49229513 chr15:48729080~48729844:- PAAD cis rs79040073 0.563 rs7167852 ENSG00000259469.1 RP11-227D13.4 -3.92 0.000132 0.0415 -0.41 -0.3 Lung cancer in ever smokers; chr15:49250004 chr15:48729080~48729844:- PAAD cis rs79040073 0.53 rs17396612 ENSG00000259469.1 RP11-227D13.4 -3.92 0.000132 0.0415 -0.41 -0.3 Lung cancer in ever smokers; chr15:49257746 chr15:48729080~48729844:- PAAD cis rs79040073 0.53 rs17475228 ENSG00000259469.1 RP11-227D13.4 -3.92 0.000132 0.0415 -0.41 -0.3 Lung cancer in ever smokers; chr15:49269619 chr15:48729080~48729844:- PAAD cis rs79040073 0.53 rs8029506 ENSG00000259469.1 RP11-227D13.4 -3.92 0.000132 0.0415 -0.41 -0.3 Lung cancer in ever smokers; chr15:49274543 chr15:48729080~48729844:- PAAD cis rs6479891 1 rs4745706 ENSG00000232075.1 MRPL35P2 3.92 0.000132 0.0415 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63399820 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12415038 ENSG00000232075.1 MRPL35P2 3.92 0.000132 0.0415 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63401098 chr10:63634317~63634827:- PAAD cis rs77372450 0.591 rs6879838 ENSG00000251405.2 CTB-109A12.1 3.92 0.000132 0.0415 0.46 0.3 Bipolar disorder (body mass index interaction); chr5:157539559 chr5:157362615~157460078:- PAAD cis rs77372450 0.688 rs6875485 ENSG00000251405.2 CTB-109A12.1 3.92 0.000132 0.0415 0.46 0.3 Bipolar disorder (body mass index interaction); chr5:157539587 chr5:157362615~157460078:- PAAD cis rs42490 0.664 rs39767 ENSG00000251136.7 RP11-37B2.1 -3.92 0.000132 0.0415 -0.26 -0.3 Leprosy; chr8:89807770 chr8:89609409~89757727:- PAAD cis rs7759001 0.744 rs1014227 ENSG00000271755.1 RP1-153G14.4 3.92 0.000132 0.0415 0.37 0.3 Glomerular filtration rate (creatinine); chr6:27476178 chr6:27404010~27406964:- PAAD cis rs1910358 0.554 rs2343381 ENSG00000248874.4 C5orf17 -3.92 0.000133 0.0415 -0.42 -0.3 Venous thromboembolism (SNP x SNP interaction); chr5:23736629 chr5:23951348~24178263:+ PAAD cis rs1910358 0.554 rs2880616 ENSG00000248874.4 C5orf17 -3.92 0.000133 0.0415 -0.42 -0.3 Venous thromboembolism (SNP x SNP interaction); chr5:23736656 chr5:23951348~24178263:+ PAAD cis rs17507216 0.56 rs2871011 ENSG00000278603.1 RP13-608F4.5 3.92 0.000133 0.0415 0.39 0.3 Excessive daytime sleepiness; chr15:82560792 chr15:82472203~82472426:+ PAAD cis rs950169 0.922 rs17531523 ENSG00000259683.1 RP11-182J1.14 3.92 0.000133 0.0415 0.25 0.3 Schizophrenia; chr15:84589218 chr15:84389729~84395903:+ PAAD cis rs700651 0.856 rs9288280 ENSG00000231621.1 AC013264.2 -3.92 0.000133 0.0416 -0.3 -0.3 Intracranial aneurysm; chr2:197879600 chr2:197197991~197199273:+ PAAD cis rs2832077 0.883 rs35672956 ENSG00000176054.6 RPL23P2 -3.92 0.000133 0.0416 -0.35 -0.3 Cognitive test performance; chr21:28816719 chr21:28997613~28998033:- PAAD cis rs2832077 0.943 rs11700746 ENSG00000176054.6 RPL23P2 -3.92 0.000133 0.0416 -0.35 -0.3 Cognitive test performance; chr21:28816884 chr21:28997613~28998033:- PAAD cis rs2832077 0.943 rs2272701 ENSG00000176054.6 RPL23P2 -3.92 0.000133 0.0416 -0.35 -0.3 Cognitive test performance; chr21:28818585 chr21:28997613~28998033:- PAAD cis rs2832077 0.943 rs2832106 ENSG00000176054.6 RPL23P2 -3.92 0.000133 0.0416 -0.35 -0.3 Cognitive test performance; chr21:28819445 chr21:28997613~28998033:- PAAD cis rs2832077 0.943 rs4816336 ENSG00000176054.6 RPL23P2 -3.92 0.000133 0.0416 -0.35 -0.3 Cognitive test performance; chr21:28821197 chr21:28997613~28998033:- PAAD cis rs2832077 0.943 rs11702320 ENSG00000176054.6 RPL23P2 -3.92 0.000133 0.0416 -0.35 -0.3 Cognitive test performance; chr21:28822929 chr21:28997613~28998033:- PAAD cis rs11603023 0.805 rs687190 ENSG00000255239.1 AP002954.6 3.92 0.000133 0.0416 0.38 0.3 Cholesterol, total; chr11:118671674 chr11:118688039~118690600:- PAAD cis rs6547741 0.816 rs7560847 ENSG00000234072.1 AC074117.10 -3.92 0.000133 0.0416 -0.25 -0.3 Oral cavity cancer; chr2:27659833 chr2:27356246~27367622:+ PAAD cis rs7260598 0.642 rs73023276 ENSG00000268442.1 CTD-2027I19.2 3.92 0.000133 0.0416 0.44 0.3 Response to taxane treatment (placlitaxel); chr19:23976045 chr19:24162370~24163425:- PAAD cis rs2216164 0.966 rs4913277 ENSG00000234925.2 ATP5HP4 -3.92 0.000133 0.0416 -0.37 -0.3 Alopecia areata; chr12:68188392 chr12:68642519~68642993:- PAAD cis rs172166 0.637 rs1233691 ENSG00000204709.4 LINC01556 3.92 0.000133 0.0416 0.46 0.3 Cardiac Troponin-T levels; chr6:28186119 chr6:28943877~28944537:+ PAAD cis rs9876781 1 rs9812647 ENSG00000229759.1 MRPS18AP1 -3.92 0.000133 0.0416 -0.33 -0.3 Longevity; chr3:48407507 chr3:48256350~48256938:- PAAD cis rs8042680 0.592 rs11073960 ENSG00000278370.1 RP11-387D10.4 -3.92 0.000133 0.0416 -0.37 -0.3 Type 2 diabetes; chr15:90940027 chr15:90650631~90651103:+ PAAD cis rs7554672 0.961 rs11118662 ENSG00000232679.1 RP11-400N13.3 -3.92 0.000133 0.0416 -0.31 -0.3 Hypertension; chr1:221171881 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs1539140 ENSG00000232679.1 RP11-400N13.3 -3.92 0.000133 0.0416 -0.31 -0.3 Hypertension; chr1:221181660 chr1:222041705~222064763:- PAAD cis rs6435957 0.568 rs2372938 ENSG00000233143.1 DIRC3-AS1 -3.92 0.000133 0.0416 -0.39 -0.3 Primary tooth development (number of teeth); chr2:217030386 chr2:217282739~217336120:+ PAAD cis rs17772222 0.917 rs17188228 ENSG00000258983.2 RP11-507K2.2 3.92 0.000133 0.0417 0.39 0.3 Coronary artery calcification; chr14:88738921 chr14:88499334~88515502:+ PAAD cis rs1832007 0.554 rs75353459 ENSG00000224034.1 RP11-445P17.8 -3.92 0.000133 0.0417 -0.45 -0.3 Triglyceride levels;Triglycerides; chr10:5202899 chr10:5266033~5271236:- PAAD cis rs1832007 0.554 rs77506074 ENSG00000224034.1 RP11-445P17.8 -3.92 0.000133 0.0417 -0.45 -0.3 Triglyceride levels;Triglycerides; chr10:5202905 chr10:5266033~5271236:- PAAD cis rs1832007 0.554 rs11594428 ENSG00000224034.1 RP11-445P17.8 -3.92 0.000133 0.0417 -0.45 -0.3 Triglyceride levels;Triglycerides; chr10:5203006 chr10:5266033~5271236:- PAAD cis rs4468007 0.865 rs4308812 ENSG00000235865.2 GSN-AS1 3.92 0.000133 0.0417 0.3 0.3 Educational attainment; chr9:121850999 chr9:121280768~121285530:- PAAD cis rs2216164 1 rs2870951 ENSG00000234925.2 ATP5HP4 3.92 0.000133 0.0417 0.37 0.3 Alopecia areata; chr12:68190765 chr12:68642519~68642993:- PAAD cis rs9595066 0.712 rs4391951 ENSG00000227258.4 SMIM2-AS1 -3.92 0.000133 0.0417 -0.45 -0.3 Schizophrenia; chr13:44180935 chr13:44110451~44240517:+ PAAD cis rs748404 0.578 rs2278856 ENSG00000205771.5 CATSPER2P1 -3.92 0.000133 0.0417 -0.42 -0.3 Lung cancer; chr15:43339158 chr15:43726918~43747094:- PAAD cis rs7617773 0.963 rs12495221 ENSG00000228638.1 FCF1P2 3.92 0.000133 0.0417 0.34 0.3 Coronary artery disease; chr3:48137688 chr3:48290793~48291375:- PAAD cis rs9322193 0.923 rs12529698 ENSG00000223701.3 RAET1E-AS1 3.92 0.000133 0.0417 0.34 0.3 Lung cancer; chr6:149650951 chr6:149884431~149919508:+ PAAD cis rs57339844 1 rs57339844 ENSG00000273080.1 RP11-301O19.1 -3.92 0.000133 0.0417 -0.34 -0.3 Mean platelet volume; chr2:85891155 chr2:86195590~86196049:+ PAAD cis rs950169 0.84 rs62029595 ENSG00000275120.1 RP11-182J1.17 3.92 0.000133 0.0417 0.31 0.3 Schizophrenia; chr15:84400603 chr15:84599434~84606463:- PAAD cis rs8067545 0.532 rs12449914 ENSG00000261033.1 RP11-209D14.2 -3.92 0.000133 0.0417 -0.38 -0.3 Schizophrenia; chr17:20100656 chr17:20008051~20009234:- PAAD cis rs8067545 0.532 rs12943904 ENSG00000261033.1 RP11-209D14.2 -3.92 0.000133 0.0417 -0.38 -0.3 Schizophrenia; chr17:20104254 chr17:20008051~20009234:- PAAD cis rs7829975 0.688 rs6601703 ENSG00000253981.4 ALG1L13P 3.92 0.000134 0.0418 0.35 0.3 Mood instability; chr8:8522714 chr8:8236003~8244667:- PAAD cis rs3738443 0.868 rs7536883 ENSG00000259865.1 RP11-488L18.10 3.92 0.000134 0.0418 0.28 0.3 Alcohol dependence; chr1:247196266 chr1:247187281~247188526:- PAAD cis rs3738443 0.817 rs61839996 ENSG00000259865.1 RP11-488L18.10 3.92 0.000134 0.0418 0.28 0.3 Alcohol dependence; chr1:247197571 chr1:247187281~247188526:- PAAD cis rs3738443 0.868 rs60698393 ENSG00000259865.1 RP11-488L18.10 3.92 0.000134 0.0418 0.28 0.3 Alcohol dependence; chr1:247198135 chr1:247187281~247188526:- PAAD cis rs3738443 0.83 rs58405512 ENSG00000259865.1 RP11-488L18.10 3.92 0.000134 0.0418 0.28 0.3 Alcohol dependence; chr1:247198454 chr1:247187281~247188526:- PAAD cis rs13178541 0.641 rs62364708 ENSG00000250378.1 RP11-119J18.1 -3.92 0.000134 0.0418 -0.44 -0.3 IgG glycosylation; chr5:135796164 chr5:135812667~135826582:+ PAAD cis rs10932679 0.532 rs2712162 ENSG00000229352.1 AC007563.3 -3.92 0.000134 0.0418 -0.32 -0.3 Pulse pressure; chr2:216797065 chr2:216799608~216805335:+ PAAD cis rs7246657 1 rs12709812 ENSG00000267422.1 CTD-2554C21.1 3.92 0.000134 0.0418 0.54 0.3 Coronary artery calcification; chr19:37303948 chr19:37779686~37792865:+ PAAD cis rs7246657 1 rs35398388 ENSG00000267422.1 CTD-2554C21.1 -3.92 0.000134 0.0418 -0.54 -0.3 Coronary artery calcification; chr19:37249456 chr19:37779686~37792865:+ PAAD cis rs7246657 1 rs7247672 ENSG00000267422.1 CTD-2554C21.1 -3.92 0.000134 0.0418 -0.54 -0.3 Coronary artery calcification; chr19:37253026 chr19:37779686~37792865:+ PAAD cis rs7246657 1 rs8110011 ENSG00000267422.1 CTD-2554C21.1 -3.92 0.000134 0.0418 -0.54 -0.3 Coronary artery calcification; chr19:37254911 chr19:37779686~37792865:+ PAAD cis rs7246657 0.941 rs7259618 ENSG00000267422.1 CTD-2554C21.1 -3.92 0.000134 0.0418 -0.54 -0.3 Coronary artery calcification; chr19:37259817 chr19:37779686~37792865:+ PAAD cis rs2262909 0.962 rs439574 ENSG00000279377.1 AC003973.3 3.92 0.000134 0.0418 0.28 0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22049222 chr19:21965708~21968529:- PAAD cis rs1062177 0.774 rs2964574 ENSG00000253921.1 CTB-113P19.3 -3.92 0.000134 0.0418 -0.38 -0.3 Preschool internalizing problems; chr5:151776150 chr5:151753992~151767247:+ PAAD cis rs1062177 0.826 rs2053063 ENSG00000253921.1 CTB-113P19.3 -3.92 0.000134 0.0418 -0.38 -0.3 Preschool internalizing problems; chr5:151787203 chr5:151753992~151767247:+ PAAD cis rs2439831 0.681 rs884704 ENSG00000275601.1 AC011330.13 -3.92 0.000134 0.0418 -0.51 -0.3 Lung cancer in ever smokers; chr15:43398952 chr15:43642389~43643023:- PAAD cis rs7626444 0.625 rs9872035 ENSG00000272359.1 U4 -3.92 0.000134 0.0418 -0.35 -0.3 Monocyte count; chr3:196767831 chr3:196747192~196747324:- PAAD cis rs2348418 0.832 rs1907692 ENSG00000247934.4 RP11-967K21.1 3.92 0.000134 0.0418 0.29 0.3 Lung function (FEV1);Lung function (FVC); chr12:28385178 chr12:28163298~28190738:- PAAD cis rs875971 1 rs3981131 ENSG00000232559.3 GS1-124K5.12 3.92 0.000134 0.0419 0.33 0.3 Aortic root size; chr7:66486690 chr7:66554588~66576923:- PAAD cis rs13178541 0.552 rs6881599 ENSG00000250378.1 RP11-119J18.1 -3.92 0.000134 0.0419 -0.38 -0.3 IgG glycosylation; chr5:135705961 chr5:135812667~135826582:+ PAAD cis rs7829975 0.688 rs13270194 ENSG00000253981.4 ALG1L13P 3.92 0.000134 0.0419 0.35 0.3 Mood instability; chr8:8520592 chr8:8236003~8244667:- PAAD cis rs5760092 0.627 rs6519489 ENSG00000206090.4 AP000350.7 -3.92 0.000134 0.0419 -0.45 -0.3 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:23939998~23942798:+ PAAD cis rs6545883 0.524 rs2463101 ENSG00000273302.1 RP11-493E12.2 -3.92 0.000134 0.0419 -0.27 -0.3 Tuberculosis; chr2:61347287 chr2:61199979~61200769:+ PAAD cis rs878939 0.625 rs17578234 ENSG00000233690.1 EBAG9P1 3.92 0.000134 0.0419 0.39 0.3 Warfarin maintenance dose; chr10:99583560 chr10:99697407~99697949:- PAAD cis rs878939 0.625 rs61871279 ENSG00000233690.1 EBAG9P1 3.92 0.000134 0.0419 0.39 0.3 Warfarin maintenance dose; chr10:99583948 chr10:99697407~99697949:- PAAD cis rs763121 0.752 rs6001190 ENSG00000228274.3 RP3-508I15.9 -3.92 0.000134 0.042 -0.3 -0.3 Menopause (age at onset); chr22:38677806 chr22:38667585~38681820:- PAAD cis rs35762459 1 rs35762459 ENSG00000254860.4 TMEM9B-AS1 3.92 0.000134 0.042 0.33 0.3 Immature fraction of reticulocytes; chr11:8823106 chr11:8964675~8977527:+ PAAD cis rs12908161 1 rs11632465 ENSG00000275120.1 RP11-182J1.17 3.92 0.000135 0.042 0.32 0.3 Schizophrenia; chr15:84738814 chr15:84599434~84606463:- PAAD cis rs7202877 0.561 rs8050662 ENSG00000261783.1 RP11-252K23.2 3.92 0.000135 0.042 0.48 0.3 Type 1 diabetes;Type 2 diabetes; chr16:75326836 chr16:75379818~75381260:- PAAD cis rs700651 0.789 rs1147169 ENSG00000231621.1 AC013264.2 3.92 0.000135 0.042 0.31 0.3 Intracranial aneurysm; chr2:198036671 chr2:197197991~197199273:+ PAAD cis rs12908161 0.853 rs11633788 ENSG00000225151.9 GOLGA2P7 -3.92 0.000135 0.042 -0.35 -0.3 Schizophrenia; chr15:84761911 chr15:84199311~84230136:- PAAD cis rs6539288 0.77 rs1468908 ENSG00000260329.1 RP11-412D9.4 -3.92 0.000135 0.042 -0.26 -0.3 Total body bone mineral density; chr12:106904539 chr12:106954029~106955497:- PAAD cis rs6539288 0.933 rs1470380 ENSG00000260329.1 RP11-412D9.4 -3.92 0.000135 0.042 -0.26 -0.3 Total body bone mineral density; chr12:106904961 chr12:106954029~106955497:- PAAD cis rs2288073 0.965 rs36101491 ENSG00000242628.4 AC009228.1 3.92 0.000135 0.042 0.38 0.3 Venous thromboembolism (SNP x SNP interaction); chr2:24164663 chr2:24214381~24221516:+ PAAD cis rs17772222 0.917 rs12588535 ENSG00000258789.1 RP11-507K2.3 -3.92 0.000135 0.042 -0.33 -0.3 Coronary artery calcification; chr14:88781900 chr14:88551597~88552493:+ PAAD cis rs7539624 0.577 rs1222158 ENSG00000272645.2 RP11-504P24.8 3.92 0.000135 0.042 0.26 0.3 Schizophrenia; chr1:223800999 chr1:223951388~223953439:- PAAD cis rs748404 0.697 rs471122 ENSG00000205771.5 CATSPER2P1 3.92 0.000135 0.042 0.39 0.3 Lung cancer; chr15:43266376 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs555001 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43253530 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs475261 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43254258 chr15:43726918~43747094:- PAAD cis rs748404 0.723 rs573169 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43258383 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs524547 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43258825 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs564946 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43264074 chr15:43726918~43747094:- PAAD cis rs748404 0.723 rs565658 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43264109 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs579651 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43266178 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs473016 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43266625 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs531910 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43268409 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs491804 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43268627 chr15:43726918~43747094:- PAAD cis rs748404 0.697 rs492743 ENSG00000205771.5 CATSPER2P1 -3.92 0.000135 0.042 -0.39 -0.3 Lung cancer; chr15:43268747 chr15:43726918~43747094:- PAAD cis rs7829975 0.688 rs7837587 ENSG00000253981.4 ALG1L13P 3.92 0.000135 0.042 0.35 0.3 Mood instability; chr8:8521482 chr8:8236003~8244667:- PAAD cis rs7829975 0.688 rs7826654 ENSG00000253981.4 ALG1L13P 3.92 0.000135 0.042 0.35 0.3 Mood instability; chr8:8521596 chr8:8236003~8244667:- PAAD cis rs7829975 0.688 rs7826660 ENSG00000253981.4 ALG1L13P 3.92 0.000135 0.042 0.35 0.3 Mood instability; chr8:8521597 chr8:8236003~8244667:- PAAD cis rs7923837 1 rs10786053 ENSG00000236493.2 EIF2S2P3 3.92 0.000135 0.042 0.39 0.3 Multiple sclerosis;Body mass index; chr10:92714340 chr10:92668745~92669743:- PAAD cis rs7923837 0.928 rs10882105 ENSG00000236493.2 EIF2S2P3 3.92 0.000135 0.042 0.39 0.3 Multiple sclerosis;Body mass index; chr10:92714354 chr10:92668745~92669743:- PAAD cis rs494459 0.733 rs556437 ENSG00000278376.1 RP11-158I9.8 -3.92 0.000135 0.042 -0.27 -0.3 Height; chr11:118835044 chr11:118791254~118793137:+ PAAD cis rs9309473 1 rs13383871 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73404651 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs10179134 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73410391 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs6755241 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73414236 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs7564890 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73414725 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs6705489 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73421683 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs7598396 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73425500 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs10190219 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73431203 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs7594511 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73454512 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs62151652 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73473004 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs13421462 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73492748 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs13398956 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73493131 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs56154726 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73494640 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs7572722 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73497548 chr2:73644919~73685576:+ PAAD cis rs9309473 0.948 rs13391552 ENSG00000163016.8 ALMS1P 3.92 0.000135 0.042 0.43 0.3 Metabolite levels; chr2:73591809 chr2:73644919~73685576:+ PAAD cis rs7246657 0.551 rs4806414 ENSG00000267422.1 CTD-2554C21.1 -3.92 0.000135 0.0421 -0.57 -0.3 Coronary artery calcification; chr19:37147886 chr19:37779686~37792865:+ PAAD cis rs848486 0.936 rs10268139 ENSG00000213542.3 RP11-467H10.1 3.92 0.000135 0.0421 0.32 0.3 Glomerular filtration rate; chr7:77698783 chr7:77115399~77116192:- PAAD cis rs1876905 0.68 rs3749867 ENSG00000230177.1 RP5-1112D6.4 -3.92 0.000135 0.0421 -0.33 -0.3 Mean corpuscular hemoglobin; chr6:111103615 chr6:111277932~111278742:+ PAAD cis rs2980439 0.525 rs1850511 ENSG00000253981.4 ALG1L13P 3.92 0.000135 0.0421 0.35 0.3 Neuroticism; chr8:8312807 chr8:8236003~8244667:- PAAD cis rs2278034 0.578 rs881753 ENSG00000231443.2 AC024937.6 3.92 0.000135 0.0421 0.26 0.3 Bronchopulmonary dysplasia; chr3:195879899 chr3:195937243~195938739:+ PAAD cis rs10800713 0.954 rs6660637 ENSG00000260088.1 RP11-92G12.3 -3.92 0.000135 0.0421 -0.43 -0.3 Tandem gait; chr1:200550893 chr1:200669507~200694250:+ PAAD cis rs10800713 0.954 rs10737572 ENSG00000260088.1 RP11-92G12.3 -3.92 0.000135 0.0421 -0.43 -0.3 Tandem gait; chr1:200552003 chr1:200669507~200694250:+ PAAD cis rs10800713 0.862 rs7533417 ENSG00000260088.1 RP11-92G12.3 -3.92 0.000135 0.0421 -0.43 -0.3 Tandem gait; chr1:200558177 chr1:200669507~200694250:+ PAAD cis rs7487075 0.93 rs4076248 ENSG00000270429.1 KNOP1P2 3.92 0.000135 0.0421 0.34 0.3 Itch intensity from mosquito bite; chr12:46439822 chr12:45880950~45882266:- PAAD cis rs8026198 0.929 rs4329897 ENSG00000260571.1 BNIP3P5 -3.92 0.000135 0.0421 -0.49 -0.3 Fibrinogen levels; chr15:42357726 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs8024732 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42278520 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs11631983 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42279532 chr15:42313687~42314386:+ PAAD cis rs8026198 0.866 rs11631917 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42279555 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs2412685 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42281882 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs11070370 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42285342 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs8031315 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42286912 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs8036596 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42287908 chr15:42313687~42314386:+ PAAD cis rs8026198 0.866 rs4924653 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42298958 chr15:42313687~42314386:+ PAAD cis rs8026198 0.866 rs4923943 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42301048 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs4924658 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42307177 chr15:42313687~42314386:+ PAAD cis rs8026198 0.778 rs765830 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42313808 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs1659217 ENSG00000260571.1 BNIP3P5 3.92 0.000135 0.0421 0.49 0.3 Fibrinogen levels; chr15:42324142 chr15:42313687~42314386:+ PAAD cis rs28374715 0.662 rs28554139 ENSG00000247556.5 OIP5-AS1 3.92 0.000135 0.0421 0.33 0.3 Ulcerative colitis; chr15:41238886 chr15:41283990~41309737:+ PAAD cis rs11992162 0.636 rs11250182 ENSG00000254866.2 DEFB109P3 3.92 0.000135 0.0421 0.4 0.3 Monocyte count; chr8:11950067 chr8:12150895~12151134:- PAAD cis rs9326248 0.569 rs10047459 ENSG00000280143.1 AP000892.6 3.92 0.000135 0.0421 0.46 0.3 Blood protein levels; chr11:116851110 chr11:117204967~117210292:+ PAAD cis rs2348418 0.832 rs11611406 ENSG00000247934.4 RP11-967K21.1 3.92 0.000135 0.0421 0.29 0.3 Lung function (FEV1);Lung function (FVC); chr12:28310910 chr12:28163298~28190738:- PAAD cis rs2348418 0.832 rs11611382 ENSG00000247934.4 RP11-967K21.1 3.92 0.000135 0.0421 0.29 0.3 Lung function (FEV1);Lung function (FVC); chr12:28310959 chr12:28163298~28190738:- PAAD cis rs2348418 0.798 rs7310297 ENSG00000247934.4 RP11-967K21.1 3.92 0.000135 0.0421 0.29 0.3 Lung function (FEV1);Lung function (FVC); chr12:28313638 chr12:28163298~28190738:- PAAD cis rs4218 0.648 rs12910987 ENSG00000259732.1 RP11-59H7.3 -3.92 0.000135 0.0421 -0.42 -0.3 Social communication problems; chr15:59092782 chr15:59121034~59133250:+ PAAD cis rs6504622 0.818 rs758391 ENSG00000214401.4 KANSL1-AS1 3.92 0.000135 0.0421 0.39 0.3 Orofacial clefts; chr17:46939875 chr17:46193576~46196723:+ PAAD cis rs321358 0.895 rs17536059 ENSG00000271390.1 RP11-89C3.3 -3.92 0.000135 0.0421 -0.41 -0.3 Body mass index; chr11:111086611 chr11:111089870~111090368:- PAAD cis rs498136 0.734 rs624894 ENSG00000250508.1 RP11-757G1.6 3.92 0.000135 0.0421 0.39 0.3 Cutaneous malignant melanoma;Melanoma; chr11:69530701 chr11:68870664~68874542:+ PAAD cis rs6142102 0.961 rs6088361 ENSG00000276073.1 RP5-1125A11.7 -3.92 0.000135 0.0422 -0.33 -0.3 Skin pigmentation; chr20:33969520 chr20:33985617~33988989:- PAAD cis rs193541 0.593 rs30042 ENSG00000263432.2 RN7SL689P 3.92 0.000135 0.0422 0.39 0.3 Glucose homeostasis traits; chr5:122936946 chr5:123022487~123022783:- PAAD cis rs12712135 0.706 rs6543114 ENSG00000234389.1 AC007278.3 -3.92 0.000135 0.0422 -0.29 -0.3 Blood protein levels; chr2:102309534 chr2:102438713~102440475:+ PAAD cis rs6539288 0.63 rs1055332 ENSG00000260329.1 RP11-412D9.4 -3.92 0.000136 0.0422 -0.26 -0.3 Total body bone mineral density; chr12:106954847 chr12:106954029~106955497:- PAAD cis rs6539288 0.677 rs2287163 ENSG00000260329.1 RP11-412D9.4 -3.92 0.000136 0.0422 -0.26 -0.3 Total body bone mineral density; chr12:106955516 chr12:106954029~106955497:- PAAD cis rs172166 0.637 rs1233708 ENSG00000204709.4 LINC01556 3.92 0.000136 0.0422 0.46 0.3 Cardiac Troponin-T levels; chr6:28205441 chr6:28943877~28944537:+ PAAD cis rs6540731 1 rs12402397 ENSG00000229983.1 RP11-15I11.2 3.92 0.000136 0.0422 0.34 0.3 Intelligence (childhood); chr1:212222602 chr1:212168207~212190259:+ PAAD cis rs10129255 0.5 rs1974468 ENSG00000280411.1 IGHV1-69-2 -3.92 0.000136 0.0422 -0.26 -0.3 Kawasaki disease; chr14:106686149 chr14:106762092~106762588:- PAAD cis rs7759001 0.69 rs6933354 ENSG00000271755.1 RP1-153G14.4 3.92 0.000136 0.0423 0.36 0.3 Glomerular filtration rate (creatinine); chr6:27496279 chr6:27404010~27406964:- PAAD cis rs7829975 0.511 rs2976902 ENSG00000254340.1 RP11-10A14.3 3.92 0.000136 0.0423 0.37 0.3 Mood instability; chr8:8483595 chr8:9141424~9145435:+ PAAD cis rs10759883 0.627 rs816672 ENSG00000175611.10 LINC00476 3.92 0.000136 0.0423 0.3 0.3 Nicotine dependence; chr9:95812171 chr9:95759231~95875977:- PAAD cis rs7927592 0.717 rs7126451 ENSG00000212093.1 AP000807.1 -3.92 0.000136 0.0423 -0.33 -0.3 Total body bone mineral density; chr11:68489918 chr11:68506083~68506166:- PAAD cis rs755249 0.51 rs582883 ENSG00000261798.1 RP1-118J21.25 3.92 0.000136 0.0423 0.36 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39369868 chr1:39788976~39790171:+ PAAD cis rs12908161 0.959 rs17598603 ENSG00000259728.4 LINC00933 -3.92 0.000136 0.0423 -0.38 -0.3 Schizophrenia; chr15:84656980 chr15:84570649~84580175:+ PAAD cis rs7617773 1 rs12496784 ENSG00000228638.1 FCF1P2 3.92 0.000136 0.0423 0.34 0.3 Coronary artery disease; chr3:48144777 chr3:48290793~48291375:- PAAD cis rs7617773 0.963 rs9822496 ENSG00000228638.1 FCF1P2 -3.92 0.000136 0.0423 -0.34 -0.3 Coronary artery disease; chr3:48139843 chr3:48290793~48291375:- PAAD cis rs11079159 0.637 rs7218159 ENSG00000263096.1 RP11-515O17.2 -3.92 0.000136 0.0423 -0.49 -0.3 QRS duration; chr17:55277434 chr17:55271504~55273653:- PAAD cis rs858239 0.539 rs4295546 ENSG00000226816.2 AC005082.12 3.92 0.000136 0.0423 0.35 0.3 Cerebrospinal fluid biomarker levels; chr7:23151402 chr7:23206013~23208045:+ PAAD cis rs8031584 0.678 rs798127 ENSG00000260382.1 RP11-540B6.2 -3.92 0.000136 0.0423 -0.4 -0.3 Huntington's disease progression; chr15:30825200 chr15:30882267~30883231:- PAAD cis rs13178541 0.641 rs10077151 ENSG00000250378.1 RP11-119J18.1 -3.92 0.000136 0.0423 -0.44 -0.3 IgG glycosylation; chr5:135805145 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs10077216 ENSG00000250378.1 RP11-119J18.1 -3.92 0.000136 0.0423 -0.44 -0.3 IgG glycosylation; chr5:135805239 chr5:135812667~135826582:+ PAAD cis rs9309711 0.772 rs9309715 ENSG00000225234.1 TRAPPC12-AS1 3.92 0.000136 0.0423 0.33 0.3 Neurofibrillary tangles; chr2:3488547 chr2:3481242~3482409:- PAAD cis rs72627509 0.857 rs781658 ENSG00000269949.1 RP11-738E22.3 3.92 0.000136 0.0423 0.48 0.3 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56913401 chr4:56960927~56961373:- PAAD cis rs957448 1 rs72674843 ENSG00000253704.1 RP11-267M23.4 3.92 0.000136 0.0423 0.39 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94520772 chr8:94553722~94569745:+ PAAD cis rs151234 0.676 rs151320 ENSG00000259982.1 CDC37P1 3.92 0.000136 0.0423 0.54 0.3 Platelet distribution width; chr16:28557357 chr16:28700294~28701540:- PAAD cis rs151234 0.676 rs231970 ENSG00000259982.1 CDC37P1 -3.92 0.000136 0.0423 -0.54 -0.3 Platelet distribution width; chr16:28555683 chr16:28700294~28701540:- PAAD cis rs7864204 0.752 rs10869115 ENSG00000276032.1 RP11-12A20.6 3.92 0.000136 0.0423 0.34 0.3 Body mass index (recreational physical activity interaction); chr9:68609002 chr9:67723736~67724105:+ PAAD cis rs7864204 0.964 rs10781073 ENSG00000276032.1 RP11-12A20.6 3.92 0.000136 0.0423 0.34 0.3 Body mass index (recreational physical activity interaction); chr9:68609880 chr9:67723736~67724105:+ PAAD cis rs6545883 0.524 rs811871 ENSG00000271889.1 RP11-493E12.1 -3.92 0.000136 0.0423 -0.32 -0.3 Tuberculosis; chr2:61350814 chr2:61151433~61162105:- PAAD cis rs7824557 0.767 rs2060463 ENSG00000205879.4 FAM90A2P 3.92 0.000136 0.0423 0.4 0.3 Retinal vascular caliber; chr8:11304101 chr8:12172202~12178575:- PAAD cis rs7637701 0.901 rs4680312 ENSG00000240875.4 LINC00886 -3.92 0.000136 0.0423 -0.37 -0.3 Breast cancer; chr3:156888140 chr3:156747346~156817062:- PAAD cis rs7637701 0.967 rs11712111 ENSG00000240875.4 LINC00886 -3.92 0.000136 0.0423 -0.37 -0.3 Breast cancer; chr3:156891151 chr3:156747346~156817062:- PAAD cis rs4925386 1 rs6089351 ENSG00000273619.1 RP5-908M14.9 3.92 0.000136 0.0423 0.26 0.3 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62341097 chr20:62386303~62386970:- PAAD cis rs875971 0.545 rs6460281 ENSG00000222364.1 RNU6-96P -3.92 0.000136 0.0423 -0.4 -0.3 Aortic root size; chr7:66216128 chr7:66395191~66395286:+ PAAD cis rs875971 0.862 rs1983372 ENSG00000232559.3 GS1-124K5.12 -3.92 0.000136 0.0423 -0.33 -0.3 Aortic root size; chr7:66146364 chr7:66554588~66576923:- PAAD cis rs1927790 0.759 rs35092596 ENSG00000247400.3 DNAJC3-AS1 -3.91 0.000136 0.0423 -0.28 -0.3 Body mass index; chr13:96325138 chr13:95648733~95676925:- PAAD cis rs6565180 0.962 rs6565183 ENSG00000261487.1 AC135048.13 -3.91 0.000136 0.0424 -0.42 -0.3 Tonsillectomy; chr16:30371434 chr16:30948386~30956511:+ PAAD cis rs1873386 0.901 rs1490711 ENSG00000255910.1 RP11-405A12.2 3.91 0.000136 0.0424 0.43 0.3 Personality dimensions; chr12:18915181 chr12:19775451~20009937:+ PAAD cis rs9813712 0.595 rs1993217 ENSG00000228252.7 COL6A4P2 -3.91 0.000136 0.0424 -0.36 -0.3 Response to amphetamines; chr3:130284832 chr3:130212823~130273806:+ PAAD cis rs9813712 0.595 rs16825656 ENSG00000228252.7 COL6A4P2 -3.91 0.000136 0.0424 -0.36 -0.3 Response to amphetamines; chr3:130286225 chr3:130212823~130273806:+ PAAD cis rs9813712 0.571 rs9846596 ENSG00000228252.7 COL6A4P2 -3.91 0.000136 0.0424 -0.36 -0.3 Response to amphetamines; chr3:130288318 chr3:130212823~130273806:+ PAAD cis rs9813712 0.595 rs1453239 ENSG00000228252.7 COL6A4P2 -3.91 0.000136 0.0424 -0.36 -0.3 Response to amphetamines; chr3:130288915 chr3:130212823~130273806:+ PAAD cis rs9813712 0.571 rs9866568 ENSG00000228252.7 COL6A4P2 -3.91 0.000136 0.0424 -0.36 -0.3 Response to amphetamines; chr3:130297539 chr3:130212823~130273806:+ PAAD cis rs9813712 0.523 rs9866942 ENSG00000228252.7 COL6A4P2 -3.91 0.000136 0.0424 -0.36 -0.3 Response to amphetamines; chr3:130297796 chr3:130212823~130273806:+ PAAD cis rs12507634 0.6 rs11133033 ENSG00000251216.1 RP11-161D15.3 -3.91 0.000136 0.0424 -0.35 -0.3 Thiazide-induced adverse metabolic effects in hypertensive patients; chr4:174139617 chr4:173924207~173990861:- PAAD cis rs12507634 0.565 rs13131326 ENSG00000251216.1 RP11-161D15.3 -3.91 0.000136 0.0424 -0.35 -0.3 Thiazide-induced adverse metabolic effects in hypertensive patients; chr4:174140441 chr4:173924207~173990861:- PAAD cis rs950169 0.58 rs11636189 ENSG00000259295.5 CSPG4P12 3.91 0.000136 0.0424 0.34 0.3 Schizophrenia; chr15:84650323 chr15:85191438~85213905:+ PAAD cis rs950169 0.58 rs35516100 ENSG00000259295.5 CSPG4P12 3.91 0.000136 0.0424 0.34 0.3 Schizophrenia; chr15:84652199 chr15:85191438~85213905:+ PAAD cis rs950169 0.58 rs62021208 ENSG00000259295.5 CSPG4P12 3.91 0.000136 0.0424 0.34 0.3 Schizophrenia; chr15:84653013 chr15:85191438~85213905:+ PAAD cis rs8037818 1 rs4544214 ENSG00000261064.1 RP11-1000B6.3 3.91 0.000136 0.0424 0.35 0.3 Obesity-related traits; chr15:32639703 chr15:32536047~32587613:+ PAAD cis rs7692387 0.813 rs115917428 ENSG00000260244.1 RP11-588K22.2 3.91 0.000136 0.0424 0.31 0.3 Coronary artery disease; chr4:155709196 chr4:155734448~155737062:+ PAAD cis rs7202877 0.61 rs10871307 ENSG00000261783.1 RP11-252K23.2 -3.91 0.000136 0.0424 -0.47 -0.3 Type 1 diabetes;Type 2 diabetes; chr16:75301216 chr16:75379818~75381260:- PAAD cis rs7202877 0.519 rs3743606 ENSG00000261783.1 RP11-252K23.2 -3.91 0.000136 0.0424 -0.47 -0.3 Type 1 diabetes;Type 2 diabetes; chr16:75301576 chr16:75379818~75381260:- PAAD cis rs7202877 0.61 rs3784936 ENSG00000261783.1 RP11-252K23.2 -3.91 0.000136 0.0424 -0.47 -0.3 Type 1 diabetes;Type 2 diabetes; chr16:75303685 chr16:75379818~75381260:- PAAD cis rs9322193 0.924 rs9322189 ENSG00000223701.3 RAET1E-AS1 3.91 0.000136 0.0424 0.34 0.3 Lung cancer; chr6:149588797 chr6:149884431~149919508:+ PAAD cis rs2688608 0.62 rs7098444 ENSG00000272140.2 RP11-574K11.29 3.91 0.000136 0.0424 0.26 0.3 Inflammatory bowel disease; chr10:73820284 chr10:73703735~73713581:- PAAD cis rs7617773 0.963 rs6766754 ENSG00000228638.1 FCF1P2 3.91 0.000136 0.0424 0.33 0.3 Coronary artery disease; chr3:48141099 chr3:48290793~48291375:- PAAD cis rs7617773 0.832 rs6775114 ENSG00000228638.1 FCF1P2 3.91 0.000136 0.0424 0.33 0.3 Coronary artery disease; chr3:48141130 chr3:48290793~48291375:- PAAD cis rs1056107 0.933 rs4978481 ENSG00000225513.1 RP11-165N19.2 -3.91 0.000137 0.0424 -0.38 -0.3 Colorectal cancer; chr9:112309164 chr9:112173522~112173971:- PAAD cis rs875971 0.861 rs801215 ENSG00000232559.3 GS1-124K5.12 -3.91 0.000137 0.0425 -0.34 -0.3 Aortic root size; chr7:66546951 chr7:66554588~66576923:- PAAD cis rs7202877 0.706 rs11149812 ENSG00000261783.1 RP11-252K23.2 -3.91 0.000137 0.0425 -0.47 -0.3 Type 1 diabetes;Type 2 diabetes; chr16:75289747 chr16:75379818~75381260:- PAAD cis rs4660214 0.666 rs2275186 ENSG00000228060.1 RP11-69E11.8 3.91 0.000137 0.0425 0.28 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39300383 chr1:39565160~39573203:+ PAAD cis rs4660214 0.666 rs12025847 ENSG00000228060.1 RP11-69E11.8 3.91 0.000137 0.0425 0.28 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39300977 chr1:39565160~39573203:+ PAAD cis rs12940030 0.693 rs7223237 ENSG00000236088.8 COX10-AS1 3.91 0.000137 0.0425 0.29 0.3 Corneal structure; chr17:14676265 chr17:13756478~14069495:- PAAD cis rs7911264 0.739 rs6583827 ENSG00000236493.2 EIF2S2P3 3.91 0.000137 0.0425 0.39 0.3 Inflammatory bowel disease; chr10:92598266 chr10:92668745~92669743:- PAAD cis rs7911264 0.739 rs7096101 ENSG00000236493.2 EIF2S2P3 3.91 0.000137 0.0425 0.39 0.3 Inflammatory bowel disease; chr10:92603171 chr10:92668745~92669743:- PAAD cis rs7911264 0.703 rs7894183 ENSG00000236493.2 EIF2S2P3 3.91 0.000137 0.0425 0.39 0.3 Inflammatory bowel disease; chr10:92622283 chr10:92668745~92669743:- PAAD cis rs7911264 0.739 rs7071905 ENSG00000236493.2 EIF2S2P3 3.91 0.000137 0.0425 0.39 0.3 Inflammatory bowel disease; chr10:92626365 chr10:92668745~92669743:- PAAD cis rs7911264 0.739 rs10882094 ENSG00000236493.2 EIF2S2P3 3.91 0.000137 0.0425 0.39 0.3 Inflammatory bowel disease; chr10:92627919 chr10:92668745~92669743:- PAAD cis rs7617773 0.963 rs12493256 ENSG00000228638.1 FCF1P2 3.91 0.000137 0.0425 0.34 0.3 Coronary artery disease; chr3:48135257 chr3:48290793~48291375:- PAAD cis rs7617773 0.963 rs12494304 ENSG00000228638.1 FCF1P2 3.91 0.000137 0.0425 0.34 0.3 Coronary artery disease; chr3:48136539 chr3:48290793~48291375:- PAAD cis rs6968419 0.788 rs67915501 ENSG00000237870.5 AC073130.1 3.91 0.000137 0.0425 0.41 0.3 Intraocular pressure; chr7:116181982 chr7:116275606~116286734:- PAAD cis rs6968419 0.788 rs60671526 ENSG00000237870.5 AC073130.1 3.91 0.000137 0.0425 0.41 0.3 Intraocular pressure; chr7:116183015 chr7:116275606~116286734:- PAAD cis rs6968419 0.788 rs7459377 ENSG00000237870.5 AC073130.1 3.91 0.000137 0.0425 0.41 0.3 Intraocular pressure; chr7:116185554 chr7:116275606~116286734:- PAAD cis rs6968419 0.788 rs72603592 ENSG00000237870.5 AC073130.1 3.91 0.000137 0.0425 0.41 0.3 Intraocular pressure; chr7:116191141 chr7:116275606~116286734:- PAAD cis rs6968419 0.788 rs6946058 ENSG00000237870.5 AC073130.1 3.91 0.000137 0.0425 0.41 0.3 Intraocular pressure; chr7:116199199 chr7:116275606~116286734:- PAAD cis rs6968419 0.788 rs1317791 ENSG00000237870.5 AC073130.1 3.91 0.000137 0.0425 0.41 0.3 Intraocular pressure; chr7:116199667 chr7:116275606~116286734:- PAAD cis rs74233809 0.591 rs284853 ENSG00000213277.3 MARCKSL1P1 -3.91 0.000137 0.0425 -0.45 -0.3 Birth weight; chr10:102814885 chr10:103175554~103176094:+ PAAD cis rs16846053 0.534 rs1227926 ENSG00000227403.1 AC009299.3 3.91 0.000137 0.0425 0.51 0.3 Blood osmolality (transformed sodium); chr2:161827383 chr2:161244739~161249050:+ PAAD cis rs4853012 0.793 rs6707619 ENSG00000257800.1 FNBP1P1 3.91 0.000137 0.0425 0.41 0.3 Gestational age at birth (maternal effect); chr2:74117529 chr2:74120680~74123218:+ PAAD cis rs2985684 0.846 rs10150624 ENSG00000259113.1 RP11-406H23.2 -3.91 0.000137 0.0425 -0.42 -0.3 Carotid intima media thickness; chr14:49584847 chr14:50448807~50456742:+ PAAD cis rs2985684 0.802 rs10150823 ENSG00000259113.1 RP11-406H23.2 -3.91 0.000137 0.0425 -0.42 -0.3 Carotid intima media thickness; chr14:49585033 chr14:50448807~50456742:+ PAAD cis rs2736345 0.502 rs12680762 ENSG00000251402.3 FAM90A25P -3.91 0.000137 0.0425 -0.41 -0.3 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11474517 chr8:12415080~12418090:- PAAD cis rs7394190 0.748 rs3740293 ENSG00000272140.2 RP11-574K11.29 -3.91 0.000137 0.0425 -0.33 -0.3 Incident atrial fibrillation; chr10:73646383 chr10:73703735~73713581:- PAAD cis rs2712184 0.875 rs2541382 ENSG00000229352.1 AC007563.3 -3.91 0.000137 0.0425 -0.3 -0.3 Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine); chr2:216815311 chr2:216799608~216805335:+ PAAD cis rs6435957 0.568 rs62174839 ENSG00000233143.1 DIRC3-AS1 3.91 0.000137 0.0425 0.4 0.3 Primary tooth development (number of teeth); chr2:217032618 chr2:217282739~217336120:+ PAAD cis rs11081761 0.79 rs7230250 ENSG00000265008.1 RP11-53I6.3 -3.91 0.000137 0.0425 -0.56 -0.3 Resting heart rate; chr18:32331136 chr18:32091295~32092119:- PAAD cis rs2243480 0.831 rs57294491 ENSG00000273142.1 RP11-458F8.4 3.91 0.000137 0.0425 0.27 0.3 Diabetic kidney disease; chr7:66219914 chr7:66902857~66906297:+ PAAD cis rs4374383 0.884 rs1996325 ENSG00000243389.1 AC012442.5 3.91 0.000137 0.0425 0.36 0.3 Hepatitis C induced liver fibrosis; chr2:111984498 chr2:112589040~112614431:+ PAAD cis rs1555322 1 rs2425037 ENSG00000279253.1 RP4-614O4.13 3.91 0.000137 0.0425 0.38 0.3 Attention deficit hyperactivity disorder; chr20:35268626 chr20:35262727~35264187:- PAAD cis rs780096 0.545 rs6716894 ENSG00000234072.1 AC074117.10 -3.91 0.000137 0.0425 -0.24 -0.3 Total body bone mineral density; chr2:27360406 chr2:27356246~27367622:+ PAAD cis rs6968419 0.537 rs7811113 ENSG00000237870.5 AC073130.1 3.91 0.000137 0.0425 0.41 0.3 Intraocular pressure; chr7:116160765 chr7:116275606~116286734:- PAAD cis rs9652601 0.779 rs11648679 ENSG00000274038.1 RP11-66H6.4 -3.91 0.000137 0.0426 -0.33 -0.3 Systemic lupus erythematosus; chr16:11082127 chr16:11056556~11057034:+ PAAD cis rs3790645 1 rs364977 ENSG00000225159.1 NPM1P39 3.91 0.000137 0.0426 0.39 0.3 Glucose homeostasis traits; chr1:26567345 chr1:27206930~27207796:+ PAAD cis rs10838687 0.669 rs830084 ENSG00000255007.1 CTD-2589M5.4 -3.91 0.000137 0.0426 -0.36 -0.3 Proinsulin levels; chr11:47230101 chr11:46256355~46274547:- PAAD cis rs10838687 0.736 rs830083 ENSG00000255007.1 CTD-2589M5.4 -3.91 0.000137 0.0426 -0.36 -0.3 Proinsulin levels; chr11:47232500 chr11:46256355~46274547:- PAAD cis rs6840258 0.891 rs151451 ENSG00000251411.1 RP11-397E7.4 -3.91 0.000137 0.0426 -0.35 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87085215 chr4:86913266~86914817:- PAAD cis rs2638953 0.924 rs11049619 ENSG00000247934.4 RP11-967K21.1 -3.91 0.000137 0.0426 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28453495 chr12:28163298~28190738:- PAAD cis rs9425766 0.678 rs1951625 ENSG00000227373.4 RP11-160H22.5 3.91 0.000137 0.0426 0.45 0.3 Life satisfaction; chr1:173867464 chr1:174115300~174160004:- PAAD cis rs9425766 0.64 rs1322774 ENSG00000227373.4 RP11-160H22.5 3.91 0.000137 0.0426 0.45 0.3 Life satisfaction; chr1:173870102 chr1:174115300~174160004:- PAAD cis rs2777491 0.874 rs28716108 ENSG00000247556.5 OIP5-AS1 3.91 0.000137 0.0426 0.27 0.3 Ulcerative colitis; chr15:41363325 chr15:41283990~41309737:+ PAAD cis rs12134133 0.752 rs4844579 ENSG00000274245.1 RP11-357P18.2 3.91 0.000137 0.0426 0.51 0.3 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207204546 chr1:207372559~207373252:+ PAAD cis rs12134133 0.688 rs6540875 ENSG00000274245.1 RP11-357P18.2 3.91 0.000137 0.0426 0.51 0.3 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207221686 chr1:207372559~207373252:+ PAAD cis rs12134133 0.719 rs6696142 ENSG00000274245.1 RP11-357P18.2 3.91 0.000137 0.0426 0.51 0.3 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207228898 chr1:207372559~207373252:+ PAAD cis rs12134133 0.752 rs57003024 ENSG00000274245.1 RP11-357P18.2 3.91 0.000137 0.0426 0.51 0.3 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207230999 chr1:207372559~207373252:+ PAAD cis rs12134133 0.752 rs61821050 ENSG00000274245.1 RP11-357P18.2 3.91 0.000137 0.0426 0.51 0.3 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207235253 chr1:207372559~207373252:+ PAAD cis rs12134133 0.752 rs61821051 ENSG00000274245.1 RP11-357P18.2 3.91 0.000137 0.0426 0.51 0.3 Blood protein levels;Posterior cortical atrophy and Alzheimer's disease; chr1:207235624 chr1:207372559~207373252:+ PAAD cis rs7665090 0.728 rs227279 ENSG00000246560.2 RP11-10L12.4 -3.91 0.000137 0.0426 -0.33 -0.3 Primary biliary cholangitis; chr4:102675875 chr4:102828055~102844075:+ PAAD cis rs797680 0.681 rs4847406 ENSG00000223745.6 RP4-717I23.3 3.91 0.000137 0.0426 0.24 0.3 Eosinophil percentage of white cells;Sum eosinophil basophil counts; chr1:93292893 chr1:93262186~93346025:- PAAD cis rs11718455 0.629 rs4082418 ENSG00000280435.1 RP4-555D20.1 3.91 0.000137 0.0426 0.4 0.3 Coronary artery disease; chr3:43866751 chr3:44115818~44117487:- PAAD cis rs79349575 0.756 rs2643361 ENSG00000270781.1 RP11-501C14.9 -3.91 0.000137 0.0426 -0.35 -0.3 Type 2 diabetes; chr17:48900100 chr17:48899131~48899748:+ PAAD cis rs5758511 0.514 rs5751211 ENSG00000205702.9 CYP2D7 3.91 0.000137 0.0426 0.27 0.3 Birth weight; chr22:42090052 chr22:42140203~42144577:- PAAD cis rs5758511 0.514 rs5758580 ENSG00000205702.9 CYP2D7 3.91 0.000137 0.0426 0.27 0.3 Birth weight; chr22:42097871 chr22:42140203~42144577:- PAAD cis rs1065852 0.906 rs9611734 ENSG00000205702.9 CYP2D7 3.91 0.000137 0.0426 0.27 0.3 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels); chr22:42106066 chr22:42140203~42144577:- PAAD cis rs5758511 0.514 rs3985938 ENSG00000205702.9 CYP2D7 3.91 0.000137 0.0426 0.27 0.3 Birth weight; chr22:42115723 chr22:42140203~42144577:- PAAD cis rs5758511 0.514 rs5751221 ENSG00000205702.9 CYP2D7 3.91 0.000137 0.0426 0.27 0.3 Birth weight; chr22:42120362 chr22:42140203~42144577:- PAAD cis rs5758511 0.514 rs5758586 ENSG00000205702.9 CYP2D7 3.91 0.000137 0.0426 0.27 0.3 Birth weight; chr22:42121467 chr22:42140203~42144577:- PAAD cis rs7829975 0.593 rs2921061 ENSG00000254340.1 RP11-10A14.3 3.91 0.000137 0.0427 0.37 0.3 Mood instability; chr8:8460105 chr8:9141424~9145435:+ PAAD cis rs7119038 0.818 rs11826521 ENSG00000255239.1 AP002954.6 -3.91 0.000138 0.0427 -0.43 -0.3 Sjögren's syndrome; chr11:118739840 chr11:118688039~118690600:- PAAD cis rs28374715 0.662 rs16971558 ENSG00000247556.5 OIP5-AS1 3.91 0.000138 0.0427 0.32 0.3 Ulcerative colitis; chr15:41166421 chr15:41283990~41309737:+ PAAD cis rs10129255 0.957 rs10142918 ENSG00000211972.2 IGHV3-66 3.91 0.000138 0.0427 0.27 0.3 Kawasaki disease; chr14:106782206 chr14:106675017~106675544:- PAAD cis rs10129255 0.957 rs10142859 ENSG00000211972.2 IGHV3-66 3.91 0.000138 0.0427 0.27 0.3 Kawasaki disease; chr14:106782238 chr14:106675017~106675544:- PAAD cis rs10129255 0.957 rs10136560 ENSG00000211972.2 IGHV3-66 3.91 0.000138 0.0427 0.27 0.3 Kawasaki disease; chr14:106787630 chr14:106675017~106675544:- PAAD cis rs950880 0.71 rs17027166 ENSG00000234389.1 AC007278.3 -3.91 0.000138 0.0427 -0.32 -0.3 Serum protein levels (sST2); chr2:102438960 chr2:102438713~102440475:+ PAAD cis rs7911264 0.739 rs10882091 ENSG00000236493.2 EIF2S2P3 3.91 0.000138 0.0427 0.39 0.3 Inflammatory bowel disease; chr10:92614620 chr10:92668745~92669743:- PAAD cis rs17836934 0.765 rs10858948 ENSG00000258302.2 RP11-981P6.1 3.91 0.000138 0.0427 0.27 0.3 Total body bone mineral density; chr12:90084874 chr12:89561129~89594878:+ PAAD cis rs34526934 0.608 rs34720456 ENSG00000226363.3 HAGLROS 3.91 0.000138 0.0427 0.43 0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176162564 chr2:176177717~176179008:+ PAAD cis rs34526934 0.608 rs7591820 ENSG00000226363.3 HAGLROS 3.91 0.000138 0.0427 0.43 0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176163416 chr2:176177717~176179008:+ PAAD cis rs34526934 0.608 rs7606110 ENSG00000226363.3 HAGLROS 3.91 0.000138 0.0427 0.43 0.3 Obstructive sleep apnea trait (apnea hypopnea index); chr2:176163823 chr2:176177717~176179008:+ PAAD cis rs9326248 0.581 rs11216267 ENSG00000280143.1 AP000892.6 3.91 0.000138 0.0427 0.33 0.3 Blood protein levels; chr11:117081676 chr11:117204967~117210292:+ PAAD cis rs950880 1 rs12470864 ENSG00000234389.1 AC007278.3 -3.91 0.000138 0.0427 -0.29 -0.3 Serum protein levels (sST2); chr2:102309902 chr2:102438713~102440475:+ PAAD cis rs4666002 0.789 rs6727388 ENSG00000234072.1 AC074117.10 3.91 0.000138 0.0427 0.29 0.3 Phospholipid levels (plasma); chr2:27709720 chr2:27356246~27367622:+ PAAD cis rs4666002 0.789 rs4616435 ENSG00000234072.1 AC074117.10 3.91 0.000138 0.0427 0.29 0.3 Phospholipid levels (plasma); chr2:27710775 chr2:27356246~27367622:+ PAAD cis rs4666002 0.789 rs6727215 ENSG00000234072.1 AC074117.10 3.91 0.000138 0.0427 0.29 0.3 Phospholipid levels (plasma); chr2:27711864 chr2:27356246~27367622:+ PAAD cis rs17772222 0.917 rs4635267 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88621922 chr14:88499334~88515502:+ PAAD cis rs17772222 0.876 rs56144430 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88622013 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs17188046 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88624417 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs8006652 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88631290 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs12587200 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88632060 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs12431548 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88635826 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs61984737 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88637028 chr14:88499334~88515502:+ PAAD cis rs17772222 0.876 rs12586348 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88643523 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs12434935 ENSG00000258983.2 RP11-507K2.2 3.91 0.000138 0.0427 0.39 0.3 Coronary artery calcification; chr14:88645449 chr14:88499334~88515502:+ PAAD cis rs3096299 0.503 rs9925045 ENSG00000261118.1 RP11-104N10.1 3.91 0.000138 0.0428 0.27 0.3 Multiple myeloma (IgH translocation); chr16:89490068 chr16:89492017~89504460:- PAAD cis rs3892715 0.521 rs2676891 ENSG00000214145.5 LINC00887 3.91 0.000138 0.0428 0.36 0.3 Attention deficit hyperactivity disorder (time to onset); chr3:195042217 chr3:194296465~194312803:- PAAD cis rs79349575 0.783 rs318095 ENSG00000270781.1 RP11-501C14.9 -3.91 0.000138 0.0428 -0.35 -0.3 Type 2 diabetes; chr17:48897372 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs318096 ENSG00000270781.1 RP11-501C14.9 -3.91 0.000138 0.0428 -0.35 -0.3 Type 2 diabetes; chr17:48898008 chr17:48899131~48899748:+ PAAD cis rs79349575 0.777 rs28517720 ENSG00000270781.1 RP11-501C14.9 -3.91 0.000138 0.0428 -0.35 -0.3 Type 2 diabetes; chr17:48899394 chr17:48899131~48899748:+ PAAD cis rs79349575 0.749 rs2546491 ENSG00000270781.1 RP11-501C14.9 -3.91 0.000138 0.0428 -0.35 -0.3 Type 2 diabetes; chr17:48900554 chr17:48899131~48899748:+ PAAD cis rs79349575 0.783 rs962272 ENSG00000270781.1 RP11-501C14.9 -3.91 0.000138 0.0428 -0.35 -0.3 Type 2 diabetes; chr17:48900921 chr17:48899131~48899748:+ PAAD cis rs8081395 0.836 rs2150879 ENSG00000266992.1 DHX40P1 -3.91 0.000138 0.0428 -0.31 -0.3 White blood cell count; chr17:59781849 chr17:59976009~60002384:- PAAD cis rs34375054 0.623 rs2297478 ENSG00000279233.1 RP11-158L12.4 3.91 0.000138 0.0428 0.27 0.3 Post bronchodilator FEV1/FVC ratio; chr12:125107298 chr12:125138245~125141711:+ PAAD cis rs6669008 1 rs1891969 ENSG00000232450.1 RP4-730K3.3 -3.91 0.000138 0.0428 -0.36 -0.3 Bacteremia; chr1:113643233 chr1:113698884~113699631:- PAAD cis rs6539288 0.739 rs7302653 ENSG00000260329.1 RP11-412D9.4 -3.91 0.000138 0.0428 -0.27 -0.3 Total body bone mineral density; chr12:106979744 chr12:106954029~106955497:- PAAD cis rs2337406 0.778 rs58113768 ENSG00000211974.3 IGHV2-70 -3.91 0.000138 0.0428 -0.43 -0.3 Alzheimer's disease (late onset); chr14:106700213 chr14:106723574~106724093:- PAAD cis rs2337406 1 rs75651733 ENSG00000211974.3 IGHV2-70 -3.91 0.000138 0.0428 -0.43 -0.3 Alzheimer's disease (late onset); chr14:106701309 chr14:106723574~106724093:- PAAD cis rs2742417 1 rs2742421 ENSG00000244357.3 RN7SL145P -3.91 0.000138 0.0428 -0.28 -0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45691023 chr3:45742675~45742970:+ PAAD cis rs13178541 0.872 rs11950260 ENSG00000250378.1 RP11-119J18.1 -3.91 0.000138 0.0428 -0.46 -0.3 IgG glycosylation; chr5:135809171 chr5:135812667~135826582:+ PAAD cis rs5742933 0.744 rs12693557 ENSG00000273240.1 RP11-455J20.3 3.91 0.000138 0.0428 0.36 0.3 Ferritin levels; chr2:189726211 chr2:189763859~189764456:- PAAD cis rs5742933 0.817 rs13035966 ENSG00000273240.1 RP11-455J20.3 3.91 0.000138 0.0428 0.36 0.3 Ferritin levels; chr2:189726507 chr2:189763859~189764456:- PAAD cis rs5742933 0.762 rs2033746 ENSG00000273240.1 RP11-455J20.3 3.91 0.000138 0.0428 0.36 0.3 Ferritin levels; chr2:189734726 chr2:189763859~189764456:- PAAD cis rs5742933 0.762 rs12992061 ENSG00000273240.1 RP11-455J20.3 3.91 0.000138 0.0428 0.36 0.3 Ferritin levels; chr2:189736026 chr2:189763859~189764456:- PAAD cis rs11096990 0.593 rs35552004 ENSG00000249207.1 RP11-360F5.1 -3.91 0.000138 0.0428 -0.31 -0.3 Cognitive function; chr4:39170914 chr4:39112677~39126818:- PAAD cis rs11096990 0.552 rs7655170 ENSG00000249207.1 RP11-360F5.1 -3.91 0.000138 0.0428 -0.31 -0.3 Cognitive function; chr4:39171984 chr4:39112677~39126818:- PAAD cis rs11668609 0.515 rs58278214 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000138 0.0428 0.49 0.3 Response to taxane treatment (docetaxel); chr19:23888887 chr19:24162370~24163425:- PAAD cis rs11668609 0.515 rs2195971 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000138 0.0428 0.49 0.3 Response to taxane treatment (docetaxel); chr19:23897191 chr19:24162370~24163425:- PAAD cis rs7260598 0.605 rs78358879 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000138 0.0428 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23904434 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs10424758 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000138 0.0428 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23907698 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs10425192 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000138 0.0428 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23907909 chr19:24162370~24163425:- PAAD cis rs11722228 0.522 rs77691548 ENSG00000261490.1 RP11-448G15.3 3.91 0.000138 0.0428 0.29 0.3 Urate levels;Serum uric acid levels;Gout; chr4:10134491 chr4:10068089~10073019:- PAAD cis rs11089937 0.626 rs9619811 ENSG00000211638.2 IGLV8-61 -3.91 0.000138 0.0428 -0.29 -0.3 Periodontitis (PAL4Q3); chr22:22159186 chr22:22098700~22099212:+ PAAD cis rs7927592 0.956 rs2155730 ENSG00000212093.1 AP000807.1 3.91 0.000138 0.0429 0.35 0.3 Total body bone mineral density; chr11:68562006 chr11:68506083~68506166:- PAAD cis rs11723261 0.546 rs57839456 ENSG00000275426.1 CH17-262A2.1 3.91 0.000138 0.0429 0.47 0.3 Immune response to smallpox vaccine (IL-6); chr4:154494 chr4:149738~150317:+ PAAD cis rs748404 0.666 rs12900259 ENSG00000249839.1 AC011330.5 -3.91 0.000138 0.0429 -0.52 -0.3 Lung cancer; chr15:43427369 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs34921640 ENSG00000249839.1 AC011330.5 -3.91 0.000138 0.0429 -0.52 -0.3 Lung cancer; chr15:43429187 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs62020574 ENSG00000249839.1 AC011330.5 -3.91 0.000138 0.0429 -0.52 -0.3 Lung cancer; chr15:43429380 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs16957730 ENSG00000249839.1 AC011330.5 -3.91 0.000138 0.0429 -0.52 -0.3 Lung cancer; chr15:43438288 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs12913977 ENSG00000249839.1 AC011330.5 -3.91 0.000138 0.0429 -0.52 -0.3 Lung cancer; chr15:43438913 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs12914122 ENSG00000249839.1 AC011330.5 -3.91 0.000138 0.0429 -0.52 -0.3 Lung cancer; chr15:43438956 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs34697113 ENSG00000249839.1 AC011330.5 -3.91 0.000138 0.0429 -0.52 -0.3 Lung cancer; chr15:43442041 chr15:43663654~43684339:- PAAD cis rs6929812 0.702 rs4713096 ENSG00000271755.1 RP1-153G14.4 -3.91 0.000138 0.0429 -0.35 -0.3 Neuroticism (multi-trait analysis); chr6:27411630 chr6:27404010~27406964:- PAAD cis rs8181477 1 rs8181477 ENSG00000240291.1 RP11-499P20.2 3.91 0.000139 0.0429 0.25 0.3 Obesity-related traits; chr10:18493951 chr10:18513115~18545651:- PAAD cis rs7302981 0.775 rs706790 ENSG00000272368.2 RP4-605O3.4 3.91 0.000139 0.0429 0.3 0.3 Systolic blood pressure; chr12:50070687 chr12:50112197~50165618:+ PAAD cis rs2243480 1 rs4718334 ENSG00000273142.1 RP11-458F8.4 3.91 0.000139 0.0429 0.27 0.3 Diabetic kidney disease; chr7:66324467 chr7:66902857~66906297:+ PAAD cis rs6545883 0.524 rs17482440 ENSG00000273302.1 RP11-493E12.2 -3.91 0.000139 0.0429 -0.27 -0.3 Tuberculosis; chr2:61321722 chr2:61199979~61200769:+ PAAD cis rs72843506 0.586 rs75721433 ENSG00000189423.10 USP32P3 3.91 0.000139 0.0429 0.47 0.3 Schizophrenia; chr17:19978747 chr17:20415547~20431008:+ PAAD cis rs919433 0.889 rs10931782 ENSG00000231621.1 AC013264.2 3.91 0.000139 0.0429 0.29 0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197346855 chr2:197197991~197199273:+ PAAD cis rs1799955 1 rs11571725 ENSG00000279314.1 RP1-257C22.2 -3.91 0.000139 0.043 -0.33 -0.3 LDL cholesterol levels; chr13:32364744 chr13:31960325~31961946:- PAAD cis rs8031584 0.706 rs798084 ENSG00000260382.1 RP11-540B6.2 3.91 0.000139 0.043 0.39 0.3 Huntington's disease progression; chr15:30834732 chr15:30882267~30883231:- PAAD cis rs6142102 0.961 rs4911389 ENSG00000276073.1 RP5-1125A11.7 -3.91 0.000139 0.043 -0.33 -0.3 Skin pigmentation; chr20:33977235 chr20:33985617~33988989:- PAAD cis rs6142102 0.923 rs6057961 ENSG00000276073.1 RP5-1125A11.7 -3.91 0.000139 0.043 -0.33 -0.3 Skin pigmentation; chr20:33986005 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs1007090 ENSG00000276073.1 RP5-1125A11.7 -3.91 0.000139 0.043 -0.33 -0.3 Skin pigmentation; chr20:33995065 chr20:33985617~33988989:- PAAD cis rs6142102 0.923 rs2284377 ENSG00000276073.1 RP5-1125A11.7 -3.91 0.000139 0.043 -0.33 -0.3 Skin pigmentation; chr20:33998876 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2284378 ENSG00000276073.1 RP5-1125A11.7 -3.91 0.000139 0.043 -0.33 -0.3 Skin pigmentation; chr20:34000289 chr20:33985617~33988989:- PAAD cis rs2300206 1 rs2300206 ENSG00000276073.1 RP5-1125A11.7 -3.91 0.000139 0.043 -0.33 -0.3 Cancer (pleiotropy);Cancer; chr20:34002002 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2284379 ENSG00000276073.1 RP5-1125A11.7 -3.91 0.000139 0.043 -0.33 -0.3 Skin pigmentation; chr20:34006836 chr20:33985617~33988989:- PAAD cis rs6142102 0.961 rs2268080 ENSG00000276073.1 RP5-1125A11.7 -3.91 0.000139 0.043 -0.33 -0.3 Skin pigmentation; chr20:34009910 chr20:33985617~33988989:- PAAD cis rs6479901 0.895 rs7073932 ENSG00000232075.1 MRPL35P2 -3.91 0.000139 0.043 -0.44 -0.3 Intelligence (multi-trait analysis); chr10:63350160 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7083356 ENSG00000232075.1 MRPL35P2 -3.91 0.000139 0.043 -0.44 -0.3 Intelligence (multi-trait analysis); chr10:63356028 chr10:63634317~63634827:- PAAD cis rs6479901 0.947 rs7909692 ENSG00000232075.1 MRPL35P2 -3.91 0.000139 0.043 -0.44 -0.3 Intelligence (multi-trait analysis); chr10:63368517 chr10:63634317~63634827:- PAAD cis rs172166 0.637 rs1071893 ENSG00000204709.4 LINC01556 3.91 0.000139 0.043 0.46 0.3 Cardiac Troponin-T levels; chr6:28199857 chr6:28943877~28944537:+ PAAD cis rs539096 0.54 rs3011219 ENSG00000200913.1 SNORD46 -3.91 0.000139 0.043 -0.34 -0.3 Intelligence (multi-trait analysis); chr1:43840448 chr1:44776490~44776593:+ PAAD cis rs950169 0.922 rs11639244 ENSG00000259683.1 RP11-182J1.14 3.91 0.000139 0.043 0.25 0.3 Schizophrenia; chr15:84163898 chr15:84389729~84395903:+ PAAD cis rs950169 0.845 rs4106951 ENSG00000259683.1 RP11-182J1.14 3.91 0.000139 0.043 0.25 0.3 Schizophrenia; chr15:84164642 chr15:84389729~84395903:+ PAAD cis rs2348418 0.767 rs7972954 ENSG00000247934.4 RP11-967K21.1 3.91 0.000139 0.043 0.29 0.3 Lung function (FEV1);Lung function (FVC); chr12:28260273 chr12:28163298~28190738:- PAAD cis rs2348418 0.733 rs11049508 ENSG00000247934.4 RP11-967K21.1 3.91 0.000139 0.043 0.29 0.3 Lung function (FEV1);Lung function (FVC); chr12:28289633 chr12:28163298~28190738:- PAAD cis rs2403083 0.505 rs2006767 ENSG00000258256.1 RP11-219B4.5 -3.91 0.000139 0.043 -0.33 -0.3 Plasma amyloid beta peptide concentrations (ABx-40); chr8:85268715 chr8:85222446~85245717:- PAAD cis rs11668609 0.506 rs8113480 ENSG00000268442.1 CTD-2027I19.2 -3.91 0.000139 0.043 -0.49 -0.3 Response to taxane treatment (docetaxel); chr19:23878217 chr19:24162370~24163425:- PAAD cis rs193541 0.632 rs246276 ENSG00000263432.2 RN7SL689P 3.91 0.000139 0.043 0.39 0.3 Glucose homeostasis traits; chr5:122904262 chr5:123022487~123022783:- PAAD cis rs11096990 0.593 rs35552004 ENSG00000249685.1 RP11-360F5.3 3.91 0.000139 0.043 0.31 0.3 Cognitive function; chr4:39170914 chr4:39133913~39135608:+ PAAD cis rs11096990 0.552 rs7655170 ENSG00000249685.1 RP11-360F5.3 3.91 0.000139 0.043 0.31 0.3 Cognitive function; chr4:39171984 chr4:39133913~39135608:+ PAAD cis rs7554672 0.961 rs4427411 ENSG00000232679.1 RP11-400N13.3 3.91 0.000139 0.043 0.31 0.3 Hypertension; chr1:221136008 chr1:222041705~222064763:- PAAD cis rs7554672 0.961 rs12127195 ENSG00000232679.1 RP11-400N13.3 3.91 0.000139 0.043 0.31 0.3 Hypertension; chr1:221136075 chr1:222041705~222064763:- PAAD cis rs6908034 0.607 rs12525152 ENSG00000228412.5 RP4-625H18.2 3.91 0.000139 0.043 0.59 0.3 Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions; chr6:19809193 chr6:19802164~19804752:- PAAD cis rs2439831 0.867 rs935901 ENSG00000275601.1 AC011330.13 -3.91 0.000139 0.043 -0.56 -0.3 Lung cancer in ever smokers; chr15:43359058 chr15:43642389~43643023:- PAAD cis rs10266483 0.545 rs116760071 ENSG00000234585.5 CCT6P3 -3.91 0.000139 0.043 -0.3 -0.3 Response to statin therapy; chr7:64289082 chr7:65038354~65074713:+ PAAD cis rs4268898 0.552 rs7560342 ENSG00000242628.4 AC009228.1 -3.91 0.000139 0.043 -0.32 -0.3 Asthma; chr2:24148821 chr2:24214381~24221516:+ PAAD cis rs4268898 0.516 rs7597149 ENSG00000242628.4 AC009228.1 -3.91 0.000139 0.043 -0.32 -0.3 Asthma; chr2:24149092 chr2:24214381~24221516:+ PAAD cis rs4268898 0.529 rs4426488 ENSG00000242628.4 AC009228.1 -3.91 0.000139 0.043 -0.32 -0.3 Asthma; chr2:24149945 chr2:24214381~24221516:+ PAAD cis rs4268898 0.552 rs11125454 ENSG00000242628.4 AC009228.1 -3.91 0.000139 0.043 -0.32 -0.3 Asthma; chr2:24150799 chr2:24214381~24221516:+ PAAD cis rs4268898 0.552 rs11125455 ENSG00000242628.4 AC009228.1 -3.91 0.000139 0.043 -0.32 -0.3 Asthma; chr2:24151687 chr2:24214381~24221516:+ PAAD cis rs10483853 0.806 rs10151605 ENSG00000258695.2 RP3-414A15.2 -3.91 0.000139 0.0431 -0.4 -0.3 Coronary artery calcification; chr14:73417109 chr14:73522878~73530610:+ PAAD cis rs13256369 1 rs885000 ENSG00000253981.4 ALG1L13P 3.91 0.000139 0.0431 0.4 0.3 Obesity-related traits; chr8:8711365 chr8:8236003~8244667:- PAAD cis rs13256369 1 rs13266699 ENSG00000253981.4 ALG1L13P -3.91 0.000139 0.0431 -0.4 -0.3 Obesity-related traits; chr8:8712803 chr8:8236003~8244667:- PAAD cis rs4964805 0.594 rs954920 ENSG00000257681.1 RP11-341G23.4 3.91 0.000139 0.0431 0.34 0.3 Attention deficit hyperactivity disorder; chr12:103779532 chr12:103746315~103768858:- PAAD cis rs763121 0.889 rs1043402 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000139 0.0431 -0.29 -0.3 Menopause (age at onset); chr22:38483683 chr22:38667585~38681820:- PAAD cis rs56804039 0.524 rs11785096 ENSG00000173295.6 FAM86B3P -3.91 0.000139 0.0431 -0.49 -0.3 Cervical cancer; chr8:8515304 chr8:8228595~8244865:+ PAAD cis rs9393813 0.528 rs4713108 ENSG00000271755.1 RP1-153G14.4 3.91 0.000139 0.0431 0.35 0.3 Bipolar disorder; chr6:27490234 chr6:27404010~27406964:- PAAD cis rs1150668 0.699 rs2394049 ENSG00000204709.4 LINC01556 3.91 0.000139 0.0431 0.38 0.3 Pubertal anthropometrics; chr6:28271903 chr6:28943877~28944537:+ PAAD cis rs1799955 1 rs9567600 ENSG00000279314.1 RP1-257C22.2 3.91 0.000139 0.0431 0.33 0.3 LDL cholesterol levels; chr13:32359789 chr13:31960325~31961946:- PAAD cis rs1799955 1 rs11571717 ENSG00000279314.1 RP1-257C22.2 3.91 0.000139 0.0431 0.33 0.3 LDL cholesterol levels; chr13:32360774 chr13:31960325~31961946:- PAAD cis rs875971 0.545 rs10261710 ENSG00000222364.1 RNU6-96P -3.91 0.00014 0.0431 -0.4 -0.3 Aortic root size; chr7:66249202 chr7:66395191~66395286:+ PAAD cis rs5769707 0.837 rs1573726 ENSG00000235111.1 RP1-29C18.8 -3.91 0.00014 0.0431 -0.29 -0.3 Monocyte percentage of white cells;Monocyte count; chr22:49639224 chr22:49612657~49615716:- PAAD cis rs748404 0.666 rs16957680 ENSG00000249839.1 AC011330.5 -3.91 0.00014 0.0431 -0.52 -0.3 Lung cancer; chr15:43396207 chr15:43663654~43684339:- PAAD cis rs11089937 0.864 rs5757041 ENSG00000211644.2 IGLV1-51 3.91 0.00014 0.0432 0.18 0.3 Periodontitis (PAL4Q3); chr22:22140538 chr22:22322472~22322980:+ PAAD cis rs1075265 0.587 rs2949811 ENSG00000233266.1 HMGB1P31 3.91 0.00014 0.0432 0.4 0.3 Chronotype;Morning vs. evening chronotype; chr2:53797028 chr2:54051334~54051760:+ PAAD cis rs79040073 0.564 rs34606419 ENSG00000259531.2 RP11-295H24.3 3.91 0.00014 0.0432 0.51 0.3 Lung cancer in ever smokers; chr15:49240390 chr15:49365124~49366685:- PAAD cis rs9595908 0.931 rs55645971 ENSG00000212293.1 SNORA16 3.91 0.00014 0.0432 0.35 0.3 Body mass index; chr13:32615452 chr13:32420390~32420516:- PAAD cis rs6545883 0.507 rs12617371 ENSG00000271889.1 RP11-493E12.1 -3.91 0.00014 0.0432 -0.32 -0.3 Tuberculosis; chr2:61341999 chr2:61151433~61162105:- PAAD cis rs6545883 0.507 rs62149712 ENSG00000271889.1 RP11-493E12.1 -3.91 0.00014 0.0432 -0.32 -0.3 Tuberculosis; chr2:61374137 chr2:61151433~61162105:- PAAD cis rs10483853 0.806 rs66498577 ENSG00000258695.2 RP3-414A15.2 -3.91 0.00014 0.0432 -0.4 -0.3 Coronary artery calcification; chr14:73292012 chr14:73522878~73530610:+ PAAD cis rs829883 0.714 rs249847 ENSG00000245017.2 RP11-181C3.1 -3.91 0.00014 0.0432 -0.3 -0.3 Colorectal adenoma (advanced); chr12:98473938 chr12:98485544~98503855:- PAAD cis rs7615952 0.8 rs35390120 ENSG00000239804.1 RP11-379B18.1 3.91 0.00014 0.0432 0.53 0.3 Blood pressure (smoking interaction); chr3:125880966 chr3:125787888~125788146:- PAAD cis rs950169 0.544 rs12913702 ENSG00000259683.1 RP11-182J1.14 3.91 0.00014 0.0432 0.25 0.3 Schizophrenia; chr15:84609953 chr15:84389729~84395903:+ PAAD cis rs17214007 0.778 rs17213271 ENSG00000263335.1 AF001548.5 -3.91 0.00014 0.0433 -0.43 -0.3 Cognitive function; chr16:15770487 chr16:15726674~15732993:+ PAAD cis rs710913 0.587 rs6690413 ENSG00000243970.1 PPIEL 3.91 0.00014 0.0433 0.26 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39620620 chr1:39531838~39558707:- PAAD cis rs7735319 0.533 rs2331146 ENSG00000249572.1 CTD-2203K17.1 -3.91 0.00014 0.0433 -0.33 -0.3 Systolic blood pressure; chr5:33052415 chr5:33424025~33440619:- PAAD cis rs321358 0.848 rs78087740 ENSG00000271390.1 RP11-89C3.3 3.91 0.00014 0.0433 0.44 0.3 Body mass index; chr11:111079016 chr11:111089870~111090368:- PAAD cis rs321358 0.848 rs73015146 ENSG00000271390.1 RP11-89C3.3 3.91 0.00014 0.0433 0.44 0.3 Body mass index; chr11:111079143 chr11:111089870~111090368:- PAAD cis rs10759883 0.563 rs12348051 ENSG00000175611.10 LINC00476 3.91 0.00014 0.0433 0.29 0.3 Nicotine dependence; chr9:95905928 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs689710 ENSG00000175611.10 LINC00476 3.91 0.00014 0.0433 0.29 0.3 Nicotine dependence; chr9:95908339 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs623438 ENSG00000175611.10 LINC00476 3.91 0.00014 0.0433 0.29 0.3 Nicotine dependence; chr9:95938114 chr9:95759231~95875977:- PAAD cis rs10759883 0.539 rs966217 ENSG00000175611.10 LINC00476 3.91 0.00014 0.0433 0.29 0.3 Nicotine dependence; chr9:95943247 chr9:95759231~95875977:- PAAD cis rs957448 1 rs72674861 ENSG00000253704.1 RP11-267M23.4 3.91 0.00014 0.0433 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94550051 chr8:94553722~94569745:+ PAAD cis rs957448 1 rs60655325 ENSG00000253704.1 RP11-267M23.4 3.91 0.00014 0.0433 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94552606 chr8:94553722~94569745:+ PAAD cis rs957448 1 rs16916881 ENSG00000253704.1 RP11-267M23.4 3.91 0.00014 0.0433 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94554042 chr8:94553722~94569745:+ PAAD cis rs957448 1 rs12680965 ENSG00000253704.1 RP11-267M23.4 3.91 0.00014 0.0433 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94554069 chr8:94553722~94569745:+ PAAD cis rs957448 1 rs28817653 ENSG00000253704.1 RP11-267M23.4 3.91 0.00014 0.0433 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94557822 chr8:94553722~94569745:+ PAAD cis rs875971 1 rs1544549 ENSG00000237310.1 GS1-124K5.4 -3.91 0.00014 0.0433 -0.3 -0.3 Aortic root size; chr7:66625676 chr7:66493706~66495474:+ PAAD cis rs4819052 0.655 rs2330103 ENSG00000223768.1 LINC00205 -3.91 0.00014 0.0433 -0.29 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45274599 chr21:45293285~45297354:+ PAAD cis rs891378 0.959 rs6681853 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207325299 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs4844591 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207326948 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs6700079 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207328527 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs6702997 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207329002 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs6703002 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207329027 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs7548463 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207329546 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs925130 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207330087 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs6662070 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207332364 chr1:207372559~207373252:+ PAAD cis rs891378 0.959 rs12133548 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207333261 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs11120733 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207333304 chr1:207372559~207373252:+ PAAD cis rs891378 0.959 rs1507759 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207334283 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs7555030 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207335385 chr1:207372559~207373252:+ PAAD cis rs891378 1 rs7512422 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207335605 chr1:207372559~207373252:+ PAAD cis rs891378 0.958 rs10746462 ENSG00000274245.1 RP11-357P18.2 -3.91 0.00014 0.0433 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207337203 chr1:207372559~207373252:+ PAAD cis rs763121 0.962 rs1980455 ENSG00000228274.3 RP3-508I15.9 -3.91 0.00014 0.0433 -0.28 -0.3 Menopause (age at onset); chr22:38529714 chr22:38667585~38681820:- PAAD cis rs4554975 0.514 rs1986584 ENSG00000274723.1 RP11-618L22.1 -3.91 0.00014 0.0433 -0.35 -0.3 Metabolite levels (small molecules and protein measures); chr12:46909419 chr12:46970504~46972155:+ PAAD cis rs11603023 0.569 rs573905 ENSG00000255239.1 AP002954.6 3.91 0.00014 0.0433 0.38 0.3 Cholesterol, total; chr11:118701558 chr11:118688039~118690600:- PAAD cis rs7429990 0.932 rs6442101 ENSG00000228638.1 FCF1P2 3.91 0.00014 0.0433 0.34 0.3 Educational attainment (years of education); chr3:48089403 chr3:48290793~48291375:- PAAD cis rs4453827 1 rs2359204 ENSG00000271916.1 RP11-884K10.6 3.91 0.00014 0.0433 0.34 0.3 Blood protein levels; chr3:53715713 chr3:53797764~53798019:- PAAD cis rs763121 0.853 rs2072795 ENSG00000228274.3 RP3-508I15.9 3.91 0.000141 0.0434 0.29 0.3 Menopause (age at onset); chr22:38668204 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs35565791 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38667006 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs35522482 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38667010 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2072796 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38668225 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2281019 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38668373 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2281020 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38668401 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2281021 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38668662 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5995610 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38668676 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs3761454 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38670815 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs3747170 ENSG00000228274.3 RP3-508I15.9 -3.91 0.000141 0.0434 -0.29 -0.3 Menopause (age at onset); chr22:38671326 chr22:38667585~38681820:- PAAD cis rs62229266 0.557 rs4817760 ENSG00000231106.2 LINC01436 3.91 0.000141 0.0434 0.48 0.3 Mitral valve prolapse; chr21:36023003 chr21:36005338~36007838:+ PAAD cis rs9425766 0.64 rs2208850 ENSG00000227373.4 RP11-160H22.5 3.91 0.000141 0.0434 0.45 0.3 Life satisfaction; chr1:173862569 chr1:174115300~174160004:- PAAD cis rs2677744 0.626 rs12905855 ENSG00000259704.1 CTD-3094K11.1 -3.91 0.000141 0.0434 -0.39 -0.3 Attention deficit hyperactivity disorder; chr15:90955199 chr15:90839724~90841378:+ PAAD cis rs9322193 0.962 rs9397022 ENSG00000268592.3 RAET1E-AS1 3.91 0.000141 0.0434 0.35 0.3 Lung cancer; chr6:149812052 chr6:149863494~149919507:+ PAAD cis rs9322193 0.962 rs9397357 ENSG00000268592.3 RAET1E-AS1 3.91 0.000141 0.0434 0.35 0.3 Lung cancer; chr6:149812465 chr6:149863494~149919507:+ PAAD cis rs7260598 0.642 rs4313914 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000141 0.0434 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23994194 chr19:24162370~24163425:- PAAD cis rs172166 0.585 rs149963 ENSG00000219891.2 ZSCAN12P1 3.91 0.000141 0.0434 0.4 0.3 Cardiac Troponin-T levels; chr6:28049354 chr6:28091154~28093664:+ PAAD cis rs7569084 0.687 rs11126038 ENSG00000281920.1 RP11-418H16.1 3.91 0.000141 0.0434 0.35 0.3 Sum eosinophil basophil counts; chr2:65436100 chr2:65623272~65628424:+ PAAD cis rs7554672 0.961 rs6693821 ENSG00000232679.1 RP11-400N13.3 3.91 0.000141 0.0434 0.31 0.3 Hypertension; chr1:221140766 chr1:222041705~222064763:- PAAD cis rs6504950 0.548 rs714896 ENSG00000275710.1 RP11-257O5.4 3.91 0.000141 0.0434 0.46 0.3 Breast cancer; chr17:55179621 chr17:54964474~54964679:+ PAAD cis rs6504950 0.579 rs7212321 ENSG00000275710.1 RP11-257O5.4 3.91 0.000141 0.0434 0.46 0.3 Breast cancer; chr17:55181076 chr17:54964474~54964679:+ PAAD cis rs950169 1 rs11638297 ENSG00000259683.1 RP11-182J1.14 3.91 0.000141 0.0434 0.25 0.3 Schizophrenia; chr15:84113665 chr15:84389729~84395903:+ PAAD cis rs528301 0.766 rs473098 ENSG00000259439.2 RP11-89K21.1 3.91 0.000141 0.0434 0.4 0.3 Alcohol and nicotine co-dependence; chr2:44912640 chr2:44921077~44939199:- PAAD cis rs780096 0.527 rs59644396 ENSG00000234072.1 AC074117.10 -3.91 0.000141 0.0434 -0.24 -0.3 Total body bone mineral density; chr2:27423216 chr2:27356246~27367622:+ PAAD cis rs7260598 0.642 rs8102034 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000141 0.0434 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23914417 chr19:24162370~24163425:- PAAD cis rs7260598 0.642 rs10405341 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000141 0.0434 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23924450 chr19:24162370~24163425:- PAAD cis rs7260598 0.642 rs7259787 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000141 0.0434 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23935633 chr19:24162370~24163425:- PAAD cis rs7260598 0.71 rs10402319 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000141 0.0434 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23945263 chr19:24162370~24163425:- PAAD cis rs7260598 0.642 rs56977104 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000141 0.0434 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23956560 chr19:24162370~24163425:- PAAD cis rs7260598 0.642 rs8112289 ENSG00000268442.1 CTD-2027I19.2 3.91 0.000141 0.0434 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23956571 chr19:24162370~24163425:- PAAD cis rs2638953 0.886 rs11049393 ENSG00000247934.4 RP11-967K21.1 -3.91 0.000141 0.0434 -0.35 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28170273 chr12:28163298~28190738:- PAAD cis rs9649213 0.555 rs6968193 ENSG00000272950.1 RP11-307C18.1 3.91 0.000141 0.0434 0.34 0.3 Prostate cancer (SNP x SNP interaction); chr7:98286590 chr7:98322853~98323430:+ PAAD cis rs7302981 0.51 rs860698 ENSG00000272368.2 RP4-605O3.4 3.91 0.000141 0.0434 0.3 0.3 Systolic blood pressure; chr12:50092539 chr12:50112197~50165618:+ PAAD cis rs1832007 0.529 rs7100517 ENSG00000224034.1 RP11-445P17.8 -3.91 0.000141 0.0435 -0.45 -0.3 Triglyceride levels;Triglycerides; chr10:5201007 chr10:5266033~5271236:- PAAD cis rs1832007 0.529 rs7085249 ENSG00000224034.1 RP11-445P17.8 -3.91 0.000141 0.0435 -0.45 -0.3 Triglyceride levels;Triglycerides; chr10:5201054 chr10:5266033~5271236:- PAAD cis rs1832007 0.529 rs7088788 ENSG00000224034.1 RP11-445P17.8 -3.91 0.000141 0.0435 -0.45 -0.3 Triglyceride levels;Triglycerides; chr10:5201130 chr10:5266033~5271236:- PAAD cis rs10028773 0.666 rs12498657 ENSG00000248280.1 RP11-33B1.2 3.91 0.000141 0.0435 0.28 0.3 Educational attainment; chr4:119341711 chr4:119440561~119450157:- PAAD cis rs7119038 0.629 rs73001429 ENSG00000255239.1 AP002954.6 -3.91 0.000141 0.0435 -0.4 -0.3 Sjögren's syndrome; chr11:118732456 chr11:118688039~118690600:- PAAD cis rs2832077 1 rs12329875 ENSG00000176054.6 RPL23P2 -3.91 0.000141 0.0435 -0.34 -0.3 Cognitive test performance; chr21:28765474 chr21:28997613~28998033:- PAAD cis rs4660214 0.666 rs11205696 ENSG00000237624.1 OXCT2P1 -3.91 0.000141 0.0435 -0.38 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39155880 chr1:39514956~39516490:+ PAAD cis rs4660214 0.666 rs6600290 ENSG00000237624.1 OXCT2P1 -3.91 0.000141 0.0435 -0.38 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39157151 chr1:39514956~39516490:+ PAAD cis rs889398 0.802 rs9940315 ENSG00000226232.7 RP11-419C5.2 -3.91 0.000141 0.0435 -0.24 -0.3 Body mass index; chr16:69842261 chr16:69976388~69996188:- PAAD cis rs3825776 0.862 rs9920144 ENSG00000274719.1 RP11-86K22.2 -3.91 0.000141 0.0435 -0.38 -0.3 Amyotrophic lateral sclerosis; chr15:58457476 chr15:57990217~57990636:- PAAD cis rs755249 0.917 rs72663503 ENSG00000228060.1 RP11-69E11.8 -3.9 0.000141 0.0436 -0.3 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39503387 chr1:39565160~39573203:+ PAAD cis rs7017914 0.652 rs56156614 ENSG00000254031.4 RP11-326E22.1 3.9 0.000141 0.0436 0.34 0.3 Bone mineral density; chr8:70730816 chr8:71155457~71204223:+ PAAD cis rs7829975 0.502 rs11785183 ENSG00000253893.2 FAM85B 3.9 0.000141 0.0436 0.45 0.3 Mood instability; chr8:8708447 chr8:8167819~8226614:- PAAD cis rs10951983 0.904 rs1880118 ENSG00000272719.1 CTB-161C1.1 3.9 0.000142 0.0436 0.36 0.3 Coronary artery disease; chr7:6395589 chr7:5556731~5557245:+ PAAD cis rs9813712 0.597 rs10934931 ENSG00000228252.7 COL6A4P2 -3.9 0.000142 0.0436 -0.34 -0.3 Response to amphetamines; chr3:130261365 chr3:130212823~130273806:+ PAAD cis rs6840258 0.941 rs6854749 ENSG00000251411.1 RP11-397E7.4 -3.9 0.000142 0.0436 -0.34 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87047646 chr4:86913266~86914817:- PAAD cis rs2348418 0.832 rs12303069 ENSG00000247934.4 RP11-967K21.1 3.9 0.000142 0.0436 0.29 0.3 Lung function (FEV1);Lung function (FVC); chr12:28294319 chr12:28163298~28190738:- PAAD cis rs7225151 0.522 rs56229705 ENSG00000234327.6 AC012146.7 -3.9 0.000142 0.0436 -0.4 -0.3 Alzheimer's disease (late onset); chr17:5111494 chr17:5111468~5115004:+ PAAD cis rs2832077 0.883 rs11702413 ENSG00000176054.6 RPL23P2 -3.9 0.000142 0.0437 -0.36 -0.3 Cognitive test performance; chr21:28816072 chr21:28997613~28998033:- PAAD cis rs950169 0.92 rs2135551 ENSG00000275120.1 RP11-182J1.17 3.9 0.000142 0.0437 0.32 0.3 Schizophrenia; chr15:84039099 chr15:84599434~84606463:- PAAD cis rs13178541 0.638 rs6861738 ENSG00000250378.1 RP11-119J18.1 -3.9 0.000142 0.0437 -0.39 -0.3 IgG glycosylation; chr5:135714486 chr5:135812667~135826582:+ PAAD cis rs11233413 0.874 rs11233443 ENSG00000247137.7 RP11-727A23.5 -3.9 0.000142 0.0437 -0.27 -0.3 Economic and political preferences (feminism/equality); chr11:83060764 chr11:83184491~83193794:- PAAD cis rs11233413 0.834 rs11233444 ENSG00000247137.7 RP11-727A23.5 -3.9 0.000142 0.0437 -0.27 -0.3 Economic and political preferences (feminism/equality); chr11:83060852 chr11:83184491~83193794:- PAAD cis rs11233413 0.874 rs4944424 ENSG00000247137.7 RP11-727A23.5 -3.9 0.000142 0.0437 -0.27 -0.3 Economic and political preferences (feminism/equality); chr11:83063823 chr11:83184491~83193794:- PAAD cis rs11233413 0.874 rs17505158 ENSG00000247137.7 RP11-727A23.5 -3.9 0.000142 0.0437 -0.27 -0.3 Economic and political preferences (feminism/equality); chr11:83064699 chr11:83184491~83193794:- PAAD cis rs11233413 0.874 rs4944426 ENSG00000247137.7 RP11-727A23.5 -3.9 0.000142 0.0437 -0.27 -0.3 Economic and political preferences (feminism/equality); chr11:83066067 chr11:83184491~83193794:- PAAD cis rs6480314 0.831 rs17538164 ENSG00000233590.1 RP11-153K11.3 3.9 0.000142 0.0437 0.44 0.3 Optic nerve measurement (disc area); chr10:68215920 chr10:68233251~68242379:- PAAD cis rs7260598 0.539 rs13345286 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23886611 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs73525884 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23886899 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs73525888 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23887039 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs73525890 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23887109 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs73525891 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23887131 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs76305873 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23887151 chr19:24162370~24163425:- PAAD cis rs11668609 0.515 rs73525894 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (docetaxel); chr19:23887976 chr19:24162370~24163425:- PAAD cis rs11668609 0.515 rs13346480 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (docetaxel); chr19:23889271 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs1347177 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23896658 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs10412189 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23897536 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs7254143 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23897735 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs10418417 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23898005 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs10418377 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23898542 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs10425498 ENSG00000268442.1 CTD-2027I19.2 3.9 0.000142 0.0437 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23898869 chr19:24162370~24163425:- PAAD cis rs9876781 1 rs6442118 ENSG00000229759.1 MRPS18AP1 3.9 0.000142 0.0437 0.33 0.3 Longevity; chr3:48398582 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs7651407 ENSG00000229759.1 MRPS18AP1 3.9 0.000142 0.0437 0.33 0.3 Longevity; chr3:48402409 chr3:48256350~48256938:- PAAD cis rs7927592 0.912 rs55767696 ENSG00000212093.1 AP000807.1 3.9 0.000142 0.0437 0.35 0.3 Total body bone mineral density; chr11:68607652 chr11:68506083~68506166:- PAAD cis rs2904524 1 rs74716820 ENSG00000257815.4 RP11-611E13.2 -3.9 0.000142 0.0437 -0.33 -0.3 Amyotrophic lateral sclerosis (age of onset); chr12:70246074 chr12:69904033~70243360:- PAAD cis rs748404 0.697 rs513970 ENSG00000205771.5 CATSPER2P1 -3.9 0.000142 0.0437 -0.4 -0.3 Lung cancer; chr15:43287368 chr15:43726918~43747094:- PAAD cis rs10065350 0.872 rs9292178 ENSG00000248132.2 CTD-2037L6.2 -3.9 0.000142 0.0438 -0.46 -0.3 IgG glycosylation; chr5:58796202 chr5:58108082~58122341:- PAAD cis rs7246657 0.943 rs10409204 ENSG00000267422.1 CTD-2554C21.1 -3.9 0.000142 0.0438 -0.52 -0.3 Coronary artery calcification; chr19:37426790 chr19:37779686~37792865:+ PAAD cis rs13178541 0.593 rs6874289 ENSG00000250378.1 RP11-119J18.1 -3.9 0.000142 0.0438 -0.39 -0.3 IgG glycosylation; chr5:135708142 chr5:135812667~135826582:+ PAAD cis rs9322193 0.884 rs7450246 ENSG00000268592.3 RAET1E-AS1 3.9 0.000143 0.0438 0.36 0.3 Lung cancer; chr6:149702517 chr6:149863494~149919507:+ PAAD cis rs2735413 0.563 rs11640933 ENSG00000276007.1 RP11-358L22.3 3.9 0.000143 0.0438 0.43 0.3 Systolic blood pressure (alcohol consumption interaction); chr16:78031710 chr16:78123243~78124332:+ PAAD cis rs7017914 0.967 rs35115527 ENSG00000254031.4 RP11-326E22.1 3.9 0.000143 0.0438 0.32 0.3 Bone mineral density; chr8:70730774 chr8:71155457~71204223:+ PAAD cis rs2638953 0.962 rs11049533 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0438 -0.35 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28327471 chr12:28163298~28190738:- PAAD cis rs41271473 0.539 rs763519 ENSG00000279306.1 RP5-915N17.11 -3.9 0.000143 0.0439 -0.44 -0.3 Chronic lymphocytic leukemia; chr1:228757108 chr1:228486188~228487120:- PAAD cis rs1211375 0.606 rs1203977 ENSG00000268836.1 LA16c-OS12.2 -3.9 0.000143 0.0439 -0.27 -0.3 Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin; chr16:206279 chr16:185748~186294:- PAAD cis rs6543140 0.964 rs6736135 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102448464 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs6543138 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102449672 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs918000 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102451402 chr2:102438713~102440475:+ PAAD cis rs6543140 0.927 rs917999 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102451409 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs1523206 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102453715 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs1523205 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102453716 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs10169192 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102455751 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs11886793 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102455760 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs2310301 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102456475 chr2:102438713~102440475:+ PAAD cis rs6543140 1 rs6543140 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102457814 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs13390895 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102459039 chr2:102438713~102440475:+ PAAD cis rs6543140 0.855 rs4851591 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102460963 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs7561351 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102461320 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs13393175 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102462389 chr2:102438713~102440475:+ PAAD cis rs6543140 0.865 rs6760275 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102463147 chr2:102438713~102440475:+ PAAD cis rs6543140 0.964 rs6734203 ENSG00000234389.1 AC007278.3 3.9 0.000143 0.0439 0.34 0.3 Blood protein levels; chr2:102463606 chr2:102438713~102440475:+ PAAD cis rs7927592 0.871 rs871212 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.0439 0.35 0.3 Total body bone mineral density; chr11:68581227 chr11:68506083~68506166:- PAAD cis rs4664293 0.528 rs56027129 ENSG00000226266.5 AC009961.3 3.9 0.000143 0.0439 0.41 0.3 Monocyte percentage of white cells; chr2:159600091 chr2:159670708~159712435:- PAAD cis rs3743772 0.5 rs35346613 ENSG00000279722.1 RP11-44F14.6 3.9 0.000143 0.0439 0.42 0.3 Depressive symptoms (SSRI exposure interaction); chr16:53408246 chr16:53487607~53489943:- PAAD cis rs3743772 0.5 rs28804772 ENSG00000279722.1 RP11-44F14.6 3.9 0.000143 0.0439 0.42 0.3 Depressive symptoms (SSRI exposure interaction); chr16:53411252 chr16:53487607~53489943:- PAAD cis rs3743772 0.5 rs62048485 ENSG00000279722.1 RP11-44F14.6 3.9 0.000143 0.0439 0.42 0.3 Depressive symptoms (SSRI exposure interaction); chr16:53414065 chr16:53487607~53489943:- PAAD cis rs7119038 0.774 rs10892290 ENSG00000255239.1 AP002954.6 -3.9 0.000143 0.0439 -0.44 -0.3 Sjögren's syndrome; chr11:118782794 chr11:118688039~118690600:- PAAD cis rs7119038 0.774 rs874621 ENSG00000255239.1 AP002954.6 -3.9 0.000143 0.0439 -0.44 -0.3 Sjögren's syndrome; chr11:118784936 chr11:118688039~118690600:- PAAD cis rs7119038 0.818 rs57494551 ENSG00000255239.1 AP002954.6 -3.9 0.000143 0.0439 -0.44 -0.3 Sjögren's syndrome; chr11:118790689 chr11:118688039~118690600:- PAAD cis rs9322193 0.923 rs55993747 ENSG00000268592.3 RAET1E-AS1 3.9 0.000143 0.0439 0.35 0.3 Lung cancer; chr6:149622016 chr6:149863494~149919507:+ PAAD cis rs9322193 0.847 rs12191643 ENSG00000268592.3 RAET1E-AS1 3.9 0.000143 0.0439 0.35 0.3 Lung cancer; chr6:149628912 chr6:149863494~149919507:+ PAAD cis rs2638953 0.924 rs1478336 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28189186 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs1478335 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28189244 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs1478334 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28189425 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049417 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28192152 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs12372059 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28192370 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs12372073 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28192462 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs56318627 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28192719 chr12:28163298~28190738:- PAAD cis rs2638953 0.814 rs11049419 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28192951 chr12:28163298~28190738:- PAAD cis rs2638953 0.85 rs11049420 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28193179 chr12:28163298~28190738:- PAAD cis rs2638953 0.744 rs11049421 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28193324 chr12:28163298~28190738:- PAAD cis rs13178541 0.578 rs10463942 ENSG00000250378.1 RP11-119J18.1 -3.9 0.000143 0.0439 -0.44 -0.3 IgG glycosylation; chr5:135803482 chr5:135812667~135826582:+ PAAD cis rs13178541 0.641 rs2345447 ENSG00000250378.1 RP11-119J18.1 -3.9 0.000143 0.0439 -0.44 -0.3 IgG glycosylation; chr5:135804058 chr5:135812667~135826582:+ PAAD cis rs11997175 0.624 rs12677772 ENSG00000240738.1 RP1-273G13.1 3.9 0.000143 0.0439 0.36 0.3 Body mass index; chr8:33915003 chr8:33859480~33860223:- PAAD cis rs7911264 0.739 rs10736069 ENSG00000236493.2 EIF2S2P3 3.9 0.000143 0.0439 0.39 0.3 Inflammatory bowel disease; chr10:92635636 chr10:92668745~92669743:- PAAD cis rs7911264 0.739 rs7900689 ENSG00000236493.2 EIF2S2P3 3.9 0.000143 0.0439 0.39 0.3 Inflammatory bowel disease; chr10:92635991 chr10:92668745~92669743:- PAAD cis rs7911264 0.739 rs6583830 ENSG00000236493.2 EIF2S2P3 3.9 0.000143 0.0439 0.39 0.3 Inflammatory bowel disease; chr10:92638361 chr10:92668745~92669743:- PAAD cis rs2638953 0.888 rs10843189 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000143 0.0439 -0.32 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28506985 chr12:28163298~28190738:- PAAD cis rs6479901 0.895 rs10822162 ENSG00000232075.1 MRPL35P2 -3.9 0.000143 0.0439 -0.44 -0.3 Intelligence (multi-trait analysis); chr10:63364320 chr10:63634317~63634827:- PAAD cis rs891378 1 rs10864178 ENSG00000274245.1 RP11-357P18.2 -3.9 0.000143 0.0439 -0.42 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207272333 chr1:207372559~207373252:+ PAAD cis rs613391 0.536 rs554191 ENSG00000224549.1 RP11-370B11.3 -3.9 0.000143 0.0439 -0.37 -0.3 Quantitative traits; chr9:22720123 chr9:22767175~22768316:+ PAAD cis rs6903823 0.508 rs1150721 ENSG00000204709.4 LINC01556 3.9 0.000143 0.0439 0.4 0.3 Pulmonary function; chr6:28287263 chr6:28943877~28944537:+ PAAD cis rs16846053 0.551 rs1515186 ENSG00000227403.1 AC009299.3 -3.9 0.000143 0.0439 -0.55 -0.3 Blood osmolality (transformed sodium); chr2:161699850 chr2:161244739~161249050:+ PAAD cis rs2439831 1 rs9920763 ENSG00000275601.1 AC011330.13 -3.9 0.000143 0.0439 -0.57 -0.3 Lung cancer in ever smokers; chr15:43468310 chr15:43642389~43643023:- PAAD cis rs12935418 0.616 rs13332890 ENSG00000261061.1 RP11-303E16.2 -3.9 0.000143 0.0439 -0.39 -0.3 Mean corpuscular volume; chr16:80971836 chr16:81030770~81031485:+ PAAD cis rs17023223 0.537 rs12086549 ENSG00000231365.4 RP11-418J17.1 3.9 0.000143 0.0439 0.35 0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119071714 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs7525871 ENSG00000231365.4 RP11-418J17.1 -3.9 0.000143 0.0439 -0.35 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119079271 chr1:119140396~119275973:+ PAAD cis rs7927592 0.913 rs12272917 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68495902 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs59056571 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68505505 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs66752716 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68506158 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs11228262 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68507439 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs55883802 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68511361 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs11228268 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68519979 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs4084149 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68521099 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs7925275 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68522965 chr11:68506083~68506166:- PAAD cis rs7927592 0.913 rs6591340 ENSG00000212093.1 AP000807.1 3.9 0.000143 0.044 0.36 0.3 Total body bone mineral density; chr11:68530168 chr11:68506083~68506166:- PAAD cis rs7989336 0.562 rs9554349 ENSG00000247400.3 DNAJC3-AS1 -3.9 0.000143 0.044 -0.27 -0.3 Obesity; chr13:96371575 chr13:95648733~95676925:- PAAD cis rs7989336 0.562 rs7995352 ENSG00000247400.3 DNAJC3-AS1 -3.9 0.000143 0.044 -0.27 -0.3 Obesity; chr13:96371579 chr13:95648733~95676925:- PAAD cis rs7989336 0.562 rs1925100 ENSG00000247400.3 DNAJC3-AS1 -3.9 0.000143 0.044 -0.27 -0.3 Obesity; chr13:96371896 chr13:95648733~95676925:- PAAD cis rs7989336 0.562 rs1925099 ENSG00000247400.3 DNAJC3-AS1 -3.9 0.000143 0.044 -0.27 -0.3 Obesity; chr13:96372044 chr13:95648733~95676925:- PAAD cis rs56804039 0.524 rs58668637 ENSG00000173295.6 FAM86B3P -3.9 0.000143 0.044 -0.55 -0.3 Cervical cancer; chr8:8519590 chr8:8228595~8244865:+ PAAD cis rs17214007 0.597 rs4781677 ENSG00000263335.1 AF001548.5 -3.9 0.000143 0.044 -0.41 -0.3 Cognitive function; chr16:15636388 chr16:15726674~15732993:+ PAAD cis rs7824557 0.679 rs7004362 ENSG00000254527.1 ENPP7P12 -3.9 0.000143 0.044 -0.35 -0.3 Retinal vascular caliber; chr8:11278465 chr8:12205759~12206389:- PAAD cis rs7017914 0.934 rs6987313 ENSG00000254031.4 RP11-326E22.1 3.9 0.000143 0.044 0.31 0.3 Bone mineral density; chr8:70658754 chr8:71155457~71204223:+ PAAD cis rs7017914 0.902 rs35580034 ENSG00000254031.4 RP11-326E22.1 3.9 0.000143 0.044 0.31 0.3 Bone mineral density; chr8:70659838 chr8:71155457~71204223:+ PAAD cis rs7017914 0.934 rs17760050 ENSG00000254031.4 RP11-326E22.1 3.9 0.000143 0.044 0.31 0.3 Bone mineral density; chr8:70662016 chr8:71155457~71204223:+ PAAD cis rs7017914 0.934 rs35214141 ENSG00000254031.4 RP11-326E22.1 3.9 0.000143 0.044 0.31 0.3 Bone mineral density; chr8:70662329 chr8:71155457~71204223:+ PAAD cis rs7017914 0.934 rs10504479 ENSG00000254031.4 RP11-326E22.1 3.9 0.000143 0.044 0.31 0.3 Bone mineral density; chr8:70665280 chr8:71155457~71204223:+ PAAD cis rs7017914 0.934 rs35109143 ENSG00000254031.4 RP11-326E22.1 3.9 0.000143 0.044 0.31 0.3 Bone mineral density; chr8:70665665 chr8:71155457~71204223:+ PAAD cis rs7017914 0.902 rs13269513 ENSG00000254031.4 RP11-326E22.1 3.9 0.000143 0.044 0.31 0.3 Bone mineral density; chr8:70665844 chr8:71155457~71204223:+ PAAD cis rs4660456 0.913 rs657149 ENSG00000272145.1 NFYC-AS1 -3.9 0.000144 0.044 -0.26 -0.3 Platelet count; chr1:40692486 chr1:40690380~40692066:- PAAD cis rs1927790 0.759 rs7982697 ENSG00000247400.3 DNAJC3-AS1 -3.9 0.000144 0.0441 -0.28 -0.3 Body mass index; chr13:96336585 chr13:95648733~95676925:- PAAD cis rs1927790 0.727 rs12583988 ENSG00000247400.3 DNAJC3-AS1 -3.9 0.000144 0.0441 -0.28 -0.3 Body mass index; chr13:96339348 chr13:95648733~95676925:- PAAD cis rs1927790 0.759 rs12583996 ENSG00000247400.3 DNAJC3-AS1 -3.9 0.000144 0.0441 -0.28 -0.3 Body mass index; chr13:96339448 chr13:95648733~95676925:- PAAD cis rs1927790 0.759 rs12585563 ENSG00000247400.3 DNAJC3-AS1 -3.9 0.000144 0.0441 -0.28 -0.3 Body mass index; chr13:96339593 chr13:95648733~95676925:- PAAD cis rs12701220 0.857 rs1057558 ENSG00000229043.2 AC091729.9 -3.9 0.000144 0.0441 -0.42 -0.3 Bronchopulmonary dysplasia; chr7:1022730 chr7:1160374~1165267:+ PAAD cis rs56046484 0.913 rs17611290 ENSG00000259295.5 CSPG4P12 3.9 0.000144 0.0441 0.42 0.3 Testicular germ cell tumor; chr15:85031188 chr15:85191438~85213905:+ PAAD cis rs56046484 0.913 rs12906544 ENSG00000259295.5 CSPG4P12 3.9 0.000144 0.0441 0.42 0.3 Testicular germ cell tumor; chr15:85032832 chr15:85191438~85213905:+ PAAD cis rs56046484 0.871 rs34978449 ENSG00000259295.5 CSPG4P12 3.9 0.000144 0.0441 0.42 0.3 Testicular germ cell tumor; chr15:85036917 chr15:85191438~85213905:+ PAAD cis rs56046484 0.871 rs62021230 ENSG00000259295.5 CSPG4P12 3.9 0.000144 0.0441 0.42 0.3 Testicular germ cell tumor; chr15:85040721 chr15:85191438~85213905:+ PAAD cis rs56046484 0.956 rs17540501 ENSG00000259295.5 CSPG4P12 3.9 0.000144 0.0441 0.42 0.3 Testicular germ cell tumor; chr15:85094870 chr15:85191438~85213905:+ PAAD cis rs56046484 0.956 rs35204319 ENSG00000259295.5 CSPG4P12 3.9 0.000144 0.0441 0.42 0.3 Testicular germ cell tumor; chr15:85107246 chr15:85191438~85213905:+ PAAD cis rs7119038 0.629 rs10892272 ENSG00000255239.1 AP002954.6 -3.9 0.000144 0.0441 -0.4 -0.3 Sjögren's syndrome; chr11:118731998 chr11:118688039~118690600:- PAAD cis rs17711722 0.528 rs73138179 ENSG00000213640.3 EEF1DP4 -3.9 0.000144 0.0441 -0.31 -0.3 Calcium levels; chr7:65829495 chr7:64862999~64864370:+ PAAD cis rs11690935 0.632 rs35854151 ENSG00000228389.1 AC068039.4 -3.9 0.000144 0.0441 -0.36 -0.3 Schizophrenia; chr2:171800929 chr2:171773482~171775844:+ PAAD cis rs189798 0.845 rs330904 ENSG00000253893.2 FAM85B 3.9 0.000144 0.0441 0.44 0.3 Myopia (pathological); chr8:9134315 chr8:8167819~8226614:- PAAD cis rs7189233 1 rs7189819 ENSG00000279722.1 RP11-44F14.6 -3.9 0.000144 0.0441 -0.32 -0.3 Intelligence (multi-trait analysis); chr16:53502433 chr16:53487607~53489943:- PAAD cis rs11018904 0.636 rs61903695 ENSG00000280385.1 AP000648.5 -3.9 0.000144 0.0441 -0.4 -0.3 Intelligence (multi-trait analysis); chr11:90189249 chr11:90193614~90198120:+ PAAD cis rs17111230 0.617 rs1176971 ENSG00000251363.2 RP11-129M6.1 -3.9 0.000144 0.0441 -0.47 -0.3 Congenital heart disease (inherited effect); chr14:40966630 chr14:40954898~40975877:+ PAAD cis rs17111230 0.617 rs1176956 ENSG00000251363.2 RP11-129M6.1 3.9 0.000144 0.0441 0.47 0.3 Congenital heart disease (inherited effect); chr14:40941846 chr14:40954898~40975877:+ PAAD cis rs17111230 0.617 rs1176957 ENSG00000251363.2 RP11-129M6.1 3.9 0.000144 0.0441 0.47 0.3 Congenital heart disease (inherited effect); chr14:40943895 chr14:40954898~40975877:+ PAAD cis rs17111230 0.617 rs1176960 ENSG00000251363.2 RP11-129M6.1 3.9 0.000144 0.0441 0.47 0.3 Congenital heart disease (inherited effect); chr14:40947083 chr14:40954898~40975877:+ PAAD cis rs17111230 0.617 rs1176964 ENSG00000251363.2 RP11-129M6.1 3.9 0.000144 0.0441 0.47 0.3 Congenital heart disease (inherited effect); chr14:40948513 chr14:40954898~40975877:+ PAAD cis rs17111230 0.57 rs1615517 ENSG00000251363.2 RP11-129M6.1 3.9 0.000144 0.0441 0.47 0.3 Congenital heart disease (inherited effect); chr14:40948908 chr14:40954898~40975877:+ PAAD cis rs17111230 0.617 rs1176967 ENSG00000251363.2 RP11-129M6.1 3.9 0.000144 0.0441 0.47 0.3 Congenital heart disease (inherited effect); chr14:40961450 chr14:40954898~40975877:+ PAAD cis rs17111230 0.617 rs1176975 ENSG00000251363.2 RP11-129M6.1 3.9 0.000144 0.0441 0.47 0.3 Congenital heart disease (inherited effect); chr14:40968475 chr14:40954898~40975877:+ PAAD cis rs17111230 0.617 rs1779597 ENSG00000251363.2 RP11-129M6.1 3.9 0.000144 0.0441 0.47 0.3 Congenital heart disease (inherited effect); chr14:40999728 chr14:40954898~40975877:+ PAAD cis rs832187 0.679 rs9879045 ENSG00000280620.1 SCAANT1 3.9 0.000144 0.0441 0.39 0.3 Schizophrenia; chr3:64016249 chr3:63911518~63911772:- PAAD cis rs848490 0.515 rs6973656 ENSG00000213542.3 RP11-467H10.1 3.9 0.000144 0.0441 0.33 0.3 Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine); chr7:77793266 chr7:77115399~77116192:- PAAD cis rs3738443 0.904 rs61840000 ENSG00000259865.1 RP11-488L18.10 3.9 0.000144 0.0442 0.27 0.3 Alcohol dependence; chr1:247199027 chr1:247187281~247188526:- PAAD cis rs77372450 0.591 rs17054697 ENSG00000251405.2 CTB-109A12.1 3.9 0.000144 0.0442 0.45 0.3 Bipolar disorder (body mass index interaction); chr5:157539217 chr5:157362615~157460078:- PAAD cis rs2249296 0.557 rs272487 ENSG00000230721.1 RP4-612B15.2 3.9 0.000144 0.0442 0.37 0.3 Crohn's disease-related phenotypes; chr1:86340197 chr1:86784913~86785467:+ PAAD cis rs12073837 0.5 rs4143772 ENSG00000221571.3 RNU6ATAC35P -3.9 0.000144 0.0442 -0.36 -0.3 F-cell distribution; chr1:220815004 chr1:220825620~220826063:+ PAAD cis rs9322193 0.962 rs7745915 ENSG00000268592.3 RAET1E-AS1 3.9 0.000144 0.0442 0.36 0.3 Lung cancer; chr6:149834111 chr6:149863494~149919507:+ PAAD cis rs7915414 0.585 rs4641393 ENSG00000230338.1 MTND4P19 -3.9 0.000144 0.0442 -0.36 -0.3 Clopidogrel active metabolite levels; chr10:94807629 chr10:94774156~94774633:- PAAD cis rs72843506 0.722 rs3764436 ENSG00000154898.14 CCDC144CP 3.9 0.000144 0.0442 0.56 0.3 Schizophrenia; chr17:20110489 chr17:20321164~20403557:+ PAAD cis rs440932 0.717 rs330944 ENSG00000254340.1 RP11-10A14.3 3.9 0.000144 0.0442 0.37 0.3 High light scatter reticulocyte percentage of red cells; chr8:9163783 chr8:9141424~9145435:+ PAAD cis rs153916 0.593 rs987068 ENSG00000250551.1 RP11-254I22.1 -3.9 0.000145 0.0443 -0.4 -0.3 Pulmonary function; chr5:95689442 chr5:96050115~96215519:+ PAAD cis rs7592578 0.882 rs16832765 ENSG00000231858.4 AC067945.4 -3.9 0.000145 0.0443 -0.36 -0.3 Diastolic blood pressure; chr2:190604036 chr2:191021526~191032314:+ PAAD cis rs2262909 0.962 rs55728714 ENSG00000268079.1 BNIP3P30 -3.9 0.000145 0.0443 -0.35 -0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22080097 chr19:22203128~22204003:+ PAAD cis rs2262909 0.962 rs12609368 ENSG00000268079.1 BNIP3P30 -3.9 0.000145 0.0443 -0.35 -0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22081194 chr19:22203128~22204003:+ PAAD cis rs2262909 0.962 rs56369285 ENSG00000268079.1 BNIP3P30 -3.9 0.000145 0.0443 -0.35 -0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22084383 chr19:22203128~22204003:+ PAAD cis rs6545883 0.507 rs2442025 ENSG00000271889.1 RP11-493E12.1 -3.9 0.000145 0.0443 -0.32 -0.3 Tuberculosis; chr2:61344310 chr2:61151433~61162105:- PAAD cis rs6545883 0.524 rs2593631 ENSG00000271889.1 RP11-493E12.1 -3.9 0.000145 0.0443 -0.32 -0.3 Tuberculosis; chr2:61345151 chr2:61151433~61162105:- PAAD cis rs6545883 0.542 rs2593628 ENSG00000271889.1 RP11-493E12.1 -3.9 0.000145 0.0443 -0.32 -0.3 Tuberculosis; chr2:61346152 chr2:61151433~61162105:- PAAD cis rs1113500 0.565 rs1781071 ENSG00000226822.1 RP11-356N1.2 3.9 0.000145 0.0443 0.38 0.3 Growth-regulated protein alpha levels; chr1:108028412 chr1:108071482~108074519:+ PAAD cis rs9876781 1 rs11130170 ENSG00000229759.1 MRPS18AP1 3.9 0.000145 0.0443 0.33 0.3 Longevity; chr3:48408490 chr3:48256350~48256938:- PAAD cis rs9876781 1 rs10470686 ENSG00000229759.1 MRPS18AP1 3.9 0.000145 0.0443 0.33 0.3 Longevity; chr3:48408549 chr3:48256350~48256938:- PAAD cis rs616147 0.671 rs675595 ENSG00000232439.1 RPL18AP7 -3.9 0.000145 0.0443 -0.4 -0.3 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39458987 chr3:38526802~38527325:- PAAD cis rs7849270 1 rs1107328 ENSG00000268707.1 RP11-247A12.7 3.9 0.000145 0.0443 0.37 0.3 Blood metabolite ratios; chr9:129155255 chr9:129170434~129170940:+ PAAD cis rs72615157 0.539 rs12673441 ENSG00000078319.8 PMS2P1 -3.9 0.000145 0.0443 -0.4 -0.3 Lung function (FEV1/FVC); chr7:100072705 chr7:100320992~100341908:- PAAD cis rs72615157 0.539 rs72615159 ENSG00000078319.8 PMS2P1 -3.9 0.000145 0.0443 -0.4 -0.3 Lung function (FEV1/FVC); chr7:100076663 chr7:100320992~100341908:- PAAD cis rs8177876 0.822 rs77475047 ENSG00000261838.4 RP11-303E16.6 3.9 0.000145 0.0443 0.72 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81073355 chr16:81069854~81076598:+ PAAD cis rs8177876 0.822 rs55939311 ENSG00000261838.4 RP11-303E16.6 3.9 0.000145 0.0443 0.72 0.3 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81075493 chr16:81069854~81076598:+ PAAD cis rs11089937 0.597 rs5757027 ENSG00000211660.3 IGLV2-23 3.9 0.000145 0.0443 0.21 0.3 Periodontitis (PAL4Q3); chr22:22137683 chr22:22697789~22698407:+ PAAD cis rs4713118 0.662 rs156744 ENSG00000219392.1 RP1-265C24.5 -3.9 0.000145 0.0444 -0.42 -0.3 Parkinson's disease; chr6:27999496 chr6:28115628~28116551:+ PAAD cis rs2287838 0.638 rs55832059 ENSG00000267289.1 CTD-2623N2.11 3.9 0.000145 0.0444 0.34 0.3 Sleep duration; chr19:9845000 chr19:9834079~9835013:- PAAD cis rs1430740 0.84 rs1036066 ENSG00000228431.1 ARL5AP3 3.9 0.000145 0.0444 0.38 0.3 Bone mineral density; chr1:68194522 chr1:68049360~68049745:- PAAD cis rs1430740 0.84 rs2039154 ENSG00000228431.1 ARL5AP3 3.9 0.000145 0.0444 0.38 0.3 Bone mineral density; chr1:68197130 chr1:68049360~68049745:- PAAD cis rs9287719 0.674 rs12620209 ENSG00000243819.4 RN7SL832P 3.9 0.000145 0.0444 0.29 0.3 Prostate cancer; chr2:10580315 chr2:10690344~10692099:+ PAAD cis rs9992667 0.956 rs73232890 ENSG00000231160.8 KLF3-AS1 3.9 0.000145 0.0444 0.34 0.3 Eosinophil percentage of granulocytes; chr4:38683420 chr4:38612701~38664883:- PAAD cis rs7923837 0.687 rs2185756 ENSG00000236493.2 EIF2S2P3 3.9 0.000145 0.0444 0.37 0.3 Multiple sclerosis;Body mass index; chr10:92670740 chr10:92668745~92669743:- PAAD cis rs7824557 0.701 rs4568582 ENSG00000205879.4 FAM90A2P 3.9 0.000145 0.0444 0.39 0.3 Retinal vascular caliber; chr8:11302986 chr8:12172202~12178575:- PAAD cis rs6480314 0.522 rs7895740 ENSG00000233590.1 RP11-153K11.3 -3.9 0.000145 0.0444 -0.5 -0.3 Optic nerve measurement (disc area); chr10:68313912 chr10:68233251~68242379:- PAAD cis rs7811142 0.83 rs1063945 ENSG00000078319.8 PMS2P1 -3.9 0.000145 0.0444 -0.42 -0.3 Platelet count; chr7:100332824 chr7:100320992~100341908:- PAAD cis rs7811142 0.83 rs11761253 ENSG00000078319.8 PMS2P1 -3.9 0.000145 0.0444 -0.42 -0.3 Platelet count; chr7:100341698 chr7:100320992~100341908:- PAAD cis rs7811142 0.83 rs11771936 ENSG00000078319.8 PMS2P1 -3.9 0.000145 0.0444 -0.42 -0.3 Platelet count; chr7:100345660 chr7:100320992~100341908:- PAAD cis rs7811142 0.779 rs77370288 ENSG00000078319.8 PMS2P1 -3.9 0.000145 0.0444 -0.42 -0.3 Platelet count; chr7:100350274 chr7:100320992~100341908:- PAAD cis rs7811142 0.72 rs7795656 ENSG00000078319.8 PMS2P1 -3.9 0.000145 0.0444 -0.42 -0.3 Platelet count; chr7:100352674 chr7:100320992~100341908:- PAAD cis rs7811142 0.83 rs7341507 ENSG00000078319.8 PMS2P1 -3.9 0.000145 0.0444 -0.42 -0.3 Platelet count; chr7:100353692 chr7:100320992~100341908:- PAAD cis rs11203649 0.57 rs2034005 ENSG00000250483.1 PPM1AP1 3.9 0.000145 0.0444 0.32 0.3 Obesity-related traits; chr8:14813368 chr8:15806149~15807283:- PAAD cis rs6929812 0.628 rs4713097 ENSG00000271755.1 RP1-153G14.4 3.9 0.000145 0.0444 0.35 0.3 Neuroticism (multi-trait analysis); chr6:27411768 chr6:27404010~27406964:- PAAD cis rs9374007 0.744 rs6900313 ENSG00000225093.1 RPL3P7 -3.9 0.000145 0.0444 -0.64 -0.3 Major depressive disorder; chr6:108036951 chr6:108004357~108005568:- PAAD cis rs35000415 0.515 rs35518304 ENSG00000281490.1 CICP14 -3.9 0.000145 0.0445 -0.34 -0.3 Systemic lupus erythematosus; chr7:129092265 chr7:128655962~128658791:- PAAD cis rs7586673 0.725 rs6715870 ENSG00000227403.1 AC009299.3 -3.9 0.000145 0.0445 -0.39 -0.3 Intelligence (multi-trait analysis); chr2:161038275 chr2:161244739~161249050:+ PAAD cis rs4908769 0.66 rs10779702 ENSG00000232912.4 RP5-1115A15.1 -3.9 0.000145 0.0445 -0.32 -0.3 Allergy; chr1:8363450 chr1:8424645~8434838:+ PAAD cis rs891378 1 rs1507760 ENSG00000274245.1 RP11-357P18.2 3.9 0.000145 0.0445 0.42 0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207336020 chr1:207372559~207373252:+ PAAD cis rs10761482 0.6 rs1572843 ENSG00000254271.1 RP11-131N11.4 3.9 0.000146 0.0445 0.39 0.3 Schizophrenia; chr10:60467222 chr10:60734342~60741828:+ PAAD cis rs1789 0.872 rs4333182 ENSG00000273133.1 RP11-799M12.2 -3.9 0.000146 0.0445 -0.37 -0.3 Blood protein levels; chr4:15683089 chr4:15563698~15564253:- PAAD cis rs4713118 0.662 rs149947 ENSG00000219392.1 RP1-265C24.5 -3.9 0.000146 0.0445 -0.42 -0.3 Parkinson's disease; chr6:28004655 chr6:28115628~28116551:+ PAAD cis rs4713118 0.662 rs149946 ENSG00000219392.1 RP1-265C24.5 3.9 0.000146 0.0445 0.42 0.3 Parkinson's disease; chr6:28002253 chr6:28115628~28116551:+ PAAD cis rs8005677 0.828 rs8016027 ENSG00000257285.4 RP11-298I3.1 3.9 0.000146 0.0445 0.32 0.3 Cognitive ability (multi-trait analysis); chr14:22950944 chr14:22929609~22955562:+ PAAD cis rs2638953 0.962 rs12371059 ENSG00000247934.4 RP11-967K21.1 -3.9 0.000146 0.0446 -0.35 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28375375 chr12:28163298~28190738:- PAAD cis rs17123764 0.818 rs4045193 ENSG00000257464.1 RP11-161H23.8 -3.9 0.000146 0.0446 -0.52 -0.3 Intelligence (multi-trait analysis); chr12:49610197 chr12:49442424~49442652:- PAAD cis rs9595066 0.667 rs3809350 ENSG00000227258.4 SMIM2-AS1 3.9 0.000146 0.0446 0.45 0.3 Schizophrenia; chr13:44162043 chr13:44110451~44240517:+ PAAD cis rs7572733 0.534 rs700688 ENSG00000231621.1 AC013264.2 3.9 0.000146 0.0446 0.3 0.3 Dermatomyositis; chr2:197859109 chr2:197197991~197199273:+ PAAD cis rs8108269 0.518 rs12972158 ENSG00000267395.4 AC074212.6 3.9 0.000146 0.0446 0.36 0.3 Type 2 diabetes; chr19:45655215 chr19:45767796~45772504:+ PAAD cis rs755249 0.51 rs582883 ENSG00000237624.1 OXCT2P1 3.9 0.000146 0.0446 0.39 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39369868 chr1:39514956~39516490:+ PAAD cis rs3738443 0.768 rs6668154 ENSG00000259865.1 RP11-488L18.10 3.9 0.000146 0.0446 0.28 0.3 Alcohol dependence; chr1:247187981 chr1:247187281~247188526:- PAAD cis rs3738443 0.768 rs6665647 ENSG00000259865.1 RP11-488L18.10 3.9 0.000146 0.0446 0.28 0.3 Alcohol dependence; chr1:247188127 chr1:247187281~247188526:- PAAD cis rs3738443 0.817 rs1115202 ENSG00000259865.1 RP11-488L18.10 3.9 0.000146 0.0446 0.28 0.3 Alcohol dependence; chr1:247189878 chr1:247187281~247188526:- PAAD cis rs3738443 0.868 rs4351686 ENSG00000259865.1 RP11-488L18.10 3.9 0.000146 0.0446 0.28 0.3 Alcohol dependence; chr1:247190028 chr1:247187281~247188526:- PAAD cis rs3738443 0.868 rs61839994 ENSG00000259865.1 RP11-488L18.10 3.9 0.000146 0.0446 0.28 0.3 Alcohol dependence; chr1:247195479 chr1:247187281~247188526:- PAAD cis rs11992186 0.57 rs17628941 ENSG00000253893.2 FAM85B 3.9 0.000146 0.0446 0.44 0.3 Neuroticism; chr8:8730024 chr8:8167819~8226614:- PAAD cis rs2816938 1 rs2816945 ENSG00000236468.1 RP11-104D3.2 3.9 0.000146 0.0446 0.35 0.3 Pancreatic cancer; chr1:200023237 chr1:199387141~199388475:+ PAAD cis rs79040073 0.911 rs34895054 ENSG00000259531.2 RP11-295H24.3 3.9 0.000146 0.0446 0.47 0.3 Lung cancer in ever smokers; chr15:48992804 chr15:49365124~49366685:- PAAD cis rs7236632 1 rs7236632 ENSG00000267787.4 RP11-35G9.5 -3.9 0.000146 0.0446 -0.27 -0.3 Attention deficit hyperactivity disorder and conduct disorder; chr18:57766970 chr18:57639455~57738044:+ PAAD cis rs6545883 0.507 rs34668697 ENSG00000271889.1 RP11-493E12.1 -3.9 0.000146 0.0446 -0.32 -0.3 Tuberculosis; chr2:61341214 chr2:61151433~61162105:- PAAD cis rs6545883 0.542 rs10177225 ENSG00000271889.1 RP11-493E12.1 -3.9 0.000146 0.0446 -0.32 -0.3 Tuberculosis; chr2:61367363 chr2:61151433~61162105:- PAAD cis rs321358 0.731 rs17460676 ENSG00000271390.1 RP11-89C3.3 3.9 0.000146 0.0447 0.4 0.3 Body mass index; chr11:111166625 chr11:111089870~111090368:- PAAD cis rs2262909 0.962 rs7255049 ENSG00000279377.1 AC003973.3 3.9 0.000146 0.0447 0.28 0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22030309 chr19:21965708~21968529:- PAAD cis rs2262909 1 rs431328 ENSG00000279377.1 AC003973.3 3.9 0.000146 0.0447 0.28 0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22039434 chr19:21965708~21968529:- PAAD cis rs10129255 0.5 rs4774008 ENSG00000280411.1 IGHV1-69-2 -3.9 0.000146 0.0447 -0.25 -0.3 Kawasaki disease; chr14:106681273 chr14:106762092~106762588:- PAAD cis rs3743772 0.5 rs9924562 ENSG00000279722.1 RP11-44F14.6 3.9 0.000146 0.0447 0.43 0.3 Depressive symptoms (SSRI exposure interaction); chr16:53415152 chr16:53487607~53489943:- PAAD cis rs6700559 0.74 rs11582610 ENSG00000260088.1 RP11-92G12.3 3.9 0.000146 0.0447 0.4 0.3 Coronary artery disease; chr1:200675973 chr1:200669507~200694250:+ PAAD cis rs6700559 0.74 rs10919997 ENSG00000260088.1 RP11-92G12.3 3.9 0.000146 0.0447 0.4 0.3 Coronary artery disease; chr1:200677522 chr1:200669507~200694250:+ PAAD cis rs6700559 0.74 rs4437908 ENSG00000260088.1 RP11-92G12.3 3.9 0.000146 0.0447 0.4 0.3 Coronary artery disease; chr1:200679311 chr1:200669507~200694250:+ PAAD cis rs6700559 0.74 rs4072551 ENSG00000260088.1 RP11-92G12.3 3.9 0.000146 0.0447 0.4 0.3 Coronary artery disease; chr1:200679993 chr1:200669507~200694250:+ PAAD cis rs6700559 0.74 rs4072554 ENSG00000260088.1 RP11-92G12.3 3.9 0.000146 0.0447 0.4 0.3 Coronary artery disease; chr1:200680238 chr1:200669507~200694250:+ PAAD cis rs6700559 0.74 rs10919999 ENSG00000260088.1 RP11-92G12.3 3.9 0.000146 0.0447 0.4 0.3 Coronary artery disease; chr1:200680631 chr1:200669507~200694250:+ PAAD cis rs6700559 0.654 rs12061556 ENSG00000260088.1 RP11-92G12.3 3.9 0.000146 0.0447 0.4 0.3 Coronary artery disease; chr1:200681111 chr1:200669507~200694250:+ PAAD cis rs6700559 0.74 rs4387211 ENSG00000260088.1 RP11-92G12.3 -3.9 0.000146 0.0447 -0.4 -0.3 Coronary artery disease; chr1:200676810 chr1:200669507~200694250:+ PAAD cis rs7225151 0.522 rs78534596 ENSG00000234327.6 AC012146.7 -3.9 0.000146 0.0447 -0.34 -0.3 Alzheimer's disease (late onset); chr17:5232065 chr17:5111468~5115004:+ PAAD cis rs10779751 0.69 rs28729193 ENSG00000238199.1 UBE2V2P3 3.9 0.000146 0.0447 0.38 0.3 Body mass index; chr1:11120094 chr1:11278616~11279351:- PAAD cis rs595244 0.908 rs2118181 ENSG00000259705.1 RP11-227D13.1 -3.9 0.000146 0.0447 -0.44 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48623687 chr15:48645951~48652016:+ PAAD cis rs1969253 0.803 rs843357 ENSG00000205955.4 HSP90AA5P -3.9 0.000146 0.0447 -0.38 -0.3 Major depressive disorder; chr3:184143962 chr3:184115352~184117898:+ PAAD cis rs2929278 0.617 rs575082 ENSG00000275601.1 AC011330.13 3.9 0.000146 0.0447 0.33 0.3 Schizophrenia; chr15:43817944 chr15:43642389~43643023:- PAAD cis rs2929278 0.617 rs2955969 ENSG00000275601.1 AC011330.13 3.9 0.000146 0.0447 0.33 0.3 Schizophrenia; chr15:43822329 chr15:43642389~43643023:- PAAD cis rs829883 0.966 rs249853 ENSG00000227825.4 SLC9A7P1 3.9 0.000146 0.0447 0.32 0.3 Colorectal adenoma (advanced); chr12:98471130 chr12:98453835~98457145:- PAAD cis rs7202877 0.61 rs1010631 ENSG00000261783.1 RP11-252K23.2 -3.9 0.000147 0.0447 -0.48 -0.3 Type 1 diabetes;Type 2 diabetes; chr16:75294692 chr16:75379818~75381260:- PAAD cis rs9322193 0.923 rs4354168 ENSG00000268592.3 RAET1E-AS1 3.9 0.000147 0.0447 0.35 0.3 Lung cancer; chr6:149696642 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs4455682 ENSG00000268592.3 RAET1E-AS1 3.9 0.000147 0.0447 0.35 0.3 Lung cancer; chr6:149700161 chr6:149863494~149919507:+ PAAD cis rs7829975 0.627 rs876954 ENSG00000253981.4 ALG1L13P 3.9 0.000147 0.0447 0.35 0.3 Mood instability; chr8:8453413 chr8:8236003~8244667:- PAAD cis rs9905759 0.622 rs4338847 ENSG00000275011.1 RP11-599B13.9 -3.9 0.000147 0.0448 -0.38 -0.3 Childhood ear infection; chr17:8026459 chr17:8063936~8072533:+ PAAD cis rs11089937 0.568 rs2876996 ENSG00000211638.2 IGLV8-61 -3.9 0.000147 0.0448 -0.28 -0.3 Periodontitis (PAL4Q3); chr22:22132006 chr22:22098700~22099212:+ PAAD cis rs2380205 0.503 rs685852 ENSG00000232807.2 RP11-536K7.3 -3.9 0.000147 0.0448 -0.32 -0.3 Breast cancer; chr10:5892654 chr10:5934270~5945900:- PAAD cis rs6479901 0.639 rs10995448 ENSG00000232075.1 MRPL35P2 -3.89 0.000147 0.0448 -0.45 -0.3 Intelligence (multi-trait analysis); chr10:63127299 chr10:63634317~63634827:- PAAD cis rs6479901 0.639 rs7082200 ENSG00000232075.1 MRPL35P2 -3.89 0.000147 0.0448 -0.45 -0.3 Intelligence (multi-trait analysis); chr10:63128561 chr10:63634317~63634827:- PAAD cis rs6539288 0.933 rs6539285 ENSG00000260329.1 RP11-412D9.4 -3.89 0.000147 0.0448 -0.25 -0.3 Total body bone mineral density; chr12:106903683 chr12:106954029~106955497:- PAAD cis rs11089937 0.864 rs5757041 ENSG00000211640.3 IGLV6-57 3.89 0.000147 0.0448 0.19 0.3 Periodontitis (PAL4Q3); chr22:22140538 chr22:22195713~22196460:+ PAAD cis rs8031584 1 rs890159 ENSG00000270015.1 RP11-540B6.6 -3.89 0.000147 0.0448 -0.25 -0.3 Huntington's disease progression; chr15:30999431 chr15:30926514~30928407:+ PAAD cis rs2250402 0.655 rs2307101 ENSG00000245849.5 RAD51-AS1 3.89 0.000147 0.0448 0.43 0.3 Corneal curvature; chr15:40030259 chr15:40686724~40695107:- PAAD cis rs2019137 0.868 rs3748916 ENSG00000274877.1 RP11-65I12.1 3.89 0.000147 0.0448 0.34 0.3 Lymphocyte counts; chr2:113226456 chr2:113237595~113240825:+ PAAD cis rs5758659 0.714 rs7245 ENSG00000273366.1 CTA-989H11.1 3.89 0.000147 0.0448 0.37 0.3 Cognitive function; chr22:42085845 chr22:42278188~42278846:+ PAAD cis rs6929812 0.613 rs13215560 ENSG00000271755.1 RP1-153G14.4 3.89 0.000147 0.0448 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27514160 chr6:27404010~27406964:- PAAD cis rs957448 1 rs957447 ENSG00000253704.1 RP11-267M23.4 3.89 0.000147 0.0448 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94528995 chr8:94553722~94569745:+ PAAD cis rs957448 1 rs72674852 ENSG00000253704.1 RP11-267M23.4 3.89 0.000147 0.0448 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94536523 chr8:94553722~94569745:+ PAAD cis rs957448 1 rs16916874 ENSG00000253704.1 RP11-267M23.4 3.89 0.000147 0.0448 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94537749 chr8:94553722~94569745:+ PAAD cis rs957448 1 rs1992370 ENSG00000253704.1 RP11-267M23.4 3.89 0.000147 0.0448 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94546466 chr8:94553722~94569745:+ PAAD cis rs17772222 0.917 rs17260408 ENSG00000258983.2 RP11-507K2.2 3.89 0.000147 0.0448 0.39 0.3 Coronary artery calcification; chr14:88715464 chr14:88499334~88515502:+ PAAD cis rs17772222 0.917 rs8021690 ENSG00000258983.2 RP11-507K2.2 3.89 0.000147 0.0448 0.39 0.3 Coronary artery calcification; chr14:88717806 chr14:88499334~88515502:+ PAAD cis rs193541 0.556 rs30024 ENSG00000263432.2 RN7SL689P 3.89 0.000147 0.0448 0.39 0.3 Glucose homeostasis traits; chr5:122949465 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs30023 ENSG00000263432.2 RN7SL689P 3.89 0.000147 0.0448 0.39 0.3 Glucose homeostasis traits; chr5:122949604 chr5:123022487~123022783:- PAAD cis rs7712401 0.502 rs30066 ENSG00000263432.2 RN7SL689P 3.89 0.000147 0.0448 0.39 0.3 Mean platelet volume; chr5:122958007 chr5:123022487~123022783:- PAAD cis rs193541 0.632 rs30063 ENSG00000263432.2 RN7SL689P 3.89 0.000147 0.0448 0.39 0.3 Glucose homeostasis traits; chr5:122959998 chr5:123022487~123022783:- PAAD cis rs853679 0.666 rs200956 ENSG00000219392.1 RP1-265C24.5 -3.89 0.000147 0.0448 -0.47 -0.3 Depression; chr6:27871968 chr6:28115628~28116551:+ PAAD cis rs1740073 0.624 rs9472179 ENSG00000203362.2 RP3-337H4.8 3.89 0.000147 0.0448 0.37 0.3 Vascular endothelial growth factor levels; chr6:43971194 chr6:43588230~43591362:- PAAD cis rs763121 0.853 rs5757196 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38643850 chr22:38667585~38681820:- PAAD cis rs763121 0.785 rs5757199 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38644612 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs7289577 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38646209 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs9610993 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38646813 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757200 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38647486 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757203 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38648147 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2205802 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38650322 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757204 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38650695 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs8138996 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38651430 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs6001182 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38651438 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757208 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38653225 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757211 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38655700 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs6001184 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38656111 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs6001185 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38656150 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2294296 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38657044 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs2064088 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38657377 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757213 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38657883 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs3747172 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38671519 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5750659 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38672784 chr22:38667585~38681820:- PAAD cis rs763121 0.819 rs3747173 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38673040 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs3747174 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38673176 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs1065201 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38673505 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757226 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38674545 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5757232 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38675672 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs9306329 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38676449 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5750662 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38676467 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs5750664 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38676764 chr22:38667585~38681820:- PAAD cis rs763121 0.626 rs5757236 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38677819 chr22:38667585~38681820:- PAAD cis rs763121 0.819 rs5757237 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38677830 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs6001191 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38678447 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs11704021 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38678711 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs4821811 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38679140 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs4821812 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38679230 chr22:38667585~38681820:- PAAD cis rs763121 0.853 rs9607566 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38679429 chr22:38667585~38681820:- PAAD cis rs2839627 0.638 rs28567463 ENSG00000225218.1 AP001628.6 3.89 0.000147 0.0449 0.41 0.3 Information processing speed; chr21:42855347 chr21:42831040~42836477:- PAAD cis rs633715 0.692 rs12735657 ENSG00000254154.7 RP4-798P15.3 -3.89 0.000147 0.0449 -0.28 -0.3 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177839998 chr1:177928788~178038007:- PAAD cis rs10771431 0.738 rs11049697 ENSG00000111788.10 RP11-22B23.1 3.89 0.000147 0.0449 0.3 0.3 Breast size; chr12:9232743 chr12:9277235~9313241:+ PAAD cis rs11676348 0.703 rs6737563 ENSG00000261338.2 RP11-378A13.1 -3.89 0.000147 0.0449 -0.37 -0.3 Ulcerative colitis; chr2:218080951 chr2:218255319~218257366:+ PAAD cis rs2262909 0.924 rs4290587 ENSG00000279377.1 AC003973.3 3.89 0.000147 0.0449 0.29 0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:21981844 chr19:21965708~21968529:- PAAD cis rs6929812 0.691 rs10807024 ENSG00000271755.1 RP1-153G14.4 3.89 0.000147 0.0449 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27460926 chr6:27404010~27406964:- PAAD cis rs17123764 0.579 rs74089557 ENSG00000257464.1 RP11-161H23.8 -3.89 0.000147 0.0449 -0.59 -0.3 Intelligence (multi-trait analysis); chr12:49536583 chr12:49442424~49442652:- PAAD cis rs763121 0.962 rs5757135 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000147 0.0449 -0.29 -0.3 Menopause (age at onset); chr22:38556568 chr22:38667585~38681820:- PAAD cis rs2439831 0.85 rs12442129 ENSG00000275601.1 AC011330.13 -3.89 0.000147 0.0449 -0.51 -0.3 Lung cancer in ever smokers; chr15:43763658 chr15:43642389~43643023:- PAAD cis rs2439831 0.702 rs7175032 ENSG00000275601.1 AC011330.13 -3.89 0.000147 0.0449 -0.51 -0.3 Lung cancer in ever smokers; chr15:43768038 chr15:43642389~43643023:- PAAD cis rs2439831 0.85 rs12441861 ENSG00000275601.1 AC011330.13 -3.89 0.000147 0.0449 -0.51 -0.3 Lung cancer in ever smokers; chr15:43768685 chr15:43642389~43643023:- PAAD cis rs2439831 0.85 rs3862142 ENSG00000275601.1 AC011330.13 -3.89 0.000147 0.0449 -0.51 -0.3 Lung cancer in ever smokers; chr15:43772608 chr15:43642389~43643023:- PAAD cis rs2439831 0.702 rs2788 ENSG00000275601.1 AC011330.13 -3.89 0.000147 0.0449 -0.51 -0.3 Lung cancer in ever smokers; chr15:43772688 chr15:43642389~43643023:- PAAD cis rs2439831 0.85 rs2277531 ENSG00000275601.1 AC011330.13 -3.89 0.000147 0.0449 -0.51 -0.3 Lung cancer in ever smokers; chr15:43776871 chr15:43642389~43643023:- PAAD cis rs2439831 0.85 rs28891769 ENSG00000275601.1 AC011330.13 -3.89 0.000147 0.0449 -0.51 -0.3 Lung cancer in ever smokers; chr15:43780662 chr15:43642389~43643023:- PAAD cis rs2439831 0.85 rs28578398 ENSG00000275601.1 AC011330.13 -3.89 0.000147 0.0449 -0.51 -0.3 Lung cancer in ever smokers; chr15:43782848 chr15:43642389~43643023:- PAAD cis rs11634944 0.716 rs1030389 ENSG00000261529.1 RP13-487P22.1 -3.89 0.000147 0.0449 -0.29 -0.3 Interleukin-8 levels; chr15:25032641 chr15:25345633~25347235:- PAAD cis rs853679 0.713 rs200991 ENSG00000219392.1 RP1-265C24.5 3.89 0.000147 0.0449 0.48 0.3 Depression; chr6:27847716 chr6:28115628~28116551:+ PAAD cis rs1790761 0.806 rs7114510 ENSG00000231793.4 DOC2GP 3.89 0.000147 0.0449 0.25 0.3 Mean corpuscular volume; chr11:67457123 chr11:67612653~67616257:- PAAD cis rs7923609 0.875 rs6479877 ENSG00000232075.1 MRPL35P2 -3.89 0.000148 0.045 -0.36 -0.3 Liver enzyme levels (alkaline phosphatase);Educational attainment; chr10:63118358 chr10:63634317~63634827:- PAAD cis rs496547 0.719 rs472641 ENSG00000255239.1 AP002954.6 3.89 0.000148 0.045 0.37 0.3 Hip minimal joint space width; chr11:118746835 chr11:118688039~118690600:- PAAD cis rs8070463 0.515 rs11655943 ENSG00000228782.6 CTD-2026D20.3 3.89 0.000148 0.045 0.31 0.3 Multiple sclerosis;Ankylosing spondylitis; chr17:47308274 chr17:47450568~47492492:- PAAD cis rs7429990 0.932 rs6803741 ENSG00000228638.1 FCF1P2 3.89 0.000148 0.045 0.34 0.3 Educational attainment (years of education); chr3:48082050 chr3:48290793~48291375:- PAAD cis rs2262909 0.962 rs1526884 ENSG00000268079.1 BNIP3P30 -3.89 0.000148 0.045 -0.35 -0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22120849 chr19:22203128~22204003:+ PAAD cis rs42490 0.7 rs410663 ENSG00000251136.7 RP11-37B2.1 3.89 0.000148 0.045 0.28 0.3 Leprosy; chr8:89859461 chr8:89609409~89757727:- PAAD cis rs3015497 0.904 rs3015501 ENSG00000270062.1 RP11-248J18.3 3.89 0.000148 0.0451 0.28 0.3 Mean platelet volume; chr14:50641806 chr14:50723777~50724272:- PAAD cis rs3015497 1 rs3015497 ENSG00000270062.1 RP11-248J18.3 3.89 0.000148 0.0451 0.28 0.3 Mean platelet volume; chr14:50646680 chr14:50723777~50724272:- PAAD cis rs3015497 1 rs3015495 ENSG00000270062.1 RP11-248J18.3 3.89 0.000148 0.0451 0.28 0.3 Mean platelet volume; chr14:50647985 chr14:50723777~50724272:- PAAD cis rs4802666 0.961 rs55929162 ENSG00000161643.11 SIGLEC16 -3.89 0.000148 0.0451 -0.43 -0.3 Disc degeneration (lumbar); chr19:50223678 chr19:49969673~49975814:+ PAAD cis rs4802666 1 rs55762838 ENSG00000161643.11 SIGLEC16 -3.89 0.000148 0.0451 -0.43 -0.3 Disc degeneration (lumbar); chr19:50223922 chr19:49969673~49975814:+ PAAD cis rs172166 0.694 rs2791332 ENSG00000204709.4 LINC01556 3.89 0.000148 0.0451 0.47 0.3 Cardiac Troponin-T levels; chr6:28141010 chr6:28943877~28944537:+ PAAD cis rs35785195 0.593 rs35304519 ENSG00000257231.1 DYNLL1P4 3.89 0.000148 0.0451 0.44 0.3 Daytime sleep phenotypes; chr12:113798872 chr12:113789542~113789807:- PAAD cis rs6024905 0.904 rs6014744 ENSG00000224635.1 RP4-564F22.5 3.89 0.000148 0.0451 0.34 0.3 Bipolar disorder and schizophrenia; chr20:38329182 chr20:38406011~38416797:- PAAD cis rs6024905 0.935 rs6069759 ENSG00000224635.1 RP4-564F22.5 3.89 0.000148 0.0451 0.34 0.3 Bipolar disorder and schizophrenia; chr20:38329217 chr20:38406011~38416797:- PAAD cis rs6024905 1 rs6069760 ENSG00000224635.1 RP4-564F22.5 3.89 0.000148 0.0451 0.34 0.3 Bipolar disorder and schizophrenia; chr20:38329349 chr20:38406011~38416797:- PAAD cis rs6024905 1 rs4592915 ENSG00000224635.1 RP4-564F22.5 3.89 0.000148 0.0451 0.34 0.3 Bipolar disorder and schizophrenia; chr20:38329519 chr20:38406011~38416797:- PAAD cis rs2787702 0.5 rs11591943 ENSG00000237233.2 TMEM26-AS1 3.89 0.000148 0.0451 0.48 0.3 Response to taxane treatment (placlitaxel); chr10:61560817 chr10:61452639~61481956:+ PAAD cis rs633715 0.766 rs4132288 ENSG00000254154.7 RP4-798P15.3 -3.89 0.000148 0.0452 -0.28 -0.3 Obesity;Body mass index;Body mass index in physically inactive individuals;Menarche (age at onset);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Waist circumference; chr1:177833575 chr1:177928788~178038007:- PAAD cis rs6142102 0.961 rs2235597 ENSG00000276073.1 RP5-1125A11.7 -3.89 0.000148 0.0452 -0.32 -0.3 Skin pigmentation; chr20:34077808 chr20:33985617~33988989:- PAAD cis rs792448 0.545 rs6679796 ENSG00000229983.1 RP11-15I11.2 3.89 0.000148 0.0452 0.35 0.3 White blood cell count (basophil); chr1:212229182 chr1:212168207~212190259:+ PAAD cis rs3738443 0.868 rs17269923 ENSG00000259865.1 RP11-488L18.10 3.89 0.000148 0.0452 0.27 0.3 Alcohol dependence; chr1:247208861 chr1:247187281~247188526:- PAAD cis rs11668609 0.515 rs58278214 ENSG00000269397.1 CTB-92J24.2 3.89 0.000148 0.0452 0.59 0.3 Response to taxane treatment (docetaxel); chr19:23888887 chr19:23927788~23929287:+ PAAD cis rs11668609 0.515 rs2195971 ENSG00000269397.1 CTB-92J24.2 3.89 0.000148 0.0452 0.59 0.3 Response to taxane treatment (docetaxel); chr19:23897191 chr19:23927788~23929287:+ PAAD cis rs7260598 0.605 rs78358879 ENSG00000269397.1 CTB-92J24.2 3.89 0.000148 0.0452 0.59 0.3 Response to taxane treatment (placlitaxel); chr19:23904434 chr19:23927788~23929287:+ PAAD cis rs7260598 0.539 rs10424758 ENSG00000269397.1 CTB-92J24.2 3.89 0.000148 0.0452 0.59 0.3 Response to taxane treatment (placlitaxel); chr19:23907698 chr19:23927788~23929287:+ PAAD cis rs7260598 0.539 rs10425192 ENSG00000269397.1 CTB-92J24.2 3.89 0.000148 0.0452 0.59 0.3 Response to taxane treatment (placlitaxel); chr19:23907909 chr19:23927788~23929287:+ PAAD cis rs2034650 0.544 rs600791 ENSG00000223313.1 RNU6-516P 3.89 0.000148 0.0452 0.41 0.3 Interstitial lung disease; chr15:40428868 chr15:40529570~40529673:+ PAAD cis rs2034650 0.544 rs661488 ENSG00000223313.1 RNU6-516P 3.89 0.000148 0.0452 0.41 0.3 Interstitial lung disease; chr15:40429221 chr15:40529570~40529673:+ PAAD cis rs8031584 1 rs11638409 ENSG00000260382.1 RP11-540B6.2 3.89 0.000148 0.0452 0.4 0.3 Huntington's disease progression; chr15:30995987 chr15:30882267~30883231:- PAAD cis rs1429411 1 rs1429411 ENSG00000231621.1 AC013264.2 3.89 0.000148 0.0452 0.29 0.3 Interferon alpha levels in systemic lupus erythematosus; chr2:197279278 chr2:197197991~197199273:+ PAAD cis rs6479901 0.557 rs7920768 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Intelligence (multi-trait analysis); chr10:63300754 chr10:63634317~63634827:- PAAD cis rs6479901 0.512 rs7100372 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Intelligence (multi-trait analysis); chr10:63304484 chr10:63634317~63634827:- PAAD cis rs6479891 0.778 rs7896676 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63305542 chr10:63634317~63634827:- PAAD cis rs6479891 0.915 rs7896677 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63305545 chr10:63634317~63634827:- PAAD cis rs6479891 0.841 rs7085869 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63310403 chr10:63634317~63634827:- PAAD cis rs6479891 0.818 rs9299455 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63313841 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9414793 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63315349 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs7899715 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63318695 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs4525102 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0452 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63326513 chr10:63634317~63634827:- PAAD cis rs9419788 0.708 rs10882405 ENSG00000233377.1 MTND4P20 3.89 0.000149 0.0452 0.27 0.3 Personality traits in bipolar disorder; chr10:94214451 chr10:94940253~94941121:- PAAD cis rs2412819 0.571 rs2930531 ENSG00000249839.1 AC011330.5 3.89 0.000149 0.0452 0.47 0.3 Lung cancer; chr15:43829372 chr15:43663654~43684339:- PAAD cis rs748404 0.666 rs12899865 ENSG00000249839.1 AC011330.5 -3.89 0.000149 0.0452 -0.54 -0.3 Lung cancer; chr15:43448819 chr15:43663654~43684339:- PAAD cis rs8026198 0.929 rs7086 ENSG00000278493.1 CTD-2382E5.6 3.89 0.000149 0.0452 0.43 0.3 Fibrinogen levels; chr15:42158910 chr15:41908204~41908714:- PAAD cis rs7202877 0.706 rs37602 ENSG00000261783.1 RP11-252K23.2 3.89 0.000149 0.0452 0.48 0.3 Type 1 diabetes;Type 2 diabetes; chr16:75471148 chr16:75379818~75381260:- PAAD cis rs1990950 1 rs1990950 ENSG00000251405.2 CTB-109A12.1 -3.89 0.000149 0.0452 -0.35 -0.3 Lung function (FEV1/FVC); chr5:157493748 chr5:157362615~157460078:- PAAD cis rs17023223 0.537 rs2765533 ENSG00000231365.4 RP11-418J17.1 -3.89 0.000149 0.0452 -0.33 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119054772 chr1:119140396~119275973:+ PAAD cis rs812925 0.855 rs777592 ENSG00000271889.1 RP11-493E12.1 3.89 0.000149 0.0453 0.33 0.3 Immature fraction of reticulocytes; chr2:61191208 chr2:61151433~61162105:- PAAD cis rs3015497 0.789 rs8003372 ENSG00000270062.1 RP11-248J18.3 3.89 0.000149 0.0453 0.29 0.3 Mean platelet volume; chr14:50635633 chr14:50723777~50724272:- PAAD cis rs3015497 0.789 rs2934688 ENSG00000270062.1 RP11-248J18.3 3.89 0.000149 0.0453 0.29 0.3 Mean platelet volume; chr14:50645642 chr14:50723777~50724272:- PAAD cis rs853679 1 rs6905391 ENSG00000204709.4 LINC01556 3.89 0.000149 0.0453 0.56 0.3 Depression; chr6:28294909 chr6:28943877~28944537:+ PAAD cis rs704795 0.651 rs11693959 ENSG00000234072.1 AC074117.10 -3.89 0.000149 0.0453 -0.26 -0.3 Menopause (age at onset); chr2:27351292 chr2:27356246~27367622:+ PAAD cis rs3096644 0.544 rs112734318 ENSG00000210741.1 MIR196A1 -3.89 0.000149 0.0453 -0.34 -0.3 Metabolite levels (Dihydroxy docosatrienoic acid); chr17:48687101 chr17:48632490~48632559:- PAAD cis rs5758511 0.68 rs5758698 ENSG00000205702.9 CYP2D7 3.89 0.000149 0.0453 0.25 0.3 Birth weight; chr22:42288812 chr22:42140203~42144577:- PAAD cis rs2562456 0.958 rs2562508 ENSG00000213976.4 CTD-2561J22.2 3.89 0.000149 0.0453 0.33 0.3 Pain; chr19:21543479 chr19:21382865~21387177:+ PAAD cis rs2562456 0.833 rs2562507 ENSG00000213976.4 CTD-2561J22.2 3.89 0.000149 0.0453 0.33 0.3 Pain; chr19:21543535 chr19:21382865~21387177:+ PAAD cis rs17680741 0.697 rs11185829 ENSG00000230091.5 TMEM254-AS1 -3.89 0.000149 0.0453 -0.37 -0.3 Coronary artery disease; chr10:80508094 chr10:80046860~80078912:- PAAD cis rs17680741 0.657 rs12246432 ENSG00000230091.5 TMEM254-AS1 -3.89 0.000149 0.0453 -0.37 -0.3 Coronary artery disease; chr10:80510462 chr10:80046860~80078912:- PAAD cis rs1472147 1 rs4323418 ENSG00000281896.1 RP11-274B21.13 -3.89 0.000149 0.0453 -0.26 -0.3 Calcium levels; chr7:128866916 chr7:128617865~128625905:+ PAAD cis rs3743772 0.5 rs11859135 ENSG00000279722.1 RP11-44F14.6 3.89 0.000149 0.0453 0.43 0.3 Depressive symptoms (SSRI exposure interaction); chr16:53404267 chr16:53487607~53489943:- PAAD cis rs11098499 0.657 rs10434028 ENSG00000248280.1 RP11-33B1.2 3.89 0.000149 0.0454 0.29 0.3 Corneal astigmatism; chr4:119373309 chr4:119440561~119450157:- PAAD cis rs9487094 0.666 rs1074765 ENSG00000260273.1 RP11-425D10.10 -3.89 0.000149 0.0454 -0.36 -0.3 Height; chr6:109360458 chr6:109382795~109383666:+ PAAD cis rs7260598 0.605 rs67492250 ENSG00000268442.1 CTD-2027I19.2 3.89 0.000149 0.0454 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23924293 chr19:24162370~24163425:- PAAD cis rs7260598 0.585 rs8112076 ENSG00000268442.1 CTD-2027I19.2 3.89 0.000149 0.0454 0.43 0.3 Response to taxane treatment (placlitaxel); chr19:23956561 chr19:24162370~24163425:- PAAD cis rs2776353 0.51 rs2309102 ENSG00000280109.1 PLAC4 -3.89 0.000149 0.0454 -0.32 -0.3 Basal cell carcinoma; chr21:41665833 chr21:41175231~41185239:- PAAD cis rs453301 0.686 rs7017868 ENSG00000254340.1 RP11-10A14.3 -3.89 0.000149 0.0454 -0.37 -0.3 Joint mobility (Beighton score); chr8:9015783 chr8:9141424~9145435:+ PAAD cis rs453301 0.686 rs3895823 ENSG00000254340.1 RP11-10A14.3 -3.89 0.000149 0.0454 -0.37 -0.3 Joint mobility (Beighton score); chr8:9016136 chr8:9141424~9145435:+ PAAD cis rs2742234 0.541 rs10793427 ENSG00000273008.1 RP11-351D16.3 3.89 0.000149 0.0454 0.3 0.3 Hirschsprung disease; chr10:43251995 chr10:43136824~43138334:- PAAD cis rs10411161 0.752 rs4584941 ENSG00000270248.1 CTC-471J1.10 3.89 0.000149 0.0454 0.56 0.3 Breast cancer; chr19:51888888 chr19:52110318~52110726:- PAAD cis rs17772222 0.917 rs58550317 ENSG00000258789.1 RP11-507K2.3 -3.89 0.000149 0.0454 -0.33 -0.3 Coronary artery calcification; chr14:88775243 chr14:88551597~88552493:+ PAAD cis rs7260598 0.539 rs11672512 ENSG00000268442.1 CTD-2027I19.2 3.89 0.000149 0.0454 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23885948 chr19:24162370~24163425:- PAAD cis rs453301 0.686 rs11785819 ENSG00000254340.1 RP11-10A14.3 -3.89 0.000149 0.0454 -0.37 -0.3 Joint mobility (Beighton score); chr8:9012868 chr8:9141424~9145435:+ PAAD cis rs7674212 0.581 rs13150953 ENSG00000248971.2 KRT8P46 -3.89 0.000149 0.0454 -0.31 -0.3 Type 2 diabetes; chr4:103021341 chr4:102728746~102730171:- PAAD cis rs6479901 0.947 rs10761755 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0454 -0.44 -0.3 Intelligence (multi-trait analysis); chr10:63412212 chr10:63634317~63634827:- PAAD cis rs6479901 0.895 rs10761757 ENSG00000232075.1 MRPL35P2 -3.89 0.000149 0.0454 -0.44 -0.3 Intelligence (multi-trait analysis); chr10:63412790 chr10:63634317~63634827:- PAAD cis rs7246657 0.943 rs4801803 ENSG00000267422.1 CTD-2554C21.1 3.89 0.000149 0.0454 0.51 0.3 Coronary artery calcification; chr19:37476021 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs2303131 ENSG00000267422.1 CTD-2554C21.1 -3.89 0.000149 0.0454 -0.51 -0.3 Coronary artery calcification; chr19:37445123 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs1015848 ENSG00000267422.1 CTD-2554C21.1 -3.89 0.000149 0.0454 -0.51 -0.3 Coronary artery calcification; chr19:37454372 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs4801759 ENSG00000267422.1 CTD-2554C21.1 -3.89 0.000149 0.0454 -0.51 -0.3 Coronary artery calcification; chr19:37464083 chr19:37779686~37792865:+ PAAD cis rs9435732 1 rs2076600 ENSG00000235241.1 RP11-108M9.5 3.89 0.00015 0.0454 0.39 0.3 Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour); chr1:17010896 chr1:16889095~16889602:+ PAAD cis rs9992667 0.91 rs17428945 ENSG00000231160.8 KLF3-AS1 3.89 0.00015 0.0455 0.35 0.3 Eosinophil percentage of granulocytes; chr4:38688124 chr4:38612701~38664883:- PAAD cis rs2742417 1 rs2742447 ENSG00000244357.3 RN7SL145P 3.89 0.00015 0.0455 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45722485 chr3:45742675~45742970:+ PAAD cis rs72615157 0.634 rs2272343 ENSG00000242294.5 STAG3L5P 3.89 0.00015 0.0455 0.23 0.3 Lung function (FEV1/FVC); chr7:100180662 chr7:100336079~100351900:+ PAAD cis rs875971 0.502 rs2946580 ENSG00000222364.1 RNU6-96P 3.89 0.00015 0.0455 0.4 0.3 Aortic root size; chr7:66066855 chr7:66395191~66395286:+ PAAD cis rs2439831 1 rs2584726 ENSG00000275601.1 AC011330.13 -3.89 0.00015 0.0455 -0.52 -0.3 Lung cancer in ever smokers; chr15:43423184 chr15:43642389~43643023:- PAAD cis rs2439831 1 rs565007 ENSG00000275601.1 AC011330.13 -3.89 0.00015 0.0455 -0.52 -0.3 Lung cancer in ever smokers; chr15:43424443 chr15:43642389~43643023:- PAAD cis rs2439831 1 rs550239 ENSG00000275601.1 AC011330.13 -3.89 0.00015 0.0455 -0.52 -0.3 Lung cancer in ever smokers; chr15:43427999 chr15:43642389~43643023:- PAAD cis rs919433 0.68 rs12621129 ENSG00000231621.1 AC013264.2 3.89 0.00015 0.0455 0.29 0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197400626 chr2:197197991~197199273:+ PAAD cis rs8081395 0.801 rs2665405 ENSG00000266992.1 DHX40P1 -3.89 0.00015 0.0455 -0.31 -0.3 White blood cell count; chr17:59797931 chr17:59976009~60002384:- PAAD cis rs7120173 0.571 rs634044 ENSG00000254851.1 RP11-109L13.1 -3.89 0.00015 0.0455 -0.49 -0.3 Visceral adipose tissue adjusted for BMI; chr11:116881842 chr11:117135528~117138582:+ PAAD cis rs11089937 0.626 rs5757051 ENSG00000211660.3 IGLV2-23 -3.89 0.00015 0.0455 -0.21 -0.3 Periodontitis (PAL4Q3); chr22:22141753 chr22:22697789~22698407:+ PAAD cis rs7829975 0.688 rs7827182 ENSG00000253981.4 ALG1L13P 3.89 0.00015 0.0455 0.34 0.3 Mood instability; chr8:8522961 chr8:8236003~8244667:- PAAD cis rs4925386 1 rs4925382 ENSG00000273619.1 RP5-908M14.9 3.89 0.00015 0.0455 0.25 0.3 Colorectal cancer (SNP x SNP interaction);Colorectal cancer; chr20:62343486 chr20:62386303~62386970:- PAAD cis rs5015933 0.902 rs1969045 ENSG00000232630.1 PRPS1P2 -3.89 0.00015 0.0455 -0.27 -0.3 Body mass index; chr9:125368261 chr9:125150653~125151589:+ PAAD cis rs9928842 0.712 rs10871304 ENSG00000280152.1 RP11-331F4.5 3.89 0.00015 0.0455 0.38 0.3 Alcoholic chronic pancreatitis; chr16:75189593 chr16:75245994~75250077:- PAAD cis rs5758659 0.622 rs6519298 ENSG00000273366.1 CTA-989H11.1 -3.89 0.00015 0.0455 -0.36 -0.3 Cognitive function; chr22:41968993 chr22:42278188~42278846:+ PAAD cis rs30380 1 rs26510 ENSG00000272109.1 CTD-2260A17.3 -3.89 0.00015 0.0456 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96790207 chr5:96804353~96806105:+ PAAD cis rs30380 1 rs27529 ENSG00000272109.1 CTD-2260A17.3 -3.89 0.00015 0.0456 -0.36 -0.3 Cerebrospinal fluid biomarker levels; chr5:96790605 chr5:96804353~96806105:+ PAAD cis rs39841 1 rs39841 ENSG00000248734.2 CTD-2260A17.1 3.89 0.00015 0.0456 0.29 0.3 Inflammatory skin disease; chr5:96784466 chr5:96784777~96785999:+ PAAD cis rs812925 0.762 rs3213951 ENSG00000273302.1 RP11-493E12.2 3.89 0.00015 0.0456 0.27 0.3 Immature fraction of reticulocytes; chr2:61395116 chr2:61199979~61200769:+ PAAD cis rs7394190 1 rs7394190 ENSG00000272140.2 RP11-574K11.29 -3.89 0.00015 0.0456 -0.32 -0.3 Incident atrial fibrillation; chr10:73661890 chr10:73703735~73713581:- PAAD cis rs4698412 0.651 rs3756246 ENSG00000214846.4 RP11-115L11.1 3.89 0.00015 0.0456 0.32 0.3 Parkinson's disease; chr4:15705167 chr4:15730962~15731627:- PAAD cis rs367615 0.879 rs2201015 ENSG00000249476.1 CTD-2587M2.1 3.89 0.00015 0.0456 0.38 0.3 Colorectal cancer (SNP x SNP interaction); chr5:109611749 chr5:109237120~109326369:- PAAD cis rs4660214 0.666 rs4660550 ENSG00000243970.1 PPIEL -3.89 0.00015 0.0456 -0.29 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39222787 chr1:39531838~39558707:- PAAD cis rs9322193 0.962 rs1889473 ENSG00000268592.3 RAET1E-AS1 3.89 0.00015 0.0456 0.35 0.3 Lung cancer; chr6:149825485 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs1984111 ENSG00000268592.3 RAET1E-AS1 3.89 0.00015 0.0456 0.35 0.3 Lung cancer; chr6:149831720 chr6:149863494~149919507:+ PAAD cis rs116139393 0.611 rs62439722 ENSG00000187953.9 PMS2CL -3.89 0.00015 0.0456 -0.38 -0.3 Alzheimer's disease (APOE e4 interaction); chr7:6725309 chr7:6710128~6753862:+ PAAD cis rs11668609 0.81 rs10407383 ENSG00000269397.1 CTB-92J24.2 3.89 0.00015 0.0456 0.52 0.3 Response to taxane treatment (docetaxel); chr19:24134099 chr19:23927788~23929287:+ PAAD cis rs12478296 1 rs59036157 ENSG00000261186.2 RP11-341N2.1 -3.89 0.00015 0.0456 -0.51 -0.3 Obesity-related traits; chr2:242098077 chr2:242087351~242088457:- PAAD cis rs12478296 1 rs56323081 ENSG00000261186.2 RP11-341N2.1 -3.89 0.00015 0.0456 -0.51 -0.3 Obesity-related traits; chr2:242098656 chr2:242087351~242088457:- PAAD cis rs7202877 0.706 rs4887813 ENSG00000261783.1 RP11-252K23.2 -3.89 0.00015 0.0456 -0.48 -0.3 Type 1 diabetes;Type 2 diabetes; chr16:75278596 chr16:75379818~75381260:- PAAD cis rs4218 0.648 rs35769647 ENSG00000259732.1 RP11-59H7.3 -3.89 0.00015 0.0456 -0.42 -0.3 Social communication problems; chr15:59081670 chr15:59121034~59133250:+ PAAD cis rs875971 0.862 rs1612452 ENSG00000232559.3 GS1-124K5.12 -3.89 0.00015 0.0456 -0.33 -0.3 Aortic root size; chr7:66108909 chr7:66554588~66576923:- PAAD cis rs227932 0.571 rs3801898 ENSG00000234286.1 AC006026.13 -3.89 0.00015 0.0457 -0.52 -0.3 Schizophrenia; chr7:23762526 chr7:23680195~23680786:- PAAD cis rs7143963 0.609 rs4906270 ENSG00000259775.1 RP11-45P15.4 -3.89 0.00015 0.0457 -0.4 -0.3 Body mass index; chr14:102898400 chr14:103331674~103332367:- PAAD cis rs950169 1 rs12902672 ENSG00000259683.1 RP11-182J1.14 3.89 0.000151 0.0457 0.25 0.3 Schizophrenia; chr15:84048234 chr15:84389729~84395903:+ PAAD cis rs950169 1 rs12903820 ENSG00000259683.1 RP11-182J1.14 3.89 0.000151 0.0457 0.25 0.3 Schizophrenia; chr15:84055068 chr15:84389729~84395903:+ PAAD cis rs4713118 0.616 rs9348789 ENSG00000280107.1 AL022393.9 -3.89 0.000151 0.0457 -0.49 -0.3 Parkinson's disease; chr6:28057708 chr6:28170845~28172521:+ PAAD cis rs748404 0.556 rs7166467 ENSG00000205771.5 CATSPER2P1 3.89 0.000151 0.0457 0.38 0.3 Lung cancer; chr15:43148324 chr15:43726918~43747094:- PAAD cis rs7572733 0.555 rs11903129 ENSG00000231621.1 AC013264.2 -3.89 0.000151 0.0457 -0.31 -0.3 Dermatomyositis; chr2:198053867 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs2342558 ENSG00000231621.1 AC013264.2 -3.89 0.000151 0.0457 -0.31 -0.3 Dermatomyositis; chr2:198055418 chr2:197197991~197199273:+ PAAD cis rs7572733 0.515 rs13382697 ENSG00000231621.1 AC013264.2 -3.89 0.000151 0.0457 -0.31 -0.3 Dermatomyositis; chr2:198055836 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs35563720 ENSG00000231621.1 AC013264.2 -3.89 0.000151 0.0457 -0.31 -0.3 Dermatomyositis; chr2:198058351 chr2:197197991~197199273:+ PAAD cis rs7264396 0.779 rs2425162 ENSG00000207635.1 MIR499A -3.89 0.000151 0.0457 -0.39 -0.3 Total cholesterol levels; chr20:35842052 chr20:34990376~34990497:+ PAAD cis rs7615952 0.688 rs17334074 ENSG00000171084.14 FAM86JP -3.89 0.000151 0.0457 -0.39 -0.3 Blood pressure (smoking interaction); chr3:125821617 chr3:125916620~125930024:+ PAAD cis rs1873386 0.948 rs990348 ENSG00000255910.1 RP11-405A12.2 3.89 0.000151 0.0457 0.43 0.3 Personality dimensions; chr12:18909955 chr12:19775451~20009937:+ PAAD cis rs867371 0.717 rs3858954 ENSG00000255769.6 GOLGA2P10 -3.89 0.000151 0.0457 -0.28 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82265693 chr15:82472993~82513950:- PAAD cis rs4432245 0.793 rs711906 ENSG00000248508.5 SRP14-AS1 -3.89 0.000151 0.0457 -0.56 -0.3 Body mass index; chr15:40033490 chr15:40039311~40067290:+ PAAD cis rs7078219 0.543 rs7092009 ENSG00000228778.1 RP11-129J12.1 -3.89 0.000151 0.0457 -0.32 -0.3 Dental caries; chr10:99517482 chr10:99527081~99528261:+ PAAD cis rs7692387 0.704 rs34914832 ENSG00000260244.1 RP11-588K22.2 3.89 0.000151 0.0457 0.31 0.3 Coronary artery disease; chr4:155704926 chr4:155734448~155737062:+ PAAD cis rs7143963 0.58 rs3783385 ENSG00000259775.1 RP11-45P15.4 -3.89 0.000151 0.0458 -0.39 -0.3 Body mass index; chr14:102901330 chr14:103331674~103332367:- PAAD cis rs7143963 0.609 rs3783386 ENSG00000259775.1 RP11-45P15.4 -3.89 0.000151 0.0458 -0.39 -0.3 Body mass index; chr14:102901371 chr14:103331674~103332367:- PAAD cis rs748404 0.666 rs34178146 ENSG00000205771.5 CATSPER2P1 -3.89 0.000151 0.0458 -0.5 -0.3 Lung cancer; chr15:43384406 chr15:43726918~43747094:- PAAD cis rs28374715 0.532 rs28477406 ENSG00000247556.5 OIP5-AS1 3.89 0.000151 0.0458 0.32 0.3 Ulcerative colitis; chr15:41349838 chr15:41283990~41309737:+ PAAD cis rs7615952 0.932 rs13065725 ENSG00000241288.6 RP11-379B18.5 -3.89 0.000151 0.0458 -0.32 -0.3 Blood pressure (smoking interaction); chr3:125913446 chr3:125827238~125916384:- PAAD cis rs7615952 0.551 rs6438945 ENSG00000241288.6 RP11-379B18.5 -3.89 0.000151 0.0458 -0.32 -0.3 Blood pressure (smoking interaction); chr3:125915630 chr3:125827238~125916384:- PAAD cis rs7615952 0.673 rs7632557 ENSG00000241288.6 RP11-379B18.5 -3.89 0.000151 0.0458 -0.32 -0.3 Blood pressure (smoking interaction); chr3:125916038 chr3:125827238~125916384:- PAAD cis rs7615952 0.932 rs9841157 ENSG00000241288.6 RP11-379B18.5 -3.89 0.000151 0.0458 -0.32 -0.3 Blood pressure (smoking interaction); chr3:125916812 chr3:125827238~125916384:- PAAD cis rs7615952 0.551 rs12695470 ENSG00000241288.6 RP11-379B18.5 -3.89 0.000151 0.0458 -0.32 -0.3 Blood pressure (smoking interaction); chr3:125916875 chr3:125827238~125916384:- PAAD cis rs871012 0.542 rs58995342 ENSG00000248544.2 CTB-47B11.3 -3.89 0.000151 0.0458 -0.39 -0.3 IgG glycosylation; chr5:157401332 chr5:157375741~157384950:- PAAD cis rs5167 0.82 rs204468 ENSG00000280087.1 CTB-129P6.7 -3.89 0.000151 0.0458 -0.38 -0.3 Blood protein levels; chr19:44987378 chr19:44909375~44914968:+ PAAD cis rs5167 0.789 rs204467 ENSG00000280087.1 CTB-129P6.7 -3.89 0.000151 0.0458 -0.38 -0.3 Blood protein levels; chr19:44987916 chr19:44909375~44914968:+ PAAD cis rs1823913 0.927 rs35339956 ENSG00000227542.1 AC092614.2 3.89 0.000151 0.0458 0.38 0.3 Obesity-related traits; chr2:191261668 chr2:191229165~191246172:- PAAD cis rs1823913 0.927 rs56209234 ENSG00000227542.1 AC092614.2 3.89 0.000151 0.0458 0.38 0.3 Obesity-related traits; chr2:191261748 chr2:191229165~191246172:- PAAD cis rs7119038 0.818 rs4936444 ENSG00000255239.1 AP002954.6 3.89 0.000151 0.0458 0.45 0.3 Sjögren's syndrome; chr11:118872629 chr11:118688039~118690600:- PAAD cis rs7246657 0.653 rs4805208 ENSG00000267422.1 CTD-2554C21.1 -3.89 0.000151 0.0458 -0.58 -0.3 Coronary artery calcification; chr19:37183357 chr19:37779686~37792865:+ PAAD cis rs41369048 0.669 rs11589654 ENSG00000257551.1 HLX-AS1 -3.89 0.000151 0.0458 -0.44 -0.3 Eosinophil counts;Sum eosinophil basophil counts; chr1:220866646 chr1:220832763~220880140:- PAAD cis rs950169 0.922 rs4586394 ENSG00000259683.1 RP11-182J1.14 -3.89 0.000151 0.0458 -0.25 -0.3 Schizophrenia; chr15:84153633 chr15:84389729~84395903:+ PAAD cis rs875971 0.825 rs6951503 ENSG00000232559.3 GS1-124K5.12 -3.89 0.000151 0.0458 -0.34 -0.3 Aortic root size; chr7:66253949 chr7:66554588~66576923:- PAAD cis rs4713118 0.505 rs276371 ENSG00000219891.2 ZSCAN12P1 3.89 0.000151 0.0458 0.4 0.3 Parkinson's disease; chr6:27942930 chr6:28091154~28093664:+ PAAD cis rs11997175 0.603 rs6468199 ENSG00000240738.1 RP1-273G13.1 3.89 0.000151 0.0458 0.36 0.3 Body mass index; chr8:33881252 chr8:33859480~33860223:- PAAD cis rs2011013 0.6 rs62027787 ENSG00000274128.1 RP11-342A23.2 -3.89 0.000151 0.0458 -0.53 -0.3 Sitting height ratio; chr15:83924226 chr15:83962176~83962583:+ PAAD cis rs3892715 0.521 rs2720896 ENSG00000214145.5 LINC00887 -3.89 0.000151 0.0459 -0.36 -0.3 Attention deficit hyperactivity disorder (time to onset); chr3:195043674 chr3:194296465~194312803:- PAAD cis rs4835473 0.742 rs7695853 ENSG00000251600.4 RP11-673E1.1 3.89 0.000151 0.0459 0.35 0.3 Immature fraction of reticulocytes; chr4:143883243 chr4:143912331~143982454:+ PAAD cis rs4218 0.813 rs8036907 ENSG00000259732.1 RP11-59H7.3 -3.89 0.000151 0.0459 -0.39 -0.3 Social communication problems; chr15:59121144 chr15:59121034~59133250:+ PAAD cis rs7040386 0.639 rs10816032 ENSG00000225706.1 PTPRD-AS1 -3.89 0.000151 0.0459 -0.48 -0.3 Pediatric bone mineral content (radius); chr9:9009303 chr9:8858130~8862255:+ PAAD cis rs847577 0.609 rs11768309 ENSG00000272950.1 RP11-307C18.1 3.89 0.000151 0.0459 0.38 0.3 Breast cancer; chr7:98144500 chr7:98322853~98323430:+ PAAD cis rs8026198 0.929 rs4923940 ENSG00000260571.1 BNIP3P5 3.89 0.000151 0.0459 0.49 0.3 Fibrinogen levels; chr15:42293176 chr15:42313687~42314386:+ PAAD cis rs8026198 0.929 rs1359004 ENSG00000260571.1 BNIP3P5 -3.89 0.000151 0.0459 -0.49 -0.3 Fibrinogen levels; chr15:42364857 chr15:42313687~42314386:+ PAAD cis rs12586317 0.576 rs10143314 ENSG00000258704.4 SRP54-AS1 3.89 0.000152 0.0459 0.29 0.3 Psoriasis; chr14:35168698 chr14:34920858~34982532:- PAAD cis rs6929812 0.639 rs7754724 ENSG00000271755.1 RP1-153G14.4 3.89 0.000152 0.0459 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27483018 chr6:27404010~27406964:- PAAD cis rs9393813 0.528 rs13207497 ENSG00000271755.1 RP1-153G14.4 3.89 0.000152 0.0459 0.34 0.3 Bipolar disorder; chr6:27489601 chr6:27404010~27406964:- PAAD cis rs9393813 0.528 rs6903282 ENSG00000271755.1 RP1-153G14.4 3.89 0.000152 0.0459 0.34 0.3 Bipolar disorder; chr6:27498933 chr6:27404010~27406964:- PAAD cis rs755249 0.753 rs72663529 ENSG00000228060.1 RP11-69E11.8 -3.89 0.000152 0.0459 -0.28 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557684 chr1:39565160~39573203:+ PAAD cis rs2777491 0.507 rs11854081 ENSG00000247556.5 OIP5-AS1 3.89 0.000152 0.0459 0.31 0.3 Ulcerative colitis; chr15:41354200 chr15:41283990~41309737:+ PAAD cis rs763121 0.819 rs138700 ENSG00000228274.3 RP3-508I15.9 -3.89 0.000152 0.046 -0.29 -0.3 Menopause (age at onset); chr22:38733994 chr22:38667585~38681820:- PAAD cis rs12935418 0.83 rs7188549 ENSG00000261838.4 RP11-303E16.6 3.89 0.000152 0.046 0.54 0.3 Mean corpuscular volume; chr16:81016371 chr16:81069854~81076598:+ PAAD cis rs12935418 0.83 rs7195459 ENSG00000261838.4 RP11-303E16.6 3.89 0.000152 0.046 0.54 0.3 Mean corpuscular volume; chr16:81016376 chr16:81069854~81076598:+ PAAD cis rs7539624 0.577 rs1153944 ENSG00000272645.2 RP11-504P24.8 -3.89 0.000152 0.046 -0.26 -0.3 Schizophrenia; chr1:223782623 chr1:223951388~223953439:- PAAD cis rs9487094 0.626 rs1322124 ENSG00000260273.1 RP11-425D10.10 3.89 0.000152 0.046 0.36 0.3 Height; chr6:109741670 chr6:109382795~109383666:+ PAAD cis rs7927592 0.956 rs10896343 ENSG00000212093.1 AP000807.1 3.89 0.000152 0.046 0.35 0.3 Total body bone mineral density; chr11:68550392 chr11:68506083~68506166:- PAAD cis rs528301 0.833 rs564207 ENSG00000259439.2 RP11-89K21.1 3.89 0.000152 0.046 0.4 0.3 Alcohol and nicotine co-dependence; chr2:44909603 chr2:44921077~44939199:- PAAD cis rs17772222 0.917 rs61984708 ENSG00000258983.2 RP11-507K2.2 3.89 0.000152 0.0461 0.41 0.3 Coronary artery calcification; chr14:88565523 chr14:88499334~88515502:+ PAAD cis rs6540731 1 rs7518329 ENSG00000229983.1 RP11-15I11.2 3.89 0.000152 0.0461 0.34 0.3 Intelligence (childhood); chr1:212225191 chr1:212168207~212190259:+ PAAD cis rs10932679 0.901 rs72958213 ENSG00000229352.1 AC007563.3 3.89 0.000152 0.0461 0.37 0.3 Pulse pressure; chr2:216781800 chr2:216799608~216805335:+ PAAD cis rs5769765 1 rs5770728 ENSG00000278869.1 CITF22-49E9.3 -3.89 0.000152 0.0461 -0.43 -0.3 Schizophrenia; chr22:49866336 chr22:49933198~49934074:- PAAD cis rs2179367 0.92 rs560051 ENSG00000231760.4 RP11-350J20.5 3.89 0.000152 0.0461 0.39 0.3 Dupuytren's disease; chr6:149345841 chr6:149796151~149826294:- PAAD cis rs12439619 1 rs35152457 ENSG00000276710.3 CSPG4P8 -3.89 0.000152 0.0461 -0.29 -0.3 Intelligence (multi-trait analysis); chr15:82254207 chr15:82459472~82477258:+ PAAD cis rs9322193 0.923 rs7767622 ENSG00000268592.3 RAET1E-AS1 3.89 0.000152 0.0461 0.35 0.3 Lung cancer; chr6:149681766 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs3798761 ENSG00000268592.3 RAET1E-AS1 3.89 0.000152 0.0461 0.35 0.3 Lung cancer; chr6:149683643 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs9322210 ENSG00000268592.3 RAET1E-AS1 3.89 0.000152 0.0461 0.35 0.3 Lung cancer; chr6:149695440 chr6:149863494~149919507:+ PAAD cis rs12291225 0.535 rs10832248 ENSG00000251991.1 RNU7-49P 3.89 0.000152 0.0461 0.36 0.3 Sense of smell; chr11:14391541 chr11:14478892~14478953:+ PAAD cis rs755249 0.614 rs10888798 ENSG00000243970.1 PPIEL -3.88 0.000152 0.0461 -0.27 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39492408 chr1:39531838~39558707:- PAAD cis rs748404 0.666 rs34178146 ENSG00000249839.1 AC011330.5 -3.88 0.000152 0.0461 -0.52 -0.3 Lung cancer; chr15:43384406 chr15:43663654~43684339:- PAAD cis rs9309473 0.948 rs11884776 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73519796 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs10207220 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73557919 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs9653557 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73568835 chr2:73644919~73685576:+ PAAD cis rs9309473 0.898 rs10185080 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73570380 chr2:73644919~73685576:+ PAAD cis rs9309473 0.898 rs10197755 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73570496 chr2:73644919~73685576:+ PAAD cis rs9309473 0.848 rs17009159 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73570635 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs7586463 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73571349 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs1114380 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73577581 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs6745368 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73582847 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs13432605 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73583854 chr2:73644919~73685576:+ PAAD cis rs9309473 0.848 rs9750915 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73584753 chr2:73644919~73685576:+ PAAD cis rs9309473 0.898 rs28879089 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73585759 chr2:73644919~73685576:+ PAAD cis rs9309473 0.948 rs10173534 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73586305 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs7582606 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73586818 chr2:73644919~73685576:+ PAAD cis rs9309473 0.948 rs7603647 ENSG00000163016.8 ALMS1P 3.88 0.000152 0.0461 0.43 0.3 Metabolite levels; chr2:73590111 chr2:73644919~73685576:+ PAAD cis rs7260598 0.539 rs11670271 ENSG00000268442.1 CTD-2027I19.2 3.88 0.000152 0.0461 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23883921 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs11670335 ENSG00000268442.1 CTD-2027I19.2 3.88 0.000152 0.0461 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23884108 chr19:24162370~24163425:- PAAD cis rs7260598 0.539 rs11672509 ENSG00000268442.1 CTD-2027I19.2 3.88 0.000152 0.0461 0.49 0.3 Response to taxane treatment (placlitaxel); chr19:23885967 chr19:24162370~24163425:- PAAD cis rs7302981 0.719 rs835592 ENSG00000272368.2 RP4-605O3.4 3.88 0.000152 0.0461 0.3 0.3 Systolic blood pressure; chr12:50067048 chr12:50112197~50165618:+ PAAD cis rs9876781 0.563 rs4858821 ENSG00000229759.1 MRPS18AP1 -3.88 0.000152 0.0461 -0.34 -0.3 Longevity; chr3:48512515 chr3:48256350~48256938:- PAAD cis rs6480314 1 rs3814184 ENSG00000233590.1 RP11-153K11.3 -3.88 0.000152 0.0461 -0.46 -0.3 Optic nerve measurement (disc area); chr10:68206494 chr10:68233251~68242379:- PAAD cis rs11048470 0.614 rs8311 ENSG00000256234.1 RP11-283G6.4 -3.88 0.000153 0.0461 -0.35 -0.3 Waist-hip ratio; chr12:26337157 chr12:26211164~26335856:- PAAD cis rs10783487 0.895 rs4762049 ENSG00000257542.4 OR7E47P -3.88 0.000153 0.0462 -0.4 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52092455 chr12:52079696~52108261:+ PAAD cis rs10783487 0.895 rs7134974 ENSG00000257542.4 OR7E47P -3.88 0.000153 0.0462 -0.4 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr12:52093175 chr12:52079696~52108261:+ PAAD cis rs7119038 0.865 rs7951740 ENSG00000255239.1 AP002954.6 3.88 0.000153 0.0462 0.46 0.3 Sjögren's syndrome; chr11:118869709 chr11:118688039~118690600:- PAAD cis rs7119038 0.865 rs7117261 ENSG00000255239.1 AP002954.6 3.88 0.000153 0.0462 0.46 0.3 Sjögren's syndrome; chr11:118870448 chr11:118688039~118690600:- PAAD cis rs7119038 0.865 rs4938573 ENSG00000255239.1 AP002954.6 3.88 0.000153 0.0462 0.46 0.3 Sjögren's syndrome; chr11:118871133 chr11:118688039~118690600:- PAAD cis rs11098499 0.863 rs17050695 ENSG00000248280.1 RP11-33B1.2 3.88 0.000153 0.0462 0.32 0.3 Corneal astigmatism; chr4:119568372 chr4:119440561~119450157:- PAAD cis rs7225151 0.901 rs75511804 ENSG00000234327.6 AC012146.7 -3.88 0.000153 0.0462 -0.33 -0.3 Alzheimer's disease (late onset); chr17:5235009 chr17:5111468~5115004:+ PAAD cis rs16849225 0.526 rs11678269 ENSG00000277998.1 RP11-452N17.1 -3.88 0.000153 0.0462 -0.33 -0.3 Systolic blood pressure;Blood pressure; chr2:163997307 chr2:164573741~164574054:+ PAAD cis rs7119038 0.779 rs73005502 ENSG00000255239.1 AP002954.6 -3.88 0.000153 0.0462 -0.45 -0.3 Sjögren's syndrome; chr11:118827197 chr11:118688039~118690600:- PAAD cis rs771998 0.909 rs4762039 ENSG00000261308.1 FIGNL2 3.88 0.000153 0.0462 0.42 0.3 Post bronchodilator FEV1/FVC ratio; chr12:51993553 chr12:51820459~51822415:- PAAD cis rs7572733 0.576 rs4850441 ENSG00000231621.1 AC013264.2 3.88 0.000153 0.0462 0.31 0.3 Dermatomyositis; chr2:198048689 chr2:197197991~197199273:+ PAAD cis rs7572733 0.555 rs2164071 ENSG00000231621.1 AC013264.2 -3.88 0.000153 0.0462 -0.31 -0.3 Dermatomyositis; chr2:198050743 chr2:197197991~197199273:+ PAAD cis rs919433 0.68 rs7582536 ENSG00000231621.1 AC013264.2 3.88 0.000153 0.0462 0.29 0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197571379 chr2:197197991~197199273:+ PAAD cis rs2554380 0.628 rs7179507 ENSG00000230373.7 GOLGA6L5P -3.88 0.000153 0.0463 -0.3 -0.3 Height; chr15:83804779 chr15:84507885~84516814:- PAAD cis rs11690935 0.61 rs3770458 ENSG00000228389.1 AC068039.4 -3.88 0.000153 0.0463 -0.36 -0.3 Schizophrenia; chr2:171794777 chr2:171773482~171775844:+ PAAD cis rs8031584 0.678 rs798125 ENSG00000260382.1 RP11-540B6.2 -3.88 0.000153 0.0463 -0.39 -0.3 Huntington's disease progression; chr15:30824597 chr15:30882267~30883231:- PAAD cis rs8031584 0.697 rs798080 ENSG00000260382.1 RP11-540B6.2 -3.88 0.000153 0.0463 -0.39 -0.3 Huntington's disease progression; chr15:30829966 chr15:30882267~30883231:- PAAD cis rs7246657 0.598 rs10417545 ENSG00000267422.1 CTD-2554C21.1 -3.88 0.000153 0.0463 -0.57 -0.3 Coronary artery calcification; chr19:37163361 chr19:37779686~37792865:+ PAAD cis rs7246657 0.598 rs28660259 ENSG00000267422.1 CTD-2554C21.1 -3.88 0.000153 0.0463 -0.57 -0.3 Coronary artery calcification; chr19:37167779 chr19:37779686~37792865:+ PAAD cis rs2688608 0.592 rs10762563 ENSG00000271816.1 BMS1P4 3.88 0.000153 0.0463 0.31 0.3 Inflammatory bowel disease; chr10:73765044 chr10:73699151~73730487:- PAAD cis rs4879656 0.966 rs1016673 ENSG00000231193.1 RP11-462B18.2 -3.88 0.000153 0.0463 -0.35 -0.3 Menopause (age at onset); chr9:32982450 chr9:32840598~32841762:- PAAD cis rs4879656 0.966 rs1016674 ENSG00000231193.1 RP11-462B18.2 -3.88 0.000153 0.0463 -0.35 -0.3 Menopause (age at onset); chr9:32982689 chr9:32840598~32841762:- PAAD cis rs853679 0.882 rs2743555 ENSG00000204709.4 LINC01556 3.88 0.000153 0.0463 0.54 0.3 Depression; chr6:28273304 chr6:28943877~28944537:+ PAAD cis rs853679 1 rs1419183 ENSG00000204709.4 LINC01556 3.88 0.000153 0.0463 0.54 0.3 Depression; chr6:28275017 chr6:28943877~28944537:+ PAAD cis rs7899628 1 rs7899628 ENSG00000226864.1 ATE1-AS1 -3.88 0.000153 0.0464 -0.4 -0.3 Breast cancer; chr10:121904429 chr10:121928312~121951965:+ PAAD cis rs216345 0.966 rs1971430 ENSG00000230074.1 RP11-195F19.9 3.88 0.000153 0.0464 0.41 0.3 Bipolar disorder; chr9:33782377 chr9:34665665~34681298:+ PAAD cis rs7674212 0.541 rs2623070 ENSG00000230069.3 LRRC37A15P 3.88 0.000153 0.0464 0.3 0.3 Type 2 diabetes; chr4:103116231 chr4:102727274~102730721:- PAAD cis rs7674212 0.541 rs2045746 ENSG00000230069.3 LRRC37A15P 3.88 0.000153 0.0464 0.3 0.3 Type 2 diabetes; chr4:103162421 chr4:102727274~102730721:- PAAD cis rs7674212 0.541 rs2720458 ENSG00000230069.3 LRRC37A15P -3.88 0.000153 0.0464 -0.3 -0.3 Type 2 diabetes; chr4:103131806 chr4:102727274~102730721:- PAAD cis rs7674212 0.541 rs2720464 ENSG00000230069.3 LRRC37A15P -3.88 0.000153 0.0464 -0.3 -0.3 Type 2 diabetes; chr4:103152044 chr4:102727274~102730721:- PAAD cis rs7674212 0.51 rs2720468 ENSG00000230069.3 LRRC37A15P -3.88 0.000153 0.0464 -0.3 -0.3 Type 2 diabetes; chr4:103163996 chr4:102727274~102730721:- PAAD cis rs7674212 0.541 rs4699050 ENSG00000230069.3 LRRC37A15P -3.88 0.000153 0.0464 -0.3 -0.3 Type 2 diabetes; chr4:103193140 chr4:102727274~102730721:- PAAD cis rs7674212 0.541 rs17217473 ENSG00000230069.3 LRRC37A15P -3.88 0.000153 0.0464 -0.3 -0.3 Type 2 diabetes; chr4:103193585 chr4:102727274~102730721:- PAAD cis rs7520050 0.966 rs1768816 ENSG00000280836.1 AL355480.1 3.88 0.000154 0.0464 0.34 0.3 Reticulocyte count;Red blood cell count; chr1:46062927 chr1:45581219~45581321:- PAAD cis rs7302981 0.719 rs836188 ENSG00000272368.2 RP4-605O3.4 3.88 0.000154 0.0464 0.3 0.3 Systolic blood pressure; chr12:50067569 chr12:50112197~50165618:+ PAAD cis rs7302981 0.719 rs836189 ENSG00000272368.2 RP4-605O3.4 3.88 0.000154 0.0464 0.3 0.3 Systolic blood pressure; chr12:50067715 chr12:50112197~50165618:+ PAAD cis rs9487094 0.67 rs729888 ENSG00000260273.1 RP11-425D10.10 -3.88 0.000154 0.0464 -0.36 -0.3 Height; chr6:109636120 chr6:109382795~109383666:+ PAAD cis rs3015497 0.616 rs3825571 ENSG00000270062.1 RP11-248J18.3 3.88 0.000154 0.0465 0.29 0.3 Mean platelet volume; chr14:50585400 chr14:50723777~50724272:- PAAD cis rs3015497 0.616 rs1494181 ENSG00000270062.1 RP11-248J18.3 3.88 0.000154 0.0465 0.29 0.3 Mean platelet volume; chr14:50589882 chr14:50723777~50724272:- PAAD cis rs2412819 0.571 rs678084 ENSG00000249839.1 AC011330.5 3.88 0.000154 0.0465 0.46 0.3 Lung cancer; chr15:43828361 chr15:43663654~43684339:- PAAD cis rs28374715 0.681 rs77187862 ENSG00000247556.5 OIP5-AS1 3.88 0.000154 0.0465 0.31 0.3 Ulcerative colitis; chr15:41327078 chr15:41283990~41309737:+ PAAD cis rs755249 0.51 rs582883 ENSG00000228060.1 RP11-69E11.8 -3.88 0.000154 0.0465 -0.28 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39369868 chr1:39565160~39573203:+ PAAD cis rs7674212 0.541 rs11727498 ENSG00000230069.3 LRRC37A15P -3.88 0.000154 0.0465 -0.3 -0.3 Type 2 diabetes; chr4:103179830 chr4:102727274~102730721:- PAAD cis rs9393813 0.528 rs6901629 ENSG00000271755.1 RP1-153G14.4 3.88 0.000154 0.0465 0.35 0.3 Bipolar disorder; chr6:27380029 chr6:27404010~27406964:- PAAD cis rs4849303 0.967 rs4849310 ENSG00000204588.5 LINC01123 3.88 0.000154 0.0465 0.31 0.3 Colorectal cancer (diet interaction); chr2:110978355 chr2:109987063~109996140:+ PAAD cis rs595244 1 rs11638586 ENSG00000259705.1 RP11-227D13.1 3.88 0.000154 0.0465 0.49 0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr15:48480646 chr15:48645951~48652016:+ PAAD cis rs7829975 0.742 rs1533058 ENSG00000254340.1 RP11-10A14.3 3.88 0.000154 0.0465 0.36 0.3 Mood instability; chr8:8827680 chr8:9141424~9145435:+ PAAD cis rs9309473 1 rs11899740 ENSG00000163016.8 ALMS1P 3.88 0.000154 0.0465 0.42 0.3 Metabolite levels; chr2:73404084 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs6755217 ENSG00000163016.8 ALMS1P 3.88 0.000154 0.0465 0.42 0.3 Metabolite levels; chr2:73414157 chr2:73644919~73685576:+ PAAD cis rs9309473 1 rs6736866 ENSG00000163016.8 ALMS1P 3.88 0.000154 0.0465 0.42 0.3 Metabolite levels; chr2:73434858 chr2:73644919~73685576:+ PAAD cis rs17507216 1 rs3850610 ENSG00000276710.3 CSPG4P8 3.88 0.000154 0.0465 0.32 0.3 Excessive daytime sleepiness; chr15:82552642 chr15:82459472~82477258:+ PAAD cis rs4604732 0.536 rs4925674 ENSG00000227135.1 GCSAML-AS1 -3.88 0.000154 0.0465 -0.43 -0.3 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid); chr1:247473604 chr1:247524679~247526752:- PAAD cis rs11159086 0.793 rs11845370 ENSG00000270000.1 RP3-449M8.9 3.88 0.000154 0.0465 0.45 0.3 Advanced glycation end-product levels; chr14:74481587 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs11850070 ENSG00000270000.1 RP3-449M8.9 3.88 0.000154 0.0465 0.45 0.3 Advanced glycation end-product levels; chr14:74487575 chr14:74471930~74472360:- PAAD cis rs11159086 0.793 rs28378078 ENSG00000270000.1 RP3-449M8.9 3.88 0.000154 0.0465 0.45 0.3 Advanced glycation end-product levels; chr14:74487940 chr14:74471930~74472360:- PAAD cis rs73019876 0.712 rs1859092 ENSG00000268433.1 RP11-420K14.2 3.88 0.000154 0.0465 0.35 0.3 Testicular germ cell tumor; chr19:21960639 chr19:21677550~21678221:- PAAD cis rs7592578 0.825 rs12477369 ENSG00000231858.4 AC067945.4 3.88 0.000154 0.0465 0.36 0.3 Diastolic blood pressure; chr2:190590898 chr2:191021526~191032314:+ PAAD cis rs7119038 0.818 rs7942535 ENSG00000255239.1 AP002954.6 3.88 0.000154 0.0466 0.42 0.3 Sjögren's syndrome; chr11:118810755 chr11:118688039~118690600:- PAAD cis rs9309473 1 rs7580825 ENSG00000163016.8 ALMS1P 3.88 0.000154 0.0466 0.41 0.3 Metabolite levels; chr2:73408020 chr2:73644919~73685576:+ PAAD cis rs17680741 0.697 rs2343550 ENSG00000230091.5 TMEM254-AS1 -3.88 0.000154 0.0466 -0.37 -0.3 Coronary artery disease; chr10:80504667 chr10:80046860~80078912:- PAAD cis rs17680741 0.697 rs12269333 ENSG00000230091.5 TMEM254-AS1 -3.88 0.000154 0.0466 -0.37 -0.3 Coronary artery disease; chr10:80507049 chr10:80046860~80078912:- PAAD cis rs350251 0.817 rs4781183 ENSG00000263307.1 RP11-166B2.8 3.88 0.000154 0.0466 0.27 0.3 Intelligence (multi-trait analysis); chr16:12114469 chr16:11851649~11895611:+ PAAD cis rs7615952 0.673 rs115942855 ENSG00000239804.1 RP11-379B18.1 3.88 0.000154 0.0466 0.53 0.3 Blood pressure (smoking interaction); chr3:125883117 chr3:125787888~125788146:- PAAD cis rs9517313 0.591 rs9554480 ENSG00000231194.1 FARP1-AS1 -3.88 0.000154 0.0466 -0.34 -0.3 Neuroticism; chr13:98568884 chr13:98435405~98435840:- PAAD cis rs2688608 0.592 rs7076585 ENSG00000271816.1 BMS1P4 3.88 0.000154 0.0466 0.31 0.3 Inflammatory bowel disease; chr10:73743934 chr10:73699151~73730487:- PAAD cis rs35000415 0.515 rs13240595 ENSG00000281490.1 CICP14 -3.88 0.000154 0.0466 -0.33 -0.3 Systemic lupus erythematosus; chr7:129091723 chr7:128655962~128658791:- PAAD cis rs2736345 0.672 rs2618473 ENSG00000255518.1 RP11-148O21.4 -3.88 0.000154 0.0466 -0.28 -0.3 Systemic lupus erythematosus;Sjögren's syndrome; chr8:11486618 chr8:11556251~11558022:- PAAD cis rs4725617 0.686 rs1804527 ENSG00000229153.4 EPHA1-AS1 -3.88 0.000154 0.0466 -0.67 -0.3 Blood protein levels; chr7:143391730 chr7:143407813~143523449:+ PAAD cis rs6030 0.789 rs9332596 ENSG00000213062.4 RP1-206D15.6 -3.88 0.000155 0.0466 -0.3 -0.3 Uric acid levels; chr1:169545099 chr1:169486076~169486986:+ PAAD cis rs763121 0.853 rs5750626 ENSG00000228274.3 RP3-508I15.9 -3.88 0.000155 0.0466 -0.29 -0.3 Menopause (age at onset); chr22:38581885 chr22:38667585~38681820:- PAAD cis rs35851103 0.6 rs4841662 ENSG00000227888.4 FAM66A -3.88 0.000155 0.0467 -0.37 -0.3 Neuroticism; chr8:11986249 chr8:12362019~12388296:+ PAAD cis rs8072100 0.676 rs7221345 ENSG00000228782.6 CTD-2026D20.3 3.88 0.000155 0.0467 0.33 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47327778 chr17:47450568~47492492:- PAAD cis rs8072100 0.676 rs9905308 ENSG00000228782.6 CTD-2026D20.3 3.88 0.000155 0.0467 0.33 0.3 Very long-chain saturated fatty acid levels (fatty acid 20:0); chr17:47332020 chr17:47450568~47492492:- PAAD cis rs3738443 0.599 rs6693807 ENSG00000259865.1 RP11-488L18.10 -3.88 0.000155 0.0467 -0.25 -0.3 Alcohol dependence; chr1:247230353 chr1:247187281~247188526:- PAAD cis rs30380 0.734 rs27044 ENSG00000248734.2 CTD-2260A17.1 3.88 0.000155 0.0467 0.29 0.3 Cerebrospinal fluid biomarker levels; chr5:96783148 chr5:96784777~96785999:+ PAAD cis rs30380 0.69 rs27432 ENSG00000248734.2 CTD-2260A17.1 3.88 0.000155 0.0467 0.29 0.3 Cerebrospinal fluid biomarker levels; chr5:96783569 chr5:96784777~96785999:+ PAAD cis rs30380 0.734 rs30376 ENSG00000248734.2 CTD-2260A17.1 3.88 0.000155 0.0467 0.29 0.3 Cerebrospinal fluid biomarker levels; chr5:96784555 chr5:96784777~96785999:+ PAAD cis rs2274273 0.967 rs10147667 ENSG00000258413.1 RP11-665C16.6 3.88 0.000155 0.0467 0.37 0.3 Protein biomarker; chr14:55104131 chr14:55262767~55272075:- PAAD cis rs302972 0.826 rs9461103 ENSG00000168405.13 CMAHP 3.88 0.000155 0.0467 0.41 0.3 Creatinine levels in ischemic stroke; chr6:25098888 chr6:25081068~25166555:- PAAD cis rs6782228 0.606 rs2253144 ENSG00000242551.2 POU5F1P6 3.88 0.000155 0.0467 0.35 0.3 Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts; chr3:128611077 chr3:128674735~128677005:- PAAD cis rs7617773 1 rs9832957 ENSG00000228638.1 FCF1P2 3.88 0.000155 0.0467 0.33 0.3 Coronary artery disease; chr3:48143776 chr3:48290793~48291375:- PAAD cis rs9487094 0.689 rs9487066 ENSG00000260273.1 RP11-425D10.10 3.88 0.000155 0.0467 0.36 0.3 Height; chr6:109347707 chr6:109382795~109383666:+ PAAD cis rs7503807 1 rs12936076 ENSG00000232083.3 RPL31P7 3.88 0.000155 0.0467 0.36 0.3 Obesity; chr17:80627395 chr17:80602549~80602926:- PAAD cis rs2243480 1 rs316327 ENSG00000228409.4 CCT6P1 -3.88 0.000155 0.0467 -0.32 -0.3 Diabetic kidney disease; chr7:66144214 chr7:65751142~65763354:+ PAAD cis rs4819052 0.851 rs1006779 ENSG00000223768.1 LINC00205 -3.88 0.000155 0.0468 -0.3 -0.3 Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes; chr21:45250837 chr21:45293285~45297354:+ PAAD cis rs6024905 1 rs6024905 ENSG00000224635.1 RP4-564F22.5 3.88 0.000155 0.0468 0.34 0.3 Bipolar disorder and schizophrenia; chr20:38329435 chr20:38406011~38416797:- PAAD cis rs10129255 0.701 rs2005643 ENSG00000223648.3 IGHV3-64 3.88 0.000155 0.0468 0.29 0.3 Kawasaki disease; chr14:106676288 chr14:106643132~106658258:- PAAD cis rs7617773 0.925 rs6442105 ENSG00000228638.1 FCF1P2 3.88 0.000155 0.0468 0.33 0.3 Coronary artery disease; chr3:48140836 chr3:48290793~48291375:- PAAD cis rs10838687 0.736 rs4647754 ENSG00000255007.1 CTD-2589M5.4 3.88 0.000155 0.0468 0.36 0.3 Proinsulin levels; chr11:47235789 chr11:46256355~46274547:- PAAD cis rs494459 0.536 rs7103067 ENSG00000255435.5 RP11-770J1.3 3.88 0.000155 0.0468 0.29 0.3 Height; chr11:118852670 chr11:118511911~118531094:- PAAD cis rs11098499 0.691 rs10010355 ENSG00000248280.1 RP11-33B1.2 3.88 0.000155 0.0468 0.27 0.3 Corneal astigmatism; chr4:119339888 chr4:119440561~119450157:- PAAD cis rs11098499 0.691 rs9307471 ENSG00000248280.1 RP11-33B1.2 3.88 0.000155 0.0468 0.27 0.3 Corneal astigmatism; chr4:119340107 chr4:119440561~119450157:- PAAD cis rs7078219 0.965 rs11190141 ENSG00000228778.1 RP11-129J12.1 -3.88 0.000155 0.0468 -0.33 -0.3 Dental caries; chr10:99532633 chr10:99527081~99528261:+ PAAD cis rs792448 0.743 rs11119904 ENSG00000229983.1 RP11-15I11.2 3.88 0.000155 0.0468 0.35 0.3 White blood cell count (basophil); chr1:212293262 chr1:212168207~212190259:+ PAAD cis rs1391511 1 rs1391511 ENSG00000151631.8 AKR1C6P -3.88 0.000155 0.0468 -0.38 -0.3 Major depressive disorder;Neonatal lupus; chr10:4677604 chr10:4871901~4891975:- PAAD cis rs4834272 0.662 rs2106993 ENSG00000260526.1 RP11-73K9.2 3.88 0.000155 0.0469 0.33 0.3 Body mass index; chr4:112383186 chr4:112229561~112231596:- PAAD cis rs4834272 0.662 rs6851489 ENSG00000260526.1 RP11-73K9.2 3.88 0.000155 0.0469 0.33 0.3 Body mass index; chr4:112384277 chr4:112229561~112231596:- PAAD cis rs4834272 0.662 rs12507761 ENSG00000260526.1 RP11-73K9.2 3.88 0.000155 0.0469 0.33 0.3 Body mass index; chr4:112384467 chr4:112229561~112231596:- PAAD cis rs6446731 1 rs6446731 ENSG00000261643.1 RP11-529E10.6 -3.88 0.000156 0.0469 -0.28 -0.3 Mean platelet volume; chr4:3283024 chr4:3503597~3504457:- PAAD cis rs10506328 0.509 rs1056010 ENSG00000248265.1 FLJ12825 3.88 0.000156 0.0469 0.26 0.3 Mean platelet volume; chr12:54232968 chr12:54058254~54122234:+ PAAD cis rs58873874 0.737 rs11134766 ENSG00000248544.2 CTB-47B11.3 3.88 0.000156 0.0469 0.65 0.3 Bipolar disorder (body mass index interaction); chr5:157481309 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs11134767 ENSG00000248544.2 CTB-47B11.3 3.88 0.000156 0.0469 0.65 0.3 Bipolar disorder (body mass index interaction); chr5:157481645 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs11466807 ENSG00000248544.2 CTB-47B11.3 3.88 0.000156 0.0469 0.65 0.3 Bipolar disorder (body mass index interaction); chr5:157487920 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs77273565 ENSG00000248544.2 CTB-47B11.3 3.88 0.000156 0.0469 0.65 0.3 Bipolar disorder (body mass index interaction); chr5:157489547 chr5:157375741~157384950:- PAAD cis rs58873874 0.737 rs111759027 ENSG00000248544.2 CTB-47B11.3 3.88 0.000156 0.0469 0.65 0.3 Bipolar disorder (body mass index interaction); chr5:157489628 chr5:157375741~157384950:- PAAD cis rs2288073 1 rs6708328 ENSG00000242628.4 AC009228.1 3.88 0.000156 0.0469 0.36 0.3 Venous thromboembolism (SNP x SNP interaction); chr2:24189544 chr2:24214381~24221516:+ PAAD cis rs6860540 0.796 rs6861100 ENSG00000251405.2 CTB-109A12.1 -3.88 0.000156 0.0469 -0.38 -0.3 Inflammatory skin disease; chr5:157504344 chr5:157362615~157460078:- PAAD cis rs6860540 0.796 rs17659250 ENSG00000251405.2 CTB-109A12.1 3.88 0.000156 0.0469 0.38 0.3 Inflammatory skin disease; chr5:157513865 chr5:157362615~157460078:- PAAD cis rs73081554 0.611 rs35975336 ENSG00000272360.1 RP11-359I18.5 -3.88 0.000156 0.0469 -0.5 -0.3 Rheumatoid arthritis; chr3:58465907 chr3:58490830~58491291:- PAAD cis rs911186 0.947 rs9379962 ENSG00000216901.1 AL022393.7 3.88 0.000156 0.047 0.4 0.3 Autism spectrum disorder or schizophrenia; chr6:27177532 chr6:28176188~28176674:+ PAAD cis rs5742933 0.681 rs4525728 ENSG00000273240.1 RP11-455J20.3 3.88 0.000156 0.047 0.36 0.3 Ferritin levels; chr2:189780324 chr2:189763859~189764456:- PAAD cis rs9322193 0.923 rs9322209 ENSG00000268592.3 RAET1E-AS1 3.88 0.000156 0.047 0.35 0.3 Lung cancer; chr6:149691226 chr6:149863494~149919507:+ PAAD cis rs9900062 0.586 rs35018407 ENSG00000270714.1 MINOS1P2 -3.88 0.000156 0.047 -0.41 -0.3 QT interval; chr17:64694063 chr17:64747264~64747492:- PAAD cis rs6951245 0.529 rs76001997 ENSG00000229043.2 AC091729.9 -3.88 0.000156 0.047 -0.41 -0.3 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1112979 chr7:1160374~1165267:+ PAAD cis rs6951245 0.554 rs79367977 ENSG00000229043.2 AC091729.9 -3.88 0.000156 0.047 -0.41 -0.3 C-reactive protein levels or total cholesterol levels (pleiotropy); chr7:1113021 chr7:1160374~1165267:+ PAAD cis rs6547741 0.844 rs7586655 ENSG00000234072.1 AC074117.10 -3.88 0.000156 0.047 -0.24 -0.3 Oral cavity cancer; chr2:27692792 chr2:27356246~27367622:+ PAAD cis rs9326248 0.861 rs1871757 ENSG00000280143.1 AP000892.6 3.88 0.000156 0.047 0.39 0.3 Blood protein levels; chr11:117159865 chr11:117204967~117210292:+ PAAD cis rs847577 0.609 rs6977321 ENSG00000272950.1 RP11-307C18.1 3.88 0.000156 0.047 0.38 0.3 Breast cancer; chr7:98145547 chr7:98322853~98323430:+ PAAD cis rs6465657 0.903 rs11767962 ENSG00000272950.1 RP11-307C18.1 3.88 0.000156 0.047 0.38 0.3 Prostate cancer;Prostate cancer (SNP x SNP interaction); chr7:98149264 chr7:98322853~98323430:+ PAAD cis rs375066 0.935 rs108775 ENSG00000267058.1 RP11-15A1.3 -3.88 0.000156 0.047 -0.27 -0.3 Breast cancer; chr19:43901770 chr19:43891804~43901805:- PAAD cis rs1790761 0.806 rs11601325 ENSG00000231793.4 DOC2GP -3.88 0.000156 0.047 -0.25 -0.3 Mean corpuscular volume; chr11:67459535 chr11:67612653~67616257:- PAAD cis rs338389 0.542 rs28694418 ENSG00000260657.2 RP11-315D16.4 -3.88 0.000156 0.0471 -0.35 -0.3 Survival in rectal cancer; chr15:67949855 chr15:68267792~68277994:- PAAD cis rs338389 0.542 rs12914946 ENSG00000260657.2 RP11-315D16.4 -3.88 0.000156 0.0471 -0.35 -0.3 Survival in rectal cancer; chr15:67949990 chr15:68267792~68277994:- PAAD cis rs30380 0.69 rs2216752 ENSG00000248734.2 CTD-2260A17.1 -3.88 0.000156 0.0471 -0.29 -0.3 Cerebrospinal fluid biomarker levels; chr5:96849764 chr5:96784777~96785999:+ PAAD cis rs2273156 0.929 rs4573843 ENSG00000258738.1 RP11-73E17.2 -3.88 0.000156 0.0471 -0.44 -0.3 Immunoglobulin light chain (AL) amyloidosis; chr14:34922563 chr14:34874343~34876459:+ PAAD cis rs5758511 0.68 rs5758699 ENSG00000226450.2 CYP2D8P 3.88 0.000156 0.0471 0.29 0.3 Birth weight; chr22:42292028 chr22:42149886~42155001:- PAAD cis rs6921919 0.697 rs6942030 ENSG00000204709.4 LINC01556 3.88 0.000156 0.0471 0.43 0.3 Autism spectrum disorder or schizophrenia; chr6:28348181 chr6:28943877~28944537:+ PAAD cis rs6565180 1 rs8049108 ENSG00000261487.1 AC135048.13 -3.88 0.000156 0.0471 -0.41 -0.3 Tonsillectomy; chr16:30365165 chr16:30948386~30956511:+ PAAD cis rs867371 1 rs7181655 ENSG00000255769.6 GOLGA2P10 -3.88 0.000156 0.0471 -0.28 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163275 chr15:82472993~82513950:- PAAD cis rs867371 1 rs7180584 ENSG00000255769.6 GOLGA2P10 -3.88 0.000156 0.0471 -0.28 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82163493 chr15:82472993~82513950:- PAAD cis rs867371 1 rs6495642 ENSG00000255769.6 GOLGA2P10 -3.88 0.000156 0.0471 -0.28 -0.3 Cognitive ability;Cognitive ability (multi-trait analysis); chr15:82165156 chr15:82472993~82513950:- PAAD cis rs12760731 0.511 rs10429850 ENSG00000273384.1 RP5-1098D14.1 -3.88 0.000156 0.0471 -0.42 -0.3 Obesity-related traits; chr1:178642865 chr1:178651706~178652282:+ PAAD cis rs11098499 0.698 rs4422403 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0471 0.27 0.3 Corneal astigmatism; chr4:119337039 chr4:119440561~119450157:- PAAD cis rs11098499 0.569 rs10023641 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0471 0.27 0.3 Corneal astigmatism; chr4:119337255 chr4:119440561~119450157:- PAAD cis rs11098499 0.644 rs3986377 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0471 0.27 0.3 Corneal astigmatism; chr4:119339115 chr4:119440561~119450157:- PAAD cis rs10028773 0.556 rs4473640 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0471 0.27 0.3 Educational attainment; chr4:119339282 chr4:119440561~119450157:- PAAD cis rs2742417 0.603 rs2742449 ENSG00000244357.3 RN7SL145P 3.88 0.000157 0.0472 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45723052 chr3:45742675~45742970:+ PAAD cis rs10540 1 rs61876335 ENSG00000255237.1 RP13-317D12.3 3.88 0.000157 0.0472 0.45 0.3 Body mass index; chr11:488878 chr11:462930~463899:- PAAD cis rs11098499 0.644 rs17517414 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119340946 chr4:119440561~119450157:- PAAD cis rs11098499 0.722 rs10006192 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119341867 chr4:119440561~119450157:- PAAD cis rs11098499 0.615 rs28551750 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119343746 chr4:119440561~119450157:- PAAD cis rs11098499 0.691 rs9995716 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119343841 chr4:119440561~119450157:- PAAD cis rs10028773 0.6 rs4001390 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Educational attainment; chr4:119344628 chr4:119440561~119450157:- PAAD cis rs11098499 0.691 rs2136911 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119344704 chr4:119440561~119450157:- PAAD cis rs11098499 0.554 rs2175381 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119344812 chr4:119440561~119450157:- PAAD cis rs11098499 0.599 rs3864142 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119345036 chr4:119440561~119450157:- PAAD cis rs11098499 0.605 rs6833140 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119345667 chr4:119440561~119450157:- PAAD cis rs11098499 0.779 rs6815934 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Corneal astigmatism; chr4:119346155 chr4:119440561~119450157:- PAAD cis rs10028773 0.568 rs6838457 ENSG00000248280.1 RP11-33B1.2 3.88 0.000157 0.0472 0.27 0.3 Educational attainment; chr4:119346212 chr4:119440561~119450157:- PAAD cis rs11098499 0.722 rs17595727 ENSG00000248280.1 RP11-33B1.2 -3.88 0.000157 0.0472 -0.27 -0.3 Corneal astigmatism; chr4:119340919 chr4:119440561~119450157:- PAAD cis rs2287838 0.638 rs62105751 ENSG00000267289.1 CTD-2623N2.11 3.88 0.000157 0.0472 0.34 0.3 Sleep duration; chr19:9847213 chr19:9834079~9835013:- PAAD cis rs7246657 0.508 rs1628959 ENSG00000267422.1 CTD-2554C21.1 -3.88 0.000157 0.0472 -0.55 -0.3 Coronary artery calcification; chr19:36999474 chr19:37779686~37792865:+ PAAD cis rs9309473 1 rs11674602 ENSG00000163016.8 ALMS1P 3.88 0.000157 0.0472 0.42 0.3 Metabolite levels; chr2:73496058 chr2:73644919~73685576:+ PAAD cis rs7674212 0.541 rs2720448 ENSG00000230069.3 LRRC37A15P -3.88 0.000157 0.0472 -0.3 -0.3 Type 2 diabetes; chr4:103109432 chr4:102727274~102730721:- PAAD cis rs7674212 0.541 rs2623064 ENSG00000230069.3 LRRC37A15P -3.88 0.000157 0.0472 -0.3 -0.3 Type 2 diabetes; chr4:103109635 chr4:102727274~102730721:- PAAD cis rs780096 0.506 rs1647285 ENSG00000234072.1 AC074117.10 -3.88 0.000157 0.0472 -0.23 -0.3 Total body bone mineral density; chr2:27491644 chr2:27356246~27367622:+ PAAD cis rs780096 0.506 rs1647286 ENSG00000234072.1 AC074117.10 -3.88 0.000157 0.0472 -0.23 -0.3 Total body bone mineral density; chr2:27491650 chr2:27356246~27367622:+ PAAD cis rs2408955 0.521 rs11168437 ENSG00000240399.1 RP1-228P16.1 3.88 0.000157 0.0472 0.33 0.3 Glycated hemoglobin levels; chr12:48172373 chr12:48054813~48055591:- PAAD cis rs375066 0.87 rs7258418 ENSG00000267058.1 RP11-15A1.3 -3.88 0.000157 0.0472 -0.27 -0.3 Breast cancer; chr19:43878931 chr19:43891804~43901805:- PAAD cis rs375066 0.935 rs396874 ENSG00000267058.1 RP11-15A1.3 -3.88 0.000157 0.0472 -0.27 -0.3 Breast cancer; chr19:43893073 chr19:43891804~43901805:- PAAD cis rs375066 0.935 rs397346 ENSG00000267058.1 RP11-15A1.3 -3.88 0.000157 0.0472 -0.27 -0.3 Breast cancer; chr19:43894963 chr19:43891804~43901805:- PAAD cis rs6142102 0.651 rs1015361 ENSG00000276073.1 RP5-1125A11.7 3.88 0.000157 0.0472 0.34 0.3 Skin pigmentation; chr20:34150880 chr20:33985617~33988989:- PAAD cis rs59104589 0.517 rs15129 ENSG00000229996.1 AC093585.6 3.88 0.000157 0.0472 0.49 0.3 Fibrinogen levels; chr2:241229561 chr2:241010045~241010744:- PAAD cis rs8012947 0.916 rs4901853 ENSG00000279636.2 LINC00216 3.88 0.000157 0.0472 0.29 0.3 Alcohol consumption in current drinkers; chr14:58382581 chr14:58288033~58289158:+ PAAD cis rs41278232 0.623 rs1999708 ENSG00000196421.6 LINC00176 3.88 0.000157 0.0473 0.35 0.3 Tonsillectomy; chr20:64040424 chr20:64034344~64039962:+ PAAD cis rs5769765 0.908 rs138889 ENSG00000278869.1 CITF22-49E9.3 3.88 0.000157 0.0473 0.44 0.3 Schizophrenia; chr22:49833025 chr22:49933198~49934074:- PAAD cis rs2562456 0.682 rs11085464 ENSG00000213976.4 CTD-2561J22.2 -3.88 0.000157 0.0473 -0.32 -0.3 Pain; chr19:21568976 chr19:21382865~21387177:+ PAAD cis rs2562456 0.876 rs11085467 ENSG00000213976.4 CTD-2561J22.2 -3.88 0.000157 0.0473 -0.32 -0.3 Pain; chr19:21569041 chr19:21382865~21387177:+ PAAD cis rs6840258 1 rs6840258 ENSG00000251411.1 RP11-397E7.4 -3.88 0.000157 0.0473 -0.34 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87052516 chr4:86913266~86914817:- PAAD cis rs28374715 0.681 rs7163989 ENSG00000247556.5 OIP5-AS1 3.88 0.000157 0.0473 0.31 0.3 Ulcerative colitis; chr15:41322423 chr15:41283990~41309737:+ PAAD cis rs28374715 0.681 rs59000092 ENSG00000247556.5 OIP5-AS1 3.88 0.000157 0.0473 0.31 0.3 Ulcerative colitis; chr15:41333950 chr15:41283990~41309737:+ PAAD cis rs28374715 0.681 rs11629979 ENSG00000247556.5 OIP5-AS1 3.88 0.000157 0.0473 0.31 0.3 Ulcerative colitis; chr15:41334381 chr15:41283990~41309737:+ PAAD cis rs28374715 0.681 rs8037574 ENSG00000247556.5 OIP5-AS1 3.88 0.000157 0.0473 0.31 0.3 Ulcerative colitis; chr15:41338572 chr15:41283990~41309737:+ PAAD cis rs6969780 0.545 rs983184 ENSG00000233429.8 HOTAIRM1 -3.88 0.000157 0.0473 -0.41 -0.3 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27148760 chr7:27095647~27100265:+ PAAD cis rs6969780 0.63 rs3735530 ENSG00000233429.8 HOTAIRM1 -3.88 0.000157 0.0473 -0.41 -0.3 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27150363 chr7:27095647~27100265:+ PAAD cis rs6969780 0.722 rs4722666 ENSG00000233429.8 HOTAIRM1 -3.88 0.000157 0.0473 -0.41 -0.3 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27157982 chr7:27095647~27100265:+ PAAD cis rs6969780 0.722 rs985652 ENSG00000233429.8 HOTAIRM1 -3.88 0.000157 0.0473 -0.41 -0.3 Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis); chr7:27158464 chr7:27095647~27100265:+ PAAD cis rs10411161 0.748 rs56705839 ENSG00000269483.1 AC006272.1 3.88 0.000157 0.0473 0.59 0.3 Breast cancer; chr19:51873983 chr19:51839924~51843324:- PAAD cis rs12908161 0.515 rs12907646 ENSG00000259728.4 LINC00933 3.88 0.000157 0.0473 0.41 0.3 Schizophrenia; chr15:84860265 chr15:84570649~84580175:+ PAAD cis rs17711722 0.503 rs453835 ENSG00000226002.1 RP11-460N20.5 -3.88 0.000157 0.0473 -0.31 -0.3 Calcium levels; chr7:66046172 chr7:65084103~65100232:+ PAAD cis rs10761482 0.5 rs4540900 ENSG00000254271.1 RP11-131N11.4 3.88 0.000157 0.0473 0.36 0.3 Schizophrenia; chr10:60548976 chr10:60734342~60741828:+ PAAD cis rs6929812 0.664 rs12529840 ENSG00000271755.1 RP1-153G14.4 3.88 0.000157 0.0473 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27426105 chr6:27404010~27406964:- PAAD cis rs4948275 0.55 rs10994742 ENSG00000237233.2 TMEM26-AS1 3.88 0.000157 0.0473 0.36 0.3 Night sleep phenotypes; chr10:61372482 chr10:61452639~61481956:+ PAAD cis rs4948275 0.55 rs7904815 ENSG00000237233.2 TMEM26-AS1 3.88 0.000157 0.0473 0.36 0.3 Night sleep phenotypes; chr10:61376854 chr10:61452639~61481956:+ PAAD cis rs3096299 0.781 rs3102381 ENSG00000274627.1 RP11-104N10.2 3.88 0.000157 0.0473 0.27 0.3 Multiple myeloma (IgH translocation); chr16:89343312 chr16:89516797~89522217:+ PAAD cis rs9322193 0.923 rs10782316 ENSG00000268592.3 RAET1E-AS1 3.88 0.000158 0.0473 0.35 0.3 Lung cancer; chr6:149752755 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs11155677 ENSG00000268592.3 RAET1E-AS1 3.88 0.000158 0.0473 0.35 0.3 Lung cancer; chr6:149756953 chr6:149863494~149919507:+ PAAD cis rs30380 0.506 rs469735 ENSG00000272109.1 CTD-2260A17.3 -3.88 0.000158 0.0474 -0.41 -0.3 Cerebrospinal fluid biomarker levels; chr5:96794311 chr5:96804353~96806105:+ PAAD cis rs13068223 0.84 rs11709829 ENSG00000243926.1 TIPARP-AS1 3.88 0.000158 0.0474 0.36 0.3 Age-related hearing impairment (SNP x SNP interaction); chr3:156716300 chr3:156671862~156674378:- PAAD cis rs7829975 0.514 rs2920991 ENSG00000253981.4 ALG1L13P 3.88 0.000158 0.0474 0.35 0.3 Mood instability; chr8:8401607 chr8:8236003~8244667:- PAAD cis rs2034650 0.544 rs8034217 ENSG00000223313.1 RNU6-516P -3.88 0.000158 0.0474 -0.4 -0.3 Interstitial lung disease; chr15:40429501 chr15:40529570~40529673:+ PAAD cis rs950169 1 rs12902672 ENSG00000275120.1 RP11-182J1.17 3.88 0.000158 0.0474 0.32 0.3 Schizophrenia; chr15:84048234 chr15:84599434~84606463:- PAAD cis rs950169 1 rs12903820 ENSG00000275120.1 RP11-182J1.17 3.88 0.000158 0.0474 0.32 0.3 Schizophrenia; chr15:84055068 chr15:84599434~84606463:- PAAD cis rs6061231 0.834 rs2427311 ENSG00000275437.1 RP5-908M14.10 3.88 0.000158 0.0474 0.27 0.3 Colorectal cancer; chr20:62395067 chr20:62402236~62405935:- PAAD cis rs763121 0.651 rs738249 ENSG00000228274.3 RP3-508I15.9 -3.88 0.000158 0.0474 -0.29 -0.3 Menopause (age at onset); chr22:38641974 chr22:38667585~38681820:- PAAD cis rs8127691 0.967 rs4380337 ENSG00000237604.1 AP001056.1 3.88 0.000158 0.0474 0.36 0.3 Inflammatory bowel disease; chr21:44196166 chr21:44175489~44176453:+ PAAD cis rs2011013 0.6 rs34047645 ENSG00000274128.1 RP11-342A23.2 -3.88 0.000158 0.0474 -0.5 -0.3 Sitting height ratio; chr15:83942615 chr15:83962176~83962583:+ PAAD cis rs2337406 0.866 rs4583128 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106780669 chr14:106643132~106658258:- PAAD cis rs2337406 0.929 rs12050200 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106780983 chr14:106643132~106658258:- PAAD cis rs2337406 0.852 rs12050239 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781132 chr14:106643132~106658258:- PAAD cis rs2337406 0.929 rs59263250 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781183 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs58083017 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781256 chr14:106643132~106658258:- PAAD cis rs2337406 0.789 rs60390024 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781327 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74092532 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781363 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74092534 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781364 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74092535 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781722 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74092537 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781883 chr14:106643132~106658258:- PAAD cis rs2337406 0.81 rs74092538 ENSG00000223648.3 IGHV3-64 3.88 0.000158 0.0474 0.34 0.3 Alzheimer's disease (late onset); chr14:106781942 chr14:106643132~106658258:- PAAD cis rs9900062 0.586 rs6504250 ENSG00000270714.1 MINOS1P2 -3.88 0.000158 0.0474 -0.4 -0.3 QT interval; chr17:64684435 chr17:64747264~64747492:- PAAD cis rs7429990 0.965 rs1061003 ENSG00000228638.1 FCF1P2 -3.88 0.000158 0.0475 -0.34 -0.3 Educational attainment (years of education); chr3:47851089 chr3:48290793~48291375:- PAAD cis rs8081395 0.801 rs12938273 ENSG00000266992.1 DHX40P1 -3.88 0.000158 0.0475 -0.3 -0.3 White blood cell count; chr17:59824291 chr17:59976009~60002384:- PAAD cis rs8081395 0.836 rs1292061 ENSG00000266992.1 DHX40P1 -3.88 0.000158 0.0475 -0.3 -0.3 White blood cell count; chr17:59833869 chr17:59976009~60002384:- PAAD cis rs2934442 0.611 rs11632811 ENSG00000276524.1 RP11-323F24.3 -3.88 0.000158 0.0475 -0.39 -0.3 Bipolar disorder (age of onset and psychotic symptoms); chr15:57471789 chr15:56887107~56888219:+ PAAD cis rs4660214 0.666 rs1180383 ENSG00000243970.1 PPIEL 3.87 0.000158 0.0475 0.28 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39380595 chr1:39531838~39558707:- PAAD cis rs6929812 0.702 rs2064220 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27420248 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs6456782 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27420960 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs7753569 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27421371 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs7771598 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27421479 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs7754086 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27421711 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs62401131 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27422113 chr6:27404010~27406964:- PAAD cis rs6929812 0.729 rs6456784 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27422242 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs6928314 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27423214 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs12212288 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27423464 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs12205189 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27423541 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs12525544 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27424262 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs13207099 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27424369 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs7747444 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27425930 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs2206253 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27428287 chr6:27404010~27406964:- PAAD cis rs6929812 0.628 rs2206254 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27431852 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs1569566 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27432252 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs979353 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27433159 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs979352 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27433417 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs6908086 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27434244 chr6:27404010~27406964:- PAAD cis rs6929812 0.664 rs6914542 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27435446 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs6914585 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27435566 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs12197858 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27436992 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs10484397 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27437904 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs12200018 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27438377 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs4713101 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27440019 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs57647048 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27441385 chr6:27404010~27406964:- PAAD cis rs6929812 0.702 rs55705181 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27441508 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs7754678 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27444951 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs10946919 ENSG00000271755.1 RP1-153G14.4 3.87 0.000158 0.0475 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27445188 chr6:27404010~27406964:- PAAD cis rs59586681 0.542 rs2064846 ENSG00000226644.4 RP11-128M1.1 3.87 0.000158 0.0475 0.37 0.3 Basal cell carcinoma; chr20:2252606 chr20:2207217~2213151:+ PAAD cis rs7487075 0.93 rs11183468 ENSG00000270429.1 KNOP1P2 3.87 0.000158 0.0475 0.34 0.3 Itch intensity from mosquito bite; chr12:46412478 chr12:45880950~45882266:- PAAD cis rs875971 0.862 rs778736 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66348861 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs778711 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66386670 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs1083554 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66387354 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778707 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66392040 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778705 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66396128 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs778697 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66405439 chr7:66554588~66576923:- PAAD cis rs875971 0.798 rs7789615 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66413674 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6978028 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66421313 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6947339 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66423483 chr7:66554588~66576923:- PAAD cis rs875971 0.798 rs12698522 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66502354 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs28714531 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66503250 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs12698526 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66504118 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs13232191 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66521661 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs35378740 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66522725 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10950043 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66523623 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs17747530 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66529742 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs13226170 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66534311 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs2420611 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66534333 chr7:66554588~66576923:- PAAD cis rs875971 0.767 rs61348003 ENSG00000232559.3 GS1-124K5.12 3.87 0.000158 0.0475 0.33 0.3 Aortic root size; chr7:66540947 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs1875057 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66266868 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6960446 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66268272 chr7:66554588~66576923:- PAAD cis rs875971 0.789 rs10260426 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66271055 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs7796162 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66280771 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs2901152 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66300017 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10263690 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66301466 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10250544 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66301574 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs12531677 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66304099 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs7798630 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66306492 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs11984115 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66308872 chr7:66554588~66576923:- PAAD cis rs875971 0.755 rs10228885 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66315542 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs3893216 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66325720 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6958294 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66329809 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs2088655 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66330724 chr7:66554588~66576923:- PAAD cis rs875971 0.895 rs10447522 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66331087 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs2088653 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66343621 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6460293 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66345205 chr7:66554588~66576923:- PAAD cis rs875971 0.756 rs2901210 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66552518 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs13536 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66554203 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs801209 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66554403 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs801206 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66556979 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs801204 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66557934 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs801203 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66558025 chr7:66554588~66576923:- PAAD cis rs875971 0.825 rs801202 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66558942 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs801195 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66561128 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs801194 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66563508 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs2024192 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66576460 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6955837 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66578155 chr7:66554588~66576923:- PAAD cis rs875971 0.825 rs10281499 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66583979 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs4718377 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66584691 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs10278014 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66586277 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs1968126 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66592017 chr7:66554588~66576923:- PAAD cis rs875971 0.862 rs6460306 ENSG00000232559.3 GS1-124K5.12 -3.87 0.000158 0.0475 -0.33 -0.3 Aortic root size; chr7:66595806 chr7:66554588~66576923:- PAAD cis rs62355901 0.545 rs12654176 ENSG00000271828.1 CTD-2310F14.1 3.87 0.000158 0.0475 0.58 0.3 Breast cancer; chr5:56762660 chr5:56927874~56929573:+ PAAD cis rs11096990 0.593 rs4580660 ENSG00000249685.1 RP11-360F5.3 3.87 0.000158 0.0475 0.3 0.3 Cognitive function; chr4:39152216 chr4:39133913~39135608:+ PAAD cis rs11096990 0.551 rs11724855 ENSG00000249685.1 RP11-360F5.3 3.87 0.000158 0.0475 0.3 0.3 Cognitive function; chr4:39163379 chr4:39133913~39135608:+ PAAD cis rs950169 0.519 rs7237 ENSG00000259728.4 LINC00933 3.87 0.000158 0.0475 0.39 0.3 Schizophrenia; chr15:84643346 chr15:84570649~84580175:+ PAAD cis rs10129255 0.5 rs2078686 ENSG00000280411.1 IGHV1-69-2 -3.87 0.000158 0.0475 -0.26 -0.3 Kawasaki disease; chr14:106703345 chr14:106762092~106762588:- PAAD cis rs2742417 0.603 rs2673062 ENSG00000244357.3 RN7SL145P 3.87 0.000158 0.0475 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45722143 chr3:45742675~45742970:+ PAAD cis rs5760092 0.627 rs6519489 ENSG00000215464.4 AP000354.2 3.87 0.000159 0.0475 0.41 0.3 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23919659 chr22:24269346~24270134:- PAAD cis rs3733829 1 rs3733829 ENSG00000233622.1 CYP2T1P 3.87 0.000159 0.0476 0.41 0.3 Smoking behavior; chr19:40804666 chr19:40808525~40811390:- PAAD cis rs7849270 1 rs3124511 ENSG00000268707.1 RP11-247A12.7 3.87 0.000159 0.0476 0.35 0.3 Blood metabolite ratios; chr9:129139179 chr9:129170434~129170940:+ PAAD cis rs7849270 1 rs2254230 ENSG00000268707.1 RP11-247A12.7 3.87 0.000159 0.0476 0.35 0.3 Blood metabolite ratios; chr9:129142898 chr9:129170434~129170940:+ PAAD cis rs2278796 0.789 rs12136572 ENSG00000226330.1 RP11-739N20.2 -3.87 0.000159 0.0476 -0.24 -0.3 Mean platelet volume; chr1:204993532 chr1:204377850~204435846:+ PAAD cis rs11098499 0.71 rs4145952 ENSG00000248280.1 RP11-33B1.2 3.87 0.000159 0.0476 0.28 0.3 Corneal astigmatism; chr4:119234651 chr4:119440561~119450157:- PAAD cis rs375066 0.934 rs2191564 ENSG00000267058.1 RP11-15A1.3 -3.87 0.000159 0.0476 -0.27 -0.3 Breast cancer; chr19:43863459 chr19:43891804~43901805:- PAAD cis rs375066 0.935 rs11673020 ENSG00000267058.1 RP11-15A1.3 -3.87 0.000159 0.0476 -0.27 -0.3 Breast cancer; chr19:43870479 chr19:43891804~43901805:- PAAD cis rs375066 0.935 rs10414702 ENSG00000267058.1 RP11-15A1.3 -3.87 0.000159 0.0476 -0.27 -0.3 Breast cancer; chr19:43876384 chr19:43891804~43901805:- PAAD cis rs375066 0.935 rs10421518 ENSG00000267058.1 RP11-15A1.3 -3.87 0.000159 0.0476 -0.27 -0.3 Breast cancer; chr19:43877134 chr19:43891804~43901805:- PAAD cis rs8005677 0.611 rs11624528 ENSG00000279656.1 RP11-298I3.6 3.87 0.000159 0.0476 0.37 0.3 Cognitive ability (multi-trait analysis); chr14:22989947 chr14:23023083~23024217:- PAAD cis rs1841770 0.5 rs9812195 ENSG00000241627.3 UBQLN4P1 -3.87 0.000159 0.0476 -0.37 -0.3 Multiple sclerosis; chr3:148067423 chr3:148985868~148987668:- PAAD cis rs1841770 0.521 rs9851029 ENSG00000241627.3 UBQLN4P1 -3.87 0.000159 0.0476 -0.37 -0.3 Multiple sclerosis; chr3:148067876 chr3:148985868~148987668:- PAAD cis rs1841770 0.521 rs1564112 ENSG00000241627.3 UBQLN4P1 -3.87 0.000159 0.0476 -0.37 -0.3 Multiple sclerosis; chr3:148068570 chr3:148985868~148987668:- PAAD cis rs1841770 0.521 rs6764882 ENSG00000241627.3 UBQLN4P1 -3.87 0.000159 0.0476 -0.37 -0.3 Multiple sclerosis; chr3:148069417 chr3:148985868~148987668:- PAAD cis rs7939886 0.92 rs7950386 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56164037 chr11:56890613~56927885:+ PAAD cis rs7939886 0.844 rs7106504 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56165351 chr11:56890613~56927885:+ PAAD cis rs7939886 0.844 rs12421584 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56169934 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs61887958 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56170758 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs17150117 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56173710 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs11227428 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56174496 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs7934132 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56174987 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs4489763 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56176998 chr11:56890613~56927885:+ PAAD cis rs7939886 0.764 rs7113688 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56179389 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs7113835 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56179531 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs4612826 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56180529 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs17145425 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56182554 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs11227463 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56187971 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs59168428 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56188542 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs7112815 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56192628 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs59300271 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56194316 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs78769647 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56198051 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs1031978 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56198165 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs80232778 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56203179 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs11227507 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56204798 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs1481926 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56205805 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs7936219 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56209859 chr11:56890613~56927885:+ PAAD cis rs7939886 0.841 rs79254833 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56219420 chr11:56890613~56927885:+ PAAD cis rs7939886 0.92 rs7107736 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56220504 chr11:56890613~56927885:+ PAAD cis rs7939886 0.841 rs79902631 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56227765 chr11:56890613~56927885:+ PAAD cis rs7939886 0.841 rs11227582 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56228260 chr11:56890613~56927885:+ PAAD cis rs7939886 0.841 rs11227583 ENSG00000274150.1 FADS2P1 3.87 0.000159 0.0476 0.63 0.3 Myopia (pathological); chr11:56228261 chr11:56890613~56927885:+ PAAD cis rs8016982 0.633 rs72695758 ENSG00000258999.1 RP11-114N19.3 3.87 0.000159 0.0476 0.38 0.3 Schizophrenia; chr14:81253802 chr14:81107033~81170414:- PAAD cis rs6860540 0.704 rs4704743 ENSG00000251405.2 CTB-109A12.1 -3.87 0.000159 0.0476 -0.38 -0.3 Inflammatory skin disease; chr5:157499975 chr5:157362615~157460078:- PAAD cis rs216345 0.674 rs216358 ENSG00000230074.1 RP11-195F19.9 3.87 0.000159 0.0476 0.39 0.3 Bipolar disorder; chr9:33808378 chr9:34665665~34681298:+ PAAD cis rs875971 0.564 rs313804 ENSG00000232559.3 GS1-124K5.12 3.87 0.000159 0.0477 0.32 0.3 Aortic root size; chr7:66049635 chr7:66554588~66576923:- PAAD cis rs875971 0.662 rs448725 ENSG00000232559.3 GS1-124K5.12 3.87 0.000159 0.0477 0.32 0.3 Aortic root size; chr7:66049641 chr7:66554588~66576923:- PAAD cis rs875971 0.658 rs432667 ENSG00000232559.3 GS1-124K5.12 3.87 0.000159 0.0477 0.32 0.3 Aortic root size; chr7:66049646 chr7:66554588~66576923:- PAAD cis rs17711722 0.51 rs11767457 ENSG00000213640.3 EEF1DP4 -3.87 0.000159 0.0477 -0.31 -0.3 Calcium levels; chr7:65825628 chr7:64862999~64864370:+ PAAD cis rs10506328 0.509 rs4759075 ENSG00000248265.1 FLJ12825 3.87 0.000159 0.0477 0.27 0.3 Mean platelet volume; chr12:54273501 chr12:54058254~54122234:+ PAAD cis rs11998649 0.64 rs7821407 ENSG00000253930.1 RP11-1149O23.2 -3.87 0.000159 0.0477 -0.33 -0.3 Visceral fat; chr8:22775277 chr8:23189279~23190675:+ PAAD cis rs948562 0.681 rs11229573 ENSG00000255299.4 RP11-655C2.3 3.87 0.000159 0.0477 0.34 0.3 Lymphoma; chr11:58667095 chr11:58497888~58505758:- PAAD cis rs498136 1 rs2006905 ENSG00000250508.1 RP11-757G1.6 -3.87 0.000159 0.0477 -0.37 -0.3 Cutaneous malignant melanoma;Melanoma; chr11:69557015 chr11:68870664~68874542:+ PAAD cis rs6991838 0.765 rs4424306 ENSG00000200714.1 Y_RNA 3.87 0.000159 0.0477 0.35 0.3 Intelligence (multi-trait analysis); chr8:65618674 chr8:65592731~65592820:+ PAAD cis rs755249 0.565 rs722357 ENSG00000228060.1 RP11-69E11.8 3.87 0.000159 0.0477 0.27 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39479096 chr1:39565160~39573203:+ PAAD cis rs6968419 0.537 rs2402034 ENSG00000237870.5 AC073130.1 3.87 0.00016 0.0477 0.39 0.3 Intraocular pressure; chr7:116125770 chr7:116275606~116286734:- PAAD cis rs6968419 0.537 rs10953809 ENSG00000237870.5 AC073130.1 3.87 0.00016 0.0477 0.39 0.3 Intraocular pressure; chr7:116127110 chr7:116275606~116286734:- PAAD cis rs6968419 0.504 rs56038916 ENSG00000237870.5 AC073130.1 3.87 0.00016 0.0477 0.39 0.3 Intraocular pressure; chr7:116127662 chr7:116275606~116286734:- PAAD cis rs6968419 0.537 rs9641558 ENSG00000237870.5 AC073130.1 3.87 0.00016 0.0477 0.39 0.3 Intraocular pressure; chr7:116129257 chr7:116275606~116286734:- PAAD cis rs6968419 0.537 rs61487707 ENSG00000237870.5 AC073130.1 3.87 0.00016 0.0477 0.39 0.3 Intraocular pressure; chr7:116141002 chr7:116275606~116286734:- PAAD cis rs12291225 0.546 rs11023199 ENSG00000251991.1 RNU7-49P 3.87 0.00016 0.0477 0.35 0.3 Sense of smell; chr11:14372712 chr11:14478892~14478953:+ PAAD cis rs6472827 0.904 rs11996617 ENSG00000253983.2 RP1-16A9.1 -3.87 0.00016 0.0477 -0.45 -0.3 Uterine fibroids; chr8:74208452 chr8:74199396~74208441:+ PAAD cis rs6472827 0.953 rs35446151 ENSG00000253983.2 RP1-16A9.1 -3.87 0.00016 0.0477 -0.45 -0.3 Uterine fibroids; chr8:74209236 chr8:74199396~74208441:+ PAAD cis rs6472827 0.953 rs4449781 ENSG00000253983.2 RP1-16A9.1 -3.87 0.00016 0.0477 -0.45 -0.3 Uterine fibroids; chr8:74209309 chr8:74199396~74208441:+ PAAD cis rs6472827 0.953 rs4604419 ENSG00000253983.2 RP1-16A9.1 3.87 0.00016 0.0477 0.45 0.3 Uterine fibroids; chr8:74209330 chr8:74199396~74208441:+ PAAD cis rs9926296 0.572 rs8047581 ENSG00000260259.1 RP11-368I7.4 -3.87 0.00016 0.0477 -0.34 -0.3 Vitiligo; chr16:89818094 chr16:89682620~89686569:- PAAD cis rs7811142 0.83 rs78256546 ENSG00000078319.8 PMS2P1 -3.87 0.00016 0.0477 -0.41 -0.3 Platelet count; chr7:100355347 chr7:100320992~100341908:- PAAD cis rs7811142 0.83 rs41280971 ENSG00000078319.8 PMS2P1 -3.87 0.00016 0.0477 -0.41 -0.3 Platelet count; chr7:100356834 chr7:100320992~100341908:- PAAD cis rs7811142 0.83 rs3087502 ENSG00000078319.8 PMS2P1 -3.87 0.00016 0.0477 -0.41 -0.3 Platelet count; chr7:100357741 chr7:100320992~100341908:- PAAD cis rs7811142 0.83 rs61735533 ENSG00000078319.8 PMS2P1 -3.87 0.00016 0.0477 -0.41 -0.3 Platelet count; chr7:100358243 chr7:100320992~100341908:- PAAD cis rs7811142 0.83 rs11761426 ENSG00000078319.8 PMS2P1 -3.87 0.00016 0.0477 -0.41 -0.3 Platelet count; chr7:100359270 chr7:100320992~100341908:- PAAD cis rs713477 0.654 rs12886848 ENSG00000258413.1 RP11-665C16.6 3.87 0.00016 0.0478 0.36 0.3 Pediatric bone mineral content (femoral neck); chr14:55444420 chr14:55262767~55272075:- PAAD cis rs10761482 0.5 rs2393644 ENSG00000254271.1 RP11-131N11.4 3.87 0.00016 0.0478 0.36 0.3 Schizophrenia; chr10:60551516 chr10:60734342~60741828:+ PAAD cis rs3015497 0.616 rs10131107 ENSG00000270062.1 RP11-248J18.3 3.87 0.00016 0.0478 0.29 0.3 Mean platelet volume; chr14:50595737 chr14:50723777~50724272:- PAAD cis rs3015497 0.586 rs7144714 ENSG00000270062.1 RP11-248J18.3 3.87 0.00016 0.0478 0.29 0.3 Mean platelet volume; chr14:50611867 chr14:50723777~50724272:- PAAD cis rs3015497 0.616 rs1389650 ENSG00000270062.1 RP11-248J18.3 3.87 0.00016 0.0478 0.29 0.3 Mean platelet volume; chr14:50614731 chr14:50723777~50724272:- PAAD cis rs3015497 0.587 rs1353204 ENSG00000270062.1 RP11-248J18.3 3.87 0.00016 0.0478 0.29 0.3 Mean platelet volume; chr14:50614797 chr14:50723777~50724272:- PAAD cis rs878939 0.625 rs17578367 ENSG00000233690.1 EBAG9P1 3.87 0.00016 0.0478 0.39 0.3 Warfarin maintenance dose; chr10:99584410 chr10:99697407~99697949:- PAAD cis rs878939 0.625 rs35564340 ENSG00000233690.1 EBAG9P1 3.87 0.00016 0.0478 0.39 0.3 Warfarin maintenance dose; chr10:99584506 chr10:99697407~99697949:- PAAD cis rs302972 0.826 rs303005 ENSG00000168405.13 CMAHP 3.87 0.00016 0.0478 0.42 0.3 Creatinine levels in ischemic stroke; chr6:25086416 chr6:25081068~25166555:- PAAD cis rs2015599 0.56 rs3948497 ENSG00000275476.1 RP11-996F15.4 -3.87 0.00016 0.0478 -0.28 -0.3 Platelet count;Mean platelet volume; chr12:29247552 chr12:29277397~29277882:- PAAD cis rs9309473 0.904 rs79145598 ENSG00000163016.8 ALMS1P 3.87 0.00016 0.0478 0.43 0.3 Metabolite levels; chr2:73594255 chr2:73644919~73685576:+ PAAD cis rs9309473 0.904 rs62149783 ENSG00000163016.8 ALMS1P 3.87 0.00016 0.0478 0.43 0.3 Metabolite levels; chr2:73594257 chr2:73644919~73685576:+ PAAD cis rs12808519 1 rs12808519 ENSG00000255191.1 RP11-626H12.1 -3.87 0.00016 0.0478 -0.67 -0.3 Urate levels in overweight individuals; chr11:69785769 chr11:69985876~70015815:+ PAAD cis rs11790994 0.915 rs114106234 ENSG00000271384.1 RP11-435O5.7 -3.87 0.00016 0.0478 -0.59 -0.3 Inattentive symptoms; chr9:95665886 chr9:95406990~95407662:- PAAD cis rs6929812 0.665 rs6456786 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27448052 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs7744110 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27453525 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs2235252 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27454714 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs2235254 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27455015 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs12199110 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27455789 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs2092121 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27456405 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs2092122 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27456532 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs764460 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27456595 chr6:27404010~27406964:- PAAD cis rs6929812 0.594 rs764461 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27456664 chr6:27404010~27406964:- PAAD cis rs6929812 0.629 rs10484398 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27457181 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs1883216 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27457406 chr6:27404010~27406964:- PAAD cis rs2064219 0.662 rs7761989 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Depressive symptoms;Depressive symptoms (multi-trait analysis); chr6:27458055 chr6:27404010~27406964:- PAAD cis rs6929812 0.639 rs6456789 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27458719 chr6:27404010~27406964:- PAAD cis rs6929812 0.629 rs7743443 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27458880 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs7743465 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27458938 chr6:27404010~27406964:- PAAD cis rs6929812 0.665 rs7748366 ENSG00000271755.1 RP1-153G14.4 3.87 0.00016 0.0479 0.34 0.3 Neuroticism (multi-trait analysis); chr6:27459763 chr6:27404010~27406964:- PAAD cis rs7927592 0.956 rs2510384 ENSG00000212093.1 AP000807.1 3.87 0.00016 0.0479 0.35 0.3 Total body bone mineral density; chr11:68624369 chr11:68506083~68506166:- PAAD cis rs7849270 0.959 rs2900271 ENSG00000268707.1 RP11-247A12.7 3.87 0.00016 0.0479 0.35 0.3 Blood metabolite ratios; chr9:129132655 chr9:129170434~129170940:+ PAAD cis rs7849270 1 rs7037163 ENSG00000268707.1 RP11-247A12.7 -3.87 0.00016 0.0479 -0.35 -0.3 Blood metabolite ratios; chr9:129132061 chr9:129170434~129170940:+ PAAD cis rs2739330 0.828 rs5760107 ENSG00000206090.4 AP000350.7 3.87 0.00016 0.0479 0.38 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23939998~23942798:+ PAAD cis rs2739330 0.789 rs5760109 ENSG00000206090.4 AP000350.7 3.87 0.00016 0.0479 0.38 0.3 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23939998~23942798:+ PAAD cis rs7766910 1 rs3799924 ENSG00000234261.2 RP11-146I2.1 3.87 0.00016 0.0479 0.37 0.3 Pediatric bone mineral content (radius); chr6:14128110 chr6:14661829~15090003:- PAAD cis rs9326248 0.581 rs7121898 ENSG00000280143.1 AP000892.6 3.87 0.00016 0.0479 0.34 0.3 Blood protein levels; chr11:116926130 chr11:117204967~117210292:+ PAAD cis rs9326248 0.52 rs1446105 ENSG00000280143.1 AP000892.6 3.87 0.00016 0.0479 0.34 0.3 Blood protein levels; chr11:116927828 chr11:117204967~117210292:+ PAAD cis rs9326248 0.581 rs10790167 ENSG00000280143.1 AP000892.6 3.87 0.00016 0.0479 0.34 0.3 Blood protein levels; chr11:116930227 chr11:117204967~117210292:+ PAAD cis rs2688608 0.592 rs10824032 ENSG00000271816.1 BMS1P4 3.87 0.00016 0.0479 0.31 0.3 Inflammatory bowel disease; chr10:73768372 chr10:73699151~73730487:- PAAD cis rs7927592 0.913 rs7123564 ENSG00000212093.1 AP000807.1 3.87 0.00016 0.0479 0.35 0.3 Total body bone mineral density; chr11:68594696 chr11:68506083~68506166:- PAAD cis rs9322193 0.884 rs11155675 ENSG00000223701.3 RAET1E-AS1 3.87 0.00016 0.0479 0.36 0.3 Lung cancer; chr6:149742883 chr6:149884431~149919508:+ PAAD cis rs11723261 0.582 rs11248005 ENSG00000275426.1 CH17-262A2.1 3.87 0.00016 0.0479 0.47 0.3 Immune response to smallpox vaccine (IL-6); chr4:172826 chr4:149738~150317:+ PAAD cis rs11723261 0.582 rs11733927 ENSG00000275426.1 CH17-262A2.1 3.87 0.00016 0.0479 0.47 0.3 Immune response to smallpox vaccine (IL-6); chr4:173039 chr4:149738~150317:+ PAAD cis rs2742417 0.603 rs2742453 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45724366 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs2742455 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45725624 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs2742458 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45726110 chr3:45742675~45742970:+ PAAD cis rs2742417 0.609 rs2673066 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45729708 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs2531755 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45731250 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs2673055 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45731280 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs2253979 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45731828 chr3:45742675~45742970:+ PAAD cis rs2742417 0.609 rs11709306 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45732240 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs9826208 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45732499 chr3:45742675~45742970:+ PAAD cis rs2742417 0.603 rs7631818 ENSG00000244357.3 RN7SL145P 3.87 0.00016 0.048 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45734439 chr3:45742675~45742970:+ PAAD cis rs891378 0.755 rs10157327 ENSG00000274245.1 RP11-357P18.2 -3.87 0.000161 0.048 -0.41 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207191756 chr1:207372559~207373252:+ PAAD cis rs5742933 0.817 rs1055091 ENSG00000273240.1 RP11-455J20.3 3.87 0.000161 0.048 0.36 0.3 Ferritin levels; chr2:189770417 chr2:189763859~189764456:- PAAD cis rs5742933 0.817 rs6942 ENSG00000273240.1 RP11-455J20.3 3.87 0.000161 0.048 0.36 0.3 Ferritin levels; chr2:189771685 chr2:189763859~189764456:- PAAD cis rs5742933 0.817 rs3816196 ENSG00000273240.1 RP11-455J20.3 3.87 0.000161 0.048 0.36 0.3 Ferritin levels; chr2:189775749 chr2:189763859~189764456:- PAAD cis rs5742933 0.817 rs6738042 ENSG00000273240.1 RP11-455J20.3 3.87 0.000161 0.048 0.36 0.3 Ferritin levels; chr2:189776958 chr2:189763859~189764456:- PAAD cis rs5742933 0.948 rs7592066 ENSG00000273240.1 RP11-455J20.3 3.87 0.000161 0.048 0.36 0.3 Ferritin levels; chr2:189778792 chr2:189763859~189764456:- PAAD cis rs5742933 0.779 rs7595020 ENSG00000273240.1 RP11-455J20.3 3.87 0.000161 0.048 0.36 0.3 Ferritin levels; chr2:189778950 chr2:189763859~189764456:- PAAD cis rs1707322 0.647 rs6686944 ENSG00000280836.1 AL355480.1 -3.87 0.000161 0.048 -0.35 -0.3 Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction); chr1:45690636 chr1:45581219~45581321:- PAAD cis rs2287838 0.593 rs62105747 ENSG00000267289.1 CTD-2623N2.11 3.87 0.000161 0.048 0.34 0.3 Sleep duration; chr19:9839590 chr19:9834079~9835013:- PAAD cis rs4794202 0.755 rs11651698 ENSG00000264920.1 RP11-6N17.4 -3.87 0.000161 0.0481 -0.44 -0.3 Alzheimer's disease (cognitive decline); chr17:47854937 chr17:47891255~47895812:- PAAD cis rs7246657 0.943 rs2291004 ENSG00000267422.1 CTD-2554C21.1 -3.87 0.000161 0.0481 -0.51 -0.3 Coronary artery calcification; chr19:37507050 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs35540940 ENSG00000267422.1 CTD-2554C21.1 -3.87 0.000161 0.0481 -0.51 -0.3 Coronary artery calcification; chr19:37517333 chr19:37779686~37792865:+ PAAD cis rs748404 0.578 rs538238 ENSG00000205771.5 CATSPER2P1 -3.87 0.000161 0.0481 -0.43 -0.3 Lung cancer; chr15:43293322 chr15:43726918~43747094:- PAAD cis rs875971 0.502 rs2465121 ENSG00000222364.1 RNU6-96P 3.87 0.000161 0.0481 0.39 0.3 Aortic root size; chr7:66156017 chr7:66395191~66395286:+ PAAD cis rs4948275 0.55 rs10994749 ENSG00000237233.2 TMEM26-AS1 3.87 0.000161 0.0481 0.37 0.3 Night sleep phenotypes; chr10:61396464 chr10:61452639~61481956:+ PAAD cis rs4268898 0.552 rs12620938 ENSG00000242628.4 AC009228.1 -3.87 0.000161 0.0481 -0.32 -0.3 Asthma; chr2:24144252 chr2:24214381~24221516:+ PAAD cis rs4268898 0.552 rs11125444 ENSG00000242628.4 AC009228.1 -3.87 0.000161 0.0481 -0.32 -0.3 Asthma; chr2:24144335 chr2:24214381~24221516:+ PAAD cis rs4268898 0.552 rs12621083 ENSG00000242628.4 AC009228.1 -3.87 0.000161 0.0481 -0.32 -0.3 Asthma; chr2:24144670 chr2:24214381~24221516:+ PAAD cis rs4268898 0.552 rs35331966 ENSG00000242628.4 AC009228.1 -3.87 0.000161 0.0481 -0.32 -0.3 Asthma; chr2:24144958 chr2:24214381~24221516:+ PAAD cis rs9900062 0.586 rs2676307 ENSG00000270714.1 MINOS1P2 -3.87 0.000161 0.0481 -0.41 -0.3 QT interval; chr17:64694595 chr17:64747264~64747492:- PAAD cis rs8062405 0.54 rs480400 ENSG00000251417.2 RP11-1348G14.4 -3.87 0.000161 0.0481 -0.25 -0.3 Cognitive ability (multi-trait analysis);Cognitive ability; chr16:28563294 chr16:28802743~28817828:+ PAAD cis rs987724 0.515 rs1320011 ENSG00000240875.4 LINC00886 -3.87 0.000161 0.0482 -0.43 -0.3 Venous thromboembolism adjusted for sickle cell variant rs77121243-T; chr3:156899993 chr3:156747346~156817062:- PAAD cis rs11089937 0.54 rs2329931 ENSG00000211638.2 IGLV8-61 -3.87 0.000161 0.0482 -0.28 -0.3 Periodontitis (PAL4Q3); chr22:22131994 chr22:22098700~22099212:+ PAAD cis rs7119038 0.731 rs10892283 ENSG00000255239.1 AP002954.6 -3.87 0.000161 0.0482 -0.43 -0.3 Sjögren's syndrome; chr11:118766272 chr11:118688039~118690600:- PAAD cis rs7119038 0.774 rs11217020 ENSG00000255239.1 AP002954.6 -3.87 0.000161 0.0482 -0.43 -0.3 Sjögren's syndrome; chr11:118768644 chr11:118688039~118690600:- PAAD cis rs7119038 0.818 rs10892286 ENSG00000255239.1 AP002954.6 -3.87 0.000161 0.0482 -0.43 -0.3 Sjögren's syndrome; chr11:118771376 chr11:118688039~118690600:- PAAD cis rs13178541 0.872 rs11242286 ENSG00000250378.1 RP11-119J18.1 -3.87 0.000161 0.0482 -0.47 -0.3 IgG glycosylation; chr5:135790036 chr5:135812667~135826582:+ PAAD cis rs9322193 0.923 rs9322214 ENSG00000268592.3 RAET1E-AS1 3.87 0.000161 0.0482 0.35 0.3 Lung cancer; chr6:149703986 chr6:149863494~149919507:+ PAAD cis rs9322193 0.887 rs9767113 ENSG00000268592.3 RAET1E-AS1 3.87 0.000161 0.0482 0.35 0.3 Lung cancer; chr6:149718157 chr6:149863494~149919507:+ PAAD cis rs6921919 0.583 rs1054372 ENSG00000219891.2 ZSCAN12P1 3.87 0.000161 0.0482 0.42 0.3 Autism spectrum disorder or schizophrenia; chr6:28368965 chr6:28091154~28093664:+ PAAD cis rs6921919 0.583 rs9468354 ENSG00000219891.2 ZSCAN12P1 3.87 0.000161 0.0482 0.42 0.3 Autism spectrum disorder or schizophrenia; chr6:28370024 chr6:28091154~28093664:+ PAAD cis rs6921919 0.583 rs7773051 ENSG00000219891.2 ZSCAN12P1 3.87 0.000161 0.0482 0.42 0.3 Autism spectrum disorder or schizophrenia; chr6:28372539 chr6:28091154~28093664:+ PAAD cis rs2638953 0.924 rs12369144 ENSG00000247934.4 RP11-967K21.1 -3.87 0.000162 0.0482 -0.35 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28341109 chr12:28163298~28190738:- PAAD cis rs2799081 1 rs2799081 ENSG00000219891.2 ZSCAN12P1 3.87 0.000162 0.0482 0.43 0.3 Myopia; chr6:28302807 chr6:28091154~28093664:+ PAAD cis rs4944571 0.864 rs7947537 ENSG00000255471.1 RP11-736K20.5 -3.87 0.000162 0.0482 -0.29 -0.3 Urate levels in obese individuals; chr11:86400553 chr11:86892214~86925037:- PAAD cis rs4944571 0.864 rs12272824 ENSG00000255471.1 RP11-736K20.5 -3.87 0.000162 0.0482 -0.29 -0.3 Urate levels in obese individuals; chr11:86400658 chr11:86892214~86925037:- PAAD cis rs4944571 0.864 rs4944573 ENSG00000255471.1 RP11-736K20.5 -3.87 0.000162 0.0482 -0.29 -0.3 Urate levels in obese individuals; chr11:86403320 chr11:86892214~86925037:- PAAD cis rs4944571 0.833 rs10501617 ENSG00000255471.1 RP11-736K20.5 -3.87 0.000162 0.0482 -0.29 -0.3 Urate levels in obese individuals; chr11:86404975 chr11:86892214~86925037:- PAAD cis rs4944571 0.864 rs10501618 ENSG00000255471.1 RP11-736K20.5 -3.87 0.000162 0.0482 -0.29 -0.3 Urate levels in obese individuals; chr11:86405701 chr11:86892214~86925037:- PAAD cis rs919433 0.647 rs1979239 ENSG00000231621.1 AC013264.2 -3.87 0.000162 0.0482 -0.3 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197633592 chr2:197197991~197199273:+ PAAD cis rs16849225 0.526 rs3901479 ENSG00000277998.1 RP11-452N17.1 -3.87 0.000162 0.0482 -0.33 -0.3 Systolic blood pressure;Blood pressure; chr2:163987046 chr2:164573741~164574054:+ PAAD cis rs858239 0.537 rs6942981 ENSG00000226816.2 AC005082.12 3.87 0.000162 0.0482 0.36 0.3 Cerebrospinal fluid biomarker levels; chr7:23191929 chr7:23206013~23208045:+ PAAD cis rs2278034 0.502 rs3747672 ENSG00000272792.1 RP11-141C7.4 -3.87 0.000162 0.0482 -0.36 -0.3 Bronchopulmonary dysplasia; chr3:195885163 chr3:195639990~195640460:+ PAAD cis rs9595908 0.9 rs9595850 ENSG00000212293.1 SNORA16 3.87 0.000162 0.0482 0.33 0.3 Body mass index; chr13:32579773 chr13:32420390~32420516:- PAAD cis rs1665050 0.534 rs56402153 ENSG00000277144.1 RP11-59H7.4 -3.87 0.000162 0.0482 -0.35 -0.3 Atopic dermatitis; chr15:58941113 chr15:59115547~59116089:- PAAD cis rs2288073 0.93 rs7604097 ENSG00000242628.4 AC009228.1 3.87 0.000162 0.0482 0.36 0.3 Venous thromboembolism (SNP x SNP interaction); chr2:24178936 chr2:24214381~24221516:+ PAAD cis rs2288073 0.965 rs10173949 ENSG00000242628.4 AC009228.1 3.87 0.000162 0.0482 0.36 0.3 Venous thromboembolism (SNP x SNP interaction); chr2:24187387 chr2:24214381~24221516:+ PAAD cis rs2288073 0.965 rs13395596 ENSG00000242628.4 AC009228.1 3.87 0.000162 0.0482 0.36 0.3 Venous thromboembolism (SNP x SNP interaction); chr2:24187869 chr2:24214381~24221516:+ PAAD cis rs2288073 0.896 rs13404513 ENSG00000242628.4 AC009228.1 3.87 0.000162 0.0482 0.36 0.3 Venous thromboembolism (SNP x SNP interaction); chr2:24187911 chr2:24214381~24221516:+ PAAD cis rs4660456 0.504 rs542214 ENSG00000272145.1 NFYC-AS1 -3.87 0.000162 0.0483 -0.28 -0.3 Platelet count; chr1:40632806 chr1:40690380~40692066:- PAAD cis rs73173548 0.528 rs13161403 ENSG00000247828.6 TMEM161B-AS1 3.87 0.000162 0.0483 0.25 0.3 Macular telangiectasia type 2; chr5:88471144 chr5:88268895~88436685:+ PAAD cis rs2985684 0.841 rs7158577 ENSG00000259113.1 RP11-406H23.2 -3.87 0.000162 0.0483 -0.42 -0.3 Carotid intima media thickness; chr14:49591915 chr14:50448807~50456742:+ PAAD cis rs2985684 0.789 rs1957979 ENSG00000259113.1 RP11-406H23.2 -3.87 0.000162 0.0483 -0.42 -0.3 Carotid intima media thickness; chr14:49596614 chr14:50448807~50456742:+ PAAD cis rs2985684 0.789 rs7161649 ENSG00000259113.1 RP11-406H23.2 -3.87 0.000162 0.0483 -0.42 -0.3 Carotid intima media thickness; chr14:49597310 chr14:50448807~50456742:+ PAAD cis rs2985684 0.841 rs2281836 ENSG00000259113.1 RP11-406H23.2 -3.87 0.000162 0.0483 -0.42 -0.3 Carotid intima media thickness; chr14:49598999 chr14:50448807~50456742:+ PAAD cis rs2243480 1 rs10807702 ENSG00000228409.4 CCT6P1 3.87 0.000162 0.0483 0.32 0.3 Diabetic kidney disease; chr7:66302856 chr7:65751142~65763354:+ PAAD cis rs79040073 0.564 rs34606419 ENSG00000259469.1 RP11-227D13.4 -3.87 0.000162 0.0483 -0.47 -0.3 Lung cancer in ever smokers; chr15:49240390 chr15:48729080~48729844:- PAAD cis rs440932 1 rs440932 ENSG00000254340.1 RP11-10A14.3 3.87 0.000162 0.0483 0.38 0.3 High light scatter reticulocyte percentage of red cells; chr8:9169419 chr8:9141424~9145435:+ PAAD cis rs7927592 0.913 rs7106010 ENSG00000212093.1 AP000807.1 3.87 0.000162 0.0483 0.35 0.3 Total body bone mineral density; chr11:68597744 chr11:68506083~68506166:- PAAD cis rs2688608 0.592 rs13013 ENSG00000271816.1 BMS1P4 3.87 0.000162 0.0483 0.31 0.3 Inflammatory bowel disease; chr10:73802403 chr10:73699151~73730487:- PAAD cis rs4853525 0.522 rs10490538 ENSG00000235852.1 AC005540.3 -3.87 0.000162 0.0483 -0.41 -0.3 Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count; chr2:190725340 chr2:190880797~190882059:- PAAD cis rs6921919 0.806 rs213230 ENSG00000216901.1 AL022393.7 3.87 0.000162 0.0483 0.46 0.3 Autism spectrum disorder or schizophrenia; chr6:28362487 chr6:28176188~28176674:+ PAAD cis rs728616 0.867 rs1054054 ENSG00000225484.5 NUTM2B-AS1 -3.87 0.000162 0.0483 -0.6 -0.3 Chronic obstructive pulmonary disease-related biomarkers; chr10:79922972 chr10:79663088~79826594:- PAAD cis rs728616 0.867 rs61859766 ENSG00000225484.5 NUTM2B-AS1 -3.87 0.000162 0.0483 -0.6 -0.3 Chronic obstructive pulmonary disease-related biomarkers; chr10:79923284 chr10:79663088~79826594:- PAAD cis rs4660214 0.666 rs2275187 ENSG00000228060.1 RP11-69E11.8 3.87 0.000162 0.0483 0.28 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39297570 chr1:39565160~39573203:+ PAAD cis rs7674212 0.57 rs2711899 ENSG00000230069.3 LRRC37A15P -3.87 0.000162 0.0483 -0.29 -0.3 Type 2 diabetes; chr4:103141257 chr4:102727274~102730721:- PAAD cis rs17201317 0.609 rs16870093 ENSG00000272037.1 KB-431C1.5 3.87 0.000162 0.0483 0.24 0.3 Small vessel stroke; chr8:103104863 chr8:102256392~102257821:+ PAAD cis rs2337406 1 rs7145100 ENSG00000223648.3 IGHV3-64 3.87 0.000162 0.0483 0.36 0.3 Alzheimer's disease (late onset); chr14:106704673 chr14:106643132~106658258:- PAAD cis rs8127691 0.967 rs4456788 ENSG00000237604.1 AP001056.1 3.87 0.000162 0.0484 0.37 0.3 Inflammatory bowel disease; chr21:44196441 chr21:44175489~44176453:+ PAAD cis rs8127691 0.967 rs8134436 ENSG00000237604.1 AP001056.1 3.87 0.000162 0.0484 0.37 0.3 Inflammatory bowel disease; chr21:44196614 chr21:44175489~44176453:+ PAAD cis rs8127691 0.904 rs2070552 ENSG00000237604.1 AP001056.1 3.87 0.000162 0.0484 0.37 0.3 Inflammatory bowel disease; chr21:44197186 chr21:44175489~44176453:+ PAAD cis rs394563 0.967 rs447025 ENSG00000231760.4 RP11-350J20.5 3.87 0.000162 0.0484 0.4 0.3 Dupuytren's disease; chr6:149477992 chr6:149796151~149826294:- PAAD cis rs2980436 1 rs2980436 ENSG00000254340.1 RP11-10A14.3 -3.87 0.000162 0.0484 -0.39 -0.3 Schizophrenia; chr8:8234503 chr8:9141424~9145435:+ PAAD cis rs8127691 1 rs762421 ENSG00000237604.1 AP001056.1 -3.87 0.000162 0.0484 -0.37 -0.3 Inflammatory bowel disease; chr21:44195678 chr21:44175489~44176453:+ PAAD cis rs2688608 0.592 rs2306328 ENSG00000271816.1 BMS1P4 3.87 0.000163 0.0485 0.31 0.3 Inflammatory bowel disease; chr10:73819752 chr10:73699151~73730487:- PAAD cis rs2262909 0.925 rs56073035 ENSG00000268079.1 BNIP3P30 -3.87 0.000163 0.0485 -0.35 -0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22093496 chr19:22203128~22204003:+ PAAD cis rs2262909 0.962 rs73019889 ENSG00000268079.1 BNIP3P30 -3.87 0.000163 0.0485 -0.35 -0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22095024 chr19:22203128~22204003:+ PAAD cis rs2262909 0.962 rs17459246 ENSG00000268079.1 BNIP3P30 -3.87 0.000163 0.0485 -0.35 -0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22095319 chr19:22203128~22204003:+ PAAD cis rs2262909 0.925 rs73019900 ENSG00000268079.1 BNIP3P30 -3.87 0.000163 0.0485 -0.35 -0.3 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity; chr19:22103878 chr19:22203128~22204003:+ PAAD cis rs9873618 0.503 rs34595556 ENSG00000279673.1 RP11-185E8.2 3.87 0.000163 0.0485 0.42 0.3 Fasting plasma glucose; chr3:170913924 chr3:171460612~171462256:+ PAAD cis rs17772222 0.917 rs61986669 ENSG00000258983.2 RP11-507K2.2 3.87 0.000163 0.0485 0.39 0.3 Coronary artery calcification; chr14:88727121 chr14:88499334~88515502:+ PAAD cis rs7829975 0.577 rs79495969 ENSG00000233609.3 RP11-62H7.2 -3.87 0.000163 0.0485 -0.31 -0.3 Mood instability; chr8:8687740 chr8:8961200~8979025:+ PAAD cis rs17137566 0.808 rs73081762 ENSG00000236318.1 AC019117.1 3.87 0.000163 0.0485 0.46 0.3 Plasma kynurenine levels in major depressive disorder; chr7:17376956 chr7:17374867~17466664:+ PAAD cis rs10411161 1 rs3848562 ENSG00000269483.1 AC006272.1 -3.87 0.000163 0.0485 -0.52 -0.3 Breast cancer; chr19:51876582 chr19:51839924~51843324:- PAAD cis rs919433 0.679 rs10497806 ENSG00000231621.1 AC013264.2 -3.87 0.000163 0.0485 -0.3 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197644227 chr2:197197991~197199273:+ PAAD cis rs919433 0.679 rs10166328 ENSG00000231621.1 AC013264.2 -3.87 0.000163 0.0485 -0.3 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197647193 chr2:197197991~197199273:+ PAAD cis rs12554020 0.892 rs3815563 ENSG00000227603.1 RP11-165J3.6 3.87 0.000163 0.0485 0.44 0.3 Schizophrenia; chr9:93450864 chr9:93435332~93437121:- PAAD cis rs12554020 1 rs7853605 ENSG00000227603.1 RP11-165J3.6 3.87 0.000163 0.0485 0.44 0.3 Schizophrenia; chr9:93451247 chr9:93435332~93437121:- PAAD cis rs12118297 0.769 rs12140005 ENSG00000236915.1 RP4-651E10.4 -3.87 0.000163 0.0485 -0.47 -0.3 Breast cancer; chr1:87301024 chr1:86571181~86693203:- PAAD cis rs6903823 0.508 rs1150724 ENSG00000204709.4 LINC01556 3.87 0.000163 0.0486 0.39 0.3 Pulmonary function; chr6:28282459 chr6:28943877~28944537:+ PAAD cis rs9873618 0.509 rs7430672 ENSG00000279673.1 RP11-185E8.2 -3.87 0.000163 0.0486 -0.42 -0.3 Fasting plasma glucose; chr3:170945134 chr3:171460612~171462256:+ PAAD cis rs6539288 0.901 rs11113143 ENSG00000260329.1 RP11-412D9.4 -3.87 0.000163 0.0486 -0.26 -0.3 Total body bone mineral density; chr12:106910081 chr12:106954029~106955497:- PAAD cis rs2404602 0.735 rs2436994 ENSG00000259422.1 RP11-593F23.1 -3.87 0.000163 0.0486 -0.35 -0.3 Blood metabolite levels; chr15:76508722 chr15:76174891~76181486:- PAAD cis rs7319075 0.607 rs9533547 ENSG00000271216.1 LINC01050 -3.87 0.000163 0.0486 -0.42 -0.3 Photic sneeze reflex; chr13:43605165 chr13:42810366~42812562:- PAAD cis rs7319075 0.607 rs9567231 ENSG00000271216.1 LINC01050 -3.87 0.000163 0.0486 -0.42 -0.3 Photic sneeze reflex; chr13:43605627 chr13:42810366~42812562:- PAAD cis rs728616 0.867 rs61859763 ENSG00000225484.5 NUTM2B-AS1 -3.87 0.000163 0.0486 -0.6 -0.3 Chronic obstructive pulmonary disease-related biomarkers; chr10:79911859 chr10:79663088~79826594:- PAAD cis rs2742417 1 rs2742379 ENSG00000244357.3 RN7SL145P 3.87 0.000163 0.0486 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45746343 chr3:45742675~45742970:+ PAAD cis rs7927592 0.956 rs7116899 ENSG00000212093.1 AP000807.1 3.87 0.000163 0.0486 0.35 0.3 Total body bone mineral density; chr11:68618067 chr11:68506083~68506166:- PAAD cis rs7927592 0.956 rs7102273 ENSG00000212093.1 AP000807.1 3.87 0.000163 0.0486 0.35 0.3 Total body bone mineral density; chr11:68618111 chr11:68506083~68506166:- PAAD cis rs7246657 0.943 rs10405064 ENSG00000267422.1 CTD-2554C21.1 -3.87 0.000163 0.0486 -0.51 -0.3 Coronary artery calcification; chr19:37370959 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs713256 ENSG00000267422.1 CTD-2554C21.1 -3.87 0.000163 0.0486 -0.51 -0.3 Coronary artery calcification; chr19:37374463 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs8111782 ENSG00000267422.1 CTD-2554C21.1 -3.87 0.000163 0.0486 -0.51 -0.3 Coronary artery calcification; chr19:37377002 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs9917081 ENSG00000267422.1 CTD-2554C21.1 -3.87 0.000163 0.0486 -0.51 -0.3 Coronary artery calcification; chr19:37385714 chr19:37779686~37792865:+ PAAD cis rs7246657 0.943 rs10404920 ENSG00000267422.1 CTD-2554C21.1 -3.87 0.000163 0.0486 -0.51 -0.3 Coronary artery calcification; chr19:37390654 chr19:37779686~37792865:+ PAAD cis rs10759883 0.58 rs690495 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95893511 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs10739705 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95900857 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs624075 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95902665 chr9:95759231~95875977:- PAAD cis rs10759883 0.539 rs10987963 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95903798 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs1327997 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95913600 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs1327996 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95913710 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs617187 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95917359 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs689619 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95921689 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs10512245 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95929529 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs690063 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95931019 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs690056 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95938704 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs689738 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95939738 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs682682 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95939980 chr9:95759231~95875977:- PAAD cis rs10759883 0.539 rs10988755 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95944085 chr9:95759231~95875977:- PAAD cis rs10759883 0.587 rs603947 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95944647 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs7847983 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95948046 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs10819650 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95951161 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs10760679 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95951511 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs694230 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95954227 chr9:95759231~95875977:- PAAD cis rs10759883 0.563 rs10819668 ENSG00000175611.10 LINC00476 3.87 0.000163 0.0486 0.29 0.3 Nicotine dependence; chr9:95959848 chr9:95759231~95875977:- PAAD cis rs748404 0.578 rs576557 ENSG00000205771.5 CATSPER2P1 -3.87 0.000163 0.0486 -0.43 -0.3 Lung cancer; chr15:43305539 chr15:43726918~43747094:- PAAD cis rs748404 0.578 rs510108 ENSG00000205771.5 CATSPER2P1 -3.87 0.000163 0.0486 -0.43 -0.3 Lung cancer; chr15:43313241 chr15:43726918~43747094:- PAAD cis rs2337406 0.866 rs4280141 ENSG00000223648.3 IGHV3-64 -3.87 0.000163 0.0486 -0.34 -0.3 Alzheimer's disease (late onset); chr14:106780476 chr14:106643132~106658258:- PAAD cis rs4713118 0.699 rs573179 ENSG00000219392.1 RP1-265C24.5 -3.87 0.000164 0.0487 -0.44 -0.3 Parkinson's disease; chr6:27881898 chr6:28115628~28116551:+ PAAD cis rs4713118 0.699 rs200978 ENSG00000219392.1 RP1-265C24.5 -3.87 0.000164 0.0487 -0.44 -0.3 Parkinson's disease; chr6:27885390 chr6:28115628~28116551:+ PAAD cis rs4713118 0.699 rs200969 ENSG00000219392.1 RP1-265C24.5 -3.87 0.000164 0.0487 -0.44 -0.3 Parkinson's disease; chr6:27891675 chr6:28115628~28116551:+ PAAD cis rs1790761 0.772 rs36089024 ENSG00000231793.4 DOC2GP -3.87 0.000164 0.0487 -0.25 -0.3 Mean corpuscular volume; chr11:67477173 chr11:67612653~67616257:- PAAD cis rs12701220 0.689 rs12536282 ENSG00000229043.2 AC091729.9 -3.87 0.000164 0.0487 -0.43 -0.3 Bronchopulmonary dysplasia; chr7:1076014 chr7:1160374~1165267:+ PAAD cis rs12586317 0.576 rs6571702 ENSG00000258704.4 SRP54-AS1 -3.87 0.000164 0.0487 -0.3 -0.3 Psoriasis; chr14:35181352 chr14:34920858~34982532:- PAAD cis rs12586317 0.576 rs10143690 ENSG00000258704.4 SRP54-AS1 -3.87 0.000164 0.0487 -0.3 -0.3 Psoriasis; chr14:35182739 chr14:34920858~34982532:- PAAD cis rs12586317 0.597 rs28452109 ENSG00000258704.4 SRP54-AS1 -3.87 0.000164 0.0487 -0.3 -0.3 Psoriasis; chr14:35183850 chr14:34920858~34982532:- PAAD cis rs12586317 0.557 rs4488360 ENSG00000258704.4 SRP54-AS1 -3.87 0.000164 0.0487 -0.3 -0.3 Psoriasis; chr14:35187005 chr14:34920858~34982532:- PAAD cis rs2742417 1 rs2742418 ENSG00000244357.3 RN7SL145P 3.87 0.000164 0.0487 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45690428 chr3:45742675~45742970:+ PAAD cis rs2742417 0.967 rs2742419 ENSG00000244357.3 RN7SL145P 3.87 0.000164 0.0487 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45690437 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742420 ENSG00000244357.3 RN7SL145P 3.87 0.000164 0.0487 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45690745 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2673051 ENSG00000244357.3 RN7SL145P 3.87 0.000164 0.0487 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45690917 chr3:45742675~45742970:+ PAAD cis rs2742417 1 rs2742422 ENSG00000244357.3 RN7SL145P 3.87 0.000164 0.0487 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45691328 chr3:45742675~45742970:+ PAAD cis rs964611 0.625 rs1531916 ENSG00000259488.2 RP11-154J22.1 3.87 0.000164 0.0487 0.33 0.3 Metabolite levels (Pyroglutamine); chr15:48234074 chr15:48312353~48331856:- PAAD cis rs2742417 1 rs17328701 ENSG00000244357.3 RN7SL145P 3.87 0.000164 0.0487 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45692766 chr3:45742675~45742970:+ PAAD cis rs5742933 0.725 rs1132360 ENSG00000253559.1 OSGEPL1-AS1 3.87 0.000164 0.0487 0.31 0.3 Ferritin levels; chr2:189661498 chr2:189762704~189765556:+ PAAD cis rs10800713 0.866 rs6703783 ENSG00000260088.1 RP11-92G12.3 -3.87 0.000164 0.0487 -0.43 -0.3 Tandem gait; chr1:200544290 chr1:200669507~200694250:+ PAAD cis rs11668609 1 rs10413344 ENSG00000268442.1 CTD-2027I19.2 3.87 0.000164 0.0487 0.44 0.3 Response to taxane treatment (docetaxel); chr19:24186158 chr19:24162370~24163425:- PAAD cis rs11668609 1 rs10414556 ENSG00000268442.1 CTD-2027I19.2 3.87 0.000164 0.0487 0.44 0.3 Response to taxane treatment (docetaxel); chr19:24186167 chr19:24162370~24163425:- PAAD cis rs28386778 0.863 rs3817182 ENSG00000240280.5 TCAM1P -3.87 0.000164 0.0487 -0.42 -0.3 Prudent dietary pattern; chr17:63706548 chr17:63849292~63864379:+ PAAD cis rs4664293 0.836 rs4516379 ENSG00000226266.5 AC009961.3 -3.87 0.000164 0.0488 -0.4 -0.3 Monocyte percentage of white cells; chr2:159808892 chr2:159670708~159712435:- PAAD cis rs1665050 0.534 rs10444841 ENSG00000277144.1 RP11-59H7.4 -3.87 0.000164 0.0488 -0.35 -0.3 Atopic dermatitis; chr15:58941849 chr15:59115547~59116089:- PAAD cis rs1665050 0.534 rs8028828 ENSG00000277144.1 RP11-59H7.4 -3.87 0.000164 0.0488 -0.35 -0.3 Atopic dermatitis; chr15:58943853 chr15:59115547~59116089:- PAAD cis rs1665050 0.534 rs12911441 ENSG00000277144.1 RP11-59H7.4 -3.87 0.000164 0.0488 -0.35 -0.3 Atopic dermatitis; chr15:58944341 chr15:59115547~59116089:- PAAD cis rs1665050 0.534 rs4775106 ENSG00000277144.1 RP11-59H7.4 -3.87 0.000164 0.0488 -0.35 -0.3 Atopic dermatitis; chr15:58946062 chr15:59115547~59116089:- PAAD cis rs1665050 0.534 rs12900291 ENSG00000277144.1 RP11-59H7.4 -3.87 0.000164 0.0488 -0.35 -0.3 Atopic dermatitis; chr15:58948220 chr15:59115547~59116089:- PAAD cis rs11096990 0.551 rs2060005 ENSG00000249207.1 RP11-360F5.1 -3.87 0.000164 0.0488 -0.31 -0.3 Cognitive function; chr4:39160901 chr4:39112677~39126818:- PAAD cis rs1061377 0.501 rs62308278 ENSG00000249207.1 RP11-360F5.1 -3.87 0.000164 0.0488 -0.31 -0.3 Uric acid levels; chr4:39161038 chr4:39112677~39126818:- PAAD cis rs12530845 0.887 rs6948382 ENSG00000223718.3 AC093107.7 3.87 0.000164 0.0488 0.51 0.3 Red blood cell traits; chr7:135638828 chr7:135660039~135660647:+ PAAD cis rs6547741 0.844 rs7382 ENSG00000234072.1 AC074117.10 -3.86 0.000164 0.0488 -0.24 -0.3 Oral cavity cancer; chr2:27650548 chr2:27356246~27367622:+ PAAD cis rs6547741 0.844 rs9678851 ENSG00000234072.1 AC074117.10 -3.86 0.000164 0.0488 -0.24 -0.3 Oral cavity cancer; chr2:27664167 chr2:27356246~27367622:+ PAAD cis rs6547741 0.844 rs9941696 ENSG00000234072.1 AC074117.10 -3.86 0.000164 0.0488 -0.24 -0.3 Oral cavity cancer; chr2:27697197 chr2:27356246~27367622:+ PAAD cis rs28374715 0.681 rs7168307 ENSG00000247556.5 OIP5-AS1 3.86 0.000164 0.0488 0.31 0.3 Ulcerative colitis; chr15:41328336 chr15:41283990~41309737:+ PAAD cis rs12554020 1 rs7859267 ENSG00000227603.1 RP11-165J3.6 3.86 0.000164 0.0488 0.43 0.3 Schizophrenia; chr9:93426827 chr9:93435332~93437121:- PAAD cis rs2742417 0.967 rs9877499 ENSG00000244357.3 RN7SL145P 3.86 0.000164 0.0488 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45692912 chr3:45742675~45742970:+ PAAD cis rs498136 0.701 rs596209 ENSG00000250508.1 RP11-757G1.6 3.86 0.000164 0.0488 0.38 0.3 Cutaneous malignant melanoma;Melanoma; chr11:69532452 chr11:68870664~68874542:+ PAAD cis rs2011013 1 rs56373916 ENSG00000274128.1 RP11-342A23.2 -3.86 0.000164 0.0488 -0.39 -0.3 Sitting height ratio; chr15:83957989 chr15:83962176~83962583:+ PAAD cis rs11089937 0.857 rs5750580 ENSG00000211644.2 IGLV1-51 3.86 0.000164 0.0488 0.17 0.3 Periodontitis (PAL4Q3); chr22:22137471 chr22:22322472~22322980:+ PAAD cis rs539096 0.566 rs3011220 ENSG00000200913.1 SNORD46 -3.86 0.000164 0.0488 -0.34 -0.3 Intelligence (multi-trait analysis); chr1:43843195 chr1:44776490~44776593:+ PAAD cis rs10759883 0.627 rs10125109 ENSG00000175611.10 LINC00476 -3.86 0.000164 0.0488 -0.29 -0.3 Nicotine dependence; chr9:95799228 chr9:95759231~95875977:- PAAD cis rs2742417 1 rs9821974 ENSG00000244357.3 RN7SL145P 3.86 0.000164 0.0488 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45743471 chr3:45742675~45742970:+ PAAD cis rs7260598 0.539 rs11665842 ENSG00000269397.1 CTB-92J24.2 3.86 0.000164 0.0489 0.59 0.3 Response to taxane treatment (placlitaxel); chr19:23911846 chr19:23927788~23929287:+ PAAD cis rs7260598 0.539 rs7250219 ENSG00000269397.1 CTB-92J24.2 3.86 0.000164 0.0489 0.59 0.3 Response to taxane treatment (placlitaxel); chr19:23912809 chr19:23927788~23929287:+ PAAD cis rs847577 0.587 rs34307903 ENSG00000272950.1 RP11-307C18.1 3.86 0.000164 0.0489 0.39 0.3 Breast cancer; chr7:98099137 chr7:98322853~98323430:+ PAAD cis rs847577 0.63 rs6969384 ENSG00000272950.1 RP11-307C18.1 3.86 0.000164 0.0489 0.39 0.3 Breast cancer; chr7:98103530 chr7:98322853~98323430:+ PAAD cis rs1062177 0.756 rs2964589 ENSG00000253921.1 CTB-113P19.3 3.86 0.000164 0.0489 0.4 0.3 Preschool internalizing problems; chr5:151738628 chr5:151753992~151767247:+ PAAD cis rs1729407 0.814 rs2542051 ENSG00000254851.1 RP11-109L13.1 3.86 0.000164 0.0489 0.37 0.3 Apolipoprotein A-IV levels; chr11:116827022 chr11:117135528~117138582:+ PAAD cis rs950880 0.767 rs12712142 ENSG00000234389.1 AC007278.3 3.86 0.000164 0.0489 0.29 0.3 Serum protein levels (sST2); chr2:102344124 chr2:102438713~102440475:+ PAAD cis rs7120173 0.778 rs548638 ENSG00000254851.1 RP11-109L13.1 -3.86 0.000164 0.0489 -0.49 -0.3 Visceral adipose tissue adjusted for BMI; chr11:116866377 chr11:117135528~117138582:+ PAAD cis rs7120173 0.735 rs518547 ENSG00000254851.1 RP11-109L13.1 -3.86 0.000164 0.0489 -0.49 -0.3 Visceral adipose tissue adjusted for BMI; chr11:116867330 chr11:117135528~117138582:+ PAAD cis rs847577 0.506 rs7808528 ENSG00000272950.1 RP11-307C18.1 3.86 0.000165 0.0489 0.39 0.3 Breast cancer; chr7:98092113 chr7:98322853~98323430:+ PAAD cis rs1555322 1 rs2425041 ENSG00000279253.1 RP4-614O4.13 -3.86 0.000165 0.0489 -0.39 -0.3 Attention deficit hyperactivity disorder; chr20:35271210 chr20:35262727~35264187:- PAAD cis rs10759883 0.587 rs6478977 ENSG00000175611.10 LINC00476 -3.86 0.000165 0.0489 -0.29 -0.3 Nicotine dependence; chr9:95797994 chr9:95759231~95875977:- PAAD cis rs957448 0.948 rs1470153 ENSG00000253704.1 RP11-267M23.4 3.86 0.000165 0.0489 0.38 0.3 Nonsyndromic cleft lip with cleft palate; chr8:94514587 chr8:94553722~94569745:+ PAAD cis rs2688608 0.592 rs7080579 ENSG00000271816.1 BMS1P4 3.86 0.000165 0.0489 0.3 0.3 Inflammatory bowel disease; chr10:73744271 chr10:73699151~73730487:- PAAD cis rs2278796 0.918 rs11240324 ENSG00000226330.1 RP11-739N20.2 -3.86 0.000165 0.049 -0.24 -0.3 Mean platelet volume; chr1:204986191 chr1:204377850~204435846:+ PAAD cis rs2278796 0.881 rs11240325 ENSG00000226330.1 RP11-739N20.2 -3.86 0.000165 0.049 -0.24 -0.3 Mean platelet volume; chr1:204986201 chr1:204377850~204435846:+ PAAD cis rs2278796 0.918 rs11240326 ENSG00000226330.1 RP11-739N20.2 -3.86 0.000165 0.049 -0.24 -0.3 Mean platelet volume; chr1:204986288 chr1:204377850~204435846:+ PAAD cis rs9322193 0.847 rs62439808 ENSG00000268592.3 RAET1E-AS1 3.86 0.000165 0.049 0.35 0.3 Lung cancer; chr6:149629690 chr6:149863494~149919507:+ PAAD cis rs2708377 0.656 rs116607079 ENSG00000247157.5 LINC01252 3.86 0.000165 0.049 0.52 0.3 Bitter taste perception; chr12:11109445 chr12:11548030~11590369:+ PAAD cis rs2708377 0.929 rs73066828 ENSG00000247157.5 LINC01252 3.86 0.000165 0.049 0.52 0.3 Bitter taste perception; chr12:11118055 chr12:11548030~11590369:+ PAAD cis rs2708377 0.656 rs73066852 ENSG00000247157.5 LINC01252 3.86 0.000165 0.049 0.52 0.3 Bitter taste perception; chr12:11123942 chr12:11548030~11590369:+ PAAD cis rs2708377 0.858 rs117212341 ENSG00000247157.5 LINC01252 3.86 0.000165 0.049 0.52 0.3 Bitter taste perception; chr12:11129957 chr12:11548030~11590369:+ PAAD cis rs2708377 0.858 rs68045377 ENSG00000247157.5 LINC01252 3.86 0.000165 0.049 0.52 0.3 Bitter taste perception; chr12:11141853 chr12:11548030~11590369:+ PAAD cis rs2708377 0.858 rs115781584 ENSG00000247157.5 LINC01252 3.86 0.000165 0.049 0.52 0.3 Bitter taste perception; chr12:11151961 chr12:11548030~11590369:+ PAAD cis rs755249 0.546 rs7533743 ENSG00000243970.1 PPIEL -3.86 0.000165 0.049 -0.27 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39491497 chr1:39531838~39558707:- PAAD cis rs755249 0.565 rs7555699 ENSG00000243970.1 PPIEL -3.86 0.000165 0.049 -0.27 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39491629 chr1:39531838~39558707:- PAAD cis rs755249 0.565 rs1809697 ENSG00000243970.1 PPIEL -3.86 0.000165 0.049 -0.27 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39493413 chr1:39531838~39558707:- PAAD cis rs2341534 1 rs2341534 ENSG00000258413.1 RP11-665C16.6 -3.86 0.000165 0.049 -0.41 -0.3 Morning vs. evening chronotype; chr14:55318019 chr14:55262767~55272075:- PAAD cis rs10129255 0.5 rs9324092 ENSG00000280411.1 IGHV1-69-2 3.86 0.000165 0.049 0.25 0.3 Kawasaki disease; chr14:106683806 chr14:106762092~106762588:- PAAD cis rs7572733 0.555 rs7600269 ENSG00000231621.1 AC013264.2 -3.86 0.000165 0.049 -0.31 -0.3 Dermatomyositis; chr2:198058744 chr2:197197991~197199273:+ PAAD cis rs9925964 0.933 rs10871454 ENSG00000232748.3 RP11-196G11.6 3.86 0.000165 0.049 0.35 0.3 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31036758 chr16:31056460~31062803:+ PAAD cis rs9925964 0.933 rs12448321 ENSG00000232748.3 RP11-196G11.6 3.86 0.000165 0.049 0.35 0.3 BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index; chr16:31036959 chr16:31056460~31062803:+ PAAD cis rs528301 0.833 rs472140 ENSG00000259439.2 RP11-89K21.1 3.86 0.000165 0.049 0.4 0.3 Alcohol and nicotine co-dependence; chr2:44912765 chr2:44921077~44939199:- PAAD cis rs2015599 0.54 rs12301475 ENSG00000275476.1 RP11-996F15.4 3.86 0.000165 0.049 0.28 0.3 Platelet count;Mean platelet volume; chr12:29253144 chr12:29277397~29277882:- PAAD cis rs293748 0.605 rs13188136 ENSG00000250155.1 CTD-2353F22.1 -3.86 0.000165 0.049 -0.4 -0.3 Obesity-related traits; chr5:37117132 chr5:36666214~36725195:- PAAD cis rs189798 0.807 rs9949 ENSG00000253893.2 FAM85B -3.86 0.000165 0.049 -0.47 -0.3 Myopia (pathological); chr8:9137002 chr8:8167819~8226614:- PAAD cis rs9910055 0.571 rs10208 ENSG00000267080.4 ASB16-AS1 -3.86 0.000165 0.0491 -0.23 -0.3 Total body bone mineral density; chr17:44222910 chr17:44175973~44186717:- PAAD cis rs11121246 0.565 rs914994 ENSG00000270282.1 RP5-1115A15.2 3.86 0.000165 0.0491 0.38 0.3 Plateletcrit; chr1:8857153 chr1:8512653~8513021:+ PAAD cis rs4660214 0.724 rs10788933 ENSG00000228060.1 RP11-69E11.8 3.86 0.000165 0.0491 0.28 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39229483 chr1:39565160~39573203:+ PAAD cis rs7487075 1 rs12813763 ENSG00000270429.1 KNOP1P2 -3.86 0.000165 0.0491 -0.34 -0.3 Itch intensity from mosquito bite; chr12:46429121 chr12:45880950~45882266:- PAAD cis rs4706831 0.647 rs627240 ENSG00000272129.1 RP11-250B2.6 -3.86 0.000165 0.0491 -0.38 -0.3 Joint mobility (Beighton score); chr6:80276168 chr6:80355424~80356859:+ PAAD cis rs17023223 0.537 rs2361270 ENSG00000231365.4 RP11-418J17.1 -3.86 0.000165 0.0491 -0.33 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119060699 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs2361271 ENSG00000231365.4 RP11-418J17.1 -3.86 0.000165 0.0491 -0.33 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119060782 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs2361272 ENSG00000231365.4 RP11-418J17.1 -3.86 0.000165 0.0491 -0.33 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119060794 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs2361273 ENSG00000231365.4 RP11-418J17.1 -3.86 0.000165 0.0491 -0.33 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119061077 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs10923741 ENSG00000231365.4 RP11-418J17.1 -3.86 0.000165 0.0491 -0.33 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119061850 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs10802073 ENSG00000231365.4 RP11-418J17.1 -3.86 0.000165 0.0491 -0.33 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119062032 chr1:119140396~119275973:+ PAAD cis rs17023223 0.537 rs1343723 ENSG00000231365.4 RP11-418J17.1 -3.86 0.000165 0.0491 -0.33 -0.3 Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals; chr1:119062431 chr1:119140396~119275973:+ PAAD cis rs2439831 0.702 rs2467402 ENSG00000249839.1 AC011330.5 3.86 0.000165 0.0491 0.6 0.3 Lung cancer in ever smokers; chr15:43732292 chr15:43663654~43684339:- PAAD cis rs394563 0.601 rs432582 ENSG00000223701.3 RAET1E-AS1 3.86 0.000165 0.0491 0.36 0.3 Dupuytren's disease; chr6:149473007 chr6:149884431~149919508:+ PAAD cis rs79349575 0.756 rs4793605 ENSG00000270781.1 RP11-501C14.9 -3.86 0.000165 0.0491 -0.35 -0.3 Type 2 diabetes; chr17:48958507 chr17:48899131~48899748:+ PAAD cis rs7617773 1 rs6442108 ENSG00000228638.1 FCF1P2 3.86 0.000165 0.0491 0.33 0.3 Coronary artery disease; chr3:48151469 chr3:48290793~48291375:- PAAD cis rs7617773 1 rs6442109 ENSG00000228638.1 FCF1P2 3.86 0.000165 0.0491 0.33 0.3 Coronary artery disease; chr3:48151491 chr3:48290793~48291375:- PAAD cis rs7617773 1 rs11711766 ENSG00000228638.1 FCF1P2 3.86 0.000165 0.0491 0.33 0.3 Coronary artery disease; chr3:48151680 chr3:48290793~48291375:- PAAD cis rs7617773 1 rs7617773 ENSG00000228638.1 FCF1P2 3.86 0.000165 0.0491 0.33 0.3 Coronary artery disease; chr3:48152025 chr3:48290793~48291375:- PAAD cis rs7617773 0.963 rs6771787 ENSG00000228638.1 FCF1P2 3.86 0.000165 0.0491 0.33 0.3 Coronary artery disease; chr3:48152752 chr3:48290793~48291375:- PAAD cis rs7617773 1 rs6771889 ENSG00000228638.1 FCF1P2 3.86 0.000165 0.0491 0.33 0.3 Coronary artery disease; chr3:48152836 chr3:48290793~48291375:- PAAD cis rs7617773 0.823 rs9839446 ENSG00000228638.1 FCF1P2 3.86 0.000165 0.0491 0.33 0.3 Coronary artery disease; chr3:48153176 chr3:48290793~48291375:- PAAD cis rs7617773 0.823 rs9839447 ENSG00000228638.1 FCF1P2 3.86 0.000165 0.0491 0.33 0.3 Coronary artery disease; chr3:48153177 chr3:48290793~48291375:- PAAD cis rs9928842 0.664 rs7205074 ENSG00000280152.1 RP11-331F4.5 -3.86 0.000166 0.0491 -0.38 -0.3 Alcoholic chronic pancreatitis; chr16:75186111 chr16:75245994~75250077:- PAAD cis rs293748 0.771 rs16903490 ENSG00000250155.1 CTD-2353F22.1 -3.86 0.000166 0.0491 -0.45 -0.3 Obesity-related traits; chr5:37067944 chr5:36666214~36725195:- PAAD cis rs704795 0.702 rs11689803 ENSG00000234072.1 AC074117.10 -3.86 0.000166 0.0491 -0.26 -0.3 Menopause (age at onset); chr2:27343653 chr2:27356246~27367622:+ PAAD cis rs6547741 0.743 rs7564625 ENSG00000234072.1 AC074117.10 -3.86 0.000166 0.0491 -0.24 -0.3 Oral cavity cancer; chr2:27639530 chr2:27356246~27367622:+ PAAD cis rs6547741 0.844 rs55826602 ENSG00000234072.1 AC074117.10 -3.86 0.000166 0.0491 -0.24 -0.3 Oral cavity cancer; chr2:27640585 chr2:27356246~27367622:+ PAAD cis rs891378 0.727 rs11120492 ENSG00000274245.1 RP11-357P18.2 -3.86 0.000166 0.0491 -0.41 -0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207234553 chr1:207372559~207373252:+ PAAD cis rs11668609 0.81 rs8105851 ENSG00000269397.1 CTB-92J24.2 3.86 0.000166 0.0491 0.53 0.3 Response to taxane treatment (docetaxel); chr19:24080533 chr19:23927788~23929287:+ PAAD cis rs11668609 1 rs7260280 ENSG00000269397.1 CTB-92J24.2 3.86 0.000166 0.0491 0.53 0.3 Response to taxane treatment (docetaxel); chr19:24140020 chr19:23927788~23929287:+ PAAD cis rs11668609 1 rs4452076 ENSG00000269397.1 CTB-92J24.2 3.86 0.000166 0.0491 0.53 0.3 Response to taxane treatment (docetaxel); chr19:24143981 chr19:23927788~23929287:+ PAAD cis rs2732480 0.577 rs2732481 ENSG00000258273.1 RP11-370I10.4 -3.86 0.000166 0.0492 -0.37 -0.3 Red blood cell count;Hematocrit;Hemoglobin concentration; chr12:48343202 chr12:48333755~48333901:- PAAD cis rs2337406 0.866 rs8003852 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106776648 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs988131 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106776833 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs8005518 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106777009 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs988130 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106777154 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs57684263 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106777263 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs7152038 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106778230 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs7152809 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106778385 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs7152832 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106778427 chr14:106643132~106658258:- PAAD cis rs2337406 0.5 rs7152934 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106778702 chr14:106643132~106658258:- PAAD cis rs2337406 0.789 rs12050392 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106779073 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74092505 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106779163 chr14:106643132~106658258:- PAAD cis rs2337406 0.789 rs74092507 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106779174 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74092511 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106779234 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74092512 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106779306 chr14:106643132~106658258:- PAAD cis rs2337406 0.789 rs74092514 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106779385 chr14:106643132~106658258:- PAAD cis rs2337406 0.866 rs74092520 ENSG00000223648.3 IGHV3-64 3.86 0.000166 0.0492 0.33 0.3 Alzheimer's disease (late onset); chr14:106779632 chr14:106643132~106658258:- PAAD cis rs2439831 1 rs2439850 ENSG00000275601.1 AC011330.13 -3.86 0.000166 0.0492 -0.54 -0.3 Lung cancer in ever smokers; chr15:43492656 chr15:43642389~43643023:- PAAD cis rs2439831 1 rs2467736 ENSG00000275601.1 AC011330.13 -3.86 0.000166 0.0492 -0.54 -0.3 Lung cancer in ever smokers; chr15:43492719 chr15:43642389~43643023:- PAAD cis rs2439831 1 rs2444250 ENSG00000275601.1 AC011330.13 -3.86 0.000166 0.0492 -0.54 -0.3 Lung cancer in ever smokers; chr15:43492853 chr15:43642389~43643023:- PAAD cis rs2439831 1 rs101094 ENSG00000275601.1 AC011330.13 -3.86 0.000166 0.0492 -0.54 -0.3 Lung cancer in ever smokers; chr15:43495124 chr15:43642389~43643023:- PAAD cis rs2742417 1 rs2742423 ENSG00000244357.3 RN7SL145P 3.86 0.000166 0.0492 0.28 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45691938 chr3:45742675~45742970:+ PAAD cis rs9487094 0.689 rs9487064 ENSG00000260273.1 RP11-425D10.10 3.86 0.000166 0.0492 0.36 0.3 Height; chr6:109346560 chr6:109382795~109383666:+ PAAD cis rs894157 0.92 rs11630003 ENSG00000255571.5 LINC00925 -3.86 0.000166 0.0492 -0.47 -0.3 Obesity-related traits; chr15:89652534 chr15:89361579~89398487:+ PAAD cis rs5769765 0.632 rs13056783 ENSG00000278869.1 CITF22-49E9.3 -3.86 0.000166 0.0492 -0.43 -0.3 Schizophrenia; chr22:49865504 chr22:49933198~49934074:- PAAD cis rs1150668 0.799 rs1150707 ENSG00000219891.2 ZSCAN12P1 3.86 0.000166 0.0492 0.37 0.3 Pubertal anthropometrics; chr6:28229827 chr6:28091154~28093664:+ PAAD cis rs1150668 0.768 rs1233713 ENSG00000219891.2 ZSCAN12P1 3.86 0.000166 0.0492 0.37 0.3 Pubertal anthropometrics; chr6:28230503 chr6:28091154~28093664:+ PAAD cis rs755249 0.756 rs72637908 ENSG00000228060.1 RP11-69E11.8 -3.86 0.000166 0.0492 -0.28 -0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557375 chr1:39565160~39573203:+ PAAD cis rs720064 0.557 rs12969459 ENSG00000264745.1 TTC39C-AS1 3.86 0.000166 0.0492 0.38 0.3 Strep throat; chr18:23922095 chr18:23994213~24015339:- PAAD cis rs720064 0.589 rs12956613 ENSG00000264745.1 TTC39C-AS1 3.86 0.000166 0.0492 0.38 0.3 Strep throat; chr18:23923151 chr18:23994213~24015339:- PAAD cis rs17123764 0.605 rs73305085 ENSG00000257464.1 RP11-161H23.8 -3.86 0.000166 0.0492 -0.54 -0.3 Intelligence (multi-trait analysis); chr12:49662450 chr12:49442424~49442652:- PAAD cis rs7927592 0.956 rs10896337 ENSG00000212093.1 AP000807.1 3.86 0.000166 0.0492 0.35 0.3 Total body bone mineral density; chr11:68516768 chr11:68506083~68506166:- PAAD cis rs7927592 0.956 rs11228269 ENSG00000212093.1 AP000807.1 3.86 0.000166 0.0492 0.35 0.3 Total body bone mineral density; chr11:68522328 chr11:68506083~68506166:- PAAD cis rs2832077 0.943 rs11701777 ENSG00000176054.6 RPL23P2 -3.86 0.000166 0.0492 -0.34 -0.3 Cognitive test performance; chr21:28783506 chr21:28997613~28998033:- PAAD cis rs950169 0.887 rs220333 ENSG00000275120.1 RP11-182J1.17 3.86 0.000166 0.0493 0.31 0.3 Schizophrenia; chr15:84547902 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs11630507 ENSG00000275120.1 RP11-182J1.17 3.86 0.000166 0.0493 0.31 0.3 Schizophrenia; chr15:84552494 chr15:84599434~84606463:- PAAD cis rs950169 0.881 rs34117475 ENSG00000275120.1 RP11-182J1.17 3.86 0.000166 0.0493 0.31 0.3 Schizophrenia; chr15:84565212 chr15:84599434~84606463:- PAAD cis rs950169 0.686 rs12906474 ENSG00000275120.1 RP11-182J1.17 3.86 0.000166 0.0493 0.31 0.3 Schizophrenia; chr15:84566006 chr15:84599434~84606463:- PAAD cis rs950169 0.81 rs2879976 ENSG00000275120.1 RP11-182J1.17 3.86 0.000166 0.0493 0.31 0.3 Schizophrenia; chr15:84566347 chr15:84599434~84606463:- PAAD cis rs950169 0.922 rs12915832 ENSG00000275120.1 RP11-182J1.17 3.86 0.000166 0.0493 0.31 0.3 Schizophrenia; chr15:84568226 chr15:84599434~84606463:- PAAD cis rs4683346 0.616 rs11922832 ENSG00000173811.9 CCDC13-AS1 -3.86 0.000166 0.0493 -0.32 -0.3 Granulocyte percentage of myeloid white cells; chr3:42775829 chr3:42732575~42746768:+ PAAD cis rs4432245 1 rs4432245 ENSG00000248508.5 SRP14-AS1 3.86 0.000166 0.0493 0.55 0.3 Body mass index; chr15:40032280 chr15:40039311~40067290:+ PAAD cis rs6597981 0.604 rs7945912 ENSG00000255142.1 AP006621.6 3.86 0.000166 0.0493 0.23 0.3 Breast cancer; chr11:750849 chr11:781645~782105:+ PAAD cis rs2816938 0.955 rs2816946 ENSG00000236468.1 RP11-104D3.2 3.86 0.000166 0.0493 0.34 0.3 Pancreatic cancer; chr1:200024323 chr1:199387141~199388475:+ PAAD cis rs919433 0.713 rs6719483 ENSG00000231621.1 AC013264.2 -3.86 0.000166 0.0493 -0.3 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197608162 chr2:197197991~197199273:+ PAAD cis rs919433 0.68 rs2124317 ENSG00000231621.1 AC013264.2 -3.86 0.000166 0.0493 -0.3 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197612882 chr2:197197991~197199273:+ PAAD cis rs919433 0.713 rs1455653 ENSG00000231621.1 AC013264.2 -3.86 0.000166 0.0493 -0.3 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197613596 chr2:197197991~197199273:+ PAAD cis rs919433 0.713 rs6719729 ENSG00000231621.1 AC013264.2 -3.86 0.000166 0.0493 -0.3 -0.3 Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy); chr2:197615348 chr2:197197991~197199273:+ PAAD cis rs7759001 0.857 rs980963 ENSG00000271755.1 RP1-153G14.4 3.86 0.000166 0.0493 0.38 0.3 Glomerular filtration rate (creatinine); chr6:27393158 chr6:27404010~27406964:- PAAD cis rs7759001 0.857 rs980962 ENSG00000271755.1 RP1-153G14.4 3.86 0.000166 0.0493 0.38 0.3 Glomerular filtration rate (creatinine); chr6:27393229 chr6:27404010~27406964:- PAAD cis rs7759001 0.857 rs980961 ENSG00000271755.1 RP1-153G14.4 3.86 0.000166 0.0493 0.38 0.3 Glomerular filtration rate (creatinine); chr6:27393240 chr6:27404010~27406964:- PAAD cis rs10838687 0.736 rs2633083 ENSG00000255007.1 CTD-2589M5.4 -3.86 0.000166 0.0493 -0.36 -0.3 Proinsulin levels; chr11:47227869 chr11:46256355~46274547:- PAAD cis rs12908161 0.92 rs35738019 ENSG00000275120.1 RP11-182J1.17 3.86 0.000166 0.0493 0.32 0.3 Schizophrenia; chr15:84736979 chr15:84599434~84606463:- PAAD cis rs12908161 1 rs34570071 ENSG00000275120.1 RP11-182J1.17 3.86 0.000166 0.0493 0.32 0.3 Schizophrenia; chr15:84736981 chr15:84599434~84606463:- PAAD cis rs6539288 0.933 rs1444583 ENSG00000260329.1 RP11-412D9.4 3.86 0.000166 0.0493 0.25 0.3 Total body bone mineral density; chr12:106919068 chr12:106954029~106955497:- PAAD cis rs2638953 0.853 rs1355473 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000167 0.0494 -0.32 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28463632 chr12:28163298~28190738:- PAAD cis rs35785195 0.593 rs35746281 ENSG00000257231.1 DYNLL1P4 3.86 0.000167 0.0494 0.43 0.3 Daytime sleep phenotypes; chr12:113798781 chr12:113789542~113789807:- PAAD cis rs79040073 0.679 rs76231511 ENSG00000259469.1 RP11-227D13.4 -3.86 0.000167 0.0494 -0.47 -0.3 Lung cancer in ever smokers; chr15:49222243 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs17396119 ENSG00000259469.1 RP11-227D13.4 -3.86 0.000167 0.0494 -0.47 -0.3 Lung cancer in ever smokers; chr15:49242167 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs73392277 ENSG00000259469.1 RP11-227D13.4 -3.86 0.000167 0.0494 -0.47 -0.3 Lung cancer in ever smokers; chr15:49243772 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs79311354 ENSG00000259469.1 RP11-227D13.4 -3.86 0.000167 0.0494 -0.47 -0.3 Lung cancer in ever smokers; chr15:49255987 chr15:48729080~48729844:- PAAD cis rs79040073 0.599 rs17396536 ENSG00000259469.1 RP11-227D13.4 -3.86 0.000167 0.0494 -0.47 -0.3 Lung cancer in ever smokers; chr15:49256871 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs78881953 ENSG00000259469.1 RP11-227D13.4 -3.86 0.000167 0.0494 -0.47 -0.3 Lung cancer in ever smokers; chr15:49269019 chr15:48729080~48729844:- PAAD cis rs79040073 0.637 rs11634636 ENSG00000259469.1 RP11-227D13.4 -3.86 0.000167 0.0494 -0.47 -0.3 Lung cancer in ever smokers; chr15:49315407 chr15:48729080~48729844:- PAAD cis rs79040073 0.636 rs74339964 ENSG00000259469.1 RP11-227D13.4 -3.86 0.000167 0.0494 -0.47 -0.3 Lung cancer in ever smokers; chr15:49329916 chr15:48729080~48729844:- PAAD cis rs755249 0.546 rs7533743 ENSG00000228060.1 RP11-69E11.8 3.86 0.000167 0.0494 0.27 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39491497 chr1:39565160~39573203:+ PAAD cis rs755249 0.565 rs7555699 ENSG00000228060.1 RP11-69E11.8 3.86 0.000167 0.0494 0.27 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39491629 chr1:39565160~39573203:+ PAAD cis rs755249 0.565 rs1809697 ENSG00000228060.1 RP11-69E11.8 3.86 0.000167 0.0494 0.27 0.3 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39493413 chr1:39565160~39573203:+ PAAD cis rs7189233 1 rs62048543 ENSG00000279722.1 RP11-44F14.6 -3.86 0.000167 0.0494 -0.32 -0.3 Intelligence (multi-trait analysis); chr16:53500712 chr16:53487607~53489943:- PAAD cis rs7189233 1 rs7194519 ENSG00000279722.1 RP11-44F14.6 -3.86 0.000167 0.0494 -0.32 -0.3 Intelligence (multi-trait analysis); chr16:53501364 chr16:53487607~53489943:- PAAD cis rs9309473 0.95 rs6546854 ENSG00000163016.8 ALMS1P 3.86 0.000167 0.0494 0.44 0.3 Metabolite levels; chr2:73606907 chr2:73644919~73685576:+ PAAD cis rs73019876 0.836 rs58974981 ENSG00000268433.1 RP11-420K14.2 3.86 0.000167 0.0494 0.34 0.3 Testicular germ cell tumor; chr19:21968774 chr19:21677550~21678221:- PAAD cis rs9649213 0.593 rs7796611 ENSG00000272950.1 RP11-307C18.1 3.86 0.000167 0.0494 0.34 0.3 Prostate cancer (SNP x SNP interaction); chr7:98278911 chr7:98322853~98323430:+ PAAD cis rs9649213 0.574 rs13238610 ENSG00000272950.1 RP11-307C18.1 3.86 0.000167 0.0494 0.34 0.3 Prostate cancer (SNP x SNP interaction); chr7:98279965 chr7:98322853~98323430:+ PAAD cis rs933117 0.792 rs111976385 ENSG00000232687.1 RPL12P9 3.86 0.000167 0.0495 0.63 0.3 Body mass index; chr21:29636473 chr21:29127701~29128188:- PAAD cis rs933117 0.792 rs76724506 ENSG00000232687.1 RPL12P9 3.86 0.000167 0.0495 0.63 0.3 Body mass index; chr21:29638406 chr21:29127701~29128188:- PAAD cis rs41307935 0.908 rs17162313 ENSG00000260063.1 RP5-968P14.2 3.86 0.000167 0.0495 0.58 0.3 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL); chr1:26849628 chr1:26692132~26694131:- PAAD cis rs1456305 0.55 rs2392733 ENSG00000254286.4 RP11-89K10.1 -3.86 0.000167 0.0495 -0.5 -0.3 Prostate cancer; chr8:127088427 chr8:126557875~126713415:+ PAAD cis rs7592578 0.679 rs4287794 ENSG00000231858.4 AC067945.4 -3.86 0.000167 0.0495 -0.34 -0.3 Diastolic blood pressure; chr2:190462421 chr2:191021526~191032314:+ PAAD cis rs7592578 0.679 rs59929070 ENSG00000231858.4 AC067945.4 -3.86 0.000167 0.0495 -0.34 -0.3 Diastolic blood pressure; chr2:190463126 chr2:191021526~191032314:+ PAAD cis rs9322193 0.923 rs9322204 ENSG00000268592.3 RAET1E-AS1 3.86 0.000167 0.0495 0.34 0.3 Lung cancer; chr6:149636047 chr6:149863494~149919507:+ PAAD cis rs1167827 1 rs1167827 ENSG00000223705.8 NSUN5P1 3.86 0.000167 0.0495 0.19 0.3 Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction); chr7:75533848 chr7:75410322~75416787:+ PAAD cis rs1873386 0.79 rs12582650 ENSG00000255910.1 RP11-405A12.2 3.86 0.000167 0.0495 0.43 0.3 Personality dimensions; chr12:18912953 chr12:19775451~20009937:+ PAAD cis rs3760982 0.967 rs12463346 ENSG00000267058.1 RP11-15A1.3 -3.86 0.000167 0.0495 -0.26 -0.3 Breast cancer (estrogen-receptor negative);Breast cancer; chr19:43788092 chr19:43891804~43901805:- PAAD cis rs896655 1 rs896655 ENSG00000266446.1 RP11-149I2.4 -3.86 0.000167 0.0495 -0.38 -0.3 Coronary artery disease; chr9:21706572 chr9:21995482~21996013:+ PAAD cis rs9322193 0.923 rs9383812 ENSG00000268592.3 RAET1E-AS1 3.86 0.000167 0.0495 0.35 0.3 Lung cancer; chr6:149712355 chr6:149863494~149919507:+ PAAD cis rs9322193 0.847 rs9383844 ENSG00000268592.3 RAET1E-AS1 3.86 0.000167 0.0495 0.35 0.3 Lung cancer; chr6:149716268 chr6:149863494~149919507:+ PAAD cis rs9322193 0.923 rs56397000 ENSG00000268592.3 RAET1E-AS1 3.86 0.000167 0.0495 0.35 0.3 Lung cancer; chr6:149739347 chr6:149863494~149919507:+ PAAD cis rs9322193 0.884 rs9689702 ENSG00000268592.3 RAET1E-AS1 3.86 0.000167 0.0495 0.35 0.3 Lung cancer; chr6:149740720 chr6:149863494~149919507:+ PAAD cis rs2832077 0.527 rs2776210 ENSG00000176054.6 RPL23P2 3.86 0.000167 0.0496 0.31 0.3 Cognitive test performance; chr21:28896236 chr21:28997613~28998033:- PAAD cis rs11227306 0.934 rs2303384 ENSG00000255468.5 RP11-867G23.8 3.86 0.000167 0.0496 0.27 0.3 DNA methylation (variation); chr11:65872733 chr11:66347950~66364804:+ PAAD cis rs11227306 0.934 rs2303385 ENSG00000255468.5 RP11-867G23.8 3.86 0.000167 0.0496 0.27 0.3 DNA methylation (variation); chr11:65873091 chr11:66347950~66364804:+ PAAD cis rs2243480 1 rs4718317 ENSG00000273142.1 RP11-458F8.4 3.86 0.000168 0.0496 0.27 0.3 Diabetic kidney disease; chr7:66183914 chr7:66902857~66906297:+ PAAD cis rs9322193 0.923 rs11155671 ENSG00000268592.3 RAET1E-AS1 3.86 0.000168 0.0496 0.34 0.3 Lung cancer; chr6:149650996 chr6:149863494~149919507:+ PAAD cis rs36051354 0.573 rs2581792 ENSG00000242142.1 SERBP1P3 3.86 0.000168 0.0496 0.39 0.3 Intelligence (multi-trait analysis); chr3:53001028 chr3:53064283~53065091:- PAAD cis rs1873386 0.948 rs990349 ENSG00000255910.1 RP11-405A12.2 3.86 0.000168 0.0496 0.42 0.3 Personality dimensions; chr12:18909765 chr12:19775451~20009937:+ PAAD cis rs7923837 0.65 rs10882098 ENSG00000236493.2 EIF2S2P3 3.86 0.000168 0.0496 0.38 0.3 Multiple sclerosis;Body mass index; chr10:92685036 chr10:92668745~92669743:- PAAD cis rs172166 0.561 rs149976 ENSG00000219891.2 ZSCAN12P1 -3.86 0.000168 0.0496 -0.4 -0.3 Cardiac Troponin-T levels; chr6:28019998 chr6:28091154~28093664:+ PAAD cis rs922107 0.576 rs1563786 ENSG00000231999.5 FLJ27354 3.86 0.000168 0.0496 0.28 0.3 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin); chr1:89486998 chr1:89583241~89632894:- PAAD cis rs73019876 0.869 rs812673 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0496 0.34 0.3 Testicular germ cell tumor; chr19:21939533 chr19:21677550~21678221:- PAAD cis rs17836934 0.845 rs7958749 ENSG00000258302.2 RP11-981P6.1 3.86 0.000168 0.0496 0.26 0.3 Total body bone mineral density; chr12:90050234 chr12:89561129~89594878:+ PAAD cis rs17836934 0.845 rs4842710 ENSG00000258302.2 RP11-981P6.1 3.86 0.000168 0.0496 0.26 0.3 Total body bone mineral density; chr12:90052157 chr12:89561129~89594878:+ PAAD cis rs17836934 0.845 rs4842711 ENSG00000258302.2 RP11-981P6.1 3.86 0.000168 0.0496 0.26 0.3 Total body bone mineral density; chr12:90054081 chr12:89561129~89594878:+ PAAD cis rs17836934 0.845 rs12227543 ENSG00000258302.2 RP11-981P6.1 3.86 0.000168 0.0496 0.26 0.3 Total body bone mineral density; chr12:90056289 chr12:89561129~89594878:+ PAAD cis rs17836934 0.845 rs10858947 ENSG00000258302.2 RP11-981P6.1 3.86 0.000168 0.0496 0.26 0.3 Total body bone mineral density; chr12:90057274 chr12:89561129~89594878:+ PAAD cis rs17836934 0.845 rs6538220 ENSG00000258302.2 RP11-981P6.1 3.86 0.000168 0.0496 0.26 0.3 Total body bone mineral density; chr12:90063091 chr12:89561129~89594878:+ PAAD cis rs17836934 0.771 rs7139279 ENSG00000258302.2 RP11-981P6.1 3.86 0.000168 0.0496 0.26 0.3 Total body bone mineral density; chr12:90068211 chr12:89561129~89594878:+ PAAD cis rs17836934 0.838 rs7306280 ENSG00000258302.2 RP11-981P6.1 3.86 0.000168 0.0496 0.26 0.3 Total body bone mineral density; chr12:90083900 chr12:89561129~89594878:+ PAAD cis rs2564921 0.513 rs12638195 ENSG00000242142.1 SERBP1P3 -3.86 0.000168 0.0496 -0.37 -0.3 Height; chr3:52842623 chr3:53064283~53065091:- PAAD cis rs6840258 0.825 rs72667747 ENSG00000251411.1 RP11-397E7.4 -3.86 0.000168 0.0496 -0.36 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87000911 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs72667750 ENSG00000251411.1 RP11-397E7.4 -3.86 0.000168 0.0496 -0.36 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87009273 chr4:86913266~86914817:- PAAD cis rs6840258 1 rs56406125 ENSG00000251411.1 RP11-397E7.4 -3.86 0.000168 0.0496 -0.36 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87019053 chr4:86913266~86914817:- PAAD cis rs6840258 0.941 rs72667757 ENSG00000251411.1 RP11-397E7.4 -3.86 0.000168 0.0496 -0.36 -0.3 Mean corpuscular volume;Basophil percentage of granulocytes; chr4:87025842 chr4:86913266~86914817:- PAAD cis rs2243480 1 rs316331 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66139635 chr7:66848496~66858136:+ PAAD cis rs2243480 0.908 rs2460431 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66157859 chr7:66848496~66858136:+ PAAD cis rs2243480 0.711 rs2460426 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66158142 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs4718309 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66162777 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6460274 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66163497 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs7787230 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66164112 chr7:66848496~66858136:+ PAAD cis rs2243480 0.711 rs2420172 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66170354 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2420171 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66172773 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6974723 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66172952 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs9769882 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66177938 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6966322 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66181767 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs4145008 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66182524 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs4718315 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66183554 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs4718316 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66183744 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1873494 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66184912 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6959002 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66185509 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1546059 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66189722 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2420170 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66191066 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6958289 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66192124 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs7804223 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66199572 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs12530490 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66226660 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs7778911 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66229519 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1979823 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66239626 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6964245 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66253730 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs10807701 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66259699 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1499613 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66265873 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1553174 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66266207 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs10950032 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66273604 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs6958420 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66286184 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1392104 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66294120 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs4718333 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66307771 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs7792391 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66308442 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs10247526 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66315709 chr7:66848496~66858136:+ PAAD cis rs2243480 0.908 rs1532573 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Diabetic kidney disease; chr7:66333815 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs1882655 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Gout; chr7:66682070 chr7:66848496~66858136:+ PAAD cis rs1499614 0.831 rs3800822 ENSG00000232546.1 RP11-458F8.1 3.86 0.000168 0.0496 0.36 0.3 Gout; chr7:66682162 chr7:66848496~66858136:+ PAAD cis rs2243480 0.908 rs313822 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66108952 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs313820 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66109479 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs160639 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66115000 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs313824 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66116220 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs186378 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66117071 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs160637 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66119331 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs422164 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66121618 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316313 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66128561 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316312 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66131504 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs419603 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66132354 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs387676 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66133233 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs13310597 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66133553 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs431076 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66135333 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2257790 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66135463 chr7:66848496~66858136:+ PAAD cis rs2243480 0.764 rs2460423 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66136229 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2460422 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66136518 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316334 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66137139 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316332 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66139312 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316329 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66143429 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316326 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66144466 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316325 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66144531 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316322 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66146246 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316321 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66146626 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316318 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66147917 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316317 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66148650 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs316304 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66151907 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2465120 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66155987 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1499614 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66265811 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs778729 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66359432 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs4149468 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66360703 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs778687 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66370832 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs778679 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66375924 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs778704 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66398480 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs778693 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66407358 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs778691 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66408105 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs13235972 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66418618 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs34192067 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66422670 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs34807232 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66500146 chr7:66848496~66858136:+ PAAD cis rs2243480 0.901 rs35823062 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66500834 chr7:66848496~66858136:+ PAAD cis rs2243480 0.708 rs35825036 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66521515 chr7:66848496~66858136:+ PAAD cis rs2243480 0.803 rs13224048 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66528779 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs13237037 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66532895 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1796228 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66568097 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1267820 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66585308 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2533288 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66591724 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2707844 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66594522 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs1796220 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66597113 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs2707831 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Diabetic kidney disease; chr7:66597524 chr7:66848496~66858136:+ PAAD cis rs1499614 0.803 rs1796229 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66654674 chr7:66848496~66858136:+ PAAD cis rs1499614 0.901 rs3936 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66661502 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2707832 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66671562 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs1638731 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66679692 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2659913 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66692349 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2707840 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66693028 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2659911 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66693433 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2707838 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66694214 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs60326618 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66701371 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2707830 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66702658 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2707828 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66706390 chr7:66848496~66858136:+ PAAD cis rs1499614 0.803 rs1922723 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66710076 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2659903 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66715944 chr7:66848496~66858136:+ PAAD cis rs1499614 1 rs2141924 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66721259 chr7:66848496~66858136:+ PAAD cis rs1499614 0.901 rs2178742 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000168 0.0496 -0.36 -0.3 Gout; chr7:66732812 chr7:66848496~66858136:+ PAAD cis rs342442 0.526 rs342462 ENSG00000248196.1 RP11-476C8.2 -3.86 0.000168 0.0496 -0.43 -0.3 Response to radiotherapy in prostate cancer (toxicity, urinary frequency); chr4:87136329 chr4:87166844~87167734:+ PAAD cis rs11718455 0.585 rs17076170 ENSG00000280435.1 RP4-555D20.1 -3.86 0.000168 0.0496 -0.37 -0.3 Coronary artery disease; chr3:43876454 chr3:44115818~44117487:- PAAD cis rs293748 0.771 rs292179 ENSG00000250155.1 CTD-2353F22.1 -3.86 0.000168 0.0496 -0.45 -0.3 Obesity-related traits; chr5:36947511 chr5:36666214~36725195:- PAAD cis rs293748 0.771 rs35011787 ENSG00000250155.1 CTD-2353F22.1 -3.86 0.000168 0.0496 -0.45 -0.3 Obesity-related traits; chr5:37010302 chr5:36666214~36725195:- PAAD cis rs4299518 0.504 rs2673052 ENSG00000244357.3 RN7SL145P 3.86 0.000168 0.0496 0.29 0.3 Hirschsprung disease; chr3:45692335 chr3:45742675~45742970:+ PAAD cis rs2688608 0.653 rs12775558 ENSG00000271816.1 BMS1P4 3.86 0.000168 0.0496 0.31 0.3 Inflammatory bowel disease; chr10:73811110 chr10:73699151~73730487:- PAAD cis rs792448 0.743 rs1774249 ENSG00000229983.1 RP11-15I11.2 3.86 0.000168 0.0496 0.36 0.3 White blood cell count (basophil); chr1:212342271 chr1:212168207~212190259:+ PAAD cis rs17345786 0.602 rs11923273 ENSG00000244119.1 PDCL3P4 3.86 0.000168 0.0496 0.24 0.3 Colonoscopy-negative controls vs population controls; chr3:101619019 chr3:101712472~101713191:+ PAAD cis rs10483853 0.747 rs10132481 ENSG00000258695.2 RP3-414A15.2 -3.86 0.000168 0.0496 -0.39 -0.3 Coronary artery calcification; chr14:73452066 chr14:73522878~73530610:+ PAAD cis rs9926296 0.632 rs9935559 ENSG00000260259.1 RP11-368I7.4 3.86 0.000168 0.0496 0.34 0.3 Vitiligo; chr16:89734121 chr16:89682620~89686569:- PAAD cis rs35785195 0.593 rs12821514 ENSG00000257231.1 DYNLL1P4 3.86 0.000168 0.0497 0.44 0.3 Daytime sleep phenotypes; chr12:113796020 chr12:113789542~113789807:- PAAD cis rs61841072 0.961 rs1985630 ENSG00000253326.2 RP11-261C10.7 -3.86 0.000168 0.0497 -0.4 -0.3 Schizophrenia; chr1:242971392 chr1:243054861~243056394:- PAAD cis rs61841072 0.961 rs7517403 ENSG00000253326.2 RP11-261C10.7 -3.86 0.000168 0.0497 -0.4 -0.3 Schizophrenia; chr1:242972590 chr1:243054861~243056394:- PAAD cis rs875971 0.8 rs427557 ENSG00000232559.3 GS1-124K5.12 3.86 0.000168 0.0497 0.31 0.3 Aortic root size; chr7:66054263 chr7:66554588~66576923:- PAAD cis rs875971 0.83 rs587360 ENSG00000232559.3 GS1-124K5.12 3.86 0.000168 0.0497 0.31 0.3 Aortic root size; chr7:66057711 chr7:66554588~66576923:- PAAD cis rs2599510 0.783 rs2710630 ENSG00000276334.1 AL133243.1 -3.86 0.000168 0.0497 -0.36 -0.3 Interleukin-18 levels; chr2:32540930 chr2:32521927~32523547:+ PAAD cis rs5015933 0.872 rs491283 ENSG00000232630.1 PRPS1P2 -3.86 0.000168 0.0497 -0.27 -0.3 Body mass index; chr9:125255437 chr9:125150653~125151589:+ PAAD cis rs763121 0.889 rs6001209 ENSG00000228274.3 RP3-508I15.9 3.86 0.000168 0.0497 0.29 0.3 Menopause (age at onset); chr22:38725247 chr22:38667585~38681820:- PAAD cis rs7119038 0.818 rs11217032 ENSG00000255239.1 AP002954.6 -3.86 0.000168 0.0497 -0.42 -0.3 Sjögren's syndrome; chr11:118798896 chr11:118688039~118690600:- PAAD cis rs7119038 0.818 rs11217033 ENSG00000255239.1 AP002954.6 -3.86 0.000168 0.0497 -0.42 -0.3 Sjögren's syndrome; chr11:118802997 chr11:118688039~118690600:- PAAD cis rs11217036 1 rs11217036 ENSG00000255239.1 AP002954.6 -3.86 0.000168 0.0497 -0.42 -0.3 Allergy; chr11:118805063 chr11:118688039~118690600:- PAAD cis rs7119038 0.774 rs11217037 ENSG00000255239.1 AP002954.6 -3.86 0.000168 0.0497 -0.42 -0.3 Sjögren's syndrome; chr11:118806377 chr11:118688039~118690600:- PAAD cis rs7119038 0.774 rs11217038 ENSG00000255239.1 AP002954.6 -3.86 0.000168 0.0497 -0.42 -0.3 Sjögren's syndrome; chr11:118806646 chr11:118688039~118690600:- PAAD cis rs7119038 0.731 rs28409215 ENSG00000255239.1 AP002954.6 -3.86 0.000168 0.0497 -0.42 -0.3 Sjögren's syndrome; chr11:118808595 chr11:118688039~118690600:- PAAD cis rs7119038 0.774 rs73005423 ENSG00000255239.1 AP002954.6 -3.86 0.000168 0.0497 -0.42 -0.3 Sjögren's syndrome; chr11:118810370 chr11:118688039~118690600:- PAAD cis rs2179367 0.959 rs9373592 ENSG00000231760.4 RP11-350J20.5 3.86 0.000168 0.0497 0.38 0.3 Dupuytren's disease; chr6:149412119 chr6:149796151~149826294:- PAAD cis rs73019876 0.869 rs2522093 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21942794 chr19:21677550~21678221:- PAAD cis rs73019876 0.869 rs2666457 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21944078 chr19:21677550~21678221:- PAAD cis rs73019876 0.869 rs2522092 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21944190 chr19:21677550~21678221:- PAAD cis rs73019876 0.868 rs2666450 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21948886 chr19:21677550~21678221:- PAAD cis rs73019876 0.901 rs2666449 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21949122 chr19:21677550~21678221:- PAAD cis rs73019876 0.901 rs2522089 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21949885 chr19:21677550~21678221:- PAAD cis rs73019876 0.901 rs2214296 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21950978 chr19:21677550~21678221:- PAAD cis rs73019876 0.901 rs1848999 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21952471 chr19:21677550~21678221:- PAAD cis rs73019876 0.805 rs1849003 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21959459 chr19:21677550~21678221:- PAAD cis rs73019876 0.803 rs2522102 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21961493 chr19:21677550~21678221:- PAAD cis rs73019876 0.869 rs2522101 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21961508 chr19:21677550~21678221:- PAAD cis rs73019876 0.869 rs6511303 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21963066 chr19:21677550~21678221:- PAAD cis rs73019876 0.869 rs58270321 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21963497 chr19:21677550~21678221:- PAAD cis rs73019876 0.869 rs8108093 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21964648 chr19:21677550~21678221:- PAAD cis rs73019876 0.839 rs1064170 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21966242 chr19:21677550~21678221:- PAAD cis rs73019876 0.869 rs10412331 ENSG00000268433.1 RP11-420K14.2 3.86 0.000168 0.0497 0.34 0.3 Testicular germ cell tumor; chr19:21967560 chr19:21677550~21678221:- PAAD cis rs7208859 0.623 rs9898084 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30755316 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs28556733 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30756927 chr17:30709299~30790908:+ PAAD cis rs17826219 0.5 rs28452421 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30756962 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs28433704 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757267 chr17:30709299~30790908:+ PAAD cis rs7208859 0.573 rs28779471 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30757351 chr17:30709299~30790908:+ PAAD cis rs17826219 0.5 rs61685770 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30758695 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs57486336 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30758713 chr17:30709299~30790908:+ PAAD cis rs17826219 0.706 rs55764512 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30758740 chr17:30709299~30790908:+ PAAD cis rs7208859 0.524 rs73988172 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759314 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs12103440 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759639 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs12103508 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30759763 chr17:30709299~30790908:+ PAAD cis rs7208859 0.524 rs11653605 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30761367 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs11657777 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30764767 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs73269913 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765165 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs7217984 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30765748 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs73269916 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30769308 chr17:30709299~30790908:+ PAAD cis rs7208859 0.524 rs60114476 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30770649 chr17:30709299~30790908:+ PAAD cis rs7208859 0.524 rs8065744 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30772431 chr17:30709299~30790908:+ PAAD cis rs17826219 0.706 rs8071236 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30772984 chr17:30709299~30790908:+ PAAD cis rs17826219 0.636 rs2449770 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30774046 chr17:30709299~30790908:+ PAAD cis rs7208859 0.524 rs59913838 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774545 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs56163556 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30774850 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs8067035 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775170 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs8067338 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775327 chr17:30709299~30790908:+ PAAD cis rs7208859 0.573 rs4055105 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30775532 chr17:30709299~30790908:+ PAAD cis rs7208859 0.562 rs8078897 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779239 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs8075163 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30779292 chr17:30709299~30790908:+ PAAD cis rs17826219 0.706 rs8075107 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30779631 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs7223209 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780202 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs7223404 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780345 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9916725 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780453 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9916727 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780454 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9914499 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30780570 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs73269945 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781741 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9897728 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30781786 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs1054400 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30782936 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs1054397 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783178 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9890558 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783337 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs12006 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30783634 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs3752021 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784025 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs3752020 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784107 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9890855 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784689 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9893422 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784697 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9891166 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30784884 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs73269974 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785366 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs34756112 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30785998 chr17:30709299~30790908:+ PAAD cis rs7208859 0.573 rs60724269 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786255 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs76633166 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30786347 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs1061346 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787211 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs1061343 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787258 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs1061342 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30787445 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs55938328 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30789992 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs73269988 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30791127 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs55961983 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792268 chr17:30709299~30790908:+ PAAD cis rs7208859 0.573 rs7222803 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30792879 chr17:30709299~30790908:+ PAAD cis rs7208859 0.673 rs9899525 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30793278 chr17:30709299~30790908:+ PAAD cis rs17826219 0.568 rs7213925 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30794616 chr17:30709299~30790908:+ PAAD cis rs7208859 0.524 rs11653098 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795483 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs11658945 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30795491 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs11657990 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797182 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9911784 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797562 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9911997 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30797630 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9890862 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30798432 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs78071511 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30801136 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs11650982 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30802937 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs2035494 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803375 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs3794796 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30803862 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9915546 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805126 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9915566 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30805140 chr17:30709299~30790908:+ PAAD cis rs17826219 0.706 rs28469200 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30806554 chr17:30709299~30790908:+ PAAD cis rs7208859 0.573 rs8064686 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30807821 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs11657369 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809450 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs8075341 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30809547 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs73271842 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30810137 chr17:30709299~30790908:+ PAAD cis rs7208859 0.673 rs9895815 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811015 chr17:30709299~30790908:+ PAAD cis rs7208859 0.573 rs7214313 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30811578 chr17:30709299~30790908:+ PAAD cis rs7208859 0.673 rs8077116 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813144 chr17:30709299~30790908:+ PAAD cis rs7208859 0.524 rs28760584 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30813999 chr17:30709299~30790908:+ PAAD cis rs17826219 0.706 rs73271850 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30815122 chr17:30709299~30790908:+ PAAD cis rs17826219 0.636 rs79565452 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Body mass index; chr17:30815823 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs7208088 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816649 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs7212991 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816731 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs7208441 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30816845 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs28627615 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30818799 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9912440 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30821754 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs7220999 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822280 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs55638872 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30822534 chr17:30709299~30790908:+ PAAD cis rs7208859 0.623 rs9899268 ENSG00000264538.5 SUZ12P1 -3.86 0.000168 0.0497 -0.29 -0.3 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30823237 chr17:30709299~30790908:+ PAAD cis rs2348418 0.832 rs7294553 ENSG00000247934.4 RP11-967K21.1 3.86 0.000168 0.0497 0.28 0.3 Lung function (FEV1);Lung function (FVC); chr12:28334832 chr12:28163298~28190738:- PAAD cis rs2348418 0.798 rs11049546 ENSG00000247934.4 RP11-967K21.1 3.86 0.000168 0.0497 0.28 0.3 Lung function (FEV1);Lung function (FVC); chr12:28346942 chr12:28163298~28190738:- PAAD cis rs2348418 0.832 rs12301674 ENSG00000247934.4 RP11-967K21.1 3.86 0.000168 0.0497 0.28 0.3 Lung function (FEV1);Lung function (FVC); chr12:28357543 chr12:28163298~28190738:- PAAD cis rs2348418 0.798 rs10843161 ENSG00000247934.4 RP11-967K21.1 3.86 0.000168 0.0497 0.28 0.3 Lung function (FEV1);Lung function (FVC); chr12:28367688 chr12:28163298~28190738:- PAAD cis rs1991601 0.673 rs35808589 ENSG00000235655.3 H3F3AP4 -3.86 0.000168 0.0497 -0.5 -0.3 QRS complex (12-leadsum); chr2:174698903 chr2:174719908~174720318:+ PAAD cis rs1991601 0.673 rs35444726 ENSG00000235655.3 H3F3AP4 -3.86 0.000168 0.0497 -0.5 -0.3 QRS complex (12-leadsum); chr2:174699977 chr2:174719908~174720318:+ PAAD cis rs10800713 0.954 rs6667081 ENSG00000260088.1 RP11-92G12.3 -3.86 0.000168 0.0497 -0.41 -0.3 Tandem gait; chr1:200593366 chr1:200669507~200694250:+ PAAD cis rs10800713 0.954 rs6673474 ENSG00000260088.1 RP11-92G12.3 -3.86 0.000168 0.0497 -0.41 -0.3 Tandem gait; chr1:200594991 chr1:200669507~200694250:+ PAAD cis rs2638953 0.889 rs11049481 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28252087 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049482 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28252088 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049484 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28252254 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049485 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28252522 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs10843143 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28253484 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049488 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28259439 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs57618147 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28259902 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs716687 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28261517 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs11049491 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28262340 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049493 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28263115 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049496 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28267327 chr12:28163298~28190738:- PAAD cis rs2638953 0.819 rs10843146 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28268352 chr12:28163298~28190738:- PAAD cis rs2638953 0.889 rs2045887 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28270825 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs2172299 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28280180 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049503 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28282714 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs61922974 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28283302 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs61922975 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28283705 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs61922976 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28283837 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs61922977 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28286889 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049505 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28288087 chr12:28163298~28190738:- PAAD cis rs2638953 0.924 rs11049507 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28289554 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049509 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28290055 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs11049510 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28290839 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs61922978 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28292075 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs17432330 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28292336 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs12372448 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28293956 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs11049511 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000168 0.0497 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28294393 chr12:28163298~28190738:- PAAD cis rs4791774 1 rs4791331 ENSG00000269947.1 RP11-849F2.9 -3.86 0.000168 0.0497 -0.31 -0.3 Nonsyndromic cleft lip with or without cleft palate; chr17:9028765 chr17:8277763~8278436:+ PAAD cis rs17137566 0.808 rs9639287 ENSG00000236318.1 AC019117.1 3.86 0.000169 0.0497 0.46 0.3 Plasma kynurenine levels in major depressive disorder; chr7:17378331 chr7:17374867~17466664:+ PAAD cis rs11696845 0.899 rs2868198 ENSG00000276223.1 RP4-781B1.5 -3.86 0.000169 0.0497 -0.41 -0.3 Obesity-related traits; chr20:44739294 chr20:44746642~44747201:+ PAAD cis rs2688608 0.62 rs7080350 ENSG00000271816.1 BMS1P4 -3.86 0.000169 0.0497 -0.31 -0.3 Inflammatory bowel disease; chr10:73818085 chr10:73699151~73730487:- PAAD cis rs4725617 0.822 rs7806586 ENSG00000229153.4 EPHA1-AS1 -3.86 0.000169 0.0497 -0.72 -0.3 Blood protein levels; chr7:143410988 chr7:143407813~143523449:+ PAAD cis rs2243480 0.708 rs13242216 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000169 0.0497 -0.38 -0.3 Diabetic kidney disease; chr7:66433290 chr7:66848496~66858136:+ PAAD cis rs2243480 0.615 rs34363376 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000169 0.0497 -0.38 -0.3 Diabetic kidney disease; chr7:66474549 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs67536397 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000169 0.0497 -0.38 -0.3 Diabetic kidney disease; chr7:66482930 chr7:66848496~66858136:+ PAAD cis rs2243480 1 rs58669269 ENSG00000232546.1 RP11-458F8.1 -3.86 0.000169 0.0497 -0.38 -0.3 Diabetic kidney disease; chr7:66486966 chr7:66848496~66858136:+ PAAD cis rs6991838 0.671 rs13251307 ENSG00000272010.1 CTD-3025N20.3 3.86 0.000169 0.0497 0.31 0.3 Intelligence (multi-trait analysis); chr8:65664911 chr8:65591850~65592472:- PAAD cis rs6991838 0.733 rs10111844 ENSG00000272010.1 CTD-3025N20.3 3.86 0.000169 0.0497 0.31 0.3 Intelligence (multi-trait analysis); chr8:65690374 chr8:65591850~65592472:- PAAD cis rs2019137 0.901 rs4849176 ENSG00000274877.1 RP11-65I12.1 3.86 0.000169 0.0497 0.34 0.3 Lymphocyte counts; chr2:113220359 chr2:113237595~113240825:+ PAAD cis rs4664293 0.51 rs3903306 ENSG00000226266.5 AC009961.3 3.86 0.000169 0.0497 0.41 0.3 Monocyte percentage of white cells; chr2:159592171 chr2:159670708~159712435:- PAAD cis rs11121246 0.518 rs6684644 ENSG00000270282.1 RP5-1115A15.2 3.86 0.000169 0.0497 0.38 0.3 Plateletcrit; chr1:8850519 chr1:8512653~8513021:+ PAAD cis rs2777491 0.957 rs2015781 ENSG00000247556.5 OIP5-AS1 3.86 0.000169 0.0498 0.27 0.3 Ulcerative colitis; chr15:41356769 chr15:41283990~41309737:+ PAAD cis rs2777491 0.957 rs919961 ENSG00000247556.5 OIP5-AS1 3.86 0.000169 0.0498 0.27 0.3 Ulcerative colitis; chr15:41359523 chr15:41283990~41309737:+ PAAD cis rs891378 0.876 rs1367067 ENSG00000274245.1 RP11-357P18.2 3.86 0.000169 0.0498 0.42 0.3 Spherical equivalent (joint analysis main effects and education interaction); chr1:207269019 chr1:207372559~207373252:+ PAAD cis rs3760982 1 rs11669175 ENSG00000267058.1 RP11-15A1.3 -3.86 0.000169 0.0498 -0.26 -0.3 Breast cancer (estrogen-receptor negative);Breast cancer; chr19:43785672 chr19:43891804~43901805:- PAAD cis rs3760982 1 rs4803658 ENSG00000267058.1 RP11-15A1.3 -3.86 0.000169 0.0498 -0.26 -0.3 Breast cancer (estrogen-receptor negative);Breast cancer; chr19:43785861 chr19:43891804~43901805:- PAAD cis rs3760982 0.626 rs12463370 ENSG00000267058.1 RP11-15A1.3 -3.86 0.000169 0.0498 -0.26 -0.3 Breast cancer (estrogen-receptor negative);Breast cancer; chr19:43788014 chr19:43891804~43901805:- PAAD cis rs2562456 0.561 rs12610883 ENSG00000213976.4 CTD-2561J22.2 -3.86 0.000169 0.0498 -0.33 -0.3 Pain; chr19:21567257 chr19:21382865~21387177:+ PAAD cis rs2562456 0.837 rs11085462 ENSG00000213976.4 CTD-2561J22.2 -3.86 0.000169 0.0498 -0.33 -0.3 Pain; chr19:21567449 chr19:21382865~21387177:+ PAAD cis rs2562456 0.793 rs7259708 ENSG00000213976.4 CTD-2561J22.2 -3.86 0.000169 0.0498 -0.33 -0.3 Pain; chr19:21567846 chr19:21382865~21387177:+ PAAD cis rs193541 0.593 rs246309 ENSG00000263432.2 RN7SL689P 3.86 0.000169 0.0498 0.39 0.3 Glucose homeostasis traits; chr5:122934024 chr5:123022487~123022783:- PAAD cis rs2638953 0.924 rs7955094 ENSG00000247934.4 RP11-967K21.1 -3.86 0.000169 0.0498 -0.34 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28157097 chr12:28163298~28190738:- PAAD cis rs62560775 0.688 rs3217986 ENSG00000265194.1 RP11-70L8.4 3.86 0.000169 0.0498 0.57 0.3 Lung cancer;Lung adenocarcinoma; chr9:22005331 chr9:21858910~21861926:- PAAD cis rs7259811 0.56 rs56049479 ENSG00000279794.1 CTD-2621I17.3 -3.86 0.000169 0.0498 -0.3 -0.3 Western dietary pattern; chr19:56706204 chr19:56149817~56150490:+ PAAD cis rs7259811 0.56 rs56185441 ENSG00000279794.1 CTD-2621I17.3 -3.86 0.000169 0.0498 -0.3 -0.3 Western dietary pattern; chr19:56706268 chr19:56149817~56150490:+ PAAD cis rs7259811 0.56 rs2191435 ENSG00000279794.1 CTD-2621I17.3 -3.86 0.000169 0.0498 -0.3 -0.3 Western dietary pattern; chr19:56706439 chr19:56149817~56150490:+ PAAD cis rs4266290 0.671 rs12651314 ENSG00000214846.4 RP11-115L11.1 3.86 0.000169 0.0498 0.45 0.3 Parkinson's disease; chr4:15751947 chr4:15730962~15731627:- PAAD cis rs6723226 0.721 rs3769600 ENSG00000276334.1 AL133243.1 -3.86 0.000169 0.0499 -0.34 -0.3 Intelligence (multi-trait analysis); chr2:32391811 chr2:32521927~32523547:+ PAAD cis rs17772222 0.876 rs61983303 ENSG00000258789.1 RP11-507K2.3 -3.86 0.000169 0.0499 -0.32 -0.3 Coronary artery calcification; chr14:88764459 chr14:88551597~88552493:+ PAAD cis rs17772222 0.917 rs7157149 ENSG00000258789.1 RP11-507K2.3 -3.86 0.000169 0.0499 -0.32 -0.3 Coronary artery calcification; chr14:88765501 chr14:88551597~88552493:+ PAAD cis rs17772222 0.917 rs2224333 ENSG00000258789.1 RP11-507K2.3 -3.86 0.000169 0.0499 -0.32 -0.3 Coronary artery calcification; chr14:88768748 chr14:88551597~88552493:+ PAAD cis rs17772222 0.917 rs12590826 ENSG00000258789.1 RP11-507K2.3 -3.86 0.000169 0.0499 -0.32 -0.3 Coronary artery calcification; chr14:88769357 chr14:88551597~88552493:+ PAAD cis rs17772222 0.917 rs57889459 ENSG00000258789.1 RP11-507K2.3 -3.86 0.000169 0.0499 -0.32 -0.3 Coronary artery calcification; chr14:88770820 chr14:88551597~88552493:+ PAAD cis rs17772222 0.917 rs61982733 ENSG00000258789.1 RP11-507K2.3 -3.86 0.000169 0.0499 -0.32 -0.3 Coronary artery calcification; chr14:88776244 chr14:88551597~88552493:+ PAAD cis rs17772222 0.917 rs2145120 ENSG00000258789.1 RP11-507K2.3 -3.86 0.000169 0.0499 -0.32 -0.3 Coronary artery calcification; chr14:88777699 chr14:88551597~88552493:+ PAAD cis rs7429990 0.965 rs319686 ENSG00000228638.1 FCF1P2 -3.86 0.00017 0.0499 -0.34 -0.3 Educational attainment (years of education); chr3:47888930 chr3:48290793~48291375:- PAAD cis rs2742417 0.603 rs2742456 ENSG00000244357.3 RN7SL145P 3.86 0.00017 0.0499 0.27 0.3 Response to anti-depressant treatment in major depressive disorder; chr3:45725684 chr3:45742675~45742970:+ PAAD cis rs9487094 0.689 rs9487070 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109361200 chr6:109382795~109383666:+ PAAD cis rs9487094 0.689 rs8465 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109367335 chr6:109382795~109383666:+ PAAD cis rs9487094 0.666 rs974034 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109368228 chr6:109382795~109383666:+ PAAD cis rs9487094 0.689 rs3818933 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109370741 chr6:109382795~109383666:+ PAAD cis rs9487094 0.689 rs9487076 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109371524 chr6:109382795~109383666:+ PAAD cis rs9487094 0.696 rs1853330 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109375548 chr6:109382795~109383666:+ PAAD cis rs9487094 0.67 rs1885691 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109382188 chr6:109382795~109383666:+ PAAD cis rs9487094 0.644 rs3757230 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109383239 chr6:109382795~109383666:+ PAAD cis rs9487094 0.644 rs3757231 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109383248 chr6:109382795~109383666:+ PAAD cis rs9487094 0.666 rs2211288 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109383848 chr6:109382795~109383666:+ PAAD cis rs9487094 0.666 rs4946970 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109384807 chr6:109382795~109383666:+ PAAD cis rs9487094 0.62 rs6939953 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109390116 chr6:109382795~109383666:+ PAAD cis rs9487094 0.666 rs3757235 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109390638 chr6:109382795~109383666:+ PAAD cis rs9487094 0.666 rs746794 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109391534 chr6:109382795~109383666:+ PAAD cis rs9487094 0.643 rs730089 ENSG00000260273.1 RP11-425D10.10 3.86 0.00017 0.0499 0.36 0.3 Height; chr6:109393881 chr6:109382795~109383666:+ PAAD cis rs453301 0.658 rs9329175 ENSG00000253893.2 FAM85B 3.86 0.00017 0.0499 0.4 0.3 Joint mobility (Beighton score); chr8:9009151 chr8:8167819~8226614:- PAAD cis rs9322193 0.884 rs10872647 ENSG00000223701.3 RAET1E-AS1 3.86 0.00017 0.0499 0.37 0.3 Lung cancer; chr6:149758687 chr6:149884431~149919508:+ PAAD cis rs9322193 0.884 rs11155679 ENSG00000223701.3 RAET1E-AS1 3.86 0.00017 0.0499 0.37 0.3 Lung cancer; chr6:149758881 chr6:149884431~149919508:+ PAAD cis rs6921919 0.697 rs758398 ENSG00000204709.4 LINC01556 3.86 0.00017 0.0499 0.43 0.3 Autism spectrum disorder or schizophrenia; chr6:28352897 chr6:28943877~28944537:+ PAAD cis rs6479891 0.818 rs9415700 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63385805 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9415701 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63391749 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs9415708 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63430282 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs72837025 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63434731 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12784772 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63435695 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs77494594 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63437549 chr10:63634317~63634827:- PAAD cis rs6479891 0.908 rs2616631 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63448154 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs2466128 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63448561 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs2719815 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63450534 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs2616630 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63453579 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs2616629 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63454056 chr10:63634317~63634827:- PAAD cis rs6479891 0.915 rs2616628 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63460197 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs2393980 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63464750 chr10:63634317~63634827:- PAAD cis rs6479891 0.818 rs59215788 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63474074 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs59246603 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63474182 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12414159 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63479017 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs10995543 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63479787 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs4746138 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63481981 chr10:63634317~63634827:- PAAD cis rs6479891 0.818 rs2393976 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63493679 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs72837056 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63500718 chr10:63634317~63634827:- PAAD cis rs6479891 0.818 rs11815969 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63506095 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs72837070 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63514919 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs61853635 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63516750 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs4745729 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63517323 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs12416349 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63517783 chr10:63634317~63634827:- PAAD cis rs6479891 0.908 rs12412946 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63529792 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs59035163 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63532283 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs16918567 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63534910 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs16918573 ENSG00000232075.1 MRPL35P2 3.86 0.00017 0.0499 0.48 0.3 Arthritis (juvenile idiopathic); chr10:63541045 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs2893922 ENSG00000232075.1 MRPL35P2 -3.86 0.00017 0.0499 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63487259 chr10:63634317~63634827:- PAAD cis rs6479891 1 rs16918575 ENSG00000232075.1 MRPL35P2 -3.86 0.00017 0.0499 -0.48 -0.3 Arthritis (juvenile idiopathic); chr10:63541565 chr10:63634317~63634827:- PAAD cis rs2086824 0.702 rs3114896 ENSG00000274627.1 RP11-104N10.2 -3.86 0.00017 0.0499 -0.27 -0.3 Multiple myeloma (IgH translocation); chr16:89327154 chr16:89516797~89522217:+ PAAD cis rs498136 1 rs660963 ENSG00000250508.1 RP11-757G1.6 -3.86 0.00017 0.05 -0.36 -0.3 Cutaneous malignant melanoma;Melanoma; chr11:69572194 chr11:68870664~68874542:+ PAAD cis rs853679 0.825 rs8180562 ENSG00000204709.4 LINC01556 3.86 0.00017 0.05 0.58 0.3 Depression; chr6:28173682 chr6:28943877~28944537:+ PAAD cis rs853679 0.882 rs9380064 ENSG00000204709.4 LINC01556 3.86 0.00017 0.05 0.58 0.3 Depression; chr6:28175340 chr6:28943877~28944537:+ PAAD cis rs5769765 0.908 rs138891 ENSG00000278869.1 CITF22-49E9.3 3.86 0.00017 0.05 0.45 0.3 Schizophrenia; chr22:49834093 chr22:49933198~49934074:- PAAD cis rs2638953 0.925 rs7312201 ENSG00000247934.4 RP11-967K21.1 -3.86 0.00017 0.05 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28417885 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049586 ENSG00000247934.4 RP11-967K21.1 -3.86 0.00017 0.05 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28418028 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs11049588 ENSG00000247934.4 RP11-967K21.1 -3.86 0.00017 0.05 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28418628 chr12:28163298~28190738:- PAAD cis rs2638953 0.962 rs12372172 ENSG00000247934.4 RP11-967K21.1 -3.86 0.00017 0.05 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28419945 chr12:28163298~28190738:- PAAD cis rs2638953 0.925 rs10843166 ENSG00000247934.4 RP11-967K21.1 -3.86 0.00017 0.05 -0.33 -0.3 Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI; chr12:28422811 chr12:28163298~28190738:- PAAD cis rs4965272 0.83 rs11637820 ENSG00000254744.3 CTD-3076O17.1 3.86 0.00017 0.05 0.45 0.3 Gastroesophageal reflux disease; chr15:100020034 chr15:99970215~99974010:+ PAAD trans rs928391 0.681 rs12145743 ENSG00000227183.3 HDGFP1 23.68 7.14e-53 2.91e-42 1.12 0.89 Platelet count; chr1:156730859 chrX:131646639~131646890:+ PAAD trans rs928391 0.681 rs11264535 ENSG00000227183.3 HDGFP1 23.19 8.83e-52 1.81e-41 1.12 0.88 Platelet count; chr1:156752632 chrX:131646639~131646890:+ PAAD trans rs928391 0.681 rs3806417 ENSG00000227183.3 HDGFP1 22.65 1.4e-50 9.76e-41 1.12 0.88 Platelet count; chr1:156741831 chrX:131646639~131646890:+ PAAD trans rs928391 0.624 rs4399146 ENSG00000227183.3 HDGFP1 22.65 1.4e-50 9.76e-41 1.12 0.88 Platelet count; chr1:156743766 chrX:131646639~131646890:+ PAAD trans rs928391 0.681 rs11264533 ENSG00000227183.3 HDGFP1 22.65 1.4e-50 9.76e-41 1.12 0.88 Platelet count; chr1:156748656 chrX:131646639~131646890:+ PAAD trans rs928391 0.681 rs12161427 ENSG00000227183.3 HDGFP1 22.38 5.87e-50 2.78e-40 1.11 0.88 Platelet count; chr1:156736030 chrX:131646639~131646890:+ PAAD trans rs1816752 0.905 rs9511264 ENSG00000237917.1 PARP4P1 -22.27 1.05e-49 4.35e-40 -1.13 -0.87 Obesity-related traits; chr13:24438079 chrY:26594851~26634652:- PAAD trans rs928391 0.681 rs4501833 ENSG00000227183.3 HDGFP1 21.7 2.02e-48 7.05e-39 1.1 0.87 Platelet count; chr1:156746806 chrX:131646639~131646890:+ PAAD trans rs928391 0.681 rs9427242 ENSG00000227183.3 HDGFP1 -21.34 1.44e-47 1.99e-38 -1.13 -0.87 Platelet count; chr1:156755209 chrX:131646639~131646890:+ PAAD trans rs1816752 0.905 rs8002215 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24416229 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs9511242 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24419261 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs7317850 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24419899 chrY:26594851~26634652:- PAAD trans rs1816752 0.719 rs11841989 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24423560 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs9581025 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24423687 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs9581026 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24423788 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs9581027 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24423790 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs9318529 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24424190 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs7991450 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24425898 chrY:26594851~26634652:- PAAD trans rs1816752 0.774 rs7986162 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24425941 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs4769352 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24426237 chrY:26594851~26634652:- PAAD trans rs1816752 0.805 rs4769353 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24426318 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs7571 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24426479 chrY:26594851~26634652:- PAAD trans rs1816752 0.837 rs7324645 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24426717 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs1050112 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24435159 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs13428 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24435303 chrY:26594851~26634652:- PAAD trans rs1816752 0.875 rs1050110 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24435347 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs8000215 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24435648 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs11839006 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24435893 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs2033955 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24436406 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs2033954 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24436429 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs9511260 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24437038 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs7320102 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24437435 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs7339140 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24437764 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs9511266 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24438366 chrY:26594851~26634652:- PAAD trans rs1816752 0.817 rs7985394 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24438714 chrY:26594851~26634652:- PAAD trans rs1816752 0.789 rs7986037 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24438715 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs7995492 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24438885 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs7995909 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24439159 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs6490927 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24439802 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs6490928 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24439921 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs6490929 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24440114 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs3825449 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24440303 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs7998797 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24440850 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs7981337 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24440915 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs7981480 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24440966 chrY:26594851~26634652:- PAAD trans rs1816752 0.837 rs4769355 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24441059 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs4770680 ENSG00000237917.1 PARP4P1 21.21 2.88e-47 1.99e-38 1.1 0.86 Obesity-related traits; chr13:24441110 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs4770666 ENSG00000237917.1 PARP4P1 21.2 3.05e-47 2.07e-38 1.1 0.86 Obesity-related traits; chr13:24414891 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs7400631 ENSG00000237917.1 PARP4P1 21.2 3.05e-47 2.07e-38 1.1 0.86 Obesity-related traits; chr13:24415927 chrY:26594851~26634652:- PAAD trans rs1816752 0.837 rs7139748 ENSG00000237917.1 PARP4P1 21.17 3.56e-47 2.32e-38 1.1 0.86 Obesity-related traits; chr13:24411531 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs73469543 ENSG00000237917.1 PARP4P1 21.11 4.86e-47 3.1e-38 1.1 0.86 Obesity-related traits; chr13:24424832 chrY:26594851~26634652:- PAAD trans rs1816752 0.719 rs11843470 ENSG00000237917.1 PARP4P1 21.11 4.93e-47 3.11e-38 1.1 0.86 Obesity-related traits; chr13:24423561 chrY:26594851~26634652:- PAAD trans rs1816752 0.837 rs9318530 ENSG00000237917.1 PARP4P1 -20.98 9.74e-47 6.09e-38 -1.11 -0.86 Obesity-related traits; chr13:24424419 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs4769348 ENSG00000237917.1 PARP4P1 20.95 1.17e-46 6.28e-38 1.1 0.86 Obesity-related traits; chr13:24400975 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs8002309 ENSG00000237917.1 PARP4P1 20.95 1.17e-46 6.28e-38 1.1 0.86 Obesity-related traits; chr13:24402217 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs2000153 ENSG00000237917.1 PARP4P1 20.94 1.18e-46 6.28e-38 1.1 0.86 Obesity-related traits; chr13:24405752 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs1348110 ENSG00000237917.1 PARP4P1 20.87 1.81e-46 9.39e-38 1.09 0.86 Obesity-related traits; chr13:24406537 chrY:26594851~26634652:- PAAD trans rs6477998 0.58 rs10759638 ENSG00000238072.1 RP11-305M3.2 -20.75 3.33e-46 1.7e-37 -1.2 -0.86 Hematology traits; chr9:113280212 chr7:129410113~129410370:- PAAD trans rs6477998 0.58 rs9299214 ENSG00000238072.1 RP11-305M3.2 20.46 1.67e-45 7.3e-37 1.25 0.86 Hematology traits; chr9:113273416 chr7:129410113~129410370:- PAAD trans rs6477998 0.58 rs11552582 ENSG00000238072.1 RP11-305M3.2 20.42 2.09e-45 8.25e-37 1.21 0.86 Hematology traits; chr9:113282718 chr7:129410113~129410370:- PAAD trans rs7949030 0.626 rs7943191 ENSG00000186676.3 EEF1GP1 20.39 2.45e-45 9.5e-37 1.16 0.86 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561079 chr7:125033453~125035301:+ PAAD trans rs7949030 0.626 rs11231145 ENSG00000186676.3 EEF1GP1 20.39 2.45e-45 9.5e-37 1.16 0.86 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561382 chr7:125033453~125035301:+ PAAD trans rs7949030 0.626 rs71490390 ENSG00000186676.3 EEF1GP1 20.39 2.45e-45 9.5e-37 1.16 0.86 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561713 chr7:125033453~125035301:+ PAAD trans rs1816752 0.805 rs61614647 ENSG00000237917.1 PARP4P1 20.38 2.54e-45 9.75e-37 1.1 0.86 Obesity-related traits; chr13:24441829 chrY:26594851~26634652:- PAAD trans rs1816752 0.774 rs55888616 ENSG00000237917.1 PARP4P1 20.38 2.54e-45 9.75e-37 1.1 0.86 Obesity-related traits; chr13:24441954 chrY:26594851~26634652:- PAAD trans rs7949030 0.626 rs11231144 ENSG00000186676.3 EEF1GP1 20.37 2.62e-45 9.99e-37 1.16 0.86 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62560566 chr7:125033453~125035301:+ PAAD trans rs1816752 0.905 rs9511249 ENSG00000237917.1 PARP4P1 20.31 3.81e-45 1.42e-36 1.1 0.85 Obesity-related traits; chr13:24425457 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs9511261 ENSG00000237917.1 PARP4P1 20.29 4.24e-45 1.54e-36 1.1 0.85 Obesity-related traits; chr13:24437880 chrY:26594851~26634652:- PAAD trans rs1816752 0.905 rs9511262 ENSG00000237917.1 PARP4P1 20.29 4.24e-45 1.54e-36 1.1 0.85 Obesity-related traits; chr13:24437885 chrY:26594851~26634652:- PAAD trans rs13177918 0.677 rs3857421 ENSG00000213058.3 RP4-765C7.2 -20.26 4.8e-45 1.71e-36 -1.16 -0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:178411616~178411972:+ PAAD trans rs1816752 0.774 rs2862895 ENSG00000237917.1 PARP4P1 20.15 9.14e-45 3.14e-36 1.1 0.85 Obesity-related traits; chr13:24410328 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs4770665 ENSG00000237917.1 PARP4P1 20.08 1.32e-44 4.34e-36 1.09 0.85 Obesity-related traits; chr13:24414810 chrY:26594851~26634652:- PAAD trans rs1816752 0.721 rs7399656 ENSG00000237917.1 PARP4P1 20.08 1.32e-44 4.34e-36 1.09 0.85 Obesity-related traits; chr13:24415708 chrY:26594851~26634652:- PAAD trans rs1816752 0.749 rs77832754 ENSG00000237917.1 PARP4P1 20.08 1.32e-44 4.34e-36 1.09 0.85 Obesity-related traits; chr13:24416016 chrY:26594851~26634652:- PAAD trans rs1816752 0.633 rs8002387 ENSG00000237917.1 PARP4P1 20.08 1.32e-44 4.34e-36 1.09 0.85 Obesity-related traits; chr13:24416306 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs7985478 ENSG00000237917.1 PARP4P1 20.08 1.32e-44 4.34e-36 1.09 0.85 Obesity-related traits; chr13:24417135 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs6490917 ENSG00000237917.1 PARP4P1 20.08 1.32e-44 4.34e-36 1.09 0.85 Obesity-related traits; chr13:24423119 chrY:26594851~26634652:- PAAD trans rs7949030 0.626 rs11231141 ENSG00000186676.3 EEF1GP1 20.07 1.36e-44 4.44e-36 1.15 0.85 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62558793 chr7:125033453~125035301:+ PAAD trans rs1816752 0.777 rs6490915 ENSG00000237917.1 PARP4P1 20.07 1.38e-44 4.5e-36 1.09 0.85 Obesity-related traits; chr13:24413724 chrY:26594851~26634652:- PAAD trans rs1816752 0.755 rs1981277 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24409375 chrY:26594851~26634652:- PAAD trans rs1816752 0.712 rs9507335 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24409766 chrY:26594851~26634652:- PAAD trans rs1816752 0.811 rs9507337 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24410807 chrY:26594851~26634652:- PAAD trans rs1816752 0.783 rs7317439 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24410939 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs7316961 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24411039 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs7317504 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24411287 chrY:26594851~26634652:- PAAD trans rs1816752 0.783 rs7317712 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24411365 chrY:26594851~26634652:- PAAD trans rs1816752 0.783 rs7139527 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24411374 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs9511240 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24411768 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs7988388 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24412675 chrY:26594851~26634652:- PAAD trans rs1816752 0.875 rs7993132 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24412903 chrY:26594851~26634652:- PAAD trans rs1816752 0.792 rs7330956 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24413174 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs4770664 ENSG00000237917.1 PARP4P1 20.04 1.66e-44 4.92e-36 1.09 0.85 Obesity-related traits; chr13:24414695 chrY:26594851~26634652:- PAAD trans rs1816752 0.748 rs6490912 ENSG00000237917.1 PARP4P1 20.02 1.83e-44 5.3e-36 1.09 0.85 Obesity-related traits; chr13:24408941 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs1981276 ENSG00000237917.1 PARP4P1 20.02 1.83e-44 5.3e-36 1.09 0.85 Obesity-related traits; chr13:24409361 chrY:26594851~26634652:- PAAD trans rs1816752 0.837 rs57052031 ENSG00000237917.1 PARP4P1 20.02 1.83e-44 5.3e-36 1.09 0.85 Obesity-related traits; chr13:24409730 chrY:26594851~26634652:- PAAD trans rs13177918 0.677 rs13161099 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:178411616~178411972:+ PAAD trans rs13177918 0.629 rs13161261 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13161417 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13161156 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs4541646 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs3900644 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs2070844 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs2073472 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:178411616~178411972:+ PAAD trans rs13177918 0.629 rs2070842 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13171800 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs2070841 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13177951 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13177970 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13164105 ENSG00000213058.3 RP4-765C7.2 20 2.1e-44 5.57e-36 1.18 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:178411616~178411972:+ PAAD trans rs1816752 0.633 rs9578729 ENSG00000237917.1 PARP4P1 19.99 2.21e-44 5.79e-36 1.11 0.85 Obesity-related traits; chr13:24425106 chrY:26594851~26634652:- PAAD trans rs1816752 0.87 rs9581029 ENSG00000237917.1 PARP4P1 19.99 2.21e-44 5.79e-36 1.11 0.85 Obesity-related traits; chr13:24425147 chrY:26594851~26634652:- PAAD trans rs928391 0.681 rs11264534 ENSG00000227183.3 HDGFP1 19.9 3.59e-44 8.35e-36 1.14 0.85 Platelet count; chr1:156750758 chrX:131646639~131646890:+ PAAD trans rs928391 0.652 rs12030654 ENSG00000227183.3 HDGFP1 19.9 3.59e-44 8.35e-36 1.14 0.85 Platelet count; chr1:156751240 chrX:131646639~131646890:+ PAAD trans rs1816752 0.875 rs8001187 ENSG00000237917.1 PARP4P1 19.86 4.51e-44 1.04e-35 1.09 0.85 Obesity-related traits; chr13:24402276 chrY:26594851~26634652:- PAAD trans rs1816752 0.783 rs9507333 ENSG00000237917.1 PARP4P1 19.86 4.51e-44 1.04e-35 1.09 0.85 Obesity-related traits; chr13:24404172 chrY:26594851~26634652:- PAAD trans rs6477998 0.58 rs10981715 ENSG00000238072.1 RP11-305M3.2 19.83 5.29e-44 1.21e-35 1.19 0.85 Hematology traits; chr9:113287218 chr7:129410113~129410370:- PAAD trans rs13177918 0.677 rs4841 ENSG00000213058.3 RP4-765C7.2 19.77 7.45e-44 1.68e-35 1.17 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13183077 ENSG00000213058.3 RP4-765C7.2 19.77 7.45e-44 1.68e-35 1.17 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs3797622 ENSG00000213058.3 RP4-765C7.2 19.62 1.66e-43 3.71e-35 1.17 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13181401 ENSG00000213058.3 RP4-765C7.2 19.61 1.8e-43 4e-35 1.17 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:178411616~178411972:+ PAAD trans rs13177918 0.686 rs12654827 ENSG00000213058.3 RP4-765C7.2 19.57 2.22e-43 4.82e-35 1.17 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13160685 ENSG00000213058.3 RP4-765C7.2 19.57 2.22e-43 4.82e-35 1.17 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:178411616~178411972:+ PAAD trans rs7949030 0.626 rs7930896 ENSG00000186676.3 EEF1GP1 19.56 2.31e-43 4.94e-35 1.12 0.85 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62557800 chr7:125033453~125035301:+ PAAD trans rs1816752 0.806 rs3816218 ENSG00000237917.1 PARP4P1 19.54 2.59e-43 5.22e-35 1.1 0.85 Obesity-related traits; chr13:24443033 chrY:26594851~26634652:- PAAD trans rs1816752 0.666 rs7994022 ENSG00000237917.1 PARP4P1 19.54 2.59e-43 5.22e-35 1.1 0.85 Obesity-related traits; chr13:24443092 chrY:26594851~26634652:- PAAD trans rs1816752 0.712 rs6490932 ENSG00000237917.1 PARP4P1 19.54 2.59e-43 5.22e-35 1.1 0.85 Obesity-related traits; chr13:24443313 chrY:26594851~26634652:- PAAD trans rs7949030 0.626 rs61296092 ENSG00000186676.3 EEF1GP1 19.46 4.22e-43 8.41e-35 1.12 0.84 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62553366 chr7:125033453~125035301:+ PAAD trans rs7949030 0.626 rs7124057 ENSG00000186676.3 EEF1GP1 19.38 6.39e-43 1.24e-34 1.15 0.84 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62566624 chr7:125033453~125035301:+ PAAD trans rs7949030 0.626 rs1061093 ENSG00000186676.3 EEF1GP1 19.38 6.39e-43 1.24e-34 1.15 0.84 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62567436 chr7:125033453~125035301:+ PAAD trans rs7949030 0.626 rs72927213 ENSG00000186676.3 EEF1GP1 19.38 6.39e-43 1.24e-34 1.15 0.84 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62583726 chr7:125033453~125035301:+ PAAD trans rs1816752 0.638 rs9578730 ENSG00000237917.1 PARP4P1 19.35 7.5e-43 1.46e-34 1.09 0.84 Obesity-related traits; chr13:24425545 chrY:26594851~26634652:- PAAD trans rs1816752 0.712 rs2862898 ENSG00000237917.1 PARP4P1 19.33 8.48e-43 1.63e-34 1.08 0.84 Obesity-related traits; chr13:24414323 chrY:26594851~26634652:- PAAD trans rs1816752 0.652 rs2902356 ENSG00000237917.1 PARP4P1 19.33 8.48e-43 1.63e-34 1.08 0.84 Obesity-related traits; chr13:24414333 chrY:26594851~26634652:- PAAD trans rs1816752 0.776 rs7998843 ENSG00000237917.1 PARP4P1 19.22 1.59e-42 3.06e-34 1.1 0.84 Obesity-related traits; chr13:24443147 chrY:26594851~26634652:- PAAD trans rs1816752 0.819 rs4769349 ENSG00000237917.1 PARP4P1 -19.17 2.07e-42 3.8e-34 -1.07 -0.84 Obesity-related traits; chr13:24408694 chrY:26594851~26634652:- PAAD trans rs6477998 0.603 rs10117451 ENSG00000238072.1 RP11-305M3.2 19.13 2.61e-42 4.76e-34 1.23 0.84 Hematology traits; chr9:113273610 chr7:129410113~129410370:- PAAD trans rs13177918 0.677 rs3857421 ENSG00000224114.1 RP11-343H5.4 -19.06 3.99e-42 7.19e-34 -1.17 -0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs57890152 ENSG00000213058.3 RP4-765C7.2 19.05 4.18e-42 7.51e-34 1.17 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs13161099 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr5:116562562~116562930:+ PAAD trans rs13177918 0.629 rs13161261 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13161417 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13161156 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs4541646 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs3900644 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs2070844 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs2073472 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr5:116562562~116562930:+ PAAD trans rs13177918 0.629 rs2070842 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13171800 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs2070841 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13177951 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13177970 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13164105 ENSG00000239528.1 RPS14P8 18.88 1.07e-41 1.83e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr5:116562562~116562930:+ PAAD trans rs13177918 0.686 rs12654827 ENSG00000239528.1 RPS14P8 18.76 2.11e-41 3.54e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13160685 ENSG00000239528.1 RPS14P8 18.76 2.11e-41 3.54e-33 1.18 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr5:116562562~116562930:+ PAAD trans rs7949030 0.59 rs12225213 ENSG00000186676.3 EEF1GP1 18.73 2.45e-41 4.1e-33 1.15 0.84 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62582776 chr7:125033453~125035301:+ PAAD trans rs13177918 0.677 rs13161099 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:206695837~206696269:- PAAD trans rs13177918 0.629 rs13161261 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs13161417 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs13161156 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs4541646 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs3900644 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs2070844 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs2073472 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:206695837~206696269:- PAAD trans rs13177918 0.629 rs2070842 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs13171800 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs2070841 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs13177951 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs13177970 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs13164105 ENSG00000224114.1 RP11-343H5.4 18.56 6.69e-41 1.06e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:206695837~206696269:- PAAD trans rs1816752 0.819 rs7400583 ENSG00000237917.1 PARP4P1 18.51 8.79e-41 1.39e-32 1.06 0.83 Obesity-related traits; chr13:24415916 chrY:26594851~26634652:- PAAD trans rs1816752 0.713 rs7336357 ENSG00000237917.1 PARP4P1 18.48 1.02e-40 1.58e-32 1.09 0.83 Obesity-related traits; chr13:24443452 chrY:26594851~26634652:- PAAD trans rs1816752 0.683 rs7330532 ENSG00000237917.1 PARP4P1 18.48 1.02e-40 1.58e-32 1.09 0.83 Obesity-related traits; chr13:24443453 chrY:26594851~26634652:- PAAD trans rs1816752 0.59 rs61947036 ENSG00000237917.1 PARP4P1 18.48 1.02e-40 1.58e-32 1.09 0.83 Obesity-related traits; chr13:24443544 chrY:26594851~26634652:- PAAD trans rs1816752 0.746 rs9511270 ENSG00000237917.1 PARP4P1 18.48 1.02e-40 1.58e-32 1.09 0.83 Obesity-related traits; chr13:24444542 chrY:26594851~26634652:- PAAD trans rs13177918 0.677 rs4841 ENSG00000239528.1 RPS14P8 18.48 1.04e-40 1.59e-32 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13183077 ENSG00000239528.1 RPS14P8 18.48 1.04e-40 1.59e-32 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr5:116562562~116562930:+ PAAD trans rs13177918 0.75 rs58256223 ENSG00000213058.3 RP4-765C7.2 18.43 1.39e-40 2.12e-32 1.12 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr1:178411616~178411972:+ PAAD trans rs13177918 0.75 rs59354956 ENSG00000213058.3 RP4-765C7.2 18.43 1.39e-40 2.12e-32 1.12 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr1:178411616~178411972:+ PAAD trans rs13177918 0.677 rs57890152 ENSG00000239528.1 RPS14P8 18.43 1.42e-40 2.15e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr5:116562562~116562930:+ PAAD trans rs13177918 0.686 rs12654827 ENSG00000224114.1 RP11-343H5.4 18.41 1.57e-40 2.37e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs13160685 ENSG00000224114.1 RP11-343H5.4 18.41 1.57e-40 2.37e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs3857421 ENSG00000239528.1 RPS14P8 -18.39 1.71e-40 2.57e-32 -1.15 -0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs4841 ENSG00000224114.1 RP11-343H5.4 18.39 1.78e-40 2.66e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs13183077 ENSG00000224114.1 RP11-343H5.4 18.39 1.78e-40 2.66e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs3797622 ENSG00000224114.1 RP11-343H5.4 18.36 2.11e-40 3.15e-32 1.18 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:206695837~206696269:- PAAD trans rs13177918 0.677 rs3797622 ENSG00000239528.1 RPS14P8 18.33 2.47e-40 3.68e-32 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs13181401 ENSG00000239528.1 RPS14P8 18.31 2.79e-40 4.15e-32 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr5:116562562~116562930:+ PAAD trans rs6477998 0.557 rs3750534 ENSG00000238072.1 RP11-305M3.2 18.19 5.61e-40 8.3e-32 1.16 0.83 Hematology traits; chr9:113297844 chr7:129410113~129410370:- PAAD trans rs6477998 0.58 rs3750532 ENSG00000238072.1 RP11-305M3.2 18.19 5.61e-40 8.3e-32 1.16 0.83 Hematology traits; chr9:113298207 chr7:129410113~129410370:- PAAD trans rs13177918 0.677 rs13181401 ENSG00000224114.1 RP11-343H5.4 18.09 9.68e-40 1.43e-31 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:206695837~206696269:- PAAD trans rs7949030 0.626 rs11231154 ENSG00000186676.3 EEF1GP1 18.09 1e-39 1.46e-31 1.15 0.83 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62594821 chr7:125033453~125035301:+ PAAD trans rs7949030 0.591 rs11231156 ENSG00000186676.3 EEF1GP1 18.09 1e-39 1.46e-31 1.15 0.83 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598982 chr7:125033453~125035301:+ PAAD trans rs7949030 0.591 rs12049914 ENSG00000186676.3 EEF1GP1 18.09 1e-39 1.46e-31 1.15 0.83 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62601964 chr7:125033453~125035301:+ PAAD trans rs7949030 0.591 rs35156678 ENSG00000186676.3 EEF1GP1 18.09 1e-39 1.46e-31 1.15 0.83 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602409 chr7:125033453~125035301:+ PAAD trans rs7949030 0.596 rs71490394 ENSG00000186676.3 EEF1GP1 18.09 1e-39 1.46e-31 1.15 0.83 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602683 chr7:125033453~125035301:+ PAAD trans rs6477998 0.58 rs4979231 ENSG00000238072.1 RP11-305M3.2 18.01 1.54e-39 2.22e-31 1.17 0.83 Hematology traits; chr9:113286475 chr7:129410113~129410370:- PAAD trans rs6477998 0.58 rs2296073 ENSG00000238072.1 RP11-305M3.2 17.91 2.79e-39 4e-31 1.14 0.82 Hematology traits; chr9:113299348 chr7:129410113~129410370:- PAAD trans rs13177918 0.75 rs58256223 ENSG00000239528.1 RPS14P8 17.87 3.42e-39 4.85e-31 1.13 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr5:116562562~116562930:+ PAAD trans rs13177918 0.75 rs59354956 ENSG00000239528.1 RPS14P8 17.87 3.42e-39 4.85e-31 1.13 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr5:116562562~116562930:+ PAAD trans rs13177918 0.677 rs57890152 ENSG00000224114.1 RP11-343H5.4 17.72 8.15e-39 1.15e-30 1.17 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:206695837~206696269:- PAAD trans rs6477998 0.58 rs4979233 ENSG00000238072.1 RP11-305M3.2 17.55 2.28e-38 3.16e-30 1.15 0.82 Hematology traits; chr9:113295501 chr7:129410113~129410370:- PAAD trans rs941207 0.756 rs2926743 ENSG00000121089.4 NACA3P 17.49 3.08e-38 4.2e-30 1.22 0.82 Platelet count; chr12:56720316 chr4:164943290~164943937:+ PAAD trans rs13177918 0.557 rs12520101 ENSG00000213058.3 RP4-765C7.2 17.44 4.19e-38 5.69e-30 1.14 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:178411616~178411972:+ PAAD trans rs7949030 0.596 rs11231138 ENSG00000186676.3 EEF1GP1 17.43 4.59e-38 6.2e-30 1.11 0.82 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62548723 chr7:125033453~125035301:+ PAAD trans rs6477998 0.557 rs11789755 ENSG00000238072.1 RP11-305M3.2 17.4 5.18e-38 6.98e-30 1.15 0.82 Hematology traits; chr9:113292796 chr7:129410113~129410370:- PAAD trans rs941207 0.724 rs4788 ENSG00000121089.4 NACA3P 17.19 1.79e-37 2.37e-29 1.2 0.81 Platelet count; chr12:56712876 chr4:164943290~164943937:+ PAAD trans rs1816752 1 rs1816752 ENSG00000237917.1 PARP4P1 17.1 3e-37 3.96e-29 1.07 0.81 Obesity-related traits; chr13:24406811 chrY:26594851~26634652:- PAAD trans rs13177918 0.557 rs12520101 ENSG00000239528.1 RPS14P8 17.05 4.15e-37 5.41e-29 1.16 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr5:116562562~116562930:+ PAAD trans rs13177918 0.626 rs3819332 ENSG00000213058.3 RP4-765C7.2 16.93 8.12e-37 1.04e-28 1.09 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:178411616~178411972:+ PAAD trans rs13177918 0.626 rs13170300 ENSG00000213058.3 RP4-765C7.2 16.93 8.12e-37 1.04e-28 1.09 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:178411616~178411972:+ PAAD trans rs13177918 0.603 rs13175992 ENSG00000213058.3 RP4-765C7.2 16.93 8.12e-37 1.04e-28 1.09 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr1:178411616~178411972:+ PAAD trans rs13177918 0.559 rs10447224 ENSG00000213058.3 RP4-765C7.2 16.91 9.19e-37 1.17e-28 1.03 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:178411616~178411972:+ PAAD trans rs13177918 0.559 rs10447225 ENSG00000213058.3 RP4-765C7.2 16.91 9.19e-37 1.17e-28 1.03 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:178411616~178411972:+ PAAD trans rs6477998 0.58 rs12343629 ENSG00000238072.1 RP11-305M3.2 16.9 9.95e-37 1.26e-28 1.14 0.81 Hematology traits; chr9:113279301 chr7:129410113~129410370:- PAAD trans rs13177918 0.626 rs3819332 ENSG00000224114.1 RP11-343H5.4 16.86 1.28e-36 1.61e-28 1.11 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:206695837~206696269:- PAAD trans rs13177918 0.626 rs13170300 ENSG00000224114.1 RP11-343H5.4 16.86 1.28e-36 1.61e-28 1.11 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:206695837~206696269:- PAAD trans rs13177918 0.603 rs13175992 ENSG00000224114.1 RP11-343H5.4 16.86 1.28e-36 1.61e-28 1.11 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr1:206695837~206696269:- PAAD trans rs13177918 0.559 rs10447224 ENSG00000224114.1 RP11-343H5.4 16.82 1.64e-36 2.05e-28 1.05 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:206695837~206696269:- PAAD trans rs13177918 0.559 rs10447225 ENSG00000224114.1 RP11-343H5.4 16.82 1.64e-36 2.05e-28 1.05 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:206695837~206696269:- PAAD trans rs13177918 0.626 rs13175436 ENSG00000224114.1 RP11-343H5.4 16.81 1.65e-36 2.05e-28 1.12 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr1:206695837~206696269:- PAAD trans rs13177918 0.559 rs12109637 ENSG00000224114.1 RP11-343H5.4 16.79 1.96e-36 2.43e-28 1.04 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr1:206695837~206696269:- PAAD trans rs941207 0.756 rs2958149 ENSG00000121089.4 NACA3P 16.78 2.05e-36 2.53e-28 1.21 0.81 Platelet count; chr12:56716008 chr4:164943290~164943937:+ PAAD trans rs941207 0.724 rs1979325 ENSG00000121089.4 NACA3P 16.78 2.05e-36 2.53e-28 1.21 0.81 Platelet count; chr12:56728152 chr4:164943290~164943937:+ PAAD trans rs6477998 0.58 rs7027833 ENSG00000238072.1 RP11-305M3.2 16.77 2.12e-36 2.61e-28 1.14 0.81 Hematology traits; chr9:113301377 chr7:129410113~129410370:- PAAD trans rs13177918 0.578 rs35919198 ENSG00000224114.1 RP11-343H5.4 16.71 3.01e-36 3.7e-28 1.11 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr1:206695837~206696269:- PAAD trans rs13177918 0.626 rs13175436 ENSG00000213058.3 RP4-765C7.2 16.71 3.07e-36 3.77e-28 1.09 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr1:178411616~178411972:+ PAAD trans rs13177918 0.75 rs58256223 ENSG00000224114.1 RP11-343H5.4 16.71 3.12e-36 3.78e-28 1.11 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr1:206695837~206696269:- PAAD trans rs13177918 0.75 rs59354956 ENSG00000224114.1 RP11-343H5.4 16.71 3.12e-36 3.78e-28 1.11 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr1:206695837~206696269:- PAAD trans rs13177918 0.578 rs35919198 ENSG00000213058.3 RP4-765C7.2 16.7 3.26e-36 3.93e-28 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr1:178411616~178411972:+ PAAD trans rs941207 0.756 rs7313074 ENSG00000121089.4 NACA3P -16.7 3.27e-36 3.94e-28 -1.18 -0.8 Platelet count; chr12:56760705 chr4:164943290~164943937:+ PAAD trans rs1816752 1 rs9507341 ENSG00000237917.1 PARP4P1 -16.68 3.62e-36 4.35e-28 -1.04 -0.8 Obesity-related traits; chr13:24432440 chrY:26594851~26634652:- PAAD trans rs13177918 0.626 rs67026795 ENSG00000224114.1 RP11-343H5.4 16.68 3.73e-36 4.47e-28 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr1:206695837~206696269:- PAAD trans rs13177918 0.603 rs10447222 ENSG00000224114.1 RP11-343H5.4 16.68 3.73e-36 4.47e-28 1.12 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr1:206695837~206696269:- PAAD trans rs13177918 0.559 rs12109637 ENSG00000213058.3 RP4-765C7.2 16.63 5.05e-36 6.02e-28 1.01 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr1:178411616~178411972:+ PAAD trans rs941207 0.756 rs7978685 ENSG00000121089.4 NACA3P 16.61 5.5e-36 6.55e-28 1.21 0.8 Platelet count; chr12:56709370 chr4:164943290~164943937:+ PAAD trans rs13177918 0.626 rs67026795 ENSG00000213058.3 RP4-765C7.2 16.49 1.15e-35 1.35e-27 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr1:178411616~178411972:+ PAAD trans rs13177918 0.603 rs10447222 ENSG00000213058.3 RP4-765C7.2 16.49 1.15e-35 1.35e-27 1.08 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr1:178411616~178411972:+ PAAD trans rs7949030 0.62 rs2428551 ENSG00000186676.3 EEF1GP1 16.37 2.28e-35 2.68e-27 1.08 0.8 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62562286 chr7:125033453~125035301:+ PAAD trans rs7949030 0.591 rs35880596 ENSG00000186676.3 EEF1GP1 16.32 3.14e-35 3.68e-27 1.12 0.8 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602412 chr7:125033453~125035301:+ PAAD trans rs1816752 0.935 rs4770676 ENSG00000237917.1 PARP4P1 16.25 4.72e-35 5.42e-27 1.04 0.8 Obesity-related traits; chr13:24429745 chrY:26594851~26634652:- PAAD trans rs1816752 1 rs7326932 ENSG00000237917.1 PARP4P1 16.25 4.72e-35 5.42e-27 1.04 0.8 Obesity-related traits; chr13:24430355 chrY:26594851~26634652:- PAAD trans rs1816752 1 rs7999554 ENSG00000237917.1 PARP4P1 16.25 4.72e-35 5.42e-27 1.04 0.8 Obesity-related traits; chr13:24435631 chrY:26594851~26634652:- PAAD trans rs1816752 1 rs9511265 ENSG00000237917.1 PARP4P1 16.25 4.72e-35 5.42e-27 1.04 0.8 Obesity-related traits; chr13:24438221 chrY:26594851~26634652:- PAAD trans rs13177918 0.603 rs2343806 ENSG00000213058.3 RP4-765C7.2 16.1 1.12e-34 1.27e-26 1.03 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr1:178411616~178411972:+ PAAD trans rs13177918 0.557 rs12520101 ENSG00000224114.1 RP11-343H5.4 16 2.15e-34 2.42e-26 1.14 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:206695837~206696269:- PAAD trans rs6477998 0.535 rs3750535 ENSG00000238072.1 RP11-305M3.2 15.96 2.65e-34 2.97e-26 1.13 0.79 Hematology traits; chr9:113297453 chr7:129410113~129410370:- PAAD trans rs12291225 0.679 rs34238445 ENSG00000236360.2 RP11-334A14.2 15.93 3.16e-34 3.53e-26 1.06 0.79 Sense of smell; chr11:14294369 chr1:52993201~52993702:- PAAD trans rs1816752 1 rs9511272 ENSG00000237917.1 PARP4P1 15.89 3.96e-34 4.42e-26 1.05 0.79 Obesity-related traits; chr13:24446495 chrY:26594851~26634652:- PAAD trans rs12291225 0.679 rs11605531 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14270048 chr1:52993201~52993702:- PAAD trans rs12291225 0.639 rs61883858 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14273162 chr1:52993201~52993702:- PAAD trans rs12291225 0.679 rs11023170 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14273363 chr1:52993201~52993702:- PAAD trans rs12291225 0.679 rs11023172 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14273821 chr1:52993201~52993702:- PAAD trans rs12291225 0.679 rs4757245 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14276326 chr1:52993201~52993702:- PAAD trans rs12291225 0.637 rs8570 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14279213 chr1:52993201~52993702:- PAAD trans rs12291225 0.753 rs1431374 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14282429 chr1:52993201~52993702:- PAAD trans rs12291225 0.679 rs10832240 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14283198 chr1:52993201~52993702:- PAAD trans rs12291225 0.679 rs7934671 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14283555 chr1:52993201~52993702:- PAAD trans rs12291225 0.679 rs11023178 ENSG00000236360.2 RP11-334A14.2 15.85 5.04e-34 5.47e-26 1.06 0.79 Sense of smell; chr11:14288736 chr1:52993201~52993702:- PAAD trans rs12291225 0.679 rs4756786 ENSG00000236360.2 RP11-334A14.2 15.82 6.03e-34 6.51e-26 1.06 0.79 Sense of smell; chr11:14264354 chr1:52993201~52993702:- PAAD trans rs13253073 0.657 rs35135010 ENSG00000260318.1 COX6CP1 15.81 6.5e-34 7.01e-26 1.37 0.79 Glucose homeostasis traits; chr8:99864209 chr16:11903923~11904137:- PAAD trans rs12291225 0.679 rs1043237 ENSG00000236360.2 RP11-334A14.2 15.79 7.25e-34 7.72e-26 1.05 0.79 Sense of smell; chr11:14267507 chr1:52993201~52993702:- PAAD trans rs941207 0.789 rs2958145 ENSG00000121089.4 NACA3P -15.77 8.25e-34 8.77e-26 -1.19 -0.79 Platelet count; chr12:56662290 chr4:164943290~164943937:+ PAAD trans rs6477998 0.58 rs3750533 ENSG00000238072.1 RP11-305M3.2 15.69 1.33e-33 1.4e-25 1.12 0.79 Hematology traits; chr9:113297941 chr7:129410113~129410370:- PAAD trans rs2950393 0.509 rs10459247 ENSG00000121089.4 NACA3P -15.64 1.77e-33 1.87e-25 -1.18 -0.79 Platelet distribution width; chr12:56777732 chr4:164943290~164943937:+ PAAD trans rs12291225 0.679 rs11369 ENSG00000236360.2 RP11-334A14.2 15.63 1.89e-33 1.98e-25 1.04 0.79 Sense of smell; chr11:14266550 chr1:52993201~52993702:- PAAD trans rs12291225 0.679 rs11238 ENSG00000236360.2 RP11-334A14.2 -15.63 1.89e-33 1.98e-25 -1.04 -0.79 Sense of smell; chr11:14266582 chr1:52993201~52993702:- PAAD trans rs1816752 0.935 rs3816219 ENSG00000237917.1 PARP4P1 15.63 1.95e-33 2.03e-25 1.04 0.79 Obesity-related traits; chr13:24442995 chrY:26594851~26634652:- PAAD trans rs1816752 1 rs7988810 ENSG00000237917.1 PARP4P1 15.63 1.95e-33 2.03e-25 1.04 0.79 Obesity-related traits; chr13:24444958 chrY:26594851~26634652:- PAAD trans rs7949030 0.653 rs17773169 ENSG00000186676.3 EEF1GP1 15.61 2.16e-33 2.24e-25 1.04 0.78 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62551058 chr7:125033453~125035301:+ PAAD trans rs13253073 0.723 rs4510829 ENSG00000260318.1 COX6CP1 15.58 2.56e-33 2.64e-25 1.35 0.78 Glucose homeostasis traits; chr8:99878982 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs7812991 ENSG00000260318.1 COX6CP1 15.58 2.56e-33 2.64e-25 1.35 0.78 Glucose homeostasis traits; chr8:99884095 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs12548840 ENSG00000260318.1 COX6CP1 15.58 2.56e-33 2.64e-25 1.35 0.78 Glucose homeostasis traits; chr8:99885580 chr16:11903923~11904137:- PAAD trans rs941207 0.756 rs2958153 ENSG00000121089.4 NACA3P 15.55 3.08e-33 3.11e-25 1.18 0.78 Platelet count; chr12:56687733 chr4:164943290~164943937:+ PAAD trans rs13253073 0.723 rs35429753 ENSG00000260318.1 COX6CP1 15.52 3.74e-33 3.75e-25 1.34 0.78 Glucose homeostasis traits; chr8:99891015 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs1130474 ENSG00000260318.1 COX6CP1 15.52 3.74e-33 3.75e-25 1.34 0.78 Glucose homeostasis traits; chr8:99892049 chr16:11903923~11904137:- PAAD trans rs7121616 0.563 rs1461494 ENSG00000234176.1 HSPA8P1 15.48 4.67e-33 4.64e-25 1.02 0.78 Breast cancer; chr11:123055777 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs4802 ENSG00000234176.1 HSPA8P1 15.48 4.67e-33 4.64e-25 1.02 0.78 Breast cancer; chr11:123057914 chrX:121203182~121205014:- PAAD trans rs7121616 0.595 rs7949414 ENSG00000234176.1 HSPA8P1 15.48 4.67e-33 4.64e-25 1.02 0.78 Breast cancer; chr11:123072787 chrX:121203182~121205014:- PAAD trans rs13253073 0.723 rs34830464 ENSG00000260318.1 COX6CP1 15.45 5.8e-33 5.75e-25 1.38 0.78 Glucose homeostasis traits; chr8:99866638 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs12546882 ENSG00000260318.1 COX6CP1 15.44 5.87e-33 5.81e-25 1.32 0.78 Glucose homeostasis traits; chr8:99869919 chr16:11903923~11904137:- PAAD trans rs941207 0.756 rs7315472 ENSG00000121089.4 NACA3P -15.39 7.95e-33 7.78e-25 -1.17 -0.78 Platelet count; chr12:56648276 chr4:164943290~164943937:+ PAAD trans rs941207 0.756 rs67046307 ENSG00000121089.4 NACA3P -15.39 7.95e-33 7.78e-25 -1.17 -0.78 Platelet count; chr12:56651152 chr4:164943290~164943937:+ PAAD trans rs941207 0.756 rs10876915 ENSG00000121089.4 NACA3P -15.39 7.95e-33 7.78e-25 -1.17 -0.78 Platelet count; chr12:56655280 chr4:164943290~164943937:+ PAAD trans rs13177918 1 rs13161334 ENSG00000213058.3 RP4-765C7.2 15.28 1.55e-32 1.49e-24 1.2 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr1:178411616~178411972:+ PAAD trans rs13177918 1 rs35007082 ENSG00000213058.3 RP4-765C7.2 15.28 1.55e-32 1.49e-24 1.2 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr1:178411616~178411972:+ PAAD trans rs13177918 1 rs13177918 ENSG00000213058.3 RP4-765C7.2 15.28 1.55e-32 1.49e-24 1.2 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr1:178411616~178411972:+ PAAD trans rs13177918 0.798 rs12516161 ENSG00000213058.3 RP4-765C7.2 15.27 1.67e-32 1.61e-24 1.15 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr1:178411616~178411972:+ PAAD trans rs7121616 0.562 rs7131452 ENSG00000234176.1 HSPA8P1 15.24 2.07e-32 1.99e-24 1.01 0.78 Breast cancer; chr11:123065314 chrX:121203182~121205014:- PAAD trans rs12291225 0.645 rs3763950 ENSG00000236360.2 RP11-334A14.2 15.23 2.2e-32 2.11e-24 1.05 0.78 Sense of smell; chr11:14256503 chr1:52993201~52993702:- PAAD trans rs13177918 0.626 rs13175436 ENSG00000239528.1 RPS14P8 15.22 2.25e-32 2.16e-24 1.07 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr5:116562562~116562930:+ PAAD trans rs7121616 0.576 rs11218967 ENSG00000234176.1 HSPA8P1 15.2 2.58e-32 2.46e-24 1.02 0.78 Breast cancer; chr11:123087551 chrX:121203182~121205014:- PAAD trans rs13177918 0.871 rs11745133 ENSG00000213058.3 RP4-765C7.2 15.18 2.92e-32 2.77e-24 1.14 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150457826 chr1:178411616~178411972:+ PAAD trans rs13177918 0.871 rs11745194 ENSG00000213058.3 RP4-765C7.2 15.18 2.92e-32 2.77e-24 1.14 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150458065 chr1:178411616~178411972:+ PAAD trans rs13177918 0.834 rs13163277 ENSG00000213058.3 RP4-765C7.2 15.18 2.92e-32 2.77e-24 1.14 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459359 chr1:178411616~178411972:+ PAAD trans rs13177918 0.626 rs67026795 ENSG00000239528.1 RPS14P8 15.14 3.8e-32 3.57e-24 1.07 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr5:116562562~116562930:+ PAAD trans rs13177918 0.603 rs10447222 ENSG00000239528.1 RPS14P8 15.14 3.8e-32 3.57e-24 1.07 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr5:116562562~116562930:+ PAAD trans rs13253073 0.723 rs7009713 ENSG00000260318.1 COX6CP1 15.12 4.2e-32 3.93e-24 1.32 0.78 Glucose homeostasis traits; chr8:99869626 chr16:11903923~11904137:- PAAD trans rs928391 1 rs2768766 ENSG00000227183.3 HDGFP1 15.09 5.14e-32 4.79e-24 1.01 0.77 Platelet count; chr1:156805842 chrX:131646639~131646890:+ PAAD trans rs941207 0.756 rs1465081 ENSG00000121089.4 NACA3P -15.05 6.26e-32 5.81e-24 -1.19 -0.77 Platelet count; chr12:56656390 chr4:164943290~164943937:+ PAAD trans rs7121616 0.563 rs4936770 ENSG00000234176.1 HSPA8P1 15 8.83e-32 8.08e-24 1.01 0.77 Breast cancer; chr11:123058167 chrX:121203182~121205014:- PAAD trans rs13177918 0.626 rs3819332 ENSG00000239528.1 RPS14P8 14.99 9.23e-32 8.41e-24 1.06 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr5:116562562~116562930:+ PAAD trans rs13177918 0.626 rs13170300 ENSG00000239528.1 RPS14P8 14.99 9.23e-32 8.41e-24 1.06 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr5:116562562~116562930:+ PAAD trans rs13177918 0.603 rs13175992 ENSG00000239528.1 RPS14P8 14.99 9.23e-32 8.41e-24 1.06 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr5:116562562~116562930:+ PAAD trans rs7121616 0.562 rs2061602 ENSG00000234176.1 HSPA8P1 14.99 9.34e-32 8.48e-24 1.02 0.77 Breast cancer; chr11:123065079 chrX:121203182~121205014:- PAAD trans rs13177918 0.906 rs12652032 ENSG00000213058.3 RP4-765C7.2 14.93 1.34e-31 1.19e-23 1.2 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr1:178411616~178411972:+ PAAD trans rs13177918 0.603 rs2748241 ENSG00000213058.3 RP4-765C7.2 14.92 1.41e-31 1.26e-23 0.99 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr1:178411616~178411972:+ PAAD trans rs13177918 0.578 rs35919198 ENSG00000239528.1 RPS14P8 14.9 1.58e-31 1.4e-23 1.06 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr5:116562562~116562930:+ PAAD trans rs13177918 0.822 rs62382255 ENSG00000213058.3 RP4-765C7.2 14.89 1.69e-31 1.5e-23 1.14 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459154 chr1:178411616~178411972:+ PAAD trans rs941207 0.756 rs2950388 ENSG00000121089.4 NACA3P -14.89 1.72e-31 1.52e-23 -1.14 -0.77 Platelet count; chr12:56639569 chr4:164943290~164943937:+ PAAD trans rs1816752 0.716 rs9553289 ENSG00000237917.1 PARP4P1 -14.88 1.82e-31 1.61e-23 -1 -0.77 Obesity-related traits; chr13:24400640 chrY:26594851~26634652:- PAAD trans rs13253073 0.723 rs4626565 ENSG00000260318.1 COX6CP1 14.79 3.11e-31 2.71e-23 1.32 0.77 Glucose homeostasis traits; chr8:99878314 chr16:11903923~11904137:- PAAD trans rs928391 1 rs928391 ENSG00000227183.3 HDGFP1 14.76 3.69e-31 3.19e-23 1.02 0.77 Platelet count; chr1:156806925 chrX:131646639~131646890:+ PAAD trans rs928391 1 rs2644606 ENSG00000227183.3 HDGFP1 14.76 3.69e-31 3.19e-23 1.02 0.77 Platelet count; chr1:156808053 chrX:131646639~131646890:+ PAAD trans rs13177918 0.559 rs10447224 ENSG00000239528.1 RPS14P8 14.76 3.82e-31 3.3e-23 1 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr5:116562562~116562930:+ PAAD trans rs13177918 0.559 rs10447225 ENSG00000239528.1 RPS14P8 14.76 3.82e-31 3.3e-23 1 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr5:116562562~116562930:+ PAAD trans rs13253073 0.662 rs34513504 ENSG00000260318.1 COX6CP1 14.75 3.87e-31 3.34e-23 1.32 0.77 Glucose homeostasis traits; chr8:99848918 chr16:11903923~11904137:- PAAD trans rs13253073 0.662 rs4434590 ENSG00000260318.1 COX6CP1 14.67 6.32e-31 5.39e-23 1.35 0.77 Glucose homeostasis traits; chr8:99848429 chr16:11903923~11904137:- PAAD trans rs7949030 0.626 rs35587183 ENSG00000186676.3 EEF1GP1 14.67 6.67e-31 5.67e-23 1.16 0.77 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62551184 chr7:125033453~125035301:+ PAAD trans rs941207 0.756 rs9634246 ENSG00000121089.4 NACA3P -14.66 6.95e-31 5.89e-23 -1.16 -0.77 Platelet count; chr12:56640604 chr4:164943290~164943937:+ PAAD trans rs941207 0.756 rs2950394 ENSG00000121089.4 NACA3P -14.66 6.95e-31 5.89e-23 -1.16 -0.77 Platelet count; chr12:56644548 chr4:164943290~164943937:+ PAAD trans rs13177918 0.559 rs12109637 ENSG00000239528.1 RPS14P8 14.63 8.38e-31 7.05e-23 0.99 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr5:116562562~116562930:+ PAAD trans rs7949030 0.688 rs2849031 ENSG00000186676.3 EEF1GP1 -14.61 9.1e-31 7.63e-23 -1.05 -0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598193 chr7:125033453~125035301:+ PAAD trans rs7949030 0.653 rs2849030 ENSG00000186676.3 EEF1GP1 -14.61 9.1e-31 7.63e-23 -1.05 -0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62599514 chr7:125033453~125035301:+ PAAD trans rs7949030 0.653 rs2516634 ENSG00000186676.3 EEF1GP1 -14.61 9.1e-31 7.63e-23 -1.05 -0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62599714 chr7:125033453~125035301:+ PAAD trans rs928391 1 rs2644615 ENSG00000227183.3 HDGFP1 14.6 1.01e-30 8.42e-23 1.03 0.76 Platelet count; chr1:156791826 chrX:131646639~131646890:+ PAAD trans rs928391 1 rs2768767 ENSG00000227183.3 HDGFP1 14.6 1.01e-30 8.42e-23 1.03 0.76 Platelet count; chr1:156797933 chrX:131646639~131646890:+ PAAD trans rs13253073 0.723 rs1130569 ENSG00000260318.1 COX6CP1 14.52 1.6e-30 1.29e-22 1.32 0.76 Glucose homeostasis traits; chr8:99887565 chr16:11903923~11904137:- PAAD trans rs928391 1 rs12129173 ENSG00000227183.3 HDGFP1 14.49 1.89e-30 1.51e-22 1.03 0.76 Platelet count; chr1:156803833 chrX:131646639~131646890:+ PAAD trans rs13253073 0.723 rs6468695 ENSG00000260318.1 COX6CP1 14.49 1.94e-30 1.55e-22 1.35 0.76 Glucose homeostasis traits; chr8:99857123 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs6468696 ENSG00000260318.1 COX6CP1 14.49 1.94e-30 1.55e-22 1.35 0.76 Glucose homeostasis traits; chr8:99857130 chr16:11903923~11904137:- PAAD trans rs928391 1 rs2777929 ENSG00000227183.3 HDGFP1 14.47 2.17e-30 1.73e-22 1.03 0.76 Platelet count; chr1:156797879 chrX:131646639~131646890:+ PAAD trans rs7949030 0.688 rs11231155 ENSG00000186676.3 EEF1GP1 14.47 2.26e-30 1.79e-22 1.04 0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598147 chr7:125033453~125035301:+ PAAD trans rs13253073 0.723 rs7828241 ENSG00000260318.1 COX6CP1 14.46 2.4e-30 1.89e-22 1.33 0.76 Glucose homeostasis traits; chr8:99880417 chr16:11903923~11904137:- PAAD trans rs13177918 1 rs13161334 ENSG00000239528.1 RPS14P8 14.45 2.54e-30 2e-22 1.2 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr5:116562562~116562930:+ PAAD trans rs13177918 1 rs35007082 ENSG00000239528.1 RPS14P8 14.45 2.54e-30 2e-22 1.2 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr5:116562562~116562930:+ PAAD trans rs13177918 1 rs13177918 ENSG00000239528.1 RPS14P8 14.45 2.54e-30 2e-22 1.2 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr5:116562562~116562930:+ PAAD trans rs7943191 0.81 rs7942154 ENSG00000186676.3 EEF1GP1 14.45 2.56e-30 2.01e-22 1.16 0.76 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62569691 chr7:125033453~125035301:+ PAAD trans rs7943191 0.81 rs7942991 ENSG00000186676.3 EEF1GP1 -14.43 2.83e-30 2.22e-22 -1.13 -0.76 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62569731 chr7:125033453~125035301:+ PAAD trans rs13177918 0.626 rs2748240 ENSG00000213058.3 RP4-765C7.2 14.4 3.33e-30 2.61e-22 0.97 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr1:178411616~178411972:+ PAAD trans rs13177918 0.603 rs2343806 ENSG00000239528.1 RPS14P8 14.4 3.4e-30 2.66e-22 1 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr5:116562562~116562930:+ PAAD trans rs13177918 0.871 rs11745133 ENSG00000224114.1 RP11-343H5.4 14.38 3.81e-30 2.96e-22 1.15 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150457826 chr1:206695837~206696269:- PAAD trans rs13177918 0.871 rs11745194 ENSG00000224114.1 RP11-343H5.4 14.38 3.81e-30 2.96e-22 1.15 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150458065 chr1:206695837~206696269:- PAAD trans rs13177918 0.834 rs13163277 ENSG00000224114.1 RP11-343H5.4 14.38 3.81e-30 2.96e-22 1.15 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459359 chr1:206695837~206696269:- PAAD trans rs13177918 0.603 rs2343806 ENSG00000224114.1 RP11-343H5.4 14.37 3.99e-30 3.09e-22 1 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr1:206695837~206696269:- PAAD trans rs13253073 0.723 rs1135382 ENSG00000260318.1 COX6CP1 14.35 4.64e-30 3.59e-22 1.32 0.76 Glucose homeostasis traits; chr8:99879402 chr16:11903923~11904137:- PAAD trans rs7121616 0.576 rs4936767 ENSG00000234176.1 HSPA8P1 14.32 5.54e-30 4.23e-22 1.02 0.76 Breast cancer; chr11:123047451 chrX:121203182~121205014:- PAAD trans rs13177918 0.603 rs2748241 ENSG00000239528.1 RPS14P8 14.3 6.1e-30 4.64e-22 0.99 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr5:116562562~116562930:+ PAAD trans rs13177918 0.798 rs12516161 ENSG00000224114.1 RP11-343H5.4 14.3 6.11e-30 4.65e-22 1.15 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr1:206695837~206696269:- PAAD trans rs928391 0.948 rs2735657 ENSG00000227183.3 HDGFP1 14.26 7.78e-30 5.81e-22 0.98 0.76 Platelet count; chr1:156810514 chrX:131646639~131646890:+ PAAD trans rs13177918 0.822 rs62382255 ENSG00000224114.1 RP11-343H5.4 14.24 8.77e-30 6.52e-22 1.14 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459154 chr1:206695837~206696269:- PAAD trans rs13253073 0.76 rs62534633 ENSG00000260318.1 COX6CP1 14.23 9.48e-30 7.03e-22 1.34 0.76 Glucose homeostasis traits; chr8:99884533 chr16:11903923~11904137:- PAAD trans rs13177918 1 rs13161334 ENSG00000224114.1 RP11-343H5.4 14.22 1.03e-29 7.63e-22 1.2 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443110 chr1:206695837~206696269:- PAAD trans rs13177918 1 rs35007082 ENSG00000224114.1 RP11-343H5.4 14.22 1.03e-29 7.63e-22 1.2 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150445015 chr1:206695837~206696269:- PAAD trans rs13177918 1 rs13177918 ENSG00000224114.1 RP11-343H5.4 14.22 1.03e-29 7.63e-22 1.2 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446307 chr1:206695837~206696269:- PAAD trans rs12291225 0.546 rs12291662 ENSG00000236360.2 RP11-334A14.2 14.21 1.09e-29 7.99e-22 0.97 0.76 Sense of smell; chr11:14321403 chr1:52993201~52993702:- PAAD trans rs12291225 0.545 rs11023187 ENSG00000236360.2 RP11-334A14.2 14.21 1.09e-29 7.99e-22 0.97 0.76 Sense of smell; chr11:14324013 chr1:52993201~52993702:- PAAD trans rs12291225 0.546 rs12795545 ENSG00000236360.2 RP11-334A14.2 14.21 1.09e-29 7.99e-22 0.97 0.76 Sense of smell; chr11:14334018 chr1:52993201~52993702:- PAAD trans rs12291225 0.585 rs11023194 ENSG00000236360.2 RP11-334A14.2 14.21 1.09e-29 7.99e-22 0.97 0.76 Sense of smell; chr11:14348223 chr1:52993201~52993702:- PAAD trans rs12291225 0.585 rs10832242 ENSG00000236360.2 RP11-334A14.2 -14.21 1.09e-29 7.99e-22 -0.97 -0.76 Sense of smell; chr11:14318958 chr1:52993201~52993702:- PAAD trans rs928391 0.895 rs12042999 ENSG00000227183.3 HDGFP1 14.19 1.19e-29 8.67e-22 1.01 0.75 Platelet count; chr1:156768636 chrX:131646639~131646890:+ PAAD trans rs928391 0.895 rs11264547 ENSG00000227183.3 HDGFP1 14.19 1.19e-29 8.67e-22 1.01 0.75 Platelet count; chr1:156776326 chrX:131646639~131646890:+ PAAD trans rs928391 1 rs61816272 ENSG00000227183.3 HDGFP1 14.19 1.19e-29 8.67e-22 1.01 0.75 Platelet count; chr1:156778073 chrX:131646639~131646890:+ PAAD trans rs928391 0.947 rs11264549 ENSG00000227183.3 HDGFP1 14.19 1.19e-29 8.67e-22 1.01 0.75 Platelet count; chr1:156781017 chrX:131646639~131646890:+ PAAD trans rs928391 1 rs12134991 ENSG00000227183.3 HDGFP1 14.19 1.19e-29 8.67e-22 1.01 0.75 Platelet count; chr1:156781285 chrX:131646639~131646890:+ PAAD trans rs928391 1 rs2274501 ENSG00000227183.3 HDGFP1 14.19 1.19e-29 8.67e-22 1.01 0.75 Platelet count; chr1:156782460 chrX:131646639~131646890:+ PAAD trans rs13253073 0.723 rs12548542 ENSG00000260318.1 COX6CP1 14.17 1.34e-29 9.72e-22 1.33 0.75 Glucose homeostasis traits; chr8:99890167 chr16:11903923~11904137:- PAAD trans rs928391 1 rs10157555 ENSG00000227183.3 HDGFP1 -14.17 1.35e-29 9.8e-22 -1 -0.75 Platelet count; chr1:156802060 chrX:131646639~131646890:+ PAAD trans rs928391 1 rs928392 ENSG00000227183.3 HDGFP1 14.17 1.35e-29 9.8e-22 1 0.75 Platelet count; chr1:156801024 chrX:131646639~131646890:+ PAAD trans rs12291225 0.585 rs12270374 ENSG00000236360.2 RP11-334A14.2 14.17 1.4e-29 1e-21 0.98 0.75 Sense of smell; chr11:14353533 chr1:52993201~52993702:- PAAD trans rs12291225 0.585 rs10832246 ENSG00000236360.2 RP11-334A14.2 14.17 1.4e-29 1e-21 0.98 0.75 Sense of smell; chr11:14359282 chr1:52993201~52993702:- PAAD trans rs12291225 0.585 rs4517475 ENSG00000236360.2 RP11-334A14.2 14.17 1.4e-29 1e-21 0.98 0.75 Sense of smell; chr11:14364599 chr1:52993201~52993702:- PAAD trans rs13177918 0.798 rs12514700 ENSG00000213058.3 RP4-765C7.2 14.13 1.81e-29 1.29e-21 1.11 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr1:178411616~178411972:+ PAAD trans rs13253073 0.525 rs35509895 ENSG00000260318.1 COX6CP1 14.08 2.44e-29 1.72e-21 1.32 0.75 Glucose homeostasis traits; chr8:99872093 chr16:11903923~11904137:- PAAD trans rs12291225 0.585 rs4757250 ENSG00000236360.2 RP11-334A14.2 14.08 2.46e-29 1.74e-21 0.98 0.75 Sense of smell; chr11:14354137 chr1:52993201~52993702:- PAAD trans rs13177918 0.906 rs12652032 ENSG00000239528.1 RPS14P8 14.07 2.48e-29 1.75e-21 1.19 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr5:116562562~116562930:+ PAAD trans rs13177918 0.871 rs11745133 ENSG00000239528.1 RPS14P8 14.03 3.31e-29 2.29e-21 1.13 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150457826 chr5:116562562~116562930:+ PAAD trans rs13177918 0.871 rs11745194 ENSG00000239528.1 RPS14P8 14.03 3.31e-29 2.29e-21 1.13 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150458065 chr5:116562562~116562930:+ PAAD trans rs13177918 0.834 rs13163277 ENSG00000239528.1 RPS14P8 14.03 3.31e-29 2.29e-21 1.13 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459359 chr5:116562562~116562930:+ PAAD trans rs13253073 0.723 rs12548344 ENSG00000260318.1 COX6CP1 14.01 3.65e-29 2.53e-21 1.25 0.75 Glucose homeostasis traits; chr8:99868676 chr16:11903923~11904137:- PAAD trans rs12291225 0.585 rs34171876 ENSG00000236360.2 RP11-334A14.2 14.01 3.7e-29 2.55e-21 0.97 0.75 Sense of smell; chr11:14332411 chr1:52993201~52993702:- PAAD trans rs928391 1 rs12043405 ENSG00000227183.3 HDGFP1 14.01 3.76e-29 2.59e-21 1 0.75 Platelet count; chr1:156784508 chrX:131646639~131646890:+ PAAD trans rs13177918 0.798 rs12516161 ENSG00000239528.1 RPS14P8 13.92 6.41e-29 4.34e-21 1.13 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr5:116562562~116562930:+ PAAD trans rs13177918 0.822 rs62382255 ENSG00000239528.1 RPS14P8 13.92 6.51e-29 4.39e-21 1.13 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150459154 chr5:116562562~116562930:+ PAAD trans rs13177918 0.603 rs2748241 ENSG00000224114.1 RP11-343H5.4 13.84 1.05e-28 6.85e-21 0.98 0.75 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr1:206695837~206696269:- PAAD trans rs12291225 0.585 rs11023197 ENSG00000236360.2 RP11-334A14.2 13.83 1.08e-28 7.06e-21 0.97 0.75 Sense of smell; chr11:14359452 chr1:52993201~52993702:- PAAD trans rs13177918 0.798 rs13182116 ENSG00000213058.3 RP4-765C7.2 -13.74 1.93e-28 1.21e-20 -1.09 -0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr1:178411616~178411972:+ PAAD trans rs12291225 0.546 rs11023199 ENSG00000236360.2 RP11-334A14.2 13.69 2.59e-28 1.58e-20 0.96 0.74 Sense of smell; chr11:14372712 chr1:52993201~52993702:- PAAD trans rs13177918 0.626 rs2748240 ENSG00000239528.1 RPS14P8 13.68 2.82e-28 1.71e-20 0.97 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr5:116562562~116562930:+ PAAD trans rs13253073 0.723 rs7840626 ENSG00000260318.1 COX6CP1 13.67 2.95e-28 1.79e-20 1.32 0.74 Glucose homeostasis traits; chr8:99867598 chr16:11903923~11904137:- PAAD trans rs13177918 0.906 rs12652032 ENSG00000224114.1 RP11-343H5.4 13.66 3.27e-28 1.97e-20 1.18 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442060 chr1:206695837~206696269:- PAAD trans rs13253073 0.723 rs7831963 ENSG00000260318.1 COX6CP1 13.62 4.13e-28 2.46e-20 1.29 0.74 Glucose homeostasis traits; chr8:99853014 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs7832488 ENSG00000260318.1 COX6CP1 13.62 4.13e-28 2.46e-20 1.29 0.74 Glucose homeostasis traits; chr8:99853185 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs7813557 ENSG00000260318.1 COX6CP1 13.62 4.19e-28 2.49e-20 1.33 0.74 Glucose homeostasis traits; chr8:99878665 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs7157 ENSG00000260318.1 COX6CP1 13.59 4.74e-28 2.81e-20 1.32 0.74 Glucose homeostasis traits; chr8:99877449 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs7844439 ENSG00000260318.1 COX6CP1 13.54 6.85e-28 4.01e-20 1.29 0.74 Glucose homeostasis traits; chr8:99878567 chr16:11903923~11904137:- PAAD trans rs928391 1 rs3765787 ENSG00000227183.3 HDGFP1 -13.49 8.93e-28 5.18e-20 -0.96 -0.74 Platelet count; chr1:156784673 chrX:131646639~131646890:+ PAAD trans rs13177918 0.798 rs12514700 ENSG00000224114.1 RP11-343H5.4 13.49 9.21e-28 5.33e-20 1.11 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr1:206695837~206696269:- PAAD trans rs7121616 0.595 rs7941144 ENSG00000234176.1 HSPA8P1 13.46 1.06e-27 6.13e-20 0.97 0.74 Breast cancer; chr11:123079805 chrX:121203182~121205014:- PAAD trans rs13177918 0.626 rs2748240 ENSG00000224114.1 RP11-343H5.4 13.38 1.82e-27 1.03e-19 0.96 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr1:206695837~206696269:- PAAD trans rs7949030 0.523 rs12223627 ENSG00000186676.3 EEF1GP1 13.37 1.87e-27 1.06e-19 1.13 0.74 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62601085 chr7:125033453~125035301:+ PAAD trans rs1816752 0.669 rs7984513 ENSG00000237917.1 PARP4P1 -13.34 2.34e-27 1.32e-19 -0.98 -0.73 Obesity-related traits; chr13:24445117 chrY:26594851~26634652:- PAAD trans rs7943191 0.805 rs12226821 ENSG00000186676.3 EEF1GP1 13.31 2.71e-27 1.51e-19 1.13 0.73 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62601546 chr7:125033453~125035301:+ PAAD trans rs13253073 0.723 rs13274441 ENSG00000260318.1 COX6CP1 13.29 3.07e-27 1.7e-19 1.31 0.73 Glucose homeostasis traits; chr8:99861038 chr16:11903923~11904137:- PAAD trans rs13253073 0.723 rs62534626 ENSG00000260318.1 COX6CP1 13.24 4.21e-27 2.32e-19 1.3 0.73 Glucose homeostasis traits; chr8:99866119 chr16:11903923~11904137:- PAAD trans rs13177918 0.798 rs13182116 ENSG00000224114.1 RP11-343H5.4 -13.13 8.2e-27 4.39e-19 -1.1 -0.73 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr1:206695837~206696269:- PAAD trans rs5758343 1 rs5758343 ENSG00000268568.1 AC007228.9 13.06 1.26e-26 6.62e-19 1.18 0.73 Allergic disease (asthma, hay fever or eczema); chr22:41420648 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs5758344 ENSG00000268568.1 AC007228.9 13.06 1.26e-26 6.62e-19 1.18 0.73 Vitiligo; chr22:41421681 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs2142505 ENSG00000268568.1 AC007228.9 13.06 1.26e-26 6.62e-19 1.18 0.73 Vitiligo; chr22:41424537 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs5758347 ENSG00000268568.1 AC007228.9 13.05 1.37e-26 7.09e-19 1.17 0.73 Vitiligo; chr22:41425015 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs202613 ENSG00000268568.1 AC007228.9 13.05 1.37e-26 7.09e-19 1.17 0.73 Vitiligo; chr22:41425989 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs202614 ENSG00000268568.1 AC007228.9 13.05 1.37e-26 7.09e-19 1.17 0.73 Vitiligo; chr22:41426146 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs202616 ENSG00000268568.1 AC007228.9 13.05 1.37e-26 7.09e-19 1.17 0.73 Vitiligo; chr22:41426217 chr19:56672574~56673901:- PAAD trans rs9611565 0.569 rs188057 ENSG00000268568.1 AC007228.9 13.05 1.37e-26 7.09e-19 1.17 0.73 Vitiligo; chr22:41426301 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs202618 ENSG00000268568.1 AC007228.9 13.05 1.37e-26 7.09e-19 1.17 0.73 Vitiligo; chr22:41426852 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs5751107 ENSG00000268568.1 AC007228.9 13.05 1.37e-26 7.09e-19 1.17 0.73 Vitiligo; chr22:41461808 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs5751108 ENSG00000268568.1 AC007228.9 13.05 1.37e-26 7.09e-19 1.17 0.73 Vitiligo; chr22:41462031 chr19:56672574~56673901:- PAAD trans rs7554547 0.668 rs2038028 ENSG00000261819.1 RP11-680G24.4 13.02 1.71e-26 8.79e-19 0.94 0.73 Nonsyndromic cleft lip with cleft palate; chr1:11919499 chr16:14988259~14990160:- PAAD trans rs916888 0.773 rs199457 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45506741~45550335:- PAAD trans rs916888 0.687 rs199456 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45506741~45550335:- PAAD trans rs916888 0.773 rs199451 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45506741~45550335:- PAAD trans rs916888 0.773 rs199448 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45506741~45550335:- PAAD trans rs916888 0.773 rs199445 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45506741~45550335:- PAAD trans rs916888 0.773 rs199443 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45506741~45550335:- PAAD trans rs916888 0.773 rs199535 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45506741~45550335:- PAAD trans rs916888 0.779 rs199528 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs199525 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs70600 ENSG00000214425.5 LRRC37A4P -12.99 2.03e-26 1.03e-18 -0.98 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45506741~45550335:- PAAD trans rs9611565 0.649 rs202666 ENSG00000268568.1 AC007228.9 12.98 2.17e-26 1.1e-18 1.18 0.72 Vitiligo; chr22:41418715 chr19:56672574~56673901:- PAAD trans rs916888 0.773 rs199447 ENSG00000214425.5 LRRC37A4P -12.94 2.74e-26 1.38e-18 -0.98 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45506741~45550335:- PAAD trans rs9611565 0.694 rs202664 ENSG00000268568.1 AC007228.9 12.93 2.81e-26 1.42e-18 1.18 0.72 Vitiligo; chr22:41417882 chr19:56672574~56673901:- PAAD trans rs7554547 0.739 rs7518827 ENSG00000261819.1 RP11-680G24.4 12.9 3.52e-26 1.76e-18 0.94 0.72 Nonsyndromic cleft lip with cleft palate; chr1:11916688 chr16:14988259~14990160:- PAAD trans rs9611565 0.694 rs202622 ENSG00000268568.1 AC007228.9 12.9 3.58e-26 1.78e-18 1.18 0.72 Vitiligo; chr22:41429338 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs202625 ENSG00000268568.1 AC007228.9 12.9 3.58e-26 1.78e-18 1.18 0.72 Vitiligo; chr22:41431078 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs7285041 ENSG00000268568.1 AC007228.9 12.9 3.58e-26 1.78e-18 1.18 0.72 Vitiligo; chr22:41433145 chr19:56672574~56673901:- PAAD trans rs916888 0.773 rs538628 ENSG00000214425.5 LRRC37A4P -12.89 3.65e-26 1.81e-18 -0.98 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45506741~45550335:- PAAD trans rs916888 0.773 rs199534 ENSG00000214425.5 LRRC37A4P -12.89 3.79e-26 1.88e-18 -0.98 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45506741~45550335:- PAAD trans rs9611565 0.649 rs202645 ENSG00000268568.1 AC007228.9 12.85 4.6e-26 2.27e-18 1.17 0.72 Vitiligo; chr22:41402516 chr19:56672574~56673901:- PAAD trans rs13177918 0.798 rs12514700 ENSG00000239528.1 RPS14P8 12.85 4.61e-26 2.27e-18 1.08 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr5:116562562~116562930:+ PAAD trans rs9611565 0.592 rs5751101 ENSG00000268568.1 AC007228.9 12.82 5.57e-26 2.74e-18 1.18 0.72 Vitiligo; chr22:41432107 chr19:56672574~56673901:- PAAD trans rs941207 0.542 rs11171978 ENSG00000121089.4 NACA3P 12.81 6.13e-26 3.01e-18 1.03 0.72 Platelet count; chr12:56800015 chr4:164943290~164943937:+ PAAD trans rs916888 0.773 rs169201 ENSG00000214425.5 LRRC37A4P -12.81 6.22e-26 3.05e-18 -0.98 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45506741~45550335:- PAAD trans rs916888 0.773 rs199439 ENSG00000214425.5 LRRC37A4P -12.81 6.22e-26 3.05e-18 -0.98 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45506741~45550335:- PAAD trans rs13253073 0.545 rs35769167 ENSG00000260318.1 COX6CP1 12.81 6.24e-26 3.05e-18 1.32 0.72 Glucose homeostasis traits; chr8:99872095 chr16:11903923~11904137:- PAAD trans rs9611565 0.694 rs202617 ENSG00000268568.1 AC007228.9 12.79 6.69e-26 3.27e-18 1.17 0.72 Vitiligo; chr22:41426789 chr19:56672574~56673901:- PAAD trans rs941207 1 rs941207 ENSG00000121089.4 NACA3P -12.78 7.33e-26 3.56e-18 -1.1 -0.72 Platelet count; chr12:56629500 chr4:164943290~164943937:+ PAAD trans rs9611565 0.694 rs202665 ENSG00000268568.1 AC007228.9 12.77 7.57e-26 3.66e-18 1.17 0.72 Vitiligo; chr22:41418397 chr19:56672574~56673901:- PAAD trans rs916888 0.773 rs1378358 ENSG00000214425.5 LRRC37A4P -12.75 8.64e-26 4.17e-18 -0.97 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45506741~45550335:- PAAD trans rs916888 0.773 rs199533 ENSG00000214425.5 LRRC37A4P -12.75 8.82e-26 4.21e-18 -0.97 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45506741~45550335:- PAAD trans rs9611565 0.694 rs202656 ENSG00000268568.1 AC007228.9 12.74 9.34e-26 4.45e-18 1.18 0.72 Vitiligo; chr22:41446199 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs202637 ENSG00000268568.1 AC007228.9 12.68 1.36e-25 6.43e-18 1.17 0.72 Vitiligo; chr22:41457924 chr19:56672574~56673901:- PAAD trans rs916888 0.773 rs9896243 ENSG00000214425.5 LRRC37A4P -12.62 1.97e-25 9.23e-18 -0.97 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45506741~45550335:- PAAD trans rs9611565 0.765 rs132907 ENSG00000268568.1 AC007228.9 12.61 2.15e-25 1e-17 1.17 0.71 Vitiligo; chr22:41405264 chr19:56672574~56673901:- PAAD trans rs9611565 0.681 rs6002372 ENSG00000268568.1 AC007228.9 12.61 2.15e-25 1e-17 1.17 0.71 Vitiligo; chr22:41405295 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs132908 ENSG00000268568.1 AC007228.9 12.61 2.15e-25 1e-17 1.17 0.71 Vitiligo; chr22:41405791 chr19:56672574~56673901:- PAAD trans rs6477998 0.535 rs10981712 ENSG00000238072.1 RP11-305M3.2 12.6 2.29e-25 1.06e-17 1.06 0.71 Hematology traits; chr9:113283846 chr7:129410113~129410370:- PAAD trans rs7121616 0.531 rs10892958 ENSG00000234176.1 HSPA8P1 12.53 3.35e-25 1.53e-17 1 0.71 Breast cancer; chr11:123061415 chrX:121203182~121205014:- PAAD trans rs7121616 0.531 rs11218941 ENSG00000234176.1 HSPA8P1 12.53 3.35e-25 1.53e-17 1 0.71 Breast cancer; chr11:123061701 chrX:121203182~121205014:- PAAD trans rs9611565 0.694 rs106860 ENSG00000268568.1 AC007228.9 -12.53 3.46e-25 1.57e-17 -1.15 -0.71 Vitiligo; chr22:41444403 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs169361 ENSG00000268568.1 AC007228.9 12.52 3.64e-25 1.66e-17 1.17 0.71 Vitiligo; chr22:41481985 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs132920 ENSG00000268568.1 AC007228.9 12.52 3.68e-25 1.67e-17 1.16 0.71 Vitiligo; chr22:41414166 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs202659 ENSG00000268568.1 AC007228.9 12.52 3.68e-25 1.67e-17 1.16 0.71 Vitiligo; chr22:41415616 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs132921 ENSG00000268568.1 AC007228.9 12.52 3.68e-25 1.67e-17 1.16 0.71 Vitiligo; chr22:41416040 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs202663 ENSG00000268568.1 AC007228.9 12.52 3.68e-25 1.67e-17 1.16 0.71 Vitiligo; chr22:41416815 chr19:56672574~56673901:- PAAD trans rs941207 0.542 rs67808059 ENSG00000121089.4 NACA3P -12.5 4.25e-25 1.91e-17 -1.02 -0.71 Platelet count; chr12:56805228 chr4:164943290~164943937:+ PAAD trans rs941207 0.762 rs10450 ENSG00000121089.4 NACA3P 12.49 4.31e-25 1.93e-17 1.01 0.71 Platelet count; chr12:56590822 chr4:164943290~164943937:+ PAAD trans rs941207 0.855 rs2256341 ENSG00000121089.4 NACA3P -12.46 5.34e-25 2.35e-17 -1.08 -0.71 Platelet count; chr12:56599930 chr4:164943290~164943937:+ PAAD trans rs916888 0.697 rs199516 ENSG00000214425.5 LRRC37A4P 12.45 5.52e-25 2.42e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs199514 ENSG00000214425.5 LRRC37A4P 12.45 5.52e-25 2.42e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs199513 ENSG00000214425.5 LRRC37A4P 12.45 5.52e-25 2.42e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs199512 ENSG00000214425.5 LRRC37A4P 12.45 5.52e-25 2.42e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs199509 ENSG00000214425.5 LRRC37A4P 12.45 5.52e-25 2.42e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs199507 ENSG00000214425.5 LRRC37A4P 12.45 5.52e-25 2.42e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs199505 ENSG00000214425.5 LRRC37A4P 12.45 5.52e-25 2.42e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs70602 ENSG00000214425.5 LRRC37A4P 12.45 5.52e-25 2.42e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45506741~45550335:- PAAD trans rs13177918 0.798 rs13182116 ENSG00000239528.1 RPS14P8 -12.43 6.31e-25 2.76e-17 -1.07 -0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr5:116562562~116562930:+ PAAD trans rs61990749 0.597 rs2299930 ENSG00000235400.1 RP4-641G12.4 -12.41 7.22e-25 3.15e-17 -1.08 -0.71 Fibroblast growth factor basic levels; chr14:77697379 chr1:78749073~78750659:+ PAAD trans rs941207 0.805 rs2958139 ENSG00000121089.4 NACA3P -12.4 7.53e-25 3.28e-17 -1.08 -0.71 Platelet count; chr12:56610884 chr4:164943290~164943937:+ PAAD trans rs9611565 0.765 rs132905 ENSG00000268568.1 AC007228.9 12.39 8.38e-25 3.6e-17 1.15 0.71 Vitiligo; chr22:41403102 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs132909 ENSG00000268568.1 AC007228.9 12.39 8.38e-25 3.6e-17 1.15 0.71 Vitiligo; chr22:41406027 chr19:56672574~56673901:- PAAD trans rs9611565 0.681 rs5751094 ENSG00000268568.1 AC007228.9 12.39 8.38e-25 3.6e-17 1.15 0.71 Vitiligo; chr22:41407275 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs132914 ENSG00000268568.1 AC007228.9 12.39 8.38e-25 3.6e-17 1.15 0.71 Vitiligo; chr22:41409745 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs132915 ENSG00000268568.1 AC007228.9 12.39 8.38e-25 3.6e-17 1.15 0.71 Vitiligo; chr22:41409778 chr19:56672574~56673901:- PAAD trans rs9611565 0.681 rs132918 ENSG00000268568.1 AC007228.9 12.39 8.38e-25 3.6e-17 1.15 0.71 Vitiligo; chr22:41412346 chr19:56672574~56673901:- PAAD trans rs9611565 0.722 rs202635 ENSG00000268568.1 AC007228.9 12.39 8.38e-25 3.6e-17 1.15 0.71 Vitiligo; chr22:41413633 chr19:56672574~56673901:- PAAD trans rs941207 0.542 rs2126068 ENSG00000121089.4 NACA3P -12.38 8.5e-25 3.61e-17 -1.01 -0.71 Platelet count; chr12:56804716 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs1870674 ENSG00000121089.4 NACA3P -12.38 8.5e-25 3.61e-17 -1.01 -0.71 Platelet count; chr12:56805721 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs11171980 ENSG00000121089.4 NACA3P -12.38 8.5e-25 3.61e-17 -1.01 -0.71 Platelet count; chr12:56806397 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs12366897 ENSG00000121089.4 NACA3P -12.38 8.5e-25 3.61e-17 -1.01 -0.71 Platelet count; chr12:56808329 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs12367312 ENSG00000121089.4 NACA3P -12.38 8.5e-25 3.61e-17 -1.01 -0.71 Platelet count; chr12:56809369 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs12367339 ENSG00000121089.4 NACA3P -12.38 8.5e-25 3.61e-17 -1.01 -0.71 Platelet count; chr12:56809521 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs12367822 ENSG00000121089.4 NACA3P -12.38 8.5e-25 3.61e-17 -1.01 -0.71 Platelet count; chr12:56810376 chr4:164943290~164943937:+ PAAD trans rs9611565 0.729 rs2413646 ENSG00000268568.1 AC007228.9 -12.36 9.84e-25 4.16e-17 -1.17 -0.71 Vitiligo; chr22:41510321 chr19:56672574~56673901:- PAAD trans rs9611565 0.729 rs2413647 ENSG00000268568.1 AC007228.9 -12.36 9.84e-25 4.16e-17 -1.17 -0.71 Vitiligo; chr22:41511144 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs9611602 ENSG00000268568.1 AC007228.9 -12.36 9.84e-25 4.16e-17 -1.17 -0.71 Vitiligo; chr22:41512401 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs1569516 ENSG00000268568.1 AC007228.9 -12.36 9.84e-25 4.16e-17 -1.17 -0.71 Vitiligo; chr22:41514240 chr19:56672574~56673901:- PAAD trans rs916888 0.821 rs199506 ENSG00000214425.5 LRRC37A4P 12.35 1.03e-24 4.36e-17 0.95 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45506741~45550335:- PAAD trans rs916888 0.821 rs415430 ENSG00000214425.5 LRRC37A4P 12.35 1.05e-24 4.43e-17 0.96 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45506741~45550335:- PAAD trans rs916888 0.779 rs430685 ENSG00000214425.5 LRRC37A4P 12.35 1.05e-24 4.43e-17 0.96 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45506741~45550335:- PAAD trans rs941207 0.542 rs4277148 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet count; chr12:56787071 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs6581102 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet count; chr12:56790632 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs6581103 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet count; chr12:56790641 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs12370142 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet count; chr12:56790801 chr4:164943290~164943937:+ PAAD trans rs12367822 0.956 rs9706160 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet aggregation; chr12:56791119 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs2888095 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet count; chr12:56793689 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs2888096 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet count; chr12:56793851 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs6581106 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet count; chr12:56796759 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs7311381 ENSG00000121089.4 NACA3P -12.31 1.34e-24 5.48e-17 -1.02 -0.71 Platelet count; chr12:56800286 chr4:164943290~164943937:+ PAAD trans rs2950393 0.857 rs1563896 ENSG00000121089.4 NACA3P 12.29 1.5e-24 6.14e-17 1 0.71 Platelet distribution width; chr12:56699312 chr4:164943290~164943937:+ PAAD trans rs7554547 0.667 rs2336377 ENSG00000261819.1 RP11-680G24.4 -12.28 1.6e-24 6.54e-17 -0.89 -0.71 Nonsyndromic cleft lip with cleft palate; chr1:11889913 chr16:14988259~14990160:- PAAD trans rs9611565 0.659 rs9611603 ENSG00000268568.1 AC007228.9 -12.27 1.69e-24 6.88e-17 -1.16 -0.71 Vitiligo; chr22:41516746 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs11090049 ENSG00000268568.1 AC007228.9 -12.27 1.69e-24 6.88e-17 -1.16 -0.71 Vitiligo; chr22:41519325 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs9611604 ENSG00000268568.1 AC007228.9 -12.27 1.69e-24 6.88e-17 -1.16 -0.71 Vitiligo; chr22:41519997 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs12484694 ENSG00000268568.1 AC007228.9 -12.27 1.69e-24 6.88e-17 -1.16 -0.71 Vitiligo; chr22:41523326 chr19:56672574~56673901:- PAAD trans rs9611565 0.579 rs73178621 ENSG00000268568.1 AC007228.9 -12.27 1.69e-24 6.88e-17 -1.16 -0.71 Vitiligo; chr22:41525661 chr19:56672574~56673901:- PAAD trans rs941207 0.542 rs11171979 ENSG00000121089.4 NACA3P -12.27 1.71e-24 6.94e-17 -1 -0.71 Platelet count; chr12:56802199 chr4:164943290~164943937:+ PAAD trans rs61990749 0.544 rs11628888 ENSG00000235400.1 RP4-641G12.4 -12.26 1.82e-24 7.33e-17 -1.1 -0.71 Fibroblast growth factor basic levels; chr14:77695163 chr1:78749073~78750659:+ PAAD trans rs9611565 0.694 rs202639 ENSG00000268568.1 AC007228.9 12.23 2.25e-24 9e-17 1.1 0.7 Vitiligo; chr22:41460133 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs5758365 ENSG00000268568.1 AC007228.9 12.23 2.25e-24 9e-17 1.1 0.7 Vitiligo; chr22:41462653 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs79009 ENSG00000268568.1 AC007228.9 12.23 2.25e-24 9e-17 1.1 0.7 Vitiligo; chr22:41464860 chr19:56672574~56673901:- PAAD trans rs916888 0.738 rs199515 ENSG00000214425.5 LRRC37A4P 12.22 2.32e-24 9.26e-17 0.92 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45506741~45550335:- PAAD trans rs5022636 0.594 rs7489 ENSG00000180764.13 PIPSL 12.22 2.37e-24 9.36e-17 0.87 0.7 Gut microbiota (functional units); chr1:151266575 chr10:93958191~93961540:- PAAD trans rs13253073 0.8 rs7015733 ENSG00000260318.1 COX6CP1 12.22 2.38e-24 9.39e-17 1.22 0.7 Glucose homeostasis traits; chr8:99899353 chr16:11903923~11904137:- PAAD trans rs9611565 0.685 rs169363 ENSG00000268568.1 AC007228.9 12.19 2.92e-24 1.14e-16 1.1 0.7 Vitiligo; chr22:41457113 chr19:56672574~56673901:- PAAD trans rs5022636 0.594 rs12048670 ENSG00000180764.13 PIPSL 12.17 3.13e-24 1.22e-16 0.87 0.7 Gut microbiota (functional units); chr1:151272510 chr10:93958191~93961540:- PAAD trans rs9611565 0.659 rs28530678 ENSG00000268568.1 AC007228.9 -12.17 3.23e-24 1.26e-16 -1.16 -0.7 Vitiligo; chr22:41538957 chr19:56672574~56673901:- PAAD trans rs7554547 0.63 rs4845889 ENSG00000261819.1 RP11-680G24.4 12.17 3.32e-24 1.29e-16 0.91 0.7 Nonsyndromic cleft lip with cleft palate; chr1:11911288 chr16:14988259~14990160:- PAAD trans rs7554547 0.667 rs7525521 ENSG00000261819.1 RP11-680G24.4 12.17 3.32e-24 1.29e-16 0.91 0.7 Nonsyndromic cleft lip with cleft palate; chr1:11915109 chr16:14988259~14990160:- PAAD trans rs941207 0.542 rs6581107 ENSG00000121089.4 NACA3P -12.16 3.39e-24 1.32e-16 -1.02 -0.7 Platelet count; chr12:56801197 chr4:164943290~164943937:+ PAAD trans rs9611565 0.649 rs79005 ENSG00000268568.1 AC007228.9 12.16 3.45e-24 1.34e-16 1.13 0.7 Vitiligo; chr22:41439540 chr19:56672574~56673901:- PAAD trans rs9611565 0.608 rs202652 ENSG00000268568.1 AC007228.9 12.16 3.45e-24 1.34e-16 1.13 0.7 Vitiligo; chr22:41442788 chr19:56672574~56673901:- PAAD trans rs6477998 0.535 rs4979232 ENSG00000238072.1 RP11-305M3.2 -12.15 3.62e-24 1.4e-16 -1.04 -0.7 Hematology traits; chr9:113286594 chr7:129410113~129410370:- PAAD trans rs61990749 0.597 rs10142722 ENSG00000235400.1 RP4-641G12.4 12.11 4.77e-24 1.83e-16 1.07 0.7 Fibroblast growth factor basic levels; chr14:77809206 chr1:78749073~78750659:+ PAAD trans rs916888 0.821 rs199504 ENSG00000214425.5 LRRC37A4P 12.1 4.91e-24 1.89e-16 0.94 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45506741~45550335:- PAAD trans rs61990749 0.597 rs2267761 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77681506 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs9323650 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77683993 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs7151211 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77685558 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs2364584 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77685943 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs72685264 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77686655 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs7147516 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77687637 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs10136053 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77688862 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs28534379 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77705797 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs176943 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77709454 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs176944 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77709868 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs176946 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77712096 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs176952 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77714393 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs176955 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77714877 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs2544566 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77715395 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs2544567 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77715396 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs176962 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77719167 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs176971 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77725256 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs176979 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77731729 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs176980 ENSG00000235400.1 RP4-641G12.4 -12.08 5.73e-24 2.1e-16 -1.1 -0.7 Fibroblast growth factor basic levels; chr14:77732106 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs12887282 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77734242 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs12887606 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77734277 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs6574391 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77741778 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs8003691 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77744882 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs8003979 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77744947 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs8016416 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77746757 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs2032781 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77748532 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs2267768 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77749671 chr1:78749073~78750659:+ PAAD trans rs61990749 0.686 rs11159288 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77750629 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs3783980 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77753464 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs1549119 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77753469 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs8016447 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77755725 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs1477262 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77760310 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs1978416 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77761558 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs3759728 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77763816 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs2112136 ENSG00000235400.1 RP4-641G12.4 12.08 5.73e-24 2.1e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77782609 chr1:78749073~78750659:+ PAAD trans rs9611565 0.694 rs5758368 ENSG00000268568.1 AC007228.9 -12.06 6.52e-24 2.38e-16 -1.09 -0.7 Vitiligo; chr22:41466284 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs202631 ENSG00000268568.1 AC007228.9 12.06 6.52e-24 2.38e-16 1.09 0.7 Vitiligo; chr22:41467419 chr19:56672574~56673901:- PAAD trans rs941207 0.526 rs2950390 ENSG00000121089.4 NACA3P 12.05 6.72e-24 2.45e-16 0.95 0.7 Platelet count; chr12:56661507 chr4:164943290~164943937:+ PAAD trans rs9611565 0.659 rs17367716 ENSG00000268568.1 AC007228.9 -12.05 6.8e-24 2.48e-16 -1.14 -0.7 Vitiligo; chr22:41517840 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs202653 ENSG00000268568.1 AC007228.9 12.05 6.82e-24 2.49e-16 1.12 0.7 Vitiligo; chr22:41444154 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs202655 ENSG00000268568.1 AC007228.9 12.05 6.82e-24 2.49e-16 1.12 0.7 Vitiligo; chr22:41445560 chr19:56672574~56673901:- PAAD trans rs9611565 0.527 rs73178638 ENSG00000268568.1 AC007228.9 -12.02 7.96e-24 2.89e-16 -1.17 -0.7 Vitiligo; chr22:41546900 chr19:56672574~56673901:- PAAD trans rs941207 0.542 rs1813109 ENSG00000121089.4 NACA3P -12.02 8.11e-24 2.94e-16 -1.03 -0.7 Platelet count; chr12:56798079 chr4:164943290~164943937:+ PAAD trans rs9611565 0.649 rs202657 ENSG00000268568.1 AC007228.9 12.02 8.24e-24 2.98e-16 1.13 0.7 Vitiligo; chr22:41448782 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs202641 ENSG00000268568.1 AC007228.9 11.97 1.1e-23 3.95e-16 1.12 0.7 Vitiligo; chr22:41437112 chr19:56672574~56673901:- PAAD trans rs7554547 0.765 rs6541010 ENSG00000261819.1 RP11-680G24.4 11.97 1.14e-23 4.09e-16 0.89 0.7 Nonsyndromic cleft lip with cleft palate; chr1:11913785 chr16:14988259~14990160:- PAAD trans rs61990749 0.597 rs7142390 ENSG00000235400.1 RP4-641G12.4 11.96 1.19e-23 4.25e-16 1.11 0.7 Fibroblast growth factor basic levels; chr14:77766537 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs1008988 ENSG00000235400.1 RP4-641G12.4 11.96 1.22e-23 4.32e-16 1.07 0.7 Fibroblast growth factor basic levels; chr14:77794452 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs6574402 ENSG00000235400.1 RP4-641G12.4 11.96 1.22e-23 4.32e-16 1.07 0.7 Fibroblast growth factor basic levels; chr14:77801607 chr1:78749073~78750659:+ PAAD trans rs9611565 0.694 rs79008 ENSG00000268568.1 AC007228.9 -11.95 1.25e-23 4.4e-16 -1.08 -0.7 Vitiligo; chr22:41454496 chr19:56672574~56673901:- PAAD trans rs202629 1 rs202629 ENSG00000268568.1 AC007228.9 11.95 1.25e-23 4.4e-16 1.08 0.7 Cannabis dependence symptom count; chr22:41453971 chr19:56672574~56673901:- PAAD trans rs61990749 0.597 rs10148373 ENSG00000235400.1 RP4-641G12.4 11.94 1.3e-23 4.59e-16 1.1 0.7 Fibroblast growth factor basic levels; chr14:77813856 chr1:78749073~78750659:+ PAAD trans rs9611565 0.659 rs4822035 ENSG00000268568.1 AC007228.9 11.93 1.4e-23 4.91e-16 1.16 0.7 Vitiligo; chr22:41539908 chr19:56672574~56673901:- PAAD trans rs7554547 0.756 rs11121840 ENSG00000261819.1 RP11-680G24.4 11.93 1.46e-23 5.11e-16 0.89 0.7 Nonsyndromic cleft lip with cleft palate; chr1:11908299 chr16:14988259~14990160:- PAAD trans rs7554547 0.721 rs12092734 ENSG00000261819.1 RP11-680G24.4 11.93 1.46e-23 5.11e-16 0.89 0.7 Nonsyndromic cleft lip with cleft palate; chr1:11908349 chr16:14988259~14990160:- PAAD trans rs727563 0.58 rs202626 ENSG00000268568.1 AC007228.9 11.92 1.51e-23 5.27e-16 1.13 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41451186 chr19:56672574~56673901:- PAAD trans rs9611565 0.532 rs202627 ENSG00000268568.1 AC007228.9 11.92 1.51e-23 5.27e-16 1.13 0.7 Vitiligo; chr22:41451363 chr19:56672574~56673901:- PAAD trans rs61990749 0.597 rs4903643 ENSG00000235400.1 RP4-641G12.4 11.91 1.58e-23 5.5e-16 1.1 0.69 Fibroblast growth factor basic levels; chr14:77788448 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs1477260 ENSG00000235400.1 RP4-641G12.4 11.91 1.58e-23 5.5e-16 1.1 0.69 Fibroblast growth factor basic levels; chr14:77790475 chr1:78749073~78750659:+ PAAD trans rs9611565 0.694 rs202628 ENSG00000268568.1 AC007228.9 -11.91 1.64e-23 5.69e-16 -1.08 -0.69 Vitiligo; chr22:41453509 chr19:56672574~56673901:- PAAD trans rs1816752 0.583 rs6490918 ENSG00000237917.1 PARP4P1 -11.89 1.79e-23 6.18e-16 -0.91 -0.69 Obesity-related traits; chr13:24427977 chrY:26594851~26634652:- PAAD trans rs1816752 0.74 rs6490924 ENSG00000237917.1 PARP4P1 -11.89 1.79e-23 6.18e-16 -0.91 -0.69 Obesity-related traits; chr13:24432914 chrY:26594851~26634652:- PAAD trans rs1816752 0.704 rs7995968 ENSG00000237917.1 PARP4P1 -11.89 1.81e-23 6.25e-16 -0.93 -0.69 Obesity-related traits; chr13:24392754 chrY:26594851~26634652:- PAAD trans rs7554547 0.667 rs4846072 ENSG00000261819.1 RP11-680G24.4 11.88 1.93e-23 6.65e-16 0.88 0.69 Nonsyndromic cleft lip with cleft palate; chr1:11890334 chr16:14988259~14990160:- PAAD trans rs5022636 0.525 rs6587559 ENSG00000180764.13 PIPSL 11.88 1.99e-23 6.85e-16 0.86 0.69 Gut microbiota (functional units); chr1:151245262 chr10:93958191~93961540:- PAAD trans rs941207 0.542 rs7315786 ENSG00000121089.4 NACA3P -11.87 2.01e-23 6.91e-16 -1.03 -0.69 Platelet count; chr12:56801595 chr4:164943290~164943937:+ PAAD trans rs6477998 0.513 rs10981720 ENSG00000238072.1 RP11-305M3.2 11.86 2.16e-23 7.4e-16 1.09 0.69 Hematology traits; chr9:113293831 chr7:129410113~129410370:- PAAD trans rs941207 0.542 rs11171983 ENSG00000121089.4 NACA3P -11.81 2.93e-23 9.98e-16 -0.96 -0.69 Platelet count; chr12:56814461 chr4:164943290~164943937:+ PAAD trans rs61990749 0.597 rs4632066 ENSG00000235400.1 RP4-641G12.4 -11.79 3.38e-23 1.14e-15 -1.08 -0.69 Fibroblast growth factor basic levels; chr14:77780939 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs12896026 ENSG00000235400.1 RP4-641G12.4 11.79 3.38e-23 1.14e-15 1.08 0.69 Fibroblast growth factor basic levels; chr14:77778093 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs12435761 ENSG00000235400.1 RP4-641G12.4 11.79 3.38e-23 1.14e-15 1.08 0.69 Fibroblast growth factor basic levels; chr14:77779734 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs759808 ENSG00000235400.1 RP4-641G12.4 11.79 3.38e-23 1.14e-15 1.08 0.69 Fibroblast growth factor basic levels; chr14:77784502 chr1:78749073~78750659:+ PAAD trans rs9611565 0.659 rs17367849 ENSG00000268568.1 AC007228.9 -11.78 3.56e-23 1.2e-15 -1.14 -0.69 Vitiligo; chr22:41527640 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs1810461 ENSG00000268568.1 AC007228.9 -11.78 3.56e-23 1.2e-15 -1.14 -0.69 Vitiligo; chr22:41531816 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs73178626 ENSG00000268568.1 AC007228.9 -11.78 3.56e-23 1.2e-15 -1.14 -0.69 Vitiligo; chr22:41532367 chr19:56672574~56673901:- PAAD trans rs1816752 0.679 rs8181826 ENSG00000237917.1 PARP4P1 -11.76 3.99e-23 1.34e-15 -0.9 -0.69 Obesity-related traits; chr13:24396570 chrY:26594851~26634652:- PAAD trans rs5022636 0.631 rs6587562 ENSG00000180764.13 PIPSL -11.73 4.84e-23 1.62e-15 -0.86 -0.69 Gut microbiota (functional units); chr1:151273765 chr10:93958191~93961540:- PAAD trans rs9611565 0.659 rs4822036 ENSG00000268568.1 AC007228.9 -11.72 5.19e-23 1.73e-15 -1.13 -0.69 Vitiligo; chr22:41540015 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs12483786 ENSG00000268568.1 AC007228.9 -11.72 5.19e-23 1.73e-15 -1.13 -0.69 Vitiligo; chr22:41542532 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs12484228 ENSG00000268568.1 AC007228.9 -11.72 5.19e-23 1.73e-15 -1.13 -0.69 Vitiligo; chr22:41543735 chr19:56672574~56673901:- PAAD trans rs9611565 0.643 rs202634 ENSG00000268568.1 AC007228.9 11.71 5.54e-23 1.84e-15 1.15 0.69 Vitiligo; chr22:41413619 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs1810460 ENSG00000268568.1 AC007228.9 -11.7 6.04e-23 2e-15 -1.14 -0.69 Vitiligo; chr22:41531696 chr19:56672574~56673901:- PAAD trans rs941207 0.526 rs7303216 ENSG00000121089.4 NACA3P 11.69 6.33e-23 2.05e-15 0.94 0.69 Platelet count; chr12:56680909 chr4:164943290~164943937:+ PAAD trans rs941207 0.507 rs7297289 ENSG00000121089.4 NACA3P 11.69 6.33e-23 2.05e-15 0.94 0.69 Platelet count; chr12:56682703 chr4:164943290~164943937:+ PAAD trans rs941207 0.526 rs4759028 ENSG00000121089.4 NACA3P 11.69 6.33e-23 2.05e-15 0.94 0.69 Platelet count; chr12:56686399 chr4:164943290~164943937:+ PAAD trans rs7554547 0.755 rs6662295 ENSG00000261819.1 RP11-680G24.4 11.67 6.99e-23 2.26e-15 0.88 0.69 Nonsyndromic cleft lip with cleft palate; chr1:11907848 chr16:14988259~14990160:- PAAD trans rs7554547 0.756 rs6684539 ENSG00000261819.1 RP11-680G24.4 11.67 6.99e-23 2.26e-15 0.88 0.69 Nonsyndromic cleft lip with cleft palate; chr1:11908216 chr16:14988259~14990160:- PAAD trans rs9611565 0.625 rs73178625 ENSG00000268568.1 AC007228.9 -11.66 7.72e-23 2.48e-15 -1.13 -0.69 Vitiligo; chr22:41532316 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs9607813 ENSG00000268568.1 AC007228.9 -11.64 8.49e-23 2.72e-15 -1.14 -0.69 Vitiligo; chr22:41545475 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs4822034 ENSG00000268568.1 AC007228.9 -11.64 8.67e-23 2.76e-15 -1.14 -0.69 Vitiligo; chr22:41535006 chr19:56672574~56673901:- PAAD trans rs9611565 0.625 rs9611606 ENSG00000268568.1 AC007228.9 -11.64 8.67e-23 2.76e-15 -1.14 -0.69 Vitiligo; chr22:41535070 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs116959331 ENSG00000268568.1 AC007228.9 -11.64 8.67e-23 2.76e-15 -1.14 -0.69 Vitiligo; chr22:41536770 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs56319767 ENSG00000268568.1 AC007228.9 -11.64 8.67e-23 2.76e-15 -1.14 -0.69 Vitiligo; chr22:41537833 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs73178632 ENSG00000268568.1 AC007228.9 -11.64 8.67e-23 2.76e-15 -1.14 -0.69 Vitiligo; chr22:41538569 chr19:56672574~56673901:- PAAD trans rs61990749 0.5 rs8011337 ENSG00000235400.1 RP4-641G12.4 11.64 8.72e-23 2.76e-15 1.09 0.69 Fibroblast growth factor basic levels; chr14:77806283 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs717683 ENSG00000235400.1 RP4-641G12.4 11.63 8.98e-23 2.83e-15 1.08 0.69 Fibroblast growth factor basic levels; chr14:77789110 chr1:78749073~78750659:+ PAAD trans rs61990749 0.544 rs1477259 ENSG00000235400.1 RP4-641G12.4 11.63 8.98e-23 2.83e-15 1.08 0.69 Fibroblast growth factor basic levels; chr14:77789795 chr1:78749073~78750659:+ PAAD trans rs9467773 0.62 rs2504565 ENSG00000242375.1 RP11-498P14.3 11.63 9.03e-23 2.85e-15 0.86 0.69 Intelligence (multi-trait analysis); chr6:26656662 chr9:97195351~97197687:- PAAD trans rs5022636 0.594 rs11204791 ENSG00000180764.13 PIPSL 11.61 1.07e-22 3.34e-15 0.83 0.69 Gut microbiota (functional units); chr1:151268066 chr10:93958191~93961540:- PAAD trans rs6477998 0.535 rs10817475 ENSG00000238072.1 RP11-305M3.2 11.59 1.15e-22 3.61e-15 1.05 0.69 Hematology traits; chr9:113296774 chr7:129410113~129410370:- PAAD trans rs2950393 0.895 rs2926740 ENSG00000121089.4 NACA3P 11.59 1.16e-22 3.62e-15 0.93 0.69 Platelet distribution width; chr12:56666751 chr4:164943290~164943937:+ PAAD trans rs9611565 0.694 rs19573 ENSG00000268568.1 AC007228.9 11.59 1.17e-22 3.65e-15 1.08 0.68 Vitiligo; chr22:41469805 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs79011 ENSG00000268568.1 AC007228.9 11.59 1.17e-22 3.65e-15 1.08 0.68 Vitiligo; chr22:41470934 chr19:56672574~56673901:- PAAD trans rs9467773 0.62 rs2494696 ENSG00000242375.1 RP11-498P14.3 11.59 1.17e-22 3.67e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26620666 chr9:97195351~97197687:- PAAD trans rs2885056 0.783 rs73007347 ENSG00000227534.1 RP3-323B6.1 11.57 1.3e-22 4.04e-15 1 0.68 Red cell distribution width; chr19:10539973 chrX:65469087~65470380:+ PAAD trans rs5022636 0.559 rs41302131 ENSG00000180764.13 PIPSL 11.57 1.31e-22 4.09e-15 0.83 0.68 Gut microbiota (functional units); chr1:151267532 chr10:93958191~93961540:- PAAD trans rs9611565 0.729 rs73176686 ENSG00000268568.1 AC007228.9 -11.56 1.39e-22 4.3e-15 -1.1 -0.68 Vitiligo; chr22:41386115 chr19:56672574~56673901:- PAAD trans rs9611565 0.729 rs4822027 ENSG00000268568.1 AC007228.9 -11.56 1.39e-22 4.3e-15 -1.1 -0.68 Vitiligo; chr22:41390223 chr19:56672574~56673901:- PAAD trans rs9611565 0.729 rs73176689 ENSG00000268568.1 AC007228.9 -11.56 1.45e-22 4.49e-15 -1.1 -0.68 Vitiligo; chr22:41386629 chr19:56672574~56673901:- PAAD trans rs9467773 0.62 rs1490488 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26614580 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2494692 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26614995 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2451737 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26618813 chr9:97195351~97197687:- PAAD trans rs9467773 0.596 rs2494693 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26618998 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2494694 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26619100 chr9:97195351~97197687:- PAAD trans rs9467773 0.595 rs2451736 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26620316 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2101581 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26622541 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2451731 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26624594 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs9295701 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26627280 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2451741 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26629176 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2494700 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26631078 chr9:97195351~97197687:- PAAD trans rs9467773 0.584 rs1021372 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26632216 chr9:97195351~97197687:- PAAD trans rs9467773 0.583 rs1021373 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26632229 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2451744 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26633235 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2494701 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26634204 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs1027204 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26639385 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2504592 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26640723 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2504599 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26640832 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2504540 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26641398 chr9:97195351~97197687:- PAAD trans rs9467773 0.596 rs2451750 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26646351 chr9:97195351~97197687:- PAAD trans rs9467773 0.596 rs2451751 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26646486 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2504600 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26648106 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2130657 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26650598 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2498351 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26659414 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2504566 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26660260 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2494716 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26662508 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2451711 ENSG00000242375.1 RP11-498P14.3 11.55 1.51e-22 4.58e-15 0.85 0.68 Intelligence (multi-trait analysis); chr6:26662882 chr9:97195351~97197687:- PAAD trans rs9467773 0.583 rs2498380 ENSG00000242375.1 RP11-498P14.3 -11.55 1.51e-22 4.58e-15 -0.85 -0.68 Intelligence (multi-trait analysis); chr6:26643768 chr9:97195351~97197687:- PAAD trans rs9611565 0.659 rs28623192 ENSG00000268568.1 AC007228.9 -11.49 2.25e-22 6.73e-15 -1.14 -0.68 Vitiligo; chr22:41544520 chr19:56672574~56673901:- PAAD trans rs9467773 0.62 rs2504571 ENSG00000242375.1 RP11-498P14.3 11.48 2.32e-22 6.94e-15 0.84 0.68 Intelligence (multi-trait analysis); chr6:26643207 chr9:97195351~97197687:- PAAD trans rs9611565 0.659 rs4822037 ENSG00000268568.1 AC007228.9 -11.47 2.5e-22 7.4e-15 -1.14 -0.68 Vitiligo; chr22:41549109 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs9611609 ENSG00000268568.1 AC007228.9 -11.47 2.5e-22 7.4e-15 -1.14 -0.68 Vitiligo; chr22:41549353 chr19:56672574~56673901:- PAAD trans rs2950393 0.895 rs2958154 ENSG00000121089.4 NACA3P -11.46 2.58e-22 7.63e-15 -0.93 -0.68 Platelet distribution width; chr12:56671929 chr4:164943290~164943937:+ PAAD trans rs9611565 0.659 rs9607812 ENSG00000268568.1 AC007228.9 -11.46 2.58e-22 7.63e-15 -1.14 -0.68 Vitiligo; chr22:41545239 chr19:56672574~56673901:- PAAD trans rs12291225 0.535 rs16930126 ENSG00000236360.2 RP11-334A14.2 -11.46 2.62e-22 7.72e-15 -0.89 -0.68 Sense of smell; chr11:14383437 chr1:52993201~52993702:- PAAD trans rs9467773 0.62 rs9461275 ENSG00000242375.1 RP11-498P14.3 11.46 2.68e-22 7.88e-15 0.86 0.68 Intelligence (multi-trait analysis); chr6:26590573 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs6925087 ENSG00000242375.1 RP11-498P14.3 11.46 2.68e-22 7.88e-15 0.86 0.68 Intelligence (multi-trait analysis); chr6:26592625 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs4368798 ENSG00000242375.1 RP11-498P14.3 11.46 2.68e-22 7.88e-15 0.86 0.68 Intelligence (multi-trait analysis); chr6:26593243 chr9:97195351~97197687:- PAAD trans rs9467773 0.595 rs7767847 ENSG00000242375.1 RP11-498P14.3 11.46 2.68e-22 7.88e-15 0.86 0.68 Intelligence (multi-trait analysis); chr6:26597665 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs3800303 ENSG00000242375.1 RP11-498P14.3 11.46 2.68e-22 7.88e-15 0.86 0.68 Intelligence (multi-trait analysis); chr6:26597960 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs9467810 ENSG00000242375.1 RP11-498P14.3 11.46 2.68e-22 7.88e-15 0.86 0.68 Intelligence (multi-trait analysis); chr6:26608033 chr9:97195351~97197687:- PAAD trans rs941207 0.547 rs56183434 ENSG00000121089.4 NACA3P 11.45 2.78e-22 8.18e-15 0.93 0.68 Platelet count; chr12:56676145 chr4:164943290~164943937:+ PAAD trans rs12291225 0.877 rs2303974 ENSG00000236360.2 RP11-334A14.2 11.45 2.86e-22 8.41e-15 0.92 0.68 Sense of smell; chr11:14243433 chr1:52993201~52993702:- PAAD trans rs5022636 0.564 rs2275900 ENSG00000180764.13 PIPSL 11.42 3.31e-22 9.62e-15 0.83 0.68 Gut microbiota (functional units); chr1:151265746 chr10:93958191~93961540:- PAAD trans rs61990749 0.597 rs1006039 ENSG00000235400.1 RP4-641G12.4 -11.42 3.34e-22 9.71e-15 -1.07 -0.68 Fibroblast growth factor basic levels; chr14:77796853 chr1:78749073~78750659:+ PAAD trans rs5022636 0.525 rs6681163 ENSG00000180764.13 PIPSL 11.42 3.42e-22 9.93e-15 0.83 0.68 Gut microbiota (functional units); chr1:151259161 chr10:93958191~93961540:- PAAD trans rs9611565 0.694 rs9607816 ENSG00000268568.1 AC007228.9 -11.41 3.67e-22 1.06e-14 -1.12 -0.68 Vitiligo; chr22:41554893 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs56364401 ENSG00000268568.1 AC007228.9 -11.41 3.67e-22 1.06e-14 -1.12 -0.68 Vitiligo; chr22:41555239 chr19:56672574~56673901:- PAAD trans rs5022636 0.594 rs10888408 ENSG00000180764.13 PIPSL 11.39 4.05e-22 1.17e-14 0.82 0.68 Gut microbiota (functional units); chr1:151267094 chr10:93958191~93961540:- PAAD trans rs9467773 0.596 rs3001369 ENSG00000242375.1 RP11-498P14.3 11.38 4.2e-22 1.21e-14 0.86 0.68 Intelligence (multi-trait analysis); chr6:26670741 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs1027203 ENSG00000242375.1 RP11-498P14.3 11.36 4.93e-22 1.42e-14 0.85 0.68 Intelligence (multi-trait analysis); chr6:26639104 chr9:97195351~97197687:- PAAD trans rs9467773 0.595 rs2172007 ENSG00000242375.1 RP11-498P14.3 11.36 4.93e-22 1.42e-14 0.85 0.68 Intelligence (multi-trait analysis); chr6:26639549 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs9461276 ENSG00000242375.1 RP11-498P14.3 11.35 5.25e-22 1.51e-14 0.86 0.68 Intelligence (multi-trait analysis); chr6:26594940 chr9:97195351~97197687:- PAAD trans rs2885056 0.891 rs12978228 ENSG00000227534.1 RP3-323B6.1 11.34 5.62e-22 1.61e-14 0.95 0.68 Red cell distribution width; chr19:10580647 chrX:65469087~65470380:+ PAAD trans rs9467773 0.62 rs2101582 ENSG00000242375.1 RP11-498P14.3 11.31 6.5e-22 1.86e-14 0.84 0.68 Intelligence (multi-trait analysis); chr6:26622506 chr9:97195351~97197687:- PAAD trans rs12291225 0.877 rs11023160 ENSG00000236360.2 RP11-334A14.2 11.28 8.06e-22 2.28e-14 0.92 0.67 Sense of smell; chr11:14242679 chr1:52993201~52993702:- PAAD trans rs9467773 0.595 rs13207371 ENSG00000242375.1 RP11-498P14.3 11.27 8.37e-22 2.37e-14 0.85 0.67 Intelligence (multi-trait analysis); chr6:26590846 chr9:97195351~97197687:- PAAD trans rs941207 0.542 rs10876928 ENSG00000121089.4 NACA3P -11.27 8.49e-22 2.4e-14 -0.95 -0.67 Platelet count; chr12:56813646 chr4:164943290~164943937:+ PAAD trans rs941207 0.526 rs12229457 ENSG00000121089.4 NACA3P -11.27 8.5e-22 2.4e-14 -0.92 -0.67 Platelet count; chr12:56639896 chr4:164943290~164943937:+ PAAD trans rs941207 0.526 rs2950393 ENSG00000121089.4 NACA3P -11.27 8.5e-22 2.4e-14 -0.92 -0.67 Platelet count; chr12:56642239 chr4:164943290~164943937:+ PAAD trans rs9467773 0.595 rs12525810 ENSG00000242375.1 RP11-498P14.3 11.27 8.51e-22 2.4e-14 0.85 0.67 Intelligence (multi-trait analysis); chr6:26623283 chr9:97195351~97197687:- PAAD trans rs941207 0.526 rs11171916 ENSG00000121089.4 NACA3P -11.27 8.68e-22 2.45e-14 -0.93 -0.67 Platelet count; chr12:56653236 chr4:164943290~164943937:+ PAAD trans rs5022636 0.525 rs4291501 ENSG00000180764.13 PIPSL 11.25 9.9e-22 2.78e-14 0.85 0.67 Gut microbiota (functional units); chr1:151196681 chr10:93958191~93961540:- PAAD trans rs5022636 0.525 rs4971013 ENSG00000180764.13 PIPSL 11.25 9.9e-22 2.78e-14 0.85 0.67 Gut microbiota (functional units); chr1:151200637 chr10:93958191~93961540:- PAAD trans rs9611565 0.729 rs132902 ENSG00000268568.1 AC007228.9 -11.21 1.26e-21 3.51e-14 -1.1 -0.67 Vitiligo; chr22:41401754 chr19:56672574~56673901:- PAAD trans rs12291225 0.883 rs1864658 ENSG00000236360.2 RP11-334A14.2 -11.2 1.31e-21 3.65e-14 -0.89 -0.67 Sense of smell; chr11:14234898 chr1:52993201~52993702:- PAAD trans rs2885056 0.843 rs1821280 ENSG00000227534.1 RP3-323B6.1 11.18 1.46e-21 4.07e-14 0.94 0.67 Red cell distribution width; chr19:10582331 chrX:65469087~65470380:+ PAAD trans rs7554547 0.595 rs12092731 ENSG00000261819.1 RP11-680G24.4 11.16 1.68e-21 4.65e-14 0.83 0.67 Nonsyndromic cleft lip with cleft palate; chr1:11908338 chr16:14988259~14990160:- PAAD trans rs2885056 0.83 rs10409805 ENSG00000227534.1 RP3-323B6.1 11.14 1.85e-21 5.1e-14 0.93 0.67 Red cell distribution width; chr19:10580769 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs12978787 ENSG00000227534.1 RP3-323B6.1 11.14 1.85e-21 5.1e-14 0.93 0.67 Red cell distribution width; chr19:10580881 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs12979033 ENSG00000227534.1 RP3-323B6.1 11.14 1.85e-21 5.1e-14 0.93 0.67 Red cell distribution width; chr19:10580942 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs1045361 ENSG00000227534.1 RP3-323B6.1 11.14 1.85e-21 5.1e-14 0.93 0.67 Red cell distribution width; chr19:10581324 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs2304161 ENSG00000227534.1 RP3-323B6.1 11.14 1.85e-21 5.1e-14 0.93 0.67 Red cell distribution width; chr19:10581441 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs2304160 ENSG00000227534.1 RP3-323B6.1 11.14 1.85e-21 5.1e-14 0.93 0.67 Red cell distribution width; chr19:10581453 chrX:65469087~65470380:+ PAAD trans rs55665837 0.559 rs11023209 ENSG00000236360.2 RP11-334A14.2 11.14 1.88e-21 5.15e-14 0.89 0.67 Vitamin D levels; chr11:14401054 chr1:52993201~52993702:- PAAD trans rs2950393 0.804 rs3214051 ENSG00000121089.4 NACA3P 11.14 1.89e-21 5.19e-14 0.9 0.67 Platelet distribution width; chr12:56725452 chr4:164943290~164943937:+ PAAD trans rs928391 0.744 rs11264555 ENSG00000227183.3 HDGFP1 -11.14 1.91e-21 5.25e-14 -0.85 -0.67 Platelet count; chr1:156794246 chrX:131646639~131646890:+ PAAD trans rs928391 0.744 rs3765783 ENSG00000227183.3 HDGFP1 -11.14 1.91e-21 5.25e-14 -0.85 -0.67 Platelet count; chr1:156796181 chrX:131646639~131646890:+ PAAD trans rs2950393 0.927 rs11171914 ENSG00000121089.4 NACA3P -11.13 2.03e-21 5.56e-14 -0.92 -0.67 Platelet distribution width; chr12:56649462 chr4:164943290~164943937:+ PAAD trans rs9611565 0.659 rs12483998 ENSG00000268568.1 AC007228.9 -11.13 2.06e-21 5.64e-14 -1.13 -0.67 Vitiligo; chr22:41539358 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs12484175 ENSG00000268568.1 AC007228.9 -11.12 2.14e-21 5.85e-14 -1.13 -0.67 Vitiligo; chr22:41557735 chr19:56672574~56673901:- PAAD trans rs13177918 0.734 rs6579790 ENSG00000224114.1 RP11-343H5.4 11.11 2.23e-21 6.08e-14 1.01 0.67 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr1:206695837~206696269:- PAAD trans rs9467773 0.62 rs2504567 ENSG00000242375.1 RP11-498P14.3 11.1 2.41e-21 6.53e-14 0.83 0.67 Intelligence (multi-trait analysis); chr6:26662692 chr9:97195351~97197687:- PAAD trans rs9467773 0.62 rs2451732 ENSG00000242375.1 RP11-498P14.3 -11.1 2.41e-21 6.53e-14 -0.83 -0.67 Intelligence (multi-trait analysis); chr6:26622676 chr9:97195351~97197687:- PAAD trans rs2950393 0.804 rs1466382 ENSG00000121089.4 NACA3P -11.1 2.41e-21 6.54e-14 -0.87 -0.67 Platelet distribution width; chr12:56723050 chr4:164943290~164943937:+ PAAD trans rs5022636 0.525 rs4971021 ENSG00000180764.13 PIPSL 11.1 2.43e-21 6.57e-14 0.82 0.67 Gut microbiota (functional units); chr1:151246152 chr10:93958191~93961540:- PAAD trans rs9611565 0.659 rs9607815 ENSG00000268568.1 AC007228.9 -11.1 2.47e-21 6.67e-14 -1.12 -0.67 Vitiligo; chr22:41554667 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs73178641 ENSG00000268568.1 AC007228.9 -11.1 2.47e-21 6.67e-14 -1.12 -0.67 Vitiligo; chr22:41556071 chr19:56672574~56673901:- PAAD trans rs9611565 0.802 rs9611577 ENSG00000268568.1 AC007228.9 -11.09 2.57e-21 6.94e-14 -1.07 -0.67 Vitiligo; chr22:41397086 chr19:56672574~56673901:- PAAD trans rs5022636 0.927 rs943637 ENSG00000180764.13 PIPSL 11.09 2.6e-21 7.02e-14 0.84 0.67 Gut microbiota (functional units); chr1:151310543 chr10:93958191~93961540:- PAAD trans rs5022636 0.896 rs4971032 ENSG00000180764.13 PIPSL 11.09 2.6e-21 7.02e-14 0.84 0.67 Gut microbiota (functional units); chr1:151317948 chr10:93958191~93961540:- PAAD trans rs5022636 1 rs4970948 ENSG00000180764.13 PIPSL 11.09 2.6e-21 7.02e-14 0.84 0.67 Gut microbiota (functional units); chr1:151318767 chr10:93958191~93961540:- PAAD trans rs5022636 0.964 rs7518924 ENSG00000180764.13 PIPSL 11.09 2.6e-21 7.02e-14 0.84 0.67 Gut microbiota (functional units); chr1:151319225 chr10:93958191~93961540:- PAAD trans rs5022636 1 rs5022636 ENSG00000180764.13 PIPSL 11.08 2.71e-21 7.3e-14 0.83 0.67 Gut microbiota (functional units); chr1:151322585 chr10:93958191~93961540:- PAAD trans rs55665837 0.559 rs9667144 ENSG00000236360.2 RP11-334A14.2 -11.08 2.76e-21 7.42e-14 -0.88 -0.67 Vitamin D levels; chr11:14399555 chr1:52993201~52993702:- PAAD trans rs9611565 0.605 rs202638 ENSG00000268568.1 AC007228.9 11.07 2.89e-21 7.75e-14 0.96 0.67 Vitiligo; chr22:41459454 chr19:56672574~56673901:- PAAD trans rs13177918 0.734 rs6579791 ENSG00000224114.1 RP11-343H5.4 11.07 2.94e-21 7.9e-14 1 0.67 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr1:206695837~206696269:- PAAD trans rs9467773 0.596 rs62396201 ENSG00000242375.1 RP11-498P14.3 11.07 2.98e-21 7.98e-14 0.86 0.67 Intelligence (multi-trait analysis); chr6:26667988 chr9:97195351~97197687:- PAAD trans rs2885056 0.891 rs1821282 ENSG00000227534.1 RP3-323B6.1 11.07 2.99e-21 8e-14 0.93 0.67 Red cell distribution width; chr19:10582038 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs1821281 ENSG00000227534.1 RP3-323B6.1 11.07 2.99e-21 8e-14 0.93 0.67 Red cell distribution width; chr19:10582184 chrX:65469087~65470380:+ PAAD trans rs916888 0.773 rs538628 ENSG00000264070.1 DND1P1 11.07 2.99e-21 8e-14 1.02 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45585871~45586929:+ PAAD trans rs916888 0.773 rs199534 ENSG00000264070.1 DND1P1 11.07 3.02e-21 8.08e-14 1.02 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45585871~45586929:+ PAAD trans rs2885056 0.843 rs35769432 ENSG00000227534.1 RP3-323B6.1 11.06 3.04e-21 8.13e-14 0.93 0.67 Red cell distribution width; chr19:10585148 chrX:65469087~65470380:+ PAAD trans rs916888 0.773 rs199533 ENSG00000264070.1 DND1P1 11.06 3.16e-21 8.45e-14 1.02 0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45585871~45586929:+ PAAD trans rs2950393 0.804 rs2926748 ENSG00000121089.4 NACA3P 11.05 3.38e-21 9.01e-14 0.89 0.67 Platelet distribution width; chr12:56715628 chr4:164943290~164943937:+ PAAD trans rs9467773 0.549 rs9467805 ENSG00000242375.1 RP11-498P14.3 11.04 3.51e-21 9.35e-14 0.84 0.67 Intelligence (multi-trait analysis); chr6:26583138 chr9:97195351~97197687:- PAAD trans rs916888 0.61 rs199529 ENSG00000214425.5 LRRC37A4P -11.04 3.58e-21 9.53e-14 -0.88 -0.67 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45506741~45550335:- PAAD trans rs2950393 0.804 rs2958127 ENSG00000121089.4 NACA3P 11.03 3.68e-21 9.8e-14 0.88 0.67 Platelet distribution width; chr12:56720523 chr4:164943290~164943937:+ PAAD trans rs6477998 0.903 rs4979226 ENSG00000238072.1 RP11-305M3.2 11.03 3.83e-21 1.02e-13 0.91 0.67 Hematology traits; chr9:113239516 chr7:129410113~129410370:- PAAD trans rs6477998 0.903 rs7041615 ENSG00000238072.1 RP11-305M3.2 11.03 3.83e-21 1.02e-13 0.91 0.67 Hematology traits; chr9:113244747 chr7:129410113~129410370:- PAAD trans rs2885056 0.891 rs73016784 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10578109 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs73016785 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10578263 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs73018643 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10578293 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs73018644 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10578339 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs116449616 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10578347 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs115850646 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10578351 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs28367549 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10578508 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs73018656 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10579121 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs12460574 ENSG00000227534.1 RP3-323B6.1 11.02 4.06e-21 1.07e-13 0.93 0.67 Red cell distribution width; chr19:10579279 chrX:65469087~65470380:+ PAAD trans rs5022636 0.525 rs4520422 ENSG00000180764.13 PIPSL 11.01 4.35e-21 1.14e-13 0.84 0.67 Gut microbiota (functional units); chr1:151207467 chr10:93958191~93961540:- PAAD trans rs5022636 0.525 rs7539584 ENSG00000180764.13 PIPSL 11.01 4.35e-21 1.14e-13 0.84 0.67 Gut microbiota (functional units); chr1:151210477 chr10:93958191~93961540:- PAAD trans rs6477998 0.874 rs10739390 ENSG00000238072.1 RP11-305M3.2 11.01 4.36e-21 1.15e-13 0.91 0.67 Hematology traits; chr9:113226209 chr7:129410113~129410370:- PAAD trans rs2885056 0.843 rs1821279 ENSG00000227534.1 RP3-323B6.1 10.99 4.84e-21 1.27e-13 0.93 0.67 Red cell distribution width; chr19:10582332 chrX:65469087~65470380:+ PAAD trans rs2885056 0.83 rs2360748 ENSG00000227534.1 RP3-323B6.1 10.99 4.84e-21 1.27e-13 0.93 0.67 Red cell distribution width; chr19:10582948 chrX:65469087~65470380:+ PAAD trans rs2885056 1 rs2885056 ENSG00000227534.1 RP3-323B6.1 10.99 4.84e-21 1.27e-13 0.93 0.67 Red cell distribution width; chr19:10582952 chrX:65469087~65470380:+ PAAD trans rs2885056 0.824 rs2360747 ENSG00000227534.1 RP3-323B6.1 10.99 4.84e-21 1.27e-13 0.93 0.67 Red cell distribution width; chr19:10583077 chrX:65469087~65470380:+ PAAD trans rs2885056 0.843 rs2360745 ENSG00000227534.1 RP3-323B6.1 10.99 4.84e-21 1.27e-13 0.93 0.67 Red cell distribution width; chr19:10583160 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs11085739 ENSG00000227534.1 RP3-323B6.1 10.99 4.84e-21 1.27e-13 0.93 0.67 Red cell distribution width; chr19:10583563 chrX:65469087~65470380:+ PAAD trans rs2885056 0.843 rs11085740 ENSG00000227534.1 RP3-323B6.1 10.99 4.84e-21 1.27e-13 0.93 0.67 Red cell distribution width; chr19:10583568 chrX:65469087~65470380:+ PAAD trans rs7554547 0.526 rs4846078 ENSG00000261819.1 RP11-680G24.4 10.99 4.95e-21 1.29e-13 0.84 0.67 Nonsyndromic cleft lip with cleft palate; chr1:11907299 chr16:14988259~14990160:- PAAD trans rs55665837 0.559 rs11023210 ENSG00000236360.2 RP11-334A14.2 -10.98 5.11e-21 1.33e-13 -0.87 -0.67 Vitamin D levels; chr11:14401216 chr1:52993201~52993702:- PAAD trans rs6477998 0.868 rs10513189 ENSG00000238072.1 RP11-305M3.2 10.98 5.15e-21 1.34e-13 0.9 0.67 Hematology traits; chr9:113227941 chr7:129410113~129410370:- PAAD trans rs6477998 0.9 rs7850357 ENSG00000238072.1 RP11-305M3.2 10.98 5.26e-21 1.37e-13 0.91 0.66 Hematology traits; chr9:113222319 chr7:129410113~129410370:- PAAD trans rs928391 0.744 rs6700964 ENSG00000227183.3 HDGFP1 -10.97 5.37e-21 1.4e-13 -0.84 -0.66 Platelet count; chr1:156790244 chrX:131646639~131646890:+ PAAD trans rs6477998 0.934 rs4979223 ENSG00000238072.1 RP11-305M3.2 10.97 5.41e-21 1.41e-13 0.91 0.66 Hematology traits; chr9:113219836 chr7:129410113~129410370:- PAAD trans rs916888 0.773 rs199457 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45585871~45586929:+ PAAD trans rs916888 0.687 rs199456 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45585871~45586929:+ PAAD trans rs916888 0.773 rs199451 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45585871~45586929:+ PAAD trans rs916888 0.773 rs199448 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45585871~45586929:+ PAAD trans rs916888 0.773 rs199445 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45585871~45586929:+ PAAD trans rs916888 0.773 rs199443 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45585871~45586929:+ PAAD trans rs916888 0.773 rs199535 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45585871~45586929:+ PAAD trans rs916888 0.779 rs199528 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs199525 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs70600 ENSG00000264070.1 DND1P1 10.97 5.42e-21 1.41e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45585871~45586929:+ PAAD trans rs928391 0.572 rs11264548 ENSG00000227183.3 HDGFP1 -10.96 5.65e-21 1.46e-13 -0.83 -0.66 Platelet count; chr1:156779339 chrX:131646639~131646890:+ PAAD trans rs928391 0.744 rs2274503 ENSG00000227183.3 HDGFP1 -10.96 5.65e-21 1.46e-13 -0.83 -0.66 Platelet count; chr1:156782256 chrX:131646639~131646890:+ PAAD trans rs61990749 0.597 rs11623088 ENSG00000235400.1 RP4-641G12.4 -10.96 5.69e-21 1.47e-13 -1.11 -0.66 Fibroblast growth factor basic levels; chr14:77671392 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs11624101 ENSG00000235400.1 RP4-641G12.4 -10.96 5.69e-21 1.47e-13 -1.11 -0.66 Fibroblast growth factor basic levels; chr14:77671716 chr1:78749073~78750659:+ PAAD trans rs2950393 0.804 rs898609 ENSG00000121089.4 NACA3P 10.96 5.72e-21 1.47e-13 0.88 0.66 Platelet distribution width; chr12:56713026 chr4:164943290~164943937:+ PAAD trans rs2950393 0.804 rs4902 ENSG00000121089.4 NACA3P 10.96 5.72e-21 1.47e-13 0.88 0.66 Platelet distribution width; chr12:56714419 chr4:164943290~164943937:+ PAAD trans rs2950393 0.804 rs2035081 ENSG00000121089.4 NACA3P 10.96 5.72e-21 1.47e-13 0.88 0.66 Platelet distribution width; chr12:56732095 chr4:164943290~164943937:+ PAAD trans rs2950393 0.804 rs10783796 ENSG00000121089.4 NACA3P 10.96 5.72e-21 1.47e-13 0.88 0.66 Platelet distribution width; chr12:56733387 chr4:164943290~164943937:+ PAAD trans rs12291225 0.535 rs11023203 ENSG00000236360.2 RP11-334A14.2 10.96 5.76e-21 1.48e-13 0.88 0.66 Sense of smell; chr11:14388269 chr1:52993201~52993702:- PAAD trans rs55665837 0.583 rs78843135 ENSG00000236360.2 RP11-334A14.2 10.96 5.76e-21 1.48e-13 0.88 0.66 Vitamin D levels; chr11:14389708 chr1:52993201~52993702:- PAAD trans rs12291225 0.535 rs12806025 ENSG00000236360.2 RP11-334A14.2 10.96 5.76e-21 1.48e-13 0.88 0.66 Sense of smell; chr11:14392271 chr1:52993201~52993702:- PAAD trans rs55665837 0.524 rs2882128 ENSG00000236360.2 RP11-334A14.2 10.96 5.76e-21 1.48e-13 0.88 0.66 Vitamin D levels; chr11:14393088 chr1:52993201~52993702:- PAAD trans rs5022636 0.891 rs4971027 ENSG00000180764.13 PIPSL 10.96 5.86e-21 1.5e-13 0.83 0.66 Gut microbiota (functional units); chr1:151277945 chr10:93958191~93961540:- PAAD trans rs5022636 0.79 rs10399679 ENSG00000180764.13 PIPSL 10.96 5.86e-21 1.5e-13 0.83 0.66 Gut microbiota (functional units); chr1:151278361 chr10:93958191~93961540:- PAAD trans rs916888 0.779 rs199526 ENSG00000214425.5 LRRC37A4P 10.96 5.87e-21 1.51e-13 0.84 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:45506741~45550335:- PAAD trans rs7554547 0.967 rs4845888 ENSG00000261819.1 RP11-680G24.4 10.95 6.14e-21 1.57e-13 0.84 0.66 Nonsyndromic cleft lip with cleft palate; chr1:11910946 chr16:14988259~14990160:- PAAD trans rs7554547 1 rs7554547 ENSG00000261819.1 RP11-680G24.4 10.95 6.14e-21 1.57e-13 0.84 0.66 Nonsyndromic cleft lip with cleft palate; chr1:11913831 chr16:14988259~14990160:- PAAD trans rs7554547 1 rs2336378 ENSG00000261819.1 RP11-680G24.4 10.95 6.14e-21 1.57e-13 0.84 0.66 Nonsyndromic cleft lip with cleft palate; chr1:11915626 chr16:14988259~14990160:- PAAD trans rs7554547 1 rs926271 ENSG00000261819.1 RP11-680G24.4 10.94 6.43e-21 1.65e-13 0.84 0.66 Nonsyndromic cleft lip with cleft palate; chr1:11909860 chr16:14988259~14990160:- PAAD trans rs9611565 0.765 rs9607800 ENSG00000268568.1 AC007228.9 -10.9 8.29e-21 2.11e-13 -1.08 -0.66 Vitiligo; chr22:41388558 chr19:56672574~56673901:- PAAD trans rs9611565 0.802 rs73176692 ENSG00000268568.1 AC007228.9 -10.9 8.29e-21 2.11e-13 -1.08 -0.66 Vitiligo; chr22:41389731 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs28604950 ENSG00000268568.1 AC007228.9 -10.9 8.29e-21 2.11e-13 -1.08 -0.66 Vitiligo; chr22:41389808 chr19:56672574~56673901:- PAAD trans rs9611565 0.802 rs73176694 ENSG00000268568.1 AC007228.9 -10.9 8.29e-21 2.11e-13 -1.08 -0.66 Vitiligo; chr22:41390784 chr19:56672574~56673901:- PAAD trans rs9467773 0.62 rs2451738 ENSG00000242375.1 RP11-498P14.3 -10.89 8.69e-21 2.21e-13 -0.82 -0.66 Intelligence (multi-trait analysis); chr6:26618231 chr9:97195351~97197687:- PAAD trans rs9611565 0.802 rs9611571 ENSG00000268568.1 AC007228.9 -10.89 8.95e-21 2.27e-13 -1.08 -0.66 Vitiligo; chr22:41388863 chr19:56672574~56673901:- PAAD trans rs1816752 0.905 rs3818938 ENSG00000237917.1 PARP4P1 10.87 1.02e-20 2.58e-13 0.86 0.66 Obesity-related traits; chr13:24454945 chrY:26594851~26634652:- PAAD trans rs61990749 0.597 rs1048147 ENSG00000235400.1 RP4-641G12.4 -10.87 1.03e-20 2.59e-13 -1.11 -0.66 Fibroblast growth factor basic levels; chr14:77673645 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs13379065 ENSG00000235400.1 RP4-641G12.4 -10.87 1.03e-20 2.59e-13 -1.11 -0.66 Fibroblast growth factor basic levels; chr14:77674952 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs17106157 ENSG00000235400.1 RP4-641G12.4 -10.87 1.03e-20 2.59e-13 -1.11 -0.66 Fibroblast growth factor basic levels; chr14:77680535 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs2267758 ENSG00000235400.1 RP4-641G12.4 -10.87 1.03e-20 2.59e-13 -1.11 -0.66 Fibroblast growth factor basic levels; chr14:77681086 chr1:78749073~78750659:+ PAAD trans rs61990749 0.597 rs2267759 ENSG00000235400.1 RP4-641G12.4 -10.87 1.03e-20 2.59e-13 -1.11 -0.66 Fibroblast growth factor basic levels; chr14:77681272 chr1:78749073~78750659:+ PAAD trans rs916888 0.773 rs199447 ENSG00000264070.1 DND1P1 10.87 1.03e-20 2.59e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45585871~45586929:+ PAAD trans rs727563 0.648 rs6002406 ENSG00000268568.1 AC007228.9 -10.86 1.05e-20 2.65e-13 -1.12 -0.66 Crohn's disease;Inflammatory bowel disease; chr22:41569233 chr19:56672574~56673901:- PAAD trans rs9611565 0.729 rs505533 ENSG00000268568.1 AC007228.9 10.86 1.07e-20 2.7e-13 0.96 0.66 Vitiligo; chr22:41468212 chr19:56672574~56673901:- PAAD trans rs2885056 0.83 rs7259124 ENSG00000227534.1 RP3-323B6.1 10.82 1.37e-20 3.43e-13 0.98 0.66 Red cell distribution width; chr19:10560988 chrX:65469087~65470380:+ PAAD trans rs2950393 0.804 rs2290894 ENSG00000121089.4 NACA3P 10.81 1.49e-20 3.7e-13 0.87 0.66 Platelet distribution width; chr12:56714911 chr4:164943290~164943937:+ PAAD trans rs2950393 0.777 rs2926747 ENSG00000121089.4 NACA3P 10.81 1.49e-20 3.7e-13 0.87 0.66 Platelet distribution width; chr12:56716147 chr4:164943290~164943937:+ PAAD trans rs12291225 0.535 rs10832248 ENSG00000236360.2 RP11-334A14.2 10.81 1.5e-20 3.72e-13 0.87 0.66 Sense of smell; chr11:14391541 chr1:52993201~52993702:- PAAD trans rs916888 0.773 rs1378358 ENSG00000264070.1 DND1P1 10.8 1.54e-20 3.82e-13 1 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs199506 ENSG00000264070.1 DND1P1 -10.79 1.7e-20 4.21e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45585871~45586929:+ PAAD trans rs916888 0.773 rs169201 ENSG00000264070.1 DND1P1 10.78 1.77e-20 4.37e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45585871~45586929:+ PAAD trans rs916888 0.773 rs199439 ENSG00000264070.1 DND1P1 10.78 1.77e-20 4.37e-13 1.01 0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45585871~45586929:+ PAAD trans rs2950393 0.804 rs1131514 ENSG00000121089.4 NACA3P -10.77 1.88e-20 4.63e-13 -0.88 -0.66 Platelet distribution width; chr12:56739356 chr4:164943290~164943937:+ PAAD trans rs9611565 0.802 rs4822028 ENSG00000268568.1 AC007228.9 -10.73 2.34e-20 5.76e-13 -1.06 -0.66 Vitiligo; chr22:41393404 chr19:56672574~56673901:- PAAD trans rs9611565 0.729 rs169362 ENSG00000268568.1 AC007228.9 10.72 2.56e-20 6.27e-13 0.96 0.66 Vitiligo; chr22:41431585 chr19:56672574~56673901:- PAAD trans rs2950393 0.777 rs12828563 ENSG00000121089.4 NACA3P 10.72 2.56e-20 6.28e-13 0.88 0.66 Platelet distribution width; chr12:56709378 chr4:164943290~164943937:+ PAAD trans rs9467773 0.523 rs2498399 ENSG00000242375.1 RP11-498P14.3 10.72 2.6e-20 6.37e-13 0.81 0.66 Intelligence (multi-trait analysis); chr6:26795343 chr9:97195351~97197687:- PAAD trans rs941207 0.514 rs6581105 ENSG00000121089.4 NACA3P -10.71 2.78e-20 6.79e-13 -0.99 -0.66 Platelet count; chr12:56792184 chr4:164943290~164943937:+ PAAD trans rs916888 0.697 rs199516 ENSG00000264070.1 DND1P1 -10.7 2.81e-20 6.84e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs199514 ENSG00000264070.1 DND1P1 -10.7 2.81e-20 6.84e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs199513 ENSG00000264070.1 DND1P1 -10.7 2.81e-20 6.84e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs199512 ENSG00000264070.1 DND1P1 -10.7 2.81e-20 6.84e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs199509 ENSG00000264070.1 DND1P1 -10.7 2.81e-20 6.84e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs199507 ENSG00000264070.1 DND1P1 -10.7 2.81e-20 6.84e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs199505 ENSG00000264070.1 DND1P1 -10.7 2.81e-20 6.84e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45585871~45586929:+ PAAD trans rs916888 0.821 rs70602 ENSG00000264070.1 DND1P1 -10.7 2.81e-20 6.84e-13 -0.99 -0.66 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45585871~45586929:+ PAAD trans rs2885056 0.783 rs12459941 ENSG00000227534.1 RP3-323B6.1 -10.7 2.86e-20 6.97e-13 -0.95 -0.66 Red cell distribution width; chr19:10555436 chrX:65469087~65470380:+ PAAD trans rs2885056 0.83 rs2018810 ENSG00000227534.1 RP3-323B6.1 10.7 2.91e-20 7.08e-13 0.96 0.66 Red cell distribution width; chr19:10558496 chrX:65469087~65470380:+ PAAD trans rs9611565 0.729 rs12165508 ENSG00000268568.1 AC007228.9 10.68 3.16e-20 7.67e-13 0.96 0.65 Vitiligo; chr22:41423956 chr19:56672574~56673901:- PAAD trans rs7554547 1 rs926270 ENSG00000261819.1 RP11-680G24.4 10.68 3.17e-20 7.69e-13 0.83 0.65 Nonsyndromic cleft lip with cleft palate; chr1:11909729 chr16:14988259~14990160:- PAAD trans rs916888 0.738 rs199515 ENSG00000264070.1 DND1P1 -10.68 3.31e-20 8.02e-13 -0.96 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45585871~45586929:+ PAAD trans rs2950393 0.804 rs11171951 ENSG00000121089.4 NACA3P 10.65 3.79e-20 9.16e-13 0.88 0.65 Platelet distribution width; chr12:56718853 chr4:164943290~164943937:+ PAAD trans rs941207 0.542 rs1903370 ENSG00000121089.4 NACA3P -10.65 3.91e-20 9.4e-13 -0.92 -0.65 Platelet count; chr12:56812900 chr4:164943290~164943937:+ PAAD trans rs727563 0.569 rs73178647 ENSG00000268568.1 AC007228.9 -10.65 3.99e-20 9.52e-13 -1.11 -0.65 Crohn's disease;Inflammatory bowel disease; chr22:41568164 chr19:56672574~56673901:- PAAD trans rs2885056 0.599 rs73018654 ENSG00000227534.1 RP3-323B6.1 10.64 4.23e-20 1.01e-12 0.93 0.65 Red cell distribution width; chr19:10578842 chrX:65469087~65470380:+ PAAD trans rs9467773 0.572 rs13213953 ENSG00000242375.1 RP11-498P14.3 10.63 4.46e-20 1.06e-12 0.85 0.65 Intelligence (multi-trait analysis); chr6:26594306 chr9:97195351~97197687:- PAAD trans rs9467773 0.572 rs62394558 ENSG00000242375.1 RP11-498P14.3 10.63 4.46e-20 1.06e-12 0.85 0.65 Intelligence (multi-trait analysis); chr6:26604422 chr9:97195351~97197687:- PAAD trans rs9467773 0.534 rs34453863 ENSG00000242375.1 RP11-498P14.3 10.63 4.46e-20 1.06e-12 0.85 0.65 Intelligence (multi-trait analysis); chr6:26627777 chr9:97195351~97197687:- PAAD trans rs916888 0.821 rs199504 ENSG00000264070.1 DND1P1 -10.63 4.46e-20 1.06e-12 -0.98 -0.65 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45585871~45586929:+ PAAD trans rs7121616 0.515 rs76088419 ENSG00000234176.1 HSPA8P1 10.62 4.72e-20 1.12e-12 1.1 0.65 Breast cancer; chr11:123066813 chrX:121203182~121205014:- PAAD trans rs2885056 0.739 rs4363951 ENSG00000227534.1 RP3-323B6.1 10.61 4.86e-20 1.15e-12 0.93 0.65 Red cell distribution width; chr19:10538797 chrX:65469087~65470380:+ PAAD trans rs2950393 0.794 rs1563897 ENSG00000121089.4 NACA3P 10.61 4.92e-20 1.16e-12 0.89 0.65 Platelet distribution width; chr12:56699316 chr4:164943290~164943937:+ PAAD trans rs5022636 0.927 rs10888409 ENSG00000180764.13 PIPSL 10.61 5.02e-20 1.18e-12 0.8 0.65 Gut microbiota (functional units); chr1:151299306 chr10:93958191~93961540:- PAAD trans rs2950393 0.804 rs2926752 ENSG00000121089.4 NACA3P 10.61 5.11e-20 1.2e-12 0.87 0.65 Platelet distribution width; chr12:56710144 chr4:164943290~164943937:+ PAAD trans rs2950393 0.777 rs2958148 ENSG00000121089.4 NACA3P 10.61 5.11e-20 1.2e-12 0.87 0.65 Platelet distribution width; chr12:56710153 chr4:164943290~164943937:+ PAAD trans rs9611565 0.592 rs4822038 ENSG00000268568.1 AC007228.9 -10.6 5.41e-20 1.27e-12 -1.1 -0.65 Vitiligo; chr22:41562491 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs9611591 ENSG00000268568.1 AC007228.9 10.6 5.45e-20 1.28e-12 0.96 0.65 Vitiligo; chr22:41434208 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs12484467 ENSG00000268568.1 AC007228.9 -10.59 5.53e-20 1.3e-12 -1.09 -0.65 Vitiligo; chr22:41561606 chr19:56672574~56673901:- PAAD trans rs9611565 0.625 rs2076199 ENSG00000268568.1 AC007228.9 -10.59 5.73e-20 1.34e-12 -0.98 -0.65 Vitiligo; chr22:41507739 chr19:56672574~56673901:- PAAD trans rs9611565 0.659 rs9611610 ENSG00000268568.1 AC007228.9 -10.56 6.71e-20 1.57e-12 -1.07 -0.65 Vitiligo; chr22:41553255 chr19:56672574~56673901:- PAAD trans rs1816752 0.679 rs7999480 ENSG00000237917.1 PARP4P1 -10.56 6.88e-20 1.6e-12 -0.86 -0.65 Obesity-related traits; chr13:24397865 chrY:26594851~26634652:- PAAD trans rs13177918 0.734 rs6579791 ENSG00000213058.3 RP4-765C7.2 10.54 7.89e-20 1.83e-12 0.95 0.65 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr1:178411616~178411972:+ PAAD trans rs2950393 0.804 rs1026565 ENSG00000121089.4 NACA3P 10.53 8.26e-20 1.91e-12 0.84 0.65 Platelet distribution width; chr12:56744044 chr4:164943290~164943937:+ PAAD trans rs2950393 0.857 rs9989034 ENSG00000121089.4 NACA3P 10.53 8.29e-20 1.92e-12 0.86 0.65 Platelet distribution width; chr12:56674508 chr4:164943290~164943937:+ PAAD trans rs2950393 0.929 rs2290893 ENSG00000121089.4 NACA3P 10.53 8.29e-20 1.92e-12 0.86 0.65 Platelet distribution width; chr12:56684836 chr4:164943290~164943937:+ PAAD trans rs9611565 0.625 rs12483991 ENSG00000268568.1 AC007228.9 -10.53 8.32e-20 1.92e-12 -0.96 -0.65 Vitiligo; chr22:41539281 chr19:56672574~56673901:- PAAD trans rs7554547 0.818 rs4993566 ENSG00000261819.1 RP11-680G24.4 10.52 8.52e-20 1.97e-12 0.8 0.65 Nonsyndromic cleft lip with cleft palate; chr1:11909937 chr16:14988259~14990160:- PAAD trans rs5022636 0.927 rs4522000 ENSG00000180764.13 PIPSL 10.52 8.95e-20 2e-12 0.8 0.65 Gut microbiota (functional units); chr1:151283612 chr10:93958191~93961540:- PAAD trans rs9611565 0.765 rs727563 ENSG00000268568.1 AC007228.9 10.51 9.36e-20 2.08e-12 0.99 0.65 Vitiligo; chr22:41471373 chr19:56672574~56673901:- PAAD trans rs5022636 0.929 rs7552906 ENSG00000180764.13 PIPSL 10.51 9.36e-20 2.08e-12 0.81 0.65 Gut microbiota (functional units); chr1:151341298 chr10:93958191~93961540:- PAAD trans rs2885056 0.699 rs34275421 ENSG00000227534.1 RP3-323B6.1 10.5 9.87e-20 2.19e-12 0.92 0.65 Red cell distribution width; chr19:10534136 chrX:65469087~65470380:+ PAAD trans rs13177918 0.734 rs6579790 ENSG00000213058.3 RP4-765C7.2 10.49 1.03e-19 2.27e-12 0.95 0.65 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr1:178411616~178411972:+ PAAD trans rs9611565 0.729 rs137831 ENSG00000268568.1 AC007228.9 -10.49 1.05e-19 2.33e-12 -0.96 -0.65 Vitiligo; chr22:41507809 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs132767 ENSG00000268568.1 AC007228.9 -10.49 1.06e-19 2.35e-12 -1.1 -0.65 Vitiligo; chr22:41613516 chr19:56672574~56673901:- PAAD trans rs7949030 0.754 rs36104523 ENSG00000186676.3 EEF1GP1 -10.48 1.12e-19 2.48e-12 -0.88 -0.65 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62628268 chr7:125033453~125035301:+ PAAD trans rs12709013 0.536 rs1646260 ENSG00000230849.2 GOT2P2 10.47 1.18e-19 2.6e-12 0.86 0.65 Blood metabolite ratios; chr16:58734951 chr1:173141100~173142350:- PAAD trans rs9611565 0.729 rs202654 ENSG00000268568.1 AC007228.9 10.47 1.19e-19 2.63e-12 0.94 0.65 Vitiligo; chr22:41445030 chr19:56672574~56673901:- PAAD trans rs2950393 0.895 rs2958123 ENSG00000121089.4 NACA3P 10.45 1.31e-19 2.89e-12 0.86 0.65 Platelet distribution width; chr12:56668441 chr4:164943290~164943937:+ PAAD trans rs5022636 0.927 rs4971030 ENSG00000180764.13 PIPSL -10.45 1.32e-19 2.9e-12 -0.79 -0.65 Gut microbiota (functional units); chr1:151308519 chr10:93958191~93961540:- PAAD trans rs9611565 0.729 rs203320 ENSG00000268568.1 AC007228.9 -10.45 1.32e-19 2.9e-12 -0.98 -0.65 Vitiligo; chr22:41517473 chr19:56672574~56673901:- PAAD trans rs5022636 0.821 rs4246525 ENSG00000180764.13 PIPSL 10.45 1.34e-19 2.94e-12 0.83 0.65 Gut microbiota (functional units); chr1:151285263 chr10:93958191~93961540:- PAAD trans rs5022636 0.74 rs11204795 ENSG00000180764.13 PIPSL 10.45 1.34e-19 2.95e-12 0.79 0.65 Gut microbiota (functional units); chr1:151275522 chr10:93958191~93961540:- PAAD trans rs9611565 0.802 rs132916 ENSG00000268568.1 AC007228.9 10.44 1.4e-19 3.06e-12 1 0.65 Vitiligo; chr22:41410764 chr19:56672574~56673901:- PAAD trans rs5022636 0.927 rs10788803 ENSG00000180764.13 PIPSL 10.43 1.51e-19 3.31e-12 0.8 0.65 Gut microbiota (functional units); chr1:151291306 chr10:93958191~93961540:- PAAD trans rs6477998 0.966 rs7851395 ENSG00000238072.1 RP11-305M3.2 10.43 1.55e-19 3.39e-12 0.88 0.65 Hematology traits; chr9:113240184 chr7:129410113~129410370:- PAAD trans rs2885056 0.891 rs3760648 ENSG00000227534.1 RP3-323B6.1 10.43 1.55e-19 3.39e-12 0.91 0.65 Red cell distribution width; chr19:10569427 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs892082 ENSG00000227534.1 RP3-323B6.1 10.43 1.55e-19 3.39e-12 0.91 0.65 Red cell distribution width; chr19:10569802 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs892081 ENSG00000227534.1 RP3-323B6.1 10.43 1.55e-19 3.39e-12 0.91 0.65 Red cell distribution width; chr19:10570008 chrX:65469087~65470380:+ PAAD trans rs727563 0.608 rs2076200 ENSG00000268568.1 AC007228.9 -10.41 1.72e-19 3.74e-12 -1.11 -0.65 Crohn's disease;Inflammatory bowel disease; chr22:41589952 chr19:56672574~56673901:- PAAD trans rs727563 0.552 rs4822045 ENSG00000268568.1 AC007228.9 -10.41 1.72e-19 3.74e-12 -1.11 -0.65 Crohn's disease;Inflammatory bowel disease; chr22:41589954 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs9611619 ENSG00000268568.1 AC007228.9 -10.41 1.72e-19 3.74e-12 -1.11 -0.65 Vitiligo; chr22:41590710 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs4822046 ENSG00000268568.1 AC007228.9 -10.41 1.72e-19 3.74e-12 -1.11 -0.65 Vitiligo; chr22:41591539 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs4822048 ENSG00000268568.1 AC007228.9 -10.41 1.72e-19 3.74e-12 -1.11 -0.65 Vitiligo; chr22:41592221 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs4822049 ENSG00000268568.1 AC007228.9 -10.41 1.72e-19 3.74e-12 -1.11 -0.65 Vitiligo; chr22:41597492 chr19:56672574~56673901:- PAAD trans rs7121616 0.515 rs11218966 ENSG00000234176.1 HSPA8P1 10.41 1.74e-19 3.78e-12 1.1 0.65 Breast cancer; chr11:123086510 chrX:121203182~121205014:- PAAD trans rs2950393 0.804 rs2958130 ENSG00000121089.4 NACA3P 10.38 2e-19 4.33e-12 0.84 0.64 Platelet distribution width; chr12:56746722 chr4:164943290~164943937:+ PAAD trans rs7949030 1 rs7949030 ENSG00000186676.3 EEF1GP1 10.38 2.1e-19 4.53e-12 0.86 0.64 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62627409 chr7:125033453~125035301:+ PAAD trans rs5022636 0.896 rs7531495 ENSG00000180764.13 PIPSL 10.37 2.23e-19 4.79e-12 0.79 0.64 Gut microbiota (functional units); chr1:151352996 chr10:93958191~93961540:- PAAD trans rs4822044 0.56 rs7284839 ENSG00000268568.1 AC007228.9 10.32 2.93e-19 6.27e-12 1.1 0.64 Cannabis dependence symptom count; chr22:41614898 chr19:56672574~56673901:- PAAD trans rs55665837 0.524 rs61884009 ENSG00000236360.2 RP11-334A14.2 10.32 2.99e-19 6.4e-12 0.87 0.64 Vitamin D levels; chr11:14404916 chr1:52993201~52993702:- PAAD trans rs9467773 0.549 rs9461273 ENSG00000242375.1 RP11-498P14.3 -10.31 3.1e-19 6.64e-12 -0.8 -0.64 Intelligence (multi-trait analysis); chr6:26584298 chr9:97195351~97197687:- PAAD trans rs9611565 0.559 rs132771 ENSG00000268568.1 AC007228.9 10.31 3.12e-19 6.66e-12 1.1 0.64 Vitiligo; chr22:41629346 chr19:56672574~56673901:- PAAD trans rs727563 0.52 rs132773 ENSG00000268568.1 AC007228.9 10.31 3.12e-19 6.66e-12 1.1 0.64 Crohn's disease;Inflammatory bowel disease; chr22:41635764 chr19:56672574~56673901:- PAAD trans rs2950393 0.804 rs7980317 ENSG00000121089.4 NACA3P 10.31 3.19e-19 6.8e-12 0.82 0.64 Platelet distribution width; chr12:56764399 chr4:164943290~164943937:+ PAAD trans rs8010715 0.816 rs6573565 ENSG00000248988.1 RP11-815N9.2 -10.31 3.22e-19 6.87e-12 -0.88 -0.64 IgG glycosylation; chr14:24125524 chr4:159007119~159007835:+ PAAD trans rs916888 0.773 rs9896243 ENSG00000264070.1 DND1P1 10.31 3.24e-19 6.9e-12 0.98 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45585871~45586929:+ PAAD trans rs6477998 0.676 rs10981693 ENSG00000238072.1 RP11-305M3.2 -10.3 3.32e-19 7.06e-12 -0.92 -0.64 Hematology traits; chr9:113223137 chr7:129410113~129410370:- PAAD trans rs5022636 0.964 rs7545392 ENSG00000180764.13 PIPSL 10.29 3.5e-19 7.45e-12 0.79 0.64 Gut microbiota (functional units); chr1:151337779 chr10:93958191~93961540:- PAAD trans rs5022636 0.964 rs1056847 ENSG00000180764.13 PIPSL 10.29 3.54e-19 7.53e-12 0.78 0.64 Gut microbiota (functional units); chr1:151315696 chr10:93958191~93961540:- PAAD trans rs9611565 0.592 rs4822044 ENSG00000268568.1 AC007228.9 -10.29 3.54e-19 7.53e-12 -1.11 -0.64 Vitiligo; chr22:41583664 chr19:56672574~56673901:- PAAD trans rs8010715 0.771 rs2277481 ENSG00000248988.1 RP11-815N9.2 10.29 3.58e-19 7.59e-12 0.87 0.64 IgG glycosylation; chr14:24118336 chr4:159007119~159007835:+ PAAD trans rs9611565 0.559 rs1006407 ENSG00000268568.1 AC007228.9 -10.28 3.78e-19 8.02e-12 -1.1 -0.64 Vitiligo; chr22:41576028 chr19:56672574~56673901:- PAAD trans rs5022636 0.927 rs10888410 ENSG00000180764.13 PIPSL 10.27 3.95e-19 8.34e-12 0.78 0.64 Gut microbiota (functional units); chr1:151299975 chr10:93958191~93961540:- PAAD trans rs2950393 0.777 rs7966391 ENSG00000121089.4 NACA3P 10.27 4.05e-19 8.54e-12 0.83 0.64 Platelet distribution width; chr12:56745272 chr4:164943290~164943937:+ PAAD trans rs9611565 0.512 rs1534932 ENSG00000268568.1 AC007228.9 10.27 4.13e-19 8.7e-12 1.09 0.64 Vitiligo; chr22:41754142 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs739136 ENSG00000268568.1 AC007228.9 -10.27 4.13e-19 8.7e-12 -1.09 -0.64 Vitiligo; chr22:41704271 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs9611613 ENSG00000268568.1 AC007228.9 -10.26 4.28e-19 8.98e-12 -1.03 -0.64 Vitiligo; chr22:41565827 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs12483860 ENSG00000268568.1 AC007228.9 -10.26 4.28e-19 8.98e-12 -1.03 -0.64 Vitiligo; chr22:41565912 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs12484254 ENSG00000268568.1 AC007228.9 -10.26 4.28e-19 8.98e-12 -1.03 -0.64 Vitiligo; chr22:41565999 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs4822040 ENSG00000268568.1 AC007228.9 -10.26 4.28e-19 8.98e-12 -1.03 -0.64 Vitiligo; chr22:41567549 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs7290990 ENSG00000268568.1 AC007228.9 -10.26 4.28e-19 8.98e-12 -1.03 -0.64 Vitiligo; chr22:41568353 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs7290991 ENSG00000268568.1 AC007228.9 -10.26 4.28e-19 8.98e-12 -1.03 -0.64 Vitiligo; chr22:41568357 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs5996037 ENSG00000268568.1 AC007228.9 -10.26 4.28e-19 8.98e-12 -1.03 -0.64 Vitiligo; chr22:41569288 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs5996038 ENSG00000268568.1 AC007228.9 -10.26 4.28e-19 8.98e-12 -1.03 -0.64 Vitiligo; chr22:41569296 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs139571 ENSG00000268568.1 AC007228.9 -10.26 4.34e-19 9.1e-12 -1.11 -0.64 Vitiligo; chr22:41818234 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs139573 ENSG00000268568.1 AC007228.9 -10.26 4.34e-19 9.1e-12 -1.11 -0.64 Vitiligo; chr22:41818781 chr19:56672574~56673901:- PAAD trans rs2885056 0.713 rs58713728 ENSG00000227534.1 RP3-323B6.1 10.26 4.34e-19 9.1e-12 0.89 0.64 Red cell distribution width; chr19:10569056 chrX:65469087~65470380:+ PAAD trans rs2885056 0.713 rs58573889 ENSG00000227534.1 RP3-323B6.1 10.26 4.34e-19 9.1e-12 0.89 0.64 Red cell distribution width; chr19:10569057 chrX:65469087~65470380:+ PAAD trans rs2885056 0.891 rs4804509 ENSG00000227534.1 RP3-323B6.1 10.26 4.34e-19 9.1e-12 0.89 0.64 Red cell distribution width; chr19:10570965 chrX:65469087~65470380:+ PAAD trans rs9611565 0.592 rs8779 ENSG00000268568.1 AC007228.9 10.25 4.6e-19 9.58e-12 1.07 0.64 Vitiligo; chr22:41674272 chr19:56672574~56673901:- PAAD trans rs727563 0.594 rs132807 ENSG00000268568.1 AC007228.9 10.25 4.6e-19 9.58e-12 1.07 0.64 Crohn's disease;Inflammatory bowel disease; chr22:41675580 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs1811113 ENSG00000268568.1 AC007228.9 10.25 4.6e-19 9.58e-12 1.07 0.64 Vitiligo; chr22:41677130 chr19:56672574~56673901:- PAAD trans rs727563 0.594 rs5758408 ENSG00000268568.1 AC007228.9 10.25 4.6e-19 9.58e-12 1.07 0.64 Crohn's disease;Inflammatory bowel disease; chr22:41681733 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs5758412 ENSG00000268568.1 AC007228.9 10.25 4.6e-19 9.58e-12 1.07 0.64 Vitiligo; chr22:41684799 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs13056262 ENSG00000268568.1 AC007228.9 10.25 4.6e-19 9.58e-12 1.07 0.64 Vitiligo; chr22:41685917 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs9611612 ENSG00000268568.1 AC007228.9 -10.24 4.83e-19 1e-11 -1.02 -0.64 Vitiligo; chr22:41565185 chr19:56672574~56673901:- PAAD trans rs2950393 0.804 rs2958132 ENSG00000121089.4 NACA3P 10.23 5.03e-19 1.03e-11 0.82 0.64 Platelet distribution width; chr12:56750749 chr4:164943290~164943937:+ PAAD trans rs2950393 0.929 rs7973157 ENSG00000121089.4 NACA3P -10.23 5.21e-19 1.07e-11 -0.86 -0.64 Platelet distribution width; chr12:56655409 chr4:164943290~164943937:+ PAAD trans rs9611565 0.559 rs132761 ENSG00000268568.1 AC007228.9 10.22 5.37e-19 1.09e-11 1.09 0.64 Vitiligo; chr22:41608367 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs132765 ENSG00000268568.1 AC007228.9 10.22 5.37e-19 1.09e-11 1.09 0.64 Vitiligo; chr22:41612064 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs132768 ENSG00000268568.1 AC007228.9 10.22 5.37e-19 1.09e-11 1.09 0.64 Vitiligo; chr22:41617519 chr19:56672574~56673901:- PAAD trans rs8010715 0.816 rs11574503 ENSG00000248988.1 RP11-815N9.2 -10.22 5.4e-19 1.09e-11 -0.86 -0.64 IgG glycosylation; chr14:24132109 chr4:159007119~159007835:+ PAAD trans rs8010715 0.816 rs762093 ENSG00000248988.1 RP11-815N9.2 10.22 5.4e-19 1.09e-11 0.86 0.64 IgG glycosylation; chr14:24122709 chr4:159007119~159007835:+ PAAD trans rs8010715 0.816 rs1134340 ENSG00000248988.1 RP11-815N9.2 10.22 5.4e-19 1.09e-11 0.86 0.64 IgG glycosylation; chr14:24125004 chr4:159007119~159007835:+ PAAD trans rs8010715 0.785 rs2877611 ENSG00000248988.1 RP11-815N9.2 10.22 5.4e-19 1.09e-11 0.86 0.64 IgG glycosylation; chr14:24126221 chr4:159007119~159007835:+ PAAD trans rs8010715 0.816 rs7153156 ENSG00000248988.1 RP11-815N9.2 10.22 5.4e-19 1.09e-11 0.86 0.64 IgG glycosylation; chr14:24129637 chr4:159007119~159007835:+ PAAD trans rs8010715 0.816 rs6573572 ENSG00000248988.1 RP11-815N9.2 10.22 5.4e-19 1.09e-11 0.86 0.64 IgG glycosylation; chr14:24130021 chr4:159007119~159007835:+ PAAD trans rs8010715 0.816 rs6573573 ENSG00000248988.1 RP11-815N9.2 10.22 5.4e-19 1.09e-11 0.86 0.64 IgG glycosylation; chr14:24130048 chr4:159007119~159007835:+ PAAD trans rs8010715 0.816 rs8015168 ENSG00000248988.1 RP11-815N9.2 10.22 5.4e-19 1.09e-11 0.86 0.64 IgG glycosylation; chr14:24130663 chr4:159007119~159007835:+ PAAD trans rs727563 0.638 rs5996058 ENSG00000268568.1 AC007228.9 10.22 5.51e-19 1.12e-11 1.09 0.64 Crohn's disease;Inflammatory bowel disease; chr22:41745448 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs5758450 ENSG00000268568.1 AC007228.9 10.22 5.51e-19 1.12e-11 1.09 0.64 Vitiligo; chr22:41745636 chr19:56672574~56673901:- PAAD trans rs7949030 1 rs10897289 ENSG00000186676.3 EEF1GP1 10.21 5.64e-19 1.14e-11 0.88 0.64 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62632544 chr7:125033453~125035301:+ PAAD trans rs7949030 1 rs2956993 ENSG00000186676.3 EEF1GP1 -10.21 5.66e-19 1.14e-11 -0.88 -0.64 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62638690 chr7:125033453~125035301:+ PAAD trans rs2950393 0.929 rs7980835 ENSG00000121089.4 NACA3P 10.21 5.85e-19 1.18e-11 0.84 0.64 Platelet distribution width; chr12:56676847 chr4:164943290~164943937:+ PAAD trans rs2950393 0.929 rs10747769 ENSG00000121089.4 NACA3P 10.21 5.85e-19 1.18e-11 0.84 0.64 Platelet distribution width; chr12:56677056 chr4:164943290~164943937:+ PAAD trans rs2950393 0.804 rs7967600 ENSG00000121089.4 NACA3P 10.2 6.11e-19 1.23e-11 0.82 0.64 Platelet distribution width; chr12:56768208 chr4:164943290~164943937:+ PAAD trans rs727563 0.593 rs132770 ENSG00000268568.1 AC007228.9 10.2 6.23e-19 1.25e-11 1.1 0.64 Crohn's disease;Inflammatory bowel disease; chr22:41621260 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs5758397 ENSG00000268568.1 AC007228.9 10.2 6.23e-19 1.25e-11 1.1 0.64 Vitiligo; chr22:41623247 chr19:56672574~56673901:- PAAD trans rs12709013 0.636 rs1657161 ENSG00000230849.2 GOT2P2 10.19 6.41e-19 1.29e-11 0.82 0.64 Blood metabolite ratios; chr16:58743234 chr1:173141100~173142350:- PAAD trans rs6477998 0.627 rs10114381 ENSG00000238072.1 RP11-305M3.2 10.19 6.56e-19 1.31e-11 0.92 0.64 Hematology traits; chr9:113213692 chr7:129410113~129410370:- PAAD trans rs6477998 0.651 rs10114423 ENSG00000238072.1 RP11-305M3.2 10.19 6.56e-19 1.31e-11 0.92 0.64 Hematology traits; chr9:113213751 chr7:129410113~129410370:- PAAD trans rs6477998 0.676 rs10817460 ENSG00000238072.1 RP11-305M3.2 10.19 6.56e-19 1.31e-11 0.92 0.64 Hematology traits; chr9:113214118 chr7:129410113~129410370:- PAAD trans rs6477998 0.603 rs7859189 ENSG00000238072.1 RP11-305M3.2 10.19 6.56e-19 1.31e-11 0.92 0.64 Hematology traits; chr9:113217389 chr7:129410113~129410370:- PAAD trans rs6477998 0.676 rs6477997 ENSG00000238072.1 RP11-305M3.2 10.19 6.56e-19 1.31e-11 0.92 0.64 Hematology traits; chr9:113218833 chr7:129410113~129410370:- PAAD trans rs6477998 0.627 rs3810914 ENSG00000238072.1 RP11-305M3.2 10.19 6.56e-19 1.31e-11 0.92 0.64 Hematology traits; chr9:113219441 chr7:129410113~129410370:- PAAD trans rs6477998 0.676 rs4978536 ENSG00000238072.1 RP11-305M3.2 10.19 6.56e-19 1.31e-11 0.92 0.64 Hematology traits; chr9:113220123 chr7:129410113~129410370:- PAAD trans rs9611565 0.512 rs139566 ENSG00000268568.1 AC007228.9 -10.19 6.71e-19 1.34e-11 -1.11 -0.64 Vitiligo; chr22:41803273 chr19:56672574~56673901:- PAAD trans rs2950393 0.804 rs7295862 ENSG00000121089.4 NACA3P -10.19 6.74e-19 1.35e-11 -0.82 -0.64 Platelet distribution width; chr12:56775374 chr4:164943290~164943937:+ PAAD trans rs12709013 0.613 rs4238801 ENSG00000230849.2 GOT2P2 10.18 6.99e-19 1.39e-11 0.83 0.64 Blood metabolite ratios; chr16:58738275 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs4575523 ENSG00000230849.2 GOT2P2 10.18 6.99e-19 1.39e-11 0.83 0.64 Blood metabolite ratios; chr16:58738559 chr1:173141100~173142350:- PAAD trans rs9611565 0.512 rs4820444 ENSG00000268568.1 AC007228.9 10.18 7e-19 1.39e-11 1.11 0.64 Vitiligo; chr22:41806602 chr19:56672574~56673901:- PAAD trans rs7121616 0.545 rs7109336 ENSG00000234176.1 HSPA8P1 10.17 7.36e-19 1.46e-11 0.97 0.64 Breast cancer; chr11:123056530 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs7948948 ENSG00000234176.1 HSPA8P1 10.17 7.36e-19 1.46e-11 0.97 0.64 Breast cancer; chr11:123057467 chrX:121203182~121205014:- PAAD trans rs9611565 0.513 rs739135 ENSG00000268568.1 AC007228.9 10.17 7.38e-19 1.47e-11 1.08 0.64 Vitiligo; chr22:41694065 chr19:56672574~56673901:- PAAD trans rs727563 0.636 rs2187795 ENSG00000268568.1 AC007228.9 10.17 7.38e-19 1.47e-11 1.08 0.64 Crohn's disease;Inflammatory bowel disease; chr22:41696221 chr19:56672574~56673901:- PAAD trans rs4822044 0.68 rs8138780 ENSG00000268568.1 AC007228.9 10.17 7.38e-19 1.47e-11 1.08 0.64 Cannabis dependence symptom count; chr22:41701458 chr19:56672574~56673901:- PAAD trans rs941207 0.507 rs73337030 ENSG00000121089.4 NACA3P -10.17 7.59e-19 1.5e-11 -0.85 -0.64 Platelet count; chr12:56652410 chr4:164943290~164943937:+ PAAD trans rs9611565 0.84 rs3788584 ENSG00000268568.1 AC007228.9 -10.17 7.62e-19 1.51e-11 -0.99 -0.64 Vitiligo; chr22:41383069 chr19:56672574~56673901:- PAAD trans rs9611565 0.765 rs767593 ENSG00000268568.1 AC007228.9 -10.17 7.62e-19 1.51e-11 -0.99 -0.64 Vitiligo; chr22:41383967 chr19:56672574~56673901:- PAAD trans rs2950393 0.929 rs10876916 ENSG00000121089.4 NACA3P 10.16 7.66e-19 1.52e-11 0.85 0.64 Platelet distribution width; chr12:56692728 chr4:164943290~164943937:+ PAAD trans rs9611565 0.512 rs4820446 ENSG00000268568.1 AC007228.9 -10.15 8.23e-19 1.63e-11 -1.11 -0.64 Vitiligo; chr22:41819680 chr19:56672574~56673901:- PAAD trans rs6477998 0.676 rs4979224 ENSG00000238072.1 RP11-305M3.2 10.15 8.39e-19 1.66e-11 0.92 0.64 Hematology traits; chr9:113219998 chr7:129410113~129410370:- PAAD trans rs6477998 0.676 rs4979225 ENSG00000238072.1 RP11-305M3.2 10.15 8.39e-19 1.66e-11 0.92 0.64 Hematology traits; chr9:113225130 chr7:129410113~129410370:- PAAD trans rs9611565 0.512 rs4512 ENSG00000268568.1 AC007228.9 -10.15 8.61e-19 1.7e-11 -1.1 -0.64 Vitiligo; chr22:41810080 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs5758389 ENSG00000268568.1 AC007228.9 -10.15 8.63e-19 1.7e-11 -0.99 -0.64 Vitiligo; chr22:41545745 chr19:56672574~56673901:- PAAD trans rs941207 0.526 rs2255074 ENSG00000121089.4 NACA3P -10.14 9.07e-19 1.78e-11 -0.85 -0.64 Platelet count; chr12:56636242 chr4:164943290~164943937:+ PAAD trans rs916888 0.647 rs199524 ENSG00000214425.5 LRRC37A4P 10.14 9.07e-19 1.78e-11 0.79 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45506741~45550335:- PAAD trans rs916888 0.647 rs199523 ENSG00000214425.5 LRRC37A4P 10.14 9.07e-19 1.78e-11 0.79 0.64 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45506741~45550335:- PAAD trans rs7121616 0.576 rs1064585 ENSG00000234176.1 HSPA8P1 10.13 9.73e-19 1.91e-11 0.97 0.63 Breast cancer; chr11:123058699 chrX:121203182~121205014:- PAAD trans rs6477998 0.676 rs10817470 ENSG00000238072.1 RP11-305M3.2 10.12 9.98e-19 1.95e-11 0.92 0.63 Hematology traits; chr9:113252129 chr7:129410113~129410370:- PAAD trans rs13253073 0.55 rs6468697 ENSG00000260318.1 COX6CP1 10.11 1.05e-18 2.05e-11 0.97 0.63 Glucose homeostasis traits; chr8:99858154 chr16:11903923~11904137:- PAAD trans rs9611565 0.512 rs9611672 ENSG00000268568.1 AC007228.9 -10.11 1.06e-18 2.06e-11 -1.1 -0.63 Vitiligo; chr22:41813918 chr19:56672574~56673901:- PAAD trans rs12709013 0.585 rs7188608 ENSG00000230849.2 GOT2P2 10.1 1.13e-18 2.18e-11 0.81 0.63 Blood metabolite ratios; chr16:58736236 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1657176 ENSG00000230849.2 GOT2P2 10.1 1.13e-18 2.18e-11 0.81 0.63 Blood metabolite ratios; chr16:58736833 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1646282 ENSG00000230849.2 GOT2P2 10.1 1.13e-18 2.18e-11 0.81 0.63 Blood metabolite ratios; chr16:58741296 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs4784977 ENSG00000230849.2 GOT2P2 10.1 1.13e-18 2.18e-11 0.81 0.63 Blood metabolite ratios; chr16:58742120 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1646268 ENSG00000230849.2 GOT2P2 10.1 1.13e-18 2.18e-11 0.81 0.63 Blood metabolite ratios; chr16:58743292 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1646269 ENSG00000230849.2 GOT2P2 10.1 1.13e-18 2.18e-11 0.81 0.63 Blood metabolite ratios; chr16:58743412 chr1:173141100~173142350:- PAAD trans rs916888 0.821 rs415430 ENSG00000264070.1 DND1P1 -10.1 1.13e-18 2.19e-11 -0.97 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45585871~45586929:+ PAAD trans rs916888 0.779 rs430685 ENSG00000264070.1 DND1P1 -10.1 1.13e-18 2.19e-11 -0.97 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45585871~45586929:+ PAAD trans rs12291225 0.839 rs4757244 ENSG00000236360.2 RP11-334A14.2 -10.1 1.14e-18 2.21e-11 -0.84 -0.63 Sense of smell; chr11:14237109 chr1:52993201~52993702:- PAAD trans rs5022636 0.865 rs12069445 ENSG00000180764.13 PIPSL 10.1 1.15e-18 2.24e-11 0.78 0.63 Gut microbiota (functional units); chr1:151362964 chr10:93958191~93961540:- PAAD trans rs9611565 0.512 rs45500192 ENSG00000268568.1 AC007228.9 -10.09 1.2e-18 2.31e-11 -1.07 -0.63 Vitiligo; chr22:41781895 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs5758465 ENSG00000268568.1 AC007228.9 10.09 1.2e-18 2.31e-11 1.07 0.63 Vitiligo; chr22:41779310 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs5751160 ENSG00000268568.1 AC007228.9 10.09 1.2e-18 2.31e-11 1.07 0.63 Vitiligo; chr22:41779691 chr19:56672574~56673901:- PAAD trans rs2950393 0.804 rs898611 ENSG00000121089.4 NACA3P -10.09 1.21e-18 2.34e-11 -0.81 -0.63 Platelet distribution width; chr12:56769532 chr4:164943290~164943937:+ PAAD trans rs6477998 0.651 rs10121845 ENSG00000238072.1 RP11-305M3.2 10.09 1.21e-18 2.34e-11 0.92 0.63 Hematology traits; chr9:113227443 chr7:129410113~129410370:- PAAD trans rs2950393 0.929 rs2958155 ENSG00000121089.4 NACA3P 10.08 1.25e-18 2.42e-11 0.84 0.63 Platelet distribution width; chr12:56670761 chr4:164943290~164943937:+ PAAD trans rs9611565 0.765 rs132906 ENSG00000268568.1 AC007228.9 10.08 1.28e-18 2.48e-11 0.99 0.63 Vitiligo; chr22:41403763 chr19:56672574~56673901:- PAAD trans rs6477998 0.676 rs10981698 ENSG00000238072.1 RP11-305M3.2 10.07 1.39e-18 2.63e-11 0.92 0.63 Hematology traits; chr9:113233500 chr7:129410113~129410370:- PAAD trans rs6477998 0.676 rs10759631 ENSG00000238072.1 RP11-305M3.2 10.07 1.39e-18 2.63e-11 0.92 0.63 Hematology traits; chr9:113233764 chr7:129410113~129410370:- PAAD trans rs6477998 0.676 rs10081797 ENSG00000238072.1 RP11-305M3.2 10.07 1.39e-18 2.63e-11 0.92 0.63 Hematology traits; chr9:113237973 chr7:129410113~129410370:- PAAD trans rs6477998 0.676 rs10759632 ENSG00000238072.1 RP11-305M3.2 10.07 1.39e-18 2.63e-11 0.92 0.63 Hematology traits; chr9:113238703 chr7:129410113~129410370:- PAAD trans rs9611565 0.592 rs5751139 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41703977 chr19:56672574~56673901:- PAAD trans rs9611565 0.546 rs739129 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41722245 chr19:56672574~56673901:- PAAD trans rs9611565 0.546 rs739132 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41727095 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs5758436 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41728261 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs7291736 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41728870 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs5758439 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41735758 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs5751145 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41737548 chr19:56672574~56673901:- PAAD trans rs727563 0.635 rs5758444 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Crohn's disease;Inflammatory bowel disease; chr22:41737917 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs768414 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41739747 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs8141103 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41740926 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs5751147 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41743050 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs5751148 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41743074 chr19:56672574~56673901:- PAAD trans rs727563 0.635 rs5751149 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Crohn's disease;Inflammatory bowel disease; chr22:41743497 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs964899 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41746382 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs715498 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41752463 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs2050031 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41756262 chr19:56672574~56673901:- PAAD trans rs5751150 1 rs5751150 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Cannabis dependence symptom count; chr22:41757288 chr19:56672574~56673901:- PAAD trans rs727563 0.562 rs5758458 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Crohn's disease;Inflammatory bowel disease; chr22:41758128 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs2899347 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41762200 chr19:56672574~56673901:- PAAD trans rs727563 0.635 rs713988 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Crohn's disease;Inflammatory bowel disease; chr22:41763068 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs2050033 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41763225 chr19:56672574~56673901:- PAAD trans rs727563 0.593 rs5758461 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Crohn's disease;Inflammatory bowel disease; chr22:41766185 chr19:56672574~56673901:- PAAD trans rs727563 0.635 rs2899348 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Crohn's disease;Inflammatory bowel disease; chr22:41768512 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs2899349 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41768656 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs1983576 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41770482 chr19:56672574~56673901:- PAAD trans rs9611565 0.503 rs5996062 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41771460 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs6002474 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41772177 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs5996063 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41772763 chr19:56672574~56673901:- PAAD trans rs9611565 0.503 rs5751156 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41774021 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs6519289 ENSG00000268568.1 AC007228.9 10.07 1.39e-18 2.63e-11 1.07 0.63 Vitiligo; chr22:41774428 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs964898 ENSG00000268568.1 AC007228.9 -10.07 1.39e-18 2.63e-11 -1.07 -0.63 Vitiligo; chr22:41746302 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs9607841 ENSG00000268568.1 AC007228.9 -10.07 1.39e-18 2.63e-11 -1.07 -0.63 Vitiligo; chr22:41790834 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs9611667 ENSG00000268568.1 AC007228.9 -10.07 1.39e-18 2.63e-11 -1.07 -0.63 Vitiligo; chr22:41791011 chr19:56672574~56673901:- PAAD trans rs7121616 0.576 rs7111590 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123055419 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs7111598 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123055438 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs1841580 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123055956 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs7123232 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123056237 chrX:121203182~121205014:- PAAD trans rs7121616 0.545 rs7109348 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123056555 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs7949127 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123057408 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs7949220 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123057418 chrX:121203182~121205014:- PAAD trans rs7121616 0.531 rs1461497 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123060505 chrX:121203182~121205014:- PAAD trans rs7121616 0.531 rs41361350 ENSG00000234176.1 HSPA8P1 10.06 1.45e-18 2.74e-11 0.96 0.63 Breast cancer; chr11:123060917 chrX:121203182~121205014:- PAAD trans rs9611565 0.84 rs4822025 ENSG00000268568.1 AC007228.9 -10.06 1.48e-18 2.78e-11 -0.98 -0.63 Vitiligo; chr22:41380642 chr19:56672574~56673901:- PAAD trans rs9611565 0.527 rs2234053 ENSG00000268568.1 AC007228.9 -10.06 1.48e-18 2.78e-11 -0.98 -0.63 Vitiligo; chr22:41381311 chr19:56672574~56673901:- PAAD trans rs9611565 0.802 rs2234058 ENSG00000268568.1 AC007228.9 -10.06 1.48e-18 2.78e-11 -0.98 -0.63 Vitiligo; chr22:41381879 chr19:56672574~56673901:- PAAD trans rs9611565 0.84 rs2234059 ENSG00000268568.1 AC007228.9 -10.06 1.48e-18 2.78e-11 -0.98 -0.63 Vitiligo; chr22:41381909 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs5758405 ENSG00000268568.1 AC007228.9 10.05 1.58e-18 2.97e-11 1.01 0.63 Vitiligo; chr22:41680377 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs5758406 ENSG00000268568.1 AC007228.9 10.05 1.58e-18 2.97e-11 1.01 0.63 Vitiligo; chr22:41680637 chr19:56672574~56673901:- PAAD trans rs9611565 0.5 rs10775759 ENSG00000268568.1 AC007228.9 10.05 1.58e-18 2.97e-11 1.01 0.63 Vitiligo; chr22:41692154 chr19:56672574~56673901:- PAAD trans rs12709013 0.613 rs1657178 ENSG00000230849.2 GOT2P2 10.04 1.62e-18 3.04e-11 0.82 0.63 Blood metabolite ratios; chr16:58735300 chr1:173141100~173142350:- PAAD trans rs10716881 1 rs10716881 ENSG00000121089.4 NACA3P -10.04 1.64e-18 3.07e-11 -0.84 -0.63 High light scatter reticulocyte count; chr12:56644387 chr4:164943290~164943937:+ PAAD trans rs9611565 0.84 rs2234052 ENSG00000268568.1 AC007228.9 -10.04 1.65e-18 3.09e-11 -0.98 -0.63 Vitiligo; chr22:41381237 chr19:56672574~56673901:- PAAD trans rs9611565 0.84 rs9607799 ENSG00000268568.1 AC007228.9 -10.04 1.65e-18 3.09e-11 -0.98 -0.63 Vitiligo; chr22:41381554 chr19:56672574~56673901:- PAAD trans rs7121616 0.576 rs1461495 ENSG00000234176.1 HSPA8P1 -10.04 1.67e-18 3.12e-11 -0.95 -0.63 Breast cancer; chr11:123056136 chrX:121203182~121205014:- PAAD trans rs9611565 0.729 rs203319 ENSG00000268568.1 AC007228.9 -10.03 1.79e-18 3.35e-11 -0.92 -0.63 Vitiligo; chr22:41518589 chr19:56672574~56673901:- PAAD trans rs9611565 0.545 rs5758432 ENSG00000268568.1 AC007228.9 10.02 1.86e-18 3.47e-11 1.08 0.63 Vitiligo; chr22:41715689 chr19:56672574~56673901:- PAAD trans rs916888 0.531 rs183211 ENSG00000214425.5 LRRC37A4P -10.02 1.88e-18 3.51e-11 -0.78 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45506741~45550335:- PAAD trans rs916888 0.61 rs199436 ENSG00000214425.5 LRRC37A4P 10.02 1.88e-18 3.51e-11 0.78 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45506741~45550335:- PAAD trans rs916888 0.61 rs199453 ENSG00000214425.5 LRRC37A4P -10.02 1.88e-18 3.51e-11 -0.78 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45506741~45550335:- PAAD trans rs916888 0.647 rs199449 ENSG00000214425.5 LRRC37A4P -10.02 1.88e-18 3.51e-11 -0.78 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45506741~45550335:- PAAD trans rs916888 0.61 rs199444 ENSG00000214425.5 LRRC37A4P -10.02 1.91e-18 3.55e-11 -0.78 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45506741~45550335:- PAAD trans rs916888 0.61 rs199442 ENSG00000214425.5 LRRC37A4P -10.02 1.91e-18 3.55e-11 -0.78 -0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45506741~45550335:- PAAD trans rs7121616 0.576 rs60405069 ENSG00000234176.1 HSPA8P1 10.01 1.97e-18 3.67e-11 0.97 0.63 Breast cancer; chr11:123043616 chrX:121203182~121205014:- PAAD trans rs9611565 0.694 rs4822032 ENSG00000268568.1 AC007228.9 -10.01 2.01e-18 3.71e-11 -0.96 -0.63 Vitiligo; chr22:41529531 chr19:56672574~56673901:- PAAD trans rs12709013 0.591 rs149479 ENSG00000230849.2 GOT2P2 -10 2.05e-18 3.79e-11 -0.9 -0.63 Blood metabolite ratios; chr16:58703171 chr1:173141100~173142350:- PAAD trans rs12709013 0.569 rs30837 ENSG00000230849.2 GOT2P2 10 2.06e-18 3.81e-11 0.89 0.63 Blood metabolite ratios; chr16:58711942 chr1:173141100~173142350:- PAAD trans rs9611565 0.625 rs9607819 ENSG00000268568.1 AC007228.9 -9.98 2.34e-18 4.3e-11 -1 -0.63 Vitiligo; chr22:41562858 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs5758428 ENSG00000268568.1 AC007228.9 9.98 2.35e-18 4.32e-11 1.08 0.63 Vitiligo; chr22:41710212 chr19:56672574~56673901:- PAAD trans rs727563 0.636 rs2413653 ENSG00000268568.1 AC007228.9 9.98 2.35e-18 4.32e-11 1.08 0.63 Crohn's disease;Inflammatory bowel disease; chr22:41710992 chr19:56672574~56673901:- PAAD trans rs6477998 1 rs7038769 ENSG00000238072.1 RP11-305M3.2 9.98 2.37e-18 4.34e-11 0.87 0.63 Hematology traits; chr9:113245303 chr7:129410113~129410370:- PAAD trans rs6477998 1 rs7022397 ENSG00000238072.1 RP11-305M3.2 9.98 2.37e-18 4.34e-11 0.87 0.63 Hematology traits; chr9:113245397 chr7:129410113~129410370:- PAAD trans rs6477998 1 rs10759636 ENSG00000238072.1 RP11-305M3.2 9.98 2.37e-18 4.34e-11 0.87 0.63 Hematology traits; chr9:113256497 chr7:129410113~129410370:- PAAD trans rs9611565 0.546 rs739134 ENSG00000268568.1 AC007228.9 9.98 2.39e-18 4.37e-11 1.02 0.63 Vitiligo; chr22:41693619 chr19:56672574~56673901:- PAAD trans rs12709013 0.591 rs30834 ENSG00000230849.2 GOT2P2 9.97 2.46e-18 4.49e-11 0.88 0.63 Blood metabolite ratios; chr16:58715394 chr1:173141100~173142350:- PAAD trans rs6477998 0.966 rs10759637 ENSG00000238072.1 RP11-305M3.2 9.97 2.51e-18 4.58e-11 0.87 0.63 Hematology traits; chr9:113262744 chr7:129410113~129410370:- PAAD trans rs6477998 0.932 rs4129395 ENSG00000238072.1 RP11-305M3.2 9.96 2.63e-18 4.8e-11 0.87 0.63 Hematology traits; chr9:113213109 chr7:129410113~129410370:- PAAD trans rs6477998 0.966 rs7859354 ENSG00000238072.1 RP11-305M3.2 9.96 2.63e-18 4.8e-11 0.87 0.63 Hematology traits; chr9:113214165 chr7:129410113~129410370:- PAAD trans rs6477998 1 rs10739388 ENSG00000238072.1 RP11-305M3.2 9.96 2.63e-18 4.8e-11 0.87 0.63 Hematology traits; chr9:113214895 chr7:129410113~129410370:- PAAD trans rs13177918 0.734 rs6579791 ENSG00000239528.1 RPS14P8 9.96 2.67e-18 4.84e-11 0.94 0.63 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr5:116562562~116562930:+ PAAD trans rs916888 0.61 rs199530 ENSG00000214425.5 LRRC37A4P 9.95 2.79e-18 5.04e-11 0.76 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:45506741~45550335:- PAAD trans rs9611565 0.512 rs139562 ENSG00000268568.1 AC007228.9 -9.94 3.01e-18 5.42e-11 -1.08 -0.63 Vitiligo; chr22:41800680 chr19:56672574~56673901:- PAAD trans rs3749237 0.595 rs4855873 ENSG00000197582.5 GPX1P1 9.94 3.1e-18 5.58e-11 0.81 0.63 Resting heart rate; chr3:49421681 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs1464566 ENSG00000197582.5 GPX1P1 9.94 3.1e-18 5.58e-11 0.81 0.63 Resting heart rate; chr3:49421943 chrX:13378735~13379340:- PAAD trans rs3749237 0.537 rs4459909 ENSG00000197582.5 GPX1P1 9.94 3.1e-18 5.58e-11 0.81 0.63 Resting heart rate; chr3:49431784 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs11130196 ENSG00000197582.5 GPX1P1 9.94 3.1e-18 5.58e-11 0.81 0.63 Resting heart rate; chr3:49452716 chrX:13378735~13379340:- PAAD trans rs916888 0.61 rs199446 ENSG00000214425.5 LRRC37A4P 9.93 3.18e-18 5.71e-11 0.78 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45506741~45550335:- PAAD trans rs916888 0.61 rs199536 ENSG00000214425.5 LRRC37A4P 9.93 3.18e-18 5.71e-11 0.78 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45506741~45550335:- PAAD trans rs916888 0.61 rs199454 ENSG00000214425.5 LRRC37A4P 9.93 3.27e-18 5.87e-11 0.78 0.63 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45506741~45550335:- PAAD trans rs3749237 0.595 rs4855839 ENSG00000197582.5 GPX1P1 9.92 3.3e-18 5.93e-11 0.81 0.63 Resting heart rate; chr3:49470414 chrX:13378735~13379340:- PAAD trans rs12709013 0.574 rs839418 ENSG00000230849.2 GOT2P2 9.92 3.4e-18 6.1e-11 0.88 0.63 Blood metabolite ratios; chr16:58705426 chr1:173141100~173142350:- PAAD trans rs7121616 0.545 rs11600517 ENSG00000234176.1 HSPA8P1 9.91 3.58e-18 6.41e-11 0.97 0.63 Breast cancer; chr11:123047247 chrX:121203182~121205014:- PAAD trans rs61990749 0.571 rs2364841 ENSG00000235400.1 RP4-641G12.4 9.9 3.76e-18 6.72e-11 1.07 0.63 Fibroblast growth factor basic levels; chr14:77817693 chr1:78749073~78750659:+ PAAD trans rs7121616 0.576 rs73608699 ENSG00000234176.1 HSPA8P1 9.9 3.88e-18 6.9e-11 0.96 0.63 Breast cancer; chr11:123044718 chrX:121203182~121205014:- PAAD trans rs12709013 0.636 rs72792430 ENSG00000230849.2 GOT2P2 -9.86 5.05e-18 8.83e-11 -0.82 -0.62 Blood metabolite ratios; chr16:58746990 chr1:173141100~173142350:- PAAD trans rs12709013 0.597 rs1616072 ENSG00000230849.2 GOT2P2 9.86 5.05e-18 8.83e-11 0.82 0.62 Blood metabolite ratios; chr16:58747194 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs2575374 ENSG00000230849.2 GOT2P2 9.86 5.05e-18 8.83e-11 0.82 0.62 Blood metabolite ratios; chr16:58747494 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1657164 ENSG00000230849.2 GOT2P2 9.86 5.05e-18 8.83e-11 0.82 0.62 Blood metabolite ratios; chr16:58747949 chr1:173141100~173142350:- PAAD trans rs8010715 0.816 rs2332224 ENSG00000248988.1 RP11-815N9.2 9.85 5.11e-18 8.93e-11 0.86 0.62 IgG glycosylation; chr14:24129335 chr4:159007119~159007835:+ PAAD trans rs5022636 0.896 rs744536 ENSG00000180764.13 PIPSL 9.84 5.48e-18 9.54e-11 0.74 0.62 Gut microbiota (functional units); chr1:151356318 chr10:93958191~93961540:- PAAD trans rs13177918 0.734 rs6579790 ENSG00000239528.1 RPS14P8 9.84 5.69e-18 9.9e-11 0.93 0.62 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr5:116562562~116562930:+ PAAD trans rs5022636 0.896 rs10788804 ENSG00000180764.13 PIPSL 9.83 5.81e-18 1.01e-10 0.76 0.62 Gut microbiota (functional units); chr1:151365312 chr10:93958191~93961540:- PAAD trans rs13177918 0.717 rs6874318 ENSG00000213058.3 RP4-765C7.2 -9.83 5.9e-18 1.03e-10 -0.87 -0.62 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr1:178411616~178411972:+ PAAD trans rs6477998 1 rs4560868 ENSG00000238072.1 RP11-305M3.2 -9.83 5.92e-18 1.03e-10 -0.87 -0.62 Hematology traits; chr9:113223219 chr7:129410113~129410370:- PAAD trans rs916888 0.61 rs199529 ENSG00000264070.1 DND1P1 9.82 6.07e-18 1.05e-10 0.92 0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45585871~45586929:+ PAAD trans rs13190036 1 rs28580074 ENSG00000217325.2 PRELID1P1 9.82 6.07e-18 1.05e-10 1.12 0.62 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177294197 chr6:126643488~126644390:+ PAAD trans rs941207 0.507 rs1107479 ENSG00000121089.4 NACA3P -9.82 6.42e-18 1.11e-10 -0.83 -0.62 Platelet count; chr12:56636902 chr4:164943290~164943937:+ PAAD trans rs13177918 0.717 rs6874318 ENSG00000224114.1 RP11-343H5.4 -9.81 6.53e-18 1.13e-10 -0.89 -0.62 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr1:206695837~206696269:- PAAD trans rs7121616 0.576 rs11600486 ENSG00000234176.1 HSPA8P1 9.81 6.84e-18 1.18e-10 0.96 0.62 Breast cancer; chr11:123047060 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs73610510 ENSG00000234176.1 HSPA8P1 9.81 6.84e-18 1.18e-10 0.96 0.62 Breast cancer; chr11:123049365 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs7942164 ENSG00000234176.1 HSPA8P1 9.81 6.84e-18 1.18e-10 0.96 0.62 Breast cancer; chr11:123050459 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs7102045 ENSG00000234176.1 HSPA8P1 9.81 6.84e-18 1.18e-10 0.96 0.62 Breast cancer; chr11:123052713 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs56131320 ENSG00000234176.1 HSPA8P1 9.81 6.84e-18 1.18e-10 0.96 0.62 Breast cancer; chr11:123053058 chrX:121203182~121205014:- PAAD trans rs7121616 0.576 rs7929869 ENSG00000234176.1 HSPA8P1 9.81 6.84e-18 1.18e-10 0.96 0.62 Breast cancer; chr11:123054435 chrX:121203182~121205014:- PAAD trans rs916888 0.61 rs199452 ENSG00000214425.5 LRRC37A4P -9.8 7e-18 1.21e-10 -0.76 -0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45506741~45550335:- PAAD trans rs12709013 0.591 rs30841 ENSG00000230849.2 GOT2P2 9.8 7.01e-18 1.21e-10 0.87 0.62 Blood metabolite ratios; chr16:58709819 chr1:173141100~173142350:- PAAD trans rs3749237 0.595 rs2878298 ENSG00000197582.5 GPX1P1 9.79 7.68e-18 1.32e-10 0.82 0.62 Resting heart rate; chr3:49368647 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs17595772 ENSG00000197582.5 GPX1P1 9.79 7.68e-18 1.32e-10 0.82 0.62 Resting heart rate; chr3:49372271 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs7621003 ENSG00000197582.5 GPX1P1 9.78 8.09e-18 1.38e-10 0.82 0.62 Resting heart rate; chr3:49373971 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs4955412 ENSG00000197582.5 GPX1P1 9.78 8.09e-18 1.38e-10 0.82 0.62 Resting heart rate; chr3:49380735 chrX:13378735~13379340:- PAAD trans rs3749237 0.557 rs7631908 ENSG00000197582.5 GPX1P1 9.78 8.09e-18 1.38e-10 0.82 0.62 Resting heart rate; chr3:49388274 chrX:13378735~13379340:- PAAD trans rs3749237 0.615 rs55957735 ENSG00000197582.5 GPX1P1 9.78 8.09e-18 1.38e-10 0.82 0.62 Resting heart rate; chr3:49400725 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs4855877 ENSG00000197582.5 GPX1P1 9.78 8.09e-18 1.38e-10 0.82 0.62 Resting heart rate; chr3:49411094 chrX:13378735~13379340:- PAAD trans rs12709013 0.591 rs30842 ENSG00000230849.2 GOT2P2 -9.77 8.29e-18 1.41e-10 -0.87 -0.62 Blood metabolite ratios; chr16:58709550 chr1:173141100~173142350:- PAAD trans rs727563 0.635 rs5751141 ENSG00000268568.1 AC007228.9 9.76 8.97e-18 1.53e-10 1.05 0.62 Crohn's disease;Inflammatory bowel disease; chr22:41711741 chr19:56672574~56673901:- PAAD trans rs9611565 0.559 rs6002408 ENSG00000268568.1 AC007228.9 -9.76 9.01e-18 1.53e-10 -1.01 -0.62 Vitiligo; chr22:41571866 chr19:56672574~56673901:- PAAD trans rs6708331 0.517 rs6743372 ENSG00000232654.1 FAM136BP 9.74 9.92e-18 1.68e-10 0.73 0.62 Obesity-related traits; chr2:70125508 chr6:3045384~3045800:+ PAAD trans rs7121616 0.576 rs73610509 ENSG00000234176.1 HSPA8P1 9.74 1e-17 1.69e-10 0.95 0.62 Breast cancer; chr11:123048564 chrX:121203182~121205014:- PAAD trans rs12709013 0.636 rs1646272 ENSG00000230849.2 GOT2P2 9.73 1.1e-17 1.86e-10 0.81 0.62 Blood metabolite ratios; chr16:58746508 chr1:173141100~173142350:- PAAD trans rs12709013 0.66 rs1657163 ENSG00000230849.2 GOT2P2 9.73 1.1e-17 1.86e-10 0.81 0.62 Blood metabolite ratios; chr16:58746688 chr1:173141100~173142350:- PAAD trans rs12709013 0.576 rs2432622 ENSG00000230849.2 GOT2P2 9.72 1.15e-17 1.93e-10 0.82 0.62 Blood metabolite ratios; chr16:58749681 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1646281 ENSG00000230849.2 GOT2P2 9.72 1.15e-17 1.93e-10 0.82 0.62 Blood metabolite ratios; chr16:58750512 chr1:173141100~173142350:- PAAD trans rs12709013 0.613 rs1618602 ENSG00000230849.2 GOT2P2 9.72 1.15e-17 1.93e-10 0.82 0.62 Blood metabolite ratios; chr16:58756080 chr1:173141100~173142350:- PAAD trans rs12709013 0.613 rs8049462 ENSG00000230849.2 GOT2P2 9.72 1.15e-17 1.93e-10 0.82 0.62 Blood metabolite ratios; chr16:58757654 chr1:173141100~173142350:- PAAD trans rs12709013 0.66 rs257629 ENSG00000230849.2 GOT2P2 9.72 1.15e-17 1.93e-10 0.82 0.62 Blood metabolite ratios; chr16:58758044 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs8045466 ENSG00000230849.2 GOT2P2 9.72 1.15e-17 1.93e-10 0.82 0.62 Blood metabolite ratios; chr16:58765113 chr1:173141100~173142350:- PAAD trans rs13190036 1 rs7714695 ENSG00000217325.2 PRELID1P1 -9.72 1.16e-17 1.94e-10 -1.07 -0.62 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177130444 chr6:126643488~126644390:+ PAAD trans rs13190036 0.901 rs28684504 ENSG00000217325.2 PRELID1P1 9.72 1.17e-17 1.96e-10 1.1 0.62 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177300437 chr6:126643488~126644390:+ PAAD trans rs916888 0.61 rs199438 ENSG00000214425.5 LRRC37A4P -9.71 1.21e-17 2.03e-10 -0.77 -0.62 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45506741~45550335:- PAAD trans rs2885056 0.8 rs8105074 ENSG00000227534.1 RP3-323B6.1 9.68 1.46e-17 2.43e-10 0.97 0.62 Red cell distribution width; chr19:10598016 chrX:65469087~65470380:+ PAAD trans rs12709013 0.591 rs30838 ENSG00000230849.2 GOT2P2 9.67 1.51e-17 2.52e-10 0.86 0.62 Blood metabolite ratios; chr16:58711513 chr1:173141100~173142350:- PAAD trans rs9611565 0.546 rs132793 ENSG00000268568.1 AC007228.9 9.66 1.68e-17 2.79e-10 1.07 0.62 Vitiligo; chr22:41667677 chr19:56672574~56673901:- PAAD trans rs9611565 0.918 rs73176685 ENSG00000268568.1 AC007228.9 -9.65 1.73e-17 2.88e-10 -0.97 -0.62 Vitiligo; chr22:41385090 chr19:56672574~56673901:- PAAD trans rs12709013 0.537 rs1657167 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58748955 chr1:173141100~173142350:- PAAD trans rs12709013 0.601 rs2432621 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58749676 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs8054414 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58749772 chr1:173141100~173142350:- PAAD trans rs12709013 0.597 rs11076259 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58749860 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs12325516 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58749899 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs11076260 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58749942 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1646278 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58750084 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1646280 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58750420 chr1:173141100~173142350:- PAAD trans rs12709013 0.597 rs1646286 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58752651 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1624301 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58753491 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1626006 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58753691 chr1:173141100~173142350:- PAAD trans rs12709013 0.684 rs1646287 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58753774 chr1:173141100~173142350:- PAAD trans rs12709013 0.671 rs1369933 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58753927 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1369934 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58754124 chr1:173141100~173142350:- PAAD trans rs12709013 0.561 rs1657174 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58755139 chr1:173141100~173142350:- PAAD trans rs12709013 0.613 rs1646288 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58755576 chr1:173141100~173142350:- PAAD trans rs12709013 0.561 rs727484 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58756568 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs257628 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58758924 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs257627 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58758956 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs191783 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58759994 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs257624 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58760994 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs8060717 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58765574 chr1:173141100~173142350:- PAAD trans rs12709013 0.559 rs8060721 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58765581 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs8044542 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58765620 chr1:173141100~173142350:- PAAD trans rs12709013 0.621 rs6499974 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58769642 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs4499224 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58770364 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1595180 ENSG00000230849.2 GOT2P2 9.65 1.77e-17 2.92e-10 0.8 0.62 Blood metabolite ratios; chr16:58770545 chr1:173141100~173142350:- PAAD trans rs6708331 0.54 rs28623550 ENSG00000232654.1 FAM136BP 9.65 1.8e-17 2.96e-10 0.71 0.62 Obesity-related traits; chr2:70139260 chr6:3045384~3045800:+ PAAD trans rs6708331 0.517 rs12999042 ENSG00000232654.1 FAM136BP 9.65 1.8e-17 2.96e-10 0.71 0.62 Obesity-related traits; chr2:70139679 chr6:3045384~3045800:+ PAAD trans rs6708331 0.54 rs11890701 ENSG00000232654.1 FAM136BP 9.64 1.87e-17 3.06e-10 0.71 0.62 Obesity-related traits; chr2:70133325 chr6:3045384~3045800:+ PAAD trans rs3749237 0.595 rs4855864 ENSG00000197582.5 GPX1P1 9.64 1.91e-17 3.12e-10 0.8 0.62 Resting heart rate; chr3:49484541 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs11130199 ENSG00000197582.5 GPX1P1 9.64 1.91e-17 3.12e-10 0.8 0.62 Resting heart rate; chr3:49501366 chrX:13378735~13379340:- PAAD trans rs12709013 0.636 rs6499976 ENSG00000230849.2 GOT2P2 9.63 1.97e-17 3.22e-10 0.8 0.62 Blood metabolite ratios; chr16:58770330 chr1:173141100~173142350:- PAAD trans rs4822044 0.561 rs132781 ENSG00000268568.1 AC007228.9 9.61 2.27e-17 3.69e-10 1.06 0.61 Cannabis dependence symptom count; chr22:41650118 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs132784 ENSG00000268568.1 AC007228.9 9.61 2.27e-17 3.69e-10 1.06 0.61 Vitiligo; chr22:41656359 chr19:56672574~56673901:- PAAD trans rs8010715 1 rs8010715 ENSG00000248988.1 RP11-815N9.2 9.6 2.32e-17 3.77e-10 0.88 0.61 IgG glycosylation; chr14:24139938 chr4:159007119~159007835:+ PAAD trans rs13190036 0.892 rs71601339 ENSG00000217325.2 PRELID1P1 -9.6 2.37e-17 3.84e-10 -1.07 -0.61 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117495 chr6:126643488~126644390:+ PAAD trans rs61990749 0.597 rs59848135 ENSG00000235400.1 RP4-641G12.4 -9.6 2.38e-17 3.85e-10 -1.06 -0.61 Fibroblast growth factor basic levels; chr14:77662657 chr1:78749073~78750659:+ PAAD trans rs13190036 1 rs4976682 ENSG00000217325.2 PRELID1P1 9.6 2.44e-17 3.95e-10 1.09 0.61 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177299001 chr6:126643488~126644390:+ PAAD trans rs12709013 0.636 rs1865836 ENSG00000230849.2 GOT2P2 9.57 2.89e-17 4.65e-10 0.81 0.61 Blood metabolite ratios; chr16:58768143 chr1:173141100~173142350:- PAAD trans rs9611565 0.512 rs9607842 ENSG00000268568.1 AC007228.9 -9.56 2.94e-17 4.72e-10 -1.04 -0.61 Vitiligo; chr22:41796718 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs139560 ENSG00000268568.1 AC007228.9 -9.56 2.94e-17 4.72e-10 -1.04 -0.61 Vitiligo; chr22:41798958 chr19:56672574~56673901:- PAAD trans rs13253073 0.545 rs13265660 ENSG00000260318.1 COX6CP1 9.56 3.05e-17 4.89e-10 1.14 0.61 Glucose homeostasis traits; chr8:99815931 chr16:11903923~11904137:- PAAD trans rs9611565 0.918 rs9611566 ENSG00000268568.1 AC007228.9 9.54 3.46e-17 5.54e-10 0.93 0.61 Vitiligo; chr22:41372621 chr19:56672574~56673901:- PAAD trans rs6708331 0.517 rs12617812 ENSG00000232654.1 FAM136BP 9.53 3.58e-17 5.72e-10 0.71 0.61 Obesity-related traits; chr2:70132339 chr6:3045384~3045800:+ PAAD trans rs6708331 0.517 rs7599072 ENSG00000232654.1 FAM136BP 9.53 3.58e-17 5.72e-10 0.71 0.61 Obesity-related traits; chr2:70132874 chr6:3045384~3045800:+ PAAD trans rs6708331 0.517 rs12992553 ENSG00000232654.1 FAM136BP 9.53 3.58e-17 5.72e-10 0.71 0.61 Obesity-related traits; chr2:70133130 chr6:3045384~3045800:+ PAAD trans rs6708331 0.517 rs11890741 ENSG00000232654.1 FAM136BP 9.53 3.58e-17 5.72e-10 0.71 0.61 Obesity-related traits; chr2:70133374 chr6:3045384~3045800:+ PAAD trans rs10242455 0.702 rs112475236 ENSG00000228834.1 RP11-249L21.4 9.53 3.62e-17 5.77e-10 1.67 0.61 Blood metabolite levels; chr7:99447056 chr6:108907615~108907873:- PAAD trans rs10242455 0.557 rs45529541 ENSG00000228834.1 RP11-249L21.4 9.53 3.62e-17 5.77e-10 1.67 0.61 Blood metabolite levels; chr7:99450520 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs3528 ENSG00000228834.1 RP11-249L21.4 9.53 3.62e-17 5.77e-10 1.67 0.61 Blood metabolite levels; chr7:99458317 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs55927283 ENSG00000228834.1 RP11-249L21.4 9.53 3.62e-17 5.77e-10 1.67 0.61 Blood metabolite levels; chr7:99459568 chr6:108907615~108907873:- PAAD trans rs12709013 0.636 rs4538000 ENSG00000230849.2 GOT2P2 9.52 3.84e-17 6.12e-10 0.8 0.61 Blood metabolite ratios; chr16:58744506 chr1:173141100~173142350:- PAAD trans rs8010715 1 rs3742500 ENSG00000248988.1 RP11-815N9.2 9.52 3.88e-17 6.18e-10 0.88 0.61 IgG glycosylation; chr14:24142769 chr4:159007119~159007835:+ PAAD trans rs12709013 0.646 rs8046154 ENSG00000230849.2 GOT2P2 -9.5 4.23e-17 6.69e-10 -0.81 -0.61 Blood metabolite ratios; chr16:58773978 chr1:173141100~173142350:- PAAD trans rs3749237 0.595 rs1568661 ENSG00000197582.5 GPX1P1 9.5 4.23e-17 6.69e-10 0.8 0.61 Resting heart rate; chr3:49483525 chrX:13378735~13379340:- PAAD trans rs13190036 1 rs59737888 ENSG00000217325.2 PRELID1P1 -9.5 4.33e-17 6.82e-10 -1.07 -0.61 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177160374 chr6:126643488~126644390:+ PAAD trans rs6708331 0.517 rs11692018 ENSG00000232654.1 FAM136BP 9.48 4.9e-17 7.68e-10 0.7 0.61 Obesity-related traits; chr2:70142022 chr6:3045384~3045800:+ PAAD trans rs9611565 0.918 rs9538 ENSG00000268568.1 AC007228.9 -9.47 5.16e-17 8.07e-10 -0.93 -0.61 Vitiligo; chr22:41359853 chr19:56672574~56673901:- PAAD trans rs9611565 0.918 rs9611561 ENSG00000268568.1 AC007228.9 -9.47 5.16e-17 8.07e-10 -0.93 -0.61 Vitiligo; chr22:41361230 chr19:56672574~56673901:- PAAD trans rs13190036 1 rs17078781 ENSG00000217325.2 PRELID1P1 -9.47 5.19e-17 8.12e-10 -1.07 -0.61 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117227 chr6:126643488~126644390:+ PAAD trans rs13253073 0.545 rs13260744 ENSG00000260318.1 COX6CP1 9.47 5.28e-17 8.24e-10 1.17 0.61 Glucose homeostasis traits; chr8:99819032 chr16:11903923~11904137:- PAAD trans rs3749237 0.595 rs1464568 ENSG00000197582.5 GPX1P1 9.47 5.28e-17 8.24e-10 0.78 0.61 Resting heart rate; chr3:49420833 chrX:13378735~13379340:- PAAD trans rs6708331 0.504 rs2169837 ENSG00000232654.1 FAM136BP 9.47 5.31e-17 8.28e-10 0.75 0.61 Obesity-related traits; chr2:70324775 chr6:3045384~3045800:+ PAAD trans rs1816752 0.603 rs9551099 ENSG00000237917.1 PARP4P1 -9.47 5.33e-17 8.3e-10 -0.73 -0.61 Obesity-related traits; chr13:24410978 chrY:26594851~26634652:- PAAD trans rs9611565 0.512 rs5758464 ENSG00000268568.1 AC007228.9 9.45 5.71e-17 8.88e-10 1.06 0.61 Vitiligo; chr22:41775296 chr19:56672574~56673901:- PAAD trans rs10242455 0.557 rs73403272 ENSG00000228834.1 RP11-249L21.4 9.44 6.24e-17 9.66e-10 1.59 0.61 Blood metabolite levels; chr7:99536585 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs7794068 ENSG00000228834.1 RP11-249L21.4 9.44 6.24e-17 9.66e-10 1.59 0.61 Blood metabolite levels; chr7:99549250 chr6:108907615~108907873:- PAAD trans rs10242455 0.571 rs56167514 ENSG00000228834.1 RP11-249L21.4 9.44 6.24e-17 9.66e-10 1.59 0.61 Blood metabolite levels; chr7:99563724 chr6:108907615~108907873:- PAAD trans rs10242455 0.571 rs7805661 ENSG00000228834.1 RP11-249L21.4 9.44 6.24e-17 9.66e-10 1.59 0.61 Blood metabolite levels; chr7:99573899 chr6:108907615~108907873:- PAAD trans rs12709013 0.636 rs10852565 ENSG00000230849.2 GOT2P2 9.43 6.47e-17 9.99e-10 0.8 0.61 Blood metabolite ratios; chr16:58771277 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs9937713 ENSG00000230849.2 GOT2P2 9.43 6.47e-17 9.99e-10 0.8 0.61 Blood metabolite ratios; chr16:58771921 chr1:173141100~173142350:- PAAD trans rs12709013 0.597 rs8051078 ENSG00000230849.2 GOT2P2 9.43 6.47e-17 9.99e-10 0.8 0.61 Blood metabolite ratios; chr16:58774200 chr1:173141100~173142350:- PAAD trans rs9611565 0.592 rs5758427 ENSG00000268568.1 AC007228.9 9.43 6.71e-17 1.03e-09 0.98 0.61 Vitiligo; chr22:41703684 chr19:56672574~56673901:- PAAD trans rs9611565 0.546 rs5758430 ENSG00000268568.1 AC007228.9 9.43 6.71e-17 1.03e-09 0.98 0.61 Vitiligo; chr22:41713840 chr19:56672574~56673901:- PAAD trans rs9611565 0.546 rs5758431 ENSG00000268568.1 AC007228.9 9.43 6.71e-17 1.03e-09 0.98 0.61 Vitiligo; chr22:41713913 chr19:56672574~56673901:- PAAD trans rs9611565 0.546 rs2092274 ENSG00000268568.1 AC007228.9 9.43 6.71e-17 1.03e-09 0.98 0.61 Vitiligo; chr22:41727733 chr19:56672574~56673901:- PAAD trans rs9611565 0.512 rs4822052 ENSG00000268568.1 AC007228.9 -9.42 7.13e-17 1.1e-09 -0.98 -0.61 Vitiligo; chr22:41797737 chr19:56672574~56673901:- PAAD trans rs12709013 0.636 rs1646284 ENSG00000230849.2 GOT2P2 9.42 7.17e-17 1.1e-09 0.81 0.61 Blood metabolite ratios; chr16:58752093 chr1:173141100~173142350:- PAAD trans rs9611565 0.918 rs7290404 ENSG00000268568.1 AC007228.9 -9.39 8.62e-17 1.32e-09 -0.91 -0.61 Vitiligo; chr22:41353792 chr19:56672574~56673901:- PAAD trans rs10242455 0.557 rs2404487 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99440434 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs73711280 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99441981 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs73397499 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99442004 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs45448997 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99443975 chr6:108907615~108907873:- PAAD trans rs10242455 0.557 rs45492501 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99449407 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs17854665 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99452416 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs45461000 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99455087 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs73401510 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99468189 chr6:108907615~108907873:- PAAD trans rs10242455 0.557 rs73401516 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99470728 chr6:108907615~108907873:- PAAD trans rs10242455 0.557 rs77997620 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99472792 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs59240302 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99475368 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs73403247 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99491107 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs6974831 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99533982 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs73403286 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99557242 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs73403290 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99560205 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs73405247 ENSG00000228834.1 RP11-249L21.4 9.38 9.14e-17 1.38e-09 1.67 0.61 Blood metabolite levels; chr7:99561551 chr6:108907615~108907873:- PAAD trans rs13190036 0.901 rs55741473 ENSG00000217325.2 PRELID1P1 -9.35 1.05e-16 1.59e-09 -1.05 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr6:126643488~126644390:+ PAAD trans rs13190036 1 rs13157667 ENSG00000217325.2 PRELID1P1 -9.35 1.05e-16 1.59e-09 -1.05 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr6:126643488~126644390:+ PAAD trans rs12709013 0.636 rs1646279 ENSG00000230849.2 GOT2P2 9.35 1.06e-16 1.59e-09 0.8 0.6 Blood metabolite ratios; chr16:58750235 chr1:173141100~173142350:- PAAD trans rs12709013 0.597 rs1657171 ENSG00000230849.2 GOT2P2 9.35 1.06e-16 1.59e-09 0.8 0.6 Blood metabolite ratios; chr16:58752083 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs1646285 ENSG00000230849.2 GOT2P2 9.35 1.06e-16 1.59e-09 0.8 0.6 Blood metabolite ratios; chr16:58752102 chr1:173141100~173142350:- PAAD trans rs928391 0.592 rs1888861 ENSG00000227183.3 HDGFP1 -9.34 1.12e-16 1.68e-09 -0.86 -0.6 Platelet count; chr1:156828169 chrX:131646639~131646890:+ PAAD trans rs13190036 1 rs34446750 ENSG00000217325.2 PRELID1P1 -9.34 1.12e-16 1.69e-09 -1.05 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177168079 chr6:126643488~126644390:+ PAAD trans rs12709013 0.591 rs30840 ENSG00000230849.2 GOT2P2 9.34 1.13e-16 1.69e-09 0.86 0.6 Blood metabolite ratios; chr16:58710165 chr1:173141100~173142350:- PAAD trans rs12709013 0.591 rs899375 ENSG00000230849.2 GOT2P2 9.34 1.14e-16 1.71e-09 0.8 0.6 Blood metabolite ratios; chr16:58792325 chr1:173141100~173142350:- PAAD trans rs9611565 0.512 rs139561 ENSG00000268568.1 AC007228.9 9.34 1.16e-16 1.74e-09 1.03 0.6 Vitiligo; chr22:41799406 chr19:56672574~56673901:- PAAD trans rs727563 0.638 rs4820443 ENSG00000268568.1 AC007228.9 -9.34 1.16e-16 1.74e-09 -1.03 -0.6 Crohn's disease;Inflammatory bowel disease; chr22:41797909 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs56021266 ENSG00000268568.1 AC007228.9 -9.33 1.21e-16 1.8e-09 -1.06 -0.6 Vitiligo; chr22:41360567 chr19:56672574~56673901:- PAAD trans rs10242455 0.702 rs74416635 ENSG00000228834.1 RP11-249L21.4 9.32 1.27e-16 1.9e-09 1.68 0.6 Blood metabolite levels; chr7:99582946 chr6:108907615~108907873:- PAAD trans rs3749237 0.595 rs11130192 ENSG00000197582.5 GPX1P1 9.32 1.28e-16 1.91e-09 0.78 0.6 Resting heart rate; chr3:49429773 chrX:13378735~13379340:- PAAD trans rs13096760 1 rs13096760 ENSG00000197582.5 GPX1P1 9.32 1.28e-16 1.91e-09 0.78 0.6 Intelligence (multi-trait analysis); chr3:49439373 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs10865955 ENSG00000197582.5 GPX1P1 9.32 1.28e-16 1.91e-09 0.78 0.6 Resting heart rate; chr3:49462396 chrX:13378735~13379340:- PAAD trans rs3749237 0.555 rs2117939 ENSG00000197582.5 GPX1P1 9.3 1.42e-16 2.11e-09 0.78 0.6 Resting heart rate; chr3:49377746 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs6797765 ENSG00000197582.5 GPX1P1 9.3 1.42e-16 2.11e-09 0.78 0.6 Resting heart rate; chr3:49386543 chrX:13378735~13379340:- PAAD trans rs13190036 1 rs13167431 ENSG00000217325.2 PRELID1P1 -9.3 1.42e-16 2.11e-09 -1.05 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr6:126643488~126644390:+ PAAD trans rs13190036 1 rs35535623 ENSG00000217325.2 PRELID1P1 -9.3 1.42e-16 2.11e-09 -1.05 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr6:126643488~126644390:+ PAAD trans rs13190036 1 rs71601343 ENSG00000217325.2 PRELID1P1 -9.29 1.51e-16 2.23e-09 -1.04 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr6:126643488~126644390:+ PAAD trans rs13190036 1 rs71601344 ENSG00000217325.2 PRELID1P1 -9.29 1.51e-16 2.23e-09 -1.04 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr6:126643488~126644390:+ PAAD trans rs13190036 1 rs3733875 ENSG00000217325.2 PRELID1P1 -9.29 1.51e-16 2.23e-09 -1.04 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr6:126643488~126644390:+ PAAD trans rs12709013 0.591 rs4784986 ENSG00000230849.2 GOT2P2 9.29 1.55e-16 2.3e-09 0.81 0.6 Blood metabolite ratios; chr16:58803007 chr1:173141100~173142350:- PAAD trans rs9611565 0.918 rs9611562 ENSG00000268568.1 AC007228.9 -9.28 1.61e-16 2.38e-09 -0.92 -0.6 Vitiligo; chr22:41364168 chr19:56672574~56673901:- PAAD trans rs3749237 0.595 rs6784820 ENSG00000197582.5 GPX1P1 -9.28 1.64e-16 2.41e-09 -0.78 -0.6 Resting heart rate; chr3:49413431 chrX:13378735~13379340:- PAAD trans rs13177918 0.717 rs6874318 ENSG00000239528.1 RPS14P8 -9.28 1.65e-16 2.42e-09 -0.85 -0.6 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr5:116562562~116562930:+ PAAD trans rs3749237 0.595 rs17650792 ENSG00000197582.5 GPX1P1 9.27 1.69e-16 2.47e-09 0.79 0.6 Resting heart rate; chr3:49352817 chrX:13378735~13379340:- PAAD trans rs12709013 0.574 rs35321124 ENSG00000230849.2 GOT2P2 9.26 1.78e-16 2.59e-09 0.79 0.6 Blood metabolite ratios; chr16:58786561 chr1:173141100~173142350:- PAAD trans rs3749237 0.595 rs1464567 ENSG00000197582.5 GPX1P1 -9.25 1.94e-16 2.7e-09 -0.77 -0.6 Resting heart rate; chr3:49421819 chrX:13378735~13379340:- PAAD trans rs61990749 0.597 rs117131659 ENSG00000235400.1 RP4-641G12.4 -9.25 1.98e-16 2.76e-09 -1.04 -0.6 Fibroblast growth factor basic levels; chr14:77664783 chr1:78749073~78750659:+ PAAD trans rs7399018 0.739 rs10747608 ENSG00000223825.5 DAZAP2P1 9.24 2.1e-16 2.92e-09 0.78 0.6 Cisplatin-induced ototoxicity; chr12:51222798 chr2:202201384~202201886:- PAAD trans rs9611565 0.838 rs4239894 ENSG00000268568.1 AC007228.9 -9.23 2.2e-16 3.06e-09 -0.9 -0.6 Vitiligo; chr22:41349544 chr19:56672574~56673901:- PAAD trans rs916888 0.61 rs142167 ENSG00000214425.5 LRRC37A4P 9.2 2.55e-16 3.52e-09 0.75 0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:45506741~45550335:- PAAD trans rs9467773 0.525 rs1535274 ENSG00000242375.1 RP11-498P14.3 9.2 2.68e-16 3.69e-09 0.77 0.6 Intelligence (multi-trait analysis); chr6:26520519 chr9:97195351~97197687:- PAAD trans rs9467773 0.565 rs6925047 ENSG00000242375.1 RP11-498P14.3 9.2 2.68e-16 3.69e-09 0.77 0.6 Intelligence (multi-trait analysis); chr6:26521207 chr9:97195351~97197687:- PAAD trans rs9467773 0.565 rs4343916 ENSG00000242375.1 RP11-498P14.3 9.2 2.68e-16 3.69e-09 0.77 0.6 Intelligence (multi-trait analysis); chr6:26522447 chr9:97195351~97197687:- PAAD trans rs12709013 0.591 rs6499980 ENSG00000230849.2 GOT2P2 9.19 2.76e-16 3.79e-09 0.78 0.6 Blood metabolite ratios; chr16:58787972 chr1:173141100~173142350:- PAAD trans rs916888 0.779 rs199526 ENSG00000264070.1 DND1P1 -9.18 2.91e-16 3.96e-09 -0.85 -0.6 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:45585871~45586929:+ PAAD trans rs3749237 0.595 rs35701831 ENSG00000197582.5 GPX1P1 9.18 2.95e-16 4.02e-09 0.77 0.6 Resting heart rate; chr3:49477567 chrX:13378735~13379340:- PAAD trans rs12709013 0.535 rs9924136 ENSG00000230849.2 GOT2P2 9.15 3.44e-16 4.66e-09 0.79 0.6 Blood metabolite ratios; chr16:58779573 chr1:173141100~173142350:- PAAD trans rs3749237 0.615 rs6792911 ENSG00000197582.5 GPX1P1 9.15 3.57e-16 4.83e-09 0.79 0.6 Resting heart rate; chr3:49392423 chrX:13378735~13379340:- PAAD trans rs12709013 0.536 rs9930758 ENSG00000230849.2 GOT2P2 9.14 3.65e-16 4.92e-09 0.8 0.6 Blood metabolite ratios; chr16:58803167 chr1:173141100~173142350:- PAAD trans rs12709013 0.591 rs9932967 ENSG00000230849.2 GOT2P2 9.14 3.65e-16 4.92e-09 0.8 0.6 Blood metabolite ratios; chr16:58805583 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs967852 ENSG00000230849.2 GOT2P2 9.14 3.65e-16 4.92e-09 0.8 0.6 Blood metabolite ratios; chr16:58807313 chr1:173141100~173142350:- PAAD trans rs12709013 0.591 rs7184377 ENSG00000230849.2 GOT2P2 9.14 3.65e-16 4.92e-09 0.8 0.6 Blood metabolite ratios; chr16:58808765 chr1:173141100~173142350:- PAAD trans rs12709013 0.613 rs6499984 ENSG00000230849.2 GOT2P2 9.14 3.65e-16 4.92e-09 0.8 0.6 Blood metabolite ratios; chr16:58810209 chr1:173141100~173142350:- PAAD trans rs12709013 0.574 rs9302706 ENSG00000230849.2 GOT2P2 9.14 3.65e-16 4.92e-09 0.8 0.6 Blood metabolite ratios; chr16:58812060 chr1:173141100~173142350:- PAAD trans rs13190036 1 rs351862 ENSG00000217325.2 PRELID1P1 -9.14 3.69e-16 4.98e-09 -1.03 -0.6 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177114369 chr6:126643488~126644390:+ PAAD trans rs3749237 0.595 rs12489092 ENSG00000197582.5 GPX1P1 9.14 3.81e-16 5.13e-09 0.76 0.6 Resting heart rate; chr3:49513481 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs3870337 ENSG00000197582.5 GPX1P1 9.14 3.81e-16 5.13e-09 0.76 0.6 Resting heart rate; chr3:49519662 chrX:13378735~13379340:- PAAD trans rs9611565 0.921 rs761366 ENSG00000268568.1 AC007228.9 -9.1 4.73e-16 6.27e-09 -0.89 -0.59 Vitiligo; chr22:41348018 chr19:56672574~56673901:- PAAD trans rs61990749 0.597 rs9788540 ENSG00000235400.1 RP4-641G12.4 -9.1 4.81e-16 6.38e-09 -1.01 -0.59 Fibroblast growth factor basic levels; chr14:77665829 chr1:78749073~78750659:+ PAAD trans rs916888 0.779 rs199498 ENSG00000214425.5 LRRC37A4P -9.1 4.83e-16 6.41e-09 -0.78 -0.59 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:45506741~45550335:- PAAD trans rs10242455 0.571 rs11972210 ENSG00000228834.1 RP11-249L21.4 9.09 5.05e-16 6.68e-09 1.6 0.59 Blood metabolite levels; chr7:99609320 chr6:108907615~108907873:- PAAD trans rs9611565 0.559 rs8139993 ENSG00000268568.1 AC007228.9 -9.08 5.42e-16 7.13e-09 -0.95 -0.59 Vitiligo; chr22:41599331 chr19:56672574~56673901:- PAAD trans rs928391 0.592 rs7522395 ENSG00000227183.3 HDGFP1 -9.07 5.59e-16 7.35e-09 -0.82 -0.59 Platelet count; chr1:156826905 chrX:131646639~131646890:+ PAAD trans rs928391 0.592 rs6427332 ENSG00000227183.3 HDGFP1 -9.07 5.59e-16 7.35e-09 -0.82 -0.59 Platelet count; chr1:156827052 chrX:131646639~131646890:+ PAAD trans rs9611565 0.592 rs4481089 ENSG00000268568.1 AC007228.9 -9.07 5.78e-16 7.59e-09 -0.95 -0.59 Vitiligo; chr22:41584888 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs5996039 ENSG00000268568.1 AC007228.9 -9.07 5.78e-16 7.59e-09 -0.95 -0.59 Vitiligo; chr22:41585953 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs57102627 ENSG00000268568.1 AC007228.9 -9.07 5.78e-16 7.59e-09 -0.95 -0.59 Vitiligo; chr22:41591623 chr19:56672574~56673901:- PAAD trans rs9611565 0.592 rs28750375 ENSG00000268568.1 AC007228.9 -9.07 5.78e-16 7.59e-09 -0.95 -0.59 Vitiligo; chr22:41594640 chr19:56672574~56673901:- PAAD trans rs13190036 1 rs6889220 ENSG00000217325.2 PRELID1P1 9.05 6.46e-16 8.4e-09 1.05 0.59 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177266887 chr6:126643488~126644390:+ PAAD trans rs10242455 0.571 rs6955162 ENSG00000228834.1 RP11-249L21.4 9.05 6.47e-16 8.4e-09 1.64 0.59 Blood metabolite levels; chr7:99586777 chr6:108907615~108907873:- PAAD trans rs3749237 0.595 rs885592 ENSG00000197582.5 GPX1P1 9.05 6.56e-16 8.52e-09 0.77 0.59 Resting heart rate; chr3:49460450 chrX:13378735~13379340:- PAAD trans rs7399018 0.643 rs6580810 ENSG00000223825.5 DAZAP2P1 9.04 6.94e-16 8.98e-09 0.83 0.59 Cisplatin-induced ototoxicity; chr12:51216694 chr2:202201384~202201886:- PAAD trans rs9611565 0.918 rs12484074 ENSG00000268568.1 AC007228.9 -9.03 7.02e-16 9.08e-09 -0.91 -0.59 Vitiligo; chr22:41356743 chr19:56672574~56673901:- PAAD trans rs3749237 0.636 rs1568662 ENSG00000197582.5 GPX1P1 9.03 7.26e-16 9.35e-09 0.77 0.59 Resting heart rate; chr3:49483830 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs3924462 ENSG00000197582.5 GPX1P1 9.03 7.26e-16 9.35e-09 0.77 0.59 Resting heart rate; chr3:49486803 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs4855861 ENSG00000197582.5 GPX1P1 9.03 7.26e-16 9.35e-09 0.77 0.59 Resting heart rate; chr3:49488529 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs4855859 ENSG00000197582.5 GPX1P1 9.03 7.26e-16 9.35e-09 0.77 0.59 Resting heart rate; chr3:49488867 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs7643845 ENSG00000197582.5 GPX1P1 9.03 7.26e-16 9.35e-09 0.77 0.59 Resting heart rate; chr3:49493278 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs7637999 ENSG00000197582.5 GPX1P1 9.03 7.26e-16 9.35e-09 0.77 0.59 Resting heart rate; chr3:49497682 chrX:13378735~13379340:- PAAD trans rs3749237 0.576 rs3877784 ENSG00000197582.5 GPX1P1 9.03 7.26e-16 9.35e-09 0.77 0.59 Resting heart rate; chr3:49501984 chrX:13378735~13379340:- PAAD trans rs9611565 0.918 rs4820438 ENSG00000268568.1 AC007228.9 -9.02 7.58e-16 9.76e-09 -0.9 -0.59 Vitiligo; chr22:41371131 chr19:56672574~56673901:- PAAD trans rs12709013 0.514 rs8062639 ENSG00000230849.2 GOT2P2 9.02 7.66e-16 9.85e-09 0.79 0.59 Blood metabolite ratios; chr16:58800264 chr1:173141100~173142350:- PAAD trans rs12709013 0.591 rs4410065 ENSG00000230849.2 GOT2P2 9.02 7.66e-16 9.85e-09 0.79 0.59 Blood metabolite ratios; chr16:58800968 chr1:173141100~173142350:- PAAD trans rs12709013 0.591 rs2406234 ENSG00000230849.2 GOT2P2 9.02 7.66e-16 9.85e-09 0.79 0.59 Blood metabolite ratios; chr16:58801840 chr1:173141100~173142350:- PAAD trans rs12709013 0.591 rs2086206 ENSG00000230849.2 GOT2P2 9.02 7.66e-16 9.85e-09 0.79 0.59 Blood metabolite ratios; chr16:58802094 chr1:173141100~173142350:- PAAD trans rs116095464 0.558 rs28635197 ENSG00000185986.11 SDHAP3 9.02 7.68e-16 9.87e-09 0.75 0.59 Breast cancer; chr5:278956 chr5:1572222~1594620:- PAAD trans rs13190036 0.786 rs10068127 ENSG00000217325.2 PRELID1P1 -9.02 7.79e-16 9.96e-09 -1.01 -0.59 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177204786 chr6:126643488~126644390:+ PAAD trans rs17711722 0.583 rs10085415 ENSG00000226824.5 RP4-756H11.3 8.99 8.89e-16 1.13e-08 0.7 0.59 Calcium levels; chr7:65628655 chr7:66654538~66669855:+ PAAD trans rs116095464 0.558 rs1541822 ENSG00000185986.11 SDHAP3 -8.98 9.57e-16 1.17e-08 -0.75 -0.59 Breast cancer; chr5:269119 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6872854 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:208923 chr5:1572222~1594620:- PAAD trans rs116095464 0.619 rs2303741 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:218241 chr5:1572222~1594620:- PAAD trans rs116095464 0.614 rs10067482 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:219213 chr5:1572222~1594620:- PAAD trans rs116095464 0.614 rs56299325 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:220479 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs62346526 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:220499 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs56043030 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:220802 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10067021 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:221375 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9312977 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:221801 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6881920 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:222296 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6878061 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:222957 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6882584 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:223296 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs3213838 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:223775 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6555052 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:224153 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs61689490 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:224789 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs61492827 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:225659 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs56342538 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:225681 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6555055 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:226045 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6555056 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:226107 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10043002 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:226638 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs62347678 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:227381 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs73031482 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:227479 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs2162870 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:228014 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs28729548 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:228910 chr5:1572222~1594620:- PAAD trans rs116095464 0.681 rs9687745 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:229194 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9688136 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:229233 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs62347683 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:230216 chr5:1572222~1594620:- PAAD trans rs116095464 0.51 rs55750776 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:230352 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10079760 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:230663 chr5:1572222~1594620:- PAAD trans rs116095464 0.764 rs10069197 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:230707 chr5:1572222~1594620:- PAAD trans rs116095464 0.867 rs10074958 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:230713 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs2288459 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:231028 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs2288458 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:231145 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs2288457 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:231155 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7736600 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:231222 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7725227 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:233402 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7710005 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:233457 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7708182 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:234673 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10058428 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:235493 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10036253 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:238404 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10076655 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:239349 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10057492 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:239388 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs28418643 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:240744 chr5:1572222~1594620:- PAAD trans rs116095464 0.614 rs62344339 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:252880 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9687898 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:253837 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9688045 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:253920 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs112343653 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:257059 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs73024831 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:257077 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs62344345 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:257305 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6869925 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:263921 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6875291 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:264077 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6866776 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:264380 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs6874745 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:264412 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7715108 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:264546 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7730700 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:264598 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10057674 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:266698 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs1812843 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:267543 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs1971229 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:268072 chr5:1572222~1594620:- PAAD trans rs116095464 0.614 rs4371799 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:268077 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs12173244 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:269409 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs56127718 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:270158 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs55664502 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:270370 chr5:1572222~1594620:- PAAD trans rs116095464 0.51 rs7723883 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:270683 chr5:1572222~1594620:- PAAD trans rs116095464 0.614 rs10061564 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:271214 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs55776650 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:273711 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs59113266 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:279850 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs11959126 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:283765 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7356696 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:284136 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7356561 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:284266 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs59284383 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:284410 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs28558836 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:285633 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7731089 ENSG00000185986.11 SDHAP3 8.98 9.57e-16 1.17e-08 0.75 0.59 Breast cancer; chr5:290307 chr5:1572222~1594620:- PAAD trans rs3749237 0.576 rs62259939 ENSG00000197582.5 GPX1P1 8.97 1e-15 1.22e-08 0.79 0.59 Resting heart rate; chr3:49348614 chrX:13378735~13379340:- PAAD trans rs9467773 1 rs10484442 ENSG00000242375.1 RP11-498P14.3 8.97 1.04e-15 1.26e-08 0.75 0.59 Intelligence (multi-trait analysis); chr6:26555651 chr9:97195351~97197687:- PAAD trans rs3749237 0.595 rs3870338 ENSG00000197582.5 GPX1P1 8.95 1.13e-15 1.37e-08 0.75 0.59 Resting heart rate; chr3:49519618 chrX:13378735~13379340:- PAAD trans rs116095464 0.51 rs7714944 ENSG00000185986.11 SDHAP3 8.95 1.15e-15 1.39e-08 0.73 0.59 Breast cancer; chr5:231650 chr5:1572222~1594620:- PAAD trans rs13190036 0.901 rs28715668 ENSG00000217325.2 PRELID1P1 8.94 1.24e-15 1.49e-08 1.04 0.59 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177272267 chr6:126643488~126644390:+ PAAD trans rs3749237 0.576 rs4241406 ENSG00000197582.5 GPX1P1 8.94 1.26e-15 1.52e-08 0.76 0.59 Resting heart rate; chr3:49562993 chrX:13378735~13379340:- PAAD trans rs7399018 0.739 rs6580811 ENSG00000223825.5 DAZAP2P1 8.93 1.29e-15 1.55e-08 0.84 0.59 Cisplatin-induced ototoxicity; chr12:51218717 chr2:202201384~202201886:- PAAD trans rs116095464 0.558 rs7703803 ENSG00000185986.11 SDHAP3 8.93 1.29e-15 1.56e-08 0.75 0.59 Breast cancer; chr5:292196 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9654452 ENSG00000185986.11 SDHAP3 8.93 1.29e-15 1.56e-08 0.75 0.59 Breast cancer; chr5:299446 chr5:1572222~1594620:- PAAD trans rs7554547 0.778 rs2008113 ENSG00000261819.1 RP11-680G24.4 -8.92 1.35e-15 1.62e-08 -0.72 -0.59 Nonsyndromic cleft lip with cleft palate; chr1:11878809 chr16:14988259~14990160:- PAAD trans rs116095464 0.614 rs28736753 ENSG00000185986.11 SDHAP3 8.92 1.37e-15 1.64e-08 0.75 0.59 Breast cancer; chr5:273966 chr5:1572222~1594620:- PAAD trans rs8010715 0.848 rs2277483 ENSG00000248988.1 RP11-815N9.2 8.92 1.37e-15 1.65e-08 0.79 0.59 IgG glycosylation; chr14:24122683 chr4:159007119~159007835:+ PAAD trans rs8010715 0.848 rs8009511 ENSG00000248988.1 RP11-815N9.2 8.92 1.37e-15 1.65e-08 0.79 0.59 IgG glycosylation; chr14:24124771 chr4:159007119~159007835:+ PAAD trans rs8010715 0.804 rs1134334 ENSG00000248988.1 RP11-815N9.2 8.92 1.37e-15 1.65e-08 0.79 0.59 IgG glycosylation; chr14:24124905 chr4:159007119~159007835:+ PAAD trans rs9611565 0.918 rs28638318 ENSG00000268568.1 AC007228.9 -8.92 1.4e-15 1.68e-08 -0.93 -0.59 Vitiligo; chr22:41357055 chr19:56672574~56673901:- PAAD trans rs7554547 0.871 rs6661289 ENSG00000261819.1 RP11-680G24.4 8.91 1.45e-15 1.73e-08 0.72 0.59 Nonsyndromic cleft lip with cleft palate; chr1:11882724 chr16:14988259~14990160:- PAAD trans rs116095464 0.558 rs57335027 ENSG00000185986.11 SDHAP3 8.9 1.57e-15 1.87e-08 0.74 0.59 Breast cancer; chr5:262792 chr5:1572222~1594620:- PAAD trans rs8010715 0.848 rs927494 ENSG00000248988.1 RP11-815N9.2 8.89 1.61e-15 1.92e-08 0.78 0.59 IgG glycosylation; chr14:24131181 chr4:159007119~159007835:+ PAAD trans rs12709013 0.755 rs1424245 ENSG00000230849.2 GOT2P2 8.89 1.68e-15 2.01e-08 0.73 0.58 Blood metabolite ratios; chr16:58729926 chr1:173141100~173142350:- PAAD trans rs116095464 0.558 rs113796397 ENSG00000185986.11 SDHAP3 8.89 1.69e-15 2.01e-08 0.73 0.58 Breast cancer; chr5:246388 chr5:1572222~1594620:- PAAD trans rs727563 0.555 rs5751136 ENSG00000268568.1 AC007228.9 8.88 1.78e-15 2.12e-08 0.96 0.58 Crohn's disease;Inflammatory bowel disease; chr22:41679577 chr19:56672574~56673901:- PAAD trans rs9611565 0.921 rs6002333 ENSG00000268568.1 AC007228.9 -8.87 1.83e-15 2.18e-08 -0.87 -0.58 Vitiligo; chr22:41323465 chr19:56672574~56673901:- PAAD trans rs9611565 1 rs5751086 ENSG00000268568.1 AC007228.9 -8.87 1.92e-15 2.27e-08 -0.83 -0.58 Vitiligo; chr22:41372858 chr19:56672574~56673901:- PAAD trans rs55665837 0.778 rs11023212 ENSG00000236360.2 RP11-334A14.2 8.86 2.02e-15 2.39e-08 0.78 0.58 Vitamin D levels; chr11:14410163 chr1:52993201~52993702:- PAAD trans rs116095464 0.558 rs7713524 ENSG00000185986.11 SDHAP3 -8.84 2.17e-15 2.56e-08 -0.7 -0.58 Breast cancer; chr5:276085 chr5:1572222~1594620:- PAAD trans rs9467773 1 rs6456733 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26566576 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6456734 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26566737 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs1535277 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26567574 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs1884948 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26567760 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs1884949 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26567839 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9467796 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26568183 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9467797 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26568245 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs1078679 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26568513 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6932156 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26571278 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6924838 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26571528 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6925895 ENSG00000242375.1 RP11-498P14.3 8.84 2.21e-15 2.61e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26571937 chr9:97195351~97197687:- PAAD trans rs55665837 1 rs4412729 ENSG00000236360.2 RP11-334A14.2 8.83 2.42e-15 2.83e-08 0.78 0.58 Vitamin D levels; chr11:14417454 chr1:52993201~52993702:- PAAD trans rs9467773 1 rs9467773 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26498198 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6926629 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26499675 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6903973 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26499714 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs2255070 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26501549 chr9:97195351~97197687:- PAAD trans rs9467773 0.844 rs2393669 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26503645 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9461259 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26504607 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9467774 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26504808 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs3736781 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26505134 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs3736782 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26505175 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs2208331 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26507091 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9393728 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26509102 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs1056667 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26510336 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs9295694 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26512766 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs9467775 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26513207 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9393729 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26513938 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs6456732 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26514217 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs4713006 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26519644 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs6924865 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26521125 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6925703 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26521361 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6910899 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26524111 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs9461267 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26525227 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs1056347 ENSG00000242375.1 RP11-498P14.3 8.82 2.52e-15 2.93e-08 0.74 0.58 Intelligence (multi-trait analysis); chr6:26527296 chr9:97195351~97197687:- PAAD trans rs928391 0.592 rs6689750 ENSG00000227183.3 HDGFP1 -8.81 2.69e-15 3.12e-08 -0.83 -0.58 Platelet count; chr1:156828933 chrX:131646639~131646890:+ PAAD trans rs116095464 0.681 rs10060016 ENSG00000185986.11 SDHAP3 8.81 2.73e-15 3.16e-08 0.74 0.58 Breast cancer; chr5:240985 chr5:1572222~1594620:- PAAD trans rs7554547 0.838 rs885770 ENSG00000261819.1 RP11-680G24.4 8.8 2.75e-15 3.18e-08 0.7 0.58 Nonsyndromic cleft lip with cleft palate; chr1:11878699 chr16:14988259~14990160:- PAAD trans rs1816752 0.875 rs17384871 ENSG00000237917.1 PARP4P1 8.8 2.8e-15 3.24e-08 0.76 0.58 Obesity-related traits; chr13:24484959 chrY:26594851~26634652:- PAAD trans rs61990749 0.571 rs4903655 ENSG00000235400.1 RP4-641G12.4 8.78 3.09e-15 3.55e-08 1 0.58 Fibroblast growth factor basic levels; chr14:77839983 chr1:78749073~78750659:+ PAAD trans rs61990749 0.571 rs4448861 ENSG00000235400.1 RP4-641G12.4 8.78 3.09e-15 3.55e-08 1 0.58 Fibroblast growth factor basic levels; chr14:77841392 chr1:78749073~78750659:+ PAAD trans rs9467773 1 rs9393731 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26529146 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs11756120 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26529580 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9393732 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26530670 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs9358954 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26530950 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs28558133 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26531205 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs1321480 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26532514 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs10946834 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26533436 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs10946835 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26533529 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9467778 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26534515 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs2393670 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26535313 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs1321481 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26537982 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs4713008 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26538040 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs6932865 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26539938 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6933176 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26539950 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9467782 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26542545 chr9:97195351~97197687:- PAAD trans rs9467773 0.935 rs9461270 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26543882 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs4871 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26545404 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9986382 ENSG00000242375.1 RP11-498P14.3 8.78 3.1e-15 3.55e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26550391 chr9:97195351~97197687:- PAAD trans rs10242455 0.702 rs73397447 ENSG00000228834.1 RP11-249L21.4 8.78 3.2e-15 3.65e-08 1.6 0.58 Blood metabolite levels; chr7:99413326 chr6:108907615~108907873:- PAAD trans rs9467773 1 rs6922824 ENSG00000242375.1 RP11-498P14.3 -8.78 3.24e-15 3.7e-08 -0.73 -0.58 Intelligence (multi-trait analysis); chr6:26553587 chr9:97195351~97197687:- PAAD trans rs9611565 0.918 rs4822024 ENSG00000268568.1 AC007228.9 -8.77 3.29e-15 3.73e-08 -0.88 -0.58 Vitiligo; chr22:41361643 chr19:56672574~56673901:- PAAD trans rs9467773 0.967 rs6941022 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26553303 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs2224380 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26553715 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9461271 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26554740 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6930120 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26555256 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9467787 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26556541 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs767471 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26557626 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs7753565 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26559784 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6940188 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26561801 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs6940053 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26561894 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs10214634 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26564354 chr9:97195351~97197687:- PAAD trans rs9467773 0.873 rs9295698 ENSG00000242375.1 RP11-498P14.3 8.77 3.3e-15 3.73e-08 0.73 0.58 Intelligence (multi-trait analysis); chr6:26565871 chr9:97195351~97197687:- PAAD trans rs1816752 0.875 rs59686377 ENSG00000237917.1 PARP4P1 8.77 3.31e-15 3.73e-08 0.76 0.58 Obesity-related traits; chr13:24475869 chrY:26594851~26634652:- PAAD trans rs9611565 0.512 rs139572 ENSG00000268568.1 AC007228.9 -8.77 3.34e-15 3.76e-08 -1.03 -0.58 Vitiligo; chr22:41818528 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs139553 ENSG00000268568.1 AC007228.9 8.76 3.67e-15 4.1e-08 0.88 0.58 Vitiligo; chr22:41791195 chr19:56672574~56673901:- PAAD trans rs6708331 0.517 rs2028879 ENSG00000232654.1 FAM136BP 8.75 3.7e-15 4.14e-08 0.66 0.58 Obesity-related traits; chr2:70127505 chr6:3045384~3045800:+ PAAD trans rs7554547 0.871 rs11588551 ENSG00000261819.1 RP11-680G24.4 -8.75 3.89e-15 4.33e-08 -0.7 -0.58 Nonsyndromic cleft lip with cleft palate; chr1:11881879 chr16:14988259~14990160:- PAAD trans rs116095464 0.558 rs10057299 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:242020 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs13357299 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:242096 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs13354585 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:242148 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs13356367 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:242280 chr5:1572222~1594620:- PAAD trans rs116095464 0.85 rs10055295 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:243634 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10055354 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:243679 chr5:1572222~1594620:- PAAD trans rs116095464 0.614 rs62344292 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:244515 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs60251075 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:245177 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs62344300 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:246221 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10462754 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:246554 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10462755 ENSG00000185986.11 SDHAP3 8.74 4.05e-15 4.43e-08 0.74 0.58 Breast cancer; chr5:246633 chr5:1572222~1594620:- PAAD trans rs9611565 0.592 rs6519270 ENSG00000268568.1 AC007228.9 8.74 4.13e-15 4.5e-08 0.95 0.58 Vitiligo; chr22:41682662 chr19:56672574~56673901:- PAAD trans rs3749237 0.555 rs7637665 ENSG00000197582.5 GPX1P1 8.72 4.49e-15 4.83e-08 0.73 0.58 Resting heart rate; chr3:49514862 chrX:13378735~13379340:- PAAD trans rs116095464 0.867 rs7726582 ENSG00000185986.11 SDHAP3 8.72 4.6e-15 4.94e-08 0.74 0.58 Breast cancer; chr5:215234 chr5:1572222~1594620:- PAAD trans rs6708331 0.517 rs7579922 ENSG00000232654.1 FAM136BP 8.71 4.66e-15 4.99e-08 0.65 0.58 Obesity-related traits; chr2:70134781 chr6:3045384~3045800:+ PAAD trans rs116095464 0.51 rs60844864 ENSG00000185986.11 SDHAP3 8.71 4.73e-15 5.07e-08 0.74 0.58 Breast cancer; chr5:266885 chr5:1572222~1594620:- PAAD trans rs7503168 0.558 rs11656872 ENSG00000234130.2 RP13-88F20.1 -8.71 4.79e-15 5.08e-08 -1.26 -0.58 Plateletcrit; chr17:35611585 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs71381460 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35564602 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs11655098 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35567831 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs17638076 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35569254 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs12939138 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35574559 chrX:93222220~93225015:- PAAD trans rs73990293 0.737 rs12951703 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Clopidogrel active metabolite levels; chr17:35586035 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs79468963 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35590408 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs71381461 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35593601 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs34937989 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35594744 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs75787089 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35598042 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs12945102 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35601894 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs117414856 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35604168 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs71381463 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35610247 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs12936539 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35611677 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs34063751 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35611893 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs11650225 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35613947 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs17669281 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35616776 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs17606150 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35616789 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs12940422 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35620400 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs12949877 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35621517 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs80278654 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35622193 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs11650621 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35631827 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs12947274 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35635146 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs12936693 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35639391 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs112693485 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35643688 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs71381465 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35647713 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs12943224 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35650519 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs11651380 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35654677 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs11654542 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35662289 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs34874930 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35667961 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs17670584 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35671885 chrX:93222220~93225015:- PAAD trans rs7503168 0.643 rs71381467 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35693030 chrX:93222220~93225015:- PAAD trans rs7503168 0.643 rs17676508 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35693589 chrX:93222220~93225015:- PAAD trans rs7503168 0.643 rs17608253 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35699451 chrX:93222220~93225015:- PAAD trans rs73990293 0.737 rs11657558 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Clopidogrel active metabolite levels; chr17:35702305 chrX:93222220~93225015:- PAAD trans rs7503168 0.558 rs71381469 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Plateletcrit; chr17:35712127 chrX:93222220~93225015:- PAAD trans rs73990293 0.531 rs74324437 ENSG00000234130.2 RP13-88F20.1 8.71 4.79e-15 5.08e-08 1.26 0.58 Clopidogrel active metabolite levels; chr17:35712668 chrX:93222220~93225015:- PAAD trans rs10242455 0.702 rs17161726 ENSG00000228834.1 RP11-249L21.4 8.7 4.97e-15 5.26e-08 1.51 0.58 Blood metabolite levels; chr7:99410772 chr6:108907615~108907873:- PAAD trans rs9611565 0.921 rs3927 ENSG00000268568.1 AC007228.9 -8.7 4.98e-15 5.27e-08 -0.86 -0.58 Vitiligo; chr22:41326860 chr19:56672574~56673901:- PAAD trans rs116095464 0.558 rs9312957 ENSG00000185986.11 SDHAP3 8.69 5.29e-15 5.58e-08 0.78 0.58 Breast cancer; chr5:202079 chr5:1572222~1594620:- PAAD trans rs9611565 0.546 rs5758426 ENSG00000268568.1 AC007228.9 8.67 5.95e-15 6.24e-08 0.96 0.58 Vitiligo; chr22:41702759 chr19:56672574~56673901:- PAAD trans rs9467773 1 rs9357010 ENSG00000242375.1 RP11-498P14.3 8.66 6.27e-15 6.57e-08 0.73 0.57 Intelligence (multi-trait analysis); chr6:26527717 chr9:97195351~97197687:- PAAD trans rs116095464 0.542 rs28650039 ENSG00000185986.11 SDHAP3 8.66 6.29e-15 6.59e-08 0.72 0.57 Breast cancer; chr5:273839 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs55838121 ENSG00000185986.11 SDHAP3 8.66 6.38e-15 6.68e-08 0.72 0.57 Breast cancer; chr5:266775 chr5:1572222~1594620:- PAAD trans rs6732160 0.574 rs12465780 ENSG00000236165.1 PRADC1P1 -8.66 6.54e-15 6.84e-08 -0.7 -0.57 Intelligence (multi-trait analysis); chr2:73244884 chr3:36976316~36976840:+ PAAD trans rs10242455 0.557 rs59672032 ENSG00000228834.1 RP11-249L21.4 8.65 6.72e-15 7.02e-08 1.54 0.57 Blood metabolite levels; chr7:99461074 chr6:108907615~108907873:- PAAD trans rs9611565 0.592 rs80477 ENSG00000268568.1 AC007228.9 8.64 7.09e-15 7.4e-08 0.92 0.57 Vitiligo; chr22:41605179 chr19:56672574~56673901:- PAAD trans rs9467773 0.933 rs35355150 ENSG00000242375.1 RP11-498P14.3 8.64 7.13e-15 7.44e-08 0.73 0.57 Intelligence (multi-trait analysis); chr6:26525811 chr9:97195351~97197687:- PAAD trans rs6708331 0.517 rs9989836 ENSG00000232654.1 FAM136BP 8.64 7.18e-15 7.49e-08 0.64 0.57 Obesity-related traits; chr2:70115595 chr6:3045384~3045800:+ PAAD trans rs116095464 0.558 rs10075018 ENSG00000185986.11 SDHAP3 8.64 7.19e-15 7.49e-08 0.74 0.57 Breast cancer; chr5:239060 chr5:1572222~1594620:- PAAD trans rs9611565 0.592 rs5751129 ENSG00000268568.1 AC007228.9 8.64 7.27e-15 7.57e-08 0.92 0.57 Vitiligo; chr22:41619761 chr19:56672574~56673901:- PAAD trans rs13190036 1 rs13177748 ENSG00000217325.2 PRELID1P1 -8.62 7.92e-15 8.22e-08 -0.99 -0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177216953 chr6:126643488~126644390:+ PAAD trans rs13190036 1 rs34832871 ENSG00000217325.2 PRELID1P1 -8.62 7.92e-15 8.22e-08 -0.99 -0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228928 chr6:126643488~126644390:+ PAAD trans rs8010715 0.596 rs12435995 ENSG00000248988.1 RP11-815N9.2 8.61 8.44e-15 8.73e-08 0.78 0.57 IgG glycosylation; chr14:24120255 chr4:159007119~159007835:+ PAAD trans rs61990749 0.511 rs2052444 ENSG00000235400.1 RP4-641G12.4 8.61 8.86e-15 9.14e-08 0.93 0.57 Fibroblast growth factor basic levels; chr14:77846575 chr1:78749073~78750659:+ PAAD trans rs61990749 0.511 rs724263 ENSG00000235400.1 RP4-641G12.4 8.61 8.86e-15 9.14e-08 0.93 0.57 Fibroblast growth factor basic levels; chr14:77855531 chr1:78749073~78750659:+ PAAD trans rs61990749 0.511 rs10130790 ENSG00000235400.1 RP4-641G12.4 8.61 8.86e-15 9.14e-08 0.93 0.57 Fibroblast growth factor basic levels; chr14:77857849 chr1:78749073~78750659:+ PAAD trans rs61990749 0.511 rs10146144 ENSG00000235400.1 RP4-641G12.4 8.61 8.86e-15 9.14e-08 0.93 0.57 Fibroblast growth factor basic levels; chr14:77858957 chr1:78749073~78750659:+ PAAD trans rs8010715 0.52 rs12435994 ENSG00000248988.1 RP11-815N9.2 8.6 9.31e-15 9.56e-08 0.78 0.57 IgG glycosylation; chr14:24120252 chr4:159007119~159007835:+ PAAD trans rs3749237 0.615 rs11130202 ENSG00000197582.5 GPX1P1 8.59 9.94e-15 1.02e-07 0.73 0.57 Resting heart rate; chr3:49529282 chrX:13378735~13379340:- PAAD trans rs3749237 0.595 rs11720264 ENSG00000197582.5 GPX1P1 8.59 9.94e-15 1.02e-07 0.73 0.57 Resting heart rate; chr3:49542914 chrX:13378735~13379340:- PAAD trans rs116095464 0.558 rs6879656 ENSG00000185986.11 SDHAP3 8.58 9.98e-15 1.02e-07 0.73 0.57 Breast cancer; chr5:264313 chr5:1572222~1594620:- PAAD trans rs13190036 0.901 rs4631 ENSG00000217325.2 PRELID1P1 8.58 1.01e-14 1.04e-07 1.04 0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177306115 chr6:126643488~126644390:+ PAAD trans rs55665837 1 rs12804549 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14416212 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10047429 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14417486 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10047457 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14417913 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs3923294 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14419856 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs12283797 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14420716 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10832256 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14421329 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10832257 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14421770 chr1:52993201~52993702:- PAAD trans rs55665837 0.961 rs12795972 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14422229 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs12287715 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14423029 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs7121171 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14424874 chr1:52993201~52993702:- PAAD trans rs55665837 0.922 rs12287212 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14428315 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs12295723 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14428655 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs12288873 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14428919 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs12295888 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14428985 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10832268 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14443522 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10832269 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14443523 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10832271 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14445373 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10832275 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14456678 chr1:52993201~52993702:- PAAD trans rs55665837 0.961 rs12576926 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14458746 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs55665837 ENSG00000236360.2 RP11-334A14.2 8.58 1.05e-14 1.07e-07 0.75 0.57 Vitamin D levels; chr11:14473503 chr1:52993201~52993702:- PAAD trans rs916888 0.61 rs199454 ENSG00000264070.1 DND1P1 -8.58 1.05e-14 1.08e-07 -0.8 -0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45585871~45586929:+ PAAD trans rs116095464 0.558 rs7708515 ENSG00000185986.11 SDHAP3 8.57 1.08e-14 1.1e-07 0.68 0.57 Breast cancer; chr5:234874 chr5:1572222~1594620:- PAAD trans rs73099903 0.611 rs10876400 ENSG00000229939.1 RP11-111F16.2 8.57 1.12e-14 1.14e-07 0.86 0.57 Systolic blood pressure; chr12:53043071 chrX:111618808~111619094:+ PAAD trans rs6732160 0.525 rs2303907 ENSG00000236165.1 PRADC1P1 8.56 1.18e-14 1.2e-07 0.69 0.57 Intelligence (multi-trait analysis); chr2:73243369 chr3:36976316~36976840:+ PAAD trans rs6732160 0.574 rs7557055 ENSG00000236165.1 PRADC1P1 8.56 1.18e-14 1.2e-07 0.69 0.57 Intelligence (multi-trait analysis); chr2:73245542 chr3:36976316~36976840:+ PAAD trans rs6732160 0.574 rs1991612 ENSG00000236165.1 PRADC1P1 8.56 1.18e-14 1.2e-07 0.69 0.57 Intelligence (multi-trait analysis); chr2:73253373 chr3:36976316~36976840:+ PAAD trans rs6732160 0.549 rs6744529 ENSG00000236165.1 PRADC1P1 8.56 1.18e-14 1.2e-07 0.69 0.57 Intelligence (multi-trait analysis); chr2:73253741 chr3:36976316~36976840:+ PAAD trans rs116095464 0.51 rs73016876 ENSG00000185986.11 SDHAP3 8.56 1.19e-14 1.2e-07 0.78 0.57 Breast cancer; chr5:244360 chr5:1572222~1594620:- PAAD trans rs55665837 1 rs12792120 ENSG00000236360.2 RP11-334A14.2 8.55 1.23e-14 1.25e-07 0.75 0.57 Vitamin D levels; chr11:14447897 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs34382046 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14429772 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs7945167 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14430274 chr1:52993201~52993702:- PAAD trans rs55665837 0.961 rs60622588 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14435452 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs11023223 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14435566 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs11023224 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14436193 chr1:52993201~52993702:- PAAD trans rs55665837 0.961 rs11023226 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14437271 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs11023227 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14437541 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10832264 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14438436 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs11023229 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14439455 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs12276938 ENSG00000236360.2 RP11-334A14.2 8.55 1.26e-14 1.27e-07 0.75 0.57 Vitamin D levels; chr11:14441942 chr1:52993201~52993702:- PAAD trans rs116095464 0.558 rs7714335 ENSG00000185986.11 SDHAP3 8.55 1.26e-14 1.27e-07 0.74 0.57 Breast cancer; chr5:263398 chr5:1572222~1594620:- PAAD trans rs9611565 0.877 rs3817999 ENSG00000268568.1 AC007228.9 8.53 1.35e-14 1.36e-07 0.84 0.57 Vitiligo; chr22:41351713 chr19:56672574~56673901:- PAAD trans rs116095464 0.558 rs10056628 ENSG00000185986.11 SDHAP3 8.53 1.35e-14 1.36e-07 0.77 0.57 Breast cancer; chr5:279397 chr5:1572222~1594620:- PAAD trans rs916888 0.61 rs199452 ENSG00000264070.1 DND1P1 8.52 1.43e-14 1.43e-07 0.78 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45585871~45586929:+ PAAD trans rs116095464 0.51 rs10057501 ENSG00000185986.11 SDHAP3 8.52 1.45e-14 1.46e-07 0.73 0.57 Breast cancer; chr5:239430 chr5:1572222~1594620:- PAAD trans rs916888 0.61 rs199436 ENSG00000264070.1 DND1P1 -8.52 1.48e-14 1.48e-07 -0.79 -0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45585871~45586929:+ PAAD trans rs916888 0.531 rs183211 ENSG00000264070.1 DND1P1 8.52 1.48e-14 1.48e-07 0.79 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45585871~45586929:+ PAAD trans rs916888 0.61 rs199453 ENSG00000264070.1 DND1P1 8.52 1.48e-14 1.48e-07 0.79 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45585871~45586929:+ PAAD trans rs916888 0.647 rs199449 ENSG00000264070.1 DND1P1 8.52 1.48e-14 1.48e-07 0.79 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45585871~45586929:+ PAAD trans rs9467773 1 rs9467791 ENSG00000242375.1 RP11-498P14.3 -8.51 1.53e-14 1.53e-07 -0.73 -0.57 Intelligence (multi-trait analysis); chr6:26562258 chr9:97195351~97197687:- PAAD trans rs1045902 0.967 rs10207625 ENSG00000236165.1 PRADC1P1 8.51 1.57e-14 1.57e-07 0.69 0.57 Intelligence (multi-trait analysis); chr2:73237680 chr3:36976316~36976840:+ PAAD trans rs1045902 0.967 rs1469530 ENSG00000236165.1 PRADC1P1 8.51 1.57e-14 1.57e-07 0.69 0.57 Intelligence (multi-trait analysis); chr2:73237820 chr3:36976316~36976840:+ PAAD trans rs916888 0.779 rs199498 ENSG00000264070.1 DND1P1 8.51 1.59e-14 1.59e-07 0.84 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:45585871~45586929:+ PAAD trans rs916888 0.61 rs199438 ENSG00000264070.1 DND1P1 8.5 1.64e-14 1.64e-07 0.79 0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45585871~45586929:+ PAAD trans rs916888 0.61 rs199446 ENSG00000264070.1 DND1P1 -8.49 1.72e-14 1.71e-07 -0.8 -0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45585871~45586929:+ PAAD trans rs916888 0.61 rs199536 ENSG00000264070.1 DND1P1 -8.49 1.72e-14 1.71e-07 -0.8 -0.57 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45585871~45586929:+ PAAD trans rs13190036 0.901 rs28563911 ENSG00000217325.2 PRELID1P1 8.49 1.72e-14 1.72e-07 0.99 0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177287942 chr6:126643488~126644390:+ PAAD trans rs9467773 1 rs9295695 ENSG00000242375.1 RP11-498P14.3 -8.48 1.79e-14 1.78e-07 -0.71 -0.57 Intelligence (multi-trait analysis); chr6:26528022 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs9467779 ENSG00000242375.1 RP11-498P14.3 -8.48 1.79e-14 1.78e-07 -0.71 -0.57 Intelligence (multi-trait analysis); chr6:26536459 chr9:97195351~97197687:- PAAD trans rs13190036 0.551 rs4976639 ENSG00000217325.2 PRELID1P1 8.48 1.8e-14 1.79e-07 0.87 0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177123300 chr6:126643488~126644390:+ PAAD trans rs9467773 1 rs9467783 ENSG00000242375.1 RP11-498P14.3 8.48 1.8e-14 1.79e-07 0.71 0.57 Intelligence (multi-trait analysis); chr6:26542666 chr9:97195351~97197687:- PAAD trans rs55665837 1 rs10766182 ENSG00000236360.2 RP11-334A14.2 8.47 1.91e-14 1.89e-07 0.75 0.57 Vitamin D levels; chr11:14477990 chr1:52993201~52993702:- PAAD trans rs55665837 0.961 rs11023237 ENSG00000236360.2 RP11-334A14.2 8.47 1.91e-14 1.89e-07 0.75 0.57 Vitamin D levels; chr11:14478788 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs10466412 ENSG00000236360.2 RP11-334A14.2 8.47 1.91e-14 1.89e-07 0.75 0.57 Vitamin D levels; chr11:14483643 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs12364959 ENSG00000236360.2 RP11-334A14.2 8.47 1.91e-14 1.89e-07 0.75 0.57 Vitamin D levels; chr11:14485889 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs34980103 ENSG00000236360.2 RP11-334A14.2 8.47 1.91e-14 1.89e-07 0.75 0.57 Vitamin D levels; chr11:14491339 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs2305306 ENSG00000236360.2 RP11-334A14.2 8.47 1.91e-14 1.89e-07 0.75 0.57 Vitamin D levels; chr11:14513453 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs11023246 ENSG00000236360.2 RP11-334A14.2 8.47 1.91e-14 1.89e-07 0.75 0.57 Vitamin D levels; chr11:14515410 chr1:52993201~52993702:- PAAD trans rs13190036 0.792 rs6874206 ENSG00000217325.2 PRELID1P1 -8.47 1.94e-14 1.92e-07 -0.97 -0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177223970 chr6:126643488~126644390:+ PAAD trans rs13190036 0.901 rs10072499 ENSG00000217325.2 PRELID1P1 -8.47 1.94e-14 1.92e-07 -0.97 -0.57 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228236 chr6:126643488~126644390:+ PAAD trans rs116095464 0.614 rs78905930 ENSG00000185986.11 SDHAP3 8.47 1.96e-14 1.93e-07 0.73 0.57 Breast cancer; chr5:246445 chr5:1572222~1594620:- PAAD trans rs9467773 1 rs1884946 ENSG00000242375.1 RP11-498P14.3 8.47 2.01e-14 1.98e-07 0.72 0.57 Intelligence (multi-trait analysis); chr6:26545080 chr9:97195351~97197687:- PAAD trans rs9467773 0.967 rs1535276 ENSG00000242375.1 RP11-498P14.3 8.46 2.1e-14 2.07e-07 0.73 0.57 Intelligence (multi-trait analysis); chr6:26520713 chr9:97195351~97197687:- PAAD trans rs7503168 0.558 rs17670614 ENSG00000234130.2 RP13-88F20.1 8.44 2.35e-14 2.28e-07 1.25 0.56 Plateletcrit; chr17:35672348 chrX:93222220~93225015:- PAAD trans rs1816752 0.875 rs3783076 ENSG00000237917.1 PARP4P1 8.43 2.42e-14 2.35e-07 0.73 0.56 Obesity-related traits; chr13:24490319 chrY:26594851~26634652:- PAAD trans rs916888 0.61 rs199444 ENSG00000264070.1 DND1P1 8.43 2.48e-14 2.4e-07 0.79 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45585871~45586929:+ PAAD trans rs916888 0.61 rs199442 ENSG00000264070.1 DND1P1 8.43 2.48e-14 2.4e-07 0.79 0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45585871~45586929:+ PAAD trans rs55665837 1 rs11023215 ENSG00000236360.2 RP11-334A14.2 8.43 2.53e-14 2.45e-07 0.75 0.56 Vitamin D levels; chr11:14415424 chr1:52993201~52993702:- PAAD trans rs727563 0.565 rs132774 ENSG00000268568.1 AC007228.9 -8.42 2.68e-14 2.58e-07 -0.86 -0.56 Crohn's disease;Inflammatory bowel disease; chr22:41635949 chr19:56672574~56673901:- PAAD trans rs116095464 0.558 rs34629844 ENSG00000185986.11 SDHAP3 8.42 2.69e-14 2.6e-07 0.76 0.56 Breast cancer; chr5:200714 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs1968374 ENSG00000185986.11 SDHAP3 8.41 2.75e-14 2.65e-07 0.73 0.56 Breast cancer; chr5:248910 chr5:1572222~1594620:- PAAD trans rs3749237 0.595 rs1050088 ENSG00000197582.5 GPX1P1 -8.41 2.82e-14 2.72e-07 -0.72 -0.56 Resting heart rate; chr3:49533449 chrX:13378735~13379340:- PAAD trans rs10242455 0.702 rs1045012 ENSG00000228834.1 RP11-249L21.4 8.4 2.93e-14 2.81e-07 1.56 0.56 Blood metabolite levels; chr7:99386731 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs10251282 ENSG00000228834.1 RP11-249L21.4 8.4 2.93e-14 2.81e-07 1.56 0.56 Blood metabolite levels; chr7:99392613 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs28460612 ENSG00000228834.1 RP11-249L21.4 8.4 2.93e-14 2.81e-07 1.56 0.56 Blood metabolite levels; chr7:99395582 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs28753399 ENSG00000228834.1 RP11-249L21.4 8.4 2.93e-14 2.81e-07 1.56 0.56 Blood metabolite levels; chr7:99399636 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs28668326 ENSG00000228834.1 RP11-249L21.4 8.4 2.93e-14 2.81e-07 1.56 0.56 Blood metabolite levels; chr7:99400530 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs917152 ENSG00000228834.1 RP11-249L21.4 8.4 2.93e-14 2.81e-07 1.56 0.56 Blood metabolite levels; chr7:99406874 chr6:108907615~108907873:- PAAD trans rs13190036 0.901 rs6898107 ENSG00000217325.2 PRELID1P1 8.4 2.93e-14 2.81e-07 0.95 0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177252694 chr6:126643488~126644390:+ PAAD trans rs116095464 0.558 rs10052012 ENSG00000185986.11 SDHAP3 8.4 3e-14 2.88e-07 0.75 0.56 Breast cancer; chr5:231793 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10077076 ENSG00000185986.11 SDHAP3 8.4 3e-14 2.88e-07 0.75 0.56 Breast cancer; chr5:231825 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10080225 ENSG00000185986.11 SDHAP3 8.4 3e-14 2.88e-07 0.75 0.56 Breast cancer; chr5:232060 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10475136 ENSG00000185986.11 SDHAP3 8.4 3e-14 2.88e-07 0.75 0.56 Breast cancer; chr5:232681 chr5:1572222~1594620:- PAAD trans rs916888 0.647 rs199524 ENSG00000264070.1 DND1P1 -8.4 3.01e-14 2.88e-07 -0.79 -0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45585871~45586929:+ PAAD trans rs916888 0.647 rs199523 ENSG00000264070.1 DND1P1 -8.4 3.01e-14 2.88e-07 -0.79 -0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45585871~45586929:+ PAAD trans rs55665837 1 rs10832278 ENSG00000236360.2 RP11-334A14.2 8.39 3.2e-14 3.06e-07 0.74 0.56 Vitamin D levels; chr11:14475073 chr1:52993201~52993702:- PAAD trans rs877636 0.692 rs2271194 ENSG00000225071.1 GS1-184P14.2 -8.38 3.23e-14 3.1e-07 -0.64 -0.56 Cognitive function; chr12:56083910 chrX:24429573~24429920:- PAAD trans rs10242455 0.571 rs13438288 ENSG00000228834.1 RP11-249L21.4 8.38 3.35e-14 3.19e-07 1.58 0.56 Blood metabolite levels; chr7:99318791 chr6:108907615~108907873:- PAAD trans rs13190036 0.901 rs10056655 ENSG00000217325.2 PRELID1P1 8.37 3.43e-14 3.26e-07 0.95 0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177249350 chr6:126643488~126644390:+ PAAD trans rs7121616 0.92 rs7109445 ENSG00000234176.1 HSPA8P1 8.37 3.49e-14 3.31e-07 0.65 0.56 Breast cancer; chr11:123094779 chrX:121203182~121205014:- PAAD trans rs116095464 0.558 rs6866632 ENSG00000185986.11 SDHAP3 8.36 3.6e-14 3.42e-07 0.72 0.56 Breast cancer; chr5:264314 chr5:1572222~1594620:- PAAD trans rs12709013 0.636 rs1646256 ENSG00000230849.2 GOT2P2 8.36 3.61e-14 3.43e-07 0.74 0.56 Blood metabolite ratios; chr16:58712114 chr1:173141100~173142350:- PAAD trans rs12367822 0.597 rs2371559 ENSG00000121089.4 NACA3P -8.36 3.66e-14 3.47e-07 -0.77 -0.56 Platelet aggregation; chr12:56805073 chr4:164943290~164943937:+ PAAD trans rs116095464 0.558 rs28636067 ENSG00000185986.11 SDHAP3 8.35 3.86e-14 3.66e-07 0.77 0.56 Breast cancer; chr5:199300 chr5:1572222~1594620:- PAAD trans rs55665837 0.54 rs11023302 ENSG00000236360.2 RP11-334A14.2 8.35 3.92e-14 3.71e-07 0.72 0.56 Vitamin D levels; chr11:14672389 chr1:52993201~52993702:- PAAD trans rs13190036 0.591 rs78523677 ENSG00000217325.2 PRELID1P1 -8.34 4.07e-14 3.85e-07 -0.87 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177124102 chr6:126643488~126644390:+ PAAD trans rs13190036 0.901 rs6556309 ENSG00000217325.2 PRELID1P1 8.33 4.43e-14 4.18e-07 0.95 0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177266834 chr6:126643488~126644390:+ PAAD trans rs55665837 0.519 rs1451677 ENSG00000236360.2 RP11-334A14.2 8.33 4.48e-14 4.22e-07 0.72 0.56 Vitamin D levels; chr11:14724466 chr1:52993201~52993702:- PAAD trans rs116095464 0.558 rs6878087 ENSG00000185986.11 SDHAP3 -8.33 4.5e-14 4.25e-07 -0.69 -0.56 Breast cancer; chr5:223002 chr5:1572222~1594620:- PAAD trans rs13190036 1 rs13175695 ENSG00000217325.2 PRELID1P1 8.32 4.59e-14 4.33e-07 0.96 0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177272810 chr6:126643488~126644390:+ PAAD trans rs55665837 0.54 rs10832299 ENSG00000236360.2 RP11-334A14.2 8.32 4.62e-14 4.35e-07 0.72 0.56 Vitamin D levels; chr11:14747846 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs2305305 ENSG00000236360.2 RP11-334A14.2 8.31 4.85e-14 4.57e-07 0.74 0.56 Vitamin D levels; chr11:14519396 chr1:52993201~52993702:- PAAD trans rs13190036 1 rs628506 ENSG00000217325.2 PRELID1P1 -8.31 5.02e-14 4.73e-07 -0.94 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107422 chr6:126643488~126644390:+ PAAD trans rs13190036 1 rs6880798 ENSG00000217325.2 PRELID1P1 8.3 5.25e-14 4.93e-07 0.95 0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177277456 chr6:126643488~126644390:+ PAAD trans rs55665837 0.54 rs4757261 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14648256 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs10128681 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14680030 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs7938266 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14687778 chr1:52993201~52993702:- PAAD trans rs55665837 0.52 rs10766189 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14712377 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs10832294 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14725881 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs10219313 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14728303 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs4144487 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14728905 chr1:52993201~52993702:- PAAD trans rs55665837 0.519 rs10832297 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14736191 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs12788030 ENSG00000236360.2 RP11-334A14.2 8.3 5.27e-14 4.94e-07 0.72 0.56 Vitamin D levels; chr11:14743138 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs1007392 ENSG00000236360.2 RP11-334A14.2 8.3 5.32e-14 4.98e-07 0.72 0.56 Vitamin D levels; chr11:14753045 chr1:52993201~52993702:- PAAD trans rs55665837 0.523 rs10832301 ENSG00000236360.2 RP11-334A14.2 8.3 5.32e-14 4.98e-07 0.72 0.56 Vitamin D levels; chr11:14767418 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs12416696 ENSG00000236360.2 RP11-334A14.2 8.3 5.32e-14 4.98e-07 0.72 0.56 Vitamin D levels; chr11:14769343 chr1:52993201~52993702:- PAAD trans rs55665837 0.54 rs10766192 ENSG00000236360.2 RP11-334A14.2 8.3 5.32e-14 4.98e-07 0.72 0.56 Vitamin D levels; chr11:14790140 chr1:52993201~52993702:- PAAD trans rs116095464 0.558 rs62346506 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:201479 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9312956 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:201697 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs62346508 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:203553 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10059907 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:205245 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10060089 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:205450 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10068203 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:206503 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs73029475 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:206854 chr5:1572222~1594620:- PAAD trans rs116095464 1 rs28416084 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:217525 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9312978 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:221815 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9312979 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:221942 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs9687621 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:229079 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs56081398 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:247203 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10065584 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:253882 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs56298907 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:283165 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs7356535 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:284002 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs55833259 ENSG00000185986.11 SDHAP3 8.3 5.39e-14 5.03e-07 0.76 0.56 Breast cancer; chr5:286613 chr5:1572222~1594620:- PAAD trans rs116095464 0.558 rs10065239 ENSG00000185986.11 SDHAP3 8.29 5.47e-14 5.1e-07 0.75 0.56 Breast cancer; chr5:275173 chr5:1572222~1594620:- PAAD trans rs61990749 0.571 rs11628049 ENSG00000235400.1 RP4-641G12.4 -8.29 5.53e-14 5.15e-07 -0.92 -0.56 Fibroblast growth factor basic levels; chr14:77842108 chr1:78749073~78750659:+ PAAD trans rs7395662 0.794 rs11511967 ENSG00000134612.10 FOLH1B -8.29 5.69e-14 5.3e-07 -0.68 -0.56 HDL cholesterol; chr11:48798901 chr11:89639227~89698718:+ PAAD trans rs6708331 0.517 rs6546572 ENSG00000232654.1 FAM136BP 8.28 5.84e-14 5.43e-07 0.62 0.56 Obesity-related traits; chr2:70146510 chr6:3045384~3045800:+ PAAD trans rs55665837 1 rs10832254 ENSG00000236360.2 RP11-334A14.2 8.27 6.33e-14 5.85e-07 0.74 0.56 Vitamin D levels; chr11:14413152 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs11023214 ENSG00000236360.2 RP11-334A14.2 8.27 6.33e-14 5.85e-07 0.74 0.56 Vitamin D levels; chr11:14414713 chr1:52993201~52993702:- PAAD trans rs55665837 1 rs11023216 ENSG00000236360.2 RP11-334A14.2 8.27 6.33e-14 5.85e-07 0.74 0.56 Vitamin D levels; chr11:14415607 chr1:52993201~52993702:- PAAD trans rs877636 0.692 rs10876870 ENSG00000225071.1 GS1-184P14.2 -8.27 6.33e-14 5.85e-07 -0.64 -0.56 Cognitive function; chr12:56084218 chrX:24429573~24429920:- PAAD trans rs877636 0.692 rs7971751 ENSG00000225071.1 GS1-184P14.2 -8.27 6.33e-14 5.85e-07 -0.64 -0.56 Cognitive function; chr12:56084874 chrX:24429573~24429920:- PAAD trans rs6708331 0.517 rs6546570 ENSG00000232654.1 FAM136BP 8.27 6.41e-14 5.92e-07 0.63 0.56 Obesity-related traits; chr2:70122901 chr6:3045384~3045800:+ PAAD trans rs1816752 0.564 rs9511223 ENSG00000237917.1 PARP4P1 -8.26 6.73e-14 6.2e-07 -0.69 -0.56 Obesity-related traits; chr13:24380142 chrY:26594851~26634652:- PAAD trans rs116095464 0.558 rs9654453 ENSG00000185986.11 SDHAP3 8.25 6.89e-14 6.35e-07 0.75 0.56 Breast cancer; chr5:299506 chr5:1572222~1594620:- PAAD trans rs13190036 0.551 rs7732930 ENSG00000217325.2 PRELID1P1 -8.25 7.19e-14 6.59e-07 -0.86 -0.56 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177121593 chr6:126643488~126644390:+ PAAD trans rs73990293 0.737 rs4531775 ENSG00000234130.2 RP13-88F20.1 8.25 7.2e-14 6.59e-07 1.23 0.56 Clopidogrel active metabolite levels; chr17:35559919 chrX:93222220~93225015:- PAAD trans rs916888 0.61 rs199530 ENSG00000264070.1 DND1P1 -8.24 7.61e-14 6.96e-07 -0.76 -0.56 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:45585871~45586929:+ PAAD trans rs6708331 0.54 rs6546576 ENSG00000232654.1 FAM136BP 8.23 7.71e-14 7.04e-07 0.62 0.56 Obesity-related traits; chr2:70174356 chr6:3045384~3045800:+ PAAD trans rs7503168 0.558 rs12945980 ENSG00000234130.2 RP13-88F20.1 8.22 8.12e-14 7.41e-07 1.19 0.55 Plateletcrit; chr17:35603002 chrX:93222220~93225015:- PAAD trans rs2950393 0.611 rs7138821 ENSG00000121089.4 NACA3P -8.22 8.31e-14 7.57e-07 -0.78 -0.55 Platelet distribution width; chr12:56796206 chr4:164943290~164943937:+ PAAD trans rs916888 0.61 rs142167 ENSG00000264070.1 DND1P1 -8.21 8.59e-14 7.82e-07 -0.78 -0.55 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:45585871~45586929:+ PAAD trans rs1816752 0.608 rs4770690 ENSG00000224976.2 PARP4P2 8.2 9.24e-14 8.39e-07 0.67 0.55 Obesity-related traits; chr13:24467049 chr13:19349137~19407962:+ PAAD trans rs9611565 0.921 rs4822021 ENSG00000268568.1 AC007228.9 -8.19 9.97e-14 9.03e-07 -0.83 -0.55 Vitiligo; chr22:41330049 chr19:56672574~56673901:- PAAD trans rs1816752 0.624 rs9553312 ENSG00000224976.2 PARP4P2 8.19 1e-13 9.06e-07 0.68 0.55 Obesity-related traits; chr13:24474055 chr13:19349137~19407962:+ PAAD trans rs9467773 1 rs1321479 ENSG00000242375.1 RP11-498P14.3 -8.17 1.09e-13 9.82e-07 -0.7 -0.55 Intelligence (multi-trait analysis); chr6:26501669 chr9:97195351~97197687:- PAAD trans rs9611565 0.57 rs12159188 ENSG00000268568.1 AC007228.9 8.17 1.11e-13 1.01e-06 0.86 0.55 Vitiligo; chr22:41725121 chr19:56672574~56673901:- PAAD trans rs7973618 1 rs7973618 ENSG00000121089.4 NACA3P -8.17 1.13e-13 1.02e-06 -0.73 -0.55 Mean platelet volume; chr12:56625659 chr4:164943290~164943937:+ PAAD trans rs7395662 0.895 rs1121000 ENSG00000134612.10 FOLH1B -8.15 1.22e-13 1.1e-06 -0.67 -0.55 HDL cholesterol; chr11:48690238 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs8189397 ENSG00000134612.10 FOLH1B -8.15 1.22e-13 1.1e-06 -0.67 -0.55 HDL cholesterol; chr11:48690318 chr11:89639227~89698718:+ PAAD trans rs9467773 0.935 rs1056668 ENSG00000242375.1 RP11-498P14.3 8.15 1.22e-13 1.1e-06 0.73 0.55 Intelligence (multi-trait analysis); chr6:26510377 chr9:97195351~97197687:- PAAD trans rs9467773 1 rs12526680 ENSG00000242375.1 RP11-498P14.3 8.15 1.24e-13 1.11e-06 0.72 0.55 Intelligence (multi-trait analysis); chr6:26550726 chr9:97195351~97197687:- PAAD trans rs6708331 0.564 rs4632370 ENSG00000232654.1 FAM136BP 8.15 1.27e-13 1.15e-06 0.61 0.55 Obesity-related traits; chr2:70149693 chr6:3045384~3045800:+ PAAD trans rs2731664 0.792 rs337374 ENSG00000215571.5 GRK6P1 -8.14 1.34e-13 1.21e-06 -0.72 -0.55 Intelligence (multi-trait analysis); chr5:177463415 chr13:21319156~21320866:+ PAAD trans rs6732160 0.593 rs2288630 ENSG00000236165.1 PRADC1P1 8.13 1.38e-13 1.24e-06 0.67 0.55 Intelligence (multi-trait analysis); chr2:73230424 chr3:36976316~36976840:+ PAAD trans rs7395662 0.889 rs11039972 ENSG00000134612.10 FOLH1B 8.13 1.43e-13 1.27e-06 0.66 0.55 HDL cholesterol; chr11:48737700 chr11:89639227~89698718:+ PAAD trans rs7395662 0.697 rs11530291 ENSG00000134612.10 FOLH1B 8.13 1.43e-13 1.27e-06 0.66 0.55 HDL cholesterol; chr11:48742651 chr11:89639227~89698718:+ PAAD trans rs7395662 0.892 rs11040010 ENSG00000134612.10 FOLH1B 8.13 1.43e-13 1.27e-06 0.66 0.55 HDL cholesterol; chr11:48755377 chr11:89639227~89698718:+ PAAD trans rs7395662 0.784 rs75694945 ENSG00000134612.10 FOLH1B 8.13 1.43e-13 1.27e-06 0.66 0.55 HDL cholesterol; chr11:48843911 chr11:89639227~89698718:+ PAAD trans rs7395662 0.784 rs79037165 ENSG00000134612.10 FOLH1B 8.13 1.43e-13 1.27e-06 0.66 0.55 HDL cholesterol; chr11:48843912 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs11039903 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48658153 chr11:89639227~89698718:+ PAAD trans rs7395662 0.895 rs2221553 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48667232 chr11:89639227~89698718:+ PAAD trans rs7395662 0.817 rs1848151 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48671106 chr11:89639227~89698718:+ PAAD trans rs7395662 0.889 rs1848158 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48675742 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs9645642 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48683903 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs11039937 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48691030 chr11:89639227~89698718:+ PAAD trans rs7395662 0.895 rs1827971 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48696950 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs4882170 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48702662 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs2865923 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48703403 chr11:89639227~89698718:+ PAAD trans rs7395662 0.7 rs11493668 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48706030 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs2135681 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48706836 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs2135680 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48706873 chr11:89639227~89698718:+ PAAD trans rs7395662 0.895 rs8186350 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48717709 chr11:89639227~89698718:+ PAAD trans rs7395662 0.781 rs11499902 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48721179 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs10454482 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48733425 chr11:89639227~89698718:+ PAAD trans rs7395662 0.895 rs4882238 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48733988 chr11:89639227~89698718:+ PAAD trans rs7395662 0.547 rs10769442 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48743475 chr11:89639227~89698718:+ PAAD trans rs7395662 0.746 rs8186207 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48743813 chr11:89639227~89698718:+ PAAD trans rs7395662 0.622 rs2865620 ENSG00000134612.10 FOLH1B -8.13 1.43e-13 1.27e-06 -0.66 -0.55 HDL cholesterol; chr11:48786359 chr11:89639227~89698718:+ PAAD trans rs12709013 0.66 rs30839 ENSG00000230849.2 GOT2P2 8.12 1.48e-13 1.3e-06 0.71 0.55 Blood metabolite ratios; chr16:58711437 chr1:173141100~173142350:- PAAD trans rs12709013 0.636 rs30835 ENSG00000230849.2 GOT2P2 8.12 1.48e-13 1.3e-06 0.71 0.55 Blood metabolite ratios; chr16:58714117 chr1:173141100~173142350:- PAAD trans rs7395662 0.667 rs2865612 ENSG00000134612.10 FOLH1B 8.12 1.48e-13 1.3e-06 0.66 0.55 HDL cholesterol; chr11:48758670 chr11:89639227~89698718:+ PAAD trans rs7395662 0.658 rs2865610 ENSG00000134612.10 FOLH1B -8.12 1.48e-13 1.3e-06 -0.66 -0.55 HDL cholesterol; chr11:48751065 chr11:89639227~89698718:+ PAAD trans rs7395662 0.819 rs12269855 ENSG00000134612.10 FOLH1B -8.12 1.48e-13 1.3e-06 -0.66 -0.55 HDL cholesterol; chr11:48757100 chr11:89639227~89698718:+ PAAD trans rs7395662 0.818 rs34486360 ENSG00000134612.10 FOLH1B -8.12 1.48e-13 1.3e-06 -0.66 -0.55 HDL cholesterol; chr11:48760920 chr11:89639227~89698718:+ PAAD trans rs13190036 1 rs13185316 ENSG00000217325.2 PRELID1P1 -8.12 1.5e-13 1.32e-06 -0.93 -0.55 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177213339 chr6:126643488~126644390:+ PAAD trans rs941207 0.526 rs2950387 ENSG00000121089.4 NACA3P -8.11 1.57e-13 1.38e-06 -0.73 -0.55 Platelet count; chr12:56627222 chr4:164943290~164943937:+ PAAD trans rs9467773 0.935 rs1884947 ENSG00000242375.1 RP11-498P14.3 8.11 1.58e-13 1.39e-06 0.72 0.55 Intelligence (multi-trait analysis); chr6:26553045 chr9:97195351~97197687:- PAAD trans rs55665837 1 rs10832276 ENSG00000236360.2 RP11-334A14.2 8.11 1.61e-13 1.42e-06 0.73 0.55 Vitamin D levels; chr11:14461728 chr1:52993201~52993702:- PAAD trans rs1816752 0.646 rs7328391 ENSG00000224976.2 PARP4P2 8.1 1.65e-13 1.45e-06 0.68 0.55 Obesity-related traits; chr13:24470325 chr13:19349137~19407962:+ PAAD trans rs116095464 0.558 rs10055993 ENSG00000185986.11 SDHAP3 8.1 1.67e-13 1.47e-06 0.75 0.55 Breast cancer; chr5:264181 chr5:1572222~1594620:- PAAD trans rs7395662 1 rs12366208 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48541576 chr11:89639227~89698718:+ PAAD trans rs7395662 0.864 rs12366262 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48541920 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882117 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48543916 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882015 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48544021 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882017 ENSG00000134612.10 FOLH1B 8.1 1.71e-13 1.49e-06 0.67 0.55 HDL cholesterol; chr11:48548630 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs11039826 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48550846 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs6485865 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48554437 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7107184 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48555517 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs6485872 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48558158 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs7952580 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48573654 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882019 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48577196 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882134 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48577243 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7483920 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48578417 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs6485888 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48583787 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10838971 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48585072 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7944356 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48588602 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039857 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48589301 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039859 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48590436 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7928083 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48591596 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882021 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48594414 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7129386 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48595142 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10838975 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48596063 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs12418721 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48596899 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs7108559 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48597599 chr11:89639227~89698718:+ PAAD trans rs7395662 0.864 rs7482764 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48604306 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs34584314 ENSG00000134612.10 FOLH1B -8.1 1.71e-13 1.49e-06 -0.67 -0.55 HDL cholesterol; chr11:48606134 chr11:89639227~89698718:+ PAAD trans rs9467773 0.935 rs11752946 ENSG00000242375.1 RP11-498P14.3 8.09 1.73e-13 1.5e-06 0.72 0.55 Intelligence (multi-trait analysis); chr6:26560136 chr9:97195351~97197687:- PAAD trans rs13190036 0.551 rs1052432 ENSG00000217325.2 PRELID1P1 -8.09 1.73e-13 1.5e-06 -0.86 -0.55 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177137188 chr6:126643488~126644390:+ PAAD trans rs7395662 0.857 rs11040074 ENSG00000134612.10 FOLH1B -8.09 1.76e-13 1.53e-06 -0.66 -0.55 HDL cholesterol; chr11:48835174 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs60772766 ENSG00000134612.10 FOLH1B -8.09 1.78e-13 1.54e-06 -0.66 -0.55 HDL cholesterol; chr11:48699459 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs11493665 ENSG00000134612.10 FOLH1B -8.09 1.78e-13 1.54e-06 -0.66 -0.55 HDL cholesterol; chr11:48699483 chr11:89639227~89698718:+ PAAD trans rs13190036 0.579 rs13159114 ENSG00000217325.2 PRELID1P1 8.07 1.94e-13 1.68e-06 1.06 0.55 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177234807 chr6:126643488~126644390:+ PAAD trans rs7395662 0.597 rs2135684 ENSG00000134612.10 FOLH1B -8.07 1.95e-13 1.69e-06 -0.66 -0.55 HDL cholesterol; chr11:48726917 chr11:89639227~89698718:+ PAAD trans rs10242455 0.702 rs58348977 ENSG00000228834.1 RP11-249L21.4 8.06 2.03e-13 1.76e-06 1.42 0.55 Blood metabolite levels; chr7:99590391 chr6:108907615~108907873:- PAAD trans rs11023332 1 rs11023332 ENSG00000236360.2 RP11-334A14.2 8.06 2.06e-13 1.78e-06 0.71 0.55 Vitamin D levels;Adiponectin levels; chr11:14762564 chr1:52993201~52993702:- PAAD trans rs7395662 0.963 rs11040016 ENSG00000134612.10 FOLH1B 8.06 2.1e-13 1.82e-06 0.65 0.55 HDL cholesterol; chr11:48761945 chr11:89639227~89698718:+ PAAD trans rs10037055 0.853 rs9313749 ENSG00000217325.2 PRELID1P1 -8.06 2.11e-13 1.82e-06 -0.79 -0.55 Migraine without aura; chr5:177170693 chr6:126643488~126644390:+ PAAD trans rs1816752 0.646 rs9507355 ENSG00000224976.2 PARP4P2 -8.06 2.13e-13 1.84e-06 -0.67 -0.55 Obesity-related traits; chr13:24476819 chr13:19349137~19407962:+ PAAD trans rs941207 0.526 rs2242497 ENSG00000121089.4 NACA3P -8.06 2.15e-13 1.85e-06 -0.73 -0.55 Platelet count; chr12:56598846 chr4:164943290~164943937:+ PAAD trans rs55665837 0.54 rs12290926 ENSG00000236360.2 RP11-334A14.2 8.05 2.19e-13 1.89e-06 0.7 0.55 Vitamin D levels; chr11:14673500 chr1:52993201~52993702:- PAAD trans rs2731664 0.792 rs652242 ENSG00000215571.5 GRK6P1 8.05 2.26e-13 1.95e-06 0.71 0.55 Intelligence (multi-trait analysis); chr5:177446009 chr13:21319156~21320866:+ PAAD trans rs2731664 0.792 rs465670 ENSG00000215571.5 GRK6P1 8.05 2.26e-13 1.95e-06 0.71 0.55 Intelligence (multi-trait analysis); chr5:177450623 chr13:21319156~21320866:+ PAAD trans rs2731664 0.792 rs335452 ENSG00000215571.5 GRK6P1 8.05 2.26e-13 1.95e-06 0.71 0.55 Intelligence (multi-trait analysis); chr5:177452670 chr13:21319156~21320866:+ PAAD trans rs6708331 0.517 rs13017427 ENSG00000232654.1 FAM136BP 8.04 2.32e-13 2e-06 0.61 0.55 Obesity-related traits; chr2:70154399 chr6:3045384~3045800:+ PAAD trans rs6708331 0.54 rs9677885 ENSG00000232654.1 FAM136BP 8.04 2.32e-13 2e-06 0.61 0.55 Obesity-related traits; chr2:70154687 chr6:3045384~3045800:+ PAAD trans rs6708331 0.54 rs9679269 ENSG00000232654.1 FAM136BP 8.04 2.32e-13 2e-06 0.61 0.55 Obesity-related traits; chr2:70154696 chr6:3045384~3045800:+ PAAD trans rs13253073 1 rs4480092 ENSG00000260318.1 COX6CP1 8.04 2.34e-13 2.01e-06 1.15 0.55 Glucose homeostasis traits; chr8:99873372 chr16:11903923~11904137:- PAAD trans rs6732160 0.631 rs7557285 ENSG00000236165.1 PRADC1P1 8.04 2.38e-13 2.05e-06 0.65 0.55 Intelligence (multi-trait analysis); chr2:73215684 chr3:36976316~36976840:+ PAAD trans rs10242455 0.702 rs2293256 ENSG00000228834.1 RP11-249L21.4 -8.03 2.46e-13 2.11e-06 -1.31 -0.55 Blood metabolite levels; chr7:99460078 chr6:108907615~108907873:- PAAD trans rs116095464 0.614 rs10059220 ENSG00000185986.11 SDHAP3 8.03 2.47e-13 2.12e-06 0.74 0.55 Breast cancer; chr5:242698 chr5:1572222~1594620:- PAAD trans rs7395662 0.819 rs11039913 ENSG00000134612.10 FOLH1B -8.03 2.55e-13 2.19e-06 -0.66 -0.55 HDL cholesterol; chr11:48670529 chr11:89639227~89698718:+ PAAD trans rs7395662 0.864 rs11039917 ENSG00000134612.10 FOLH1B -8.03 2.55e-13 2.19e-06 -0.66 -0.55 HDL cholesterol; chr11:48673876 chr11:89639227~89698718:+ PAAD trans rs7395662 0.824 rs4882180 ENSG00000134612.10 FOLH1B -8.03 2.55e-13 2.19e-06 -0.66 -0.55 HDL cholesterol; chr11:48727805 chr11:89639227~89698718:+ PAAD trans rs8081395 0.741 rs2645462 ENSG00000187870.7 RNFT1P3 8.02 2.64e-13 2.25e-06 0.65 0.55 White blood cell count; chr17:59906198 chr17:20743333~20754501:- PAAD trans rs8081395 0.711 rs1292034 ENSG00000187870.7 RNFT1P3 8.02 2.64e-13 2.25e-06 0.65 0.55 White blood cell count; chr17:59912499 chr17:20743333~20754501:- PAAD trans rs8081395 0.741 rs180532 ENSG00000187870.7 RNFT1P3 8.02 2.64e-13 2.25e-06 0.65 0.55 White blood cell count; chr17:59925936 chr17:20743333~20754501:- PAAD trans rs8081395 0.741 rs180530 ENSG00000187870.7 RNFT1P3 8.02 2.64e-13 2.25e-06 0.65 0.55 White blood cell count; chr17:59926233 chr17:20743333~20754501:- PAAD trans rs8081395 0.741 rs180519 ENSG00000187870.7 RNFT1P3 8.02 2.64e-13 2.25e-06 0.65 0.55 White blood cell count; chr17:59938910 chr17:20743333~20754501:- PAAD trans rs8081395 0.707 rs1024637 ENSG00000187870.7 RNFT1P3 -8.02 2.64e-13 2.25e-06 -0.65 -0.55 White blood cell count; chr17:59961532 chr17:20743333~20754501:- PAAD trans rs7395662 1 rs7482528 ENSG00000134612.10 FOLH1B -8.01 2.76e-13 2.36e-06 -0.67 -0.54 HDL cholesterol; chr11:48618500 chr11:89639227~89698718:+ PAAD trans rs6732160 0.691 rs10197935 ENSG00000236165.1 PRADC1P1 8 2.88e-13 2.46e-06 0.65 0.54 Intelligence (multi-trait analysis); chr2:73185234 chr3:36976316~36976840:+ PAAD trans rs55665837 0.54 rs3206554 ENSG00000236360.2 RP11-334A14.2 8 2.92e-13 2.49e-06 0.7 0.54 Vitamin D levels; chr11:14776399 chr1:52993201~52993702:- PAAD trans rs1816752 0.646 rs7322323 ENSG00000224976.2 PARP4P2 8 2.95e-13 2.51e-06 0.67 0.54 Obesity-related traits; chr13:24479189 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs7322329 ENSG00000224976.2 PARP4P2 8 2.95e-13 2.51e-06 0.67 0.54 Obesity-related traits; chr13:24479193 chr13:19349137~19407962:+ PAAD trans rs1816752 0.608 rs9511290 ENSG00000224976.2 PARP4P2 8 2.96e-13 2.52e-06 0.67 0.54 Obesity-related traits; chr13:24467189 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511291 ENSG00000224976.2 PARP4P2 8 2.96e-13 2.52e-06 0.67 0.54 Obesity-related traits; chr13:24467609 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511292 ENSG00000224976.2 PARP4P2 8 2.96e-13 2.52e-06 0.67 0.54 Obesity-related traits; chr13:24467623 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511293 ENSG00000224976.2 PARP4P2 8 2.96e-13 2.52e-06 0.67 0.54 Obesity-related traits; chr13:24467747 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511294 ENSG00000224976.2 PARP4P2 8 2.96e-13 2.52e-06 0.67 0.54 Obesity-related traits; chr13:24467773 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511295 ENSG00000224976.2 PARP4P2 8 2.96e-13 2.52e-06 0.67 0.54 Obesity-related traits; chr13:24467794 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511296 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24467962 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9634401 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468072 chr13:19349137~19407962:+ PAAD trans rs1816752 0.624 rs9634402 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468119 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9634403 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468211 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9581064 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468251 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs4770692 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468689 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs4769361 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468834 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs4770693 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468835 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs4770694 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468891 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs4770695 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24468895 chr13:19349137~19407962:+ PAAD trans rs1816752 0.624 rs9507354 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24469227 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs7337981 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24469245 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs4480642 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24471358 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9551108 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24471434 chr13:19349137~19407962:+ PAAD trans rs1816752 0.603 rs4238178 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24472344 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs2862903 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24473169 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs7319207 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24473220 chr13:19349137~19407962:+ PAAD trans rs1816752 0.583 rs9553311 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24474016 chr13:19349137~19407962:+ PAAD trans rs1816752 0.524 rs7996445 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24475329 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs7995190 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24475709 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs6490937 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24475834 chr13:19349137~19407962:+ PAAD trans rs1816752 0.608 rs7326664 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24475868 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511301 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24477034 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs7332220 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24477081 chr13:19349137~19407962:+ PAAD trans rs1816752 0.624 rs11149109 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24477290 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511302 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24477580 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs8002599 ENSG00000224976.2 PARP4P2 8 2.98e-13 2.53e-06 0.67 0.54 Obesity-related traits; chr13:24478486 chr13:19349137~19407962:+ PAAD trans rs2731664 0.74 rs2731670 ENSG00000215571.5 GRK6P1 -8 2.99e-13 2.53e-06 -0.72 -0.54 Intelligence (multi-trait analysis); chr5:177421018 chr13:21319156~21320866:+ PAAD trans rs1816752 0.624 rs2096093 ENSG00000224976.2 PARP4P2 8 3.03e-13 2.57e-06 0.67 0.54 Obesity-related traits; chr13:24472753 chr13:19349137~19407962:+ PAAD trans rs9611565 0.918 rs2281333 ENSG00000268568.1 AC007228.9 -7.99 3.1e-13 2.63e-06 -0.81 -0.54 Vitiligo; chr22:41353626 chr19:56672574~56673901:- PAAD trans rs1816752 0.646 rs4770700 ENSG00000224976.2 PARP4P2 7.99 3.12e-13 2.64e-06 0.67 0.54 Obesity-related traits; chr13:24494796 chr13:19349137~19407962:+ PAAD trans rs1816752 0.624 rs7330766 ENSG00000224976.2 PARP4P2 7.99 3.12e-13 2.64e-06 0.67 0.54 Obesity-related traits; chr13:24495579 chr13:19349137~19407962:+ PAAD trans rs1816752 0.603 rs7984094 ENSG00000224976.2 PARP4P2 7.99 3.12e-13 2.64e-06 0.67 0.54 Obesity-related traits; chr13:24496212 chr13:19349137~19407962:+ PAAD trans rs1816752 0.624 rs4770701 ENSG00000224976.2 PARP4P2 7.99 3.12e-13 2.64e-06 0.67 0.54 Obesity-related traits; chr13:24508806 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs750390 ENSG00000224976.2 PARP4P2 7.99 3.16e-13 2.67e-06 0.66 0.54 Obesity-related traits; chr13:24461603 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs750389 ENSG00000224976.2 PARP4P2 7.99 3.16e-13 2.67e-06 0.66 0.54 Obesity-related traits; chr13:24461677 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs750388 ENSG00000224976.2 PARP4P2 7.99 3.16e-13 2.67e-06 0.66 0.54 Obesity-related traits; chr13:24461690 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs2902359 ENSG00000224976.2 PARP4P2 7.99 3.16e-13 2.67e-06 0.66 0.54 Obesity-related traits; chr13:24461783 chr13:19349137~19407962:+ PAAD trans rs2731664 0.792 rs466256 ENSG00000215571.5 GRK6P1 7.98 3.27e-13 2.76e-06 0.72 0.54 Intelligence (multi-trait analysis); chr5:177448955 chr13:21319156~21320866:+ PAAD trans rs7395662 1 rs7925955 ENSG00000134612.10 FOLH1B -7.98 3.28e-13 2.76e-06 -0.66 -0.54 HDL cholesterol; chr11:48625981 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs12806328 ENSG00000134612.10 FOLH1B -7.98 3.28e-13 2.76e-06 -0.66 -0.54 HDL cholesterol; chr11:48626419 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs6485906 ENSG00000134612.10 FOLH1B -7.98 3.28e-13 2.76e-06 -0.66 -0.54 HDL cholesterol; chr11:48630109 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs6485907 ENSG00000134612.10 FOLH1B -7.98 3.28e-13 2.76e-06 -0.66 -0.54 HDL cholesterol; chr11:48630143 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039890 ENSG00000134612.10 FOLH1B -7.98 3.28e-13 2.76e-06 -0.66 -0.54 HDL cholesterol; chr11:48631916 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs4882146 ENSG00000134612.10 FOLH1B -7.98 3.28e-13 2.76e-06 -0.66 -0.54 HDL cholesterol; chr11:48638617 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs8186263 ENSG00000134612.10 FOLH1B -7.98 3.28e-13 2.76e-06 -0.66 -0.54 HDL cholesterol; chr11:48716383 chr11:89639227~89698718:+ PAAD trans rs6732160 0.691 rs6728147 ENSG00000236165.1 PRADC1P1 -7.98 3.35e-13 2.82e-06 -0.66 -0.54 Intelligence (multi-trait analysis); chr2:73196362 chr3:36976316~36976840:+ PAAD trans rs6732160 0.691 rs11886257 ENSG00000236165.1 PRADC1P1 7.98 3.36e-13 2.82e-06 0.66 0.54 Intelligence (multi-trait analysis); chr2:73189745 chr3:36976316~36976840:+ PAAD trans rs6732160 0.691 rs13402225 ENSG00000236165.1 PRADC1P1 7.98 3.36e-13 2.82e-06 0.66 0.54 Intelligence (multi-trait analysis); chr2:73189778 chr3:36976316~36976840:+ PAAD trans rs6732160 0.691 rs1960233 ENSG00000236165.1 PRADC1P1 7.98 3.36e-13 2.82e-06 0.66 0.54 Intelligence (multi-trait analysis); chr2:73194250 chr3:36976316~36976840:+ PAAD trans rs6732160 0.691 rs2007191 ENSG00000236165.1 PRADC1P1 7.98 3.36e-13 2.82e-06 0.66 0.54 Intelligence (multi-trait analysis); chr2:73194335 chr3:36976316~36976840:+ PAAD trans rs6732160 0.691 rs7599223 ENSG00000236165.1 PRADC1P1 7.98 3.36e-13 2.82e-06 0.66 0.54 Intelligence (multi-trait analysis); chr2:73199975 chr3:36976316~36976840:+ PAAD trans rs6732160 0.691 rs13432787 ENSG00000236165.1 PRADC1P1 7.98 3.36e-13 2.82e-06 0.66 0.54 Intelligence (multi-trait analysis); chr2:73203106 chr3:36976316~36976840:+ PAAD trans rs1816752 0.646 rs2862905 ENSG00000224976.2 PARP4P2 7.98 3.37e-13 2.83e-06 0.68 0.54 Obesity-related traits; chr13:24485142 chr13:19349137~19407962:+ PAAD trans rs7395662 0.824 rs12785858 ENSG00000134612.10 FOLH1B -7.98 3.39e-13 2.84e-06 -0.66 -0.54 HDL cholesterol; chr11:48757254 chr11:89639227~89698718:+ PAAD trans rs8081395 0.775 rs2645482 ENSG00000187870.7 RNFT1P3 7.97 3.51e-13 2.94e-06 0.66 0.54 White blood cell count; chr17:59865754 chr17:20743333~20754501:- PAAD trans rs8081395 0.805 rs2645485 ENSG00000187870.7 RNFT1P3 7.97 3.51e-13 2.94e-06 0.66 0.54 White blood cell count; chr17:59866920 chr17:20743333~20754501:- PAAD trans rs1816752 0.646 rs7328391 ENSG00000237917.1 PARP4P1 -7.97 3.51e-13 2.94e-06 -0.72 -0.54 Obesity-related traits; chr13:24470325 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs7997248 ENSG00000224976.2 PARP4P2 7.97 3.52e-13 2.94e-06 0.67 0.54 Obesity-related traits; chr13:24507050 chr13:19349137~19407962:+ PAAD trans rs116095464 0.558 rs62347677 ENSG00000185986.11 SDHAP3 7.97 3.56e-13 2.98e-06 0.71 0.54 Breast cancer; chr5:227338 chr5:1572222~1594620:- PAAD trans rs7395662 1 rs7938880 ENSG00000134612.10 FOLH1B -7.95 3.94e-13 3.28e-06 -0.66 -0.54 HDL cholesterol; chr11:48620602 chr11:89639227~89698718:+ PAAD trans rs877636 0.669 rs7297175 ENSG00000225071.1 GS1-184P14.2 -7.95 4e-13 3.34e-06 -0.61 -0.54 Cognitive function; chr12:56080024 chrX:24429573~24429920:- PAAD trans rs6708331 0.517 rs9989876 ENSG00000232654.1 FAM136BP 7.94 4.06e-13 3.38e-06 0.6 0.54 Obesity-related traits; chr2:70115578 chr6:3045384~3045800:+ PAAD trans rs6708331 0.517 rs10496178 ENSG00000232654.1 FAM136BP 7.94 4.06e-13 3.38e-06 0.6 0.54 Obesity-related traits; chr2:70115683 chr6:3045384~3045800:+ PAAD trans rs1816752 0.646 rs2862905 ENSG00000237917.1 PARP4P1 -7.94 4.08e-13 3.4e-06 -0.72 -0.54 Obesity-related traits; chr13:24485142 chrY:26594851~26634652:- PAAD trans rs2727020 0.553 rs61904166 ENSG00000134612.10 FOLH1B -7.94 4.11e-13 3.42e-06 -0.62 -0.54 Coronary artery disease; chr11:49559909 chr11:89639227~89698718:+ PAAD trans rs2727020 0.553 rs7479975 ENSG00000134612.10 FOLH1B -7.94 4.11e-13 3.42e-06 -0.62 -0.54 Coronary artery disease; chr11:49560412 chr11:89639227~89698718:+ PAAD trans rs2731664 0.792 rs335467 ENSG00000215571.5 GRK6P1 7.94 4.19e-13 3.48e-06 0.72 0.54 Intelligence (multi-trait analysis); chr5:177463641 chr13:21319156~21320866:+ PAAD trans rs13190036 0.551 rs11955537 ENSG00000217325.2 PRELID1P1 -7.93 4.38e-13 3.63e-06 -0.84 -0.54 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147087 chr6:126643488~126644390:+ PAAD trans rs10037055 0.636 rs13166688 ENSG00000217325.2 PRELID1P1 -7.93 4.38e-13 3.63e-06 -0.84 -0.54 Migraine without aura; chr5:177156965 chr6:126643488~126644390:+ PAAD trans rs13190036 0.551 rs7710269 ENSG00000217325.2 PRELID1P1 -7.93 4.38e-13 3.63e-06 -0.84 -0.54 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177187528 chr6:126643488~126644390:+ PAAD trans rs13190036 0.515 rs2878686 ENSG00000217325.2 PRELID1P1 -7.93 4.38e-13 3.63e-06 -0.84 -0.54 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206748 chr6:126643488~126644390:+ PAAD trans rs11039571 0.588 rs61917001 ENSG00000134612.10 FOLH1B 7.91 4.86e-13 4e-06 0.83 0.54 D-dimer levels; chr11:48212115 chr11:89639227~89698718:+ PAAD trans rs9467773 0.933 rs2024970 ENSG00000242375.1 RP11-498P14.3 7.9 5.27e-13 4.33e-06 0.71 0.54 Intelligence (multi-trait analysis); chr6:26497292 chr9:97195351~97197687:- PAAD trans rs7395662 0.963 rs6485900 ENSG00000134612.10 FOLH1B -7.89 5.4e-13 4.44e-06 -0.66 -0.54 HDL cholesterol; chr11:48615863 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs6485903 ENSG00000134612.10 FOLH1B -7.89 5.4e-13 4.44e-06 -0.66 -0.54 HDL cholesterol; chr11:48617452 chr11:89639227~89698718:+ PAAD trans rs6732160 0.65 rs7560224 ENSG00000236165.1 PRADC1P1 7.89 5.59e-13 4.58e-06 0.64 0.54 Intelligence (multi-trait analysis); chr2:73179054 chr3:36976316~36976840:+ PAAD trans rs877636 0.692 rs2271194 ENSG00000234513.1 AC073072.7 -7.89 5.59e-13 4.59e-06 -0.61 -0.54 Cognitive function; chr12:56083910 chr7:22773646~22773993:- PAAD trans rs6732160 0.691 rs4536673 ENSG00000236165.1 PRADC1P1 7.88 5.78e-13 4.73e-06 0.65 0.54 Intelligence (multi-trait analysis); chr2:73186334 chr3:36976316~36976840:+ PAAD trans rs6732160 0.657 rs10171459 ENSG00000236165.1 PRADC1P1 7.88 5.78e-13 4.74e-06 0.65 0.54 Intelligence (multi-trait analysis); chr2:73207600 chr3:36976316~36976840:+ PAAD trans rs9611565 0.571 rs2050032 ENSG00000268568.1 AC007228.9 7.88 5.82e-13 4.77e-06 0.9 0.54 Vitiligo; chr22:41756425 chr19:56672574~56673901:- PAAD trans rs9611565 1 rs5758314 ENSG00000268568.1 AC007228.9 -7.88 5.83e-13 4.77e-06 -0.79 -0.54 Vitiligo; chr22:41366519 chr19:56672574~56673901:- PAAD trans rs7937890 1 rs2970335 ENSG00000236360.2 RP11-334A14.2 7.88 5.86e-13 4.8e-06 0.73 0.54 Mitochondrial DNA levels; chr11:14303855 chr1:52993201~52993702:- PAAD trans rs2731664 0.792 rs163199 ENSG00000215571.5 GRK6P1 7.87 6.33e-13 5.17e-06 0.71 0.54 Intelligence (multi-trait analysis); chr5:177463066 chr13:21319156~21320866:+ PAAD trans rs7395662 0.581 rs10769445 ENSG00000134612.10 FOLH1B 7.86 6.42e-13 5.22e-06 0.65 0.54 HDL cholesterol; chr11:48744042 chr11:89639227~89698718:+ PAAD trans rs7395662 0.654 rs12289625 ENSG00000134612.10 FOLH1B 7.86 6.42e-13 5.22e-06 0.65 0.54 HDL cholesterol; chr11:48795690 chr11:89639227~89698718:+ PAAD trans rs7395662 0.625 rs11040006 ENSG00000134612.10 FOLH1B 7.86 6.69e-13 5.42e-06 0.65 0.54 HDL cholesterol; chr11:48752750 chr11:89639227~89698718:+ PAAD trans rs9899728 0.572 rs4365317 ENSG00000234925.2 ATP5HP4 7.85 7e-13 5.67e-06 0.88 0.54 Alzheimer's disease or small vessel stroke; chr17:75063725 chr12:68642519~68642993:- PAAD trans rs2731664 0.765 rs2630766 ENSG00000215571.5 GRK6P1 7.84 7.4e-13 5.97e-06 0.71 0.54 Intelligence (multi-trait analysis); chr5:177447940 chr13:21319156~21320866:+ PAAD trans rs6732160 0.684 rs2043095 ENSG00000236165.1 PRADC1P1 7.84 7.44e-13 6e-06 0.65 0.54 Intelligence (multi-trait analysis); chr2:73180314 chr3:36976316~36976840:+ PAAD trans rs9611565 0.649 rs139540 ENSG00000268568.1 AC007228.9 -7.84 7.54e-13 6.08e-06 -0.83 -0.54 Vitiligo; chr22:41782036 chr19:56672574~56673901:- PAAD trans rs2731664 0.792 rs2731662 ENSG00000215571.5 GRK6P1 -7.83 7.57e-13 6.1e-06 -0.71 -0.54 Intelligence (multi-trait analysis); chr5:177445493 chr13:21319156~21320866:+ PAAD trans rs7395662 0.611 rs11040073 ENSG00000134612.10 FOLH1B 7.83 7.61e-13 6.13e-06 0.65 0.54 HDL cholesterol; chr11:48834072 chr11:89639227~89698718:+ PAAD trans rs1816752 0.716 rs9553330 ENSG00000237917.1 PARP4P1 -7.83 7.65e-13 6.16e-06 -0.7 -0.54 Obesity-related traits; chr13:24516018 chrY:26594851~26634652:- PAAD trans rs1816752 0.669 rs3783072 ENSG00000224976.2 PARP4P2 7.83 7.69e-13 6.19e-06 0.65 0.54 Obesity-related traits; chr13:24493258 chr13:19349137~19407962:+ PAAD trans rs7937890 0.904 rs11023169 ENSG00000236360.2 RP11-334A14.2 -7.83 7.79e-13 6.27e-06 -0.73 -0.54 Mitochondrial DNA levels; chr11:14269439 chr1:52993201~52993702:- PAAD trans rs8081395 0.737 rs4968401 ENSG00000187870.7 RNFT1P3 -7.83 7.89e-13 6.34e-06 -0.64 -0.54 White blood cell count; chr17:59963369 chr17:20743333~20754501:- PAAD trans rs8081395 0.741 rs1292055 ENSG00000187870.7 RNFT1P3 7.82 7.99e-13 6.43e-06 0.64 0.54 White blood cell count; chr17:59881707 chr17:20743333~20754501:- PAAD trans rs8081395 0.741 rs1292051 ENSG00000187870.7 RNFT1P3 7.82 7.99e-13 6.43e-06 0.64 0.54 White blood cell count; chr17:59886562 chr17:20743333~20754501:- PAAD trans rs7395662 0.791 rs4347396 ENSG00000134612.10 FOLH1B 7.82 8.08e-13 6.49e-06 0.65 0.54 HDL cholesterol; chr11:48874377 chr11:89639227~89698718:+ PAAD trans rs7395662 0.759 rs4347397 ENSG00000134612.10 FOLH1B 7.82 8.08e-13 6.49e-06 0.65 0.54 HDL cholesterol; chr11:48874394 chr11:89639227~89698718:+ PAAD trans rs9611565 0.649 rs139559 ENSG00000268568.1 AC007228.9 -7.82 8.08e-13 6.49e-06 -0.84 -0.54 Vitiligo; chr22:41795632 chr19:56672574~56673901:- PAAD trans rs6688567 1 rs6688567 ENSG00000213331.4 RP11-713C19.2 7.82 8.1e-13 6.5e-06 0.66 0.54 Mosquito bite size; chr1:173614275 chr4:187970273~187971284:+ PAAD trans rs2731664 0.792 rs2630765 ENSG00000215571.5 GRK6P1 7.82 8.1e-13 6.5e-06 0.71 0.54 Intelligence (multi-trait analysis); chr5:177449824 chr13:21319156~21320866:+ PAAD trans rs13190036 0.681 rs28461408 ENSG00000217325.2 PRELID1P1 7.82 8.12e-13 6.52e-06 1.01 0.54 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177235292 chr6:126643488~126644390:+ PAAD trans rs7937890 0.967 rs963212 ENSG00000236360.2 RP11-334A14.2 -7.82 8.25e-13 6.61e-06 -0.73 -0.54 Mitochondrial DNA levels; chr11:14303186 chr1:52993201~52993702:- PAAD trans rs7937890 1 rs2970334 ENSG00000236360.2 RP11-334A14.2 -7.82 8.25e-13 6.61e-06 -0.73 -0.54 Mitochondrial DNA levels; chr11:14307809 chr1:52993201~52993702:- PAAD trans rs9899728 0.572 rs9915968 ENSG00000234925.2 ATP5HP4 7.82 8.27e-13 6.63e-06 0.88 0.54 Alzheimer's disease or small vessel stroke; chr17:75063521 chr12:68642519~68642993:- PAAD trans rs7395662 0.759 rs11529442 ENSG00000134612.10 FOLH1B 7.81 8.47e-13 6.78e-06 0.65 0.54 HDL cholesterol; chr11:48798434 chr11:89639227~89698718:+ PAAD trans rs1816752 0.646 rs750390 ENSG00000237917.1 PARP4P1 -7.81 8.47e-13 6.78e-06 -0.7 -0.54 Obesity-related traits; chr13:24461603 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs750389 ENSG00000237917.1 PARP4P1 -7.81 8.47e-13 6.78e-06 -0.7 -0.54 Obesity-related traits; chr13:24461677 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs750388 ENSG00000237917.1 PARP4P1 -7.81 8.47e-13 6.78e-06 -0.7 -0.54 Obesity-related traits; chr13:24461690 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs2902359 ENSG00000237917.1 PARP4P1 -7.81 8.47e-13 6.78e-06 -0.7 -0.54 Obesity-related traits; chr13:24461783 chrY:26594851~26634652:- PAAD trans rs9899728 0.764 rs7219493 ENSG00000234925.2 ATP5HP4 7.81 8.56e-13 6.85e-06 0.84 0.54 Alzheimer's disease or small vessel stroke; chr17:75048093 chr12:68642519~68642993:- PAAD trans rs10037055 0.741 rs4976640 ENSG00000217325.2 PRELID1P1 -7.81 8.69e-13 6.95e-06 -0.78 -0.54 Migraine without aura; chr5:177125006 chr6:126643488~126644390:+ PAAD trans rs7395662 0.791 rs12273724 ENSG00000134612.10 FOLH1B 7.81 8.71e-13 6.97e-06 0.65 0.54 HDL cholesterol; chr11:48824158 chr11:89639227~89698718:+ PAAD trans rs10037055 0.898 rs4976636 ENSG00000217325.2 PRELID1P1 -7.81 8.76e-13 7e-06 -0.78 -0.54 Migraine without aura; chr5:177118091 chr6:126643488~126644390:+ PAAD trans rs10037055 0.898 rs4976637 ENSG00000217325.2 PRELID1P1 -7.81 8.76e-13 7e-06 -0.78 -0.54 Migraine without aura; chr5:177118141 chr6:126643488~126644390:+ PAAD trans rs9611565 0.879 rs5758311 ENSG00000268568.1 AC007228.9 -7.81 8.8e-13 7.03e-06 -0.81 -0.54 Vitiligo; chr22:41363371 chr19:56672574~56673901:- PAAD trans rs9611565 0.879 rs4820437 ENSG00000268568.1 AC007228.9 -7.81 8.8e-13 7.03e-06 -0.81 -0.54 Vitiligo; chr22:41365286 chr19:56672574~56673901:- PAAD trans rs1816752 0.716 rs7995304 ENSG00000237917.1 PARP4P1 -7.81 8.87e-13 7.08e-06 -0.71 -0.53 Obesity-related traits; chr13:24514284 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs2862902 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24461965 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs734715 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24462041 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs730030 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24462509 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs7992667 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24462821 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs7995958 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24462895 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs8002741 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24462918 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs7998198 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24462979 chr13:19349137~19407962:+ PAAD trans rs1816752 0.609 rs7998203 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24462989 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs7998600 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24463222 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511279 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24463348 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511280 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24463364 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9511281 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24463441 chr13:19349137~19407962:+ PAAD trans rs1816752 0.624 rs9511282 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24463597 chr13:19349137~19407962:+ PAAD trans rs1816752 0.583 rs9511283 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24463656 chr13:19349137~19407962:+ PAAD trans rs1816752 0.583 rs9511284 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24463660 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9507351 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24465118 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs4770688 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24466007 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs4770689 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24466008 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs12431171 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24466380 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs12854523 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24466460 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs9578740 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24466692 chr13:19349137~19407962:+ PAAD trans rs1816752 0.631 rs4769358 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24466940 chr13:19349137~19407962:+ PAAD trans rs1816752 0.608 rs4769359 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24466966 chr13:19349137~19407962:+ PAAD trans rs1816752 0.608 rs4769360 ENSG00000224976.2 PARP4P2 7.8 8.98e-13 7.14e-06 0.65 0.53 Obesity-related traits; chr13:24467016 chr13:19349137~19407962:+ PAAD trans rs1816752 0.692 rs6490944 ENSG00000224976.2 PARP4P2 7.8 9.06e-13 7.2e-06 0.67 0.53 Obesity-related traits; chr13:24513866 chr13:19349137~19407962:+ PAAD trans rs1816752 0.669 rs2862906 ENSG00000237917.1 PARP4P1 -7.8 9.12e-13 7.24e-06 -0.71 -0.53 Obesity-related traits; chr13:24494482 chrY:26594851~26634652:- PAAD trans rs1816752 0.716 rs1539096 ENSG00000237917.1 PARP4P1 -7.8 9.12e-13 7.24e-06 -0.71 -0.53 Obesity-related traits; chr13:24501721 chrY:26594851~26634652:- PAAD trans rs1816752 0.692 rs2282409 ENSG00000237917.1 PARP4P1 -7.8 9.12e-13 7.24e-06 -0.71 -0.53 Obesity-related traits; chr13:24512388 chrY:26594851~26634652:- PAAD trans rs1816752 0.692 rs6490944 ENSG00000237917.1 PARP4P1 -7.8 9.25e-13 7.34e-06 -0.71 -0.53 Obesity-related traits; chr13:24513866 chrY:26594851~26634652:- PAAD trans rs12709013 0.635 rs6993 ENSG00000230849.2 GOT2P2 7.79 9.52e-13 7.55e-06 0.7 0.53 Blood metabolite ratios; chr16:58707463 chr1:173141100~173142350:- PAAD trans rs1816752 0.716 rs7995304 ENSG00000224976.2 PARP4P2 7.79 9.55e-13 7.57e-06 0.67 0.53 Obesity-related traits; chr13:24514284 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs3783073 ENSG00000224976.2 PARP4P2 7.79 9.73e-13 7.7e-06 0.66 0.53 Obesity-related traits; chr13:24493222 chr13:19349137~19407962:+ PAAD trans rs1816752 0.646 rs1361578 ENSG00000224976.2 PARP4P2 7.79 9.9e-13 7.84e-06 0.66 0.53 Obesity-related traits; chr13:24491117 chr13:19349137~19407962:+ PAAD trans rs877636 0.692 rs11171739 ENSG00000225071.1 GS1-184P14.2 7.78 1.01e-12 7.99e-06 0.6 0.53 Cognitive function; chr12:56076841 chrX:24429573~24429920:- PAAD trans rs7937890 0.904 rs7484197 ENSG00000236360.2 RP11-334A14.2 7.78 1.01e-12 8.01e-06 0.73 0.53 Mitochondrial DNA levels; chr11:14262108 chr1:52993201~52993702:- PAAD trans rs9611565 0.921 rs8137373 ENSG00000268568.1 AC007228.9 7.78 1.02e-12 8.08e-06 0.78 0.53 Vitiligo; chr22:41333212 chr19:56672574~56673901:- PAAD trans rs7395662 0.655 rs2202458 ENSG00000134612.10 FOLH1B 7.78 1.03e-12 8.16e-06 0.64 0.53 HDL cholesterol; chr11:48834995 chr11:89639227~89698718:+ PAAD trans rs3740713 0.669 rs2896526 ENSG00000235847.2 LDHAP7 7.78 1.04e-12 8.19e-06 0.89 0.53 Amyotrophic lateral sclerosis (sporadic); chr11:18398259 chr2:84777259~84778223:- PAAD trans rs1816752 0.669 rs2862906 ENSG00000224976.2 PARP4P2 7.78 1.05e-12 8.28e-06 0.67 0.53 Obesity-related traits; chr13:24494482 chr13:19349137~19407962:+ PAAD trans rs1816752 0.716 rs1539096 ENSG00000224976.2 PARP4P2 7.78 1.05e-12 8.28e-06 0.67 0.53 Obesity-related traits; chr13:24501721 chr13:19349137~19407962:+ PAAD trans rs1816752 0.692 rs2282409 ENSG00000224976.2 PARP4P2 7.78 1.05e-12 8.28e-06 0.67 0.53 Obesity-related traits; chr13:24512388 chr13:19349137~19407962:+ PAAD trans rs9467773 0.935 rs4573 ENSG00000242375.1 RP11-498P14.3 7.78 1.05e-12 8.32e-06 0.69 0.53 Intelligence (multi-trait analysis); chr6:26546580 chr9:97195351~97197687:- PAAD trans rs12709013 0.536 rs1646260 ENSG00000233719.3 GOT2P3 7.77 1.08e-12 8.52e-06 0.69 0.53 Blood metabolite ratios; chr16:58734951 chr12:9641802~9643007:+ PAAD trans rs1816752 0.669 rs9553309 ENSG00000224976.2 PARP4P2 7.77 1.1e-12 8.65e-06 0.66 0.53 Obesity-related traits; chr13:24471476 chr13:19349137~19407962:+ PAAD trans rs7395662 0.624 rs11040162 ENSG00000134612.10 FOLH1B 7.77 1.12e-12 8.83e-06 0.65 0.53 HDL cholesterol; chr11:48938439 chr11:89639227~89698718:+ PAAD trans rs13190036 1 rs655623 ENSG00000217325.2 PRELID1P1 7.76 1.12e-12 8.84e-06 0.94 0.53 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177107515 chr6:126643488~126644390:+ PAAD trans rs9611565 0.649 rs5758466 ENSG00000268568.1 AC007228.9 7.76 1.12e-12 8.85e-06 0.85 0.53 Vitiligo; chr22:41780055 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs6002480 ENSG00000268568.1 AC007228.9 -7.76 1.13e-12 8.89e-06 -0.85 -0.53 Vitiligo; chr22:41780913 chr19:56672574~56673901:- PAAD trans rs7395662 0.593 rs8188975 ENSG00000134612.10 FOLH1B 7.76 1.14e-12 8.98e-06 0.64 0.53 HDL cholesterol; chr11:48870325 chr11:89639227~89698718:+ PAAD trans rs7395662 0.687 rs11602892 ENSG00000134612.10 FOLH1B -7.76 1.17e-12 9.17e-06 -0.65 -0.53 HDL cholesterol; chr11:48937600 chr11:89639227~89698718:+ PAAD trans rs7786410 1 rs7786410 ENSG00000204894.4 RP11-208G20.2 7.75 1.22e-12 9.54e-06 0.88 0.53 Age-related hearing impairment; chr7:55854630 chr7:152367171~152367260:+ PAAD trans rs7395662 0.724 rs10400308 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48869694 chr11:89639227~89698718:+ PAAD trans rs7395662 0.709 rs11040113 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48874101 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs7120743 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48901093 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs7119550 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48906102 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs10839173 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48909206 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs1857786 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48945872 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs11040172 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48946945 chr11:89639227~89698718:+ PAAD trans rs7395662 0.824 rs12787989 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48949335 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs1809986 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48965987 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs12418254 ENSG00000134612.10 FOLH1B -7.74 1.27e-12 9.89e-06 -0.64 -0.53 HDL cholesterol; chr11:48966710 chr11:89639227~89698718:+ PAAD trans rs7395662 0.553 rs11040122 ENSG00000134612.10 FOLH1B 7.74 1.27e-12 9.89e-06 0.64 0.53 HDL cholesterol; chr11:48879486 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10839171 ENSG00000134612.10 FOLH1B 7.74 1.27e-12 9.89e-06 0.64 0.53 HDL cholesterol; chr11:48901482 chr11:89639227~89698718:+ PAAD trans rs7395662 0.791 rs7945791 ENSG00000134612.10 FOLH1B 7.74 1.27e-12 9.89e-06 0.64 0.53 HDL cholesterol; chr11:48914788 chr11:89639227~89698718:+ PAAD trans rs7395662 0.791 rs11040136 ENSG00000134612.10 FOLH1B 7.74 1.27e-12 9.89e-06 0.64 0.53 HDL cholesterol; chr11:48918239 chr11:89639227~89698718:+ PAAD trans rs7395662 0.617 rs1976509 ENSG00000134612.10 FOLH1B 7.74 1.27e-12 9.89e-06 0.64 0.53 HDL cholesterol; chr11:48943051 chr11:89639227~89698718:+ PAAD trans rs55665837 0.502 rs4757269 ENSG00000236360.2 RP11-334A14.2 7.74 1.27e-12 9.94e-06 0.7 0.53 Vitamin D levels; chr11:14814646 chr1:52993201~52993702:- PAAD trans rs1816752 0.669 rs9553309 ENSG00000237917.1 PARP4P1 -7.74 1.28e-12 1e-05 -0.7 -0.53 Obesity-related traits; chr13:24471476 chrY:26594851~26634652:- PAAD trans rs4240897 0.561 rs12043045 ENSG00000261819.1 RP11-680G24.4 7.74 1.32e-12 1.03e-05 0.68 0.53 Tuberculosis; chr1:11900294 chr16:14988259~14990160:- PAAD trans rs4240897 0.544 rs7542773 ENSG00000261819.1 RP11-680G24.4 7.74 1.32e-12 1.03e-05 0.68 0.53 Tuberculosis; chr1:11901073 chr16:14988259~14990160:- PAAD trans rs13253073 1 rs10955222 ENSG00000260318.1 COX6CP1 -7.73 1.37e-12 1.07e-05 -1.11 -0.53 Glucose homeostasis traits; chr8:99875122 chr16:11903923~11904137:- PAAD trans rs7395662 0.963 rs12800770 ENSG00000134612.10 FOLH1B -7.73 1.37e-12 1.07e-05 -0.66 -0.53 HDL cholesterol; chr11:48583375 chr11:89639227~89698718:+ PAAD trans rs6477998 0.702 rs7861707 ENSG00000238072.1 RP11-305M3.2 7.71 1.49e-12 1.16e-05 0.75 0.53 Hematology traits; chr9:113251428 chr7:129410113~129410370:- PAAD trans rs7121616 0.961 rs11218976 ENSG00000234176.1 HSPA8P1 7.71 1.57e-12 1.21e-05 0.62 0.53 Breast cancer; chr11:123090950 chrX:121203182~121205014:- PAAD trans rs3740713 0.592 rs73434674 ENSG00000235847.2 LDHAP7 7.7 1.58e-12 1.22e-05 0.89 0.53 Amyotrophic lateral sclerosis (sporadic); chr11:18389950 chr2:84777259~84778223:- PAAD trans rs7395662 1 rs2221559 ENSG00000134612.10 FOLH1B 7.7 1.61e-12 1.25e-05 0.64 0.53 HDL cholesterol; chr11:48686421 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs8189391 ENSG00000134612.10 FOLH1B 7.7 1.62e-12 1.25e-05 0.64 0.53 HDL cholesterol; chr11:48838237 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs12419576 ENSG00000134612.10 FOLH1B -7.7 1.62e-12 1.25e-05 -0.65 -0.53 HDL cholesterol; chr11:48560092 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs61930968 ENSG00000134612.10 FOLH1B -7.7 1.62e-12 1.25e-05 -0.65 -0.53 HDL cholesterol; chr11:48560097 chr11:89639227~89698718:+ PAAD trans rs9611565 0.614 rs4822053 ENSG00000268568.1 AC007228.9 -7.7 1.62e-12 1.25e-05 -0.81 -0.53 Vitiligo; chr22:41816932 chr19:56672574~56673901:- PAAD trans rs877636 0.669 rs7297175 ENSG00000212829.8 RPS26P3 -7.7 1.64e-12 1.27e-05 -0.62 -0.53 Cognitive function; chr12:56080024 chr9:9090898~9091245:+ PAAD trans rs2731664 0.792 rs385981 ENSG00000215571.5 GRK6P1 7.69 1.68e-12 1.3e-05 0.7 0.53 Intelligence (multi-trait analysis); chr5:177459538 chr13:21319156~21320866:+ PAAD trans rs9611565 0.694 rs5758411 ENSG00000268568.1 AC007228.9 7.69 1.68e-12 1.3e-05 0.83 0.53 Vitiligo; chr22:41683730 chr19:56672574~56673901:- PAAD trans rs9611565 0.918 rs6002351 ENSG00000268568.1 AC007228.9 -7.69 1.69e-12 1.31e-05 -0.8 -0.53 Vitiligo; chr22:41361219 chr19:56672574~56673901:- PAAD trans rs13253073 1 rs13252579 ENSG00000260318.1 COX6CP1 7.69 1.69e-12 1.31e-05 1.17 0.53 Glucose homeostasis traits; chr8:99885073 chr16:11903923~11904137:- PAAD trans rs13253073 1 rs13253073 ENSG00000260318.1 COX6CP1 7.69 1.69e-12 1.31e-05 1.17 0.53 Glucose homeostasis traits; chr8:99885155 chr16:11903923~11904137:- PAAD trans rs13253073 1 rs13259066 ENSG00000260318.1 COX6CP1 7.69 1.69e-12 1.31e-05 1.17 0.53 Glucose homeostasis traits; chr8:99889455 chr16:11903923~11904137:- PAAD trans rs2731664 0.792 rs335466 ENSG00000215571.5 GRK6P1 7.69 1.74e-12 1.34e-05 0.71 0.53 Intelligence (multi-trait analysis); chr5:177462529 chr13:21319156~21320866:+ PAAD trans rs6708331 0.938 rs13000514 ENSG00000232654.1 FAM136BP 7.68 1.78e-12 1.37e-05 0.69 0.53 Obesity-related traits; chr2:70167884 chr6:3045384~3045800:+ PAAD trans rs6708331 1 rs7578027 ENSG00000232654.1 FAM136BP 7.68 1.78e-12 1.37e-05 0.69 0.53 Obesity-related traits; chr2:70173976 chr6:3045384~3045800:+ PAAD trans rs7395662 1 rs10838931 ENSG00000134612.10 FOLH1B -7.68 1.83e-12 1.4e-05 -0.64 -0.53 HDL cholesterol; chr11:48519421 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs12366252 ENSG00000134612.10 FOLH1B -7.68 1.83e-12 1.4e-05 -0.64 -0.53 HDL cholesterol; chr11:48520766 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7121460 ENSG00000134612.10 FOLH1B -7.68 1.83e-12 1.4e-05 -0.64 -0.53 HDL cholesterol; chr11:48523680 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs10838934 ENSG00000134612.10 FOLH1B -7.68 1.83e-12 1.4e-05 -0.64 -0.53 HDL cholesterol; chr11:48525520 chr11:89639227~89698718:+ PAAD trans rs10037055 0.853 rs10036193 ENSG00000217325.2 PRELID1P1 -7.68 1.84e-12 1.41e-05 -0.78 -0.53 Migraine without aura; chr5:177141519 chr6:126643488~126644390:+ PAAD trans rs10037055 0.853 rs9885210 ENSG00000217325.2 PRELID1P1 -7.68 1.84e-12 1.41e-05 -0.78 -0.53 Migraine without aura; chr5:177142187 chr6:126643488~126644390:+ PAAD trans rs6708331 1 rs13429940 ENSG00000232654.1 FAM136BP 7.68 1.85e-12 1.42e-05 0.69 0.53 Obesity-related traits; chr2:70152736 chr6:3045384~3045800:+ PAAD trans rs10037055 0.685 rs10039241 ENSG00000217325.2 PRELID1P1 -7.68 1.86e-12 1.43e-05 -0.83 -0.53 Migraine without aura; chr5:177151071 chr6:126643488~126644390:+ PAAD trans rs877636 0.692 rs10876870 ENSG00000234513.1 AC073072.7 -7.68 1.86e-12 1.43e-05 -0.6 -0.53 Cognitive function; chr12:56084218 chr7:22773646~22773993:- PAAD trans rs877636 0.692 rs7971751 ENSG00000234513.1 AC073072.7 -7.68 1.86e-12 1.43e-05 -0.6 -0.53 Cognitive function; chr12:56084874 chr7:22773646~22773993:- PAAD trans rs7395662 0.927 rs2135690 ENSG00000134612.10 FOLH1B 7.67 1.86e-12 1.43e-05 0.64 0.53 HDL cholesterol; chr11:48712049 chr11:89639227~89698718:+ PAAD trans rs7395662 0.658 rs8189235 ENSG00000134612.10 FOLH1B 7.67 1.86e-12 1.43e-05 0.64 0.53 HDL cholesterol; chr11:48718512 chr11:89639227~89698718:+ PAAD trans rs1816752 0.716 rs9553331 ENSG00000237917.1 PARP4P1 -7.67 1.87e-12 1.44e-05 -0.7 -0.53 Obesity-related traits; chr13:24516030 chrY:26594851~26634652:- PAAD trans rs2727020 0.553 rs3862350 ENSG00000134612.10 FOLH1B -7.67 1.88e-12 1.44e-05 -0.61 -0.53 Coronary artery disease; chr11:49574360 chr11:89639227~89698718:+ PAAD trans rs7937890 0.904 rs67623158 ENSG00000236360.2 RP11-334A14.2 -7.67 1.89e-12 1.45e-05 -0.71 -0.53 Mitochondrial DNA levels; chr11:14273650 chr1:52993201~52993702:- PAAD trans rs8081395 0.729 rs12453125 ENSG00000187870.7 RNFT1P3 -7.67 1.92e-12 1.47e-05 -0.64 -0.53 White blood cell count; chr17:59968715 chr17:20743333~20754501:- PAAD trans rs116095464 0.558 rs6555058 ENSG00000185986.11 SDHAP3 -7.67 1.96e-12 1.5e-05 -0.66 -0.53 Breast cancer; chr5:226261 chr5:1572222~1594620:- PAAD trans rs9611565 0.649 rs2064189 ENSG00000268568.1 AC007228.9 7.66 1.98e-12 1.52e-05 0.85 0.53 Vitiligo; chr22:41731995 chr19:56672574~56673901:- PAAD trans rs7395662 1 rs10742862 ENSG00000134612.10 FOLH1B -7.66 1.99e-12 1.52e-05 -0.64 -0.53 HDL cholesterol; chr11:48627764 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039862 ENSG00000134612.10 FOLH1B -7.66 2e-12 1.53e-05 -0.64 -0.53 HDL cholesterol; chr11:48596754 chr11:89639227~89698718:+ PAAD trans rs3740713 0.669 rs78098319 ENSG00000235847.2 LDHAP7 7.66 2e-12 1.53e-05 0.88 0.53 Amyotrophic lateral sclerosis (sporadic); chr11:18382752 chr2:84777259~84778223:- PAAD trans rs1816752 0.646 rs2862902 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24461965 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs734715 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24462041 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs730030 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24462509 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs7992667 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24462821 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs7995958 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24462895 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs8002741 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24462918 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs7998198 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24462979 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs7998203 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24462989 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs7998600 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24463222 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511279 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24463348 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511280 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24463364 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511281 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24463441 chrY:26594851~26634652:- PAAD trans rs1816752 0.624 rs9511282 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24463597 chrY:26594851~26634652:- PAAD trans rs1816752 0.583 rs9511283 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24463656 chrY:26594851~26634652:- PAAD trans rs1816752 0.583 rs9511284 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24463660 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9507351 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24465118 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs4770688 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24466007 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs4770689 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24466008 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs12431171 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24466380 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs12854523 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24466460 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9578740 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24466692 chrY:26594851~26634652:- PAAD trans rs1816752 0.631 rs4769358 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24466940 chrY:26594851~26634652:- PAAD trans rs1816752 0.608 rs4769359 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24466966 chrY:26594851~26634652:- PAAD trans rs1816752 0.608 rs4769360 ENSG00000237917.1 PARP4P1 -7.66 2.04e-12 1.55e-05 -0.68 -0.53 Obesity-related traits; chr13:24467016 chrY:26594851~26634652:- PAAD trans rs3740713 0.669 rs113003553 ENSG00000235847.2 LDHAP7 7.66 2.05e-12 1.56e-05 0.88 0.53 Amyotrophic lateral sclerosis (sporadic); chr11:18389314 chr2:84777259~84778223:- PAAD trans rs8081395 0.711 rs11368 ENSG00000187870.7 RNFT1P3 7.66 2.06e-12 1.57e-05 0.63 0.53 White blood cell count; chr17:59954051 chr17:20743333~20754501:- PAAD trans rs2731664 0.792 rs2630767 ENSG00000215571.5 GRK6P1 7.65 2.14e-12 1.61e-05 0.71 0.53 Intelligence (multi-trait analysis); chr5:177443699 chr13:21319156~21320866:+ PAAD trans rs7395662 1 rs11039820 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48540700 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs55834832 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48541031 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039821 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48541323 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs12361812 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48541552 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882016 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48548573 chr11:89639227~89698718:+ PAAD trans rs7395662 0.864 rs10838951 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48549536 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882120 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48551977 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882123 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48554187 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10838954 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48557771 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7931984 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48559283 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs6485875 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48559482 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs10838956 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48560213 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7949554 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48560440 chr11:89639227~89698718:+ PAAD trans rs7395662 0.895 rs7924481 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48560905 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs10838959 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48563180 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882129 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48567222 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882130 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48567402 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10838966 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48568171 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs34636547 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48568551 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs10769382 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48568863 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs7951432 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48569728 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7121992 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48571030 chr11:89639227~89698718:+ PAAD trans rs7395662 0.89 rs4882133 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48571898 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs10838967 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48573455 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7481308 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48578515 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039851 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48579287 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039854 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48586136 chr11:89639227~89698718:+ PAAD trans rs7395662 0.777 rs7114291 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48586699 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs6485889 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48587233 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7481880 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48587795 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs7946248 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48591964 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882136 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48593759 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs4882137 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48594119 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs10769389 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48596459 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10769390 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48596670 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039868 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48600594 chr11:89639227~89698718:+ PAAD trans rs7395662 0.895 rs11039869 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48600760 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs12421159 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48603289 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7479134 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48603857 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs11039870 ENSG00000134612.10 FOLH1B -7.65 2.14e-12 1.61e-05 -0.64 -0.53 HDL cholesterol; chr11:48604926 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7395662 ENSG00000134612.10 FOLH1B 7.65 2.14e-12 1.61e-05 0.64 0.53 HDL cholesterol; chr11:48497341 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039871 ENSG00000134612.10 FOLH1B 7.65 2.14e-12 1.61e-05 0.64 0.53 HDL cholesterol; chr11:48605068 chr11:89639227~89698718:+ PAAD trans rs7395662 0.816 rs12420341 ENSG00000134612.10 FOLH1B -7.64 2.32e-12 1.74e-05 -0.64 -0.53 HDL cholesterol; chr11:48871832 chr11:89639227~89698718:+ PAAD trans rs7395662 0.658 rs11493304 ENSG00000134612.10 FOLH1B -7.64 2.32e-12 1.74e-05 -0.64 -0.53 HDL cholesterol; chr11:48874039 chr11:89639227~89698718:+ PAAD trans rs7395662 0.889 rs11517696 ENSG00000134612.10 FOLH1B -7.64 2.32e-12 1.74e-05 -0.64 -0.53 HDL cholesterol; chr11:48918521 chr11:89639227~89698718:+ PAAD trans rs7395662 0.75 rs10838985 ENSG00000134612.10 FOLH1B -7.63 2.34e-12 1.75e-05 -0.65 -0.53 HDL cholesterol; chr11:48623533 chr11:89639227~89698718:+ PAAD trans rs6708331 0.941 rs11903933 ENSG00000232654.1 FAM136BP 7.63 2.37e-12 1.78e-05 0.69 0.53 Obesity-related traits; chr2:70149812 chr6:3045384~3045800:+ PAAD trans rs7554547 0.508 rs7520898 ENSG00000261819.1 RP11-680G24.4 7.63 2.41e-12 1.8e-05 0.68 0.53 Nonsyndromic cleft lip with cleft palate; chr1:11901078 chr16:14988259~14990160:- PAAD trans rs3740713 0.669 rs34740438 ENSG00000235847.2 LDHAP7 7.63 2.42e-12 1.81e-05 0.88 0.53 Amyotrophic lateral sclerosis (sporadic); chr11:18393783 chr2:84777259~84778223:- PAAD trans rs7395662 1 rs7482176 ENSG00000134612.10 FOLH1B -7.62 2.48e-12 1.85e-05 -0.64 -0.53 HDL cholesterol; chr11:48583068 chr11:89639227~89698718:+ PAAD trans rs13253073 1 rs12541837 ENSG00000260318.1 COX6CP1 -7.62 2.52e-12 1.88e-05 -1.12 -0.53 Glucose homeostasis traits; chr8:99869645 chr16:11903923~11904137:- PAAD trans rs7121616 1 rs7121616 ENSG00000234176.1 HSPA8P1 7.61 2.64e-12 1.96e-05 0.63 0.53 Breast cancer; chr11:123095918 chrX:121203182~121205014:- PAAD trans rs7121616 0.96 rs7122306 ENSG00000234176.1 HSPA8P1 7.61 2.64e-12 1.96e-05 0.63 0.53 Breast cancer; chr11:123096254 chrX:121203182~121205014:- PAAD trans rs9611565 0.608 rs2003816 ENSG00000268568.1 AC007228.9 7.61 2.72e-12 2.02e-05 0.83 0.53 Vitiligo; chr22:41699136 chr19:56672574~56673901:- PAAD trans rs9611565 0.694 rs11090056 ENSG00000268568.1 AC007228.9 7.61 2.72e-12 2.02e-05 0.83 0.53 Vitiligo; chr22:41699900 chr19:56672574~56673901:- PAAD trans rs9611565 0.644 rs2413652 ENSG00000268568.1 AC007228.9 7.61 2.72e-12 2.02e-05 0.83 0.53 Vitiligo; chr22:41701234 chr19:56672574~56673901:- PAAD trans rs703108 0.731 rs7898954 ENSG00000220749.4 RPL21P28 7.61 2.73e-12 2.03e-05 0.57 0.53 Monocyte percentage of white cells; chr10:22034717 chr1:212051524~212052006:- PAAD trans rs877636 0.669 rs7297175 ENSG00000234513.1 AC073072.7 -7.6 2.76e-12 2.05e-05 -0.59 -0.52 Cognitive function; chr12:56080024 chr7:22773646~22773993:- PAAD trans rs7395662 0.711 rs11512405 ENSG00000134612.10 FOLH1B -7.6 2.84e-12 2.11e-05 -0.64 -0.52 HDL cholesterol; chr11:48914805 chr11:89639227~89698718:+ PAAD trans rs2731664 0.792 rs2544809 ENSG00000215571.5 GRK6P1 7.6 2.86e-12 2.12e-05 0.71 0.52 Intelligence (multi-trait analysis); chr5:177458498 chr13:21319156~21320866:+ PAAD trans rs7937890 0.9 rs7118682 ENSG00000236360.2 RP11-334A14.2 -7.6 2.9e-12 2.15e-05 -0.7 -0.52 Mitochondrial DNA levels; chr11:14253004 chr1:52993201~52993702:- PAAD trans rs8081395 0.576 rs1292032 ENSG00000187870.7 RNFT1P3 7.59 2.93e-12 2.17e-05 0.61 0.52 White blood cell count; chr17:59914982 chr17:20743333~20754501:- PAAD trans rs1816752 0.646 rs9511296 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24467962 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9634401 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468072 chrY:26594851~26634652:- PAAD trans rs1816752 0.624 rs9634402 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468119 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9634403 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468211 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9581064 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468251 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs4770692 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468689 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs4769361 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468834 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs4770693 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468835 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs4770694 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468891 chrY:26594851~26634652:- PAAD trans rs1816752 0.609 rs4770695 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24468895 chrY:26594851~26634652:- PAAD trans rs1816752 0.624 rs9507354 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24469227 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs7337981 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24469245 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs4480642 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24471358 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9551108 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24471434 chrY:26594851~26634652:- PAAD trans rs1816752 0.603 rs4238178 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24472344 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs2862903 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24473169 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs7319207 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24473220 chrY:26594851~26634652:- PAAD trans rs1816752 0.583 rs9553311 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24474016 chrY:26594851~26634652:- PAAD trans rs1816752 0.524 rs7996445 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24475329 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs7995190 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24475709 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs6490937 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24475834 chrY:26594851~26634652:- PAAD trans rs1816752 0.608 rs7326664 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24475868 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511301 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24477034 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs7332220 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24477081 chrY:26594851~26634652:- PAAD trans rs1816752 0.624 rs11149109 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24477290 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511302 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24477580 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs8002599 ENSG00000237917.1 PARP4P1 -7.59 2.98e-12 2.19e-05 -0.68 -0.52 Obesity-related traits; chr13:24478486 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs7322323 ENSG00000237917.1 PARP4P1 -7.59 2.99e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24479189 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs7322329 ENSG00000237917.1 PARP4P1 -7.59 2.99e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24479193 chrY:26594851~26634652:- PAAD trans rs1816752 0.624 rs2096093 ENSG00000237917.1 PARP4P1 -7.59 3e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24472753 chrY:26594851~26634652:- PAAD trans rs1816752 0.608 rs9511290 ENSG00000237917.1 PARP4P1 -7.59 3e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24467189 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511291 ENSG00000237917.1 PARP4P1 -7.59 3e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24467609 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511292 ENSG00000237917.1 PARP4P1 -7.59 3e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24467623 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511293 ENSG00000237917.1 PARP4P1 -7.59 3e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24467747 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511294 ENSG00000237917.1 PARP4P1 -7.59 3e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24467773 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs9511295 ENSG00000237917.1 PARP4P1 -7.59 3e-12 2.21e-05 -0.68 -0.52 Obesity-related traits; chr13:24467794 chrY:26594851~26634652:- PAAD trans rs9611565 0.572 rs139569 ENSG00000268568.1 AC007228.9 -7.59 3.01e-12 2.22e-05 -0.8 -0.52 Vitiligo; chr22:41815137 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs9623450 ENSG00000268568.1 AC007228.9 7.59 3.04e-12 2.23e-05 0.83 0.52 Vitiligo; chr22:41779227 chr19:56672574~56673901:- PAAD trans rs9611565 0.568 rs5751159 ENSG00000268568.1 AC007228.9 7.59 3.04e-12 2.23e-05 0.83 0.52 Vitiligo; chr22:41779361 chr19:56672574~56673901:- PAAD trans rs7937890 1 rs6486190 ENSG00000236360.2 RP11-334A14.2 7.59 3.06e-12 2.25e-05 0.73 0.52 Mitochondrial DNA levels; chr11:14379670 chr1:52993201~52993702:- PAAD trans rs877636 0.692 rs2271194 ENSG00000235459.5 RPS26P31 -7.59 3.07e-12 2.26e-05 -0.59 -0.52 Cognitive function; chr12:56083910 chr7:122681315~122681662:+ PAAD trans rs1816752 0.716 rs9553331 ENSG00000224976.2 PARP4P2 7.58 3.21e-12 2.35e-05 0.65 0.52 Obesity-related traits; chr13:24516030 chr13:19349137~19407962:+ PAAD trans rs9611565 0.879 rs5758307 ENSG00000268568.1 AC007228.9 -7.58 3.23e-12 2.37e-05 -0.79 -0.52 Vitiligo; chr22:41354215 chr19:56672574~56673901:- PAAD trans rs7395662 0.892 rs11040014 ENSG00000134612.10 FOLH1B 7.57 3.31e-12 2.42e-05 0.63 0.52 HDL cholesterol; chr11:48761505 chr11:89639227~89698718:+ PAAD trans rs9611565 0.879 rs2235845 ENSG00000268568.1 AC007228.9 -7.57 3.32e-12 2.43e-05 -0.75 -0.52 Vitiligo; chr22:41333290 chr19:56672574~56673901:- PAAD trans rs9611565 0.921 rs5751080 ENSG00000268568.1 AC007228.9 -7.57 3.32e-12 2.43e-05 -0.75 -0.52 Vitiligo; chr22:41340263 chr19:56672574~56673901:- PAAD trans rs9611565 0.921 rs2235846 ENSG00000268568.1 AC007228.9 -7.57 3.32e-12 2.43e-05 -0.75 -0.52 Vitiligo; chr22:41345038 chr19:56672574~56673901:- PAAD trans rs9611565 0.921 rs5751081 ENSG00000268568.1 AC007228.9 -7.57 3.32e-12 2.43e-05 -0.75 -0.52 Vitiligo; chr22:41346784 chr19:56672574~56673901:- PAAD trans rs9611565 0.921 rs2281332 ENSG00000268568.1 AC007228.9 -7.57 3.32e-12 2.43e-05 -0.75 -0.52 Vitiligo; chr22:41350208 chr19:56672574~56673901:- PAAD trans rs6732160 0.656 rs2043093 ENSG00000236165.1 PRADC1P1 7.57 3.37e-12 2.47e-05 0.63 0.52 Intelligence (multi-trait analysis); chr2:73180214 chr3:36976316~36976840:+ PAAD trans rs8081395 0.741 rs180520 ENSG00000187870.7 RNFT1P3 7.56 3.45e-12 2.52e-05 0.62 0.52 White blood cell count; chr17:59937788 chr17:20743333~20754501:- PAAD trans rs7395662 0.713 rs11512404 ENSG00000134612.10 FOLH1B -7.56 3.51e-12 2.57e-05 -0.64 -0.52 HDL cholesterol; chr11:48914619 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs11499897 ENSG00000134612.10 FOLH1B 7.56 3.53e-12 2.58e-05 0.63 0.52 HDL cholesterol; chr11:48696314 chr11:89639227~89698718:+ PAAD trans rs7395662 0.895 rs3903506 ENSG00000134612.10 FOLH1B 7.56 3.53e-12 2.58e-05 0.63 0.52 HDL cholesterol; chr11:48696961 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs9666932 ENSG00000134612.10 FOLH1B 7.56 3.53e-12 2.58e-05 0.63 0.52 HDL cholesterol; chr11:48704688 chr11:89639227~89698718:+ PAAD trans rs7395662 0.926 rs7122869 ENSG00000134612.10 FOLH1B 7.56 3.53e-12 2.58e-05 0.63 0.52 HDL cholesterol; chr11:48706447 chr11:89639227~89698718:+ PAAD trans rs7395662 0.892 rs9667579 ENSG00000134612.10 FOLH1B 7.56 3.53e-12 2.58e-05 0.63 0.52 HDL cholesterol; chr11:48708596 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs8189076 ENSG00000134612.10 FOLH1B 7.56 3.53e-12 2.58e-05 0.63 0.52 HDL cholesterol; chr11:48711423 chr11:89639227~89698718:+ PAAD trans rs7395662 0.857 rs3902433 ENSG00000134612.10 FOLH1B 7.56 3.53e-12 2.58e-05 0.63 0.52 HDL cholesterol; chr11:48711772 chr11:89639227~89698718:+ PAAD trans rs877636 0.692 rs11171739 ENSG00000212829.8 RPS26P3 7.56 3.59e-12 2.61e-05 0.61 0.52 Cognitive function; chr12:56076841 chr9:9090898~9091245:+ PAAD trans rs1816752 0.624 rs9553312 ENSG00000237917.1 PARP4P1 -7.56 3.63e-12 2.64e-05 -0.68 -0.52 Obesity-related traits; chr13:24474055 chrY:26594851~26634652:- PAAD trans rs7395662 0.864 rs11039872 ENSG00000134612.10 FOLH1B -7.55 3.74e-12 2.72e-05 -0.64 -0.52 HDL cholesterol; chr11:48607981 chr11:89639227~89698718:+ PAAD trans rs1816752 0.716 rs1441058 ENSG00000237917.1 PARP4P1 -7.55 3.8e-12 2.76e-05 -0.69 -0.52 Obesity-related traits; chr13:24516275 chrY:26594851~26634652:- PAAD trans rs4240897 0.935 rs4846082 ENSG00000261819.1 RP11-680G24.4 7.55 3.82e-12 2.77e-05 0.64 0.52 Tuberculosis; chr1:11982386 chr16:14988259~14990160:- PAAD trans rs4240897 0.935 rs3766744 ENSG00000261819.1 RP11-680G24.4 7.54 3.86e-12 2.8e-05 0.64 0.52 Tuberculosis; chr1:11983660 chr16:14988259~14990160:- PAAD trans rs7395662 1 rs7479498 ENSG00000134612.10 FOLH1B -7.54 3.86e-12 2.8e-05 -0.63 -0.52 HDL cholesterol; chr11:48638947 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs2089209 ENSG00000134612.10 FOLH1B -7.54 3.9e-12 2.83e-05 -0.64 -0.52 HDL cholesterol; chr11:48965568 chr11:89639227~89698718:+ PAAD trans rs9467773 0.649 rs2145318 ENSG00000242375.1 RP11-498P14.3 7.54 3.94e-12 2.86e-05 0.68 0.52 Intelligence (multi-trait analysis); chr6:26496375 chr9:97195351~97197687:- PAAD trans rs9611565 0.571 rs7364123 ENSG00000268568.1 AC007228.9 -7.53 4.14e-12 2.99e-05 -0.8 -0.52 Vitiligo; chr22:41820322 chr19:56672574~56673901:- PAAD trans rs2731664 0.819 rs449351 ENSG00000215571.5 GRK6P1 7.53 4.2e-12 3.03e-05 0.68 0.52 Intelligence (multi-trait analysis); chr5:177445590 chr13:21319156~21320866:+ PAAD trans rs2727020 0.553 rs11040400 ENSG00000134612.10 FOLH1B -7.53 4.2e-12 3.03e-05 -0.6 -0.52 Coronary artery disease; chr11:49496744 chr11:89639227~89698718:+ PAAD trans rs2727020 0.553 rs10839295 ENSG00000134612.10 FOLH1B -7.53 4.2e-12 3.03e-05 -0.6 -0.52 Coronary artery disease; chr11:49505793 chr11:89639227~89698718:+ PAAD trans rs2727020 0.553 rs3907576 ENSG00000134612.10 FOLH1B -7.53 4.2e-12 3.03e-05 -0.6 -0.52 Coronary artery disease; chr11:49515087 chr11:89639227~89698718:+ PAAD trans rs2727020 0.575 rs10769587 ENSG00000134612.10 FOLH1B -7.53 4.2e-12 3.03e-05 -0.6 -0.52 Coronary artery disease; chr11:49528297 chr11:89639227~89698718:+ PAAD trans rs2727020 0.514 rs4980444 ENSG00000134612.10 FOLH1B -7.53 4.2e-12 3.03e-05 -0.6 -0.52 Coronary artery disease; chr11:49529212 chr11:89639227~89698718:+ PAAD trans rs2727020 0.576 rs1814175 ENSG00000134612.10 FOLH1B -7.53 4.2e-12 3.03e-05 -0.6 -0.52 Coronary artery disease; chr11:49537620 chr11:89639227~89698718:+ PAAD trans rs1816752 0.646 rs9511309 ENSG00000237917.1 PARP4P1 -7.52 4.35e-12 3.13e-05 -0.68 -0.52 Obesity-related traits; chr13:24515435 chrY:26594851~26634652:- PAAD trans rs9899728 0.665 rs2307008 ENSG00000234925.2 ATP5HP4 7.52 4.35e-12 3.13e-05 0.82 0.52 Alzheimer's disease or small vessel stroke; chr17:75046587 chr12:68642519~68642993:- PAAD trans rs916888 0.773 rs199533 ENSG00000204650.12 CRHR1-IT1 7.52 4.43e-12 3.18e-05 0.64 0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45620328~45648216:+ PAAD trans rs7395662 0.927 rs4882141 ENSG00000134612.10 FOLH1B -7.52 4.48e-12 3.22e-05 -0.64 -0.52 HDL cholesterol; chr11:48605973 chr11:89639227~89698718:+ PAAD trans rs13253073 0.941 rs13264726 ENSG00000260318.1 COX6CP1 7.52 4.53e-12 3.26e-05 1.14 0.52 Glucose homeostasis traits; chr8:99851139 chr16:11903923~11904137:- PAAD trans rs7395662 0.963 rs7483713 ENSG00000134612.10 FOLH1B -7.52 4.55e-12 3.27e-05 -0.63 -0.52 HDL cholesterol; chr11:48607662 chr11:89639227~89698718:+ PAAD trans rs877636 0.692 rs10876870 ENSG00000212829.8 RPS26P3 -7.51 4.6e-12 3.31e-05 -0.62 -0.52 Cognitive function; chr12:56084218 chr9:9090898~9091245:+ PAAD trans rs877636 0.692 rs7971751 ENSG00000212829.8 RPS26P3 -7.51 4.6e-12 3.31e-05 -0.62 -0.52 Cognitive function; chr12:56084874 chr9:9090898~9091245:+ PAAD trans rs9611565 0.573 rs9306355 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41715892 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs5758434 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41720159 chr19:56672574~56673901:- PAAD trans rs9611565 0.5 rs2011053 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41725274 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs738422 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41727395 chr19:56672574~56673901:- PAAD trans rs9611565 0.568 rs2413656 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41733353 chr19:56672574~56673901:- PAAD trans rs4822044 0.617 rs13054514 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Cannabis dependence symptom count; chr22:41734379 chr19:56672574~56673901:- PAAD trans rs9611565 0.568 rs5758441 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41736884 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs5758442 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41737056 chr19:56672574~56673901:- PAAD trans rs9611565 0.58 rs5758449 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41744156 chr19:56672574~56673901:- PAAD trans rs9611565 0.504 rs5758452 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41748923 chr19:56672574~56673901:- PAAD trans rs9611565 0.532 rs4401299 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41760513 chr19:56672574~56673901:- PAAD trans rs9611565 0.649 rs2413659 ENSG00000268568.1 AC007228.9 7.5 4.89e-12 3.5e-05 0.82 0.52 Vitiligo; chr22:41768858 chr19:56672574~56673901:- PAAD trans rs7937890 1 rs7937890 ENSG00000236360.2 RP11-334A14.2 7.5 5.04e-12 3.6e-05 0.74 0.52 Mitochondrial DNA levels; chr11:14374939 chr1:52993201~52993702:- PAAD trans rs7395662 1 rs7948486 ENSG00000134612.10 FOLH1B 7.5 5.07e-12 3.62e-05 0.63 0.52 HDL cholesterol; chr11:48890588 chr11:89639227~89698718:+ PAAD trans rs7395662 0.5 rs7947055 ENSG00000134612.10 FOLH1B 7.5 5.07e-12 3.62e-05 0.63 0.52 HDL cholesterol; chr11:48955534 chr11:89639227~89698718:+ PAAD trans rs7395662 0.747 rs11040106 ENSG00000134612.10 FOLH1B 7.49 5.16e-12 3.67e-05 0.63 0.52 HDL cholesterol; chr11:48867574 chr11:89639227~89698718:+ PAAD trans rs877636 0.562 rs1131017 ENSG00000225071.1 GS1-184P14.2 -7.49 5.17e-12 3.68e-05 -0.58 -0.52 Cognitive function; chr12:56042145 chrX:24429573~24429920:- PAAD trans rs13253073 1 rs35935983 ENSG00000260318.1 COX6CP1 7.49 5.23e-12 3.72e-05 1.13 0.52 Glucose homeostasis traits; chr8:99888966 chr16:11903923~11904137:- PAAD trans rs877636 0.692 rs10876870 ENSG00000235459.5 RPS26P31 -7.49 5.35e-12 3.8e-05 -0.59 -0.52 Cognitive function; chr12:56084218 chr7:122681315~122681662:+ PAAD trans rs877636 0.692 rs7971751 ENSG00000235459.5 RPS26P31 -7.49 5.35e-12 3.8e-05 -0.59 -0.52 Cognitive function; chr12:56084874 chr7:122681315~122681662:+ PAAD trans rs916888 0.773 rs199534 ENSG00000204650.12 CRHR1-IT1 7.48 5.39e-12 3.83e-05 0.64 0.52 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45620328~45648216:+ PAAD trans rs6708331 0.646 rs12713688 ENSG00000232654.1 FAM136BP 7.48 5.45e-12 3.87e-05 0.68 0.52 Obesity-related traits; chr2:70142371 chr6:3045384~3045800:+ PAAD trans rs11023332 0.832 rs10832289 ENSG00000236360.2 RP11-334A14.2 -7.47 5.75e-12 4.08e-05 -0.68 -0.52 Vitamin D levels;Adiponectin levels; chr11:14647950 chr1:52993201~52993702:- PAAD trans rs7395662 1 rs6485911 ENSG00000134612.10 FOLH1B -7.47 5.76e-12 4.09e-05 -0.62 -0.52 HDL cholesterol; chr11:48633232 chr11:89639227~89698718:+ PAAD trans rs877636 0.692 rs2271194 ENSG00000212829.8 RPS26P3 -7.47 5.78e-12 4.1e-05 -0.62 -0.52 Cognitive function; chr12:56083910 chr9:9090898~9091245:+ PAAD trans rs877636 0.692 rs11171739 ENSG00000234513.1 AC073072.7 7.47 5.93e-12 4.2e-05 0.57 0.52 Cognitive function; chr12:56076841 chr7:22773646~22773993:- PAAD trans rs6708331 0.941 rs12989076 ENSG00000232654.1 FAM136BP 7.46 6.09e-12 4.31e-05 0.69 0.52 Obesity-related traits; chr2:70176275 chr6:3045384~3045800:+ PAAD trans rs2731664 0.792 rs2545795 ENSG00000215571.5 GRK6P1 7.45 6.38e-12 4.51e-05 0.7 0.52 Intelligence (multi-trait analysis); chr5:177460105 chr13:21319156~21320866:+ PAAD trans rs12709013 0.59 rs982848 ENSG00000230849.2 GOT2P2 7.45 6.44e-12 4.55e-05 0.59 0.52 Blood metabolite ratios; chr16:58704294 chr1:173141100~173142350:- PAAD trans rs12709013 0.613 rs1657178 ENSG00000233719.3 GOT2P3 7.45 6.55e-12 4.63e-05 0.65 0.52 Blood metabolite ratios; chr16:58735300 chr12:9641802~9643007:+ PAAD trans rs7937890 0.874 rs2303972 ENSG00000236360.2 RP11-334A14.2 -7.45 6.61e-12 4.67e-05 -0.7 -0.52 Mitochondrial DNA levels; chr11:14281736 chr1:52993201~52993702:- PAAD trans rs7395662 0.609 rs10839190 ENSG00000134612.10 FOLH1B 7.44 6.79e-12 4.79e-05 0.63 0.52 HDL cholesterol; chr11:48935456 chr11:89639227~89698718:+ PAAD trans rs1816752 0.646 rs9507355 ENSG00000237917.1 PARP4P1 7.44 6.81e-12 4.8e-05 0.67 0.52 Obesity-related traits; chr13:24476819 chrY:26594851~26634652:- PAAD trans rs10037055 1 rs10037055 ENSG00000217325.2 PRELID1P1 -7.44 6.94e-12 4.89e-05 -0.76 -0.52 Migraine without aura; chr5:177264278 chr6:126643488~126644390:+ PAAD trans rs10037055 1 rs6886255 ENSG00000217325.2 PRELID1P1 7.44 6.98e-12 4.92e-05 0.76 0.52 Migraine without aura; chr5:177291360 chr6:126643488~126644390:+ PAAD trans rs1816752 0.646 rs7997248 ENSG00000237917.1 PARP4P1 -7.44 7.11e-12 5.01e-05 -0.67 -0.52 Obesity-related traits; chr13:24507050 chrY:26594851~26634652:- PAAD trans rs13190036 1 rs625882 ENSG00000217325.2 PRELID1P1 -7.43 7.22e-12 5.08e-05 -0.9 -0.52 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177108030 chr6:126643488~126644390:+ PAAD trans rs1814175 0.654 rs1164676 ENSG00000134612.10 FOLH1B 7.42 7.73e-12 5.42e-05 0.62 0.52 Height; chr11:49303316 chr11:89639227~89698718:+ PAAD trans rs877636 0.692 rs11171739 ENSG00000235459.5 RPS26P31 7.42 7.86e-12 5.51e-05 0.57 0.52 Cognitive function; chr12:56076841 chr7:122681315~122681662:+ PAAD trans rs1816752 0.646 rs3783073 ENSG00000237917.1 PARP4P1 -7.42 7.91e-12 5.54e-05 -0.67 -0.52 Obesity-related traits; chr13:24493222 chrY:26594851~26634652:- PAAD trans rs1816752 0.646 rs1361578 ENSG00000237917.1 PARP4P1 -7.41 8.1e-12 5.67e-05 -0.67 -0.52 Obesity-related traits; chr13:24491117 chrY:26594851~26634652:- PAAD trans rs7395662 0.963 rs11039950 ENSG00000134612.10 FOLH1B 7.41 8.36e-12 5.85e-05 0.62 0.51 HDL cholesterol; chr11:48715919 chr11:89639227~89698718:+ PAAD trans rs7395662 0.606 rs11512384 ENSG00000134612.10 FOLH1B -7.41 8.38e-12 5.86e-05 -0.63 -0.51 HDL cholesterol; chr11:48816635 chr11:89639227~89698718:+ PAAD trans rs4240897 0.835 rs4845891 ENSG00000261819.1 RP11-680G24.4 7.4 8.48e-12 5.93e-05 0.63 0.51 Tuberculosis; chr1:11982449 chr16:14988259~14990160:- PAAD trans rs4240897 0.935 rs1474868 ENSG00000261819.1 RP11-680G24.4 -7.4 8.58e-12 5.99e-05 -0.63 -0.51 Tuberculosis; chr1:11984107 chr16:14988259~14990160:- PAAD trans rs12709013 0.613 rs4238801 ENSG00000233719.3 GOT2P3 7.4 8.78e-12 6.13e-05 0.65 0.51 Blood metabolite ratios; chr16:58738275 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs4575523 ENSG00000233719.3 GOT2P3 7.4 8.78e-12 6.13e-05 0.65 0.51 Blood metabolite ratios; chr16:58738559 chr12:9641802~9643007:+ PAAD trans rs7554547 0.905 rs4993564 ENSG00000261819.1 RP11-680G24.4 7.4 8.85e-12 6.18e-05 0.66 0.51 Nonsyndromic cleft lip with cleft palate; chr1:11909934 chr16:14988259~14990160:- PAAD trans rs8081395 0.741 rs1292053 ENSG00000187870.7 RNFT1P3 -7.39 8.89e-12 6.21e-05 -0.6 -0.51 White blood cell count; chr17:59886176 chr17:20743333~20754501:- PAAD trans rs8081395 0.741 rs1292056 ENSG00000187870.7 RNFT1P3 7.39 9.09e-12 6.33e-05 0.61 0.51 White blood cell count; chr17:59881686 chr17:20743333~20754501:- PAAD trans rs6477998 0.647 rs10981704 ENSG00000238072.1 RP11-305M3.2 -7.38 9.5e-12 6.61e-05 -0.73 -0.51 Hematology traits; chr9:113253989 chr7:129410113~129410370:- PAAD trans rs916888 0.738 rs199515 ENSG00000204650.12 CRHR1-IT1 -7.38 9.64e-12 6.71e-05 -0.61 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45620328~45648216:+ PAAD trans rs9611565 0.921 rs5758297 ENSG00000268568.1 AC007228.9 -7.38 9.75e-12 6.78e-05 -0.76 -0.51 Vitiligo; chr22:41324693 chr19:56672574~56673901:- PAAD trans rs9611565 0.921 rs5751077 ENSG00000268568.1 AC007228.9 -7.38 9.75e-12 6.78e-05 -0.76 -0.51 Vitiligo; chr22:41324724 chr19:56672574~56673901:- PAAD trans rs73099903 0.611 rs7957445 ENSG00000229939.1 RP11-111F16.2 7.37 1.01e-11 7e-05 0.82 0.51 Systolic blood pressure; chr12:53014796 chrX:111618808~111619094:+ PAAD trans rs7395662 0.591 rs7483212 ENSG00000134612.10 FOLH1B -7.37 1.02e-11 7.1e-05 -0.6 -0.51 HDL cholesterol; chr11:48585630 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs7482521 ENSG00000134612.10 FOLH1B -7.37 1.02e-11 7.1e-05 -0.6 -0.51 HDL cholesterol; chr11:48588183 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs10838972 ENSG00000134612.10 FOLH1B -7.37 1.02e-11 7.1e-05 -0.6 -0.51 HDL cholesterol; chr11:48589848 chr11:89639227~89698718:+ PAAD trans rs7395662 0.571 rs4882020 ENSG00000134612.10 FOLH1B -7.37 1.02e-11 7.1e-05 -0.6 -0.51 HDL cholesterol; chr11:48594106 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs4882138 ENSG00000134612.10 FOLH1B -7.37 1.02e-11 7.1e-05 -0.6 -0.51 HDL cholesterol; chr11:48597769 chr11:89639227~89698718:+ PAAD trans rs12709013 0.686 rs151817 ENSG00000230849.2 GOT2P2 -7.37 1.03e-11 7.17e-05 -0.59 -0.51 Blood metabolite ratios; chr16:58704014 chr1:173141100~173142350:- PAAD trans rs916888 0.773 rs199457 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45620328~45648216:+ PAAD trans rs916888 0.687 rs199456 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45620328~45648216:+ PAAD trans rs916888 0.773 rs199451 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45620328~45648216:+ PAAD trans rs916888 0.773 rs199448 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45620328~45648216:+ PAAD trans rs916888 0.773 rs199445 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45620328~45648216:+ PAAD trans rs916888 0.773 rs199443 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45620328~45648216:+ PAAD trans rs916888 0.773 rs199535 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45620328~45648216:+ PAAD trans rs916888 0.779 rs199528 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs199525 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs70600 ENSG00000204650.12 CRHR1-IT1 7.37 1.04e-11 7.19e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45620328~45648216:+ PAAD trans rs9611565 0.921 rs2143695 ENSG00000268568.1 AC007228.9 -7.37 1.04e-11 7.23e-05 -0.75 -0.51 Vitiligo; chr22:41332616 chr19:56672574~56673901:- PAAD trans rs12709013 0.792 rs1473206 ENSG00000230849.2 GOT2P2 7.36 1.05e-11 7.26e-05 0.59 0.51 Blood metabolite ratios; chr16:58737529 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs1473205 ENSG00000230849.2 GOT2P2 7.36 1.05e-11 7.26e-05 0.59 0.51 Blood metabolite ratios; chr16:58737547 chr1:173141100~173142350:- PAAD trans rs7395662 0.963 rs4882072 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48458339 chr11:89639227~89698718:+ PAAD trans rs7395662 0.816 rs11039764 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48463064 chr11:89639227~89698718:+ PAAD trans rs7395662 0.927 rs12793888 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48466504 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7949348 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48472249 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10838912 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48474925 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4881994 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48476587 chr11:89639227~89698718:+ PAAD trans rs7395662 0.895 rs1945183 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48480875 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10838917 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48481575 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs11039774 ENSG00000134612.10 FOLH1B -7.36 1.05e-11 7.26e-05 -0.62 -0.51 HDL cholesterol; chr11:48492407 chr11:89639227~89698718:+ PAAD trans rs12709013 0.755 rs1424245 ENSG00000233719.3 GOT2P3 7.36 1.05e-11 7.27e-05 0.62 0.51 Blood metabolite ratios; chr16:58729926 chr12:9641802~9643007:+ PAAD trans rs1292048 1 rs1292048 ENSG00000187870.7 RNFT1P3 7.36 1.08e-11 7.43e-05 0.6 0.51 Red cell distribution width; chr17:59877710 chr17:20743333~20754501:- PAAD trans rs1816752 0.646 rs4770700 ENSG00000237917.1 PARP4P1 -7.36 1.08e-11 7.46e-05 -0.67 -0.51 Obesity-related traits; chr13:24494796 chrY:26594851~26634652:- PAAD trans rs1816752 0.624 rs7330766 ENSG00000237917.1 PARP4P1 -7.36 1.08e-11 7.46e-05 -0.67 -0.51 Obesity-related traits; chr13:24495579 chrY:26594851~26634652:- PAAD trans rs1816752 0.603 rs7984094 ENSG00000237917.1 PARP4P1 -7.36 1.08e-11 7.46e-05 -0.67 -0.51 Obesity-related traits; chr13:24496212 chrY:26594851~26634652:- PAAD trans rs1816752 0.624 rs4770701 ENSG00000237917.1 PARP4P1 -7.36 1.08e-11 7.46e-05 -0.67 -0.51 Obesity-related traits; chr13:24508806 chrY:26594851~26634652:- PAAD trans rs4240897 0.935 rs2236055 ENSG00000261819.1 RP11-680G24.4 7.35 1.13e-11 7.76e-05 0.63 0.51 Tuberculosis; chr1:11982204 chr16:14988259~14990160:- PAAD trans rs55665837 0.539 rs10766196 ENSG00000236360.2 RP11-334A14.2 7.34 1.18e-11 8.11e-05 0.67 0.51 Vitamin D levels; chr11:14891585 chr1:52993201~52993702:- PAAD trans rs55665837 0.539 rs12794714 ENSG00000236360.2 RP11-334A14.2 7.34 1.18e-11 8.11e-05 0.67 0.51 Vitamin D levels; chr11:14892029 chr1:52993201~52993702:- PAAD trans rs8081395 0.775 rs2526355 ENSG00000187870.7 RNFT1P3 7.34 1.2e-11 8.2e-05 0.6 0.51 White blood cell count; chr17:59875872 chr17:20743333~20754501:- PAAD trans rs7395662 0.591 rs11039858 ENSG00000134612.10 FOLH1B -7.34 1.2e-11 8.23e-05 -0.61 -0.51 HDL cholesterol; chr11:48590099 chr11:89639227~89698718:+ PAAD trans rs11039798 0.507 rs56994343 ENSG00000134612.10 FOLH1B 7.34 1.22e-11 8.31e-05 0.81 0.51 Axial length; chr11:48875418 chr11:89639227~89698718:+ PAAD trans rs916888 0.821 rs199506 ENSG00000204650.12 CRHR1-IT1 -7.34 1.22e-11 8.32e-05 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45620328~45648216:+ PAAD trans rs9899728 0.764 rs9660 ENSG00000234925.2 ATP5HP4 7.34 1.22e-11 8.33e-05 0.79 0.51 Alzheimer's disease or small vessel stroke; chr17:75042651 chr12:68642519~68642993:- PAAD trans rs73099903 0.611 rs7485642 ENSG00000229939.1 RP11-111F16.2 7.34 1.22e-11 8.34e-05 0.81 0.51 Systolic blood pressure; chr12:52997717 chrX:111618808~111619094:+ PAAD trans rs1816752 0.646 rs9511309 ENSG00000224976.2 PARP4P2 7.34 1.23e-11 8.43e-05 0.63 0.51 Obesity-related traits; chr13:24515435 chr13:19349137~19407962:+ PAAD trans rs916888 0.773 rs199447 ENSG00000204650.12 CRHR1-IT1 7.33 1.27e-11 8.66e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45620328~45648216:+ PAAD trans rs2731664 0.792 rs335468 ENSG00000215571.5 GRK6P1 -7.33 1.27e-11 8.69e-05 -0.66 -0.51 Intelligence (multi-trait analysis); chr5:177465348 chr13:21319156~21320866:+ PAAD trans rs12709013 0.686 rs244919 ENSG00000230849.2 GOT2P2 -7.33 1.28e-11 8.73e-05 -0.59 -0.51 Blood metabolite ratios; chr16:58704146 chr1:173141100~173142350:- PAAD trans rs7395662 0.963 rs7952491 ENSG00000134612.10 FOLH1B -7.33 1.29e-11 8.76e-05 -0.61 -0.51 HDL cholesterol; chr11:48641743 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs1588068 ENSG00000134612.10 FOLH1B -7.33 1.29e-11 8.76e-05 -0.61 -0.51 HDL cholesterol; chr11:48650193 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs1605364 ENSG00000134612.10 FOLH1B -7.33 1.29e-11 8.76e-05 -0.61 -0.51 HDL cholesterol; chr11:48663291 chr11:89639227~89698718:+ PAAD trans rs7395662 0.926 rs12288788 ENSG00000134612.10 FOLH1B -7.33 1.29e-11 8.76e-05 -0.61 -0.51 HDL cholesterol; chr11:48665311 chr11:89639227~89698718:+ PAAD trans rs9611565 0.649 rs5751144 ENSG00000268568.1 AC007228.9 -7.33 1.3e-11 8.89e-05 -0.8 -0.51 Vitiligo; chr22:41732093 chr19:56672574~56673901:- PAAD trans rs8081395 0.805 rs1295927 ENSG00000187870.7 RNFT1P3 7.32 1.35e-11 9.2e-05 0.61 0.51 White blood cell count; chr17:59852174 chr17:20743333~20754501:- PAAD trans rs6708331 0.938 rs13389246 ENSG00000232654.1 FAM136BP 7.31 1.39e-11 9.47e-05 0.67 0.51 Obesity-related traits; chr2:70127099 chr6:3045384~3045800:+ PAAD trans rs11039798 0.588 rs7108164 ENSG00000134612.10 FOLH1B 7.31 1.4e-11 9.52e-05 0.77 0.51 Axial length; chr11:48604811 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs10838979 ENSG00000134612.10 FOLH1B 7.31 1.4e-11 9.52e-05 0.77 0.51 Axial length; chr11:48605258 chr11:89639227~89698718:+ PAAD trans rs7399018 0.739 rs7953955 ENSG00000223825.5 DAZAP2P1 7.31 1.41e-11 9.55e-05 0.67 0.51 Cisplatin-induced ototoxicity; chr12:51214683 chr2:202201384~202201886:- PAAD trans rs7395662 0.927 rs8188938 ENSG00000134612.10 FOLH1B 7.31 1.41e-11 9.57e-05 0.61 0.51 HDL cholesterol; chr11:48669314 chr11:89639227~89698718:+ PAAD trans rs1816752 0.716 rs9553330 ENSG00000224976.2 PARP4P2 7.31 1.41e-11 9.57e-05 0.63 0.51 Obesity-related traits; chr13:24516018 chr13:19349137~19407962:+ PAAD trans rs11039798 0.511 rs717896 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48353783 chr11:89639227~89698718:+ PAAD trans rs11039798 0.582 rs1483119 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48360782 chr11:89639227~89698718:+ PAAD trans rs11039798 0.557 rs4436575 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48377342 chr11:89639227~89698718:+ PAAD trans rs11039798 0.623 rs635632 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48377980 chr11:89639227~89698718:+ PAAD trans rs11039798 0.623 rs594615 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48381252 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs643668 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48391847 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs589834 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48397830 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs584899 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48409856 chr11:89639227~89698718:+ PAAD trans rs11039798 0.623 rs588700 ENSG00000134612.10 FOLH1B -7.31 1.43e-11 9.7e-05 -0.78 -0.51 Axial length; chr11:48428337 chr11:89639227~89698718:+ PAAD trans rs7312770 0.637 rs705700 ENSG00000225071.1 GS1-184P14.2 7.3 1.46e-11 9.9e-05 0.58 0.51 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chrX:24429573~24429920:- PAAD trans rs916888 0.773 rs538628 ENSG00000204650.12 CRHR1-IT1 7.3 1.47e-11 9.96e-05 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45620328~45648216:+ PAAD trans rs7395662 1 rs11039745 ENSG00000134612.10 FOLH1B -7.3 1.5e-11 0.000101 -0.62 -0.51 HDL cholesterol; chr11:48442259 chr11:89639227~89698718:+ PAAD trans rs7395662 0.926 rs10742848 ENSG00000134612.10 FOLH1B -7.3 1.5e-11 0.000101 -0.62 -0.51 HDL cholesterol; chr11:48447236 chr11:89639227~89698718:+ PAAD trans rs7395662 0.889 rs11039754 ENSG00000134612.10 FOLH1B -7.3 1.5e-11 0.000101 -0.62 -0.51 HDL cholesterol; chr11:48453661 chr11:89639227~89698718:+ PAAD trans rs6708331 0.878 rs12994100 ENSG00000232654.1 FAM136BP 7.3 1.52e-11 0.000102 0.66 0.51 Obesity-related traits; chr2:70133785 chr6:3045384~3045800:+ PAAD trans rs6708331 0.816 rs10196979 ENSG00000232654.1 FAM136BP 7.3 1.52e-11 0.000102 0.66 0.51 Obesity-related traits; chr2:70140265 chr6:3045384~3045800:+ PAAD trans rs13253073 1 rs6986006 ENSG00000260318.1 COX6CP1 7.29 1.54e-11 0.000104 1.13 0.51 Glucose homeostasis traits; chr8:99857251 chr16:11903923~11904137:- PAAD trans rs12709013 0.729 rs1657179 ENSG00000230849.2 GOT2P2 7.29 1.55e-11 0.000104 0.59 0.51 Blood metabolite ratios; chr16:58735115 chr1:173141100~173142350:- PAAD trans rs7811142 0.775 rs1059129 ENSG00000228546.2 CTA-313A17.3 7.29 1.63e-11 0.000109 0.75 0.51 Platelet count; chr7:100328899 chr7:102337316~102339115:+ PAAD trans rs7811142 0.562 rs7786844 ENSG00000228546.2 CTA-313A17.3 7.29 1.63e-11 0.000109 0.75 0.51 Platelet count; chr7:100336385 chr7:102337316~102339115:+ PAAD trans rs7811142 0.667 rs3873746 ENSG00000228546.2 CTA-313A17.3 7.29 1.63e-11 0.000109 0.75 0.51 Platelet count; chr7:100337474 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs6979910 ENSG00000228546.2 CTA-313A17.3 7.29 1.63e-11 0.000109 0.75 0.51 Platelet count; chr7:100343007 chr7:102337316~102339115:+ PAAD trans rs61990749 0.511 rs7146020 ENSG00000235400.1 RP4-641G12.4 7.28 1.64e-11 0.00011 0.85 0.51 Fibroblast growth factor basic levels; chr14:77891976 chr1:78749073~78750659:+ PAAD trans rs12709013 0.585 rs7188608 ENSG00000233719.3 GOT2P3 7.28 1.64e-11 0.00011 0.63 0.51 Blood metabolite ratios; chr16:58736236 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1657176 ENSG00000233719.3 GOT2P3 7.28 1.64e-11 0.00011 0.63 0.51 Blood metabolite ratios; chr16:58736833 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1646282 ENSG00000233719.3 GOT2P3 7.28 1.64e-11 0.00011 0.63 0.51 Blood metabolite ratios; chr16:58741296 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs4784977 ENSG00000233719.3 GOT2P3 7.28 1.64e-11 0.00011 0.63 0.51 Blood metabolite ratios; chr16:58742120 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1646268 ENSG00000233719.3 GOT2P3 7.28 1.64e-11 0.00011 0.63 0.51 Blood metabolite ratios; chr16:58743292 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1646269 ENSG00000233719.3 GOT2P3 7.28 1.64e-11 0.00011 0.63 0.51 Blood metabolite ratios; chr16:58743412 chr12:9641802~9643007:+ PAAD trans rs9611565 0.607 rs132792 ENSG00000268568.1 AC007228.9 7.28 1.65e-11 0.000111 0.8 0.51 Vitiligo; chr22:41666818 chr19:56672574~56673901:- PAAD trans rs2731664 0.792 rs2630764 ENSG00000215571.5 GRK6P1 7.28 1.66e-11 0.000111 0.67 0.51 Intelligence (multi-trait analysis); chr5:177453084 chr13:21319156~21320866:+ PAAD trans rs877636 0.562 rs1131017 ENSG00000235459.5 RPS26P31 -7.28 1.69e-11 0.000113 -0.56 -0.51 Cognitive function; chr12:56042145 chr7:122681315~122681662:+ PAAD trans rs6708331 0.941 rs6720799 ENSG00000232654.1 FAM136BP -7.27 1.72e-11 0.000115 -0.67 -0.51 Obesity-related traits; chr2:70144897 chr6:3045384~3045800:+ PAAD trans rs7395662 0.591 rs4882093 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48509268 chr11:89639227~89698718:+ PAAD trans rs7395662 0.548 rs4882000 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48524944 chr11:89639227~89698718:+ PAAD trans rs7395662 0.611 rs7478698 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48527587 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs4882110 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48536697 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs4882012 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48539045 chr11:89639227~89698718:+ PAAD trans rs7395662 0.571 rs10838947 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48547141 chr11:89639227~89698718:+ PAAD trans rs7395662 0.517 rs10838960 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48563189 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs12807777 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48572202 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs10838968 ENSG00000134612.10 FOLH1B -7.27 1.75e-11 0.000117 -0.59 -0.51 HDL cholesterol; chr11:48573494 chr11:89639227~89698718:+ PAAD trans rs12200782 0.505 rs1535275 ENSG00000242375.1 RP11-498P14.3 7.27 1.76e-11 0.000117 0.92 0.51 Small cell lung carcinoma; chr6:26520539 chr9:97195351~97197687:- PAAD trans rs6732160 0.619 rs12105975 ENSG00000236165.1 PRADC1P1 7.26 1.82e-11 0.000121 0.59 0.51 Intelligence (multi-trait analysis); chr2:73178921 chr3:36976316~36976840:+ PAAD trans rs12709013 0.694 rs1616798 ENSG00000230849.2 GOT2P2 7.26 1.86e-11 0.000124 0.59 0.51 Blood metabolite ratios; chr16:58739433 chr1:173141100~173142350:- PAAD trans rs8081395 0.801 rs2645479 ENSG00000187870.7 RNFT1P3 7.26 1.87e-11 0.000124 0.61 0.51 White blood cell count; chr17:59843171 chr17:20743333~20754501:- PAAD trans rs7395662 1 rs10769371 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48509632 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs4882094 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48510908 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882096 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48512550 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs7478900 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48522451 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs7125110 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48523955 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs4882002 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48525179 chr11:89639227~89698718:+ PAAD trans rs7395662 0.89 rs11039806 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48526164 chr11:89639227~89698718:+ PAAD trans rs7395662 0.864 rs7483617 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48530107 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs12365220 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48534405 chr11:89639227~89698718:+ PAAD trans rs7395662 0.929 rs12363679 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48534471 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10838943 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48535890 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs4882109 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48536133 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882111 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48536895 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4882010 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48537621 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs10838944 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48538019 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs4882112 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48539531 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039817 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48539928 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs12365014 ENSG00000134612.10 FOLH1B -7.26 1.9e-11 0.000126 -0.62 -0.51 HDL cholesterol; chr11:48607882 chr11:89639227~89698718:+ PAAD trans rs1816752 0.669 rs3783072 ENSG00000237917.1 PARP4P1 -7.26 1.92e-11 0.000127 -0.66 -0.51 Obesity-related traits; chr13:24493258 chrY:26594851~26634652:- PAAD trans rs7399018 0.739 rs7399073 ENSG00000223825.5 DAZAP2P1 7.25 1.95e-11 0.000129 0.67 0.51 Cisplatin-induced ototoxicity; chr12:51220266 chr2:202201384~202201886:- PAAD trans rs7395662 0.571 rs4881998 ENSG00000134612.10 FOLH1B -7.25 1.99e-11 0.000131 -0.59 -0.51 HDL cholesterol; chr11:48503634 chr11:89639227~89698718:+ PAAD trans rs916888 0.773 rs169201 ENSG00000204650.12 CRHR1-IT1 7.24 2.06e-11 0.000136 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45620328~45648216:+ PAAD trans rs916888 0.773 rs199439 ENSG00000204650.12 CRHR1-IT1 7.24 2.06e-11 0.000136 0.63 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45620328~45648216:+ PAAD trans rs916888 0.773 rs1378358 ENSG00000204650.12 CRHR1-IT1 7.24 2.1e-11 0.000139 0.62 0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45620328~45648216:+ PAAD trans rs7395662 0.929 rs10838982 ENSG00000134612.10 FOLH1B -7.24 2.13e-11 0.000141 -0.64 -0.51 HDL cholesterol; chr11:48618616 chr11:89639227~89698718:+ PAAD trans rs6708331 1 rs7597199 ENSG00000232654.1 FAM136BP 7.23 2.17e-11 0.000143 0.67 0.51 Obesity-related traits; chr2:70114443 chr6:3045384~3045800:+ PAAD trans rs1816752 0.716 rs1441058 ENSG00000224976.2 PARP4P2 7.23 2.18e-11 0.000144 0.63 0.51 Obesity-related traits; chr13:24516275 chr13:19349137~19407962:+ PAAD trans rs916888 0.697 rs199516 ENSG00000204650.12 CRHR1-IT1 -7.23 2.22e-11 0.000146 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs199514 ENSG00000204650.12 CRHR1-IT1 -7.23 2.22e-11 0.000146 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs199513 ENSG00000204650.12 CRHR1-IT1 -7.23 2.22e-11 0.000146 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs199512 ENSG00000204650.12 CRHR1-IT1 -7.23 2.22e-11 0.000146 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs199509 ENSG00000204650.12 CRHR1-IT1 -7.23 2.22e-11 0.000146 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs199507 ENSG00000204650.12 CRHR1-IT1 -7.23 2.22e-11 0.000146 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs199505 ENSG00000204650.12 CRHR1-IT1 -7.23 2.22e-11 0.000146 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45620328~45648216:+ PAAD trans rs916888 0.821 rs70602 ENSG00000204650.12 CRHR1-IT1 -7.23 2.22e-11 0.000146 -0.62 -0.51 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45620328~45648216:+ PAAD trans rs7395662 1 rs4882132 ENSG00000134612.10 FOLH1B -7.22 2.27e-11 0.000149 -0.62 -0.51 HDL cholesterol; chr11:48571573 chr11:89639227~89698718:+ PAAD trans rs8081395 0.801 rs2665404 ENSG00000187870.7 RNFT1P3 7.22 2.36e-11 0.000155 0.59 0.51 White blood cell count; chr17:59798035 chr17:20743333~20754501:- PAAD trans rs7554547 0.667 rs12065911 ENSG00000261819.1 RP11-680G24.4 7.22 2.38e-11 0.000156 0.64 0.51 Nonsyndromic cleft lip with cleft palate; chr1:11908323 chr16:14988259~14990160:- PAAD trans rs7554547 0.714 rs4845890 ENSG00000261819.1 RP11-680G24.4 7.22 2.38e-11 0.000156 0.64 0.51 Nonsyndromic cleft lip with cleft palate; chr1:11912612 chr16:14988259~14990160:- PAAD trans rs9956878 0.555 rs8085188 ENSG00000220749.4 RPL21P28 7.22 2.38e-11 0.000157 0.58 0.51 Obesity-related traits; chr18:75832721 chr1:212051524~212052006:- PAAD trans rs12709013 0.636 rs1646272 ENSG00000233719.3 GOT2P3 7.2 2.61e-11 0.000171 0.64 0.5 Blood metabolite ratios; chr16:58746508 chr12:9641802~9643007:+ PAAD trans rs12709013 0.66 rs1657163 ENSG00000233719.3 GOT2P3 7.2 2.61e-11 0.000171 0.64 0.5 Blood metabolite ratios; chr16:58746688 chr12:9641802~9643007:+ PAAD trans rs4240897 0.548 rs10746496 ENSG00000261819.1 RP11-680G24.4 7.19 2.68e-11 0.000176 0.65 0.5 Tuberculosis; chr1:11904090 chr16:14988259~14990160:- PAAD trans rs13190036 0.551 rs9313751 ENSG00000217325.2 PRELID1P1 -7.19 2.71e-11 0.000177 -0.78 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177217174 chr6:126643488~126644390:+ PAAD trans rs13190036 0.551 rs11957608 ENSG00000217325.2 PRELID1P1 -7.19 2.71e-11 0.000177 -0.78 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177228344 chr6:126643488~126644390:+ PAAD trans rs12709013 0.636 rs1657161 ENSG00000233719.3 GOT2P3 7.19 2.73e-11 0.000178 0.62 0.5 Blood metabolite ratios; chr16:58743234 chr12:9641802~9643007:+ PAAD trans rs6708331 1 rs62151174 ENSG00000232654.1 FAM136BP 7.19 2.79e-11 0.000183 0.65 0.5 Obesity-related traits; chr2:70136836 chr6:3045384~3045800:+ PAAD trans rs877636 0.562 rs1131017 ENSG00000212829.8 RPS26P3 -7.19 2.8e-11 0.000183 -0.58 -0.5 Cognitive function; chr12:56042145 chr9:9090898~9091245:+ PAAD trans rs11039798 0.66 rs717897 ENSG00000134612.10 FOLH1B -7.18 2.9e-11 0.000189 -0.78 -0.5 Axial length; chr11:48354052 chr11:89639227~89698718:+ PAAD trans rs916888 0.821 rs415430 ENSG00000204650.12 CRHR1-IT1 -7.18 2.94e-11 0.000191 -0.62 -0.5 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45620328~45648216:+ PAAD trans rs916888 0.779 rs430685 ENSG00000204650.12 CRHR1-IT1 -7.18 2.94e-11 0.000191 -0.62 -0.5 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45620328~45648216:+ PAAD trans rs2731664 0.756 rs2545796 ENSG00000215571.5 GRK6P1 7.18 2.94e-11 0.000191 0.67 0.5 Intelligence (multi-trait analysis); chr5:177437268 chr13:21319156~21320866:+ PAAD trans rs2731664 0.792 rs1130857 ENSG00000215571.5 GRK6P1 7.18 2.94e-11 0.000191 0.67 0.5 Intelligence (multi-trait analysis); chr5:177436518 chr13:21319156~21320866:+ PAAD trans rs2657294 0.62 rs4746259 ENSG00000172974.11 AC007318.5 7.18 2.95e-11 0.000192 0.6 0.5 Pneumonia; chr10:75082310 chr2:65205108~65205988:+ PAAD trans rs13253073 1 rs34029308 ENSG00000260318.1 COX6CP1 7.17 2.99e-11 0.000194 1.13 0.5 Glucose homeostasis traits; chr8:99892425 chr16:11903923~11904137:- PAAD trans rs877636 0.562 rs1131017 ENSG00000234513.1 AC073072.7 -7.17 3.02e-11 0.000196 -0.55 -0.5 Cognitive function; chr12:56042145 chr7:22773646~22773993:- PAAD trans rs7395662 0.591 rs11039766 ENSG00000134612.10 FOLH1B -7.17 3.02e-11 0.000196 -0.58 -0.5 HDL cholesterol; chr11:48467163 chr11:89639227~89698718:+ PAAD trans rs11332131 1 rs11332131 ENSG00000187870.7 RNFT1P3 7.17 3.07e-11 0.000199 0.6 0.5 Platelet distribution width; chr17:59849031 chr17:20743333~20754501:- PAAD trans rs2657294 0.62 rs9783273 ENSG00000172974.11 AC007318.5 7.17 3.12e-11 0.000202 0.6 0.5 Pneumonia; chr10:75081982 chr2:65205108~65205988:+ PAAD trans rs12200782 0.53 rs6929908 ENSG00000242375.1 RP11-498P14.3 7.17 3.14e-11 0.000203 0.92 0.5 Small cell lung carcinoma; chr6:26555061 chr9:97195351~97197687:- PAAD trans rs8010715 0.636 rs2277482 ENSG00000248988.1 RP11-815N9.2 7.16 3.19e-11 0.000206 0.71 0.5 IgG glycosylation; chr14:24118586 chr4:159007119~159007835:+ PAAD trans rs10242455 0.571 rs79694709 ENSG00000228834.1 RP11-249L21.4 7.16 3.3e-11 0.000212 1.33 0.5 Blood metabolite levels; chr7:99617088 chr6:108907615~108907873:- PAAD trans rs11039798 0.588 rs61932767 ENSG00000134612.10 FOLH1B 7.15 3.38e-11 0.000217 0.76 0.5 Axial length; chr11:48683254 chr11:89639227~89698718:+ PAAD trans rs12709013 0.646 rs8046154 ENSG00000233719.3 GOT2P3 -7.15 3.42e-11 0.00022 -0.64 -0.5 Blood metabolite ratios; chr16:58773978 chr12:9641802~9643007:+ PAAD trans rs8081395 0.801 rs2665405 ENSG00000187870.7 RNFT1P3 -7.15 3.44e-11 0.000221 -0.59 -0.5 White blood cell count; chr17:59797931 chr17:20743333~20754501:- PAAD trans rs6477998 0.58 rs10817467 ENSG00000238072.1 RP11-305M3.2 7.14 3.52e-11 0.000226 0.77 0.5 Hematology traits; chr9:113246803 chr7:129410113~129410370:- PAAD trans rs916888 0.821 rs199504 ENSG00000204650.12 CRHR1-IT1 -7.14 3.59e-11 0.00023 -0.61 -0.5 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45620328~45648216:+ PAAD trans rs11039798 0.511 rs2047812 ENSG00000134612.10 FOLH1B -7.14 3.6e-11 0.000231 -0.77 -0.5 Axial length; chr11:48140490 chr11:89639227~89698718:+ PAAD trans rs11039571 0.544 rs7947811 ENSG00000134612.10 FOLH1B -7.14 3.6e-11 0.000231 -0.77 -0.5 D-dimer levels; chr11:48146186 chr11:89639227~89698718:+ PAAD trans rs11039798 0.511 rs7948129 ENSG00000134612.10 FOLH1B -7.14 3.6e-11 0.000231 -0.77 -0.5 Axial length; chr11:48146276 chr11:89639227~89698718:+ PAAD trans rs6708331 1 rs13000817 ENSG00000232654.1 FAM136BP 7.14 3.66e-11 0.000235 0.66 0.5 Obesity-related traits; chr2:70046575 chr6:3045384~3045800:+ PAAD trans rs10037055 0.853 rs10035180 ENSG00000217325.2 PRELID1P1 -7.14 3.67e-11 0.000235 -0.73 -0.5 Migraine without aura; chr5:177171501 chr6:126643488~126644390:+ PAAD trans rs10037055 0.853 rs1546363 ENSG00000217325.2 PRELID1P1 -7.14 3.67e-11 0.000235 -0.73 -0.5 Migraine without aura; chr5:177174030 chr6:126643488~126644390:+ PAAD trans rs10037055 0.853 rs10056008 ENSG00000217325.2 PRELID1P1 -7.14 3.67e-11 0.000235 -0.73 -0.5 Migraine without aura; chr5:177194147 chr6:126643488~126644390:+ PAAD trans rs10037055 0.853 rs10476219 ENSG00000217325.2 PRELID1P1 -7.14 3.67e-11 0.000235 -0.73 -0.5 Migraine without aura; chr5:177201547 chr6:126643488~126644390:+ PAAD trans rs10037055 0.853 rs1363405 ENSG00000217325.2 PRELID1P1 7.14 3.67e-11 0.000235 0.73 0.5 Migraine without aura; chr5:177209881 chr6:126643488~126644390:+ PAAD trans rs1814175 0.935 rs7482690 ENSG00000134612.10 FOLH1B -7.13 3.7e-11 0.000237 -0.58 -0.5 Height; chr11:49627262 chr11:89639227~89698718:+ PAAD trans rs2657294 0.62 rs2395132 ENSG00000172974.11 AC007318.5 7.13 3.72e-11 0.000238 0.61 0.5 Pneumonia; chr10:75080840 chr2:65205108~65205988:+ PAAD trans rs7554547 0.714 rs926269 ENSG00000261819.1 RP11-680G24.4 7.13 3.73e-11 0.000238 0.63 0.5 Nonsyndromic cleft lip with cleft palate; chr1:11909691 chr16:14988259~14990160:- PAAD trans rs7554547 0.714 rs2878679 ENSG00000261819.1 RP11-680G24.4 7.13 3.73e-11 0.000238 0.63 0.5 Nonsyndromic cleft lip with cleft palate; chr1:11915586 chr16:14988259~14990160:- PAAD trans rs13190036 0.551 rs28932178 ENSG00000217325.2 PRELID1P1 -7.13 3.88e-11 0.000248 -0.76 -0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210575 chr6:126643488~126644390:+ PAAD trans rs12709013 0.597 rs1616072 ENSG00000233719.3 GOT2P3 7.13 3.88e-11 0.000248 0.63 0.5 Blood metabolite ratios; chr16:58747194 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs2575374 ENSG00000233719.3 GOT2P3 7.13 3.88e-11 0.000248 0.63 0.5 Blood metabolite ratios; chr16:58747494 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1657164 ENSG00000233719.3 GOT2P3 7.13 3.88e-11 0.000248 0.63 0.5 Blood metabolite ratios; chr16:58747949 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs72792430 ENSG00000233719.3 GOT2P3 -7.13 3.88e-11 0.000248 -0.63 -0.5 Blood metabolite ratios; chr16:58746990 chr12:9641802~9643007:+ PAAD trans rs703108 0.731 rs7898954 ENSG00000218426.5 RP11-475C16.1 -7.13 3.89e-11 0.000248 -0.5 -0.5 Monocyte percentage of white cells; chr10:22034717 chr6:153282287~153282733:- PAAD trans rs8010715 0.636 rs2277480 ENSG00000248988.1 RP11-815N9.2 7.12 3.98e-11 0.000253 0.71 0.5 IgG glycosylation; chr14:24118306 chr4:159007119~159007835:+ PAAD trans rs11039798 0.588 rs12278284 ENSG00000134612.10 FOLH1B 7.12 4.07e-11 0.000259 0.76 0.5 Axial length; chr11:48590511 chr11:89639227~89698718:+ PAAD trans rs2731664 0.792 rs335435 ENSG00000215571.5 GRK6P1 7.12 4.09e-11 0.00026 0.68 0.5 Intelligence (multi-trait analysis); chr5:177440942 chr13:21319156~21320866:+ PAAD trans rs7554547 0.667 rs11121839 ENSG00000261819.1 RP11-680G24.4 7.12 4.11e-11 0.000261 0.63 0.5 Nonsyndromic cleft lip with cleft palate; chr1:11908280 chr16:14988259~14990160:- PAAD trans rs1814175 0.867 rs7926002 ENSG00000134612.10 FOLH1B -7.11 4.14e-11 0.000263 -0.58 -0.5 Height; chr11:49594466 chr11:89639227~89698718:+ PAAD trans rs8081395 0.801 rs2777895 ENSG00000187870.7 RNFT1P3 -7.11 4.14e-11 0.000263 -0.58 -0.5 White blood cell count; chr17:59802249 chr17:20743333~20754501:- PAAD trans rs8081395 0.769 rs12449331 ENSG00000187870.7 RNFT1P3 -7.11 4.14e-11 0.000263 -0.58 -0.5 White blood cell count; chr17:59806285 chr17:20743333~20754501:- PAAD trans rs13253073 1 rs4409375 ENSG00000260318.1 COX6CP1 7.11 4.17e-11 0.000265 1.1 0.5 Glucose homeostasis traits; chr8:99877759 chr16:11903923~11904137:- PAAD trans rs116095464 0.558 rs6962 ENSG00000185986.11 SDHAP3 7.11 4.27e-11 0.000271 0.67 0.5 Breast cancer; chr5:256394 chr5:1572222~1594620:- PAAD trans rs10838798 0.523 rs4752907 ENSG00000134612.10 FOLH1B -7.11 4.29e-11 0.000272 -0.59 -0.5 Height; chr11:48149029 chr11:89639227~89698718:+ PAAD trans rs10838798 0.523 rs2019093 ENSG00000134612.10 FOLH1B -7.11 4.29e-11 0.000272 -0.59 -0.5 Height; chr11:48175001 chr11:89639227~89698718:+ PAAD trans rs12709013 0.792 rs1646270 ENSG00000230849.2 GOT2P2 7.1 4.37e-11 0.000277 0.58 0.5 Blood metabolite ratios; chr16:58745823 chr1:173141100~173142350:- PAAD trans rs11039798 0.588 rs6485891 ENSG00000134612.10 FOLH1B 7.1 4.37e-11 0.000277 0.76 0.5 Axial length; chr11:48590472 chr11:89639227~89698718:+ PAAD trans rs2727020 0.658 rs4980440 ENSG00000134612.10 FOLH1B -7.1 4.44e-11 0.000281 -0.58 -0.5 Coronary artery disease; chr11:49364465 chr11:89639227~89698718:+ PAAD trans rs11039798 0.557 rs4441015 ENSG00000134612.10 FOLH1B 7.1 4.53e-11 0.000286 0.8 0.5 Axial length; chr11:49005518 chr11:89639227~89698718:+ PAAD trans rs12200782 0.53 rs9379892 ENSG00000242375.1 RP11-498P14.3 7.1 4.57e-11 0.000289 0.93 0.5 Small cell lung carcinoma; chr6:26582186 chr9:97195351~97197687:- PAAD trans rs616147 0.627 rs9871799 ENSG00000183298.5 RP11-556K13.1 7.1 4.57e-11 0.000289 0.69 0.5 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39442829 chr1:101786340~101787219:- PAAD trans rs7312770 0.612 rs1873914 ENSG00000225071.1 GS1-184P14.2 7.1 4.58e-11 0.000289 0.57 0.5 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chrX:24429573~24429920:- PAAD trans rs12200782 0.505 rs9295696 ENSG00000242375.1 RP11-498P14.3 7.09 4.61e-11 0.000291 0.9 0.5 Small cell lung carcinoma; chr6:26550060 chr9:97195351~97197687:- PAAD trans rs616147 0.627 rs816487 ENSG00000183298.5 RP11-556K13.1 -7.09 4.72e-11 0.000298 -0.71 -0.5 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39445999 chr1:101786340~101787219:- PAAD trans rs7395662 0.745 rs10838830 ENSG00000134612.10 FOLH1B 7.09 4.73e-11 0.000298 0.62 0.5 HDL cholesterol; chr11:48212380 chr11:89639227~89698718:+ PAAD trans rs12709013 0.576 rs2432622 ENSG00000233719.3 GOT2P3 7.09 4.74e-11 0.000299 0.64 0.5 Blood metabolite ratios; chr16:58749681 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1646281 ENSG00000233719.3 GOT2P3 7.09 4.74e-11 0.000299 0.64 0.5 Blood metabolite ratios; chr16:58750512 chr12:9641802~9643007:+ PAAD trans rs12709013 0.613 rs1618602 ENSG00000233719.3 GOT2P3 7.09 4.74e-11 0.000299 0.64 0.5 Blood metabolite ratios; chr16:58756080 chr12:9641802~9643007:+ PAAD trans rs12709013 0.613 rs8049462 ENSG00000233719.3 GOT2P3 7.09 4.74e-11 0.000299 0.64 0.5 Blood metabolite ratios; chr16:58757654 chr12:9641802~9643007:+ PAAD trans rs12709013 0.66 rs257629 ENSG00000233719.3 GOT2P3 7.09 4.74e-11 0.000299 0.64 0.5 Blood metabolite ratios; chr16:58758044 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs8045466 ENSG00000233719.3 GOT2P3 7.09 4.74e-11 0.000299 0.64 0.5 Blood metabolite ratios; chr16:58765113 chr12:9641802~9643007:+ PAAD trans rs1816752 0.608 rs4770690 ENSG00000237917.1 PARP4P1 -7.09 4.75e-11 0.000299 -0.64 -0.5 Obesity-related traits; chr13:24467049 chrY:26594851~26634652:- PAAD trans rs6708331 0.941 rs7609359 ENSG00000232654.1 FAM136BP 7.08 4.87e-11 0.000306 0.64 0.5 Obesity-related traits; chr2:70131844 chr6:3045384~3045800:+ PAAD trans rs6708331 0.941 rs7595262 ENSG00000232654.1 FAM136BP 7.08 4.87e-11 0.000306 0.64 0.5 Obesity-related traits; chr2:70131865 chr6:3045384~3045800:+ PAAD trans rs6708331 0.941 rs10173330 ENSG00000232654.1 FAM136BP 7.08 4.87e-11 0.000306 0.64 0.5 Obesity-related traits; chr2:70139981 chr6:3045384~3045800:+ PAAD trans rs6708331 0.941 rs10173259 ENSG00000232654.1 FAM136BP 7.08 4.87e-11 0.000306 0.64 0.5 Obesity-related traits; chr2:70140078 chr6:3045384~3045800:+ PAAD trans rs6708331 0.941 rs12989257 ENSG00000232654.1 FAM136BP 7.08 4.87e-11 0.000306 0.64 0.5 Obesity-related traits; chr2:70141466 chr6:3045384~3045800:+ PAAD trans rs10037055 0.947 rs10063803 ENSG00000217325.2 PRELID1P1 7.08 4.94e-11 0.00031 0.73 0.5 Migraine without aura; chr5:177240326 chr6:126643488~126644390:+ PAAD trans rs12709013 0.636 rs1646284 ENSG00000233719.3 GOT2P3 7.08 4.95e-11 0.000311 0.64 0.5 Blood metabolite ratios; chr16:58752093 chr12:9641802~9643007:+ PAAD trans rs2727020 0.558 rs1164675 ENSG00000134612.10 FOLH1B 7.08 4.99e-11 0.000313 0.61 0.5 Coronary artery disease; chr11:49304420 chr11:89639227~89698718:+ PAAD trans rs11039798 0.66 rs28435129 ENSG00000134612.10 FOLH1B 7.08 5.05e-11 0.000317 0.76 0.5 Axial length; chr11:48608243 chr11:89639227~89698718:+ PAAD trans rs12709013 0.792 rs12325510 ENSG00000230849.2 GOT2P2 7.07 5.14e-11 0.000323 0.57 0.5 Blood metabolite ratios; chr16:58749707 chr1:173141100~173142350:- PAAD trans rs6708331 1 rs6708331 ENSG00000232654.1 FAM136BP 7.07 5.19e-11 0.000325 0.63 0.5 Obesity-related traits; chr2:70141791 chr6:3045384~3045800:+ PAAD trans rs877636 0.669 rs7297175 ENSG00000235459.5 RPS26P31 -7.07 5.27e-11 0.000331 -0.55 -0.5 Cognitive function; chr12:56080024 chr7:122681315~122681662:+ PAAD trans rs10037055 0.853 rs2336237 ENSG00000217325.2 PRELID1P1 7.06 5.52e-11 0.000346 0.7 0.5 Migraine without aura; chr5:177238878 chr6:126643488~126644390:+ PAAD trans rs73099903 0.611 rs7306523 ENSG00000229939.1 RP11-111F16.2 7.06 5.54e-11 0.000347 0.79 0.5 Systolic blood pressure; chr12:53000180 chrX:111618808~111619094:+ PAAD trans rs12709013 0.591 rs899375 ENSG00000233719.3 GOT2P3 7.06 5.62e-11 0.000352 0.63 0.5 Blood metabolite ratios; chr16:58792325 chr12:9641802~9643007:+ PAAD trans rs7395662 1 rs11039800 ENSG00000134612.10 FOLH1B 7.06 5.67e-11 0.000355 0.6 0.5 HDL cholesterol; chr11:48521027 chr11:89639227~89698718:+ PAAD trans rs9611565 1 rs1109151 ENSG00000268568.1 AC007228.9 -7.05 5.8e-11 0.000362 -0.75 -0.5 Vitiligo; chr22:41356940 chr19:56672574~56673901:- PAAD trans rs12709013 0.636 rs4538000 ENSG00000233719.3 GOT2P3 7.05 5.84e-11 0.000364 0.63 0.5 Blood metabolite ratios; chr16:58744506 chr12:9641802~9643007:+ PAAD trans rs12709013 0.792 rs12325054 ENSG00000230849.2 GOT2P2 7.05 5.85e-11 0.000365 0.57 0.5 Blood metabolite ratios; chr16:58749804 chr1:173141100~173142350:- PAAD trans rs2657294 0.62 rs7475340 ENSG00000172974.11 AC007318.5 7.05 5.9e-11 0.000368 0.6 0.5 Pneumonia; chr10:75079597 chr2:65205108~65205988:+ PAAD trans rs7554547 0.69 rs4846064 ENSG00000261819.1 RP11-680G24.4 7.05 5.91e-11 0.000368 0.62 0.5 Nonsyndromic cleft lip with cleft palate; chr1:11874785 chr16:14988259~14990160:- PAAD trans rs7554547 0.703 rs7543258 ENSG00000261819.1 RP11-680G24.4 7.05 5.92e-11 0.000369 0.63 0.5 Nonsyndromic cleft lip with cleft palate; chr1:11901599 chr16:14988259~14990160:- PAAD trans rs13190036 1 rs28580074 ENSG00000226986.4 RP11-543B16.2 7.05 5.95e-11 0.00037 0.8 0.5 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177294197 chr1:211207239~211207897:+ PAAD trans rs7395662 0.571 rs1605358 ENSG00000134612.10 FOLH1B -7.05 5.97e-11 0.000371 -0.61 -0.5 HDL cholesterol; chr11:48667766 chr11:89639227~89698718:+ PAAD trans rs7395662 0.804 rs8186428 ENSG00000134612.10 FOLH1B -7.05 5.97e-11 0.000371 -0.61 -0.5 HDL cholesterol; chr11:48713125 chr11:89639227~89698718:+ PAAD trans rs7395662 0.782 rs66468703 ENSG00000134612.10 FOLH1B -7.05 5.97e-11 0.000371 -0.61 -0.5 HDL cholesterol; chr11:48717221 chr11:89639227~89698718:+ PAAD trans rs7395662 0.736 rs4882036 ENSG00000134612.10 FOLH1B -7.05 5.97e-11 0.000371 -0.61 -0.5 HDL cholesterol; chr11:48727832 chr11:89639227~89698718:+ PAAD trans rs13253073 1 rs12544943 ENSG00000260318.1 COX6CP1 7.05 5.98e-11 0.000372 1.07 0.5 Glucose homeostasis traits; chr8:99891662 chr16:11903923~11904137:- PAAD trans rs9693857 1 rs9693857 ENSG00000253893.2 FAM85B 7.04 6.05e-11 0.000376 0.68 0.5 Systolic blood pressure; chr8:9409607 chr8:8167819~8226614:- PAAD trans rs11039798 0.582 rs60764175 ENSG00000134612.10 FOLH1B 7.04 6.08e-11 0.000378 0.76 0.5 Axial length; chr11:48754304 chr11:89639227~89698718:+ PAAD trans rs1816752 0.603 rs9511278 ENSG00000237917.1 PARP4P1 -7.04 6.14e-11 0.000381 -0.62 -0.5 Obesity-related traits; chr13:24455766 chrY:26594851~26634652:- PAAD trans rs6708331 1 rs35734267 ENSG00000232654.1 FAM136BP 7.04 6.2e-11 0.000385 0.66 0.5 Obesity-related traits; chr2:70054058 chr6:3045384~3045800:+ PAAD trans rs916888 0.773 rs9896243 ENSG00000204650.12 CRHR1-IT1 7.04 6.31e-11 0.000391 0.61 0.5 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45620328~45648216:+ PAAD trans rs12709013 0.636 rs10852565 ENSG00000233719.3 GOT2P3 7.04 6.33e-11 0.000392 0.63 0.5 Blood metabolite ratios; chr16:58771277 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs9937713 ENSG00000233719.3 GOT2P3 7.04 6.33e-11 0.000392 0.63 0.5 Blood metabolite ratios; chr16:58771921 chr12:9641802~9643007:+ PAAD trans rs12709013 0.597 rs8051078 ENSG00000233719.3 GOT2P3 7.04 6.33e-11 0.000392 0.63 0.5 Blood metabolite ratios; chr16:58774200 chr12:9641802~9643007:+ PAAD trans rs7260598 0.535 rs13343732 ENSG00000261770.1 CTC-459F4.1 7.03 6.41e-11 0.000396 0.64 0.5 Response to taxane treatment (placlitaxel); chr19:23928479 chr19:27757184~27760849:- PAAD trans rs10838798 0.523 rs11039593 ENSG00000134612.10 FOLH1B -7.03 6.47e-11 0.000399 -0.58 -0.5 Height; chr11:48218560 chr11:89639227~89698718:+ PAAD trans rs6708331 0.938 rs36025045 ENSG00000232654.1 FAM136BP 7.03 6.53e-11 0.000403 0.65 0.5 Obesity-related traits; chr2:70121829 chr6:3045384~3045800:+ PAAD trans rs8081395 0.801 rs12938273 ENSG00000187870.7 RNFT1P3 -7.03 6.56e-11 0.000405 -0.58 -0.5 White blood cell count; chr17:59824291 chr17:20743333~20754501:- PAAD trans rs8081395 0.836 rs1292061 ENSG00000187870.7 RNFT1P3 -7.03 6.56e-11 0.000405 -0.58 -0.5 White blood cell count; chr17:59833869 chr17:20743333~20754501:- PAAD trans rs12709013 0.792 rs1657165 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58747980 chr1:173141100~173142350:- PAAD trans rs12709013 0.818 rs1646273 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58748318 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs1646276 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58749654 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs1646277 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58750037 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs62066815 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58751577 chr1:173141100~173142350:- PAAD trans rs12709013 0.766 rs1657175 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58755527 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs1646290 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58755807 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs1364346 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58756420 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs257626 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58759574 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs257625 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58759978 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs1646262 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58760593 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs257623 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58761247 chr1:173141100~173142350:- PAAD trans rs12709013 0.693 rs1627257 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58763764 chr1:173141100~173142350:- PAAD trans rs12709013 0.755 rs1628029 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58763846 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs12926512 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58768317 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs12595974 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58769132 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs1836877 ENSG00000230849.2 GOT2P2 7.03 6.63e-11 0.000408 0.57 0.5 Blood metabolite ratios; chr16:58769821 chr1:173141100~173142350:- PAAD trans rs877636 0.692 rs10876870 ENSG00000196656.7 AC004057.1 -7.02 6.78e-11 0.000416 -0.5 -0.49 Cognitive function; chr12:56084218 chr4:113214046~113217170:- PAAD trans rs877636 0.692 rs7971751 ENSG00000196656.7 AC004057.1 -7.02 6.78e-11 0.000416 -0.5 -0.49 Cognitive function; chr12:56084874 chr4:113214046~113217170:- PAAD trans rs9650657 0.645 rs4841408 ENSG00000253893.2 FAM85B 7.02 6.86e-11 0.000421 0.67 0.49 Neuroticism; chr8:10658826 chr8:8167819~8226614:- PAAD trans rs10838798 0.504 rs11039673 ENSG00000134612.10 FOLH1B -7.02 6.91e-11 0.000424 -0.58 -0.49 Height; chr11:48313604 chr11:89639227~89698718:+ PAAD trans rs12709013 0.792 rs12935488 ENSG00000230849.2 GOT2P2 7.02 6.93e-11 0.000425 0.57 0.49 Blood metabolite ratios; chr16:58766320 chr1:173141100~173142350:- PAAD trans rs7395662 0.926 rs11039893 ENSG00000134612.10 FOLH1B -7.02 7.02e-11 0.000431 -0.61 -0.49 HDL cholesterol; chr11:48636202 chr11:89639227~89698718:+ PAAD trans rs12709013 0.574 rs35321124 ENSG00000233719.3 GOT2P3 7.02 7.08e-11 0.000434 0.63 0.49 Blood metabolite ratios; chr16:58786561 chr12:9641802~9643007:+ PAAD trans rs6708331 1 rs12999430 ENSG00000232654.1 FAM136BP 7.01 7.11e-11 0.000436 0.66 0.49 Obesity-related traits; chr2:70079653 chr6:3045384~3045800:+ PAAD trans rs6477998 0.603 rs12338803 ENSG00000238072.1 RP11-305M3.2 7.01 7.17e-11 0.000439 0.74 0.49 Hematology traits; chr9:113263148 chr7:129410113~129410370:- PAAD trans rs7312770 0.637 rs705699 ENSG00000225071.1 GS1-184P14.2 7.01 7.25e-11 0.000444 0.56 0.49 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chrX:24429573~24429920:- PAAD trans rs10838798 0.523 rs4752917 ENSG00000134612.10 FOLH1B -7.01 7.28e-11 0.000446 -0.57 -0.49 Height; chr11:48220087 chr11:89639227~89698718:+ PAAD trans rs6708331 0.941 rs6749886 ENSG00000232654.1 FAM136BP 7.01 7.29e-11 0.000446 0.66 0.49 Obesity-related traits; chr2:70062968 chr6:3045384~3045800:+ PAAD trans rs7395662 1 rs12420372 ENSG00000134612.10 FOLH1B 7.01 7.36e-11 0.00045 0.59 0.49 HDL cholesterol; chr11:48476051 chr11:89639227~89698718:+ PAAD trans rs7395662 0.611 rs4882089 ENSG00000134612.10 FOLH1B -7 7.55e-11 0.00046 -0.57 -0.49 HDL cholesterol; chr11:48494060 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs11039776 ENSG00000134612.10 FOLH1B -7 7.55e-11 0.00046 -0.57 -0.49 HDL cholesterol; chr11:48495154 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs666165 ENSG00000134612.10 FOLH1B -7 7.65e-11 0.000467 -0.75 -0.49 Axial length; chr11:48435887 chr11:89639227~89698718:+ PAAD trans rs11039798 0.557 rs683180 ENSG00000134612.10 FOLH1B -7 7.65e-11 0.000467 -0.75 -0.49 Axial length; chr11:48442397 chr11:89639227~89698718:+ PAAD trans rs12709013 0.792 rs12598527 ENSG00000230849.2 GOT2P2 6.99 7.96e-11 0.000484 0.57 0.49 Blood metabolite ratios; chr16:58772987 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs12600201 ENSG00000230849.2 GOT2P2 6.99 7.96e-11 0.000484 0.57 0.49 Blood metabolite ratios; chr16:58773132 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs12600206 ENSG00000230849.2 GOT2P2 6.99 7.96e-11 0.000484 0.57 0.49 Blood metabolite ratios; chr16:58773169 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs11076263 ENSG00000230849.2 GOT2P2 6.99 7.96e-11 0.000484 0.57 0.49 Blood metabolite ratios; chr16:58773295 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs11646756 ENSG00000230849.2 GOT2P2 6.99 7.96e-11 0.000484 0.57 0.49 Blood metabolite ratios; chr16:58773598 chr1:173141100~173142350:- PAAD trans rs703108 0.731 rs7898954 ENSG00000227063.5 RPL41P1 -6.99 8.08e-11 0.000491 -0.62 -0.49 Monocyte percentage of white cells; chr10:22034717 chr20:21755270~21755350:+ PAAD trans rs10838798 0.504 rs11039634 ENSG00000134612.10 FOLH1B -6.99 8.09e-11 0.000491 -0.57 -0.49 Height; chr11:48276291 chr11:89639227~89698718:+ PAAD trans rs12709013 0.636 rs6499976 ENSG00000233719.3 GOT2P3 6.99 8.29e-11 0.000502 0.62 0.49 Blood metabolite ratios; chr16:58770330 chr12:9641802~9643007:+ PAAD trans rs12709013 0.591 rs30838 ENSG00000233719.3 GOT2P3 6.99 8.33e-11 0.000504 0.66 0.49 Blood metabolite ratios; chr16:58711513 chr12:9641802~9643007:+ PAAD trans rs12709013 0.766 rs12599331 ENSG00000230849.2 GOT2P2 6.98 8.37e-11 0.000506 0.56 0.49 Blood metabolite ratios; chr16:58805307 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs12928733 ENSG00000230849.2 GOT2P2 6.98 8.37e-11 0.000506 0.56 0.49 Blood metabolite ratios; chr16:58807216 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs62066381 ENSG00000230849.2 GOT2P2 6.98 8.37e-11 0.000506 0.56 0.49 Blood metabolite ratios; chr16:58807981 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs8049572 ENSG00000230849.2 GOT2P2 6.98 8.37e-11 0.000506 0.56 0.49 Blood metabolite ratios; chr16:58809672 chr1:173141100~173142350:- PAAD trans rs12709013 0.766 rs34438483 ENSG00000230849.2 GOT2P2 6.98 8.37e-11 0.000506 0.56 0.49 Blood metabolite ratios; chr16:58810530 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs36098613 ENSG00000230849.2 GOT2P2 6.98 8.37e-11 0.000506 0.56 0.49 Blood metabolite ratios; chr16:58810562 chr1:173141100~173142350:- PAAD trans rs7258465 1 rs10405636 ENSG00000267533.1 RP11-815J4.7 6.98 8.51e-11 0.000514 0.61 0.49 Breast cancer; chr19:18427932 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs3810429 ENSG00000267533.1 RP11-815J4.7 6.98 8.51e-11 0.000514 0.61 0.49 Breast cancer; chr19:18432460 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs10442 ENSG00000267533.1 RP11-815J4.7 6.98 8.51e-11 0.000514 0.61 0.49 Breast cancer; chr19:18434531 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs2303697 ENSG00000267533.1 RP11-815J4.7 6.98 8.51e-11 0.000514 0.61 0.49 Breast cancer; chr19:18435868 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs4595905 ENSG00000267533.1 RP11-815J4.7 6.98 8.51e-11 0.000514 0.61 0.49 Breast cancer; chr19:18436495 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs10427083 ENSG00000267533.1 RP11-815J4.7 6.98 8.51e-11 0.000514 0.61 0.49 Breast cancer; chr19:18439466 chr18:12067173~12068417:- PAAD trans rs12709013 0.537 rs1657167 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58748955 chr12:9641802~9643007:+ PAAD trans rs12709013 0.601 rs2432621 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58749676 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs8054414 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58749772 chr12:9641802~9643007:+ PAAD trans rs12709013 0.597 rs11076259 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58749860 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs12325516 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58749899 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs11076260 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58749942 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1646278 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58750084 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1646280 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58750420 chr12:9641802~9643007:+ PAAD trans rs12709013 0.597 rs1646286 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58752651 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1624301 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58753491 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1626006 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58753691 chr12:9641802~9643007:+ PAAD trans rs12709013 0.684 rs1646287 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58753774 chr12:9641802~9643007:+ PAAD trans rs12709013 0.671 rs1369933 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58753927 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1369934 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58754124 chr12:9641802~9643007:+ PAAD trans rs12709013 0.561 rs1657174 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58755139 chr12:9641802~9643007:+ PAAD trans rs12709013 0.613 rs1646288 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58755576 chr12:9641802~9643007:+ PAAD trans rs12709013 0.561 rs727484 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58756568 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs257628 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58758924 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs257627 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58758956 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs191783 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58759994 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs257624 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58760994 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs8060717 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58765574 chr12:9641802~9643007:+ PAAD trans rs12709013 0.559 rs8060721 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58765581 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs8044542 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58765620 chr12:9641802~9643007:+ PAAD trans rs12709013 0.621 rs6499974 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58769642 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs4499224 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58770364 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1595180 ENSG00000233719.3 GOT2P3 6.98 8.54e-11 0.000514 0.62 0.49 Blood metabolite ratios; chr16:58770545 chr12:9641802~9643007:+ PAAD trans rs10838798 0.504 rs10838852 ENSG00000134612.10 FOLH1B -6.98 8.54e-11 0.000514 -0.57 -0.49 Height; chr11:48264704 chr11:89639227~89698718:+ PAAD trans rs10838798 0.504 rs7479393 ENSG00000134612.10 FOLH1B -6.98 8.54e-11 0.000514 -0.57 -0.49 Height; chr11:48273751 chr11:89639227~89698718:+ PAAD trans rs10838798 0.504 rs1483123 ENSG00000134612.10 FOLH1B -6.98 8.54e-11 0.000514 -0.57 -0.49 Height; chr11:48305221 chr11:89639227~89698718:+ PAAD trans rs8081395 0.836 rs1295926 ENSG00000187870.7 RNFT1P3 -6.97 9.05e-11 0.000543 -0.58 -0.49 White blood cell count; chr17:59832012 chr17:20743333~20754501:- PAAD trans rs12709013 0.597 rs1657171 ENSG00000233719.3 GOT2P3 6.97 9.25e-11 0.000553 0.62 0.49 Blood metabolite ratios; chr16:58752083 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs1646285 ENSG00000233719.3 GOT2P3 6.97 9.25e-11 0.000553 0.62 0.49 Blood metabolite ratios; chr16:58752102 chr12:9641802~9643007:+ PAAD trans rs9650657 0.645 rs4841411 ENSG00000253893.2 FAM85B -6.96 9.33e-11 0.000557 -0.71 -0.49 Neuroticism; chr8:10664380 chr8:8167819~8226614:- PAAD trans rs12200782 0.505 rs7765920 ENSG00000242375.1 RP11-498P14.3 6.96 9.33e-11 0.000558 0.85 0.49 Small cell lung carcinoma; chr6:26514543 chr9:97195351~97197687:- PAAD trans rs7937890 0.874 rs6486191 ENSG00000236360.2 RP11-334A14.2 6.96 9.34e-11 0.000558 0.67 0.49 Mitochondrial DNA levels; chr11:14382193 chr1:52993201~52993702:- PAAD trans rs7312770 0.612 rs1873914 ENSG00000212829.8 RPS26P3 6.96 9.44e-11 0.000564 0.59 0.49 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr9:9090898~9091245:+ PAAD trans rs7811142 1 rs68116612 ENSG00000228546.2 CTA-313A17.3 6.96 9.48e-11 0.000566 0.72 0.49 Platelet count; chr7:100408870 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs28490152 ENSG00000228546.2 CTA-313A17.3 6.96 9.48e-11 0.000566 0.72 0.49 Platelet count; chr7:100423359 chr7:102337316~102339115:+ PAAD trans rs7811142 0.943 rs28660238 ENSG00000228546.2 CTA-313A17.3 6.96 9.48e-11 0.000566 0.72 0.49 Platelet count; chr7:100425685 chr7:102337316~102339115:+ PAAD trans rs7395662 0.963 rs11039772 ENSG00000134612.10 FOLH1B -6.96 9.69e-11 0.000578 -0.59 -0.49 HDL cholesterol; chr11:48492340 chr11:89639227~89698718:+ PAAD trans rs7395662 0.963 rs11039773 ENSG00000134612.10 FOLH1B -6.96 9.69e-11 0.000578 -0.59 -0.49 HDL cholesterol; chr11:48492379 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039777 ENSG00000134612.10 FOLH1B -6.96 9.69e-11 0.000578 -0.59 -0.49 HDL cholesterol; chr11:48495497 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs11039779 ENSG00000134612.10 FOLH1B -6.96 9.69e-11 0.000578 -0.59 -0.49 HDL cholesterol; chr11:48496343 chr11:89639227~89698718:+ PAAD trans rs7395662 0.526 rs4882001 ENSG00000134612.10 FOLH1B -6.95 9.8e-11 0.000584 -0.56 -0.49 HDL cholesterol; chr11:48525123 chr11:89639227~89698718:+ PAAD trans rs2950393 0.572 rs10783794 ENSG00000121089.4 NACA3P -6.95 9.83e-11 0.000585 -0.63 -0.49 Platelet distribution width; chr12:56593395 chr4:164943290~164943937:+ PAAD trans rs616147 0.627 rs816510 ENSG00000183298.5 RP11-556K13.1 -6.95 9.84e-11 0.000586 -0.68 -0.49 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39430804 chr1:101786340~101787219:- PAAD trans rs7121616 0.824 rs10892962 ENSG00000234176.1 HSPA8P1 6.95 9.9e-11 0.000589 0.57 0.49 Breast cancer; chr11:123101034 chrX:121203182~121205014:- PAAD trans rs7312770 0.612 rs773114 ENSG00000225071.1 GS1-184P14.2 6.95 9.99e-11 0.000594 0.54 0.49 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chrX:24429573~24429920:- PAAD trans rs10838798 0.504 rs11039627 ENSG00000134612.10 FOLH1B -6.95 1.01e-10 0.000601 -0.57 -0.49 Height; chr11:48272379 chr11:89639227~89698718:+ PAAD trans rs2731664 0.756 rs335433 ENSG00000215571.5 GRK6P1 6.95 1.02e-10 0.000608 0.65 0.49 Intelligence (multi-trait analysis); chr5:177440206 chr13:21319156~21320866:+ PAAD trans rs12709013 0.636 rs1865836 ENSG00000233719.3 GOT2P3 6.94 1.03e-10 0.000614 0.62 0.49 Blood metabolite ratios; chr16:58768143 chr12:9641802~9643007:+ PAAD trans rs12709013 0.792 rs1615326 ENSG00000230849.2 GOT2P2 6.94 1.03e-10 0.000614 0.56 0.49 Blood metabolite ratios; chr16:58747148 chr1:173141100~173142350:- PAAD trans rs7258465 0.897 rs1043327 ENSG00000267533.1 RP11-815J4.7 6.94 1.06e-10 0.000628 0.6 0.49 Breast cancer; chr19:18444162 chr18:12067173~12068417:- PAAD trans rs2731664 0.792 rs335434 ENSG00000215571.5 GRK6P1 6.94 1.08e-10 0.00064 0.65 0.49 Intelligence (multi-trait analysis); chr5:177440275 chr13:21319156~21320866:+ PAAD trans rs2727020 0.615 rs4980435 ENSG00000134612.10 FOLH1B -6.93 1.12e-10 0.00066 -0.57 -0.49 Coronary artery disease; chr11:49570024 chr11:89639227~89698718:+ PAAD trans rs7258465 0.896 rs8103660 ENSG00000267533.1 RP11-815J4.7 6.93 1.13e-10 0.000666 0.59 0.49 Breast cancer; chr19:18455585 chr18:12067173~12068417:- PAAD trans rs916888 0.61 rs199529 ENSG00000204650.12 CRHR1-IT1 6.93 1.14e-10 0.000674 0.59 0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45620328~45648216:+ PAAD trans rs7811142 0.666 rs28401739 ENSG00000228546.2 CTA-313A17.3 6.93 1.15e-10 0.000677 0.74 0.49 Platelet count; chr7:100308061 chr7:102337316~102339115:+ PAAD trans rs6708331 0.941 rs13028968 ENSG00000232654.1 FAM136BP 6.92 1.15e-10 0.000681 0.63 0.49 Obesity-related traits; chr2:70179991 chr6:3045384~3045800:+ PAAD trans rs11039798 0.512 rs11040205 ENSG00000134612.10 FOLH1B 6.92 1.16e-10 0.000684 0.78 0.49 Axial length; chr11:48985808 chr11:89639227~89698718:+ PAAD trans rs11039798 0.512 rs1988465 ENSG00000134612.10 FOLH1B 6.92 1.16e-10 0.000684 0.78 0.49 Axial length; chr11:48989751 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs59777067 ENSG00000134612.10 FOLH1B 6.92 1.16e-10 0.000684 0.78 0.49 Axial length; chr11:48993798 chr11:89639227~89698718:+ PAAD trans rs11039798 0.591 rs74992349 ENSG00000134612.10 FOLH1B 6.92 1.16e-10 0.000684 0.78 0.49 Axial length; chr11:48997700 chr11:89639227~89698718:+ PAAD trans rs2727020 0.617 rs1917311 ENSG00000134612.10 FOLH1B -6.92 1.17e-10 0.000689 -0.57 -0.49 Coronary artery disease; chr11:49401113 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs1847640 ENSG00000134612.10 FOLH1B 6.92 1.17e-10 0.00069 0.78 0.49 Axial length; chr11:48982473 chr11:89639227~89698718:+ PAAD trans rs3779195 0.627 rs6950023 ENSG00000225169.1 BRI3P1 6.92 1.18e-10 0.000695 0.8 0.49 Sex hormone-binding globulin levels; chr7:98286323 chr1:100213293~100213670:+ PAAD trans rs3779195 0.627 rs6967728 ENSG00000225169.1 BRI3P1 6.92 1.18e-10 0.000695 0.8 0.49 Sex hormone-binding globulin levels; chr7:98286325 chr1:100213293~100213670:+ PAAD trans rs9329221 0.905 rs10283145 ENSG00000253893.2 FAM85B 6.92 1.18e-10 0.000695 0.68 0.49 Neuroticism; chr8:10383901 chr8:8167819~8226614:- PAAD trans rs12709013 0.792 rs1646289 ENSG00000230849.2 GOT2P2 6.92 1.19e-10 0.000702 0.55 0.49 Blood metabolite ratios; chr16:58755689 chr1:173141100~173142350:- PAAD trans rs11039798 0.588 rs6485869 ENSG00000134612.10 FOLH1B 6.92 1.2e-10 0.000708 0.75 0.49 Axial length; chr11:48555351 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs3924476 ENSG00000134612.10 FOLH1B 6.92 1.2e-10 0.000708 0.75 0.49 Axial length; chr11:48560181 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs7483361 ENSG00000134612.10 FOLH1B 6.92 1.2e-10 0.000708 0.75 0.49 Axial length; chr11:48572234 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs10160381 ENSG00000134612.10 FOLH1B 6.92 1.2e-10 0.000708 0.75 0.49 Axial length; chr11:48577939 chr11:89639227~89698718:+ PAAD trans rs12709013 0.569 rs30837 ENSG00000233719.3 GOT2P3 6.91 1.24e-10 0.000727 0.66 0.49 Blood metabolite ratios; chr16:58711942 chr12:9641802~9643007:+ PAAD trans rs9467773 0.838 rs3734540 ENSG00000242375.1 RP11-498P14.3 6.91 1.24e-10 0.000729 0.62 0.49 Intelligence (multi-trait analysis); chr6:26463093 chr9:97195351~97197687:- PAAD trans rs9467773 0.869 rs9295689 ENSG00000242375.1 RP11-498P14.3 6.91 1.24e-10 0.00073 0.62 0.49 Intelligence (multi-trait analysis); chr6:26455583 chr9:97195351~97197687:- PAAD trans rs12709013 0.804 rs8051459 ENSG00000230849.2 GOT2P2 6.91 1.25e-10 0.000735 0.57 0.49 Blood metabolite ratios; chr16:58783436 chr1:173141100~173142350:- PAAD trans rs7811142 0.943 rs67196635 ENSG00000228546.2 CTA-313A17.3 6.91 1.27e-10 0.000745 0.72 0.49 Platelet count; chr7:100427941 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs6962151 ENSG00000228546.2 CTA-313A17.3 6.91 1.27e-10 0.000745 0.72 0.49 Platelet count; chr7:100430861 chr7:102337316~102339115:+ PAAD trans rs7811142 0.943 rs67483801 ENSG00000228546.2 CTA-313A17.3 6.91 1.27e-10 0.000745 0.72 0.49 Platelet count; chr7:100434135 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11761784 ENSG00000228546.2 CTA-313A17.3 6.91 1.27e-10 0.000745 0.72 0.49 Platelet count; chr7:100442347 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs112317829 ENSG00000228546.2 CTA-313A17.3 6.91 1.27e-10 0.000745 0.72 0.49 Platelet count; chr7:100445550 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs2406253 ENSG00000228546.2 CTA-313A17.3 6.91 1.27e-10 0.000745 0.72 0.49 Platelet count; chr7:100479650 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs2897358 ENSG00000228546.2 CTA-313A17.3 6.91 1.27e-10 0.000745 0.72 0.49 Platelet count; chr7:100491017 chr7:102337316~102339115:+ PAAD trans rs9611565 0.649 rs126092 ENSG00000268568.1 AC007228.9 6.91 1.28e-10 0.000749 0.73 0.49 Vitiligo; chr22:41782437 chr19:56672574~56673901:- PAAD trans rs11039798 0.623 rs6485879 ENSG00000134612.10 FOLH1B 6.9 1.28e-10 0.000749 0.75 0.49 Axial length; chr11:48566432 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs10437592 ENSG00000134612.10 FOLH1B 6.9 1.28e-10 0.000749 0.75 0.49 Axial length; chr11:48577307 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs10838970 ENSG00000134612.10 FOLH1B 6.9 1.28e-10 0.000749 0.75 0.49 Axial length; chr11:48584715 chr11:89639227~89698718:+ PAAD trans rs2731664 0.792 rs335420 ENSG00000215571.5 GRK6P1 -6.9 1.29e-10 0.000752 -0.66 -0.49 Intelligence (multi-trait analysis); chr5:177471618 chr13:21319156~21320866:+ PAAD trans rs9650657 0.59 rs10096777 ENSG00000253893.2 FAM85B 6.9 1.29e-10 0.000754 0.71 0.49 Neuroticism; chr8:10660990 chr8:8167819~8226614:- PAAD trans rs12709013 0.535 rs9924136 ENSG00000233719.3 GOT2P3 6.9 1.3e-10 0.000757 0.62 0.49 Blood metabolite ratios; chr16:58779573 chr12:9641802~9643007:+ PAAD trans rs12709013 0.591 rs30842 ENSG00000233719.3 GOT2P3 -6.9 1.3e-10 0.000757 -0.66 -0.49 Blood metabolite ratios; chr16:58709550 chr12:9641802~9643007:+ PAAD trans rs10037055 0.687 rs6556308 ENSG00000217325.2 PRELID1P1 -6.9 1.31e-10 0.000763 -0.7 -0.49 Migraine without aura; chr5:177219700 chr6:126643488~126644390:+ PAAD trans rs10037055 0.853 rs6890580 ENSG00000217325.2 PRELID1P1 -6.9 1.31e-10 0.000763 -0.7 -0.49 Migraine without aura; chr5:177226519 chr6:126643488~126644390:+ PAAD trans rs10037055 0.741 rs2336405 ENSG00000217325.2 PRELID1P1 -6.9 1.31e-10 0.000763 -0.7 -0.49 Migraine without aura; chr5:177230288 chr6:126643488~126644390:+ PAAD trans rs2727020 0.637 rs1164673 ENSG00000134612.10 FOLH1B 6.9 1.33e-10 0.000773 0.59 0.49 Coronary artery disease; chr11:49306804 chr11:89639227~89698718:+ PAAD trans rs61990749 1 rs61990749 ENSG00000235400.1 RP4-641G12.4 -6.89 1.37e-10 0.000797 -0.91 -0.49 Fibroblast growth factor basic levels; chr14:77906158 chr1:78749073~78750659:+ PAAD trans rs13253073 1 rs6468694 ENSG00000260318.1 COX6CP1 6.89 1.37e-10 0.000797 1.1 0.49 Glucose homeostasis traits; chr8:99853608 chr16:11903923~11904137:- PAAD trans rs12709013 0.792 rs62064901 ENSG00000230849.2 GOT2P2 6.89 1.37e-10 0.000797 0.56 0.49 Blood metabolite ratios; chr16:58776758 chr1:173141100~173142350:- PAAD trans rs12709013 0.729 rs34324769 ENSG00000230849.2 GOT2P2 6.89 1.37e-10 0.000797 0.56 0.49 Blood metabolite ratios; chr16:58778131 chr1:173141100~173142350:- PAAD trans rs2727020 0.595 rs11040416 ENSG00000134612.10 FOLH1B -6.89 1.37e-10 0.000797 -0.57 -0.49 Coronary artery disease; chr11:49544877 chr11:89639227~89698718:+ PAAD trans rs7811142 0.83 rs6955367 ENSG00000228546.2 CTA-313A17.3 6.89 1.37e-10 0.000798 0.72 0.49 Platelet count; chr7:100363571 chr7:102337316~102339115:+ PAAD trans rs7312770 1 rs7312770 ENSG00000212829.8 RPS26P3 -6.89 1.39e-10 0.000807 -0.57 -0.49 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr9:9090898~9091245:+ PAAD trans rs1814175 0.904 rs7924371 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49599043 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs11040438 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49600969 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs1827017 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49611040 chr11:89639227~89698718:+ PAAD trans rs1814175 0.717 rs11040450 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49629086 chr11:89639227~89698718:+ PAAD trans rs1814175 0.803 rs11040451 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49629087 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs10839317 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49635676 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs6485999 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49637434 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs7479914 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49639799 chr11:89639227~89698718:+ PAAD trans rs1814175 0.715 rs7479622 ENSG00000134612.10 FOLH1B -6.89 1.39e-10 0.00081 -0.56 -0.49 Height; chr11:49651788 chr11:89639227~89698718:+ PAAD trans rs7811142 0.83 rs11768967 ENSG00000228546.2 CTA-313A17.3 6.89 1.4e-10 0.000811 0.72 0.49 Platelet count; chr7:100370021 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs7792959 ENSG00000228546.2 CTA-313A17.3 6.89 1.4e-10 0.000811 0.72 0.49 Platelet count; chr7:100374780 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs6975660 ENSG00000228546.2 CTA-313A17.3 6.89 1.4e-10 0.000811 0.72 0.49 Platelet count; chr7:100377643 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs73401443 ENSG00000228546.2 CTA-313A17.3 6.89 1.4e-10 0.000811 0.72 0.49 Platelet count; chr7:100379959 chr7:102337316~102339115:+ PAAD trans rs2929451 0.566 rs17658270 ENSG00000253893.2 FAM85B -6.89 1.42e-10 0.000824 -0.67 -0.49 Nose size; chr8:9296109 chr8:8167819~8226614:- PAAD trans rs9329221 0.868 rs7831557 ENSG00000253893.2 FAM85B 6.88 1.43e-10 0.000831 0.67 0.49 Neuroticism; chr8:10422718 chr8:8167819~8226614:- PAAD trans rs1814175 0.935 rs7925863 ENSG00000134612.10 FOLH1B -6.88 1.45e-10 0.000843 -0.56 -0.49 Height; chr11:49594250 chr11:89639227~89698718:+ PAAD trans rs1814175 0.904 rs1846289 ENSG00000134612.10 FOLH1B -6.88 1.45e-10 0.000843 -0.56 -0.49 Height; chr11:49598701 chr11:89639227~89698718:+ PAAD trans rs10242455 0.571 rs11734 ENSG00000228834.1 RP11-249L21.4 -6.88 1.48e-10 0.000857 -1.23 -0.49 Blood metabolite levels; chr7:99632145 chr6:108907615~108907873:- PAAD trans rs9611565 0.525 rs9611548 ENSG00000268568.1 AC007228.9 -6.88 1.49e-10 0.000861 -0.65 -0.49 Vitiligo; chr22:41308139 chr19:56672574~56673901:- PAAD trans rs12138950 0.625 rs12041608 ENSG00000224237.1 MINOS1P3 -6.88 1.49e-10 0.000866 -0.68 -0.49 Hypothyroidism;Thyroid volume; chr1:19515431 chr3:27214816~27215018:- PAAD trans rs12709013 0.792 rs1657170 ENSG00000230849.2 GOT2P2 6.87 1.51e-10 0.000874 0.56 0.49 Blood metabolite ratios; chr16:58752082 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs11644344 ENSG00000230849.2 GOT2P2 6.87 1.52e-10 0.000878 0.56 0.49 Blood metabolite ratios; chr16:58803080 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs11649387 ENSG00000230849.2 GOT2P2 6.87 1.52e-10 0.000878 0.56 0.49 Blood metabolite ratios; chr16:58803176 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs11649133 ENSG00000230849.2 GOT2P2 6.87 1.52e-10 0.000878 0.56 0.49 Blood metabolite ratios; chr16:58803275 chr1:173141100~173142350:- PAAD trans rs12709013 0.591 rs4784986 ENSG00000233719.3 GOT2P3 6.87 1.52e-10 0.000878 0.63 0.49 Blood metabolite ratios; chr16:58803007 chr12:9641802~9643007:+ PAAD trans rs7811142 0.83 rs10085549 ENSG00000228546.2 CTA-313A17.3 6.87 1.57e-10 0.000907 0.72 0.49 Platelet count; chr7:100385512 chr7:102337316~102339115:+ PAAD trans rs2727020 0.576 rs10839305 ENSG00000134612.10 FOLH1B -6.87 1.59e-10 0.000915 -0.56 -0.49 Coronary artery disease; chr11:49577181 chr11:89639227~89698718:+ PAAD trans rs12709013 0.766 rs11648511 ENSG00000230849.2 GOT2P2 6.86 1.6e-10 0.000924 0.56 0.49 Blood metabolite ratios; chr16:58798171 chr1:173141100~173142350:- PAAD trans rs12709013 0.716 rs11647582 ENSG00000230849.2 GOT2P2 6.86 1.6e-10 0.000924 0.56 0.49 Blood metabolite ratios; chr16:58801474 chr1:173141100~173142350:- PAAD trans rs12709013 0.792 rs35684307 ENSG00000230849.2 GOT2P2 6.86 1.6e-10 0.000924 0.56 0.49 Blood metabolite ratios; chr16:58801651 chr1:173141100~173142350:- PAAD trans rs916888 0.779 rs199526 ENSG00000204650.12 CRHR1-IT1 -6.86 1.64e-10 0.000941 -0.56 -0.49 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:45620328~45648216:+ PAAD trans rs7554547 0.69 rs57044570 ENSG00000261819.1 RP11-680G24.4 6.86 1.64e-10 0.000942 0.61 0.49 Nonsyndromic cleft lip with cleft palate; chr1:11899181 chr16:14988259~14990160:- PAAD trans rs12709013 0.591 rs6499980 ENSG00000233719.3 GOT2P3 6.86 1.65e-10 0.000952 0.61 0.49 Blood metabolite ratios; chr16:58787972 chr12:9641802~9643007:+ PAAD trans rs11098499 0.738 rs72918577 ENSG00000275858.1 RP11-291L22.8 6.86 1.66e-10 0.000956 0.63 0.49 Corneal astigmatism; chr4:119405546 chr10:38450738~38451069:- PAAD trans rs1816752 0.875 rs59686377 ENSG00000224976.2 PARP4P2 -6.85 1.7e-10 0.000976 -0.6 -0.49 Obesity-related traits; chr13:24475869 chr13:19349137~19407962:+ PAAD trans rs2727020 0.513 rs10839307 ENSG00000134612.10 FOLH1B -6.85 1.7e-10 0.000978 -0.56 -0.49 Coronary artery disease; chr11:49588291 chr11:89639227~89698718:+ PAAD trans rs7395662 0.853 rs10838885 ENSG00000134612.10 FOLH1B -6.85 1.75e-10 0.001 -0.59 -0.49 HDL cholesterol; chr11:48377254 chr11:89639227~89698718:+ PAAD trans rs7395662 0.818 rs2200181 ENSG00000134612.10 FOLH1B -6.85 1.75e-10 0.001 -0.59 -0.49 HDL cholesterol; chr11:48391623 chr11:89639227~89698718:+ PAAD trans rs7395662 0.853 rs35255233 ENSG00000134612.10 FOLH1B -6.85 1.75e-10 0.001 -0.59 -0.49 HDL cholesterol; chr11:48421318 chr11:89639227~89698718:+ PAAD trans rs7395662 0.853 rs10769356 ENSG00000134612.10 FOLH1B -6.85 1.75e-10 0.001 -0.59 -0.49 HDL cholesterol; chr11:48423102 chr11:89639227~89698718:+ PAAD trans rs7312770 0.637 rs705700 ENSG00000235459.5 RPS26P31 6.85 1.76e-10 0.00101 0.54 0.49 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr7:122681315~122681662:+ PAAD trans rs10037055 0.853 rs12660023 ENSG00000217325.2 PRELID1P1 6.84 1.77e-10 0.00102 0.69 0.49 Migraine without aura; chr5:177273884 chr6:126643488~126644390:+ PAAD trans rs10037055 0.853 rs4976680 ENSG00000217325.2 PRELID1P1 6.84 1.77e-10 0.00102 0.69 0.49 Migraine without aura; chr5:177275745 chr6:126643488~126644390:+ PAAD trans rs10037055 0.853 rs4976681 ENSG00000217325.2 PRELID1P1 6.84 1.77e-10 0.00102 0.69 0.49 Migraine without aura; chr5:177277662 chr6:126643488~126644390:+ PAAD trans rs11098499 0.865 rs28634456 ENSG00000275858.1 RP11-291L22.8 6.84 1.79e-10 0.00102 0.63 0.49 Corneal astigmatism; chr4:119454623 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs78332141 ENSG00000275858.1 RP11-291L22.8 6.84 1.79e-10 0.00102 0.63 0.49 Corneal astigmatism; chr4:119454627 chr10:38450738~38451069:- PAAD trans rs12709013 0.536 rs9930758 ENSG00000233719.3 GOT2P3 6.84 1.79e-10 0.00102 0.63 0.49 Blood metabolite ratios; chr16:58803167 chr12:9641802~9643007:+ PAAD trans rs12709013 0.591 rs9932967 ENSG00000233719.3 GOT2P3 6.84 1.79e-10 0.00102 0.63 0.49 Blood metabolite ratios; chr16:58805583 chr12:9641802~9643007:+ PAAD trans rs12709013 0.636 rs967852 ENSG00000233719.3 GOT2P3 6.84 1.79e-10 0.00102 0.63 0.49 Blood metabolite ratios; chr16:58807313 chr12:9641802~9643007:+ PAAD trans rs12709013 0.591 rs7184377 ENSG00000233719.3 GOT2P3 6.84 1.79e-10 0.00102 0.63 0.49 Blood metabolite ratios; chr16:58808765 chr12:9641802~9643007:+ PAAD trans rs12709013 0.613 rs6499984 ENSG00000233719.3 GOT2P3 6.84 1.79e-10 0.00102 0.63 0.49 Blood metabolite ratios; chr16:58810209 chr12:9641802~9643007:+ PAAD trans rs12709013 0.574 rs9302706 ENSG00000233719.3 GOT2P3 6.84 1.79e-10 0.00102 0.63 0.49 Blood metabolite ratios; chr16:58812060 chr12:9641802~9643007:+ PAAD trans rs6477998 0.58 rs7851623 ENSG00000238072.1 RP11-305M3.2 6.84 1.79e-10 0.00102 0.74 0.49 Hematology traits; chr9:113240285 chr7:129410113~129410370:- PAAD trans rs12709013 0.591 rs30841 ENSG00000233719.3 GOT2P3 6.84 1.79e-10 0.00103 0.65 0.49 Blood metabolite ratios; chr16:58709819 chr12:9641802~9643007:+ PAAD trans rs877636 0.692 rs2271194 ENSG00000196656.7 AC004057.1 -6.84 1.8e-10 0.00103 -0.49 -0.49 Cognitive function; chr12:56083910 chr4:113214046~113217170:- PAAD trans rs11098499 0.779 rs80242894 ENSG00000275858.1 RP11-291L22.8 6.84 1.8e-10 0.00103 0.63 0.49 Corneal astigmatism; chr4:119454597 chr10:38450738~38451069:- PAAD trans rs7258465 1 rs34171762 ENSG00000267533.1 RP11-815J4.7 6.84 1.82e-10 0.00104 0.59 0.49 Breast cancer; chr19:18448600 chr18:12067173~12068417:- PAAD trans rs6732160 0.845 rs6718690 ENSG00000236165.1 PRADC1P1 -6.83 1.86e-10 0.00106 -0.56 -0.48 Intelligence (multi-trait analysis); chr2:73160034 chr3:36976316~36976840:+ PAAD trans rs1816752 0.875 rs17384871 ENSG00000224976.2 PARP4P2 -6.83 1.87e-10 0.00107 -0.6 -0.48 Obesity-related traits; chr13:24484959 chr13:19349137~19407962:+ PAAD trans rs7395662 0.591 rs4882085 ENSG00000134612.10 FOLH1B -6.83 1.87e-10 0.00107 -0.56 -0.48 HDL cholesterol; chr11:48483017 chr11:89639227~89698718:+ PAAD trans rs9467773 0.901 rs1407045 ENSG00000242375.1 RP11-498P14.3 6.83 1.88e-10 0.00107 0.62 0.48 Intelligence (multi-trait analysis); chr6:26475927 chr9:97195351~97197687:- PAAD trans rs3096299 0.503 rs4785677 ENSG00000215030.5 RPL13P12 -6.83 1.89e-10 0.00108 -0.52 -0.48 Multiple myeloma (IgH translocation); chr16:89488693 chr17:17383377~17384012:- PAAD trans rs7937890 0.56 rs2597194 ENSG00000236360.2 RP11-334A14.2 6.83 1.93e-10 0.0011 0.67 0.48 Mitochondrial DNA levels; chr11:14475723 chr1:52993201~52993702:- PAAD trans rs7937890 0.593 rs2597189 ENSG00000236360.2 RP11-334A14.2 6.83 1.93e-10 0.0011 0.67 0.48 Mitochondrial DNA levels; chr11:14490514 chr1:52993201~52993702:- PAAD trans rs61990749 1 rs6574411 ENSG00000235400.1 RP4-641G12.4 -6.83 1.94e-10 0.0011 -0.91 -0.48 Fibroblast growth factor basic levels; chr14:77907984 chr1:78749073~78750659:+ PAAD trans rs13190036 0.901 rs28684504 ENSG00000226986.4 RP11-543B16.2 6.82 1.97e-10 0.00112 0.78 0.48 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177300437 chr1:211207239~211207897:+ PAAD trans rs877636 1 rs877636 ENSG00000225071.1 GS1-184P14.2 -6.82 2.03e-10 0.00115 -0.58 -0.48 Cognitive function; chr12:56086799 chrX:24429573~24429920:- PAAD trans rs9650657 0.644 rs4395858 ENSG00000253893.2 FAM85B -6.82 2.05e-10 0.00116 -0.68 -0.48 Neuroticism; chr8:10663511 chr8:8167819~8226614:- PAAD trans rs2727020 0.636 rs11040368 ENSG00000134612.10 FOLH1B -6.82 2.05e-10 0.00116 -0.57 -0.48 Coronary artery disease; chr11:49432050 chr11:89639227~89698718:+ PAAD trans rs7554547 0.791 rs4846069 ENSG00000261819.1 RP11-680G24.4 6.81 2.1e-10 0.00119 0.61 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11888974 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs11121837 ENSG00000261819.1 RP11-680G24.4 6.81 2.1e-10 0.00119 0.61 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11889414 chr16:14988259~14990160:- PAAD trans rs7554547 0.765 rs4846070 ENSG00000261819.1 RP11-680G24.4 6.81 2.1e-10 0.00119 0.61 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11889464 chr16:14988259~14990160:- PAAD trans rs7554547 0.739 rs61527718 ENSG00000261819.1 RP11-680G24.4 6.81 2.1e-10 0.00119 0.61 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11889583 chr16:14988259~14990160:- PAAD trans rs7554547 0.714 rs4846071 ENSG00000261819.1 RP11-680G24.4 6.81 2.1e-10 0.00119 0.61 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11889612 chr16:14988259~14990160:- PAAD trans rs7937890 1 rs2915401 ENSG00000236360.2 RP11-334A14.2 -6.81 2.13e-10 0.0012 -0.69 -0.48 Mitochondrial DNA levels; chr11:14353467 chr1:52993201~52993702:- PAAD trans rs7937890 1 rs2915402 ENSG00000236360.2 RP11-334A14.2 -6.81 2.13e-10 0.0012 -0.69 -0.48 Mitochondrial DNA levels; chr11:14356082 chr1:52993201~52993702:- PAAD trans rs2727020 0.658 rs1851992 ENSG00000134612.10 FOLH1B -6.81 2.13e-10 0.00121 -0.57 -0.48 Coronary artery disease; chr11:49416558 chr11:89639227~89698718:+ PAAD trans rs2727020 0.636 rs10839275 ENSG00000134612.10 FOLH1B -6.81 2.13e-10 0.00121 -0.57 -0.48 Coronary artery disease; chr11:49417410 chr11:89639227~89698718:+ PAAD trans rs2727020 0.658 rs4980442 ENSG00000134612.10 FOLH1B -6.81 2.13e-10 0.00121 -0.57 -0.48 Coronary artery disease; chr11:49423464 chr11:89639227~89698718:+ PAAD trans rs2727020 0.615 rs10128582 ENSG00000134612.10 FOLH1B -6.81 2.13e-10 0.00121 -0.57 -0.48 Coronary artery disease; chr11:49425872 chr11:89639227~89698718:+ PAAD trans rs2727020 0.658 rs10839278 ENSG00000134612.10 FOLH1B -6.81 2.13e-10 0.00121 -0.57 -0.48 Coronary artery disease; chr11:49429295 chr11:89639227~89698718:+ PAAD trans rs2727020 0.563 rs10769582 ENSG00000134612.10 FOLH1B -6.81 2.13e-10 0.00121 -0.57 -0.48 Coronary artery disease; chr11:49452488 chr11:89639227~89698718:+ PAAD trans rs7937890 0.599 rs2597204 ENSG00000236360.2 RP11-334A14.2 6.81 2.15e-10 0.00122 0.66 0.48 Mitochondrial DNA levels; chr11:14459471 chr1:52993201~52993702:- PAAD trans rs11098499 0.954 rs6849561 ENSG00000275858.1 RP11-291L22.8 -6.8 2.19e-10 0.00124 -0.63 -0.48 Corneal astigmatism; chr4:119488539 chr10:38450738~38451069:- PAAD trans rs76228276 0.737 rs73271394 ENSG00000260318.1 COX6CP1 6.8 2.21e-10 0.00124 1.12 0.48 Childhood ear infection; chr8:99841632 chr16:11903923~11904137:- PAAD trans rs7554547 0.765 rs4845886 ENSG00000261819.1 RP11-680G24.4 6.8 2.22e-10 0.00125 0.61 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11888603 chr16:14988259~14990160:- PAAD trans rs7258465 0.931 rs11673604 ENSG00000267533.1 RP11-815J4.7 6.8 2.22e-10 0.00125 0.6 0.48 Breast cancer; chr19:18430178 chr18:12067173~12068417:- PAAD trans rs12138950 0.596 rs10917471 ENSG00000224237.1 MINOS1P3 6.8 2.24e-10 0.00126 0.69 0.48 Hypothyroidism;Thyroid volume; chr1:19521118 chr3:27214816~27215018:- PAAD trans rs12709013 0.74 rs12927495 ENSG00000230849.2 GOT2P2 6.8 2.25e-10 0.00127 0.56 0.48 Blood metabolite ratios; chr16:58821934 chr1:173141100~173142350:- PAAD trans rs13190036 1 rs4976682 ENSG00000226986.4 RP11-543B16.2 6.8 2.25e-10 0.00127 0.77 0.48 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177299001 chr1:211207239~211207897:+ PAAD trans rs7811142 0.943 rs111757992 ENSG00000228546.2 CTA-313A17.3 6.79 2.31e-10 0.0013 0.7 0.48 Platelet count; chr7:100418731 chr7:102337316~102339115:+ PAAD trans rs12709013 0.792 rs7185513 ENSG00000230849.2 GOT2P2 6.79 2.33e-10 0.00131 0.56 0.48 Blood metabolite ratios; chr16:58794889 chr1:173141100~173142350:- PAAD trans rs3740713 0.748 rs35292478 ENSG00000235847.2 LDHAP7 6.79 2.35e-10 0.00132 0.86 0.48 Amyotrophic lateral sclerosis (sporadic); chr11:18408444 chr2:84777259~84778223:- PAAD trans rs2727020 0.658 rs7120136 ENSG00000134612.10 FOLH1B -6.79 2.35e-10 0.00132 -0.56 -0.48 Coronary artery disease; chr11:49362806 chr11:89639227~89698718:+ PAAD trans rs2727020 0.658 rs10839269 ENSG00000134612.10 FOLH1B -6.79 2.35e-10 0.00132 -0.56 -0.48 Coronary artery disease; chr11:49364044 chr11:89639227~89698718:+ PAAD trans rs7824557 0.547 rs4512344 ENSG00000253893.2 FAM85B 6.79 2.35e-10 0.00132 0.66 0.48 Retinal vascular caliber; chr8:11221272 chr8:8167819~8226614:- PAAD trans rs11039798 0.512 rs1588069 ENSG00000134612.10 FOLH1B 6.79 2.4e-10 0.00134 0.74 0.48 Axial length; chr11:48673319 chr11:89639227~89698718:+ PAAD trans rs11039798 0.623 rs7294273 ENSG00000134612.10 FOLH1B 6.79 2.4e-10 0.00134 0.74 0.48 Axial length; chr11:48683822 chr11:89639227~89698718:+ PAAD trans rs1814175 0.869 rs10769600 ENSG00000134612.10 FOLH1B -6.79 2.41e-10 0.00135 -0.55 -0.48 Height; chr11:49660280 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs11040462 ENSG00000134612.10 FOLH1B -6.79 2.41e-10 0.00135 -0.55 -0.48 Height; chr11:49661606 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs11040463 ENSG00000134612.10 FOLH1B -6.79 2.41e-10 0.00135 -0.55 -0.48 Height; chr11:49664022 chr11:89639227~89698718:+ PAAD trans rs11098499 0.954 rs12502423 ENSG00000275858.1 RP11-291L22.8 6.79 2.43e-10 0.00136 0.63 0.48 Corneal astigmatism; chr4:119503017 chr10:38450738~38451069:- PAAD trans rs877636 0.692 rs2271194 ENSG00000243403.1 RP11-330L19.1 -6.78 2.43e-10 0.00136 -0.53 -0.48 Cognitive function; chr12:56083910 chr15:64592979~64593326:+ PAAD trans rs10037055 0.853 rs10077929 ENSG00000217325.2 PRELID1P1 6.78 2.44e-10 0.00136 0.64 0.48 Migraine without aura; chr5:177270843 chr6:126643488~126644390:+ PAAD trans rs12709013 0.792 rs12596434 ENSG00000230849.2 GOT2P2 6.78 2.48e-10 0.00139 0.56 0.48 Blood metabolite ratios; chr16:58792309 chr1:173141100~173142350:- PAAD trans rs7937890 0.869 rs2915404 ENSG00000236360.2 RP11-334A14.2 6.78 2.53e-10 0.00141 0.66 0.48 Mitochondrial DNA levels; chr11:14383279 chr1:52993201~52993702:- PAAD trans rs12709013 0.716 rs4784987 ENSG00000230849.2 GOT2P2 6.78 2.53e-10 0.00141 0.58 0.48 Blood metabolite ratios; chr16:58824135 chr1:173141100~173142350:- PAAD trans rs12709013 0.591 rs30834 ENSG00000233719.3 GOT2P3 6.78 2.55e-10 0.00142 0.65 0.48 Blood metabolite ratios; chr16:58715394 chr12:9641802~9643007:+ PAAD trans rs13253073 0.883 rs12545602 ENSG00000260318.1 COX6CP1 6.78 2.55e-10 0.00142 1.14 0.48 Glucose homeostasis traits; chr8:99834612 chr16:11903923~11904137:- PAAD trans rs2731664 0.721 rs2450333 ENSG00000215571.5 GRK6P1 6.78 2.55e-10 0.00142 0.66 0.48 Intelligence (multi-trait analysis); chr5:177472545 chr13:21319156~21320866:+ PAAD trans rs6732160 0.838 rs13411380 ENSG00000236165.1 PRADC1P1 6.77 2.56e-10 0.00143 0.55 0.48 Intelligence (multi-trait analysis); chr2:73155718 chr3:36976316~36976840:+ PAAD trans rs6732160 0.809 rs13406142 ENSG00000236165.1 PRADC1P1 6.77 2.56e-10 0.00143 0.55 0.48 Intelligence (multi-trait analysis); chr2:73156970 chr3:36976316~36976840:+ PAAD trans rs6732160 0.741 rs6546806 ENSG00000236165.1 PRADC1P1 6.77 2.56e-10 0.00143 0.55 0.48 Intelligence (multi-trait analysis); chr2:73159032 chr3:36976316~36976840:+ PAAD trans rs7258465 1 rs10164323 ENSG00000267533.1 RP11-815J4.7 6.77 2.58e-10 0.00144 0.58 0.48 Breast cancer; chr19:18458682 chr18:12067173~12068417:- PAAD trans rs12709013 0.792 rs62064940 ENSG00000230849.2 GOT2P2 6.77 2.58e-10 0.00144 0.56 0.48 Blood metabolite ratios; chr16:58796560 chr1:173141100~173142350:- PAAD trans rs6732160 0.809 rs13387480 ENSG00000236165.1 PRADC1P1 6.77 2.58e-10 0.00144 0.55 0.48 Intelligence (multi-trait analysis); chr2:73143879 chr3:36976316~36976840:+ PAAD trans rs11098499 0.866 rs72676074 ENSG00000275858.1 RP11-291L22.8 6.77 2.59e-10 0.00144 0.62 0.48 Corneal astigmatism; chr4:119438686 chr10:38450738~38451069:- PAAD trans rs10242455 0.702 rs73713531 ENSG00000228834.1 RP11-249L21.4 6.77 2.63e-10 0.00146 1.28 0.48 Blood metabolite levels; chr7:99624756 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs59574285 ENSG00000228834.1 RP11-249L21.4 6.77 2.63e-10 0.00146 1.28 0.48 Blood metabolite levels; chr7:99638528 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs6956305 ENSG00000228834.1 RP11-249L21.4 6.77 2.63e-10 0.00146 1.28 0.48 Blood metabolite levels; chr7:99643687 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs73713580 ENSG00000228834.1 RP11-249L21.4 6.77 2.63e-10 0.00146 1.28 0.48 Blood metabolite levels; chr7:99643987 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs6976017 ENSG00000228834.1 RP11-249L21.4 6.77 2.63e-10 0.00146 1.28 0.48 Blood metabolite levels; chr7:99652376 chr6:108907615~108907873:- PAAD trans rs10242455 0.702 rs6977165 ENSG00000228834.1 RP11-249L21.4 6.77 2.63e-10 0.00146 1.28 0.48 Blood metabolite levels; chr7:99671774 chr6:108907615~108907873:- PAAD trans rs2727020 0.658 rs7111215 ENSG00000134612.10 FOLH1B -6.77 2.64e-10 0.00146 -0.56 -0.48 Coronary artery disease; chr11:49409000 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs28586931 ENSG00000134612.10 FOLH1B -6.77 2.64e-10 0.00146 -0.55 -0.48 Height; chr11:49672320 chr11:89639227~89698718:+ PAAD trans rs1814175 0.935 rs10839329 ENSG00000134612.10 FOLH1B -6.77 2.64e-10 0.00146 -0.55 -0.48 Height; chr11:49672654 chr11:89639227~89698718:+ PAAD trans rs6683419 0.729 rs10917477 ENSG00000224237.1 MINOS1P3 -6.77 2.69e-10 0.00149 -0.61 -0.48 Serum thyroid-stimulating hormone levels; chr1:19534612 chr3:27214816~27215018:- PAAD trans rs3779195 0.929 rs2906184 ENSG00000225169.1 BRI3P1 -6.76 2.7e-10 0.0015 -0.79 -0.48 Sex hormone-binding globulin levels; chr7:98310675 chr1:100213293~100213670:+ PAAD trans rs3096299 0.503 rs9940093 ENSG00000215030.5 RPL13P12 -6.76 2.71e-10 0.0015 -0.52 -0.48 Multiple myeloma (IgH translocation); chr16:89492297 chr17:17383377~17384012:- PAAD trans rs2657294 0.796 rs1259499 ENSG00000172974.11 AC007318.5 6.76 2.74e-10 0.00152 0.6 0.48 Pneumonia; chr10:75228308 chr2:65205108~65205988:+ PAAD trans rs2657294 0.796 rs4746272 ENSG00000172974.11 AC007318.5 6.76 2.76e-10 0.00152 0.6 0.48 Pneumonia; chr10:75203869 chr2:65205108~65205988:+ PAAD trans rs2657294 0.765 rs2804533 ENSG00000172974.11 AC007318.5 6.76 2.76e-10 0.00152 0.6 0.48 Pneumonia; chr10:75207723 chr2:65205108~65205988:+ PAAD trans rs2657294 0.726 rs4746275 ENSG00000172974.11 AC007318.5 6.76 2.76e-10 0.00152 0.6 0.48 Pneumonia; chr10:75214940 chr2:65205108~65205988:+ PAAD trans rs2657294 0.796 rs1259501 ENSG00000172974.11 AC007318.5 6.76 2.76e-10 0.00152 0.6 0.48 Pneumonia; chr10:75230427 chr2:65205108~65205988:+ PAAD trans rs6708331 0.646 rs12989348 ENSG00000232654.1 FAM136BP -6.76 2.8e-10 0.00155 -0.83 -0.48 Obesity-related traits; chr2:70150521 chr6:3045384~3045800:+ PAAD trans rs11039798 0.545 rs7118670 ENSG00000134612.10 FOLH1B 6.76 2.83e-10 0.00157 0.74 0.48 Axial length; chr11:48510504 chr11:89639227~89698718:+ PAAD trans rs61990749 1 rs17106604 ENSG00000235400.1 RP4-641G12.4 6.76 2.84e-10 0.00157 0.88 0.48 Fibroblast growth factor basic levels; chr14:77912813 chr1:78749073~78750659:+ PAAD trans rs11039798 0.588 rs11039781 ENSG00000134612.10 FOLH1B 6.75 2.85e-10 0.00158 0.74 0.48 Axial length; chr11:48501533 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs11039782 ENSG00000134612.10 FOLH1B 6.75 2.85e-10 0.00158 0.74 0.48 Axial length; chr11:48503233 chr11:89639227~89698718:+ PAAD trans rs11098499 0.954 rs59394118 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119374396 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs9996417 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119374707 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs59866101 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119375436 chr10:38450738~38451069:- PAAD trans rs11098499 0.618 rs6858383 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119375617 chr10:38450738~38451069:- PAAD trans rs11098499 0.697 rs6832410 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119375645 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs1112817 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119376645 chr10:38450738~38451069:- PAAD trans rs11098499 0.779 rs10016060 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119377257 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10005644 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119377322 chr10:38450738~38451069:- PAAD trans rs11098499 0.697 rs10016448 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119377690 chr10:38450738~38451069:- PAAD trans rs11098499 0.657 rs9996569 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119377849 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs11723839 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119378518 chr10:38450738~38451069:- PAAD trans rs11098499 0.908 rs11729050 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119378911 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs28429722 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119378938 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10014845 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119379922 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs12506546 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119380463 chr10:38450738~38451069:- PAAD trans rs11098499 0.779 rs7674500 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119382438 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs28884220 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119386056 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs28793658 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119386059 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs4507344 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119386330 chr10:38450738~38451069:- PAAD trans rs11098499 0.697 rs4373140 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119386543 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs13113483 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119387884 chr10:38450738~38451069:- PAAD trans rs11098499 0.542 rs10440343 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119388632 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs28668716 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119388720 chr10:38450738~38451069:- PAAD trans rs11098499 0.779 rs10011097 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119389204 chr10:38450738~38451069:- PAAD trans rs11098499 0.779 rs7699346 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119389387 chr10:38450738~38451069:- PAAD trans rs11098499 0.542 rs7677836 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119389483 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs10002083 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119389997 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10024844 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119390373 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs7437420 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119391748 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs4345162 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119391804 chr10:38450738~38451069:- PAAD trans rs11098499 0.657 rs4463052 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119392103 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs13151285 ENSG00000275858.1 RP11-291L22.8 6.75 2.88e-10 0.00158 0.62 0.48 Corneal astigmatism; chr4:119393586 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs4309825 ENSG00000275858.1 RP11-291L22.8 -6.75 2.88e-10 0.00158 -0.62 -0.48 Corneal astigmatism; chr4:119393726 chr10:38450738~38451069:- PAAD trans rs76228276 0.737 rs7003135 ENSG00000260318.1 COX6CP1 6.75 2.89e-10 0.00158 1.1 0.48 Childhood ear infection; chr8:99844405 chr16:11903923~11904137:- PAAD trans rs7312770 1 rs7312770 ENSG00000225071.1 GS1-184P14.2 -6.75 2.89e-10 0.00159 -0.54 -0.48 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chrX:24429573~24429920:- PAAD trans rs877636 0.692 rs10876870 ENSG00000234354.3 RPS26P47 -6.75 2.9e-10 0.00159 -0.6 -0.48 Cognitive function; chr12:56084218 chr13:100539901~100540248:- PAAD trans rs877636 0.692 rs7971751 ENSG00000234354.3 RPS26P47 -6.75 2.9e-10 0.00159 -0.6 -0.48 Cognitive function; chr12:56084874 chr13:100539901~100540248:- PAAD trans rs7312770 0.637 rs705700 ENSG00000234513.1 AC073072.7 6.75 2.9e-10 0.00159 0.54 0.48 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr7:22773646~22773993:- PAAD trans rs9611565 0.649 rs4822050 ENSG00000268568.1 AC007228.9 -6.74 3.01e-10 0.00164 -0.79 -0.48 Vitiligo; chr22:41781449 chr19:56672574~56673901:- PAAD trans rs11098499 0.954 rs67265404 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119438115 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs9759478 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119446843 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs71629403 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119451412 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs28571712 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119454825 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs9994730 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119460409 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs11098526 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119469204 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs12499324 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119472631 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs1480931 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119474654 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs9998585 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119475647 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs6842762 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119477081 chr10:38450738~38451069:- PAAD trans rs11098499 0.908 rs11098527 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119478751 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10518328 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119480624 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs6848389 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119481467 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs6822679 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119481547 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs4577559 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119482888 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs7656252 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119483113 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs28845498 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119484031 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs28753180 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119484212 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs56270433 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119484875 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10006706 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119487997 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs7681544 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119490100 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs11940028 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119490752 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs11935596 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119491302 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs12507964 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119491906 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs11098530 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119491999 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs6834796 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119493538 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs11729521 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119495633 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs11734241 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119495717 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs17006190 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119497683 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs28685688 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119499179 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs7687843 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119500056 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs2306455 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119500814 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10031483 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119501481 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10031665 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119501697 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs3733519 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119502293 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs3733523 ENSG00000275858.1 RP11-291L22.8 6.74 3.02e-10 0.00164 0.63 0.48 Corneal astigmatism; chr4:119502564 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs3890049 ENSG00000275858.1 RP11-291L22.8 6.74 3.04e-10 0.00165 0.63 0.48 Corneal astigmatism; chr4:119405128 chr10:38450738~38451069:- PAAD trans rs7824557 0.505 rs2736313 ENSG00000253893.2 FAM85B -6.74 3.04e-10 0.00165 -0.66 -0.48 Retinal vascular caliber; chr8:11229433 chr8:8167819~8226614:- PAAD trans rs7811142 0.943 rs28578163 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100447131 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs67239991 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100448881 chr7:102337316~102339115:+ PAAD trans rs7811142 0.943 rs111493473 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100452119 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs4472444 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100473135 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs7809801 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100474408 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11766752 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100475669 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11559117 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100478991 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs4463351 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100480603 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs60844404 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100482851 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs113738841 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100483683 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11763511 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100484321 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs60478351 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100491394 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs7787620 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100491611 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11769700 ENSG00000228546.2 CTA-313A17.3 6.74 3.11e-10 0.00169 0.7 0.48 Platelet count; chr7:100492426 chr7:102337316~102339115:+ PAAD trans rs7554547 0.685 rs12724129 ENSG00000261819.1 RP11-680G24.4 6.74 3.15e-10 0.00171 0.62 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11897582 chr16:14988259~14990160:- PAAD trans rs7121616 1 rs7113273 ENSG00000234176.1 HSPA8P1 -6.73 3.21e-10 0.00174 -0.57 -0.48 Breast cancer; chr11:123092192 chrX:121203182~121205014:- PAAD trans rs11098499 0.865 rs11098513 ENSG00000275858.1 RP11-291L22.8 6.73 3.24e-10 0.00175 0.6 0.48 Corneal astigmatism; chr4:119394920 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs28572238 ENSG00000275858.1 RP11-291L22.8 6.73 3.24e-10 0.00175 0.6 0.48 Corneal astigmatism; chr4:119395531 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs28714195 ENSG00000275858.1 RP11-291L22.8 6.73 3.24e-10 0.00175 0.6 0.48 Corneal astigmatism; chr4:119395795 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs12508173 ENSG00000275858.1 RP11-291L22.8 6.73 3.24e-10 0.00175 0.6 0.48 Corneal astigmatism; chr4:119397371 chr10:38450738~38451069:- PAAD trans rs11098499 0.908 rs12504149 ENSG00000275858.1 RP11-291L22.8 6.73 3.24e-10 0.00175 0.6 0.48 Corneal astigmatism; chr4:119397422 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10008392 ENSG00000275858.1 RP11-291L22.8 6.73 3.24e-10 0.00175 0.6 0.48 Corneal astigmatism; chr4:119397684 chr10:38450738~38451069:- PAAD trans rs12709013 0.514 rs8062639 ENSG00000233719.3 GOT2P3 6.73 3.29e-10 0.00178 0.62 0.48 Blood metabolite ratios; chr16:58800264 chr12:9641802~9643007:+ PAAD trans rs12709013 0.591 rs4410065 ENSG00000233719.3 GOT2P3 6.73 3.29e-10 0.00178 0.62 0.48 Blood metabolite ratios; chr16:58800968 chr12:9641802~9643007:+ PAAD trans rs12709013 0.591 rs2406234 ENSG00000233719.3 GOT2P3 6.73 3.29e-10 0.00178 0.62 0.48 Blood metabolite ratios; chr16:58801840 chr12:9641802~9643007:+ PAAD trans rs12709013 0.591 rs2086206 ENSG00000233719.3 GOT2P3 6.73 3.29e-10 0.00178 0.62 0.48 Blood metabolite ratios; chr16:58802094 chr12:9641802~9643007:+ PAAD trans rs7811142 0.72 rs112622797 ENSG00000228546.2 CTA-313A17.3 6.72 3.35e-10 0.00181 0.73 0.48 Platelet count; chr7:100319793 chr7:102337316~102339115:+ PAAD trans rs9611519 0.78 rs9611546 ENSG00000268568.1 AC007228.9 -6.72 3.4e-10 0.00183 -0.63 -0.48 Neuroticism; chr22:41302538 chr19:56672574~56673901:- PAAD trans rs11098499 0.954 rs9993199 ENSG00000275858.1 RP11-291L22.8 -6.72 3.42e-10 0.00183 -0.61 -0.48 Corneal astigmatism; chr4:119471718 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10518331 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119402440 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs13133522 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119403269 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs35091806 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119404374 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs35165976 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119404475 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs6846442 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119405168 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs4001305 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119438081 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs71614422 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119438185 chr10:38450738~38451069:- PAAD trans rs11098499 0.738 rs34566984 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119440115 chr10:38450738~38451069:- PAAD trans rs11098499 0.738 rs34965784 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119440431 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs17009122 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119441248 chr10:38450738~38451069:- PAAD trans rs11098499 0.505 rs75122014 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119441271 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs9685777 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119444810 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs71614438 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119450097 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs66506550 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119450290 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs7659501 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119450397 chr10:38450738~38451069:- PAAD trans rs11098499 0.697 rs28655325 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119451844 chr10:38450738~38451069:- PAAD trans rs11098499 0.779 rs28495013 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119454676 chr10:38450738~38451069:- PAAD trans rs11098499 0.738 rs28408407 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119454875 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs1809406 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119455967 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs2389809 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119456244 chr10:38450738~38451069:- PAAD trans rs11098499 0.657 rs71614442 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119458191 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs2892848 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119460186 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs9994810 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119460435 chr10:38450738~38451069:- PAAD trans rs11098499 0.697 rs10020027 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119460724 chr10:38450738~38451069:- PAAD trans rs11098499 0.779 rs7356491 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119460819 chr10:38450738~38451069:- PAAD trans rs11098499 0.697 rs11941899 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119461603 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs7681978 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119462620 chr10:38450738~38451069:- PAAD trans rs11098499 0.821 rs28665282 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119463031 chr10:38450738~38451069:- PAAD trans rs11098499 0.738 rs10026493 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119463039 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs7681214 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119464165 chr10:38450738~38451069:- PAAD trans rs11098499 0.908 rs28559989 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119465472 chr10:38450738~38451069:- PAAD trans rs11098499 0.908 rs28499576 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119465522 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs28632018 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119465575 chr10:38450738~38451069:- PAAD trans rs11098499 0.908 rs71614449 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119465900 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs35063680 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119465947 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs34858317 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119465955 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs17046116 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119466104 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs17046118 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119466341 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs7654587 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119467251 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs11098525 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119468997 chr10:38450738~38451069:- PAAD trans rs11098499 0.821 rs10032151 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119470473 chr10:38450738~38451069:- PAAD trans rs11098499 0.865 rs10032158 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119470477 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs6838814 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119471288 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs13107475 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119471856 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs7436506 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119472614 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10008459 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119473076 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs2127821 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119473380 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10006525 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119487776 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs6849171 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119488394 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs12508504 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119489452 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs17005535 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119490407 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs3733520 ENSG00000275858.1 RP11-291L22.8 6.72 3.42e-10 0.00183 0.61 0.48 Corneal astigmatism; chr4:119502325 chr10:38450738~38451069:- PAAD trans rs6732160 0.845 rs6546809 ENSG00000236165.1 PRADC1P1 6.72 3.45e-10 0.00184 0.56 0.48 Intelligence (multi-trait analysis); chr2:73162553 chr3:36976316~36976840:+ PAAD trans rs7614738 1 rs7614738 ENSG00000197582.5 GPX1P1 6.72 3.46e-10 0.00184 0.64 0.48 Red cell distribution width; chr3:49273698 chrX:13378735~13379340:- PAAD trans rs7554547 0.69 rs7516708 ENSG00000261819.1 RP11-680G24.4 6.72 3.48e-10 0.00186 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11890148 chr16:14988259~14990160:- PAAD trans rs7554547 0.739 rs4846073 ENSG00000261819.1 RP11-680G24.4 6.72 3.48e-10 0.00186 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11890521 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs57678332 ENSG00000261819.1 RP11-680G24.4 6.72 3.48e-10 0.00186 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11890834 chr16:14988259~14990160:- PAAD trans rs7554547 0.765 rs57176983 ENSG00000261819.1 RP11-680G24.4 6.72 3.48e-10 0.00186 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11891041 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs1321072 ENSG00000261819.1 RP11-680G24.4 6.72 3.48e-10 0.00186 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11891261 chr16:14988259~14990160:- PAAD trans rs7258465 1 rs34746918 ENSG00000267533.1 RP11-815J4.7 6.72 3.51e-10 0.00187 0.6 0.48 Breast cancer; chr19:18428934 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs10408290 ENSG00000267533.1 RP11-815J4.7 6.72 3.51e-10 0.00187 0.6 0.48 Breast cancer; chr19:18431891 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs10409003 ENSG00000267533.1 RP11-815J4.7 6.72 3.51e-10 0.00187 0.6 0.48 Breast cancer; chr19:18432244 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs2385088 ENSG00000267533.1 RP11-815J4.7 6.72 3.51e-10 0.00187 0.6 0.48 Breast cancer; chr19:18434730 chr18:12067173~12068417:- PAAD trans rs6732160 0.774 rs11890053 ENSG00000236165.1 PRADC1P1 6.71 3.64e-10 0.00194 0.55 0.48 Intelligence (multi-trait analysis); chr2:73146320 chr3:36976316~36976840:+ PAAD trans rs6732160 0.774 rs1367291 ENSG00000236165.1 PRADC1P1 6.71 3.64e-10 0.00194 0.55 0.48 Intelligence (multi-trait analysis); chr2:73147737 chr3:36976316~36976840:+ PAAD trans rs11098499 0.909 rs10026736 ENSG00000275858.1 RP11-291L22.8 6.71 3.65e-10 0.00194 0.62 0.48 Corneal astigmatism; chr4:119463167 chr10:38450738~38451069:- PAAD trans rs8081395 0.836 rs2063353 ENSG00000187870.7 RNFT1P3 -6.71 3.66e-10 0.00194 -0.57 -0.48 White blood cell count; chr17:59811831 chr17:20743333~20754501:- PAAD trans rs11098499 0.908 rs7696649 ENSG00000275858.1 RP11-291L22.8 6.7 3.79e-10 0.00201 0.63 0.48 Corneal astigmatism; chr4:119401022 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs2389803 ENSG00000275858.1 RP11-291L22.8 -6.7 3.83e-10 0.00204 -0.63 -0.48 Corneal astigmatism; chr4:119472356 chr10:38450738~38451069:- PAAD trans rs4646450 0.588 rs17161695 ENSG00000228834.1 RP11-249L21.4 6.69 3.92e-10 0.00208 1.04 0.48 Blood metabolite levels; chr7:99367083 chr6:108907615~108907873:- PAAD trans rs7258465 1 rs28572537 ENSG00000267533.1 RP11-815J4.7 6.69 3.94e-10 0.00209 0.6 0.48 Breast cancer; chr19:18441398 chr18:12067173~12068417:- PAAD trans rs12138950 0.681 rs10917468 ENSG00000224237.1 MINOS1P3 -6.69 3.96e-10 0.0021 -0.67 -0.48 Hypothyroidism;Thyroid volume; chr1:19516860 chr3:27214816~27215018:- PAAD trans rs7554547 0.791 rs6665662 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11891804 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs34117126 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11892138 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs17037520 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11892349 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs12749498 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11892570 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs12036266 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11893257 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs2065611 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11893469 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs2064614 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11893883 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs4492637 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11895787 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs4846074 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11896172 chr16:14988259~14990160:- PAAD trans rs7554547 0.791 rs4846076 ENSG00000261819.1 RP11-680G24.4 6.69 3.97e-10 0.0021 0.6 0.48 Nonsyndromic cleft lip with cleft palate; chr1:11896708 chr16:14988259~14990160:- PAAD trans rs7395662 1 rs11039819 ENSG00000134612.10 FOLH1B -6.69 4.02e-10 0.00212 -0.57 -0.48 HDL cholesterol; chr11:48540629 chr11:89639227~89698718:+ PAAD trans rs12709013 0.574 rs839418 ENSG00000233719.3 GOT2P3 6.69 4.02e-10 0.00213 0.64 0.48 Blood metabolite ratios; chr16:58705426 chr12:9641802~9643007:+ PAAD trans rs9650657 0.645 rs4841407 ENSG00000253893.2 FAM85B 6.69 4.08e-10 0.00216 0.66 0.48 Neuroticism; chr8:10658675 chr8:8167819~8226614:- PAAD trans rs8081395 0.836 rs2150879 ENSG00000187870.7 RNFT1P3 -6.69 4.09e-10 0.00216 -0.56 -0.48 White blood cell count; chr17:59781849 chr17:20743333~20754501:- PAAD trans rs9611519 0.78 rs9611542 ENSG00000268568.1 AC007228.9 -6.69 4.1e-10 0.00216 -0.61 -0.48 Neuroticism; chr22:41281313 chr19:56672574~56673901:- PAAD trans rs11098499 0.618 rs35265692 ENSG00000275858.1 RP11-291L22.8 6.68 4.13e-10 0.00218 0.63 0.48 Corneal astigmatism; chr4:119403980 chr10:38450738~38451069:- PAAD trans rs11039798 0.565 rs7118675 ENSG00000134612.10 FOLH1B 6.68 4.16e-10 0.00219 0.73 0.48 Axial length; chr11:48510511 chr11:89639227~89698718:+ PAAD trans rs7937890 0.732 rs7946902 ENSG00000236360.2 RP11-334A14.2 -6.68 4.2e-10 0.00221 -0.66 -0.48 Mitochondrial DNA levels; chr11:14251762 chr1:52993201~52993702:- PAAD trans rs3779195 0.86 rs12704986 ENSG00000225169.1 BRI3P1 6.68 4.26e-10 0.00224 0.73 0.48 Sex hormone-binding globulin levels; chr7:98357118 chr1:100213293~100213670:+ PAAD trans rs3779195 0.858 rs3779196 ENSG00000225169.1 BRI3P1 6.68 4.26e-10 0.00224 0.73 0.48 Sex hormone-binding globulin levels; chr7:98360794 chr1:100213293~100213670:+ PAAD trans rs3779195 0.789 rs6965424 ENSG00000225169.1 BRI3P1 6.68 4.26e-10 0.00224 0.73 0.48 Sex hormone-binding globulin levels; chr7:98361813 chr1:100213293~100213670:+ PAAD trans rs11098499 0.58 rs12509234 ENSG00000275858.1 RP11-291L22.8 6.68 4.26e-10 0.00224 0.61 0.48 Corneal astigmatism; chr4:119398279 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs10014719 ENSG00000275858.1 RP11-291L22.8 6.68 4.26e-10 0.00224 0.61 0.48 Corneal astigmatism; chr4:119399560 chr10:38450738~38451069:- PAAD trans rs11098499 0.954 rs10017543 ENSG00000275858.1 RP11-291L22.8 6.68 4.26e-10 0.00224 0.61 0.48 Corneal astigmatism; chr4:119400265 chr10:38450738~38451069:- PAAD trans rs11098499 0.908 rs7695996 ENSG00000275858.1 RP11-291L22.8 6.68 4.26e-10 0.00224 0.61 0.48 Corneal astigmatism; chr4:119400878 chr10:38450738~38451069:- PAAD trans rs10037055 0.812 rs11949435 ENSG00000217325.2 PRELID1P1 6.68 4.27e-10 0.00225 0.67 0.48 Migraine without aura; chr5:177287931 chr6:126643488~126644390:+ PAAD trans rs7395662 0.782 rs4882064 ENSG00000134612.10 FOLH1B 6.68 4.28e-10 0.00225 0.58 0.48 HDL cholesterol; chr11:48434205 chr11:89639227~89698718:+ PAAD trans rs7395662 0.853 rs4882054 ENSG00000134612.10 FOLH1B -6.68 4.28e-10 0.00225 -0.58 -0.48 HDL cholesterol; chr11:48378347 chr11:89639227~89698718:+ PAAD trans rs12138950 0.681 rs10917472 ENSG00000224237.1 MINOS1P3 6.68 4.28e-10 0.00225 0.69 0.48 Hypothyroidism;Thyroid volume; chr1:19524218 chr3:27214816~27215018:- PAAD trans rs2896526 0.736 rs78950598 ENSG00000235847.2 LDHAP7 6.68 4.32e-10 0.00227 0.8 0.48 Amyloid A serum levels; chr11:18375599 chr2:84777259~84778223:- PAAD trans rs12709013 0.636 rs1646279 ENSG00000233719.3 GOT2P3 6.67 4.38e-10 0.0023 0.61 0.48 Blood metabolite ratios; chr16:58750235 chr12:9641802~9643007:+ PAAD trans rs12138950 0.681 rs9783019 ENSG00000224237.1 MINOS1P3 6.67 4.43e-10 0.00232 0.69 0.48 Hypothyroidism;Thyroid volume; chr1:19523162 chr3:27214816~27215018:- PAAD trans rs877636 0.692 rs10876870 ENSG00000243403.1 RP11-330L19.1 -6.67 4.46e-10 0.00234 -0.52 -0.48 Cognitive function; chr12:56084218 chr15:64592979~64593326:+ PAAD trans rs877636 0.692 rs7971751 ENSG00000243403.1 RP11-330L19.1 -6.67 4.46e-10 0.00234 -0.52 -0.48 Cognitive function; chr12:56084874 chr15:64592979~64593326:+ PAAD trans rs12138950 0.681 rs28630511 ENSG00000224237.1 MINOS1P3 6.67 4.46e-10 0.00234 0.67 0.48 Hypothyroidism;Thyroid volume; chr1:19516538 chr3:27214816~27215018:- PAAD trans rs11098499 0.909 rs11723757 ENSG00000275858.1 RP11-291L22.8 6.67 4.48e-10 0.00235 0.61 0.48 Corneal astigmatism; chr4:119378514 chr10:38450738~38451069:- PAAD trans rs3096299 0.503 rs9925045 ENSG00000215030.5 RPL13P12 -6.67 4.5e-10 0.00236 -0.52 -0.48 Multiple myeloma (IgH translocation); chr16:89490068 chr17:17383377~17384012:- PAAD trans rs2060793 0.712 rs10832290 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14650684 chr1:52993201~52993702:- PAAD trans rs2060793 0.774 rs1403249 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14651438 chr1:52993201~52993702:- PAAD trans rs7937890 0.505 rs1403248 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Mitochondrial DNA levels; chr11:14657471 chr1:52993201~52993702:- PAAD trans rs2060793 0.741 rs7119073 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14669416 chr1:52993201~52993702:- PAAD trans rs2060793 0.741 rs10741653 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14683294 chr1:52993201~52993702:- PAAD trans rs2060793 0.741 rs4344519 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14701347 chr1:52993201~52993702:- PAAD trans rs2060793 0.712 rs11023310 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14703717 chr1:52993201~52993702:- PAAD trans rs2060793 0.712 rs10741654 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14726506 chr1:52993201~52993702:- PAAD trans rs7937890 0.505 rs9971395 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Mitochondrial DNA levels; chr11:14745580 chr1:52993201~52993702:- PAAD trans rs7937890 0.506 rs10741655 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Mitochondrial DNA levels; chr11:14746838 chr1:52993201~52993702:- PAAD trans rs2060793 0.741 rs2060794 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14791437 chr1:52993201~52993702:- PAAD trans rs2060793 0.741 rs10741656 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14803699 chr1:52993201~52993702:- PAAD trans rs2060793 0.741 rs3740823 ENSG00000236360.2 RP11-334A14.2 6.67 4.55e-10 0.00238 0.61 0.48 Vitamin D levels; chr11:14804158 chr1:52993201~52993702:- PAAD trans rs7312770 0.612 rs1873914 ENSG00000235459.5 RPS26P31 6.67 4.55e-10 0.00238 0.54 0.48 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr7:122681315~122681662:+ PAAD trans rs7395662 0.833 rs1963073 ENSG00000134612.10 FOLH1B -6.66 4.62e-10 0.00241 -0.59 -0.48 HDL cholesterol; chr11:48953542 chr11:89639227~89698718:+ PAAD trans rs7312770 0.612 rs1873914 ENSG00000234513.1 AC073072.7 6.66 4.62e-10 0.00241 0.54 0.48 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr7:22773646~22773993:- PAAD trans rs61990749 1 rs4533193 ENSG00000235400.1 RP4-641G12.4 -6.66 4.65e-10 0.00242 -0.85 -0.48 Fibroblast growth factor basic levels; chr14:77913825 chr1:78749073~78750659:+ PAAD trans rs2731664 0.792 rs335432 ENSG00000215571.5 GRK6P1 6.66 4.68e-10 0.00244 0.63 0.48 Intelligence (multi-trait analysis); chr5:177439257 chr13:21319156~21320866:+ PAAD trans rs7824557 0.843 rs2572418 ENSG00000253893.2 FAM85B 6.66 4.76e-10 0.00248 0.67 0.48 Retinal vascular caliber; chr8:11255580 chr8:8167819~8226614:- PAAD trans rs1045902 0.583 rs36106493 ENSG00000236165.1 PRADC1P1 6.66 4.76e-10 0.00248 0.61 0.48 Intelligence (multi-trait analysis); chr2:73215211 chr3:36976316~36976840:+ PAAD trans rs8010715 0.636 rs3825584 ENSG00000248988.1 RP11-815N9.2 6.66 4.78e-10 0.00249 0.67 0.48 IgG glycosylation; chr14:24118430 chr4:159007119~159007835:+ PAAD trans rs2060793 0.741 rs10734227 ENSG00000236360.2 RP11-334A14.2 6.66 4.78e-10 0.00249 0.61 0.48 Vitamin D levels; chr11:14767471 chr1:52993201~52993702:- PAAD trans rs2060793 0.741 rs1542291 ENSG00000236360.2 RP11-334A14.2 6.66 4.78e-10 0.00249 0.61 0.48 Vitamin D levels; chr11:14784720 chr1:52993201~52993702:- PAAD trans rs2060793 0.659 rs1839834 ENSG00000236360.2 RP11-334A14.2 6.66 4.78e-10 0.00249 0.61 0.48 Vitamin D levels; chr11:14807914 chr1:52993201~52993702:- PAAD trans rs10838798 0.523 rs11039543 ENSG00000134612.10 FOLH1B -6.66 4.79e-10 0.00249 -0.56 -0.48 Height; chr11:48146551 chr11:89639227~89698718:+ PAAD trans rs12709013 0.591 rs149479 ENSG00000233719.3 GOT2P3 -6.66 4.81e-10 0.0025 -0.66 -0.48 Blood metabolite ratios; chr16:58703171 chr12:9641802~9643007:+ PAAD trans rs2727020 0.731 rs10450572 ENSG00000134612.10 FOLH1B 6.66 4.82e-10 0.0025 0.57 0.48 Coronary artery disease; chr11:49259521 chr11:89639227~89698718:+ PAAD trans rs2727020 0.729 rs2866328 ENSG00000134612.10 FOLH1B 6.66 4.82e-10 0.0025 0.57 0.48 Coronary artery disease; chr11:49260869 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs12294395 ENSG00000134612.10 FOLH1B 6.66 4.83e-10 0.00251 0.73 0.48 Axial length; chr11:48455308 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs10838923 ENSG00000134612.10 FOLH1B 6.66 4.83e-10 0.00251 0.73 0.48 Axial length; chr11:48513312 chr11:89639227~89698718:+ PAAD trans rs9650657 0.707 rs11250076 ENSG00000253893.2 FAM85B 6.65 4.85e-10 0.00252 0.64 0.47 Neuroticism; chr8:10790313 chr8:8167819~8226614:- PAAD trans rs11039798 0.512 rs3974936 ENSG00000134612.10 FOLH1B 6.65 4.87e-10 0.00253 0.75 0.47 Axial length; chr11:48983460 chr11:89639227~89698718:+ PAAD trans rs11039798 0.512 rs28453037 ENSG00000134612.10 FOLH1B 6.65 4.87e-10 0.00253 0.75 0.47 Axial length; chr11:48985377 chr11:89639227~89698718:+ PAAD trans rs877636 0.692 rs2271194 ENSG00000212994.5 RPS26P6 -6.65 4.99e-10 0.00259 -0.53 -0.47 Cognitive function; chr12:56083910 chr8:100895771~100896118:+ PAAD trans rs7395662 0.5 rs1605360 ENSG00000134612.10 FOLH1B -6.65 4.99e-10 0.00259 -0.56 -0.47 HDL cholesterol; chr11:48664162 chr11:89639227~89698718:+ PAAD trans rs7395662 0.517 rs10454483 ENSG00000134612.10 FOLH1B -6.65 4.99e-10 0.00259 -0.56 -0.47 HDL cholesterol; chr11:48733445 chr11:89639227~89698718:+ PAAD trans rs877636 0.692 rs10876870 ENSG00000223416.3 RPS26P15 -6.65 4.99e-10 0.00259 -0.57 -0.47 Cognitive function; chr12:56084218 chr1:58056133~58056480:- PAAD trans rs877636 0.692 rs7971751 ENSG00000223416.3 RPS26P15 -6.65 4.99e-10 0.00259 -0.57 -0.47 Cognitive function; chr12:56084874 chr1:58056133~58056480:- PAAD trans rs11039798 0.588 rs11039855 ENSG00000134612.10 FOLH1B 6.65 5.07e-10 0.00262 0.72 0.47 Axial length; chr11:48588539 chr11:89639227~89698718:+ PAAD trans rs2727020 0.755 rs652655 ENSG00000134612.10 FOLH1B 6.64 5.15e-10 0.00266 0.57 0.47 Coronary artery disease; chr11:49229741 chr11:89639227~89698718:+ PAAD trans rs7811142 1 rs1000215 ENSG00000228546.2 CTA-313A17.3 6.64 5.16e-10 0.00267 0.7 0.47 Platelet count; chr7:100406920 chr7:102337316~102339115:+ PAAD trans rs2727020 0.729 rs1164685 ENSG00000134612.10 FOLH1B 6.64 5.22e-10 0.00269 0.57 0.47 Coronary artery disease; chr11:49272108 chr11:89639227~89698718:+ PAAD trans rs2727020 0.729 rs1164666 ENSG00000134612.10 FOLH1B -6.64 5.22e-10 0.00269 -0.57 -0.47 Coronary artery disease; chr11:49274315 chr11:89639227~89698718:+ PAAD trans rs1045902 0.583 rs2303904 ENSG00000236165.1 PRADC1P1 -6.64 5.23e-10 0.0027 -0.6 -0.47 Intelligence (multi-trait analysis); chr2:73220647 chr3:36976316~36976840:+ PAAD trans rs7811142 0.775 rs1636980 ENSG00000228546.2 CTA-313A17.3 -6.64 5.29e-10 0.00273 -0.7 -0.47 Platelet count; chr7:100341241 chr7:102337316~102339115:+ PAAD trans rs7395662 0.517 rs11039885 ENSG00000134612.10 FOLH1B -6.64 5.3e-10 0.00273 -0.56 -0.47 HDL cholesterol; chr11:48625555 chr11:89639227~89698718:+ PAAD trans rs11098499 0.909 rs10017335 ENSG00000275858.1 RP11-291L22.8 -6.64 5.32e-10 0.00274 -0.61 -0.47 Corneal astigmatism; chr4:119460368 chr10:38450738~38451069:- PAAD trans rs2727020 0.521 rs11039902 ENSG00000134612.10 FOLH1B -6.64 5.34e-10 0.00275 -0.56 -0.47 Coronary artery disease; chr11:48657915 chr11:89639227~89698718:+ PAAD trans rs7395662 0.5 rs1304199 ENSG00000134612.10 FOLH1B -6.64 5.34e-10 0.00275 -0.56 -0.47 HDL cholesterol; chr11:48677480 chr11:89639227~89698718:+ PAAD trans rs7395662 0.553 rs4882155 ENSG00000134612.10 FOLH1B -6.64 5.34e-10 0.00275 -0.56 -0.47 HDL cholesterol; chr11:48684249 chr11:89639227~89698718:+ PAAD trans rs7395662 0.591 rs4882233 ENSG00000134612.10 FOLH1B -6.64 5.34e-10 0.00275 -0.56 -0.47 HDL cholesterol; chr11:48718101 chr11:89639227~89698718:+ PAAD trans rs9650657 0.645 rs11774552 ENSG00000253893.2 FAM85B 6.64 5.35e-10 0.00275 0.66 0.47 Neuroticism; chr8:10658169 chr8:8167819~8226614:- PAAD trans rs9650657 0.617 rs7814795 ENSG00000253893.2 FAM85B 6.63 5.39e-10 0.00278 0.68 0.47 Neuroticism; chr8:10661775 chr8:8167819~8226614:- PAAD trans rs3779195 0.697 rs13232861 ENSG00000225169.1 BRI3P1 6.63 5.4e-10 0.00278 0.77 0.47 Sex hormone-binding globulin levels; chr7:98299769 chr1:100213293~100213670:+ PAAD trans rs4663866 0.522 rs111276182 ENSG00000279192.1 PWAR5 -6.63 5.4e-10 0.00278 -0.69 -0.47 Irritable bowel syndrome; chr2:238210191 chr15:24985053~24988232:+ PAAD trans rs2731664 0.792 rs2630763 ENSG00000215571.5 GRK6P1 6.63 5.43e-10 0.0028 0.66 0.47 Intelligence (multi-trait analysis); chr5:177474004 chr13:21319156~21320866:+ PAAD trans rs7395662 0.525 rs1945189 ENSG00000134612.10 FOLH1B -6.63 5.58e-10 0.00287 -0.55 -0.47 HDL cholesterol; chr11:48397337 chr11:89639227~89698718:+ PAAD trans rs7395662 0.504 rs2019666 ENSG00000134612.10 FOLH1B -6.63 5.58e-10 0.00287 -0.55 -0.47 HDL cholesterol; chr11:48416177 chr11:89639227~89698718:+ PAAD trans rs7395662 0.57 rs11039737 ENSG00000134612.10 FOLH1B -6.63 5.58e-10 0.00287 -0.55 -0.47 HDL cholesterol; chr11:48428648 chr11:89639227~89698718:+ PAAD trans rs11098499 0.954 rs10034623 ENSG00000275858.1 RP11-291L22.8 6.63 5.58e-10 0.00287 0.61 0.47 Corneal astigmatism; chr4:119476674 chr10:38450738~38451069:- PAAD trans rs2657294 1 rs2657294 ENSG00000172974.11 AC007318.5 6.63 5.61e-10 0.00288 0.59 0.47 Pneumonia; chr10:75193267 chr2:65205108~65205988:+ PAAD trans rs12138950 0.681 rs4362008 ENSG00000224237.1 MINOS1P3 6.63 5.65e-10 0.0029 0.66 0.47 Hypothyroidism;Thyroid volume; chr1:19511064 chr3:27214816~27215018:- PAAD trans rs877636 0.692 rs2271194 ENSG00000234354.3 RPS26P47 -6.62 5.7e-10 0.00293 -0.59 -0.47 Cognitive function; chr12:56083910 chr13:100539901~100540248:- PAAD trans rs9650657 0.589 rs12542037 ENSG00000253893.2 FAM85B -6.62 5.73e-10 0.00294 -0.65 -0.47 Neuroticism; chr8:10900986 chr8:8167819~8226614:- PAAD trans rs7395662 0.504 rs11039701 ENSG00000134612.10 FOLH1B -6.62 5.74e-10 0.00294 -0.54 -0.47 HDL cholesterol; chr11:48368286 chr11:89639227~89698718:+ PAAD trans rs7395662 0.525 rs4882060 ENSG00000134612.10 FOLH1B -6.62 5.74e-10 0.00294 -0.54 -0.47 HDL cholesterol; chr11:48420322 chr11:89639227~89698718:+ PAAD trans rs9650657 0.645 rs4841409 ENSG00000253893.2 FAM85B -6.62 5.8e-10 0.00297 -0.66 -0.47 Neuroticism; chr8:10658864 chr8:8167819~8226614:- PAAD trans rs2727020 0.729 rs685789 ENSG00000134612.10 FOLH1B 6.62 5.81e-10 0.00298 0.57 0.47 Coronary artery disease; chr11:49219676 chr11:89639227~89698718:+ PAAD trans rs7312770 0.637 rs705700 ENSG00000212829.8 RPS26P3 6.62 5.82e-10 0.00298 0.56 0.47 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr9:9090898~9091245:+ PAAD trans rs9650657 0.645 rs9969657 ENSG00000253893.2 FAM85B -6.61 6.04e-10 0.00308 -0.65 -0.47 Neuroticism; chr8:10657768 chr8:8167819~8226614:- PAAD trans rs3779195 0.929 rs10953259 ENSG00000225169.1 BRI3P1 -6.61 6.11e-10 0.00311 -0.74 -0.47 Sex hormone-binding globulin levels; chr7:98383795 chr1:100213293~100213670:+ PAAD trans rs7395662 0.784 rs2170661 ENSG00000134612.10 FOLH1B -6.61 6.14e-10 0.00312 -0.58 -0.47 HDL cholesterol; chr11:48356634 chr11:89639227~89698718:+ PAAD trans rs2727020 0.688 rs11040338 ENSG00000134612.10 FOLH1B 6.61 6.22e-10 0.00316 0.57 0.47 Coronary artery disease; chr11:49339049 chr11:89639227~89698718:+ PAAD trans rs877636 1 rs4759229 ENSG00000225071.1 GS1-184P14.2 -6.61 6.27e-10 0.00319 -0.57 -0.47 Cognitive function; chr12:56080696 chrX:24429573~24429920:- PAAD trans rs7824557 0.547 rs2409749 ENSG00000253893.2 FAM85B 6.6 6.29e-10 0.00319 0.65 0.47 Retinal vascular caliber; chr8:11221440 chr8:8167819~8226614:- PAAD trans rs7312770 0.612 rs773114 ENSG00000235459.5 RPS26P31 6.6 6.32e-10 0.00321 0.52 0.47 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chr7:122681315~122681662:+ PAAD trans rs12138950 0.711 rs10799821 ENSG00000224237.1 MINOS1P3 6.6 6.4e-10 0.00324 0.66 0.47 Hypothyroidism;Thyroid volume; chr1:19511475 chr3:27214816~27215018:- PAAD trans rs12138950 0.681 rs60066365 ENSG00000224237.1 MINOS1P3 6.6 6.4e-10 0.00324 0.66 0.47 Hypothyroidism;Thyroid volume; chr1:19512191 chr3:27214816~27215018:- PAAD trans rs12138950 0.681 rs10799822 ENSG00000224237.1 MINOS1P3 6.6 6.4e-10 0.00324 0.66 0.47 Hypothyroidism;Thyroid volume; chr1:19513327 chr3:27214816~27215018:- PAAD trans rs2727020 0.729 rs588458 ENSG00000134612.10 FOLH1B 6.6 6.4e-10 0.00324 0.57 0.47 Coronary artery disease; chr11:49192496 chr11:89639227~89698718:+ PAAD trans rs2727020 0.729 rs4315497 ENSG00000134612.10 FOLH1B 6.6 6.4e-10 0.00324 0.57 0.47 Coronary artery disease; chr11:49192947 chr11:89639227~89698718:+ PAAD trans rs2727020 0.702 rs609054 ENSG00000134612.10 FOLH1B 6.6 6.4e-10 0.00324 0.57 0.47 Coronary artery disease; chr11:49198173 chr11:89639227~89698718:+ PAAD trans rs1814175 0.538 rs1684260 ENSG00000134612.10 FOLH1B 6.6 6.4e-10 0.00324 0.57 0.47 Height; chr11:49202679 chr11:89639227~89698718:+ PAAD trans rs2727020 0.688 rs2734002 ENSG00000134612.10 FOLH1B 6.6 6.4e-10 0.00324 0.57 0.47 Coronary artery disease; chr11:49212610 chr11:89639227~89698718:+ PAAD trans rs2727020 0.612 rs603672 ENSG00000134612.10 FOLH1B 6.6 6.4e-10 0.00324 0.57 0.47 Coronary artery disease; chr11:49213014 chr11:89639227~89698718:+ PAAD trans rs616147 0.548 rs2370965 ENSG00000183298.5 RP11-556K13.1 -6.6 6.57e-10 0.00332 -0.65 -0.47 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39448996 chr1:101786340~101787219:- PAAD trans rs7395662 0.786 rs12791074 ENSG00000134612.10 FOLH1B -6.6 6.59e-10 0.00333 -0.58 -0.47 HDL cholesterol; chr11:48983471 chr11:89639227~89698718:+ PAAD trans rs7811142 1 rs67040465 ENSG00000228546.2 CTA-313A17.3 6.6 6.62e-10 0.00334 0.7 0.47 Platelet count; chr7:100485455 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs6979335 ENSG00000228546.2 CTA-313A17.3 6.6 6.62e-10 0.00334 0.7 0.47 Platelet count; chr7:100492237 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs73405353 ENSG00000228546.2 CTA-313A17.3 6.6 6.62e-10 0.00334 0.7 0.47 Platelet count; chr7:100493592 chr7:102337316~102339115:+ PAAD trans rs877636 0.692 rs10876870 ENSG00000212994.5 RPS26P6 -6.59 6.64e-10 0.00335 -0.53 -0.47 Cognitive function; chr12:56084218 chr8:100895771~100896118:+ PAAD trans rs877636 0.692 rs7971751 ENSG00000212994.5 RPS26P6 -6.59 6.64e-10 0.00335 -0.53 -0.47 Cognitive function; chr12:56084874 chr8:100895771~100896118:+ PAAD trans rs7824557 0.843 rs2736375 ENSG00000253893.2 FAM85B 6.59 6.83e-10 0.00344 0.65 0.47 Retinal vascular caliber; chr8:11258240 chr8:8167819~8226614:- PAAD trans rs7032940 0.533 rs7868072 ENSG00000228236.2 TXNP5 6.59 6.96e-10 0.0035 0.57 0.47 Height; chr9:110205824 chr2:149068596~149068910:- PAAD trans rs877636 0.562 rs1131017 ENSG00000243403.1 RP11-330L19.1 -6.58 7.03e-10 0.00353 -0.5 -0.47 Cognitive function; chr12:56042145 chr15:64592979~64593326:+ PAAD trans rs7395662 0.819 rs1473579 ENSG00000134612.10 FOLH1B -6.58 7.22e-10 0.00362 -0.58 -0.47 HDL cholesterol; chr11:48880001 chr11:89639227~89698718:+ PAAD trans rs7395662 1 rs4929903 ENSG00000134612.10 FOLH1B -6.58 7.22e-10 0.00362 -0.58 -0.47 HDL cholesterol; chr11:48891780 chr11:89639227~89698718:+ PAAD trans rs11098499 0.954 rs12510138 ENSG00000275858.1 RP11-291L22.8 6.58 7.28e-10 0.00365 0.62 0.47 Corneal astigmatism; chr4:119502780 chr10:38450738~38451069:- PAAD trans rs7554547 0.69 rs6667637 ENSG00000261819.1 RP11-680G24.4 6.58 7.29e-10 0.00366 0.59 0.47 Nonsyndromic cleft lip with cleft palate; chr1:11887900 chr16:14988259~14990160:- PAAD trans rs9650657 0.571 rs4240673 ENSG00000253893.2 FAM85B 6.58 7.3e-10 0.00366 0.67 0.47 Neuroticism; chr8:10930102 chr8:8167819~8226614:- PAAD trans rs877636 0.562 rs1131017 ENSG00000223416.3 RPS26P15 -6.58 7.33e-10 0.00368 -0.55 -0.47 Cognitive function; chr12:56042145 chr1:58056133~58056480:- PAAD trans rs11098499 0.954 rs3733524 ENSG00000275858.1 RP11-291L22.8 6.58 7.34e-10 0.00368 0.62 0.47 Corneal astigmatism; chr4:119502574 chr10:38450738~38451069:- PAAD trans rs877636 0.562 rs1131017 ENSG00000212994.5 RPS26P6 -6.57 7.36e-10 0.00369 -0.52 -0.47 Cognitive function; chr12:56042145 chr8:100895771~100896118:+ PAAD trans rs2657294 0.796 rs2657290 ENSG00000172974.11 AC007318.5 6.57 7.39e-10 0.0037 0.58 0.47 Pneumonia; chr10:75207404 chr2:65205108~65205988:+ PAAD trans rs2727020 0.595 rs10769583 ENSG00000134612.10 FOLH1B -6.57 7.42e-10 0.00371 -0.55 -0.47 Coronary artery disease; chr11:49461641 chr11:89639227~89698718:+ PAAD trans rs2727020 0.595 rs10839281 ENSG00000134612.10 FOLH1B -6.57 7.42e-10 0.00371 -0.55 -0.47 Coronary artery disease; chr11:49461821 chr11:89639227~89698718:+ PAAD trans rs2727020 0.595 rs10839286 ENSG00000134612.10 FOLH1B -6.57 7.42e-10 0.00371 -0.55 -0.47 Coronary artery disease; chr11:49475511 chr11:89639227~89698718:+ PAAD trans rs2727020 0.595 rs10466496 ENSG00000134612.10 FOLH1B -6.57 7.42e-10 0.00371 -0.55 -0.47 Coronary artery disease; chr11:49479962 chr11:89639227~89698718:+ PAAD trans rs2727020 0.595 rs7924311 ENSG00000134612.10 FOLH1B -6.57 7.42e-10 0.00371 -0.55 -0.47 Coronary artery disease; chr11:49486021 chr11:89639227~89698718:+ PAAD trans rs2727020 0.615 rs35423199 ENSG00000134612.10 FOLH1B -6.57 7.42e-10 0.00371 -0.55 -0.47 Coronary artery disease; chr11:49493362 chr11:89639227~89698718:+ PAAD trans rs2727020 0.576 rs12293522 ENSG00000134612.10 FOLH1B -6.57 7.42e-10 0.00371 -0.55 -0.47 Coronary artery disease; chr11:49536873 chr11:89639227~89698718:+ PAAD trans rs7554547 0.765 rs34175640 ENSG00000261819.1 RP11-680G24.4 -6.57 7.45e-10 0.00372 -0.59 -0.47 Nonsyndromic cleft lip with cleft palate; chr1:11892155 chr16:14988259~14990160:- PAAD trans rs2060793 0.741 rs4757268 ENSG00000236360.2 RP11-334A14.2 6.57 7.54e-10 0.00376 0.6 0.47 Vitamin D levels; chr11:14789216 chr1:52993201~52993702:- PAAD trans rs12493123 0.702 rs13085992 ENSG00000249936.3 RAC1P2 -6.57 7.58e-10 0.00379 -0.95 -0.47 Reading and spelling; chr3:162387767 chr4:46723830~46724408:- PAAD trans rs3942852 0.688 rs10742834 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48148165 chr11:89639227~89698718:+ PAAD trans rs3942852 0.726 rs1503171 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48153600 chr11:89639227~89698718:+ PAAD trans rs3942852 0.726 rs10742836 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48154279 chr11:89639227~89698718:+ PAAD trans rs3942852 0.696 rs4597030 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48155021 chr11:89639227~89698718:+ PAAD trans rs3942852 0.774 rs924715 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48159508 chr11:89639227~89698718:+ PAAD trans rs3942852 0.774 rs1039481 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48160685 chr11:89639227~89698718:+ PAAD trans rs3942852 0.774 rs2270990 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48163431 chr11:89639227~89698718:+ PAAD trans rs3942852 0.774 rs10838811 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48165243 chr11:89639227~89698718:+ PAAD trans rs3942852 0.774 rs10838812 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48165372 chr11:89639227~89698718:+ PAAD trans rs3942852 0.774 rs10838813 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48165417 chr11:89639227~89698718:+ PAAD trans rs3942852 0.774 rs10838814 ENSG00000134612.10 FOLH1B -6.57 7.64e-10 0.00381 -0.61 -0.47 Acute lymphoblastic leukemia (childhood); chr11:48165626 chr11:89639227~89698718:+ PAAD trans rs2727020 0.587 rs1164658 ENSG00000134612.10 FOLH1B 6.57 7.7e-10 0.00384 0.56 0.47 Coronary artery disease; chr11:49276999 chr11:89639227~89698718:+ PAAD trans rs2727020 0.576 rs11040223 ENSG00000134612.10 FOLH1B -6.56 7.82e-10 0.00389 -0.55 -0.47 Coronary artery disease; chr11:49013081 chr11:89639227~89698718:+ PAAD trans rs7395662 0.504 rs1814158 ENSG00000134612.10 FOLH1B -6.56 7.84e-10 0.0039 -0.52 -0.47 HDL cholesterol; chr11:48416385 chr11:89639227~89698718:+ PAAD trans rs12709013 0.591 rs30840 ENSG00000233719.3 GOT2P3 6.56 7.9e-10 0.00393 0.65 0.47 Blood metabolite ratios; chr16:58710165 chr12:9641802~9643007:+ PAAD trans rs7554547 0.69 rs6669571 ENSG00000261819.1 RP11-680G24.4 6.56 8.04e-10 0.004 0.58 0.47 Nonsyndromic cleft lip with cleft palate; chr1:11887253 chr16:14988259~14990160:- PAAD trans rs7554547 0.69 rs1474576 ENSG00000261819.1 RP11-680G24.4 6.56 8.04e-10 0.004 0.58 0.47 Nonsyndromic cleft lip with cleft palate; chr1:11887572 chr16:14988259~14990160:- PAAD trans rs7554547 0.69 rs1474577 ENSG00000261819.1 RP11-680G24.4 6.56 8.04e-10 0.004 0.58 0.47 Nonsyndromic cleft lip with cleft palate; chr1:11887712 chr16:14988259~14990160:- PAAD trans rs2657294 0.761 rs1259498 ENSG00000172974.11 AC007318.5 6.56 8.11e-10 0.00403 0.59 0.47 Pneumonia; chr10:75226983 chr2:65205108~65205988:+ PAAD trans rs11098499 0.863 rs7699064 ENSG00000275858.1 RP11-291L22.8 -6.56 8.15e-10 0.00404 -0.62 -0.47 Corneal astigmatism; chr4:119507154 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs1383532 ENSG00000275858.1 RP11-291L22.8 -6.56 8.15e-10 0.00404 -0.62 -0.47 Corneal astigmatism; chr4:119513249 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs13134665 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119505275 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3775843 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119506689 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3775844 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119506878 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3822190 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119506943 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3822191 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119506946 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs7664986 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119508797 chr10:38450738~38451069:- PAAD trans rs11098499 0.818 rs10008791 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119510314 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs11736416 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119510506 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3775845 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119511292 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs1383533 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119513421 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs2291185 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119513678 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs10030660 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119515549 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs13149407 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119516670 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs34868248 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119521275 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3733525 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119525893 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3775847 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119526487 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3775848 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119526569 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs10013305 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119529269 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3775849 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119529753 chr10:38450738~38451069:- PAAD trans rs11098499 0.818 rs7688802 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119530513 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs7695620 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119531621 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs12502389 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119533036 chr10:38450738~38451069:- PAAD trans rs11098499 0.821 rs3775852 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119533401 chr10:38450738~38451069:- PAAD trans rs11098499 0.82 rs6534140 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119534156 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs7657849 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119534339 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs10034450 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119534494 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs1480939 ENSG00000275858.1 RP11-291L22.8 6.56 8.15e-10 0.00404 0.62 0.47 Corneal astigmatism; chr4:119535772 chr10:38450738~38451069:- PAAD trans rs7937890 0.681 rs4756784 ENSG00000236360.2 RP11-334A14.2 -6.56 8.17e-10 0.00405 -0.65 -0.47 Mitochondrial DNA levels; chr11:14249358 chr1:52993201~52993702:- PAAD trans rs6732160 0.845 rs11894833 ENSG00000236165.1 PRADC1P1 -6.55 8.18e-10 0.00405 -0.54 -0.47 Intelligence (multi-trait analysis); chr2:73161290 chr3:36976316~36976840:+ PAAD trans rs7121616 1 rs7123187 ENSG00000234176.1 HSPA8P1 6.55 8.24e-10 0.00408 0.56 0.47 Breast cancer; chr11:123090915 chrX:121203182~121205014:- PAAD trans rs7121616 0.774 rs74693612 ENSG00000234176.1 HSPA8P1 6.55 8.24e-10 0.00408 0.56 0.47 Breast cancer; chr11:123092310 chrX:121203182~121205014:- PAAD trans rs7312770 1 rs7312770 ENSG00000235459.5 RPS26P31 -6.55 8.25e-10 0.00409 -0.52 -0.47 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr7:122681315~122681662:+ PAAD trans rs7554547 0.622 rs2179110 ENSG00000261819.1 RP11-680G24.4 6.55 8.29e-10 0.0041 0.61 0.47 Nonsyndromic cleft lip with cleft palate; chr1:11912754 chr16:14988259~14990160:- PAAD trans rs7258465 1 rs2303695 ENSG00000267533.1 RP11-815J4.7 6.55 8.31e-10 0.00411 0.57 0.47 Breast cancer; chr19:18451814 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs8107367 ENSG00000267533.1 RP11-815J4.7 6.55 8.31e-10 0.00411 0.57 0.47 Breast cancer; chr19:18453895 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs2007981 ENSG00000267533.1 RP11-815J4.7 6.55 8.31e-10 0.00411 0.57 0.47 Breast cancer; chr19:18456745 chr18:12067173~12068417:- PAAD trans rs11039798 0.588 rs11039807 ENSG00000134612.10 FOLH1B 6.55 8.35e-10 0.00413 0.72 0.47 Axial length; chr11:48527839 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs11039818 ENSG00000134612.10 FOLH1B 6.55 8.35e-10 0.00413 0.72 0.47 Axial length; chr11:48540568 chr11:89639227~89698718:+ PAAD trans rs11098499 0.618 rs28491261 ENSG00000275858.1 RP11-291L22.8 6.55 8.43e-10 0.00417 0.6 0.47 Corneal astigmatism; chr4:119373745 chr10:38450738~38451069:- PAAD trans rs864643 0.678 rs1398668 ENSG00000183298.5 RP11-556K13.1 6.55 8.48e-10 0.00419 0.69 0.47 Attention deficit hyperactivity disorder; chr3:39475753 chr1:101786340~101787219:- PAAD trans rs11039798 0.528 rs10769559 ENSG00000134612.10 FOLH1B 6.54 8.84e-10 0.00435 0.74 0.47 Axial length; chr11:49010894 chr11:89639227~89698718:+ PAAD trans rs7811142 0.83 rs75636500 ENSG00000228546.2 CTA-313A17.3 6.54 8.85e-10 0.00435 0.71 0.47 Platelet count; chr7:100350034 chr7:102337316~102339115:+ PAAD trans rs864643 0.625 rs1707958 ENSG00000183298.5 RP11-556K13.1 6.54 8.86e-10 0.00435 0.68 0.47 Attention deficit hyperactivity disorder; chr3:39481931 chr1:101786340~101787219:- PAAD trans rs11039798 0.588 rs7116858 ENSG00000134612.10 FOLH1B 6.54 8.99e-10 0.00441 0.72 0.47 Axial length; chr11:48522368 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs7946443 ENSG00000134612.10 FOLH1B 6.54 8.99e-10 0.00441 0.72 0.47 Axial length; chr11:48523952 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs12284168 ENSG00000134612.10 FOLH1B 6.54 8.99e-10 0.00441 0.72 0.47 Axial length; chr11:48534075 chr11:89639227~89698718:+ PAAD trans rs11039798 0.588 rs6485857 ENSG00000134612.10 FOLH1B 6.54 8.99e-10 0.00441 0.72 0.47 Axial length; chr11:48534959 chr11:89639227~89698718:+ PAAD trans rs11039798 0.544 rs114343057 ENSG00000134612.10 FOLH1B 6.54 8.99e-10 0.00441 0.72 0.47 Axial length; chr11:48536620 chr11:89639227~89698718:+ PAAD trans rs1569419 0.706 rs4648452 ENSG00000279421.1 RP11-335K5.3 6.54 9e-10 0.00442 0.77 0.47 Mean corpuscular hemoglobin;Red blood cell count;Mean platelet volume;Plateletcrit;Platelet distribution width;Mean corpuscular volume; chr1:3079958 chr15:78599892~78600013:- PAAD trans rs7819412 0.668 rs920047 ENSG00000253893.2 FAM85B 6.53 9.12e-10 0.00446 0.63 0.47 Triglycerides; chr8:11229966 chr8:8167819~8226614:- PAAD trans rs2727020 0.729 rs34647977 ENSG00000134612.10 FOLH1B -6.53 9.38e-10 0.00459 -0.56 -0.47 Coronary artery disease; chr11:49173991 chr11:89639227~89698718:+ PAAD trans rs12709013 0.716 rs6416775 ENSG00000230849.2 GOT2P2 6.53 9.46e-10 0.00463 0.56 0.47 Blood metabolite ratios; chr16:58830410 chr1:173141100~173142350:- PAAD trans rs2727020 0.664 rs4929893 ENSG00000134612.10 FOLH1B -6.53 9.47e-10 0.00463 -0.56 -0.47 Coronary artery disease; chr11:49174780 chr11:89639227~89698718:+ PAAD trans rs2727020 0.688 rs4929894 ENSG00000134612.10 FOLH1B -6.53 9.47e-10 0.00463 -0.56 -0.47 Coronary artery disease; chr11:49174781 chr11:89639227~89698718:+ PAAD trans rs7395662 0.681 rs2865641 ENSG00000134612.10 FOLH1B -6.53 9.5e-10 0.00464 -0.58 -0.47 HDL cholesterol; chr11:48919547 chr11:89639227~89698718:+ PAAD trans rs11098499 0.863 rs1010739 ENSG00000275858.1 RP11-291L22.8 6.52 9.71e-10 0.00474 0.62 0.47 Corneal astigmatism; chr4:119542316 chr10:38450738~38451069:- PAAD trans rs877636 0.692 rs2271194 ENSG00000223416.3 RPS26P15 -6.52 9.75e-10 0.00476 -0.56 -0.47 Cognitive function; chr12:56083910 chr1:58056133~58056480:- PAAD trans rs9329221 0.905 rs17765901 ENSG00000253893.2 FAM85B 6.52 1e-09 0.00487 0.63 0.47 Neuroticism; chr8:10391970 chr8:8167819~8226614:- PAAD trans rs9329221 0.905 rs17709397 ENSG00000253893.2 FAM85B 6.52 1e-09 0.00487 0.63 0.47 Neuroticism; chr8:10392351 chr8:8167819~8226614:- PAAD trans rs9329221 0.905 rs28507213 ENSG00000253893.2 FAM85B 6.52 1e-09 0.00487 0.63 0.47 Neuroticism; chr8:10393339 chr8:8167819~8226614:- PAAD trans rs9329221 0.905 rs28712068 ENSG00000253893.2 FAM85B 6.52 1e-09 0.00487 0.63 0.47 Neuroticism; chr8:10393635 chr8:8167819~8226614:- PAAD trans rs13190036 0.748 rs28395268 ENSG00000217325.2 PRELID1P1 6.51 1.01e-09 0.00493 0.74 0.47 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177283546 chr6:126643488~126644390:+ PAAD trans rs7032940 0.626 rs4314718 ENSG00000228236.2 TXNP5 6.51 1.02e-09 0.00496 0.56 0.47 Height; chr9:110211368 chr2:149068596~149068910:- PAAD trans rs13253073 0.941 rs4076509 ENSG00000260318.1 COX6CP1 6.51 1.02e-09 0.00497 1.05 0.47 Glucose homeostasis traits; chr8:99842928 chr16:11903923~11904137:- PAAD trans rs877636 1 rs705696 ENSG00000225071.1 GS1-184P14.2 6.51 1.02e-09 0.00497 0.57 0.47 Cognitive function; chr12:56086864 chrX:24429573~24429920:- PAAD trans rs877636 0.692 rs11171739 ENSG00000234354.3 RPS26P47 6.51 1.03e-09 0.005 0.57 0.47 Cognitive function; chr12:56076841 chr13:100539901~100540248:- PAAD trans rs11098499 0.909 rs73842633 ENSG00000275858.1 RP11-291L22.8 6.51 1.03e-09 0.00501 0.62 0.47 Corneal astigmatism; chr4:119454309 chr10:38450738~38451069:- PAAD trans rs13253073 0.941 rs12548827 ENSG00000260318.1 COX6CP1 6.51 1.04e-09 0.00503 1.05 0.47 Glucose homeostasis traits; chr8:99841495 chr16:11903923~11904137:- PAAD trans rs2657294 0.62 rs7903537 ENSG00000172974.11 AC007318.5 6.51 1.04e-09 0.00503 0.57 0.47 Pneumonia; chr10:75087732 chr2:65205108~65205988:+ PAAD trans rs6732160 0.809 rs6728959 ENSG00000236165.1 PRADC1P1 6.51 1.05e-09 0.00512 0.53 0.47 Intelligence (multi-trait analysis); chr2:73156199 chr3:36976316~36976840:+ PAAD trans rs6732160 0.845 rs6752507 ENSG00000236165.1 PRADC1P1 6.51 1.05e-09 0.00512 0.53 0.47 Intelligence (multi-trait analysis); chr2:73158030 chr3:36976316~36976840:+ PAAD trans rs6732160 0.845 rs6546805 ENSG00000236165.1 PRADC1P1 6.51 1.05e-09 0.00512 0.53 0.47 Intelligence (multi-trait analysis); chr2:73158987 chr3:36976316~36976840:+ PAAD trans rs9650657 0.589 rs10107145 ENSG00000253893.2 FAM85B 6.51 1.06e-09 0.00513 0.65 0.47 Neuroticism; chr8:10900703 chr8:8167819~8226614:- PAAD trans rs8081395 0.899 rs2645477 ENSG00000187870.7 RNFT1P3 -6.5 1.07e-09 0.00517 -0.55 -0.47 White blood cell count; chr17:59768263 chr17:20743333~20754501:- PAAD trans rs8081395 0.834 rs11650106 ENSG00000187870.7 RNFT1P3 -6.5 1.07e-09 0.00517 -0.55 -0.47 White blood cell count; chr17:59772890 chr17:20743333~20754501:- PAAD trans rs11098499 0.909 rs79026312 ENSG00000275858.1 RP11-291L22.8 6.5 1.1e-09 0.00529 0.63 0.47 Corneal astigmatism; chr4:119519522 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs35111518 ENSG00000275858.1 RP11-291L22.8 6.5 1.1e-09 0.00529 0.63 0.47 Corneal astigmatism; chr4:119519527 chr10:38450738~38451069:- PAAD trans rs7395662 0.853 rs4882062 ENSG00000134612.10 FOLH1B 6.5 1.1e-09 0.0053 0.57 0.47 HDL cholesterol; chr11:48431719 chr11:89639227~89698718:+ PAAD trans rs7811142 1 rs6953107 ENSG00000228546.2 CTA-313A17.3 6.5 1.1e-09 0.00531 0.69 0.47 Platelet count; chr7:100498041 chr7:102337316~102339115:+ PAAD trans rs2657294 0.62 rs2395136 ENSG00000172974.11 AC007318.5 6.5 1.1e-09 0.00533 0.57 0.47 Pneumonia; chr10:75088213 chr2:65205108~65205988:+ PAAD trans rs3779195 0.697 rs1688606 ENSG00000225169.1 BRI3P1 6.5 1.11e-09 0.00535 0.72 0.47 Sex hormone-binding globulin levels; chr7:98345539 chr1:100213293~100213670:+ PAAD trans rs7258465 1 rs7252848 ENSG00000267533.1 RP11-815J4.7 6.49 1.15e-09 0.00553 0.56 0.47 Breast cancer; chr19:18501541 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs10164319 ENSG00000267533.1 RP11-815J4.7 6.49 1.16e-09 0.00557 0.57 0.47 Breast cancer; chr19:18459023 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs1560118 ENSG00000267533.1 RP11-815J4.7 6.49 1.16e-09 0.00557 0.57 0.47 Breast cancer; chr19:18459225 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs4808136 ENSG00000267533.1 RP11-815J4.7 -6.48 1.18e-09 0.00569 -0.57 -0.47 Breast cancer; chr19:18508057 chr18:12067173~12068417:- PAAD trans rs916888 0.61 rs199454 ENSG00000204650.12 CRHR1-IT1 -6.48 1.19e-09 0.00573 -0.53 -0.47 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45620328~45648216:+ PAAD trans rs11098499 1 rs11098499 ENSG00000275858.1 RP11-291L22.8 6.48 1.22e-09 0.00583 0.58 0.47 Corneal astigmatism; chr4:119266456 chr10:38450738~38451069:- PAAD trans rs11098499 1 rs7659194 ENSG00000275858.1 RP11-291L22.8 6.48 1.22e-09 0.00583 0.58 0.47 Corneal astigmatism; chr4:119285992 chr10:38450738~38451069:- PAAD trans rs7811142 1 rs6972167 ENSG00000228546.2 CTA-313A17.3 6.48 1.22e-09 0.00587 0.69 0.47 Platelet count; chr7:100482390 chr7:102337316~102339115:+ PAAD trans rs7258465 0.931 rs8107347 ENSG00000267533.1 RP11-815J4.7 6.48 1.22e-09 0.00587 0.56 0.47 Breast cancer; chr19:18501938 chr18:12067173~12068417:- PAAD trans rs7258465 0.931 rs8107351 ENSG00000267533.1 RP11-815J4.7 6.48 1.22e-09 0.00587 0.56 0.47 Breast cancer; chr19:18501948 chr18:12067173~12068417:- PAAD trans rs9611565 0.569 rs6002328 ENSG00000268568.1 AC007228.9 -6.48 1.24e-09 0.00593 -0.63 -0.46 Vitiligo; chr22:41314030 chr19:56672574~56673901:- PAAD trans rs7811142 0.83 rs76798830 ENSG00000228546.2 CTA-313A17.3 6.47 1.24e-09 0.00594 0.71 0.46 Platelet count; chr7:100355205 chr7:102337316~102339115:+ PAAD trans rs7811142 0.775 rs6946768 ENSG00000228546.2 CTA-313A17.3 6.47 1.24e-09 0.00594 0.71 0.46 Platelet count; chr7:100356770 chr7:102337316~102339115:+ PAAD trans rs9611565 0.506 rs1883825 ENSG00000268568.1 AC007228.9 -6.47 1.25e-09 0.00595 -0.61 -0.46 Vitiligo; chr22:41307404 chr19:56672574~56673901:- PAAD trans rs9611565 0.525 rs1883827 ENSG00000268568.1 AC007228.9 -6.47 1.25e-09 0.00595 -0.61 -0.46 Vitiligo; chr22:41307575 chr19:56672574~56673901:- PAAD trans rs13190036 1 rs6889220 ENSG00000226986.4 RP11-543B16.2 6.47 1.25e-09 0.00596 0.74 0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177266887 chr1:211207239~211207897:+ PAAD trans rs3779195 0.929 rs4268041 ENSG00000225169.1 BRI3P1 -6.47 1.25e-09 0.00597 -0.71 -0.46 Sex hormone-binding globulin levels; chr7:98376226 chr1:100213293~100213670:+ PAAD trans rs877636 0.669 rs7297175 ENSG00000243403.1 RP11-330L19.1 -6.47 1.26e-09 0.00599 -0.5 -0.46 Cognitive function; chr12:56080024 chr15:64592979~64593326:+ PAAD trans rs7258465 1 rs10411009 ENSG00000267533.1 RP11-815J4.7 6.47 1.26e-09 0.00602 0.56 0.46 Breast cancer; chr19:18495456 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs34256197 ENSG00000267533.1 RP11-815J4.7 6.47 1.26e-09 0.00602 0.56 0.46 Breast cancer; chr19:18495662 chr18:12067173~12068417:- PAAD trans rs7258465 0.931 rs7249020 ENSG00000267533.1 RP11-815J4.7 6.47 1.26e-09 0.00602 0.56 0.46 Breast cancer; chr19:18497337 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs7251653 ENSG00000267533.1 RP11-815J4.7 6.47 1.26e-09 0.00602 0.56 0.46 Breast cancer; chr19:18497473 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs4808133 ENSG00000267533.1 RP11-815J4.7 6.47 1.26e-09 0.00602 0.56 0.46 Breast cancer; chr19:18497708 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs4808134 ENSG00000267533.1 RP11-815J4.7 6.47 1.26e-09 0.00602 0.56 0.46 Breast cancer; chr19:18497769 chr18:12067173~12068417:- PAAD trans rs7258465 0.931 rs875396 ENSG00000267533.1 RP11-815J4.7 6.47 1.26e-09 0.00602 0.56 0.46 Breast cancer; chr19:18500337 chr18:12067173~12068417:- PAAD trans rs11098499 0.863 rs1480940 ENSG00000275858.1 RP11-291L22.8 6.47 1.26e-09 0.00603 0.62 0.46 Corneal astigmatism; chr4:119536527 chr10:38450738~38451069:- PAAD trans rs76228276 0.737 rs112539331 ENSG00000260318.1 COX6CP1 6.47 1.29e-09 0.00613 1.18 0.46 Childhood ear infection; chr8:99851125 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs76837451 ENSG00000260318.1 COX6CP1 6.47 1.29e-09 0.00613 1.18 0.46 Childhood ear infection; chr8:99870495 chr16:11903923~11904137:- PAAD trans rs7258465 0.965 rs2561043 ENSG00000267533.1 RP11-815J4.7 6.47 1.29e-09 0.00613 0.56 0.46 Breast cancer; chr19:18511873 chr18:12067173~12068417:- PAAD trans rs11039798 0.588 rs7479642 ENSG00000134612.10 FOLH1B 6.47 1.3e-09 0.00619 0.72 0.46 Axial length; chr11:48532256 chr11:89639227~89698718:+ PAAD trans rs2060793 0.712 rs6486202 ENSG00000236360.2 RP11-334A14.2 6.46 1.32e-09 0.00628 0.59 0.46 Vitamin D levels; chr11:14777260 chr1:52993201~52993702:- PAAD trans rs11098499 0.954 rs13145352 ENSG00000275858.1 RP11-291L22.8 -6.46 1.33e-09 0.00631 -0.62 -0.46 Corneal astigmatism; chr4:119488808 chr10:38450738~38451069:- PAAD trans rs7258465 0.931 rs1560119 ENSG00000267533.1 RP11-815J4.7 6.46 1.34e-09 0.00633 0.56 0.46 Breast cancer; chr19:18462865 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs7256534 ENSG00000267533.1 RP11-815J4.7 6.46 1.34e-09 0.00633 0.56 0.46 Breast cancer; chr19:18475981 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs7254249 ENSG00000267533.1 RP11-815J4.7 6.46 1.34e-09 0.00633 0.56 0.46 Breast cancer; chr19:18480935 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs7253990 ENSG00000267533.1 RP11-815J4.7 6.46 1.34e-09 0.00633 0.56 0.46 Breast cancer; chr19:18493275 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs8109573 ENSG00000267533.1 RP11-815J4.7 6.46 1.34e-09 0.00633 0.56 0.46 Breast cancer; chr19:18506341 chr18:12067173~12068417:- PAAD trans rs10838798 0.563 rs11039516 ENSG00000134612.10 FOLH1B -6.46 1.35e-09 0.00638 -0.55 -0.46 Height; chr11:48102605 chr11:89639227~89698718:+ PAAD trans rs7819412 0.837 rs17724467 ENSG00000253893.2 FAM85B 6.46 1.35e-09 0.00641 0.63 0.46 Triglycerides; chr8:11118172 chr8:8167819~8226614:- PAAD trans rs1079467 1 rs1079467 ENSG00000233426.3 EIF3FP3 -6.46 1.36e-09 0.00646 -0.67 -0.46 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7948164 chr2:58251440~58252525:+ PAAD trans rs11039798 0.588 rs1814768 ENSG00000134612.10 FOLH1B 6.46 1.36e-09 0.00646 0.72 0.46 Axial length; chr11:48965903 chr11:89639227~89698718:+ PAAD trans rs2657294 0.796 rs2804535 ENSG00000172974.11 AC007318.5 -6.45 1.38e-09 0.00653 -0.57 -0.46 Pneumonia; chr10:75212086 chr2:65205108~65205988:+ PAAD trans rs9329221 0.905 rs4610752 ENSG00000253893.2 FAM85B 6.45 1.38e-09 0.00654 0.62 0.46 Neuroticism; chr8:10391452 chr8:8167819~8226614:- PAAD trans rs76228276 0.737 rs111320394 ENSG00000260318.1 COX6CP1 6.45 1.4e-09 0.00664 1.18 0.46 Childhood ear infection; chr8:99879888 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs111843118 ENSG00000260318.1 COX6CP1 6.45 1.4e-09 0.00664 1.18 0.46 Childhood ear infection; chr8:99885459 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs74434116 ENSG00000260318.1 COX6CP1 6.45 1.4e-09 0.00664 1.18 0.46 Childhood ear infection; chr8:99885805 chr16:11903923~11904137:- PAAD trans rs7258465 1 rs2278238 ENSG00000267533.1 RP11-815J4.7 6.45 1.41e-09 0.00664 0.55 0.46 Breast cancer; chr19:18465674 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs10425982 ENSG00000267533.1 RP11-815J4.7 6.45 1.41e-09 0.00664 0.55 0.46 Breast cancer; chr19:18475709 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs8100767 ENSG00000267533.1 RP11-815J4.7 6.45 1.41e-09 0.00664 0.55 0.46 Breast cancer; chr19:18478278 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs10409483 ENSG00000267533.1 RP11-815J4.7 6.45 1.41e-09 0.00664 0.55 0.46 Breast cancer; chr19:18479413 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs10409505 ENSG00000267533.1 RP11-815J4.7 6.45 1.41e-09 0.00664 0.55 0.46 Breast cancer; chr19:18479441 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs10403249 ENSG00000267533.1 RP11-815J4.7 6.45 1.41e-09 0.00664 0.55 0.46 Breast cancer; chr19:18494132 chr18:12067173~12068417:- PAAD trans rs7258465 0.931 rs271629 ENSG00000267533.1 RP11-815J4.7 6.45 1.41e-09 0.00664 0.55 0.46 Breast cancer; chr19:18512388 chr18:12067173~12068417:- PAAD trans rs7258465 0.965 rs271628 ENSG00000267533.1 RP11-815J4.7 6.45 1.41e-09 0.00664 0.55 0.46 Breast cancer; chr19:18513523 chr18:12067173~12068417:- PAAD trans rs13190036 0.901 rs28715668 ENSG00000226986.4 RP11-543B16.2 6.45 1.41e-09 0.00665 0.74 0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177272267 chr1:211207239~211207897:+ PAAD trans rs76228276 0.737 rs76858490 ENSG00000260318.1 COX6CP1 6.45 1.41e-09 0.00665 1.19 0.46 Childhood ear infection; chr8:99816765 chr16:11903923~11904137:- PAAD trans rs5751901 1 rs5751901 ENSG00000280208.1 RP11-341D18.4 -6.45 1.41e-09 0.00668 -0.61 -0.46 Protein quantitative trait loci; chr22:24596299 chr13:18253526~18270822:- PAAD trans rs9329221 0.905 rs4433149 ENSG00000253893.2 FAM85B 6.45 1.41e-09 0.00668 0.63 0.46 Neuroticism; chr8:10391758 chr8:8167819~8226614:- PAAD trans rs9650657 0.571 rs11783247 ENSG00000253893.2 FAM85B 6.45 1.43e-09 0.00674 0.67 0.46 Neuroticism; chr8:10931365 chr8:8167819~8226614:- PAAD trans rs76228276 0.737 rs77010544 ENSG00000260318.1 COX6CP1 6.45 1.44e-09 0.0068 1.2 0.46 Childhood ear infection; chr8:99838434 chr16:11903923~11904137:- PAAD trans rs7811142 0.83 rs1063945 ENSG00000228546.2 CTA-313A17.3 6.45 1.44e-09 0.00681 0.69 0.46 Platelet count; chr7:100332824 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs11761253 ENSG00000228546.2 CTA-313A17.3 6.45 1.44e-09 0.00681 0.69 0.46 Platelet count; chr7:100341698 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs11771936 ENSG00000228546.2 CTA-313A17.3 6.45 1.44e-09 0.00681 0.69 0.46 Platelet count; chr7:100345660 chr7:102337316~102339115:+ PAAD trans rs7811142 0.779 rs77370288 ENSG00000228546.2 CTA-313A17.3 6.45 1.44e-09 0.00681 0.69 0.46 Platelet count; chr7:100350274 chr7:102337316~102339115:+ PAAD trans rs7811142 0.72 rs7795656 ENSG00000228546.2 CTA-313A17.3 6.45 1.44e-09 0.00681 0.69 0.46 Platelet count; chr7:100352674 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs7341507 ENSG00000228546.2 CTA-313A17.3 6.45 1.44e-09 0.00681 0.69 0.46 Platelet count; chr7:100353692 chr7:102337316~102339115:+ PAAD trans rs11023332 0.617 rs1879888 ENSG00000236360.2 RP11-334A14.2 6.45 1.45e-09 0.00682 0.58 0.46 Vitamin D levels;Adiponectin levels; chr11:14657701 chr1:52993201~52993702:- PAAD trans rs11023332 0.617 rs1451678 ENSG00000236360.2 RP11-334A14.2 6.45 1.45e-09 0.00682 0.58 0.46 Vitamin D levels;Adiponectin levels; chr11:14760075 chr1:52993201~52993702:- PAAD trans rs11023332 0.641 rs4281505 ENSG00000236360.2 RP11-334A14.2 6.45 1.45e-09 0.00682 0.58 0.46 Vitamin D levels;Adiponectin levels; chr11:14779114 chr1:52993201~52993702:- PAAD trans rs11023332 0.65 rs2122942 ENSG00000236360.2 RP11-334A14.2 6.45 1.45e-09 0.00682 0.58 0.46 Vitamin D levels;Adiponectin levels; chr11:14785829 chr1:52993201~52993702:- PAAD trans rs6732160 0.845 rs13413175 ENSG00000236165.1 PRADC1P1 6.44 1.46e-09 0.0069 0.54 0.46 Intelligence (multi-trait analysis); chr2:73162788 chr3:36976316~36976840:+ PAAD trans rs1816752 0.524 rs1965154 ENSG00000224976.2 PARP4P2 6.44 1.48e-09 0.00695 0.58 0.46 Obesity-related traits; chr13:24498062 chr13:19349137~19407962:+ PAAD trans rs76228276 0.737 rs79340210 ENSG00000260318.1 COX6CP1 6.44 1.49e-09 0.00702 1.2 0.46 Childhood ear infection; chr8:99841815 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs113418230 ENSG00000260318.1 COX6CP1 6.44 1.49e-09 0.00702 1.2 0.46 Childhood ear infection; chr8:99841987 chr16:11903923~11904137:- PAAD trans rs7937890 0.587 rs11023204 ENSG00000236360.2 RP11-334A14.2 6.44 1.5e-09 0.00708 0.63 0.46 Mitochondrial DNA levels; chr11:14389677 chr1:52993201~52993702:- PAAD trans rs13253073 1 rs13273257 ENSG00000260318.1 COX6CP1 6.44 1.5e-09 0.00708 1.05 0.46 Glucose homeostasis traits; chr8:99852468 chr16:11903923~11904137:- PAAD trans rs11098499 0.697 rs4560394 ENSG00000275858.1 RP11-291L22.8 6.44 1.51e-09 0.00711 0.61 0.46 Corneal astigmatism; chr4:119392280 chr10:38450738~38451069:- PAAD trans rs13190036 1 rs7714695 ENSG00000228305.2 AC016734.2 -6.44 1.52e-09 0.00715 -0.8 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177130444 chr2:63622178~63622831:- PAAD trans rs877636 0.692 rs11171739 ENSG00000243403.1 RP11-330L19.1 6.44 1.52e-09 0.00716 0.5 0.46 Cognitive function; chr12:56076841 chr15:64592979~64593326:+ PAAD trans rs7554547 0.69 rs12087996 ENSG00000261819.1 RP11-680G24.4 6.43 1.53e-09 0.00717 0.57 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11897152 chr16:14988259~14990160:- PAAD trans rs7312770 1 rs7312770 ENSG00000234513.1 AC073072.7 -6.43 1.55e-09 0.00727 -0.51 -0.46 Polycystic ovary syndrome;Hypothyroidism; chr12:56073803 chr7:22773646~22773993:- PAAD trans rs916888 0.61 rs199446 ENSG00000204650.12 CRHR1-IT1 -6.43 1.55e-09 0.00727 -0.53 -0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45620328~45648216:+ PAAD trans rs916888 0.61 rs199536 ENSG00000204650.12 CRHR1-IT1 -6.43 1.55e-09 0.00727 -0.53 -0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45620328~45648216:+ PAAD trans rs7824557 0.547 rs2409745 ENSG00000253893.2 FAM85B -6.43 1.55e-09 0.00728 -0.63 -0.46 Retinal vascular caliber; chr8:11219126 chr8:8167819~8226614:- PAAD trans rs7937890 0.598 rs10734225 ENSG00000236360.2 RP11-334A14.2 6.43 1.55e-09 0.00728 0.63 0.46 Mitochondrial DNA levels; chr11:14421448 chr1:52993201~52993702:- PAAD trans rs877636 0.692 rs11171739 ENSG00000212994.5 RPS26P6 6.43 1.56e-09 0.0073 0.51 0.46 Cognitive function; chr12:56076841 chr8:100895771~100896118:+ PAAD trans rs7937890 0.572 rs2597218 ENSG00000236360.2 RP11-334A14.2 6.43 1.56e-09 0.00733 0.63 0.46 Mitochondrial DNA levels; chr11:14510792 chr1:52993201~52993702:- PAAD trans rs11098499 0.863 rs10004484 ENSG00000275858.1 RP11-291L22.8 6.43 1.58e-09 0.0074 0.61 0.46 Corneal astigmatism; chr4:119521273 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs1155576 ENSG00000275858.1 RP11-291L22.8 6.43 1.58e-09 0.0074 0.61 0.46 Corneal astigmatism; chr4:119529004 chr10:38450738~38451069:- PAAD trans rs7395662 1 rs6485882 ENSG00000134612.10 FOLH1B 6.43 1.58e-09 0.00741 0.56 0.46 HDL cholesterol; chr11:48570883 chr11:89639227~89698718:+ PAAD trans rs10940346 0.936 rs303219 ENSG00000231752.4 EMBP1 6.43 1.59e-09 0.00744 0.58 0.46 Schizophrenia; chr5:50407795 chr1:121519112~121571892:+ PAAD trans rs9650657 0.504 rs10108347 ENSG00000253893.2 FAM85B 6.43 1.59e-09 0.00747 0.63 0.46 Neuroticism; chr8:11176008 chr8:8167819~8226614:- PAAD trans rs9650657 0.504 rs10109167 ENSG00000253893.2 FAM85B 6.43 1.59e-09 0.00747 0.63 0.46 Neuroticism; chr8:11176016 chr8:8167819~8226614:- PAAD trans rs7395662 0.864 rs10839201 ENSG00000134612.10 FOLH1B 6.42 1.61e-09 0.00753 0.57 0.46 HDL cholesterol; chr11:48967865 chr11:89639227~89698718:+ PAAD trans rs13190036 0.892 rs71601339 ENSG00000228305.2 AC016734.2 -6.42 1.64e-09 0.00766 -0.8 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117495 chr2:63622178~63622831:- PAAD trans rs703108 0.731 rs7898954 ENSG00000264281.3 CTD-2031P19.4 -6.42 1.64e-09 0.0077 -0.55 -0.46 Monocyte percentage of white cells; chr10:22034717 chr5:55944656~55944733:+ PAAD trans rs7312770 0.637 rs705699 ENSG00000235459.5 RPS26P31 6.42 1.65e-09 0.00771 0.51 0.46 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr7:122681315~122681662:+ PAAD trans rs9329221 0.935 rs3750310 ENSG00000253893.2 FAM85B 6.42 1.68e-09 0.00785 0.64 0.46 Neuroticism; chr8:10425916 chr8:8167819~8226614:- PAAD trans rs1814175 0.791 rs10769593 ENSG00000134612.10 FOLH1B -6.41 1.69e-09 0.00792 -0.54 -0.46 Height; chr11:49594665 chr11:89639227~89698718:+ PAAD trans rs55665837 0.701 rs10766188 ENSG00000236360.2 RP11-334A14.2 6.41 1.7e-09 0.00792 0.59 0.46 Vitamin D levels; chr11:14639280 chr1:52993201~52993702:- PAAD trans rs55665837 0.701 rs2007361 ENSG00000236360.2 RP11-334A14.2 6.41 1.7e-09 0.00792 0.59 0.46 Vitamin D levels; chr11:14641176 chr1:52993201~52993702:- PAAD trans rs877636 0.692 rs11171739 ENSG00000196656.7 AC004057.1 6.41 1.7e-09 0.00795 0.45 0.46 Cognitive function; chr12:56076841 chr4:113214046~113217170:- PAAD trans rs7937890 0.572 rs2597202 ENSG00000236360.2 RP11-334A14.2 6.41 1.7e-09 0.00795 0.63 0.46 Mitochondrial DNA levels; chr11:14463099 chr1:52993201~52993702:- PAAD trans rs13190036 1 rs17078781 ENSG00000228305.2 AC016734.2 -6.41 1.71e-09 0.00798 -0.8 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117227 chr2:63622178~63622831:- PAAD trans rs864643 0.678 rs1707960 ENSG00000183298.5 RP11-556K13.1 -6.41 1.72e-09 0.00801 -0.68 -0.46 Attention deficit hyperactivity disorder; chr3:39481761 chr1:101786340~101787219:- PAAD trans rs4663866 0.522 rs111276182 ENSG00000261069.3 RP11-701H24.4 -6.41 1.73e-09 0.00806 -0.75 -0.46 Irritable bowel syndrome; chr2:238210191 chr15:25087661~25088896:+ PAAD trans rs10940346 1 rs2668024 ENSG00000231752.4 EMBP1 -6.41 1.73e-09 0.00809 -0.57 -0.46 Schizophrenia; chr5:50414421 chr1:121519112~121571892:+ PAAD trans rs7395662 0.517 rs2021248 ENSG00000134612.10 FOLH1B -6.4 1.79e-09 0.00833 -0.55 -0.46 HDL cholesterol; chr11:48991502 chr11:89639227~89698718:+ PAAD trans rs12493123 0.702 rs13085992 ENSG00000235065.1 RPL24P2 6.4 1.84e-09 0.00853 0.94 0.46 Reading and spelling; chr3:162387767 chr20:21114723~21115197:+ PAAD trans rs7824557 0.547 rs6601570 ENSG00000253893.2 FAM85B 6.4 1.85e-09 0.00858 0.63 0.46 Retinal vascular caliber; chr8:11221858 chr8:8167819~8226614:- PAAD trans rs864643 0.678 rs1768201 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39476050 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs1768203 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39476377 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs1708100 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39476400 chr1:101786340~101787219:- PAAD trans rs864643 0.625 rs7613883 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39476825 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs6779639 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39477191 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs6782255 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39477236 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs7631217 ENSG00000183298.5 RP11-556K13.1 -6.4 1.85e-09 0.0086 -0.68 -0.46 Attention deficit hyperactivity disorder; chr3:39478568 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs512923 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39480472 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs621842 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39480785 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs610006 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39481104 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs1707959 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39481807 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs1707957 ENSG00000183298.5 RP11-556K13.1 6.4 1.85e-09 0.0086 0.68 0.46 Attention deficit hyperactivity disorder; chr3:39482000 chr1:101786340~101787219:- PAAD trans rs10908521 1 rs10908521 ENSG00000227183.3 HDGFP1 6.4 1.85e-09 0.0086 0.63 0.46 Uric acid clearance; chr1:156843858 chrX:131646639~131646890:+ PAAD trans rs916888 0.61 rs199452 ENSG00000204650.12 CRHR1-IT1 6.4 1.86e-09 0.00861 0.51 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45620328~45648216:+ PAAD trans rs7312770 0.637 rs705699 ENSG00000212829.8 RPS26P3 6.4 1.86e-09 0.00863 0.54 0.46 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr9:9090898~9091245:+ PAAD trans rs11098499 0.863 rs1552092 ENSG00000275858.1 RP11-291L22.8 6.4 1.87e-09 0.00866 0.62 0.46 Corneal astigmatism; chr4:119567341 chr10:38450738~38451069:- PAAD trans rs76228276 0.737 rs113450604 ENSG00000260318.1 COX6CP1 6.39 1.88e-09 0.0087 1.16 0.46 Childhood ear infection; chr8:99892424 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs28372694 ENSG00000260318.1 COX6CP1 6.39 1.88e-09 0.0087 1.16 0.46 Childhood ear infection; chr8:99894365 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs78974869 ENSG00000260318.1 COX6CP1 6.39 1.88e-09 0.0087 1.16 0.46 Childhood ear infection; chr8:99896126 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs77330553 ENSG00000260318.1 COX6CP1 6.39 1.88e-09 0.0087 1.16 0.46 Childhood ear infection; chr8:99898549 chr16:11903923~11904137:- PAAD trans rs13190036 0.901 rs28684504 ENSG00000228305.2 AC016734.2 6.39 1.91e-09 0.00881 0.82 0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177300437 chr2:63622178~63622831:- PAAD trans rs7312770 0.612 rs773114 ENSG00000234513.1 AC073072.7 6.39 1.93e-09 0.00891 0.51 0.46 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chr7:22773646~22773993:- PAAD trans rs9329221 0.935 rs3750311 ENSG00000253893.2 FAM85B 6.39 1.94e-09 0.00893 0.63 0.46 Neuroticism; chr8:10426092 chr8:8167819~8226614:- PAAD trans rs7395662 0.534 rs12418219 ENSG00000134612.10 FOLH1B -6.39 1.94e-09 0.00893 -0.55 -0.46 HDL cholesterol; chr11:48966539 chr11:89639227~89698718:+ PAAD trans rs3905510 0.561 rs113995342 ENSG00000279332.1 RP11-799B12.1 6.39 1.94e-09 0.00894 0.7 0.46 Total body bone mineral density; chr5:123548388 chr18:24135468~24135829:- PAAD trans rs3905510 0.561 rs80025107 ENSG00000279332.1 RP11-799B12.1 6.39 1.94e-09 0.00894 0.7 0.46 Total body bone mineral density; chr5:123549433 chr18:24135468~24135829:- PAAD trans rs2727020 0.533 rs10839195 ENSG00000134612.10 FOLH1B -6.39 1.95e-09 0.00896 -0.55 -0.46 Coronary artery disease; chr11:48951908 chr11:89639227~89698718:+ PAAD trans rs13190036 1 rs28580074 ENSG00000228305.2 AC016734.2 6.39 1.96e-09 0.009 0.82 0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177294197 chr2:63622178~63622831:- PAAD trans rs7554547 0.791 rs1321073 ENSG00000261819.1 RP11-680G24.4 6.38 1.99e-09 0.00917 0.6 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11891569 chr16:14988259~14990160:- PAAD trans rs7395662 0.5 rs10838984 ENSG00000134612.10 FOLH1B -6.38 2.01e-09 0.00924 -0.55 -0.46 HDL cholesterol; chr11:48618933 chr11:89639227~89698718:+ PAAD trans rs11098499 0.863 rs3822192 ENSG00000275858.1 RP11-291L22.8 6.38 2.01e-09 0.00924 0.62 0.46 Corneal astigmatism; chr4:119524565 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs10019674 ENSG00000275858.1 RP11-291L22.8 -6.38 2.01e-09 0.00924 -0.62 -0.46 Corneal astigmatism; chr4:119522334 chr10:38450738~38451069:- PAAD trans rs55665837 0.701 rs12286408 ENSG00000236360.2 RP11-334A14.2 6.38 2.02e-09 0.00927 0.59 0.46 Vitamin D levels; chr11:14557830 chr1:52993201~52993702:- PAAD trans rs7811142 0.83 rs78256546 ENSG00000228546.2 CTA-313A17.3 6.38 2.03e-09 0.00932 0.68 0.46 Platelet count; chr7:100355347 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs41280971 ENSG00000228546.2 CTA-313A17.3 6.38 2.03e-09 0.00932 0.68 0.46 Platelet count; chr7:100356834 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs3087502 ENSG00000228546.2 CTA-313A17.3 6.38 2.03e-09 0.00932 0.68 0.46 Platelet count; chr7:100357741 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs61735533 ENSG00000228546.2 CTA-313A17.3 6.38 2.03e-09 0.00932 0.68 0.46 Platelet count; chr7:100358243 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs11761426 ENSG00000228546.2 CTA-313A17.3 6.38 2.03e-09 0.00932 0.68 0.46 Platelet count; chr7:100359270 chr7:102337316~102339115:+ PAAD trans rs10838798 0.504 rs11039530 ENSG00000134612.10 FOLH1B -6.38 2.04e-09 0.00938 -0.54 -0.46 Height; chr11:48124194 chr11:89639227~89698718:+ PAAD trans rs10940346 0.967 rs6450134 ENSG00000231752.4 EMBP1 -6.37 2.11e-09 0.00966 -0.57 -0.46 Schizophrenia; chr5:50471121 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs7380816 ENSG00000231752.4 EMBP1 -6.37 2.11e-09 0.00966 -0.57 -0.46 Schizophrenia; chr5:50472059 chr1:121519112~121571892:+ PAAD trans rs10940346 0.875 rs13172257 ENSG00000231752.4 EMBP1 6.37 2.11e-09 0.00966 0.57 0.46 Schizophrenia; chr5:50462916 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs10074196 ENSG00000231752.4 EMBP1 6.37 2.11e-09 0.00966 0.57 0.46 Schizophrenia; chr5:50464713 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs13186891 ENSG00000231752.4 EMBP1 6.37 2.11e-09 0.00966 0.57 0.46 Schizophrenia; chr5:50467244 chr1:121519112~121571892:+ PAAD trans rs7312770 0.612 rs773114 ENSG00000212829.8 RPS26P3 6.37 2.12e-09 0.00968 0.53 0.46 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chr9:9090898~9091245:+ PAAD trans rs11098499 0.863 rs6534139 ENSG00000275858.1 RP11-291L22.8 -6.37 2.12e-09 0.00968 -0.61 -0.46 Corneal astigmatism; chr4:119528301 chr10:38450738~38451069:- PAAD trans rs11098499 0.82 rs13128602 ENSG00000275858.1 RP11-291L22.8 -6.37 2.12e-09 0.00968 -0.61 -0.46 Corneal astigmatism; chr4:119538211 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs1010740 ENSG00000275858.1 RP11-291L22.8 -6.37 2.12e-09 0.00968 -0.61 -0.46 Corneal astigmatism; chr4:119542254 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs58452170 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119538519 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs1552095 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119539151 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs7678400 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119540802 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs1480936 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119541706 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs11098531 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119543846 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs28718422 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119545149 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs12498539 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119547215 chr10:38450738~38451069:- PAAD trans rs11098499 0.818 rs12498599 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119547348 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs10009626 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119548850 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3822194 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119550493 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3822195 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119550505 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3775854 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119550816 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs2306456 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119551267 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs11947234 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119553704 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs6853998 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119554705 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs6858777 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119554811 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs11933966 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119555560 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs36040693 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119556461 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs11731756 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119557541 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs34308924 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119560276 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs2170276 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119564669 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs59732491 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119568433 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs9884402 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119568827 chr10:38450738~38451069:- PAAD trans rs11098499 0.731 rs9995026 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119569344 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs11723090 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119569437 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs11098532 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119569571 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs13140391 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119582282 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs13140409 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119582305 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs6833334 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119583072 chr10:38450738~38451069:- PAAD trans rs11098499 0.82 rs6829903 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119585729 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs7669520 ENSG00000275858.1 RP11-291L22.8 6.37 2.12e-09 0.00968 0.61 0.46 Corneal astigmatism; chr4:119594123 chr10:38450738~38451069:- PAAD trans rs2060793 1 rs10741657 ENSG00000236360.2 RP11-334A14.2 6.37 2.14e-09 0.00977 0.61 0.46 Vitamin D levels; chr11:14893332 chr1:52993201~52993702:- PAAD trans rs55665837 0.701 rs11023278 ENSG00000236360.2 RP11-334A14.2 6.37 2.18e-09 0.00993 0.59 0.46 Vitamin D levels; chr11:14619638 chr1:52993201~52993702:- PAAD trans rs2997457 0.872 rs298441 ENSG00000202000.1 RNU1-36P -6.36 2.21e-09 0.0101 -0.72 -0.46 Facial morphology (factor 16); chr1:25973829 chr4:88000237~88000401:+ PAAD trans rs76228276 0.737 rs112884531 ENSG00000260318.1 COX6CP1 6.36 2.21e-09 0.0101 1.16 0.46 Childhood ear infection; chr8:99904178 chr16:11903923~11904137:- PAAD trans rs11195620 0.617 rs2900933 ENSG00000279419.1 RP5-907C10.3 6.36 2.21e-09 0.0101 0.59 0.46 Inhibitory control; chr10:111483408 chr7:124742312~124745017:- PAAD trans rs11098499 1 rs11726229 ENSG00000275858.1 RP11-291L22.8 6.36 2.22e-09 0.0101 0.57 0.46 Corneal astigmatism; chr4:119290425 chr10:38450738~38451069:- PAAD trans rs7937890 0.559 rs2597208 ENSG00000236360.2 RP11-334A14.2 6.36 2.22e-09 0.0101 0.61 0.46 Mitochondrial DNA levels; chr11:14450783 chr1:52993201~52993702:- PAAD trans rs76228276 0.737 rs7841162 ENSG00000260318.1 COX6CP1 6.36 2.22e-09 0.0101 1.03 0.46 Childhood ear infection; chr8:99895567 chr16:11903923~11904137:- PAAD trans rs10940346 0.967 rs13173678 ENSG00000231752.4 EMBP1 6.36 2.22e-09 0.0101 0.57 0.46 Schizophrenia; chr5:50422314 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs6450108 ENSG00000231752.4 EMBP1 6.36 2.22e-09 0.0101 0.57 0.46 Schizophrenia; chr5:50434427 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs28445612 ENSG00000231752.4 EMBP1 6.36 2.22e-09 0.0101 0.57 0.46 Schizophrenia; chr5:50439676 chr1:121519112~121571892:+ PAAD trans rs10940346 0.967 rs2353436 ENSG00000231752.4 EMBP1 6.36 2.22e-09 0.0101 0.57 0.46 Schizophrenia; chr5:50445695 chr1:121519112~121571892:+ PAAD trans rs10940346 0.967 rs1849200 ENSG00000231752.4 EMBP1 6.36 2.22e-09 0.0101 0.57 0.46 Schizophrenia; chr5:50448053 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs6899048 ENSG00000231752.4 EMBP1 6.36 2.22e-09 0.0101 0.57 0.46 Schizophrenia; chr5:50451256 chr1:121519112~121571892:+ PAAD trans rs10940346 0.967 rs2353437 ENSG00000231752.4 EMBP1 6.36 2.22e-09 0.0101 0.57 0.46 Schizophrenia; chr5:50452078 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs2102454 ENSG00000231752.4 EMBP1 6.36 2.22e-09 0.0101 0.57 0.46 Schizophrenia; chr5:50452446 chr1:121519112~121571892:+ PAAD trans rs11039798 0.528 rs10839208 ENSG00000134612.10 FOLH1B 6.36 2.22e-09 0.0101 0.71 0.46 Axial length; chr11:49008904 chr11:89639227~89698718:+ PAAD trans rs13190036 1 rs4976682 ENSG00000228305.2 AC016734.2 6.36 2.23e-09 0.0101 0.81 0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177299001 chr2:63622178~63622831:- PAAD trans rs1816752 0.875 rs3783076 ENSG00000224976.2 PARP4P2 -6.36 2.23e-09 0.0102 -0.55 -0.46 Obesity-related traits; chr13:24490319 chr13:19349137~19407962:+ PAAD trans rs11195620 0.617 rs12413903 ENSG00000279419.1 RP5-907C10.3 6.36 2.24e-09 0.0102 0.62 0.46 Inhibitory control; chr10:111492453 chr7:124742312~124745017:- PAAD trans rs10940346 1 rs7712749 ENSG00000231752.4 EMBP1 6.36 2.24e-09 0.0102 0.57 0.46 Schizophrenia; chr5:50400441 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs2036901 ENSG00000231752.4 EMBP1 6.36 2.24e-09 0.0102 0.57 0.46 Schizophrenia; chr5:50401306 chr1:121519112~121571892:+ PAAD trans rs10940346 0.967 rs2271236 ENSG00000231752.4 EMBP1 6.36 2.24e-09 0.0102 0.57 0.46 Schizophrenia; chr5:50405921 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs34044167 ENSG00000231752.4 EMBP1 6.36 2.24e-09 0.0102 0.57 0.46 Schizophrenia; chr5:50410136 chr1:121519112~121571892:+ PAAD trans rs7312770 0.637 rs705699 ENSG00000234513.1 AC073072.7 6.36 2.25e-09 0.0102 0.51 0.46 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr7:22773646~22773993:- PAAD trans rs9650657 0.538 rs6984496 ENSG00000253893.2 FAM85B 6.36 2.25e-09 0.0102 0.65 0.46 Neuroticism; chr8:10938583 chr8:8167819~8226614:- PAAD trans rs11098499 0.909 rs10020034 ENSG00000275858.1 RP11-291L22.8 6.36 2.25e-09 0.0102 0.59 0.46 Corneal astigmatism; chr4:119373176 chr10:38450738~38451069:- PAAD trans rs1618992 0.729 rs11663444 ENSG00000236530.2 AC097711.1 6.36 2.27e-09 0.0103 0.55 0.46 Gut microbiome composition (summer and winter); chr18:28592123 chr4:80079532~80081122:+ PAAD trans rs11098499 1 rs35643470 ENSG00000275858.1 RP11-291L22.8 6.36 2.27e-09 0.0103 0.57 0.46 Corneal astigmatism; chr4:119263793 chr10:38450738~38451069:- PAAD trans rs11098499 1 rs12506395 ENSG00000275858.1 RP11-291L22.8 6.36 2.27e-09 0.0103 0.57 0.46 Corneal astigmatism; chr4:119263939 chr10:38450738~38451069:- PAAD trans rs11098499 1 rs13116504 ENSG00000275858.1 RP11-291L22.8 6.36 2.27e-09 0.0103 0.57 0.46 Corneal astigmatism; chr4:119288257 chr10:38450738~38451069:- PAAD trans rs11098499 0.909 rs28555550 ENSG00000275858.1 RP11-291L22.8 6.36 2.27e-09 0.0103 0.57 0.46 Corneal astigmatism; chr4:119289885 chr10:38450738~38451069:- PAAD trans rs11098499 1 rs28419773 ENSG00000275858.1 RP11-291L22.8 6.36 2.27e-09 0.0103 0.57 0.46 Corneal astigmatism; chr4:119289906 chr10:38450738~38451069:- PAAD trans rs55665837 0.701 rs10160597 ENSG00000236360.2 RP11-334A14.2 6.36 2.28e-09 0.0104 0.59 0.46 Vitamin D levels; chr11:14582446 chr1:52993201~52993702:- PAAD trans rs55665837 0.701 rs11023265 ENSG00000236360.2 RP11-334A14.2 6.36 2.28e-09 0.0104 0.59 0.46 Vitamin D levels; chr11:14594492 chr1:52993201~52993702:- PAAD trans rs55665837 0.701 rs11023272 ENSG00000236360.2 RP11-334A14.2 6.36 2.28e-09 0.0104 0.59 0.46 Vitamin D levels; chr11:14608824 chr1:52993201~52993702:- PAAD trans rs55665837 0.665 rs11023273 ENSG00000236360.2 RP11-334A14.2 6.36 2.28e-09 0.0104 0.59 0.46 Vitamin D levels; chr11:14609273 chr1:52993201~52993702:- PAAD trans rs916888 0.531 rs183211 ENSG00000204650.12 CRHR1-IT1 6.36 2.29e-09 0.0104 0.52 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45620328~45648216:+ PAAD trans rs916888 0.61 rs199436 ENSG00000204650.12 CRHR1-IT1 -6.36 2.29e-09 0.0104 -0.52 -0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45620328~45648216:+ PAAD trans rs916888 0.61 rs199453 ENSG00000204650.12 CRHR1-IT1 6.36 2.29e-09 0.0104 0.52 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45620328~45648216:+ PAAD trans rs916888 0.647 rs199449 ENSG00000204650.12 CRHR1-IT1 6.36 2.29e-09 0.0104 0.52 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45620328~45648216:+ PAAD trans rs13190036 1 rs71601343 ENSG00000226986.4 RP11-543B16.2 -6.35 2.32e-09 0.0105 -0.72 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr1:211207239~211207897:+ PAAD trans rs13190036 1 rs71601344 ENSG00000226986.4 RP11-543B16.2 -6.35 2.32e-09 0.0105 -0.72 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr1:211207239~211207897:+ PAAD trans rs13190036 1 rs3733875 ENSG00000226986.4 RP11-543B16.2 -6.35 2.32e-09 0.0105 -0.72 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr1:211207239~211207897:+ PAAD trans rs11195620 0.617 rs1914113 ENSG00000279419.1 RP5-907C10.3 6.35 2.32e-09 0.0105 0.62 0.46 Inhibitory control; chr10:111495482 chr7:124742312~124745017:- PAAD trans rs10940346 0.967 rs13154223 ENSG00000231752.4 EMBP1 6.35 2.35e-09 0.0107 0.57 0.46 Schizophrenia; chr5:50403152 chr1:121519112~121571892:+ PAAD trans rs10940346 0.967 rs62365887 ENSG00000231752.4 EMBP1 6.35 2.35e-09 0.0107 0.57 0.46 Schizophrenia; chr5:50408254 chr1:121519112~121571892:+ PAAD trans rs10940346 0.875 rs13159506 ENSG00000231752.4 EMBP1 6.35 2.35e-09 0.0107 0.57 0.46 Schizophrenia; chr5:50415061 chr1:121519112~121571892:+ PAAD trans rs7937890 0.559 rs1116739 ENSG00000236360.2 RP11-334A14.2 6.35 2.36e-09 0.0107 0.61 0.46 Mitochondrial DNA levels; chr11:14467636 chr1:52993201~52993702:- PAAD trans rs12709013 0.729 rs1657179 ENSG00000233719.3 GOT2P3 6.35 2.37e-09 0.0107 0.51 0.46 Blood metabolite ratios; chr16:58735115 chr12:9641802~9643007:+ PAAD trans rs7395662 0.674 rs7124275 ENSG00000134612.10 FOLH1B -6.35 2.37e-09 0.0107 -0.55 -0.46 HDL cholesterol; chr11:48140753 chr11:89639227~89698718:+ PAAD trans rs877636 0.692 rs11171739 ENSG00000223416.3 RPS26P15 6.34 2.46e-09 0.0111 0.53 0.46 Cognitive function; chr12:56076841 chr1:58056133~58056480:- PAAD trans rs11250098 0.51 rs4840525 ENSG00000253893.2 FAM85B 6.34 2.5e-09 0.0113 0.65 0.46 Morning vs. evening chronotype; chr8:10908125 chr8:8167819~8226614:- PAAD trans rs12709013 0.935 rs8046667 ENSG00000230849.2 GOT2P2 6.34 2.51e-09 0.0113 0.52 0.46 Blood metabolite ratios; chr16:58790935 chr1:173141100~173142350:- PAAD trans rs12709013 1 rs8046998 ENSG00000230849.2 GOT2P2 6.34 2.51e-09 0.0113 0.52 0.46 Blood metabolite ratios; chr16:58791109 chr1:173141100~173142350:- PAAD trans rs7258465 1 rs8111708 ENSG00000267533.1 RP11-815J4.7 6.34 2.52e-09 0.0114 0.57 0.46 Breast cancer; chr19:18448066 chr18:12067173~12068417:- PAAD trans rs7258465 1 rs34010330 ENSG00000267533.1 RP11-815J4.7 6.34 2.52e-09 0.0114 0.57 0.46 Breast cancer; chr19:18448847 chr18:12067173~12068417:- PAAD trans rs703108 0.731 rs7898954 ENSG00000213315.5 CTD-3035D6.1 -6.33 2.56e-09 0.0115 -0.47 -0.46 Monocyte percentage of white cells; chr10:22034717 chr14:90766531~90766989:+ PAAD trans rs877636 0.859 rs3741499 ENSG00000225071.1 GS1-184P14.2 -6.33 2.58e-09 0.0116 -0.54 -0.46 Cognitive function; chr12:56080595 chrX:24429573~24429920:- PAAD trans rs11098499 0.863 rs3775841 ENSG00000275858.1 RP11-291L22.8 6.33 2.61e-09 0.0117 0.61 0.46 Corneal astigmatism; chr4:119504622 chr10:38450738~38451069:- PAAD trans rs11039571 0.588 rs10734564 ENSG00000134612.10 FOLH1B -6.33 2.66e-09 0.0119 -0.77 -0.46 D-dimer levels; chr11:48138877 chr11:89639227~89698718:+ PAAD trans rs12497850 0.627 rs4974078 ENSG00000197582.5 GPX1P1 6.33 2.66e-09 0.0119 0.59 0.46 Parkinson's disease; chr3:48971953 chrX:13378735~13379340:- PAAD trans rs7554547 0.69 rs7524721 ENSG00000261819.1 RP11-680G24.4 6.32 2.69e-09 0.0121 0.57 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11890119 chr16:14988259~14990160:- PAAD trans rs11195620 0.617 rs1914110 ENSG00000279419.1 RP5-907C10.3 6.32 2.7e-09 0.0121 0.61 0.46 Inhibitory control; chr10:111498889 chr7:124742312~124745017:- PAAD trans rs11195620 0.617 rs1914108 ENSG00000279419.1 RP5-907C10.3 6.32 2.7e-09 0.0121 0.61 0.46 Inhibitory control; chr10:111503635 chr7:124742312~124745017:- PAAD trans rs11195620 0.617 rs1914107 ENSG00000279419.1 RP5-907C10.3 6.32 2.7e-09 0.0121 0.61 0.46 Inhibitory control; chr10:111503842 chr7:124742312~124745017:- PAAD trans rs11195620 0.617 rs11195611 ENSG00000279419.1 RP5-907C10.3 6.32 2.7e-09 0.0121 0.61 0.46 Inhibitory control; chr10:111504254 chr7:124742312~124745017:- PAAD trans rs9611565 0.506 rs4822020 ENSG00000268568.1 AC007228.9 -6.32 2.71e-09 0.0121 -0.6 -0.46 Vitiligo; chr22:41304199 chr19:56672574~56673901:- PAAD trans rs9611519 0.732 rs1883826 ENSG00000268568.1 AC007228.9 -6.32 2.71e-09 0.0121 -0.6 -0.46 Neuroticism; chr22:41307424 chr19:56672574~56673901:- PAAD trans rs9611565 0.525 rs9611549 ENSG00000268568.1 AC007228.9 -6.32 2.71e-09 0.0121 -0.6 -0.46 Vitiligo; chr22:41309905 chr19:56672574~56673901:- PAAD trans rs2562152 0.613 rs216599 ENSG00000265178.1 MIR4728 6.32 2.73e-09 0.0122 0.63 0.46 Glioblastoma; chr16:59673 chr17:39726495~39726561:+ PAAD trans rs864643 0.678 rs521139 ENSG00000183298.5 RP11-556K13.1 6.32 2.73e-09 0.0123 0.67 0.46 Attention deficit hyperactivity disorder; chr3:39486128 chr1:101786340~101787219:- PAAD trans rs7554547 0.667 rs6666533 ENSG00000261819.1 RP11-680G24.4 6.32 2.77e-09 0.0124 0.58 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11889068 chr16:14988259~14990160:- PAAD trans rs864643 0.678 rs568085 ENSG00000183298.5 RP11-556K13.1 6.32 2.81e-09 0.0126 0.67 0.46 Attention deficit hyperactivity disorder; chr3:39472661 chr1:101786340~101787219:- PAAD trans rs864643 0.625 rs628725 ENSG00000183298.5 RP11-556K13.1 6.32 2.81e-09 0.0126 0.67 0.46 Attention deficit hyperactivity disorder; chr3:39472887 chr1:101786340~101787219:- PAAD trans rs864643 0.625 rs570136 ENSG00000183298.5 RP11-556K13.1 6.32 2.81e-09 0.0126 0.67 0.46 Attention deficit hyperactivity disorder; chr3:39472922 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs7615732 ENSG00000183298.5 RP11-556K13.1 6.32 2.81e-09 0.0126 0.67 0.46 Attention deficit hyperactivity disorder; chr3:39473732 chr1:101786340~101787219:- PAAD trans rs877636 0.669 rs7297175 ENSG00000212994.5 RPS26P6 -6.31 2.85e-09 0.0128 -0.51 -0.46 Cognitive function; chr12:56080024 chr8:100895771~100896118:+ PAAD trans rs11098499 0.818 rs55825515 ENSG00000275858.1 RP11-291L22.8 6.31 2.89e-09 0.0129 0.61 0.46 Corneal astigmatism; chr4:119565247 chr10:38450738~38451069:- PAAD trans rs7312770 0.612 rs773114 ENSG00000243403.1 RP11-330L19.1 6.31 2.89e-09 0.0129 0.49 0.46 Polycystic ovary syndrome;Hypothyroidism; chr12:55985276 chr15:64592979~64593326:+ PAAD trans rs6852928 0.562 rs5029557 ENSG00000279948.1 CTD-2233K9.1 -6.31 2.91e-09 0.013 -0.62 -0.46 Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1; chr4:89132792 chr19:46946535~46949156:+ PAAD trans rs7554547 0.739 rs2050269 ENSG00000261819.1 RP11-680G24.4 6.31 2.93e-09 0.0131 0.6 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11886432 chr16:14988259~14990160:- PAAD trans rs7554547 0.765 rs2050268 ENSG00000261819.1 RP11-680G24.4 6.31 2.93e-09 0.0131 0.6 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11886487 chr16:14988259~14990160:- PAAD trans rs7554547 0.765 rs2050267 ENSG00000261819.1 RP11-680G24.4 6.31 2.93e-09 0.0131 0.6 0.46 Nonsyndromic cleft lip with cleft palate; chr1:11886516 chr16:14988259~14990160:- PAAD trans rs11195620 0.617 rs8181297 ENSG00000279419.1 RP5-907C10.3 6.31 2.95e-09 0.0132 0.62 0.46 Inhibitory control; chr10:111486530 chr7:124742312~124745017:- PAAD trans rs7258465 1 rs7252707 ENSG00000267533.1 RP11-815J4.7 6.31 2.97e-09 0.0132 0.56 0.46 Breast cancer; chr19:18501447 chr18:12067173~12068417:- PAAD trans rs5877 0.568 rs1951627 ENSG00000213331.4 RP11-713C19.2 6.31 2.97e-09 0.0133 0.54 0.46 Subjective well-being (multi-trait analysis); chr1:173922679 chr4:187970273~187971284:+ PAAD trans rs13190036 0.901 rs55741473 ENSG00000226986.4 RP11-543B16.2 -6.3 2.98e-09 0.0133 -0.71 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr1:211207239~211207897:+ PAAD trans rs13190036 1 rs13157667 ENSG00000226986.4 RP11-543B16.2 -6.3 2.98e-09 0.0133 -0.71 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr1:211207239~211207897:+ PAAD trans rs916888 0.61 rs199444 ENSG00000204650.12 CRHR1-IT1 6.3 2.99e-09 0.0133 0.51 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45620328~45648216:+ PAAD trans rs916888 0.61 rs199442 ENSG00000204650.12 CRHR1-IT1 6.3 2.99e-09 0.0133 0.51 0.46 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45620328~45648216:+ PAAD trans rs11098499 0.908 rs9995234 ENSG00000275858.1 RP11-291L22.8 6.3 2.99e-09 0.0134 0.6 0.46 Corneal astigmatism; chr4:119400672 chr10:38450738~38451069:- PAAD trans rs13190036 1 rs13167431 ENSG00000226986.4 RP11-543B16.2 -6.3 3.01e-09 0.0134 -0.71 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr1:211207239~211207897:+ PAAD trans rs13190036 1 rs35535623 ENSG00000226986.4 RP11-543B16.2 -6.3 3.01e-09 0.0134 -0.71 -0.46 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr1:211207239~211207897:+ PAAD trans rs7811142 0.945 rs34989573 ENSG00000228546.2 CTA-313A17.3 6.3 3.02e-09 0.0134 0.68 0.46 Platelet count; chr7:100500272 chr7:102337316~102339115:+ PAAD trans rs7811142 0.945 rs6974282 ENSG00000228546.2 CTA-313A17.3 6.3 3.02e-09 0.0134 0.68 0.46 Platelet count; chr7:100500672 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs118119933 ENSG00000228546.2 CTA-313A17.3 6.3 3.03e-09 0.0135 0.7 0.46 Platelet count; chr7:100341427 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs11765869 ENSG00000228546.2 CTA-313A17.3 6.3 3.03e-09 0.0135 0.69 0.46 Platelet count; chr7:100367166 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs705866 ENSG00000228546.2 CTA-313A17.3 6.3 3.03e-09 0.0135 0.69 0.46 Platelet count; chr7:100367662 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs6965458 ENSG00000228546.2 CTA-313A17.3 6.3 3.03e-09 0.0135 0.69 0.46 Platelet count; chr7:100375779 chr7:102337316~102339115:+ PAAD trans rs10940346 0.846 rs2663076 ENSG00000231752.4 EMBP1 6.3 3.05e-09 0.0136 0.56 0.46 Schizophrenia; chr5:50430593 chr1:121519112~121571892:+ PAAD trans rs10940346 0.934 rs303231 ENSG00000231752.4 EMBP1 6.3 3.05e-09 0.0136 0.56 0.46 Schizophrenia; chr5:50447369 chr1:121519112~121571892:+ PAAD trans rs7554547 0.765 rs2050270 ENSG00000261819.1 RP11-680G24.4 6.3 3.08e-09 0.0137 0.6 0.45 Nonsyndromic cleft lip with cleft palate; chr1:11886399 chr16:14988259~14990160:- PAAD trans rs11098499 0.954 rs2389802 ENSG00000275858.1 RP11-291L22.8 6.3 3.13e-09 0.0139 0.59 0.45 Corneal astigmatism; chr4:119404577 chr10:38450738~38451069:- PAAD trans rs10242455 1 rs73395547 ENSG00000228834.1 RP11-249L21.4 6.29 3.15e-09 0.014 0.95 0.45 Blood metabolite levels; chr7:99325123 chr6:108907615~108907873:- PAAD trans rs10242455 1 rs2301889 ENSG00000228834.1 RP11-249L21.4 6.29 3.15e-09 0.014 0.95 0.45 Blood metabolite levels; chr7:99333482 chr6:108907615~108907873:- PAAD trans rs10242455 1 rs73395557 ENSG00000228834.1 RP11-249L21.4 6.29 3.15e-09 0.014 0.95 0.45 Blood metabolite levels; chr7:99336801 chr6:108907615~108907873:- PAAD trans rs10242455 1 rs6948775 ENSG00000228834.1 RP11-249L21.4 6.29 3.15e-09 0.014 0.95 0.45 Blood metabolite levels; chr7:99347857 chr6:108907615~108907873:- PAAD trans rs7811142 0.779 rs111312383 ENSG00000228546.2 CTA-313A17.3 6.29 3.19e-09 0.0142 0.69 0.45 Platelet count; chr7:100307702 chr7:102337316~102339115:+ PAAD trans rs7811142 0.779 rs28680963 ENSG00000228546.2 CTA-313A17.3 6.29 3.19e-09 0.0142 0.69 0.45 Platelet count; chr7:100307852 chr7:102337316~102339115:+ PAAD trans rs10940346 1 rs6874016 ENSG00000231752.4 EMBP1 -6.29 3.2e-09 0.0142 -0.54 -0.45 Schizophrenia; chr5:50549640 chr1:121519112~121571892:+ PAAD trans rs864643 0.677 rs1708087 ENSG00000183298.5 RP11-556K13.1 6.29 3.22e-09 0.0143 0.66 0.45 Attention deficit hyperactivity disorder; chr3:39468197 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs1768158 ENSG00000183298.5 RP11-556K13.1 -6.29 3.22e-09 0.0143 -0.66 -0.45 Attention deficit hyperactivity disorder; chr3:39465870 chr1:101786340~101787219:- PAAD trans rs916888 0.779 rs199498 ENSG00000204650.12 CRHR1-IT1 6.29 3.24e-09 0.0144 0.54 0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:45620328~45648216:+ PAAD trans rs864643 0.678 rs625898 ENSG00000183298.5 RP11-556K13.1 -6.29 3.25e-09 0.0144 -0.65 -0.45 Attention deficit hyperactivity disorder; chr3:39471624 chr1:101786340~101787219:- PAAD trans rs7554547 0.667 rs12567187 ENSG00000261819.1 RP11-680G24.4 6.28 3.31e-09 0.0147 0.56 0.45 Nonsyndromic cleft lip with cleft palate; chr1:11896095 chr16:14988259~14990160:- PAAD trans rs11098499 0.863 rs3736115 ENSG00000275858.1 RP11-291L22.8 -6.28 3.33e-09 0.0147 -0.6 -0.45 Corneal astigmatism; chr4:119567548 chr10:38450738~38451069:- PAAD trans rs2727020 0.729 rs4980439 ENSG00000134612.10 FOLH1B -6.28 3.39e-09 0.015 -0.56 -0.45 Coronary artery disease; chr11:49320694 chr11:89639227~89698718:+ PAAD trans rs1569419 0.698 rs2993488 ENSG00000279421.1 RP11-335K5.3 6.28 3.39e-09 0.015 0.76 0.45 Mean corpuscular hemoglobin;Red blood cell count;Mean platelet volume;Plateletcrit;Platelet distribution width;Mean corpuscular volume; chr1:3078337 chr15:78599892~78600013:- PAAD trans rs4240897 1 rs4240897 ENSG00000261819.1 RP11-680G24.4 -6.28 3.4e-09 0.015 -0.55 -0.45 Tuberculosis; chr1:11982698 chr16:14988259~14990160:- PAAD trans rs3905510 0.561 rs2013279 ENSG00000279332.1 RP11-799B12.1 6.28 3.45e-09 0.0152 0.69 0.45 Total body bone mineral density; chr5:123540718 chr18:24135468~24135829:- PAAD trans rs9650657 0.617 rs28680211 ENSG00000253893.2 FAM85B 6.28 3.46e-09 0.0152 0.63 0.45 Neuroticism; chr8:10661935 chr8:8167819~8226614:- PAAD trans rs7395662 0.5 rs7951327 ENSG00000134612.10 FOLH1B -6.27 3.52e-09 0.0155 -0.54 -0.45 HDL cholesterol; chr11:48903807 chr11:89639227~89698718:+ PAAD trans rs7937890 0.559 rs2034480 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14445377 chr1:52993201~52993702:- PAAD trans rs7937890 0.504 rs2575847 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14449626 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575825 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14450550 chr1:52993201~52993702:- PAAD trans rs7937890 0.532 rs2575827 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14453969 chr1:52993201~52993702:- PAAD trans rs7937890 0.532 rs2256884 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14454856 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597206 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14455992 chr1:52993201~52993702:- PAAD trans rs7937890 0.531 rs2575828 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14462646 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575829 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14463475 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597201 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14463858 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597200 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14464054 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575830 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14464056 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575831 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14464648 chr1:52993201~52993702:- PAAD trans rs7937890 0.532 rs2575832 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14467264 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597197 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14468286 chr1:52993201~52993702:- PAAD trans rs7937890 0.532 rs2575833 ENSG00000236360.2 RP11-334A14.2 6.27 3.53e-09 0.0155 0.6 0.45 Mitochondrial DNA levels; chr11:14470959 chr1:52993201~52993702:- PAAD trans rs11098499 1 rs11098500 ENSG00000275858.1 RP11-291L22.8 6.27 3.56e-09 0.0156 0.56 0.45 Corneal astigmatism; chr4:119298084 chr10:38450738~38451069:- PAAD trans rs916888 0.647 rs199524 ENSG00000204650.12 CRHR1-IT1 -6.27 3.6e-09 0.0158 -0.51 -0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45620328~45648216:+ PAAD trans rs916888 0.647 rs199523 ENSG00000204650.12 CRHR1-IT1 -6.27 3.6e-09 0.0158 -0.51 -0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45620328~45648216:+ PAAD trans rs3779195 0.524 rs76976120 ENSG00000225169.1 BRI3P1 -6.27 3.62e-09 0.0159 -0.8 -0.45 Sex hormone-binding globulin levels; chr7:98264860 chr1:100213293~100213670:+ PAAD trans rs2727020 0.729 rs1917325 ENSG00000134612.10 FOLH1B -6.26 3.66e-09 0.016 -0.55 -0.45 Coronary artery disease; chr11:49348452 chr11:89639227~89698718:+ PAAD trans rs2727020 0.704 rs4144700 ENSG00000134612.10 FOLH1B -6.26 3.66e-09 0.016 -0.55 -0.45 Coronary artery disease; chr11:49349282 chr11:89639227~89698718:+ PAAD trans rs2727020 0.681 rs1976901 ENSG00000134612.10 FOLH1B -6.26 3.66e-09 0.016 -0.55 -0.45 Coronary artery disease; chr11:49357145 chr11:89639227~89698718:+ PAAD trans rs2727020 0.729 rs10839268 ENSG00000134612.10 FOLH1B -6.26 3.66e-09 0.016 -0.55 -0.45 Coronary artery disease; chr11:49358776 chr11:89639227~89698718:+ PAAD trans rs10242455 1 rs28468623 ENSG00000228834.1 RP11-249L21.4 6.26 3.68e-09 0.0161 0.93 0.45 Blood metabolite levels; chr7:99325189 chr6:108907615~108907873:- PAAD trans rs12709013 1 rs11641836 ENSG00000230849.2 GOT2P2 6.26 3.68e-09 0.0161 0.51 0.45 Blood metabolite ratios; chr16:58798143 chr1:173141100~173142350:- PAAD trans rs877636 0.669 rs7297175 ENSG00000234354.3 RPS26P47 -6.26 3.72e-09 0.0163 -0.56 -0.45 Cognitive function; chr12:56080024 chr13:100539901~100540248:- PAAD trans rs1008953 1 rs1008953 ENSG00000262728.4 RP11-1000B6.8 -6.26 3.72e-09 0.0163 -0.67 -0.45 Psoriasis; chr20:45352086 chr15:32586105~32615158:- PAAD trans rs1814175 0.935 rs11040465 ENSG00000134612.10 FOLH1B -6.26 3.76e-09 0.0164 -0.53 -0.45 Height; chr11:49667771 chr11:89639227~89698718:+ PAAD trans rs13190036 1 rs71601343 ENSG00000228305.2 AC016734.2 -6.26 3.79e-09 0.0166 -0.78 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177205106 chr2:63622178~63622831:- PAAD trans rs13190036 1 rs71601344 ENSG00000228305.2 AC016734.2 -6.26 3.79e-09 0.0166 -0.78 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177206492 chr2:63622178~63622831:- PAAD trans rs13190036 1 rs3733875 ENSG00000228305.2 AC016734.2 -6.26 3.79e-09 0.0166 -0.78 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177210239 chr2:63622178~63622831:- PAAD trans rs13190036 1 rs7714695 ENSG00000226986.4 RP11-543B16.2 -6.26 3.8e-09 0.0166 -0.71 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177130444 chr1:211207239~211207897:+ PAAD trans rs7811142 0.945 rs6978739 ENSG00000228546.2 CTA-313A17.3 6.26 3.84e-09 0.0167 0.68 0.45 Platelet count; chr7:100501057 chr7:102337316~102339115:+ PAAD trans rs6499255 0.904 rs10852458 ENSG00000257513.6 NPIPB1P 6.25 3.87e-09 0.0169 0.63 0.45 IgE levels; chr16:69638507 chr18:11619509~11639699:- PAAD trans rs10940346 1 rs7704686 ENSG00000231752.4 EMBP1 -6.25 3.87e-09 0.0169 -0.56 -0.45 Schizophrenia; chr5:50548995 chr1:121519112~121571892:+ PAAD trans rs10908521 0.685 rs1998977 ENSG00000227183.3 HDGFP1 -6.25 3.94e-09 0.0172 -0.64 -0.45 Uric acid clearance; chr1:156834329 chrX:131646639~131646890:+ PAAD trans rs7944735 0.517 rs74763661 ENSG00000134612.10 FOLH1B 6.25 3.95e-09 0.0172 0.85 0.45 Intraocular pressure; chr11:48212220 chr11:89639227~89698718:+ PAAD trans rs2727020 0.566 rs10839234 ENSG00000134612.10 FOLH1B -6.25 3.95e-09 0.0172 -0.54 -0.45 Coronary artery disease; chr11:49163972 chr11:89639227~89698718:+ PAAD trans rs3096299 0.504 rs4785574 ENSG00000215030.5 RPL13P12 -6.25 4e-09 0.0174 -0.49 -0.45 Multiple myeloma (IgH translocation); chr16:89502467 chr17:17383377~17384012:- PAAD trans rs9611519 0.754 rs4820435 ENSG00000268568.1 AC007228.9 -6.25 4.02e-09 0.0175 -0.6 -0.45 Neuroticism; chr22:41256842 chr19:56672574~56673901:- PAAD trans rs2727020 0.729 rs6485965 ENSG00000134612.10 FOLH1B 6.25 4.02e-09 0.0175 0.54 0.45 Coronary artery disease; chr11:49145178 chr11:89639227~89698718:+ PAAD trans rs2727020 0.729 rs10742932 ENSG00000134612.10 FOLH1B -6.25 4.02e-09 0.0175 -0.54 -0.45 Coronary artery disease; chr11:49151682 chr11:89639227~89698718:+ PAAD trans rs2727020 0.729 rs2299650 ENSG00000134612.10 FOLH1B -6.25 4.02e-09 0.0175 -0.54 -0.45 Coronary artery disease; chr11:49152455 chr11:89639227~89698718:+ PAAD trans rs2727020 0.638 rs1164668 ENSG00000134612.10 FOLH1B 6.25 4.02e-09 0.0175 0.55 0.45 Coronary artery disease; chr11:49309075 chr11:89639227~89698718:+ PAAD trans rs13190036 1 rs34446750 ENSG00000226986.4 RP11-543B16.2 -6.25 4.04e-09 0.0175 -0.71 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177168079 chr1:211207239~211207897:+ PAAD trans rs2727020 0.729 rs2204366 ENSG00000134612.10 FOLH1B 6.24 4.05e-09 0.0176 0.55 0.45 Coronary artery disease; chr11:49327815 chr11:89639227~89698718:+ PAAD trans rs2727020 0.658 rs4980431 ENSG00000134612.10 FOLH1B -6.24 4.05e-09 0.0176 -0.55 -0.45 Coronary artery disease; chr11:49328519 chr11:89639227~89698718:+ PAAD trans rs7180079 0.62 rs4474637 ENSG00000215246.5 RP11-43F13.3 -6.24 4.06e-09 0.0176 -0.7 -0.45 Monocyte count; chr15:64747520 chr5:987180~997308:- PAAD trans rs864643 0.678 rs1707953 ENSG00000183298.5 RP11-556K13.1 6.24 4.08e-09 0.0177 0.67 0.45 Attention deficit hyperactivity disorder; chr3:39483918 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs683089 ENSG00000183298.5 RP11-556K13.1 6.24 4.08e-09 0.0177 0.67 0.45 Attention deficit hyperactivity disorder; chr3:39484334 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs590805 ENSG00000183298.5 RP11-556K13.1 6.24 4.08e-09 0.0177 0.67 0.45 Attention deficit hyperactivity disorder; chr3:39485463 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs606973 ENSG00000183298.5 RP11-556K13.1 6.24 4.08e-09 0.0177 0.67 0.45 Attention deficit hyperactivity disorder; chr3:39485876 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs521226 ENSG00000183298.5 RP11-556K13.1 6.24 4.08e-09 0.0177 0.67 0.45 Attention deficit hyperactivity disorder; chr3:39486099 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs519385 ENSG00000183298.5 RP11-556K13.1 6.24 4.08e-09 0.0177 0.67 0.45 Attention deficit hyperactivity disorder; chr3:39486304 chr1:101786340~101787219:- PAAD trans rs864643 0.678 rs604831 ENSG00000183298.5 RP11-556K13.1 6.24 4.08e-09 0.0177 0.67 0.45 Attention deficit hyperactivity disorder; chr3:39486327 chr1:101786340~101787219:- PAAD trans rs864643 0.625 rs517376 ENSG00000183298.5 RP11-556K13.1 6.24 4.08e-09 0.0177 0.67 0.45 Attention deficit hyperactivity disorder; chr3:39486571 chr1:101786340~101787219:- PAAD trans rs11098499 0.863 rs6858592 ENSG00000275858.1 RP11-291L22.8 6.24 4.08e-09 0.0177 0.6 0.45 Corneal astigmatism; chr4:119537537 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs9997631 ENSG00000275858.1 RP11-291L22.8 6.24 4.08e-09 0.0177 0.6 0.45 Corneal astigmatism; chr4:119548840 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs10018280 ENSG00000275858.1 RP11-291L22.8 6.24 4.08e-09 0.0177 0.6 0.45 Corneal astigmatism; chr4:119556984 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs6534141 ENSG00000275858.1 RP11-291L22.8 6.24 4.08e-09 0.0177 0.6 0.45 Corneal astigmatism; chr4:119564068 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs2127823 ENSG00000275858.1 RP11-291L22.8 6.24 4.08e-09 0.0177 0.6 0.45 Corneal astigmatism; chr4:119564515 chr10:38450738~38451069:- PAAD trans rs11098499 0.863 rs3775858 ENSG00000275858.1 RP11-291L22.8 6.24 4.08e-09 0.0177 0.6 0.45 Corneal astigmatism; chr4:119564873 chr10:38450738~38451069:- PAAD trans rs13190036 1 rs59737888 ENSG00000228305.2 AC016734.2 -6.24 4.12e-09 0.0178 -0.79 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177160374 chr2:63622178~63622831:- PAAD trans rs916888 0.61 rs199438 ENSG00000204650.12 CRHR1-IT1 6.24 4.19e-09 0.0181 0.51 0.45 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45620328~45648216:+ PAAD trans rs7258465 1 rs7258465 ENSG00000267533.1 RP11-815J4.7 6.24 4.21e-09 0.0182 0.56 0.45 Breast cancer; chr19:18422832 chr18:12067173~12068417:- PAAD trans rs864643 0.574 rs1768192 ENSG00000183298.5 RP11-556K13.1 6.24 4.21e-09 0.0182 0.66 0.45 Attention deficit hyperactivity disorder; chr3:39470669 chr1:101786340~101787219:- PAAD trans rs877636 0.562 rs1131017 ENSG00000234354.3 RPS26P47 -6.24 4.25e-09 0.0183 -0.55 -0.45 Cognitive function; chr12:56042145 chr13:100539901~100540248:- PAAD trans rs12709013 0.792 rs1473206 ENSG00000233719.3 GOT2P3 6.23 4.3e-09 0.0185 0.5 0.45 Blood metabolite ratios; chr16:58737529 chr12:9641802~9643007:+ PAAD trans rs12709013 0.792 rs1473205 ENSG00000233719.3 GOT2P3 6.23 4.3e-09 0.0185 0.5 0.45 Blood metabolite ratios; chr16:58737547 chr12:9641802~9643007:+ PAAD trans rs724950 1 rs9307600 ENSG00000259565.2 KRT8P23 6.23 4.31e-09 0.0186 0.54 0.45 Obesity-related traits; chr4:127424176 chr15:76979245~76980451:- PAAD trans rs7312770 0.637 rs705699 ENSG00000243403.1 RP11-330L19.1 6.23 4.35e-09 0.0187 0.49 0.45 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr15:64592979~64593326:+ PAAD trans rs877636 0.669 rs7297175 ENSG00000196656.7 AC004057.1 -6.23 4.39e-09 0.0189 -0.45 -0.45 Cognitive function; chr12:56080024 chr4:113214046~113217170:- PAAD trans rs3779195 0.585 rs73709460 ENSG00000225169.1 BRI3P1 -6.23 4.46e-09 0.0192 -0.8 -0.45 Sex hormone-binding globulin levels; chr7:98265942 chr1:100213293~100213670:+ PAAD trans rs3779195 0.585 rs56694862 ENSG00000225169.1 BRI3P1 -6.23 4.46e-09 0.0192 -0.8 -0.45 Sex hormone-binding globulin levels; chr7:98267808 chr1:100213293~100213670:+ PAAD trans rs7258465 0.931 rs271626 ENSG00000267533.1 RP11-815J4.7 -6.22 4.51e-09 0.0194 -0.54 -0.45 Breast cancer; chr19:18516257 chr18:12067173~12068417:- PAAD trans rs71597109 0.736 rs35476121 ENSG00000212206.1 SNORA69 6.22 4.54e-09 0.0195 0.53 0.45 Chronic lymphocytic leukemia; chr4:101848354 chr17:8329583~8329719:+ PAAD trans rs11098499 0.955 rs11944880 ENSG00000275858.1 RP11-291L22.8 -6.22 4.54e-09 0.0195 -0.56 -0.45 Corneal astigmatism; chr4:119238179 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs6815725 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119237255 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs1551 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119237345 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs11931312 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119237868 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs1511018 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119240425 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs1397608 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119240589 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs7684942 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119241046 chr10:38450738~38451069:- PAAD trans rs11098499 0.913 rs10010696 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119243148 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs1511019 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119244852 chr10:38450738~38451069:- PAAD trans rs11098499 0.913 rs11098496 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119246311 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs35197422 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119248159 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs35434465 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119248223 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs1511015 ENSG00000275858.1 RP11-291L22.8 6.22 4.54e-09 0.0195 0.56 0.45 Corneal astigmatism; chr4:119249318 chr10:38450738~38451069:- PAAD trans rs7258465 1 rs8103622 ENSG00000267533.1 RP11-815J4.7 6.22 4.56e-09 0.0196 0.55 0.45 Breast cancer; chr19:18462024 chr18:12067173~12068417:- PAAD trans rs13253073 0.883 rs2305290 ENSG00000260318.1 COX6CP1 6.22 4.58e-09 0.0196 1.06 0.45 Glucose homeostasis traits; chr8:99819066 chr16:11903923~11904137:- PAAD trans rs9425766 0.639 rs10798295 ENSG00000213331.4 RP11-713C19.2 6.22 4.6e-09 0.0197 0.5 0.45 Life satisfaction; chr1:173714815 chr4:187970273~187971284:+ PAAD trans rs4606360 1 rs4606360 ENSG00000213331.4 RP11-713C19.2 6.22 4.6e-09 0.0197 0.5 0.45 Subjective well-being; chr1:173729868 chr4:187970273~187971284:+ PAAD trans rs9425766 0.511 rs10912676 ENSG00000213331.4 RP11-713C19.2 6.22 4.6e-09 0.0197 0.5 0.45 Life satisfaction; chr1:173740477 chr4:187970273~187971284:+ PAAD trans rs2455799 0.593 rs2047852 ENSG00000224631.4 RP11-51O6.1 6.22 4.65e-09 0.0199 0.49 0.45 Mean platelet volume; chr3:15691032 chr16:61055399~61055964:- PAAD trans rs76228276 0.737 rs113265871 ENSG00000260318.1 COX6CP1 6.22 4.65e-09 0.0199 1.18 0.45 Childhood ear infection; chr8:99834586 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs75750707 ENSG00000260318.1 COX6CP1 6.22 4.65e-09 0.0199 1.18 0.45 Childhood ear infection; chr8:99837884 chr16:11903923~11904137:- PAAD trans rs6732160 0.845 rs72807999 ENSG00000236165.1 PRADC1P1 6.22 4.66e-09 0.0199 0.53 0.45 Intelligence (multi-trait analysis); chr2:73164567 chr3:36976316~36976840:+ PAAD trans rs10493389 0.673 rs4259616 ENSG00000258682.1 CTD-2002H8.2 -6.22 4.66e-09 0.0199 -0.33 -0.45 Echocardiographic traits; chr1:65818053 chr14:58264662~58269681:+ PAAD trans rs1079467 0.73 rs72846600 ENSG00000233426.3 EIF3FP3 -6.22 4.68e-09 0.02 -0.67 -0.45 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7952994 chr2:58251440~58252525:+ PAAD trans rs12570744 0.515 rs17141695 ENSG00000234062.6 RP11-308D16.2 -6.22 4.7e-09 0.0201 -0.51 -0.45 Response to anti-TNF therapy in rheumatoid arthritis; chr10:6749504 chrX:136909395~137021630:+ PAAD trans rs7811142 0.83 rs28495773 ENSG00000228546.2 CTA-313A17.3 6.21 4.72e-09 0.0202 0.69 0.45 Platelet count; chr7:100345960 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs7783159 ENSG00000228546.2 CTA-313A17.3 6.21 4.73e-09 0.0202 0.67 0.45 Platelet count; chr7:100419831 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs77861211 ENSG00000228546.2 CTA-313A17.3 6.21 4.73e-09 0.0202 0.67 0.45 Platelet count; chr7:100364473 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs11769057 ENSG00000228546.2 CTA-313A17.3 6.21 4.73e-09 0.0202 0.67 0.45 Platelet count; chr7:100367038 chr7:102337316~102339115:+ PAAD trans rs12709013 0.967 rs2118019 ENSG00000230849.2 GOT2P2 -6.21 4.75e-09 0.0203 -0.5 -0.45 Blood metabolite ratios; chr16:58797825 chr1:173141100~173142350:- PAAD trans rs6477998 1 rs6477998 ENSG00000238072.1 RP11-305M3.2 -6.21 4.77e-09 0.0204 -0.57 -0.45 Hematology traits; chr9:113234969 chr7:129410113~129410370:- PAAD trans rs12709013 1 rs11648514 ENSG00000230849.2 GOT2P2 6.21 4.86e-09 0.0207 0.5 0.45 Blood metabolite ratios; chr16:58798176 chr1:173141100~173142350:- PAAD trans rs12709013 1 rs8057892 ENSG00000230849.2 GOT2P2 6.21 4.86e-09 0.0207 0.5 0.45 Blood metabolite ratios; chr16:58798855 chr1:173141100~173142350:- PAAD trans rs10940346 1 rs2137132 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50353988 chr1:121519112~121571892:+ PAAD trans rs10940346 0.967 rs1995795 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50356233 chr1:121519112~121571892:+ PAAD trans rs10940346 0.967 rs6874829 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50357573 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs1812994 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50364397 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs13185587 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50365409 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs3849670 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50365641 chr1:121519112~121571892:+ PAAD trans rs10940346 0.905 rs4030569 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50371779 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs4030570 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50371829 chr1:121519112~121571892:+ PAAD trans rs10940346 0.967 rs4030572 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50375897 chr1:121519112~121571892:+ PAAD trans rs10940346 0.875 rs10076490 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50389037 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs4643959 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50391631 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs2883164 ENSG00000231752.4 EMBP1 6.21 4.9e-09 0.0208 0.56 0.45 Schizophrenia; chr5:50397624 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs1328253 ENSG00000231752.4 EMBP1 -6.21 4.9e-09 0.0208 -0.56 -0.45 Schizophrenia; chr5:50286916 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs4865522 ENSG00000231752.4 EMBP1 -6.21 4.9e-09 0.0208 -0.56 -0.45 Schizophrenia; chr5:50303674 chr1:121519112~121571892:+ PAAD trans rs7312770 0.637 rs705700 ENSG00000223416.3 RPS26P15 6.21 4.95e-09 0.021 0.53 0.45 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr1:58056133~58056480:- PAAD trans rs7192380 0.639 rs7186296 ENSG00000257513.6 NPIPB1P -6.21 4.95e-09 0.021 -0.56 -0.45 Sjögren's syndrome; chr16:69775095 chr18:11619509~11639699:- PAAD trans rs13190036 0.892 rs71601339 ENSG00000226986.4 RP11-543B16.2 -6.2 4.97e-09 0.0211 -0.71 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117495 chr1:211207239~211207897:+ PAAD trans rs11098499 1 rs1011054 ENSG00000275858.1 RP11-291L22.8 -6.2 5e-09 0.0212 -0.57 -0.45 Corneal astigmatism; chr4:119281232 chr10:38450738~38451069:- PAAD trans rs6708331 1 rs10195155 ENSG00000232654.1 FAM136BP 6.2 5e-09 0.0212 0.56 0.45 Obesity-related traits; chr2:70127343 chr6:3045384~3045800:+ PAAD trans rs2060793 1 rs1993116 ENSG00000236360.2 RP11-334A14.2 6.2 5.01e-09 0.0213 0.6 0.45 Vitamin D levels; chr11:14888688 chr1:52993201~52993702:- PAAD trans rs7258465 0.931 rs34053595 ENSG00000267533.1 RP11-815J4.7 6.2 5.03e-09 0.0213 0.56 0.45 Breast cancer; chr19:18445939 chr18:12067173~12068417:- PAAD trans rs10242455 0.85 rs3779354 ENSG00000228834.1 RP11-249L21.4 6.2 5.07e-09 0.0215 0.95 0.45 Blood metabolite levels; chr7:99454805 chr6:108907615~108907873:- PAAD trans rs11098499 0.78 rs12504773 ENSG00000275858.1 RP11-291L22.8 6.2 5.08e-09 0.0215 0.58 0.45 Corneal astigmatism; chr4:119640994 chr10:38450738~38451069:- PAAD trans rs11098499 0.78 rs7680914 ENSG00000275858.1 RP11-291L22.8 6.2 5.08e-09 0.0215 0.58 0.45 Corneal astigmatism; chr4:119641898 chr10:38450738~38451069:- PAAD trans rs7937890 0.559 rs4369365 ENSG00000236360.2 RP11-334A14.2 6.2 5.11e-09 0.0216 0.6 0.45 Mitochondrial DNA levels; chr11:14422969 chr1:52993201~52993702:- PAAD trans rs1814175 0.647 rs10839394 ENSG00000134612.10 FOLH1B -6.2 5.2e-09 0.022 -0.51 -0.45 Height; chr11:49823195 chr11:89639227~89698718:+ PAAD trans rs10198124 0.564 rs12712423 ENSG00000212802.4 RPL15P3 6.2 5.21e-09 0.022 0.54 0.45 Parental lifespan; chr2:35224975 chr6:12514110~12514724:+ PAAD trans rs7399018 1 rs7399018 ENSG00000223825.5 DAZAP2P1 -6.19 5.28e-09 0.0223 -0.63 -0.45 Cisplatin-induced ototoxicity; chr12:51216581 chr2:202201384~202201886:- PAAD trans rs11098499 1 rs10029750 ENSG00000275858.1 RP11-291L22.8 6.19 5.29e-09 0.0223 0.56 0.45 Corneal astigmatism; chr4:119251388 chr10:38450738~38451069:- PAAD trans rs11098499 1 rs6837898 ENSG00000275858.1 RP11-291L22.8 6.19 5.29e-09 0.0223 0.56 0.45 Corneal astigmatism; chr4:119257999 chr10:38450738~38451069:- PAAD trans rs11098499 1 rs28374891 ENSG00000275858.1 RP11-291L22.8 6.19 5.29e-09 0.0223 0.56 0.45 Corneal astigmatism; chr4:119262395 chr10:38450738~38451069:- PAAD trans rs7811142 0.83 rs6945952 ENSG00000228546.2 CTA-313A17.3 6.19 5.29e-09 0.0223 0.67 0.45 Platelet count; chr7:100384152 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs73401450 ENSG00000228546.2 CTA-313A17.3 6.19 5.29e-09 0.0223 0.67 0.45 Platelet count; chr7:100384236 chr7:102337316~102339115:+ PAAD trans rs7811142 0.83 rs73401451 ENSG00000228546.2 CTA-313A17.3 6.19 5.29e-09 0.0223 0.67 0.45 Platelet count; chr7:100384272 chr7:102337316~102339115:+ PAAD trans rs11098499 0.863 rs2306457 ENSG00000275858.1 RP11-291L22.8 6.19 5.32e-09 0.0224 0.61 0.45 Corneal astigmatism; chr4:119551684 chr10:38450738~38451069:- PAAD trans rs11023332 0.706 rs10766197 ENSG00000236360.2 RP11-334A14.2 6.19 5.4e-09 0.0227 0.57 0.45 Vitamin D levels;Adiponectin levels; chr11:14900334 chr1:52993201~52993702:- PAAD trans rs12709013 0.875 rs9924389 ENSG00000230849.2 GOT2P2 6.19 5.43e-09 0.0228 0.51 0.45 Blood metabolite ratios; chr16:58779849 chr1:173141100~173142350:- PAAD trans rs12709013 1 rs12599931 ENSG00000230849.2 GOT2P2 6.19 5.43e-09 0.0228 0.51 0.45 Blood metabolite ratios; chr16:58792627 chr1:173141100~173142350:- PAAD trans rs12709013 1 rs12709013 ENSG00000230849.2 GOT2P2 -6.19 5.43e-09 0.0228 -0.51 -0.45 Blood metabolite ratios; chr16:58795886 chr1:173141100~173142350:- PAAD trans rs76228276 0.609 rs117561980 ENSG00000260318.1 COX6CP1 6.19 5.44e-09 0.0229 1.17 0.45 Childhood ear infection; chr8:99910537 chr16:11903923~11904137:- PAAD trans rs12709013 0.636 rs1646256 ENSG00000233719.3 GOT2P3 6.19 5.45e-09 0.023 0.57 0.45 Blood metabolite ratios; chr16:58712114 chr12:9641802~9643007:+ PAAD trans rs7937890 0.505 rs4403769 ENSG00000236360.2 RP11-334A14.2 6.19 5.48e-09 0.023 0.59 0.45 Mitochondrial DNA levels; chr11:14428630 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575853 ENSG00000236360.2 RP11-334A14.2 6.18 5.52e-09 0.0232 0.59 0.45 Mitochondrial DNA levels; chr11:14512417 chr1:52993201~52993702:- PAAD trans rs11195620 0.591 rs2900932 ENSG00000279419.1 RP5-907C10.3 6.18 5.55e-09 0.0233 0.61 0.45 Inhibitory control; chr10:111482434 chr7:124742312~124745017:- PAAD trans rs10940346 1 rs10940359 ENSG00000231752.4 EMBP1 -6.18 5.58e-09 0.0234 -0.56 -0.45 Schizophrenia; chr5:50538645 chr1:121519112~121571892:+ PAAD trans rs13190036 1 rs13167431 ENSG00000228305.2 AC016734.2 -6.18 5.58e-09 0.0234 -0.78 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177194074 chr2:63622178~63622831:- PAAD trans rs13190036 1 rs35535623 ENSG00000228305.2 AC016734.2 -6.18 5.58e-09 0.0234 -0.78 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177202295 chr2:63622178~63622831:- PAAD trans rs9527419 0.512 rs11843439 ENSG00000223820.5 CFL1P1 6.18 5.62e-09 0.0235 0.63 0.45 Response to platinum-based chemotherapy (cisplatin); chr13:55525875 chr10:87817928~87845612:+ PAAD trans rs11250097 0.506 rs13281992 ENSG00000253893.2 FAM85B 6.18 5.62e-09 0.0235 0.69 0.45 Neuroticism; chr8:11451785 chr8:8167819~8226614:- PAAD trans rs2882926 0.764 rs10957238 ENSG00000231246.1 RP5-965F6.2 6.18 5.64e-09 0.0236 0.64 0.45 Periodontitis (PAL4Q3); chr8:62779703 chr1:112177234~112360528:- PAAD trans rs2882926 0.764 rs1600540 ENSG00000231246.1 RP5-965F6.2 6.18 5.64e-09 0.0236 0.64 0.45 Periodontitis (PAL4Q3); chr8:62780272 chr1:112177234~112360528:- PAAD trans rs5751901 0.929 rs2330805 ENSG00000280208.1 RP11-341D18.4 6.18 5.64e-09 0.0236 0.61 0.45 Protein quantitative trait loci; chr22:24602652 chr13:18253526~18270822:- PAAD trans rs7811142 0.83 rs7792525 ENSG00000228546.2 CTA-313A17.3 6.18 5.64e-09 0.0236 0.67 0.45 Platelet count; chr7:100374499 chr7:102337316~102339115:+ PAAD trans rs453301 0.624 rs330049 ENSG00000253893.2 FAM85B -6.18 5.65e-09 0.0236 -0.62 -0.45 Joint mobility (Beighton score); chr8:9229789 chr8:8167819~8226614:- PAAD trans rs9650657 0.504 rs6986032 ENSG00000253893.2 FAM85B 6.18 5.66e-09 0.0237 0.63 0.45 Neuroticism; chr8:11174731 chr8:8167819~8226614:- PAAD trans rs13148252 0.915 rs17440746 ENSG00000249047.2 COX6B1P5 -6.18 5.67e-09 0.0237 -0.51 -0.45 IgG glycosylation; chr4:110292451 chr4:2234251~2234499:+ PAAD trans rs724950 1 rs1961494 ENSG00000259565.2 KRT8P23 6.18 5.69e-09 0.0238 0.55 0.45 Obesity-related traits; chr4:127421139 chr15:76979245~76980451:- PAAD trans rs2562152 0.654 rs216600 ENSG00000265178.1 MIR4728 6.18 5.72e-09 0.0239 0.62 0.45 Glioblastoma; chr16:60167 chr17:39726495~39726561:+ PAAD trans rs2562152 0.53 rs216604 ENSG00000265178.1 MIR4728 6.18 5.72e-09 0.0239 0.62 0.45 Glioblastoma; chr16:62515 chr17:39726495~39726561:+ PAAD trans rs724950 0.935 rs10434048 ENSG00000259565.2 KRT8P23 6.18 5.76e-09 0.0241 0.55 0.45 Obesity-related traits; chr4:127424503 chr15:76979245~76980451:- PAAD trans rs2727020 0.656 rs7925524 ENSG00000134612.10 FOLH1B -6.17 5.8e-09 0.0242 -0.54 -0.45 Coronary artery disease; chr11:49415990 chr11:89639227~89698718:+ PAAD trans rs11098499 0.955 rs56386062 ENSG00000275858.1 RP11-291L22.8 6.17 5.84e-09 0.0243 0.56 0.45 Corneal astigmatism; chr4:119233980 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs4145951 ENSG00000275858.1 RP11-291L22.8 6.17 5.84e-09 0.0243 0.56 0.45 Corneal astigmatism; chr4:119234662 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs35916640 ENSG00000275858.1 RP11-291L22.8 6.17 5.84e-09 0.0243 0.56 0.45 Corneal astigmatism; chr4:119234697 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs13113112 ENSG00000275858.1 RP11-291L22.8 6.17 5.84e-09 0.0243 0.56 0.45 Corneal astigmatism; chr4:119234885 chr10:38450738~38451069:- PAAD trans rs11098499 0.955 rs13114751 ENSG00000275858.1 RP11-291L22.8 6.17 5.84e-09 0.0243 0.56 0.45 Corneal astigmatism; chr4:119235462 chr10:38450738~38451069:- PAAD trans rs11098499 0.913 rs35271032 ENSG00000275858.1 RP11-291L22.8 6.17 5.84e-09 0.0243 0.56 0.45 Corneal astigmatism; chr4:119235504 chr10:38450738~38451069:- PAAD trans rs7180079 0.62 rs2593698 ENSG00000215246.5 RP11-43F13.3 -6.17 5.85e-09 0.0244 -0.66 -0.45 Monocyte count; chr15:64617804 chr5:987180~997308:- PAAD trans rs7258465 1 rs4808801 ENSG00000267533.1 RP11-815J4.7 6.17 5.86e-09 0.0244 0.54 0.45 Breast cancer; chr19:18460331 chr18:12067173~12068417:- PAAD trans rs7811142 0.83 rs6948685 ENSG00000228546.2 CTA-313A17.3 6.17 5.88e-09 0.0245 0.67 0.45 Platelet count; chr7:100372565 chr7:102337316~102339115:+ PAAD trans rs7819412 0.635 rs2409716 ENSG00000234498.3 RPL13AP20 -6.17 5.9e-09 0.0246 -0.5 -0.45 Triglycerides; chr8:11153238 chr12:12875499~12876107:+ PAAD trans rs10838798 0.563 rs4752894 ENSG00000134612.10 FOLH1B -6.17 5.91e-09 0.0246 -0.53 -0.45 Height; chr11:48099384 chr11:89639227~89698718:+ PAAD trans rs10838798 0.584 rs17198859 ENSG00000134612.10 FOLH1B -6.17 5.91e-09 0.0246 -0.53 -0.45 Height; chr11:48118802 chr11:89639227~89698718:+ PAAD trans rs10838798 0.584 rs4752899 ENSG00000134612.10 FOLH1B -6.17 5.91e-09 0.0246 -0.53 -0.45 Height; chr11:48120303 chr11:89639227~89698718:+ PAAD trans rs10838798 0.563 rs4752902 ENSG00000134612.10 FOLH1B -6.17 5.91e-09 0.0246 -0.53 -0.45 Height; chr11:48127227 chr11:89639227~89698718:+ PAAD trans rs10838798 0.584 rs1566732 ENSG00000134612.10 FOLH1B 6.17 5.91e-09 0.0246 0.53 0.45 Height; chr11:48129942 chr11:89639227~89698718:+ PAAD trans rs7312770 0.612 rs1873914 ENSG00000243403.1 RP11-330L19.1 6.17 5.93e-09 0.0247 0.49 0.45 Polycystic ovary syndrome;Hypothyroidism; chr12:55985643 chr15:64592979~64593326:+ PAAD trans rs7937890 0.561 rs2575849 ENSG00000236360.2 RP11-334A14.2 6.17 5.93e-09 0.0247 0.59 0.45 Mitochondrial DNA levels; chr11:14518093 chr1:52993201~52993702:- PAAD trans rs9650657 0.589 rs6985109 ENSG00000253893.2 FAM85B -6.17 5.97e-09 0.0248 -0.6 -0.45 Neuroticism; chr8:10904075 chr8:8167819~8226614:- PAAD trans rs76228276 0.737 rs74664758 ENSG00000260318.1 COX6CP1 6.17 6e-09 0.0249 1.18 0.45 Childhood ear infection; chr8:99815292 chr16:11903923~11904137:- PAAD trans rs76228276 0.737 rs75297924 ENSG00000260318.1 COX6CP1 6.17 6e-09 0.0249 1.18 0.45 Childhood ear infection; chr8:99819280 chr16:11903923~11904137:- PAAD trans rs2882926 0.764 rs1480127 ENSG00000231246.1 RP5-965F6.2 -6.17 6.01e-09 0.025 -0.63 -0.45 Periodontitis (PAL4Q3); chr8:62746444 chr1:112177234~112360528:- PAAD trans rs2882926 0.688 rs13259878 ENSG00000231246.1 RP5-965F6.2 6.17 6.01e-09 0.025 0.63 0.45 Periodontitis (PAL4Q3); chr8:62810030 chr1:112177234~112360528:- PAAD trans rs2882926 0.688 rs7464426 ENSG00000231246.1 RP5-965F6.2 6.17 6.01e-09 0.025 0.63 0.45 Periodontitis (PAL4Q3); chr8:62810221 chr1:112177234~112360528:- PAAD trans rs2882926 0.688 rs9650208 ENSG00000231246.1 RP5-965F6.2 6.17 6.01e-09 0.025 0.63 0.45 Periodontitis (PAL4Q3); chr8:62814249 chr1:112177234~112360528:- PAAD trans rs2882926 0.609 rs1351349 ENSG00000231246.1 RP5-965F6.2 6.17 6.01e-09 0.025 0.63 0.45 Periodontitis (PAL4Q3); chr8:62818189 chr1:112177234~112360528:- PAAD trans rs10028773 0.632 rs34481394 ENSG00000275858.1 RP11-291L22.8 6.16 6.09e-09 0.0253 0.55 0.45 Educational attainment; chr4:119327219 chr10:38450738~38451069:- PAAD trans rs10028773 0.666 rs35231872 ENSG00000275858.1 RP11-291L22.8 6.16 6.09e-09 0.0253 0.55 0.45 Educational attainment; chr4:119327221 chr10:38450738~38451069:- PAAD trans rs10028773 0.7 rs35653026 ENSG00000275858.1 RP11-291L22.8 6.16 6.09e-09 0.0253 0.55 0.45 Educational attainment; chr4:119327223 chr10:38450738~38451069:- PAAD trans rs7811142 0.943 rs11769886 ENSG00000228546.2 CTA-313A17.3 6.16 6.12e-09 0.0254 0.67 0.45 Platelet count; chr7:100400984 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs7803454 ENSG00000228546.2 CTA-313A17.3 6.16 6.12e-09 0.0254 0.67 0.45 Platelet count; chr7:100393925 chr7:102337316~102339115:+ PAAD trans rs76419734 0.85 rs17036142 ENSG00000213049.3 HNRNPA1P34 -6.16 6.23e-09 0.0258 -0.88 -0.45 Post bronchodilator FEV1; chr4:105713579 chr12:9027532~9029089:- PAAD trans rs13190036 0.901 rs55741473 ENSG00000228305.2 AC016734.2 -6.16 6.24e-09 0.0259 -0.78 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177147218 chr2:63622178~63622831:- PAAD trans rs13190036 1 rs13157667 ENSG00000228305.2 AC016734.2 -6.16 6.24e-09 0.0259 -0.78 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177186876 chr2:63622178~63622831:- PAAD trans rs864643 0.678 rs1708089 ENSG00000183298.5 RP11-556K13.1 6.16 6.27e-09 0.026 0.66 0.45 Attention deficit hyperactivity disorder; chr3:39470371 chr1:101786340~101787219:- PAAD trans rs10838798 0.563 rs2870080 ENSG00000134612.10 FOLH1B -6.16 6.27e-09 0.026 -0.53 -0.45 Height; chr11:48122672 chr11:89639227~89698718:+ PAAD trans rs7312770 0.637 rs705700 ENSG00000243403.1 RP11-330L19.1 6.16 6.31e-09 0.0261 0.49 0.45 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr15:64592979~64593326:+ PAAD trans rs2727020 0.538 rs11040373 ENSG00000134612.10 FOLH1B -6.16 6.34e-09 0.0263 -0.53 -0.45 Coronary artery disease; chr11:49440239 chr11:89639227~89698718:+ PAAD trans rs2727020 0.521 rs11040377 ENSG00000134612.10 FOLH1B -6.16 6.34e-09 0.0263 -0.53 -0.45 Coronary artery disease; chr11:49452794 chr11:89639227~89698718:+ PAAD trans rs9329221 0.543 rs2952205 ENSG00000253893.2 FAM85B -6.16 6.35e-09 0.0263 -0.62 -0.45 Neuroticism; chr8:10282355 chr8:8167819~8226614:- PAAD trans rs6732160 1 rs6732160 ENSG00000236165.1 PRADC1P1 6.16 6.36e-09 0.0263 0.52 0.45 Intelligence (multi-trait analysis); chr2:73160100 chr3:36976316~36976840:+ PAAD trans rs7811142 0.943 rs10241492 ENSG00000228546.2 CTA-313A17.3 6.16 6.37e-09 0.0263 0.65 0.45 Platelet count; chr7:100397190 chr7:102337316~102339115:+ PAAD trans rs3779195 0.52 rs17169479 ENSG00000225169.1 BRI3P1 6.15 6.43e-09 0.0266 0.78 0.45 Sex hormone-binding globulin levels; chr7:98238721 chr1:100213293~100213670:+ PAAD trans rs10037055 0.898 rs4976636 ENSG00000226986.4 RP11-543B16.2 -6.15 6.49e-09 0.0268 -0.59 -0.45 Migraine without aura; chr5:177118091 chr1:211207239~211207897:+ PAAD trans rs10037055 0.898 rs4976637 ENSG00000226986.4 RP11-543B16.2 -6.15 6.49e-09 0.0268 -0.59 -0.45 Migraine without aura; chr5:177118141 chr1:211207239~211207897:+ PAAD trans rs7819412 0.805 rs2409710 ENSG00000253893.2 FAM85B 6.15 6.51e-09 0.0269 0.62 0.45 Triglycerides; chr8:11122311 chr8:8167819~8226614:- PAAD trans rs2882926 0.686 rs1480125 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62744795 chr1:112177234~112360528:- PAAD trans rs2882926 0.764 rs3943272 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62758546 chr1:112177234~112360528:- PAAD trans rs2882926 0.764 rs1383159 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62759598 chr1:112177234~112360528:- PAAD trans rs2882926 0.764 rs1351352 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62761478 chr1:112177234~112360528:- PAAD trans rs2882926 0.686 rs10089763 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62774828 chr1:112177234~112360528:- PAAD trans rs2882926 0.686 rs1585873 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62777250 chr1:112177234~112360528:- PAAD trans rs2882926 0.534 rs9632832 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62812091 chr1:112177234~112360528:- PAAD trans rs2882926 0.688 rs978969 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62812804 chr1:112177234~112360528:- PAAD trans rs2882926 0.688 rs978396 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62816846 chr1:112177234~112360528:- PAAD trans rs2882926 0.688 rs1351348 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62818326 chr1:112177234~112360528:- PAAD trans rs2882926 0.688 rs2199835 ENSG00000231246.1 RP5-965F6.2 6.15 6.53e-09 0.0269 0.63 0.45 Periodontitis (PAL4Q3); chr8:62823810 chr1:112177234~112360528:- PAAD trans rs2882926 0.688 rs1871571 ENSG00000231246.1 RP5-965F6.2 -6.15 6.53e-09 0.0269 -0.63 -0.45 Periodontitis (PAL4Q3); chr8:62824782 chr1:112177234~112360528:- PAAD trans rs6601450 0.522 rs10095190 ENSG00000253893.2 FAM85B -6.15 6.55e-09 0.027 -0.61 -0.45 Eosinophil percentage of white cells;Eosinophil percentage of granulocytes; chr8:10382102 chr8:8167819~8226614:- PAAD trans rs740160 0.558 rs17161662 ENSG00000228834.1 RP11-249L21.4 6.15 6.6e-09 0.0272 1 0.45 Dehydroepiandrosterone sulphate levels; chr7:99309773 chr6:108907615~108907873:- PAAD trans rs740160 0.558 rs12538893 ENSG00000228834.1 RP11-249L21.4 6.15 6.6e-09 0.0272 1 0.45 Dehydroepiandrosterone sulphate levels; chr7:99310874 chr6:108907615~108907873:- PAAD trans rs740160 0.558 rs17161669 ENSG00000228834.1 RP11-249L21.4 6.15 6.6e-09 0.0272 1 0.45 Dehydroepiandrosterone sulphate levels; chr7:99311040 chr6:108907615~108907873:- PAAD trans rs7819412 0.805 rs4333549 ENSG00000253893.2 FAM85B 6.15 6.65e-09 0.0274 0.62 0.45 Triglycerides; chr8:11122051 chr8:8167819~8226614:- PAAD trans rs3779195 1 rs3779195 ENSG00000225169.1 BRI3P1 -6.15 6.67e-09 0.0274 -0.71 -0.45 Sex hormone-binding globulin levels; chr7:98364050 chr1:100213293~100213670:+ PAAD trans rs6703335 0.87 rs10803142 ENSG00000218426.5 RP11-475C16.1 6.15 6.68e-09 0.0275 0.42 0.45 Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder; chr1:243434932 chr6:153282287~153282733:- PAAD trans rs11195620 0.606 rs11195615 ENSG00000279419.1 RP5-907C10.3 6.14 6.71e-09 0.0276 0.6 0.45 Inhibitory control; chr10:111513093 chr7:124742312~124745017:- PAAD trans rs13190036 1 rs351862 ENSG00000226986.4 RP11-543B16.2 -6.14 6.73e-09 0.0277 -0.69 -0.45 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177114369 chr1:211207239~211207897:+ PAAD trans rs10940346 1 rs4865674 ENSG00000231752.4 EMBP1 -6.14 6.84e-09 0.0281 -0.55 -0.45 Schizophrenia; chr5:50277531 chr1:121519112~121571892:+ PAAD trans rs7824557 0.51 rs1435274 ENSG00000253893.2 FAM85B 6.14 6.88e-09 0.0282 0.62 0.45 Retinal vascular caliber; chr8:11378401 chr8:8167819~8226614:- PAAD trans rs6499255 0.951 rs16959025 ENSG00000257513.6 NPIPB1P -6.14 6.98e-09 0.0285 -0.67 -0.45 IgE levels; chr16:69661686 chr18:11619509~11639699:- PAAD trans rs2657294 0.931 rs2804522 ENSG00000172974.11 AC007318.5 6.14 7e-09 0.0286 0.55 0.45 Pneumonia; chr10:75159132 chr2:65205108~65205988:+ PAAD trans rs2657294 0.965 rs2047951 ENSG00000172974.11 AC007318.5 6.14 7e-09 0.0286 0.55 0.45 Pneumonia; chr10:75161310 chr2:65205108~65205988:+ PAAD trans rs2657294 0.965 rs2804523 ENSG00000172974.11 AC007318.5 6.14 7e-09 0.0286 0.55 0.45 Pneumonia; chr10:75161584 chr2:65205108~65205988:+ PAAD trans rs2657294 0.965 rs2657285 ENSG00000172974.11 AC007318.5 6.14 7e-09 0.0286 0.55 0.45 Pneumonia; chr10:75164166 chr2:65205108~65205988:+ PAAD trans rs11098499 0.863 rs6835635 ENSG00000275858.1 RP11-291L22.8 6.14 7.04e-09 0.0287 0.6 0.45 Corneal astigmatism; chr4:119537712 chr10:38450738~38451069:- PAAD trans rs2882926 0.688 rs1471509 ENSG00000231246.1 RP5-965F6.2 6.13 7.06e-09 0.0288 0.63 0.45 Periodontitis (PAL4Q3); chr8:62794388 chr1:112177234~112360528:- PAAD trans rs9956878 0.555 rs8085188 ENSG00000218426.5 RP11-475C16.1 -6.13 7.07e-09 0.0289 -0.47 -0.45 Obesity-related traits; chr18:75832721 chr6:153282287~153282733:- PAAD trans rs9611565 0.506 rs2024566 ENSG00000268568.1 AC007228.9 -6.13 7.11e-09 0.029 -0.59 -0.45 Vitiligo; chr22:41301334 chr19:56672574~56673901:- PAAD trans rs60338266 0.898 rs4709610 ENSG00000272750.1 RP11-378J18.8 6.13 7.12e-09 0.029 0.44 0.45 Post bronchodilator FEV1/FVC ratio; chr6:162448009 chr1:222658867~222661512:- PAAD trans rs12709013 0.935 rs34657766 ENSG00000230849.2 GOT2P2 6.13 7.16e-09 0.0292 0.5 0.45 Blood metabolite ratios; chr16:58779468 chr1:173141100~173142350:- PAAD trans rs12709013 0.729 rs71400031 ENSG00000230849.2 GOT2P2 6.13 7.16e-09 0.0292 0.5 0.45 Blood metabolite ratios; chr16:58779554 chr1:173141100~173142350:- PAAD trans rs12709013 1 rs34319345 ENSG00000230849.2 GOT2P2 6.13 7.16e-09 0.0292 0.5 0.45 Blood metabolite ratios; chr16:58786688 chr1:173141100~173142350:- PAAD trans rs12709013 1 rs12926993 ENSG00000230849.2 GOT2P2 6.13 7.16e-09 0.0292 0.5 0.45 Blood metabolite ratios; chr16:58789218 chr1:173141100~173142350:- PAAD trans rs12364992 0.609 rs10890563 ENSG00000224945.1 RP11-82L18.2 -6.13 7.18e-09 0.0292 -0.89 -0.45 Obesity-related traits; chr11:106675610 chr9:89088604~89109934:- PAAD trans rs2657294 0.965 rs7899946 ENSG00000172974.11 AC007318.5 6.13 7.23e-09 0.0295 0.55 0.45 Pneumonia; chr10:75166013 chr2:65205108~65205988:+ PAAD trans rs2657294 0.965 rs4746270 ENSG00000172974.11 AC007318.5 6.13 7.23e-09 0.0295 0.55 0.45 Pneumonia; chr10:75185189 chr2:65205108~65205988:+ PAAD trans rs6732160 0.932 rs768851 ENSG00000236165.1 PRADC1P1 6.13 7.28e-09 0.0296 0.52 0.45 Intelligence (multi-trait analysis); chr2:73151113 chr3:36976316~36976840:+ PAAD trans rs6732160 0.934 rs2421390 ENSG00000236165.1 PRADC1P1 6.13 7.28e-09 0.0296 0.52 0.45 Intelligence (multi-trait analysis); chr2:73151975 chr3:36976316~36976840:+ PAAD trans rs6732160 0.932 rs6546802 ENSG00000236165.1 PRADC1P1 6.13 7.28e-09 0.0296 0.52 0.45 Intelligence (multi-trait analysis); chr2:73152436 chr3:36976316~36976840:+ PAAD trans rs6732160 0.932 rs13417029 ENSG00000236165.1 PRADC1P1 6.13 7.28e-09 0.0296 0.52 0.45 Intelligence (multi-trait analysis); chr2:73153295 chr3:36976316~36976840:+ PAAD trans rs6732160 0.932 rs6546803 ENSG00000236165.1 PRADC1P1 6.13 7.28e-09 0.0296 0.52 0.45 Intelligence (multi-trait analysis); chr2:73154187 chr3:36976316~36976840:+ PAAD trans rs61931739 0.613 rs1817500 ENSG00000226564.1 FTH1P20 -6.13 7.29e-09 0.0296 -0.45 -0.45 Morning vs. evening chronotype; chr12:33526874 chr2:180872867~180873414:- PAAD trans rs11023332 0.706 rs11023380 ENSG00000236360.2 RP11-334A14.2 6.13 7.29e-09 0.0296 0.56 0.45 Vitamin D levels;Adiponectin levels; chr11:14908512 chr1:52993201~52993702:- PAAD trans rs11023332 0.8 rs12271890 ENSG00000236360.2 RP11-334A14.2 6.13 7.29e-09 0.0296 0.56 0.45 Vitamin D levels;Adiponectin levels; chr11:14913140 chr1:52993201~52993702:- PAAD trans rs2657294 0.62 rs4746261 ENSG00000172974.11 AC007318.5 -6.13 7.36e-09 0.0299 -0.51 -0.45 Pneumonia; chr10:75085874 chr2:65205108~65205988:+ PAAD trans rs11098499 0.954 rs6847248 ENSG00000275858.1 RP11-291L22.8 6.13 7.39e-09 0.03 0.58 0.44 Corneal astigmatism; chr4:119304800 chr10:38450738~38451069:- PAAD trans rs3942852 0.568 rs2904315 ENSG00000134612.10 FOLH1B 6.12 7.47e-09 0.0303 0.57 0.44 Acute lymphoblastic leukemia (childhood); chr11:48088396 chr11:89639227~89698718:+ PAAD trans rs3942852 0.545 rs10838798 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48069751 chr11:89639227~89698718:+ PAAD trans rs3942852 0.545 rs7395231 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48070137 chr11:89639227~89698718:+ PAAD trans rs3942852 0.594 rs10769311 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48072457 chr11:89639227~89698718:+ PAAD trans rs3942852 0.568 rs10838800 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48073327 chr11:89639227~89698718:+ PAAD trans rs3942852 0.568 rs10769313 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48075914 chr11:89639227~89698718:+ PAAD trans rs3942852 0.568 rs10769314 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48076068 chr11:89639227~89698718:+ PAAD trans rs3942852 0.568 rs1039484 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48076396 chr11:89639227~89698718:+ PAAD trans rs3942852 0.568 rs4412719 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48080108 chr11:89639227~89698718:+ PAAD trans rs3942852 0.568 rs6485807 ENSG00000134612.10 FOLH1B -6.12 7.47e-09 0.0303 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48081315 chr11:89639227~89698718:+ PAAD trans rs11098499 0.955 rs7685268 ENSG00000275858.1 RP11-291L22.8 6.12 7.48e-09 0.0304 0.55 0.44 Corneal astigmatism; chr4:119241033 chr10:38450738~38451069:- PAAD trans rs7811142 1 rs60257855 ENSG00000228546.2 CTA-313A17.3 6.12 7.51e-09 0.0305 0.65 0.44 Platelet count; chr7:100429157 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11771241 ENSG00000228546.2 CTA-313A17.3 6.12 7.55e-09 0.0306 0.65 0.44 Platelet count; chr7:100397162 chr7:102337316~102339115:+ PAAD trans rs11099942 1 rs9685607 ENSG00000252361.1 RNU6-118P -6.12 7.56e-09 0.0306 -0.92 -0.44 Type 2 diabetes (age of onset); chr4:154189855 chr11:62815966~62816067:- PAAD trans rs864643 0.678 rs500507 ENSG00000183298.5 RP11-556K13.1 6.12 7.56e-09 0.0306 0.68 0.44 Attention deficit hyperactivity disorder; chr3:39492886 chr1:101786340~101787219:- PAAD trans rs12709013 0.694 rs1616798 ENSG00000233719.3 GOT2P3 6.12 7.58e-09 0.0307 0.5 0.44 Blood metabolite ratios; chr16:58739433 chr12:9641802~9643007:+ PAAD trans rs1814175 0.817 rs12290508 ENSG00000134612.10 FOLH1B -6.12 7.58e-09 0.0307 -0.5 -0.44 Height; chr11:49599485 chr11:89639227~89698718:+ PAAD trans rs11098499 1 rs3749591 ENSG00000275858.1 RP11-291L22.8 6.12 7.6e-09 0.0307 0.56 0.44 Corneal astigmatism; chr4:119292875 chr10:38450738~38451069:- PAAD trans rs7937890 0.559 rs2575836 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14476318 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575837 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14476455 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575838 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14476675 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2167160 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14485903 chr1:52993201~52993702:- PAAD trans rs7937890 0.531 rs2575859 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14489190 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597188 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14495360 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597187 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14495473 chr1:52993201~52993702:- PAAD trans rs7937890 0.504 rs2575822 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14498305 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575823 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14499808 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597221 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14505529 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs6486197 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14508328 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597219 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14509320 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2597217 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14511337 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs2575852 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14511822 chr1:52993201~52993702:- PAAD trans rs7937890 0.531 rs2597216 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14512370 chr1:52993201~52993702:- PAAD trans rs7937890 0.559 rs1548074 ENSG00000236360.2 RP11-334A14.2 6.12 7.61e-09 0.0308 0.59 0.44 Mitochondrial DNA levels; chr11:14513279 chr1:52993201~52993702:- PAAD trans rs3779195 0.591 rs77968419 ENSG00000225169.1 BRI3P1 -6.12 7.65e-09 0.0309 -0.78 -0.44 Sex hormone-binding globulin levels; chr7:98237168 chr1:100213293~100213670:+ PAAD trans rs9611519 0.78 rs5751072 ENSG00000268568.1 AC007228.9 -6.12 7.65e-09 0.0309 -0.58 -0.44 Neuroticism; chr22:41260505 chr19:56672574~56673901:- PAAD trans rs17158483 0.698 rs4722966 ENSG00000279652.1 RP1-78B3.1 -6.12 7.65e-09 0.0309 -1.14 -0.44 Obesity-related traits; chr7:30020988 chr22:35992321~36000469:+ PAAD trans rs1814175 0.817 rs2866545 ENSG00000134612.10 FOLH1B -6.12 7.66e-09 0.0309 -0.5 -0.44 Height; chr11:49609272 chr11:89639227~89698718:+ PAAD trans rs2997457 0.872 rs2245979 ENSG00000202000.1 RNU1-36P -6.12 7.69e-09 0.031 -0.72 -0.44 Facial morphology (factor 16); chr1:25988073 chr4:88000237~88000401:+ PAAD trans rs7937890 0.507 rs4463820 ENSG00000236360.2 RP11-334A14.2 6.12 7.77e-09 0.0313 0.59 0.44 Mitochondrial DNA levels; chr11:14534796 chr1:52993201~52993702:- PAAD trans rs9611565 0.506 rs2024567 ENSG00000268568.1 AC007228.9 -6.11 7.9e-09 0.0318 -0.59 -0.44 Vitiligo; chr22:41303202 chr19:56672574~56673901:- PAAD trans rs13190036 1 rs351862 ENSG00000228305.2 AC016734.2 -6.11 7.93e-09 0.0319 -0.77 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177114369 chr2:63622178~63622831:- PAAD trans rs10908521 0.611 rs7516736 ENSG00000227183.3 HDGFP1 -6.11 7.94e-09 0.0319 -0.61 -0.44 Uric acid clearance; chr1:156825994 chrX:131646639~131646890:+ PAAD trans rs1814175 0.817 rs7924619 ENSG00000134612.10 FOLH1B -6.11 7.94e-09 0.0319 -0.5 -0.44 Height; chr11:49599080 chr11:89639227~89698718:+ PAAD trans rs1814175 0.754 rs10219245 ENSG00000134612.10 FOLH1B -6.11 7.94e-09 0.0319 -0.5 -0.44 Height; chr11:49623500 chr11:89639227~89698718:+ PAAD trans rs1814175 0.817 rs10839318 ENSG00000134612.10 FOLH1B -6.11 7.94e-09 0.0319 -0.5 -0.44 Height; chr11:49635959 chr11:89639227~89698718:+ PAAD trans rs1814175 0.817 rs10769598 ENSG00000134612.10 FOLH1B -6.11 7.94e-09 0.0319 -0.5 -0.44 Height; chr11:49647774 chr11:89639227~89698718:+ PAAD trans rs10197862 0.518 rs13018263 ENSG00000170846.14 AC093323.3 -6.11 7.96e-09 0.032 -0.62 -0.44 Asthma and hay fever;Asthma; chr2:102475811 chr4:6673451~6676047:+ PAAD trans rs55665837 0.539 rs10500804 ENSG00000236360.2 RP11-334A14.2 6.11 7.98e-09 0.032 0.57 0.44 Vitamin D levels; chr11:14888727 chr1:52993201~52993702:- PAAD trans rs6732160 0.834 rs57456443 ENSG00000236165.1 PRADC1P1 6.11 7.99e-09 0.0321 0.52 0.44 Intelligence (multi-trait analysis); chr2:73139313 chr3:36976316~36976840:+ PAAD trans rs10940346 1 rs2016360 ENSG00000231752.4 EMBP1 -6.11 8.02e-09 0.0322 -0.56 -0.44 Schizophrenia; chr5:50491064 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs7378983 ENSG00000231752.4 EMBP1 -6.11 8.02e-09 0.0322 -0.56 -0.44 Schizophrenia; chr5:50491889 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs6450164 ENSG00000231752.4 EMBP1 -6.11 8.02e-09 0.0322 -0.56 -0.44 Schizophrenia; chr5:50502814 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs1962832 ENSG00000231752.4 EMBP1 -6.11 8.02e-09 0.0322 -0.56 -0.44 Schizophrenia; chr5:50502962 chr1:121519112~121571892:+ PAAD trans rs453301 0.624 rs330056 ENSG00000253893.2 FAM85B 6.11 8.07e-09 0.0324 0.61 0.44 Joint mobility (Beighton score); chr8:9232185 chr8:8167819~8226614:- PAAD trans rs453301 0.624 rs330058 ENSG00000253893.2 FAM85B 6.11 8.07e-09 0.0324 0.61 0.44 Joint mobility (Beighton score); chr8:9232299 chr8:8167819~8226614:- PAAD trans rs7180079 0.62 rs486330 ENSG00000215246.5 RP11-43F13.3 -6.1 8.22e-09 0.0329 -0.69 -0.44 Monocyte count; chr15:64511051 chr5:987180~997308:- PAAD trans rs7811142 1 rs67471932 ENSG00000228546.2 CTA-313A17.3 6.1 8.23e-09 0.0329 0.65 0.44 Platelet count; chr7:100412362 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs73161759 ENSG00000228546.2 CTA-313A17.3 6.1 8.23e-09 0.0329 0.65 0.44 Platelet count; chr7:100412371 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs67315960 ENSG00000228546.2 CTA-313A17.3 6.1 8.23e-09 0.0329 0.65 0.44 Platelet count; chr7:100417501 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11763414 ENSG00000228546.2 CTA-313A17.3 6.1 8.23e-09 0.0329 0.65 0.44 Platelet count; chr7:100419221 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs66632384 ENSG00000228546.2 CTA-313A17.3 6.1 8.23e-09 0.0329 0.65 0.44 Platelet count; chr7:100421281 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs67163493 ENSG00000228546.2 CTA-313A17.3 6.1 8.23e-09 0.0329 0.65 0.44 Platelet count; chr7:100426215 chr7:102337316~102339115:+ PAAD trans rs7811142 0.943 rs73403312 ENSG00000228546.2 CTA-313A17.3 6.1 8.23e-09 0.0329 0.65 0.44 Platelet count; chr7:100426530 chr7:102337316~102339115:+ PAAD trans rs2562152 0.706 rs216596 ENSG00000265178.1 MIR4728 6.1 8.31e-09 0.0333 0.58 0.44 Glioblastoma; chr16:55320 chr17:39726495~39726561:+ PAAD trans rs7312770 0.637 rs705700 ENSG00000234354.3 RPS26P47 6.1 8.33e-09 0.0333 0.55 0.44 Polycystic ovary syndrome;Hypothyroidism; chr12:55995509 chr13:100539901~100540248:- PAAD trans rs12709013 0.967 rs11643969 ENSG00000230849.2 GOT2P2 6.1 8.33e-09 0.0333 0.5 0.44 Blood metabolite ratios; chr16:58785354 chr1:173141100~173142350:- PAAD trans rs7937890 0.559 rs2597196 ENSG00000236360.2 RP11-334A14.2 -6.1 8.33e-09 0.0333 -0.59 -0.44 Mitochondrial DNA levels; chr11:14470055 chr1:52993201~52993702:- PAAD trans rs7258465 0.965 rs748609 ENSG00000267533.1 RP11-815J4.7 6.1 8.37e-09 0.0335 0.56 0.44 Breast cancer; chr19:18449472 chr18:12067173~12068417:- PAAD trans rs7312770 0.637 rs705699 ENSG00000212994.5 RPS26P6 6.1 8.53e-09 0.034 0.49 0.44 Polycystic ovary syndrome;Hypothyroidism; chr12:55991020 chr8:100895771~100896118:+ PAAD trans rs13190036 1 rs59737888 ENSG00000226986.4 RP11-543B16.2 -6.1 8.55e-09 0.0341 -0.7 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177160374 chr1:211207239~211207897:+ PAAD trans rs7811142 1 rs11771419 ENSG00000228546.2 CTA-313A17.3 6.1 8.57e-09 0.0342 0.65 0.44 Platelet count; chr7:100390780 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs76913697 ENSG00000228546.2 CTA-313A17.3 6.1 8.57e-09 0.0342 0.65 0.44 Platelet count; chr7:100405149 chr7:102337316~102339115:+ PAAD trans rs10940346 0.967 rs6449782 ENSG00000231752.4 EMBP1 -6.1 8.58e-09 0.0342 -0.56 -0.44 Schizophrenia; chr5:50291694 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs7721808 ENSG00000231752.4 EMBP1 6.1 8.58e-09 0.0342 0.56 0.44 Schizophrenia; chr5:50363136 chr1:121519112~121571892:+ PAAD trans rs2727020 0.681 rs2866362 ENSG00000134612.10 FOLH1B -6.1 8.59e-09 0.0342 -0.54 -0.44 Coronary artery disease; chr11:49357764 chr11:89639227~89698718:+ PAAD trans rs10838801 1 rs10838801 ENSG00000134612.10 FOLH1B -6.1 8.61e-09 0.0343 -0.56 -0.44 Height; chr11:48076728 chr11:89639227~89698718:+ PAAD trans rs10515750 0.588 rs10214194 ENSG00000229893.2 AC004549.6 -6.1 8.62e-09 0.0343 -0.61 -0.44 Lung function (FEV1/FVC); chr5:157343201 chr7:27733064~27740395:- PAAD trans rs10515750 0.588 rs10077326 ENSG00000229893.2 AC004549.6 -6.1 8.62e-09 0.0343 -0.61 -0.44 Lung function (FEV1/FVC); chr5:157343761 chr7:27733064~27740395:- PAAD trans rs10515750 0.588 rs10077470 ENSG00000229893.2 AC004549.6 -6.1 8.62e-09 0.0343 -0.61 -0.44 Lung function (FEV1/FVC); chr5:157343975 chr7:27733064~27740395:- PAAD trans rs237899 0.554 rs401015 ENSG00000234595.1 AC013733.3 -6.09 8.7e-09 0.0346 -0.5 -0.44 Depression and alcohol dependence; chr3:8772326 chr2:181683113~181685707:+ PAAD trans rs7819412 0.595 rs2409712 ENSG00000253893.2 FAM85B 6.09 8.73e-09 0.0348 0.61 0.44 Triglycerides; chr8:11129327 chr8:8167819~8226614:- PAAD trans rs1075265 0.933 rs918357 ENSG00000212802.4 RPL15P3 6.09 8.75e-09 0.0348 0.49 0.44 Chronotype;Morning vs. evening chronotype; chr2:54108826 chr6:12514110~12514724:+ PAAD trans rs616147 0.671 rs675595 ENSG00000183298.5 RP11-556K13.1 -6.09 8.75e-09 0.0348 -0.63 -0.44 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39458987 chr1:101786340~101787219:- PAAD trans rs9447004 0.789 rs6939653 ENSG00000230728.1 RP11-240D10.4 -6.09 8.79e-09 0.035 -0.54 -0.44 Calcium levels;Blood protein levels; chr6:73765047 chr1:54621477~54628438:- PAAD trans rs7819412 0.775 rs4840551 ENSG00000253893.2 FAM85B 6.09 8.8e-09 0.035 0.63 0.44 Triglycerides; chr8:11171530 chr8:8167819~8226614:- PAAD trans rs2727020 0.553 rs4103567 ENSG00000134612.10 FOLH1B -6.09 8.82e-09 0.0351 -0.51 -0.44 Coronary artery disease; chr11:49233837 chr11:89639227~89698718:+ PAAD trans rs9425766 0.679 rs7552939 ENSG00000213331.4 RP11-713C19.2 6.09 8.83e-09 0.0351 0.5 0.44 Life satisfaction; chr1:173798305 chr4:187970273~187971284:+ PAAD trans rs2657294 0.796 rs2804534 ENSG00000172974.11 AC007318.5 -6.09 8.87e-09 0.0352 -0.55 -0.44 Pneumonia; chr10:75208023 chr2:65205108~65205988:+ PAAD trans rs1618992 0.791 rs6508558 ENSG00000236530.2 AC097711.1 6.09 8.88e-09 0.0353 0.53 0.44 Gut microbiome composition (summer and winter); chr18:28648523 chr4:80079532~80081122:+ PAAD trans rs9650657 0.504 rs6601565 ENSG00000253893.2 FAM85B 6.09 8.9e-09 0.0353 0.62 0.44 Neuroticism; chr8:11174719 chr8:8167819~8226614:- PAAD trans rs12709013 0.792 rs1646270 ENSG00000233719.3 GOT2P3 6.09 8.92e-09 0.0354 0.49 0.44 Blood metabolite ratios; chr16:58745823 chr12:9641802~9643007:+ PAAD trans rs13253073 0.765 rs35615286 ENSG00000260318.1 COX6CP1 6.09 8.95e-09 0.0355 1.02 0.44 Glucose homeostasis traits; chr8:99834866 chr16:11903923~11904137:- PAAD trans rs6732160 0.967 rs6760964 ENSG00000236165.1 PRADC1P1 6.09 8.97e-09 0.0356 0.51 0.44 Intelligence (multi-trait analysis); chr2:73160258 chr3:36976316~36976840:+ PAAD trans rs60338266 0.898 rs9365436 ENSG00000272750.1 RP11-378J18.8 6.09 9.04e-09 0.0359 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162447699 chr1:222658867~222661512:- PAAD trans rs3942852 0.524 rs7118665 ENSG00000134612.10 FOLH1B 6.09 9.05e-09 0.0359 0.57 0.44 Acute lymphoblastic leukemia (childhood); chr11:48056875 chr11:89639227~89698718:+ PAAD trans rs3942852 0.568 rs7479361 ENSG00000134612.10 FOLH1B -6.09 9.05e-09 0.0359 -0.57 -0.44 Acute lymphoblastic leukemia (childhood); chr11:48088241 chr11:89639227~89698718:+ PAAD trans rs11098499 0.566 rs17051356 ENSG00000275858.1 RP11-291L22.8 6.08 9.1e-09 0.0361 0.61 0.44 Corneal astigmatism; chr4:119664153 chr10:38450738~38451069:- PAAD trans rs60338266 0.866 rs6933733 ENSG00000272750.1 RP11-378J18.8 6.08 9.13e-09 0.0362 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162446980 chr1:222658867~222661512:- PAAD trans rs60338266 0.863 rs12193308 ENSG00000272750.1 RP11-378J18.8 6.08 9.13e-09 0.0362 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162447389 chr1:222658867~222661512:- PAAD trans rs60338266 0.898 rs12207190 ENSG00000272750.1 RP11-378J18.8 6.08 9.13e-09 0.0362 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162447463 chr1:222658867~222661512:- PAAD trans rs60338266 0.898 rs12214107 ENSG00000272750.1 RP11-378J18.8 6.08 9.16e-09 0.0363 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162447437 chr1:222658867~222661512:- PAAD trans rs60338266 0.898 rs4708956 ENSG00000272750.1 RP11-378J18.8 6.08 9.16e-09 0.0363 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162447793 chr1:222658867~222661512:- PAAD trans rs11098499 0.604 rs2389882 ENSG00000275858.1 RP11-291L22.8 6.08 9.18e-09 0.0363 0.59 0.44 Corneal astigmatism; chr4:119645578 chr10:38450738~38451069:- PAAD trans rs11098499 0.604 rs2389887 ENSG00000275858.1 RP11-291L22.8 6.08 9.18e-09 0.0363 0.59 0.44 Corneal astigmatism; chr4:119649489 chr10:38450738~38451069:- PAAD trans rs11098499 0.604 rs34278750 ENSG00000275858.1 RP11-291L22.8 6.08 9.18e-09 0.0363 0.59 0.44 Corneal astigmatism; chr4:119649981 chr10:38450738~38451069:- PAAD trans rs11098499 0.604 rs10022185 ENSG00000275858.1 RP11-291L22.8 6.08 9.18e-09 0.0363 0.59 0.44 Corneal astigmatism; chr4:119650610 chr10:38450738~38451069:- PAAD trans rs11098499 0.604 rs12642411 ENSG00000275858.1 RP11-291L22.8 6.08 9.18e-09 0.0363 0.59 0.44 Corneal astigmatism; chr4:119659370 chr10:38450738~38451069:- PAAD trans rs7824557 0.872 rs1347410 ENSG00000253893.2 FAM85B 6.08 9.19e-09 0.0364 0.61 0.44 Retinal vascular caliber; chr8:11253733 chr8:8167819~8226614:- PAAD trans rs10197862 0.518 rs35181686 ENSG00000170846.14 AC093323.3 -6.08 9.22e-09 0.0365 -0.62 -0.44 Asthma and hay fever;Asthma; chr2:102476125 chr4:6673451~6676047:+ PAAD trans rs864643 0.625 rs1708083 ENSG00000183298.5 RP11-556K13.1 6.08 9.24e-09 0.0365 0.64 0.44 Attention deficit hyperactivity disorder; chr3:39464295 chr1:101786340~101787219:- PAAD trans rs864643 0.625 rs1768182 ENSG00000183298.5 RP11-556K13.1 6.08 9.24e-09 0.0365 0.64 0.44 Attention deficit hyperactivity disorder; chr3:39464531 chr1:101786340~101787219:- PAAD trans rs11098499 0.604 rs2389886 ENSG00000275858.1 RP11-291L22.8 6.08 9.27e-09 0.0366 0.59 0.44 Corneal astigmatism; chr4:119649267 chr10:38450738~38451069:- PAAD trans rs11250098 0.516 rs7843666 ENSG00000253893.2 FAM85B 6.08 9.33e-09 0.0368 0.63 0.44 Morning vs. evening chronotype; chr8:10884549 chr8:8167819~8226614:- PAAD trans rs11250098 0.541 rs6997839 ENSG00000253893.2 FAM85B 6.08 9.36e-09 0.0369 0.63 0.44 Morning vs. evening chronotype; chr8:10908518 chr8:8167819~8226614:- PAAD trans rs11250098 0.541 rs6997997 ENSG00000253893.2 FAM85B 6.08 9.36e-09 0.0369 0.63 0.44 Morning vs. evening chronotype; chr8:10908572 chr8:8167819~8226614:- PAAD trans rs6755404 0.54 rs17403136 ENSG00000250404.1 AC090587.2 6.08 9.4e-09 0.0371 0.34 0.44 Malaria; chr2:185178166 chr11:3816752~3821900:+ PAAD trans rs2455799 0.613 rs2470542 ENSG00000224631.4 RP11-51O6.1 6.08 9.42e-09 0.0371 0.48 0.44 Mean platelet volume; chr3:15682626 chr16:61055399~61055964:- PAAD trans rs13190036 1 rs34446750 ENSG00000228305.2 AC016734.2 -6.08 9.51e-09 0.0374 -0.77 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177168079 chr2:63622178~63622831:- PAAD trans rs58616815 0.857 rs4933586 ENSG00000270808.1 RP11-574K11.27 -6.08 9.51e-09 0.0374 -0.47 -0.44 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr10:90403463 chr10:73740538~73740823:- PAAD trans rs58616815 0.857 rs11186167 ENSG00000270808.1 RP11-574K11.27 -6.08 9.51e-09 0.0374 -0.47 -0.44 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr10:90413204 chr10:73740538~73740823:- PAAD trans rs58616815 0.857 rs2153745 ENSG00000270808.1 RP11-574K11.27 -6.08 9.51e-09 0.0374 -0.47 -0.44 3-hydroxy-1-methylpropylmercapturic acid levels in smokers; chr10:90424827 chr10:73740538~73740823:- PAAD trans rs10774214 0.966 rs7132832 ENSG00000273989.1 RP11-425D17.2 -6.07 9.54e-09 0.0376 -0.53 -0.44 Colorectal cancer; chr12:4256783 chr12:28236227~28236828:+ PAAD trans rs2657294 0.965 rs10824286 ENSG00000172974.11 AC007318.5 6.07 9.55e-09 0.0376 0.54 0.44 Pneumonia; chr10:75172251 chr2:65205108~65205988:+ PAAD trans rs237899 0.554 rs180789 ENSG00000234595.1 AC013733.3 6.07 9.56e-09 0.0376 0.5 0.44 Depression and alcohol dependence; chr3:8772241 chr2:181683113~181685707:+ PAAD trans rs616147 0.671 rs674192 ENSG00000183298.5 RP11-556K13.1 -6.07 9.61e-09 0.0378 -0.63 -0.44 Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis; chr3:39458653 chr1:101786340~101787219:- PAAD trans rs7937890 0.535 rs2575857 ENSG00000236360.2 RP11-334A14.2 6.07 9.64e-09 0.0379 0.59 0.44 Mitochondrial DNA levels; chr11:14479750 chr1:52993201~52993702:- PAAD trans rs2657294 0.704 rs10824266 ENSG00000172974.11 AC007318.5 6.07 9.71e-09 0.0381 0.54 0.44 Pneumonia; chr10:75083476 chr2:65205108~65205988:+ PAAD trans rs12709013 0.935 rs11648634 ENSG00000230849.2 GOT2P2 6.07 9.89e-09 0.0387 0.5 0.44 Blood metabolite ratios; chr16:58785256 chr1:173141100~173142350:- PAAD trans rs9876781 0.563 rs4858821 ENSG00000235912.1 RP1-159A19.3 6.07 9.89e-09 0.0387 0.57 0.44 Longevity; chr3:48512515 chr1:27649419~27649610:+ PAAD trans rs7824557 0.564 rs7828263 ENSG00000253893.2 FAM85B 6.07 9.91e-09 0.0388 0.6 0.44 Retinal vascular caliber; chr8:11374377 chr8:8167819~8226614:- PAAD trans rs60338266 0.897 rs2142527 ENSG00000272750.1 RP11-378J18.8 6.07 9.94e-09 0.0389 0.43 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162382613 chr1:222658867~222661512:- PAAD trans rs7554547 0.667 rs4304595 ENSG00000261819.1 RP11-680G24.4 6.07 9.99e-09 0.0391 0.58 0.44 Nonsyndromic cleft lip with cleft palate; chr1:11886332 chr16:14988259~14990160:- PAAD trans rs11195620 0.579 rs11195612 ENSG00000279419.1 RP5-907C10.3 6.06 1.01e-08 0.0393 0.58 0.44 Inhibitory control; chr10:111504782 chr7:124742312~124745017:- PAAD trans rs13190036 0.901 rs28563911 ENSG00000226986.4 RP11-543B16.2 6.06 1.01e-08 0.0393 0.7 0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177287942 chr1:211207239~211207897:+ PAAD trans rs60338266 0.901 rs741982 ENSG00000272750.1 RP11-378J18.8 6.06 1.01e-08 0.0394 0.43 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162441236 chr1:222658867~222661512:- PAAD trans rs1814175 0.669 rs17472879 ENSG00000134612.10 FOLH1B -6.06 1.02e-08 0.0396 -0.52 -0.44 Height; chr11:49477968 chr11:89639227~89698718:+ PAAD trans rs7824557 0.872 rs2572417 ENSG00000253893.2 FAM85B 6.06 1.02e-08 0.0396 0.6 0.44 Retinal vascular caliber; chr8:11253953 chr8:8167819~8226614:- PAAD trans rs864643 0.678 rs1768191 ENSG00000183298.5 RP11-556K13.1 6.06 1.02e-08 0.0397 0.65 0.44 Attention deficit hyperactivity disorder; chr3:39469772 chr1:101786340~101787219:- PAAD trans rs12709013 0.792 rs12598527 ENSG00000233719.3 GOT2P3 6.06 1.02e-08 0.0398 0.49 0.44 Blood metabolite ratios; chr16:58772987 chr12:9641802~9643007:+ PAAD trans rs12709013 0.792 rs12600201 ENSG00000233719.3 GOT2P3 6.06 1.02e-08 0.0398 0.49 0.44 Blood metabolite ratios; chr16:58773132 chr12:9641802~9643007:+ PAAD trans rs12709013 0.792 rs12600206 ENSG00000233719.3 GOT2P3 6.06 1.02e-08 0.0398 0.49 0.44 Blood metabolite ratios; chr16:58773169 chr12:9641802~9643007:+ PAAD trans rs12709013 0.792 rs11076263 ENSG00000233719.3 GOT2P3 6.06 1.02e-08 0.0398 0.49 0.44 Blood metabolite ratios; chr16:58773295 chr12:9641802~9643007:+ PAAD trans rs12709013 0.792 rs11646756 ENSG00000233719.3 GOT2P3 6.06 1.02e-08 0.0398 0.49 0.44 Blood metabolite ratios; chr16:58773598 chr12:9641802~9643007:+ PAAD trans rs1814175 0.791 rs11040472 ENSG00000134612.10 FOLH1B -6.06 1.02e-08 0.0399 -0.5 -0.44 Height; chr11:49681564 chr11:89639227~89698718:+ PAAD trans rs1814175 0.817 rs11040474 ENSG00000134612.10 FOLH1B -6.06 1.02e-08 0.0399 -0.5 -0.44 Height; chr11:49686889 chr11:89639227~89698718:+ PAAD trans rs10940346 0.934 rs2353960 ENSG00000231752.4 EMBP1 -6.06 1.03e-08 0.04 -0.55 -0.44 Schizophrenia; chr5:50481153 chr1:121519112~121571892:+ PAAD trans rs10940346 0.935 rs4971258 ENSG00000231752.4 EMBP1 -6.06 1.03e-08 0.04 -0.55 -0.44 Schizophrenia; chr5:50498560 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs11948752 ENSG00000231752.4 EMBP1 -6.06 1.03e-08 0.04 -0.55 -0.44 Schizophrenia; chr5:50504082 chr1:121519112~121571892:+ PAAD trans rs9650657 0.537 rs4841457 ENSG00000253893.2 FAM85B 6.06 1.03e-08 0.0401 0.61 0.44 Neuroticism; chr8:10916001 chr8:8167819~8226614:- PAAD trans rs7824557 0.527 rs2409756 ENSG00000253893.2 FAM85B 6.06 1.04e-08 0.0405 0.61 0.44 Retinal vascular caliber; chr8:11384516 chr8:8167819~8226614:- PAAD trans rs6063399 0.641 rs6067077 ENSG00000258794.3 DUX4L27 6.06 1.04e-08 0.0405 0.49 0.44 Obesity-related traits; chr20:49395781 chr12:34208415~34209675:- PAAD trans rs17473412 0.677 rs11749673 ENSG00000279332.1 RP11-799B12.1 -6.06 1.04e-08 0.0406 -0.65 -0.44 Total body bone mineral density; chr5:123498545 chr18:24135468~24135829:- PAAD trans rs10940346 0.935 rs2353959 ENSG00000231752.4 EMBP1 -6.05 1.06e-08 0.041 -0.54 -0.44 Schizophrenia; chr5:50473217 chr1:121519112~121571892:+ PAAD trans rs60338266 0.901 rs986313 ENSG00000272750.1 RP11-378J18.8 -6.05 1.06e-08 0.041 -0.44 -0.44 Post bronchodilator FEV1/FVC ratio; chr6:162430522 chr1:222658867~222661512:- PAAD trans rs12709013 0.967 rs56107162 ENSG00000230849.2 GOT2P2 6.05 1.06e-08 0.0413 0.5 0.44 Blood metabolite ratios; chr16:58804358 chr1:173141100~173142350:- PAAD trans rs12709013 1 rs6499983 ENSG00000230849.2 GOT2P2 6.05 1.06e-08 0.0413 0.5 0.44 Blood metabolite ratios; chr16:58810005 chr1:173141100~173142350:- PAAD trans rs12709013 0.967 rs8054482 ENSG00000230849.2 GOT2P2 6.05 1.06e-08 0.0413 0.5 0.44 Blood metabolite ratios; chr16:58810532 chr1:173141100~173142350:- PAAD trans rs3905510 0.561 rs77442454 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123572059 chr18:24135468~24135829:- PAAD trans rs3905510 0.561 rs7707274 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123572873 chr18:24135468~24135829:- PAAD trans rs3905510 0.609 rs6595461 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123575370 chr18:24135468~24135829:- PAAD trans rs3905510 0.609 rs4546375 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123576767 chr18:24135468~24135829:- PAAD trans rs3905510 0.609 rs7716499 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123578269 chr18:24135468~24135829:- PAAD trans rs3905510 0.609 rs7700628 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123578530 chr18:24135468~24135829:- PAAD trans rs3905510 0.609 rs77779977 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123582594 chr18:24135468~24135829:- PAAD trans rs3905510 0.609 rs17150494 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123582720 chr18:24135468~24135829:- PAAD trans rs3905510 0.595 rs78357398 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123585384 chr18:24135468~24135829:- PAAD trans rs3905510 0.609 rs2112468 ENSG00000279332.1 RP11-799B12.1 6.05 1.07e-08 0.0415 0.67 0.44 Total body bone mineral density; chr5:123592855 chr18:24135468~24135829:- PAAD trans rs60338266 0.901 rs9365434 ENSG00000272750.1 RP11-378J18.8 6.05 1.07e-08 0.0415 0.43 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162438019 chr1:222658867~222661512:- PAAD trans rs3905510 0.609 rs10036728 ENSG00000279332.1 RP11-799B12.1 6.05 1.08e-08 0.0418 0.69 0.44 Total body bone mineral density; chr5:123577548 chr18:24135468~24135829:- PAAD trans rs9650657 0.501 rs3021500 ENSG00000253893.2 FAM85B 6.05 1.08e-08 0.0419 0.62 0.44 Neuroticism; chr8:11166488 chr8:8167819~8226614:- PAAD trans rs7819412 0.744 rs4841503 ENSG00000253893.2 FAM85B 6.05 1.08e-08 0.0419 0.62 0.44 Triglycerides; chr8:11166817 chr8:8167819~8226614:- PAAD trans rs7811142 1 rs74460138 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100429716 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs6975729 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100430564 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs1073 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100433989 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs4989959 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100434665 chr7:102337316~102339115:+ PAAD trans rs7811142 0.887 rs4074838 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100435042 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11764818 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100445432 chr7:102337316~102339115:+ PAAD trans rs7811142 0.945 rs6955362 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100458543 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs6975514 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100458597 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs7811142 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100467820 chr7:102337316~102339115:+ PAAD trans rs7811142 1 rs11773661 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100475446 chr7:102337316~102339115:+ PAAD trans rs7811142 0.943 rs66958101 ENSG00000228546.2 CTA-313A17.3 6.05 1.09e-08 0.0422 0.65 0.44 Platelet count; chr7:100476397 chr7:102337316~102339115:+ PAAD trans rs9650657 0.535 rs7011756 ENSG00000253893.2 FAM85B 6.05 1.1e-08 0.0423 0.62 0.44 Neuroticism; chr8:11162068 chr8:8167819~8226614:- PAAD trans rs7811142 1 rs7783550 ENSG00000228546.2 CTA-313A17.3 -6.05 1.1e-08 0.0426 -0.63 -0.44 Platelet count; chr7:100390182 chr7:102337316~102339115:+ PAAD trans rs1079467 0.679 rs12286813 ENSG00000233426.3 EIF3FP3 -6.05 1.1e-08 0.0426 -0.66 -0.44 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7949826 chr2:58251440~58252525:+ PAAD trans rs11098499 0.604 rs17051352 ENSG00000275858.1 RP11-291L22.8 6.04 1.13e-08 0.0434 0.6 0.44 Corneal astigmatism; chr4:119660272 chr10:38450738~38451069:- PAAD trans rs7937890 0.81 rs10734224 ENSG00000236360.2 RP11-334A14.2 6.04 1.13e-08 0.0434 0.6 0.44 Mitochondrial DNA levels; chr11:14402578 chr1:52993201~52993702:- PAAD trans rs55665837 0.701 rs1522633 ENSG00000236360.2 RP11-334A14.2 6.04 1.13e-08 0.0436 0.57 0.44 Vitamin D levels; chr11:14623692 chr1:52993201~52993702:- PAAD trans rs11098499 0.82 rs28394116 ENSG00000275858.1 RP11-291L22.8 6.04 1.14e-08 0.0438 0.58 0.44 Corneal astigmatism; chr4:119603128 chr10:38450738~38451069:- PAAD trans rs11098499 0.866 rs3756156 ENSG00000275858.1 RP11-291L22.8 6.04 1.14e-08 0.0438 0.58 0.44 Corneal astigmatism; chr4:119603686 chr10:38450738~38451069:- PAAD trans rs1814175 0.817 rs4084376 ENSG00000134612.10 FOLH1B -6.04 1.15e-08 0.044 -0.5 -0.44 Height; chr11:49809608 chr11:89639227~89698718:+ PAAD trans rs1814175 0.817 rs1851858 ENSG00000134612.10 FOLH1B -6.04 1.15e-08 0.044 -0.5 -0.44 Height; chr11:49834086 chr11:89639227~89698718:+ PAAD trans rs7824557 0.527 rs57629785 ENSG00000253893.2 FAM85B 6.04 1.15e-08 0.044 0.61 0.44 Retinal vascular caliber; chr8:11377641 chr8:8167819~8226614:- PAAD trans rs7824557 0.564 rs2572395 ENSG00000253893.2 FAM85B 6.04 1.15e-08 0.044 0.61 0.44 Retinal vascular caliber; chr8:11377851 chr8:8167819~8226614:- PAAD trans rs7824557 0.564 rs2437152 ENSG00000253893.2 FAM85B 6.04 1.15e-08 0.044 0.61 0.44 Retinal vascular caliber; chr8:11377988 chr8:8167819~8226614:- PAAD trans rs2727020 0.754 rs1851990 ENSG00000134612.10 FOLH1B -6.04 1.15e-08 0.0441 -0.54 -0.44 Coronary artery disease; chr11:49391784 chr11:89639227~89698718:+ PAAD trans rs2727020 0.612 rs9787891 ENSG00000134612.10 FOLH1B -6.04 1.15e-08 0.0441 -0.54 -0.44 Coronary artery disease; chr11:49391942 chr11:89639227~89698718:+ PAAD trans rs2727020 0.718 rs1404366 ENSG00000134612.10 FOLH1B -6.04 1.15e-08 0.0441 -0.54 -0.44 Coronary artery disease; chr11:49394347 chr11:89639227~89698718:+ PAAD trans rs330048 0.561 rs1825100 ENSG00000253893.2 FAM85B 6.04 1.15e-08 0.0442 0.64 0.44 Systemic lupus erythematosus; chr8:9288760 chr8:8167819~8226614:- PAAD trans rs1814175 0.791 rs10769625 ENSG00000134612.10 FOLH1B -6.04 1.16e-08 0.0444 -0.5 -0.44 Height; chr11:49848335 chr11:89639227~89698718:+ PAAD trans rs1814175 0.817 rs7947286 ENSG00000134612.10 FOLH1B -6.04 1.16e-08 0.0444 -0.5 -0.44 Height; chr11:49853105 chr11:89639227~89698718:+ PAAD trans rs1814175 0.791 rs7395713 ENSG00000134612.10 FOLH1B -6.04 1.16e-08 0.0444 -0.5 -0.44 Height; chr11:49856335 chr11:89639227~89698718:+ PAAD trans rs1814175 0.715 rs10839409 ENSG00000134612.10 FOLH1B -6.04 1.16e-08 0.0444 -0.5 -0.44 Height; chr11:49863095 chr11:89639227~89698718:+ PAAD trans rs1814175 0.781 rs2866734 ENSG00000134612.10 FOLH1B -6.04 1.16e-08 0.0444 -0.5 -0.44 Height; chr11:49864786 chr11:89639227~89698718:+ PAAD trans rs1814175 0.817 rs1615305 ENSG00000134612.10 FOLH1B -6.04 1.16e-08 0.0444 -0.5 -0.44 Height; chr11:49873670 chr11:89639227~89698718:+ PAAD trans rs1814175 0.817 rs1621090 ENSG00000134612.10 FOLH1B -6.04 1.16e-08 0.0444 -0.5 -0.44 Height; chr11:49874316 chr11:89639227~89698718:+ PAAD trans rs1814175 0.765 rs1722003 ENSG00000134612.10 FOLH1B -6.04 1.16e-08 0.0444 -0.5 -0.44 Height; chr11:49874344 chr11:89639227~89698718:+ PAAD trans rs13190036 1 rs17078781 ENSG00000226986.4 RP11-543B16.2 -6.04 1.16e-08 0.0444 -0.69 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177117227 chr1:211207239~211207897:+ PAAD trans rs3779195 0.585 rs7777991 ENSG00000225169.1 BRI3P1 -6.03 1.17e-08 0.0445 -0.78 -0.44 Sex hormone-binding globulin levels; chr7:98236445 chr1:100213293~100213670:+ PAAD trans rs9467773 0.869 rs742090 ENSG00000242375.1 RP11-498P14.3 -6.03 1.17e-08 0.0447 -0.54 -0.44 Intelligence (multi-trait analysis); chr6:26415409 chr9:97195351~97197687:- PAAD trans rs5755703 0.798 rs133402 ENSG00000258957.1 RP11-363J20.1 -6.03 1.18e-08 0.0449 -0.51 -0.44 Smoking cessation; chr22:35349103 chr14:69183020~69214092:- PAAD trans rs10940346 1 rs1423645 ENSG00000231752.4 EMBP1 -6.03 1.18e-08 0.0451 -0.55 -0.44 Schizophrenia; chr5:50540881 chr1:121519112~121571892:+ PAAD trans rs7824557 0.564 rs2736290 ENSG00000253893.2 FAM85B 6.03 1.19e-08 0.0453 0.61 0.44 Retinal vascular caliber; chr8:11376789 chr8:8167819~8226614:- PAAD trans rs7824557 0.564 rs2572400 ENSG00000253893.2 FAM85B 6.03 1.19e-08 0.0453 0.61 0.44 Retinal vascular caliber; chr8:11376858 chr8:8167819~8226614:- PAAD trans rs13148252 0.915 rs12499868 ENSG00000249047.2 COX6B1P5 6.03 1.19e-08 0.0454 0.51 0.44 IgG glycosylation; chr4:110296135 chr4:2234251~2234499:+ PAAD trans rs10016947 1 rs6533086 ENSG00000224476.3 RPL36P16 6.03 1.19e-08 0.0454 0.81 0.44 Breast cancer; chr4:103373632 chr19:41169861~41170166:+ PAAD trans rs3905510 0.658 rs17150506 ENSG00000279332.1 RP11-799B12.1 -6.03 1.19e-08 0.0454 -0.66 -0.44 Total body bone mineral density; chr5:123608154 chr18:24135468~24135829:- PAAD trans rs60338266 0.901 rs9356016 ENSG00000272750.1 RP11-378J18.8 6.03 1.2e-08 0.0457 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162433626 chr1:222658867~222661512:- PAAD trans rs60338266 0.866 rs9365433 ENSG00000272750.1 RP11-378J18.8 6.03 1.2e-08 0.0457 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162435378 chr1:222658867~222661512:- PAAD trans rs60338266 0.901 rs7771809 ENSG00000272750.1 RP11-378J18.8 6.03 1.2e-08 0.0457 0.44 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162439115 chr1:222658867~222661512:- PAAD trans rs703108 0.731 rs7898954 ENSG00000230330.1 HMGN2P3 -6.03 1.21e-08 0.0458 -0.58 -0.44 Monocyte percentage of white cells; chr10:22034717 chr16:26032539~26032811:- PAAD trans rs7819412 0.838 rs3021494 ENSG00000253893.2 FAM85B 6.03 1.21e-08 0.0459 0.61 0.44 Triglycerides; chr8:11126024 chr8:8167819~8226614:- PAAD trans rs76228276 0.737 rs77547719 ENSG00000260318.1 COX6CP1 6.03 1.21e-08 0.0459 1 0.44 Childhood ear infection; chr8:99583331 chr16:11903923~11904137:- PAAD trans rs11098499 0.675 rs11098534 ENSG00000275858.1 RP11-291L22.8 6.03 1.21e-08 0.046 0.55 0.44 Corneal astigmatism; chr4:119635617 chr10:38450738~38451069:- PAAD trans rs7937890 0.559 rs10766184 ENSG00000236360.2 RP11-334A14.2 6.03 1.21e-08 0.046 0.59 0.44 Mitochondrial DNA levels; chr11:14521031 chr1:52993201~52993702:- PAAD trans rs11098499 0.82 rs2389885 ENSG00000275858.1 RP11-291L22.8 6.03 1.21e-08 0.046 0.59 0.44 Corneal astigmatism; chr4:119612776 chr10:38450738~38451069:- PAAD trans rs7824557 0.564 rs2572394 ENSG00000253893.2 FAM85B 6.03 1.21e-08 0.0461 0.61 0.44 Retinal vascular caliber; chr8:11377884 chr8:8167819~8226614:- PAAD trans rs7824557 0.603 rs2736278 ENSG00000253893.2 FAM85B -6.03 1.22e-08 0.0461 -0.59 -0.44 Retinal vascular caliber; chr8:11362272 chr8:8167819~8226614:- PAAD trans rs10037055 0.741 rs4976640 ENSG00000226986.4 RP11-543B16.2 -6.03 1.22e-08 0.0463 -0.58 -0.44 Migraine without aura; chr5:177125006 chr1:211207239~211207897:+ PAAD trans rs7824557 0.564 rs2736293 ENSG00000253893.2 FAM85B 6.03 1.22e-08 0.0464 0.61 0.44 Retinal vascular caliber; chr8:11377104 chr8:8167819~8226614:- PAAD trans rs7824557 0.564 rs2736294 ENSG00000253893.2 FAM85B 6.03 1.22e-08 0.0464 0.61 0.44 Retinal vascular caliber; chr8:11377117 chr8:8167819~8226614:- PAAD trans rs7824557 0.527 rs2736296 ENSG00000253893.2 FAM85B 6.03 1.22e-08 0.0464 0.61 0.44 Retinal vascular caliber; chr8:11377335 chr8:8167819~8226614:- PAAD trans rs7824557 0.51 rs2736297 ENSG00000253893.2 FAM85B 6.03 1.22e-08 0.0464 0.61 0.44 Retinal vascular caliber; chr8:11377376 chr8:8167819~8226614:- PAAD trans rs1079467 0.735 rs75941265 ENSG00000233426.3 EIF3FP3 -6.02 1.23e-08 0.0465 -0.65 -0.44 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7949542 chr2:58251440~58252525:+ PAAD trans rs1079467 0.786 rs2136907 ENSG00000233426.3 EIF3FP3 -6.02 1.23e-08 0.0465 -0.65 -0.44 Response to anti-TNF therapy in rheumatoid arthritis; chr11:7951686 chr2:58251440~58252525:+ PAAD trans rs6708331 0.517 rs12614547 ENSG00000232654.1 FAM136BP 6.02 1.23e-08 0.0465 0.46 0.44 Obesity-related traits; chr2:70056839 chr6:3045384~3045800:+ PAAD trans rs2434529 0.531 rs76530294 ENSG00000224094.1 RPS24P8 6.02 1.23e-08 0.0465 0.69 0.44 Autism spectrum disorder or schizophrenia; chr5:154175575 chr3:45159774~45160175:- PAAD trans rs10908521 0.685 rs7534418 ENSG00000227183.3 HDGFP1 -6.02 1.24e-08 0.0467 -0.62 -0.44 Uric acid clearance; chr1:156836011 chrX:131646639~131646890:+ PAAD trans rs60338266 0.933 rs6455822 ENSG00000272750.1 RP11-378J18.8 6.02 1.24e-08 0.047 0.43 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162408268 chr1:222658867~222661512:- PAAD trans rs3779195 0.585 rs58699591 ENSG00000225169.1 BRI3P1 -6.02 1.25e-08 0.047 -0.76 -0.44 Sex hormone-binding globulin levels; chr7:98247392 chr1:100213293~100213670:+ PAAD trans rs3779195 0.524 rs80195155 ENSG00000225169.1 BRI3P1 -6.02 1.25e-08 0.047 -0.76 -0.44 Sex hormone-binding globulin levels; chr7:98248841 chr1:100213293~100213670:+ PAAD trans rs13190036 0.786 rs10068127 ENSG00000226986.4 RP11-543B16.2 -6.02 1.25e-08 0.0471 -0.68 -0.44 Lymphocyte percentage of white cells;Neutrophil percentage of white cells; chr5:177204786 chr1:211207239~211207897:+ PAAD trans rs864643 0.678 rs1768198 ENSG00000183298.5 RP11-556K13.1 6.02 1.25e-08 0.0472 0.65 0.44 Attention deficit hyperactivity disorder; chr3:39474994 chr1:101786340~101787219:- PAAD trans rs7682317 0.502 rs7687207 ENSG00000279948.1 CTD-2233K9.1 -6.02 1.25e-08 0.0473 -0.59 -0.44 Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio; chr4:89128817 chr19:46946535~46949156:+ PAAD trans rs6499255 0.904 rs74029403 ENSG00000257513.6 NPIPB1P 6.02 1.26e-08 0.0474 0.66 0.44 IgE levels; chr16:69676569 chr18:11619509~11639699:- PAAD trans rs7824557 0.603 rs2246606 ENSG00000253893.2 FAM85B -6.02 1.27e-08 0.048 -0.58 -0.44 Retinal vascular caliber; chr8:11361825 chr8:8167819~8226614:- PAAD trans rs17158483 0.543 rs34511420 ENSG00000279652.1 RP1-78B3.1 -6.02 1.28e-08 0.0482 -1.1 -0.44 Obesity-related traits; chr7:29970882 chr22:35992321~36000469:+ PAAD trans rs7824557 0.527 rs2736298 ENSG00000253893.2 FAM85B 6.02 1.28e-08 0.0483 0.61 0.44 Retinal vascular caliber; chr8:11377627 chr8:8167819~8226614:- PAAD trans rs2997457 0.872 rs298448 ENSG00000202000.1 RNU1-36P -6.02 1.28e-08 0.0483 -0.71 -0.44 Facial morphology (factor 16); chr1:25983138 chr4:88000237~88000401:+ PAAD trans rs2997457 0.872 rs3008241 ENSG00000202000.1 RNU1-36P -6.02 1.28e-08 0.0483 -0.71 -0.44 Facial morphology (factor 16); chr1:26001260 chr4:88000237~88000401:+ PAAD trans rs2997457 0.872 rs3008412 ENSG00000202000.1 RNU1-36P -6.02 1.28e-08 0.0483 -0.71 -0.44 Facial morphology (factor 16); chr1:26002572 chr4:88000237~88000401:+ PAAD trans rs724950 1 rs724950 ENSG00000259565.2 KRT8P23 -6.01 1.29e-08 0.0485 -0.53 -0.44 Obesity-related traits; chr4:127420965 chr15:76979245~76980451:- PAAD trans rs7811142 0.887 rs35111986 ENSG00000228546.2 CTA-313A17.3 6.01 1.29e-08 0.0486 0.65 0.44 Platelet count; chr7:100402651 chr7:102337316~102339115:+ PAAD trans rs1814175 0.817 rs7483795 ENSG00000134612.10 FOLH1B -6.01 1.3e-08 0.0488 -0.5 -0.44 Height; chr11:49683378 chr11:89639227~89698718:+ PAAD trans rs16974161 1 rs16974161 ENSG00000279348.1 RP11-566E18.1 6.01 1.3e-08 0.0489 0.8 0.44 Cold sores; chr18:10313582 chr2:216211404~216213519:+ PAAD trans rs60338266 0.933 rs12193416 ENSG00000272750.1 RP11-378J18.8 6.01 1.3e-08 0.049 0.43 0.44 Post bronchodilator FEV1/FVC ratio; chr6:162447577 chr1:222658867~222661512:- PAAD trans rs12709013 0.792 rs12325510 ENSG00000233719.3 GOT2P3 6.01 1.31e-08 0.0491 0.49 0.44 Blood metabolite ratios; chr16:58749707 chr12:9641802~9643007:+ PAAD trans rs5022636 0.533 rs4971029 ENSG00000180764.13 PIPSL 6.01 1.31e-08 0.0492 0.62 0.44 Gut microbiota (functional units); chr1:151304783 chr10:93958191~93961540:- PAAD trans rs5022636 0.507 rs2031797 ENSG00000180764.13 PIPSL 6.01 1.31e-08 0.0492 0.62 0.44 Gut microbiota (functional units); chr1:151306029 chr10:93958191~93961540:- PAAD trans rs11793049 1 rs11793049 ENSG00000270010.1 CTD-2132N18.4 6.01 1.31e-08 0.0493 0.48 0.44 Coronary artery aneurysm in Kawasaki disease; chr9:114011589 chr17:42038232~42038734:- PAAD trans rs2567519 0.71 rs2714012 ENSG00000220749.4 RPL21P28 -6.01 1.31e-08 0.0493 -0.48 -0.44 Smoking initiation; chr17:72787618 chr1:212051524~212052006:- PAAD trans rs703108 0.731 rs7898954 ENSG00000204253.4 HNRNPCP2 -6.01 1.32e-08 0.0494 -0.49 -0.44 Monocyte percentage of white cells; chr10:22034717 chr2:189923336~189924216:+ PAAD trans rs10940346 1 rs56387400 ENSG00000231752.4 EMBP1 -6.01 1.32e-08 0.0496 -0.55 -0.44 Schizophrenia; chr5:50517577 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs12520874 ENSG00000231752.4 EMBP1 -6.01 1.32e-08 0.0496 -0.55 -0.44 Schizophrenia; chr5:50523857 chr1:121519112~121571892:+ PAAD trans rs10940346 1 rs7708897 ENSG00000231752.4 EMBP1 -6.01 1.32e-08 0.0496 -0.55 -0.44 Schizophrenia; chr5:50528209 chr1:121519112~121571892:+ PAAD trans rs7811142 1 rs7794485 ENSG00000228546.2 CTA-313A17.3 6.01 1.32e-08 0.0496 0.65 0.44 Platelet count; chr7:100471313 chr7:102337316~102339115:+